<SEC-DOCUMENT>0001013762-24-000530.txt : 20240722
<SEC-HEADER>0001013762-24-000530.hdr.sgml : 20240722
<ACCEPTANCE-DATETIME>20240722171717
ACCESSION NUMBER:		0001013762-24-000530
CONFORMED SUBMISSION TYPE:	S-4/A
PUBLIC DOCUMENT COUNT:		86
FILED AS OF DATE:		20240722
DATE AS OF CHANGE:		20240722

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-4/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279387
		FILM NUMBER:		241132294

	BUSINESS ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		7209402200

	MAIL ADDRESS:	
		STREET 1:		10170 CHURCH RANCH WAY
		STREET 2:		SUITE 100
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-4/A
<SEQUENCE>1
<FILENAME>ea0205122-06.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Jul 22 20:39:22 UTC 2024 -->
<html xmlns:abio="http://www.arcabiopharma.com/20240331" xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head><title> </title>
<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="margin:0;padding:0;border-width:0;text-justify-trim: punctuation; margin: 0; padding: 10pt;"><div style="margin:0;padding:0;border-width:0;width:600px;margin: 0 auto;">
	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As filed with the Securities and Exchange Commission on July 22, 2024</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:right;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">No. 333-279387</span></p>
		<div style="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></div>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"> UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/>Washington, D.C. 20549</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:2pt;text-align:center;margin-top:2pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">AMENDMENT NO. 3<br/>to<br/>FORM <span style="-sec-ix-hidden: hidden-fact-0">S-4</span><br/>REGISTRATION STATEMENT<br/></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">UNDER<br/>THE SECURITIES ACT OF 1933</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-32"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:16pt;">ARCA BIOPHARMA, INC.<br/></span></ix:nonNumeric><span class="Bold" style="font-style:normal;font-weight:bold;">(Exact name of registrant as specified in its charter)</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-42"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:10pt;">Delaware</span></ix:nonNumeric></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:10pt;">2835</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:10pt;">36-3855489</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">(State or other jurisdiction of <br/>incorporation or organization)</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">(Primary Standard Industrial <br/>Classification Code Number)</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">(I.R.S.&#160;Employer <br/>Identification No.)</span></p>	</td>	</tr>	</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:4pt;text-align:center;margin-top:4pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">10170 Church Ranch Way, Suite 100<br/>Westminster, CO&#160;80021<br/>(720)&#160;940-2100<br/>(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:2pt;text-align:center;margin-top:2pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Thomas A.&#160;Keuer<br/>President and Chief Operating Officer<br/>ARCA biopharma, Inc.<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, CO&#160;80021<br/>(720)&#160;940</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-2100</span></span><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>(Name, address, including zip code, and telephone number, including area code, of agent for service)</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:1pt;text-align:center;margin-top:1pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Copies of all communications, including communications sent to agent for service, should be sent to:</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;vertical-align:top;width: 48.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">Brent Fassett <br/>Ethan Lutske <br/>Ross Tanaka <br/>Savir S.&#160;Punia <br/>Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. <br/>1881 9</span><span class="Bold" style="font-style:normal;font-weight:bold;font-size:58%;vertical-align:super;">th</span><span class="Bold" style="font-style:normal;font-weight:bold;"> Street, Suite 110 <br/>Boulder, CO&#160;80302 <br/>(303)&#160;256</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-5900</span></span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">Ryan A.&#160;Murr, Esq. <br/>Branden C.&#160;Berns, Esq. <br/>Chris W.&#160;Trester, Esq. <br/>Gibson, Dunn&#160;&amp; Crutcher LLP <br/>One Embarcadero Center, Suite 2600 <br/>San Francisco, CA&#160;94111 <br/>(415)&#160;393</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-8373</span></span></p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:6pt;">__________________________</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Approximate date of commencement of proposed sale of the securities to the public: </span><span class="CharOverride-6" style="font-size:9pt;">As soon as practicable after the effective date of this registration statement and the satisfaction or waiver of all other conditions under the Merger Agreement described herein.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-6" style="font-size:9pt;">If the securities being registered on this Form are being offered in connection with the formation of a holding company and there is compliance with General Instruction G, check the following box </span><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-6" style="font-size:9pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </span><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-6" style="font-size:9pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d)&#160;under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </span><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-6" style="font-size:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange&#160;Act.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 3.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 18.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">ARCA&#160;biopharma,&#160;Inc. <br/></span><span class="CharOverride-6" style="font-size:9pt;">Large&#160;accelerated&#160;filer</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 26.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="GrepStyle" style="font-family:'Wingdings 2', sans-serif;font-size:9pt;"><br/>&#163;</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 21.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-6" style="font-size:9pt;">Accelerated filer</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 25.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;vertical-align:top;width: 3.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 18.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-160"><span class="CharOverride-6" style="font-size:9pt;">Non-accelerated&#160;filer</span></ix:nonNumeric></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 26.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9746;</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 21.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-6" style="font-size:9pt;">Smaller&#160;reporting&#160;company</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 25.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness" id="ixv-173"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9746;</span></ix:nonNumeric></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;vertical-align:top;width: 3.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 18.89%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 26.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 21.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-6" style="font-size:9pt;">Emerging&#160;growth&#160;company</span></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 1.11%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;vertical-align:top;width: 25.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">	<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany" id="ixv-188"><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></ix:nonNumeric></p>	</td>	</tr>	</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:4pt;margin-top:4pt;"><span class="CharOverride-6" style="font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B)&#160;of the Securities Act. </span><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-6" style="font-size:9pt;">If applicable, place an&#160;X in the box to designate the appropriate rule provision relied upon in conducting this transaction:</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-6" style="font-size:9pt;">Exchange&#160;Act Rule&#160;13e-4(i)&#160;(Cross-Border Issuer Tender Offer) </span><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="CharOverride-6" style="font-size:9pt;">Exchange&#160;Act Rule&#160;14d-1(d)&#160;(Cross-Border Third-Party Tender Offer) </span><span class="GrepStyle" style="font-family:'Wingdings 24', sans-serif;font-size:9pt;">&#9744;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:2pt;margin-top:2pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a)&#160;of the Securities Act&#160;of&#160;1933, as amended, or until the registration statement shall become&#160;effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine.</span></p>
		<div style="border: none; border-bottom: double windowtext 6.0pt; padding: 0in 0in 4.0pt 0in; margin-left: 0in; margin-right: 0.0pt;"></div>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>





	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:justify;margin-top:8pt;"><span class="CharOverride-7" style="color:#d2232a;">The information in this preliminary proxy statement/prospectus is not complete and may be changed. ARCA biopharma, Inc. may not sell the securities described in this preliminary proxy statement/prospectus until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary proxy statement/prospectus is not an offer to sell and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</span></p>
		</div>
	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;color:#d2232a;">PRELIMINARY PROXY STATEMENT/PROSPECTUS <br/>SUBJECT TO COMPLETION, DATED JULY</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;color:#d2232a;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;color:#d2232a;">22, 2024</span></p>
		<table class="Basic-Table _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="Basic-Table _idGenTableRowColumn-19" style="height:12pt;">
					<td class="Basic-Table CellOverride-11" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;vertical-align:bottom;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="Basic-Table CellOverride-12" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="Basic-Table CellOverride-12" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 35.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Basic-Paragraph" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><img alt="" src="tarca_001.jpg" style="width:206.08px;max-width:100%;"/></p>
					</td>
					<td class="Basic-Table CellOverride-12" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="Basic-Table CellOverride-12" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 35.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Basic-Paragraph" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><img alt="" src="toruka_logo.jpg" style="width:107.52px;max-width:100%;"/></p>
					</td>
					<td class="Basic-Table CellOverride-12" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="Basic-Table CellOverride-12" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:bottom;width: 12.82%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PROPOSED MERGER<br/>YOUR VOTE IS VERY IMPORTANT</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">_______________________________</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:7pt;margin-top:7pt;">To the Stockholders of ARCA biopharma, Inc. and Oruka Therapeutics, Inc.,</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221;), and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka&#8221;), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) on April&#160;3, 2024, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Atlas Merger Sub Corp, a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Oruka will merge with and into Atlas Merger Sub&#160;II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). After the completion of the Merger, Second Merger Sub will change its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; The term &#8220;combined company&#8221; when used in the following proxy statement/prospectus refers to the post<span class="nobreak">-Merger</span> corporate structure including Oruka Therapeutics, Inc. (f/k/a ARCA biopharma, Inc.) as the parent entity and Oruka Therapeutics Operating Company, LLC as its wholly<span class="nobreak">-owned</span> subsidiary.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">At the closing of the First Merger (the &#8220;First Effective Time&#8221;), upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (as defined below) and excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio (described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page&#160;136 of the accompanying proxy statement/prospectus), (ii)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B non<span class="nobreak">-voting</span> convertible preferred stock, par value $0.001 per share (&#8220;ARCA Series&#160;B Preferred Stock&#8221;), which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the exchange ratio divided by 1,000, (iii)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Oruka Options</span>&#8221; beginning on page 139 of the accompanying proxy statement/prospectus, (iv)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Oruka Warrants</span>&#8221; beginning on page 139 of the accompanying proxy statement/prospectus, (v)&#160;each in<span class="nobreak">-the-money</span> option to acquire shares of ARCA&#8217;s common stock that is issued and outstanding (whether vested or unvested) will be cancelled and converted into the right to receive an amount in cash equal to the excess (if any) of the volume weighted average closing price of ARCA&#8217;s common stock for the five consecutive&#160;trading days ending three (3)&#160;trading days prior to the closing of the First Merger (the &#8220;Parent Closing Price&#8221;) over the option&#8217;s exercise price and (vi)&#160;each share of ARCA common stock that is issued and outstanding at the First Effective Time will remain issued and outstanding in accordance with its terms and such shares, subject to the proposed reverse stock split, and will be unaffected by the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Based on ARCA&#8217;s and Oruka&#8217;s capitalization as of July<span class="nobreak"> </span>16, 2024 and taking into account ARCA&#8217;s current cash position, each share of Oruka capital stock is currently estimated to be entitled to receive approximately 6.8699<span class="nobreak"> </span>shares of ARCA common stock. This estimated exchange ratio does not give effect to the proposed ARCA reverse stock split and is </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:7pt;">subject to adjustment based on ARCA&#8217;s estimated net cash at the closing of the First Merger as described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 136 of the accompanying proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the First Effective Time, ARCA&#8217;s board of directors expects to declare a special cash dividend (the &#8220;special cash dividend&#8221;) to stockholders of record of outstanding shares of ARCA common stock as of a record date prior to the First Effective Time, to be set by ARCA&#8217;s board of directors as close as reasonably practicable to (but not later than) the First Effective Time. The ex<span class="nobreak">-dividend</span> date in respect of such special cash dividend will be determined by The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;). ARCA stockholders of record who continue to hold their eligible shares of ARCA common stock until market open on the ex<span class="nobreak">-dividend</span> date will be entitled to payment of the special cash dividend. The special cash dividend will be equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) is expected to exceed $5.0&#160;million. ARCA currently estimates that the aggregate amount of cash to be distributed to stockholders of record as of the record date of the special cash dividend will be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, concurrently with the execution and delivery of the Merger Agreement, Oruka entered into a subscription agreement with certain investors to purchase shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span>&#160;warrants for an aggregate purchase price of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note), which subscription agreement was subsequently amended and restated on July<span class="nobreak"> </span>3, 2024 (the &#8220;Subscription Agreement&#8221;) to provide for, among other things, the issuance of warrants to certain of Oruka&#8217;s employees, directors and service providers (the &#8220;employee warrants&#8221;), immediately prior to the closing of the Merger (referred to herein as the &#8220;Oruka pre<span class="nobreak">-closing</span> financing&#8221;). The shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span>&#160;warrants that are issued in the Oruka pre<span class="nobreak">-closing</span>&#160;financing will be converted into the right to receive a number of shares of ARCA common stock and warrants to purchase shares of ARCA common stock, respectively, equal to the exchange ratio described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page&#160;136 of the accompanying proxy statement/prospectus. ARCA, Oruka and the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing have also agreed to enter into a registration rights agreement (the &#8220;registration rights agreement&#8221;) at the closing of the Oruka pre<span class="nobreak">-closing</span> financing, pursuant to which, among other things, the combined company will agree to provide for the registration and resale of certain shares of ARCA common stock that are held by the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing from time to time pursuant to Rule&#160;415 under the Securities Act (&#8220;Rule&#160;415&#8221;). The Oruka pre<span class="nobreak">-closing</span> financing is more fully described in the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Subscription Agreement</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Registration Rights Agreement</span>&#8221; beginning on page 153 and 155, respectively, of the accompanying proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately after the Merger, based solely on the estimated exchange ratio as described in the accompanying proxy statement/prospectus, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully diluted basis), and former holders of Oruka securities (including those issued in the Oruka pre<span class="nobreak">-closing</span> financing) are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully diluted basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. Under certain circumstances described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 136 of the accompanying proxy statement/prospectus, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash as of closing is less than $5.0&#160;million. ARCA currently estimates that its net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Shares of ARCA common stock are currently listed on Nasdaq under the symbol &#8220;ABIO.&#8221; ARCA has filed an initial listing application for the combined company with Nasdaq. After completion of the Merger, ARCA will be renamed &#8220;Oruka Therapeutics, Inc.&#8221; and it is expected that the common stock of the combined company will trade on Nasdaq under the symbol &#8220;ORKA.&#8221; It is a condition to the consummation of the Merger that ARCA will receive confirmation from Nasdaq that the combined company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that ARCA will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties. On July<span class="nobreak"> </span>19, 2024, the last&#160;trading day before the date of the accompanying proxy statement/prospectus, the closing sale price of ARCA common stock was $3.29 per share.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA stockholders are cordially invited to attend the special meeting in lieu of the annual meeting of ARCA stockholders. ARCA is holding its special meeting in lieu of the annual meeting of stockholders (the &#8220;ARCA special meeting&#8221;) on August<span class="nobreak"> </span>22, 2024, at 9:00 a.m. Mountain Time, unless postponed or adjourned to a later date, in order to obtain the stockholder approvals necessary to complete the Merger and related matters. At the ARCA special meeting, ARCA will ask its stockholders to:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve (i)&#160;the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to the accompanying proxy statement/prospectus, and (ii)&#160;the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a)&#160;and 5635(b), respectively (the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal&#160;No. 1&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the amended and restated certificate of incorporation of ARCA (the &#8220;ARCA Charter&#8221;) to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000<span class="nobreak"> </span>shares to 545,000,000, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to the accompanying proxy statement/prospectus (the &#8220;Authorized Share Increase Proposal&#8221; or &#8220;Proposal&#160;No. 2&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range between 6:1 to 12:1, inclusive, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H </span>to the accompanying proxy statement/prospectus, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, determined solely by ARCA&#8217;s board of directors (the &#8220;Reverse Stock Split Proposal&#8221; or &#8220;Proposal&#160;No. 3&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I</span> (the &#8220;Officer Exculpation Proposal&#8221; or &#8220;Proposal&#160;No. 4&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Elect the Class&#160;III director, Jacob Ma<span class="nobreak">-Weaver</span>, to ARCA&#8217;s board of directors and to hold office until ARCA&#8217;s 2027 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal (the &#8220;Director Election Proposal&#8221; or &#8220;Proposal&#160;No. 5&#8221;), provided that if the Merger is consummated, the approval of Proposal&#160;No. 5 will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Ratify the appointment of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for fiscal year ending December&#160;31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed (the &#8220;Auditor Ratification Proposal&#8221; or &#8220;Proposal&#160;No. 6&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (the &#8220;Stock Plan Proposal&#8221; or &#8220;Proposal&#160;No. 7&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the &#8220;ESPP Proposal&#8221; or &#8220;Proposal&#160;No. 8&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger (the &#8220;the Merger Compensation Proposal&#8221; or &#8220;Proposal&#160;No. 9&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal&#160;No. 10&#8221;); and</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Transact such other business as may properly come before the stockholders at the ARCA special meeting or any adjournment or postponement thereof.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As described in the accompanying proxy statement/prospectus, certain ARCA stockholders who in the aggregate owned approximately 28.5% of the outstanding shares of ARCA capital stock as of July<span class="nobreak"> </span>16, 2024, and certain Oruka stockholders who in the aggregate owned approximately 90% of the outstanding shares of Oruka capital stock as of July<span class="nobreak"> </span>16, 2024, are parties to stockholder support agreements with ARCA and Oruka, respectively, whereby such stockholders have agreed to vote in favor of the adoption of the Merger Agreement and the approval of the Merger and related transactions contemplated by the Merger Agreement, subject to the terms of the support agreements. Following the effectiveness of the registration statement on Form&#160;S<span class="nobreak">-4</span> of which the accompanying proxy statement/prospectus is a part and pursuant to the Merger Agreement, Oruka stockholders holding a sufficient number of shares of Oruka capital stock to adopt the Merger Agreement and approve the Merger and related transactions will be asked to execute written consents providing for such adoption and approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While the combined company will not be considered a &#8220;controlled company&#8221; under the relevant listing rules of Nasdaq, it is anticipated that the combined company&#8217;s executive officers, directors and principal stockholders will, in the aggregate, beneficially own approximately 47% of the combined company&#8217;s outstanding shares of common stock (on a fully<span class="nobreak">-diluted</span> basis). As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval, as well as the combined company&#8217;s management and affairs, though they have no agreement to do so or any expectation of entering into such an agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After careful consideration, each of ARCA&#8217;s and Oruka&#8217;s boards of directors have approved the Merger Agreement and have determined that it is advisable to consummate the Merger. ARCA&#8217;s board of directors has approved the proposals described in the accompanying proxy statement/prospectus and recommends that its stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the proposals described in the accompanying proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">More information about ARCA, Oruka, the Merger Agreement and transactions contemplated thereby and the foregoing proposals is contained in the accompanying proxy statement/prospectus. ARCA urges you to read the accompanying proxy statement/prospectus carefully and in its entirety. IN PARTICULAR, YOU SHOULD CAREFULLY CONSIDER THE MATTERS DISCUSSED UNDER &#8220;RISK FACTORS&#8221; BEGINNING ON PAGE 15 OF THE ACCOMPANYING PROXY STATEMENT/PROSPECTUS.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Oruka are excited about the opportunities the Merger brings to ARCA&#8217;s and Oruka&#8217;s stockholders and thank you for your consideration and continued support.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 39.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lawrence Klein</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Italic" style="font-style:italic;font-weight:normal;">President and Chief Operating Officer</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 39.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Italic" style="font-style:italic;font-weight:normal;">Chief Executive Officer</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 59.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ARCA biopharma, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 39.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Oruka Therapeutics, Inc.</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the accompanying proxy&#160;statement/prospectus. Any representation to the contrary is a criminal offense.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The accompanying proxy statement/prospectus is dated July</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">22, 2024, and is first being mailed to ARCA&#8217;s stockholders on or about July</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">26, 2024.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, CO&#160;80021</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">NOTICE OF SPECIAL MEETING OF STOCKHOLDERS IN LIEU OF ANNUAL MEETING OF STOCKHOLDERS</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To the stockholders of ARCA biopharma, Inc.:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">NOTICE IS HEREBY GIVEN</span> that a special meeting in lieu of annual meeting of stockholders (the &#8220;ARCA special meeting&#8221;) will be held on Thursday, August<span class="nobreak"> </span>22, 2024 at 9:00 a.m. Mountain Time, unless postponed or adjourned to a later date. The ARCA special meeting will be held in person at the Denver Marriott Westminster, 7000 Church Ranch Blvd, Westminster, Colorado 80021.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The ARCA special meeting will be held for the following purposes:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve (i)&#160;the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to the accompanying proxy statement/prospectus, and (ii)&#160;the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a)&#160;and 5635(b), respectively;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve an amendment to the amended and restated certificate of incorporation of ARCA (the &#8220;ARCA Charter&#8221;) to increase the number of shares of ARCA common stock that ARCA is authorized from 100,000,000 to issue to 545,000,000, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to the accompanying proxy statement/prospectus;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range between 6:1 to 12:1, inclusive, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H </span>to the accompanying proxy statement/prospectus, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, determined solely by ARCA&#8217;s board of directors;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I </span>to the accompanying proxy statement/prospectus;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To elect the Class&#160;III director, Jacob Ma<span class="nobreak">-Weaver</span>, to ARCA&#8217;s board of directors and to hold office until ARCA&#8217;s 2027 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal, provided that if the Merger is consummated, the approval of Proposal&#160;No. 5 will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To ratify the appointment of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for fiscal year ending December&#160;31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>To approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal; and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To transact such other business as may properly come before the stockholders at the ARCA special meeting or any adjournment or postponement thereof.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These proposals are collectively referred to as the &#8220;Proposals.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors has fixed July<span class="nobreak"> </span>22, 2024 as the record date (the &#8220;Record Date&#8221;) for the determination of stockholders entitled to notice of, and to vote at, the ARCA special meeting and any adjournment or postponement thereof. Only holders of record of shares of ARCA common stock at the close of business on the Record Date are entitled to notice of, and to vote at, the ARCA special meeting. At the close of business on the Record Date, ARCA had 14,507,143<span class="nobreak"> </span>shares of common stock outstanding and entitled to vote.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Your vote is important. The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">1, Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">6, Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">7, Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">8, Proposal&#160;No. 9 and Proposal&#160;No. 10. The affirmative vote of a majority of the votes properly cast by the holders of ARCA common stock at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;No. 2 and Proposal&#160;No. 3. The affirmative vote of a majority of the outstanding shares of ARCA common stock is required for approval of Proposal&#160;No. 4. With respect to Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">5, the director is elected by a plurality of the votes properly cast at the ARCA special meeting, and the one nominee for director receiving the highest number of affirmative votes properly cast will be elected. Proposal&#160;No. 1 is conditioned on the approval of Proposal&#160;No. 2. Notwithstanding the approval of Proposal&#160;No.</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">1, if Proposal&#160;No. 2 is not approved, the actions contemplated by Proposal&#160;No. 1 will not be effected and the Merger will not be consummated.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">All stockholders are cordially invited to attend the special meeting in person. Even if you plan to attend the ARCA special meeting, ARCA requests that you sign and return the enclosed proxy or vote by mail or online to ensure that your shares will be represented at the ARCA special meeting if you are unable to attend. You may change or revoke your proxy at any time before it is voted at the ARCA special meeting.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;S BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT EACH OF THE PROPOSALS OUTLINED ABOVE IS FAIR TO, IN THE BEST INTERESTS OF, AND ADVISABLE TO ARCA AND ITS STOCKHOLDERS AND HAS APPROVED EACH SUCH PROPOSAL.&#160;ARCA&#8217;S BOARD OF DIRECTORS RECOMMENDS THAT ARCA STOCKHOLDERS VOTE &#8220;FOR&#8221; EACH SUCH PROPOSAL.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Important Notice Regarding the Availability of Proxy Materials for the Stockholders&#8217; Meeting to Be Held on August</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">22, 2024 at 9:00 a.m. Mountain Time</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The proxy statement/prospectus, which also serves as the annual report to stockholders in connection with the special meeting in lieu of annual meeting, is available at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com.</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">By Order of ARCA&#8217;s Board of Directors,</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Thomas A.&#160;Keuer</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">President and Chief Operating Officer</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">July<span class="nobreak"> </span>22, 2024</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">EXPLANATORY NOTE</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" name="dei:AmendmentDescription" id="ixv-459">The issuances of (i)&#160;all shares of ARCA common stock in exchange for each share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing), (ii)&#160;all shares of ARCA common stock issuable upon exercise of pre<span class="nobreak">-funded</span> warrants issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing, and (iii)&#160;all shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for each share of Oruka preferred stock, are intended to be covered by this registration statement on Form&#160;S<span class="nobreak">-4</span> of which the accompanying proxy statement/prospectus is a part. There is no difference between the shares of ARCA common stock that will be issued in exchange for each share of Oruka common stock issued in the pre<span class="nobreak">-closing</span> financing, the shares of ARCA common stock that will be issued in exchange for each other share of Oruka common stock, the shares of ARCA common stock that will be issuable upon the exercise of pre<span class="nobreak">-funded</span> warrants that will be issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the pre<span class="nobreak">-closing</span> financing and the shares of ARCA common stock that will be issuable upon conversion of ARCA Series&#160;B Preferred Stock that will be issued in exchange for each share of Oruka preferred stock.</ix:nonNumeric></p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">REFERENCES TO ADDITIONAL INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying proxy statement/prospectus incorporates important business and financial information about ARCA biopharma, Inc. that is not included in or delivered with this document. You may obtain this information without charge through the Securities and Exchange Commission (&#8220;SEC&#8221;) website (<span class="Italic" style="font-style:italic;font-weight:normal;">www.sec.gov</span>) or upon your written or oral request by contacting 10170 Church Ranch Way, Suite 100, Westminster, Colorado, Attention: Corporate Secretary, or by calling (720)&#160;940<span class="nobreak">-2100</span>. ARCA also maintains a website at <span class="Italic" style="font-style:italic;font-weight:normal;">https://arcabio.com/</span>, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC.&#160;However, the information contained in or accessible through ARCA&#8217;s website is not part of the accompanying proxy statement/prospectus or the registration statement of which the accompanying proxy statement/prospectus forms a part.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">To ensure timely delivery of these documents, any request should be made no later than August</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">9, 2024 to receive them before the ARCA special meeting.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For additional details about where you can find information about ARCA, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Where You Can Find More Information</span>&#8221; beginning on page 321 of the accompanying proxy statement/prospectus.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="TOC001"></a><p class="H1_TOC" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">TABLE OF CONTENTS</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;font-variant:normal;">Page</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T27"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">QUESTIONS AND ANSWERS ABOUT THE MERGER</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">iii</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T26"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROSPECTUS SUMMARY</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T25"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">MARKET PRICE AND DIVIDEND INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">14</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T24"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">RISK FACTORS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">15</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T23"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">88</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T22"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">THE SPECIAL MEETING IN LIEU OF ANNUAL MEETING OF ARCA STOCKHOLDERS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">91</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T991188"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">THE MERGER</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">96</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T21"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">THE MERGER AGREEMENT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">135</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T20"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">AGREEMENTS RELATED TO THE MERGER</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">153</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T19"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA DIRECTORS, OFFICERS AND CORPORATE GOVERNANCE</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">156</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T18"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ADDITIONAL INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">159</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T17"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA EXECUTIVE COMPENSATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">166</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T16"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA EQUITY COMPENSATION PLAN INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">172</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T15"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ORUKA EXECUTIVE COMPENSATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">173</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T14"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ORUKA DIRECTOR COMPENSATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">175</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9980"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">MATTERS BEING SUBMITTED TO A VOTE OF ARCA STOCKHOLDERS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">176</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9981"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 1 &#8212; THE NASDAQ STOCK ISSUANCE PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">176</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9982"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 2 &#8212; THE AUTHORIZED SHARE INCREASE PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">178</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9983"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 3 &#8212; THE REVERSE STOCK SPLIT PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">180</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9984"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 4 &#8212; THE OFFICER EXCULPATION PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">187</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9985"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 5 &#8212; THE DIRECTOR ELECTION PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">189</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9986"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 6 &#8212; THE AUDITOR RATIFICATION PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">190</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9992"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 7 &#8212; THE STOCK PLAN PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">191</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9993"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 8 &#8212; THE ESPP PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">194</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9994"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 9 &#8212; THE MERGER COMPENSATION PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">196</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9987"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PROPOSAL NO. 10 &#8212; THE ADJOURNMENT PROPOSAL</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">197</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T13"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA&#8217;S BUSINESS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">198</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T12"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ORUKA&#8217;S BUSINESS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">214</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9988"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ARCA&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">250</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T11"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">ORUKA&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">261</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T10"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">MANAGEMENT FOLLOWING THE MERGER</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">273</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9989"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS OF THE COMBINED COMPANY</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">280</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">284</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9990"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">NOTES TO THE UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">289</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T8"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">DESCRIPTION OF ARCA CAPITAL STOCK</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">296</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T7"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">COMPARISON OF RIGHTS OF HOLDERS OF ARCA CAPITAL STOCK AND ORUKA CAPITAL STOCK</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">301</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T6"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF ARCA</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">312</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T5"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF ORUKA</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">315</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T4"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">317</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T3"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">LEGAL MATTERS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">320</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T2"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">EXPERTS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">320</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T1"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">WHERE YOU CAN FIND MORE INFORMATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">321</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T9991"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">STOCKHOLDER PROPOSALS OR DIRECTOR NOMINATIONS FOR 2025 ANNUAL MEETING</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">322</span></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">i</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;font-variant:normal;">Page</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T111">INDEX TO FINANCIAL STATEMENTS</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">F-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T100"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;A AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">A-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T101"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;B OPINION OF LUCID CAPITAL MARKETS</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">B-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T102"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;C FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">C-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T103"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;D FORM OF ARCA STOCKHOLDER SUPPORT AGREEMENT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">D-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T104"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;E FORM OF LOCK-UP AGREEMENT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">E-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T105"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;F CERTIFICATE OF DESIGNATION OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">F-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T106"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;G CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE&#160;OF INCORPORATION OF ARCA BIOPHARMA, INC.&#160;TO REFLECT INCREASE&#160;IN AUTHORIZED SHARES</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">G-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T107"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;H CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE&#160;OF INCORPORATION OF ARCA BIOPHARMA, INC.&#160;TO REFLECT REVERSE&#160;STOCK SPLIT</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">H-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T108"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;I CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE&#160;OF INCORPORATION OF ARCA BIOPHARMA, INC.&#160;TO REFLECT DELAWARE&#160;LAW PROVISIONS REGARDING OFFICER EXCULPATION</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">I-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T109"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">Annex&#160;J Appraisal Rights (Section&#160;262 of the Delaware General Corporation&#160;Law)</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">J-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T110"><span class="CharOverride-2" style="font-variant:normal;text-transform:uppercase;">Annex&#160;K 2024 Oruka Therapeutics, Inc. Stock Incentive Plan</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">K-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T112"><span class="CharOverride-2" style="font-variant:normal;text-transform:uppercase;">Annex&#160;L 2024 Oruka Therapeutics, Inc. Employee Stock Purchase Plan</span></a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">L-1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T881">ANNEX M FORM OF ARCA BIOPHARMA, INC. PROXY CARD</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="AllCaps" style="font-variant:normal;text-transform:uppercase;">M-1</span></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">ii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T27"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">QUESTIONS AND ANSWERS ABOUT THE MERGER</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal&#160;No.&#160;3 of this proxy statement/prospectus</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">All references to Oruka&#8217;s &#8220;product candidates,&#8221; &#8220;programs,&#8221; &#8220;portfolio&#8221; and &#8220;pipeline&#8221; in this proxy statement/prospectus refer to the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to those certain antibody discovery and option agreements, each dated March&#160;6, 2024 and subsequently amended and restated on March&#160;28, 2024, by and among Oruka, Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) and Paruka Holding LLC (&#8220;Paruka&#8221;) (the &#8220;Paragon Option Agreements&#8221;).</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following section provides answers to frequently asked questions about the Merger. This section, however, provides only summary information. For a more complete response to these questions and for additional information, please refer to the cross<span class="nobreak">-referenced</span> sections.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What is the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>On April&#160;3, 2024, ARCA, Oruka, First Merger Sub and Second Merger Sub entered into the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span>.&#160;The Merger Agreement contains the terms and conditions of the proposed Merger. Pursuant to the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger. Oruka will then merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger. This entire transaction is referred to in this proxy statement/prospectus as the Merger. In connection with the Merger, ARCA will change its corporate name to &#8220;Oruka Therapeutics, Inc.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio (described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 136 of this proxy statement/prospectus), (ii)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the exchange ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement, and (iv)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and the form of warrant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Each share of ARCA common stock that is issued and outstanding at the First Effective Time will remain issued and outstanding in accordance with its terms and such shares, subject to the proposed reverse stock split, will be unaffected by the Merger. Immediately after the Merger, based solely on the estimated exchange ratio as described in this proxy statement/prospectus, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), and former holders of Oruka securities (including those issued in the Oruka pre<span class="nobreak">-closing</span> financing) are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. Under certain circumstances described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 136 of this proxy statement/prospectus, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash as of closing is less than $5.0&#160;million. ARCA currently estimates that its net cash as of closing will be approximately $5.0<span class="nobreak"> </span>million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">In addition, prior to the First Effective Time, ARCA&#8217;s board of directors expects to declare the special cash dividend to stockholders of record of outstanding shares of ARCA common stock as of the record date prior to the First Effective Time, to be set by ARCA&#8217;s board of directors as close as reasonably practicable to (but not later than) the First Effective Time. The ex<span class="nobreak">-dividend</span> date in respect of such special cash dividend </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">iii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">will be determined by Nasdaq. ARCA stockholders of record who continue to hold their eligible shares of ARCA common stock until market open on the ex<span class="nobreak">-dividend</span> date will be entitled to payment of the special cash dividend. The special cash dividend will be equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) is expected to exceed $5.0&#160;million. ARCA currently estimates that the aggregate amount of cash to be distributed to stockholders of record as of the record date for the special cash dividend will be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Why are the two companies proposing to merge?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA and Oruka believe that combining the two companies will result in a company with a promising pipeline, a strong leadership team and substantial capital resources, focused on developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. For a more complete description of the reasons for the Merger, please see the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;ARCA&#8217;s Reasons for the Merger</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;Oruka&#8217;s Reasons for the Merger</span>&#8221; beginning on pages 104 and 110, respectively, of this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What will happen to ARCA if, for any reason, the merger with Oruka does not close?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA has invested significant time and incurred, and expects to continue to incur, significant expenses related to the proposed merger with Oruka. In the event the Merger does not close, ARCA will have a limited ability to continue its current operations without obtaining additional financing. Although ARCA&#8217;s board of directors may elect, among other things, to attempt to complete another strategic transaction if the merger with Oruka does not close, ARCA&#8217;s board of directors may instead divest all or a portion of ARCA&#8217;s business or take steps necessary to liquidate or dissolve ARCA&#8217;s business and assets if a viable alternative strategic transaction is not available. If ARCA decides to dissolve and liquidate its assets, ARCA would be required to pay all of its contractual obligations, and to set aside certain reserves for potential future claims, and there can be no assurance as to the amount of and the timing of such liquidation and distribution of available cash left to distribute to stockholders after paying the obligations of ARCA and setting aside funds for reserves.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Why am&#160;I receiving this proxy statement/prospectus?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>You are receiving this proxy statement/prospectus because you have been identified as a stockholder of ARCA as of the applicable Record Date, and you are entitled to vote to approve the matters set forth herein. This document serves as:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a proxy statement of ARCA used to solicit proxies for the ARCA special meeting to vote on the matters set forth herein;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a prospectus of ARCA used to offer (i)&#160;shares of ARCA common stock issued in exchange for shares of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing), (ii)&#160;shares of ARCA common stock issuable upon exercise of pre<span class="nobreak">-funded</span> warrants issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing, and (iii)&#160;shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for shares of Oruka preferred stock in the Merger; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the annual report of ARCA provided in connection with the special meeting in lieu of annual meeting.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What is the Oruka pre</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-closing</span></span><span class="Bold" style="font-style:normal;font-weight:bold;"> financing?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>On April&#160;3, 2024, concurrently with the execution and delivery of the Merger Agreement, Oruka entered into the Subscription Agreement with certain investors named therein, including, among others, Fairmount, Venrock Healthcare Capital Partners, RTW Investments, Access Biotechnology, Commodore Capital, Deep Track Capital, Perceptive Advisors, Blackstone Multi<span class="nobreak">-Asset</span> Investing, Avidity Partners, Great Point Partners LLC, Paradigm BioCapital, Braidwell LP and Redmile Group, pursuant to which such investors agreed to purchase shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock for an aggregate purchase price of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note). Shares of Oruka common stock and&#160;pre<span class="nobreak">-funded</span>&#160;warrants issued pursuant to this financing transaction will be converted into shares of ARCA common stock and&#160;pre<span class="nobreak">-funded</span>&#160;warrants to acquire shares ARCA common stock, in accordance with the exchange ratio and the Merger Agreement.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">iv</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Immediately after the First Merger, the shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants issued in the Oruka pre<span class="nobreak">-closing</span> financing are expected to represent approximately 63% of the outstanding shares of common stock of the combined company, on a fully<span class="nobreak">-diluted</span> basis. ARCA, Oruka and the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing have also agreed to enter into a registration rights agreement at the closing of the Oruka pre<span class="nobreak">-closing</span> financing, pursuant to which, among other things, the combined company will agree to provide for the registration and resale of certain shares of ARCA common stock that are held by the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing from time to time pursuant to Rule&#160;415. The closing of the Oruka pre<span class="nobreak">-closing</span> financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the Merger as well as certain other conditions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">For a more complete description of the Oruka pre<span class="nobreak">-closing</span> financing, please see the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Subscription Agreement</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">&#8212;&#160;Registration Rights Agreement</span>&#8221; beginning on pages&#160;153 and 155 of this proxy statement/prospectus, respectively.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What proposals will be voted on at the ARCA special meeting in connection with the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Pursuant to the terms of the Merger Agreement, the following proposals must be approved by the requisite stockholder vote at the ARCA special meeting in order for the Merger to close:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No. 1 &#8212;&#160;The Nasdaq Stock Issuance Proposal</span> to approve (i)&#160;the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to this proxy statement/prospectus, and (ii)&#160;the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a)&#160;and 5635(b), respectively;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No. 2 &#8212;&#160;Authorized Share Increase Proposal</span> to approve an amendment to the ARCA Charter to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000 to 545,000,000, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to this proxy statement/prospectus;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Additionally, Proposal&#160;No. 2 must be approved to have an adequate number of authorized but unissued shares of ARCA common stock to complete the Merger; and</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No. 3 &#8212;&#160;Reverse Stock Split Proposal</span> to approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range between 6:1 to 12:1, inclusive, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, determined solely by ARCA&#8217;s board of directors, the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H</span> to this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">Each of Proposal&#160;No. 1 and Proposal&#160;No. 2 is a condition to completion of the Merger. The issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and ARCA Series&#160;B Preferred Stock in connection with the Merger and the change of control of ARCA resulting from the Merger will not take place unless Proposal&#160;No. 1 and Proposal&#160;No. 2 are approved by ARCA stockholders and the Merger is consummated. ARCA&#8217;s board of directors may determine to effect the authorized share increase or the reverse stock split if one or both are approved and Proposal&#160;No. 1 is not approved by ARCA stockholders, following the special meeting.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">In addition to the requirement of obtaining ARCA stockholder approval of Proposal&#160;No. 1 and Proposal&#160;No.<span class="nobreak"> </span>2, the closing of the Merger is subject to the satisfaction or waiver of each of the other closing conditions set forth in the Merger Agreement. For a more complete description of the closing conditions under the Merger Agreement, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Conditions to the Completion of the Merger</span>&#8221; beginning on page 148 of this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">The presence, by attending in person or being represented by proxy, at the ARCA special meeting of the holders of at least one<span class="nobreak">-third</span> of the shares of ARCA common stock outstanding and entitled to vote at the ARCA special meeting is necessary to constitute a quorum at the meeting for the Proposals.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">v</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What proposals are to be voted on at the ARCA special meeting, other than the Nasdaq Stock Issuance Proposal, the Reverse Stock Split Proposal and the Authorized Share Increase Proposal?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>At the ARCA special meeting, the holders of ARCA common stock will also be asked to consider the following proposal:</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;4 &#8212;&#160;The Officer Exculpation Proposal</span> to approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I</span>;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;5 &#8212;&#160;The Director Election Proposal</span> to elect one (1)&#160;Class&#160;III director nominee named in the accompany proxy statement/prospectus to ARCA&#8217;s board of directors, to serve until ARCA&#8217;s 2027 annual meeting of stockholders or until his successor has been duly elected and qualified, or until his earlier death, resignation or removal;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;6 &#8212;&#160;The Auditor Ratification Proposal</span> to ratify the selection of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2024;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;7 &#8212;&#160;The Stock Plan Proposal</span> to approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;8 &#8212;&#160;The ESPP Proposal</span> to approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan;</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;9 &#8212;&#160;The Merger Compensation Proposal</span> to approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger; and</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Proposal&#160;No.&#160;10 &#8212;&#160;The Adjournment Proposal</span> to approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">The approval of Proposal&#160;Nos.<span class="nobreak"> </span>3,<span class="nobreak"> </span>4,<span class="nobreak"> </span>5,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10 are not a condition to the Merger. ARCA does not expect that any matter other than the Proposals will be brought before the ARCA special meeting.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">The presence, by attending in person or being represented by proxy, at the ARCA special meeting of the holders of at least one<span class="nobreak">-third</span> of the shares of ARCA common stock outstanding and entitled to vote at the ARCA special meeting is necessary to constitute a quorum at the meeting for the purpose of approving the Proposals.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What stockholder votes are required to approve the Proposals at the ARCA special meeting?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10. The affirmative vote of a majority of the votes properly cast by the holders of ARCA common stock at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;Nos. 2 and 3. The affirmative vote of a majority of the outstanding shares of ARCA common stock is required for approval of Proposal&#160;No. 4. With respect to Proposal&#160;No.&#160;5, directors are elected by a plurality of the votes properly cast at the ARCA special meeting, and the one nominee for director receiving the highest number of affirmative votes properly cast will be elected. Proposal&#160;No. 1 is conditioned on the approval of Proposal&#160;No. 2. Notwithstanding the approval of Proposal&#160;No.<span class="nobreak"> </span>1, if Proposal&#160;No. 2 is not approved, the actions contemplated by Proposal&#160;No. 1 will not be effected and the Merger will not be consummated.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What will Oruka stockholders, participants in Oruka&#8217;s 2024 Equity Incentive Plan, option holders and warrant holders receive in the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Oruka stockholders will receive shares of ARCA common stock. ARCA will assume Oruka&#8217;s 2024 Equity Incentive Plan, as amended, along with issued and outstanding awards under such plan. Outstanding and unexercised options to purchase shares of Oruka common stock immediately prior to the First Effective Time will be converted into options to purchase shares of ARCA&#8217;s common stock, with necessary adjustments being made to the number of shares and exercise price underlying such options in order to reflect the economic equivalent of the prior equity award in light of the exchange ratio. Oruka warrant holders&#8217; outstanding and </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">vi</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">unexercised warrants to purchase shares of Oruka common stock immediately prior to the First Effective Time will be assumed by ARCA and each outstanding and unexercised warrant will be converted into a warrant to purchase shares of ARCA&#8217;s common stock, with necessary adjustments to the number of shares and exercise price to reflect the exchange ratio. Applying the exchange ratio, the former Oruka securityholders immediately before the Merger are expected to own approximately 97.61% of the aggregate number of shares of the combined company&#8217;s capital stock following the Merger (on a fully<span class="nobreak">-diluted</span> basis), and ARCA securityholders immediately before the Merger are expected to own approximately 2.39% of the aggregate number of shares of the combined company capital stock following the Merger (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash less than $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">For a more complete description of the treatment of Oruka common stock, Oruka&#8217;s 2024 Equity Incentive Plan, Oruka options and Oruka warrants in the Merger, please see the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Merger Consideration</span>&#8221;<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>and<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>&#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on pages 135 and 136, respectively, of this proxy statement/prospectus. For a description of the effect of the Oruka pre<span class="nobreak">-closing</span> financing on ARCA&#8217;s and Oruka&#8217;s current securityholders, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Subscription Agreement</span>&#8221; beginning on page 153 of this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Will the common stock of the combined company trade on an exchange?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Shares of ARCA common stock are currently listed on Nasdaq under the symbol &#8220;ABIO.&#8221; ARCA intends to file an initial listing application for the common stock of the combined company with Nasdaq. After completion of the Merger, ARCA will be renamed &#8220;Oruka Therapeutics, Inc.&#8221; and it is expected that the common stock of the combined company will trade on Nasdaq under the symbol &#8220;ORKA.&#8221; It is a condition to the consummation of the Merger that ARCA will receive confirmation from Nasdaq that the combined company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that ARCA will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties. </p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">On July<span class="nobreak"> </span>19, 2024, the last&#160;trading day before the date of this proxy statement/prospectus, the closing sale price of ARCA common stock was $3.29 per share.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Who will be the directors of the combined company immediately following the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Immediately following the Merger, the combined company&#8217;s board of directors will be composed of six members, all of whom will have been designated by Oruka.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">Effective as of the First Effective Time, ARCA&#8217;s board of directors will appoint the following Oruka designees: Lawrence Klein, Kristine Ball, Carl Dambkowski, Peter Harwin, Samarth Kulkarni and Cameron Turtle, to the board of directors of the combined company and concurrently therewith all of ARCA&#8217;s current directors will resign from their positions as directors of ARCA&#8217;s board of directors effective as of the First Effective Time. Dr.&#160;Kulkarni is expected to be appointed as Chair of the board of directors of the combined company.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:8pt;">The staggered structure of three classes of directors of ARCA&#8217;s board of directors will remain in place for the combined company following the completion of the Merger. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Management Following the Merger</span>&#8221; for additional information.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">vii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Who will be the executive officers of the combined company immediately following the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Immediately following the Merger, the executive management team of the combined company is expected to consist of the following members of the Oruka executive management team:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Title</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President, Chief Executive Officer and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Senior Vice President, Finance and Treasurer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Medical Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">General Counsel and Secretary</p>
					</td>
				</tr>

		</table>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>As an ARCA stockholder, how does ARCA&#8217;s board of directors recommend that&#160;I vote?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA&#8217;s board of directors, in consultation with financial and legal advisors and management, evaluated the terms of the Merger Agreement and the related transactions contemplated thereby and: (i)&#160;determined that the Merger and the related transactions contemplated by the Merger Agreement are fair to, advisable and in the best interests of ARCA and its stockholders; (ii)&#160;approved and declared advisable the Merger Agreement and the related transactions contemplated by the Merger Agreement and the Subscription Agreement, including the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, in connection with the Merger and the Oruka pre<span class="nobreak">-closing</span> financing, respectively; and (iii)&#160;recommends that ARCA&#8217;s stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; each of the Proposals.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What risks should&#160;I consider in deciding whether to vote in favor of the Merger?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>You should carefully review the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; beginning on page 15 of this proxy statement/prospectus and the documents incorporated by reference herein, which set forth certain risks and uncertainties related to the Merger, risks and uncertainties to which the combined company&#8217;s business will be subject, and risks and uncertainties to which each of ARCA and Oruka, as independent companies, are subject.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>When do you expect the Merger to be consummated?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The Merger is anticipated to close in the third quarter of 2024, but the exact timing cannot be predicted. For more information, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Conditions to the Completion of the Merger</span>&#8221; beginning on page 148 of this proxy statement/prospectus.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What do&#160;I need to do now?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA urges you to read this proxy statement/prospectus carefully, including the annexes and the documents incorporated by reference, and to consider how the Merger affects you.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stockholder of Record: Shares Registered in Your Name</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">If you are a stockholder of record, you may vote in person at the ARCA special meeting, vote by proxy over the telephone, vote by proxy through the Internet or vote by proxy using a proxy card that you may request or that we may elect to deliver at a later time, the form of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex M</span>. Whether or not you plan to attend the meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the meeting and vote in person even if you have already voted by proxy.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote in person, come to the special meeting and we will give you a ballot when you arrive.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote using the proxy card, simply complete, sign and date the proxy card that you may request or that we may elect to deliver at a later time and return it promptly in the envelope provided. If you return your signed proxy card to us before the special meeting, we will vote your shares as you direct.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote over the telephone, dial toll<span class="nobreak">-free</span> 1<span class="nobreak">-800-652-VOTE</span> (8683) using a touch<span class="nobreak">-tone</span> phone and follow the recorded instructions. You will be asked to provide the company number and control number found on the Notice. Your vote must be received by 1:00 a.m. Mountain Time on August<span class="nobreak"> </span>22, 2024 to be counted.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">viii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote through the Internet, go to <span class="Italic" style="font-style:italic;font-weight:normal;">http://www.investorvote.com/ABIO</span> to complete an electronic proxy card. You will be asked to provide the company number and control number from the Notice. Your vote must be received by 1:00 a.m. Mountain Time on August<span class="nobreak"> </span>22, 2024 to be counted.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Beneficial Owner: Shares Registered in the Name of Broker or Bank</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you should have received a Notice containing voting instructions from that organization rather than from ARCA.&#160;Simply follow the voting instructions in the Notice to ensure that your vote is counted. You may vote by telephone or over the Internet as instructed by your broker or bank. To vote in person at the ARCA special meeting, you must obtain a valid proxy from your broker, bank, or other agent. Follow the instructions from your broker or bank included with these proxy materials, or contact your broker or bank to request a proxy form.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What if&#160;I return a proxy card or otherwise vote but do not make specific choices?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, &#8220;For&#8221; the Nasdaq Stock Issuance Proposal, &#8220;For&#8221; the Authorized Share Proposal, &#8220;For&#8221; the Reverse Stock Split Proposal, &#8220;For&#8221; the Officer Exculpation<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>Proposal, &#8220;For&#8221; the Director Election Proposal, &#8220;For&#8221; the Auditor Ratification Proposal, &#8220;For&#8221; the Stock Plan Proposal, &#8220;For&#8221; the ESPP Proposal, &#8220;For&#8221; the Merger Compensation Proposal, and &#8220;For&#8221; the Adjournment Proposal. If any other matter is properly presented at the meeting, your proxy holder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What happens if&#160;I do not return a proxy card or otherwise vote or provide proxy instructions, as applicable?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If you are an ARCA stockholder, the failure to return your proxy card or otherwise vote or provide proxy instructions will reduce the aggregate number of votes required to approve Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8,<span class="nobreak"> </span>9, and 10.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If my ARCA shares are held in &#8220;street name&#8221; by my broker and&#160;I do not provide my broker or bank with voting instructions, what happens?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If you are a beneficial owner of shares held in street name and you do not instruct your broker, bank or other agent how to vote your shares, your broker, bank or other agent may still be able to vote your shares in its discretion or your shares may constitute &#8220;broker non<span class="nobreak">-votes</span>.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">If an ARCA stockholder does not return voting instructions to their broker on how to vote their shares of ARCA common stock, such broker may be prevented from voting, or may otherwise choose not to vote, such shares held by such broker, resulting in broker non<span class="nobreak">-votes</span> with respect to such shares. To make sure that your vote is counted, you should instruct your broker to vote your shares of ARCA common stock, following the procedures provided by your broker.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What are broker non</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-votes</span></span><span class="Bold" style="font-style:normal;font-weight:bold;"> and do they count for determining a quorum?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Generally, a &#8220;broker non<span class="nobreak">-vote</span>&#8221; occurs when shares held by a broker are not voted with respect to a particular proposal because the broker has not received voting instructions from its client(s)&#160;with respect to such shares on how to vote and does not have or did not exercise discretionary authority to vote on the matter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Broker non<span class="nobreak">-votes</span>, if any, will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the ARCA special meeting. Broker non<span class="nobreak">-votes</span>, if any, will not be counted as &#8220;votes properly cast&#8221; or &#8220;shares entitled to vote&#8221; and will therefore have no effect on Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>2,<span class="nobreak"> </span>3,<span class="nobreak"> </span>5,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and<span class="nobreak"> </span>10, but will have the same effect as votes &#8220;AGAINST&#8221; Proposal&#160;No. 4.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>May&#160;I revoke and/or change my vote after&#160;I have submitted a proxy or provided proxy instructions?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>ARCA stockholders of record, unless such stockholder&#8217;s vote is subject to a support agreement, may revoke and/or change their vote at any time before their proxy is voted at the ARCA special meeting in one of four ways:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You may submit another properly completed proxy with a later date by mail or via the internet.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You can provide your proxy instructions via telephone at a later date.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">ix</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You may send a notice that you are revoking your proxy over the internet, following the instructions provided on your proxy card.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You may attend the ARCA special meeting in person and vote during the meeting. Simply attending the ARCA special meeting will not, by itself, revoke your proxy and/or change your vote.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What are the material U.S.&#160;federal income tax consequences of the Merger to U.S.&#160;holders of Oruka common stock and Oruka preferred stock?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The Merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) for U.S. federal income tax purposes. As a result, subject to the limitations and qualifications described in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger &#8212; Material U.S. Federal Income Tax Consequences of the Merger</span>&#8221; beginning on page 128, a U.S. holder of Oruka stock (as defined in therein) will generally not recognize any gain or loss for U.S. federal income tax purposes on the receipt of ARCA stock (as defined therein) in the Merger. For a more complete discussion of the material U.S.&#160;federal income tax consequences of the Merger, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Consequences of the Merger</span>&#8221; beginning on page 128.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What are the material U.S.&#160;federal income tax consequences of the reverse stock split to holders of ARCA common stock?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The reverse stock split is intended to be treated as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)(1)(E) of the Code for U.S.&#160;federal income tax purposes. Assuming it so qualifies, a U.S.&#160;holder of ARCA common stock should not recognize gain or loss for U.S.&#160;federal income tax purposes upon the reverse stock split, except with respect to cash received in lieu of a fractional share of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">Please review the information in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Proposal&#160;No. 3 &#8212;&#160;The Reverse Stock Split Proposal&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Consequences of the Reverse Stock Split</span>&#8221; beginning on page&#160;184 of this proxy statement/prospectus for a more complete description of the material U.S.&#160;federal income tax consequences of the reverse stock split to a U.S.&#160;holder of ARCA common stock.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>What are the material U.S.&#160;federal income tax consequences of the special cash dividend that ARCA will declare and pay to holders of ARCA common stock?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The U.S.&#160;federal income tax consequences of a holder&#8217;s receipt of the special cash dividend generally should be treated first as a dividend to the extent of ARCA&#8217;s current and accumulated earnings and profits, then as a non<span class="nobreak">-taxable</span> return of capital to the extent of the holder&#8217;s basis in ARCA common stock, and then as capital gain from the sale or exchange of ARCA common stock with respect to any remaining amount. ARCA currently has an accumulated deficit and expects additional losses in the current period. Thus, ARCA expects most or all of the distribution of the special cash dividend to be treated as other than a dividend for U.S.&#160;federal income tax purposes. However, there can be no assurance that it will be so treated. Please review the information in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Considerations &#8212; Material U.S.&#160;Federal Income Tax Consequences of the Special Cash Dividend to Holders of ARCA Common Stock</span>&#8221; beginning on page 130 of this proxy statement/prospectus for a discussion of the material U.S.&#160;federal income tax consequences of the special cash dividend to holders of ARCA common stock.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Q:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Who can help answer my questions?</span></p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">A:<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If you are an ARCA stockholder and would like additional copies of this proxy statement/prospectus without charge or if you have questions about the Merger or related matters, including the procedures for voting your shares, you should contact:</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:0pt;text-align:center;text-indent:0pt;margin-top:8pt;">Innisfree M&amp;A Incorporated <br/>Banks and Brokers Call: (877) 750<span class="nobreak">-8310</span><br/>Stockholders Call Toll Free: (212) 750<span class="nobreak">-5833</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">x</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<a id="T26"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROSPECTUS SUMMARY</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This summary highlights selected information from this proxy statement/prospectus and may not contain all of the information that is important to you. To better understand the Merger and the proposals being considered at the ARCA special meeting, you should read this entire proxy statement/prospectus carefully, including the Merger Agreement and the other annexes to which you are referred in this proxy statement/prospectus, and the documents incorporated by reference therein. For more information, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Where You Can Find More Information</span>&#8221; beginning on page 321 of this proxy statement/prospectus. Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal&#160;No.<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>3 of this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The Companies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is a biotechnology company dedicated to applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. Precision medicine refers to the tailoring of medical treatment to the individual characteristics of patients, using genomic, non<span class="nobreak">-genomic</span> biomarker and other information that extends beyond routine diagnostic categorization. ARCA believes that when implemented correctly precision medicine can enhance therapeutic response, improve patient outcomes, and reduce healthcare costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s principal executive offices are located at 10170 Church Ranch Way, Suite 100, Westminster, CO&#160;80021, and its telephone number is (720)&#160;940<span class="nobreak">-2100</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka&#8217;s mission is to offer patients suffering from chronic skin diseases like psoriasis (&#8220;PsO&#8221;) the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as one or twice a year. Oruka is advancing a proprietary portfolio of antibodies that were engineered by Paragon and target the core mechanisms underlying PsO and other dermatologic and inflammatory diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s lead program, ORKA<span class="nobreak">-001</span>, is designed to target the p19 subunit of interleukin<span class="nobreak">-23</span> (IL<span class="nobreak">-23p19</span>) for the treatment of PsO.&#160;Oruka&#8217;s co<span class="nobreak">-lead</span> program, ORKA<span class="nobreak">-002</span>, is designed to target interleukin<span class="nobreak">-17A</span> and interleukin<span class="nobreak">-17F</span> for the treatment of PsO, psoriatic arthritis (&#8220;PsA&#8221;), and other conditions. These programs each bind their respective targets at high affinity and incorporate half<span class="nobreak">-life</span> extension technology with the aim to increase exposure and decrease dosing frequency. Oruka believes that its focused strategy, differentiated portfolio, and deep expertise position it to set a new treatment standard in large inflammatory and immunology (&#8220;I&amp;I&#8221;) markets with continued unmet need.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s principal executive offices are located at 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025, and its telephone number is (650)&#160;606<span class="nobreak">-7910</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">First Merger Sub</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">First Merger Sub is a direct, wholly owned subsidiary of ARCA and was formed solely for the purpose of carrying out the Merger. First Merger Sub&#8217;s principal executive offices are located at 10170 Church Ranch Way, Suite 100, Westminster, CO&#160;80021, and its telephone number is (720)&#160;940<span class="nobreak">-2100</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Second Merger Sub</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Second Merger Sub is a direct, wholly owned subsidiary of ARCA and was formed solely for the purpose of carrying out the Merger. Second Merger Sub&#8217;s principal executive offices are located at 10170 Church Ranch Way, Suite 100, Westminster, CO&#160;80021, and its telephone number is (720)&#160;940<span class="nobreak">-2100</span>.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The Merger</span> <span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 96)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the satisfaction or waiver of the conditions to closing set forth in the Merger Agreement, at the closing of the Merger, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger and as part of the same overall transaction, Oruka will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;s Reasons for the Merger</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (see page 104)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In reaching its decision to approve the Merger Agreement and the transactions contemplated by the Merger Agreement, ARCA&#8217;s board of directors considered a number of factors that it viewed as supporting its decision to approve the Merger Agreement, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The financial condition and prospects of ARCA and the risks associated with continuing to operate ARCA on a stand<span class="nobreak">-alone</span> basis as well as the risks of accomplishing those objectives;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; belief that, after a thorough review of strategic alternatives, including further advancing the development of its internal programs, entering into a licensing, sale or other strategic agreement related to certain assets sufficient to fund operations, combining with other potential strategic transaction candidates, and discussions with ARCA&#8217;s senior management, financial advisors and legal counsel, the Merger is more favorable to ARCA stockholders than the potential value that might have resulted from other strategic alternatives available to ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view that the $6.0&#160;million enterprise value ascribed to ARCA would provide the existing ARCA stockholders significant value for ARCA&#8217;s public listing and afford the ARCA stockholders a significant opportunity to participate in the potential growth of the combined company following the Merger at the negotiated exchange ratio while also receiving a cash payment on account of the special cash dividend; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view, following a review with ARCA&#8217;s management and advisors of Oruka&#8217;s current development and clinical trial plans, of the likelihood that the combined company would possess sufficient cash resources at the closing of the Merger to fund development of Oruka&#8217;s product candidates through upcoming value inflection points, including Oruka&#8217;s ongoing IND<span class="nobreak">-enabling</span> preclinical development work and its anticipated initiation of its Phase&#160;1 trials of ORKA<span class="nobreak">-001</span> in the first half of 2025 and Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Reasons for the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 110)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the course of reaching its decision to approve the Merger and the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing, Oruka&#8217;s board of directors held numerous meetings, consulted with Oruka&#8217;s senior management, legal counsel and financial advisors, and considered a wide variety of factors. Ultimately, Oruka&#8217;s board of directors concluded that a merger with ARCA, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, was the best option to generate capital resources to support the advancement of Oruka&#8217;s pipeline and fund the combined organization.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additional factors Oruka&#8217;s board of directors considered included the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Merger will potentially expand the access to capital and the range of investors available as a public company to support the clinical development of Oruka&#8217;s pipeline, compared to the capital and investors Oruka could otherwise gain access to if it continued to operate as a privately<span class="nobreak">-held</span> company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential benefits from increased public market awareness of Oruka and its pipeline;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical and current information concerning Oruka&#8217;s business, including its financial performance and condition, operations, management and preclinical and clinical data;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; belief that no alternatives to the Merger, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, were reasonably likely to create greater value for Oruka stockholders, after considering the various financing and other strategic options to enhance stockholder value that were considered by the Oruka board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; expectation that the Merger, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, would be a higher probability and more cost<span class="nobreak">-effective</span> means to access capital than other options considered, including an initial public offering (&#8220;IPO&#8221;);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expected financial position, operations, management structure and operating plans of the combined company (including the ability to support the combined company&#8217;s current and planned preclinical and clinical trials);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the business, history, operations, financial resources, assets, technology and credibility of ARCA; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s board of directors also considered a number of uncertainties and risks in its deliberations concerning the Merger, the Oruka pre<span class="nobreak">-closing</span> financing, and the other transactions contemplated by the Merger Agreement, including the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possibility that the Merger or Oruka pre<span class="nobreak">-closing</span> financing might not be completed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>there is no adjustment to the exchange ratio if ARCA&#8217;s net cash as of closing is above $5.0&#160;million, and thus Oruka stockholders are expected to own at least approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis) following the completion of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential effect of the $440,000 termination fee payable by Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential reduction of ARCA&#8217;s net cash to an amount below $5.0&#160;million prior to the closing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possibility that ARCA could consider certain unsolicited acquisition proposals;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs, time and effort involved in connection with completing the Merger, related disruptions or potential disruptions to Oruka&#8217;s business and related administrative challenges associated with combining the companies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the additional expenses and obligations to which Oruka&#8217;s business will be subject following the Merger as a public company; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>various other risks associated with the combined organization and the Merger, including the risks described in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; in this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Recommendation of ARCA&#8217;s Board of Directors </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 92)</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, pursuant to the Merger Agreement, and the change of control of ARCA resulting from the Merger, is fair to, in the best interests of, and advisable to, ARCA and its stockholders. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the approval of Nasdaq Stock Issuance Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that it is advisable and in the best interests of ARCA and its stockholders to approve the amendment to the ARCA Charter to effect the increase in authorized shares. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Authorized Share Increase Proposal as described in this proxy statement/prospectus.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that it is advisable and in the best interests of ARCA and its stockholders to approve the amendment to the ARCA Charter to effect the reverse stock split, if necessary. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the Reverse Stock Split Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the amendment to the ARCA Charter to provide for the exculpation of officers, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Officer Exculpation Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to elect Jacob Ma<span class="nobreak">-Weaver</span> to serve on the ARCAs board of directors in the class of directors with terms expiring at ARCA&#8217;s 2027 annual meeting of stockholders. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the director nominee named in the Director Election Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to ratify the selection of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December<span class="nobreak">&#160;</span>31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the Auditor Ratification Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes it that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the 2024 Stock Incentive Plan, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Stock Plan Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the 2024 Employee Stock Purchase Plan, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the ESPP Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Merger Compensation Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that adjourning the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal is fair to, in the best interests of, and advisable to, ARCA and its stockholders and has approved and adopted the proposal. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Adjournment Proposal, if necessary, as described in this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Interests of ARCA&#8217;s Directors and Executive Officers in the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 121)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In considering the recommendation of ARCA&#8217;s board of directors with respect to issuing shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, in the Merger and the other matters to be acted upon by the ARCA stockholders at the ARCA special meeting, the ARCA stockholders should be aware that ARCA&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of ARCA stockholders generally. These interests may present ARCA&#8217;s directors and executive officers with actual or potential conflicts of interest. These interests include the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>in connection with the Merger, each option to purchase shares of ARCA common stock held by ARCA&#8217;s executive officers and directors will accelerate and fully vest, and (i)&#160;each such option with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option and (ii)&#160;each other option to acquire shares of ARCA&#8217;s common stock will be cancelled for no consideration;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>certain of ARCA&#8217;s executive officers will be eligible to receive retention bonuses and severance payments in connection with the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>certain of ARCA&#8217;s directors will be eligible to receive special committee fees in connection with the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash will exceed $5.0&#160;million, and any of ARCA&#8217;s directors and executive officers that are also ARCA stockholders will share in any such cash dividend proportionally to their pre<span class="nobreak">-First</span> Merger ownership of ARCA common stock (see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of ARCA</span>&#8221; beginning on page 312 of this proxy statement/prospectus for additional information regarding ARCA&#8217;s directors&#8217; and officers&#8217; holdings of ARCA common stock; notably, Jacob Ma<span class="nobreak">-Weaver</span> and affiliated entities together hold 4,000,452<span class="nobreak"> </span>shares of ARCA common stock, representing over 27% of outstanding shares of ARCA common stock); and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>under the Merger Agreement, ARCA&#8217;s directors and executive officers are entitled to continued indemnification, expense advancement and insurance coverage.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the ARCA stockholders approve the proposals to be presented to the ARCA stockholders for consideration at the ARCA special meeting as contemplated by this proxy statement/prospectus. As of July<span class="nobreak"> </span>16, 2024, the directors and executive officers of ARCA owned or controlled 28.5% of the outstanding shares of ARCA common stock entitled to vote at the ARCA special meeting.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Interests of Oruka&#8217;s Directors and Executive Officers in the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 124)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In considering the recommendation of Oruka&#8217;s board of directors with respect to approving the Merger, stockholders should be aware that Oruka&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Oruka stockholders generally. These interests may present them with actual or potential conflicts of interest. These interests include the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>as of July<span class="nobreak"> </span>16, 2024, Oruka&#8217;s current non<span class="nobreak">-employee</span> directors and executive officers beneficially owned, in the aggregate, approximately 73.5% of the shares of Oruka capital stock, which for purposes of this subsection excludes any Oruka shares issuable upon exercise or settlement of Oruka options held by such individual;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Fairmount Healthcare Fund&#160;II L.P. (&#8220;Fairmount Fund&#160;II&#8221;), an affiliate of Peter Harwin, an Oruka director, currently holds shares of Oruka capital stock and an unsecured convertible promissory note with an initial principal amount of $25.0&#160;million at an interest rate of 12% per annum (the &#8220;Convertible Note&#8221;) of Oruka and has agreed to purchase shares and pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>in connection with the Merger, each option to purchase shares of Oruka common stock held by Oruka&#8217;s executive officers and directors, whether or not vested, will be converted into an option to purchase shares of the combined company&#8217;s common stock, on the same terms and conditions (including any vesting and acceleration provisions);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s directors and executive officers are expected to become directors and executive officers of the combined company upon completion of the Merger; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s directors and executive officers are entitled to certain indemnification and liability insurance coverage pursuant to the terms of the Merger Agreement.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Oruka stockholders approve the Merger as contemplated by this proxy statement/prospectus. As of July<span class="nobreak"> </span>16, 2024, the directors and executive officers of Oruka owned or controlled 73.5% of the outstanding shares of Oruka capital stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Opinion of Lucid Capital Markets to the ARCA Board</span> <span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 112)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;2, 2024, Lucid Capital Markets, LLC (&#8220;Lucid&#8221;) orally rendered its opinion to ARCA&#8217;s board of directors (which was subsequently confirmed in writing by delivery of Lucid&#8217;s written opinion addressed to ARCA&#8217;s board of directors dated April&#160;2, 2024), that, as of such date and based upon and subject to the various assumptions and limitations made, and such other factors Lucid deemed relevant upon the review undertaken by Lucid in preparing its opinion, the exchange ratio proposed to be paid by ARCA pursuant to the terms of the Merger Agreement was fair, from a financial point of view, to the holders of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The full text of the written opinion of Lucid, dated April&#160;2, 2024, which describes the assumptions made and the qualifications and limitations upon the review undertaken by Lucid in preparing its opinion, is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;B</span> to this proxy statement/prospectus and is incorporated herein by reference. <span class="Bold" style="font-style:normal;font-weight:bold;">Lucid&#8217;s financial advisory services and opinion were provided for the information and assistance of ARCA&#8217;s board of directors (in their capacity as directors and not in any other capacity) in connection with and for purposes of ARCA&#8217;s board of directors&#8217; consideration of the Merger and the opinion of Lucid addressed only the fairness, from a financial point of view, as of the date thereof, to the holders of ARCA common stock of the exchange ratio proposed to be paid by ARCA pursuant to the terms of the Merger Agreement. The opinion of Lucid did not address any other term or aspect of the Merger Agreement or the Merger and does not constitute a recommendation to any stockholder of ARCA or Oruka as to whether or how such holder should vote with respect to the Merger or otherwise act with respect to the Merger or any other matter.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The full text of the written opinion of Lucid should be read carefully in its entirety for a description of the assumptions made and qualifications and limitations upon the review undertaken by Lucid in preparing its opinion.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The Merger Agreement </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 135)</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Merger Consideration </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 135)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio (described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 136 of this proxy statement/prospectus), (ii)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the exchange ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement, and (iv)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and the form of warrant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately after the Merger, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully diluted basis), and former holders of Oruka securities are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis). Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash as of closing is lower than $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the First Effective Time, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $5.0&#160;million. ARCA management currently anticipates that ARCA&#8217;s net cash as of closing to be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Options and Oruka&#8217;s 2024 Equity Incentive Plan</span> <span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 174)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, ARCA will assume Oruka&#8217;s 2024 Equity Incentive Plan and each option to purchase shares of Oruka common stock that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be assumed and converted into an option to purchase shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Oruka stock option assumed by ARCA may be exercised solely for shares of ARCA common stock; (ii)&#160;the number of shares of ARCA common stock subject to each outstanding Oruka stock option assumed by ARCA will be determined by multiplying (A)&#160;the number of shares of Oruka common stock that were subject to such Oruka stock option assumed by ARCA, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of ARCA common stock; and (iii)&#160;the per share exercise price of each Oruka stock option assumed by ARCA will be determined by dividing (A)&#160;the per share exercise price of such Oruka stock option, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent. Each Oruka stock option assumed by ARCA will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Oruka stock option will otherwise remain unchanged.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each Oruka stock option shall, in accordance with its terms, continue to be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of ARCA common stock subsequent to the First Effective Time. In addition, the combined company&#8217;s compensation committee will succeed to the authority and responsibility of Oruka&#8217;s board of directors as administrator of the Oruka 2024 Equity Incentive Plan.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Warrants</span> <span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 139)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, each warrant to purchase shares of Oruka capital stock that is outstanding and unexercised immediately prior to the First Effective Time (including any pre<span class="nobreak">-funded</span> warrant issued pursuant to the Oruka pre<span class="nobreak">-closing</span>&#160;financing), whether or not vested, will be converted into a warrant to purchase shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Oruka warrant assumed by ARCA may be exercised solely for shares of ARCA common stock; (ii)&#160;the number of shares of ARCA common stock subject to each outstanding Oruka warrant assumed by ARCA will be determined by multiplying (A)&#160;the number of shares of Oruka common stock that were subject to such Oruka warrant, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of ARCA common stock; and (iii)&#160;the per share exercise price of each Oruka warrant assumed by ARCA will be determined by dividing (A)&#160;the per share exercise price of such Oruka warrant, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent. Each Oruka warrant assumed by ARCA will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Oruka warrant will otherwise remain unchanged.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each Oruka warrant shall, in accordance with its terms, continue to be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of ARCA common stock subsequent to the First Effective Time.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA Common Stock and ARCA Options</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 140)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except as contemplated by the proposed increase in the number of authorized shares of ARCA common stock described in Proposal No. 2 of this proxy statement/prospectus and the proposed reverse stock split of issued and outstanding ARCA common stock described in Proposal&#160;No. 3 of this proxy statement/prospectus, ARCA common stock will remain unaffected by the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, prior to the closing of the Merger, ARCA&#8217;s board of directors will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option to acquire shares of ARCA&#8217;s common stock with an exercise price per share greater than the Parent Closing Price, in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, (i)&#160;each option to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option and (ii)&#160;each other option to acquire shares of ARCA common stock will be cancelled for no consideration.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Conditions to the Completion of the Merger</span> (see page 148)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To complete the Merger, ARCA stockholders must approve Proposal&#160;No. 1 and Proposal&#160;No. 2 and Oruka stockholders must adopt the Merger Agreement and approve the Merger and the related transactions contemplated by the Merger Agreement. Additionally, each of the other closing conditions set forth in the Merger Agreement must be satisfied or waived.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non</span><span class="nobreak"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">-Solicitation</span></span> (see page 145)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains&#160;non<span class="nobreak">-solicitation</span>&#160;provisions prohibiting ARCA and Oruka from soliciting a competing transaction. Each of ARCA and Oruka have agreed that, subject to certain exceptions, ARCA and Oruka and any of their respective subsidiaries will not, nor will either party or any of its subsidiaries authorize or permit any of the directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors or representatives retained by it or any of its subsidiaries to, directly or indirectly:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of, any acquisition proposal or acquisition inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>furnish any non<span class="nobreak">-public</span> information with respect to it to any person in connection with or in response to an acquisition proposal or acquisition inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>engage in discussions or negotiations with any person with respect to any acquisition proposal or acquisition inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>execute or enter into any letter of intent or any contract contemplating or otherwise relating to any acquisition transaction; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>publicly propose to do any of the foregoing.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Board Recommendation Change</span> (see page 146)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Neither Oruka&#8217;s board of directors nor ARCA&#8217;s board of directors may change its recommendation in favor of the Merger, except that prior to receipt by such party of its stockholder approval, such party&#8217;s board of directors may effect a change in recommendation as a result of a material development or change in circumstances (&#8220;Intervening Event&#8221;) or with respect to a superior offer that did not result from a material breach of the Merger Agreement if:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such party&#8217;s board of directors shall have determined in good faith, based on the advice of its outside legal counsel, that the failure to effect such change in recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such party has provided at least four&#160;business days&#8217; prior written notice to the other party that it intends to effect a change in recommendation, and during such period has, and has caused its lead financial advisor and outside legal counsel to, negotiate with the other party in good faith to make such adjustments to the terms and conditions so that the acquisition proposal ceases to constitute a superior offer; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if after the other party shall have delivered to such party a written offer to alter the terms or conditions of the Merger Agreement during the four<span class="nobreak">-business</span>&#160;day period referred to above, such party&#8217;s board of directors shall have determined in good faith (based on the advice of its outside legal counsel), that the failure to effect a change in recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of any material amendment to any superior offer, the party considering the superior offer would be required to provide the other party with notice of such material amendment and there would be a new three<span class="nobreak">-business</span>&#160;day period following such notification during which the parties would be obligated to comply again with the requirements described above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the case of an Intervening Event, the party suffering such event shall promptly notify the other party before effecting a change in recommendation. The written notice is required to state the material facts and circumstances related to the applicable Intervening Event and that such party&#8217;s board of directors intends to make a change in recommendation.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination of the Merger Agreement </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 150)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Either ARCA or Oruka may terminate the Merger Agreement under certain circumstances, which would prevent the Merger from being consummated.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination Fee </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 151)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Merger Agreement is terminated under certain circumstances, ARCA could be required to pay Oruka a termination fee of $440,000 or Oruka could be required to pay ARCA a termination fee of $440,000.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Support Agreements </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 153)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain Oruka stockholders holding approximately 90% of the outstanding shares of Oruka capital stock have entered into support agreements with ARCA and Oruka to vote all of their shares of Oruka capital stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against any alternative acquisition proposals (the &#8220;Oruka Support Agreements&#8221;). Certain ARCA stockholders holding approximately 28.5% of the outstanding shares of ARCA common stock have entered into support agreements with ARCA and Oruka to vote all of their shares of ARCA common stock in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and the Reverse Stock Split Proposal and against any alternative acquisition proposals (the &#8220;ARCA Support Agreements,&#8221; and, together with the Oruka Support Agreements, the &#8220;Support Agreements&#8221;).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Lock-Up Agreements </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 153)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain of Oruka&#8217;s executive officers, directors and stockholders have entered into&#160;lock<span class="nobreak">-up</span>&#160;agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of ARCA&#8217;s common stock or any securities convertible into or exercisable or exchangeable for ARCA common stock, currently or thereafter owned, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for shares of Oruka preferred stock in the Merger, but excluding, as applicable, shares purchased in the Oruka pre<span class="nobreak">-closing</span>&#160;financing (including any shares of ARCA common stock issuable upon exercise of pre<span class="nobreak">-funded</span> warrants issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing), until 180&#160;days following the closing of the Merger.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Subscription Agreement and Registration Rights Agreement </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see pages 153 and 155)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately prior to the execution and delivery of the Merger Agreement, certain new and existing investors of Oruka entered into the Subscription Agreement with Oruka, pursuant to which such investors have agreed to purchase Oruka common stock or, in lieu thereof, Oruka pre<span class="nobreak">-funded</span> warrants, representing an aggregate commitment of $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note), in the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants that are issued in the Oruka pre<span class="nobreak">-closing</span> financing will be or will have the right to be, respectively, converted into shares of ARCA common stock in the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Subscription Agreement contains customary representations and warranties of Oruka and also contains customary representations and warranties of the purchaser parties thereto.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Subscription Agreement also contemplates ARCA, Oruka and the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing entering into a registration rights agreement at the closing of the Oruka pre<span class="nobreak">-closing</span> financing, pursuant to which, among other things, the combined company will agree to provide for the registration and resale of certain shares of ARCA common stock that are held by the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing from time to time pursuant to Rule&#160;415.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Management Following the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 273)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth the name, age as of July<span class="nobreak"> </span>22, 2024 and position of each of the individuals who are expected to serve as executives and directors of the combined company following completion of the Merger:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Age</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Position</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Executive Officers</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">42</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President, Chief Executive Officer and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">48</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Senior Vice President, Finance and Treasurer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">51</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Medical Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">61</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">General Counsel and Secretary</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-Employee Directors</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Samarth Kulkarni</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">45</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chair and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Kristine Ball</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">52</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Carl Dambkowski</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">39</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Peter Harwin</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">38</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cameron Turtle</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">34</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Material U.S.&#160;Federal Income Tax Consequences of the Merger </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 128)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code for U.S. federal income tax purposes. As a result, subject to the limitations and qualifications described in the section titled &#8220;The Merger &#8212; Material U.S. Federal Income Tax Consequences of the Merger&#8221; beginning on page 128, a U.S. holder of Oruka stock (as defined therein) will generally not recognize any gain or loss for U.S. federal income tax purposes on the receipt of ARCA stock in the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risk Factors </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 15)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Both ARCA and Oruka are subject to various risks associated with their businesses and their industries. In addition, the Merger, including the possibility that the Merger may not be completed, poses a number of risks to each company and its respective securityholders, including the following risks:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Risks Related to the Merger</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Failure to complete, or delays in completing, the potential merger with Oruka could materially and adversely affect ARCA&#8217;s results of operations, business, financial results and/or common stock price.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The exchange ratio will not change or otherwise be adjusted based on the market price of ARCA common stock.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka stockholders pursuant to the Merger Agreement and the resulting change in control from the First Merger must be approved by ARCA stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Oruka stockholders. Failure to obtain these approvals would prevent the closing of the Merger.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>If ARCA completes the Merger, the combined company will need to raise additional capital and satisfy certain contractual obligations by issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the combined company&#8217;s stockholders or restrict the combined company&#8217;s operations.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s expected disposal of its historical assets and operations in connection with its proposed Merger with Oruka will make it a shell company. As a result, ARCA will be subject to more stringent reporting requirements, offering limitations and resale restrictions.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Some of ARCA and Oruka directors and executive officers have interests in the Merger that are different from yours and that may influence them to support or approve the Merger without regard to your interests.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA stockholders and Oruka stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger, including the conversion of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Risks Related to ARCA</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Failure to complete, or delays in completing, the proposed merger with Oruka could expose ARCA to other operational and financial risks;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA has a limited operating history, no history of commercializing products, has not generated any product revenue, has incurred significant operating losses since inception and anticipates continuing to incur net losses for the foreseeable future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>If ARCA does not successfully consummate the Merger or another strategic transaction, ARCA&#8217;s board of directors may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>If the Merger is not consummated and should ARCA pursue additional clinical trials for its product candidates, it may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s failure to meet Nasdaq&#8217;s continued listing requirements could result in a delisting of its common stock, which could have a material adverse effect on its ability to consummate the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Risks Related to Oruka</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Even if the Merger and Oruka pre<span class="nobreak">-closing</span> financing are successful, Oruka will need to raise additional capital, and if it is unable to do so when needed, that will raise substantial doubt about Oruka&#8217;s ability to continue as a going concern. If Oruka is unable to raise such capital when needed, or on acceptable terms, Oruka may be forced to delay, reduce or eliminate clinical trials, product development programs or future commercialization efforts and/or file for bankruptcy or cease operations altogether;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka has never generated any revenue from product sales and may never be profitable;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka is a preclinical stage biopharmaceutical company with a limited operating history on which to assess its business; it has not initiated, conducted or completed any clinical trials, has no products approved for commercial sale, has historically incurred losses, and anticipates that it will continue to incur significant losses for the foreseeable future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s programs are in preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If Oruka or its current or future collaborators are unable to complete development of or commercialize Oruka&#8217;s product candidates, or experience significant delays in doing so, Oruka&#8217;s business will be materially harmed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka is substantially dependent on the success of its two most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>, and its anticipated clinical trials of such programs may not be successful;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka currently relies on licensing arrangements with Paragon through the Paragon Option Agreements. If Oruka is unable to maintain collaborations or licensing arrangements, or if its collaborations or licensing arrangements are not successful, Oruka&#8217;s business could be negatively impacted;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>In order to successfully implement Oruka&#8217;s plans and strategies, Oruka will need to grow the size of its organization and it may experience difficulties in managing this growth;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s ability to obtain and protect its patents and other proprietary rights is uncertain, exposing Oruka to the possible loss of competitive advantage; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The regulatory approval processes of the U.S.&#160;Food and Drug Administration (&#8220;FDA&#8221;) and other comparable foreign regulatory authorities are lengthy, time<span class="nobreak">-consuming</span> and inherently unpredictable. If Oruka is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its product candidates, Oruka will not be able to commercialize, or will be delayed in commercializing, its product candidates, and its ability to generate revenue will be materially impaired.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Risks Related to the Combined Company</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The market price of the combined company&#8217;s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The combined company may incur losses for the foreseeable future and might never achieve profitability;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The combined company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Provisions that will be in the combined company&#8217;s certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of the combined company more difficult and may prevent attempts by its stockholders to replace or remove its management;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>After completion of the Merger, the combined company&#8217;s executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The combined company will have broad discretion in the use of the cash and cash equivalents of the combined company and the proceeds from the Oruka pre<span class="nobreak">-closing</span> financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These risks and other risks are discussed in greater detail under the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; beginning on page 15 of this proxy statement/prospectus. ARCA and Oruka both encourage you to read and consider all of these risks carefully.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">12</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="BOXSTYLE" style="margin:0;padding:0;border-width:0;border-color:#000000;border-width:1pt;border: solid windowtext 1.0pt; padding: 10.0pt 4.0pt 10.0pt 4.0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Regulatory Approvals </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 128)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Oruka do not intend to seek any regulatory approval from antitrust authorities to consummate the transactions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Nasdaq Stock Market Listing </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 131)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka intends to file an initial listing application for the combined company common stock with Nasdaq. If such application is accepted, it is anticipated that the common stock of the combined company will be listed on Nasdaq following the closing of the Merger under the trading symbol &#8220;ORKA.&#8221; It is a condition to the consummation of the Merger that ARCA will receive confirmation from Nasdaq that the combined company has been approved for listing on Nasdaq, but there can be no assurance such listing condition will be met or that ARCA will obtain such confirmation from Nasdaq. If such listing condition is not met or if such confirmation is not obtained, the Merger will not be consummated unless the condition is waived. The Nasdaq condition set forth in the Merger Agreement is not expected to be waived by the applicable parties.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Anticipated Accounting Treatment </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 132)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is expected to be treated by ARCA as a reverse merger and will be accounted for as an in<span class="nobreak">-substance</span> reverse recapitalization of ARCA by Oruka in accordance with U.S.&#160;generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as, at close, the transaction is, in essence, the issuance of equity for ARCA&#8217;s net asset, which primarily consist of cash and other nominal non<span class="nobreak">-operating</span> assets and liabilities. For accounting purposes, Oruka is considered to be acquiring the assets and liabilities of ARCA in this transaction based on the terms of the Merger Agreement and other factors, including: (i)&#160;Oruka&#8217;s equity holders will own a substantial majority of the voting rights in the combined company; (ii)&#160;Oruka&#8217;s largest stockholder will retain the largest interest in the combined company; (iii)&#160;Oruka will designate all of the initial members of the board of directors of the combined company; and (iv)&#160;Oruka&#8217;s executive management team will become the management of the combined company. The combined company will be named Oruka Therapeutics, Inc. and be headquartered in Menlo Park, California. Accordingly, the Merger is expected to be treated as the equivalent of Oruka issuing stock to acquire the net assets of ARCA.&#160;As a result of the Merger, the net assets of ARCA will be stated at fair value, which approximates carrying value, with no goodwill or other intangible assets recorded, and the historical results of operations prior to the Merger will be those of Oruka. The direct and incremental costs related to the transaction will be treated as a reduction of the net proceeds received within additional paid<span class="nobreak">-in-capital</span>. See the &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; elsewhere in this proxy statement/prospectus for additional information.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal Rights and Dissenters&#8217; Rights </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 132)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Holders of ARCA common stock are not entitled to appraisal rights in connection with the Merger under Delaware law. Holders of Oruka capital stock are entitled to appraisal rights in connection with the Merger under Delaware law.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Comparison of Stockholder Rights </span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(see page 301)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Both ARCA and Oruka are incorporated under the laws of the State of Delaware and, accordingly, the rights of the stockholders of each are currently, and will continue to be, governed by the Delaware General Corporation Law (&#8220;DGCL&#8221;). If the Merger is completed, Oruka stockholders will become ARCA stockholders, and their rights will be governed by the DGCL, the amended and restated bylaws of ARCA (the &#8220;ARCA Bylaws&#8221;) and the ARCA Charter, as may be further amended by Proposal&#160;Nos.<span class="nobreak"> </span>2, 3 and 4 if approved by the ARCA stockholders at the ARCA special meeting. The rights of ARCA stockholders contained in the ARCA Charter and ARCA Bylaws differ from the rights of Oruka stockholders under the amended and restated certificate of incorporation of Oruka (the &#8220;Oruka Charter&#8221;) and bylaws of Oruka (the &#8220;Oruka Bylaws&#8221;), as more fully described under the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Comparison of Rights of Holders of ARCA Capital Stock and Oruka Capital Stock</span>&#8221; beginning on page 301 of this proxy statement/prospectus.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">13</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T25"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MARKET PRICE AND DIVIDEND INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA common stock is currently listed on The Nasdaq Capital Market under the symbol &#8220;ABIO.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The closing price of the ARCA common stock on April&#160;2, 2024, the last&#160;day of trading prior to the announcement of the Merger, as reported on The Nasdaq Capital Market, was $1.71 per share. The closing price of the ARCA common stock on July<span class="nobreak"> </span>19, 2024, as reported on The Nasdaq Capital Market, was $3.29 per share.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because the market price of the ARCA common stock is subject to fluctuation, the market value of the shares of the ARCA common stock that the Oruka stockholders will be entitled to receive in the Merger may increase or decrease.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a private company, and its shares of common stock and preferred stock are not publicly traded.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Assuming approval of Proposal&#160;Nos. 1 and 2 and successful application for initial listing with Nasdaq, following the consummation of the Merger, shares of ARCA common stock will trade on Nasdaq under ARCA&#8217;s new name, &#8220;Oruka Therapeutics, Inc.,&#8221; and new trading symbol &#8220;ORKA.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of July<span class="nobreak"> </span>22, 2024, the Record Date for the ARCA special meeting, there were approximately 14 registered holders of record of the ARCA common stock. As of July<span class="nobreak"> </span>22, 2024, Oruka had nine holders of record of Oruka common stock and one holder of record of Oruka preferred stock. For detailed information regarding the beneficial ownership of certain ARCA and Oruka stockholders, see the sections of this proxy statement/prospectus titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of ARCA</span>,&#8221; &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of Oruka</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of the Combined Company</span>.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Dividends</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has never declared or paid any cash dividends on the ARCA common stock and does not anticipate paying cash dividends on the ARCA common stock for the foreseeable future, except the&#160;special&#160;cash&#160;dividend&#160;that ARCA will declare and pay to the holders of record of outstanding shares of ARCA common stock as of a record date prior to the First Effective Time, to be set by ARCA&#8217;s board of directors as close as reasonably practicable to (but not later than) the anticipated closing date of the First Merger. The aggregate amount of the special cash dividend shall be up to an amount equal to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as calculated pursuant to the terms and conditions of the Merger Agreement) will exceed $5,000,000. Notwithstanding the foregoing, any determination to pay cash dividends subsequent to the Merger will be at the discretion of the combined organization&#8217;s then<span class="nobreak">-current</span> board of directors and will depend upon a number of factors, including the combined organization&#8217;s results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors the then<span class="nobreak">-current</span> board of directors deems relevant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has never paid or declared any cash dividends on Oruka capital stock. If the Merger does not occur, Oruka does not anticipate paying any cash dividends on the Oruka capital stock in the foreseeable future, and Oruka intends to retain all available funds and any future earnings to fund the development and expansion of its business. Any future determination to pay dividends will be at the discretion of the Oruka board of directors and will depend upon a number of factors, including its results of operations, financial condition, future prospects, contractual restrictions, and restrictions imposed by applicable laws and other factors the Oruka board of directors deems relevant.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">14</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T24"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">RISK FACTORS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The combined company will be faced with a market environment that cannot be predicted and that involves significant risks, many of which will be beyond its control. In addition to the other information contained or incorporated by reference in this proxy statement/prospectus, you should carefully consider the material risks described below before deciding how to vote your shares of ARCA common stock. You should also read and consider the other information in this proxy statement/prospectus. Please see the section titled &#8220;Where You Can Find More Information&#8221; beginning on page 321 of this proxy statement/prospectus for further information.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to the Merger</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Failure to complete, or delays in completing, the potential merger with Oruka, announced on April&#160;3, 2024, could materially and adversely affect ARCA&#8217;s results of operations, business, financial results and/or common stock price.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA entered into the Merger Agreement with Oruka, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Second Merger Sub, with Second Merger Sub continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger.&#160;Consummation of the Merger is subject to certain closing conditions, a number of which are not within ARCA&#8217;s control. Any failure to satisfy these required conditions to closing may prevent, delay or otherwise materially adversely affect the completion of the transaction. ARCA cannot predict with certainty whether or when any of the required closing conditions will be satisfied or if another uncertainty may arise and cannot assure you that it will be able to successfully consummate the Merger as currently contemplated under the Merger Agreement or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s efforts to complete the Merger could cause substantial disruptions in, and create uncertainty surrounding, its business, which may materially adversely affect its results of operation and its business. Uncertainty as to whether the Merger will be completed in a timely manner or at all may affect ARCA&#8217;s ability to retain and motivate existing employees. Uncertainty as to whether the Merger will be completed in a timely manner or at all could adversely affect ARCA&#8217;s business and its relationship with collaborators, suppliers, vendors, regulators and other business partners. For example, vendors, collaborators and other counterparties may defer their decisions to work with ARCA or seek to change their existing business relationships with ARCA.&#160;Changes to, or termination of, existing business relationships could adversely affect ARCA&#8217;s results of operations and financial condition, as well as the market price of ARCA common stock. The adverse effects of the pendency of the transaction could be exacerbated by any delays in completion of the transaction or termination of the Merger Agreement.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the conditions to the Merger are not satisfied or waived, the Merger may not occur.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if the Merger is approved by the stockholders of Oruka and ARCA, specified conditions must be satisfied or, to the extent permitted by applicable law, waived to complete the Merger. These conditions are set forth in the Merger Agreement and described further in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>&#8221; of this proxy statement/prospectus. ARCA cannot assure you that all of the conditions to the consummation of the Merger will be satisfied or waived. If the conditions are not satisfied or waived, the Merger may not occur or the closing may be delayed.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The exchange ratio will not change or otherwise be adjusted based on the market price of ARCA common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Applying the exchange ratio, the former Oruka securityholders immediately before the Merger are expected to own approximately 97.61% of the aggregate number of shares of the combined company&#8217;s capital stock following the Merger (on a fully<span class="nobreak">-diluted</span> basis), and ARCA securityholders immediately before the Merger are expected to own approximately 2.39% of the aggregate number of shares of the combined company capital stock following the Merger (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">15</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">closing being equal to $5.0&#160;million. In the event ARCA&#8217;s net cash is below $5.0&#160;million, the exchange ratio will be adjusted such that the number of shares issued to Oruka&#8217;s pre<span class="nobreak">-closing</span> securityholders will be increased, and ARCA stockholders will own a smaller percentage of the combined company following the consummation of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any changes in the market price of ARCA&#8217;s stock before the completion of the First Merger will not affect the number of shares Oruka stockholders will be entitled to receive pursuant to the Merger Agreement. Therefore, if before the completion of the First Merger, the market price of ARCA common stock increases from the market price on the date of the Merger Agreement, then Oruka stockholders could receive merger consideration with substantially more value for their shares of Oruka capital stock than the parties had negotiated when they established the exchange ratio. Similarly, if before the completion of the First Merger, the market price of ARCA common stock declines from the market price on the date of the Merger Agreement, then Oruka stockholders could receive merger consideration with substantially lower value. The Merger Agreement does not include a price<span class="nobreak">-based</span> termination right.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The issuance of ARCA common stock, including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka stockholders pursuant to the Merger Agreement and the resulting change in control from the First Merger must be approved by ARCA stockholders, and the Merger Agreement and transactions contemplated thereby must be approved by the Oruka stockholders. Failure to obtain these approvals would prevent the closing of the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before the Merger can be completed, ARCA stockholders must approve, among other things, the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka stockholders pursuant to the Merger Agreement and the resulting change in control from the First Merger, and Oruka stockholders must adopt the Merger Agreement and approve the Merger and the related transactions. Failure to obtain the required stockholder approvals may result in a material delay in, or the abandonment of, the Merger. Any delay in completing the Merger may materially adversely affect the timing and benefits that are expected to be achieved from the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The Merger may be completed even though a material adverse effect may result from the announcement of the Merger, industry-wide changes or other causes.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In general, neither ARCA nor Oruka is obligated to complete the Merger if there is a material adverse effect affecting the other party between April&#160;3, 2024, the date of the Merger Agreement, and the closing of the Merger. However, certain types of causes are excluded from the concept of a &#8220;material adverse effect.&#8221; Such exclusions include, but are not limited to, changes in general economic or political conditions, industry<span class="nobreak">-wide</span> changes, changes resulting from the announcement of the Merger, natural disasters, pandemics, other public health events or force majeure events and changes in U.S.&#160;generally accepted accounting principles. Therefore, if any of these events were to occur and adversely affect ARCA or Oruka, the other party would still be obliged to consummate the closing of the Merger notwithstanding such material adverse effect. If any such adverse effects occur and ARCA consummates the closing of the Merger, the stock price of the combined company may suffer. This in turn may reduce the value of the Merger to the stockholders of ARCA, Oruka or both.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the Merger is not completed, ARCA&#8217;s stock price may decline significantly.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The market price of ARCA common stock is subject to significant fluctuations. Market prices for securities of pharmaceutical, biotechnology and other life science companies have historically been particularly volatile. In addition, the market price of ARCA common stock will likely be volatile based on whether stockholders and other investors believe that ARCA can complete the Merger or otherwise raise additional capital to support ARCA&#8217;s operations if the Merger is not consummated and another strategic transaction cannot be identified, negotiated and consummated in a timely manner, if at all. The volatility of the market price of ARCA common stock has been and may be exacerbated by low trading volume. Additional factors that may cause the market price of ARCA common stock to fluctuate include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the entry into, or termination of, key agreements, including commercial partner agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>announcements by commercial partners or competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the loss of key employees;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">16</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>future sales of ARCA common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general and industry<span class="nobreak">-specific</span> economic conditions that may affect ARCA&#8217;s research and development expenditures; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>period<span class="nobreak">-to-period</span> fluctuations in financial results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of ARCA common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA completes the Merger, the combined company will need to raise additional capital and satisfy certain contractual obligations by issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the combined company&#8217;s stockholders or restrict the combined company&#8217;s operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, Oruka entered into the Subscription Agreement with certain investors, including existing investors of Oruka, pursuant to which the investors agreed to purchase, in the aggregate, $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note) in shares of common stock and pre<span class="nobreak">-funded</span> warrants of Oruka immediately prior to the closing of the Merger, referred to as the Oruka pre<span class="nobreak">-closing</span> financing. The closing of the Oruka pre<span class="nobreak">-closing</span> financing is conditioned upon the satisfaction or waiver of the conditions to the closing of the Merger as well as certain other conditions. The shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants issued in the Oruka pre<span class="nobreak">-closing</span> financing will result in dilution to all securityholders of the combined company (i.e., both ARCA&#8217;s pre<span class="nobreak">-Merger</span> securityholders and former Oruka securityholders). Furthermore, pursuant to the amended and restated offer letter agreement between Oruka and Lawrence Klein, Oruka is obligated to issue additional options to purchase shares of Oruka common stock in order to maintain Dr.&#160;Klein&#8217;s ownership in Oruka at approximately 5.0% on a fully<span class="nobreak">-diluted</span> basis (the &#8220;Target Ownership Percentage&#8221;) until Oruka has raised an aggregate of $200.0&#160;million (the &#8220;Covered Limit&#8221;). As a result, Oruka expects to issue Dr.&#160;Klein warrants of Oruka in full satisfaction of such obligation to maintain his ownership in Oruka at the Target Ownership Percentage concurrently with the closing of the Oruka pre<span class="nobreak">-closing</span> financing up to the Covered Limit. Such warrants will result in further dilution to all securityholders of the combined company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additional financing may not be available to the combined company when it is needed or may not be available on favorable terms. To the extent that the combined company raises additional capital by issuing equity securities, such financing will cause additional dilution to all securityholders of the combined company, including ARCA&#8217;s pre<span class="nobreak">-Merger</span> securityholders and Oruka&#8217;s former securityholders. It is also possible that the terms of any new equity securities may have preferences over the combined company&#8217;s common stock. Any debt financing the combined company enters into may involve covenants that restrict its operations. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of the combined company&#8217;s assets, as well as prohibitions on its ability to create liens, pay dividends, redeem its stock or make investments. In addition, if the combined company raises additional funds through licensing arrangements, it may be necessary to grant licenses on terms that are not favorable to the combined company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, as a result of ARCA&#8217;s assumption of the Paragon Option Agreements in connection with the Merger, the combined company will be subject to the obligation to grant to Paruka, on each of December&#160;31, 2024 and December&#160;31, 2025, warrants to purchase a number of shares equal to 1.00% of the outstanding shares of ARCA common stock as of the date of the grant on a fully<span class="nobreak">-diluted</span> basis, with an exercise price equal to the fair market value of the underlying shares on the grant date. Such warrants granted will result in further dilution to all securityholders of the combined company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Transfers of the combined company&#8217;s securities utilizing Rule&#160;144 of the Securities Act may be limited.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A significant portion of the combined company&#8217;s securities will be restricted from immediate resale. Holders should be aware that transfers of the combined company&#8217;s securities pursuant to Rule&#160;144 may be limited as Rule&#160;144 is not available, subject to certain exceptions, for the resale of securities initially issued by shell companies (other than business combination related shell companies) or issuers that have been at any time previously a shell company. ARCA&#8217;s expected disposal of its historical assets and operations in connection with the Merger with Oruka will make it a shell company. ARCA anticipates that following the consummation of the Merger, the combined </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">17</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">company will no longer be a shell company. As a result, ARCA anticipates that holders will not be able to sell their restricted combined company securities pursuant to Rule&#160;144 without registration until one year after ARCA files the Current Report on Form&#160;8<span class="nobreak">-K</span> following the closing that includes the required Form&#160;10 information that reflects that the combined company is no longer a shell company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s expected disposal of its historical assets and operations in connection with its proposed Merger with Oruka will make it a shell company. As a result, ARCA will be subject to more stringent reporting requirements, offering limitations and resale restrictions.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has two remaining ongoing development programs, Gencaro and rNAPc2, and it will dispose of (or is in the process of disposing of) its legacy technology and intellectual property, including those related to Gencaro and rNAPc2. Any such disposal of legacy technology and intellectual property will be contingent upon obtaining stockholder approval for the Merger. As such, ARCA expects to become a shell company upon consummation of the Merger, and its Merger with Oruka would be subject to the requirements applicable to shell company business combinations; provided, however, that if the Merger is not consummated, the disposal of ARCA&#8217;s legacy technology and intellectual property is not expected to occur and ARCA would therefore not expect to become a shell company. </p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The requirements applicable to shell company business combinations are as follows:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the combined company will need to file a Form&#160;8<span class="nobreak">-K</span> to report the Form&#160;10 type information after closing with the SEC reflecting its status as an entity that is not a shell company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA is not, and the combined company will not be, eligible to use a Form&#160;S<span class="nobreak">-3</span> until 12 full calendar&#160;months after closing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the combined company will need to wait at least 60 calendar&#160;days after closing to file a Form&#160;S<span class="nobreak">-8</span> for any equity plans or awards;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the combined company will be an &#8220;ineligible issuer&#8221; for three&#160;years following the closing, which will prevent the combined company from (i)&#160;incorporating by reference in its Form&#160;S<span class="nobreak">-1</span> filings, (ii)&#160;using a free writing prospectus, or (iii)&#160;taking advantage of well<span class="nobreak">-known</span> seasoned issuer status despite its public float;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>investors who (i)&#160;are affiliates of Oruka at the time the Merger is submitted for the vote or consent of Oruka stockholders, (ii)&#160;receive securities of the combined company in the Merger (i.e., Rule&#160;145(c)&#160;securities) and (iii)&#160;publicly offer or sell such securities, will be deemed to be engaged in a distribution of such securities, and therefore to be underwriters with respect to resales of those securities, and accordingly such securities may not be included in the Form&#160;S<span class="nobreak">-1</span> resale registration statement anticipated to be filed after the closing of the Merger unless such securities are sold only in a fixed price offering in which such investors are named as underwriters in the prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Rule&#160;144(i)(2)&#160;will limit the ability to publicly resell Rule&#160;145(c)&#160;securities per Rule&#160;145(d), as well as any other &#8220;restricted&#8221; or &#8220;control&#8221; securities of the combined company per Rule&#160;144 (i.e., holders of restricted securities and any affiliates of the public company are also affected) until one year after the Form&#160;10 information is filed with the SEC.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The foregoing SEC requirements would increase the combined company&#8217;s time and cost of raising capital, offering stock under equity plans, and complying with securities laws. Further, such requirements will add burdensome restrictions on the resale of combined company shares by affiliates of Oruka and any holders of &#8220;restricted&#8221; or &#8220;control&#8221; securities.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Some of ARCA&#8217;s and Oruka&#8217;s directors and executive officers have interests in the Merger that are different from yours and that may influence them to support or approve the Merger without regard to your interests.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Directors and executive officers of ARCA and Oruka may have interests in the Merger that are different from, or in addition to, the interests of other ARCA stockholders generally. These interests with respect to ARCA&#8217;s directors and executive officers may include, among others, retention bonus payments, extension of exercisability periods of previously issued stock option grants, severance payments if employment is terminated in a qualifying termination in connection with the Merger and rights to continued indemnification, expense advancement and insurance coverage.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">18</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Further, certain current members of Oruka&#8217;s board of directors will continue as directors of the combined company after the effective time, and, following the closing of the Merger, will be eligible to be compensated as non<span class="nobreak">-employee</span> directors of the combined company pursuant to ARCA&#8217;s non<span class="nobreak">-employee</span> director compensation policy that is expected to remain in place following the effective time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors was aware of and considered those interests, among other matters, in reaching their decisions to approve and adopt the Merger Agreement, approve the Merger, and recommend the approval of the Merger Agreement to ARCA and Oruka stockholders. These interests, among other factors, may have influenced the directors and executive officers of each company to support or approve the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA stockholders and Oruka stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger, including the conversion of Oruka common stock issued in the Oruka pre-closing financing.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the combined company is unable to realize the full strategic and financial benefits currently anticipated from the Merger, ARCA stockholders and Oruka stockholders will have experienced substantial dilution of their ownership interests without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the combined company is able to realize only part of the strategic and financial benefits currently anticipated from the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA securityholders will generally have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company following the completion of the Merger as compared to their current ownership and voting interests in the respective companies.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the completion of the Merger, ARCA&#8217;s current stockholders will generally own a smaller percentage of the combined company than their ownership of ARCA prior to the Merger. Immediately after the Merger, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), and former holders of Oruka securities are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. The Chief Executive Officer of Oruka will serve as the Chief Executive Officer of the combined company following the completion of the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Certain provisions of the Merger Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the transactions contemplated by the Merger Agreement.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While the Merger Agreement is in effect, each party is generally prohibited from, among other things, soliciting, initiating or knowingly encouraging, inducing or facilitating the communication, making, submission or announcement of any acquisition proposal or acquisition inquiry. In addition, ARCA&#8217;s current directors and executive officers and certain significant stockholders have entered into support agreements pursuant to the terms of the Merger Agreement, and as an inducement to Oruka&#8217;s willingness to enter into the Merger Agreement, by which they have agreed to vote all of their shares of ARCA capital stock in favor of the Merger Agreement and the transactions contemplated thereby and against any competing proposals, subject to certain limited exceptions. These provisions could discourage a potential competing acquirer from considering or proposing an acquisition or merger, even if it were prepared to pay consideration with a higher value than that implied by the merger consideration in the combination.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Because the lack of a public market for Oruka common stock makes it difficult to evaluate the fair market value of its capital stock, the value of ARCA common stock to be issued to Oruka stockholders may be more or less than the fair market value of Oruka common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The outstanding capital stock of Oruka is privately held and is not traded on any public market. The lack of a public market makes it difficult to determine the fair market value of Oruka capital stock. Because the percentage of ARCA&#8217;s equity to be issued to Oruka stockholders was determined based on negotiations between the parties, it is possible that the value of ARCA common stock and ARCA Series&#160;B Preferred Stock to be issued to Oruka stockholders will be more or less than the fair market value of Oruka capital stock.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">19</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Lawsuits may be filed against ARCA, Oruka, or any of the members of their respective boards of directors arising out of the Merger, which may delay or prevent the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Putative stockholder complaints, including stockholder class action complaints, and other complaints may be filed against ARCA, ARCA&#8217;s board of directors, Oruka, Oruka&#8217;s board of directors and others in connection with the transactions contemplated by the Merger Agreement. The outcome of litigation is uncertain, and ARCA or Oruka may not be successful in defending against any such future claims. Lawsuits that may be filed against ARCA, ARCA&#8217;s board of directors, Oruka, or Oruka&#8217;s board of directors could delay or prevent the Merger, divert the attention of ARCA&#8217;s and Oruka&#8217;s management and employees from their&#160;day<span class="nobreak">-to-day</span> business and otherwise adversely affect ARCA and Oruka financially.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of July<span class="nobreak"> </span>8, 2024, one complaint has been filed by a purported ARCA stockholder against ARCA and ARCA&#8217;s board of directors in connection with the proposed Merger.  On May<span class="nobreak"> </span>20, 2024, a purported stockholder filed a complaint, captioned <span class="Italic" style="font-style:italic;font-weight:normal;">Wynter v. ARCA biopharma, Inc., et al.,</span> No.: 1:24<span class="nobreak">-cv-1418-STV</span> (D. Colo.) (the &#8220;Complaint&#8221;), against ARCA and ARCA&#8217;s board of directors. The Complaint alleges that the defendants filed or caused to be filed a materially incomplete and misleading preliminary registration statement with the SEC and asserts claims under Sections 14(a) and 20(a) of the Exchange Act. The Complaint seeks an order enjoining the proposed Merger, or in the event that the proposed Merger is consummated, an order rescinding the Merger or awarding rescissory damages, as well as costs, including attorneys&#8217; and experts&#8217; fees. ARCA cannot predict the outcome of the Complaint.  ARCA believes that the allegations and claims asserted in the Complaint are without merit and intends to defend against them vigorously. Additional lawsuits arising out of the Merger may be filed.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA has never paid and, other than in connection with the Merger with Oruka, does not intend to pay any cash dividends in the foreseeable future.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has never paid cash dividends on any of its capital stock. Pursuant to the terms of the Merger Agreement, ARCA may declare and pay a special cash dividend to ARCA stockholders of record prior to the Merger consisting of cash up to an amount equal in the aggregate of the amount by which ARCA&#8217;s net cash will exceed $5.0&#160;million. The amount of such special cash dividend is currently uncertain, pending the determination of ARCA&#8217;s outstanding obligations and net cash position as of the closing of the Merger. Other than such potential special cash dividend in connection with the closing of the Merger, ARCA does not currently anticipate declaring or paying cash dividends on its capital stock in the foreseeable future.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA does not successfully consummate the Merger or another strategic transaction, ARCA&#8217;s board of directors may decide to pursue a dissolution and liquidation of ARCA.&#160;In such an event, the amount of cash available for distribution to ARCA stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities, as to which ARCA can give you no assurance.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There can be no assurance that the Merger will be completed. If the Merger is not completed, ARCA&#8217;s board of directors may decide to pursue a dissolution and liquidation of ARCA.&#160;In such an event, the amount of cash available for distribution to ARCA stockholders will depend heavily on the timing of such decision and, ultimately, such liquidation, since the amount of cash available for distribution continues to decrease as ARCA funds its operations while pursuing the Merger. In addition, if ARCA&#8217;s board of directors were to approve and recommend, and ARCA stockholders were to approve, a dissolution and liquidation of ARCA, ARCA would be required under Delaware law to pay ARCA&#8217;s outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to stockholders. ARCA&#8217;s commitments and contingent liabilities may include obligations under ARCA&#8217;s employment and related agreements with certain employees that provide for severance and other payments following a termination of employment occurring for various reasons, including a change in control of ARCA, litigation against ARCA, and other various claims and legal actions arising in the ordinary course of business, and other unexpected and/or contingent liabilities. As a result of this requirement, a portion of ARCA&#8217;s assets would need to be reserved pending the resolution of such obligations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, ARCA may be subject to litigation or other claims related to a dissolution and liquidation of ARCA.&#160;If a dissolution and liquidation were to be pursued, ARCA&#8217;s board of directors, in consultation with ARCA&#8217;s advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, holders of ARCA common stock could lose all or a significant portion of their investment in the event of liquidation, dissolution or winding up of ARCA.&#160;A liquidation would be a lengthy and uncertain process with no assurance of any value ever being returned to ARCA stockholders.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">20</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA is substantially dependent on its remaining employees to facilitate the consummation of the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of April&#160;4, 2024, ARCA had only three full<span class="nobreak">-time</span> employees and one part<span class="nobreak">-time</span> employee. ARCA&#8217;s ability to successfully complete the Merger depends in large part on its ability to retain certain remaining personnel. Despite ARCA&#8217;s efforts to retain these employees, one or more employees may terminate their employment with ARCA on short notice. The loss of the services of certain employees could potentially harm ARCA&#8217;s ability to consummate the Merger and run its&#160;day<span class="nobreak">-to-day</span> business operations, as well as fulfill its reporting obligations as a public company.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to the Proposed Reverse Stock Split</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The reverse stock split may not increase the combined company&#8217;s stock price over the long-term.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The principal purposes of the reverse stock split are to (i)&#160;increase the&#160;per<span class="nobreak">-share</span>&#160;market price of ARCA common stock above the minimum bid price requirement under the Nasdaq rules so that the listing of ARCA and the shares of ARCA common stock being issued in the Merger on Nasdaq will be approved and (ii)&#160;increase the number of authorized and unissued shares available for future issuance in connection with the Merger, though such increase will not alone be sufficient to complete the Merger. It cannot be assured, however, that the reverse stock split will accomplish any increase in the per<span class="nobreak">-share</span> market price of ARCA common stock for any meaningful period of time. While it is expected that the reduction in the number of outstanding shares of ARCA common stock will proportionally increase the market price of ARCA common stock, it cannot be assured that the reverse stock split will increase the market price of ARCA common stock by a multiple of the reverse stock split ratio mutually agreed by ARCA and Oruka, or result in any permanent or sustained increase in the market price of ARCA common stock, which is dependent upon many factors, including ARCA&#8217;s business and financial performance, general market conditions and prospects for future success. Thus, while the stock price of ARCA common stock might meet the listing requirements for Nasdaq initially after the reverse stock split, it cannot be assured that it will continue to do so.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The reverse stock split may decrease the liquidity of the combined company&#8217;s common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although ARCA&#8217;s board of directors believes that the anticipated increase in the market price of the combined company&#8217;s common stock resulting from the proposed reverse stock split could encourage interest in its common stock and possibly promote greater liquidity for its stockholders, such liquidity could also be adversely affected by the reduced number of shares outstanding after the reverse stock split. The reduction in the number of outstanding shares may lead to reduced trading and a smaller number of market makers for the combined company&#8217;s common stock. In addition, the reverse stock split may not result in an increase in the combined company&#8217;s stock price necessary to satisfy Nasdaq&#8217;s initial listing requirements for the combined company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The reverse stock split may lead to a decrease in the combined company&#8217;s overall market capitalization.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Should the market price of the combined company&#8217;s common stock decline after the reverse stock split, the percentage decline will be greater, due to the smaller number of shares outstanding, than it would have been prior to the reverse stock split. A reverse stock split is often viewed negatively by the market and, consequently, can lead to a decrease in the combined company&#8217;s overall market capitalization. If the per share market price does not increase in proportion to the reverse stock split ratio, then the value of the combined company, as measured by its stock capitalization, will be reduced. In some cases, the&#160;per<span class="nobreak">-share</span>&#160;stock price of companies that have effected reverse stock splits subsequently declined back to&#160;pre<span class="nobreak">-reverse</span>&#160;split levels, and accordingly, it cannot be assured that the total market value of the combined company&#8217;s common stock will remain the same after the reverse stock split is effected, or that the reverse stock split will not have an adverse effect on the combined company&#8217;s stock price due to the reduced number of shares outstanding after the reverse stock split.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">21</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to ARCA</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to ARCA&#8217;s Business and Financial Condition</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA is not able to successfully develop, obtain FDA approval for and provide for the commercialization of Gencaro or rNAPc2 in a timely manner, it may not be able to continue its business operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA currently has no products that have received regulatory approval for commercial sale. The process to develop, obtain regulatory approval for and commercialize potential product candidates is long, complex and costly.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Failure to demonstrate that a product candidate, including Gencaro or rNAPc2, is safe and effective, or significant delays in demonstrating such safety and efficacy, would adversely affect ARCA&#8217;s business. Failure to obtain marketing approval of Gencaro or rNAPc2 from appropriate regulatory authorities, or significant delays in obtaining such approval, would also adversely affect ARCA&#8217;s business and could, among other things, preclude ARCA from completing a strategic transaction or obtaining additional financing necessary to continue as a going concern.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if approved for sale, a product candidate must be successfully commercialized to generate value. ARCA does not currently have the capital resources or management expertise to commercialize Gencaro, rNAPc2 or any of its other product candidates and, as a result, will need to complete a strategic transaction or, alternatively, raise substantial additional funds to enable commercialization of Gencaro, rNAPc2 or any of its other product candidates, if approved. Failure to successfully provide for the commercialization of Gencaro, rNAPc2 or any other product candidate, if approved, would damage ARCA&#8217;s business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA encounters difficulties enrolling patients in its future clinical trial of Gencaro, any potential enrollment milestones or potential regulatory approvals could be delayed or otherwise adversely affected.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA may encounter difficulty enrolling a sufficient number of patients in its clinical trials, due to circumstances which are outside its control, including other clinical trials that may limit the availability of study participants. As a result, ARCA may need to delay or terminate its trials, which would have a negative impact on its business. Delays in enrolling patients in the clinical trial would also adversely affect ARCA&#8217;s ability to meet projected enrollment milestones or timelines for completing the study and obtaining regulatory approval.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s clinical trials from its product candidates may not yield results that will enable ARCA to further develop its products as a therapy and obtain regulatory approvals necessary to be used as a drug.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA will receive regulatory approval for its product candidates only if it can demonstrate, in carefully designed and conducted clinical trials, that the product candidate is safe and effective. ARCA does not know whether any future clinical trials for Gencaro, rNAPc2 or any other product candidate will demonstrate sufficient safety and efficacy to obtain the requisite regulatory approvals or will result in marketable products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The results from preclinical testing and early clinical trials may not be predictive of results from later studies. ARCA may suffer significant setbacks in advanced clinical trials, even after seeing promising results in earlier studies. Based on results at any stage of clinical trials, ARCA may decide to repeat or redesign a trial or discontinue development of one or more of ARCA&#8217;s product candidates. If ARCA fails to adequately demonstrate the safety and efficacy of its product candidates, ARCA will not be able to obtain the required regulatory approvals to commercialize those product candidates and ARCA&#8217;s business, results of operations and financial condition would be materially adversely affected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, administering ARCA&#8217;s product candidates to humans may produce undesirable side effects. These side effects could interrupt, delay or halt clinical trials of ARCA&#8217;s product candidates, and could result in the FDA or other regulatory authorities denying approval of ARCA&#8217;s product candidates, for any or all targeted indications.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA may not achieve its projected development goals in the time frames it announces and expects.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA sets goals for, and makes public statements regarding, the timing of certain accomplishments, such as the initiation of its clinical trials, the steps for commencing and continuing its clinical trials, the disclosure of trial results, the obtainment of regulatory approval and the sale of drug products, which ARCA sometimes refers to as milestones. These milestones may not be achieved, and the actual timing of these events can vary </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">22</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">dramatically due to a number of factors such as delays or failures in ARCA&#8217;s clinical trials, disagreements with any collaborative partners, the uncertainties inherent in the regulatory approval process and manufacturing scale<span class="nobreak">-up</span>, delays in achieving manufacturing or marketing arrangements sufficient to commercialize ARCA&#8217;s products or ARCA&#8217;s inability to obtain sufficient financing in a timely manner. There can be no assurance that ARCA will make regulatory submissions or receive regulatory approvals as planned. If ARCA fails to achieve one or more of these milestones as planned, its business will be materially adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA expects a Phase&#160;3 PRECISION-AF clinical trial will require substantially more capital, and ARCA cannot guarantee when or if it will be able to secure such additional financing.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA will need to secure additional financing in order to initiate enrollment of its Phase&#160;3 PRECISION<span class="nobreak">-AF</span> clinical trial. Even if ARCA can<span class="BoldItalic" style="font-style:italic;font-weight:bold;"> </span>begin enrolling patients, it expects to have to raise significant additional capital to continue enrollment. If ARCA is not able to obtain financing in the future or on acceptable terms, it may have to terminate the clinical trial early, which could adversely affect its business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA will need to raise substantial additional funds through public or private equity or debt transactions and/or complete one or more strategic transactions or partnerships, to continue development of Gencaro, rNAPc2 or any of its other product candidates. If ARCA is unable to raise such financing or complete such a transaction, it may not be able to continue operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a result of the expected development timeline to potentially obtain FDA approval for Gencaro or rNAPc2, if at all, the substantial additional costs associated with the development of ARCA&#8217;s product candidates, including the costs associated with clinical trials related thereto, and the substantial cost of commercializing Gencaro or rNAPc2, if approved, ARCA will need to raise substantial additional funding through public or private equity or debt transactions or a strategic combination or partnership. If ARCA is delayed in obtaining funding or are unable to complete a strategic transaction, it may discontinue its development activities on Gencaro, rNAPc2 and its other product candidates or discontinue its operations. Even if ARCA is able to fund continued development of Gencaro, rNAPc2 or any of ARCA&#8217;s other product candidates, ARCA expects that it will need to complete a strategic transaction or raise substantial additional funding through public or private equity or debt securities or partnership to successfully commercialize Gencaro, rNAPc2 or any other product candidate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial clinical trial would likely require additional financing. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing. In 2020, ARCA entered into a new sales agreement with a placement agent to sell, from time to time, ARCA common stock in an &#8220;at the market offering.&#8221; As of December&#160;31, 2022, ARCA sold an aggregate of 9,928,272<span class="nobreak"> </span>shares of ARCA common stock pursuant to the terms of such sales agreement for aggregate gross proceeds of approximately $54.0&#160;million. Net proceeds received in this offering were approximately $52.2&#160;million, after deducting expenses for executing the &#8220;at the market offering&#8221; and commissions paid to the placement agent. In 2021, ARCA amended the new sales agreement and the amount available for the offering under its prospectus to its registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated such sales agreement in accordance with its terms. Sales of ARCA common stock dilute the ownership interest of ARCA stockholders and may cause the price per share of ARCA common stock to decrease. Changing circumstances may cause ARCA to consume capital significantly faster or slower than it currently anticipates. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">23</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2 and ARCA&#8217;s other product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of ARCA common stock on the Nasdaq Capital Market;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial dilution to ARCA stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of its capital stock and could contain covenants that would restrict its operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA has received a Special Protocol Assessment agreement from the FDA relating to its planned Phase&#160;3 program for Gencaro. This Special Protocol Assessment agreement does not guarantee approval of Gencaro or any other particular outcome from regulatory review.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2019, ARCA received a Special Protocol Assessment (&#8220;SPA&#8221;) agreement from the FDA for its planned Phase&#160;3 clinical trial of Gencaro. The FDA&#8217;s SPA process is designed to facilitate the FDA&#8217;s review and approval of drugs by allowing the FDA to evaluate the proposed design and size of certain clinical trials that are intended to form the primary basis for determining a drug product&#8217;s efficacy. Upon specific request by a clinical trial sponsor, the FDA will evaluate the protocol and respond to a sponsor&#8217;s questions regarding, among other things, primary efficacy endpoints, trial conduct and data analysis, within 45&#160;days of receipt of the request. The FDA ultimately assesses whether the protocol design and planned analysis of the trial are acceptable to support regulatory approval of the product candidate with respect to the effectiveness of the indication studied. All agreements and disagreements between the FDA and the sponsor regarding a SPA must be clearly documented in a SPA letter or the minutes of a meeting between the sponsor and the FDA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, an SPA agreement does not guarantee approval of a product candidate, even if the trial is conducted in accordance with the protocol. Moreover, the FDA may revoke or alter ARCA&#8217;s SPA agreement in certain circumstances. In particular, a SPA agreement is not binding on the FDA if public health concerns emerge that were unrecognized at the time of the SPA agreement, other new scientific concerns regarding product safety or efficacy arise, ARCA fails to comply with the agreed upon trial protocols, or the relevant data, assumptions or information provided by ARCA in its request for the SPA change or are found to be false or omit relevant facts. In addition, even after an SPA agreement is finalized, the SPA agreement may be modified, and such modification will be deemed binding on the FDA review division, except under the circumstances described above, if the FDA and the sponsor agree in writing to modify the protocol and such modification is intended to improve the study. The FDA retains significant latitude and discretion in interpreting the terms of the SPA agreement and the data and results from any study that is the subject of the SPA agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even though ARCA obtained an agreement on its SPA, ARCA cannot assure you that its planned Phase&#160;3 clinical trial will succeed, will be deemed binding by the FDA under its SPA agreement or will result in any FDA approval for Gencaro. ARCA may also alter the design of the trial to focus on endpoints that are not covered by the SPA.&#160;Moreover, if the FDA revokes or alters its agreement under ARCA&#8217;s SPA, or interprets the data collected from </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">24</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the clinical trial differently than ARCA does, the FDA may not deem the data sufficient to support an application for regulatory approval, which could materially adversely affect ARCA&#8217;s business, financial condition and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA is not able to maintain the requirements for listing on the Nasdaq Capital Market, it could be delisted, which could have a material adverse effect on its ability to consummate the Merger, raise additional funds as well as the price and liquidity of ARCA common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA common stock is currently listed on the Nasdaq Capital Market. To maintain the listing of ARCA common stock on the Nasdaq Capital Market, ARCA is required to meet certain listing requirements, including, among others, (i)&#160;a minimum closing bid price of $1.00 per share, (ii)&#160;a market value of publicly held shares (excluding shares held by ARCA&#8217;s executive officers, directors and 10% or more stockholders) of at least $1&#160;million and (iii)&#160;either: (x)&#160;stockholders&#8217; equity of at least $2.5&#160;million; or (y)&#160;a total market value of listed securities of at least $35&#160;million. In addition, pursuant to the terms of the Merger Agreement ARCA is required to use commercially reasonable efforts to maintain its listing on Nasdaq until the First Merger Effective Time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has received three potential delisting notices from Nasdaq since 2012. In each of 2012, 2015 and 2018, ARCA received notification from Nasdaq of potential delisting of its shares from the Nasdaq Capital Market because the closing bid price of ARCA common stock had not met the minimum closing bid price of $1.00 per share during the preceding 30&#160;business days. ARCA subsequently regained compliance with Nasdaq&#8217;s minimum closing bid price requirements related to the 2012, 2015 and 2018 notices, by effecting a 1<span class="nobreak">-for-6</span> reverse split of ARCA common stock in March&#160;2013, a 1<span class="nobreak">-for-7</span> reverse split of ARCA common stock in September&#160;2015 and a 1<span class="nobreak">-for-18</span> reverse split of ARCA common stock in April&#160;2019. Despite effecting a 1<span class="nobreak">-for-18</span> reverse split of ARCA common stock in April&#160;2019, there can be no assurance that the market price per share of ARCA common stock will remain in excess of the $1.00 minimum bid price for a sustained period of time. The continuing effect of ARCA&#8217;s reverse stock split on the market price of ARCA common stock cannot be predicted with any certainty, and the history of similar stock split combinations for companies in like circumstances is varied. It is possible that the per share price of ARCA common stock after the reverse stock split will not rise in proportion to the reduction in the number of shares of common stock outstanding resulting from the reverse stock split, effectively reducing ARCA&#8217;s market capitalization, and there can be no assurance that the market price per post<span class="nobreak">-reverse</span> split share will either exceed or remain in excess of the $1.00 minimum bid price for a sustained period of time. The market price of ARCA common stock may vary based on other factors that are unrelated to the number of shares outstanding, including ARCA&#8217;s future performance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The delisting of ARCA common stock from a national exchange may impair ARCA&#8217;s ability to consummate the Merger and could impair the liquidity and market price of the common stock. It could also materially adversely affect ARCA&#8217;s access to the capital markets, and any limitation on market liquidity or reduction in the price of the common stock as a result of that delisting could adversely affect ARCA&#8217;s ability to consummate the Merger or raise capital on terms acceptable to ARCA, or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In future periods, if ARCA does not meet the minimum stockholders&#8217; equity, minimum closing bid price requirements, or any other listing requirements, it would be subject to delisting from the Nasdaq Capital Market.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of July<span class="nobreak"> </span>19, 2024, the closing price of ARCA common stock was $3.29 per share, and the total market value of ARCA&#8217;s listed securities was approximately $47.66&#160;million. As of March&#160;31, 2024, ARCA had stockholders&#8217; equity of $35.1&#160;million.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s financial statements for the quarter ended March&#160;31, 2024 were prepared assuming that ARCA will continue as a going concern. ARCA&#8217;s management has concluded that due to ARCA&#8217;s need for additional capital, and the uncertainties surrounding ARCA&#8217;s ability to raise such funding, there may be uncertainty about ARCA&#8217;s ability to continue as a going concern in future&#160;years.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s financial statements for the quarter ended March&#160;31, 2024 were prepared assuming that ARCA will continue as a going concern. The going concern basis of presentation assumes that ARCA will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from ARCA&#8217;s inability to continue as a going concern. As of December&#160;31, 2019, ARCA&#8217;s management and independent </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">25</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">registered public accounting firm concluded that, due to ARCA&#8217;s need for additional capital and the uncertainties surrounding ARCA&#8217;s ability to raise such funding, substantial doubt existed as to ARCA&#8217;s ability to continue as a going concern for a period from one year after ARCA&#8217;s annual financial statements had been issued. ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s future viability beyond that point is dependent on the results of the strategic review process and ARCA&#8217;s ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see discussion above regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction. ARCA&#8217;s Merger Agreement discussed above may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing, subject to ARCA&#8217;s pursuits of a potential strategic transaction and the consummation of such potential transaction. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing. ARCA cannot be certain that it will be able to make any other sale of ARCA common stock in any future offering to cover its future capital needs, or at all. Changing circumstances may cause ARCA to consume capital significantly faster or slower than it currently anticipates. If ARCA is delayed in completing or is unable to complete additional funding and/or a strategic transaction, it may discontinue its development activities or operations, but there are no assurances that these reductions would be sufficient to allow ARCA to continue to operate as a going concern. Therefore, even if ARCA resolves this uncertainty, its independent registered public accountants and/or management could conclude that uncertainty as to its ability to continue as a going concern could exist at a future date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. ARCA may be forced to reduce its operating expenses and raise additional funds to meet its working capital needs, principally through the additional sales of its securities or debt financings. However, ARCA cannot guarantee that it will be able to obtain sufficient additional funds when needed or that such funds, if available, will be obtainable on satisfactory terms. If ARCA is unable to raise sufficient additional capital or complete a strategic transaction, it may be unable to continue to fund its operations, develop Gencaro, rNAPc2 or its other product candidates, or realize value from its assets and discharge its liabilities in the normal course of business. If ARCA cannot raise sufficient funds, it may have to liquidate its assets, and might realize significantly less than the values at which they are carried on its financial statements, and stockholders may lose all or part of their investment in ARCA&#8217;s securities.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Market conditions and changing circumstances, some of which may be beyond ARCA&#8217;s control, could impair ARCA&#8217;s ability to access its existing cash, cash equivalents and investments and to timely pay key vendors and others.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Market conditions and changing circumstances, some of which may be beyond ARCA&#8217;s control, could impair ARCA&#8217;s ability to access its existing cash, cash equivalents and investments and to timely pay key vendors and others. For example, on March&#160;10, 2023, Silicon Valley Bank (SVB), where ARCA maintains certain accounts, was placed into receivership with the Federal Deposit Insurance Corporation (FDIC), which resulted in all funds held at SVB being temporarily inaccessible by SVB&#8217;s customers. If other banks and financial institutions with whom ARCA has banking relationships enter receivership or become insolvent in the future, ARCA may be unable to access, and may lose, some or all of its existing cash, cash equivalents and investments to the extent those funds are not insured or otherwise protected by the FDIC.&#160;In addition, in such circumstances, ARCA might not be able to timely pay key vendors and others. ARCA regularly maintains cash balances that are not insured or are in excess of the FDIC&#8217;s insurance limit. Any delay in ARCA&#8217;s ability to access its cash, cash equivalents and investments (or the loss of some or all of such funds) or to timely pay key vendors and others could have a material adverse effect on ARCA&#8217;s operations and cause it to need to seek additional capital sooner than planned.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">26</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s business could be adversely affected by the effects of health epidemics in regions where ARCA or third parties on which ARCA relies may have clinical trial sites or other business operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s business could be adversely affected by health epidemics in regions where ARCA may have concentrations of future clinical trial sites or other business operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, third<span class="nobreak">-party</span> manufacturing of ARCA&#8217;s drug product candidates and suppliers of the materials used in the production of ARCA&#8217;s drug product candidates may be impacted by significant delays or restrictions resulting from any future health epidemic which may disrupt ARCA&#8217;s supply chain or limit ARCA&#8217;s ability to manufacture drug product candidates for its clinical trials.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ultimate impact of any future health epidemic is highly uncertain and subject to change. These effects could have a material impact on ARCA&#8217;s operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA encounters difficulties enrolling patients in any future clinical trials, its future trials could be delayed or otherwise adversely affected.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA has difficulty enrolling a sufficient number of patients in any future clinical trial, ARCA may need to delay or terminate its trial, which would have a negative impact on its business. Delays in enrolling patients in any future clinical trials would also adversely affect ARCA&#8217;s ability to generate any product, milestone and royalty revenues under collaboration agreements, if any, and could impose significant additional costs on ARCA or on any future collaborators.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For example, the development of vaccines for the SARS<span class="nobreak">-CoV-2</span> virus and the development of other therapies for COVID<span class="nobreak">-19</span> disease impacted ARCA&#8217;s ability to enroll patients in its rNAPc2 (AB201) Phase&#160;2b clinical trial and such enrollment was slower than expected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The GENETIC<span class="nobreak">-AF</span> clinical trial required that ARCA identify and enroll a large number of patients with the condition under investigation and the trial enrolled only those patients having a specific genotype, and certain patients who have or are willing to have a Medtronic device implanted for monitoring and recording AFB data. As a result, enrollment for GENETIC<span class="nobreak">-AF</span> was slower than expected, with ARCA&#8217;s first patient enrolled in June&#160;2014 and enrollment completed in August&#160;2017. Because of the rigorous enrollment criteria, ARCA&#8217;s clinical trial timelines were delayed from ARCA&#8217;s original projections. ARCA anticipates that any future Phase&#160;3 clinical trial of Gencaro, including PRECISION<span class="nobreak">-AF</span>, may have similar enrollment criteria, and ARCA cannot guarantee that it will not have similar enrollment issues in any future clinical trials.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA may also encounter difficulty enrolling a sufficient number of patients in any future clinical trial, due to circumstances which are outside ARCA&#8217;s control, including as a result of continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA will rely on contract research organizations to conduct substantial portions of its clinical trials, including any future clinical trial of Gencaro, rNAPc2, and as a result, ARCA will be unable to directly control the timing, conduct and expense of all aspects of its clinical trials.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA does not currently have sufficient staff with the requisite experience to conduct its clinical trials and therefore will rely on third parties to conduct certain aspects of any future clinical trials. ARCA previously contracted with a CRO to conduct components of its GENETIC<span class="nobreak">-AF</span> clinical trial and anticipate contracting with a CRO to conduct components of any future clinical trial for Gencaro and components of the clinical study of rNAPc2 or any future clinical trials for ARCA&#8217;s other product candidates. As a result, ARCA will have less control over many details and steps of any clinical trial, the timing and completion of any clinical trial, the required reporting of adverse events and the management of data developed through any clinical trial than would be the case if ARCA were relying entirely upon its own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties, such as CROs, may have staffing difficulties, may undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct ARCA&#8217;s clinical trial. ARCA may experience unexpected cost increases that are beyond its control. Problems with the timeliness or quality of the work of a CRO may lead ARCA to seek to terminate the relationship and use an alternative service provider. However, making any change may be costly </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">27</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">and may delay ongoing trials, if any, and contractual restrictions may make such a change difficult or impossible. Additionally, it may be impossible to find a replacement organization that can conduct clinical trials in an acceptable manner and at an acceptable cost.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even though ARCA anticipates relying on CROs in the future, it will likely have to devote substantial resources and rely on the expertise of ARCA&#8217;s employees to manage the work being done by the CROs. Due to ARCA&#8217;s limited experience in managing clinical trials, ARCA cannot guarantee its employees will do so effectively.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA expects to depend on existing and future collaborations with third parties for the development of some of ARCA&#8217;s product candidates. If those collaborations are not successful, ARCA may not be able to complete the development of these product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA collaborated with one or more clinical trial networks in its development program for rNAPc2. As a result, ARCA lacked direct control over certain aspects of the development program and the amount and timing of resources that these collaborators devote to the project.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA had a collaboration agreement with Medtronic that supported ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial. If ARCA&#8217;s arrangement with Medtronic, as amended, is continued as part of ARCA&#8217;s future development of Gencaro, ARCA will have limited control over the amount and timing of resources that they dedicate to the development of Gencaro. This is also likely to be true in any future collaboration with third parties and ARCA may seek additional third<span class="nobreak">-party</span> collaborators for the development of Gencaro, rNAPc2 or any other product candidates. ARCA&#8217;s ability to benefit from these arrangements will depend on its collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Collaborations involving ARCA&#8217;s product candidates pose the following risks to us:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may not pursue development and commercialization of ARCA&#8217;s product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with ARCA&#8217;s product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ARCA&#8217;s;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may not properly maintain or defend ARCA&#8217;s intellectual property rights or may use ARCA&#8217;s proprietary information in such a way as to invite litigation that could jeopardize or invalidate its proprietary information or expose it to potential litigation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>disputes may arise between the collaborators and ARCA that result in the delay or termination of the research, development or commercialization of ARCA&#8217;s product candidates or that result in costly litigation or arbitration that diverts management attention and resources;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may elect to take over manufacturing rather than retain ARCA as manufacturer and may encounter problems in starting up or gaining approval for their manufacturing facility and so be unable to continue development of product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA may be required to undertake the expenditure of substantial operational, financial and management resources in connection with any collaboration;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">28</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA may be required to issue equity securities to collaborators that would dilute ARCA&#8217;s existing stockholders&#8217; percentage ownership;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA may be required to assume substantial actual or contingent liabilities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may not commit adequate resources to the marketing and distribution of ARCA&#8217;s product candidates, limiting ARCA&#8217;s potential revenues from these products; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>collaborators may experience financial difficulties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA faces a number of challenges in seeking additional collaborations. Collaborations are complex and any potential discussions may not result in a definitive agreement for many reasons. For example, whether ARCA reaches a definitive agreement for a collaboration will depend, among other things, upon its assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#8217;s evaluation of a number of factors, such as the design or results of ARCA&#8217;s clinical trials, the potential market for ARCA&#8217;s product candidates, the costs and complexities of manufacturing and delivering ARCA&#8217;s product candidates to patients, the potential of competing products, the existence of uncertainty with respect to ownership or the coverage of ARCA&#8217;s intellectual property, and industry and market conditions generally. If ARCA were to determine that additional collaborations for its Gencaro development are necessary and were unable to enter into such collaborations on acceptable terms, ARCA might elect to delay or scale back the development or commercialization of Gencaro in order to preserve its financial resources or to allow it adequate time to develop the required physical resources and systems and expertise itself.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Collaboration agreements may not lead to development or commercialization of ARCA&#8217;s product candidates in the most efficient manner, or at all. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If a present or future collaborator of ARCA were to be involved in a business combination, the continued pursuit and emphasis on ARCA&#8217;s product development or commercialization program could be delayed, diminished or terminated.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Any future clinical trial for Gencaro will require the use of a third-party diagnostic services provider to administer a genetic test needed to identify the patient receptor genotypes of clinical trial participants, and as a result, ARCA will be unable to directly control the timing, conduct and expense of the genetic test.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA anticipates that any future clinical trial of Gencaro, if any, will require a companion diagnostic test that identifies the patient&#8217;s receptor genotype. The trial would only enroll those patients with the receptor that has the potential for enhanced efficacy, the beta<span class="nobreak">-1</span> 389 Arg receptor as detected by a beta<span class="nobreak">-1</span> 389 Arg/Arg genotype. Accordingly, ARCA anticipates that any future clinical trial for Gencaro will require the use of a third<span class="nobreak">-party</span> diagnostic service to perform the genetic testing. There has been limited experience in ARCA&#8217;s industry in prospective development of companion diagnostics required to perform the required molecular profiling. ARCA entered into an agreement with LabCorp to provide the diagnostic services of the genetic test needed to support ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial. To provide those services, LabCorp obtained from the FDA an investigational device exemption (&#8220;IDE&#8221;) for the companion diagnostic test being used in ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial. ARCA would expect a similar agreement and approval would be necessary for any companion diagnostic used in any future clinical trials for Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA and similar regulatory authorities outside the United&#160;States regulate companion diagnostics. Companion diagnostics require separate or coordinated regulatory approval prior to commercialization. Changes to regulatory advice could delay ARCA&#8217;s development programs or delay or prevent eventual marketing approval for ARCA&#8217;s product candidates that may otherwise be approvable. In July&#160;2011, the FDA issued draft guidance that stated that if safe and effective use of a therapeutic depends on an <span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span> diagnostic, the FDA generally will not approve the therapeutic unless the FDA approves or clears this &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span> companion diagnostic device&#8221; at the same time that the FDA approves the therapeutic. The approval or clearance of the companion diagnostic would occur through the FDA&#8217;s Center for Devices and Radiological Health. In 2014, the FDA issued guidance on in vitro companion diagnostic devices. The guidance allows for flexibility by the FDA in the case of therapeutic products to treat serious conditions for which no alternative treatment exists and the benefits of using the companion diagnostic outweigh the risk, but it is unclear how this discretion may be applied by the agency with respect to the companion diagnostic test related to any Gencaro clinical trials. The FDA&#8217;s evolving position on the topic of companion </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">29</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">diagnostics could affect ARCA&#8217;s clinical development programs that utilize companion diagnostics. In particular, the FDA may limit ARCA&#8217;s ability to use retrospective data, otherwise disagree with ARCA&#8217;s approaches to trial design, biomarker qualification, clinical and analytical validity, and clinical utility, or make ARCA repeat aspects of a trial or initiate new trials.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Given ARCA&#8217;s limited experience in developing diagnostics, ARCA expects to rely primarily on third parties for the design and manufacture of the companion diagnostics for its product candidates. If ARCA, or any third parties that ARCA engages to assist it, are unable to successfully develop companion diagnostics for its product candidates that require such diagnostics, or experiences delays in doing so, the development of its product candidates may be adversely affected, its product candidates may not receive marketing approval and it may not realize the full commercial potential of any products that receive marketing approval. As a result, ARCA&#8217;s business could be materially harmed.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA will need to establish a collaborative arrangement with a third-party diagnostics services provider to obtain marketing clearance or approval of the companion genetic test for Gencaro. There is no guarantee that the FDA will grant timely clearance or approval of the genetic test, if at all, and failure to obtain such timely clearance or approval would adversely affect ARCA&#8217;s ability to market Gencaro.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The drug label ARCA intends to seek for Gencaro would identify the patient receptor genotype for which the drug is approved. Accordingly, ARCA believes developing a genetic test that is simple to administer and widely available will be critical to the successful commercialization of Gencaro. The genetic test will be subject to regulation by the FDA and by comparable agencies in various foreign countries. The process of complying with the requirements of the FDA and comparable agencies is costly, time consuming and burdensome.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Despite the time and expense expended, regulatory clearance or approval is never guaranteed. If regulatory clearance or approval is delayed, or if one or more third<span class="nobreak">-party</span> diagnostic services providers are unable to obtain FDA approval of the genetic test at all or in parallel with the approval of Gencaro, or are unable to commercialize the test successfully and in a manner that effectively supports the commercial efforts for Gencaro, or if the information concerning the differential response to Gencaro resulting from certain genetic variation is not included in the approval label for Gencaro, the commercial launch of Gencaro may be significantly and adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Regulatory approval is required for the genetic test to be used in ARCA&#8217;s Gencaro clinical trials and to support the commercialization of the test, if approved. Delays or failures in obtaining such regulatory approval, including any required validation analyses may prevent a third-party diagnostics provider from commercializing such genetic test and will adversely affect ARCA&#8217;s business, operating results and prospects.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before a genetic test can be used commercially, including in conjunction with Gencaro, if it is approved for marketing, the third<span class="nobreak">-party</span> diagnostics provider must obtain FDA Premarket Approval (&#8220;PMA&#8221;), for such test. The FDA may require additional validation of the genetic test ARCA used in GENETIC<span class="nobreak">-AF</span> prior to any approval of Gencaro or the genetic test or prior to the use of such test in any future clinical trials for Gencaro. ARCA anticipates the genetic test will be required as a condition to prescribing Gencaro. There is no guarantee the FDA will approve the anticipated PMA submission for the genetic test. Even if the genetic test is eventually approved, performing additional validation work necessary to support the PMA, if required, for current or future genetic test products, including one associated with Gencaro, would require additional time and expense and the outcome would be uncertain. Moreover, such delays or increased costs or failures could adversely affect ARCA&#8217;s business, operating results and prospects for commercializing the genetic test.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If a third-party diagnostics provider responsible for the genetic test associated with Gencaro or certain of its third-party suppliers fails to comply with ongoing FDA or other foreign regulatory authority requirements, or if there are unanticipated problems with the genetic test, these products could be subject to restrictions or withdrawal from use in a trial or from the market.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any diagnostic for which a third<span class="nobreak">-party</span> diagnostics provider obtains clearance or approval, and the manufacturing processes, reporting requirements, post<span class="nobreak">-approval</span> clinical data and promotional activities for such product, will be subject to continued regulatory review, oversight and periodic inspections by the FDA and other domestic and foreign regulatory bodies. With respect to the genetic test, to the extent applicable, any third<span class="nobreak">-party</span> diagnostics provider and certain of its suppliers will be required to comply with the FDA&#8217;s Quality System </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">30</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Regulation (&#8220;QSR&#8221;) and International Standards Organization (&#8220;ISO&#8221;) requirements which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any product for which clearance or approval is obtained. Regulatory bodies, such as the FDA, enforce the QSR and other regulations through periodic inspections. The failure by a third<span class="nobreak">-party</span> diagnostics provider, or certain of its third<span class="nobreak">-party</span> manufacturers or suppliers, as the case may be, to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, enforcement actions. If any of these actions were to occur, it could harm ARCA&#8217;s reputation and cause product sales and profitability of Gencaro, if approved, to suffer and may prevent ARCA from generating revenue or utilizing the genetic test further in any clinical trial. Even if regulatory clearance or approval is granted, such clearance or approval may be subject to limitations on the intended uses for which the product may be marketed and reduce ARCA&#8217;s potential to successfully commercialize the product and generate revenue from the product.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Future sales of Gencaro may suffer if its marketplace acceptance is negatively affected by the genetic test.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The genetic test is an important component of the commercial strategy for Gencaro in addition to being required for ARCA&#8217;s clinical trials. ARCA believes that the genetic test helps predict patient response to Gencaro, and that this aspect of the drug is important to its ability to compete effectively with current therapies. The genetic test adds an additional step in the prescribing process, an additional cost for the patient and payors, the risk that the test results may not be rapidly available and the possibility that it may not be available at all to hospitals and medical centers. Although ARCA anticipates that Gencaro, if approved in a timely manner, would be the first genetically<span class="nobreak">-targeted</span> cardiovascular drug, Gencaro will be one of a number of successful drugs in the beta<span class="nobreak">-blocker</span> class currently on the market. Prescribers may be more familiar with these other beta<span class="nobreak">-blockers</span>, and may be resistant to prescribing Gencaro as an AF therapy in patients with HF.&#160;For instance, the top<span class="nobreak">-line</span> results of ARCA&#8217;s Phase&#160;2B GENETIC<span class="nobreak">-AF</span> clinical trial indicated that Gencaro demonstrated a similar treatment benefit compared to the active comparator, metoprolol succinate (TOPROL<span class="nobreak">-XL</span>). If ARCA&#8217;s future clinical trials in Gencaro do not show that Gencaro has a clear therapeutic benefit as compared to other drugs in the beta<span class="nobreak">-blocker</span> class currently on the market, then prescribers may be unlikely to prescribe Gencaro to patients, even if approved. Any one of these factors could affect prescriber behavior, which in turn may substantially impede market acceptance of the genetic test, which could cause significant harm to Gencaro&#8217;s ability to compete, and in turn harm ARCA&#8217;s business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Unless ARCA is able to generate sufficient product revenue, it will continue to incur losses from operations and will not achieve or maintain profitability. ARCA is&#160;years away from commercializing a product and generating product revenue.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s historical losses have had, and will continue to have, an adverse effect on ARCA stockholders&#8217; equity and working capital, among other things. ARCA is&#160;years away from commercializing a product and generating any product revenue. As a result, ARCA expects to continue to incur significant operating losses for the foreseeable future. Even if ARCA ultimately receives regulatory approval for Gencaro, rNAPc2 or ARCA&#8217;s other product candidates, sales of such products may not generate sufficient revenue for it to achieve or maintain profitability. Because of the numerous risks and uncertainties associated with developing therapeutic drugs, ARCA may experience larger than expected future losses and may never reach profitability.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s product candidates are subject to extensive regulation, which can be costly and time-consuming, and unsuccessful or delayed regulatory approvals could increase ARCA&#8217;s future development costs or impair ARCA&#8217;s future revenue.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preclinical and clinical development, testing, manufacture, safety, efficacy, labeling, storage, recordkeeping, and subsequent advertising, promotion, sale, marketing, and distribution, if approved, of ARCA&#8217;s product candidates are subject to extensive regulation by the FDA and other regulatory authorities in the United&#160;States and elsewhere. These regulations also vary in important, meaningful ways from country to country. ARCA is not permitted to market a potential drug in the United&#160;States until it receives approval of a New Drug Application (&#8220;NDA&#8221;) from the FDA for such drug. ARCA has not received an NDA approval from the FDA for Gencaro, rNAPc2 or any of its other product candidates. There can be no guarantees with respect to ARCA&#8217;s product candidates that clinical studies will adequately support an NDA, that the products will receive necessary regulatory approvals, or that they will prove to be commercially successful.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">31</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To receive regulatory approval for the commercial sale of any product candidates, ARCA must demonstrate safety and efficacy in humans to the satisfaction of regulatory authorities through preclinical studies and adequate and well<span class="nobreak">-controlled</span> clinical trials of the product candidates. This process is expensive and can take many&#160;years, and failure can occur at any stage of the testing. ARCA&#8217;s failure to adequately demonstrate the safety and efficacy of ARCA&#8217;s product candidates will prevent regulatory approval and commercialization of such products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2008, ARCA submitted and the FDA accepted ARCA&#8217;s NDA filing for Gencaro for the treatment of chronic HF.&#160;In 2009, the FDA issued a Complete Response Letter in which the FDA stated that it could not approve the Gencaro NDA in its current form and specified actions required for approval of the NDA, including conducting an additional Phase&#160;3 clinical trial of Gencaro in patients with HF.&#160;ARCA completed a Phase&#160;2B clinical study of Gencaro in HF patients to assess its efficacy in reducing or preventing AF.&#160;ARCA enrolled 267 HF patients with AF in the Phase&#160;2B clinical trial. ARCA reported top<span class="nobreak">-line</span> Phase&#160;2B data in February&#160;2018. In the third quarter of 2018, ARCA submitted a SPA to the FDA for a Phase&#160;3 clinical trial. In 2019, the FDA approved ARCA&#8217;s SPA request for a Phase&#160;3 clinical trial of Gencaro. Even though the FDA approved ARCA&#8217;s SPA, this product candidate will require&#160;years of additional clinical development. Even if ARCA conducts additional studies in accordance with ARCA&#8217;s SPA agreement or further FDA guidance and submit or file a new or amended NDA, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event that ARCA or its collaborators conduct preclinical studies that do not comply with Good Laboratory Practices (&#8220;GLP&#8221;) or incorrectly design or carry out human clinical trials in accordance with Good Clinical Practices (&#8220;GCP&#8221;) or those clinical trials fail to demonstrate clinical significance, it is unlikely that ARCA will be able to obtain FDA approval for product development candidates. ARCA&#8217;s inability to successfully initiate and effectively complete clinical trials for any product candidate on schedule, or at all, will severely harm ARCA&#8217;s business. Significant delays in clinical development could materially increase product development costs or allow ARCA&#8217;s competitors to bring products to market before ARCA does, impairing ARCA&#8217;s ability to effectively commercialize any future product candidate. ARCA does not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays or failures in obtaining regulatory authorization to commence a trial because of safety concerns of regulators relating to ARCA&#8217;s product candidates or similar product candidates of ARCA&#8217;s competitors or failure to follow regulatory guidelines;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays or failures in obtaining clinical materials and manufacturing sufficient quantities of the product candidates for use in trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure of clinical materials to meet pre<span class="nobreak">-established</span> specifications at product release or during ongoing stability studies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays or failures in reaching agreement on acceptable terms with prospective study sites;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays or failures in obtaining approval of ARCA&#8217;s clinical trial protocol from an institutional review board to conduct a clinical trial at a prospective study site;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delays in recruiting patients to participate in a clinical trial, which may be due to the size of the patient population, eligibility criteria, protocol design, perceived risks and benefits of the drug, availability of other approved and standard of care therapies or, availability of clinical trial sites;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other clinical trials seeking to enroll subjects with similar profile;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure of ARCA&#8217;s clinical trials and clinical investigators to be in compliance with GCP;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>unforeseen safety issues, including negative results from ongoing preclinical studies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>inability to monitor patients adequately during or after treatment;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>difficulty recruiting and monitoring multiple study sites;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">32</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure of ARCA&#8217;s third<span class="nobreak">-party</span> contract research organizations, clinical site organizations and other clinical trial managers, to satisfy their contractual duties, comply with regulations or meet expected deadlines; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an insufficient number of patients who have, or are willing to have, a Medtronic device implanted for monitoring and recording AF burden data.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, any approvals ARCA may obtain may not cover all of the clinical indications for which it seeks approval or permit it to make claims of superiority over currently marketed competitive products. Also, an approval might contain significant limitations in the form of narrow indications, warnings, precautions or contraindications with respect to conditions of use. If the FDA determines that a risk evaluation and mitigation strategy, or REMS, is necessary to ensure that the benefits of the drug outweigh the risks, ARCA may be required to include as part of the NDA a proposed REMS that may include a package insert directed to patients, a plan for communication with healthcare providers, restrictions on a drug&#8217;s distribution, or a Medication Guide, to provide better information to consumers about the drug&#8217;s risks and benefits. Finally, an approval could be conditioned on ARCA&#8217;s commitment to conduct further clinical trials, which ARCA may not have the resources to conduct or which may negatively impact ARCA&#8217;s financial situation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The manufacture and analytical testing of Gencaro and rNAPc2 is performed by third<span class="nobreak">-party</span> suppliers, who must also meet cGMP requirements and pass a pre<span class="nobreak">-approval</span> inspection of their facilities before ARCA can obtain marketing approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All of ARCA&#8217;s product candidates are prone to the risks of failure inherent in drug development. The results from preclinical animal testing and early human clinical trials may not be predictive of results obtained in later human clinical trials. Further, although a new product may show promising results in preclinical or early human clinical trials, it may subsequently prove unfeasible or impossible to generate sufficient safety and efficacy data to obtain necessary regulatory approvals. The data obtained from preclinical and clinical studies are susceptible to varying interpretations that may delay, limit or prevent regulatory approval, and the FDA and other regulatory authorities in the United&#160;States and elsewhere exercise substantial discretion in the drug approval process. The numbers, size and design of preclinical studies and clinical trials that will be required for FDA or other regulatory approval will vary depending on the product candidate, the disease or condition for which the product candidate is intended to be used and the regulations and guidance documents applicable to any particular product candidate. The FDA or other regulators can delay, limit or deny approval of any product candidate for many reasons, including, but not limited to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>side effects;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>safety and efficacy;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>defects in the design of clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the fact that the FDA or other regulatory officials may not approve ARCA&#8217;s or ARCA&#8217;s third<span class="nobreak">-party</span> manufacturer&#8217;s processes or facilities; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the fact that new regulations may be enacted by the FDA or other regulators may change their approval policies or adopt new regulations requiring new or different evidence of safety and efficacy for the intended use of a product candidate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In light of widely publicized events concerning the safety of certain drug products, regulatory authorities, members of Congress, the Government Accountability Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of certain drug products, revisions to certain drug labeling that further limit use of the drug products and establishment of risk management programs that may, for instance, restrict distribution of drug products. The increased attention to drug safety issues may result in a more cautious approach by the FDA to clinical trials and approval. Data from clinical trials may receive greater scrutiny with respect to safety and the product&#8217;s risk/benefit profile, which may make the FDA or other regulatory authorities more likely to terminate clinical trials before completion, or require longer or additional clinical trials that may result in substantial additional expense, and a delay or failure in obtaining </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">33</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">approval or approval for a more limited indication than originally sought. Aside from issues concerning the quality and sufficiency of submitted preclinical and clinical data, the FDA may be constrained by limited resources from reviewing and determining the approvability of the Gencaro NDA in a timely manner.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In pursuing clinical development of Gencaro for an AF indication, ARCA will be required to amend the Gencaro HF NDA or prepare a new NDA.&#160;The FDA could approve Gencaro, but without including some or all of the prescribing information that ARCA has requested. For instance, the FDA could approve Gencaro for AF in a more limited patient population or include additional warnings in the drug&#8217;s label. This, in turn, could substantially and detrimentally impact ARCA&#8217;s ability to successfully commercialize Gencaro and effectively protect ARCA&#8217;s intellectual property rights in Gencaro.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA&#8217;s product candidates receive regulatory approval, ARCA would be subject to ongoing regulatory obligations and restrictions, which may result in significant expenses and limit its ability to develop and commercialize other potential products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a product candidate of ARCA&#8217;s is approved by the FDA or by another regulatory authority, ARCA would be held to extensive regulatory requirements over product manufacturing, testing, distribution, labeling, packaging, adverse event reporting and other reporting to regulatory authorities, storage, advertising, marketing, promotion, distribution, and record keeping. Regulatory approvals may also be subject to significant limitations on the indicated uses or marketing of the product candidates. Potentially costly follow<span class="nobreak">-up</span> or post<span class="nobreak">-marketing</span> clinical studies may be required as a condition of approval to further substantiate safety or efficacy, or to investigate specific issues of interest to the regulatory authority. Previously unknown problems with the product candidate, including adverse events of unanticipated severity or frequency, may result in additional regulatory controls or restrictions on the marketing or use of the product or the need for post marketing studies, and could include suspension or withdrawal of the products from the market.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, ARCA&#8217;s third<span class="nobreak">-party</span> manufacturers and the manufacturing facilities that they use to make ARCA&#8217;s product candidates are regulated by the FDA.&#160;Quality control and manufacturing procedures must continue to conform to cGMP after approval. Drug manufacturers and their subcontractors are required to register their facilities and products manufactured annually with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA, state and/or other foreign authorities. Any subsequent discovery of problems with a product, or a manufacturing or laboratory facility used by ARCA or its collaborators, may result in restrictions on the product, or on the manufacturing or laboratory facility, including a withdrawal of the drug from the market or suspension of manufacturing. Any changes to an approved product, including the way it is manufactured or promoted, often require FDA approval before the product, as modified, can be marketed. ARCA and its third<span class="nobreak">-party</span> manufacturers will also be subject to ongoing FDA requirements for submission of safety and other post<span class="nobreak">-market</span> information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The marketing and advertising of ARCA&#8217;s drug products by its collaborators or itself will be regulated by the FDA, certain state agencies or foreign regulatory authorities. Violations of these laws and regulations, including promotion of ARCA&#8217;s products for unapproved uses or failing to disclose risk information, are punishable by criminal and civil sanctions and may result in the issuance of enforcement letters or other enforcement action by the FDA, U.S.&#160;Department of Justice, state agencies, or foreign regulatory authorities that could jeopardize ARCA&#8217;s ability to market the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the FDA, state or foreign regulations, the marketing of ARCA&#8217;s drug products by itself or its collaborators will be regulated by federal, state or foreign laws pertaining to health care &#8220;fraud and abuse,&#8221; such as the federal anti<span class="nobreak">-kickback</span> law prohibiting bribes, kickbacks or other remuneration for the order or recommendation of items or services reimbursed by federal health care programs. Many states have similar laws applicable to items or services reimbursed by commercial insurers. Violations of these laws are punishable by criminal and civil sanctions, including, in some instances, imprisonment and exclusion from participation in federal and state health care programs, including the Medicare, Medicaid and Veterans Affairs healthcare programs. Because of the far<span class="nobreak">-reaching</span> nature of these laws, ARCA may be required to discontinue one or more of its practices to be in compliance with these laws. Healthcare fraud and abuse regulations are complex, and even minor irregularities can potentially give rise to claims that a statute or prohibition has been violated. Any violations of these laws, or any action against ARCA for violations of these laws, even if ARCA successfully defends against it, could have a material adverse effect on ARCA&#8217;s business, financial condition and results of operations.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">34</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA could also become subject to false claims litigation under federal statutes, which can lead to civil money penalties, restitution, criminal fines and imprisonment, and exclusion from participation in Medicare, Medicaid and other federal and state health care programs. These false claims statutes include the False Claims Act, which allows any person to bring a suit on behalf of the federal government alleging submission of false or fraudulent claims, or causing to present such false or fraudulent claims, under federal programs or contracts claims or other violations of the statute and to share in any amounts paid by the entity to the government in fines or settlement. These suits against pharmaceutical companies have increased significantly in volume and breadth in recent&#160;years. Some of these suits have been brought on the basis of certain sales practices promoting drug products for unapproved uses. This new growth in litigation has increased the risk that a pharmaceutical company will have to defend a false claim action, pay fines or restitution, or be excluded from the Medicare, Medicaid, Veterans Affairs and other federal and state healthcare programs as a result of an investigation arising out of such action. ARCA may become subject to such litigation and, if ARCA is not successful in defending against such actions, those actions may have a material adverse effect on its business, financial condition and results of operations. ARCA could also become subject to false claims litigation and consumer protection claims under state statutes, which also could lead to civil monetary penalties, restitution, criminal fines and imprisonment, and exclusion from participation in state health care programs. Of note, over the past few&#160;years there has been an increased focus on the sales and marketing practices of the pharmaceutical industry at both the federal and state level. Additionally, the law or regulatory policies governing pharmaceuticals may change. New statutory requirements may be enacted or additional regulations may be adopted that could prevent or delay regulatory approval of ARCA&#8217;s product candidates or limit ARCA&#8217;s ability to commercialize its products. ARCA cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United&#160;States or elsewhere.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA, its collaborators or its third<span class="nobreak">-party</span> manufacturers fail to comply with applicable continuing regulatory requirements, ARCA&#8217;s business could be seriously harmed because a regulatory agency may:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>issue untitled or warning letters;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>suspend or withdraw ARCA&#8217;s regulatory approval for approved products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seize or detain products or recommend a product recall of a drug or medical device, or issue a mandatory recall of a medical device;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>refuse to approve pending applications or supplements to approved applications filed by ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>suspend ARCA&#8217;s ongoing clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>restrict ARCA&#8217;s operations, including costly new manufacturing requirements, or restrict the sale, marketing and/or distribution of ARCA&#8217;s products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seek an injunction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursue criminal prosecutions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>close the facilities of ARCA&#8217;s contract manufacturers; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>impose civil or criminal penalties.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Reliance on third parties to commercialize Gencaro, rNAPc2 or ARCA&#8217;s other product candidates could negatively impact ARCA&#8217;s business. If ARCA is required to establish a direct sales force in the United&#160;States and are unable to do so, its business may be harmed.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Commercialization of Gencaro, rNAPc2 or any other product candidate, if approved, particularly the establishment of a sales organization, will require substantial additional capital resources. ARCA currently intends to pursue a strategic partnership alternative for the commercialization of Gencaro or rNAPc2, if it is approved, and ARCA has suspended its efforts to build internal sales, marketing and distribution capabilities. If ARCA elects to rely on third parties to sell Gencaro, rNAPc2 and any other products, then it may receive less revenue than if it sold such products directly. In addition, ARCA may have little or no control over the sales efforts of those third parties. If ARCA is unable to complete a strategic transaction, ARCA would be unable to commercialize Gencaro, rNAPc2 </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">35</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">or any other product candidate without substantial additional capital. Even if such capital were secured, ARCA would be required to build internal sales, marketing and distribution capabilities to market Gencaro or rNAPc2 in the United&#160;States. None of ARCA&#8217;s current employees have experience in establishing and managing a sales force.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event ARCA is unable to sell Gencaro, rNAPc2 and other selected product candidates, either directly or through third parties via a strategic transaction, the commercialization of Gencaro or rNAPc2, if approved, may be delayed indefinitely.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA is dependent on ARCA&#8217;s key personnel.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The success of ARCA&#8217;s business is highly dependent on the principal members of ARCA&#8217;s board of directors and executive management. The loss of the services of any such individual might seriously harm ARCA&#8217;s product development, partnering and financing efforts. Recruiting and training personnel with the requisite skills is challenging and ARCA competes for talent with companies that are larger and have more financial resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA has no manufacturing capacity which puts it at risk of lengthy and costly delays of bringing its products to market.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA does not currently operate manufacturing facilities for clinical or commercial production of its product candidates, including their drug substance or active pharmaceutical ingredients, or API.&#160;ARCA has no experience in drug formulation or manufacturing, and it lacks the resources and the capabilities to manufacture any of its product candidates on a clinical or commercial scale. ARCA does not intend to develop facilities for the manufacture of product candidates for clinical trials or commercial purposes in the foreseeable future. ARCA has contracted with several third<span class="nobreak">-party</span> manufacturing organizations for production and analytical testing of its product candidates. These contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store and distribute ARCA&#8217;s products. In addition, these manufacturers may have staffing difficulties, may experience delays due to key material or component availability, may not be able to manufacture ARCA&#8217;s products on a timely basis or may become financially distressed. In the event of errors in forecasting production quantities required to meet demand, natural disaster, equipment malfunctions or failures, technology malfunctions, strikes, lock<span class="nobreak">-outs</span> or work stoppages, regional power outages, product tampering, war or terrorist activities, actions of regulatory authorities, business failure, strike or other difficulty, ARCA may be unable to find an alternative third<span class="nobreak">-party</span> manufacturer in a timely manner and the production of its product candidates would be interrupted, resulting in delays and additional costs, which could impact ARCA&#8217;s ability to commercialize and sell its product candidates. ARCA or its contract manufacturers may also fail to achieve and maintain required manufacturing standards, which could result in patient injury or death, product recalls or withdrawals, an order by governmental authorities to halt production, delays or failures in product testing or delivery, stability testing failures, cost overruns or other problems that could seriously hurt ARCA&#8217;s business. Contract manufacturers also often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. In addition, ARCA&#8217;s contract manufacturers are subject to ongoing inspections and regulation by the FDA, the U.S.&#160;Drug Enforcement Agency and corresponding foreign and state agencies and they may fail to meet these agencies&#8217; acceptable standards of compliance. If ARCA&#8217;s contract manufacturers fail to comply with applicable governmental regulations, such as quality control, quality assurance and the maintenance of records and documentation, ARCA may not be able to continue production of the API or finished product. If the safety of any API or product supplied is compromised due to failure to adhere to applicable laws or for other reasons, this may jeopardize ARCA&#8217;s regulatory approval for Gencaro, rNAPc2 and other product candidates, and ARCA may be held liable for any injuries sustained as a result. Upon the occurrence of one of the aforementioned events, the ability to switch manufacturers may be difficult for a number of reasons, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the number of potential manufacturers is limited and ARCA may not be able to negotiate agreements with alternative manufacturers on commercially reasonable terms, if at all;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>long lead times are often needed to manufacture drugs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the manufacturing process is complex and may require a significant learning curve; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the FDA must approve any replacement prior to manufacturing, which requires new testing and compliance inspections.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">36</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Transitioning from a clinical development stage company will require successful completion of a number of steps, many of which are outside of ARCA&#8217;s control and, consequently, ARCA can provide no assurance of its successful and timely transition from a clinical development stage company.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is a clinical development stage biopharmaceutical company with a limited operating history. To date ARCA has not generated any product revenue and has historically funded ARCA&#8217;s operations through investment capital. ARCA&#8217;s future growth depends on its ability to emerge from the clinical development stage and successfully commercialize or provide for the commercialization of Gencaro, rNAPc2 and ARCA&#8217;s other product candidates, which in turn will depend, among other things, on ARCA&#8217;s ability to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>conduct additional clinical trials and develop and obtain regulatory approval for Gencaro, rNAPc2 or other product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>successfully partner a companion genetic test with the commercial launch of Gencaro or rNAPc2;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>enter into a strategic transaction enabling the continued development and commercialization of Gencaro or rNAPc2, or alternatively, raise significant additional capital to enable these activities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursue additional indications for Gencaro or rNAPc2 and develop other product candidates, including other cardiovascular therapies; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>obtain commercial quantities of Gencaro, rNAPc2 or other product candidates at acceptable cost levels.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any one of these factors or other factors discussed in this report could affect ARCA&#8217;s ability to successfully commercialize Gencaro and other product candidates, which could impact ARCA&#8217;s ability to earn sufficient revenues to transition from a clinical development stage company and continue ARCA&#8217;s business.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If approved by the FDA, Gencaro or rNAPc2 will be entering a competitive marketplace and may not succeed.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro is a new type of beta<span class="nobreak">-blocker</span> and vasodilator being developed for AF.&#160;While ARCA anticipates that this drug, if approved, would be the first genetically<span class="nobreak">-targeted</span> cardiovascular drug, and potentially the only beta<span class="nobreak">-blocker</span> approved for AF, Gencaro will be one of a number of accepted treatments for AF.&#160;In addition, ARCA&#8217;s proposed prescribing information for Gencaro is expected to include a requirement for genetic testing of the patient to ascertain if they have the genotype that ARCA believes responds best to Gencaro. This additional step will add incremental cost and procedures to prescribing Gencaro, which could make it more difficult to compete against existing therapies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA does not yet know what the commercial opportunity will be, if any, for rNAPc2 if it is approved for treating COVID<span class="nobreak">-19</span> disease. ARCA does not know how and to whom rNAPc2 would be marketed and what the commercial arrangements would be for its sales and reimbursement. While ARCA anticipates that rNAPc2, if approved, could potentially be used in combination with antiviral drugs and other therapies, there are other vaccines and therapies under development.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s commercial opportunity may be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient or are less expensive than Gencaro. If products with any of these properties are developed, or any of the existing products are better marketed, then prescriptions of Gencaro by physicians and patient use of Gencaro could be significantly reduced or rendered obsolete and noncompetitive. Further, public announcements regarding the development of any such competing drugs could adversely affect the market price of ARCA common stock and the value of ARCA&#8217;s assets.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Future sales of ARCA&#8217;s products may suffer if they are not accepted in the marketplace by physicians, patients and the medical community.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro, rNAPc2 or ARCA&#8217;s other product candidates may not gain market acceptance among physicians, patients and the medical community. The degree of market acceptance of Gencaro, rNAPc2 or ARCA&#8217;s other product candidates will depend on a number of factors, such as its effectiveness and tolerability, as compared with competitive drugs. For instance, if rNAPc2 is approved, by that time there may be superior alternatives in terms of vaccines and/or therapeutics that may significantly impact the relative medical benefits offered by rNAPc2. If </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">37</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">ARCA&#8217;s future clinical trials for rNAPc2 do not show that rNAPc2 has a clear therapeutic benefit as compared to other therapies or vaccines that are approved in the interim, then there may be a limited or no commercial market for rNAPc2. Also, prevalence and severity of side<span class="nobreak">-effects</span> could negatively affect market acceptance of rNAPc2. Failure to achieve market acceptance of Gencaro or rNAPc2 would significantly harm ARCA&#8217;s business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA is unable to obtain acceptable prices or adequate reimbursement from third<span class="nobreak">-party</span> payors for Gencaro, rNAPc2, or any other product candidates that it may seek to commercialize, then ARCA&#8217;s revenues and prospects for profitability will suffer.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s or any strategic partner&#8217;s ability to commercialize Gencaro, rNAPc2, or any other product candidates that ARCA may seek to commercialize, is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>governmental payors, such as Medicare and Medicaid;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>private health insurers, including managed<span class="nobreak">-care</span> organizations; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other third<span class="nobreak">-party</span> payors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Many patients will not be capable of paying for ARCA&#8217;s potential products themselves and will rely on third<span class="nobreak">-party</span> payors to pay for their medical needs. A primary current trend in the U.S.&#160;health care industry is toward cost containment. Large private payors, managed<span class="nobreak">-care</span> organizations, group purchasing organizations and similar organizations are exerting increasing influence on decisions regarding the use of, and reimbursement levels for, particular treatments. Such third<span class="nobreak">-party</span> payors, including Medicare, are challenging the prices charged for medical products and services, and many third<span class="nobreak">-party</span> payors limit reimbursement for newly approved health care products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cost<span class="nobreak">-control</span> initiatives could decrease the price ARCA might establish for products, which could result in product revenues lower than anticipated. If the prices for ARCA&#8217;s product candidates decrease, or if governmental and other third<span class="nobreak">-party</span> payors do not provide adequate coverage and reimbursement levels, then ARCA&#8217;s revenue and prospects for profitability will suffer.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Health care reform measures could materially and adversely affect ARCA&#8217;s business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The business and financial condition of pharmaceutical and biotechnology companies are affected by the efforts of governmental and third<span class="nobreak">-party</span> payors to contain or reduce the costs of health care. The U.S.&#160;Congress has enacted legislation to reform the health care system. While ARCA anticipates that this legislation may, over time, increase the number of patients who have insurance coverage for pharmaceutical products, it also imposes cost containment measures that may adversely affect the amount of reimbursement for pharmaceutical products. These measures include increasing the minimum rebates for products covered by Medicaid programs and extending such rebates to drugs dispensed to Medicaid beneficiaries enrolled in Medicaid managed care organizations as well as expansion of the 340(B)&#160;Public Health Services drug discount program. In addition, such legislation contains a number of provisions designed to generate the revenues necessary to fund the coverage expansion, including new fees or taxes on certain health<span class="nobreak">-related</span> industries, including medical device manufacturers. Each medical device manufacturer has to pay an excise tax (or sales tax) in an amount equal to 2.3% of the price for which such manufacturer sells its medical devices. Such excise taxes may impact any potential sales of the genetic test if it is approved for marketing. On January&#160;22, 2018, legislation was enacted suspending the medical device tax in 2018 and 2019. In December&#160;2019, a permanent repeal of the medical device tax was enacted. The Gencaro Test (as defined elsewhere in this proxy statement/prospectus) is likely to be subject to this tax if this tax is reinstated in the future. In foreign jurisdictions there have been, and ARCA expects that there will continue to be, a number of legislative and regulatory proposals aimed at changing the health care system. For example, in some countries other than the United&#160;States, pricing of prescription drugs is subject to government control and ARCA expects to see continued efforts to reduce healthcare costs in international markets.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Some states are also considering legislation that would control the prices of drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Managed care organizations continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs. </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">38</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on prices and reimbursement for drugs. It is likely that federal and state legislatures and health agencies will continue to focus on additional health care reform in the future although ARCA is unable to predict what additional legislation or regulation, if any, relating to the health care industry or third<span class="nobreak">-party</span> coverage and reimbursement may be enacted in the future or what effect such legislation or regulation would have on ARCA&#8217;s business. ARCA&#8217;s or any strategic partner&#8217;s ability to commercialize Gencaro, rNAPc2, or any other product candidates that ARCA may seek to commercialize, is highly dependent on the extent to which coverage and reimbursement for these product candidates will be available from government payors, such as Medicare and Medicaid, private health insurers, including managed care organizations, and other third<span class="nobreak">-party</span> payors, and any change in reimbursement levels could materially and adversely affect ARCA&#8217;s business. Further, the pendency or approval of future proposals or reforms could result in a decrease in ARCA&#8217;s stock price or limit ARCA&#8217;s ability to raise capital or to obtain strategic partnerships or licenses.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s competitors may be better positioned in the marketplace and thereby may be more successful than ARCA at developing, manufacturing and marketing approved products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Many of ARCA&#8217;s competitors currently have significantly greater financial resources and expertise in conducting clinical trials, obtaining regulatory approvals, managing manufacturing and marketing approved products than ARCA.&#160;Other early<span class="nobreak">-stage</span> companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. In addition, these third parties compete with ARCA in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring therapies and therapy licenses complementary to ARCA&#8217;s programs or advantageous to ARCA&#8217;s business. ARCA expects that its ability to compete effectively will depend upon its ability to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>successfully and rapidly complete clinical trials for any product candidates and obtain all requisite regulatory approvals in a cost<span class="nobreak">-effective</span> manner;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>build an adequate sales and marketing infrastructure, raise additional funding, or enter into strategic transactions enabling the commercialization of ARCA&#8217;s products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>develop competitive formulations of ARCA&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>attract and retain key personnel; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>identify and obtain other product candidates on commercially reasonable terms.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA fails to identify and license or acquire other products or product candidates, then it may be unable to expand its business, and the acquisition or licensing of other products or product candidates may put a strain on its operations and will likely require it to seek additional financing.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">One of ARCA&#8217;s strategies is to license or acquire clinical<span class="nobreak">-stage</span> products or product candidates and further develop them for commercialization. The market for licensing and acquiring products and product candidates is intensely competitive and many of ARCA&#8217;s competitors may have greater resources than ARCA does. If ARCA undertakes any additional acquisitions, whether of product candidates or other biopharmaceutical companies, the process of integrating an acquired product candidate or complementary company into ARCA&#8217;s business may put a strain on ARCA&#8217;s operations, divert personnel, financial resources and management&#8217;s attention. In 2020, ARCA&#8217;s research and development activities were dedicated to initiating the clinical trial of rNAPc2. If ARCA is not able to substantially expand ARCA&#8217;s research and development efforts, or identify, or license or acquire other products or product candidates or complete future acquisitions, then it will likely be unable expand its pipeline of product candidates. In addition, any future acquisition would give rise to additional operating costs and will likely require ARCA to seek additional financing. Future acquisitions could result in additional issuances of equity securities that would dilute the ownership of existing stockholders. Future acquisitions could also result in the incurrence of debt, contingent liabilities or the amortization of expenses related to other intangible assets, any of which could adversely affect ARCA&#8217;s operating results.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">39</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA would be subject to applicable regulatory approval requirements of the foreign countries in which it markets its products, which are costly and may prevent or delay ARCA from marketing its products in those countries.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to regulatory requirements in the United&#160;States, ARCA would be subject to the regulatory approval requirements in each foreign country where it markets its products. In addition, ARCA might be required to identify one or more collaborators in these foreign countries to develop, seek approval for and manufacture ARCA&#8217;s products and any companion genetic test for Gencaro. If ARCA decides to pursue regulatory approvals and commercialization of its product candidates internationally, it may not be able to obtain the required foreign regulatory approvals on a timely basis, if at all, and any failure to do so may cause ARCA to incur additional costs or prevent it from marketing it products in foreign countries, which may have a material adverse effect on its business, financial condition and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If ARCA&#8217;s internal control over financial reporting is not considered effective, ARCA&#8217;s business and stock price could be adversely affected.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act&#160;of&#160;2002 requires ARCA to evaluate the effectiveness of its internal control over financial reporting as of the end of each fiscal year, and to include a management report assessing the effectiveness of its internal control over financial reporting in its annual report on Form&#160;10<span class="nobreak">-K</span> for that fiscal year. ARCA&#8217;s management, including ARCA&#8217;s principal executive officer and principal financial officer, does not expect that ARCA&#8217;s internal control over financial reporting will prevent all error and all fraud. ARCA continues to operate with a small staff for financial reporting. Though the process and design of ARCA&#8217;s internal controls over financial reporting have not been altered, the small number of staff involved in financial reporting may limit ARCA&#8217;s ability to properly segregate internal control procedures which could result in deficiencies or material weaknesses in ARCA&#8217;s internal controls in the future. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud involving a company have been, or will be, detected. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and ARCA cannot assure you that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become ineffective because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost<span class="nobreak">-effective</span> control system, misstatements due to error or fraud may occur and not be detected. ARCA cannot assure you that it or its independent registered public accounting firm will not identify a material weakness in ARCA&#8217;s internal control over financial reporting in the future. A material weakness in ARCA&#8217;s internal control over financial reporting would require management to consider ARCA&#8217;s internal control over financial reporting as ineffective. If ARCA&#8217;s internal control over financial reporting is not considered effective, ARCA may experience a loss of public confidence, which could have an adverse effect on its business and on the market price of ARCA common stock.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Changes in tax laws or regulations that are applied adversely to ARCA or its customers may have a material adverse effect on ARCA&#8217;s business, cash flow, financial condition or results of operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of ARCA&#8217;s domestic and foreign earnings. Any new taxes could adversely affect ARCA&#8217;s domestic and international business operations, and ARCA&#8217;s business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to ARCA.&#160;For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, significantly revised the Internal Revenue Code of 1986, as amended, or the Code. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Cuts and Jobs Act may affect ARCA, and certain aspects of the Tax Cuts and Jobs Act could be repealed or modified in future legislation. In addition, it is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to ARCA&#8217;s operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Cuts and Jobs Act or future reform legislation could have a material impact on the value of ARCA&#8217;s deferred tax assets, could result in significant one<span class="nobreak">-time</span> charges, and could increase ARCA&#8217;s future U.S.&#160;tax expense.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">40</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s ability to use ARCA&#8217;s net operating losses to offset future taxable income may be subject to certain limitations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, ARCA had net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $208.1&#160;million, and approximately $2.4&#160;million of research and development credits that may be used to offset future taxable income. ARCA had net operating loss carryforwards of $156.4&#160;million generated prior to 2018, which will expire beginning in 2025 if not utilized. Under the Tax Cuts and Jobs Act, ARCA&#8217;s U.S.&#160;federal NOLs of $51.7&#160;million incurred in tax&#160;years beginning after December&#160;31, 2017, may be carried forward indefinitely, but the deductibility of federal NOLs generated in tax&#160;years beginning after December&#160;31, 2017, is limited to 80% of taxable income. In addition, under Section&#160;382 of the Code, a corporation that undergoes an &#8220;ownership change&#8221; (as defined under Section&#160;382 of the Code and applicable Treasury Regulations) is subject to limitations on its ability to utilize its pre<span class="nobreak">-change</span> NOLs to offset future taxable income. ARCA has not determined whether it has experienced an ownership change in the past, and ARCA may experience ownership changes in the future as a result of subsequent shifts in ARCA&#8217;s stock ownership, some of which may be outside of ARCA&#8217;s control. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs or other unforeseen reasons, ARCA&#8217;s existing NOLs could expire or otherwise be unavailable to reduce future income tax liabilities, including for state tax purposes. For these reasons, ARCA may not be able to utilize a material portion of the NOLs reflected on its balance sheet, offset by a full valuation, even if it attains profitability, which could potentially result in increased future tax liability to ARCA and could adversely affect its operating results and financial condition.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Security breaches, cyber-attacks, or other disruptions or incidents could expose ARCA to liability and affect its business and reputation.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is increasingly dependent on its information technology systems and infrastructure for its business. ARCA, its collaborators and its service providers collect, store, and transmit sensitive information including intellectual property, proprietary business information, clinical trial data and personal information in connection with ARCA&#8217;s business operations. The secure maintenance of this information is critical to ARCA&#8217;s operations and business strategy. Some of this information could be an attractive target of criminal attack by third parties with a wide range of motives and expertise, including organized criminal groups, &#8220;hacktivists,&#8221; patient groups, disgruntled current or former employees, nation<span class="nobreak">-state</span> and nation<span class="nobreak">-state</span> supported actors, and others. Cyber<span class="nobreak">-attacks</span> are of ever<span class="nobreak">-increasing</span> levels of sophistication, and despite ARCA&#8217;s security measures, ARCA&#8217;s information technology and infrastructure may be vulnerable to such attacks or may be breached, including due to employee error or malfeasance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has implemented information security measures to protect ARCA&#8217;s systems, proprietary information and sensitive data against the risk of inappropriate and unauthorized external use and disclosure and other types of compromise. However, despite these measures, and due to the ever<span class="nobreak">-changing</span> information cyber<span class="nobreak">-threat</span> landscape, ARCA cannot guarantee that these measures will be adequate to detect, prevent or mitigate security breaches and other incidents and ARCA may be subject to data breaches through cyber<span class="nobreak">-attacks</span>, malicious code (such as viruses and worms), phishing attacks, social engineering schemes, and insider theft or misuse. Any such breach could compromise ARCA&#8217;s networks and the information stored there could be accessed, modified, destroyed, publicly disclosed, lost or stolen. If ARCA&#8217;s systems become compromised, ARCA may not promptly discover the intrusion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any security breach of other incident, whether real or perceived, could cause ARCA to suffer reputational damage. Such incidents could result in costs to respond to, investigate and remedy such incidents, notification obligations to affected individuals, government agencies, credit reporting agencies and other third parties, legal claims or proceedings, and liability under ARCA&#8217;s contracts with other parties and federal and state laws that protect the privacy and security of personal information. Any one of these events could cause ARCA&#8217;s business to be materially harmed and its results of operations would be adversely impacted.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Failure to comply with data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect ARCA&#8217;s operating results and business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and its partners may be subject to federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). In the United&#160;States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">41</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">and federal and state consumer protection laws and regulations (e.g., Section&#160;5 of the FTC Act), that govern the collection, use, disclosure, and protection of health<span class="nobreak">-related</span> and other personal information could apply to ARCA&#8217;s operations or the operations of ARCA&#8217;s partners. In addition, ARCA may obtain health information from third parties (including research institutions from which ARCA obtains clinical trial data) that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act&#160;of&#160;1996, as amended, or HIPAA.&#160;Depending on the facts and circumstances, ARCA could be subject to criminal penalties if it knowingly obtains, uses or discloses individually identifiable health information maintained by a HIPAA<span class="nobreak">-covered</span> entity in a manner that is not authorized or permitted by HIPAA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the California Consumer Privacy Act, or the CCPA, became effective on January&#160;1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt<span class="nobreak">-out</span> of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although there are limited exemptions for clinical trial data and the CCPA&#8217;s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, the CCPA may increase ARCA&#8217;s compliance costs and potential liability. Many similar privacy laws have been proposed at the federal level and in other states.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Foreign data protection laws, including, without limitation, the European Union Directive 95/46/EC (the &#8220;Directive&#8221;) and the European Union&#8217;s General Data Protection Regulation (the &#8220;GDPR&#8221;) that became effective in May&#160;2018, and member state data protection legislation, may also apply to health<span class="nobreak">-related</span> and other personal information obtained outside of the United&#160;States. These laws impose strict obligations on the ability to process health<span class="nobreak">-related</span> and other personal information of data subjects in the European Union and the United Kingdom, including in relation to use, collection, analysis, and transfer (including cross<span class="nobreak">-border</span> transfer) of such personal information. These laws include several requirements relating to the consent of the individuals to whom the personal data relates, limitations on data processing, establishing a legal basis for processing, notification of data processing obligations or security incidents to appropriate data protection authorities or data subjects, the security and confidentiality of the personal data and various rights that data subjects may exercise.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Directive and the GDPR prohibit, without an appropriate legal basis, the transfer of personal data to countries outside of the European Economic Area, or EEA, such as the United&#160;States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted similar restrictions. Although there are legal mechanisms to allow for the transfer of personal data from the EEA and Switzerland to the United&#160;States, uncertainty about compliance with European Union data protection laws remains. For example, ongoing legal challenges in Europe to the mechanisms allowing companies to transfer personal data from the EEA to the United&#160;States could result in further limitations on the ability to transfer personal data across borders, particularly if governments are unable or unwilling to reach new or maintain existing agreements that support cross<span class="nobreak">-border</span> data transfers, such as the European Union<span class="nobreak">-U</span>.S.&#160;and Swiss<span class="nobreak">-U</span>.S.&#160;Privacy Shield framework. Additionally, other countries have passed or are considering passing laws requiring local data residency.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the GDPR, regulators may impose substantial fines and penalties for non<span class="nobreak">-compliance</span>. Companies that violate the GDPR can face fines of up to the greater of 20&#160;million Euros or 4% of their worldwide annual turnover (revenue). The GDPR increases ARCA&#8217;s responsibility and potential liability in relation to personal data that ARCA processes, and ARCA may be required to put in place additional mechanisms to ensure compliance with the GDPR and other EU and international data protection rules.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Compliance with U.S.&#160;and foreign privacy and security laws, rules and regulations could require ARCA to take on more onerous obligations in its contracts, require it to engage in costly compliance exercises, restrict its ability to collect, use and disclose data, or in some cases, impact its or its partners&#8217; or suppliers&#8217; ability to operate in certain jurisdictions. Each of these constantly evolving laws can be subject to varying interpretations. Failure to comply with U.S.&#160;and foreign data protection laws and regulations could result in government investigations and enforcement actions (which could include civil or criminal penalties), fines, private litigation, and/or adverse publicity and could negatively affect ARCA&#8217;s operating results and business. Moreover, patients about whom ARCA or its partners obtain information, as well as the providers who share this information with ARCA, may contractually limit ARCA&#8217;s </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">42</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">ability to use and disclose the information. Claims that ARCA has violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached its contractual obligations, even if ARCA is not found liable, could be expensive and time<span class="nobreak">-consuming</span> to defend and could result in adverse publicity that could harm ARCA&#8217;s business.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Intellectual Property and Other Legal Matters</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If product liability lawsuits are successfully brought against ARCA, then ARCA will incur substantial liabilities and may be required to limit commercialization of Gencaro, rNAPc2 or other product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA faces product liability exposure related to the testing of its product candidates in human clinical trials, and may face exposure to claims by an even greater number of persons once it begins marketing and distributing ARCA&#8217;s products commercially. If ARCA cannot successfully defend against product liability claims, then it will incur substantial liabilities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regardless of merit or eventual outcome, liability claims may result in:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>decreased demand for ARCA&#8217;s products and product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>injury to ARCA&#8217;s reputation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>withdrawal of clinical trial participants;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>costs of related litigation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>substantial monetary awards to patients and others;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>loss of revenues; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the inability to commercialize ARCA&#8217;s products and product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has obtained limited product liability insurance coverage. Such coverage, however, may not be adequate or may not continue to be available to ARCA in sufficient amounts or at an acceptable cost, or at all. ARCA may not be able to obtain commercially reasonable product liability insurance for any product candidate.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Defending against claims relating to improper handling, storage or disposal of hazardous chemicals, radioactive or biological materials could be time consuming and expensive.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s research and development of product candidates may involve the controlled use of hazardous materials, including chemicals, radioactive and biological materials. ARCA cannot eliminate the risk of accidental contamination or discharge and any resultant injury from the materials. Various laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. ARCA may be sued or be required to pay fines for any injury or contamination that results from its use or the use by third parties of these materials. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair ARCA&#8217;s research, development and production efforts.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The loss of any rights to market key products would significantly impair ARCA&#8217;s operating results.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s patent portfolios relating to Gencaro, including a patent that issued in 2021, are either owned by ARCA or are subject to licenses that impose no royalty obligations or milestone payments relating to the further development, approval and commercialization of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Termination of ARCA&#8217;s license agreements could result in the loss of its further rights to develop and commercialize Gencaro for any indication. The termination of any such license, or of any other agreement which enables ARCA to market a key product or product candidate, could significantly and adversely affect its business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain intellectual property licensed by ARCA is the subject of additional licensing arrangements to which the party that has licensed rights to ARCA is subject. If such parties were to breach the terms of such licenses or such licenses were otherwise to terminate, ARCA&#8217;s and ARCA&#8217;s partners&#8217; rights to use such technology and develop and commercialize their products such as the genetic test may terminate and ARCA&#8217;s business would be materially harmed.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">43</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Third parties may own or control patents or patent applications that ARCA may be required to license to commercialize ARCA&#8217;s product candidates or that could result in litigation that would be costly and time consuming.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s or any strategic partner&#8217;s ability to commercialize Gencaro, rNAPc2 and other product candidates depends upon ARCA&#8217;s ability to develop, manufacture, market and sell these drugs without infringing the proprietary rights of third parties. A number of pharmaceutical and biotechnology companies, universities and research institutions have or may be granted patents that cover technologies similar to the technologies owned by or licensed to ARCA.&#160;ARCA may choose to seek, or be required to seek, licenses under third<span class="nobreak">-party</span> patents, which would likely require the payment of license fees or royalties or both. ARCA may also be unaware of existing patents that may be infringed by Gencaro or rNAPc2, the genetic testing ARCA intends to use in connection with Gencaro or its other product candidates. Because patent applications can take many&#160;years to issue, there may be other currently pending applications that may later result in issued patents that are infringed by Gencaro, rNAPc2 or ARCA&#8217;s other product candidates. Moreover, a license may not be available to ARCA on commercially reasonable terms, or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims that ARCA is infringing on its technology, then ARCA&#8217;s business and results of operations could be harmed by a number of factors, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>infringement and other intellectual property claims, even if without merit, are expensive and time<span class="nobreak">-consuming</span> to litigate and can divert management&#8217;s attention from ARCA&#8217;s core business;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>monetary damage awards for past infringement can be substantial;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a court may prohibit ARCA from selling or licensing product candidates unless the patent holder chooses to license the patent to ARCA; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if a license is available from a patent holder, ARCA may have to pay substantial royalties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA may also be forced to bring an infringement action if its believes that a competitor is infringing ARCA&#8217;s protected intellectual property. Any such litigation will be costly, time<span class="nobreak">-consuming</span> and divert management&#8217;s attention, and the outcome of any such litigation may not be favorable to ARCA.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s intellectual property rights may not preclude competitors from developing competing products and ARCA&#8217;s business may suffer.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s competitive success will depend, in part, on ARCA&#8217;s ability to obtain and maintain patent protection for its inventions, technologies and discoveries, including intellectual property that ARCA licenses. The patent positions of biotechnology companies involve complex legal and factual questions, and ARCA cannot be certain that its patents and licenses will successfully preclude others from using its technology. Consequently, ARCA cannot be certain that any of its patents will provide significant market protection or will not be circumvented or challenged and found to be unenforceable or invalid. In some cases, patent applications in the United&#160;States and certain other jurisdictions are maintained in secrecy until patents issue, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, ARCA cannot be certain of the priority of inventions covered by pending patent applications. Moreover, ARCA may have to participate in interference proceedings declared by the U.S.&#160;Patent and Trademark Office to determine priority of invention, in opposition proceedings in a foreign patent office, or in a post<span class="nobreak">-grant</span> challenge proceeding such as an <span class="Italic" style="font-style:italic;font-weight:normal;">ex parte</span> reexamination or <span class="Italic" style="font-style:italic;font-weight:normal;">inter partes</span> review at the U.S.&#160;Patent and Trademark Office, any of which could result in substantial cost to ARCA, even if the eventual outcome is favorable. There can be no assurance that a court of competent jurisdiction would hold any claims in any issued patent to be valid and enforceable. An adverse outcome could subject ARCA to significant liabilities to third parties, require disputed rights to be licensed from third parties or require ARCA to cease using such technology.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA owns the clinical development program of rNAPc2, including Phase&#160;2b clinical trials. If rNAPc2 is successfully developed, ARCA believes it will have intellectual property protection for a specific use, including 12&#160;years of market exclusivity as an innovative biologic product under FDA law in the United&#160;States, 10&#160;years data protection exclusivity in the EU, and potentially patent protection in addition to this. However, another competitor could develop a compound with similar biological properties to rNAPc2 that may not be barred by ARCA&#8217;s exclusivity. ARCA has also filed a patent application for rNAPc2 and its use for COVID<span class="nobreak">-19</span> disease, but there is no assurance that this application will ultimately result in an issued patent.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">44</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regardless of merit, the listing of patents in the FDA Orange Book for Gencaro may be challenged as being improperly listed. ARCA may have to defend against such claims and possible associated antitrust issues. ARCA could also incur substantial costs in seeking to enforce its proprietary rights against infringement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While the composition of matter patents on the compound that comprises Gencaro have expired, ARCA holds intellectual property concerning the interaction of Gencaro with the polymorphisms of the beta<span class="nobreak">-1</span> and alpha<span class="nobreak">-2C</span> receptors. ARCA has obtained patents that claim methods involving Gencaro after a patient&#8217;s receptor genotype has been determined. ARCA anticipates that any NDA for Gencaro will request a label including a claim that efficacy varies based on receptor genotype and a recommendation in the prescribing information that prospective patients be tested for their receptor genotype. ARCA believes that under applicable law, a generic bucindolol label would likely be required to include this recommendation as it pertains directly to the safe or efficacious use of the drug. Such a label may be considered as inducing infringement, carrying the same liability as direct infringement. If the label with the genotype information for Gencaro is not approved or it is approved after the relevant patents expire, or if generic labels are not required to copy the approved label, competitors could have an easier path to introduce competing products and ARCA&#8217;s business may suffer. The approved label may not contain language covered by the patents, or ARCA may be unsuccessful in enforcing them.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA also has obtained intellectual property related to the use of Gencaro for various cardiovascular indications in the genetic population it plans to study in Phase&#160;3. The approved label may not contain language covered by ARCA&#8217;s patents and it is possible the intellectual property may not preclude others from commercializing a generic version of Gencaro, which could cause ARCA&#8217;s business to suffer. Additionally, the patents may be invalidated and/or ARCA may be unsuccessful in enforcing them.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA may not be able to effectively protect its intellectual property rights in some foreign countries, as its patents are limited by jurisdiction and many countries do not offer the same level of legal protection for intellectual property as the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA requires its employees, consultants, business partners and members of its scientific advisory board to execute confidentiality agreements upon the commencement of employment, consulting or business relationships with ARCA.&#160;These agreements provide that all confidential information developed or made known during the course of the relationship with ARCA be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions resulting from work performed for ARCA, utilizing the property or relating to ARCA&#8217;s business and conceived or completed by the individual during employment shall be ARCA&#8217;s exclusive property to the extent permitted by applicable law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Third parties may breach these and other agreements with ARCA regarding its intellectual property and ARCA may not have adequate remedies for the breach. Third parties could also fail to take necessary steps to protect ARCA&#8217;s licensed intellectual property, which could seriously harm ARCA&#8217;s intellectual property position.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA is not able to protect its proprietary technology, trade secrets and know<span class="nobreak">-how</span>, then its competitors may develop competing products. Any issued patent may not be sufficient to prevent others from competing with ARCA.&#160;Further, ARCA has trade secrets relating to rNAPc2 and Gencaro, and such trade secrets may become known or independently discovered. ARCA&#8217;s issued patents and those that may issue in the future, or those licensed to ARCA, may be challenged, opposed, invalidated or circumvented, which could allow competitors to market similar products or limit the patent protection term of ARCA&#8217;s product candidates. All of these factors may affect ARCA&#8217;s competitive position.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the manufacture, use or sale of ARCA&#8217;s products infringe on the intellectual property rights of others, ARCA could face costly litigation, which could cause it to pay substantial damages or licensing fees and limit its ability to sell some or all of its products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Extensive litigation regarding patents and other intellectual property rights has been common in the biopharmaceutical industry. Litigation may be necessary to assert infringement claims, enforce patent rights, protect trade secrets or know<span class="nobreak">-how</span> and determine the enforceability, scope and validity of certain proprietary rights. Litigation may even be necessary to defend disputes of inventorship or ownership of proprietary rights. The defense and prosecution of intellectual property lawsuits, U.S.&#160;Patent and Trademark Office interference proceedings, and related legal and administrative proceedings (e.g., a reexamination, <span class="Italic" style="font-style:italic;font-weight:normal;">inter partes</span> review, or post<span class="nobreak">-grant</span> review) in the United&#160;States and internationally involve complex legal and factual questions. As a result, such proceedings are costly and time<span class="nobreak">-consuming</span> to pursue, and their outcome is uncertain.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">45</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regardless of merit or outcome, ARCA&#8217;s involvement in any litigation, interference or other administrative proceedings could cause it to incur substantial expense and could significantly divert the efforts of its technical and management personnel. Any public announcements related to litigation or interference proceedings initiated or threatened against ARCA could cause ARCA&#8217;s stock price to decline. Adverse outcomes in patent litigation may potentially subject ARCA to antitrust litigation which, regardless of the outcome, would adversely affect ARCA&#8217;s business. An adverse determination may subject ARCA to the loss of its proprietary position or to significant liabilities, or require it to seek licenses that may include substantial cost and ongoing royalties. Licenses may not be available from third parties, or may not be obtainable on satisfactory terms. An adverse determination or a failure to obtain necessary licenses may restrict or prevent ARCA from manufacturing and selling its products, if any. These outcomes could materially harm ARCA&#8217;s business, financial condition and results of operations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Ownership of ARCA Common Stock and Stock Price Volatility</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s stock price has been and is expected to be volatile.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA common stock has in the past been, and in the future could be, subject to significant fluctuations. Market prices for securities of early<span class="nobreak">-stage</span> pharmaceutical, biotechnology and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of ARCA common stock to fluctuate include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure to complete, or delays in completing, the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the regulatory status of Gencaro, rNAPc2 and the genetic test, and whether and when they are approved for sale, if at all, and the labeling or other conditions of use imposed by the FDA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to secure additional funding or complete a strategic transaction or to complete development of and commercialize Gencaro or rNAPc2;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>progress of any future clinical trials for Gencaro, rNAPc2 or ARCA&#8217;s other product candidate, including enrollment and any data that may become available;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the results of ARCA&#8217;s future clinical trials and any future NDAs of ARCA&#8217;s current and future product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the entry into, or termination of, key agreements, including key strategic alliance agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the results and timing of regulatory reviews relating to ARCA&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure of any of ARCA&#8217;s product candidates, if approved, to achieve commercial success;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general and industry<span class="nobreak">-specific</span> economic conditions that may affect ARCA&#8217;s research and development expenditures;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the results of clinical trials conducted by others on drugs that would compete with ARCA&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>issues in manufacturing or testing ARCA&#8217;s product candidates or any approved products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the initiation of or material developments in or the conclusion of litigation to enforce or defend any of ARCA&#8217;s intellectual property rights;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the loss of key employees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the introduction of technological innovations or new commercial products by ARCA&#8217;s competitors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>changes in estimates or recommendations by securities analysts, if any, who cover ARCA common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>future sales of ARCA common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>changes in the structure of health care payment systems;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>period<span class="nobreak">-to-period</span> fluctuations in ARCA&#8217;s financial results; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of ARCA common stock on the Nasdaq Capital Market.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">46</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict. These broad market fluctuations may also adversely affect the trading price of ARCA common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm ARCA&#8217;s profitability and reputation.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Future sales or the possibility of future sales of ARCA common stock may depress the market price of ARCA common stock.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Sales in the public market of substantial amounts of ARCA common stock could depress prevailing market prices of ARCA common stock. As of March&#160;31, 2024, approximately 14.5<span class="nobreak"> </span>million shares of common stock were outstanding, and all of these shares are freely transferable without restriction or further registration under the Securities Act&#160;of&#160;1933, as amended, or the Securities Act, except for shares held by ARCA&#8217;s directors, officers and other affiliates and unregistered shares held by non<span class="nobreak">-affiliates</span>. The sale of these additional shares, or the perception that such sales may occur, could depress the market price of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, there were approximately 646,000<span class="nobreak"> </span>shares of ARCA common stock which may be issued upon the exercise of outstanding stock options, and ARCA anticipates that it will continue to issue stock option and restricted stock unit awards to its employees and consultants in the fiscal year ended December&#160;31, 2024 and thereafter. If and when these options are exercised, such shares will be available for sale in the open market without further registration under the Securities Act. The existence of these outstanding options may negatively affect ARCA&#8217;s ability to complete future equity financings at acceptable prices and on acceptable terms. The exercise of those options, and the prompt resale of shares of ARCA common stock received, may also result in downward pressure on the price of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the absence of a significant strategic transaction, ARCA will need to raise significant additional capital to finance the research, development and commercialization of Gencaro, rNAPc2 and its other product candidate. If future securities offerings occur, they would dilute ARCA&#8217;s current stockholders&#8217; equity interests and could reduce the market price of ARCA common stock.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA does not expect to pay cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their investment.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has never paid cash dividends on any of its capital stock. As a result, other than the potential special cash dividend described below, only appreciation of the price of ARCA common stock will provide a return to stockholders. Investors seeking cash dividends should not invest in ARCA common stock. In addition, pursuant to the terms of the Merger Agreement, ARCA may declare and pay a special cash dividend to ARCA stockholders of record prior to the closing of the Merger consisting of cash up to an amount equal in the aggregate of the amount by which ARCA&#8217;s net cash will exceed $5.0&#160;million. See, &#8220;ARCA has never paid and, other than in connection with the Merger with Oruka, do not intend to pay any cash dividends in the foreseeable future&#8221; for further discussion on the special cash dividend.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA&#8217;s business could be negatively affected as a result of actions of activist shareholders.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Responding to actions by activist shareholders could be costly and time<span class="nobreak">-consuming</span>, disrupt ARCA&#8217;s operations and divert the attention of management and ARCA&#8217;s employees. For example, in connection with the negotiation and entry into a cooperation agreement in June&#160;2022 with Cable Car Capital LLC, The Funicular Fund, LP, Funicular Funds, LP and Jacob Ma<span class="nobreak">-Weaver</span>, collectively, Cable Car, one of ARCA&#8217;s stockholders, ARCA appointed two new directors in 2022. Activist shareholders may advocate for certain governance and strategic changes at ARCA.&#160;In the event of stockholder activism, particularly with respect to matters which ARCA&#8217;s board of directors, in exercising their fiduciary duties, disagree with or have determined not to pursue, ARCA&#8217;s business could be adversely affected because responding to actions by activist stockholders can be costly and time<span class="nobreak">-consuming</span>, disrupting ARCA&#8217;s </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">47</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">operations and diverting the attention of management, and perceived uncertainties as to ARCA&#8217;s future direction may result in the loss of potential business opportunities and may make it more difficult to attract and retain qualified personnel, business partners, and customers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, if faced with a consent solicitation or proxy contest, ARCA may not be able to respond successfully to the contest or dispute, which would be disruptive to its business. If individuals are elected to ARCA&#8217;s board of directors with a differing agenda, ARCA&#8217;s ability to effectively and timely implement its strategic plan and create additional value for ARCA stockholders may be adversely affected. In addition, ARCA&#8217;s share price could experience periods of increased volatility as a result of shareholder activism.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA has implemented anti-takeover provisions that could discourage, prevent or delay a takeover, even if the acquisition would be beneficial to ARCA stockholders.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Provisions of the ARCA Charter and ARCA Bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire ARCA, even if doing so would benefit ARCA stockholders. These provisions:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establish a classified board of directors so that not all members of ARCA&#8217;s board may be elected at one time;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>authorize the issuance of up to approximately 5&#160;million additional shares of preferred stock that could be issued by ARCA&#8217;s board of directors to increase the number of outstanding shares and hinder a takeover attempt;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>limit who may call a special meeting of stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>prohibit stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of ARCA stockholders; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establish advance notice requirements for nominations for election to ARCA&#8217;s board of directors or for proposing matters that can be acted upon at a stockholder meeting.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Specifically, the ARCA Charter provides that all stockholder action must be effected at a duly called meeting and not by a written consent. The ARCA Bylaws provide, however, that ARCA stockholders may call a special meeting of stockholders only upon a request of stockholders owning at least 50% of ARCA&#8217;s outstanding common stock. These provisions of the ARCA Charter and ARCA Bylaws could discourage potential acquisition proposals and could delay or prevent a change in control. ARCA designed these provisions to reduce its vulnerability to unsolicited acquisition proposals and to discourage certain tactics that may be used in proxy fights. These provisions, however, could also have the effect of discouraging others from making tender offers for ARCA&#8217;s shares. As a consequence, they also may inhibit fluctuations in the market price of ARCA&#8217;s shares that could result from actual or rumored takeover attempts. Such provisions also may have the effect of preventing changes in ARCA&#8217;s management.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is permitted to issue shares of ARCA preferred stock without stockholder approval upon such terms as ARCA&#8217;s board of directors determines. Therefore, the rights of the holders of ARCA common stock are subject to, and may be adversely affected by, the rights of the holders of ARCA preferred stock that may be issued in the future. In addition, the issuance of preferred stock could have a dilutive effect on the holdings of ARCA&#8217;s current stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is subject to the Delaware anti<span class="nobreak">-takeover</span> laws regulating corporate takeovers. These anti<span class="nobreak">-takeover</span> laws prevent a Delaware corporation from engaging in a merger or sale of more than 10% of its assets with any stockholder, including all affiliates and associates of the stockholder, who owns 15% or more of the corporation&#8217;s outstanding voting stock, for three&#160;years following the date that the stockholder acquired 15% or more of the corporation&#8217;s stock unless:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the board of directors approved the transaction where the stockholder acquired 15% or more of the corporation&#8217;s stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>after the transaction in which the stockholder acquired 15% or more of the corporation&#8217;s stock, the stockholder owned at least 85% of the corporation&#8217;s outstanding voting stock, excluding shares owned </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">48</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">by directors, officers and employee stock plans in which employee participants do not have the right to determine confidentially whether shares held under the plan will be tendered in a tender or exchange offer; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>on or after this date, the merger or sale is approved by the board of directors and the holders of at least two<span class="nobreak">-thirds</span> of the outstanding voting stock that is not owned by the stockholder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The provisions of ARCA&#8217;s governing documents and current Delaware law may, collectively:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>lengthen the time required for a person or entity to acquire control of ARCA through a proxy contest for the election of a majority of ARCA&#8217;s board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>discourage bids for ARCA common stock at a premium over market price; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>generally deter efforts to obtain control of ARCA.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Oruka</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Oruka&#8217;s Financial Condition and Capital Requirements</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Even if the Merger and Oruka pre-closing financing are successful, Oruka will need to raise additional capital, and if it is unable to do so when needed, that will raise substantial doubt about Oruka&#8217;s ability to continue as a going concern.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, Oruka had $27.7&#160;million of cash. Should this financing be successful, Oruka will need to raise additional capital to continue to fund its operations and service its debt obligations in the future. If Oruka is unable to raise additional capital when needed, that will raise substantial doubt about Oruka&#8217;s ability to continue as a going concern. As a result, Oruka has concluded there is substantial doubt about its ability to continue as a going concern for at least twelve months from the date its financial statement as of February<span class="nobreak"> </span>6, 2024 is available to be issued. In light of these concerns, Oruka&#8217;s independent registered public accounting firm included in its opinion on the financial statement an explanatory paragraph expressing substantial doubt about Oruka&#8217;s ability to continue as a going concern beyond twelve months from the date Oruka&#8217;s financial statement is available to be issued.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Developing Oruka&#8217;s product candidates requires a substantial amount of capital. Following the Merger and Oruka pre<span class="nobreak">-closing</span> financing, the combined company will also incur additional costs associated with operating as a public company. Oruka expects its research and development expenses to increase in connection with its ongoing activities, particularly as it advances its product candidates through clinical trials. Oruka will need to raise additional capital to fund its operations and such funding may not be available to Oruka on acceptable terms, or at all, and such funding may become even more difficult to obtain due to rising interest rates and the current downturn in the U.S.&#160;capital markets and the biotechnology sector in general. Competition for additional capital among biotechnology companies may be particularly intense during this present economic downturn. Oruka may be unable to raise capital through public offerings of its common stock and may need to turn to alternative financing arrangements. Such arrangements, if Oruka pursues them, could involve issuances of one or more types of securities, including common stock, preferred stock, convertible debt, warrants to acquire common stock or other securities. These securities could be issued at or below the then prevailing market price for Oruka common stock. In addition, if Oruka issues debt securities, the holders of the debt would have a claim to Oruka&#8217;s assets that would be superior to the rights of stockholders until the principal, accrued and unpaid interest and any premium or make<span class="nobreak">-whole</span> has been paid. Interest on any newly<span class="nobreak">-issued</span> debt securities and/or newly<span class="nobreak">-incurred</span> borrowings would increase Oruka&#8217;s operating costs and reduce its net income (or increase its net loss), and these impacts may be material. If the issuance of new securities results in diminished rights to holders of Oruka common stock, the market price of Oruka common stock could be materially and adversely affected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka does not currently have any products approved for sale and does not generate any revenue from product sales. Accordingly, Oruka expects to rely primarily on equity and/or debt financings to fund its continued operations. Oruka&#8217;s ability to raise additional funds will depend, in part, on the success of its preclinical studies and clinical trials and other product development activities, regulatory events, its ability to identify and enter into licensing or other strategic arrangements, and other events or conditions that may affect its value or prospects, as well as factors related to financial, economic and market conditions, many of which are beyond Oruka&#8217;s control. There can be no assurances that sufficient funds will be available to Oruka when required or on acceptable terms, if at all.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">49</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka is unable to raise additional capital when required or on acceptable terms, it may be required to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>significantly delay, scale back, or discontinue the development or commercialization of its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seek strategic partnerships, or amend existing partnerships, for research and development programs at an earlier stage than otherwise would be desirable or that Oruka otherwise would have sought to develop independently, or on terms that are less favorable than might otherwise be available in the future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>dispose of technology assets, or relinquish or license on unfavorable terms, Oruka&#8217;s rights to technologies or any of its product candidates that it otherwise would seek to develop or commercialize itself;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursue the sale of the company to a third party at a price that may result in a loss on investment for Oruka&#8217;s stockholders; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>file for bankruptcy or cease operations altogether (and face any related legal proceedings).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any of these events could have a material adverse effect on Oruka&#8217;s business, operating results, and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if successful in raising new capital, Oruka could be limited in the amount of capital it raises due to investor demand restrictions placed on the amount of capital it raises or other reasons.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, any capital raising efforts are subject to significant risks and contingencies, as described in more detail under the risk factor titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Raising additional capital may cause dilution to Oruka&#8217;s stockholders, restrict its operations, or require it to relinquish rights.</span>&#8221;</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka has never generated any revenue from product sales and may never be profitable.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has no products approved for commercialization and has never generated any revenue from product sales. Oruka&#8217;s ability to generate revenue and achieve profitability depends on its ability, alone or with strategic collaborators, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize one or more of its product candidates. Oruka does not anticipate generating revenue from product sales for the foreseeable future. Oruka&#8217;s ability to generate future revenue from product sales depends heavily on its success in many areas, including but not limited to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>completing research and development of its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>obtaining regulatory and marketing approvals for its product candidates for which it completes clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>manufacturing product candidates and establishing and maintaining supply and manufacturing relationships with third parties that are commercially feasible, meet regulatory requirements and Oruka&#8217;s supply needs in sufficient quantities to meet market demand for its product candidates, if approved;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>qualifying for adequate coverage and reimbursement by government and third<span class="nobreak">-party</span> payors for any product candidates for which Oruka obtains regulatory and marketing approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>marketing, launching, and commercializing product candidates for which Oruka obtains regulatory and marketing approval, either directly or with a collaborator or distributor;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>gaining market acceptance of Oruka&#8217;s product candidates as treatment options;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>addressing any competing products and technological and market developments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>implementing internal systems and infrastructure, as needed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>protecting and enforcing Oruka&#8217;s intellectual property rights, including patents, trade secrets, and&#160;know<span class="nobreak">-how</span>;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>negotiating favorable terms in any collaboration, licensing, or other arrangements into which Oruka may enter;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">50</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>obtaining coverage and adequate reimbursement from third<span class="nobreak">-party</span> payors and maintaining pricing for Oruka&#8217;s product candidates that supports profitability; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>attracting, hiring, and retaining qualified personnel.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if one or more of the product candidates that Oruka develops is approved for commercial sale, Oruka anticipates incurring significant costs associated with commercializing any approved product candidate. Oruka&#8217;s expenses could increase beyond expectations if it is required by regulatory authorities to perform clinical and other studies in addition to those that Oruka anticipates. Even if Oruka is able to generate revenues from the sale of any approved products, it may not become profitable and may need to obtain additional funding to continue operations. Oruka will also have to develop or acquire manufacturing capabilities or continue to contract with contract manufacturers in order to continue development and potential commercialization of its product candidates. For instance, if the costs of manufacturing Oruka&#8217;s drug product are not commercially feasible, Oruka will need to develop or procure its drug product in a commercially feasible manner in order to successfully commercialize a future approved product, if any. Additionally, if Oruka is not able to generate revenue from the sale of any approved products, it may never become profitable.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is a preclinical stage biopharmaceutical company with a limited operating history on which to assess its business; it has not initiated, conducted or completed any clinical trials, has no products approved for commercial sale, has historically incurred losses, and anticipates that it will continue to incur significant losses for the foreseeable future.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a preclinical stage biopharmaceutical company with a limited operating history. Since February&#160;6, 2024 (inception), Oruka has incurred significant operating losses. For the period between February&#160;6, 2024 (inception) to March&#160;31, 2024, Oruka reported a net loss of $7.1&#160;million and had an accumulated deficit of $7.1&#160;million. Oruka will need to raise substantial additional capital to continue to fund its operations in the future. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on Oruka&#8217;s financial condition and its ability to develop its product candidates. Changing circumstances may cause Oruka to consume capital significantly faster or slower than it currently anticipates. If Oruka is unable to acquire additional capital or resources, it will be required to modify its operational plans to complete future milestones and it may be required to delay, limit, reduce or eliminate development or future commercialization efforts of product candidates and/or programs. Oruka has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Oruka may be forced to reduce its operating expenses and raise additional funds to meet its working capital needs, principally through the additional sales of its securities or debt financings or entering into strategic collaborations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has devoted substantially all of its financial resources to identify, acquire, and develop its product candidates, organizing and staffing its company, and providing general and administrative support for its operations. To date, Oruka has funded its operations primarily from the sale and issuance of convertible preferred and common equity securities and unsecured convertible notes. The amount of Oruka&#8217;s future net losses will depend, in part, on the rate of its future expenditures and its ability to obtain funding through equity or debt financings, strategic collaborations, or grants.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. Oruka expects its losses to increase as its product candidates enter more advanced clinical trials. It may be several&#160;years, if ever, before Oruka completes pivotal clinical trials or has a product candidate approved for commercialization. Oruka expects to invest significant funds into the research and development of its current programs to determine the potential to advance product candidates to regulatory approval. If Oruka obtains regulatory approval to market a product candidate, its future revenue will depend upon the size of any markets in which its product candidates may receive approval, and its ability to achieve sufficient market acceptance, pricing, coverage and adequate reimbursement from third<span class="nobreak">-party</span> payors, and adequate market share for its product candidates in those markets. Even if Oruka obtains adequate market share for its product candidates, because the potential markets in which its product candidates may ultimately receive regulatory approval could be very small, Oruka may never become profitable despite obtaining such market share and acceptance of its products.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">51</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expects to continue to incur significant expenses and increasing operating losses for the foreseeable future and its expenses will increase substantially if and as it:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continues the preclinical development and initiates the clinical development of its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continues efforts to discover and develop new product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continues the manufacturing of its product candidates or increases volumes manufactured by third parties;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>advances its product candidates into larger, more expensive clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>initiates additional preclinical studies or clinical trials for its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks regulatory and marketing approvals and reimbursement for its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establishes a sales, marketing, and distribution infrastructure to commercialize any products for which it may obtain marketing approval and market for itself;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks to identify, assess, acquire, and/or develop other product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>makes milestone, royalty, or other payments under third<span class="nobreak">-party</span> license agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks to maintain, protect, and expand its intellectual property portfolio;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>is required to pay penalties under its registration rights agreement for failing to timely register the applicable securities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks to attract and retain skilled personnel; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>experiences any delays or encounters issues with the development and potential regulatory approval of its clinical and product candidates such as safety issues, manufacturing delays, clinical trial accrual delays, longer&#160;follow<span class="nobreak">-up</span>&#160;for planned studies or trials, additional major studies or trials, or supportive trials necessary to support marketing approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has no significant experience as a company in initiating, conducting or completing clinical trials. In part because of this lack of experience, Oruka cannot be certain that its planned clinical trials will begin or be completed on time, if at all. In addition, Oruka has not yet demonstrated an ability to obtain marketing approvals, manufacture a commercial<span class="nobreak">-scale</span> product or arrange for a third party to do so on its behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently, any predictions you make about Oruka&#8217;s future success or viability may not be as accurate as they could be if Oruka had a longer operating history. Further, the net losses Oruka incurs may fluctuate significantly from quarter to quarter and year to year, such that a&#160;period<span class="nobreak">-to-period</span>&#160;comparison of its results of operations may not be a good indication of its future performance.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to Oruka&#8217;s stockholders, restrict its operations, or require it to relinquish rights.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Until such time, if ever, as Oruka can generate substantial revenue from the sale of its product candidates, Oruka expects to finance its cash needs through a combination of equity offerings, debt financings and license and development agreements. To the extent that Oruka raises additional capital through the sale of equity securities or convertible debt securities, the ownership interest of its stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of holders of Oruka common stock. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting Oruka&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka raises additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, it may be required to relinquish valuable rights to its research programs or product candidates or grant licenses on terms that may not be favorable to it. If Oruka is unable to raise additional </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">52</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">funds through equity or debt financings or other arrangements with third parties when needed, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to third parties to develop and market product candidates that Oruka would otherwise prefer to develop and market itself.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To the extent that Oruka raises additional capital through the sale of equity, including pursuant to any sales under convertible debt or other securities convertible into equity, the ownership interest of its stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of its stockholders. For instance, in March&#160;2024, Oruka sold an aggregate of 20,000,000<span class="nobreak"> </span>shares of Series&#160;A preferred stock and the Convertible Note to Fairmount Fund&#160;II for gross proceeds of $28.0&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Debt financing, if available, would likely involve agreements that include covenants limiting or restricting Oruka&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends. If Oruka raises additional funds through strategic collaborations or licensing arrangements with third parties, Oruka may have to relinquish valuable rights to its product candidates or future revenue streams or grant licenses on terms that are not favorable to Oruka. Oruka cannot assure that it will be able to obtain additional funding if and when necessary to fund its entire portfolio of product candidates to meet its projected plans. If Oruka is unable to obtain funding on a timely basis, it may be required to delay or discontinue one or more of its development programs or the commercialization of any product candidates or be unable to expand its operations or otherwise capitalize on potential business opportunities, which could materially harm Oruka&#8217;s business, financial condition, and results of operations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Discovery, Development and Commercialization</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka faces competition from entities that have developed or may develop programs for the diseases addressed by product candidates developed by Oruka.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The development and commercialization of drugs is highly competitive. Product candidates developed by Oruka, if approved, will face significant competition and Oruka&#8217;s failure to effectively compete may prevent it from achieving significant market penetration. Oruka competes with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, as well as academic institutions, governmental agencies, and public and private research institutions, among others. Many of the companies with which Oruka is currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trial conduct, regulatory approvals, and marketing than Oruka does. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of Oruka&#8217;s competitors. Smaller or early<span class="nobreak">-stage</span> companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with Oruka in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, recruiting participants for clinical trials, as well as in acquiring technologies complementary to, or necessary for, Oruka&#8217;s product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s competitors have developed, are developing or will develop programs and processes competitive with its programs and processes. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments. Oruka&#8217;s success will depend partially on its ability to develop and commercialize products that have a competitive safety, efficacy, dosing and/or presentation profile. Oruka&#8217;s commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective, have a more attractive dosing profile or presentation or are less expensive than the products Oruka develops, or if Oruka&#8217;s competitors develop competing products or if biosimilars enter the market more quickly than Oruka does and are able to gain market acceptance. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Competition</span>&#8221; for more discussion about Oruka&#8217;s competitors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, because of the competitive landscape for&#160;I&amp;I indications, Oruka may also face competition for clinical trial enrollment. Clinical trial enrollment will depend on many factors, including if potential clinical trial participants choose to undergo treatment with approved products or enroll in competitors&#8217; ongoing clinical trials for programs that are under development for the same indications as Oruka&#8217;s programs. An increase in the number of </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">53</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">approved products for the indications Oruka is targeting with its programs may further exacerbate this competition. Oruka&#8217;s inability to enroll a sufficient number of participants could, among other things, delay its development timeline, which may further harm its competitive position.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s programs are in preclinical stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability. If Oruka or its current or future collaborators are unable to complete development of or commercialize Oruka&#8217;s product candidates, or experience significant delays in doing so, Oruka&#8217;s business will be materially harmed.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has no products on the market, and all of its programs are in preclinical stages of development and have not been tested in humans. As a result, Oruka expects it will be many&#160;years before it commercializes any product candidate, if ever. Oruka&#8217;s ability to achieve and sustain profitability depends on obtaining regulatory approvals for, and successfully commercializing, its product candidates, either alone or with third parties, and Oruka cannot guarantee you that it will ever obtain regulatory approval for any of its product candidates. Oruka has not yet demonstrated its ability to initiate or complete any clinical trials, obtain regulatory approvals, manufacture a clinical or commercial scale product or arrange for a third party to do so on its behalf, or conduct sales and marketing activities necessary for successful product commercialization. Before obtaining regulatory approval for the commercial distribution of Oruka&#8217;s product candidates, Oruka or an existing or future collaborator must conduct extensive preclinical tests and clinical trials to demonstrate the safety and efficacy in humans of Oruka&#8217;s programs and product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka or its collaborators may experience delays in initiating or completing clinical trials. Oruka or its collaborators also may experience numerous unforeseen events during, or as a result of, any clinical trials that they could conduct that could delay or prevent Oruka&#8217;s ability to receive marketing approval or commercialize its product candidates, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>regulators or institutional review boards (&#8220;IRBs&#8221;), the FDA or ethics committees may not authorize Oruka or its investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations (&#8220;CROs&#8221;), the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>clinical trial sites deviating from trial protocol or dropping out of a trial;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>clinical trials of any product candidates may fail to show safety or efficacy, produce negative or inconclusive results, and Oruka may decide, or regulators may require it, to conduct additional preclinical studies or clinical trials or Oruka may decide to abandon product development programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the number of subjects required for clinical trials of any product candidates may be larger than Oruka anticipates, especially if regulatory bodies require completion of&#160;non<span class="nobreak">-inferiority</span>&#160;or superiority trials, enrollment in these clinical trials may be slower than Oruka anticipates or subjects may drop out of these clinical trials or fail to return for post<span class="nobreak">-treatment</span>&#160;follow<span class="nobreak">-up</span>&#160;at a higher rate than Oruka anticipates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s third<span class="nobreak">-party</span> contractors may fail to comply with regulatory requirements or meet their contractual obligations to Oruka in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that Oruka add new clinical trial sites or investigators;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka may elect to, or regulators, IRBs or ethics committees may require that Oruka or its investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in Oruka&#8217;s trials are being exposed to unacceptable health risks;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the cost of clinical trials of any of Oruka&#8217;s programs may be greater than Oruka anticipates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the quality of Oruka&#8217;s product candidates or other materials necessary to conduct clinical trials of Oruka&#8217;s product candidates may be inadequate to initiate or complete a given clinical trial;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s inability to manufacture sufficient quantities of its product candidates for use in clinical trials;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">54</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reports from clinical testing of other therapies may raise safety or efficacy concerns about Oruka&#8217;s programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s failure to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidates as well as data emerging from other therapies in the same class as Oruka&#8217;s product candidates; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the FDA or other regulatory authorities may require Oruka to submit additional data such as long<span class="nobreak">-term</span> toxicology studies, or impose other requirements before permitting Oruka to initiate a clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Commencing clinical trials in the United&#160;States is subject to acceptance by the FDA of an investigational new drug application (&#8220;IND&#8221;), biologics license application (&#8220;BLA&#8221;) or similar application and finalizing the trial design based on discussions with the FDA and other regulatory authorities. In the event that the FDA requires Oruka to complete additional preclinical studies or it is required to satisfy other FDA requests prior to commencing clinical trials, the start of Oruka&#8217;s first clinical trials may be delayed. Even after Oruka receives and incorporates guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that Oruka has satisfied their requirements to commence any clinical trial or change their position on the acceptability of Oruka&#8217;s trial design or the clinical endpoints selected, which may require Oruka to complete additional preclinical studies or clinical trials, delay the enrollment of Oruka&#8217;s clinical trials or impose stricter approval conditions than Oruka currently expects. There are equivalent processes and risks applicable to clinical trial applications in other countries, including countries in the European Union (&#8220;EU&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if it experiences any issues that delay or prevent regulatory approval of, or its ability to commercialize, its product candidates. Oruka or its current or future collaborators&#8217; inability to complete development of, or commercialize Oruka&#8217;s product candidates, or significant delays in doing so, could have a material and adverse effect on Oruka&#8217;s business, financial condition, results of operations and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is substantially dependent on the success of its two most advanced programs, ORKA-001 and ORKA-002, and its anticipated clinical trials of such programs may not be successful.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future success is substantially dependent on its ability to timely obtain marketing approval for, and then successfully commercialize, its two most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. Oruka is investing a majority of its efforts and financial resources into the research and development of these programs. Oruka anticipates initiating a Phase&#160;1 clinical trial in healthy volunteers of ORKA<span class="nobreak">-001</span> in the first half of 2025 and of ORKA<span class="nobreak">-002</span> in the second half of 2025, each subject to the filing of an IND or foreign equivalent and regulatory approval. The success of Oruka&#8217;s programs is dependent on observing a longer half<span class="nobreak">-life</span> of Oruka&#8217;s product candidates in humans than other extended half<span class="nobreak">-life</span> monoclonal antibodies (&#8220;mAbs&#8221;) currently marketed and in development as Oruka believes this longer half<span class="nobreak">-life</span> has the potential to result in a more favorable dosing schedule for Oruka&#8217;s product candidates, assuming they successfully complete clinical development and obtain marketing approval. This is based in part on the assumption that the longer half<span class="nobreak">-life</span> Oruka has observed in&#160;non<span class="nobreak">-human</span>&#160;primates (&#8220;NHPs&#8221;) will translate into an extended half<span class="nobreak">-life</span> of Oruka&#8217;s product candidates in humans. To the extent Oruka does not observe this extended half<span class="nobreak">-life</span> when it doses humans with its product candidates, it would significantly and adversely affect the clinical and commercial potential of its product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s programs will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, product development, marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before Oruka generates any revenues from product sales. Oruka is not permitted to market or promote these programs, or any other programs, before it receives marketing approval from the FDA and comparable foreign regulatory authorities, and Oruka may never receive such marketing approvals.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The success of Oruka&#8217;s product candidates will depend on a variety of factors. Oruka does not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to Oruka&#8217;s intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any current or future collaborator. Accordingly, Oruka cannot assure you that it will ever be able to generate revenue through the sale of these product candidates, even if approved. If Oruka is not successful in commercializing its ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span> programs, or is significantly delayed in doing so, Oruka&#8217;s business will be materially harmed.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">55</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If Oruka does not achieve its projected development goals in the time frames it announces and expects, the commercialization of Oruka&#8217;s product candidates may be delayed and its expenses may increase and, as a result, its stock price may decline.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, Oruka estimates the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product development goals, which it sometimes refers to as milestones. These milestones may include the commencement or completion of scientific studies and clinical trials, such as the expected timing for the anticipated commencement of Oruka&#8217;s Phase&#160;1 studies, clinical trials in PsO and other target indications, as well as the submission of regulatory filings. From time to time, Oruka may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions. The actual timing of these milestones can vary dramatically compared to Oruka&#8217;s estimates, in some cases for reasons beyond Oruka&#8217;s control. If Oruka does not meet these milestones as publicly announced, or at all, the commercialization of its product candidates may be delayed or never achieved and, as a result, its stock price may decline. Additionally, delays relative to Oruka&#8217;s projected timelines are likely to cause overall expenses to increase, which may require Oruka to raise additional capital sooner than expected and prior to achieving targeted development milestones.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Any drug delivery device that Oruka potentially uses to deliver its product candidates may have its own regulatory, development, supply and other risks.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expects to deliver its product candidates via a drug delivery device, such as an injector or other delivery system. There may be unforeseen technical complications related to the development activities required to bring such a product to market, including primary container compatibility and/or dose volume requirements. Oruka&#8217;s product candidates may not be approved or may be substantially delayed in receiving approval if the devices that Oruka chooses to develop do not gain and/or maintain their own regulatory approvals or clearances. Where approval of the drug product and device is sought under a single application, the increased complexity of the review process may delay approval. In addition, some drug delivery devices are provided by single<span class="nobreak">-source</span> unaffiliated third<span class="nobreak">-party</span> companies. Oruka may be dependent on the sustained cooperation and effort of those third<span class="nobreak">-party</span> companies both to supply the devices and, in some cases, to conduct the studies required for approval or other regulatory clearance of the devices. Even if approval is obtained, Oruka may also be dependent on those third<span class="nobreak">-party</span> companies continuing to maintain such approvals or clearances once they have been received. Failure of third<span class="nobreak">-party</span> companies to supply the devices, to successfully complete studies on the devices in a timely manner, or to obtain or maintain required approvals or clearances of the devices could result in increased development costs, delays in or failure to obtain regulatory approval and delays in product candidates reaching the market or in gaining approval or clearance for expanded labels for new indications.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s approach to the discovery and development of its programs is unproven, and Oruka may not be successful in its efforts to build a pipeline of programs with commercial value.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s approach to the discovery and development of the research programs with respect to which it has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements leverages clinically validated mechanisms of action and incorporates advanced antibody engineering to optimize half<span class="nobreak">-life</span> and other properties designed to overcome limitations of existing therapies. Oruka&#8217;s programs are purposefully designed to improve upon existing product candidates and products while maintaining the same, well<span class="nobreak">-established</span> mechanisms of action. However, the scientific research that forms the basis of Oruka&#8217;s efforts to develop programs using half<span class="nobreak">-life</span> extension technologies is ongoing and may not result in viable programs. There is limited clinical data available on product candidates utilizing half<span class="nobreak">-life</span> extension technologies, especially in&#160;I&amp;I indications, demonstrating whether they are safe or effective for long<span class="nobreak">-term</span> treatment in humans. The long<span class="nobreak">-term</span> safety and efficacy of these technologies and the extended half<span class="nobreak">-life</span> and exposure profile of Oruka&#8217;s programs compared to currently approved products is unknown.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may ultimately discover that utilizing half<span class="nobreak">-life</span> extension technologies for its specific targets and indications and any programs resulting therefrom does not possess certain properties required for therapeutic effectiveness. Oruka currently has only preclinical data regarding the increased half<span class="nobreak">-life</span> properties of its programs and the same results may not be seen in humans. In addition, programs using half<span class="nobreak">-life</span> extension technologies may </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">56</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">demonstrate different chemical and pharmacological properties in participants than they do in laboratory studies. This technology and any programs resulting therefrom may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, Oruka may in the future seek to discover and develop programs that are based on novel targets and technologies that are unproven. If Oruka&#8217;s discovery activities fail to identify novel targets or technologies for drug discovery, or such targets prove to be unsuitable for treating human disease, Oruka may not be able to develop viable additional programs. Oruka and its existing or future collaborators may never receive approval to market and commercialize any product candidate. Even if Oruka or an existing or future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as Oruka intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. If the products resulting from the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements prove to be ineffective, unsafe or commercially unviable, such programs would have little, if any, value, which would have a material and adverse effect on Oruka&#8217;s business, financial condition, results of operations and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preclinical and clinical development involves a lengthy and expensive process that is subject to delays and uncertain outcomes, and results of earlier studies and trials may not be predictive of future clinical trial results. If Oruka&#8217;s preclinical studies and clinical trials are not sufficient to support regulatory approval of any of its product candidates, Oruka may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development of such product candidate.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, Oruka must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of such product candidate in humans. Oruka&#8217;s clinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process. For example, Oruka depends on the availability of NHPs to conduct certain preclinical studies that it is required to complete prior to submitting an IND and initiating clinical development. There is currently a global shortage of NHPs available for drug development. This could cause the cost of obtaining NHPs for Oruka&#8217;s future preclinical studies to increase significantly and, if the shortage continues, could also result in delays to Oruka&#8217;s development timelines.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, a failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early<span class="nobreak">-stage</span> clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. In addition, Oruka expects to rely on participants to provide feedback on measures such as measures of quality of life, which are subjective and inherently difficult to evaluate. These measures can be influenced by factors outside of Oruka&#8217;s control, and can vary widely from&#160;day<span class="nobreak">-to-day</span> for a particular participant, and from participant to participant and from site to site within a clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka cannot be sure that the FDA will agree with its clinical development plan. Oruka plans to use the data from its planned Phase&#160;1 trials of its ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> programs in healthy volunteers to support Phase&#160;2 trials in PsO and other&#160;I&amp;I indications. If the FDA requires Oruka to conduct additional trials or enroll additional participants, Oruka&#8217;s development timelines may be delayed. Oruka cannot be sure that submission of an IND, BLA or similar application will result in the FDA or comparable foreign regulatory authorities, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Events that may prevent successful or timely initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or other&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">in vivo&#160;</span>or&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">in vitro&#160;</span>data to support the initiation or continuation of clinical trials; delays in reaching a consensus with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization to commence a trial; delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; delays in identifying, recruiting and training suitable clinical investigators; delays in obtaining required IRB approval at each clinical trial site; delays in manufacturing, </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">57</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">testing, releasing, validating or importing/exporting sufficient stable quantities of Oruka&#8217;s product candidates for use in clinical trials or the inability to do any of the foregoing; failure by Oruka&#8217;s CROs, other third parties or Oruka to adhere to clinical trial protocols; failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s current Good Clinical Practice requirements (&#8220;GCPs&#8221;) or applicable regulatory guidelines in other countries; changes to the clinical trial protocols; clinical sites deviating from trial protocol or dropping out of a trial; changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; selection of clinical endpoints that require prolonged periods of observation or analyses of resulting data; transfer of manufacturing processes to facilities operated by a contract manufacturing organization (&#8220;CMO&#8221;) and delays or failure by Oruka&#8217;s CMOs or Oruka to make any necessary changes to such manufacturing process; and third parties being unwilling or unable to satisfy their contractual obligations to Oruka.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka could also encounter delays if a clinical trial is suspended or terminated by it, by the IRBs of the institutions in which such clinical trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or comparable foreign regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or Oruka&#8217;s clinical trial protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from the programs, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If Oruka is required to conduct additional clinical trials or other testing of its product candidates beyond those that Oruka currently contemplates, if Oruka is unable to successfully complete clinical trials of its product candidates, if the results of these trials are not positive or are only moderately positive or if there are safety concerns, Oruka&#8217;s business and results of operations may be adversely affected and it may incur significant additional costs.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If Oruka encounters difficulties enrolling participants in its future clinical trials, its clinical development activities could be delayed or otherwise adversely affected.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may experience difficulties in patient participant enrollment in its future clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on Oruka&#8217;s ability to enroll a sufficient number of participants who remain in the trial until its conclusion. The enrollment of participants in future trials for any of Oruka&#8217;s programs will depend on many factors, including if participants choose to enroll in clinical trials, rather than using approved products, or if Oruka&#8217;s competitors have ongoing clinical trials for programs that are under development for the same indications as its programs, and participants instead enroll in such clinical trials. Additionally, the number of participants required for clinical trials of Oruka&#8217;s programs may be larger than Oruka anticipates, especially if regulatory bodies require the completion of&#160;non<span class="nobreak">-inferiority</span>&#160;or superiority trials. Even if Oruka is able to enroll a sufficient number of participants for its future clinical trials, it may have difficulty maintaining participants in its clinical trials. Oruka&#8217;s inability to enroll or maintain a sufficient number of participants would result in significant delays in completing clinical trials or receipt of marketing approvals and increased development costs or may require Oruka to abandon one or more clinical trials altogether.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preliminary, &#8220;topline&#8221; or interim data from Oruka&#8217;s clinical trials that it announces or publishes from time to time may change as more participant data become available and are subject to audit and verification procedures.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, Oruka may publicly disclose preliminary or topline data from its preclinical studies and clinical trials, which are based on a preliminary analysis of then<span class="nobreak">-available</span> data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data. Oruka also makes assumptions, estimations, calculations and conclusions as part of its analyses of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or topline results that Oruka reports may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any preliminary or topline data should be viewed with caution until the final data are available. From time to time, Oruka may also disclose interim data from its preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become available or as participants from Oruka&#8217;s clinical trials continue other treatments. Further, others, including regulatory agencies, may not accept or agree with Oruka&#8217;s assumptions, estimates, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">58</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular product candidate, the approvability or commercialization of the particular product candidate and Oruka&#8217;s company in general. In addition, the information Oruka chooses to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information, and you or others may not agree with what Oruka determines is material or otherwise appropriate information to include in its disclosure. If the preliminary, topline or interim data that Oruka reports differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, Oruka&#8217;s ability to obtain approval for, and commercialize, its product candidates may be harmed, which could harm its business, operating results, prospects or financial condition.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s future clinical trials or those of its future collaborators may reveal significant adverse events or undesirable side effects not seen in Oruka&#8217;s preclinical studies and may result in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance of any of Oruka&#8217;s product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Results of Oruka&#8217;s clinical trials could reveal a high and unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics. While preclinical studies in NHPs conducted with respect to Oruka&#8217;s programs have not shown any such characteristics to date, Oruka has not yet initiated any clinical trials in humans. If significant adverse events or other side effects are observed in any of Oruka&#8217;s future clinical trials, Oruka may have difficulty recruiting participants to such trials, participants may drop out of the trials, or Oruka may be required to abandon the trials or its development efforts of one or more programs altogether. Oruka, the FDA or other applicable regulatory authorities, or an IRB, may suspend any clinical trials of any program at any time for various reasons, including a belief that subjects or patients in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential products developed in the biotechnology industry that initially showed therapeutic promise in early<span class="nobreak">-stage</span> studies and trials have later been found to cause side effects that prevented their further development. Other potential products have shown side effects in preclinical studies, which side effects do not present themselves in clinical trials in humans. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. In addition, an extended half<span class="nobreak">-life</span> could prolong the duration of undesirable side effects, which could also inhibit market acceptance. Treatment<span class="nobreak">-emergent</span> adverse events could also affect participant recruitment or the ability of enrolled subjects to complete Oruka&#8217;s clinical trials or could result in potential product liability claims. Potential side effects associated with Oruka&#8217;s product candidates may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from Oruka&#8217;s product candidates may not be normally encountered in the general patient population and by medical personnel. Any of these occurrences could harm Oruka&#8217;s business, financial condition, results of operations and prospects significantly.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, even if Oruka successfully advances its product candidates or any future product candidates through clinical trials, such trials will only include a limited number of participants and limited duration of exposure to Oruka&#8217;s product candidates. As a result, Oruka cannot be assured that adverse effects of its product candidates will not be uncovered when a significantly larger number of participants are exposed to the product candidate after approval. Further, any clinical trials may not be sufficient to determine the effect and safety consequences of using Oruka&#8217;s product candidates over a multi<span class="nobreak">-year</span> period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any of the foregoing events occur or if one or more of the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements prove to be unsafe, Oruka&#8217;s entire pipeline could be affected, which would have a material adverse effect on its business, financial condition, results of operations and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may expend its limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for which there is a greater likelihood of success.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because Oruka has limited financial and managerial resources, it focuses its research and development efforts on certain selected programs. For example, Oruka is initially focused on its most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. As a result, Oruka may forgo or delay pursuit of opportunities with other programs that later prove to have greater commercial potential. Oruka&#8217;s resource allocation decisions may cause it to fail to capitalize on viable commercial products or profitable market opportunities. Oruka&#8217;s spending on current and future research and development programs for specific indications may not yield any commercially viable product candidates. If Oruka </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">59</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">does not accurately evaluate the commercial potential or target market for a particular product candidate, it may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for it to retain sole development and commercialization rights to such product candidate.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Any approved products resulting from Oruka&#8217;s current programs or any future program may not achieve adequate market acceptance among clinicians, patients, healthcare third-party payors and others in the medical community necessary for commercial success and Oruka may not generate any future revenue from the sale or licensing of such products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even if regulatory approval is obtained for a product candidate resulting from one of Oruka&#8217;s current or future programs, they may not gain market acceptance among physicians, patients, healthcare payors or the medical community. Oruka may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted in the market. There are several approved products and product candidates in later stages of development for the treatment of PsO.&#160;However, Oruka&#8217;s programs incorporate advanced antibody engineering to optimize the half<span class="nobreak">-life</span> and formulation of antibodies; to date, no such antibody has been approved by the FDA for the treatment of PsO.&#160;Market participants with significant influence over acceptance of new treatments, such as clinicians and third<span class="nobreak">-party</span> payors, may not adopt a biologic that incorporates half<span class="nobreak">-life</span> extension for Oruka&#8217;s targeted indications, and Oruka may not be able to convince the medical community and third<span class="nobreak">-party</span> payors to accept and use, or to provide favorable reimbursement for, any programs developed by it or its existing or future collaborators. An extended half<span class="nobreak">-life</span> may make it more difficult for patients to change treatments and there is a perception that half<span class="nobreak">-life</span> extension could exacerbate side effects, each of which may adversely affect Oruka&#8217;s ability to gain market acceptance. Market acceptance of Oruka&#8217;s product candidates will depend on many factors, including factors that are not within Oruka&#8217;s control.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Sales of medical products also depend on the willingness of clinicians to prescribe the treatment. Oruka cannot predict whether clinicians, clinicians&#8217; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that its product is safe, therapeutically effective, cost effective or less burdensome as compared with competing treatments. If any of Oruka&#8217;s product candidates is approved but does not achieve an adequate level of acceptance by such parties, Oruka may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Certain of Oruka&#8217;s programs may compete with its other programs, which could negatively impact Oruka&#8217;s business and reduce its future revenue.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is developing product candidates for the same indication, PsO, and may in the future develop its programs for other&#160;I&amp;I indications. Each such program targets a different mechanism of action. However, developing multiple programs for a single indication may negatively impact Oruka&#8217;s business if the programs compete with each other. For example, if multiple programs are conducting clinical trials at the same time, they could compete for the enrollment of participants. In addition, if multiple product candidates are approved for the same indication, they may compete for market share, which could limit Oruka&#8217;s future revenue.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may conduct clinical trials for programs at sites outside the United&#160;States, and the FDA may not accept data from trials conducted in such locations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may choose to conduct one or more of its future clinical trials outside the United&#160;States. Although the FDA may accept data from clinical trials conducted outside the United&#160;States, acceptance of this data is subject to conditions imposed by the FDA.&#160;For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S.&#160;population, and the data must be applicable to the U.S.&#160;population and U.S.&#160;medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S.&#160;laws and regulations. If the FDA does not accept the data from any trial that Oruka conducts outside the United&#160;States, it would likely result in the need for additional trials, which would be costly and time<span class="nobreak">-consuming</span> and would delay or permanently halt Oruka&#8217;s development of the applicable product candidates. Even if the FDA accepted such data, it could require Oruka to modify its planned clinical trials to receive clearance to initiate such trials in the United&#160;States or to continue such trials once initiated.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">60</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Further, conducting international clinical trials presents additional risks that may delay completion of Oruka&#8217;s clinical trials. These risks include the failure of enrolled participants in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs that could restrict or limit Oruka&#8217;s ability to conduct its clinical trials, the administrative burdens of conducting clinical trials under multiple sets of foreign regulations, foreign exchange fluctuations, diminished protection of intellectual property in some countries, as well as political and economic risks relevant to foreign countries.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Government Regulation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If Oruka is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its product candidates, Oruka will not be able to commercialize, or will be delayed in commercializing, its product candidates, and its ability to generate revenue will be materially impaired.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The process of obtaining regulatory approvals, both in the United&#160;States and abroad, is unpredictable, expensive and typically takes many&#160;years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Oruka cannot commercialize product candidates in the United&#160;States without first obtaining regulatory approval from the FDA.&#160;Similarly, Oruka cannot commercialize product candidates outside of the United&#160;States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of Oruka&#8217;s product candidates, including its most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>, Oruka must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that its product candidates are both safe and effective for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, Oruka&#8217;s product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude Oruka&#8217;s obtaining marketing approval. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that Oruka&#8217;s data are insufficient for approval and require additional preclinical, clinical or other data. Oruka&#8217;s product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of Oruka&#8217;s clinical trials; Oruka may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug<span class="nobreak">-related</span> side effects may be experienced by participants in Oruka&#8217;s clinical trials or by individuals using drugs similar to Oruka&#8217;s product candidates; Oruka may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; the FDA or comparable foreign regulatory authorities may disagree with Oruka&#8217;s interpretation of data from preclinical studies or clinical trials; the data collected from clinical trials of Oruka&#8217;s product candidates may not be acceptable or sufficient to support the submission of a BLA or other submission or to obtain regulatory approval in the United&#160;States or elsewhere, and Oruka may be required to conduct additional clinical trials; the FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of Oruka&#8217;s product candidates; the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third<span class="nobreak">-party</span> manufacturers with which Oruka contracts for clinical and commercial supplies; and the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering Oruka&#8217;s clinical data insufficient for approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in Oruka&#8217;s failing to obtain regulatory approval to market its product candidates, which would significantly harm Oruka&#8217;s business, results of operations and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka were to obtain approval, regulatory authorities may approve any of Oruka&#8217;s product candidates for fewer or more limited indications than Oruka requests, including failing to approve the most commercially promising indications, may grant approval contingent on the performance of costly post<span class="nobreak">-marketing</span> clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">61</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the successful commercialization of that product candidate. If Oruka is not able to obtain, or if there are delays in obtaining, required regulatory approvals for its product candidates, Oruka will not be able to commercialize, or will be delayed in commercializing, its product candidates and its ability to generate revenue will be materially impaired.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may not be able to meet requirements for the chemistry, manufacturing and control of its programs.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In order to receive approval of its products by the FDA and comparable foreign regulatory authorities, Oruka must show that it and its contract manufacturing partners are able to characterize, control and manufacture its drug products safely and in accordance with regulatory requirements. This includes manufacturing the active ingredient, developing an acceptable formulation, manufacturing the drug product, performing tests to adequately characterize the formulated product, documenting a repeatable manufacturing process, and demonstrating that Oruka&#8217;s drug products meet stability requirements. Meeting these chemistry, manufacturing and control requirements is a complex task that requires specialized expertise. If Oruka is not able to meet the chemistry, manufacturing and control requirements, it may not be successful in getting its products approved.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s product candidates for which it intends to seek approval as biologics may face competition sooner than anticipated.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Patient Protection and Affordable Act, as amended by the Healthcare and Education Reconciliation Act (the &#8220;ACA&#8221;), includes a subtitle called the Biologics Price Competition and Innovation Act&#160;of&#160;2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an&#160;FDA<span class="nobreak">-licensed</span>&#160;reference biological product. Under the BPCIA, an application for a highly similar or &#8220;biosimilar&#8221; product may not be submitted to the FDA until four&#160;years following the date that the reference product was first approved by the FDA.&#160;In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first approved. During this&#160;12<span class="nobreak">-year</span>&#160;period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well<span class="nobreak">-controlled</span> clinical trials to demonstrate the safety, purity and potency of their product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that any of its product candidates approved as biologics under a BLA should qualify for the&#160;12<span class="nobreak">-year</span>&#160;period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider Oruka&#8217;s product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a way that is similar to traditional generic substitution for&#160;non<span class="nobreak">-biological</span>&#160;products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Even if Oruka receives regulatory approval of its product candidates, Oruka will be subject to extensive ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and Oruka may be subject to penalties if it fails to comply with regulatory requirements or experiences unanticipated problems with its product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any regulatory approvals that Oruka may receive for its product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post<span class="nobreak">-approval</span> study or risk management requirements. For example, the FDA may require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) in order to approve Oruka&#8217;s product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or comparable foreign regulatory authorities approve Oruka&#8217;s product candidates, its product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA and other regulatory agencies in the United&#160;States and by comparable foreign regulatory authorities. These requirements include submissions of safety and other post<span class="nobreak">-marketing</span> information and reports, registration, as </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">62</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">well as&#160;on<span class="nobreak">-going</span>&#160;compliance with current cGMPs and GCPs for any clinical trials that Oruka conducts following approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMPs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka or a regulatory authority discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or Oruka, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, restrictions on Oruka&#8217;s ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials, restrictions on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or import bans, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly new manufacturing requirements. The occurrence of any event or penalty described above may inhibit Oruka&#8217;s ability to commercialize its product candidates and generate revenue and could require Oruka to expend significant time and resources in response and could generate negative publicity.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may face difficulties from healthcare legislative reform measures.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of Oruka&#8217;s product candidates. Oruka cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United&#160;States or abroad. If Oruka is slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if it is not able to maintain regulatory compliance, Oruka may lose any marketing approval that it may have obtained and it may not achieve or sustain profitability. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Healthcare Reform</span>&#8221; for a more detailed description of healthcare reform measures that may prevent or limit Oruka&#8217;s ability to generate revenue, attain profitability, or commercialize its product candidates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose Oruka to penalties.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s business operations and current and future arrangements with investigators, healthcare professionals, consultants, third<span class="nobreak">-party</span> payors, patient organizations and customers may expose Oruka to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which Oruka conducts its operations, including how Oruka researches, markets, sells and distributes its product candidates, if approved. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Other Healthcare Laws and Compliance Requirements</span>&#8221; for a more detailed description of the laws that may affect Oruka&#8217;s ability to operate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Ensuring that Oruka&#8217;s internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. If Oruka&#8217;s operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to it, Oruka may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government<span class="nobreak">-funded</span> healthcare programs, integrity oversight and reporting obligations to resolve allegations of&#160;non<span class="nobreak">-compliance</span>,&#160;disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of Oruka&#8217;s operations. Further, defending against any such actions can be costly and time<span class="nobreak">-consuming</span> and may require significant personnel resources. Therefore, even if Oruka is successful in defending against any such actions that may be brought against it, its business may be impaired.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Even if Oruka is able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement policies, it may not be able to offer such product candidates at competitive prices which would seriously harm its business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka intends to seek approval to market its product candidates in both the United&#160;States and in selected foreign jurisdictions. If Oruka obtains approval in one or more foreign jurisdictions for its product candidates, Oruka will be subject to rules and regulations in those jurisdictions. Oruka&#8217;s ability to successfully commercialize any product candidates that it may develop will depend in part on the extent to which reimbursement for these product </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">63</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">candidates and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third<span class="nobreak">-party</span> payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and other third<span class="nobreak">-party</span> payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. These entities may create preferential access policies for a competitor&#8217;s product, including a branded or generic/biosimilar product, over Oruka&#8217;s products in an attempt to reduce their costs, which may reduce Oruka&#8217;s commercial opportunity. Additionally, if any of Oruka&#8217;s product candidates are approved and Oruka is found to have improperly promoted off<span class="nobreak">-label</span> uses of those product candidates, Oruka may become subject to significant liability, which would materially adversely affect its business and financial condition. See the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Coverage and Reimbursement</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Other Government Regulation&#160;Outside of the United&#160;States&#160;&#8212;&#160;Regulation in the European Union</span>&#8221; for a more detailed description of the government regulations and third<span class="nobreak">-party</span> payor practices that may affect Oruka&#8217;s ability to commercialize its product candidates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is subject to U.S.&#160;and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Oruka can face criminal liability and other serious consequences for violations, which can harm its business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is subject to export control and import laws and regulations, including the U.S.&#160;Export Administration Regulations, U.S.&#160;Customs regulations, various economic and trade sanctions regulations administered by the U.S.&#160;Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S.&#160;Foreign Corrupt Practices Act&#160;of&#160;1977, as amended, the U.S.&#160;domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S.&#160;Travel Act, the USA PATRIOT Act, and other state and national anti<span class="nobreak">-bribery</span> and anti<span class="nobreak">-money</span> laundering laws in the countries in which Oruka conducts activities. Anti<span class="nobreak">-corruption</span> laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to or from recipients in the public or private sector. Oruka may engage third parties to sell its products outside the United&#160;States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. Oruka has direct or indirect interactions with officials and employees of government agencies or government<span class="nobreak">-affiliated</span> hospitals, universities, and other organizations. Oruka can be held liable for the corrupt or other illegal activities of its employees, agents, contractors, and other collaborators, even if Oruka does not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Governments outside the United&#160;States tend to impose strict price controls, which may adversely affect Oruka&#8217;s revenue, if any.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In some countries, particularly member states of the EU (&#8220;EU Member States&#8221;), the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between&#160;low<span class="nobreak">-priced</span>&#160;and high<span class="nobreak">-priced</span> EU Member States, can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, Oruka or current or future collaborators may be required to conduct a clinical trial or other studies that compare the cost<span class="nobreak">-effectiveness</span> of Oruka&#8217;s product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third<span class="nobreak">-party</span> payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, Oruka&#8217;s business, financial condition, results of operations or prospects could be materially and adversely affected. Brexit could lead to legal uncertainty and potentially divergent national laws and regulations, including those related to the pricing of prescription pharmaceuticals, as the United Kingdom (&#8220;UK&#8221;) determines which EU laws to replicate or replace. If the UK were to significantly alter its regulations affecting the pricing of prescription pharmaceuticals, Oruka could face significant new costs.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">64</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">A breakthrough therapy, fast track, or other expedited designation for Oruka&#8217;s product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that those product candidates will receive marketing approval.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may seek a breakthrough therapy, fast track, or other designation for appropriate product candidates. Designations such as these are within the discretion of the FDA, or other comparable regulatory authorities. The receipt of a designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA.&#160;In addition, even if one or more of Oruka&#8217;s product candidates qualifies under one of FDA&#8217;s designation programs, the FDA may later decide that the products no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Expedited Development and Review Programs</span>&#8221; for a more detailed description of the process for seeking expedited designations such as fast track or breakthrough therapy designations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Oruka&#8217;s Intellectual Property</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s ability to obtain and protect its patents and other proprietary rights is uncertain, exposing Oruka to the possible loss of competitive advantage.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka relies upon a combination of patents, trademarks, trade secret protection, confidentiality agreements and the Paragon Option Agreements to protect the intellectual property related to its programs and technologies and to prevent third parties from competing unfairly with it. Oruka&#8217;s success depends in large part on its ability to obtain and maintain patent protection for its platform technologies, programs and their uses, as well as its ability to operate without infringing on or violating the proprietary rights of others. Paragon has filed provisional patent applications and intends to file one or more additional provisional patent applications directed to antibodies that target IL<span class="nobreak">-23</span>, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA<span class="nobreak">-001</span>. In addition, Paragon has filed provisional patent applications and intends to file one or more additional provisional patent applications directed to antibodies that target IL<span class="nobreak">-17</span>, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA<span class="nobreak">-002</span>. However, Oruka may not be able to protect its intellectual property rights throughout the world and the legal systems in certain countries may not favor enforcement or protection of patents, trade secrets and other intellectual property. Filing, prosecuting and defending patents on programs worldwide would be expensive and Oruka&#8217;s intellectual property rights in some foreign jurisdictions can be less extensive than those in the United&#160;States; the reverse may also occur. As such, Oruka may not have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if it applies for them. Oruka&#8217;s competitors may operate in countries where Oruka does not have patent protection and can freely use Oruka&#8217;s technologies and discoveries in such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where Oruka does have patent protection or pending patent applications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s pending and future patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection of Oruka&#8217;s programs or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed, designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products or programs. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that Oruka may license or own covering Oruka&#8217;s programs could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United&#160;States or abroad, including the United&#160;States Patent and Trademark Office (&#8220;USPTO&#8221;). Further, if Oruka encounters delays in its clinical trials or delays in obtaining regulatory approval, the period of time during which Oruka could market its product candidates under patent protection would be reduced. Thus, the patents that Oruka may own and license may not afford Oruka any meaningful competitive advantage.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to seeking patents for some of its technology and programs, Oruka may also rely on trade secrets, including unpatented&#160;know<span class="nobreak">-how</span>,&#160;technology and other proprietary information, to maintain its competitive position. Any disclosure, either intentional or unintentional, by Oruka&#8217;s employees, the employees of third parties with whom Oruka shares its facilities or third<span class="nobreak">-party</span> consultants and vendors that Oruka engages to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of Oruka&#8217;s trade secrets or proprietary information could enable competitors to duplicate or surpass Oruka&#8217;s technological achievements, thus eroding Oruka&#8217;s competitive position in its market. In order to protect </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">65</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Oruka&#8217;s proprietary technology and processes, it relies in part on confidentiality agreements with its collaborators, employees, consultants, outside scientific collaborators and sponsored researchers and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Oruka may need to share its proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or state actors and those affiliated with or controlled by state actors. In addition, while Oruka undertakes efforts to protect its trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, Oruka may not be able to assert any trade secret rights against such party. Costly and time<span class="nobreak">-consuming</span> litigation could be necessary to enforce and determine the scope of Oruka&#8217;s proprietary rights and failure to obtain or maintain trade secret protection could adversely affect Oruka&#8217;s competitive business position.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lastly, if Oruka&#8217;s trademarks and trade names are not registered or adequately protected, then Oruka may not be able to build name recognition in its markets of interest and its business may be adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may not be successful in obtaining or maintaining necessary rights to its programs through acquisitions and&#160;in-licenses.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because Oruka&#8217;s development programs currently do and may in the future require the use of proprietary rights held by third parties, the growth of Oruka&#8217;s business may depend in part on its ability to acquire,&#160;in<span class="nobreak">-license</span>,&#160;or use these third<span class="nobreak">-party</span> proprietary rights. Oruka may be unable to acquire or&#160;in<span class="nobreak">-license</span>&#160;any compositions, methods of use, processes or other third<span class="nobreak">-party</span> intellectual property rights from third parties that it identifies as necessary for its programs. The licensing and acquisition of third<span class="nobreak">-party</span> intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third<span class="nobreak">-party</span> intellectual property rights that Oruka may consider attractive or necessary. These established companies may have a competitive advantage over Oruka due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive Oruka to be a competitor may be unwilling to assign or license rights to Oruka. Oruka also may be unable to license or acquire third<span class="nobreak">-party</span> intellectual property rights on terms that would allow it to make an appropriate return on Oruka&#8217;s investment or at all. If Oruka is unable to successfully obtain rights to required third<span class="nobreak">-party</span> intellectual property rights or maintain the existing intellectual property rights it does obtain, Oruka may have to abandon development of the relevant program, which could have a material adverse effect on its business, financial condition, results of operations, and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While Oruka plans to obtain the right to control prosecution, maintenance and enforcement of the patents relating to its programs, there may be times when the filing and prosecution activities for patents and patent applications relating to Oruka&#8217;s programs are controlled by its current and future licensors or collaboration partners. If any of Oruka&#8217;s current and future licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of Oruka&#8217;s business, including by payment of all applicable fees for patents covering its product candidates, Oruka could lose its rights to the intellectual property or its exclusivity with respect to those rights, its ability to develop and commercialize those product candidates may be adversely affected and it may not be able to prevent competitors from making, using and selling competing products. In addition, even where Oruka has the right to control patent prosecution of patents and patent applications it has licensed to and from third parties, Oruka may still be adversely affected or prejudiced by actions or inactions of its licensees, its future licensors and their counsel that took place prior to the date upon which Oruka assumed control over patent prosecution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future licensors may rely on third<span class="nobreak">-party</span> consultants or collaborators or on funds from third parties such that Oruka&#8217;s future licensors are not the sole and exclusive owners of the patents Oruka&#160;in<span class="nobreak">-licenses</span>.&#160;If other third parties have ownership rights to Oruka&#8217;s future&#160;in<span class="nobreak">-licensed</span>&#160;patents, they may be able to license such patents to Oruka&#8217;s competitors, and Oruka&#8217;s competitors could market competing products and technology. This could have a material adverse effect on Oruka&#8217;s competitive position, business, financial conditions, results of operations, and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">It is possible that Oruka may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if Oruka is able to obtain a license, it may be&#160;non<span class="nobreak">-exclusive</span>,&#160;thereby giving Oruka&#8217;s competitors access to the same technologies licensed to Oruka. In that event, Oruka may be required to expend significant time and resources </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">66</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">to redesign its technology, programs, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If Oruka is unable to do so, it may be unable to develop or commercialize the affected product candidates, which could harm its business, financial condition, results of operations, and prospects significantly. Oruka cannot provide any assurances that third<span class="nobreak">-party</span> patents do not exist which might be enforced against Oruka&#8217;s current technology, manufacturing methods, programs, or future methods or products resulting in either an injunction prohibiting Oruka&#8217;s manufacture or future sales, or, with respect to its future sales, an obligation on Oruka&#8217;s part to pay royalties and/or other forms of compensation to third parties, which could be significant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Disputes may arise between Oruka and its future licensors regarding intellectual property subject to a license agreement, including: the scope of rights granted under the license agreement and other interpretation<span class="nobreak">-related</span> issues; whether and the extent to which Oruka&#8217;s technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; Oruka&#8217;s right to sublicense patents and other rights to third parties; Oruka&#8217;s right to transfer or assign the license; the inventorship and ownership of inventions and&#160;know<span class="nobreak">-how</span>&#160;resulting from the joint creation or use of intellectual property by Oruka&#8217;s future licensors and it and its partners; and the priority of invention of patented technology.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may be subject to patent infringement claims or may need to file claims to protect its intellectual property, which could result in substantial costs and liability and prevent Oruka from commercializing its potential products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because the intellectual property landscape in the biotechnology industry is rapidly evolving and interdisciplinary, it is difficult to conclusively assess Oruka&#8217;s freedom to operate and guarantee that Oruka can operate without infringing on or violating third<span class="nobreak">-party</span> rights. If certain of Oruka&#8217;s product candidates are ultimately granted regulatory approval, patent rights held by third parties, if found to be valid and enforceable, could be alleged to render one or more of Oruka&#8217;s product candidates infringing. If a third party successfully brings a claim against Oruka, Oruka may be required to pay substantial damages, be forced to abandon any affected product candidate and/or seek a license from the patent holder. In addition, any intellectual property claims (e.g., patent infringement or trade secret theft) brought against Oruka, whether or not successful, may cause Oruka to incur significant legal expenses and divert the attention of its management and key personnel from other business concerns. Oruka cannot be certain that patents owned or licensed by it will not be challenged by others in the course of litigation. Some of Oruka&#8217;s competitors may be able to sustain the costs of complex intellectual property litigation more effectively than Oruka can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on Oruka&#8217;s ability to raise funds.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Competitors may infringe or otherwise violate Oruka&#8217;s patents, trademarks, copyrights or other intellectual property. To counter infringement or other violations, Oruka may be required to file claims, which can be expensive and time<span class="nobreak">-consuming</span>. Any such claims could provoke these parties to assert counterclaims against Oruka, including claims alleging that Oruka infringes their patents or other intellectual property rights. In addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents Oruka asserts is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to prevent the other party from using the technology at issue on the grounds that Oruka&#8217;s patents do not cover the technology. Similarly, if Oruka asserts trademark infringement claims, a court or administrative body may determine that the marks Oruka has asserted are invalid or unenforceable or that the party against whom Oruka has asserted trademark infringement has superior rights to the marks in question. In such a case, Oruka could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if Oruka is successful, any award of monetary damages or other remedy Oruka receives may not be commercially valuable.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Further, Oruka may be required to protect its patents through procedures created to attack the validity of a patent at the USPTO.&#160;An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, Oruka&#8217;s patent rights, which could adversely affect Oruka&#8217;s competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S.&#160;federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">67</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, if Oruka&#8217;s programs are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against Oruka&#8217;s future licensees and other parties with whom Oruka has business relationships and Oruka may be required to indemnify those parties for any damages they suffer as a result of these claims, which may require Oruka to initiate or defend protracted and costly litigation on behalf of licensees and other parties regardless of the merits of such claims. If any of these claims succeed, Oruka may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to Oruka&#8217;s intellectual property rights, there is a risk that some of Oruka&#8217;s confidential information could be compromised by disclosure during this type of litigation or other proceedings.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may be subject to claims that it has wrongfully hired an employee from a competitor or that its employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As is common in the biotechnology industry, in addition to Oruka&#8217;s employees, Oruka engages the services of consultants to assist it in the development of its programs. Many of these consultants, and many of Oruka&#8217;s employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including Oruka&#8217;s competitors or potential competitors. Oruka could in the future be subject to claims that it or its employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although Oruka tries to ensure that its employees and consultants do not use the intellectual property, proprietary information,&#160;know<span class="nobreak">-how</span>&#160;or trade secrets of others in their work for Oruka, Oruka may become subject to claims that it caused an employee to breach the terms of his or her&#160;non<span class="nobreak">-competition</span>&#160;or&#160;non<span class="nobreak">-solicitation</span>&#160;agreement, or that Oruka or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a former employer or competitor.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While Oruka may litigate to defend itself against these claims, even if it is successful, litigation could result in substantial costs and could be a distraction to management. If Oruka&#8217;s defenses to these claims fail, in addition to requiring it to pay monetary damages, a court could prohibit Oruka from using technologies or features that are essential to its programs, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect Oruka&#8217;s reputation, its ability to form strategic alliances or sublicense its rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on Oruka&#8217;s business, results of operations and financial condition. Even if Oruka is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Changes to patent laws in the United&#160;States and other jurisdictions could diminish the value of patents in general, thereby impairing Oruka&#8217;s ability to protect its products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Changes in either the patent laws or interpretation of patent laws in the United&#160;States, including patent reform legislation such as the Leahy<span class="nobreak">-Smith</span> America Invents Act (the &#8220;Leahy<span class="nobreak">-Smith</span> Act&#8221;) could increase the uncertainties and costs surrounding the prosecution of Oruka&#8217;s owned and&#160;in<span class="nobreak">-licensed</span>&#160;patent applications and the maintenance, enforcement or defense of its owned and&#160;in<span class="nobreak">-licensed</span>&#160;issued patents. The Leahy<span class="nobreak">-Smith</span> Act includes a number of significant changes to United&#160;States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost<span class="nobreak">-effective</span> avenues for competitors to challenge the validity of patents, and enable third<span class="nobreak">-party</span> submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO<span class="nobreak">-administered</span> post<span class="nobreak">-grant</span> proceedings, including post<span class="nobreak">-grant</span> review, inter partes review and derivation proceedings. Assuming that other requirements for patentability are met, prior to March&#160;2013, in the United&#160;States, the first to invent the claimed invention was entitled to the patent, while outside the United&#160;States, the first to file a patent application was entitled to the patent. After March&#160;2013, under the Leahy<span class="nobreak">-Smith</span> Act, the United&#160;States transitioned to a&#160;first<span class="nobreak">-to-file</span>&#160;system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">68</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">claimed invention. As such, the Leahy<span class="nobreak">-Smith</span> Act and its implementation could increase the uncertainties and costs surrounding the prosecution of Oruka&#8217;s patent applications and the enforcement or defense of its issued patents, all of which could have a material adverse effect on Oruka&#8217;s business, financial condition, results of operations and prospects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. U.S.&#160;Supreme Court and U.S.&#160;Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. For example, the United&#160;States Supreme Court in&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Amgen, Inc. v. Sanofi</span>&#160;(<span class="Italic" style="font-style:italic;font-weight:normal;">Amgen</span>) recently held that Amgen&#8217;s patent claims to a class of antibodies functionally defined by their ability to bind a particular antigen were invalid for lack of enablement where the patent specification provided twenty<span class="nobreak">-six</span> exemplary antibodies, but the claimed class of antibodies covered a &#8220;vast number&#8221; of additional antibodies not disclosed in the specification. The Court stated that if patent claims are directed to an entire class of compositions of matter, then the patent specification must enable a person skilled in the art to make and use the entire class of compositions. This decision makes it unlikely that Oruka will be granted U.S.&#160;patents with composition of matter claims directed to antibodies functionally defined by their ability to bind a particular antigen. Even if Oruka is granted claims directed to functionally defined antibodies, it is possible that a third party may challenge Oruka&#8217;s patents, when issued, relying on the reasoning in&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Amgen</span>&#160;or other recent precedential court decisions. Additionally, there have been proposals for additional changes to the patent laws of the United&#160;States and other countries that, if adopted, could impact Oruka&#8217;s ability to enforce its proprietary technology. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S.&#160;Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on Oruka&#8217;s patent rights and its ability to protect, defend and enforce its patent rights in the future.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Geopolitical instability in the United&#160;States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. For example, the United&#160;States and foreign government actions related to Russia&#8217;s invasion of Ukraine may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on Oruka&#8217;s business. In addition, a decree was adopted by the Russian government in March&#160;2022 allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit<span class="nobreak">-making</span> activities in the United&#160;States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, Oruka would not be able to prevent third parties from practicing its inventions in Russia or from selling or importing products made using its inventions in and into Russia. Accordingly, Oruka&#8217;s competitive position may be impaired, and its business, financial condition, results of operations and prospects may be adversely affected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, a European Unified Patent Court (&#8220;UPC&#8221;) entered into force on June&#160;1, 2023. The UPC is a common patent court that hears patent infringement and revocation proceedings effective for EU Member States. This could enable third parties to seek revocation of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which the European patent is validated.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although Oruka does not currently own any European patents or applications, if it obtains such patents and applications in the future, any such revocation and loss of patent protection could have a material adverse impact on Oruka&#8217;s business and its ability to commercialize or license its technology and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect Oruka&#8217;s ability to enforce or defend the validity of any European patents it may obtain. Oruka may decide to opt out from the UPC any future European patent applications that it may file and any patents it may obtain. If certain formalities and requirements are not met, however, such European patents and patent applications could be challenged for&#160;non<span class="nobreak">-compliance</span>&#160;and brought under the jurisdiction of the UPC.&#160;Oruka cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if Oruka decides to opt out of the UPC.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">69</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent agencies, and Oruka&#8217;s patent protection could be reduced or eliminated for&#160;non-compliance&#160;with these requirements.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Periodic maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.&#160;Non<span class="nobreak">-compliance</span>&#160;events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits,&#160;non<span class="nobreak">-payment</span>&#160;of fees and failure to properly legalize and submit formal documents. If Oruka fails to maintain the patents and patent applications covering its programs, Oruka&#8217;s competitive position would be adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect Oruka&#8217;s ability to develop and market its products.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka cannot guarantee that any of its patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can Oruka be certain that it has identified each and every third<span class="nobreak">-party</span> patent and pending application in the United&#160;States and abroad that is relevant to or necessary for the commercialization of its product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Oruka&#8217;s interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, Oruka may incorrectly determine that its products are not covered by a third<span class="nobreak">-party</span> patent or may incorrectly predict whether a third<span class="nobreak">-party</span>&#8217;s pending application will issue with claims of relevant scope. Oruka&#8217;s determination of the expiration date of any patent in the United&#160;States or abroad that it considers relevant may be incorrect. Oruka&#8217;s failure to identify and correctly interpret relevant patents may negatively impact its ability to develop and market its products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, because some patent applications in the United&#160;States may be maintained in secrecy until the patents are issued, patent applications in the United&#160;States and many foreign jurisdictions are typically not published until 18&#160;months after filing, and publications in the scientific literature often lag behind actual discoveries, Oruka cannot be certain that others have not filed patent applications for technology covered by its issued patents or its pending applications, or that Oruka was the first to invent the technology. Oruka&#8217;s competitors may have filed, and may in the future file, patent applications covering products or technology similar to Oruka&#8217;s. Any such patent application may have priority over Oruka&#8217;s patent applications or patents, which could require Oruka to obtain rights to issued patents covering such technologies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may become subject to claims challenging the inventorship or ownership of its patents and other intellectual property.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may be subject to claims that former employees, collaborators or other third parties have an interest in Oruka&#8217;s patents or other intellectual property as an inventor or&#160;co<span class="nobreak">-inventor</span>.&#160;The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing Oruka&#8217;s programs or as a result of questions regarding&#160;co<span class="nobreak">-ownership</span>&#160;of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, Oruka may enter into agreements to clarify the scope of its rights in such intellectual property. If Oruka fails in defending any such claims, in addition to paying monetary damages, it may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on Oruka&#8217;s business. Even if Oruka is successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">70</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future licensors may rely on third<span class="nobreak">-party</span> consultants or collaborators or on funds from third parties, such as the U.S.&#160;government, such that Oruka&#8217;s licensors would not be the sole and exclusive owners of any patents Oruka&#160;in<span class="nobreak">-licenses</span>.&#160;If other third parties have ownership rights or other rights to Oruka&#8217;s&#160;in<span class="nobreak">-licensed</span>&#160;patents, they may be able to license such patents to Oruka&#8217;s competitors, and Oruka&#8217;s competitors could market competing products and technology. This could have a material adverse effect on Oruka&#8217;s competitive position, business, financial conditions, results of operations, and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent terms may be inadequate to protect the competitive position of Oruka&#8217;s product candidates for an adequate amount of time.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Patents have a limited lifespan. In the United&#160;States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest United&#160;States&#160;non<span class="nobreak">-provisional</span>&#160;filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering Oruka&#8217;s product candidates are obtained, once the patent life has expired, Oruka may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, Oruka&#8217;s owned and licensed patent portfolio may not provide it with sufficient rights to exclude others from commercializing products similar or identical to Oruka&#8217;s.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s technology licensed from various third parties may be subject to retained rights.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future licensors may retain certain rights under the relevant agreements with Oruka, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether Oruka&#8217;s licensors limit their use of the technology to these uses, and Oruka could incur substantial expenses to enforce its rights to its licensed technology in the event of misuse.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Oruka&#8217;s Reliance on Third Parties</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka currently relies on licensing arrangements with Paragon through the Paragon Option Agreements. If Oruka is unable to maintain collaborations or licensing arrangements, or if its collaborations or licensing arrangements are not successful, Oruka&#8217;s business could be negatively impacted.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka currently relies on its licensing arrangements with Paragon through the Paragon Option Agreements for a substantial portion of its discovery capabilities and&#160;in<span class="nobreak">-licenses</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Collaborations or licensing arrangements that Oruka enters into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators or licensors. If any of Oruka&#8217;s current or future collaborators or licensors experiences delays in performance of, or fails to perform its obligations under their agreement with Oruka, disagrees with Oruka&#8217;s interpretation of the terms of such agreement or terminates their agreement with Oruka, the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements and development timeline could be adversely affected. If Oruka fails to comply with any of the obligations under its collaborations or license agreements, including payment terms and diligence terms, Oruka&#8217;s collaborators or licensors may have the right to terminate such agreements, in which event Oruka may lose intellectual property rights and may not be able to develop, manufacture, market or sell the products covered by its agreements or may face other penalties under its agreements. Oruka&#8217;s collaborators and licensors may also fail to properly maintain or defend the intellectual property Oruka has licensed from them, if required by Oruka&#8217;s agreement with them, or even infringe upon, Oruka&#8217;s intellectual property rights, leading to the potential invalidation of Oruka&#8217;s intellectual property or subjecting it to litigation or arbitration, any of which would be time<span class="nobreak">-consuming</span> and expensive and could harm Oruka&#8217;s ability to commercialize its product candidates. In addition, collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with Oruka&#8217;s programs and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than Oruka&#8217;s.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">71</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of Oruka&#8217;s strategy, Oruka plans to evaluate additional opportunities to enhance its capabilities and expand its development pipeline or provide development or commercialization capabilities that complement Oruka&#8217;s. Oruka may not realize the benefits of such collaborations, alliances or licensing arrangements. Any of these relationships may require Oruka to incur&#160;non<span class="nobreak">-recurring</span>&#160;and other charges, increase its near and long<span class="nobreak">-term</span> expenditures, issue securities that dilute its existing stockholders or disrupt its management and business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may face significant competition in attracting appropriate collaborators, and more established companies may also be pursuing strategies to license or acquire third<span class="nobreak">-party</span> intellectual property rights that Oruka considers attractive. These companies may have a competitive advantage over Oruka due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive Oruka to be a competitor may be unwilling to assign or license rights to Oruka. Whether Oruka reaches a definitive agreement for a collaboration will depend upon, among other things, its assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Collaborations are complex and time<span class="nobreak">-consuming</span> to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology companies has reduced the number of potential future collaborators. Oruka may not be able to negotiate additional collaborations on a timely basis, on acceptable terms or at all. If Oruka fails to enter into collaborations and does not have sufficient funds or expertise to undertake the necessary development and commercialization activities, it may not be able to further develop its product candidates or bring them to market.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka currently relies, and plans to rely in the future, on third parties to conduct and support its preclinical studies and clinical trials. If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, Oruka may not be able to obtain regulatory approval of or commercialize its product candidates.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has utilized and plans to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions, CROs, contract testing labs and strategic partners, to conduct and support its preclinical studies and clinical trials under agreements with Oruka. Oruka will rely heavily on these third parties over the course of its preclinical studies and clinical trials, and Oruka controls only certain aspects of their activities. As a result, Oruka will have less direct control over the conduct, timing and completion of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials than would be the case if it were relying entirely upon its own staff. Nevertheless, Oruka is responsible for ensuring that each of its studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and its reliance on these third parties does not relieve Oruka of its regulatory responsibilities. Oruka and its third<span class="nobreak">-party</span> contractors and CROs are required to comply with GCP regulations, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of Oruka&#8217;s programs in clinical development. If Oruka or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in Oruka&#8217;s clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require Oruka to perform additional clinical trials before approving Oruka&#8217;s marketing applications. Oruka cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of Oruka&#8217;s clinical trials comply with GCP regulations. In addition, Oruka&#8217;s clinical trials must be conducted with products produced under cGMP regulations. Oruka&#8217;s failure to comply with these regulations may require it to repeat clinical trials, which would delay the regulatory approval process. Moreover, Oruka&#8217;s business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any third parties conducting Oruka&#8217;s clinical trials will not be Oruka&#8217;s employees and, except for remedies available to Oruka under its agreements with such third parties, Oruka cannot control whether they devote sufficient time and resources to Oruka&#8217;s programs. These third parties may be involved in mergers, acquisitions or similar transactions and may have relationships with other commercial entities, including Oruka&#8217;s competitors, for whom they may also be conducting clinical trials or other product development activities, which could negatively affect their performance on Oruka&#8217;s behalf and the timing thereof and could lead to products that compete directly or indirectly with Oruka&#8217;s product candidates. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to Oruka&#8217;s clinical protocols or regulatory requirements or for other reasons, Oruka&#8217;s clinical trials may be extended, delayed or terminated and Oruka may not be able to complete development of, obtain regulatory approval of or successfully commercialize its product candidates.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">72</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, Oruka currently relies on foreign CROs and CMOs, including WuXi Biologics (Hong&#160;Kong) Limited (&#8220;WuXi&#8221;) for formulation and manufacturing of Oruka&#8217;s stage 1 clinical trial materials, and will likely continue to rely on foreign CROs and CMOs in the future. WuXi is a subsidiary or affiliate of WuXi Biologics, which is identified in the proposed U.S. legislation known as the BIOSECURE Act as a biotechnology &#8220;company of concern.&#8221; The BIOSECURE Act, if passed, would prohibit federal agencies from entering into procurement contracts with an entity that uses biotechnology equipment or services from a biotechnology company of concern. Foreign CMOs may be subject to U.S.&#160;legislation, including the proposed BIOSECURE Act, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to Oruka, delay the procurement or supply of such material or have an adverse effect on Oruka&#8217;s ability to secure significant commitments from governments to purchase its potential therapies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For example, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on Oruka&#8217;s collaborators in China which could have an adverse effect on Oruka&#8217;s business, financial condition, results of operations and prospects. Evolving changes in China&#8217;s public health, economic, political, and social conditions and the uncertainty around China&#8217;s relationship with other governments, such as the United&#160;States and the UK, could also negatively impact Oruka&#8217;s ability to manufacture its product candidates for its planned clinical trials or have an adverse effect on its ability to secure government funding, which could adversely affect Oruka&#8217;s financial condition and cause it to delay its clinical development programs. Furthermore, if the BIOSECURE Act is passed and one or more of Oruka&#8217;s collaborators or vendors in China, including WuXi, is deemed to be a biotechnology company of concern, Oruka&#8217;s operations and financial condition may be negatively impacted as a result of any delays or increased costs arising from the trade restrictions and other foreign regulatory requirements affecting such collaborators. In addition, while Oruka has established relationships with CROs and CMOs outside of China, moving to those suppliers in the event of a geopolitical instability affecting Oruka&#8217;s collaborators in China could introduce delays into the development program.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka currently relies and expects to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture its product candidates, and Oruka may rely on third parties to produce and process its products, if approved. Oruka&#8217;s business could be adversely affected if it is unable to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka does not currently own any facility that may be used as its clinical or commercial manufacturing and processing facility and must currently rely on CMOs to manufacture its product candidates. Oruka has not yet caused any product candidates to be manufactured on a commercial scale and may not be able to do so for any of its product candidates, if approved. Oruka currently has a sole source relationship for its supply of the ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> program. If there should be any disruption in such supply arrangement, including any adverse events affecting Oruka&#8217;s sole supplier, it could have a negative effect on the clinical development of Oruka&#8217;s programs and other operations while Oruka works to identify and qualify an alternate supply source. Oruka may not control the manufacturing process of, and may be completely dependent on, its contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the FDA or comparable foreign regulatory authorities for the manufacture of its product candidates. Beyond periodic audits, Oruka has limited control over the ability of its CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of Oruka&#8217;s product candidates or if it withdraws any approval in the future, Oruka may need to find alternative manufacturing facilities, which would require the incurrence of significant additional costs, delays, and materially adversely affect Oruka&#8217;s ability to develop, obtain regulatory approval for or market its product candidates, if approved. Similarly, Oruka&#8217;s failure, or the failure of its CMOs, to comply with applicable regulations could result in sanctions being imposed on Oruka, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of Oruka&#8217;s product candidates or drugs and harm Oruka&#8217;s business and results of operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, Oruka&#8217;s CMOs may experience manufacturing difficulties due to resource constraints, supply chain issues, or as a result of labor disputes or unstable political environments. If any CMOs on which Oruka will rely fail to manufacture quantities of Oruka&#8217;s product candidates at quality levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows Oruka to achieve profitability, Oruka&#8217;s business, financial condition and prospects could be materially and adversely affected. In addition, Oruka&#8217;s CMOs </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">73</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">are responsible for transporting temperature<span class="nobreak">-controlled</span> materials that can be inadvertently degraded during transport due to several factors, rendering certain batches unsuitable for trial use for failure to meet, among others, Oruka&#8217;s integrity and purity specifications. Oruka and any of its CMOs may also face product seizure or detention or refusal to permit the import or export of products. Oruka&#8217;s business could be materially adversely affected by business disruptions to its third<span class="nobreak">-party</span> providers that could materially adversely affect its anticipated timelines, potential future revenue and financial condition and increase its costs and expenses. Each of these risks could delay or prevent the completion of Oruka&#8217;s preclinical studies and clinical trials or the approval of any of its product candidates by the FDA, result in higher costs or adversely impact commercialization of its product candidates. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Manufacturing</span>&#8221; for a more detailed description of Oruka&#8217;s manufacturing plans and assumptions and the factors that may affect the success of Oruka&#8217;s programs.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to Employee Matters, Managing Growth and Other Risks Related to Oruka&#8217;s Business</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">In order to successfully implement Oruka&#8217;s plans and strategies, Oruka will need to grow the size of its organization and it may experience difficulties in managing this growth.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expects to experience significant growth in the number of its employees and the scope of its operations, particularly in the areas of preclinical and clinical drug development, technical operations, clinical operations, regulatory affairs and, potentially, sales and marketing. To manage Oruka&#8217;s anticipated future growth, Oruka must continue to implement and improve its managerial, operational and financial personnel and systems, expand its facilities and continue to recruit and train additional qualified personnel. Due to Oruka&#8217;s limited financial resources and the limited experience of its management team working together in managing a company with such anticipated growth, Oruka may not be able to effectively manage the expansion of its operations or recruit and train additional qualified personnel.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is highly dependent on its key personnel and anticipates hiring new key personnel. If Oruka is not successful in attracting and retaining highly qualified personnel, it may not be able to successfully implement its business strategy.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a preclinical stage biotechnology company with a limited operating history, and, as of May&#160;3, 2024, it had ten full<span class="nobreak">-time</span> employees. Oruka has been and will continue to be highly dependent on the research and development, clinical and business development expertise of its executive officers, as well as the other principal members of its management, scientific and clinical team. Any of Oruka&#8217;s management team members may terminate their employment with Oruka at any time. Oruka does not maintain &#8220;key person&#8221; insurance for any of its executives or other employees.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Attracting and retaining qualified personnel will also be critical to Oruka&#8217;s success, including with respect to any strategic transaction that it may pursue. The loss of the services of Oruka&#8217;s executive officers or other key employees could impede the achievement of its research, development and commercialization objectives and seriously harm its ability to successfully implement its business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in Oruka&#8217;s industry with the breadth of skills and experience required to successfully develop, facilitate regulatory approval of and commercialize product candidates. Competition to hire from this limited pool is intense, and Oruka may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. Oruka also experiences competition for the hiring of scientific and clinical personnel from universities and research institutions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, Oruka relies on consultants and advisors, including scientific and clinical advisors, to assist it in formulating its discovery and nonclinical and clinical development and commercialization strategy. Oruka&#8217;s consultants and advisors may be employed by employers other than Oruka and may have commitments under consulting or advisory contracts with other entities that may limit their availability to Oruka. If Oruka is unable to continue to attract and retain high quality personnel, its ability to pursue its growth strategy will be limited.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">74</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s future growth may depend, in part, on its ability to operate in foreign markets, where it would be subject to additional regulatory burdens and other risks and uncertainties.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s future growth may depend, in part, on its ability to develop and commercialize its product candidates in foreign markets for which it may rely on collaboration with third parties. Oruka is not permitted to market or promote any of its product candidates before it receives regulatory approval from the applicable foreign regulatory authority, and may never receive such regulatory approval for any of its product candidates. To obtain separate regulatory approval in many other countries, Oruka must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of its product candidates, and Oruka cannot predict success in these jurisdictions. If Oruka fails to comply with the regulatory requirements in international markets and receive applicable marketing approvals, its target market will be reduced and its ability to realize the full market potential of its product candidates will be harmed and its business will be adversely affected. Moreover, even if Oruka obtains approval of its product candidates and ultimately commercializes its product candidates in foreign markets, Oruka would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and reduced protection of intellectual property rights in some foreign countries.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which Oruka competes achieve the forecasted growth, its business may not grow at similar rates, or at all.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Oruka&#8217;s estimates and forecasts relating to size and expected growth of its target market may prove to be inaccurate. Even if the markets in which Oruka competes meet Oruka&#8217;s size estimates and growth forecasts, Oruka&#8217;s business may not grow at similar rates, or at all. Oruka&#8217;s growth is subject to many factors, including its success in implementing its business strategy, which is subject to many risks and uncertainties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s revenue will be dependent, in part, upon the size of the markets in the territories for which it gains regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether Oruka owns the commercial rights for that territory. If the number of Oruka&#8217;s addressable patients is not as significant as it estimates, the indication approved by regulatory authorities is narrower than it expects or the treatment population is narrowed by competition, physician choice or treatment guidelines, Oruka may not generate significant revenue from sales of such products, even if approved.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is exposed to the risk that its employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors acting for or on its behalf may engage in misconduct or other improper activities. Oruka has adopted a code of conduct and ethics, but it is not always possible to identify and deter misconduct by these parties and the precautions Oruka takes to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting Oruka from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">75</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s internal information technology systems, or those of any of its CROs, manufacturers, other contractors or consultants, third-party service providers, or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of Oruka&#8217;s proprietary or confidential data, employee data or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to Oruka&#8217;s brand and material disruption of its operations.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the ordinary course of its business, Oruka and the third parties upon which it relies collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) proprietary, confidential, and sensitive data, including personal data, intellectual property, trade secrets, and other sensitive data (collectively, sensitive information).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Despite the implementation of security measures in an effort to protect systems that store Oruka&#8217;s information, given their size and complexity and the increasing amounts of information maintained on Oruka&#8217;s internal information technology systems and those of its third<span class="nobreak">-party</span> CROs, other contractors (including sites performing Oruka&#8217;s clinical trials), third<span class="nobreak">-party</span> service providers and supply chain companies, and consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by Oruka&#8217;s employees, contractors, consultants, business partners and/or other third parties, or from cyber<span class="nobreak">-attacks</span> by malicious third parties, which may compromise Oruka&#8217;s system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, Oruka&#8217;s data.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Some actors now engage and are expected to continue to engage in cyber<span class="nobreak">-attacks</span>, including without limitation nation<span class="nobreak">-state</span> actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, Oruka, and the third parties upon which it relies, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber<span class="nobreak">-attacks</span>, that could materially disrupt Oruka&#8217;s systems and operations, supply chain, and ability to produce, sell and distribute its goods and services. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in Oruka&#8217;s operations, ability to provide its products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but Oruka may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting such payments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To the extent that any disruption or security breach were to result in loss, destruction, unavailability, alteration or dissemination of, or damage to, Oruka&#8217;s data or applications, or for it to be believed or reported that any of these occurred, Oruka could incur liability and reputational damage and the development and commercialization of its product candidates could be delayed. Further, Oruka&#8217;s insurance policies may not be adequate to compensate it for the potential losses arising from any such disruption in, or failure or security breach of, its systems or third<span class="nobreak">-party</span> systems where information important to Oruka&#8217;s business operations or commercial development is stored.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s fully<span class="nobreak">-remote</span> workforce may create additional risks for its information technology systems and data because its employees work remotely and utilize network connections, computers, and devices working at home, while in transit and in public locations. Additionally, business transactions (such as acquisitions or integrations) could expose Oruka to additional cybersecurity risks and vulnerabilities, as its systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While Oruka has implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. Oruka may be unable in the future to detect vulnerabilities in its information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Further, Oruka may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. Applicable data privacy and security obligations may require Oruka to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka relies on third<span class="nobreak">-party</span> service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts. Oruka&#8217;s ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If Oruka&#8217;s third<span class="nobreak">-party</span> service providers experience a security incident or other interruption, Oruka could experience adverse </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">76</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">consequences. While Oruka may be entitled to damages if its third<span class="nobreak">-party</span> service providers fail to satisfy their privacy or security<span class="nobreak">-related</span> obligations to it, any award may be insufficient to cover Oruka&#8217;s damages, or Oruka may be unable to recover such award. In addition, supply<span class="nobreak">-chain</span> attacks have increased in frequency and severity, and Oruka cannot guarantee that third parties&#8217; infrastructure in its supply chain or its third<span class="nobreak">-party</span> partners&#8217; supply chains have not been compromised.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka (or a third party upon whom it relies) experiences a security incident or are perceived to have experienced a security incident, Oruka may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in Oruka&#8217;s operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause stakeholders (including investors and potential customers) to stop supporting Oruka&#8217;s platform, deter new customers from products, and negatively impact Oruka&#8217;s ability to grow and operate its business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in Oruka&#8217;s contracts are sufficient to protect Oruka from liabilities, damages, or claims related to its data privacy and security obligations. Oruka cannot be sure that its insurance coverage will be adequate or sufficient to protect it from or to mitigate liabilities arising out of its privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka is subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection, and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect Oruka&#8217;s operating results and business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and third parties who it works with are or may become subject to numerous domestic and foreign laws, regulations, and standards relating to privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations, and may be inconsistent among countries, or conflict with other rules. Oruka is or may become subject to the terms of contractual obligations related to privacy, data protection and data security. Oruka&#8217;s obligations may also change or expand as its business grows. The actual or perceived failure by Oruka or third parties related to Oruka to comply with such laws, regulations and obligations could increase Oruka&#8217;s compliance and operational costs, expose it to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of customers, result in litigation and liability, and otherwise cause a material adverse effect on its business, financial condition, and results of operations. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;Government Regulation&#160;&#8212;&#160;Data Privacy and Security</span>&#8221; for a more detailed description of the laws that may affect Oruka&#8217;s ability to operate.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If Oruka fails to comply with environmental, health and safety laws and regulations, it could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of its business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Oruka&#8217;s operations may involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. In addition, Oruka may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair Oruka&#8217;s research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may be subject to adverse legislative or regulatory tax changes that could negatively impact its financial condition.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The rules dealing with U.S.&#160;federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S.&#160;Treasury Department. Changes to tax laws (which may have retroactive application) could adversely affect Oruka&#8217;s stockholders or Oruka. Oruka assesses the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">77</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">where it has operations to determine the potential effect on its business and any assumptions it has made about its future taxable income. Oruka cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted. For example, the United&#160;States recently enacted the Inflation Reduction Act&#160;of&#160;2022 (&#8220;IRA&#8221;), which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Cuts and&#160;Jobs Act&#160;eliminated the previously available option to deduct research and development expenditures and requires taxpayers to amortize them generally over five&#160;years for research activities conducted in the United&#160;States and over 15&#160;years for research activities conducted outside the United&#160;States. The U.S.&#160;Congress is considering legislation that would restore the current deductibility of research and development expenditures; however, Oruka has no assurance that the provision will be repealed or otherwise modified. Such changes, among others, may adversely affect Oruka&#8217;s effective tax rate, results of operation and general business condition.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that it believes will complement or augment its existing business. If Oruka acquires businesses with promising markets or technologies, it may not be able to realize the benefit of acquiring such businesses if it is unable to successfully integrate them with its existing operations and company culture. Oruka may encounter numerous difficulties in developing, manufacturing and marketing any new product candidates or products resulting from a strategic alliance or acquisition that delay or prevent it from realizing their expected benefits or enhancing Oruka&#8217;s business. There is no assurance that, following any such acquisition, Oruka will achieve the synergies expected in order to justify the transaction, which could result in a material adverse effect on Oruka&#8217;s business and prospects.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka maintains its cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions could adversely affect Oruka&#8217;s ability to pay its operational expenses or make other payments.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s cash held in&#160;non<span class="nobreak">-interest-bearing</span>&#160;and interest<span class="nobreak">-bearing</span> accounts exceeds the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. If such banking institutions were to fail, Oruka could lose all or a portion of those amounts held in excess of such insurance limitations. For example, the FDIC took control of Silicon Valley Bank on March&#160;10, 2023. The Federal Reserve subsequently announced that account holders would be made whole. However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders&#8217; access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that Oruka may experience in the future or inability for a material time period to access its cash and cash equivalents could have an adverse effect on its ability to pay its operational expenses or make other payments, which could adversely affect its business.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General Risk Factors</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s estimates&#160;of market&#160;opportunity&#160;and forecasts&#160;of market&#160;growth may&#160;prove&#160;to be inaccurate,&#160;and even if the markets&#160;in which Oruka competes&#160;achieve&#160;the forecasted&#160;growth, its business&#160;may&#160;not grow at similar&#160;rates, or at all.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. Oruka&#8217;s estimates and forecasts relating to size and expected growth of its target market may prove to be inaccurate. Even if the markets in which Oruka competes meet its size estimates and growth forecasts, Oruka&#8217;s business may not grow at similar rates, or at all. Oruka&#8217;s growth is subject to many factors, including its success in implementing its business strategy, which is subject to many risks and uncertainties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s revenue will be dependent, in part, upon the size of the markets in the territories for which Oruka gains regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement and whether Oruka owns the commercial rights for that territory. If the number of its addressable patients is not as </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">78</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">significant as Oruka estimates, the indication approved by regulatory authorities is narrower than Oruka expects or the treatment population is narrowed by competition, physician choice or treatment guidelines, Oruka may not generate significant revenue from sales of such products, even if approved.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka may become exposed to costly and damaging liability claims, either when testing a product candidate in the clinical or at the commercial stage, and its product liability insurance may not cover all damages from such claims.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of pharmaceutical products. While Oruka currently has no products that have been approved for commercial sale, the future use of a product candidate in clinical trials, and the sale of any approved products in the future, may expose Oruka to liability claims. These claims may be made by patients that use the product, healthcare providers, pharmaceutical companies, or others selling such product. Any claims against Oruka, regardless of their merit, could be difficult and costly to defend and could materially and adversely affect the market for Oruka&#8217;s products or any prospects for commercialization of its products. Although Oruka intends to obtain product liability insurance for its future clinical trials, it is possible that any liabilities could exceed Oruka&#8217;s insurance coverage or that in the future Oruka may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against Oruka for uninsured liabilities or in excess of insured liabilities, Oruka&#8217;s assets may not be sufficient to cover such claims and its business operations could be impaired.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Litigation costs and the outcome of litigation could have a material adverse effect on Oruka&#8217;s business.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time&#160;Oruka&#160;may&#160;be&#160;subject&#160;to&#160;litigation&#160;claims through the ordinary course of its business operations regarding, but not limited to, employment matters, security of patient and employee personal information, contractual relations with collaborators and intellectual property rights. Litigation to defend itself against claims by third parties, or to enforce any rights that Oruka may have against third parties, may continue to be necessary, which could result in substantial costs and diversion of its resources, causing a material adverse effect on its business, financial condition, results of operations or cash flows.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka&#8217;s business could be adversely affected by economic downturns, inflation, increases in interest rates, natural disasters, public health crises, political crises, geopolitical events, or other macroeconomic conditions, which could have a material and adverse effect on its results of operations and financial condition.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things, diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases in inflation rates, higher interest rates, and uncertainty about economic stability. For example, the&#160;COVID<span class="nobreak">-19</span>&#160;pandemic resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. The Federal Reserve has raised interest rates multiple times in response to concerns about inflation and it may raise them again. Higher interest rates, coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending. Similarly, the ongoing military conflict between Russia and Ukraine and in the Middle East and rising tensions with China have created extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of the global supply chain. Any such volatility and disruptions may adversely affect Oruka&#8217;s business or the third parties on whom Oruka relies. If the equity and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing more costly, more dilutive, or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates can adversely affect Oruka by increasing its costs, including labor and employee benefit costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have a material and adverse effect on Oruka&#8217;s results of operations and financial condition.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">79</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Risks Related to the Combined Company</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If any of the events described in &#8220;Risks Related to ARCA&#8221; or &#8220;Risks Related to Oruka&#8221; occur, those events could cause potential benefits of the Merger not to be realized.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following completion of the Merger, the combined company will be susceptible to many of the risks described in the sections herein entitled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risks Related to ARCA</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risks Related to Oruka</span>.&#8221; To the extent any of the events in the risks described in those sections occur, the potential benefits of the Merger may not be realized and the results of operations and financial condition of the combined company could be adversely affected in a material way. This could cause the market price of the combined company&#8217;s common stock to decline.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The market price of the combined company&#8217;s common stock is expected to be volatile, and the market price of the common stock may drop following the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The market price of the combined company&#8217;s common stock following the Merger could be subject to significant fluctuations. Some of the factors that may cause the market price of the combined company&#8217;s common stock to fluctuate include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>results of clinical trials and preclinical studies of the combined company&#8217;s product candidates, or those of the combined company&#8217;s competitors or the combined company&#8217;s existing or future collaborators;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure to meet or exceed financial and development projections the combined company may provide to the public;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>failure to meet or exceed the financial and development projections of the investment community;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if the combined company does not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by the combined company or its competitors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>actions taken by regulatory agencies with respect to the combined company&#8217;s product candidates, clinical studies, manufacturing process or sales and marketing terms;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>disputes or other developments relating to proprietary rights, including patents, litigation matters, and the combined company&#8217;s ability to obtain patent protection for its technologies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>additions or departures of key personnel;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>significant lawsuits, including patent or stockholder litigation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if securities or industry analysts do not publish research or reports about the combined company&#8217;s business, or if they issue adverse or misleading opinions regarding its business and stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>changes in the market valuations of similar companies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general market or macroeconomic conditions or market conditions in the pharmaceutical and biotechnology sectors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>sales of securities by the combined company or its securityholders in the future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>if the combined company fails to raise an adequate amount of capital to fund its operations or continued development of its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>trading volume of the combined company&#8217;s common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>announcements by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or capital commitments;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">80</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>adverse publicity relating to precision medicine product candidates, including with respect to other products in such markets;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the introduction of technological innovations or new therapies that compete with the products and services of the combined company; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>period<span class="nobreak">-to-period</span>&#160;fluctuations in the combined company&#8217;s financial results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of the combined company&#8217;s common stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect the combined company&#8217;s business and the value of its common stock. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against such companies. Furthermore, market volatility may lead to increased shareholder activism if the combined company experiences a market valuation that activists believe is not reflective of its intrinsic value. Activist campaigns that contest or conflict with the combined company&#8217;s strategic direction or seek changes in the composition of its board of directors could have an adverse effect on its operating results, financial condition and cash flows.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company may incur losses for the foreseeable future and may never achieve profitability.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company may never become profitable, even if it is able to complete clinical development for one or more product candidates and eventually commercialize such product candidates. The combined company will need to successfully complete significant research, development, testing and regulatory compliance activities that, together with projected general and administrative expenses, is expected to result in substantial increased operating losses for at least the next several&#160;years. Even if the combined company does achieve profitability, it may not be able to sustain or increase profitability on a quarterly or annual basis.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the combined company fails to attract and retain management and other key personnel, it may be unable to continue to successfully develop or commercialize its product candidates or otherwise implement its business plan.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company&#8217;s ability to compete in the highly competitive pharmaceuticals industry depends on its ability to attract and retain highly qualified managerial, scientific, medical, legal, sales and marketing and other personnel. The combined company will be highly dependent on its management and scientific personnel. The loss of the services of any of these individuals could impede, delay, or prevent the successful development of the combined company&#8217;s product pipeline, completion of its planned clinical trials, commercialization of its product candidates or&#160;in<span class="nobreak">-licensing</span>&#160;or acquisition of new assets and could impact negatively its ability to implement successfully its business plan. If the combined company loses the services of any of these individuals, it might not be able to find suitable replacements on a timely basis or at all, and its business could be harmed as a result. The combined company might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company will need to raise additional financing in the future to fund its operations, which may not be available to it on favorable terms or at all.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company will require substantial additional funds to conduct the costly and time<span class="nobreak">-consuming</span> clinical efficacy trials necessary to pursue regulatory approval of each potential product candidate and to continue the development of ORKA<span class="nobreak">-001</span>, ORKA<span class="nobreak">-002</span> and Oruka&#8217;s other programs and future product candidates. The combined company&#8217;s future capital requirements will depend upon a number of factors, including: the number and timing of future product candidates in the pipeline; progress with and results from preclinical testing and clinical trials; the ability to manufacture sufficient drug supplies to complete preclinical and clinical trials; the costs involved in preparing, filing, acquiring, prosecuting, maintaining and enforcing patent and other intellectual property claims; and the time and costs involved in obtaining regulatory approvals and favorable reimbursement or formulary acceptance. Raising additional capital may be costly or difficult to obtain and could, for example, through the sale of common stock or securities convertible or exchangeable into common stock, significantly dilute the combined company&#8217;s stockholders&#8217; ownership interests or inhibit the combined company&#8217;s ability to achieve its business objectives. If the combined company raises additional funds through public or private equity offerings, the terms of </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">81</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">these securities may include liquidation or other preferences that adversely the rights of its common stockholders. In addition, any debt financing may subject the combined company to fixed payment obligations and covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If the combined company raises additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, the combined company may have to relinquish certain valuable intellectual property or other rights to its product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to it. Even if the combined company were to obtain sufficient funding, there can be no assurance that it will be available on terms acceptable to the combined company or its stockholders.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company will incur significant legal, accounting and other expenses as a public company that Oruka did not incur as a private company, including costs associated with public company reporting obligations under the Securities Exchange&#160;Act&#160;of&#160;1934, as amended (the &#8220;Exchange&#160;Act&#8221;). The combined company&#8217;s management team will consist of the executive officers of Oruka prior to the Merger. These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that the combined company complies with all of these requirements. Any changes the combined company makes to comply with these obligations may not be sufficient to allow it to satisfy its obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for the combined company to attract and retain qualified persons to serve on the board of directors or on board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Upon completion of the Merger, failure by the combined company to comply with the initial listing standards of Nasdaq will prevent its stock from being listed on Nasdaq.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon completion of the Merger, ARCA, under the new name &#8220;Oruka Therapeutics, Inc.,&#8221; will be required to meet the initial listing requirements to maintain the listing and continued trading of its shares on Nasdaq. These initial listing requirements are more difficult to achieve than the continued listing requirements. Pursuant to the Merger Agreement, ARCA agreed to use its commercially reasonable efforts to cause the shares of ARCA common stock being issued in the Merger (including any common stock issuable upon conversion of the ARCA Series&#160;B Preferred Stock) to be approved for listing on Nasdaq at or prior to the effective time of the Merger. Based on information currently available to ARCA, ARCA anticipates that its stock will be unable to meet the $4.00 minimum bid price initial listing requirement at the closing of the Merger unless it effects a reverse stock split. ARCA&#8217;s board of directors intends to effect a reverse stock split of the shares of ARCA common stock at a ratio of between 6:1 to 12:1. In addition, often times a reverse stock split will not result in a trading price for the affected common stock that is proportional to the ratio of the split. Following the Merger, if the combined company is unable to satisfy Nasdaq listing requirements, Nasdaq may notify the combined company that its shares of common stock will not be listed on Nasdaq.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon a potential delisting from Nasdaq, if the common stock of the combined company is not then eligible for quotation on another market or exchange, trading of the shares could be conducted in the&#160;over<span class="nobreak">-the-counter</span>&#160;market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it is likely that there would be significantly less liquidity in the trading of the common stock of the combined company; decreases in institutional and other investor demand for the shares, coverage by securities analysts, market making activity and information available concerning trading prices and volume; and fewer broker dealers willing to execute trades in the common stock of the combined company. Also, it may be difficult for the combined company to raise additional capital if the combined company&#8217;s common stock is not listed on a major exchange. The occurrence of any of these events could result in a further decline in the market price of the common stock of the combined company and could have a material adverse effect on the combined company.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">82</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Once the combined company is no longer a smaller reporting company or otherwise no longer qualifies for applicable exemptions, the combined company will be subject to additional laws and regulations affecting public companies that will increase the combined company&#8217;s costs and the demands on management and could harm the combined company&#8217;s operating results and cash flows.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company will be subject to the reporting requirements of the Exchange&#160;Act, which requires, among other things, that the combined company file with the SEC, annual, quarterly and current reports with respect to the combined company&#8217;s business and financial condition as well as other disclosure and corporate governance requirements. However, as a &#8220;smaller reporting company,&#8221; as such term is defined in Rule&#160;12b<span class="nobreak">-2</span> under the Exchange&#160;Act, in at least the near term, the combined company may take advantage of exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act and reduced disclosure obligations regarding executive compensation in this proxy statement/prospectus and in the combined company&#8217;s periodic reports and proxy statements. Once the combined company is no longer a smaller reporting company or otherwise no longer qualifies for these exemptions, the combined company will be required to comply with these additional legal and regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do so. If the combined company is not able to comply with the requirements in a timely manner or at all, the combined company&#8217;s financial condition or the market price of the combined company&#8217;s common stock may be harmed. For example, if the combined company or its independent auditor identifies deficiencies in the combined company&#8217;s internal control over financial reporting that are deemed to be material weaknesses the combined company could face additional costs to remedy those deficiencies, the market price of the combined company&#8217;s stock could decline or the combined company could be subject to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If the combined company fails to maintain proper and effective internal controls, its ability to produce accurate financial statements on a timely basis could be impaired.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Provided the combined company continues to be listed on Nasdaq, the combined company will be subject to the reporting requirements of the Exchange&#160;Act, the Sarbanes<span class="nobreak">-Oxley</span> Act and the rules and regulations of Nasdaq. The Sarbanes<span class="nobreak">-Oxley</span> Act requires, among other things, that the combined company maintain effective disclosure controls and procedures and internal control over financial reporting. The combined company must perform system and process evaluation and testing of its internal control over financial reporting to allow management to report on the effectiveness of its internal controls over financial reporting in its Annual Report on Form&#160;10<span class="nobreak">-K</span>&#160;filing for that year, as required by Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act. As a private company, Oruka has not been required to document and test its internal controls over financial reporting nor has its management been required to certify the effectiveness of its internal controls and its auditors have not been required to opine on the effectiveness of its internal control over financial reporting. Following the Merger, the combined company will be required to incur substantial professional fees and internal costs to expand its accounting and finance functions and expend significant management efforts. The combined company may experience difficulty in meeting these reporting requirements in a timely manner.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company may discover weaknesses in its system of internal financial and accounting controls and procedures that could result in a material misstatement of its financial statements. The combined company&#8217;s internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the combined company is not able to comply with the requirements of Section&#160;404 of the Sarbanes<span class="nobreak">-Oxley</span> Act, or if it is unable to maintain proper and effective internal controls, the combined company may not be able to produce timely and accurate financial statements. If that were to happen, the market price of its common stock could decline and it could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">83</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The unaudited pro forma condensed combined financial information for ARCA and Oruka included in this proxy statement/prospectus are preliminary, and the combined company&#8217;s actual financial position and operations after the Merger may differ materially from the unaudited pro forma financial information included in this proxy statement/prospectus.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma financial information for ARCA and Oruka included in this proxy statement/prospectus are presented for illustrative purposes only and is not necessarily indicative of the combined company&#8217;s actual financial condition or results of operations of future periods, or the financial condition or results of operations that would have been realized had the entities been combined during the period presented. The combined company&#8217;s actual results and financial position after the Merger may differ materially and adversely from the unaudited pro forma financial information included in this proxy statement/prospectus. The exchange ratio reflected in this proxy statement/prospectus is preliminary. The final exchange ratio could differ materially from the preliminary exchange ratio used to prepare the pro forma adjustments. For more information see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; beginning on page&#160;284.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Provisions that will be in the combined company&#8217;s certificate of incorporation and bylaws and provisions under Delaware law could make an acquisition of the combined company more difficult and may prevent attempts by its stockholders to replace or remove its management.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Provisions that will be included in the combined company&#8217;s certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the combined company that stockholders may consider favorable, including transactions in which its common stockholders might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of the combined company&#8217;s common stock, thereby depressing the market price of its common stock. In addition, because the combined company&#8217;s board of directors will be responsible for appointing the members of the combined company&#8217;s management team, these provisions may frustrate or prevent any attempts by the combined company&#8217;s stockholders to replace or remove its current management by making it more difficult for stockholders to replace members of the combined company&#8217;s board of directors. Among other things, these provisions will:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continue the use of a classified board of directors such that not all members of the combined company board of directors are elected at one time;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>allow the authorized number of the combined company&#8217;s directors to be changed only by resolution of its board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>limit the manner in which stockholders can remove directors from the combined company&#8217;s board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>provide for advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on at stockholder meetings;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by its stockholders by written consent;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>limit who may call a special meeting of stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>authorize the combined company&#8217;s board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by the combined company&#8217;s board of directors; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>require the approval of the holders of at least 66 2/3% of the votes that all combined company stockholders would be entitled to cast to amend or repeal certain provisions of the combined company&#8217;s certificate of incorporation or bylaws.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Moreover, because the combined company will be incorporated in Delaware, it is governed by the provisions of Section&#160;203 of the DGCL, which prohibits stockholders owning in excess of 15% of the outstanding combined company voting stock from merging or combining with the combined company. Although ARCA and Oruka believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with the combined company&#8217;s board of directors, they would apply even if the offer may be considered </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">84</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:6pt;">beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by the combined company&#8217;s stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA and Oruka expect the combined company to amend its bylaws to provide that, unless the combined company consents in writing to the selection of an alternative forum, certain designated courts will be the sole and exclusive forum for certain legal actions between the combined company and its stockholders, which could limit its stockholders&#8217; ability to obtain a favorable judicial forum for disputes with the combined company or its directors, officers, employees or stockholders.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA and Oruka expect the combined company to amend its bylaws to provide that, unless the combined company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the sole and exclusive forum for the following types of proceedings (i)&#160;any derivative action or proceeding brought on the combined company&#8217;s behalf, (ii)&#160;any action asserting a claim of or based on a breach of a fiduciary duty owed by any of the combined company&#8217;s current or former directors, officers, employees or stockholders to the combined company or its stockholders, (iii)&#160;any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (iv)&#160;any action asserting a claim arising pursuant to any provision of the combined company&#8217;s certificate of incorporation or its bylaws (in each case, as they may be amended from time to time) or that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein, which for purposes of this risk factor refers to herein as the &#8220;Delaware Forum Provision.&#8221; The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act and the Exchange&#160;Act. ARCA and Oruka expect the combined company to also amend its bylaws to provide that, unless it consents in writing to an alternative forum, federal district courts of the United&#160;States will be the sole and exclusive forum for any complaint asserting a cause of action arising under the Securities Act, which for purposes of this risk factor is referred to herein as the &#8220;Federal Forum Provision.&#8221; There is uncertainty as to whether a court would enforce such a provision. In addition, the bylaws of the combined company will provide that any person or entity purchasing or otherwise acquiring any interest in shares of its capital stock is deemed to have notice of and consented to the foregoing Delaware Forum Provision and Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived the combined company&#8217;s compliance with the U.S.&#160;federal securities laws and the rules and regulations thereunder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The Delaware Forum Provision and the Federal Forum Provision may impose additional costs on stockholders of the combined company in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or were permitted to select another jurisdiction. Additionally, the forum selection clauses in the bylaws of the combined company may limit its stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with the combined company or its directors, officers, employees or stockholders, which may discourage such lawsuits against the combined company and its directors, officers, employees and stockholders even though an action, if successful, might benefit its stockholders. Alternatively, if a court were to find the Delaware Forum Provision or the Federal Forum Provision contained in the combined company&#8217;s bylaws to be inapplicable or unenforceable in an action, the combined company may incur additional costs associated with resolving such action in other jurisdictions, which could materially and adversely affect its business, financial condition and results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA and Oruka do not anticipate that the combined company will pay any cash dividends in the foreseeable future.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current expectation is that the combined company will retain its future earnings, if any, to fund the growth of the combined company&#8217;s business as opposed to paying dividends. As a result, capital appreciation, if any, of the common stock of the combined company will be your sole source of gain, if any, for the foreseeable future.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">An active trading market for the combined company&#8217;s common stock may not develop and its stockholders may not be able to resell their shares of common stock for a profit, if at all.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the Merger, there had been no public market for shares of Oruka capital stock. An active trading market for the combined company&#8217;s shares of common stock may never develop or be sustained. If an active market for the combined company&#8217;s common stock does not develop or is not sustained, it may be difficult for the combined company&#8217;s stockholders to sell their shares at an attractive price or at all.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">85</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Future sales of shares by existing stockholders could cause the combined company&#8217;s stock price to decline.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">If existing securityholders of ARCA and Oruka sell, or indicate an intention to sell, substantial amounts of the combined company&#8217;s common stock in the public market after legal restrictions on resale discussed in this proxy statement/prospectus lapse, the trading price of the common stock of the combined company could decline. Based on shares outstanding as of July<span class="nobreak"> </span>16, 2024, after giving effect to the estimated exchange ratio and the shares of Oruka common stock to be issued in the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing and shares expected to be issued upon completion of the Merger and prior to giving effect to the anticipated ARCA reverse stock split, the combined company is expected to have outstanding a total of approximately 354.5<span class="nobreak"> </span>million shares of common stock immediately following the completion of the Merger (or approximately 592.6<span class="nobreak"> </span>million shares of common stock after giving effect to the conversion of the ARCA Series B Preferred Stock and the exercise of the Oruka pre<span class="nobreak">-funded</span> warrants to be issued in the Oruka pre<span class="nobreak">-closing</span> financing). Approximately 308.9<span class="nobreak"> </span>million&#160;shares will be freely tradeable upon completion of the Merger and approximately 45.6<span class="nobreak"> </span>million&#160;shares (or approximately 183<span class="nobreak"> </span>million, if the ARCA Series B Preferred Stock is converted and the Oruka pre<span class="nobreak">-funded</span> warrants are exercised) will become available for sale in the public market beginning 180&#160;days after the closing of the Merger as a result of the expiration of&#160;lock<span class="nobreak">-up</span>&#160;agreements between ARCA on the one hand and certain securityholders of Oruka on the other hand (and without giving effect to any restrictions on resale under securities laws). In addition, shares of common stock that are subject to outstanding options or warrants of Oruka (excluding the&#160;pre<span class="nobreak">-funded</span>&#160;warrants issued in the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing) will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act. If these shares are sold, the trading price of the combined company&#8217;s common stock could decline.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">After completion of the Merger, the combined company&#8217;s executive officers, directors and principal stockholders will have the ability to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Upon the completion of the Merger, and giving effect to the issuance of the shares of Oruka common stock and the Oruka&#160;pre<span class="nobreak">-funded</span>&#160;warrants prior to the closing of the Merger pursuant to the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing, it is anticipated that the combined company&#8217;s executive officers, directors and principal stockholders will, in the aggregate, beneficially own approximately 47% of the combined company&#8217;s outstanding shares of common stock (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to the combined company&#8217;s stockholders for approval, as well as the combined company&#8217;s management and affairs. For example, these stockholders, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of the combined company&#8217;s assets. This concentration of voting power could delay or prevent an acquisition of the combined company on terms that other stockholders may desire.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the combined company, its business or its market, its stock price and trading volume could decline.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The trading market for the combined company&#8217;s common stock will be influenced by the research and reports that equity research analysts publish about it and its business. Equity research analysts may elect to not provide research coverage of the combined company&#8217;s common stock after the completion of the Merger, and such lack of research coverage may adversely affect the market price of its common stock. In the event it does have equity research analyst coverage, the combined company will not have any control over the analysts or the content and opinions included in their reports. The price of the combined company&#8217;s common stock could decline if one or more equity research analysts downgrade its stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of the combined company or fails to publish reports on it regularly, demand for its common stock could decrease, which in turn could cause its stock price or trading volume to decline.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company will have broad discretion in the use of the cash and cash equivalents of the combined company and the proceeds from the Oruka&#160;pre-closing&#160;financing and may invest or spend the proceeds in ways with which you do not agree and in ways that may not increase the value of your investment.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The combined company will have broad discretion over the use of the cash and cash equivalents of the combined company and the proceeds from the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing. You may not agree with the combined company&#8217;s decisions, and its use of the proceeds may not yield any return on your investment. The combined </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">86</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:6pt;">company&#8217;s failure to apply these resources effectively could compromise its ability to pursue its growth strategy and the combined company might not be able to yield a significant return, if any, on its investment of these net proceeds. You will not have the opportunity to influence its decisions on how to use the combined company&#8217;s cash resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company may be subject to adverse legislative or regulatory tax changes that could negatively impact its financial condition.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The rules dealing with U.S.&#160;federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service and the U.S.&#160;Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect the combined company or its stockholders. The combined company will assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where the combined company has operations to determine the potential effect on its business and any assumptions the combined company will make about its future taxable income. It cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on its business if they were to be enacted. For example, the United&#160;States recently enacted the IRA, which implements, among other changes, a 1% excise tax on certain stock buybacks. In addition, beginning in 2022, the Tax Act eliminates the currently available option to deduct research and development expenditures and requires taxpayers to amortize them generally over five&#160;years. The U.S.&#160;Congress is considering legislation that would restore the current deductibility of research and development expenditures, however, there is no assurance that the provision will be repealed or otherwise modified. Such changes, among others, may adversely affect its effective tax rate, results of operation and general business condition.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The combined company&#8217;s ability to use NOL carryforwards and other tax attributes may be limited, including as a result of the Merger.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As discussed above, ARCA has incurred losses during its history, and the combined company does not expect to become profitable in the near future and may never achieve profitability. As of December&#160;31, 2023, ARCA had NOL carryforwards of approximately $208.1&#160;million, and approximately $2.4&#160;million of research and development credits that may be used to offset future taxable income. ARCA had operating loss carryforwards of $156.4&#160;million generated prior to 2018, which will expire beginning in 2025 if not utilized. Under current law, ARCA&#8217;s U.S.&#160;federal NOLs of $51.7&#160;million incurred in tax&#160;years beginning after December&#160;31, 2017 may be carried forward indefinitely, but the deductibility of such net operating loss carryforwards is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal law. In addition, under Sections&#160;382 and 383 of the Code, U.S.&#160;federal net operating loss carryforwards and other tax attributes may become subject to an annual limitation in the event of certain cumulative changes in ownership. An &#8220;ownership change&#8221; pursuant to Section&#160;382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#8217;s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three<span class="nobreak">-year</span> period. The combined company&#8217;s ability to utilize its net operating loss carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including, as discussed above, in connection with the Merger or other transactions. Similar rules may apply under state tax laws. If the combined company earns taxable income, such limitations could result in increased future income tax liability to the combined company, and the combined company&#8217;s future cash flows could be adversely affected.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Unfavorable global economic conditions could adversely affect the combined company&#8217;s business, financial condition, results of operations or cash flows.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company&#8217;s results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to the combined company&#8217;s business, including, weakened demand for the combined company&#8217;s product candidates and the combined company&#8217;s ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain the combined company&#8217;s suppliers, possibly resulting in supply disruption, or cause the combined company&#8217;s customers to delay making payments for its services. Any of the foregoing could harm the combined company&#8217;s business and the combined company cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact its business.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">87</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T23"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This proxy statement/prospectus contains or incorporates statements that constitute forward<span class="nobreak">-looking</span> statements within the meaning of the federal securities laws in relation to ARCA, Oruka, the Merger and the other proposed transactions contemplated thereby. Any express or implied statements that do not relate to historical or current facts or matters are forward<span class="nobreak">-looking</span> statements. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward<span class="nobreak">-looking</span> statements. These forward<span class="nobreak">-looking</span> statements include, but are not limited to, express or implied statements regarding ARCA&#8217;s or Oruka&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future. In some cases, you can identify forward<span class="nobreak">-looking</span> statements by terminology such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;seeks,&#8221; &#8220;target,&#8221; &#8220;endeavor,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;contemplate&#8221; or the negative of these terms or other comparable terminology, but the absence of these words does not mean that a statement is not forward<span class="nobreak">-looking</span>. These forward<span class="nobreak">-looking</span> statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting ARCA, Oruka or the proposed transaction will be those that have been anticipated. These forward<span class="nobreak">-looking</span> statements involve a number of risks, uncertainties (some of which are beyond ARCA&#8217;s or Oruka&#8217;s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward<span class="nobreak">-looking</span> statements. In addition to other factors and matters contained in or incorporated by reference in this document, ARCA and Oruka believe the following factors could cause actual results to differ materially from those discussed in the forward<span class="nobreak">-looking</span> statements:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the conditions to the closing of the Merger are not satisfied, including the failure to obtain stockholder approval required to complete the Merger and transactions contemplated thereby;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s and Oruka&#8217;s ability to meet expectations regarding the timing and completion of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the Oruka pre<span class="nobreak">-closing</span> financing is not completed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>uncertainties as to the timing and costs of the consummation of the Merger and the ability of each of ARCA and Oruka to consummate the Merger and the transactions contemplated thereby, including the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>statements regarding the special cash dividend that ARCA may pay to ARCA stockholders in connection with the completion of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>risks related to ARCA&#8217;s continued listing on the Nasdaq until closing of the proposed Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expectations regarding the strategies, prospects, plans expectations and objectives of management of ARCA or Oruka for future operations of the combined company following the closing of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ability of the combined company to recognize the benefits that may be derived from the Merger, including the commercial or market opportunity of the product candidates of ARCA, Oruka and the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>risks related to ARCA&#8217;s and Oruka&#8217;s ability to correctly estimate their respective operating expenses and expenses associated with the transaction, uncertainties regarding the impact any delay in the closing of the Merger would have on the anticipated cash resources of the combined company upon closing and other events and unanticipated spending and costs that could reduce the combined company&#8217;s cash resources;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the accuracy of the parties&#8217; estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the fact that under the terms of the Merger Agreement, ARCA and Oruka are restrained from soliciting other acquisition proposals during the pendency of the Merger, except in certain circumstances;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">88</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the effect of the announcement or pendency of the Merger on ARCA&#8217;s or Oruka&#8217;s business relationships, operating results and business generally, including disruption of ARCA&#8217;s and Oruka&#8217;s management&#8217;s attention from ongoing business operations due to the Merger and potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the Merger Agreement may be terminated in circumstances that require ARCA or Oruka to pay a termination fee;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the outcome of any legal proceedings that may be instituted against ARCA, Oruka or any of their respective directors or officers related to the Merger Agreement or the transactions contemplated thereby;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ability of ARCA and Oruka to protect their respective intellectual property rights;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>competitive responses to the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>legislative, regulatory, political and economic developments beyond the parties&#8217; control;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the initiation, timing and success of clinical trials for ARCA&#8217;s and Oruka&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>success in retaining, or changes required in, ARCA&#8217;s and Oruka&#8217;s officers, key employees or directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s public securities&#8217; potential liquidity and trading;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>regulatory actions with respect to ARCA&#8217;s and Oruka&#8217;s product candidates or their respective competitors&#8217; products and product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s and Oruka&#8217;s ability to manufacture their product candidates in conformity with the FDA&#8217;s requirements and to scale up manufacturing of their product candidates to commercial scale, if approved;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s and Oruka&#8217;s reliance on third<span class="nobreak">-party</span> contract development and manufacturer organizations to manufacture and supply product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the beneficial characteristics, and the potential safety, efficacy and therapeutic effects of ARCA&#8217;s and Oruka&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expected potential benefits of strategic collaboration with third parties and ARCA&#8217;s and Oruka&#8217;s ability to attract collaborators with development, regulatory and commercialization expertise;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s and Oruka&#8217;s ability to successfully commercialize product candidates, if approved, and the rate and degree of market acceptance of such product candidates; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>developments and projections relating to ARCA&#8217;s and Oruka&#8217;s competitors or industry.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Should one or more of these risks or uncertainties materialize, or should any of ARCA&#8217;s or Oruka&#8217;s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward<span class="nobreak">-looking</span> statements. There may be additional risks that ARCA or Oruka considers immaterial or which are unknown. You are urged to carefully review the disclosures ARCA and Oruka make concerning these risks and other factors that may affect ARCA&#8217;s and Oruka&#8217;s business and operating results under the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; beginning on page 15 of this proxy statement/prospectus. Additional factors that could cause actual results to differ materially from those expressed in the forward<span class="nobreak">-looking</span> statements are discussed in reports filed with the SEC by ARCA and incorporated by reference herein. Please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Where You Can Find More Information</span>&#8221; beginning on page 321 of this proxy statement/prospectus. There can be no assurance that the Merger will be completed, or if it is completed, that it will be completed within the anticipated time period or that the expected benefits of the Merger will be realized.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">89</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any of these risks or uncertainties materialize or any of these assumptions prove incorrect, the results of ARCA, Oruka or the combined company could differ materially from the forward<span class="nobreak">-looking</span> statements. Any public statements or disclosures by ARCA and Oruka following this proxy statement/prospectus that modify or impact any of the forward<span class="nobreak">-looking</span> statements contained in this proxy statement/prospectus will be deemed to modify or supersede such statements in this proxy statement/prospectus. You are cautioned not to place undue reliance on these forward<span class="nobreak">-looking</span> statements, which speak only as of the date of this document and are qualified in their entirety by reference to the cautionary statements herein. ARCA and Oruka do not intend, and undertake no obligation, to update any forward<span class="nobreak">-looking</span> information to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events, unless required by law to do so.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">90</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T22"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">THE SPECIAL MEETING IN LIEU OF ANNUAL MEETING OF ARCA STOCKHOLDERS</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Date, Time and Place</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA special meeting will be held on August<span class="nobreak"> </span>22, 2024, commencing at 9:00 a.m. Mountain Time, unless postponed or adjourned to a later date. The ARCA special meeting will be held at the Denver Marriott Westminster, 7000 Church Ranch Blvd, Westminster, Colorado 80021. ARCA is sending this proxy statement/prospectus to its stockholders in connection with the solicitation of proxies by ARCA&#8217;s board of directors for use at the ARCA special meeting and any adjournments or postponements of the ARCA special meeting. This proxy statement/prospectus is first being furnished to ARCA stockholders on or about July<span class="nobreak"> </span>26, 2024.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Purpose of the ARCA Special Meeting</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The purposes of the ARCA special meeting are:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve (i)&#160;the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger, to stockholders of Oruka, pursuant to the terms of the Merger Agreement, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to this proxy statement/prospectus, and (ii)&#160;the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a)&#160;and 5635(b), respectively (the &#8220;Nasdaq Stock Issuance Proposal&#8221; or &#8220;Proposal&#160;No. 1&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the amended and restated certificate of incorporation of ARCA (the &#8220;ARCA Charter&#8221;) to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000<span class="nobreak"> </span>shares to 545,000,000, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to this proxy statement/prospectus (the &#8220;Authorized Share Increase Proposal&#8221; or &#8220;Proposal&#160;No. 2&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range between 6:1 to 12:1, inclusive, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H </span>to this proxy statement/prospectus, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time or, if the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, determined solely by ARCA&#8217;s board of directors (the &#8220;Reverse Stock Split Proposal&#8221; or &#8220;Proposal&#160;No. 3&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I</span> (the &#8220;Officer Exculpation Proposal&#8221; or &#8220;Proposal&#160;No. 4&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Elect the Class&#160;III director, Jacob Ma<span class="nobreak">-Weaver</span>, to ARCA&#8217;s board of directors and to hold office until ARCA&#8217;s 2027 annual meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation or removal (the &#8220;Director Election Proposal&#8221; or &#8220;Proposal&#160;No. 5&#8221;), provided that if the Merger is consummated, the approval of Proposal&#160;No. 5 will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Ratify the appointment of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for fiscal year ending December&#160;31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed (the &#8220;Auditor Ratification Proposal&#8221; or &#8220;Proposal&#160;No. 6&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (the &#8220;Stock Plan Proposal&#8221; or &#8220;Proposal&#160;No. 7&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the &#8220;ESPP Proposal&#8221; or &#8220;Proposal&#160;No. 8&#8221;);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger (the &#8220;the Merger Compensation Proposal&#8221; or &#8220;Proposal&#160;No. 9&#8221;);</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">91</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal (the &#8220;Adjournment Proposal&#8221; or &#8220;Proposal&#160;No. 10&#8221;); and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Transact such other business as may properly come before the stockholders at the ARCA special meeting or any adjournment or postponement thereof.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of Proposal&#160;No. 1 and Proposal&#160;No. 2 is a condition to completion of the Merger. The issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and ARCA Series&#160;B Preferred Stock in connection with the Merger and the change of control of ARCA resulting from the Merger will not take place unless Proposal&#160;No. 1 and Proposal&#160;No. 2 are approved by ARCA stockholders and the Merger is consummated. The amendment to the ARCA Charter to increase the number of authorized shares of ARCA common stock will not take place unless Proposal&#160;No. 2 is approved by the requisite ARCA stockholders. The amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock will not take place unless Proposal&#160;No. 3 is approved by the requisite ARCA stockholders. ARCA&#8217;s board of directors may determine to effect the authorized share increase or the reverse stock split if one or both are approved and Proposal&#160;No. 1 is not approved by ARCA stockholders, following the special meeting.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Recommendation of ARCA&#8217;s Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">ARCA&#8217;s board of directors recommends that you vote:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, pursuant to the Merger Agreement is fair to, in the best interests of, and advisable to, ARCA and its stockholders. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the approval of Nasdaq Stock Issuance Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that it is advisable and in the best interests of ARCA and its stockholders to approve the amendment to the ARCA Charter to effect the increase in authorized shares. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Authorized Share Increase Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and declared that it is advisable and in the best interests of ARCA and its stockholders to approve the amendment to the ARCA Charter to effect the reverse stock split, if necessary. ARCA&#8217;s board of directors recommends that ARCA stockholder vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the Reverse Stock Split Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the amendment to the ARCA Charter to provide for the exculpation of officers, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Officer Exculpation Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to elect Jacob Ma<span class="nobreak">-Weaver</span> to serve on ARCA&#8217;s board of directors in the class of directors with terms expiring at ARCA&#8217;s 2027 annual meeting of stockholders, provided that if the Merger is consummated, the approval of Proposal&#160;No. 5 will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement. ARCA&#8217;s board of directors that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the director nominee named in the Director Election Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to ratify the selection of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December<span class="nobreak">&#160;</span>31, 2024, provided that </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">92</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221;<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>the Auditor Ratification Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the 2024 Stock Incentive Plan, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Stock Plan Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve the 2024 Employee Stock Purchase Plan, as described in this proxy statement/prospectus. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the ESPP Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that it is advisable to, and in the best interests of, ARCA and its stockholders to approve certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Merger Compensation Proposal as described in this proxy statement/prospectus.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors has determined and believes that adjourning the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal is fair to, in the best interests of, and advisable to, ARCA and its stockholders and has approved and adopted the proposal. ARCA&#8217;s board of directors recommends that ARCA stockholders vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Adjournment Proposal, if necessary, as described in this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Record Date and Voting Power</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Only holders of record of ARCA common stock at the close of business on the Record Date of July<span class="nobreak"> </span>22, 2024, are entitled to notice of, and to vote at, the ARCA special meeting. At the close of business on the Record Date, there were 14 registered holders of record of ARCA common stock and there were 14,507,143<span class="nobreak"> </span>shares of ARCA common stock issued and outstanding. Each share of ARCA common stock entitles the holder thereof to one vote on each matter submitted for stockholder approval.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Voting and Revocation of Proxies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The proxy accompanying this proxy statement/prospectus is solicited on behalf of ARCA&#8217;s board of directors for use at the ARCA special meeting.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If, as of the Record Date referred to above, your shares were registered directly in your name with the transfer agent for ARCA common stock, Computershare Trust Company, N.A., then you are a stockholder of record. As a stockholder of record, you may vote in person at the ARCA special meeting or vote by proxy. Whether or not you plan to attend the ARCA special meeting, we urge you to vote by proxy over the telephone or on the Internet as instructed below or return the proxy card we may mail to you to ensure your vote is counted, the form of which is attached hereto as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex M</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The procedures for voting are as follows:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you are a stockholder of record, you may vote at the ARCA special meeting. Alternatively, you may vote by proxy by using the accompanying proxy card, over the internet or by telephone. Whether or not you plan to attend the ARCA special meeting, ARCA encourages you to vote by proxy to ensure your vote is counted. Even if you have submitted a proxy before the ARCA special meeting, you may still attend the ARCA special meeting and vote. In such case, your previously submitted proxy will be disregarded.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote in person, come to the ARCA special meeting and we will give you a ballot when you arrive. If you attend the ARCA special meeting and vote in person, your vote will revoke any proxy that you have previously submitted. Simply attending the ARCA special meeting will not, by itself, revoke your proxy.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">93</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>To vote using the proxy card, simply complete, sign and date the proxy card that you may request or that we may elect to deliver at a later time and return it promptly in the envelope provided. If you return your signed proxy card to us before the special meeting, we will vote your shares as you direct.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You can vote by proxy over the telephone by calling the toll<span class="nobreak">-free</span> number found on the proxy card.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>You can vote by proxy over the internet by following the instructions provided on the proxy card.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a voting instruction card and voting instructions with these proxy materials from that organization rather than from ARCA.&#160;Simply complete and mail the voting instruction card to ensure that your vote is counted. To vote at the ARCA special meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions from your broker, bank or other agent included with these proxy materials, or contact your broker, bank or other agent to request a proxy form.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA provides internet proxy voting to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you hold shares beneficially in street name and do not provide your broker or other agent with voting instructions, your shares may constitute &#8220;broker non<span class="nobreak">-votes</span>.&#8221; A &#8220;broker non<span class="nobreak">-vote</span>&#8221; occurs when shares held by a broker are not voted with respect to a particular proposal because the broker has not received voting instructions from its client(s)&#160;with respect to such shares on how to vote and does not have or did not exercise discretionary authority to vote on the matter. Abstentions will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the ARCA special meeting. Abstentions will be counted towards the vote totals for each proposal, and will have the same effect of a vote &#8220;AGAINST&#8221; Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>4,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10. Broker non<span class="nobreak">-votes</span>, if any, will not be counted as &#8220;votes properly cast&#8221; or &#8220;shares entitled to vote&#8221; and will therefore have no effect on Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>2,<span class="nobreak"> </span>3,<span class="nobreak"> </span>5,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and<span class="nobreak"> </span>10, but will have the same effect of a vote &#8220;AGAINST&#8221; Proposal&#160;No. 4. If an ARCA stockholder does not return voting instructions to their broker on how to vote their shares of ARCA common stock, such broker may be prevented from voting, or may otherwise choose not to vote, such shares held by such broker, resulting in broker non<span class="nobreak">-votes</span> with respect to such shares. To make sure that your vote is counted, you should instruct your broker to vote your shares of ARCA common stock, following the procedures provided by your broker.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All properly executed proxies that are not revoked will be voted at the ARCA special meeting and at any adjournments or postponements of the ARCA special meeting in accordance with the instructions contained in the proxy. <span class="Bold" style="font-style:normal;font-weight:bold;">If a holder of ARCA common stock executes and returns a proxy and does not specify otherwise, the shares represented by that proxy will be voted &#8220;FOR&#8221; all of the proposals in accordance with the recommendation of ARCA&#8217;s board of directors.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The presence at the ARCA special meeting of the holders of a majority of the shares of ARCA common stock outstanding and entitled to vote at the ARCA special meeting is necessary to constitute a quorum at the meeting. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will be counted towards the presence of a quorum. The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10. The affirmative vote of a majority of the votes properly cast by the holders of ARCA common stock at the ARCA special meeting, assuming a quorum is present, is required for approval of Proposal&#160;Nos. 2 and 3. The affirmative vote of a majority of the outstanding shares of ARCA common stock is required for approval of Proposal&#160;No. 4. With respect to Proposal&#160;No.&#160;5, directors are elected by a plurality of the votes properly cast at the ARCA special meeting, and the one nominee for director receiving the highest number of affirmative votes properly cast will be elected. Proposal&#160;No. 1 is conditioned on the approval of Proposal&#160;No. 2. Notwithstanding the approval of Proposal&#160;No.<span class="nobreak"> </span>1, if Proposal&#160;No. 2 is not approved, the actions contemplated by Proposal&#160;No. 1 will not be effected and the Merger will not be consummated.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">94</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of Proposal&#160;No. 1 and Proposal&#160;No. 2 is a condition to completion of the Merger. The issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and ARCA Series&#160;B Preferred Stock in connection with the Merger and the change of control of ARCA resulting from the Merger will not take place unless Proposal&#160;No. 1 and Proposal&#160;No. 2 are approved by ARCA stockholders and the Merger is consummated. The amendment to the ARCA Charter to increase the number of authorized shares of ARCA common stock will not take place unless Proposal&#160;No. 2 is approved by the requisite ARCA stockholders. The amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock, if deemed necessary, will not take place unless Proposal&#160;No. 3 is approved by the requisite ARCA stockholders. ARCA&#8217;s board of directors may determine to effect the authorized share increase or the reverse stock split if one or both are approved and Proposal&#160;No. 1 is not approved by ARCA stockholders, following the special meeting.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Votes will be counted by the inspector of election appointed for the meeting, who will separately count &#8220;FOR,&#8221; &#8220;AGAINST&#8221; and &#8220;WITHHOLD&#8221; votes, abstentions and broker non<span class="nobreak">-votes</span>, if any, as applicable to each proposal. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will be treated as shares present for the purpose of determining the presence of a quorum for the transaction of business at the ARCA special meeting. Abstentions will be counted towards the vote totals for each proposal, and will have the same effect of a vote &#8220;AGAINST&#8221; Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>4,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and 10. Broker non<span class="nobreak">-votes</span>, if any, will not be counted as &#8220;votes properly cast&#8221; or &#8220;shares entitled to vote&#8221; and will therefore have no effect on Proposal&#160;Nos.<span class="nobreak"> </span>1,<span class="nobreak"> </span>2,<span class="nobreak"> </span>3,<span class="nobreak"> </span>5,<span class="nobreak"> </span>6,<span class="nobreak"> </span>7,<span class="nobreak"> </span>8, 9 and<span class="nobreak"> </span>10, but will have the same effect of a vote &#8220;AGAINST&#8221; Proposal&#160;No. 4.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-indent:24pt;margin-top:8pt;">As of July<span class="nobreak"> </span>16, 2024, the directors and executive officers of ARCA owned or controlled 28.5% of the outstanding shares of ARCA common stock entitled to vote at the ARCA special meeting. As of July<span class="nobreak"> </span>16, 2024, the ARCA stockholders that are party to a support agreement, including the directors, executive officers and certain stockholders of ARCA, owned an aggregate number of shares of ARCA common stock representing approximately 28.5% of the outstanding shares of ARCA common stock. Each stockholder that entered into a support agreement, including the directors and executive officers of ARCA, has agreed to vote all shares of ARCA common stock owned by him or her as of the Record Date in favor of the adoption of the Merger Agreement and the transactions contemplated thereby, including the Merger, the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to the stockholders of Oruka pursuant to the Merger Agreement and the change of control resulting from the First Merger, and against any alternative acquisition proposals.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Solicitation of Proxies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to solicitation by mail, the directors, officers, employees and agent of ARCA may solicit proxies from ARCA stockholders by personal interview, telephone, email, fax or otherwise. ARCA and Oruka will share equally the costs of printing and filing this proxy statement/prospectus and proxy card. Arrangements will also be made with brokerage firms and other custodians, nominees and fiduciaries who are record holders of ARCA common stock for the forwarding of solicitation materials to the beneficial owners of ARCA common stock. ARCA will reimburse these brokers, custodians, nominees and fiduciaries for the reasonable out of pocket expenses they incur in connection with the forwarding of solicitation materials. ARCA has retained Innisfree M&amp;A Incorporated as its proxy solicitor.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Other Matters</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of this proxy statement/prospectus, ARCA&#8217;s board of directors does not know of any business to be presented at the ARCA special meeting other than as set forth in the notice accompanying this proxy statement/prospectus. If any other matters should properly come before the ARCA special meeting, it is intended that the shares represented by proxies will be voted with respect to such matters in accordance with the judgment of the persons voting the proxies.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">95</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T991188"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE MERGER</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">This section and the section titled &#8220;The Merger Agreement&#8221; beginning on page 135 of this proxy statement/prospectus describe the material aspects of the Merger and the Merger Agreement. While ARCA and Oruka believe that this description covers the material terms of the Merger and the Merger Agreement, it may not contain all of the information that is important to you. You should read carefully this entire proxy statement/prospectus for a more complete understanding of the Merger and the Merger Agreement and the other documents to which you are referred in this proxy statement/prospectus. See the section titled &#8220;Where You Can Find More Information&#8221; beginning on page 321 of this proxy statement/prospectus.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Background of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">ARCA&#8217;s board of directors and management regularly review ARCA&#8217;s operating and strategic plans in an effort to enhance stockholder value. This review involves, among other things, discussions of opportunities and risks associated with ARCA&#8217;s product candidates, development programs, financial condition and market, as well as a consideration of strategic alternatives available to ARCA.&#160;On March&#160;28, 2022, members of ARCA&#8217;s board of directors and management reviewed the results of ARCA&#8217;s Phase&#160;2 clinical trial of Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201) (the &#8220;Clinical Trial&#8221;). The results of the Clinical Trial indicated that neither studied dose of rNAPc2 achieved statistical significance for the primary efficacy endpoint.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In light of these results, ARCA&#8217;s board of directors initiated a process to identify and evaluate strategic alternatives available to ARCA that ultimately resulted in the execution of the Merger Agreement. The following is a summary of the background of the process undertaken by ARCA, the identification and evaluation of strategic alternatives and the negotiation of the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On March&#160;28, 2022, ARCA&#8217;s board of directors held video conference meetings with members of ARCA&#8217;s management and a representative of its legal advisor, Cooley LLP (&#8220;Cooley&#8221;) in attendance, to review the Clinical Trial results. ARCA&#8217;s board of directors discussed strategic alternatives available to ARCA in light of the negative Clinical Trial results, including continuation of the development of ARCA&#8217;s current products, possible licensing opportunities or a sale of ARCA.&#160;Following this meeting, Mr.&#160;Conway, Chairman of ARCA&#8217;s board of directors, instructed management to provide ARCA&#8217;s board of directors with management&#8217;s assessment of the viability of continuing to develop ARCA&#8217;s current products in light of the negative Clinical Trial results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On March&#160;29, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and a representative of Cooley in attendance to discuss a proposed product development plan prepared by ARCA&#8217;s management which included a plan to conduct a Phase&#160;3 trial for ARCA&#8217;s Gencaro product in patients with higher ejection fraction heart failure. ARCA&#8217;s board of directors instructed management to further refine ARCA&#8217;s product development plan and to explore other potential strategic alternatives to the product development plan available to ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Following the close of markets on March&#160;31, 2022, ARCA publicly announced the Clinical Trial results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On April&#160;10, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and a representative of Cooley in attendance to discuss a refined product development plan prepared by ARCA&#8217;s management and the strategic alternatives to that development plan including a sale of ARCA or other strategic transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Later that same&#160;day, ARCA&#8217;s board of directors held a video conference meeting without members of ARCA&#8217;s management or representatives of Cooley in attendance. ARCA&#8217;s board of directors discussed ARCA&#8217;s prospects as a stand<span class="nobreak">-alone</span> company pursuant to the refined product development plan presented by ARCA&#8217;s management earlier that same&#160;day, and the potential strategic alternatives thereto that were available to ARCA including a broad outreach to potential reverse merger counterparties or a liquidation of ARCA.&#160;It was the consensus of ARCA&#8217;s board of directors that in light of the negative Clinical Trial results, ARCA should explore and evaluate its strategic alternatives while continuing to evaluate its ability to continue on as a stand<span class="nobreak">-alone</span> enterprise. ARCA&#8217;s board of directors discussed the evaluation and retention of a financial advisor to assist ARCA&#8217;s board of directors in its exploration and evaluation of strategic alternatives.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On April&#160;17, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and a representative of Cooley in attendance. ARCA&#8217;s board of directors discussed the formation of a special committee of ARCA&#8217;s  board of directors (the &#8220;Special Committee&#8221;) for the purpose of identifying, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">96</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:7pt;">considering, evaluating and making recommendations to ARCA&#8217;s board of directors regarding potential strategic alternatives. ARCA&#8217;s board of directors approved the formation the Special Committee and appointed Mr.&#160;Conway, Dr.&#160;Hove and Dr.&#160;Grais to serve on the Special Committee, with Mr.&#160;Conway serving as chair. The Special Committee was not formed for the purposes of addressing potential or actual conflicts of interest of any director or officer of ARCA.&#160;ARCA&#8217;s board of directors delegated to the Special Committee the full power and authority of ARCA&#8217;s board of directors to, among other things, identify, consider, evaluate and make recommendations to ARCA&#8217;s board of directors regarding potential strategic alternatives and proposals which may be available to ARCA and further resolved to not approve any transaction unless the Special Committee had recommended that ARCA&#8217;s board of directors approve such a transaction. It was also discussed and concluded that: (1)&#160;ARCA&#8217;s board of directors would continue to have an active role in (i)&#160;the evaluation of any acquisition proposal, (ii)&#160;any discussions with potential acquirers with respect to a potential strategic transaction and (iii)&#160;any broader review of strategic alternatives; (2)&#160;the Special Committee would update and seek input from ARCA&#8217;s board of directors as appropriate; and (3)&#160;members of ARCA&#8217;s board of directors who were not also members of the Special Committee would be invited to attend the meetings of the Special Committee. ARCA&#8217;s board of directors also discussed potential candidates to act as financial advisor to ARCA in connection with a potential strategic transaction and directed the Special Committee to interview potential candidates and engage a financial advisor in connection with a strategic transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On April&#160;18, 2022, ARCA publicly announced its initiation of a process to evaluate strategic options for maximizing stockholder value and the establishment of the Special Committee to assist in the pursuit of such a transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Between April&#160;25, 2022, and April&#160;29, 2022, the Special Committee, and members of ARCA&#8217;s management team met with representatives from five investment banking firms telephonically to assess their ability to act as ARCA&#8217;s financial advisor in connection with a review of potential strategic alternatives.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On May&#160;2, 2022, the Special Committee held a video conference meeting with members of ARCA&#8217;s management team in attendance. The Special Committee discussed the qualifications of the financial advisors it had interviewed. After consideration of the relative qualifications and expertise of the candidates, including industry expertise, knowledge, access to potential transaction candidates, and recent transaction experience, the Special Committee approved the selection of Ladenburg Thalmann&#160;&amp; Co., Inc. (&#8220;Ladenburg&#8221;) as ARCA&#8217;s financial advisor to assist ARCA in its review of potential strategic alternatives and authorized and directed ARCA&#8217;s management to negotiate an engagement letter with Ladenburg. The Special Committee also determined that Ladenburg&#8217;s outreach should be focused on identifying potential reverse merger transaction candidates because the Special Committee believed such a transaction had the highest likelihood of presenting the highest value for stockholders in light of (i)&#160;the value that would be ascribed to ARCA&#8217;s public listing in such a transaction which would not be taken into account in a traditional merger or other similar strategic transaction and (ii)&#160;ARCA&#8217;s limited non<span class="nobreak">-cash</span> assets.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On May&#160;4, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and a representative of Cooley in attendance. ARCA&#8217;s board of directors reviewed the qualifications of the potential candidates to serve as ARCA&#8217;s financial advisor, the terms of the proposed engagement letter with Ladenburg and the Special Committee&#8217;s recommendation to appoint Ladenburg as ARCA&#8217;s financial advisor. ARCA&#8217;s board of directors approved the engagement of Ladenburg and authorized ARCA&#8217;s management to enter into an engagement letter in substantially the form presented to ARCA&#8217;s board of directors, which ARCA&#8217;s management executed later that same day.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On May&#160;5, 2022, ARCA publicly announced it had retained Ladenburg to act as its financial advisor to explore and review a range of strategic alternatives focused on maximizing stockholder value including an acquisition, merger, business combination or other strategic transaction involving ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On May&#160;6, 2022, the Special Committee held a video conference meeting with members of ARCA&#8217;s management team, and representatives of Cooley and Ladenburg in attendance. At this meeting, Ladenburg reviewed the process it proposed to undertake in order to identify and evaluate potential strategic alternatives and over 250 potential counterparties that it believed may be interested in pursuing a reverse merger transaction with ARCA.&#160;The Special Committee discussed the anticipated timeline for contacting and receiving and evaluating proposals from interested parties in connection with a strategic transaction. Ladenburg also reviewed its proposed selection criteria to be used by the Special Committee in identifying and evaluating potential counterparties. This criteria included an evaluation of (i)&#160;the quality of the assets owned by the potential counterparty, (ii)&#160;whether the potential counterparty had clear, proof of concept clinic data, (iii)&#160;the development stage of the potential counterparty, (iv)&#160;the </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">97</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;text-indent:0pt;margin-top:7pt;">counterparty&#8217;s product pipeline, (v)&#160;whether the counterparty was pursuing a concurrent private placement financing in order to ensure the counterparty had sufficient cash resources to reach the upcoming milestones with respect to the counterparty&#8217;s product candidates, (vi)&#160;the quality of the potential investors that would participate in such a concurrent financing, (vii)&#160;the amount of cash from ARCA required by the potential counterparty and the amount of cash ARCA would be able to distribute to its stockholders in a special dividend immediately prior to the closing of a transaction, (viii)&#160;the industry within which the counterparty was engaged, (ix)&#160;whether the counterparty was willing to ascribe any value to ARCA&#8217;s products in the proposed transaction, (x)&#160;whether the counterparty was expected to have value inflection points within 18&#160;months, (xi)&#160;the capital structure of the counterparty, (xii)&#160;whether the counterparty had sufficient infrastructure to maintain ARCA&#8217;s public listing or the ability to maintain such infrastructure, including whether the counterparty had financial statements sufficient to satisfy public company reporting standards, and (xiii)&#160;whether the relative valuations ascribed to ARCA and the potential counterparty in light of the foregoing factors was fair. Ladenburg also proposed limiting outreach efforts to companies in the pharmaceutical and biotechnology industry in light of ARCA&#8217;s enhanced ability to evaluate and assess the products, and related operational, industry, regulatory, financial, market and other risks and opportunities, of companies within those particular industries. Following a discussion, the Special Committee authorized Ladenburg to begin outreach to all of the potential counterparties presented by Ladenburg and adopted the proposed criteria for purposes of evaluating potential offers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Beginning on May&#160;6, 2022, Ladenburg conducted a process of identifying and evaluating potential counterparties for a strategic transaction with assistance from the Special Committee and members of ARCA&#8217;s management. In its outreach efforts, members of ARCA&#8217;s board of directors, ARCA&#8217;s management, and representatives of Ladenburg, contacted over 250 companies that met the criteria adopted by the Special Committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From May&#160;6, 2022 until June&#160;15, 2022, ARCA delivered bid process letters to 74 companies, received a total of 50 formal non<span class="nobreak">-binding</span> proposals (all of which were for reverse merger styled transactions) and entered into 37&#160;non<span class="nobreak">-disclosure</span> agreements to facilitate further diligence with potential counterparties which also contained a customary &#8220;standstill&#8221; restriction that would terminate upon entry into a definitive agreement for an acquisition of more than 50% of the shares of capital stock of ARCA. During that same period, the Special Committee, members of ARCA&#8217;s management and outside advisors met numerous times to consider the various non<span class="nobreak">-binding</span> proposals, and to receive updates regarding the solicitation and evaluation of the proposals. The Special Committee determined not to pursue 48 of the 50 non<span class="nobreak">-binding</span> proposals that were submitted due to, among other reasons, the failure of those potential counterparties to adequately satisfy many of the criteria adopted by the Special Committee. Of the two non<span class="nobreak">-binding</span> proposals that the Special Committee determined to pursue, the Special Committee determined to abandon one in June&#160;2022 in light of that counterparty&#8217;s early stage of development (Phase 1/Phase 2 clinical trial for its lead product candidate) and its need for all of ARCA&#8217;s cash to fund its operations. The other counterparty informed the Special Committee in December&#160;2022 that it was no longer interested in pursuing a transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On June&#160;15, 2022, ARCA entered into a Cooperation Agreement with Cable Car Capital LLC, The Funicular Fund, LP, Funicular Funds, LP and Jacob Ma<span class="nobreak">-Weaver</span>. Pursuant to the Cooperation Agreement, ARCA&#8217;s board of directors appointed Jacob Ma<span class="nobreak">-Weaver</span> as a Class&#160;III director with a term expiring at ARCA&#8217;s 2024 annual meeting of stockholders, effective June&#160;15, 2022, and appointed Mr.&#160;Ma<span class="nobreak">-Weaver</span> to the Special Committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From June&#160;15, 2022 until December&#160;15, 2022, at the direction of the Special Committee, ARCA&#8217;s management engaged third<span class="nobreak">-party</span> experts to examine and evaluate its ability to further develop Gencaro as a stand<span class="nobreak">-alone</span> enterprise and prepared an analysis of the potential value of ARCA&#8217;s assets in a liquidation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;15, 2022, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management and representatives of Wilson Sonsini Goodrich &amp; Rosati, P.C. (&#8220;Wilson Sonsini&#8221;) (who at such point had been engaged as ARCA&#8217;s counsel) and Ladenburg in attendance to discuss the strategic alternatives available to ARCA including having Ladenburg undertake a renewed search for new strategic transaction counterparties, pursuing a liquidation or continuing to pursue ARCA&#8217;s development plans as a stand<span class="nobreak">-alone</span> enterprise. The Special Committee determined that continuing to pursue potential strategic transactions was reasonably likely to result in a superior alternative to a liquidation and ARCA&#8217;s development plan as a stand<span class="nobreak">-alone</span> enterprise and as a result authorized and directed Ladenburg to re<span class="nobreak">-engage</span> with potential counterparties. As part of that authorization, it directed Ladenburg to broaden the scope of potential counterparties to include companies outside the pharmaceutical and biotechnology industry in order to evaluate all possible alternatives available to ARCA and determined to further refine its selection criteria to favor companies with later stage assets and/or near<span class="nobreak">-term</span> revenue as well as companies that did not require all of ARCA&#8217;s cash in order to achieve its key milestones to ensure a significant dividend of its </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">98</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">cash assets could be made as part of any such transaction. In addition, the Special Committee also determined that ARCA&#8217;s management should continue to further refine and pursue its development plan as a potential alternative if a compelling counterparty for a strategic transaction was not able to be found.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">From December&#160;15, 2022, until January&#160;5, 2023, the Special Committee and representatives of Ladenburg met on multiple occasions to review eleven potential counterparties for a strategic transaction in light of ARCA&#8217;s board of directors&#8217; revised selection criteria and ultimately refined the number of potential counterparties down to three potential counterparties that presented a reasonable likelihood of resulting in a superior alternative to the strategic alternatives the Special Committee was considering including a liquidation of ARCA or the continuation of its business as a standalone enterprise. ARCA and these three potential counterparties entered into non<span class="nobreak">-disclosure</span> agreements to facilitate their discussions which contained a customary &#8220;standstill&#8221; restriction that would terminate upon entry into a definitive agreement for an acquisition of more than 50% of the shares of capital stock of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">From January&#160;5, 2023, until January&#160;20, 2023, the Special Committee, members of ARCA&#8217;s management and representatives of Ladenburg met with and reviewed presentations prepared by the three potential counterparties selected by the Special Committee. Following the presentations, the Special Committee determined that a potential transaction with Party A was the most attractive because (i)&#160;it had a promising late stage asset that was expected to reach near term value inflection points along with a promising early stage product candidate and (ii)&#160;it did not require all of ARCA&#8217;s cash to fund its operations. While it did not abandon the other two potential counterparties, the Special Committee focused its efforts on engaging with Party A in light of the attractiveness of that counterparty when compared to the other two potential counterparties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On January&#160;26, 2023, members of ARCA&#8217;s management and representatives of Ladenburg were given access to a virtual data room hosted by Party A.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">From January&#160;26, 2023, until March&#160;10, 2023, ARCA&#8217;s management and representatives of Ladenburg undertook an extensive preliminary due diligence review of Party A and engaged numerous advisors to assist ARCA in its due diligence review.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On March&#160;10, 2023, at the direction of the Special Committee, representatives of Ladenburg delivered a draft term sheet to Party A providing for a reverse merger transaction and which ascribed an enterprise value to ARCA in the merger of $10,000,000 and an enterprise value to Party A of $75,000,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">From March&#160;10, 2023, until May&#160;30, 2023, the Special Committee and representatives of Party A met multiple times to negotiate the substantive economic terms of a potential reverse merger transaction including the size and type of investor for a private placement transaction contemplated to close substantially concurrently with the closing of a reverse merger transaction and the relative valuations to be ascribed to each party.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On May&#160;30, 2023, the Special Committee held a video conference meeting with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Ladenburg in attendance to discuss the final terms of the term sheet negotiated with Party A, which provided for a reverse merger transaction ascribing a $11,000,000 enterprise valuation to ARCA and a $60,000,000 enterprise valuation to Party A.&#160;The term sheet also, among other things, allowed ARCA to distribute to its pre<span class="nobreak">-closing</span> stockholders all of ARCA&#8217;s net cash in excess of $21,000,000 and gave ARCA&#8217;s stockholders a contingent value right representing the right to receive net proceeds of any sale of ARCA&#8217;s legacy product candidates. The term sheet also obligated each party to exclusively negotiate a transaction with one another. The Special Committee determined that it should continue to pursue a transaction with Party A on an exclusive basis in light of (i)&#160;the Special Committee&#8217;s view that each of (A)&#160;pursuing ARCA&#8217;s corporate objectives on a stand<span class="nobreak">-alone</span> basis, including the proposed development plan and (B)&#160;the liquidation of ARCA, was not reasonably likely to result in superior value to ARCA&#8217;s stockholders when compared to the proposed transaction; (ii)&#160;the Special Committee&#8217;s view that the $11&#160;million enterprise value ascribed to ARCA would give ARCA&#8217;s stockholders a significant opportunity to participate in the potential growth of the combined company following the Merger at the negotiated exchange ratio while also receiving a cash payment on account of the special cash dividend; (iii)&#160;the Special Committee&#8217;s view that the combined company was likely to possess sufficient cash resources at the closing of the Merger to fund development of Party A&#8217;s product candidates through upcoming value inflection points; (iv)&#160;ARCA&#8217;s positive preliminary due diligence performed to date and the recommendations of its advisors with respect to the viability of Party A&#8217;s assets and (v)&#160;the Special Committee&#8217;s view that the proposal from Party A was more favorable to ARCA than the potential value that might have resulted from further pursuing other strategic transactions available to ARCA in light of the extensive outreach process undertaken to date. As a result of that determination, the Special Committee authorized and directed ARCA&#8217;s management to execute and deliver the term sheet to Party A and began exclusively negotiating a potential reverse merger transaction with Party A.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">99</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same day, ARCA and Party A executed the non<span class="nobreak">-binding</span> term sheet and representatives of ARCA, Party A, and each of their respective legal and financial advisors participated in a video conference meeting during which the timeline and process for the signing of definitive agreements providing for a potential business combination were discussed, including the signing of definitive agreements for a private placement in ARCA that was contemplated to close concurrently with the business combination. The participants tentatively agreed on a work plan that contemplated the execution of definitive agreements in late June or early July&#160;2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Between May&#160;30, 2023, and July&#160;20, 2023, representatives of ARCA and Party A engaged in exclusive negotiations regarding a potential reverse merger and conducted detailed due diligence reviews of one another.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;20, 2023, Party A informed ARCA that its product approval had been delayed due to a request for additional information by the Office of New Drugs at the FDA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Between July&#160;20, 2023, and August&#160;25, 2023, the Special Committee, Party A, and each of their respective legal and financial advisors participated in numerous video conference meetings to discuss the current status of Party A&#8217;s drug approval with the Office of New Drugs at the FDA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, the Special Committee met with members of ARCA&#8217;s management, and representatives of Wilson Sonsini and Ladenburg to review the status of Party A&#8217;s application with the Office of New Drugs at the FDA and discussed the other strategic alternatives available to ARCA if Party A&#8217;s approval continued to be delayed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;25, 2023, the Special Committee determined that it was no longer viable to continue to exclusively pursue a transaction with Party A in light of Party A&#8217;s ongoing financing challenges, regulatory difficulties, increased expenditures and the Special Committees determination that Party A would not be able to successfully market or obtain commitments for the private placement investment contemplated by the term sheet in light of the foregoing. On that same&#160;day, ARCA allowed its obligation to exclusively negotiate with Party A lapse without extension.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From August&#160;25, 2023, until December&#160;7, 2023, the Special Committee continued to participate in numerous video conference meetings to discuss the current status of Party A&#8217;s drug approval with the Office of New Drugs at the FDA.&#160;At each of these meetings, Party A stated that regulatory approval was imminent.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During this same period, the Special Committee conducted video conference meetings with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Ladenburg in attendance to discuss the strategic alternatives available to ARCA if Party A&#8217;s regulatory approval continued to be delayed including a renewed search by Ladenburg for potential reverse merger partners or a liquidation of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December<span class="nobreak"> </span>7, 2023, Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> called Mr.<span class="nobreak"> </span>Conway and verbally proposed a potential partial tender offer for 50.1% of the shares of ARCA&#8217;s capital stock at a price per share range of $1.95 to $2.05 to be led by a stockholder affiliated with Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same day, the Special Committee conducted a video conference meeting (without Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> attending) with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Ladenburg in attendance. The Special Committee further discussed the strategic alternatives available to ARCA including the proposal made by Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> earlier that day. The Special Committee discussed the proposal and noted that the proposal was unlikely to be attractive in light of (i)&#160;the fact that ARCA stockholders were expected to receive approximately $2.25 per share in cash if ARCA liquidated at that time based on the previous liquidation analysis prepared by ARCA&#8217;s management in June&#160;2022 and (ii)&#160;the outcomes that the Special Committee expected it could achieve in a potential strategic transaction. The Special Committee authorized Mr.&#160;Conway to continue conversations with Mr.&#160;Ma<span class="nobreak">-Weaver</span> regarding a potential tender offer in order to see if negotiations with Mr.&#160;Ma<span class="nobreak">-Weaver</span> could eventually result in a price per share that presented a superior alternative to the various strategic alternatives the Special Committee was considering and instructed ARCA&#8217;s management to prepare an updated liquidation analysis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From December&#160;7, 2023, until January&#160;12, 2024, the Special Committee (without Mr.&#160;Ma<span class="nobreak">-Weaver</span> attending), conducted numerous video conference meetings to discuss the strategic alternatives available to ARCA which included, a liquidation of ARCA, a renewed search by Ladenburg for potential reverse merger partners, and a tender offer by the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, Mr.&#160;Conway and Mr.&#160;Ma<span class="nobreak">-Weaver</span> met multiple times to discuss and negotiate a potential tender offer by the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span>.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">100</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, on December&#160;12, 2023, the Nominating and Corporate Governance Committee of ARCA&#8217;s board of directors met to discuss, among other matters, the compensation that should be paid to each of the directors serving as members of the Special Committee in light of the prolonged strategic process that the committee had undertaken and the extensive work that the Committee had performed and was expected to continue to perform. The Nominating and Corporate Governance Committee of ARCA&#8217;s board of directors determined that each member of the Special Committee would be entitled to $7,500 for each month of substantive service on the Special Committee that each such member had previously performed and would perform going forward.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On January&#160;12, 2024, the Special Committee conducted a video conference meeting with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Ladenburg in attendance to discuss the strategic alternatives ARCA had been considering. At this meeting representatives of Ladenburg delivered a presentation comparing the potential value to ARCA&#8217;s stockholders that would result from a traditional merger, a reverse merger, a partial tender offer, or a liquidation. The Special Committee also reviewed a presentation prepared by ARCA&#8217;s management comparing the tender offer proposal made by Mr.&#160;Ma<span class="nobreak">-Weaver</span> on December<span class="nobreak"> </span>7, 2023 to the liquidation analysis that it had prepared which showed a potential value of $2.04 per share to stockholders in a liquidation. For more information regarding the liquidation analysis including the key assumptions therein, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger &#8212; ARCA Liquidation Analysis</span>,&#8221; beginning on page 108 of this proxy statement/prospectus. Following those presentations, Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> left the meeting. The Special Committee then discussed the presentations and determined that pursuing a tender offer at the price per share offered by Mr.&#160;Ma<span class="nobreak">-Weaver</span> did not have a reasonable likelihood of resulting in a superior alternative when compared to the other strategic alternatives available to ARCA.&#160;In light of that determination, and the continuing delay of regulatory approvals for Party A, the Special Committee directed Ladenburg to renew its search for potential reverse merger partners and to focus its outreach on companies that did not require a material amount of cash to remain on ARCA&#8217;s balance sheet after the closing of a transaction. The Special Committee further instructed Mr.&#160;Conway to continue negotiating the terms and conditions of a potential tender offer by the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span> in parallel with Ladenburg&#8217;s renewed search and ARCA&#8217;s continued discussions with Party A.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From January&#160;12, 2024, until February&#160;26, 2024, Ladenburg renewed its search for a potential counterparty in line with the Special Committee&#8217;s revised criteria and received non<span class="nobreak">-binding</span> proposals from eight potential counterparties interested in a reverse merger transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, Mr.&#160;Conway continued his discussions with Mr.&#160;Ma<span class="nobreak">-Weaver</span> regarding a potential tender offer and the Special Committee met multiple times to discuss the status of those discussions, and the other strategic alternatives the Special Committee was considering.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February<span class="nobreak"> </span>15, 2024, the Special Committee (without Mr.&#160;Ma<span class="nobreak">-Weaver</span> attending) conducted a video conference meeting with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini attending. As a result of the negotiations that Mr.<span class="nobreak"> </span>Conway and Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> had been engaging in, Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> increased his verbal offer to a price per share of $2.25 for 50.1% of the shares of ARCA&#8217;s capital stock. Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> then left the meeting. The Special Committee discussed Mr.&#160;Ma<span class="nobreak">-Weaver</span>&#8217;s offer of $2.25 per share and determined that while the price per share was higher than the most recent liquidation analysis presented at the January&#160;12, 2024, meeting, the offer was still not reasonably likely to result in a superior alternative when compared to the other strategic alternatives available to ARCA, including a reverse merger transaction which was expected to provide ARCA&#8217;s stockholders additional value for ARCA&#8217;s public listing. Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> then rejoined the meeting and the Special Committee informed him that his offer was not compelling in light of the other strategic alternatives available to ARCA, and that the stockholder affiliated with Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> needed to increase its proposal to a price of at least $2.50 per share for 100% of the shares of ARCA&#8217;s capital stock. The Special Committee directed Mr.&#160;Conway to continue negotiations with the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From February<span class="nobreak"> </span>15, 2024, until February&#160;23, 2024, Mr.&#160;Conway and Mr.&#160;Ma<span class="nobreak">-Weaver</span> met multiple times to continue to discuss the potential tender offer. On February&#160;23, 2024, Mr.&#160;Ma<span class="nobreak">-Weaver</span> informed the Special Committee that the stockholder affiliated with Mr.&#160;Ma<span class="nobreak">-Weaver</span> was no longer interested in pursuing a tender offer.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;26, 2024, the Special Committee conducted a video conference meeting with representatives of Ladenburg to review, discuss and evaluate the eight non<span class="nobreak">-binding</span> proposals it had received to date as a result of Ladenburg&#8217;s renewed outreach. The Special Committee determined that Oruka was a counterparty that merited serious consideration because (i)&#160;it required the least amount of ARCA&#8217;s cash and would therefore permit ARCA to distribute the largest amount of cash to its stockholders, (ii)&#160;the company was backed by a reputable investor </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">101</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">with a history of successful reverse merger transactions and (iii)&#160;the company already had informal commitments for a substantial private placement investment that was contemplated to close concurrently with the closing of the Merger. As a result, the Special Committee focused its efforts on pursing a transaction with Oruka while continuing to discuss a potential transaction with two of the other potential counterparties that had submitted non<span class="nobreak">-binding</span> proposals in case a transaction with Oruka did not come to fruition. The Special Committee determined that the remaining five non<span class="nobreak">-binding</span> proposals that had been submitted were not compelling in light of the quality of the counterparties&#8217; assets, the substantial cash needs of the potential counterparties, and the valuations sought by the potential counterparties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;28, 2024, the Special Committee conducted a video conference meeting with representatives of Ladenburg and Oruka in attendance to discuss Oruka&#8217;s fitness as a strategic transaction partner.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, at the direction of the Special Committee, representatives of Ladenburg delivered a draft term sheet to representatives of Wedbush Securities Inc. (&#8220;Wedbush&#8221;), Oruka&#8217;s financial advisor, which proposed a reverse merger transaction ascribing a $10,000,000 enterprise valuation to ARCA and a $175,000,000 enterprise valuation of Oruka (which would be reduced to the extent the price per share in the proposed private placement financing ascribed a value to Oruka of less than $175,000,000) and setting forth certain other material terms including (1)&#160;the minimum investment amount to be received by Oruka as a result of a private placement transaction investment to close substantially concurrent with the business combination; (2)&#160;conditions to execution of any definitive agreement, (3)&#160;conditions to the closing of the business combination transaction; (4)&#160;the ability of ARCA to distribute any net cash in excess of $5,000,000 to the pre<span class="nobreak">-Merger</span> stockholders of ARCA; and (5)&#160;the exclusivity period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;28, 2024 and February&#160;29, 2024, the Special Committee conducted video conference meetings with representatives of Ladenburg and the other two counterparties that it was considering in attendance to discuss each counterparty&#8217;s value as a strategic transaction partner.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;29, 2024, representatives of Wedbush delivered a revised term sheet to Ladenburg which ascribed a $6,000,000 enterprise valuation to ARCA and included proposed changes to a number of the other legal terms.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, Mr.&#160;Conway spoke with representatives of Oruka and proposed an ascribed enterprise value of $7,500,000. Representatives of Oruka informed Mr.&#160;Conway that it was not willing to pursue a transaction at an ascribed enterprise value over $6,000,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, the Special Committee held a video conference meeting with members of ARCA&#8217;s management and representatives of Wilson Sonsini and Ladenburg in attendance to discuss the revised proposal received by Oruka. The Special Committee determined that the revised proposal represented a promising strategic alternative that was worth pursuing on an exclusive basis in light of: (i)&#160;the Special Committee&#8217;s view that ARCA was not likely to accomplish its corporate objectives on a stand<span class="nobreak">-alone</span> basis in light of its financial condition and product candidates; (ii)&#160;the Special Committee&#8217;s view that the $6,000,000 enterprise value ascribed to ARCA was within the range of values ascribed in other recent reverse merger transactions (for more information regarding the range of values ascribed to recent reverse merger transactions, please see the section titled &#8220;The Merger &#8212; Opinion of Lucid &#8212; Analysis of precedent Reverse Merger Transactions,&#8221; beginning on page 118 of this proxy statement/prospectus) and would give ARCA&#8217;s stockholders a significant opportunity to participate in the potential growth of the combined company following the Merger at the negotiated exchange ratio while also receiving an immediate cash payment on account of the special cash dividend ARCA would be permitted to make; (iii)&#160;the fact that the $175,000,000 enterprise value ascribed to Oruka would be validated by independent third parties in the private placement investment and that any reduction in the valuation ascribed to Oruka by such investors would also reduce Oruka&#8217;s valuation for purposes of calculating the exchange ratio; (iv)&#160;the Special Committee&#8217;s view that as a result of the substantial private placement financing that Oruka was committing to obtain at the closing of the Merger the combined company was likely to possess sufficient cash resources to fund development of Oruka&#8217;s product candidates through upcoming value inflection points; (vi)&#160;the increased likelihood that the transaction could be consummated in a timely manner in light of the informal private placement commitments that Oruka had already obtained, and (vii)&#160;the Special Committee&#8217;s view that the proposal from Oruka was more favorable to ARCA than the potential value that might have resulted from further pursuing other strategic alternatives available to ARCA in light of the extensive outreach process undertaken to date. The Special Committee concluded the meeting by directing Ladenburg to continue negotiating the final legal terms of the term sheet and authorized ARCA&#8217;s management to execute and deliver the term sheet once the remaining legal terms had been finalized.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">102</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the morning of March&#160;1, 2024, representatives of Ladenburg delivered an updated draft term sheet to representatives of Wedbush finalizing the remaining legal terms in the term sheet and finalizing the $6,000,000 enterprise value that Mr.&#160;Conway and representatives of Oruka had agreed to. Later that afternoon, representatives of Wedbush returned a proposed final draft term sheet which finalized the remaining legal terms.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, at the direction of the Special Committee, ARCA&#8217;s management executed and delivered the term sheet to Oruka and began exclusively negotiating a transaction with Oruka.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;4, 2024, the Special Committee met with representatives of ARCA&#8217;s management team, representatives of Wilson Sonsini and Ladenburg, Oruka&#8217;s management team, and representatives of Wedbush and Gibson, Dunn&#160;&amp; Crutcher LLP (&#8220;Gibson&#8221;), Oruka&#8217;s legal advisor, via video conference to discuss the timeline and process for signing definitive agreements providing for a potential business combination and a concurrent private placement financing and discussed and tentatively agreed on a work plan for such definitive agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, ARCA provided Oruka and its advisors with access to an online data room for purposes of conducting further business, financial, legal, tax, intellectual property, insurance and other due diligence with respect to ARCA and its business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;7, 2024, Oruka provided ARCA and its advisors with access to an online data room for purposes of conducting further business, financial, legal, tax, intellectual property, insurance and other due diligence with respect to Oruka and its business.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Also on March&#160;7, 2024, Oruka met with representatives of Jefferies LLC and Cowen and Company, LLC (together, the &#8220;Placement Agents&#8221;), representatives of Cooley, counsel to the Placement Agents, and Gibson, via video conference, to discuss the timeline and process for completing the concurrent private placement financing. Later that&#160;day, representatives of Gibson and Cooley met, via video conference, and tentatively agreed on a work plan for the definitive agreements related to such concurrent private placement financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;11, 2024, Mr.&#160;Conway met with ARCA&#8217;s management team and representatives of Wilson Sonsini to discuss the proposed terms of a draft of the Merger Agreement prepared by representatives of Wilson Sonsini. Mr.&#160;Conway then authorized Wilson Sonsini to distribute the draft Merger Agreement to Gibson which was sent out later that same&#160;day.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Also on March&#160;11, 2024, Oruka authorized representatives of Gibson to distribute the draft form of subscription agreement for the concurrent financing and other related documents to Cooley and Wilson Sonsini, on behalf of the Placement Agents and ARCA, respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;15, 2024, the Special Committee met with representatives of Oruka and ARCA&#8217;s management team in attendance to discuss Oruka&#8217;s business and answer the Special Committee&#8217;s questions regarding the materials provided in the virtual data room.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Between March&#160;15, 2024 and April&#160;2, 2024, representatives of ARCA&#8217;s management team conducted further business and financial due diligence with respect to Oruka, its business and the market for treatment of chronic skin diseases and, over the same period of time, ARCA&#8217;s legal and financial advisors conducted due diligence with respect to Oruka and its business based on information available in the data room and written responses from Oruka&#8217;s management team, and such advisors negotiated the terms and conditions of the Merger Agreement at the direction of and in coordination with the Special Committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, representatives of Wilson Sonsini and Gibson met on numerous occasions to discuss and negotiate the legal terms of the Merger Agreement, including the form of subscription agreement for the Oruka pre<span class="nobreak">-closing</span> financing attached as an exhibit thereto.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During that same period, representatives of Oruka and its financial advisors held conversations with the representatives of the Placement Agents and prospective investors to discuss the contemplated private placement financing, addressed questions from potential investors and negotiated the terms and conditions of the definitive agreements for such a transaction, including the form of subscription agreement for the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">103</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;19, 2024, at the direction of the Special Committee, ARCA entered into a new engagement letter with Lucid Capital Markets, LLC (&#8220;Lucid&#8221;) engaging Lucid as ARCA&#8217;s financial advisor in light of restructuring events that had occurred at Ladenburg which resulted in the financial advisors primarily responsible for this transaction moving from Ladenburg to Lucid.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;20, 2024, at the direction of the Special Committee, ARCA terminated its engagement letter with Ladenburg.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;2, 2024, ARCA&#8217;s board of directors held a video conference meeting with members of ARCA&#8217;s management team, and representatives of Wilson Sonsini and Lucid in attendance. At the meeting, ARCA&#8217;s board of directors was provided with an overview of the proposed Merger (including the potential benefits and the risks related thereto), the key terms of the related ancillary documents, and its fiduciary duties. ARCA&#8217;s board of directors also reviewed the proposed resolutions which would be adopted by ARCA&#8217;s board of directors in order to approve the entry into the proposed Merger and related transactions, including among other things, the form of Certificate of Designation of Preferences, Rights and Limitations of Series B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock. Lucid then presented its oral opinion that, as of the date thereof, and subject to the assumptions more fully described below under the caption &#8220;The Merger&#160;&#8212;&#160;Opinion of Lucid, ARCA&#8217;s Financial Advisor, to ARCA&#8217;s board of directors,&#8221; beginning on page 112 in this proxy statement/prospectus, the Exchange Ratio is fair, from a financial point of view to the holders of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors&#8217; meeting was then adjourned and a meeting of the Special Committee was held via video conference with members of ARCA&#8217;s management team and representatives of Wilson Sonsini in attendance. The Special Committee then unanimously (i)&#160;determined that the transactions contemplated by the Merger Agreement including the Merger Agreement and related ancillary agreements contemplated thereunder, are fair to, advisable and in the best interests of ARCA and its stockholders and (ii)&#160;recommended that ARCA&#8217;s board of directors approve and adopt the Merger Agreement, the related ancillary agreements and the transactions contemplated by the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Special Committee meeting was then adjourned and a meeting of ARCA&#8217;s board of directors was held via video conference with members of ARCA&#8217;s management team and representatives of Wilson Sonsini in attendance. Based on the factors described below under the caption &#8220;The Merger&#160;&#8212;&#160;ARCA&#8217;s Reasons for the Merger,&#8221; ARCA&#8217;s board of directors then adopted and approved, among other resolutions, resolutions (a)&#160;determining that it is in the best interests of ARCA and its stockholders to adopt and approve the execution and delivery of the Merger Agreement and the ancillary documents thereto, (b)&#160;adopting and approving the Merger Agreement and ancillary documents thereto and approving ARCA&#8217;s execution, delivery and performance of the same and the consummation of the transactions contemplated by the Merger Agreement and the ancillary documents thereto, (c)&#160;recommending that the ARCA stockholders vote in favor of the Proposals with Dr.&#160;Bristow abstaining from voting on the passage of such resolutions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, the parties entered into the Merger Agreement and the related ancillary documents and the private placement investors executed and delivered the Subscription Agreement for the $275.0<span class="nobreak"> </span>million Oruka pre<span class="nobreak">-closing</span> financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Later that same&#160;day, ARCA and Oruka issued a joint press release announcing the execution and delivery of the Merger Agreement, and ARCA filed a Current Report on Form&#160;8<span class="nobreak">-K</span>, which filed as an exhibit (a)&#160;the Merger Agreement, (b)&#160;the form of Certificate of Designation of Preferences, Rights and Limitations of Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock, (c)&#160;the form of Oruka Support Agreement, (d)&#160;the form of Oruka Subscription Agreement, (e)&#160;form of ARCA Support Agreement, (f)&#160;the form of Lock<span class="nobreak">-up</span> Agreement, (g)&#160;a joint press release, dated April&#160;3, 2024 (h)&#160;an investor presentation providing information on Oruka, and (i)&#160;a transcript of a conference call held to announce the proposed transactions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;s Reasons for the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the course of its evaluation of the Merger Agreement and the transactions contemplated by the Merger Agreement, ARCA&#8217;s board of directors and the members of its Special Committee held numerous meetings, consulted with ARCA&#8217;s senior management, ARCA&#8217;s legal counsel and financial advisors, and reviewed and </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">104</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">assessed a significant amount of information. In reaching its decision to approve the Merger Agreement and the transactions contemplated by the Merger Agreement, ARCA&#8217;s board of directors took into account the input and recommendations of the Special Committee, as well as other information presented to it during the process, and considered a number of factors that it viewed as supporting its decision to approve the Merger Agreement, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The financial condition and prospects of ARCA and the risks associated with continuing to operate ARCA on a stand<span class="nobreak">-alone</span> basis in light of:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s decision, announced on May<span class="nobreak">&#160;</span>5, 2022, to initiate a process to explore strategic alternatives in light of and its subsequent decision announced in July of 2022 to reduce its workforce by 67%, which were each driven in large part by the results of ARCA&#8217;s Phase&#160;2 clinical trial of its primary product candidate Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201), which found that neither studied dose of rNAPc2 achieved statistical significance for the primary efficacy endpoint;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>investor interest and value perception for possible further development of its programs, the product candidates&#8217; efficacy and safety profiles, stage of development, regulatory agencies&#8217; feedback regarding development pathways, and probability of success in relation to the requisite time and costs; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>difficulties encountered in ARCA&#8217;s related business development efforts to license, sell or otherwise partner its assets that could result in meaningful new capital or shared future development costs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s product pipeline and development candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the recommendation of the Special Committee that ARCA&#8217;s board of directors approve the contemplated transactions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view that, after a thorough review of strategic alternatives, including further advancing the development of its internal programs, entering into a licensing, sale or other strategic agreement related to certain assets sufficient to fund operations, combining with other potential strategic transaction candidates, and discussions with ARCA&#8217;s senior management, financial advisors and legal counsel, the Merger is more favorable to ARCA stockholders than the potential value that might have resulted from other strategic alternatives available to ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; belief that the $6.0&#160;million enterprise value ascribed to ARCA would provide the existing ARCA stockholders significant value for ARCA&#8217;s public listing and afford the ARCA stockholders a significant opportunity to participate in the potential growth of the combined company following the Merger at the negotiated exchange ratio while also receiving a cash payment on account of the special cash dividend;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; belief, after thorough discussions with ARCA&#8217;s management, financial advisors and legal counsel, that a potential liquidation and dissolution was not reasonably likely to create greater value for ARCA stockholders than the Merger based on, among other things, the need to hold back a potential meaningful amount of ARCA&#8217;s current cash balance to cover current and potential unknown future liabilities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; belief that, as a result of arm&#8217;s length negotiations with Oruka, terms of the Merger Agreement include the most favorable terms to ARCA in the aggregate that were achievable and consistent with other similar transactions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view that Oruka&#8217;s product candidates have the potential to create meaningful value for the stockholders of the combined company and an opportunity for ARCA&#8217;s stockholders to participate in the growth of the combined company, based on the business, scientific, regulatory, </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">105</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">intellectual property, financial, accounting and legal due diligence conducted by ARCA management and advisors (which included diligence calls and a comprehensive review of Oruka&#8217;s due diligence materials) regarding:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the regulatory pathway for, and market opportunity of, Oruka&#8217;s product candidates, including in light of the stage of development of Oruka&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the quality and scope of the preclinical and clinical results available for Oruka as opposed to other parties with which ARCA engaged in discussions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s plans to explore the potential of its product candidates to treat other diseases, including through collaborations; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the likelihood of value inflection milestones prior to the time in which the combined company would need to raise additional financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; consideration of the expected cash balances of the combined company as of the closing of the Merger resulting from the approximately $5.0&#160;million of net cash, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, expected to be held by ARCA upon completion of the Merger, together with the cash Oruka currently holds and the $275&#160;million of expected gross proceeds from the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view, following a review with ARCA&#8217;s management and advisors of Oruka&#8217;s current development and clinical trial plans, of the likelihood that the combined company would possess sufficient cash resources at the closing of the Merger to fund development of Oruka&#8217;s product candidates through upcoming value inflection points, including Oruka&#8217;s ongoing IND<span class="nobreak">-enabling</span> preclinical development work and its anticipated initiation of its Phase&#160;1 trials of ORKA<span class="nobreak">-001</span> in the first half of 2025 and Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expected operations, management structure, operating plans and cash burn rate of the combined company and the expected cash resources of the combined company (including the ability to support the combined company&#8217;s current and planned clinical trials and operations);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ability of Oruka to take advantage of the potential benefits resulting from becoming a public reporting company listed on Nasdaq, should it be required to raise additional capital in the future through the sale of equity or debt securities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the prospects of and risks associated with the other strategic candidates that had made proposals for a strategic transaction with ARCA based on the business, scientific, regulatory, intellectual property, financial, accounting and legal due diligence conducted by the Special Committee, ARCA&#8217;s management and its advisors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors&#8217; view that the combined company will be led by an experienced senior management team from Oruka, many members of which have extensive experience in drug development, research and development, business and regulatory expertise; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the financial analysis reviewed by Lucid with ARCA&#8217;s board of directors as well as the oral opinion of Lucid rendered to ARCA&#8217;s board of directors on April<span class="nobreak">&#160;</span>2, 2024 (which was subsequently confirmed in writing by delivery of Lucid&#8217;s written opinion dated April<span class="nobreak">&#160;</span>2, 2024 addressed to ARCA&#8217;s board of directors), as to, as of April<span class="nobreak">&#160;</span>2, 2024, the fairness, of the exchange ratio from a financial point of view, to ARCA&#8217;s stockholders, as more fully described below under the caption &#8220;Opinion of Lucid, ARCA&#8217;s Financial Advisor, to ARCA&#8217;s Board of Directors,&#8221; beginning on page 112 in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors also reviewed the terms of the Merger Agreement and related transaction documents, including those described below, and concluded that the terms of the Merger Agreement and related transaction documents, in the aggregate, were reasonable under the circumstances:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the calculation of the exchange ratio, closing net cash and the estimated number of shares of ARCA common stock to be issued in the Merger;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">106</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to dividend all of its net cash (as determined in accordance with the terms of the Merger Agreement) in excess of $5.0&#160;million to the current ARCA stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the number and nature of the conditions to Oruka&#8217;s and ARCA&#8217;s respective obligations to complete the Merger and the likelihood that the Merger will be completed on a timely basis, including the fact that Oruka&#8217;s obligation to complete the Merger would not be conditioned on ARCA having a specified level of closing net cash, as more fully described below under the caption &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Conditions to the Completion of the Merger</span>,&#8221; beginning on page 148 in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the respective rights of, and limitations on, ARCA and Oruka under the Merger Agreement to consider and engage in discussions regarding unsolicited acquisition proposals under certain circumstances, and the limitations on the board of directors of each party to change its recommendation in favor of the Merger, as more fully described below under the caption &#8220;The Merger Agreement&#160;&#8212;&#160;Non<span class="nobreak">-Solicitation</span>,&#8221; beginning on page 145 in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential termination fee of $440,000, in the case of the fee payable by ARCA, or $440,000, in the case of the fee payable by Oruka, if the Merger Agreement is terminated in certain circumstances, as more fully described below under the caption &#8220;The Merger Agreement&#160;&#8212;&#160;Termination and Termination Fees,&#8221; beginning on page 150 in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the lock<span class="nobreak">-up</span> agreements, pursuant to which certain stockholders of Oruka and ARCA, respectively, have, subject to certain exceptions, agreed not to transfer their shares of ARCA common stock during the period of 180&#160;days following the completion of the Merger, as more fully described below under the caption &#8220;Agreements Related to the Merger&#160;&#8212;&#160;Lock<span class="nobreak">-Up</span> Agreements,&#8221; beginning on page 153 in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the support agreements, pursuant to which certain stockholders of ARCA and Oruka, respectively, have agreed, solely in their capacities as stockholders, to vote all of their shares of ARCA common stock or Oruka common stock in favor of the proposals submitted to them in connection with the Merger and against any alternative acquisition proposals, as more fully described below under the caption &#8220;Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements,&#8221; beginning on page 153 in this proxy statement/prospectus; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expectation that the Merger will qualify as a reorganization within the meaning of Section&#160;368(a)&#160;of the Code, and will constitute a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations Section&#160;1.368<span class="nobreak">-2</span>(g)&#160;and 1.368<span class="nobreak">-3</span>(a), with the result that Oruka stockholders will generally not recognize taxable gain or loss for U.S.&#160;federal income tax purposes upon the exchange of Oruka common stock for ARCA common stock pursuant to the Merger Agreement, as more fully described below under the caption &#8220;The Merger&#160;&#8212;&#160;Material U.S.&#160;Federal Income Tax Consequences of the Merger,&#8221; beginning on page 128 in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the course of its deliberations, and in addition to the consideration, input and recommendations of the Special Committee, ARCA&#8217;s board of directors also considered a variety of risks, uncertainties and other countervailing factors related to entering into the Merger, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the potential benefits of the Merger may not be fully achieved, or may not be achieved within the expected timeframe;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the future financial performance of Oruka may not meet ARCA&#8217;s board of directors&#8217; expectations due to factors both in and outside of Oruka&#8217;s control;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that, while ARCA&#8217;s management team performed an extensive due diligence review of Oruka, there may have been relevant Oruka information not considered by ARCA&#8217;s management team and accordingly, ARCA may not have properly valued Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential effect of the $440,000 termination fee payable by ARCA upon the occurrence of certain events in deterring other potential companies from proposing an alternative acquisition proposal that may be more advantageous to ARCA&#8217;s stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s obligation to not solicit alternative acquisition proposals during the pendency of the Merger;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">107</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the substantial expenses to be incurred by ARCA in connection with the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possible volatility of the trading price of the ARCA common stock resulting from the announcement, pendency or completion of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the scientific, technical, regulatory and other risks and uncertainties associated with development and commercialization of Oruka&#8217;s product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>various risks impacting the financial condition, results of operations and prospects for ARCA, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risks and challenges associated with pursuing any strategic alternative to the Merger available to ARCA, including the discussions that ARCA&#8217;s management and ARCA&#8217;s board of directors of directors previously conducted with other potential transaction partners, and the time to negotiate and complete an alternative strategic transaction and anticipated cash burn;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risks and delays associated with, and uncertain value and costs to ARCA stockholders of, liquidating ARCA, including the uncertainties of continuing cash burn while contingent liabilities are resolved, uncertainty of timing of release of cash until contingent liabilities are resolved, and the risks and costs associated with being a shell company prior to cash distribution;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risks and challenges of attempting to continue to operate ARCA on a stand<span class="nobreak">-alone</span> basis, including, without limitation, (i)&#160;the considerable time and resources that would have been required to successfully address the uncertainties associated with its Gencaro product, (ii)&#160;the inability to finance ARCA&#8217;s continuing operations through the sale of securities in the capital markets due to, among other things, the lack of near term data catalysts and the general downturn in the U.S.&#160;capital markets for biotechnology companies and (iii)&#160;ARCA&#8217;s other product candidate profiles, stage of development, feedback from regulatory agencies regarding development pathway, and probability of success in relation to the requisite time and costs required as well as management&#8217;s related business development efforts to license, sell or otherwise partner the assets;.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the challenges of retaining or rebuilding staff with limited cash runway in light of the reductions in force that ARCA previously undertook; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the challenges of maintaining ARCA&#8217;s Nasdaq listing without completing the merger and the transactions contemplated in the Merger Agreement, including the reverse stock split; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the various other risks associated with the combined company and the Merger, including those described in the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Cautionary Note Regarding Forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Statements</span>&#8221; in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The foregoing information and factors considered by the Special Committee and ARCA&#8217;s board of directors are not intended to be exhaustive but are believed to include all of the material factors considered by the Special Committee and ARCA&#8217;s board of directors. In view of the wide variety of factors considered in connection with its evaluation of the Merger and the complexity of these matters, the Special Committee and ARCA&#8217;s board of directors did not find it useful, and did not attempt, to quantify, rank or otherwise assign relative weights to these factors. In considering the factors described above, individual members of the Special Committee and ARCA&#8217;s board of directors may have given different weight to different factors. The Special Committee and ARCA&#8217;s board of directors conducted an overall analysis of the factors described above, including thorough discussions with, and questioning of, ARCA&#8217;s management team and the legal and financial advisors of ARCA, and considered the factors overall to be favorable to, and to support, its determination.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA Liquidation Analysis</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the evaluation of the Merger by ARCA&#8217;s board of directors and the Special Committee, ARCA&#8217;s management prepared an analysis with respect to the estimated value of the liquidation or dissolution of ARCA as a potential alternative to the Merger, including for such purposes ARCA&#8217;s estimated cash position at the time of the potential dissolution or liquidation, ARCA&#8217;s estimated expenses in connection with any such liquidation or dissolution, and the amount of cash available to be distributed to ARCA&#8217;s stockholders in connection with any such proposed future dissolution or liquidation (the &#8220;Liquidation Analysis&#8221;). Although the Liquidation Analysis </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">108</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">assumes that the entirety of ARCA&#8217;s cash balance at the time of the dissolution or liquidation would be available for distribution to ARCA&#8217;s stockholders, it is unlikely that the entirety of such cash balance would be available at the time of an actual dissolution or liquidation due to the requirements of applicable law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The inclusion of the Liquidation Analysis should not be deemed an admission or representation by ARCA or any of its officers, directors, affiliates, advisors, or other representatives with respect to the Liquidation Analysis. The Liquidation Analysis is not included to influence your views on the Merger, the Merger Agreement and the transactions contemplated thereby and is summarized in this proxy statement/prospectus solely to provide stockholders access to certain information considered by ARCA&#8217;s board of directors and the Special Committee in connection with its evaluation of the Merger, the Merger Agreement and the transactions contemplated thereby. Any estimates contained in these analyses are not necessarily indicative of actual values or predictive of future results or values, which may be significantly more or less favorable than as set forth below. In addition, analyses relating to the value of ARCA do not purport to be appraisals or reflect the prices at which shares of ARCA common stock may actually be valued or trade, either before or after the consummation of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Liquidation Analysis was not prepared with a view toward public disclosure, nor was it prepared with a view toward compliance with published guidelines of the SEC, the guidelines established by the American Institute of Certified Public Accountants for preparation and presentation of prospective financial information, or GAAP.&#160;Neither the independent registered public accounting firm of ARCA nor any other independent accountant has audited, reviewed, compiled, examined or performed any procedures with respect to the accompanying unaudited prospective financial information for the purpose of its inclusion herein, and accordingly, neither the independent registered public accounting firm of ARCA nor any other independent accountant expresses an opinion or provides any form of assurance with respect thereto for the purpose of this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The prospective financial information included in this proxy statement/prospectus has been prepared by, and is the responsibility of, ARCA management. PricewaterhouseCoopers LLP has not audited, reviewed, examined, compiled nor applied agreed<span class="nobreak">-upon</span> procedures with respect to the accompanying prospective financial information and, accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto. The PricewaterhouseCoopers LLP report included in this proxy statement/prospectus relates to Oruka&#8217;s financial statement. It does not extend to the prospective financial information and should not be read to do so.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Liquidation Analysis includes estimates of cash and of certain expenditures, which for the purpose of the Liquidation Analysis were not calculated in accordance with GAAP.&#160;Non<span class="nobreak">-GAAP</span>&#160;financial measures should not be viewed as a substitute for GAAP financial measures and may be different from&#160;non<span class="nobreak">-GAAP</span>&#160;financial measures used by other companies. Furthermore, there are limitations inherent in&#160;non<span class="nobreak">-GAAP</span>&#160;financial measures because they exclude charges and credits that are required to be included in a GAAP presentation. Accordingly,&#160;non<span class="nobreak">-GAAP</span>&#160;financial measures should be considered together with, and not as an alternative to, financial measures prepared in accordance with GAAP.&#160;The SEC rules, which otherwise would require a reconciliation of a&#160;non<span class="nobreak">-GAAP</span>&#160;financial measure to a GAAP financial measure, do not apply to&#160;non<span class="nobreak">-GAAP</span>&#160;financial measures provided to a board of directors or financial advisors in connection with a proposed business combination transaction such as the Merger if the disclosure is included in a document such as this proxy statement/prospectus to comply with requirements under state laws, including case law.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-indent:24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">In light of the foregoing factors and the uncertainties inherent in estimated cash balances, stockholders are cautioned not to place undue reliance, if any, on the Liquidation Analysis.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The below summary of the Liquidation Analysis is subject to the statements above, and it represents estimates prepared by ARCA&#8217;s management of the cash which could be distributed to stockholders as permitted under applicable law pursuant to a plan of dissolution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Key assumptions underlying the Liquidation Analysis included: (i)&#160;that the entire distribution of ARCA&#8217;s net cash would be made in June&#160;2024; (ii)&#160;that ARCA would have approximately $29.65&#160;million of net cash as June&#160;2024, after deducting costs and expenses, including legal fees, the fees payable to ARCA&#8217;s strategic financial advisor, accounting fees, employee retention bonuses, severance and benefits, insurance expenses, other transaction<span class="nobreak">-related</span> costs and other liabilities; (iii)&#160;that these costs and expenses were forecasted to total approximately $7.28&#160;million assuming the closing of a liquidation in June&#160;2024; and (iv)&#160;approximately 14.5&#160;million total shares of ARCA common stock outstanding as of December&#160;31, 2023. The analysis resulted in an estimated cash distribution per share in June&#160;2024 of $2.04 per share.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">109</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Reasons for the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the course of reaching its decision to approve the Merger and the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing, Oruka&#8217;s board of directors held numerous meetings, consulted with Oruka&#8217;s senior management, legal counsel and financial advisors, and considered a wide variety of factors. Ultimately, Oruka&#8217;s board of directors concluded that a merger with ARCA, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, was the best option to generate capital resources to support the advancement of Oruka&#8217;s pipeline and fund the combined organization.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additional factors Oruka&#8217;s&#160;board of directors considered included the following (which factors are not necessarily presented in any order of relative importance):</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Merger will potentially expand the access to capital and the range of investors available as a public company to support the clinical development of Oruka&#8217;s pipeline, compared to the capital and investors Oruka could otherwise gain access to if it continued to operate as a privately<span class="nobreak">-held</span> company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Oruka pre<span class="nobreak">-closing</span> financing will generate capital resources to fund the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential benefits from increased public market awareness of Oruka and its pipeline;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical and current information concerning Oruka&#8217;s business, including its financial performance and condition, operations, management and preclinical and clinical data;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the competitive nature of the industry in which Oruka operates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; fiduciary duties to Oruka stockholders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; belief that no alternatives to the Merger, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, were reasonably likely to create greater value for Oruka stockholders, after considering the various financing and other strategic options to enhance stockholder value that were considered by the Oruka board of directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors&#8217; expectation that the Merger, together with the additional financing committed from the Oruka pre<span class="nobreak">-closing</span> financing, would be a higher probability and more cost<span class="nobreak">-effective</span> means to access capital than other options considered, including an IPO;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expected operations, management structure and operating plans of the combined company (including the ability to support the combined company&#8217;s current and planned preclinical and clinical trials);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the business, history, operations, financial resources, assets, technology and credibility of ARCA;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the availability of appraisal rights under the DGCL to holders of Oruka capital stock who comply with the required procedures under the DGCL, which allow such holders to seek appraisal of the fair value of their shares of Oruka capital stock as determined by the Delaware Court of Chancery;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of the Merger Agreement, including the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the determination that the expected relative percentage ownership of ARCA stockholders and Oruka stockholders in the combined organization was appropriate, based on Oruka&#8217;s board of directors&#8217; judgment and assessment of the approximate valuations of ARCA (including the value of the net cash ARCA is expected to provide to the combined organization) and Oruka (including the value of the amount of proceeds from the Oruka pre<span class="nobreak">-closing</span> financing);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the expectation that the Merger will be treated as a reorganization for U.S.&#160;federal income tax purposes, with the result that the Oruka stockholders will generally not recognize taxable gain or loss for U.S.&#160;federal income tax purposes with respect to the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the limited number and nature of the conditions of the obligation of ARCA to consummate the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the rights of Oruka under the Merger Agreement to consider certain unsolicited acquisition proposals under certain circumstances should Oruka receive a superior offer;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">110</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the rights of Oruka under the Merger Agreement to effect a change in recommendation in favor of the Merger as a result of a material development or change in circumstances (i.e., applicable Intervening Events);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the conclusion of Oruka&#8217;s board of directors that the potential termination fees payable by ARCA or Oruka to the other party, and the circumstances when such fee may be payable, were reasonable; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the belief that the other terms of the Merger Agreement, including the parties&#8217; representations, warranties and covenants, and the conditions to their respective obligations, were reasonable in light of the entire transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the shares of ARCA&#8217;s common stock issued to Oruka stockholders, including shares of ARCA common stock issued in exchange for shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing, will be registered on a Form&#160;S<span class="nobreak">-4</span> registration statement and will become freely tradable for Oruka stockholders who are not affiliates of Oruka and who are not parties to lock<span class="nobreak">-up</span> agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the support agreements, pursuant to which certain directors, officers and stockholders of Oruka and ARCA, respectively, have agreed, solely in their capacity as stockholders of Oruka and ARCA, respectively, to vote all of their shares of Oruka capital stock or ARCA common stock in favor of the adoption or approval, respectively, of the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ability to obtain a Nasdaq listing and the change of the combined organization&#8217;s name to Oruka Therapeutics, Inc. prior to or upon the closing of the Merger; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the likelihood that the Merger will be consummated on a timely basis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s board of directors also considered a number of uncertainties and risks in its deliberations concerning the Merger and the other transactions contemplated by the Merger Agreement, including the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possibility that the Merger might not be completed and the potential adverse effect of the public announcement of the Merger on the reputation of Oruka&#160;and the ability of Oruka&#160;to obtain financing in the future in the event the Merger is not completed; the possibility that the Oruka&#160;pre<span class="nobreak">-closing</span> financing might not be completed or completed in accordance with the terms of the Merger Agreement and the potential adverse effect of the public announcement of the Oruka&#160;pre<span class="nobreak">-closing</span> financing on the reputation of Oruka&#160;and the ability of Oruka&#160;to obtain financing in the future in the event the Oruka&#160;pre<span class="nobreak">-closing</span> financing is not completed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the exchange ratio used to establish the number of shares of ARCA&#8217;s common stock to be issued to Oruka&#160;stockholders in the Merger is fixed, except for adjustments due to ARCA&#8217;s net cash balances, the amount of proceeds from the Oruka&#160;pre<span class="nobreak">-closing</span> financing and outstanding capital stock at closing, and thus the relative percentage ownership of ARCA stockholders and Oruka&#160;stockholders in the combined organization immediately following the completion of the Merger is similarly fixed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the potential reduction of ARCA&#8217;s net cash prior to the closing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the possibility that ARCA could, under certain circumstances, consider unsolicited acquisition proposals if superior to the Merger or change its recommendation to approve the Merger upon certain events;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that the Merger might not be consummated in a timely manner or at all, for a variety of reasons, such as the failure of ARCA to obtain the required stockholder vote or the failure of Oruka&#160;to close the Oruka&#160;pre<span class="nobreak">-closing</span> financing, and the potential adverse effect on the reputation of Oruka&#160;and the ability of Oruka&#160;to obtain financing in the future in the event the Merger is not completed;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs involved in connection with completing the Merger, the time and effort of Oruka&#160;senior management required to complete the Merger, the related disruptions or potential disruptions to Oruka&#8217;s business operations and future prospects, including its relationships with its employees, suppliers and partners and others that do business or may do business in the future with Oruka, and related administrative challenges associated with combining the companies;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">111</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the additional expenses and obligations to which Oruka&#8217;s business will be subject to following the Merger that Oruka&#160;has not previously been subject to, and the operational changes to Oruka&#8217;s business, in each case that may result from being a public company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the fact that the representations and warranties in the Merger Agreement do not survive the closing of the Merger and the potential risk of liabilities that may arise post<span class="nobreak">-closing</span>;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the risk that future sales of common stock by existing ARCA stockholders may cause the price of ARCA common stock to fall, thus reducing the potential value of ARCA common stock received by Oruka stockholders following the Merger; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>various other risks associated with the combined organization and the Merger, including the risks described in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors</span>&#8221; in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The foregoing information is not intended to be exhaustive, but is believed to include a summary of all of the material factors considered by Oruka&#8217;s&#160;board of directors in its consideration of the Merger Agreement, the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing, and the transactions contemplated thereby. After conducting an overall analysis of these and other factors, including thorough discussions with, and questioning of, Oruka&#8217;s senior management and legal counsel, Oruka&#8217;s&#160;board of directors concluded that the benefits, advantages and opportunities of a potential transaction outweighed the uncertainties and risks described above. Based on this overall analysis of the factors described above, Oruka&#8217;s&#160;board of directors unanimously approved the Merger Agreement, the Merger, the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing and the other transactions contemplated by the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Opinion of Lucid, ARCA&#8217;s Financial Advisor, to ARCA&#8217;s Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As stated above, pursuant to an engagement letter dated March&#160;19, 2024 (the &#8220;Engagement Letter&#8221;), ARCA retained Lucid to act as a financial advisor in connection with the Merger and to render Lucid&#8217;s opinion (the &#8220;Lucid Opinion&#8221;) to ARCA&#8217;s board of directors as to the fairness of the exchange ratio, from a financial point of view, to the stockholders of ARCA.&#160;On April&#160;2, 2024, at the request of ARCA&#8217;s board of directors, Lucid rendered the oral opinion, subsequently confirmed by delivery of the written opinion dated April&#160;2, 2024, to ARCA&#8217;s board of directors, that the exchange ratio was fair, from a financial point of view, to the stockholders of ARCA as of the date of the Lucid Opinion and based upon the various assumptions, qualifications and limitations set forth therein.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-indent:24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The full text of the Lucid Opinion is attached as Annex&#160;B to this proxy statement and is incorporated by reference. ARCA encourages its stockholders to read the Lucid Opinion in its entirety for the assumptions made, procedures followed, other matters considered and limits of the review by Lucid. The summary of the Lucid Opinion set forth herein is qualified by reference to the full text of the Lucid Opinion. Lucid provided the Lucid Opinion for the sole benefit and use by ARCA&#8217;s board of directors in its consideration of the Merger. The Lucid Opinion is not a recommendation to ARCA&#8217;s board of directors or to any stockholder as to how to vote with respect to the proposed Merger or to take any other action in connection with the Merger or otherwise.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Lucid Opinion, Lucid took into account an assessment of general economic, market and financial conditions as well as its experience in connection with similar transactions and securities valuations generally and, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed a draft of the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain publicly available financial and other information for each of ARCA and Oruka, respectively, including equity research on comparable companies and on ARCA, and certain other relevant financial and operating data furnished to Lucid by the management of each of ARCA and Oruka, respectively;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain relevant historical financial and operating data concerning Oruka furnished to Lucid by the management of Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Discussed with certain members of the management of ARCA the historical and current business operations, financial condition and prospects of ARCA and Oruka;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">112</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain operating results of Oruka as compared to operating results and the reported price and trading histories of certain publicly traded companies that Lucid deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain financial terms of the Merger Agreement as compared to the publicly available financial terms of certain selected business combinations that Lucid deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain financial terms of completed IPOs for certain companies that Lucid deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed certain pro forma financial effects of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain internal financial analyses, including the cash burn model over the next year, projections as to cost and expenses and whether concurrent capital raised would sufficiently cover select programs, reports, and other information  concerning Oruka prepared by Oruka; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed such other information and such other factors, and conducted such other financial studies, analyses and investigations, as Lucid deemed relevant for the purposes of the Lucid Opinion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In conducting Lucid&#8217;s review and arriving at the Lucid Opinion, Lucid has, with ARCA&#8217;s consent, assumed and relied, without independent verification or investigation, upon the accuracy and completeness of all financial and other information provided to or discussed with Lucid by ARCA and Oruka, respectively (for their respective employees, representatives or affiliates), or which is publicly available or was otherwise reviewed by Lucid. Lucid has not undertaken any responsibility for the accuracy, completeness or reasonableness of, or independent verification of, such information. Lucid has relied upon, without independent verifications, the assessment of ARCA management and Oruka management as to the viability of, and risks associated with, the current and future products and services of Oruka (including without limitation, the development, testing and marketing of such products and services, the receipt of all necessary governmental and other regulatory approvals for the development, testing and marketing thereof, and the life and enforceability of all relevant patents and other intellectual and other property rights associated with such products and services). In addition, Lucid has not conducted, nor has it assumed any obligation to conduct any physical inspection of the properties or facilities of ARCA or Oruka. Furthermore, Lucid has assumed, with ARCA&#8217;s consent, that there will be no further adjustments to the exchange ratio between the date hereof and the date the final exchange ratio is determined. Lucid has, with ARCA&#8217;s consent, relied upon the assumption that all information provided to Lucid by ARCA and Oruka is accurate and complete in all material respects.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid expressly disclaimed any undertaking or obligation to advise any person of any change in any fact or matter affecting the Lucid Opinion of which Lucid has become aware after the date of the Lucid Opinion. Lucid assumed there were no material changes in the assets, liabilities, financial condition, results of operations, business or prospects of ARCA or Oruka since the date of the last financial statements made available to Lucid. Lucid has not obtained any independent evaluations, valuations or appraisals of the assets or liabilities of ARCA or Oruka, nor has Lucid been furnished with such materials. Further, as ARCA&#8217;s board of directors was aware, Oruka&#8217;s management did not provide Lucid with, and Lucid did not otherwise have access to, financial forecasts regarding Oruka&#8217;s businesses, other than certain cash burn projections, which indicated that Oruka believes that the expected net proceeds from the Merger and the Oruka pre<span class="nobreak">-closing</span> financing, together with Oruka&#8217;s existing cash and sales of additional convertible notes under the Purchase Agreement (as defined in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Management Discussion &amp; Analysis of Financial Condition and Results of Operations</span>&#8221;), will enable Oruka to fund its operating expenses through 2027, and, accordingly, Lucid did not perform either a discounted cash flow analysis or any multiples<span class="nobreak">-based</span> analyses with respect to Oruka. In addition, Lucid has not evaluated the solvency or fair value of ARCA or Oruka under any state or federal laws relating to bankruptcy, insolvency or similar matters. The Lucid Opinion does not address any legal, tax or accounting matters related to the merger, as to which Lucid has assumed that ARCA and ARCA&#8217;s board of directors have received such advice from legal, regulatory, tax and accounting advisors as each has determined appropriate. The Lucid Opinion addresses only the fairness of the exchange ratio, from a financial point of view, to the ARCA stockholders. Lucid expresses no view as to any other aspect or implication of the merger or any other agreement or arrangement entered into in connection with the merger. The Lucid Opinion is necessarily based upon economic and market conditions and other circumstances as they existed and could be evaluated by Lucid on the date of the Lucid Opinion. It should be understood that although subsequent developments may affect the Lucid Opinion, Lucid does not have any obligation to update, revise or reaffirm the Lucid Opinion and Lucid expressly disclaims any responsibility to do so.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">113</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid did not consider any potential legislative or regulatory changes currently being considered or recently enacted by the United&#160;States or any foreign government, or any domestic or foreign regulatory body, or any changes in accounting methods or generally accepted accounting principles that may be adopted by the Securities and Exchange Commission, the Financial Accounting Standards Board, or any similar foreign regulatory body or board.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For purposes of rendering the Lucid Opinion, Lucid assumed in all respects material to Lucid&#8217;s analysis, that the representations and warranties of each party contained in the merger agreement were true and correct, that each party will perform all of the standards of the covenants and agreements required to be performed by it under the merger agreement and that all conditions to the consummation of the merger will be satisfied without waiver or amendment of any term or condition thereof. Lucid has assumed that the final form of the merger agreement will be substantially similar to the last draft reviewed by Lucid. Lucid has also assumed that all governmental, regulatory and other consents and approvals contemplated by the merger agreement or otherwise required for the transactions contemplated thereby will be obtained and that in the course of obtaining any of those consents no restrictions will be imposed or waivers made that would have an adverse effect on ARCA, Oruka or the contemplated benefits of the Merger. Lucid has assumed that the merger will be consummated in a manner that complies with the applicable provisions of the Securities Act&#160;of&#160;1933, as amended, the Securities Exchange&#160;Act&#160;of&#160;1934, as amended, and all other applicable federal and state statutes, rules and regulations. ARCA has informed Lucid, and Lucid has assumed, that the merger is intended to constitute a reorganization within the meaning of Section&#160;368(a)&#160;of the Code and the Treasury Regulations promulgated thereunder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">It is understood that the Lucid Opinion is intended for the benefit and use of ARCA&#8217;s board of directors in its consideration of the financial terms of the Merger and, except as set forth in Lucid&#8217;s Engagement Letter, may not be used for any other purpose or reproduced, disseminated, quoted or referred to at any time, in any manner or for any purpose without Lucid&#8217;s prior written consent, unless pursuant to applicable law or regulations or required by other regulatory authority by the order or ruling of a court or administrative body, except that the Lucid Opinion may be included in its entirety in any filing related to the merger to be filed with the Securities and Exchange Commission and the proxy statement to be mailed to the ARCA stockholders. The Lucid Opinion does not constitute a recommendation to ARCA&#8217;s board of directors of whether or not to approve the merger or to any ARCA stockholder or any other person as to how to vote with respect to the merger or to take any other action in connection with the merger or otherwise. The Lucid Opinion does not address ARCA&#8217;s underlying business decision to proceed with the merger or the relative merits of the merger compared to other alternatives available to ARCA.&#160;Lucid expressed no opinion as to the prices or ranges of prices at which shares or the securities of any person, including ARCA, will trade at any time, including following the announcement or consummation of the merger. Lucid has not been requested to opine as to, and the Lucid Opinion does not in any manner address, the amount or nature of compensation to any of the officers, directors or employees of any party to the merger, or any class of such persons, relative to the compensation to be paid to the ARCA stockholders in connection with the merger or with respect to the fairness of any such compensation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Lucid Opinion may not be published or otherwise used or referred to, nor shall any public reference to Lucid be made, without Lucid&#8217;s prior written consent.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Principal Financial Analyses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a summary of the principal financial analyses performed by Lucid to arrive at the Lucid Opinion. Some of the summaries of financial analyses include information presented in tabular format. In order to fully understand the financial analyses, the tables must be read together with the text of each summary. The tables alone do not constitute a complete description of the financial analyses. Considering the data set forth in the tables without considering the full narrative description of the financial analyses, including the methodologies and assumptions underlying the analyses, could create a misleading or incomplete view of the financial analyses. Lucid performed certain procedures, including each of the financial analyses described below and reviewed with ARCA&#8217;s board of directors the assumptions on which such analyses were based and other factors, including the historical and projected financial results of ARCA and Oruka.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">114</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Transaction Overview as of the Date of the Lucid Opinion</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based upon the exchange ratio of 7.4631 at the time of the signing of the merger agreement, it was estimated that at the closing: (a)&#160;Oruka equity holders as of immediately prior to the merger (including the shares issued in the approximately $275&#160;million Oruka pre<span class="nobreak">-closing</span> financing) will own approximately 97.61% of the fully<span class="nobreak">-diluted</span> shares of ARCA common stock at the closing of the merger, and (b)&#160;the ARCA equity holders as of immediately prior to the merger (excluding for this purpose the ARCA Out of the Money Options) will own approximately 2.39% of the fully<span class="nobreak">-diluted</span> shares of ARCA common stock at the closing of the merger, in each case, subject to adjustment of the exchange ratio as set forth in the merger agreement and described herein.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:11pt;margin-top:11pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pre-Financing Oruka Equity Value</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the purpose of the Lucid Opinion, Lucid utilized a Oruka equity value of $175.0&#160;million, which was the pre<span class="nobreak">-money</span> valuation utilized in the Oruka pre<span class="nobreak">-closing</span> financing. The post<span class="nobreak">-money</span> Oruka valuation is calculated by adding the negotiated value of $175.0&#160;million plus $275.0&#160;million raised in the pre<span class="nobreak">-closing</span> financing totaling $450.0&#160;million.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:11pt;margin-top:11pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Analysis of Selected Initial Public Offering Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid reviewed certain publicly available information for the IPOs of 19 dermatology/inflammation/autoimmune<span class="nobreak">-focused</span> biopharmaceutical companies that have completed an IPO since September&#160;2017 and whose lead product at the time of IPO was in a preclinical or Phase&#160;1 stage of clinical development. Although the companies referred to below were used for comparison purposes, none of these companies are directly comparable to Oruka. Accordingly, an analysis of the results of such a comparison is not purely mathematical but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the selected companies below. These companies, which are referred to as the &#8220;Selected Precedent IPO Companies,&#8221; were:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Apogee Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Applied Molecular Transport</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Avidity Biosciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Azitra</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Biora Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Cabaletta Bio</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>DICE Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Dyne Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Evelo Biosciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Hoth Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Kezar Life Sciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Krystal Biotech</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Kymera Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Kyverna Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Morphic Holding</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Prometheus Biosciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Third Harmonic Bio</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Ventyx Biosciences</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Virpax Pharmaceuticals</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">115</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The total enterprise value at IPO is defined as the&#160;pre<span class="nobreak">-money</span>&#160;equity value plus indebtedness, liquidation value of preferred stock and&#160;non<span class="nobreak">-controlling</span>&#160;interest, minus cash and cash equivalents at the time of its IPO.&#160;The Selected Precedent IPO Companies had total enterprise values between $33.0&#160;million and $638.5&#160;million. Lucid derived a median total enterprise value of $315.2&#160;million for the Selected Precedent IPO Companies. Using the 25<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span>&#160;percentile and the 75<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile of the implied total enterprise values, Lucid then calculated a range of implied total equity values for Oruka (by adding an estimated $2.7&#160;million in net cash at closing), which was approximately $177.4&#160;million to $504.2&#160;million. This compares to Oruka&#8217;s pre<span class="nobreak">-financing</span> equity value as per the merger agreement of $175.0&#160;million.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Selected Precedent IPO Companies</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Filing Date</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Issuer</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Enterprise<br/>Value&#160;($M)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/7/24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kyverna Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">511.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/13/23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Apogee Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">384.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/15/23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Azitra</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58.6</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/14/22</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Third Harmonic Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">359.8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/20/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ventyx Biosciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">466.6</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/14/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">DICE Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">343.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/11/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prometheus Biosciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">442.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/16/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Virpax Pharmaceuticals</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">33.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/17/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dyne Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">460.4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/20/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kymera Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">526.2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/19/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Biora Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">638.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/12/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Avidity Biosciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">292.2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/4/20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Applied Molecular Transport</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">260.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/24/19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cabaletta Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">108.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/26/19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Morphic Holding</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">154.4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/15/19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Hoth Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/20/18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kezar Life Sciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">141.5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/8/18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Evelo Biosciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">315.2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/19/17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Krystal Biotech</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45.3</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Analysis of Selected Publicly Traded Companies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on its experience and professional judgment and using financial screening sources and databases to find companies that share similar business characteristics to Oruka within the biopharmaceutical industry, Lucid selected financial data of 13 publicly traded companies (referred to as the &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">Selected Publicly</span>&#160;<span class="Bold" style="font-style:normal;font-weight:bold;">Traded</span>&#160;<span class="Bold" style="font-style:normal;font-weight:bold;">Companies</span>&#8221;). Each of the Selected Publicly Traded Companies had a lead candidate in preclinical or Phase&#160;I stage of clinical development and focused on the dermatology/inflammation/autoimmune space. Although the companies referred to below were used for comparison purposes, none of those companies is directly comparable to Oruka. Accordingly, an analysis of the results of such a comparison is not purely mathematical but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the selected companies below. The total enterprise values are based on closing stock prices on April&#160;1, 2024. The Selected Publicly Traded Companies were:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Aditxt</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Apogee Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Astria Therapeutics, Inc.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Azitra</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Cabaletta Bio</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Forte Biosciences, Inc.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">116</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Kyverna Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Rani Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Spyre Therapeutics</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Surrozen, Inc.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Tharimmune</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Third Harmonic Bio</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ZyVersa Therapeutics</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Selected Publicly Traded Companies had implied total enterprise values between negative $18.8&#160;million and $2.9&#160;billion. Lucid derived a median implied total enterprise value of $63.1&#160;million for the Selected Publicly Traded Companies. Using the 25<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile and the 75<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile of the implied total enterprise values, Lucid then calculated a range of implied total equity values for Oruka (by adding an estimated $2.7&#160;million in net cash at closing), which was approximately $5.3&#160;million to $539.2&#160;million. This compares to Oruka&#8217;s pre<span class="nobreak">-financing</span> equity value as per the merger agreement of $175.0&#160;million.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Selected Publicly Traded Companies</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Company Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Enterprise <br/>Value&#160;($M)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Apogee Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,863.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Spyre Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">818.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cabaletta Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">575.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kyverna Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">536.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Astria Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">370.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Third Harmonic Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Rani Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">63.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Azitra</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Aditxt</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ZyVersa Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tharimmune</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forte Biosciences, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(11.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Surrozen, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(18.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Analysis of Selected Precedent M&amp;A Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid reviewed the financial terms, to the extent the information was publicly available, of the 9 most recent qualifying merger transactions of companies in the biopharmaceutical industry, which had a lead candidate in the preclinical or phase&#160;I stage of clinical development and focused on the dermatology/inflammation/autoimmune space (referred to as the &#8220;Selected Precedent&#160;M&amp;A Transactions&#8221;). Although the precedent transactions referred to below were used for comparison purposes, none of the target companies is directly comparable to Oruka. Accordingly, an analysis of the results of such a comparison is not purely mathematical, but instead involves complex considerations and judgments concerning differences in historical and projected financial and operating characteristics of the companies involved and other factors that could affect the merger value of such companies and Oruka to which they are being compared. Lucid reviewed the total enterprise values of the target companies (including future milestone payments). These transactions, including the date each was closed, were as follows below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Selected Precedent M&amp;A Transactions had total implied enterprise values between $20.0&#160;million and $2.0&#160;billion. Lucid derived a median total enterprise value of $250.0&#160;million for the Selected Precedent M&amp;A Transactions. Using the 25<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile and the 75<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span> percentile of the implied total enterprise values, Lucid then calculated a range of implied total enterprise values for Oruka (by adding an estimated $2.7&#160;million in net cash at closing), which was approximately $65.0&#160;million to $1.0&#160;billion. This compares to Oruka&#8217;s pre<span class="nobreak">-financing</span> equity value as per the merger agreement of $175.0&#160;million.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">117</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Selected Precedent M&amp;A Transactions</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Announced Date</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Target</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Acquirer</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.66%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Implied&#160;Enterprise</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Value ($M)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/13/24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">IMF Tre</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Novartis AG</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">90.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/15/24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Aiolos Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">GSK</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,000.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/18/24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Calypso Biotech</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Novartis AG</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">250.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/9/23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">DICE Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Eli Lilly</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,028.7</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/1/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ORIGIMM Biotechnology</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Sanofi</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">62.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/1/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pandion Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Merck</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,850.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/20/21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Rodeo Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amgen</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/8/17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Confluence Life Sciences</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Aclaris Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20.0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/26/17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 25.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Delinia, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Celegene Corporation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.70%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">300.0</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Analysis of Precedent Reverse Merger Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid reviewed the financial terms, to the extent the information was publicly available, of life sciences reverse merger transactions dating back to January&#160;2018 (referred to as the &#8220;Selected Precedent Reverse Merger Transactions&#8221;). Lucid reviewed the total premium to cash delivered to each target, along with other quantitative metrics. These transactions, including the date each was closed, are as follows:</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Selected Precedent Reverse Merger Transactions</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Closed&#160;Date</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Surviving Company</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Public Company</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Value Delivered <br/>for Public Vehicle <br/>Net of Cash <br/>($ mm&#8217;s)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/21/2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">LENZ Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Graphite Bio (Nasdaq: GRPH)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">$12</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/14/2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Immunogenx</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Wave BioPharma (FWBI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/6/2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Adaptive Phage Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Biomx (NYSEAM:&#160;PHGE)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">NA</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/27/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cyclo Therapeutics (Nasdaq: CYTH)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Applied Molecular Transport (Nasdaq: AMTI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/18/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Neurogene</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Neoleukin Therapeutics (Nasdaq: NLTX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">14</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11/13/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cartesian Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Selecta Biosciences (Nasdaq: RNAC)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">13</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11/3/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Korro Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Frequency Therapeutics (Nasdaq: FREQ)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/31/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lung Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aileron Therapeutics (Nasdaq: ALRN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/16/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Notable Labs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Vascular Biogenics Ltd. (Nasdaq: VBLT)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/11/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dianthus Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Magenta Therapeutics (Nasdaq: MGTA)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/16/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">EIP Pharma (CervoMed)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Diffusion Pharmaceuticals (Nasdaq: DFFN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/29/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">TeraImmune</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Baudax Bio (Nasdaq: BXRX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/22/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Spyre Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aeglea BioTherapeutics (Nasdaq: AGLE)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/1/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Elicio Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Angion Biomedica (Nasdaq: ANGN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">7</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/22/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">GRI Bio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Vallon Pharmaceuticals (Nasdaq: VLON)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">29</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/20/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">CalciMedica</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Graybug Vision (Nasdaq: GRAY)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/7/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Carisma Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Sesen Bio (Nasdaq: SESN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/23/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Enliven Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Imara (Nasdaq: IMRA)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/9/2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Catheter Precision, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ra Medical Systems (NYSE: RMED)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/29/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Disc Medicine</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Gemini Therapeutics (Nasdaq: GMTX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/27/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">GNI Group (Gyre Therapeutics)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Catalyst Biosciences (Nasdaq: CBIO)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">9</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/19/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Kineta, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Yumanity Therapeutics (Nasdaq: YMTX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">26</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11/8/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">ARS Pharmaceuticals</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Silverback Therapeutics (Nasdaq: SBTX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/28/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aceragen, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Idera Pharmaceuticals (Nasdaq: IDRA)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">7</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/15/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lisata Therapeutics (Cend)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Caladrius Biosciences (Nasdaq: CLBS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/30/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Vivani Medical (Nano Precision)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Second Sight Medical (Nasdaq: EYES)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">NA</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">118</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Closed&#160;Date</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Surviving Company</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Public Company</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Value Delivered <br/>for Public Vehicle <br/>Net of Cash <br/>($ mm&#8217;s)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/5/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Syros Pharmaceuticals (Nasdaq: SYRS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Tyme Technologies (Nasdaq: TYME)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/16/2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aprea Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Atrin Pharmaceuticals (NasdaqGS: APRE)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/24/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Quoin Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cellect Biotechnology Ltd. (Nasdaq: APOP)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">13</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/26/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aadi Bioscience, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/3/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Decoy Biosystems, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Indaptus Therapeutics (Intec) (Nasdaq: INDP)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/27/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cytocom, Inc. (Statera)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cleveland BioLabs, Inc. (Nasdaq: CBLI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">NA</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/28/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Tempest Therapeutics Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Millendo Therapeutics, Inc. (Nasdaq: MLND)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">19</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/15/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">ReShape Lifesciences Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Obalon Therapeutics, Inc. (Nasdaq: OBLN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/27/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Leading BioSciences, Inc. (Palisade)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Seneca Biopharma, Inc. (Nasdaq: SNCA)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">30</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/16/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">MyMD Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Akers Biosciences, Inc. (Nasdaq: AKER)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/31/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">StemoniX Inc. (Vyant Bio)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cancer Genetics, Inc. (Nasdaq: CGIX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/16/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">ChemomAb Ltd.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Anchiano Therapeutics Ltd. (Nasdaq: ANCN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/24/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Viracta Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Sunesis Pharmaceuticals (Nasdaq: SNSS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">16</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/28/2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Quellis Biosciences, Inc. (Astria)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Catabasis Pharmaceuticals (Nasdaq: CATB)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/22/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Yumanity Therapeutics Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Proteostasis Therapeutics (Nasdaq: PTI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/1/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Petros Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Neurotrope, Inc. (NasdaqCM: NTRP)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11/23/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">F<span class="nobreak">-star</span> Therapeutics, Limited</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Spring Bank Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">23</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11/5/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ocuphire Pharma, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Rexahn Pharmaceuticals (Nasdaq: REXN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">16</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/27/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Viridian Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Miragen Therapeutics, Inc. (NasdaqCM: MGEN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/15/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Adicet Bio, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">resTORbio, Inc. (NasdaqGS: TORC)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/14/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Anelixis Therapeutics (Eledon)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Novus Therapeutics, Inc. (NasdaqCM: NVUS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/6/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Kiq Bio (Cogent)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Unum Therapeutics, Inc. (NASDAQ:&#160;UMRX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">17</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/15/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Forte Biosciences, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Tocagen Inc. (NasdaqGS: TOCA)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/28/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Larimar Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Zafgen, Inc. (NasdaqGS: ZFGN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/26/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Histogen, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Conatus Pharmaceuticals (Nasdaq: CNAT)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">23</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/22/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Qualigen, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ritter Pharmaceuticals (Nasdaq: RTTR)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">NA</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/18/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Timber Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">BioPharmX Corporation (AMEX: BPMX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">16</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/1/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Curetis NV (Euronext: CURE)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">OpGen, Inc. (NasdaqCM: OPGN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">7</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/9/2020</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Protara Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Proteon Therapeutics, Inc. (NASDAQ:&#160;PRTO)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/30/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">NeuroBo Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Gemphire Therapeutics Inc. (NASDAQ:&#160;GEMP)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11/7/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Venus Concept Ltd.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Restoration Robotics, Inc. (NASDAQ:&#160;HAIR)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9/27/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ocugen, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Histogenics Corporation (NASDAQ:&#160;HSGX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">NA</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8/31/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Brickell Biotech, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Vical Incorporated (NASDAQ:&#160;VICL)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/31/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">ESSA Pharma (NASDAQ: EPIX)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Realm Therapeutics plc (NASDAQ:&#160;RLM)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/22/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Salarius Pharmaceuticals, LLC</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Flex Pharma, Inc. (NASDAQ:&#160;FLKS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7/15/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">NeuBase Therapeutics</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ohr Pharmaceutical (NASDAQ:&#160;OHRP)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">7</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/10/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Oncternal Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">GTx, Inc. (NASDAQ:&#160;GTXI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">9</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6/9/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Edesa Biotech Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Stellar Biotechnologies, Inc. (NASDAQ:&#160;SBOT)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/9/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Armata Pharmaceuticals (f.k.a C3J)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ampliphi Biosciences (NYSE:&#160;APHB)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5/6/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Adynxx, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Alliqua BioMedical, Inc. (NASDAQ:&#160;ALQA)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/23/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Mereo BioPharma (AIM: MPH)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Oncomed Pharmaceuticals (NASDAQ:&#160;OMED)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4/12/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Immunic AG</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Vital Therapies, Inc. (NASDAQ: VTL)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">10</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">119</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Closed&#160;Date</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Surviving Company</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Public Company</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Value Delivered <br/>for Public Vehicle <br/>Net of Cash <br/>($ mm&#8217;s)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/26/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Enlivex Therapeutics Ltd.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Bioblast Pharma Ltd. (NASDAQ:&#160;ORPN)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/18/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">PDS Biotechnology Corporation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Edge Therapeutics, Inc. (NASDAQ:&#160;EDGE)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3/13/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">X4 Pharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Arsanis, Inc. (NASDAQ:&#160;ASNS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">29</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/24/2019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Seelos Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Apricus Biosciences, Inc. (NASDAQ: APRI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">8</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">12/7/2018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Millendo Therapeutics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">OvaScience, Inc. (NASDAQ:&#160;OVAS)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10/12/2018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aravive Biologics, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Versartis, Inc. (NASDAQ:&#160;VSAR)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">0</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2/13/2018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Vaxart, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Aviragen Therapeutics, Inc. (NASDAQ:&#160;AVIR)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">44</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/30/2018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Innovate Biopharmaceuticals, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Monster Digital, Inc. (NASDAQ:&#160;MSDI)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">6</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/17/2018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Evofem Biosciences, Inc.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Neothetics, Inc. (NASDAQ:&#160;NEOT)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">29</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1/4/2018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 28.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Rocket Pharmaceuticals, Ltd</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 40.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Inotek Pharmaceuticals Corp (NASDAQ:&#160;ITEK)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 16.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">5</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid reviewed the value delivered for the public vehicle (net of cash) from the Selected Precedent Reverse Merger Transactions, which ranged from $0.0&#160;million to $44.0&#160;million. The 25<span class="Superscript" style="vertical-align:super;font-size:58%;">th</span> percentile and the 75<span class="Superscript" style="vertical-align:super;font-size:58%;">th</span> percentile for the value delivered for the public vehicle (net of cash), was $5.0&#160;million and $17.0&#160;million respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The summary set forth above does not purport to be a complete description of all the analyses performed by Lucid. The preparation of a fairness opinion involves various determinations as to the most appropriate and relevant methods of financial analysis and the application of these methods to the particular circumstances. Therefore, such an opinion is not readily susceptible to partial analysis or summary description. Lucid did not attribute any particular weight to any analysis or factor considered by it, but rather made qualitative judgments as to the significance and relevance of each analysis and factor. Accordingly, notwithstanding the separate factors summarized above, Lucid believes, and advised ARCA&#8217;s board of directors, that its analyses must be considered as a whole. Selecting portions of its analyses and the factors considered by it without considering all analyses and factors could create an incomplete view of the process underlying the Lucid Opinion. In performing its analyses, Lucid made numerous assumptions with respect to industry performance, business and economic conditions and other matters, many of which are beyond the control of ARCA and Oruka. These analyses performed by Lucid are not necessarily indicative of actual values or future results, which may be significantly more or less favorable than suggested by such analyses. In addition, analyses relating to the value of businesses do not purport to be appraisals or to reflect the prices at which businesses or securities may actually be sold. Accordingly, such analyses and estimates are inherently subject to uncertainty, being based upon numerous factors or events beyond the control of the parties or their respective advisors. None of ARCA, Oruka, Lucid or any other person assumes responsibility if future results are materially different from those projected. The analyses supplied by Lucid and the Lucid Opinion were among several factors taken into consideration by ARCA&#8217;s board of directors in making its decision to enter into the merger agreement and should not be considered as determinative of such a decision.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid was selected by ARCA&#8217;s board of directors to render an opinion to ARCA&#8217;s board of directors because Lucid is a nationally recognized investment banking firm and because, as part of its investment banking business, Lucid is continually engaged in the valuation of businesses and their securities in connection with mergers, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for corporate and other purposes. In addition, in the ordinary course of its business, Lucid and its affiliates may trade the equity securities of ARCA for its own account and for the accounts of their customers, and, accordingly, may at any time hold a long or short position in such securities. In the two&#160;years preceding the date hereof, Lucid has not received any fees from ARCA.&#160;In the two&#160;years preceding the date hereof, Lucid has not had a relationship with Oruka and has not received any fees from Oruka. Lucid and its affiliates may in the future seek to provide investment banking or financial advisory services to ARCA and Oruka and/or certain of their respective affiliates and expect to receive fees for the rendering of these services.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Engagement Letter between Lucid and ARCA as of the time the merger agreement was approved, if the merger is consummated, Lucid will be entitled to receive a transaction fee of $800,000 payable in cash at the closing of the transaction. ARCA has also paid Lucid a fee for the Lucid Opinion of $250,000 </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">120</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">(in addition to the $800,000 transaction fee payable upon closing of the transaction) upon delivery of the Lucid Opinion. Additionally, ARCA has agreed to reimburse Lucid for its&#160;out<span class="nobreak">-of-pocket</span>&#160;expenses and has agreed to indemnify Lucid against certain liabilities, including liabilities under the federal securities laws. The terms of the fee arrangement with Lucid, which are customary in transactions of this nature, were negotiated at arm&#8217;s length between ARCA and Lucid, and ARCA&#8217;s board of directors was aware of the arrangement, including the fact that a portion of the fee payable to Lucid is contingent upon the completion of the merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Interests of ARCA&#8217;s Directors and Executive Officers in the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In considering the recommendation of ARCA&#8217;s board of directors with respect to issuing shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, in the Merger and the other matters to be acted upon by the ARCA stockholders at the ARCA special meeting, the ARCA stockholders should be aware that ARCA&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of ARCA stockholders generally. These interests may present ARCA&#8217;s directors and executive officers with actual or potential conflicts of interest.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the ARCA stockholders approve the proposals to be presented to the ARCA stockholders for consideration at the ARCA special meeting as contemplated by this proxy statement/prospectus.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Treatment of ARCA Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Under the terms of the Merger Agreement, prior to the closing of the Merger, ARCA&#8217;s board of directors will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable. At the closing of the First Merger, (i)&#160;each option to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option and (ii)&#160;each other option to acquire shares of ARCA&#8217;s common stock will be cancelled for no consideration. The following table sets forth, for each ARCA executive officer and each member of ARCA&#8217;s board of directors the aggregate number of ARCA stock options that were unvested and vested as of July<span class="nobreak"> </span>16, 2024 and the weighted<span class="nobreak">-average</span> exercise price.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-25" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Unvested<br/>ARCA<br/>Options<br/>(#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted-Average<br/>Exercise&#160;Price&#160;of<br/>Unvested&#160;ARCA<br/>Options<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Vested&#160;ARCA<br/>Options<br/>(#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted-Average<br/>Exercise&#160;Price&#160;of<br/>Vested&#160;ARCA<br/>Options<br/>($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Executive Officers</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13,611</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.56</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">93,763</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.84</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13,916</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.92</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">58,784</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.86</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Directors</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Linda Grais, M.D.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21,895</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.86</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Robert E.&#160;Conway</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21,895</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.86</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Anders Hove</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21,499</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Jacob Ma-Weaver</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,166</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.96</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16,834</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.19</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 32.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">James Flynn</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,166</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 16.67%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.06</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8,834</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.13</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Retention Bonus Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Each of ARCA&#8217;s current executive officers is party to a retention bonus letter, as amended from time to time, pursuant to which the ARCA executive officer will receive a retention bonus of $165,000, subject to his continued employment with ARCA in good standing through the earlier of a corporate transaction of ARCA or certain clinical development decisions. The Merger will constitute a corporate transaction of ARCA for purposes of the retention bonus letters.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">121</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Each of ARCA&#8217;s current executive officers is party to an employment agreement that provides certain payments and benefits upon a termination of employment without cause by ARCA or a resignation by the officer for good reason (each as defined below) on the same&#160;day as a corporation transaction of ARCA or within 13&#160;months after a corporation transaction of ARCA.&#160;The Merger will constitute a corporate transaction of ARCA for purposes of the employment agreements. These payments and benefits include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Severance pay equal to (i)&#160;12&#160;months of the ARCA executive officer&#8217;s base salary, payable in installments over 12&#160;months, plus (ii)&#160;a pro rata portion of any bonus compensation approved for the fiscal year in which the termination occurs, payable when bonuses for such year are otherwise paid;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reimbursement of out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA for up to 12&#160;months.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the employment agreements provides that ARCA may, in its sole discretion, pay additional severance pay of up to 12&#160;months of base salary to extend the term of the restrictive covenants applicable to the ARCA executive officer. The severance payments and benefits are subject to the ARCA executive officer&#8217;s release of claims in a form acceptable to ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The employment agreements do not contain tax gross<span class="nobreak">-up</span> provisions with respect to excise taxes under Section&#160;4999 of the Code. Instead, the severance payments and benefits are subject to a &#8220;best<span class="nobreak">-of-net</span>&#8221; provision in the event of excess parachute payments under Section&#160;280G of the Code. In the event excise taxes under Section&#160;4999 of the Code would be imposed on payments made under the employment agreements, the ARCA executive officer will either pay the excise tax or have his payments and benefits reduced to an amount at which an excise tax no longer applies, based on which result is more favorable to the ARCA executive officer on an after<span class="nobreak">-tax</span> basis</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">For purposes of the employment agreements:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Cause&#8221; generally means that the ARCA executive officer has committed or engaged in: (i)&#160;willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to ARCA; (ii)&#160;refusal, unwillingness, failure, or inability to perform material job duties or habitual absenteeism; or (iii)&#160;violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of the employment agreement, intellectual property agreement or any other contract with ARCA</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Good Reason&#8221; generally means, with the ARCA executive officer&#8217;s consent: (i)&#160;geographic relocation by more than 30 miles; (ii)&#160;a decrease in base salary by more than 15%, other than a decrease resulting from a general reduction in the base salary of all ARCA executive officers; or (iii)&#160;significant detrimental reductions in the ARCA executive officer&#8217;s job responsibilities, in each case, subject to standard notice and cure provisions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Director Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">As discussed under &#8220;ARCA Director Compensation&#8221; below, Chairman of ARCA&#8217;s board of directors, Robert&#160;E. Conway, and other members of ARCA&#8217;s board of directors, including Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma<span class="nobreak">-Weaver</span> (served from June 2022 to April 2024), served on the Special Committee beginning in 2022, pursuant to which they each received enhanced retainers totaling: $105,000 for each of Robert E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and $90,000 for Jacob Ma<span class="nobreak">-Weaver</span>. In April 2024, James Flynn replaced Mr.<span class="nobreak"> </span>Ma<span class="nobreak">-Weaver</span> on the Special Committee. Each member of the Special Committee will continue to be paid $7,500 per month for each month of substantive service on the Special Committee.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Dividend</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash will exceed $5.0<span class="nobreak"> </span>million, and any of ARCA&#8217;s directors and executive officers that are also ARCA stockholders will share in any such cash dividend proportionally to their pre<span class="nobreak">-First</span> Merger ownership of ARCA common stock (see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of ARCA</span>&#8221; beginning on page 312 of this </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">122</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;text-indent:0pt;margin-top:6pt;">proxy statement/prospectus for additional information regarding ARCA&#8217;s directors&#8217; and officers&#8217; holdings of ARCA common stock; notably, Jacob Ma<span class="nobreak">-Weaver</span> and affiliated entities together hold 4,000,452<span class="nobreak"> </span>shares of ARCA common stock, representing over 27% of outstanding shares of ARCA common stock).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Indemnification and Insurance</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Under the Merger Agreement, ARCA&#8217;s directors and executive officers are entitled to continued indemnification, expense advancement and insurance coverage. For a discussion of the indemnification and insurance provisions related to the ARCA directors and officers under the Merger Agreement, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement &#8212; Indemnification and Insurance for Directors and Officers</span>&#8221; beginning on page 147 of this proxy statement/prospectus.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Quantification of Potential Payments and Benefits to ARCA Named Executive Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In accordance with Item&#160;402(t)&#160;of Regulation&#160;S<span class="nobreak">-K</span>, the table below sets forth the compensation that is based on or otherwise relates to the Offer and the Merger that may be paid or become payable to each of ARCA named executive officer in connection with the Merger. Please see the previous portions of this section for further information regarding this compensation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The amounts indicated in the table below are estimates of the amounts that would be payable assuming, solely for purposes of this table, that (i)&#160;the Merger was consummated on July<span class="nobreak"> </span>16, 2024, (ii)&#160;each ARCA named executive officer&#8217;s employment was terminated by ARCA without cause immediately following consummation of the Merger, (ii)&#160;the value per share of ARCA common stock on consummation of the Merger is $3.09 (which, in accordance with SEC requirements, is equal to the average closing price of a share of ARCA common stock over the first five&#160;business days following the first public announcement of the Merger on April&#160;3, 2024), and (iii)&#160;the Parent Closing Price is $3.09. The ARCA named executive officer will not receive pension, tax reimbursement or other benefits in connection with the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Some of the amounts set forth in the table would be payable solely by virtue of the consummation of the Merger. In addition to the assumptions regarding the consummation date of the Merger and the termination of employment, these estimates are based on certain other assumptions that are described in the footnotes accompanying the table below. Accordingly, the ultimate values to be received by an ARCA named executive officer in connection with the Merger may differ from the amounts set forth below.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash&#160;($)</span><span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Equity&#160;($)</span><span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Perquisites/<br/>Benefits&#160;($)</span><span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total&#160;($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">370,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,555</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">380,555</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">505,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,889</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,746</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">549,635</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">435,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,310</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">36,579</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473,889</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The cash amounts represent: (i)&#160;with respect to Mr.&#160;Bristow, the cash severance payments that are payable to him in connection with his prior termination of employment pursuant to his Separation Agreement and Release with ARCA dated April&#160;3, 2024, as described under &#8220;ARCA Executive Compensation&#160;&#8212;&#160;Narrative Disclosure to Summary Compensation Table&#160;&#8212;&#160;Employment Agreements or Arrangements&#8221; below, which are being included herein out of an abundance of caution but which will be payable notwithstanding the consummation of the Merger, and (ii)&#160;with respect to Mr.&#160;Keuer and Mr.&#160;Dekker, (A)&#160;a $165,000 retention bonus payable in connection with the closing of the Merger, which constitutes a single<span class="nobreak">-trigger</span> benefit, and (B)&#160;aggregate cash severance payments of $340,000 with respect to Mr.&#160;Keuer and $270,000 with respect to Mr.&#160;Dekker that may be payable in connection with the Merger pursuant to their respective employment agreements upon a termination by ARCA without Cause or by the ARCA named executive officer for Good Reason on or within 13&#160;months following a Corporate Transaction (as such terms are defined in the applicable employment agreement) subject to their timely execution and non<span class="nobreak">-revocation</span> of a release in favor of ARCA, which constitutes a double<span class="nobreak">-trigger</span> benefit. For more information, please see the section above captioned &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">&#8212;&#160;Employment Agreements</span>.&#8221;</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents ARCA stock options (which ARCA refers to as the &#8220;Executive Equity Awards&#8221;) that will accelerate and vest in the Merger, assuming, solely for purposes of this table, continued employment or service of each ARCA named executive officer through the Closing Date. Pursuant to the Merger Agreement, each Executive Equity Award will fully accelerate on the Closing Date and thus constitute a single<span class="nobreak">-trigger</span> benefit. No value is reflected herein for any Executive Equity Award with an exercise price in excess of $3.09, as Executive Equity Awards with values in excess of the Parent Closing Price will </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">123</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:0pt;">be cancelled for no consideration. The values for each Executive Equity Award with an exercise price in excess of $3.09 in the table below represent the product of (i)&#160;the difference between $3.09 and the applicable exercise price of the Executive Equity Award, multiplied by (ii)&#160;the number of shares of ARCA common stock subject to the Executive Equity Award, as applicable, that accelerate and vest in connection with the Merger:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-25" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>ARCA<br/>Shares&#160;Subject&#160;to<br/>Executive&#160;Equity<br/>Award (#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Per&#160;Share&#160;Value<br/>of&#160;Executive<br/>Equity&#160;Award <br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total ($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13,194</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.80</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,555</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,861</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.80</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,889</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,458</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.80</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,966</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 54.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C. Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,458</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0.03</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.81%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">344</p>
					</td>
				</tr>

		</table>
		<p class="Textfootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;margin-top:8pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents the estimated value of the premiums ARCA would be required to reimburse to Messrs. Keuer and Dekker for continued health coverage under COBRA for a period of 12&#160;months that may be payable in connection with the Merger pursuant to their respective employment agreements upon a termination by ARCA without Cause or by the ARCA named executive officer for Good Reason on or within 13&#160;months following a Corporate Transaction (as such terms are defined in the applicable employment agreement) subject to their timely execution and non<span class="nobreak">-revocation</span> of a release in favor of ARCA, which constitutes a double<span class="nobreak">-trigger</span> benefit. For more information, please see the section above captioned &#8220;&#8212;&#160;Employment Agreements.&#8221;</p>
		<p class="Textfootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Dr.&#160;Bristow, ARCA&#8217;s former President and Chief Executive Officer, terminated employment with ARCA on April&#160;3, 2024.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Interests of Oruka&#8217;s Directors and Executive Officers in the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In considering the recommendation of Oruka&#8217;s board of directors with respect to approving the Merger, stockholders should be aware that Oruka&#8217;s directors and executive officers have interests in the Merger that are different from, or in addition to, the interests of Oruka stockholders generally. These interests may present them with actual or potential conflicts of interest, and these interests, to the extent material, are described below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s board of directors was aware of these potential conflicts of interest and considered them, among other matters, in reaching its decision to approve the Merger Agreement and the Merger, and to recommend that the Oruka stockholders approve the Merger as contemplated by this proxy statement/prospectus.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Ownership Interests</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of July<span class="nobreak"> </span>16, 2024, Oruka&#8217;s current non<span class="nobreak">-employee</span> directors and executive officers beneficially owned, in the aggregate approximately 73.5% of the shares of Oruka capital stock, which for purposes of this subsection excludes any Oruka shares issuable upon exercise or settlement of Oruka options held by such individual. Each of Oruka&#8217;s officers, directors and affiliated stockholders have also entered into a support agreement in connection with the Merger. For a more detailed discussion of the support agreements, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements</span>&#8221; beginning on page 153 of this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As noted above, Fairmount Fund&#160;II, an affiliate of Peter Harwin, an Oruka director, Dr. Lawrence Klein, Oruka&#8217;s President and Chief Executive Officer, and Turtle Family Trust, of which Cameron Turtle, an Oruka director, is a trustee, also currently hold shares of Oruka capital stock. The table below sets forth the ownership of Oruka capital stock by Fairmount Fund&#160;II, Lawrence Klein and Turtle Family Trust as of July<span class="nobreak"> </span>16, 2024. Fairmount Fund II also holds the Convertible Note and has agreed to purchase shares and pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing. For a more detailed discussion of these relationships, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Certain Relationships and Related Party Transactions of the Combined Company&#160;&#8212;&#160;Oruka Transactions&#160;&#8212;&#160;Private Placement of Securities</span>&#8221; beginning on page 281 of this proxy statement/prospectus.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">124</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Stockholder</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Shares of <br/>Capital Stock <br/>hel</span>d</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fairmount Healthcare Fund&#160;II L.P.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,491,646</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Turtle Family Trust</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">149,164</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 20,000,000<span class="nobreak"> </span>shares of Oruka common stock issuable upon conversion of 20,000,000<span class="nobreak"> </span>shares of Oruka Series&#160;A Preferred Stock held by Fairmount Fund&#160;II.&#160;Fairmount Healthcare Fund&#160;II GP LLC (&#8220;Fairmount GP&#160;II&#8221;) is the general partner of Fairmount Fund&#160;II.&#160;Fairmount Funds Management LLC (&#8220;Fairmount Funds Management&#8221;), as the investment manager, along with Fairmount GP&#160;II, as the general partner, exercise voting and investment power over Fairmount Fund&#160;II.&#160;Fairmount Funds Management has voting and dispositive power over the common stock held by Fairmount Fund&#160;II, which is deemed shared with Fairmount GP&#160;II.&#160;As managing members of Fairmount Funds Management and Fairmount GP&#160;II, Peter Harwin and Tomas Kiselak may be deemed beneficial owners of any securities beneficially owned by Fairmount Funds Management. Fairmount Funds Management, Fairmount GP&#160;II, Mr.&#160;Harwin and Mr.&#160;Kiselak disclaim beneficial ownership of such shares of Oruka Series&#160;A Preferred Stock and the underlying shares of Oruka common stock except to the extent of their pecuniary interest therein. The principal business address for these persons and entities is 200&#160;Barr Harbor Drive, Suite 400, West Conshohocken, Pennsylvania 19428.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 1,491,646<span class="nobreak"> </span>shares of Oruka common stock held by Lawrence Klein. Such shares were purchased by Dr.&#160;Klein, in anticipation of his service as Oruka&#8217;s Chief Executive Officer, at the fair market value on the purchase date. The purchased shares are subject to vesting as to 25% on February 26, 2025 and in equal monthly installments for the 36&#160;months thereafter.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 149,164<span class="nobreak"> </span>shares of Oruka common stock held by Turtle Family Trust, of which Cameron Turtle is a trustee. Such shares were purchased by Dr. Turtle, in anticipation of his service on the Oruka board of directors, at the fair market value on the purchase date. The purchased shares are subject to vesting as to 25% on March 1, 2025 and in equal monthly installments for the 36 months thereafter.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Klein Anti-Dilution Provision</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the amended and restated offer letter agreement between Oruka and Lawrence Klein, Oruka is obligated to issue additional options to purchase shares of Oruka common stock in order to maintain Dr.&#160;Klein&#8217;s ownership in Oruka at the Target Ownership Percentage until Oruka has raised an aggregate of the Covered Limit. As a result, Oruka expects to issue Dr.&#160;Klein warrants of Oruka in full satisfaction of such obligation to maintain his ownership in Oruka at the Target Ownership Percentage concurrently with the closing of the Oruka pre<span class="nobreak">-closing</span> financing up to the Covered Limit.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Options and Warrants</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, each option to purchase shares of Oruka common stock that is outstanding and unexercised immediately prior to the effective time of the First Merger under Oruka&#8217;s 2024 Equity Incentive Plan and that, following assumption by ARCA at the effective time of the First Merger, will be eligible to be registered on Form&#160;S<span class="nobreak">-8</span>, whether or not vested, will be converted into an option to purchase shares of ARCA common stock. ARCA will assume Oruka&#8217;s 2024 Equity Incentive Plan and each such outstanding option to purchase shares of Oruka common stock in accordance with the terms (as in effect as of the date of the Merger Agreement) of Oruka&#8217;s 2024 Equity Incentive Plan and the terms of the stock option agreement by which such option to purchase shares of Oruka common stock is evidenced.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, each warrant held by Oruka employees and non<span class="nobreak">-employee</span> directors to purchase shares of Oruka common stock that is outstanding and unexercised immediately prior to the effective time of the First Merger, whether or not vested, will be converted into a warrant to purchase shares of ARCA common stock. ARCA will assume each such outstanding warrant to purchase shares of Oruka common stock in accordance with the terms (as in effect as of the date of the Merger Agreement) of the warrant agreement by which such warrant to purchase shares of Oruka common stock is evidenced. Such Oruka warrants will be eligible to be registered on Form S<span class="nobreak">-8</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The table below sets forth information regarding the Oruka stock options and warrants held as of July<span class="nobreak"> </span>16, 2024 by each of Oruka&#8217;s current executive officers and non<span class="nobreak">-employee</span> directors. The number of shares of common stock underlying such options and the exercise price will be adjusted appropriately to reflect the exchange ratio. All outstanding Oruka stock options and warrants are unvested as of July<span class="nobreak"> </span>16, 2024.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">125</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-34" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Number of</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Unvested</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Warrants <br/>(#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Weighted</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Average</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Exercise&#160;Price</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">of Unvested</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Warrants<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Number of</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Unvested</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Options<br/>(#)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Weighted</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Average</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Exercise&#160;Price</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">of Unvested</span><span class="CharOverride-3" style="font-style:normal;font-weight:bold;text-decoration:underline;"><br/></span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Options<br/>($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Executive Officers</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,850,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.44</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">350,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.44</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">400,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.89</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">150,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.44</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">225,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">175,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.44</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">400,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.89</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Non-Employee Directors</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Peter Harwin</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cameron Turtle</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">15,836</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.44</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Carl Dambkowski</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.44</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.89</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Samarth Kulkarni</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">350,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kristine Ball</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.44</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.96%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">125,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.89</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Management Following the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As described in the section captioned &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Management Following the Merger</span>&#8221; beginning on page 273 of this proxy statement/prospectus certain of Oruka&#8217;s directors and executive officers are expected to become the directors and executive officers of the combined company upon the closing of the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Indemnification and Insurance</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For a discussion of the indemnification and insurance provisions related to the Oruka directors and officers under the Merger Agreement, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Indemnification and Insurance for Directors and Officers</span>&#8221; beginning on page 147 of this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Form of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, and in accordance with the DGCL, (i)&#160;at the First Effective Time, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger and (ii)&#160;as part of the same overall transaction at the completion of the Second Merger (the &#8220;Second Effective Time&#8221;), Oruka will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Merger Consideration and Adjustment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, (i)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing and excluding shares to be canceled pursuant to the Merger Agreement and dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio (described in more detail in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement&#160;&#8212;&#160;Exchange Ratio</span>&#8221; beginning on page 136 of this proxy statement/prospectus), (ii)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the exchange ratio divided by 1,000, in accordance with the terms of the Merger Agreement, (iii)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment based on the exchange ratio as set forth in the Merger Agreement, and (iv)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment based on the exchange ratio as set forth in the Merger Agreement and the form of warrant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No fractional shares of ARCA common stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued. Any fractional shares of ARCA common stock resulting from the conversion of shares of Oruka common stock (including shares of Oruka common stock issued in the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">126</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Oruka pre<span class="nobreak">-closing</span> financing) shall be issued as follows: (i)&#160;one share of ARCA common stock if the aggregate amount of fractional shares of ARCA common stock of any individual holder of Oruka capital stock if upon conversion is equal to or exceeds 0.50 or (ii)&#160;no shares of ARCA common stock if the aggregate amount of fractional shares of ARCA common stock of any individual holder of Oruka capital stock if upon conversion is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of ARCA Series&#160;B Preferred Stock that a holder of Oruka preferred stock would otherwise be entitled to receive will be aggregated with all fractional shares of ARCA preferred stock issuable to such holder and rounded up to the nearest whole share of ARCA&#8217;s convertible preferred stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Procedures for Exchanging Stock Certificates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On or prior to the closing date, ARCA and Oruka will select an exchange agent and, at the First Effective Time (as defined herein), ARCA will deposit with the exchange agent evidence of book<span class="nobreak">-entry</span> shares representing the shares of ARCA common stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) and the shares of ARCA Series&#160;B Preferred Stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Oruka preferred stock calculated in accordance with the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Promptly after the First Effective Time, the exchange agent will mail to each record holder of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) and each record holder of Oruka preferred stock who will receive ARCA Series&#160;B Preferred Stock issuable in exchange for such Oruka preferred stock pursuant to the terms, and calculated in accordance with, the Merger Agreement (i)&#160;a letter of transmittal and (ii)&#160;instructions for surrendering the record holder&#8217;s stock certificates in exchange for the merger consideration. Upon delivery to the exchange agent of a duly executed letter of transmittal in accordance with the exchange agent&#8217;s instructions and the declaration for tax withholding purposes, the surrender of the record holder&#8217;s stock certificates, if applicable, and delivery to the exchange agent of such other documents as may be reasonably required by the exchange agent or ARCA, the record holder of such stock certificates or book<span class="nobreak">-entry</span> shares, as applicable, will be entitled to receive in exchange therefor book<span class="nobreak">-entry</span> shares representing the number of whole shares of ARCA common stock or ARCA Series&#160;B Preferred Stock issuable to such holder pursuant to the Merger Agreement. The surrendered certificates representing shares of Oruka common stock or Oruka preferred stock will be canceled.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the First Effective Time, each certificate representing Oruka common stock or Oruka preferred stock that has not been surrendered will represent only the right to receive shares of ARCA common stock or ARCA Series&#160;B Preferred Stock, as applicable, issuable pursuant to the Merger Agreement to which the holder of any such certificate is entitled.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-indent:24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">HOLDERS OF ORUKA COMMON STOCK OR ORUKA PREFERRED STOCK SHOULD NOT SEND IN THEIR ORUKA STOCK CERTIFICATES UNTIL THEY RECEIVE A LETTER OF TRANSMITTAL FROM THE EXCHANGE AGENT WITH INSTRUCTIONS FOR THE SURRENDER OF ORUKA STOCK CERTIFICATES.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">First Effective Time and Second Effective Time</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement requires the parties to consummate the Merger as promptly as practicable (and in any event within two&#160;business days) after all of the conditions to the consummation of the Merger contained in the Merger Agreement are satisfied or waived, including the adoption of the Merger Agreement by the Oruka stockholders and the approval by the ARCA stockholders of the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and the other transactions proposed under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the closing of the Merger. The First Merger will become effective upon the filing of a certificate of merger (the &#8220;First Certificate of Merger&#8221;) with the Secretary of State of the State of Delaware or at such later time as is agreed by ARCA and Oruka and specified in the First Certificate of Merger. The Second Merger will become effective upon the filing of a certificate of merger (the &#8220;Second Certificate of Merger&#8221;) with the Secretary of State of the State of Delaware or at such later time as is agreed by ARCA and Oruka and specified in the Second Certificate of Merger. Neither ARCA nor Oruka can predict the exact timing of the consummation of the Merger.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">127</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Regulatory Approvals</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the United&#160;States, ARCA must comply with applicable federal and state securities laws and the rules and regulations of Nasdaq in connection with the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka&#8217;s stockholders in connection with the transactions contemplated by the Merger Agreement and the filing of this proxy statement/prospectus with the SEC.&#160;ARCA and Oruka do not intend to seek any regulatory approval from antitrust authorities to consummate the transactions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Material U.S.&#160;Federal Income Tax Consequences of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following discussion is a summary of U.S.&#160;federal income tax consequences of the Merger generally applicable to a U.S.&#160;holder (as defined below) of Oruka common stock or Oruka preferred stock (&#8220;Oruka stock&#8221;). This discussion applies only to a U.S.&#160;holder that holds its Oruka stock as a capital asset for U.S.&#160;federal income tax purposes (generally, property held for investment). This discussion is a summary only and does not discuss all aspects of U.S.&#160;federal income taxation that may be relevant to U.S.&#160;holders in light of their particular circumstances or U.S.&#160;holders with special status, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual funds;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>real estate investment trusts; regulated investment companies; tax<span class="nobreak">-exempt</span> organizations or governmental organizations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pass<span class="nobreak">-through</span> entities such as partnerships, S corporations, disregarded entities for federal income tax purposes and limited liability companies (and investors therein);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that have a functional currency other than the U.S.&#160;dollar;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>taxpayers that are subject to the mark<span class="nobreak">-to-market</span> accounting rules;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who hold their Oruka stock that constitutes &#8220;qualified small business stock&#8221; under Section&#160;1202 of the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that hold their Oruka stock as part of a straddle, constructive sale, hedging, conversion or other integrated or similar transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who exercise dissenters&#8217; rights;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their shares of Oruka stock pursuant to the exercise of options or otherwise as compensation or through a tax<span class="nobreak">-qualified</span> retirement plan or through the exercise of a warrant or conversion rights under convertible instruments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their Oruka stock in a transaction subject to the gain rollover provisions of Section&#160;1045 of the Code; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expatriates or former citizens or long<span class="nobreak">-term</span> residents of the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This discussion is based on the Code, proposed, temporary and final Treasury Regulations promulgated under the Code, and judicial and administrative interpretations thereof, all as of the date hereof and all of which are subject to change, which change could apply retroactively and could affect the tax consequences described herein. This discussion does not address (i)&#160;the tax consequences of the Merger under U.S.&#160;federal non<span class="nobreak">-income</span> tax law (including estate, gift, or other non<span class="nobreak">-income</span> taxes), (ii)&#160;the tax consequences of the Merger under state, local or non<span class="nobreak">-U</span>.S.&#160;tax laws, (iii)&#160;the impact of the alternative minimum tax provisions of the Code (including the 15% minimum tax applicable to the adjusted financial statement income of certain corporations) or the Medicare contribution tax on net investment income, (iv)&#160;the tax consequences of transactions effectuated before, subsequent to or concurrently with the Merger (whether or not any such transactions are consummated in connection with the Merger), including any transaction in which shares of Oruka stock are acquired, or (v)&#160;the tax consequences to holders of Oruka stock options, Oruka warrants or similar rights to acquire Oruka stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has not and does not intend to seek any rulings from the Internal Revenue Service (the &#8220;IRS&#8221;) regarding the Merger. There can be no assurance that the IRS will not take positions inconsistent with the consequences discussed below or that any such positions would not be sustained by a court.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">128</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any entity or arrangement classified as a partnership for U.S.&#160;federal income tax purposes holds Oruka stock, the tax treatment of such partnership and any person treated as a partner of such partnership will generally depend on the status and activities of the partner and the activities of the partnership. Each partnership holding any Oruka stock and each person that is treated as a partner of such partnership should consult its tax advisor as to the particular U.S.&#160;federal income tax consequences of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As used herein, a &#8220;U.S.&#160;holder&#8221; is a beneficial owner of Oruka stock that is, for U.S.&#160;federal income tax purposes:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an individual citizen or resident of the United&#160;States;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a corporation (or other entity that is classified as a corporation for U.S.&#160;federal income tax purposes) that is created or organized (or treated as created or organized) in or under the laws of the United&#160;States, any state thereof, or the District of Columbia or otherwise treated as a U.S.&#160;tax resident for U.S.&#160;federal income tax purposes;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an estate whose income is subject to U.S.&#160;federal income tax regardless of its source; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a trust if (1)&#160;a U.S.&#160;court can exercise primary supervision over the administration of such trust and one or more U.S.&#160;persons have the authority to control all substantial decisions of the trust or (2)&#160;it has a valid election in place to be treated as a U.S.&#160;person.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effects of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the filing of this Registration Statement, Gibson, Dunn &amp; Crutcher LLP, counsel to Oruka, and Wilson Sonsini Goodrich &amp; Rosati, P.C., counsel to ARCA, will each deliver an opinion that the Merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code (the &#8220;Tax Opinions&#8221;). The Tax Opinions will be based on, among other things, certain assumptions stated in the Tax Opinions and in the Registration Statement, as well as on the accuracy, correctness and completeness of certain covenants, representations and statements made by Oruka and ARCA. If any of the assumptions, representations or statements made by Oruka or ARCA are, or become, inaccurate, incorrect or incomplete, or if Oruka or ARCA breach any of their covenants, the Tax Opinions may be invalid and the conclusions reached therein could be jeopardized. Neither ARCA nor Oruka intends to request any ruling from the IRS as to the U.S. federal income tax considerations of the Merger. Consequently, no assurance can be given that the IRS will not challenge the conclusions reflected below or in the Tax Opinions or that a court would not sustain such a challenge.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on the assumptions, qualifications and limitations described herein and in the Tax Opinions, the Merger will qualify as a &#8220;reorganization&#8221; within the meaning of Section 368(a) of the Code. As a result, a U.S. holder of Oruka stock generally will not recognize any gain or loss for U.S. federal income tax purposes upon receipt of ARCA common stock or ARCA Series B Preferred Stock (&#8220;ARCA stock&#8221;) in the Merger, as applicable. Each U.S.&#160;holder&#8217;s aggregate tax basis in the ARCA stock received in the Merger will equal such U.S.&#160;holder&#8217;s aggregate adjusted tax basis in the Oruka stock surrendered in the Merger. The holding period of the ARCA stock received by a U.S.&#160;holder in the Merger will include such U.S.&#160;holder&#8217;s holding period for the Oruka stock surrendered in the Merger. If a U.S.&#160;holder holds different blocks of Oruka stock (generally, Oruka stock acquired on different dates or at different prices), such U.S.&#160;holder is urged to consult his, her or its tax advisor with respect to the determination of the tax bases and/or holding periods of the shares of ARCA stock received in the Merger.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Information Reporting</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each U.S.&#160;holder who receives ARCA stock in the Merger is required to retain permanent records pertaining to the Merger and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property, and relevant facts regarding any liabilities assumed or extinguished as part of such reorganization. Each U.S.&#160;holder who owned immediately before the Merger at least one percent (by vote or value) of the total outstanding stock of Oruka is required to attach a statement to its tax return for the year in which the Merger is consummated that contains the information listed in Treasury Regulation&#160;Section&#160;1.368<span class="nobreak">-3</span>(b). Such statement must include the U.S.&#160;holder&#8217;s tax basis in such U.S.&#160;holder&#8217;s Oruka stock surrendered in the Merger, the fair market value of such Oruka stock, the date of the Merger and the name and employer identification number of each of Oruka and ARCA.&#160;Each U.S.&#160;holder is urged to consult with its tax advisor to comply with these rules.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">129</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">This discussion of U.S.&#160;federal income tax considerations of the Merger is for general information purposes only and is not intended to be, and should not be construed as, tax advice. Determining the actual tax consequences of the Merger to you may be complex and will depend on your specific situation and on factors that are not within ARCA&#8217;s knowledge or control. You should consult your tax advisor with respect to the application of U.S.&#160;federal income tax laws to your specific situation as well as any tax consequences arising under the U.S.&#160;federal estate or gift tax rules or under the laws of any state, local, non</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-U</span></span><span class="Bold" style="font-style:normal;font-weight:bold;">.S.&#160;or other taxing jurisdiction.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Material U.S.&#160;Federal Income Tax Consequences of the Special Cash Dividend to Holders of ARCA Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The following discussion is a summary of the material U.S.&#160;federal income tax considerations generally applicable to U.S.&#160;holder (as defined below) of ARCA common stock who receive the special cash dividend. This section applies only to U.S.&#160;holders that hold their ARCA common stock as capital assets for U.S.&#160;federal income tax purposes (generally, property held for investment). This discussion is a summary only and does not discuss all aspects of U.S.&#160;federal income taxation that may be relevant to U.S.&#160;holders in light of their particular circumstances or status including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual funds;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>real estate investment trusts; regulated investment companies; tax<span class="nobreak">-exempt</span> organizations or governmental organizations; qualified foreign pension funds (or entities wholly owned by one or more qualified foreign pension funds);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that have a functional currency other than the U.S.&#160;dollar;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>taxpayers that are subject to the mark<span class="nobreak">-to-market</span> accounting rules</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who hold shares of ARCA common stock that constitute &#8220;qualified small business stock&#8221; under Section&#160;1202 of the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that hold their ARCA common stock as part of a straddle, constructive sale, hedging, conversion or other integrated or similar transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their shares of ARCA common stock in a transaction subject to the gain rollover provisions under Section&#160;1045 of the Code;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their shares of ARCA common stock pursuant to the exercise of options or otherwise as compensation or through a tax<span class="nobreak">-qualified</span> retirement plan or through the exercise of a warrant or conversion right under convertible instruments; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expatriates or former citizens or long<span class="nobreak">-term</span> residents of the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">This discussion is based on the Code, proposed, temporary and final Treasury Regulations promulgated under the Code, and judicial and administrative interpretations thereof, all as of the date hereof. All of the foregoing is subject to change, which change could apply retroactively and could affect the tax considerations described herein. This discussion does not address U.S.&#160;federal taxes other than those pertaining to U.S.&#160;federal income taxation (such as estate or gift taxes, the alternative minimum tax or the Medicare tax on investment income), nor does it address any aspects of U.S.&#160;state or local or non<span class="nobreak">-U</span>.S.&#160;taxation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">ARCA has not and does not intend to seek any rulings from the IRS regarding the special cash dividend. There can be no assurance that the IRS will not take positions inconsistent with the considerations discussed below or that any such positions would not be sustained by a court.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">If any entity or arrangement classified as a partnership for U.S.&#160;federal income tax purposes holds ARCA common stock, the tax treatment of such partnership and any person treated as a partner of such partnership will generally depend on the status and activities of the partner and the activities of the partnership. Partnerships holding any ARCA common stock and persons that are treated as partners of such partnerships should consult their tax advisors as to the particular U.S.&#160;federal income tax consequences of the special cash dividend to them.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">As used herein, a &#8220;U.S.&#160;holder&#8221; is a beneficial owner of ARCA common stock that is, for U.S.&#160;federal income tax purposes:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an individual who is a citizen or resident of the United&#160;States;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">130</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a corporation (or other entity that is treated as a corporation for U.S.&#160;federal income tax purposes) that is created or organized (or treated as created or organized) in or under the laws of the United&#160;States, any state thereof or the District of Columbia or otherwise treated as a U.S.&#160;tax resident for U.S.&#160;federal income tax purposes;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an estate whose income is subject to U.S.&#160;federal income tax regardless of its source; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a trust if (1)&#160;a U.S.&#160;court can exercise primary supervision over the administration of such trust and one or more U.S.&#160;persons (within the meaning of Section&#160;7701(a)(30)&#160;of the Code) have the authority to control all substantial decisions of the trust or (2)&#160;it has a valid election in place to be treated as a U.S.&#160;person (within the meaning of Section&#160;7701(a)(30)&#160;of the Code).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This discussion assumes that the distribution of the special cash dividend to holders of ARCA common stock will be treated for U.S.&#160;federal income tax purposes as a transaction that is separate and distinct from the Merger and the proposed reverse stock split. If, contrary to that assumption, the distribution of the special cash dividend to a holder of ARCA common stock were integrated for tax purposes with the proposed reverse stock split, this could affect the calculation of the extent to which the distribution constitutes a taxable dividend or capital gain.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Receipt of the Special Cash Dividend by U.S.&#160;Holders</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The distribution of the special cash dividend should be treated first as a dividend to the extent of ARCA&#8217;s current and accumulated earnings and profits, then as a non<span class="nobreak">-taxable</span> return of capital to the extent of the U.S.&#160;holder&#8217;s basis in its ARCA common stock, and then as capital gain from the sale or exchange of ARCA common stock with respect to any remaining value. Such capital gain will be long<span class="nobreak">-term</span> capital gain if the U.S.&#160;holder&#8217;s holding period in the ARCA common stock exceeds one year at the time of the special cash dividend. Preferential tax rates may apply to long<span class="nobreak">-term</span> capital gains of non<span class="nobreak">-corporate</span> U.S.&#160;holders (including individuals). ARCA currently has an accumulated deficit and expects additional losses in the current period. Thus, ARCA expects most or all of the distribution of the special cash dividend to be treated as other than a dividend for U.S.&#160;federal income tax purposes. However, there can be no assurance that it will be so treated.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Information Reporting and Backup Withholding</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A U.S.&#160;holder of ARCA common stock may be subject to information reporting and backup withholding for U.S.&#160;federal income tax purposes with respect to the special cash dividends. Backup withholding will not apply, however, to a U.S.&#160;holder who (i)&#160;furnishes a correct taxpayer identification number and certifies the holder is not subject to backup withholding on IRS Form&#160;W<span class="nobreak">-9</span> or a substantially similar form, or (ii)&#160;certifies the holder is otherwise exempt from backup withholding. If a U.S.&#160;holder does not provide a correct taxpayer identification number on IRS Form&#160;W<span class="nobreak">-9</span> or other proper certification, the stockholder may be subject to penalties imposed by the IRS.&#160;Any amounts withheld under the backup withholding rules may be refunded or allowed as a credit against the federal income tax liability of a U.S.&#160;holder of ARCA common stock, if any, provided the required information is timely furnished to the IRS.&#160;U.S.&#160;holders should consult their tax advisors regarding their qualification for an exemption from backup withholding, the procedures for obtaining such an exemption, and in the event backup withholding is applied, to determine if any tax credit, tax refund or other tax benefit may be obtained.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Nasdaq Stock Market Listing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Shares of ARCA common stock are currently listed on Nasdaq under the symbol &#8220;ABIO.&#8221; ARCA has agreed to use commercially reasonable efforts to (a)&#160;maintain its listing on Nasdaq until the First Effective Time and to obtain approval of the listing of the combined corporation on Nasdaq; (b)&#160;to the extent required by the rules and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of ARCA common stock to be issued in connection with the Merger and transactions contemplated thereunder, and to cause such shares to be approved for listing (subject to official notice of issuance); (c)&#160;prepare and timely submit to Nasdaq a notification form for the proposed reverse stock split (if required) and to submit a copy of the amendment to the ARCA Charter effecting the proposed reverse stock split, certified by the Secretary of State of the State of Delaware, to Nasdaq on the closing date of the Merger; and (d)&#160;to the extent required by Nasdaq Marketplace Rule&#160;5110, assist Oruka in preparing and filing an initial listing application for the ARCA common stock issued to Oruka stockholders </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">131</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">(including any common stock issuable upon conversion of the ARCA Series&#160;B Preferred Stock) (the &#8220;Nasdaq Listing Application&#8221;) and to cause such Nasdaq Listing Application to be conditionally approved prior to the First Effective Time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, under the Merger Agreement, each of ARCA&#8217;s and Oruka&#8217;s obligation to complete the Merger is subject to the satisfaction or waiver by each of the parties, at or prior to the closing of the Merger, of various conditions, including that the Nasdaq Listing Application shall have been approved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Nasdaq Listing Application is approved, ARCA anticipates that the common stock of the combined company will be listed on Nasdaq following the closing of the Merger under the trading symbol &#8220;ORKA.&#8221; In order for the Nasdaq Listing Application to be accepted, among other requirements, the combined company must maintain a bid price of $4.00 or higher for a certain period of time following the proposed reverse stock split.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Anticipated Accounting Treatment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is expected to be treated by ARCA as a reverse merger and will be accounted for as an in<span class="nobreak">-substance</span> reverse recapitalization of ARCA by Oruka in accordance with U.S.&#160;GAAP as, at close, the transaction is, in essence, the issuance of equity for ARCA&#8217;s net asset, which primarily consist of cash and other nominal non<span class="nobreak">-operating</span> assets and liabilities. For accounting purposes, Oruka is considered to be acquiring the assets and liabilities of ARCA in this transaction based on the terms of the Merger Agreement and other factors, including: (i)&#160;Oruka&#8217;s equity holders will own a substantial majority of the voting rights in the combined company; (ii)&#160;Oruka&#8217;s largest stockholder will retain the largest interest in the combined company; (iii)&#160;Oruka will designate all of the initial members of the board of directors of the combined company; and (iv)&#160;Oruka&#8217;s executive management team will become the management of the combined company. The combined company will be named Oruka Therapeutics, Inc. and be headquartered in Menlo Park, California. Accordingly, the Merger is expected to be treated as the equivalent of Oruka issuing stock to acquire the net assets of ARCA.&#160;As a result of the Merger, the net assets of ARCA will be stated at fair value, which approximates carrying value, with no goodwill or other intangible assets recorded, and the historical results of operations prior to the Merger will be those of Oruka. The direct and incremental costs related to the transaction will be treated as a reduction of the net proceeds received within additional paid<span class="nobreak">-in-capital</span>. See the &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information</span>&#8221; elsewhere in this proxy statement/prospectus for additional information.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal Rights and Dissenters&#8217; Rights</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the DGCL, ARCA stockholders are not entitled to appraisal rights in connection with the Merger. Oruka stockholders are entitled to appraisal rights in connection with the Merger under Section&#160;262 of the DGCL.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The discussion below is not a complete summary regarding Oruka&#8217;s stockholders&#8217; appraisal rights under Delaware law and is qualified in its entirety by reference to the text of the relevant provisions of Delaware law, which are attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;J</span> in this proxy statement/prospectus. Stockholders intending to exercise appraisal rights should carefully review <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;J</span>.&#160;Failure to follow precisely any of the statutory procedures set forth in <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;J</span> may result in a termination or waiver of these rights. This summary does not constitute legal or other advice, nor does it constitute a recommendation that Oruka stockholders exercise their appraisal rights under Delaware law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under Section&#160;262, where a merger is adopted by stockholders by written consent in lieu of a meeting of stockholders pursuant to Section&#160;228 of the DGCL, either the constituent corporation before the effective date of such merger or the surviving corporation, within ten&#160;days after the effective date of such merger, must notify each stockholder of the constituent corporation entitled to appraisal rights of the approval of such merger, the effective date of such merger and that appraisal rights are available.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Merger is completed, within ten&#160;days after the effective date of the Merger, Oruka will notify its stockholders that the Merger has been approved, the effective date of the Merger and that appraisal rights are available to any stockholder who has not approved the Merger. Holders of shares of Oruka capital stock who desire to exercise their appraisal rights must deliver a written demand for appraisal to Oruka within 20&#160;days after the date of mailing of that notice, and that stockholder must not have delivered a written consent approving the Merger. A demand for appraisal must reasonably inform Oruka of the identity of the stockholder and that such stockholder intends thereby to demand appraisal of the shares of Oruka capital stock held by such stockholder. Failure to deliver </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">132</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">a written consent approving the Merger will not in and of itself constitute a written demand for appraisal satisfying the requirements of Section&#160;262. All demands for appraisal should be addressed to c/o Oruka Therapeutics, Inc., 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025 and should be executed by, or on behalf of, the record holder of shares of Oruka capital stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ALL DEMANDS MUST BE RECEIVED BY ORUKA WITHIN&#160;20 DAYS AFTER THE DATE ORUKA MAILS A NOTICE TO ITS STOCKHOLDERS NOTIFYING THEM THAT THE MERGER HAS BEEN APPROVED, THE EFFECTIVE DATE OF THE MERGER AND THAT APPRAISAL RIGHTS ARE AVAILABLE TO ANY STOCKHOLDER WHO HAS NOT APPROVED THE MERGER.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you fail to deliver a written demand for appraisal within the time period specified above, you will be entitled to receive the merger consideration for your shares of Oruka capital stock as provided for in the Merger Agreement, but you will have no appraisal rights with respect to your shares of Oruka capital stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To be effective, a demand for appraisal by a holder of shares of Oruka capital stock must be made by, or in the name of, the registered stockholder, fully and correctly, as the stockholder&#8217;s name appears on the stockholder&#8217;s stock certificate(s). Beneficial owners who do not also hold the shares of record may not directly make appraisal demands to Oruka. The beneficial owner must, in these cases, have the registered owner, such as a broker, bank or other custodian, submit the required demand in respect of those shares. If shares are owned of record in a fiduciary capacity, such as by a trustee, guardian or custodian, execution of a demand for appraisal should be made by or for the fiduciary; and if the shares are owned of record by more than one person, as in a joint tenancy or tenancy in common, the demand should be executed by or for all joint owners. An authorized agent, including an authorized agent for two or more joint owners, may execute the demand for appraisal for a stockholder of record; however, the agent must identify the record owner or owners and expressly disclose the fact that, in executing the demand, he or she is acting as agent for the record owner. A record owner, such as a broker, who holds shares as a custodian for others, may exercise the record owner&#8217;s right of appraisal with respect to the shares held for one or more beneficial owners, while not exercising this right for other beneficial owners. In that case, the written demand should state the number of shares as to which appraisal is sought. Where no number of shares is expressly mentioned, the demand will be presumed to cover all shares held in the name of the record owner. In addition, the stockholder must continuously hold the shares of record from the date of making the demand through the effective time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you hold your shares of Oruka capital stock in a brokerage account or in other custodian form and you wish to exercise appraisal rights, you should consult with your bank, broker or other custodian to determine the appropriate procedures for the making of a demand for appraisal by the custodian.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At any time within 60&#160;days after the effective time, any stockholder who has demanded an appraisal, but has neither commenced an appraisal proceeding or joined an appraisal proceeding as a named party, has the right to withdraw such stockholder&#8217;s demand and accept the terms of the Merger by delivering a written withdrawal to Oruka. If, following a demand for appraisal, you have withdrawn your demand for appraisal in accordance with Section&#160;262, you will have the right to receive the merger consideration for your shares of Oruka capital stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Within 120&#160;days after the effective date of the Merger, any stockholder who has delivered a demand for appraisal in accordance with Section&#160;262 will, upon written request to the surviving corporation, be entitled to receive a written statement setting forth the aggregate number of shares not voted in favor of the Merger Agreement and with respect to which demands for appraisal rights have been received and the aggregate number of holders of these shares. This written statement will be mailed to the requesting stockholder within 10&#160;days after the stockholder&#8217;s written request is received by the surviving corporation or within 10&#160;days after expiration of the period for delivery of demands for appraisal, whichever is later. Within 120&#160;days after the effective date of the Merger, either the surviving corporation or any stockholder who has delivered a demand for appraisal in accordance with Section&#160;262 may file a petition in the Delaware Court of Chancery demanding a determination of the fair value of the shares held by all such stockholders. Upon the filing of the petition by a stockholder, service of a copy of the petition must be made upon the surviving corporation. The surviving corporation has no obligation to file a petition in the Delaware Court of Chancery in the event there are dissenting stockholders, and ARCA, which is expected to be the surviving corporation, has no present intent to file a petition in the Delaware Court of Chancery. Accordingly, the failure of a stockholder to file a petition within the period specified could nullify the stockholder&#8217;s previously written demand for appraisal.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">133</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a petition for appraisal is duly filed by a stockholder and a copy of the petition is delivered to the surviving corporation, the surviving corporation will then be obligated, within 20&#160;days after receiving service of a copy of the petition, to provide the Delaware Court of Chancery with a duly verified list containing the names and addresses of all stockholders who have demanded an appraisal of their shares and with whom agreements as to the value of their shares have not been reached by the surviving corporation. After notice to dissenting stockholders who demanded appraisal of their shares, the Delaware Court of Chancery is empowered to conduct a hearing upon the petition, and to determine those stockholders who have complied with Section&#160;262 and who have become entitled to the appraisal rights provided thereby. The Delaware Court of Chancery may require the stockholders who have demanded appraisal for their shares to submit their stock certificates to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any stockholder fails to comply with that direction, the Delaware Court of Chancery may dismiss the proceedings as to that stockholder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">After determination of the stockholders entitled to appraisal of their shares, the Delaware Court of Chancery will appraise the &#8220;fair value&#8221; of the shares owned by those stockholders. This value will be exclusive of any element of value arising from the accomplishment or expectation of the Merger, but may include a fair rate of interest, if any, upon the amount determined to be the fair value. When the value is determined, the Delaware Court of Chancery will direct the payment of the value, with interest thereon accrued during the pendency of the proceeding, if the Delaware Court of Chancery so determines, to the stockholders entitled to receive the same, upon surrender by the holders of the certificates representing those shares. At any time before the entry of judgment in the proceedings, the surviving corporation may pay to each stockholder entitled to appraisal an amount in cash, in which case interest shall accrue thereafter only upon the sum of (i)&#160;the difference, if any, between the amount so paid and the fair value of the shares subject to appraisal as determined by the Delaware Court of Chancery and (ii)&#160;interest theretofore accrued, unless paid at that time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In determining fair value and, if applicable, a fair rate of interest, the Delaware Court of Chancery is required to take into account all relevant factors. In Weinberger v. UOP, Inc., the Delaware Supreme Court discussed the factors that could be considered in determining fair value in an appraisal proceeding, stating that &#8220;proof of value by any techniques or methods which are generally considered acceptable in the financial community and otherwise admissible in court&#8221; should be considered, and that &#8220;fair price obviously requires consideration of all relevant factors involving the value of a company.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Section&#160;262 provides that fair value is to be &#8220;exclusive of any element of value arising from the accomplishment or expectation of the merger.&#8221; In Cede&#160;&amp; Co. v. Technicolor, Inc., the Delaware Supreme Court stated that this exclusion is a &#8220;narrow exclusion [that] does not encompass known elements of value,&#8221; but which rather applies only to the speculative elements of value arising from such accomplishment or expectation. In Weinberger, the Delaware Supreme Court construed Section&#160;262 to mean that &#8220;elements of future value, including the nature of the enterprise, which are known or susceptible of proof as of the date of the merger and not the product of speculation, may be considered.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">You should be aware that the fair value of your shares as determined under Section&#160;262 could be more than, the same as, or less than the value that you are entitled to receive under the terms of the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Costs of the appraisal proceeding may be imposed upon the surviving corporation and the stockholders participating in the appraisal proceeding by the Delaware Court of Chancery as the Court deems equitable in the circumstances. Upon the application of a stockholder, the Delaware Court of Chancery may order all or a portion of the expenses incurred by any stockholder in connection with the appraisal proceeding, including, without limitation, reasonable attorneys&#8217; fees and the fees and expenses of experts, to be charged pro rata against the value of all shares entitled to appraisal. In the absence of such a determination of assessment, each party bears its own expenses. Any stockholder who had demanded appraisal rights will not, after the effective time, be entitled to vote shares subject to that demand for any purpose or to receive payments of dividends or any other distribution with respect to those shares, other than with respect to payment as of a record date prior to the effective time; however, if no petition for appraisal is filed within 120&#160;days after the effective time, or if the stockholder delivers a written withdrawal of his or her demand for appraisal and an acceptance of the terms of the Merger within 60&#160;days after the effective time, then the right of that stockholder to appraisal will cease and that stockholder will be entitled to receive the merger consideration for shares of his or her Oruka capital stock pursuant to the Merger Agreement. Any withdrawal of a demand for appraisal made more than 60&#160;days after the effective time may only be made with the written approval of the surviving corporation. No appraisal proceeding in the Delaware Court of Chancery will be dismissed as to any stockholder without the approval of the court.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Failure to follow the steps required by Section&#160;262 for perfecting appraisal rights may result in the loss of appraisal rights. In view of the complexity of Section&#160;262, stockholders who may wish to dissent from the Merger and pursue appraisal rights should consult their legal advisors.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">134</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T21"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">THE MERGER AGREEMENT</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The following is a summary of the material terms of the Merger Agreement. A copy of the Merger Agreement is attached to this proxy statement/prospectus as Annex&#160;A and is incorporated by reference into this proxy statement/prospectus. The Merger Agreement has been attached to this proxy statement/prospectus to provide you with information regarding its terms. It is not intended to provide any other factual information about ARCA, Oruka, First Merger Sub or Second Merger Sub. The following description does not purport to be complete and is qualified in its entirety by reference to the Merger Agreement. You should refer to the full text of the Merger Agreement for details of the Merger and the terms and conditions of the Merger Agreement.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement contains representations and warranties that ARCA, First Merger Sub and Second Merger Sub, on the one hand, and Oruka, on the other hand, have made to one another as of specific dates. These representations and warranties have been made for the benefit of the other parties to the Merger Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if those statements prove to be incorrect. In addition, the assertions embodied in the representations and warranties are qualified by information in confidential disclosure letters exchanged by the parties in connection with signing the Merger Agreement. While ARCA and Oruka do not believe that these disclosure letters contain information required to be publicly disclosed under the applicable securities laws, other than information that has already been so disclosed, the disclosure letters do contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the attached Merger Agreement. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about ARCA or Oruka, because they were made as of specific dates, may be intended merely as a risk allocation mechanism between ARCA, First Merger Sub, Second Merger Sub and Oruka and are modified by the disclosure letters.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Structure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, and in accordance with Delaware law, at the closing of the Merger, First Merger Sub, a wholly owned subsidiary of ARCA formed by ARCA in connection with the Merger, will merge with and into Oruka, with Oruka surviving as a wholly owned subsidiary of ARCA, and immediately following such Merger, and as part of the same overall transaction, Oruka will merge with and into Second Merger Sub and with Second Merger Sub being the surviving entity of such Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Completion and Effectiveness of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement requires the parties to consummate the Merger as promptly as practicable (and in any event within two&#160;business days) after all of the conditions to the consummation of the Merger contained in the Merger Agreement are satisfied or waived, including the adoption of the Merger Agreement by the Oruka stockholders and the approval by the ARCA stockholders of the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and the other transactions proposed under the Merger Agreement, other than those conditions that by their nature are to be satisfied at the closing of the Merger. The Merger will become effective upon the filing of certificates of Merger with the Secretary of State of the State of Delaware or at such later time as is agreed by ARCA and Oruka and specified in the certificates of Merger. Neither ARCA nor Oruka can predict the exact timing of the consummation of the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Merger Consideration</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the First Effective Time, upon the terms and subject to the conditions set forth in the Merger Agreement, each share of Oruka common stock (including any shares of Oruka common stock issued pursuant to Oruka&#8217;s pre<span class="nobreak">-closing</span> financing) outstanding immediately prior to the First Effective Time (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA common stock equal to the exchange ratio described in more detail below, and each share of Oruka&#8217;s preferred stock outstanding immediately prior to the First Effective Time (excluding shares to be canceled pursuant to the Merger Agreement and excluding dissenting shares) will be automatically converted solely into the right to receive a number of shares of ARCA&#8217;s convertible preferred stock equal to (x)&#160;the exchange ratio described in more details below <span class="Italic" style="font-style:italic;font-weight:normal;">divided by</span> (y)&#160;1,000. No fractional shares of ARCA common stock will be issued in connection with the Merger, and no certificates or scrip for any such fractional shares will be issued. Any fractional shares of ARCA common stock resulting from the conversion of shares of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre<span class="nobreak">-closing</span> financing) shall </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">135</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">be issued as follows: (i)&#160;one share of ARCA common stock if the aggregate amount of fractional shares of ARCA common stock of any individual holder of Oruka capital stock if upon conversion is equal to or exceeds 0.50 or (ii)&#160;no shares of ARCA common stock if the aggregate amount of fractional shares of ARCA common stock of any individual holder of Oruka capital stock if upon conversion is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of ARCA Series&#160;B Preferred Stock would otherwise be entitled to receive will be aggregated with all fractional shares of ARCA preferred stock issuable to such holder and rounded up to the nearest whole share of ARCA&#8217;s convertible preferred stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exchange Ratio</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The exchange ratio is calculated using a formula intended to allocate existing ARCA and Oruka securityholders a percentage of the combined company. Based on ARCA&#8217;s and Oruka&#8217;s capitalization as of July<span class="nobreak"> </span>16, 2024, the exchange ratio was estimated to be equal to approximately 6.8699<span class="nobreak"> </span>shares of ARCA common stock. This estimate is subject to adjustment prior to closing of the First Merger for net cash as of 11:59&#160;p.m. Eastern Time on the business&#160;day prior to the anticipated closing date (and as a result, ARCA securityholders could own less, and Oruka securityholders (including, for this purpose, investors in the Oruka pre<span class="nobreak">-closing</span> financing) could own more, or vice versa, of the combined company). ARCA management currently anticipates that ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on the estimates set forth above, after giving effect to the Oruka pre<span class="nobreak">-closing</span> financing, and certain other assumptions, immediately following the completion of the Merger, ARCA securityholders would own approximately 2.39% of the capital stock of the combined company post<span class="nobreak">-Merger</span>, and Oruka securityholders, including shares of Oruka common stock and Oruka warrants purchased in the Oruka pre<span class="nobreak">-closing</span> financing, would own approximately 97.61% of the capital stock of the combined company post<span class="nobreak">-Merger</span>. Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down including, but not limited to, if ARCA&#8217;s net cash as of closing is lower than $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection. There can be no assurances any of these assumptions will be accurate at closing when the final exchange ratio is determined. For more information on the Oruka pre<span class="nobreak">-closing</span> financing, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger &#8212; Subscription Agreement</span>&#8221; beginning on page 153 in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The exchange ratio formula is the quotient obtained (rounded to four decimal places) by dividing the number of Oruka merger shares (defined below) by the Oruka outstanding shares (defined below), in which:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Aggregate valuation&#8221; means the sum of (i)&#160;the Oruka valuation plus (ii)&#160;the ARCA valuation.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Oruka allocation percentage&#8221; means the percentage (rounded to four decimal places) determined by subtracting the ARCA allocation percentage from 100%.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Oruka merger shares&#8221; means the product determined by multiplying (i)&#160;the post<span class="nobreak">-closing</span> ARCA shares by (ii)&#160;the Oruka allocation percentage.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Oruka outstanding shares&#8221; means, without duplication, the total number of shares of Oruka capital stock outstanding immediately prior to the First Effective Time, (including any shares of Oruka common stock or Oruka preferred stock that are issued in, or issuable upon the exercise or conversion of securities issued in, the Oruka pre<span class="nobreak">-closing</span> financing), expressed on a fully diluted and as<span class="nobreak">-converted-to-Oruka</span> common stock basis, assuming, without limitation or duplication, the exercise of all options and warrants to acquire Oruka&#8217;s capital stock and other rights or commitments to receive shares of Oruka common stock or Oruka preferred stock (or securities convertible or exercisable into shares of Oruka common stock or Oruka preferred stock, including the convertible promissory note convertible into Oruka common stock), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time. The calculation of Oruka outstanding shares:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>excludes, to avoid the double<span class="nobreak">-counting</span> of, any shares of Oruka common stock or Oruka preferred stock (or securities convertible or exercisable into shares of Oruka common stock or Oruka preferred stock, including any convertible promissory note convertible into Oruka common stock) to the extent such shares or securities are contributed as consideration in the Oruka pre<span class="nobreak">-closing</span> financing; and</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">136</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>includes to the extent not already issued prior to the First Effective Time, (i)&#160;any shares of Oruka common stock or Oruka preferred stock (or securities convertible or exercisable into shares of Oruka common stock or Oruka preferred stock) issuable to the &#8220;Paragon Entities&#8221; (as such term is defined in Oruka&#8217;s organizational documents) as a result of the contemplated transactions pursuant to Oruka&#8217;s organizational documents and (ii)&#160;any shares of Oruka common stock or Oruka preferred stock (or securities convertible or exercisable into shares of Oruka common stock or Oruka preferred stock) issuable pursuant to an offer letter set forth in the Oruka disclosure letter.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Oruka valuation&#8221; means (i)&#160;$175&#160;million <span class="Italic" style="font-style:italic;font-weight:normal;">plus</span> (ii)&#160;the amount of proceeds actually received by Oruka from the Oruka pre<span class="nobreak">-closing</span> financing (including in the proceeds actually received from any convertible promissory notes convertible into Oruka common stock, and any interest thereon, contributed as consideration in the Oruka pre<span class="nobreak">-closing</span> financing).</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;ARCA allocation percentage&#8221; means the quotient (expressed as a percentage and rounded to four decimal places) determined by dividing (i)&#160;the ARCA valuation by (ii)&#160;the aggregate valuation.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;ARCA outstanding shares&#8221; means, without duplication, (including, without limitation, the effects of any reverse split, if completed) the total number of shares of ARCA common stock outstanding immediately prior to the First Effective Time expressed on a fully<span class="nobreak">-diluted</span> basis, and assuming, without limitation or duplication, the issuance of shares of ARCA common stock in respect of all options, warrants or other rights or commitments to receive shares of ARCA common stock or ARCA preferred stock (or securities convertible or exercisable into shares of ARCA common stock or ARCA preferred stock, but excluding any ARCA convertible preferred stock issuable as a result of the Merger), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time other than options to acquire shares of ARCA common stock to the extent cancelled at or prior to closing under Section&#160;6.6(c)&#160;of the Merger Agreement.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;ARCA valuation&#8221; means (i)&#160;$11,000,000, minus (ii)&#160;the amount by which ARCA net cash is less than $5,000,000 (if any).</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;Post<span class="nobreak">-closing</span> ARCA shares&#8221; means the quotient determined by dividing (i)&#160;the ARCA outstanding shares by (ii)&#160;the ARCA allocation percentage. The estimated exchange ratio for purposes of the unaudited pro forma condensed combined financial information was derived on a fully<span class="nobreak">-diluted</span> basis as of March<span class="nobreak">&#160;</span>31, 2024 using a stipulated value of Oruka of approximately $175&#160;million (excluding the Oruka pre<span class="nobreak">-closing</span> financing) and of ARCA of approximately $11&#160;million. For more information, see &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Unaudited Pro Forma Condensed Combined Financial Information.</span>&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Calculation of ARCA&#8217;s Net Cash</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the terms of the Merger Agreement, ARCA&#8217;s &#8220;net cash&#8221; means, as of 11:59&#160;p.m. Eastern Time on the last business&#160;day prior to the anticipated closing date, the sum (without duplication) of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s unrestricted cash and cash equivalents and marketable securities determined, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in ARCA&#8217;s SEC filings or ARCA&#8217;s balance sheet;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Certain ARCA prepaid expenses set forth in ARCA&#8217;s disclosure letter; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>All receivables which ARCA and Oruka may mutually agree are recoverable by or provide benefit to ARCA after the First Effective Time (if any).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-style:italic;font-weight:normal;text-decoration:underline;">minus</span> the sum (without duplication) of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s consolidated short<span class="nobreak">-term</span> and long<span class="nobreak">-term</span> contractual obligations and liabilities accrued at the closing date, in each case determined in accordance with GAAP and, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the ARCA&#8217;s SEC reports and its balance sheet;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">137</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The aggregate amount (without duplication) of all fees and expenses incurred by ARCA prior to the First Effective Time in connection with the contemplated transactions or the sale of ARCA&#8217;s legacy business, in each case, to the extent unpaid as of the First Effective Time, including;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any fees and expenses of legal counsel, accountants, financial advisors, investment bankers, brokers, consultants, tax advisors, and other professional advisors of ARCA in connection with the transactions contemplated by the Merger Agreement or the sale of ARCA&#8217;s legacy business;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>50% of the fees paid to the SEC in connection with filing this registration statement and any amendments and supplements thereto, with the SEC;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>50% of the fees and expenses in connection with the printing, mailing and distribution of this proxy statement and any amendments and supplements thereto;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>50% of the fees associated with the filing of Oruka&#8217;s initial listing application with Nasdaq;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any bonus, retention payments, severance, change<span class="nobreak">-in-control</span> payments or similar payment obligations (including payments with &#8220;single<span class="nobreak">-trigger</span>&#8221; provisions triggered at and as of the consummation of the transactions contemplated hereby) that become due or payable to any director, officer, employee or consultant in connection with the consummation of the contemplated transactions or the sale of ARCA&#8217;s legacy business, together with any payroll taxes associated therewith;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the dividend by ARCA of any excess net cash (but only to the extent declared and unpaid) and all costs and expenses associated therewith; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs associated with obtaining the &#8220;D&amp;O tail policy&#8221; pursuant to Section&#160;6.7 of the Merger Agreement.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>All remaining rent payments and any other liabilities under ARCA&#8217;s lease obligations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Any unpaid taxes of ARCA and its subsidiaries for tax periods (or portions thereof) ending on or before the closing date;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>All costs and expenses to be mutually agreed by ARCA and Oruka relating to the winding down of ARCA&#8217;s legacy business, including the sale, license or other disposition of any or all of ARCA&#8217;s legacy business to the extent unpaid as of the closing; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The amounts due and payable to holders of options to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the Parent Closing Price that are cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such options, in accordance with the Merger Agreement, to the extent unpaid as of the First Effective Time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No later than five&#160;business days prior to the anticipated closing date, (i)&#160;ARCA will deliver to Oruka a net cash schedule setting forth, in reasonable detail, ARCA&#8217;s good faith estimated calculation of its net cash and (ii)&#160;Oruka will deliver to ARCA a Oruka valuation schedule setting forth, in reasonable detail, Oruka&#8217;s good faith estimated calculations of the components of Oruka&#8217;s valuation, in each case, as of 11:59&#160;p.m. Eastern Time on the last business&#160;day prior to the anticipated closing date, prepared and certified by ARCA&#8217;s and Oruka&#8217;s chief financial officer (or if there is no chief financial officer, the principal financial and accounting officer), as the case may be, and, if requested, the relevant work papers and back<span class="nobreak">-up</span> materials used or useful in preparing the net cash schedule and Oruka valuation schedule, respectively. No later than three&#160;business days after delivery of such net cash schedule (the last&#160;day of such period referred to as the response date), Oruka will have the right to dispute any part of the net cash schedule by delivering a written notice to that effect to ARCA (referred to herein as a dispute notice). Any dispute notice will identify, in reasonable detail and, to the extent known, the nature and amounts of any proposed revisions to ARCA&#8217;s net cash calculation. No later than three&#160;business days after delivery of such Oruka valuation schedule (the last&#160;day of such period referred to as the response date), ARCA will have the right to dispute any part of such schedule by delivering a written notice to that effect to Oruka (referred to herein as an Oruka valuation dispute notice). Any dispute notice will identify, in reasonable detail and, to the extent known, the nature and amounts of any proposed revisions to Oruka&#8217;s valuation calculation.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">138</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka disputes the net cash schedule or ARCA disputes the Oruka valuation schedule, the parties shall attempt in good faith to resolve the disputed items and negotiate an agreed<span class="nobreak">-upon</span> determination of net cash and/or Oruka&#8217;s valuation, as the case may be. If the parties are unable to negotiate an agreed<span class="nobreak">-upon</span> determination of the disputed items or component thereof within three&#160;days after the delivery of the relevant dispute notice, any remaining disagreements will be referred to an independent auditor of recognized national standing mutually agreed upon by ARCA and Oruka. The determination of the amount of net cash or Oruka valuation made by such auditor shall be final and binding on ARCA and Oruka.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s net cash balance is subject to numerous factors, some of which are outside of ARCA&#8217;s control. The actual amount of net cash will depend significantly on the timing of the closing of the Merger. In addition, the closing of the Merger could be delayed if ARCA and Oruka are not able to agree upon the amount of ARCA&#8217;s net cash as of 11:59&#160;p.m. Eastern Time on the last business&#160;day prior to the anticipated closing date.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, each option to purchase shares of Oruka common stock that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be assumed and converted into an option to purchase shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Oruka stock option assumed by ARCA may be exercised solely for shares of ARCA common stock; (ii)&#160;the number of shares of ARCA common stock subject to each outstanding Oruka stock option assumed by ARCA will be determined by multiplying (A)&#160;the number of shares of Oruka common stock that were subject to such Oruka stock option assumed by ARCA, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of ARCA common stock; and (iii)&#160;the per share exercise price of each Oruka stock option assumed by will be determined by dividing (A)&#160;the per share exercise price of such Oruka stock option, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent. Each Oruka stock option assumed by ARCA will otherwise continue in full force and effect and the term, exercisability, vesting schedule, acceleration rights and other terms and conditions of such Oruka stock option will otherwise remain unchanged.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To the extent provided under the terms of a Oruka stock option assumed by ARCA in accordance with the terms of the Merger Agreement, such Oruka stock option shall, in accordance with its terms, be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of ARCA common stock subsequent to the First Effective Time. In addition, ARCA&#8217;s board of directors or a committee thereof will succeed to the authority and responsibility of Oruka&#8217;s board of directors or any committee thereof with respect to each Oruka option assumed by ARCA in accordance with the terms of the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Warrants</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, each warrant to purchase shares of Oruka capital stock (including any pre<span class="nobreak">-funded</span> Oruka warrants issued pursuant to the Oruka pre<span class="nobreak">-closing</span> financing) that is outstanding and unexercised immediately prior to the First Effective Time, whether or not vested, will be converted into a warrant to purchase shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accordingly, from and after the First Effective Time: (i)&#160;each outstanding Oruka warrant assumed by ARCA may be exercised solely for shares of ARCA common stock; (ii)&#160;the number of shares of ARCA common stock subject to each outstanding Oruka warrant assumed by ARCA will be determined by multiplying (A)&#160;the number of shares of Oruka common stock issuable upon exercise of the Oruka warrant that were subject to such Oruka warrant, as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio, and rounding the resulting number down to the nearest whole number of shares of ARCA common stock; and (iii)&#160;the per share exercise price for the ARCA common stock issuable upon exercise of each Oruka warrant assumed by ARCA will be determined by dividing (A)&#160;the per share exercise price of ARCA common stock subject to such Oruka warrant as in effect immediately prior to the First Effective Time, by (B)&#160;the exchange ratio and rounding the resulting exercise price up to the nearest whole cent. Each Oruka warrant assumed by ARCA will otherwise continue in full force and effect and the term, any restriction on the exercise and other provisions of such Oruka warrant will otherwise remain unchanged.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">139</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To the extent provided under the terms of a Oruka warrant assumed by ARCA in accordance with the terms of the Merger Agreement, such Oruka warrant shall, in accordance with its terms, be subject to further adjustment as appropriate to reflect any stock split, division or subdivision of shares, stock dividend, reverse stock split, consolidation of shares, reclassification, recapitalization or other similar transaction with respect to shares of ARCA common stock subsequent to the First Effective Time. In addition, ARCA&#8217;s board of directors or a committee thereof will succeed to the authority and responsibility of Oruka&#8217;s board of directors or any committee thereof with respect to each Oruka warrant assumed by ARCA in accordance with the terms of the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA Common Stock and ARCA Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except as contemplated by the proposed increase in the number of authorized shares of ARCA common stock described in Proposal No. 2 of this proxy statement/prospectus and<span class="Superscript" style="vertical-align:super;"> </span>the proposed reverse stock split of issued and outstanding ARCA common stock described in Proposal&#160;No. 3 of this proxy statement/prospectus, ARCA common stock will remain unaffected by the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, prior to the closing of the Merger, ARCA&#8217;s board of directors will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option to acquire shares of ARCA&#8217;s common stock with an exercise price per share greater than the Parent Closing Price, in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, (i)&#160;each option to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the volume weighted average closing trading price of a share of ARCA common stock on Nasdaq for the five (5)&#160;consecutive&#160;trading days ending three (3)&#160;days immediately prior to the closing date of the First Merger (the &#8220;Parent Closing Price&#8221;) will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option and (ii)&#160;each other option to acquire shares of ARCA&#8217;s common stock will be cancelled for no consideration.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Procedures for Exchanging Oruka Stock Certificates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the closing date of the First Merger, ARCA will select an exchange agent and, at the First Effective Time, ARCA will deposit with the exchange agent evidence of book<span class="nobreak">-entry</span> shares representing the shares of ARCA common stock and ARCA Series&#160;B Preferred Stock issuable pursuant to the terms of the Merger Agreement in exchange for shares of Oruka common stock and Oruka preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Promptly after the First Effective Time, the exchange agent will mail to each record holder of Oruka common stock or Oruka preferred stock (i)&#160;a letter of transmittal and (ii)&#160;instructions for surrendering the record holder&#8217;s stock certificates in exchange for the Merger consideration. Upon delivery to the exchange agent of a duly executed letter of transmittal in accordance with the exchange agent&#8217;s instructions and the declaration for tax withholding purposes, the surrender of the record holder&#8217;s stock certificates, if applicable, and delivery to the exchange agent of such other documents as may be reasonably required by the exchange agent or ARCA, the record holder of such stock certificates or book<span class="nobreak">-entry</span> shares, as applicable, will be entitled to receive in exchange therefor book<span class="nobreak">-entry</span> shares representing the number of whole shares of ARCA common stock issuable to such holder pursuant to the Merger Agreement. The surrendered certificates representing shares of Oruka common stock or Oruka preferred stock will be canceled.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the First Effective Time, each certificate representing Oruka common stock or Oruka preferred stock that has not been surrendered will represent only the right to receive shares of ARCA common stock or preferred stock (as applicable) issuable pursuant to the Merger Agreement to which the holder of any such certificate is entitled.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">HOLDERS OF ORUKA COMMON STOCK OR ORUKA PREFERRED STOCK SHOULD NOT SEND IN THEIR ORUKA STOCK CERTIFICATES UNTIL THEY RECEIVE A LETTER OF TRANSMITTAL FROM THE EXCHANGE AGENT WITH INSTRUCTIONS FOR THE SURRENDER OF ORUKA STOCK CERTIFICATES.</span></p>
		</div>


		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">140</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Directors and Officers of ARCA Following the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Merger Agreement, each of the directors and officers of ARCA will resign effective as of the First Effective Time and ARCA&#8217;s board of directors will thereafter consist of a total of six new directors designated by Oruka. Oruka has designated Lawrence Klein, Kristine Ball, Carl Dambkowski, Cameron Turtle, Peter Harwin, and Samarth Kulkarni to serve as members of ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, upon the closing of the Merger, Lawrence Klein will serve as Chief Executive Officer and President, Arjun Agarwal will serve as Senior Vice President, Finance and Treasurer, Joana Goncalves will serve as Chief Medical Officer, and Paul Quinlan will serve as General Counsel and Secretary.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amendment of the Amended and Restated Certificate of Incorporation of ARCA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA agreed to amend its amended and restated certificate of incorporation to (i)&#160;change ARCA&#8217;s name to &#8220;Oruka Therapeutics, Inc.&#8221;, (ii)&#160;effect the proposed reverse stock split, if needed, (iii)&#160;authorize a sufficient number of shares of common stock to issue the Merger consideration and (iv)&#160;increase the number of shares of ARCA common stock that ARCA is authorized to the amount proposed in this Proxy Statement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Representations and Warranties</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains customary representations and warranties of ARCA, First Merger Sub and Second Merger Sub, on one hand, and Oruka, on the other hand, for a transaction of this type relating to, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>corporate organization and power, and similar corporate matters;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>due organization;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>subsidiaries;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>organizational documents;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>authority to enter into the Merger Agreement and the related agreements;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>votes required for completion of the Merger and approval of the proposals that will come before the ARCA special meeting of stockholders and that will be the subject of the Oruka stockholder approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>except as otherwise specifically disclosed in the Merger Agreement, the fact that the consummation of the Merger would not contravene the organizational documents, certain laws, governmental authorizations or certain contracts of the parties; result in any encumbrances on the parties&#8217; assets or require the consent of any third party;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the parties&#8217; efforts with respect to ensuring the inapplicability of Section&#160;203 of the DGCL and other similar takeover laws;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>capitalization;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>financial statements and, with respect to ARCA, documents filed with the SEC and the accuracy of information contained in those documents;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>material changes or events;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>liabilities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>title to assets;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>real property and leaseholds;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>intellectual property;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>material contracts;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">141</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the validity of material contracts to which the parties or their subsidiaries are a party and any violation, default or breach of such contracts;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>regulatory compliance, permits and restrictions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>legal proceedings and orders;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>tax matters;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>employee and labor matters and benefit plans;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>environmental matters;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>insurance;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>financial advisors fees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>certain transactions or relationships with affiliates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>privacy and data security;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>with respect to ARCA, the valid issuance in the Merger of ARCA common stock; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>with respect to Oruka, the lack of ownership of ARCA&#8217;s common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The representations and warranties are, in many respects, qualified by materiality and knowledge, and will not survive the Merger. The accuracy of the representations and warranties of the Company form the basis of certain of the conditions to the obligations of ARCA and Oruka to complete the Merger, subject to materiality thresholds.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Covenants; Conduct of Business Pending the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has agreed that, except as permitted by the Merger Agreement, as required by law, or unless Oruka has provided written consent, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement, ARCA and its subsidiaries will use commercially reasonable efforts to conduct their business and operations in the ordinary course consistent with past practices and in compliance with all applicable laws, regulations and certain material contracts. ARCA has also agreed that, subject to certain limited exceptions, without the consent of Oruka, it will not, and will not cause or permit any of its subsidiaries to, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of capital stock; or repurchase, redeem or otherwise reacquire any shares of capital stock or other securities (except for shares of ARCA common stock from terminated employees, directors or consultants of ARCA);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of any capital stock or other security (except for ARCA common stock issued upon the valid exercise of outstanding ARCA options or ARCA RSUs), any option, warrant or right to acquire any capital stock or any other security or any instrument convertible into or exchangeable for any capital stock or other security;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>except as required to give effect to anything in contemplation of the closing, amend the certificate of incorporation, bylaws or other similar organizational documents of ARCA or its subsidiaries, or effect or be a party to any Merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except as related to the transactions contemplated in the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>form any subsidiary or acquire any equity interest or other interest in any other entity or enter into any joint venture with any other entity;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">142</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>lend money to any person or entity; incur or guarantee any indebtedness for borrowed money; guarantee any debt securities of others; or make any capital expenditure or commitment in excess of $25,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>adopt, establish or enter into certain agreements, plans or arrangements relating to employment or benefits matters; cause or permit any such agreement, plan or arrangement to be amended other than as required by law or in order to make amendments for purposes of Section&#160;409A of the Code; pay any bonus or make any profit<span class="nobreak">-sharing</span> or similar payment to, or increase the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its directors, officers, employees or independent contractors; increase the severance or change of control benefits offered to any current or new employees, directors or consultants; or hire any officer, employee or consultant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant any encumbrance with respect to such assets or properties;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>sell, assign, transfer, license, sublicense or otherwise dispose of any material intellectual property rights of ARCA (other than pursuant to non<span class="nobreak">-exclusive</span> licenses in the ordinary course of business);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other than in the ordinary course of business: make, change or revoke any material tax election; file any amended income or other material tax return; adopt or change any material accounting method in respect of taxes; enter into any material tax closing agreement or settle any material tax claim or assessment; consent to any extension or waiver of the limitation period applicable to or relating to any material tax claim or assessment; or surrender any material claim for refund;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>waive, settle or compromise any pending or threatened legal proceeding against ARCA or any of its subsidiaries, other than waivers, settlements or agreements for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and that do not impose any material restrictions on the operations or businesses of ARCA or its subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by ARCA or any of its subsidiaries;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>delay or fail to repay when due any material obligation, including accounts payable and accrued expenses;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>forgive any loans to any person, including its employees, officers, directors or affiliate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>terminate or modify in any material respect, or fail to exercise renewal rights to, any material insurance policy;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>materially change pricing or royalties or other payments set or charged by ARCA or any of subsidiaries to its customers or licensees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>agree to materially change pricing or royalties or other payments set or charged by persons who have licensed intellectual property to ARCA or any of subsidiaries;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>enter into, amend in a manner adverse to ARCA or terminate any of ARCA&#8217;s material contracts outside the ordinary course of business; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>agree, resolve or commit to do any of the foregoing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Notwithstanding the foregoing restrictions, ARCA is expressly permitted to engage in the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or winding down of its legacy business (including terminating its real estate leases and other contracts) and is expressly permitted to declare and pay a dividend on the shares of ARCA common stock outstanding prior to the First Effective Time (excluding for the avoidance of doubt any shares of ARCA&#8217;s common stock issuable pursuant to the Merger), up to an amount equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash at the First Effective Time will exceed $5.0&#160;million.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">143</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has agreed that, except as permitted by the Merger Agreement, as required by law, or unless ARCA shall have provided its written consent, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement, Oruka will use commercially reasonable efforts to conduct its business and operations in the ordinary course consistent with past practices and in compliance with all applicable laws, regulations and certain contracts. Oruka has also agreed that, subject to certain limited exceptions, without the consent of ARCA, it will not, and will not cause or permit its subsidiary to, during the period commencing on the date of the Merger Agreement and continuing until the earlier to occur of the First Effective Time and the termination of the Merger Agreement:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of capital stock; or repurchase, redeem or otherwise reacquire any shares of capital stock or other securities (except for shares of common stock from terminated employees, directors or consultants of Oruka);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>except as required to give effect to anything in contemplation of the closing, amend the certificate of incorporation, bylaws or other organizational documents of Oruka or its subsidiaries, or effect or be a party to any Merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except as related to the transactions contemplated in the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other than in the ordinary course of its business, sell, issue, grant, pledge or otherwise dispose of or encumber or authorize any of the foregoing actions with respect to more than 25% of the shares of Oruka capital stock outstanding as of the date the Merger Agreement was signed: any capital stock or other security of Oruka or its subsidiaries (except for shares of outstanding Oruka common stock issued upon the valid exercise or settlement of Oruka options or warrants in accordance with their terms as in effect as of the date of the Merger Agreement); any option, warrant or right to acquire any capital stock or any other security; or any instrument convertible into or exchangeable for any capital stock or other security of Oruka or its subsidiaries;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>other than in the ordinary course of its business, acquire any equity interest or other interest in any other entity or enter into a joint venture with any other entity;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>lend money to any person or entity; incur or guarantee any indebtedness for borrowed money; guarantee any debt securities of others;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>acquire any material asset or sell, lease or otherwise irrevocably dispose of any of its assets or properties, or grant any encumbrance with respect to such assets or properties, except in the ordinary course of business;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>sell, assign, transfer, license, sublicense or otherwise dispose of any material intellectual property rights owned by Oruka, other than pursuant to non<span class="nobreak">-exclusive</span> licenses in the ordinary course of business;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>waive, settle or compromise any pending or threatened legal proceeding against Oruka, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B)&#160;that do not impose any material restrictions on the operations or businesses of Oruka or any equitable relief on, or the admission of wrongdoing by Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>enter into, amend in a manner adverse to Oruka or terminate any material contract outside of the ordinary course of its business; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>agree, resolve or commit to do any of the foregoing.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">144</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Non-Solicitation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka have agreed that, except as described below, ARCA and Oruka and any of their respective subsidiaries will not, nor will either party or any of its subsidiaries authorize any of the directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors or representatives retained by it or any of its subsidiaries to, directly or indirectly:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of, any Acquisition Proposal or Acquisition Inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>furnish any non<span class="nobreak">-public</span> information with respect to it to any person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>engage in discussions or negotiations with any person with respect to any Acquisition Proposal or Acquisition Inquiry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>execute or enter into any letter of intent or any contract contemplating or otherwise relating to an Acquisition Proposal; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>publicly propose to do any of the foregoing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An &#8220;Acquisition Inquiry&#8221; means, with respect to a party, an inquiry, indication of interest or request for non<span class="nobreak">-public</span> information (other than an inquiry, indication of interest or request for information made or submitted by Oruka, on the one hand, or ARCA on the other hand, to the other party) that would reasonably be expected to lead to an Acquisition Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An &#8220;Acquisition Proposal&#8221; means, with respect to a party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of Oruka or any of its affiliates, on the one hand, or by or on behalf of ARCA or any of its affiliates, on the other hand, to the other party) contemplating or otherwise relating to any Acquisition Transaction with such party.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An &#8220;Acquisition Transaction&#8221; means any transaction or series of related transactions (other than a sale by ARCA of its legacy assets, the issuance of convertible notes by Oruka or the Oruka pre<span class="nobreak">-closing</span> financing) involving:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any merger, consolidation, amalgamation, share exchange, business combination, issuance or acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or similar transaction: (i)&#160;in which any individual, entity, governmental entity, or &#8220;group,&#8221; as defined under applicable securities laws, directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of ARCA or Oruka or any of their respective subsidiaries or (ii)&#160;in which ARCA, Oruka or Merger Subs or any of their respective subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such party or any of its subsidiaries or issues securities convertible into more than 20% of the outstanding securities of any class of voting securities; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of ARCA or Oruka and their respective subsidiaries, as applicable, taken as a whole.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Notwithstanding the foregoing, before obtaining the applicable approvals of the ARCA stockholders or Oruka stockholders required to consummate the Merger, each party may furnish non<span class="nobreak">-public</span> information regarding such party and its subsidiaries to, and may enter into discussions or negotiations with, any third party in response to a bona fide written Acquisition Proposal, which such party&#8217;s board of directors determines in good faith, after consultation with such party&#8217;s financial advisors and outside legal counsel, constitutes or is reasonably likely to result in a Superior Offer (and is not withdrawn), if:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such Acquisition Proposal was not obtained or made as a direct or indirect result of a breach of the Merger Agreement;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">145</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such party&#8217;s board of directors concludes in good faith, based on the advice of outside legal counsel, that the failure to take such action would reasonably be expected to be inconsistent with the fiduciary duties of such board of directors under applicable law;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>at least two&#160;business days prior to furnishing any non<span class="nobreak">-public</span> information or entering into discussions with a third party, such party gives the other party written notice of the identity of the third party and of that party&#8217;s intention to furnish non<span class="nobreak">-public</span> information to, or enter into discussions with, such third party;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>such party receives from the third party an executed confidentiality agreement containing provisions at least as favorable to such party as those contained in the confidentiality agreement between ARCA and Oruka; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>at least two&#160;business days prior to furnishing any non<span class="nobreak">-public</span> information to a third party, such party furnishes the same non<span class="nobreak">-public</span> information to the other party to the extent not previously furnished.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A &#8220;Superior Offer&#8221; means an unsolicited <span class="Italic" style="font-style:italic;font-weight:normal;">bona fide</span> written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes) that (a)&#160;was not obtained or made as a direct or indirect result of a breach of the Merger Agreement, (b)&#160;is on terms and conditions that the board of directors of the party receiving the offer determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the other party to the Merger Agreement to amend the terms of the Merger Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to that party&#8217;s stockholders than the terms of the transactions contemplated by the Merger Agreement, (c)&#160;is not subject to any financing conditions (and if financing is required, such financing is then fully committed to the third party) and (d)&#160;is reasonably capable of being completed on the terms proposed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement also provides that each party will promptly (and in no event later than one business&#160;day after such party receives any such Acquisition Proposal or Acquisition Inquiry) advise the other party of the status and terms of, and keep the other party reasonably informed with respect to, any Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Recommendation Change</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Merger Agreement, subject to certain exceptions described below, both Oruka and ARCA agreed that their respective board of directors may not withhold, amend, withdraw or modify (or publicly propose to withhold, amend, withdraw or modify) the recommendation of such party&#8217;s board of directors in a manner adverse to the other party except for in limited circumstances described below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At any time prior to the approval of the Merger by each party&#8217;s respective stockholders, if (i)&#160;such party has received a bona fide written Acquisition Proposal that the such party&#8217;s board of directors determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer, or (ii)&#160;a material development or change in circumstances (other than any such event, development or change to the extent related to any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof, the fact, in and of itself, that ARCA meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations or, in the case of ARCA, any sale of ARCA&#8217;s legacy business) that affects the business, assets or operations of such party and occurs or arises after the date the Merger Agreement was executed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the case of a change recommendation due to a material development or change in circumstance, such party&#8217;s board of directors must first promptly notify the other party, in writing, at least four&#160;business days before making a change in its recommendation, stating the material facts and circumstances related to the applicable material development or change in circumstance and that such party&#8217;s board of directors intends to make a change in its recommendation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the case of a change its recommendation due to a Superior Offer, such party&#8217;s board of directors must first:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>determine in good faith, based on the advice of its outside legal counsel, that the failure to make a change in its recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law; and</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">146</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>negotiate with the other party in good faith to make such adjustments to the terms and conditions of the Merger Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer, during the required four business&#160;day notice period and provide the other party with certain information regarding such Superior Offer.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the other party delivers a written offer to alter the terms or conditions of the Merger Agreement during the required four business&#160;day notice period, the party considering a change in the recommendation of its board of directors must redetermine in good faith, based on the advice of its outside legal counsel and financial advisors, that the failure to make a change in its recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable law (after taking into account such alterations of the terms and conditions of the Merger Agreement);</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Stockholder Approvals</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is obligated under the Merger Agreement to take all action necessary under applicable law to call, give notice of and hold a meeting of the holders of ARCA common stock for the purpose of considering and voting to approve the Merger Agreement and the transactions contemplated thereby (including the Merger) and an amendment to the ARCA Charter as further described herein (collectively, the &#8220;Merger proposals&#8221;). The ARCA special meeting will be held as promptly as practicable after this registration statement on Form&#160;S<span class="nobreak">-4</span> is declared effective under the Securities Act, and in any event no later than 45&#160;days after the effective date of this registration statement on Form&#160;S<span class="nobreak">-4</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Promptly after this registration statement on Form&#160;S<span class="nobreak">-4</span> has been declared effective, and no later than two business days thereafter, Oruka is required to obtain the approval by written consent from the holders of a majority of the outstanding shares of Oruka&#8217;s capital stock, voting as a single class on an as<span class="nobreak">-converted</span> basis and the holders of a majority of the outstanding shares of Oruka Series&#160;A preferred stock, voting as a separate class, in each case, to (x)&#160;adopt and approve the Merger Agreement and the Merger or the transactions contemplated thereby (including the Merger), (y)&#160;acknowledge that the approval given thereby is irrevocable and that such stockholders are aware of their rights to demand appraisal for their shares pursuant to Section&#160;262 of the DGCL, and that such stockholder has received and read a copy of Section&#160;262 of the DGCL and (z)&#160;acknowledge that by their approval of the Merger, they are not entitled to appraisal rights with respect to their shares in connection with the Merger and thereby waive any rights to receive payment of the fair value of their capital stock under the DGCL.&#160;Reasonably promptly following receipt of such consents, Oruka will prepare, and cause to be mailed to its stockholders who did not execute such consents, a notice in accordance with the DGCL.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Regulatory Approvals</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each party agreed to use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of the Merger Agreement, all applications, notices, reports and other documents reasonably required to be filed by such party with or otherwise submitted by such party to any governmental authority with respect to the transactions contemplated by the Merger Agreement, and to submit promptly any additional information requested by any such governmental authority. ARCA and Oruka do not intend to seek any regulatory approval from antitrust or other regulatory authorities to consummate the transactions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Indemnification and Insurance for Directors and Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Merger Agreement, from the First Merger Effective Time through the sixth anniversary of the date on which the First Merger Effective Time occurs, ARCA and the surviving entity in the Second Merger agreed to indemnify and hold harmless each person who is now, or has been at any time prior to the date of the Merger Agreement, or who becomes prior to the First Merger Effective Time, a director or officer of ARCA or Oruka, respectively, against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the indemnified officer or director is or was a director or officer of ARCA or of Oruka, whether asserted or claimed prior to, at or after the First Merger Effective Time. From and after the First Merger Effective Time, ARCA and the surviving corporation in the Merger will also fulfill ARCA&#8217;s and Oruka&#8217; indemnity obligations, respectively, to each person who is, has been, or who becomes prior to the First Merger Effective Time, a director or officer of ARCA or Oruka.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">147</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The certificate of formation and limited liability company agreement of the surviving entity will contain provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the ARCA Charter and ARCA Bylaws.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From and after the First Merger Effective Time, ARCA will maintain director and officers&#8217; liability insurance policies, with an effective date as of the closing date of the First Merger, on commercially available terms and conditions and with coverage limits customary for U.S.&#160;public companies similarly situated to ARCA.&#160;In addition, ARCA will secure and purchase a six year &#8220;tail policy&#8221; on ARCA&#8217;s existing directors&#8217; and officers&#8217; liability insurance policy with an effective date as of the date of the closing of the First Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Additional Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka has agreed to use its reasonable best efforts to cause to be taken all actions necessary to consummate the Merger and the other transactions contemplated by the Merger Agreement. In connection therewith, each party has agreed to:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such party in connection with the transactions contemplated by the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>use commercially reasonable efforts to obtain each consent (if any) reasonably required to be obtained (pursuant to any applicable law or contract, or otherwise) in connection with the Merger and the other transactions contemplated by the Merger Agreement or for such contract to remain in full force and effect;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the transactions contemplated by the Merger Agreement; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>use commercially reasonable efforts to satisfy the conditions precedent to the consummation of the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Merger Agreement, ARCA and Oruka have further agreed that:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA will use its commercially reasonable efforts to maintain its listing on Nasdaq and cause the shares of ARCA common stock (including any shares of ARCA&#8217;s common stock issuable upon conversion of the ARCA Series&#160;B Preferred Stock) being issued in the Merger to be approved for listing on Nasdaq at or prior to the First Merger Effective Time.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA will keep Oruka reasonably informed regarding any stockholder litigation against ARCA or any of its directors relating to the Merger Agreement or the transactions contemplated thereby.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;">ARCA will (i)&#160;give Oruka the opportunity to participate in, but not control, the defense, settlement or prosecution of any such litigation (to the extent that the attorney<span class="nobreak">-client</span> privilege is not undermined or otherwise adversely affected), (ii)&#160;consult with Oruka with respect to the defense, settlement and prosecution of any such litigation and (iii)&#160;consider in good faith Oruka&#8217;s advice with respect to such litigation.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Conditions to the Completion of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following contains a description of all material conditions to the completion of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each party&#8217;s obligation to complete the Merger is subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the parties, at or prior to the closing, of various conditions, which include the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the registration statement on Form&#160;S<span class="nobreak">-4</span>, of which this proxy statement/prospectus is a part, must have been declared effective by the SEC in accordance with the Securities Act and must not be subject to any stop order or any proceeding seeking a stop order that has not been withdrawn; and any material state securities laws applicable to the issuance of the shares of ARCA&#8217;s capital stock in connection with the Merger or any of the other transactions contemplated by the Merger Agreement shall have been </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">148</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">complied with and no stop order (or similar order) shall have been issued or threatened in writing in respect of such shares of ARCA&#8217;s capital stock by any applicable state securities commissioner or court of competent jurisdiction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>there must not have been issued, and remain in effect, any order preventing the consummation of the Merger or any of the other transactions contemplated by the Merger Agreement by any governmental authority of competent jurisdiction, and no law, statute, rule, regulation, ruling or decree will be in effect which has the effect of making the consummation of the Merger or any of the other transactions contemplated by the Merger Agreement illegal;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the holders of a majority of the outstanding shares of Oruka common stock, voting as a single class on an as<span class="nobreak">-converted</span> basis and the holders of a majority of the outstanding shares of Oruka Series&#160;A preferred stock, voting as a separate class, must have adopted and approved the Merger Agreement and the transactions contemplated thereby by written consent (the &#8220;Oruka stockholder approval&#8221;);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the holders of the shares of ARCA common stock constituting a majority of the votes properly cast at the ARCA special meeting must have approved the Merger Agreement and the transactions contemplated thereby;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the initial listing application for ARCA&#8217;s common stock on Nasdaq (including any shares of ARCA&#8217;s common stock issuable upon conversion of the shares of ARCA Series&#160;B Preferred Stock) shall have been approved by Nasdaq;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the lock<span class="nobreak">-up</span> agreements executed by certain stockholders of Oruka will continue to be in full force and effect;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the ARCA Charter amendment shall have been duly filed with the Secretary of State of the State of Delaware, containing such amendments as are necessary to consummate the transactions contemplated by the Merger Agreement; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA shall have filed a Certificate of Designation with the Secretary of State of the State of Delaware designating the ARCA Series&#160;B Preferred Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, each party&#8217;s obligation to complete the Merger is further subject to the satisfaction or waiver by that party of the following additional conditions:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the other party&#8217;s representations and warranties being true and correct as of the closing date, subject to applicable materiality qualifiers;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the other party to the Merger Agreement must have performed or complied with in all material respects all of such party&#8217;s agreements and covenants required to be performed or complied with by it under the Merger Agreement at or prior to the First Merger Effective Time;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the lack of a material adverse effect that is continuing with respect to the other party; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the other party having delivered certain certificates and other documents required under the Merger Agreement for the closing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the obligation of ARCA and Merger Subs to complete the Merger is further subject to the Subscription Agreement being in full force and effect and cash proceeds of not less than $175&#160;million having been received by Oruka, substantially simultaneously with the closing of the First Merger.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">149</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Termination and Termination Fees</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination of the Merger Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement may be terminated at any time before the First Merger Effective Time, whether before or after the required stockholder approvals to complete the Merger have been obtained, as set forth below:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by mutual written consent of ARCA and Oruka;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>by either ARCA or Oruka, if the Merger has not been consummated by October&#160;3, 2024 (subject to possible extension as provided in the Merger Agreement); <span class="Italic" style="font-style:italic;font-weight:normal;">provided, however</span>, that this right to terminate the Merger Agreement will not be available to any party whose action or failure to act has been a principal cause of the failure of the Merger to occur on or before October&#160;3, 2024 and such action or failure to act constitutes a breach of the Merger Agreement; and <span class="Italic" style="font-style:italic;font-weight:normal;">provided, further</span>, that such date will be extended by 60&#160;days by either party in the event that the SEC has not declared effective the registration statement on Form&#160;S<span class="nobreak">-4</span>, of which this proxy statement/prospectus is a part, by the date which is 60&#160;days following October&#160;3, 2024;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by either ARCA or Oruka, if a court of competent jurisdiction or governmental entity has issued a final and non<span class="nobreak">-appealable</span> order, decree or ruling or having the effect of permanently restrains, enjoins or otherwise prohibits the Merger or any of the transactions contemplated by the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>by ARCA, if the Oruka stockholder approval has not been obtained within two&#160;business days of the registration statement on Form&#160;S<span class="nobreak">-4</span>, of which this proxy statement/prospectus is a part, becoming effective; <span class="Italic" style="font-style:italic;font-weight:normal;">provided</span> that this right to terminate the Merger Agreement will not be available to ARCA once Oruka obtains such stockholder approval;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(e)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by either ARCA or Oruka, if the ARCA special meeting has been held and completed and ARCA stockholders have taken a final vote on the Merger proposals set forth herein to be considered at the ARCA special meeting, and such proposals have not been approved by the ARCA stockholders; <span class="Italic" style="font-style:italic;font-weight:normal;">provided</span> that ARCA may not terminate the Merger Agreement pursuant to this provision if the failure to obtain the approval of ARCA stockholders was caused by the action or failure to act of ARCA and such action or failure to act constitutes a material breach by ARCA of the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(f)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by Oruka, at any time prior to obtaining the approval by ARCA stockholders of the Merger proposals set forth herein to be considered at the ARCA special meeting, if any of the following circumstances shall occur:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA fails to include in this proxy statement/prospectus ARCA&#8217;s board of directors&#8217; recommendation that ARCA stockholders vote to approve the Merger proposals set forth herein to be considered at the ARCA special meeting;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors, or any committee thereof, makes an ARCA board recommendation change or publicly approves, endorses or recommends any Acquisition Proposal; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal, other than a confidentiality agreement permitted pursuant to the Merger Agreement;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(g)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>by ARCA, at any time prior to obtaining the Oruka stockholder approval, if any of the following circumstances shall occur:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s board of directors makes a Oruka board recommendation change or publicly proposes, endorses or recommends any Acquisition Proposal; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka enters into any letter of intent or similar document or any contract relating to any Acquisition Proposal;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">150</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(h)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>by Oruka, if ARCA or Merger Subs have breached any of their representations, warranties, covenants or agreements contained in the Merger Agreement or if any representation or warranty of ARCA has become inaccurate, in either case such that the conditions to the closing would not be satisfied as of time of such breach or inaccuracy; <span class="Italic" style="font-style:italic;font-weight:normal;">provided</span> that Oruka is not then in material breach of any representation, warranty covenant or agreement under the Merger Agreement; <span class="Italic" style="font-style:italic;font-weight:normal;">provided, further</span>, if such breach or inaccuracy is curable, then ARCA shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of a particular breach or inaccuracy until the earlier of the expiration of a 30<span class="nobreak">-day</span> period after delivery of written notice of such breach or inaccuracy from Oruka to ARCA or Merger Subs and Oruka&#8217;s intention to terminate pursuant to this paragraph (it being understood that ARCA shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by ARCA or Merger Subs is cured prior to such termination becoming effective);</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by ARCA, if Oruka has breached any of its representations, warranties, covenants or agreements contained in the Merger Agreement or if any representation or warranty of Oruka has become inaccurate, in either case such that the conditions to the closing would not be satisfied as of time of such breach or inaccuracy; <span class="Italic" style="font-style:italic;font-weight:normal;">provided </span>that ARCA is not then in material breach of any representation, warranty covenant or agreement under the Merger Agreement; <span class="Italic" style="font-style:italic;font-weight:normal;">provided, further</span>, if such breach or inaccuracy is curable, then ARCA shall not be permitted to terminate the Merger Agreement pursuant to this paragraph as a result of a particular breach or inaccuracy until the earlier of the expiration of a 30<span class="nobreak">-day</span> period after delivery of written notice of such breach or inaccuracy from ARCA to Oruka and ARCA&#8217;s intention to terminate pursuant to this paragraph (it being understood that the Merger Agreement will not terminate pursuant to this paragraph as a result of such particular breach or inaccuracy if such breach by Oruka is cured prior to such termination becoming effective); or</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(j)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>by ARCA (at any time prior to obtaining the ARCA stockholder approval), upon ARCA&#8217;s board of directors authorizing ARCA to enter into a definitive agreement that contemplates or otherwise relates to an Acquisition Transaction that constitutes a superior offer, subject to certain conditions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination Fees Payable by ARCA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA must pay Oruka a termination fee of $440,000 if (i)&#160;the Merger Agreement is terminated by ARCA or Oruka pursuant to clause (e)&#160;above or by Oruka pursuant to clause (f)&#160;above, (ii)&#160;at any time after the date of the Merger Agreement and prior to the ARCA special meeting, an Acquisition Proposal with respect to ARCA will have been publicly announced, disclosed or otherwise communicated to ARCA&#8217;s board of directors (and will not have been withdrawn), and (iii)&#160;in the event the Merger Agreement is terminated pursuant to clause (e)&#160;above, within 12&#160;months after the date of such termination, ARCA enters into a definitive agreement with respect to a subsequent transaction or consummates a subsequent transaction.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Termination Fees Payable by Oruka</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka must pay ARCA a termination fee of $440,000 if (i)&#160;the Merger Agreement is terminated by ARCA pursuant to clause (d)&#160;or (g)&#160;above, (ii)&#160;at any time after the date of the Merger Agreement and before obtaining the Oruka stockholder approval, an Acquisition Proposal with respect to Oruka will have been publicly announced, disclosed or otherwise communicated to Oruka&#8217;s board of directors (and will not have been withdrawn), and (iii)&#160;in the event the Merger Agreement is terminated pursuant to clause (d)&#160;above, within 12&#160;months after the date of such termination, Oruka enters into a definitive agreement with respect to a subsequent transaction or consummates a subsequent transaction.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amendment and Waiver</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement may not be amended except by an instrument in writing signed on behalf of each of the parties to the Merger Agreement and authorized by such party&#8217;s boards of directors at any time, unless the Merger Agreement has been adopted and approved by any party&#8217;s stockholders, in which case no amendment which by law requires further approval by the such party&#8217;s stockholders, may be made without such further approval.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">151</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any provision of the Merger Agreement may be waived by any party solely on that party&#8217;s behalf, without the consent of any other party. The waiver must be expressly set forth in a written instrument duly executed and delivered on behalf of such party, which will only be valid in the specific instance in which it is given. No failure or delay on the part of any party with respect to the exercise of any power, right, privilege or remedy under the Merger Agreement will operate as a waiver of such power, right, privilege or remedy. Furthermore, no single or partial exercise of any such power, right, privilege or remedy will preclude any other or further exercise thereof or of any other power, right, privilege or remedy.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">152</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T20"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">AGREEMENTS RELATED TO THE MERGER</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Support Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain Oruka stockholders holding approximately 90% of the outstanding shares of Oruka capital stock have entered into Oruka Support Agreements with ARCA and Oruka to vote all of their shares of Oruka capital stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby and against any alternative acquisition proposals. Certain ARCA stockholders holding approximately 28.5% of the outstanding shares of ARCA common stock have entered into ARCA Support Agreements with ARCA and Oruka to vote all of their shares of ARCA common stock in favor of the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and the Reverse Stock Split Proposal and against any alternative acquisition proposals.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Lock-Up Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain of Oruka&#8217;s executive officers, directors and stockholders have entered into&#160;lock<span class="nobreak">-up</span>&#160;agreements, pursuant to which such parties have agreed not to, except in limited circumstances, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of ARCA&#8217;s common stock or any securities convertible into or exercisable or exchangeable for ARCA common stock, currently or thereafter owned, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for shares of Oruka preferred stock in the Merger, but excluding, as applicable, shares purchased by existing Oruka stockholders in the Oruka pre<span class="nobreak">-closing</span>&#160;financing (including any shares of ARCA common stock issuable upon exercise of pre<span class="nobreak">-funded</span> warrants issued in exchange for pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing), until 180&#160;days after the effective time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Oruka stockholders who have executed&#160;lock<span class="nobreak">-up</span>&#160;agreements as of July<span class="nobreak"> </span>16, 2024 owned, in the aggregate, approximately 90% of the shares of Oruka&#8217;s outstanding capital stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The foregoing description of the&#160;lock<span class="nobreak">-up</span>&#160;agreements does not purport to be complete and is qualified in its entirety by the full text of the form of&#160;lock<span class="nobreak">-up</span>&#160;agreement, which is attached hereto as&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;E</span>.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Subscription Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution and delivery of the Merger Agreement, certain new and existing investors of Oruka entered into the Subscription Agreement with Oruka, pursuant to which such investors have agreed to purchase immediately prior to the First Merger, shares of Oruka common stock or, in lieu thereof, Oruka pre<span class="nobreak">-funded</span>&#160;warrants, representing an aggregate commitment of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note), in the Oruka pre<span class="nobreak">-closing</span>&#160;financing. Under the Subscription Agreement, the number of shares of Oruka common stock or pre<span class="nobreak">-funded</span> warrants, as applicable, shall be determined at a purchase price per share or warrant equal to (i)&#160;a valuation for Oruka equal to approximately $175.0&#160;million, (ii)&#160;divided by the number of shares of Oruka common stock outstanding immediately prior to the First Effective Time of the Merger (but excluding the securities being issued under the Subscription Agreement). Each share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, calculated in accordance with the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span>&#160;warrants that are issued in the Oruka pre<span class="nobreak">-closing</span>&#160;financing will be or will have the right to be, respectively, converted into shares of ARCA common stock in the Merger. Accordingly, by approving Proposal&#160;No.&#160;1 relating to the Merger, ARCA stockholders will also be approving the issuance of shares of ARCA common stock to be issued in exchange for all shares of Oruka common stock and&#160;pre<span class="nobreak">-funded</span>&#160;warrants that are sold in the Oruka pre<span class="nobreak">-closing</span>&#160;financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Subscription Agreement contains customary representations and warranties of Oruka and also contains customary representations and warranties of the purchaser parties thereto.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">153</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each purchaser&#8217;s obligation to purchase shares of Oruka common stock and/or Oruka pre<span class="nobreak">-funded</span> warrants from Oruka pursuant to the Subscription Agreement is subject to the satisfaction or waiver of certain conditions, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s representations and warranties in the Subscription Agreement being true and correct in all respects as of the effective date of the Subscription Agreement and true and correct in all material respects as of the closing date for the Oruka pre<span class="nobreak">-closing</span> financing, subject to certain exceptions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka having performed and complied in all material respects with all covenants, agreements, obligations and conditions required to be performed or complied with by it;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the issuance of a compliance certificate by the chief executive officer of Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>all registrations, qualifications, permits and approvals, if any, required under applicable state securities laws having been obtained;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the issuance of a secretary&#8217;s certificate by the secretary of Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the satisfaction or waiver of all conditions to the closing of the Merger set forth in the Merger Agreement (other than the condition regarding the Oruka pre<span class="nobreak">-closing</span> financing) and the closing of Merger being set to occur substantially concurrently with the closing of the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>no injunction having been issued prohibiting the consummation of the Oruka pre<span class="nobreak">-closing</span> financing;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka having delivered the registration rights agreement required by the Subscription Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>this registration statement on Form&#160;S<span class="nobreak">-4</span> shall have been become effective under the Securities Act, no stop order shall be suspending the effectiveness of this registration statement and no proceeding for that purpose shall have been initiated or threatened in writing by the SEC;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Nasdaq Listing Application shall have been approved by Nasdaq;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>no material adverse effect shall have occurred that is continuing, since the date of the Subscription Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka shall receive at closing aggregate proceeds from the purchase of securities pursuant to the Subscription Agreement of not less than $175,000,000 (including in the proceeds any convertible securities contributed as consideration in accordance with the Subscription Agreement); and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an opinion from Company counsel, dated as of the closing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s obligation to sell shares of Oruka common stock to each purchaser pursuant to the Subscription Agreement is subject to the satisfaction or waiver of certain conditions, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the representations and warranties made by the purchasers being true and correct as of the effective date of the Subscription Agreement and true and correct in all material respects as of the closing date of the Oruka pre<span class="nobreak">-closing</span> financing, subject to certain exceptions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each purchaser having performed and complied with all covenants, agreements, obligations and conditions required to be performed or complied with by each purchaser;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>all registrations, qualifications, permits and approvals, if any, required under applicable state securities laws having been obtained; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the satisfaction or waiver of all conditions to the closing of the Merger set forth in the Merger Agreement (other than those conditions which are to be satisfied at the closing of the transactions contemplated by the Merger Agreement)) and the closing of Merger being set to occur substantially concurrently with the closing of the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">154</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Registration Rights Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Subscription Agreement contemplates ARCA, Oruka and the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing entering into a registration rights agreement at the closing of the Oruka pre<span class="nobreak">-closing</span> financing, pursuant to which, among other things, the combined company will agree to provide for the registration and resale of certain shares of Oruka common stock that are held by the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing from time to time, including the shares of ARCA common stock issued in exchange for shares of Oruka common stock sold in the Oruka pre<span class="nobreak">-closing</span> financing and ARCA pre<span class="nobreak">-funded</span> warrants assumed upon conversion of the Oruka pre<span class="nobreak">-funded</span> warrants sold in the Oruka pre<span class="nobreak">-closing</span> financing (including shares issuable upon exercise of such warrants).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the registration rights agreement, the combined company will agree to prepare and file a resale registration statement covering the resale of the ARCA common stock within 45&#160;days of the closing of the merger pursuant to&#160;Rule&#160;415&#160;and to use its reasonable best efforts to keep such registration statement continuously effective under the&#160;Securities Act&#160;until the earlier of (a)&#160;the date that all registrable securities covered by such registration statement (i)&#160;have been sold, thereunder or pursuant to&#160;Rule&#160;144&#160;of the&#160;Securities Act&#160;(&#8220;Rule&#160;144&#8221;), or (ii)&#160;may be sold without volume or manner<span class="nobreak">-of-sale</span> restrictions pursuant to&#160;Rule&#160;144&#160;and without the requirement for the combined company to be in compliance with the current public information requirement under&#160;Rule&#160;144, and (b)&#160;five&#160;years after the date of the registration rights agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the registration rights agreement, the combined company will agree that neither the combined company nor securityholders of the combined company (other than the investors participating in the Oruka pre<span class="nobreak">-closing</span> financing and party to the registration rights agreement) may have &#8220;piggyback&#8221; registration rights and that the combined company will be prohibited from filing any other registration statements until all of the registerable securities subject to the registration rights agreement are registered pursuant to an effective registration statement, subject to certain exceptions. The registration rights agreement also provides that the combined company will pay certain expenses relating to such registrations and indemnify the applicable securityholders against certain liabilities. The form of registration rights agreement is attached as Exhibit A to the Subscription Agreement filed as Exhibit 10.2 to this registration statement on Form&#160;S<span class="nobreak">-4</span> of which this proxy statement/prospectus is a part, and the foregoing description of the registration rights agreement is qualified in its entirety by reference thereto.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">155</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T19"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA DIRECTORS, OFFICERS AND CORPORATE GOVERNANCE</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following sets forth certain information, as of July<span class="nobreak"> </span>16, 2024, concerning ARCA&#8217;s directors and executive officers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s directors, executive officers and key employees as of July<span class="nobreak"> </span>16, 2024 are as follows:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;">Name</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Age</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Position</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">65</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President and Chief Operating Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">60</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Financial Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dr.&#160;Linda Grais<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)(2)*(3)(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">68</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;I Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Mr.&#160;Robert E.&#160;Conway<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)*(2)(3)(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">70</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;II Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dr.&#160;Anders Hove<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)(3)*(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">58</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;I Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Mr.&#160;Jacob Ma-Weaver</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">37</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;III Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Mr.&#160;James Flynn<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">43</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 58.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Class&#160;I Director<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Committee Chairperson</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Member of the Audit Committee of ARCA&#8217;s board of directors</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Member of the Compensation Committee of ARCA&#8217;s board of directors</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Member of the Nominating and Corporate Governance Committee of ARCA&#8217;s board of directors</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Member of the Special Committee of ARCA&#8217;s board of directors</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>See &#8220;Election of Board of Directors&#8221; below for discussion of Class&#160;I&#160;&#8212;&#160;III Director service terms.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Thomas A.&#160;Keuer</span>. Mr.&#160;Keuer has served as ARCA&#8217;s Chief Operating Officer since December&#160;2014, and ARCA&#8217;s President since April&#160;2024. Mr.&#160;Keuer served as ARCA&#8217;s Executive Vice President, Pharmaceutical Operations from 2006 to 2014. Prior to joining ARCA, Mr.&#160;Keuer served as the SVP of Operations for Insmed, Inc. from 2004 to 2006. Prior to Insmed, Mr.&#160;Keuer served as the VP of Engineering for Baxter Healthcare from 1998 to 2004. Prior to Baxter, Mr.&#160;Keuer served as the VP of Operations for Somatogen, Inc. Mr.&#160;Keuer received his M.S. in Biochemical Engineering from Rice University and received his B.S. in Chemical Engineering from the University of Texas, Austin.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">C. Jeffrey Dekker</span>. Mr.&#160;Dekker has served as ARCA&#8217;s Chief Financial Officer and Treasurer since May&#160;2021 and ARCA&#8217;s Secretary since April&#160;2023. Prior to joining ARCA, Mr.&#160;Dekker served in multiple roles of increasing responsibility at GlobeImmune, Inc. from 2006 to 2021, including President, Vice President of Finance, and Senior Director, Finance and Controller. Before joining GlobeImmune, Mr.&#160;Dekker held leadership positions in finance and accounting at private software companies since 1993, including posts ranging from Corporate Controller to Vice President at Webroot Software Inc., Requisite Technology Inc. and NxTrend Technology Inc. Earlier in his career, Mr.&#160;Dekker worked at ITT Rayonier Port Angeles Pulp Division and at KPMG in Los Angeles. He earned a B.S. in accounting from Utah State University and is a certified public accountant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Linda Grais, M.D.</span><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span>Dr.&#160;Grais has served as a member of ARCA&#8217;s board of directors since May&#160;2007. Dr.&#160;Grais was a director of Ocera Therapeutics, Inc., a public biopharmaceutical company, since January&#160;2008 and became President and Chief Executive Officer of Ocera in June&#160;2012, and served in that role until Ocera&#8217;s acquisition by Mallinckrodt Pharmaceuticals in December&#160;2017. Dr.&#160;Grais served as a Managing Member at InterWest Partners, a venture capital firm from May&#160;2005 until February&#160;2011. From July&#160;1998 to July&#160;2003, Dr.&#160;Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich&#160;&amp; Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr.&#160;Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. Dr.&#160;Grais received a B.A. from Yale University, magna cum laude, and Phi Beta Kappa, an M.D. from Yale Medical School and a J.D. from Stanford Law School. Since September&#160;2015, Dr.&#160;Grais served on the board of PRA Health Sciences, which was acquired by ICON plc in 2021, a public contract research organization, and currently serves on the board of ICON plc. Dr.&#160;Grais also joined the board of Corvus Pharmaceuticals., a publicly traded pharmaceutical company, in January&#160;2019, and joined the board of Collective Health, a private healthcare services company, in March&#160;2023. ARCA believes Dr.&#160;Grais is an appropriate member of the Board of Directors because of her diverse training and experience as both a medical doctor and a lawyer, her experience as a founder and senior executive of a pharmaceutical company, and her experience as an investor in new life sciences companies. She also has extensive experience with and knowledge of ARCA&#8217;s business from her service on ARCA&#8217;s board of directors since 2007.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">156</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Robert E.&#160;Conway</span><span class="Bold" style="font-style:normal;font-weight:bold;"> </span>Mr.&#160;Conway was appointed to ARCA&#8217;s board of directors in September&#160;2013, and has served as the Chairman of ARCA&#8217;s board of directors since 2014. Mr.&#160;Conway served as the Chief Executive Officer and member of the board of directors of Array Biopharma, a publicly traded biopharmaceutical company, from 1999 to 2012. Prior to joining Array, Mr.&#160;Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc., from 1996 to 1999. From 1979 until 1996, Mr.&#160;Conway held various executive positions for Corning Inc. including Corporate Vice President and General Manager of Corning Hazleton, Inc., a contract research organization. From 2004 to 2013, he served on the board of directors of PRA International, Inc., which was a public company for a portion of his tenure there, from 2012 to the present, he has served on the board of directors of eResearch Technology, Inc., a private company, and from 2015 to July&#160;2017, Advarra, Inc. from 2019 to August&#160;2022, and he has served on the board of directors of Nivalis Therapeutics, Inc. a public, clinical stage pharmaceutical company. In July&#160;2017, Nivalis Therapeutics, Inc. combined with Alpine Immune Sciences, Inc., a public, clinical stage pharmaceutical company, and Mr.&#160;Conway served on the board of directors following such combination until May 2024. In addition, Mr.&#160;Conway is a member of the Strategic Advisory Committee of Genstar Capital, LLC and is a member of the board of directors of Signant Health. In April&#160;2023, Mr.&#160;Conway became Executive Chairman and member of the board of directors of ClinOne, Inc. Mr.&#160;Conway received a B.S. in accounting from Marquette University in 1976. ARCA believes Mr.&#160;Conway is an appropriate member of ARCA&#8217;s board of directors given his experience and expertise in the pharmaceutical industry, in pharmaceutical development and clinical trials, and in corporate finance, governance, accounting and public company compliance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Anders Hove, M.D.</span><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span>Dr.&#160;Hove has served as a member of ARCA&#8217;s board of directors since February&#160;2017. Dr.&#160;Hove is the manager of Acorn Bioventures, a partnership focusing on long<span class="nobreak">-term</span> investments in biotech, specialty pharma and medical device companies. Before Dr.&#160;Hove was a general partner of Venrock Associates, a venture capital firm, which he joined in 2004 and remained at through 2016. In 2008, Dr.&#160;Hove was a founder of Venrock Healthcare Capital Partners, Venrock&#8217;s public funds focused on small capitalization biotech companies and late<span class="nobreak">-stage</span> private companies. From 1996 to 2004, Dr.&#160;Hove was a fund manager at BB Biotech, an investment firm, and from 2002 to 2003 he also served as Chief Executive Officer of Bellevue Asset Management, an investment company. Dr.&#160;Hove previously held senior level positions in the medical, clinical and business operations of the pharmaceuticals division of Ciba<span class="nobreak">-Geigy</span> and Novartis. Mr.&#160;Hove was a member of the boards of directors of Anacor Pharmaceuticals, a publicly traded pharmaceutical company, from 2005 until its acquisition by Pfizer in June&#160;2016, and Edge Therapeutics, a publicly traded biotechnology company, from 2015 to 2016. In addition, Dr.&#160;Hove is a member of the board of directors of MC2 Therapeutics. He received a M.Sc. in Biotechnology Engineering from the Technical University of Denmark, an M.D. from the University of Copenhagen and an M.B.A. from INSEAD (the Institut Europ&#233;en d&#8217;Administration des Affaires). ARCA believes Dr.&#160;Hove is an appropriate member of ARCA&#8217;s board of directors, given his extensive training and experience as a medical doctor and masters of business administration, an executive in the pharmaceutical industry, and as an investor in biotechnology companies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Jacob Ma</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Weaver</span></span> Mr.&#160;Ma<span class="nobreak">-Weaver</span> was appointed to ARCA&#8217;s board of directors in June&#160;2022. He is the Managing Member of Cable Car Capital LLC, an investment adviser he founded in 2013. Cable Car Capital LLC is the General Partner of Funicular Funds, LP, a hedge fund. From 2012 to 2013, Mr.&#160;Ma<span class="nobreak">-Weaver</span> was employed as an investment analyst at Amici Capital LLC, where he focused on healthcare. He was previously employed as an equity research associate at Dodge&#160;&amp; Cox and a corporate finance business analyst at McKinsey&#160;&amp; Company. Mr.&#160;Ma<span class="nobreak">-Weaver</span> received a Bachelor of Arts in Comparative Literature&#160;&amp; Society and Economics and a Master of Arts in Statistics from Columbia University. He is a Chartered Financial Analyst (CFA) charterholder. ARCA believes Mr.&#160;Ma<span class="nobreak">-Weaver</span> is an appropriate member of ARCA&#8217;s board of directors because of his experience as an investor in life sciences companies, an analyst for investment firms and his academic background.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">James Flynn</span> Mr.&#160;Flynn has served as a member of ARCA&#8217;s board of directors since December&#160;2022. Mr.&#160;Flynn is currently a Managing Member and Portfolio Manager of Nerium Capital LLC, an investment adviser he founded in 2021. Mr.&#160;Flynn has served as a board member for Axiom Health (a provider of software and big<span class="nobreak">-data</span> solutions to the healthcare industry) since 2022, a board member for MEI Pharma, Inc (a pharmaceutical company committed to the development of novel and differentiated cancer therapies) since 2023, joined the board of RiceBran Technologies (an innovative specialty ingredients company) in January&#160;2024, and joined the board of Synlogic, Inc. (a publicly traded biopharmaceutical company with a focus on rare metabolic disorders) in March 2024. From 2017 to 2018, Mr.&#160;Flynn worked as a therapeutics analyst at Aptigon Capital (a Citadel Company), an investment firm. Prior to that, from 2003 to 2017, Mr.&#160;Flynn served in various roles at Amici Capital, LLC, an investment firm, including healthcare portfolio manager (2008 to 2017). From 2002 to 2003, Mr.&#160;Flynn worked in the credit research/high yield group at Putnam Investments, an investment firm. Mr.&#160;Flynn earned a S.B. degree in Management Science with a </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">157</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">concentration in Finance and a minor in Economic Science from the Massachusetts Institute of Technology (MIT). Mr.&#160;Flynn is a Chartered Financial Analyst (CFA) charterholder. ARCA believes Mr.&#160;Flynn is an appropriate member of ARCA&#8217;s board of directors because of his experience as an investor in life sciences companies, an analyst for investment firms and his academic background.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Diversity Matrix (as of July 16, 2024)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The table below provides certain highlights of the composition of ARCA&#8217;s board members as of July<span class="nobreak"> </span>16, 2024. Each of the categories listed in the table below has the meaning as it is used in Nasdaq Rule&#160;5605(f).</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12">
					<td class="TCH" colspan="9" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Diversity Matrix as of July 16, 2024</span></p>



					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Total&#160;Number&#160;of&#160;Directors&#160;and&#160;nominees:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" colspan="7" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">5</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Part&#160;I:&#160;Gender Identity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Male</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Female</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Non-Binary</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Did Not <br/>Disclose&#160;Gender</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Directors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Part&#160;II:&#160;Demographic Background</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">African American or Black</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Alaskan Native or American Indian</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Asian</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Hispanic or Latinx</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Native Hawaiian or Pacific Islander</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">White</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Two or More Races or Ethnicities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">LGBTQ+</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Did Not Disclose Demographic Background</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.03%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">158</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T18"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ADDITIONAL INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Independence of The Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As required under the Nasdaq listing standards, a majority of the members of a listed company&#8217;s board of directors must qualify as &#8220;independent,&#8221; as affirmatively determined by the board of directors. ARCA&#8217;s board of directors consults with ARCA&#8217;s counsel to ensure that the board of directors&#8217; determinations are consistent with relevant securities and other laws and regulations regarding the definition of &#8220;independent,&#8221; including those set forth in pertinent listing standards of the Nasdaq, as in effect from time to time.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and ARCA, its senior management and its independent registered public accounting firm, the Board of Directors has affirmatively determined that the following four  directors are independent directors within the meaning of the applicable Nasdaq&#160;listing standards: Mr.&#160;Conway, Dr.&#160;Grais, Dr.&#160;Hove and Mr.&#160;Flynn. In making this determination, the Board of Directors found that none of the directors had a material or other disqualifying relationship with ARCA.&#160;Dr.&#160;Bristow, ARCA&#8217;s former President and Chief Executive Officer was not an&#160;independent director in 2023 by virtue of his employment relationship with ARCA.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Leadership Structure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has structured its board of directors in a way that ARCA believes effectively serves its objectives of corporate governance and management oversight. ARCA separates the roles of President and Chairman of the board of directors in recognition of the differences between the two roles. ARCA believes that the President should be responsible for the&#160;day<span class="nobreak">-to-day</span> leadership and performance of ARCA, while the Chairman of the board of directors should work with the President and the rest of the board of directors to set the strategic direction for ARCA and provide guidance to, and oversight of the President. The Chairman also sets the agenda for meetings of the board of directors and presides over them.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Mr.&#160;Conway, who is an independent director, was elected Chairman of the board of directors in 2014. In this capacity, Mr.&#160;Conway, among other things, calls and presides over board meetings, including meetings of the independent directors, and sets meeting agendas. In this role, Mr.&#160;Conway can effectively coordinate between the board of directors and management regarding risk management issues and the implementation of appropriate responses, and can help ensure the effective independent functioning of the board of directors in its oversight responsibilities. Accordingly, the Chairman has substantial ability to shape the work of the board of directors.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Role of the Board of Directors in Risk Oversight and Risk Management</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">One of the board of directors&#8217; key functions is informed oversight of ARCA&#8217;s risk management process. The board of directors does not have a standing risk management committee, but rather administers this oversight function directly through the board of directors as a whole, as well as through various standing committees of the board of directors that address risks inherent in their respective areas of oversight. In particular, while the board of directors is responsible for monitoring and assessing strategic risk exposure, the Audit Committee has the responsibility to consider and discuss the major financial risk exposures and the steps management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The Audit Committee also monitors compliance with legal and regulatory requirements, in addition to oversight of the performance of ARCA&#8217;s accounting and financial reporting processes. The Nominating and Corporate Governance Committee monitors the effectiveness of the corporate governance guidelines, including whether they are successful in preventing illegal or improper liability<span class="nobreak">-creating</span> conduct. The Compensation Committee of the board of directors of ARCA (the &#8220;Compensation Committee&#8221;) assesses and monitors whether any compensation policies and programs have the potential to encourage excessive risk<span class="nobreak">-taking</span>. The entire board of directors and its committees address risk management issues from time<span class="nobreak">-to-time</span> and at least annually meet with the employees responsible for risk management in the committees&#8217; respective areas of oversight. Both the board of directors as a whole and the various standing committees receive periodic reports </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">159</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">from the employees responsible for risk management, as well as&#160;incidental reports as matters may arise. It is the responsibility of the committee chairs to report findings regarding material risk exposures to the board of directors as quickly as possible.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Meetings of The Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors met three times during the 2023 fiscal year. The independent members of the board of directors met separately as a group at each of the board meetings in 2023. All members of the board of directors attended at least 75% of the aggregate of (i)&#160;the total number of meetings of the board of directors held during the period for which each director served and (ii)&#160;the total number of meetings held by all committees of the board of directors of which each director was a member during the periods that they served. All of ARCA&#8217;s directors then on the board of directors attended ARCA&#8217;s 2023 annual meeting of stockholders (the &#8220;2023 Annual Meeting&#8221;) whether in person or via telephone.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Election of Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Directors are elected by a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote on the election of directors at ARCA&#8217;s annual stockholders&#8217; meetings. The ARCA Charter, as amended, provides that the board of directors is divided into three classes to provide for staggered terms and that each director will serve for a term of three&#160;years or less, depending on the class to which the board of directors has assigned a director not previously elected by the stockholders. There is currently one Class&#160;III director whose term expires at the annual stockholders&#8217; meeting in 2024, three Class&#160;I directors whose terms expire at the annual stockholders&#8217; meeting in 2025 and one Class&#160;II directors whose term expires at the annual meeting in 2026. The one Class&#160;III director, Mr.&#160;Jacob Ma<span class="nobreak">-Weaver</span>, is currently scheduled for re<span class="nobreak">-election</span> to the board of directors at this 2024 special meeting in lieu of an annual stockholders&#8217; meeting, for a three<span class="nobreak">-year</span> term ending on the date of the annual meeting in 2027 or until his successor is duly elected and qualified or appointed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s executive officers are appointed by and serve at the discretion of ARCA&#8217;s board of directors. There are no family relationships between ARCA&#8217;s directors and executive officers.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Code of Ethics</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has adopted the ARCA biopharma, Inc. Code of Business Conduct and Ethics that applies to all officers, directors and employees. The Code of Business Conduct and Ethics is available on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabiopharma.com</span>. If ARCA makes any substantive amendments to the Code of Business Conduct and Ethics or grants any waiver from a provision of the Code of Business Conduct and Ethics to any executive officer or director, ARCA will promptly disclose the nature of the amendment or waiver on its website and file any current report on Form&#160;8<span class="nobreak">-K</span> required by applicable law or Nasdaq listing standards.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Insider Trading Policy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has adopted an Insider Trading Policy that governs the purchase, sale and/or other dispositions of its securities by its directors, officers and employees, as well as their immediate family members and entities owned or controlled by them, and that is designed to promote compliance with insider trading laws, rules and regulations.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">160</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Information Regarding Committees of the Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">ARCA&#8217;s board of directors has three standing committees: The Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee. The following table provides membership and meeting information for the fiscal year ended December&#160;31, 2023, for each of the committees of the board of directors:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Audit</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Compensation</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Nominating <br/>and <br/>Corporate <br/>Governance</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dr.&#160;Michael R.&#160;Bristow</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dr.&#160;Linda Grais</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dr.&#160;Raymond L.&#160;Woosley</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X*</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Mr.&#160;Robert E.&#160;Conway</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Mr.&#160;Dan J.&#160;Mitchell</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dr.&#160;Anders Hove</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">X</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total meetings in fiscal 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">1</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Committee Chairperson.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2022, the board of directors established a Special Committee to evaluate strategic options for maximizing stockholder value. The Special Committee includes ARCA board Chairman Robert E.&#160;Conway (chair), and board members Linda Grais, M.D., Anders Hove, M.D and James Flynn (joined the Special Committee in April&#160;2024). Jacob Ma<span class="nobreak">-Weaver</span> served as a member of the Special Committee from June&#160;2022 to April&#160;2024.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Below is a description of each committee of the board of directors. Each of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities.<span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">&#160;</span>The board of directors has determined that each member of each committee meets the applicable Nasdaq rules and regulations regarding &#8220;independence&#8221; and that each member is free of any relationship that would impair his or her individual exercise of independent judgment regarding the Company.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Audit Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Audit Committee of ARCA&#8217;s board of directors of ARCA (the &#8220;Audit Committee&#8221;) was established by the board of directors in accordance with Section&#160;3(a)(58)(A)&#160;of the Exchange&#160;Act, to oversee ARCA&#8217;s corporate accounting and financial reporting processes and audits of its financial statements. For this purpose, the Audit Committee performs several functions. The Audit Committee evaluates the performance of and assesses the qualifications of the independent registered public accounting firm; determines and approves the engagement of the independent registered public accounting firm; determines whether to retain or terminate the existing independent registered public accounting firm or to appoint and engage a new independent registered public accounting firm; reviews and approves the retention of the independent registered public accounting firm to perform any proposed permissible non<span class="nobreak">-audit</span> services; monitors the rotation of partners of the independent registered public accounting firm on ARCA&#8217;s audit engagement team as required by law; reviews and approves or rejects transactions between the company and any related persons; confers with management and the independent registered public accounting firm regarding the effectiveness of internal controls over financial reporting; establishes procedures, as required under applicable law, for the receipt, retention and treatment of complaints received by ARCA regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; and meets to review ARCA&#8217;s annual audited financial statements and quarterly financial statements with management and the independent registered public accounting firm, including a review of ARCA&#8217;s disclosures under the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; discussion in its Annual Reports on Form&#160;10<span class="nobreak">-K</span> and Quarterly Reports on Form&#160;10<span class="nobreak">-Q</span>.&#160;The Audit Committee is currently composed of three<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>directors: Mr.&#160;Conway (chair), Mr.&#160;Flynn and Dr.&#160;Grais. The Audit Committee met six times during the 2023 fiscal year. The board of directors has adopted a written charter of the Audit Committee that is available to stockholders<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>on ARCA&#8217;s website at&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">161</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors reviews the Nasdaq<span class="SmallCaps" style="font-variant:small-caps;"> </span>listing standards definition of independence for audit committee members on an annual basis and has determined that all members of the Audit Committee are independent (as independence is currently defined in Rule&#160;5605(c)(2)(A)(i)&#160;and (ii)&#160;of the Nasdaq<span class="SmallCaps" style="font-variant:small-caps;"> </span>listing standards). The board of directors has also determined that Mr.&#160;Conway qualifies as an &#8220;audit committee financial expert,&#8221; as defined in applicable SEC rules. The board of directors made a qualitative assessment of Mr.&#160;Conway&#8217;s level of knowledge and experience based on several factors, including his prior experience, business acumen and independence.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Compensation Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Compensation Committee is currently composed of three directors: Mr.&#160;Conway, Dr.&#160;Grais (chair) and Dr.&#160;Hove. All members of the Compensation Committee are independent, as independence is currently defined in Rule&#160;5605(a)(2)&#160;of the Nasdaq listing standards. The Compensation Committee met two times during the 2023 fiscal year. The Compensation Committee has adopted a written charter that is available to stockholders on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Compensation Committee of ARCA&#8217;s board of directors acts on behalf of the board of directors to review, adopt and oversee ARCA&#8217;s compensation strategy, policies, plans and programs, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>overseeing succession planning for senior management of ARCA, including a review of the performance and advancement potential of current and future senior management and succession plans for each and recommending, as appropriate, the retention of potential succession candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>assessing the overall compensation structure of ARCA and evaluating and recommending changes to ARCA&#8217;s compensation philosophies and strategies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>reviewing and approving performance<span class="nobreak">-based</span> compensation plans or programs, including establishing goals and targets, applicable to the Chief Executive Officer and other members of the management team;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>administering, reviewing, and approving all executive compensation programs or plans, and all of ARCA&#8217;s incentive compensation and stock plans and awards thereunder of ARCA, including amendments to the programs, plans or awards made thereunder; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>preparing and approving the report of the Compensation Committee to be included as part of ARCA&#8217;s annual meeting proxy statement, to the extent required.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Compensation Committee Processes and Procedures</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Typically, the Compensation Committee meets, as it deems appropriate. The agenda for each meeting is usually developed by the Chair of the Compensation Committee. However, from time to time, various members of management and other employees as well as outside advisors or consultants<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>may be invited by the Compensation Committee to make<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>presentations, to provide financial or other<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer may not participate in, or be present during, any deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives. The Compensation Committee has the sole authority to retain compensation consultants to assist in its evaluation of<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>executive<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>and director compensation, including the authority to approve the consultant&#8217;s reasonable fees and other retention terms. In general, the Compensation Committee has set executive compensation to be in line with peer companies identified by the Compensation Committee and to incentivize ARCA&#8217;s executive officers in achieving ARCA&#8217;s short- and long<span class="nobreak">-term</span> corporate goals.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, the Compensation and Nominating and Corporate Governance Committees of ARCA reviewed ARCA&#8217;s current employee and director compensation, including ARCA&#8217;s 2013 Equity Incentive Plan. As part of this review, the Committees considered certain changes to the ARCA&#160;2013 Equity Incentive Plan that were included in the 2020 ARCA Equity Incentive Plan. Both Committees recommended approval of the 2020 ARCA Equity Incentive Plan, and the Plan was subsequently approved by the board of directors and ARCA&#8217;s stockholders on December&#160;10, 2020.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">162</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current compensation for the ARCA named executive officers was set by the Compensation Committee and the board of directors in 2020. On December&#160;21, 2020, the Compensation Committee approved the following base salary compensation and target bonus percentages for the ARCA named executive officers and principal financial officer for the 2021 fiscal year:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Michael R.&#160;Bristow, former President and Chief Executive Officer, $345,000 base salary and target bonus of 50% of base salary; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Thomas A.&#160;Keuer, Chief Operating Officer, $340,000 base salary and target bonus of 40% of base salary.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May&#160;3, 2021, the Compensation Committee approved a $270,000 base salary and target bonus of 35% of base salary for C.&#160;Jeffrey Dekker, Chief Financial Officer, ARCA&#8217;s principal financial officer hired in May&#160;2021.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Historically, the Compensation Committee has made most of the significant adjustments to annual compensation, determined bonus and equity awards and established new performance objectives at one or more meetings held during the first quarter of the year. However, the Compensation Committee also considers matters related to individual compensation, such as compensation for new executive hires, as well as high<span class="nobreak">-level</span> strategic issues, such as the efficacy of ARCA&#8217;s compensation strategy, potential modifications to that strategy and new trends, plans or approaches to compensation, at various meetings throughout the year. Generally, the Compensation Committee&#8217;s process comprises two related elements: the determination of compensation levels and the establishment of performance objectives for the current year.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Compensation Committee reviews and approves the compensation of the President and the other executive officers of ARCA, including annual base salaries, annual and long<span class="nobreak">-term</span> incentive or bonus awards, employment agreements, and severance and change in control agreements/provisions, in each case as, when and if appropriate, and any special or supplemental benefits. For executives other than the President, the Compensation Committee solicits and considers evaluations and recommendations submitted to the Compensation Committee<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>by the President. The Compensation Committee evaluates the performance of the President in light of Company and individual goals and objectives, and makes appropriate recommendations for improving performance. In performing the evaluation, the Chair of the Compensation Committee may solicit comments from the other non<span class="nobreak">-employee</span> members of the board of directors and lead the board of directors in an overall review of the President&#8217;s performance in an executive session of non<span class="nobreak">-employee</span> members of the board of directors. If the compensation for the President or any other executive officer is governed by an employment agreement, the Compensation Committee approves such employment agreement and any amendments thereto.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For all executives as part of its deliberations, the Compensation Committee may review and consider, as appropriate,<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>materials such as financial reports and projections, operational data, tax and accounting information, tally sheets that set forth the total compensation that may become payable to executives in various hypothetical scenarios, executive and director stock ownership information, company stock performance data, analyses of historical executive compensation levels and current Company<span class="nobreak">-wide</span> compensation levels.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Compensation Committee also considers the results of any &#8220;say<span class="nobreak">-on-pay</span>&#8221; vote of ARCA&#8217;s stockholders with regard to the compensation of ARCA&#8217;s executive officers when making compensation decisions. At the 2023 Annual Meeting, ARCA&#8217;s stockholders approved, on an advisory basis, the compensation of ARCA named executive officers as described in the proxy statement for such annual meeting, with over 81% of stockholder votes cast in favor of ARCA&#8217;s &#8220;say<span class="nobreak">-on-pay</span>&#8221; resolution. The Compensation Committee believes that this advisory vote supports that ARCA&#8217;s current compensation practices are aligned with the best interests of stockholders and anticipates taking into account the results of the advisory vote, and any future advisory votes, when making compensation decisions in the future.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Nominating and Corporate Governance Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Nominating and Corporate Governance Committee of the board of directors of ARCA (the &#8220;Nominating and Corporate Governance Committee&#8221;) is responsible for identifying, reviewing and evaluating candidates to serve as directors of ARCA (consistent with criteria approved by the board of directors), reviewing and evaluating incumbent directors, recommending to the board of directors candidates for election to the board of directors , making recommendations to the board of directors regarding compensation for service on the board of directors and the committees thereof, making recommendations to the board of directors regarding the membership of the </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">163</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">committees of the board of directors, assessing the performance of the board of directors and developing a set of corporate governance principles for ARCA.&#160;The Nominating and Corporate Governance Committee is currently composed of three<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>directors: Dr.&#160;Hove (chair), Mr.&#160;Conway and Dr.&#160;Grais. All members of the Nominating and Corporate Governance Committee in 2023 were independent (as independence is currently defined in Rule&#160;5605(a)(2) of the Nasdaq listing standards). The Nominating and Corporate Governance Committee met once during the 2023 fiscal year. The Nominating and Corporate Governance Committee has adopted a written charter that is available to stockholders on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Nominating and Corporate Governance Committee periodically reviews the compensation of non<span class="nobreak">-employee</span> Directors for service on the board of directors and committees thereof. In 2015, the Nominating and Corporate Governance Committee began a review of its Director compensation levels considering general market conditions in the life science industry, and in comparison to other clinical stage biopharmaceutical companies, and in early 2016, the Committee recommended, and the board of directors approved, revised compensation for non<span class="nobreak">-employee</span> Directors, discussed in &#8220;ARCA Director Compensation&#8221; below. Since adoption of this policy, the Nominating and Corporate Governance Committee has reviewed Director compensation on an annual basis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, the Nominating and Corporate Governance Committee (together with the Compensation Committee) engaged a consultant to evaluate the current compensation of ARCA&#8217;s non<span class="nobreak">-employee</span> directors and make recommendations to the Nominating and Corporate Governance Committee. The changes made as a result of this evaluation are discussed in &#8220;ARCA Director Compensation&#8221; below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The board of directors has adopted a process for identifying and evaluating director nominees, including stockholder nominees. Before recommending an individual to the board of directors for membership on the board of directors, the Nominating and Corporate Governance Committee canvasses its members and ARCA&#8217;s management team for potential candidates for the board of directors. The Nominating and Corporate Governance Committee also uses its network of contacts to identify potential candidates and, if it deems appropriate, may also engage a professional search firm. The Nominating and Corporate Governance Committee will consider stockholders&#8217; recommendations for nominees to serve as director if notice is timely received by the Secretary of ARCA.&#160;Candidates nominated by stockholders will be evaluated in the same manner as other candidates. The Nominating and Corporate Governance Committee keeps the board of directors apprised of its discussions with potential nominees, and the names of potential nominees received from its current directors, management, and stockholders, if the stockholder notice of nomination is timely made.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although the board of directors has not adopted a fixed set of minimum qualifications for candidates for membership on the board of directors, the Nominating and Corporate Governance Committee generally considers several factors in its evaluation of a potential member, such as the candidate&#8217;s education, professional background and field of expertise including industry or academic experience in the pharmaceutical and biotechnology fields, experience in corporate governance and management, the reasonable availability of the potential member to devote time to the affairs of ARCA, as well as any other criteria deemed relevant by the board of directors or the Nominating and Corporate Governance Committee. However, the Nominating and Corporate Governance Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the board of directors, the operating requirements of ARCA and the long<span class="nobreak">-term</span> interests of stockholders. In conducting this assessment, the Nominating and Corporate Governance Committee typically considers diversity, age, skills and such other factors as it deems appropriate given the current needs of the board of directors and ARCA, to maintain a balance of knowledge, experience and capability. The Nominating and Corporate Governance Committee believes it is essential that board of directors members come from a variety of backgrounds and experiences.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the case of incumbent directors whose terms of office are set to expire, the Nominating and Corporate Governance Committee reviews these directors&#8217; overall contributions to ARCA and the board of directors during their terms, including level of attendance, level of participation, quality of performance and contribution to the board of directors&#8217; responsibilities and actions, and any relationships and transactions that might impair the directors&#8217; independence. In the case of new director candidates, the Nominating and Corporate Governance Committee also determines whether the nominee is independent for Nasdaq and SEC purposes, which determination is based upon applicable Nasdaq<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. The Nominating and Corporate Governance Committee conducts any appropriate and necessary inquiries into the </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">164</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">backgrounds and qualifications of possible candidates after considering the function and needs of the board of directors. The Nominating and Corporate Governance Committee meets to discuss and consider the candidates&#8217; qualifications and then determines whether to recommend a nominee to the board of directors by majority vote.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Stockholders who wish to recommend individuals for consideration by the Nominating and Corporate Governance Committee to become nominees for election to the board of directors may do so by delivering a written recommendation to the Nominating and Corporate Governance Committee addressed to the Corporate Secretary, between 60 and 90&#160;days before the one<span class="nobreak">-year</span> anniversary date of ARCA&#8217;s last annual meeting of stockholders. Recommendations must include the full name of the proposed nominee, a description of the proposed nominee&#8217;s business experience for at least the previous five&#160;years, complete biographical information, a description of the proposed nominee&#8217;s qualifications as a director, and a representation that the recommending stockholder is a beneficial or record owner of ARCA&#8217;s stock. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected. To date, the Nominating and Corporate Governance Committee has not rejected a timely director nominee from a stockholder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2023, the Nominating and Corporate Governance Committee did not pay any fees to assist in the process of identifying or evaluating director candidates.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Anti-Hedging Prohibition</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s employees, directors and consultants are prohibited from engaging in any hedging transactions of ARCA&#8217;s securities, including through the use of financial instruments such as prepaid variable forwards, equity swaps, collars and exchange funds, as required by ARCA&#8217;s insider trading policy.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholder Communications with the Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Stockholders who wish to communicate with ARCA&#8217;s board of directors may do so by e<span class="nobreak">-mail</span> by using the following email address: <span class="Italic" style="font-style:italic;font-weight:normal;">directors@arcabio.com</span>; or by mail by following the directions as set forth on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>, under the section titled &#8220;Corporate Governance&#8221; and the subsection titled &#8220;Governance Documents&#8221;. Communications sent in accordance with this process will be transmitted by ARCA to the appropriate board members.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">165</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T17"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA EXECUTIVE COMPENSATION</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Executive Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table shows for the fiscal&#160;years ended December&#160;31, 2023 and December&#160;31, 2022, compensation awarded to, paid to, or earned by ARCA&#8217;s principal executive officer and its two most highly compensated executive officers as of December&#160;31, 2023, collectively, the ARCA named executive officers:</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">Summary Compensation Table</span></p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name and Principal Position</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Year</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Salary <br/>($)<span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Bonus <br/>($)<span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Stock <br/>Awards <br/>($)</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">All&#160;Other <br/>Compensation <br/>($)<span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Total <br/>($)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">345,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13,800</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">358,800</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-indent:0pt;">Former President and Chief Executive Officer<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">345,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13,800</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">358,800</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">340,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,802</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">400,802</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-indent:0pt;">President and Chief Operating Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">340,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">88,400</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,593</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">448,993</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">270,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18,072</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">323,072</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 31.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-indent:0pt;">Chief Financial Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.12%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.70%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The amounts reported under &#8220;Salary&#8221; in the above table represent the actual amounts paid during the calendar year. Because ARCA&#8217;s actual pay dates do not always coincide with the first and last&#160;days of the year, these amounts may differ from the base salary amounts authorized by ARCA&#8217;s board of directors.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The amounts reported under &#8220;Bonus&#8221; in the above table represent retention bonuses paid to each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker in December&#160;2023. These amounts were previously reported as &#8220;All Other Compensation&#8221; in ARCA&#8217;s Annual Report on Form&#160;10<span class="nobreak">-K</span> for the fiscal year ended December&#160;31, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents 401(k)&#160;Company match in the amount of $13,800 for Michael R.&#160;Bristow in each of 2023 and 2022, $15,000 and $13,600 for Thomas A.&#160;Keuer in 2023 and 2022, and $11,579 for C.&#160;Jeffrey Dekker in 2023, Health Savings Account contributions by ARCA in the amount of $850 for Thomas A.&#160;Keuer in 2022, and $3,960 for C.&#160;Jeffrey Dekker in 2023, group term life premiums in the amount of $9,602 and $4,989 for Thomas A.&#160;Keuer in 2023 and 2022, and $2,533 for C.&#160;Jeffrey Dekker in 2023, and cell phone reimbursements in the amount of $1,200 and $1,154 for Thomas A.&#160;Keuer in 2023 and 2022.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Dr.&#160;Bristow and ARCA mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment effective April&#160;3, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Narrative Disclosure to Summary Compensation Table</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Employment Agreements or Arrangements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Michael R.&#160;Bristow, M.D., Ph.D.</span>&#160;&#160;&#160;&#160;Dr.&#160;Bristow served as ARCA&#8217;s President and Chief Executive Officer under an Employment and Retention Agreement dated as of June&#160;4, 2008, as amended. Pursuant to such employment agreement, Dr.&#160;Bristow was permitted to continue his academic work for the University of Colorado Health Sciences Center and for the Cardiovascular Institute, so long as it did not interfere with his duties as President and Chief Executive Officer of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with Dr.&#160;Bristow&#8217;s separation on April&#160;3, 2024, ARCA and Dr.&#160;Bristow entered into a separation agreement (the &#8220;Separation Agreement&#8221;) pursuant to which ARCA paid Dr.&#160;Bristow a lump sum amount equal to $370,000, less applicable tax withholding, which consisted of (i)&#160;12&#160;months of Dr.&#160;Bristow&#8217;s base salary as of the last date of his employment and (ii)&#160;a $25,000 cash payment. The separation payments were conditioned on Dr.&#160;Bristow not revoking the Separation Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Bristow also entered into a consulting agreement, effective April&#160;3, 2024 (the &#8220;Consulting Agreement&#8221;), pursuant to which Dr.&#160;Bristow provides certain consulting services to ARCA through the earlier of (i)&#160;the completion of services under the Consulting Agreement, (ii)&#160;a termination in accordance with the terms of the Consulting Agreement, and (iii)&#160;a change of control of ARCA (as defined in ARCA&#8217;s 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;)). During the consulting term, Dr.&#160;Bristow will continue to vest in his outstanding equity awards.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">166</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Thomas A.&#160;Keuer.</span>&#160;&#160;&#160;&#160;Mr.&#160;Keuer serves as ARCA&#8217;s President and Chief Operating Officer under an Amended and Restated Employment Agreement that was effective as of January&#160;1, 2015.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;8, 2022, the Compensation Committee approved a retention bonus of $100,000 for Mr.&#160;Keuer, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions. On November&#160;29, 2023, the Compensation Committee approved the amendment of the retention bonus letter between ARCA and Mr.&#160;Keuer to (i)&#160;increase the aggregate amount of the retention bonus by 50%, to $150,000, and (ii)&#160;in order to assist with tax obligations associated with the vesting of certain ARCA restricted stock unit awards, provided that $35,000 of&#160;Mr.&#160;Keuer&#8217;s retention bonus was paid on December&#160;8, 2023. On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of the retention bonus letter between ARCA and Mr.&#160;Keuer to increase the aggregate amount of the retention bonus by 33.33% to $200,000. The remaining portion of the retention bonus with respect to Mr.&#160;Keuer, consisting of $165,000, will become payable consistent with the original terms of the retention bonus letter and the first amendment to the retention bonus letter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA terminates Mr.&#160;Keuer&#8217;s employment without &#8220;cause,&#8221; or if Mr.&#160;Keuer terminates his employment with &#8220;good reason&#8221; (as these terms are defined in his employment agreement), ARCA has agreed to pay Mr.&#160;Keuer a severance payment equivalent to (i)&#160;(a)&#160;12&#160;months of his base salary, if such termination occurs on the same&#160;day as or within 13&#160;months after a change of control of ARCA, or (b)&#160;six&#160;months of his base salary if such termination does not occur on the same&#160;day as or within 13&#160;months after a change of control of ARCA, (ii)&#160;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by ARCA&#8217;s board of directors payable to him for the fiscal year in which his employment terminated to be paid at the same time that such incentive bonus would have been paid had the termination not occurred, and (iii)&#160;reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA for (x)&#160;12&#160;months, if such termination occurs on the same&#160;day as or within 13&#160;months after a change of control of ARCA, or (y)&#160;six&#160;months if such termination does not occur on the same&#160;day as or within 13&#160;months after a change of control of ARCA, whether he elects or is eligible to receive COBRA (provided, in either event, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out<span class="nobreak">-of-pocket</span> expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). In addition, ARCA may elect in its sole discretion, to pay additional severance equal to up to 12&#160;months of base salary, which additional payment would extend the covenants and obligations under Mr.&#160;Keuer&#8217;s Employee Intellectual Property, Confidentiality and Non<span class="nobreak">-Compete</span> Agreement for such additional period. The severance payment is conditioned on the execution by Mr.&#160;Keuer of a legal release in a form acceptable to ARCA.&#160;A termination for &#8220;cause&#8221; includes Mr.&#160;Keuer&#8217;s willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to ARCA; refusal, unwillingness, failure, or inability to perform his material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of his employment agreement or his Employee Intellectual Property, Confidentiality and Non<span class="nobreak">-Compete</span> Agreement, or any other agreement, with ARCA. &#8220;Good reason&#8221; includes a relocation by us of Mr.&#160;Keuer&#8217;s normal work location greater than 30 miles; a decrease in current base salary by more than 15%, with certain exceptions; and ARCA&#8217;s unilateral decision to significantly and detrimentally reduce Mr.&#160;Keuer&#8217;s job responsibilities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective as of April&#160;3, 2024, ARCA&#8217;s board of directors appointed Mr.&#160;Keuer to serve as ARCA&#8217;s President and principal executive officer. Mr.&#160;Keuer will not receive any additional compensation in connection with his appointment as President and principal executive officer. Mr.&#160;Keuer&#8217;s employment is expected to conclude upon closing of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">C.&#160;Jeffrey Dekker.</span>&#160;&#160;&#160;&#160;Mr.&#160;Dekker serves as ARCA&#8217;s Chief Financial Officer under an Employment Agreement that was effective as of May&#160;10, 2021. Mr.&#160;Dekker has served as ARCA&#8217;s Secretary since April&#160;2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under his employment agreement, Mr.&#160;Dekker is entitled to receive an annual base salary of $270,000, subject to annual increases if approved by ARCA&#8217;s board of directors or Compensation Committee and is eligible to receive an annual target bonus of 35% of his base salary as determined by ARCA&#8217;s board of directors or Compensation Committee in its sole discretion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;8, 2022, the Compensation Committee approved a retention bonus of $100,000 for Mr.&#160;Dekker, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions. On November&#160;29, 2023, the Compensation Committee approved the amendment of the retention bonus letter between ARCA and Mr.&#160;Dekker to (i)&#160;increase the aggregate amount of the retention bonus by 50%, to $150,000, and (ii)&#160;in order to assist with tax obligations associated with the vesting of certain ARCA </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">167</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">restricted stock unit awards, provided that $35,000 of&#160;Mr.&#160;Dekker&#8217;s retention bonus was paid on December&#160;8, 2023. On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of the retention bonus letter between ARCA and Mr.&#160;Dekker to increase the aggregate amount of the retention bonus by 33.33% to $200,000. The remaining portion of the retention bonus with respect to Mr.&#160;Dekker, consisting of $165,000, will become payable consistent with the original terms of the retention bonus letter and the first amendment to the retention bonus letter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA terminates Mr.&#160;Dekker&#8217;s employment without &#8220;cause,&#8221; or if Mr.&#160;Dekker terminates his employment with &#8220;good reason&#8221; (as these terms are defined in his employment agreement), ARCA has agreed to pay Mr.&#160;Dekker a severance payment equivalent to (i)&#160;(a)&#160;12&#160;months of his base salary, if such termination occurs on the same&#160;day as or within 13&#160;months after a change of control of ARCA, or (b)&#160;six&#160;months of his base salary if such termination does not occur on the same&#160;day as or within 13&#160;months after a change of control of ARCA, (ii)&#160;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by ARCA&#8217;s board of directors payable to him for the fiscal year in which his employment terminated to be paid at the same time that such incentive bonus would have been paid had the termination not occurred, and (iii)&#160;reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA for (x)&#160;12&#160;months, if such termination occurs on the same&#160;day as or within 13&#160;months after a change of control of ARCA, or (y)&#160;six&#160;months if such termination does not occur on the same&#160;day as or within 13&#160;months after a change of control of ARCA, whether he elects or is eligible to receive COBRA (provided, in either event, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out<span class="nobreak">-of-pocket</span> expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). In addition, ARCA may elect in its sole discretion, to pay additional severance equal to up to 12&#160;months of base salary, which additional payment would extend the covenants and obligations under Mr.&#160;Dekker&#8217;s Employee Intellectual Property, Confidentiality and Non<span class="nobreak">-Compete</span> Agreement for such additional period. The severance payment is conditioned on the execution by Mr.&#160;Dekker of a legal release in a form acceptable to ARCA.&#160;A termination for &#8220;cause&#8221; includes Mr.&#160;Dekker&#8217;s willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to ARCA; refusal, unwillingness, failure, or inability to perform his material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of his employment agreement or his Employee Intellectual Property, Confidentiality and Non<span class="nobreak">-Compete</span> Agreement, or any other agreement, with ARCA. &#8220;Good reason&#8221; includes a relocation by us of Mr.&#160;Dekker&#8217;s normal work location greater than 30 miles; a decrease in current base salary by more than 15%, with certain exceptions; and ARCA&#8217;s unilateral decision to significantly and detrimentally reduce Mr.&#160;Dekker&#8217;s job responsibilities.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">168</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">Outstanding Equity Awards at Fiscal Year End</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table shows for the fiscal year ended December&#160;31, 2023, certain information regarding outstanding equity awards at fiscal year<span class="nobreak">-end</span> for ARCA named executive officers.</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="8" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Option Awards</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Securities <br/>Underlying <br/>Unexercised<br/>Options<br/>(#) <br/>Exercisable</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Securities <br/>Underlying <br/>Unexercised<br/>Options<br/>(#) <br/>Unexercisable</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Option <br/>Exercise<br/>Price<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Option<br/>Expiration<br/>Date</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow, Former President and Chief Executive Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">408</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">245.70</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/26/2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">205</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">84.42</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/11/2025</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,511</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">59.40</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6/8/2026</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,333</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45.00</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/15/2027</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">142,500</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">47,500</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.27</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/21/2030</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">63,334</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">31,666</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.29</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/14/2031</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer, President and Chief Operating Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">83</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">245.70</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/26/2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">108</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">84.42</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/11/2025</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">866</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">59.40</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6/8/2026</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,400</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">45.00</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">2/15/2027</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52,500</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17,500</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.27</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/21/2030</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">23,334</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,666</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.29</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/14/2031</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker, Secretary, Chief Financial Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,521</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">19,479</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.06</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5/10/2031</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11,800</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,900</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">&#8203;<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)(4)</span></p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.29</p>
					</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB_Repeat" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">12/14/2031</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Options vest in 48<span class="nobreak"> </span>monthly installments measured from December&#160;21, 2020.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Options vest in 36<span class="nobreak"> </span>monthly installments measured from December&#160;14, 2021.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Options vested 25% after one year, then in 36<span class="nobreak"> </span>monthly installments measured from May&#160;10, 2021.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>In the event of a change in control of ARCA, 50% of the unvested shares subject to this award shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i)&#160;the one<span class="nobreak">-year</span> anniversary of the closing date or (ii)&#160;involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested. </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">169</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">ARCA Director Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table shows for the fiscal year ended December&#160;31, 2023, certain information with respect to the compensation of all non<span class="nobreak">-employee</span> directors of ARCA:</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold-SmallCaps" style="font-style:normal;font-variant:small-caps;font-weight:bold;">Director Compensation</span><span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(1)</span></p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-31" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Fees&#160;Earned <br/>or&#160;Paid&#160;in <br/>Cash&#160;<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Option <br/>Awards <br/>($)</span><span class="Bold-Superscript" style="font-style:normal;font-weight:bold;vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Nonqualified <br/>Deferred <br/>Compensation <br/>Earnings&#160;<br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">All&#160;Other <br/>Compensation <br/>($)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Total&#160;<br/>($)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Linda Grais, M.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">162,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">162,500</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Raymond L.&#160;Woosley, M.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)(10)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Robert E.&#160;Conway<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">195,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">195,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Dan J.&#160;Mitchell<span class="Superscript" style="vertical-align:super;font-size:58%;">(6)(10)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52,500</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">52,500</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Anders Hove<span class="Superscript" style="vertical-align:super;font-size:58%;">(7)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">150,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">150,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Jacob Ma-Weaver<span class="Superscript" style="vertical-align:super;font-size:58%;">(8)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">James Flynn<span class="Superscript" style="vertical-align:super;font-size:58%;">(9)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.34%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.13%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.62%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,000</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Dr.&#160;Bristow, ARCA&#8217;s former President and Chief Executive Officer, was also a director during the year ended December&#160;31, 2023, but did not receive any additional compensation for his service as a director. Dr.&#160;Bristow&#8217;s compensation as an executive officer is set forth above under &#8220;Executive Compensation&#160;&#8212;&#160;Summary Compensation Table.&#8221;</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The amounts reported under &#8220;Option Awards&#8221; in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic&#160;718, Compensation&#160;&#8212;&#160;Stock Compensation, excluding the effects of estimated forfeitures. The value of stock option awards was estimated using the Black<span class="nobreak">-Scholes</span> option<span class="nobreak">-pricing</span> model. The valuation assumptions used in the valuation of option grants may be found in Note&#160;8 to ARCA&#8217;s financial statements included in this annual report on Form&#160;10<span class="nobreak">-K</span> for the year ended December&#160;31, 2023.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Dr.&#160;Grais was 19,458, all of which were fully vested. Includes $52,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Dr.&#160;Woosley was 19,458, all of which were fully vested.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Mr.&#160;Conway, Chairman of ARCA&#8217;s board of directors, was 19,458, all of which were fully vested. Includes $52,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Mr.&#160;Mitchell was 19,577, all of which were fully vested.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(7)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Dr.&#160;Hove was 18,999, all of which were fully vested. Includes $52,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(8)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Mr.&#160;Ma<span class="nobreak">-Weaver</span> was 18,000, of which 12,000 shares were fully vested. Includes $37,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(9)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>The aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31, 2023, for Mr.&#160;Flynn was 12,000, of which 4,000 shares were vested.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(10)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>These directors resigned from ARCA&#8217;s board of directors effective February&#160;2, 2024.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA revised its compensation plan for non<span class="nobreak">-employee</span> directors to provide that non<span class="nobreak">-employee</span> directors will be compensated for their service on ARCA&#8217;s board of directors, as follows:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Each non<span class="nobreak">-employee</span> director will receive an annual retainer fee of $40,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>As additional compensation for their services, each non<span class="nobreak">-employee</span> director will receive (i), upon joining ARCA&#8217;s board of directors, an initial option grant to purchase 12,000<span class="nobreak"> </span>shares of ARCA&#8217;s Common Stock under the 2020 Plan, (ii), in 2021 the members of the board of directors received a one<span class="nobreak">-time</span> retention option grant to purchase 12,000<span class="nobreak"> </span>shares of ARCA&#8217;s Common Stock under the 2020 Plan and (iii), on an annual basis as of the date of ARCA&#8217;s annual stockholder meeting, an annual option grant to purchase 6,000<span class="nobreak"> </span>shares of ARCA&#8217;s Common Stock under the 2020 Plan; provided that such non<span class="nobreak">-employee</span> director </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">170</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">has served on ARCA&#8217;s board of directors for at least six&#160;months prior to the date of grant (unless such six<span class="nobreak">-month</span> period is modified by recommendation of the Nominating and Corporate Governance Committee and approved by the Compensation Committee);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The Chairman of ARCA&#8217;s board of directors will receive an additional annual retainer fee of $30,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s Audit Committee chair will receive an additional annual retainer fee of $15,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The chairs of ARCA&#8217;s Compensation Committee and Nominating and Corporate Governance Committee will each receive an additional annual retainer fee of $10,000;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Each non<span class="nobreak">-chair</span> member of ARCA&#8217;s Audit Committee will receive an additional annual retainer fee of $7,500; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Each non<span class="nobreak">-chair</span> member of ARCA&#8217;s Compensation Committee and Nominating and Corporate Governance Committees will receive an additional annual retainer fee of $5,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On January&#160;30, 2024, ARCA approved paying compensation to its existing non<span class="nobreak">-employee</span> directors, pursuant to ARCA&#8217;s Director Compensation Policy, by granting to Dr.&#160;Linda Grais, Dr.&#160;Anders Hove, Mr.&#160;Robert Conway, Mr.&#160;Daniel Mitchell, Dr.&#160;Raymond Woosley, Mr.&#160;James Flynn and Mr.&#160;Jacob Ma<span class="nobreak">-Weaver</span> options to purchase 6,000<span class="nobreak"> </span>shares of common stock at an exercise price of $1.64 per share, the closing price of ARCA&#8217;s common stock on January&#160;30, 2024. The options are subject to the terms and conditions of the Plan and ARCA&#8217;s standard forms of Stock Option Agreement and Option Grant Notice for the Plan. The options vest in 12 equal monthly installments beginning on January&#160;30, 2024, assuming Dr.&#160;Grais&#8217;, Dr.&#160;Hove&#8217;s, Mr.&#160;Conway&#8217;s, Mr.&#160;Mitchell&#8217;s, Dr.&#160;Woosley&#8217;s, Mr.&#160;Flynn&#8217;s and Mr.&#160;Ma<span class="nobreak">-Weaver</span>&#8217;s continued service on the Board for such periods.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2022, ARCA&#8217;s board of directors established a Special Committee to evaluate strategic options for maximizing stockholder value. The Special Committee includes ARCA board Chairman Robert E.&#160;Conway (chair), and board members Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma<span class="nobreak">-Weaver</span>. In December&#160;2023, based on the recommendation of the Nominating and Corporate Governance Committee, the board determined that each member of the Special Committee will be paid $7,500 per month for each month of substantive service on the Special Committee. In December&#160;2023, payments for 2022 service were made to the members of the Special Committee of $52,500 to each of Robert E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and $37,500 to Jacob Ma<span class="nobreak">-Weaver</span> (joined the Committee in June&#160;2022). Payments for 2023 service were paid in 2024 to the members of the Special Committee consisting of $52,500 to each of Robert E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma<span class="nobreak">-Weaver</span>. Payments for 2024 service through April&#160;2024 were paid in 2024 to the members of the Special Committee consisting of $30,000 to each of Robert E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma<span class="nobreak">-Weaver</span>.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">171</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T16"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA EQUITY COMPENSATION PLAN INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth information as of December&#160;31, 2023, for all of ARCA&#8217;s equity compensation plans:</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-34" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 47.22%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Plan Category</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Securities <br/>to&#160;be&#160;Issued&#160;Upon <br/>Exercise&#160;of <br/>Outstanding <br/>Options&#160;or&#160;Upon <br/>Vesting&#160;of <br/>Restricted&#160;Stock <br/>Unit</span>s<br/><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">(a)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Weighted <br/>Average <br/>Exercise <br/>Price&#160;of <br/>Outstanding <br/>Options<br/>($)<br/>(b)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.44%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of&#160;Securities <br/>Remaining <br/>Available&#160;for <br/>Future&#160;Issuance <br/>Under&#160;Equity <br/>Compensation <br/>Plans&#160;(Excluding <br/>Securities <br/>Reflected&#160;in<br/>Column(a)) <br/>(c)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 47.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Equity compensation plans approved by security holders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.44%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">459,718</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 47.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Equity compensation plans not approved by security holders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.44%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 47.22%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 19.44%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">459,718</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On December&#160;10, 2020, ARCA stockholders approved the ARCA biopharma, Inc. 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;) at ARCA&#8217;s 2020 annual meeting of stockholders. The 2020 Plan is the successor to the Amended and Restated ARCA biopharma, Inc. 2013 Equity Incentive Plan (the &#8220;2013 Plan&#8221;). A description of the 2020 Plan is set forth in Note&#160;8 to ARCA&#8217;s financial statements included in this proxy statement/prospectus. The 2020 Plan only has options outstanding as of December&#160;31, 2023; no warrants or rights are outstanding under this plan; therefore, all values in the above table relate solely to the outstanding options.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On September&#160;17, 2013, ARCA stockholders approved the 2013 Plan at ARCA&#8217;s 2013 annual meeting of stockholders. On June&#160;9, 2016, ARCA stockholders approved an amendment to the 2013 Plan (as amended, the &#8220;Amended 2013 Plan&#8221;). A description of the 2013 Plan and the Amended 2013 Plan is set forth in Note&#160;8 to ARCA&#8217;s financial statements included in this proxy statement/prospectus. The Amended 2013 Plan only has options outstanding as of December&#160;31, 2023; no warrants or rights are outstanding under this plan; therefore, all values in the above table relate solely to the outstanding options.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Compensation Risks</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its approach to goal setting, setting of targets with payouts at multiple levels of performance, and evaluation of performance results assist in mitigating excessive risk<span class="nobreak">-taking</span> that could harm the value or reward poor judgment by its executives. ARCA believes several features of its programs reflect sound risk management practices. ARCA believes it has allocated compensation among base salary and short and long<span class="nobreak">-term</span> compensation target opportunities in such a way as to not encourage excessive risk<span class="nobreak">-taking</span>. The multi<span class="nobreak">-year</span> vesting of equity awards properly accounts for the time horizon of risk. Furthermore, ARCA&#8217;s Compensation Committee assesses and monitors whether any of ARCA&#8217;s compensation policies and programs has the potential to encourage excessive risk<span class="nobreak">-taking</span> on an annual basis.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">172</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T15"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA EXECUTIVE COMPENSATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following completion of the Merger, certain executive officers of Oruka will become executive officers of the combined company. Because Oruka was not formed until 2024, there were no executive officers during 2023. This section sets forth the current compensatory arrangements for the following executive officers of Oruka as of March&#160;31, 2024, each of whom is expected to become an executive officer of the combined company.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Position</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appointment Date</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President and Chief Executive Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">February&#160;26, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">General Counsel and Secretary</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">April&#160;30, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Medical Officer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">April&#160;18, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 32.05%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Senior Vice President, Finance and Treasurer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">March&#160;22, 2024</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Employment Agreements</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreement with Dr.&#160;Klein</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and Dr.&#160;Klein are party to an employment letter agreement, pursuant to which Dr.&#160;Klein receives an annual base salary of $600,000 and a target annual bonus of 50% of his base salary, pro<span class="nobreak">-rated</span> for 2024. In connection with his entry into his employment agreement, Dr.&#160;Klein purchased 1,491,646<span class="nobreak"> </span>shares of Oruka common stock at the fair market value on the purchase date, which will vest as to 25% on February&#160;26, 2025 and in equal monthly installments for the 36&#160;months thereafter. The employment agreement also provides that Dr.&#160;Klein will receive periodic grants of stock options, subject to approval by Oruka&#8217;s board of directors, sufficient to maintain Dr.&#160;Klein&#8217;s ownership at approximately 5% on a fully<span class="nobreak">-diluted</span> basis (the &#8220;Target Ownership Percentage&#8221;) until Oruka has raised an aggregate of $200&#160;million in financing (the &#8220;Covered Limit&#8221;). As a result, Oruka expects to issue Dr.&#160;Klein warrants of Oruka in full satisfaction of such obligation to maintain his ownership in Oruka at the Target Ownership Percentage concurrently with the closing of the Oruka pre<span class="nobreak">-closing</span> financing up to the Covered Limit. Such warrants will vest 25% on April<span class="nobreak"> </span>3, 2025 and in equal monthly installments thereafter over 36<span class="nobreak"> </span>months.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of Dr.&#160;Klein&#8217;s termination by Oruka without cause prior to (or more than 12&#160;months following) a change in control of Oruka, Dr.&#160;Klein is eligible for the following severance benefits, subject to his execution and non<span class="nobreak">-revocation</span> of a release of claims: (i)&#160;severance payments equal to 12&#160;months of his base salary, (ii)&#160;any earned but unpaid bonus for the year preceding the date of termination, (iii)&#160;accelerated vesting of 30% of the unvested portion of any outstanding time<span class="nobreak">-based</span> equity awards, and (iv)&#160;Oruka<span class="nobreak">-subsidized</span> continuation coverage under Oruka&#8217;s group health plans for up to 12&#160;months. If Dr.&#160;Klein is terminated by Oruka without cause or by Dr.&#160;Klein for good reason on or within 12&#160;months following a change in control of Oruka, Dr.&#160;Klein will receive the foregoing benefits, as well as full acceleration of all outstanding time<span class="nobreak">-based</span> equity awards.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements with Other Executive Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and Mr.&#160;Quinlan are party to an employment letter agreement, pursuant to which Mr.&#160;Quinlan receives an annual base salary of $460,000 and a target annual bonus of 40% of his base salary, pro<span class="nobreak">-rated</span> for 2024. Mr.&#160;Quinlan&#8217;s employment agreement also provided for an initial grant of stock options to purchase 400,000<span class="nobreak"> </span>shares of Oruka common stock, which vest as to 25% on the first anniversary of his start date and in equal monthly installments for the 36&#160;months thereafter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and Dr. Goncalves are party to an employment letter agreement, pursuant to which Dr. Goncalves receives an annual base salary of $460,000 and a target annual bonus of 40% of her base salary, pro<span class="nobreak">-rated</span> for 2024. In connection with her appointment, Dr. Goncalves was granted stock options to purchase 400,000<span class="nobreak"> </span>shares of Oruka common stock, which vest as to 25% on the first anniversary of her start date and in equal monthly installments for the 36&#160;months thereafter. The employment agreement also provided for a $100,000 signing bonus, which is subject to pro<span class="nobreak">-rata</span> repayment if Dr. Goncalves is terminated for cause or resigns within one year following her start date.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">173</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and Mr.&#160;Agarwal are party to an employment letter agreement, pursuant to which Mr.&#160;Agarwal receives an annual base salary of $360,000 and a target annual bonus of 35% of his base salary. Mr.&#160;Agarwal&#8217;s employment agreement also provided for an initial grant of stock options to purchase 225,000<span class="nobreak"> </span>shares of Oruka common stock, which vest as to 25% on the first anniversary of his start date and in equal monthly installments for the 36&#160;months thereafter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The employment agreements with Messrs. Quinlan and Agarwal and Dr. Goncalves provide for the following severance benefits upon their termination by Oruka without cause prior to (or more than 12&#160;months following) a change in control of Oruka, subject to the executive&#8217;s execution and non<span class="nobreak">-revocation</span> of a release of claims: (i)&#160;severance payments equal to six&#160;months of the executive&#8217;s base salary, (ii)&#160;any earned but unpaid bonus for the year preceding the date of termination and (iii)&#160;Oruka<span class="nobreak">-subsidized</span> continuation coverage under Oruka&#8217;s group health plans for up to six&#160;months. If the executive is terminated by Oruka without cause or by the executive for good reason on or within 12&#160;months following a change in control of Oruka, the executive will receive the foregoing benefits, as well as full acceleration of all outstanding time<span class="nobreak">-based</span> equity awards.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Summary Description of Oruka&#8217;s 2024 Equity Incentive Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka maintains the 2024 Equity Incentive Plan, the purpose of which is to advance the interests of Oruka&#8217;s stockholders by enhancing Oruka&#8217;s ability to attract, retain and motivate persons who are expected to make important contributions to Oruka and by providing such persons with equity ownership opportunities and performance<span class="nobreak">-based</span> incentives that are intended to better align the interests of such persons with those of Oruka&#8217;s stockholders. The 2024 Equity Incentive Plan provides for the issuance of up to 872,912<span class="nobreak"> </span>shares of Oruka common stock, which may be granted as stock options, restricted stock, restricted stock units and other stock<span class="nobreak">-based</span> awards to eligible employees, officers, directors, consultants and advisors of Oruka on such terms and conditions as approved by Oruka&#8217;s board of directors or any committee appointed by Oruka&#8217;s board of directors to administer the 2024 Equity Incentive Plan. No grants will be made under the 2024 Equity Incentive Plan following consummation of the Merger.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">174</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T14"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA DIRECTOR COMPENSATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because Oruka was not formed until 2024, there were no directors during 2023. In connection with his appointment as a member of Oruka&#8217;s board of directors, Dr.&#160;Kulkarni entered into a letter agreement, pursuant to which he received: (i)&#160;stock options to purchase 250,000<span class="nobreak"> </span>shares of Oruka common stock, which vest 25% on the first anniversary of his appointment date and in equal monthly installments for the 36&#160;months thereafter; and (ii)&#160;stock options to purchase 100,000<span class="nobreak"> </span>shares of Oruka common stock, which vest upon the first anniversary of the date Dr.&#160;Kulkarni is appointed Chairman of Oruka&#8217;s board of directors and will be forfeited if Dr.&#160;Kulkarni is not appointed Chairman of Oruka&#8217;s board of directors prior to March&#160;22, 2025. In connection with her appointment as a member of Oruka&#8217;s board of directors, Ms. Ball entered into a letter agreement, pursuant to which she received stock options to purchase 125,000<span class="nobreak"> </span>shares of Oruka common stock, which vest 25% on the first anniversary of her appointment date and in equal monthly installments for the 36&#160;months thereafter. In connection with his appointment as a member of Oruka&#8217;s board of directors, Mr.&#160;Dambkowski received stock options to purchase 125,000<span class="nobreak"> </span>shares of Oruka common stock, which vest 25% on the first anniversary of his appointment date and in equal monthly installments for the 36&#160;months thereafter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In anticipation of his service on the Oruka board of directors, Dr.&#160;Turtle purchased 149,164<span class="nobreak"> </span>shares of Oruka common stock at the fair market value on the purchase date. The purchased shares are subject to vesting as to 25% on the first anniversary of his appointment date and in equal monthly installments for the 36&#160;months thereafter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">It is expected that Oruka will implement cash retainers for all non<span class="nobreak">-employee</span> directors, including an annual cash retainer.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">175</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9980"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MATTERS BEING SUBMITTED TO A VOTE OF ARCA STOCKHOLDERS </span></p>
		<a id="T9981"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 1&#160;&#8212;&#160;THE NASDAQ STOCK ISSUANCE PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve (i)&#160;the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to the stockholders of Oruka pursuant to the Merger Agreement, which shares of ARCA common stock will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the First Merger and (ii)&#160;the change of control of ARCA resulting from the First Merger, pursuant to Nasdaq Listing Rules&#160;5635(a)&#160;and 5635(b), respectively.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately after the First Merger, ARCA securityholders as of immediately prior to the First Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), and former holders of Oruka securities are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. Under certain circumstances further described in the Merger Agreement, the ownership percentages may be adjusted up or down, including if ARCA&#8217;s net cash as of closing is lower than $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA will assume outstanding and unexercised options and warrants to purchase shares of Oruka common stock, and such securities will be converted into options and warrants, as applicable, to purchase shares of ARCA common stock, subject to certain adjustments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $5.0&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The terms of, reasons for and other aspects of the Merger Agreement and the Merger are described in detail in the section of this proxy statement/prospectus titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>.&#8221; A copy of the Merger Agreement is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Reason for the Proposal</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under Nasdaq Listing Rule&#160;5635(a)(1), a company listed on Nasdaq is required to obtain stockholder approval prior to the issuance of common stock, among other things, in connection with the acquisition of another company&#8217;s stock, if the number of shares of common stock to be issued is in excess of 20% of the number of shares of common stock then outstanding. The potential issuance of the shares of ARCA common stock in the Merger exceeds the 20% under the Nasdaq Listing Rules and is expected to represent approximately 97.61% of ARCA common stock on a fully<span class="nobreak">-diluted</span> basis immediately following the Merger. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(a)(1), ARCA must obtain the approval of ARCA stockholders for the issuance of these shares of common stock in the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under Nasdaq Listing Rule&#160;5635(b), a company listed on Nasdaq is required to obtain stockholder approval prior to an issuance of stock that will result in a &#8220;change of control&#8221; of the listed company. It is expected that Nasdaq will determine that the Merger constitutes a &#8220;change of control&#8221; of the listed company. Accordingly, in order to ensure compliance with Nasdaq Listing Rule&#160;5635(b), ARCA must obtain the approval of ARCA stockholders of the change of control resulting from the Merger.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">176</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting is required to approve the Nasdaq Stock Issuance Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Nasdaq Stock Issuance Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Nasdaq Stock Issuance Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is conditioned upon the approval of the Nasdaq Stock Issuance Proposal. Notwithstanding the approval of the Nasdaq Stock Issuance Proposal, if the Merger is not consummated for any reason, the actions contemplated by the Nasdaq Stock Issuance Proposal will not be effected.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Nasdaq Stock Issuance Proposal is conditioned on the approval of the Authorized Share Increase Proposal. Notwithstanding the approval of the Nasdaq Stock Issuance Proposal, if the Authorized Share Increase Proposal is not approved, the actions contemplated by the Nasdaq Stock Issuance Proposal will not be effected and the Merger will not be consummated.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain ARCA stockholders have agreed to vote any shares of ARCA common stock owned by them in favor of the Nasdaq Stock Issuance Proposal. See &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements</span>&#8221; beginning on page 153 of this proxy statement/prospectus for more information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Nasdaq Stock Issuance Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE NASDAQ STOCK ISSUANCE PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">177</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9982"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 2&#160;&#8212;&#160;THE AUTHORIZED SHARE INCREASE PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve an amendment to the ARCA Charter to increase the number of authorized shares of ARCA common stock (the &#8220;ARCA Share Increase Amendment&#8221;). On July<span class="nobreak"> </span>20, 2024, ARCA&#8217;s board of directors approved a proposal to amend the ARCA Charter to increase the number of authorized shares of ARCA common stock from 100,000,000<span class="nobreak"> </span>shares to 545,000,000, which would also have the effect of increasing the total number of authorized shares from 105,000,000, including ARCA preferred stock, to 550,000,000 (the &#8220;ARCA Share Increase&#8221;), in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G</span> to this proxy statement/prospectus. On the Record Date, there were 14,507,143<span class="nobreak"> </span>shares of ARCA common stock issued and outstanding, and 1,070,425<span class="nobreak"> </span>shares of ARCA common stock reserved for issuance. Accordingly, approximately 84,422,432<span class="nobreak"> </span>shares of the total number of ARCA common stock currently authorized remain available for issuance or may be reserved for issuance.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Form of the ARCA Share Increase Amendment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Share Increase Amendment would amend and restate the first paragraph of Article&#160;IV of the ARCA Charter in its entirety as follows:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">&#8220;The total number of shares of all classes of stock this Corporation shall have authority to issue is 550,000,000, consisting of 545,000,000<span class="nobreak"> </span>shares of Common Stock, par value $0.001 per share, and 5,000,000<span class="nobreak"> </span>shares of Preferred Stock, par value $0.001 per share. The Preferred Stock may be issued from time to time, in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issue of any shares thereof.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Background and Reasons for the ARCA Share Increase Amendment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter currently authorizes the issuance of up to 100,000,000<span class="nobreak"> </span>shares of ARCA common stock and 5,000,000<span class="nobreak"> </span>shares of preferred stock. As of the close of business on the Record Date, there were 14,507,143<span class="nobreak"> </span>shares of ARCA common stock issued and outstanding, and 1,070,425<span class="nobreak"> </span>shares of ARCA common stock reserved for issuance. Accordingly, 84,422,432<span class="nobreak"> </span>shares of the total number of ARCA common stock currently authorized remain available for issuance or may be reserved for issuance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As described in greater detail in the section of this proxy statement/prospectus titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>,&#8221; pursuant to the Merger Agreement, ARCA will be required to issue shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, to Oruka stockholders and to assume Oruka&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Oruka common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The number of shares of ARCA common stock currently authorized and unissued and not reserved for issuance is not sufficient for (i)&#160;the issuance of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, pursuant to the Merger Agreement and (ii)&#160;the assumption of Oruka&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Oruka common stock. In addition, there will not be sufficient shares of ARCA common stock available for issuance in connection with possible future acquisitions, equity and equity<span class="nobreak">-based</span> financings, possible future awards under employee benefit plans and other corporate purposes that ARCA&#8217;s board of directors may determine to be desirable. Therefore, ARCA&#8217;s board of directors has determined that the ARCA Share Increase Amendment is in the best interests of ARCA and its stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the ARCA Share Increase Amendment is approved by stockholders, upon its effectiveness, and without giving effect to the proposed reverse stock split described in Proposal&#160;No. 3 of this proxy statement/prospectus, ARCA will have a total of 545,000,000 authorized shares of ARCA common stock, with 14,507,143<span class="nobreak"> </span>shares of ARCA common stock issued and outstanding (as of the Record Date), and 1,070,425<span class="nobreak"> </span>shares reserved for issuance (as of the Record Date), leaving a balance of 529,422,432<span class="nobreak"> </span>shares of ARCA common stock authorized and unissued and not reserved for any specific purpose. Such outstanding share amounts will be correspondingly adjusted to the extent the proposed reverse stock split is effected prior to effectiveness of the ARCA Share Increase Amendment, but the reverse stock split will not change the number of authorized shares of common or preferred stock. The ARCA Share Increase Amendment will have no effect on the authorized shares of ARCA Preferred Stock.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">178</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except for (i)&#160;the issuance of shares of ARCA common stock, including shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock, and (ii)&#160;the issuance of shares of ARCA common stock that may result from the assumption of Oruka&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Oruka common stock, each pursuant to the terms of the Merger Agreement, ARCA does not currently have any plans, proposals or arrangement to issue any of its authorized but unissued shares of common stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Possible Effects of the ARCA Share Increase Amendment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the ARCA Share Increase Amendment is approved and becomes effective, the additional authorized shares would be available for issuance at the discretion of ARCA&#8217;s board of directors and without further stockholder approval, except as may be required by law or Nasdaq rules. The additional shares of authorized ARCA common stock would have the same rights and privileges as the shares of ARCA common stock currently issued and outstanding. Holders of ARCA common stock have no preemptive rights. The ARCA Share Increase would not change the number of shares of common stock outstanding, nor will it have any immediate dilutive effect; however, the issuance of additional shares of ARCA common stock authorized by the ARCA Share Increase may, among other things, have a dilutive effect on earnings per share and on stockholders&#8217; equity and voting rights. Furthermore, future sales of substantial amounts of ARCA common stock, or the perception that these sales might occur, could adversely affect the prevailing market price of ARCA common stock or limit ARCA&#8217;s ability to raise additional capital. ARCA stockholders should recognize that, as a result of this proposal, they will own a smaller percentage of shares relative to the total authorized shares of the company than they presently own.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal or Dissenters&#8217; Rights</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the DGCL, stockholders are not entitled to appraisal rights or dissenter&#8217;s rights with respect to the ARCA Share Increase Amendment or the ARCA Share Increase.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Effectiveness of Amendment</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the ARCA Share Increase Amendment is approved by the stockholders at the ARCA special meeting, it will become effective upon the filing of a certificate of amendment, a copy of which is attached as&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G&#160;</span>to this proxy statement/prospectus, with the Delaware Secretary of State or such later effective date and time as specified in the certificate of amendment in accordance with Delaware law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Copies of the ARCA Charter and the certificates of amendment to the ARCA Charter are available as exhibits to this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the votes properly cast for or against the Authorized Share Increase Proposal by the holders of ARCA common stock is required to approve the Authorized Share Increase Proposal. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Authorized Share Increase Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Nasdaq Stock Issuance Proposal and the Merger are conditioned upon the approval of the Authorized Share Increase Proposal. In order to have an adequate number of available shares to effect the Merger, the stockholders of ARCA will need to approve the Authorized Share Increase Proposal. Additionally, ARCA&#8217;s board of directors may determine to effect the Authorized Share Increase Proposal, if approved, even if the Nasdaq Stock Issuance Proposal is not approved by the ARCA stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain ARCA stockholders have agreed to vote any shares of ARCA common stock owned by them in favor of the Authorized Share Increase Proposal. See &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements</span>&#8221; beginning on page 153 of this proxy statement/prospectus for more information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Authorized Share Increase Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE AUTHORIZED SHARE INCREASE PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">179</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9983"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 3&#160;&#8212;&#160;THE REVERSE STOCK SPLIT PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range of 6<span class="nobreak">-for-1</span> to 12<span class="nobreak">-for-1</span>, to be determined mutually by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors (the &#8220;Split Ratio&#8221;). The final Split Ratio and effectiveness of such amendment and the abandonment of such amendment will be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time, assuming this proposal is approved by ARCA&#8217;s stockholders. On July<span class="nobreak"> </span>20, 2024, ARCA&#8217;s board of directors adopted resolutions approving the proposed certificate of amendment to the ARCA Charter in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;H</span> to this proxy statement/prospectus. If this certificate of amendment is filed with the Secretary of State of the State of Delaware, upon its effectiveness (the &#8220;reverse stock split effective time&#8221;), it will effect the reverse stock split by the Split Ratio but will not increase the par value of ARCA common stock. At the reverse stock split effective time, the issued and outstanding shares of ARCA common stock immediately prior to the reverse stock split effective time will automatically without further action on the part of ARCA be combined into a smaller number of shares in accordance with the final Split Ratio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">By approving the Reverse Stock Split Proposal, ARCA stockholders will approve the amendment to the ARCA Charter pursuant to which any whole number of issued and outstanding shares of ARCA common stock, between and including six (6) and twelve (12), would be combined into one share of ARCA common stock, and will authorize ARCA&#8217;s board of directors to file the certificate of amendment. As of the Record Date, 100,000,000<span class="nobreak"> </span>shares of ARCA common stock were authorized, 14,507,143<span class="nobreak"> </span>shares of ARCA common stock were outstanding and no shares of ARCA common stock were held in treasury.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The reverse stock split will not change the number of authorized shares of ARCA common stock or preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All holders of ARCA common stock will be affected proportionately by the reverse stock split. No fractional shares of ARCA common stock will be issued as a result of the reverse stock split. Instead, ARCA stockholders who otherwise would be entitled to receive fractional shares will be entitled to receive cash as set forth below under the caption &#8220;No Fractional Shares.&#8221; Each ARCA stockholder will hold the same percentage of the outstanding ARCA common stock immediately following the reverse stock split as that ARCA stockholder did immediately prior to the reverse stock split, except to the extent that the reverse stock split results in ARCA stockholders receiving cash in lieu of fractional shares.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Reasons for the Reverse Stock Split</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors approved the proposal approving the amendment to the ARCA Charter effecting the reverse stock split for the following reasons:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes effecting the reverse stock split will result in an increase in the minimum bid price of ARCA common stock and reduce the risk of a delisting of ARCA common stock from Nasdaq in the future;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes a higher stock price may help generate investor interest in ARCA, and ultimately the combined company, and help ARCA attract and retain employees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes a higher stock price may increase trading volume in ARCA common stock and facilitate future financings by the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes that the resulting increase in the number of authorized and unissued shares available for future issuance will be necessary for the issuance of shares to the stockholders of Oruka pursuant to the Merger Agreement, as described in the Nasdaq Stock Issuance Proposal, the issuance of shares of ARCA common stock that may result from the assumption of Oruka&#8217;s 2024 Equity Incentive Plan and outstanding options and warrants to purchase Oruka common stock, pursuant to the Merger Agreement, and ultimately the consummation of the Merger; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:7pt;margin-top:7pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s board of directors believes that a range of reverse stock split ratios provides it with the most flexibility to achieve the desired results of the reverse stock split.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">180</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Requirements for Listing on Nasdaq</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA common stock is currently listed on The Nasdaq Capital Market under the symbol &#8220;ABIO.&#8221; ARCA intends to file an initial listing application pursuant to the terms of the Merger Agreement for the combined company to list the securities of the combined company on Nasdaq.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">According to the Nasdaq rules, an issuer must, in a case such as this, apply for initial inclusion following a transaction whereby the issuer combines with a non<span class="nobreak">-Nasdaq</span> entity, resulting in a change of control of the issuer and potentially allowing the non<span class="nobreak">-Nasdaq</span> entity to obtain a Nasdaq listing. Accordingly, the listing standards of Nasdaq will require ARCA to have, among other things, a $4.00 per share minimum bid price for a certain number of&#160;trading days preceding the closing of the Merger. Therefore, the reverse stock split may be necessary in order to satisfy Nasdaq requirements and consummate the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, it is a condition to the closing of the Merger that the shares of ARCA common stock to be issued in the Merger pursuant to the Merger Agreement have been approved for listing on Nasdaq.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">One of the effects of the reverse stock split will be to effectively increase the proportion of authorized shares which are unissued relative to those which are issued. This could result in ARCA&#8217;s management being able to issue more shares without further stockholder approval. The reverse stock split will not affect the number of authorized shares of ARCA capital stock, which will continue to be authorized pursuant to the ARCA Charter.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potential Increased Investor Interest</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:0pt;text-indent:24pt;margin-top:8pt;">On July<span class="nobreak"> </span>19, 2024, ARCA common stock closed at $3.29 per share. An investment in ARCA common stock may not appeal to brokerage firms that are reluctant to recommend lower priced securities to their clients. Investors may also be dissuaded from purchasing lower priced stocks because the brokerage commissions, as a percentage of the total transaction, tend to be higher for such stocks. Moreover, the analysts at many brokerage firms do not monitor the trading activity or otherwise provide research coverage of lower priced stocks. Also, ARCA&#8217;s board of directors believes that most investment funds are reluctant to invest in lower priced stocks.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There are risks associated with the reverse stock split, including that the reverse stock split may not result in an increase in the per share price of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA cannot predict whether the reverse stock split will increase the market price for ARCA common stock. The history of similar stock split combinations for companies in like circumstances is varied. There is no assurance that:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price per share of ARCA common stock after the reverse stock split will rise in proportion to the reduction in the number of shares of ARCA common stock outstanding before the reverse stock split;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the reverse stock split will result in a per share price that will attract brokers and investors who do not trade in lower priced stocks;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the reverse stock split will result in a per share price that will increase the ability of ARCA to attract and retain employees;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price per share will either exceed or remain in excess of the $1.00 minimum bid price as required by Nasdaq for continued listing; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price per share will achieve and maintain the $4.00 minimum bid price requirement for a sufficient period of time for the combined company&#8217;s common stock to be approved for listing by Nasdaq.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The market price of ARCA common stock will also be based on the performance of ARCA, and after the Merger, on the performance of the combined company, and other factors, some of which are unrelated to the number of shares outstanding. If the reverse stock split is effected and the market price of ARCA common stock declines, the percentage decline as an absolute number and as a percentage of the overall market capitalization of ARCA may be greater than would occur in the absence of a reverse stock split. Furthermore, the liquidity of ARCA common stock could be adversely affected by the reduced number of shares that would be outstanding after the reverse stock split.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">181</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effects of the Reverse Stock Split</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the reverse stock split is implemented, after the reverse stock split effective time, the issued and outstanding shares of ARCA common stock immediately prior to the reverse stock split effective time will automatically, without further action on the part of ARCA, be combined into a smaller number of shares proportionately based on the Split Ratio and each ARCA stockholder will own a reduced number of shares of ARCA common stock. The reverse stock split will affect all ARCA stockholders uniformly and will not affect any stockholder&#8217;s percentage ownership interests in ARCA, except that ARCA stockholders who would have otherwise received fractional shares will receive cash in lieu of such fractional shares. After the reverse stock split, each share of ARCA common stock will have the same voting rights and rights to dividends and distributions and will be identical in all other respects to the ARCA common stock now authorized, and ARCA common stock issued pursuant to the reverse stock split will remain fully paid and non<span class="nobreak">-assessable</span>. The reverse stock split is not intended as, and will not have the effect of, a &#8220;going private transaction&#8221; covered by&#160;Rule&#160;13e<span class="nobreak">-3</span>&#160;under the&#160;Exchange&#160;Act. ARCA will continue to be subject to the periodic reporting requirements of the&#160;Exchange&#160;Act.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effect on Shares of ARCA Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The reverse stock split will not change the number of authorized shares of ARCA common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the reverse stock split effective time, ARCA common stock would have a new committee on uniform securities identification procedures number, which is used to identify ARCA common stock. ARCA common stock is currently registered under Section&#160;12(b)&#160;of the&#160;Exchange&#160;Act&#160;and ARCA is subject to the periodic reporting and other requirements of the&#160;Exchange&#160;Act.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effect on ARCA Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The reverse stock split will not change the number of authorized shares of ARCA preferred stock.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Reduction in Stated Capital</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The reverse stock split will not affect the par value of ARCA common stock. As a result, after the reverse stock split effective time, the stated capital on ARCA&#8217;s balance sheet attributable to ARCA common stock will be reduced proportionately based on the Split Ratio, subject to a minor adjustment in respect of the treatment of fractional shares, and the additional paid<span class="nobreak">-in</span> capital account will be credited with the amount by which the stated capital is reduced. ARCA stockholders&#8217; equity, in the aggregate, will remain unchanged.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Effect on Equity Plans and Outstanding Derivative and Convertible Securities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Proportionate adjustments will be made to the per share exercise price, the number of shares issuable upon the exercise, vesting or settlement of all outstanding options and warrants to purchase or acquire, as applicable, shares of ARCA common stock, and the number of shares reserved for issuance pursuant to ARCA&#8217;s existing equity incentive, stock option and employee stock purchase plans will be reduced proportionately based on the Split Ratio.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Procedure for Effecting Reverse Stock Split and Exchange of Stock Certificates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If (i)&#160;the ARCA stockholders approve the Nasdaq Stock Issuance Proposal and the Reverse Stock Split Proposal, (ii)&#160;ARCA&#8217;s board of directors and Oruka&#8217;s board of directors mutually agree that a reverse stock split is necessary, and (iii)&#160;ARCA&#8217;s board of directors still believes that a reverse stock split is in the best interests of ARCA and its stockholders, ARCA will file the certificate of amendment to the ARCA Charter with the Secretary of State of the State of Delaware at such time as ARCA&#8217;s board of directors has determined to be the appropriate reverse stock split effective time at the Split Ratio. If the Reverse Stock Split Proposal is approved and the Nasdaq Stock Issuance Proposal is not approved by ARCA stockholders, ARCA&#8217;s board of directors and Oruka&#8217;s board of directors may mutually agree to delay effecting the reverse stock split without resoliciting stockholder approval or abandon effecting the reverse stock split; otherwise, ARCA&#8217;s board of directors may, in its sole discretion, delay without resolicitation of stockholder approval or abandon effecting the reverse stock split. Beginning at the reverse stock split effective time, each stock certificate representing pre<span class="nobreak">-split</span> shares will be deemed for all corporate purposes to evidence ownership of post<span class="nobreak">-split</span> shares.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">182</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Beneficial Owners of Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the implementation of the reverse stock split, ARCA intends to treat shares held by stockholders in &#8220;street name&#8221; (i.e., through a bank, broker, custodian or other nominee), in the same manner as registered stockholders whose shares are registered in their names. Banks, brokers, custodians or other nominees will be instructed to effect the reverse stock split for their beneficial holders holding ARCA common stock in street name. However, these banks, brokers, custodians or other nominees may have different procedures than registered stockholders for processing the reverse stock split and making payment for fractional shares. If a stockholder holds shares of ARCA common stock with a bank, broker, custodian or other nominee and has any questions in this regard, stockholders are encouraged to contact their bank, broker, custodian or other nominee.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Registered Holders of Common Stock in Book-Entry Form</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain of ARCA&#8217;s registered holders of common stock hold some or all of their shares electronically in book<span class="nobreak">-entry</span> form with ARCA&#8217;s transfer agent,<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>Computershare Trust Company, N.A.&#160;These stockholders do not hold physical stock certificates evidencing their ownership of ARCA common stock. However, they are provided with a statement reflecting the number of<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>shares of ARCA common stock registered in their accounts. If a stockholder holds registered shares in book<span class="nobreak">-entry</span> form with ARCA&#8217;s transfer agent, no action needs to be taken to receive post<span class="nobreak">-reverse</span> stock split shares or payment in lieu of fractional shares, if applicable. If a stockholder is entitled to post<span class="nobreak">-reverse</span> stock split shares, a transaction statement will automatically be sent to the stockholder&#8217;s address of record indicating the number of shares of ARCA common stock held following the reverse stock split.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Registered Holders of Common Stock in Certificate Form</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As soon as practicable after the reverse stock split effective time, the ARCA stockholders will be notified that the reverse stock split has been effected. ARCA expects that the ARCA transfer agent will act as exchange agent for purposes of implementing the exchange of stock certificates. Holders of pre<span class="nobreak">-split</span> shares will be asked to surrender to the exchange agent certificates representing pre<span class="nobreak">-split</span> shares held in certificated form in exchange for certificates representing post<span class="nobreak">-split</span> shares in accordance with the procedures to be set forth in a letter of transmittal to be sent by ARCA.&#160;No new certificates will be issued to a stockholder until such stockholder has surrendered such stockholder&#8217;s outstanding certificate(s)&#160;together with the properly completed and executed letter of transmittal to the exchange agent. Any pre<span class="nobreak">-split</span> shares submitted for transfer, whether pursuant to a sale or other disposition, or otherwise, will automatically be exchanged for post<span class="nobreak">-split</span> shares.&#160;<span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders should not destroy any stock certificate(s)&#160;and should not submit any certificate(s)&#160;unless and until requested to do so</span><span class="Italic" style="font-style:italic;font-weight:normal;">.</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">No Fractional Shares</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No fractional shares will be issued in connection with the reverse stock split. Stockholders of record who otherwise would be entitled to receive fractional shares because they hold a number of pre<span class="nobreak">-split</span> shares not evenly divisible by the number of pre<span class="nobreak">-split</span> shares for which each post<span class="nobreak">-split</span> share is to be reclassified, will be entitled, upon surrender to the exchange agent of certificates representing such shares, to a cash payment in lieu thereof at a price equal to the fraction of a share to which the stockholder would otherwise be entitled multiplied by the closing price of the common stock on Nasdaq on the date of the filing of the certificate of amendment to the ARCA Charter effecting the reverse stock split. For the foregoing purposes, all shares of common stock held by a holder will be aggregated (thus resulting in no more than one fractional share per holder). The ownership of a fractional interest will not give the holder thereof any voting, dividend or other rights except to receive payment therefor as described herein.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Stockholders should be aware that, under the escheat laws of the various jurisdictions where stockholders reside, where ARCA is domiciled and where the funds will be deposited, sums due for fractional interests that are not timely claimed after the effective date of the split may be required to be paid to the designated agent for each such jurisdiction, unless correspondence has been received by ARCA or the exchange agent concerning ownership of such funds within the time permitted in such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds will have to seek to obtain them directly from the state to which they were paid.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">183</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potential Anti-Takeover Effect</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Although the increased proportion of unissued authorized shares to issued shares could, under certain circumstances, have an anti<span class="nobreak">-takeover</span> effect, for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of ARCA&#8217;s board of directors or contemplating a tender offer or other transaction for the combination of ARCA with another company, the reverse stock split is not being proposed in response to any effort of which ARCA is aware to accumulate shares of ARCA common stock or obtain control of ARCA, other than in connection with the Merger, nor is it part of a plan by management to recommend a series of similar amendments to ARCA&#8217;s board of directors and stockholders. Other than the proposals being submitted to the ARCA stockholders for their consideration at the ARCA special meeting, ARCA&#8217;s board of directors does not currently contemplate recommending the<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>adoption of any other actions that could be construed to affect the ability of third parties to take over or change<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>control of ARCA.&#160;For more information, please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors&#160;&#8212;&#160;Risks Related to the Combined Company</span>&#8221; beginning on page 80 of this proxy statement/prospectus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Material U.S.&#160;Federal Income Tax Consequences of the Reverse Stock Split</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a discussion of material U.S.&#160;federal income tax consequences of the reverse stock split that are applicable to a U.S.&#160;holder (as defined below) of ARCA common stock. This discussion applies only to a U.S.&#160;holder that holds its ARCA common stock as a capital asset for U.S.&#160;federal income tax purposes (generally, property held for investment). This discussion is a summary only and does not discuss all aspects of U.S.&#160;federal income taxation that may be relevant to U.S.&#160;holders in light of their particular circumstances or U.S.&#160;holders with special status including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>brokers, dealers or traders in securities, banks, insurance companies, other financial institutions or mutual funds;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>real estate investment trusts; regulated investment companies; tax<span class="nobreak">-exempt</span> organizations or governmental organizations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pass<span class="nobreak">-through</span> entities such as partnerships, S corporations, disregarded entities for federal income tax purposes and limited liability companies (and investors therein);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that have a functional currency other than the U.S.&#160;dollar;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>taxpayers that are subject to the mark<span class="nobreak">-to-market</span> accounting rules;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who hold their shares of ARCA common stock that constitute &#8220;qualified small business stock&#8221; under Section&#160;1202 of the Code or as &#8220;Section&#160;1244 stock&#8221; for purposes of Section&#160;1244 of the Code;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons that hold their ARCA common stock as part of a straddle, constructive sale, hedging, conversion or other integrated or similar transaction;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their shares of ARCA common stock pursuant to the exercise of options or otherwise as compensation or through a tax<span class="nobreak">-qualified</span> retirement plan or through the exercise of a warrant or conversion rights under convertible instruments;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>persons who acquired their ARCA common stock in a transaction subject to the gain rollover provisions of Section&#160;1045 of the Code; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>expatriates or former citizens or long<span class="nobreak">-term</span> residents of the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">This discussion is based on the Code, proposed, temporary and final Treasury Regulations promulgated under the Code, and judicial and administrative interpretations thereof, all as of the date hereof and all of which are subject to change, which change could apply retroactively and could affect the tax consequences described herein. This discussion does not address (i)&#160;the tax consequences of the reverse stock split under U.S.&#160;federal non<span class="nobreak">-income</span> tax law (including estate, gift, or other non<span class="nobreak">-income</span> taxes), (ii)&#160;the tax consequences of the reverse stock split under state, local or non<span class="nobreak">-U</span>.S.&#160;tax laws, (iii)&#160;the impact of the alternative minimum tax provisions of the Code (including the 15% minimum tax applicable to the adjusted financial statement income of certain corporations) or the Medicare contribution tax on net investment income, or (iv)&#160;the tax consequences of transactions effectuated before, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">184</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">subsequent to or concurrently with the reverse stock split (whether or not any such transactions are consummated in connection with the reverse stock split), including, any transaction in which shares of ARCA common stock are acquired.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have not and do not intend to seek any rulings from the IRS regarding the reverse stock split. There can be no assurance that the IRS will not take positions inconsistent with the considerations discussed below or that any such positions would not be sustained by a court.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If any entity or arrangement classified as a partnership for U.S.&#160;federal income tax purposes holds ARCA common stock, the tax treatment of such partnership and any person treated as a partner of such partnership will generally depend on the status and activities of the partner and the activities of the partnership. Each partnership holding any ARCA common stock and each person that is treated as a partner of such partnerships is urged to consult its tax advisor as to the particular U.S.&#160;federal income tax consequences of the reverse stock split.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As used herein, a &#8220;U.S.&#160;holder&#8221; is a beneficial owner of ARCA common stock that is for U.S.&#160;federal income tax purposes:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an individual citizen or resident of the United&#160;States;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a corporation (or other entity that is classified as a corporation for U.S.&#160;federal income tax purposes) that is created or organized (or treated as created or organized) in or under the laws of the United&#160;States, any state thereof, or the District of Columbia or otherwise treated as a U.S.&#160;tax resident for U.S.&#160;federal income tax purposes;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>an estate whose income is subject to U.S.&#160;federal income tax regardless of its source; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a trust if (1)&#160;a U.S.&#160;court can exercise primary supervision over the administration of such trust and one or more U.S.&#160;persons have the authority to control all substantial decisions of the trust or (2)&#160;it has a valid election in place to be treated as a U.S.&#160;person.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Treatment of U.S.&#160;Holders in the Reverse Stock Split</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA intends to treat the reverse stock split as a &#8220;recapitalization&#8221; within the meaning of Section&#160;368(a)&#160;of the Code. Assuming the reverse stock split so qualifies, a U.S.&#160;holder generally will not recognize gain or loss upon the reverse stock split. A U.S.&#160;holder&#8217;s aggregate tax basis in the shares of ARCA common stock received pursuant to the reverse stock split will equal the aggregate tax basis of the shares of the ARCA common stock surrendered, and such U.S.&#160;holder&#8217;s holding period in the shares of ARCA common stock received will include the holding period in the shares of ARCA common stock surrendered. Treasury Regulations provide detailed rules for allocating the tax basis and holding period of the shares of ARCA common stock surrendered for the shares of ARCA common stock received in a recapitalization pursuant to the reverse stock split. If a U.S.&#160;holder holds different blocks of ARCA common stock (generally, ARCA common stock acquired on different dates or at different prices), such U.S.&#160;holder is urged to consult its tax advisor with respect to the determination of the tax bases and/or holding periods of the shares of ARCA common stock received in the reverse stock split.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A U.S.&#160;holder that receives cash in lieu of a fractional share of ARCA common stock pursuant to the reverse stock split will generally recognize capital gain or loss in an amount equal to the difference between the amount of cash received and the U.S.&#160;holder&#8217;s tax basis in the shares of ARCA common stock surrendered that is allocated to such fractional share of ARCA common stock. Any such gain or loss will be long<span class="nobreak">-term</span> capital gain or loss if, as of the effective time of the reverse stock split, the U.S.&#160;holder&#8217;s holding period for such fractional share exceeds one year. Long<span class="nobreak">-term</span> capital gains of certain non<span class="nobreak">-corporate</span> taxpayers, including individuals, are generally taxed at preferential rates. The deductibility of capital losses is subject to limitations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Information Reporting and Backup Withholding</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Assuming the reverse stock split qualifies as a recapitalization within the meaning of Section&#160;368(a)&#160;of the Code, each U.S.&#160;holder who receives shares of ARCA common stock in the reverse stock split is required to retain permanent records pertaining to the reverse stock split and make such records available to any authorized IRS officers and employees. Such records should specifically include information regarding the amount, basis, and fair market value of all transferred property and relevant facts regarding any liabilities assumed or extinguished </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">185</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">as part of such reorganization. Each U.S.&#160;holder who owned immediately before the reverse stock split at least five percent (by vote or value) of the total outstanding stock of ARCA is required to attach a statement to its tax return for the year in which the reverse stock split is consummated that contains the information listed in Treasury Regulation&#160;Section&#160;1.368<span class="nobreak">-3</span>(b). Such statement must include the U.S.&#160;holder&#8217;s tax basis in such holder&#8217;s ARCA common stock surrendered in the reverse stock split, the fair market value of such stock, the date of the reverse stock split and the name and employer identification number of ARCA.&#160;Each U.S.&#160;holder is urged to consult with its tax advisor to comply with these rules.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A U.S.&#160;holder may be subject to information reporting and backup withholding for U.S.&#160;federal income tax purposes on cash paid in lieu of fractional shares in connection with the reverse stock split. Backup withholding will not apply, however, to a U.S.&#160;holder who (i)&#160;furnishes a correct taxpayer identification number and certifies the holder is not subject to backup withholding on IRS Form&#160;W<span class="nobreak">-9</span> or a substantially similar form, or (ii)&#160;certifies the holder is otherwise exempt from backup withholding. If a U.S.&#160;holder does not provide a correct taxpayer identification number on IRS Form&#160;W<span class="nobreak">-9</span> or other proper certification, the stockholder may be subject to penalties imposed by the IRS.&#160;Any amounts withheld under the backup withholding rules may be refunded or allowed as a credit against the federal income tax liability of a U.S.&#160;holder of ARCA common stock, if any, provided the required information is timely furnished to the IRS.&#160;U.S.&#160;holders should consult their tax advisors regarding their qualification for an exemption from backup withholding, the procedures for obtaining such an exemption, and in the event backup withholding is applied, to determine if any tax credit, tax refund or other tax benefit may be obtained.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">This discussion of U.S.&#160;federal income tax considerations of the reverse stock split is for general information purposes only and is not intended to be, and should not be construed as, tax advice. Determining the actual tax consequences of the reverse stock split to you may be complex and will depend on your specific situation and on factors that are not within ARCA&#8217;s knowledge or control. You should consult your tax advisor with respect to the application of U.S.&#160;federal income tax laws to your specific situation as well as any tax consequences arising under the U.S.&#160;federal estate or gift tax rules or under the laws of any state, local, non</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-U</span></span><span class="Bold" style="font-style:normal;font-weight:bold;">.S.&#160;or other taxing jurisdiction.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal or Dissenters&#8217; Rights</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the DGCL, stockholders are not entitled to appraisal rights or dissenter&#8217;s rights with respect to the proposed amendment to the ARCA Charter to effect the reverse stock split.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the votes properly cast for or against the Reverse Stock Split Proposal by the holders of ARCA common stock is required to approve the Reverse Stock Split Proposal. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Reverse Stock Split Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Reverse Stock Split Proposal. Additionally, ARCA&#8217;s board of directors may determine to effect the Reverse Stock Split Proposal, if approved, even if Proposal&#160;No. 1 is not approved by the ARCA stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain ARCA stockholders have agreed to vote any shares of ARCA common stock owned by them in favor of the Reverse Stock Split Proposal. See &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Support Agreements</span>&#8221; beginning on&#160;page 153 of this proxy statement/prospectus for more information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Reverse Stock Split Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE REVERSE STOCK&#160;SPLIT&#160;PROPOSAL.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">186</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9984"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 4&#160;&#8212;&#160;THE OFFICER EXCULPATION PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;102(b)(7)&#160;of the DGCL was amended effective August&#160;1, 2022 to authorize exculpation of certain officers of Delaware corporations (the &#8220;Section&#160;102(b)(7)&#160;Amendment&#8221;). Specifically, the amendments extend the opportunity for Delaware corporations to exculpate their officers, in addition to their directors, for personal liability for breach of the duty of care in certain actions (the &#8220;officer exculpation&#8221;). This provision would not exculpate officers from liability for breach of the duty of loyalty, acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, or any transaction in which the officer derived an improper personal benefit. Nor would this provision exculpate such officers from liability for claims brought by or in the right of the corporation, such as derivative claims.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors believes it is necessary to provide protection to officers to the fullest extent permitted by law in order to attract and retain top talent. Similar protection has long been afforded to directors. Accordingly, ARCA&#8217;s board of directors believes that the proposal to extend exculpation to officers is fair and in the best interests of ARCA and its stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A copy of the proposed form of certificate of amendment to the ARCA Charter to effect the officer exculpation is attached as<span class="Italic" style="font-style:italic;font-weight:normal;"> Annex&#160;I</span> to this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors may determine to effect the officer exculpation, if it is approved by the stockholders, even if the other proposals to be acted upon at the meeting are not approved, including the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and the Reverse Stock Split Proposal. In addition, notwithstanding approval of this proposal by ARCA stockholders, ARCA&#8217;s board of directors may, in its sole discretion, abandon the proposed amendment and determine prior to the effectiveness of any filing with the Secretary of State of the State of Delaware not to effect the officer exculpation, as permitted under Section&#160;242(c)&#160;of the DGCL.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Reasons for the Proposal</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors desires to amend the ARCA Charter to maintain provisions consistent with the governing statutes contained in the DGCL, as it may be amended from time to time. Prior to the Section&#160;102(b)(7) Amendment, Delaware law has permitted Delaware corporations to exculpate directors from personal liability for monetary damages associated with breaches of the duty of care, but that protection did not extend to a Delaware corporation&#8217;s officers. Consequently, stockholder plaintiffs have employed a tactic of bringing certain claims that would otherwise be exculpated if brought against directors, against individual officers to avoid dismissal of such claims. The Section&#160;102(b)(7)&#160;Amendment was adopted to address inconsistent treatment between officers and directors and address rising litigation and insurance costs for stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As is currently the case with directors under the ARCA Charter, this provision would not exculpate officers from liability for breach of the duty of loyalty, acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, or any transaction in which the officer derived an improper personal benefit. Nor would this provision exculpate such officers from liability for claims brought by or in the right of the corporation, such as derivative claims. ARCA&#8217;s board of directors believes it is necessary to provide protection to officers to the fullest extent permitted by law in order to attract and retain top talent. Similar protection has long been afforded to directors, and accordingly, ARCA&#8217;s board of directors believes that this proposal which would extend exculpation to officers, as specifically permitted by the Section&#160;102(b)(7)&#160;Amendment, is fair and in the best interests of ARCA and its stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the outstanding shares of ARCA common stock is required to approve the Officer Exculpation Proposal. Abstentions and broker non<span class="nobreak">-votes</span>, if any, will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Officer Exculpation Proposal.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">187</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Officer Exculpation Proposal. If the Merger is not consummated for any reason, the actions contemplated by the Officer Exculpation Proposal may still be effected if the Officer Exculpation Proposal is approved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Officer Exculpation Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE OFFICER EXCULPATION&#160;PROPOSAL.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">188</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9985"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 5&#160;&#8212;&#160;THE DIRECTOR ELECTION PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors currently consists of five members. In accordance with the terms of the ARCA Charter and ARCA Bylaws, ARCA&#8217;s board of directors is divided into three classes, Class&#160;I, Class&#160;II and Class&#160;III, with members of each class serving staggered three<span class="nobreak">-year</span> terms. The members of the classes are divided as follows:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Class&#160;I directors are James Flynn, Linda Grais, M.D. and Anders Hove, M.D., whose terms will expire at ARCA&#8217;s annual meeting of stockholders to be held in 2025;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Class&#160;II director is Robert E.&#160;Conway, whose term will expire at ARCA&#8217;s annual meeting of stockholders to be held in 2026; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the Class&#160;III director is Jacob Ma<span class="nobreak">-Weaver</span>, whose term will expire at ARCA&#8217;s annual meeting of stockholders to be held in 2024.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the expiration of the term of a class of ARCA&#8217;s board of directors, any director in that class will be eligible to be elected for a new three<span class="nobreak">-year</span> term at the annual meeting of stockholders in the year in which their term expires.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter and ARCA Bylaws provide that the authorized number of directors shall not be less than two nor more than ten and may be changed only by resolution of ARCA&#8217;s board of directors. ARCA Bylaws also provide that ARCA&#8217;s directors may be removed only for cause by the affirmative vote of the holders of at least two<span class="nobreak">-thirds</span> of the voting rights of the shares of capital stock then entitled to vote in an annual election of directors, and that any vacancy on ARCA&#8217;s board of directors, including a vacancy resulting from an increase in the size of ARCA&#8217;s board of directors, may be filled only by vote of a majority of its directors then in office.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors has nominated Jacob Ma<span class="nobreak">-Weaver</span> for election as a Class&#160;III director at the ARCA special meeting. Mr.&#160;Ma<span class="nobreak">-Weaver</span> is currently a director and has consented to continue to serve as a director if elected. If Mr.&#160;Ma<span class="nobreak">-Weaver</span> becomes unable or unwilling to serve, however, the proxies may be voted for a substitute nominee selected by ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA stockholders should understand, however, that if the Merger is consummated, the approval of the director nominee named in the Director Election Proposal will only have an effect until the completion of the Merger because the composition of ARCA&#8217;s board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement. Following the Merger, the combined company&#8217;s board of directors will consist of six members designated by Oruka, including Carl Dambkowski, Peter Harwin, Lawrence Klein, Samarth&#160;Kulkarni, Cameron Turtle and Kristine Ball. All of ARCA&#8217;s current directors are expected to resign from their positions as directors of ARCA, effective as of the closing of the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The nominee for Class&#160;III director who receives the most votes properly cast (also known as a plurality) will be elected. You may either vote &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the nominee or &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">WITHHOLD</span>&#8221; your vote from the nominee. Withheld votes and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Director Election Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the election of the director nominee named in the Director Election Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the election of the director nominee named in the Director Election Proposal. However, if the nominee is unable to serve or for good cause will not serve as a director, the proxies will be voted for the election of such substitute nominee as ARCA&#8217;s board of directors may designate.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE DIRECTOR NOMINEE NAMED IN THE DIRECTOR ELECTION PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">189</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9986"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 6&#160;&#8212;&#160;THE AUDITOR RATIFICATION PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to ratify the appointment by the audit committee of ARCA&#8217;s board of directors (the &#8220;ARCA audit committee&#8221;) of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for the fiscal year ending December&#160;31, 2024 if the Merger is completed. KPMG LLP has served as ARCA&#8217;s independent registered public accounting firm since 2006.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA audit committee is solely responsible for selecting ARCA&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2024. Stockholder approval is not required to appoint KPMG LLP as ARCA&#8217;s independent registered public accounting firm. However, ARCA&#8217;s board of directors believes that submitting the selection of KPMG LLP to ARCA stockholders for ratification is good corporate governance. If ARCA stockholders do not ratify this appointment, the ARCA audit committee will reconsider whether to retain KPMG LLP.&#160;If the selection of KPMG LLP is ratified, the ARCA audit committee, at its discretion, may direct the selection of a different independent registered public accounting firm at any time it decides that such a change would be in the best interest of ARCA and its stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A representative of KPMG LLP is expected to be present at the ARCA special meeting and will have an opportunity to make a statement if he or she desires to do so and to respond to appropriate questions from ARCA stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting required to approve the Auditor Ratification Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Auditor Ratification Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Auditor Ratification Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Auditor Ratification Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Auditor Ratification Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE AUDITOR RATIFICATION PROPOSAL, PROVIDED THAT PRICEWATERHOUSECOOPERS LLP IS EXPECTED TO BE APPOINTED FOR THE FISCAL YEAR ENDING DECEMBER</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">31, 2024 IF THE MERGER IS COMPLETED.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">190</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9992"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PROPOSAL NO. 7</span><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">&#160;&#8212;&#160;</span><span class="Bold" style="font-style:normal;font-weight:bold;">THE STOCK PLAN PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (the &#8220;2024 Stock Plan&#8221;) to be effective on the closing date of the Merger. The 2024 Stock Plan was approved by ARCA&#8217;s board of directors on July<span class="nobreak"> </span>20, 2024, subject to stockholder approval. If the 2024 Stock Plan is approved by stockholders, no further awards will be granted under the 2020 Plan.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The purpose of the 2024 Stock Plan is to promote and closely align the interests of employees, officers, non<span class="nobreak">-employee</span> directors and individual consultants of the combined company and its stockholders by providing stock<span class="nobreak">-based</span> compensation and other performance<span class="nobreak">-based</span> compensation. The objectives of the 2024 Stock Plan are to attract and retain the best available employees, officers, non<span class="nobreak">-employee</span> directors and individual consultants for positions of substantial responsibility and to motivate participants to optimize the profitability and growth of the combined company through incentives that are consistent with the combined company&#8217;s goals and that link the personal interests of participants to those of the combined company&#8217;s stockholders. The 2024 Stock Plan allows for the grant of stock options, stock appreciation rights (&#8220;SARs&#8221;), restricted stock, restricted stock units (&#8220;RSUs&#8221;), other stock<span class="nobreak">-based</span> awards and incentive bonuses (collectively, &#8220;Awards&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the ARCA stockholders approve the Stock Plan Proposal, subject to the closing of the Merger, the combined company will file with the SEC a registration statement on Form S<span class="nobreak">-8</span>, as soon as reasonably practicable after the closing of the Merger, to register the shares available for issuance under the 2024 Stock Plan.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Summary of the 2024 Stock Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following description of the 2024 Stock Plan is not intended to be complete and is qualified in its entirety by the complete text of the 2024 Stock Plan, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;K</span> to this proxy statement. Stockholders are urged to read the 2024 Stock Plan in its entirety.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Federal Income Tax Consequences</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a summary of the U.S.&#160;federal income tax treatment applicable to the combined company and the participants who receive Awards under the 2024 Stock Plan based on the federal income tax laws in effect on the date of this proxy statement/prospectus. This summary is not intended to be exhaustive and does not address all matters relevant to a particular participant based on their specific circumstances. The summary expressly does not discuss the income tax laws of any state, municipality, or non<span class="nobreak">-U</span>.S.&#160;taxing jurisdiction, or the gift, estate, excise (including the rules applicable to deferred compensation under Section&#160;409A of the Code), or tax laws other than U.S.&#160;federal income tax law. Because individual circumstances may vary, all participants should consult their own tax advisor concerning the tax implications of Awards granted under the 2024 Stock Plan.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Incentive Stock Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Options granted under the 2024 Stock Plan may be either incentive stock options, which satisfy the requirements of Section&#160;422 of the Code, or non<span class="nobreak">-qualified</span> stock options, which are not intended to meet such requirements. No taxable income is recognized by the optionee at the time of the option grant, and no taxable income is recognized for ordinary income tax purposes at the time the option is exercised, although taxable income may arise at that time for alternative minimum tax purposes. Unless there is a &#8220;disqualifying disposition&#8221;, as described below, the optionee will recognize long<span class="nobreak">-term</span> capital gain in an amount equal to the excess of (i)&#160;the amount realized upon the sale or other disposition of the purchased shares over (ii)&#160;the exercise price paid for the shares. A disqualifying disposition occurs if the disposition is less than two&#160;years after the date of grant or less than one year after the exercise date. If there is a disqualifying disposition of the shares, then the excess of (i)&#160;the fair market value of those shares on the exercise date or (if less) the amount realized upon such sale or disposition over (ii)&#160;the exercise price paid for the shares will be taxable as ordinary income to the optionee. Any additional gain or loss recognized upon the disposition will be a capital gain or loss. If the optionee makes a disqualifying disposition of the purchased shares, then the combined company will be entitled to an income tax deduction for the taxable year in which such disposition occurs equal to the amount of ordinary income recognized by the optionee as a result of the disposition. The combined company will not be entitled to any income tax deduction if the optionee makes a qualifying disposition of the shares.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">191</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Nonqualified Stock Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No taxable income is recognized by an optionee upon the grant of a non<span class="nobreak">-qualified</span> stock option. The optionee in general will recognize ordinary income, in the year in which the option is exercised, equal to the excess of the fair market value of the purchased shares on the exercise date over the exercise price paid for the shares, and the optionee will be required to satisfy the tax withholding requirements applicable to such income. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the optionee with respect to the exercised non<span class="nobreak">-qualified</span> stock option.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Appreciation Rights</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No taxable income is recognized upon receipt of a SAR.&#160;The participant will recognize ordinary income in the year in which the SAR is exercised, in an amount equal to the excess of the fair market value of the underlying shares of common stock on the exercise date over the base price in effect for the exercised right, and the participant will be required to satisfy the tax withholding requirements applicable to such income. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant in connection with the exercise of the SAR.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Awards</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A participant who receives unvested shares of combined company common stock will not recognize any taxable income at the time those shares are granted but will have to report as ordinary income, as and when those shares subsequently vest, an amount equal to the excess of (i)&#160;the fair market value of the shares on the vesting date over (ii)&#160;the cash consideration (if any) paid for the shares. The participant may, however, elect under Section&#160;83(b)&#160;of the Code to include as ordinary income in the year the unvested shares are issued an amount equal to the excess of (a)&#160;the fair market value of those shares on the issue date over (b)&#160;the cash consideration (if any) paid for such shares. If the Section&#160;83(b)&#160;election is made, the participant will not recognize any additional income as and when the shares subsequently vest. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time such ordinary income is recognized by the participant.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Units, Other Stock-Based Awards, Incentive Bonuses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Generally, no taxable income is recognized upon the grant of RSUs, other stock<span class="nobreak">-based</span> awards or incentive bonuses. The participant will recognize ordinary income in the year in which the award is settled in shares or cash. The amount of that income will be equal to the fair market value of the shares on the date of issuance or the amount of the cash paid in settlement of the award, and the participant will be required to satisfy the tax withholding requirements applicable to the income. The combined company will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time the shares are issued or the cash amount is paid.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Deductibility of Executive Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;162(m)&#160;of the Code limits the deductibility for federal income tax purposes of certain compensation paid to any &#8220;covered employee&#8221; in excess of $1&#160;million. It is expected that compensation deductions for any covered employee with respect to awards granted under the 2024 Stock Plan will be subject to the $1&#160;million annual deduction limitation. The Administrator may grant Awards under the 2024 Stock Plan or otherwise that are or may become non<span class="nobreak">-deductible</span> when it believes doing so is in the best interests of the combined company and its stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">New Plan Benefits</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA cannot currently determine the benefits or number of shares subject to Awards that may be granted in the future to eligible participants under the 2024 Stock Plan because the grant of Awards and terms of such Awards are to be determined in the sole discretion of the Administrator.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">192</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting required to approve the Stock Plan Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Stock Plan Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Stock Plan Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Stock Plan Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the Stock Plan Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE STOCK PLAN PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">193</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9993"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PROPOSAL NO. 8</span><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">&#160;&#8212;&#160;</span><span class="Bold" style="font-style:normal;font-weight:bold;">THE ESPP PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the ARCA special meeting, ARCA will ask its stockholders to approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) to be effective on the closing date of the Merger. The ESPP was approved by ARCA&#8217;s board of directors on July<span class="nobreak"> </span>20, 2024, subject to stockholder approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The purpose of the ESPP is to provide employees of the combined company and its designated subsidiaries with an opportunity to purchase Common Stock through accumulated contributions. The ESPP, and the rights of participants to make purchases thereunder, is intended to qualify under Section&#160;423 of the Code; however, sub<span class="nobreak">-plans</span> that do not meet the requirements of Section&#160;423 of the Code may be established for the benefit of eligible employees of non<span class="nobreak">-U</span>.S.&#160;subsidiaries of the combined company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the ARCA stockholders approve the ESPP Proposal, subject to the closing of the Merger, the combined company will file with the SEC a registration statement on Form S<span class="nobreak">-8</span>, as soon as reasonably practicable after the closing of the Merger, to register the shares available for issuance under the ESPP.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Summary of the ESPP</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following description of the ESPP is not intended to be complete and is qualified in its entirety by the complete text of the ESPP, a copy of which is attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;L</span> to this proxy statement. Stockholders are urged to read the 2024 Stock Plan in its entirety.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Federal Income Tax Consequences</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a brief description of the federal income tax treatment that will generally apply to the grant and exercise of rights under the ESPP, based on federal income tax laws in effect on the date of this proxy statement/prospectus. The exact federal income tax treatment of options will depend on the specific nature of any such option and the individual tax attributes of the participant. The following summary is not intended to be exhaustive and, among other considerations, does not describe gift, estate, social security, state, local or international tax consequences. In addition, if one or more sub<span class="nobreak">-plans</span> are established for employees of non<span class="nobreak">-U</span>.S.&#160;subsidiaries, the tax rules may be different than discussed below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code and, as a result, employees who participate in the ESPP will be afforded favorable tax treatment subject to meeting certain requirements specified by the Code. In general, there are no federal income tax consequences to a participant upon the grant of the option to purchase shares under the ESPP at the beginning of an option period or upon its exercise on the exercise date at the end of an option period. Upon the disposition of shares of common stock acquired upon exercise of an option, the participant will generally be subject to tax and the nature and amount of the tax will depend on whether the employee has satisfied the statutory holding period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the employee holds shares acquired under the ESPP for at least two&#160;years from the grant date of his or her option and at least one year from the date he or she acquired the shares (referred to as the &#8220;statutory holding period&#8221;), any gain on the sale of the shares will be taxed as ordinary income to the extent of the lesser of (i)&#160;the amount by which the fair market value of the shares on the grant date (i.e., the first&#160;day of the option period) exceeded the exercise price for the option, or (ii)&#160;the amount by which the fair market value of the shares on the date of sale exceeds the exercise price of the option. Any additional gain or loss will be taxed as long<span class="nobreak">-term</span> capital gain or loss.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the participant sells or otherwise disposes of the shares before the expiration of the statutory holding period, then in the year of such &#8220;disqualifying&#8221; disposition, the participant will be required to recognize ordinary income equal to the difference between the fair market value of the shares on the date of the exercise of the option and the exercise price of the option. Any additional gain or loss will be short<span class="nobreak">-term</span> or long<span class="nobreak">-term</span> capital gain or loss depending on the length of time the employee has held the shares.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">194</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company is not entitled to any deduction with respect to the difference between the fair market value of the common stock and the option exercise price if the participant satisfies the statutory holding period described above. If shares are sold before the statutory holding period is satisfied, the combined company receives a tax deduction for any ordinary income recognized by the participant.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">New Plan Benefits</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The benefits that will be received by or allocated to eligible employees under the ESPP cannot be determined at this time because the amount of payroll deductions contributed to purchase shares of combined company common stock under the ESPP is entirely within the discretion of each participant (subject to the limitations discussed above).</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting required to approve the ESPP Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the ESPP Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the ESPP Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the ESPP Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the ESPP Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE ESPP PROPOSAL.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">195</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T9994"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PROPOSAL NO. 9</span><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">&#160;&#8212;&#160;</span><span class="Bold" style="font-style:normal;font-weight:bold;">THE MERGER COMPENSATION PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to Section&#160;14A of the Exchange&#160;Act and Rule&#160;14a<span class="nobreak">-21</span>(c)&#160;thereunder, ARCA is seeking non<span class="nobreak">-binding</span>, advisory stockholder approval of certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger, as disclosed pursuant to Item&#160;402(t)&#160;of Regulation&#160;S<span class="nobreak">-K</span> in the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger &#8212; Interests of ARCA&#8217;s Directors and Executive Officers in the Merger&#160;&#8212;&#160;Quantification of Potential Payments and Benefits to ARCA Named Executive Officers</span>&#8221; beginning on page 123 of this proxy statement/prospectus. At the ARCA special meeting, ARCA will therefore ask its stockholders to adopt the following resolution:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#8220;RESOLVED:<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>That certain compensation arrangements for ARCA named executive officers in connection with the Merger, as disclosed pursuant to Item&#160;402(t)&#160;of Regulation&#160;S</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-K</span></span><span class="Bold" style="font-style:normal;font-weight:bold;"> in the section titled &#8220;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The Merger &#8212; Interests of ARCA&#8217;s Directors and Executive Officers in the Merger&#160;&#8212;&#160;Quantification of Potential Payments and Benefits to ARCA Named Executive Officers</span><span class="Bold" style="font-style:normal;font-weight:bold;">&#8221; in the proxy statement/prospectus, are hereby APPROVED on a non</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;">-binding</span></span><span class="Bold" style="font-style:normal;font-weight:bold;">, advisory basis.&#8221;</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because the vote is advisory in nature only, it will not be binding on ARCA.&#160;Accordingly, to the extent ARCA is contractually obligated to pay the compensation, the compensation will be payable to the named executive officers, subject only to the conditions applicable thereto, if the Merger is completed, regardless of the outcome of the advisory vote.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA common stock is required to approve the Merger Compensation Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Merger Compensation Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Merger Compensation Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Merger Compensation Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Merger Compensation Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE MERGER COMPENSATION PROPOSAL.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">196</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T9987"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PROPOSAL NO. 10&#160;&#8212;&#160;THE ADJOURNMENT PROPOSAL</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">General</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If ARCA fails to receive a sufficient number of votes to approve the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal, ARCA may propose to adjourn the ARCA special meeting, for a period of not more than 60&#160;days, for the purpose of soliciting additional proxies to approve the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal. ARCA currently does not intend to propose adjournment at the ARCA special meeting if there are sufficient votes to approve the Nasdaq Stock Issuance Proposal, the Authorized Share Increase Proposal and/or the Reverse Stock Split Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a quorum is not present at the ARCA special meeting, under ARCA Bylaws, stockholders holding a majority of the shares present in person or by proxy and entitled to vote, or if no stockholders are present any officer entitled to preside at or act as secretary of the special meeting, will have the power to adjourn the special meeting until a quorum is present or represented.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Required Vote</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If a quorum is present, the affirmative vote of a majority of the shares of ARCA common stock entitled to vote on the subject matter and present in person or represented by proxy at the ARCA special meeting is required to approve the Adjournment Proposal. Abstentions will have the same effect as votes &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">AGAINST</span>&#8221; the Adjournment Proposal and broker non<span class="nobreak">-votes</span>, if any, will have no effect on the Adjournment Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger is <span class="CharOverride-1" style="font-style:normal;font-weight:bold;text-decoration:underline;">not</span> conditioned upon the approval of the Adjournment Proposal.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise instructed, it is the intention of the persons named in the accompanying proxy card to vote shares represented by properly executed proxy cards &#8220;<span class="Bold" style="font-style:normal;font-weight:bold;">FOR</span>&#8221; the approval of the Adjournment Proposal.</p>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">THE ARCA BOARD OF DIRECTORS RECOMMENDS A VOTE &#8220;FOR&#8221; THE ADJOURNMENT PROPOSAL, IF NECESSARY.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">197</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T13"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA&#8217;S BUSINESS</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Overview</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA is a biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. Precision medicine refers to the tailoring of medical treatment to the individual characteristics of patients, using genomic, non<span class="nobreak">-genomic</span> biomarker and other information that extends beyond routine diagnostic categorization. ARCA believes that when implemented correctly precision medicine can enhance therapeutic response, improve patient outcomes, and reduce healthcare costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In April&#160;2022, ARCA&#8217;s board of directors established a Special Committee and subsequently retained Lucid to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#8217;s assets, or other alternatives with the goal of maximizing stockholder value (the &#8220;Strategic Review&#8221;). ARCA and Lucid have reviewed several potential strategic transactions and continue to evaluate further potential development of ARCA&#8217;s existing assets, in order to maximize stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, First Merger Sub, Second&#160;Merger Sub and Oruka entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the First Merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Second Merger Sub with Second Merger Sub continuing as a wholly owned subsidiary of ARCA and the surviving entity of the Second Merger. The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In connection with the Merger, ARCA will dispose of (or is in the process of disposing of) its legacy technology and intellectual property, including those related to Gencaro and rNAPc2. Any such disposal of legacy technology and intellectual property will be contingent upon obtaining stockholder approval for the Merger and is expected to occur immediately prior to or concurrently with the closing of the Merger. In the event that ARCA shall enter into an agreement for any such sale or other disposition of its legacy assets at or prior to the closing of the Merger, the net proceeds received at or prior to the closing of the Merger will be included in the calculation of the net cash of ARCA as of the closing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, ARCA may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation, (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro&#8482; (bucindolol hydrochloride) for Atrial Fibrillation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Gencaro&#8482; (bucindolol hydrochloride) is a pharmacogenetically<span class="nobreak">-targeted</span> beta<span class="nobreak">-adrenergic</span> receptor antagonist with mild vasodilator properties that ARCA is developing for the treatment of atrial fibrillation in patients with heart failure. ARCA believes the pharmacology of Gencaro is unique and its efficacy can be enhanced by prescribing it to patients with a common genotypic variant that is present in approximately 50% of the North American and European general populations. This gene can be detected with a simple genetic test.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA is developing Gencaro to treat AF in patients with HF.&#160;AF is the most common form of cardiac arrhythmia, a disruption of the heart&#8217;s normal rhythm or rate. HF is a chronic condition in which the heart is unable to pump enough blood to meet the body&#8217;s needs. AF and HF commonly occur together. In HF patients, the development of AF leads to worsening symptoms, and increased risk of hospitalization and death. Current treatment options for AF in HF patients are limited, and can be invasive, costly and dangerous.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA&#8217;s development plan for Gencaro focuses on the treatment of AF in patients with higher ejection fraction HF, those who have an ejection fraction (&#8220;EF&#8221;) of 40% and higher who also have the genotype ARCA believes is optimal for Gencaro efficacy. This population of HF encompasses more than half of all HF patients in the United&#160;States and Europe. There are currently few approved or effective drug therapies to treat AF or HF in this patient population.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">198</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s development plan for Gencaro is based on ARCA&#8217;s published analysis of the Phase&#160;2b clinical trial of Gencaro for the prevention of AF in HF patients, known as GENETIC<span class="nobreak">-AF</span>.&#160;This analysis showed novel results for Gencaro in patients in the clinical trial with EF&#8217;s of 40% and higher. ARCA currently has an agreement with the FDA, known as a Special Protocol Assessment (&#8220;SPA&#8221;) for the requirements of a Gencaro Phase&#160;3 clinical trial, PRECISION<span class="nobreak">-AF</span>, that would support approval of Gencaro if successful. The Phase&#160;3 pivotal clinical trial of Gencaro conducted under an SPA will include secondary endpoints that are intended to capture some of this information, such as a reduction in the need to deploy rhythm control interventions including electrical cardioversion, catheter ablation and use of anti<span class="nobreak">-arrhythmic</span> drugs and avoidance of drug<span class="nobreak">-related</span> complications such as bradycardia. ARCA was issued a United&#160;States patent in February&#160;2021 for the use of Gencaro in a patient population identified as part of the clinical trial. ARCA believes this patent will substantially extend the patent protection for ARCA&#8217;s planned development of Gencaro into 2039. ARCA has sought or is seeking similar patent protection in other countries.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that patients with HF and AF represent a major unmet medical need, and this need is most pronounced in patients with EF values of 40% and above. This EF range constitutes more than half of all chronic HF in the United&#160;States and Europe, as well as in Japan and China, and there are currently few approved, effective or guideline<span class="nobreak">-recommended</span> therapies for these patients to treat either their AF or HF.&#160;AF is a very common complication in these patients, with estimates of AF incidence ranging from 40% to 60%. Beta<span class="nobreak">-blockers</span> approved for HF are commonly used off<span class="nobreak">-label</span> to control heart rate in these patients, but they are not considered effective in preventing AF and none are approved for patients with EF &#8805; 40%. Other anti<span class="nobreak">-arrhythmic</span> drugs approved for the treatment of AF have adverse side effects and in HF patients are either contraindicated or have label warnings for use due to an increased risk of mortality. Interventional procedures for AF, such as catheter ablation and electrical cardioversion, are invasive, expensive, and often temporary; these interventions also typically require the continued use of beta blockers and other anti<span class="nobreak">-arrhythmic</span> drugs post<span class="nobreak">-intervention</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that Gencaro, if approved, may be a safe and more effective therapy for the treatment of higher ejection fraction HF patients with AF.&#160;ARCA believes there are several potentially important attributes that would differentiate Gencaro from existing therapies, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>More effective rhythm control compared to the current standard of care;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduction in the need for catheter ablation, electrical cardioversion, or toxic anti<span class="nobreak">-arrhythmic</span> drugs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Maintenance of rhythm control after a successful AF catheter ablation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Effective rate control with lower risk of treatment<span class="nobreak">-limiting</span>, adverse event producing bradycardia;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduction in symptoms and improvement in quality of life;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduced health care burden;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Foundational beta<span class="nobreak">-blocker</span> benefits for HF and unique evidence of efficacy in HF patients with AF;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>One of the only drug therapies approved and shown effective for AF in HF patients with EF &#8805; 40%, and the only one in its drug class.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has an international patent portfolio for Gencaro in the United&#160;States, the EU, and other major markets, as well as new chemical entity status, including a new patent that ARCA believes will give it a strong intellectual property position to at least approximately 2039 in the United&#160;States; ARCA has filed applications similar to this new patent in international territories. ARCA has developed a laboratory platform for the diagnostic test that would be used to prescribe Gencaro; this platform was approved by FDA for use in the Phase&#160;2B clinical trial. ARCA retains all rights to this test platform; ARCA expects to use it in future clinical trials, and ARCA believes it could be one of multiple diagnostic platforms used for commercialization.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">rNAPc2 (AB201) for treatment of COVID-19</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Recombinant Nematode Anticoagulant Protein c2 (&#8220;rNAPc2&#8221;) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID<span class="nobreak">-19</span>. Based on its unique mechanism of action, development history and the clinical evidence from the SARS<span class="nobreak">-CoV-2</span> pandemic, ARCA believes rNAPc2 has potential to be a beneficial therapy for patients with this serious viral disease. ARCA initiated a Phase&#160;2b clinical trial of rNAPc2 as a potential treatment for patients hospitalized with COVID<span class="nobreak">-19</span> in the fourth quarter of 2020 and </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">199</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">completed patient enrollment in the fourth quarter 2021. In the clinical trial, both doses of rNAPc2 demonstrated a treatment benefit for patients based on the coagulation biomarker D<span class="nobreak">-dimer</span>, however, neither dose achieved statistical significance for the primary efficacy endpoint of change in D<span class="nobreak">-dimer</span> level from Baseline to Day 8 compared to standard of care heparin.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On the secondary endpoints measuring thrombotic events and time<span class="nobreak">-to-recovery</span>, there was a numerical imbalance in favor of rNAPc2 that was non<span class="nobreak">-significant</span>. rNAPc2 was well<span class="nobreak">-tolerated</span> at both doses. There were no serious treatment<span class="nobreak">-related</span> adverse events and no dose dependent increase in adverse events was observed. There was no difference between rNAPc2 and standard<span class="nobreak">-of-care</span> heparin in major or non<span class="nobreak">-major</span> clinically relevant bleeding. ARCA currently does not plan additional clinical development of rNAPc2 unless ARCA is able to find a commercial or government partner to pay for development and commercialization or expansion into clinical trials for other disease indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To support the continued development of Gencaro and rNAPc2, ARCA will need additional financing to fully fund any clinical trials, and ARCA&#8217;s general and administrative costs through the clinical trials&#8217; projected completion and potential commercialization. Considering the substantial time and costs associated with the development of Gencaro and rNAPc2 and the risk that ARCA may be unable to raise a significant amount of capital on acceptable terms, ARCA is also pursuing co<span class="nobreak">-development</span> and commercialization partnering opportunities with large pharmaceutical and/or specialty pharmaceutical companies and may pursue a strategic combination or other strategic transactions. If ARCA is unable to obtain sufficient financing or are unable to complete a strategic transaction, ARCA may discontinue its development activities on Gencaro or rNAPc2 or discontinue operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipate; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;s Strategy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s mission is to become a leading biopharmaceutical company developing precision targeted cardiovascular therapies to enhance therapeutic response, improve patient outcomes, and reduce healthcare costs. To achieve this goal, ARCA is pursuing the following strategies:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Evaluate strategic options.&#160;&#160;&#160;&#160;</span>In April&#160;2022, ARCA&#8217;s board of directors established the Special Committee and, subsequently retained Ladenburg Thalmann to evaluate the Strategic Review. In March&#160;2024, ARCA terminated its engagement with Ladenburg Thalmann and retained Lucid Capital Markets to evaluate the Strategic Review. ARCA and Lucid have reviewed several potential strategic transactions and continue to evaluate further potential development of ARCA&#8217;s existing assets, in order to maximize stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction. Following a comprehensive review, on April<span class="nobreak">&#160;</span>3, 2024, ARCA, First Merger Sub, Second Merger Sub and Oruka, entered into Merger Agreement pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Second Merger Sub with Second Merger Sub continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Advance the development of Gencaro for the treatment of AF in HF patients.&#160;&#160;&#160;&#160;</span>ARCA is planning a Phase&#160;3 clinical trial for Gencaro as a therapy for AF in HF patients, focusing on patients with EF &#8805; 40%, a patient population for whom few approved or effective drug therapies currently exist.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;font-style:italic;font-weight:normal;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Partner the development of rNAPc2.&#160;&#160;&#160;&#160;</span>ARCA plans to pursue strategic development and partnering opportunities with commercial or government partners for rNAPc2 development and commercialization or expansion into clinical trials for other disease indications.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">200</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;font-style:italic;font-weight:normal;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="Italic" style="font-style:italic;font-weight:normal;">Build a cardiovascular pipeline.&#160;&#160;&#160;&#160;</span>ARCA&#8217;s management, employees and consultants are experienced in cardiovascular research, molecular genetics and clinical development of cardiovascular therapies. ARCA is seeking to leverage this expertise to identify, acquire and develop other cardiovascular products or candidates, particularly those with potential for targeted development based on genetic or other biomarkers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The above strategies are dependent upon ARCA&#8217;s ability to obtain additional funding through the sale of public or private equity or debt securities, the completion of a strategic transaction, or a combination thereof. If ARCA is unable to secure additional funding or complete a strategic transaction, ARCA may not be able to continue development of Gencaro or rNAPc2, or to continue operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Atrial Fibrillation in Heart Failure</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Market Background and Opportunity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Heart failure is a chronic condition in which the heart is unable to pump enough blood to meet the body&#8217;s needs. HF has numerous serious consequences, including severe impacts on quality of life, increased hospitalizations, loss of economic productivity, and premature death. HF is a leading cause of death in the developed world, and despite the availability of multiple effective drug classes, mortality due to HF is increasing. According to the 2020 American Heart Association (&#8220;AHA&#8221;) Heart Disease and Stroke Statistics, there were an estimated 6.2&#160;million Americans aged 20&#160;years or more with HF in 2016, projected to increase to between 8.3&#160;million and 10.7&#160;million by 2030. One of the fundamental classifications of heart failure is based on the percentage of blood in the left ventricle of the heart that is ejected with each heartbeat, known as EF.&#160;The spectrum of HF includes HF in which EF is 50% or more and is considered preserved ejection fraction, known as HFpEF; HF in which the EF is less than 40%, considered reduced ejection fraction (&#8220;HFrEF&#8221;); and HF in which the EF is at least 40%, but less than 50%, sometimes referred to as mid<span class="nobreak">-range</span> ejection fraction, known as HFmrEF.&#160;Together, HFmrEF and HFpEF, that is HF with EF &#8805; 40%, comprise more than half of all chronic HF in the United&#160;States and Europe. In 2012, the economic cost of HF in the United&#160;States was estimated to be nearly $31&#160;billion, of which two<span class="nobreak">-thirds</span>, or over $20&#160;billion, was attributable to direct medical costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Atrial fibrillation, the most common sustained cardiac arrhythmia, is a serious disorder in which the normally regular and coordinated contraction pattern of the heart&#8217;s two small upper chambers, or the atria, becomes irregular, rapid and uncoordinated. AF can have significant quality of life impacts and potentially serious medical consequences, including increasing the risk of stroke and other cardiovascular problems. In individuals with HF, AF contributes to the disease processes that lead to the progression of HF and worsening of clinical outcomes. AF is considered an epidemic cardiovascular disease and a major public health burden, similar to HF.&#160;The estimated number of individuals with AF globally in 2015 was 33.3&#160;million. According to AHA Heart Disease and Stroke Statistics Reports from&#160;2017<span class="nobreak">-2020</span>, the prevalence of AF in the United&#160;States was estimated to be 5.2&#160;million people in 2015. In the European Union, the prevalence of AF was estimated to be 8.8&#160;million (age 55 and over) in 2010. It is estimated that AF costs the U.S.&#160;economy about $6.0&#160;billion annually.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">AF and HF share many of the same risk factors and commonly occur together. It has been estimated that&#160;30<span class="nobreak">-60</span>% of HF patients will also develop AF, with this incidence increasing in HF patients with higher EF; ARCA estimates that&#160;40<span class="nobreak">-60</span>% of HF patients with EF &#8805; 40% will also be diagnosed with AF.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Medical Need and Current Therapy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The goals of current medical therapy for AF are to provide anticoagulation to reduce the risk of stroke, and also either maintain sinus rhythm (known as rhythm control), or reduce the high heart rate caused by AF (known as rate control), in both cases to minimize patient symptoms and reduce the risk of further complications and disease progression. Unfortunately, the current treatment options for treating AF in patients with HF have significant limitations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Beta<span class="nobreak">-blockers</span> are considered standard of care for the treatment of HF patients, including in patients with co<span class="nobreak">-morbid</span> AF.&#160;They are also viewed as foundational therapy to treat AF in HF patients for their ability to provide rate control. Their safety in this patient population is well established.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">201</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, current beta blockers approved for HF patients are only modestly effective at providing rhythm control, and none are FDA approved for this indication. Importantly, none of these drugs have been shown to be effective for treating HF in patients with EF &#8805; 40%, so they are currently used off<span class="nobreak">-label</span> in this setting. When used for rate control, these drugs can cause bradycardia, a condition in which the heart rate drops below a safe threshold, which often leads to dose reductions and potential loss of the drug&#8217;s treatment effect. Furthermore, recent evidence indicates that the mortality and other clinical benefits of these beta blockers in heart failure patients are uncertain when sustained or permanent AF is present.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Anti<span class="nobreak">-arrhythmic</span> drugs are a drug class that is often prescribed to provide rhythm control. These drugs are frequently used in patients with both HF and AF when a rate control strategy using a beta blocker fails to control the patient&#8217;s symptoms. However, these agents have significant safety issues. For example, in the United&#160;States, anti<span class="nobreak">-arrhythmic</span> drug therapy for AF used in addition to beta<span class="nobreak">-blockers</span> is generally confined to the drugs amiodarone and dofetilide, which have multiple safety and toxicity concerns. Because of these concerns, physicians treating HF patients seek to limit the use of these anti<span class="nobreak">-arrhythmic</span> drugs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Non<span class="nobreak">-pharmacologic</span> interventions such as catheter ablation and electrical cardioversion (ECV), are also used to treat AF in patients with HF.&#160;Catheter ablation is now guideline<span class="nobreak">-recommended</span> in this patient population and its use is increasing. However, it is not a replacement for drug therapy; it is invasive, expensive and generally impermanent. Drug therapy, including beta blockers, is generally continued in patients post<span class="nobreak">-ablation</span>, both for rhythm control and for HF benefit. ECV is expensive and less permanent than ablation, but like ablation, post<span class="nobreak">-ECV</span> patients will generally remain on drug therapy to treat their AF and HF, including beta<span class="nobreak">-blockers</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In light of the serious medical consequences presented by AF in the presence of HF as well as, the limitations of current therapies, ARCA believes there is an unmet need for a drug therapy that can provide greater rhythm control compared to the current standard of care; can reduce the need for toxic anti<span class="nobreak">-arrhythmic</span> drugs, catheter ablation, and electrical cardioversion; can provide effective rate control with a lower risk of treatment<span class="nobreak">-limiting</span> bradycardia; and can provide foundational beta<span class="nobreak">-blocker</span> benefits for HF.&#160;This need is particularly significant for HF patients with EF &#8805; 40%, for whom there are few approved or Class&#160;I guideline<span class="nobreak">-recommended</span> drug therapies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro Clinical Development</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The GENETIC-AF Phase&#160;2B Clinical Trial</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">GENETIC<span class="nobreak">-AF</span> enrolled 267 patients from the United&#160;States, Canada and Europe. The primary analysis compared the evidence of safety and efficacy of Gencaro versus an active comparator, TOPROL<span class="nobreak">-XL</span>.&#160;The primary endpoint of the trial was time to first event of AF/atrial flutter (AFL) or All Cause Mortality (ACM) during a 24<span class="nobreak">-week</span> follow<span class="nobreak">-up</span> period after the establishment of sinus rhythm. Randomized patients had an EF &#8804; 55%, a history of AF in the past 6&#160;months, and the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype that ARCA believes responds best to Gencaro. Laboratory Corporation of America (&#8220;LabCorp&#8221;) developed the genetic test, obtained an IDE from the FDA and provided the companion diagnostic test and services to support ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the primary endpoint of time to AF recurrence, Gencaro demonstrated a similar treatment benefit in the overall population (p = 0.961) compared to the active comparator, TOPROL<span class="nobreak">-XL</span>.&#160;However, based on further analysis of the trial, ARCA believes it has identified a population that shows greater response to Gencaro compared to TOPROL<span class="nobreak">-XL</span> across multiple important clinical assessments, including the primary endpoint of time to AF recurrence, maintenance of normal sinus rhythm, cumulative AF burden, and AF<span class="nobreak">-related</span> clinical interventions and complications. ARCA plans to study this population in ARCA&#8217;s Phase&#160;3 clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These further analyses of the GENETIC<span class="nobreak">-AF</span> population (shown in the table below) demonstrated that Gencaro, as compared to metoprolol, reduced AF burden, improved maintenance of sinus rhythm and lowered the need for additional rhythm control interventions.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">202</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Endpoint</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Entire GENETIC-AF Cohort</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Time to 1</span><span class="CharOverride-3" style="font-size:58%;font-style:normal;font-weight:bold;vertical-align:super;">st</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;"> AF/AFL/ACM <br/>(Primary Endpoint)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1.01<br/>(neutral)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(0.71, 1.42)<br/>p = 0.961<br/>N = 267</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Cumulative 24-week AF Burden <br/>(substudy</span>)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">0.64<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="Bold" style="font-style:normal;font-weight:bold;">36%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(0.46, 0.86)<br/>p = 0.002<br/>N = 67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">AF Burden at Week 24</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">0.45<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="Bold" style="font-style:normal;font-weight:bold;">55%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(0.39, 0.50)<br/>p &lt; 0.001<br/>N = 67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">ECGs in Normal Sinus Rhythm</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1.39<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="Bold" style="font-style:normal;font-weight:bold;">39%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(1.22, 1.58)<br/>p &lt; 0.001<br/>N = 257</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 52.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">AF Interventions <br/>(ECVs, Ablations,&#160;&amp; Class&#160;3 AA Drugs)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">0.68<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="Bold" style="font-style:normal;font-weight:bold;">32%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">(0.50, 0.91)<br/>p = 0.011<br/>N = 257</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:middle;width: 26.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:4pt;text-indent:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Bradycardia prevalence <br/></span>(Buc. vs. met., VR &lt; 60 bpm) </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 12.60%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">0.39<br/>(</span><span class="CharOverride-4" style="font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8595;</span><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">61%)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.57%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:6pt;text-indent:0pt;">(0.31, 0.49)<br/>P &lt; 0.001<br/>N = 256</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 21.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Dose reductions</span> <br/>(pts. w/bradycardia vs. non-b.)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 10.99%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="middle">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">4.25<br/>(</span><span class="Bold" style="font-style:normal;font-weight:bold;font-family:Symbol, sans-serif;font-size:9pt;font-style:normal;font-weight:normal;">&#8593;</span><span class="Bold" style="font-style:normal;font-weight:bold;">4X)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:middle;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="middle">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:4pt;text-indent:0pt;">(2.06, 9.60)<br/>P &lt; 0.001<br/>N = 257</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Time to first AF/AFL/ACM treatment effect = hazard ratio (95% CI). AF burden = % time in AF per&#160;day. Cumulative AF burden treatment effect = AUC ratio (i.e., AUC<span class="Subscript" style="vertical-align:sub;font-size:58%;">BUC</span>/AUC<span class="Subscript" style="vertical-align:sub;font-size:58%;">MET</span>) over 24<span class="nobreak">-week</span> follow<span class="nobreak">-up</span> period with significance assessed via null permutation. AFB at Week 24 = Instantaneous estimates of average daily AF burden at week 24 with comparison between groups expressed as the ratio of the estimates and tested for significance using a Wald test. Normal Sinus Rhythm = total number ECGs in sinus rhythm with ventricular rate&#160;&#8805;&#160;60&#160;and&#160;&#8804;&#160;100 bpm during efficacy follow<span class="nobreak">-up</span> period. AF Interventions = ECV, ablation, or guideline<span class="nobreak">-recommended</span> antiarrhythmic use during efficacy follow<span class="nobreak">-up</span> period. Treatment effect for normal sinus rhythm, AF interventions and bradycardia&#160;=&#160;prevalence rate ratio (i.e., PRR<span class="Subscript" style="vertical-align:sub;font-size:58%;">BUC</span>/PRR<span class="Subscript" style="vertical-align:sub;font-size:58%;">MET</span>) modeled to test significance using Poisson regression.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Treatment with Gencaro was associated with a 36% reduction in cumulative AF burden over 24&#160;weeks of follow<span class="nobreak">-up</span> compared to metoprolol, leading to a 55% reduction in AF burden at the end of 24&#160;weeks. Consistent with the results in the device substudy, there was a 39% increase in the prevalence of ECGs demonstrating normal sinus rhythm in the overall study population. Treatment with Gencaro also led to a 32% lower utilization of adjunctive rhythm control therapies, including electrical cardioversion, catheter ablation and antiarrhythmic drug therapy. There was also a 61% reduction in bradycardia with Gencaro versus metoprolol. The consequence of bradycardia is a reduction in beta<span class="nobreak">-blocker</span> dose, which 4.2<span class="nobreak">-fold</span> higher in patients exhibiting bradycardia than without bradycardia.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The BEST Phase&#160;3 Heart Failure Trial</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The effect of Gencaro on heart failure endpoints in an advanced HFrEF population was evaluated in the 2,708&#160;patient, placebo<span class="nobreak">-controlled</span> Phase&#160;3 BEST clinical trial co<span class="nobreak">-sponsored</span> by the NHLBI and Department of Veterans Affairs. In addition to the parent population, BEST included a 1,040 patient DNA substudy that evaluated the effects of adrenergic receptor (&#8220;AR&#8221;) polymorphisms on Gencaro effectiveness. The BEST trial was terminated early because, after positive mortality results from two HF trials involving other beta<span class="nobreak">-blockers</span> had been reported, a substantial number of BEST trial investigators concluded that it was unethical to continue to give placebo to BEST trial participants. ARCA&#8217;s reanalysis of the BEST results in accordance with the FDA approved, pre<span class="nobreak">-specified</span> statistical analysis plans (which had not been performed by the sponsors of BEST) demonstrated a 13% risk reduction on the primary endpoint of ACM in the BEST trial with a p<span class="nobreak">-value</span> of 0.053. The risk reduction on HF clinical efficacy endpoints such as mortality and hospitalization ranged from 34% to 48% in this beta<span class="nobreak">-1</span> 389 arginine homozygous genotype. The DNA substudy revealed that Gencaro exhibited greater efficacy in patients homozygous for the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype (<span class="Italic" style="font-style:italic;font-weight:normal;">ADRB1</span> Arg389Arg), encoding for receptors that exhibit higher function and greater affinity for norepinephrine compared to the patients who did not have the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype (i.e., beta<span class="nobreak">-1</span> 389 Gly carriers). In the 47% of BEST trial patients with a <span class="Italic" style="font-style:italic;font-weight:normal;">ADRB1</span> Arg389Arg genotype Gencaro reduced (p &lt;0.05) the primary endpoint of mortality or heart transplantation by 43%, all<span class="nobreak">-cause</span> mortality, cardiovascular mortality, heart failure hospitalizations, heart failure progression, development of atrial </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">203</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">fibrillation, and incidence of ventricular tachycardia or ventricular fibrillation with degrees of reduction (effect sizes) ranging from 34% (heart failure progression) to 74% (atrial fibrillation). Beta<span class="nobreak">-1</span> 389 Gly carriers had no statistically significant reduction in any endpoint.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pharmacology and Pharmacogenetics of Gencaro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro (bucindolol hydrochloride) is a nonselective (blocks both beta<span class="nobreak">-1</span> and beta<span class="nobreak">-2</span> adrenergic receptors) beta- receptor blocking agent with mild vasodilator properties. This combination of properties initially placed Gencaro in the &#8220;3<span class="CharOverride-6" style="font-size:58%;vertical-align:super;">rd</span> Generation&#8221; category of beta<span class="nobreak">-blockers</span> that is based on the strategy of their development. When its pharmacogenetic properties were elucidated and its development became pharmacogenetically based, ARCA subsequently considered Gencaro a fourth<span class="nobreak">-generation</span> beta<span class="nobreak">-blocker</span>. The dominant beta<span class="nobreak">-receptor</span> on human heart cells is the beta<span class="nobreak">-1</span>, with smaller number of beta<span class="nobreak">-2</span> receptors present. Importantly, beta<span class="nobreak">-2</span> receptors are also present on adrenergic nerve terminals in the heart, where they regulate the release of the neurotransmitter norepinephrine (&#8220;NE&#8221;). The blocking of these receptors prevents them from binding with other molecules, primarily NE, which activates these receptors to release more NE.&#160;ARCA believes Gencaro has two unique anti<span class="nobreak">-adrenergic</span> properties not possessed by other beta<span class="nobreak">-blockers</span> currently approved for the treatment of HF: (1)&#160;it is moderately sympatholytic, i.e., by blocking beta<span class="nobreak">-2</span> receptors on adrenergic nerves it lowers adrenergic drive to a level that can be detected on measurements of central or systemic venous NE levels, and, (2)&#160;through &#8220;inverse agonism,&#8221; as it binds to a polymorphic &#8220;389 arginine&#8221; form of heart cell beta<span class="nobreak">-1</span> receptor in isolated human heart preparations it promotes the inactivation of the active<span class="nobreak">-state</span> of this receptor. These properties, as described below, were observed to interact with receptor polymorphisms in such a way that ARCA believes targeting a specific genotype of the beta<span class="nobreak">-1</span> receptor gene (known as ADRB1) could improve the therapeutic response of patients. ARCA believes Gencaro&#8217;s efficacy is enhanced in patients with the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype (<span class="Italic" style="font-style:italic;font-weight:normal;">ADRB1</span> Arg389Arg), which has been shown to be present in approximately 50% of the North American and European general populations. To date no other beta<span class="nobreak">-blocker</span> has been shown to possess pharmacological sympatholysis, or beta<span class="nobreak">-1</span> AR inverse agonism in human heart preparations. ARCA believes that Gencaro&#8217;s sympatholytic and beta<span class="nobreak">-1</span> AR inverse agonist properties contribute to its enhanced lowering of HF and arrhythmia event rates in patients who have an <span class="Italic" style="font-style:italic;font-weight:normal;">ADRB1</span> Arg389Arg genotype.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro Clinical and Regulatory Strategy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA intends to advance Phase&#160;3 clinical development of Gencaro as a therapy for HF patients with AF, focusing on HF with EF &#8805; 40%. The regulatory strategy for Gencaro is to obtain an initial approval to treat AF in a HF population with EF &#8805; 40% and &#8804; 55% and the beta<span class="nobreak">-1</span> 389 arginine homozygous genotype; the population demonstrating the greatest efficacy in the Phase&#160;2B GENETIC<span class="nobreak">-AF</span> clinical trial. Indication expansion for Gencaro will focus on genotype<span class="nobreak">-positive</span> HF patients with EF &gt;55%, which ARCA believes would substantially expand the addressable patient population, if successful. ARCA has obtained an SPA agreement with the FDA to conduct a single, 400<span class="nobreak">-patient</span> Phase&#160;3 clinical trial that, if successful at a statistical threshold of p &#8804; 0.01, may be sufficient to support an NDA for the marketing approval of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The clinical trial design is similar to GENETIC<span class="nobreak">-AF</span>, including the active comparator, TOPROL<span class="nobreak">-XL</span>, and the primary endpoint of time to AF or atrial flutter (&#8220;AF/AFL&#8221;) recurrence or mortality during a 6<span class="nobreak">-month</span> follow<span class="nobreak">-up</span> period. The planned clinical trial will use a standard significance criterion of p &#8804; 0.05 for the primary endpoint; however, if the primary endpoint is significant with a p<span class="nobreak">-value</span> &#8804; 0.01, then this single Phase&#160;3 clinical trial may be sufficient for regulatory approval per the SPA agreement. The NDA submission for Gencaro is eligible for expedited review in the United&#160;States under the Fast Track development program designation that was granted to Gencaro in 2015. Based on the use of this same endpoint in GENETIC<span class="nobreak">-AF</span> it is anticipated that &#8805;90% of the primary events will be due to recurrent AF/AFL.&#160;Secondary objectives will examine other important endpoints, such as AF burden and AF treatment<span class="nobreak">-related</span> interventions. The planned clinical trial will use a standard significance criterion of p&#160;&#8804;&#160;0.05 for the primary endpoint; however, if the primary endpoint is significant with a p<span class="nobreak">-value</span> &#8804; 0.01, then this single&#160;Phase&#160;3 clinical trial may be sufficient for regulatory approval per the SPA agreement.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">The Gencaro Test</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If approved, ARCA believes that Gencaro will be the first cardiovascular drug to be integrated with a companion diagnostic. This would be a test for the patient genotype approved for the drug, and could be performed by a variety of laboratory processes or platforms.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">204</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In collaboration with LabCorp, ARCA developed one such genetic test, obtained an IDE from the FDA and used this test in ARCA&#8217;s GENETIC<span class="nobreak">-AF</span> clinical trial. ARCA retains all rights to this particular test platform, and ARCA believes it could be used for commercialization. Future clinical trials of Gencaro, including PRECISION<span class="nobreak">-AF</span>, are expected to use a similar diagnostic test to identify the patient&#8217;s receptor genotype (the &#8220;Gencaro Test&#8221;). ARCA believes the Gencaro Test could be developed and commercialized through one or more diagnostic providers, by the company potentially marketing Gencaro, or a combination of approaches. ARCA also believes that point of care genetic tests, which could be performed during the patient&#8217;s visit to the physician, will be part of the commercialization strategy for Gencaro.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Development Pipeline</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation in patients with chronic heart failure.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro, is a potential treatment for HF patients with AF.&#160;Gencaro (bucindolol hydrochloride) is a pharmacogenetic<span class="nobreak">-targeted</span> beta<span class="nobreak">-adrenergic</span> receptor antagonist with mild vasodilator properties that is considered a fourth<span class="nobreak">-generation</span> beta<span class="nobreak">-blocker</span> based on its novel pharmacogenetic profile. ARCA believes the treatment of AF in HF patients with EF &#8805; 40% is an unmet medical need with a near term and straightforward regulatory pathway.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s plan is to obtain an initial approval for Gencaro to treat AF in a genotype specific HF population; HF patients with EF between 40% and 55% in patients with the genotype ARCA studied in the Phase&#160;2B GENETIC<span class="nobreak">-AF</span> clinical trial. ARCA believes that, if approved, there are additional indication expansion opportunities for Gencaro in other AF populations, including expanding the patient population to selected HF patients with EF &gt;55%. ARCA continues to evaluate the feasibility and potential timing for initiating PRECISION<span class="nobreak">-AF</span> relative to the COVID<span class="nobreak">-19</span> pandemic. ARCA may seek additional capital or a strategic partnership for the Phase&#160;3 clinical trial and potential commercialization of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA plans to pursue strategic development and partnering opportunities with commercial or government partners for rNAPc2 development and commercialization or expansion into clinical trials for other disease indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA also has exclusive pharmacogenetic and other patent rights to drug targets and candidates that have potential indications in cardiovascular disease, oncology and other therapeutic areas. ARCA may seek partners to assist it in the development of these candidates or who may license them. ARCA may also seek funds to advance the development of the compounds on ARCA&#8217;s own.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Financial Resources</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To support the continued development of Gencaro and rNAPc2, ARCA will need additional financing to fully fund any clinical trials, and its general and administrative costs through the clinical trials&#8217; projected completion and potential commercialization. Considering the substantial time and costs associated with the development of Gencaro and rNAPc2 and the risk that ARCA may be unable to raise a significant amount of capital on acceptable terms, ARCA is also pursuing co<span class="nobreak">-development</span> and commercialization partnering opportunities with large pharmaceutical and/or specialty pharmaceutical companies and may pursue a strategic combination or other strategic transactions. If ARCA is unable to obtain sufficient financing or is unable to complete a strategic transaction, ARCA may discontinue its development activities on Gencaro or rNAPc2 or discontinue operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes ARCA&#8217;s cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund ARCA&#8217;s operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipate; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">205</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Licensing and Royalty Obligations</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s patent portfolios relating to Gencaro, including a patent issued in 2021, are either owned by ARCA or are subject to licenses that impose no royalty obligations or milestone payments relating to the further development, approval and commercialization of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is also a party to licenses for patents relating to Gencaro that are now expired. ARCA believes that there are no future milestone or royalty obligations that will be payable under these licenses.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Competition</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Current HF treatments include three beta<span class="nobreak">-blockers</span> approved for HF in the United&#160;States. However, their efficacy in providing control of the arrhythmia caused by AF, or rhythm control, is only mild. It is also now acknowledged that evidence is lacking that the approved beta<span class="nobreak">-blockers</span> provide outcome benefits for patients who develop permanent AF.&#160;Furthermore, these drugs have not demonstrated efficacy for HF patients with EF &#8805; 40%, which is the focus of the Gencaro development program. Current AF treatments include pharmaceutical, procedural or device intervention. There are several antiarrhythmic drugs approved by the FDA for the treatment and/or prevention of recurrent AF.&#160;However, these drugs have safety and/or administration concerns and all but one have contraindications or label warnings regarding their prescription in patients with HF.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Drugs that are currently approved or used for the treatment or prevention of AF in HF either have not demonstrated efficacy in these patients, or have notable risks due to adverse side effects or lack sufficient efficacy. Therefore, in HF, and specifically in HF patients with EF &#8805; 40%, ARCA believes there is a substantial unmet medical need for AF therapies that are more effective and have fewer side effects than those currently available. ARCA believes that Gencaro&#8217;s treatment of AF in HF patients could provide a more effective and safer pharmacotherapy than treatments currently used in these patients.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The pharmaceutical industry is highly competitive. ARCA faces significant competition from pharmaceutical companies and biotechnology companies that are researching and selling products designed to treat cardiovascular conditions. Most of these companies have significantly greater financial, product development, manufacturing, and commercial resources than ARCA has.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If approved, some of the drugs which Gencaro would potentially compete with are generic in the United&#160;States and are used, though not approved or shown to be effective, for the treatment of AF or in HF patients with EF &#8805; 40%. Gencaro could be priced at a premium compared to some of these therapies. In addition, Gencaro, if approved, would be prescribed in conjunction with a diagnostic test, adding additional procedures to the process of prescribing Gencaro, which could make it more difficult for ARCA to compete against existing or future therapies.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Manufacturing and Product Supply</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro is a small molecule drug with an established manufacturing history. Multiple manufacturers of both the active pharmaceutical ingredients (&#8220;API&#8221;) and drug product have successfully produced Gencaro for use in clinical trials over the course of its clinical development. ARCA outsources all manufacturing and analytical testing of the Gencaro API and drug product. ARCA has selected third<span class="nobreak">-party</span> contract manufacturing organizations on the basis of their technical and regulatory expertise. ARCA&#8217;s approach with its contract manufacturing partners has been to replicate the manufacturing processes that were used to support the prior pivotal clinical trial with Gencaro, and to minimize any changes from these baseline processes, thereby reducing technical and regulatory risk. For API production, ARCA contracted with Groupe Novasep which completed the drug substance registration batches successfully. The resulting drug substance was used to manufacture the drug product used in the clinical trial material for the Phase&#160;2B clinical trial and is expected to be used in the proposed Phase&#160;3 clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For drug product production, ARCA has contracted with Patheon, Inc. to manufacture the Gencaro tablets. Gencaro is produced in a tablet form, utilizing standard solid oral dosage processing techniques. Six separate dosage strengths have been manufactured, with the maximum recommended dose of 100mg twice daily. Registration </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">206</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">batches were successfully completed by Patheon, Inc. and tablets from these runs were placed in cGMP storage to supply clinical trials. In addition, ARCA contracted with a separate service provider for packaging and distribution of its clinical trial materials.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Government Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Governmental authorities in the United&#160;States at the federal, state, and local levels and foreign countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, marketing, distribution, sampling, and import and export of pharmaceutical and medical device products. In the United&#160;States, the FDA regulates these activities at the federal level pursuant to the Federal Food Drug and Cosmetic Act (&#8220;FDCA&#8221;) and the regulations promulgated thereunder. In Canada, Health Canada regulates these activities. In Europe, the Competent Authorities and Ethics Committees of the respective countries regulate these activities. In South America, the Health Authorities and Ethics Committees of their respective countries regulate these activities. ARCA anticipates that all of its product candidates will require regulatory approval by governmental agencies prior to commercialization. The process of obtaining approval and the subsequent process of maintaining compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. In addition, these statutes, rules, regulations and policies may change and ARCA&#8217;s products may be subject to new legislation or regulations. Both before and after approval or clearance, failure to comply with the requirements of the FDA and other state and federal statutes can lead to significant penalties or could disrupt ARCA&#8217;s ability to manufacture and sell these products. In addition, the FDA could refuse to provide certificates needed to export ARCA&#8217;s products if the agency determines that ARCA is not in compliance.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Premarket Approval of Drugs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">FDA approval is required for marketing of any new drug, dosage form, indication, or strength. The steps required before new human therapeutic drug products are marketed in the United&#160;States and foreign countries include rigorous preclinical and clinical testing and other approval requirements by regulatory agencies, such as the FDA and comparable agencies in foreign countries. There is no guarantee that products will be approved in a specific timeframe or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Preclinical Phase.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Preclinical studies are generally conducted in the laboratory to identify potential drug candidates and to evaluate their potential efficacy and safety. These studies include laboratory evaluation of product chemistry, formulation and stability, as well as studies to evaluate short and long<span class="nobreak">-term</span> toxicity in animals. Preclinical studies are governed by numerous regulations, including but not limited to FDA&#8217;s Good Laboratory Practices.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Clinical Phase.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Before human clinical trials can commence, an Investigational New Drug (&#8220;IND&#8221;) application, submitted to FDA must become effective. For an IND to become effective, the applicant must submit, among other things, information on design of the proposed investigation, reports necessary to assess the safety of the drug for use in clinical investigation, and information on the chemistry and manufacturing of the drug, controls available for the drug, and primary data tabulations from animal or human studies. The clinical phase of development involves the performance of human studies, including adequate and well<span class="nobreak">-controlled</span> human clinical trials to establish the safety and efficacy of the product candidate for each proposed indication. Typically, clinical evaluation involves three sequential phases, which may overlap. During Phase&#160;1, clinical trials are conducted with a relatively small number of subjects or patients to determine the early safety profile of a product candidate, as well as dose tolerance, absorption, and the pattern of drug distribution and drug metabolism. Phase&#160;2 trials are conducted with groups of patients afflicted by a specific target disease to determine preliminary efficacy, optimal dosages and dosage tolerance and to identify possible adverse effects and safety risks. In Phase&#160;3, larger<span class="nobreak">-scale</span>, multi- center trials are conducted with patients afflicted with a specific target disease over a longer term to confirm Phase&#160;2 results and provide reliable and conclusive data supporting efficacy and safety of a drug as required by regulatory agencies for drug approval. The conduct of clinical trials is subject to extensive regulation. FDA may delay or suspend clinical trials through clinical holds.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">NDA Submission.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>In the United&#160;States, the results of preclinical and clinical testing along with chemistry, manufacturing and controls information, are submitted to the FDA in the form of a NDA.&#160;Under the current Prescription Drug User Fee Act after submission of an NDA and payment, or waiver, of the required fee, the FDA&#8217;s goal is to review most standard NDAs within 10&#160;months from the time that a sponsor&#8217;s application is accepted as </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">207</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">filed by the FDA, which can occur within a 60<span class="nobreak">-day</span> window following the initial submission of the application. At the end of the 10&#160;months, the FDA&#8217;s goal is to issue a &#8220;complete response,&#8221; or approve the NDA.&#160;While FDA&#8217;s goal is to issue a complete response within 10&#160;months, the process may take longer than 10&#160;months, particularly if multiple review cycles are required. Gencaro has been granted Fast Track Designation which allows for a rolling review of a marketing application. A rolling review allows FDA to consider reviewing portions of an NDA before the sponsor submits the complete application.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In responding to an NDA, the FDA may grant marketing approval or deny the application if the FDA determines that the application does not satisfy the statutory and regulatory approval criteria. A denial may include a request for additional information, including additional clinical data and/or an additional Phase&#160;3 clinical trial. Data from clinical trials are not always conclusive and FDA may interpret data differently than ARCA interprets data. Under the Food and Drug Modernization Act&#160;of&#160;1997, the FDA is authorized to approve a drug based on a single adequate and well<span class="nobreak">-controlled</span> study if such study and other confirmatory data are sufficient to establish the drug&#8217;s effectiveness. However, it has long been the FDA&#8217;s general position that the standard of proof of a drug&#8217;s effectiveness generally requires at least two well<span class="nobreak">-controlled</span> and adequate Phase&#160;3 clinical studies demonstrating statistically significant results as compared to a placebo or active control (with p<span class="nobreak">-values</span> of less than 0.05) with respect to the primary endpoint or endpoints of the trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, in accordance with current FDA law and regulations, the FDA may refer a drug to an advisory committee for review prior to approval. Most new compounds are referred to an FDA advisory committee, which could add additional time to the review process. There is no guarantee that the advisory committee will recommend approval of a drug candidate. In some cases, FDA may require completion, within a specified time period, of additional clinical studies after approval, referred to as Phase&#160;4 clinical studies, to monitor the effect of a new product and may prevent or limit future marketing of the product based on the results of these post<span class="nobreak">-marketing</span> programs. Furthermore, prior to granting approval, the FDA generally conducts an inspection of the facilities, including outsourced facilities that will be involved in the manufacture, production, packaging, testing and control of the drug substance and finished drug product for compliance with current Good Manufacturing Practice (&#8220;cGMP&#8221;) requirements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the FDA approves the NDA, the sponsor is authorized to begin commercialization of the drug in accordance with the approval. Even if the FDA approves the NDA, the FDA may decide later to suspend or withdraw product approval if compliance with regulatory standards is not maintained or if safety problems are recognized after the product reaches the market. In addition, the FDA requires surveillance programs to monitor approved products that have been commercialized, and the agency has the power to require additional clinical studies, to require changes in labeling or to prevent further marketing of a product based on the results of these post<span class="nobreak">-marketing</span> programs. The FDA also has authority to request implementation of a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) that could restrict distribution of Gencaro or require ARCA to provide additional risk information to prescribers. Whether or not FDA approval has been obtained, approval of a product candidate by comparable foreign regulatory authorities is necessary prior to the commencement of marketing of a product candidate in those countries. The approval procedures vary among countries and can involve additional testing. The time required to obtain approval may differ from that required for FDA approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Post</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-approval</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Compliance.&#160;&#160;&#160;&#160;</span>If regulatory approval for a drug or medical device is obtained, the product and the facilities manufacturing the product are subject to periodic inspection and continued regulation by regulatory authorities, including compliance with cGMP, as well as labeling, advertising, promotion, recordkeeping, and reporting requirements, including the reporting of adverse events. In addition, the FDA closely regulates the post<span class="nobreak">-approval</span> marketing and promotion of drugs, including standards and regulations for labeling, promotion to health care professionals, direct<span class="nobreak">-to-consumer</span> advertising, off<span class="nobreak">-label</span> promotion, industry<span class="nobreak">-sponsored</span> scientific and educational activities and promotional activities involving the Internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Companies are responsible for compliance with such requirements and would be responsible to ensure that all contract manufacturing organizations who perform work for them also comply with such requirements. Similarly, if a drug manufacturer hires contract sales representatives or consultants to promote its products, such organizations or individuals must comply with all of the same requirements applicable to the drug manufacturer. The FDA regularly inspects companies to determine compliance with cGMPs and other post<span class="nobreak">-market</span> requirements. Failure to comply with statutory requirements and the FDA&#8217;s regulations can result in a variety of administrative or enforcement actions, including but not limited to an FDA Form&#160;483 (which is issued by the FDA at the conclusions of an inspection when an investigator has observed </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">208</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">any conditions that may constitute violations), a public warning letter, suspension or withdrawal of regulatory approvals, product recalls, product detentions, refusal to provide export certificates, seizure of products and criminal prosecution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Drug Price Competition and Patent Term Restoration Act&#160;of&#160;1984.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Under the Drug Price Competition and Patent Term Restoration Act&#160;of&#160;1984, also known as the Hatch<span class="nobreak">-Waxman</span> Act, Congress created an abbreviated FDA review process for generic versions of pioneer (brand name) drug products. The Hatch<span class="nobreak">-Waxman</span> Act also provides for patent term restoration and the award, in certain circumstances, of non<span class="nobreak">-patent</span> marketing exclusivities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Generic Drug Approval.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The Hatch<span class="nobreak">-Waxman</span> Act established an abbreviated FDA review process for drugs that are shown to be equivalent to approved pioneer drugs. Approval for a generic drug is obtained by filing an abbreviated NDA, or ANDA.&#160;Generic drug applications are &#8220;abbreviated&#8221; because they generally do not include clinical data to demonstrate safety and effectiveness. Instead, an ANDA applicant must establish that its product is bioequivalent to an approved drug and that it is the same as the approved drug with respect to active ingredient(s), route of administration, dosage form, strength and recommended conditions of use (labeling). The FDA will approve the generic as suitable for an ANDA if it finds that the generic does not raise questions of safety and effectiveness as compared to the pioneer drug. A drug is not eligible for ANDA approval if the FDA determines that it is not equivalent to the pioneer drug or if it is intended for a different use. Any applicant who files an ANDA seeking approval of a generic version of an approved drug listed in FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (the &#8220;Orange Book&#8221;) must certify to the FDA that (i)&#160;no patent information on the drug has been listed in the Orange Book; (ii)&#160;that each patent listed in the Orange Book for that approved drug has expired; (iii)&#160;FDA should approve the product on the date on which a listed patent expires; or (iv)&#160;that such patent is invalid, unenforceable or will not be infringed by the manufacture, use or sale of the generic drug. If the ANDA applicant makes a certification pursuant to (iv)&#160;above, or a Paragraph&#160;IV certification, and the NDA holder files an infringement suit against the ANDA applicant within 45&#160;days of receiving the Paragraph&#160;IV notification, the NDA owner is entitled to an automatic 30<span class="nobreak">-month</span> stay of FDA&#8217;s ability to approve the ANDA.&#160;This 30<span class="nobreak">-month</span> stay will end early upon any decision by a court that the patent is invalid, unenforceable or not infringed by the generic drug.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Patent Term Extension.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>While the term of a U.S.&#160;patent is generally 20&#160;years from the earliest priority date of a patent application (excluding a provisional patent application), a U.S.&#160;patent that covers subject matter requiring regulatory approval to market is eligible for an extension of that patent term. The Hatch<span class="nobreak">-Waxman</span> Act provides for the restoration of a portion of the patent term lost during product development and FDA review of an application. Patent Term Extension (&#8220;PTE&#8221;), extends the term of an issued patent for generally (i)&#160;the length of the FDA approval process, i.e., the complete period of NDA review, and (ii)&#160;half of the time spent in clinical trials, i.e., the IND period. However, the maximum period of restoration cannot exceed five&#160;years, or restore the total remaining term of the patent to greater than 14&#160;years from the date of FDA approval of the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under 35 U.S.C. &#167; 156(a), a patent covering a method of using a product is eligible for PTE if the following conditions are met:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">1)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the patent has not yet expired;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">2)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the patent was not previously extended;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">3)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the patent owner submits an application for PTE that includes all necessary supporting information within 60&#160;days of FDA approval;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">4)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the product was subject to regulatory review before its commercial marketing or use; and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the drug application is for the first permitted commercial marketing of the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that, if Gencaro is approved by the FDA, one of its U.S.&#160;patents may be eligible for PTE, which could provide up to 5&#160;years of additional patent life for that patent based on ARCA&#8217;s current clinical trial plans.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A Supplementary Protection Certificate (&#8220;SPC&#8221;) is a form of patent term extension that is available for pharmaceutical products approved for marketing in the European Union (&#8220;EU&#8221;). ARCA obtained a patent in Europe on methods for using Gencaro that is similar to one of its U.S.&#160;patents and this EU patent is in force in certain countries in Europe, including the United Kingdom, France, Germany, Italy and Spain. ARCA believes that this </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">209</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">patent may be eligible for an SPC, if Gencaro is approved for marketing in any European country in which the patent is in force, which could provide up to five&#160;years of additional patent life. ARCA believes that its patents in other jurisdictions may also be eligible for similar term extensions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Non</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Patent</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Marketing Exclusivities.&#160;&#160;&#160;&#160;</span>Separate and apart from patent protection, the Hatch<span class="nobreak">-Waxman</span> Act entitles approved drugs to various periods of non<span class="nobreak">-patent</span> statutory protection, known as marketing exclusivity. The Hatch<span class="nobreak">-Waxman</span> Act provides five&#160;years of &#8220;new chemical entity&#8221; marketing exclusivity to the first applicant to gain approval of an NDA for a product that contains an active moiety not found in any other approved product. This exclusivity means that another manufacturer cannot submit an ANDA or 505(b)(2)&#160;NDA until the marketing exclusivity period ends. This exclusivity protects the entire new chemical entity franchise, including all products containing the active ingredient for any use and in any strength or dosage form, but will not prevent the submission or approval of stand<span class="nobreak">-alone</span> NDAs where the applicants have conducted their own clinical studies to demonstrate safety and effectiveness. There is an exception, however, for a competitor that seeks to challenge a patent with a Paragraph&#160;IV certification. Four&#160;years into the five<span class="nobreak">-year</span> exclusivity period, a manufacturer who alleges that one or more of the patents listed with the NDA is invalid, unenforceable or not infringed may submit an ANDA or 505(b)(2) NDA for a generic or modified version of the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Hatch<span class="nobreak">-Waxman</span> Act also provides three&#160;years of &#8220;new use&#8221; marketing exclusivity for the approval of NDAs, and supplements, where those applications contain the results of new clinical investigations (other than bioavailability studies) essential to the FDA&#8217;s approval of the applications. Such applications may be submitted for new indications, dosage forms, strengths, or new conditions of use of approved products. So long as the studies are essential to the FDA&#8217;s approval or were conducted by or for the applicant, this three<span class="nobreak">-year</span> exclusivity prohibits the final approval of ANDAs or 505(b)(2)&#160;NDAs for products with the specific changes associated with those studies. It does not prohibit the FDA from approving ANDAs or 505(b)(2)&#160;NDAs for other products containing the same active ingredient, without those changes.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Similar non<span class="nobreak">-patent</span> market exclusivity is provided for in the EU and other international jurisdictions. ARCA believes that, if approved in the EU, Gencaro may be eligible for ten&#160;years of market exclusivity in the EU, measured from the date of approval there.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">FDA Premarket Review of Medical Devices</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless an exemption applies, each medical device that a company wishes to market in the United&#160;States requires either approval of a premarket approval application (&#8220;PMA&#8221;), or clearance of a premarket notification, commonly known as a &#8220;510(k)&#8221; from the FDA.&#160;The FDA classifies medical devices into one of three classes. Devices deemed to pose lower risks are placed in either class&#160;I or&#160;II, which may require the manufacturer to submit to the FDA a 510(k)&#160;requesting permission to commercially distribute the device. Clearance of a 510(k)&#160;usually requires between three&#160;months and one year from the time of submission of the 510(k), although the process may take longer. The FDA&#8217;s 510(k)&#160;clearance procedure is less rigorous than the PMA approval procedure, but is available only to companies who can establish that their device is substantially equivalent to a legally<span class="nobreak">-marketed</span> &#8220;predicate&#8221; device that was (i)&#160;on the market prior to the enactment of the Medical Device Amendments of 1976, (ii)&#160;reclassified from Class&#160;III to Class&#160;II, or (iii)&#160;has been cleared through the 510(k)&#160;procedure. 510(k)s must typically be supported by performance data, including preclinical data, bench testing, and in some cases, clinical data. Some low risk devices are exempted from this requirement. Devices deemed by the FDA to pose the greatest risks, or for which there is no predicate, are placed in class&#160;III, and require a PMA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">PMA Pathway.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Generally, a PMA must be supported by extensive data and valid scientific evidence, including, but not limited to, technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA&#8217;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use. After a PMA is sufficiently complete, the FDA will accept the application and begin an in<span class="nobreak">-depth</span> review of the submitted information and will generally conduct a pre<span class="nobreak">-approval</span> inspection of the manufacturing facility or facilities to ensure compliance with FDA&#8217;s QSR. By statute, the FDA has 180&#160;days to review the &#8220;accepted application&#8221;, although, generally, review of the application can take between one and three&#160;years, and it may take significantly longer. The PMA application process can be expensive, and there is a substantial &#8220;user fee&#8221; that must be paid to FDA in connection with the submission of a PMA application. If the FDA&#8217;s evaluation of the PMA application or the manufacturing facility is not favorable, the FDA may deny approval of the PMA application or issue a &#8220;not approvable&#8221; letter. The FDA may also require additional clinical trials, which can delay the PMA approval process by several&#160;years. In addition, if FDA discovers that an applicant has </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">210</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">submitted false or misleading information, FDA may refuse to review submissions until certain requirements are met pursuant to its Application Integrity Policy. If the FDA approves the PMA, it may place restrictions on the device. After the PMA is approved, if significant changes are made to a device, its manufacturing or labeling, a PMA supplement containing additional information must be filed for prior FDA approval. PMA supplements often must be approved by the FDA before the modification to the device, the labeling, or the manufacturing process may be implemented. Delays in receipt of or failure to receive such clearances or approvals, the loss of previously received clearances or approvals, or the failure to comply with existing or future regulatory requirements could have a material adverse effect on ARCA&#8217;s business, financial condition and results of operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Clinical Trials.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Clinical trials are generally required to support a PMA application and are sometimes required for 510(k)&#160;clearance. These trials generally require an IDE application approved in advance by the FDA for a specified number of patients, unless the proposed study is deemed a non<span class="nobreak">-significant</span> risk study, which is eligible for an exemption from the IDE requirements. The IDE application must be supported by appropriate data, such as animal and laboratory testing results. Clinical trials may begin if the IDE application is approved by the FDA and the appropriate IRBs at the clinical trial sites. Submission of an IDE application does not give assurance that the FDA will issue the IDE.&#160;If the IDE application is approved, there can be no assurance the FDA will determine that the data derived from the trials support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to and approved by the FDA before a sponsor or investigator may make a change to the investigational plan in such a way that may affect its scientific soundness, study indication or the rights, safety or welfare of human subjects. The trial must also comply with the FDA&#8217;s regulations, including the requirement that informed consent be obtained from each subject. Even if a trial is completed, the results of clinical testing may not adequately demonstrate the safety and efficacy of the device or may otherwise not be sufficient to obtain FDA clearance to market the product in the United&#160;States.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">In Vitro Diagnostic Companion Diagnostic Devices.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The FDA has described <span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span> diagnostics (&#8220;IVD&#8221;) companion diagnostic devices as in vitro diagnostic devices that provide information that is essential for the safe and effective use of a corresponding therapeutic product. The use of an IVD companion diagnostic device with a particular therapeutic product is stipulated in the instructions for use in the labeling of both the diagnostic device and the corresponding therapeutic product, as well as in the labeling of any generic equivalents of the therapeutic product. An IVD companion diagnostic device could be used to (i)&#160;identify patients who are most likely to benefit from a particular therapeutic product; (ii)&#160;identify patients likely to be at increased risk for serious adverse reactions as a result of treatment with a particular therapeutic product; or (iii)&#160;monitor response to treatment for the purpose of adjusting treatment (e.g., schedule, dose, discontinuation) to achieve improved safety or effectiveness. Although FDA&#8217;s regulation of IVD companion diagnostic devices is evolving and implemented on a case<span class="nobreak">-by-case</span> basis, FDA&#8217;s stated policy for a novel therapeutic product is that an IVD companion diagnostic device should be developed and approved or cleared contemporaneously to support the therapeutic product&#8217;s safe and effective use. The clinical performance and clinical significance of the IVD companion diagnostic device is to be established using data from the clinical development program of the corresponding therapeutic product. FDA recognizes, however, that there may be cases where contemporaneous development may not be possible. With respect to the Gencaro Test, there is no assurance that ARCA will be able to develop and obtain approval or clearance contemporaneously with Gencaro. Failure to develop the Gencaro Test or obtain clearance or approval could delay approval of Gencaro, if FDA regards the Gencaro Test as an IVD companion diagnostic test that is essential to the safe and effective use of Gencaro.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Continuing Regulation.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>After a device is placed on the market, numerous regulatory requirements apply to the manufacturer, or holder of a PMA approval. Unless subject to an exemption, medical devices distributed in the United&#160;States must be manufactured in compliance with the FDA&#8217;s QSRs and current good manufacturing practices. These regulations govern the manufacturing process, including design, manufacture, testing, release, packaging, distribution, documentation and purchasing, as well as complaint handling, corrective and preventative actions and internal auditing. In complying with the QSRs, manufacturers must expend significant time, money and effort. Companies are also subject to other post<span class="nobreak">-market</span> and general requirements, including but not limited to product listing and establishment registration, post<span class="nobreak">-market</span> surveillance requirements, limitations on promotion, and requirements for recordkeeping and reporting of certain adverse events, malfunctions, corrections and removals. As discussed above, FDA regularly inspects companies to assess compliance with the QSRs and other post<span class="nobreak">-market</span> requirements. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, and potential civil and criminal penalties. As part of such arrangement, ARCA will seek to have the diagnostic company take responsibility for compliance with the FDA&#8217;s device approval and on<span class="nobreak">-going</span> regulatory requirements.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">211</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">International Marketing Approvals.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>International sales of medical devices are subject to foreign government regulations, which vary substantially from country to country and are subject to change. The time required to obtain approval by a foreign country may be longer or shorter than that required for FDA clearance or approval, and the requirements may differ.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Other Regulatory Requirements.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>ARCA is also subject to various federal, state and local laws, regulations and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its work. The extent and character of governmental regulation that might result from future legislation or administrative action cannot be accurately predicted.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Medical Device Tax</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2010, the U.S.&#160;Congress adopted and President Obama signed into law comprehensive health care reform legislation. Among other initiatives, these laws impose significant new taxes on medical device makers in the form of a 2.3% excise tax on U.S.&#160;medical device sales, with certain exemptions, beginning on January&#160;1, 2013. On January&#160;22, 2018, legislation was enacted suspending the medical device tax in 2018 and 2019. In December&#160;2019, a permanent repeal of the medical device tax was enacted. The Gencaro Test is likely to be subject to this tax if this tax is reinstated in the future.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Intellectual Property</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The future success of ARCA&#8217;s business will partly depend on its ability to maintain market exclusivity for its product candidates, if approved, in the United&#160;States and important international markets, and for other products or product candidates that ARCA may acquire or develop. ARCA will rely on statutory protection, patent protection, trade secrets, know<span class="nobreak">-how</span>, and in<span class="nobreak">-licensing</span> of technology rights to maintain protection for ARCA&#8217;s products.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that Gencaro, if approved, will have market exclusivity in the United&#160;States and in major international markets. ARCA recently obtained a patent in the United&#160;States for the use of Gencaro for the patient population ARCA plans to study in the Phase&#160;3 pivotal trial. ARCA has filed similar patent applications in international jurisdictions. If Gencaro is approved by the FDA or international regulatory agencies based on this planned clinical development, ARCA believes that the commercialization of Gencaro will have patent protection extending into 2039.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has an existing patent portfolio of United&#160;States and international patents covering the use of Gencaro for various cardiovascular indications in the genetic population it plans to study in Phase&#160;3, that ARCA believes will provide additional patent protection.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to patent protection, Gencaro will qualify as a new chemical entity and if approved will have data protection in the United&#160;States and other jurisdictions in which it is approved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA also has other patent rights in additional drug candidates having possible indications in cardiovascular disease, oncology, and other therapeutic areas; these are in both early and later stages of development. ARCA may seek collaborators to assist it in the development of these candidates or it may seek to raise funds to advance the development of the compounds on its own.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Information about ARCA&#8217;s Executive Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Information relating to ARCA&#8217;s executive officers is included under &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA&#8217;s Directors, Executive Officers and Corporate Governance</span>&#8221; in the proxy statement/prospectus and such information is incorporated herein by reference.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Human Capital Management</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, ARCA had 5 employees, 4 of which are full<span class="nobreak">-time</span>. None of ARCA&#8217;s employees are represented by any collective bargaining unit. ARCA believes that it maintains good relations with its employees.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">212</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Information relating to compensation of ARCA executive officers is included in &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA&#8217;s Executive Compensation</span>&#8221; of this proxy statement/prospectus and such information is incorporated herein by reference. The structure of ARCA&#8217;s compensation programs balances incentive earnings for both short<span class="nobreak">-term</span> and long<span class="nobreak">-term</span> performance. ARCA is committed to providing comprehensive benefit options and offering benefits that will allow ARCA&#8217;s employees and their families to live healthier and more secure lives. Some examples are employees are eligible for health insurance, prescription drug benefits, dental insurance, vision insurance, life insurance, disability insurance, health savings accounts, flexible spending accounts, paid and unpaid leaves, a retirement plan and life and disability/accident coverage. ARCA also offers a variety of voluntary benefits that allow employees to select the options that meet their needs, including hospital indemnity insurance, accident insurance and critical illness insurance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA continually monitors employee turnover rates as its success depends upon retaining its highly trained personnel. ARCA believes the combination of competitive compensation and career growth and development opportunities have helped increase employee tenure and reduce voluntary turnover. The average tenure of ARCA&#8217;s employees, as of March&#160;31, 2024, was approximately eleven&#160;years and approximately 40% of ARCA&#8217;s employees, as of March&#160;31, 2024, have been employed by ARCA for more than ten&#160;years.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA&#8217;s Corporate Information</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On January&#160;27, 2009, ARCA completed a business combination between Nuvelo, Inc., a corporation originally incorporated in 1992, and its subsidiary, ARCA biopharma, Inc. Immediately following the business combinations, ARCA changed its name from Nuvelo, Inc. to ARCA biopharma, Inc. ARCA&#8217;s principal offices are located in Westminster, Colorado.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA files its annual reports on Form&#160;10<span class="nobreak">-K</span>, quarterly reports on Form&#160;10<span class="nobreak">-Q</span> and current reports on Form&#160;8<span class="nobreak">-K</span> pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Exchange&#160;Act electronically with the SEC.&#160;The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.&#160;The address of that site is <span class="Italic" style="font-style:italic;font-weight:normal;">http://www.sec.gov</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">You may obtain a free copy of ARCA&#8217;s annual reports on Form&#160;10<span class="nobreak">-K</span>, quarterly reports on Form&#160;10<span class="nobreak">-Q</span>, current reports on Form&#160;8<span class="nobreak">-K</span> and amendments to those reports on ARCA&#8217;s website at <span class="Italic" style="font-style:italic;font-weight:normal;">http://www.arcabiopharma.com</span> on the earliest practicable date following the filing with the SEC or by contacting the Investor Relations Department at ARCA&#8217;s corporate office by calling (720)&#160;940<span class="nobreak">-2100</span>. Information found on ARCA&#8217;s website is not incorporated by reference into this report.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Properties and Facilities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s headquarters facility consists of approximately 5,200 square feet of office space in Westminster, Colorado, of which approximately 5,200 square feet is leased until September&#160;2024, after which ARCA can continue to lease on a month<span class="nobreak">-to-month</span> basis. ARCA believes that this facility is adequate to meet its current needs.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Legal Proceedings</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, ARCA may become involved in legal proceedings. Except for as disclosed herein, ARCA is not currently a party to or aware of any proceedings that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on ARCA because of defense and settlement costs, diversion of management resources and other factors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of July<span class="nobreak"> </span>8, 2024, one complaint has been filed by a purported ARCA stockholder against ARCA and ARCA&#8217;s board of directors in connection with the proposed Merger.  On May<span class="nobreak"> </span>20, 2024, a purported stockholder filed a complaint, captioned Wynter v. ARCA biopharma, Inc., et al., No.: 1:24<span class="nobreak">-cv-1418-STV</span> (D. Colo.) (the &#8220;Complaint&#8221;), against ARCA and ARCA&#8217;s board of directors. The Complaint alleges that the defendants filed or caused to be filed a materially incomplete and misleading preliminary registration statement with the SEC and asserts claims under Sections 14(a) and 20(a) of the Exchange Act. The Complaint seeks an order enjoining the proposed Merger, or in the event that the proposed Merger is consummated, an order rescinding the Merger or awarding rescissory damages, as well as costs, including attorneys&#8217; and experts&#8217; fees. ARCA cannot predict the outcome of the Complaint. ARCA believes that the allegations and claims asserted in the Complaint are without merit and intends to defend against them vigorously. Additional lawsuits arising out of the Merger may be filed.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">213</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T12"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA&#8217;S BUSINESS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">All references to Oruka&#8217;s &#8220;product candidates,&#8221; &#8220;programs,&#8221; &#8220;portfolio&#8221; and &#8220;pipeline&#8221; in this proxy statement/prospectus refer to the research programs with respect to which Oruka has the option to acquire intellectual property license rights to pursuant to the Paragon Option Agreements.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Overview</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a biotechnology company focused on developing novel monoclonal antibody therapeutics for PsO and other&#160;I&amp;I indications. Oruka&#8217;s name is derived from <span class="Italic" style="font-style:italic;font-weight:normal;">or</span>, for &#8220;skin,&#8221; and <span class="Italic" style="font-style:italic;font-weight:normal;">arukah</span>, for &#8220;restoration&#8221; and reflects the company&#8217;s mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition. Oruka&#8217;s strategy is to apply antibody engineering and format innovations to validated modes of action, which Oruka believes will enable it to improve meaningfully upon the efficacy and dosing regimens of standard<span class="nobreak">-of-care</span> medicines while significantly reducing technical and biological risk. Oruka&#8217;s programs aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety involved in disease pathology and the activity of pathogenic tissue<span class="nobreak">-resident</span> memory T cells (&#8220;TRMs&#8221;). Oruka&#8217;s lead program, ORKA<span class="nobreak">-001</span>, is designed to target the p19 subunit of interleukin<span class="nobreak">-23</span> (IL<span class="nobreak">-23p19</span>) for the treatment of PsO.&#160;Oruka&#8217;s co<span class="nobreak">-lead</span> program, ORKA<span class="nobreak">-002</span>, is designed to target interleukin<span class="nobreak">-17A</span> and interleukin<span class="nobreak">-17F</span> (&#8220;IL<span class="nobreak">-17A</span>/F&#8221;) for the treatment of PsO, PsA, and other conditions. These programs each bind their respective targets at high affinity and incorporate half<span class="nobreak">-life</span> extension technology with the aim to increase exposure and decrease dosing frequency. Oruka believes that its focused strategy, differentiated portfolio, and deep expertise position it to set a new treatment standard in large&#160;I&amp;I markets with continued unmet need.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Pipeline</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_001.jpg" style="width:596.48px;max-width:100%;"/></span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ORKA-001</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-001</span> is a high affinity, extended half<span class="nobreak">-life</span> monoclonal antibody (&#8220;mAb&#8221;) designed to target IL<span class="nobreak">-23p19</span>. IL<span class="nobreak">-23</span> is a pro<span class="nobreak">-inflammatory</span> cytokine that plays a critical role in the proliferation and development of T helper 17 (&#8220;Th17&#8221;) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL<span class="nobreak">-23</span> is composed of two subunits: a p40 subunit that is shared with IL<span class="nobreak">-12</span> and a p19 subunit that is specific to IL<span class="nobreak">-23</span>. First<span class="nobreak">-generation</span> IL<span class="nobreak">-23</span> antibodies bound p40 and inhibited both IL<span class="nobreak">-12</span> and IL<span class="nobreak">-23</span> signaling, while more recent IL<span class="nobreak">-23</span> antibodies targeting the p19 subunit have shown improved efficacy and safety. Based on preclinical evidence, Oruka believes that ORKA<span class="nobreak">-001</span> could achieve higher response rates than established therapies in PsO while requiring less frequent dosing and maintaining the favorable safety profile of therapies targeting IL<span class="nobreak">-23p19</span>. ORKA<span class="nobreak">-001</span> is engineered with YTE half<span class="nobreak">-life</span> extension technology, a specific three amino acid change in the fragment crystallizable (&#8220;Fc&#8221;) domain to modify the pH<span class="nobreak">-dependent</span> binding to the neonatal Fc receptor (&#8220;FcRn&#8221;). As a result, it has a pharmacokinetic profile designed to support a subcutaneous (&#8220;SQ&#8221;) injection as infrequently as once or twice a year. In addition, emerging evidence suggests that IL<span class="nobreak">-23</span> blockade can modify the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;Oruka believes that the expected characteristics of ORKA<span class="nobreak">-001</span> increase its potential to deliver these disease<span class="nobreak">-modifying</span> benefits. Oruka plans to initiate a Phase&#160;1 trial of ORKA<span class="nobreak">-001</span> in the first half of 2025 that will have the potential not only to generate important pharmacokinetic and safety data but also to demonstrate its efficacy in PsO patients.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">214</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">PsO is a chronic autoimmune skin disorder that affects an estimated 125&#160;million people worldwide with steadily increasing prevalence. It is the largest pharmaceutical market within dermatology, with annual sales of approximately $25&#160;billion in 2022, which is estimated to grow to $32&#160;billion by 2028. Around half of PsO patients have moderate or severe disease that cannot be adequately addressed by topical corticosteroids or oral therapies. The American Academy of Dermatology<span class="nobreak">-National</span> Psoriasis Foundation recommends biologics as first<span class="nobreak">-line</span> therapy for moderate<span class="nobreak">-to-severe</span> PsO.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Several classes of biologic therapies have been approved for PsO over the past 20&#160;years, resulting in progressively more complete symptom relief. Efficacy in PsO is typically measured via the psoriasis area and severity index (&#8220;PASI&#8221;) scoring system. The first biologics approved for PsO were tumor necrosis alpha (&#8220;TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span>&#8221;) inhibitors such as Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab), which achieved a 90%&#160;improvement in PASI score (&#8220;PASI 90&#8221;) at 16&#160;weeks in around&#160;25&#160;&#8211;&#160;50% of patients and a 100% improvement in PASI score (&#8220;PASI 100&#8221;) in&#160;around 5&#160;&#8211;&#160;20% of patients. Stelara (ustekinumab), which targets the p40 subunit of IL<span class="nobreak">-23</span> that is shared with IL<span class="nobreak">-12</span>, was approved next and achieved efficacy on par with Humira. IL<span class="nobreak">-17A</span> inhibitors Cosentyx (secukinumab), Taltz (ixekizumab), and Siliq (brodalumab) followed and achieved responses of PASI 90 in around&#160;70% of patients and PASI 100 in&#160;around 40% of patients with some risk of certain side effects such as oral candidiasis. Most recently, IL<span class="nobreak">-23p19</span> inhibitors such as Ilumya (tildrakizumab), Tremfya (guselkumab), and Skyrizi (risankizumab) have achieved responses of PASI 90 in&#160;around 70&#160;&#8211;&#160;80% of patients and PASI 100 in around 30&#160;&#8211;&#160;50% of patients with highly tolerable profiles. Finally, IL<span class="nobreak">-17A</span>/F inhibitors such as Bimzelx (bimekizumab) have recently shown even higher response rates than IL<span class="nobreak">-23</span> inhibitors, but with slightly less tolerable profiles.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Treatment expectations in PsO have evolved progressively with this continued innovation. A 75% improvement in PASI score was previously thought to be an adequate depth of response, and weekly SQ dosing was viewed as acceptable. With each subsequent generation of innovation, patient and caregiver expectations have advanced. Today, Skyrizi, is widely viewed as the leader in PsO biologic therapy and achieves PASI 100 in&#160;40&#160;&#8211;&#160;50% of patients at the 16<span class="nobreak">-week</span> primary endpoint with maintenance dosing every three&#160;months. While this is a remarkable advancement, there is still significant unmet need. Approximately half of moderate<span class="nobreak">-to-severe</span> PsO patients do not achieve full skin clarity, and a continued desire for more convenient dosing options has driven significant interest in orally delivered medicines targeting these same pathways. However, oral therapies have yet to match the efficacy and safety profile of biologics. Oruka believes that a long<span class="nobreak">-acting</span> biologic with higher efficacy and potential for disease modification represents the next step in advancing the standard of care in PsO.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-001</span> is expected to enter Phase&#160;1 clinical trials in the first half of 2025. Oruka plans to carry out a Phase&#160;1 program that could provide validation of half<span class="nobreak">-life</span> extension in 2025. In addition, Oruka plans to include PsO patients in its Phase&#160;1 program, which would give Oruka the opportunity to demonstrate 16<span class="nobreak">-week</span> PASI response rates by the end of 2026. Oruka then plans to proceed into Phase&#160;2/3 development. Based on recent precedent for PsO, Oruka anticipates that the entire development program from first<span class="nobreak">-in-human</span> to biologics license application (&#8220;BLA&#8221;) filing could take as little as six to seven&#160;years based on the averages for recently approved medicines. However, Oruka has no control over the length of time needed for FDA review, and this timeline could vary.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORKA-002</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-002</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target IL<span class="nobreak">-17A</span> and IL<span class="nobreak">-17F</span> (IL<span class="nobreak">-17A</span>/F). IL<span class="nobreak">-17</span> inhibition has become central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in other&#160;I&amp;I indications, such as hidradenitis suppurativa (&#8220;HS&#8221;) and axial spondyloarthritis (&#8220;axSpA&#8221;). More recently, the importance of inhibiting the IL<span class="nobreak">-17F</span> isoform along with IL<span class="nobreak">-17A</span> has become appreciated, and dual blockade with the recently approved therapy Bimzelx (bimekizumab) has led to higher response rates in patients than blockade of IL<span class="nobreak">-17A</span> alone. ORKA<span class="nobreak">-002</span> is designed to bind IL<span class="nobreak">-17A</span>/F at similar epitopes, or binding sites, and affinity ranges as bimekizumab, but incorporates half<span class="nobreak">-life</span> extension technology that could enable more convenient dosing intervals. Oruka plans to initiate Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka views ORKA<span class="nobreak">-002</span> and ORKA<span class="nobreak">-001</span> as highly complementary. Patients with moderate<span class="nobreak">-to-severe</span> PsO that have purely skin manifestations are most often treated with IL<span class="nobreak">-23</span> inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have joint involvement, or signs and symptoms of </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">215</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">PsA, an IL<span class="nobreak">-17</span> inhibitor is typically used due to its efficacy in addressing both skin and joint symptoms. In addition, IL<span class="nobreak">-17</span> inhibitors are often used in patients with highly resistant skin symptoms that do not adequately resolve through treatment with an IL<span class="nobreak">-23</span> inhibitor. Together, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> provide the potential to offer a highly compelling product profile for most patients with PsO and/or PsA, as well as the opportunity to address additional&#160;I&amp;I indications.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Additional Pipeline Programs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has a third mAb program, ORKA<span class="nobreak">-003</span>, designed to target an undisclosed pathway. Oruka&#8217;s strategy as a company is to remain highly focused on&#160;I&amp;I diseases, and specifically on inflammatory dermatology conditions. Oruka&#8217;s third program provides the potential for indication expansion beyond PsO and creates combination opportunities with Oruka&#8217;s more advanced programs.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Team, Investors, and Paragon Collaboration</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka was founded in February&#160;2024 by leading healthcare investor Fairmount Funds Management and hold options to acquire intellectual property rights with respect to certain research programs, including ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>, from Paragon. Fairmount Funds Management has launched other successful biotechnology companies leveraging antibody technologies generated by Paragon, including Apogee Therapeutics and Spyre Therapeutics. Oruka is led by a management team with significant experience in developing novel treatments for patients at biopharmaceutical companies such as CRISPR Therapeutics, Celgene, Novartis, and Protagonist Therapeutics. Together, Oruka&#8217;s team has a proven track record of building successful biotech organizations in high<span class="nobreak">-growth</span> environments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since its inception, Oruka has raised $3.0&#160;million in gross proceeds from the issuance of Series&#160;A convertible preferred stock and $25.0&#160;million in gross proceeds from the issuance of the Convertible Note. On April&#160;3, 2024, Oruka entered into a definitive merger agreement with ARCA to create a new public company focused on advancing Oruka&#8217;s pipeline of antibody therapies. In support of the Merger, Oruka has secured commitments for a $275.0&#160;million private investment (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note) in Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase Oruka common stock from a syndicate of premier healthcare investors led by Fairmount Funds Management and Venrock Healthcare Capital Partners, with participation from RTW Investments, Access Biotechnology, Commodore Capital, Deep Track Capital, Perceptive Advisors, Blackstone Multi<span class="nobreak">-Asset</span> Investing, Avidity Partners, Great Point Partners LLC, Paradigm BioCapital, Braidwell LP, and Redmile Group, as well as other investors, including multiple large investment management firms, that is expected to close immediately prior to completion of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the exercise of its Options (defined below) under the Paragon Option Agreements and execution of the respective license agreements, Oruka will have exclusive worldwide development and commercialization rights to Oruka&#8217;s programs, with IL<span class="nobreak">-23</span> rights for all indications outside of inflammatory bowel disease (&#8220;IBD&#8221;), pursuant to such agreements, as applicable. Fairmount Funds Management founded Paragon in 2021 as the firm&#8217;s discovery engine for biologics that potentially overcome limitations of existing therapies. Paragon leverages a dedicated in<span class="nobreak">-house</span> team of scientific experts in antibody development, as well as its partnership with FairJourney Biologics, to generate unique therapeutic concepts and enable its rapid proof<span class="nobreak">-of-concept</span> validation. Oruka considers Paragon to be a related party. See the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Certain Relationships and Related Party Transactions&#160;&#8212;&#160;Oruka Transactions&#160;&#8212;&#160;Oruka&#8217;s Relationship with Paragon and Paruka</span>&#8221; for additional information.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">216</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Strategy</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To achieve its goal of developing leading therapeutic antibodies for patients with inflammatory skin diseases, Oruka is applying antibody engineering to validated modes of action. Oruka believes this approach will enable it to improve meaningfully upon the efficacy and convenience of standard<span class="nobreak">-of-care</span> medicines while significantly reducing technical and biological risk. The key elements of Oruka&#8217;s strategy include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employ advanced antibody engineering to build biologics that could significantly improve upon existing therapies:&#160;&#160;&#160;&#160;</span>Oruka and its collaborators at Paragon have optimized a variety of parameters using a suite of antibody technologies to develop candidates with the potential to improve upon existing therapies. These parameters include extending half<span class="nobreak">-life</span> to increase exposure and reduce dosing frequency, enhancing affinity and specificity to maximize potency and safety, and optimizing developability to ensure consistency and enable convenient, high<span class="nobreak">-dose</span> formulations. Together, Oruka believes these features have the potential to translate into more efficacious and convenient medicines for patients.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Target validated mechanisms of action:&#160;&#160;&#160;&#160;</span>Oruka&#8217;s initial targets, IL<span class="nobreak">-23p19</span> and IL<span class="nobreak">-17A</span>/F, have established efficacy and safety for the treatment of PsO, PsA, and other indications. The FDA has approved four biologics in the IL<span class="nobreak">-23</span> class, including three targeting IL<span class="nobreak">-23p19</span>, and four biologics in the IL<span class="nobreak">-17</span> class, including one targeting IL<span class="nobreak">-17A</span>/F.&#160;While these therapies have advanced the standard of care in PsO and PsA, they have not addressed these diseases completely, and a significant fraction of patients do not achieve complete skin clearance. By applying Oruka&#8217;s advanced antibody engineering to these validated targets, Oruka believes it can maximize its chances of developing superior medicines for patients. In addition, the reduced technical and biological risk of these validated mechanisms may allow Oruka to progress its programs more efficiently and rapidly.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leverage insights from earlier entrants to optimize Oruka&#8217;s approach:&#160;&#160;&#160;&#160;</span>Oruka benefits from a large body of clinical evidence generated by prior therapies targeting IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17</span>. Oruka continues to extract and apply learnings from this precedent to its programs, including in development candidate selection, clinical trial design, dosing regimens, formulations and presentations, regulatory pathway, and indication prioritization. For instance, based on correlations between affinity and efficacy, Oruka has designed ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> to bind to similar epitopes and at similar or greater affinities as the leading antibodies in each class: risankizumab and bimekizumab, respectively, with the aim of maximizing efficacy. Also, by understanding the exposure<span class="nobreak">-response</span> relationships for efficacy and safety for other therapies, Oruka plans to select dose levels and regimens that could maximize efficacy and maintenance of response while maintaining safety.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pursue opportunities with strong prospects of yielding meaningful new medicines as a &#8220;base case&#8221; and the potential to shift the treatment paradigm entirely as an &#8220;upside case&#8221;:&#160;&#160;&#160;&#160;</span>Oruka&#8217;s strategy seeks to maximize the potential for Oruka&#8217;s programs to reach a base case product profile that could meaningfully advance the standard of care&#160;&#8212;&#160;for instance, for ORKA<span class="nobreak">-001</span>, SQ dosing one or twice a year with equal or greater efficacy compared to today&#8217;s standard of care. At the same time, Oruka aims to deliver an upside case that dramatically improves outcomes for patients&#160;&#8212;&#160;for instance, significantly increasing rates of complete skin clearance via higher antibody exposures or offering patients durable remissions free from therapy by introducing patient<span class="nobreak">-specific</span> dosing intervals.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Build a preeminent biotechnology company focused on chronic skin disease and other&#160;I&amp;I indications:&#160;&#160;&#160;&#160;</span>Oruka is assembling a team of exceptional people and helping them reach their full potential and flourish so that together it can bring forward meaningful new medicines for patients.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that pursuing the focused strategy outlined above will help it to succeed in its mission of offering patients living with PsO, PsA, and other dermatologic and inflammatory diseases the greatest possible freedom from their condition.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Targeting IL-23 and IL-17 to Treat Multiple&#160;I&amp;I Indications</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s programs benefit from significant advances in the understanding of the biology of&#160;I&amp;I diseases over the past four decades. ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> are designed to target two key cytokines that play a related role in multiple indications. IL<span class="nobreak">-23</span> is an upstream regulator of Th17 cells, a pro<span class="nobreak">-inflammatory</span> subset of T helper cells </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">217</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">characterized by their production of IL<span class="nobreak">-17</span>. IL<span class="nobreak">-23</span> has a critical role in maintaining Th17 cells in the tissue as well as activating these cells to secrete IL<span class="nobreak">-17</span>, which acts downstream to trigger inflammation and other disease symptoms. Th17 cells are involved in PsO, PsA, HS, axSpA, and many other diseases. They play a particularly central role in PsO and PsA.&#160;The diagram below depicting the immunopathogenesis of PsO provides an example of how Th17 cells can mediate disease and how blocking IL<span class="nobreak">-23</span> or IL<span class="nobreak">-17</span> can break the inflammatory cycle that drives disease.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Immunopathogenesis of PsO and the role of IL-23 and IL-17</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><img alt="" src="timage_002.jpg" style="width:599.04px;max-width:100%;"/></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">PsO develops when environmental triggers and a genetic predisposition combine to cause activation of an inflammatory cycle in the skin that leads to the formation of plaques and other disease manifestations. This process begins with the aberrant activation of the dendritic cells (&#8220;DCs&#8221;), specifically those producing IL<span class="nobreak">-23</span> and other cytokines like IL<span class="nobreak">-1</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#946;</span>, IL<span class="nobreak">-21</span>, TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span>, and IL<span class="nobreak">-12</span>. These cytokines induce the differentiation of Th17 cells, as well as other cell types, such as T helper type 1 (&#8220;Th1&#8221;) cells that produce IFN<span class="CharOverride-1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#947;</span> and TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> and T helper type 22 (&#8220;Th22&#8221;) cells that produce IL<span class="nobreak">-22</span>. IL<span class="nobreak">-23</span> plays a key role in the differentiation and activation of Th17 cells to secrete IL<span class="nobreak">-17</span>, as well as Th22 cells to produce IL<span class="nobreak">-22</span>. IL<span class="nobreak">-17</span> and these other cytokines induce keratinocyte hyperproliferation leading to plaque formation and a feedforward inflammatory response, with changes in gene expression in keratinocytes, the production of antimicrobial peptides, and neutrophil recruitment driving further inflammation. While many cytokines and cell types contribute to the pathogenesis of PsO, the IL<span class="nobreak">-23</span>/IL<span class="nobreak">-17</span> axis plays an important role, as supported by the success of therapies targeting this axis.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While the successful treatment of PsO&#160;&#8212;&#160;for instance, with mAbs targeting IL<span class="nobreak">-23</span> or IL<span class="nobreak">-17</span> &#8212;&#160;can result in lesional skin returning to an apparently normal state, disease tends to recur at previously affected sites following cessation of therapy, suggesting a mechanism of &#8220;immunological memory&#8221; that predisposes individuals to recurrence in the same locations. Evidence suggests that pathogenic TRMs play a critical role in this memory. TRMs may arise from the Th17 cells and other cells that drove disease in the first place and remain in their resident tissue, in this case the epidermis and dermis, for long periods of time. Upon a disease trigger, these TRMs can actively produce proinflammatory cytokines, causing disease recurrence. IL<span class="nobreak">-23</span> appears to play an important role in maintaining and </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">218</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">potentiating TRMs, as indicated by the depletion of TRMs following treatment with an IL<span class="nobreak">-23</span> inhibitor but not an IL<span class="nobreak">-17</span> inhibitor, which may explain the longer remissions observed with IL<span class="nobreak">-23</span> inhibitors following withdrawal of therapy. This type of data has raised the prospect that efficient IL<span class="nobreak">-23</span> blockade could modify the disease biology of PsO, possibly leading to durable remissions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The scientific discoveries that refined our understanding of the immunopathogenesis of PsO have led to waves of therapeutic advances, ultimately leading to today&#8217;s standard of care. Before the 1980s, PsO was not even thought of as an immunologic disease, but rather a disease of keratinocyte dysfunction, leading to treatments such as phototherapy, methotrexate, and retinoids. The discovery in the 1980s that PsO results from immune dysfunction led to the use of broad immunosuppressants like cyclosporine. From 1990 to 2008, it was believed that Th1 cells, a subpopulation of T helper cells that produce pro<span class="nobreak">-inflammatory</span> cytokines such as IFN<span class="CharOverride-1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#947;</span> and TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span>, were the predominant mediators of the disease, which led to the use of biologics targeting TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> such as Enbrel (etanercept) and Humira (adalimumab). Finally, the revelation that PsO is driven principally by Th17 cells resulted in the development of the primary therapies used today, which target IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17</span>. This increasingly refined understanding of the disease has narrowed the standard of care from broad immunosuppressive agents (such as cyclosporine) to more specific immunomodulators (TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> inhibitors) to precise biologic therapies targeting the key cytokines involved in disease pathology (IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17</span> inhibitors), with each new therapeutic class raising the bar on both safety and efficacy.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Biologic therapies, especially mAbs, are now mainstays in the treatment of a wide variety of&#160;I&amp;I diseases, including PsO and PsA.&#160;Each biologic approved in PsO has raised the bar on standard of care, with therapies that have improved upon efficacy and/or reduced dosing frequency achieving the most commercial success, even when launching many&#160;years after other biologics. Enbrel was first approved for PsO in 2004 with a weekly maintenance dosing schedule. Four&#160;years later, Humira was approved for PsO with an every<span class="nobreak">-other-week</span> (Q2W) dosing schedule. Stelara (ustekinumab) was approved a year later with similar Phase&#160;3 data to Humira, but with a significantly improved dosing schedule of every twelve&#160;weeks (Q12W). Several drugs for PsO have been approved since 2009 that demonstrated higher efficacy in their pivotal studies compared to Stelara, but with more burdensome dosing schedules, including Tremfya (guselkumab), which has a dosing schedule of every eight&#160;weeks (Q8W), and Cosentyx (secukinumab) and Taltz (ixekizumab), which have dosing schedules of every four&#160;weeks (Q4W). While these therapies have all become generally successful products, the most commercially successful drug in the PsO market today is Skyrizi (risankizumab), which combines Stelara&#8217;s Q12W dosing schedule with improvements in efficacy, as evidenced by higher PASI 90 and PASI 100 rates in clinical trials. In addition, Bimzelx (bimekizumab), approved by the FDA in 2023, has shown evidence of efficacy that exceeds even Skyrizi, though with a less convenient Q8W dosing schedule. Although many biologics have entered the PsO market over the past two decades, new entrants have had significant commercial success when they have improved upon efficacy and/or dosing frequency, and room remains to improve in both areas to set a new standard for the treatment of PsO.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Biologics have raised the bar on the standard of care in PsO, but leave room for improvement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_003.jpg" style="width:500.48px;max-width:100%;"/></span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">219</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The biology driving PsO and PsA is well understood today, and the standard of care has progressed dramatically. Oruka believes that it is unlikely that a novel mechanism will emerge that is as safe and efficacious as targeting the IL<span class="nobreak">-23</span>/IL<span class="nobreak">-17</span> axis. Therefore, Oruka believes that innovation now should be focused on optimizing the product profile that can be offered to patients. While much effort is being directed toward daily oral formats to inhibit this axis, oral medicines have yet to match the efficacy of biologics. Oruka believes that a better biologic with a longer dosing interval and the potential for improved efficacy will present a more attractive product profile for most patients.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Overview of Psoriasis (PsO)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">PsO is a chronic autoimmune skin disorder that affects an estimated 125&#160;million people worldwide with steadily increasing prevalence, estimated to be around&#160;2&#160;&#8211;&#160;3% of the population currently, according to the World Psoriasis Day consortium. The most common form of PsO is plaque psoriasis. Patients with chronic plaque psoriasis have well<span class="nobreak">-demarcated</span>, erythematous plaques with overlying, coarse, silvery<span class="nobreak">-scaled</span> patches. These plaques can occur anywhere on the body, though are typically found on the scalp, extensor areas of the knees and elbows, and gluteal cleft. Involvement of the palms, soles, or nails, and intertriginous areas, including the genitals, can also occur and can be particularly difficult to treat. Around half of PsO patients have moderate disease, defined as having 3% to 10% of the body surface area (&#8220;BSA&#8221;) involved, or severe disease, defined as having more than 10% BSA involvement. The chronic inflammation in PsO is associated with multiple comorbidities, including PsA, obesity, metabolic syndrome, hypertension, diabetes, and atherosclerotic cardiovascular disease.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As discussed earlier, PsO is a complex immune<span class="nobreak">-mediated</span> disease driven primarily by Th17 cells and the cytokines IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17</span>. The interplay of environmental and behavioral risk factors and genetics is believed to trigger PsO.&#160;Multiple lines of evidence support a genetic component to the disease, including the observation that approximately 40% of patients with PsO and PsA have a family history of the disease and the identification of multiple susceptibility loci, many containing genes related to the regulation of the immune system, in genome<span class="nobreak">-wide</span> association studies.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Current PsO Treatments and Limitations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While patients with mild PsO typically rely on topical corticosteroids or oral therapies like Otezla (apremilast), these agents often do not provide an adequate response for patients with moderate<span class="nobreak">-to-severe</span> PsO.&#160;As a result, the American Academy of Dermatology<span class="nobreak">-National</span> Psoriasis Foundation recommends biologics as first<span class="nobreak">-line</span> therapy for moderate<span class="nobreak">-to-severe</span> PsO.&#160;Today, Skyrizi (risankizumab) is widely viewed as the leader in PsO biologic therapy. In Phase&#160;3 clinical trials, 43% and 58% of patients achieved PASI 100 at 16 and 52&#160;weeks, respectively, with SQ maintenance dosing every three&#160;months. Most recently, Bimzelx (bimekizumab) has shown evidence of efficacy that exceeds even Skyrizi, achieving a 64% PASI 100 rate at 16&#160;weeks in Phase&#160;3 trials. However, the increased efficacy comes with a less convenient Q8W dosing schedule and an increased risk of certain side effects, most notably oral candidiasis. While agents like Skyrizi and Bimzelx reflect the remarkable advancement in PsO treatment, there remains significant unmet need. Approximately half of moderate<span class="nobreak">-to-severe</span> PsO patients do not achieve full skin clarity, and while early signs are present, the promise of disease modifying therapy remains unrealized. Oruka believes that ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> could represent the next step in biologic innovation in PsO, with the potential for higher rates of complete skin clearance, more durable remissions, and markedly more convenient dosing regimens.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Overview of Psoriatic Arthritis (PsA)</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">PsA is a chronic inflammatory condition that affects both the skin and joints, and often coexists with PsO.&#160;Around a quarter to a third of patients with moderate<span class="nobreak">-to-severe</span> PsO also have PsA.&#160;Most individuals develop PsO before being diagnosed with PsA, with a median gap of seven to eight&#160;years between the diagnosis of skin and joint disease, though in up to 30% of patients with PsA, joint symptoms appear before or simultaneously with skin manifestations. Patients with PsA present with joint pain, stiffness, and swelling affecting the peripheral joints, axial skeleton, or both. Entheses, dactylitis, nail lesions, fatigue, and ocular inflammation all occur commonly. PsA can lead to irreversible joint damage, including bony fusion across a joint (ankylosis). The pathogenesis of PsA is likely to be closely related to the mechanisms that underlie PsO.&#160;Like PsO, the exact cause of PsA remains unknown, but environmental triggers, including infection and trauma, and genetic factors play a role.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">220</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Current PsA Treatments and Limitations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective treatment of PsA requires a coordinated approach to address the unique combination of disease manifestations each patient has, which can include peripheral and axial arthritis, enthesitis, dactylitis, and skin and nail involvement. Many patients with milder disease symptoms will start with nonsteroidal anti<span class="nobreak">-inflammatory</span> drugs (&#8220;NSAIDs&#8221;) and/or local treatments to address specific disease manifestations. However, those with more moderate or severe disease and/or multidomain involvement will typically receive a biologic therapy targeting TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> or IL<span class="nobreak">-17</span>, or less commonly an oral Janus kinase (&#8220;JAK&#8221;) inhibitor. Comorbid conditions can also influence treatment selection. For example, an IL<span class="nobreak">-17</span> inhibitor would be preferred for a patient with significant skin involvement, but not for patients with IBD or ocular symptoms, where a TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> inhibitor would be preferred. The most common endpoint used to measure the efficacy of TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> or IL<span class="nobreak">-17</span> inhibitors in PsA is ACR response, or the proportion of patients achieving a specified percent improvement in American College of Rheumatology (&#8220;ACR&#8221;) score, which measures peripheral joint disease. Approved TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> inhibitors, including Humira (adalimumab) and Cimzia (certolizumab), achieved a placebo<span class="nobreak">-adjusted</span> ACR50 response of around&#160;30&#160;&#8211;&#160;35% at 24&#160;weeks with Q2W dosing. Approved IL<span class="nobreak">-17</span> inhibitors, including Cosentyx (secukinumab) and Taltz (ixekizumab), achieved a slightly lower placebo<span class="nobreak">-adjusted</span> ACR50 response of around&#160;25&#160;&#8211;&#160;30% at 24&#160;weeks, but with more convenient Q4W dosing. Bimzelx (bimekizumab) has not yet received approval in the United&#160;States for PsA; however, in two Phase&#160;3 clinical trials, bimekizumab achieved a placebo<span class="nobreak">-adjusted</span> ACR50 response of 34% and 37% at 16&#160;weeks with Q4W dosing. A significant fraction of patients with PsA still do not achieve a satisfactory response with available therapies, and even the most convenient regimens require monthly SQ dosing.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Overview of additional opportunities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to PsO and PsA, inhibition of IL<span class="nobreak">-23</span> or IL<span class="nobreak">-17</span> has demonstrated efficacy in a number of additional&#160;I&amp;I indications, including HS and axSpA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">HS is a chronic inflammatory skin disease characterized by lesions that include deep<span class="nobreak">-seated</span> nodules and abscesses, draining tracts, and fibrotic scars that occur most commonly in intertriginous areas, such as the armpits and groin. Due to the associated pain, sensitive locations, drainage, odor, and scarring, this condition can have a particularly negative psychosocial impact on affected individuals. HS is believed to be underdiagnosed and could have a prevalence well above 1% worldwide. Treatment varies depending on severity and can include topical and systemic antibiotics, hormone therapy, immune modulators, and surgery. Humira (adalimumab) was the only FDA<span class="nobreak">-approved</span> medication for the treatment of moderate<span class="nobreak">-to-severe</span> HS from its approval in 2015 until the approval of Cosentyx (secukinumab) in October&#160;2023. However, now multiple other biologics, including Bimzelx (bimekizumab), are advancing through development and have demonstrated encouraging data in clinical trials, though a significant fraction of patients still do not achieve adequate responses.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">axSpA is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints that comprise the axial skeleton. The disease causes severe pain, stiffness, and fatigue, and can have additional clinical manifestations like uveitis, enthesitis, peripheral arthritis, and PsO.&#160;Patients with axSpA may develop further structural damage in their spine, which can lead to the fusion of vertebra (spinal ankylosis), which has a massive negative impact on mobility, physical function, and quality of life. The overall prevalence of axSpA is estimated to be around 1% in the United&#160;States. Treatment of axSpA starts with physical therapy and NSAIDs. If patients do not have an adequate response to NSAIDs, a TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span> inhibitor is typically used, followed by an IL<span class="nobreak">-17</span> inhibitor, such as Cosentyx (secukinumab), Taltz (ixekizumab), or Bimzelx (bimekizumab), or less frequently a JAK inhibitor. Patients often need to cycle through therapies over time due to inadequate responses or loss of response.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Solution: Half-Life Extension and Antibody Engineering Technologies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s antibody engineering campaigns are designed to optimize multiple attributes in parallel: binding affinity, potency in a variety of assays, developability, and consistently extended serum half<span class="nobreak">-life</span> in non<span class="nobreak">-human</span> primates (&#8220;NHPs&#8221;). Half<span class="nobreak">-life</span> extension is possible by modifying the pH<span class="nobreak">-dependent</span> binding affinity of the antibody Fc domain for FcRn. A primary mechanism of elimination of antibodies from the serum is through pinocytosis and degradation in the lysosomes of cells. Throughout this process, antibodies can be recycled back into the serum by binding to FcRn while they are in endosomes. The interior of the endosome is acidic, and therefore the efficiency of this recycling process depends on the ability of the antibody Fc domain to bind to FcRn at low pH.&#160;If this low pH binding is efficient enough, antibody recycling can be favored over degradation, potentially resulting in a much longer serum half<span class="nobreak">-life</span>.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">221</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Antibody engineers have discovered methods of modifying the Fc domain to optimize the efficiency of recycling via FcRn binding. Several engineering strategies have been identified over the past two decades, with the so<span class="nobreak">-called</span> &#8220;YTE&#8221; mutations (M252Y/S254T/T256E) and &#8220;LS&#8221; mutations (M428L/N434S) being the most frequently used. Importantly, while these strategies have been known for some time, it was only relatively recently that enough clinical precedent was established to provide confidence in how these mutations perform in humans. Two products incorporating YTE modification were approved in 2023 by the FDA, Beyfortus (nirsevimab) and Evusheld (tixagevimab and cilgavimab), and several more candidates are in clinical trials. Two products using LS mutations were approved in 2021 and 2022, Xevudy (sotrovima) and Ultomiris (ravulizumab), respectively, and several more candidates are in clinical trials. Based on clinical data in humans, antibodies with YTE mutations typically have a half<span class="nobreak">-life</span> that is two to four times longer than wildtype antibodies. In addition, preclinical data in NHPs can be used to predict the approximate half<span class="nobreak">-life</span> in humans, with the human half<span class="nobreak">-life</span> equaling around 3.1&#160;times the NHP half<span class="nobreak">-life</span>.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Clinical experience with YTE-modified mAbs predicts significant half-life extension over wildtype mAbs</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_004.jpg" style="width:380.16px;max-width:100%;"/></span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While this increasing body of clinical precedent serves to validate half<span class="nobreak">-life</span> extension, Oruka does not yet have clinical data showing that the introduction of these amino acid substitutions in its programs leads to a longer serum half<span class="nobreak">-life</span>. However, Oruka aims to establish this favorable pharmacokinetic profile early in the clinical development of its product candidates.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORKA-001</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Summary</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-001</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target the p19 subunit of IL<span class="nobreak">-23</span>. Based on preclinical data generated to date, Oruka believes ORKA<span class="nobreak">-001</span> has the potential to become the leading IL<span class="nobreak">-23</span> inhibitor and achieve an optimal product profile in PsO consisting of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;font-style:italic;font-weight:bold;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">One to two maintenance doses per year.&#160;&#160;&#160;&#160;</span>Standard<span class="nobreak">-of-care</span> therapies targeting IL<span class="nobreak">-23</span> require maintenance dosing every eight to twelve&#160;weeks. Oruka engineered the Fc portion of ORKA<span class="nobreak">-001</span> to include YTE mutations to increase the half<span class="nobreak">-life</span> of ORKA<span class="nobreak">-001</span> in circulation, which may enable dosing every six to twelve&#160;months&#160;&#8212;&#160;a dosing interval made feasible by half<span class="nobreak">-life</span> extension technology. In </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">222</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;text-indent:0pt;margin-top:8pt;">preclinical studies, serum levels from&#160;NHPs indicated an elimination half<span class="nobreak">-life</span> of 24&#160;days following SQ administration of a precursor antibody to ORKA<span class="nobreak">-001</span>. Based on published scientific literature on other antibodies incorporating YTE mutations and pharmacokinetic modeling, Oruka anticipates this half<span class="nobreak">-life</span> in NHPs to translate to a half<span class="nobreak">-life</span> in humans that could allow subcutaneous dosing every six to twelve&#160;months while maintaining high antibody exposures.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Higher PASI 100.&#160;&#160;&#160;&#160;</span>ORKA<span class="nobreak">-001</span> benefits from the robust validation of IL<span class="nobreak">-23</span> inhibition in PsO by multiple approved therapies, such as Skyrizi (risankizumab) and Tremfya (guselkumab), while leveraging insights from these therapies to improve upon their clinical profile. ORKA<span class="nobreak">-001</span> is designed to bind a similar epitope to the market<span class="nobreak">-leading</span> anti<span class="nobreak">-IL-23</span> antibody, Skyrizi, with similar or greater affinity and could achieve much higher exposures in patients due to half<span class="nobreak">-life</span> extension. Skyrizi and Tremfya both have a robust exposure<span class="nobreak">-response</span> relationship, with higher drug exposures leading to higher response rates. Published data indicates that these therapies have not saturated this exposure<span class="nobreak">-response</span> relationship, and ORKA<span class="nobreak">-001</span> could lead to higher response rates, including higher rates of complete skin clearance, or PASI 100, through increased exposure, even while having more convenient dosing with as few as one or two maintenance doses per year.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Validated IL</span><span class="nobreak"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">-23p19</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;"> safety profile.&#160;&#160;&#160;&#160;</span>Existing commercially approved antibodies targeting IL<span class="nobreak">-23</span> provide a robust precedent for the safety of IL<span class="nobreak">-23</span> inhibition. Across thousands of patients dosed in dermatology and IBD indications, no correlations have been observed at the patient level between exposure and safety. While Oruka is not pursuing IBD, the approved Skyrizi regimen for Crohn&#8217;s disease supports the safety of high peak exposures. Peak Skyrizi exposures during the&#160;IV induction phase in Crohn&#8217;s disease are over 2.5 times higher than the peak ORKA<span class="nobreak">-001</span> exposures at dose levels Oruka currently plans to evaluate in PsO.&#160;In addition, an exposure<span class="nobreak">-response</span> analysis for Skyrizi in ulcerative colitis showed no relationship between exposures and evaluated safety endpoints in the 12<span class="nobreak">-week</span> induction or 52<span class="nobreak">-week</span> maintenance periods. In this assessment, the top quartile of average exposures spanned 176 to 342 &#181;g/mL in the induction period and 25 to 62 &#181;g/mL in the maintenance period, which are approximately 7 and 5 times higher, respectively, than the highest anticipated exposures with ORKA<span class="nobreak">-001</span> in the same periods.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Potential to offer longer term remission to some patients.&#160;&#160;&#160;&#160;</span>Emerging evidence suggests that IL<span class="nobreak">-23</span> blockade can modify the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;Dr.&#160;Andrew Blauvelt, chair of Oruka&#8217;s Scientific Advisory Board, pioneered some of this work by using two- and four<span class="nobreak">-times</span> the approved dose levels of risankizumab to achieve best<span class="nobreak">-in-indication</span> response rates. This study, called KNOCKOUT, showed a robust depletion of TRMs following high dose IL<span class="nobreak">-23</span> inhibition, which could lead to longer<span class="nobreak">-lasting</span> remissions in some patients. Additional evidence from a study of guselkumab, called GUIDE, showed that intervention early in the disease course can lead to longer treatment<span class="nobreak">-free</span> remissions. In addition, retrospective claims data suggests that treatment with an IL<span class="nobreak">-23</span> inhibitor could help prevent progression to PsA, though this finding has yet to be confirmed by a prospective clinical trial. Given the high antibody exposures expected with ORKA<span class="nobreak">-001</span>, Oruka believes that ORKA<span class="nobreak">-001</span> could lead to durable remissions for some patients, especially those with short disease duration. Oruka plans to pursue patient<span class="nobreak">-specific</span> dosing intervals to provide each patient the greatest possible freedom from their disease.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that this target profile for ORKA<span class="nobreak">-001</span> could offer improved freedom from disease to many patients affected by PsO and represent a step forward in the standard of care.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preclinical Data</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka evaluated ORKA<span class="nobreak">-001</span> in numerous preclinical studies for several key features:</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Potency that matches or exceeds Skyrizi (risankizumab) in vitro</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has tested the potency of ORKA<span class="nobreak">-001</span> <span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span>&#160;in multiple assays, including assays evaluating the inhibition of IL<span class="nobreak">-17</span> release from human peripheral mononuclear blood cells, in comparison to risankizumab generated recombinantly based on amino acid sequences from patent filings. Based on the results of these </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">223</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">experiments, Oruka believes ORKA<span class="nobreak">-001</span> has the potential for greater potency than risankizumab. Data from the existing commercially approved therapies targeting IL<span class="nobreak">-23</span> indicate that the potency of IL<span class="nobreak">-23</span> inhibition, in this case, measured by affinity, correlates tightly with efficacy.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;text-align:center;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The affinity of approved mAbs targeting IL-23 correlates tightly with efficacy</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_005.jpg" style="width:272.64px;max-width:100%;"/></span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Significant half-life extension in NHPs that could enable a maintenance dosing interval of once or twice a year in humans</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka assessed the impact of incorporating YTE modifications into a precursor antibody to ORKA<span class="nobreak">-001</span> in NHPs in comparison to risankizumab generated recombinantly based on amino acid sequences from patent filings. The mAb with YTE modifications had a significantly longer half<span class="nobreak">-life</span>, reaching approximately 24&#160;days with SQ administration. Based on clinical experience with YTE<span class="nobreak">-modified</span> mAbs and pharmacokinetic modeling, Oruka believes that this half<span class="nobreak">-life</span> extension could enable dosing once or twice per year, as shown in the figure below.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;text-align:center;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">The incorporation of YTE mutations significantly extends half-life in NHPs, which could enable once or twice yearly dosing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_006.jpg" style="width:590.08px;max-width:100%;"/></span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to enabling less frequent dosing, an extended half<span class="nobreak">-life</span> would increase the exposure of ORKA<span class="nobreak">-001</span>, which has the potential to increase efficacy. Based on published literature, Skyrizi (risankizumab) demonstrates a clear relationship between antibody exposure and efficacy, with higher average serum antibody concentration correlating with higher PASI 90 and PASI 100 rates short<span class="nobreak">-term</span> (at 16&#160;weeks) and long<span class="nobreak">-term</span> (at 52&#160;weeks), as shown for PASI 100 in the figure below. In addition, the KNOCKOUT study, which evaluated two- and four<span class="nobreak">-times</span> higher doses of Skyrizi than the approved regimen, yielded some of the highest PASI 100 rates observed to date, reaching 67% at 16&#160;weeks. Based on Oruka&#8217;s pharmacokinetic modeling, ORKA<span class="nobreak">-001</span> could achieve four<span class="nobreak">-fold</span> higher average exposures than the approved Skyrizi regimen over the first 16&#160;weeks and over two<span class="nobreak">-fold</span> higher average exposures at steady<span class="nobreak">-state</span>, exceeding even the exposures in KNOCKOUT.&#160;Based on the exposure<span class="nobreak">-response</span> relationship observed with other IL<span class="nobreak">-23</span> inhibiting antibodies, Oruka believes that these increased exposures could result in higher efficacy.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">224</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORKA-001 is projected to extend the exposure-response relationship established by studies of Skyrizi</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="timage_007.jpg" style="width:536.32px;max-width:100%;"/></span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Safety in vitro and in vivo</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has evaluated ORKA<span class="nobreak">-001</span> in several&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span>&#160;and&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">in vivo</span>&#160;preclinical studies to assess safety. In addition, Oruka has initiated a robust nonclinical program to characterize the toxicology, toxicokinetics, and anti<span class="nobreak">-drug</span> antibody profile of ORKA<span class="nobreak">-001</span> in NHPs, including a single<span class="nobreak">-dose</span> non<span class="nobreak">-GLP</span> dose<span class="nobreak">-range</span> finding study and one<span class="nobreak">-month</span> and six<span class="nobreak">-month</span> GLP toxicology studies. Collectively, this nonclinical program is designed to support the initiation of clinical trials. In addition, ORKA<span class="nobreak">-001</span> benefits from the favorable safety precedent for IL<span class="nobreak">-23</span> inhibition provided by the existing commercially approved IL<span class="nobreak">-23-targeted</span> antibodies across several indications.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Characteristics that support ease of manufacturing and potentially enable high-concentration formulations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Finally, Oruka has assessed a variety of attributes essential for manufacturability and high<span class="nobreak">-concentration</span> formulation, including viscosity, solubility, and stability, among others. ORKA<span class="nobreak">-001</span> shows evidence of desirable properties across these characteristics, which Oruka believes will enhance its ability to manufacture ORKA<span class="nobreak">-001</span> successfully and consistently and to deliver high doses of ORKA<span class="nobreak">-001</span> subcutaneously using convenient, low<span class="nobreak">-volume</span> presentations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Clinical Development Plans</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on these potential advantages and preclinical data, Oruka is advancing ORKA<span class="nobreak">-001</span> towards a Phase&#160;1 clinical trial in the first half of 2025. This trial will encompass a Phase&#160;1a single<span class="nobreak">-ascending</span> dose portion in healthy volunteers, followed by a Phase&#160;1b, multiple<span class="nobreak">-dose</span> portion in patients with moderate<span class="nobreak">-to-severe</span> PsO.&#160;Following completion of Phase&#160;1b, patients will become eligible for an open<span class="nobreak">-label</span> extension study. Initial data from the Phase&#160;1a cohort has the potential to provide key validation of both early safety and pharmacokinetics, including half<span class="nobreak">-life</span>, to support extended dosing intervals. Initial data from the Phase&#160;1b cohort has the potential to provide preliminary efficacy data in patients with PsO.&#160;Pending the results from the Phase&#160;1 clinical trial, Oruka plans to initiate a Phase&#160;2 clinical trial in PsO in 2026. Several aspects of PsO facilitate clinical development, including well<span class="nobreak">-established</span>, reproducible endpoints based on PASI scores, low placebo rates, particularly with PASI 90 and PASI 100, a rapid efficacy readout at 16&#160;weeks, and potentially rapid enrollment due to the large patient population. Oruka has not yet submitted an IND with the FDA for its Phase 1 clinical trials for ORKA<span class="nobreak">-001</span>.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORKA-002</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Summary</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-002</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target IL<span class="nobreak">-17A</span>/F.&#160;Dual inhibition of both IL<span class="nobreak">-17A</span> and IL<span class="nobreak">-17F</span> has shown superior efficacy compared to IL<span class="nobreak">-17A</span> inhibition alone in PsO and other indications, as shown by the performance of Bimzelx (bimekizumab) compared to Cosentyx (secukinumab) and Taltz (ixekizumab) in Phase&#160;3 trials. These therapies all utilize Q8W dosing in PsO and Q4W dosing in PsA.&#160;By binding </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">225</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">IL<span class="nobreak">-17A</span>/F at similar epitopes and affinity ranges as Bimzelx while incorporating half<span class="nobreak">-life</span> extension technology to potentially enable dosing two to three times a year in PsO and PsA, Oruka believes that ORKA<span class="nobreak">-002</span> could become the leading therapy in the IL<span class="nobreak">-17</span> class.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Preclinical Data</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preclinical program Oruka is conducting to inform development candidate selection and support clinical trial initiation for ORKA<span class="nobreak">-002</span> mirrors that for ORKA<span class="nobreak">-001</span> and spans potency, pharmacokinetics, safety, and manufacturing characteristics. Based on the results of these experiments, Oruka believes ORKA<span class="nobreak">-002</span> has the potential for comparable potency to bimekizumab, but with a significantly longer half<span class="nobreak">-life</span>, which Oruka believes could support dosing two or three times per year based on extrapolation from clinical precedent and pharmacokinetic modeling.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Clinical Development Plans</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka plans to initiate Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025 following ORKA<span class="nobreak">-001</span>. As with ORKA<span class="nobreak">-001</span>, initial data on ORKA<span class="nobreak">-002</span> in healthy volunteers has the potential to provide key validation of both early safety and pharmacokinetics to support extended dosing intervals. Though clinical development of ORKA<span class="nobreak">-002</span> will initially focus on one lead indication, Oruka plans to evaluate ORKA<span class="nobreak">-002</span> in a range of indications over time. Oruka sees ORKA<span class="nobreak">-002</span> as highly complementary to ORKA<span class="nobreak">-001</span>, with the potential to provide an optimal therapy for the approximately one<span class="nobreak">-quarter</span> to one<span class="nobreak">-third</span> of moderate<span class="nobreak">-to-severe</span> PsO patients who have PsA, as well as for PsO patients with highly resistant skin symptoms that do not respond adequately to an IL<span class="nobreak">-23</span> inhibitor. Furthermore, ORKA<span class="nobreak">-002</span> could address indications beyond PsO, including PsA with limited skin involvement, HS, axSpA, and additional&#160;I&amp;I diseases. Oruka has not yet submitted an IND with the FDA for its Phase 1 clinical trials for ORKA<span class="nobreak">-002</span>.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Additional Pipeline Programs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has a third mAb program, ORKA<span class="nobreak">-003</span>, that targets an undisclosed pathway. A core tenet of Oruka&#8217;s strategy is to remain highly focused on&#160;I&amp;I diseases, and specifically on inflammatory dermatology conditions. ORKA<span class="nobreak">-003</span> provides the potential for indication expansion beyond PsO as well as combination opportunities with Oruka&#8217;s more advanced programs. In the future, Oruka may add additional programs to its portfolio beyond ORKA<span class="nobreak">-001</span>, ORKA<span class="nobreak">-002</span>, and ORKA<span class="nobreak">-003</span> that fit its strategic focus.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Intellectual Property</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka strives to protect the proprietary programs and technologies that it believes are important to its business, including seeking and maintaining patent protection intended to cover the composition of matter of its programs, their methods of use and manufacture, related technologies, diagnostics, and other inventions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Paragon has filed provisional patent applications, and intends to file one or more additional provisional patent applications directed to antibodies that target IL<span class="nobreak">-23</span>, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA<span class="nobreak">-001</span>. In addition, Paragon has filed provisional patent applications, and intends to file one or more additional provisional patent applications directed to antibodies that target IL<span class="nobreak">-17</span>, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA<span class="nobreak">-002</span>. Oruka has not yet exercised its option to acquire exclusive rights to any IL<span class="nobreak">-23</span> or IL<span class="nobreak">-17</span> patent applications, but retains the right to do so. If the provisional patent applications are pursued non<span class="nobreak">-provisionally</span> and mature into one or more issued patents covering ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span>, Oruka would expect those patents to expire in 2045, absent any applicable patent term adjustments or extensions.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Commercial</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Should any of its product candidates be approved for commercialization, Oruka intends to develop a plan to commercialize them in the United&#160;States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable Oruka to realize the full commercial value of its programs. Given its stage of development, Oruka has not yet established a commercial organization or distribution capabilities. Oruka currently holds exclusive Options (as defined below) to acquire worldwide development and commercialization rights to all of its programs.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">226</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Manufacturing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka does not currently own or operate facilities for product manufacturing, testing, storage, and distribution. Oruka has contracted and expect to continue to contract with third parties for the manufacture and distribution of its product candidates. Because Oruka relies on contract manufacturers, it employs personnel with extensive technical, manufacturing, analytical and quality experience. Oruka&#8217;s team has deep knowledge and understanding of the regulations that govern manufacturing, documentation, quality assurance, and quality control of drug supply that are required to support Oruka&#8217;s regulatory filings.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Competition</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The biotechnology and biopharmaceutical industries are characterized by continuing technological advancement and significant competition. While Oruka believes that its programs, technology, development experience and scientific knowledge provide it with competitive advantages, Oruka faces competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions, among others. Any product candidates that Oruka successfully develops and commercialize will compete with existing therapies and new therapies that may become available in the future. Many of the companies with which Oruka is currently competing or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than Oruka does. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of Oruka&#8217;s competitors. Smaller or early<span class="nobreak">-stage</span> companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with Oruka in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, patient enrollment for clinical trials as well as in acquiring technologies complementary to, or necessary for, Oruka&#8217;s programs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Key competitive factors affecting the success of all of Oruka&#8217;s product candidates that it develops, if approved, are likely to be efficacy, safety, convenience, presentation, price, the level of generic competition, and the availability of reimbursement from government and other third<span class="nobreak">-party</span> payors. Oruka&#8217;s competitors may also obtain FDA or other regulatory approval for their products more rapidly than Oruka may obtain approval for its products, which could result in Oruka&#8217;s competitors establishing a strong market position before Oruka is able to enter the market.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Specifically, there are several companies developing or marketing treatments that may be approved for the same indications and/or diseases as Oruka&#8217;s two most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>, including major pharmaceutical companies. Oruka does not yet have clinical data for any of its programs and there can be no assurance that its programs will have similar or comparable results.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There are several approved biologic therapies for the treatment of moderate<span class="nobreak">-to-severe</span> PsO.&#160;These include mAbs targeting IL<span class="nobreak">-23</span>, such as Skyrizi (risankizumab) from AbbVie, Tremfya (guselkumab) from Janssen, and Ilumya (tildrakizumab) from Sun Pharma, also marketed as Ilumetri by Almirall in Europe, which all target the p19 subunit, and Stelara (ustekinumab) from Janssen, which targets the p40 subunit; mAbs targeting IL<span class="nobreak">-17</span>, such as Bimzelx (bimekizumab) from UCB, which targets IL<span class="nobreak">-17A</span>/F, Cosentyx (secukinumab) from Novartis and Taltz (ixekizumab) from Eli Lilly, which both target IL<span class="nobreak">-17A</span>, and Siliq (brodalumab) from Ortho Dermatologics, also marketed as Kyntheum by LEO Pharma in Europe, which targets IL<span class="nobreak">-17</span> receptor A; and biologics targeting TNF<span class="nobreak">-</span><span class="nobreak" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">&#945;</span>, such as Humira (adalimumab) from AbbVie, Enbrel (etanercept) from Amgen, and Remicade (infliximab) from Janssen, and various biosimilar versions of each. In addition, there are several approved oral medicines in these indications, including the phosphodiesterase<span class="nobreak">-4</span> (PDE4) inhibitor Otezla (apremilast) from Amgen and the tyrosine kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) from Bristol<span class="nobreak">-Myers</span> Squibb. Many of these therapies also are approved or in development for PsA, HS, axSpA, and other&#160;I&amp;I indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, Oruka is aware of several product candidates in clinical development for moderate<span class="nobreak">-to-severe</span> PsO, along with PsA, HS, axSpA, and other indications. These include the biologics picankibart from Innovent Biologics targeting IL<span class="nobreak">-23p19</span>, sonelokimab from MoonLake Immunotherapeutics targeting IL<span class="nobreak">-17A</span>/F, and izokibep from ACELYRIN targeting IL<span class="nobreak">-17A</span>.&#160;Also, there are several oral agents in development, including JNJ<span class="nobreak">-2113</span> from Janssen targeting the IL<span class="nobreak">-23</span> receptor, DC<span class="nobreak">-806</span> and DC<span class="nobreak">-853</span> from Eli Lilly targeting IL<span class="nobreak">-17A</span>, and TAK<span class="nobreak">-279</span> from Takeda and ESK<span class="nobreak">-001</span> from Alumis, both targeting TYK2.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">227</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">License Agreements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Paragon Therapeutics</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, Oruka entered into the Paragon Option Agreements. Under the terms of each agreement, Paragon identifies, evaluates, and develops antibodies directed against certain mutually agreed therapeutic targets of interest to us. Each Paragon Option Agreement initially included one of two selected targets: IL<span class="nobreak">-23</span> and IL<span class="nobreak">-17A</span>/F.&#160;Under the Paragon Option Agreements, Oruka has the exclusive option to, on a research program<span class="nobreak">-by-research</span> program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the selected target(s)&#160;(each, an &#8220;Option&#8221;). In the case of IL<span class="nobreak">-23</span>, Oruka&#8217;s Option excludes the therapeutic area of IBD.&#160;From time to time, Oruka can choose to add additional targets to the collaboration by mutual agreement with Paragon and Paruka. As of the date hereof, Oruka has not exercised any Options.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the terms of the Paragon Option Agreements, Oruka initiated certain research programs with Paragon that generally focus on a particular target (each, a &#8220;Research Program&#8221;). Each Research Program is aimed at discovering, generating, identifying, and/or characterizing antibodies directed to the respective target. For each Research Program, Oruka established or may establish in the future a research plan with Paragon that sets forth the activities that will be conducted, and the associated research budget (each, a &#8220;Research Plan&#8221;). Oruka&#8217;s exclusive option with respect to each Research Program is exercisable at Oruka&#8217;s sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following (i)&#160;with respect to any Research Program other than ORKA<span class="nobreak">-001</span>, the delivery of the data package from Paragon related to the results of the Research Plan activities or (ii)&#160;with respect to ORKA<span class="nobreak">-001</span>, the completion of the IL<span class="nobreak">-23</span> antibody selection process described in the agreement (the &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless terminated earlier, each Paragon Option Agreement shall continue in force on a Research Program<span class="nobreak">-by-Research</span> Program basis until the earlier of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by us; (ii)&#160;the expiration of the 30<span class="nobreak">-day</span> period after Oruka exercises its Option with respect to a Research Program, subject to mutually agreed extension, during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii)&#160;the expiration of the applicable Research Term (as defined under each Paragon Option Agreement) (the &#8220;Term&#8221;). Oruka may terminate any Paragon Option Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon, provided that Oruka must pay certain unpaid fees due to Paragon upon such termination, as well as any non<span class="nobreak">-cancellable</span> obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate any Paragon Option Agreement or a Research Program immediately upon written notice to Oruka if, as a result of any action or failure to act by Oruka or its affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of&#160;months. Each party has the right to terminate the Paragon Option Agreements or any Research Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30<span class="nobreak">-day</span> period and (ii)&#160;the other party&#8217;s bankruptcy.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon signing of the Paragon Option Agreement for ORKA<span class="nobreak">-001</span>, a one<span class="nobreak">-time</span>, non<span class="nobreak">-refundable</span> research initiation fee of $0.8&#160;million became payable by Oruka to Paragon. This amount was recognized by Oruka as a research and development expense during the period ended March&#160;31, 2024, and paid to Paragon in April&#160;2024. Oruka is also responsible for 50% of the development costs incurred by Paragon prior to March&#160;31, 2024, provided that Oruka receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. Oruka&#8217;s share of development costs incurred by Paragon prior to March&#160;31, 2024 is $5.9&#160;million. As of the date of filing of this proxy statement/prospectus, Oruka has not received rights to a selected IL<span class="nobreak">-23</span> antibody and has not paid or accrued the $5.9&#160;million of development costs incurred by Paragon prior to March&#160;31, 2024. Oruka will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred by Paragon from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Paragon Option Agreement for ORKA<span class="nobreak">-002</span>, Oruka was required to reimburse Paragon $3.3&#160;million for development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon through December&#160;31, 2023 and certain other development costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024 (the &#8220;pre<span class="nobreak">-effective</span> date development costs&#8221;). This amount was recognized as a research and development expense during the period from </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">228</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">February 6 (inception) to March<span class="nobreak"> </span>31, 2024, and accounts payable as of March<span class="nobreak"> </span>31, 2024. Oruka paid $3.3&#160;million to Paragon in April&#160;2024. Oruka is also responsible for the development costs incurred by Paragon from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period ended March&#160;31, 2024. Oruka will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> research plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>. Oruka will be responsible for ORKA<span class="nobreak">-002</span> development costs incurred from and after March<span class="nobreak"> </span>31, 2024, through the completion of the IL<span class="nobreak">-17</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the filing date of this proxy statement/prospectus, Oruka has not exercised its options with respect to ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span>. For each of these agreements, if Oruka exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million upon the achievement of certain clinical development milestones, up to $10.0&#160;million upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, as part of the Paragon Option Agreements, on each of December&#160;31, 2024 and December&#160;31, 2025, Oruka will grant Paruka warrants to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully<span class="nobreak">-diluted</span> basis, with an exercise price equal to the fair market value of the underlying shares on the grant date.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Government Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post<span class="nobreak">-approval</span> monitoring and post<span class="nobreak">-approval</span> reporting of biologics such as those Oruka is developing. Oruka, along with its third<span class="nobreak">-party</span> contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which Oruka wishes to conduct studies or seek approval or licensure of its product candidates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">United&#160;States Biologics Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the United&#160;States, biological products are subject to regulation under the FDCA, the Public Health Service Act (&#8220;PHSA&#8221;) and other federal, state, local, and foreign statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S.&#160;requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative action and judicial sanctions. The process required by the FDA before biologic product candidates may be marketed in the United&#160;States generally involves the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices (&#8220;GLP&#8221;) regulation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>approval by an independent IRB, or ethics committee at each clinical site before the trial is commenced;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>manufacture of the proposed biologic candidate in accordance with current Good Manufacturing Practices (&#8220;cGMPs&#8221;);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>performance of adequate and well<span class="nobreak">-controlled</span> human clinical trials in accordance with GCP requirements to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>preparation of and submission to the FDA of a BLA, after completion of all pivotal clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>satisfactory completion of an FDA Advisory Committee review, if applicable;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>a determination by the FDA within 60&#160;days of its receipt of a BLA to file the application for review;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">229</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>satisfactory completion of an FDA pre<span class="nobreak">-approval</span> inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>FDA review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United&#160;States.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Preclinical and Clinical Development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to beginning any clinical trial with a product candidate, in the United&#160;States, Oruka must submit an IND to the FDA.&#160;An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes results of animal and <span class="Italic" style="font-style:italic;font-weight:normal;">in vitro</span> studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30<span class="nobreak">-day</span> period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the IND submission process, supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee (&#8220;IBC&#8221;), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment and such review may result in some delay before initiation of a clinical trial.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Phase&#160;1.&#160;&#160;&#160;&#160;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">230</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Phase&#160;2.&#160;&#160;&#160;&#160;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase&#160;2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase&#160;3 clinical trials.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Phase&#160;3.&#160;&#160;&#160;&#160;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so<span class="nobreak">-called</span> Phase&#160;4 studies may be made a condition to approval of the BLA.&#160;Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND.&#160;When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval or licensure, including that the study was conducted in accordance with GCP, including review and approval by an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">BLA Submission and Review</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company<span class="nobreak">-sponsored</span> clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, under the Pediatric Research Equity Act (&#8220;PREA&#8221;), a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a biological product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial pediatric study plan within sixty&#160;days after an end<span class="nobreak">-of-Phase</span>&#160;2 meeting or as may be agreed between the sponsor and FDA.&#160;Unless otherwise required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Within 60&#160;days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once a BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within ten&#160;months after the filing date, or, if the application qualifies </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">231</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">for priority review, six&#160;months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post<span class="nobreak">-marketing</span> testing and surveillance to monitor safety or efficacy of a product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post<span class="nobreak">-marketing</span> requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase&#160;4 post<span class="nobreak">-market</span> studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post<span class="nobreak">-marketing</span> studies.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Expedited Development and Review Programs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life<span class="nobreak">-threatening</span> disease or condition and data demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">232</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A product intended to treat a serious or life<span class="nobreak">-threatening</span> disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase&#160;1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any marketing application for a biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if there is evidence it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition. For original BLAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six&#160;months of the 60<span class="nobreak">-day</span> filing date (as compared to ten&#160;months under standard review).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, products studied for their safety and effectiveness in treating serious or life<span class="nobreak">-threatening</span> diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well<span class="nobreak">-controlled</span> post<span class="nobreak">-marketing</span> clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Under the Food and Drug Omnibus Reform Act&#160;of&#160;2022 the FDA may require, as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post<span class="nobreak">-marketing</span> studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre<span class="nobreak">-approval</span> of promotional materials, which could adversely impact the timing of the commercial launch of the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fast track designation, breakthrough therapy designation and priority review do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Post-Approval Requirements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any products manufactured or distributed by Oruka pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record<span class="nobreak">-keeping</span>, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA.&#160;Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon Oruka and its third<span class="nobreak">-party</span> manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon Oruka and any third<span class="nobreak">-party</span> manufacturers that Oruka may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">233</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post<span class="nobreak">-market</span> studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>fines, warning letters or holds on post<span class="nobreak">-approval</span> clinical studies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>product seizure or detention, or refusal of the FDA to permit the import or export of products;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>mandated modification of promotional materials and labeling and the issuance of corrective information;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>injunctions or the imposition of civil or criminal penalties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off<span class="nobreak">-label</span> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by Oruka and approved by the FDA.&#160;Such off<span class="nobreak">-label</span> uses are common across medical specialties. Physicians may believe that such off<span class="nobreak">-label</span> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off<span class="nobreak">-label</span> use of their products.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Biosimilars and Reference Product Exclusivity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ACA includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are highly similar, or &#8220;biosimilar,&#8221; to or interchangeable with an FDA<span class="nobreak">-approved</span> reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable with an FDA<span class="nobreak">-approved</span> reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.&#160;In September&#160;2021, the FDA issued two guidance documents intended to inform prospective applicants and facilitate the development of proposed biosimilars and interchangeable biosimilars, as well as to describe the FDA&#8217;s interpretation of certain statutory requirements added by the BPCIA.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">234</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four&#160;years following the date that the reference product was first licensed by the FDA.&#160;In addition, the approval of a biosimilar product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first licensed. During this 12<span class="nobreak">-year</span> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well<span class="nobreak">-controlled</span> clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A reference biologic is granted twelve&#160;years of exclusivity from the time of first licensure of the reference product. The first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics submitted under the abbreviated approval pathway for the lesser of (i)&#160;one year after the first commercial marketing, (ii)&#160;18&#160;months after approval if there is no legal challenge, (iii)&#160;18&#160;months after the resolution in the applicant&#8217;s favor of a lawsuit challenging the biologics&#8217; patents if an application has been submitted, or (iv)&#160;42&#160;months after the application has been approved if a lawsuit is ongoing within the 42<span class="nobreak">-month</span> period.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A biological product can also obtain pediatric market exclusivity in the United&#160;States. Pediatric exclusivity, if granted, adds six&#160;months to existing exclusivity periods and patent terms. This six<span class="nobreak">-month</span> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA<span class="nobreak">-issued</span> &#8220;Written Request&#8221; for such a study. The BPCIA is complex and continues to be interpreted and implemented by the FDA.&#160;In July&#160;2018, the FDA announced an action plan to encourage the development and efficient review of biosimilars, including the establishment of a new office within the agency that will focus on therapeutic biologics and biosimilars. On December&#160;20, 2020, Congress amended the PHSA as part of the COVID<span class="nobreak">-19</span> relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed in labeling have been previously approved for the reference product, which used to be a requirement of the application. In addition, government proposals have sought to reduce the 12<span class="nobreak">-year</span> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As discussed below, the Inflation Reduction Act&#160;of&#160;2022 (&#8220;IRA&#8221;) is a significant new law that intends to foster generic and biosimilar competition and to lower drug and biologic costs.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Other Healthcare Laws and Compliance Requirements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti<span class="nobreak">-Kickback</span> Statute (&#8220;AKS&#8221;); the federal False Claims Act (&#8220;FCA&#8221;); the Health Insurance Portability and Accountability Act&#160;of&#160;1996 (&#8220;HIPAA&#8221;) and similar foreign, federal and state fraud, abuse and transparency laws.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals, even if there are other legitimate purposes for the remuneration. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Oruka&#8217;s practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">235</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">se illegal under the AKS.&#160;Instead, the legality of the arrangement will be evaluated on a case<span class="nobreak">-by-case</span> basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Civil and criminal false claims laws, including the FCA, and civil monetary penalty laws, which can be enforced through civil whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment of federal government funds, including in federal healthcare programs, that are false or fraudulent. Pharmaceutical and other healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that &#8220;caused&#8221; the submission of false claims to federal healthcare programs. Under the AKS, for example, a claim resulting from a violation of the AKS is deemed to be a false or fraudulent claim for purposes of the FCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">HIPAA created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third<span class="nobreak">-party</span> payors, and making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order to have committed a violation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The U.S.&#160;federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicaid&#160;&amp; Medicare Services (&#8220;CMS&#8221;) information related to payments or other transfers of value to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse<span class="nobreak">-midwives</span>, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Beginning on January&#160;1, 2023, California Assembly Bill 1278 requires California physicians and surgeons to notify patients of the Open Payments database established under the federal Physician Payments Sunshine Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We are also subject to additional similar U.S.&#160;state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If Oruka&#8217;s operations are found to be in violation of any of such laws or any other governmental regulations that apply, Oruka may be subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government<span class="nobreak">-funded</span> healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non<span class="nobreak">-compliance</span>, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of Oruka&#8217;s operations.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Data Privacy and Security</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Numerous state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information, including health<span class="nobreak">-related</span> information. In the United&#160;States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the collection, use, disclosure, and protection of health<span class="nobreak">-related</span> and other personal information could apply to Oruka&#8217;s operations or the operations of Oruka&#8217;s partners. For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;), and their respective implementing regulations imposes data privacy, security, and breach notification obligations on certain health care providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates and their covered subcontractors that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually identifiable protected health information (&#8220;PHI&#8221;) for or on behalf of such covered entities. These requirements imposed by HIPAA and the HITECH Act on covered entities and business associates include entering into agreements that require business associates protect PHI provided by the covered entity against improper use or disclosure, among other things; following certain standards for the privacy of PHI, which limit the disclosure of a patient&#8217;s past, present, or future physical or mental health or condition or information about a </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">236</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">patient&#8217;s receipt of health care if the information identifies, or could reasonably be used to identify, the individual; ensuring the confidentiality, integrity, and availability of all PHI created, received, maintained, or transmitted in electronic form, to identify and protect against reasonably anticipated threats or impermissible uses or disclosures to the security and integrity of such PHI; and reporting of breaches of PHI to individuals and regulators. Entities that are found to be in violation of HIPAA may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with the U.S.&#160;Department of Health and Human Services (&#8220;HHS&#8221;) to settle allegations of HIPAA non<span class="nobreak">-compliance</span>. A covered entity or business associate is also liable for civil money penalties for a violation that is based on an act or omission of any of its agents, which may include a downstream business associate, as determined according to the federal common law of agency. HITECH also increased the civil and criminal penalties applicable to covered entities and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. To the extent that Oruka submit electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established under HIPAA and HITECH, payments to Oruka may be delayed or denied.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Even when HIPAA does not apply, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&#160;5(a)&#160;of the Federal Trade Commission Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, certain state laws, such as the California Consumer Privacy Act&#160;of&#160;2018 (&#8220;CCPA&#8221;), as amended by the California Privacy Rights Act&#160;of&#160;2020 (&#8220;CPRA&#8221;), govern the privacy and security of personal information, including health<span class="nobreak">-related</span> information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. The CCPA/CPRA applies to personal data of consumers, business representatives, and employees, and imposes obligations on certain businesses that do business in California, including to provide specific disclosures in privacy notices, rights to California residents in relation to their personal information. Health information falls under the CCPA/CPRA&#8217;s definition of personal information where it identifies, relates to, describes, or is reasonably capable of being associated with or could reasonably be linked with a particular consumer or household&#160;&#8212;&#160;unless it is subject to HIPAA&#160;&#8212;&#160;and is included under a new category of personal information, &#8220;sensitive personal information,&#8221; which is offered greater protection. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data processing. Additionally, Oruka&#8217;s use of artificial intelligence and machine learning may be subject to laws and evolving regulations regarding the use of artificial intelligence/machine learning, controlling for data bias, and antidiscrimination.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the CPRA expands the CCPA&#8217;s requirements, including by adding a new right for individuals to correct their personal information and establishing a new regulatory agency to implement and enforce the law. Other states, such as Virginia, Colorado, Connecticut and Utah, have also passed comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal and local levels. While the laws in these states, like the CCPA, also exempt some data processed in the context of clinical trials, such developments further complicate compliance efforts, and increase legal risk and compliance costs for Oruka and the third parties upon whom Oruka relies.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Coverage and Reimbursement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which Oruka obtains regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third<span class="nobreak">-party</span> payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement, if any, for such product by third<span class="nobreak">-party</span> payors. Decisions regarding whether to cover any of Oruka&#8217;s product candidates, if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan<span class="nobreak">-by-plan</span> basis. Further, no uniform policy for coverage and reimbursement exists in the United&#160;States, and coverage and reimbursement can differ significantly from payor to payor. Third<span class="nobreak">-party</span> payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">237</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">methods and approval process apart from Medicare determinations. As a result, the coverage determination process is often a time<span class="nobreak">-consuming</span> and costly process that will require Oruka to provide scientific and clinical support for the use of Oruka&#8217;s product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Third<span class="nobreak">-party</span> payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost<span class="nobreak">-containment</span> measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third<span class="nobreak">-party</span> reimbursement for any product or a decision by a third<span class="nobreak">-party</span> not to cover a product could reduce physician usage and patient demand for the product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the U.S.&#160;government, state legislatures and foreign governments have continued implementing cost<span class="nobreak">-containment</span> programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The IRA provides CMS with significant new authorities intended to curb drug costs and to encourage market competition. For the first time, CMS will be able to directly negotiate prescription drug prices and to cap out<span class="nobreak">-of-pocket</span> costs. Each year, CMS will select and negotiate a preset number of high<span class="nobreak">-spend</span> drugs and biologics that are covered under Medicare Part&#160;B and Part&#160;D that do not have generic or biosimilar competition. On August&#160;29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations. These price negotiations will begin in 2023, although the Medicare drug price negotiation program is currently subject to legal challenges. The IRA also provides a new &#8220;inflation rebate&#8221; covering Medicare patients that took effect in 2023 and is intended to counter certain price increases in prescriptions drugs. The inflation rebate provision will require drug manufacturers to pay a rebate to the federal government if the price for a drug or biologic under Medicare Part&#160;B and Part&#160;D increases faster than the rate of inflation. To support biosimilar competition, beginning in October&#160;2022, qualifying biosimilars may receive a Medicare Part&#160;B payment increase for a period of five&#160;years. Separately, if a biologic drug for which no biosimilar exists delays a biosimilar&#8217;s market entry beyond two&#160;years, CMS will be authorized to subject the biologics manufacturer to price negotiations intended to ensure fair competition. Notwithstanding these provisions, the IRA&#8217;s impact on commercialization and competition remains largely uncertain.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Healthcare Reform</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The United&#160;States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United&#160;States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government<span class="nobreak">-funded</span> health care programs, and increased governmental control of drug pricing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ACA, which was enacted in March&#160;2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United&#160;States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and Oruka expects there will be additional challenges and amendments to the ACA in </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">238</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the future. For example, the IRA, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part&#160;D program beginning in 2025 by significantly lowering the beneficiary maximum out<span class="nobreak">-of-pocket</span> cost and creating a new manufacturer discount program.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Other legislative changes have been proposed and adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments to providers of on average 2% per fiscal year as part of the federal budget sequestration under the Budget Control Act&#160;of&#160;2011. These reductions went into effect in April&#160;2013 and, due to subsequent legislative amendments, will remain in effect until 2032 unless additional action is taken by Congress.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the Bipartisan Budget Act&#160;of&#160;2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the point<span class="nobreak">-of-sale</span> discounts that manufacturers must agree to offer under the Medicare Part&#160;D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs being covered under Medicare Part&#160;D.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in May&#160;2019, CMS adopted a final rule allowing Medicare Advantage Plans the option to use step therapy for Part&#160;B drugs, permitting Medicare Part&#160;D plans to apply certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part&#160;D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives, which went into effect on January&#160;1, 2021. In response to the Biden administration&#8217;s October&#160;2022 executive order, on February&#160;14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December&#160;7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march<span class="nobreak">-in</span> rights under the Bayh<span class="nobreak">-Dole</span> Act. On December&#160;8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March<span class="nobreak">-In</span> Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march<span class="nobreak">-in</span> rights. While march<span class="nobreak">-in</span> rights have not previously been exercised, it is uncertain if that will continue under the new framework.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Notwithstanding the IRA, continued legislative and enforcement interest exists in the United&#160;States with respect to specialty drug pricing practices. Specifically, Oruka expects regulators to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under Medicare, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement methodologies for drugs.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Other Government Regulation&#160;Outside of the United&#160;States</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to regulations in the United&#160;States, Oruka is subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological products as well as authorization, approval as well as post<span class="nobreak">-approval</span> monitoring and reporting of Oruka&#8217;s products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Whether or not Oruka obtains FDA approval for a product, Oruka must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United&#160;States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product licensing, safety reporting, post<span class="nobreak">-authorization</span> requirements, marketing and promotion, interactions with healthcare professionals, pricing and reimbursement may vary widely from country </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">239</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">to country. No action can be taken to market any product in a country until an appropriate approval application has been approved by the regulatory authorities in that country. The current approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially unfeasible in such countries.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Regulation in the European Union</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">European Data Laws</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The collection and use of personal health data and other personal data in the EU is governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;), which came into force in May&#160;2018, and related data protection laws in individual EU Member States. The GDPR imposes a number of strict obligations and restrictions on the ability to process, including collecting, analyzing and transferring, personal data of individuals, in particular with respect to health data from clinical trials and adverse event reporting. The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal data relates), the information provided to the individuals prior to processing their personal data, the notification obligations to the national data protection authorities, and the security and confidentiality of the personal data. EU Member States may also impose additional requirements in relation to health, genetic and biometric data through their national legislation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the European Economic Area (&#8220;EEA&#8221;) that are not considered by the European Commission (&#8220;EC&#8221;) to provide an adequate level of data protection. Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may use the standard contractual clauses (&#8220;SCCs&#8221;). With regard to the transfer of data from the EEA to the United&#160;States, on July&#160;10, 2023, the EC adopted its adequacy decision for the EU<span class="nobreak">-US</span> Data Privacy Framework. On the basis of the new adequacy decision, personal data can flow from the EEA to U.S.&#160;companies participating in the framework.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant monetary fines for noncompliance of up to &#8364;20&#160;million or 4% of the annual global revenues of the noncompliant company, whichever is greater, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and, in certain cases, their directors and officers, as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU.&#160;Guidance developed at both the EU level and at the national level in individual EU Member States concerning implementation and compliance practices are often updated or otherwise revised.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, there is a growing trend towards the required public disclosure of clinical trial data in the EU, which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials Regulation&#160;No. 536/2014 (&#8220;CTR&#8221;), European Medical Agency (&#8220;EMA&#8221;) disclosure initiatives and voluntary commitments by industry. Failure to comply with these obligations could lead to government enforcement actions and significant penalties against Oruka, harm to Oruka&#8217;s reputation, and adversely impact Oruka&#8217;s business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the CTR and the GDPR, further adds to the complexity that Oruka faces with regard to data protection regulation. With regard to the transfer of personal data from the EEA to the UK, personal data may now freely flow from the EEA to the UK since the UK is deemed to have an adequate data protection level.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, the adequacy decisions include a &#8216;sunset clause&#8217; which entails that the decisions will automatically expire four&#160;years after their entry into force. Additionally, following the UK&#8217;s withdrawal from the EU and the EEA, companies also have to comply with the UK&#8217;s data protection laws (including the UK GDPR (as defined </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">240</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">in section&#160;3(10)&#160;(as supplemented by section 205(4)) of the Data Protection Act&#160;2018 (the &#8220;DPA&#160;2018&#8221;)), the DPA&#160;2018, and related data protection laws in the UK). Separate from the fines that can be imposed by the GDPR, the UK regime has the ability to fine up to the greater of &#163;17.5&#160;million or 4% of global turnover.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the UK&#8217;s withdrawal from the EU and the EEA, companies are subject to specific transfer rules under the UK regime; personal data may flow freely from the UK to the EEA, since the EEA is deemed to have an adequate data protection level for purposes of the UK regime. These UK international transfer rules broadly mirror the GDPR rules. On February&#160;2, 2022, the UK Secretary of State laid before the UK Parliament the international data transfer agreement (&#8220;IDTA&#8221;) and the international data transfer addendum to the EC&#8217;s standard contractual clauses for international data transfers (Addendum) and a document setting out transitional provisions. The IDTA and Addendum came into force on March&#160;21, 2022 and replaced the old SCCs for the purposes of the UK regime. However, the transitional provisions, adopted with the IDTA and the Addendum, provide that contracts concluded on or before September&#160;21, 2022 on the basis of any old SCCs continue to provide appropriate safeguards for the purpose of the UK regime until March&#160;21, 2024, provided that the processing operations that are the subject matter of the contract remain unchanged and reliance on those clauses ensures that the transfer of personal data is subject to appropriate safeguards.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">With regard to the transfer of personal data from the UK to the United&#160;States, the UK government has adopted an adequacy decision for the United&#160;States, the UK<span class="nobreak">-US</span> Data Bridge, which came into force on October&#160;12, 2023. The UK<span class="nobreak">-US</span> Data Bridge recognizes the United&#160;States as offering an adequate level of data protection where the transfer is to a U.S.&#160;company participating in the EU<span class="nobreak">-US</span> Data Privacy Framework and the UK Extension.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Drug and Biologic Development Process</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Regardless of where they are conducted, all clinical trials included in applications for marketing authorization (&#8220;MA&#8221;) for human medicines in the EU/EEA must have been carried out in accordance with EU regulations. This means that clinical trials conducted in the EU/EEA have to comply with EU clinical trial legislation but also that clinical trials conducted outside the EU/EEA have to comply with ethical principles equivalent to those set out in the EEA, including adhering to international good clinical practice and the Declaration of Helsinki. The conduct of clinical trials in the EU is governed by the CTR, which entered into force on January&#160;31, 2022. The CTR replaced the Clinical Trials Directive 2001/20/EC, (&#8220;Clinical Trials Directive&#8221;) and introduced a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the former regime, which will expire after a transition period of three&#160;years as outlined below in more detail, before a clinical trial can be initiated it must be approved in each EU member state where there is a site at which the clinical trial is to be conducted. The approval must be obtained from two separate entities: the National Competent Authority (&#8220;NCA&#8221;) and one or more Ethics Committees. NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU member state before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU member state where they occur.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A more unified procedure will apply under the new CTR.&#160;A sponsor will be able to submit a single application for approval of a clinical trial through a centralized EU clinical trials portal (the &#8220;CTIS&#8221;). One national regulatory authority (the reporting EU member state proposed by the applicant) will take the lead in validating and evaluating the application and consult and coordinate with the other concerned EU Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned EU Member States. However, a concerned EU member state may in limited circumstances declare an &#8220;opt<span class="nobreak">-out</span>&#8221; from an approval and prevent the clinical trial from being conducted in such member state. The CTR also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. The CTR foresees a three<span class="nobreak">-year</span> transition period. EU Member States will work in CTIS immediately after the system has gone live. Since January&#160;31, 2023, submission of initial clinical trial applications via CTIS is mandatory, and by January&#160;31, 2025, all ongoing trials approved under the former Clinical Trials Directive will need to comply with the CTR and have to be transitioned to CTIS.&#160;On July&#160;19, 2023, the EC </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">241</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">published guidance concerning the steps to be taken in this transition. This guidance provides, among other things, that (i)&#160;documentation which was previously assessed will not be reassessed, (ii)&#160;templates that were developed and endorsed by the EU Clinical Trials Expert Group to provide compliance with the CTR do not need to be updated and (iii)&#160;there is no need to retrospectively create a site suitability form, which are only necessary for new trial sites.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under both the former regime and the new CTR, national laws, regulations, and the applicable GCP and GLP standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines on Good Clinical Practice and the ethical principles that have their origin in the Declaration of Helsinki.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party. A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk<span class="nobreak">-management</span> programs. Advice is not legally binding with regard to any future Marketing Authorization Application (&#8220;MAA&#8221;) of the product concerned.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Drug Marketing Authorization</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the EEA, after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining a MA.&#160;To obtain a MA of a drug under European Union regulatory systems, an applicant can submit an MAA through, amongst others, a centralized or decentralized procedure.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To be used or sold in the UK, a drug must have an effective MA obtained by a centralized application through EMA or a national application. National applications are governed by the Human Medicines Regulations (SI 2012/1916). Applications are made electronically through the Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) Submissions Portal. The process from application to authorizations generally takes up to 210&#160;days, excluding time taken to provide any additional information or data required by the MHRA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;30, 2023, the MHRA published detailed guidance on its recently announced new International Reliance Procedure (&#8220;IRP&#8221;) for MAAs. The IRP applies since January&#160;1, 2024 and replaces existing EU reliance procedures to apply for authorizations from seven international regulators (e.g., Health Canada, Swiss Medic, FDA, EMA, among others). The IRP allows medicinal products approved in other jurisdictions that meet certain criteria to undergo a fast<span class="nobreak">-tracked</span> MHRA review to obtain and/or update a MA in the UK or Great Britain.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Applicants can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post<span class="nobreak">-authorization</span> procedures including line extensions, variations and renewals.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Centralized Authorization Procedure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The centralized procedure provides for the grant of a single MA that is issued by the EC following the scientific assessment of the application by the EMA that is valid for all EU Member States as well as in the three additional member states of the EEA.&#160;The centralized procedure is compulsory for certain types of medicinal products, including for medicines developed by means of certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (&#8220;ATMP&#8221;) and medicinal products with a new active substance indicated for the treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto<span class="nobreak">-immune</span> and viral diseases). For medicinal products containing a new active substance not yet authorized in the EEA before May&#160;20, 2004 and indicated for the treatment of other diseases, medicinal products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant may voluntarily submit an application for a MA through the centralized procedure.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the centralized procedure, the CHMP established at the EMA, is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post<span class="nobreak">-authorization</span> and maintenance activities, such as the assessment of modifications or extensions to an existing MA.&#160;Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle, 210&#160;days from receipt of a valid MAA.&#160;However, </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">242</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless the application is eligible for an accelerated assessment. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. Upon request, the CHMP can reduce the time frame to 150&#160;days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements. This opinion is then transmitted to the EC, which has the ultimate authority for granting MA within 67&#160;days after receipt of the CHMP opinion.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Decentralized Authorization Procedure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Medicines that fall outside the mandatory scope of the centralized procedure have three routes to authorization: (i)&#160;they can be authorized under the centralized procedure if they concern a significant therapeutic, scientific or technical innovation, or if their authorization would be in the interest of public health; (ii)&#160;they can be authorized under a decentralized procedure where an applicant applies for simultaneous authorization in more than one EU member state; or (iii)&#160;they can be authorized in an EU member state in accordance with that state&#8217;s national procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the validity of the original, national MA (mutual recognition procedure).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various EU Member States simultaneously if such medicinal product has not received marketing approval in any EU Member State before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant a MA for their territories on the basis of this assessment. The only exception to this is where the competent authority of an EU Member State considers that there are concerns of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision is binding for all EU Member States.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Risk Management Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All new MAAs must include a Risk Management Plan (&#8220;RMP&#8221;) describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available. An updated RMP must be submitted: (i)&#160;at the request of EMA or a national competent authority, or (ii)&#160;whenever the risk<span class="nobreak">-management</span> system is modified, especially as the result of new information being received that may lead to a significant change to the benefit<span class="nobreak">-risk</span> profile or as a result of an important pharmacovigilance or risk<span class="nobreak">-minimization</span> milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA.&#160;Since October&#160;20, 2023, all RMPs for centrally authorized products are published by the EMA, subject only to limited redactions.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">MA Validity Period</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">MAs have an initial duration of five&#160;years. After these five&#160;years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk<span class="nobreak">-benefit</span> balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five<span class="nobreak">-year</span> renewal. Applications for renewal must be made to the EMA at least nine&#160;months before the five<span class="nobreak">-year</span> period expires.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">243</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three&#160;years after authorization ceases to be valid.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the UK, the period of three&#160;years during which the drug has not been marketed in Great Britain will be restarted from the date of conversion to a Great Britain MA.&#160;Conversion refers to the procedure by which, as of January&#160;1, 2021, MAs granted on the basis of a centralized procedure in the EU are only valid in Northern Ireland but not in Great Britain, whereas, prior EU authorizations have all been automatically converted into UK MAs effective in Great Britain only.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On the other hand, for the EU, in the case the drug has been marketed in the UK, the placing on the UK market before the end of the period starting when the UK left the EU on January&#160;31, 2020 and ending on December&#160;31, 2020 (the &#8220;Brexit Transition Period&#8221;) will be taken into account. If, after the end of the Brexit Transition Period, the drug is not placed on any other market of the remaining EU Member States, the three<span class="nobreak">-year</span> period will start running from the last date the drug was placed on the UK market before the end of the Brexit Transition Period.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Advanced Therapy Medicinal Products</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the EU, medicinal products, including ATMPs are subject to extensive pre- and post<span class="nobreak">-market</span> regulation by regulatory authorities at both the EU and national levels. ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products, which are genes, cells or tissues that have undergone substantial manipulation and that are administered to human beings in order to cure, diagnose or prevent diseases or regenerate, repair or replace a human tissue. Pursuant to the ATMP Regulation, the Committee on Advanced Therapies (&#8220;CAT&#8221;) is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT are also responsible for providing guidelines on ATMPs. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs. Although such guidelines are not legally binding, compliance with them is often necessary to gain and maintain approval for product candidates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the mandatory RMP, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Exceptional Circumstances/Conditional Approval</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Similar to accelerated approval regulations in the United&#160;States, conditional MAs can be granted in the EU in exceptional circumstances. A conditional MA can be granted for medicinal products where, although comprehensive clinical data referring to the safety and efficacy of the medicinal product have not been supplied, a number of criteria are fulfilled: (i)&#160;the benefit/risk balance of the product is positive, (ii)&#160;it is likely that the applicant will be in a position to provide the comprehensive clinical data, (iii)&#160;unmet medical needs will be fulfilled by the grant of the MA and (iv)&#160;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional MA must be renewed annually.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Data and Market Exclusivity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As in the United&#160;States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received a MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the market. New Chemical Entities (&#8220;NCEs&#8221;) approved in the EU qualify for eight&#160;years of data exclusivity and 10&#160;years of marketing exclusivity.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">An additional non<span class="nobreak">-cumulative</span> one<span class="nobreak">-year</span> period of marketing exclusivity is possible if during the data exclusivity period (the first eight&#160;years of the 10<span class="nobreak">-year</span> marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">244</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The data exclusivity period begins on the date of the product&#8217;s first MA in the EU.&#160;After eight&#160;years, a generic product application may be submitted and generic companies may rely on the MA holder&#8217;s data. However, a generic product cannot launch until two&#160;years later (or a total of 10&#160;years after the first MA in the EU of the innovator product), or three&#160;years later (or a total of 11&#160;years after the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within the eight<span class="nobreak">-year</span> data exclusivity period. Additionally, another non<span class="nobreak">-cumulative</span> one<span class="nobreak">-year</span> period of data exclusivity can be added to the eight&#160;years of data exclusivity where an application is made for a new indication for a well<span class="nobreak">-established</span> substance, provided that significant preclinical or clinical studies were carried out in relation to the new indication.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Another year of data exclusivity may be added to the eight&#160;years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant pre<span class="nobreak">-trial</span> tests or clinical trials (when examining an application by another applicant for or holder of MA for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one year after the initial change was authorized).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to include an NCE.&#160;Even if a compound is considered to be an NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the medicinal product if such company can complete a full MAA with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation. The current draft envisages e.g., a shortening of the periods of data exclusivity, however, there is currently neither a final version of this draft nor a date for its entry into force.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Orphan Designation and Exclusivity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The criteria for designating an orphan medicinal product in the EU are similar in principle to those in the U.S.&#160;The EMA grants orphan drug designation if the medicinal product is intended for the diagnosis, prevention or treatment of a life<span class="nobreak">-threatening</span> or chronically debilitating condition affecting no more than five in 10,000 persons in the EU (prevalence criterion). In addition, orphan drug designation can be granted if, for economic reasons, the medicinal product would be unlikely to be developed without incentives and if there is no other satisfactory method approved in the EU of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed medicinal product is a significant benefit to patients affected by the condition. An application for orphan drug designation (which is not a MA, as not all orphan<span class="nobreak">-designated</span> medicines reach the authorization application stage) must be submitted first before an application for MA of the medicinal product is submitted. The applicant will receive a fee reduction for the MAA if the orphan drug designation has been granted, but not if the designation is still pending at the time the MA is submitted, and sponsors must submit an annual report to EMA summarizing the status of development of the medicine. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Designated orphan medicines are eligible for conditional MA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The EMA&#8217;s Committee for Orphan Medicinal Products reassesses the orphan drug designation of a product in parallel with the review for a MA; for a product to benefit from market exclusivity it must maintain its orphan drug designation at the time of MA review by the EMA and approval by the EC.&#160;Additionally, any MA granted for an orphan medicinal product must only cover the therapeutic indication(s)&#160;that are covered by the orphan drug designation. Upon the grant of a MA, orphan drug designation provides up to ten&#160;years of market exclusivity in the orphan indication.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">During the 10<span class="nobreak">-year</span> period of market exclusivity, with a limited number of exceptions, the regulatory authorities of the EU Member States and the EMA may not accept applications for MA, accept an application to extend an existing MA or grant a MA for other similar medicinal products for the same therapeutic indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan medicinal product can also obtain an additional two&#160;years of market exclusivity for an orphan<span class="nobreak">-designated</span> condition when the results of specific studies are reflected in the Summary of Product </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">245</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Characteristics (&#8220;SmPC&#8221;) addressing the pediatric population and completed in accordance with a fully compliant Pediatric Investigation Plan (&#8220;PIP&#8221;). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The 10<span class="nobreak">-year</span> market exclusivity may be reduced to six&#160;years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, i.e., the condition prevalence or financial returns criteria under Article&#160;3 of Regulation (EC) No. 141/2000 on orphan medicinal products. When the period of orphan market exclusivity for an indication ends, the orphan drug designation for that indication expires as well. Orphan exclusivity runs in parallel with normal rules on data exclusivity and market protection. Additionally, a MA may be granted to a similar medicinal product (orphan or not) for the same or overlapping indication subject to certain requirements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the UK, following the post<span class="nobreak">-Brexit</span> transition period, a system for incentivizing the development of orphan medicines was introduced. Overall, the requirements for orphan designation largely replicate the requirements in the EU and the benefit of market exclusivity has been retained. Products with an orphan designation in the EU can be considered for an orphan MA in Great Britain, but a UK<span class="nobreak">-wide</span> orphan MA can only be considered in the absence of an active EU orphan designation. The MHRA will review applications for orphan designation at the time of a MA, and will offer incentives, such as market exclusivity and full or partial refunds for MA fees to encourage the development of medicines in rare diseases.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Pediatric Development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the EU, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a PIP together with a request for agreement to the EMA.&#160;The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric Committee. Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (e.g., until enough information to demonstrate its effectiveness and safety in adults is available) or waiver (e.g., because the relevant disease or condition occurs only in adults) has been granted by the EMA.&#160;The MAA for the medicinal product must include the results of all pediatric clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral has been granted, in which case the pediatric clinical trials may be completed at a later date. Medicinal products that are granted an MA on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six<span class="nobreak">-month</span> extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval), or, in the case of orphan medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required when a MA holder wants to add a new indication, medicinal form or route of administration for a medicine that is already authorized and covered by intellectual property rights.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the UK, the MHRA has published guidance on the procedures for UK PIPs which, where possible, mirror the submission format and requirements of the EU system. EU PIPs remain applicable for Northern Ireland and EU PIPs agreed by the EMA prior to January&#160;1, 2021 have been adopted as UK PIPs.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">PRIME Designation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The Priority Medicines (&#8220;PRIME&#8221;) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small<span class="nobreak">-and</span> medium<span class="nobreak">-sized</span> enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling non<span class="nobreak">-clinical</span> data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur from the CHMP or CAT are appointed facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick<span class="nobreak">-off</span> meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">246</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">guidance on the overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Post-Approval Regulation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Similar to the United&#160;States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of manufacturing licenses and MAs. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of medicinal products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Failure by Oruka or by any of its third<span class="nobreak">-party</span> partners, including suppliers, manufacturers and distributors to comply with EU laws and the related national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, MA of medicinal products and marketing of such products, both before and after grant of MA, statutory health insurance, bribery and anti<span class="nobreak">-corruption</span> or other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The holder of MA for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post<span class="nobreak">-authorization</span> safety studies to obtain further information on a medicine&#8217;s safety, or to measure the effectiveness of risk<span class="nobreak">-management</span> measures, which may be time consuming and expensive and could impact Oruka&#8217;s profitability. MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of Periodic Safety Update Reports (&#8220;PSURs&#8221;) in relation to medicinal products for which they hold MAs. The EMA reviews PSURs for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise that the MA holder be obliged to conduct post<span class="nobreak">-authorization</span> Phase&#160;4 safety studies. If the EC agrees with the opinion, it can adopt a decision varying the existing MA.&#160;Failure by the MA holder to fulfill the obligations for which the EC&#8217;s decision provides can undermine the ongoing validity of the MA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">More generally, non<span class="nobreak">-compliance</span> with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the MA for the product or imposition of financial penalties or other enforcement measures.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The manufacturing process for pharmaceutical products in the EU is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice (&#8220;GMP&#8221;). These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU.&#160;Similarly, the distribution of pharmaceutical products into and within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution in the EU or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">247</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Sales and Marketing Regulations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The advertising and promotion of Oruka&#8217;s products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU Member States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s SmPC as approved by the competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the MA granted for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off<span class="nobreak">-label</span> promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off<span class="nobreak">-label</span> promotion is prohibited. Direct<span class="nobreak">-to-consumer</span> advertising of prescription<span class="nobreak">-only</span> medicines is also prohibited in the EU.&#160;Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of Oruka&#8217;s products to the general public and may also impose limitations on its promotional activities with healthcare professionals.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">EU regulation with regards to dispensing, sale and purchase of medicines has generally been preserved in the UK following Brexit, through the Human Medicines Regulations 2012. However, organizations wishing to sell medicines online need to register with the MHRA.&#160;Following Brexit, the requirements to display the common logo no longer apply to UK<span class="nobreak">-based</span> online sellers, except for those established in Northern Ireland.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Anti-Corruption Legislation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self<span class="nobreak">-regulation</span> codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is prohibited in the EU.&#160;The provision of benefits or advantages to physicians is also governed by the national anti<span class="nobreak">-bribery</span> laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Payments made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the UK, the pharmaceutical sector is recognized as being particularly vulnerable to corrupt practices, some of which fall within the scope of the Bribery Act&#160;2010. Due to the Bribery Act&#160;2010&#8217;s far<span class="nobreak">-reaching</span> territorial application, the potential penalized act does not have to occur in the UK to become within its scope. If the act or omission does not take place in the UK, but the person&#8217;s act or omission would constitute an offense if carried out there and the person has a close connection with the UK, an offense will still have been committed.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Bribery Act&#160;2010 is comprised of four offenses that cover (i)&#160;individuals, companies and partnerships that give, promise or offer bribes, (ii)&#160;individuals, companies and partnerships that request, agree to receive or accept bribes, (iii)&#160;individuals, companies and partnerships that bribe foreign public officials, and (iv)&#160;companies and partnerships that fail to prevent persons acting on their behalf from paying bribes. The penalties imposed under the Bribery Act&#160;2010 depend on the offence committed, harm and culpability and penalties range from unlimited fines to imprisonment for a maximum term of ten&#160;years and in some cases both.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Regulations in the UK and Other Markets</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The UK formally left the EU on January&#160;31, 2020 and EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol on Ireland and Northern Ireland and as amended by the Windsor Framework sets out a long<span class="nobreak">-term</span> set of arrangements for the supply of medicines into Northern Ireland. The EU and the UK agreed on a trade and cooperation agreement (&#8220;TCA&#8221;), which includes provisions affecting the life </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">248</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">sciences sector (including on customs and tariffs). There are some specific provisions concerning pharmaceuticals, including the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP issued documents. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The UK government has adopted the Medicines and Medical Devices Act&#160;2021 (the &#8220;MMDA&#8221;) to enable the UK&#8217;s regulatory frameworks to be updated following the UK&#8217;s departure from the EU.&#160;The MMDA introduces regulation<span class="nobreak">-making</span>, delegated powers covering the fields of human medicines, clinical trials of human medicines, veterinary medicines and medical devices. The MHRA has since been consulting on future regulations for medicines and medical devices in the UK.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCPs and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If Oruka fails to comply with applicable foreign regulatory requirements, it may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Employees and Human Capital Resources</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of May&#160;3, 2024, Oruka had ten full<span class="nobreak">-time</span> employees. Oruka also engages temporary employees and consultants to augment its existing workforce. None of Oruka&#8217;s employees are represented by a labor union or covered under a collective bargaining agreement. Oruka considers its relationship with its employees to be good.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka recognizes that attracting, motivating, and retaining talent at all levels is vital to continuing its success. Oruka invests in its employees through high<span class="nobreak">-quality</span> benefits, professional development opportunities, and various health and wellness initiatives and offers competitive compensation packages (base salary and incentive plans), ensuring fairness in internal compensation practices. The principal purposes of Oruka&#8217;s incentive plans (bonus and equity) are to align with the long<span class="nobreak">-term</span> interests of its stakeholders and stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Properties and Facilities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka currently operates as a virtual company and does not maintain physical corporate offices. Oruka&#8217;s employees currently work remotely. Oruka believe these arrangements support its current needs. Oruka maintains a mailing address at 221 Crescent St., Building<span class="nobreak"> </span>23, Suite 105, Waltham, MA.&#160;In April&#160;2024, Oruka entered into a lease agreement with Oak Grove LP for office space located in Menlo Park, California. The lease began on June&#160;15, 2024 with an initial term of 39.5&#160;months.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Legal Proceedings</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, Oruka may become involved in legal proceedings. Oruka is not currently a party to or aware of any proceedings that it believes will have, individually or in the aggregate, a material adverse effect on its business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on Oruka because of defense and settlement costs, diversion of management resources and other factors.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">249</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9988"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The following discussion and analysis of ARCA&#8217;s financial condition and results of operations should be read in conjunction with ARCA&#8217;s consolidated financial statements and notes thereto appearing elsewhere in this proxy statement/prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this proxy statement/prospectus, including information with respect to ARCA&#8217;s plans and strategy for ARCA&#8217;s business, includes forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements that involve risks and uncertainties. As a result of many factors, ARCA&#8217;s actual results could differ materially from the results described in or implied by the forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements contained in the following discussion and analysis</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Overview</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is dedicated to applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. Precision medicine refers to the tailoring of medical treatment to the individual characteristics of patients, using genomic, non<span class="nobreak">-genomic</span> biomarker and other information that extends beyond routine diagnostic categorization. ARCA believes that when implemented correctly precision medicine can enhance therapeutic response, improve patient outcomes, and reduce healthcare costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA, First Merger Sub, Second Merger Sub and Oruka entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA&#8217;s and the surviving corporation of the First Merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Second Merger Sub with Second Merger Sub continuing as a wholly owned subsidiary of ARCA&#8217;s and the surviving entity of the Second Merger. The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, at the closing of the First Merger, (a)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the financing transaction described below) will be converted solely into the right to receive a number of shares of ARCA&#8217;s common stock calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;), (b)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of ARCA Series&#160;B Preferred Stock calculated in accordance with the Merger Agreement, (c)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and (d)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA&#8217;s common stock, subject to adjustment as set forth in the Merger Agreement and form of warrant. Under the terms of the Merger Agreement, prior to the closing of the transaction, ARCA&#8217;s board of directors will accelerate the vesting of all equity awards of ARCA&#8217;s then outstanding but not then vested or exercisable, and cancel each Out of the Money Options to acquire shares of ARCA&#8217;s common stock with an exercise price per share greater than the Parent Closing Price, in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, each option to acquire shares of ARCA&#8217;s common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Exchange Ratio formula in the Merger Agreement, upon the closing of the First Merger, on a pro forma basis and based upon the number of shares of ARCA&#8217;s common stock expected to be issued in the First Merger, pre<span class="nobreak">-First</span> Merger Oruka stockholders (including Oruka stockholders issued shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing) will own approximately 97.61% of the combined </p>
		</div>


		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">250</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">company and pre<span class="nobreak">-First</span> Merger ARCA stockholders will own approximately 2.39% of the combined company. For purposes of calculating the Exchange Ratio, (i)&#160;shares of ARCA&#8217;s common stock underlying warrants and other rights to receive shares (other than Options to acquire shares of ARCA&#8217;s common stock, to the extent cancelled at or prior to closing of the First Merger in accordance with the Merger Agreement) outstanding as of immediately prior to the closing of the First Merger will be deemed to be outstanding, and (ii)&#160;all shares of Oruka common stock underlying outstanding Oruka stock options and warrants will be deemed to be outstanding. The Exchange Ratio will be adjusted to the extent that ARCA&#8217;s net cash at closing is less than $5.0&#160;million and will be based on the amount of proceeds actually received by Oruka in the financing transaction described below, as further described in the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the First Effective Time, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $5.0&#160;million. ARCA management currently anticipates that ARCA&#8217;s net cash as of closing to be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Merger, ARCA is required to seek the approval of its stockholders to, among other things, (a)&#160;issue shares of ARCA&#8217;s common stock issuable in connection with the First Merger (including the shares of ARCA common stock issuable under the ARCA Series&#160;B Preferred Stock) under the rules of Nasdaq, and (b)&#160;amend its amended and restated certificate of incorporation, to (i)&#160;effect a reverse stock split of ARCA&#8217;s common stock (if deemed necessary by ARCA and Oruka), (ii)&#160;increase the number of shares of ARCA&#8217;s common stock that it is authorized to issue, and (iii)&#160;such other changes as are mutually agreeable to ARCA and Oruka (the &#8220;ARCA Voting Proposals&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1)&#160;using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2)&#160;non<span class="nobreak">-solicitation</span> of alternative acquisition proposals, (3)&#160;the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, (4)&#160;ARCA using commercially reasonable efforts to maintain the existing listing of ARCA&#8217;s common stock on Nasdaq and cause the shares of ARCA&#8217;s common stock to be issued in connection with the First Merger to be approved for listing on Nasdaq prior to the closing of the First Merger, and (5)&#160;ARCA filing with the SEC and causing to become effective a registration statement to register shares of ARCA&#8217;s common stock to be issued in connection with the First Merger, except as set forth in the Merger Agreement (the &#8220;Registration Statement&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA&#8217;s stockholders of the ARCA Voting Proposals, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the initial listing application to be submitted in connection with the First Merger, (4)&#160;the effectiveness of the Registration Statement, (5)&#160;the expiration of any applicable waiting periods (or extensions thereof) under the Hart Scott<span class="nobreak">-Rodino</span> Antitrust Improvements Act&#160;of&#160;1976, as amended, (6)&#160;the Subscription Agreement (described below) being in full force and effect providing for the receipt of proceeds of not less than $175,000,000 (including in the proceeds any notes contributed as consideration in the Oruka pre<span class="nobreak">-closing</span> financing described below) and (7)&#160;to the extent ARCA has declared the cash dividend described above, ARCA delivering the aggregate amount distributable to the pre<span class="nobreak">-First</span> Merger ARCA stockholders to its&#8217; transfer agent for further distribution to the pre<span class="nobreak">-First</span> Merger ARCA stockholders. Each party&#8217;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the date of the closing of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains certain termination rights of each of ARCA and Oruka. Upon termination of the Merger Agreement under specified circumstances, ARCA and Oruka may each be required to pay the other party a termination fee of $440,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to a Certificate of Designation of Preferences, Rights and Limitations of the Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to be filed by ARCA with the Secretary of State of the State of Delaware (the &#8220;Certificate of Designation&#8221;) in connection with the Merger Agreement and the transactions thereunder, ARCA will establish the terms of a new series of preferred stock of ARCA designated as Series&#160;B Non<span class="nobreak">-Voting</span> Convertible </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">251</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Preferred Stock, par value $0.001 per share (the &#8220;ARCA Series&#160;B Preferred Stock&#8221;). Holders of the ARCA Series&#160;B Preferred Stock will be entitled to receive dividends on shares of ARCA Series&#160;B Preferred Stock equal to, on an as<span class="nobreak">-if-converted-to-ARCA</span> common stock basis, and in the same form as dividends actually paid on shares of ARCA&#8217;s common stock. Except as otherwise required by the Certificate of Designation or law, the ARCA Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of ARCA Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the ARCA Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the ARCA Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend ARCA&#8217;s certificate of incorporation, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the ARCA Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the ARCA Series&#160;B Preferred Stock, (e)&#160;issue further shares of the ARCA Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the ARCA Series&#160;B Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued ARCA Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which ARCA&#8217;s stockholders immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The ARCA Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding<span class="nobreak">-up</span> of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the closing of the First Merger, each share of ARCA Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the ARCA Series&#160;B Preferred Stock, into a number of shares equal to 1,000<span class="nobreak"> </span>shares of ARCA&#8217;s common stock, subject to certain limitations, including that a holder of ARCA Series&#160;B Preferred Stock is prohibited from converting shares of ARCA Series&#160;B Preferred Stock into shares of ARCA&#8217;s common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 9.99%) of the total number of shares of ARCA&#8217;s common stock issued and outstanding immediately after giving effect to such conversion.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the First Merger Effective Time (the &#8220;Effective Time&#8221;), the combined company&#8217;s board of directors is expected to consist of six (6)&#160;members, all of whom will be designated by Oruka. Upon the closing of the transaction, the combined company will be led by Oruka&#8217;s chief executive officer.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Financing Transaction</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution and delivery of the Merger Agreement, certain parties have entered into the Subscription Agreement with Oruka, pursuant to which they have agreed, subject to the terms and conditions of such agreement, to purchase immediately prior to the consummation of the First Merger, shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock for an aggregate purchase price of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note). The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the Subscription Agreement. Shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock issued pursuant to this financing transaction will be converted into shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to acquire shares ARCA common stock, in accordance with the exchange ratio and the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. There can be no assurance that the strategic review process or any transaction relating to a specific asset, including the Merger or any asset sale, will result in ARCA pursuing such a transaction(s), or that any transaction(s), if pursued, will be completed on terms favorable to ARCA and its stockholders in the existing entity or any possible entity that results from a combination of entities. If the strategic review process is unsuccessful, ARCA&#8217;s board of directors may decide to pursue a dissolution and liquidation.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">252</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro&#8482; (bucindolol hydrochloride) for Atrial Fibrillation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Gencaro&#8482; (bucindolol hydrochloride) is a pharmacogenetically<span class="nobreak">-targeted</span> beta<span class="nobreak">-adrenergic</span> receptor antagonist with mild vasodilator properties that ARCA is developing for the treatment of atrial fibrillation in patients with heart failure. ARCA believes the pharmacology of Gencaro is unique and its efficacy can be enhanced by prescribing it to patients with a common genotypic variant that is present in approximately 50% of the North American and European general populations. This gene can be detected with a simple genetic test.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is developing Gencaro to treat AF in patients with chronic HF.&#160;AF is the most common form of cardiac arrhythmia, a disruption of the heart&#8217;s normal rhythm or rate. HF is a chronic condition in which the heart is unable to pump enough blood to meet the body&#8217;s needs. AF and HF commonly occur together. In HF patients, the development of AF leads to worsening symptoms, and increased risk of hospitalization and death. Current treatment options for AF in HF patients are limited, and can be invasive, costly and dangerous.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s development plan for Gencaro focuses on the treatment of AF in patients with higher ejection fraction HF, those who have an ejection fraction, or EF, of 40% and higher who also have the genotype ARCA believes is optimal for Gencaro efficacy. This population of HF encompasses more than half of all HF patients in the United&#160;States and Europe. There are currently few approved or effective drug therapies to treat AF or HF in this patient population.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s development plan for Gencaro is based on ARCA&#8217;s published analysis of the Phase&#160;2b clinical trial of Gencaro for the prevention of AF in HF patients, known as GENETIC<span class="nobreak">-AF</span>.&#160;This analysis showed novel results for Gencaro in patients in the clinical trial with EF&#8217;s of 40% and higher. ARCA currently has an agreement with the FDA, known as a Special Protocol Assessment (&#8220;SPA&#8221;), for the requirements of a Gencaro Phase&#160;3 clinical trial, PRECISION<span class="nobreak">-AF</span>, that would support approval of Gencaro if successful. The Phase&#160;3 pivotal clinical trial of Gencaro conducted under a SPA will include secondary endpoints that are intended to capture some of this information, such as a reduction in the need to deploy rhythm control interventions including electrical cardioversion, catheter ablation and use of anti<span class="nobreak">-arrhythmic</span> drugs and avoidance of drug<span class="nobreak">-related</span> complications such as bradycardia. ARCA was issued a United&#160;States patent in February&#160;2021 for the use of Gencaro in a patient population identified as part of the clinical trial. ARCA believes this patent will substantially extend the patent protection for its planned development of Gencaro into 2039. ARCA has sought or is seeking similar patent protection in other countries.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that patients with HF and AF represent a major unmet medical need, and this need is most pronounced in patients with EF values of 40% and above. This EF range constitutes more than half of all chronic HF in the United&#160;States and Europe, as well as in Japan and China, and there are currently few approved, effective or guideline<span class="nobreak">-recommended</span> therapies for these patients to treat either their AF or HF.&#160;AF is a very common complication in these patients, with estimates of AF incidence ranging from 40% to 60%. Beta<span class="nobreak">-blockers</span> approved for HF are commonly used off<span class="nobreak">-label</span> to control heart rate in these patients, but they are not considered effective in preventing AF and none are approved for patients with EF &#8805; 40%. Other anti<span class="nobreak">-arrhythmic</span> drugs approved for the treatment of AF have adverse side effects and in HF patients are either contraindicated or have label warnings for use due to an increased risk of mortality. Interventional procedures for AF, such as catheter ablation and electrical cardioversion, are invasive, expensive, and often temporary; these interventions also typically require the continued use of beta blockers and other anti<span class="nobreak">-arrhythmic</span> drugs post<span class="nobreak">-intervention</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that Gencaro, if approved, may be a safe and more effective therapy for the treatment of higher ejection fraction HF patients with AF.&#160;ARCA believes there are several potentially important attributes that would differentiate Gencaro from existing therapies, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>More effective rhythm control compared to the current standard of care;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduction in the need for catheter ablation, electrical cardioversion, or toxic anti<span class="nobreak">-arrhythmic</span> drugs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Maintenance of rhythm control after a successful AF catheter ablation;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Effective rate control with lower risk of treatment<span class="nobreak">-limiting</span>, adverse event producing bradycardia;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduction in symptoms and improvement in quality of life;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reduced health care burden;</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">253</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Foundational beta<span class="nobreak">-blocker</span> benefits for HF and unique evidence of efficacy in HF patients with AF;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>One of the only drug therapies approved and shown effective for AF in HF patients with EF &#8805; 40%, and the only one in its drug class.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has an international patent portfolio for Gencaro in the United&#160;States, the EU, and other major markets, as well as new chemical entity status, including a new patent that ARCA believes will give it a strong intellectual property position to at least approximately 2039 in the United&#160;States; ARCA has filed applications similar to this new patent in international territories. ARCA has developed a laboratory platform for the diagnostic test that would be used to prescribe Gencaro; this platform was approved by FDA for use in the Phase&#160;2B clinical trial. ARCA retains all rights to this test platform; ARCA expects to use it in future clinical trials, and ARCA believes it could be one of multiple diagnostic platforms used for commercialization.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">rNAPc2 (AB201) for treatment of COVID-19</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Recombinant Nematode Anticoagulant Protein c2 (&#8220;rNAPc2&#8221;) (AB201) is a protein therapeutic in clinical development as a potential treatment for patients with COVID<span class="nobreak">-19</span>. Based on its unique mechanism of action, development history and the clinical evidence from the SARS<span class="nobreak">-CoV-2</span> pandemic, ARCA believes rNAPc2 has potential to be a beneficial therapy for patients with this serious viral disease. ARCA initiated a Phase&#160;2b clinical trial of rNAPc2 as a potential treatment for patients hospitalized with COVID<span class="nobreak">-19</span> in the fourth quarter of 2020 and completed patient enrollment in the fourth quarter 2021. In the clinical trial, both doses of rNAPc2 demonstrated a treatment benefit for patients based on the coagulation biomarker D<span class="nobreak">-dimer</span>, however, neither dose achieved statistical significance for the primary efficacy endpoint of change in D<span class="nobreak">-dimer</span> level from Baseline to Day 8 compared to standard of care heparin.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On the secondary endpoints measuring thrombotic events and time<span class="nobreak">-to-recovery</span>, there was a numerical imbalance in favor of rNAPc2 that was non<span class="nobreak">-significant</span>. rNAPc2 was well<span class="nobreak">-tolerated</span> at both doses. There were no serious treatment<span class="nobreak">-related</span> adverse events and no dose dependent increase in adverse events was observed. There was no difference between rNAPc2 and standard<span class="nobreak">-of-care</span> heparin in major or non<span class="nobreak">-major</span> clinically relevant bleeding. ARCA currently does not plan additional clinical development of rNAPc2 unless ARCA is able to find a commercial or government partner to pay for development and commercialization or expansion into clinical trials for other disease indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To support the continued development of Gencaro and rNAPc2, ARCA will need additional financing to fully fund any clinical trials, and ARCA&#8217;s general and administrative costs through the clinical trials&#8217; projected completion and potential commercialization. Considering the substantial time and costs associated with the development of Gencaro and rNAPc2 and the risk that ARCA may be unable to raise a significant amount of capital on acceptable terms, ARCA is also pursuing co<span class="nobreak">-development</span> and commercialization partnering opportunities with large pharmaceutical and/or specialty pharmaceutical companies and may pursue a strategic combination or other strategic transactions. If ARCA is unable to obtain sufficient financing or is unable to complete a strategic transaction, ARCA may discontinue its development activities on Gencaro or rNAPc2 or discontinue operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund ARCA&#8217;s operations through the middle of fiscal year 2025. ARCA&#8217;s future viability beyond that point is dependent on the results of the strategic review process and ARCA&#8217;s ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>&#8221; in this proxy statement/prospectus. Should ARCA pursue additional clinical trials for its product candidates, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction. The Merger discussed above may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing, subject to ARCA&#8217;s pursuit of a potential strategic transaction and the consummation of such potential transaction. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">254</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, ARCA entered into a new sales agreement with a placement agent to sell, from time to time, in an &#8220;at the market offering.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA amended the new sales agreement and the amount available for the offering under ARCA&#8217;s prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated such sales agreement in accordance with its terms. No sales were made under this sales agreement in 2024 or 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Results of Operations</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">General and Administrative Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative (&#8220;G&amp;A&#8221;) expenses primarily consist of personnel costs, consulting and professional fees, insurance, facilities and depreciation expenses, and various other administrative costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">G&amp;A expenses were $2.3&#160;million for the three&#160;months ended March&#160;31, 2024 compared to $1.4&#160;million for the corresponding period of 2023, an increase of $0.9&#160;million. During the three&#160;months ended March&#160;31, 2023, ARCA recorded $159,000 for one<span class="nobreak">-time</span> termination benefits related to the mutually agreed to conclusion of Christopher D.&#160;Ozeroff&#8217;s employment, the former Secretary, Senior Vice President and General Counsel of ARCA, effective March&#160;31, 2023. The increase for the three<span class="nobreak">-month</span> period was primarily a result of a $1.1&#160;million increase in professional fees primarily related to the Merger Agreement discussed above, offset by $0.2&#160;million lower one<span class="nobreak">-time</span> termination benefits and lower personnel costs from the reduction discussed above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">G&amp;A expenses were $6.3&#160;million for the year ended December&#160;31, 2023, compared to $5.8&#160;million for 2022, an increase of approximately $0.4&#160;million. During the year ended December&#160;31, 2023, ARCA recorded $159,000 for one<span class="nobreak">-time</span> termination benefits related to the mutually<span class="nobreak">-agreed</span> to conclusion of Christopher D.&#160;Ozeroff&#8217;s employment, the former Secretary, Senior Vice President and General Counsel of ARCA, effective March&#160;31, 2023. During the year ended December&#160;31, 2022, ARCA recorded total restructuring charges of approximately $755,000, of which $470,000 and $285,000 were recognized in research and development and general and administrative expenses, respectively, in connection with the restructuring, all in the form of one<span class="nobreak">-time</span> termination benefits. The increase in expenses during 2023 was primarily a result of increases in professional fees and fees to the Special Committee in connection with the Strategic Review, offset by lower one<span class="nobreak">-time</span> termination benefits and lower personnel costs from the reductions discussed above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">G&amp;A expenses in 2024 are expected to be higher than those in 2023 as ARCA incurs professional fees related to the Merger Agreement discussed above and maintains administrative activities to support its ongoing operations. ARCA does expect to incur significant costs related to ARCA&#8217;s exploration of strategic alternatives and the Merger, including legal, accounting and advisory expenses and other related charges.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While ARCA does not believe that inflation had a material effect on its financial condition and results of operations during the periods presented, it may result in increased costs in the foreseeable future.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Research and Development Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development (&#8220;R&amp;D&#8221;) expense is comprised primarily of personnel costs, clinical development, manufacturing process development, and regulatory activities and costs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D expense for the three&#160;months ended March&#160;31, 2024 was $0.2&#160;million compared to $0.4&#160;million for the corresponding period of 2023, a decrease of $0.2&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D personnel costs decreased approximately $0.2&#160;million for the three&#160;months ended March&#160;31, 2024, as compared to the corresponding period of 2023, due to decreased headcount.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Manufacturing process development costs for the three&#160;months ended March&#160;31, 2024 and 2023 were consistent.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D expense decreased $0.1&#160;million related to the unrestricted research grants with ARCA&#8217;s former President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. There was no expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">255</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">for the three&#160;months ended March&#160;31, 2023 was $108,000. In December&#160;2023, the Company made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the former President and Chief Executive Officer resigned.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s research and development expenses were $1.0&#160;million for the year ended December&#160;31, 2023 as compared to $4.7&#160;million for 2022, a decrease of $3.7&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D personnel costs decreased approximately $1.2&#160;million for the year ended December&#160;31, 2023, as compared to the corresponding periods of 2022, due to one<span class="nobreak">-time</span> termination benefits incurred in 2022 and decreased headcount from the July&#160;2022 personnel reduction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Clinical expense decreased approximately $1.0&#160;million for the year ended December&#160;31, 2023, as compared to the corresponding period of 2022. Manufacturing process development costs decreased approximately $1.1&#160;million for the year ended December&#160;31, 2023, as compared to the corresponding period of 2022.&#160;The majority of clinical and manufacturing close out costs related to ARCA&#8217;s rNAPc2 (AB201) international Phase&#160;2b clinical trial were incurred in the first half of 2022, with no comparable costs for the corresponding periods of 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">R&amp;D expense in 2024 is expected to be lower than 2023, as ARCA completed its rNAPc2 (AB201) international Phase&#160;2b clinical trial. Should ARCA resume clinical trials of product candidates, it expects research and development costs to increase significantly for the foreseeable future as ARCA&#8217;s product candidate development programs progress.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Interest and Other Income</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Interest and other income was $473,000 and $450,000 in the three&#160;months ended March&#160;31, 2024 and 2023, respectively. Interest income was higher due to higher interest rates in 2024 compared to the corresponding periods of 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Interest and other income was $2.0&#160;million of interest income for the year ended December&#160;31, 2023 as compared to $0.7&#160;million for 2022, resulting in an increase of $1.3&#160;million. Interest income was higher due to higher interest rates in 2023 compared to the corresponding periods of 2022. ARCA expects interest income in 2024 to be lower than 2023, as ARCA continues to use its cash and cash equivalents to fund operations, assuming interest rates remain consistent with 2023.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Other Expense</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There was no other expense for the year ended December&#160;31, 2023. Other expense was $5,000 for the year ended December&#160;31, 2022. The amounts were nominal to ARCA&#8217;s overall operations. Based on ARCA&#8217;s current capital structure, other expense is expected to be negligible in 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Capital Resources</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Cash and Cash Equivalents as of March&#160;31, 2024 and 2023</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,903</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37,431</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, ARCA had total cash and cash equivalents of $35.9&#160;million, as compared to $37.4&#160;million as of December&#160;31, 2023. The net decrease of $1.5&#160;million primarily reflects the cash used in operating activities during the three&#160;months ended March&#160;31, 2024.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Cash and Cash Equivalents as of December&#160;31, 2023 and 2022</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37,431</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">42,445</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">256</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, ARCA had total cash and cash equivalents of approximately $37.4&#160;million, as compared to $42.4&#160;million as of December&#160;31, 2022. The net decrease of $5.0&#160;million during the year primarily reflects cash used in operating activities during the year ended December&#160;31, 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Flows from Operating, Investing and Financing Activities</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Three&#160;Months Ended March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,528</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,595</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Investing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net decrease in cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,528</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,595</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Net cash used in operating activities for the three&#160;months ended March&#160;31, 2024 was consistent with the same period in 2023. This was primarily due to lower outflows related to changes in operating assets and liabilities and a higher net loss in 2024, as discussed in Results of Operations above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were no investing activities in the three&#160;months ended March&#160;31, 2024 and 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">There were no financing activities in the three&#160;months ended March&#160;31, 2024 and 2023.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Years Ended December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:none;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by (used in):</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-style:none;border-top-color:#000000;border-top-style:none;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,014</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(10,912</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Investing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net increase in cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,014</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(10,914</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-style:none;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">Net cash used in operating activities for the year ended December&#160;31, 2023 decreased approximately $5.9&#160;million compared with 2022. This was primarily due to lower outflows related to changes in operating assets and liabilities and a lower net loss in 2022, as discussed in Results of Operations above.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were no investing activities in the year ended December&#160;31, 2023. Net cash used in investing activities for the year ended December&#160;31, 2022 was $2,000 for the purchase of property and equipment.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were no financing activities in the&#160;years ended December&#160;31, 2023 or 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Sources and Uses of Capital</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s primary sources of liquidity to date have been capital raised from issuances of shares of its preferred and common stock. The primary uses of ARCA&#8217;s capital resources to date have been to fund operating activities, including research, clinical development and drug manufacturing expenses, license payments, and spending on capital items.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, ARCA entered into a new sales agreement with a placement agent to sell, from time to time, in an &#8220;at the market offering.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA amended the new sales agreement and the amount available for the offering under its prospectus to its registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated such sales agreement in accordance with its terms. No sales were made under this sales agreement in 2024 or 2023.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">257</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s ability to execute its development programs in accordance with ARCA&#8217;s projected timeline depends on a number of factors, including, but not limited to, the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2 or any other product candidate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes its cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund operations through the middle of fiscal year 2025. ARCA&#8217;s future viability beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger Agreement</span>&#8221; in this proxy statement/prospectus. Should ARCA pursue additional clinical trials for its product candidates, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction. The Merger Agreement discussed above may impact this projection. Conducting a Phase&#160;3 PRECISION<span class="nobreak">-AF</span> trial would likely require additional financing, subject to ARCA&#8217;s pursuit of a potential strategic transaction and the consummation of such potential transaction. However, changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than ARCA currently anticipates; therefore, ARCA may have to raise additional capital for other clinical trials. Initiating any Phase&#160;3 clinical trial of Gencaro will require additional financing. If ARCA resumes the development of product candidates, ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development and potential commercialization Gencaro or to otherwise continue operations and may not be able to execute any strategic transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, ARCA established a Special Committee of ARCA&#8217;s board of directors to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Contractual Obligations and Commitments</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s board of directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">258</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain ARCA restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. On April&#160;20, 2024, ARCA&#8217;s board of directors approved the second amendment of certain retention bonus letters between ARCA and each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker to increase the aggregate amount of the retention bonus with respect to each such executive to $200,000. The remaining portion of the retention bonus with respect to Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker, consisting of $165,000, will become payable consistent with the original terms of the applicable retention bonus letter and first amendment to retention bonus letter. Any payment related to the retention bonuses of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker will be paid by ARCA via payroll within 30&#160;business days of the date of occurrence of the applicable &#8220;Payment Event Date&#8221; (as such term is otherwise defined in the applicable second amendment to the retention bonus letter). Each such retention bonus letter and first amendment to retention bonus letter will otherwise remain subject to their original terms and conditions.&#160;As of March&#160;31, 2024, the unpaid retention bonuses totaled $311,000, none of which was accrued as of March&#160;31, 2024, since there had not been a change in control or clinical development decision. In April&#160;2024, the retention bonuses were again amended to increase the aggregate amount of the retention bonus, with the unpaid retention bonus increasing to $444,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020, ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as ARCA&#8217;s primary business office effective October&#160;1, 2020 (the &#8220;October&#160;2020 Lease&#8221;). The lease term was 42&#160;months beginning October&#160;1, 2020. In March&#160;2024, ARCA entered into an amendment to extend the lease term six (6)&#160;months through September&#160;2024. If ARCA elects to stay in the property after September&#160;2024, it will pay rent month to month equal to 125% of the base rent paid in September&#160;2024. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in ARCA&#8217;s primary business office. The sublease term was 29&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation. Rent expense, which is included in general and administrative expense, for the three&#160;months ended March&#160;31, 2024 and 2023 was $22,000 and $31,000, respectively. As of March&#160;31, 2024, the lease liability was $48,000.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has licensed worldwide rights to all preclinical and clinical data through the BEST trial for development of bucindolol. The patents that were the subject of this license are expired. If the license agreement is deemed enforceable, ARCA would incur milestone and royalty obligations upon the occurrence of certain events, including if the FDA grants marketing approval for Gencaro, upon regulatory marketing approval in Europe and Japan and based on achievement of specified product sales levels.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Critical Accounting Policies and Estimates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A critical accounting policy is one that is both important to the portrayal of ARCA&#8217;s financial condition and results of operation and requires management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. While ARCA&#8217;s significant accounting policies are described in Note&#160;1 of ARCA&#8217;s consolidated financial statements and notes thereto appearing elsewhere in this proxy statement/prospectus, ARCA believes the following critical accounting policy affected its most significant judgments, assumptions, and estimates used in the preparation of ARCA&#8217;s financial statements and, therefore, is important in understanding ARCA&#8217;s financial condition and results of operations. ARCA had no significant outsourcing expense activity in 2023 or 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing ARCA&#8217;s financial statements, ARCA may be required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">259</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Indemnifications</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the ordinary course of business, ARCA enters into contractual arrangements under which it may agree to indemnify certain parties from any losses incurred relating to the services they perform on ARCA&#8217;s behalf or for losses arising from certain events as defined within the particular contract. Such indemnification obligations may not be subject to maximum loss clauses. ARCA has entered into indemnity agreements with each of ARCA&#8217;s directors, officers and certain employees. Such indemnity agreements contain provisions, which are in some respects broader than the specific indemnification provisions contained in Delaware law. ARCA also maintains an insurance policy for its directors and executive officers insuring against certain liabilities arising in their capacities as such.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">260</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T11"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA&#8217;S MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">You should read the following discussion and analysis of Oruka&#8217;s financial condition and results of operations together with the sectioned titled &#8220;Oruka&#8217;s Business&#8221; and Oruka&#8217;s financial statements and the related notes appearing elsewhere in this proxy statement/prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this proxy statement/prospectus, including information with respect to Oruka&#8217;s plans and strategy for its business and related financing, includes forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements that involve risks, uncertainties, and assumptions. As a result of many factors, including those factors set forth in the section titled &#8220;Risk Factors&#160;&#8212;&#160;Risks Related to Oruka,&#8221; Oruka&#8217;s actual results could differ materially from the results described in or implied by these forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements. You should carefully read the section titled &#8220;Risk Factors&#160;&#8212;&#160;Risks Related to Oruka&#8221; to gain an understanding of the factors that could cause actual results to differ materially from Oruka&#8217;s forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> statements. Please also see the section titled &#8220;Cautionary Note&#160;Regarding Forward</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Looking</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Statements.&#8221;</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Overview</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is a biotechnology company focused on developing novel monoclonal antibody therapeutics for psoriasis and other&#160;I&amp;I indications. Oruka&#8217;s name is derived from <span class="Italic" style="font-style:italic;font-weight:normal;">or</span>, for &#8220;skin,&#8221; and <span class="Italic" style="font-style:italic;font-weight:normal;">arukah</span>, for &#8220;restoration&#8221;&#8212;&#160;reflects Oruka&#8217;s mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition. Oruka&#8217;s strategy is to apply antibody engineering and format innovations to validated modes of action, which Oruka believes will enable it to improve meaningfully upon the efficacy and dosing regimens of standard<span class="nobreak">-of-care</span> medicines while significantly intending to reduce technical and biological risk. Oruka&#8217;s programs aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety involved in disease pathology and the activity of pathogenic tissue<span class="nobreak">-resident</span> memory T cells. Oruka&#8217;s lead program, ORKA<span class="nobreak">-001</span>, is designed to target the p19 subunit of interleukin<span class="nobreak">-23</span> (&#8220;IL<span class="nobreak">-23p19</span>&#8221;) for the treatment of psoriasis. Oruka&#8217;s co<span class="nobreak">-lead</span> program, ORKA<span class="nobreak">-002</span>, is designed to target interleukin<span class="nobreak">-17A</span> and interleukin<span class="nobreak">-17F</span> (&#8220;IL<span class="nobreak">-17A</span>/F&#8221;) for the treatment of PsO, PsA, and other conditions. These programs each bind their respective targets at high affinity and incorporate half<span class="nobreak">-life</span> extension technology with the aim to increase exposure and decrease dosing frequency. Oruka believes that its focused strategy, differentiated portfolio, and deep expertise position it to set a new treatment standard in large&#160;I&amp;I markets with continued unmet need.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka Therapeutics, Inc. was established and incorporated under the laws of the state of Delaware on February&#160;6, 2024. Oruka Therapeutics, Inc. was founded by Paragon and has since assembled a management team with significant experience in clinical development.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-001</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target IL<span class="nobreak">-23p19</span>. IL<span class="nobreak">-23</span> is a pro<span class="nobreak">-inflammatory</span> cytokine that plays a critical role in the proliferation and development of Th17 cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO.&#160;IL<span class="nobreak">-23</span> is composed of two subunits: a p40 subunit that is shared with IL<span class="nobreak">-12</span> and a p19 subunit that is specific to IL<span class="nobreak">-23</span>. First<span class="nobreak">-generation</span> IL<span class="nobreak">-23</span> antibodies bound p40 and inhibited both IL<span class="nobreak">-12</span> and IL<span class="nobreak">-23</span> signaling, while more recent IL<span class="nobreak">-23</span> antibodies targeting the p19 subunit have shown improved efficacy and safety when applied by other companies. Based on preclinical evidence, Oruka believes that ORKA<span class="nobreak">-001</span> could achieve higher response rates than established therapies in PsO while requiring less frequent dosing and maintaining the favorable safety profile of therapies targeting IL<span class="nobreak">-23p19</span>. ORKA<span class="nobreak">-001</span> is engineered with YTE half<span class="nobreak">-life</span> extension technology, a specific three amino acid change in the Fc domain to modify the pH<span class="nobreak">-dependent</span> binding to the neonatal FcRn. As a result, it has a pharmacokinetic profile designed to support an SQ injection as infrequently as once or twice a year. In addition, emerging evidence suggests that IL<span class="nobreak">-23</span> blockade can modify the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;Oruka believes that the expected characteristics of ORKA<span class="nobreak">-001</span> increase its potential to deliver these disease<span class="nobreak">-modifying</span> benefits. Oruka plans to initiate a Phase&#160;1 trial of ORKA<span class="nobreak">-001</span> in the first half of 2025 that will have the potential to not only generate important pharmacokinetic and safety data but also to demonstrate its efficacy in PsO patients.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ORKA<span class="nobreak">-002</span> is a high affinity, extended half<span class="nobreak">-life</span> mAb designed to target IL<span class="nobreak">-17A</span>/F.&#160;IL<span class="nobreak">-17</span> inhibition has become central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in other&#160;I&amp;I indications, such as HS and axSpA.&#160;More recently, the importance of inhibiting the IL<span class="nobreak">-17F</span> isoform along with IL<span class="nobreak">-17A</span> has become appreciated, and dual blockade with the recently approved therapy Bimzelx (bimekizumab) has </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">261</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">led to higher response rates in patients than blockade of IL<span class="nobreak">-17A</span> alone. ORKA<span class="nobreak">-002</span> is designed to bind IL<span class="nobreak">-17A</span>/F at similar epitopes, or binding sites, and affinity ranges as bimekizumab, but incorporates half<span class="nobreak">-life</span> extension technology that could enable more convenient dosing intervals. Oruka plans to initiate Phase&#160;1 trials of ORKA<span class="nobreak">-002</span> in the second half of 2025.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka views ORKA<span class="nobreak">-002</span> and ORKA<span class="nobreak">-001</span> as highly complementary. Patients with moderate<span class="nobreak">-to-severe</span> PsO that have purely skin manifestations are most often treated with IL<span class="nobreak">-23</span> inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have joint involvement, or signs and symptoms of PsA, an IL<span class="nobreak">-17</span> inhibitor is typically used due to its efficacy in addressing both skin and joint symptoms. In addition, IL<span class="nobreak">-17</span> inhibitors are often used in patients with highly resistant skin symptoms that do not adequately resolve through treatment with an IL<span class="nobreak">-23</span> inhibitor. Together, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span> provide the potential to offer a highly compelling product profile for most patients with PsO and/or PsA, as well as the opportunity to address additional&#160;I&amp;I indications.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has a third mAb program, ORKA<span class="nobreak">-003</span>, designed to target an undisclosed pathway. Oruka&#8217;s strategy as a company is to remain highly focused on&#160;I&amp;I diseases, and specifically on inflammatory dermatology conditions. Oruka&#8217;s third program provides the potential for indication expansion beyond PsO and creates combination opportunities with Oruka&#8217;s more advanced programs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since Oruka&#8217;s inception in February&#160;2024, it has devoted substantially all of its resources to raising capital, organizing and staffing the company, business and scientific planning, conducting discovery and research activities, establishing arrangements with third parties for the manufacture of Oruka&#8217;s programs and component materials, and providing general and administrative support for these operations. Oruka does not have any programs approved for sale and have not generated any revenue from product sales. To date, Oruka has funded its operations primarily with proceeds from the issuance of its Series&#160;A convertible preferred stock and the issuance of the Convertible Note, both of which were related party transactions. Through March&#160;31, 2024, Oruka received gross proceeds of $3.0&#160;million from the issuance of its Series&#160;A convertible preferred stock and gross proceeds of $25.0&#160;million from the issuance of the Convertible Note. Under the Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) pursuant to which the Convertible Note was sold, Oruka can sell up to an additional $30.0&#160;million in convertible notes. Oruka intends to sell an additional $30.0&#160;million in convertible notes but there is currently no expectation as to when that will occur.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has incurred operating losses since inception. Oruka&#8217;s ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of any programs Oruka may develop. Oruka generated net losses of $7.1&#160;million for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024. As of March&#160;31, 2024, Oruka had an accumulated deficit of $7.1&#160;million. Oruka expects to continue to incur significantly increased expenses for the foreseeable future if and as it:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>continues its research and development and discovery<span class="nobreak">-related</span> development of its programs, ORKA<span class="nobreak">-001</span>, ORKA<span class="nobreak">-002</span>, and ORKA<span class="nobreak">-003</span>;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>submits for and receives allowance to proceed with its investigational new drug applications, or INDs, for certain of its programs in order to commence future clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>successfully completes future preclinical studies for its pipeline;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks and identifies additional research programs and product candidates and initiates discovery<span class="nobreak">-related</span> activities and preclinical studies for those programs;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>hires additional research and development and clinical personnel;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>experiences any delays, challenges, or other issues associated with the pre<span class="nobreak">-clinical</span> and clinical development of its programs, including with respect to its regulatory strategies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks marketing approvals for any programs for which it successfully completes clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>develops, maintains and enhances a sustainable, scalable, reproducible and transferable manufacturing process for the programs it may develop;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ultimately establishes a sales, marketing and distribution infrastructure to commercialize any programs for which it may obtain marketing approval;</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">262</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>adds operational, financial and management information systems and personnel, including personnel to support its product development;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks timely and successful completion of preclinical studies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursues effective investigational new drug applications or comparable foreign applications that allow commencement of its planned clinical trials or future clinical trials for any programs it may develop;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>initiates enrollment and successful completion of clinical trials;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>pursues positive results from its future clinical trials that support a finding of safety and effectiveness, and an acceptable risk<span class="nobreak">-benefit</span> profile in the intended populations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks marketing approvals from applicable regulatory authorities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>maintains, expands, enforces, defends and protects its intellectual property portfolio and other intellectual property protection or regulatory exclusivity for any products it may develop;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>seeks maintenance of a continued acceptable safety, tolerability and efficacy profile of any programs it may develop following approval;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>further acquires or in<span class="nobreak">-licenses</span> product candidates or programs, intellectual property and technologies;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>establishes and maintains any future collaborations, including making royalty, milestone or other payments thereunder;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>maintains a continued acceptable safety profile of its products following approval; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>incurs additional costs of operating as a public company, including audit, legal, regulatory and tax related services associated with maintaining compliance with an exchange listing and SEC requirements, director and officer insurance premium and investor relation cost.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Any changes in the outcome of any of these variables with respect to the development of programs that Oruka may identify could mean a significant change in the costs and timing associated with the development of such programs. For example, if the FDA or another regulatory authority were to require Oruka to conduct clinical trials beyond those that Oruka currently anticipates will be required for the completion of clinical development of a program, or if Oruka&#8217;s experiences significant delays in its clinical trials due to patient enrollment or other reasons, Oruka would be required to expend significant additional financial resources and time on the completion of clinical development. Oruka may never obtain regulatory approval for any of its programs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka will not generate revenue from product sales unless and until it successfully initiate and complete clinical development and obtain regulatory approval for any product candidates. If Oruka obtains regulatory approval for any of its programs and do not enter into a commercialization partnership, Oruka expects to incur significant expenses related to developing Oruka&#8217;s commercialization capability to support product sales, manufacturing, marketing, and distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a result, Oruka will need substantial additional funding to support its continued operations and growth strategy. Until such a time as Oruka can generate significant revenue from product sales, if ever, it expects to finance its operations through the sale of equity, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. Oruka may be unable to raise additional funds or enter into such other agreements on favorable terms, or at all. If Oruka fails to raise capital or enter into such agreements as, and when, needed, Oruka may have to significantly delay, scale back or discontinue the development and commercialization of one or more of Oruka&#8217;s programs.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because of the numerous risks associated with product development, Oruka is unable to accurately predict the timing or amount of increased expenses or when or if Oruka will be able to achieve or maintain profitability. Even if Oruka is able to generate product sales, it may not become profitable. If Oruka fails to become profitable or are unable to sustain profitability on a continuing basis, then Oruka may be unable to continue Oruka&#8217;s operations at planned levels and be forced to reduce or terminate its operations.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">263</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that the expected net proceeds from the Merger and the Oruka pre<span class="nobreak">-closing</span> financing, together with Oruka&#8217;s existing cash and sales of additional convertible notes under the Purchase Agreement, will enable Oruka to fund its operating expenses through 2027. Oruka has based this estimate on assumptions that may prove to be wrong, and Oruka could exhaust its available capital resources sooner than Oruka expects. See &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">&#8212;&#160;Liquidity and Capital Resources</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors&#160;&#8212;&#160;Risks Related to Oruka&#8217;s Financial Condition and Capital Requirements</span>.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Without giving effect to any proceeds from this Merger and the Oruka pre<span class="nobreak">-closing</span> financing, as well as any proceeds from additional borrowings under the Convertible Note, as of March&#160;31, 2024, Oruka expects that its existing cash will be sufficient to fund its operating expenses through the end of second quarter of 2024. Beyond that point, Oruka will need to raise additional capital to finance its operations, which cannot be assured. As disclosed in Oruka&#8217;s financial statements for the period February&#160;6, 2024 (inception) to March&#160;31, 2024, Oruka concluded that there is substantial doubt about its ability to continue as a going concern within one year of the date those financial statements are available to be issued. See Note&#160;1 to Oruka&#8217;s financial statements appearing at the end of this proxy statement/prospectus for additional information on its assessment.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Impact of Risk Factors on Oruka&#8217;s Operations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Uncertainty in the global economy presents significant risks to Oruka&#8217;s business. Oruka is subject to continuing risks and uncertainties in connection with the current macroeconomic environment, including increases in inflation, rising interest rates, recent bank failures, geopolitical factors, including the ongoing conflicts between Russia and Ukraine and Israel and Gaza and the responses thereto, and supply chain disruptions. While Oruka is closely monitoring the impact of the current macroeconomic conditions on all aspects of Oruka&#8217;s business, including the impacts on its participants in future clinical trials, employees, suppliers, vendors and business partners, the ultimate extent of the impact on its business remains highly uncertain and will depend on future developments and factors that continue to evolve. Most of these developments and factors are outside Oruka&#8217;s control and could exist for an extended period of time. Oruka will continue to evaluate the nature and extent of the potential impacts to Oruka&#8217;s business, results of operations, liquidity and capital resources. For additional information, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Risk Factors&#160;&#8212;&#160;Risks Related to Oruka</span>.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Components of Results of Operations</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Revenue</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To date, Oruka has not generated revenue from any sources, including product sales, and do not expect to generate any revenue from the sale of products in the foreseeable future. If Oruka&#8217;s development efforts for its product candidates are successful and result in regulatory approval, Oruka may generate revenue in the future from product sales or payments from future collaboration or license agreements that Oruka may enter into with third parties, or any combination thereof. Oruka cannot predict if, when, or to what extent it will generate revenue from the commercialization and sale of its product candidates. Oruka may never succeed in obtaining regulatory approval for any of its product candidates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Expenses</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Research and Development</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development expenses consist primarily of costs incurred in connection with the development and research of Oruka&#8217;s programs. These expenses include costs of funding research performed by third parties, including Paragon, that conduct research and development activities on Oruka&#8217;s behalf, expenses incurred in connection with continuing Oruka&#8217;s current research programs and discovery<span class="nobreak">-phase</span> development of any programs Oruka may identify, including under future agreements with third parties, such as consultants and contractors, and personnel related expenses, including salaries, bonuses, benefits, and equity<span class="nobreak">-based</span> compensation expense.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expenses research and development costs as incurred. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 Oruka recognized $5.0&#160;million of expenses, in connection with services provided by Paragon and Paruka under the Option Agreements, including nonrefundable research and development expense fees associated with each Research Plan on its condensed statement of operations and comprehensive loss. See &#8220;&#8212;<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;Contractual Obligations and Commitments</span>&#8221; below for further details on Oruka&#8217;s research plans.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">264</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s primary focus since inception has been the identification and development of its pipeline programs. Oruka&#8217;s research and development expenses primarily consist of external costs, such as fees paid to Paragon under the Paragon Option Agreements. Oruka separately tracks the amount of costs incurred under the Paragon Option Agreements with Paragon between ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. See &#8220;&#8212;&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">Contractual Obligations and Commitments</span>&#8221; below for further details on the Paragon Option Agreements.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">General and Administrative</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative expenses consist primarily of personnel related expenses, including salaries, bonuses, benefits, and equity<span class="nobreak">-based</span> compensation, for individuals in Oruka&#8217;s executive, finance, operations, human resources, business development and other administrative functions. Other significant general and administrative expenses include legal fees relating to corporate matters, professional fees for accounting, auditing, tax, information technology, insurance, and recruiting costs. Oruka currently operates as a virtual company. Therefore, Oruka does not incur material operating expenses for the rent, maintenance and insurance of facilities or for depreciation of fixed assets. In April&#160;2024, Oruka entered into a lease agreement with Oak Grove LP (&#8220;Oak Grove Lease&#8221;) for office space located in Menlo Park, California. The Oak Grove Lease begins on June&#160;15, 2024 with an initial term of 39.5&#160;months. Oruka&#8217;s lease payment is expected to be $1.4&#160;million over the initial lease term.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expects that its general and administrative expenses will increase substantially for the foreseeable future as Oruka increases its headcount to support the expected growth. Oruka also expects to incur increased expenses associated with a reverse merger public transaction and becoming a public company, including increased costs of accounting, audit, legal, regulatory and tax related services associated with maintaining compliance with SEC requirements, additional director and officer insurance costs, and investor and public relations costs. Oruka also expects to incur additional intellectual property<span class="nobreak">-related</span> expenses as Oruka files patent applications to protect innovations arising from its research and development activities.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Other Expense</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Interest expense of $0.2&#160;million incurred for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 relates to the Convertible Note issued to Fairmount Fund&#160;II in March&#160;2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No provision for income taxes was recorded for the period of February&#160;6, 2024 (inception) through March&#160;31, 2024. Deferred tax assets generated from Oruka&#8217;s net operating losses have been fully reserved as Oruka believes it is not more likely than not that the benefit will be realized due to its cumulative losses generated to date.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Results of Operations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes Oruka&#8217;s statement of operations and comprehensive loss for the period presented (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period&#160;from <br/>February&#160;6, <br/>2024&#160;(Inception) <br/>to&#160;March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,193</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,670</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Loss from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Net loss and comprehensive loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $5,051 (see Note&#160;12 to Oruka&#8217;s unaudited condensed financial statements for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024)</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">265</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $848 (see Note&#160;12 to Oruka&#8217;s unaudited condensed financial statements for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024)</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $214 (see Note&#160;12 to Oruka&#8217;s unaudited condensed financial statements for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024)</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes Oruka&#8217;s research and development expenses incurred for the period presented (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period&#160;from <br/>February&#160;6, <br/>2024&#160;(Inception) <br/>to&#160;March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">External research and development costs by selected target:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:20pt;">ORKA-002<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,155</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:20pt;">ORKA-001<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">750</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Other research and development costs:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Personnel-related (including stock-based compensation)<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">264</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:20pt;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:30pt;">Total research and development expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,193</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $4,155 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $750 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $146 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development expenses were $5.2&#160;million for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 and consisted primarily of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$4.2&#160;million of research and development expense due to Paragon for services rendered under the Paragon Option Agreement for ORKA<span class="nobreak">-002</span>;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.8&#160;million of research initiation fee expense due to Paragon related to the Paragon Option Agreement for ORKA<span class="nobreak">-001</span>; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.2&#160;million of personnel<span class="nobreak">-related</span> costs related to recruiting costs, salaries, benefits and other compensation<span class="nobreak">-related</span> costs, including stock<span class="nobreak">-based</span> compensation of less than $0.1&#160;million and $0.1&#160;million of personnel<span class="nobreak">-related</span> costs are amounts due to Paragon related to recruiting costs for hiring Oruka&#8217;s research and development team.</p>
		<p class="H3_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes Oruka&#8217;s total general and administrative expenses for the period presented (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period&#160;from <br/>February&#160;6, <br/>2024&#160;(Inception) <br/>to&#160;March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Personnel-related (including stock-based compensation)<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">781</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Professional and consulting fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">444</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:10pt;">Legal fees related to patent<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">256</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">189</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:20pt;">Total general and administrative expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,670</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $505 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $256 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes related party amount of $87 for the period February&#160;6, 2024 (Inception) to March&#160;31, 2024</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">266</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative expenses were $1.7&#160;million for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 and consisted primarily of the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.8&#160;million of personnel<span class="nobreak">-related</span> costs related to recruiting costs, salaries, benefits and other compensation<span class="nobreak">-related</span> costs, including stock<span class="nobreak">-based</span> compensation of less than $0.1&#160;million and $0.5&#160;million of personnel<span class="nobreak">-related</span> costs are amounts due to Paragon related to recruiting costs for hiring Oruka&#8217;s executive team, legal, and finance and accounting functions;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.4&#160;million of professional and consulting fees associated with increases in accounting, audit, and legal fees due to an increase in Oruka&#8217;s business activity and as Oruka began preparation to become a public company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.3&#160;million of legal fees due to Paragon associated with patent related activities;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.1&#160;million of investor and public relations costs and fees associated with company formation; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>$0.1&#160;million of costs due to Paragon related to company formation fees.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Liquidity and Capital Resources</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since Oruka&#8217;s inception, Oruka has incurred significant operating losses. Oruka expects to incur significant expenses and operating losses for the foreseeable future as Oruka commences the pre<span class="nobreak">-clinical</span> and clinical development of its programs and continue its early<span class="nobreak">-stage</span> research activities. Oruka has not yet commercialized any products and Oruka does not expect to generate revenue from sales of products for several&#160;years, if at all. To date, Oruka has funded its operations primarily with proceeds from the sale of its Series&#160;A convertible preferred stock and the issuance of the Convertible Note. In March&#160;2024, Oruka received $3.0&#160;million in gross proceeds from the issuance of Series&#160;A convertible preferred stock and $25.0&#160;million in gross proceeds from the issuance of the Convertible Note, both of which were related party transactions. As of March&#160;31, 2024, Oruka had cash of $27.7&#160;million.</p>
		<p class="H3_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Flows</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes Oruka&#8217;s cash flows for the period presented (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period&#160;from <br/>February&#160;6, <br/>2024&#160;(Inception) <br/>to&#160;March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(168</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,911</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net increase in cash</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Operating Activities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From February&#160;6, 2024 (inception) to March&#160;31, 2024, net cash used in operating activities was $0.2&#160;million and was primarily attributable to a net loss of $7.1&#160;million, offset by a $6.1&#160;million increase in related parties accounts payable and other current liabilities and a $0.8&#160;million increase in accrued expenses and other current liabilities. The increase in amounts due to related parties and accrued expenses and other current liabilities was primarily due to an increase in Oruka&#8217;s business activity, as well as vendor invoicing and payments.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Financing Activities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From February&#160;6, 2024 (inception) to March&#160;31, 2024, net cash provided by financing activities was $27.9&#160;million, consisting of $2.9&#160;million of net proceeds from the issuance of Oruka&#8217;s Series&#160;A convertible preferred&#160;stock and $25.0&#160;million of net proceeds from the issuance of the Convertible Note.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">267</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H3_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Funding Requirements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">To date, Oruka has not generated any revenue from product sales. Oruka has devoted substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if Oruka&#8217;s development efforts are successful, it is uncertain when, if ever, Oruka will realize significant revenue from product sales. If Oruka obtains regulatory approval for any of its product candidates and start to generate revenue, Oruka expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes its existing cash, together with the anticipated net proceeds from this Merger and the Oruka pre<span class="nobreak">-closing</span> financing, as well as issuances of additional convertible notes under the Purchase Agreement, will be sufficient to fund its operating expenses requirements through 2027. Oruka has based this estimate on assumptions that may prove to be wrong, and Oruka could exhaust its available capital resources sooner than Oruka expects. Oruka expects that it will require additional funding to advance its potential product candidates through development, regulatory approval and commercialization if any of its product candidates are approved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Until such time, if ever, as Oruka can generate substantial product revenue, Oruka expects to finance its cash needs through a combination of equity offerings and debt financings. To the extent that Oruka raises additional capital through the sale of equity or convertible debt securities, ownership interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include restrictive covenants that limit Oruka&#8217;s ability to take specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. If Oruka is unable to raise additional funds, it may be required to delay, reduce or eliminate some or all of its planned operations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Contractual Obligations and Commitments</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Paragon Option Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, Oruka entered into the Paragon Option Agreements. Under the terms of the Paragon Option Agreements, Paragon identifies, evaluates and develops antibodies directed against certain mutually agreed therapeutic targets of interest to Oruka. The Option Agreement includes two selected targets, IL<span class="nobreak">-23</span> (ORKA<span class="nobreak">-001</span>) and IL<span class="nobreak">-17A</span>/F (ORKA<span class="nobreak">-002</span>). Under each of the Paragon Option Agreements, Oruka has the exclusive option to, on a research program<span class="nobreak">-by-research</span> program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture and commercialize the antibodies and potential products directed to the selected targets. If Oruka exercises its options, Oruka will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0&#160;million under each respective agreement upon the achievement of certain regulatory milestones, as well tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale. From time to time, Oruka can choose to add additional targets to the collaboration by mutual agreement with Paragon.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the terms of the Paragon Option Agreements, the parties initiated certain Research Programs. Each Research Program is aimed at discovering, generating, identifying and/or characterizing antibodies directed to the respective target. For each Research Program, the parties established a Research Plan that sets forth the activities that will be conducted, and the associated research budget. Oruka and Paragon will agree on initial Research Plans that outline the services that will be performed commencing at inception of the arrangement related to IL<span class="nobreak">-17</span> and IL<span class="nobreak">-23</span>. Oruka&#8217;s exclusive option with respect to each Research Program is exercisable at Oruka&#8217;s sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following the delivery of the data package from Paragon related to the results of the Research Plan activities. There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreements.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">268</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Paragon Option Agreements, on a research program<span class="nobreak">-by-research</span> program basis following the finalization of the Research Plan for each respective research program, Oruka was required to pay Paragon a nonrefundable fee in cash of $0.8&#160;million related to the research initiation fee for ORKA<span class="nobreak">-001</span>. This amount was recognized as a research and development expense during the period from February&#160;6 (inception) to March&#160;31, 2024, and paid to Paragon in April&#160;2024. Oruka is also responsible for 50% of the development costs incurred prior to March&#160;31, 2024, provided that Oruka receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. Oruka&#8217;s share of development costs incurred prior to March&#160;31, 2024 is $5.9&#160;million. As of the date of issuance of Oruka&#8217;s condensed financial statements, Oruka has not received rights to a selected IL<span class="nobreak">-23</span> antibody and has not paid or accrued the $5.9&#160;million of development costs incurred prior to March&#160;31, 2024. Oruka will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka was also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon through December&#160;31, 2023 and certain other development costs incurred between January&#160;1, 2024 and March&#160;6, 2024. This amount was recognized as a research and development expense during the period from February 6 (inception) to March<span class="nobreak"> </span>31, 2024, and accounts payable as of March<span class="nobreak"> </span>31, 2024. Oruka paid $3.3&#160;million to Paragon in April&#160;2024. Oruka is also responsible for the development costs incurred from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period from February&#160;6 (inception) to March&#160;31, 2024. Oruka will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> Research Plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>. Oruka will be responsible for ORKA<span class="nobreak">-002</span> development costs incurred from and after March<span class="nobreak"> </span>31, 2024, through the completion of the IL<span class="nobreak">-17</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, the Paragon Option Agreements provide for an annual equity grant of warrants to purchase 1.00% of the then outstanding shares of Oruka common stock, on a fully diluted basis, on each of December&#160;31, 2024 and December&#160;31, 2025, during the term of the Paragon Option Agreements, at the fair market value determined by Oruka&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses in the accompanying statement of operations and comprehensive loss.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Note&#160;Payable with Related Party</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, Oruka entered into the Purchase Agreement with Fairmount Fund&#160;II, whereby Oruka issued a convertible note, with an initial principal amount of $25.0<span class="nobreak"> </span>million that can be converted into Series&#160;A Preferred Stock (or a Series&#160;of preferred shares that is identical in respect to the shares of preferred shares issued in its next equity financing) or shares of the Company&#8217;s common stock in exchange for aggregate proceeds of $25.0&#160;million. The Convertible Note accrues interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled to mature on December&#160;31, 2025 (the &#8220;Maturity Date&#8221;). Prepayment is not permitted without prior written consent of Fairmount Fund II. Pursuant to the Purchase Agreement, the Company has the right to sell and issue additional convertible notes up to an aggregate principal amount equal to $30.0<span class="nobreak"> </span>million, in addition to the $25.0<span class="nobreak"> </span>million of initial principal amount of the Convertible Note.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the proposed reverse recapitalization transaction, the Convertible Note will convert into a number of shares of common stock based on the aggregate principal amount, plus any unpaid accrued interest, divided by the conversion price, which is an amount to be determined based upon Oruka&#8217;s fully<span class="nobreak">-diluted</span> capitalization immediately prior to the reverse recapitalization transaction. In the event the proposed reverse recapitalization transaction or any other proposed corporate transactions do not close prior to Oruka&#8217;s next equity financing, the Convertible Note will convert into the series of issued convertible preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, the aggregate principal amount of outstanding borrowings under the Convertible Note was $25.0&#160;million and Oruka has the right to issue and sell up to an additional $30.0&#160;million in convertible notes under the Purchase Agreement.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">269</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s management&#8217;s discussion and analysis of its financial condition and results of operations is based on its financial statements, which have been prepared in accordance with U.S. GAAP.&#160;The preparation of these condensed financial statements requires Oruka to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues recognized and expenses incurred during the reporting periods. Oruka&#8217;s estimates are based on its historical experience and on various other factors that Oruka believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">While Oruka&#8217;s significant accounting policies are described in more detail in Note&#160;2 to its financial statement and condensed financial statements included elsewhere in this proxy statement/prospectus, Oruka believes the following accounting policies used in the preparation of its financial statements require the most significant judgments and estimates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Research and Development Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing Oruka&#8217;s financial statements, Oruka is required to estimate its accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for the services when Oruka has not yet been invoiced or otherwise notified of actual costs. The majority of Oruka&#8217;s service providers invoice the company in arrears for services performed, on a pre<span class="nobreak">-determined</span> schedule or when contractual milestones are met; however, some require advance payments. Oruka makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to Oruka at that time. At each period end, Oruka corroborates the accuracy of these estimates with the service providers and make adjustments, if necessary. Estimated accrued research and development expenses include those related to fees paid to vendors in connection with discovery development activities and any research organizations in connection with studies and testing. Although Oruka does not expect its estimates to be materially different from amounts actually incurred, Oruka&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka measures stock<span class="nobreak">-based</span> awards granted to employees, directors, and non<span class="nobreak">-employees</span> in the form of stock options to purchase shares of Oruka common stock, based on their fair value on the date of the grant using the Black<span class="nobreak">-Scholes</span> model. Oruka measures restricted common stock awards using the difference, if any, between the purchase price per share of the award and the fair value of Oruka common stock at the date of grant. Compensation expense for those awards is recognized over the requisite service period, which is generally the vesting period of the respective award for employees. Compensation expense for awards to non<span class="nobreak">-employee</span> with service<span class="nobreak">-based</span> vesting conditions is recognized in the same manner as if Oruka had paid cash in exchange for the goods or services, which is generally the over the vesting period of the award. Oruka uses the straight<span class="nobreak">-line</span> method to recognize the expense of awards with service<span class="nobreak">-based</span> vesting conditions. Oruka accounts for forfeitures as they occur.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Black<span class="nobreak">-Scholes</span> model uses inputs that are determined by the Board on the date of grant and assumptions Oruka makes for the volatility of stock<span class="nobreak">-based</span> awards, the expected term of stock<span class="nobreak">-based</span> awards, the risk<span class="nobreak">-free</span> interest rate for a period that approximates the expected term of Oruka&#8217;s stock<span class="nobreak">-based</span> awards and its expected dividend yield. Oruka has historically been a private company and lack company<span class="nobreak">-specific</span> historical and implied volatility information of Oruka&#8217;s stock. Therefore, Oruka estimates its expected stock volatility based on the historical volatility of a representative group of public companies in the biotechnology industry for a term equal to the remaining time of the expected term. The expected term of Oruka&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain<span class="nobreak">-vanilla</span>&#8221; stock options. The risk<span class="nobreak">-free</span> interest rate is determined by reference to the U.S.&#160;Treasury yield curve for time periods approximately equal to the remaining contractual term of the options on the date of measurement. Oruka has estimated a 0% dividend yield based on the expected dividend yield and the fact that Oruka has never paid, and do not expect to pay, any cash dividends in the foreseeable future.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">270</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Determination of Fair Value of Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As there has been no public market for Oruka&#8217;s stock<span class="nobreak">-based</span> awards to date, the estimated fair value of stock<span class="nobreak">-based</span> awards has been determined by Oruka&#8217;s board of directors as of the date of grant, with input from management, and with consideration of additional objective and subjective factors that it believed were relevant. In addition, Oruka&#8217;s board of directors considered various objective and subjective factors to determine the fair value of its share<span class="nobreak">-based</span> awards as of each grant date, including:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the prices at which Oruka sold shares of Series&#160;A convertible preferred stock and preferences of the Series&#160;A convertible preferred stock relative to Oruka&#8217;s stock<span class="nobreak">-based</span> awards at the time of each grant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the progress of Oruka&#8217;s research and development programs, including the status of discovery<span class="nobreak">-phase</span> studies for its product candidates;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s stage of development and business strategy;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>external market conditions affecting the biotechnology industry and trends within the biotechnology industry;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s financial position, including cash on hand, and Oruka&#8217;s historical and forecasted performance and operating results;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the lack of an active public market for Oruka common stock and its Series&#160;A convertible preferred stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the likelihood of achieving a liquidity event, such as the proposed reverse recapitalization transaction, or sale of Oruka in light of prevailing market conditions; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the analysis of reverse recapitalization transactions and market performance of similar companies in the biotechnology industry.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s common stock valuations were prepared using a hybrid method, including an option pricing method (&#8220;OPM&#8221;). The OPM treats common stock and preferred stock as call options on the total equity value&#160;of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability<span class="nobreak">-weighted</span> expected return method (&#8220;PWERM&#8221;), where the equity value in one or more of the scenarios is calculated using an OPM.&#160;The PWERM is a scenario<span class="nobreak">-based</span> methodology that estimates the fair value of common stock based upon an analysis of future values for the company, assuming various outcomes. The common stock value is based on the probability<span class="nobreak">-weighted</span> present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk<span class="nobreak">-adjusted</span> discount rate and probability weighted to arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if Oruka had used significantly different assumptions or estimates, the fair value of Oruka&#8217;s incentive shares and its stock<span class="nobreak">-based</span> compensation expense could have been materially different.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Once a public trading market for Oruka common stock has been established in connection with the completion of this Merger, it will no longer be necessary for Oruka&#8217;s board of directors to estimate the fair value of its stock<span class="nobreak">-based</span> awards in connection with its accounting for granted stock<span class="nobreak">-based</span> awards or other such awards Oruka may grant, as the fair value of Oruka&#8217;s common stock and share<span class="nobreak">-based</span> awards will be determined based on the quoted market price of Oruka&#8217;s common stock.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Recently Issued Accounting Pronouncements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A description of recently issued accounting pronouncements that may potentially impact Oruka&#8217;s financial position, results of operations or cash flows is disclosed in Note&#160;2 to Oruka&#8217;s condensed financial statements as of March&#160;31, 2024 appearing at the end of this proxy statement/prospectus.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">271</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Off-Balance Sheet Arrangements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, Oruka did not have any off<span class="nobreak">-balance</span> sheet arrangements, as defined in the rules and regulations of the SEC.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Quantitative and Qualitative Disclosures about Market Risk</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Interest Rate Risk</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Convertible Note bears interest until December&#160;2025 at a fixed rate per annum equal 12%. An immediate 10% change in the prime rate would not have a material impact on Oruka&#8217;s debt<span class="nobreak">-related</span> obligations, financial position or results of operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Inflation Risk</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka&#8217;s results of operations and financial condition are presented based on historical cost. While it is difficult to accurately measure the impact of inflation due to the imprecise nature of the estimates required, Oruka believes the effects of inflation, if any, on Oruka&#8217;s results of operations and financial condition have been immaterial. Oruka cannot assure you its business will not be affected in the future by inflation.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">272</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T10"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">MANAGEMENT FOLLOWING THE MERGER</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Executive Officers and Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the completion of the Merger, the business and affairs of the combined company will be managed under the direction of the combined company&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The combined company&#8217;s board of directors will initially be fixed at six members, consisting of six current Oruka board members, namely Lawrence Klein, Kristine Ball, Carl Dambkowski, Peter Harwin, Samarth Kulkarni and Cameron Turtle. The staggered structure of the current ARCA board of directors will remain in place for the combined company following the completion of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each executive officer of the combined company will serve at the discretion of the combined company&#8217;s board of directors and holds office until his or her successor is duly elected and qualified or until his or her earlier resignation or removal. There are no family relationships among any of the proposed combined company&#8217;s directors or executive officers.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All of ARCA&#8217;s current directors are expected to resign from their positions as directors of ARCA, effective as of the closing of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth the name, age as of July<span class="nobreak"> </span>22, 2024 and position of each of the individuals who are expected to serve as executives and directors of the combined company following completion of the Merger:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Age</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Position</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Executive Officers</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lawrence Klein</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">42</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President, Chief Executive Officer and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">48</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Senior Vice President, Finance and Treasurer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">51</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Medical Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">61</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">General Counsel and Secretary</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-Employee Directors</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Samarth Kulkarni</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">45</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chair and Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Kristine Ball</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">52</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Carl Dambkowski</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">39</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Peter Harwin</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">38</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cameron Turtle</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 7.37%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">34</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 59.29%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Director</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Executive Officers</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Lawrence Klein, Ph.D.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Klein has served as Chief Executive Officer of Oruka and as a member of its board of directors since February&#160;2024. Prior to joining Oruka, Dr.&#160;Klein was a Partner at Versant Venture Management, LLC, a healthcare and biotechnology venture capital firm, from January&#160;2023 to February&#160;2024, where he invested in and helped to grow early<span class="nobreak">-stage</span> biotechnology companies. Prior to Versant, Dr.&#160;Klein served in various positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, including Chief Operating Officer from January&#160;2020 to October&#160;2022, Chief Business Officer from January&#160;2019 to January&#160;2020, Senior Vice President, Business Development and Strategy from November&#160;2017 to December&#160;2018 and as Vice President, Strategy from February&#160;2016 to November&#160;2017, where he helped to initiate and execute on several transformative partnerships, establish the strategic direction of the company, oversee important pipeline programs and led several functions, including program and portfolio management. Before joining CRISPR, Dr.&#160;Klein was an Associate Partner at McKinsey&#160;&amp; Company, a global management consulting firm, from October&#160;2014 to February&#160;2016. Dr.&#160;Klein served as a member of the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN) from September&#160;2019 to May&#160;2023 and of Jasper Therapeutics, Inc. (Nasdaq: JSPR) from September&#160;2021 to June&#160;2023. Dr.&#160;Klein received his B.S. in biochemistry and physics from the University of Wisconsin<span class="nobreak">-Madison</span> and his Ph.D. in biophysics from Stanford University.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Dr.&#160;Klein is qualified to serve as a member of the board of directors of the combined company because of his business development, operational and senior management experience in the biotechnology industry and his academic expertise and accomplishments.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">273</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Arjun Agarwal.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Mr.&#160;Agarwal has served as the Senior Vice President of Finance of Oruka since March&#160;2024, where he is responsible for overseeing the company&#8217;s finance and accounting functions. Prior to joining Oruka, Mr.&#160;Agarwal served as VP of Finance at Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company, from June&#160;2021 to March&#160;2024, including through multiple financings and the company&#8217;s successful transition to become a publicly traded entity. Before joining Jasper, Mr.&#160;Agarwal served as Vice President, Corporate Controller at Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a biotechnology company, from August&#160;2019 to June&#160;2021, where he was responsible for overseeing the company&#8217;s finance and accounting functions. Prior to joining Protagonist, Mr.&#160;Agarwal served in various roles of increasing responsibility at McKesson Corporation (NYSE:&#160;MCK),&#160;an international healthcare services company, from 2009 to 2019. Prior to McKesson, Mr.&#160;Agarwal worked at PricewaterhouseCoopers LLP, where he managed a portfolio of audit clients. He is a graduate of Sydenham College of Commerce and Economics at Mumbai University, India. He is a Certified Public Accountant (CPA) and a Chartered Accountant accredited by the Institute of Chartered Accountants of India.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Joana Goncalves, MBChB.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Goncalves has served as the Chief Medical Officer of Oruka since April&#160;2024. Prior to joining Oruka, Dr.&#160;Goncalves served as Chief Medical Officer of Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company, from October&#160;2018 to April&#160;2024, where she was responsible for representing Cara Therapeutics in interactions with regulatory agencies, the investor and scientific communities and the board of directors, building multifunctional terms and developing the clinical development strategy in dermatological conditions. Prior to Cara, Dr.&#160;Goncalves held various positions at Celgene Corporation, a pharmaceutical company, which was later acquired by Bristol<span class="nobreak">-Myers</span> Squibb Company, from April&#160;2014 to October&#160;2018, where she most recently served as Vice President, Medical Affairs for Dermatology and Neurology and was instrumental in planning and executing medical support activities for a number of programs, including OTEZLA&#174; for psoriasis. Prior to Celgene, Dr.&#160;Goncalves served as Vice President, Medical Strategy and Scientific Affairs at LEO Pharma Inc., the U.S.&#160;subsidiary of LEO Pharma A/S, a global healthcare company specializing in dermatology and critical care, from February&#160;2012 to April&#160;2014. She began her pharmaceutical career at Novartis Pharmaceuticals, working on a range of products across various therapeutic areas from 2001 to 2012. Dr.&#160;Goncalves received her MBChB from the University of Cape Town, South Africa.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Paul Quinlan.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Mr.&#160;Quinlan has served as General Counsel of Oruka since April&#160;2024. Prior to joining Oruka, Mr.&#160;Quinlan served as General Counsel, Chief Compliance Officer and Corporate Secretary of CymaBay Therapeutics, Inc., a biopharmaceutical company, from October&#160;2020 to March&#160;2024, where he was responsible for the general supervision of the company&#8217;s legal affairs. From December&#160;2017 to February&#160;2020, he served as General Counsel and Corporate Secretary of CymaBay, where he was responsible for the general supervision of the company&#8217;s legal affairs. Prior to CymaBay, Mr.&#160;Quinlan served as General Counsel and Secretary, from 2010 to January&#160;2018, and Chief Legal Officer from 2016 to January&#160;2018, of TerraVia Holdings, Inc., a biotechnology company, where he was responsible for the general supervision of the company&#8217;s legal affairs. Prior to joining TerraVia, Mr.&#160;Quinlan served as General Counsel of Metabolex, Inc., a biopharmaceutical company, from 2005 to 2010. Prior to joining Metabolex, Mr.&#160;Quinlan held various positions at Maxygen, Inc., a biopharmaceutical company, from 2000 to 2005. Prior to Maxygen, Mr.&#160;Quinlan practiced law at Cooley LLP and Cravath, Swaine,&#160;&amp; Moore LLP.&#160;Mr.&#160;Quinlan received a law degree from Columbia Law School and an M.Sc. in Medical Biophysics from the University of Toronto.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-Employee Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Kristine Ball.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Ms. Ball has served as a member of the board of directors of Oruka since May&#160;2024. Ms.&#160;Ball has served as President and Chief Executive Officer of Antiva Biosciences, Inc., a private biopharmaceutical company, since April&#160;2023. Prior to Antiva, Ms. Ball served as Chief Executive Officer of Soteria Biotherapeutics, Inc., a private biotechnology company, from September&#160;2020 to August&#160;2022. Prior to joining Soteria, Ms. Ball served as Senior Vice President, Corporate Strategy and Chief Financial Officer of Menlo Therapeutics, Inc., a Nasdaq<span class="nobreak">-listed</span> biopharmaceutical company, which later became VYNE Therapeutics Inc. (Nasdaq: VYNE), from September&#160;2017 to March&#160;2020, where she was responsible for leading all non<span class="nobreak">-R</span>&amp;D functions, including strategic planning, corporate development, commercial, human resources, legal, finance and information technology. Prior to joining Menlo, Ms. Ball served as Chief Financial Officer and Senior Vice President of Relypsa, Inc., a Nasdaq<span class="nobreak">-listed</span> pharmaceutical company, which was later acquired by Galenica Group, from November&#160;2012 to October&#160;2016. Prior to Relypsa, Ms. Ball held various other finance roles in the life sciences industry, including Senior Vice President of Finance&#160;&amp; Administration and Chief Financial Officer of KAI Pharmaceuticals, Inc., a </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">274</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">biopharmaceutical company, and Vice President of Finance at Exelixis, Inc. (Nasdaq: EXEL), a biotechnology company. Prior to that, Ms. Ball served as a senior manager in life sciences audit practice of Ernst&#160;&amp; Young LLP. Ms.&#160;Ball has previously served on the boards of directors of Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company, from 2020 to 2024, Soteria from 2020 to 2022 and Forty Seven, Inc., a Nasdaq<span class="nobreak">-listed</span> biotechnology company, which was later acquired by Gilead Sciences, Inc., from 2018 to 2020. Ms. Ball received a B.S. from Babson College.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Ms. Ball is qualified to serve as a member of the board of directors of the combined company because of her experience as an executive officer and director of life sciences companies and her background in finance, corporate development and strategic planning. </p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Carl Dambkowski, M.D.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Dambkowski has served as a member of the board of directors of Oruka since February&#160;2024. Dr.&#160;Dambkowski has served as the Chief Medical Officer of Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company, since September&#160;2022. Prior to joining Apogee, Dr.&#160;Dambkowski served as a strategic and clinical leader for a variety of companies, including as Chief Medical Officer of QED Therapeutics, Inc., a private biotechnology company, from July&#160;2021 to September&#160;2022; Chief Strategy Officer and EVP of Operations of Origin Biosciences, Inc., a private bioecology company, from March&#160;2018 to June&#160;2021; and Chief Medical Officer of Navire Pharma, Inc., a private biotechnology company, from January&#160;2020 to September&#160;2022, where he served as the clinical lead starting prior to IND for BBP<span class="nobreak">-398</span> through the out licensing of the compound to Bristol<span class="nobreak">-Myers</span> Squibb based on initial clinical data and for low<span class="nobreak">-dose</span> infigratinib in achondroplasia through initial proof<span class="nobreak">-of-concept</span> data. He was part of the core team that brought TRUSELTIQ<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> (infigratinib) and NULIBRY<span class="Superscript" style="vertical-align:super;font-size:58%;">&#174;</span> (fosdenopterin) through regulatory review and FDA approval at QED Therapeutics and Origin Biosciences, respectively. From July&#160;2016 to March&#160;2018, Dr.&#160;Dambkowski was an associate at McKinsey&#160;&amp; Company, a global management consulting firm, where he advised biotech and pharmaceutical companies across the world on a range of research and development activities. Dr.&#160;Dambkowski co<span class="nobreak">-founded</span> Novonate, Inc., a private medical device company focused on building life<span class="nobreak">-saving</span> devices for neonates, in January&#160;2015. Dr.&#160;Dambkowski has coauthored numerous peer<span class="nobreak">-reviewed</span> publications and scientific abstracts and is a named inventor on multiple published and granted patents. Dr.&#160;Dambkowski was trained as a physician at Stanford University, where he also received his M.D. with a concentration in bioengineering. He also received a B.A. (with honors) from Stanford University and an M.A. from Columbia University.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Dr.&#160;Dambkowski is qualified to serve as a member of the board of directors of the combined company because of his significant experience and innovations in the biotechnology industry and his academic expertise and accomplishments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Peter Harwin.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Mr.&#160;Harwin has served as a member of the board of directors of Oruka since February&#160;2024. Mr.&#160;Harwin is a Managing Member at Fairmount Funds Management, a healthcare investment firm he co<span class="nobreak">-founded</span> in April&#160;2016. Prior to Fairmount Funds Management, Mr.&#160;Harwin was a member of the investment team at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego. Mr.&#160;Harwin also serves as chairman of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT) and is a member of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), Viridian Therapeutics, Inc. (Nasdaq: VRDN) and Spyre Therapeutics, Inc. (Nasdaq: SYRE). Mr.&#160;Harwin received a B.B.A. from Emory University.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Mr.&#160;Harwin is qualified to serve as a member of the board of directors of the combined company because his experience serving as a director of biotechnology companies and as a manager of funds specializing in the area of life sciences.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Samarth Kulkarni, Ph.D.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Kulkarni has served as a member of the board of directors of Oruka since February&#160;2024. Dr.&#160;Kulkarni has served as the Chief Executive Officer of CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, since December&#160;2017, where he has also served as a member and chair of the board of directors since June&#160;2018 and September&#160;2023, respectively. Previously, Dr.&#160;Kulkarni served as CRISPR&#8217;s President and Chief Business Officer from May&#160;2017 to November&#160;2017 and as Chief Business Officer from August&#160;2015. Prior to joining CRISPR, Dr.&#160;Kulkarni was at McKinsey&#160;&amp; Company, a global management consulting firm, from 2006 to 2015, with various titles, his most recent being Partner within the Pharmaceuticals and Biotechnology practice. Dr.&#160;Kulkarni has also served as a member of the boards of directors of Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology company, since 2019, including as lead independent director since September&#160;2023, Repare Therapeutics Inc. (Nasdaq: RPTX), a precision oncology company, since November&#160;2019 and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a biotechnology company, </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">275</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">since February&#160;2021. Dr.&#160;Kulkarni received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B.&#160;Tech. from the Indian Institute of Technology. Dr.&#160;Kulkarni has authored several publications in leading scientific and business journals.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes that Dr.&#160;Kulkarni is qualified to serve as a member of the board of directors of the combined company because of his experience as a consultant and an executive in the biopharmaceutical industry and his academic expertise and accomplishments.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cameron Turtle, D.Phil.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Dr.&#160;Turtle has served as a member of the board of directors of Oruka since February&#160;2024. Dr.&#160;Turtle has served as Chief Executive Officer and a member of the board of directors of Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) (Nasdaq: SYRE), a biotechnology company, since November&#160;2023 and, before that, as Chief Operating Officer from June&#160;2023 to November&#160;2023. Prior to joining Spyre, Dr.&#160;Turtle was an advisor to Spyre Therapeutics, Inc., a private biotechnology company, from May&#160;2023 to June&#160;2023. Previously, he served as Venture Partner at Foresite Labs, a life sciences investment firm, from July&#160;2022 to May&#160;2023; Chief Strategy Officer of BridgeBio Pharma (Nasdaq: BBIO), a biotechnology company, from January&#160;2021 to April&#160;2022; and Chief Business Officer of Eidos Therapeutics (Nasdaq: EIDX), a biopharmaceutical company, from November&#160;2018 to January&#160;2021, where he led business development, investor relations, and multiple operational functions as the company advanced an investigational medicine for a form of heart failure. Prior to joining BridgeBio and Eidos, he was a consultant at McKinsey&#160;&amp; Company, a global management consulting firm, where he worked with pharmaceutical and medical device companies on topics including M&amp;A, growth strategy, clinical trial strategy, and sales force optimization. Dr.&#160;Turtle received his B.S. with honors in Bioengineering from the University of Washington and his D.Phil. in Cardiovascular Medicine from the University of Oxford, St. John&#8217;s College. He is the recipient of several awards, including a Rhodes Scholarship, Goldwater Scholarship, Forbes 30 Under<span class="nobreak"> </span>30, San Francisco Business Times 40 Under<span class="nobreak"> </span>40, and the Biocom Life Sciences Catalyst Award.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka believes Dr.&#160;Turtle is qualified to serve as a member of the board of directors of the combined company because of his experience as a leader in building, financing, and shaping biopharmaceutical organizations from preclinical development to late<span class="nobreak">-stage</span> clinical trials and commercialization.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Composition of the Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors currently consists of five members, divided into three staggered classes, with one class to be elected at each annual meeting to serve for a three<span class="nobreak">-year</span> term. The staggered structure of the board of directors will remain in place for the combined company following the completion of the Merger, with Class&#160;I directors holding terms expiring at the 2025 annual meeting of stockholders, Class&#160;II directors holding terms expiring at the 2026 annual meeting of stockholders and Class&#160;III directors holding terms expiring at the 2027 annual meeting of stockholders. It is anticipated that the incoming directors will be appointed to classes of the combined company board of directors following the completion of the Merger as follows: Carl Dambkowski and Peter Harwin are expected to be Class&#160;I directors; Cameron Turtle and Lawrence Klein are expected to be Class&#160;II directors; and Samarth Kulkarni and Kristine Ball are expected to be Class&#160;III directors.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Director Independence</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Nasdaq listing rules require a majority of a listed company&#8217;s board of directors to be comprised of independent directors who, in the opinion of the board of directors, do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Subject to specified exceptions, each member of a listed company&#8217;s audit, compensation and nominating committees must be independent, and audit and compensation committee members must satisfy additional independence criteria under the Exchange&#160;Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based on information provided by each proposed director concerning her or his background, employment and affiliations, ARCA and Oruka expect that the combined company&#8217;s board of directors will determine that each of the directors other than Lawrence Klein, Oruka&#8217;s current President and Chief Executive Officer, who is expected to serve as President and Chief Executive Officer of the combined company, will qualify as an &#8220;independent director&#8221; as defined under applicable Nasdaq listing rules. In making these determinations, the combined company&#8217;s board of directors will consider the current and prior relationships that each director has with ARCA and Oruka and all other facts and circumstances that the company&#8217;s board of directors deems relevant in determining the independence of each proposed director, including the interests of each combined company director in the Merger, any relevant </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">276</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">related party transactions and the beneficial ownership of securities of ARCA, Oruka or the combined company by each combined company director. See also the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">The Merger &#8212; Interests of Oruka&#8217;s Directors and Executive Officers in the Merger</span>,&#8221; &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Certain Relationships and Related Party Transactions of the Combined Company</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Stockholders of Oruka</span>&#8221; beginning on pages 124, 280 and 315, respectively, of this proxy statement/prospectus for additional information.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Board Leadership Structure</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, Dr.&#160;Kulkarni is expected to serve as Chair of the board of directors of the combined company. The combined company&#8217;s Principles of Corporate Governance will provide its board of directors with the flexibility to combine or separate the positions of Chair of the board of directors and Chief Executive Officer. Oruka believes that having these positions be separate is the appropriate leadership structure for the combined company at this time as it will help facilitate independent oversight of management by the board of directors of the combined company and allow the Chief Executive Officer to focus on strategy execution and managing the business while the Chair focuses on corporate governance and managing the combined company&#8217;s board of directors.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Committees of the Board of Directors</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, ARCA and Oruka anticipate that the board of directors of the combined company will establish an audit committee, a compensation committee and a nominating and corporate governance committee, each of which will operate pursuant to a charter adopted by the board of directors of the combined company. ARCA and Oruka believe that following the completion of the Merger the functioning and composition of these committees of the combined company will comply with the requirements of Nasdaq listing rules and SEC rules and regulations. The board of directors of the combined company may also establish other committees from time to time to assist the combined company and its board of directors. Each of the audit committee, compensation committee, nominating and corporate governance committee is expected to have the responsibilities described below.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Audit Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, the initial members of the combined company&#8217;s audit committee are expected to be Kristine Ball, Carl Dambkowski and Cameron Turtle, each of whom qualifies as an independent director for audit committee purposes, as defined under the rules of the SEC and the applicable Nasdaq listing rules and has sufficient knowledge in financial and auditing matters to serve on the combined company&#8217;s audit committee. Kristine Ball is expected to chair the audit committee. Kristine Ball is an &#8220;audit committee financial expert&#8221; as defined in Item&#160;407(d)(5)(ii)&#160;of Regulation&#160;S<span class="nobreak">-K</span> promulgated under the Securities Act.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The primary responsibilities of the combined company&#8217;s audit committee will be to oversee the combined company&#8217;s accounting and financial reporting processes, including the audits of the financial statements, and the internal and external audit processes. The audit committee will also oversee the system of internal controls established by management and the combined company&#8217;s compliance with legal and regulatory requirements. The audit committee will also be responsible for the review, consideration and approval or ratification of related party transactions. The audit committee will oversee the independent auditors, including their independence and objectivity. The audit committee will be empowered to retain outside legal counsel and other advisors as it deems necessary or appropriate to assist it in fulfilling its responsibilities and to approve the fees and other retention terms of the advisors.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Compensation Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, the initial members of the combined company&#8217;s compensation committee are expected to be Peter Harwin, Samarth Kulkarni and Cameron Turtle, each of whom qualifies as an independent director, as defined under applicable Nasdaq listing rules and also meets the additional, heightened independence criteria applicable to members of the compensation committee. Cameron Turtle is expected to chair the compensation committee.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">277</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:9pt;margin-top:9pt;">The primary responsibilities of the combined company&#8217;s compensation committee will be to periodically review and approve the compensation and other benefits for the combined company&#8217;s senior officers and directors. This will include reviewing and approving corporate goals and objectives relevant to the compensation of the combined company&#8217;s Chief Executive Officer and other executive officers, evaluating the performance of these officers in light of the goals and objectives and setting or recommending to the combined company&#8217;s board of directors the officers&#8217; compensation. The compensation committee will also administer and make recommendations to the combined company&#8217;s board of directors regarding equity incentive plans that are subject to the board of directors&#8217; approval and approve the grant of equity awards under the plans.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Nominating and Corporate Governance Committee</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, the initial members of the combined company&#8217;s nominating and corporate governance committee are expected to be Kristine Ball, Samarth Kulkarni and Peter Harwin, each of whom qualifies as an independent director, as defined under applicable Nasdaq listing rules. Peter Harwin is expected to chair the nominating and corporate governance committee.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:9pt;margin-top:9pt;">The combined company&#8217;s nominating and corporate governance committee will be responsible for engaging in succession planning for the combined company&#8217;s board of directors, developing and recommending to the combined company&#8217;s board of directors criteria for identifying and evaluating qualified director candidates and making recommendations to the combined company&#8217;s board of directors regarding candidates for election or reelection to the board of directors at each annual stockholders&#8217; meeting. In addition, the nominating and corporate governance committee will be responsible for overseeing the combined company&#8217;s corporate governance matters. The nominating and corporate governance committee will also be responsible for overseeing the structure, composition and functioning of the combined company&#8217;s board of directors and its committees.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Compensation Committee Interlocks and Insider Participation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:9pt;margin-top:9pt;">None of the expected members of the combined company&#8217;s compensation committee has at any time been one of the officers or employees of the combined company. None of the combined company&#8217;s expected executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers that is or are expected to serve on the combined company&#8217;s board of directors or compensation committee following the completion of the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Code of Conduct and Ethics</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the completion of the Merger, the combined company will adopt a Code of Conduct and Ethics that establishes the standards of ethical conduct applicable to all of the combined company&#8217;s directors, officers and employees. The full text of the combined company&#8217;s Code of Conduct and Ethics will be posted on the combined company&#8217;s website. The Code of Conduct and Ethics is expected to address, among other matters, compliance with laws and policies, conflicts of interest, corporate opportunities, regulatory reporting, external communications, confidentiality requirements, insider trading, proper use of assets and how to report compliance concerns. The combined company intends to disclose any amendments to the Code of Conduct and Ethics, or any waivers of its requirements, on its website to the extent required by applicable rules. The combined company&#8217;s audit committee will be responsible for applying and interpreting the Code of Conduct and Ethics in situations where questions are presented to it. Information contained on, or that can be accessed through, the combined company&#8217;s website is not incorporated by reference into this proxy statement/prospectus, and you should not consider information on the combined company&#8217;s website to be part of this proxy statement/prospectus.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">278</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Director Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Prior to the Merger, Oruka did not have a formal policy to provide any cash or equity compensation to its non<span class="nobreak">-employee</span> directors for their service on its board of directors or committees of its board of directors. Oruka&#8217;s non<span class="nobreak">-employee</span> director compensation is described under &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka Director Compensation</span>&#8221; in this proxy statement/prospectus. Except as described below, determinations with respect to director compensation after the closing of the Merger have not yet been made. In connection with closing of the Merger, it is expected that the board of directors of the combined company will adopt a non<span class="nobreak">-employee</span> director compensation policy designed to enable the combined company to attract and retain, on a long<span class="nobreak">-term</span> basis, highly qualified non<span class="nobreak">-employee</span> directors and align its directors&#8217; interests with those of its stockholders. Employee directors will not receive additional compensation for their services as directors. It is expected that each director who is not an employee will be paid cash and equity compensation for serving on the board of directors of the combined company, the amount and terms of which have not yet been determined. The combined company will also reimburse its non<span class="nobreak">-employee</span> directors for reasonable travel and out<span class="nobreak">-of-pocket</span> expenses incurred in connection with attending the board of director and committee meetings.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">279</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9989"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS<br/>OF THE COMBINED COMPANY</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, with Oruka&#8217;s and ARCA&#8217;s directors and executive officers, including those discussed in the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Management Following the Merger</span>,&#8221; &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka Executive Compensation</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA Executive Compensation</span>,&#8221; the following is a description of each transaction involving ARCA since January&#160;1, 2022, each transaction involving Oruka since February&#160;6, 2024 (inception) and each currently proposed transaction in which:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>either Oruka or ARCA has been or is to be a participant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of the average of Oruka&#8217;s or ARCA&#8217;s total assets at year<span class="nobreak">-end</span> for the last two completed fiscal&#160;years, as applicable; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any of Oruka&#8217;s or ARCA&#8217;s directors, executive officers or holders of more than 5% of Oruka&#8217;s or ARCA&#8217;s capital stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">ARCA Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a smaller reporting company, SEC rules require ARCA to disclose any transaction for the last two completed fiscal&#160;years or any currently proposed transaction in which ARCA is a participant and in which any related person has or will have a direct or indirect material interest involving an amount in excess of $120,000 or 1% of the average of ARCA&#8217;s total assets at year<span class="nobreak">-end</span> for the last two fiscal&#160;years. A related person is any executive officer, director, nominee for director or holder of 5% or more of ARCA&#8217;s common stock or an affiliate or immediate family member of any of those persons.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Other than the compensation arrangements and other arrangements disclosed above under the headings &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA Executive Compensation</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA Director Compensation</span>&#8221; and the transactions described below, since January&#160;1, 2022, there has not been and there is not currently proposed, any transaction or series of similar transactions to which ARCA was, or will be, a party in which the amount involved exceeded, or will exceed, $120,000 (or, if less, 1% of the average of ARCA&#8217;s total assets amounts at December&#160;31, 2022 and 2023) and in which any director, executive officer, holder of 5% or more of any class of ARCA&#8217;s capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Transactions With ARCA&#8217;s Former President and Chief Executive Officer</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its former President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. There was no expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements for the three&#160;months ended March&#160;31, 2023 was $108,000. Total expense under these arrangements for the&#160;years ended December&#160;31, 2023 and 2022 was $(91,000) and $432,000, respectively. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the President and Chief Executive Officer resigned.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cooperation Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is party to a Cooperation Agreement (the &#8220;Cooperation Agreement&#8221;) with Cable Car Capital LLC, The Funicular Fund, LP, Funicular Funds, LP and Jacob Ma<span class="nobreak">-Weaver</span> (collectively, &#8220;Cable Car&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Cooperation Agreement, ARCA&#8217;s board of directors appointed Mr.&#160;Ma<span class="nobreak">-Weaver</span> as a Class&#160;III director with a term expiring at ARCA&#8217;s 2024 annual meeting of stockholders, effective June&#160;15, 2022 and appointed Mr.&#160;Ma<span class="nobreak">-Weaver</span> to the Special Committee of ARCA&#8217;s board of directors (the &#8220;First Director Appointment&#8221;).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, under the terms of the Cooperation Agreement, ARCA and Cable Car initiated a process and subsequently identified a mutually acceptable second independent director, Mr.&#160;James Flynn, to join ARCA&#8217;s board of directors. Mr.&#160;Flynn was elected as director at the 2022 annual meeting of stockholders.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">280</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Cooperation Agreement, Cable Car agreed to abide by customary standstill restrictions from the date of the Cooperation Agreement until the earlier to occur of (i)&#160;the 180<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span>&#160;day after the First Director Appointment is no longer serving as a director of ARCA and (ii)&#160;the 90<span class="CharOverride-1" style="font-size:58%;vertical-align:super;">th</span>&#160;day prior to the 2023 Annual Meeting (such period, the &#8220;Cooperation Period&#8221;), including that Cable Car will not, among other things, (i)&#160;seek additional representation, or the removal of an existing director, on ARCA&#8217;s board of directors, (ii)&#160;engage in any solicitation of proxies, or (iii)&#160;initiate, propose or otherwise solicit, including any solicitations of the type contemplated by Rule&#160;14a<span class="nobreak">-2</span>(b)&#160;promulgated under the Securities Exchange&#160;Act&#160;of&#160;1934 of ARCA&#8217;s stockholders for the approval of, any stockholder proposal. The Cooperation Period expired on November&#160;1, 2023, the 90<span class="Superscript" style="vertical-align:super;font-size:58%;">th</span><span class="Superscript" style="vertical-align:super;">&#160;</span>day prior to the 2023 Annual Meeting.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Cable Car also agreed to customary mutual non<span class="nobreak">-disparagement</span> obligations.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Policies and Procedures for Related Party Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s Audit Committee reviews and approves all related party transactions. This review covers any material transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which ARCA was or will be a participant, and a related party had or will have a direct or indirect material interest, including, purchases of goods or services by or from the related party or entities in which the related party has a material interest, indebtedness, guarantees of indebtedness and employment by ARCA of a related party. In evaluating any related party transaction, ARCA&#8217;s Audit Committee considers, among&#160;other things, the relative benefits of the transaction to ARCA, what, if any, alternatives may be available from persons not affiliated to ARCA, if the terms of the transaction have been negotiated on an arm&#8217;s length basis and any other matters that ARCA&#8217;s Audit Committee may deem relevant in determining whether such related party transaction is in the best interests of ARCA and its stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a summary of each transaction or series of similar transactions since February&#160;6, 2024 (inception) or any currently proposed transaction, to which Oruka was or is a party in which:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of Oruka&#8217;s total assets; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any of Oruka&#8217;s directors or executive officers, any holder of 5% of any class of Oruka capital stock or an affiliate or immediate family member of the foregoing persons had or will have a direct or indirect material interest.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Compensation arrangements for Oruka named executive officers and directors are described elsewhere in this proxy statement/prospectus under &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka Executive Compensation</span>&#8221; and &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka Director Compensation</span>.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Private Placements of Securities</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Series&#160;A Preferred Stock and Convertible Note&#160;Financing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, Oruka completed a preferred stock and convertible note financing (the &#8220;Oruka Series&#160;A Financing&#8221;) and issued and sold to Fairmount Fund&#160;II (i)&#160;an aggregate of 20,000,000<span class="nobreak"> </span>shares of Series&#160;A preferred stock at a purchase price of $0.15 per share and (ii)&#160;the Convertible Note with an initial principal amount of $25,000,000 at an interest rate of 12% per annum, for aggregate gross proceeds of $28&#160;million. Fairmount Fund&#160;II is expected to contribute the aggregate principal amount and all accrued interest under the Convertible Note in exchange for Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants in connection with Oruka&#8217;s pre<span class="nobreak">-closing</span> financing. Fairmount Funds Management is the investment manager of Fairmount. Peter Harwin, a director of Oruka, is a managing member of Fairmount Funds Management.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oruka Pre-Closing Financing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, in connection with the execution of the Merger Agreement, Oruka entered into the Subscription Agreement with certain investors to consummate the Oruka pre<span class="nobreak">-closing</span> financing. Pursuant to the Subscription Agreement, the investors agreed to purchase an estimated aggregate of 40,033,228<span class="nobreak"> </span>shares of Oruka common stock and 9,504,686 Oruka pre<span class="nobreak">-funded</span> warrants, at an estimated price of $5.55 per share of common stock </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">281</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">and per warrant, for aggregate gross proceeds of approximately $275.0&#160;million (which includes $25.0<span class="nobreak"> </span>million of proceeds previously received from the issuance of the Convertible Note and accrued interest on such note). The aggregate purchase price of $275.0&#160;million is fixed, while the purchase price per share or warrant and the aggregate number of shares and warrants to be purchased is subject to change pursuant to the terms of the Subscription Agreement. Please see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Agreements Related to the Merger&#160;&#8212;&#160;Subscription Agreement</span>.&#8221; The closing of the Oruka pre<span class="nobreak">-closing</span> financing is conditioned upon the satisfaction or waiver of the conditions to the Merger as well as certain other conditions. Three of the investors or their affiliates are, or are expected to be as of immediately following the Oruka pre<span class="nobreak">-closing</span> financing, beneficial holders of more than 5% of Oruka&#8217;s capital stock, and the table below sets forth the number of shares of Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants expected to be purchased by such holders at the closing of the Oruka pre<span class="nobreak">-closing</span> financing (based on the currently estimated purchase price per share or warrant, as applicable).</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Participant</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Shares of <br/>Oruka <br/>Common Stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Pre-funded <br/>Warrants of <br/>Oruka</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Total <br/>Purchase <br/>Price</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Fairmount</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,155,246</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,255,792</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">80,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="top">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Venrock Healthcare Capital Partners</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,155,245</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">248,894</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">30,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with FMR LLC</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,503,445</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes $25.0<span class="nobreak"> </span>million of proceeds previously received by Oruka from the issuance of the Convertible Note and accrued interest on such note, with the remainder of the purchase price to be paid in cash.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka&#8217;s Relationship with Paragon and Paruka</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka is party to a number of agreements with Paragon and Paruka. Paragon and Paruka each beneficially own more than 5% of Oruka&#8217;s capital stock through their respective holdings of Oruka common stock. Fairmount beneficially owns more than 5% of Oruka&#8217;s capital stock, has one seat on Oruka&#8217;s board of directors and beneficially owns more than 5% of Paragon. Fairmount appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon, but is not the beneficial owner of Paragon&#8217;s securities. Paruka is an entity formed by Paragon as a vehicle to hold equity in Oruka in order to share profits with certain employees of Paragon.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, Oruka entered into the Paragon Option Agreements. Under the Paragon Option Agreements, Oruka has the exclusive option to, on a research program<span class="nobreak">-by-research</span> program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the selected target(s).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon signing of the Paragon Option Agreement for ORKA<span class="nobreak">-001</span>, a one<span class="nobreak">-time</span>, non<span class="nobreak">-refundable</span> research initiation fee of $0.8&#160;million was due from Oruka to Paragon. This amount was recognized by Oruka as a research and development expense during the period ended March&#160;31, 2024, and paid to Paragon in April&#160;2024. Oruka is also responsible for 50% of the development costs incurred prior to March&#160;31, 2024, provided that Oruka receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. Oruka&#8217;s share of development costs incurred prior to March&#160;31, 2024 is $5.9&#160;million. As of the date of filing of this proxy statement/prospectus, Oruka has not received such rights and has not paid such development costs. Oruka will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Paragon Option Agreement for ORKA<span class="nobreak">-002</span>, Oruka was required to reimburse Paragon for the pre<span class="nobreak">-effective</span> date development costs. During the period ended March&#160;31, 2024, this was recognized as a research and development expense, and Oruka paid $3.3&#160;million to Paragon in April&#160;2024. Oruka is also responsible for the development costs incurred from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period ended March&#160;31, 2024. Oruka will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> research plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">282</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of filing of this proxy statement/prospectus, Oruka has not exercised its options with respect to ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span>. For each of the Paragon Option Agreements, if Oruka exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million upon the achievement of certain clinical development milestones, up to $10.0&#160;million upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, as part of the Paragon Option Agreements, on each of December&#160;31, 2024 and December&#160;31, 2025, Oruka will grant Paruka warrants to purchase a number of shares equal to 1.00% of Oruka&#8217;s outstanding shares on a fully<span class="nobreak">-diluted</span> basis as of the date of the grant, with an exercise price equal to the fair market value of the underlying shares on the grant date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For additional detail regarding Oruka&#8217;s arrangements with Paragon, including the Paragon Option Agreements, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Business&#160;&#8212;&#160;License Agreements</span>.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Other Agreements with Oruka Stockholders</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Oruka Series&#160;A Financing, Oruka entered into investors&#8217; rights, voting and right of first refusal and co<span class="nobreak">-sale</span> agreements containing registration rights, information rights, voting rights and rights of first refusal, among other things, with certain holders of Oruka preferred stock and certain holders of Oruka common stock. These stockholder agreements will terminate upon the closing of the Merger.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Indemnification Agreements and Insurance</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has entered into an indemnification agreement with each of its directors and officers and purchased directors&#8217; and officers&#8217; liability insurance. The indemnification agreements require Oruka to indemnify its directors and officers to the fullest extent permitted under Delaware law.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka Policies for Approval of Related Party Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka does not have a formal policy regarding approval of transactions with related parties. To date, all disclosable transactions with related parties have been approved by the directors not interested in such transaction pursuant to Section&#160;144(a)(1)&#160;of the DGCL.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">283</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Defined terms included below shall have the same meaning as terms defined and included elsewhere in this proxy statement/prospectus.</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, Oruka entered into a Merger Agreement with ARCA and the Merger Subs, pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, First Merger Sub will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the Merger. Immediately following the First Merger and as part of the same overall transaction, Oruka will merge with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger. The transaction is expected to be completed in the third quarter of 2024 (the &#8220;Closing Date&#8221; or the &#8220;Effective Time&#8221;) following the filed Form&#160;S<span class="nobreak">-4</span> being deemed effective by the SEC and receipt of approval by the stockholders of each of Oruka and ARCA, in the latter case pursuant to a special meeting. In connection with the Merger, Second Merger Sub will change its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; ARCA following the Merger is referred to herein as the &#8220;combined company.&#8221; The combined company will be led by Oruka&#8217;s management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with an exchange ratio determined in accordance with the terms of the Merger Agreement (the &#8220;Exchange Ratio&#8221;) (together with the Oruka pre<span class="nobreak">-closing</span> financing, the &#8220;Transactions&#8221;), immediately prior to the Effective Time, (i) each share of Oruka common stock outstanding, including outstanding and unvested Oruka restricted stock and shares of Oruka common stock issued in connection with the Subscription Agreement (both defined in Note&#160;1 of the accompanying notes), will be converted into the right to receive shares of ARCA common stock, which will be subject to the same vesting provisions as those immediately prior to the Merger, (ii) each share of Oruka Series A convertible preferred stock will be converted into the right to receive ARCA Series B convertible preferred stock, (iii) each option or warrant to purchase Oruka common stock will be converted into the right to receive an option or warrant to purchase ARCA common stock, which will be subject to the same vesting provisions as those immediately prior to the Merger, and (iv) each pre<span class="nobreak">-funded</span> warrant to purchase shares of Oruka common stock issued in connection with the Subscription Agreement will be converted into the right to receive a pre<span class="nobreak">-funded</span> warrant to purchase shares of ARCA common stock. </p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Exchange Ratio is currently estimated to be approximately 6.8699<span class="nobreak"> </span>shares of ARCA common stock for each fully<span class="nobreak">-diluted</span> share of Oruka common stock. Under the Exchange Ratio formula, the former Oruka stockholders immediately before the effective time, including those purchasing shares and pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing, are currently estimated to own approximately 97.6% of the outstanding common stock of the combined company on a fully<span class="nobreak">-diluted</span> basis, and the stockholders of ARCA immediately before the effective time are currently estimated to own approximately 2.4% of the outstanding common stock of the combined company on a fully<span class="nobreak">-diluted</span> basis and are subject to certain assumptions, including, but not limited to, (a)&#160;ARCA&#8217;s net cash balance (as defined in the Merger Agreement) as of the Closing being approximately $5.0&#160;million, (b)&#160;Oruka closing on approximately $275.0&#160;million in the Oruka pre<span class="nobreak">-closing</span> financing described in this proxy statement/prospectus, (c)&#160;a valuation for ARCA equal to its net cash as of the business&#160;day immediately prior to the closing date of the Merger, plus $6.0&#160;million, and (d)&#160;a valuation for Oruka equal to $175.0&#160;million, in each case as further described in the Merger Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following unaudited pro forma condensed combined financial information gives effect to the Merger, which is expected to be accounted for as a reverse recapitalization under United&#160;States Generally Accepted Accounting Principles, or U.S.&#160;GAAP.&#160;For further detail related to the accounting for the Merger, please see Notes 1 and&#160;3 below.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma condensed combined balance sheet combines the historical balance sheets of ARCA and Oruka as of March&#160;31, 2024 and depicts the accounting of the transactions prepared pursuant to the rules and regulations of Article&#160;11 of SEC Regulation&#160;S<span class="nobreak">-X</span>, as amended (&#8220;pro forma balance sheet transaction accounting adjustments&#8221;). The unaudited pro forma condensed combined statements of operations for the three&#160;months ended March&#160;31, 2024 for ARCA, the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 for Oruka, and the year ended December&#160;31, 2023 for ARCA combine the historical results of ARCA and Oruka for those periods and depict the pro forma transaction accounting adjustments assuming that those adjustments were made as of January&#160;1, 2023 </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">284</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">(&#8220;pro forma statements of operations transaction accounting adjustments&#8221;). Collectively, pro forma balance sheet transaction accounting adjustments and pro forma statements of operations transaction accounting adjustments are referred to as &#8220;transaction accounting adjustments&#8221; or &#8220;pro forma adjustments&#8221;.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These unaudited pro forma condensed combined financial information and related notes have been derived from and should be read in conjunction with:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical unaudited condensed financial statements of Oruka as of March<span class="nobreak">&#160;</span>31, 2024 and for the period from February<span class="nobreak">&#160;</span>6, 2024 (inception) to March<span class="nobreak">&#160;</span>31, 2024, and the related notes included elsewhere in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical unaudited condensed consolidated financial statements of ARCA as of and for the three&#160;months ended March<span class="nobreak">&#160;</span>31, 2024, and the related notes included elsewhere in this proxy statement/prospectus;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the historical audited consolidated financial statements of ARCA for the year ended December<span class="nobreak">&#160;</span>31, 2023, and the related notes included elsewhere in this proxy statement/prospectus; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the sections titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">ARCA&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>,&#8221; &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Oruka&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation</span>,&#8221; and other financial information relating to ARCA and Oruka included elsewhere in this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma condensed combined financial information is based on the assumptions and pro forma adjustments that are described in the accompanying notes. The pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed including but not limited to additional financing, additional direct and incremental offering costs and a reverse stock split. Adjustments have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary estimates and the final accounting, expected to be completed after the Closing, may occur and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The unaudited pro forma condensed combined financial information does not give effect to the potential impact of current financial conditions, regulatory matters, operating efficiencies or other savings or expenses that may be associated with the integration of the two companies. The unaudited pro forma condensed combined financial information is not necessarily indicative of the financial position or results of operations in the future periods or the result that actually would have been realized had ARCA and Oruka been a combined organization during the specified periods. The actual results reported in periods following the Merger may differ significantly from those reflected in the unaudited condensed combined pro forma financial information presented herein for a number of reasons, including, but not limited to, differences in the assumptions used to prepare this unaudited pro forma condensed combined financial information.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">285</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET<br/>AS OF MARCH 31, 2024<br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(In thousands, except share amounts)</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 18.98%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Historical</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.92%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.73%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.35%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:8pt;">5(A)<br/>ARCA<br/></span><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">biopharma, <br/>Inc.</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.49%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:8pt;">5(B)<br/>Oruka<br/>Therapeutics,<br/></span><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Inc.</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.92%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:8pt;">Transaction<br/>Accounting<br/></span><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Adjustments</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Notes</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.73%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:8pt;">Pro&#160;Forma<br/></span><span class="CharOverride-2" style="font-size:8pt;font-style:normal;font-weight:bold;">Combined</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Current assets:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Cash and cash equivalents</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">35,903</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">27,743</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(1,687</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(a)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">267,004</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">249,786</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(19,512</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(d)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(4,973</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(e)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(256</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(h)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(20,000</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(i)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Prepaid expenses and other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">767</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(716</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(f)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">51</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total current assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">36,670</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">27,743</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">202,642</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">267,055</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Operating lease right-of-use assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(g)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Property and equipment, net</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">7</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(7</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(g)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Other assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">12</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">488</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(488</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(d)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">12</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">36,706</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">28,231</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">202,130</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="text-decoration:underline;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">267,067</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Current liabilities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Accounts payable</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">529</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">4</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">533</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Accrued expenses and other current liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,052</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,262</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(21</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,326</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(919</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(e)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(48</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(g)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Related party accounts payable and other current liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">5,899</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">5,899</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total current liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,581</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">7,165</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(988</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">7,758</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Long term liabilities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Accrued interest payable, related party</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">214</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(214</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Notes payable to related parties, noncurrent</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">24,980</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(24,980</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1,581</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">32,359</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(26,182</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">7,758</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Oruka convertible preferred stock</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(b)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">ARCA convertible preferred stock</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(b)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Stockholders&#8217; equity (deficit) </span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">ARCA common stock, $0.001 par value</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">14</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(14</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(j)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Oruka common stock, $0.0001 par value</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">1</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">0</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">6</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">4</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Additional paid-in capital</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">225,861</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">25,214</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">263,449</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">249,782</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(c)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(20,000</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(d)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">22</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(h)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(20,000</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(i)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(197,446</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(j)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Accumulated deficit</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(190,750</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(7,077</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(1,687</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(a)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(7,077</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(4,053</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(e)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(716</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(f)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">24</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(g)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(278</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(h)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">197,460</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">5(j)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total stockholders&#8217; equity (deficit)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">35,125</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">(7,059</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">228,312</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">256,378</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 54.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="CharOverride-4" style="font-size:9pt;">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.31%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">36,706</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 6.45%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">28,231</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">202,130</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-5" style="text-decoration:underline;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 4.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.14%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 5.69%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">267,067</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">See accompanying notes to the unaudited pro forma condensed combined financial information.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">286</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS<br/>FOR THE THREE MONTHS ENDED MARCH 31, 2024<br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(In thousands, except share and per share amounts)</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 23.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Historical</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-21" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 11.20%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">6(A) <br/>ARCA <br/>biopharma, <br/>Inc.</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.81%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">6(B) <br/>Oruka <br/>Therapeutics, <br/>Inc.</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Transaction <br/>Accounting <br/>Adjustments</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Notes</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 12.16%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Pro&#160;Forma <br/>Combined</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Notes</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">165</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,193</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">304</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(f)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,662</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,317</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,670</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">829</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(f)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,816</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,482</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,133</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,478</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income (loss) from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,482</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,133</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(10,478</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other income (expense), net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(e)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other income (expense), net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">473</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,009</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(919</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(10,005</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,009</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(10,005</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average common shares outstanding, basic&#160;and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,501,143</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">393,270,139</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(g)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 38.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share attributable to common stockholders, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.83%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.07%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.03</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.54%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.16%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">See accompanying notes to the unaudited pro forma condensed combined financial information.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">287</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS<br/>FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2023<br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;">(In thousands, except share and per share amounts)</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="6" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 21.64%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Historical</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.14%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-21" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-top:2pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 9.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">6(A) <br/>ARCA <br/>biopharma, <br/>Inc.</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.92%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">6(B) <br/>Oruka <br/>Therapeutics, <br/>Inc.</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.14%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Transaction <br/>Accounting <br/>Adjustments</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Notes</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 10.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Pro&#160;Forma <br/>Combined</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:2pt;padding-left:0pt;padding-right:0pt;padding-top:2pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Notes</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,013</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,215</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(f)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,228</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,283</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,687</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(a)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">12,256</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">716</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(b)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(c)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">278</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(d)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,316</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(f)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,296</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,188</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,484</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income (loss) from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,296</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,188</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(14,484</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other income (expense), net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other income (expense), net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,957</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,339</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,188</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(12,527</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5,339</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(12,527</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average common shares outstanding, basic&#160;and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,415,877</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">393,184,873</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">6(g)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 41.13%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share attributable to common stockholders, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.43%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.37</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.36%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.02%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 4.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 7.21%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(0.03</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.56%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.17%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.04%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">See accompanying notes to the unaudited pro forma condensed combined financial information.</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">288</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T9990"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1. Description of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA, Oruka, First Merger Sub, and Second Merger Sub entered into the Merger Agreement to which the First Merger Sub merges with and into Oruka, with Oruka becoming a wholly owned subsidiary of ARCA.&#160;Oruka will merge with and into the Second Merger Sub, with the Second Merger Sub being the surviving entity. Subsequent to the Second Merger, Second Merger Sub would remain a wholly owned subsidiary of ARCA and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; Subject to the terms and conditions of the Merger Agreement, at closing of the Merger (the &#8220;Closing&#8221;):</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">a)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each outstanding share of, and pre<span class="nobreak">-funded</span> warrant related to, Oruka common stock, including (i)&#160;outstanding and unvested Oruka Restricted Stock (defined below) will be converted into the right to receive a number of shares of, and pre<span class="nobreak">-funded</span> warrants related to, ARCA common stock, based on the Exchange Ratio;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">b)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each outstanding share of Oruka Series A convertible preferred stock at closing will be exchanged into ARCA Series B convertible preferred stock, which are each convertible into 1,000<span class="nobreak"> </span>shares of ARCA common stock, equal to the Exchange Ratio divided by 1,000; and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">c)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each outstanding and unexercised option or warrant to purchase shares of Oruka common stock (&#8220;Oruka options&#8221; or &#8220;Oruka warrants&#8221;, respectively) immediately prior to Closing will be assumed by ARCA and will be converted into an option or warrant to purchase shares of ARCA common stock which continues to vest pursuant to the original terms, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">All Oruka restricted stock outstanding and unvested immediately prior to Closing (&#8220;Oruka Restricted Stock&#8221;) that is assumed by ARCA in the Merger will remain unvested to the same extent and will be subject to the same repurchase option, risk of forfeiture or other condition under any applicable restricted stock purchase agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Merger Agreement, the board of directors of ARCA will take actions to accelerate the vesting of certain outstanding options to purchase ARCA common stock held by a current employee, director or consultant of ARCA as of the closing of the Merger. The acceleration of vesting of ARCA&#8217;s options occurs either upon a change of control as defined, pursuant to the terms of the original awards, or a modification of the awards as a result of the Merger. The incremental fair value of ARCA&#8217;s options associated with the modification to accelerate vesting has been included as an adjustment to the unaudited pro forma condensed combined financial information.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">Immediately following the Merger, ARCA stockholders are expected to own approximately 2.4% of the outstanding capital stock of the combined company on a fully diluted basis, former Oruka stockholders are expected to own approximately 41.5% of the outstanding capital stock of the combined company on a fully diluted basis, and investors participating in the Subscription Agreement (defined below) are expected to own approximately 56.1% of the outstanding capital stock of the combined company on a fully diluted basis. Oruka stockholders are expected to receive approximately 251,912,528<span class="nobreak"> </span>shares on a fully diluted basis in connection with the Merger, including (i) 76,066,047<span class="nobreak"> </span>shares of ARCA common stock, stock options and warrants subject to vesting terms, based on the number of shares of Oruka common stock outstanding immediately prior to the Merger, including Oruka Restricted Stock, (ii) the number of shares of, and pre<span class="nobreak">-funded</span> warrants related to, Oruka common stock issued to investors participating in the Subscription Agreement (defined below), and (iii) Oruka convertible preferred stock outstanding as of March&#160;31, 2024, which will be exchanged into shares of ARCA Series B convertible preferred stock. These estimates are subject to certain inputs, which include, but are not limited to, (a)&#160;ARCA&#8217;s net cash balance (as defined in the Merger Agreement) as of the Closing being approximately $5.0&#160;million, (b)&#160;Oruka raising approximately $275.0&#160;million in the Oruka pre<span class="nobreak">-closing</span> financing described in this proxy statement/prospectus, (c)&#160;a valuation for ARCA equal to its net cash as of the business&#160;day immediately prior </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">289</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;text-indent:0pt;margin-top:5pt;">to the closing date of the Merger, plus $6.0&#160;million and (d)&#160;a valuation for Oruka equal to $175.0&#160;million, in each case as further described in the Merger Agreement. The following table summarizes the pro forma number of shares of common stock of the combined company outstanding following the consummation of the Transactions:</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-31" style="height:12pt;">
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-6" style="font-style:normal;font-weight:bold;">Equity Capitalization Summary (fully diluted basis) <br/>Upon Consummation of the Merger</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-6" style="font-style:normal;font-weight:bold;">Pro&#160;Forma <br/>(Assuming&#160;ARCA&#160;Net&#160;Cash <br/>at&#160;Closing&#160;of&#160;$5.0&#160;Million)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-6" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Shares&#160;Owned</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-6" style="font-style:normal;font-weight:bold;">% <br/>Ownership</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Oruka stockholders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">251,912,528</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">41.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">ARCA stockholders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,501,143</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Investors participating in the Subscription Agreement<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">340,320,515</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">56.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total common stock of the combined company</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">606,734,186</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes 65,296,242 pre<span class="nobreak">-funded</span> warrants related to the Subscription Agreement after reflecting the estimated Exchange Ratio.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA stockholders, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the listing of the shares of ARCA common stock to be issued in connection with the Merger and (4)&#160;the effectiveness of a registration statement filed with the SEC in connection with the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">The employment agreements for ARCA employees include entitlement to change in control payments for certain executives, and severance and retention bonus payments for certain non<span class="nobreak">-executives</span>, the aggregate of which will be treated as pre<span class="nobreak">-Merger</span> compensation expense of ARCA and will be reflected as an increase to accrued expenses of ARCA, which will be assumed by the combined company at Closing. Prior to the Closing, ARCA also (i)&#160;discontinued its research and development activities, (ii)&#160;sold its assets held for sale, and (iii)&#160;terminated and/or expired its operating leases. Additionally, ARCA&#8217;s current Directors&#160;&amp; Officers (&#8220;D&amp;O&#8221;) policy will be fully utilized at Closing.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Private Financing Transaction&#160;&#8212;&#160;Subscription Agreement</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">Concurrently with the execution of the Merger Agreement, certain parties entered into a subscription agreement with Oruka to purchase, prior to the consummation of the Merger, approximately 40,033,288<span class="nobreak"> </span>shares of Oruka common stock and 9,504,686 pre<span class="nobreak">-funded</span> warrants, at an estimated purchase price of $5.55 per share and $5.54 per warrant, for an aggregate purchase price of approximately $275.0&#160;million, which includes $25.0&#160;million proceeds received as of March&#160;31, 2024 from the issuance of a convertible note and accrued interest. The subscription agreement was subsequently amended and restated on July<span class="nobreak"> </span>3, 2024 (the &#8220;Subscription Agreement&#8221;) to provide for, among other things, the issuance of warrants to certain of Oruka&#8217;s employees, directors and service providers. The purchase price of the common stock and pre<span class="nobreak">-funded</span> warrants was reduced to the amounts above due to the issuance of employee stock options since the original Subscription Agreement signing. Shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock issued pursuant to the Subscription Agreement will be converted into shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of ARCA common stock at Closing per the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2. Basis of Presentation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article&#160;11 of SEC Regulation&#160;S<span class="nobreak">-X</span>, as amended. The adjustments presented in the unaudited pro forma condensed combined financial information have been identified and presented to provide relevant information necessary for an understanding of the combined company upon consummation of the Merger. The unaudited pro forma condensed combined statement of operations data for the three&#160;months ended March&#160;31, 2024 and the unaudited pro forma condensed combined statement of operations data for the year ended December&#160;31, 2023, give effect to the Merger as if it had been consummated on January&#160;1, 2023. The unaudited pro forma condensed combined balance sheet as of March&#160;31, 2024 gives effect to the Merger and combines the historical balance sheets of ARCA and Oruka as of such date.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;margin-top:5pt;">The unaudited pro forma condensed combined financial information is based on the assumptions and adjustments that are described in the accompanying notes. Accordingly, the pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed and have been made solely for the purpose of providing unaudited pro forma condensed combined financial information. Differences between these preliminary accounting conclusions and estimates and the final accounting conclusions and amounts may occur as a result of, among other reasons: (i)&#160;changes in initial assumptions in the determination of </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">290</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:5pt;text-indent:0pt;margin-top:5pt;">the accounting acquirer and related accounting, (ii)&#160;changes in the amount of ARCA&#8217;s net cash to be assumed at the Closing Date, and (iii)&#160;other changes in ARCA&#8217;s assets and liabilities, which are expected to be completed after the Closing, and these differences could have a material impact on the accompanying unaudited pro forma condensed combined financial information and the combined company&#8217;s future results of operations and financial position.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">3. Accounting for the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The unaudited pro forma condensed combined financial information gives effect to the Merger, which will be accounted for under U.S.&#160;GAAP as an in<span class="nobreak">-substance</span> reverse recapitalization of ARCA by Oruka, as the transaction is, in essence, the issuance of equity for ARCA&#8217;s net assets, which will primarily consist of cash and other nominal non<span class="nobreak">-operating</span> assets and liabilities. Under this method of accounting, Oruka will be considered the accounting acquirer for financial reporting purposes. This determination is based on the expectations that, immediately following the Merger:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka is not a variable interest entity as it has sufficient equity at risk in order to fund its next development milestones;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka stockholders will own a substantial majority of the voting rights in the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s largest stockholder will retain the largest interest in the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka will designate the initial members of the board of directors of the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka&#8217;s executive management team will become the management of the combined company; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>The combined company will be renamed &#8220;Oruka Therapeutics, Inc.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">As a result of Oruka being the accounting acquirer, Oruka&#8217;s assets and liabilities will be recorded at their pre<span class="nobreak">-combination</span> carrying amounts. ARCA&#8217;s assets and liabilities will be measured and recognized at their fair values as of the effective time, which are expected to approximate the carrying value of the acquired cash and other non<span class="nobreak">-operating</span> assets, with no goodwill or other intangible assets recorded. Any difference between the consideration transferred and the fair value of the net assets of ARCA following the determination of the actual consideration transferred for ARCA will be reflected as an adjustment to additional paid<span class="nobreak">-in</span> capital. For periods prior to Closing, the historical financial statements of Oruka shall become the historical financial statements of the combined company.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">4. Shares of ARCA Common Stock, Convertible Preferred Stock, Options, and Warrants Issued to Oruka Stockholders upon Closing of the Merger</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">At Closing, all outstanding shares of Oruka common stock, on a fully<span class="nobreak">-diluted</span> basis, will be exchanged for shares of ARCA common stock based on the preliminary estimated Exchange Ratio of 6.8699, determined in accordance with the terms of the Merger Agreement. The estimated number of shares of ARCA common stock that ARCA expects to issue to Oruka&#8217;s stockholders assumes ARCA&#8217;s net cash at Closing is $5.0&#160;million and is determined as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shares of Oruka common stock outstanding as of March&#160;31, 2024<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,460,019</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shares of Oruka common stock to be issued upon conversion of Oruka convertible preferred&#160;stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Shares of Oruka common stock issued upon exercise of Oruka stock options and warrants<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,209,005</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated shares of Oruka common stock to be issued in connection with the Subscription Agreement, see Note&#160;5(c)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">40,033,228</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated shares of Oruka common stock to be issued upon exercise of Oruka pre-funded warrants to be issued in connection with the Subscription Agreement,&#160;see Note&#160;5(c)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9,504,686</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total Oruka fully diluted shares prior to the closing of the Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">86,206,938</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated Exchange&#160;Ratio</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.8699</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.42%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated fully diluted shares to be issued to Oruka stockholders and Investors participating in Subscription Agreement upon closing of the Merger<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.30%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">592,233,043</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents shares of Oruka common stock outstanding as of March&#160;31, 2024, including 3,863,361 shares of unvested Oruka Restricted Stock.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents the outstanding options and warrants to acquire Oruka common stock as of March&#160;31, 2024. Such stock options and warrants will become exercisable for shares of ARCA common stock following the Merger.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents the total estimated fully diluted shares to be issued to Oruka stockholders at Closing based on the preliminary estimated Exchange Ratio of 6.8699.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">291</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:7pt;margin-top:7pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">5. Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet as of March&#160;31, 2024</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:7pt;margin-top:7pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pro forma notes:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">5(A)&#160;&#160;Derived from the unaudited condensed consolidated balance sheet of ARCA as of March&#160;31, 2024.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">5(B)&#160;&#160;Derived from the unaudited condensed balance sheet of Oruka as of March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:7pt;margin-top:7pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pro forma Balance Sheet Transaction Accounting Adjustments:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">5(a)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect preliminary estimated incremental compensation expense of $1.7&#160;million related to severance, retention bonuses and change in control payments resulting from pre<span class="nobreak">-existing</span> employment agreements or from approval from ARCA&#8217;s board of directors that is expected to be incurred upon closing of the Merger. The pro forma adjustment is reflected as a decrease in cash of $1.7&#160;million for the severance and retention bonuses payments made subsequent to March&#160;31, 2024 and an increase to accumulated deficit of $1.7&#160;million.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">5(b)&#160;&#160;To reflect the exchange of all outstanding shares of Oruka Series&#160;A convertible preferred stock, with a carrying amount of $2.9&#160;million, into ARCA Series&#160;B convertible preferred stock at closing of the Merger, with the terms of ARCA Series B convertible preferred stock resulting in classification within stockholders&#8217; equity.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:7pt;margin-top:7pt;">5(c)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect the issuance of 40,033,228<span class="nobreak"> </span>shares of Oruka common stock and 9,504,686 pre<span class="nobreak">-funded</span> warrants, pursuant to the Subscription Agreement entered into concurrently with the execution of the Merger Agreement, for an aggregate purchase price of $275.0<span class="nobreak"> </span>million, which includes $25.0<span class="nobreak"> </span>million proceeds received as of March<span class="nobreak"> </span>31, 2024 from the issuance of the convertible note. The aggregate proceeds are net less than $0.1<span class="nobreak"> </span>million of debt issuance costs and include accrued interest of $0.2<span class="nobreak"> </span>million as of March<span class="nobreak"> </span>31, 2024 adjusted through accumulated deficit (see Note 6(e)), for net proceeds prior to transaction costs of $249.8<span class="nobreak"> </span>million. The proceeds received in connection with the Subscription Agreement are recorded net of transaction costs deemed to be direct and incremental costs of the equity financing in the amount of approximately $20.0<span class="nobreak"> </span>million (see Note 5(d)) for net proceeds from the Subscription Agreement post<span class="nobreak">-transaction</span> costs of $229.8<span class="nobreak"> </span>million. The issuance of shares in connection with the Subscription Agreement are recorded as the issuance of Oruka common stock at par value, with the remaining amount recorded to additional paid<span class="nobreak">-in-capital</span>.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">&#160;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The net cash proceeds received prior to direct and incremental transaction costs from the Subscription Agreement and corresponding adjustment to additional paid<span class="nobreak">-in-capital</span> upon close of the Merger is determined as follows (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Aggregate purchase price of the Subscription Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">275,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net proceeds previously received from issuance of convertible note as of March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24,980</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Debt issuance costs recorded as part of issuance of convertible note as of March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued interest payable as part of issuance of convertible note as of March&#160;31, 2024, see <br/>Note&#160;6(e)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net proceeds received prior to direct and incremental transaction costs from the Subscription Agreement upon close of the Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">249,786</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Issuance of Oruka common stock and pre-funded warrants at par value upon close of the Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-35" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 85.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital related to the issuance of Oruka common stock and pre-funded <br/>warrants upon close of the Merger (excluding Oruka common stock to be issued in connection with conversion of convertible note)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.25%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">249,782</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">292</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(d)&#160;&#160;To reflect preliminary estimated transaction costs of $19.5&#160;million, not yet reflected in the historical financial statements, that are expected to be incurred by Oruka in connection with the Merger, and $0.5&#160;million reflected in the historical financial statements as deferred offering costs, such as advisory, legal and auditor fees, as a reduction in cash and a reduction in other assets in the unaudited pro forma condensed combined balance sheet. As the Merger will be accounted for as a reverse recapitalization equivalent to the issuance of equity for the net assets, primarily cash, of ARCA, these direct and incremental costs are treated as a reduction of the net proceeds received within additional paid<span class="nobreak">-in</span> capital.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(e)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect preliminary estimated transaction costs of $4.1&#160;million, not yet reflected in the historical financial statements and $0.9&#160;million reflected in the historical financial statements, which are expected to be incurred by ARCA in connection with the Merger, such as advisory, legal and auditor fees and including the estimated $1.7<span class="nobreak"> </span>million cost of a D&amp;O tail policy, as a reduction in cash of $5.0<span class="nobreak"> </span>million, a reduction in accrued expenses of $0.9<span class="nobreak"> </span>million, and a reduction in accumulated deficit of $4.1<span class="nobreak"> </span>million in the unaudited pro forma condensed combined balance sheet.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(f)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To derecognize $0.7&#160;million of ARCA&#8217;s prepaid expenses consisting of $0.1&#160;million of prepaid expenses related to software that will not be utilized and $0.6&#160;million of prepaid insurance primarily related to the current ARCA&#8217;s D&amp;O policy that will be fully utilized at Closing.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(g)&#160;&#160;To reflect the derecognition of ARCA&#8217;s operating leases that will expire prior to the closing of the Merger and the derecognition of property and equipment that will be fully depreciated prior to the closing of the Merger. The operating lease right<span class="nobreak">-of-use</span> assets and property and equipment of less than $0.1&#160;million will be derecognized.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(h)&#160;&#160;To reflect the one<span class="nobreak">-time</span> stock compensation expense of $0.3&#160;million in general and administrative expense related to the acceleration of stock options pursuant to pre<span class="nobreak">-existing</span> grant agreements, which provide for such acceleration upon a change in control provision, which will be triggered by the Merger, as well as a modification to accelerate vesting of in<span class="nobreak">-the-money</span> stock options, and to reflect the one<span class="nobreak">-time</span> cash payment of $0.3&#160;million to settle in<span class="nobreak">-the-money</span> stock options per terms of the Merger Agreement.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(i)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect an estimate of the one<span class="nobreak">-time</span> dividend of $20.0&#160;million declared and paid on the shares of ARCA common stock outstanding prior to the Merger. The dividend will be treated as a decrease in additional paid<span class="nobreak">-in</span> capital in the unaudited pro forma condensed combined balance sheet.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">5(j)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect the recapitalization of Oruka, pursuant to the Merger Agreement, through the contribution of 251,912,528<span class="nobreak"> </span>shares of Oruka common stock, including 76,066,047<span class="nobreak"> </span>shares of Oruka Restricted Stock, Oruka stock options and Oruka warrants (see Note&#160;4), and the issuance of 275,024,273<span class="nobreak"> </span>shares of Oruka common stock and 65,296,242 pre<span class="nobreak">-funded</span> warrants and 137,398,000 preferred stock, reflecting the estimated Exchange Ratio of 6.8699 and to reflect the derecognition of the accumulated deficit of ARCA which is reversed to additional paid<span class="nobreak">-in</span> capital.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:24pt;margin-top:8pt;">The derecognition of accumulated deficit of ARCA of $197.5&#160;million is determined as follows (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit of ARCA as of March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">190,750</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Compensation expense related to ARCA severance, retention bonuses and change in control payments, see Note&#160;5(a)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,687</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Preliminary estimated transaction costs of ARCA, see Note&#160;5(e)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,053</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Derecognition of ARCA prepaid software expenses and prepaid insurance, see Note&#160;5(f)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">716</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Derecognition of ARCA operating leases, see Note&#160;5(g)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pre-Merger stock-based compensation expense for ARCA&#8217;s accelerated awards, see Note&#160;5(h)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">278</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total adjustment to derecognize the accumulated deficit of ARCA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">197,460</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">293</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">6. Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The pro forma notes and adjustments, based on preliminary estimates that could change materially as additional information is obtained, are as follows:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pro forma notes:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(A)&#160;&#160;Derived from the unaudited condensed consolidated statement of operations and comprehensive loss of ARCA for the three&#160;months ended March&#160;31, 2024.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(B)&#160;&#160;Derived from the unaudited condensed statement of operations and comprehensive loss of Oruka for the period February&#160;6, 2024 (inception) to March&#160;31, 2024.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(C)&#160;&#160;Derived from the audited consolidated statement of operations and comprehensive loss of ARCA for the year ended December&#160;31, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(D)&#160;&#160;Derived from the unaudited condensed statement of operations and comprehensive loss of Oruka for the year ended December&#160;31, 2023.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka and ARCA did not record any provision or benefit for income taxes during the three&#160;months ended March&#160;31, 2024 because each company expects to incur a pre<span class="nobreak">-tax</span> loss in 2024 and each company maintains a full valuation allowance on its deferred tax assets. Accordingly, no pro forma adjustments have an impact on associated income tax.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Pro forma Statements of Operations Transaction Accounting Adjustments:</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(a)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect preliminary estimated incremental compensation expense related to severance, retention bonuses and change in control payments recorded in general and administrative expenses of $1.7&#160;million, resulting from pre<span class="nobreak">-existing</span> employment agreements or from approval from ARCA&#8217;s board of directors that will be incurred upon Closing assuming that the adjustment described in Note&#160;5(a)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(b)&#160;&#160;To reflect the derecognition of ARCA&#8217;s prepaid expenses of $0.1&#160;million related to software that will not be utilized, and prepaid insurance of $0.6&#160;million primarily related to the current ARCA D&amp;O policy that will be fully utilized at Closing, assuming the adjustment made in Note&#160;5(f)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(c)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect the derecognition of ARCA&#8217;s operating leases that will expire prior to the closing of the Merger and the derecognition of property and equipment that will be fully depreciated prior to the closing of the Merger. The operating lease right<span class="nobreak">-of-use</span> assets and property and equipment of less than $0.1&#160;million will be derecognized, assuming the adjustment made in Note&#160;5(g)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(d)&#160;&#160;To reflect the one<span class="nobreak">-time</span> stock compensation expense of $0.3&#160;million in general and administrative expense related to the acceleration of stock options pursuant to pre<span class="nobreak">-existing</span> grant agreements which provide for such acceleration upon a change in control provision, which will be triggered by the Merger, as well as a modification to accelerate vesting of in<span class="nobreak">-the-money</span> stock options, assuming the adjustment made in Note&#160;5(h)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(e)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect Oruka&#8217;s interest expense related to its convertible note that is recorded in its historical financial statements, to be derecognized in the unaudited pro forma condensed combined statement of operations for the three&#160;months ended March&#160;31, 2024 assuming that the adjustment described in Note&#160;5(c)&#160;was made on January&#160;1, 2023.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(f)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To reflect stock compensation expenses of $3.3&#160;million and $0.8<span class="nobreak"> </span>million for the year ended December<span class="nobreak"> </span>31, 2023 and the three months ended March<span class="nobreak"> </span>31, 2024, respectively, in general and administrative expense and reflect stock compensation expenses of $1.2<span class="nobreak"> </span>million and $0.3<span class="nobreak"> </span>million for the year ended December<span class="nobreak"> </span>31, 2023 and the three months ended March<span class="nobreak"> </span>31, 2024, respectively in research and development, related to warrants to be issued to certain employees, directors and service providers pursuant to the Subscription Agreement as amended and restated, assuming the adjustment was made on January<span class="nobreak"> </span>1, 2023. These warrants vest over 4 years from the date of issuance.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">294</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">6(g)&#160;&#160;The pro forma combined basic and diluted net loss per share has been adjusted to reflect the pro forma net loss for the three&#160;months ended March&#160;31, 2024. In addition, the number of shares used in calculating the pro forma combined basic and diluted net loss per share has been adjusted to reflect the estimated total number of shares of common stock of the combined company for the respective periods. Pro forma weighted average shares outstanding includes the pre<span class="nobreak">-funded</span> warrants related to the Subscription Agreement as the exercise price is negligible and they are fully vested and exercisable. For the three&#160;months ended March&#160;31, 2024, the pro forma weighted average shares have been calculated as follows:</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31, 2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December 31, <br/>2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Basic and <br/>Diluted</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Basic and <br/>Diluted</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Historical weighted average number of ARCA common shares outstanding</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,501,143</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">14,415,877</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-35" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Estimated shares of ARCA common stock expected to be issued to Oruka stockholders upon Closing, assuming consummation of the Merger as of January&#160;1, 2023, see Note&#160;4<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">378,768,996</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">378,768,996</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pro forma combined weighted average number of common shares <br/>outstanding</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">393,270,139</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">393,184,873</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Represents the estimated shares of ARCA common stock expected to be issued to Oruka stockholders at Closing, excluding (i)&#160;the outstanding and unvested Oruka Restricted Stock, Oruka stock options and Oruka warrants at Closing that will be converted to the right to receive 26,540,904<span class="nobreak"> </span>shares of ARCA common stock, 14,177,200 stock options, and 35,347,944 warrants respectively, after reflecting the estimated Exchange Ratio and (ii)&#160;the outstanding Oruka convertible preferred stock that will be exchanged for 137,398,000<span class="nobreak"> </span>shares of ARCA convertible preferred stock. The 26,540,904<span class="nobreak"> </span>shares of ARCA common stock, 14,177,200 stock options, and 35,347,944 warrants are subject to the same vesting conditions (see Note&#160;4).</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">295</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T8"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">DESCRIPTION OF ARCA CAPITAL STOCK</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">The following description of ARCA capital stock and provisions of the ARCA Charter and ARCA Bylaws are summaries and are qualified by reference to such charter and bylaws and applicable provisions of Delaware corporate law. Copies of these documents are filed as exhibits to the registration statement of which this proxy/prospectus forms part.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Authorized Capital Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter authorizes ARCA to issue 100,000,000<span class="nobreak"> </span>shares of ARCA common stock and 5,000,000<span class="nobreak"> </span>shares of preferred stock, $0.001 par value per share (&#8220;ARCA preferred stock&#8221;).</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Voting Rights.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Each holder of ARCA common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors; provided, however, holders of ARCA common stock may not, unless otherwise required by law, vote on any amendment to the ARCA Charter that relates solely to the terms of one or more series of ARCA preferred stock that ARCA may issue if the holders of such ARCA preferred stock are entitled to vote on such amendment. In all such matters other than the election of directors, the affirmative vote of the majority of shares present in person, by remote communication, or represented by proxy at a meeting of the stockholders and entitled to vote generally on the subject matter shall be the act of the stockholders. Directors shall be elected by a plurality of the votes of the shares present in person, by remote communication, or represented by proxy at a meeting of the stockholders and entitled to vote generally on the election of directors. ARCA&#8217;s stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors to be elected at any particular time. See the section of this proxy statement/prospectus titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Description of ARCA Capital Stock &#8212; Anti</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Takeover</span></span><span class="Italic" style="font-style:italic;font-weight:normal;"> Effects of Delaware Law and Provisions of the ARCA Charter and ARCA Bylaws</span>&#8221; for a description of elections of members of ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Dividends.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Subject to preferences that may be applicable to any then outstanding ARCA preferred stock, holders of ARCA common stock are entitled to receive dividends, if any, as may be declared from time to time by ARCA&#8217;s board of directors out of legally available funds.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Liquidation.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>In the event of ARCA&#8217;s liquidation, dissolution or winding up, holders of ARCA common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of ARCA&#8217;s debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of ARCA preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Rights and Preferences.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Holders of ARCA common stock have no preemptive, conversion, subscription or other rights, and there are no redemption provisions applicable to ARCA common stock. The rights, preferences and privileges of the holders of ARCA common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of ARCA preferred stock that ARCA may designate in the future.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Fully Paid and Nonassessable.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>All outstanding shares of ARCA common stock are fully paid and nonassessable.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the ARCA Charter, ARCA&#8217;s board of directors has the authority, without further action by ARCA&#8217;s stockholders, to issue up to 5,000,000<span class="nobreak"> </span>shares of ARCA preferred stock, in one or more series, to establish from time to time the number of shares to be included in each such series, and to fix the designations, powers, preferences, privileges and relative participating, optional or special rights and the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, voting rights, terms of redemption and repurchase, liquidation preferences and sinking fund terms, any or all of which may be greater than the rights of ARCA common stock. ARCA preferred stock may be convertible into ARCA common stock or other securities of ARCA, or may be exchangeable for debt securities. Conversion may be mandatory or at the holder&#8217;s option and would be at prescribed conversion rates. Because ARCA&#8217;s board of directors, without stockholder approval, can issue ARCA preferred stock with voting, conversion or other rights, ARCA preferred stock could be issued quickly </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">296</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">with terms calculated to delay or prevent a change in control of ARCA or make removal of management more difficult. Additionally, the issuance of ARCA preferred stock may have the effect of decreasing the market price of ARCA common stock and may adversely affect the voting power of holders of ARCA common stock and reduce the likelihood that ARCA&#8217;s common stockholders will receive dividend payments and payments upon liquidation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Delaware General Corporation Law provides that the holders of any class or series of ARCA preferred stock will have the right to vote separately as a class on any proposed amendment to the ARCA Charter that would alter or change the powers, preferences or special rights of the holders of such class or series of ARCA preferred stock so as to affect them adversely. This right is in addition to any voting rights that may be provided for in the applicable certificate of designation.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Series&#160;A Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors has designated 135,000 of the 5,000,000 authorized shares of preferred stock as &#8220;Series&#160;A Convertible Preferred Stock.&#8221;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Series&#160;A Convertible Preferred Stock ranks:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>senior to all of ARCA&#8217;s common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>on parity with any class or series of ARCA capital stock specifically ranking by its terms on parity with the Preferred Stock; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>junior to any class or series of ARCA capital stock specifically ranking by its terms senior to the Preferred Stock;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">in each case, as to distributions of assets upon ARCA&#8217;s liquidation, dissolution or winding up whether voluntarily or involuntarily.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each share of Series&#160;A Convertible Preferred Stock is convertible into 100<span class="nobreak"> </span>shares of ARCA&#8217;s common stock (subject to adjustment as provided in the related certificate of designation of preferences) at any time at the option of the holder, provided that the holder is prohibited from converting Preferred Stock into shares of ARCA&#8217;s common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of ARCA&#8217;s common stock then issued and outstanding.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of ARCA&#8217;s liquidation, dissolution, or winding up, holders of Series&#160;A Convertible Preferred Stock will receive a payment equal to $0.001 per share of Series&#160;A Convertible Preferred Stock before any proceeds are distributed to the holders of ARCA&#8217;s common stock. In addition, each share of Series&#160;A Convertible Preferred Stock will be entitled to receive, on an as<span class="nobreak">-if-converted</span> basis, <span class="Italic" style="font-style:italic;font-weight:normal;">pari passu</span> with each share of ARCA&#8217;s common stock, any distributions of ARCA&#8217;s assets or surplus funds which ARCA makes upon shares of ARCA&#8217;s common stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Shares of Series&#160;A Convertible Preferred Stock have no voting rights, except as required by law.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Except for stock dividends or certain other distributions set forth in the certificate of designation, shares of Series&#160;A Convertible Preferred Stock will be entitled to receive dividends (on an as<span class="nobreak">-converted</span> basis) in the same form as dividends actually paid on shares of ARCA&#8217;s common stock when and if declared by ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is not obligated to redeem or repurchase any shares of Series&#160;A Convertible Preferred Stock. Shares of Series&#160;A Convertible Preferred Stock are not otherwise entitled to any redemption rights, or mandatory sinking fund or analogous fund provisions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No shares of Series&#160;A Convertible Preferred Stock are currently issued and outstanding.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Series&#160;B Non-Voting Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s board of directors will designate approximately 137,398<span class="nobreak"> </span>shares of ARCA preferred stock as ARCA Series&#160;B Preferred Stock through its certificate of designation in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex</span>&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">F </span>(the &#8220;Certificate of Designation&#8221;), after giving effect to the estimated exchange ratio of 6.8699. Holders of the ARCA Series&#160;B Preferred Stock will be entitled to receive dividends on shares of ARCA Series&#160;B Preferred Stock equal to, on an </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">297</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">as<span class="nobreak">-if-converted-to-ARCA</span> common stock basis, and in the same form as dividends actually paid on shares of ARCA common stock. Except as otherwise required by the Certificate of Designation or law, the ARCA Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of ARCA Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the ARCA Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the ARCA Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend ARCA&#8217;s charter, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the ARCA Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the ARCA Series&#160;B Preferred Stock, (e)&#160;issue further shares of the ARCA Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the ARCA Series&#160;B Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued ARCA Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The ARCA Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding<span class="nobreak">-up</span> of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the closing of the First Merger (as defined elsewhere in this proxy statement/prospectus), each share of ARCA Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the ARCA Series&#160;B Preferred Stock, into a number of shares equal to 1,000<span class="nobreak"> </span>shares of ARCA common stock, subject to certain limitations, including that a holder of ARCA Series&#160;B Preferred Stock is prohibited from converting shares of ARCA Series&#160;B Preferred Stock into shares of ARCA common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 9.99%) of the total number of shares of ARCA common stock issued and outstanding immediately after giving effect to such conversion.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Anti-Takeover Effects of Delaware Law and Provisions of the ARCA Charter and ARCA Bylaws</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Certificate of Incorporation and Bylaws</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter and ARCA Bylaws include a number of provisions that may deter or impede hostile takeovers or changes of control. These provisions include:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Issuance of Undesignated ARCA preferred stock.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>Under the ARCA Charter, ARCA&#8217;s board of directors has the authority, without further action by the stockholders, to issue up to 5,000,000<span class="nobreak"> </span>shares of undesignated ARCA preferred stock with rights and preferences, including voting rights, designated from time to time by ARCA&#8217;s board of directors. The existence of authorized but unissued shares of ARCA preferred stock enables ARCA&#8217;s board of directors to make it more difficult or to discourage an attempt to obtain control of ARCA by means of a merger, tender offer, proxy contest or otherwise.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Classified Board.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The ARCA Charter provides for a classified board of directors consisting of three classes of directors, with staggered three<span class="nobreak">-year</span> terms. Only one class of directors will be elected at each annual meeting of ARCA&#8217;s stockholders, with the other classes continuing for the remainder of their respective three<span class="nobreak">-year</span> terms. This provision may have the effect of delaying a change in control of ARCA&#8217;s board of directors.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Board of Directors Vacancies.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The ARCA Charter and ARCA Bylaws authorize only ARCA&#8217;s board of directors to fill vacant directorships, unless ARCA&#8217;s board of directors determines by resolution that the stockholders shall fill such vacant directorships. In addition, the number of directors constituting ARCA&#8217;s board of directors may be set only by resolution adopted by a majority vote of ARCA&#8217;s entire board of directors. These provisions prevent a stockholder from increasing the size of ARCA&#8217;s board of directors and gaining control of ARCA&#8217;s board of directors by filling the resulting vacancies with its own nominees.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stockholder Action; Special Meetings of Stockholders.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The ARCA Charter provides that ARCA&#8217;s stockholders may not take action by written consent, but may only take action at annual or special meetings of ARCA&#8217;s stockholders. Under the ARCA Bylaws, stockholders are not permitted to cumulate their votes for the election of directors. The ARCA Bylaws further provide that special meetings of the stockholders may be called by </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">298</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the chief executive officer, president, ARCA&#8217;s board of directors, or by holders of ARCA common stock who hold, in the aggregate, not less than fifty percent (50%) of the outstanding shares of ARCA common stock for the purpose or purposes stated in the call of the meeting. These provisions may prevent stockholders from corporate actions as stockholders at times when they otherwise would like to do so.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Advance Notice Requirements for Stockholder Proposals and Director Nominations.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span>The ARCA Bylaws provide advance notice procedures for stockholders seeking to bring business before ARCA&#8217;s annual meeting of stockholders, or to nominate candidates for election as directors at ARCA&#8217;s annual meeting of stockholders. The ARCA Bylaws also specify certain requirements as to the form and content of a stockholder&#8217;s notice. These provisions may make it more difficult for ARCA&#8217;s stockholders to bring matters before ARCA&#8217;s annual meeting of stockholders or to nominate directors at ARCA&#8217;s annual meeting of stockholders.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">These provisions are intended to enhance the likelihood of continued stability in the composition of ARCA&#8217;s board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of ARCA.&#160;These provisions are designed to reduce ARCA&#8217;s vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, these provisions could have the effect of discouraging others from making tender offers for ARCA&#8217;s shares and, as a consequence, they may also reduce fluctuations in the market price of ARCA&#8217;s shares that could result from actual or rumored takeover attempts.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Section&#160;203 of the Delaware General Corporation Law</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is subject to Section&#160;203 of the Delaware General Corporation Law. Section&#160;203 generally prohibits certain Delaware corporations from engaging, under certain circumstances, in a &#8220;business combination&#8221; with any &#8220;interested stockholder for a period of three&#160;years following the time that such stockholder became an interested stockholder, unless:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>prior to such time the board of directors approved either the business combination or transaction which resulted in the stockholder becoming an interested stockholder;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (a)&#160;shares owned by persons who are directors and also officers and (b)&#160;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>at or subsequent to such time the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least&#160;66<span class="nobreak">-2</span>/3% of the outstanding voting stock which is not owned by the interested stockholder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;203 defines a business combination to include:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any merger or consolidation involving the corporation and the interested stockholder;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>any sale, lease, exchange, mortgage, pledge, transfer or other disposition (in one transaction or a series of transactions) involving the interested stockholder of 10% or more of the assets of the corporation (or its majority<span class="nobreak">-owned</span> subsidiary);</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>subject to exceptions, any transaction involving the corporation that has the effect, directly or indirectly, of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of such corporation), of any loans, advances, guarantees, pledges or other financial benefits, other than certain benefits set forth in Section&#160;203, provided by or through the corporation.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">299</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In general, Section&#160;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person that is an affiliate or associate of such entity or person.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or bylaws resulting from a stockholders&#8217; amendment approved by a majority of the outstanding voting shares. ARCA has not &#8220;opted out&#8221; of these provisions and do not plan to do so. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire ARCA.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potential Effects of Authorized but Unissued Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Shares of ARCA common stock and ARCA preferred stock are available for future issuance without stockholder approval. ARCA may utilize these additional shares for a variety of corporate purposes, including future public offerings to raise additional capital, to facilitate corporate acquisitions, payment as a dividend on the capital stock or as equity compensation to ARCA&#8217;s service providers under ARCA&#8217;s equity compensation plans.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The existence of unissued and unreserved ARCA common stock and ARCA preferred stock may enable ARCA&#8217;s board of directors to issue shares to persons friendly to current management or to issue ARCA preferred stock with terms that could render more difficult or discourage a third<span class="nobreak">-party</span> attempt to obtain control by means of a merger, tender offer, proxy contest or otherwise, thereby protecting the continuity of ARCA&#8217;s management. In addition, ARCA&#8217;s board of directors has the discretion to determine designations, rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences of each series of ARCA preferred stock, all to the fullest extent permissible under the Delaware General Corporation Law and subject to any limitations set forth in the ARCA Charter. The purpose of authorizing the board of directors to issue ARCA preferred stock and to determine the rights and preferences applicable to such ARCA preferred stock is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of ARCA preferred stock, while providing desirable flexibility in connection with possible financings, acquisitions and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from acquiring, a majority of ARCA&#8217;s outstanding voting stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Also, if ARCA issues additional shares of authorized, but unissued, ARCA common stock, these issuances will dilute the voting power and distribution rights of ARCA&#8217;s existing common stockholders.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amendments to Governing Documents</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Generally, the amendment of the ARCA Charter requires approval by ARCA&#8217;s board of directors and a majority vote of stockholders, provided that the provisions of the ARCA Charter relating to (i)&#160;the requirement that all stockholder action be taken only at a duly called annual meeting or special meeting; (ii)&#160;the authority and power of ARCA&#8217;s board of directors and the procedure required to amend ARCA Bylaws; (iii)&#160;the percentage of the shares necessary to amend the ARCA Charter; (iv)&#160;the elimination of directors&#8217; personal liability for monetary damages arising from their negligence and gross negligence; and (v)&#160;indemnification of directors, officers and other persons requires approval of ARCA&#8217;s stockholders holding at least&#160;66<span class="nobreak">-2</span>/3% of ARCA&#8217;s capital stock then outstanding and entitled to vote. Any amendment to ARCA Bylaws requires the approval of either a majority of ARCA&#8217;s board of directors or approval of ARCA&#8217;s stockholders holding at least&#160;66<span class="nobreak">-2</span>/3% of ARCA&#8217;s capital stock then outstanding and entitled to vote.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Listing</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA common stock is listed on the Nasdaq Capital Market under the symbol &#8220;ABIO.&#8221;</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Transfer Agent and Registrar</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The transfer agent and registrar for ARCA common stock is Computershare Trust Company N.A.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">300</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T7"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">COMPARISON OF RIGHTS OF HOLDERS OF ARCA CAPITAL STOCK AND <br/>ORUKA CAPITAL STOCK</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Merger is completed, Oruka stockholders will receive shares of ARCA common stock and ARCA Series&#160;B Preferred Stock, pursuant to the terms of the Merger Agreement. Prior to or upon the closing of the Merger, assuming that Proposal&#160;Nos.<span class="nobreak"> </span>2, 3 and 4 are approved by ARCA&#8217;s stockholders, the ARCA Charter will be amended to increase the number of shares of ARCA common stock that ARCA is authorized to issue from 100,000,000 to 545,000,000, to effect the proposed reverse stock split and to reflect Delaware law provisions regarding officer exculpation, respectively, as set forth in the forms of certificates of amendment attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;G, Annex&#160;H </span>and <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;I</span>,<span class="Italic" style="font-style:italic;font-weight:normal;">&#160;</span>to this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Oruka are both incorporated under the laws of the State of Delaware. The rights of ARCA stockholders and Oruka stockholders are generally governed by the DGCL.&#160;Upon completion of the Merger, Oruka stockholders will become ARCA stockholders, and their rights will be governed by the DGCL, the ARCA Bylaws and the ARCA Charter, as amended.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The material differences between the current rights of Oruka stockholders under the Oruka Charter and Oruka Bylaws and their rights as ARCA stockholders, after the Merger, under the ARCA Charter and ARCA Bylaws, both as will be in effect immediately following the completion of the Merger and assuming that that Proposal&#160;Nos.<span class="nobreak"> </span>2, 3 and 4 are approved by ARCA&#8217;s stockholders, are summarized below. The summary below does not purport to be complete and is subject to, and qualified in its entirety by reference to, the DGCL and the governing corporate instruments that are subject to amendment in accordance with their terms. You should carefully read this entire document and the other referenced documents, including the governing corporate instruments, for a more complete understanding of the differences between being a stockholder of ARCA or Oruka before the Merger and being a stockholder of the combined company following the completion of the Merger. For more information on how to obtain these documents, see the section titled &#8220;<span class="Italic" style="font-style:italic;font-weight:normal;">Where You Can Find More Information</span>&#8221; beginning on page 321 of this proxy statement/prospectus.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Organizational Documents</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">The rights of ARCA stockholders are governed by the ARCA Charter, ARCA Bylaws and the DGCL.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The rights of Oruka stockholders are governed by the Oruka Charter, Oruka Bylaws and the DGCL.&#160;Rights of certain holders of Oruka preferred stock are governed by the Investors&#8217; Rights Agreement (the &#8220;Oruka IRA&#8221;), the Right of First Refusal and Co<span class="nobreak">-Sale</span> Agreement (the &#8220;Oruka ROFR Agreement&#8221;), and the Voting Agreement, each dated as of March&#160;6, 2024.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Authorized Capital Stock</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">ARCA is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares that ARCA is authorized to issue is 105,000,000, of which 100,000,000<span class="nobreak"> </span>shares are common stock, par value $0.001 per share, and 5,000,000<span class="nobreak"> </span>shares are preferred stock, par value $0.001 per share.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka is authorized to issue two classes of capital stock which are designated, respectively, &#8220;common stock&#8221; and &#8220;preferred stock.&#8221; The total number of shares that Oruka is authorized to issue is 85,000,000, of which 65,000,000<span class="nobreak"> </span>shares are common stock, par value $0.0001 per share, and 20,000,000<span class="nobreak"> </span>shares are preferred stock, par value $0.0001 per share. The number of authorized shares of Oruka common stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Oruka preferred stock that may be required under the Oruka Charter) the affirmative vote of the holders of shares of Oruka capital stock representing a majority of the votes represented by all outstanding shares of Oruka capital stock entitled to vote, irrespective of the provisions of Section&#160;242(b)(2) of the DGCL.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">301</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Common Stock</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">ARCA&#8217;s authorized common stock consists of 100,000,000<span class="nobreak"> </span>shares of common stock, par value $0.001 per share. </p>
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">Each holder of a share of ARCA common stock is entitled to one vote for each such share held of record on the applicable record date on each matter voted on at a meeting of stockholders.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka&#8217;s authorized common stock consists of 65,000,000<span class="nobreak"> </span>shares of common stock, par value $0.0001 per share. </p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Each holder of a share of Oruka common stock is entitled to one vote for each such share held of record on the applicable record date on each matter voted on at a meeting of stockholders (and written actions in lieu of meetings).</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Preferred Stock</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">ARCA&#8217;s authorized preferred stock consists of 5,000,000<span class="nobreak"> </span>shares of preferred stock of which ARCA&#8217;s board of directors has designated 135,000<span class="nobreak"> </span>shares of preferred stock as &#8220;Series&#160;A Convertible Preferred Stock.&#8221; </p>
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">No shares of ARCA Series&#160;A Convertible Preferred Stock or undesignated preferred stock are currently outstanding. ARCA&#8217;s board of directors is authorized to issue shares of undesignated preferred stock in one or more series and to fix the designations, powers, preferences and relative, participating, optional and other rights, and any qualifications, limitations and restrictions, on such shares. </p>
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;margin-top:8pt;text-indent:0pt;">In connection with the Merger, ARCA&#8217;s board of directors intends to designate shares of undesignated preferred stock as Series&#160;B Non-Voting Convertible Preferred Stock through a certificate of designation in the form attached as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;F </span>(the &#8220;Certificate of Designation&#8221;). No shares of Series&#160;B Non-Voting Convertible Preferred Stock are currently authorized or outstanding. As long as any shares of Series&#160;B Non-Voting Preferred Stock are outstanding, ARCA will not, without the affirmative vote or written waiver of the holders of a majority of the then outstanding shares of the Series&#160;B Non-Voting Preferred Stock: (i)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;B Non-Voting Preferred Stock or alter or amend the Certificate of Designation, amend or repeal any provision of, or add any provision to, the ARCA Charter or ARCA Bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of ARCA preferred stock, in each case if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;B Non-Voting Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the ARCA Charter or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (ii)&#160;issue further shares of Series&#160;B Non-Voting Preferred Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than by conversion) the number of authorized shares of Series&#160;B Non-Voting Preferred Stock, (iii)&#160;at any time while at least 30% of the originally issued ARCA Series&#160;B Non-Voting Preferred Stock remains issued and outstanding, consummate either: (A)&#160;any Fundamental Transaction</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">All of Oruka&#8217;s 20,000,000<span class="nobreak"> </span>shares of preferred stock are designated as shares of &#8220;Series&#160;A Preferred Stock,&#8221; of which 20,000,000 are issued and outstanding. Each holder of a share of Oruka preferred stock is entitled to cast the number of votes equal to the number of whole shares of Oruka common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">302</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">(as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA with or into another entity or any stock sale to, or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority on an as<span class="nobreak">-converted-to-ARCA</span> common stock basis of the capital stock of ARCA, immediately after such transaction or (iv)&#160;enter into any agreement with respect to any of the foregoing that does not explicitly require the approval contemplated herein to consummate such transaction.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Number and Qualification of Directors</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The number of ARCA directors is not less than two (2)&#160;nor more than ten (10), the exact number determined from time to time by resolution of ARCA&#8217;s board of directors, acting by the affirmative vote of a majority of the directors. The ARCA&#8217;s board of directors currently consists of five (5)&#160;members. No decrease in the authorized number of directors constituting ARCA&#8217;s board of directors will shorten the term of any incumbent director. Directors of ARCA need not be stockholders of ARCA.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The number of directors of Oruka is established from time to time by the board of directors. Oruka&#8217;s board of directors currently consists of six members.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Structure of Board of Directors; Term of Directors; Election of Directors</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA&#8217;s board of directors is divided into three classes, designated as Class&#160;I, Class&#160;II and Class&#160;III, respectively. Election of directors need not be by written ballot. The term of office of the first class expired at the first annual meeting of stockholders or any special meeting in lieu thereof following January&#160;1, 2004, the term of office of the second class expired at the second annual meeting of stockholders or any special meeting in lieu thereof following January&#160;1, 2004 and the term of office of the third class expired at the third annual meeting of stockholders or any special meeting in lieu thereof following January&#160;1, 2004.&#160;At each succeeding annual meeting of stockholders, or special meeting in lieu thereof, directors are elected for a full term of three&#160;years to succeed the directors of the class whose terms expire at such annual meeting or special meeting lieu of thereof. Notwithstanding the foregoing, directors elected to each class hold office until their successors are duly elected and qualified.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka directors shall be elected at the annual meeting of stockholders by such stockholders as have the right to vote on such election. Election of directors need not be by written ballot. Each director shall hold office for a term of one year and until his or her successor is elected and qualified, or until such director&#8217;s earlier resignation or removal. </p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The holders of record of the shares of Oruka&#8217;s Series&#160;A Preferred Stock, voting together exclusively and as a separate class, are entitled to elect one director of Oruka. The holders of record of the shares of common stock and of any other class or series of voting stock (including the Series&#160;A Preferred Stock), exclusively and voting together as a single class on an as<span class="nobreak">-converted</span> to Common Stock basis, shall be entitled to elect the balance of the total number of directors.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Removal of Directors</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any director may be removed from office at any time, but only with cause and only by the affirmative vote of the holders of sixty<span class="nobreak">-six</span> and two<span class="nobreak">-third</span> percent or more of the voting power of the outstanding shares of capital stock of ARCA entitled to vote at an election of directors, unless otherwise provided under the DGCL or the ARCA Charter.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any one or more or all of the Oruka directors may be removed, with or without cause, by the holders of a majority of shares entitled to vote at an election of directors, except that any director elected by the holders of Series&#160;A Preferred Stock may be removed without cause only by the affirmative vote of the holders of a majority of the outstanding shares of Series&#160;A Preferred Stock, together as a single class on an as<span class="nobreak">-converted</span> to common stock basis, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">303</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Vacancies on the Board of Directors</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any director may resign at any time by giving notice in writing to ARCA Chairperson of the board of directors, if one is elected, the ARCA Vice Chairperson of the board of directors, if one is elected, the Chief Executive Officer or the President. Such resignation shall be effective upon receipt, unless the resignation otherwise provides. Any vacancies and any newly created directorships resulting from any increase in the number of directors, will be filled solely and exclusively by the affirmative vote of a majority of the remaining directors then in office, even if less than a quorum, or by a sole remaining director, and not by the ARCA stockholders. Any director elected in accordance with the preceding sentence will hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#8217;s successor is elected and qualified or until his or her earlier resignation, death or removal.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any director may resign at any time upon notice given in writing or by electronic transmission to Oruka. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other event. A vacancy in any director seat not reserved for holders of Series&#160;A Preferred Stock can be filled by either (A)&#160;the vote or written consent in lieu of a meeting of the stockholders entitled elect those directors, or (B)&#160;the vote or written consent in lieu of a meeting of a majority of the remaining director(s), although less than a quorum. Vacancies and newly created directorships resulting from any increase in the authorized number of directors may be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and the directors so chosen shall hold office until the next annual election and until their successors are duly elected and shall qualify, unless sooner displaced. If there are no directors in office, then an election of directors may be held in the manner provided by statute. </p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">If the holders of shares of Series&#160;A Preferred Stock fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, then any directorship not so filled shall remain vacant until such time as the holders of the Series&#160;A Preferred Stock elect a person to fill such directorship.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stockholder Action by Written Consent</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-16" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">No action may be taken by the ARCA stockholders except at an annual or special meeting of the ARCA stockholders called in accordance with the ARCA Bylaws, and no action may be taken by the ARCA stockholders by written consent in lieu of a meeting.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Any action required or permitted to be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, is signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. Every written consent shall bear the date of signature of each stockholder who signs the consent, and no written consent shall be effective to take the corporate action referred to therein unless, within 60&#160;days of the earliest dated consent delivered to Oruka, a written consent signed by a sufficient number of stockholders to take action are delivered to Oruka.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">304</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Quorum</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Subject to the provisions of the ARCA Bylaws, ARCA Charter and the DGCL as to the vote that is required for a specified action, the presence in person or by proxy of the holders of at least one<span class="nobreak">-third</span> of the outstanding shares of ARCA entitled to vote at any meeting of stockholders shall constitute a quorum for the transaction of business.&#160;In the absence of a quorum, stockholders holding a majority of the shares present in person or by proxy and entitled to vote, regardless of whether or not they constitute a quorum, or if no stockholders are present, any officer entitled to preside at or act as secretary of the meeting, may adjourn the meeting to another time and place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Except as otherwise provided by the DGCL or the Oruka Charter, the holders of a majority of the voting power of all of the shares of stock entitled to vote at the meeting, present in person or by proxy, shall constitute a quorum for all purposes. Where a separate vote by a class or series is required, a majority of the voting power of the shares of such class or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter. The stockholders present at a duly constituted meeting may continue to transact business until adjournment notwithstanding the withdrawal of enough stockholders to reduce the voting shares below a quorum. If a quorum shall fail to attend any meeting, the chairman of the meeting or the holders of a majority of the shares of stock entitled to vote who are present, in person or by proxy, may adjourn the meeting to another place, if any, date, or time.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Special Meetings of Stockholders</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Special meetings of the stockholders may be called by ARCA&#8217;s board of directors, Chief Executive Officer, President, or by holders of ARCA common stock who hold, in the aggregate, not less than fifty percent (50%) of the outstanding shares of ARCA common stock for the purpose or purposes stated in the call of the meeting.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Special meetings of the stockholders, for any purpose or purposes prescribed in the notice of the meeting, may be called by Oruka&#8217;s board of directors or the Chief Executive Officer if one is elected, or the President, and shall be held at such place, date, and time as they or he or she shall fix.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Notice of Stockholder Meetings</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Notice of all meetings of ARCA stockholders shall state the place, if any, date and hour of the meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called, shall be given to each stockholder entitled to vote at the meeting, and unless otherwise provided in the DGCL, the ARCA Charter or the ARCA Bylaws, the notice shall be given not less than ten nor more than sixty&#160;days before the meeting to each stockholder entitled to vote at the meeting as of the record date for determining the stockholders entitled to notice of the meeting, and, if mailed, shall be deposited in the United&#160;States mail, postage prepaid, directed to the stockholder at the stockholder&#8217;s address as it appears on the records of ARCA.&#160;The notice to stockholders for any meeting will be given in accordance with Section&#160;232 of the DGCL.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Except as otherwise provided by the DGCL or the Oruka Charter, notice of the place, date, and time of all meetings of the stockholders, the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders entitled to vote at the meeting, shall be given not less than 10&#160;days nor more than 60&#160;days before date of the meeting to each stockholder entitled to vote at such meeting as of the record date for determining the stockholders entitled to notice of the meeting.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">305</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Advance Notice Requirements for Stockholder Proposals</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Nominations of persons for election to ARCA&#8217;s board of directors and the proposal of business to be considered by the stockholders may be made at an annual meeting of stockholders (i)&#160;pursuant to the corporation&#8217;s notice of meeting, (ii)&#160;by or at the direction of ARCA&#8217;s board of directors, or (iii)&#160;by any stockholder of ARCA who is a stockholder of record at the time of giving notice provided for in the ARCA Bylaws, who is entitled to vote at the meeting, who is present (in person or by proxy) at the meeting and who complies with the notice procedures set forth in the ARCA Bylaws as to such nomination or business. </p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">For the avoidance of doubt, the foregoing clause (ii)&#160;shall be the exclusive means for a stockholder to bring nominations or business properly before an annual meeting of stockholders (other than matters properly brought under Rule&#160;14a<span class="nobreak">-8</span> (or any successor rule) under the Exchange&#160;Act).</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Neither the Oruka Charter nor the Oruka Bylaws contain advance notice requirements for stockholder proposals.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Amendment of Certificate of Incorporation</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The ARCA Charter provides that it may be amended by the affirmative vote of the majority of the voting rights of all classes of capital stock entitled to vote, provided, however, that no amendment, alteration, change or repeal of any provision requiring the affirmative vote of the holders of more than a majority of the voting rights may be made unless approved by the affirmative vote of such greater number of holders. The affirmative vote of the holders of 66 2/3% of the voting rights is required to amend, repeal or adopt any provision inconsistent with the provisions of the ARCA Charter relating to: (i)&#160;the requirement that all stockholder action be taken only at a duly called annual meeting or special meeting; (ii)&#160;the authority and power of ARCA&#8217;s board of directors and the procedure required to amend the ARCA Bylaws; (iii)&#160;the percentage of the shares necessary to amend the ARCA Charter; (iv)&#160;the elimination of ARCA&#8217;s directors&#8217; personal liability for monetary damages arising from their negligence and gross negligence; and (v)&#160;indemnification of ARCA&#8217;s directors, officers and other persons.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The Oruka Charter may be amended pursuant to Section&#160;242 of the DGCL; provided that, at any time when shares of preferred stock are outstanding, the written consent or affirmative vote of the holders of at least a majority of the outstanding shares of preferred stock, voting together as a single class on an as<span class="nobreak">-converted</span> to common stock basis (the &#8220;Requisite Holders&#8221;), is required to (i)&#160;amend, alter or repeal of any provision of the Oruka Charter in a manner that adversely affects the special rights, powers, and preferences of the preferred stock or any series thereof, (ii)&#160;create or issue any capital stock unless the same ranks junior to the preferred stock with respect to its special rights, powers and preferences or (iii)&#160;increase the authorized number of shares of preferred stock or any additional class or series of capital stock of Oruka unless the same ranks junior to the preferred stock with respect to its special rights, powers and preferences.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Amendment of Bylaws</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-20" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Except as otherwise provided by law, the ARCA Bylaws may be amended or repealed by ARCA&#8217;s board of directors. The ARCA Bylaws may also be amended or repealed by the stockholders by the affirmative vote of not less than&#160;66<span class="nobreak">-2</span>/3% of the outstanding shares of capital stock entitled to vote, voting together as a single class.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The Oruka Bylaws may be amended or repealed by Oruka&#8217;s board of directors or by the stockholders; provided that, at any time when shares of preferred stock are outstanding, the written consent or affirmative vote of the Requisite Holders is required to amend, alter or repeal of any provision of the Oruka Bylaws in a manner that adversely affects the special rights, powers, and preferences of the preferred stock or any series thereof.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">306</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Limitation on Director and Officer Liability</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-21" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">To the fullest extent permitted by the DGCL, as the same exists or as may hereafter be amended, a director of ARCA shall not be personally liable to ARCA or its stockholders for monetary damages for breach of fiduciary duty as a director. Any amendment, repeal or modification of Article&#160;IX of the ARCA Charter shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring before such amendment, repeal or modification of a person serving as a director at the time of such amendment, repeal or modification.</p>
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">To the fullest extent permitted by the DGCL, as the same exists or may hereafter be amended, an officer of ARCA shall not be personally liable to ARCA or its stockholders for monetary damages for breach of fiduciary duty as an officer. Any amendment, repeal or modification of Article XIII of the ARCA Charter shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring before such amendment, repeal or modification of a person serving as an officer at the time of such amendment, repeal or modification.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">To the fullest extent permitted by law, a director or officer of Oruka shall not be personally liable to Oruka or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the DGCL or any other law of the State of Delaware is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of Oruka shall be eliminated or limited to the fullest extent permitted by the DGCL as so amended. Any amendment, repeal or elimination of the foregoing provisions by the Oruka stockholders shall not adversely affect any right or protection of a director of Oruka existing at the time of, or increase the liability of any Oruka director with respect to any acts or omissions of such director occurring prior to, such amendment, repeal or elimination.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Indemnification</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-22" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA will indemnify any person who was or is a party or is threatened to be made a party to, or otherwise becomes involved in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative and whether internal or external to ARCA (a &#8220;Proceeding&#8221;), by reason of the fact that the person is or was a director, officer, employee, or other agent of ARCA, or is or was serving at the request of ARCA as a director, officer, employee or agent of another foreign or domestic corporation, partnership, joint venture, trust or other enterprise (any such person, an &#8220;Agent of ARCA&#8221;). Expenses incurred by an Agent in connection with a Proceeding shall be paid by ARCA as they are incurred and in advance of the final disposition of such Proceeding, subject to certain conditions. These rights to indemnification and advancement of expenses shall not be deemed exclusive of any other rights to which a person seeking indemnification or advancement of expenses may be entitled. ARCA has the power to purchase and maintain insurance on behalf of any person who is or was an Agent of ARCA against any liability asserted against the person and incurred by the person in any such capacity, or arising out of the person&#8217;s status as such, whether or not ARCA would have the power to indemnify the person against such liability.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">To the fullest extent permitted by applicable law, Oruka is authorized to provide indemnification of (and advancement of expenses to) its directors, officers and agents (and any other persons to which the DGCL permits Oruka to provide indemnification) through Oruka Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section&#160;145 of the DGCL.&#160;Any amendment, repeal, modification or elimination of the foregoing provisions shall not (a)&#160;adversely affect any right or protection of any director, officer or other agent of Oruka existing at the time of such amendment, repeal, modification or elimination; or (b)&#160;increase the liability of any Oruka director, officer or agent with respect to any acts or omissions of such director, officer or agent occurring prior to, such amendment, repeal, modification or elimination. The Oruka Bylaws require Oruka to indemnify, to the fullest extent permitted by Delaware law, as the same exists or may hereafter be amended, and except in certain circumstances, each person who was or is made a party to or is threatened to be made a party to or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a &#8220;proceeding&#8221;), by reason of the fact that he or she is or was a director or an officer of Oruka or is or was serving at the request of Oruka as a director, officer, or trustee of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to an employee benefit</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">307</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">plan, whether the basis of such proceeding is alleged action in an official capacity as a director, officer or trustee, or in any other capacity while serving as a director, officer or trustee (an &#8220;indemnitee&#8221;). The Oruka Bylaws also provide that an indemnitee will have the right to be paid by Oruka expenses (including attorney&#8217;s fees) incurred in defending any such proceeding in advance of its final disposition, provided, however, that, if the DGCL requires, an advancement of expenses incurred by an indemnitee in his or her capacity as a director or officer shall be made only upon delivery to Oruka of an undertaking, by or on behalf of such indemnitee, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right to appeal that such indemnitee is not entitled to be indemnified for such expenses. The Oruka Bylaws also provide that the rights to indemnification and advance of expenses shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, the Oruka Charter, the Oruka Bylaws, agreement, vote of stockholders or disinterested directors or otherwise.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Conversion Rights</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have any outstanding shares of Series&#160;A Convertible Preferred Stock or undesignated preferred stock. When the Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock is issued in connection with the Merger, the holders of Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock will have the right to convert such shares into ARCA common stock at any time a ratio of 1<span class="nobreak"> </span>share of Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to 1000<span class="nobreak"> </span>shares of ARCA common stock.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The Oruka Charter provides that holders of preferred stock have the right to convert such shares into shares of common stock, at the option of the holder, at any time, at a conversion rate in accordance with the terms set forth in the Oruka Charter. In addition, upon the earliest to occur of (i)&#160;immediately prior to the closing of the sale of shares of common stock to the public at a price of at least $1.00 per share (subject to appropriate adjustment for any stock dividend, stock split, combination or other similar recapitalization with respect to the common stock) in a firm<span class="nobreak">-commitment</span> underwritten public offering pursuant to an effective registration statement under the Securities Act, resulting in at least $50,000,000 of gross proceeds to Oruka and in connection with such offering the shares of Oruka common stock are listed for trading on the Nasdaq Stock Market&#8217;s National Market, the New&#160;York Stock Exchange or another exchange or marketplace approved by Oruka&#8217;s board of directors; and (ii)&#160;the date and time, or the occurrence of an event, specified by vote or written consent of the Requisite Holders, all outstanding shares of preferred stock will automatically be converted into shares of common stock, at the then effective conversion rate as calculated in accordance with the Oruka Charter.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">308</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Right of First Refusal</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-25" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have a right of first refusal in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Certain stockholders party to the Oruka ROFR Agreement wishing to transfer any shares of Oruka capital stock (other than any shares of preferred stock or common stock that are issued or issuable upon conversion of preferred stock) must first provide Oruka with the right to purchase such shares. In such an event, if Oruka does not elect to exercise its right of first refusal in full, certain stockholders party to the Oruka ROFR Agreement have a secondary refusal right to purchase all or any portion of such shares of Oruka capital stock which are proposed for sale or transfer and not purchased by Oruka pursuant to its right of first refusal.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Right of Co</span><span class="nobreak"><span class="Italic" style="font-style:italic;font-weight:normal;">-Sale</span></span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-26" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have a right of co<span class="nobreak">-sale</span> in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Certain stockholders party to the Oruka ROFR Agreement have a right of co<span class="nobreak">-sale</span> with respect to any Oruka capital stock proposed to be transferred or sold that is not either purchased by Oruka by exercise of its right of first refusal (as further described above) or by any Oruka stockholder by exercise of their secondary refusal right (as further described above), each pursuant to the Oruka ROFR Agreement.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Preemptive Rights</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA stockholders do not have preemptive rights. Thus, if additional shares of ARCA common stock are issued, the current holders of ARCA common stock will own a proportionately smaller interest in a larger number of outstanding shares of common stock to the extent that they do not participate in the additional issuance.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Pursuant to the Oruka IRA, if Oruka proposes to offer or sell certain new equity securities, Oruka must first offer such securities to each Major Investor (as defined in the Oruka IRA, who will then have a right to purchase securities in such new offering equal to the proportion of the ownership interest of such Major Investor prior to such offering.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Distributions to Stockholders</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-27" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Dividends upon ARCA capital stock, subject to the provisions of the ARCA Charter and applicable law, if any, may be declared by ARCA&#8217;s board of directors. Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of the ARCA Charter and applicable law. ARCA&#8217;s board of directors may fix a record date for the determination of holders of ARCA capital stock entitled to receive payment of a dividend or distribution declared thereon, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date may not be more than 60&#160;days prior to the date fixed for the payment thereof.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka shall not declare, pay or set aside any dividends (other than dividends on shares of common stock payable in shares of common stock) unless holders of preferred stock first receive, or simultaneously receive, a dividend on each outstanding share of preferred stock in an amount calculated in accordance with the Oruka Charter.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">309</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Exclusive Forum</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-28" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have an exclusive forum in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">The Oruka Charter provides that, unless Oruka consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&#160;any derivative action or proceeding brought on behalf of Oruka, (ii)&#160;any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of Oruka to Oruka or Oruka&#8217;s stockholders, (iii)&#160;any action asserting a claim against Oruka, its directors, officers or employees arising pursuant to any provision of the DGCL, the Oruka Charter or the Oruka Bylaws or (iv)&#160;any action asserting a claim against Oruka, its directors, officers or employees governed by the internal affairs doctrine or that otherwise relates to the internal affairs of Oruka, except for, as to each of (i)&#160;through (iv)&#160;above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten&#160;days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. These provisions may impose additional costs on Oruka&#8217;s stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or were permitted to select another jurisdiction. Additionally, these provisions may limit Oruka&#8217;s stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with Oruka or its directors, officers or other employees, which may discourage such lawsuits against Oruka and its directors, officers and other employees even though an action, if successful, might benefit its stockholders.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Registration Rights</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have any registration rights in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Under the Oruka IRA, certain holders of Oruka capital stock that are party to the Oruka IRA, have certain registration rights, including the right to demand that Oruka file a registration statement, so called &#8220;demand&#8221; registration rights, or request that their shares be covered by a registration statement that Oruka is otherwise filing, so<span class="nobreak">-called</span> &#8220;piggyback&#8221; registration rights. The registration rights granted under the Oruka IRA will terminate upon the earlier of: (i)&#160;the closing of a Deemed Liquidation Event (as such term is defined in the Oruka Charter), (ii)&#160;such time after Oruka&#8217;s initial public offering when all registrable securities could be sold under Rule&#160;144 of the Securities Act or a similar exemption without limitation during a three<span class="nobreak">-month</span> period without registration or (iii)&#160;the third anniversary of Oruka&#8217;s initial public offering.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">310</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Oruka</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stock Transfer Restrictions Applicable to Stockholders</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-29" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Shares of ARCA are transferable in the manner prescribed by the DGCL.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Shares of Oruka are transferable in the manner prescribed by the DGCL, subject to additional limits on certain holders of Oruka capital stock party to the Oruka ROFR Agreement and Oruka IRA.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 100.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stockholder Rights Plan</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-30" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">ARCA does not have a stockholder rights plan in place.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Oruka does not have a stockholder rights plan in place.</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">311</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T6"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF ARCA</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Security Ownership of Certain Beneficial Owners</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth certain information regarding the ownership of ARCA common stock as of July<span class="nobreak"> </span>16, 2024, by: (i)&#160;each director of ARCA, (ii)&#160;each ARCA named executive officer, (iii)&#160;all executive officers and directors of ARCA as a group and (iv)&#160;all those known by ARCA to be beneficial owners of more than five percent of its common stock. Unless otherwise noted below, the address of each beneficial owner listed on the table is c/o ARCA biopharma, Inc., 10170 Church Ranch Way, Suite 100, Westminster, Colorado, 80021.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has determined beneficial ownership in accordance with the rules of the SEC and includes voting or investment power with respect to ARCA common stock. Except as indicated by the footnotes below, ARCA believes, based on the information furnished to it, that the persons and entities named in the table below have sole voting and investment power with respect to all shares of ARCA common stock that they beneficially own, subject to applicable community property laws. The table is based upon information supplied by officers, directors and principal stockholders of ARCA and Schedules 13G or 13D, Form&#160;4s or other ownership reports filed with the SEC.&#160;Except as contemplated by the Merger and the Merger Agreement, ARCA does not know of any arrangements, including any pledge by any person of its securities, the operation of which may at a subsequent date result in a change of control of ARCA.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In computing the number of shares of ARCA common stock beneficially owned by a person and the percentage ownership of that person, ARCA deemed outstanding shares of ARCA common stock subject to options or warrants held by that person that are currently exercisable or exercisable within 60&#160;days of July<span class="nobreak"> </span>16, 2024. ARCA did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">The percentages below are based on 14,507,143<span class="nobreak"> </span>shares of ARCA common stock outstanding as of July<span class="nobreak"> </span>16, 2024.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Beneficial Owner</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Shares <br/>Beneficially<br/>Owned</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Percentage<br/>Shares <br/>Beneficially<br/>Owned</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Directors and Named Executive Officers</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Michael R.&#160;Bristow, M.D., Ph.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">270,108</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Thomas A.&#160;Keuer<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">139,355</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">C.&#160;Jeffrey Dekker<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">102,059</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Linda Grais, M.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">22,895</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Robert E.&#160;Conway<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">72,895</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Anders Hove, M.D.<span class="Superscript" style="vertical-align:super;font-size:58%;">(6)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">22,499</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Jacob Ma-Weaver<span class="Superscript" style="vertical-align:super;font-size:58%;">(7)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,018,619</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">James Flynn<span class="Superscript" style="vertical-align:super;font-size:58%;">(8)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,167</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">All current directors and executive officers as a group (7 persons)</span><span class="Superscript" style="vertical-align:super;font-size:58%;font-style:normal;font-weight:bold;">(9)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,388,489</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">29.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">5% Stockholders</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Funicular Funds, LP<span class="Superscript" style="vertical-align:super;font-size:58%;">(10)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,018,619</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Adage Capital<span class="Superscript" style="vertical-align:super;font-size:58%;">(11)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,200,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Janus Henderson<span class="Superscript" style="vertical-align:super;font-size:58%;">(12)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,891,312</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Allostery Investments<span class="Superscript" style="vertical-align:super;font-size:58%;">(13)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,065,016</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Avidity Partners<span class="Superscript" style="vertical-align:super;font-size:58%;">(14)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Venrock Healthcare Capital Partners<span class="Superscript" style="vertical-align:super;font-size:58%;">(15)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">754,669</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Less than 1%.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes the following: (i)&#160;1,109<span class="nobreak"> </span>shares owned by Investocor Trust, of which Dr.&#160;Bristow is the sole trustee; (ii)&#160;1,414<span class="nobreak"> </span>shares owned by NFS as Custodian for Michael Bristow&#8217;s IRA; and (iii)&#160;options to purchase 265,300<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of July 16, 2024. Dr. Bristow and ARCA mutually agreed to conclude Dr. Bristow&#8217;s employment effective April 3, 2024. Dr. Bristow&#8217;s equity awards continue to vest during the term of his Consulting Agreement, dated as of April 3, 2024, with ARCA.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 98,625<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of July 16, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 62,059<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of July 16, 2024.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">312</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 22,895<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of July 16, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 22,895<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of July 16, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 22,499<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of July 16, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(7)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 18,167<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of July 16, 2024. Also see Footnote (10)&#160;below.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(8)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes options to purchase 10,167<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of July 16, 2024.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(9)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>See Notes (2)&#160;through (8)&#160;above.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(10)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Includes options to purchase 18,167<span class="nobreak"> </span>shares that are exercisable within 60&#160;days of July 16, 2024 by Jacob Ma<span class="nobreak">-Weaver</span> and shares reported on the Form&#160;4 filed on December&#160;19, 2022 by The Funicular Funds, LP (the &#8220;Fund&#8221;) and Mr.&#160;Ma<span class="nobreak">-Weaver</span>, reporting stock ownership as of December&#160;16, 2022. The Fund, the Funicular Fund (&#8220;Funicular&#8221;), Cable Car Capital LLC (&#8220;Cable Car&#8221;) and Mr.&#160;Ma<span class="nobreak">-Weaver</span> may be deemed to be a member of a Section&#160;13(d)&#160;group that may be deemed to collectively beneficially own more than 10% of ARCA&#8217;s outstanding shares of common stock. Despite such shared beneficial ownership, the reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein. Funicular, as a feeder fund to the Fund, may be deemed to beneficially own the securities directly owned by the Fund. Cable Car, as the general partner of the Fund, may be deemed to beneficially own the securities directly owned by the Fund. Mr.&#160;Ma<span class="nobreak">-Weaver</span>, as the Managing Member of Cable Car, may be deemed to beneficially own the securities directly owned by the Fund.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(11)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13D filed on April&#160;5, 2024 reporting stock ownership as of April&#160;3, 2024 with respect to the following reporting persons: Adage Capital Management, L.P. (&#8220;ACM&#8221;), Robert Atchinson, and Phillip Gross. ACM and Messrs. Consists of 1,200,000 shares of ARCA common stock held directly by Adage Capital Partners, L.P. (&#8220;ACP&#8221;). Adage Capital Partners GP, L.L.C. (&#8220;ACPGP&#8221;) is the general partner of ACP. ACM is the investment manager of ACP. Adage Capital Advisors, L.L.C. (&#8220;ACA&#8221;) is managing member of ACPGP. Adage Capital Partners LLC (&#8220;ACPLLC&#8221;) is general partner of ACM. Messrs. Atchinson and Gross are managing members of ACA and ACPLLC. Messrs. Atchinson and Gross may be deemed to have shared voting power and dispositive power over the shares held directly by ACP. The address of each of the entities and persons listed above is 200&#160;Clarendon Street, 52<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">nd</span> Floor, Boston, Massachusetts 02116.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(12)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based on a Schedule&#160;13G filed on July 5, 2024 reporting stock ownership as of July 2, 2024 and the Form 4 filed July 12, 2024 reporting stock ownership as of July 11, 2024, each with respect to the following reporting persons: Janus Henderson Group plc (&#8220;JHG&#8221;) and Janus Henderson Biotech Innovation Master Fund Ltd (&#8220;JHB&#8221;). Consists of 1,891,312 shares of ARCA common stock held directly by JHB. JHG and JHB each reported that they hold shared voting power and shared dispositive power with respect to shares of ARCA common stock. JHG has a 100% ownership stake in Janus Henderson Investors U.S.&#160;LLC (&#8220;JHIUS&#8221;), Janus Henderson Investors UK Limited and Janus Henderson Investors Australia Institutional Funds Management Limited, (each an &#8220;Asset Manager&#8221; and collectively as the &#8220;Asset Managers&#8221;). Due to the above ownership structure, holdings for the Asset Managers are aggregated. Each Asset Manager is an investment adviser registered or authorized in its relevant jurisdiction and each furnishing investment advice to various fund, individual and/or institutional clients (collectively referred to herein as &#8220;Managed Portfolios&#8221;). As a result of its role as investment adviser or sub<span class="nobreak">-adviser</span> to the Managed Portfolios, JHIUS may be deemed to be the beneficial owner of 1,891,312 shares of ARCA common stock held by such Managed Portfolios. However, JHIUS does not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaims any ownership associated with such rights. The address of JHG is 201 Bishopsgate, EC2M 3AE, United Kingdom, and the address of JHB is C/O Janus Henderson Investors US LLC, 151 Detroit Street, Denver, Colorado 80206.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(13)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13G filed on April&#160;15, 2024 reporting stock ownership as of April&#160;3, 2024 with respect to the following reporting persons: Allostery Master Fund LP (&#8220;Allostery Master Fund&#8221;), Allostery Investments LP (&#8220;Allostery Investments&#8221;), Allostery Investments GP LLC (&#8220;Allostery Investments GP&#8221;), Christopher Staral, and David Modest. Allostery Master Fund, Allostery Investments LP, Allostery Investments GP, and Messrs. Staral and Modest each reported that they hold shared voting power and shared dispositive power with respect to 1,065,016 shares of ARCA common stock. Allostery Investments, as the investment manager of Allostery Master Fund, may be deemed to have beneficially owned the 1,065,016 shares beneficially owned by Allostery Master Fund. Allostery Investments GP, as the general partner of Allostery Investments, may be deemed to have beneficially owned the 1,065,016 shares beneficially owned by Allostery Investments. Messrs. Modest and Staral, as the managing members of Allostery Investments GP, may be deemed to have beneficially owned the 1,065,016 shares beneficially owned by Allostery Investment GP.&#160;The address of each of the entities and persons listed above is One Stamford Plaza, 9<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span> Floor, 263 Tresser Boulevard, Stamford, Connecticut 06901.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(14)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13G filed on April&#160;9, 2024 reporting stock ownership as of April&#160;3, 2024 with respect to the following reporting persons: Avidity Partners Management LP, Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, Avidity Capital Partners (GP) LLC, Avidity Private Master Fund&#160;I LP, David Witzke, and Michael Gregory, which each reported that they hold shared voting power and shared dispositive power with respect to 1,000,000 shares of ARCA common stock. Avidity Partners Management (GP) LLC serves as the general partner of Avidity Partners Management LP. Avidity Capital Partners Fund (GP) LP serves as the general partner of Avidity Private Master Fund I LP. Avidity Capital Partners (GP) LLC serves as the general partner of Avidity Capital Partners Fund (GP) LP. Messrs. Witzke and Gregory serve as the managing members of Avidity Partners Management (GP) LLC and Avidity Capital Partners (GP) LLC. The address of each of the entities and persons listed above is 2828 N Harwood Street, Suite 1220, Dallas, Texas 75201.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">313</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(15)<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Based solely on a Schedule&#160;13G filed on April&#160;29, 2024 reporting stock ownership as of April&#160;17, 2024 with respect to the following reporting persons: Venrock Healthcare Capital Partners&#160;III, L.P., VHCP Co<span class="nobreak">-Investment</span> Holdings&#160;III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management&#160;III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, which each reported that they hold shared voting power and shared dispositive power with respect to 754,669 shares of ARCA common stock, consisting of (i)&#160;164,442 shares held by Venrock Healthcare Capital Partners&#160;III, L.P., (ii)&#160;16,450 shares held by VHCP Co<span class="nobreak">-Investment</span> Holdings&#160;III, LLC, and (iii)&#160;573,777 shares held by Venrock Healthcare Capital Partners EG, L.P.&#160;VHCP Management&#160;III, LLC is the general partner of Venrock Healthcare Capital Partners&#160;III, L.P. and the manager of VHCP Co<span class="nobreak">-Investment</span> Holdings&#160;III, LLC.&#160;VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P.&#160;Messrs. Shah and Koh are the voting members of VHCP Management&#160;III, LLC and VHCP Management EG, LLC.&#160;The address of each of the entities and persons listed above is 7&#160;Bryant Park, 23<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">rd</span> Floor, New&#160;York, New&#160;York 10018.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">314</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T5"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF ORUKA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth certain information known to Oruka regarding beneficial ownership of Oruka capital stock on an as<span class="nobreak">-converted</span> to Oruka common stock basis as of July<span class="nobreak"> </span>16, 2024 for:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each person or group of affiliated persons, who is known by Oruka to be the beneficial owner of more than 5% of Oruka capital stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each of Oruka&#8217;s directors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each Oruka named executive officer; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>all of Oruka&#8217;s directors and executive officers and directors as a group.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Beneficial ownership is determined in accordance with the rules of the SEC and thus represents voting or investment power with respect to Oruka&#8217;s securities. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60&#160;days of July<span class="nobreak"> </span>16, 2024. Shares of Oruka&#160;common stock that an individual has the right to acquire within 60&#160;days of July<span class="nobreak"> </span>16, 2024 are deemed to be outstanding and beneficially owned by the individual for the purpose of computing the percentage ownership of that individual, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. To Oruka&#8217;s knowledge and subject to applicable community property rules, and except as otherwise indicated below, the persons and entities named in the table have sole voting and sole investment power with respect to all shares beneficially owned. The percentage of beneficial ownership shown prior to the Merger and Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing in the table below is based on 29,460,019<span class="nobreak"> </span>shares of Oruka&#160;common stock deemed to be outstanding as of July<span class="nobreak"> </span>16, 2024, assuming the conversion of all outstanding shares of Oruka&#160;preferred stock into shares of Oruka&#160;common stock. The following table does not reflect any shares of Oruka&#160;common stock or Oruka&#160;pre<span class="nobreak">-funded</span> warrants that such holders have agreed to purchase in the Oruka&#160;pre<span class="nobreak">-closing</span>&#160;financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless otherwise indicated, the address for each beneficial owner is c/o Oruka Therapeutics, Inc., 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Name of Beneficial Owner</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Shares <br/>Beneficially <br/>Owned</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Percentage <br/>of&#160;Shares <br/>Outstanding <br/>Beneficially <br/>Owned</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Fairmount Healthcare Fund&#160;II, L.P.<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">67.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paragon Therapeutics, Inc.<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,500,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paruka Holding LLC<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,500,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">McKenna Capital Partners LLC<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,491,646</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Named Executive Officers and Directors:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,491,646</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cameron Turtle<span class="Superscript" style="vertical-align:super;font-size:58%;">(6)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">149,164</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Samarth Kulkarni</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Peter Harwin<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">67.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Carl Dambkowski</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kristine Ball</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">All executive officers and directors as a group (9 persons)<span class="Superscript" style="vertical-align:super;font-size:58%;">(7)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">21,640,810</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">73.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Less than 1%.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 20,000,000<span class="nobreak"> </span>shares of Oruka common stock issuable upon conversion of 20,000,000 Oruka Series&#160;A Preferred Stock held by Fairmount Fund&#160;II.&#160;Fairmount GP&#160;II is the general partner of Fairmount Fund&#160;II.&#160;Fairmount Funds Management, as the investment manager, along with Fairmount GP&#160;II, as the general partner, exercise voting and investment power over Fairmount Fund&#160;II.&#160;Fairmount Funds Management has voting and dispositive power over the common stock held by Fairmount Fund&#160;II, which is deemed shared with Fairmount GP&#160;II.&#160;As managing members of </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">315</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;text-indent:0pt;margin-top:0pt;">Fairmount Funds Management and Fairmount GP&#160;II, Peter Harwin and Tomas Kiselak may be deemed beneficial owners of any securities beneficially owned by Fairmount Funds Management. Fairmount Funds Management, Fairmount GP&#160;II, Mr.&#160;Harwin and Mr.&#160;Kiselak disclaim beneficial ownership of such shares of Oruka Series&#160;A Preferred Stock and the underlying shares of Oruka common stock except to the extent of their pecuniary interest therein. The principal business address for these persons and entities is 200 Barr Harbor Drive, Suite 400, West Conshohocken, Pennsylvania 19428.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 2,500,000<span class="nobreak"> </span>shares of Oruka common stock held by Paragon. Paragon is managed by its board of directors, consisting of Peter Harwin, Tomas Kiselak, and Evan Thompson.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 2,500,000<span class="nobreak"> </span>shares of Oruka common stock held by Paruka. Paruka is managed by its sole manager, Evan Thompson.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 1,491,646<span class="nobreak"> </span>shares of Oruka common stock held by McKenna Capital Partners LLC (&#8220;McKenna Capital Partners&#8221;). Mark McKenna is the Chief Investment Officer and Managing Director of McKenna Capital Partners, a family office. Mr.&#160;McKenna disclaims beneficial ownership of such shares of Oruka common stock except to the extent of his pecuniary interest therein. The principal business address for these persons and entities is PO Box 9542, Rancho, Santa Fe, CA 92067.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 1,491,646<span class="nobreak"> </span>shares of restricted voting common stock that Dr. Klein has the right to acquire within 60 days after the date of this table.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 149,164<span class="nobreak"> </span>shares of restricted voting common stock held by the Turtle Family Trust, for which Mr.<span class="nobreak"> </span>Turtle serves as Trustee, that will vest within 60 days of the date of this table.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(7)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of (i)&#160;20,000,000<span class="nobreak"> </span>shares of Oruka common stock issuable upon conversion of 20,000,000<span class="nobreak"> </span>shares of Oruka Series&#160;A Preferred Stock and (ii)&#160;1,640,810<span class="nobreak"> </span>shares of restricted voting common stock.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">316</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T4"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">PRINCIPAL STOCKHOLDERS OF THE COMBINED COMPANY</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Except where specifically noted, the following information and all other information contained in this proxy statement/prospectus does not give effect to the proposed reverse stock split described in Proposal&#160;No. 3 of this proxy statement/prospectus</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table sets forth certain information regarding beneficial ownership of the combined company&#8217;s common stock immediately after consummation of the Merger, assuming the consummation of the Merger occurred on July<span class="nobreak"> </span>16, 2024 for:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each person or group of affiliated persons, who is expected by ARCA and Oruka to be the beneficial owner of more than 5% of the combined company&#8217;s common stock;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each person expected to be a director of the combined company;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>each person expected to be a named executive officer of the combined company; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>all of the combined company&#8217;s expected directors and executive officers and directors as a group.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Beneficial ownership is determined in accordance with the rules of the SEC and thus represents voting or investment power with respect to the combined company&#8217;s securities. Under such rules, beneficial ownership includes any shares over which the individual or entity has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60&#160;days of July<span class="nobreak"> </span>16, 2024. Shares of the combined company&#8217;s common stock that an individual or entity has the right to acquire within 60&#160;days of July<span class="nobreak"> </span>16, 2024 are deemed to be outstanding and beneficially owned by the individual or entity for the purpose of computing the percentage ownership of that individual, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. To ARCA&#8217;s and Oruka&#8217;s knowledge and subject to applicable community property rules, and except as otherwise indicated below, the persons and entities named in the table have sole voting and sole investment power with respect to all shares beneficially owned.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The table lists applicable percentage ownership based on 354,514,799<span class="nobreak"> </span>shares of common stock expected to be outstanding upon consummation of the merger, after giving effect to the Oruka pre<span class="nobreak">-closing</span> financing and prior to giving effect to the anticipated ARCA reverse stock split and includes 11,272,201<span class="nobreak"> </span>shares of unvested restricted common stock. The number of shares beneficially owned includes shares of common stock that each person has the right to acquire within 60&#160;days, including upon the exercise of stock options and warrants. These stock options and warrants shall be deemed to be outstanding for the purpose of computing the percentage of outstanding shares of the combined company&#8217;s common stock expected to be owned by such person but shall not be deemed to be outstanding for the purpose of computing the percentage of outstanding shares of the combined organization&#8217;s common stock expected to be owned by any other person.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Immediately after the Merger, ARCA securityholders as of immediately prior to the Merger are expected to own approximately 2.39% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), and former holders of Oruka securities are expected to own approximately 97.61% of the outstanding shares of capital stock of the combined company (on a fully<span class="nobreak">-diluted</span> basis), subject to certain assumptions, including, but not limited to, ARCA&#8217;s net cash as of closing being equal to $5.0&#160;million. ARCA management currently anticipates ARCA&#8217;s net cash as of closing will be approximately $5.0&#160;million, after giving effect to the special cash dividend, which is expected to be approximately $20.0<span class="nobreak"> </span>million, and the currently estimated ownership percentages reflect this projection. There can be no assurances any of these assumptions will be accurate at closing when the final exchange ratio is determined. The table below assumes that, based on ARCA&#8217;s and Oruka&#8217;s capitalization as of July<span class="nobreak"> </span>16, 2024, the exchange ratio is estimated to be equal to approximately 6.8699<span class="nobreak"> </span>shares of ARCA common stock, prior to giving effect to the anticipated ARCA reverse stock split. The estimated exchange ratio was derived on a fully<span class="nobreak">-diluted</span> basis as of July<span class="nobreak"> </span>16, 2024, using a stipulated value of Oruka of approximately $175.0&#160;million and of ARCA of approximately $11.0<span class="nobreak"> </span>million, assuming net cash of $5.0&#160;million as of closing. The final exchange ratio is subject to adjustment prior to the closing of the Merger based upon ARCA&#8217;s net cash at closing and the aggregate proceeds from the sale of Oruka common stock and Oruka pre<span class="nobreak">-funded</span> warrants in the Oruka pre<span class="nobreak">-closing</span> financing.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">317</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">Unless otherwise indicated, the address for each beneficial owner is c/o Oruka Therapeutics, Inc., 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Name of Beneficial Owner</span></p>



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Number&#160;of <br/>Shares <br/>Beneficially <br/>Owned</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Percentage <br/>of&#160;Shares <br/>Outstanding <br/>Beneficially <br/>Owned</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Fairmount Funds Management LLC<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,416,024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9.99</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with Venrock Healthcare Capital Partners<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,416,018</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9.99</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">FMR LLC<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">30,938,216</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.73</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entities affiliated with RTW Investments, LP<span class="Superscript" style="vertical-align:super;font-size:58%;">(4)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18,562,944</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Named Executive Officers and Directors:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lawrence Klein<span class="Superscript" style="vertical-align:super;font-size:58%;">(5)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10,247,459</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.89</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Arjun Agarwal</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Joana Goncalves</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paul Quinlan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cameron Turtle<span class="Superscript" style="vertical-align:super;font-size:58%;">(6)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,024,742</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Samarth Kulkarni</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Peter Harwin<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">35,416,024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">9.99</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Carl Dambkowski</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Kristine Ball</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">All executive officers and directors as a group (9&#160;persons)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">46,688,225</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">13.17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Less than 1%. </p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of (i)&#160;4,477,780<span class="nobreak"> </span>shares of the combined company&#8217;s common stock held by Fairmount Healthcare Fund&#160;II L.P. (&#8220;Fairmount Fund&#160;II&#8221;) and (ii)&#160;30,938,244<span class="nobreak"> </span>shares of the combined company&#8217;s common stock held by Fairmount Healthcare Co<span class="nobreak">-Invest</span>&#160;III L.P. (&#8220;Fairmount Fund&#160;III&#8221;).&#160;Excludes (i)&#160;63,586,365<span class="nobreak"> </span>shares issuable upon the exercise of the pre<span class="nobreak">-funded</span> warrants and (ii)&#160;137,398,000<span class="nobreak"> </span>shares of preferred stock owned by Fairmount Fund&#160;II.&#160;The pre<span class="nobreak">-funded</span> warrants and shares of preferred stock are subject to a beneficial ownership limitation of 9.99%, which such limitations restrict Fairmount Funds Management LLC (&#8220;Fairmount Funds Management&#8221;) and its affiliates from exercising that portion of the warrants and converting those shares of preferred stock that would result in Fairmount Funds Management and its affiliates owning, after exercise or conversion, a number of shares of the combined company&#8217;s common stock in excess of the applicable ownership limitation. Fairmount Funds Management serves as investment manager for Fairmount Fund&#160;II and Fairmount Fund&#160;III.&#160;Fairmount Fund&#160;II and Fairmount Fund&#160;III have delegated to Fairmount Funds Management the sole power to vote and the sole power to dispose of all securities held in Fairmount Fund&#160;II and Fairmount Fund&#160;III&#8217;s portfolios. Because Fairmount Fund&#160;II and Fairmount Fund&#160;III have divested themselves of voting and investment power over the securities they hold and may not revoke that delegation on less than 61&#160;days&#8217; notice, Fairmount Fund&#160;II and Fairmount Fund&#160;III disclaim beneficial ownership of the securities they hold. The general partner of Fairmount Funds Management is Fairmount Founds Management GP LLC (&#8220;Fairmount GP&#8221;). As managing members of Fairmount GP, Peter Harwin and Tomas Kiselak may be deemed to have voting and investment power over the shares held by Fairmount Fund&#160;II and Fairmount Fund&#160;III.&#160;Fairmount Funds Management, Fairmount GP, Peter Harwin and Tomas Kiselak disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The address of the entities and individuals listed is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA&#160;19428.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists (i)&#160;26,926,800<span class="nobreak"> </span>shares of the combined company&#8217;s common stock held by Venrock Healthcare Capital Partners EG, L.P. (&#8220;VHCPEG&#8221;), (ii)&#160;7,717,151<span class="nobreak"> </span>shares of the combined company&#8217;s common stock held by Venrock Healthcare Capital Partners&#160;III, L.P. (&#8220;VHCP3&#8221;), and (iii)&#160;772,067<span class="nobreak"> </span>shares of the combined company&#8217;s common stock held by VHCP Co<span class="nobreak">-Investment</span> Holdings&#160;III, LLC (&#8220;VHCPCo3&#8221;). Excludes 1,300,019, 372,582 and 37,276 shares issuable upon the exercise of the pre<span class="nobreak">-funded</span> warrants held by VHCPEG, VHCP3 and VHCPCo3, respectively. The pre<span class="nobreak">-funded</span> warrants are subject to a beneficial ownership limitation of 9.99%, which such limitations restrict Venrock Healthcare Capital Partners and its affiliates from exercising that portion of the warrants that would result in Venrock Healthcare Capital Partners and its affiliates owning, after exercise, a number of shares of the combined company&#8217;s common stock in excess of the applicable ownership limitation. VHCP Management&#160;III, LLC (&#8220;VHCPM3&#8221;) is the sole general partner of VHCP3 and the sole manager of VHCPCo3. VHCP Management EG, LLC (&#8220;VHCPM EG&#8221;) is the sole general partner of VHCPEG.&#160;As voting members of VHCPM3 and VHCPM EG, Dr.&#160;Bong Koh and Nimish Shah may be deemed beneficial owners of any securities beneficially owned by VHCPM3 and VHCPM EG.&#160;The principal business address of each of these persons and entities is 7 Bryant Park, 23<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">rd</span> Floor, New&#160;York, NY&#160;10018.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">318</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>These shares of the combined company&#8217;s common stock are held by funds and accounts managed by direct or indirect subsidiaries of FMR LLC.&#160;Abigail P.&#160;Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC.&#160;Members of the Johnson family, including Abigail P.&#160;Johnson, are the predominant owners, directly or through trusts, of Series&#160;B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC.&#160;The Johnson family group and all other Series&#160;B shareholders have entered into a shareholders&#8217; voting agreement under which all Series&#160;B voting common shares will be voted in accordance with the majority vote of Series&#160;B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act&#160;of&#160;1940, to form a controlling group with respect to FMR LLC.&#160;The principal business address of each of these persons and entities is 245 Summer Street, Boston, MA&#160;02210.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(4)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Consists of 18,562,944<span class="nobreak"> </span>shares of the combined company&#8217;s common stock held in the aggregate by RTW Master Fund, Ltd. (&#8220;RTW Master Fund&#8221;), RTW Innovation Master Fund, Ltd. (&#8220;RTW Innovation Master Fund&#8221;), and RTW Biotech Opportunities Operating Ltd. (&#8220;RTW Biotech&#8221; and together with RTW Master Fund and RTW Innovation Fund, the &#8220;RTW Funds&#8221;). RTW Investments, LP (&#8220;RTW&#8221;), in its capacity as the investment manager of the RTW Funds, has the power to vote and the power to direct the disposition of the shares held by the RTW Funds. Accordingly, RTW may be deemed to be the beneficial owner of such securities. Roderick Wong, M.D., as the Managing Partner of RTW, has the power to direct the vote and disposition of the securities held by RTW.&#160;Dr.&#160;Wong disclaims beneficial ownership of the shares held by the RTW Funds, except to the extent of his pecuniary interest therein. The principal business address of RTW Investments, LP is 40 10<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span> Avenue, Floor 7, New&#160;York, NY&#160;10014, and the address of Dr.&#160;Wong and each of the RTW Funds is c/o RTW Investments, LP, 40 10<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span> Avenue, Floor 7, New&#160;York, NY&#160;10014.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(5)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes 10,247,459<span class="nobreak"> </span>shares of restricted voting common stock that Dr.&#160;Klein has the right to acquire within 60&#160;days after the date of this table.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">(6)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes 1,024,742<span class="nobreak"> </span>shares of restricted voting common stock held by the Turtle Family Trust, for which Mr.&#160;Turtle serves as Trustee, that will vest within 60&#160;days of the date of this table.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">319</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T3"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">LEGAL MATTERS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. will pass upon the validity of ARCA&#8217;s common stock offered by this proxy statement/prospectus.</p>
		<a id="T2"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">EXPERTS</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The financial statements of ARCA biopharma, Inc. as of December&#160;31, 2023 and 2022 and for each of the&#160;years in the two<span class="nobreak">-year</span> period ended December&#160;31, 2023, have been included herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The financial statement of Oruka Therapeutics, Inc. as of February&#160;6, 2024 included in this proxy statement/prospectus has been so included in reliance on the report (which contains an explanatory paragraph relating to Oruka&#8217;s ability to continue as a going concern as described in Note&#160;1 to the financial statement) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">320</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T1"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">WHERE YOU CAN FIND MORE INFORMATION</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is subject to the informational requirements of the Exchange&#160;Act and in accordance therewith, files annual, quarterly and current reports, proxy statements and other information with the SEC electronically, and the SEC maintains a website that contains ARCA&#8217;s filings as well as reports, proxy and information statements, and other information issuers file electronically with the SEC at <span class="Italic" style="font-style:italic;font-weight:normal;">www.sec.gov</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA also makes available free of charge on or through its website at <span class="Italic" style="font-style:italic;font-weight:normal;">www.arcabio.com</span>, its Annual Reports on Form&#160;10<span class="nobreak">-K</span>, Quarterly Reports on Form&#160;10<span class="nobreak">-Q</span>, Current Reports on Form&#160;8<span class="nobreak">-K</span> and amendments to those reports filed or furnished pursuant to Section&#160;13(a)&#160;or 15(d)&#160;of the Exchange&#160;Act as soon as reasonably practicable after ARCA electronically files such material with or otherwise furnishes it to the SEC.&#160;The website addresses for the SEC and ARCA are inactive textual references and except as specifically incorporated by reference into this proxy statement/prospectus, information on those websites is not part of this proxy statement/prospectus.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has filed with the SEC a registration statement on Form&#160;S<span class="nobreak">-4</span>, of which this proxy statement/prospectus is a part, under the Securities Act to register the shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock) to be issued to Oruka stockholders in the Merger. The registration statement, including the attached annexes, exhibits and schedules, contains additional relevant information about ARCA and ARCA common stock. This proxy statement/prospectus does not contain all of the information set forth in the registration statement because certain parts of the registration statement are omitted in accordance with the rules and regulations of the SEC.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has supplied all information contained in this proxy statement/prospectus relating to ARCA and Oruka has supplied all information contained in this proxy statement/prospectus relating to Oruka.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you would like to request documents from ARCA or Oruka, please send a request in writing or by telephone to either ARCA or Oruka at the following addresses:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">ARCA biopharma, Inc.<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, CO&#160;80021<br/>Attn: Corporate Secretary<br/>Tel: (720)&#160;940-2100</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">Oruka Therapeutics, Inc.<br/>855 Oak Grove Ave., Suite 100 <br/>Menlo Park, CA 94025 <br/>Attn: Secretary<br/>Tel: (650)&#160;606<span class="nobreak">-7910</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If you are a ARCA stockholder and would like additional copies, without charge, of this proxy statement/prospectus or if you have questions about the Merger, including the procedures for voting your shares, you should contact ARCA&#8217;s proxy solicitor, Innisfree M&amp;A Incorporated, at the following telephone number:</p>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">Banks and Brokers Call: (877) 750<span class="nobreak">-8310</span><br/>Stockholders Call Toll Free: (212) 750<span class="nobreak">-5833</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">321</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T9991"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold-AllCaps" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">STOCKHOLDER PROPOSALS OR DIRECTOR NOMINATIONS FOR&#160;2025 ANNUAL MEETING</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If an ARCA stockholder would like ARCA to consider including a proposal in ARCA&#8217;s proxy statement for its 2025 annual meeting pursuant to Rule&#160;14a<span class="nobreak">-8</span> of the Exchange&#160;Act, then the proposal must be received by ARCA&#8217;s corporate secretary at ARCA&#8217;s principal executive offices on or before March<span class="nobreak"> </span>28, 2025. In addition, stockholder proposals must comply with the requirements of Rule&#160;14a<span class="nobreak">-8</span> regarding the inclusion of stockholder proposals in company<span class="nobreak">-sponsored</span> proxy materials. Proposals should be addressed to:</p>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">ARCA biopharma, Inc.<br/>Attention: Corporate Secretary<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, Colorado, 80021</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Bylaws also establish an advance notice procedure for stockholders who wish to present a proposal or nominate a director at an annual meeting, but do not seek to include the proposal or director nominee in ARCA&#8217;s proxy statement. In order to be properly brought before ARCA&#8217;s 2025 annual meeting, the stockholder must provide timely written notice to ARCA&#8217;s corporate secretary, at ARCA&#8217;s principal executive offices, and any such proposal or nomination must constitute a proper matter for stockholder action. The written notice must contain the information specified in the ARCA Bylaws. To be timely, a stockholder&#8217;s written notice must be received by ARCA&#8217;s corporate secretary at ARCA&#8217;s principal executive offices:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>no earlier than May<span class="nobreak"> </span>24, 2025, and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>no later than June<span class="nobreak"> </span>23, 2025.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event that ARCA holds its 2025 annual meeting more than 30&#160;days before, or more than 60&#160;days after, the one<span class="nobreak">-year</span> anniversary of this year&#8217;s annual meeting, then such written notice must be received by ARCA&#8217;s corporate secretary at ARCA&#8217;s principal executive offices:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>no earlier than the 90<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span>&#160;day prior to the&#160;day of ARCA&#8217;s 2025 annual meeting, and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>no later than close of business on the later of: (i)&#160;the 60<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span>&#160;day prior to the&#160;day of ARCA&#8217;s 2025 annual meeting or (ii)&#160;the 10<span class="CharOverride-3" style="font-size:58%;vertical-align:super;">th</span>&#160;day following the earlier of the&#160;day on which public announcement of the date of ARCA&#8217;s 2025 annual meeting is first made or notice is first given.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Availability of Bylaws</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A copy of the ARCA Bylaws may be obtained by accessing ARCA&#8217;s filings on the SEC&#8217;s website at&#160;<span class="Italic" style="font-style:italic;font-weight:normal;">www.sec.gov</span>. You may also contact ARCA&#8217;s corporate secretary at ARCA&#8217;s principal executive offices for a copy of the relevant bylaw provisions regarding the requirements for making stockholder proposals and nominating director candidates.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Householding of Proxy Materials</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy materials with respect to two or more stockholders sharing the same address by delivering a single set of the proxy materials addressed to those stockholders. This process, which is commonly referred to as &#8220;householding,&#8221; potentially means extra convenience for stockholders and cost savings for companies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the ARCA special meeting, a number of brokers with account holders who are ARCA stockholders will be &#8220;householding&#8221; the proxy materials. A single set of the proxy materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be &#8220;householding&#8221; communications to your address, &#8220;householding&#8221; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in &#8220;householding&#8221; and would prefer to receive a separate set of the proxy materials, please notify your broker or ARCA.&#160;Direct your written request to Secretary, ARCA biopharma, Inc., 10170 Church Ranch Way, Suite 100, Westminster, Colorado, 80021 or contact Investor Relations at (720)&#160;940<span class="nobreak">-2100</span>. ARCA undertakes to promptly deliver a separate set of the proxy materials upon receiving your written request. Stockholders who currently receive multiple copies of the proxy materials at their addresses and would like to request &#8220;householding&#8221; of their communications should contact their brokers.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">322</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T111"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.</span></p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">INDEX TO FINANCIAL STATEMENTS </span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years ended December</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">31, 2023 and 2022</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Page</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T201">Report of Independent Registered Public Accounting Firm, KPMG LLP</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T202">Balance Sheets as of December 31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T203">Statements of Operations for the years ended December 31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T204">Statements of Stockholders&#8217; Equity for the years ended December 31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-5</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T205">Statements of Cash Flows for the years ended December 31, 2023 and 2022</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-6</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T206">Notes to Financial Statements</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-7</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Three months ended March</span><span class="nobreak"><span class="Bold" style="font-style:normal;font-weight:bold;"> </span></span><span class="Bold" style="font-style:normal;font-weight:bold;">31, 2024 and 2023 Interim Financial Statements (Unaudited)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T207">Balance Sheets as of March 31, 2024 and December 31, 2023</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-19</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T208">Statements of Operations for the three months ended March 31, 2024 and 2023</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T209">Statements of Stockholders&#8217; Equity for the three months ended March 31, 2024 and 2023 and interim&#160;periods </a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-21</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T210">Statements of Cash Flows for the three months ended March 31, 2024 and 2023</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 89.52%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T211">Notes to Financial Statements</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:center;">F-23</p>
					</td>
				</tr>

		</table>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As of February 6, 2024</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Page</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T212">Report of Independent Registered Public Accounting Firm</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T213">Balance Sheet as of February&#160;6, 2024</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-35</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T214">Notes to Financial Statement</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-36</p>
					</td>
				</tr>

		</table>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from February&#160;6, 2024 (Inception) to March&#160;31, 2024</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T215">Unaudited Condensed Balance Sheets</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-41</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T216">Unaudited Condensed Statement of Operations and Comprehensive Loss</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-42</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T217">Unaudited Condensed Statement of Convertible Preferred Stock and Stockholders&#8217; Deficit</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-43</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T218">Unaudited Condensed Statement of Cash Flows</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-44</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><a href="#T219">Notes to Unaudited Condensed Financial Statements</a></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">F-45</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; color: black;">F-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T201"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Report of Independent Registered Public Accounting Firm</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To the Stockholders and Board of Directors <br/>ARCA biopharma, Inc.:</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Opinion on the Financial Statements</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have audited the accompanying balance sheets of ARCA biopharma, Inc. (the Company) as of December&#160;31, 2023 and December&#160;31, 2022, the related statements of operations, stockholders&#8217; equity, and cash flows for the&#160;years then ended, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2023 and December&#160;31, 2022, and the results of its operations and its cash flows for the&#160;years then ended, in conformity with U.S.&#160;generally accepted accounting principles.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Basis for Opinion</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United&#160;States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We conducted our audits in accordance with the standards of the PCAOB.&#160;Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Critical Audit Matters</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1)&#160;relate to accounts or disclosures that are material to the financial statements and (2)&#160;involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">/s/ KPMG LLP </p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have served as the Company&#8217;s auditor since 2006.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Boulder, Colorado <br/>February&#160;1, 2024</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; color: black;">F-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T202"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>BALANCE SHEETS</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and <br/>per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ASSETS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-37899">37,431</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-37900">42,445</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-37901">161</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-37902">254</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-37903">37,592</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-37904">42,699</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset&#160;&#8211;&#160;operating</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-37905">247</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-37906">343</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-37907">10</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-37908">25</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-37909">12</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-37910">18</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-37911">37,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-37912">43,085</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-37913">362</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-37914">334</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation and employee benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-37915">100</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-37916">173</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other liabilities (related party&#160;&#8211;&#160;$<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-37917">0</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-37918">216</ix:nonFraction>&#160;at December&#160;31, 2023 and 2022, respectively)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-37919">175</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-37920">625</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-37921">637</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-37922">1,132</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-37923">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-37924">280</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-37925">841</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-37926">1,412</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"><div style="-sec-ix-hidden: hidden-fact-2">&#160;</div></td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders&#8217; equity:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Preferred stock, $<ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-37927"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-37928">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-37929"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-37930">5</ix:nonFraction></ix:nonFraction>&#160;million shares authorized; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-37931"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-37932"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-37933"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-37934">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares&#160;issued or outstanding at December&#160;31, 2023 and 2022</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-3; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-4; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, $<ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-37935"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-37936">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-37937"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-37938">100</ix:nonFraction></ix:nonFraction>&#160;million shares authorized at December&#160;31, 2023 and 2022; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-37939"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-37940">14,501,143</ix:nonFraction></ix:nonFraction>&#160;and <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-37941"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-37942">14,410,143</ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding at December&#160;31, 2023 and 2022, respectively</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-37943">14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-37944">14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-37945">225,747</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-37946">225,061</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-37947">188,741</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-37948">183,402</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37949">37,020</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37950">41,673</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total liabilities and stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-37951">37,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-37952">43,085</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; color: black;">F-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T203"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF OPERATIONS</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Years Ended December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and <br/>per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Costs and expenses:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37953">6,283</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-37954">5,847</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development (related party&#160;&#8211;&#160;$(<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="3" sign="-" unitRef="usd" id="ixv-37955">91</ix:nonFraction>)&#160;and $<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="3" unitRef="usd" id="ixv-37956">432</ix:nonFraction> as of the&#160;years&#160;ended December&#160;31, 2023 and 2022, respectively)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37957">1,013</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-37958">4,749</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total costs and expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-37959">7,296</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-37960">10,596</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37961">7,296</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37962">10,596</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest and other income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" unitRef="usd" id="ixv-37963">1,957</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" unitRef="usd" id="ixv-37964">675</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-6; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" unitRef="usd" id="ixv-37965">5</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37966">5,339</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37967">9,926</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share:</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_2" style="-sec-ix-hidden: hidden-fact-8; -sec-ix-hidden: hidden-fact-7; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-37968">0.37</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-37969">0.69</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average shares outstanding:</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_2" style="-sec-ix-hidden: hidden-fact-10; -sec-ix-hidden: hidden-fact-9; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-37970">14,415,877</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-37971">14,410,143</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; color: black;">F-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T204"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="15" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 65.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders&#8217; Equity</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Common stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Additional<br/>Paid-In<br/>Capital</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Accumulated<br/>Deficit</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="15" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 65.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2021</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-37972">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37973">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37974">224,505</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-37975">173,476</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37976">51,043</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-15; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-37977">556</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-16; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-37978">556</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-17; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-18; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37979">9,926</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37980">9,926</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2022</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-37981">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37982">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37983">225,061</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-37984">183,402</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37985">41,673</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Issuance of common stock upon vesting&#160;of Restricted Stock Units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" unitRef="shares" id="ixv-37986">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-19; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-20; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-21; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-22; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-23; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-37987">686</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-24; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-37988">686</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-25; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-26; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37989">5,339</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37990">5,339</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-37991">14,501,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37992">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37993">225,747</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-37994">188,741</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-37995">37,020</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; color: black;">F-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<a id="T205"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF CASH FLOWS</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Years Ended December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from operating activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37996">5,339</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-37997">9,926</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-37998">15</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-37999">20</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of right-of-use asset&#160;&#8211;&#160;operating</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-38000">96</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-38001">94</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-38002">686</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-38003">556</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from disposal of property and equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-51; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" sign="-" unitRef="usd" id="ixv-38004">5</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in operating assets and liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-38005">93</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-38006">808</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-38007">6</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-52; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd" id="ixv-38008">28</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" sign="-" unitRef="usd" id="ixv-38009">783</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation and employee benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-38010">73</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-38011">752</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-38012">526</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-38013">934</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash used in operating activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-38014">5,014</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-38015">10,912</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from investing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Purchase of property and equipment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-53; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38016">2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash used in investing activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-54; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-38017">2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from financing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash provided by financing activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-55; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-56; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net decrease in cash and cash equivalents</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-38018">5,014</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-38019">10,914</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents, beginning of year</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-38020">42,445</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-38021">53,359</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash and cash equivalents, end of year</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-38022">37,431</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-38023">42,445</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Supplemental cash flow information:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-57; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-58; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax refund received</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-59; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-60; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; color: black;">F-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T206"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<ix:nonNumeric contextRef="c6" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="ixv-21138"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span></p>
		<ix:nonNumeric contextRef="c6" continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c6_cont_1" escape="true" name="abio:DescriptionOfBusinessPolicyTextBlock" id="ixv-21141"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c6_cont_2" id="abio_DescriptionOfBusinessPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical<span class="nobreak">-stage</span> biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p></ix:continuation>
		<ix:continuation id="abio_DescriptionOfBusinessPolicyTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#8217;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_1" escape="true" name="abio:LiquidityAndGoingConcernPolicyTextBlock" id="ixv-21149"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_2" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has <ix:nonFraction contextRef="c6" decimals="INF" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-38024">no</ix:nonFraction>t generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_3" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_4" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_5" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_4"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_6" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_5"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_7" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_6"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_8" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_7"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_9" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_8"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_10" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_9"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_11" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_10"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p></ix:continuation></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_1"><ix:continuation id="abio_LiquidityAndGoingConcernPolicyTextBlock-c6_cont_11"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-21199"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p></ix:nonNumeric>
		<ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of ARCA&#8217;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#8217;s activities through the date of filing of the Annual Report on Form&#160;10<span class="nobreak">-K</span>.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-21205"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p></ix:nonNumeric>
		<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_UseOfEstimates-c6_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-21210"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accounting Estimates in the Preparation of Financial Statements</span></p></ix:nonNumeric>
		<ix:continuation id="_UseOfEstimates-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-21215"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Equivalents</span></p></ix:nonNumeric>
		<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_ConcentrationRiskCreditRisk-c6_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-21220"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p></ix:nonNumeric>
		<ix:continuation id="_ConcentrationRiskCreditRisk-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:fixed-zero" name="us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset" scale="0" unitRef="usd" id="ixv-38025">no</ix:nonFraction> off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-21226"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Property and Equipment</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of </p></ix:continuation></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_2"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">property and equipment is depreciated using the straight<span class="nobreak">-line</span> method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="abio_ComprehensiveLossPolicyPolicyTextBlock-c6_cont_1" escape="true" name="abio:ComprehensiveLossPolicyPolicyTextBlock" id="ixv-21245"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p></ix:nonNumeric>
		<ix:continuation id="abio_ComprehensiveLossPolicyPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_LesseeLeasesPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-21251"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c6_cont_2" id="_LesseeLeasesPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s December&#160;31, 2023 and 2022 balance sheets.</p></ix:continuation>
		<ix:continuation id="_LesseeLeasesPolicyTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="abio_AccruedOutsourcingExpensesPolicyTextBlock-c6_cont_1" escape="true" name="abio:AccruedOutsourcingExpensesPolicyTextBlock" id="ixv-21260"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p></ix:nonNumeric>
		<ix:continuation id="abio_AccruedOutsourcingExpensesPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-21265"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segments</span></p></ix:nonNumeric>
		<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA operates in <ix:nonFraction contextRef="c6" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure" id="ixv-38026">one</ix:nonFraction> segment. Management uses one measure of profitability and does not segment its business for internal reporting.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_ResearchAndDevelopmentExpensePolicy-c6_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-21270"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c6_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.</p></ix:continuation>
		<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c6_cont_3" id="_ResearchAndDevelopmentExpensePolicy-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#8220;CROs&#8221;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre<span class="nobreak">-approval</span> of any changes in scope of the services to be performed. Certain significant vendors may also provide </p></ix:continuation></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c6_cont_3"><ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c6_cont_4" id="_ResearchAndDevelopmentExpensePolicy-c6_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.</p></ix:continuation>
		<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c6_cont_4"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c6_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-21293"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p></ix:nonNumeric>
		<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s stock<span class="nobreak">-based</span> compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_IncomeTaxPolicyTextBlock-c6_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-21301"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p></ix:nonNumeric>
		<ix:continuation id="_IncomeTaxPolicyTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.</p></ix:continuation></ix:continuation>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-21306"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(2)&#160;Net Loss Per Share</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#8217;s potentially dilutive shares include stock options and restricted stock units.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-38027">Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-38028">616,707</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-38029">704,960</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-70; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-38030">91,000</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-38031">616,707</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-38032">795,960</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-21371"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(3)&#160;Fair Value Disclosures</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#8220;exit price&#8221;). Inputs used to measure fair value are classified into the following hierarchy:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 1 &#8212;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#8217;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 2 &#8212;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA&#8217;s Level 2 assets consist of corporate bonds and commercial paper securities. ARCA does not have any Level 2 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 3 &#8212;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023 and 2022, ARCA had $<ix:nonFraction contextRef="c66" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" unitRef="usd" id="ixv-38033">37.4</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c67" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" unitRef="usd" id="ixv-38034">42.4</ix:nonFraction>&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were <span style="-sec-ix-hidden: hidden-fact-73"><span style="-sec-ix-hidden: hidden-fact-74">no</span></span> transfers between any fair value hierarchy levels in 2023 or 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities. As of December&#160;31, 2023 and 2022, ARCA did <span style="-sec-ix-hidden: hidden-fact-71"><span style="-sec-ix-hidden: hidden-fact-72">not</span></span> have any debt outstanding.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-21392"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(4)&#160;Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_PropertyPlantAndEquipmentTextBlock-c6_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-38035">Property and equipment consist of the following (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2022</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c69" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-38036">3</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38037">39</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38038">39</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c71" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-38039">5</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38040">130</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38041">130</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c73" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-38042">5</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38043">37</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38044">44</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c75" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-38045">3</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38046">16</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38047">16</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38048">222</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38049">229</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38050">212</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38051">204</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-38052">10</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-38053">25</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the&#160;years ended December&#160;31, 2023 and 2022, depreciation and amortization expense was $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-38054">15</ix:nonFraction>,000 and $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-38055">20</ix:nonFraction>,000, respectively.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-21552"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(5)&#160;Related Party Arrangements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Transactions with ARCA&#8217;s President and Chief Executive Officer</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. Total expense under these arrangements for the&#160;years ended December&#160;31, 2023 and 2022 was $(<ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="0" sign="-" unitRef="usd" id="ixv-38056">91,000</ix:nonFraction>) and $<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="0" unitRef="usd" id="ixv-38057">432,000</ix:nonFraction>, respectively. In December&#160;2023, ARCA made a payment of $<ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="abio:PaymentOfUnrestrictedResearchGrants" scale="0" unitRef="usd" id="ixv-38058">125,000</ix:nonFraction> for the grant period July&#160;2022 through December&#160;2023 under these arrangements.</p></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<ix:nonNumeric contextRef="c6" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-21565"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has or is subject to the following commitments and contingencies:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements and Reduction of Workforce</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-38059">265,000</ix:nonFraction>. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by <ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="abio:PercentageOfRetentionBonuses" scale="-2" unitRef="pure" id="ixv-38060">50</ix:nonFraction>% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonusPaid" scale="0" unitRef="usd" id="ixv-38061">86,000</ix:nonFraction> was paid in December&#160;2023. As of December&#160;31, 2023, the unpaid retention bonuses totaled $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-38062">311,000</ix:nonFraction>, none of which was accrued as of December&#160;31, 2023, since there had not been a change in control or clinical development decision.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Christopher D.&#160;Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#8217;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#8217;s existing employment agreement, as previously amended, ARCA will provide Mr.&#160;Ozeroff severance benefits pursuant to the terms of his existing employment agreement with ARCA, as previously amended. The severance benefits include severance payments and reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out<span class="nobreak">-of-pocket</span> expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). During the year ended December&#160;31, 2023, ARCA recorded an expense of $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="0" unitRef="usd" id="ixv-38063">159,000</ix:nonFraction> for these severance benefits, <span style="-sec-ix-hidden: hidden-fact-75">none</span> of which remains unpaid.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2022, ARCA implemented a strategic reduction of the workforce by approximately <ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" unitRef="pure" id="ixv-38064">67</ix:nonFraction>%, or <ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" unitRef="pure" id="ixv-38065">12</ix:nonFraction> employees. Personnel reductions were primarily focused in research and development and general and administrative functions. The restructuring was a result of ARCA&#8217;s decision to manage operating costs and expenses. During the year ended December&#160;31, 2022, ARCA recorded total restructuring charges of approximately $<ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="0" unitRef="usd" id="ixv-38066">755,000</ix:nonFraction>, of which $<ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="0" unitRef="usd" id="ixv-38067">470,000</ix:nonFraction> and $<ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestructuringCharges" scale="0" unitRef="usd" id="ixv-38068">285,000</ix:nonFraction> were recognized in research and development and general and administrative expenses, respectively, in connection with the restructuring, all in the form of one<span class="nobreak">-time</span> termination benefits, none of which remains unpaid.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Lease</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020 ARCA entered into a lease agreement for approximately <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" unitRef="sqft" id="ixv-38069">5,200</ix:nonFraction> square feet of office facilities in Westminster, Colorado which serves as ARCA&#8217;s primary business office effective October&#160;1, 2020 (&#8220;October&#160;2020 Lease&#8221;). The lease term is <ix:nonNumeric contextRef="c85" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-38070">42&#160;months</ix:nonNumeric> beginning October&#160;1, 2020 and includes an <ix:nonNumeric contextRef="c86" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="ixv-21582">option to renew for an additional <ix:nonNumeric contextRef="c85" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ixv-38071">36</ix:nonNumeric><span class="nobreak"> </span>month term at the then prevailing rental rate.</ix:nonNumeric> The exercise of the lease renewal option is at ARCA&#8217;s sole discretion. The amounts recorded assume ARCA will exercise its renewal option. In June&#160;2021, ARCA entered into a sublease agreement for approximately <ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" scale="0" unitRef="sqft" id="ixv-38072">3,000</ix:nonFraction> square feet of additional office facilities in its primary business office (&#8220;2021 Lease&#8221;). The sublease term was <ix:nonNumeric contextRef="c88" format="ixt-sec:durwordsen" name="abio:LesseeOperatingSubleaseTermOfContract" id="ixv-38073">29&#160;months</ix:nonNumeric> and terminated in October&#160;2023. <ix:nonNumeric contextRef="c6" name="us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" id="ixv-21584">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation.</ix:nonNumeric></p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-12</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c6_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-38074">Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-38075">93</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-38076">96</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd" id="ixv-38077">100</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" unitRef="usd" id="ixv-38078">25</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-38079">314</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-38080">34</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-38081">76</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-38082">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Rent expense, which is included in general and administrative expense, under these leases for the&#160;years ended December&#160;31, 2023 and 2022 was $<ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-38083">119,000</ix:nonFraction> and $<ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-38084">125,000</ix:nonFraction>, respectively.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, the lease liability was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-38085">280,000</ix:nonFraction> and the current portion is included in accrued expenses and other liabilities and the non<span class="nobreak">-current</span> portion is in operating lease liability, net of current portion in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the&#160;years ended December&#160;31, 2023 and 2022 were $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-38086">127,000</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-38087">131,000</ix:nonFraction>, respectively. The weighted<span class="nobreak">-average</span> remaining lease term for the operating lease as of December&#160;31, 2023 is <ix:nonNumeric contextRef="c1" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-38088">3.2</ix:nonNumeric>&#160;years. The weighted<span class="nobreak">-average</span> discount rate for the operating lease is <ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-38089">7</ix:nonFraction>%.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In July&#160;2021, ARCA entered into a patent assignment agreement (the &#8220;Agreement&#8221;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Agreement, ARCA received exclusive world<span class="nobreak">-wide</span> patent rights relating to the use of rNAPc2 as a potential treatment for COVID<span class="nobreak">-19</span>, and other indications, based on the research and discoveries from Univ.<span class="nobreak">-Prof</span>. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#8220;CTH&#8221;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#8364;<ix:nonFraction contextRef="c91" decimals="-5" format="ixt:num-dot-decimal" name="abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" scale="6" unitRef="eur" id="ixv-38090">1.6</ix:nonFraction>&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro License</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has licensed worldwide rights to all preclinical and clinical data through the BEST trial for development of bucindolol. The patents that were the subject of this license are expired. If the license agreement is deemed enforceable, ARCA would incur milestone and royalty obligations upon the occurrence of certain events, including if the FDA grants marketing approval for Gencaro, upon regulatory marketing approval in Europe and Japan and based on achievement of specified product sales levels.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-21695"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;Equity Financings</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">At the Market Equity Financing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;22, 2020, ARCA entered into a Capital on Demand<span class="Superscript" style="vertical-align:super;font-size:58%;">TM</span> Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as agent (&#8220;JonesTrading&#8221;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#8217;s common stock, par value $<ix:nonFraction contextRef="c92" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-38091">0.001</ix:nonFraction> per share (&#8220;ARCA&#160;common stock&#8221;), having an aggregate offering price of up to $<ix:nonFraction contextRef="c92" decimals="-5" format="ixt:num-dot-decimal" name="abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell" scale="6" unitRef="usd" id="ixv-38092">54.0</ix:nonFraction>&#160;million (the &#8220;Shares&#8221;).</p></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-13</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;Equity Financings</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Sales Agreement, JonesTrading may sell the Shares by any method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415 promulgated under the Securities Act&#160;of&#160;1933, as amended, including sales made directly on or through the Nasdaq Capital Market, on any other existing trading market for ARCA common stock or to or through a market maker. In addition, under the amended Sales Agreement, JonesTrading may sell the Shares by any other method permitted by law, including in negotiated transactions. ARCA may instruct JonesTrading not to sell Shares if the sales cannot be effected at or above the price designated by ARCA from time to time.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a)&#160;the sale of all of the Shares subject to the Sales Agreement or (b)&#160;the termination of the Sales Agreement by JonesTrading or ARCA, as permitted therein.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA paid JonesTrading a commission rate equal to <ix:nonFraction contextRef="c93" decimals="3" format="ixt:num-dot-decimal" name="abio:SellingCommissionPerAdditionalSharesSoldPercentage" scale="-2" unitRef="pure" id="ixv-38093">3.0</ix:nonFraction>% of the aggregate gross proceeds from each sale of Shares and agreed to provide JonesTrading with customary indemnification and contribution rights. ARCA will also reimburse JonesTrading for certain specified expenses in connection with entering into the Sales Agreement.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonFraction contextRef="c94" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-38094"><ix:nonFraction contextRef="c95" decimals="0" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-38095">No</ix:nonFraction></ix:nonFraction> sales were made in 2023 or 2022.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>). The amount available for the offering under the prospectus supplement is subject to the limitation of not selling a total value amount of shares exceeding more than one<span class="nobreak">-third</span> of ARCA&#8217;s public float in any 12<span class="nobreak">-month</span> period.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-21722"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Plans</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s equity incentive plan, <span class="Italic" style="font-style:italic;font-weight:normal;">the 2020 Equity Incentive Plan </span>(the &#8220;Equity Plan&#8221;),<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>was approved by stockholders on December&#160;10, 2020. The maximum number of shares issuable under this plan is <ix:nonFraction contextRef="c96" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares" id="ixv-38096">1,167,425</ix:nonFraction><span class="nobreak"> </span>shares.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Equity Plan provides for the granting of stock options (including indexed options), restricted stock units, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, performance shares, performance units and deferred stock units. Under the Equity Plan, awards may be granted to employees, directors and consultants of ARCA, except for incentive stock options, which may be granted only to employees. As of December&#160;31, 2023, options to purchase <ix:nonFraction contextRef="c97" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-38097">601,900</ix:nonFraction><span class="nobreak"> </span>shares with a weighted average exercise price of $<ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38098">3.45</ix:nonFraction> per share were outstanding under the Equity Plan, and <ix:nonFraction contextRef="c97" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-38099">459,718</ix:nonFraction><span class="nobreak"> </span>shares were reserved for future awards.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In general, the Equity Plan authorizes the grant of stock options that vest at rates set by the Board of Directors or the Compensation Committee thereof. Generally, stock options granted by ARCA under the equity incentive plans become exercisable ratably for a period of <span style="-sec-ix-hidden: hidden-fact-97">three</span> to <span style="-sec-ix-hidden: hidden-fact-98">four</span>&#160;years from the date of grant and have a maximum term of <span style="-sec-ix-hidden: hidden-fact-99">ten</span>&#160;years. The exercise prices of stock options under the equity incentive plan generally meet the following criteria: the exercise price of incentive stock options must be at least <ix:nonFraction contextRef="c100" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" unitRef="pure" id="ixv-38100">100</ix:nonFraction>% of the fair market value on the grant date and exercise price of options granted to <ix:nonFraction contextRef="c98" decimals="INF" format="ixt:num-dot-decimal" name="abio:PercentageHoldingForStockOptionsExercisePrice" scale="-2" unitRef="pure" id="ixv-38101">10</ix:nonFraction>% (or greater) stockholders must be at least <ix:nonFraction contextRef="c101" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" unitRef="pure" id="ixv-38102">110</ix:nonFraction>% of the fair market value on the grant date.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In conjunction with the adoption of the Equity Plan, ARCA discontinued grants under the 2013 Plan, effective December&#160;10, 2020. As of December&#160;31, 2023, options to purchase <ix:nonFraction contextRef="c102" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-38103">14,807</ix:nonFraction><span class="nobreak"> </span>shares with a weighted average exercise price of $<ix:nonFraction contextRef="c102" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38104">57.73</ix:nonFraction> per share were outstanding under the 2013 plan.</p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-14</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA did <ix:nonFraction contextRef="c103" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" unitRef="shares" id="ixv-38105">no</ix:nonFraction>t grant options in 2023. ARCA granted options to purchase an aggregate of <ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="abio:PurchaseAggregateShares" scale="0" unitRef="shares" id="ixv-38106">60,000</ix:nonFraction><span class="nobreak"> </span>shares of ARCA common stock in the year ended December&#160;31, 2022. <ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-21753">The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black<span class="nobreak">-Scholes</span> model with the following assumptions and had the following estimated weighted average grant date fair value per share:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Year Ended<br/>December&#160;31,<br/>2022</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected term</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-38107">5.5</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected volatility</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-38108">107</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free interest rate</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-38109">3.56</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected dividend yield</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-38110">0</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average grant date fair value per share</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-38111">1.87</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-38112">A summary of ARCA&#8217;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c6_cont_1"><table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in&#160;years)</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2021</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-38113">904,123</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c16" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38114">5.59</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-38115">60,000</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38116">2.31</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-76; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-77; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares" id="ixv-38117">259,163</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38118">4.74</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2022</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-38119">704,960</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38120">5.62</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-38121">8.29</ix:nonNumeric></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd" id="ixv-38122">18</ix:nonFraction></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-78; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-79; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-80; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-81; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares" id="ixv-38123">88,253</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38124">11.68</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-38125">616,707</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38126">4.76</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-38127">7.35</ix:nonNumeric></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-82; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-38128">463,068</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38129">5.28</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-38130">7.29</ix:nonNumeric></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-83; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-38131">616,661</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38132">4.76</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-38133">7.35</ix:nonNumeric></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-84; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	</tr>	</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The aggregate intrinsic value in the table above represents the total intrinsic value, based on ARCA&#8217;s closing price as of December&#160;31 of the respective year, which would have been received by the option holders had all the option holders with in<span class="nobreak">-the-money</span> options exercised as of that date. As of December&#160;31, 2023, the unrecognized compensation expense related to unvested options, excluding estimated forfeitures, was $<ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" unitRef="usd" id="ixv-38134">367,000</ix:nonFraction> which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c106" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-38135">1.1</ix:nonNumeric>&#160;years. ARCA recognizes compensation costs for its share<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Units</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA granted restricted stock units (&#8220;RSUs&#8221;) under the Equity Plan to employees during 2022. The fair value of RSU awards is the closing price of ARCA common stock on the date of the grant and is recognized as compensation expense on a straight<span class="nobreak">-line</span> basis over the respective vesting period. The stock awards granted had a requisite service period of <span style="-sec-ix-hidden: hidden-fact-100">one</span> year.</p></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-15</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="ixv-38136">A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Restricted Stock Units<br/>Outstanding</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-85; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-86; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-38137">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-38138">2.21</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-87; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-88; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-89; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-90; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-38139">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-38140">2.21</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-91; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-92; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-38141">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-38142">2.21</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-93; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-94; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-95; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-96; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, there was <ix:nonFraction contextRef="c108" decimals="INF" format="ixt:fixed-zero" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="0" unitRef="usd" id="ixv-38143">no</ix:nonFraction> unrecognized compensation cost related to unvested stock awards.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-cash Stock-based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ixv-22234">For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c89" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38144">526</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c90" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38145">423</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c109" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38146">160</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38147">133</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38148">686</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38149">556</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA did not recognize any tax benefit related to employee stock<span class="nobreak">-based</span> compensation cost as a result of the full valuation allowance on its net deferred tax assets.</p></ix:continuation>
		<ix:nonNumeric contextRef="c6" escape="true" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="ixv-22297"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(9)&#160;Employee Benefit Plans</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has a 401(k)&#160;plan and makes a <ix:nonNumeric contextRef="c6" name="us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" id="ixv-38150">matching contribution equal to <ix:nonFraction contextRef="c111" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" unitRef="pure" id="ixv-38151">100</ix:nonFraction>% of the employee&#8217;s first <ix:nonFraction contextRef="c111" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" unitRef="pure" id="ixv-38152">3</ix:nonFraction>% of the employee&#8217;s contributions and <ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" unitRef="pure" id="ixv-38153">50</ix:nonFraction>% of the employee&#8217;s next <ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" unitRef="pure" id="ixv-38154">2</ix:nonFraction>% of contributions.</ix:nonNumeric> ARCA adopted the plan in 2006 and contributed $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" unitRef="usd" id="ixv-38155">56,000</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" unitRef="usd" id="ixv-38156">96,000</ix:nonFraction> for the&#160;years ended December&#160;31, 2023 and 2022, respectively.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c6" continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-22301"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">(<span class="Bold" style="font-style:normal;font-weight:bold;">10)&#160;Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective June&#160;1, 2005, ARCA changed from an S<span class="nobreak">-Corporation</span> to a C<span class="nobreak">-Corporation</span>. As an S<span class="nobreak">-Corporation</span>, the net operating loss carryforwards were distributed to ARCA&#8217;s stockholders; such amounts were not significant. As of December&#160;31, 2023, ARCA has net operating loss carryforwards of approximately $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" unitRef="usd" id="ixv-38157">208.1</ix:nonFraction>&#160;million, and approximately $<ix:nonFraction contextRef="c113" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" unitRef="usd" id="ixv-38158">2.4</ix:nonFraction>&#160;million of research and development credits that may be used to offset future taxable income. ARCA&#8217;s net operating loss carryforwards through December&#160;31, 2017 will expire beginning <span style="-sec-ix-hidden: hidden-fact-107">2025</span> through <span style="-sec-ix-hidden: hidden-fact-108">2037</span>. <ix:nonNumeric contextRef="c6" name="us-gaap:TaxCreditCarryforwardDescription" id="ixv-38159">The net operating loss carryforwards beginning in 2018, have no expiration.</ix:nonNumeric> <ix:nonNumeric contextRef="c116" continuedAt="_TaxCreditCarryforwardLimitationsOnUse-c116_cont_1" name="us-gaap:TaxCreditCarryforwardLimitationsOnUse" id="ixv-38160">Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit </ix:nonNumeric></p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-16</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">(<span class="Bold" style="font-style:normal;font-weight:bold;">10)&#160;Income Taxes</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c6_cont_2" id="_IncomeTaxDisclosureTextBlock-c6_cont_1"><ix:continuation id="_TaxCreditCarryforwardLimitationsOnUse-c116_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#8217;s net operating loss carryforwards may be limited.</p></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due primarily to ARCA&#8217;s history of operating losses, management is unable to conclude that it is more likely than not that ARCA will realize the benefits of these deductible differences, and accordingly has provided a valuation allowance against the entire net deferred tax assets and liabilities of approximately $<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetsAndLiabilitiesValuationAllowance" scale="6" unitRef="usd" id="ixv-38161">55.5</ix:nonFraction>&#160;million at December&#160;31, 2023, reflecting an increase of approximately $<ix:nonFraction contextRef="c6" decimals="-5" format="ixt:num-dot-decimal" name="abio:ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" scale="6" unitRef="usd" id="ixv-38162">1.2</ix:nonFraction>&#160;million from December&#160;31, 2022. The deferred tax assets are primarily comprised of net operating loss carryforwards and research and experimentation credit carryforwards. As of December&#160;31, 2023, ARCA has not performed an Internal Revenue Code Section&#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. A limitation in the carryforwards would decrease the carrying amount of the gross amount of the net operating loss carryforwards, with a corresponding decrease in the valuation allowance recorded against these gross deferred tax assets.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-38163">Income tax benefit attributable to ARCA&#8217;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of <ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-38164"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-38165">21</ix:nonFraction></ix:nonFraction>% for 2023 and 2022, as a result of the following (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-c6_cont_1"><table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">U.S.&#160;federal income tax benefit at statutory rates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-38166">1,121</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-38167">2,085</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State income tax benefit, net of federal benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" sign="-" unitRef="usd" id="ixv-38168">192</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" sign="-" unitRef="usd" id="ixv-38169">357</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-101; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-102; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax asset adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" scale="3" unitRef="usd" id="ixv-38170">47</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" scale="3" unitRef="usd" id="ixv-38171">2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" unitRef="usd" id="ixv-38172">107</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" unitRef="usd" id="ixv-38173">186</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-38174">1,159</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-38175">2,254</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-103; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-104; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-17</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">(<span class="Bold" style="font-style:normal;font-weight:bold;">10)&#160;Income Taxes</span><span class="CharOverride-1" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_IncomeTaxDisclosureTextBlock-c6_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c6" continuedAt="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c6_cont_1" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-38176">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#8217;s net deferred tax assets and liabilities consisted of the following (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-c6_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net operating loss carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-38177">51,190</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" scale="3" unitRef="usd" id="ixv-38178">50,008</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Charitable contribution carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" scale="3" unitRef="usd" id="ixv-38179">371</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards" scale="3" unitRef="usd" id="ixv-38180">393</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" unitRef="usd" id="ixv-38181">2,420</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" unitRef="usd" id="ixv-38182">2,420</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized research and development costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-38183">951</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-38184">979</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized intangibles</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" unitRef="usd" id="ixv-38185">354</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" unitRef="usd" id="ixv-38186">356</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" unitRef="usd" id="ixv-38187">232</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" unitRef="usd" id="ixv-38188">205</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" unitRef="usd" id="ixv-38189">7</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" unitRef="usd" id="ixv-38190">6</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lease liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetsLeaseLiabilities" scale="3" unitRef="usd" id="ixv-38191">69</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxAssetsLeaseLiabilities" scale="3" unitRef="usd" id="ixv-38192">94</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total deferred tax assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-38193">55,594</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-38194">54,461</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-38195">55,531</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-38196">54,372</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets, net of valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-38197">63</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-38198">89</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" unitRef="usd" id="ixv-38199">61</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abio:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" unitRef="usd" id="ixv-38200">84</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38201">2</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38202">5</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net deferred tax liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since ARCA is in a loss carryforward position, it is generally subject to U.S.&#160;federal and state income tax examinations by tax authorities for all&#160;years for which a loss carryforward is available. Thus, ARCA&#8217;s open tax&#160;years extend back to <span style="-sec-ix-hidden: hidden-fact-109">2009</span>. ARCA believes that its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and does not anticipate any adjustment will result in a material adverse effect on ARCA&#8217;s financial condition, result of operations, or cash flow. For the&#160;years ended December&#160;31, 2023 and 2022, ARCA has <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:fixed-zero" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="0" unitRef="usd" id="ixv-38203"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:fixed-zero" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" scale="0" unitRef="usd" id="ixv-38204">no</ix:nonFraction></ix:nonFraction> reserve for uncertain tax positions. ARCA does not expect that the total amounts of unrecognized tax benefits will significantly increase or decrease within the subsequent twelve&#160;months. In the event ARCA concludes it is subject to interest or penalties arising from uncertain tax positions, it will record interest and penalties as a component of other income and expense. <ix:nonFraction contextRef="c6" decimals="0" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="0" unitRef="usd" id="ixv-38205"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="0" unitRef="usd" id="ixv-38206">No</ix:nonFraction></ix:nonFraction> interest or penalties were recognized in the financial statements for the&#160;years ended December&#160;31, 2023 and 2022.</p></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-18</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T207"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>BALANCE SHEETS<br/>(Unaudited)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">March&#160;31, <br/>2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">December&#160;31, <br/>2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and <br/>per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:center;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ASSETS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-38207">35,903</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-38208">37,431</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-38209">767</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-38210">161</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-38211">36,670</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-38212">37,592</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset&#160;&#8211;&#160;operating</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-38213">17</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-38214">247</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-38215">7</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-38216">10</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-38217">12</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-38218">12</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-38219">36,706</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-38220">37,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;text-indent:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-38221">529</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-38222">362</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation and employee benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-38223">84</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-38224">100</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-38225">968</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-38226">175</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-38227">1,581</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-38228">637</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-5; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-38229">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total liabilities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-38230">1,581</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-38231">841</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders&#8217; equity:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, $<ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-38232"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-38233">0.001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-38234"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" unitRef="shares" id="ixv-38235">100</ix:nonFraction></ix:nonFraction>&#160;million shares authorized at March&#160;31,&#160;2024 and December&#160;31, 2023; <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-38236"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-38237"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-38238"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-38239">14,501,143</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding at March&#160;31, 2024 and December&#160;31, 2023, respectively</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-38240">14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-38241">14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-38242">225,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-38243">225,747</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-38244">190,750</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-38245">188,741</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38246">35,125</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38247">37,020</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total liabilities and stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-38248">36,706</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-38249">37,861</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-19</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T208"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF OPERATIONS<br/>(Unaudited)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and <br/>per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Costs and expenses:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38250">2,317</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-38251">1,406</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development (related party&#160;&#8211;&#160;$<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="3" unitRef="usd" id="ixv-38252">0</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="3" unitRef="usd" id="ixv-38253">108</ix:nonFraction> as of March&#160;31,&#160;2024&#160;and 2023, respectively)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-38254">165</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-38255">390</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total costs and expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-38256">2,482</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-38257">1,796</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38258">2,482</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38259">1,796</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest and other income</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" unitRef="usd" id="ixv-38260">473</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestAndOtherIncome" scale="3" unitRef="usd" id="ixv-38261">450</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38262">2,009</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38263">1,346</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share:</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_2" style="-sec-ix-hidden: hidden-fact-12; -sec-ix-hidden: hidden-fact-11; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-38264">0.14</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-38265">0.09</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted average shares outstanding:</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody-ind_2" style="-sec-ix-hidden: hidden-fact-14; -sec-ix-hidden: hidden-fact-13; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Basic and diluted</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-38266">14,501,143</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-38267">14,410,143</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-20</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T209"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF STOCKHOLDERS&#8217; EQUITY<br/>(Unaudited)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="15" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 65.17%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Stockholders&#8217; Equity</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 24.36%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Common stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Additional <br/>Paid-In <br/>Capital</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Accumulated<br/>Deficit</span></p>
					</td>
					<td class="TCH" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.75%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="15" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 65.17%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands, except share and per share amounts)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2022</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-38268">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38269">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38270">225,061</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-38271">183,402</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38272">41,673</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-27; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38273">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-28; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38274">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-29; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-30; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38275">1,346</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38276">1,346</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, March&#160;31, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-38277">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38278">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38279">225,265</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-38280">184,748</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38281">40,531</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-31; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38282">187</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-32; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38283">187</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-33; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-34; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38284">1,480</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38285">1,480</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, June&#160;30, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-38286">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38287">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38288">225,452</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-38289">186,228</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38290">39,238</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-35; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38291">154</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-36; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38292">154</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-37; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-38; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38293">1,424</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38294">1,424</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, September&#160;30, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-38295">14,410,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38296">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38297">225,606</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-38298">187,652</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38299">37,968</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Issuance of common stock upon vesting&#160;of Restricted Stock Units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" unitRef="shares" id="ixv-38300">91,000</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-39; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-40; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-41; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-42; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-3" style="font-style:normal;font-weight:normal;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-43; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38301">141</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-44; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38302">141</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-45; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-46; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38303">1,089</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38304">1,089</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, December&#160;31, 2023</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-38305">14,501,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38306">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38307">225,747</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-38308">188,741</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38309">37,020</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-47; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38310">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-48; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-38311">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-49; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-50; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38312">2,009</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38313">2,009</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 33.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Balance, March&#160;31, 2024</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-38314">14,501,143</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38315">14</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38316">225,861</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 9.19%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">(<ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-38317">190,750</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-38318">35,125</ix:nonFraction></span></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">&#160;</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-21</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T210"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>STATEMENTS OF CASH FLOWS<br/>(Unaudited)</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">Quarter Ended March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(in thousands)</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from operating activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38319">2,009</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-38320">1,346</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-38321">3</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-38322">4</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amortization of right-of-use asset&#160;&#8211;&#160;operating</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-38323">16</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-38324">25</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Share-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-38325">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-38326">204</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in operating assets and liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" unitRef="usd" id="ixv-38327">606</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" unitRef="usd" id="ixv-38328">598</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd" id="ixv-38329">167</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd" id="ixv-38330">32</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation and employee benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-38331">16</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" unitRef="usd" id="ixv-38332">62</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" unitRef="usd" id="ixv-38333">803</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" unitRef="usd" id="ixv-38334">22</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash used in operating activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-38335">1,528</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-38336">1,595</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from investing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash used in investing activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-61; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-62; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from financing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net cash provided by financing activities</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-63; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-64; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net decrease in cash and cash equivalents</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-38337">1,528</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-38338">1,595</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash and cash equivalents, beginning of year</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-38339">37,431</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-38340">42,445</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash and cash equivalents, end of year</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-38341">35,903</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-38342">40,850</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Supplemental cash flow information:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-65; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-66; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax refund received</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-67; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-68; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Supplemental disclosure of noncash investing and financing transactions:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Leased assets and operating lease liabilities&#160;&#8211;&#160;amended lease term</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-38343">214</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-69; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush_Center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">See accompanying Notes to Financial Statements</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-22</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T211"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="ixv-24534"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span></p>
		<ix:nonNumeric contextRef="c0" continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_1" escape="true" name="abio:DescriptionOfBusinessPolicyTextBlock" id="ixv-24537"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_2" id="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p></ix:continuation>
		<ix:continuation continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_3" id="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#8220;Board&#8221;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.</p></ix:continuation>
		<ix:continuation continuedAt="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_4" id="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;I&#8221;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;II&#8221;) and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka<span class="CharOverride-1" style="text-decoration:underline;">&#8221;</span>), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;). The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p></ix:continuation>
		<ix:continuation id="abio_DescriptionOfBusinessPolicyTextBlock-c0_cont_4"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_1" escape="true" name="abio:LiquidityAndGoingConcernPolicyTextBlock" id="ixv-24552"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_2" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has <ix:nonFraction contextRef="c0" decimals="INF" format="ixt:fixed-zero" name="us-gaap:Revenues" scale="0" unitRef="usd" id="ixv-38344">no</ix:nonFraction>t generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_3" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be </p></ix:continuation></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-23</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_4" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_5" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_4"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_6" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_5"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_7" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_6"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_8" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_7"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_9" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_8"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_10" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_9"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_11" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_10"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_12" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_11"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_13" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_12"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p></ix:continuation>
		<ix:continuation continuedAt="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_14" id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_13"><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p></ix:continuation>
		<ix:continuation id="abio_LiquidityAndGoingConcernPolicyTextBlock-c0_cont_14"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-24614"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2" id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S<span class="nobreak">-X</span>.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring </p></ix:continuation></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-24</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-24634"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p></ix:nonNumeric>
		<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:fixed-zero" name="us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset" scale="0" unitRef="usd" id="ixv-38345">no</ix:nonFraction> off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="abio_ComprehensiveLossPolicyPolicyTextBlock-c0_cont_1" escape="true" name="abio:ComprehensiveLossPolicyPolicyTextBlock" id="ixv-24640"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p></ix:nonNumeric>
		<ix:continuation id="abio_ComprehensiveLossPolicyPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-24646"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p></ix:nonNumeric>
		<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.</p></ix:continuation>
		<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="abio_AccruedOutsourcingExpensesPolicyTextBlock-c0_cont_1" escape="true" name="abio:AccruedOutsourcingExpensesPolicyTextBlock" id="ixv-24655"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p></ix:nonNumeric>
		<ix:continuation id="abio_AccruedOutsourcingExpensesPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p></ix:continuation>
		<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-24660"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p></ix:nonNumeric>
		<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p></ix:continuation></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-25</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-24673"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(2)&#160;Net Loss Per Share</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#8217;s potentially dilutive shares include stock options and restricted stock units.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-38346">Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-38347">645,845</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-38348">664,857</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-110; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-38349">91,000</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-38350">645,845</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-38351">755,857</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-24730"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(3)&#160;Fair Value Disclosures</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were <span style="-sec-ix-hidden: hidden-fact-111"><span style="-sec-ix-hidden: hidden-fact-112">no</span></span> marketable securities as of March&#160;31, 2024 or December&#160;31, 2023.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#8220;exit price&#8221;). Inputs used to measure fair value are classified into the following hierarchy:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 1 &#8212;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#8217;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 2 &#8212;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA does not have any Level 2 assets or liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 3 &#8212;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024 and December&#160;31, 2023, ARCA had $<ix:nonFraction contextRef="c121" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" unitRef="usd" id="ixv-38352">35.9</ix:nonFraction>&#160;million and $<ix:nonFraction contextRef="c66" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" unitRef="usd" id="ixv-38353">37.4</ix:nonFraction>&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were <span style="-sec-ix-hidden: hidden-fact-113">no</span> transfers of assets between fair value hierarchy levels during the three&#160;months ended March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities.</p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-26</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-24759"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(4)&#160;Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-38354">Property and equipment consist of the following (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c122" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-38355">3</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38356">39</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38357">39</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c123" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-38358">5</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c123" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38359">130</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38360">130</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c124" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-38361">5</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38362">37</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38363">37</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><ix:nonNumeric contextRef="c125" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-38364">3</ix:nonNumeric>&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38365">16</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38366">16</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38367">222</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-38368">222</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38369">215</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-38370">212</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-38371">7</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-38372">10</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the three&#160;months ended March&#160;31, 2024 and 2023, depreciation and amortization expense was $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-38373">3</ix:nonFraction>,000 and $<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-38374">4</ix:nonFraction>,000 respectively.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-24919"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(5)&#160;Related Party Arrangements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Transactions with ARCA&#8217;s Former President and Chief Executive Officer</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its former President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. There was <ix:nonFraction contextRef="c127" decimals="0" format="ixt:fixed-zero" name="abio:ResearchAndDevelopmentExpenseReversed" scale="0" unitRef="usd" id="ixv-38375">no</ix:nonFraction> expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements for the three&#160;months ended March&#160;31, 2023 was $<ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="abio:ResearchAndDevelopmentExpenseReversed" scale="0" unitRef="usd" id="ixv-38376">108,000</ix:nonFraction>. In December&#160;2023, ARCA made a payment of $<ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="abio:PaymentOfUnrestrictedResearchGrants" scale="0" unitRef="usd" id="ixv-38377">125,000</ix:nonFraction> for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the President and Chief Executive Officer resigned, see Note&#160;10.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-24925"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has or is subject to the following commitments and contingencies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements and Reduction of Workforce</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from the date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $<ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-38378">265,000</ix:nonFraction>. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by <ix:nonFraction contextRef="c81" decimals="2" format="ixt:num-dot-decimal" name="abio:PercentageOfRetentionBonuses" scale="-2" unitRef="pure" id="ixv-38379">50</ix:nonFraction>% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonusPaid" scale="0" unitRef="usd" id="ixv-38380">86,000</ix:nonFraction> was paid in December&#160;2023. As of March&#160;31, 2024, the unpaid retention bonuses totaled $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-38381">311,000</ix:nonFraction>, none of which was accrued as of March&#160;31, 2024, since there had not been a change in control or clinical development decision. In April&#160;2024, the retention bonuses were again amended to increase the aggregate amount of the retention bonus, with the unpaid retention bonus increasing to $<ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-38382">444,000</ix:nonFraction>. See Note&#160;10.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Christopher D.&#160;Ozeroff, the former Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#8217;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#8217;s existing employment agreement, as previously amended, ARCA provided Mr.&#160;Ozeroff severance benefits pursuant to the terms </p></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-27</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">of his existing employment agreement with ARCA, as previously amended. The severance benefits included severance payments and reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA.&#160;During the year ended December&#160;31, 2023, ARCA recorded an expense of $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="0" unitRef="usd" id="ixv-38383">159,000</ix:nonFraction> for these severance benefits, <span style="-sec-ix-hidden: hidden-fact-115">none</span> of which remains unpaid.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Michael Bristow, former President, Chief Executive Officer and a member of the board of directors of ARCA mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment and service as a director, effective April&#160;3, 2024. See Note&#160;10.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Leases</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020 ARCA entered into a lease agreement for approximately <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" unitRef="sqft" id="ixv-38384">5,200</ix:nonFraction> square feet of office facilities in Westminster, Colorado which serves as its primary business office effective October&#160;1, 2020 (&#8220;October&#160;2020 Lease&#8221;). The lease term was <ix:nonNumeric contextRef="c85" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-38385">42</ix:nonNumeric>&#160;months beginning October&#160;1, 2020. In March&#160;2024, ARCA entered into an amendment <ix:nonNumeric contextRef="c0" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="ixv-38386">to extend the <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="ixv-38387">lease</ix:nonNumeric> term six (<ix:nonNumeric contextRef="c5" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="ixv-38388">6</ix:nonNumeric>)&#160;months through <ix:nonNumeric contextRef="c0" name="abio:OperatingLeasesExtendedExpiryYearsAndMonth" id="ixv-38389">September&#160;2024</ix:nonNumeric></ix:nonNumeric>. If ARCA elects to stay in the property after September&#160;2024, it will pay rent month to month equal to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="abio:PercentageOfBaseRentToBePaidMonthly" scale="-2" unitRef="pure" id="ixv-38390">125</ix:nonFraction>% of the base rent paid in September&#160;2024. In June&#160;2021, ARCA entered into a sublease agreement for approximately <ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" scale="0" unitRef="sqft" id="ixv-38391">3,000</ix:nonFraction> square feet of additional office facilities in its primary business office (&#8220;2021 Lease&#8221;). The sublease term was <ix:nonNumeric contextRef="c131" format="ixt-sec:durmonth" name="abio:LesseeOperatingSubleaseTermOfContract" id="ixv-38392">29</ix:nonNumeric>&#160;months and terminated in October&#160;2023. <ix:nonNumeric contextRef="c0" name="us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" id="ixv-24953">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation.</ix:nonNumeric></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-38393">Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" unitRef="usd" id="ixv-38394">49</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-38395">49</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-38396">1</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-38397">48</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-114; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Rent expense, which is included in general and administrative expense, for the three&#160;months ended March&#160;31, 2024 and 2023 was $<ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-38398">22,000</ix:nonFraction> and $<ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd" id="ixv-38399">31,000</ix:nonFraction>, respectively.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, the lease liability was $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd" id="ixv-38400">48,000</ix:nonFraction>, it is all current and is included in accrued expenses and other liabilities in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the three&#160;months ended March&#160;31, 2024 and 2023 were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-38401">23,000</ix:nonFraction> and $<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="0" unitRef="usd" id="ixv-38402">33,000</ix:nonFraction>, respectively. The weighted<span class="nobreak">-average</span> remaining lease term for the operating lease as of March&#160;31, 2024 is <ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-38403">0.5</ix:nonNumeric>&#160;years. The discount rate for the operating lease is <ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-38404">7</ix:nonFraction>%.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In July&#160;2021, ARCA entered into a patent assignment agreement (the &#8220;Agreement&#8221;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Agreement, ARCA received exclusive world<span class="nobreak">-wide</span> patent rights relating to the use of rNAPc2 as a potential treatment for COVID<span class="nobreak">-19</span>, and other indications, based on the research and discoveries from Univ.<span class="nobreak">-Prof</span>. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#8220;CTH&#8221;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#8364;<ix:nonFraction contextRef="c91" decimals="-5" format="ixt:num-dot-decimal" name="abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" scale="6" unitRef="eur" id="ixv-38405">1.6</ix:nonFraction>&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.</p></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-28</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-25026"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-style:normal;font-weight:bold;">Equity Financings</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">At the Market Equity Financing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, ARCA entered into a Capital on Demand&#8482; Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as agent (&#8220;JonesTrading&#8221;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#8217;s common stock, par value $<ix:nonFraction contextRef="c132" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-38406">0.001</ix:nonFraction> per share (&#8220;ARCA common stock&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated the Sales Agreement in accordance with its terms.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonFraction contextRef="c133" decimals="INF" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-38407"><ix:nonFraction contextRef="c134" decimals="INF" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-38408">No</ix:nonFraction></ix:nonFraction> sales were made under the Sales Agreement in 2024 or 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">See &#8220;Financing Transaction&#8221; discussion in Note&#160;10 below.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-25040"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ixv-25044">For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense in the statements of operations (in thousands):</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c0_cont_1"><table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Three&#160;Months Ended<br/>March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c129" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38409">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38410">163</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-116; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38411">41</ix:nonFraction></p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38412">114</ix:nonFraction></p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-38413">204</ix:nonFraction></p>	</td>
				</tr>

		</table></ix:continuation>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-38414">Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#8217;s stock incentive plans were as follows:</ix:nonNumeric></p>
		<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1"><table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in&#160;years)</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-38415">616,707</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38416">4.76</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c137" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-38417">7.35</ix:nonNumeric></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-38418">42,000</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38419">1.64</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-117; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-118; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares" id="ixv-38420">12,862</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38421">17.45</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-38422">645,845</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38423">4.30</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-38424">6.82</ix:nonNumeric></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-38425">502,517</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38426">4.71</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-38427">6.55</ix:nonNumeric></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-38428">645,816</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-38429">4.30</ix:nonFraction></p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-38430">6.82</ix:nonNumeric></p>	</td>	</tr>	</table></ix:continuation></ix:nonNumeric>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-29</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-bottom:10pt;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-25254"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(9)&#160;Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with GAAP, a valuation allowance should be provided if it is more likely than not that some or all of ARCA&#8217;s deferred tax assets will not be realized. ARCA&#8217;s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, ARCA has recorded a full valuation allowance against its net deferred tax assets. ARCA believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has <span style="-sec-ix-hidden: hidden-fact-119">no</span> reserve for uncertain tax positions.</p></ix:nonNumeric>
		<ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-25259"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA, Merger Sub&#160;I, Merger Sub&#160;II and Oruka, entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger. The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, at the closing of the First Merger, (a)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the financing transaction described below) will be converted solely into the right to receive a number of shares of ARCA common stock calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;), (b)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of Series&#160;B Preferred Stock (as defined below) of ARCA, calculated in accordance with the Merger Agreement (c)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and (d)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and form of warrant. Under the terms of the Merger Agreement, prior to the closing of the transaction, the Board will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option (the &#8220;Out of the Money Options&#8221;) to acquire shares of ARCA common stock with an exercise price per share greater than the volume weighted average closing trading price of a share of ARCA common stock on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) for the five (<ix:nonNumeric contextRef="c138" format="ixt-sec:durday" name="abio:NumberOfConsecutiveTradingDays" id="ixv-38431">5</ix:nonNumeric>)&#160;consecutive&#160;trading days ending three (3)&#160;days immediately prior to the closing date of the First Merger (the &#8220;Parent Closing Price&#8221;), in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, each option to acquire shares of ARCA common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Exchange Ratio formula in the Merger Agreement, upon the closing of the First Merger, on a pro forma basis and based upon the number of shares of ARCA common stock expected to be issued in the First Merger, pre<span class="nobreak">-First</span> Merger Oruka stockholders (including Oruka stockholders issued shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants in the financing transaction described below) will own approximately <ix:nonFraction contextRef="c139" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" unitRef="pure" id="ixv-38432">97.62</ix:nonFraction>% of the combined company and pre<span class="nobreak">-First</span> Merger ARCA stockholders will own approximately <ix:nonFraction contextRef="c140" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" unitRef="pure" id="ixv-38433">2.38</ix:nonFraction>% of the combined company. For purposes of calculating the Exchange Ratio, (i)&#160;shares of ARCA common stock underlying warrants and other rights to receive shares (other than Options to acquire shares of ARCA common stock, to the extent cancelled at or prior to closing of the First Merger in accordance with the Merger Agreement) outstanding as of immediately prior to the closing of the First Merger will be deemed to be outstanding, and (ii)&#160;all shares of Oruka common stock underlying outstanding Oruka stock options and warrants will be deemed to be outstanding. The Exchange Ratio will be </p></ix:nonNumeric>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-30</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_2" id="_SubsequentEventsTextBlock-c0_cont_1"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">adjusted to the extent that ARCA&#8217;s net cash at closing is less than $<ix:nonFraction contextRef="c138" decimals="-5" format="ixt:num-dot-decimal" name="abio:ThresholdAmountOfAdjustedExchangeRatio" scale="6" unitRef="usd" id="ixv-38434">5.0</ix:nonFraction>&#160;million and will be based on the amount of proceeds actually received by Oruka in the financing transaction described below, as further described in the Merger Agreement.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $<ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="abio:ThresholdAmountOfDeclaredCashDividend" scale="0" unitRef="usd" id="ixv-38435">5,000,000</ix:nonFraction>.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Merger, ARCA is required to seek the approval of its stockholders to, among other things, (a)&#160;issue shares of ARCA common stock issuable in connection with the First Merger (including the shares of ARCA common stock issuable under the Series&#160;B Preferred Stock) under the rules of Nasdaq, and (b)&#160;amend its amended and restated certificate of incorporation, to (i)&#160;effect a reverse stock split of ARCA common stock (if deemed necessary by ARCA and Oruka), (ii)&#160;increase the number of shares of ARCA common stock that ARCA is authorized to issue, and (iii)&#160;such other changes as are mutually agreeable to ARCA and Oruka (the &#8220;ARCA Voting Proposals&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1)&#160;using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2)&#160;non<span class="nobreak">-solicitation</span> of alternative acquisition proposals, (3)&#160;the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, (4)&#160;ARCA using commercially reasonable efforts to maintain the existing listing of the ARCA common stock on Nasdaq and cause the shares of ARCA common stock to be issued in connection with the First Merger to be approved for listing on Nasdaq prior to the closing of the First Merger, and (5)&#160;ARCA filing with the U.S.&#160;Securities and Exchange Commission (the &#8220;SEC&#8221;) and causing to become effective a registration statement to register shares of ARCA common stock to be issued in connection with the First Merger, except as set forth in the Merger Agreement (the &#8220;Registration Statement&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA stockholders of the ARCA Voting Proposals, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the initial listing application to be submitted in connection with the First Merger, (4)&#160;the effectiveness of the Registration Statement, (5)&#160;the expiration of any applicable waiting periods (or extensions thereof) under the Hart Scott<span class="nobreak">-Rodino</span> Antitrust Improvements Act&#160;of&#160;1976, as amended, (6)&#160;the subscription agreements (described below) being in full force and effect providing for the receipt of proceeds of not less than $<ix:nonFraction contextRef="c142" decimals="INF" format="ixt:num-dot-decimal" name="abio:SubscriptionAgreementReceiptAmount" scale="0" unitRef="usd" id="ixv-38436">175,000,000</ix:nonFraction> (including in the proceeds any notes contributed as consideration in the financing transaction described below) and (7)&#160;to the extent ARCA has declared the cash dividend described above, ARCA delivering the aggregate amount distributable to the pre<span class="nobreak">-First</span> Merger ARCA stockholders to ARCA&#8217;s transfer agent for further distribution to the pre<span class="nobreak">-First</span> Merger ARCA stockholders. Each party&#8217;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the date of the closing of the Merger.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains certain termination rights of each of ARCA and Oruka. Upon termination of the Merger Agreement under specified circumstances, ARCA and Oruka may each be required to pay the other party a termination fee of $<ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="abio:PaymentOfOtherPartyTerminationFee" scale="0" unitRef="usd" id="ixv-38437">440,000</ix:nonFraction>.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to a Certificate of Designation of Preferences, Rights and Limitations of the Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to be filed by ARCA with the Secretary of State of the State of Delaware (the &#8220;Certificate of Designation&#8221;) in connection with the Merger Agreement and the transactions thereunder, ARCA will establish the terms of a new series of preferred stock of ARCA designated as Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock, par value $<ix:nonFraction contextRef="c144" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-38438">0.001</ix:nonFraction> per share (the &#8220;Series&#160;B Preferred Stock&#8221;). Holders of the Series&#160;B Preferred Stock will be entitled to receive dividends on shares of Series&#160;B Preferred Stock equal to, on an as<span class="nobreak">-if-converted-to-ARCA</span> common stock </p></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-31</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_3" id="_SubsequentEventsTextBlock-c0_cont_2"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">basis, and in the same form as dividends actually paid on shares of the ARCA common stock. Except as otherwise required by the Certificate of Designation or law, the Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend its certificate of incorporation, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;B Preferred Stock, (e)&#160;issue further shares of the Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the Series&#160;B Preferred Stock, (f)&#160;at any time while at least <ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="abio:MinimumPercentageOfOriginallyIssuedShares" scale="-2" unitRef="pure" id="ixv-38439"><ix:nonFraction contextRef="c145" decimals="2" format="ixt:num-dot-decimal" name="abio:MinimumPercentageOfOriginallyIssuedOutstanding" scale="-2" unitRef="pure" id="ixv-38440">30</ix:nonFraction></ix:nonFraction>% of the originally issued Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding<span class="nobreak">-up</span> of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the closing of the First Merger, each share of Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the Series&#160;B Preferred Stock, into a number of shares equal to <ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-38441">1,000</ix:nonFraction><span class="nobreak"> </span>shares of ARCA common stock, subject to certain limitations, including that a holder of Series&#160;B Preferred Stock is prohibited from converting shares of Series&#160;B Preferred Stock into shares of ARCA common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at <ix:nonFraction contextRef="c147" decimals="4" format="ixt:num-dot-decimal" name="abio:InitiallySpecifiedPercentageForBeneficialNumberOfShares" scale="-2" unitRef="pure" id="ixv-38442">9.99</ix:nonFraction>%) of the total number of shares of ARCA common stock issued and outstanding immediately after giving effect to such conversion.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the effective time of the First Merger (the &#8220;First Effective Time&#8221;), the combined company&#8217;s board of directors is expected to consist of <ix:nonFraction contextRef="c148" decimals="0" format="ixt-sec:numwordsen" name="abio:ExceptedNumberOfBoardMembers" scale="0" unitRef="pure" id="ixv-38443">five</ix:nonFraction> (5)&#160;members, all of whom will be designated by Oruka. Upon the closing of the transaction, the combined company will be led by Oruka&#8217;s chief executive officer.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Financing Transaction</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution and delivery of the Merger Agreement, certain parties have entered into a subscription agreements with Oruka, pursuant to which they have agreed, subject to the terms and conditions of such agreements, to purchase immediately prior to the consummation of the First Merger, shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock (together, the &#8220;PIPE Securities&#8221;) for an aggregate purchase price of approximately $<ix:nonFraction contextRef="c149" decimals="-5" format="ixt:num-dot-decimal" name="abio:AggregatePurchasePrice" scale="6" unitRef="usd" id="ixv-38444">275.0</ix:nonFraction>&#160;million. The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the subscription agreement. Shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock issued pursuant to this financing transaction will be converted into shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to acquire shares ARCA common stock, in accordance with the Exchange Ratio and the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Separation of Michael Bristow, M.D., President, Chief Executive Officer and Director</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective April&#160;3, 2024, ARCA and Dr.&#160;Michael Bristow, President, Chief Executive Officer and a member of the Board mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment and service as a director.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with Dr.&#160;Bristow&#8217;s separation, ARCA and Dr.&#160;Bristow entered into a separation agreement (the &#8220;Separation Agreement&#8221;) on April&#160;3, 2024. Pursuant to the terms of the Separation Agreement, ARCA provided to Dr.&#160;Bristow a lump sum payment equal to (i)&#160;twelve (<ix:nonNumeric contextRef="c150" format="ixt-sec:durmonth" name="abio:NumberOfMonthsBaseSalary" id="ixv-38445">12</ix:nonNumeric>)&#160;months of Dr.&#160;Bristow&#8217;s base salary as of the last date of his employment and (ii)&#160;a cash payment of $<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="abio:CashPayment" scale="0" unitRef="usd" id="ixv-38446">25,000</ix:nonFraction>, less applicable withholdings. The severance benefits were conditioned on the non<span class="nobreak">-revocation</span> by Dr.&#160;Bristow of a legal release of claims.</p></ix:continuation>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-32</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-align:center;text-indent:0pt;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.<br/>NOTES TO FINANCIAL STATEMENTS<br/>(Unaudited)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span><span class="CharOverride-2" style="font-style:normal;font-weight:normal;"> (cont.)</span></p>
		<ix:continuation id="_SubsequentEventsTextBlock-c0_cont_3"><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Bristow entered into a consulting agreement, effective April&#160;3, 2024 (the &#8220;Consulting Agreement&#8221;), pursuant to which Dr.&#160;Bristow is providing certain consulting services provided for in the Consulting Agreement to ARCA until the earlier of (i)&#160;the completion of services under the Consulting Agreement, (ii)&#160;a termination in accordance with the terms of the Consulting Agreement, and (iii)&#160;upon a Change of Control (as defined in ARCA&#8217;s 2020 Equity Incentive Plan (the &#8220;Plan&#8221;)). Pursuant to the Consulting Agreement, Dr.&#160;Bristow provision of services under the Consulting Agreement are deemed to be a Continuous Service (as defined in the Plan) and, as a result, his equity awards under the Plan continue to vest during the term of the Consulting Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appointment of Thomas Keuer as President</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective as of April&#160;3, 2024, the Board appointed Thomas A.&#160;Keuer, ARCA&#8217;s Chief Operating Officer, to serve as ARCA&#8217;s President and principal executive officer. Mr.&#160;Keuer has been with ARCA since 2006, and as its Chief Operating Officer for the last nine&#160;years, a position he will continue to serve in. Mr.&#160;Keuer will not receive any additional compensation in connection with his appointment as President and principal executive officer. Mr.&#160;Keuer&#8217;s position will end upon closing of the merger transaction with Oruka Therapeutics, Inc. as previously disclosed on a Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on April&#160;3, 2024.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Second Amendment to Retention Bonus Letter of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of certain retention bonus letters between ARCA and each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker to increase the aggregate amount of the retention bonus with respect to each such executive to $<ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="abio:IncreaseOfRetentionBonusToEachExecutive" scale="0" unitRef="usd" id="ixv-38447"><ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="abio:IncreaseOfRetentionBonusToEachExecutive" scale="0" unitRef="usd" id="ixv-38448">200,000</ix:nonFraction></ix:nonFraction>. The remaining portion of the retention bonus with respect to Thomas A. Keuer and C. Jeffrey Dekker, consisting of $<ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="abio:RetentionBonuses" scale="0" unitRef="usd" id="ixv-38449">165,000</ix:nonFraction>, will become payable consistent with the original terms of the applicable retention bonus letter and first amendment to retention bonus letter. Any payment related to the retention bonuses of Thomas A. Keuer and C. Jeffrey Dekker will be paid by ARCA via payroll within&#160;30 business days of the date of occurrence of the applicable &#8220;Payment Event Date&#8221; (as such term is otherwise defined in the applicable second amendment to the retention bonus letter). Each such retention bonus letter and first amendment to retention bonus letter will otherwise remain subject to their original terms and conditions.</p></ix:continuation>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-33</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T212"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">To the Board of Directors and Stockholders of Oruka Therapeutics, Inc.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Opinion on the Financial Statement&#160;&#8212;&#160;Balance Sheet</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have audited the accompanying<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>balance sheet of Oruka Therapeutics, Inc. (the &#8220;Company&#8221;) as of February&#160;6, 2024, including the related notes (collectively referred to as the &#8220;financial statement&#8221;). In our opinion, the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement presents fairly, in all material respects, the financial position of the Company as of February&#160;6, 2024<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>in conformity with accounting principles generally accepted in the United&#160;States of America.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Substantial Doubt about the Company&#8217;s Ability to Continue as a Going Concern</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The accompanying financial statement has been prepared assuming that the Company will continue as a going concern. As discussed in Note&#160;1 to the financial statement, the Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception, which raises substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note&#160;1. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis for Opinion</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement is the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United&#160;States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We conducted our audit of this financial statement in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United&#160;States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement is free of material misstatement, whether due to error or fraud.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Our audit included performing procedures to assess the risks of material misstatement of the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the<span class="Bold" style="font-style:normal;font-weight:bold;"> </span>financial statement. We believe that our audit provides a reasonable basis for our opinion.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Critical Audit Matters</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Critical audit matters are matters arising from the current period audit of the financial statement that were communicated or required to be communicated to the audit committee and that (i)&#160;relate to accounts or disclosures that are material to the financial statement and (ii)&#160;involved our especially challenging, subjective, or complex judgments. We determined there are no critical audit matters.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">/s/ PricewaterhouseCoopers LLP</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Boston, Massachusetts<br/><span class="Bold" style="font-style:normal;font-weight:bold;font-style:normal;font-weight:normal;">May&#160;13, 2024</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">We have served as the Company&#8217;s auditor since 2024.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-34</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T213"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>BALANCE SHEET<br/>(In thousands, except share amounts)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">February&#160;6, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ASSETS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current Assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total assets</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">1</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies (Note&#160;5)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">STOCKHOLDERS&#8217; EQUITY</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;A convertible preferred stock, $0.0001 par value, 20,000,000 shares authorized, no shares issued and outstanding as of February&#160;6, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, $0.0001 par value, 65,000,000 shares authorized, 5,596,658 issued and outstanding as of February&#160;6, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Total stockholders&#8217; equity</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-4" style="font-style:normal;font-weight:bold;">1</span></p>
					</td>
				</tr>

		</table>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">The accompanying notes are an integral part of this financial statement.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-35</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T214"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Nature of the Business and Basis of Presentation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Background and Basis of Presentation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">Oruka Therapeutics, Inc. (&#8220;Oruka&#8221; or the &#8220;Company&#8221;) was established and incorporated under the laws of the state of Delaware on February&#160;6, 2024. Oruka was founded by Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;). The Company currently operates as a virtual company, and thus, does not maintain a corporate headquarters or other significant facilities. Oruka was formed to develop biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The Company is subject to risks and uncertainties common to early<span class="nobreak">-stage</span> companies in the biopharmaceutical industry, including, but not limited to, completing preclinical and clinical trials, obtaining regulatory approval for product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third<span class="nobreak">-party</span> organizations, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to raise additional capital to fund operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The Company&#8217;s potential products will require approval from the U.S.&#160;Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There can be no assurance that the Company&#8217;s potential products will receive all the required approvals. In addition, there can be no assurance that the Company&#8217;s potential products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed, if at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The financial statement and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The accompanying financial statement has been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of February&#160;6, 2024, the Company had no cash.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">The Company will devote substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials and regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval for any of its product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">As a result, the Company will need substantial additional funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">If the Company is unable to obtain additional funding, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned operations, which may have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and ability to operate as a going concern. The financial statement does not include any adjustments that may result if the Company is not able to continue as a going concern.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-36</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">In March&#160;2024, the Company received $3.0&#160;million in proceeds from the sale of Series&#160;A convertible preferred stock and $25.0&#160;million in proceeds from the sale of an unsecured convertible promissory note, both of which were related party transactions (see Note&#160;7<span class="Italic" style="font-style:italic;font-weight:normal;"> Subsequent Events</span>).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221;), and the Company entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) on April&#160;3, 2024, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Atlas Merger Sub Corp, a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Oruka will merge with and into Atlas Merger Sub&#160;II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). In connection with the Merger, Second Merger Sub will change its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; ARCA following the Merger is referred to herein as the &#8220;combined company.&#8221; The combined company will be led by Oruka&#8217;s management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Concurrent with the execution of the Merger Agreement, the Company entered into a subscription agreement with certain investors to which the Company agreed to issue and sell to investors in a private placement financing (the &#8220;Private Placement&#8221;) shares and pre<span class="nobreak">-funded</span> warrants of the Company&#8217;s common stock at an estimated purchase price of $5.80 per share of common stock and $5.79 per warrant for gross proceeds of approximately $275.0&#160;million, which will precede the closing of the Merger Agreement transaction. Shares of the Company&#8217;s common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of the Company&#8217;s common stock issued pursuant to the Private Placement will be converted into the right to receive shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to purchase ARCA common stock, respectively, in accordance with the exchange ratio at the effective time of the close of the transaction. The proceeds from the Private Placement are expected to advance the Company&#8217;s pipeline, business development activities, working capital, and other general corporate purposes.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">However, the agreements are subject to the satisfaction of customary closing conditions, and there are no assurances that such conditions will be achieved nor that such financing or other strategic transactions will be available on acceptable terms, or at all. If the Merger Agreement is terminated under certain circumstances, ARCA could be required to pay Oruka a termination fee of $0.4<span class="nobreak"> </span>million or Oruka could be required to pay ARCA a termination fee of $0.4<span class="nobreak"> </span>million. Based on its expectation of continuing operating losses for the foreseeable future, as of May<span class="nobreak"> </span>13, 2024, the date the Company&#8217;s financial statement is available to be issued, the Company has concluded there is substantial doubt about its ability to continue as a going concern for at least twelve&#160;months from the date the financial statement is available to be issued.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Summary of Significant Accounting Policies</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Subscription receivable</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement is available to be issued.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:9pt;margin-top:9pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">As of February&#160;6, 2024, the Company has the authority to issue a total of 65,000,000<span class="nobreak"> </span>shares of common stock at a par value of $0.0001. As of February&#160;6, 2024, 5,596,658<span class="nobreak"> </span>shares of common stock were issued and outstanding for a nominal consideration, which was received in March&#160;2024, prior to the date the financial statement is available to be issued. Each share of common stock entitles the holder to one vote for each share of common stock held of record by such holder on all matters on which stockholders generally are entitled to vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Company&#8217;s Board of Directors. Upon dissolution, liquidation or winding up of the Company, the holders of shares of common stock, subject to the rights of the holders of any outstanding series of preferred stock, shall be entitled to receive the assets of the Company available for distribution to its stockholders ratably in proportion to the number of shares held.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-37</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Related Party Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company issued 5,596,658<span class="nobreak"> </span>shares of common stock, through a series of contribution agreements, to Paragon, Paruka Holding, LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, and Oruka Advisors LLC (&#8220;Oruka Advisors&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, as part of its common stock subscription agreement with such entities. As of February&#160;6, 2024, Paragon, Paruka and Oruka Advisors each beneficially own approximately 44.7%, 44.7% and 10.6%, respectively, of the Company through their common stock holdings.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Commitments and Contingencies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company may be subject to legal proceedings that arise in the ordinary course of business. As of February&#160;6, 2024, there were no material proceedings to which the Company was a party, nor did the Company have knowledge of any proceedings threatened against it.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Stock-Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On February&#160;6, 2024, the Company&#8217;s Board of Directors approved the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;), under which the Company may grant stock options, restricted stock awards, restricted stock units, or other stock<span class="nobreak">-based</span> awards to its employees, officers, directors, consultants, and advisors. The Company reserved 372,912<span class="nobreak"> </span>shares of its common stock for issuance under the 2024 Plan. As of February&#160;6, 2024, no awards had been issued under the plan.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Subsequent Events</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company evaluated all events subsequent to February&#160;6, 2024, through May<span class="nobreak"> </span>13, 2024, the date on which the financial statement was available to be issued.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Stock-Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In February&#160;2024, the Company&#8217;s Board of Directors authorized and granted 2,073,387 restricted stock awards at a price of $0.0001 per share to employees of the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March 2024, the Company&#8217;s Board of Directors authorized and granted 1,789,974 restricted stock awards at a price of $0.0001 per share to consultants and a director of the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;5, 2024, the Company&#8217;s Board of Directors approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from 372,912 to 872,912.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;22, 2024, the Company granted options for the purchase of an aggregate 698,669<span class="nobreak"> </span>shares of common stock, at an exercise price of $2.90 per share.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May<span class="nobreak"> </span>7, 2024, the Company&#8217;s Board of Directors approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from 872,912 to 2,063,669.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May<span class="nobreak"> </span>7, 2024, the Company granted options for the purchase of an aggregate 1,365,000<span class="nobreak"> </span>shares of common stock, at an exercise price of $3.89 per share.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Antibody Discovery and Option Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, the Company entered into an Antibody Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March&#160;28, 2024, whereby the Company was granted an exclusive, worldwide option, on a research program<span class="nobreak">-by-research</span> program basis, to all of Paragon&#8217;s right, title and interest in and to the intellectual property (&#8220;ORKA<span class="nobreak">-001</span>&#8221;) resulting from the applicable research program to develop, manufacture and commercialize products directed at the selected target (&#8220;IL<span class="nobreak">-23</span>&#8221;), with the exception of pursuing ORKA<span class="nobreak">-001</span> for the treatment of inflammatory bowel disease. Upon signing of the Antibody Discovery and Option Agreement for ORKA<span class="nobreak">-001</span>, a one<span class="nobreak">-time</span>, non<span class="nobreak">-refundable</span> research initiation fee of $0.8&#160;million was due to Paragon. This amount was recognized as a research and development expense during the period ended March&#160;31, 2024, and paid to Paragon in April&#160;2024. The Company is also responsible for 50% of the development costs incurred prior to </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-38</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">March&#160;31, 2024, provided that the Company receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. As of the date this financial statement is available to be issued, the Company has not received rights to a selected IL<span class="nobreak">-23</span> antibody and has not paid or accrued the $5.9&#160;million of development costs incurred prior to March&#160;31, 2024. The Company will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, the Company also entered into an Antibody Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March&#160;28, 2024, whereby the Company was granted an exclusive, worldwide option, on a research program<span class="nobreak">-by-research</span> program basis, to all of Paragon&#8217;s right, title and interest in and to the intellectual property (&#8220;ORKA<span class="nobreak">-002</span>&#8221;) resulting from the applicable research program to develop, manufacture and commercialize products directed at the selected target (&#8220;IL<span class="nobreak">-17</span>&#8221;). The Company was also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon through December&#160;31, 2023 and certain other development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024. This amount was recognized as a research and development expenses during the period from February&#160;6 (inception) to March&#160;31, 2024 and accounts payable as of March&#160;31, 2024. The Company paid $3.3&#160;million to Paragon in April&#160;2024. The Company is also responsible for the development costs incurred by Paragon from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period from February&#160;6 (inception) to March&#160;31, 2024. The Company will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> research plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of the date of issuance of the Company&#8217;s financial statement, the Company has not exercised its options with respect to ORKA<span class="nobreak">-001</span> or ORKA<span class="nobreak">-002</span>. For each of these agreements, if the Company exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million upon the achievement of certain clinical development milestones, up to $10.0&#160;million upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Additionally, as part of the Antibody Discovery and Option Agreements, on each of December&#160;31, 2024 and December&#160;31, 2025, the Company will grant Paruka warrants to purchase a number of shares equal to 1.00% of the then outstanding shares of the Company&#8217;s common stock as of the date of the grant on a fully<span class="nobreak">-diluted</span> basis, with an exercise price equal to the fair market value of the underlying shares on the grant date.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Series&#160;A Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On March&#160;6, 2024, the Company issued 20,000,000<span class="nobreak"> </span>shares of Series&#160;A convertible preferred stock to Fairmount Healthcare Fund&#160;II, L.P. (&#8220;Fairmount&#8221;), a related party of the Company, at a purchase price of $0.15 per share for gross proceeds of $3.0&#160;million. The Company incurred less than $0.1&#160;million of issuance costs in connection with this transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The holders of Series&#160;A convertible preferred stock are entitled to vote, together with the holders of common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding shares of Series&#160;A convertible preferred stock is entitled to the number of votes equal to the number of shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each share of Series&#160;A convertible preferred stock is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. In addition, each share of Series&#160;A convertible preferred stock will be automatically converted into shares of common stock at the applicable conversion ratio then in effect upon either (i)&#160;the closing of a firm<span class="nobreak">-commitment</span> underwritten public offering of the Company&#8217;s common stock at a price of at least $1.00 per share resulting in at least $50.0&#160;million of gross proceeds to the Company, or (ii)&#160;the vote or written consent of the holders of a majority of the Preferred Stock, voting as a single class.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-39</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO FINANCIAL STATEMENT</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The conversion ratio of Series&#160;A convertible preferred stock is determined by dividing the Original Issue Price by the Conversion Price in effect at the time of conversion. The Original Issue Price is $0.15 per share for Series&#160;A convertible preferred stock (in each case subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#8217;s certificate of incorporation, as amended and restated). The Conversion Price is $0.15 per share for Series&#160;A convertible preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">The Company may not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock) unless the holders of the Series&#160;A convertible preferred stock then outstanding first receive, or simultaneously receive, a dividend on each outstanding share of Series&#160;A convertible preferred stock in an amount at least equal to (i)&#160;in the case of a dividend being distributed to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as<span class="nobreak">-converted</span> basis or (ii)&#160;in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Series&#160;A convertible preferred stock calculated based on the respective Original Issue Price of Series&#160;A convertible preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares of Series&#160;A convertible preferred stock then outstanding are entitled to be paid out of the assets or funds of the Company available for distribution to stockholders before any payment is made to the holders of common stock. The holders of Series&#160;A convertible preferred stock are entitled to an amount equal to the greater of (i)&#160;the applicable Original Issue Price per share of Series&#160;A convertible preferred stock, plus any declared but unpaid dividends thereon, or (ii)&#160;the amount per share that would have been payable had all shares of Series&#160;A convertible preferred stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are insufficient to pay the full amount to which they are entitled, then the holders of shares of Series&#160;A convertible preferred stock will share ratably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would otherwise be payable if it were paid in full.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Unless the holders of a majority in voting power of the then outstanding shares of Series&#160;A convertible preferred stock elect otherwise, a Deemed Liquidation Event shall include a merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company&#8217;s assets.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">Series&#160;A convertible preferred stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Convertible Notes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:6pt;margin-top:6pt;">On March&#160;6, 2024, the Company entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Fairmount, whereby the Company issued a convertible note (the &#8220;Convertible Note&#8221;), with an initial principal amount of $25.0<span class="nobreak"> </span>million, that can be converted into Series&#160;A preferred stock (or a Series&#160;of preferred shares that is identical in respect to the shares of preferred shares issued in its next equity financing) or shares of the Company&#8217;s common stock in exchange for proceeds of $25.0&#160;million. The Convertible Note will automatically convert into shares of the Company&#8217;s common stock upon the closing of a corporate transaction, including the reverse recapitalization transaction, and is otherwise due and payable at the request of the holder at any time. The Convertible Note accrues interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled to mature on December&#160;31, 2025. Prepayment is not permitted without prior written consent of Fairmount. Pursuant to the Purchase Agreement, the Company has the right to sell and issue additional convertible notes up to an aggregate principal amount equal to $30.0<span class="nobreak"> </span>million, in addition to the $25.0<span class="nobreak"> </span>million of initial principal amount of the Convertible Note.</p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:10pt;margin-top:10pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Oak Grove Lease</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:7pt;margin-top:7pt;">On April&#160;12, 2024, the Company entered into a lease agreement with Oak Grove LP (&#8220;Oak Grove Lease&#8221;) for office space located in Menlo Park, California. The lease commencement date is June&#160;15, 2024 with an initial term of 39.5&#160;months. The total lease payment is expected to be $1.4&#160;million over the initial lease term.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-40</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T215"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>CONDENSED BALANCE SHEETS <br/>(UNAUDITED)<br/>(In thousands, except share and per share amounts)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">February&#160;6,<br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">ASSETS</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">488</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">28,231</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,262</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Related party accounts payable and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,899</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7,165</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Long term liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued interest payable, related party</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Note payable to related party, noncurrent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24,980</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">32,359</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Commitments and contingencies (Note&#160;10)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-9" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;A convertible preferred stock, $0.0001 par value; 20,000,000 shares authorized as of March&#160;31, 2024 and February&#160;6, 2024; 20,000,000 and no&#160;shares issued and outstanding as of March&#160;31, 2024 and February&#160;6, 2024, respectively; liquidation preference of $3,000 and $0 as of March&#160;31, 2024 and February&#160;6, 2024, respectively</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stockholders&#8217; deficit:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-10" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Common stock, $0.0001 par value; 65,000,000 shares authorized, 9,460,019 and 5,596,658 shares issued and outstanding as of March&#160;31, 2024 and February 6, 2024, respectively</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Additional paid-in capital</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total stockholders&#8217; deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,059</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">28,231</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-41</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T216"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>CONDENSED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS <br/>(UNAUDITED)<br/>(In thousands, except share and per share amounts)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">Period&#160;from <br/>February&#160;6,<br/>2024 <br/>(Inception)&#160;to<br/>March&#160;31, <br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development<span class="Superscript" style="vertical-align:super;font-size:58%;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,193</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative<span class="Superscript" style="vertical-align:super;font-size:58%;">(2)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,670</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total operating expenses</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Loss from operations </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(6,863</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Interest expense<span class="Superscript" style="vertical-align:super;font-size:58%;">(3)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total other expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss and comprehensive loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss per share attributable to common stockholders, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1.26</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average common shares outstanding, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,596,658</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;"><span class="Styles-for-Word-RTF-Imported-Lists_Word-Imported-List-Style1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Includes related party amount of $5,051 (see Note&#160;12)</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;"><span class="Styles-for-Word-RTF-Imported-Lists_Word-Imported-List-Style1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">(2)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Includes related party amount of $848 (see Note&#160;12)</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;"><span class="Styles-for-Word-RTF-Imported-Lists_Word-Imported-List-Style1" style="font-family:Times New Roman, serif;font-style:normal;font-weight:normal;">(3)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Includes related party amount of $214 (see Note&#160;12)</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-42</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>






	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T217"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>CONDENSED&#160;STATEMENT&#160;OF&#160;CONVERTIBLE&#160;PREFERRED&#160;STOCK&#160;AND&#160;STOCKHOLDERS&#8217;&#160;DEFICIT<br/>(UNAUDITED)<br/>(In thousands)</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-right-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-color:#000000;border-right-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="4" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 17.50%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Convertible<br/>Preferred Stock</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-right-color:#000000;border-right-width:1pt;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-left-width:1pt;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-top:3pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-color:#000000;padding-bottom:3pt;padding-top:3pt;width: 18.60%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Common Stock</span></p>
					</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 9.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Additional<br/>Paid-in<br/>Capital</span></p>
					</td>
					<td class="TCH" colspan="2" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 9.58%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Accumulated<br/>Deficit</span></p>
					</td>
					<td class="TCH" colspan="4" rowspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 12.52%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Total<br/>Stockholders&#8217;<br/>Deficit</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-right-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-top:3pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Amount</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-right-width:1pt;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-left-width:1pt;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-top:3pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-width:0pt;border-left-color:#000000;border-right-color:#000000;border-top-color:#000000;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-color:#000000;padding-bottom:3pt;padding-top:3pt;width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Shares</span></p>
					</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-bottom:3pt;padding-left:0pt;padding-right:0pt;padding-top:3pt;width: 8.66%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Amount</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-23" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Balances as of February&#160;6, 2024 (inception)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;border-top-color:#000000;border-top-width:0pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-color:#000000;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB _idGenCellOverride-1" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">5,596,658</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="No-Table-Style TB _idGenCellOverride-1" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">1</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="No-Table-Style TB _idGenCellOverride-2" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="No-Table-Style TB _idGenCellOverride-2" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;"><span class="CharOverride-2" style="font-size:9pt;">$</span></p>
					</td>
					<td class="No-Table-Style TB _idGenCellOverride-2" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">1</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-2" style="font-size:9pt;">Issuance of common stock</span><span class="Superscript" style="vertical-align:super;font-size:6pt;">(1)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">3,863,361</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-24" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-2" style="font-size:9pt;">Issuance of Series&#160;A convertible preferred stock, net of issuance costs of $69</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">20,000,000</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">2,931</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-2" style="font-size:9pt;">Stock-based compensation expense</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;"><span class="CharOverride-2" style="font-size:9pt;">17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#8212;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">17</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-2" style="font-size:9pt;">&#160;</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="CharOverride-2" style="font-size:9pt;">Net loss</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 28.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-right:3pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:9pt;">Balances as of March&#160;31, 2024</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 8.84%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.08%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-right-width:1pt;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-right: windowtext 1pt none; border-right-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-width:1pt;width: 0.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-left: windowtext 1pt none; border-left-style: solid;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.10%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="No-Table-Style TB" style="width: 9.94%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">9,460,019</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.18%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="No-Table-Style TB" style="width: 7.55%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="No-Table-Style TB" style="width: 8.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,059</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Textfootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Textfootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">(1)<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Includes issuance of 3,863,361 restricted stock awards (see Note 7)</p>
		<p class="Text_ind_center" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:3;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-43</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T218"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC. <br/>CONDENSED STATEMENT OF CASH FLOWS<br/>(UNAUDITED)<br/>(In thousands)</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Period&#160;from<br/>February&#160;6,<br/>2024<br/>(Inception) to<br/>March&#160;31, <br/>2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from operating activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">85</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-cash interest expense</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Changes in operating assets and liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Subscription receivable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accounts payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued expenses and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">773</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Related party accounts payable and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,831</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued interest payable, related party</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash used in operating activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(168</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Cash flows from financing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from issuance of Series&#160;A convertible preferred stock, net of issuance costs paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Proceeds from issuance of notes payable to related parties, net of issuance costs paid</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24,980</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:30pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net cash provided by financing activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,911</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Net increase in cash</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash at beginning of period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cash at end of period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">27,743</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Supplemental disclosure of non-cash financing activities:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred offering costs in accrued expenses and other current liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">488</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;">The accompanying notes are an integral part of these condensed financial statements.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-44</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T219"></a><p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</span></p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Nature of the Business and Basis of Presentation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Background and Basis of Presentation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka Therapeutics, Inc. (&#8220;Oruka&#8221; or the &#8220;Company&#8221;) was established and incorporated under the laws of the state of Delaware on February&#160;6, 2024. Oruka was founded by Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;). The Company currently operates as a virtual company, and thus, does not maintain a corporate headquarters or other significant facilities. Oruka was formed to develop biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company is subject to risks and uncertainties common to early stage companies in biopharmaceutical industry, including, but not limited to, completing preclinical and clinical trials, obtaining regulatory approval for product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third<span class="nobreak">-party</span> organizations, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to raise additional capital to fund operations.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s potential products require approval from the U.S.&#160;Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There can be no assurance that the Company&#8217;s potential products will receive all the required approvals. In addition, there can be no assurance that the Company&#8217;s potential products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products will be successfully marketed, if at all.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;) and pursuant to the rules and regulations of the U.S.&#160;Securities and Exchange Commission (&#8220;SEC&#8221;) regarding interim financial information. Accordingly, they do not include all of the information and notes required by U.S.&#160;GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments the Company believes are necessary to fairly state the Company&#8217;s financial position and the results of its operations and cash flows. The results for the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 are not necessarily indicative of results expected for the full fiscal year or any subsequent interim period.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Going Concern</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying condensed financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. As of March&#160;31, 2024, the Company had $27.7&#160;million in cash.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations. Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and regulatory approvals to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval for any of its product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal commercialization capability to support product sales, marketing, and distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As a result, the Company will need substantial additional funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-45</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">If the Company is unable to obtain additional funding, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned operations, which may have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and ability to operate as a going concern.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception. The Company has incurred a net loss of $7.1&#160;million during the period from February&#160;6, 2024 (inception) to March&#160;31, 2024. As of March&#160;31, 2024, the Company had an accumulated deficit of $7.1&#160;million.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company received $3.0&#160;million in gross proceeds from the issuance of Series&#160;A convertible preferred stock (&#8220;Series A Preferred Stock&#8221;) and $25.0&#160;million in gross proceeds from the issuance of a convertible note, both of which were related party transactions (see Note&#160;12).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221;), and the Company entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) on April&#160;3, 2024, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Atlas Merger Sub Corp, a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Oruka will merge with and into Atlas Merger Sub&#160;II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;). In connection with the Merger, Second Merger Sub will change its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221; ARCA following the Merger is referred to herein as the &#8220;combined company.&#8221; The combined company will be led by Oruka&#8217;s management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrent with the execution of the Merger Agreement, the Company entered into a subscription agreement with certain investors pursuant to which the Company agreed to issue and sell to investors in a private placement financing (the &#8220;Private Placement&#8221;) shares of the Company&#8217;s common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of the Company&#8217;s common stock at an estimated purchase price of $5.80 per share of common stock and $5.79 per warrant for gross proceeds of approximately $275.0&#160;million, inclusive of $25.0&#160;million proceeds received as of March&#160;31, 2024 from the issuance of the Company&#8217;s convertible note, which will precede the closing of the Merger. Shares of the Company&#8217;s common stock and warrants to purchase shares of the Company&#8217;s common stock issued pursuant to the Private Placement will be converted into the right to receive shares of ARCA common stock and warrants to purchase shares of ARCA common stock, respectively, in accordance with the exchange ratio at the effective time of the close of the transaction. The proceeds from the Private Placement are expected to advance the Company&#8217;s pipeline, as well as for general corporate purposes, which may include capital expenditure, working capital and general and administrative expenses.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">However, the agreements are subject to the satisfaction of customary closing conditions, and there are no assurances that such conditions will be achieved nor that such financing or other strategic transactions will be available on acceptable terms, or at all. If the Merger Agreement is terminated under certain circumstances, ARCA could be required to pay Oruka a termination fee of $0.4<span class="nobreak"> </span>million or Oruka could be required to pay ARCA a termination fee of $0.4<span class="nobreak"> </span>million. Based on its expectation of continuing operating losses for the foreseeable future, and the need to raise future capital, as of May<span class="nobreak"> </span>13, 2024, the date the Company&#8217;s condensed financial statements are available to be issued, the Company has concluded there is substantial doubt about its ability to continue as a going concern for one year from the date that these condensed financial statements are available to be issued.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying condensed financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Accordingly, the condensed financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-46</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Summary of Significant Accounting Policies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Use of Estimates</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of the Company&#8217;s condensed financial statements in conformity with U.S.&#160;GAAP requires management to make estimates, assumptions, and judgements that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected within these condensed financial statements include but are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock<span class="nobreak">-based</span> compensation awards and related expenses. The Company bases its estimates on known trends and other market<span class="nobreak">-specific</span> or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts, and experience. Actual results may differ materially from those estimates or assumptions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash. The Company maintains its cash balances at an accredited financial institution in amounts that, at times, may exceed federally insured limits. However, the Company has not experienced any losses on its deposits of cash.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company is dependent on third<span class="nobreak">-party</span> organizations to research, develop, manufacture, and process its product candidates for its development programs, including its two most advanced programs, ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. The Company expects to continue to be dependent on a small number of manufacturers to supply it with its requirements for all products. The Company&#8217;s research and development programs could be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#8217;s research and development activities are performed under its agreements with Paragon (see Note&#160;9).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Deferred Offering Costs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company capitalizes certain legal, professional, accounting, and other third<span class="nobreak">-party</span> fees that are directly associated with in<span class="nobreak">-process</span> equity financings as deferred offering costs until such financings are consummated. After the consummation of equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the preferred stock or in stockholders&#8217; deficit as a reduction of additional paid<span class="nobreak">-in</span> capital generated as a result of the offering. Should the in<span class="nobreak">-process</span> equity financing (see Note&#160;1) be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the statement of operations and comprehensive loss. As of March&#160;31, 2024, deferred offering costs of $0.5&#160;million were recorded as Other assets in the condensed balance sheet.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Debt Issuance Costs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Debt issuance costs incurred in connection with the Company&#8217;s convertible note (see Note&#160;4) are recorded as a reduction of the carrying value of the notes payable liability on the Company&#8217;s balance sheet and are amortized to interest expense over the term of the loan using the effective interest method.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Subscription receivable</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement is available to be issued.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value Measurements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Certain assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-47</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level&#160;1 &#8212;&#160;Quoted prices in active markets that are identical assets or liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level&#160;2&#160;&#8212;&#160;Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies, and similar techniques.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying values of the Company&#8217;s prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their relatively short maturity period. The Company accounts for its convertible note at amortized cost.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Classification of Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has classified the convertible preferred stock outside of stockholders&#8217; deficit on the Company&#8217;s condensed balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event that, in certain situations, is not solely within the control of the Company and would require the redemption of the then<span class="nobreak">-outstanding</span> convertible preferred stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s Series&#160;A Preferred Stock is not redeemable, except in the event of deemed liquidation (see Note&#160;5). Because the occurrence of a deemed liquidation event is not currently probable, the carrying values of the convertible preferred stock are not being accreted to their redemption values. Subsequent adjustments to the carrying values of the convertible preferred stock would be made only when a deemed liquidation event becomes probable.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Note&#160;Payable to Related Party</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for its convertible note at amortized cost. The Company considers if optional conversion features are required to be bifurcated and separately accounted for as a derivative. Costs related to the issuance of the convertible note are recorded as a debt discount, amortized over the term of the convertible note (see&#160;Note&#160;4) and are accounted as interest expense in other expenses within the condensed statements of operations and comprehensive loss using the effective interest method.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development Contract Costs Accruals</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company records the costs associated with research studies and manufacturing development as incurred. These costs are a significant component of the Company&#8217;s research and development expenses, with a substantial portion of the Company&#8217;s ongoing research and development activities conducted by third<span class="nobreak">-party</span> service providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;), and the Company&#8217;s related<span class="nobreak">-party</span> Paragon (see Note&#160;9).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accrues for expenses resulting from obligations under its two antibody discovery and option agreements (the &#8220;Option Agreements&#8221;) between Paragon, Paruka Holding LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, and the Company and agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-48</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the services. The Company makes significant judgments and estimates in determining the accrual balance in each reporting period. In the event advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations. As of March&#160;31, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segment Information</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions. The Company&#8217;s chief executive officer, who is the chief operating decision maker (the &#8220;CODM&#8221;), reviews the Company&#8217;s financial information on an aggregated basis for purposes of evaluating financial performance and allocating resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock<span class="nobreak">-based</span> compensation, employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses on the accompanying condensed balance sheet. The prepaid amounts are expensed as the related goods are delivered or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable advance payments represent a one<span class="nobreak">-time</span> cost for obtaining goods or services, with anticipated benefits to be utilized within a year of period end, the payment is expensed immediately.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">General and Administrative Expenses</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">General and administrative expenses consist primarily of salaries and bonuses, stock<span class="nobreak">-based</span> compensation, employee benefits, finance and administration costs, human resources costs, information technology costs, professional service fees, and other general overhead costs to support the Company&#8217;s operations.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Commitments and Contingencies</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible losses. As of March&#160;31, 2024, no liabilities were recorded for loss contingencies (see Note&#160;10).</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company measures all stock<span class="nobreak">-based</span> awards granted to employees, directors, and non<span class="nobreak">-employees</span> in the form of stock options to purchase shares of its common stock, based on the fair value of the awards on the date of grant using the Black<span class="nobreak">-Scholes</span> option<span class="nobreak">-pricing</span> model. The Company measures restricted common stock awards (&#8220;RSAs&#8221;) using the difference, if any, between the purchase price per share of the award and the fair value of the Company&#8217;s common stock at the date of grant.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company grants stock options and restricted stock awards that are subject to either service or performance<span class="nobreak">-based</span> vesting conditions. Compensation expense for awards to employees and directors with service<span class="nobreak">-based</span> vesting conditions is recognized using the straight<span class="nobreak">-line</span> method over the requisite service period, which is generally the </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-49</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">vesting period of the respective award. Compensation expense for awards to non<span class="nobreak">-employees</span> with service<span class="nobreak">-based</span> vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation expense until it is probable that the performance<span class="nobreak">-based</span> vesting condition will be achieved.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has issued stock options and RSAs with service<span class="nobreak">-based</span> vesting conditions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company classifies stock<span class="nobreak">-based</span> compensation expense in its condensed statement of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Net Loss per Share Attributable to Common Stockholders</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company applies the two<span class="nobreak">-class</span> method when computing net loss per share attributable to the Company&#8217;s common stockholders as the Company has issued shares that meet the definition of participating securities. The&#160;two<span class="nobreak">-class</span>&#160;method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The&#160;two<span class="nobreak">-class</span>&#160;method requires loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the undistributed earnings as if all loss for the period had been distributed. The Company considers its convertible preferred stock to be participating securities as, in the event a dividend is paid on common stock, the holders of convertible preferred stock would be entitled to receive dividends on a basis consistent with the Company&#8217;s common stockholders. There is no allocation required under the two<span class="nobreak">-class</span> method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to the Company&#8217;s common stockholders by the weighted average number of common shares outstanding for the period, excluding potentially dilutive common shares. Diluted net loss per share attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss by the weighted average number of common shares outstanding for the period, including potential dilutive common shares. For purposes of this calculation, the Company&#8217;s outstanding convertible preferred stock, stock options to purchase common stock and unvested RSAs are considered potential dilutive common shares.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company generated a net loss for the period presented. Accordingly, basic and diluted net loss per share is the same because the inclusion of the potentially dilutive securities would be anti<span class="nobreak">-dilutive</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company accounts for uncertainty in income taxes recognized in the condensed financial statements by applying a two<span class="nobreak">-step</span> process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-50</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">the amount of benefit to recognize in the condensed financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to uncertain tax positions as of March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In November&#160;2023, the FASB issued ASU No.&#160;2023<span class="nobreak">-07</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Segment Reporting</span> (<span class="Italic" style="font-style:italic;font-weight:normal;">Topic&#160;280</span>) (&#8220;ASU&#160;2023<span class="nobreak">-07</span>&#8221;), which enhances the segment disclosure requirements for public entities on an annual and interim basis. Under this proposal, public entities will be required to disclose significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current annual disclosures about a reportable segment&#8217;s profit or loss and assets will be required on an interim basis. Entities will also be required to disclose information about the CODM&#8217;s title and position at the Company along with an explanation of how the CODM uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources. Finally, ASU&#160;2023<span class="nobreak">-07</span> requires all segment disclosures for public entities that have only a single reportable segment. The amendments in ASU&#160;2023<span class="nobreak">-07</span> are effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years beginning after December&#160;15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its condensed financial statements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2023, the FASB issued ASU&#160;2023<span class="nobreak">-09</span>, <span class="Italic" style="font-style:italic;font-weight:normal;">Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures</span>. This ASU expands disclosures in an entity&#8217;s income tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and foreign jurisdictions. This update is effective beginning with the Company&#8217;s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of this standard on its condensed financial statements.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Accrued Expenses and Other Current Liabilities</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Accrued expenses and other current liabilities consisted of the following (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">March&#160;31,</span><span class="CharOverride-2" style="text-decoration:underline;"><br/></span><span class="CharOverride-1" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued professional and consulting fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,040</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued recruiting fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">88</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued employee compensation and benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">78</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">56</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,262</p>
					</td>
				</tr>

		</table>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Note&#160;Payable with Related Party</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Fairmount Healthcare Fund&#160;II, L.P. (&#8220;Fairmount&#8221;), whereby the Company issued a convertible note (the &#8220;Convertible Note&#8221;), with an initial principal amount of $25.0<span class="nobreak"> </span>million, that can be converted into Series&#160;A Preferred Stock (or a Series&#160;of preferred shares that is identical in respect to the shares of preferred shares issued in its next equity financing) or shares of the Company&#8217;s common stock in exchange for aggregate proceeds of $25.0&#160;million. The Convertible Note will automatically convert into shares of the Company&#8217;s common stock upon the closing of a corporate transaction, including the Private Placement, and is otherwise due and payable at the request of the holder at any time. The Convertible Note accrues interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled to mature on December&#160;31, 2025 (the &#8220;Maturity Date&#8221;). Prepayment is not permitted without prior written consent of Fairmount. Pursuant to the Purchase Agreement, the Company has the right to sell and issue additional convertible notes up to an aggregate principal amount equal to $30.0<span class="nobreak"> </span>million, in addition to the $25.0<span class="nobreak"> </span>million of initial principal amount of the Convertible </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-51</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">Note. The principal payment along with the accrued interest on the Convertible Note is due in full on the Maturity Date. As of March&#160;31, 2024, the Company had outstanding borrowings of $25.0&#160;million from Fairmount under its Convertible Note.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the proposed reverse recapitalization transaction, the Convertible Note will convert into a number of shares of common stock based on the aggregate principal amount, plus any unpaid accrued interest, divided by the conversion price, which is an amount to be determined based upon the Company&#8217;s fully<span class="nobreak">-diluted</span> capitalization immediately prior to the reverse recapitalization transaction. In the event the proposed reverse recapitalization transaction or any other proposed corporate transactions do not close prior to the Company&#8217;s next equity financing, the Convertible Note will convert into the next series of issued convertible preferred stock. </p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting. The Company determined that the conversion options of the Convertible Note were not clearly and closely associated with a debt host. However, these features did not meet the definition of a derivative under ASC&#160;815, <span class="Italic" style="font-style:italic;font-weight:normal;">Derivatives and Hedging</span>, and as a result did not require separate accounting as a derivative liability.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company paid debt issuance costs of less than $0.1&#160;million in relation to the Convertible Note. The debt issuance costs are reflected as a reduction of the carrying value of Convertible Note on the condensed balance sheet and are being amortized as interest expense over the term of the Convertible Note using the effective interest method. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024, the Company recognized interest expense related to the Convertible Note of $0.2&#160;million, which includes non<span class="nobreak">-cash</span> interest expense related to the amortization of debt issuance costs of less than $0.1&#160;million. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024, the weighted average effective interest rate of the Convertible Note was approximately 12.0%.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Convertible Preferred Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company issued and sold an aggregate of 20,000,000<span class="nobreak"> </span>shares of Series&#160;A Preferred Stock to Fairmount, at a purchase price of $0.15 per share, for gross proceeds of $3.0&#160;million. The Company incurred less than $0.1&#160;million of issuance costs in connection with this transaction.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Upon the issuance of the Series&#160;A Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities as described below and determined that such features did not require the Company to separately account for these features.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, convertible preferred stock consisted of the following (in thousands, except share amounts):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 24.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="11" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 73.93%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-12" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 24.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Preferred&#160;Stock<br/>Authorized</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Preferred Stock<br/>Issued and<br/>Outstanding</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Carrying<br/>Value</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Liquidation<br/>Preference</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Common Stock<br/>Issuable Upon<br/>Conversion</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 24.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Series&#160;A Preferred Stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 24.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,931</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,000</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The holders of the Series A Preferred Stock have the following rights and preferences:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Voting</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The holders of Series&#160;A Preferred Stock are entitled to vote, together with the holders of common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding shares of Series&#160;A Preferred Stock is entitled to the number of votes equal to the number of shares of common stock into which the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-52</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">matter. A majority vote of the holders of Series&#160;A Preferred Stock is required to liquidate or dissolve the Company, amend the certificate of incorporation or bylaws, reclassify common stock or establish another class of capital stock, create shares that would rank senior to or authorize additional shares of Preferred Stock, declare a dividend or make a distribution.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, the holders of shares of Series&#160;A Preferred Stock are entitled to elect one director of the Company. The holders of shares of common stock and any other class or series of voting stock (including Series&#160;A convertible preferred stock), exclusively and voting together as a single class, are entitled to elect the balance of the total number of directors of the Company. The Company controls the Board of Directors.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Conversion</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each share of Series&#160;A Preferred Stock is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. In addition, each share of Series&#160;A Preferred Stock will be automatically converted into shares of common stock at the applicable conversion ratio then in effect upon either (i)&#160;the closing of a firm<span class="nobreak">-commitment</span> underwritten public offering of the Company&#8217;s common stock at a price of at least $1.00 per share resulting in at least $50.0&#160;million of gross proceeds to the Company, net of the underwriting discount and commissions, or (ii)&#160;the vote or written consent of the holders of a majority of the outstanding shares of preferred stock, voting as a single class.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The conversion ratio of Series&#160;A Preferred Stock is determined by dividing the original issue price by the conversion price in effect at the time of conversion. The original issue price is $0.15 per share for Series&#160;A Preferred Stock (in each case subject to appropriate adjustment in the event of any stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#8217;s certificate of incorporation, as amended and restated). The Conversion Price is $0.15 per share for Series&#160;A convertible preferred stock. As of March&#160;31, 2024, each outstanding share of Series&#160;A Preferred Stock was convertible into common stock on a one<span class="nobreak">-for-one</span> basis.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Dividends</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company may not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock) unless the holders of the Series&#160;A Preferred Stock then outstanding first receive, or simultaneously receive, a dividend on each outstanding share of Series&#160;A Preferred Stock in an amount at least equal to (i)&#160;in the case of a dividend being distributed to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as<span class="nobreak">-converted</span> basis or (ii)&#160;in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Series&#160;A Preferred Stock calculated based on the respective original issue price of Series&#160;A Preferred Stock. For the period from February&#160;6, 2024 (inception) through March&#160;31, 2024, no cash dividends had been declared or paid by the Company.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares of Series&#160;A Preferred Stock then outstanding are entitled to be paid out of the assets or funds of the Company available for distribution to stockholders before any payment is made to the holders of common stock. The holders of Series&#160;A Preferred Stock are entitled to an amount equal to the greater of (i)&#160;the applicable original issue price per share of Series&#160;A Preferred Stock, plus any declared but unpaid dividends thereon, or (ii)&#160;the amount per share that would have been payable had all shares of Series&#160;A Preferred Stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are insufficient to pay the full amount to which they are entitled, then the holders of shares of Series&#160;A Preferred Stock will share ratably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would otherwise be payable if it were paid in full.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-53</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless the holders of a majority in voting power of the then outstanding shares of Series&#160;A Preferred Stock elect otherwise, a Deemed Liquidation Event shall include a merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the Company&#8217;s assets.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Redemption</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Series&#160;A Preferred Stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Common Stock</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, the Board of Directors authorized up to 65,000,000<span class="nobreak"> </span>shares of common stock at a $0.0001 par value. As of March&#160;31, 2024, 5,596,658<span class="nobreak"> </span>shares of common stock were issued and outstanding and 3,863,361<span class="nobreak"> </span>shares of RSAs were issued and outstanding. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock and RSAs are subject to and qualified by the rights, powers and preferences of the holders of Series&#160;A Preferred Stock set forth above. Each share of common stock entitles the holder to one vote, together with the holders of Series&#160;A Preferred Stock, on all matters submitted to the stockholders for a vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Company&#8217;s Board of Directors, subject to the preferential dividend rights of Series&#160;A Preferred Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, there are 20,698,669<span class="nobreak"> </span>shares of common stock reserved for issuance for the potential conversion of shares of Series&#160;A preferred stock into common stock, the exercise of outstanding stock options for common stock under the Company&#8217;s 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;).</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Stock-Based Compensation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">2024 Equity Incentive Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The 2024 Plan was adopted by the Company&#8217;s Board of Directors on February&#160;6, 2024. The 2024 Plan provides for the Company to grant stock options, restricted stock awards, restricted stock units, and other stock<span class="nobreak">-based</span> awards to employees, officers, directors, consultants, and advisors. The 2024 Plan is administered by the Board of Directors, or at the discretion of the Board of Directors, by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee, if so delegated. Stock options granted under the 2024 Plan generally vest over four&#160;years, subject to the participant&#8217;s continued service, and expire after ten&#160;years, although stock options have been granted with vesting terms less than four&#160;years. Upon adoption, the 2024 Plan authorized 372,912<span class="nobreak"> </span>shares of common stock reserved for issuance under the plan. On March&#160;5, 2024, the 2024 Plan was amended to increase the number of shares of common stock reserved for issuance by 500,000<span class="nobreak"> </span>shares. As of March&#160;31, 2024, the total number of shares of common stock reserved for issuance under the 2024 Plan was 872,912, with 174,243<span class="nobreak"> </span>shares available for future grants.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Option Valuation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The fair value of each stock option grant is estimated on the grant date using the Black<span class="nobreak">-Scholes</span> option<span class="nobreak">-pricing</span> model. The Company is a private company and lacks company<span class="nobreak">-specific</span> historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For stock options with service<span class="nobreak">-based</span> vesting conditions, the expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain<span class="nobreak">-vanilla</span>&#8221; stock options. The risk<span class="nobreak">-free</span> interest rate is determined by reference to the U.S.&#160;Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-54</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the weighted<span class="nobreak">-average</span> assumptions used in calculating the fair value of the awards from February&#160;6, 2024 (inception) to March&#160;31, 2024:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6, 2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected volatility</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">103.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected term (in&#160;years) </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free interest rate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 81.94%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected dividend yield</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.06%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>
					</td>
				</tr>

		</table>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Options</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the stock option activity for the period of February&#160;6, 2024 (inception) through March&#160;31, 2024:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.89%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Aggregate<br/>Intrinsic<br/>Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of February&#160;6, 2024 (inception)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Balance as of March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and expected to vest, March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.90</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10.0</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 43.16%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercisable, March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.90%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.18%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The weighted average grant<span class="nobreak">-date</span> fair value of stock options granted from February&#160;6, 2024 (inception) to March&#160;31, 2024 was $2.37. As of March&#160;31, 2024, there was no aggregate intrinsic value for the outstanding options. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s common stock for those stock options that had an exercise price lower than the fair value of the Company&#8217;s common stock.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Awards</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In February 2024 and March&#160;2024, the Company issued 3,863,361<span class="nobreak"> </span>shares of RSAs to certain employees, directors, and consultants at a price of $0.0001 per share, the par value of the common stock. Such RSAs have service<span class="nobreak">-based</span> vesting conditions only and vest over a four<span class="nobreak">-year</span> period, during which time all unvested shares are subject to forfeiture by the Company in the event the holder&#8217;s service with the Company voluntarily or involuntarily terminates.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the RSAs activity for the period from February&#160;6, 2024 (inception) through March&#160;31, 2024:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>RSAs</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested balance as of February&#160;6, 2024 (inception)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,863,361</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested balance as of March&#160;31, 2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,863,361</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-55</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Paruka Warrant Obligation</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company entered into the Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paruka will be entitled to grants of warrants to purchase a number of shares equal to 1.00% of then outstanding shares of the Company&#8217;s stock, on a fully diluted basis, on December&#160;31, 2024 and December&#160;31, 2025, at the fair market value determined by the Board of Directors of the Company (the &#8220;Paruka Warrant Obligation&#8221;). The grant dates for the issuance of warrants are expected to be December&#160;31, 2024 and December&#160;31, 2025 as all terms of the award, including number of shares and exercise price, will be known by all parties. The service inception period for the grant precedes the grant date, with the full award being vested as of the grant date with no post<span class="nobreak">-grant</span> date service requirement. As of March&#160;31, 2024, the pro<span class="nobreak">-rated</span> estimated fair value of warrants to be granted on December&#160;31, 2024 was $0.7&#160;million. For the period February&#160;6, 2024 (inception) to March&#160;31, 2024, $0.1&#160;million was recognized as stock<span class="nobreak">-based</span> compensation expense related to the Paruka Warrant Obligation. The warrants expected to be granted to Paruka are liability<span class="nobreak">-classified</span> and after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the statement of operations and comprehensive loss.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation Expense</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the classification of the Company&#8217;s stock<span class="nobreak">-based</span> compensation expense in the condensed statement of operations and comprehensive loss (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6,&#160;2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">70</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">85</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, total unrecognized compensation cost related to the unvested stock options was $1.6&#160;million, which is expected to be recognized over a weighted average period of approximately 3.40&#160;years. As of March&#160;31, 2024, total unrecognized compensation cost related to the unvested RSAs was less than $0.1&#160;million, which is expected to be recognized over a weighted average period of 3.92&#160;years. As of March&#160;31, 2024, the unrecognized compensation cost related to the Paruka Warrant Obligation was $0.6&#160;million, which is expected to be recognized over a weighted average period of 0.8&#160;years.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following table summarizes the award types of the Company&#8217;s stock<span class="nobreak">-based</span> compensation expense in the condensed statement of operations and comprehensive loss (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6, 2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paruka warrant obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 16.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">85</p>
					</td>
				</tr>

		</table>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Income Taxes</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No provision for income taxes was recorded for the period of February&#160;6, 2024 (inception) through March&#160;31, 2024. Deferred tax assets generated from the Company&#8217;s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized due to the Company&#8217;s cumulative losses generated to date.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-56</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Paragon Option Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In March&#160;2024, the Company entered into the Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paragon identifies, evaluates and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company. The Option Agreements includes two selected targets, IL<span class="nobreak">-23</span> (ORKA<span class="nobreak">-001</span>) and IL<span class="nobreak">-17</span> A/F (ORKA<span class="nobreak">-002</span>). Under the Option Agreements, the Company has the exclusive options to, on a research program<span class="nobreak">-by-research</span> program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture and commercialize the antibodies and products directed to the selected targets (each, an &#8220;Option&#8221;), with the exception of pursuing ORKA<span class="nobreak">-001</span> for the treatment of inflammatory bowel disease. If the Company exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0&#160;million under each respective agreement upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale. From time to time, the Company can choose to add additional targets to the collaboration by mutual agreement with Paragon.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the terms of the Option Agreements, the parties initiated certain research programs that generally focus on a particular target (each, a &#8220;Research Program&#8221;). Each Research Program is aimed at discovering, generating, identifying and/or characterizing antibodies directed to the respective target. For each Research Program, the parties will establish a research plan that sets forth the activities that will be conducted, and the associated research budget (each, a &#8220;Research Plan&#8221;). The Company and Paragon will agree on initial Research Plans that outline the services that will be performed commencing at the inception of the arrangement related to ORKA<span class="nobreak">-001</span> and ORKA<span class="nobreak">-002</span>. The Company&#8217;s exclusive Option with respect to each Research Program is exercisable at its sole discretion at any time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following (i) with respect to any Research Program other than ORKA<span class="nobreak">-001</span>, the delivery of the data package from Paragon related to the results of the Research Plan activities, or (ii) with respect to ORKA<span class="nobreak">-001</span>, the completion of the IL<span class="nobreak">-23</span> antibody selection process described in the agreement (the &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Option Agreements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Unless terminated earlier, the Option Agreements shall continue in force on a Research Program<span class="nobreak">-by-Research</span> Program basis until the earlier of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by the Company; (ii)&#160;the expiration of the 30<span class="nobreak">-day</span> period after Oruka exercises its Option with respect to such Research Program, subject to mutually agreed extension, during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii) the expiration of the applicable research term (the &#8220;Term&#8221;). Upon the expiration of the Term for all then<span class="nobreak">-existing</span> Research Programs, under the Option Agreements, the Option Agreements will automatically expire in its entirety. The Company may terminate the Option Agreements or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon, provided that the Company must pay certain unpaid fees due to Paragon upon such termination, as well as any non<span class="nobreak">-cancellable</span> obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Each party has the right to terminate the Option Agreements or any Research Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30<span class="nobreak">-day</span> period and (ii)&#160;the other party&#8217;s bankruptcy.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the Option Agreements, on a research program<span class="nobreak">-by-research</span> program basis following the finalization of the research plan for each respective research program, the Company was required to pay Paragon a one<span class="nobreak">-time</span>, nonrefundable research initiation fee of $0.8&#160;million. This amount was recognized as a research and development expense during the period from February&#160;6 (inception) to March&#160;31, 2024 and accounts payable as of March&#160;31, 2024, and paid to Paragon in April&#160;2024. The Company is also responsible for 50% of the development costs incurred prior to March&#160;31, 2024, provided that the Company receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. Oruka&#8217;s share of development costs incurred prior to March&#160;31, 2024 is $5.9&#160;million. As of the date these condensed financial statements are available to be issued, the Company has not received rights to a selected IL<span class="nobreak">-23</span> antibody and has not paid or accrued the $5.9&#160;million of development costs incurred prior to March&#160;31, 2024. The Company will be responsible for 50% of the ORKA<span class="nobreak">-001</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-23</span> selection process.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-57</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company was also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA<span class="nobreak">-002</span> incurred by Paragon through December&#160;31, 2023 and certain other development costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024. This amount was recognized as a research and development expense during the period from February&#160;6 (inception) to March&#160;31, 2024, and accounts payable as of March&#160;31, 2024. The Company paid $3.3&#160;million to Paragon in April&#160;2024. The Company is also responsible for the development costs incurred by Paragon from January&#160;1, 2024 to March&#160;31, 2024 of $0.9&#160;million, which was recognized as a research and development expense in the period from February&#160;6 (inception) to March&#160;31, 2024. The Company will be required to pay Paragon $0.8&#160;million for the research initiation fee related to ORKA<span class="nobreak">-002</span> within 30&#160;days following finalization of the ORKA<span class="nobreak">-002</span> research plan as well as for subsequent development costs related to ORKA<span class="nobreak">-002</span>. The Company will be responsible for ORKA<span class="nobreak">-002</span> development costs incurred from and after March&#160;31, 2024, through the completion of the IL<span class="nobreak">-17</span> selection process.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Furthermore, the Paragon Agreement provides for an annual equity grant of warrants to Paruka to purchase 1.00% of the then outstanding shares of the Company&#8217;s common stock, on a fully diluted basis, on December&#160;31, 2024 and December&#160;31, 2025, during the term of the Paragon Agreement, at the fair market value determined by the Board of Directors of the Company. The warrants are liability<span class="nobreak">-classified</span> and after the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the statement of operations and comprehensive loss (see Note&#160;7).</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified within research and development expenses in the accompanying statement of operations and comprehensive loss.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise in<span class="nobreak">-process</span> research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent a group of similar identifiable assets. The research initiation fee represents a one<span class="nobreak">-time</span> cost on a research program<span class="nobreak">-by</span> research program basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of on<span class="nobreak">-going</span> development cost, monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior to the effective date of the Option Agreement that associated with services being rendered under the related Research Programs is recognized as research and development expense when incurred.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 the Company recognized $5.0&#160;million of expenses in connection with services provided by Paragon under the Option Agreements, including nonrefundable research and development expense fees following the finalization of a Research Plan.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Commitments and Contingencies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">401(k)&#160;Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company maintains a defined<span class="nobreak">-contribution</span> plan under Section&#160;401(k)&#160;of the Internal Revenue Code of 1986 (the &#8220;401(k)&#160;Plan&#8221;). The 401(k)&#160;Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre<span class="nobreak">-tax</span> basis. Matching contributions to the 401(k)&#160;Plan may be made at the discretion of management. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024, the Company has not recorded any expense related to 401(k)&#160;match contributions.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Indemnification Agreements</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-58</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">third parties. In addition, the Company has entered into indemnification agreements with each of its directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or executive officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed financial statements as of March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Legal Proceedings</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">From time to time, the Company may become involved in legal proceedings or other litigation relating to claims arising in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and estimated exposure amount. Legal fees and other costs associated with such proceedings are expensed as incurred. As of March&#160;31, 2024, the Company was not a party to any material legal proceedings or claims.</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Net Loss per Share</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6, 2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Numerator:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(7,077</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Denominator:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average common shares outstanding, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,596,658</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net loss attributable to common stockholders, basic and diluted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;">(1.26</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2-brack-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;text-align:left;">)</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the computation of basic net loss per share attributable to common stockholders, the amount of weighted<span class="nobreak">-average</span> common shares outstanding excludes all shares of unvested restricted common stock as such shares are not considered outstanding for accounting purposes until vested.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company&#8217;s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted<span class="nobreak">-average</span> number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded potential common shares from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have had an anti<span class="nobreak">-dilutive</span> effect:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Period from<br/>February&#160;6, 2024<br/>(Inception) to<br/>March&#160;31, 2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Convertible preferred stock (as converted to common stock)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">20,000,000</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock awards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3,863,361</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock options to purchase common stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">698,669</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 80.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 17.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24,562,030</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-59</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">12.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Related Party Transactions</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Paragon and Paruka each currently beneficially own more than 5% of the Company&#8217;s capital stock through its common stock holdings. For the period from February&#160;6, 2024 (inception) to March&#160;31, 2024 the Company recognized $5.0&#160;million of expenses, in connection with services provided by Paragon and Paruka under the Option Agreements, including nonrefundable research and development expense fees following the finalization of a Research Plan on its condensed statement of operations and comprehensive loss. As of March&#160;31, 2024, the Company had $5.8&#160;million in amounts due to related parties pertaining to services provided by Paragon and Paruka under the Option Agreements and reimbursements of recruiting and start<span class="nobreak">-up</span> fees on its condensed balance sheet. In addition, under the terms of the Option Agreements, Paruka will be entitled to grants of warrants to purchase a number of shares equal to 1.00% of outstanding shares of the Company&#8217;s common stock, on a fully diluted basis, as of the date of the grants (see Note&#160;7). If the Company exercises its options, it will be required to make non<span class="nobreak">-refundable</span> milestone payments to Paragon of up to $12.0&#160;million under each respective agreement upon the achievement of certain clinical development milestones, up to $10.0&#160;million under each respective agreement upon the achievement of certain regulatory milestones, as well as tiered royalty payments in the low<span class="nobreak">-to-mid</span> single<span class="nobreak">-digits</span> beginning on the first commercial sale.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fairmount Funds Management LLC (&#8220;Fairmount Funds Management&#8221;) beneficially owns more than 5% of the Company&#8217;s capital, currently has one representative appointed to the Company&#8217;s Board of Directors, and beneficially owns more than 5% of Paragon. In March&#160;2024, the Company issued and sold an aggregate of 20,000,000<span class="nobreak"> </span>shares of Series&#160;A Preferred Stock to Fairmount, an affiliated fund of Fairmount Funds Management, at a purchase price of $0.15 per share, for gross proceeds of $3.0&#160;million (see Note&#160;4). In March&#160;2024, Fairmount entered into the Purchase Agreement with the Company and holds a convertible note with an initial principal amount of $25.0&#160;million (see Note&#160;4). As of March&#160;31, 2024, the Company had $0.2&#160;million in amounts due to related parties pertaining to accrued interest related to the Company&#8217;s outstanding borrowings of $25.0&#160;million under the Purchase Agreement with Fairmount.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The following is a summary of related party accounts payable and other current liabilities (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paragon reimbursable Option Agreement fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4,983</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paragon reimbursable recruiting and start-up fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">848</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Paruka Warrant Obligation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5,899</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">The following is a summary of noncurrent liability, related party (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued interest payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">214</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Note payable</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">24,980</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25,194</p>
					</td>
				</tr>

		</table>
		<p class="Note_H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:justify;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">13.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Subsequent Events</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Company has evaluated events and transactions occurring subsequent to March<span class="nobreak"> </span>31, 2024 through May<span class="nobreak"> </span>13, 2024, the date at which the condensed financial statements were available to be issued. In connection with the reissuance of the condensed financial statements, the Company has evaluated subsequent events through July<span class="nobreak"> </span>22, 2024, the date these condensed financial statements were available to be reissued.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Oak Grove Lease</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;12, 2024, the Company entered into a lease agreement with Oak Grove LP (&#8220;Oak Grove Lease&#8221;) for office space located in Menlo Park, California. The lease commencement date is June&#160;15, 2024 with an initial term of 39.5&#160;months. The total lease payment is expected to be $1.4&#160;million over the initial lease term.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-60</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Note_H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-bottom:10pt;margin-top:12pt;">ORUKA THERAPEUTICS, INC.<br/>NOTES TO CONDENSED FINANCIAL STATEMENTS<br/>(UNAUDITED)</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Amended 2024 Stock Plan</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On May<span class="nobreak"> </span>7, 2024, the Company&#8217;s Board of Directors approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from 872,912 to 2,063,669. On May&#160;7, 2024, the Company granted options for the purchase of an aggregate 1,365,000 stock options, at an exercise price of $3.89 per share.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">Other events</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process of its development candidate for IL<span class="nobreak">-23</span> antibody for ORKA<span class="nobreak">-001</span> program. The Company is responsible for 50% of the development costs incurred through the completion of the IL<span class="nobreak">-23</span> selection process, provided that the Company receives rights to at least one selected IL<span class="nobreak">-23</span> antibody. Oruka&#8217;s share of development costs incurred prior to March<span class="nobreak"> </span>31, 2024 is $5.9<span class="nobreak"> </span>million, which was recorded as a research and development expense during the quarter ended June<span class="nobreak"> </span>30, 2024 and accounts payable as of June<span class="nobreak"> </span>30, 2024. Amounts related to development cost incurred subsequent to March<span class="nobreak"> </span>31, 2024, have not been determined as of the reissuance date of these condensed financial statements.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On July<span class="nobreak"> </span>3, 2024, the Private Placement agreement was amended and restated (the &#8220;A&amp;R Private Placement agreement&#8221;) to provide for, among other things, warrants to be issued to certain of Oruka&#8217;s employees, directors and service providers. On July<span class="nobreak"> </span>15, 2024, the Company&#8217;s Board of Directors approved the issuance of 5,145,336 warrants at an exercise price of $4.44 per share to certain employees, directors and service providers pursuant to the A&amp;R Private Placement agreement, with such issuances to occur immediately prior to the closing of the Merger.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The price per share for the shares of the Company&#8217;s common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of the Company&#8217;s common stock in the original Private Placement agreement decreased from $5.80 and $5.79 per share, respectively, to $5.55 and $5.54 per share, respectively, for the shares of common stock and the pre<span class="nobreak">-funded</span> warrants pursuant to the A&amp;R Private Placement Agreement due to the May<span class="nobreak"> </span>7, 2024 option grants described above.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">F-61</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T100"></a><p class="ParaOverride-1" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:right;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Annex A</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:210pt;orphans:3;text-align:center;widows:3;margin-top:210pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">among:</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA BIOPHARMA, Inc.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">;</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ATLAS MERGER SUB CORP.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">;</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Atlas Merger Sub II, LLC</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; and</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ORUKA THERAPEUTICS, Inc.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Dated as of April 3, 2024</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">&#160;</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>


	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;">Table of Contents</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Annex&#160;A<br/>Page Nos.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;1. Definitions and Interpretative Provisions</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-2</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Definitions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-2</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">1.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other Definitional and Interpretative Provisions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-14</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;2. Description of Transaction</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-15</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">The Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effects of the Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Closing; First Effective Time; Second Effective Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Organizational Documents; Directors and Officers</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Conversion of Company, First Merger Sub and Second Merger Sub Equity Securities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-16</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Closing of the Company&#8217;s Transfer Books</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-17</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Surrender of Company Capital Stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-18</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Calculation of Net Cash and Company Valuation.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-19</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Further Action</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intended Tax Treatment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Withholding</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-20</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2.12</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Appraisal Rights</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-21</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;3. Representations and Warranties of the Company</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-21</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Due Organization; Subsidiaries</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-21</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Organizational Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Authority; Binding Nature of Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vote Required</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-Contravention; Consents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalization.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-23</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Financial Statements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-24</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Absence of Changes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-24</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Absence of Undisclosed Liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-24</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Title to Assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Real Property; Leasehold</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.12</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intellectual Property</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-25</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.13</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Agreements, Contracts and Commitments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-27</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Compliance; Permits; Restrictions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-29</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.15</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Legal Proceedings; Orders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-30</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.16</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tax Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-31</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Employee and Labor Matters; Benefit Plans.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-32</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Environmental Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Insurance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Financial Advisors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Transactions with Affiliates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.22</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Privacy and Data Security</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-34</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Ownership of Parent Capital Stock</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-35</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">3.24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Other Representations or Warranties</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-35</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;4. Representations and Warranties of Parent, First Merger and Second Merger Sub</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-35</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Due Organization; Subsidiaries</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-35</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Organizational Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-36</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Authority; Binding Nature of Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-36</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vote Required</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-36</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-i</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Annex&#160;A<br/>Page Nos.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-Contravention; Consents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-37</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-37</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">SEC Filings; Financial Statements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-38</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Absence of Changes</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Absence of Undisclosed Liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Title to Assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Real Property; Leasehold</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.12</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Intellectual Property</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-40</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.13</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Agreements, Contracts and Commitments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-42</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Compliance; Permits; Restrictions</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-44</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.15</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Legal Proceedings; Orders</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-46</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.16</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tax Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-46</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Employee and Labor Matters; Benefit Plans</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-47</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Environmental Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Insurance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Transactions with Affiliates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Financial Advisors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.22</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valid Issuance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.23</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Privacy and Data Security</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-49</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">4.24</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Other Representations or Warranties</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-50</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;5. Certain Covenants of the Parties</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-50</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operation of Parent&#8217;s Business</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-50</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operation of the Company&#8217;s Business.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-52</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Access and Investigation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-53</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Solicitation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-54</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">5.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Notification of Certain Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-55</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;6. Additional Agreements of the Parties</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-55</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Registration Statement, Proxy Statement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-55</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Company Stockholder Written Consent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-57</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Stockholder Meeting</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-58</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Efforts; Regulatory Approvals.</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-60</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Company Options; Company Warrants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-60</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Employee Benefits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-61</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Indemnification of Officers and Directors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-62</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Disclosure</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-63</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Listing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-63</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Tax Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-64</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Legends</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-64</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.12</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Officers and Directors</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-64</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.13</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Termination of Certain Agreements and Rights</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.14</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Section&#160;16 Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.15</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Allocation Information</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.16</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent SEC Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.17</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Wind-Down Activities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.18</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Obligations of Merger Subs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.19</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Pre-Closing Financing Restructuring</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-65</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.20</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Pre-Closing Dividend</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">6.21</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Re-Domestication</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-ii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;">Annex&#160;A<br/>Page Nos.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;7. Conditions Precedent to Obligations of Each Party</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-66</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effectiveness of Registration Statement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Regulatory Approvals</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Restraints</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stockholder Approval</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Listing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lock-Up Agreements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Charter Amendment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">7.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Certificate of Designation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;8. Additional Conditions Precedent to Obligations of Parent and Merger Subs</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-66</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accuracy of Representations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-66</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Performance of Covenants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Company Material Adverse Effect</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Company Stockholder Written Consent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Company Pre-Closing Financing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">8.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Parent Pre-Closing Dividend</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;9. Additional Conditions Precedent to Obligation of the Company</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-67</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accuracy of Representations</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-67</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Performance of Covenants</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">9.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Parent Material Adverse Effect</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;10. Termination</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-68</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Termination</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-68</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Effect of Termination</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-70</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">10.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expenses; Termination Fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-70</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 88.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Section&#160;11. Miscellaneous Provisions</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;"><span class="Bold" style="font-style:normal;font-weight:bold;">A-71</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Non-Survival of Representations and Warranties</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-71</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Amendment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-71</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Waiver</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-71</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-71</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Applicable Law; Jurisdiction</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-72</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Assignability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-72</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Notices</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-72</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.8</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Cooperation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-73</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.9</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Severability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-73</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.10</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other Remedies; Specific Performance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-73</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:40pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">11.11</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 75.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">No Third-Party Beneficiaries</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.26%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:center;">A-73</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Exhibits:</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;A-1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Parent Stockholder Support Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;A-2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Company Stockholder Support Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;B</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Lock-Up Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;C</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Subscription Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;D-1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">First Certificate of Merger, including certificate of incorporation of the First Step Surviving Corporation attached as Exhibit&#160;A thereto, incorporated by reference into this Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;D-2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Second Certificate of Merger, incorporated by reference into this Agreement</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 11.54%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="TOC_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exhibit&#160;E</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 87.18%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Form of Certificate of Designation</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-iii</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">AGREEMENT AND PLAN OF MERGER AND REORGANIZATION</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">This Agreement and Plan of Merger and Reorganization </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(this &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is made and entered into as of April 3, 2024, by and among </span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">ARCA biopharma, Inc.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, a Delaware corporation (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), </span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Atlas Merger Sub Corp.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, a Delaware corporation and wholly owned subsidiary of Parent (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First Merger Sub</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), </span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Atlas Merger Sub II, LLC</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, a Delaware limited liability company and wholly owned subsidiary of Parent (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Second Merger Sub</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and, together with First Merger Sub, &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Merger Subs</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and </span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Oruka Therapeutics, Inc.</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, a Delaware corporation (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Certain capitalized terms used in this Agreement are defined </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Recitals</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">A.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent and the Company intend to effect a merger of First Merger Sub with and into the Company (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) in accordance with this Agreement and the DGCL.  Upon consummation of the First Merger, First Merger Sub will cease to exist and the Company will become a wholly owned subsidiary of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">B.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Immediately following the First Merger and as part of the same overall transaction as the First Merger, the Company will merge with and into Second Merger Sub (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Second Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and, together with the First Merger, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), with Second Merger Sub being the surviving entity of the Second Merger.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">C.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parties intend that, (i) the First Merger and the Second Merger, taken together, will constitute an integrated transaction described in Rev. Rul. 2001-46, 2001-2 C.B. 321 that qualifies as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Code, and (ii) this Agreement will constitute, and is hereby adopted as, a plan of reorganization within the meaning of Treasury Regulations Sections&#160;1.368-2(g) and 1.368-3(a).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">D.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Transaction Committee of the Parent Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders and (ii) recommended that the Parent Board approve and adopt this Agreement.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">E.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parent Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to the terms of this Agreement and the constructive issuance by the Company of shares of Company Common Stock to stockholders of Parent (as reflected in Rule&#160;145(a) of the Securities Act) (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Constructive Issuance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve this Agreement and thereby approve the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to the terms of this Agreement, the Constructive Issuance, and, if deemed necessary by the Parties, an amendment to Parent&#8217;s certificate of incorporation to effect the Nasdaq Reverse Split.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">F.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The First Merger Sub Board has (i) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of First Merger Sub and its sole stockholder, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of First Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">G.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The sole member of the Second Merger Sub has (i) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Second Merger Sub and its sole member, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the sole member of Second Merger Sub votes to adopt this Agreement and thereby approve the Contemplated Transactions.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">H.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to adopt this Agreement and thereby approve the Contemplated Transactions.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">I.<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Concurrently with the execution and delivery of this Agreement and as a condition and inducement to the Company&#8217;s willingness to enter into this Agreement, each of the officers, directors and stockholders set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;A</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter (solely in their capacity as stockholders of Parent) are executing support agreements in favor of the Company in substantially the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;A-1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Stockholder Support Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which such Persons have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of capital stock of Parent in favor of the approval of this Agreement and thereby approve the Contemplated Transactions, and, if deemed necessary by Parent, an amendment to Parent&#8217;s certificate of incorporation to effect the Nasdaq Reverse Split, and against any competing proposals.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">J.<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span><span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent&#8217;s willingness to enter into this Agreement, each of the officers, directors and stockholders of the Company listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;A</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter (solely in their capacity as stockholders of the Company) are executing support agreements in favor of Parent in substantially the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;A-2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Stockholder Support Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which such Persons have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of Company Capital Stock in favor of the adoption of this Agreement and thereby approve the Contemplated Transactions and against any competing proposals.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">K.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Concurrently with the execution and delivery of this Agreement and as a condition and inducement to Parent&#8217;s and the Company&#8217;s willingness to enter into this Agreement, all of the stockholders of the Company or Parent listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;B</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter are executing lock-up agreements in substantially the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;B</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Lock-Up Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">,&#8221; and collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Lock-Up Agreements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">L.&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>It is expected that within two (2) Business Days after the Registration Statement is declared effective under the Securities Act, the holders of shares of Company Capital Stock sufficient to adopt and approve this Agreement and the Merger as required under the DGCL and the Company&#8217;s certificate of incorporation and bylaws will execute and deliver an action by written consent adopting this Agreement, in form and substance reasonably acceptable to Parent, in order to obtain the Required Company Stockholder Vote.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">M.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Concurrently with the execution and delivery of this Agreement, certain investors have executed a Subscription Agreement in the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;C</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> among the Company and the Persons named therein (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Subscription Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which such Persons will have agreed to purchase in the amounts set forth therein (including by contribution of Company Notes) (i) shares of Company Common Stock and (ii) pre-funded Company Warrants, in each case, immediately prior to the First Effective Time (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Pre-Closing Financing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-11" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Agreement</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Parties, intending to be legally bound, agree as follows:</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;1. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Definitions and Interpretative Provisions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Definitions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>For purposes of this Agreement (including this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">):</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Acceptable Confidentiality Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a confidentiality agreement containing terms not materially less restrictive in the aggregate to the counterparty thereto than the terms of the Confidentiality Agreement, except such confidentiality agreement need not contain any standstill, non-solicitation or no hire provisions. Notwithstanding the foregoing, a Person who has previously entered into a confidentiality agreement with Parent relating to a potential Acquisition Proposal on terms that are not materially less restrictive than the Confidentiality Agreement with respect to the scope of coverage and restrictions on disclosure and use shall not be required to enter into a new or revised confidentiality agreement, and such existing confidentiality agreement shall be deemed to be an Acceptable Confidentiality Agreement.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Acquisition Inquiry</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to a Party, an inquiry, indication of interest or request for non-public information (other than an inquiry, indication of interest or request for information made or submitted by the Company, on the one hand, or Parent, on the other hand, to the other Party) that would reasonably be expected to lead to an Acquisition Proposal.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Acquisition</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Proposal</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to a Party, any offer or proposal, whether written or oral (other than an offer or proposal made or submitted by or on behalf of the Company or any of its Affiliates, on the one hand, or by or on behalf of Parent or any of its Affiliates, on the other hand, to the other Party) contemplating or otherwise relating to any Acquisition Transaction with such Party.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Acquisition</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Transaction</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any transaction or series of related transactions (other than any Parent Legacy Transaction, the issuance of Company Notes, or the Company Pre-Closing Financing) involving:</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any merger, consolidation, amalgamation, share exchange, business combination, issuance of securities, acquisition of securities, reorganization, recapitalization, tender offer, exchange offer or other similar transaction: (i) in which a Person or &#8220;group&#8221; (as defined in the Exchange Act and the rules promulgated thereunder) of Persons directly or indirectly acquires beneficial or record ownership of securities representing more than 20% of the outstanding securities of any class of voting securities of a Party or any of its Subsidiaries or (ii) in which a Party or any of its Subsidiaries issues securities representing more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries, or issues securities convertible into more than 20% of the outstanding securities of any class of voting securities of such Party or any of its Subsidiaries; or</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any sale, lease, exchange, transfer, license, acquisition or disposition of any business or businesses or assets that constitute or account for 20% or more of the consolidated book value or the fair market value of the assets of a Party and its Subsidiaries, taken as a whole.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Affiliate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall have the meaning given to such term in Rule&#160;145 under the Securities Act.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Affordable Care Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Patient Protection and Affordable Care Act.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Anticipated Closing Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the anticipated Closing Date, as agreed upon by Parent and the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Business</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Day</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any day other than a day on which banks in the State of New York are authorized or obligated to be closed.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Certificate of Designation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Certificate of Designation of Preferences, Rights and Limitations of Parent Convertible Preferred Stock in the form attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;E</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">COBRA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Consolidated Omnibus Budget Reconciliation Act of 1985, as set forth in Section&#160;4980B of the Code and Section&#160;6 of Title I of ERISA.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Code</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Internal Revenue Code of 1986, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Associate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any current employee, independent contractor, officer or director of the Company or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Board</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the board of directors of the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Capital Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Company Common Stock and the Company Preferred Stock.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Capitalization Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the representations and warranties of the Company set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;3.6(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.6(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Common Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the common stock, $0.0001 par value per share, of the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Contract: (a) to which the Company or any of its Subsidiaries is a Party, (b) by which the Company or any of its Subsidiaries is or may become bound or under which the Company or any of its Subsidiaries has, or may become subject to, any obligation or (c) under which the Company or any of its Subsidiaries has or may acquire any right or interest.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Employee Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Employee Plan that the Company or any of its Subsidiaries (i) sponsors, maintains, administers, or contributes to, or (ii) provides benefits under or through, or (iii) has any obligation to contribute to or provide benefits under or through, or (iv) may reasonably be expected to have any Liability, or (v) utilizes to provide benefits to or otherwise cover any current or former employee, officer, director or other service provider of the Company or any of its Subsidiaries (or their spouses, dependents, or beneficiaries).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Fundamental Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the representations and warranties of the Company set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;3.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.5(a)(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.20</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company IP Rights</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means all Intellectual Property rights that are owned or purported to be owned by, assigned to, exclusively licensed to, or controlled by the Company or its Subsidiaries that are necessary for, or used or held for use in, the operation of the business of the Company and its Subsidiaries as presently conducted.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company IP Rights Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Contract governing, related to or pertaining to any Company IP Rights other than any confidential information provided under confidentiality agreements.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Key Employee</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any executive officer of the Company or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Material Adverse Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of a Company Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the business, financial condition, assets, liabilities or results of operations of the Company or its Subsidiaries, taken as a whole; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Effects arising or resulting from the following shall not be taken into account in determining whether there has been a Company Material Adverse Effect: (a) the announcement of this Agreement or the pendency of the Contemplated Transactions, (b) the taking of any action, or the failure to take any action, by the Company that is required to comply with the terms of this Agreement, (c) any natural disaster, calamity or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the world or any governmental or other response or reaction to any of the foregoing, (d) any change in GAAP or applicable Law or the interpretation thereof, (e) general economic or political conditions or conditions generally affecting the industries in which the Company and its Subsidiaries operate or (f) any change in the cash position of the Company and its Subsidiaries which results from operations in the Ordinary Course of Business; except in each case with respect to clauses&#160;(c), (d) and (e), to the extent disproportionately affecting the Company and its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which the Company and its Subsidiaries operate.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Merger Shares</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the product determined by </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">multiplying</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (i) the Post-Closing Parent Shares </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">by</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (ii) the Company Allocation Percentage, in which:</span></p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Aggregate Valuation</span>&#8221; means the sum of (i) the Company Valuation, <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">plus</span> (ii) the Parent Valuation.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Company Allocation Percentage</span>&#8221; means the percentage (rounded to four decimal places) determined by <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">subtracting</span> (i)&#160;the Parent Allocation Percentage <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">from</span> (ii)&#160;100 percent.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Company Equity Value</span>&#8221; means $175,000,000.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-left:72pt;margin-top:8pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Company Outstanding Shares</span>&#8221; means, without duplication, the total number of shares of Company Capital Stock outstanding immediately prior to the First Effective Time (including any shares of Company Common Stock or Company Preferred Stock that are issued in, or issuable upon the exercise or conversion of securities issued in, the Company Pre-Closing Financing), expressed on a fully diluted and as-converted-to-Company Common Stock basis assuming, without limitation or duplication the exercise of all Company Options, Company Warrants or other rights or commitments to receive shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock, including the Company Notes), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time. For the avoidance of doubt, Company Outstanding Shares shall (a) exclude, to avoid the double-counting of, any shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock, including any Company Notes) to the extent such shares or securities are contributed as consideration in the Company Pre-Closing Financing and (b) include (i) to the extent not already issued prior to the First Effective Time, any shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock) issuable to the Paragon Entities (as such term is defined in the Company&#8217;s Organizational Documents) as a result of the Contemplated Transactions pursuant to the </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-position:inside;list-style-type:none;margin-left:72pt;text-indent:0pt;margin-top:8pt;">Company&#8217;s Organizational Documents and (ii) to the extent not already issued prior to the First Effective Time, any shares of Company Common Stock or Company Preferred Stock (or securities convertible or exercisable into shares of Company Common Stock or Company Preferred Stock) issuable pursuant to the offer letter set forth in Section&#160;3.6(d) of the Company Disclosure Letter.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Company Valuation</span>&#8221; means the (i) Company Equity Value plus (ii) the amount of proceeds actually received by the Company from the Company Pre-Closing Financing (including in the proceeds actually received from any Company Notes, and any interest thereon, contributed as consideration in the Company Pre-Closing Financing).</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Exchange Ratio</span>&#8221; means the ratio (rounded to four decimal places) equal to the quotient obtained by dividing (i) the Company Merger Shares by (ii) the Company Outstanding Shares.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Parent Allocation Percentage</span>&#8221; means the quotient (expressed as a percentage and rounded to four decimal places) determined by <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">dividing</span> (i) the Parent Valuation <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">by</span> (ii)&#160;the Aggregate Valuation.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Parent Outstanding Shares</span>&#8221; means, without duplication, (including, without limitation, the effects of the Nasdaq Reverse Split, if completed) the total number of shares of Parent Common Stock outstanding immediately prior to the First Effective Time expressed on a fully-diluted basis, and assuming, without limitation or duplication, the issuance of shares of Parent Common Stock in respect of all Parent Options, warrants or other rights or commitments to receive shares of Parent Common Stock or Parent Preferred Stock (or securities convertible or exercisable into shares of Parent Common Stock or Parent Preferred Stock, but excluding any Parent Convertible Preferred Stock issuable in accordance herewith), whether conditional or unconditional, that are outstanding as of immediately prior to the First Effective Time. Notwithstanding any of the foregoing, no Parent Options, if any, shall be included in the total number of shares of Parent Common Stock outstanding for purposes of determining the Parent Outstanding Shares to the extent cancelled at or prior to Closing under <span class="CharOverride-9" style="text-decoration:underline;">Section&#160;6.6(c)</span>.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Parent Valuation</span>&#8221; means (i) $11,000,000, <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">minus</span> (ii) the amount by which Parent Net Cash is less than $5,000,000 (if any).</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;"><span class="_idGenBNMarker-1" style="display:inline-block;text-indent:0;width:24pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>&#8220;<span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Post-Closing Parent Shares</span>&#8221; mean the quotient determined by <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">dividing</span> (i) the Parent Outstanding Shares <span class="CharOverride-8" style="font-style:italic;font-weight:normal;text-decoration:underline;">by</span> (ii) the Parent Allocation Percentage.</p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Notes</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the convertible notes issued pursuant to that certain Series A Preferred Stock and Convertible Note Purchase Agreement among the Company and the purchasers party thereto, dated as of March 6, 2024, or any additional convertible promissory notes that may be issued from time to time prior to the Closing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Options</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means options or other rights to purchase shares of Company Capital Stock issued by the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Preferred Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the shares of the Company&#8217;s capital stock designated as preferred stock, including the Company Series A Preferred Stock.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Registered IP</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means all Company IP Rights that are owned or exclusively licensed by the Company that are registered, filed or issued under the authority of, with or by any Governmental Authority, including all patents, registered copyrights and registered trademarks and all applications and registrations for any of the foregoing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Series A Preferred Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a series of the Company&#8217;s preferred stock designated as Series A Preferred Stock, $0.0001 par value per share.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Stock Plans</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Company&#8217;s Amended and Restated 2024 Equity Incentive Plan.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Triggering Event</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall be deemed to have occurred if, at any time prior to the adoption of this Agreement and the approval of the Contemplated Transactions by the Required Company Stockholder Vote: (a) the Company Board shall have made a Company Board Adverse Recommendation Change; (b) the Company Board or </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">any committee thereof shall have publicly proposed, endorsed or recommended any Acquisition Proposal; or (c) the Company shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Warrants</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means warrants to purchase shares of Company Capital Stock issued by the Company.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Confidentiality</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the letter agreement dated as of February 9, 2024, between the Company and Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Consent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any approval, consent, ratification, permission, waiver or authorization (including any Governmental Authorization).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Contemplated</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Transactions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Merger, the Constructive Issuance and the other transactions contemplated by this Agreement (other than the Parent Legacy Transaction and Parent Charter Amendment), the Company Pre-Closing Financing and the Nasdaq Reverse Split (to the extent applicable and deemed necessary by Parent and the Company).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any Person, any written agreement, contract, subcontract, lease (whether for real or personal property), mortgage, license, or other legally binding commitment or undertaking of any nature to which such Person is a party or by which such Person or any of its assets are bound or affected under applicable Law.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">DGCL</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the General Corporation Law of the State of Delaware.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">DLLCA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Delaware Limited Liability Company Act.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any effect, change, event, circumstance, or development.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Employee Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (A) an &#8220;employee benefit plan&#8221; within the meaning of Section&#160;3(3) of ERISA whether or not subject to ERISA; (B) other plan, program, policy or arrangement providing for stock options, stock purchases, equity-based compensation, bonuses (including any annual bonuses and retention bonuses) or other incentives, severance pay, deferred compensation, employment, compensation, change in control or transaction bonuses, supplemental, vacation, retirement benefits (including post-retirement health and welfare benefits), pension benefits, profit-sharing benefits, fringe benefits, life insurance benefits, perquisites, health benefits, medical benefits, dental benefits, vision benefits, and all other employee benefit plans, agreements, and arrangements, not described in (A) above; and (C) all other plans, programs, policies or arrangements providing compensation to employees, consultants and non-employee directors.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Encumbrance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any lien, pledge, hypothecation, charge, mortgage, security interest, lease, exclusive license, option, easement, reservation, servitude, adverse title, claim, infringement, interference, option, right of first refusal, preemptive right, community property interest or restriction or encumbrance of any nature (including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Enforceability Exceptions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the (a) Laws of general application relating to bankruptcy, insolvency and the relief of debtors and (b) rules of law governing specific performance, injunctive relief and other equitable remedies.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Entity</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any corporation (including any nonprofit corporation), partnership (including any general partnership, limited partnership or limited liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), firm, society or other enterprise, association, organization or entity, and each of its successors.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Environmental</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Law</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any federal, state, local or foreign Law relating to pollution or protection of human health or the environment (including ambient air, surface water, ground water, land surface or subsurface strata), including any law or regulation relating to emissions, discharges, releases or threatened releases of Hazardous Materials, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ERISA Affiliate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any Entity, any other Person that would be treated as a single employer with such Entity or part of the same &#8220;controlled group&#8221; as such Entity under Sections&#160;414(b),(c),(m) or (o) of the Code.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ERISA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Employee Retirement Income Security Act of 1974, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Exchange</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Exchange Act of 1934, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Merger Sub Board</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the board of directors of First Merger Sub.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Governmental Authority</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature, (b) federal, state, local, municipal, foreign, supra-national or other government, (c) governmental or quasi-governmental authority of any nature (including any governmental division, department, agency, commission, bureau, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any taxing authority) or (d) self-regulatory organization (including Nasdaq).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Governmental Authorization</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any: (a)&#160;permit, license, certificate, franchise, permission, variance, exception, order, approval, clearance, registration, qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental Authority or pursuant to any Law or (b)&#160;right under any Contract with any Governmental Authority.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Hazardous Materials</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any pollutant, chemical, substance and any toxic, infectious, carcinogenic, reactive, corrosive, ignitable or flammable chemical, or chemical compound, or hazardous substance, material or waste, whether solid, liquid or gas, that is subject to regulation, control or remediation under any Environmental Law, including without limitation, crude oil or any fraction thereof, and petroleum products or by-products.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">HSR Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the U.S. Hart Scott-Rodino Antitrust Improvements Act of 1976, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">In the Money Parent Option</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall mean Parent Options with an exercise price equal to or less than the Parent Closing Price.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Intellectual Property</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means: (a) United States, foreign and international patents, patent applications, including all provisionals, nonprovisionals, substitutions, divisionals, continuations, continuations-in-part, reissues, extensions, supplementary protection certificates, reexaminations, term extensions, certificates of invention and the equivalents of any of the foregoing, statutory invention registrations, invention disclosures and inventions (collectively, &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Patents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), (b) trademarks, service marks, trade names, domain names, corporate names, brand names, URLs, trade dress, logos and other source identifiers, including registrations and applications for registration thereof and goodwill associated therewith, (c) copyrights, including registrations and applications for registration thereof, (d) software, including all source code, object code and related documentation, (e) formulae, customer lists, trade secrets, know-how, confidential information and other proprietary rights and intellectual property, whether patentable or not, and (f) all United States and foreign rights arising under or associated with any of the foregoing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">IRS</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the United States Internal Revenue Service.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Knowledge</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, (i) with respect to an individual, that such individual is actually aware of the relevant fact or such individual would reasonably be expected to know such fact in the ordinary course of the performance of such individual&#8217;s employment responsibilities, (ii) with respect Parent, the Knowledge of the individuals listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Schedule&#160;A</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter as of the date of such knowledge is imputed and (iii) with respect to any Person that is an Entity (other than Parent) the Knowledge of any executive officer of such Person as of the date such knowledge is imputed. With respect to any matters relating to Intellectual Property, such awareness or reasonable expectation to have knowledge does not require any such individual to conduct or have conducted or obtain or have obtained any freedom to operate opinions of counsel or any Intellectual Property rights clearance searches.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Law</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any federal, state, national, supra-national, foreign, local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Authority (including under the authority of Nasdaq or the Financial Industry Regulatory Authority).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Legal Proceeding</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before any court or other Governmental Authority or any arbitrator or arbitration panel.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Multiemployer</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a &#8220;multiemployer plan,&#8221; as defined in Section&#160;3(37) or 4001(a)(3) of ERISA.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Multiple Employer Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a &#8220;multiple employer plan&#8221; within the meaning of Section&#160;413(c) of the Code or Section&#160;3(40) of ERISA.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Multiple Employer Welfare Arrangement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a &#8220;multiple employer welfare arrangement&#8221; within the meaning of Section&#160;3(40) of ERISA.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Nasdaq Reverse Split</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a reverse stock split of all outstanding shares of Parent Common Stock effected by Parent for the purpose of maintaining compliance with Nasdaq listing standards.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Nasdaq</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means The Nasdaq Stock Market.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Order</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any judgment, order, writ, injunction, ruling, decision or decree of (that is binding on a Party), or any plea agreement, corporate integrity agreement, resolution agreement or deferred prosecution agreement with, or any settlement under the jurisdiction of, any court or Governmental Authority.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Ordinary</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Course of Business</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, in the case of each of the Company and Parent, such actions taken in the ordinary course of its business and consistent with its past practice or, with respect to the Company, the customary practices of a recently formed company at a similar stage of development; provided, however, that during the Pre-Closing Period, the Ordinary Course of Business of Parent shall also include actions required to effect and effecting any Parent Legacy Transaction.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Organizational Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any Person (other than an individual), (a) the certificate or articles of association or incorporation or organization or limited partnership or limited liability company, and any joint venture, limited liability company, operating or partnership agreement and other similar documents adopted or filed in connection with the creation, formation or organization of such Person and (b) all bylaws, regulations and similar documents or agreements relating to the organization or governance of such Person, in each case, as amended or supplemented.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Out of the Money Parent Options</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall mean Parent Options with an exercise price greater than the Parent Closing Price.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Associate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any current employee, independent contractor, officer or director of Parent or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Balance Sheet</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the audited balance sheet of Parent as of December 31, 2023, included in Parent&#8217;s Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Board</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the board of directors of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Capital Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Parent Common Stock and the Parent Preferred Stock.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Capitalization Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the representations and warranties of Parent and Merger Subs set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;4.6(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.6(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Closing Price</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the volume weighted average closing trading price of a share of Parent Common Stock on Nasdaq for the five (5) consecutive trading days ending three (3) trading days immediately prior to the Closing Date as reported by Bloomberg L.P.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Common Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the common stock, $0.001 par value per share, of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Contract: (a) to which Parent is a party, (b) by which Parent or any Parent IP Rights or any other asset of Parent is or may become bound or under which Parent has, or may become subject to, any obligation or (c) under which Parent has or may acquire any right or interest.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Convertible Preferred Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Parent&#8217;s non-voting convertible preferred stock, par value $0.001 per share, with the rights, preferences, powers and privileges specified in the Certificate of Designation.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Employee Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Employee Plan that Parent or any of its Subsidiaries (i) sponsors, maintains, administers, or contributes to, or (ii) provides benefits under or through, or (iii) has any obligation to contribute to or provide benefits under or through, or (iv) may reasonably be expected to have any Liability, or (v)&#160;utilizes to provide benefits to or otherwise cover any current or former employee, officer, director or other service provider of Parent or any of its Subsidiaries (or their spouses, dependents, or beneficiaries).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Fundamental Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the representations and warranties of Parent and Merger Subs set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;4.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.5(a)(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.21</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent IP Rights Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Contract governing, related or pertaining to any Parent IP Rights.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent IP Rights</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means all Intellectual Property owned, licensed or controlled by Parent that is necessary for, or used or held for use in, the operation of the business of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Key Employee</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (i) an executive officer of Parent; and (ii) any employee of Parent that reports directly to the Parent Board or to an executive officer of Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Legacy Business</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the business of Parent as conducted at any time prior to the date of this Agreement, including but not limited to business related to the assets listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Material Adverse Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Effect that, considered together with all other Effects that have occurred prior to the date of determination of the occurrence of the Parent Material Adverse Effect, has or would reasonably be expected to have a material adverse effect on the business, financial condition, assets, liabilities or results of operations of Parent and its Subsidiaries, taken as a whole; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Effects arising or resulting from the following shall not be taken into account in determining whether there has been a Parent Material Adverse Effect: (a) the announcement of this Agreement or the pendency of the Contemplated Transactions, (b) any change in the stock price or trading volume of Parent Common Stock (it being understood, however, that any Effect causing or contributing to any change in stock price or trading volume of Parent Common Stock may be taken into account in determining whether a Parent Material Adverse Effect has occurred, unless such Effects are otherwise excepted from this definition), (c) the taking of any action, or the failure to take any action, by Parent that is required to comply with the terms of this Agreement, (d) any natural disaster, calamity or epidemics, pandemics or other force majeure events, or any act or threat of terrorism or war, any armed hostilities or terrorist activities (including any escalation or general worsening of any of the foregoing) anywhere in the world, or any governmental or other response or reaction to any of the foregoing, (e) any change in GAAP or applicable Law or the interpretation thereof or (f) general economic or political conditions or conditions generally affecting the industries in which Parent or any of its Subsidiaries operates; except, in each case with respect to clauses&#160;(d), (e) and (f), to the extent materially and disproportionately affecting Parent or any of its Subsidiaries, taken as a whole, relative to other similarly situated companies in the industries in which Parent or any of its Subsidiaries operates. Notwithstanding the above, a delisting of Parent Common Stock on Nasdaq shall constitute a Parent Material Adverse Effect, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that the Company has not refused or unreasonably delayed its consent to reasonable actions by Parent to maintain the listing of Parent Common Stock on Nasdaq.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Net Cash</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means without duplication, (i) Parent&#8217;s unrestricted cash and cash equivalents and marketable securities determined, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents and the Parent Balance Sheet, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">plus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (ii) all prepaid expenses set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">plus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (iii) all receivables which the parties may mutually agree (each in their sole discretion) are recoverable by or provide benefit to Parent after the First Effective Time (if any), </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (iv) the sum of Parent&#8217;s consolidated short-term and long-term contractual obligations and liabilities accrued at the Closing Date, in each case determined in accordance with GAAP and, to the extent in accordance with GAAP, in a manner consistent with the manner in which such items were historically determined and in accordance with the financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents and the Parent Balance Sheet, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (v) the aggregate amount (without duplication) </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">of all fees and expenses incurred by Parent prior to the First Effective Time in connection with the Contemplated Transactions or the Parent Legacy Transaction, including: (a) any fees and expenses of legal counsel, accountants, financial advisors, investment bankers, brokers, consultants, tax advisors, and other professional advisors of Parent in connection with the Contemplated Transactions or the Parent Legacy Transaction; (b) 50% of the fees paid to the SEC in connection with filing the Registration Statement and any amendments and supplements thereto, with the SEC; (c)&#160;50% of the fees and expenses in connection with the printing, mailing and distribution of the Proxy Statement and any amendments and supplements thereto; (d) 50% of the Nasdaq Fees; (e)&#160;any bonus, retention payments, severance, change-in-control payments or similar payment obligations (including payments with &#8220;single-trigger&#8221; provisions triggered at and as of the consummation of the transactions contemplated hereby) that become due or payable to any director, officer, employee or consultant in connection with the consummation of the Contemplated Transactions or any Parent Legacy Transaction, together with any payroll Taxes associated therewith; (f) the dividend of any excess Parent Net Cash (but only to the extent declared and unpaid) and all costs and expenses associated therewith; and (g)&#160;the costs associated with obtaining the &#8220;D&amp;O tail policy&#8221; pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7,</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> in each case, to the extent unpaid as of the First Effective Time, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;"> </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi) all remaining rent payments and any other Liabilities under Parent&#8217;s lease obligations, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (vii) any unpaid Taxes of Parent and its Subsidiaries for Tax periods (or portions thereof) ending on or before the Closing Date, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (viii) all costs and expenses to be mutually agreed by Parent and the Company relating to the winding down of Parent Legacy Business, including the sale, license or other disposition of any or all of the Parent Legacy Business to the extent unpaid as of the Closing, including any costs incurred costs incurred by Parent following the Closing pursuant to Section&#160;6.17 and </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">minus</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (ix) the amounts due and payable to holders of Parent Options pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> to the extent unpaid as of the First Effective Time; </span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">that if any portion of the fees and expenses described in subclauses&#160;(b), (c), and (d) of clause&#160;(v) have been paid by Parent prior to the First Effective Time in an amount greater than Parent&#8217;s share of such fee and expense described in subclauses&#160;(b), (c), and (d), then (x) such portion in excess of Parent&#8217;s shares of such fee and expense described in subclauses&#160;(b), (c), and (d) shall not be deducted by reason of subclauses&#160;(b), (c), and (d) of clause&#160;(v) and (y) such portion shall be added to the calculation of Parent Net Cash.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Options</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means options or other rights to purchase shares of Parent Common Stock granted by Parent, including pursuant to any Parent Stock Plan.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Preferred Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the shares of Parent&#8217;s capital stock designated as preferred stock, par value $0.001 per share of Parent, including the Parent Convertible Preferred Stock.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Registered IP</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means all Parent IP Rights that are owned or exclusively licensed by Parent that are registered, filed or issued under the authority of, with or by any Governmental Authority, including all patents, registered copyrights and registered trademarks and all applications for any of the foregoing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Restricted Stock Units</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any equity award with respect to Parent Common Stock that represents the right to receive in the future shares of Parent Common Stock pursuant to any Parent Stock Plan.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Triggering Event</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall be deemed to have occurred if, prior to the approval of this Agreement and the Contemplated Transactions by Parent&#8217;s stockholders and subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">: (a) Parent shall have failed to include in the Proxy Statement the Parent Board Recommendation, (b) the Parent Board or any committee thereof shall have made a Parent Board Adverse Recommendation Change or subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, publicly proposed, endorsed or recommended any Acquisition Proposal or (c) Parent shall have entered into any letter of intent or similar document or any Contract relating to any Acquisition Proposal (other than an Acceptable Confidentiality Agreement permitted pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Party</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Company, Merger Subs and Parent.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Permitted Alternative Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a definitive agreement that contemplates or otherwise relates to an Acquisition Transaction that constitutes a Superior Offer.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Permitted Encumbrance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (a) any statutory liens for current Taxes not yet due and payable or for Taxes that are being contested in good faith by the appropriate proceedings and for which adequate reserves have been made on the Company Budget or the Parent Balance Sheet, as applicable, in accordance with GAAP, (b)&#160;minor non-monetary liens that have arisen in the Ordinary Course of Business and that do not (in any case or in the aggregate) materially detract from the value of the assets subject thereto or materially impair the operations of the Company or Parent, as applicable, (c)&#160;statutory liens to secure obligations to landlords, lessors or renters under </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">leases or rental agreements, (d) deposits or pledges made in connection with, or to secure payment of, workers&#8217; compensation, unemployment insurance or similar programs mandated by Law, (e) statutory liens in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor, materials or supplies for amounts that are not yet due and payable and (f) liens arising under applicable securities Law.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Person</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any individual, Entity or Governmental Authority.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Personal Information</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any data or information that constitutes &#8220;personal information,&#8221; &#8220;personal data,&#8221; &#8220;personally identifiable information,&#8221; &#8220;protected health information,&#8221; or any analogous term under applicable Law, including any such information that identifies, relates to, describes, is linked to, is reasonably capable of being associated with, or could reasonably be linked, directly or indirectly, with any identified or identifiable individual or household.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Privacy Laws</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; mean, collectively, (i) all Laws governing privacy, data protection, data security, trans-border data flow, data loss, data theft, breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of Personal Information, including any such legally binding requirements set forth in regulations and agreements containing consent orders published by regulatory authorities of competent jurisdiction such as the U.S. Federal Trade Commission, U.S. Federal Communications Commission, and state data protection authorities, including HIPAA, Section&#160;5 of the Federal Trade Commission Act, the Telephone Consumer Protection Act and U.S. state consumer protection and data breach notification Laws, and (ii) any legally binding requirements of any self-regulatory organizations governing data privacy, data protection, data security, trans-border data flow, data loss, data theft, breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of Personal Information.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Representatives</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means with respect to a Person, such Person&#8217;s directors, officers, employees, agents, attorneys, accountants, investment bankers, advisors and other representatives.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Sarbanes-Oxley Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Sarbanes-Oxley Act of 2002.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">SEC</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the United States Securities and Exchange Commission.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Securities Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Act of 1933, as amended.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Subsequent Transaction</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Acquisition Transaction (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Subsidiary</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to an Entity, a Person if such Person directly or indirectly owns or purports to own, beneficially or of record, (a) an amount of voting securities or other interests in such Entity that is sufficient to enable such Person to elect at least a majority of the members of such entity&#8217;s board of directors or other governing body or (b) at least 50% of the outstanding equity, voting, beneficial or financial interests in such Entity.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Superior</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Offer</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an unsolicited bona fide written Acquisition Proposal (with all references to 20% in the definition of Acquisition Transaction being treated as references to 50% for these purposes) that: (a) was not obtained or made as a direct or indirect result of a breach of this Agreement, (b) is on terms and conditions that the Parent Board or the Company Board, as applicable, determines in good faith, based on such matters that it deems relevant (including the likelihood of consummation thereof and the financing terms thereof), as well as any written offer by the other Party to this Agreement to amend the terms of this Agreement, and following consultation with its outside legal counsel and financial advisors, if any, are more favorable, from a financial point of view, to Parent&#8217;s stockholders or the Company&#8217;s stockholders, as applicable, than the terms of the Contemplated Transactions, (c) is not subject to any financing conditions (and if financing is required, such financing is then fully committed to the third party) and (d) is reasonably capable of being completed on the terms proposed.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Tax Return</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any return (including any information return), report, statement, declaration, claim or refund, estimate, schedule, notice, notification, form, election, certificate or other document or information, and any amendment or supplement to any of the foregoing, filed or required to be filed with any Governmental Authority (or provided to a payee) in connection with the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with any Law relating to any Tax.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Tax</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any U.S. federal, state, local, foreign or other tax, including any income tax, franchise tax, capital gains tax, gross receipts tax, value-added tax, surtax, estimated tax, employment tax, unemployment tax, national health insurance tax, environmental tax, excise tax, ad valorem tax, transfer tax, conveyance tax, stamp tax, sales tax, use tax, property tax, business tax, withholding tax, payroll tax, social security tax, customs duty, licenses tax, alternative or add-on minimum or other tax or similar charge, duty, levy, fee, tariff, impost, obligation or assessment in the nature of a tax (whether imposed directly or through withholding and whether or not disputed), and including any fine, penalty, addition to tax, interest or additional amount imposed by a Governmental Authority with respect thereto (or attributable to the nonpayment thereof).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Treasury Regulations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the United States Treasury regulations promulgated under the Code.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b) Each of the following terms is defined in the Section&#160;set forth opposite such term:</span></p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Terms</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Section</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">AAA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(i)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Accounting Firm</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(i)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Allocation Certificate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.15</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Assumed Option</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.5(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Assumed Warrant</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.5(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Capitalization Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.6(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Cash Determination Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Certificate of Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Certifications</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Closing Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Closing</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company 409A Plan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.17(j)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Audited Financial Statements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(e)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Board Adverse Recommendation Change</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Board Recommendation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Budget</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Disclosure Letter</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Section&#160;3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Interim Financial Statements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(e)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Intervening Event</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Material Contract</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.13(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Material Contracts</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.13(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Permits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Product Candidates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Real Estate Leases</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.11</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Regulatory Permits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Required S-4 Information</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Stockholder Support Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Stockholder Written Consents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Termination Fee</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.3(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Calculation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Delivery Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Determination Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Dispute Notice</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Response Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company Valuation Schedule</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Company</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Concurrent Investment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.7(a)</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-12</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Terms</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Section</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">D&amp;O Indemnified Parties</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dispute Notice</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Dissenting Shares</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.12(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Drug/Device Regulatory Agency</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Employment-Related Laws</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.17(k)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">End Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.1(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Exchange Agent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">FDA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">FDCA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Certificate of Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Effective Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">First Step Surviving Corporation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Form S-4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">GAAP</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Intended Tax Treatment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.10</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.9</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lock-Up Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lock-Up Agreements</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Merger Consideration</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.5(a)(ii)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Merger Subs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Nasdaq Fees</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.9</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Nasdaq Listing Application</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.9</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Notice Period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Ordinary Course Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.16(g)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent 409A Plan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.17(j)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Board Adverse Recommendation Change</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Board Recommendation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Charter Amendment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.4(b)(ii)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Disclosure Letter</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Section&#160;4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Intervening Event</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Legacy Transaction</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Material Contract</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.13(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Material Contracts</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.13(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Net Cash Calculation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Net Cash Schedule</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Notice Period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Permits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.14(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Pre-Closing Dividend</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1(c)(ii)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Pre-Closing Dividend Amount</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1(c)(ii)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Product Candidates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.14(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Real Estate Leases</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.11</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Regulatory Permits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.14(d)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent SEC Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.7(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Stock Plans</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.6(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Stockholder Matters</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Stockholder Meeting</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.3(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent Stockholder Support Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Parent</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Preamble</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-13</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-14" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Terms</p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">Section</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">PHSA</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.14(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Post-Closing Welfare Plan</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.6(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Pre-Closing Period</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Privacy Policies</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.22</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Proxy Statement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Registration Statement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.1(a)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Required Company Stockholder Vote</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Required Parent Stockholder Vote</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.4</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Response Date</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.8(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">SEC Documents</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.16</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Second Certificate of Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Second Effective Time</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.3</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Second Merger</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Stockholder Notice</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.2(b)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Subscription Agreement</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Recital</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Surviving Entity</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.1</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Tax Certificates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.10(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Transaction Litigation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">6.4(c)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">WARN Act</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.17(k)</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Other Definitional and Interpretative Provisions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections, Exhibits and Schedules&#160;are to Sections, Exhibits and Schedules&#160;of this Agreement unless otherwise specified. Any capitalized terms used in any Exhibit&#160;or Schedule&#160;but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract (except for references to any agreements or Contracts listed on the Parent Disclosure Letter or Company Disclosure Letter) are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. The Exhibits to this Agreement, the Parent Disclosure Letter and the Company Disclosure Letter are integral parts of the interpretation of this Agreement, but only Exhibit&#160;D-1 (including Exhibit&#160;A to such Exhibit) and Exhibit&#160;D-2 is incorporated by reference and made a part hereof for purposes of Section&#160;251 of the DGCL. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof, substituted, from time to time. References to &#8220;$&#8221; and &#8220;dollars&#8221; are to the currency of the United&#160;States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement. The Parties agree that the Company Disclosure Letter or Parent Disclosure Letter shall be arranged in sections and subsections corresponding to the numbered and lettered sections and subsections contained in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, respectively. The disclosures in any section or subsection of the Company Disclosure Letter or the Parent Disclosure Letter shall qualify other sections and subsections in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, respectively, to the extent it is readily apparent from a reading of the disclosure that such disclosure is </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-14</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">applicable to such other sections and subsections. The words &#8220;delivered&#8221; or &#8220;made available&#8221; mean, with respect to any documentation, that prior to 5:00 p.m. (New York City time) on the date that is the day prior to the date of this Agreement, a copy of such material has been (a)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">&#160;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">posted to and continuously made available by a Party to the other Party and its Representatives in the electronic data room maintained by such disclosing Party for the purposes of the Contemplated Transactions or (b) delivered by or on behalf of a Party or its Representatives to the other Party or its Representatives via electronic mail or in hard copy form prior to the execution of this Agreement.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;2. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Description of Transaction</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">The Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Upon the terms and subject to the conditions set forth in this Agreement, at the First Effective Time, First Merger Sub shall be merged with and into the Company, and the separate existence of First Merger Sub shall cease. The Company will continue as the surviving corporation in the First Merger (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First Step Surviving Corporation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).  Upon the terms and subject to the conditions set forth in this Agreement, at the Second Effective Time, the First Step Surviving Corporation will merge with and into Second Merger Sub, and the separate existence of the First Step Surviving Corporation shall cease.  As a result of the Second Merger, Second Merger Sub will continue as the surviving entity in the Second Merger (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Surviving Entity</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Effects of the Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The First Merger shall have the effects set forth in this Agreement and in the applicable provisions of the DGCL. As a result of the First Merger, the Company will become a wholly owned subsidiary of Parent. The Second Merger shall have the effects set forth in this Agreement and in the applicable provisions of the DGCL and the DLLCA.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Closing; First Effective Time; Second Effective Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Unless this Agreement is earlier terminated pursuant to the provisions of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, and subject to the satisfaction or waiver of the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the consummation of the Merger (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Closing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall take place remotely, as promptly as practicable (but in no event later than the second Business Day following the satisfaction or waiver of the last to be satisfied or waived of the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, other than those conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction or waiver of each of such conditions), or at such other time, date and place as Parent and the Company may mutually agree in writing. The date on which the Closing actually takes place is referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Closing Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.&#8221; Immediately prior to the Closing on the Closing Date, Parent shall file the Certificate of Designation with the office of the Secretary of State of the State of Delaware. At the Closing, (i) the Parties shall cause the First Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the Merger, satisfying the applicable requirements of the DGCL and in form and substance attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;D-1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and incorporated herein by reference (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First Certificate of Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) the Parties shall cause the Second Merger to be consummated by executing and filing with the Secretary of State of the State of Delaware a certificate of merger with respect to the Second Merger, satisfying the applicable requirements of the DGCL and the DLLCA and in form and substance attached hereto as </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;D-2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and incorporated herein by reference (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Second Certificate of Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and together with the First Certificate of Merger, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Certificate of Merger</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The First Merger shall become effective at the time of the filing of such Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in such Certificate of Merger with the consent of Parent and the Company (the time as of which the Merger becomes effective being referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">First</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Effective Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The Second Merger shall become effective at the time of the filing of such Second Certificate of Merger with the Secretary of State of the State of Delaware or at such later time as may be specified in such Second Certificate of Merger with the consent of Parent and the Company (the time as of which the Second Merger becomes effective being referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Second Effective Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Organizational Documents; Directors and Officers</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the First Effective Time:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The certificate of incorporation of the First Step Surviving Corporation shall be amended and restated in the Merger to read as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Exhibit&#160;A</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> to the Certificate of Merger, until thereafter amended as provided by the DGCL and such certificate of incorporation;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The bylaws of the First Step Surviving Corporation shall be identical to the bylaws of the Company as in effect immediately prior to the First Effective Time, until thereafter amended as provided by the DGCL and such bylaws; and</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-15</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>the directors and officers of the First Step Surviving Corporation, each to hold office in accordance with the certificate of incorporation and bylaws of the First Step Surviving Corporation, shall be such persons as shall be mutually agreed upon by Parent and the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the Second Effective Time:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The certificate of formation of the Surviving Entity shall be the certificate of formation of Second Merger Sub as in effect immediately prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such certificate of formation; provided, however, that at the Second Effective Time (as part of the Second Certificate of Merger), the certificate of formation shall be amended to (A) change the name of the Surviving Entity to &#8220;Oruka Therapeutics Operating Company, LLC,&#8221; and (B) make such other changes as are mutually agreed to by Parent and the Company;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The limited liability company agreement of the Surviving Entity shall be amended and restated in its entirety to read identically to the limited liability company agreement of Second Merger Sub as in effect immediately prior to the Second Effective Time, until thereafter amended as provided by the DLLCA and such limited liability company agreement; provided, however, that following the Second Effective Time (but as soon thereafter as practicable), the limited liability company agreement shall be amended to change the name of the Surviving Entity to &#8220;Oruka Therapeutics Operating Company, LLC&#8221;;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The certificate of incorporation of Parent shall be identical to the certificate of incorporation of Parent immediately prior to the Second Effective Time, until thereafter amended as provided by the DGCL and such certificate of incorporation; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that at the Second Effective Time, Parent shall file an amendment to its certificate of incorporation to (i) change the name of Parent to &#8220;Oruka Therapeutics, Inc.&#8221;, (ii) effect the Nasdaq Reverse Split (to the extent applicable and necessary), (iii) increase the number of shares of Parent Common Stock that Parent is authorized to issue to a number mutually agreed between Parent and the Company, and (iv) make such other changes as are mutually agreeable to Parent and the Company (such amendment, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Charter Amendment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;);</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The directors and officers of Parent, each to hold office in accordance with the certificate of incorporation and bylaws of Parent, shall be as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; and</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The directors and officers of Surviving Entity, each to hold office in accordance with the certificate of formation and limited liability company agreement of Second Merger Sub, shall be as set forth in&#160;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#160;after giving effect to the provisions of&#160;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, or such other persons as shall be mutually agreed upon by Parent and the Company.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conversion of Company, First Merger Sub and Second Merger Sub Equity Securities</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the First Effective Time, by virtue of the Merger and without any further action on the part of Parent, Merger Subs, the Company or any stockholder of the Company or Parent:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any shares of Company Capital Stock held as treasury stock immediately prior to the First Effective Time shall be canceled and retired and shall cease to exist, and no consideration shall be delivered in exchange therefor; and</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (A) each share of Company Common Stock (including any shares of Company Common Stock issued pursuant to the Company Pre-Closing Financing) outstanding immediately prior to the First Effective Time (excluding shares of Company Capital Stock to be canceled pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and excluding Dissenting Shares) shall be converted solely into the right to receive a number of shares of Parent Common Stock equal to the Exchange Ratio, and (B) each share of Company Preferred Stock outstanding immediately prior to the First Effective Time (excluding shares of Company Capital Stock to be canceled pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and excluding Dissenting Shares) shall be converted solely into the right to receive a number of shares of Parent Convertible Preferred Stock equal to (x) the Exchange Ratio </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;text-decoration:underline;">divided by</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (y) 1,000 (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Merger Consideration</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-16</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If any shares of Company Capital Stock outstanding immediately prior to the First Effective Time are unvested or are subject to a repurchase option or a risk of forfeiture under any applicable restricted stock purchase agreement or other similar agreement with the Company, then the shares of Parent Capital Stock issued in exchange for such shares of Company Capital Stock will to the same extent be unvested and subject to the same repurchase option or risk of forfeiture, and such shares of Parent Capital Stock shall accordingly be marked with appropriate legends. The Company shall take all actions that may be necessary to ensure that, from and after the First Effective Time, Parent is entitled to exercise any such repurchase option or other right set forth in any such restricted stock purchase agreement or other agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No fractional shares of Parent Capital Stock shall be issued in connection with the Merger, and no certificates or scrip for any such fractional shares shall be issued. Any holder of Company Common Stock who would otherwise be entitled to receive a fraction of a share of Parent Common Stock (after aggregating all fractional shares of Parent Common Stock issuable to such holder) shall receive from Parent, in lieu of such fractional share and upon surrender by such holder of a letter of transmittal in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and any accompanying documents as required therein: (i) one share of Parent Common Stock if the aggregate amount of fractional shares of Parent Common Stock such holder of Company Common Stock would otherwise be entitled to is equal to or exceeds 0.50; or (ii) no shares of Parent Common Stock if the aggregate amount of fractional shares of Parent Common Stock such holder of Company Common Stock would otherwise be entitled to is less than 0.50, with no cash being paid for any fractional share eliminated by such rounding. Any fractional shares of Parent Preferred Stock that a holder of Company Preferred Stock would otherwise be entitled to receive shall be aggregated with all fractional shares of Parent Preferred Stock issuable to such and any remaining fractional shares shall be, in lieu of such fractional share and upon surrender by such holder of a letter of transmittal in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and any accompanying documents as required therein, rounded up to the nearest whole share of Parent Preferred Stock.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All Company Options outstanding immediately prior to the First Effective Time shall be treated in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All Company Warrants outstanding immediately prior to the First Effective Time shall be treated in accordance with&#160;</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.5(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each share of common stock, $0.001 par value per share, of First Merger Sub issued and outstanding immediately prior to the First Effective Time shall be converted into and exchanged for one validly issued, fully paid and nonassessable share of common stock, $0.001 par value per share, of the First Step Surviving Corporation. Each book entry share of First Merger Sub evidencing ownership of any such shares shall, as of the First Effective Time, evidence ownership of such shares of common stock of the First Step Surviving Corporation.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If, between the date of this Agreement and the First Effective Time, the outstanding Company Capital Stock or Parent Capital Stock shall have been changed into, or exchanged for, a different number of shares or a different class, by reason of any stock dividend, subdivision, reclassification, recapitalization, split (including the Nasdaq Reverse Split to the extent such split has not previously been taken into account in calculating the Exchange Ratio), combination or exchange of shares or other like change, the Exchange Ratio shall, to the extent necessary, be equitably adjusted to reflect such change to the extent necessary to provide the holders of Company Capital Stock, Company Options, Company Warrants and Parent Capital Stock with the same economic effect as contemplated by this Agreement prior to such stock dividend, subdivision, reclassification, recapitalization, split, combination or exchange of shares or other like change; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that nothing herein will be construed to permit the Company or Parent to take any action with respect to Company Capital Stock or Parent Capital Stock, respectively, that is prohibited or not expressly permitted by the terms of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the Second Effective Time, by virtue of the Second Merger and without any action on the part of Parent, the First Step Surviving Corporation, Second Merger Sub or their respective stockholders, each share of the First Step Surviving Corporation issued and outstanding immediately prior to the Second Effective Time shall be canceled and extinguished without any conversion thereof and no payment or distribution shall be made with respect thereto.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Closing of the Company&#8217;s Transfer Books</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. At the First Effective Time: (a)&#160;all Company Capital Stock outstanding immediately prior to the First Effective Time shall be treated in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, and all holders of certificates representing Company Capital Stock that were outstanding immediately prior to the First Effective Time shall cease to have any rights as stockholders of the Company and (b) the stock </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-17</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">transfer books of the Company shall be closed with respect to all Company Capital Stock outstanding immediately prior to the First Effective Time. No further transfer of any such Company Capital Stock shall be made on such stock transfer books after the First Effective Time.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Surrender of Company Capital Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>On or prior to the Closing Date, Parent and the Company shall jointly select a reputable bank, transfer agent or trust company to act as exchange agent in the Merger (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Exchange Agent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). At the First Effective Time, Parent shall deposit with the Exchange Agent evidence of book-entry shares representing the shares of Parent Capital Stock issuable pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> in exchange for Company Capital Stock.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Promptly after the First Effective Time, the Parties shall cause the Exchange Agent to mail to the Persons who were record holders of shares of Company Capital Stock that were converted into the right to receive the Merger Consideration: (i) a letter of transmittal in customary form and containing such provisions as Parent may reasonably specify (including a provision confirming that delivery of physical stock certificates representing shares of Company Capital Stock, (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Stock Certificates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall be effected, and risk of loss and title shall pass, only upon delivery of such Company Stock Certificates to the Exchange Agent) and (ii) instructions for effecting the surrender of Company Stock Certificates, or uncertificated shares of Company Capital Stock, in exchange for book-entry shares of Parent Capital Stock. Upon surrender of a Company Stock Certificate or other reasonable evidence of the ownership of uncertificated Company Capital Stock to the Exchange Agent for exchange, together with a duly executed letter of transmittal and such other documents as may be reasonably required by the Exchange Agent or Parent: (A) the holder of such Company Stock Certificate or uncertificated shares of Company Capital Stock shall be entitled to receive in exchange therefor book-entry shares representing the Merger Consideration (in a number of whole shares of Parent Capital Stock) that such holder has the right to receive pursuant to the provisions of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and (B) the Company Stock Certificate or uncertificated shares of Company Capital Stock so surrendered shall be canceled. Until surrendered as contemplated by this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.7(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, each Company Stock Certificate or uncertificated shares of Company Capital Stock shall be deemed, from and after the First Effective Time, to represent only the right to receive book-entry shares of Parent Capital Stock representing the Merger Consideration. If any Company Stock Certificate shall have been lost, stolen or destroyed, Parent may, in its discretion and as a condition precedent to the delivery of any shares of Parent Capital Stock, require the owner of such lost, stolen or destroyed Company Stock Certificate to provide an applicable affidavit with respect to such Company Stock Certificate and post a bond indemnifying Parent against any claim suffered by Parent related to the lost, stolen or destroyed Company Stock Certificate or any Parent Capital Stock issued in exchange therefor as Parent may reasonably request.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No dividends or other distributions declared or made with respect to Parent Capital Stock with a record date after the First Effective Time shall be paid to the holder of any unsurrendered Company Stock Certificate with respect to the shares of Parent Capital Stock that such holder has the right to receive in the Merger until such holder surrenders such Company Stock Certificate or uncertificated shares of Company Capital Stock or provides an affidavit of loss or destruction in lieu thereof in accordance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (at which time such holder shall be entitled, subject to the effect of applicable abandoned property, escheat or similar Laws, to receive all such dividends and distributions, without interest).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Any shares of Parent Capital Stock deposited with the Exchange Agent that remain undistributed to holders of Company Stock Certificates as of the date that is 180 days after the Closing Date shall be delivered to Parent upon demand, and any holders of Company Stock Certificates who have not theretofore surrendered their Company Stock Certificates or uncertificated shares of Company Capital Stock in accordance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall thereafter look only to Parent for satisfaction of their claims for Parent Capital Stock and any dividends or distributions with respect to shares of Parent Capital Stock.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No Person shall be liable to any holder of any Company Stock Certificate or uncertificated shares of Company Capital Stock or to any other Person with respect to any shares of Parent Capital Stock (or dividends or distributions with respect thereto) or for any cash amounts delivered to any public official pursuant to any applicable abandoned property Law, escheat Law or similar Law.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-18</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Calculation of Net Cash and Company Valuation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No later than five (5) Business Days before the Closing, Parent will deliver to the Company a schedule (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Net Cash Schedule</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) setting forth, in reasonable detail, Parent&#8217;s good faith, estimated calculation of Parent Net Cash (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Net Cash Calculation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) as of 11:59 p.m. on the Business Day prior to the Anticipated Closing Date (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Cash</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Determination Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) prepared and certified by Parent&#8217;s chief financial officer (or if there is no chief financial officer at such time, the principal financial and accounting officer for Parent). Parent shall make available to the Company (electronically to the greatest extent possible) as reasonably requested by the Company, the work papers and back-up materials used or useful in preparing the Parent Net Cash Schedule&#160;and, if reasonably requested by the Company, Parent&#8217;s internal finance personnel and its accountants and counsel at reasonable times and upon reasonable notice. The Parent Net Cash Calculation shall include Parent&#8217;s determination, as of the Cash Determination Time, of the defined terms in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;1.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> necessary to calculate the Exchange Ratio.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No later than five (5) Business Days before the Closing, the Company will deliver to Parent a schedule (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Schedule</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) setting forth, in reasonable detail, the Company&#8217;s good faith, estimated calculations of the components of the Company Valuation (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Calculation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and the date of delivery of such schedule being (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Delivery Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) as of 11:59 p.m. on the last Business Day prior to the Anticipated Closing Date (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Determination Time</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) prepared and certified by the Company&#8217;s chief financial officer (or if there is no chief financial officer at such time, the principal financial and accounting officer for the Company). The Company shall make available to Parent, as reasonably requested by Parent, the work papers and back-up materials used or useful in preparing the Company Valuation Schedule&#160;and, if reasonably requested by Parent, the Company&#8217;s accountants and counsel at reasonable times and upon reasonable notice.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No later than three (3) Business Days after the Cash Determination Time (the last day of such period, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Response Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Company shall have the right to dispute any part of the Parent Net Cash Calculation by delivering a written notice to that effect to Parent (a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Dispute Notice</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Any Dispute Notice shall identify in reasonable detail and to the extent known the nature and amounts of any proposed revisions to the Parent Net Cash Calculation and will be accompanied by reasonably detailed materials supporting the basis for such revisions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No later than three (3) Business Days after the Company Valuation Delivery Date (the last day of such period, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Response Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), Parent shall have the right to dispute any part of the Company Valuation Calculation by delivering a written notice to that effect to the Company (a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Valuation Dispute Notice</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Any Company Valuation Dispute Notice shall identify in reasonable detail and to the extent known the nature and amounts of any proposed revisions to the Company Valuation Calculation and will be accompanied by reasonably detailed materials supporting the basis for such revisions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If, on or prior to the Response Date, the Company notifies Parent in writing that it has no objections to the Parent Net Cash Calculation or, if on the Response Date, the Company fails to deliver a Dispute Notice as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, then the Parent Net Cash Calculation as set forth in the Parent Net Cash Schedule&#160;shall be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time for purposes of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If, on or prior to the Company Valuation Response Date, Parent notifies the Company in writing that it has no objections to the Company Valuation Calculation or, if on the Company Valuation Response Date, Parent fails to deliver a Company Valuation Dispute Notice as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, then the Company Valuation Calculation as set forth in the Company Valuation Schedule&#160;shall be deemed to have been finally determined for purposes of this Agreement and to represent the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If the Company delivers a Dispute Notice on or prior to the Response Date, then Representatives of Parent and the Company shall promptly meet and attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of Parent Net Cash, which agreed upon the Parent Net Cash amount shall be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time for purposes of this Agreement.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-19</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If Parent delivers a Company Valuation Dispute Notice on or prior to the Company Valuation Response Date, then Representatives of Parent and the Company shall promptly meet and attempt in good faith to resolve the disputed item(s) and negotiate an agreed-upon determination of the components of the Company Valuation, which agreed upon Company Valuation amount shall be deemed to have been finally determined for purposes of this Agreement and to represent the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If Representatives of Parent and the Company are unable to negotiate an agreed-upon determination of Parent Net Cash as of the Cash Determination Time pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(g)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or the components of Company Valuation as of the Company Valuation Determination Time pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> within three days after delivery of the Dispute Notice or the Company Valuation Dispute Notice, as applicable, (or such other period as Parent and the Company may mutually agree upon), then any remaining disagreements as to the calculation of Parent Net Cash or Company Valuation shall be referred to an independent auditor of recognized national standing jointly selected by Parent and the Company. If the parties are unable to select an independent auditor within five (5) days, then either Parent or the Company may thereafter request that the Boston, Massachusetts Office of the American Arbitration Association (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">AAA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) make such selection (either the independent auditor jointly selected by both parties or such independent auditor selected by the AAA, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Accounting Firm</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Parent and the Company shall promptly deliver to the Accounting Firm the work papers and back-up materials used in preparing the Parent Net Cash Schedule&#160;and the Dispute Notice and the Company Valuation Schedule&#160;and the Company Valuation Dispute Notice, and Parent and the Company shall use commercially reasonable efforts to cause the Accounting Firm to make its determination within five&#160;(5) Business Days of accepting its selection. Parent and the Company shall be afforded the opportunity to present to the Accounting Firm any material related to the unresolved disputes and to discuss the issues with the Accounting Firm; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that no such presentation or discussion shall occur without the presence of a Representative of each of Parent and the Company. The determination of the Accounting Firm shall be limited to the disagreements submitted to the Accounting Firm. The determination of the amount of Parent Net Cash or the components of the Company Valuation made by the Accounting Firm shall be made in writing delivered to each of Parent and the Company, shall be final and binding on Parent and the Company and shall (absent manifest error) be deemed to have been finally determined for purposes of this Agreement and to represent the Parent Net Cash at the Cash Determination Time or the components of the Company Valuation at the Company Valuation Determination Time for purposes of this Agreement. The Parties shall delay the Closing until the resolution of the matters described in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The fees and expenses of the Accounting Firm shall be allocated between Parent and the Company in the same proportion that the disputed amount of the Parent Net Cash or the Company Valuation that was unsuccessfully disputed by such Party (as finally determined by the Accounting Firm) bears to the total disputed amount of the Parent Net Cash amount or the components of the Company Valuation. If this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> applies as to the determination of the Parent Net Cash at the Cash Determination Time or to the determination of the components of the Company Valuation at the Company Valuation Determination Time, as applicable, upon resolution of the matter in accordance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.8(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Parties shall not be required to determine Parent Net Cash or the Company Valuation again even though the Closing may occur later than the Anticipated Closing Date, except that either Parent and the Company may request a redetermination of Parent Net Cash or the Company Valuation if the Closing Date is more than thirty (30) days after the Anticipated Closing Date.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.9<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Further Action</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If, at any time after the First Effective Time, any further action is determined by the Surviving Entity to be necessary or desirable to carry out the purposes of this Agreement or to vest the Surviving Entity with full right, title and possession of and to all rights and property of the Company, then the officers and directors of the Surviving Entity shall be fully authorized, and shall use their and its commercially reasonable efforts (in the name of the Company, in the name of First Merger Sub, in the name of Second Merger Sub, in the name of the Surviving Entity and otherwise) to take such action.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.10<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Intended Tax Treatment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parties acknowledge and agree that, for U.S. federal (and applicable state and local) income Tax purposes, the Merger is intended to qualify as a reorganization within the meaning of Section&#160;368(a) of the Code (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Intended Tax Treatment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The Parties adopt this Agreement as a &#8220;plan of reorganization&#8221; within the meaning of Treasury Regulations Sections&#160;1.368-2(g) and 1.368-3.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.11<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Withholding</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each of the Exchange Agent, Parent and the Surviving Entity shall be entitled to deduct and withhold from any consideration deliverable pursuant to this Agreement to any Person such amounts as are required to be deducted or withheld from such consideration under applicable Law; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-20</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">the Exchange Agent, Parent and the Surviving Entity shall use commercially reasonable efforts to promptly notify such Persons of any intention to withhold any portion of such consideration and cooperate with such Persons to reduce or eliminate any such withholding to the extent permitted by applicable Law. To the extent such amounts are so deducted or withheld and remitted to the appropriate Governmental Authority, such amounts shall be treated for all purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid. All payments made under this agreement that constitute compensation to employees for services for Tax purposes shall be made through the payroll of the Surviving Entity or Parent, as applicable.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.12<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appraisal Rights</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding any provision of this Agreement to the contrary, shares of Company Capital Stock that are outstanding immediately prior to the First Effective Time and which are held by stockholders or owned by beneficial owners who have exercised and perfected appraisal rights for such shares of Company Capital Stock in accordance with the DGCL (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Dissenting Shares</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall not be converted into or represent the right to receive the Merger Consideration described in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;2.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> attributable to such Dissenting Shares. Such stockholders or beneficial owners shall be entitled to receive payment of the fair value of such shares of Company Capital Stock held by them in accordance with the DGCL, unless and until such stockholders or beneficial owners fail to perfect or effectively withdraw or otherwise lose their appraisal rights under the DGCL. All Dissenting Shares held by stockholders or owned by beneficial owners who shall have failed to perfect or shall have effectively withdrawn or lost their right to appraisal of such shares of Company Capital Stock under the DGCL (whether occurring before, at or after the First Effective Time) shall thereupon be deemed to be converted into and to have become exchangeable for, as of the First Effective Time, the right to receive the Merger Consideration, without interest, attributable to such Dissenting Shares upon their surrender in the manner provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;2.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">2.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company shall give Parent prompt written notice of any demands by dissenting stockholders or beneficial owners received by the Company, withdrawals of such demands and any other instruments served on the Company and any material correspondence received by the Company in connection with such demands, and Parent shall have the right to participate in all negotiations and proceedings with respect to such demands. The Company shall not, except with Parent&#8217;s prior written consent, not to be unreasonably withheld, delayed or conditioned, make any payment with respect to, or settle or offer to settle, any such demands, or approve any withdrawal of any such demands or agree to do any of the foregoing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;3. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Representations and Warranties of the Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except as set forth in the written disclosure document delivered by the Company to Parent (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Disclosure Letter</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) concurrently with the execution of this Agreement, the Company represents and warrants to Parent and Merger Subs as follows:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Due Organization; Subsidiaries</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is a corporation or other legal entity duly incorporated or otherwise organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation or organization and has all necessary power and authority: (i) to conduct its business in the manner in which its business is currently being conducted, (ii) to own or lease and use its property and assets in the manner in which its property and assets are currently owned or leased and used and (iii) to perform its obligations under all Contracts by which it is bound.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is duly licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business in the manner in which its business is currently being conducted requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Company Material Adverse Effect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has no Subsidiaries and the Company does not own any capital stock or membership interests of, or any equity, ownership or profit sharing interest of any nature in, or controls directly or indirectly, any other Entity. The Company is not and has never otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. The Company has not agreed or is obligated to make, or is bound by any Contract under which it may become obligated to make, any </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-21</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">future investment in or capital contribution to any other Entity. The Company has not, at any time, been a general partner of, or has otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Organizational Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company has delivered to Parent accurate and complete copies of the Organizational Documents of the Company. The Company is not in breach or violation of its Organizational Documents in any material respect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Authority; Binding Nature of Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and to consummate the Contemplated Transactions. The Company Board has (i) determined that the Contemplated Transactions are fair to, advisable and in the best interests of the Company and its stockholders, (ii) approved and declared advisable this Agreement and the Contemplated Transactions and (iii) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of the Company vote to adopt this Agreement and thereby approve the Contemplated Transactions. This Agreement has been duly executed and delivered by the Company and assuming the due authorization, execution and delivery by Parent, First Merger Sub and Second Merger Sub, constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to the Enforceability Exceptions.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Vote Required</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The affirmative vote (or written consent) of (i)&#160;the holders of a majority of the shares of Company Capital Stock outstanding on the record date, voting as a single class on an as-converted&#160;basis, and (ii) the holders of a majority of the shares of Company Series A Preferred Stock outstanding on the record date and entitled to vote thereon, voting as a separate class, is the only vote of the holders of any class or series of Company Capital Stock necessary to adopt and approve this Agreement and approve the Contemplated Transactions (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Required Company Stockholder Vote</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Non-Contravention; Consents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Subject to obtaining the Required Company Stockholder Vote, compliance with any applicable requirements of the HSR Act (if applicable) and the filing of the Certificate of Merger and Certificate of Designation required by the DGCL or DLLCA, neither (x) the execution, delivery or performance of this Agreement by the Company, nor (y) the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time):</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a violation of any of the provisions of the Company&#8217;s Organizational Documents;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a material violation of, or give any Governmental Authority or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any Order by which the Company, or any of the assets owned or used by the Company, is subject;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by the Company or that otherwise relates to the business of the Company, or any of the assets owned, leased or used by the Company;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Company Material Contract, or give any Person the right to: (A)&#160;declare a default or exercise any remedy under any Company Material Contract, (B) any material payment, rebate, chargeback, penalty or change in delivery schedule under any Company Material Contract, (C) accelerate the maturity or performance of any Company Material Contract or (D) cancel, terminate or modify any term of any Company Material Contract, except in the case of any nonmaterial breach, default, penalty or modification; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by the Company (except for Permitted Encumbrances).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-22</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for (i) the Required Company Stockholder Vote, (ii) the filing of the Certificate of Merger and Certificate of Designation with the Secretary of State of the State of Delaware pursuant to the DGCL or DLLCA, (iii) compliance with any applicable requirements of the HSR Act (if applicable) and (iv)&#160;such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities laws, the Company was not, is not, nor will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x) the execution, delivery or performance of this Agreement or (y) the consummation of the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement, the Company Stockholder Support Agreements or any of the Contemplated Transactions.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Capitalization.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The authorized capital stock of the Company consists of (i) 65,000,000 shares of Company Common Stock of which 9,460,019 shares have been issued and are outstanding as of the date hereof and (ii) 20,000,000 shares of Company Preferred Stock, of which 20,000,000 shares have been designated Series A Preferred Stock and 20,000,000 have been issued and are outstanding as of the date hereof. The Company does not hold any shares of its capital stock in its treasury. As of the date of this Agreement, the Company&#8217;s capital stock is held by the Persons and in the amounts set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, which further sets forth for each such Person (i) the&#160;name of such Person and the number of shares held, (ii)&#160;the class and series of such shares, (iii)&#160;the number of the applicable book-entry positions representing such shares or the number of the certificate representing such shares, (iv)&#160;whether such Person is or has ever been an employee, and (v) the state of residence of such Person. Each share of Company Preferred Stock is convertible into one share of Company Common Stock. There are no declared or accrued but unpaid dividends with respect to any shares of the Company&#8217;s capital stock and the Company has never declared or paid any dividend or other distribution.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All of the outstanding Company Capital Stock as set out in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter have been duly authorized and validly issued, and are fully paid and nonassessable and are free of any Encumbrances other than Encumbrances set forth in the Organizational Documents or under applicable securities Laws. None of the outstanding Company Capital Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding Company Capital Stock is subject to any right of first refusal in favor of the Company. Except as contemplated herein, there is no Company Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any Company Capital Stock. The Company is not under any obligation, nor is it bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding Company Capital Stock or other securities. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter accurately and completely describes all repurchase rights held by the Company with respect to Company Capital Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently exercisable.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for the Company Stock Plans and except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, the Company does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter sets forth the following information with respect to each Company Option outstanding as of the date hereof: (i) the name of the holder, (ii) the number of shares of Company Common Stock subject to such Company Option as of the date hereof, (iii) the exercise price of such Company Option, (iv) the date on which such Company Option was granted, (v) the applicable vesting schedule, including any acceleration provisions, (vi)&#160;the date on which such Company Option expires, (vii) whether such Company Option is intended to be an &#8220;incentive stock option&#8221; (as defined in the Code) or a nonqualified stock option and (viii) in the case of a Company Option, the plan pursuant to which such Company Option was granted. The Company has made available to Parent accurate and complete copies of equity incentive plans pursuant to which the Company has equity-based awards, the forms of all award agreements evidencing such equity-based awards and evidence of board and stockholder approval of the Company Stock Plans and any amendments thereto.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for the outstanding Company Options or as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.6(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any Company Capital Stock or other securities of the Company, (ii) outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-23</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">capital stock or other securities of the Company, (iii)&#160;stockholder rights plan (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contract under which the Company is or may become obligated to sell or otherwise issue any Company Capital Stock or any other securities or (iv) condition or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of the Company. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All outstanding Company Capital Stock, Company Options and other securities of the Company have been issued and granted in compliance in all material respects with (i) all applicable securities laws and other applicable Law and (ii) all requirements set forth in applicable Contracts.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company Capital Stock are uncertificated.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Financial Statements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.7(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter includes true and complete copies of the Company&#8217;s budget overview for March 2024 (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Budget</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company maintains a system of internal accounting controls designed to provide reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of the financial statements of the Company in conformity with GAAP and to maintain accountability of the Company&#8217;s assets, (iii) access to the Company&#8217;s assets is permitted only in accordance with management&#8217;s general or specific authorization and (iv)&#160;the recorded accountability for the Company&#8217;s assets is compared with the existing assets at regular intervals and appropriate action is taken with respect to any differences. The Company maintains internal controls consistent with the practices of similarly situated private companies over financial reporting that provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.7(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter lists, and the Company has delivered to Parent accurate and complete copies of the documentation creating or governing, all securitization transactions and &#8220;off-balance sheet arrangements&#8221; (as defined in Item 303(c) of Regulation S-K under the Exchange Act) effected by the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer or general counsel of the Company, the Company Board or any committee thereof. Neither the Company nor its independent auditors have identified (i) any significant deficiency or material weakness in the design or operation of the system of internal accounting controls utilized by the Company, (ii) any fraud, whether or not material, that involves the Company, the Company&#8217;s management or other employees who have a role in the preparation of financial statements or the internal accounting controls utilized by the Company or (iii) any claim or allegation regarding any of the foregoing.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Absence of Changes</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, between the date of its incorporation and the date of this Agreement, the Company has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a) Company Material Adverse Effect or (b) action, event or occurrence that would have required consent of Parent pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.2(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.9<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Absence of Undisclosed Liabilities</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since the date of its incorporation, the Company does not have any liability, indebtedness, obligation, expense, claim, deficiency, guaranty or endorsement of any kind, whether accrued, absolute, contingent, matured, unmatured or otherwise (each a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Liability</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), except for: (a) Liabilities disclosed, reflected or reserved against in the Company Budget, (b) normal and recurring current Liabilities that have been incurred by the Company since the date of the Company Budget in the Ordinary Course of Business (none of which relates to any breach of contract, breach of warranty, tort, infringement or violation of Law), (c) Liabilities for performance of obligations of the Company under Company Contracts, (d) Liabilities incurred in connection with the Contemplated Transactions and the Subscription Agreement, (e)&#160;Liabilities described in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter and (f) those Liabilities that are not material to the Company.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-24</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.10<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Title to Assets</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company owns and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a) all tangible assets reflected on the Company Budget and (b) all other tangible assets reflected in the books and records of the Company as being owned by the Company. All of such assets are owned or, in the case of leased assets, leased by the Company free and clear of any Encumbrances, other than Permitted Encumbrances.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.11<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Real Property; Leasehold</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company does not own and has never owned any real property, nor is the Company party to any agreement to purchase or sell any real property. The Company has made available to Parent (a) an accurate and complete list of&#160;all real properties with respect to which the Company directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by the Company and (b)&#160;copies of all leases under which any such real property is possessed (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Real Estate Leases</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), each of which is in full force and effect, with no existing material default thereunder by the Company or to the Company&#8217;s Knowledge, the other party thereto.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.12<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Intellectual Property</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.12(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter is an accurate, true and complete listing of all Company Registered IP.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.12(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter accurately identifies (i) all Company Contracts pursuant to which any Company IP Rights are licensed to the Company (other than (A) any non-customized software that (1) is so licensed solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2)&#160;is not incorporated into, or material to the development, manufacturing or distribution of, any of the Company&#8217;s products or services, (B) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of services, equipment, reagents or other materials, (C) any confidential information provided under confidentiality agreements and (D) agreements between Company and its employees in Company&#8217;s standard form thereof) and (ii)&#160;whether the license or licenses granted to the Company are exclusive or nonexclusive.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter accurately identifies each Company Contract pursuant to which any Person has been granted any license or covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Company IP Rights (other than (i) any confidential information provided under confidentiality agreements and (ii) any Company IP Rights nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service providers to provide services for the Company&#8217;s benefit).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not bound by, and no Company IP Rights are subject to, any Contract containing any covenant or other provision that in any way limits or restricts the ability of the Company to use, exploit, assert or enforce any Company IP Rights anywhere in the world.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company exclusively owns all right, title and interest to and in Company IP Rights (other than (i) Company IP Rights licensed to the Company, or co-owned rights each as identified in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.12(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, (ii) any non-customized software that (A) is licensed to the Company solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (B) is not incorporated into, or material to the development, manufacturing or distribution of, any of the Company&#8217;s products or services and (iii) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials), in each case, free and clear of any Encumbrances (other than Permitted Encumbrances). Without limiting the generality of the foregoing:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All documents and instruments necessary to register or apply for or renew registration of Company Registered IP have been validly executed, delivered and filed in a timely manner with the appropriate Governmental Authority.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-25</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Person who is or was an employee or contractor of the Company and who is or was involved in the creation or development of any Intellectual Property for the Company has signed a valid, enforceable agreement containing a present assignment of such Intellectual Property to the Company and confidentiality provisions protecting trade secrets and confidential information of the Company.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of the Company, no current or former stockholder, officer, director or employee of the Company has any claim, right (whether currently exercisable, or exercisable in the future) or interest to or in any Company IP Rights purported to be owned by the Company. To the Knowledge of the Company, no employee of the Company is (a) bound by or otherwise subject to any Contract restricting him or her from performing his or her duties for the Company or (b) in breach of any Contract with any former employer or other Person concerning Company IP Rights purported to be owned by the Company or confidentiality provisions protecting trade secrets and confidential information comprising Company IP Rights purported to be owned by the Company.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No funding, facilities or personnel of any Governmental Authority or any university, college, research institute or other educational institution were used, directly or indirectly, to develop or create, in whole or in part, any Company IP Rights in which the Company has an ownership interest, except for any such funding or use of facilities or personnel that does not result in such Governmental Authority or institution owning such Company IP Rights or the right to receive royalties or other remuneration for the practice of such Company IP Rights as of the date of this Agreement.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has taken reasonable steps to maintain the confidentiality of and otherwise protect and enforce its rights in all proprietary information that the Company holds, or purports to hold, as confidential or a trade secret.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Company IP Rights to any other Person.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has delivered or made available to Parent, a complete and accurate copy of all Company IP Rights Agreements. With respect to each of the Company IP Rights Agreements: (i) each such agreement is valid and binding on the Company and in full force and effect, (ii) the Company has not received any written notice of termination or cancellation under such agreement, or received any written notice of breach or default under such agreement, which breach has not been cured or waived and (iii) the Company, and to the Knowledge of the Company, no other party to any such agreement, is not in breach or default thereof in any material respect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by the Company does not violate any license or agreement between the Company and any other third party, and, to the Knowledge of the Company, does not infringe or misappropriate any valid and issued Patent right or other Intellectual Property of any other Person, which infringement or misappropriation would reasonably be expected to have a Company Material Adverse Effect. To the Knowledge of the Company, no third party is infringing upon any Patents owned by Company within the Company IP Rights, or otherwise violating any Company IP Rights Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As of the date of this Agreement, Company is not a party to any Legal Proceeding (including, but not limited to, opposition, interference or other proceeding in any patent or other government office) contesting the validity, enforceability, claim construction, ownership or right to use, sell, offer for sale, license or dispose of any Company IP Rights. The Company has not received any written notice asserting that any Company IP Rights or the proposed use, sale, offer for sale, license or disposition of products, methods or processes claimed or covered thereunder infringes or misappropriates or violates the rights of any other Person or that the Company has otherwise infringed, misappropriated or otherwise violated any Intellectual Property of any Person. None of the Company IP Rights is subject to any outstanding order of, judgment of, decree of or agreement with any Governmental Authority that limits the ability of the Company to exploit any Company IP Rights.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-26</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each item of Company Registered IP is and at all times has been filed and maintained in compliance in all material respects with all applicable Law and all filings, payments and other actions required to be made or taken to maintain such item of Company Registered IP in full force and effect have been made by the applicable deadline. To the Knowledge of the Company, all Company Registered IP that is issued or granted is valid and enforceable.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of the Company, no trademark (whether registered or unregistered) or trade name owned, used or applied for by the Company conflicts or interferes with any trademark (whether registered or unregistered) or trade name owned, used or applied for by any other Person. None of the goodwill associated with or inherent in any trademark (whether registered or unregistered) in which the Company has or purports to have an ownership interest has been impaired as determined by the Company in accordance with GAAP.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;3.12(b),</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">3.12(k)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter or as contained in &#8220;off-the-shelf&#8221; license agreements entered into in the Ordinary Course of Business by the Company, (i) the Company is not bound by any Contract to indemnify, defend, hold harmless or reimburse any other Person with respect to any Intellectual Property infringement, misappropriation, or similar claim which is material to the Company, taken as a whole and (ii) the Company has never assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability of another Person for infringement, misappropriation, or violation of any Intellectual Property right, which assumption, agreement or responsibility remains in force as of the date of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(l)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not party to any Contract that, as a result of such execution, delivery and performance of this Agreement, will cause the grant of any license or other right to any Company IP Rights, result in breach of, default under or termination of such Contract with respect to any Company IP Rights, or impair the right of the Company or the Surviving Entity and its Subsidiaries to use, sell or license or enforce any Company IP Rights or portion thereof, except for the occurrence of any such grant or impairment that would not individually or in the aggregate, reasonably be expected to result in a Company Material Adverse Effect.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.13<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreements, Contracts and Commitments</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.13(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter lists the following Company Contracts in effect as of the date of this Agreement other than the Subscription Agreement (each, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Material Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Material Contracts</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;):</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract containing (A) any covenant limiting the freedom of the Company or the Surviving Entity to engage in any line of business or compete with any Person, or limiting the development, manufacture or distribution of the Company&#8217;s products or services (B)&#160;any most-favored pricing arrangement, (C) any exclusivity provision or (D) any non-solicitation provision;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract (A) pursuant to which any Person granted the Company an exclusive license under any Intellectual Property, or (B) pursuant to which the Company granted any Person an exclusive license under any Company IP Rights;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of the Company, any of its Subsidiaries, or of a product;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $100,000 after the date of this Agreement;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-27</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Encumbrances with respect to any assets of the Company or any loans or debt obligations with officers or directors of the Company;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(viii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract requiring payment by or to the Company after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (A)&#160;any distribution agreement (identifying any that contain exclusivity provisions), (B) any agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of the Company, (C) any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which the Company has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which the Company has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by the Company or (D) any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of the Company or any Contract to sell, distribute or commercialize any products or service of the Company, in each case, except for Company Contracts entered into in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ix)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to the Company in connection with the Contemplated Transactions and requiring payments by Company after the date in this Agreement in excess of $100,000 pursuant to its express terms;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract to which the Company is a party or by which any of its assets and properties is currently bound, which involves annual obligations of payment by, or annual payments to, the Company in excess of $100,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Company Contract entered into in settlement of any Legal Proceeding or other dispute pursuant to which the Company or any of its Subsidiaries has outstanding obligations to pay consideration in excess of $100,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any other Company Contract that is not terminable at will (with no penalty or payment) by the Company, and (A) which involves payment or receipt by the Company after the date of this Agreement under any such agreement, contract or commitment of more than $100,000 in the aggregate, or obligations after the date of this Agreement in excess of $100,000 in the aggregate or (B) that is material to the business or operations of the Company taken as a whole; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Company Real Estate Leases.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has delivered or made available to Parent accurate and complete copies of all Company Material Contracts, including all amendments thereto. There are no Company Material Contracts that are not in written form. The Company has not, nor to the Company&#8217;s Knowledge, as of the date of this Agreement has any other party to a Company Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Company Material Contract in such a manner, and, if such Company Material Contract provides for a cure period, the Company or such other party fails to have cured such breach, violation or default, so that any other party or the Company, as the case may be, is permitted to modify, cancel or terminate any such Company Material Contract, or would permit any other party to seek damages which would reasonably be expected to have a Company Material Adverse Effect. As to the Company, as of the date of this Agreement, each Company Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Company Material Contract to change, any material amount paid or payable to the Company under any Company Material Contract or any other material term or provision of any Company Material Contract.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-28</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.14<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Compliance; Permits; Restrictions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is, and has been in material compliance with all applicable Laws. No investigation, claim, suit, proceeding, audit, Order or other Legal Proceeding or action by any Governmental Authority is pending or, to the Knowledge of the Company, threatened against the Company. There is no agreement or Order binding upon the Company which (i) has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of the Company, any acquisition of material property by the Company or the conduct of business by the Company as currently conducted, (ii) is reasonably likely to have an adverse effect on the Company&#8217;s ability to comply with or perform any covenant or obligation under this Agreement or (iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for matters regarding the U.S. Food and Drug Administration (or any successor agency thereto) (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">FDA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) or other comparable Governmental Authority responsible for regulation of the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of drug or medical device products (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Drug/Device Regulatory Agency</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Company holds all required Governmental Authorizations for the operation of the business of the Company as currently conducted (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Permits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.14(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter identifies each Company Permit. The Company is in material compliance with the terms of the Company Permits. No Legal Proceeding is pending or, to the Knowledge of the Company, threatened, which seeks to revoke, substantially limit, suspend or materially modify any Company Permit. The rights and benefits of each Company Permit will be available to the Surviving Entity or its Subsidiaries, as applicable, immediately after the Second Effective Time on terms substantially identical to those enjoyed by the Company as of the date of this Agreement and immediately prior to the First Effective Time.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There are no Legal Proceedings pending or, to the Knowledge of the Company, threatened with respect to an alleged violation by the Company of the Federal Food, Drug, and Cosmetic Act (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">FDCA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Public Health Service Act (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">PHSA</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), FDA regulations adopted thereunder, the Controlled Substances Act or any other similar Law promulgated by a Drug/Device Regulatory Agency.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company holds all required Governmental Authorizations issuable by any Drug/Device Regulatory Agency necessary for the conduct of the business of the Company as currently conducted, and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation, as currently conducted, of any of its products or product candidates (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Product Candidates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Regulatory Permits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and no such Company Regulatory Permit has been (i) revoked, withdrawn, suspended, cancelled or terminated or (ii) modified in any adverse manner, other than immaterial adverse modifications. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.14(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter identifies each Company Regulatory Permit. The Company has timely maintained and is in compliance in all material respects with the Company Regulatory Permits and has not received any written notice or correspondence or, to the Knowledge of the Company, other communication from any Drug/Device Regulatory Agency regarding (A) any material violation of or failure to comply materially with any term or requirement of any Company Regulatory Permit or (B) any revocation, withdrawal, suspension, cancellation, termination or material modification of any Company Regulatory Permit. The Company has made available to Parent all information requested by Parent in the Company&#8217;s possession or control relating to material Company Product Candidates and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of the Company Product Candidates, including but not limited to complete copies of the following (to the extent there are any): (x) adverse event reports; preclinical, clinical and other study reports and material study data; inspection reports, notices of adverse findings, untitled letters, warning letters, filings and letters and other written correspondence to and from any Drug/Device Regulatory Agency; and meeting minutes with any Drug/Device Regulatory Agency and (y) similar reports, material study data, notices, letters, filings, correspondence and meeting minutes with any other Governmental Authority. All such information is accurate and complete in all material respects.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All clinical, preclinical and other studies and tests conducted by or on behalf of, or sponsored by, the Company, or in which the Company or its current products or product candidates, including the Company Product Candidates, have participated, were, and, if still pending, are being conducted in accordance in all material respects with standard medical and scientific research procedures, in accordance in all material respects </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-29</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">with the applicable protocols and in compliance in all material respects with the applicable regulations of the Drug/Device Regulatory Agencies and other applicable Law, including 21 C.F.R. Parts 11, 50, 54, 56, 58, 312 and 812. The Company has not received any written notices, correspondence or other communications from any Drug/Device Regulatory Agency, Governmental Authority, institutional review board, ethics committee or safety monitoring committee requiring, or to the Knowledge of the Company threatening to initiate, any action to place a clinical hold order on, or otherwise terminate, delay or suspend any clinical studies conducted by or on behalf of, or sponsored by, the Company or in which the Company or its current products or product candidates, including the Company Product Candidates, have participated. Further, no clinical investigator, researcher or clinical staff participating in any clinical study conducted by or, to the Knowledge of the Company, on behalf of the Company has been disqualified from participating in studies involving the Company Product Candidates, and to the Knowledge of the Company, no such administrative action to disqualify such clinical investigators, researchers or clinical staff has been threatened or is pending.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not, and to the Knowledge of the Company, no contract manufacturer with respect to any Company Product Candidate, is the subject of any pending or, to the Knowledge of the Company, threatened investigation in respect of its business or products, including Company Product Candidates, by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto or by any other Drug/Device Regulatory Agency under a comparable policy. The Company has not, and to the Knowledge of the Company, no contract manufacturer, nor their respective officers, employees or agents, with respect to any Company Product Candidate has committed any acts, made any statement or failed to make any statement, in each case in respect of its business or products that would violate the FDA&#8217;s &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy, and any amendments thereto or a comparable policy of any other Drug/Device Regulatory Agency. None of the Company, and to the Knowledge of the Company, any contract manufacturer with respect to any Company Product Candidate, or any of their respective officers, employees or agents is currently or has been debarred, convicted of any crime or is engaging or has engaged in any conduct that could result in a debarment or exclusion under (i) 21 U.S.C. Section&#160;335a or (ii) any similar applicable Law. To the Knowledge of the Company, no debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or threatened against the Company, and to the Knowledge of the Company, any contract manufacturer with respect to any Company Product Candidate, or any of their respective officers, employees or agents.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All manufacturing operations conducted by, or to the Knowledge of the Company, for the benefit of the Company in connection with any Company Product Candidate have been and are being conducted in compliance in all material respects with applicable Laws, including the FDA&#8217;s standards for current good manufacturing practices, including applicable requirements contained in 21 C.F.R. Parts 210, 211 and 600-610 and the respective counterparts thereof promulgated by Governmental Authorities in countries outside the United States.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor, to the Knowledge of the Company, any manufacturing site of a contract manufacturer or laboratory, with respect to any Company Product Candidate, (i) is subject to a Drug/Device Regulatory Agency shutdown or import or export prohibition or (ii) has received any Form FDA 483, notice of violation, warning letter, untitled letter or similar correspondence or notice from the FDA or other Drug/Device Regulatory Agency alleging or asserting noncompliance with any applicable Law, in each case, that have not been complied with or closed to the satisfaction of the relevant Drug/Device Regulatory Agency, and, to the Knowledge of the Company, neither the FDA nor any other Drug/Device Regulatory Agency is considering such action.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.15<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Legal Proceedings; Orders</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no pending Legal Proceeding and, to the Knowledge of the Company, no Person has threatened in writing to commence any Legal Proceeding: (i) that involves the Company or any of its Subsidiaries or any Company Associate (in his or her capacity as such) or any of the material assets owned or used by the Company or any of its Subsidiaries or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-30</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no Order to which the Company or any of its Subsidiaries, or any of the material assets owned or used by the Company or any of its Subsidiaries, is subject. To the Knowledge of the Company, no officer or Company Key Employee is subject to any Order that prohibits such officer or Company Key Employee from engaging in or continuing in any conduct, activity or practice relating to the Company or any of its Subsidiaries or any material assets owned or used by the Company or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.16<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Tax Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has timely filed (or caused to be timely filed) all income Tax Returns and all other material Tax Returns required to be filed by the Company under applicable Law (taking into account any applicable extensions). All such Tax Returns were true, correct and complete in all material respects. Subject to exceptions as would not be material, no claim has been made by a Governmental Authority in a jurisdiction where the Company does not file Tax Returns that the Company is subject to taxation by that jurisdiction.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All material amounts of Taxes due and owing by the Company (whether or not shown on any Tax Return) have been timely paid (taking into account any applicable extensions).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has withheld and paid to the appropriate Governmental Authority all material Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder or other third party.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There are no Encumbrances for a material amount of Taxes (other Encumbrances described in clause&#160;(a) of the definition of &#8220;Permitted Encumbrances&#8221;) upon any of the assets of the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No deficiencies for a material amount of Taxes with respect to the Company have been claimed, proposed or assessed by any Governmental Authority in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, assessments, examinations or other actions for or relating to any liability in respect of Taxes of the Company. The Company has not granted a waiver of any statute of limitations in respect of a material amount of Taxes or an extension of time with respect to a material Tax assessment or deficiency that, in each case, is currently in effect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not been a United States real property holding corporation within the meaning of Section&#160;897(c)(2) of the Code in the last five (5) years.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not a party to any Tax allocation, Tax sharing or similar agreement (including indemnity arrangements), other than customary commercial Contracts entered into in the Ordinary Course of Business the primary purpose of which does not relate to Tax (an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Ordinary Course Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the common parent of which is the Company). The Company has no Liability for the Taxes of any Person under Treasury Regulations Section&#160;1.1502-6 (or any similar provision of state, local, or foreign law), as a transferee or successor, or by Contract (other than an Ordinary Course Agreement).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 of the Code or Section&#160;361 of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has not entered into any transaction identified as a &#8220;listed transaction&#8221; for purposes of Treasury Regulations Sections&#160;1.6011-4(b)(2) or 301.6111-2(b)(2).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company is not aware of any facts or circumstances and has not taken or agreed to take any action, in each case, that would reasonably be expected to prevent or impede the Intended Tax Treatment.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-31</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.17<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Employee and Labor Matters; Benefit Plans.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company has made available to Parent a list (on an anonymized basis) setting forth, for each Company Associate who is an employee of the Company or any of its Subsidiaries, whether full- or part-time, such employee&#8217;s annual salary (or if hourly, hourly rate), most recent annual bonus received, and current annual bonus opportunity. No Company Key Employee has indicated to the Company, or any of its Subsidiaries, that he or she intends to resign or retire as a result of the transactions contemplated by this Agreement or otherwise. The Company has made available to Parent a list (on an anonymized basis) setting forth, for each Company Associate who is an individual independent contractor engaged by the Company, such contractor&#8217;s rate of compensation.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The employment of the Company&#8217;s and each of its Subsidiaries&#8217; employees is terminable by the Company and/or its applicable Subsidiary at will. The Company has made available to Parent accurate and complete copies of all employee manuals and handbooks, to the extent currently effective and material.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its Subsidiaries is a party to, bound by the terms of, and does not have a duty to bargain under, any collective bargaining agreement or other Contract with a labor organization representing its employees, and there are no labor organizations representing or, to the Knowledge of the Company, purporting to represent or seeking to represent any employees of the Company.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.17(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter lists all Company Employee Plans (other than employment arrangements which are terminable &#8220;at will&#8221; without any contractual obligation on the part of the Company or any of its Subsidiaries to make any severance, termination, change in control or similar payment and that are substantively identical to the employment arrangements made available to Parent).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Company Employee Plan that is intended to be qualified under Section&#160;401(a) of the Code has received a favorable determination or opinion letter with respect to such qualified status from the IRS. To the Knowledge of the Company, nothing has occurred that would reasonably be expected to adversely affect the qualified status of any such Company Employee Plan or the exempt status of any related trust.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Company Employee Plan has been established, maintained and operated in compliance, in all material respects, with its terms all applicable Law, including, without limitation, the Code, ERISA and the Affordable Care Act. No Legal Proceeding (other than those relating to routine claims for benefits) is pending or, to the Knowledge of the Company, threatened with respect to any Company Employee Plan. All payments and/or contributions required to have been made with respect to all Company Employee Plans either have been made or have been accrued in accordance with the terms of the applicable Company Employee Plan and applicable Law.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its ERISA Affiliates maintains, contributes to or is required to contribute to, or has, in the past six (6) years, maintained, contributed to or been required to contribute to (i) any &#8220;employee benefit plan&#8221; that is or was subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii) a Multiemployer Plan, (iii) any funded welfare benefit plan within the meaning of Section&#160;419 of the Code, (iv) any Multiple Employer Plan, or (v) any Multiple Employer Welfare Arrangement. Neither the Company nor any of its ERISA Affiliates has ever incurred any liability under Title IV of ERISA.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No Company Employee Plan provides for medical or other welfare benefits to any service provider beyond termination of service or retirement, other than (1) pursuant to COBRA or an analogous state law requirement or (2) continuation coverage through the end of the month in which such termination or retirement occurs. The Company does not sponsor or maintain any self-funded medical or long-term disability benefit plan.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> No Company Employee Plan is subject to any law of a foreign jurisdiction outside of the United States.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Company Employee Plan that constitutes in any part a &#8220;nonqualified deferred compensation plan&#8221; (as such term is defined under Section&#160;409A(d)(1) of the Code and the guidance thereunder) (each, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">409A Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) has been operated and maintained in all material respects in </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-32</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">operational and documentary compliance with the requirements of Section&#160;409A of the Code and the applicable guidance thereunder. No payment to be made under any Company 409A Plan is or, when made in accordance with the terms of the Company 409A Plan, will be subject to the penalties of Section&#160;409A(a)(1) of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company and each of its Subsidiaries is, and has been, in material compliance with all applicable federal, state and local laws, rules and regulations respecting employment, employment practices, terms and conditions of employment, worker classification, tax withholding, prohibited discrimination, retaliation and harassment, equal employment, fair employment practices, meal and rest periods, immigration status, employee and workplace safety and health, wages (including overtime wages), compensation, hours of work, &#8220;plant closings&#8221; and &#8220;mass layoffs&#8221; within the meaning of the Worker Adjustment and Retraining Act of 1988 or similar state or local law (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">WARN Act</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), labor practices or disputes, restrictive covenants, employment agreements, workers&#8217; compensation and long-term disability policies, leaves of absence and worker privacy (collectively, &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Employment-Related Laws</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and in each case, with respect to employees of the Company and any of its Subsidiaries: (i)&#160;has withheld and reported all material amounts required by law or by agreement to be withheld and reported with respect to wages, salaries and other payments to employees, (ii)&#160;is not liable for any material amounts of arrears of wages, severance pay or any Taxes or any penalty for failure to comply with any of the foregoing and (iii)&#160;is not liable for any material payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Authority, with respect to unemployment compensation benefits, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). There are no material Legal Proceedings, claims, labor disputes or organizing activities, or grievances pending or, to the Knowledge of the Company, threatened or reasonably anticipated against or involving the Company or any of its Subsidiaries or any trustee of the Company or any of its Subsidiaries relating to any employee, contingent worker, director, employment agreement or Employee Plan (other than routine claims for benefits) or Employment-Related Laws. To the Knowledge of the Company, there are no material pending or threatened or reasonably anticipated claims or actions against the Company, any trustee or any trustee of any Subsidiary of the Company under any workers&#8217; compensation policy or long-term disability policy. The Company is not a party to a conciliation agreement, consent decree or other agreement or Order with any federal, state or local agency or Governmental Authority with respect to employment practices.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(l)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its Subsidiaries has any material liability with respect to any misclassification within the last four (4) years of: (i) any Person as an independent contractor rather than as an employee, (ii) any employee leased from another employer or (iii) any employee currently or formerly classified as exempt from overtime wages. Neither the Company nor any of its Subsidiaries has taken any action which would constitute a &#8220;plant closing&#8221; or &#8220;mass layoff&#8221; within the meaning of the WARN Act, issued any notification of a plant closing or mass layoff required by the WARN Act (nor has the Company or any of its Subsidiaries been under any requirement or obligation to issue any such notification), or incurred any liability or obligation under the WARN Act that remains unsatisfied.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(m)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Company&#8217;s Knowledge, there has never been, nor has there been any threat of, any strike, slowdown, work stoppage, lockout, job action, union, organizing activity, question concerning representation or any similar activity or dispute, by or with respect to any Company Associates. No event has occurred within the past six months, and no condition or circumstance exists, that, to the Company&#8217;s Knowledge, might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, job action, union organizing activity, question concerning representation or any similar activity or dispute.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(n)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its Subsidiaries is, nor has the Company nor any of its Subsidiaries been, engaged in any material unfair labor practice within the meaning of the National Labor Relations Act. There is no material Legal Proceeding, claim, labor dispute or grievance pending or, to the Knowledge of the Company, threatened or reasonably anticipated relating to any employment contract, privacy right, labor dispute, wages and hours, leave of absence, plant closing notification, workers&#8217; compensation policy, long-term disability policy, harassment, retaliation, immigration, employment statute or regulation, safety or discrimination matter involving any current or former employee of the Company or any of its Subsidiaries including charges of unfair labor practices or discrimination complaints.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-33</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(o)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no contract, agreement, plan or arrangement to which the Company or any of its Subsidiaries is a party or by which it is bound to compensate any of its employees or other service providers for any income or excise taxes paid pursuant to the Code, including, but not limited to, Section&#160;4999 or Section&#160;409A of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(p)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither the Company nor any of its Subsidiaries is a party to any Contract that as a result of the execution and delivery of this Agreement, the stockholder approval of this Agreement, nor the consummation of the transactions contemplated hereby, could (either alone or in conjunction with any other event) result in, or cause the accelerated vesting, payment, funding or delivery of, or increase the amount or value of, any payment or benefit to any employee, officer, director or other service provider of the Company or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.18<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Environmental Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company has complied with all applicable Environmental Laws, which compliance includes the possession by the Company of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in compliance that, individually or in the aggregate, would not result in a Company Material Adverse Effect. The Company has not received any written notice or other communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that the Company is not in compliance with any Environmental Law and, to the Knowledge of the Company, there are no circumstances that may prevent or interfere with the Company&#8217;s compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Company Material Adverse Effect. To the Knowledge of the Company: (i) no current or prior owner of any property leased or controlled by the Company has received any written notice or other communication relating to property owned or leased at any time by the Company, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or the Company is not in compliance with or violated any Environmental Law relating to such property and (ii) the Company has no material liability under any Environmental Law. The Company has made available all environmental site assessments, environmental audits and other material environmental documents in the Company&#8217;s possession or control relating to the Company, including the Company&#8217;s business and current or former facilities.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.19<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Insurance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company has delivered to Parent accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of the Company. Each of such insurance policies is in full force and effect and the Company is in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, the Company has not received any notice or other communication regarding any actual or possible: (i) cancellation or invalidation of any insurance policy or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. The Company has provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding pending against the Company, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed the Company of its intent to do so.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.20<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Financial Advisors</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.20</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of the Company.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.21<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transactions with Affiliates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.21</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter describes any material transactions or relationships between, on one hand, the Company and, on the other hand, any (a)&#160;executive officer or director of the Company or any of such executive officer&#8217;s or director&#8217;s immediate family members, (b)&#160;owner of more than 5% of the voting power of the outstanding Company Capital Stock or (c)&#160;to the Knowledge of the Company, any &#8220;related person&#8221; (within the meaning of Item&#160;404 of Regulation S-K under the Securities Act) of any such officer, director or owner (other than the Company) in the case of each of (a), (b)&#160;or (c)&#160;that is of the type that would be required to be disclosed under Item&#160;404 of Regulation&#160;S-K under the Securities Act.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.22<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Privacy and Data Security</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company is and has at all times been in compliance with all applicable Privacy Laws and the applicable terms of any Company Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-34</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">unsolicited electronic mail or text messages, cookies or other tracking technology, with respect to, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information (including any such information of individuals, clinical trial participants, patients, patient family members, caregivers or advocates, physicians and other health care professionals, clinical trial investigators, researchers, pharmacists that interact with the Company in connection with the operation of the Company&#8217;s business), except, in each case, for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. To the Knowledge of the Company, the Company (i) has implemented and maintains reasonable written policies and procedures that materially comply with applicable Privacy Laws and are designed to protect the privacy and security of Personal Information (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Privacy Policies</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) has complied with such Privacy Policies, except for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Company Material Adverse Effect. To the Knowledge of the Company, no Legal Proceeding has been asserted or threatened against the Company by any Person alleging a violation of Privacy Laws, Privacy Policies, or the applicable terms of any Company Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, with respect to, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information. To the Knowledge of the Company, there have been no data security incidents or data breaches or other adverse events or incidents that have resulted in any unauthorized access to, or collection, use, disclosure, modification or destruction of, Personal Information or other data in the possession or control of the Company or any service provider acting on behalf of the Company, in each case, where such incident, breach or event resulted in a notification obligation to any Person under applicable Law or pursuant to the terms of any Company Contract.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.23<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Ownership of Parent Capital Stock</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. None of the Company or any of their directors, officers, or Affiliates or, to the knowledge of the Company or any of its controlled Affiliates, any employees of the Company or any of its controlled Affiliates (a) has owned any shares of Parent&#8217;s capital stock; or (b) has been an &#8220;interested stockholder&#8221; (as defined in Section&#160;203 of the DGCL) of Parent, in each case during the three years prior to the date hereof.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.24<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Other Representations or Warranties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company hereby acknowledges and agrees that, except for the representations and warranties contained in this Agreement, neither Parent nor any other person on behalf of Parent makes any express or implied representation or warranty with respect to Parent or with respect to any other information provided to the Company, any of its stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of Parent set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (in each case as qualified and limited by the Parent Disclosure Letter)) none of the Company, or any of its Representatives or stockholders, has relied on any such information (including the accuracy or completeness thereof).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;4. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Representations and Warranties of Parent, First Merger and Second Merger Sub</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except (i) as set forth in the written disclosure document delivered by Parent to the Company (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Disclosure Letter</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) concurrently with the execution of this Agreement or (ii) as disclosed in the Parent SEC Documents filed with the SEC prior to the date hereof and publicly available on the SEC&#8217;s Electronic Data Gathering Analysis and Retrieval system (but (A) without giving effect to any amendment thereof filed with, or furnished to the SEC on or after the date hereof and (B) excluding any disclosures contained under the heading &#8220;Risk Factors&#8221; and any disclosure of risks included in any &#8220;forward-looking statements&#8221; disclaimer or in any other section to the extent they are forward-looking statements or cautionary, predictive or forward-looking in nature), it being understood that any matter disclosed in the Parent SEC Documents shall be deemed to be disclosed in a section of the Parent Disclosure Letter only to the extent that is readily apparent from a reading of such Parent SEC Documents that is applicable to such section or subsection of the Parent Disclosure Letter, Parent, First Merger Sub and Second Merger Sub represent and warrant to the Company as follows:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Due Organization; Subsidiaries</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent, First Merger Sub and Second Merger Sub is a corporation duly incorporated or formed, as applicable, validly existing and in good standing under the Laws of the jurisdiction of its incorporation or formation, as applicable, and has all necessary corporate power and authority: (i) to conduct its business in the manner in which its business is currently being conducted, (ii) to own or lease and use its property </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-35</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and assets in the manner in which its property and assets are currently owned or leased and used and (iii) to perform its obligations under all Contracts by which it is bound. Since the date of its incorporation, Merger Subs have not engaged in any activities other than in connection with or as contemplated by this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and its Subsidiaries is licensed and qualified to do business, and is in good standing (to the extent applicable in such jurisdiction), under the Laws of all jurisdictions where the nature of its business in the manner in which its business is currently being conducted requires such licensing or qualification other than in jurisdictions where the failure to be so qualified individually or in the aggregate would not be reasonably expected to have a Parent Material Adverse Effect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has no Subsidiaries other than Merger Subs and except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.1(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, Parent does not own any capital stock of, or any equity ownership or profit sharing interest of any nature in, or control directly or indirectly, any other Entity other than Merger Subs. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.1(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, Parent is not and has not otherwise been, directly or indirectly, a party to, member of or participant in any partnership, joint venture or similar business entity. Parent has not agreed and is not obligated to make, nor is Parent bound by any Contract under which it may become obligated to make, any future investment in or capital contribution to any other Entity. Parent has not, at any time, been a general partner of, and has not otherwise been liable for any of the debts or other obligations of, any general partnership, limited partnership or other Entity.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Organizational Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent has delivered to the Company accurate and complete copies of Parent&#8217;s Organizational Documents. Parent is not in breach or violation of its Organizational Documents in any material respect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Authority; Binding Nature of Agreement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent and each Merger Sub has all necessary corporate power and authority to enter into and to perform its obligations under this Agreement and to consummate the Contemplated Transactions. The Parent Board has: (a) determined that the Contemplated Transactions are fair to, advisable and in the best interests of Parent and its stockholders, (b) approved and declared advisable this Agreement and the Contemplated Transactions, including the issuance of shares of Parent Capital Stock to the stockholders of the Company pursuant to the terms of this Agreement and (c) determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholders of Parent vote to approve the Contemplated Transactions, and, if deemed necessary by Parent and the Company, the amendment to the certificate of incorporation of the Parent to (i) change the name of Parent to &#8220;Oruka Therapeutics, Inc.&#8221;, (ii) effect the Nasdaq Reverse Split and (iii) make such other changes as are mutually agreeable to Parent and the Company pursuant to the terms of this Agreement. The First Merger Sub Board (by unanimous written consent) has: (x)&#160;determined that the Contemplated Transactions are fair to, advisable and in the best interests of First Merger Sub and its sole stockholder, (y) deemed advisable and approved this Agreement and the Contemplated Transactions and (z)&#160;determined to recommend, upon the terms and subject to the conditions set forth in this Agreement, that the stockholder of First Merger Sub vote to adopt this Agreement and thereby approve the Contemplated Transactions.  The sole member of Second Merger Sub (by unanimous written consent) has:  (A) determined that the Contemplated Transactions are fair to, advisable, and in the best interests of Second Merger Sub and the sole member; and (B)&#160;deemed advisable and approved this Agreement and the Contemplated Transactions.  This Agreement has been duly executed and delivered by Parent and Merger Subs and, assuming the due authorization, execution and delivery by the Company and the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, constitutes the legal, valid and binding obligation of Parent and Merger Subs, enforceable against each of Parent and Merger Subs in accordance with its terms, subject to the Enforceability Exceptions.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Vote Required</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Assuming the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the affirmative vote of a majority of the shares of Parent Common Stock properly cast at the Parent Stockholder Meeting is the only vote of the holders of any class or series of Parent&#8217;s capital stock necessary to approve this Agreement and thereby approve the Contemplated Transactions and clauses&#160;(i), (ii) and (iii) of the definition of &#8220;Parent Charter Amendment&#8221; (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Required Parent Stockholder Vote</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-36</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Non-Contravention; Consents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Subject to obtaining the Required Parent Stockholder Vote, compliance with any applicable requirements of the HSR Act (if applicable) and the filing of the Certificate of Merger and Certificate of Designation required by the DGCL or DLLCA, and assuming the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, neither (x) the execution, delivery or performance of this Agreement by Parent or Merger Subs, nor (y) the consummation of the Contemplated Transactions, will directly or indirectly (with or without notice or lapse of time):</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a violation of any of the provisions of the Organizational Documents of Parent or its Subsidiaries;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a material violation of, or give any Governmental Authority or other Person the right to challenge the Contemplated Transactions or to exercise any remedy or obtain any relief under, any Law or any Order to which Parent or its Subsidiaries or any of the assets owned or used by Parent or its Subsidiaries, is subject;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a material violation of any of the terms or requirements of, or give any Governmental Authority the right to revoke, withdraw, suspend, cancel, terminate or modify, any Governmental Authorization that is held by Parent or its Subsidiaries or that otherwise relates to the business of Parent, or any of the assets owned, leased or used by Parent;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>contravene, conflict with or result in a violation or breach of, or result in a default under, any provision of any Parent Material Contract, or give any Person the right to: (A)&#160;declare a default or exercise any remedy under any Parent Material Contract, (B) any material payment, rebate, chargeback, penalty or change in delivery schedule under any such Parent Material Contract, (C)&#160;accelerate the maturity or performance of any Parent Material Contract or (D) cancel, terminate or modify any term of any Parent Material Contract, except in the case of any nonmaterial breach, default, penalty or modification; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>result in the imposition or creation of any Encumbrance upon or with respect to any asset owned or used by Parent or its Subsidiaries (except for Permitted Encumbrances).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for (i) any Consent set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.5(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter under any Parent Contract, (ii) the Required Parent Stockholder Vote, (iii) the filing of the Certificate of Merger and Certificate of Designation with the Secretary of State of the State of Delaware pursuant to the DGCL or DLLCA, (iv) compliance with any applicable requirements of the HSR Act (if applicable) and (v) such consents, waivers, approvals, orders, authorizations, registrations, declarations and filings as may be required under applicable federal and state securities laws, and assuming the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, neither Parent nor any of its Subsidiaries was, is or will be required to make any filing with or give any notice to, or to obtain any Consent from, any Person in connection with (x) the execution, delivery or performance of this Agreement or (y) the consummation of the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Assuming the accuracy of the representation in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3.23</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Parent Board and the First Merger Sub Board have taken and will take all actions necessary to ensure that the restrictions applicable to business combinations contained in Section&#160;203 of the DGCL are, and will be, inapplicable to the execution, delivery and performance of this Agreement and to the consummation of the Contemplated Transactions. No other state takeover statute or similar Law applies or purports to apply to the Merger, this Agreement or any of the other Contemplated Transactions.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Capitalization</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The authorized capital stock of Parent consists of (i)&#160;100,000,000 shares of Parent Common Stock of which 14,501,143 shares have been issued and are outstanding as of March 28, 2024 (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Capitalization Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) 5,000,000 shares of Parent Preferred Stock, par value $0.001 per share, of which 135,000 have been designated Series A Convertible Preferred Stock. No shares of Parent Preferred Stock have been issued and are outstanding as of the Capitalization Date. Parent does not hold any shares of its capital stock in its treasury.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-37</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All of the outstanding shares of Parent Common Stock have been duly authorized and validly issued, and are fully paid and nonassessable and are free of any Encumbrances other than Encumbrances set forth in the Organizational Documents or under applicable securities Laws. None of the outstanding shares of Parent Common Stock is entitled or subject to any preemptive right, right of participation, right of maintenance or any similar right and none of the outstanding shares of Parent Common Stock is subject to any right of first refusal in favor of Parent. Except as contemplated herein, there is no Parent Contract relating to the voting or registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any shares of Parent Common Stock. Parent is not under any obligation, nor is Parent bound by any Contract pursuant to which it may become obligated, to repurchase, redeem or otherwise acquire any outstanding shares of Parent Common Stock or other securities. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.6(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter accurately and completely describes all repurchase rights held by Parent with respect to shares of Parent Common Stock (including shares issued pursuant to the exercise of stock options) and specifies which of those repurchase rights are currently exercisable.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for the Parent 2004 Equity Incentive Plan, Parent 2013 Equity Incentive Plan and Parent 2020 Equity Incentive Plan, (each as may be amended from time to time, collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Stock Plans</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, Parent does not have any stock option plan or any other plan, program, agreement or arrangement providing for any equity-based compensation for any Person. Parent does not have any employee stock purchase plan or similar program. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.6(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter sets forth the following information with respect to each Parent Option outstanding as of the Capitalization Date, as applicable: (i) the name of the holder, (ii) the number of shares of Parent Common Stock subject to such Parent Option as of the Capitalization Date, (iii) the exercise price of such Parent Option, (iv) the date on which such Parent Option was granted, (v) the applicable vesting schedule, including any acceleration provisions, (vi) the date on which such Parent Option expires, (vii) whether such Parent Option is intended to be an &#8220;incentive stock option&#8221; (as defined in the Code) or a nonqualified stock option and (viii) in the case of a Parent Option, the plan pursuant to which such Parent Option was granted. Parent has made available to the Company accurate and complete copies of equity incentive plans pursuant to which Parent has equity-based awards, the forms of all award agreements evidencing such equity-based awards and evidence of board and stockholder approval of the Parent Stock Plans and any amendments thereto.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for the outstanding Parent Options or as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.6(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, there is no: (i) outstanding subscription, option, call, warrant or right (whether or not currently exercisable) to acquire any shares of the capital stock or other securities of Parent, (ii) outstanding security, instrument or obligation that is or may become convertible into or exchangeable for any shares of the capital stock or other securities of Parent, (iii) stockholder rights plan (or similar plan commonly referred to as a &#8220;poison pill&#8221;) or Contract under which Parent is or may become obligated to sell or otherwise issue any shares of its capital stock or any other securities or (iv) condition or circumstance that may give rise to or provide a basis for the assertion of a claim by any Person to the effect that such Person is entitled to acquire or receive any shares of capital stock or other securities of Parent. There are no outstanding or authorized stock appreciation, phantom stock, profit participation or other similar rights with respect to Parent.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All outstanding shares of Parent Common Stock and Parent Options, and other securities of Parent have been issued and granted in compliance in all material respects with (i) all applicable securities laws and other applicable Law and (ii) all requirements set forth in applicable Contracts.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">SEC Filings; Financial Statements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has filed or furnished, as applicable, on a timely basis all forms, statements, certifications, reports and documents required to be filed or furnished by it with the SEC under the Exchange Act or the Securities Act (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent SEC Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the Parent SEC Documents complied in all material respects with the applicable requirements of the Securities Act or the Exchange Act (as the case may be) and as of the time they were filed, none of the Parent SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The certifications and statements required by (i) Rule&#160;13a-14 under the Exchange Act and (ii) 18 U.S.C. &#167;1350 (Section&#160;906 of the Sarbanes-Oxley Act) relating to the Parent SEC </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-38</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Documents (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Certifications</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) are accurate and complete and comply as to form and content with all applicable Laws. As used in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the term &#8220;file&#8221; and variations thereof shall be broadly construed to include any manner in which a document or information is furnished, supplied or otherwise made available to the SEC.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The financial statements (including any related notes) contained or incorporated by reference in the Parent SEC Documents: (i) complied as to form in all material respects with the Securities Act and the Exchange Act, as applicable, and the published rules and regulations of the SEC applicable thereto, (ii)&#160;were prepared in accordance with GAAP (except as may be indicated in the notes to such financial statements or, in the case of unaudited financial statements, as permitted by Form 10-Q of the SEC, and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments that are not reasonably expected to be material in amount) applied on a consistent basis unless otherwise noted therein throughout the periods indicated and (iii) fairly present, in all material respects, the financial position of Parent as of the respective dates thereof and the results of operations and cash flows of Parent for the periods covered thereby. Other than as expressly disclosed in the Parent SEC Documents filed prior to the date hereof, there has been no material change in Parent&#8217;s accounting methods or principles that would be required to be disclosed in Parent&#8217;s financial statements in accordance with GAAP. The books of account and other financial records of Parent and each of its Subsidiaries are true and complete in all material respects.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent&#8217;s auditor has at all times since the date of enactment of the Sarbanes-Oxley Act been: (i) a registered public accounting firm (as defined in Section&#160;2(a)(12) of the Sarbanes-Oxley Act), (ii) to the Knowledge of Parent, &#8220;independent&#8221; with respect to Parent within the meaning of Regulation S-X under the Exchange Act and (iii) to the Knowledge of Parent, in compliance with subsections (g) through (l) of Section&#160;10A of the Exchange Act and the rules and regulations promulgated by the SEC and the Public Company Accounting Oversight Board thereunder.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.7(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, Parent has not received any comment letter from the SEC or the staff thereof or any correspondence from Nasdaq or the staff thereof relating to the delisting or maintenance of listing of the Parent Common Stock on Nasdaq. Parent has not disclosed any unresolved comments in the Parent SEC Documents.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There have been no formal internal investigations regarding financial reporting or accounting policies and practices discussed with, reviewed by or initiated at the direction of the chief executive officer, chief financial officer or general counsel of Parent, the Parent Board or any committee thereof, other than ordinary course audits or reviews of accounting policies and practices or internal controls required by the Sarbanes-Oxley Act.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent is in compliance in all material respects with the applicable provisions of the Sarbanes-Oxley Act, the Exchange Act and the applicable listing and governance rules and regulations of Nasdaq.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent maintains a system of internal control over financial reporting (as defined in Rules&#160;13a-15(f) and 15d-15(f) of the Exchange Act) that is sufficient to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i) that Parent maintains records that in reasonable detail accurately and fairly reflect Parent&#8217;s transactions and dispositions of assets, (ii)&#160;that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii) that receipts and expenditures are made only in accordance with the authorization policy and (iv) regarding prevention or timely detection of the unauthorized acquisition, use or disposition of Parent&#8217;s assets that could have a material effect on Parent&#8217;s financial statements. Parent has evaluated the effectiveness of Parent&#8217;s internal control over financial reporting and, to the extent required by applicable Law, presented in any applicable Parent SEC Document that is a report on Form 10-K or Form 10-Q (or any amendment thereto) its conclusions about the effectiveness of the internal control over financial reporting as of the end of the period covered by such report or amendment based on such evaluation. Parent has disclosed to Parent&#8217;s auditors and the Audit Committee of the Parent Board (and made available to the Company a summary of the significant aspects of such disclosure) (A) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting that are reasonably likely to adversely affect Parent&#8217;s ability to record, process, summarize and report financial information and (B) any fraud, whether or not material, that involves management or other employees who have a significant role in Parent&#8217;s or its </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-39</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Subsidiaries&#8217; internal control over financial reporting. Except as disclosed in the Parent SEC Documents filed prior to the date hereof, Parent&#8217;s internal control over financial reporting is effective at the reasonable assurance level and Parent has not identified any material weaknesses in the design or operation of Parent&#8217;s internal control over financial reporting.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent&#8217;s &#8220;disclosure controls and procedures&#8221; (as defined in Rules&#160;13a-15(e) and 15d-15(e) of the Exchange Act) are designed to ensure that all information (both financial and nonfinancial) required to be disclosed by Parent in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that all such information is accumulated and communicated to Parent&#8217;s principal executive officer and principal financial officer as appropriate to allow timely decisions regarding required disclosure and to make the Certifications and such disclosure controls and procedures are effective. Parent has carried out evaluation of the effectiveness of its disclosure controls and procedures as required by Rule&#160;13a-15 of the Exchange Act.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Absence of Changes</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, between December 31, 2023 and the date of this Agreement, Parent has conducted its business only in the Ordinary Course of Business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto) and there has not been any (a) Parent Material Adverse Effect or (b) action, event or occurrence that would have required consent of the Company pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement had such action, event or occurrence taken place after the execution and delivery of this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.9<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Absence of Undisclosed Liabilities</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since December 31, 2023, neither Parent nor any of its Subsidiaries has any Liability except for: (a) Liabilities disclosed, reflected or reserved against in the Parent Balance Sheet, (b) normal and recurring current Liabilities that have been incurred by Parent or its Subsidiaries since the date of the Parent Balance Sheet in the Ordinary Course of Business (none of which relates to any breach of contract, breach of warranty, tort, infringement or violation of Law), (c) Liabilities for performance of obligations of Parent or any of its Subsidiaries under Parent Contracts, (d) Liabilities incurred in connection with the Parent Legacy Business or the Contemplated Transactions, (e) Liabilities described in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter and (f) those Liabilities that are not material to Parent.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.10<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Title to Assets</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each of Parent and its Subsidiaries owns, and has good and valid title to, or, in the case of leased properties and assets, valid leasehold interests in, all tangible properties or tangible assets and equipment used or held for use in its business or operations or purported to be owned by it, including: (a)&#160;all tangible assets reflected on the Parent Balance Sheet and (b) all other tangible assets reflected in the books and records of Parent as being owned by Parent. All of such assets are owned or, in the case of leased assets, leased by Parent or any of its Subsidiaries free and clear of any Encumbrances, other than Permitted Encumbrances.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.11<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Real Property; Leasehold</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Neither Parent nor any of its Subsidiaries owns or has ever owned any real property, nor is Parent party to any agreement to purchase or sell any real property. Parent has made available to the Company (a) an accurate and complete list of&#160;all real properties with respect to which Parent directly or indirectly holds a valid leasehold interest as well as any other real estate that is in the possession of or leased by Parent or any of its Subsidiaries and (b)&#160;copies of all leases under which any such real property is possessed (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Real Estate Leases</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), each of which is in full force and effect, with no existing material default thereunder by Parent or its Subsidiaries or, to Parent&#8217;s Knowledge, the other party thereto.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.12<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Intellectual Property</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter is an accurate, true and complete listing of all Parent Registered IP.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter accurately identifies (i) all Parent Contracts pursuant to which any Parent IP Rights are licensed to Parent (other than (A) any non-customized software that (1) is so licensed solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (2) is not incorporated into, or material to the development, manufacturing, or distribution of, any of Parent products or services, (B) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of services, equipment, reagents or other materials, (C) any confidential information provided under confidentiality agreements and (D) agreements between Parent and its employees in Parent&#8217;s standard form thereof) and (ii) whether the license or licenses granted to Parent are exclusive or nonexclusive.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-40</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter accurately identifies each Parent Contract pursuant to which any Person has been granted any license or covenant not to sue under, or otherwise has received or acquired any right (whether or not currently exercisable) or interest in, any Parent IP Rights (other than (i) any confidential information provided under confidentiality agreements and (ii) any Parent IP Rights nonexclusively licensed to academic collaborators, suppliers or service providers for the sole purpose of enabling such academic collaborator, supplier or service providers to provide services for Parent&#8217;s benefit).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is bound by, and no Parent IP Rights are subject to, any Contract containing any covenant or other provision that in any way limits or restricts the ability of Parent or any of its Subsidiaries to use, exploit, assert, or enforce any Parent IP Rights anywhere in the world.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent or one of its Subsidiaries exclusively owns all right, title, and interest to and in the Parent IP Rights (other than (i) Parent IP Rights licensed to Parent, or co-owned rights each as identified in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, (ii) any non-customized software that (A) is licensed to Parent solely in executable or object code form pursuant to a nonexclusive, internal use software license and other Intellectual Property associated with such software and (B) is not incorporated into, or material to the development, manufacturing or distribution of, any of Parent or its Subsidiaries&#8217; products or services and (iii) any Intellectual Property licensed on a nonexclusive basis ancillary to the purchase or use of equipment, reagents or other materials), in each case, free and clear of any Encumbrances (other than Permitted Encumbrances). Without limiting the generality of the foregoing:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All documents and instruments necessary to register or apply for or renew registration of Parent Registered IP have been validly executed, delivered, and filed in a timely manner with the appropriate Governmental Authority.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Person who is or was an employee or contractor of Parent or any of its Subsidiaries and who is or was involved in the creation or development of any Intellectual Property for Parent or any of its Subsidiaries has signed a valid, enforceable agreement containing a present assignment of such Intellectual Property to Parent or such Subsidiary and confidentiality provisions protecting trade secrets and confidential information of Parent and its Subsidiaries.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of Parent, no current or former stockholder, officer, director or employee of Parent or any of its Subsidiaries has any claim, right (whether currently exercisable, or exercisable in the future), or interest to or in any Parent IP Rights purported to be owned by Parent. To the Knowledge of Parent, no employee of Parent or any of its Subsidiaries is (a) bound by or otherwise subject to any Contract restricting him or her from performing his or her duties for Parent or such Subsidiary or (b) in breach of any Contract with any former employer or other Person concerning Parent IP Rights purported to be owned by Parent or such Subsidiary or confidentiality provisions protecting trade secrets and confidential information comprising Parent IP Rights purported to be owned by Parent or such Subsidiary.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No funding, facilities or personnel of any Governmental Authority were used, directly or indirectly, to develop or create, in whole or in part, any Parent IP Rights in which Parent or any of its Subsidiaries has an ownership interest.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent and each of its Subsidiaries has taken reasonable steps to maintain the confidentiality of and otherwise protect and enforce its rights in all proprietary information that Parent or such Subsidiary holds, or purports to hold, as confidential or a trade secret.</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent or any of its Subsidiaries has not assigned or otherwise transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Parent IP Rights to any other Person.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has delivered, or made available to the Company, a complete and accurate copy of all material Parent IP Rights Agreements.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The manufacture, marketing, offering for sale, sale, importation, use or intended use or other disposal of any product as currently sold or under development by Parent does not violate any license or agreement between Parent or its Subsidiaries and any third party in any material respect, and, to the Knowledge </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-41</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">of Parent, does not infringe or misappropriate any valid and issued Patent right or other Intellectual Property of any other Person, which infringement or misappropriation would reasonably be expected to have a Parent Material Adverse Effect. To the Knowledge of Parent, no third party is infringing upon any Patents owned by Parent within the Parent IP Rights, or violating any Parent IP Rights Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As of the date of this Agreement, Parent is not a party to any Legal Proceeding (including, but not limited to, opposition, interference or other proceeding in any patent or other government office) contesting the validity, ownership or right to use, sell, offer for sale, license or dispose of any Parent IP Rights. Parent has not received any written notice asserting that any Parent Registered IP or the proposed use, sale, offer for sale, license or disposition of any products, methods or processes claimed or covered thereunder infringes or misappropriates or violates the rights of any other Person or that Parent or any of its Subsidiaries have otherwise infringed, misappropriated or otherwise violated any Intellectual Property of any Person.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of Parent, no trademark (whether registered or unregistered) or trade name owned, used or applied for by Parent conflicts or interferes with any trademark (whether registered or unregistered) or trade name owned, used or applied for by any other Person except as would not have a Parent Material Adverse Effect. None of the goodwill associated with or inherent in any trademark (whether registered or unregistered) in which Parent has or purports to have an ownership interest has been impaired as determined by Parent in accordance with GAAP.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as may be set forth in the Contracts listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">4.12(k)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter or as contained in &#8220;off-the-shelf&#8221; license agreements entered into in the Ordinary Course of Business by Parent, (i) Parent is not bound by any Contract to indemnify, defend, hold harmless or reimburse any other Person with respect to any Intellectual Property infringement, misappropriation or similar claim which is material to Parent taken as a whole and (ii) Parent has never assumed, or agreed to discharge or otherwise take responsibility for, any existing or potential liability of another Person for infringement, misappropriation or violation of any Intellectual Property right, which assumption, agreement or responsibility remains in force as of the date of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is party to any Contract that, as a result of such execution, delivery and performance of this Agreement, will cause the grant of any license or other right to any Parent IP Rights, result in breach of, default under or termination of such Contract with respect to any Parent IP Rights, or impair the right of Parent or the Surviving Entity and its Subsidiaries to use, sell or license or enforce any Parent IP Rights or portion thereof, except for the occurrence of any such grant or impairment that would not individually or in the aggregate, reasonably be expected to result in a Parent Material Adverse Effect.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.13<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreements, Contracts and Commitments</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.13</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter identifies each Parent Contract that is in effect as of the date of this Agreement (each, an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Material Contract</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Material Contracts</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;):</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to any material bonus, deferred compensation, severance, incentive compensation, pension, profit-sharing or retirement plans, or any other employee benefit plans or arrangements;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract requiring payments by Parent after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to the employment of, or the performance of employment-related services by, any Parent Associate providing employment related, consulting or independent contractor services, not terminable by Parent on thirty (30) calendar days&#8217; or less notice without liability;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to any agreement or plan, including any option plan, stock appreciation right plan or stock purchase plan, any of the benefits of which will be increased or the vesting of benefits of which will be accelerated, by the occurrence of any of the Contemplated Transactions (either alone or in conjunction with any other event, such as termination of employment), or the value of any of the benefits of which will be calculated on the basis of any of the Contemplated Transactions;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-42</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to any agreement of indemnification or guaranty not entered into in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract containing (A) any covenant limiting the freedom of Parent or any of its Subsidiaries to engage in any line of business or compete with any Person, or limiting the development, manufacture or distribution of the Parent&#8217;s products or services (B) any most-favored pricing arrangement, (C) any exclusivity provision or (D) any non-solicitation provision;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract (A) pursuant to which any Person granted Parent an exclusive license under any Intellectual Property, or (B) pursuant to which Parent granted any Person an exclusive license under any Parent IP Rights;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract containing any royalty, dividend or similar arrangement based on the revenues or profits of Parent, any of its Subsidiaries, or of a product;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(viii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to capital expenditures and requiring payments after the date of this Agreement in excess of $100,000 pursuant to its express terms and not cancelable without penalty;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ix)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to the disposition or acquisition of material assets or any ownership interest in any Entity, in each case, involving payments in excess of $100,000 after the date of this Agreement;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract entered into in settlement of any Legal Proceeding or other dispute pursuant to which Parent or any of its Subsidiaries has outstanding obligations to pay consideration in excess of $100,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract relating to any mortgages, indentures, loans, notes or credit agreements, security agreements or other agreements or instruments relating to the borrowing of money or extension of credit in excess of $100,000 or creating any material Encumbrances with respect to any assets of Parent or any loans or debt obligations with officers or directors of Parent;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract requiring payment by or to Parent after the date of this Agreement in excess of $100,000 pursuant to its express terms relating to: (A) any distribution agreement (identifying any that contain exclusivity provisions), (B) any agreement involving provision of services or products with respect to any pre-clinical or clinical development activities of Parent, (C) any dealer, distributor, joint marketing, alliance, joint venture, cooperation, development or other agreement currently in force under which Parent or any of its Subsidiaries has continuing obligations to develop or market any product, technology or service, or any agreement pursuant to which Parent or any of its Subsidiaries has continuing obligations to develop any Intellectual Property that will not be owned, in whole or in part, by Parent or such Subsidiary or (D) any Contract to license any patent, trademark registration, service mark registration, trade name or copyright registration to or from any third party to manufacture or produce any product, service or technology of Parent or any of its Subsidiaries or any Contract to sell, distribute or commercialize any products or service of Parent or any of its Subsidiaries, in each case, except for Parent Contracts entered into in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract with any Person, including any financial advisor, broker, finder, investment banker or other Person, providing advisory services to Parent in connection with the Contemplated Transactions and requiring payments by Parent after the date in this Agreement in excess of $100,000 pursuant to its express terms;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiv)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>each Parent Contract to which Parent or any of its Subsidiaries is a party or by which any of their assets and properties is currently bound (other than Parent Real Estate Leases), which involves annual obligations of payment by, or annual payments to, Parent or such Subsidiary in excess of $100,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xv)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>any Parent Real Estate Lease;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xvi)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>a Contract disclosed in or required to be disclosed in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.12(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter; or</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-43</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xvii)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>any other Parent Contract (other than Parent Real Estate Leases) that is not terminable at will (with no penalty or payment) by Parent or any of its Subsidiaries, and (A) which involves payment or receipt by Parent or such Subsidiary after the date of this Agreement under any such agreement, contract or commitment of more than $100,000 in the aggregate, or obligations after the date of this Agreement in excess of $100,000 in the aggregate or (B) that is material to the business or operations of Parent and its Subsidiaries taken as a whole.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has delivered or made available to the Company accurate and complete copies of all Parent Material Contracts, including all amendments thereto. There are no Parent Material Contracts that are not in written form. Parent has not nor, to Parent&#8217;s Knowledge as of the date of this Agreement, has any other party to a Parent Material Contract, breached, violated or defaulted under, or received notice that it breached, violated or defaulted under, any of the terms or conditions of any Parent Material Contract in such a manner, and, if such Parent Material Contract provides for a cure period, Parent or such other party fails to have cured such breach, violation or default, so that any other party or Parent, as the case may be, is permitted to modify, cancel or terminate any such Parent Material Contract, or would permit any other party to seek damages which would reasonably be expected to have a Parent Material Adverse Effect. As to Parent and its Subsidiaries, as of the date of this Agreement, each Parent Material Contract is valid, binding, enforceable and in full force and effect, subject to the Enforceability Exceptions. No Person is renegotiating, or has a right pursuant to the terms of any Parent Material Contract to change, any material amount paid or payable to Parent under any Parent Material Contract or any other material term or provision of any Parent Material Contract.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.14<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Compliance; Permits; Restrictions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent and each of its Subsidiaries is, and since January 1, 2023, has been in material compliance with all applicable Laws. No investigation, claim, suit, proceeding, audit, Order or other action by any Governmental Authority is pending or, to the Knowledge of Parent, threatened against Parent or any of its Subsidiaries. There is no agreement or Order binding upon Parent or any of its Subsidiaries which (i)&#160;has or would reasonably be expected to have the effect of prohibiting or materially impairing any business practice of Parent or any of its Subsidiaries, any acquisition of material property by Parent or any of its Subsidiaries or the conduct of business by Parent or any of its Subsidiaries as currently conducted, (ii) is reasonably likely to have an adverse effect on Parent&#8217;s ability to comply with or perform any covenant or obligation under this Agreement or (iii) is reasonably likely to have the effect of preventing, delaying, making illegal or otherwise interfering with the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except for matters regarding the FDA or other Drug/Device Regulatory Agency, each of Parent and its Subsidiaries holds all required Governmental Authorizations that are material to the operation of the business of Parent and Merger Subs as currently conducted (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Permits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.14(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter identifies each Parent Permit. Each of Parent and its Subsidiaries is in material compliance with the terms of the Parent Permits. No Legal Proceeding is pending or, to the Knowledge of Parent, threatened, which seeks to revoke, substantially limit, suspend or materially modify any Parent Permit. The rights and benefits of each Parent Permit, if any, will be available to Parent and Surviving Entity immediately after the Second Effective Time on terms substantially identical to those enjoyed by Parent and its Subsidiaries as of the date of this Agreement and immediately prior to the First Effective Time.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There are no Legal Proceedings pending or, to the Knowledge of Parent, threatened with respect to an alleged violation by Parent or any of its Subsidiaries of the FDCA, PHSA, FDA regulations adopted thereunder, the Controlled Substances Act or any other similar Law promulgated by a Drug/Device Regulatory Agency.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and its Subsidiaries holds all required Governmental Authorizations issuable by any Drug/Device Regulatory Agency necessary for the conduct of the business of Parent and Merger Subs as currently conducted, and, as applicable, the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation, as currently conducted, of any of its product candidates (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Product Candidates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Regulatory Permits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and no such Parent Regulatory Permit has been (i) revoked, withdrawn, suspended, cancelled or terminated or (ii) modified in any adverse manner other than immaterial adverse modifications. Section&#160;4.14(d) of the Parent Disclosure Letter identifies each Parent Regulatory Permit. Parent has timely maintained and is in compliance in all material respects with the Parent Regulatory Permits and neither Parent nor or any of its Subsidiaries has, since January 1, 2023, </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-44</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">received any written notice or correspondence or, to the Knowledge of Parent, other communication from any Drug/Device Regulatory Agency regarding (A) any material violation of or failure to comply materially with any term or requirement of any Parent Regulatory Permit or (B) any revocation, withdrawal, suspension, cancellation, termination or material modification of any Parent Regulatory Permit. Parent has made available to the Company all information requested by the Company in Parent&#8217;s or its Subsidiaries&#8217; possession or control relating to material Parent Product Candidates and the development, testing, manufacturing, processing, storage, labeling, sale, marketing, advertising, distribution and importation or exportation of the Parent Product Candidates, including, but not limited to, complete copies of the following (to the extent there are any): (x) adverse event reports; pre-clinical, clinical and other study reports and material study data; inspection reports, notices of adverse findings, untitled letters, warning letters, filings and letters and other written correspondence to and from any Drug/Device Regulatory Agency; and meeting minutes with any Drug/Device Regulatory Agency and (y) similar reports, material study data, notices, letters, filings, correspondence and meeting minutes with any other Governmental Authority. All such information are accurate and complete in all material respects.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All clinical, pre-clinical and other studies and tests conducted by or on behalf of, or sponsored by, Parent or its Subsidiaries, in which Parent or its Subsidiaries or their respective product candidates, including the Parent Product Candidates, have participated were, since January 1, 2023, and, if still pending, are being conducted in accordance in all material respects with standard medical and scientific research procedures, and in compliance in all material respects with the applicable regulations of the Drug/Device Regulatory Agencies and other applicable Law, including 21 C.F.R. Parts 11, 50, 54, 56, 58, 312 and 812. Since January 1, 2023, neither Parent nor any of its Subsidiaries has received any written notices, correspondence, or other communications from any Drug/Device Regulatory Agency requiring or, to the Knowledge of Parent, any action to place a clinical hold order on, or otherwise terminate, delay or suspend any clinical studies conducted by or on behalf of, or sponsored by, Parent or any of its Subsidiaries or in which Parent or any of its Subsidiaries or its current product candidates, including the Parent Product Candidates, have participated. Further, no clinical investigator, researcher or clinical staff participating in any clinical study conducted by or, to the Knowledge of Parent, on behalf of Parent or any of its Subsidiaries has been disqualified from participating in studies involving the Parent Product Candidates, and to the Knowledge of Parent, no such administrative action to disqualify such clinical investigators, researchers or clinical staff has been threatened or is pending.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries and, to the Knowledge of Parent, any contract manufacturer with respect to any Parent Product Candidate is the subject of any pending or, to the Knowledge of Parent, threatened investigation in respect of its business or products by the FDA pursuant to its &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy set forth in 56 Fed. Reg.&#160;46191 (September 10, 1991) and any amendments thereto or by any other Drug/Device Regulatory Agency under a comparable policy. Neither Parent nor any of its Subsidiaries and, to the Knowledge of Parent, any contract manufacturer, nor their respective officers, employees or agents, with respect to any Parent Product Candidate has committed any acts, made any statement or failed to make any statement, in each case in respect of its business or products that would violate FDA&#8217;s &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221; Final Policy, and any amendments thereto. None of Parent, any of its Subsidiaries, and to the Knowledge of Parent, any contract manufacturer with respect to any Parent Product Candidate, or any of their respective officers, employees or agents is currently or has been debarred, convicted of any crime or is engaging or has engaged in any conduct that could result in a material debarment or exclusion under (i) 21 U.S.C. Section&#160;335a or (ii) any similar applicable Law. To the Knowledge of Parent, no material debarment or exclusionary claims, actions, proceedings or investigations in respect of their business or products are pending or threatened against Parent, any of its Subsidiaries, and to the Knowledge of the Parent, any contract manufacturer with respect to any Parent Product Candidate, or any of its officers, employees or agents.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All manufacturing operations conducted by, or to the Knowledge of Parent, for the benefit of, Parent or its Subsidiaries in connection with any Parent Product Candidate, since January 1, 2023, have been and are being conducted in compliance in all material respects with applicable Laws, including the FDA&#8217;s standards for current good manufacturing practices, including applicable requirements contained in 21 C.F.R. Parts 210 and 211, and the respective counterparts thereof promulgated by Governmental Authorities in countries outside the United States.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-45</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>None of Parent, any of its Subsidiaries, and to the Knowledge of Parent, any manufacturing site of a contract manufacturer or laboratory, with respect to any Parent Product Candidate, (i) is subject to a Drug/Device Regulatory Agency shutdown or import or export prohibition or (ii) has received any Form&#160;FDA 483, notice of violation, warning letter, untitled letter or similar correspondence or notice from the FDA or other Drug/Device Regulatory Agency alleging or asserting noncompliance with any applicable Law, in each case, that have not been complied with or closed to the satisfaction of the relevant Drug/Device Regulatory Agency, and, to the Knowledge of Parent, neither the FDA nor any other Drug/Device Regulatory Agency is considering such action.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.15<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Legal Proceedings; Orders</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no pending Legal Proceeding and, to the Knowledge of Parent, no Person has threatened in writing to commence any Legal Proceeding: (i) that involves Parent or any of its Subsidiaries or any Parent Associate (in his or her capacity as such) or any of the material assets owned or used by Parent or any of its Subsidiaries or (ii) that challenges, or that may have the effect of preventing, delaying, making illegal or otherwise interfering with, the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no Order to which Parent or any of its Subsidiaries, or any of the material assets owned or used by Parent or any of its Subsidiaries is subject. To the Knowledge of Parent, no officer or other Parent Key Employee or any of its Subsidiaries is subject to any Order that prohibits such officer or employee from engaging in or continuing in any conduct, activity or practice relating to the business of Parent or any of its Subsidiaries or any material assets owned or used by Parent or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.16<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Tax Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and each of its Subsidiaries has timely filed (or caused to be timely filed) all income Tax Returns and all other material Tax Returns required to be filed by it under applicable Law (taking into account any applicable extensions). All such Tax Returns were true, correct and complete in all material respects. Subject to exceptions as would not be material, no claim has been made by a Governmental Authority in a jurisdiction where Parent or any of its Subsidiaries does not file Tax Returns that Parent or any of its Subsidiaries is subject to taxation by that jurisdiction.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>All material amounts of Taxes due and owing by Parent or any of its Subsidiaries (whether or not shown on any Tax Return) have been timely paid (taking into account any applicable extensions).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and each of its Subsidiaries has withheld and paid to the appropriate Governmental Authority all material Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, stockholder or other third party.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There are no Encumbrances for a material amount of Taxes (other Encumbrances described in clause&#160;(a) of the definition of &#8220;Permitted Encumbrances&#8221;) upon any of the assets of Parent or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No deficiencies for a material amount of Taxes with respect to Parent or any of its Subsidiaries have been claimed, proposed or assessed by any Governmental Authority in writing that have not been timely paid in full. There are no pending (or, based on written notice, threatened) material audits, assessments, examinations or other actions for or relating to any liability in respect of Taxes of Parent or any of its Subsidiaries. Neither Parent nor any of its Subsidiaries has granted a waiver of any statute of limitations in respect of a material amount of Taxes or an extension of time with respect to a material Tax assessment or deficiency that, in each case, is currently in effect.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is a party to any Tax allocation, Tax sharing or similar agreement (including indemnity arrangements), other than Ordinary Course Agreements.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries has been a member of an affiliated group filing a consolidated U.S. federal income Tax Return (other than a group the common parent of which is Parent). Neither Parent nor any of its Subsidiaries has any material Liability for the Taxes of any Person (other than Parent or its Subsidiaries) under Treasury Regulations Section&#160;1.1502-6 (or any similar provision of state, local, or foreign law), as a transferee or successor, or by Contract (other than an Ordinary Course Agreement).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-46</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries has distributed stock of another Person, or has had its stock distributed by another Person, in a transaction that was purported or intended to be governed in whole or in part by Section&#160;355 of the Code or Section&#160;361 of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries has entered into any transaction identified as a &#8220;listed transaction&#8221; for purposes of Treasury Regulations Sections&#160;1.6011-4(b)(2) or 301.6111-2(b)(2).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is aware of any facts or circumstances or has taken or agreed to take any action, in each case, that would reasonably be expected to prevent or impede the Intended Tax Treatment.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.17<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Employee and Labor Matters; Benefit Plans</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parent has made available to Company a list setting forth, for each Parent Associate who is an employee of Parent or any of its Subsidiaries, such employee&#8217;s name, employer, title, hire date, location, whether full- or part-time, whether active or on leave (and, if on leave, the expected return), whether exempt from the Fair Labor Standards Act and applicable state law, annual salary (or if hourly, hourly rate), most recent annual bonus received and current annual bonus opportunity. The Parent has made available to Company a list setting forth, for each Parent Associate who is an individual independent contractor engaged by Parent or any of its Subsidiaries, such contractor&#8217;s name, duties and rate of compensation.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The employment of Parent&#8217;s employees is terminable by Parent at will. Parent has made available to the Company accurate and complete copies of all employee manuals and handbooks, to the extent currently effective and material.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent is not a party to, bound by the terms of, and does not have a duty to bargain under, any collective bargaining agreement or other Contract with a labor organization representing any of its employees, and there are no labor organizations representing or, to the Knowledge of Parent, purporting to represent or seeking to represent any employees of Parent.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.17(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter lists all Parent Employee Plans (other than employment arrangements which are terminable &#8220;at will&#8221; without any contractual obligation on the part of Parent or any of its Subsidiaries to make any severance, termination, change in control or similar payment and that are substantively identical to the employment arrangements made available to the Company).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Parent Employee Plan that is intended to be qualified under Section&#160;401(a) of the Code has received a favorable determination or opinion letter with respect to such qualified status from the IRS. To the Knowledge of Parent, nothing has occurred that would reasonably be expected to adversely affect the qualified status of any such Parent Employee Plan or the exempt status of any related trust.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Parent Employee Plan has been established, maintained and operated in compliance, in all material respects, with its terms all applicable Law, including, without limitation, the Code, ERISA and the Affordable Care Act. No Legal Proceeding (other than those relating to routine claims for benefits) is pending or, to the Knowledge of Parent, threatened with respect to any Parent Employee Plan. All payments and/or contributions required to have been made with respect to all Parent Employee Plans either have been made or have been accrued in accordance with the terms of the applicable Parent Employee Plan and applicable Law.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its ERISA Affiliates maintains, contributes to or is required to contribute to, or has, in the past six (6) years, maintained, contributed to or been required to contribute to (i) any &#8220;employee benefit plan&#8221; that is or was subject to Title IV or Section&#160;302 of ERISA or Section&#160;412 of the Code, (ii) a Multiemployer Plan, (iii) any funded welfare benefit plan within the meaning of Section&#160;419 of the Code, (iv) any Multiple Employer Plan, or (v) any Multiple Employer Welfare Arrangement. Neither Parent nor any of its ERISA Affiliates has ever incurred any liability under Title IV of ERISA.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No Parent Employee Plan provides for medical or other welfare benefits to any service provider beyond termination of service or retirement, other than (1) pursuant to COBRA or an analogous state law requirement or (2) continuation coverage through the end of the month in which such termination or retirement occurs. Parent does not sponsor or maintain any self-funded medical or long-term disability benefit plan.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-47</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> No Parent Employee Plan is subject to any law of a foreign jurisdiction outside of the United States.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Parent Employee Plan that constitutes in any part a &#8220;nonqualified deferred compensation plan&#8221; (as such term is defined under Section&#160;409A(d)(1) of the Code and the guidance thereunder) (each, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent 409A Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) has been operated and maintained in all material respects in operational and documentary compliance with the requirements of Section&#160;409A of the Code and the applicable guidance thereunder. No payment to be made under any Parent 409A Plan is or, when made in accordance with the terms of the Parent 409A Plan, will be subject to the penalties of Section&#160;409A(a)(1) of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent is in material compliance with all Employment-Related Laws and in each case, with respect to the employees of Parent: (i)&#160;has withheld and reported all material amounts required by law or by agreement to be withheld and reported with respect to wages, salaries and other payments to employees, (ii)&#160;is not liable for any material amounts of arrears of wages, severance pay or any Taxes or any penalty for failure to comply with any of the foregoing and (iii)&#160;is not liable for any material payment to any trust or other fund governed by or maintained by or on behalf of any Governmental Authority, with respect to unemployment compensation benefits, social security or other benefits or obligations for employees (other than routine payments to be made in the Ordinary Course of Business). There are no material Legal Proceedings, claims, labor disputes or organizing activities, or grievances pending or, to the Knowledge of Parent, threatened or reasonably anticipated against or involving Parent or any trustee of Parent relating to any employee, contingent worker, director, employment agreement or Parent Employee Plan (other than routine claims for benefits) or Employment-Related Laws. To the Knowledge of Parent, there are no material pending or threatened or reasonably anticipated claims or actions against Parent, any Parent trustee or any trustee of any Subsidiary of Parent under any workers&#8217; compensation policy or long-term disability policy. Parent is not a party to a conciliation agreement, consent decree or other agreement or Order with any federal, state or local agency or Governmental Authority with respect to employment practices.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(l)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent has no material liability with respect to any misclassification within the past three (3) years of: (i) any Person as an independent contractor rather than as an employee, (ii) any employee leased from another employer or (iii) any employee currently or formerly classified as exempt from overtime wages. Parent has not taken any action which would constitute a &#8220;plant closing&#8221; or &#8220;mass layoff&#8221; within the meaning of the WARN Act, issued any notification of a plant closing or mass layoff required by the WARN Act (nor has Parent been under any requirement or obligation to issue any such notification), or incurred any liability or obligation under the WARN Act that remains unsatisfied.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(m)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>To the Knowledge of Parent, there has never been, nor has there been any threat of, any strike, slowdown, work stoppage, lockout, job action, union, organizing activity, question concerning representation or any similar activity or dispute, with respect to any Parent Associate. No event has occurred within the past six months, and no condition or circumstance exists, that, to the Knowledge of Parent, might directly or indirectly be likely to give rise to or provide a basis for the commencement of any such strike, slowdown, work stoppage, lockout, job action, union organizing activity, question concerning representation or any similar activity or dispute.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(n)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent is not, nor has Parent been, engaged in any material unfair labor practice within the meaning of the National Labor Relations Act. There is no material Legal Proceeding, claim, labor dispute or grievance pending or, to the Knowledge of Parent, threatened or reasonably anticipated relating to any employment contract, privacy right, labor dispute, wages and hours, leave of absence, plant closing notification, workers&#8217; compensation policy, long-term disability policy, harassment, retaliation, immigration, employment statute or regulation, safety or discrimination matter involving any current or former employee of Parent, including charges of unfair labor practices or discrimination complaints.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(o)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>There is no contract, agreement, plan or arrangement to which Parent or any of its Subsidiaries is a party or by which it is bound to compensate any of its employees or other service providers for any income or excise taxes paid pursuant to the Code, including, but not limited to, Section&#160;4999 or Section&#160;409A of the Code.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(p)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Neither Parent nor any of its Subsidiaries is a party to any Contract that as a result of the execution and delivery of this Agreement, the stockholder approval of this Agreement, nor the consummation of the transactions contemplated hereby, could (either alone or in conjunction with any other event) </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-48</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i) result in the payment of any &#8220;parachute payment&#8221; within the meaning of Section&#160;280G of the Code or (ii) result in, or cause the accelerated vesting, payment, funding or delivery of, or increase the amount or value of, any payment or benefit to any employee, officer, director or other service provider of Parent or any of its Subsidiaries.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.18<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Environmental Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since January 1, 2023, Parent and each of its Subsidiaries has complied with all applicable Environmental Laws, which compliance includes the possession by Parent of all permits and other Governmental Authorizations required under applicable Environmental Laws and compliance with the terms and conditions thereof, except for any failure to be in compliance that, individually or in the aggregate, would not result in a Parent Material Adverse Effect. Neither Parent nor any of its Subsidiaries has received since January 1, 2023, any written notice or other communication (in writing or otherwise), whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that Parent or any of its Subsidiaries is not in compliance with any Environmental Law, and, to the Knowledge of Parent, there are no circumstances that may prevent or interfere with Parent&#8217;s or any of its Subsidiaries&#8217; compliance with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Parent Material Adverse Effect. To the Knowledge of Parent: (i) no current or prior owner of any property leased or controlled by Parent or any of its Subsidiaries has received since January 1, 2023, any written notice or other communication relating to property owned or leased at any time by Parent or any of its Subsidiaries, whether from a Governmental Authority, citizens group, employee or otherwise, that alleges that such current or prior owner or Parent or any of its Subsidiaries is not in compliance with or violated any Environmental Law relating to such property and (ii) neither Parent nor any of its Subsidiaries has any material liability under any Environmental Law. Parent has made available all environmental site assessments, environmental audits and other material environmental documents in the Parent&#8217;s possession or control relating to the Parent and its Subsidiaries, including the Parent&#8217;s and its Subsidiaries&#8217; business and current or former facilities.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.19<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Insurance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;"> </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Parent has delivered to the Company accurate and complete copies of all material insurance policies and all material self-insurance programs and arrangements relating to the business, assets, liabilities and operations of Parent and its Subsidiaries (including Merger Subs). Each of such insurance policies is in full force and effect and Parent and its Subsidiaries (including Merger Subs) are in compliance in all material respects with the terms thereof. Other than customary end of policy notifications from insurance carriers, since January 1, 2023, neither Parent nor any of its Subsidiaries has received any notice or other communication regarding any actual or possible: (i) cancellation or invalidation of any insurance policy or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. Each of Parent and its Subsidiaries (including Merger Subs) has provided timely written notice to the appropriate insurance carrier(s) of each Legal Proceeding pending against Parent or such Subsidiary for which Parent or such Subsidiary has insurance coverage, and no such carrier has issued a denial of coverage or a reservation of rights with respect to any such Legal Proceeding, or informed Parent or any of its Subsidiaries of its intent to do so.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.20<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transactions with Affiliates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth in the Parent SEC Documents filed prior to the date of this Agreement, since the date of Parent&#8217;s last proxy statement filed with the SEC, no event has occurred that would be required to be reported by Parent pursuant to Item 404 of Regulation S-K promulgated by the SEC. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.20</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter identifies each Person who is (or who may be deemed to be) an Affiliate of Parent as of the date of this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.21<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Financial Advisors</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.21</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, no broker, finder or investment banker is entitled to any brokerage fee, finder&#8217;s fee, opinion fee, success fee, transaction fee or other fee or commission in connection with the Contemplated Transactions based upon arrangements made by or on behalf of Parent.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.22<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Valid Issuance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parent Capital Stock (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) to be issued in the Merger will, when issued in accordance with the provisions of this Agreement, be validly issued, fully paid and nonassessable. The Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock has been duly reserved for issuance, and upon issuance in accordance with the terms of the Certificate of Designation, will be validly issued, fully paid and nonassessable.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.23<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Privacy and Data Security</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent and its Subsidiaries are and since January 1, 2023, have been in compliance with all applicable Privacy Laws and the applicable terms of any Parent Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-49</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, with respect to, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information (including any such information of individuals, clinical trial participants, patients, patient family members, caregivers or advocates, physicians and other health care professionals, clinical trial investigators, researchers, pharmacists that interact with Parent or any of its Subsidiaries in connection with the operation of Parent&#8217;s and its Subsidiaries&#8217; business), except, in each case, for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. To the Knowledge of Parent, Parent (i) has implemented and maintains reasonable Privacy Policies that materially comply with applicable Privacy Laws and are designed to protect the privacy and security of Personal Information and (ii) has complied with such Privacy Policies, except for such noncompliance as has not had, and would not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect. To the Knowledge of Parent, no Legal Proceeding has been asserted or threatened against Parent by any Person alleging a violation of Privacy Laws, Privacy Policies, or the applicable terms of any Parent Contracts governing privacy, data protection, data security, trans-border data flow, data loss, data theft, or breach notification, data localization, sending solicited or unsolicited electronic mail or text messages, cookies or other tracking technology, with respect to, or the collection, handling, use, maintenance, storage, disclosure, transfer, or other processing of, Personal Information. To the Knowledge of Parent, there have been no data security incidents or data breaches, or other adverse events or incidents that have resulted in any unauthorized access to, or collection, use, disclosure, modification or destruction of, Personal Information or other data in the possession or control of Parent or any service provider acting on behalf of Parent, in each case, where such incident, breach, or event has resulted in a notification obligation to any Person under applicable Law or pursuant to the terms of any Parent Contract.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.24<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Other Representations or Warranties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent hereby acknowledges and agrees that, except for the representations and warranties contained in this Agreement, neither the Company nor any of its Subsidiaries nor any other person on behalf of the Company or its Subsidiaries makes any express or implied representation or warranty with respect to the Company or its Subsidiaries or with respect to any other information provided to Parent, Merger Subs or stockholders or any of their respective Affiliates in connection with the Contemplated Transactions, and (subject to the express representations and warranties of the Company set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (in each case as qualified and limited by the Company Disclosure Letter)) none of Parent, Merger Subs nor any of their respective Representatives or stockholders, has relied on any such information (including the accuracy or completeness thereof).</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;5. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Covenants of the Parties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Operation of Parent&#8217;s Business</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except (i) as expressly contemplated or permitted by this Agreement, (ii)&#160;as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, (iii) as required by applicable Law, or (iv) unless the Company shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the period commencing on the date of this Agreement and continuing until the earlier to occur of the termination of this Agreement pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and the First Effective Time (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Pre-Closing Period</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), Parent shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to (x) conduct its business and operations in the Ordinary Course of Business and in material compliance with all applicable Law and the requirements of all Contracts that constitute Parent Material Contracts and (y) continue to pay material outstanding accounts payable and other material current Liabilities (including payroll) when due and payable.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except (i)&#160;as expressly contemplated or permitted by this Agreement, (ii)&#160;as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#160;of the Parent Disclosure Letter, (iii) as required by applicable Law, or (iv)&#160;with the prior written consent of the Company (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, Parent shall not, nor shall it cause or permit any of Subsidiaries to, do any of the following:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock or repurchase, redeem or otherwise reacquire any shares of its capital stock or other securities, (except for shares of Parent Common Stock from terminated employees, directors or consultants of Parent);</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-50</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>except as required to give effect to anything in contemplation of the Closing, amend any of its Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>sell, issue, grant, pledge or otherwise dispose of or encumber or authorize the issuance of: (A) any capital stock or other security (except for Parent Common Stock issued upon the valid exercise or settlement of outstanding Parent Options or Parent Restricted Stock Units, as applicable), (B)&#160;any option, warrant or right to acquire any capital stock or any other security or (C) any instrument convertible into or exchangeable for any capital stock or other security;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>form any Subsidiary or acquire any equity interest or other interest in any other Entity or enter into a joint venture with any other Entity;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) lend money to any Person, (B) incur or guarantee any indebtedness for borrowed money, (C) guarantee any debt securities of others or (D) make any capital expenditure or commitment in excess of $25,000;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) adopt, establish or enter into any Parent Employee Plan, including, for the avoidance of doubt, any equity awards plans, (B) cause or permit any Parent Employee Plan to be amended other than as required by law or in order to make amendments for the purposes of compliance with Section&#160;409A of the Code, (C) pay any bonus or make any profit-sharing or similar payment to (except with respect to obligations in place on the date of this Agreement pursuant to any Parent Employee Plan disclosed to the Company), or increase the amount of the wages, salary, commissions, fringe benefits or other compensation or remuneration payable to, any of its directors, officers, employees or consultants, (D)&#160;increase the severance or change of control benefits offered to any current or new employees, directors or consultants, or (E)&#160;hire any officer, employee or consultant;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>acquire any material asset or sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such assets or properties;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(viii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>sell, assign, transfer, license, sublicense or otherwise dispose of any material Parent IP Rights (other than pursuant to non-exclusive licenses in the Ordinary Course of Business);</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ix)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>other than in the Ordinary Course of Business: (A) make, change or revoke any material Tax election; (B) file any amended income or other material Tax Return; (C) adopt or change any material accounting method in respect of Taxes; (D) enter into any material Tax closing agreement, settle any material Tax claim or assessment; (E) consent to any extension or waiver of the limitation period applicable to or relating to any material Tax claim or assessment; or (F) surrender any material claim for refund;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>waive, settle or compromise any pending or threatened Legal Proceeding against Parent or any of its Subsidiaries, other than waivers, settlements or agreements (A)&#160;for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B) that do not impose any material restrictions on the operations or businesses of Parent or its Subsidiaries, taken as a whole, or any equitable relief on, or the admission of wrongdoing by Parent or any of its Subsidiaries;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>delay or fail to repay when due any material obligation, including accounts payable and accrued expenses;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>forgive any loans to any Person, including its employees, officers, directors or Affiliate;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>terminate or modify in any material respect, or fail to exercise renewal rights with respect to, any material insurance policy;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-51</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xiv)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) materially change pricing or royalties or other payments set or charged by Parent or any of Subsidiaries to its customers or licensees or (B) agree to materially change pricing or royalties or other payments set or charged by Persons who have licensed Intellectual Property to Parent or any of Subsidiaries;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xv)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>enter into, amend in a manner adverse to Parent or terminate any Parent Material Contract outside of the Ordinary Course of Business; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xvi)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>agree, resolve or commit to do any of the foregoing.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Nothing contained in this Agreement shall give the Company, directly or indirectly, the right to control or direct the operations of Parent prior to the First Effective Time. Prior to the First Effective Time, Parent shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding any provision herein to the contrary (including the foregoing provisions of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">), Parent may:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>engage in the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or winding down of the Parent Legacy Business (including terminating its Parent Real Estate Leases and other Parent Contracts) or the sale, license, transfer, disposition, divestiture or other monetization transaction (i.e., a royalty transaction) or other disposition of any Parent Legacy Business (each, an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Legacy Transaction</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that to the extent any Parent Legacy Transaction results in material obligations of Parent that will extend beyond Closing, such terms shall be reasonably acceptable to the Company and any such post-Closing obligations shall be a reduction to Parent Net Cash; and</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>declare and pay a dividend on the shares of Parent Common Stock outstanding prior to the First Effective Time (excluding for the avoidance of doubt any shares of Parent Common Stock issuable pursuant to the Contemplated Transactions), up to an amount equal in the aggregate to Parent&#8217;s reasonable, good faith approximation of the amount by which Parent Net Cash will exceed $5,000,000 (such dividend, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Pre-Closing Dividend</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and such amount, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Pre-Closing Dividend Amount</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Operation of the Company&#8217;s Business.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except (i) as expressly contemplated or permitted by this Agreement or the Subscription Agreement, (ii)&#160;as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.2(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, (iii) as required by applicable Law, (iv) with respect to the issuance of any Company Notes, which is expressly permitted, or (v)&#160;unless Parent shall otherwise consent in writing (which consent shall not be unreasonably withheld, delayed or conditioned), during the Pre-Closing Period the Company shall, and shall cause its Subsidiaries to, use commercially reasonable efforts to conduct its business and operations in the Ordinary Course of Business and in material compliance with all applicable Law and the requirements of all Contracts that constitute Company Material Contracts.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except (i) as expressly contemplated or permitted by this Agreement, including the Subscription Agreement, (ii)&#160;as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.2(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Company Disclosure Letter, (iii) as required by applicable Law, (iv) with respect to the issuance of any Company Notes, which is expressly permitted, or (v) with the prior written consent of Parent (which consent shall not be unreasonably withheld, delayed or conditioned), at all times during the Pre-Closing Period, the Company shall not, nor shall it cause or permit any of its Subsidiaries to, do any of the following:</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>declare, accrue, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock; or repurchase, redeem or otherwise reacquire any shares of Company Capital Stock or other securities (except for shares of Company Common Stock from terminated employees, directors or consultants of the Company);</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-52</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>except as required to give effect to anything in contemplation of the Closing, amend any of its or its Subsidiaries&#8217; Organizational Documents, or effect or be a party to any merger, consolidation, share exchange, business combination, recapitalization, reclassification of shares, stock split, reverse stock split or similar transaction except, for the avoidance of doubt, the Contemplated Transactions;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>other than in the Ordinary Course of Business, sell, issue grant, or authorize any of the foregoing actions with respect to more than 25% of the shares of Company Capital Stock outstanding as of the date of this Agreement: (A) any capital stock or other security of the Company or any of its Subsidiaries (except for shares of outstanding Company Common Stock issued upon the valid exercise of Company Options or Company Warrants), (B) any option, warrant or right to acquire any capital stock or any other security or (C) any instrument convertible into or exchangeable for any capital stock or other security of the Company or any of its Subsidiaries;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>other than in the Ordinary Course of Business, acquire any equity interest or other interest in any other Entity or enter into a joint venture with any other Entity;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) lend money to any Person, (B) incur or guarantee any indebtedness for borrowed money, or (C) guarantee any debt securities of others;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>acquire any material asset or sell, lease, license or otherwise irrevocably dispose of any of its assets or properties, or grant any Encumbrance with respect to such assets or properties, except in the Ordinary Course of Business;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vii)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>sell, assign, transfer, license, sublicense or otherwise dispose of any material Company IP Rights (other than pursuant to non-exclusive licenses in the Ordinary Course of Business);</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(viii)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>waive, settle or compromise any pending or threatened Legal Proceeding against the Company, other than waivers, settlements or agreements (A) for an amount not in excess of $100,000 in the aggregate (excluding amounts to be paid under existing insurance policies or renewals thereof) and (B) that do not impose any material restrictions on the operations or businesses of the Company or any equitable relief on, or the admission of wrongdoing by the Company;</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ix)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>enter into, amend in a manner adverse to the Company or terminate any Company Material Contract outside of the Ordinary Course of Business; or</span></p>
		<p class="ParaOverride-19" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>agree, resolve or commit to do any of the foregoing.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Nothing contained in this Agreement shall give Parent, directly or indirectly, the right to control or direct the operations of the Company prior to the First Effective Time. Prior to the First Effective Time, the Company shall exercise, consistent with the terms and conditions of this Agreement, complete unilateral control and supervision over its business operations.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Access and Investigation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Subject to the terms of the Confidentiality Agreement, which the Parties agree will continue in full force following the date of this Agreement, during the Pre-Closing Period, upon reasonable notice, Parent, on the one hand, and the Company, on the other hand, shall and shall use commercially reasonable efforts to cause such Party&#8217;s Representatives to: (a) provide the other Party and such other Party&#8217;s Representatives with reasonable access during normal business hours to such Party&#8217;s Representatives, personnel, property and assets and to all existing books, records, Tax Returns, work papers and other documents and information relating to such Party and its Subsidiaries, (b) provide the other Party and such other Party&#8217;s Representatives with such copies of the existing books, records, Tax Returns, work papers, product data, and other documents and information relating to such Party and its Subsidiaries, and with such additional financial, operating and other data and information regarding such Party and its Subsidiaries as the other Party may reasonably request, (c) permit the other Party&#8217;s officers and other employees to meet, upon reasonable notice and during normal business hours, with the chief financial officer and other officers and managers of such Party responsible for such Party&#8217;s financial statements and the internal controls of such Party to discuss such matters as the other Party may deem necessary, and (d) make </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-53</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">available to the other Party copies of any material notice, report or other document filed with or sent to or received from any Governmental Authority in connection with the Contemplated Transactions. Any investigation conducted by either Parent or the Company pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be conducted in such manner as not to interfere unreasonably with the conduct of the business of the other Party.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything herein to the contrary in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, no access or examination contemplated by this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be permitted to the extent that it would require any Party or its Subsidiaries to waive the attorney-client privilege or attorney work product privilege, or violate any applicable Law; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that such Party or its Subsidiary (i) shall be entitled to withhold only such information that may not be provided without causing such violation or waiver, (ii) shall provide to the other Party all related information that may be provided without causing such violation or waiver (including, to the extent permitted, redacted versions of any such information) and (iii) shall enter into such effective and appropriate joint-defense agreements or other protective arrangements as may be reasonably requested by the other Party in order that all such information may be provided to the other Party without causing such violation or waiver.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Solicitation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each of Parent and the Company agrees that, during the Pre-Closing Period, neither it nor any of its Subsidiaries shall, nor shall it or any of its Subsidiaries authorize or permit any of its Representatives to, directly or indirectly: (i) solicit, initiate or knowingly encourage, induce or facilitate the communication, making, submission or announcement of any Acquisition Proposal or Acquisition Inquiry, (ii)&#160;furnish any non-public information regarding such Party to any Person in connection with or in response to an Acquisition Proposal or Acquisition Inquiry, (iii) engage in discussions or negotiations with any Person with respect to any Acquisition Proposal or Acquisition Inquiry, (iv)&#160;execute or enter into any letter of intent or any Contract contemplating or otherwise relating to any Acquisition Transaction or (v) publicly propose to do any of the foregoing; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that, notwithstanding anything contained in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and subject to compliance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, prior to the approval of this Agreement by a Party&#8217;s stockholders (i.e., the Required Company Stockholder Vote, in the case of the Company and its Subsidiaries, or the Required Parent Stockholder Vote in the case of Parent), such Party may furnish non-public information regarding such Party and its Subsidiaries to, and enter into discussions or negotiations with, any Person in response to a bona fide written Acquisition Proposal by such Person which such Party&#8217;s board of directors determines in good faith, after consultation with such Party&#8217;s financial advisors and outside legal counsel, constitutes, or is reasonably likely to result in, a Superior Offer (and is not withdrawn) if: (A) such Acquisition Proposal was not obtained or made as a direct or indirect result of a breach of this Agreement, (B) the board of directors of such Party concludes in good faith based on the advice of outside legal counsel, that the failure to take such action would reasonably be expected to be inconsistent with the board of directors&#8217; fiduciary duties under applicable Law, (C) at least two&#160;(2) Business Days prior to initially furnishing any such nonpublic information to, or entering into discussions with, such Person, such Party gives the other Party written notice of the identity of such Person and of such Party&#8217;s intention to furnish nonpublic information to, or enter into discussions with, such Person, (D) such Party receives from such Person an executed Acceptable Confidentiality Agreement and (E) at least two&#160;(2) Business Days prior to furnishing any such nonpublic information to such Person, such Party furnishes such nonpublic information to the other Party (to the extent such information has not been previously furnished by such Party to the other Party). Without limiting the generality of the foregoing, each Party acknowledges and agrees that, in the event any Representative of such Party takes any action that, if taken by such Party, would constitute a breach of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> by such Party, the taking of such action by such Representative shall be deemed to constitute a breach of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> by such Party for purposes of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If any Party or any Representative of such Party receives an Acquisition Proposal or Acquisition Inquiry at any time during the Pre-Closing Period, then such Party shall promptly (and in no event later than one&#160;(1) Business Day after such Party becomes aware of such Acquisition Proposal or Acquisition Inquiry) advise the other Party in writing of such Acquisition Proposal or Acquisition Inquiry (including the identity of the Person making or submitting such Acquisition Proposal or Acquisition Inquiry, and the terms thereof). Such Party shall keep the other Party reasonably informed with respect to the status and terms of any such Acquisition Proposal or Acquisition Inquiry and any material modification or material proposed modification thereto.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-54</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Each Party shall immediately cease and cause to be terminated any existing discussions, negotiations and communications with any Person that relate to any Acquisition Proposal or Acquisition Inquiry as of the date of this Agreement and request the destruction or return of any nonpublic information provided to such Person.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notification of Certain Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. During the Pre-Closing Period, each of the Company, on the one hand, and Parent, on the other hand, shall promptly notify the other (and, if in writing, furnish copies of) if any of the following occurs: (a) any notice or other communication is received from any Person alleging that the Consent of such Person is or may be required in connection with any of the Contemplated Transactions, (b)&#160;any Legal Proceeding against or involving or otherwise affecting such Party or its Subsidiaries is commenced, or, to the Knowledge of such Party, threatened against such Party or, to the Knowledge of such Party, any director or officer of such Party, (c) such Party becomes aware of any inaccuracy in any representation or warranty made by such Party in this Agreement or (d) the failure of such Party to comply with any covenant or obligation of such Party; in each case that could reasonably be expected to make the timely satisfaction of any of the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, as applicable, impossible or materially less likely. No such notice shall be deemed to supplement or amend the Company Disclosure Letter or the Parent Disclosure Letter for the purpose of (x)&#160;determining the accuracy of any of the representations and warranties made by the Company in this Agreement or (y) determining whether any condition set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> has been satisfied. Any failure by either Party to provide notice pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be deemed to be a breach for purposes of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, as applicable, unless such failure to provide such notice was knowing and intentional.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;6. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Additional Agreements of the Parties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Registration Statement, Proxy Statement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As promptly as practicable after the date of this Agreement, Parent, in cooperation with the Company, shall prepare and file with the SEC a registration statement on Form S-4 (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Form S-4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), in which a proxy statement relating to the Parent Stockholder Meeting to be held in connection with the Merger (together with any amendments thereof or supplements thereto, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Proxy Statement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall be included as a part (the Proxy Statement and the Form S-4, collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Registration Statement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), in connection with the registration under the Securities Act of the shares of Parent Common Stock (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) to be issued by virtue of the Contemplated Transactions, other than any shares of Parent Capital Stock which are not permitted to be registered on Form S-4 pursuant to applicable Law. Parent shall use commercially reasonable efforts to (i) cause the Registration Statement to comply with applicable rules and regulations promulgated by the SEC, (ii) cause the Registration Statement to become effective as promptly as practicable, and (iii) respond promptly to any comments or requests of the SEC or its staff related to the Registration Statement. Parent shall use commercially reasonable efforts to take all actions required under any applicable federal, state, securities and other Laws in connection with the issuance of shares of Parent Capital Stock pursuant to the Contemplated Transactions (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock). Each of the Parties shall reasonably cooperate with the other Party and furnish all information concerning itself and its Affiliates, as applicable, to the other Parties that is required by law to be included in the Registration Statement as the other Parties may reasonably request in connection with such actions and the preparation of the Registration Statement and Proxy Statement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent covenants and agrees that the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith) will (i) comply as to form in all material respects with the requirements of applicable U.S. federal securities laws and the DGCL and DLLCA, and (ii)&#160;will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company covenants and agrees that the information supplied by or on behalf of the Company to Parent for inclusion in the Registration Statement (including the Company Budget) will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make such information, in light of the circumstances under which they were made, not misleading. Notwithstanding the foregoing, neither Party makes any covenant, representation or warranty with respect to statements made in the Registration Statement (and the letter to stockholders, notice of meeting and form of proxy included therewith), if any, based on information provided by the other Party or any of its Representatives regarding such other Party or its Affiliates for inclusion therein.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-55</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent shall use commercially reasonable efforts to cause the Proxy Statement to be mailed to Parent&#8217;s stockholders as promptly as practicable after the Registration Statement is declared effective under the Securities Act. If at any time before the First Effective Time, (i)&#160;Parent, Merger Subs or the Company (A) become aware of any event or information that, pursuant to the Securities Act or the Exchange Act, should be disclosed in an amendment or supplement to the Registration Statement or Proxy Statement, (B) receives notice of any SEC request for an amendment or supplement to the Registration Statement or for additional information related thereto, or (C) receives SEC comments on the Registration Statement, or (ii) the information provided in the Registration Statement has become &#8220;stale&#8221; and new information should be disclosed in an amendment or supplement to the Registration Statement, as the case may be, then such Party, as the case may be, shall promptly inform the other Parties thereof and shall cooperate with such other Parties in Parent filing such amendment or supplement with the SEC (and, if appropriate, in mailing such amendment or supplement to the Parent stockholders) or otherwise addressing such SEC request or comments and each Party and shall use their commercially reasonable efforts to cause any such amendment to become effective, if required. Parent shall promptly notify the Company if it becomes aware (1) that the Registration Statement has become effective, (2) of the issuance of any stop order or suspension of the qualification or registration of the Parent Capital Stock issuable in connection with the Contemplated Transactions (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) for offering or sale in any jurisdiction, or (3) any order of the SEC related to the Registration Statement, and shall promptly provide to the Company copies of all written correspondence between it or any of its Representatives, on the one hand, and the SEC or staff of the SEC, on the other hand, with respect to the Registration Statement and all orders of the SEC relating to the Registration Statement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company shall reasonably cooperate with Parent and provide, and cause its Representatives to provide, Parent and its Representatives, with all true, correct and complete information regarding the Company that is required by Law to be included in the Registration Statement or reasonably requested by Parent to be included in the Registration Statement (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Required S-4 Information</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Without limiting the foregoing, the Company will use commercially reasonable efforts to cause to be delivered to Parent a consent letter of the Company&#8217;s independent accounting firm, dated no more than two (2) Business Days before the date on which the Registration Statement is filed with the SEC (and reasonably satisfactory in form and substance to Parent), that is customary in scope and substance for consent letters delivered by independent public accountants in connection with registration statements similar to the Registration Statement. The Company and its legal counsel shall be given reasonable opportunity to review and comment on the Registration Statement, including all amendments and supplements thereto, prior to the filing thereof with the SEC, and on the response to any comments of the SEC on the Registration Statement, prior to the filing thereof with the SEC. Parent may file the Registration Statement, or any amendment or supplement thereto, without the prior consent of the Company, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that Parent has included the Company Required S-4 Information in the Registration Statement in substantially the same form as it was provided to Parent by the Company pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that if the prior consent of the Company is not obtained then, notwithstanding anything else herein, the Company makes no covenant or representation regarding the portion of such information supplied by or on behalf of the Company to Parent for inclusion in such Registration Statement that the Company reasonably identifies prior to such filing of the Registration Statement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As promptly as reasonably practicable following the date of this Agreement, the Company will use commercially reasonable efforts to furnish to Parent (i) audited financial statements for each of its fiscal years required to be included in the Registration Statement, or an audited period balance sheet, as applicable (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Audited Financial Statements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) unaudited interim financial statements for each interim period completed prior to Closing that would be required to be included in the Registration Statement or any periodic report due prior to the Closing if the Company were subject to the periodic reporting requirements under the Securities Act or the Exchange Act (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Interim Financial Statements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Each of the Company Audited Financial Statements and the Company Interim Financial Statements will be suitable for inclusion in the Registration Statement and prepared in accordance with GAAP as applied on a consistent basis during the periods involved (except in each case as described in the notes thereto) and on that basis will present fairly, in all material respects, the financial position and the results of operations, changes in stockholders&#8217; equity and cash flows of the Company as of the dates of and for the periods referred to in the Company Audited Financial Statements or the Company Interim Financial Statements, as the case may be.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-56</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company Stockholder Written Consent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Promptly after the Registration Statement has been declared effective under the Securities Act, and in any event no later than two (2) Business Days thereafter, the Company shall obtain the approval by written consent from Company stockholders sufficient for the Required Company Stockholder Vote in lieu of a meeting pursuant to Section&#160;228 of the DGCL, for purposes of (i)&#160;adopting and approving this Agreement and the Contemplated Transactions, (ii) acknowledging that the approval given thereby is irrevocable and that such stockholder is aware of its rights to demand appraisal for its shares pursuant to Section&#160;262 of the DGCL, and that such stockholder has received and read a copy of Section&#160;262 of the DGCL and (iii) acknowledging that by its approval of the Merger it is not entitled to appraisal rights with respect to its shares in connection with the Merger and thereby waives any rights to receive payment of the fair value of its capital stock under the DGCL (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Stockholder Written Consents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Under no circumstances shall the Company assert that any other approval or consent is necessary by its stockholders to approve this Agreement and the Contemplated Transactions.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Reasonably promptly following receipt of the Required Company Stockholder Vote, and in any event no later than ten (10) days thereafter, the Company shall prepare and mail a notice (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Stockholder Notice</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) to every stockholder of the Company that did not execute the Company Stockholder Written Consent. The Stockholder Notice shall (i) be a statement to the effect that the Company Board determined that the Merger is advisable in accordance with Section&#160;251(b) of the DGCL and in the best interests of the stockholders of the Company and approved and adopted this Agreement, the Merger and the other Contemplated Transactions, (ii) provide the stockholders of the Company to whom it is sent with notice of the actions taken in the Company Stockholder Written Consent, including the adoption and approval of this Agreement, the Merger and the other Contemplated Transactions in accordance with Section&#160;228(e) of the DGCL and the certificate of incorporation and bylaws of the Company and (iii) include a description of the appraisal rights of the Company&#8217;s stockholders available under the DGCL, along with such other information as is required thereunder and pursuant to applicable Law. All materials (including any amendments thereto) submitted to the stockholders of the Company in accordance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be subject to Parent&#8217;s advance review and reasonable approval.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company agrees that, subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">: (i) the Company Board shall recommend that the Company&#8217;s stockholders vote to adopt and approve this Agreement and the Contemplated Transactions and shall use commercially reasonable efforts to solicit such approval within the time set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (the recommendation of the Company Board that the Company&#8217;s stockholders vote to adopt and approve this Agreement being referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Board Recommendation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and (ii) the Company Board Recommendation shall not be withdrawn or modified (and the Company Board shall not publicly propose to withdraw or modify the Company Board Recommendation) in a manner adverse to Parent, and no resolution by the Company Board or any committee thereof to withdraw or modify the Company Board Recommendation in a manner adverse to Parent or to adopt, approve or recommend (or publicly propose to adopt, approve or recommend) any Acquisition Proposal shall be adopted or proposed.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything to the contrary contained in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, and subject to compliance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, if at any time prior to approval and adoption of this Agreement by the Required Company Stockholder Vote, (i) the Company receives a bona fide written Acquisition Proposal that the Company Board determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer, or (ii) as a result of a material development or change in circumstances (other than any such event, development or change to the extent related to (A) any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof or (B) the fact, in and of itself, that the Company meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations) that affects the business, assets or operations of the Company that occurs or arises after the date of this Agreement (a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Intervening Event</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Company Board may withhold, amend, withdraw or modify the Company Board Recommendation (or publicly propose to withhold, amend, withdraw or modify the Company Board Recommendation) in a manner adverse to Parent (collectively, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Board Adverse Recommendation Change</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) if, but only if, (x) in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (i) the Company Board determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (ii) the Company has, during the Notice Period (as defined below), negotiated with Parent in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer and (iii) if, Parent has delivered </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-57</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">to the Company a written offer to alter the terms or conditions of this Agreement during the Notice Period, the Company Board shall have determined in good faith, based on the advice of its outside legal counsel and financial advisor, that the failure to withhold, amend, withdraw or modify the Company Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that (1) Parent receives written notice from the Company confirming that the Company Board has determined to change its recommendation at least four&#160;(4) Business Days in advance of the Company Board Adverse Recommendation Change (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Notice Period</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), which notice shall include a description in reasonable detail of the reasons for such Company Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (2) during any Notice Period, Parent shall be entitled to deliver to the Company one or more counterproposals to such Acquisition Proposal and the Company will, and cause its Representatives to, negotiate with Parent in good faith (to the extent Parent desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (3) in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration the Company&#8217;s stockholders would receive as a result of such potential Superior Offer), the Company shall be required to provide Parent with notice of such material amendment and the Notice Period shall be extended, if applicable, to ensure that at least three (3) Business Days remain in the Notice Period following such notification during which the parties shall comply again with the requirements of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and the Company Board shall not make a Company Board Adverse Recommendation Change prior to the end of such Notice Period as so extended (it being understood that there may be multiple extensions) or (y) in the case of a Company Intervening Event, the Company promptly notifies Parent, in writing, within the Notice Period before making a Company Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the applicable Company Intervening Event and that the Company Board intends to make a Company Board Adverse Recommendation Change.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Company&#8217;s obligation to solicit the consent of its stockholders to sign the Company Stockholder Written Consent in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer or other Acquisition Proposal or Acquisition Inquiry, or by any Company Board Adverse Recommendation Change.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Stockholder Meeting</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent shall take all action necessary under applicable Law to call, give notice of and hold a meeting of the holders of Parent Common Stock to consider and vote to approve this Agreement and thereby approve the Contemplated Transactions and the Parent Charter Amendment and, if deemed necessary by Parent the approval of the Parent Legacy Transaction (collectively, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Stockholder Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; and such meeting, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Stockholder Meeting</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The Parent Stockholder Meeting shall be held as promptly as practicable after the date that the Registration Statement is declared effective under the Securities Act, and in any event, no later than 45 days after the effective date of the Registration Statement. Parent shall take reasonable measures to ensure that all proxies solicited in connection with the Parent Stockholder Meeting are solicited in compliance with all applicable Law. Notwithstanding anything to the contrary contained herein, if on the date of the Parent Stockholder Meeting, or a date preceding the date on which the Parent Stockholder Meeting is scheduled, Parent reasonably believes that (i) it will not receive proxies sufficient to obtain the Required Parent Stockholder Vote, whether or not a quorum would be present, (ii) it will not have sufficient shares of Parent Common Stock represented (whether in person or by proxy) to constitute a quorum necessary to conduct the business of the Parent Stockholder Meeting or (iii) that the failure to postpone or adjourn the Parent Stockholder Meeting would reasonably be expected to be inconsistent with its fiduciary obligations under applicable Law, Parent may postpone or adjourn, or make one or more successive postponements or adjournments of, the Parent Stockholder Meeting as long as the date of the Parent Stockholder Meeting is not postponed or adjourned more than an aggregate of 30 days in connection with any postponements or adjournments.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent agrees that (i) the Parent Board shall recommend that the holders of Parent Common Stock vote to approve the Parent Stockholder Matters and shall use commercially reasonable efforts to solicit such approval within the timeframe set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> above and (ii) the Proxy Statement shall include a statement to the effect that the Parent Board recommends that Parent&#8217;s stockholders vote to approve the Parent Stockholder Matters (the recommendation of the Parent Board being referred to as the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Board Recommendation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-58</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything to the contrary contained in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, and subject to compliance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, if at any time prior to approval and adoption of this Agreement by the Required Parent Stockholder Vote, (i) Parent receives a bona fide written Acquisition Proposal that the Parent Board determines, following consultation with its outside legal counsel and financial advisor, to be a Superior Offer, the Parent Board may withhold, amend, withdraw or modify the Parent Board Recommendation (or publicly propose to withhold, amend, withdraw or modify the Parent Board Recommendation) in a manner adverse to the Company or (ii) as a result of a material development or change in circumstances (other than any such event, development or change to the extent related to (A) any Acquisition Proposal, Acquisition Inquiry, Acquisition Transaction or the consequences thereof, (B) the fact, in and of itself, that Parent meets or exceeds internal budgets, plans or forecasts of its revenues, earnings or other financial performance or results of operations or (C) any Parent Legacy Transaction) that affects the business, assets or operations of Parent that occurs or arises after the date of this Agreement (a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Intervening Event</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), (collectively, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Board Adverse Recommendation Change</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) if, but only if, (x) in the case of a Superior Offer, following the receipt of and on account of such Superior Offer, (i) the Parent Board determines in good faith, based on the advice of its outside legal counsel, that the failure to withhold, amend, withdraw or modify the Parent Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law, (ii) Parent has, and has caused its financial advisors and outside legal counsel to, during the Parent Notice Period (as defined below), negotiated with the Company in good faith to make such adjustments to the terms and conditions of this Agreement so that such Acquisition Proposal ceases to constitute a Superior Offer, and (iii) if, after the Company has delivered to Parent a written offer to alter the terms or conditions of this Agreement during the Parent Notice Period, the Parent Board shall have determined in good faith, based on the advice of its outside legal counsel and financial advisor, that the failure to withhold, amend, withdraw or modify the Parent Board Recommendation would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law (after taking into account such alterations of the terms and conditions of this Agreement); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that (1) the Company receives written notice from Parent confirming that the Parent Board has determined to change its recommendation at least four (4) Business Days in advance of the Parent Board Adverse Recommendation Change (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Notice Period</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), which notice shall include a description in reasonable detail of the reasons for such Parent Board Adverse Recommendation Change, and written copies of any relevant proposed transaction agreements with any party making a potential Superior Offer, (2) during any Parent Notice Period, the Company shall be entitled to deliver to Parent one or more counterproposals to such Acquisition Proposal and Parent will, and cause its Representatives to, negotiate with the Company in good faith (to the extent the Company desires to negotiate) to make such adjustments in the terms and conditions of this Agreement so that the applicable Acquisition Proposal ceases to constitute a Superior Offer and (3) in the event of any material amendment to any Superior Offer (including any revision in the amount, form or mix of consideration the Parent&#8217;s stockholders would receive as a result of such potential Superior Offer), Parent shall be required to provide the Company with notice of such material amendment and the Parent Notice Period shall be extended, if applicable, to ensure that at least three (3) Business Days remain in the Parent Notice Period following such notification during which the parties shall comply again with the requirements of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(c)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and the Parent Board shall not make a Parent Board Adverse Recommendation Change prior to the end of such Parent Notice Period as so extended (it being understood that there may be multiple extensions) or (y) in the case of a Parent Intervening Event, Parent promptly notifies the Company, in writing, within the Parent Notice Period before making a Parent Board Adverse Recommendation Change, which notice shall state expressly the material facts and circumstances related to the applicable Parent Intervening Event and that the Parent Board intends to make a Parent Board Adverse Recommendation Change.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent&#8217;s obligation to call, give notice of and hold the Parent Stockholder Meeting in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be limited or otherwise affected by the commencement, disclosure, announcement or submission of any Superior Offer, Acquisition Proposal or Acquisition Inquiry, or by any Parent Board Adverse Recommendation Change.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Nothing contained in this Agreement shall prohibit Parent or the Parent Board from (i) complying with Rules&#160;14d-9 and 14e-2(a) promulgated under the Exchange Act; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that any disclosure made by Parent or the Parent Board pursuant to Rules&#160;14d-9 and 14e-2(a) shall be limited to a statement that Parent is unable to take a position with respect to the bidder&#8217;s tender offer unless the Parent Board determines in good faith, after consultation with its outside legal counsel, that such statement would reasonably be expected to be inconsistent with its fiduciary duties under applicable Law; (ii) complying with Item 1012(a) of Regulation </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-59</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">M-A promulgated under the Exchange Act; (iii) informing any Person of the existence of the provisions contained in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; or (iv) making any disclosure to the stockholders of Parent that the Parent Board (or a committee thereof), after consultation with its outside legal counsel, has determined in good faith is required by applicable Law.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Efforts; Regulatory Approvals.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parties shall use reasonable best efforts to consummate the Contemplated Transactions. Without limiting the generality of the foregoing, each Party: (i) shall make all filings and other submissions (if any) and give all notices (if any) required to be made and given by such Party in connection with the Contemplated Transactions, (ii) shall use commercially reasonable efforts to obtain each Consent (if any) reasonably required to be obtained (pursuant to any applicable Law or Contract, or otherwise) by such Party in connection with the Contemplated Transactions or for such Contract to remain in full force and effect, (iii) shall use commercially reasonable efforts to lift any injunction prohibiting, or any other legal bar to, the Contemplated Transactions and (iv)&#160;shall use commercially reasonable efforts to satisfy the conditions precedent to the consummation of this Agreement.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding the generality of the foregoing, each Party shall use commercially reasonable efforts to file or otherwise submit, as soon as practicable after the date of this Agreement, all applications, notices, reports and other documents reasonably required to be filed by such Party with or otherwise submitted by such Party to any Governmental Authority with respect to the Contemplated Transactions, and to submit promptly any additional information requested by any such Governmental Authority. Without limiting the generality of the foregoing, the Parties shall prepare and file, if required, (a) the notification and report forms required to be filed under the Hart&#8211;Scott&#8211;Rodino Antitrust Improvements Act of 1976 and (b) any notification or other document required to be filed in connection with the Merger under any applicable foreign Law relating to antitrust or competition matters, no later than ten (10) Business Days after the date the Company and Parent receive notification (in writing or otherwise) from the Federal Trade Commission, the Department of Justice, any state attorney general, foreign antitrust or competition authority or other Governmental Authority that a filing is required in connection with antitrust or competition matters.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Without limiting the generality of the foregoing, Parent shall give the Company prompt written notice (email being sufficient) of any litigation against Parent and/or its directors relating to this Agreement or the Contemplated Transactions (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Transaction Litigation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) (including by providing copies of all pleadings with respect thereto) and keep the Company reasonably informed with respect to the status thereof. Parent will (i) give the Company the opportunity to participate in, but not control, the defense, settlement or prosecution of any Transaction Litigation (to the extent that the attorney-client privilege is not undermined or otherwise adversely affected; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that Parent and the Company will use commercially reasonable efforts to find alternative solutions to not undermine or adversely effect the privilege such as entering into common interest agreements, joint defense agreements or similar agreements), (ii) consult with the Company with respect to the defense, settlement and prosecution of any Transaction Litigation and (iii) consider in good faith the Company&#8217;s advice with respect to such Transaction Litigation. Parent will obtain the prior written consent of the Company (such consent not to be unreasonably withheld, conditioned or delayed) prior to settling or satisfying any such claim.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company Options; Company Warrants</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the First Effective Time, Parent shall assume each Company Stock Plan and each Company Option, whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall, at the First Effective Time, cease to represent a right to acquire shares of Company Common Stock and shall be converted, at the First Effective Time, into an option to purchase shares of Parent Common Stock (an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Assumed Option</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), on the same terms and conditions (including any vesting provisions and any provisions providing for accelerated vesting upon certain events) as were applicable under such Company Option as of immediately prior to the First Effective Time, except for administrative or ministerial changes as determined by the Company Board (or, following the First Effective Time, the Parent Board or compensation committee). The number of shares of Parent Common Stock subject to each such Assumed Option shall be equal to (i) the number of shares of Company Common Stock subject to the respective Company Option immediately prior to the First Effective Time multiplied by (ii)&#160;the Exchange Ratio, rounded down, if necessary, to the nearest whole share of Parent Common Stock, and such Assumed Option shall have an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of the Company Common Stock otherwise purchasable pursuant to the respective Company Option immediately prior to the First Effective Time divided by (B) the Exchange Ratio; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in the case of any Company Option </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-60</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">to which Section&#160;421 of the Code applies as of immediately prior to the First Effective Time (taking into account the effect of any accelerated vesting thereof, if applicable) by reason of its qualification under Section&#160;422 of the Code, the exercise price, the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall be determined in a manner consistent with the requirements of Section&#160;424(a) of the Code; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in the case of any Assumed Option to which Section&#160;409A of the Code applies as of the First Effective Time, the exercise price, the number of shares of Parent Common Stock subject to such option and the terms and conditions of exercise of such option shall be determined in a manner consistent with the requirements of Section&#160;409A of the Code in order to avoid the imposition of any additional taxes thereunder. The Company Board shall, prior to the First Effective Time, take all actions necessary to effect the foregoing.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>At the First Effective Time, each Company Warrant (including any pre-funded Company Warrant issued pursuant to the Company Pre-Closing Financing), whether vested or unvested, that is outstanding immediately prior to the First Effective Time shall, at the First Effective Time, cease to represent a right to acquire shares of Company Capital Stock and shall be converted, at the First Effective Time, into a warrant to purchase shares of Parent Common Stock (an &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Assumed Warrant</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), on the same terms and conditions (including any vesting provisions and any provisions providing for accelerated vesting upon certain events) as were applicable under such Assumed Warrant as of immediately prior to the First Effective Time. The number of shares of Parent Common Stock subject to each such Assumed Warrant shall be equal to (i) the number of shares of the Company Common Stock subject to each Assumed Warrant immediately prior to the First Effective Time multiplied by (ii)&#160;the Exchange Ratio, rounded down, if necessary, to the nearest whole share of Parent Common Stock, and such Assumed Warrant shall have an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of the Company Common Stock otherwise purchasable pursuant to such Assumed Warrant immediately prior to the First Effective Time divided by (B) the Exchange Ratio.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Employee Benefits</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent shall comply with the terms of any employment, severance, retention, change of control, or similar agreement specified on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;4.17(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or contemplated by </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter, subject to the provisions of such agreements.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From and after the First Effective Time, with respect to each benefit plan maintained by Parent or the Surviving Entity that is an &#8220;employee welfare benefit plan&#8221; as defined in Section&#160;3(1) of ERISA (each, a &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Post-Closing Welfare Plan</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) in which any current or former employee of Parent is or becomes eligible to participate (including under COBRA), Parent and the Surviving Entity shall use commercially reasonable efforts to cause each such Post-Closing Welfare Plan to (i) waive all limitations as to pre-existing conditions, waiting periods, required physical examinations and exclusions with respect to participation and coverage requirements applicable under such Post-Closing Welfare Plan for such current or former Parent employee and his or her eligible dependents to the same extent that such pre-existing conditions, waiting periods, required physical examinations and exclusions would not have applied or would have been waived under the corresponding Parent Employee Plan in which such current or former Parent employee was a participant immediately prior to his or her commencement of participation in such Post-Closing Welfare Plan, and (ii) provide each such current or former Parent employee and his or her eligible dependents with credit for any co-payments and deductibles paid in the plan year that includes the First Effective Time, and prior to the date that, such current or former Parent employee commences participation in such Post-Closing Welfare Plan in satisfying any applicable co-payment or deductible requirements under such Post-Closing Welfare Plan for the applicable plan year, to the extent that such expenses were recognized for such purposes under the comparable Parent Employee Plan.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>As of immediately prior to the First Effective Time, each Parent Option that is then outstanding but not then vested or exercisable shall become immediately vested and exercisable in full. At the First Effective Time, each In the Money Parent Option that is then outstanding shall be canceled and the holder thereof shall be entitled to receive (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (A) the excess of the Parent Closing Price over the exercise price per share of the Parent Common Stock underlying such Parent Option by (B) the number of shares of the Parent Common Stock underlying such Parent Option (such amount, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Parent Stock Option Cash Consideration</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Parent shall cause the Surviving Entity to pay the Parent Stock Option Cash Consideration, less applicable withholdings, at or </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-61</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">within ten (10) business days after the First Effective Time. At the First Effective Time, each Out of the Money Parent Option shall be cancelled for no consideration. Prior to the Closing, the Parent Board shall have adopted appropriate resolutions and taken all other actions necessary and appropriate to provide for the foregoing.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Indemnification of Officers and Directors</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From the First Effective Time through the sixth anniversary of the date on which the First Effective Time occurs, each of Parent and the Surviving Entity shall indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the First Effective Time, a director or officer of Parent or the Company, respectively (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">D&amp;O Indemnified Parties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including attorneys&#8217; fees and disbursements (collectively, &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Costs</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the D&amp;O Indemnified Party is or was a director or officer of Parent or of the Company, whether asserted or claimed prior to, at or after the First Effective Time, in each case, to the fullest extent permitted under the DGCL. Each D&amp;O Indemnified Party will be entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Parent and the Surviving Entity, jointly and severally, upon receipt by Parent or the Surviving Entity from the D&amp;O Indemnified Party of a request therefor; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that any such person to whom expenses are advanced provides an undertaking to Parent, to the extent then required by the DGCL, to repay such advances if it is ultimately determined that such person is not entitled to indemnification. Without otherwise limiting the D&amp;O Indemnified Parties&#8217; rights with regards to counsel, following the First Effective Time, the D&amp;O Indemnified Parties shall be entitled to continue to retain Wilson Sonsini Goodrich &amp; Rosati or such other counsel selected by the D&amp;O Indemnified Parties.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The certificate of incorporation and bylaws of the Surviving Entity shall contain, and Parent shall cause the certificate of incorporation and bylaws of the Surviving Entity to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers as those presently set forth in the certificate of incorporation and bylaws of Parent.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From and after the First Effective Time, (i) the Surviving Entity shall fulfill and honor in all respects the obligations of the Company to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under the Company&#8217;s Organizational Documents and pursuant to any indemnification agreements between the Company and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the First Effective Time and (ii) Parent shall fulfill and honor in all respects the obligations of Parent to its D&amp;O Indemnified Parties as of immediately prior to the Closing pursuant to any indemnification provisions under Parent&#8217;s Organizational Documents and pursuant to any indemnification agreements between Parent and such D&amp;O Indemnified Parties, with respect to claims arising out of matters occurring at or prior to the First Effective Time.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From and after the First Effective Time, Parent shall maintain directors&#8217; and officers&#8217; liability insurance policies, with an effective date as of the Closing Date, on commercially reasonable terms and conditions and with coverage limits customary for U.S. public companies similarly situated to Parent. In addition, Parent shall purchase at its sole expense, prior to the First Effective Time, a six (6) year prepaid &#8220;D&amp;O tail policy&#8221; for the non-cancelable extension of the directors&#8217; and officers&#8217; liability coverage of Parent&#8217;s existing directors&#8217; and officers&#8217; insurance policies for a claims reporting or discovery period of at least six (6) years from and after the First Effective Time with respect to any claim related to any period of time at or prior to the First Effective Time with terms, conditions, retentions and limits of liability that are no less favorable than the coverage provided under Parent&#8217;s existing policies as of the date of this Agreement, or otherwise acceptable to Parent, except that Parent will not commit or spend on such &#8220;D&amp;O Tail policy&#8221; annual premiums in excess of 250% of the annual premiums paid by Parent in its last full fiscal year prior to the date hereof for Parent&#8217;s current policies of directors&#8217; and officers&#8217; liability insurance and fiduciary liability insurance (nor, for the avoidance of doubt, shall Parent be obligated to spend any specific amount), and if such premiums for such &#8220;D&amp;O tail policy&#8221; would exceed 250% of such annual premium, then Parent shall purchase policies that provide the maximum coverage available at an annual premium equal to 250% of such annual premium. The Company shall in good faith cooperate with Parent prior to the First Effective Time with respect to the procurement of such &#8220;D&amp;O tail policy.&#8221;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-62</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>From and after the First Effective Time, Parent shall pay all expenses, including reasonable attorneys&#8217; fees, that are incurred by the persons referred to in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> in connection with their enforcement of the rights provided to such persons in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The provisions of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> are intended to be in addition to the rights otherwise available to the current and former officers and directors of Parent and the Company by Law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of the D&amp;O Indemnified Parties, their heirs and their Representatives.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>In the event Parent or the Surviving Entity or any of their respective successors or assigns (i) consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (ii) transfers all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that the successors and assigns of Parent or the Surviving Entity, as the case may be, shall succeed to the obligations set forth in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent shall cause the Surviving Entity to perform all of the obligations of the Surviving Entity under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Unless directed otherwise by the Company in writing no less than three&#160;(3)&#160;Business Days before the Closing Date, Parent shall use reasonable best efforts to take all actions as are necessary to terminate any 401(k) or other plan(s) with a cash or deferred arrangement (as defined in Section&#160;401(k) of the Code), effective as of no later than the day immediately preceding the Closing Date.  Parent shall provide the Company copies of all such corporate actions or documentation related to the same at least three (3) Business Days before their adoption or approval for the Company&#8217;s reasonable review and comment.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Disclosure</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parties shall use their commercially reasonable efforts to agree to the text of any initial press release and Parent&#8217;s Form 8-K announcing the execution and delivery of this Agreement. Without limiting any Party&#8217;s obligations under the Confidentiality Agreement, no Party shall, and no Party shall permit any of its Subsidiaries or any of its Representative to, issue any press release or make any public disclosure regarding the Contemplated Transactions unless: (a) the other Party shall have approved such press release or disclosure in writing, such approval not to be unreasonably conditioned, withheld or delayed; or (b) such Party shall have determined in good faith, upon the advice of outside legal counsel, that such disclosure is required by applicable Law and, to the extent practicable, before such press release or disclosure is issued or made, such Party advises the other Party of, and consults with the other Party regarding, the text of such press release or disclosure; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that each of the Company and Parent may make any public statement in response to specific questions by the press, analysts, investors or those attending industry conferences or financial analyst conference calls, so long as any such statements are consistent with previous press releases, public disclosures or public statements made by the Company or Parent in compliance with this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.8</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Notwithstanding the foregoing, a Party need not consult with any other Parties in connection with such portion of any press release, public statement or filing to be issued or made pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.2(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.9<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Listing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. At or prior to the First Effective Time, Parent shall use its commercially reasonable efforts to (a) maintain its listing on Nasdaq until the First Effective Time and to obtain approval of the listing of the combined corporation on Nasdaq, (b) to the extent required by the rules and regulations of Nasdaq, prepare and submit to Nasdaq a notification form for the listing of the shares of Parent Common Stock to be issued in connection with the Contemplated Transactions, and to cause such shares to be approved for listing (subject to official notice of issuance); (c) prepare and timely submit to Nasdaq a notification form for the Nasdaq Reverse Split (if required) and to submit a copy of the amendment to Parent&#8217;s certificate of incorporation effecting the Nasdaq Reverse Split, certified by the Secretary of State of the State of Delaware, to Nasdaq on the Closing Date; and (d) to the extent required by Nasdaq Marketplace Rule&#160;5110, assist the Company in preparing and filing an initial listing application for the Parent Common Stock on Nasdaq (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Nasdaq Listing Application</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and to cause such Nasdaq Listing Application to be conditionally approved prior to the First Effective Time. Each Party will reasonably promptly inform the other Party of all verbal or written communications between Nasdaq and such Party or its representatives. The Parties will use commercially reasonable efforts to coordinate with respect to compliance with Nasdaq rules and regulations. The Party not filing the Nasdaq Listing Application will cooperate with the other Party as reasonably requested by such filing Party with respect to the Nasdaq Listing Application and promptly furnish to such filing Party all information concerning itself and its members that may be required or reasonably requested in connection </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-63</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">with any action contemplated by this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All Nasdaq fees associated with any action contemplated by this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, including any fees related to the engagement of a consultant (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Nasdaq Fees</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), shall be shared equally by the Company and Parent.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.10<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Tax Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parties shall use reasonable best efforts (and each shall cause its Affiliates) to cause the Merger to qualify for the Intended Tax Treatment. No Party shall take any actions, or fail to take any action, which action or failure to act would reasonably be expected to prevent or impede the Intended Tax Treatment. The Parties shall report the Contemplated Transactions for all applicable Tax purposes in a manner that is consistent with the Intended Tax Treatment. No Party shall take any position that is inconsistent with the Intended Tax Treatment during the course of any audit, litigation or other proceeding with respect to Taxes, in each case, unless otherwise required by a determination within the meaning of Section&#160;1313(a) of the Code. The Parties shall comply with the recordkeeping and information reporting requirements imposed on them, including, but not limited to, those set forth in Treasury Regulation Section&#160;1.368-3.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent shall promptly notify the Company if, at any time before the First Effective Time, Parent becomes aware of any fact or circumstance that would reasonably be expected to prevent, cause a failure of, or impede the Intended Tax Treatment. The Company shall promptly notify Parent if, at any time before the First Effective Time, the Company becomes aware of any fact or circumstance that would reasonably be expected to prevent, cause a failure of, or impede the Intended Tax Treatment.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If the SEC requires that an opinion with respect to the Intended Tax Treatment be prepared and submitted in connection with the Registration Statement and Proxy Statement, (i) the Company shall use its reasonable best efforts to cause Gibson, Dunn and Crutcher LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to the Company) to furnish an opinion (as so required and subject to customary assumptions and limitations), (ii) Parent shall use its reasonable best efforts to cause Wilson Sonsini Goodrich &amp; Rosati (or such other nationally recognized law or accounting firm reasonably satisfactory to Parent) to furnish an opinion (as so required and subject to customary assumptions and limitations), and (iii) Parent and the Company shall each deliver to each of Gibson, Dunn and Crutcher LLP (or such other nationally recognized law or accounting firm reasonably satisfactory to the Company) and Wilson Sonsini Goodrich &amp; Rosati (or such other nationally recognized law or accounting firm reasonably satisfactory to Parent) a Tax certificate, dated as of the date the Registration Statement and Proxy Statement shall have been declared effective by the SEC and signed by an officer of Parent or the Company, as applicable, containing customary representations and covenants reasonably acceptable to the Company and Parent, as applicable, in each case, as reasonably necessary and appropriate to enable such advisors to render such opinions (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Tax Certificates</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Each of Parent and the Company shall use its commercially reasonable efforts not to take or cause to be taken any action that would cause to be untrue (or fail to take or cause not to be taken any action which would cause to be untrue) any of the Tax certifications, covenants or representations included in the Tax Certificates.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Parent and the Company shall reasonably cooperate in the preparation, execution and filing of all Tax Returns, questionnaires, applications or other documents regarding any real property transfer, sales, use, transfer, value added, stock transfer and stamp taxes, and transfer, recording, registration and other fees and similar Taxes which become payable in connection with the Merger that are required or permitted to be filed on or before the First Effective Time. Each of Parent and the Company shall pay, without deduction from any consideration or other amounts payable or otherwise deliverable pursuant to this Agreement and without reimbursement from the other party, any such Taxes or fees imposed on it by any Governmental Authority, which becomes payable in connection with the Merger.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.11<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Legends</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent shall be entitled to place appropriate legends on the book entries and/or certificates evidencing any shares of Parent Capital Stock to be received in the Merger by equityholders of the Company who may be considered &#8220;affiliates&#8221; of Parent for purposes of Rules&#160;144 and 145 under the Securities Act reflecting the restrictions set forth in Rules&#160;144 and 145 and to issue appropriate stop transfer instructions to the transfer agent for any such shares of Parent Capital Stock.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.12<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Officers and Directors</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Until successors are duly elected or appointed and qualified in accordance with applicable Law, the Parties shall use commercially reasonable efforts and take all necessary action so that the Persons listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter are elected or appointed, as applicable, to </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-64</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">the positions of officers or directors of Parent and the Surviving Entity, as set forth therein, to serve in such positions effective as of the Second Effective Time. If any Person listed on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter is unable or unwilling to serve as officer or director of Parent or the Surviving Entity, as set forth therein, the Party appointing such Person (as set forth on </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Parent Disclosure Letter) shall designate a successor. The Parties shall use reasonable best efforts to have each of the Persons that will serve as directors and officers of the Parent following the Closing to execute and deliver a Lock-Up Agreement prior to Closing.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.13<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination of Certain Agreements and Rights</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each of Parent and the Company shall cause any stockholder agreements, voting agreements, registration rights agreements, co-sale agreements and any other similar Contracts between either Parent or the Company and any holders of Parent Common Stock or Company Capital Stock, respectively, including any such Contract granting any Person investor rights, rights of first refusal, registration rights or director registration rights, to be terminated immediately prior to the First Effective Time, without any liability being imposed on the part of Parent or the Surviving Entity.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.14<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;16 Matters</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Prior to the First Effective Time, Parent shall take all such steps as may be required to cause any acquisitions of Parent Common Stock and any options to purchase Parent Common Stock in connection with the Contemplated Transactions, by each individual who is reasonably expected to become subject to the reporting requirements of Section&#160;16(a) of the Exchange Act with respect to Parent, to be exempt under Rule&#160;16b-3 promulgated under the Exchange Act.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.15<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Allocation Information</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company will prepare and deliver to Parent prior to the Closing a spreadsheet setting forth (as of immediately prior to the First Effective Time) (a) each holder of Company Capital Stock, (b)&#160;such holder&#8217;s name and address, (c) the number or percentage and type of Company Capital Stock held as of the Closing Date for each such holder and (d) the number of shares of Parent Capital Stock to be issued to such holder pursuant to this Agreement in respect of the Company Capital Stock held by such holder as of immediately prior to the First Effective Time (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Allocation Certificate</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.16<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent SEC Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. From the date of this Agreement to the First Effective Time, Parent shall use commercially reasonable efforts to timely file with the SEC all registration statements, proxy statements, Certifications, reports, schedules, exhibits, forms and other documents required to be filed by Parent with the SEC under the Exchange Act or the Securities Act (&#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">SEC Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). As of its filing date, or if amended after the date of this Agreement, as of the date of the last such amendment, each SEC Document filed by Parent with the SEC (a) shall comply in all material respects with the applicable requirements of the Exchange Act and the Securities Act, and (b) shall not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.17<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Wind-Down Activities</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Following the Closing, Parent shall use its commercially reasonable efforts to continue the wind-down activities of Parent associated with the Parent Legacy Business, including termination of its research and development activities set forth on Section&#160;6.17 of the Parent Disclosure Letter.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.18<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Obligations of Merger Subs</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent will take all action necessary to cause each Merger Sub to perform its obligations under this Agreement and to consummate the Merger on the terms and conditions set forth in this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.19<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Pre-Closing Financing Restructuring</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. In the event the structure of the Company Pre-Closing Financing either violates applicable Law or materially and adversely effects Parent&#8217;s ability to cause the Registration Statement to become effective in a timely manner, and in any event 60 days prior to the End Date, then Parent and the Company shall, and shall use their reasonable best efforts to cause the investors in the Company Pre-Closing Financing, to cause the Company Pre-Closing Financing to be amended, modified and/or restructured such that such investment occurs as a direct acquisition of shares of Parent Common Stock substantially contemporaneously with the Closing in a manner which preserves to the extent possible, the amount of funds ultimately received by Parent and its Subsidiaries, and the number of Parent shares ultimately held by the investor in respect of such amounts as though the Company Pre-Closing Financing has been consummated by its terms.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-65</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.20<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Pre-Closing Dividend</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If Parent declares the Parent Pre-Closing Dividend, then, prior to the First Effective Time, Parent shall deposit the Parent Pre-Closing Dividend Amount with Parent&#8217;s transfer agent for further distribution to the holders of the shares of Parent Common Stock outstanding as of the record date of the Parent Pre-Closing Dividend.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.21<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Re-Domestication</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The parties shall discuss in good faith whether to change the domicile of Parent prior to the First Effective Time.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;7. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conditions Precedent to Obligations of Each Party</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The obligations of each Party to effect the Merger and otherwise consummate the Contemplated Transactions to be consummated at the Closing are subject to the satisfaction or, to the extent permitted by applicable law, the written waiver by each of the Parties, at or prior to the Closing, of each of the following conditions:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Effectiveness of Registration Statement</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Registration Statement shall have become effective in accordance with the provisions of the Securities Act, and shall not be subject to any stop order or Legal Proceeding seeking a stop order with respect to the Registration Statement that has not been withdrawn. Any material state securities laws applicable to the issuance of the shares of Parent Capital Stock in connection with the Contemplated Transactions (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) shall have been complied with and no stop order (or similar order) shall have been issued in respect of such shares of Parent Capital Stock (including any Parent Common Stock issuable upon conversion of the Parent Convertible Preferred Stock) by any applicable state securities commissioner or court of competent jurisdiction.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Regulatory Approvals</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any applicable waiting periods (or any extensions thereof) under the HSR Act (if applicable) shall have expired or otherwise been terminated.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Restraints</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. No Order preventing the consummation of the Contemplated Transactions shall have been issued by any Governmental Authority of competent jurisdiction and remain in effect and there shall not be any Law which has the effect of making the consummation of the Contemplated Transactions illegal.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Stockholder Approval</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. (a) Parent shall have obtained the Required Parent Stockholder Vote (but solely with respect to such items as are necessary to consummate the transactions contemplated by this Agreement) and (b) the Company shall have obtained the Required Company Stockholder Vote.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Listing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Nasdaq Listing Application shall have been approved by Nasdaq.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Lock-Up Agreements</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Lock-Up Agreements shall be in full force and effect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Charter Amendment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parent Charter Amendment shall have been duly filed with the Secretary of State of the State of Delaware, containing such amendments as are necessary to consummate the transactions contemplated by this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.8<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certificate of Designation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent shall have filed the Certificate of Designation with the Secretary of State of the State of Delaware.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;8. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Additional Conditions Precedent to Obligations of Parent and Merger Subs</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The obligations of Parent and Merger Subs to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by Parent, at or prior to the Closing, of each of the following conditions:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Accuracy of Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). The Company Capitalization Representations shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date, except, in each case, (x) for such inaccuracies which are de minimis, individually or in the aggregate, (y) for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause&#160;(x), as of such particular date). The representations and warranties of the Company contained in this Agreement (other than the Company Fundamental Representations </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-66</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and the Company Capitalization Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (a) in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Company Material Adverse Effect (without giving effect to any references therein to any Company Material Adverse Effect or other materiality qualifications) or (b) for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause&#160;(a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Company Disclosure Letter made or purported to have been made after the date of this Agreement shall be disregarded).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Performance of Covenants</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company shall have performed or complied with in all material respects all agreements and covenants required to be performed or complied with by it under this Agreement at or prior to the First Effective Time.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent shall have received the following documents, each of which shall be in full force and effect:</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>a certificate executed by the Chief Executive Officer or Chief Financial Officer of the Company certifying (i) that the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;8.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">8.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">8.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">8.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">8.6</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> have been duly satisfied and (ii) that the information (other than emails and addresses) set forth in the Allocation Certificate delivered by the company in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.15</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> is true and accurate in all respects as of the Closing Date;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>a certificate pursuant to Treasury Regulations Sections&#160;1.1445-2(c) and 1.897-2(h), together with a form of notice to the IRS in accordance with the requirements of Treasury Regulations Section&#160;1.897-2(h), in each case, in form and substance reasonably acceptable to Parent;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>the Company Valuation Schedule; and</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>the Allocation Certificate.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Company Material Adverse Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since the date of this Agreement, there shall not have occurred any Company Material Adverse Effect that is continuing.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company Stockholder Written Consent</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company Stockholder Written Consent executed by the stockholders of the Company shall be in full force and effect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.6<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company Pre-Closing Financing</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Subscription Agreement (as may be amended, restated or supplemented pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.19</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) shall be in full force and effect and proceeds of not less than $175,000,000 (including in the proceeds any Company Notes contributed as consideration in the Company Pre-Closing Financing) shall have been received by the Company (or, if applicable pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.19</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, Parent or one or more of its affiliates) or will be received by the Company (or, if applicable pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.19</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, Parent or one or more of its affiliates) substantially simultaneously with the Closing in connection with the consummation of the transactions contemplated by the Subscription Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.7<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Pre-Closing Dividend</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If Parent declares the Parent Pre-Closing Dividend, then the Parent Pre-Closing Dividend Amount shall have been deposited by Parent with Parent&#8217;s transfer agent for further distribution to the holders of the shares of Parent Common Stock outstanding as of the record date of the Parent Pre-Closing Dividend.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;9. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Additional Conditions Precedent to Obligation of the Company</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The obligations of the Company to effect the Merger and otherwise consummate the transactions to be consummated at the Closing are subject to the satisfaction or the written waiver by the Company, at or prior to the Closing, of each of the following conditions:</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Accuracy of Representations</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Parent Fundamental Representations shall have been true and correct in all material respects as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on and as of such date (except to the extent such representations and warranties are specifically made as of a particular date, in which case such representations and warranties shall be true and correct as of such date). The Parent Capitalization Representations shall have been true and correct in all respects as of the date of this Agreement and shall be true and correct on and as of the Closing </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-67</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Date with the same force and effect as if made on and as of such date, except, in each case, (x) for such inaccuracies which are de minimis, individually or in the aggregate, (y) for those representations and warranties which address matters only as of a particular date (which representations and warranties shall have been true and correct, subject to the qualifications as set forth in the preceding clause&#160;(x), as of such particular date). The representations and warranties of Parent and Merger Subs contained in this Agreement (other than the Parent Fundamental Representations and the Parent Capitalization Representations) shall have been true and correct as of the date of this Agreement and shall be true and correct on and as of the Closing Date with the same force and effect as if made on the Closing Date except (a) in each case, or in the aggregate, where the failure to be so true and correct would not reasonably be expected to have a Parent Material Adverse Effect (without giving effect to any references therein to any Parent Material Adverse Effect or other materiality qualifications) or (b) for those representations and warranties which address matters only as of a particular date (which representations shall have been true and correct, subject to the qualifications as set forth in the preceding clause&#160;(a), as of such particular date) (it being understood that, for purposes of determining the accuracy of such representations and warranties, any update of or modification to the Parent Disclosure Letter made or purported to have been made after the date of this Agreement shall be disregarded).</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Performance of Covenants</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Parent and Merger Subs shall have performed or complied with in all material respects all of their agreements and covenants required to be performed or complied with by each of them under this Agreement at or prior to the First Effective Time.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Documents</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company shall have received the following documents, each of which shall be in full force and effect:</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>a certificate executed by an executive officer of Parent certifying that the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;9.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">9.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">9.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> have been duly satisfied;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>written resignations in forms satisfactory to the Company, dated as of the Closing Date and effective as of the Closing executed by the officers and directors of Parent who are not to continue as officers or directors of Parent pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.12</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> hereof; and</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>the Parent Net Cash Schedule.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Parent Material Adverse Effect</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Since the date of this Agreement, there shall not have occurred any Parent Material Adverse Effect that is continuing.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;10. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.1<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement may be terminated prior to the First Effective Time (whether before or after adoption of this Agreement by the Company&#8217;s stockholders and whether before or after approval of the Parent Stockholder Matters by Parent&#8217;s stockholders, unless otherwise specified below):</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by mutual written consent of Parent and the Company;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by either Parent or the Company if the Merger shall not have been consummated by October 3, 2024 (subject to possible extension as provided in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">End Date</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the right to terminate this Agreement under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be available to the Company or Parent if such Party&#8217;s (or in the case of Parent, Merger Subs&#8217;) action or failure to act has been a principal cause of the failure of the Merger to occur on or before the End Date and such action or failure to act constitutes a breach of this Agreement, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that, in the event that the SEC has not declared effective under the Securities Act the Registration Statement by the date which is sixty (60) days prior to the End Date, then either the Company or Parent shall be entitled to extend the End Date for an additional sixty (60)&#160;days;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by either Parent or the Company if a court of competent jurisdiction or other Governmental Authority shall have issued a final and nonappealable Order having the effect of permanently restraining, enjoining or otherwise prohibiting the Contemplated Transactions;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by Parent if the Required Company Stockholder Vote shall not have been obtained within two (2) Business Days of the Registration Statement becoming effective in accordance with the provisions of the Securities Act; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that once the Required Company Stockholder Vote has been obtained, Parent may not terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-68</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by either Parent or the Company if (i) the Parent Stockholder Meeting (including any adjournments and postponements thereof) shall have been held and completed and Parent&#8217;s stockholders shall have taken a final vote on the Parent Stockholder Matters and (ii)&#160;the Parent Stockholder Matters shall not have been approved at the Parent Stockholder Meeting (or at any adjournment or postponement thereof) by the Required Parent Stockholder Vote; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the right to terminate this Agreement under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not be available to Parent where the failure to obtain the Required Parent Stockholder Vote shall have been caused by the action or failure to act of Parent and such action or failure to act constitutes a material breach by Parent of this Agreement;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by the Company (at any time prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote) if a Parent Triggering Event shall have occurred;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by Parent (at any time prior to the adoption of this Agreement and the approval of the Contemplated Transactions by the Required Company Stockholder Vote) if a Company Triggering Event shall have occurred;</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by the Company, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by Parent or Merger Subs or if any representation or warranty of Parent or Merger Subs shall have become inaccurate, in either case, such that the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;9.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the Company is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that if such inaccuracy in Parent&#8217;s or Merger Subs&#8217; representations and warranties or breach by Parent or Merger Subs is curable by Parent or Merger Subs, then the Company shall not be permitted to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> as a result of such particular breach or inaccuracy until the earlier of (i) the expiration of a thirty (30) day period commencing upon delivery of written notice from the Company to Parent or Merger Subs of such breach or inaccuracy and its intention to terminate pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and (ii) Parent or Merger Subs (as applicable) ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from the Company to Parent or Merger Subs of such breach or inaccuracy and its intention to terminate pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (it being understood that the Company shall not be permitted to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(h)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> as a result of such particular breach or inaccuracy if such breach by Parent or Merger Subs is cured prior to such termination becoming effective);</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by Parent, upon a breach of any representation, warranty, covenant or agreement set forth in this Agreement by the Company or if any representation or warranty of the Company shall have become inaccurate, in either case, such that the conditions set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;8.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become inaccurate; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that Parent is not then in material breach of any representation, warranty, covenant or agreement under this Agreement; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that if such inaccuracy in the Company&#8217;s representations and warranties or breach by the Company is curable by the Company then Parent shall not be permitted to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> as a result of such particular breach or inaccuracy until the earlier of (i) the expiration of a thirty&#160;(30)&#160;day period commencing upon delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and (ii) the Company ceasing to exercise commercially reasonable efforts to cure such breach following delivery of written notice from Parent to the Company of such breach or inaccuracy and its intention to terminate pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (it being understood that Parent shall not be permitted to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(i)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> as a result of such particular breach or inaccuracy if such breach by the Company is cured prior to such termination becoming effective); or</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>by Parent (at any time prior to the approval of the Parent Stockholder Matters by the Required Parent Stockholder Vote) and following compliance with all of the requirements set forth in the proviso to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(j)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, upon the Parent Board authorizing Parent to enter into a Permitted Alternative Agreement; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Parent shall not enter into any Permitted Alternative Agreement unless: (i) Parent shall have complied in all material respects with its obligations under </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;5.4</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (ii) the Parent Board shall have determined in good faith, after consultation with its outside legal counsel, that the failure to enter into such Permitted Alternative Agreement would reasonably be expected to be inconsistent with its fiduciary obligations under applicable Law and (iii) Parent shall concurrently pay to the Company the Company Termination Fee in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-69</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Party desiring to terminate this Agreement pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (other than pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(a)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) shall give a notice of such termination to the other Party specifying the provisions hereof pursuant to which such termination is made and the basis therefor described in reasonable detail.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.2<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Effect of Termination</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. In the event of the termination of this Agreement as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, this Agreement shall be of no further force or effect; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that (a)&#160;this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (other than </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11.8)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and the related definitions of the defined terms in such sections shall survive the termination of this Agreement and shall remain in full force and effect and (b) the termination of this Agreement and the provisions of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall not relieve any Party of any liability for fraud or for any willful and material breach of any representation, warranty, covenant, obligation or other provision contained in this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.3<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Expenses; Termination Fees</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as set forth in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.9</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> all fees and expenses incurred in connection with this Agreement and the Contemplated Transactions shall be paid by the Party incurring such expenses, whether or not the Merger is consummated.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If (i) this Agreement is terminated by Parent or the Company pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or by the Company pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(f)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (ii) at any time after the date of this Agreement and prior to the Parent Stockholder Meeting, an Acquisition Proposal with respect to Parent shall have been publicly announced, disclosed or otherwise communicated to the Parent Board (and shall not have been withdrawn) and (iii)&#160;in the event this Agreement is terminated pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, within twelve (12) months after the date of such termination, Parent enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction, then Parent shall pay to the Company, within ten (10) Business Days after termination (or, if applicable, upon such entry into a definitive agreement or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $440,000 (the &#8220;</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Company Termination Fee</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If this Agreement is terminated (i) by the Company pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(b)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(e)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (when at the time this Agreement is terminated, the Company had the right to terminate this Agreement pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(f)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) then Parent shall pay to the Company within five (5) Business Days of such termination, the Company Termination Fee or (ii) by Parent pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(j)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, then Parent shall pay to the Company, concurrent with such termination, the Company Termination Fee.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If (i) this Agreement is terminated by Parent pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(g)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (ii) at any time after the date of this Agreement and before obtaining the Required Company Stockholder Vote, an Acquisition Proposal with respect to the Company shall have been announced, disclosed or otherwise communicated to the Company Board (and shall not have been withdrawn) and (iii) in the event this Agreement is terminated pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.1(d)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, within twelve&#160;(12) months after the date of such termination, the Company enters into a definitive agreement with respect to a Subsequent Transaction or consummates a Subsequent Transaction, then the Company shall pay to Parent, within ten (10) Business Days after termination (or, if applicable, upon such entry into a definitive agreement or consummation of a Subsequent Transaction), a nonrefundable fee in an amount equal to $440,000.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If either Party fails to pay when due any amount payable by it under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, then (i) such Party shall reimburse the other Party for reasonable costs and expenses (including reasonable fees and disbursements of counsel) incurred in connection with the collection of such overdue amount and the enforcement by the other Party of its rights under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and (ii)&#160;such Party shall pay to the other Party interest on such overdue amount (for the period commencing as of the date such overdue amount was originally required to be paid and ending on the date such overdue amount is actually paid to the other Party in full) at a rate per annum equal to the &#8220;prime rate&#8221; (as announced by Bank of America or any successor thereto) in effect on the date such overdue amount was originally required to be paid plus three percent.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Parties agree that, subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the payment of the fees and expenses set forth in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be the sole and exclusive remedy of each Party following a termination of this Agreement under the circumstances described in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, it being understood that in no event shall either Parent or the Company be required to pay the individual fees or damages payable pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> on more than one occasion. Subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.2</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, following the payment of the fees and expenses set forth in </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-70</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> by a Party, (i) such Party shall have no further liability to the other Party in connection with or arising out of this Agreement or the termination thereof, any breach of this Agreement by the other Party giving rise to such termination, or the failure of the Contemplated Transactions to be consummated, (ii) no other Party or their respective Affiliates shall be entitled to bring or maintain any other claim, action or proceeding against such Party or seek to obtain any recovery, judgment or damages of any kind against such Party (or any partner, member, stockholder, director, officer, employee, Subsidiary, Affiliate, agent or other Representative of such Party) in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated and (iii) all other Parties and their respective Affiliates shall be precluded from any other remedy against such Party and its Affiliates, at law or in equity or otherwise, in connection with or arising out of this Agreement or the termination thereof, any breach by such Party giving rise to such termination or the failure of the Contemplated Transactions to be consummated. Each of the Parties acknowledges that (x) the agreements contained in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> are an integral part of the Contemplated Transactions, (y) without these agreements, the Parties would not enter into this Agreement and (z)&#160;any amount payable pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> is not a penalty, but rather is liquidated damages in a reasonable amount that will compensate the Parties in the circumstances in which such amount is payable; provided, however, that nothing in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;10.3(f)</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall limit the rights of the Parties under </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11.10</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section&#160;11. </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Miscellaneous Provisions</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.1<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Non-Survival of Representations and Warranties</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The representations and warranties of the Company, Parent and Merger Subs contained in this Agreement or any certificate or instrument delivered pursuant to this Agreement shall terminate at the First Effective Time, and only the covenants that by their terms survive the First Effective Time and this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall survive the First Effective Time.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.2<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Amendment</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement may be amended with the approval of the respective boards of directors of the Company, Merger Subs and Parent at any time (whether before or after the adoption and approval of this Agreement by the Company&#8217;s stockholders or before or after obtaining the Required Parent Stockholder Vote); </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that after any such approval of this Agreement by a Party&#8217;s stockholders, no amendment shall be made which by Law requires further approval of such stockholders without the further approval of such stockholders. This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Company, Merger Subs and Parent.</span></p>
		<p class="ParaOverride-18" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;page-break-after:avoid;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.3<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Waiver</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Any provision hereof may be waived by the waiving Party solely on such Party&#8217;s own behalf, without the consent of any other Party. No failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further exercise thereof or of any other power, right, privilege or remedy.</span></p>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:108pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such Party and any such waiver shall not be applicable or have any effect except in the specific instance in which it is given.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.4<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement and the other schedules, exhibits, certificates, instruments and agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings, both written and oral, among or between any of the Parties with respect to the subject matter hereof and thereof; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the Confidentiality Agreement shall not be superseded and shall remain in full force and effect in accordance with its terms; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">further</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that only Exhibit&#160;D (including Exhibit&#160;A to such Exhibit) is incorporated by reference and made a part hereof for purposes of Section&#160;251 of the DGCL. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all Parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the Parties to the terms and conditions of this Agreement.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-71</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.5<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Applicable Law; Jurisdiction</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the Parties arising out of or relating to this Agreement or any of the Contemplated Transactions, each of the Parties: (a) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (b) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause&#160;(a) of this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11.5</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (c)&#160;waives any objection to laying venue in any such action or proceeding in such courts, (d) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any Party, (e) agrees that service of process upon such Party in any such action or proceeding shall be effective if notice is given in accordance with </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;11.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement and (f) irrevocably and unconditionally waives the right to trial by jury.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.6<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Assignability</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and permitted assigns; </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that neither this Agreement nor any of a Party&#8217;s rights or obligations hereunder may be assigned or delegated by such Party without the prior written consent of the other Party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other Party&#8217;s prior written consent shall be void and of no effect.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.7<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notices</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly delivered and received hereunder (a)&#160;one&#160;(1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (b)&#160;upon delivery in the case of delivery by hand or (c) on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, in each case to the intended recipient as set forth below:</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">if to Parent or Merger Subs:</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">ARCA biopharma, Inc.<br/>10170 Church Ranch Way, Suite 100<br/>Westminster, CO 80021 <br/>Attention: C. Jeffrey Dekker<br/>Email: ***</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">with a copy to (which shall not constitute notice):</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Wilson Sonsini Goodrich &amp; Rosati<br/>1881 9</span><span class="CharOverride-11" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">th</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> Street, Suite 110<br/>Boulder, CO 80302<br/>Attn: Brent Fassett<br/>Email: bfassett@wsgr.com</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Wilson Sonsini Goodrich &amp; Rosati<br/>One Market Plaza, Spear Tower, Suite 3300<br/>San Francisco, CA 94105<br/>Attn: Ethan Lutske, Ross Tanaka<br/>Email: elutske@wsgr.com, rtanaka@wsgr.com</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">if to the Company:</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Oruka Therapeutics, Inc.<br/>221 Crescent Street, Building 23, Suite 105<br/>Waltham, Massachusetts 02453<br/>Attention: Lawrence Klein<br/>Email: ***</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-72</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">with a copy to (which shall not constitute notice):</span></p>
		<p class="ParaOverride-20" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:3;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Gibson, Dunn &amp; Crutcher LLP<br/>One Embarcadero Center, Suite 2600<br/>San Francisco, CA 94111<br/>Attention: Ryan Murr, Branden Berns, Chris Trester<br/>Email: rmurr@gibsondunn.com, bberns@gibsondunn.com, ctrester@gibsondunn.com</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.8<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Cooperation</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each Party agrees to cooperate fully with the other Party and to execute and deliver such further documents, certificates, agreements and instruments and to take such other actions as may be reasonably requested by the other Party to evidence or reflect the Contemplated Transactions and to carry out the intent and purposes of this Agreement.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.9<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Severability</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.10<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Other Remedies; Specific Performance</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the Parties waives any bond, surety or other security that might be required of any other Party with respect thereto. Each of the Parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other Party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</span></p>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:72pt;widows:3;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.11<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Third-Party Beneficiaries</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person (other than the Parties and the D&amp;O Indemnified Parties to the extent of their respective rights pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.7</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Remainder of page intentionally left blank</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-73</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">In Witness Whereof</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">,</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> the Parties have caused this Agreement to be executed as of the date first above written.</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">ARCA </span><span class="CharOverride-12" style="font-style:normal;font-variant:small-caps;font-weight:bold;">biopharma, Inc</span><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">.</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Financial Officer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">ATLAS MERGER SUB CORP.</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-7" style="font-style:normal;font-weight:bold;">ATLAS MERGER SUB II, LLC</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C. Jeffrey Dekker</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Agreement and Plan of Merger and Reorganization</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-74</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-indent:36pt;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:small-caps;font-weight:bold;">In Witness Whereof</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">,</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> the Parties have caused this Agreement to be executed as of the date first above written.</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-12" style="font-style:normal;font-variant:small-caps;font-weight:bold;">Oruka Therapeutics, Inc.</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-18" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Lawrence Klein</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Lawrence Klein</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Chief Executive Officer</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:3;text-align:center;widows:3;margin-top:8pt;"><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Agreement and Plan of Merger and Reorganization</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex A-75</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T101"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;B</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">OPINION OF LUCID CAPITAL MARKETS</span></p>
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;font-size:14pt;">LUCID CAPITAL MARKETS, LLC</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">April&#160;2, 2024</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">ARCA biopharma, Inc.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;margin-top:0pt;">10170 Church Ranch Way, Suite 100</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;margin-top:0pt;">Westminster, CO&#160;80021</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;margin-top:0pt;">Attention: Robert E.&#160;Conway</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;margin-top:0pt;">Chairman of the Board of Directors</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Members of the Board of Directors:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have been advised that ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221; or &#8220;Parent&#8221;), proposes to enter into an Agreement and Plan of Merger (the &#8220;Agreement&#8221;), by and among ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of ARCA (&#8220;Merger Sub&#8221;), and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka&#8221; or the &#8220;Company&#8221;). At the Effective Time, Merger Sub will be merged with and into the Company (the &#8220;Merger&#8221;), and the separate existence of the Merger Sub will cease. The Company will continue as the surviving corporation in the Merger (the &#8220;Surviving Corporation&#8221;). Pursuant to the terms of the Agreement, upon consummation of the Merger, each share of Company Capital Stock (other than shares of Company Capital Stock held as treasury stock immediately prior to the Effective Time which shall be canceled and retired and shall cease to exist and excluding Dissenting Shares) will be converted into and become exchangeable for a number of shares of Parent Common Stock equal to the Exchange Ratio. The terms and conditions of the Merger are more fully set forth in the Agreement. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Agreement contemplates that Parent may declare and pay a dividend on the shares of Parent Common Stock outstanding prior to the Effective Time (excluding for the avoidance of doubt any shares of Parent Common Stock issuable pursuant to the Contemplated Transactions) up to an amount equal in the aggregate to Parent&#8217;s reasonable, good faith approximation of the amount by which Parent Net Cash will exceed $5,000,000 (the &#8220;Parent Pre<span class="nobreak">-Closing</span> Dividend&#8221;). The Agreement also contemplates that concurrently with the execution and delivery of the Agreement, certain investors will execute a Subscription Agreement pursuant to which such Persons will have agreed to purchase (including by contribution of Company Notes) (i)&#160;shares of Company Common Stock and (ii)&#160;pre<span class="nobreak">-funded</span> Company Warrants, in each case immediately prior to the Effective Time (the &#8220;Company Pre<span class="nobreak">-Closing</span> Financing&#8221;). It is a condition precedent to the obligations of Parent and Merger Sub to effect the Merger that proceeds of not less than $175&#160;million be received from the Company Pre<span class="nobreak">-Closing</span> Financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have assumed, with your consent, that the Parent Net Cash amount is expected to be, and we have assumed, with your consent, that it will be approximately $5.0&#160;million at Closing after taking effecting the Parent Pre<span class="nobreak">-Closing</span> Dividend.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Assuming that the Parent Pre<span class="nobreak">-Closing</span> Dividend has occurred, the holders of Company Common Stock, Company Options and Company Warrants will in the aggregate hold approximately 97.6% of the fully<span class="nobreak">-diluted</span> shares of Parent Common Stock (excluding certain Parent Options) immediately following the Merger and the holders of Parent Common Stock will in the aggregate hold approximately 2.4% of the fully<span class="nobreak">-diluted</span> shares of Parent Common Stock (excluding certain Parent Options) immediately following the Merger, in each case, after accounting for the Parent Pre<span class="nobreak">-Closing</span> Dividend and the Company Pre<span class="nobreak">-Closing</span> Financing.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have, with your consent, relied upon the assumption that all information provided to us by ARCA and Oruka is accurate and complete in all material respects. We expressly disclaim any undertaking or obligation to advise any person of any change in any fact or matter affecting our Opinion of which we become aware after the date hereof. We have assumed there were no material changes in the assets, liabilities, financial condition, results of operations, business or prospects of ARCA or Oruka since the date of the last financial statements made available to </p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex B-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">us. We have not obtained any independent evaluations, valuations or appraisals of the assets or liabilities of ARCA or Oruka, nor have we been furnished with such materials. In addition, we have not evaluated the solvency or fair value of ARCA or Oruka under any state or federal laws relating to bankruptcy, insolvency or similar matters.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Our Opinion does not address any legal, regulatory, tax or accounting matters related to the Merger, as to which we have assumed that ARCA and the Board of Directors have received such advice from legal, tax and accounting advisors as each has determined appropriate. Our Opinion addresses only the fairness from a financial point of view of the Exchange Ratio as set forth in the Merger Agreement to the holders of Parent Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We express no view as to any other aspect or implication of the Merger or any other agreement or arrangement entered into in connection with the Merger. Our Opinion is necessarily based upon economic and market conditions and other circumstances as they exist and can be evaluated by us on the date hereof. It should be understood that although subsequent developments may affect our Opinion, we do not have any obligation to update, revise or reaffirm our Opinion and we expressly disclaim any responsibility to do so.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">We have not considered any potential legislative or regulatory changes currently being considered or recently enacted by the United&#160;States or any foreign government, or any domestic or foreign regulatory body, or any changes in accounting methods or generally accepted accounting principles that may be adopted by the Securities and Exchange Commission (the &#8220;SEC&#8221;), the Financial Accounting Standards Board, or any similar foreign regulatory body or board.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In your capacity as members of the Board of Directors of ARCA (the &#8220;Board of Directors&#8221;), you have requested our opinion (our &#8220;Opinion&#8221;) as to the fairness, from a financial point of view and as of the date hereof, of the Exchange Ratio as set forth in the Agreement to the holders of Parent Common Stock.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with our Opinion, we took into account an assessment of general economic, market and financial conditions as well as our experience in connection with similar transactions and securities valuations generally and, among other things:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed a draft of the Merger Agreement;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain publicly available financial and other information for each of ARCA and Oruka, respectively, including equity research on comparable companies and on ARCA, and certain other relevant financial and operating data furnished to us by the management of each of ARCA and Oruka, respectively;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain relevant historical financial and operating data concerning Oruka furnished to us by the management of Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Discussed with certain members of the management of ARCA the historical and current business operations, financial condition and prospects of ARCA and Oruka;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain operating results of Oruka as compared to operating results and the reported price and trading histories of certain publicly traded companies that we deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain financial terms of the Merger Agreement as compared to the publicly available financial terms of certain selected business combinations that we deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain financial terms of completed initial public offerings for certain companies that we deemed relevant;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed certain pro forma financial effects of the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed certain internal financial analyses, including the cash burn model over the next year, projections as to cost and expenses and whether concurrent capital raised would sufficiently cover select programs, reports, and other information concerning Oruka prepared by Oruka; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Reviewed and analyzed such other information and such other factors, and conducted such other financial studies, analyses and investigations, as we deemed relevant for the purposes of our Opinion.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex B-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For purposes of rendering our Opinion we have assumed, with your consent, that except as would not be in any way meaningful to our analysis: (i)&#160;the final form of the Agreement will not differ from the Draft Agreement that we have reviewed; (ii)&#160;the representations and warranties of each party contained in the Agreement are true and correct in all respects; (iii)&#160;each party will perform all of the covenants and agreements required to be performed by such party under the Agreement; and (iv)&#160;the transactions contemplated by the Agreement will be consummated in accordance with the terms of the Agreement, without any waiver or amendment of any term or condition thereof. We have also assumed that all governmental, regulatory and other consents and approvals contemplated by the Agreement or otherwise required for the transactions contemplated by the Agreement will be obtained and that in the course of obtaining any of those consents no restrictions will be imposed, or waivers made that would have an adverse effect on ARCA, Oruka, or the contemplated benefits of the Merger. We have assumed that the Merger will be consummated in a manner that complies with the applicable provisions of the Securities Act&#160;of&#160;1933, as amended, the Securities Exchange&#160;Act&#160;of&#160;1934, as amended, and all other applicable federal and state statutes and the rules and regulations promulgated thereunder.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">It is understood that this letter is intended for the benefit and use of the Board of Directors (in its capacity as such) in its consideration of the financial terms of the Merger and, except as set forth in our engagement letter with ARCA, dated as of March&#160;19, 2024 (the &#8220;Engagement Letter&#8221;), may not be used for any other purpose or reproduced, disseminated, quoted or referred to at any time, in any manner or for any purpose without our prior written consent, except that this Opinion may be included in its entirety in any filing related to the Merger required to be filed with the SEC and any proxy statement to be mailed to holders of Parent Common Stock. This letter does not constitute a recommendation to the Board of Directors of whether to approve the Merger or to any stockholder of ARCA or any other person as to how to vote or act with respect to the transactions contemplated by the Agreement (including the Merger) or any other matter. Our Opinion does not address ARCA&#8217;s underlying business decision to proceed with the Merger or the relative merits of the Merger compared to other alternatives available to ARCA.&#160;We express no opinion as to the prices or ranges of prices at which shares or the securities of any person, including ARCA, will trade at any time, including following the announcement or consummation of the Merger, or as to the potential effects of volatility in the credit, financial, and stock markets on ARCA, Oruka or the transactions contemplated by the Agreement. We have not been requested to opine as to, and our Opinion does not in any manner address, the amount or nature of compensation to any of the officers, directors or employees of any party to the Merger, or any class of such persons, relative to the compensation to be paid to the holders of Parent Common Stock in connection with the Merger or with respect to the fairness of any such compensation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Lucid is an investment bank providing investment banking, brokerage, equity research, institutional sales and trading services. As part of our investment banking services, we are regularly engaged in the valuation of businesses and their securities in connection with mergers, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for corporate and other purposes. We have acted as ARCA&#8217;s financial advisor in connection with the Merger and will receive a fee for our services pursuant to the terms of our Engagement Letter, a significant portion of which is contingent upon consummation of the Merger. In addition, ARCA has agreed to reimburse our expenses and indemnify us for certain liabilities that may arise out of our engagement. We will also receive an additional fee for rendering our Opinion set forth below pursuant to the Engagement Letter, which is not contingent upon consummation of the Merger. In the two&#160;years preceding the date hereof, Lucid has not had a relationship with ARCA or its affiliates and has not received any fees from ARCA or any of its affiliates. In the two&#160;years preceding the date hereof, Lucid has not had a relationship with Oruka or any of its affiliates and has not received any fees from Oruka or any of its affiliates. Lucid and its affiliates may in the future seek to provide investment banking or financial advisory services to ARCA and Oruka and/or their respective affiliates and expect to receive fees for the rendering of these services.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In the ordinary course of business, Lucid or certain of our affiliates, as well as investment funds in which we or our affiliates may have financial interests, may acquire, hold or sell long or short positions, or trade or otherwise effect transactions in debt, equity, and other securities and financial instruments (including bank loans and other obligations) of, or investments in, ARCA, Oruka or any other party that may be involved in the Merger and/or their respective affiliates.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex B-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consistent with applicable legal and regulatory requirements, Lucid has adopted policies and procedures to establish and maintain the independence of our research department and personnel. As a result, our research analysts may hold views, make statements or investment recommendations and/or publish research reports with respect to ARCA and the proposed Merger that may differ from the views of Lucid&#8217;s investment banking personnel.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Opinion set forth below was reviewed and approved by a fairness opinion committee of Lucid.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Based upon and subject to the foregoing, including the various assumptions and limitations set forth herein and such other factors that we deem relevant, it is our opinion that, as of the date hereof, the Exchange Ratio is fair, from a financial point of view, to the holders of Parent Common Stock.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">Very truly yours,</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;"><img alt="" src="tlucid_sig.jpg" style="width:179.20000000000002px;max-width:100%;"/></span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Lucid Capital Markets, LLC</span></p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex B-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T102"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;C</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">This Support Agreement (this &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is made and entered into as of April 3, 2024, by and among Oruka Therapeutics, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), ARCA biopharma, Inc., a Delaware corporation (&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and the undersigned stockholder (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Stockholder</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of the Company. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">RECITALS</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, concurrently with the execution and delivery hereof, Parent, the Company and Atlas Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">First Merger Sub</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and Atlas Merger Sub II LLC, a Delaware limited liability company (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Second Merger Sub</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) have entered into an Agreement and Plan of Merger and Reorganization (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof, the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which (i) the First Merger Sub will merge with and into the Company, with the Company surviving the merger as the surviving corporation and a wholly owned subsidiary of Parent and (ii) the Company will merge with and into the Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger, upon the terms and subject to the conditions set forth in the Merger Agreement (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, as of the date hereof, the Stockholder is the beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of such number of shares of Company Capital Stock as indicated in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, as an inducement to the willingness of Parent to enter into the Merger Agreement, Parent has required that Stockholder enter into this Agreement.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">NOW, THEREFORE, intending to be legally bound, the parties hereby agree as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Definitions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement. For all purposes of this Agreement, the following terms shall have the following respective meanings:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Constructive Sale</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any security, a short sale with respect to such security, entering into or acquiring a derivative contract with respect to such security, entering into or acquiring a futures or forward contract to deliver such security or entering into any other hedging or other derivative transaction that has the effect of either directly or indirectly materially changing the economic benefits or risks of ownership of such security.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (i) all shares of Company Capital Stock beneficially owned by the Stockholder as of the date hereof, and (ii) all additional shares of Company Capital Stock acquired and beneficially owned by the Stockholder during the period commencing with the execution and delivery of this Agreement and expiring on the Closing Date.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transferred</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange, pledge or hypothecation, or the grant, creation or suffrage of a lien, security interest or encumbrance in or upon, or the gift, grant or placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate succession, by domestic relations order or other court order, or otherwise by operation of law) or any right, title or interest therein (including any right or power to vote to which the holder thereof may be entitled, whether such right or power is granted by proxy or otherwise), or the beneficial ownership thereof, the offer to make such a sale, transfer, Constructive Sale or other disposition, and each agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer and Voting Restrictions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder covenants to Parent and the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise permitted by Section 2(c), during the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date (as defined below), the Stockholder shall not Transfer any of the Stockholder&#8217;s Shares, or publicly announce its intention to Transfer any of its Shares.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise permitted by this Agreement or otherwise permitted or required by order of a court of competent jurisdiction or a Governmental Authority, the Stockholder will not commit any act that would restrict the Stockholder&#8217;s legal power, authority and right to vote all of the Shares held by the Stockholder or otherwise prevent or disable the Stockholder from performing any of his, her or its obligations under this Agreement. Without limiting the generality of the foregoing, except for this Agreement, the Voting Agreement of the Company, dated as of March 6, 2024 (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Voting Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and as otherwise permitted by this Agreement, the Stockholder shall not enter into any voting agreement with any person or entity with respect to any of the Stockholder&#8217;s Shares, grant any person or entity any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shares, deposit any Shares in a voting trust or otherwise enter into any agreement or arrangement with any person or entity limiting or affecting the Stockholder&#8217;s legal power, authority or right to execute and deliver the Company Stockholder Written Consent.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything else herein to the contrary, the Stockholder may, at any time, Transfer Shares (i) by will or other testamentary document or by intestacy, (ii) to such Stockholder&#8217;s Affiliates (in&#160;each case, directly or indirectly) (iii) to any member of the Stockholder&#8217;s immediate family (or, if the Stockholder is a corporation, partnership or other entity, to an immediate family member of a beneficial owner of the Shares held by the Stockholder), (iv) to any trust or other entity for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder (or, if the Stockholder is a corporation, partnership or other entity, for the direct or indirect benefit of an immediate family member of a beneficial owner of the Shares held by the Stockholder) or otherwise for estate tax or estate planning purposes, (v) in the case of a Stockholder who is not a natural person, by pro rata distributions from the Stockholder to its members, partners, or shareholders pursuant to the Stockholder&#8217;s organizational documents, (vi) purchased from the Company pursuant to the Company Pre-Closing Financing on or about the Closing Date but prior to the Closing (including any shares of the Company issued upon conversion of any pre-funded Company Warrants), and (vii) to the extent required by applicable Law; </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in the cases of clauses (i)-(v), (x) such Transferred Shares shall continue to be bound by this Agreement and (y) the applicable direct transferee (if any) of such Transferred Shares shall have executed and delivered to Parent and the Company a support agreement substantially identical to this Agreement upon consummation of the Transfer if not already a party thereto.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything to the contrary herein, nothing in this Agreement shall obligate the Stockholder to exercise any option or any other right to acquire any shares of Company Capital Stock.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreement to Vote Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder covenants to the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Until the Expiration Date (as defined below), at any meeting of the stockholders of the Company, however called, and at every adjournment or postponement thereof, and on every action or approval by written consent of the stockholders of the Company, the Stockholder shall be present (in person or by proxy) and vote, or exercise its right to consent with respect to, all Shares held by the Stockholder (A) in favor of the adoption and approval of the Merger Agreement, (B) in favor of approval of the Contemplated Transactions, and (C) against any Acquisition Proposal.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If the Stockholder is not the record holder, of Shares, the Stockholder agrees to take all actions necessary to cause the record holder and any nominees to be present (in person or by proxy) and vote all the Stockholder&#8217;s Shares in accordance with this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>In the event of a stock split, stock dividend or distribution, or any change in the capital stock of the Company by reason of any split-up, reverse stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &#8220;Shares&#8221; shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Action in Stockholder Capacity Only</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder is entering into this Agreement solely in the Stockholder&#8217;s capacity as the beneficial owner of its Shares and not in the Stockholder&#8217;s capacity as a director or officer of the Company. Nothing herein shall limit or affect the Stockholder&#8217;s ability to act as an officer or director of the Company.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Irrevocable Proxy</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted with respect to its Shares. In the event and to the extent that the Stockholder fails to vote the Shares in accordance with </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> at any applicable meeting of the stockholders of the Company or pursuant to any applicable written consent of the stockholders of the Company, the Stockholder shall be deemed to have irrevocably granted to, and appointed, the Company, and any individual designated in writing by it, and each of them individually, as his, her or its proxy and attorney-in-fact (with full power of substitution), for and in its name, place and stead, to vote his, her or its Shares in any action by written consent of Company stockholders or at any meeting of the Company stockholders called with respect to any of the matters specified in, and in accordance and consistent with, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement. The Company agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. Except as otherwise provided for herein (including the next sentence), the Stockholder hereby affirms that the irrevocable proxy is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate on the Expiration Date.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Solicitation</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder agrees not to directly or indirectly, including through any of its officers, directors or agents, take any action that the Company is prohibited from taking pursuant to Section 5.4 of the Merger Agreement and Section 5.4 of the Merger Agreement is hereby incorporated by reference </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">mutatis mutandis</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Documentation and Information</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder shall permit and hereby authorizes Parent and the Company to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that Parent or the Company reasonably determines to be necessary in connection with the Merger and any of the Contemplated Transactions, a copy of this Agreement, the Stockholder&#8217;s identity and ownership of the Shares and the nature of the Stockholder&#8217;s commitments and obligations under this Agreement; provided, that, Parent and the Company provide such documents, schedules, press release or other disclosure document to the Stockholder in advance for its review and comment. Each of Parent and the Company is an intended third-party beneficiary of this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Exercise of Appraisal Rights; Waivers</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby irrevocably and unconditionally (a)&#160;waives, and agrees to cause to be waived and to prevent the exercise of, any rights of appraisal, any dissenters&#8217; rights and any similar rights (including any notice requirements related thereto) relating to the Merger that Stockholder may have by virtue of, or with respect to, any Shares (including all rights under Section 262 of the DGCL) and (b) agrees that the Stockholder will not bring, commence, institute, maintain, prosecute or voluntarily aid or participate in any action, claim, suit or cause of action, in law or in equity, in any court or before any Governmental Authority, which (i) challenges the validity of or seeks to enjoin the operation of any provision of this Agreement or (ii) alleges that the execution and delivery of this Agreement by the Stockholder breaches any duty that such Stockholder has (or may be alleged to have) to the Company or to the other Company stockholders; provided, that (x) the Stockholder may defend against, contest or settle any such action, claim, suit or cause of action brought against the Stockholder that relates solely to the Stockholder&#8217;s capacity as a director, officer or securityholder of the Company and (y) the foregoing shall not limit or restrict in any manner the Stockholder from enforcing the Stockholder&#8217;s rights under this Agreement and the other agreements entered into by the Stockholder in connection herewith, or otherwise in connection with the Merger, including the Stockholder&#8217;s right to receive the Merger Consideration pursuant to the terms of the Merger Agreement.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Representations and Warranties of the Stockholder</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby represents and warrants to Parent and the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(i) The Stockholder is the beneficial owner of the shares of Company Capital Stock indicated in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (each of which shall be deemed to be &#8220;held&#8221; by the Stockholder for purposes of </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> unless otherwise expressly stated with respect to any shares in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">), free and clear of any and all Encumbrances (except for any Encumbrance that may be imposed pursuant to this Agreement, the Voting Agreement, the Investors&#8217; </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Rights Agreement of the Company, dated as of March 6, 2024 (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Investors&#8217; Rights Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Right of First Refusal and Co-Sale Agreement of the Company, dated as of March 6, 2024 (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">ROFR</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), any lock-up agreement entered into by and between the Stockholder, the Company and Parent, and Encumbrances arising under applicable securities or community property laws; and (ii) the Stockholder does not beneficially own any securities of the Company other than the shares of Company Capital Stock and rights to purchase shares of Company Capital Stock set forth in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise provided in this Agreement, the Stockholder has full power and authority to (i) make, enter into and carry out the terms of this Agreement and (ii) vote all of its Shares in the manner set forth in this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any Governmental Authority). Without limiting the generality of the foregoing, except for the Voting Agreement, the Stockholder has not entered into any voting agreement (other than this Agreement) with any person with respect to any of the Stockholder&#8217;s Shares, granted any person any proxy (revocable or irrevocable) or power of attorney with respect to any of the Stockholder&#8217;s Shares, deposited any of the Stockholder&#8217;s Shares in a voting trust or entered into any arrangement or agreement with any person limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares on any matter.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Agreement has been duly and validly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery by the other parties hereto) constitutes a valid and binding agreement of the Stockholder enforceable against the Stockholder in accordance with its terms, subject to the Enforceability Exceptions. The execution and delivery of this Agreement by the Stockholder and the performance by the Stockholder of the agreements and obligations hereunder will not result in any breach or violation of or be in conflict with or constitute a default under any term of any Contract or if applicable any provision of an organizational document (including a certificate of incorporation) to or by which the Stockholder is a party or bound, or any applicable law to which the Stockholder (or any of the Stockholder&#8217;s assets) is subject or bound, except for any such breach, violation, conflict or default which, individually or in the aggregate, would not reasonably be expected to materially impair or adversely affect the Stockholder&#8217;s ability to perform its obligations under this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The execution, delivery and performance of this Agreement by the Stockholder do not and will not require any consent, approval, authorization or permit of, action by, filing with or notification to, any Governmental Authority, except for any such consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain, individually or in the aggregate, has not and would not materially impair the Stockholder&#8217;s ability to perform its obligations under this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective agents or representatives with respect to the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving Corporation) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the Contemplated Transactions. The Stockholder understands and acknowledges that the Company, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&#8217;s properties or assets (including the Shares) that would reasonably be expected to prevent or materially delay or impair the ability of the Stockholder to perform its obligations hereunder or to consummate the transactions contemplated hereby.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Agreements</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Each Stockholder, by this Agreement, and with respect to such Stockholder&#8217;s Shares, severally and not jointly, hereby agrees to terminate, subject to the occurrence of, and effective immediately prior to, the Effective Time each of (a) the Voting Agreement, the Investors&#8217; Rights Agreement and the ROFR and (b)&#160;any rights under any letter agreement providing for redemption rights, put rights, purchase rights, information rights, rights to consult with and advise management, inspection rights, preemptive rights, board of directors </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">observer rights or rights to receive information delivered to the board of directors or other similar rights not generally available to stockholders of the Company between the Stockholder and the Company, but excluding, for the avoidance of doubt, any rights the Stockholder may have that relate to any indemnification, commercial, development or employment agreements or arrangements between such Stockholder and the Company or any subsidiary of the Company, which shall survive in accordance with their terms. Each Stockholder hereby terminates and waives all rights of first refusal, redemption rights and rights of notice of the Merger and the other transactions contemplated by the Merger Agreement, effective as of immediately prior to, and contingent upon, the Effective Time.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall terminate and shall cease to be of any further force or effect as of the earliest of (a) such date and time as the Merger Agreement shall have been terminated pursuant to the terms thereof as in effect on the date of this Agreement (and without giving effect to any amendments thereto unless consented to by the Stockholder), (b) the Effective Time and (c) the time this Agreement is terminated upon the written agreement of the Stockholder, the Company and Parent (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Expiration Date</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">,</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that (i) </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 12</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall survive the termination of this Agreement, and (ii) the termination of this Agreement shall not relieve any party hereto from any liability for any material and willful breach of this Agreement prior to the Effective Time.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">12.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Miscellaneous Provisions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Amendments</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. No amendment of this Agreement shall be effective against any party unless it shall be in writing and signed by each of the parties hereto.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement constitutes the entire agreement between the parties to this Agreement and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or otherwise) by all parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Applicable Law; Jurisdiction.</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the parties arising out of or relating to this Agreement, each of the parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (i) of this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 12(c)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (iii) waives any objection to laying venue in any such action or proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party, (v) agrees that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 12(h)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement and (vi)&#160;irrevocably and unconditionally waives the right to trial by jury.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Assignment</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the parties and their respective successors and permitted assigns; </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that neither this Agreement nor any of a party&#8217;s rights or obligations hereunder may be assigned or delegated (except by Merger) by such party without the prior written consent of the other party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such party without the other party&#8217;s prior written consent shall be void and of no effect.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Third Party Rights</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Severability</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Specific Performance</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties waives any bond, surety or other security that might be required of any other party with respect thereto. Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notices</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All notices and other communications hereunder shall be in writing and shall be deemed duly delivered (i) one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (ii) upon delivery in the case of delivery by hand or (iii) on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, (A) if to the Company or Parent, to the address, electronic mail address or facsimile provided in Section 11.7 of the Merger Agreement, including to the persons designated therein to receive copies; and/or (B) if to the Stockholder, to the Stockholder&#8217;s address, electronic mail address or facsimile shown below Stockholder&#8217;s signature to this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Confidentiality</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.  Except to the extent required by applicable Law or regulation, the Stockholder shall hold any non-public information regarding the Company, this Agreement, the Merger Agreement and the Merger in strict confidence and shall not divulge any such information to any third person until the Company and Parent have publicly disclosed their entry into the Merger Agreement and this Agreement; provided, however, that the Stockholder may disclose such information to its Affiliates, attorneys, accountants, consultants, and other advisors (provided that such Persons are subject to confidentiality obligations at least as restrictive as those contained herein).  Neither the Stockholder nor any of its Affiliates (other than the Company, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press release or other public announcement with respect to the Company, this Agreement, the Merger, the Merger Agreement or the other transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be required by applicable Law in which circumstance such announcing party shall make reasonable efforts to consult with the Company and Parent to the extent practicable.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Interpretation</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections and Appendixes are to Sections and Appendixes of this Agreement unless otherwise specified. Any capitalized terms used in any Appendix but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof, substituted, from time to time. References to &#8220;$&#8221;&#160;and&#160;&#8220;dollars&#8221; are to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Remainder of Page Left Intentionally Blank</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the date first above written.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">COMPANY:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-8" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Oruka Therapeutics, Inc.</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Company Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-9" style="font-variant:normal;text-transform:uppercase;">Parent</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-8" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA BIOPHARMA, Inc.</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Company Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">[STOCKHOLDER],</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">in his/her capacity as the Stockholder:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Signature:&#160;_______________________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Address:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Company Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex C-11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T103"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;D</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">FORM OF ARCA STOCKHOLDER SUPPORT AGREEMENT</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">This Support Agreement (this &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is made and entered into as of April 3, 2024, by and among Oruka Therapeutics, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), ARCA biopharma, Inc., a Delaware corporation (&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and the undersigned stockholder (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Stockholder</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of the Parent. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">RECITALS</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, concurrently with the execution and delivery hereof, Parent, the Company and Atlas Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">First</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger Sub</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and Atlas Merger Sub II, LLC, a Delaware limited liability company (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Second Merger Sub</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) have entered into an Agreement and Plan of Merger and Reorganization (as such agreement may be amended or supplemented from time to time pursuant to the terms thereof, the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), pursuant to which (i) the First Merger Sub will merge with and into the Company, with the Company surviving the merger as the surviving corporation and a wholly owned subsidiary of Parent and (ii) the Company will merge with and into the Second Merger Sub, with Second Merger Sub being the surviving entity of the Second Merger, upon the terms and subject to the conditions set forth in the Merger Agreement (together, the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, as of the date hereof, the Stockholder is the beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of such number of shares of Parent Common Stock as indicated in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">WHEREAS, as an inducement to the willingness of the Company to enter into the Merger Agreement, the Company has required that Stockholder enter into this Agreement.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">NOW, THEREFORE, intending to be legally bound, the parties hereby agree as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Definitions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Merger Agreement. For all purposes of this Agreement, the following terms shall have the following respective meanings:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Constructive Sale</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any security, a short sale with respect to such security, entering into or acquiring a derivative contract with respect to such security, entering into or acquiring a futures or forward contract to deliver such security or entering into any other hedging or other derivative transaction that has the effect of either directly or indirectly materially changing the economic benefits or risks of ownership of such security.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent Stockholder Matters</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the approval of the Merger Agreement and the Contemplated Transactions and the Parent Charter Amendment and, if deemed necessary by Parent the approval of the Parent Legacy Transaction.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means (i) all shares of Parent Common Stock owned, beneficially or of record, by the Stockholder as of the date hereof, and (ii) all additional shares of Parent Common Stock acquired by the Stockholder, beneficially owned or of record, during the period commencing with the execution and delivery of this Agreement and expiring on the Closing Date.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transferred</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to any security, the direct or indirect assignment, sale, transfer, tender, exchange, pledge or hypothecation, or the grant, creation or suffrage of a lien, security interest or encumbrance in or upon, or the gift, grant or placement in trust, or the Constructive Sale or other disposition of such security (including transfers by testamentary or intestate succession, by domestic relations order or other court order, or otherwise by operation of law) or any right, title or interest therein (including any right or power to vote to which the holder thereof may be entitled, whether such right or power is granted by proxy or otherwise), or the record or beneficial ownership thereof, the offer to make such a sale, transfer, Constructive Sale or other disposition, and each agreement, arrangement or understanding, whether or not in writing, to effect any of the foregoing.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer and Voting Restrictions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder covenants to Parent and the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise permitted by Section 2(c), during the period commencing with the execution and delivery of this Agreement and expiring on the Expiration Date (as defined below), the Stockholder shall not Transfer any of the Stockholder&#8217;s Shares, or publicly announce its intention to Transfer any of its Shares.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise permitted by this Agreement or otherwise permitted or required by order of a court of competent jurisdiction or a Governmental Authority, the Stockholder will not commit any act that would restrict the Stockholder&#8217;s legal power, authority and right to vote all of the Shares held by the Stockholder or otherwise prevent or disable the Stockholder from performing any of his, her or its obligations under this Agreement. Without limiting the generality of the foregoing, except for this Agreement, and as otherwise permitted by this Agreement, the Stockholder shall not enter into any voting agreement with any person or entity with respect to any of the Stockholder&#8217;s Shares, grant any person or entity any proxy (revocable or irrevocable) or power of attorney with respect to any of the Shares, deposit any Shares in a voting trust or otherwise enter into any agreement or arrangement with any person or entity in each case, which has the effect of limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares in favor of the Parent Stockholder Matters and against any competing proposals.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything else herein to the contrary, the Stockholder may, at any time, Transfer Shares (i) by will or other testamentary document or by intestacy, (ii) to such Stockholder&#8217;s Affiliates (in each case, directly or indirectly) (iii) to any member of the Stockholder&#8217;s immediate family (or, if the Stockholder is a corporation, partnership or other entity, to an immediate family member of a beneficial owner of the Shares held by the Stockholder), (iv) to any trust or other entity for the direct or indirect benefit of the Stockholder or the immediate family of the Stockholder (or, if the Stockholder is a corporation, partnership or other entity, for the direct or indirect benefit of an immediate family member of a beneficial owner of the Shares held by the Stockholder) or otherwise for estate tax or estate planning purposes, (v) in the case of a Stockholder who is not a natural person, by pro rata distributions from the Stockholder to its members, partners, or shareholders pursuant to the Stockholder&#8217;s organizational documents, (vi) purchased from the Company on or about the Closing Date but prior to the Closing (including any shares of the Company issued upon conversion of any pre-funded Company Warrants), (vii) to the extent required by applicable Law and (viii) pursuant to the exercise of any option to purchase any Parent Common Stock, including in order to pay the exercise price of such option or satisfy taxes applicable thereto; </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in the cases of clauses (i)-(v), (x) such Transferred Shares shall continue to be bound by this Agreement and (y) the applicable direct transferee (if any) of such Transferred Shares shall have executed and delivered to Parent and the Company a support agreement substantially identical to this Agreement upon consummation of the Transfer if not already a party thereto.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything to the contrary herein, nothing in this Agreement shall obligate the Stockholder to exercise any option or any other right to acquire any shares of Parent Common Stock.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Agreement to Vote Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder covenants to the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Until the Expiration Date (as defined below), at any meeting of the stockholders of Parent called to vote upon the Parent Stockholder Matters, however called, and at every adjournment or postponement thereof, and on every action or approval by written consent of the stockholders of Parent, the Stockholder shall be present (in person or by proxy) and vote, or exercise its right to consent with respect to, all Shares held by the Stockholder (A) in favor of the Parent Stockholder Matters, and (B) against any Acquisition Proposal.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>If the Stockholder is the beneficial owner, but not the record holder, of Shares, the Stockholder agrees to take all actions necessary to cause the record holder and any nominees to be present (in person or by proxy) and vote all the Stockholder&#8217;s Shares in accordance with this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>In the event of a stock split, stock dividend or distribution, or any change in the capital stock of Parent by reason of any split-up, reverse stock split, recapitalization, combination, reclassification, reincorporation, exchange of shares or the like, the term &#8220;Shares&#8221; shall be deemed to refer to and include such shares as well as all such stock dividends and distributions and any securities into which or for which any or all of such shares may be changed or exchanged or which are received in such transaction.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Action in Stockholder Capacity Only</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder is entering into this Agreement solely in the Stockholder&#8217;s capacity as a record holder and beneficial owner, as applicable, of its Shares and not in the Stockholder&#8217;s capacity as a director or officer of Parent. Nothing herein shall limit or affect the Stockholder&#8217;s ability to act as an officer or director of Parent.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Irrevocable Proxy</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby revokes (or agrees to cause to be revoked) any proxies that the Stockholder has heretofore granted with respect to its Shares. In the event and to the extent that the Stockholder fails to vote the Shares in accordance with </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> at any applicable meeting of the stockholders of Parent or pursuant to any applicable written consent of the stockholders of Parent, the Stockholder shall be deemed to have irrevocably granted to, and appointed, Parent, and any individual designated in writing by it, and each of them individually, as his, her or its proxy and attorney-in-fact (with full power of substitution), for and in its name, place and stead, to vote his, her or its Shares in any action by written consent of Parent stockholders or at any meeting of Parent stockholders called with respect to any of the matters specified in, and in accordance and consistent with, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement. Parent agrees not to exercise the proxy granted herein for any purpose other than the purposes described in this Agreement. Except as otherwise provided for herein, the Stockholder hereby affirms that the irrevocable proxy is coupled with an interest and may under no circumstances be revoked and that such irrevocable proxy is executed and intended to be irrevocable. Notwithstanding any other provisions of this Agreement, the irrevocable proxy granted hereunder shall automatically terminate on the Expiration Date.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Solicitation</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder agrees not to directly or indirectly, including through any of its officers, directors or agents, take any action that Parent is prohibited from taking pursuant to Section 5.4 of the Merger Agreement and Section 5.4 of the Merger Agreement is hereby incorporated by reference </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">mutatis mutandis</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Documentation and Information</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder shall permit and hereby authorizes Parent and the Company to publish and disclose in all documents and schedules filed with the SEC, and any press release or other disclosure document that Parent or the Company reasonably determines to be necessary in connection with the Merger and any of the Contemplated Transactions, a copy of this Agreement, the Stockholder&#8217;s identity and ownership of the Shares and the nature of the Stockholder&#8217;s commitments and obligations under this Agreement. Each of Parent and the Company is an intended third-party beneficiary of this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Representations and Warranties of the Stockholder</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Stockholder hereby represents and warrants to Parent and the Company as follows:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(i) The Stockholder is the beneficial or record owner of the shares of Parent Common Stock indicated in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (each of which shall be deemed to be &#8220;held&#8221; by the Stockholder for purposes of </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 3</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> unless otherwise expressly stated with respect to any shares in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">), free and clear of any and all Encumbrances (except for any Encumbrance that may be imposed pursuant to this Agreement), and Encumbrances arising under applicable securities or community property laws; and (ii) the Stockholder does not beneficially own any securities of Parent other than the shares of Parent Common Stock and rights to purchase shares of Parent Common Stock set forth in </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise provided in this Agreement, the Stockholder has full power and authority to (i) make, enter into and carry out the terms of this Agreement and (ii) vote all of its Shares in the manner set forth in this Agreement without the consent or approval of, or any other action on the part of, any other person or entity (including any Governmental Authority). Without limiting the generality of the foregoing, the Stockholder has not entered into any voting agreement (other than this Agreement) with any person with respect to any of the Stockholder&#8217;s Shares, granted any person any proxy (revocable or irrevocable) or power of attorney with respect to any of the Stockholder&#8217;s Shares, deposited any of the Stockholder&#8217;s Shares in a voting trust or entered into any arrangement or agreement with any person limiting or affecting the Stockholder&#8217;s legal power, authority or right to vote the Stockholder&#8217;s Shares on any matter.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Agreement has been duly and validly executed and delivered by the Stockholder and (assuming the due authorization, execution and delivery by the other parties hereto) constitutes a valid and binding agreement of the Stockholder enforceable against the Stockholder in accordance with its terms, subject to the Enforceability Exceptions. The execution and delivery of this Agreement by the Stockholder and the performance by the Stockholder of the agreements and obligations hereunder will not result in any breach or violation of or be in conflict with or constitute a default under any term of any Contract or if applicable any provision of an organizational document (including a certificate of incorporation) to or by which the Stockholder is a party or bound, </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">or any applicable law to which the Stockholder (or any of the Stockholder&#8217;s assets) is subject or bound, except for any such breach, violation, conflict or default which, individually or in the aggregate, would not reasonably be expected to materially impair or adversely affect the Stockholder&#8217;s ability to perform its obligations under this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The execution, delivery and performance of this Agreement by the Stockholder do not and will not require any consent, approval, authorization or permit of, action by, filing with or notification to, any Governmental Authority, except for any such consent, approval, authorization, permit, action, filing or notification the failure of which to make or obtain, individually or in the aggregate, has not and would not materially impair the Stockholder&#8217;s ability to perform its obligations under this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Stockholder has had the opportunity to review the Merger Agreement and this Agreement with counsel of the Stockholder&#8217;s own choosing. The Stockholder has had an opportunity to review with its own tax advisors the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that it must rely solely on its advisors and not on any statements or representations made by Parent, the Company or any of their respective agents or representatives with respect to the tax consequences of the Merger and the Contemplated Transactions. The Stockholder understands that such Stockholder (and not Parent, the Company or the Surviving Corporation) shall be responsible for such Stockholder&#8217;s tax liability that may arise as a result of the Merger or the Contemplated Transactions. The Stockholder understands and acknowledges that the Company, Parent and Merger Sub are entering into the Merger Agreement in reliance upon the Stockholder&#8217;s execution, delivery and performance of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>With respect to the Stockholder, as of the date hereof, there is no action, suit, investigation or proceeding pending against, or, to the knowledge of the Stockholder, threatened against, the Stockholder or any of the Stockholder&#8217;s properties or assets (including the Shares) that would reasonably be expected to prevent or materially delay or impair the ability of the Stockholder to perform its obligations hereunder or to consummate the transactions contemplated hereby.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Termination</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall terminate and shall cease to be of any further force or effect as of the earliest of (a) such date and time as the Merger Agreement shall have been terminated pursuant to the terms thereof as in effect on the date of this Agreement (and without giving effect to any amendments thereto unless consented to by the Stockholder), (b) the Effective Time and (c) the time this Agreement is terminated upon the written agreement of the Stockholder, the Company and Parent (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Expiration Date</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">,</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that (i) </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall survive the termination of this Agreement, and (ii) the termination of this Agreement shall not relieve any party hereto from any liability for any material and willful breach of this Agreement prior to the Effective Time.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Miscellaneous Provisions</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Amendments</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. No amendment of this Agreement shall be effective against any party unless it shall be in writing and signed by each of the parties hereto.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Entire Agreement; Counterparts; Exchanges by Electronic Transmission or Facsimile</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement constitutes the entire agreement between the parties to this Agreement and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof. This Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in&#160;counterparts or otherwise) by all parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Applicable Law; Jurisdiction.</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws. In any action or proceeding between any of the parties arising out of or relating to this Agreement, each of the parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with clause (i) of this </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10(c)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, (iii) waives any objection to laying </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">venue in any such action or proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party, (v) agrees that service of process upon such party in any such action or proceeding shall be effective if notice is given in accordance with </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10(h)</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Agreement and (vi)&#160;irrevocably and unconditionally waives the right to trial by jury.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Assignment</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. This Agreement shall be binding upon, and shall be enforceable by and inure solely to the benefit of, the parties and their respective successors and permitted assigns; </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that neither this Agreement nor any of a party&#8217;s rights or obligations hereunder may be assigned or delegated (except by the Merger) by such party without the prior written consent of the other party, and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such party without the other party&#8217;s prior written consent shall be void and of no effect.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">No Third Party Rights</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Severability</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable term or provision.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Specific Performance</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;"> </span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy. The parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached. It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties waives any bond, surety or other security that might be required of any other party with respect thereto. Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notices</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All notices and other communications hereunder shall be in writing and shall be deemed duly delivered (i) one (1) Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable international overnight courier service, (ii) upon delivery in the case of delivery by hand or (iii) on the date delivered in the place of delivery if sent by email or facsimile (with a written or electronic confirmation of delivery) prior to 6:00 p.m. (New York City time), otherwise on the next succeeding Business Day, (A) if to the Company or Parent, to the address, electronic mail address or facsimile provided in Section 11.7 of the Merger Agreement, including to the persons designated therein to receive copies; and/or (B) if to the Stockholder, to the Stockholder&#8217;s address, electronic mail address or facsimile shown below Stockholder&#8217;s signature to this Agreement.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Confidentiality</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.  Except to the extent required by applicable Law or regulation, the Stockholder shall hold any non-public information regarding the Company, this Agreement, the Merger Agreement and the Merger in strict confidence and shall not divulge any such information to any third person until the Company and Parent have publicly disclosed their entry into the Merger Agreement and this Agreement; provided, however, that the Stockholder may disclose such information to its Affiliates, attorneys, accountants, consultants, and other advisors (provided that such Persons are subject to confidentiality obligations at least as restrictive as those contained </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">herein).  Neither the Stockholder nor any of its Affiliates (other than Parent, whose actions shall be governed by the Merger Agreement), shall issue or cause the publication of any press release or other public announcement with respect to Parent, this Agreement, the Merger, the Merger Agreement or the other transactions contemplated hereby or thereby without the prior written consent of the Company and Parent, except as may be required by applicable Law in which circumstance such announcing party shall make reasonable efforts to consult with the Company and Parent to the extent practicable.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Interpretation</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The words &#8220;hereof,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Sections and Appendixes are to Sections and Appendixes of this Agreement unless otherwise specified. Any capitalized terms used in any Appendix but not otherwise defined therein shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular, the masculine gender shall include the feminine and neuter genders; the feminine gender shall include the masculine and neuter genders; and the neuter gender shall include masculine and feminine gender. Whenever the words &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;including&#8221; are used in this Agreement, they shall be deemed to be followed by the words &#8220;without limitation,&#8221; whether or not they are in fact followed by those words or words of like import. The word &#8220;or&#8221; is not exclusive. &#8220;Writing,&#8221; &#8220;written&#8221; and comparable terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or Contract are to that agreement or Contract as amended, modified or supplemented from time to time in accordance with the terms hereof and thereof. References to any Person include the successors and permitted assigns of that Person. References to any statute are to that statute and to the rules and regulations promulgated thereunder, in each case as amended, modified, re-enacted thereof, substituted, from time to time. References to &#8220;$&#8221;&#160;and&#160;&#8220;dollars&#8221; are to the currency of the United States. All accounting terms used herein will be interpreted, and all accounting determinations hereunder will be made, in accordance with GAAP unless otherwise expressly specified. References from or through any date shall mean, unless otherwise specified, from and including or through and including, respectively. All references to &#8220;days&#8221; shall be to calendar days unless otherwise indicated as a &#8220;Business Day.&#8221; Except as otherwise specifically indicated, for purposes of measuring the beginning and ending of time periods in this Agreement (including for purposes of &#8220;Business Day&#8221; and for hours in a day or Business Day), the time at which a thing, occurrence or event shall begin or end shall be deemed to occur in the Eastern time zone of the United States. The Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall not be applied in the construction or interpretation of this Agreement.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Remainder of Page Left Intentionally Blank</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed as of the date first above written.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">COMPANY:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-8" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Oruka Therapeutics, Inc.</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-11" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Parent Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-9" style="font-variant:normal;text-transform:uppercase;">Parent</span>:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;"><span class="CharOverride-8" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">arca biopharma, Inc.</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 35.47%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 63.25%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-11" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Parent Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">[STOCKHOLDER],</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">in his/her capacity as the Stockholder:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Signature: _______________________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Address:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 44.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_______________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 54.49%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page to Parent Stockholder Support Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Appendix A</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex D-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T104"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;E</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">FORM OF LOCK-UP AGREEMENT</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:right;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">April 3, 2024</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">ARCA biopharma, Inc.</span><span class="CharOverride-2" style="font-family:Calibri, sans-serif;"><br/></span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10170 Church Ranch Way, Suite 100</span><span class="CharOverride-2" style="font-family:Calibri, sans-serif;"><br/></span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Westminster, CO</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Ladies and Gentlemen:</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The undersigned signatory of this lock-up agreement (this &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Lock-Up Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) understands that ARCA biopharma, Inc., a Delaware corporation (&#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Parent</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), has entered into an Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024 (as the same may be amended from time to time, the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Merger Agreement</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) with Atlas Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of Parent, Atlas Merger Sub II LLC, a Delaware limited liability company and a wholly owned subsidiary of Parent, and Oruka Therapeutics, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Company</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Merger Agreement.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">As a condition and inducement to each of the parties to enter into the Merger Agreement and to consummate the transactions contemplated thereby, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby irrevocably agrees that, subject to the exceptions set forth herein, without the prior written consent of Parent, the undersigned will not, during the period commencing upon the Closing and ending on the date that is 180 days after the Closing Date (the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Restricted Period</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided,</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that if a registration statement covering the shares of Company Common Stock and pre-funded Company Warrants issued and sold in connection with the Company Pre-Closing Financing (other than any shares or pre-funded Company Warrants held by affiliates of the Company) has not been declared effective by the SEC prior to the end of such 180-day period, then the Restricted Period shall end on such later date upon which such registration statement is first declared effective:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(1)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Parent Common Stock or any securities convertible into or exercisable or exchangeable for shares of Parent Common Stock (including without limitation, shares of Parent Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the SEC and securities of Parent which may be issued upon exercise of an option to purchase shares of Parent Common Stock or a warrant to purchase shares of Parent Common Stock) that are currently or hereafter owned by the undersigned, except as set forth below (collectively, the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Undersigned&#8217;s Shares</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;);</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(2)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>enter into any swap, short sale, hedge or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Undersigned&#8217;s Shares regardless of whether any such transaction described in clause (1) above or this clause (2) is to be settled by delivery of shares of Parent Common Stock or other securities, in cash or otherwise;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(3)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>make any demand for, or exercise any right with respect to, the registration of any shares of Parent Common Stock or any security convertible into or exercisable or exchangeable for shares of Parent Common Stock (other than such rights set forth in the Merger Agreement); or</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(4)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>publicly disclose the intention to do any of the foregoing.</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">The restrictions and obligations contemplated by this Lock<span class="nobreak">-Up</span> Agreement shall not apply to:</p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>transfers of the Undersigned&#8217;s Shares:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(1)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>(A) to any person related to the undersigned (or to an ultimate beneficial owner of the undersigned) by blood or adoption who is an immediate family member of the undersigned, or by marriage or domestic partnership (each, a &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Family Member</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), or to a trust formed for the benefit of the undersigned or any of the undersigned&#8217;s Family Members, (B) to the undersigned&#8217;s estate, following the death of the undersigned, by </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">will, intestacy or other operation of Law, (C) as a bona fide gift or a charitable contribution, (D) by operation of Law pursuant to a qualified domestic order or in connection with a divorce settlement or (E) to any partnership, corporation or limited liability company which is controlled by or under common control with  the undersigned and/or by any such Family Member(s);</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(2)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>if the undersigned is a corporation, partnership, limited liability company or other entity, (A)&#160;to another corporation, partnership, limited liability company or other entity that is a direct or indirect affiliate (as defined under Rule 12b-2 of the Exchange Act) of the undersigned, including investment funds or other entities that controls or manages, is under common control or management with, or is controlled or managed by, the undersigned, (B) as a distribution or dividend to equity holders, current or former general or limited partners, members or managers (or to the estates of any of the foregoing), as applicable, of the undersigned (including upon the liquidation and dissolution of the undersigned pursuant to a plan of liquidation approved by the undersigned&#8217;s equity holders), (C) as a bona fide gift or a charitable contribution or otherwise to a trust or other entity for the direct or indirect benefit of an immediate family member of a beneficial owner (as defined in Rule 13d-3 of the Exchange Act) of the Undersigned&#8217;s Shares or (D) transfers or dispositions not involving a change in beneficial ownership; or</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:53pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(3)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>if the undersigned is a trust, to any grantors or beneficiaries of the trust;</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;"><span class="CharOverride-4" style="text-decoration:underline;">provided</span> that, in the case of any transfer or distribution pursuant to this clause (a), such transfer is not for value (other than transfers pursuant to 1(A), 1(E) or 2(A)) and each donee, heir, beneficiary or other transferee or distributee shall sign and deliver to Parent a lock<span class="nobreak">-up</span> agreement in the form of this Lock<span class="nobreak">-Up</span> Agreement with respect to the shares of Parent Common Stock or such other securities that have been so transferred or distributed;</p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the exercise of an option to purchase shares of Parent Common Stock (including a net or cashless exercise of an option to purchase shares of Parent Common Stock ), and any related transfer of shares of Parent Common Stock to Parent for the purpose of paying the exercise price of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options or for paying taxes (including estimated taxes) due as a result of the exercise of such options; </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>transfers to Parent in connection with the net settlement of any other equity award that represents the right to receive in the future shares of Parent Common Stock, settled in shares of Parent Common Stock, to pay any tax withholding obligations; </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that, for the avoidance of doubt, the underlying shares of Parent Common Stock shall continue to be subject to the restrictions on transfer set forth in this Lock-Up Agreement;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Parent Common Stock; </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that such plan does not provide for any transfers of shares of Parent Common Stock during the Restricted Period;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>transfers by the undersigned of shares of Parent Common Stock purchased by the undersigned on the open market or in a public offering by Parent, in each case following the Effective Time;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 23px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>pursuant to a bona-fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Parent&#8217;s capital stock involving a change of control of Parent, </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that in the event that such tender offer, merger, consolidation or other such transaction is not completed, the Undersigned&#8217;s Shares shall remain subject to the restrictions contained in this Lock-Up Agreement;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>pursuant to an order of a court or regulatory agency; or</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>transfers by the undersigned of shares of Parent Common Stock issued pursuant to the Merger Agreement in respect of shares of the Company (including any shares of the Company issued upon exercise of any pre-funded Company Warrants), if any, purchased from the Company on or about the Closing Date but prior to the Closing.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, further, that, with respect to each of (b), (c), and (d) above, no filing by any party (including any donor, donee, transferor, transferee, distributor or distributee) under Section 16 of the Exchange Act or other public announcement shall be made voluntarily reporting a reduction in beneficial ownership of shares of Parent Common Stock or any securities convertible into or exercisable or exchangeable for Parent Common Stock in connection with such transfer or disposition during the Restricted Period (other than any exit filings) and if any filings under </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Section 16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Parent Common Stock in connection with such transfer or distribution, shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes therein, in reasonable detail, a description of the circumstances of the transfer and that the shares remain subject to the lock-up agreement.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">For purposes of this Lock-Up Agreement, &#8220;change of control&#8221; shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of the Company&#8217;s voting securities if, after such transfer, the Company&#8217;s stockholders as of immediately prior to such transfer do not hold a majority of the outstanding voting securities of the Company (or the surviving entity).</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Any attempted transfer in violation of this Lock-Up Agreement will be of no effect and null and void, regardless of whether the purported transferee has any actual or constructive knowledge of the transfer restrictions set forth in this Lock-Up Agreement, and will not be recorded on the share register of Parent. In furtherance of the foregoing, the undersigned agrees that Parent and any duly appointed transfer agent for the registration or transfer of the securities described herein are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Lock-Up Agreement. Parent may cause the legend set forth below, or a legend substantially equivalent thereto, to be placed upon any certificate(s) or other documents, ledgers or instruments evidencing the undersigned&#8217;s ownership of Parent Common Stock:</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-left:72pt;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">THE SHARES REPRESENTED BY THIS CERTIFICATE ARE <br/>SUBJECT TO AND MAY ONLY BE TRANSFERRED IN <br/>COMPLIANCE WITH A LOCK-UP AGREEMENT, A COPY <br/>OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF <br/>THE COMPANY.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The undersigned understands that if the Merger Agreement is terminated for any reason, the undersigned shall be released from all obligations under this Lock-Up Agreement. The undersigned understands that Parent is proceeding with the transactions contemplated by the Merger Agreement in reliance upon this Lock-Up Agreement.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Except as otherwise provided herein, any and all remedies herein expressly conferred upon a party will be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party of any one remedy will not preclude the exercise of any other remedy.  The parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate remedy, would occur in the event that any of the provisions of this Lock-Up Agreement were not performed in accordance with their specific terms (including failing to take such actions as are required of it hereunder to consummate this Agreement) or were otherwise breached.  It is accordingly agreed that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Lock-Up Agreement and to enforce specifically the terms and provisions hereof in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which they are entitled at law or in equity, and each of the parties waives any bond, surety or other security that might be required of any other party with respect thereto.  Each of the parties further agrees that it will not oppose the granting of an injunction, specific performance or other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an appropriate remedy for any reason at law or in equity.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">In the event that any holder of Parent&#8217;s securities that are subject to a substantially similar agreement entered into by such holder, other than the undersigned, is permitted by Parent to sell or otherwise transfer or dispose of shares of Parent Common Stock for value other than as permitted by this or a substantially similar agreement entered into by such holder (whether in one or multiple releases or waivers), the same percentage of shares of Parent Common Stock held by the undersigned on the date of such release or waiver as the percentage of the total number of outstanding shares of Parent Common Stock held by such holder on the date of such release or waiver that are the subject of such release or waiver shall be immediately and fully released on the same terms from any remaining restrictions set forth herein (the &#8220;</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Pro-Rata Release</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;); </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">provided</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">however</span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that such Pro-Rata Release shall not be applied unless </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and until permission has been granted by Parent to an equity holder or equity holders to sell or otherwise transfer or dispose of all or a portion of such equity holders shares of Parent Common Stock in an aggregate amount in excess of 1% of the number of shares of Parent Common Stock subject to a substantially similar agreement.  In the event of any Pro-Rata Release, the Company shall promptly (and in any event within two (2) business days of such release) inform each relevant holder of Parent Common Stock or warrants of the terms of such Pro-Rata Release.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Upon the release of any of the Undersigned&#8217;s Shares from this Lock-Up Agreement, Parent will reasonably cooperate with the undersigned to facilitate the timely preparation and delivery of certificates representing the Undersigned Shares without the restrictive legend above or the withdrawal of any stop transfer instructions by virtue of this Lock-Up Agreement.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">This Lock-Up Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that might otherwise govern under applicable principles of conflicts of laws.  In any action or proceeding between any of the parties arising out of or relating to this Lock-Up Agreement, each of the parties: (i) irrevocably and unconditionally consents and submits to the exclusive jurisdiction and venue of the Court of Chancery of the State of Delaware or, to the extent such court does not have subject matter jurisdiction, the Superior Court of the State of Delaware or the United States District Court for the District of Delaware, (ii) agrees that all claims in respect of such action or proceeding shall be heard and determined exclusively in accordance with foregoing clause (i) of this paragraph, (iii) waives any objection to laying venue in any such action or proceeding in such courts, (iv) waives any objection that such courts are an inconvenient forum or do not have jurisdiction over any party and (v) irrevocably and unconditionally waives the right to trial by jury. This Lock-Up Agreement constitutes the entire agreement between the parties to this Lock-Up Agreement and supersedes all other prior agreements, arrangements and understandings, both written and oral, among the parties with respect to the subject matter hereof. This Lock-Up Agreement may be executed in several counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument.  The exchange of a fully executed Lock-Up Agreement (in&#160;counterparts or otherwise) by all parties by facsimile or electronic transmission in PDF format shall be sufficient to bind the parties to the terms and conditions of this Agreement.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-left:1pt;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">[SIGNATURE PAGE FOLLOWS]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Very truly yours,</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:right;">Print Name of Stockholder:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Signature (for individuals):</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 37.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Signature (for entities):</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 3.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 33.48%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 3.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 32.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 27.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 3.21%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 33.48%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
				</tr>

		</table>
		<p class="ParaOverride-12" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">[Signature Page to Lock-Up Agreement]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 38.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Accepted and Agreed<br/>by ARCA biopharma, Inc.:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 60.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 2.78%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 34.46%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 60.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 38.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 60.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 38.51%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 60.20%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-13" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">[Signature Page to Lock-Up Agreement]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex E-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T105"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;F</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">Arca biopharma, Inc.</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">CERTIFICATE OF DESIGNATION OF PREFERENCES,</span><span class="CharOverride-3" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">RIGHTS AND LIMITATIONS</span><span class="CharOverride-3" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">OF</span><span class="CharOverride-3" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Pursuant to Section 151 of the</span><span class="CharOverride-5" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:normal;"><br/></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">General Corporation Law of the State of Delaware</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:7.5pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of ARCA biopharma, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Corporation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), that the following resolution was duly adopted by the Board of Directors of the Corporation (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Board of Directors</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">DGCL</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), at a meeting duly called and held on July 15, 2024, which resolution provides for the creation of a series of the Corporation&#8217;s Preferred Stock, par value $0.001 per share, which is designated as &#8220;Series B Non-Voting Convertible Preferred Stock,&#8221; with the preferences, rights and limitations set forth therein relating to dividends, conversion, redemption, dissolution and distribution of assets of the Corporation.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">WHEREAS</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">:<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>the Amended and Restated Certificate of Incorporation of the Corporation (as amended from time to time, the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Certificate of Incorporation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), provides for a class of its authorized stock known as Preferred Stock, consisting of 5,000,000 shares, $0.001 par value per share (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), issuable from time to time in one or more series.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">RESOLVED</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">:<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>that, pursuant to authority conferred upon the Board of Directors by the Certificate of Incorporation, (i) a series of Preferred Stock of the Corporation be, and hereby is, authorized by the Board of Directors, (ii)&#160;the Board of Directors hereby authorizes the issuance of &#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> shares of &#8220;Series B Non-Voting Convertible Preferred Stock&#8221; pursuant to the terms of the Agreement and Plan of Merger and Reorganization, dated April 3, 2024, by and among the Corporation, Atlas Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of the Corporation, Atlas Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of Parent, and Oruka Therapeutics, Inc. (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Merger Agreement</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), and (iii) the Board of Directors hereby fixes the designations, powers, preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions thereof, of such shares of such series of Preferred Stock, in addition to any provisions set forth in the Certificate of Incorporation that are applicable to the Preferred Stock of all classes and series, as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;text-indent:20pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">TERMS OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Definitions</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. For the purposes hereof, the following terms shall have the following meanings:</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Business Day</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to&#160;close.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Buy-In</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall have the meaning set forth in </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Closing Sale Price</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, for any security as of any date, the last closing trade price for such security immediately prior to 4:00 p.m., New York City time, on the principal Trading Market where such security is listed or traded, as reported by Bloomberg, L.P. (or an equivalent, reliable reporting service), or if the foregoing do not apply, the last trade price of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg, L.P., or, if no last trade price is reported for such security by Bloomberg, L.P., the average of the bid prices of any market makers for such security as reported on the OTC Pink Market by OTC Markets Group, Inc. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as determined in good faith by the Board of Directors.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Commission</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the United States Securities and Exchange Commission.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Corporation&#8217;s common stock, par value $0.001 per share, and stock of any other class of securities into which such securities may hereafter be reclassified or changed.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Conversion Shares</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Series B Non-Voting Preferred Stock in accordance with the terms hereof.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Holder</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a holder of shares of Series B Non-Voting Preferred Stock.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Person</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Trading Day</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a day on which the principal Trading Market is open for business.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:55pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Trading Market</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Designation, Amount and Par Value</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The series of Preferred Stock shall be designated as the Corporation&#8217;s Series B Non-Voting Convertible Preferred Stock (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Series B Non-Voting Preferred Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and the number of shares so designated shall be &#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>. Each share of Series B Non-Voting Preferred Stock shall have a par value of $0.001 per share.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Dividends</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Holders shall be entitled to receive, and the Corporation shall pay, dividends on shares of the Series B Non-Voting Preferred Stock (on an as-if-converted-to-Common-Stock basis, without regard to the Beneficial Ownership Limitation (as defined below)) equal to and in the same form, and in the same manner, as dividends (other than dividends on shares of the Common Stock payable in the form of Common Stock) actually paid on shares of the Common Stock when, as and if such dividends (other than dividends payable in the form of Common Stock) are paid on shares of the Common Stock. Other than as set forth in the previous sentence, no other dividends shall be paid on shares of Series B Non-Voting Preferred Stock, and the Corporation shall pay no dividends (other than dividends payable in the form of Common Stock) on shares of the Common Stock unless it simultaneously complies with the previous sentence.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Voting Rights</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Except as otherwise provided herein or as otherwise required by the DGCL, the Series B Non-Voting Preferred Stock shall have no voting rights. However, as long as any shares of Series B Non-Voting Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote or written waiver of the holders of a majority of the then outstanding shares of the Series B Non-Voting Preferred Stock: (i) alter or change adversely the powers, preferences or rights given to the Series B Non-Voting Preferred Stock or alter or amend this Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Certificate of Designation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), amend or repeal any provision of, or add any provision to, the Certificate of Incorporation or Amended and Restated Bylaws of the Corporation, as amended, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock, in each case if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series B Non-Voting Preferred Stock, regardless of whether any of the foregoing actions shall be by means of amendment to the Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (ii) issue further shares of Series B Non-Voting Preferred Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than by conversion) the number of authorized shares of Series B Non-Voting Preferred Stock, (iii) at any time while at least &#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> shares of Series B Non-Voting Preferred Stock remains issued and outstanding, consummate either: (A) any Fundamental Transaction (as defined below) or (B) any merger or consolidation of the Corporation with or into another entity or any stock sale to, or other business combination in which the stockholders of the Corporation immediately before such transaction do not hold at least a majority on an as-converted-to-Common Stock basis of the capital stock of the Corporation, immediately after such transaction or (iv) enter into any agreement with respect to any of the foregoing that does not explicitly require the approval contemplated herein to consummate such transaction. Holders of shares of Common Stock acquired upon the conversion of shares of Series B Non-Voting Preferred Stock shall be entitled to the same voting rights as each other holder of Common Stock.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Any vote required or permitted under </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> may be taken at a meeting of the Holders or through the execution of an action by written consent in lieu of such meeting or other written waiver by such stockholders, provided that the consent or waiver is executed by Holders representing a majority of the outstanding shares of Series B Non-Voting Preferred Stock.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Rank; Liquidation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Series B Non-Voting Preferred Stock shall rank on parity with the Common Stock as to distributions of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntarily or involuntarily (a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Liquidation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Upon any Liquidation,  each Holder shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder of Common Stock would receive if the Series B Non-Voting Preferred Stock were fully converted (disregarding for such purpose any Beneficial Ownership Limitations) to Common Stock which amounts shall be paid </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">pari passu</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> with all holders of Common Stock, plus an additional amount equal to any dividends declared on but unpaid to such shares. If, upon any such Liquidation, the assets of the Corporation shall be insufficient to pay the Holders of shares of the Series B Non-Voting Preferred Stock the amount required under the preceding sentence, then all remaining assets of the Corporation shall be distributed ratably to the Holders and the holders of Common Stock in accordance with the respective amounts that would be payable on all such securities if all amounts payable thereon were paid in full. For the avoidance of any doubt, a Fundamental Transaction shall not be deemed a Liquidation unless the Corporation expressly declares that such Fundamental Transaction shall be treated as if it were a Liquidation.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conversion at Option of Holder</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Subject to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, each share of Series B Non-Voting Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the Holder thereof, into a number of shares of Common Stock equal to the Conversion Ratio, subject to the Beneficial Ownership Limitation (as defined below) (each, an &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Optional Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Holders shall effect conversions by providing the Corporation with the form of conversion notice attached hereto as </span><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:underline;">Annex A</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Notice of Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), duly completed and executed. Provided the Corporation&#8217;s transfer agent is participating in the Depository Trust Company (&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">DTC</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) Fast Automated Securities Transfer program, the Notice of Conversion may specify, at the Holder&#8217;s election, whether the applicable Conversion Shares shall be credited to the account of the Holder&#8217;s prime broker with DTC through its Deposit Withdrawal Agent Commission system (a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">DWAC Delivery</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The date on which an Optional Conversion shall be deemed effective (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Conversion Date</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) shall be the Trading Day that the Notice of Conversion, completed and executed, is sent via email to, and received during regular business hours by, the Corporation; provided, that the original certificate(s) (if any) representing such shares of Series B Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation within two (2) Trading Days thereafter. In all other cases, the Conversion Date shall be defined as the Trading Day on which the original certificate(s) (if any) representing such shares of Series B Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion, are received by the Corporation. The calculations set forth in the Notice of Conversion shall control in the absence of manifest or mathematical error.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Conversion Ratio</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Conversion Ratio</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; for each share of Series B Non-Voting Preferred Stock shall be 1,000 shares of Common Stock issuable upon the conversion (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of each share of Series B Non-Voting Preferred Stock (corresponding to a ratio of 1,000:1), subject to adjustment as provided herein.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Beneficial Ownership Limitation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Notwithstanding anything herein to the contrary, the Corporation shall not effect any conversion of any share of Series B Non-Voting Preferred Stock with respect to a Holder, and a Holder shall not have the right to convert any portion of the Series B Non-Voting Preferred Stock pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, to the extent that, after giving effect to such attempted conversion set forth on an applicable Notice of Conversion with respect to the Series B Non-Voting Preferred Stock, such Holder (or any of such Holder&#8217;s affiliates or any other Person who would be a beneficial owner of Common Stock beneficially owned by the Holder for purposes of Section 13(d) or Section 16 of the Exchange Act and the applicable rules and regulations of the United States Securities and Exchange Commission (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Commission</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), including any &#8220;group&#8221; of which the Holder is a member (the foregoing, &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Attribution Parties</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;)) would beneficially own a number of shares </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">of Common Stock in excess of the Beneficial Ownership Limitation. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Holder and its Attribution Parties shall include the number of shares of Common Stock issuable upon conversion of the Series B Non-Voting Preferred Stock subject to the Notice of Conversion with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which are issuable upon (A) conversion of the remaining, unconverted Series B Non-Voting Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to and would exceed a limitation on conversion or exercise similar to the limitation contained herein. Except as set forth in the preceding sentence, for purposes of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable rules and regulations of the Commission, and the terms &#8220;beneficial ownership&#8221; and &#8220;beneficially own&#8221; have the meanings ascribed to such terms therein. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section 13(d) of the Exchange Act and the applicable rules and regulations of the Commission. For purposes of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (A) the Corporation&#8217;s most recent periodic or annual filing with the Commission, as the case may be, (B) a more recent public announcement by the Corporation that is filed with the Commission, or (C) a more recent notice by the Corporation or the Corporation&#8217;s transfer agent to the Holder setting forth the number of shares of Common Stock then outstanding. Upon the written request of a Holder (which may be by email), the Corporation shall, within two (2) Trading Days thereof, confirm in writing to such Holder (which may be via email) the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to any actual conversion or exercise of securities of the Corporation, including shares of Series B Non-Voting Preferred Stock, by such Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was last publicly reported or confirmed to the Holder. The &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Beneficial Ownership Limitation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall initially be [19.99]% of the number of shares of Common Stock outstanding as of the applicable measurement date. The Corporation shall be entitled to rely on representations made to it by the Holder in any Notice of Conversion regarding its Beneficial Ownership Limitation. Notwithstanding the foregoing, by written notice to the Corporation (which may be via email), (i) each Holder may reset the Beneficial Ownership Limitation percentage to a higher percentage applicable to such Holder, not to exceed 19.99%, which increase will not be effective until the sixty-first (61</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">st</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) day after such written notice is delivered to the Corporation, and (ii) each Holder may reset the Beneficial Ownership Limitation percentage to a lower percentage effective immediately after the delivery of such notice to the Corporation. Upon such an increase by a Holder of the Beneficial Ownership Limitation pursuant to clause (i) applicable to such Holder, not to exceed 19.99%, the Beneficial Ownership Limitation may not be further amended by such Holder without first providing the minimum notice required by this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Notwithstanding the foregoing, (x) at any time following notice of a Fundamental Transaction, each Holder may waive and/or change the Beneficial Ownership Limitation applicable to such Holder effective immediately upon written notice to the Corporation and may reinstitute a Beneficial Ownership Limitation at any time thereafter effective immediately upon written notice to the Corporation (y) at any time that the beneficial ownership of shares of Common Stock of a Holder (together with any of such Holder&#8217;s Attribution Parties) is equal to or less than 9.00% of the number of shares of Common Stock outstanding as of any given date, then such Holder&#8217;s Beneficial Ownership Limitation shall automatically be set to 9.99%. The provisions of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be construed, corrected and implemented in a manner so as to effectuate the intended Beneficial Ownership Limitation herein contained and the shares of Common Stock underlying the Series B Non-Voting Preferred Stock in excess of the Beneficial Ownership Limitation shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the Exchange Act.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Mechanics of Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.1<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Delivery of Certificate or Electronic Issuance</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Upon Conversion not later than two (2)&#160;Trading Days after the applicable Conversion Date, or if the Holder requests the issuance of physical certificate(s), two (2)&#160;Trading Days after receipt by the Corporation of the original certificate(s) representing such shares of Series B Non-Voting Preferred Stock being converted, duly endorsed, and the accompanying Notice of Conversion (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Share Delivery Date</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), the Corporation shall either: (a)&#160;deliver, or cause to be delivered, to the converting Holder a physical certificate or certificates representing the number of Conversion Shares being acquired upon the conversion of shares of Series B Non-Voting Preferred Stock, or (b)&#160;in the case of a DWAC Delivery (if so requested by the Holder), electronically transfer such Conversion Shares by crediting the account of the Holder&#8217;s </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">prime broker with DTC through its DWAC system. If in the case of any Notice of Conversion such certificate or certificates for the Conversion Shares are not delivered to or as directed by or, in the case of a DWAC Delivery, such shares are not electronically delivered to or as directed by, the applicable Holder by the Share Delivery Date, the applicable Holder shall be entitled to elect to rescind such Notice of Conversion by written notice to the Corporation at any time on or before its receipt of such certificate or certificates for Conversion Shares or electronic receipt of such shares, as applicable, in which event the Corporation shall promptly return to such Holder any original Series B Non-Voting Preferred Stock certificate delivered to the Corporation and such Holder shall promptly return to the Corporation any Common Stock certificates or otherwise direct the return of any shares of Common Stock delivered to the Holder through the DWAC system, representing the shares of Series B Non-Voting Preferred Stock unsuccessfully tendered for conversion to the Corporation.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.2<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Obligation Absolute</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Subject to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Corporation&#8217;s obligation to issue and deliver the Conversion Shares upon conversion of Series B Non-Voting Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other Person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection with the issuance of such Conversion Shares. Subject to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, in the event a Holder shall elect to convert any or all of its Series B Non-Voting Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or anyone associated or affiliated with such Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and/or enjoining conversion of all or part of the Series B Non-Voting Preferred Stock of such Holder shall have been sought and obtained by the Corporation, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the value of the Conversion Shares into which would be converted the Series B Non-Voting Preferred Stock which is subject to such injunction, which bond shall remain in effect until the completion of arbitration/litigation of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains judgment. In the absence of such injunction, the Corporation shall, subject to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section&#160;6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and subject to Holder&#8217;s right to rescind a Notice of Conversion pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, issue Conversion Shares upon a properly noticed conversion.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.3<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Buy-In on Failure to Timely Deliver Certificates</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If the Corporation fails to deliver to a Holder the applicable certificate or certificates or to effect a DWAC Delivery, as applicable, by the Share Delivery Date pursuant to </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (other than a failure caused by materially incorrect or incomplete information provided by Holder to the Corporation or the application of the Beneficial Ownership Limitation), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the Holder&#8217;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Buy-In</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), then the Corporation shall (A) pay in cash to such Holder (in addition to any other remedies available to or elected by such Holder) the amount by which (x) such Holder&#8217;s total purchase price (including any brokerage commissions) for the shares of Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that such Holder was entitled to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation was executed (including any brokerage commissions) and (B) deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation had timely complied with its delivery requirements under </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.4.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. For example, if a Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted conversion of shares of Series B Non-Voting Preferred Stock with respect to which the actual sale price (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000 under clause (A) of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall provide the Corporation written notice, within three (3) Trading Days after the occurrence of a Buy-In, indicating the amounts payable to such Holder in respect of such Buy-In together with applicable confirmations and other evidence reasonably requested by the Corporation. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Corporation&#8217;s failure to timely deliver certificates representing shares of Common Stock upon conversion of the shares of Series B Non-Voting Preferred Stock as required pursuant to the terms hereof.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.4<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Reservation of Shares Issuable Upon Conversion</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Corporation covenants that at all times it will reserve and keep available out of its authorized and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Series B Non-Voting Preferred Stock, free from preemptive rights or any other actual contingent purchase rights of Persons other than the Holders of the Series B Non-Voting Preferred Stock, not less than such aggregate number of shares of the Common Stock as shall be issuable (taking into account the adjustments of </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) upon the conversion of all outstanding shares of Series B Non-Voting Preferred Stock. The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued, fully paid and non-assessable.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.5<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Fractional Shares</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. No fractional shares of Common Stock shall be issued upon conversion of the Series B Non-Voting Preferred Stock, no certificates or scrip for any such fractional shares shall be issued and no cash shall be paid for any such fractional shares. Any fractional shares of Common Stock that a Holder of Series B Non-Voting Preferred Stock would otherwise be entitled to receive shall be aggregated with all fractional shares of Common Stock issuable to such Holder and any remaining fractional shares shall be rounded up to the nearest whole share.</span></p>
		<p class="ParaOverride-10" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:144pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.4.6<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer Taxes</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The issuance of certificates for shares of the Common Stock upon conversion of the Series B Non-Voting Preferred Stock shall be made without charge to any Holder for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates, provided that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate upon conversion in a name other than that of the registered Holder(s) of such shares of Series B Non-Voting Preferred Stock and the Corporation shall not be required to issue or deliver such certificates unless or until the Person or Persons requesting the issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation that such tax has been paid.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.5<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Status as Stockholder</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Upon each Conversion Date, (i) the shares of Series&#160;B Non-Voting Preferred Stock being converted shall be deemed converted into shares of Common Stock and (ii)&#160;the Holder&#8217;s rights as a holder of such converted shares of Series B Non-Voting Preferred Stock shall cease and terminate, excepting only the right to receive certificates for such shares of Common Stock and to any remedies provided herein or otherwise available at law or in equity to such Holder because of a failure by the Corporation to comply with the terms of this Certificate of Designation. In all cases, the Holder shall retain all of its rights and remedies for the Corporation&#8217;s failure to convert Series B Non-Voting Preferred Stock.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Certain Adjustments</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.1<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Stock Dividends and Stock Splits</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If the Corporation, at any time while this Series B Non-Voting Preferred Stock is outstanding: (A) pays a stock dividend or otherwise makes a distribution or distributions payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of this Series B Non-Voting Preferred Stock) with respect to the then outstanding shares of Common Stock; (B) subdivides outstanding shares of Common Stock into a larger number of shares; or (C) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, then the Conversion Ratio shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Corporation) outstanding immediately after such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately before such event (excluding any treasury shares of the Corporation). Any adjustment made pursuant to this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision or combination.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.2<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Fundamental Transaction</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If, at any time while this Series B Non-Voting Preferred Stock is outstanding, (A) the Corporation effects any merger or consolidation of the Corporation with or into another Person or any stock sale to, or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, share exchange or scheme of arrangement) with or into another Person </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(other than such a transaction in which the Corporation is the surviving or continuing entity and its Common Stock is not exchanged for or converted into other securities, cash or property), (B) the Corporation effects any sale, lease, transfer or exclusive license of all or substantially all of its assets in one transaction or a series of related transactions, (C) any tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which more than 50% of the Common Stock not held by the Corporation or such Person is exchanged for or converted into other securities, cash or property, or (D) the Corporation effects any reclassification of the Common Stock or any compulsory share exchange pursuant (other than as a result of a dividend, subdivision or combination covered by </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7.1</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (in any such case, a &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Fundamental Transaction</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), then, upon any subsequent conversion of this Series B Non-Voting Preferred Stock the Holders shall have the right to receive, in lieu of the right to receive Conversion Shares, for each Conversion Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction, the same kind and amount of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had, immediately prior to such Fundamental Transaction, converted the Series B Non-Voting Preferred Stock immediately prior to such Fundamental Transaction (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Alternate Consideration</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). For purposes of any such subsequent conversion, the determination of the Conversion Ratio shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Corporation shall adjust the Conversion Ratio in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holders shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Series B Non-Voting Preferred Stock following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental Transaction shall file a new certificate of designations with the same terms and conditions and issue to the Holders new preferred stock consistent with the foregoing provisions and evidencing the Holders&#8217; right to convert such preferred stock into Alternate Consideration. The terms of any agreement to which the Corporation is a party and pursuant to which a Fundamental Transaction is effected shall include terms requiring any such successor or surviving entity to comply with the provisions of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7.2</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and insuring that this Series B Non-Voting Preferred Stock (or any such replacement security) will be similarly adjusted upon any subsequent transaction analogous to a Fundamental Transaction. The Corporation shall cause to be delivered to each Holder, at its last address as it shall appear upon the stock books of the Corporation, written notice of any Fundamental Transaction at least 20 calendar days prior to the date on which such Fundamental Transaction is expected to become effective or close. Notwithstanding anything to the contrary herein, any Parent Legacy Transaction (as defined in the Merger Agreement) shall not constitute a Fundamental Transaction.</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:108pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.3<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Calculations</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All calculations under this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be made to the nearest cent or the nearest 1/100</span><span class="CharOverride-10" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">th</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of a share, as the case may be. For purposes of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 7</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">8.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Redemption</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The shares of Series B Non-Voting Preferred Stock shall not be redeemable; provided, however, that the foregoing shall not limit the ability of the Corporation to purchase or otherwise deal in such shares to the extent otherwise permitted hereby and by law.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">9.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Transfer</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. A Holder may transfer any shares of Series B Non-Voting Preferred Stock together with the accompanying rights set forth herein, held by such holder without the consent of the Corporation; provided that such transfer is in compliance with applicable securities laws. The Corporation shall in good faith (i)&#160;do and perform, or cause to be done and performed, all such further acts and things, and (ii) execute and deliver all such other agreements, certificates, instruments and documents, in each case, as any holder of Series B Non-Voting Preferred Stock may reasonably request in order to carry out the intent and accomplish the purposes of this </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 9</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The transferee of any shares of Series B Non-Voting Preferred Stock shall be subject to the Beneficial Ownership Limitation applicable to the transferor as of the time of such transfer.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">10.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Series B Non-Voting Preferred Stock Register</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Corporation shall maintain at its principal executive offices (or such other office or agency of the Corporation as it may designate by notice to the Holders in accordance with </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 11</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">), a register for the Series B Non-Voting Preferred Stock, in which the Corporation shall record (i) the name, address, and electronic mail address of each holder in whose name the shares </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">of Series B Non-Voting Preferred Stock have been issued and (ii) the name, address, and electronic mail address of each transferee of any shares of Series B Non-Voting Preferred Stock. The Corporation may deem and treat the registered Holder of shares of Series B Non-Voting Preferred Stock as the absolute owner thereof for the purpose of any conversion thereof and for all other purposes. The Corporation shall keep the register open and available at all times during business hours for inspection by any holder of Series B Non-Voting Preferred Stock or his, her or its legal representatives.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">11.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Notices</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any notice required or permitted by the provisions of this Certificate of Designation to be given to a Holder of shares of Series B Non-Voting Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic transmission in compliance with the provisions of the DGCL, and shall be deemed sent upon such mailing or electronic transmission.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">12.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Book-Entry; Certificates</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Series B Non-Voting Preferred Stock will be issued in book-entry form; provided that, if a Holder requests that such Holder&#8217;s shares of Series B Non-Voting Preferred Stock be issued in certificated form, the Corporation will instead issue a stock certificate to such Holder representing such Holder&#8217;s shares of Series B Non-Voting Preferred Stock. To the extent that any shares of Series B Non-Voting Preferred Stock are issued in book-entry form, references herein to &#8220;certificates&#8221; shall instead refer to the book-entry notation relating to such shares.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">13.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Lost or Mutilated Series B Non-Voting Preferred Stock Certificate</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If a Holder&#8217;s Series B Non-Voting Preferred Stock certificate shall be mutilated, lost, stolen or destroyed, the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Series B Non-Voting Preferred Stock so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof reasonably satisfactory to the Corporation.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">14.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Waiver</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist upon strict adherence to that term or any other term of this Certificate of Designation. Any waiver by the Corporation or a Holder must be in writing. Notwithstanding any provision in this Certificate of Designation to the contrary, any provision contained herein and any right of the Holders of Series B Non-Voting Preferred Stock granted hereunder may be waived as to all shares of Series B Non-Voting Preferred Stock (and the Holders thereof) upon the written consent of the Holders of not less than a majority of the shares of Series B Non-Voting Preferred Stock then outstanding, provided, however, that the Beneficial Ownership Limitation applicable to a Holder, and any provisions contained herein that are related to such Beneficial Ownership Limitation, cannot be modified, waived or terminated without the consent of such Holder, provided further, that any proposed waiver that would, by its terms, have a disproportionate and materially adverse effect on any Holder shall require the consent of such Holder(s).</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">15.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Severability</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Whenever possible, each provision hereof shall be interpreted in a manner as to be effective and valid under applicable law, but if any provision hereof is held to be prohibited by or invalid under applicable law, then such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating or otherwise adversely affecting the remaining provisions hereof.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:72pt;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">16.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Status of Converted Series B Non-Voting Preferred Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. If any shares of Series B Non-Voting Preferred Stock shall be converted or redeemed by the Corporation, such shares shall, to the fullest extent permitted by applicable law, be retired and cancelled upon such acquisition, and shall not be reissued as a share of Series B Non-Voting Preferred Stock. Any share of Series B Non-Voting Preferred Stock so acquired shall, upon its retirement and cancellation, and upon the taking of any action required by applicable law, resume the status of authorized but unissued shares of preferred stock and shall no longer be designated as Series B Non-Voting Preferred Stock.</span></p>
		<p class="ParaOverride-11" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Remainder of Page Intentionally Left Blank</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-indent:24pt;margin-top:8pt;"><span class="CharOverride-11" style="font-style:normal;font-weight:bold;">IN WITNESS WHEREOF</span>, ARCA biopharma, Inc. has caused this Certificate of Designation of Preferences, Rights and Limitations of Series B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to be duly executed by its&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; on &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 45.87%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-12" style="font-style:normal;font-variant:normal;font-weight:bold;text-transform:uppercase;">ARCA biopharma, Inc.</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ANNEX A</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">NOTICE OF CONVERSION</span><span class="CharOverride-5" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:normal;"><br/><br/></span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(TO BE EXECUTED BY THE REGISTERED HOLDER IN ORDER TO CONVERT SHARES OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK)</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The undersigned Holder hereby irrevocably elects to convert the number of shares of Series B Non-Voting Convertible Preferred Stock (&#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Series B Non-Voting Preferred Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) indicated below, represented in book-entry form, into shares of common stock, par value $0.001 per share (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), of ARCA biopharma, Inc., a Delaware corporation (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Corporation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), as of the date written below. If securities are to be issued in the name of a Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect thereto. Capitalized terms utilized but not defined herein shall have the meaning ascribed to such terms in that certain Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (the &#8220;</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Certificate of Designation</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) filed by the Corporation with the Secretary of State of the State of Delaware on &#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">As of the date hereof, the number of shares of Common Stock beneficially owned by the undersigned Holder (together with such Holder&#8217;s Attribution Parties), including the number of shares of Common Stock issuable upon conversion of the Series B Non-Voting Preferred Stock subject to this Notice of Conversion, but excluding the number of shares of Common Stock which are issuable upon (A) conversion of the remaining, unconverted Series&#160;B Non-Voting Preferred Stock beneficially owned by such Holder or any of its Attribution Parties, and (B) exercise or conversion of the unexercised or unconverted portion of any other securities of the Corporation (including any warrants) beneficially owned by such Holder or any of its Attribution Parties that are subject to a limitation on conversion or exercise similar to the limitation contained in </span><span class="CharOverride-7" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6.3</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of the Certificate of Designation, is _____. For purposes hereof, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the applicable regulations of the Commission. In addition, for purposes hereof, &#8220;group&#8221; has the meaning set forth in Section 13(d) of the Exchange Act and the applicable regulations of the Commission.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">CONVERSION CALCULATIONS:</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Date to Effect Conversion:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Number&#160;of&#160;shares&#160;of&#160;Series&#160;B&#160;Non-Voting&#160;Preferred&#160;Stock&#160;owned&#160;prior&#160;to&#160;Conversion:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Number of shares of Series B Non-Voting Preferred Stock to be Converted:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Number of shares of Common Stock to be Issued:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 74.23%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Address for delivery of physical certificates:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.27%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 24.50%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">_____________________</p>
					</td>
				</tr>

		</table>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" colspan="5" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 43.09%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-align:justify;text-indent:0pt;">For DWAC Delivery, please provide the following:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 55.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 3.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 12.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:justify;">Broker No.:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 23.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">_____________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 55.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 3.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 12.86%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:justify;">Account No.:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 23.79%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">_____________________</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.29%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 55.63%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="CharOverride-13" style="font-variant:normal;text-transform:uppercase;">[HOLDER]</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex F-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T106"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;G</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-right:3pt;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">CERTIFICATE OF AMENDMENT</span><span class="CharOverride-1" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">TO THE<br/>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION<br/>OF</span><span class="CharOverride-1" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-right:3pt;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">ARCA biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Corporation</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), certifies that:</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The name of the Corporation is ARCA biopharma, Inc. The Corporation&#8217;s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on March 16, 2004&#160;under the name &#8220;Nuvelo Merger Sub, Inc.&#8221;</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Board of Directors (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Board</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of the Corporation duly adopted resolutions proposing to amend the Certificate of Incorporation of the Corporation (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Amendment</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), declaring the Amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate officers of the Corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed Amendment is as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The first paragraph of Article IV of the Corporation&#8217;s Amended and Restated Certificate of Incorporation is hereby amended and restated in its entirety as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;The total number of shares of all classes of stock this Corporation shall have authority to issue is 550,000,000, consisting of 545,000,000 shares of Common Stock, par value $0.001 per share, and 5,000,000 shares of Preferred Stock, par value $0.001 per share. The Preferred Stock may be issued from time to time, in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issue of any shares thereof.&#8221;</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Certificate of Amendment was duly adopted by the stockholders of the Corporation in accordance with Section 242 of the General Corporation Law of the State of Delaware.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Certificate of Amendment shall become effective on &#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024 at &#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> [a.m./p.m.] Eastern Time.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page Follows</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex G-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">IN WITNESS WHEREOF</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, this Certificate of Amendment is duly executed by the undersigned officer of the Corporation on ____________, 2024.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 52.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 38.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex G-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T107"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;H</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-right:3pt;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">CERTIFICATE OF AMENDMENT</span><span class="CharOverride-1" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">TO THE<br/>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION<br/>OF</span><span class="CharOverride-1" style="font-family:Times New Roman, serif;font-size:11pt;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ARCA BIOPHARMA, INC.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-right:3pt;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">ARCA biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Corporation</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), certifies that:</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The name of the Corporation is ARCA biopharma, Inc. The Corporation&#8217;s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on March 16, 2004&#160;under the name &#8220;Nuvelo Merger Sub, Inc.&#8221;</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>The Board of Directors (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Board</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) of the Corporation duly adopted resolutions proposing to amend the Certificate of Incorporation of the Corporation (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Amendment</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), declaring the Amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate officers of the Corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed Amendment is as follows:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Article IV of the Corporation&#8217;s Amended and Restated Certificate of Incorporation is hereby amended to add the following paragraph at the end of Article IV:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Upon the effectiveness of the Certificate of Amendment to the Amended and Restated Certificate of Incorporation adding this paragraph (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Effective Time</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), each six (6) to twelve (12) shares of  Common Stock issued immediately prior to the Effective Time shall automatically be combined into one (1) validly issued, fully paid and nonassessable share of Common Stock, without any further action by the Corporation or any holder thereof, the exact ratio within the six-to-one (6:1) to twelve-to-one (12:1) range to be determined by the Board of Directors of the Corporation prior to the Effective Time and publicly announced by the Corporation, subject to the treatment of fractional share interests as described below (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Reverse Stock Split</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). No fractional shares of Common Stock shall be issued in connection with the Reverse Stock Split. Each certificate that immediately prior to the Effective Time represented shares Common Stock, as applicable (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Old Certificates</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), shall, until surrendered to the Corporation in exchange for a certificate representing such new number of shares of Common Stock, automatically represent that number of shares of Common Stock into which the shares of Common Stock represented by the Old Certificate shall have been combined, subject to the elimination of fractional share interests as described above.&#8221;</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>On &#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024, the Board of Directors of the Corporation determined that each &#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> shares of the Corporation&#8217;s Common Stock, par value $0.001 per share (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Common Stock</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), issued immediately prior to the Effective Time shall automatically be combined into one (1) validly issued, fully paid and nonassessable share of Common Stock. The Corporation publicly announced this ratio on &#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Certificate of Amendment was duly adopted by the stockholders of the Corporation in accordance with Section 242 of the General Corporation Law of the State of Delaware.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>This Certificate of Amendment shall become effective on &#160;&#160;&#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2024 at &#160;<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> [a.m./p.m.] Eastern Time.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page Follows</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex H-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:36pt;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">IN WITNESS WHEREOF</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, this Certificate of Amendment is duly executed by the undersigned officer of the Corporation on ____________, 2024.</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Name:</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex H-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T108"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;I</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">CERTIFICATE OF AMENDMENT TO THE<br/>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION<br/>OF ARCA BIOPHARMA, INC.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">ARCA biopharma, Inc. (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Corporation</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">General Corporation Law</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), does hereby certify:</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:54pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The current name of the Corporation is ARCA biopharma, Inc. The date of filing of the original Certificate of Incorporation of ARCA biopharma, Inc. with the Secretary of State of the State of Delaware was March 16, 2004 under the name Nuvelo Merger Sub, Inc.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:54pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The Amended and Restated Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on March 18, 2004 (as amended, the &#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">Certificate of Incorporation</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;).</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:54pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The existing Certificate of Incorporation is hereby amended to add Article XIII to the Certificate of Incorporation to read as follows:</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">XIII.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;background-color:#ffffff;margin-top:8pt;orphans:2;text-indent:25pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">To the fullest extent permitted by the Delaware General Corporation Law, as the same exists or as may hereafter be amended, an officer of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as an officer.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;background-color:#ffffff;margin-top:8pt;orphans:2;text-indent:25pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Neither any amendment nor repeal of this Article XIII, nor the adoption of any provision of this Certificate of Incorporation inconsistent with this Article XIII, shall eliminate or reduce the effect of this Article XIII in respect of any matter occurring, or any action or proceeding accruing or arising or that, but for this Article XIII, would accrue or arise, prior to such amendment, repeal or adoption of an inconsistent provision.&#8221;</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:54pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>All other provisions of the Certificate of Incorporation shall remain in full force and effect.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:54pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The amendment of the Certificate of Incorporation herein certified has been duly adopted in accordance with the provisions of 242 of the General Corporation Law.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:54pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>This Certificate of Amendment shall become effective as of _____, 2024 at _____ Eastern Time.</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">[</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Signature Page Follows</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">]</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex I-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-2" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">IN WITNESS WHEREOF</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Corporation has caused this Certificate of Amendment to be executed by the undersigned authorized officer of the Corporation as of this _____ day of _____, 2024.</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:8pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:8pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Name:</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.98%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex I-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T109"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;J</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appraisal Rights (Section&#160;262 of the Delaware General Corporation Law)</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:8pt;">&#167; 262. Appraisal rights</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(a)&#160;Any stockholder of a corporation of this State who holds shares of stock on the date of the making of a demand pursuant to subsection (d)&#160;of this section with respect to such shares, who continuously holds such shares through the effective date of the merger, consolidation, or conversion, who has otherwise complied with subsection&#160;(d)&#160;of this section and who has neither voted in favor of the merger, consolidation or conversion nor consented thereto in writing pursuant to &#167; 228 of this title shall be entitled to an appraisal by the Court of Chancery of the fair value of the stockholder&#8217;s shares of stock under the circumstances described in subsections (b)&#160;and (c)&#160;of this section. As used in this section, the word &#8220;stockholder&#8221; means a holder of record of stock in a corporation; the words &#8220;stock&#8221; and &#8220;share&#8221; mean and include what is ordinarily meant by those words; the words &#8220;depository receipt&#8221; mean a receipt or other instrument issued by a depository representing an interest in 1 or more shares, or fractions thereof, solely of stock of a corporation, which stock is deposited with the depository; the words &#8220;beneficial owner&#8221; mean a person who is the beneficial owner of shares of stock held either in voting trust or by a nominee on behalf of such person; and the word &#8220;person&#8221; means any individual, corporation, partnership, unincorporated association or other entity.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(b)&#160;Appraisal rights shall be available for the shares of any class or series of stock of a constituent or converting corporation in a merger, consolidation or conversion to be effected pursuant to &#167; 251 (other than a merger effected pursuant to &#167; 251(g)&#160;of this title), &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264 or &#167; 266 of this title (other than, in each case and solely with respect to a domesticated corporation, a merger, consolidation or conversion authorized pursuant to and in accordance with the provisions of &#167; 388 of this title):</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(1)&#160;Provided, however, that no appraisal rights under this section shall be available for the shares of any class or series of stock, which stock, or depository receipts in respect thereof, at the record date fixed to determine the stockholders entitled to receive notice of the meeting of stockholders, or at the record date fixed to determine the stockholders entitled to consent pursuant to &#167; 228 of this title, to act upon the agreement of merger or consolidation or the resolution providing for conversion (or, in the case of a merger pursuant to &#167; 251(h)&#160;of this title, as of immediately prior to the execution of the agreement of merger), were either: (i)&#160;listed on a national securities exchange or (ii)&#160;held of record by more than 2,000 holders; and further provided that no appraisal rights shall be available for any shares of stock of the constituent corporation surviving a merger if the merger did not require for its approval the vote of the stockholders of the surviving corporation as provided in &#167; 251(f)&#160;of this title.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(2)&#160;Notwithstanding paragraph (b)(1)&#160;of this section, appraisal rights under this section shall be available for the shares of any class or series of stock of a constituent or converting corporation if the holders thereof are required by the terms of an agreement of merger or consolidation, or by the terms of a resolution providing for conversion, pursuant to &#167; 251, &#167; 252, &#167; 254, &#167; 255, &#167; 256, &#167; 257, &#167; 258, &#167; 263, &#167; 264 or &#167; 266 of this title to accept for such stock anything except:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">a. Shares of stock of the corporation surviving or resulting from such merger or consolidation, or of the converted entity if such entity is a corporation as a result of the conversion, or depository receipts in respect thereof;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">b. Shares of stock of any other corporation, or depository receipts in respect thereof, which shares of stock (or depository receipts in respect thereof) or depository receipts at the effective date of the merger, consolidation or conversion will be either listed on a national securities exchange or held of record by more than 2,000 holders;</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">c. Cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a. and b. of this section; or</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">d. Any combination of the shares of stock, depository receipts and cash in lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs (b)(2)a., b. and c. of this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(3)&#160;In the event all of the stock of a subsidiary Delaware corporation party to a merger effected under &#167; 253 or &#167; 267 of this title is not owned by the parent immediately prior to the merger, appraisal rights shall be available for the shares of the subsidiary Delaware corporation.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(4)&#160;[Repealed.]</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(c)&#160;Any corporation may provide in its certificate of incorporation that appraisal rights under this section shall be available for the shares of any class or series of its stock as a result of an amendment to its certificate of incorporation, any merger or consolidation in which the corporation is a constituent corporation, the sale of all or substantially all of the assets of the corporation or a conversion effected pursuant to &#167; 266 of this title. If the certificate of incorporation contains such a provision, the provisions of this section, including those set forth in subsections (d), (e), and (g)&#160;of this section, shall apply as nearly as is practicable.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(d)&#160;Appraisal rights shall be perfected as follows:</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(1)&#160;If a proposed merger, consolidation or conversion for which appraisal rights are provided under this section is to be submitted for approval at a meeting of stockholders, the corporation, not less than 20&#160;days prior to the meeting, shall notify each of its stockholders who was such on the record date for notice of such meeting (or such members who received notice in accordance with &#167; 255(c)&#160;of this title) with respect to shares for which appraisal rights are available pursuant to subsection (b)&#160;or (c)&#160;of this section that appraisal rights are available for any or all of the shares of the constituent corporations or the converting corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and, &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Each stockholder electing to demand the appraisal of such stockholder&#8217;s shares shall deliver to the corporation, before the taking of the vote on the merger, consolidation or conversion, a written demand for appraisal of such stockholder&#8217;s shares; provided that a demand may be delivered to the corporation by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such stockholder&#8217;s shares. A proxy or vote against the merger, consolidation or conversion shall not constitute such a demand. A stockholder electing to take such action must do so by a separate written demand as herein provided. Within 10&#160;days after the effective date of such merger, consolidation or conversion, the surviving, resulting or converted entity shall notify each stockholder of each constituent or converting corporation who has complied with this subsection and has not voted in favor of or consented to the merger, consolidation or conversion, and any beneficial owner who has demanded appraisal under paragraph (d)(3)&#160;of this section, of the date that the merger, consolidation or conversion has become effective; or</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(2)&#160;If the merger, consolidation or conversion was approved pursuant to &#167; 228, &#167; 251(h), &#167; 253, or &#167; 267 of this title, then either a constituent or converting corporation before the effective date of the merger, consolidation or conversion, or the surviving, resulting or converted entity within 10&#160;days after such effective date, shall notify each stockholder of any class or series of stock of such constituent or converting corporation who is entitled to appraisal rights of the approval of the merger, consolidation or conversion and that appraisal rights are available for any or all shares of such class or series of stock of such constituent or converting corporation, and shall include in such notice either a copy of this section (and, if 1 of the constituent corporations or the converting corporation is a nonstock corporation, a copy of &#167; 114 of this title) or information directing the stockholders to a publicly available electronic resource at which this section (and &#167; 114 of this title, if applicable) may be accessed without subscription or cost. Such notice may, and, if given on or after the effective date of the merger, consolidation or conversion, shall, also notify such stockholders of the effective date of the merger, consolidation or conversion. Any stockholder entitled to appraisal rights may, within 20&#160;days after the date of giving such notice or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, within the later of the consummation of the offer contemplated by &#167; 251(h)&#160;of this title and 20&#160;days after the date of giving such notice, demand in writing from the surviving or resulting entity the appraisal of such holder&#8217;s shares; provided that a demand may be delivered to such entity by electronic transmission if directed to an information processing system (if any) expressly designated for that purpose in such notice. Such demand will be sufficient if it reasonably informs such entity of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such holder&#8217;s shares. If such notice did not notify stockholders of the effective date of the merger, consolidation or conversion, either (i)&#160;each such constituent corporation or the converting corporation shall send a second notice before the effective date of the merger, consolidation or conversion notifying each of the holders of any class or series of stock of such constituent or converting corporation that are entitled to appraisal rights of the effective date of the merger, consolidation or conversion or (ii)&#160;the surviving, resulting or converted entity shall send such a second notice to all such holders on or within 10&#160;days after such effective date; provided, however, that if such second notice is sent more than 20&#160;days following the sending of the first notice or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, later than the later of the consummation of the offer contemplated by &#167; 251(h)&#160;of this title and 20&#160;days following the sending of the first notice, such second notice need </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder&#8217;s shares in accordance with this subsection and any beneficial owner who has demanded appraisal under paragraph (d)(3)&#160;of this section. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation or entity that is required to give either notice that such notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of determining the stockholders entitled to receive either notice, each constituent corporation or the converting corporation may fix, in advance, a record date that shall be not more than 10&#160;days prior to the date the notice is given, provided, that if the notice is given on or after the effective date of the merger, consolidation or conversion, the record date shall be such effective date. If no record date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on the&#160;day next preceding the&#160;day on which the notice is given.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(3)&#160;Notwithstanding subsection (a)&#160;of this section (but subject to this paragraph (d)(3)), a beneficial owner may, in such person&#8217;s name, demand in writing an appraisal of such beneficial owner&#8217;s shares in accordance with either paragraph (d)(1)&#160;or (2)&#160;of this section, as applicable; provided that (i)&#160;such beneficial owner continuously owns such shares through the effective date of the merger, consolidation or conversion and otherwise satisfies the requirements applicable to a stockholder under the first sentence of subsection (a)&#160;of this section and (ii)&#160;the demand made by such beneficial owner reasonably identifies the holder of record of the shares for which the demand is made, is accompanied by documentary evidence of such beneficial owner&#8217;s beneficial ownership of stock and a statement that such documentary evidence is a true and correct copy of what it purports to be, and provides an address at which such beneficial owner consents to receive notices given by the surviving, resulting or converted entity hereunder and to be set forth on the verified list required by subsection (f)&#160;of this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(e)&#160;Within 120&#160;days after the effective date of the merger, consolidation or conversion, the surviving, resulting or converted entity, or any person who has complied with subsections (a)&#160;and (d)&#160;of this section hereof and who is otherwise entitled to appraisal rights, may commence an appraisal proceeding by filing a petition in the Court of Chancery demanding a determination of the value of the stock of all such stockholders. Notwithstanding the foregoing, at any time within 60&#160;days after the effective date of the merger, consolidation or conversion, any person entitled to appraisal rights who has not commenced an appraisal proceeding or joined that proceeding as a named party shall have the right to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation or conversion. Within 120&#160;days after the effective date of the merger, consolidation or conversion, any person who has complied with the requirements of subsections (a)&#160;and (d)&#160;of this section hereof, upon request given in writing (or by electronic transmission directed to an information processing system (if any) expressly designated for that purpose in the notice of appraisal), shall be entitled to receive from the surviving, resulting or converted entity a statement setting forth the aggregate number of shares not voted in favor of the merger, consolidation or conversion (or, in the case of a merger approved pursuant to &#167; 251(h)&#160;of this title, the aggregate number of shares (other than any excluded stock (as defined in &#167; 251(h)(6)d. of this title)) that were the subject of, and were not tendered into, and accepted for purchase or exchange in, the offer referred to in &#167; 251(h)(2)&#160;of this title), and, in either case, with respect to which demands for appraisal have been received and the aggregate number of stockholders or beneficial owners holding or owning such shares (provided that, where a beneficial owner makes a demand pursuant to paragraph (d)(3)&#160;of this section, the record holder of such shares shall not be considered a separate stockholder holding such shares for purposes of such aggregate number). Such statement shall be given to the person within 10&#160;days after such person&#8217;s request for such a statement is received by the surviving, resulting or converted entity or within 10&#160;days after expiration of the period for delivery of demands for appraisal under subsection (d)&#160;of this section hereof, whichever is later.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(f)&#160;Upon the filing of any such petition by any person other than the surviving, resulting or converted entity, service of a copy thereof shall be made upon such entity, which shall within 20&#160;days after such service file in the office of the Register in Chancery in which the petition was filed a duly verified list containing the names and addresses of all persons who have demanded appraisal for their shares and with whom agreements as to the value of their shares have not been reached by such entity. If the petition shall be filed by the surviving, resulting or converted entity, the petition shall be accompanied by such a duly verified list. The Register in Chancery, if so ordered by the Court, shall give notice of the time and place fixed for the hearing of such petition by registered or certified mail to the surviving, resulting or converted entity and to the persons shown on the list at the addresses therein stated. The forms of the notices by mail and by publication shall be approved by the Court, and the costs thereof shall be borne by the surviving, resulting or converted entity.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(g)&#160;At the hearing on such petition, the Court shall determine the persons who have complied with this section and who have become entitled to appraisal rights. The Court may require the persons who have demanded an appraisal for their shares and who hold stock represented by certificates to submit their certificates of stock to the Register in Chancery for notation thereon of the pendency of the appraisal proceedings; and if any person fails to comply with such direction, the Court may dismiss the proceedings as to such person. If immediately before the merger, consolidation or conversion the shares of the class or series of stock of the constituent or converting corporation as to which appraisal rights are available were listed on a national securities exchange, the Court shall dismiss the proceedings as to all holders of such shares who are otherwise entitled to appraisal rights unless (1)&#160;the total number of shares entitled to appraisal exceeds 1% of the outstanding shares of the class or series eligible for appraisal, (2)&#160;the value of the consideration provided in the merger, consolidation or conversion for such total number of shares exceeds $1&#160;million, or (3)&#160;the merger was approved pursuant to &#167; 253 or &#167; 267 of this title.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(h)&#160;After the Court determines the persons entitled to an appraisal, the appraisal proceeding shall be conducted in accordance with the rules of the Court of Chancery, including any rules specifically governing appraisal proceedings. Through such proceeding the Court shall determine the fair value of the shares exclusive of any element of value arising from the accomplishment or expectation of the merger, consolidation or conversion, together with interest, if any, to be paid upon the amount determined to be the fair value. In determining such fair value, the Court shall take into account all relevant factors. Unless the Court in its discretion determines otherwise for good cause shown, and except as provided in this subsection, interest from the effective date of the merger, consolidation or conversion through the date of payment of the judgment shall be compounded quarterly and shall accrue at 5% over the Federal Reserve discount rate (including any surcharge) as established from time to time during the period between the effective date of the merger, consolidation or conversion and the date of payment of the judgment. At any time before the entry of judgment in the proceedings, the surviving, resulting or converted entity may pay to each person entitled to appraisal an amount in cash, in which case interest shall accrue thereafter as provided herein only upon the sum of (1)&#160;the difference, if any, between the amount so paid and the fair value of the shares as determined by the Court, and (2)&#160;interest theretofore accrued, unless paid at that time. Upon application by the surviving, resulting or converted entity or by any person entitled to participate in the appraisal proceeding, the Court may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the persons entitled to an appraisal. Any person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&#160;of this section may participate fully in all proceedings until it is finally determined that such person is not entitled to appraisal rights under this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(i)&#160;The Court shall direct the payment of the fair value of the shares, together with interest, if any, by the surviving, resulting or converted entity to the persons entitled thereto. Payment shall be so made to each such person upon such terms and conditions as the Court may order. The Court&#8217;s decree may be enforced as other decrees in the Court of Chancery may be enforced, whether such surviving, resulting or converted entity be an entity of this State or of any state.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(j)&#160;The costs of the proceeding may be determined by the Court and taxed upon the parties as the Court deems equitable in the circumstances. Upon application of a person whose name appears on the list filed by the surviving, resulting or converted entity pursuant to subsection (f)&#160;of this section who participated in the proceeding and incurred expenses in connection therewith, the Court may order all or a portion of such expenses, including, without limitation, reasonable attorney&#8217;s fees and the fees and expenses of experts, to be charged pro rata against the value of all the shares entitled to an appraisal not dismissed pursuant to subsection (k)&#160;of this section or subject to such an award pursuant to a reservation of jurisdiction under subsection (k)&#160;of this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(k)&#160;From and after the effective date of the merger, consolidation or conversion, no person who has demanded appraisal rights with respect to some or all of such person&#8217;s shares as provided in subsection (d)&#160;of this section shall be entitled to vote such shares for any purpose or to receive payment of dividends or other distributions on such shares (except dividends or other distributions payable to stockholders of record at a date which is prior to the effective date of the merger, consolidation or conversion); provided, however, that if no petition for an appraisal is filed within the time provided in subsection (e)&#160;of this section, or if a person who has made a demand for an appraisal in accordance with this section shall deliver to the surviving, resulting or converted entity a written withdrawal of such person&#8217;s demand for an appraisal in respect of some or all of such person&#8217;s shares in accordance with subsection (e)&#160;of this section, then the right of such person to an appraisal of the shares subject to the withdrawal shall cease. Notwithstanding the foregoing, no appraisal proceeding in the Court of Chancery shall be dismissed as to any person without the approval of the Court, and such approval may be conditioned upon such </p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">terms as the Court deems just, including without limitation, a reservation of jurisdiction for any application to the Court made under subsection (j)&#160;of this section; provided, however that this provision shall not affect the right of any person who has not commenced an appraisal proceeding or joined that proceeding as a named party to withdraw such person&#8217;s demand for appraisal and to accept the terms offered upon the merger, consolidation or conversion within 60&#160;days after the effective date of the merger, consolidation or conversion, as set forth in subsection (e)&#160;of this section.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">(l)&#160;The shares or other equity interests of the surviving, resulting or converted entity to which the shares of stock subject to appraisal under this section would have otherwise converted but for an appraisal demand made in accordance with this section shall have the status of authorized but not outstanding shares of stock or other equity interests of the surviving, resulting or converted entity, unless and until the person that has demanded appraisal is no longer entitled to appraisal pursuant to this section.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex J-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T110"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;K</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;page-break-after:avoid;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.</span><span class="CharOverride-2" style="font-family:Times New Roman, serif;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">2024 STOCK INCENTIVE PLAN</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Purpose</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The purpose of this Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is to promote and closely align the interests of employees, officers, non-employee directors and other individual service providers of Oruka Therapeutics, Inc. and its stockholders by providing stock-based compensation and other performance-based compensation. The objectives of the Plan are to attract and retain the best available employees, officers, non-employee directors and other individual service providers for positions of substantial responsibility and to motivate Participants to optimize the profitability and growth of the Company through incentives that are consistent with the Company&#8217;s goals and that link the personal interests of Participants to those of the Company&#8217;s stockholders. The Plan provides for the grant of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units and Other Stock-Based Awards and for Incentive Bonuses, which may be paid in cash, Common Stock or a combination thereof, as determined by the Committee.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Definitions</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">As used in the Plan, the following terms shall have the meanings set forth below:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Act</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Exchange Act of 1934, as amended.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Affiliate</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any entity in which the Company has a substantial direct or indirect equity interest, as determined by the Committee from time to time.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Award</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Option, Stock Appreciation Right, Restricted Stock, Restricted Stock Unit, Other Stock-Based Award or Incentive Bonus, or any combination of these, granted to a Participant pursuant to the provisions of the Plan, any of which may be subject to performance conditions.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Award Agreement</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a written or electronic agreement or other instrument as may be approved from time to time by the Committee and designated as such implementing the grant of each Award. An Award Agreement may be in the form of an agreement to be executed by both the Participant and the Company (or an authorized representative of the Company) or certificates, notices or similar instruments as approved by the Committee and designated as such.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Beneficial Owner</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall have the meaning set forth in Rule 13d-3 under the Act.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Board</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Board of Directors of the Company.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Cause</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in the written employment, offer, services or severance agreement or letter between the Participant and the Company or an Affiliate, or in any severance plan in which the Participant participates, or if there is no such agreement or plan or no such term is defined in such agreement or plan, means a Participant&#8217;s (i) dishonest statements or acts with respect to the Company or any Affiliate, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in material harm to the Company; (ii) conviction or plea of guilty or no contest to: (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) failure to perform in all material respects the Participant&#8217;s assigned duties and responsibilities; (iv) gross negligence, willful misconduct that results in or is reasonably anticipated to result in material harm to the Company; (v) violation of any material provision of any agreement(s) between the Participant and the Company; or (vi) material violation of any written Company policies.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Change in Control</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means, except as otherwise provided in an Award Agreement, the occurrence of any one of the following events:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>any Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including the securities beneficially owned by such Person or any securities acquired directly from the Company or its Affiliates) representing 50% or more of the combined voting power of the Company&#8217;s then outstanding securities, excluding any Person who becomes such a Beneficial Owner in connection with a transaction described in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 2(h)(iii)(A)</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> below;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>the following individuals cease for any reason to constitute a majority of the number of directors then serving: (A) individuals who, on the Effective Date (as defined below), constitute the Board and (B)&#160;any new director (other than a director whose initial assumption of office is in connection with an actual or threatened election contest, including a consent solicitation, relating to the election of directors of the Company) whose appointment or election by the Board or nomination for election by the Company&#8217;s stockholders was approved or recommended by a vote of at least a majority of the directors then still in office who were either directors on the Effective Date or whose appointment, election or nomination for election was previously so approved or recommended;</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>there is consummated a merger or consolidation of the Company or any direct or indirect subsidiary of the Company with any other entity, other than (A) a merger or consolidation which would result in the holders of the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof) at least 50% of the combined voting power of the securities of the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation;</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>the implementation of a plan of complete liquidation or dissolution of the Company; or</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>there is consummated a sale or disposition by the Company of all or substantially all of the Company&#8217;s assets, other than a sale or disposition by the Company of all or substantially all of the Company&#8217;s assets to an entity, at least 50% of the combined voting power of the voting securities of which is owned by stockholders of the Company in substantially the same proportions as their ownership of the Company immediately prior to such sale.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Code</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Internal Revenue Code of 1986, as amended from time to time, and the rulings and regulations issued thereunder.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Committee</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Compensation Committee of the Board (or any successor committee) or such other committee as designated by the Board to administer the Plan under </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the common stock of the Company, $0.001 par value per share, or such other class or kind of shares or other securities as may be applicable under </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 16</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(l)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Oruka Therapeutics, Inc., a Delaware corporation, and except as utilized in the definition of Change in Control, any successor corporation.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(m)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Disability</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in a written employment, offer, services or severance agreement or letter between the Participant and the Company or an Affiliate, or in any severance plan in which the Participant participates, or if there is no such agreement or plan or no such term is defined in such agreement or plan, means the inability of the Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment. A determination of Disability shall be made by the Committee on the basis of such medical evidence as the Committee deems warranted under the circumstances, and in this respect, Participants shall submit to an examination by a physician upon request by the Committee.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(n)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Dividend Equivalent</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an amount payable in cash or Common Stock, as determined by the Committee, equal to the dividends that would have been paid to the Participant if the share of Common Stock with respect to which the Dividend Equivalent relates had been owned by the Participant.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(o)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Effective Date</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the date on which the Plan takes effect, as defined pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 4</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(p)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Eligible Person</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; any current or prospective employee, officer, non-employee director or other individual service provider of the Company or any Subsidiary; </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Incentive Stock Options may only be granted to employees of the Company or any of its &#8220;subsidiary corporations&#8221; within the meaning of Section 424 of the Code.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(q)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Fair Market Value</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means as of any date, the value of the Common Stock determined as follows: (i)&#160;if the Common Stock is listed on any established stock exchange, system or market, its Fair Market Value shall be the closing price of a share of Common Stock as quoted on such exchange, system or market as reported in the Wall Street Journal or such other source as the Committee deems reliable (or, if no sale of Common Stock is reported for such date, on the next preceding date on which any sale shall have been reported); and (ii) in the absence of an </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">established market for the Common Stock, the Fair Market Value thereof shall be determined in good faith by the Committee by the reasonable application of a reasonable valuation method, taking into account factors consistent with Treas. Reg. &#167; 409A-1(b)(5)(iv)(B) as the Committee deems appropriate.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(r)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Incentive Bonus</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a bonus opportunity awarded under </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 12</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> pursuant to which a Participant may become entitled to receive an amount based on satisfaction of such performance criteria established for a specified performance period as specified in the Award Agreement.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(s)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Incentive Stock Option</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Option that is intended to qualify as an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Code.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(t)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Merger Agreement</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means that Agreement and Plan of Merger and Reorganization dated April 3, 2024 by and between the Company (f/k/a ARCA biopharma, Inc.) and Oruka Therapeutics Operating Company, LLC (f/k/a Oruka Therapeutics, Inc.).</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(u)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Nonqualified Stock Option</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Option that is not intended to qualify as an &#8220;incentive stock option&#8221; within the meaning of Section 422 of the Code.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Option</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a right to purchase a number of shares of Common Stock at such exercise price, at such times and on such other terms and conditions as are specified in or determined pursuant to an Award Agreement. Options granted pursuant to the Plan may be Incentive Stock Options or Nonqualified Stock Options.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(w)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Other Stock-Based Award</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Award granted to an Eligible Person under </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 11</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Outstanding Common Stock</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the sum of (i) the shares of Common Stock outstanding, (ii)&#160;the shares of Common Stock underlying unexercised pre-funded warrants, and (iii) the shares of Common Stock underlying the Company&#8217;s preferred stock, par value $0.001 (determined on an as-converted basis without regard to any limitations on such conversion).</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(y)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Participant</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Eligible Person to whom Awards have been granted from time to time by the Committee and any authorized transferee of such individual.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(z)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Person</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; shall have the meaning given in Section 3(a)(9) of the Act, as modified and used in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections&#160;14(d)</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">15(d)</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> thereof, except that such term shall not include (i) the Company or any of its Affiliates, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its Subsidiaries, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities or (iv) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(aa)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Award or issuance of Common Stock the grant, issuance, vesting and/or transferability of which is subject during specified periods of time to such conditions (including continued employment or engagement or performance conditions) and terms as the Committee deems appropriate.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(bb)&#160;&#160;&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Unit</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Award denominated in units of Common Stock under which the issuance of shares of such Common Stock (or cash payment in lieu thereof) is subject to such conditions (including continued employment or engagement or performance conditions) and terms as the Committee deems appropriate.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(cc)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Separation from Service</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Separates from Service</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a Termination of Employment that constitutes a &#8220;separation from service&#8221; within the meaning of Section 409A of the Code.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(dd)&#160;&#160;&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Stock Appreciation Right</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">SAR</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a right granted that entitles the Participant to receive, in cash or Common Stock or a combination thereof, as determined by the Committee, value equal to the excess of (i)&#160;the Fair Market Value of a specified number of shares of Common Stock at the time of exercise over (ii) the exercise price of the right, as established by the Committee on the date of grant.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:7.5pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ee)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Subsidiary</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any business association (including a corporation or a partnership, other than the Company) in an unbroken chain of such associations beginning with the Company if each of the associations other than the last association in the unbroken chain owns equity interests (including stock or partnership interests) possessing 50% or more of the total combined voting power of all classes of equity interests in one of the other associations in such chain.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ff)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Substitute Awards</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Awards granted or Common Stock issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, by a company acquired by the Company or any Subsidiary or with which the Company or any Subsidiary combines.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(gg)&#160;&#160;&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Termination of Employment</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means ceasing to serve as an employee of the Company and its Subsidiaries or, with respect to a non-employee director or other service provider, ceasing to serve as such for the Company and its Subsidiaries, except that with respect to all or any Awards held by a Participant (i) the Committee may determine that a leave of absence (including as a result of a Participant&#8217;s short-term or long-term disability or other medical leave) or employment on a less than full-time basis is considered a &#8220;Termination of Employment,&#8221; (ii) the Committee may determine that a transition from employment to service with a partnership, joint venture or corporation not meeting the requirements of a Subsidiary in which the Company or a Subsidiary is a party is not considered a &#8220;Termination of Employment,&#8221; (iii) service as a member of the Board shall constitute continued service with respect to Awards granted to a Participant while he or she served as an employee, (iv) service as an employee of the Company or a Subsidiary shall constitute continued employment with respect to Awards granted to a Participant while he or she served as a member of the Board or other service provider, and (v) the Committee may determine that a transition from employment with the Company or a Subsidiary to service to the Company or a Subsidiary other than as an employee shall constitute a &#8220;Termination of Employment&#8221;. The Committee shall determine whether any corporate transaction, such as a sale or spin-off of a division or Subsidiary that employs or engages a Participant, shall be deemed to result in a Termination of Employment with the Company and its Subsidiaries for purposes of any affected Participant&#8217;s Awards, and the Committee&#8217;s decision shall be final and binding.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Eligibility</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Any Eligible Person is eligible for selection by the Committee to receive an Award.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Effective Date and Termination of Plan</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">This Plan became effective on the Closing Date (as defined in the Merger Agreement) (the&#160;&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Effective Date</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The Plan shall remain available for the grant of Awards until July 20, 2034. Notwithstanding the foregoing, the Plan may be terminated at such earlier time as the Board may determine. Termination of the Plan will not affect the rights and obligations of the Participants and the Company arising under Awards theretofore granted.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Shares Subject to the Plan and to Awards</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Aggregate Limits</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The aggregate number of shares of Common Stock issuable under the Plan shall be equal to (i) 10% of the total number of shares of Outstanding Common Stock immediately following the closing of the transactions set forth in the Merger Agreement, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">plus</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (ii) any shares of Common Stock added as a result of the following sentence (collectively, the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Share Pool</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The Share Pool will automatically increase on January 1 of each year beginning in 2025 and ending with a final increase on January 1, 2034 in an amount equal to 5% of the Outstanding Common Stock on the preceding December 31; </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the Committee may provide that there will be no January 1 increase in the Share Pool for any such year or that the increase in the Share Pool for any such year will be a smaller number of shares of Common Stock than would otherwise occur pursuant to this sentence. The aggregate number of shares of Common Stock available for grant under this Plan and the number of shares of Common Stock subject to Awards outstanding at the time of any event described in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 16</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be subject to adjustment as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 16</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The shares of Common Stock issued under this Plan may be shares that are authorized and unissued or shares that were reacquired by the Company, including shares purchased in the open market or in private transactions.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Issuance of Shares</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. For purposes of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 5(a)</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the aggregate number of shares of Common Stock issued under this Plan at any time shall equal only the number of shares of Common Stock actually issued upon exercise or settlement of an Award. Shares of Common Stock subject to Awards that have been canceled, expired, forfeited or otherwise not issued under an Award and shares of Common Stock subject to Awards settled in cash shall not count as shares of Common Stock issued under this Plan. The aggregate number of shares available for issuance under this Plan at any time shall not be reduced by (i) shares subject to Awards that have been terminated, expired unexercised, forfeited or settled in cash, (ii) shares subject to Awards that have been retained or withheld by the Company in payment or satisfaction of the exercise price, purchase price or tax withholding obligation of an Award, or (iii) shares subject to Awards that otherwise do not result in the issuance of shares in connection with payment or settlement thereof. In addition, shares that have been delivered (either actually or by attestation) to the Company in payment or satisfaction of the exercise price, purchase price or tax withholding obligation of an Award shall be available for issuance under this Plan.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Substitute Awards</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Substitute Awards shall not reduce the shares of Common Stock authorized for issuance under the Plan or authorized for grant to a Participant in any calendar year. Additionally, in the event that a company acquired by the Company or any Subsidiary, or with which the Company or any Subsidiary combines, has shares available under a pre-existing plan approved by stockholders and not adopted in contemplation of such acquisition or combination, the shares available for grant pursuant to the terms of such pre-existing plan (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine the consideration payable to the holders of common stock of the entities party to such acquisition or combination) may be used for Awards under the Plan and shall not reduce the shares of Common Stock authorized for issuance under the Plan; </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Awards using such available shares (i) shall not be made after the date awards or grants could have been made under the terms of the pre-existing plan, absent the acquisition or combination, (ii) shall only be made to individuals who were not employees or service providers of the Company or its Affiliates at the time of such acquisition or combination, and (iii) shall comply with the requirements of any stock exchange or market or quotation system on which the Common Stock is traded, listed or quoted.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Tax Code Limits</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The aggregate number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options granted under this Plan shall be equal to 10,000,000, which number shall be calculated and adjusted pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 16</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> only to the extent that such calculation or adjustment will not affect the status of any Option intended to qualify as an Incentive Stock Option under Section 422 of the Code.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Limits on Non-Employee Director Compensation.</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> The aggregate dollar value of equity-based (based on the grant date Fair Market Value of equity-based Awards) and cash compensation granted under this Plan or otherwise to any non-employee director shall not exceed $750,000 during any calendar year; </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in the calendar year in which a non-employee director first joins the Board or during any calendar year in which a non-employee director is designated as Chairman of the Board or Lead Director, the maximum aggregate dollar value of equity-based and cash compensation granted to the non-employee director may be up to $1,000,000.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Administration of the Plan</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Administrator of the Plan</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Plan shall be administered by the Committee. The Board shall fill vacancies on, and from time to time may remove or add members to, the Committee. The Committee shall act pursuant to a majority vote or unanimous written consent. Any power of the Committee may also be exercised by the Board, except to the extent that the grant or exercise of such authority would cause any Award or transaction to become subject to (or lose an exemption under) the short-swing profit recovery provisions of Section 16 of the Act. To the extent that any permitted action taken by the Board conflicts with action taken by the Committee, the Board action shall control. To the maximum extent permissible under applicable law, the Committee (or any successor) may by resolution delegate any or all of its authority to one or more subcommittees composed of one or more directors and/or officers of the Company, and any such subcommittee shall be treated as the Committee for all purposes under this Plan. Notwithstanding the foregoing, if the Board or the Committee (or any successor) delegates to a subcommittee comprised of one or more officers of the Company the authority to grant Awards, no such subcommittee shall designate any officer serving thereon or any officer (within the meaning of Section 16 of the Act) or non-employee director of the Company as a recipient of any Awards granted under such delegated authority. The Committee hereby delegates to and designates the Senior Vice President of Finance of the Company (or such other officer with similar authority), and to his or her delegates or designees, the authority to assist the Committee in the day-to-day administration of the Plan and of Awards granted under the Plan, including those powers set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6(b)(v)</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> through </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">(xi)</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and to execute Award Agreements or other documents entered into under this Plan on behalf of the Committee or the Company. The Committee may further designate and delegate to one or more additional officers or employees of the Company or any Subsidiary, and/or one or more agents, authority to assist the Committee in any or all aspects of the day-to-day administration of the Plan and/or of Awards granted under the Plan.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Powers of Committee</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Subject to the express provisions of this Plan, the Committee shall be authorized and empowered to do all things that it determines to be necessary or appropriate in connection with the administration of this Plan, including:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>to prescribe, amend and rescind rules and regulations relating to this Plan and to define terms not otherwise defined herein;</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>to determine which Persons are Eligible Persons, to which of such Eligible Persons, if any, Awards shall be granted hereunder and the timing of any such Awards;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>to prescribe and amend the terms of the Award Agreements, to grant Awards and determine the terms and conditions thereof;</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>to reduce the exercise price of a previously awarded Option or Stock Appreciation Right or cancel and re-grant or exchange such Option or Stock Appreciation Right for cash or a new Award with a lower (or no) exercise price with any such determination made by the Committee in its sole discretion, in each case, without stockholder approval;</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>to adopt such procedures and sub-plans as are necessary or appropriate (A) to permit or facilitate participation in this Plan by Eligible Persons who are not citizens of, or subject to taxation by, the United States or who are employed outside the United States or (B) to allow Awards to qualify for special tax treatment in a jurisdiction other than the United States; </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Board approval will not be necessary for immaterial modifications to this Plan or any Award Agreement that are required for compliance with the laws of the relevant jurisdiction;</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vi)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>to establish and verify the extent of satisfaction of any performance goals or other conditions applicable to the grant, issuance, retention, vesting, exercisability or settlement of any Award;</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(vii)&#160;&#160;to prescribe and amend the terms of or form of any document or notice required to be delivered to the Company by Participants under this Plan;</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(viii)&#160;to determine the extent to which adjustments are required pursuant to Section 16;</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ix)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>to interpret and construe this Plan, any rules and regulations under this Plan and the terms and conditions of any Award granted hereunder, and to make exceptions to any such provisions if the Committee, in good faith, determines that it is appropriate to do so;</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>to approve corrections in the documentation or administration of any Award; and</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(xi)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>to make all other determinations deemed necessary or advisable for the administration of this Plan.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Notwithstanding anything in this Plan to the contrary, with respect to any Award that is &#8220;deferred compensation&#8221; under Section 409A of the Code, the Committee shall exercise its discretion in a manner that causes such Awards to be compliant with or exempt from the requirements of Section 409A of the Code. Without limiting the foregoing, unless expressly agreed to in writing by the Participant holding such Award, the Committee shall not take any action with respect to any Award which constitutes (x) a modification of a stock right within the meaning of Treas. Reg. &#167; 1.409A-1(b)(5)(v)(B) so as to constitute the grant of a new stock right, (y) an extension of a stock right, including the addition of a feature for the deferral of compensation within the meaning of Treas. Reg. &#167; 1.409A-1 (b)(5)(v)(C), or (z) an impermissible acceleration of a payment date or a subsequent deferral of a stock right subject to Section&#160;409A of the Code within the meaning of Treas. Reg. &#167; 1.409A-1(b)(5)(v)(E).</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Committee may, in its sole and absolute discretion, without amendment to the Plan but subject to the limitations otherwise set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 20</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, waive or amend the operation of Plan provisions respecting exercise after Termination of Employment. The Committee or any member thereof may, in its sole and absolute discretion, except as otherwise provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 20</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, waive, settle or adjust any of the terms of any Award so as to avoid unanticipated consequences or address unanticipated events (including any temporary closure of an applicable stock exchange, disruption of communications or natural catastrophe).</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Determinations by the Committee</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. All decisions, determinations and interpretations by the Committee regarding the Plan, any rules and regulations under the Plan, and the terms and conditions of, or operation of, any Award granted hereunder, shall be final and binding on all Participants, beneficiaries, heirs, assigns or other persons holding or claiming rights under the Plan or any Award. The Committee shall consider such factors as it deems relevant, in its sole and absolute discretion, to making such decisions, determinations and interpretations, including the recommendations or advice of any officer or other employee of the Company and such attorneys, consultants and accountants as it may select. Members of the Board and members of the Committee acting under the Plan shall be fully protected in relying in good faith upon the advice of counsel and shall incur no liability except for as a result of gross negligence or willful misconduct in the performance of their duties.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Subsidiary Awards</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. In the case of a grant of an Award to any Participant employed by a Subsidiary, such grant may, if the Committee so directs, be implemented by the Company issuing any subject shares of Common Stock to the Subsidiary, for such lawful consideration as the Committee may determine, upon the condition or understanding that the Subsidiary will transfer the shares of Common Stock to the Participant in accordance with the terms of the Award specified by the Committee pursuant to the provisions of the Plan. Notwithstanding any other provision hereof, such Award may be issued by and in the name of the Subsidiary and shall be deemed granted on such date as the Committee shall determine.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Plan Awards</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Terms Set Forth in Award Agreement</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Awards may be granted to Eligible Persons as determined by the Committee at any time and from time to time prior to the termination of the Plan. The terms and conditions of each Award shall be set forth in an Award Agreement in a form approved by the Committee for such Award, subject to and incorporating by reference or otherwise the applicable terms and conditions of the Plan, which Award Agreement may contain such terms and conditions as specified from time to time by the Committee, provided such other terms and conditions do not conflict with the Plan. The Award Agreement for any Award (other than Restricted Stock Awards) shall include the time or times at or within which and the consideration, if any, for which any shares of Common Stock or cash, as applicable, may be acquired from the Company. The terms of Awards may vary among Participants, and the Plan does not impose upon the Committee any requirement to make Awards subject to uniform terms. Accordingly, the terms of individual Award Agreements may vary.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Termination of Employment</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Subject to the express provisions of the Plan, the Committee shall specify before, at, or after the time of grant of an Award the provisions governing the effect(s) upon an Award of a Participant&#8217;s Termination of Employment.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Rights of a Stockholder</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. A Participant shall have no rights as a stockholder with respect to shares of Common Stock covered by an Award (including voting rights) until the date the Participant becomes the holder of record of such shares of Common Stock. No adjustment shall be made for dividends or other rights for which the record date is prior to such date, except as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections 10(b)</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">11(b)</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> or </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">16</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> of this Plan or as otherwise provided by the Committee.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">No Fractional Shares</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. No fractional shares of Common Stock shall be issued pursuant to an Award or in settlement thereof.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Options</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Grant, Term and Price</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The grant, issuance, retention, vesting and/or settlement of any Option shall occur at such time and be subject to such terms and conditions as determined by the Committee or under criteria established by the Committee, which may include conditions based on continued employment or engagement, passage of time, attainment of age and/or service requirements, and/or satisfaction of performance conditions. The term of an Option shall in no event be greater than 10 years; </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the term of an Option (other than an Incentive Stock Option) shall be automatically extended if, at the time of its scheduled expiration, the Participant holding such Option is prohibited by law or the Company&#8217;s insider trading policy from exercising the Option, which extension shall expire on the 30</span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">th</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> day following the date such prohibition no longer applies. The Committee will establish the price at which Common Stock may be purchased upon exercise of an Option, which in no event will be less than the Fair Market Value of such shares on the date of grant; </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the exercise price per share of Common Stock with respect to an Option that is granted as a Substitute Award may be less than the Fair Market Value of the shares of Common Stock on the date such Option is granted if such exercise price is based on a formula set forth in the terms of the options held by such optionees or in the terms of the agreement providing for such merger or other acquisition that satisfies the requirements of (i) Section 409A of the Code, if such options held by such optionees are not intended to qualify as &#8220;incentive stock options&#8221; within the meaning of Section 422 of the Code, and (ii) Section 424(a) of the Code, if such options held by such optionees are intended to qualify as &#8220;incentive stock options&#8221; within the meaning of Section 422 of the Code. The exercise price of any Option may be paid in cash to the Company or such other method as determined by the Committee, including an irrevocable commitment by a broker to pay over such amount from a sale of the shares of Common Stock issuable under an Option, the delivery of previously owned shares of Common Stock or withholding of shares of Common Stock otherwise deliverable upon exercise.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">No Reload Grants</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Options shall not be granted under the Plan in consideration for, and shall not be conditioned upon the delivery of, shares of Common Stock to the Company in payment of the exercise price and/or tax withholding obligation under any other employee stock option.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Incentive Stock Options</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Notwithstanding anything to the contrary in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 8</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, in the case of the grant of an Incentive Stock Option, if the Participant owns stock possessing more than 10% of the combined voting power of all classes of stock of the Company, the exercise price of such Option must be at least 110% of the Fair Market Value of the shares of Common Stock on the date of grant and the Option must expire within a period of not more than five years from the date of grant. Notwithstanding anything in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 8</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> to the contrary, Options designated as Incentive Stock Options shall not be eligible for treatment under the Code as Incentive Stock Options (and will be deemed to be Nonqualified Stock Options) to the extent that either (i) the aggregate Fair Market Value of shares of Common Stock (determined as of the time of grant) with respect to which such Options are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any Subsidiary) exceeds $100,000, taking Options into account in the order in which they were granted, or (ii) such Options otherwise remain exercisable but are not exercised within three months (or such other period of time provided in Section 422 of the Code) of separation of service (as determined in accordance with Section 3401(c) of the Code and the regulations promulgated thereunder).</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">No Stockholder Rights</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Participants shall have no voting rights and will have no rights to receive dividends or Dividend Equivalents in respect of an Option or any shares of Common Stock subject to an Option until the Participant has become the holder of record of such shares.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Stock Appreciation Rights</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">General Terms</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The grant, issuance, retention, vesting and/or settlement of any Stock Appreciation Right shall occur at such time and be subject to such terms and conditions as determined by the Committee or under criteria established by the Committee, which may include conditions based on continued employment or engagement, passage of time, attainment of age and/or service requirements, and/or satisfaction of performance conditions. The term of a Stock Appreciation Right shall in no event be greater than 10 years; </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the term of a Stock Appreciation Right shall be automatically extended if, at the time of its scheduled expiration, the Participant holding such Stock Appreciation Right is prohibited by law or the Company&#8217;s insider trading policy from exercising the Stock Appreciation Right which extension shall expire on the 30</span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">th</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> day following the date such prohibition no longer applies. Stock Appreciation Rights may be granted to Participants from time to time either in tandem with or as a component of Options granted under the Plan (&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">tandem SARs</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) or not in conjunction with other Awards (&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">freestanding SARs</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). Upon exercise of a tandem SAR as to some or all of the shares covered by the grant, the related Option shall be canceled automatically to the extent of the number of shares covered by such exercise. Conversely, if the related Option is exercised as to some or all of the shares covered by the grant, the related tandem SAR, if any, shall be canceled automatically to the extent of the number of shares covered by the Option exercise. Any Stock Appreciation Right granted in tandem with an Option may be granted at the same time such Option is granted or at any time thereafter before exercise or expiration of such Option, provided that the Fair Market Value of Common Stock on the date of the SAR&#8217;s grant is not greater than the exercise price of the related Option. All freestanding SARs shall be granted subject to the same terms and conditions applicable to Options as set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 8</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and all tandem SARs shall have the same exercise price as the Option to which they relate. Subject to the provisions of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 8</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and the immediately preceding sentence, the Committee may impose such other conditions or restrictions on any Stock Appreciation Right as it shall deem appropriate. Stock Appreciation Rights may be settled in Common Stock, cash, Restricted Stock or a combination thereof, as determined by the Committee and set forth in the applicable Award Agreement.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">No Stockholder Rights</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Participants shall have no voting rights and will have no rights to receive dividends or Dividend Equivalents in respect of an Award of Stock Appreciation Rights or any shares of Common Stock subject to an Award of Stock Appreciation Rights until the Participant has become the holder of record of such shares.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Restricted Stock and Restricted Stock Units</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Vesting and Performance Criteria</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The grant, issuance, vesting and/or settlement of any Award of Restricted Stock or Restricted Stock Units shall occur at such time and be subject to such terms and conditions as determined by the Committee or under criteria established by the Committee, which may include conditions based on continued employment or engagement, passage of time, attainment of age and/or service requirements, </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">and/or satisfaction of performance conditions. In addition, the Committee shall have the right to grant Restricted Stock or Restricted Stock Unit Awards as the form of payment for grants or rights earned or due under other stockholder-approved compensation plans or arrangements of the Company.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Dividends and Distributions</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Participants in whose name Restricted Stock is granted shall be entitled to receive all dividends and other distributions paid with respect to those shares of Common Stock, unless determined otherwise by the Committee. The Committee will determine whether any such dividends or distributions will be automatically reinvested in additional shares of Restricted Stock and/or subject to the same restrictions on transferability as the Restricted Stock with respect to which they were distributed or whether such dividends or distributions will be paid in cash. Shares underlying Restricted Stock Units shall be entitled to dividends or distributions only to the extent provided by the Committee.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Other Stock-Based Awards</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">General Terms. </span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Committee is authorized, subject to limitations under applicable law, to grant to Eligible Persons such other Awards that may be denominated or payable in, valued in whole or in part by reference to, or otherwise based on, or related to, Common Stock, as deemed by the Committee to be consistent with the purposes of the Plan. The Committee shall determine the terms and conditions of such Other Stock-Based Awards. Common Stock delivered pursuant to an Other Stock-Based Award in the nature of a purchase right granted under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 11</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be purchased for such consideration, paid for at such times, by such methods, and in such forms, including cash, Common Stock, other Awards, or other property, as the Committee shall determine.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Dividends and Distributions</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Shares underlying Other Stock-Based Awards shall be entitled to dividends or distributions only to the extent provided by the Committee.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">12.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Incentive Bonuses</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Vesting Criteria</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Committee shall establish the vesting conditions applicable to an Incentive Bonus, including any performance criteria and level of achievement versus such criteria that may determine the amount payable under an Incentive Bonus, which may include a target, threshold and/or maximum amount payable and any formula for determining such achievement.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Timing and Form of Payment</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Committee shall determine the timing of payment of any Incentive Bonus. Payment of the amount due under an Incentive Bonus may be made in cash or in Common Stock, as determined by the Committee.</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Discretionary Adjustments</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Notwithstanding satisfaction of any performance goals, the amount paid under an Incentive Bonus on may be adjusted by the Committee on the basis of such further considerations as the Committee shall determine.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">13.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Performance Awards</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Committee may establish performance criteria and level of achievement versus such criteria that shall determine the number of shares of Common Stock, Restricted Stock Units, Other Stock-Based Awards or cash to be granted, retained, vested, issued or issuable under or in settlement of or the amount payable pursuant to an Award (any such Award, a &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Performance Award</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). A Performance Award may be identified as &#8220;Performance Share,&#8221; &#8220;Performance Equity,&#8221; &#8220;Performance Unit&#8221; or other such term as chosen by the Committee.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">14.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Deferral of Payment</span></p>
		<p class="ParaOverride-9" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Committee may, in an Award Agreement or otherwise, provide for the deferred delivery of Common Stock or cash upon settlement, vesting or other events with respect to Restricted Stock Units, Other Stock-Based Awards or in payment or satisfaction of an Incentive Bonus. Notwithstanding anything herein to the contrary, in no event will any election to defer the delivery of Common Stock or any other payment with respect to any Award be allowed if the Committee determines, in its sole discretion, that the deferral would result in the imposition of the additional tax under Section 409A(a)(1)(B) of the Code. No Award shall provide for deferral of compensation that does not comply with Section 409A of the Code. The Company, any Subsidiary or Affiliate which is in existence or hereafter comes into existence, the Board and the Committee shall have no liability to a Participant, or any other party, if an Award that is intended to be exempt from, or compliant with, Section 409A of the Code is not so exempt or compliant or for any action taken by the Board or the Committee in respect thereof.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">15.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Conditions and Restrictions Upon Securities Subject to Awards</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Committee may provide that the Common Stock issued upon exercise of an Option or Stock Appreciation Right or otherwise subject to or issued under an Award shall be subject to such further agreements, restrictions, conditions or limitations as the Committee in its discretion may specify prior to the exercise of such Option or Stock Appreciation Right or the grant, vesting or settlement of such Award, including conditions on vesting or transferability, forfeiture or repurchase provisions and method of payment for the Common Stock issued upon exercise, vesting or settlement of such Award (including the actual or constructive surrender of Common Stock already owned by the Participant) or payment of taxes arising in connection with an Award. Without limiting the foregoing, such restrictions may address the timing and manner of any resales by the Participant or other subsequent transfers by the Participant of any shares of Common Stock issued under an Award, including (a) restrictions under an insider trading policy or pursuant to applicable law, (b) restrictions designed to delay and/or coordinate the timing and manner of sales by the Participant and holders of other Company equity compensation arrangements, (c) restrictions as to the use of a specified brokerage firm for such resales or other transfers and (d) provisions requiring Common Stock be sold on the open market or to the Company in order to satisfy tax withholding or other obligations.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">16.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Adjustment of and Changes in the Stock</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The number and kind of shares of Common Stock available for issuance under this Plan (including under any Awards then outstanding), and the number and kind of shares of Common Stock subject to the limits set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 5</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, shall be equitably adjusted by the Committee to reflect any reorganization, reclassification, combination of shares, stock split, reverse stock split, spin-off, dividend or distribution of securities, property or cash (other than regular, quarterly cash dividends), or any other event or transaction that affects the number or kind of shares of Outstanding Common Stock. Such adjustment may be designed to comply with Section 424 of the Code or may be designed to treat the shares of Common Stock available under the Plan and subject to Awards as if they were all outstanding on the record date for such event or transaction or to increase the number of such shares of Common Stock to reflect a deemed reinvestment in shares of Common Stock of the amount distributed to the Company&#8217;s securityholders. The terms of any outstanding Award shall also be equitably adjusted by the Committee as to price, number or kind of shares of Common Stock subject to such Award, vesting, performance criteria, and other terms to reflect the foregoing events, which adjustments need not be uniform as between different Awards or different types of Awards. No fractional shares of Common Stock shall be issued or issuable pursuant to such an adjustment.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>In the event there shall be any other change in the number or kind of outstanding shares of Common Stock, or any stock or other securities into which such Common Stock shall have been changed, or for which it shall have been exchanged, by reason of a Change in Control, other merger, consolidation or otherwise, then the Committee shall determine the appropriate and equitable adjustment to be effected, which adjustments need not be uniform between different Awards or different types of Awards. In addition, in the event of such change described in this paragraph, the Committee may accelerate the time or times at which any Award may be exercised, consistent with and as otherwise permitted under Section 409A of the Code, and may provide for cancellation of such accelerated Awards that are not exercised within a time prescribed by the Committee in its sole discretion.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>In the event of a Change in Control, the Committee, acting in its sole discretion without the consent or approval of any Participant, may take one or more of the following actions, which may vary among individual Participants and/or among Awards held by any individual Participant: (i) arrange for the assumption of an outstanding Award by the successor or acquiring entity (if any) of such Change in Control (or by its parents, if any), which assumption will be binding on all selected Participants; provided that the exercise price and the number and nature of shares issuable upon exercise of any such Option or Stock Appreciation Right, or any Award that is subject to Section 409A of the Code, will be adjusted appropriately pursuant to Section 424(a) of the Code; (ii) provide for the issuance of substitute awards by the successor or acquiring entity (if any) of such Change in Control (or by its parents, if any) that will substantially preserve the otherwise applicable terms of the outstanding Award as determined by the Committee in its sole discretion; (iii) accelerate vesting or waive any forfeiture conditions; (iv)&#160;accelerate the time of exercisability of an Award so that such Award may be exercised in full or in part for a limited period of time on or before a date specified by the Committee, after which specified date all unexercised Awards and all rights of Participants thereunder shall terminate; or (v) make such other adjustments to Awards then outstanding as the Committee deems appropriate to reflect such Change in Control. Notwithstanding anything herein to the contrary, in the event of a Change in Control in which the acquiring or surviving company </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">in the transaction does not assume or continue outstanding Awards or issue substitute awards upon the Change in Control, unless determined otherwise by the Committee, immediately prior to the Change in Control, all Awards that are not assumed, continued or substituted for shall be treated as follows effective immediately prior to the Change in Control: (A) in the case of an Option or Stock Appreciation Right, the Participant shall have the ability to exercise such Option or Stock Appreciation Right, including any portion of the Option or Stock Appreciation Right not previously exercisable, (B) in the case of any Award the vesting of which is in whole or in part subject to performance criteria or an Incentive Bonus, all conditions to the grant, issuance, retention, vesting or transferability of, or any other restrictions applicable to, such Award shall immediately lapse and the Participant shall have the right to receive a payment based on target level achievement or actual performance through a date determined by the Committee, and (C) in the case of outstanding Restricted Stock, Restricted Stock Units or Other Stock-Based Awards (other than those referenced in subsection (B)), all conditions to the grant, issuance, retention, vesting or transferability of, or any other restrictions applicable to, such Award shall immediately lapse. In no event shall any action be taken pursuant to this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 16(c)</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> that would change the payment or settlement date of an Award in a manner that would result in the imposition of any additional taxes or penalties pursuant to Section 409A of the Code.</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Notwithstanding anything in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 16</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> to the contrary, in the event of a Change in Control, the Committee may provide for the cancellation and cash settlement of all outstanding Awards upon such Change in Control (including the cancellation for no consideration of any Option or Stock Appreciation Right with an exercise price that equals or exceeds the per share consideration in such transaction).</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding anything in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 16</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> to the contrary, an adjustment to an Option or Stock Appreciation Right under this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 16</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> shall be made in a manner that will not result in the grant of a new Option or Stock Appreciation Right under Section 409A of the Code.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">17.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Transferability</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Each Award may not be sold, transferred for value, pledged, assigned, or otherwise alienated or hypothecated by a Participant other than by will or the laws of descent and distribution, and each Option or Stock Appreciation Right shall be exercisable only by the Participant during his or her lifetime. Notwithstanding the foregoing, (a) outstanding Options may be exercised following the Participant&#8217;s death by the Participant&#8217;s beneficiaries or as permitted by the Committee and (b) as permitted by the Committee, a Participant may transfer or assign an Award as a gift to any &#8220;family member&#8221; (as such term is defined in the Registration Statement on Form S-8) (an &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Assignee Entity</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;), provided that such Assignee Entity shall be entitled to exercise assigned Options and Stock Appreciation Rights only during the lifetime of the assigning Participant (or following the assigning Participant&#8217;s death, by the Participant&#8217;s beneficiaries or as otherwise permitted by the Committee) and provided further that such Assignee Entity shall not further sell, pledge, transfer, assign or otherwise alienate or hypothecate such Award.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">18.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Compliance with Laws and Regulations</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>This Plan, the grant, issuance, vesting, exercise and settlement of Awards hereunder, and the obligation of the Company to sell, issue or deliver shares of Common Stock under such Awards, shall be subject to all applicable foreign, federal, state and local laws, rules and regulations, stock exchange rules and regulations, and to such approvals by any governmental or regulatory agency as may be required. The Company shall not be required to register in a Participant&#8217;s name or deliver Common Stock prior to the completion of any registration or qualification of such shares under any foreign, federal, state or local law or any ruling or regulation of any government body which the Committee shall determine to be necessary or advisable. To the extent the Company is unable to or the Committee deems it infeasible to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company&#8217;s counsel to be necessary to the lawful issuance and sale of any shares of Common Stock hereunder, the Company and its Subsidiaries shall be relieved of any liability with respect to the failure to issue or sell such shares of Common Stock as to which such requisite authority shall not have been obtained. No Option shall be exercisable and no Common Stock shall be issued and/or transferable under any other Award unless a registration statement with respect to the Common Stock underlying such Option is effective and current or the Company has determined, in its sole and absolute discretion, that such registration is unnecessary.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>In the event an Award is granted to or held by a Participant who is employed or providing services outside the United States, the Committee may, in its sole discretion, modify the provisions of the Plan or of such Award as they pertain to such individual to comply with applicable foreign law or to recognize differences in local law, currency or tax policy. The Committee may also impose conditions on the grant, issuance, exercise, vesting, settlement or retention of Awards in order to comply with such foreign law and/or to minimize the Company&#8217;s obligations with respect to tax equalization for Participants employed outside their home country.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">19.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Withholding</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">To the extent required by applicable federal, state, local or foreign law, the Committee may, and/or a Participant shall, make arrangements satisfactory to the Company for the satisfaction of any withholding tax obligations that arise with respect to any Award or the issuance or sale of any shares of Common Stock. The Company shall not be required to recognize any Participant rights under an Award, to issue shares of Common Stock or to recognize the disposition of such shares of Common Stock until such obligations are satisfied. To the extent permitted or required by the Committee, these obligations may or shall be satisfied by the Company withholding cash from any compensation otherwise payable to or for the benefit of a Participant, the Company withholding a portion of the shares of Common Stock that otherwise would be issued to a Participant under such Award or any other Award held by the Participant, or by the Participant tendering to the Company cash or, if allowed by the Committee, shares of Common Stock.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">20.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Amendment of the Plan or Awards</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Board may amend, alter, suspend or terminate this Plan, and the Committee may amend or alter any Award Agreement or other document evidencing an Award made under this Plan; however, except as provided pursuant to the provisions of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 16</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, no such amendment shall, without the approval of the stockholders of the Company:</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>increase the maximum number of shares of Common Stock for which Awards may be granted under this Plan;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>extend the term of this Plan;</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>change the class of Persons eligible to be Participants; or</span></p>
		<p class="ParaOverride-5" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>otherwise amend the Plan in any manner requiring stockholder approval by law or the rules of any stock exchange or market or quotation system on which the Common Stock is traded, listed or quoted.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">No amendment or alteration to the Plan or an Award or Award Agreement shall be made which would materially impair the rights of the holder of an Award without such holder&#8217;s consent; </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that no such consent shall be required if the Committee determines in its sole discretion and prior to the date of any Change in Control that such amendment or alteration either (i) is required or advisable in order for the Company, the Plan or the Award to satisfy any law or regulation or to meet the requirements of, or avoid adverse financial accounting consequences under, any accounting standard, or (ii) is not reasonably likely to significantly diminish the benefits provided under such Award, or that any such diminishment has been adequately compensated.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">21.<span style="width: 30px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>No Liability of Company</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Company, any Subsidiary or Affiliate which is in existence or hereafter comes into existence, the Board, the Committee and any delegate thereof shall not be liable to a Participant or any other person as to: (a) the non-issuance or sale of shares of Common Stock as to which the Company has been unable to obtain from any regulatory body having jurisdiction the authority deemed by the Company&#8217;s counsel to be necessary to the lawful issuance and sale of any shares of Common Stock hereunder; and (b) any tax consequence expected, but not realized, by any Participant or other person due to the receipt, vesting, exercise or settlement of any Award granted hereunder.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">22.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Non-Exclusivity of Plan</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Neither the adoption of this Plan by the Board nor the submission of this Plan to the stockholders of the Company for approval shall be construed as creating any limitations on the power of the Board or the Committee to adopt such other incentive arrangements as either may deem desirable, including the granting of equity awards otherwise than under this Plan, and such arrangements may be either generally applicable or applicable only in specific cases.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-12</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">23.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Governing Law</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">This Plan and any agreements or other documents hereunder shall be interpreted and construed in accordance with the laws of the State of Delaware and applicable federal law. Any reference in this Plan or in the agreement or other document evidencing any Awards to a provision of law or to a rule or regulation shall be deemed to include any successor law, rule or regulation of similar effect or applicability.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">24.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>No Right to Employment, Reelection or Continued Service</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Nothing in this Plan or an Award Agreement shall interfere with or limit in any way the right of the Company, its Subsidiaries and/or its Affiliates to terminate any Participant&#8217;s employment, service on the Board or service at any time or for any reason not prohibited by law, nor shall this Plan or an Award itself confer upon any Participant any right to continue his or her employment or service for any specified period of time. Neither an Award nor any benefits arising under this Plan shall constitute an employment contract with the Company, any Subsidiary and/or its Affiliates. Subject to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections 4</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">20</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, this Plan and the benefits hereunder may be terminated at any time in the sole and exclusive discretion of the Board without giving rise to any liability on the part of the Company, its Subsidiaries and/or its Affiliates.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">25.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Specified Employee Delay</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">To the extent any payment under this Plan is considered deferred compensation subject to the restrictions contained in Section 409A of the Code, such payment may not be made to a specified employee (as determined in accordance with a uniform policy adopted by the Company with respect to all arrangements subject to Section 409A of the Code) upon Separation from Service before the date that is six months after the specified employee&#8217;s Separation from Service (or, if earlier, the specified employee&#8217;s death). Any payment that would otherwise be made during this period of delay shall be accumulated and paid on the sixth month plus one day following the specified employee&#8217;s Separation from Service (or, if earlier, as soon as administratively practicable after the specified employee&#8217;s death).</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">26.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>No Liability of Committee Members</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">No member of the Committee shall be personally liable by reason of any contract or other instrument executed by such member or on his or her behalf in his or her capacity as a member of the Committee nor for any mistake of judgment made in good faith, and the Company shall indemnify and hold harmless each member of the Committee and each other employee, officer or director of the Company to whom any duty or power relating to the administration or interpretation of the Plan may be allocated or delegated, against any cost or expense (including counsel fees) or liability (including any sum paid in settlement of a claim) arising out of any act or omission to act in connection with the Plan, unless arising out of such Person&#8217;s own fraud or willful bad faith; </span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that approval of the Board shall be required for the payment of any amount in settlement of a claim against any such Person. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such Persons may be entitled under the Company&#8217;s Certificate of Incorporation and Bylaws (as each may be amended from time to time), as a matter of law, pursuant to any individual agreement or otherwise, or any power that the Company may have to indemnify them or hold them harmless.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">27.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Severability</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">If any provision of the Plan or any Award is or becomes or is deemed to be invalid, illegal, or unenforceable in any jurisdiction or as to any Person or Award, or would disqualify the Plan or any Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to the applicable laws, or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan or the Award, such provision shall be stricken as to such jurisdiction, Person or Award, and the remainder of the Plan and any such Award shall remain in full force and effect.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">28.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Unfunded Plan</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Plan is intended to be an unfunded plan. Participants are and shall at all times be general creditors of the Company with respect to their Awards. If the Committee or the Company chooses to set aside funds in a trust or otherwise for the payment of Awards under the Plan, such funds shall at all times be subject to the claims of the creditors of the Company in the event of its bankruptcy or insolvency.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-13</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">29.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Clawback/Recoupment</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Awards granted under this Plan will be subject to recoupment in accordance with any clawback policy that the Company adopts or is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Rule 10D-1 under the Exchange Act or other applicable law. In addition, the Committee may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Committee determines necessary or appropriate, including a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of misconduct. No recovery of compensation under such a clawback policy will be an event giving rise to a right to resign for &#8220;good reason&#8221; or be deemed a &#8220;constructive termination&#8221; (or any similar term) as such terms are used in any agreement between any Participant and the Company.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">30.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Beneficiary Designation</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Participants may designate beneficiaries with respect to Awards under the Plan in accordance with the procedures determined by the Committee. In the absence of a beneficiary designation, a Participant&#8217;s estate will be the deemed beneficiary.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:36pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-36pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">31.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Interpretation</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Headings are given to the Sections and subsections of the Plan solely as a convenience to facilitate reference and shall not be deemed in any way material or relevant to the construction or interpretation of the Plan or any provision thereof. Words in the masculine gender shall include the feminine gender, and where appropriate, the plural shall include the singular and the singular shall include the plural. The use herein of the word &#8220;including&#8221; following any general statement, term or matter shall not be construed to limit such statement, term or matter to the specific items or matters set forth immediately following such word or to similar items or matters, whether or not non-limiting language (such as &#8220;without limitation&#8221;, &#8220;but not limited to&#8221;, or words of similar import) is used with reference thereto, but rather shall be deemed to refer to all other items or matters that could reasonably fall within the broadest possible scope of such general statement, term or matter. References herein to any agreement, instrument or other document means such agreement, instrument or other document as amended, supplemented and modified from time to time to the extent permitted by the provisions thereof and not prohibited by the Plan.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex K-14</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T112"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;L </span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.</span><span class="CharOverride-2" style="font-family:Times New Roman, serif;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">2024 EMPLOYEE STOCK PURCHASE PLAN</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Purpose</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The purpose of this Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) is to provide employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock through accumulated Contributions. The Company&#8217;s intention is to have the Plan qualify as an &#8220;employee stock purchase plan&#8221; under Section 423 of the Code. The provisions of the Plan, accordingly, will be construed to extend and limit Plan participation in a uniform and nondiscriminatory basis consistent with the requirements of Section 423 of the Code.</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:24pt;text-indent:-24pt;margin-top:12pt;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Definitions.</p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">As used in the Plan, the following terms shall have the meanings set forth below:</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Administrator</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Compensation Committee of the Board (or any successor committee), or such other committee as designated by the Board to administer the Plan under </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 14</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Applicable Laws</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the requirements relating to the administration of equity-based awards under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws of any foreign country or jurisdiction where options are, or will be, granted under the Plan.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Board</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Board of Directors of the Company.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Code</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Internal Revenue Code of 1986, as amended from time to time, and the rulings and regulations issued thereunder.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the common stock of the Company, $0.001 par value per share.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Company</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means Oruka Therapeutics, Inc., a Delaware corporation, and any successor corporation.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(g)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Compensation</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Eligible Employee&#8217;s base salary or base hourly rate of pay before deduction for any salary deferral contributions made by the Eligible Employee to any tax-qualified or nonqualified deferred compensation plan, but excluding commissions, overtime, incentive compensation, bonuses and other forms of compensation. The Administrator, in its discretion, may, on a uniform and nondiscriminatory basis, establish a different definition of Compensation for an Offering Period.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(h)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Contributions</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the payroll deductions and any other additional payments that the Administrator may permit to be made by a Participant to fund the exercise of options granted pursuant to the Plan, subject to Section 423 of the Code.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Designated Subsidiary</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any Subsidiary that has been designated by the Administrator from time to time in its sole discretion as eligible to participate in the Plan. As of the date of adoption of the Plan, the Designated Subsidiaries consist exclusively of: Oruka Therapeutics Operating Company, LLC.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(j)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Effective Date</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Closing Date (as defined in that Agreement and Plan of Merger and Reorganization dated April 3, 2024 by and between the Company (f/k/a ARCA biopharma, Inc.) and Oruka Therapeutics Operating Company, LLC (f/k/a Oruka Therapeutics, Inc.)).</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(k)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Eligible Employee</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means any person, including an officer, who is customarily employed by the Company or a Designated Subsidiary (i) for more than 20 hours per week and (ii) for more than five months in any calendar year. For purposes of the Plan, the employment relationship shall be treated as continuing intact while the individual is on sick leave or other leave of absence approved by the Company. Where the period of leave exceeds 90 days and the individual&#8217;s right to reemployment is not guaranteed either by statute or by contract, the employment relationship shall be deemed to have terminated on the 91</span><span class="CharOverride-6" style="font-family:Times New Roman PS Std, serif;font-size:6pt;font-style:normal;font-weight:normal;vertical-align:super;">st</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> day of such leave. &#8220;Eligible Employee&#8221; shall not include any person who is a citizen or resident of a foreign jurisdiction if granting them an option under the Plan would violate the law of such jurisdiction, or if compliance with the laws of the jurisdiction would cause the Plan to violate Section 423 of the Code.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(l)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Employer</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Company and each Designated Subsidiary.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(m)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Enrollment Date</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the first Trading Day of each Offering Period.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(n)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Exchange Act</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Securities Exchange Act of 1934, as amended, including the rules and regulations promulgated thereunder.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(o)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Exercise Date</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the last Trading Day of each Offering Period.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(p)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Fair Market Value</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means as of any date, the value of the Common Stock determined as follows: (i) if the Common Stock is listed on any established stock exchange, system or market, its Fair Market Value shall be the closing price for the Common Stock as quoted on such exchange, system or market as reported in the Wall Street Journal or such other source as the Administrator deems reliable (or, if no sale of Common Stock is reported for such date, on the next preceding date on which any sale shall have been reported); and (ii) in the absence of an established market for the Common Stock, the Fair Market Value thereof shall be determined in good faith by the Administrator.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(q)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-7" style="font-family:Times New Roman, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Merger Agreement</span><span class="CharOverride-7" style="font-family:Times New Roman, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means that Agreement and Plan of Merger and Reorganization dated April 3, 2024 by and between the Company (f/k/a ARCA biopharma, Inc.) and Oruka Therapeutics Operating Company, LLC (f/k/a Oruka Therapeutics, Inc.).</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(r)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">New Exercise Date</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a new Exercise Date if the Administrator shortens any Offering Period then in progress.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(s)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Offering</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an offer under the Plan of an option that may be exercised during an Offering Period as further described in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 4</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. For purposes of the Plan, the Administrator may designate separate Offerings under the Plan (the terms of which need not be identical) in which Eligible Employees of one or more Employers will participate, even if the dates of the applicable Offering Periods of each such Offering are identical and the provisions of the Plan will separately apply to each Offering. To the extent permitted by Treasury Regulation Section 1.423-2(a)(1), the terms of each Offering need not be identical; </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the terms of the Plan and an Offering together satisfy Treasury Regulation Sections 1.423-2(a)(2) and (a)(3).</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(t)<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Offering Periods</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the periods established by the Administrator (not to exceed 27 months) during which an option granted pursuant to the Plan may be exercised. The duration and timing of Offering Periods may be changed pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections 4</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">18,</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">19</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The first Offering Period shall commence on the Effective Date and end on the next December 9 or June 8 that follows the Effective Date, and subsequent Offering Periods shall be each six-month period commencing the day after the prior Offering Period ends and ending on each December 9 and June&#160;8.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(u)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Outstanding Common Stock</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the sum of (i) the shares of Common Stock outstanding, (ii) the shares of Common Stock underlying unexercised pre-funded warrants, and (iii) the shares of Common Stock underlying the Company&#8217;s preferred stock, par value $0.001 (determined on an as-converted basis without regard to any limitations on such conversion).</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Parent</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a &#8220;parent corporation,&#8221; whether now or hereafter existing, as defined in Section 424(e) of the Code.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(w)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Participant</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an Eligible Employee who elects to participate in the Plan.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(x)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Period</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the period during an Offering Period during which shares of Common Stock may be purchased on a Participant&#8217;s behalf in accordance with the terms of the Plan. Unless the Administrator determines otherwise, during the first Offering Period, the Purchase Period will begin on the first date of such Offering Period and end on the last day of such Offering Period, and subsequent Purchase Periods shall be each six-month period commencing thereafter. Unless the Administrator determines otherwise, each Purchase Period following the first Purchase Period will be a six-month period.</span></p>
		<p class="ParaOverride-7" style="margin:0;padding:0;border-width:0;margin-top:7pt;orphans:2;text-indent:24pt;widows:2;margin-top:7pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(y)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Price</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means an amount equal to 85% of the Fair Market Value of a share of Common Stock on the Enrollment Date or on the Exercise Date, whichever is lower; </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the Purchase Price may be determined for subsequent Offering Periods by the Administrator subject to compliance with Section 423 of the Code (or any other Applicable Law) or pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 18</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(z)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Subsidiary</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a &#8220;subsidiary corporation,&#8221; whether now or hereafter existing, as defined in Section 424(f) of the Code.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(z)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Trading Day</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means a day on which the national stock exchange upon which the Common Stock is listed is open for trading or, if the Common Stock is not listed on a national stock exchange, a business day as determined by the Administrator in good faith.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(aa)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>&#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Regulations</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221; means the Treasury regulations of the Code. Reference to a specific Treasury Regulation or Section of the Code shall include such Treasury Regulation or Section, any valid regulation promulgated under such Section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such Section or regulation.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Eligibility.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Offering Periods</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any Eligible Employee on a given Enrollment Date will be eligible to participate in the Plan if he or she was employed by the Company for at least 30 calendar days immediately preceding the Enrollment Date, subject to the requirements of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 5</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that an Eligible Employee who commences employment with the Company or a Designated Subsidiary following such 30-day period will be eligible to participate in the Plan at the beginning of the next Purchase Period to occur that is at least 30 calendar days following the commencement of his or her employment with the Company or a Designated Subsidiary. Eligible Employees who do not elect to participate in the Plan on a given Enrollment Date may elect to participate in the Plan at the beginning of any subsequent Purchase Period, as determined by the Administrator.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Non-U.S. Employees</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Employees who are citizens or residents of a non-U.S. jurisdiction (without regard to whether they also are citizens or residents of the United States or resident aliens (within the meaning of Section 7701(b)(1)(A) of the Code)) may be excluded from participation in the Plan or an Offering if the participation of such employees is prohibited under the laws of the applicable jurisdiction or if complying with the laws of the applicable jurisdiction would cause the Plan or an Offering to violate Section 423 of the Code. In addition, as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 14</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Administrator may establish one or more sub-plans of the Plan (which may, but are not required to, comply with the requirements of Section 423 of the Code) to provide benefits to employees of Designated Subsidiaries located outside the United States in a manner that complies with local law. Any such sub-plan will be a component of the Plan and will not be a separate plan.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Limitations</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any provisions of the Plan to the contrary notwithstanding, no Eligible Employee will be granted an option under the Plan (i) to the extent that, immediately after the grant, such Eligible Employee (or any other person whose stock would be attributed to such Eligible Employee pursuant to Section 424(d) of the Code) would own capital stock of the Company or any Parent or Subsidiary of the Company and/or hold outstanding options to purchase such stock possessing 5% or more of the total combined voting power or value of all classes of the capital stock of the Company or of any Parent or Subsidiary of the Company, or (ii) to the extent that his or her rights to purchase stock under all employee stock purchase plans (as defined in Section 423 of the Code) of the Company or any Parent or Subsidiary of the Company accrues at a rate that exceeds $25,000 worth of stock (determined at the Fair Market Value of the stock at the time such option is granted) for each calendar year in which such option is outstanding at any time, as determined in accordance with Section 423 of the Code and the regulations thereunder.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Offering Periods</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Plan will be implemented by consecutive Offering Periods with new Offering Periods commencing at such times as determined by the Administrator. The Administrator will have the power to change the duration of Offering Periods (including the commencement dates thereof) without stockholder approval.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Participation</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">An Eligible Employee may participate in the Plan by (i) submitting to the Company&#8217;s Finance department (or its delegate), on or before a date determined by the Administrator prior to an applicable Enrollment Date, a properly completed subscription agreement authorizing Contributions in the form provided by the Administrator for such purpose, or (ii) following an electronic or other enrollment procedure determined by the Administrator.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Contributions</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>At the time a Participant enrolls in the Plan pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 5</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, such Participant will elect to have payroll deductions made on each pay day or other Contributions (to the extent permitted by the Administrator) made during the Offering Period (or portion thereof) in an amount equal to at least 1% but not exceeding 15% of the </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Compensation (or such other percentage of Compensation as determined by the Administrator in its sole discretion, prior to the commencement of an applicable Offering Period), that the Participant receives on each pay day during the Offering Period; </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that should a pay day occur on an Exercise Date, a Participant will have any payroll deductions made on such day applied to his or her notional account under the subsequent Purchase Period or Offering Period. The minimum permissible projected Contribution by any Participant for an Offering Period shall be $500. The maximum permissible Contribution by any Participant for all Offering Periods during any calendar year shall be $25,000. The Administrator, in its sole discretion and to the extent permitted by Section 423 of the Code, may permit all Participants in a specified Offering to contribute amounts to the Plan through payment by cash, check, or other means set forth in the subscription agreement prior to each Exercise Date of each Purchase Period. A Participant&#8217;s subscription agreement will remain in effect for successive Offering Periods unless terminated as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Payroll deductions for a Participant will commence on the first pay day following the Enrollment Date (or such later date on which a Participant enrolls in the Plan pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 5</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) and will end on the last pay day prior to the Exercise Date of such Purchase Period to which such authorization is applicable, unless sooner terminated by the Participant as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">; </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that with respect to the first Offering Period, payroll deduction for a Participant will not commence until such time as determined by the Administrator.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>All Contributions made for a Participant will be credited to his or her notional account under the Plan and payroll deductions will be made in whole percentages only. Except to the extent permitted by the Administrator pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 6(a)</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, a Participant may not make any additional payments into such notional account.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(d)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>A Participant may discontinue his or her participation in the Plan as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Participants shall not be permitted to increase or to otherwise decrease their rates of Contributions during a Purchase Period unless otherwise determined by the Administrator in its sole discretion; </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that Participants shall be permitted to increase or decrease their rates of Contributions effective as of the beginning of each Purchase Period.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(e)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Notwithstanding the foregoing, to the extent necessary to comply with Section 423(b)(8) of the Code, a Participant&#8217;s Contributions may be decreased to 0% at any time during a Purchase Period. Subject to Section 423(b)(8) of the Code, Contributions will recommence at the rate originally elected by the Participant effective as of the beginning of the first Purchase Period scheduled to end in the following calendar year, unless terminated by the Participant as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(f)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>At the time the option under the Plan is exercised, in whole or in part, or at the time some or all of the Common Stock issued under the Plan is disposed of (or any other time that a taxable event related to the Plan occurs), the Participant must make adequate provision for the Company&#8217;s or Employer&#8217;s federal, state, local, or any other tax liability payable to any authority including taxes imposed by jurisdictions outside of the United States, national insurance, social security, or other tax withholding obligations, if any, that arise upon the exercise of the option or the disposition of the Common Stock (or any other time that a taxable event related to the Plan occurs). At any time, the Company or the Employer may, but will not be obligated to, withhold from the Participant&#8217;s compensation the amount necessary for the Company or the Employer to meet applicable withholding obligations, including any withholding required to make available to the Company or the Employer any tax deductions or benefits attributable to sale or early disposition of Common Stock by the Eligible Employee. In addition, the Company or the Employer may, but will not be obligated to, withhold from the proceeds of the sale of Common Stock or any other method of withholding the Company or the Employer deems appropriate to the extent permitted by Treasury Regulation Section 1.423-2(f).</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Grant of Option</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">On the Enrollment Date of each Offering Period, each Eligible Employee participating in such Offering Period (or any Purchase Period within such Offering Period) will be granted an option to purchase on each Exercise Date during such Offering Period (at the applicable Purchase Price) up to a number of shares of Common Stock determined by dividing (i) such Eligible Employee&#8217;s Contributions accumulated prior to such Exercise Date and retained in the Eligible Employee&#8217;s notional account as of the Exercise Date by (ii) the applicable Purchase Price; </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that in no event will an Eligible Employee be permitted to purchase during each Purchase Period more than 5,000 shares of Common Stock (subject to any adjustment pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 18</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">); </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, further</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that such purchase will be subject to the limitations set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections 3(c)</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">13</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Eligible Employee may accept the grant of such option by electing to participate in the Plan in accordance with the requirements of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 5</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Administrator may, for future Offering Periods, increase or decrease, in its absolute discretion, the maximum number of shares of Common Stock that an Eligible Employee may purchase during each Purchase Period of an Offering Period. Exercise of the option will occur as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 8</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, unless the Participant has withdrawn pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The option will expire on the last day of the Offering Period.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">8.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Exercise of Option</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Unless a Participant withdraws from the Plan as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, such Participant&#8217;s option for the purchase of shares of Common Stock will be exercised automatically on the Exercise Date, and the maximum number of full shares subject to the option will be purchased for such Participant at the applicable Purchase Price with the accumulated Contributions from his or her notional account. No fractional shares of Common Stock will be purchased; unless determined by the Administrator, any Contributions accumulated in a Participant&#8217;s notional account that are not sufficient to purchase a full share will be retained in the Participant&#8217;s notional account for the subsequent Purchase Period or Offering Period, subject to earlier withdrawal by the Participant as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. Any other funds left over in a Participant&#8217;s notional account after the Exercise Date will be returned to the Participant (without interest thereon, except as otherwise required under local laws, as further set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 12</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">). During a Participant&#8217;s lifetime, a Participant&#8217;s option to purchase shares hereunder is exercisable only by him or her.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>If the Administrator determines that, on a given Exercise Date, the number of shares of Common Stock with respect to which options are to be exercised may exceed (i) the number of shares of Common Stock that were available for sale under the Plan on the Enrollment Date of the applicable Offering Period, or (ii) the number of shares of Common Stock available for sale under the Plan on such Exercise Date, the Administrator may in its sole discretion (x) provide that the Company will make a pro rata allocation of the shares of Common Stock available for purchase on such Enrollment Date or Exercise Date, as applicable, in as uniform a manner as will be practicable and as it will determine in its sole discretion to be equitable among all Participants exercising options to purchase Common Stock on such Exercise Date, and continue all Offering Periods then in effect, or (y) provide that the Company will make a pro rata allocation of the shares available for purchase on such Enrollment Date or Exercise Date, as applicable, in as uniform a manner as will be practicable and as it will determine in its sole discretion to be equitable among all Participants exercising options to purchase Common Stock on such Exercise Date, and terminate any or all Offering Periods then in effect pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 19</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. The Company may make a pro rata allocation of the shares available on the Enrollment Date of any applicable Offering Period pursuant to the preceding sentence, notwithstanding any authorization of additional shares for issuance under the Plan by the Company&#8217;s stockholders subsequent to such Enrollment Date.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">9.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Delivery</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">As soon as reasonably practicable after each Exercise Date on which a purchase of shares of Common Stock occurs, the Company will arrange the delivery to each Participant of the shares purchased upon exercise of his or her option in a form determined by the Administrator (in its sole discretion) and pursuant to rules established by the Administrator. The Company may permit or require that shares be deposited directly with a broker designated by the Company or to a designated agent of the Company, and the Company may utilize electronic or automated methods of share transfer. The Company may require that shares be retained with such broker or agent for a designated period of time and/or may establish other procedures to permit tracking of disqualifying dispositions of such shares. No Participant will have any voting, dividend, or other stockholder rights with respect to shares of Common Stock subject to any option granted under the Plan until such shares have been purchased and delivered to the Participant as provided in this </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 9</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">10.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Withdrawal</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">A Participant may withdraw all, but not less than all, the Contributions credited to his or her notional account and not yet used to exercise his or her option under the Plan at any time by (a) submitting to the Company&#8217;s Finance department (or its delegate) a written notice of withdrawal in the form determined by the Administrator for such purpose, or (b) following an electronic or other withdrawal procedure determined by the Administrator. All the Participant&#8217;s Contributions credited to his or her notional account will be paid to such Participant as soon as reasonably practicable after receipt of notice of withdrawal and such Participant&#8217;s option for the Offering Period will be automatically terminated, and no further Contributions for the purchase of shares will be made for such Offering Period. If a Participant withdraws from an Offering Period, Contributions will not resume at the beginning of the succeeding Offering Period, unless the Participant re-enrolls in the Plan in accordance with the provisions of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 5</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">11.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Termination of Employment</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Upon a Participant&#8217;s ceasing to be an Eligible Employee, for any reason, he or she will be deemed to have elected to withdraw from the Plan and the Contributions credited to such Participant&#8217;s notional account during the Offering Period but not yet used to purchase shares of Common Stock under the Plan will be returned to such Participant or, in the case of his or her death, to the person or persons entitled thereto under </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 15</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, and such Participant&#8217;s option will be automatically terminated. In no event may a Participant be granted an option under the Plan following his or her termination of employment unless such Participant subsequently becomes an Eligible Employee again.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">12.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Interest</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">No interest will accrue on the Contributions of a Participant in the Plan, except as may be required by Applicable Law, as determined by the Company, and if so required by the laws of a particular jurisdiction, shall apply to all Participants in the relevant Offering except to the extent otherwise permitted by Treasury Regulation Section 1.423-2(f).</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">13.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Stock</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Subject to adjustment upon changes in capitalization of the Company as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 18</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> hereof, the maximum number of shares of Common Stock that will be made available for sale under the Plan shall be equal to (i) a number equal to the lesser of (x) 1,000,000 or (y) 1% of the total number of shares of Outstanding Common Stock immediately following the closing of the transactions set forth in the Merger Agreement, </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">plus</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> (ii) any shares of Common Stock added as a result of the following sentence (collectively, the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Share Pool</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;). The Share Pool will automatically increase on January 1 of each year beginning in 2025 and ending with a final increase on January 1, 2034 in an amount equal to 1% of the Outstanding Common Stock on the preceding December 31; </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that the Committee may provide that there will be no January 1 increase in the Share Pool for any such year or that the increase in the Share Pool for any such year will be a smaller number of shares of Common Stock than would otherwise occur pursuant to this sentence.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Until the shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), a Participant will only have the rights of an unsecured creditor with respect to such shares, and no right to vote or receive dividends or any other rights as a stockholder will exist with respect to such shares.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Shares of Common Stock to be delivered to a Participant under the Plan will be registered in the name of the Participant or in the name of the Participant and his or her spouse.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">14.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Administration</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Plan shall be administered by the Administrator. The Board shall fill vacancies on, and from time to time may remove or add members to, the Administrator. Any power of the Administrator may also be exercised by the Board. The Administrator will have full and exclusive discretionary authority to construe, interpret, and apply the terms of the Plan, to designate separate Offerings under the Plan, to determine eligibility, to adjudicate all disputed claims filed under the Plan, and to establish such procedures that it deems necessary for the administration of the Plan (including, without limitation, to adopt such procedures and sub-plans as are necessary or appropriate to permit the participation in the Plan by employees who are foreign nationals or employed outside the United States, the terms of which sub-plans may take precedence over other provisions of this Plan, with the exception of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 13(a)</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, but unless otherwise superseded by the terms of such sub-plan, the provisions of this Plan shall govern the operation of such sub-plan). Unless otherwise determined by the Administrator, the employees eligible to participate in each sub-plan will participate in a separate Offering. Without limiting the generality of the foregoing, the Administrator is specifically authorized to adopt rules and procedures regarding eligibility to participate, the definition of Compensation, handling of Contributions, making of Contributions to the Plan (including, without limitation, in forms other than payroll deductions), establishment of bank or trust accounts to hold Contributions, payment of interest, conversion of local currency, obligations to pay payroll tax, determination of beneficiary designation requirements, withholding procedures, and handling of stock certificates that vary with applicable local requirements. The Administrator also is authorized to determine that, to the extent permitted by Treasury Regulation Section 1.423-2(f), the terms of an option granted under the Plan or an Offering to citizens or residents of a non-U.S. </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">jurisdiction will be less favorable than the terms of options granted under the Plan or the same Offering to employees resident solely in the United States. The Administrator hereby delegates to and designates the Senior Vice President of Finance of the Company (or such other officer with similar authority), and to his or her delegates or designates, the authority to assist the Administrator in the day-to-day administration of the Plan. The Administrator may also delegate some or all of its responsibilities to one or more other persons (which may include Company personnel) and, to the extent there has been any such delegation, any reference in the Plan to the Administrator shall include the delegate of the Administrator. Every finding, decision, and determination made by the Administrator will, to the full extent permitted by Applicable Laws, be final and binding upon all parties.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">15.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Designation of Beneficiary</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>If permitted by the Administrator, a Participant may file a designation of a beneficiary who is to receive any shares of Common Stock and cash, if any, from the Participant&#8217;s notional account under the Plan in the event of such Participant&#8217;s death subsequent to an Exercise Date on which the option is exercised but prior to delivery to such Participant of such shares and cash. In addition, if permitted by the Administrator, a Participant may file a designation of a beneficiary who is to receive any cash from the Participant&#8217;s notional account under the Plan in the event of such Participant&#8217;s death prior to exercise of the option. If a Participant is married and the designated beneficiary is not the spouse, spousal consent will be required for such designation to be effective.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Such designation of beneficiary may be changed by the Participant at any time by notice in a form determined by the Administrator. In the event of the death of a Participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such Participant&#8217;s death, the Company will deliver such shares and/or cash to the executor or administrator of the estate of the Participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such shares and/or cash to the spouse or to any one or more dependents or relatives of the Participant, or if no spouse, dependent, or relative is known to the Company, then to such other person as the Company may designate.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>All beneficiary designations will be in such form and manner as the Administrator may designate from time to time. Notwithstanding </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections 15(a)</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">15(b)</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Company and/or the Administrator may decide not to permit such designations by Participants in non-U.S. jurisdictions to the extent permitted by Treasury Regulation Section 1.423-2(f).</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">16.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Transferability</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Neither Contributions credited to a Participant&#8217;s notional account nor any rights with regard to the exercise of an option or to receive shares of Common Stock under the Plan may be assigned, transferred, pledged, or otherwise disposed of in any way (other than by will, the laws of descent and distribution or as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 15</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) by the Participant. Any such attempt at assignment, transfer, pledge, or other disposition will be without effect, except that the Company may treat such act as an election to withdraw funds from an Offering Period in accordance with Section 10 hereof.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">17.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Use of Funds</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Company may use all Contributions received or held by it under the Plan for any corporate purpose, and the Company will not be obligated to segregate such Contributions except under Offerings in which applicable local law requires that Contributions to the Plan by Participants be segregated from the Company&#8217;s general corporate funds and/or deposited with an independent third party for Participants in non-U.S. jurisdictions. Until shares of Common Stock are issued, Participants will only have the rights of an unsecured creditor with respect to such shares.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">18.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Adjustments, Dissolution, Liquidation, Merger or Other Corporate Transaction</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Adjustments</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. In the event that any dividend or other distribution (whether in the form of cash, Common Stock, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Common Stock or other securities of the Company, or other change in the corporate structure of the Company affecting the Common Stock occurs, the Administrator, in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made </span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">available under the Plan, will, in such manner as it may deem equitable, adjust the number and class of Common Stock that may be delivered under the Plan, the Purchase Price per share and the number of shares of Common Stock covered by each option under the Plan that has not yet been exercised, and the numerical limits of </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Sections 7</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">13</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Dissolution or Liquidation</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. In the event of the proposed dissolution or liquidation of the Company, any Offering Period then in progress will be shortened by setting a New Exercise Date, and will terminate immediately prior to the consummation of such proposed dissolution or liquidation, unless provided otherwise by the Administrator. The New Exercise Date will be before the date of the Company&#8217;s proposed dissolution or liquidation. The Administrator will notify each Participant in writing or electronically, prior to the New Exercise Date, that the Exercise Date for the Participant&#8217;s option has been changed to the New Exercise Date and that the Participant&#8217;s option will be exercised automatically on the New Exercise Date, unless prior to such date the Participant has withdrawn from the Offering Period as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span></span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">Merger or Other Corporate Transaction</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">. In the event of a merger, sale, or other similar corporate transaction involving the Company, each outstanding option will be assumed or an equivalent option substituted by the successor corporation or a Parent or Subsidiary of the successor corporation. If the successor corporation refuses to assume or substitute for the option, the Offering Period with respect to which such option relates will be shortened by setting a New Exercise Date on which such Offering Period shall end. The New Exercise Date will occur before the date of the Company&#8217;s proposed merger, sale, or other similar corporate transaction. The Administrator will notify each Participant in writing or electronically prior to the New Exercise Date, that the Exercise Date for the Participant&#8217;s option has been changed to the New Exercise Date and that the Participant&#8217;s option will be exercised automatically on the New Exercise Date, unless prior to such date the Participant has withdrawn from the Offering Period as provided in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 10</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">19.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Amendment or Termination</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The Administrator, in its sole discretion, may amend, suspend, or terminate the Plan, or any part thereof, at any time and for any reason. If the Plan is terminated, the Administrator, in its discretion, may elect to terminate all outstanding Offering Periods either immediately or upon completion of the purchase of shares of Common Stock on the next Exercise Date (which may be sooner than originally scheduled, if determined by the Administrator in its discretion), or may elect to permit Offering Periods to expire in accordance with their terms (and subject to any adjustment pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 18</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">). If the Offering Periods are terminated prior to expiration, all amounts then credited to Participants&#8217; notional accounts that have not been used to purchase shares of Common Stock will be returned to the Participants (without interest thereon, except as otherwise required under local laws, as further set forth in </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 12</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">) as soon as administratively practicable.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Without stockholder consent and without limiting </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 19(a)</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, the Administrator will be entitled to change the Offering Periods or Purchase Periods, designate separate Offerings, limit the frequency and/or number of changes in the amount withheld during an Offering Period, establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, permit payroll withholding in excess of the amount designated by a Participant in order to adjust for delays or mistakes in the Company&#8217;s processing of properly completed withholding elections, establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each Participant properly correspond with Contribution amounts, and establish such other limitations or procedures as the Administrator determines in its sole discretion advisable that are consistent with the Plan.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(c)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>In the event the Administrator determines that the ongoing operation of the Plan may result in unfavorable financial accounting consequences, the Administrator may, in its discretion and, to the extent necessary or desirable, modify, amend, or terminate the Plan to reduce or eliminate such accounting consequence including, but not limited to:</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>amending the Plan to conform with the safe harbor definition under the Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto), including with respect to an Offering Period underway at the time;</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(ii)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>altering the Purchase Price for any Offering Period or Purchase Period including an Offering Period or Purchase Period underway at the time of the change in Purchase Price;</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iii)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>shortening any Offering Period or Purchase Period by setting a New Exercise Date, including an Offering Period or Purchase Period underway at the time of the Administrator action;</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(iv)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>reducing the maximum percentage of Compensation a Participant may elect to set aside as Contributions; and</span></p>
		<p class="ParaOverride-8" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(v)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>reducing the maximum number of shares of Common Stock a Participant may purchase during any Offering Period or Purchase Period.</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Such modifications or amendments will not require stockholder approval or the consent of any Participants.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">20.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Notices</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">All notices or other communications by a Participant to the Company under or in connection with the Plan will be deemed to have been duly given when received in the form and manner specified by the Company at the location, or by the person, designated by the Company for the receipt thereof.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">21.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Conditions Upon Issuance of Shares</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Shares of Common Stock will not be issued with respect to an option unless the exercise of such option and the issuance and delivery of such shares pursuant thereto will comply with all applicable provisions of law, domestic or foreign, including the Securities Act of 1933, as amended, the Exchange Act, the rules and regulations promulgated thereunder, and the requirements of any stock exchange upon which the shares may then be listed, and will be further subject to the approval of counsel for the Company with respect to such compliance.</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>As a condition to the exercise of an option, the Company may require the person exercising such option to represent and warrant at the time of any such exercise that the shares are being purchased only for investment and without any present intention to sell or distribute such shares if, in the opinion of counsel for the Company, such a representation is required by any of the aforementioned applicable provisions of Applicable Law.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">22.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Term of Plan</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Plan will become effective upon the earlier to occur of its adoption by the Board or its approval by the stockholders of the Company. It will continue in effect until terminated pursuant to </span><span class="CharOverride-5" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;text-decoration:underline;">Section 19</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">23.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Stockholder Approval</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The Plan will be subject to approval by the stockholders of the Company within 12 months after the date the Plan is adopted by the Board. Such stockholder approval will be obtained in the manner and to the degree required under Applicable Laws.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">24.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Governing Law</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">This Plan and any agreements or other documents hereunder shall be interpreted and construed in accordance with the laws of the State of Delaware and applicable federal law. Any reference in this Plan or in any agreements or other documents hereunder to a provision of law or to a rule or regulation shall be deemed to include any successor law, rule, or regulation of similar effect or applicability.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-9</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">25.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Severability</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">If any provision of the Plan is or becomes or is deemed to be invalid, illegal, or unenforceable for any reason in any jurisdiction or as to any Participant, such invalidity, illegality, or unenforceability shall not affect the remaining parts of the Plan, and the Plan shall be construed and enforced as to such jurisdiction or Participant as if the invalid, illegal, or unenforceable provision had not been included.</span></p>
		<p class="ParaOverride-3" style="margin:0;padding:0;border-width:0;margin-left:24pt;margin-top:8pt;orphans:2;page-break-after:avoid;text-indent:-24pt;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">26.<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Interpretation</span></p>
		<p class="ParaOverride-4" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">Headings are given to the Sections and subsections of the Plan solely as a convenience to facilitate reference and shall not be deemed in any way material or relevant to the construction or interpretation of the Plan or any provision thereof. Words in the masculine gender shall include the feminine gender, and where appropriate, the plural shall include the singular and the singular shall include the plural. The use herein of the word &#8220;including&#8221; following any general statement, term, or matter shall not be construed to limit such statement, term, or matter to the specific items or matters set forth immediately following such word or to similar items or matters, whether or not non-limiting language (such as &#8220;without limitation&#8221;, &#8220;but not limited to&#8221;, or words of similar import) is used with reference thereto, but rather shall be deemed to refer to all other items or matters that could reasonably fall within the broadest possible scope of such general statement, term, or matter. References herein to any agreement, instrument, or other document means such agreement, instrument, or other document as amended, supplemented, and modified from time to time to the extent permitted by the provisions thereof and not prohibited by the Plan.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-10</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-9" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:underline;">EXHIBIT A</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;margin-top:0pt;text-align:center;margin-top:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024 EMPLOYEE STOCK PURCHASE PLAN</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">SUBSCRIPTION AGREEMENT</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-top:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;vertical-align:top;width: 41.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;vertical-align:top;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-bottom:0pt;padding-left:0pt;padding-right:0pt;padding-top:0pt;vertical-align:top;width: 36.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 41.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;text-align:justify;">Original Application</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:justify;">Offering&#160;Date:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 36.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 6.41%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 41.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable_wrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-top:8pt;text-align:justify;">Change in Payroll Deduction Rate</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 12.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 36.11%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		<p class="ParaOverride-17" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">1.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>hereby elects to participate in the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Plan</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) and subscribes to purchase shares of the Company&#8217;s Common Stock in accordance with this Subscription Agreement and the Plan. Capitalized terms used but not defined in this Subscription Agreement have the meanings provided under the Plan.</span></p>
		<p class="ParaOverride-17" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">2.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>I hereby authorize payroll deductions from each paycheck in the amount of ____% of my Compensation on each payday (from 1% to 15%) during the Offering Period in accordance with the Plan, commencing with the next Offering Period; </span><span class="CharOverride-8" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:normal;">provided, however</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">, that, in no event may more than $25,000 of Common Stock be purchased under the Plan in any calendar year. The minimum permissible projected Contribution for the Offering Period is $500. (Please note that no fractional percentages are permitted.)</span></p>
		<p class="ParaOverride-17" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">3.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>I understand that the payroll deductions will be accumulated for the purchase of shares of Common Stock at the applicable Purchase Price determined in accordance with the Plan. I understand that if I do not withdraw from an Offering Period, any accumulated payroll deductions will be used to automatically exercise my option and purchase Common Stock under the Plan.</span></p>
		<p class="ParaOverride-17" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">4.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>I have received a copy of the complete Plan and its accompanying prospectus. I understand that my participation in the Plan is in all respects subject to the terms of the Plan.</span></p>
		<p class="ParaOverride-17" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">5.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Shares of Common Stock purchased for me under the Plan should be issued in the name(s) of&#160;&#160;&#160;&#160;(Eligible Employee or Eligible Employee and Spouse only).</span></p>
		<p class="ParaOverride-17" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">6.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>I understand that if I dispose of any shares received by me pursuant to the Plan within two years after the Offering Date (the first day of the Offering Period during which I purchased such shares), I will be treated for federal income tax purposes as having received ordinary income at the time of such disposition in an amount equal to the excess of the fair market value of the shares at the time such shares were purchased by me over the price that I paid for the shares. The Company may, but will not be obligated to, withhold from my compensation the amount necessary to meet any applicable withholding obligation including any withholding necessary to make available to the Company any tax deductions or benefits attributable to sale or early disposition of Common Stock by me. If I dispose of such shares at any time after the expiration of the two-year holding period, I understand that I will be treated for federal income tax purposes as having received income only at the time of such disposition, and that such income will be taxed as ordinary income only to the extent of an amount equal to the lesser of (a) the excess of the fair market value of the shares at the time of such disposition over the Purchase Price which I paid for the shares, or (b) 15% of the fair market value of the shares on the first day of the Offering Period. The remainder of the gain, if any, recognized on such disposition will be taxed as capital gain.</span></p>
		<p class="ParaOverride-17" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:justify;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">7.<span style="width: 20px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>I hereby agree to be bound by the terms of the Plan. The effectiveness of this Subscription Agreement is dependent upon my eligibility to participate in the Plan.</span></p>
		<table class="No-Table-Style _idGenTablePara-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Employee&#8217;s Social Security #:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Employee&#8217;s Address:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-11</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">I UNDERSTAND THAT THIS SUBSCRIPTION AGREEMENT WILL REMAIN IN EFFECT THROUGHOUT SUCCESSIVE OFFERING PERIODS UNLESS TERMINATED BY ME.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-width:1pt;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Date:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:1pt;padding-left:0pt;vertical-align:top;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-top: windowtext 1pt none; border-top-style: solid;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Signature</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-12</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">EXHIBIT B</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">ORUKA THERAPEUTICS, INC.</span><span class="CharOverride-2" style="font-family:Times New Roman, serif;font-style:normal;font-weight:bold;"><br/></span><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">2024 EMPLOYEE STOCK PURCHASE PLAN</span></p>
		<p class="ParaOverride-2" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-align:center;widows:2;margin-top:8pt;"><span class="CharOverride-1" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:bold;">NOTICE OF WITHDRAWAL</span></p>
		<p class="ParaOverride-6" style="margin:0;padding:0;border-width:0;margin-top:8pt;orphans:2;text-indent:24pt;widows:2;margin-top:8pt;"><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">The undersigned Participant in the Offering Period of the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan that began on ______________, ______ (the &#8220;</span><span class="CharOverride-4" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-weight:bold;">Offering Date</span><span class="CharOverride-3" style="font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-weight:normal;">&#8221;) hereby notifies the Company that he or she hereby withdraws from the Offering Period. He or she hereby directs the Company to pay to the undersigned as soon as reasonably practicable all the payroll deductions credited to his or her notional account with respect to such Offering Period. The undersigned understands and agrees that his or her option for such Offering Period will be automatically terminated. The undersigned understands further that no further payroll deductions will be made for the purchase of shares in the current Offering Period and the undersigned will be eligible to participate in succeeding Offering Periods only by delivering to the Company a new Subscription Agreement.</span></p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Participant&#8217;s Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Participant&#8217;s Address:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-8" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-width:1pt;padding-left:0pt;padding-top:10pt;vertical-align:top;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 5.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">Date:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:1pt;padding-left:0pt;vertical-align:top;width: 44.02%; padding: 0in 0in 3px 0in;border-width: 0pt;border-top: windowtext 1pt none; border-top-style: solid;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Signature</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 3.85%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 5.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 42.74%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">&#160;</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex L-13</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<a id="T881"></a><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:right;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Annex&#160;M</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">FORM OF ARCA BIOPHARMA, INC. PROXY CARD </span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="tproxy_001.jpg" style="width:900px;max-width:200%;margin-left:-150px;"/></span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>
	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Basic-Paragraph" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;"><span class="CharOverride-1" style="color:#ffffff;font-size:1pt;">ENDORSEMENT LINE SACKPACK 000001 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas. C123456789 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext Your vote matters &#8211; here&#8217;s how to vote You may vote online or by phone instead of mailing this card. Votes submitted electronically must be received by 1:00 a.m., Mountain Time, on August 22, 2024. Online: Go to www.investorvote.com/ABIO or scan the QR code &#8212; login details are located in the shaded bar below. Phone: Call toll free 1-800-652-VOTE (8683) within the USA, US territories and Canada. Mail: Mark, sign and date your proxy card and return it in the envelope provided as soon as possible. In Person: You may vote your shares in person by attending the Special Meeting. Special Meeting Proxy Card 1234 5678 9012 345 IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. A Proposals &#8212; The Board of Directors recommend A a vote FOR all Proposals. For Against Abstain 1. To approve (i) the issuance of shares of ARCA common stock (including the shares of ARCA common stock issuable upon conversion of ARCA Series B Preferred Stock), which will represent more than 20% of the shares of ARCA common stock outstanding immediately prior to the Merger (as defined below), to stockholders of Oruka Therapeutics, Inc. (&#8220;Oruka&#8221;), pursuant to the terms of the Agreement and Plan of Merger and Reorganization, dated April 3, 2024, by and among ARCA, Atlas Merger Sub Corp, Atlas Merger Sub II, LLC, and Oruka (the &#8220;Merger Agreement&#8221; and such transaction contemplated thereby, the &#8220;Merger&#8221;), a copy of which is attached as Annex A to the accompanying proxy statement/prospectus, and (ii) the change of control of ARCA resulting from the Merger, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b), respectively. 2. To approve an amendment to the amended and restated certificate of incorporation of ARCA (the &#8220;ARCA Charter&#8221;) to increase the number of shares of ARCA common stock that ARCA is authorized from 100,000,000 to issue to 545,000,000, in the form attached as Annex G to the accompanying proxy statement/prospectus. 3. To approve an amendment to the ARCA Charter to effect a reverse stock split of ARCA&#8217;s issued and outstanding common stock at a ratio in the range between 6:1 to 12:1, inclusive, in the form attached as Annex H to the accompanying proxy statement/prospectus, if deemed necessary by ARCA and Oruka, with the final ratio and effectiveness of such amendment and the abandonment of such amendment to be mutually agreed by ARCA&#8217;s board of directors and Oruka&#8217;s board of directors prior to the First Effective Time (as defined in the accompanying proxy statement/prospectus) or, if Proposal No. 1 is not approved by ARCA stockholders, determined solely by ARCA&#8217;s board of directors. 4. To approve an amendment to the ARCA Charter to reflect Delaware law provisions regarding officer exculpation, in the form attached as Annex I to the accompanying proxy statement/prospectus. 5. Election of Directors: For Withhold 01 &#8211; Mr. Jacob Ma-Weaver For Against Abstain 6. To ratify the appointment of KPMG LLP as ARCA&#8217;s independent registered public accounting firm for fiscal year ending December 31, 2024, provided that PricewaterhouseCoopers LLP is expected to be appointed for that fiscal year if the Merger is completed. 7. To approve the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (as defined in the accompanying proxy statement/prospectus). 8. To approve the Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (as defined in the accompanying proxy statement/prospectus). 9. To approve, on an advisory basis, certain compensation arrangements for ARCA named executive officers that are based on or otherwise relate to the Merger. 10. To approve an adjournment of the ARCA special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 1, Proposal No. 2 and/or Proposal No. 3. C 1234567890 1 U P X 622380 J N T MR A SAMPLE (THIS AREA IS SET UP TO ACCOMMODATE 140 CHARACTERS) MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND 0410SB</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex M-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><img alt="" src="tproxy_002.jpg" style="width:900px;max-width:200%;margin-left:-150px;"/></span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:3;text-align:center;"></p>
		<p style="margin:0;padding:0;border-width:0;"></p>
	</div>
	<div class="Basic-Text-Frame" style="margin:0;padding:0;border-width:0;">
		<p class="Basic-Paragraph" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:0pt;"><span class="CharOverride-1" style="color:#ffffff;font-size:1pt;">Special Meeting Admission Ticket Special Meeting of ARCA biopharma, Inc. Stockholders August 22, 2024, 9:00am MT Denver Marriott Westminster 7000 Church Ranch Blvd Westminster, CO 80021 Upon arrival, please present this admission ticket and photo identification at the registration desk. Small steps make an impact. Help the environment by consenting to receive electronic delivery, sign up at www.investorvote.com/ABIO IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. Proxy &#8212; ARCA biopharma, Inc. Notice of Special Meeting of Stockholders Proxy Solicited by Board of Directors for Special Meeting &#8212; August 22, 2024 Thomas A. Keuer and C. Jeffrey Dekker (the &#8220;Proxies&#8221;), and each of them, each with full power of substitution and re-substitution, are hereby authorized to represent and vote the shares of the undersigned, with all the powers which the undersigned would possess if personally present, at the Special Meeting of Stockholders of ARCA biopharma, Inc. to be held on August 22, 2024 or at any postponement or adjournment thereof. Shares represented by this proxy will be voted as directed herein. If no such directions are indicated, the Proxies will have authority to vote FOR all proposals. In their discretion, the Proxies are authorized to vote upon such other business as may properly come before the meeting or any postponement or adjournment thereof. (Items to be voted appear on reverse side) B Authorized Signatures &#8212; This section must be completed for your vote to count. Please date and sign below. Please sign exactly as name(s) appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, corporate officer, trustee, guardian, or custodian, please give full title. Date (mm/dd/yyyy) &#8212; Please print date below. Signature 1 &#8212; Please keep signature within the box. Signature 2 &#8212; Please keep signature within the box. C Non-Voting Items Change of Address &#8212; Please print new address below. Comments &#8212; Please print your comments below.</span></p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">Annex M-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>




	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">PART&#160;II <br/>INFORMATION NOT REQUIRED IN PROXY STATEMENT/PROSPECTUS</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Item&#160;20.<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Indemnification of Directors and Officers</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Delaware</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Oruka are corporations under the DGCL.&#160;Section&#160;145(a)&#160;of the DGCL provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;145(b)&#160;of the DGCL provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery of the State of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery of the State of Delaware or such other court shall deem proper.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;145 of the DGCL further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a)&#160;and (b)&#160;of Section&#160;145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection therewith; that indemnification provided for by Section&#160;145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and the indemnification provided for by Section&#160;145 shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&#8217;s heirs, executors and administrators. Section&#160;145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section&#160;145.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Section&#160;102(b)(7)&#160;of the DGCL provides that a corporation&#8217;s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, provided that such provision shall not eliminate or limit the liability of a director (i)&#160;for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (ii)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&#160;under Section&#160;174 of the DGCL, or (iv)&#160;for any transaction from which the director derived an improper personal benefit.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-1</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H5" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">ARCA</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The ARCA Charter contains provisions that eliminate, to the maximum extent permitted by the DGCL, the personal liability of directors for monetary damages for breach of fiduciary duty as a director. Please see Proposal&#160;No. 4 for details regarding the proposed amendment to the ARCA Charter to eliminate, to the maximum extent permitted by the DGCL, the personal liability of officers for monetary damages for breach of fiduciary duty as an officer. The ARCA Charter and ARCA Bylaws provide that ARCA shall indemnify its directors and executive officers and may indemnify its employees and other agents to the fullest extent permitted by the DGCL.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into indemnification agreements with its directors and executive officers, in addition to the indemnification provided for in the ARCA Charter and ARCA Bylaws, and it intends to enter into indemnification agreements with any new directors and executive officers in the future.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has purchased and intends to maintain insurance on behalf of any person who is or was a director or officer against any loss arising from any claim asserted against him or her incurred by him or her in any such capacity, subject to certain exclusions.</p>
		<p class="H5" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Oruka</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Oruka Charter contains provisions that limit or eliminate the personal liability of Oruka&#8217;s directors or officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. These limitations of liability do not alter director or officer liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission. In addition, the Oruka Bylaws provide that:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka will indemnify its directors and officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Oruka will advance expenses, including attorneys&#8217; fees, to its directors and officers in connection with legal proceedings relating to their service for or on behalf of Oruka, subject to limited exceptions.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka has entered into indemnification agreements with its directors and executive officers. These agreements provide that Oruka will indemnify each of its directors and executive officers to the fullest extent permitted by Delaware law. Oruka will advance expenses, including attorneys&#8217; fees (but excluding judgments, fines and settlement amounts), to each indemnified director or executive officer in connection with any proceeding in which indemnification is available and Oruka will indemnify its directors and officers for any action or proceeding arising out of that person&#8217;s services as a director or officer brought on behalf of Oruka or in furtherance of Oruka&#8217;s rights. Additionally, certain of Oruka&#8217;s directors may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#8217;s services as a director referenced herein. Nonetheless, Oruka has agreed in the indemnification agreements that Oruka&#8217;s obligations to those same directors are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Oruka also intends to maintain general liability insurance which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the&#160;Securities Act.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Item&#160;21.<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Exhibits and Financial Statement Schedules</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:24pt;margin-top:8pt;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Exhibit Index</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A list of exhibits filed with this registration statement on Form&#160;S<span class="nobreak">-4</span> is set forth on the Exhibit Index and is incorporated herein by reference.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:24pt;margin-top:8pt;">(b)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Financial Statements</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The financial statements filed with this registration statement on Form&#160;S<span class="nobreak">-4</span> are set forth on the Financial Statement Index and are incorporated herein by reference.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-2</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-left:48pt;text-indent:-48pt;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Item&#160;22.<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>Undertakings</span></p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:24pt;margin-top:8pt;">(a)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(1)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To file, during any period in which offers or sales are being made, a post<span class="nobreak">-effective</span> amendment to this registration statement:</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;">(i)<span style="width: 17px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;</span>To include any prospectus required by Section&#160;10(a)(3)&#160;of the Securities Act;</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;">(ii)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post<span class="nobreak">-effective</span> amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&#160;424(b)&#160;if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Filing Fee Table&#8221; table in the effective registration statement; and</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-left:72pt;margin-top:8pt;">(iii)<span style="width: 10px;display: inline-block;">&#160;&#160;&#160;</span>To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-left:72pt;text-indent:0pt;margin-top:8pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Provided, however</span>, that paragraphs (a)(1)(i)&#160;and (a)(1)(ii)&#160;herein do not apply if the information required to be included in a post<span class="nobreak">-effective</span> amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Exchange&#160;Act (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(2)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>That, for the purpose of determining any liability under the Securities Act, each such post<span class="nobreak">-effective</span> amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(3)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>To remove from registration by means of a post<span class="nobreak">-effective</span> amendment any of the securities being registered which remain unsold at the termination of the offering.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(4)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant&#8217;s annual report pursuant to Section&#160;13(a)&#160;or Section&#160;15(d)&#160;of the Exchange&#160;Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&#160;15(d)&#160;of the Exchange&#160;Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(5)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes as follows: that prior to any public reoffering of the securities registered hereunder through use of a prospectus which is a part of this registration statement, by any person or party who is deemed to be an underwriter within the meaning of Rule&#160;145(c), the issuer undertakes that such reoffering prospectus will contain the information called for by the applicable registration form with respect to reofferings by persons who may be deemed underwriters, in addition to the information called for by the other items of the applicable form.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(6)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The registrant undertakes that every prospectus: (i)&#160;that is filed pursuant to paragraph (a)(5)&#160;immediately preceding, or (ii)&#160;that purports to meet the requirements of Section&#160;10(a)(3)&#160;of the Act and is used in connection with an offering of securities subject to Rule&#160;415, will be filed as a part of an amendment to the registration statement and will not be used until such amendment is effective, and that, for purposes of determining any liability under the Securities Act&#160;of&#160;1933, each such post<span class="nobreak">-effective</span> amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</p>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-3</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(7)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes to respond to requests for information that is incorporated by reference into the prospectus pursuant to Item&#160;4, 10(b),<span class="nobreak"> </span>11, or 13 of this form, within one business&#160;day of receipt of such request, and to send the incorporated documents by first class mail or other equally prompt means. This includes information contained in documents filed subsequent to the effective date of the registration statement through the date of responding to the request.</p>
		<p class="NL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;">(8)<span style="width: 13px;display: inline-block;">&#160;&#160;&#160;&#160;</span>The undersigned registrant hereby undertakes to supply by means of a post<span class="nobreak">-effective</span> amendment all information concerning a transaction, and the company being acquired involved therein, that was not the subject of and included in the registration statement when it became effective.</p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">2.1&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="#T100">Agreement and Plan of Merger and Reorganization, dated as of April&#160;3, 2024, by and among ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas Merger Sub&#160;II, LLC, and Oruka Therapeutics, Inc. (included as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;A</span> to the proxy statement/prospectus and incorporated herein by reference).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex31.htm">Amended and Restated Certificate of Incorporation of ARCA biopharma, Inc., as amended (incorporated by reference to Exhibit 3.1 to ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.1(a)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513090814/d498361dex51.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 5.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on March&#160;5, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.1(b)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459015007723/abio-ex31_74.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;3, 2015).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.1(c)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459019010715/abio-ex31_7.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;3, 2019).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/0000907654/000156459021034792/abio-ex31_47.htm">Bylaws of ARCA biopharma, Inc., as currently in effect (incorporated by reference to Exhibit 3.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on June&#160;28, 2021).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.3</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513233692/d507513dex31b.htm">Form of Certificate of Designation of Preferences, Rights and Limitations of Series&#160;A Convertible Preferred Stock of the Registrant (incorporated by reference to Exhibit 3.1(b) of ARCA biopharma, Inc.&#8217;s Form&#160;S-1/A, filed on May 24, 2013, File No.&#160;333-187508).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.4</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex31.htm">Form of Certificate of Designation of Preferences, Rights and Limitations of Series&#160;B Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.5***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex3-5_arcabio.htm">Amended and Restated Certificate of Incorporation of Oruka Therapeutics, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">3.6***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex3-6_arcabio.htm">Bylaws of Oruka Therapeutics, Inc, as currently in effect.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509013220/dex41.htm">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on January&#160;29, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.2</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459019017210/abio-ex42_106.htm">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.2 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on May&#160;8, 2019).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">4.3***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex4-3_arcabio.htm">Investor Rights Agreement, dated March&#160;6, 2024, by and among Oruka Therapeutics, Inc. and certain parties thereto.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">5.1*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512206ex5-1_arca.htm">Opinion of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">8.1*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512206ex8-1_arca.htm">Tax Opinion of Wilson Sonsini Goodrich &amp; Rosati, P.C.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">8.2*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512206ex8-2_arca.htm">Tax Opinion of Gibson, Dunn &amp; Crutcher LLP</a></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-4</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.1</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex101.htm">Form of Oruka Support Agreement (incorporated by reference to Exhibit 10.1 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.2&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex102.htm">Form of Oruka Subscription Agreement (incorporated by reference to Exhibit 10.2 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.3&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024060156/ea020913401ex10-1_arcabio.htm">Form of Amendment (incorporated by reference to Exhibit 10.1 to ARCA biopharma, Inc&#8217;s Form 8-K filed on July 9, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.4&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024060156/ea020913401ex10-2_arcabio.htm">Form of Amended &amp; Restated Oruka Subscription Agreement (incorporated by reference to Exhibit 10.2 to ARCA biopharma, Inc&#8217;s Form 8-K filed on July 9, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.5</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex103.htm">Form of ACRA Support Agreement (incorporated by reference to Exhibit 10.3 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.6</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex104.htm">Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.4 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.7</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024041846/abio-ex10_1.htm">Separation Agreement and Release, by and between ARCA and Michael Bristow, dated as of April&#160;3, 2024 (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;4, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.8&#8224;&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024041846/abio-ex10_2.htm">Consulting Agreement, by and between ARCA and Michael Bristow, dated as of April&#160;3, 2024 (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;4, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.9#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017022026298/abio-ex10_1.htm">Memorandum Regarding Cash Retention Bonus between ARCA biopharma, Inc. and Thomas A, Keuer dated December&#160;8, 2022 (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;9, 2022).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.10#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017023067790/abio-ex10_1.htm">Amendment to Retention Bonus Letter, dated December&#160;4, 2023, by and among ARCA biopharma, Inc. and Thomas A.&#160;Keuer (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;4, 2023).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.11#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024046918/abio-ex10_1.htm">Second Amendment to Retention Bonus Letter, dated April&#160;22, 2024, by and between ARCA biopharma, Inc. and Thomas A.&#160;Keuer (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;23, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.12#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017022026298/abio-ex10_2.htm">Memorandum Regarding Cash Retention Bonus between ARCA biopharma, Inc. and C.&#160;Jeffrey Dekker dated December&#160;8, 2022 (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;9, 2022).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.13#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017023067790/abio-ex10_2.htm">Amendment to Retention Bonus Letter, dated December&#160;4, 2023, by and among ARCA biopharma, Inc. and C.&#160;Jeffrey Dekker (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;4, 2023).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.14#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024046918/abio-ex10_2.htm">Second Amendment to Retention Bonus Letter, dated April&#160;22, 2024, by and between ARCA biopharma, Inc. and C.&#160;Jeffrey Dekker (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on April&#160;23, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.15</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020042033/abio-ex101_7.htm">Office Lease Agreement, effective August&#160;7, 2020, between ARCA biopharma, Inc. and Potens Partners&#160;LLC (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on August&#160;31, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.16</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024035373/abio-ex10_1.htm">First Amendment to Office Lease Agreement, dated March&#160;19, 2024, by and between ARCA biopharma, Inc. and Lotus Church Ranch, LLC (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on March&#160;22, 2024).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.17#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex101.htm">ARCA biopharma, Inc. 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.18#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex102.htm">Form of Stock Option Agreement and Option Grant Notice under 2013 Equity Incentive Plan (Standard) (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.19#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex103.htm">Form of Stock Option Agreement and Option Grant Notice under 2013 Equity Incentive Plan (Officer) (incorporated by reference to Exhibit 10.3 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-5</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.20#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex104.htm">Form of Stock Option Agreement and Option Grant Notice under 2013 Equity Incentive Plan (Director) (incorporated by reference to Exhibit 10.4 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.21#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex105.htm">Form of Restricted Stock Unit Award Agreement and Notice of Grant Award under 2013 Equity Incentive Plan (Standard) (incorporated by reference to Exhibit 10.5 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.22#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312513374827/d601298dex106.htm">Form of Restricted Stock Unit Award Agreement and Notice of Grant Award under 2013 Equity Incentive Plan (Officer) (incorporated by reference to Exhibit 10.6 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on September&#160;23, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.23#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020056751/abio-ex101_7.htm">ARCA biopharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;10, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.24#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex101_6.htm">Form of Stock Option Agreement and Option Grant Notice under 2020 Equity Incentive Plan (Standard) (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.25#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex102_11.htm">Form of Stock Option Agreement and Option Grant Notice under 2020 Equity Incentive Plan (Officer) (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.26#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex103_7.htm">Form of Stock Option Agreement and Option Grant Notice under 2020 Equity Incentive Plan (Director) (incorporated by reference to Exhibit 10.3 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.27#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex104_8.htm">Form of Restricted Stock Unit Award Agreement Notice of Grant Award under 2020 Equity Incentive Plan (Standard) (incorporated by reference to Exhibit 10.4 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.28#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459020058225/abio-ex105_9.htm">Form of Restricted Stock Unit Award Agreement Notice of Grant Award under 2020 Equity Incentive Plan (Officer) (incorporated by reference to Exhibit 10.5 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K filed on December&#160;23, 2020).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.29&#167;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509113082/dex101.htm">License and Sublicense Agreement, dated October&#160;28, 2003, by and between ARCA Discovery, Inc. and CPEC, L.L.C. (incorporated by reference to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on May&#160;15, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.30&#167;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509113082/dex102.htm">Amendment to License and Sublicense Agreement, dated February&#160;22, 2006, by and between ARCA Discovery, Inc. and CPEC, L.L.C. (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on May&#160;15, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.31</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex1046.htm">Assignment and Assumption Agreement, dated January&#160;26, 2009, by and between ARCA biopharma, Inc. and ARCA biopharma Colorado, Inc. (incorporated by reference to Exhibit 10.46 of ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.32</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex1048.htm">Assignment and Assumption Agreement, dated January&#160;26, 2009, by and between ARCA biopharma, Inc. and ARCA biopharma Colorado, Inc. (incorporated by reference to Exhibit 10.48 of ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.33</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex1052.htm">Form of Indemnification Agreement between ARCA biopharma, Inc. and its directors and officers (incorporated by reference to Exhibit 10.52 of ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.34&#167;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312511223373/dex105.htm">Amended and Restated Exclusive License Agreement, dated August&#160;12, 2011, by and between the Regents of the University of Colorado and ARCA biopharma, Inc (incorporated by reference to Exhibit 10.5 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on August&#160;15, 2011).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.35#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312509064819/dex1043.htm">Amended and Restated Employment and Retention Agreement, dated June&#160;4, 2008, by and between ARCA biopharma, Inc. and Michael R.&#160;Bristow (incorporated by reference to Exhibit 10.43 of ARCA biopharma, Inc.&#8217;s Form&#160;10-K filed on March&#160;27, 2009).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.36#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459013000333/abio-ex10_20130629569.htm">Amendment Agreement by and between ARCA biopharma, Inc. and Michael R.&#160;Bristow, effective as of June&#160;13, 2013 (incorporated by reference to Exhibit 10.6 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed August&#160;13, 2013).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.37#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312514457143/d842508dex102.htm">Amended and Restated Employment Agreement, dated December&#160;29, 2014, by and between ARCA biopharma, Inc. and Thomas A.&#160;Keuer (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;8-K/A filed on December&#160;30, 2014).</a></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-6</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.38#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459021026534/abio-ex102_75.htm">Employment Agreement, dated April&#160;21, 2021, by and between ARCA biopharma, Inc. and C.&#160;Jeff Dekker (incorporated by reference to Exhibit 10.2 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on May&#160;11, 2021).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.39&#167;&#167;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000156459021040795/abio-ex103_140.htm">Assignment Agreement for Patent Rights, dated July&#160;1, 2021, by and between ARCA biopharma, Inc. and University Medical Center of the Johannes Gutenberg University Mainz (incorporated by reference to Exhibit 10.3 of ARCA biopharma, Inc.&#8217;s Form&#160;10-Q filed on August&#160;4, 2021).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.40*#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="#T110">Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (included as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;K </span>to the proxy statement/prospectus and incorporated herein by reference)</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.41*#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="#T112">Oruka Therapeutics, Inc. 2024 Employee Stock Purchase Plan (included as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex&#160;L </span>to the proxy statement/prospectus and incorporated herein by reference)</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.42***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-40_arcabio.htm">Amended and Restated Oruka Therapeutics, Inc. 2024 Equity Incentive Plan, as amended by the First Amendment dated May 7, 2024</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.43***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-41_arcabio.htm">Form of Restricted Stock Notice and Restricted Stock Purchase Agreement of Oruka Therapeutics, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.44***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-42_arcabio.htm">Form of Stock Option Agreement under Oruka Therapeutics, Inc. 2024 Equity Incentive Plan</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.45***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-43_arcabio.htm">Amended and Restated Director Offer Letter, dated March&#160;22, 2024, between Oruka Therapeutics, Inc. and Samarth Kulkarni</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.46***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-44_arcabio.htm">Director Offer Letter, dated April&#160;24, 2024, between Oruka Therapeutics, Inc. and Kristine Ball</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.47***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-45_arcabio.htm">Form of Indemnification Agreement between Oruka Therapeutics, Inc. and its directors and officers</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.48***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-46_arcabio.htm">Amended and Restated Employment Offer Letter, dated February&#160;14, 2024, by and between Oruka Therapeutics, Inc. and Lawrence Klein</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.49***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-47_arcabio.htm">Employment Offer Letter, dated March&#160;11, 2024, by and between Oruka Therapeutics, Inc. and Arjun Agarwal</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.50***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-48_arcabio.htm">Employment Offer Letter, dated March&#160;15, 2024, by and between Oruka Therapeutics, Inc. and Joana Goncalves</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.51***#</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-49_arcabio.htm">Employment Offer Letter, dated April&#160;12, 2024, by and between Oruka Therapeutics, Inc. and Paul Quinlan</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.52***&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea020512202ex10-50_arcabio.htm">Amended and Restated Antibody Discovery and Option Agreement (IL-17), dated March&#160;28, 2024, by and among Paragon Therapeutics, Inc., Paruka Holding LLC and Oruka Therapeutics, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">10.53***&#8224;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea020512202ex10-51_arcabio.htm">Amended and Restated Antibody Discovery and Option Agreement (IL-23), dated March&#160;28, 2024, by and among Paragon Therapeutics, Inc., Paruka Holding LLC and Oruka Therapeutics, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">21.1***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex21-1_arcabio.htm">List of Subsidiaries of ARCA biopharma, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">23.1*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512206ex23-1_arca.htm">Consent of KPMG LLP, independent registered public accounting firm of ARCA biopharma, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">23.2*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512206ex23-2_arca.htm">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm of Oruka Therapeutics, Inc.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">23.3*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="ea020512206ex5-1_arca.htm">Consent of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. (included in Exhibit 5.1).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">24.1***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea0205122-01.htm#T555">Power of Attorney (included in the signature page hereto).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.1*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="#T881">Form of ARCA biopharma, Inc. proxy card (included as <span class="Italic" style="font-style:italic;font-weight:normal;">Annex M </span>to the proxy statement/prospectus and incorporated herein by reference).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.2***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea0205122-02.htm#T106">Proposed form of Certificate of Amendment of Certificate of Incorporation of ARCA biopharma, Inc.&#160;&#8212;&#160;Increase in Authorized Shares (included as <span class="CharOverride-1" style="font-style:italic;font-weight:normal;">Annex&#160;G </span>to the proxy statement/prospectus and incorporated herein by reference).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.3***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea0205122-02.htm#T107">Proposed form of Certificate of Amendment of Certificate of Incorporation of ARCA biopharma, Inc.&#160;&#8212;&#160;Reverse Stock Split (included as <span class="CharOverride-1" style="font-style:italic;font-weight:normal;">Annex&#160;H</span> to the proxy statement/prospectus and incorporated herein by reference).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.4***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea0205122-02.htm#T108">Proposed form of Certificate of Amendment of Certificate of Incorporation of ARCA biopharma, Inc.&#160;&#8212;&#160;Officer Exculpation (included as<span class="CharOverride-1" style="font-style:italic;font-weight:normal;"> Annex&#160;I</span> to the proxy statement/prospectus and incorporated herein by reference).</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.5***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-5_arcabio.htm">Consent of Lucid Capital Markets, LLC.</a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.6***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-6_arcabio.htm">Consent of Lawrence Klein to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.7***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-7_arcabio.htm">Consent of Kristine Ball to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-7</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 3pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-4" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">



						<p class="TCH_left" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Exhibit <br/>Number</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;border-left-style:solid;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="top">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;"><br/>Description</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.8***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-width:0pt;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-8_arcabio.htm">Consent of Carl Dambkowski to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.9***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-9_arcabio.htm">Consent of Peter Harwin to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.10***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-10_arcabio.htm">Consent of Samarth Kulkarni to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">99.11***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex99-11_arcabio.htm">Consent of Cameron Turtle to serve as a director of ARCA biopharma, Inc., to be renamed Oruka Therapeutics, Inc. </a></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.INS*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Instance Document.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.SCH*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Schema.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.CAL*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Calculation Linkbase.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.DEF*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Definition Linkbase.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.LAB*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Label Linkbase.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">101.PRE*</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">XBRL Taxonomy Extension Presentation Linkbase.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;vertical-align:top;width: 9.40%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">107***</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-bottom-color:#000000;border-bottom-style:solid;border-left-color:#000000;border-left-style:solid;border-right-color:#000000;border-right-style:solid;border-top-color:#000000;border-top-style:solid;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 89.32%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Tbody_nowrap" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex-fee_arcabio.htm">Filing Fee Table.</a></p>
					</td>
				</tr>

		</table>
		<p class="Tablefootnotef" style="margin-top: 0in;  border: none; margin-right: 0in; margin-bottom: -5pt; margin-left: 24.0pt; text-align: justify; text-justify: inter-ideograph; text-indent: -24.0pt; padding: 0in; font-size: 9.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">____________</p><p class="Tablefootnote_f" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:10pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:10pt;">*<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Filed herewith.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">***<span style="width: 12px;display: inline-block;">&#160;&#160;&#160;&#160;</span>Previously filed.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">#<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Indicates management contract or compensatory plan or arrangement.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">&#8224;<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Exhibits and/or schedules have been omitted pursuant to Item&#160;601(a)(5)&#160;of Regulation&#160;S<span class="nobreak">-K</span>.&#160;The registrant hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the registrant may request confidential treatment pursuant to Rule&#160;24b<span class="nobreak">-2</span> under the Exchange&#160;Act for any exhibits or schedules so furnished. Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been omitted because they are both (i)&#160;not material and (ii)&#160;would be competitively harmful if publicly disclosed.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">&#8224;&#8224;<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been omitted because they are both (i)&#160;not material and (ii)&#160;would be competitively harmful if publicly disclosed.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">&#167;<span style="width: 24px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>Confidential treatment has been granted as to portions of the exhibit. Confidential materials omitted and filed separately with the SEC.</p>
		<p class="Tablefootnote_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:0;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:0pt;">&#167;&#167;<span style="width: 18px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;</span>Schedules have been omitted from this filing pursuant to Item&#160;601(b)(2)&#160;of Regulation&#160;S<span class="nobreak">-K</span>.&#160;ARCA agrees to furnish supplementally a copy of any omitted schedule to the SEC upon its request; provided, however, that the Company may request confidential treatment pursuant to Rule&#160;24b<span class="nobreak">-2</span> of the Exchange&#160;Act for any schedule so furnished. Certain portions of the exhibit, identified by the mark, &#8220;*,&#8221; have been omitted because such portions contained information that is both (i)&#160;not material and (ii)&#160;would likely cause competitive harm if publicly disclosed.</p>
		</div>

		<p class="LRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; page-break-after: always; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-8</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:2;margin-top:8pt;"><a href="#TOC001">Table of Contents</a></p>



	<div class="_idGenObjectStyleOverride-1" style="margin:0;padding:0;border-width:0;border-width:0pt;">
		<p class="H1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">SIGNATURES</span></p>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Westminster, State of Colorado, on July<span class="nobreak"> </span>22, 2024.</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" colspan="3" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 50.00%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">ARCA BIOPHARMA, INC.</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 6.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 41.88%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Thomas A.&#160;Keuer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Name:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 48.72%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 6.84%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Title:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 41.88%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">President and Chief Operating Officer</p>
					</td>
				</tr>

		</table>
		<p class="Text_ind" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to the requirements of the Securities Act this registration statement has been signed by the following persons in the capacities and on the dates indicated.</p>
		<table class="No-Table-Style TableOverride-2" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">



						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;text-align:left;"><span class="Bold" style="font-style:normal;font-weight:bold;">Signature</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Title</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Date</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">President and Chief Operating Officer </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">July<span class="nobreak"> </span>22, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Thomas A. Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;"><span class="Italic" style="font-style:italic;font-weight:normal;">(Principal Executive Officer)</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ C.&#160;Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Chief Financial Officer </p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">July<span class="nobreak"> </span>22, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;vertical-align:top;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="top">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">C. Jeffrey Dekker</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;vertical-align:top;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="top">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;text-align:center;">(<span class="Italic" style="font-style:italic;font-weight:normal;">Principal Financial Officer and <br/>Principal Accounting Officer</span>)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ *</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">July<span class="nobreak"> </span>22, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Linda Grais</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ *</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">July<span class="nobreak"> </span>22, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Robert Conway</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ *</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">July<span class="nobreak"> </span>22, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Anders Hove</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ *</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">July<span class="nobreak"> </span>22, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Jacob Ma<span class="nobreak">-Weaver</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-top:10pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;">/s/ *</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">Director</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;padding-top:10pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;text-align:center;">July<span class="nobreak"> </span>22, 2024</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 26.65%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">James Flynn</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 47.76%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 23.03%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 4.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">*&#160;By:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="Signature_rule" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">/s/ Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 63.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="No-Table-Style TB" style="width: 4.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Thomas A.&#160;Keuer</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 63.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="No-Table-Style TB" style="width: 4.06%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 29.91%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Texttable" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:0;widows:1;">Attorney<span class="nobreak">-in-Fact</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 63.46%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>

		</table>
		</div>

		<p class="RRH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin: 10px 0px 10px 0pt; border-bottom: 1px solid; margin-top: 10.0pt; margin-right: 0in; margin-bottom: 10.0pt; margin-left: 0in; text-align: center; font-size: 10.0pt; font-family: TimesNewRomanPSStd-Regular; color: black;">II-9</p>



</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentType">S-4/A</ix:nonNumeric>
<ix:nonFraction contextRef="c1" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-3" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-4" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-6" name="us-gaap:OtherNonoperatingExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" decimals="2" id="hidden-fact-7" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.37</ix:nonFraction>
<ix:nonFraction contextRef="c7" decimals="2" id="hidden-fact-8" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.69</ix:nonFraction>
<ix:nonFraction contextRef="c7" decimals="0" id="hidden-fact-9" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">14410143</ix:nonFraction>
<ix:nonFraction contextRef="c6" decimals="0" id="hidden-fact-10" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">14415877</ix:nonFraction>
<ix:nonFraction contextRef="c10" decimals="2" id="hidden-fact-11" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.09</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-12" name="us-gaap:EarningsPerShareDiluted" sign="-" unitRef="usdPershares">0.14</ix:nonFraction>
<ix:nonFraction contextRef="c10" decimals="0" id="hidden-fact-13" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">14410143</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="0" id="hidden-fact-14" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="shares">14501143</ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-15" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-16" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c17" id="hidden-fact-17" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-18" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-19" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-20" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-21" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-22" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-23" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-24" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-25" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-26" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-27" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-28" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-29" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-30" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-31" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c38" id="hidden-fact-32" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c36" id="hidden-fact-33" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c37" id="hidden-fact-34" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-35" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c46" id="hidden-fact-36" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-37" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c45" id="hidden-fact-38" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-39" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-40" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-41" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-42" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-43" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-44" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c52" id="hidden-fact-45" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-46" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-47" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-48" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-49" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-50" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-51" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-52" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-53" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-54" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-55" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-56" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-57" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-58" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-59" name="us-gaap:ProceedsFromIncomeTaxRefunds" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-60" name="us-gaap:ProceedsFromIncomeTaxRefunds" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-61" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-62" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-63" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-64" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-65" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-66" name="us-gaap:InterestPaidNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-67" name="us-gaap:ProceedsFromIncomeTaxRefunds" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-68" name="us-gaap:ProceedsFromIncomeTaxRefunds" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-69" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c64" id="hidden-fact-70" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-71" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-72" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-73" name="abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c68" id="hidden-fact-74" name="abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-75" name="us-gaap:RestructuringReserveCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-76" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-77" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-78" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-79" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-80" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-81" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-82" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-83" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-85" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c16" id="hidden-fact-86" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-87" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-88" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-90" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-91" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-92" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-94" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-95" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c98" id="hidden-fact-97" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">P3Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c99" id="hidden-fact-98" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">P4Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c6" id="hidden-fact-99" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">P10Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c107" id="hidden-fact-100" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">P1Y</ix:nonNumeric>
<ix:nonFraction contextRef="c6" id="hidden-fact-101" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-102" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-103" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-104" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-105" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-106" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c114" id="hidden-fact-107" name="abio:OperatingLossCarryforwardsExpirationYear">2025</ix:nonNumeric>
<ix:nonNumeric contextRef="c115" id="hidden-fact-108" name="abio:OperatingLossCarryforwardsExpirationYear">2037</ix:nonNumeric>
<ix:nonNumeric contextRef="c6" id="hidden-fact-109" name="us-gaap:OpenTaxYear">2009</ix:nonNumeric>
<ix:nonFraction contextRef="c119" id="hidden-fact-110" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-111" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-112" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-113" name="abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-114" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c1" id="hidden-fact-115" name="us-gaap:RestructuringReserveCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c135" id="hidden-fact-116" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-117" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-118" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c5" id="hidden-fact-119" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-38572">true</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-38573">0000907654</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="abio-20240331.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-07-01</xbrli:startDate>
    <xbrli:endDate>2023-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-31</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a6SJv7mHT4i4TtFvc3F7UUIS7zrUx0dX5qj5wO6LAzCWKAP1YyvCltmZDSa1A1PjhGmwdGmO+XuX7UCz5jLCkrke7lMg3unMP+n8iU9HDqCH0qa1RnmAbxLX0vVsMfna+lSvUOXK+fD+tDBGd/twVPjn31HqnmC0so=] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abio:ClinicalDevelopmentDecisionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-11-30</xbrli:startDate>
    <xbrli:endDate>2023-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-08-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-08-28</xbrli:startDate>
    <xbrli:endDate>2020-08-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-31</xbrli:startDate>
    <xbrli:endDate>2023-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abio:UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:PatentAssignmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abio:IncentiveStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abio:IncentiveStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndThirteenPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">abio:FirstThreePercentPayContributionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">abio:NextTwoPercentPayContributionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-01-01</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-01-01</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-31</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:FirstMergerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:FirstMergerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:OrukaTherapeuticsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:CommonStockAndPreFundedWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:OrukaTherapeuticsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SeperationAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:PresidentMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SecondAmendmentOfCertainRetentionBonusLettersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-20</xbrli:startDate>
    <xbrli:endDate>2024-04-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SecondAmendmentOfCertainRetentionBonusLettersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-20</xbrli:startDate>
    <xbrli:endDate>2024-04-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abio:ThomasAKeuerAndCJeffreyDekkerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="sqft">
  <xbrli:measure>utr:sqft</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="eur">
  <xbrli:measure>iso4217:EUR</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea020512206ex5-1_arca.htm
<DESCRIPTION>OPINION OF WILSON SONSINI GOODRICH & ROSATI, P.C.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 54%; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT=""></TD>
    <TD STYLE="width: 46%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 97.05pt">Wilson Sonsini Goodrich &amp; Rosati<BR>
    Professional Corporation</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 97.05pt">1881 9<SUP>th</SUP> Street, Suite 110<BR>
    Boulder, Colorado 80302-5148</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 97.05pt"><FONT STYLE="font-variant: small-caps">o</FONT>: 303.256.5900<BR>
    <FONT STYLE="font-variant: small-caps">f</FONT>: 866.974.7329</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">July 22, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ARCA biopharma, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10170 Church Ranch Way, Suite 100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Westminster, CO 80021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Re: Registration Statement on Form S-4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have examined the Registration Statement on
Form S-4 filed by ARCA biopharma, Inc. (the &ldquo;<B>Company</B>&rdquo;) with the Securities and Exchange Commission (File No. 333-279387)
(such Registration Statement, as amended, the &ldquo;<B>Registration Statement</B>&rdquo;), in connection with the registration under
the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), of shares (the &ldquo;<B>Shares</B>&rdquo;) of the Company&rsquo;s
Common Stock, par value $0.0001 per share (the &ldquo;<B>Common Stock</B>&rdquo;), to be issued by the Company pursuant to the terms of
the Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024, by and among the Company, Atlas Merger Sub Corp., a Delaware
corporation and a wholly owned subsidiary of the Company (&ldquo;<B>First Merger Sub</B>&rdquo;), Atlas Merger Sub II, LLC, a Delaware
limited liability company and a wholly owned subsidiary of the Company (&ldquo;<B>Second Merger Sub</B>&rdquo; and, together with First
Merger Sub, &ldquo;<B>Merger Subs</B>&rdquo;), and Oruka Therapeutics, Inc., a Delaware corporation (&ldquo;<B>Oruka</B>&rdquo;) (the
&ldquo;<B>Merger Agreement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have examined such instruments, documents,
certificates and records, and such questions of law, as we have considered necessary or appropriate for the basis of our opinions hereinafter
expressed. In such examination, we have assumed (i) the authenticity of original documents and the genuineness of all signatures; (ii)
the conformity to the originals of all documents submitted to us as copies; (iii) the truth, accuracy and completeness of the information,
representations and warranties contained in the instruments, documents, certificates and records we have reviewed; and (iv) the legal
capacity and competency of all natural persons. As to any facts material to the opinions expressed herein that were not independently
established or verified, we have relied upon oral or written statements and representations of officers and other representatives of
the Company. &nbsp;For purposes of the opinion set forth below, we have assumed that no event occurs that causes the number of authorized
shares of Common Stock available for issuance by the Company to be less than the number of then unissued Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based upon the foregoing, and subject to the qualifications
set forth below, it is our opinion that, as of the date hereof, the Shares have been duly authorized by all necessary corporate action
on the Company&rsquo;s part and, when issued and paid for in the manner described in the Registration Statement and the Merger Agreement,
the Shares will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We do not express any opinion on any laws other
than the General Corporation Law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">austin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;beijing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;boston&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BOULDER&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;brussels&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;hong kong&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;london&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;los angeles&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;new york&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;palo alto<BR>
SALT LAKE CITY&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;san diego&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;san francisco&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;seattle&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shanghai&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;washington, dc&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;wilmington, de</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex5-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ARCA biopharma, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 22, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page <FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This opinion is furnished to the Company solely
in connection with the Registration Statement. We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement.
We also consent to the reference to our firm name wherever appearing in the Registration Statement, including the proxy statement/prospectus
constituting a part thereof, and any amendment thereto. In giving this consent, we do not thereby admit that we are in the category of
persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Securities and Exchange Commission
thereunder, nor do we thereby admit that we are experts with respect to any part of such Registration Statement within the meaning of
the term &ldquo;experts&rdquo; as used in the Securities Act or the rules and regulations of the Securities and Exchange Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Wilson Sonsini Goodrich &amp; Rosati, P.C.&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">WILSON SONSINI GOODRICH &amp; ROSATI</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Professional Corporation</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>3
<FILENAME>ea020512206ex8-1_arca.htm
<DESCRIPTION>TAX OPINION OF WILSON SONSINI GOODRICH & ROSATI, P.C
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 8.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 72%"><IMG SRC="ex8-1_001.jpg" ALT=""></TD><TD STYLE="text-align: justify; width: 28%"><P STYLE="margin-top: 0; margin-bottom: 0">Wilson Sonsini Goodrich &amp; Rosati</P>
                                                                        <P STYLE="margin-top: 0; margin-bottom: 0">Professional Corporation</P>
                                                                        <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                        <P STYLE="margin-top: 0; margin-bottom: 0">701 5th Ave #5100</P>
                                                                        <P STYLE="margin-top: 0; margin-bottom: 0">Seattle, WA 98104</P>
                                                                        <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-variant: small-caps">o</FONT>: 206.883.2500</P></TD>
</TR></TABLE>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">July 22, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">ARCA biopharma, Inc.<BR>
10170 Church Ranch Way, Suite 100<BR>
Westminster, CO 80021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><B>RE: U.S. Federal Income Tax Consequences
of the Merger</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have acted as counsel to
ARCA biopharma, Inc., a Delaware corporation (&ldquo;<U>Parent</U>&rdquo;) in connection with that certain registration statement on
Form S-4 (Registration No. 333-279387), initially filed with the Securities and Exchange Commission on May 14, 2024 (the
&ldquo;<U>Registration Statement</U>&rdquo;), including the proxy statement/prospectus forming a part thereof (the &ldquo;<U>Proxy
Statement/Prospectus</U>&rdquo;), and the agreement and plan of merger and reorganization (the &ldquo;<U>Agreement</U>&rdquo;),
dated as of April 3, 2024, by and among Parent, Atlas Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of
Parent (&ldquo;<U>First Merger Sub</U>&rdquo;), Atlas Merger Sub II, LLC, a Delaware limited liability company and a wholly owned
subsidiary of Parent (&ldquo;<U>Second Merger Sub</U>&rdquo; and, together with First Merger Sub, &ldquo;<U>Merger Subs</U>&rdquo;),
and Oruka Therapeutics, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), pursuant to which (1) First Merger Sub will
merge with and into the Company (the &ldquo;<U>First Merger</U>&rdquo;), with the Company continuing as a wholly owned subsidiary of
Parent and the surviving corporation of the First Merger and the outstanding shares of Company capital stock being converted into
the right to receive shares of Parent; and (2) following confirmation of the effectiveness of the First Merger, the Company will
merge with and into Second Merger Sub (the &ldquo;<U>Second Merger</U>&rdquo; and, together with the First Merger, the
&ldquo;<U>Merger</U>&rdquo;), with Second Merger Sub being the surviving entity of the merger.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1 </SUP></FONT>This
opinion is being delivered in connection with the Registration Statement and the Proxy Statement/Prospectus, pursuant to Section
6.10(c) of the Agreement, concerning certain U.S. federal income tax matters. Capitalized terms used herein but not defined shall
have the meanings set forth in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In preparing the opinion
set forth below, we have examined and reviewed originals or copies, certified or otherwise identified to our satisfaction, of the Agreement,
including the exhibits thereto, the Registration Statement and the Proxy Statement/Prospectus, the representation letters of Parent and
the Company (each a &ldquo;<U>Representation Party</U>&rdquo; and together, the &ldquo;<U>Representation Parties</U>&rdquo;) delivered
to us for purposes of this opinion (the &ldquo;<U>Representation Letters</U>&rdquo;) and such other documents, certificates and records
as we have deemed necessary or appropriate as a basis for our opinion. In our examination, we have assumed the genuineness of all signatures,
the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents
of all documents submitted to us as certified, conformed, photostatic or electronic copies, and the authenticity of the originals of
such latter documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT></TD><TD STYLE="text-align: left">Except as otherwise provided, all &ldquo;Section&rdquo; references
contained herein refer to sections of the Internal Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;), and to the Treasury
Regulations promulgated thereunder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In rendering our opinion,
we have relied upon statements, representations, warranties and covenants of officers and other representatives of the Representation
Parties, and we have assumed that such statements, representations, warranties and covenants, including those set forth in the Representation
Letters, are and will continue to be true, correct and complete (and, to the extent relevant, complied with) through the Merger Effective
Time without regard to any qualification as to knowledge, belief, intent, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In rendering our opinion,
we have assumed, without any independent investigation or examination thereof, that (i) the Merger will be consummated in the manner
described in the Agreement and will be effective under applicable state law, and that none of the terms or conditions contained therein
will be waived or modified and (ii) the Agreement, the Registration Statement, the Proxy Statement/Prospectus and the Representation
Letters accurately and completely reflect the facts relating to the Merger. Our opinion assumes and is expressly conditioned on, among
other things, the initial and continuing accuracy of the facts, information, covenants, representations and warranties set forth in the
documents referred to above, including those set forth in the Representation Letters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our opinion is based on the
Code, Treasury Regulations promulgated thereunder, judicial decisions, published positions of the Internal Revenue Service (the &ldquo;<U>Service</U>&rdquo;),
and such other authorities as we have considered relevant, all as in effect on the date of this opinion and all of which are subject
to change or differing interpretations, possibly with retroactive effect. A change in the authorities upon which our opinion is based
could affect the conclusions expressed herein. Moreover, there can be no assurance that positions contrary to our opinion will not be
taken by the Service or, if challenged, by a court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Based upon the foregoing
we are of the opinion that, for U.S. federal income tax purposes, the Merger will qualify as a &ldquo;reorganization&rdquo; within the
meaning of Section 368(a) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Except as expressly set forth
above, we express no other opinion. We are furnishing this opinion solely to you in connection with the Merger, and this opinion is not
to be relied upon by any other person or for any other purpose without our prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This opinion is expressed
as of the date hereof, and we are under no obligation to supplement or revise our opinion to reflect any legal developments, any factual
matters arising subsequent to the date hereof, or the impact of any information, document, certificate, record, statement, representation,
covenant, or assumption relied upon herein that becomes incorrect or untrue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 60%"></TD><TD STYLE="text-align: justify; width: 40%">Very truly yours</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">/s/ <FONT STYLE="text-decoration: none">Wilson Sonsini Goodrich&nbsp;&amp;&nbsp;Rosati, P.C.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify"><FONT STYLE="text-decoration: none">Wilson Sonsini Goodrich&nbsp;&amp;&nbsp;Rosati, P.C.</FONT></TD></TR>
     </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">-2-</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.2
<SEQUENCE>4
<FILENAME>ea020512206ex8-2_arca.htm
<DESCRIPTION>TAX OPINION OF GIBSON, DUNN & CRUTCHER LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 8.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 75%; text-align: left"><IMG SRC="ex8-2_001.jpg" ALT=""></TD><TD STYLE="text-align: justify; width: 25%">Gibson, Dunn &amp; Crutcher LLP</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>
                                                                        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">200 Park Avenue<BR>
New York, NY 10166-0193</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">Tel 212.351.4000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in">gibsondunn.com</P>

</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OPINION AS TO TAX MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 22, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Oruka Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">221 Crescent Street, Building 23, Suite 105</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Waltham, Massachusetts 02453</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have acted as U.S. tax
counsel to Oruka Therapeutics, Inc., a corporation incorporated pursuant to the laws of Delaware (&ldquo;<U>Company</U>&rdquo;), in connection
with the proposed merger of Atlas Merger Sub Corp. (&ldquo;<U>First Merger Sub</U>&rdquo;), a newly-formed corporation incorporated pursuant
to the laws of Delaware and a direct, wholly-owned subsidiary of ARCA Biopharma, Inc., a corporation incorporated pursuant to the laws
of Delaware (&ldquo;<U>Parent</U>&rdquo;), with and into the Company, with the Company as the surviving corporation (the &ldquo;<U>First
Merger</U>&rdquo;), and the subsequent merger of Atlas Merger Sub II, LLC (&ldquo;<U>Second Merger Sub</U>&rdquo; and, together with the
First Merger Sub, &ldquo;<U>Merger Subs</U>&rdquo;), a newly-formed Delaware limited liability company and a direct, wholly-owned subsidiary
of Parent, with Second Merger Sub being the surviving entity of the merger (the &ldquo;<U>Second Merger</U>&rdquo; and, together with
the First Merger, the &ldquo;<U>Merger</U>&rdquo;) pursuant to the Agreement and Plan of Merger among Company, Parent, and Merger Subs
dated as of April 3, 2024 (the &ldquo;<U>Merger Agreement</U>&rdquo;). At your request, and in connection with the filing of the Form
S-4 (Registration No. 333-279387) (including the proxy statement/prospectus contained therein, the &ldquo;<U>Registration Statemen</U>t&rdquo;),
we are rendering our opinion concerning the qualification of the Merger as a &ldquo;reorganization&rdquo; within the meaning of section
368(a) of the Code.<FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT> Capitalized terms used but not defined in this letter shall have
the meanings ascribed to them in the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In rendering our opinion,
we have examined the Merger Agreement, the Registration Statement, (as amended or supplemented through the date of this letter), and such
other documents as we have deemed necessary or appropriate for purposes of our opinion. In addition, we have assumed that (i) the Merger
will be consummated in accordance with the provisions of the Merger Agreement and as described in the Registration Statement, (ii) no
transaction, covenant, or condition described in the Registration Statement and affecting this opinion will be waived by any party, (iii)
the statements concerning the Merger and the parties set forth in the Merger Agreement are true, complete, and correct, (iv) the Registration
Statement is true, complete, and correct, (v) the statements and representations made by Parent and the Company in their respective officer&rsquo;s
certificates dated as of the date of this letter and delivered to us for purposes of this opinion (the &ldquo;<U>Officer&rsquo;s Certificates</U>&rdquo;)
are true, complete and correct as of the date of this letter and will remain true, complete and correct at all times up to and including
the Closing Date, (vi) any such statements and representations made in the Officer&rsquo;s Certificates that are qualified by knowledge,
belief, materiality, or comparable qualification are and will be true, complete, and correct without such qualification, and (vii) Parent,
the Company, and their respective subsidiaries will treat the Merger for U.S. federal income tax purposes in a manner consistent with
the opinion set forth below. If any of the above-described assumptions are untrue for any reason, our opinion as expressed below may be
adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT></TD><TD STYLE="text-align: left">Unless otherwise indicated, all &ldquo;section&rdquo; references
are to the Internal Revenue Code of 1986 (the &ldquo;Code&rdquo;), as in effect as of the date of this Opinion.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Abu
Dhabi &ndash; Beijing &ndash; Brussels &ndash; Century City &ndash; Dallas &ndash; Denver &ndash; Dubai &ndash; Frankfurt &ndash; Hong
Kong &ndash; Houston &ndash; London &ndash; Los Angeles<BR>
Munich &ndash; New York &ndash; Orange County &ndash; Palo Alto &ndash; Paris &ndash; Riyadh &ndash; San Francisco &ndash; Singapore
&ndash; Washington, D.C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><IMG SRC="ex8-2_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Oruka Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 22, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Page 2</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Based upon and subject to
the foregoing, we are of the opinion that, under currently applicable U.S. federal income tax law, the Merger will qualify as a reorganization
within the meaning of section 368(a) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We express no opinion on any
issue relating to the tax consequences of the Merger contemplated by the Registration Statement other than the opinion set forth above.
Our opinion is based on current provisions of the Code, Treasury regulations promulgated under the Code, published pronouncements of the
Internal Revenue Service, and case law, any of which may be changed at any time with retroactive effect. Any change in applicable laws
or the facts and circumstances surrounding the Merger, or any inaccuracy in the statements, facts, assumptions, or representations upon
which we have relied, may affect the continuing validity of our opinion as set forth in this letter. We assume no responsibility to inform
Parent of any such change or inaccuracy that may occur or come to our attention.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are furnishing this opinion
in connection with the filing of the Registration Statement, and this opinion is not to be relied upon for any other purpose without our
prior written consent. We hereby consent to the filing of this opinion with the Securities and Exchange Commission as an exhibit to the
Registration Statement and to the references in the Registration Statement to us. In giving such consent, we do not admit that we are
in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">/s/ Gibson, Dunn &amp; Crutcher LLP</TD>
  <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Gibson, Dunn &amp; Crutcher LLP</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ea020512206ex23-1_arca.htm
<DESCRIPTION>CONSENT OF KPMG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ARCA BIOPHARMA, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><IMG SRC="ex23-1_001.jpg" ALT=""></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 44%; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>
                                            <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                            <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                            <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-style: normal; font-weight: normal">KPMG LLP<BR> 1023 Walnut Street<BR> Boulder, Colorado, CO 80302</FONT></P></TD>
    <TD STYLE="width: 26%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 17%; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consent of Independent Registered Public Accounting
Firm</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal">We consent to the use of our report
dated February&nbsp;1,&nbsp;2024, with respect to the financial statements of ARCA biopharma Inc., included herein, and to the reference
to our firm under the heading &ldquo;Experts&rdquo; in the prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: center"><IMG SRC="ex23-1_002.jpg" ALT=""></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">Boulder, Colorado<BR>
July 22,&nbsp;2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">KPMG LLP, a Delaware limited liability
    partnership and a member firm of<BR> the KPMG global organization of independent member firms affiliated with<BR>
 KPMG International
    Limited, a private English company limited by guarantee.</FONT></TD></TR>
  </TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>6
<FILENAME>ea020512206ex23-2_arca.htm
<DESCRIPTION>CONSENT OF PRICEWATERHOUSECOOPERS LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ORUKA THERAPEUTICS, INC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 23.2</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We hereby consent to the use in this Registration Statement on Form
S-4 of ARCA biopharma, Inc. of our report dated May 13, 2024 relating to the financial statement of Oruka Therapeutics, Inc., which appears
in this Registration Statement. We also consent to the reference to us under the heading &ldquo;Experts&rdquo; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ PricewaterhouseCoopers LLP<BR>
Boston, Massachusetts <B><BR>
</B>July 22, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>abio-20240331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Jul 22 20:39:19 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://www.arcabiopharma.com/20240331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:abio="http://www.arcabiopharma.com/20240331" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="abio-20240331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abio-20240331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abio-20240331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abio-20240331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet" id="abio_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" id="abio_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement" id="abio_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals" id="abio_r_ConsolidatedIncomeStatement_Parentheticals">
        <link:definition>004 - Statement - Statements of Operations (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3" id="abio_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Statements of Stockholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ConsolidatedCashFlow" id="abio_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies" id="abio_r_ARCAandSummaryofSignificantAccountingPolicies">
        <link:definition>007 - Disclosure - ARCA and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/NetLossPerShare" id="abio_r_NetLossPerShare">
        <link:definition>008 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/FairValueDisclosures" id="abio_r_FairValueDisclosures">
        <link:definition>009 - Disclosure - Fair Value Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/PropertyandEquipment" id="abio_r_PropertyandEquipment">
        <link:definition>010 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangements" id="abio_r_RelatedPartyArrangements">
        <link:definition>011 - Disclosure - Related Party Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingencies" id="abio_r_CommitmentsandContingencies">
        <link:definition>012 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/EquityFinancings" id="abio_r_EquityFinancings">
        <link:definition>013 - Disclosure - Equity Financings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SharebasedCompensation" id="abio_r_SharebasedCompensation">
        <link:definition>014 - Disclosure - Share-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlans" id="abio_r_EmployeeBenefitPlans">
        <link:definition>015 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/IncomeTaxes" id="abio_r_IncomeTaxes">
        <link:definition>016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SubsequentEvents" id="abio_r_SubsequentEvents">
        <link:definition>017 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy" id="abio_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/NetLossPerShareTables" id="abio_r_NetLossPerShareTables">
        <link:definition>996001 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentTables" id="abio_r_PropertyandEquipmentTables">
        <link:definition>996002 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables" id="abio_r_CommitmentsandContingenciesTables">
        <link:definition>996003 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationTables" id="abio_r_SharebasedCompensationTables">
        <link:definition>996004 - Disclosure - Share-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/IncomeTaxesTables" id="abio_r_IncomeTaxesTables">
        <link:definition>996005 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails" id="abio_r_ARCAandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996006 - Disclosure - ARCA and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable" id="abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable">
        <link:definition>996007 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails" id="abio_r_FairValueDisclosuresDetails">
        <link:definition>996008 - Disclosure - Fair Value Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails" id="abio_r_PropertyandEquipmentDetails">
        <link:definition>996009 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable" id="abio_r_ScheduleofPropertyandEquipmentTable">
        <link:definition>996010 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails" id="abio_r_RelatedPartyArrangementsDetails">
        <link:definition>996011 - Disclosure - Related Party Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails" id="abio_r_CommitmentsandContingenciesDetails">
        <link:definition>996012 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable" id="abio_r_ScheduleofFutureMinimumCommitmentsDueTable">
        <link:definition>996013 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a6SJv7mHT4i4TtFvc3F7UUIS7zrUx0dX5qj5wO6LAzCWKAP1YyvCltmZDSa1A1PjhGmwdGmO+XuX7UCz5jLCkrke7lMg3unMP+n8iU9HDqCH0qa1RnmAbxLX0vVsMfna+lSvUOXK+fD+pyyPNZRgznHiq19ekTwN+k=] CSR-->
      <link:roleType roleURI="http://www.arcabiopharma.com/role/EquityFinancingsDetails" id="abio_r_EquityFinancingsDetails">
        <link:definition>996014 - Disclosure - Equity Financings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationDetails" id="abio_r_SharebasedCompensationDetails">
        <link:definition>996015 - Disclosure - Share-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable" id="abio_r_ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable">
        <link:definition>996016 - Disclosure - Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable" id="abio_r_ScheduleofStockOptionActivitiesTable">
        <link:definition>996017 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable" id="abio_r_ScheduleofRSUActivityTable">
        <link:definition>996018 - Disclosure - Share-based Compensation (Details) - Schedule of RSU Activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable" id="abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable">
        <link:definition>996019 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails" id="abio_r_EmployeeBenefitPlansDetails">
        <link:definition>996020 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/IncomeTaxesDetails" id="abio_r_IncomeTaxesDetails">
        <link:definition>996021 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" id="abio_r_ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable">
        <link:definition>996022 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable" id="abio_r_ScheduleofNetdeferredtaxassetsandliabilitiesTable">
        <link:definition>996023 - Disclosure - Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0" id="abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable0">
        <link:definition>996024 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0" id="abio_r_ScheduleofPropertyandEquipmentTable0">
        <link:definition>996025 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0" id="abio_r_ScheduleofFutureMinimumCommitmentsDueTable0">
        <link:definition>996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0" id="abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable0">
        <link:definition>996027 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0" id="abio_r_ScheduleofStockOptionActivitiesTable0">
        <link:definition>996028 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/SubsequentEventsDetails" id="abio_r_SubsequentEventsDetails">
        <link:definition>996029 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arcabiopharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:element name="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfFutureMinimumCommitmentsDueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
  <xs:element name="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract"/>
  <xs:element name="ScheduleOfStockOptionActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfStockOptionActivitiesAbstract"/>
  <xs:element name="ScheduleOfRsuActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfRsuActivityAbstract"/>
  <xs:element name="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract"/>
  <xs:element name="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract"/>
  <xs:element name="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract1"/>
  <xs:element name="UnlabeledAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract2"/>
  <xs:element name="CostsAndExpensesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_CostsAndExpensesAbstract0"/>
  <xs:element name="UnlabeledAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract3"/>
  <xs:element name="UnlabeledAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UnlabeledAbstract4"/>
  <xs:element name="PotentiallyDilutiveSecuritiesExcludedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PotentiallyDilutiveSecuritiesExcludedAbstract"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxAssetsAbstract"/>
  <xs:element name="PotentiallyDilutiveSecuritiesExcludedAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0"/>
  <xs:element name="ResearchAndDevelopmentExpenseReversed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_ResearchAndDevelopmentExpenseReversed"/>
  <xs:element name="DescriptionOfBusinessPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_DescriptionOfBusinessPolicyTextBlock"/>
  <xs:element name="LiquidityAndGoingConcernPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_LiquidityAndGoingConcernPolicyTextBlock"/>
  <xs:element name="ComprehensiveLossPolicyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ComprehensiveLossPolicyPolicyTextBlock"/>
  <xs:element name="AccruedOutsourcingExpensesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_AccruedOutsourcingExpensesPolicyTextBlock"/>
  <xs:element name="IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
  <xs:element name="DeferredTaxAssetResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxAssetResearchAndDevelopment"/>
  <xs:element name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxAssetsLeaseLiabilities"/>
  <xs:element name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
  <xs:element name="FairValueDisclosuresDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_FairValueDisclosuresDetailsTable"/>
  <xs:element name="FairValueDisclosuresDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_FairValueDisclosuresDetailsLineItems"/>
  <xs:element name="FairValueAssetsBetweenHierarchyLevelsTransfersAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount"/>
  <xs:element name="RelatedPartyArrangementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_RelatedPartyArrangementsDetailsTable"/>
  <xs:element name="PaymentOfUnrestrictedResearchGrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_PaymentOfUnrestrictedResearchGrants"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_CommitmentsandContingenciesDetailsLineItems"/>
  <xs:element name="RetentionBonuses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_RetentionBonuses"/>
  <xs:element name="PercentageOfRetentionBonuses" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PercentageOfRetentionBonuses"/>
  <xs:element name="RetentionBonusPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_RetentionBonusPaid"/>
  <xs:element name="AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" type="dtr:areaItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities"/>
  <xs:element name="LesseeOperatingSubleaseTermOfContract" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_LesseeOperatingSubleaseTermOfContract"/>
  <xs:element name="PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations"/>
  <xs:element name="OperatingLeasesExtendedExpiryYearsAndMonth" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_OperatingLeasesExtendedExpiryYearsAndMonth"/>
  <xs:element name="PercentageOfBaseRentToBePaidMonthly" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PercentageOfBaseRentToBePaidMonthly"/>
  <xs:element name="EquityFinancingsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_EquityFinancingsDetailsTable"/>
  <xs:element name="EquityFinancingsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_EquityFinancingsDetailsLineItems"/>
  <xs:element name="CommonStockAuthorizedOfferingAmountUnderAgreementToSell" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell"/>
  <xs:element name="SellingCommissionPerAdditionalSharesSoldPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abio_SellingCommissionPerAdditionalSharesSoldPercentage"/>
  <xs:element name="SharebasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_SharebasedCompensationDetailsTable"/>
  <xs:element name="SharebasedCompensationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_SharebasedCompensationDetailsLineItems"/>
  <xs:element name="PercentageHoldingForStockOptionsExercisePrice" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PercentageHoldingForStockOptionsExercisePrice"/>
  <xs:element name="PurchaseAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PurchaseAggregateShares"/>
  <xs:element name="EmployeeBenefitPlansDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_EmployeeBenefitPlansDetailsTable"/>
  <xs:element name="EmployeeBenefitPlansDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_EmployeeBenefitPlansDetailsLineItems"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_IncomeTaxesDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_IncomeTaxesDetailsLineItems"/>
  <xs:element name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_OperatingLossCarryforwardsExpirationYear"/>
  <xs:element name="DeferredTaxAssetsAndLiabilitiesValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance"/>
  <xs:element name="ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abio_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_SubsequentEventsDetailsLineItems"/>
  <xs:element name="NumberOfConsecutiveTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_NumberOfConsecutiveTradingDays"/>
  <xs:element name="ThresholdAmountOfAdjustedExchangeRatio" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_ThresholdAmountOfAdjustedExchangeRatio"/>
  <xs:element name="ThresholdAmountOfDeclaredCashDividend" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abio_ThresholdAmountOfDeclaredCashDividend"/>
  <xs:element name="SubscriptionAgreementReceiptAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_SubscriptionAgreementReceiptAmount"/>
  <xs:element name="PaymentOfOtherPartyTerminationFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_PaymentOfOtherPartyTerminationFee"/>
  <xs:element name="MinimumPercentageOfOriginallyIssuedShares" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abio_MinimumPercentageOfOriginallyIssuedShares"/>
  <xs:element name="MinimumPercentageOfOriginallyIssuedOutstanding" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abio_MinimumPercentageOfOriginallyIssuedOutstanding"/>
  <xs:element name="InitiallySpecifiedPercentageForBeneficialNumberOfShares" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares"/>
  <xs:element name="ExceptedNumberOfBoardMembers" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ExceptedNumberOfBoardMembers"/>
  <xs:element name="AggregatePurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_AggregatePurchasePrice"/>
  <xs:element name="NumberOfMonthsBaseSalary" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_NumberOfMonthsBaseSalary"/>
  <xs:element name="CashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_CashPayment"/>
  <xs:element name="IncreaseOfRetentionBonusToEachExecutive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abio_IncreaseOfRetentionBonusToEachExecutive"/>
  <xs:element name="ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember"/>
  <xs:element name="ArcaBiopharmaIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ArcaBiopharmaIncMember"/>
  <xs:element name="CapitalOnDemandSalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_CapitalOnDemandSalesAgreementMember"/>
  <xs:element name="ClinicalDevelopmentDecisionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ClinicalDevelopmentDecisionMember"/>
  <xs:element name="CommonStockAndPreFundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_CommonStockAndPreFundedWarrantsMember"/>
  <xs:element name="FirstMergerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_FirstMergerMember"/>
  <xs:element name="FirstThreePercentPayContributionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_FirstThreePercentPayContributionMember"/>
  <xs:element name="IncentiveStockOptionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_IncentiveStockOptionMember"/>
  <xs:element name="JonesTradingInstitutionalServicesLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_JonesTradingInstitutionalServicesLLCMember"/>
  <xs:element name="MergerAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_MergerAgreementMember"/>
  <xs:element name="NewCapitalOnDemandSalesAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_NewCapitalOnDemandSalesAgreementMember"/>
  <xs:element name="NextTwoPercentPayContributionMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_NextTwoPercentPayContributionMember"/>
  <xs:element name="OrukaTherapeuticsIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_OrukaTherapeuticsIncMember"/>
  <xs:element name="PatentAssignmentAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_PatentAssignmentAgreementMember"/>
  <xs:element name="SecondAmendmentOfCertainRetentionBonusLettersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_SecondAmendmentOfCertainRetentionBonusLettersMember"/>
  <xs:element name="SeperationAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_SeperationAgreementMember"/>
  <xs:element name="ThomasAKeuerAndCJeffreyDekkerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_ThomasAKeuerAndCJeffreyDekkerMember"/>
  <xs:element name="TwoThousandAndThirteenPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_TwoThousandAndThirteenPlanMember"/>
  <xs:element name="TwoThousandAndTwentyEquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_TwoThousandAndTwentyEquityIncentivePlanMember"/>
  <xs:element name="UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember"/>
  <xs:element name="WeightedAverageSharesOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_WeightedAverageSharesOutstandingAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abio_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>abio-20240331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Jul 22 20:39:19 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedCashFlow" roleURI="http://www.arcabiopharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNetdeferredtaxassetsandliabilitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"/>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestAndOtherIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingExpense" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a6SJv7mHT4i4TtFvc3F7UUIS7zrUx0dX5qj5wO6LAzCWKAP1YyvCltmZDSa1A1PjhGmwdGmO+XuX7UCz5jLCkrke7lMg3unMP+n8iU9HDqCH0qa1RnmAbxLX0vVsMfna+lSvUOXK+fD+kimuZHwzy4cFcfYVHrfZas=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:href="abio-20240331.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="6" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="abio-20240331.xsd#abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>abio-20240331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Jul 22 20:39:19 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ShareholdersEquityType2or3" roleURI="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedCashFlow" roleURI="http://www.arcabiopharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ARCAandSummaryofSignificantAccountingPolicies" roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_NetLossPerShare" roleURI="http://www.arcabiopharma.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_FairValueDisclosures" roleURI="http://www.arcabiopharma.com/role/FairValueDisclosures"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipment" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_RelatedPartyArrangements" roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangements"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingencies" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EquityFinancings" roleURI="http://www.arcabiopharma.com/role/EquityFinancings"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensation" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EmployeeBenefitPlans" roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlans"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxes" roleURI="http://www.arcabiopharma.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SubsequentEvents" roleURI="http://www.arcabiopharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_AccountingPoliciesByPolicy" roleURI="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_NetLossPerShareTables" roleURI="http://www.arcabiopharma.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipmentTables" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingenciesTables" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensationTables" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxesTables" roleURI="http://www.arcabiopharma.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofStockOptionActivitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofRSUActivityTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNetdeferredtaxassetsandliabilitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPropertyandEquipmentTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofStockOptionActivitiesTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ARCAandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_FairValueDisclosuresDetails" roleURI="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipmentDetails" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_RelatedPartyArrangementsDetails" roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingenciesDetails" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EquityFinancingsDetails" roleURI="http://www.arcabiopharma.com/role/EquityFinancingsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensationDetails" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EmployeeBenefitPlansDetails" roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxesDetails" roleURI="http://www.arcabiopharma.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SubsequentEventsDetails" roleURI="http://www.arcabiopharma.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#DocumentAndEntityInformation" roleURI="http://www.arcabiopharma.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_WeightedAverageSharesOutstandingAbstract" xlink:href="abio-20240331.xsd#abio_WeightedAverageSharesOutstandingAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="abio_WeightedAverageSharesOutstandingAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_WeightedAverageSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abio_ResearchAndDevelopmentExpenseReversed" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/NetLossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/FairValueDisclosures" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/RelatedPartyArrangements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/EquityFinancings" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_DescriptionOfBusinessPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_DescriptionOfBusinessPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_LiquidityAndGoingConcernPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_LiquidityAndGoingConcernPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_ComprehensiveLossPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_ComprehensiveLossPolicyPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_AccruedOutsourcingExpensesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abio_AccruedOutsourcingExpensesPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/NetLossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfRsuActivityAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfRsuActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:href="abio-20240331.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsAbstract" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="abio_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="abio-20240331.xsd#abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a6SJv7mHT4i4TtFvc3F7UUIS7zrUx0dX5qj5wO6LAzCWKAP1YyvCltmZDSa1A1PjhGmwdGmO+XuX7UCz5jLCkrke7lMg3unMP+n8iU9HDqCH0qa1RnmAbxLX0vVsMfna+lSvUOXK+fD+kGD76pVQ1JKGOIzU4lR0Yg=] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_FairValueDisclosuresDetailsLineItems" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueDisclosuresDetailsTable" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="abio_FairValueDisclosuresDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:href="abio-20240331.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_RelatedPartyArrangementsDetailsTable" xlink:href="abio-20240331.xsd#abio_RelatedPartyArrangementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abio_RelatedPartyArrangementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_RelatedPartyArrangementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abio_ResearchAndDevelopmentExpenseReversed" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PaymentOfUnrestrictedResearchGrants" xlink:href="abio-20240331.xsd#abio_PaymentOfUnrestrictedResearchGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abio_PaymentOfUnrestrictedResearchGrants" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_CommitmentsandContingenciesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_CommitmentsandContingenciesDetailsTable" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ClinicalDevelopmentDecisionMember" xlink:href="abio-20240331.xsd#abio_ClinicalDevelopmentDecisionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="abio_ClinicalDevelopmentDecisionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:href="abio-20240331.xsd#abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OneTimeTerminationBenefitsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_OneTimeTerminationBenefitsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PatentAssignmentAgreementMember" xlink:href="abio-20240331.xsd#abio_PatentAssignmentAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_PatentAssignmentAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_RetentionBonuses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageOfRetentionBonuses" xlink:href="abio-20240331.xsd#abio_PercentageOfRetentionBonuses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_PercentageOfRetentionBonuses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonusPaid" xlink:href="abio-20240331.xsd#abio_RetentionBonusPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_RetentionBonusPaid" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_SeveranceCosts1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringCharges" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:href="abio-20240331.xsd#abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_LesseeOperatingSubleaseTermOfContract" xlink:href="abio-20240331.xsd#abio_LesseeOperatingSubleaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_LesseeOperatingSubleaseTermOfContract" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:href="abio-20240331.xsd#abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_OperatingLeasesExtendedExpiryYearsAndMonth" xlink:href="abio-20240331.xsd#abio_OperatingLeasesExtendedExpiryYearsAndMonth"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_OperatingLeasesExtendedExpiryYearsAndMonth" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly" xlink:href="abio-20240331.xsd#abio_PercentageOfBaseRentToBePaidMonthly"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_PercentageOfBaseRentToBePaidMonthly" order="24" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/EquityFinancingsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_EquityFinancingsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_EquityFinancingsDetailsTable" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="abio_EquityFinancingsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_EquityFinancingsDetailsTable" xlink:to="dei_LegalEntityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_EquityFinancingsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_CapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_CapitalOnDemandSalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_NewCapitalOnDemandSalesAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember" xlink:href="abio-20240331.xsd#abio_JonesTradingInstitutionalServicesLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:href="abio-20240331.xsd#abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:href="abio-20240331.xsd#abio_SellingCommissionPerAdditionalSharesSoldPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_SharebasedCompensationDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_SharebasedCompensationDetailsTable" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="abio_SharebasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_IncentiveStockOptionMember" xlink:href="abio-20240331.xsd#abio_IncentiveStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="abio_IncentiveStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndTwentyEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abio_TwoThousandAndTwentyEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_TwoThousandAndThirteenPlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndThirteenPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abio_TwoThousandAndThirteenPlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalOwnerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalOwnerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_PrincipalOwnerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:href="abio-20240331.xsd#abio_PercentageHoldingForStockOptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PurchaseAggregateShares" xlink:href="abio-20240331.xsd#abio_PurchaseAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="abio_PurchaseAggregateShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_EmployeeBenefitPlansDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_EmployeeBenefitPlansDetailsTable" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="abio_EmployeeBenefitPlansDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_EmployeeBenefitPlansDetailsTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_FirstThreePercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_FirstThreePercentPayContributionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="abio_FirstThreePercentPayContributionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_NextTwoPercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_NextTwoPercentPayContributionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="abio_NextTwoPercentPayContributionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxesDetailsTable" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxPeriodAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarliestTaxYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_EarliestTaxYearMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LatestTaxYearMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_OperatingLossCarryforwardsExpirationYear" xlink:href="abio-20240331.xsd#abio_OperatingLossCarryforwardsExpirationYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_OperatingLossCarryforwardsExpirationYear" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:href="abio-20240331.xsd#abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OpenTaxYear" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abio_SubsequentEventsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abio_SubsequentEventsDetailsTable" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="dei_LegalEntityAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="srt_OwnershipAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_MergerAgreementMember" xlink:href="abio-20240331.xsd#abio_MergerAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_MergerAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_FirstMergerMember" xlink:href="abio-20240331.xsd#abio_FirstMergerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_FirstMergerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_SeperationAgreementMember" xlink:href="abio-20240331.xsd#abio_SeperationAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_SeperationAgreementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:href="abio-20240331.xsd#abio_SecondAmendmentOfCertainRetentionBonusLettersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_CommonStockAndPreFundedWarrantsMember" xlink:href="abio-20240331.xsd#abio_CommonStockAndPreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="abio_CommonStockAndPreFundedWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_PresidentMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PresidentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_PresidentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefFinancialOfficerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:href="abio-20240331.xsd#abio_ThomasAKeuerAndCJeffreyDekkerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="abio_ThomasAKeuerAndCJeffreyDekkerMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ArcaBiopharmaIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="abio_ArcaBiopharmaIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_OrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_OrukaTherapeuticsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="abio_OrukaTherapeuticsIncMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_NumberOfConsecutiveTradingDays" xlink:href="abio-20240331.xsd#abio_NumberOfConsecutiveTradingDays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_NumberOfConsecutiveTradingDays" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfAdjustedExchangeRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_ThresholdAmountOfAdjustedExchangeRatio" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfDeclaredCashDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_ThresholdAmountOfDeclaredCashDividend" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_SubscriptionAgreementReceiptAmount" xlink:href="abio-20240331.xsd#abio_SubscriptionAgreementReceiptAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_SubscriptionAgreementReceiptAmount" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_PaymentOfOtherPartyTerminationFee" xlink:href="abio-20240331.xsd#abio_PaymentOfOtherPartyTerminationFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_PaymentOfOtherPartyTerminationFee" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_MinimumPercentageOfOriginallyIssuedShares" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_MinimumPercentageOfOriginallyIssuedOutstanding" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:href="abio-20240331.xsd#abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_ExceptedNumberOfBoardMembers" xlink:href="abio-20240331.xsd#abio_ExceptedNumberOfBoardMembers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_ExceptedNumberOfBoardMembers" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_AggregatePurchasePrice" xlink:href="abio-20240331.xsd#abio_AggregatePurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_AggregatePurchasePrice" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_NumberOfMonthsBaseSalary" xlink:href="abio-20240331.xsd#abio_NumberOfMonthsBaseSalary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_NumberOfMonthsBaseSalary" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_CashPayment" xlink:href="abio-20240331.xsd#abio_CashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_CashPayment" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:href="abio-20240331.xsd#abio_IncreaseOfRetentionBonusToEachExecutive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_IncreaseOfRetentionBonusToEachExecutive" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_RetentionBonuses" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.arcabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="9" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>abio-20240331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Jul 22 20:39:19 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents, end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">ARCA and Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Net loss per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract_lbl" xml:lang="en-US">Schedule of Potentially Dilutive Shares of Common Stock [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:to="abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Arrangements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract_lbl" xml:lang="en-US">Schedule of Future Minimum Commitments Due [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="abio_ScheduleOfFutureMinimumCommitmentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total remaining lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity Financings [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract_lbl" xml:lang="en-US">Schedule of Estimated Weighted Average Grant Date Fair Value Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Options outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Purchase options shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfRsuActivityAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfRsuActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfRsuActivityAbstract_lbl" xml:lang="en-US">Schedule of RSU Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfRsuActivityAbstract" xlink:to="abio_ScheduleOfRsuActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Shares, RSUs outstanding, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Number of Shares, RSUs outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee Benefit Plans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract_lbl" xml:lang="en-US">Schedule Of Income Tax Benefit Attributable To Our Loss From Operations Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfStockOptionActivitiesAbstract_lbl" xml:lang="en-US">Schedule of Stock Option Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfStockOptionActivitiesAbstract" xlink:to="abio_ScheduleOfStockOptionActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use asset &#8211; operating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract" xlink:to="abio_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued expenses and other liabilities - related party (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding at December 31, 2023 and 2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract0" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract0" xlink:to="abio_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">Costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ResearchAndDevelopmentExpenseReversed_lbl" xml:lang="en-US">Related party expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ResearchAndDevelopmentExpenseReversed" xlink:to="abio_ResearchAndDevelopmentExpenseReversed_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract1" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract1" xlink:to="abio_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US">Interest and other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract2" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract2_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract2" xlink:to="abio_UnlabeledAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_WeightedAverageSharesOutstandingAbstract" xlink:href="abio-20240331.xsd#abio_WeightedAverageSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_WeightedAverageSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average shares outstanding:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_WeightedAverageSharesOutstandingAbstract" xlink:to="abio_WeightedAverageSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CostsAndExpensesAbstract0" xlink:href="abio-20240331.xsd#abio_CostsAndExpensesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CostsAndExpensesAbstract0_lbl" xml:lang="en-US">Costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CostsAndExpensesAbstract0" xlink:to="abio_CostsAndExpensesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract3" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract3_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract3" xlink:to="abio_UnlabeledAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UnlabeledAbstract4" xlink:href="abio-20240331.xsd#abio_UnlabeledAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UnlabeledAbstract4_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract4" xlink:to="abio_UnlabeledAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of common stock upon vesting of Restricted Stock Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of common stock upon vesting of Restricted Stock Units (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right-of-use asset &#8211; operating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Change in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" xml:lang="en-US">Income tax refund received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of noncash investing and financing transactions:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Leased assets and operating lease liabilities &#8211; amended lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss from disposal of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ARCA and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Potentially Dilutive Shares of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract_lbl" xml:lang="en-US">Potentially dilutive securities, excluded:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potentially dilutive securities, excluded</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Commitments Due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity Financings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years) Options outstanding, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Options, Options exercisable, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options exercisable, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Options exercisable, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options exercisable, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Options vested and expected to vest, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options vested and expected to vest, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Options vested and expected to vest, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options vested and expected to vest, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of RSU Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Shares, RSUs outstanding, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Vested and released</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Shares, RSUs outstanding, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Non-cash, Share-based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Employee Benefit Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax Benefit Attributable to Our Loss from Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. federal income tax benefit at statutory rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income tax benefit, net of federal benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:href="abio-20240331.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl" xml:lang="en-US">Deferred tax asset adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Net deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsAbstract" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="abio_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xml:lang="en-US">Charitable contribution carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and experimentation credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized research and development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetResearchAndDevelopment" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Capitalized intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsLeaseLiabilities" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net of valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0_lbl" xml:lang="en-US">Potentially dilutive securities, excluded:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed lease interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: Current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options, Forfeited and cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of Shares, RSUs outstanding, Vested and released</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and experimentation credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="abio-20240331.xsd#abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Outstanding stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Unvested restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Restricted Stock Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Lab equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquipmentMember_lbl0" xml:lang="en-US">Lab Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and fixtures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Computer software</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl0" xml:lang="en-US">Computer Software</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US">Restructuring Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xml:lang="en-US">Retirement Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl" xml:lang="en-US">Off-balance-sheet concentrations of credit risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US">Cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:href="abio-20240331.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl" xml:lang="en-US">Fair value hierarchy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xml:lang="en-US">Debt outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PaymentOfUnrestrictedResearchGrants" xlink:href="abio-20240331.xsd#abio_PaymentOfUnrestrictedResearchGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PaymentOfUnrestrictedResearchGrants_lbl" xml:lang="en-US">Payment of unrestricted research grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfUnrestrictedResearchGrants" xlink:to="abio_PaymentOfUnrestrictedResearchGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_RetentionBonuses_lbl" xml:lang="en-US">Amount of retention bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonuses" xlink:to="abio_RetentionBonuses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abio_RetentionBonuses_lbl0" xml:lang="en-US">Retention bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonuses" xlink:to="abio_RetentionBonuses_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageOfRetentionBonuses" xlink:href="abio-20240331.xsd#abio_PercentageOfRetentionBonuses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PercentageOfRetentionBonuses_lbl" xml:lang="en-US">Percentage of retention bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfRetentionBonuses" xlink:to="abio_PercentageOfRetentionBonuses_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_RetentionBonusPaid" xlink:href="abio-20240331.xsd#abio_RetentionBonusPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_RetentionBonusPaid_lbl" xml:lang="en-US">Retention bonus paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonusPaid" xlink:to="abio_RetentionBonusPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US">Remains unpaid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US">Workforce reduction percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl" xml:lang="en-US">Number of employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCharges_lbl" xml:lang="en-US">Restructuring charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US">Square feet (in Square Feet)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Lease renewal option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:href="abio-20240331.xsd#abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl" xml:lang="en-US">Square feet office facilities (in Square Feet)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:to="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_LesseeOperatingSubleaseTermOfContract" xlink:href="abio-20240331.xsd#abio_LesseeOperatingSubleaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_LesseeOperatingSubleaseTermOfContract_lbl" xml:lang="en-US">Sublease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LesseeOperatingSubleaseTermOfContract" xlink:to="abio_LesseeOperatingSubleaseTermOfContract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl" xml:lang="en-US">Lessee operating lease description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:href="abio-20240331.xsd#abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl" xml:lang="en-US">Royalty obligations (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:to="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US">Indicates (true false) whether lessee has option to extend operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_OperatingLeasesExtendedExpiryYearsAndMonth" xlink:href="abio-20240331.xsd#abio_OperatingLeasesExtendedExpiryYearsAndMonth"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_OperatingLeasesExtendedExpiryYearsAndMonth_lbl" xml:lang="en-US">Additional operating lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLeasesExtendedExpiryYearsAndMonth" xlink:to="abio_OperatingLeasesExtendedExpiryYearsAndMonth_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly" xlink:href="abio-20240331.xsd#abio_PercentageOfBaseRentToBePaidMonthly"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly_lbl" xml:lang="en-US">Percentage Of Base Rent To Be Paid Monthly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfBaseRentToBePaidMonthly" xlink:to="abio_PercentageOfBaseRentToBePaidMonthly_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:href="abio-20240331.xsd#abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl" xml:lang="en-US">Aggregate offering price (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:href="abio-20240331.xsd#abio_SellingCommissionPerAdditionalSharesSoldPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl" xml:lang="en-US">Percentage of commission rate equal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Reserved shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Stock options award, vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Stock options award, expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Percentage of exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:href="abio-20240331.xsd#abio_PercentageHoldingForStockOptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice_lbl" xml:lang="en-US">Exercise price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PurchaseAggregateShares" xlink:href="abio-20240331.xsd#abio_PurchaseAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PurchaseAggregateShares_lbl" xml:lang="en-US">Purchase aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PurchaseAggregateShares" xlink:to="abio_PurchaseAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US">Stock awards granted service period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized compensation cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xml:lang="en-US">Matching contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Employee&#8217;s contribution percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Equal contribution percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Company&apos;s contribution (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Research and experimentation credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_OperatingLossCarryforwardsExpirationYear" xlink:href="abio-20240331.xsd#abio_OperatingLossCarryforwardsExpirationYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US">Operating loss carryforwards expiration year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLossCarryforwardsExpirationYear" xlink:to="abio_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xml:lang="en-US">Operating loss carryforwards, limitations on use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl" xml:lang="en-US">Tax credit carryforward, limitations on use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:to="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:href="abio-20240331.xsd#abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl" xml:lang="en-US">Increase in net deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:to="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OpenTaxYear_lbl" xml:lang="en-US">Open Tax Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xml:lang="en-US">Reserve for uncertain tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Interest or penalties recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_NumberOfConsecutiveTradingDays" xlink:href="abio-20240331.xsd#abio_NumberOfConsecutiveTradingDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_NumberOfConsecutiveTradingDays_lbl" xml:lang="en-US">Number of consecutive trading days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfConsecutiveTradingDays" xlink:to="abio_NumberOfConsecutiveTradingDays_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Percentage of ownership interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Percentage of noncontrolling ownership interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfAdjustedExchangeRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl" xml:lang="en-US">Adjusted exchange ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:to="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfDeclaredCashDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend_lbl" xml:lang="en-US">Declared cash dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfDeclaredCashDividend" xlink:to="abio_ThresholdAmountOfDeclaredCashDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SubscriptionAgreementReceiptAmount" xlink:href="abio-20240331.xsd#abio_SubscriptionAgreementReceiptAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_SubscriptionAgreementReceiptAmount_lbl" xml:lang="en-US">Subscription agreement receipt amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubscriptionAgreementReceiptAmount" xlink:to="abio_SubscriptionAgreementReceiptAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_PaymentOfOtherPartyTerminationFee" xlink:href="abio-20240331.xsd#abio_PaymentOfOtherPartyTerminationFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PaymentOfOtherPartyTerminationFee_lbl" xml:lang="en-US">Payment of other party termination fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfOtherPartyTerminationFee" xlink:to="abio_PaymentOfOtherPartyTerminationFee_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares_lbl" xml:lang="en-US">Minimum percentage of originally issued outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:to="abio_MinimumPercentageOfOriginallyIssuedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl" xml:lang="en-US">Minimum percentage of originally issued outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:to="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US">Preferred stock convertible shares issuable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:href="abio-20240331.xsd#abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl" xml:lang="en-US">Initially specified percentage for beneficial number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:to="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ExceptedNumberOfBoardMembers" xlink:href="abio-20240331.xsd#abio_ExceptedNumberOfBoardMembers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ExceptedNumberOfBoardMembers_lbl" xml:lang="en-US">Excepted number of board members</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExceptedNumberOfBoardMembers" xlink:to="abio_ExceptedNumberOfBoardMembers_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_AggregatePurchasePrice" xlink:href="abio-20240331.xsd#abio_AggregatePurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_AggregatePurchasePrice_lbl" xml:lang="en-US">Aggregate purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AggregatePurchasePrice" xlink:to="abio_AggregatePurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_NumberOfMonthsBaseSalary" xlink:href="abio-20240331.xsd#abio_NumberOfMonthsBaseSalary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_NumberOfMonthsBaseSalary_lbl" xml:lang="en-US">Number of months base salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfMonthsBaseSalary" xlink:to="abio_NumberOfMonthsBaseSalary_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CashPayment" xlink:href="abio-20240331.xsd#abio_CashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CashPayment_lbl" xml:lang="en-US">Cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CashPayment" xlink:to="abio_CashPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:href="abio-20240331.xsd#abio_IncreaseOfRetentionBonusToEachExecutive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive_lbl" xml:lang="en-US">Increase of retention bonus to each executive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:to="abio_IncreaseOfRetentionBonusToEachExecutive_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_DescriptionOfBusinessPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock_lbl" xml:lang="en-US">Description of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DescriptionOfBusinessPolicyTextBlock" xlink:to="abio_DescriptionOfBusinessPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_LiquidityAndGoingConcernPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Liquidity and Going Concern</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates in the Preparation of Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_ComprehensiveLossPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_AccruedOutsourcingExpensesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl" xml:lang="en-US">Accrued Outsourcing Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:to="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl0" xml:lang="en-US">Money Market Funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Level 1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl0" xml:lang="en-US">Fair Value Measurements, Recurring</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer [Member]</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a6SJv7mHT4i4TtFvc3F7UUIS7zrUx0dX5qj5wO6LAzCWKAP1YyvCltmZDSa1A1PjhGmwdGmO+XuX7UCz5jLCkrke7lMg3unMP+n8iU9HDqCH0qa1RnmAbxLX0vVsMfna+lSvUOXK+fD+qyDm2LAdv3IokooCLz2KFM=] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_ClinicalDevelopmentDecisionMember" xlink:href="abio-20240331.xsd#abio_ClinicalDevelopmentDecisionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ClinicalDevelopmentDecisionMember_lbl" xml:lang="en-US">Clinical Development Decision [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClinicalDevelopmentDecisionMember" xlink:to="abio_ClinicalDevelopmentDecisionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abio_ClinicalDevelopmentDecisionMember_lbl0" xml:lang="en-US">Clinical development decisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClinicalDevelopmentDecisionMember" xlink:to="abio_ClinicalDevelopmentDecisionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OneTimeTerminationBenefitsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OneTimeTerminationBenefitsMember_lbl" xml:lang="en-US">One-time Termination Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OneTimeTerminationBenefitsMember" xlink:to="us-gaap_OneTimeTerminationBenefitsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:href="abio-20240331.xsd#abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl" xml:lang="en-US">University Medical Center of Johannes Gutenberg University Mainz</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl0" xml:lang="en-US">University Medical Center Of Johannes Gutenberg University Mainz</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_PatentAssignmentAgreementMember" xlink:href="abio-20240331.xsd#abio_PatentAssignmentAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_PatentAssignmentAgreementMember_lbl" xml:lang="en-US">Patent Assignment Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PatentAssignmentAgreementMember" xlink:to="abio_PatentAssignmentAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_CapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_CapitalOnDemandSalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CapitalOnDemandSalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CapitalOnDemandSalesAgreementMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember" xlink:href="abio-20240331.xsd#abio_JonesTradingInstitutionalServicesLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember_lbl" xml:lang="en-US">Jones Trading</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_JonesTradingInstitutionalServicesLLCMember" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_NewCapitalOnDemandSalesAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember_lbl" xml:lang="en-US">2020 Sales Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NewCapitalOnDemandSalesAgreementMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndTwentyEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xml:lang="en-US">2020 Equity Incentive Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncentiveStockOptionMember" xlink:href="abio-20240331.xsd#abio_IncentiveStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_IncentiveStockOptionMember_lbl" xml:lang="en-US">Incentive Stock Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncentiveStockOptionMember" xlink:to="abio_IncentiveStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalOwnerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalOwnerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrincipalOwnerMember_lbl" xml:lang="en-US">Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalOwnerMember" xlink:to="us-gaap_PrincipalOwnerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_TwoThousandAndThirteenPlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndThirteenPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_TwoThousandAndThirteenPlanMember_lbl" xml:lang="en-US">2013 Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndThirteenPlanMember" xlink:to="abio_TwoThousandAndThirteenPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FirstThreePercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_FirstThreePercentPayContributionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_FirstThreePercentPayContributionMember_lbl" xml:lang="en-US">First 3% of pay contributed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstThreePercentPayContributionMember" xlink:to="abio_FirstThreePercentPayContributionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_NextTwoPercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_NextTwoPercentPayContributionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_NextTwoPercentPayContributionMember_lbl" xml:lang="en-US">Next 2% of pay contributed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NextTwoPercentPayContributionMember" xlink:to="abio_NextTwoPercentPayContributionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US">Research Tax Credit Carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarliestTaxYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarliestTaxYearMember_lbl" xml:lang="en-US">Earliest Tax Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LatestTaxYearMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LatestTaxYearMember_lbl" xml:lang="en-US">Latest Tax Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ArcaBiopharmaIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ArcaBiopharmaIncMember_lbl" xml:lang="en-US">ARCA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncMember" xlink:to="abio_ArcaBiopharmaIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl" xml:lang="en-US">ARCA and Oruka</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:to="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_MergerAgreementMember" xlink:href="abio-20240331.xsd#abio_MergerAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_MergerAgreementMember_lbl" xml:lang="en-US">Merger Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MergerAgreementMember" xlink:to="abio_MergerAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FirstMergerMember" xlink:href="abio-20240331.xsd#abio_FirstMergerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_FirstMergerMember_lbl" xml:lang="en-US">First Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstMergerMember" xlink:to="abio_FirstMergerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_OrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_OrukaTherapeuticsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_OrukaTherapeuticsIncMember_lbl" xml:lang="en-US">Oruka Therapeutics Inc</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OrukaTherapeuticsIncMember" xlink:to="abio_OrukaTherapeuticsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CommonStockAndPreFundedWarrantsMember" xlink:href="abio-20240331.xsd#abio_CommonStockAndPreFundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_CommonStockAndPreFundedWarrantsMember_lbl" xml:lang="en-US">Common Stock and Pre Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAndPreFundedWarrantsMember" xlink:to="abio_CommonStockAndPreFundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SeperationAgreementMember" xlink:href="abio-20240331.xsd#abio_SeperationAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_SeperationAgreementMember_lbl" xml:lang="en-US">Seperation Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SeperationAgreementMember" xlink:to="abio_SeperationAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_PresidentMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PresidentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_PresidentMember_lbl" xml:lang="en-US">Thomas A. Keuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PresidentMember" xlink:to="srt_PresidentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:href="abio-20240331.xsd#abio_SecondAmendmentOfCertainRetentionBonusLettersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl" xml:lang="en-US">Second Amendment of Certain Retention Bonus Letters</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:to="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefFinancialOfficerMember_lbl" xml:lang="en-US">C. Jeffrey Dekker</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:href="abio-20240331.xsd#abio_ThomasAKeuerAndCJeffreyDekkerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl" xml:lang="en-US">Thomas A. Keuer and C. Jeffrey Dekker [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:to="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueDisclosuresDetailsTable" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FairValueDisclosuresDetailsTable_lbl" xml:lang="en-US">Fair Value Disclosures (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueDisclosuresDetailsTable" xlink:to="abio_FairValueDisclosuresDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_FairValueDisclosuresDetailsLineItems" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FairValueDisclosuresDetailsLineItems_lbl" xml:lang="en-US">Fair Value Disclosures (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueDisclosuresDetailsLineItems" xlink:to="abio_FairValueDisclosuresDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_RelatedPartyArrangementsDetailsTable" xlink:href="abio-20240331.xsd#abio_RelatedPartyArrangementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_RelatedPartyArrangementsDetailsTable_lbl" xml:lang="en-US">Related Party Arrangements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RelatedPartyArrangementsDetailsTable" xlink:to="abio_RelatedPartyArrangementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Arrangements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US">Type of Restructuring [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CommitmentsandContingenciesDetailsTable" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommitmentsandContingenciesDetailsTable" xlink:to="abio_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_CommitmentsandContingenciesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CommitmentsandContingenciesDetailsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommitmentsandContingenciesDetailsLineItems" xlink:to="abio_CommitmentsandContingenciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_EquityFinancingsDetailsTable" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_EquityFinancingsDetailsTable_lbl" xml:lang="en-US">Equity Financings (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EquityFinancingsDetailsTable" xlink:to="abio_EquityFinancingsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_EquityFinancingsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_EquityFinancingsDetailsLineItems_lbl" xml:lang="en-US">Equity Financings (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EquityFinancingsDetailsLineItems" xlink:to="abio_EquityFinancingsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SharebasedCompensationDetailsTable" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SharebasedCompensationDetailsTable_lbl" xml:lang="en-US">Share-based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SharebasedCompensationDetailsTable" xlink:to="abio_SharebasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SharebasedCompensationDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SharebasedCompensationDetailsLineItems_lbl" xml:lang="en-US">Share-based Compensation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SharebasedCompensationDetailsLineItems" xlink:to="abio_SharebasedCompensationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xml:lang="en-US">Retirement Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_EmployeeBenefitPlansDetailsTable" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_EmployeeBenefitPlansDetailsTable_lbl" xml:lang="en-US">Employee Benefit Plans (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EmployeeBenefitPlansDetailsTable" xlink:to="abio_EmployeeBenefitPlansDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_EmployeeBenefitPlansDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_EmployeeBenefitPlansDetailsLineItems_lbl" xml:lang="en-US">Employee Benefit Plans (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_EmployeeBenefitPlansDetailsLineItems" xlink:to="abio_EmployeeBenefitPlansDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodDomain_lbl" xml:lang="en-US">Tax Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxesDetailsTable" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxesDetailsTable" xlink:to="abio_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_IncomeTaxesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncomeTaxesDetailsLineItems_lbl" xml:lang="en-US">Income Taxes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxesDetailsLineItems" xlink:to="abio_IncomeTaxesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SubsequentEventsDetailsTable" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubsequentEventsDetailsTable" xlink:to="abio_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abio_SubsequentEventsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubsequentEventsDetailsLineItems" xlink:to="abio_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl0" xml:lang="en-US">Accrued outsourcing expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:to="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_AggregatePurchasePrice_lbl0" xml:lang="en-US">Aggregate purchase price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AggregatePurchasePrice" xlink:to="abio_AggregatePurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl0" xml:lang="en-US">Area of real estate property sublease additional office facilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:to="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_CashPayment_lbl0" xml:lang="en-US">Cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CashPayment" xlink:to="abio_CashPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl0" xml:lang="en-US">Common stock, authorized offering amount under agreement to sell.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Comprehensive loss policy.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetResearchAndDevelopment" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl0" xml:lang="en-US">Deferred tax assets and liabilities valuation allowance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:to="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsLeaseLiabilities" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl0" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from right of use assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock_lbl0" xml:lang="en-US">Description of business.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DescriptionOfBusinessPolicyTextBlock" xlink:to="abio_DescriptionOfBusinessPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ExceptedNumberOfBoardMembers_lbl0" xml:lang="en-US">Excepted Number of Board Members</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExceptedNumberOfBoardMembers" xlink:to="abio_ExceptedNumberOfBoardMembers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl0" xml:lang="en-US">Fair value assets between hierarchy levels transfers amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl0" xml:lang="en-US">Adjustment of the carrying value of deferred tax assets during the year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive_lbl0" xml:lang="en-US">Increase of retention bonus to each executive.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:to="abio_IncreaseOfRetentionBonusToEachExecutive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl0" xml:lang="en-US">Initially specified percentage for beneficial number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:to="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_LesseeOperatingSubleaseTermOfContract_lbl0" xml:lang="en-US">Lessee operating sublease term of contract.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LesseeOperatingSubleaseTermOfContract" xlink:to="abio_LesseeOperatingSubleaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl0" xml:lang="en-US">Liquidity and going concern.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl0" xml:lang="en-US">Minimum percentage of originally issued outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:to="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares_lbl0" xml:lang="en-US">Minimum percentage of originally issued shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:to="abio_MinimumPercentageOfOriginallyIssuedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_NumberOfConsecutiveTradingDays_lbl0" xml:lang="en-US">Number of consecutive trading days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfConsecutiveTradingDays" xlink:to="abio_NumberOfConsecutiveTradingDays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_NumberOfMonthsBaseSalary_lbl0" xml:lang="en-US">Number of months base salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfMonthsBaseSalary" xlink:to="abio_NumberOfMonthsBaseSalary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_OperatingLossCarryforwardsExpirationYear_lbl0" xml:lang="en-US">Operating loss carryforwards expiration year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLossCarryforwardsExpirationYear" xlink:to="abio_OperatingLossCarryforwardsExpirationYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PaymentOfOtherPartyTerminationFee_lbl0" xml:lang="en-US">Payment of other party termination fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfOtherPartyTerminationFee" xlink:to="abio_PaymentOfOtherPartyTerminationFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PaymentOfUnrestrictedResearchGrants_lbl0" xml:lang="en-US">Payment of unrestricted research grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfUnrestrictedResearchGrants" xlink:to="abio_PaymentOfUnrestrictedResearchGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice_lbl0" xml:lang="en-US">Minimum ownership percentage for 110% fair market value on the grant date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly_lbl0" xml:lang="en-US">Percentage of base rent to be paid monthly.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfBaseRentToBePaidMonthly" xlink:to="abio_PercentageOfBaseRentToBePaidMonthly_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PercentageOfRetentionBonuses_lbl0" xml:lang="en-US">Percentage of retention bonuses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfRetentionBonuses" xlink:to="abio_PercentageOfRetentionBonuses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl0" xml:lang="en-US">Potential upfront and milestone obligations and royalty obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:to="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PurchaseAggregateShares_lbl0" xml:lang="en-US">Purchase aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PurchaseAggregateShares" xlink:to="abio_PurchaseAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ResearchAndDevelopmentExpenseReversed_lbl0" xml:lang="en-US">Research and development expense (reversed).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ResearchAndDevelopmentExpenseReversed" xlink:to="abio_ResearchAndDevelopmentExpenseReversed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_RetentionBonusPaid_lbl0" xml:lang="en-US">Retention bonus paid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonusPaid" xlink:to="abio_RetentionBonusPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_RetentionBonuses_lbl1" xml:lang="en-US">Retention bonuses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonuses" xlink:to="abio_RetentionBonuses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl0" xml:lang="en-US">Selling commission per additional shares sold percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_SubscriptionAgreementReceiptAmount_lbl0" xml:lang="en-US">Subscription agreement receipt amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubscriptionAgreementReceiptAmount" xlink:to="abio_SubscriptionAgreementReceiptAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl0" xml:lang="en-US">Threshold amount of adjusted exchange ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:to="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend_lbl0" xml:lang="en-US">Threshold amount of declared cash dividend.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfDeclaredCashDividend" xlink:to="abio_ThresholdAmountOfDeclaredCashDividend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl0" xml:lang="en-US">Valuation allowance deferred tax assets and liabilities change in amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:to="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl0" xml:lang="en-US">Arca Biopharma Inc and Oruka Therapeutics Inc</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:to="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ArcaBiopharmaIncMember_lbl0" xml:lang="en-US">ARCA biopharma inc member.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncMember" xlink:to="abio_ArcaBiopharmaIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_CapitalOnDemandSalesAgreementMember_lbl0" xml:lang="en-US">Capital on demand sales agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CapitalOnDemandSalesAgreementMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ClinicalDevelopmentDecisionMember_lbl1" xml:lang="en-US">Clinical Development Decision Member.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClinicalDevelopmentDecisionMember" xlink:to="abio_ClinicalDevelopmentDecisionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_CommonStockAndPreFundedWarrantsMember_lbl0" xml:lang="en-US">Common stock and pre funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAndPreFundedWarrantsMember" xlink:to="abio_CommonStockAndPreFundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_FirstMergerMember_lbl0" xml:lang="en-US">First Merge</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstMergerMember" xlink:to="abio_FirstMergerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_FirstThreePercentPayContributionMember_lbl0" xml:lang="en-US">First three percent pay contribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstThreePercentPayContributionMember" xlink:to="abio_FirstThreePercentPayContributionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_IncentiveStockOptionMember_lbl0" xml:lang="en-US">Incentive stock option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncentiveStockOptionMember" xlink:to="abio_IncentiveStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember_lbl0" xml:lang="en-US">JonesTrading Institutional Services LLC.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_JonesTradingInstitutionalServicesLLCMember" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_MergerAgreementMember_lbl0" xml:lang="en-US">Merger agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MergerAgreementMember" xlink:to="abio_MergerAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember_lbl0" xml:lang="en-US">New Capital on Demand Sales Agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NewCapitalOnDemandSalesAgreementMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_NextTwoPercentPayContributionMember_lbl0" xml:lang="en-US">Next two percent pay contribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NextTwoPercentPayContributionMember" xlink:to="abio_NextTwoPercentPayContributionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_OrukaTherapeuticsIncMember_lbl0" xml:lang="en-US">Oruka therapeutics inc member.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OrukaTherapeuticsIncMember" xlink:to="abio_OrukaTherapeuticsIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_PatentAssignmentAgreementMember_lbl0" xml:lang="en-US">Patent assignment agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PatentAssignmentAgreementMember" xlink:to="abio_PatentAssignmentAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl0" xml:lang="en-US">Second amendment of certain retention bonus letters.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:to="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_SeperationAgreementMember_lbl0" xml:lang="en-US">Seperation agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SeperationAgreementMember" xlink:to="abio_SeperationAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl0" xml:lang="en-US">Thomas A. Keuer and C. Jeffrey Dekker.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:to="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_TwoThousandAndThirteenPlanMember_lbl0" xml:lang="en-US">Two thousand and thirteen plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndThirteenPlanMember" xlink:to="abio_TwoThousandAndThirteenPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl0" xml:lang="en-US">Two thousand and twenty equity incentive plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl1" xml:lang="en-US">University medical center of Johannes Gutenberg university Mainz.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl1" xml:lang="en-US">Accrued Outsourcing Expenses Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AccruedOutsourcingExpensesPolicyTextBlock" xlink:to="abio_AccruedOutsourcingExpensesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl0" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl0" xml:lang="en-US">Area of Real Estate Property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ExceptedNumberOfBoardMembers_lbl1" xml:lang="en-US">Excepted Number Of Board Members</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ExceptedNumberOfBoardMembers" xlink:to="abio_ExceptedNumberOfBoardMembers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OpenTaxYear_lbl0" xml:lang="en-US">Open Tax Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_JonesTradingInstitutionalServicesLLCMember_lbl1" xml:lang="en-US">Jones Trading Institutional Services LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_JonesTradingInstitutionalServicesLLCMember" xlink:to="abio_JonesTradingInstitutionalServicesLLCMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="abio_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl0" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl1" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl1" xml:lang="en-US">Two Thousand And Twenty Equity Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="abio_TwoThousandAndTwentyEquityIncentivePlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl0" xml:lang="en-US">Lessee, Operating Lease, Assumptions and Judgments, Allocation of Lease and Nonlease Component</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_TwoThousandAndThirteenPlanMember_lbl1" xml:lang="en-US">Two Thousand And Thirteen Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_TwoThousandAndThirteenPlanMember" xlink:to="abio_TwoThousandAndThirteenPlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl0" xml:lang="en-US">Costs and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ThresholdAmountOfDeclaredCashDividend_lbl1" xml:lang="en-US">Threshold Amount Of Declared Cash Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfDeclaredCashDividend" xlink:to="abio_ThresholdAmountOfDeclaredCashDividend_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl0" xml:lang="en-US">Debt, Long-Term and Short-Term, Combined Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarliestTaxYearMember_lbl0" xml:lang="en-US">Earliest Tax Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarliestTaxYearMember" xlink:to="us-gaap_EarliestTaxYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_NewCapitalOnDemandSalesAgreementMember_lbl1" xml:lang="en-US">New Capital On Demand Sales Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NewCapitalOnDemandSalesAgreementMember" xlink:to="abio_NewCapitalOnDemandSalesAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PatentAssignmentAgreementMember_lbl1" xml:lang="en-US">Patent Assignment Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PatentAssignmentAgreementMember" xlink:to="abio_PatentAssignmentAgreementMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl0" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl1" xml:lang="en-US">Liquidity And Going Concern Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="abio_LiquidityAndGoingConcernPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl1" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CapitalOnDemandSalesAgreementMember_lbl1" xml:lang="en-US">Capital On Demand Sales Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CapitalOnDemandSalesAgreementMember" xlink:to="abio_CapitalOnDemandSalesAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract3_lbl0" xml:lang="en-US">Unlabeled Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract3" xlink:to="abio_UnlabeledAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl1" xml:lang="en-US">Thomas AKeuer And CJeffrey Dekker Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThomasAKeuerAndCJeffreyDekkerMember" xlink:to="abio_ThomasAKeuerAndCJeffreyDekkerMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract2_lbl0" xml:lang="en-US">Unlabeled Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract2" xlink:to="abio_UnlabeledAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract4_lbl0" xml:lang="en-US">Unlabeled Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract4" xlink:to="abio_UnlabeledAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract1" xlink:to="abio_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract0" xlink:to="abio_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl1" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl1" xml:lang="en-US">Software and Software Development Costs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl0" xml:lang="en-US">Proceeds from Income Tax Refunds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl0" xml:lang="en-US">Severance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_OperatingLeasesExtendedExpiryYearsAndMonth_lbl0" xml:lang="en-US">Operating Leases Extended Expiry Years And Month</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLeasesExtendedExpiryYearsAndMonth" xlink:to="abio_OperatingLeasesExtendedExpiryYearsAndMonth_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl1" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CashPayment_lbl1" xml:lang="en-US">Cash Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CashPayment" xlink:to="abio_CashPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl1" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ArcaBiopharmaIncMember_lbl1" xml:lang="en-US">Arca Biopharma Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncMember" xlink:to="abio_ArcaBiopharmaIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl1" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PaymentOfUnrestrictedResearchGrants_lbl1" xml:lang="en-US">Payment Of Unrestricted Research Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfUnrestrictedResearchGrants" xlink:to="abio_PaymentOfUnrestrictedResearchGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FirstThreePercentPayContributionMember_lbl1" xml:lang="en-US">First Three Percent Pay Contribution Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstThreePercentPayContributionMember" xlink:to="abio_FirstThreePercentPayContributionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl0" xml:lang="en-US">Tax Credit Carryforward, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl0" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl1" xml:lang="en-US">Fair Value Assets Between Hierarchy Levels Transfers Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:to="abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UnlabeledAbstract" xlink:to="abio_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_MinimumPercentageOfOriginallyIssuedShares_lbl1" xml:lang="en-US">Minimum Percentage Of Originally Issued Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedShares" xlink:to="abio_MinimumPercentageOfOriginallyIssuedShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl0" xml:lang="en-US">Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_RetentionBonusPaid_lbl1" xml:lang="en-US">Retention Bonus Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonusPaid" xlink:to="abio_RetentionBonusPaid_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PercentageOfBaseRentToBePaidMonthly_lbl1" xml:lang="en-US">Percentage Of Base Rent To Be Paid Monthly</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfBaseRentToBePaidMonthly" xlink:to="abio_PercentageOfBaseRentToBePaidMonthly_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl0" xml:lang="en-US">Defined Contribution Plan, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl1" xml:lang="en-US">Selling Commission Per Additional Shares Sold Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SellingCommissionPerAdditionalSharesSoldPercentage" xlink:to="abio_SellingCommissionPerAdditionalSharesSoldPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl1" xml:lang="en-US">Minimum Percentage Of Originally Issued Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MinimumPercentageOfOriginallyIssuedOutstanding" xlink:to="abio_MinimumPercentageOfOriginallyIssuedOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PercentageOfRetentionBonuses_lbl1" xml:lang="en-US">Percentage Of Retention Bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageOfRetentionBonuses" xlink:to="abio_PercentageOfRetentionBonuses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_WeightedAverageSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Shares Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_WeightedAverageSharesOutstandingAbstract" xlink:to="abio_WeightedAverageSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl0" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAbstract" xlink:to="abio_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncreaseOfRetentionBonusToEachExecutive_lbl1" xml:lang="en-US">Increase Of Retention Bonus To Each Executive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncreaseOfRetentionBonusToEachExecutive" xlink:to="abio_IncreaseOfRetentionBonusToEachExecutive_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCharges_lbl0" xml:lang="en-US">Restructuring Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CommonStockAndPreFundedWarrantsMember_lbl1" xml:lang="en-US">Common Stock And Pre Funded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAndPreFundedWarrantsMember" xlink:to="abio_CommonStockAndPreFundedWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl0" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees&apos; Gross Pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Net Deferred Tax Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl1" xml:lang="en-US">Valuation Allowance Deferred Tax Assets And Liabilities Change In Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:to="abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_FirstMergerMember_lbl1" xml:lang="en-US">First Merger Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_FirstMergerMember" xlink:to="abio_FirstMergerMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract_lbl0" xml:lang="en-US">Potentially Dilutive Securities Excluded Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PaymentOfOtherPartyTerminationFee_lbl1" xml:lang="en-US">Payment Of Other Party Termination Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PaymentOfOtherPartyTerminationFee" xlink:to="abio_PaymentOfOtherPartyTerminationFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ClinicalDevelopmentDecisionMember_lbl2" xml:lang="en-US">Clinical Development Decision Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ClinicalDevelopmentDecisionMember" xlink:to="abio_ClinicalDevelopmentDecisionMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SeperationAgreementMember_lbl1" xml:lang="en-US">Seperation Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SeperationAgreementMember" xlink:to="abio_SeperationAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl1" xml:lang="en-US">Threshold Amount Of Adjusted Exchange Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ThresholdAmountOfAdjustedExchangeRatio" xlink:to="abio_ThresholdAmountOfAdjustedExchangeRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl0" xml:lang="en-US">Other Nonoperating Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl1" xml:lang="en-US">Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_MergerAgreementMember_lbl1" xml:lang="en-US">Merger Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_MergerAgreementMember" xlink:to="abio_MergerAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl1" xml:lang="en-US">Arca Biopharma Inc And Oruka Therapeutics Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:to="abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl0" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LatestTaxYearMember_lbl0" xml:lang="en-US">Latest Tax Year [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_RetentionBonuses_lbl2" xml:lang="en-US">Retention Bonuses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_RetentionBonuses" xlink:to="abio_RetentionBonuses_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl0" xml:lang="en-US">Debt Securities, Available-for-Sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_NumberOfMonthsBaseSalary_lbl1" xml:lang="en-US">Number Of Months Base Salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfMonthsBaseSalary" xlink:to="abio_NumberOfMonthsBaseSalary_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrincipalOwnerMember_lbl0" xml:lang="en-US">Principal Owner [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalOwnerMember" xlink:to="us-gaap_PrincipalOwnerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CostsAndExpensesAbstract0_lbl0" xml:lang="en-US">Costs And Expenses Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CostsAndExpensesAbstract0" xlink:to="abio_CostsAndExpensesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PercentageHoldingForStockOptionsExercisePrice_lbl1" xml:lang="en-US">Percentage Holding For Stock Options Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PercentageHoldingForStockOptionsExercisePrice" xlink:to="abio_PercentageHoldingForStockOptionsExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl1" xml:lang="en-US">Deferred Tax Liabilities Right Of Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="abio_DeferredTaxLiabilitiesRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl0" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ResearchAndDevelopmentExpenseReversed_lbl1" xml:lang="en-US">Research And Development Expense Reversed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ResearchAndDevelopmentExpenseReversed" xlink:to="abio_ResearchAndDevelopmentExpenseReversed_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl1" xml:lang="en-US">Deferred Tax Assets And Liabilities Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:to="abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl0" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl1" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_OrukaTherapeuticsIncMember_lbl1" xml:lang="en-US">Oruka Therapeutics Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OrukaTherapeuticsIncMember" xlink:to="abio_OrukaTherapeuticsIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl1" xml:lang="en-US">Potential Upfront And Milestone Obligations And Royalty Obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:to="abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl0" xml:lang="en-US">Defined Contribution Plan, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_NextTwoPercentPayContributionMember_lbl1" xml:lang="en-US">Next Two Percent Pay Contribution Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NextTwoPercentPayContributionMember" xlink:to="abio_NextTwoPercentPayContributionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl0" xml:lang="en-US">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0" xml:lang="en-US">Subsidiary, Ownership Percentage, Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl1" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_AggregatePurchasePrice_lbl1" xml:lang="en-US">Aggregate Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AggregatePurchasePrice" xlink:to="abio_AggregatePurchasePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefFinancialOfficerMember_lbl0" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefFinancialOfficerMember" xlink:to="srt_ChiefFinancialOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PresidentMember_lbl0" xml:lang="en-US">President [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PresidentMember" xlink:to="srt_PresidentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl1" xml:lang="en-US">Common Stock Authorized Offering Amount Under Agreement To Sell</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:to="abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Non Cash Share Based Compensation Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:to="abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_NumberOfConsecutiveTradingDays_lbl1" xml:lang="en-US">Number Of Consecutive Trading Days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_NumberOfConsecutiveTradingDays" xlink:to="abio_NumberOfConsecutiveTradingDays_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl1" xml:lang="en-US">Area Of Real Estate Property Sublease Additional Office Facilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:to="abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxAssetsLeaseLiabilities_lbl1" xml:lang="en-US">Deferred Tax Assets Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetsLeaseLiabilities" xlink:to="abio_DeferredTaxAssetsLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_OperatingLossCarryforwardsExpirationYear_lbl1" xml:lang="en-US">Operating Loss Carryforwards Expiration Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_OperatingLossCarryforwardsExpirationYear" xlink:to="abio_OperatingLossCarryforwardsExpirationYear_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl1" xml:lang="en-US">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OneTimeTerminationBenefitsMember_lbl0" xml:lang="en-US">One-time Termination Benefits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OneTimeTerminationBenefitsMember" xlink:to="us-gaap_OneTimeTerminationBenefitsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncentiveStockOptionMember_lbl1" xml:lang="en-US">Incentive Stock Option Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncentiveStockOptionMember" xlink:to="abio_IncentiveStockOptionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DescriptionOfBusinessPolicyTextBlock_lbl1" xml:lang="en-US">Description Of Business Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DescriptionOfBusinessPolicyTextBlock" xlink:to="abio_DescriptionOfBusinessPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_DeferredTaxAssetResearchAndDevelopment_lbl1" xml:lang="en-US">Deferred Tax Asset Research And Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_DeferredTaxAssetResearchAndDevelopment" xlink:to="abio_DeferredTaxAssetResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl2" xml:lang="en-US">University Medical Center Of Johannes Gutenberg University Mainz Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:to="abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PurchaseAggregateShares_lbl1" xml:lang="en-US">Purchase Aggregate Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PurchaseAggregateShares" xlink:to="abio_PurchaseAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserveCurrent_lbl0" xml:lang="en-US">Restructuring Reserve, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl0" xml:lang="en-US">Retirement Benefits [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl0" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl0" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl0" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl1" xml:lang="en-US">Initially Specified Percentage For Beneficial Number Of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:to="abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl0" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl1" xml:lang="en-US">Second Amendment Of Certain Retention Bonus Letters Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:to="abio_SecondAmendmentOfCertainRetentionBonusLettersMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl1" xml:lang="en-US">Comprehensive Loss Policy Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_ComprehensiveLossPolicyPolicyTextBlock" xlink:to="abio_ComprehensiveLossPolicyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl1" xml:lang="en-US">Income Tax Reconciliation Adjustment To Deferred Tax Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:to="abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_LesseeOperatingSubleaseTermOfContract_lbl1" xml:lang="en-US">Lessee Operating Sublease Term Of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_LesseeOperatingSubleaseTermOfContract" xlink:to="abio_LesseeOperatingSubleaseTermOfContract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_SubscriptionAgreementReceiptAmount_lbl1" xml:lang="en-US">Subscription Agreement Receipt Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_SubscriptionAgreementReceiptAmount" xlink:to="abio_SubscriptionAgreementReceiptAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl0" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Charitable Contribution Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncome_lbl0" xml:lang="en-US">Interest and Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl0" xml:lang="en-US">Tax Credit Carryforward, Limitations on Use</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0_lbl0" xml:lang="en-US">Potentially Dilutive Securities Excluded Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:to="abio_PotentiallyDilutiveSecuritiesExcludedAbstract0_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>abio-20240331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Jul 22 20:39:19 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedIncomeStatement_Parentheticals" roleURI="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ShareholdersEquityType2or3" roleURI="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ConsolidatedCashFlow" roleURI="http://www.arcabiopharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ARCAandSummaryofSignificantAccountingPolicies" roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_NetLossPerShare" roleURI="http://www.arcabiopharma.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_FairValueDisclosures" roleURI="http://www.arcabiopharma.com/role/FairValueDisclosures"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipment" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_RelatedPartyArrangements" roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangements"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingencies" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EquityFinancings" roleURI="http://www.arcabiopharma.com/role/EquityFinancings"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensation" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EmployeeBenefitPlans" roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlans"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxes" roleURI="http://www.arcabiopharma.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SubsequentEvents" roleURI="http://www.arcabiopharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_AccountingPoliciesByPolicy" roleURI="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_NetLossPerShareTables" roleURI="http://www.arcabiopharma.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipmentTables" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingenciesTables" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensationTables" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxesTables" roleURI="http://www.arcabiopharma.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofStockOptionActivitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofRSUActivityTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNetdeferredtaxassetsandliabilitiesTable" roleURI="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPotentiallyDilutiveSharesofCommonStockTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofPropertyandEquipmentTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofFutureMinimumCommitmentsDueTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofNoncashSharebasedCompensationExpenseTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ScheduleofStockOptionActivitiesTable0" roleURI="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_ARCAandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_FairValueDisclosuresDetails" roleURI="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_PropertyandEquipmentDetails" roleURI="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_RelatedPartyArrangementsDetails" roleURI="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_CommitmentsandContingenciesDetails" roleURI="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EquityFinancingsDetails" roleURI="http://www.arcabiopharma.com/role/EquityFinancingsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SharebasedCompensationDetails" roleURI="http://www.arcabiopharma.com/role/SharebasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_EmployeeBenefitPlansDetails" roleURI="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_IncomeTaxesDetails" roleURI="http://www.arcabiopharma.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#abio_r_SubsequentEventsDetails" roleURI="http://www.arcabiopharma.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abio-20240331.xsd#DocumentAndEntityInformation" roleURI="http://www.arcabiopharma.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_StockholdersEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestAndOtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageSharesOutstandingAbstract" xlink:href="abio-20240331.xsd#abio_WeightedAverageSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="WeightedAverageSharesOutstandingAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ResearchAndDevelopmentExpenseReversed" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/NetLossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/FairValueDisclosures" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/RelatedPartyArrangements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/EquityFinancings" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfBusinessPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_DescriptionOfBusinessPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DescriptionOfBusinessPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiquidityAndGoingConcernPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_LiquidityAndGoingConcernPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LiquidityAndGoingConcernPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComprehensiveLossPolicyPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_ComprehensiveLossPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ComprehensiveLossPolicyPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedOutsourcingExpensesPolicyTextBlock" xlink:href="abio-20240331.xsd#abio_AccruedOutsourcingExpensesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="AccruedOutsourcingExpensesPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/NetLossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="PotentiallyDilutiveSecuritiesExcludedAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PotentiallyDilutiveSecuritiesExcludedAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRsuActivityAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfRsuActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsuActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" xlink:href="abio-20240331.xsd#abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="IncomeTaxReconciliationAdjustmentToDeferredTaxAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetResearchAndDevelopment" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetResearchAndDevelopment"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrYwqBFvPJwgls7iB/C7qgJlieUnn0NA5OCi94KNojOhCKLtgRf7Lh8PNXaX7qyF9a6SJv7mHT4i4TtFvc3F7UUIS7zrUx0dX5qj5wO6LAzCWKAP1YyvCltmZDSa1A1PjhGmwdGmO+XuX7UCz5jLCkrke7lMg3unMP+n8iU9HDqCH0qa1RnmAbxLX0vVsMfna+lSvUOXK+fD+tGlN813KsHIm3c43yO7QfQ=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetResearchAndDevelopment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsLeaseLiabilities" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsLeaseLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="abio-20240331.xsd#abio_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:href="abio-20240331.xsd#abio_PotentiallyDilutiveSecuritiesExcludedAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="PotentiallyDilutiveSecuritiesExcludedAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PotentiallyDilutiveSecuritiesExcludedAbstract0" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfFutureMinimumCommitmentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumCommitmentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNonCashShareBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivitiesAbstract" xlink:href="abio-20240331.xsd#abio_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/FairValueDisclosuresDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueDisclosuresDetailsTable" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsTable"/>
    <loc xlink:type="locator" xlink:label="FairValueDisclosuresDetailsLineItems" xlink:href="abio-20240331.xsd#abio_FairValueDisclosuresDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="FairValueDisclosuresDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsTable" xlink:to="FairValueDisclosuresDetailsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueAssetsBetweenHierarchyLevelsTransfersAmount" xlink:href="abio-20240331.xsd#abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsLineItems" xlink:to="FairValueAssetsBetweenHierarchyLevelsTransfersAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueDisclosuresDetailsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyArrangementsDetailsTable" xlink:href="abio-20240331.xsd#abio_RelatedPartyArrangementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyArrangementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyArrangementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyArrangementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpenseReversed" xlink:href="abio-20240331.xsd#abio_ResearchAndDevelopmentExpenseReversed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ResearchAndDevelopmentExpenseReversed" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfUnrestrictedResearchGrants" xlink:href="abio-20240331.xsd#abio_PaymentOfUnrestrictedResearchGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="PaymentOfUnrestrictedResearchGrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_CommitmentsandContingenciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="srt_CounterpartyNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" xlink:href="abio-20240331.xsd#abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OneTimeTerminationBenefitsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_OneTimeTerminationBenefitsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ClinicalDevelopmentDecisionMember" xlink:href="abio-20240331.xsd#abio_ClinicalDevelopmentDecisionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="ClinicalDevelopmentDecisionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PatentAssignmentAgreementMember" xlink:href="abio-20240331.xsd#abio_PatentAssignmentAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="PatentAssignmentAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="CommitmentsandContingenciesDetailsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RetentionBonuses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfRetentionBonuses" xlink:href="abio-20240331.xsd#abio_PercentageOfRetentionBonuses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PercentageOfRetentionBonuses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RetentionBonusPaid" xlink:href="abio-20240331.xsd#abio_RetentionBonusPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="RetentionBonusPaid" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_SeveranceCosts1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RestructuringCharges" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" xlink:href="abio-20240331.xsd#abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingSubleaseTermOfContract" xlink:href="abio-20240331.xsd#abio_LesseeOperatingSubleaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="LesseeOperatingSubleaseTermOfContract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" xlink:href="abio-20240331.xsd#abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesExtendedExpiryYearsAndMonth" xlink:href="abio-20240331.xsd#abio_OperatingLeasesExtendedExpiryYearsAndMonth"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="OperatingLeasesExtendedExpiryYearsAndMonth" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfBaseRentToBePaidMonthly" xlink:href="abio-20240331.xsd#abio_PercentageOfBaseRentToBePaidMonthly"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="PercentageOfBaseRentToBePaidMonthly" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/EquityFinancingsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityFinancingsDetailsTable" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityFinancingsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EquityFinancingsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="EquityFinancingsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsTable" xlink:to="dei_LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JonesTradingInstitutionalServicesLLCMember" xlink:href="abio-20240331.xsd#abio_JonesTradingInstitutionalServicesLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="JonesTradingInstitutionalServicesLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_CapitalOnDemandSalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="CapitalOnDemandSalesAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewCapitalOnDemandSalesAgreementMember" xlink:href="abio-20240331.xsd#abio_NewCapitalOnDemandSalesAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="NewCapitalOnDemandSalesAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsTable" xlink:to="EquityFinancingsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockAuthorizedOfferingAmountUnderAgreementToSell" xlink:href="abio-20240331.xsd#abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsLineItems" xlink:to="CommonStockAuthorizedOfferingAmountUnderAgreementToSell" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SellingCommissionPerAdditionalSharesSoldPercentage" xlink:href="abio-20240331.xsd#abio_SellingCommissionPerAdditionalSharesSoldPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsLineItems" xlink:to="SellingCommissionPerAdditionalSharesSoldPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityFinancingsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/SharebasedCompensationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationDetailsTable" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SharebasedCompensationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="SharebasedCompensationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandAndTwentyEquityIncentivePlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndTwentyEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandAndTwentyEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandAndThirteenPlanMember" xlink:href="abio-20240331.xsd#abio_TwoThousandAndThirteenPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandAndThirteenPlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="IncentiveStockOptionMember" xlink:href="abio-20240331.xsd#abio_IncentiveStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="IncentiveStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalOwnerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrincipalOwnerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_PrincipalOwnerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsTable" xlink:to="SharebasedCompensationDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageHoldingForStockOptionsExercisePrice" xlink:href="abio-20240331.xsd#abio_PercentageHoldingForStockOptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="PercentageHoldingForStockOptionsExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseAggregateShares" xlink:href="abio-20240331.xsd#abio_PurchaseAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="PurchaseAggregateShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SharebasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitPlansDetailsTable" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EmployeeBenefitPlansDetailsLineItems" xlink:href="abio-20240331.xsd#abio_EmployeeBenefitPlansDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="EmployeeBenefitPlansDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetirementPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstThreePercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_FirstThreePercentPayContributionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="FirstThreePercentPayContributionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NextTwoPercentPayContributionMember" xlink:href="abio-20240331.xsd#abio_NextTwoPercentPayContributionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="NextTwoPercentPayContributionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsTable" xlink:to="EmployeeBenefitPlansDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeBenefitPlansDetailsLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsLineItems" xlink:href="abio-20240331.xsd#abio_IncomeTaxesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarliestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarliestTaxYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_EarliestTaxYearMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LatestTaxYearMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LatestTaxYearMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_LatestTaxYearMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="IncomeTaxesDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLossCarryforwardsExpirationYear" xlink:href="abio-20240331.xsd#abio_OperatingLossCarryforwardsExpirationYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="OperatingLossCarryforwardsExpirationYear" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLimitationsOnUse" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAndLiabilitiesValuationAllowance" xlink:href="abio-20240331.xsd#abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="DeferredTaxAssetsAndLiabilitiesValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" xlink:href="abio-20240331.xsd#abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_OpenTaxYear" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="abio-20240331.xsd#abio_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_PresidentMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_PresidentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_PresidentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefFinancialOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefFinancialOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefFinancialOfficerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThomasAKeuerAndCJeffreyDekkerMember" xlink:href="abio-20240331.xsd#abio_ThomasAKeuerAndCJeffreyDekkerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="ThomasAKeuerAndCJeffreyDekkerMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MergerAgreementMember" xlink:href="abio-20240331.xsd#abio_MergerAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="MergerAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FirstMergerMember" xlink:href="abio-20240331.xsd#abio_FirstMergerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="FirstMergerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeperationAgreementMember" xlink:href="abio-20240331.xsd#abio_SeperationAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SeperationAgreementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecondAmendmentOfCertainRetentionBonusLettersMember" xlink:href="abio-20240331.xsd#abio_SecondAmendmentOfCertainRetentionBonusLettersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SecondAmendmentOfCertainRetentionBonusLettersMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockAndPreFundedWarrantsMember" xlink:href="abio-20240331.xsd#abio_CommonStockAndPreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="CommonStockAndPreFundedWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="dei_LegalEntityAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ArcaBiopharmaIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="ArcaBiopharmaIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_OrukaTherapeuticsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="OrukaTherapeuticsIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_OwnershipAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" xlink:href="abio-20240331.xsd#abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ArcaBiopharmaIncAndOrukaTherapeuticsIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfConsecutiveTradingDays" xlink:href="abio-20240331.xsd#abio_NumberOfConsecutiveTradingDays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="NumberOfConsecutiveTradingDays" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThresholdAmountOfAdjustedExchangeRatio" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfAdjustedExchangeRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ThresholdAmountOfAdjustedExchangeRatio" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThresholdAmountOfDeclaredCashDividend" xlink:href="abio-20240331.xsd#abio_ThresholdAmountOfDeclaredCashDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ThresholdAmountOfDeclaredCashDividend" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionAgreementReceiptAmount" xlink:href="abio-20240331.xsd#abio_SubscriptionAgreementReceiptAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="SubscriptionAgreementReceiptAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfOtherPartyTerminationFee" xlink:href="abio-20240331.xsd#abio_PaymentOfOtherPartyTerminationFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="PaymentOfOtherPartyTerminationFee" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumPercentageOfOriginallyIssuedShares" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="MinimumPercentageOfOriginallyIssuedShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MinimumPercentageOfOriginallyIssuedOutstanding" xlink:href="abio-20240331.xsd#abio_MinimumPercentageOfOriginallyIssuedOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="MinimumPercentageOfOriginallyIssuedOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InitiallySpecifiedPercentageForBeneficialNumberOfShares" xlink:href="abio-20240331.xsd#abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="InitiallySpecifiedPercentageForBeneficialNumberOfShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExceptedNumberOfBoardMembers" xlink:href="abio-20240331.xsd#abio_ExceptedNumberOfBoardMembers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ExceptedNumberOfBoardMembers" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePurchasePrice" xlink:href="abio-20240331.xsd#abio_AggregatePurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="AggregatePurchasePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfMonthsBaseSalary" xlink:href="abio-20240331.xsd#abio_NumberOfMonthsBaseSalary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="NumberOfMonthsBaseSalary" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPayment" xlink:href="abio-20240331.xsd#abio_CashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="CashPayment" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseOfRetentionBonusToEachExecutive" xlink:href="abio-20240331.xsd#abio_IncreaseOfRetentionBonusToEachExecutive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="IncreaseOfRetentionBonusToEachExecutive" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RetentionBonuses" xlink:href="abio-20240331.xsd#abio_RetentionBonuses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="RetentionBonuses" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.arcabiopharma.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="abio-20240331.xsd#abio_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ex23-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  E %X# 2(  A$! Q$!_\0
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#O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex23-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex23-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  < (0# 2(  A$! Q$!_\0
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MT.FV]MIG[0WPA;6]8U&.*%9/L^BP^)[>XEN[EW64VUC9! TC)!$J)M7@H/\
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MMXEU+X@+^S5X/35K'58--M? ?[-VK:&?'-_8W:^)]7\3:SX;UM;K1$L8;SQ
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MP]H<TEO?:WXRO?A7I/A./4I-4O+"QLH?#^HZMK^L6<27-XP!_4S17\R6D_\
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EV]AI.B:)I-O::;I6FV5NB06EC8VT%M;Q*L<42* **Z&B@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P ( # 2(  A$! Q$!_\0
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ME_9$@6L3 _(/7G.#VP#BN>USX7:/XAO[C5O#6KBRO1*PD$+;HQ*#ST.4.?\
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MFE7-_+?LN_=/)E68,2<=2>,XZU2\%>-K'QIILEQ;(8+B%MLUNS;F3T.>X/\
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GD;S$(P0R\9K7^.UM/<1:)Y$$DN&FSL0MC[GI3_Y>(G5X=^OZG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex5-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  8 $ # 2(  A$! Q$!_\0
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C9]<@"J:F:X^!.KR/ \<LM[(YBP<J3*IQ1133_0EP2N_4_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ex8-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex8-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R 'X# 2(  A$! Q$!_\0
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M7P#X%B\&6,YDN/M5_=$&>;&!@=%'?')Y[UO:[KVG>'-+?4-3G$4"G XR6;L
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M5-FX+E-$XJK+G^7H<?J-HGPY^+NG-I1:+3M2V![<'@*[;67Z X8>E=1\;?\
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94DUG;R.0F6>)23\H[D445:^-F4DO9(__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex8-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex8-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  1 *P# 2(  A$! Q$!_\0
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MD=B2/RJKH&GQZOIJ:EJZ+=SW!9E64;DC7. %4\#I65I&DRW%CX@TJVF,MCN
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M)^(?^LL_\]Z**5+_ 'Q?UT'5_P!U?]=3K-"_Y =G_P!<Q7)_$/K:T45GA?\
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'_&OG^A__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tarca_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tarca_001.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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M3FSU5-C-S_,#M6HQLLGBJ9NJNGY*.6I@ DCF2DW!V/F*.LHRSHIBJJ;&XUP
M28,A>S>_=>ZNLZR_E5?R^>J:"&BP?Q;ZRW')&O[V0[-Q4O:U?5RE0'FF?L2H
MW)31,Y%]$$4,*']"+[]U[HRJ_&'XUHJHGQYZ-1$4*JKU-L%555%E55&  55
ML /I[]U[H'.QOY<?P3[5IJZGWA\5.EO+DDD2LRNUMF8W8&X)FD1XS.=R;"3;
M6>6J"OQ**@2*0MCZ5M[KW5,_RC_X3H; S%%D]Q_$CL_,;.SJ)4U4'6W:D_\
M>+:5=*L*?;8W"[TH*2'<NW(R\9]60AS9D>3F6)%]^Z]UK ][?'SN3XS[_P A
MUEWAL'.; W?0(M1'1Y:%'H<OCI&9(,QMW-4CU&'W%A:AT9%JJ*>>'R(\982(
MZ+[KW0->_=>ZW8?^$[&[I,Y\(][[:G;]W9'R!W?04J!W>V*S>S]@Y^!BKROX
MF;*UU:-**D9"@\N7/OW7NK[_ '[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=:H'_"CCY."LR_3_ ,2=O9!C#AXSW)V3!"S!#DJZ*OV]U[BIW1@#
M+28YLK6S0.""M722?4#W[KW5*_\ +8^1A^+GS2Z/[0KLB,=M*;=$.R.PY993
M%1#8>^Q_=K/5V0L09*;;GWT675;_ .?Q\9YM8^Z]U]&?W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW6NCW;NR?>_;G8>YII!*N0W5E8J-A<VQ6-G.*PT
M9))U&'$T,"$\ E;@ <#Y[/?+FB?G+W?YBYAG(/BWT\<9%:>#;M]/;\2<B*)
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MR'R594A(E9D! 9XQKL'M?:ILK<^\_%K79H:&.,=MQ?R'X(( <A6IW2TPH)7
M9T)[[F.1KP;)LE);QOB8YC@7\3R>I'DOK2OD"".]<Q5;FR;5TU/34-)3PK0X
MC$4,8BQV%Q4+R/2XVAB %HHO*S.[7EGE=Y9"TCLQA+GC=;KF?<FO)XT@AC7P
M[>",!8K:!22D,:@# J26/<[%G8EF)Z%FTVL>W0"%&+LQU.[&K.YI5F/SI@<
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M2P ]XA<[K/S'SC?75NAD>:=DC"@DLJ'PXP !4DJHZEC92FW;1#'(=(1 6)P
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M?NO=>]^Z]U[W[KW6LGCTN;_U:W^M]/?S4;>FJ3K/J8T7I=XR/D$_X $?F_\
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M%CS!O5I&+$/H,54^$%L&E"37APZ8=T;WZYZHBEIL3A\7)G0C 8O"4U)!4AB
M1_%<A'$S4JL"/U^24BUD(Y!+S'SAR%[9Q-!MUK";RG]C;HBM6F/&D [1PXZF
MI2BD=+-NVC?.9&#W$KB'^.0L1_M%)S^5!\^B2=E=K;SW[)+#D\@]'A]1,.!Q
MK24V."W!0U2AS+D)5T@ZIF<*UR@0&WO#[W#]S.;.=B\-_.8;3-+>(E8J>6O-
M9#\W) -=(6M.I8V+ES:]E :W37+YR-0M\Z>2CY#\R>B[9*+E^!_7_8_T'^Q]
MX^;G%VGH<6[8Z0&1BX<?ZX_U_KS_ +?W&V[1<>CFW:O2!R"?6X_UA[C7=HL'
MHWMVSU;%_+V&GIG=(_IVEF__ 'E-E>^J']W_ (]G-S_Z75Q_V@[=UCE[U_\
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M98)71@58@^Z]U]-3K/L#;W;'76Q.S]I5(J]L=A[/VYO7 5 96:3$;FQ%)F*
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M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:17\_KY._Z8?EMCND\%6K4;.^-V!?
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MM9D<ID:D*\=!CQD,C+55<[#13P*\C>E3[]U[JU7_ *!_/Y@?_*ETU_Z,IO\
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M:_\ 1E-_]C_OW7NO?] _G\P/_E2Z:_\ 1E-_]C_OW7NO?] _G\P/_E2Z:_\
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MJ%)9UYM 7-'MQ=M%)?\ )%[#O]HHU'Z8TNXT\C/8M29?.I574 $DCH<;=O\
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MQ??NO=6*?RJ/D6?C/\Y.EMXUU8:/:>[\S_HHWVS&T!VOV'+3X9*NK;R1Z:3
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MF[S0/-_BQ;305U4J&ID @Y%>!QCR'0CMD95[Z5^7^S_J^?5NO\O/_F2VY_\
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M)(TBWC!&A1#6^I6_O<E@HD (R:^EK52@U2S?^8X_<"-6NQ3?E"H'4 +N*J*
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M[!5'VDTZLY^//P=./J*+>'=4%//402156-V%%-%5TL<L;:XIMSU5.\E-6:7
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MY7+&HIZ6F"%654J-1$;,P]U[HZ/QLS_<79%=NGMS?M5+@=C[LBIJ;KKKQJ9
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M&&2E#65D@IF )6=A[]U[H\'<79%!U+UMNK?E<J2MA<<W\-I') R&:K'6CPU
M=/K$=3D9XQ(PN4BU/]%/OW7NJ#^J-B9SOGM_$;<J*RIEK-UYNLS&Z,TP\LU/
M0>2;+;BRTK,"GW4D?D\6LA9*F1$)NP]^Z]UL3;?P.(VMA,5MS T,.-PN$H*;
M&8RA@!$5-1TD2PPQ@DEG?2MV=B7=B68EB3[]U[JC'YI]L2]E]R93%4=07VUU
MX]5M/#QJ^J&;(T\X&Y<FHY775Y2'P!E)62GI(F'U/OW7NC:=9[DP7Q/^/&V9
M(* ;@[F[DAI-Q8':5/#+4Y/)56:BCBVU%64M*?OH\/B:">+5'Z99JV:6*.SL
MQ3W7NCH=%8?LW#==XU.W-P-G][9*JK<U7AXZ13@HLI(M5#MWST:K#5_PQF:[
M"Z1ES#$3#%&3[KW0P^_=>ZJ _F.[QJZO?6Q]AQRN,;A-LON6:);JDF4SV1K*
M!3*" )'I:'"J4/(45#@<EO?NO=#]\%=[["P?059#D=R[>PE9A=S9^OW,N4RM
M#C9*5*D4;4F2JQ624Y6DFQ\<4:3'4C-$R!M2E5]U[H"?DOWMFN]\#O/']>O5
MXWI+KZ"DJMU;KDBJJ9MY[@JZVGH-NX2GIV$3O0S9>IBDCIW ?Q1/5R@"*./W
M[KW1.>@.NHNU.WMD[+J^,77Y-JW-G5IO@\-33Y?*PAPRF-ZNCHF@1A^EY ??
MNO=6I9CN#>/<O<F!ZPZ!RS8G8^P,E0Y7LKL''TU+/C*B"@J?'_=O%&>"2CJ*
M"80M!$%N*V74RK]K3O))[KW1Z_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW31N
M#"4&YL#F]N92,RXS<&(R6$R,0L#+096CFH*R,$@B[T\[#D'Z^_=>ZHZWA\+_
M )!;"W&TFU\#4;JH:#(+58+=&ULA1051--4+-05;8^6O@RV*R,)".0%=(Y ?
M'*X75[]U[H<<-\;_ );]UK2T/=&_LQMC:$3J\U!F,U#EZRK".K+)'MK!UBXV
M>I5E.F2NEBDB_4H8&Q]U[JP_J+I'K_I/!?P;9>*\=14I%_&-P5Y2ISV<FB%E
MER%<(XP(4))CIX5BIXB250,S%O=>Z%SW[KW7O?NO=>]^Z]U47\P?C;W)O'N;
M*[VVAMFLW;@-R4&"2D;&U%#Y<//B\118FIQ]935-53SQ))/1M4K*%,)$]M6I
M6 ]U[I??'GX,5>*?';B[PFAKXJ"K?)XGK2GK/XAAH,A+%!&]?N2:*1L?5U!%
M-&&IJ?R0RK%&)99$O"/=>ZLT55151%5$10J(H"JJJ+*JJ+!54"P ^GOW7NN7
MOW7NO>_=>ZK&WI\7NS>F^W*?N?XZ8S$[BHHZW(UK[%K9H*.3%IEJ2HI,IC:>
M*HK<=!D<)+%5R&!8IXZFF.A51] <^Z]TS=B;1^9/R=DH]O;AVCB^K=B0544]
M10U>5AI**HJ(F4I59=(JS)9_,R4QU-#&E-'2JP!(#A7]^Z]T;KX_?%_9'0]$
MU;2L=Q[WK:8T^4W;6TZ0R)#)H:7'X2C#S+BL<SQ@L-<DTQ'[DA4*B>Z]T9CW
M[KW7O?NO=$S^=78']S>C,CA::;QY3?\ DJ3:\ 4_NKC%)R><F N 87HJ,4K_
M %/^5BP_(]U[JJSX^]!YCOW,;KPV*R,.';;^UYLM!D*R.1Z!\S+5T]-B,56F
M%)9X8,B#.6D17:-(68*Y 1O=>ZL0I>P_G1B,)3;(BZ6P&0W%04D.+AWS+DJ"
M>@JX:=!319656W'3XILA+"@D+22QH9#=J<"\?OW7NL?5/PKR>1W7+V?\C]P1
M[XW565B9-MM13O6XR2K14,#[BKWC@3(Q4H543'TT:4,:Q*A>:$F(>Z]U8BJJ
MBJB*J(BA410%55465546"JH%@!]/?NO=<O?NO=>]^Z]U48OP2[>W3VM6[EW[
MFMEM@,OO"HW%N.MH<IE*JKR=%7Y:7(Y"FQM#)B:=TJ*F.0QJ)I(DB#7#-IL?
M=>ZL?[JV'D.Q^I]Z[#P=93XO)9_"&BQU1/Y(Z-)H*BGJX:6H-.IDAHZO[;P2
M,JMHCD)TL!I/NO=4X[-^(WR@H]Y42XC;E?LG*8NK#Q;P;<=!CJ+%%E9#64N6
MPV0JZVH4Q2%2*1)I"K%2OU'OW7NK6^@_COMOI#&UU7]Y+NC?NX29]T[UR2%J
M^NEFD%1/1T)F>>>EQS5=Y7U2/-4R^N9V(14]U[HP_OW7NO>_=>Z+A\J>H,IW
M3U)7[8P!@;<F+RN/W+M^"IECIX*S(X^.KHY:)ZF5DBIGJL9DJA(W<A!*5U%5
M)8>Z]U5#M+X3_(+<V62@KMHQ[2H4G,59FMQY/'14=,J,H=H::@JJ[(Y E22A
M@A>)B+%U'/OW7NK7^C_C3LKH[;U?1X623*;MS>/:BSF\ZV!%KIPZL138VF21
MEQ>*BF(<0)(7D95,LCLJ%?=>ZJ7;X7?(;^]$VVHMDF2**MDIDW(V3QD6VY:5
M'(3)I7/5>;[66&T@C\1J@#I,7D!3W[KW5JOQW^,^%Z4I:C.YG(?WO[,S5.D6
M:W75"684<&B,-B,$U86JHZ%3&HDGDTSU6A2P1 D2>Z]T:'W[KW7O?NO=$&^8
MWQZ[:[QSFRY]EU.W)=N[>QE= ^/RF3GQU;!F,I6*]?D"/LIJ:>CDH:*D1=+F
M571_18W/NO=#?\8^CVZ)ZXCVYD9\?7;HRV1J<UN?(XTSR4<M9(%IZ*CI)ZJ&
MGJ9*3'T$"*-4<8,K2.%&LW]U[HQ7OW7NO>_=>Z][]U[KWOW7NJ@MS?!/O;?/
M86=W)N;=6P_%N/<5=E,EF8<CG*B9*:LJWFO1XJ7#JX-/3,(X:=IU1 JIY HU
M>_=>ZM@VOMS%[/VW@MJX2#[?$;=Q-!AL=$;%UI,=31TL+2N /+/(L>J1SR[D
ML>2??NO=%6^7W2/:'>.%VC@MBYC;M'A\1D:_*9S&9NMKZ!J_(-3PTV'JXIJ7
M'9"*5,?3R5:E&\9!GN-7]GW7NH/Q(^+V2Z(3<>X-X5N&R6\=P0TV,IQAFJ*F
MCPV$IY6J9J>.NJZ.AGFJ<I5B)YP(Q&HIHPI8W/OW7NCJ>_=>ZH5W'\._D/)O
MG+XN'953E8ZO-UKP[F3)XE,+6TU35RRKE9:Z>MB,"2Q/Y'CD19U)*^/793[K
MW5D_QS^*6.ZD>DW?O;*#>G9BX^+'TV1EEJ*O$[3Q\5.M+'C=M_?J*EWCIAX?
MNG2)E@_:BCB0OY/=>Z.'[]U[KWOW7NJU?F_\;=_=C[FV_P!B=>8A]QS08&/;
MF?PM-4TT-?"M#75E9CLI1PUD\(K(YER4D,R1MKC\2,$8,[+[KW0 ]1_ ;LO=
M5?35W9ACZ_VU'*KU%(*FBR.Z<C"+,8J*DHY:NAQJRV*&6JD$D9]0@D'OW7NC
MQ=]_'?[_ ..LO5G36&HZ!L+D\5FZ/"">*"7<#4+R??)4Y*MD19\O5^83>:HD
M'D>%4+*NFWNO=5[]5_"CO3<NX*<YS'U/66%A9X\AN#(U4 R8I:B&2GJZ?$XO
M'UIK:R>HI96C(D:"G9'8-)]5/NO=7%]8=7[0ZBVG0[.V9C_M,=2WFJJN<QRY
M/,9"156HRN7JTCB^ZKJC0 2%6.-%6.-4C54'NO="'[]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ4?Y@?80W/V
MYCMF4D_EQW7N$2FG16+(NX,_X<GE&%K)=,<E#$P%RKQL";\#W7NCD_ 3KS^Z
M?34N[*J+1D^Q<O-E0631(N"PSSXG#0R7&I@]0M74H;V,=4MA^3[KW1Y??NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW03=L]T[!Z;V]79O=N;HHZR&FEDQ
MFW(*J!\_G:L)>GH\=C@S5!$TK*KSLH@@#:I&5>??NO=:[6[MRY#>>Z=Q;MRS
M:LEN7-Y/-U@ULZQSY*LEJWAB+\B"G\NB-> J*   +>_=>ZV5MD8[!X?9NU<1
MMBIIJW;N+V]A\=A*RCEBGIJO&4-!!34=3#-"SQ3+/!$&U!CJ)O<^_=>Z5'OW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZQ3V\,VKRZ?%)?P:_-;0;^'Q_N>6WZ=
M/-_IS[]U[K6FSG\&_C68_P"++_Q=,A_Q?/[^?QK_ (%S?\7C_JZ?\K'_ #=U
M>_=>Z1V3^V^X3[7^'>/PKJ_AG\7^WUZY+Z_XS_E7FTVOI_;TVMSJ]^Z]U8Y_
M+V\7]ZJ_7_I&U_P;+^'3]Y_HRU_<X_5Y?M_\G_O#XM7C^X_;TZ]/[FCW[KW5
MN?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
*OW7NO>_=>Z__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>timage_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_001.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
MA  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$" 0(" @$" @(" @(" @(" @(" @("
M @,# P," P,# P,# P,# P,# P,# 0$! 0(! @," @,# P,# P,# P,# P,#
M P,# P,# P0$! 0# P,$! 0$! ,$! 0$! 0$! 0$! 0$! 0$! 0$! 3_P  1
M" (@!Y<# 1$  A$! Q$!_\0!H@    8" P$             !P@&!00) PH"
M 0 + 0  !@,! 0$            &!00#!P(( 0D "@L0  (! P0! P," P,#
M @8)=0$" P01!1(&(0<3(@ (,11!,B,5"5%"%F$D,Q=2<8$88I$E0Z&Q\"8T
M<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D@W23A&6CL\/3XRDX
M9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9FJ2EIJ>HJ:JTM;:W
MN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$  @$# @0$ P4$! 0&
M!@5M 0(#$00A$@4Q!@ B$T%1!S)A%'$(0H$CD152H6(6,PFQ),'10W+P%^&"
M-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58WA(6CL\/3X_,I&I2D
MM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'U^?W2%AH>(B8J+C(
MV.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H # ,!  (1 Q$ /P!#
M=28OK3)[71<O74]/N!=S[W5ONG-@_P#'<F+DZ1]%<<7-[Z6_U/O(_;S(MI%0
MR.N@=K$%!CB*,#7_ #GJ!-SCMC=3550WB'N!IY_,'HQ5%L2KJL16-MK=V-2F
MA$<<^.@"$>.>\?FLS->)24#:%9DUJV@*&M22=1Q6A_TK?]!4_GTRL1=>R04]
M*C_H#H"=R57<6Q:UY-OFKK(XU;70T;-(R+'&.=*++'-&>-) !7U>D<#V96]O
M!. &(%?DW^1NB6]N;FRR.Z@X#3G_ (QTDL!\A<34K4T6^X,AA\M!'(IJ:=&D
M824U@8YE(22.9#_2( \ZA<6*Z3E^@J@U#US_ (#)7HOM>:M3%9NSC@_[$9Z?
M\MW+MQ:&.OQ&[<;7)(PB-'7024]5$R?K:6-AK9;BP=38FRW)('LOBV2350J:
M?+A_U<Z7'?XFX-_D_P ,?6/%]BY K0Y&ES>%J8F:*98:AU@U!E*LH(5KZU96
MOJ])7BW(]O-M(3B/Y'_(_6AO#-_H@_:!_A3I<97=M14093<5-N2BI,11B&2J
M@DK%>6-;V( $8U1D675J5K_B]_;7[O6M-/\ (_\ 0?2T;H=.JHH,UU+_ - ]
M-LW8#5NW9*_:^^]OMD*>9#!CLA5K(TJD$,JHPU1R!U;2MK/SR+>VUV[OHPH*
M^A_R.>F&W9I%U1L/Y?\ 0'0:4^Z^W-UL\(K:N-'>0)-3QO2\ L+H(SJ=5*$#
MTV_))Y]KVVZV@RPS_MO^@^D<=]>3G2,_.J_] ]"GMCJ??NZ)?%7Y'<%5#%I+
M14CR*+@ "0EF6+TWYL"18FP.DEN6>VMQ@ 8KP8_X&Z,(+29CJ=CZ<5^WR3H:
M:+K&@PJJU;)B<?30+YYI:^OCK*B0Q.Q<NI=D5K?75IY/Z/I[*FN5E^%<'@:-
M_E?HW$*P?$P'YK_T!U#W#VMU_LRB,>,BILUD.$C2F"R1M)_:;4MET\FYLQ_K
MR"OMV/:Y+C.G SQ]?^;G3%YO$5LM 03Y</3_ )I] %)V[NS/3&LQB8W"R+4:
M7@@@5E\-R-*O(%8ZK@?U%KC\>S./:D7CQ^QO^@^B+]]2RK447/'4G[/AZ:,W
MOW>[QFG&4:1(3H,:3 %G!(TH556O^D"YX)/-C8J(]KC!J1C[#_T'TGDW:8BA
M89^:_P#0'0<5FZM[8D?=U.9PJ"!UFF6:K2JE2Y'!1PT;D7/!0G\-]+^S"/:X
MGX#^3?\ 0?15-NT\52'&/FO_ $!T[0_)KL&DPR84YK&)3SLL2UN/Q$$3HCKR
M(G6,*/43ZGOI4#3;Z>Z'EJ)CJ&,^A_Z#ZV>;9XDH2/V@_P#/G3(N\=Q5;M5/
MGYC4S->$UV4DJ0K5!N0J,S!>#Q] +_BP]J5VE%XK_(_]!]>7=Y917Q!7Y4_Z
M ZQ4O:.8@/AK<S%]N8I6,P,<KDJ240,OJ"LZE;$?0 GTEF]U.T1OP6OY-_E?
MI.>8V'G_ (/^@.DIFNW)WD,-9D$>&5)D:6!A$0CC2;E2]SI-KI:]SQ_1;;[(
M?)1^P_\ 0?17<<TZ3EP,^O\ USZ#.K[:V]2*3'-#3+>0I,(E8.%NH/Y+<#^E
M@?K];$WCY>)R5&?D?^@^B.XYP@!/<":Y[*_S-.@YR_?N/58UH(ZNH!)!>10-
M)?3I.DL@9ENU^?\ 6%A8F4'*X?+ ?L_Z'Z)+OGM8_P"SSCT _P"?3_AZ1E3W
MCF:B6)12TXIE=E)-0[-I%[@ FRAA8G@W^A' N8_U4C4?A^RA_P"@^B-N?Y6/
M C\Q_D3KN;?M5F(TG>JI*.[S6IX:E@]FTMI<:5-R" "& (8^HV/MMMI6UX(,
M^A(_P$_Y.K?UJEOA0FGIJJ?^.J.FN:H>=;U6<A@0M$O^3H510FIN+J6&KBXN
M01Z@UO=4A$; !:5QEF_S=)'W"1_CEH/DA/\ (]++8U)M.GRM!6;AW#)6T)\8
M>!XQ%J;45&BTNLCDGEC8A?3;4I9OXI%PJC_>CT>;3=0@UDEU#/:4(_F >'\^
MEUN6MZD6:"/ 3T$L@U"H6:KE( F-D'EU*A)#"X'(_-F]EMM;7,AHR_\ &ST;
MWVYV*=JLN?\ 3T_P=!K/D\%$T_A? ^/RJ(0<E-%("H)"Z-6FQ!75JY%B/\"=
M16$H&0!_MR>B%]SMQ4@KY^9ZFX[<&WB(&JXL6CR,L4@BJI5 6[$2:6<L20..
M=)X')]TDVUSP_P"/-_FZO;;U;BE=/E_%_FZ5(W)U[1B.-9,&URT++4S5(:,4
MRM'^DEI.2& L"#8,2?2P+QMLYX ?[TW1O^^;3ST?GK_S=<J3?^RD]4<VU$!F
M72U5C:B9@H]6I5-Q];@ \D%>0&!]U?;9QP_X^W5XN8+1JT8?[R/\)Z5;]J]?
MT%+]RN2Q4=48T=5QN(,OIE0FVB.'0NDZT*%A8?@"0:B_]T74Q(I_QINEDO-M
MC  -53BM$!S3Y#I*9'O/:4,K&D.4J5%FD-)CTIP3_J%\GA;@_P"TC^GU!LM@
MY8G/Q:?SR?VEQT53<\6JGMJ?D(_ETGZ?O%Y9B(=LY*> ^5SKR(Y2P"6 B(L6
MU ^MOH+']7M9)RV!\>BM/]7X^DD?/0=NV(E?(E%Z@2=@Y;(5<:X_8U#&5\QA
MDKHIJL1*TG!)_;!MPOCL 02>#R&QL<,>"5_8W_0?33<V27#"D/KDT6@_VI_V
M>GBGWAO:*,/4-@\8PG+0)C*,,J*MK(59"OI 51?4Q )+<GVG;:+90:T/^U8?
MX7Z/+3?;H4K05X!3Z>NI3Z_+KO*5^X<M-(:S*Y.5)GF%1$DRT"$W)T:4(7QW
MT@!CP>!;CVTMO;Q#X%'Y$_\ /_1@]]/*<MJ'IKT_X$_*G#J%3;9Q$*+45E/#
M+]=,8F:5M0^NMM2D@6L+<?6X((LED.D]H'VY7_ Q_P '2N*$.*OGU!=F_EH'
M^'J>$V_&8TBQH<HY+:8K*P3ZW8W()-B2/P;< <(WUO@T(\\L?Y8_P]&44L,8
MH%6OKGK%4U%"S2"GAI*(R$LNAD++JO:S&Y_I]/;7@C^%?V'_ *V=*DF#9 7'
MH37^?^;I.5591@NJR3L3Y%+*=((N/]8?C\+<6]U$-?PK^P_]!];.X:>)/\O^
M@.FNLWI5H!30X^&..*-472%L38:;E1J_%SSS?F_OPLE/"G^\G_H+I_\ >[>H
M^RH_Z Z3-1N&I9FJ\G448)5=*U-?X5&JX'I3C\<7_I[M]!3\(_8?^@^F?WBT
M?Q.!\JK_ - ])NJWC@:0R,9L:\\@4ZX:-JOFWY<JP/U^EQ_C[V-K!SC]A_Z#
MZHV^*M<U_-?^@.D-D]^5<[O'32NT:DJ"46,$ \>G5P!^".1[L-M1>-/V'_H/
MIO\ >\LOPDA?+S_P1](ZOW!7S?JF!(+,SJQ)((  _4/I;_8WY][-NB_A7]A_
MZ"Z51R32TK(PK_1'_0(Z3<M?,R^M]5S<FQ/_ %TM[;TJ@P!^S_H;I<EL7R[5
M'YC_ "],U5-)*!=E #G]2D_[;UGVQ(?2G[/]GI:(%3@17YU/^7IK>%G&I]#+
M?_4$?3_D/VRRU\OY'_/T]H#88K3[//\ ;U%>G07811V%A^EO^OEO;1C'I_A_
MS].K'&,8)^RG^7J!*JV)"1Z@./VS_L/]V6]LD#T_E_L]*4C5:4'^#_/U <!O
MUK&!:Q!0_P"]!_=#3_5_Q?2@2,/^*_V>FYECC/,<)!^EXV/T_P"GGMNGR'^K
M\^GR' R0/R_V>NM47_'*#_J4_P#U\]^I\A^S_9ZU5O4?L/7M47_'*#_J4_\
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M_P"'W'_.3_8Z]_PS#EO^]I?\U7_TJ67_ .MWOW]9A_RB6?\ S@_Z&Z]^Y/\
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M_P#.#_H;KW[D_P"'W'_.3_8Z]_PS#EO^]I?\U7_TJ67_ .MWOW]9A_RB6?\
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M_P#K=[]_68?\HEG_ ,X/^ANO?N3_ (?<?\Y/]CKW_#,.6_[VE_S5?_2I9?\
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M_P"'W'_.3_8Z]_PS#EO^]I?\U7_TJ67_ .MWOW]9A_RB6?\ S@_Z&Z]^Y/\
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M_P#.#_H;KW[D_P"'W'_.3_8Z]_PS#EO^]I?\U7_TJ67_ .MWOW]9A_RB6?\
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M_P#K=[]_68?\HEG_ ,X/^ANO?N3_ (?<?\Y/]CKW_#,.6_[VE_S5?_2I9?\
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M_P"'W'_.3_8Z]_PS#EO^]I?\U7_TJ67_ .MWOW]9A_RB6?\ S@_Z&Z]^Y/\
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M_P#.#_H;KW[D_P"'W'_.3_8Z]_PS#EO^]I?\U7_TJ67_ .MWOW]9A_RB6?\
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M_P#K=[]_68?\HEG_ ,X/^ANO?N3_ (?<?\Y/]CKW_#,.6_[VE_S5?_2I9?\
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M_P"'W'_.3_8Z]_PS#EO^]I?\U7_TJ67_ .MWOW]9A_RB6?\ S@_Z&Z]^Y/\
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MKA?CV<;1NL>X>/KM;0>%;R2K2$99*4!J3C.:4/SZ+MPV]K3PM,TYURI&:R'
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MS>A^(H>K+M"0$!&-!Y9Z'? [PZUZZV=)%D&JLQDHR*9*VKQ[B&SMR0OU#@<
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M$,*O\NF7Y5O9R?$9CQ&=1K^0_P !Z:DW1&!H:ED*Z52RU ?D7Y%U'YYM]/\
M>_;XW%%X&GRJ#_EZ)[CDJX#X7!]:KY_,#K#/N57)\<,G/!+NI^IO] IX_H+_
M /%/>FWFN#D=*/ZFS@9C(-,YK^S%>H?]X9T6RK&&XYTL3_7D$V]U.Z*!Q_U?
MSZO'R9--DHWV4'V?Y.L!SU0VHZ8$+_JTTX-[&_!))!N/=!O /'_!T9CD>4#
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MJH1_7@$W_/\ 3VT&M9<#!/KCJT?[[M:YU 4S354?L!ZZ:GI[DQV((_424/\
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MWET1AWJ*U)K_ (!Z^O[.NJ>NJ4/[2E06%K'3<CG_ 'C_ %_:F"_=\*//[/\
M#TDN>7UMT)F)4YX L/*G#^9].E'23QUA,DU/(2H%S*"RZG%[E@1;\V_XW[7H
MP(J1GH(31BV- 016G$AL'B*5_/J8M?DZ:XH*:B@:[ ^.B=BP:W)9B0PX^A(
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M1^6)6Z_@FYY^AL+#;AY*OYC/^#I)-S7J_M)IF'$!3@@_[;J6_7N6^R%0M9@
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MM^@?A0;&W^M86]L-,3Z=*4VH5JQS\J_\7U!FJW)]5KD<D#VRTG2L;=$M./\
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M4G>HI7]-F5A3@:@UIC (XX(]TV*/;;^!4%8I9$&DFM*.H89X@@CCZD=73?S
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MBJ3C$#2?;ZD\ALIL+O3[$(=T&W:R1XZ0Z].>YE6M*_/A7\^F+;FPS["=Z\(
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MIZ52\L]34U#QPP0QJ"6=W55 N2![LB&0A5!).  *DG\NJ22+$I9B  *DDT
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MTBC) ],FG02YI]X+K8]XEVBUV]KJ1-&GPY',DFJ!)C1$A<]H8UH3@$X\D/\
M\.]_S-_^]/W>G_H!]@?_ &(^W_ZC;7_T=(/VP_\ 6[I)_KM;_P#],_>?LN/^
MV3K8WV[7U^4V_@LGE,>^)R>1PV,K\CBI0RM33UD"234[!PKAH9&9#J4&XY /
MN+G 4D#(J<^O4_H2R@D4) J/3HF_S[^=G6GP!Z53M??N)RF[,QGLTFU.O]AX
M2=*.HRV3E@EJ2DE5(LB4-!300O)4U+12>,:$2*6:6*)SWESEZ;F2X\"(A:#4
M[MP500*T\R20 !_(5("7.O.=KR-9_5W(9JL(XXT'<[D$TJ<  *22> &*L0#5
M#3?SQ>^NI<WUIG_F3\"-\=%='=KU%-'M_L:ERF0K)X(:E8YC4?95N*IEKC%3
M2K.],)*6J,(:2&*4@1D7_P!0+>^61;"\2>6/)CTA0:8P=1'' .5K2I%:]1PW
MO!>;.T,F\[7-:6TY 682>(5)H>Y/#0B@))4T>@.E&((&QEC<E09G'8_+XJK@
MR&+RM%2Y+&U]+()8IZ>NC66&:-QPT<D;*RD<$$'W&3*5-#@C!ZG56#@$9!R#
M\NIOO76^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JMO^:'\
M[L]_+YZ'V;W#M[KO$=EUNZ>W,)UK+A,UGIMO10Q97#9W*-5+-!3U+O(CXA(P
MA0 B1FU74 BGE'EP<SW+0&0QZ8S)J"ZJT9%I34O\7\NH_P#<?G@\@V,=XL(G
MUSK#H,GATU1R/6NA_P#?=*4\^..JJ?\ A\'YW46Q(^V\I_*W[#CZF_N]1[P;
ML)J?=^.PTF'R-*:V#+19B7:LE <7)2:9Q6!WIS$ROY-+HQ&'^M[MYE\ ;C'X
MFHKHI&6U Z=-/&KJKC3QKY8ZC8>\^\"W^K.QS^ %$GBZY0GAE2X<,;6A32*Z
MQ50*$G(K<O\  SYW]9?/CI"?MS8&)R>U<OM[+3[9W_L#-U*UE3B,G3P1U(B2
MKCCBCKZ&IIY8Y*:J2&,2+K1XH9XIH8P+S%R]-RW<>!*0U0&1UX,I)%:<0000
M0?YBA,M<E\YVO/%E]9;!ETL8Y(W^*-P :5&""&!##!!S1@5!8_Y4?\SG<W\Q
MM>^?[R=2X+JYNFSU?]H<)NFHW(*X=A_WBU^03T=+X#2_P-=.DOK\QN%T#4;\
MX\HKRKX-)3)XOB<4TZ=&C^DU:Z_EPZ#/ME[E-[A_4ZK<0?3^#PE,FOQ?%_X6
ME*>'\ZU\J9G_ ,P/^91NGX7=_?&'IG!]68#?=%\@LC38^NSN6W'48:7&>?-4
M&*+Q0PTTR5-DK?)9I(^4TWLUPSR[RNN^VUS<&0I].NK2%U:^UVI6HI\/SX]+
M>=.?6Y2OK"S$(E^ME\/69"GA_J1)6FAM7]I6E5X<<XMP]@_J2.M=;Y'?S[,+
MT1\V<W\;:;JC ;BZJV3V-M78&_>V:C>,]#4TGF>DCW'504$5%/%*,%+-5Q^-
MIU,TE*ZEHPX829M7MR^Y;?\ 6>(0[([I$$KJI72*ZA353T."./4%\P^]D.P[
MU^Z_ #1I+%'+<--H":].LZ=#5$8;-6%2",<>MB6&:*HBBG@ECG@GC2:&:%Q(
MCI( RLK*2&5@000;$<CW&9%.IT!KU0EW[_.$[@K_ ))[]^+7P+^*&6^3&]>J
M,CE,-V#NVMK*E<;!6X244U='!3T*Q^.CHJWR4KUE7DJ5):E'C@B=/'-+(>W\
ME0K:)>;C<BW20 QKIU.0>!_,4( !P021PZAO=_=&YDW&7;-EL7O9("1,_B+'
M$C"F <C!JIU%#J4@ TKU+^+/\Y#>>Y/DOA/B#\V_C=7_ !>[AW;5XS$;-R3Y
M&I%!6Y+.$KCJ&:CR$*34Z964+#054%?60U52Z4X"$AVUNW(Z16AOMOG%S$M2
MX"T90.)P36G%@0"!G(X>Y?\ =:2?<AM&\6C6%P^GPBTFM)&:M!72H&HX0@L&
M:J5#4!&+^:W_ #/-T?RY9>B(MM]2X#M#_3#'V;)6MG-T5&W/L?[@G;XC$0@I
M*KS?<_QJ35JTZ?$MKZC9)R=R@O-7C5E,?A>'P35JUZ_Z2TIH_GTN]S?<IO;W
MZ;3;B?ZCQN,ICT^%X7_"WK7Q/E2GG7HF?_#O?\S?_O3]WI_Z ?8'_P!B/L\_
MJ-M?_1T@_;#_ -;N@I_KM;__ -,_>?LN/^V3JZ/X7=W=N?(7H3;_ &AW?T?N
M#X[]@9;,[FH*_J_=&/R6+K*2##UDE/2U$D&6HL?7*M9$@E372J"K H64AB ]
M\L(=LN6A@E6=%"TD73I:J@FFEF&":<?+J7N5-XN-^L8[JZMGM)'+ZH)-6M-+
MLHKK2,]P 8548/GQZ'3L[L?:74'7>]^T]^Y-</LSKW:^:W?N;),OD,5'@:=Z
MB8HEP99F1"L<8.J20JBW9@/9?;6SWDBQ1BK.P51ZEC0='-[>1[="]Q,P6.-&
M=V/!54$D_D!UKI57\^KON?:^0^0V!_E\;SK/AYC-VQ[:J>V*_=E322Z&K(J+
MRO4QXB;%0U#5$\,(C$LM.*MA1?>F4ZA)H]NK<2"T:]07175X02HK0M2NH'@*
M\ :9TTZ@EO>N[: [DFU3';UD"&Y:95:A94)":"#W'2*,5U=I<&M-@KH;NW8?
MR/Z>Z_[QZRKJC(;'[(V_!G\'+6P"FJ(KN\%32542O(L590U<,]-4(LCJLT3J
MKNH#&-]PL9-LF>WE%'1BK#RQZ?(\1\NIOVG=(=[MHKNW.J.5 Z&E#0^H\B.!
M'D<="Y[1]&/7O?NO=>]^Z]U[W[KW52WPN_F2[F^5/S&^5_Q>RW5F"V?B_CAE
M]_XO';NQVY*C*U&4&S-TMMY'GI9:6&.F,\:^9@LTFEO0"1ZO8PW[E9=FLK:[
M$A<W"JVG331JC#TKJ->-. ZC;E#G]N:-RO\ ;S (Q92-&'$A?Q-,KQUIH73\
M%:5/&GET7OI_^=KB=V?S!-[?"WM/K+ =>;<QW</9O26R>T*?=\M::K,[0S55
MBL1%D*2>DABIUSC4AA0QSN4K)J>*S1NTB&M_R ]OMB;A%(9"8XY7CT4THZ!B
M00QKIKG Q4^70>V?WBBOM]EV:XA6$+/-;QS&74))8Y"B@J44+XE#3N/=114G
MHVW\TCY^[@_EZ=/]?=G;=ZWPW9E5O7LF/8<^)S6X)]NQP1R8O(9#[A)8*:I9
MW#42IH* 6<F]Q8DO*/+0YGN'A,ACTQEZA=5:,JTIJ7^+H4>Y'/+<@V<=VL(G
MUS"'29/#I5)'K70_\%*4\^..A1^9?R[S'Q9^$FZOECB]E8W>&8V[@>K,O'LV
MOS$N)II6[#S.$Q<J-5QPS2JM,F5>12(27,:J;!B0CV#91O=\EF7*!BXU4U4T
M(S<*CCIIQZ-.<N:#RGM,NYB,2F,1'PRV@'Q)8X_BTM2FNO UI3JFC9/\[[YZ
M=B[0H^QMA_RN.P=]]=UL5;54>]MG46\,]B:J+$U4E%5FDRE+MBHHIS354,\,
MICDD\4D4JR*#%(%'5Q[>[?:2>%+N,:.* HPC5A4:A4&4$5&17C4>HZB2Q]Y]
MXW.'ZBWV2>6(@D21O*R, V@Z6%L0Q#5!"U(H:C!I:)_+L_FA=3?S L=NG!8W
M;.6ZH[IV!3PUF].I]Q9%,K(*6200-D,77+#2-7T4-4RP5&NBIYZ:9HUF@5)H
M))0CS-RE-RT59F62*3X)5X'SH14T-,C)!' FAI)'(GN):\\I(J(\%Q#0302?
M$I.*J:#4H8%34*P([E6JU1^W/YDNYLY_--W?_+PDZLP5/MW;.(?*1=FIN2H>
MME*[0H-S:&QQI1 H\M:8+BI/I0/:YTAV;E98MH3=/$)+MI\/3@?J.E=6K^C7
MAY])[/G]KKF.;8/  $48D\?Q"2U8HI*:- I_:4KJ/"OGAR_F(_S4NN?@MD=J
M=8X/9&8[O^1/8%/25.U.J-MUGV?AARD[4E%49*HB@K*E'KZM6BHZ2GHIJBJ9
M' $2Z)&URSRA-S$&E+K%!'77*W# J0,@&@R22 !Q/5N>_<BVY*,< C>XNIJ>
M%;1_$:G2I:@8@,W:M%9F-=*FAI77FOYVOS4^.V2VEN'YH_R\MP=;=3[QR*4%
M%N#$#+;9K8S*KS>&(YA)Z"JR<=/'+(*">HQ\TJH[:HD5F E@Y!L=V#)87RR2
M(*E67!S2N#6G](!AP]>@/>^[^Z<MF.3>-ID@@D-!(DH=@:$@4*A=5!\+,A(!
M(X'K8QZQ[)V9W%UYLSM/KS,P[@V1O_;N+W3MC,0*8Q-29:)98RR, \4J7*21
MN \<BM&X#*0(RNK9[.1HI!I=&*L#Y$&AZG6RO8MQA2XA8/'(JNC#@RL*@_L/
M53W\U#^;(O\ +QW%U1L?:O6V%[4WMO\ PV>W3G,7F-S2[=CQ>+H)HJ2AG)@I
MJJ25\A5"O5 555%*Y))8#V,N3^3#S2)':0Q+&5 .G5J8U-.*\ ,Y\QU&?N7[
MGK[?&!%A\>2;6VGQ/#"(FD5)TN:DM0"E,'.,GP^,?R<H/E!\3-@_);9>%ADK
MMZ=>U>?GV;05KY3[;.X1)Z?)819A%'+,:;+TM13(_P!NCRJ%D$8U@>PYN^UM
MM%Y):N3V/IU$4JO$-2II52#Q\^/0VY;W].9-NAW"(#]6(.4#:M+THR5H*E6!
M4X&1P'5$787\\GYW=2;<DWAVM_*_WYUEM**LI<?+NGL+'[QV7CEJ*XD00-79
M+;--3":8JP1#+J<@Z0;>Y%MO;RPO7\.'<8Y&-2%01LQIQPLQ/4)7WO5N^UQF
M:YV2XAC% 7E::- 2:"K/:@"I-!G)Z&?X]_S</G?W;O\ Z2QTW\LSLC&=2]L;
MSZYQM9W%B<)N_,86BP&]Z^CAGW!'DUVV,7+0T5!4O5-*U8L 2,F21%#$(-RY
M)V^PBE;]X1&2-9#X1\-7+H#V4\6M213A7T!Z.-D]U-XW>>W0[+<+#.\(^H!E
M>)8IBOZFH6^DJJMJ/< *4)&:&X^2'\R7<W17\Q'XZ?"&@ZLP6X<'WEB.OLI7
M;_J]R5%!5X\[TS6:Q4B14*4LD,X@3$K(I:H349"I "@DCVWE9;_:Y]Q,A4PL
MR^'IJ&HJ&NK4*?'Z'AT+-YY_;:>8+79! &%S&LGC>(04J9A31H-?[+CJ''Y9
M%C^8=_,>ZA_E[=>8S.[PH*K?/9>\UKX^M^JL/D$QE1D3C= GK*ZL>.H&,Q-.
MTD:R5!III'D81P03,)/&EY9Y7GYFF*1]J+0R2$5"@^@Q5C3 J/F0,]&'/?/M
MIR':B:>KRO40PJ0&D84K4T.E!4:FH:5% 20#5!D/YQ7\R[:>SE[NWK_+)RF.
MZ+BI),Q79>:FW-@IX<?&6<UE16ST=0:*B\*EQ5SX5:=D*S!C&RW%R<D;5/+]
M-'N"F4D  *I!)\A1P"?D&K7''J.IO=/F"TMC?2[)(MN 68F5E=5!-693%K51
M2NHH!3NKISU=A\*?FQTY\ZNH(.V.I*FMHY*&M_@>]MDYWQQY3!9)4$AI:Q(G
M>.2*:,B2FJ(V,4\?(T2I-%$!=]V*?EZ<P3C/%6'PNOJ/\OF#U+'*?-EISE:"
M\LV.FNET:@>-P 2K $YS7!((H0:=5I=/_P [7$[L_F";V^%O:?66 Z\VYCNX
M>S>DMD]H4^[Y:TU69VAFJK%8B+(4D])#%3KG&I#"ACG<I634\5FC=I$%=_R
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MT;.W/PK7[#UZ'FG<67NEU?(J/E\O\O7!*7'N8]=-5,E],P@%V]7U87])(O\
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MHZXB.I8%5I5%N=107XL?=A%(XHJ?RZ8GW2VA7493Z#.,FG7$P5=CJ10"!?\
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MLQV+@JS*YBHIRS/1T]1(E-#2TSGR)#3B:41RU#P1"#:^7WV':;OQO[22&4L
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M+(%/AD49U4UTC2%51QK3NXFG$A)N\PY:M=%K$0&)&H&H0L*:C742>%*X\JC
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M_P!@;9V1_*SV%\9,E\;?COLRAV5N/#YS*SXRJAW5A=C?<4F#H]NP8V2OI*#
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MH# UU 9U.W2KF3EZ#9XD>)G)9M)U%2*4)\E7TZVNOYVG??\ +BZ&Z]Z)RO\
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M/D:MVU6!<96"[%8S0R,S232:;6^P+8;[;WML*V]RLCJ0.U7:%VI\@P[EX>8
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MJ*BHJ:F::>>:65Y9II))9'9W8F2-\OI=RY9AGG8N[S$LQ\_U9AY8  % !@
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MV?,CNGYC?!NO^8?QTQ/QVS>"W[M.CV3BL5/+4#)4M9NG$O5U#M+D,AS!,D2
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MM]3[(?;7_DK1_P"DD_XX>AA[X_\ *N7'^G@_ZO)T>3^6Q_V0#\.O_%>.KO\
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M*GY'^762"#[@L'JHH1J _<9P/I]> 5_I_P 1[O#$9OQ ?;7_ (KIK<]T7:J
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M= WKWOW7NN<?ZU_U_>CPZ=@^,?:.OJQ?R\?^R /@U_XIY\9O_>*PGO'/>O\
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MWFC>*VM&44O;^!N68(!)&91*28PZZP/%F-2M:C!!X<".G=IVB[CY[O;MH91
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MJJZMFT_Q;*O!)E<J3)45$S@35*(7!=%]B_D'?!+NDUU?3(&>!@7D9(P6UQ
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MY(94@J?])DTWC=U(5]#4VE]#6-CP;6/LI'N5NH_&G_.-/\W0C/L=RX1_8/\
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M50035>3W!BL+#2XZC@RE7-,L%-45$Q5%A5V0PRE^R6NT<ERM=->I.WAE56,
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M4^U]WT\E9-2XRFJIXZ5)ZFGC:5HQ&))8T+!G4&1O;*]AL+Z1YY$C4P, SLJ
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MKI)I6AI7C0]8X?=]V.]V;Z_ZRWG@U_2Z/&BDBU:?J:Z=:K6FH5IPJ*\>G_\
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M&?S%/^]/'?\ _P"@_OG_ .P7VG_J+MG_ $=(/VQ?];^E_P#KN;[_ -,_>?\
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MWB<O'DNPY*RF?&9&LI(:.O2HHR)XS!-('A/E4E/5[E#G&_@N=JV^..2-V2-
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MNV[W=R7C[C FO22JM$U B*G'QLFB^G'RZBGDSG7?.5=N@VR/8[R3P]0$CB=
MS22/(21]+115SQ; XGSZ.9_+$^#/R@S7RQ[/_F1_.?;U!LKMO?%-E:;8'74
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M/F259]PN70AE::0JRD$$%S0@C!!]>A3R3;R6NSV,4JLCI:6ZNC@JRL(E!!!
M((."#D'JG?YU](]S[K_G=?!SM3:W479^Y>L-J[8Z6I]T=CX#8.5S.!QLF,W5
MNN>I2OS%/228^C>G@J*>2435"&..6-V 5U)&VPW\$/+UW"\D:R-(Y6,NH=AH
MAX*34\#P'D>HLYJV>[N.=MNNHX)F@2! \RQNT2$-=89PI4'N&"?,>HZ$/^;Q
M_+X[^[)[6ZG^=GPR,U;\@>F(]OTV8V70U45%69&GVC72Y#&9/&-430TU55T3
M3SP5=#(UZZC*11"22/[>I3<E<RVUI#+MU_B":I#TJ%9ETD&@)S0$-^%A6E#4
M+O='D>_W&ZMM[V?-Y:E08]6DRHKEA0EE7MU,'4D:T8BM0%8 \O\ S@OYFVY-
MJ3]7;4_EC=F;=[YKJ)<#_?9]J;KR./I:Z;_)Y*^/;U3MR%8(XYM;H:G<$M-"
M0&G>6)'U&*<D[3$WBON,31#NT QARO&E1(36GHE?05Z)I?=3F.93;Q;'.LY[
M!(PF,0<]NJA@4::YJ90M,EJ9Z.E_)K_EW=A_#S978W;OR!J8YOD-W_58^MW+
MAAD(\S)A<?1RU%6*2KK8GDAJLM7UM7+45S12R0J4@C21V21V(N>>9HM\DCAM
M12" %4-*:C@5 .0H"@*#GB32M +?:GD:XY4@FN;]M5Y>.))@"#H%68*2#0M5
MV9BN*F@)"AB ?\J_I;N/8'\RW^9KOK??4W9FRMD[Y[$[0K-D[QW;L/*[;Q68
MAR&_LI64\N*R%92PTF0CGI'2>-H)I%>%EE4E"&]F7.5_!=;7M\<<D;LD2AU5
MU9D/A1BC $D9%,^?1%[8;1=V&^[W-/#+&DMRS1/)&Z)(OU%PU49E 84(-5)P
M0?/JL+^<5_*M[>V%\D\AVE\7>FNQ^R>I^]JBOWCEMM]6;*R>]VV_N5)';*T\
M]%B:2I:DQU<U2*NAD=0@>:LI8@D=,@<7\A\X03VH@O)4CDA&E6D94UQFE*%B
M*D4H1Z!3G-(U]X/;2\M[\WFV02S0W1UR1P(\ACN!6I*1J:*P;4K&O<7& 5!N
MX_F@_$'Y*_(OXA]+5GQJW3O?;/;_ $SA,=65_7N"WG7["DS^.R^*H(LCCW2.
MKHZ67+4%304DM*E98J%JH8GCEFT21UR?O-IM=XXO$1XI,:F17T,":,*@FE"0
M=/'!S3J;O<OEG<=_VV,[7-+%<0]P1)GA\9"H#(=+JNJH!4OP((!743T12M_F
M[?S'\KU;6])Y;^6+VKD>\,ELZJV7D-[U&TMUFCGK:RG:ADR4FU1M;45D=C(T
M(SP@+DV<1'2!*.2=I67QAN,7A!M6C5'JTUK35XG&F*Z*_*O0&/NGS&T/TIV.
M<W!7PS)IF\+Q*:=6CP*::YIXM*?CIGH_7\D7X/=J?#+XY;QE[KI3M_L7N3>-
M%NRLV-]Y'6MAL?A:,4M!!5M#)+3C)5!DJ9IUC=A'&T$3MY8Y%4.<_<P0[_=J
MUOE(TT!J4UFI)(! -,T%?M\^AI[/\FW/)NV-'>4$LTIE:,$'PQI50I()!;MJ
M2,9IFE3=%[ W4K]>]^Z]U[W[KW5+'\XC_CZ_Y4/_ (UE^)O_ +DU_L3\L\+O
M_GCG_P"?>B3>N,'_ #T1_P"7K15[%3+G>_8,23@T4O8_8-2E/]R%&ILO6@,4
MU<.%N.%X%O>5/+$$[[5::::3$*5-.%.L1N8]UV^#=;D-7Q8YI0_830,Q(R!3
M]OV5Z1].N2I6#+%"_+$.DMB2/P3_ +;\?[?V(X(KBW(HJFM?/CCSZ#U]>;7N
M]6>1X](^=1D97''[*_LZY22N "U,JL220) .3S_MO=G<J,QT)]" ?\'5(_!U
M=EV2!0:2A; !\PU<C)/^3IOF^\*:H83JN?[8;_>K_P!/9?*):553_AZ/;6.T
M%3X@-!6E:?,<?M_.O3>M#EI[(*5')NWIL>#<&]A<'GZ#_C7M'])</C2*\?+H
MYCWRT@&K6 . XD5^0Z@SXG,0ED:D*LE]2$<B_-B/K^?:=["X7.@_SZ56_,&W
MS-I$J5)'X^H#4M4-0,37TV(,/_&_I[3-$XX@_LZ._&C('>*>6>H\=)6RR6C5
MEN3J/,8L/\.?IQ[9$#N<=-S7"0"K%:>1J,_RZ?\ '[>S52;Q)JM>R@,Y_'^T
MW^I'LUM-FN+C*CH/WW-5CM^97(KY4K\N -?Y=3Y,?D*(JM6=-B"RI&S$<\:B
M0+7_ -;VJEL9K0TDQYXS^=>B^#F6SWI3],"_EW$)4XJ*&IQ7^?7.=&IS"T#%
MV>,.7C^JD_AKV8&_'T_UC[](K0T*U-17'E_E'2 Q6MQ7ZA-!!(56J P]1@@U
M]:].<%3DG9#Y*@NO&II6!%_]<W]F$%Q.U!5L?,C_ #5Z(;S8[.)6D1$8.>#*
M& H?(G4!^5>EYAMV;UH4\-'7Y98 0$423 !SR&5T8&X/-PWXY^OL16EW<'!#
M&@ID4'[<UZCS=^5-MTK)+].@8UI&=3BO %:C3YX\CZ@9@97*9C.U+MDE+S3L
M6>IK*F9""/KJ:20J >#S87_PX]LW,TLXR"!\\5_/K5KMEELC!8FC<$_Z$@9Q
MZ4!;[*\,8!Z3JX6IF8A'Q*D$G5)EJ:(\<<:Y>3>_ _'LB:V9S\*UKZ^OV]#R
M#<[>W2A>?(  ,15<?-37@.H]5M^NHD$\AI98^&\M'605J\@V!,4C '@W!L?Z
MCW5MJEC761C)J"/+\_\ !T;Q<Q65V1 '.HT 4JX))KYT.<>=.F=ZQZ<7=1^K
MFP_P_IR+W]H3=-#Q_P!7^'UZ6OMT=25$QX8"9]/X@?+T\NH[Y2]RX^BGTVO]
M/S]3_O?MAK\G)Z76]HL0H"4SDY.?F:_X>FY\E3S2A0PN6.K6='^P%^;_ %O[
M2/=*[8_S=*5BGA.H"J\0<DD>N*\?+J;"[RG1&H?5P-)U?GZ@$?\ $^U,;%S1
M17[.F;PROE@444.I@H!_,'IWDQV3H4B-12RPB6,31>5&AU*3PPN+E?\ $<?X
M^UQM9H0"1CHLM=QM[UB(YT)!(H2H/[ 37J%YYC)H9#K6,N$ U65;DM]/Z7]I
MO':M",TX?+C7I1)#%42*ZTJ%)J!J:M*5/[/7TZF1U#.$ 4#R'2I=A&/\>?I8
M>U23%Z?/&<=4GD6W[B11?BI5C\L8R:_8>GRECK*R6GQ]) U363R)3T\-/ 9W
MD>4D*B: S.S$V ')/ O[.(;DA=!(_P!7SZCW<[BT6;ZB,/KU:J4 &*>1(^?#
MK#78YJ(!JB2(3DZ9*,A_*A]5]8:-0K*1RI;4+_3VBFM] UU!'R-3_@Z$EAS#
M'N-0R%2HJ3VT.0/)F)X^E*^G3?(9%]#K8A05 E#7YM_9N/;#5X'\L]/I?6DB
M'0-!KYKIR,\2HS\O3K-25\2G1,&6-20Q$BQD<6))8?2U^+_['VOL]R$7:W ?
M9_FZ"^\;-+<U>%=3-G#,Q-?D/G\OLZ&;9M#09W%9FHI134RXFG>J<UU;H>1$
M*7/Z47])-@K7/-S^2++"]CN5J!0#\ZTZBOF.REVBX6-R-3 <>T@L!C%:Y-/+
MJ-NS^'4ZTE7B<O1U;?Y,NO&Q,R)((PYC42.^L)<!F$8NP.C4OJ]I;RZ4_ W^
MK^?5]CA=')FB#?(L0 <<:4X?;3H+9'I?.9\@*J657#.S#B\ER+#]H_0_CV'6
M>,MJEU$CSP!_@'4F16=RB)]((06^'3EA3S-2]*4SP^P]0,QN*@2!*?'T,-*J
MF19:M[3RR!M//J#".Q#6T\^JQ) %BN]W-%_LQIR<\3_@_P IZ'.R\L3D,UW*
M9&Q5%!0:LU%585I]@\^/2!K<K%+(Q$L@CT+Z(+DFWYN;"_\ L/8?GNQ*W$TI
MP'RZ&6U;4;=BS"KDG+#X?*F#PQ7_  \.N5)EJDR(E!1R2S,-"-))Y?P;D*1X
MP;<_3CZW]VBNGJ!&IKY9J?V4I_+I5>;3#I9[R1!'Q- $'EQ-=7_&L^G4L8S/
MULBBOKTHH^23*QL!_BL:D_\ )A_VWU?DM;J<_JL0/0GA^0Z*4WG:]N%;&+Q2
M0/@6E37^(C-/E\O/H2\5MK:<"QFE9<U+"E)]UD,U)'M^F$C:?(L:O,\TT<3$
MJ6TH2ERR*2![-K.RAC6K"I'F30?ZOR]>@3NO,=[>2%?%> ,>R*%-;MQ%"P(I
MD^1.2"!Y])C<&XZ6EJ:K&XZJBJ*6.:2(28A9*:FD L P$J1S,+7L9([D<V%_
M:.[W%$[4KYCMP.C79^4Y9J33E@<$"9_%:G'AI4 UX4-5&#4\$F,L0FA:<MJ(
M-VE<VX_HNA?S_3V7"]Q2E?S/^2G0UAV9(3JU#'F F?S97/\ /J,]5,5=4I-"
MN#ZU758G_7!L?\0?I[9:4G 6G^KY]+!"C$$R5(/#41C\J8ZBB>52-43Z;DD&
M5A_O%[>VA(?,']O^ST_X50<B@&2*<.LHKHB4\X &LWO+_A_K'^GNPF'GZ^O5
M3%@^%4XQCS_:.F^:JHU.J"<?3]'AU6_V)_WKVP\BU[3_ "_S]/6D4I%)!3YU
M_G0'IM:NA!X>.^H'@#_>A^/K[3^+TM 8<1C[?]CK%]PDI:Q#,W)TJ?Q^/I[K
MXE>MAF3@,?:.N:R4]K/*OT_!'Y]V# ]:,K^5!_J^SJ-/I 9U9&4 7U&S?[#Z
MW]MOGJP)<C_)PZC@QM'J$C!N;I;2/]@?R?\ 8>Z];(8&A&/MZC, 6 TL_P"2
M .>/=3UL5^S\^HTL;<D1,HN>/^1\^VF'GTVQ^>>FZ1"/4?I_L![KU8-7K$"5
M-P;'W[K9%>NO?NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO==AF7Z$CW[K1 /7+6YX+
M$CW[K6D==!F'T/OW6RH/7>M_]4??NM:!UQN3^?\ 6]^ZW3KO4WTO^;^_=:TC
MKC[]U;KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NN<?ZU_U_>CPZ=@^,?:.OJQ?
MR\?^R /@U_XIY\9O_>*PGO'/>O\ <R?_ )K2_P#'VZG;;?\ <>+_ )II_P =
M'1P_99TMZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>ZI8_G$?\?7_*A_\:R_$W_W)K_8GY9X7?\ SQS_ //O
M1)O7&#_GHC_R]:(78F?9>R.RJ>?PRQ4W8N^HO')*]M(RU:56P< !1]+6]Y0<
MM;F8=OMXFTL$B4 &OF*^HZQ,YJY6CEW6[G'B*SRDU2E:DG^B33R_+I,TN234
M9X*58@3P(N0;_CGZC_8GV([>_ .M$I_I?/HAO>7A)$8[B;4./<>X?D"!_+'K
MU-GG6ICN5J%D#&RI& OT_P!5RP/^%N/Z^UES<?5BI#@_(8_R]!_;;%=OD*IX
M#K4_$3KI\^ -/F>'6'S5/BE1X8?W%5#/*'#J%-RP/"W;\D@_FUO:75)2A 'S
M-:_MH.CA;*)W#QNWD?#0II%/*FHFGE3/3!7NE.MS54TA*ZPJ2-)^;$6N;$?T
M]E-T1%^)3]A)^70JV^&27_0V'EJ;2M<5!P!4'UZS4SY*:G,M-D:>50$)CJ4%
M-(2_X4+=6"D_ZO\ XFSL4T[K5'!'H>T_ZOSZ0WEM9K<4>!D/\2 NN"?,T(]?
MAZS,,_IN*G'Q@%06D2_ MR;W!^OM]A=D"K1C[:?[/20_NM22(KIF)K1 <FM/
M+33AU,IJF.G$BY"KH:F>:(>.6F;[4PNI/*Z&T,..0T?((M9N2Y!)H_M9%KZK
MBA^T?Y?\/1=) ;FOTMG=8(J)35&&.(<_X"3ZXQUCJ]SQ4KI]K65+RZ%$LKRD
M\_\ !@Q%K?3W:;?!;46)V)'$DFG^&G2W;N5)]Q!-Y''&#73&L<>K[#V5].!Z
M@5^^ZMU43S)7/I]+5$\E04L !I;786  _P!;^GM)/S--2E0?/S]?4'I='[<6
MP;Q!K7@"** :"E:%#GS].D_)N^NJ-)\4;>FVLJ'^G^N#?_?7]ETF^RRY-/V#
M_+7H11\CVR*M&<4X49EIFO!2.LJ;ORS:0BJ--@&CC%^/]8?T]N+S#<B@4_L
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MWJI[<?F3U(^V>WHB4I-W9KE54#%/,5\O6GY],;YC(5TB(@FE)L$33Z;"_ '
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MOREAP+_7@?3GV@: H.!_9TL&\)</H1XZUH!7SK\J]2,32BHG 9)/#S=@2/\
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MZ?AWB:4T:)>/$*Q'^#KC'%$3>/**6<<))(OX^EO7[TJ@_C_P?Y^E9OP@J\9
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M?[P/^M'7OK=E_P"4>;_>C_UNZ]_LS'_"97_O71\V?_1N5?\ ]M'W[]W\P_\
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MO]Z/_6[KW^S,?\)E?^]='S9_]&Y5_P#VT??OW?S#_P I4'^\#_K1U[ZW9?\
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M@.GO!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
M0'7O!O/]^1_\XS_T'U[_ $&_SV_^\X?AY_Z(6?\ ^MWOWU.V?[YF_P"<J_\
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MJI-@/4P_'^MQ[U5?/IY&!'G_ *ORZX%D;C0+?46-_I[]CRZL6'GUR &EB$N
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MRSQG0LHBDB6_X+(5-KBQ(O[-1= *5"DL,5S3\P1T426?B.&=@(VKVDH2?+#
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MSZ?)1UD+I/X[$:5FAU#2"WY+*&2W%'!H/-#1C^1_S=)-U4S2$"> AN[PIDJ
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M6GYL7/\ JSU"AJ8IBS38/'T"60>/[1Y+VL#;R%[-_KM]/I;GW19*\44?D?\
M+T]X#*0%E=R:YU!0/]Y QTHJ_$X21:*:E15IIF1:J414Z>,L!<% X8>H\$E0
M;6Y/U6W,$("E.!XX&/Y]$\&XW,#.K@:EKI[I#J^=2H'^'_,%=5D!25LH2CHZ
MF!&?QB4/'<"XY,<@/(_HWLB>70QH 1Y<?\G0IBUSKQ8'U6A_X\O^3J&-RI+(
MD:;:A:61UBC6EFG=F9S8 !FD))-@!8DG@7]T-W3\ _:?\M>M?3S@?%)^:Q_Y
M .K7^E_Y.7SO[@VM2;S;8FT>IL=DX(*O$8_MO=TNW<C405,:2)*V-H<?DZVB
M)#D&.MAIIP5;5$!I+565FR%/VUI_L] J]YUL+!BGB&0@T)1-0'YD@'\B>@Z^
M1'\L[YC?&.A3<78'7^W\WLDRTU/5;]Z_S#;KQU+)4OXU^^UQ4=;01W*?O5-%
M%3EB%$VHV"B%GF<+0 D@#YU_U>?2^PYRL+Y3I=@P!)5AH-%%33C7 X*2?EU#
M^.W\N?Y2_**,97K#9U!+LV.:>DJM_;AKDVYAXIZ61HY8(ZB?7/72HR$N**DJ
MO%J43:"0OM^YC^G;22"1Q"^7VDGI/<\Y6EL@=R5+9"&I<CR-%&/]L1\J]#[V
M;_)8^='76W:K<>*VKL#L]*".2HJ<)UQO#^)9(1PC4SQTF4Q^*:K:PXBIGFG<
M\1Q,3;VE:4KP!I^1_P '2*UYYL;I]!D9*X!=2 :_,,0/M-!\^JP,)M[,97)U
M^&K:O;VULMC*ZJQV2P^\<C'MF>">@9DFAGBJO"\,D<BLC*VEE=60@-]%-M_C
M&=2#[<='M]N2[<GB,EQ(/(PQAQ0T\RU/]0Z5F5Z\%)9ZOL+JZD<4TLH6CS\V
M1#&)=6D^'SR%CPJA5()_(L3[7RV=!7Q8@?0$FO\ AZ+;7F%[DCP;:^TD]Q:*
M-:>GH/7UZ!]:JK>22)<>E1H=D2JI'E4/R0"/)?@@"QT?[#V5AF-12N>(K_EZ
M%[JD5"9&%5J0^G!_VO\ GZ5M/M',3T$F6K\9DL?B(3$9:ZI5;$S,J*J*YIO,
MUR3I1KA0S'TJ?:D6STU,"!\_]0Z(Y]\AB8)&ZNQP M?0FM1K'3,=OTWW-3&M
M?0M304YG^ZD:2G25[K_D\3^.16GNY_M^.RFTAXNG\+-/+UX5Z5?O22,*"#5C
M\(&HCYD"AIC[>&.N%5B<?3PEJC52FT959)ED)\H#7 0!G%C];6]W>%5&<?L_
MR=.+>RRT,6:\6H0!0TS7A]E>H,>/HI  LH92IL-3L2#]/H./]8K_ +P/;:QJ
M?/\ P]+/'*C+9]0 ,]9TQ'^3^=(X3"7>(%ZM-5U /Z/('^GYT6/T]Z$-1C_#
M_L])Y9B#0DUXX4_YCTYT&(I7<.\DQ5+$M'&[V'_)!6]_\;?X^U4,"L<_R!_S
M=-O>L!A%)\M145/[?\E>E0VWL(L325$M9HXN?*&L3R0%NM_S^?9F;.(#54_M
M'^"O1#%S)<O(8T1-53^%J<2.-*?.G2-R?\'HI+14(G'E:-0U9ZB"-0)590PL
M+ FY%_93-X:&@6N?7_,>A#81RSBKDC%:A:"M?*J],4AUJ6%,\2_J%E;CFUKL
MQ'T^G'M*3J\NE:H-7S^=/\@ZA^BYU^EB?JU;$G_1'_$^Z5'^HC_-TL+:<X_W
M@_Y^I1&(()FF0,+$JE5Y#S_K+S[L=)_XOI&]Y*#1$)_VM/\ ">I=(-KR./)K
M8J;LLLA5?]N&4GZ^W8_!)S_,])6N+QL4T@9J/L^8/3K]Q@:=W^VBHA& 5!;3
M(>1^"Y8@_P"Q]O:XD/;3_#_AZN!*4#5<MYY(&?L KU$%?CU=62*E'J!4B55%
MQ^=(-B?]A[;$J>@Z41Q%L'5G!X_X>N-9FHG!$:QRR >CQACR+V'']?\ BGO4
MD]?3I-%MYB<D$T^9'\J])F2LR,I!9)HP+E57]JW^Q^O'^/M*7<^O1DNB'\)/
MYUZQ $F\U78<^D2F0_[P2/?OM/\ /IZA'PU_P=<C-11DZ2[FUF+2&W^V _J/
M=2RCJ@BD;S(ZZ^]0\)&+ GU!1_O)//O1DZ=%OZG/7,5+,. G/]6)/NX<]6$>
MG_5_L]<2[M]=7]#I!(]^-6ZMH\^NKH?J6_VUO=:4ZJ4(\OV]900/H&_VWOW3
M)7/EUFB*D_0_X^[KQZ;\^I-P%XM^#;VX.F7IY=<4?2VKZW^O^Q][ZHRU%.NY
M+:K@W#"]_P#6]^ZTG#K'[]U?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NLBQZK'4H%_Z^_=4+TZ[4('L3J'X-OS[]UXDTZ\450Q+?\% _WB_OW6M5
M3UP0!F )M>_/OW5R:==,-)(O>Q^OOW7@:]=>_=;Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZYQ_K
M7_7]Z/#IV#XQ]HZ^K%_+Q_[( ^#7_BGGQF_]XK">\<]Z_P!S)_\ FM+_ ,?;
MJ=MM_P!QXO\ FFG_ !T='#]EG2WKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JEC^<1_Q]?\J'_QK+\3?_<F
MO]B?EGA=_P#/'/\ \^]$F]<8/^>B/_+U\YSO>N>#N;MX1V-NT^PKJ1J^N6K"
M?S_OO]C[EW;&(M8J?P+_ (.HQORR/)I_W[)7%>+N>@@&7J)+J1&J_P#+/_D?
M]?:LNW1<97/I^RG7$U,K>B]BWT;3;Z^]*U<=:#%\$CKWBC)4R3H &NR\?\0?
MZ>[:3Z]>%N1Q84_+J=#2XIR/+4N@(YT@,?\ ;7'N]!Z];E4(*KG\Z?Y.L_VF
M'N3'/=.=):2W^\?C_?<^]A5'#IZ.,#)I^WK./X8@%I4)''T_Y%[WK7UZU]6M
M:'KGYJ <^1?]A_R/W[Q!Z]>^K4?\5US%72+ZEF _P)'X_P /K[]K'5C()?,=
M9#EX+#]+?\A?\;]V,E/GTQ].HXFO7:YB%+D*JL;V;Z_3_'_7_P ??A+3JI1%
MQ7KJ3+2NVK587O\ YRUA_P 1[T92>M^$!D9'GCJ1#FV!4"I"VL=88L1;\\,I
MN#[NMQ3'5F$3BE!7[*?X1T\4^]\W0$FAS5;$3>_CK9%O?CD!K<_['VZ+YUX,
M?VGI)+M=I*.^-#^0K_(5Z%'J#9/>7R)WU1]:]/;1SG8V]\S!/4KA<-3PDK!3
M,GEJJRIJ#%24-'$\D:O4U-1% C.BM(&=0:M>N^#G_5]G17>6^V;9&99=,:C\
M1+#/H*9)] *D^G5N]#_(>^==9C:?(56\?C3BZTP>=L17[SS<]4C*+B&1Z;:%
M11-)^+K5M'?^W;GVX)I*>7[!7_!T#DY^VJW)14N"#BND4^T5F!'[/RZ-!_*Z
M_EI]J]<?*??&Y_E?U?C\?'TAA-O9?K.5L50Y7#Y?+[KJ*Z*ES&/R-+$:>M;#
M08RID,$A%323U5%430P2B M02M+A@ //"U^60/\  >BCF[F2VFM$6PD<F4L'
MK))544"JE6;&K4!PH0#2O1-/FC_.J[]W_P!P;OP70'851UETSM?/9'![3J-I
M04PK\S#BI3",Q69)Q)/IKG1I8(:>2&%*=XTD2:57F=I9U;C_ )1_@(Z$6Q<@
M6MM C3@/*5!?7E5)_"!2F.%<DFIP, \G\J3^:;O;Y)]CS?$SY.U>,[ GWYMK
M<2[%W;EL/2TL]<^*I)JFOP66IZ>%*.M@J<5'62Q3/&DEX'AF-2U0ABVLZEJ#
M_BJ?ZO/SZ#?./)\6V1?6VG;H9=:BM ":!EKPHU,#%#7%,KG^:Y_,1W%\(SU]
M\2_BO38;KO-T^PL7F\KN6DP]-6C!XB66:CQF+Q%-513TBU<RT=1)//-3RF.)
MH3%>>5Y(O22]U*_,YR3Q\_\ 5GCTQR5RO%O8:\O.]=154J0&( J3II@5H ".
M!J*4'55'QE_G3_*_JCLG"5_;G8&4[HZMK<I!'O3;&Z**BDK(Z2KE_P HJL37
M04U/4P5M,C,T,3S-2O81-$H*21T,M,BOV?\ %]#?=^0;"^A80((I .UEU4J!
M@,*D$'SQ7T/5F/\ -G_E[;Q^0G:72W=OQ3Z_AW5NCN*&7!]D/0T]-CJ)EHJ.
M"JQ&X\A652I3TJ/0>>GJ)995>3PT<<22SOI:S,5(*BM<_P"K[?R'[>@;R=S!
M%8PRV]](46&A0%FKQ(9 %.:'(H#Q-: =$XB_D,_.&FI/XK'O3XUM7+3K*F*@
MWCG8:D,+_MJXV@E().?K]UH_VOVH65US0?RZ-VY_VQQX92?23DE1I_ZO$_RZ
MJX[]ZR^0/Q:WQ5=;]U;2W!L3<LE-]W2"7(BHH\C1ZV1:N@K::62DKJ1G0C5'
M*VAP4D5)59!O]XN,9!\Q_J_XKH46"V.ZH)[<1LO"M,@^A#"H.?,5I0] '/N^
MNJM35$T<NIE=FFB6=B4_J[HS-S^2;^ZF^9AD_P O]CHP2UA1<8^PL/\  0/V
M=-M7N9YV+S^::1B+NSZKV^@N22 /]L/Z>VVNBW'IVV B%$ I]@ZAR[L"*$>%
MV M9%95'I^E[#_"W_&O;9OAY]+C#K%<?L_V>L)WPZ H*:RM>T986Y_VG3I_W
MCWX7^,#I@62@UT@'A7%?\_\ /IO;=CDEC2H+_73)I_VP46]L&^KY=.FT8CC_
M *OSZ=:7L2NI+K'31E=-B&<D'_7X-_\ ;>U$6ZF/@.F9-G23B#^T?YNG3_2U
MG3&8_ML<X<:6,E+$[6M]2V@/?_'5?_'V]_6"0BF/V#HM'*]HC:PK UK\;4'Y
M5(_E3I.U6]:ZH8L])2 LK7< B]Q_3Z _X_7^OM&^Y>(>'1Q#9I"@568 5XL3
MQ/S'30-PU.@@4M-SR2T>O_7^OMLSL/A /SZ41QZ!\1/'B3UC&;J9./#" +\*
MI'^V]0]Z$[>8IU9WIYCK&<G5<M:--5@;I<FW^O<^Z-,1Y=- E>!Z[_B=3<BZ
M+<\G0/Q_OOZ^]"X/6F=B"./7OXG5 %=:@$_ZD?[[_>?=DG)QTQ&C#M\OMKUQ
M&0J"19RI%[ <CW?6PSU9E*GRZSKD:LL 9VN2H_V!]^60];5R#UF-3,?U3/\
M[%OZ^[ZCTH$I'K^WK(I!!4ZR+<6)_P")][J/3IRB_P +?SZE1QH?HKGC_CH3
M]/>Z _\ %];\ 'SZD+(J#1X&)!MJ(O\ [S[L"!UHL4Q0G[.LGW-N/&1_OO\
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MSX!F]Q9S'U&.J$@&H.]%B*&OFDGEL(S4R4\*&0I5+$_9PZFU>0X_,^G\Z_\
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M_P _7OI)?X'_ -Y/^;KW\5Q?_.RH/_.R/_H[W[ZN+^-/]Z'^?KWTDO\  _\
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MN+_YV5!_YV1_]'>_?5Q?QI_O0_S]>^DE_@?_ 'D_YNO?Q7%_\[*@_P#.R/\
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MG7_>?>BGS'53,U?AZY>%?J&4@?7ZC_BM_>P/]6>K+.?->N:P!E)U*--^%/\
MK?X>[!0WG3KQN*<1_AZ[\&@\2*PM8C5?Z_TX]Z*4X'JOCU\O]7\NO%$%KW']
M2"/^*^_ KYGJID8^76:-(A>[BQXX]1Y_PN/][]W0KZ]4(9\ ?MZ\7B%_4Q !
M&HC3P/\ #G_>_=V=0.JFW<^0_(GKK4FH%0;7!'!_XK[3^( :]4^G8=9/-8W
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M$1!^68#VUU9G$2EF-  223@ 9)ZW-=G]>?"S^1S\=-H=B=M8*DWY\E=Z44E
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MU:,F+*;>SN+6J>FH,HLB1Q??0EJF.DEE%/*\-5%*KK(MZ P)%,$?Y..#\_\
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MU9N@,/6/#BOXW4]:8OLC"9#=<=,$24G^%QU9AFJ1$S-]G#6R5NI&B%.9],3
M]>?=N:7P]; 5IK*'1_G_ #I_+H3-R?>K'KTJ3_ &&K_-_/JE2AVON;)[FH]E
M8S;N=R.\<CG:?:^/VE0XBHJ\G/DZNH6DBQT-!'&U5+7RU3+"E.L1E:4B,(7-
MO8N,R!/$+#335JJ-.FE:UX4IFO"G0:\)BVBAU5TZ:'56M*4XUKBGKU=7E_\
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M]U6H)5])=NG.%CM,GA2,6<89475I^TU _($D>?2W;^6+O<4\10%4Y!<TU?8
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M=4DC692C %6!!!X$$4(_/J^[86Y4WELK:NZET!L_@,7DYDC^B2U4*M-'^?\
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M@-0RVJB$TT*30$L0!/\ [:^TS7[1;ANH06[J&A@+ M<:D+*30X73W@5U&E2
MHR8SHK-Y;<?4FR,YG*Z?)Y;(XJ6>NKJDAGD?[B9=3$ "^E0/I]![EOVWW&?=
M]CL[FY<R2R1:G=N+'4V32G49>X-A#M>\W5O;H$C20!$7@HT*<?MZ+YTAV3OC
M<GR*[7VEG-QUV2VYA$WTV)Q,ZQB. XS.TE-!H*QJ_P"U!(Z"['@\W-C[BGVX
MYPW+>.;=SL+F=Y+>'ZSPHB%TIX=Y%&M**#A6(R?//4D\_<K;?M?+&WWMO"J3
MR_2>)("VI_$M))&K4D98 \.G_P"7V_=X;"VUM"MV?GJS U5?G:VEK)J,(3)'
M'3ZU5M:.+!N?I[-??GFB_P"5K*UEV^9H6>=E8KI.I?#)IW ^8Z+?97EVRYCN
M[F.]A694A5E#5P2]*X(\NGONSM/>VQNL-I56SL96Y7=6Z*&B5\K'BI,JM&D=
M+%)45+HD;Q^=WD01B0:#=V*MHTDT]QN<]RY:V>W?;HGEN;A4'B")I1$HC#,Y
M 4C420%#8R30Z:$OY#Y1L.8-VN$OI$CMX&8B,R",R$R,JH"2#I !+%<\!45K
MT V\]P_)?H6GVQO7=N^L;NW%Y?(P4&3V]*JS(LLD3SFG=OM82FJ..4"6!QI9
M>0RV#1AS%NW.'M@EON-_>QW44LBQRP$"@8J7T5\-2*A6HR$4(X$<9$V+;.5?
M<1I["RM)+:2-"\<P)!*A@FH#Q&K0LO:XR#Q!X&?[L[,K-K](5^^]M5+X[*Y2
M@V[)M^:6&.9HVSTM.URDBR1L\=,\K6*,+K_L?<R^XW-\FR<N2;G9MHD=(# 2
M%)4S,F:,&!(1B:$$5'43\A<JQ[OOZ;?=+KC1YA, 6 80J_FI4T+ #!!H>BY[
M=I/FIN?!8;<6-WSA1C\[BZ',4 JH<5!)X,E&LL3.G\+.DLC VN?<2[3;^XF\
MVL5W#>PZ)HTE34ML&T2*&6H^F-,'J3MSGY$VFXEM9;277%(\;Z3<%=2,5-#]
M0*T(Z/YCEK$Q] F0=9*]*.E6ND6UFF5%$K"P L7U'@ ?T ]Y0VH=8D$IJX5=
M9]6H*\*>?6.=R4:1S&*)J;2/1:FGKY=3/;_3'7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=4L?SB/^/K_E0_\ C67XF_\ N37^Q/RSPN_^>.?_ )]Z)-ZXP?\ /1'_
M )>OFY?((_\ &>.X_P#Q*'8/_NVJ?<BVHI;Q?Z1?\ ZCBX_M9?\ FJ_^$]!'
M_P C]N=,]=EF/U8G_7-_?NM4IUU[]UOKWOW7NN&L?X^[Z#U[KQ<#CGW<0D^G
M7NNO)_A_O/M]8P!D#KW7@UR?P+?2]O=9% '#KW7BQL 6N!]!JU6_WCVU$ >O
M=<-1_J?]O[>:,$=>IUL5?R^?Y*N'[8ZJQ?R:^8N^<EUAU-E<4VZMO;+Q^0IM
MM5=3AD3RQYG.9BN#P8?&U$0,D<:P^:2G99VJ*8,H;4&V"8:Y#I7CY"H]:G '
M^'Y=1CS1[A-M\_T6WQB68'2S$%@'X:55<LWKF@.*'--BW:_;'P!^3FU(?BM0
M]N=*_(C%P[?H,+_<#.;UH=^UF0I]J+&D-2KSRO49&LI?!',*R%WG5U%4)0W[
MGLX!AF41$AA0"AXFGS\S_/SZB:>QW79Y#?F*6 EBVM5**I<Y! PH-::3CRIY
M=%ZR/Q(_EM_RXYXN_,5\;MXUNZ*&6IEVO5[;VCO;Y"5M)4TB-,OV*3OF,;@Z
MJP(AK:N>B(/I%6.?;+P06/?I..'$_P"'%?2O1K%OF\<W#Z7QT"GXM310 @XS
M32S#U50?]+UC^"GRC^<'RL[X[-[%WOT0_3_PRJ\%287KG$]BT[X'<*UV)DJ'
MCR-$C4:5.4;+15"C("4)CZ81TR8^IEEAJ_O-6=Q+<N6(HGE7_)Z_/R_9G?,^
MR;;L=K'#'-XEV&)<H0R%3Q!S1=-.W\1R6%"-(1_(GXJ_R/MU=L9K%=H[DZ+Z
MV[>R>7GAW)C]J]XMU[)%7US^5Q7XRERJ87'5;R3%V\M#"[E[R:O3:LL5J&R0
MI^1P/\('2W:MZYDB@!B262( :=4.NH'H=.MA^9^71 N\/@]V[_* W]MWYU?#
M7=]=VWTOBM&&[$VKNN**LK:? [IDA+PY&KQT45-D<%6R1TNFOAIZ>:BJ_LY3
M#,@:8,S1-94D0U'^?UI@@^N/RQT)-NYB@YYB;;K]/"E-2A6H!=:Y4,20PSVD
MFHKGRZ-7D/EG_)9_F,8S$;H^3&#V[U]VK38V#'UT/9/\5Z_S%-'0^1DA3=6
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MB>]BZ4>73@MR< =8'K@QL58V^FIN.?\ 6_XK[VUWJ%*#[>MK;D?+K$9$))'
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MQH. 0JQ"^?XL@GB21P  !2?Y[W\G?=_3?SAZ[WG\:MFI+U'\Z.TL+L[9V&H
M4IL'V/O>K*U>!,4%.328W*-(<C0Z5?2@R$"(L5"FLTY.YI26S>.X;OMT+5\V
MB48.3DCX:8_#ZGHOYFY?9;E7A TS,%I_#(>. .!'=7/XN&.MDCYT]D?RF_@K
M\1?CY_+>^=?]Z<YT]D>L=J4>$V)M*GW4DN2@Z=J,?HRF4J]J9#'Y&G^[S:"K
M"O6".HJ4F8JWB-@)LT&Y;K<R7MG3Q Q+,=&#)JX!\<*CA@="[<Y;&P@2UN31
M"H 7O-0FGS3/&GGGK-_+S[F_E!_,;XZ=W_RW/@]%NC&=1/UEOJ7=G5V[UW9Y
MHL3VQ)-0Y6NQ5;NK)5^3;P9"MCE;P5RBDJ9X9HQ%)(']^WNUW/;)TOKRGB%E
M*N/#/='2E0@IP XC-//KVUSV%]"UK;&J!2"O>,/6N7SYG@<=:CG\OSY-=+_R
M=?E)\P^JOFO\9*GY 9_#Y:/J.CQ']T\'E$HJWKW+Y!:C*01[D6RT>6IGIYJ6
M6%3]Q3O'*&:)D9I(WS;9>;+>WEM9%04+FK-^,+CL!RI!!]#T"-HOXN7)IHKA
M&8U"BBC\);-&(P001\NM@OX&_P Y3X._+#^8E\:NO^D/BXGQBS6?V9WOL67.
MUFUML[?3*U6XZ+$9?'X_SX#0X=FVS4+&*BZ/-+'%&/+*OL#[QRE>;5:22RR+
M(H9"0&8T%2M>X#^(<,_ET+-MYDMMQN%CC1D)# %E45X&G:3Y*>/^'I =9_RY
M_E#B/^%-V[?D;6=2[RQOQRQ6X]]]\1=T56'J?[O5\&^=CU>)@QM!EA :&;,I
MN/*>";'-,E5#3P3U.@P"&297-OEN>7UMM8,IHF@?$-,NNI'II&#P)-/6B2/:
MIOWR9])$8&K4>!K'HH/GJ\O05\Q6;U+\O>L\Y_PJJ[@H*7.8R3"YSIO*_$C;
MN<AKQ7T]3N/9.%PF8R5(9$(BI)X<S@\QC!&7?550B+B><1I6YVN2/EU&H?[4
M3D$4(1M2 YXU!4_8?05ZM!?I)O3K4?V1B!!K5A1R/E2A'VCU-.H76?\ +G^4
M.(_X4W;M^1M9U+O+&_'+%;CWWWQ%W158>I_N]7P;YV/5XF#&T&6$!H9LRFX\
MIX)L<TR54-/!/4Z# (9)K3;Y;GE];;6#*:)H'Q#3+KJ1Z:1@\"33UI6/:IOW
MR9])$8&K4>!K'HH/GJ\O05\Q77Z_X4,]S;:[H_FN_(ZKVA7465P?6\>Q.G_X
MK09%<A'-D-@8:C@S<?HND,E!G),E0R1AV(DI69BKLT:#?D:S:TVZ/54%RTE"
M*4#&@^VH 8'T/04YMN1<WKA>"!4J#6I J?LH201ZCJ^?_A.9_P!N<OYCG_AZ
M=^?^^MP?L%<__P#)2@_YIQ_]77Z%7)O^X,O_ #4?_JVG6C/[F3J,.O>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZNR_P"$Z?\
MV^1^'G_EP7_OK-[^PGSQ_P DN?\ YM_]7H^A%RG_ ,E"+_;_ /5M^KB]W?\
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M;@L=%3U\\[R2E99*BJ>'RU=1KFE*KXXHQ[RM<[9:*+2SD#N>YCI8,Y R350
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M'R.>LGP2_P"/0WU_X<F/_P#<7WK[L_\ R3KS_GI7_JT.M?>$_P!SK3_F@_\
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MSM2::+<F7HZ*J/E0AX[032>M2"OU!N/;\=WJ.DXJ0/+SZ1[E(UM;R2IQ2-V
MIQ*J2/\ !ULR_P#"C?MC>FU-L?&_H';-74[?ZQW73;OW7N7$XDFAI\C+LJ3%
MTV(HIDC"(]'BQ42S+3DM&9GIYB@>F@=37=9A'I0X%*_*O#^7^7J'O::P2X:X
MNGHTBE54G)4,&+'[6X$\: ^IZU5<9E,AALAC\SB,A78G+XBMI,GBLKC*MZ"I
MI:F@=98*BGGB=)8)X955XY$8,C ,I! /LA>93P)_GU-AAU*0P# @@@BM0?(U
MXCK8J^)O\^/Y?T&%I=@;SZ!'RSS6%H8O!F]IS5^V-PR4U/I4R91L;B<W2U;
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M[[-[BR^2SN9K?!'3>:KR\SU%1+XX4CAC\DTCMI2-46]E55  .(HUA4(HH%
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MW/M?R/L<W+6TVUA.4:2&/0YC)*$ZB<%E4TSY@=(N<MYBYAW2XO8 P25]2AP
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MWOW7NJ6/YQ'_ !]?\J'_ ,:R_$W_ -R:_P!B?EGA=_\ /'/_ ,^]$F]<8/\
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MKWOW7NO>_=>Z][]U[KWOW7NO>_=>ZO Z!VXVU>G.O\3(ACG; Q9:I1A9EDW
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MJ-B 1["?./O1+RWNTNU6E@]XT2HSLDK!JNBN>U8), .M37B:8Z$W*GM)%O\
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MJ(./Y=-]9Q]!_K#V8)PZ9?CUW[<3CTV_#K)%^L?[[\^WNDC\>G"/]8_UP?\
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M2(]VFM2@MKE@!<?I**$EBU!C!H02*$\#0]$>V17 8SVXJ8?U&-0  *G.14$
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M,8%8ZB2P->T5)K@ABP%:_L/1Q^R^Z>C/YA/\NSY__'W^5A-O?J7>'2?8=?\
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M;3O]U)(:I%K9W;T!):@\JY^P<<\#'_FC_P P3:7R>RVP?C9\7,!)UE\ OBW
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M?2O6,*9F#%9@Y+-;CB7R4L<D"-3O(LB\?94<<TGDEO:61DCBU'09,:_='?\
M_72W"WY<V<"41S>)-<#,:LJE"01_H<8<ZFX,Q"K4TU9 >W.R?ZW%C/OVZDQ&
M2+1%"<2,"0X!!_&Y4:5XJH+-05TK/YEXR'"=*;%PU.[R4^(W=M_&0/)^IDH,
M3D8E+?XE4%_8@^\+:+M_+MG M2L=U!&">)"6MPH_P=$?L;=-?;]=SM@R6TSD
M#@"]Q Q_P])W8_:GR:QVRMGX_ =-8W*8*AVMM^CPN3>&H+5-)34D*4TY*UR
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M\O7S>?D#_P ST[DXOJ[2[!&H+_J<K4_\5]R-:?[C1_Z5?\'4:7(_6E_YJO\
M\>/0.?3C_C7N_5*]<BP5#8'4;_0>U2'2M>M4KUC6!G4D$ !;<_XCCWKP]>?S
MZOXNG\\=8 "MU(8_GA/Z?[;VCFC\3JXEQY==BQ^E^/J"+>TKQF/IZE>O6/\
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M(3)#42?Q:C>.2F_A= ].T>/E,_VHF::D2C7QV4=FQF#$*!6GD*_9Q^0]?7%
ME?<U7O,]M%MKQK)+XE/$(!D;@%&::3QUMBHI6G=6MOMK_A25M7%[ERV)Z4^-
M.2W?MFD:I@Q>\M_=@#:4M6T;.JSC"T>)R#14S!5= ^469U;2\<#J1[2/OF:(
MN/4G_(/\_0IL_:9BH-Q<:6.2L::@/]L6%?\ >?V]%+Z!SWR)_GI_*?'X3Y$;
MD.VOCATQ0C?>Y]A=<I+@<53K4R-2T-#3K-45-3-F<P3/&:^HEFE@HXZW[4P:
MEB9N(ON;T<X&33  QPXY/S_R4Z/=Q2T]N+(O:I6>4Z%>3N9O,DX':O'2  32
MOKU8E\BOYO'Q1_EY9VL^+OQ2^/>"WM-UQ6MA-W4NT,Q3=;[=QF0I7D2NHS60
M8[)U>9S5-.FBND>!0*AY!+63544\06O>I:'1&O#!\LC]M?MZ"NV<C7O-*"]O
MIV36-2Z@7=E.0:%E"J?P@>7  $=&+^.WSD^/_P#-ZZ5[<^.TS;^Z*[(SNPZN
MGW9M+%[J$>0CH*TQ0RY/ 9BE2F7*T%-4RP0U<-10P>1)?!54CTM02[L=PM^I
M0U4_;\_R_,=%.Y\NW/(MQ%=C1-&KC2Q7&K.&4UTFE2I!-"*@@CKEV)\DNA?Y
M+?Q9Z@Z1W%N'?/=^_J? 5L>SMK3Y?179%H'U5E;)+4O50;;VY%62&*EA1:@Q
M)^U3PU3PU$@I)<+MJ!35FR:</\]!Z<?SR>MVFSW/N#>27*A(8Z@,U*@8P,4U
MO3).!ZD54=%BZ#_GA?&OY<;BI^@?E/\ '_&=>[>[(KH-LXZLW%G*7M3;-3-E
MB(:>GS,=7BL;)CUEDD$:U'V\\,;,'EDIXPTB)EW:.?ME4 '&:$5^?I]O^#CT
M=;C[<7FR(;JQG+M&-1"@QR4&3I(9J^NG%> J<=$B^96T^Y_Y)OR>QG:7Q W$
M<9T+W[05M33]<;KCJ=TX85FU3%][@LK%),D\\=*:Z*IQM8E;!7I#/44JSLL-
M3)4HKF-]JF!B)TMY<<#B#ZTK@\<\>-1)R_<6_N+9&&_6LT)%76BM1N#J:8K2
MC+0J2 :< !YZT_X4GX^HRV,HNW_BY4XK"2&"+,;EZ]['&7GB)<"26##Y#%4J
MRH%)81G,JPM;6VJZKQN^FFI03YT/^0_Y_P ^BR[]H*@_3W.<Z5DCP?M96Q]N
MD_9U9EVO\0/B]_-2K_C+\J6[-WGO/IO T.1R$6P,=FZJGP>>@,DJM3U5'(\<
MN$R5)DH&ILEX4CJ)HX7HY3&\22J_+9IN)674=/F/7_-GC3C_ #Z!]CS!>\CK
M<6'AHLI(_4(!9#09J!WJ5-4K@$UR"1T2;O[^>3\=/B)N^M^/7Q<^.F*W]MCK
M')5.ULK7;>W!1]4;;@J<.Q@J:7!P4.(RAKHH9(S$U488(G=&:(5$129TLF[Q
MVYT1*"!Z8'Y4!K]O_%]"3:_;2[WY!=7UP4>0!@"IEDH<C469:'^CFG T-0+.
MO@K_ ##^H_GQL+<.:ZVHZS:'8^SHXDWAUANRJ2>HH7KU<4=7%54RZ:_$U,B,
M@J$A21&5DEIXF,8D,+.^6\4TPPX@_P"?S'^KTZ!?,_*,_*TJK,0\;GMD44K3
MB"#P8>E2/0G--2[^9)_,O^8?R(W-OKXY]H4>"Z@V7L/>^<VSNOJOK[[G16UV
MSZUZ<C,Y2J=JO*QTU73N\2)'2T;GQS-2-+'%(@5W*[FO 4? !RH!I4'S]:?;
M2O4\\G<H;?LJI=P:I7= RRR4PKK7M %%J#GBWE6A/50//^I9?^#>R22,IZ]2
M0KA^'7#20;@_4\CVG;ATXIIUR-_P1_L?;=#TX6]*==@-<@J1_C;WKK8->O>_
M=;!KU[W[K?7K'^A]^Z]UD-N+*1PU[F_X_P!;VHZ:S_AZ[7ZM_K^_+\0_/_!T
MQ)UF3Z_[#VJ\OSZ9\_RZYK_T2O\ Q/M1%_DZ8D\^I47]G_8_\3[=/2)^/7,_
M7_8-_P 3[>3AU=.'4A/K_L/>TX=)I.LOLQ'#IOK./H/]8>WTX=,OQZY6/UL;
M>W%P>FG..LD0Y!_QM[>Z2OQZ<(AR#^;@>WU%!U8'20/L_P /3JOUO_0C_>?;
MB=.' _/J9'^DDWY('^V]N])^I\0N?\"1_O'NRBIZUU-II%BF#&P/J6_^N#_Q
M/M[I/.AD7K%-?R,3_:-Q^??NG8^'6+W[J_7O?NO=>]^Z]U[W[KW7O?NO=&@^
M&ORV[6^#GR-ZY^3'3=10#>?7M?6L<1FEEFQV5Q^:II:+)8K)0PRPO+1UM'/*
MALX>*415$+)/#$ZEN[[7'O-NUO+P:E"*55@:@BO^HBH\^E^V[@^US+,G$5J#
MP8'!!_U8-#Y=6RC^8[_*'@W>?D31?R@*N#Y&+GVWE!LV7Y0YJHZX3.MDC5C*
M?PO[5$\"W\RXL85<<K6I5A$8%0 K_5[="GTQO1X.G37PAXNFG#U^5==:?LZ$
M(WO;PWC_ $I\6NJFLZ-5>/I\_@X_MZ#?JS^<ON#=?;7S6SGSRZ>Q7R:Z>_F
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MAM[X[G:>!^)'4FPNE]J=(?Z7?XH:W#;)I,_1M&=Q1[8HDHC61[AJ[JNWY4C
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M[KWOW7NLD44L\L<$$<DTTTB10PQ(9&=I#9551<LS$@  7)X'N\<;2L%4$L2
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M?\]$?^7KYO/?P8]Z=R6) 7M/L#_W:U7N1+3_ ''B_P!(/\ ZC6\Q/*/^&/\
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MYW-_YQ4O_1OOW_ S[;_RF7/^\Q?] ]>_X(2^_P"42#_>Y/\ /U[_ &1/9O\
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M]+[T_#_5\NGX?B7[1_EZ^J]_+Q_[( ^#7_BGGQF_]XK">\<]Z_W,G_YK2_\
M'VZG3;?]QXO^::?\='1P_99TMZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI8_G$?\ 'U_RH?\ QK+\3?\
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M,/A" _A3!KYD4R2U-1(EAP>?Q_7Z>R4VZGC_ *OY=3MXG7>ASJ"QW*AF(O\
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MZD>VWB(..MZ_7KCXEMRXO_@"?>EB:M>'6]?7,AG%@Y.DW"G@#_6'T'NTGB$
M=56@ZX%6TA&U79E^GJ'^V_K;WY(F;XJ]6+5X=9WI66)92-*LQ5"Q%SQ?4!];
M<VO]/;OT_G3IM)*D@9IQ].LQH)HZ=*J5"(I5/A.G3JM;GG\7][-OI&K]G3 O
M%D?0*$@Y^71BJ+YF_,+%XR+!XWY7_);&8>" TD.*H.]-TTE,D1%C$E/'E5A6
M/22-(2UOQ;VQ'+(#2K4'E4TZ2/L-A(=9MX"W&IAC+$^M=->CJ_RG_G[!\/\
MY+[AW!V[E<UE^L^\:&CV_P!I[AJ)9\W6TE925+SX[<$Y=VGK!12U%8E2/W)C
M3U,TD:R3(D;K;>4V[5/#@:>A\_RI_AZ(.=>6_P"L%H$A $D)U1C@"*4*>@J
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MZS#]$7_+8?[T?;;_ .7_ "=/0_$OV_YNOJ6? ??6'POPI_E_;1JZ7-29//\
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M8\,"IY!]^Z\7IT(N0S]%C=O5.Y9XJYZ"EQ;9>2&GHWGJ#$L?ETK H\C2Z>-
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M#KY\E].GU?3W[JNL=+O>6\L7L;$+FLO3Y>JI&K(:(1X7%RY>;7.KL#XH07T
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M -2W'^%O;?Y'\@3_ (.K@UX>7653.L;*K,(V(+()!8E?H2M_J/ZV]V(*BO\
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M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZSC]$7_+4_\
M$>]/\/\ J^73T'Q+]O7U7OY>/_9 'P:_\4\^,W_O%83WCGO7^YD__-:7_C[=
M3KMO^X\7_--/^.CHX?LLZ6]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4L?SB/^/K_E0_\ C67XF_\ N37^
MQ/RSPN_^>.?_ )]Z)-ZXP?\ /1'_ )>OGT=O4NOM;M%M$9U=E]A-J()_Y>]6
M/]3_ *WN<MG359P'UC7_  #J)KT%IY 3_HDA'^]G[.@]^PU(;JJ#2/P>;GZ<
M<#Z>S+PJ=)'_ $LC/4ZC^WH_(!&LY !19'(LPO9OI^/Z >WHV6.OGZ5ZI-'X
MZT5M)X&@&1Z=,^0%373/),5;DE=%]*@?T^E@/:64-*:GI/#:_3X ('Y_SKTU
MM1O]6&K4 ;@>VO"Z5^&/7KPIW^@U6']+_P#%/=-!^?5:CK-#1^37;E0+&XMR
M?Z>W%2O6R]/+JS7^3?VKMKHC^9[\,>P]WU=/1;?B[<IMFY"MG.F*F':>/KMK
M15,SZE$<%-/F8Y9'/IC1&=O2#[#O-UFUSMLZ)QT!J?)&#G^2GH[Y>E$%[$S5
M U$?86!4?S(ZWA/^%)WQ8WG\E_Y;N;S/7V,R.=W-\<^R-N]\U&W\4GGGK,-A
M:#*X?.&.*Q\G\.QV9ER+@$/X:*4)K<B-X@Y%W)-NOU\0@+(IC+'R)(8?M*@>
MF<^O4A<TV+7MH= )9&#@#SI4'^1)I\NOFCJE^=1XXM[R"P?RZA]FT]9- 'T)
M]T(IU0O7KZ(W_"6;XS[XZ:^#.^^X=\XRNP?^S+]H1[KV+C<A"]-)-MO9E"F-
MH,H8I$22-,G7R99X#8I-2)3543-%4(3!?N'?)=WPC0U\) C'RUDEB,>E0#Z&
MH\NI9Y-M7M[0NXIXC%E&1VT !SZT)'J*'K5G_P"%"7<V&[P_FL_(N7;V0I,O
M@>K5V7TQ1UU'6BN3[OK[$TT6<IR5U)%)1;BGS%+)&#Z9(6U6D+*)&Y$L3;;;
M'J!!D+24(IAC0?;55!!]#T">;KM9[UZ4(0*E:UR!4_806((^77T6>B<+M+<?
MP>Z;VYOU:1MBY[XI]>87>BU^2?"P'$Y3:%'!D1/61S4\E)":-YM<R3QM$MW6
M1"H80/<$I.Q7B)#3[0QIU+L0!C%>&D5_9U3]!_*'_P"$Y2U$+Q;/^/<LZS1-
M%&_S@W=4AF5@54QOV.RR FP*LI#?0@@V]B=N:]Y89=_^<,8_F(^B,;#MP_"O
M_.1R/V:^K4L7UK\.?Y9/QY[3[$ZLZ.V]U%U5L;;E9O[L&GZ7ZWESN7R%/@(N
M:FH2@AJ,KEY*>$D^6IG>.FA$DTTL%-'+*@?::YWJ95D<N[$*ID? J>%6- .C
M81P[;&S*H50"Q"+G'R45)Z^;S_.#_F>[P_FC?(?&;\7!5^Q>DNK,7D]K]']>
M92:&IK*6ES,L,N2R^4DAUPG,9N2EHS41Q2O!3PTU+31O,89*FHG7EGEL<O0E
M20TCD&1A6F*T KY"IS0$DGY 1/O?,)W>4%5HBBBAB <Y)- <G'F>'6TK_P )
M%]QT57\.OD[M,3*^7PGR7@W!6P^4,RTVYMK82FI6*?55>7$5@!^A*M;])]Q[
M[D@F[B)_WR!^QW_S]#/DIP]L_ ?JG@:_A7K6Z_X4;]=;@V7_ #=?DOD\[2M!
M0=BX[J+?VTZJUA4XZHVCA<6TJ_X19/%9&G/]6@8C@CV->1YUFVV,#BA=6^W6
M6_P,.@YS.AAO')'Q!6'V:0O^%3U1TM*AOR;BWX _XCV, M>B$2^HZ^H?_P )
MRNO<[U[_ "D/C>FX:&LQM9O3)]K=@4='71B)_L-R;HRIQLZCZ^&MH(:>JB)_
M5%,C?0CWC]SI,LVY3:34#2OYJB@C\B".I7Y<0QV<>H4KJ/Y,Q(_:"#U\Y3YK
M9?'9WYK_ "YW=AJA:O%Y_P"4W?FX,5-8$24^4W9EJF![J6!#QNA%F(_Q(]S=
MLB>':0>HBBJ/L1>HPW.,-<3?.20_M8]?4V_E4L6_EH_ MF^K?$OH=C^.3MS'
M^X Y@-;^X_YKR_\ 'SU+6TXM8?\ FE'_ ,='5>G?_P#PHF^&?1/SPV7\0*FL
MCW+L2')939_>OR)QF71\%L_<4TD4%!CK)'+_ !2FH9Q/'G:J.5(<8[(@:HEI
MZZ*F-K3DV[N[0W0%#@QQT[G7S(]/Z(XL/]K4ON.8X+>X$!.,AGKVHV* _P"4
M\%\_.D7^?#_*%P'\R7HF'N?I+%8=_EUU!M>:LZZRM#)3TXWKM^/R5TFT:JMU
M+%))(TLU1A)YI?!!62RPM)!39"IJ(M<J<Q-LLVB0GP7/>,G0>&L >GXJ<1Y$
M@=>W_9AND55'ZBCM..X<=)^7IZ'Y$U^9_58G*[<R65V[E\778G+XZNJL3F<3
ME:.3'55+4XZ1HJBEJ8)E26">&9'22-T#HZE6 8$>YWC966JD$, 00:@@Y!!'
MD>HKDB$9 :H*X-<9'&O^;K?N_P"$I/PG_P!'O0G8?S6WAA5I]R]T5E7UIU54
M55/:6/;&TJP/F*V%B@*Q9G/P1P$!C<8='Y#W,3^XV\_42)9(>V+O>AP9&&*^
M7:IQZ:B.A]R?MGAA[MLF2BI@=L:\:&E>YLG-#1>C1?S=/Y%':?\ -0^06V.V
M:[Y@87JK8O7^P*#8VP>M9NFZC>(HS+/+6Y7(RUB;FQB2U>3JY45R*1=-/34L
M9+&,L2;ESFJ/E^)D\$NS-5F\334 4 IH;AG]O1EO.PMN\BN9-(5:!=%<DY-=
M0XX_9UW_ "B/Y%/:O\J[Y!;K[8H_F%A^UM@]A=?5VQM]]8TW3E1LM:N2"HAK
M<3DTK'W-E$2KQ=3',B7I#>"KJHPRF2_OW,G-:<PQ*AAT,C:E;7JP10BFA>./
MV#JVS;&VTNS>)J#"A71IR#@UU'AG]O14?^%7?P5A[)Z.ZS^<^SL-%)N[HBMI
M>LNV*JFIHEEJ-H[UK#_":NHD\?FE3![CJ/#$@DTHN9J)2NE&8&?MYNO@3M:.
M>V4:E^3J/MIW+Q\R0!T7<Y66N$7"BK1X:@R4)^S-#^0!)ZT'C3JITA2!8GCG
MZ#_8#W,M.HO:4MUR-/ I!1F(\<98E/S:S?4_0-?G_>!]/>P .'6HY6!J?7A\
MNN!IU.HA3Q<DGD?[UQ[T5KUOQ&)ZX>+_ !/^P&K_ (GW4K3JA<@_ZAU[Q$6^
MMCP/Q[W2G'JX)\^N7B (# V) Y_Q_I_C[KTV[<*'@0>I7ABTZ;WOS8<'_;\G
M_>/;U 1TH64D=<#!$#Q?_8G_ (U[UH'7M1/7*.FC<G4XC 5B+B][6L.%/)_U
MQ[TJUZHS$<!7K@(T4 W(LQ_!M_K_ -3[]0#CTXI X]1S$W'T-_Z7_P"*>Z4I
MUO6>N/C:YY4_T O?_>O?J=>#EN ZS*I(MQ<<'VZHQ3IX#UZYB,?4_7_#WO2.
MO&OK_AZ[T@?@G_;>]TZU0^H_GUQ1%8D#CGC_ &/MH^@ZI(?GUGCB!O<-Q;^S
M?_B/=XQ7C7K<1KY]<F15'U)_VDKI]V=0.O2C''SZ\JKZ2;\GZ?7W32!TF8]<
MN%%_]8>_#C0=,D5ZQEB?R;?[;W?KU.N/OW6^O>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>ZSC]$7_ "U/_$>]/\/^KY=/P?$/],.OJO?R\?\ L@#X-?\ BGGQF_\
M>*PGO'/>O]S)_P#FM+_Q]NITVW_<>+_FFG_'1T</V6=+>O>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ6/YQ
M'_'U_P J'_QK+\3?_<FO]B?EGA=_\\<__/O1)O7&#_GHC_R]?/X[<J&/:G9J
MQC]/96_P2([GG,5=_P#>O<[[*U+* >D2C^0ZB6\ DN)*UQ)+^W6>D/2SQ!B)
MH@R7O8,8S_K7L;?[;V;(17(K_+HMO;5Y5_3;2?F*CIX@P])DHY:J$FE6)2QD
MG<E0>;7(!M?_  7^GM5'9"X4NO;3.>'1))?2;8R+,0[.:*J ACZT%?+CD_GT
MVRXJ98S(KTTHLS,$E$A_VWMEK=E%:J1]O1S%?JYTT(_TP8?X1TUM 0!Z; ?C
M0%X_VWM.4^72_4I].LJQ*BL?!$Q) 4D'C_6LRC_;W]^  \NF"4<X/#B !G]H
M/7HZ<.XM&%#?7C2/^-?[?WL(.G7=817\\9/4FHQB@#Q-2RL55F$<M_Q]"'^I
M'^TC_8GW:2#TI^WHK^K5S4AUK_$M/\ /\^OH6?R5?YX'6ORLZ[V?\8_E7NW#
M['^4VU<+CMJ8C/;OKDH,=V+24,24T-73U=2L=-'NB10BUN/DD#UTA-70+*KU
M--18^\X<E3;.[7$"DP$UQ4F*N:$<=/HWV YI68.6N:(=T18I'7Q:4XX>GF,
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M<AK^\A]MNDW2WCN(_AD4-3C0^8\L@U'Y=0GN-K)83/ W%"17A4>1\^(H?SZ
M*2ANY"H1<V'I^G^\_7VL,?20-I&3UQ2@:_(_3?D_3_7_ -?W[P^JM)Z'K/\
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M^@.O?ZV6P?\ *%#_ ,:_Z"Z]_LQ?=O\ S\7/?[>'_KS[]_KN\R?\I\W[(_\
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M:6>)U-FCD4V!N NVZ_CW2%9XJZ'K2HH<$J?Y@])+ZS?;Y6ADIJ6E:&HR ?\
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MMU%U8,."#[U7KW3I@]V[5W.KMMK<VWMPK$&,C8/-4V6"Z2 =1IY)+6+*#?\
MJ/Z^_5KU[I0>]]>Z][]U[KWOW7NF;"[CV]N2*IGV[GL-GH:*I:BK)L+E(,HL
M4R %HI6@>01R@$$JQ# $&WOU:]>Z>??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U2Q_.(_X^O^5#_XUE^)O_N37^Q/RSPN_P#GCG_Y]Z)-ZXP?
M\]$?^7K0Q['0CL?L5D()/8W89(O_ -7FK^OO)+EP?[K[8C_?2X_(=8\[\0]Y
M(I!_M)Q7_;CI&L9KGT,NH7%O]]R/9PVKY]%2P(13C3\S_DZZ"5! "@L1_9<6
M'^\#WK2QQTU,\,9-0<^=<']IZF045=.Z1K2T[%V*AG?Q ?XEF95 '^O[5);2
MOP0'Y_ZCT1W&[6L50SLN!6@!.?D%)Z?I-JY.IIBZ5&%14N?$F5I]7%[A5,NI
M_P#8 ^S%MFGF7 4?9CHKM.;]JM&HSS$G\3*37YT'^3]G27&"KWG%-J0.7":W
MF1$'/Y<L$'^N38>RC]V2UT_SKC_#T(8^9(F.KB,?A:M3\J5\O]0Z4D^U\'04
M9+Y-LQDV,)-+CXWCA3G]Q7EE53*XL /&-!/J#,."8'9XXAW-K;T7 _:>/1'/
MS?<W+5AC6"&I#2S#NQ4< <</.O'RZ3F6QKB0RP4,&/1D58Z2-I*@G0 "VIR[
M*3R3=K?@"W'LKNK!H\A0H/ 9)Z7;7OT%V:"4RG!9Z!%],#%>'E7[>IG6VPJ+
M?V^]O;0SN\=N=<XK.5YHZW?&[VDCQ>.58Y'\]8T"22",E @TH3J87L/9/+&R
MJ3I)IZ="V:_\!=4=6-*A%^(_8"1U8'V'_+2PO6?7&"[/SGS(^.QV[O3 ;KSW
M7+I+EH?[Q#:"I]U!BF>D"32^:6GAYL-<J7-C?VB6=C4!#\^./Y=$MOS4US*8
M1!-J5E#UT=FKA7N/VXZ*1T9\=-P]X[;[SW%@L]A\+3=$=39OMG.P96.=WK:7
M!D!Z6D\*.JU+\E3(53^I]J))/#*BG$T_P#_+T:7VX+9-&'!/BR"-:4H"U<FI
M&,=3MA?&C<>_/CKWA\CZ+<&#HMM]%Y?8&)SF K(IWKJUM_Y&FQT#TC+&:=5I
MWJ5>3R."5!T@FUW/$HX2G'-?V_+Y=:GW1+:>.WH2TP?212@T+4US7/E3I8?%
MWXIU7R@JNQH*/LC9_6F(ZMV'/V#NS<N^(*E**"@I9TAF?72),RK"KF1V=% 4
M'V[<RK$ !5B?+A_G]?3I#N6[MM^DO&6UN$4(P8DD5%=0'IZGJ#WG\=-A]/X[
M;];MKY'=2]Y2YJIR%-4T'5U553RT HHXW26K^[AA58Z@N50J2;JW'O5L/&)#
M*RXQ_J('34.^7$_:(VCI2OB#C6O#06X?/H6>FO@E!V?TEC.]MU?('IWIC9^9
MWYD^O<9_I(GKJ(RY#%P+4,@FAIWIP9(6D<7<66-RQ 'M/-(5<HJEB/2OI\@?
M7K4O,;6DO@^'+(V@/VA>!8@?$P\QT!7R4^,787Q<WY0[&W[4[:S*9S;>*WEM
M'=NRLL<[ALQB<T95IZZ@J3%!(\;20S(5D@C:Z:U#0O%+):)Q**C[*='>V[S#
MND9E74*,597%&5ER01P_F?\ #T*GQ=^"';ORMV/VKO;8-1MZ@H^MZ9HL=19M
MYDJ,_E10U>0_@F(\:NC5WVU,I/ET1KYHB6"EV1J:80D"GS_+I)N7,5MMDD:R
M%CK-"5II05"ZF^53Y>G#HCWB92K !#<$7L?]M]?S[<*TX="9V0"G^#JUW)?R
MG]T0YG:^QA\HOCA2]O;YVIA=W;.ZLW+G,CMG(9"#.(SPQTY;'R+)/(L52L:I
M&WDDB93I75(J/ZDMDKC_ %?(#S]>@A%SG$BLXMYS&C,K2*%8+IP2>^M.J]L+
MU!N*J[GQ_0F::+;>_:KM2@Z@R=/7QK504&6GRRX:H%0].[%TI*PL&,0?4JG2
M3Q=3J717Y5I3Y?;T(I]P_1^H50T8C,H8-W,NG5@$>8^SHW_</P3V1TG0=B4>
MX_F!\<LMOOKRCS;5W6U!6Y2FS516X6-W.+@BEI%3[V=U$:!F"EF%V Y]M1W.
MK!2M32M3Z_93H*P[E<;J\;PQ7$:/3N94:.A\SW5H/E^SHN?27QORO>,?;DF
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M8X]?/7[,[,W_ -R[_P!V]I]I[MS>^^Q-]YNLW%N[=VXJQJ^LKJRO:\DLLAL
M  J1QHJQQ1JD42)&B()QMK:.SC6*)0J***HX ?ZN)XDY.>HFGG>Z<R2$LS&I
M)\_]7D. &!UO2_RY-R[9_DN_R*&^:>]]KIF.R_D1NG:?9\&W%>-ZG)T_8-?3
M8O:./B=Y:0&&':R3YK1YB8Q451 <WC,-[\C\U;P;6,T" Q@G &@%FK2OXJ@?
MEU)^T,O+^V"=P26HY R3K("TK3\-"?SZ*%_PJC^-6!WIC_BM_,DZI>FS>Q^T
MMH87JO>6>QKO/#4Q9.DFW)LC+H8DDA:.OQD^8@DG:9!I@Q\:"362AK[<[B8F
MEL9,$'6H-.([7'K7X33Y$]%W.]EX@CNDR*:&(J<'N4^E..?F.M-Z_P"?S_Q3
MW*W4=];=G_"1;JG;.X_DE\K>X\I0P5>Y>K^H]C[/VM4SL6-*O:F3K9:^:&/2
M4$S1;<BA\MPZ12RQK=9I/<8>YMPR0P1 ]K.[$>I0*!_Q\]#WD.!3)-)3*JJ@
M_)BQ/_'1T</^2+_,,^3'R,_FZ?/+J+MGM?=O8W4F\,-W1O?9^S]S96IR&/V\
M_6V\\7B<-38&@FE-+A\=_ <I44]1!!3*:EXZ::=GFCD>0IYIV2WLMKM9HT"O
M^FK$?CUQER6]3J&#Y D<*4,]@W6:ZW"XB=BR=Y4'\.APH ]!0Y]3GC6IL?Y2
M_P >M@_#C=?\\3MC9V+QU-7]??*+MO:.U)#0,JX[;?6V%GWGBL5#3"X2G@&Y
M8XI3$P^Z%+"QC01Q*"GF._?<H[%&X> I^UBYC)K\_#!^7[>C+9+-+)[MAQ\9
ML_T=(<"GRUG[>BT_\)K/E5WC\[M@?S ^A_E]V+NOO[:]4FR<U'4]CYB;<U2E
M-W?!NG';EQ225<DL=/B)DQU$])0P01TM(S5/AC5)51#7GW:X-G>WEME$9(84
M7 _3T%3]O=DUJ<5S4DNY0W&7<EF2=B]"IJ>/?JJ/LQ@4QD<* 4-?R_OYN.?_
M )0^S?EG\?-E= [=[-[%WQOW>&)IN[*W>;[-J<;4[1H:K!X5I,3_  7*_?T>
M,R8GR/VKY&'R^>:F\D1;[@"_>.61S4T-RTIC7PT/AZ=7Q'4<ZEH2#2M/*ORZ
M#>V[]_5X2VXC#GQ&[]6GAVC&EO2O'SI\^MA3_A.'VI\T-T=!?+SY+_.;M[L;
M>7Q4R=+#N+9>Y?D!N2MW<DLFV8<O/O7*XR?+/431;;IZ..GAJ$C;["2H21*>
M,2T]6"">>8+.*>&WLT59%!5Q& ..G0#3BW'/'(J3B@IY3EN9(I)KEF*,04+G
M[=1%>"\*#A@T \]"S>M=MW)[RW;DMH8Z?#[3R&YL]7;8Q-4BQRTN.JZJ62BI
MY%66=5D@IFB1@)Y "IL[CU&9[9&CC57-6"J&/JP J?+B>HNN&5Y&9!12Q*CT
M!)H/V=)GV]TUU[W[KW7O?NO=>]^Z]U[W[KW6[)_.J_[AR/Y2W_EAW_OBMU>X
MGY4_Y+MY_P!1'_:0G4B<P_\ ))MO^;/_ %9;I:?\*P_^R5?@)_X>F[__ 'G,
M5[1^VW^Y4W_-/_G\=*^>?]QX_P#FI_SZ>M&?W,G48=>]^Z]UL!_RB_EO_+*^
M"'3G8?R<^1/560[Q^=FV>R\C0_'+8<-#6UD-'BJ?%8>:ERQJ*M3MG#RC,R5R
MG(M'59:".)_L*8@L)0-S1MFX;S,MO VBW* R,2 -6I\8[FP!V_#6E:<>A=R_
M?V6UQ-/,NJ8,0@%2=-%]>T9)SQI4"O#JZ;_A6WD7S'QL^#.6DC6&3*=B[\R,
MD*$LJ-6X#&RE03R0I:PO["?MJ*74P_X7_P _CH0\]9MX_P#FI_SZ>M6OXV_S
M,OYC?1NS=D?'7XS?(SLC9VT(<W48S8O6^T,9BZT-D-[9*2I>"E2;'5%3-45^
M3K9"%,C$O(%6PTJ)%W'E[;[MGN+F-2:5=RSC"K3R8# '0+L=[O;=5@@<@5HJ
MA4.6/S4\2>ML'^;-\[?D'_+2_EQ=+_$K=G>^Y>V_GQ\G]FY*O[?[4SE52O5;
M=PV3C$>X&Q24<%/!31M4RG"8>18%9XJ?(9$NM;&I:-.6MEAY@OI)Q&$MXB-*
M"IU'\()))\M3?LP"*#K?=UEV:U2(OKF<$%R *#S(  'G11^>:&NLI_(_^(T?
MS)_F0]#;#S.,CRG7_762G[T[0IYB#&V&ZOD@J8:>9"K"6#)9R7#4$J6%XZM^
M0 3[D/G'<OW982,/B?\ 27[7K7_C(;\^@5RQ8_77B \$_4;_ &M*?\:(_+K?
MB;Y/]'_S%>[_ .9=_*MST,45)UCU;@=D9'+Q2Q--DD[!Q<U+N.MH5%2\AEV?
MFZO%0,YAB\=8T8(/I=H7^@FV:*VW!3\;LR_T3&PI6HIW4)'&HZE'ZN+<I)[,
M@]JA6^8=36E#7%:'A0]?,3W[T1V7UUWUNOXU9S R3]M[1[3RG3=9M['ZS]QG
M<9E'Q @I&J$IVDBJJQ5^WD>.,21NCV4-[R$AOXI[<7(/Z93Q*GR6FHUI7(\Q
MG..H8ELI(IC;D=X?13U:M!2M,'R/IUN!?S.<[@.JOYH7\@/X";+>5=K_ !#W
M9\.D=*>=C3//NG?.U,%3*X=C--5Q8_9T$[2S!G*UVK67DFO%_+D;7&W[C>O0
MM,LPK3-1&[MY<"7'#TX8'0_WQU@O+*U2H$;1FE<4+JJ^?$:#Q]?MZ/Q_/6^-
MO\XCN[N?I#,?RUMQ=^87K["]89?&=C0]0_*RA^/M*^9ERLTL#5=#5[QVTU?4
M"B,86=:>8*EH_("-()^3[[;+1)1?B,DLNC7"9,4-:41Z?RZ,>9K2^N6C^C+@
M -JT2"/-12O<M?/K3[_F.]9?S<>A<1UIU[_,J["^0^3VYOS(YK>76NT.V_E0
MGR!QLU;L:*.AJLE#1T6[=RT=#744&=\"33)#,8JN9(69&G E'8KC;+PN]@L0
M*@!V2'PS1JD"I120=/#/#[.@!NT%_:A5O&DHQ)4-+K%5P30,P!&K^?55'L1]
M$G7O?NO=9Q^B+_EJ?^(]Z?X?]7RZ?@^(?Z8=;P7Q/_[)9^-7_B .F_\ WG<;
M[X?^Z_\ RM.\_P#2UW#_ +2YNNOWMQ_RKVU_]*ZR_P"T:+H?_8 Z&?7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U=_T'O&3?74NS,[4S&?(KC!B<K(YNS5.$9J621_
MQJF$2RFW'K_'T]](_;'F \S;%:73FLGA^'*3Q,D),;$T\VTZO]MU@+[B[&.7
MMYN;=!1/$\2,>024"0 ?)=6G\NAA]CWH$]>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:<=)_
M+Y^(7\P;_A15_-LV9\O>H_\ 2YMKK[J/XC[GVAC?[^[GV%]I79+K[8=)//YM
ML9K"U%1KI_3HFEDC'ZE0-S[8TAF-?EU[I6?S6/Y0GP(_EM?"KLSYQ_!>DW=\
M(_DU\>,CL;=_6G9VTN[][;H;*5D^>QM(NV:O';FW)F:.LI\OY](B6GL9$1JI
M)Z):FGD\Z!148Z]U?1VY\_\ 8?Q@^+?Q^[K[WVSV!F.RN^,/UCM[8W1'4NT6
MWIN_<N]=]81,FVV\#B$E@CDJDD2J#R3U4%+ $'FGCU)J<+Z0*]>Z"?JK^;3U
M[N7Y"]:?%[OSXP?+KX8]L=WPS-T</D=UKC:7 [MJ*.CGKZK&8O<6V<YN/%0Y
MBCIJ<M/1UL]++&TM-"?\HJ(H6\'S0@CKW0#_ ,X7OOO'.]I?"7^6)\:.Q<ST
MIV9_,*WMV#C^P.\]N0,<MM?KSJ+%KEMU-@*A)X9*/<&3HFE2EJ4!,45/4JLE
M+-+!4QZD/ #SZ]T(6W/^$_O\I3"=7UO6.5^(NT-\G,4U<-Q=E;[SF7W!O.OJ
M\K=JK(R;K:O3,TE;-*S2WHZFFBC<GPQ1CCW[PEZ]T6S^7WO3LSX'?S*NUOY/
M&_>T=X]R=#9SH*@^6GPAW;V;FCN/<N P,V5J,5F-D9'*S^.?*4E)6TN2DQIT
M.:>FH9 6"3"&GTO:=/EY=>ZV*?;O7NO>_=>ZTXZ3^7S\0OY@W_"BK^;9LSY>
M]1_Z7-M=?=1_$?<^T,;_ ']W/L+[2NR77VPZ2>?S;8S6%J*C73^G1-+)&/U*
M@;GVQI#,:_+KW2L_FL?RA/@1_+:^%79GSC^"])N[X1_)KX\9'8V[^M.SMI=W
M[VW0V4K)\]C:1=LU>.W-N3,T=93Y?SZ1$M/8R(C523T2U-/)YT"BHQU[J^CM
MSY_[#^,'Q;^/W=?>^V>P,QV5WQA^L=O;&Z(ZEVBV]-W[EWKOK")DVVW@<0DL
M$<E4DB50>2>J@I8 @\T\>I-3A?2!7KW03]5?S:>O=R_(7K3XO=^?&#Y=?#'M
MCN^&9NCA\CNM<;2X'=M11T<]?58S%[BVSG-QXJ',4=-3EIZ.MGI98VEIH3_E
M%1%"W@^:$$=>Z%C^:C\M)_A-\"?D5W[A&>3L'$[+EV?T]CH:*HR4M7O/L>6/
M![8ACIJ5XZFH\>6KZ:>5(I$D\$,I5U(N/.VD5Z]U25_+(Z:RO\GGYZ],?"S>
M.1FAZ^_F*?#/8G925^6W'59&-N_>A:&-.PJ6C2O>:>,9S'US5CWJ=)D%)!!&
MBA886T&@T]1_/KW6U[[?Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW5+'\XC_CZ_Y4/_ (UE^)O_ +DU_L3\L\+O_GCG_P"?>B3>N,'_ #T1_P"7
MK0\[%I93V-V(RQZE/8O8)#@?US-7;WDURU;N=NMB :&)<_D.L8^8MX@COYHS
M(%9)9P145R]?7Y=)%5=2-:,R\W_V/'U]G@5AQ!IT2/N"-\+BOK3TSY'J=!.J
M,C- &4!?2Q)^O^L0;^UD,H4CMK]O0?W)':I$I'$]M!_AJ/+U'3Q'6R?2&&)%
M%^)(8ZCZ_P#!T)M_KGV=0W!D&E !Y>1X_:.@7/9FW8RR%G\P:D%3C.'/Y8/3
MU19B2FB9&AQL@9@3Y<-3U)'XX+Q6 /\ K^S!#H%& ^>.B.XO'<_I-(#_ *;%
M1]M3P^8ZX5%3AQ.9:FFJIW<K(T5-%'BU8GZ@!=:JM_\ 4Q#Z7_/M+=21)P%3
M^P=&&TRWUP*^(5 KDC4033\_/U-,_9UEJ=VKJ$>.PF.P4*VT24"N]0-+:@35
M3-))J%[773>_]. C&XZ,: OS\_V]'DG+<EROB/<-*0=6EZ^&36M-/$#_  #^
M29K?)D9#/YI9II!=FD+2,3;^T6OJX_/M//"+ON0U/YU_G6O2^PW!]J 6:)%7
MRT :!3TI0C[,])\TV0H9FJ('EA9?I)"YC:Q_Q4@V_P!C[));.:W.JA'SST,+
M;>8-SJK:*' !(-#3.#P/5C'RV[ V7N?X;?R[MM87=.T]R[GV=M/O*#>^W\-G
M*/)9##RY7(X%Z5,E24\KS8YZM(IFB6>)#*(W9=05C[*+0LKREDKJ(R13S;AT
MCVW;F-Y<,A=%!B"$5*MV&HS\5/MQ7IQ_EQ]Q;1Z2QWR\W7ELGU]09P_&S< V
M9MGLNLH_L<]E:6IBGI\2E!4STS99ZEDLU)"3)*A(4<W]M;A )60*K 5HWG0$
MCY8Z<WZ&:80H[5 F4ZD#*RJ%8$DU-*5&>A\G^7E%\A/Y?/S"VSO3%=!=9;WF
MS?2D6SME=6[?I-B5^;AHMRXNMKIX\6U=+5Y4T,-,[O)$A6GA$C/9=1%8-O\
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M,%!55,5=45DT2QV@2G@US3&2G/\ F_FVTN;-K>W?Q&DH"5! 10P8DD@5K2@
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MAYZRAS+1)AM..\\XW%%4!%4S2112RFPAD]AGFC8KC:K" 2L'T2RU8$D#Q A
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M5HH@"%!AJ!&I II 8T&..>G;+<MIAG,L1(DD)!-)<EV!/Q=HJ?LIT\?-S^6
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M?^7K2/WN*=MV[YADQ<;LW8&^7%;Y%-]>6KCZE\#6/J(%V-K#WFGR3"K[+9U
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MQ>.3PQ#3J6D#O]79FY]TV[;(-IC\*W70E2:59LGCEB3Y>O5[V_EW%_$F;4U
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M@ZA6BUQXFFI9B0L2]Q-?AFWV[]O8)H#O>\L([*+O57J/%TFFIO/1JP%%3(<
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M)I?MZ6@J?&^KS&&I:.=Z/ZJ@?27* @"W!TEFD*F@IC_8Z*[W?MPWN9-+'34
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MIC]A_P W'K$_9/RLVA205T'6;8VE,SS19FLZK&96]20BZ*[(4M<R6460K*K
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M@VI)3SR25K%YG:1,NK$R,Q+<\D\^\7O^!TNA.UR-W<2NS,\BVS*[,Y)8DK=
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M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U2Q_.(_X^O\
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M:Y!S%%N5I"C;C*DMN9%#QQ4C9N)%3X8QCA7C3[0LV22QN96%E&T<PC8J\E7
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MT/@?&/2T<NFE>G,9IRJ&+246VIO+[>O=)O\ X4*?$;XO?'C^5)N+MOH;X_\
M4'3O9WQ<W_T#G^A-_=<=>XK:>7VW4U&]MNT,K4-?24L=44GAD#3))*Z331PS
MS*\T,;KZ50!CKW2B_GT=F[LWID_Y6WQ"GZX[:[:ZQ^7?>6?WGWOU5TC4XS%9
M7>6&Z Q>%SAV4M1F,CB***ESE5EQ/,LF9I2:?'RLDAECC'OTAK0>O7N@<^>?
M6NYOD%\::;9/Q>_DB?*'XT?)3IR3:.X_B-W?L[:G1W7U1LC,[(R./K:2*FR&
M%W_45U+AJN&@%-5TT--+')&5;PF6*)TTV1@=>ZF?S,^KJ'Y5?S+/^$]'7OR0
MV?64L/9FR?D[F>Y>M\C-]EKJ:+9FVLWF-MY1*"I\4U!55=+-C\C2K424M52/
M44LOGII71_/DBO7NK$OYC_\ +93=?\NGL;XP_P OOICI?KF6N[8ZV[FR'0.&
MH:?J;:F]UV9F,379G;F1_AB4E+2KGZ+%4T;L3#%-)3PQ3SP([5$=W3%!U[JJ
MOM/Y-_ ?>.0^/_77\S[^5CWW_*VWATUOWKK=O4GR+VUU=BHME;<W!A,G3246
M/Q79NUL:@I\/-D3!431'&_P[_)UFKI(7@A9J%@<,*=>ZV]X9H:F&*HIY8JBG
MJ(HYH)X9!*CI* RNC*2K*RD$$&Q'(]O]>ZR^_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NJ6/YQ'_ !]?\J'_ ,:R_$W_ -R:_P!B?EGA
M=_\ /'/_ ,^]$F]<8/\ GHC_ ,O6GW518R#-;EJ3B:"JKI=^[TE>IK4:9-*Y
M>L]/C_S;_07UJX(X^GO-GD*,-LME7_?0_P /7*7WDFGCYFW((S?V\F!DXX?Z
MOLZ$^@QVT\O5O4G&[1EFJ%(1?X10P<DC@QF)5 4CBXL!S^;^QX(X--&Q\_LZ
M@NYW/<U<BLN<@ 4)!IY#(^5*U],]&!V)\7=W[HS%/3X_J./*4E2E%-5UC;?C
MAI(Z>L*VG,\,!BBC59 6="=/%^5(#$^YV=J#D'&.'2W;[??]R&E3-&OG(RZB
M%]:5&/M^?RZ??D3\4-I[2KJ7+]35U?-B<?%1Q[K6JIO-%3S(#YI:,^::6>F%
MM(:3Q:F-E+#5I(=IW;ZJ9A@"M%_R>G^7[>CV]:XV>32XFE01EG9E"#6 3Q!-
M1PX@>E/4M.Z\IG<'#0X'"K!BOL1.*ZOS$(HY9'>]_1-XPK!5"JJ*H4 (H&DW
M$4KLN5 )^VO09LK6/<B[W517X0N#3/R'&OIQ_D@\INY:^A2FR^X(Q(D95J?#
M8Z2J#:?H2TT\,6H_4Z&('U'/I":2Y*8%*?9T(=OV8))K13Q_$Q(_V/\ 50=!
M=)E,=#+*:**M>!;VDJYXX6(<WYC0-:Y!^DK?GVE$X'KT(FL&EQ4?Y?Y_/I4[
M9W]38*H\K8"&I.G0K-6@ GDZF62FD+_I  U ?Z_M;;[HL9 (K3HBWGE;]Y)H
M,A5O44X\?EZ_L/#H>MO?)ZNPU'/0T&U<7CEGB2!JF&<5,OI .I&J8*E(V:W)
MBB0BY4$+Z??I[WQ'U4P:<*]!P>WQM5[9^X"A+!>%/+-<5Z7.$[FJMY9%LCG\
MKB:+QB(4]5O9X<A$-#?YJ$R)*Z)=;:*>G<+<<674JMI8HEU &G1>NPW2!D#:
M]0HS<!@TX>N.(ST)&5W)G=XTJ18K([',,Y$+93:FX<9LMZAB39YYLE@J"5E
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M>.J%UK'6XT1X"4*ZE6 ^U42#4I(L)3=2;W!(*D3$\!2O34MIK%7H//U/\_\
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MN^RB01L&!)H&-:#]N#T N[=E9#;]<:#+T&;P56H,TE!EJ&2!EU E;+,(7*D
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M7Y&O^$?YNL$T40Y635R+WCM_Q)]MN@/G_+_9Z6-<NH (I^?^P.HIC3ZZP/\
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M[&W<OE:.:#'9S^"5N-@HLNV*JY(JE:.HE6GJ&B$4UXG8%=;[7N4<BM)?:U#
MLGTT2ZE!J14&HJ,5&1TCFW"Q=&"6FEB"%;QY#I)&#0BAIQIY]#MDOYLWPD[/
M^-WQ'^/7R:_E:UO>T?Q"ZFI^M-E;GIOG'N3J9)Y\E3XX9_*_PW;VT(%B?.5V
M-@J6AGK*PT]A''._[DDJ%.6+NUGFGM[OP_'<NP^G1_-B!5G/#41@"O2MM_M[
MB&**>VU^$@53XS+Y $T51QTCUZ)]\C?D[_+D[)ZDW#M#X]?RNZSXT]JY*JP<
MN![AJ/G!O3NI<;%05L$];$-NY?#T6/K#7T<<]+KEG!@\QF0&1%]FECMU_!*'
MGN_%05K']/&FJH('<I)%#0_.E.B^[O;.:,K%;>&QI1_&=Z9!."*&HQ^=>C@Y
M+^;-\).S_C=\1_CU\FOY6M;WM'\0NIJ?K396YZ;YQ[DZF2>?)4^.&?RO\-V]
MM"!8GSE=C8*EH9ZRL-/81QSO^Y)*5IRQ=VL\T]O=^'X[EV'TZ/YL0*LYX:B,
M 5Z,&W^WN(8HI[;7X2!5/C,OD 315''2/7H.=A?S!/Y:/4G>W6G>_5W\H1L#
MD^K*/<5?A-D[H^<VX.SL#6[@K)*%\+GLK1[@V5725#;<--5-2TL,]/#+-4^>
M<O+34K0O7&Q;A=PO#)>U#T!(MU5@N:J"L@PU17[*<":MP;O9VTJRQVE"M: S
M,PKBAHR'(IC[:\0"".]L_/;Y1]S_ "YA^;V\^R\B?D#BMZ8+>FT]PXH&AI,$
MVU*A9\3B\-1%Y(Z3#8X*(HZ4F03(96JVJ)JBIEF-[?8[:UM39JOZ94A@<EB1
MEB?XO.OEBE   63;O//<"Z9N\$$4X*!P4#^'RIYU-:DD]*7^8K\O]D?.SY+9
M[Y,;7Z%A^/VX]_8';Q[2V]C^Q'[!HLMN+$P"DJMP4GDPV&.*&1IH:02TBI./
M-&]2T\DU1*S4V':GV6W%NTGBA2=!T:"JDUI\35R30_.G"G5]XW%-TF\98_#)
M U=VH,1BOPK3&/RKQKT13V==%77O?NO=94!.@?TD\@_Y!TC_ **/^\>VW_U?
MRZ>@KJ \JUZWA/B?_P!DL_&K_P 0!TW_ .\[C??$+W7_ .5IWG_I:[A_VES=
M=?\ VX_Y5[:_^E=9?]HT70_^P!T,^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z-9\4>H9]_
M[W@W3E*5CM+9E7!6SR2Q_MU5?%:2FI%)]+B,Z9IAR @1' $RGW./L;R$W-&Y
M"^G4_36C*Y)';).*,B#UTX=^-!I!%''4/>\/.J\N6!LX6_QBZ4J #F.$U5WQ
MPKE4X9J1\!ZMT]YW]88=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U59_,"^!W;W>G:/0/S#^'O;FV>E/FK\6Z7>6(V#D.Q\76YO96[]O;YA"Y
M+9N]Z7&,N3_@]3.BR155*LTU"\DU1!3O5"FFIJ.I.1QZ]T63=OP>_F+?/_M+
MHZ;^8[NSXO=1_%[X]=F[,[NHOC[\3,WNC?-=OW=>R))YL<V[,[N3'X>*@VY0
M221,E#2TM2]2QJ!,8I%I*F&NDOQZ]T8[^:+\0OE/\A:GXE]V_"S>G36VOD9\
M.N[<EVOLW _("DRDNU,Y3;GPU3@\GC\C-AHILE3L:2H;08D4N&=5J*:3QSQV
M=2>'EU[I$_.WX/?*WYO]6_RS7SV:^/VU^Z?C'\O_ (P?*;Y+PXW.;BH=LU4G
M6%%4_P!ZJ/8[28?*92<3Y&JD.*@RGVW^3Z5JZY9%+OIU+4Z]T+/\XOX5]I_S
M"/Y?G<GQ2Z8S^P-L]B=AY?JVOPN9[/RN1PN%B39&Z</G*L551BL5FJY&DI,?
M,D0CQT@:5D5S&A:1=R+J%.O=//SY^ ^0^8_2_36*V7VC/T?\DOC)V'L;NOXZ
M]UX['2;@@PVZ-D0B%HJ_'^>D_B6#RT!DIZR!S9HRCM'*$:"3S)J'V=>Z)/V?
M\;_YV_S/VAMCX^_([MCX:?$_IJ;+;3R/>/;/PTWAV)FM_;FAVCD\97MC=K29
M.EV]%M"CRQHJD5-0]?55"1RPP^.: 54%14AFP:#KW1E_DS\!^S^VOYA7\K?Y
M3[$W)L:AZG^#..^1F+[%PV\MQYB?<F0B[7VO28+#G#A<7D*;)2P3TQ>MDK\O
M22:#Y$:HD9E][9*D'TZ]T9+YZ_%S??RRZ(78O4_>N]/CEV_L[?>SNV.JNS]I
M9.O@IH<YL.=IJ:@W'C:&LHEW#MC(I)-#78VI>2FD)AJC#)/206LRZAU[JK+Y
M&?#K^;Q_,<Z.?X;?-#+_  +Z/Z WGE^NZSOCL[XUYG>O8FZ\]2]=9O&9S[/;
M&*W-A\7C-OMDLABX)A55576-2HJQ&FJ4>6-J%6;!IU[K8-PF'H-O8;$8#%Q-
M#C,'BZ##XZ%Y6F*08R)(85+N2SE8T4%B23]2;^W>O=.?OW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JEC^<1_Q]?\J'_QK+\3?_<FO]B?
MEGA=_P#/'/\ \^]$F]<8/^>B/_+UJ1Y+>C03Y[%)MS:D;TF\][^3*# )-5S$
M9:NXED>1ED^OU,0;\?10/>;/(5!LME4G^Q'^'KE)[U1?4\S;BM:$7#$4)&0*
M?GZT./V=2Z7N;<V/IVI8WQ%,Q2T4M+MV@HY!=0"0RTH(+JH4GBX%B0/8JD*$
M5.?EP_P4ZC2';Y2V)6_,UI_,_P"'I=8KY2=OT^,&#H.Q=Y87#\I)C=NY+^[]
M,Y<EF::*A-*LC'4;NX8_2YX]H6M;>5@S1@GYEL?\:Z4R3;BJZ4G<#^CI%:?(
M#(^W_+T/6YN^-_=C8S%SYC?==4T5'%15&-PJ5TL%-32TB^EHX@(HVJ&<N7D!
M,I;4S-J.HG-AL]L S!0M0?-J\*5J3_JIU&_,F_[G>,L,KN54TJ-(K3- %\ZB
ME,U\^D?F:[JG>=#21;OVY4S;M$<L,VZ\5N9,2*BP8PM5)*DT4LRDW9]"/(0+
MR78L4;V+QO6-B!_J_B!Z,]MW;P(@$C?6*=[!6K3Y9'\NB_YGI')2O)/MS,;>
MS<;1&HBI$SU-2U>@"_,,CJDC(/U")V(Y-A^GVU*I+4(/\_MZ%FV;^JI^N1&3
MQX'[.'^K]G0)Y#;^3QM6]%6TDM)41.ZR13)XSJ4E23S9OH;F_M@CH31W\<XU
M*0P&:@_[/^'K'#BIY J_;AE"@CT6M?\ H>!;U?0GCVHC@6E:](Y=Q7C3YT_X
MHC_5CI?;+ZYW/O'-T&!VS@:S-Y?*2"EH::@II:HR2$&ZI'$KO(44$FW"@$NN
MD$C5S<1VJUD./R_R=)([@WC!8@6<\5H<5X9\@<'[?EP./E_A)VYMN@^^RF*H
M:^2G53)24.8AR,RG2&T%(6(5EYNHG!N+#4;V87>K>8:0685XD?RX=-WFT7NV
MKX[1(N*:0Q(]:D:O/_57H)1B,WL29S6]>Y^JDH_\]$17P1/I(YE^WJ@0NJX%
M["QX!]F0NT  7^8&#T$C9M?D^*%H3D%$.*>I4GC]GSI7IYQ/R8RNVJFE6AZN
MV+CUIY2Q_B6/R-3)+8V(D,M>@)\>E390/3_4LQ12VHF'Q$U^=*=".W@BVU=4
M*)51DCMKGU4Y^SA\NCC;!^:>T,C#3TNZ>ORM7&4IUBQN1GI*4Q:B=+%*>JJ!
M"P/,.B50 2)3JL"R7E^9Q6*0I^=?EY]'L/.EJ$TW=OKH?(T-<T^1%*_/I2=U
M=G_$[([/.3JMAT&(SF6,%)A,9L#=$..RU362Z#J^RJ\+(3%&K'SS/5FECC#6
M;SZ(B2I>7U@X4.S4/H.'[/\ )T976P;3S)!XXB\!:9HXR:C\(R?+@1ZG'0&X
M?I'==3@HL]74,TM-4N9C@,3,<E44\$WE9DJZN2FCI8S1*B+-(8P"Q8+&"-(%
MT?,=% 8]PX5_U4ZB^^Y"9#XD*"2-B151WJ/Z)&>&,'^6.FO"[2JONJ>/;O7J
M;RK%DDCDACRF5J:=9(F/IF6AV[2LY( XAKFTV]1 M[W+NS7 .0,?+_BND]ML
M<%M1%2XE:N493I'E2IR1]IZ0^\]N]JY^MI:>JVEMC$PTA6/'XREP3[4AB6=C
MI\E4M+0Y&1BP%I:FNE<*!K?Z^T\$8T5+ZO.I\ST<C<1#,$\#PJ44".(H%&/X
M'%?M))_P](.I^,G8$F".X<S5T%(U36S8K&T@,^>DFE@50T;34L<\<)!8%%9[
MN0P4'2Q#?U2!PI(%?LZ.;B9]O19I$)->*@M7^8I_J^P(#*?&?L*GQ<F6J,=2
M5%"JLZI3U)CG<*#8K3,B2M;3:ZQ'\<D\'SRIJI4?ZCU>/?O%36 R@#@0,X_I
M?ZO7H)QM*2 JPIH9!9D*1U00<&Q UG^O%A_3\V]OZ0?AZW'S#&_$T)%<@4/'
M_53H1MF8B?&2?>/LH[@I@=3I49::G%HN&7322Q.1:]P;@_6_UU7:%J8-!]@_
MS=))=S@N364AEX@$E#Z8X>0IT9S8VV>A^Q/]P6<V=+U9N^5H!@LSE<GD*[ 3
M2)$UX:Z9G6LQHGD**)P:B)!_G% O)[+98KBT4R5U*,X !S\O/I1#N-I>NL$+
M+&[?#JD=@U* #)H.%*T)_+H3]U=!]0[,HH\?O[J+MS;F[:J#5B\CMC=M#N3#
M5QICH,E-5''SLPD;20J>0(LBEV)]+HK>Y>ZJT4M0M-:D*"I-:#@/Y]-[R!8K
MH>WN4FSB,%HV';D,2=0P>'#Y9J37L#$9?9.0@3$=:4U+20,E32YQZ&ORDTZ_
MJ1YWGD$<,RVYCCI(0#J/C( TFR2DC*Y]17_BND5F([Y ))&4_B1SI8?,C_9_
MP= WDV:IK!D,[#4T*3U)C#PE]32?JTQK(S,7 /T^ECZB -8>)!&1GY='NVPF
M%3' 0X!XDU%*Y]?RKT,?7?4K;SJ?X12Y/'82&MIFKJ5]UYBBP4;/$FMI*JJJ
MIXH*.G55<KQ)-,VE4@NQLGN)S:(9-)>GX<YJ0/+.*]-VLPW6Y,!(#Z3IJ:*O
M:34FM#PQ\^ K7IUS_P ?MJTDZJ>[NJ\YESXOXAB]K5E=D33NQ4*IGK:/'4$T
MG)XIJV= 19W3ZLDM;N2[)+1:%]2>%?S/#CGHRO98MEC$;2^+*:T5$J<<*]H_
M:!7SX]);,]:[9VM3-+)N&&:65D@IWK#XEFY*@+#!-'*C.RGZRR* "?9U'"B+
M74/Y=!>WYCN=P<QBW8Z16K$C_+_DX=/VUZ+<&(=*O:6]]C8JI=7,#4]=C\=6
M*JB[CSR,]?%P/4OG5C]2"+6H0C?B/^K'RZ;GOI+L:3;R TX4-?7T/V_Y>A\V
M_G>P*818_?<VXZS;%6\\U3N#;F?3<2QR21#54TM3'4Z4JU+*Q R$8LQ\JD$J
MR;1!)J< #2.&?V^=.D"-.66-W?) %6;@>"TU#AT(];\!?D%DZRER.V,SMC>.
MS]P!,CM_<55O"C6.II:ZWC>>F%142HZ*;NB>0\,5) ]DR\U01&A4DC!H.)'I
MPZ%-QR+=G20%"$:E?4"=)IDJ2V2*>5*Y'#H2-O\ P4VCM\4V9W!V1US-ORD@
M:<[&?/0UF-AJX=/B$KB2.K>(R $J854$Z&,@X9*_,SW;:EC[/)L_8:_9]G1G
M+R<]M!X9N$UD5TC2&S4@4QZ_;3JO/Y%],]B[(W=5P[_PE9C*VKBBGQU2*-X:
M*KIHXR(GH*DJL,\,:<74^FWKLUO9M;W4=_W*QKP*?,=$VUI-L)$$L;@-4ZVH
M*ZO/'V?E^RA/JZAJX=0F\EU8W!6UB""3:_\ 2W^^^MF1E---/2A)K^WH6V]P
M":@<?.OY^1_P].F%RK04<U++53QS'QQPQ%6:-E.D6)OP;6X*FW]3[IW5K7^?
M34]D#('(7(/$#_9ZCY>&JJWT@LL:!5^W=@H-RM_[5S:P'/\ MOP-R4D&>'VG
MJ]K((:_;2G\^DM+"](CO%*Z3*Q$3K(T9Y'(!!%O\/]X/M(KB(&@_P]&<;@M@
MBGR X=2,?F:XSQQME9X=)7QBJ+$:N+'RJ68 ?GTG^@]U$FH@$4_,]7E04.!Z
MUP?\G1GZ'>^*W[M>#:?=^/R>9H,6IBVIOW&B/(Y''!](^WFE $M50&P;QRH3
M&5NJW>ZE<]F=6I2?GQ_9GI5;;DD8H30^0-/L!_U?GT7_ 'OT=4XF?[_ 5U/N
M';]3YGQV4H'!9T1B"3#K5[J19C&KJ#=3I<,JU6E=)P>CJ*]D@74.X?E_J/Y=
M!$^T\K3L(WHZAHR"8],$B7L 2 74<C\VO;_8>W! I&H</MZN-S5L4X^G_%]/
M=+L2LJTE:'!555-! T[TRJSN5O:[A;$W((4 @DV^ONO@(W$=:3=9D<!6*_9Q
MI^SSZ#'+XFIHZR>GEH:FFGCDTR4C4SP%+\A0K@N;#Z$\G_'V3W5L QT@_E@=
M27M6\,H74X  SK[FSZ\*&O2?FI)!J4PS+I8 W%[7X^EK^RYX3Z'CT+;;>8W(
M[UR/LX?GCIM:(+<,I8CGZ$'_ &P]IRNG'0C@N!( U!G@1PI^7_%]1I%6XT@+
MQS?CW3I0&^1_G_E/6!T)'U0<_F11_O9]M%>GYY  *U_8?\@ZPNMKJ65?J+W+
M#_DV_MHK3_57K<$GG0FE/0?X>HTC0@'ES8\@*+6_K<F_U_P]T-!TM0NWI_E_
MP?Y>FN5X>2$:WY)8?[QQ[;:G2C10&M*_G_GZ;I&CN;$AK_0B_P#O7MDT\NMI
M7J#*03];_7WKITFO6+W[K77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4A>$A:POKDB_V!
MT-_M[^]/PK]H_P '2F+BOV_Y?]CKZ!7PT^+/<FX?B!\4\_B\%C9L9G/C9T9F
M,=*^?I(6:#)[7Q<T+%&E#(6C=200"/H>??)KW%]D>8-VYAW2ZABB,<VXWLL9
M,T8)22YE=2034&A&/+KIAR/[N['MNR[?;33.'BLK2-P(9" Z01JPJ%H<@Y'1
MDO\ 90>\_P#GGL7_ .A'1?\ 7[V#?]8+F3_?,7_.>/\ S]"C_7JY?_W])_S@
ME_Z!Z]_LH/>?_//8O_T(Z+_K][]_K!<R?[YB_P"<\?\ GZ]_KU<O_P"_I/\
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M_GZ]_KU<O_[^D_YP2_\ 0/7O]E![S_YY[%_^A'1?]?O?O]8+F3_?,7_.>/\
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M^L%S)_OF+_G/'_GZ]_KU<O\ ^_I/^<$O_0/7O]E![S_YY[%_^A'1?]?O?O\
M6"YD_P!\Q?\ .>/_ #]>_P!>KE__ '])_P X)?\ H'KW^R@]Y_\ //8O_P!"
M.B_Z_>_?ZP7,G^^8O^<\?^?KW^O5R_\ [^D_YP2_] ]>_P!E![S_ .>>Q?\
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M+>'<2-#$&HJ036G^H?+I;4,^U,C/$JUHPU6Y<L,A3Z8"]UMHG4U!&K43Z@A
MO<@W]W:Z6/&?Y\/V_P"3HM7;W/9K]1@CC0<3ZG[:]&(Z\ZAP&=>CFS>ZXAC)
M*E5-70Y*G\*?D%)7+QAAR0A )/ T\-[#&Z;^UNU F>AORYR9^]"/$8T)\S_F
MI_JST.?:/Q)VSG*:DKMN;LZ^V]UWA8:R?^]E7EY:JJJ:BL1;P5%0*J>GFD7Q
M(T<-)&LI#&T4[AC[(;3FDUH\98UQ0'_)3H77GMVUC_9.$7B27-*5K^(D_LSZ
M#HMT72W5N (B@R&X>S<E2Q2U GIJ>+K[##Q,(_VJC(^;+Y%@SJS0IBH)9!J1
M$:VL'/[V9P"%TU\O3_5]O09FVFV@/A-(TLF*T+ "M,?EYU!'[.@LS7R+J=A'
M)XSK&IH\54>.3&29S;] ^'C:)>62))DCR53'K5M+9*6H"!O+3TU)* %N;<75
M&<'YU)_XKHSM]5FQ6(!6H*D*&R?757/^#HNE1OS<F2F-96[DKLG5R%B]9EZZ
M;(RMIMR99I'DYL!8NP &D$KP#!8XD%%4 TZ:GMF:OB.^34=S?9]GV5!Z7>WN
MQ-]E::@BS^9:&21(X:-,G--2R>:RA9*:25Z<JVJQ#1E3>Q^I]J"JD>7Y8Z#=
MS:M&>QB:\ 0#\O6F?]1Z$7+MG\8RC.[*PM/4(S?<3)C)<=I8KRC)1RP42+J-
M[+$NDGC3?WZ)0!7_ "GHDN7>,:=/R(!(_P !^?\ J/3<M7N^M6A@V]@Z6JJ,
MM7S4>.Q6/A9M4L49=EUU,TZQQQ!0TC,MP/2NISI]IKZ^CM$J2<FF/V_Y.CKE
MS9SN/QQC2#7N)-?]Z)]?\@\^NY>J]^;.W ^^]T18J7/Z$GIJ;+/C\;% (AH1
M<?C*F5)G@A! C*4LBBXD+,3Y)4.WWD,P)8]U?.G0EW.YO(@8[>!4B0::A14#
M@:5]0?F?.O0N[.^0G;.S9*A]M[FVUMN.K\#U+8T4F))\'(4+1E)5YLP"1<L#
MP18>U5QMUK<4.FI]=3#_  $=$=MO]Y8H41M Q@A30X\R"?\ 57HY&S?D%AZS
M#XVNW_F]N[]EKEDIDK%CK,H*32=<B(:^FI3%(H*,RLZ)QJ5K6;V%;[9Y Q\+
M4!Z5)_PD]#[;N8HDB#7%')XT"AJ?[4#UZ%[:VT>G^SZ^BQ\6R-PXJHKZNL^T
MR./JUVS)(XTZ882SY2DJE2064B\BFP(:S*"^:_NML3S/Y#_-T;VO*NT<Q2:D
M1E8YJ!3^0Q_+HQO^C+K#IW!B;>5!DZ>GP;??T>/W5F'KJFJ:I/A)9(3%&U.S
MR!69J;Q"-E5U+7U$!W.>^D#*"*5_U9_V>A1^X++:H_#<.WF P!_PUZ"3/[ I
M=U8^K[7HMK[-EQV9I)*P4=+11S2)%0@'P@3 2+'$D"JJK"H=B 2" Q-;7<W5
MPCDU&#PS3\N@[N>QQ2QM-10E#1: ?X.JX5Z=V_N_)5TL&&R>)BJ)ZZHH6PT$
MCTOZN5_?CD5""CE;$II*CTFS 9?O,6R@C)Q7J'XN7WW65M=$742*BG'\NFJN
MZAJL4D-#M?)09Y)I8T--4T_\-J!+=]-S-($)(75Z6"Z3<\#DQMM\CD'>"#7(
M&.B?=^1+IE#6[(P  "DG76OI7]F.FO(]9[TQ$%3+D]K9&E>@B6LK$EA,4BT[
MKJ6>,7_?B<NA)B+JJMK+!;V,(-YAF;2 3C_5Y]$+\H;C;)58Q"14ZVH6/#*D
M@D#RX^OV]"MMQI:#;4%6<2S9#;IH\IC\E"*E33PU$KK(FJ./]M6=8CZ3J!4!
MM(5E <W$)K/X0U:4QT..75:.)&8N[H:$EVR"*'\5#P\^'EQ/2K^1FUTSFS<)
MW1#0PT-#F,3%0Y6KJI_M8VR.-\46F-6-Y99J8EA&@N0&>URQ]L[)N'@.;=ZL
M>()]":>G^KSZ4<W\MBX*WT?:&&E@K,*D"O\ %U6#N@83(9X5M(LM:M$B+3>:
M-HED>]R[J;,$#D@(/J5U,=; *)1;:R>[2/+ATDV^_:QMO#6M3D^9!]<YP?RZ
MQST6[MPX_(M%!DJ_#8.(U^07'T$LE-2)/)'&LU5H1TBCU^)%>4Z02J C4![9
M\9 =(8&OV>0Z6VH:TC\9$9UP9'((*U(I^T_L'0A[ Q77NU5QV\=[O2[GKJ:<
MY'%;'<_Q.FJ#3%O$,A'3S7T2D:Q%-) I0H)/(-413,QFJ@K0]IICCCRZ%.U[
MA;V;FXD57Q50^<C(XUK_ (.IV[Y-^=\[FFW"]%C$D6-:'%XBBCH-JT&/HP[-
M#245./LZ.D@C+D!(D16:SOJD=G][2W3;DJ>'&M2:_P ^B*?>;K?;G])0 < 4
M"T%,9Q@8'' Z%CK?X==DYJHCKMQT>,VS@:=Q++59/<-&BD JC,\M$U:U+$"P
MO+)$!J](#'E4-US##".T5/V#_-TOM.6[J[8&X>- /(2O_D?'Y=#S7[6P.U((
MCU]VELLRTLT0F.WMD5E"A2%+'PY98ZRNJYE_M-+3QLQ'J((4>RRQW-[HEI8A
MGAW,,9\A3I1N6T);4^EN Y&:&"@!'SJ:_:>N&1WUO+/S1SY;L2AS551QQ115
M60QN3IV5;"W[PHK,R%@3=%:R\V'U4A( 2?#7))XD_P"$](!-N,@I]1&*"A&E
M\9^RG[,?+IBW3MK<.]MKR2)G<!D]SXU_)M_'0Y.B^XJ6G4*8UDD6&<QLT99$
ME1)%:VA^;!R&\BMFPH Q@9'\_MZ176RW.YKXDCU9*T==2U\_(@FG#/1-\Q29
MI7;;NZL1DL.\3EA35E&\"QM(UE9!HO"7*GDJ0;.NHD,OL0K<PS=RT&.@]>PW
M-K35J88J..?6IK2O\OETC\QUQNBGQ+9FGQ4^:P"N8FRN.IOOH8B^E5$[1!UA
M9C8*2;,2!<'@(C+'JIJJ3ZGAT>VA=H@PU"GE^0X5S]G^H],V ZGW1N>I2GQ6
MU:N4RU"QM--3-1Q(ZJ78:V((*JI) !/^%S[;GN8X 0<_F>CW;X)KQ:J>'D0*
M9\_,^71DMN_#K-YFC1IZK(U65EFI$3%8#&0U=.@>Q)GJ_N'JXB4U$6Q;!;$L
M;"X#-QOZQ=H7%?GT*K/EJ=Q4U]?V8\NFSMWX:;FV'AJ;(56U<OCZ.81FGRU=
MG*.2*H><?ITN:*=6!XM]LMK#TV.MM6F^1SG3P/S]!U6[V2Z@(*QU^SYU_P!7
MSZ*;4=%;D%7%"(4IQ7)']N\L;5T>J:^E':E6:52?^H<?[;GV8->H5J"/Y?YN
ME,,,B,JO@_,?EQI_GZG4W3':E'#IQ=%392!Y)D./Q>?QV;9EC8^O[%:AZR%-
M7&IJ>.W(_P /:,;HL1'G\^ETO+DURI(4$$Y/"@/G0?;T.6QL/G-J[/S6W]W8
MV*DK<I4J<9B<G,3%3U" :9GC9V0.Q4*/&2Q7TL+^R^^NQ-*"@I7C\^C>RV<V
M]L5E-=-:9_S?ZOLZ*QF\U0/45-)D*++8"H!EA(H5,<2 !5N(9HI*AUU*6N*E
M1]"+6M[-4+M'0&GY#_+T1) L#TT']I]/MZ1E3)CX8VJ/[X9FM\"W2,P+2, O
MX4S58!^@X"G_ %C[8),7%J_D/\W1F56?(J"/M'^7I'97<>.JR!4197(%5C1#
M/6@L0HM8NRNB\VLO@DXX#+[9DF7TZ-+&U6H9F-/L_P %.DM+N/(TP>/&0IB0
MZLC3T@?SE6&G3Y69C'P.?$(@WY!''LNED8]"VU6W6A )^><\/]7GCI+RO-4D
M-(\LY&K3K)D/JY-K_@GGCVE<,^3GH46-ZEJ-*44'-#2I_;G]O3=-3EN&B"V_
M'*6_WKGVE>,^G^3H^@W=&SJK^P_X.F^2E86-P/KQ>_U_K?VPR=&K7WBBE/\
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MN*@ BN,_X:]*C?H@H0Q-?,?ZOM].E/38ZHTJL&M"(Q9E;2;D7/T^HU6M[H$
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M2E:I8^0RU])%(&D<Q1EH[",-ROI(G(34P+&A P!7K(?9=DB2$/,""56N1J;
MR0:T)\_GT7GO[?NP^J-P-AM^?'C:U&'8R8["U6Y:Z')5<4CR+%)2RTUVKHW:
M+2DT2>+R>FRL2OM=MQEGC)9\#U"U'\O7HDWDVUNX0VY?57B[J>('%6 _U?;T
M4_>G9N5@RQCVQL?:PPU7!#6XG!&'-91J:-HEUQ2#(UKA987DDX$" J20JEM
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M>_=>ZI8_G$?\?7_*A_\ &LOQ-_\ <FO]B?EGA=_\\<__ #[T2;UQ@_YZ(_\
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M_/\ #^9_R=*XOP?Z;KZKO\O'_L@#X-?^*>?&;_WBL)[QRWK_ ',G_P":TO\
MQ]NIPVW_ ''B_P"::?\ '1T</V6=+>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ6/YQ'_'U_RH?_&LOQ-_
M]R:_V)^6>%W_ ,\<_P#S[T2;UQ@_YZ(_\O50_P >:3,R=<4T]/2Y(_[GM\I2
M+1J\08G<&4 8M$-2C6/RP)L.0.1+^TRZ;2'S[!_DZQAYI@,VX7!_X:?\O0]Q
M;5WWFA&,@L&-MK2*KR5<L,JB:R:8YYW:HD+$@Z$#7(U%1:WLP>50*\.@XUFP
MX="?MOJO*83&U6<W)@OXQAH;^6$5AQS,Q'U57C2HE%B;L8T4<'R>TDMTC\".
ME,=C137TST7SL;J+J2MI*_)T,4^R*XR5%6T*UM%6(DFGUHBU*R5\VHO?UU(.
MKE?3Z NL-WE1@H.*CSZ".Z\MP7 )%!Q)'K0=5[[NZXB>MDEI\[,,? \],DGK
M@EF6G<&.0(TA$;F(&PL23<646/N0;#>I(%JH!ZB3<^5$>7B0/*GET'%9LET3
M[?'5]6P><.TJVC9C)8%BQ":-*WL02?4.#ZB%XW<2X)Z#G]5F5_\ %^-:U/'C
MT:3XW;<W!1=C4]169S!6R-.T&7JMXU1H:<TZI&#Y9GUD,D<:11B-&541$"E0
M%]A_>YTEC.A<_+J4.2MFN8[@F=J@K05X G_-U9%O[XL[7H-N3[\V#NR@WKB6
M9JG)#;^5HRU(S1JQ,8F59JF,L1ZDB\HYM&03:/OWO)8L$92:GS\NI#39EADI
MBG!J4K7[/\O31L;HS&;SP.1EJL+"V,BAECJ\ODJ&FJ98I*<.\9021L\2F1A<
M"RF_J/T]KKB^>,ZE8GAY]*CLT.DC2/M(SQZ#23J'KNB:JHEP%'DIU9E=\A3K
M40E(KV"KI&HN"06T&]S8JK&WAO$OJ0?MZ2?N2WK0HI\^ ^SH1-B[0VOCZ6FV
M[D>NMNU]!/5QRTJ5@CT 2<*"A:5RQE==!T-ZC9PWU9)->/(:^?1I%M\ 73H%
M/LZ'/"]8=-;@P,U#N#J[9&+R331TV-W'!M2CIZ@ZRBW9GAB9I)2;W*DEFMR+
M*4S;A.APS=5'+]L#J"+\\#J/M[XZ];1Y#,22[7Q4?\/QM3+1O#3?9PR$#4DQ
M=F$8]*,#J](U6LK+QYMVGDQ4G[3TU-M-M:91!4GR'Y]5I=JU_=,E?DUH,9AQ
MC/NV;&1XO!44U3&M-(V@,X+5B ,RZE\]@5/"J!86;/)#IK(>X]1WS!!N$K%8
M@-'1&]QU&[$J",S!-]S#)K6O@@JHXR\H%R?.UM0!*D!N"A%]-_8WM);8CB.H
MCO;2^1F5@U36E*]-V'&\<UEL128?'-DJW(5E+C<=!!&$\DDW^:B"(#J8@W5;
M&PUE@"#97<3VZC4Q!P>/ITU8VNXW#A%5JU'[>C2]E#O_ *NI]GT^X]U4%9NG
M<%-5551L2D6@S5710T'@\2U"PT@U_P"?,<B4TC^.560N6+6"]I)97C-4:1Y-
MZ=2?O$>Z[;#%I.MQ3]/CY=2,/LW=G:F-DE[1V=@4%.-%#+Y:B.K)F%R4:GJ?
M+3JR:7* QWX#(I LGN-P@VUO\6=C]O3MCR]=[XE+U-/[?]7Y]*W'_";K_)4\
M%=/4[FHJG(&;[;&8K(4\D48A.FP^YHGJ= ,9U,T@L/S:UF!SM,F,>G[.G?\
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MLEM:?#0RT6'K]O8Z:5I%_B%1G*3-U).DE?'- 7IHRRLI6RI^?RUR:17.L=P
MI_/JPVQ$%(R%(Z#H;)K8)?)5[AP[-(Y*O45IF+M*"-192-('T/+"_P!!]#[V
M;HCR_/JB[4S9+CJ7MW:,M-(M:^[J'&34[*\%2TT]40]E8+>FBJ#Z;*&46N!I
M!]L37!*\//HSL=N>+.JOV?/'1U]D[7VO686NW;NG<N-DG$K4\5&LU3$97B4"
M1PDM/%/.SD@1:05]5FL]P"V1F/0A$-%^?2CE[%Z_VK3S/2U5?+Z$C^WEP,T$
MC7:P=9V)2YM>PT(;D#Z6]LM&6Z\M$-?^+Z*IV7W7G\G4E\?!'CZ*,3+'25)#
MZ]8)5I-?)/\ K-93]#?D*84H.O32A^/17\_V/F<DDBLF/DJH;O'H@=5O;D*X
MEL";V)T&]S<'V8QP5Z3&5#Q/05U.Z<+G(I(<KB(J$U2O!61K&C02@_J$R'5$
MW-N!$+'G4./=E!@/837Y=,KHN5*,H^5>@3W?TGMG,15&1VY-' [EYHZ-)Q3Q
M,38,(Y6:2&,@#A2JBY(\@]-C&VW>13I?RZ*+CEF"<=M01Y#AT5_/=<93'S2Q
M1Q.LD3B-Z"I3[2HN.+B*0C6K-]-#N#^/Q[-UW1'-.B238'MZE!C[./#H-Z_%
MU5#,T%333TTJ<&*:%H'XYY1@&_/T]OLRR9%.JQAX%H5:H(X5X=,\BF]K$_7V
MPPZ-8&9J$#]OKU&D4K^JXN?Z7^@]IF'1];/09_ETV5""U])O_K?X>TS]&T<M
M1^?^KCTR5$=P?QSP2/:1QT<0RU%.F*>(\G_#GVF84Z,%:O3<\1)NMS_07'NO
M3P?J/[]TYU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4A?\ -1?]1#_[TGOS_#^9
M_P G2N+\'^FZ^J[_ "\?^R /@U_XIY\9O_>*PGO'+>O]S)_^:TO_ !]NIPVW
M_<>+_FFG_'1T</V6=+>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NJ6/YQ'_ !]?\J'_ ,:R_$W_ -R:_P!B
M?EGA=_\ /'/_ ,^]$F]<8/\ GHC_ ,O52WQS^4G8&PNML?M6BRSSX#$[AW_&
MF,3)5M%XTEW#DY66-X*N/QDNY-UC(%[ &]O<I6&W+):0DG.@'_!UCCS+?A;^
M>M,2'^6.AIJ.X\#GXILE/MBFKZB9Z<3K)E'QE0&< NRU4<<B3WX]4D-[\G2!
M8W^E*F@Z0Q7ZRK4 ?LZ9,SW'M.DIHDPFU-QBM+,U1)7YJ.KC "FX26 1F6.[
M'EHDN;6 !N-_1EOLZ3/NIC- H_9T&.2[SW36,AHZBGQU(B%0L=(2ZLK7#>0E
MI+KJ_LR:K\7%K%9%MZ$4H/V=%TN[21&N<]+O:GRO[ V_+1JVZ/N(0Z,8\M55
M&9C%]7'@K7JH$7G@^.YN?\+W_=B_+]G3\6]>-AO]GI:9CMCH_M6>E._=B/L_
M/5(>&IW!U[-$8)@7#":?&U$?@%V%R(41KL07:X'LO^DD3X22/MZMIAF_$/R_
MXOJ/7]'X0457N#KK?LN8H(R\QGHV6*5"T=T,RTYE56*@<32Q@@$<VXL;ET'<
MH%//I2NW-Y25K\^FJCE[1P/D6GKMK3075J6;<VWSD)(2H]'CFBAJHQIU7U,Y
M.H"X%Q?1N(I<L#7KQMYDP-/V],M3BMUY%OXKE$CR95Q-538J2FR"ZG5&>14?
MR,BG0P /CYLMA<>]K<!105I\^/\ AZ]](['N /\ ,?X.EECYL7!11T-!68P5
M<Z31UE#D,,E,Q7E;-:&'Z7%CJ:WIMS;VGD_4-1CUZ6)%Y$#]G#H:-FS==1TX
MI)J&LP.>J@%GK(J1=RX]M1*W2FED2>  CD:G'XXY7VFFU+PKTK$*C _9Y=.'
M:6TH\6N.KL=D,?5((D@IVP^*3&J+>HF4!7F\AO?EC_M-A[W%,2<CI')9G57_
M "= 37T;UZ0)"TEJ;5X5G)9AY"+D$D6+  $ ^WC+TS)"0*?/IXHZJ9UBI9A&
M[111PU)E7R++?Z*Z.Q#:0&YO?_;GWX./(=7CM=9SUW+L;%5?DEA1Z24QR":D
MMK1RJ:?VP1J"OIN #:Q/];^W1*_^JG3HVQ/(#/RZDX_HRLF6DR<.+:G,L@>2
M*%2QC2&QTN=(])!%KA=('X%C[I)>Z :G^?\ L]-KM2J21_@Z'W<>R\QMV*%E
MQU5#1PK3MK6&]DT-=Y. L: CEBQ^H'ZB R"*[64U!Z5:0PTTST6[M/<.X=U#
M$TU,I,.+0I'*W[3>IK-:P!!T6_X,0I/ .I8LIZ*Y@[9 _9T7?(XK<"RPS4=4
MW^3QLI@>1;G5PU@0%Y5C<7'T )M]#&WG5JAL4QT53VDSG4*_.GKTEZ.FW$&F
MGEFJ(0DDC32%E8JA8L= 7U76W!-KV!!*6/MSQ$]>D\<4RG@>A&I,CEM$(BR.
M<J:EIDAJ:<5\Z$-4D--Z 077Q^HBP8VTGB]J.R/T:0B09;HU71^SJSL+<^W)
M]TT$C4 RM%%'+E!42R3+:7Q&WD598Y#"RW_"ZV!0 ^R^72@) \N/[>C:.V8+
MK(\_\G2:^5'<6[,GNFNVC5AXMOX3)5-/B,08C!2POBF6G B50$=J<H%)8%D;
M5I8!]3:VXJXJ?VGHDOICZ'->'E3HCE9!6U\M3Y_N/'-JD8L+#7ZF4*/H2"QL
MU[ 6M_0"!&H.VGYYZ(9(6D-3J'VUZ;JF@H5;_+9JA$G$4<%/$Y<$J"HL0%:Y
M!%P2>/H >#;QS&/(#Y8_P4Z8-G3)&KRI3I54'46;W(^I<0V*BE"-]UF(2DC+
M*1;12 /5N % U&(1'2P\G 'ME]V$6>/Y]*H]A6X%2"OV="OM_H>;$,DL-3N6
ML$B05'IE7;8L\8)M 4UE"['ZRB_INJB]T+[N9*@8KC'1K!R^L=.XFGE6O1G]
MGXS^ 3@5N,V;#@)DT9%L^KY05$7[@?6\B2>1HV5B%C)+,UM#7Y0R2,_ GUXG
MH^6U4)IQ^SH3II.I\74 ;;KYJ^025+-38+*_W>QRLI<KIADAAGFC)]14P@WN
M ZAC[8:5FX_X.M+;K%W<!T '9.Z*MZ7(G^\_2U36SL:Z!LSV'605^FI F9#3
M""EAB*ZM*J:@,W# <,BJ+50#5@Q_;TFO99$':R?R_P W1,MV]J;LP-51_P .
MSVR9G=W9EVRIW L,C!AK9JF"2G*Z20BMY02&N& )!];6,5T26U#H*W6Z7$1H
M&'V@](*J[4[$RS+]SO'-PZ;B5<=5_P /CO,')O%3I BA2QTLH4A2%(LH'M6N
MWQ)\'#^?2;]X3RFM<_;3RZ5^V.W]V8/135>5R68QDJO2@561J*EU_P".;*[.
M64Q&P"W16%@;@>T]UMX(QT86V\21-WD_MQTJL]!6;TBDR%!N,9>AD:TJ5<QA
MJ(?"59E,50"9-)91=7.G4JA0--RR"D6" "#Z=+I;9KX:HV_G_L]!_6;)S)*0
M>BZHC"":+QZE%[:+C0+ _B_)L+7M[7_4 >G2,;5,E0V>D-DMM5]#2RK4&420
M.'229.5>$FX9#J*E19C9.;@@>[BY#8/#KSV,D8X=(F3)5>/1ZJNGGF(GBN99
M2%U'@7X/U)^FG\"]K#V]X8D&.M0S/;Y(IUSK=\Y"MC2(5#O#% D9@\IATGAE
M!LVE@>!R&N"1_A[J(#_J_P"*Z4_O,R?+]O\ DZ359V#FXXF@ILQDZ>.Q#P4V
M1J(H[I:Q,:.8_3]!Q9;#_6]Z,/R'2A;K6*_ZOY]!=GMT9>N^XCJLS6U,$B2J
MBSU3S_JYL-=R!S^+6^GT)]N11=--(>-:?GT%M6)9)HSYW9M=R Y^J _0CBYM
MP?\ >O:U6$?&G2-4D/KTFZX5U%4SO3U$\ J%#,B#R*QY&MH[E&(*D?2X(N"!
M];)HKTZ('AR2:?;UW0;LJJ%W-7J2[KY)Z>1CK6PL7IS=&(M]0ZD \?T-9(=1
M)'GT9V=Z(N.?MZ?X\I0[G1Z/(1T%71JC/3GEFBN"I"-;RPW(8<Z5-N49;72*
MIC:M>C'6EPM.D)FMA^82G%5M%4*%4OCL] LL8"\7AJ40Q\6-@ZH1<\L/HN2X
MIYGI&UEY#H%,KL^:G>1:K TZ3<6-%E(XP1P;A7D9;?0>E5^AX-_;\=R?4_SZ
M3268![A]GRZ0=9MS2[,()88T)1O-6PRD$?2VE@3J_P""^W5G^?[>JBV/!:_M
MKTG)]NU4EO&4Y4.MW:X%[<C3;_>_=2P?'^#I]5=.FJIVW50JQFECB L 2&YO
M_@57VV4!\^E\,CIQ'^'I)5E-%"YCU>1A<>E;C\C\G_B/;#J%QT;6\S2#T_/I
M@G6Q)"V'X)//M*13I?&>FJ1"IN;>HL1;WKI6IKUC]^ZMU[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U(7_ #47_40_^])[\_P_F?\ )TKB_!_INOJN_P O'_L@#X-?^*>?
M&;_WBL)[QRWK_<R?_FM+_P ?;J<-M_W'B_YII_QT='#]EG2WKWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JE
MC^<1_P ?7_*A_P#&LOQ-_P#<FO\ 8GY9X7?_ #QS_P#/O1)O7&#_ )Z(_P#+
MUKS;":5]N%8V*6W/OLMJ%U_XOF3L0?J".;'CZ"WT]S'M9#6D./\ 0Q_@'6+G
M-$>N_N!Y^*>'VG'2\H,G74'EEAFEM(^IHXWOJM<#]97DJ2I!_!%[V!]K"@^7
M1#&6@PO[.A8VVU+G$FI'1(,ND/GI8O,8Q/XP6*!"0NHZ00 W(5V/Z;!%,='F
M?LKT<P+XJU(%?LZ1E;#3M65*FFEI9%>2*SDRCEP+A6 8,18%;$"W!]O0S#Y=
M)9+<,>[R\NH2;3K*U7EIHTKR(TE81'000JZF\;M:PN+B[&]@/S[>\;YK^T=,
MG:M9U+PZC/@<]1S C&Y)5I]8?3 2JZ!Z 0O%P6))+C^T+?@U%T!^)?Y=)ELW
M7@&'[1T[X[);QV_51S4%?EL16T\J2Q/05DU Z^4'TAX?420Q!Y *^DW1O;+.
MDV& Z5Q1SQFH!Z$''=O;Q0L<VU/F"8B?-,HCE#+?R7G2+0>%]3/K-@6-P6!2
MO#&*T-/Y=&EO<3$@,O0M8C<-5F8HIL?MS-332HUI*+&_>H&8$C3,OB\O(7EH
ME OS?DE!(%U'/^J@Z.HV) Q3H1J;!YJ>TF4VS5T\1"-'+78_Q:DG!=',D+Z4
M#:6-RQ^E[?50PTH3 )_U?9T^L9/'^?0F[?SFV\+&L>3V/C:V6*RLZ9\T;DN&
M*Z*=IM&KDVNAL2"Q(&EJ--KXD].^#IIC_!TM?[V[/J*>KAH]IU].&IM$U'49
MA:R)G+6*1,E*Q%HQJ#%QSJ%U!!]LAP#Q)Z]X=?+H+*EZ#<>77&;8V>D4E&('
MRF3?*5%321A7\;)Z5D$U0S*/VTDM&WD$C^2-HV\TX0>?32P!VR.AIVWU)MZN
MH9:G*Y&7&5<SR245(8HX?*(2ZZUFGBBCLR\@F1EN&'# 'W3ZVG"O3[6JCX?]
M7[.N<6PL#B:C7$DV6B292&7*Q51N K,2L$DYTL2 %  LWT-K>]?6N?7K0C$?
M'_9Z,OUSNB@VW11T,.Q:=ZY)1.*[*VE<VO8Q_<:72QT6M8<"X>X(:E/U I]M
M>C.-X0OPY]:==]M9;?>_J*:BCQNU*"G>)TGB>DE:1PZLNEF$[@C06( 1?43;
MFQ]E]O;?2M@D_GT4SQ^++J- !Z"E>''HE^1Z[S4E4'EH=E12",QPPST=;2EA
M&2 P40Z2S'\EK_[4&_28BYI_J_V.F:?+I&9#K+=E.Y:+%]?50)5_#!C8V.HG
MZ*TU&' 9CJYD+%OJ1<^W8YU'$]5()KCH/-PXW?VW4^Y?:F&IT*REI8MN44Q/
MYOY8::1;D-Q=^#P0;^WUG5VI7I&T=":#H,EW?NRED6G\86!XWIX*2FQ<,!;R
MFX "1<EF_LM<7^ECZO:O4M.)Z3D'52@Z,-M^+LFEIZ/<5<N+H:K'NC+3Y3=4
M"U091;4#%]U]NP6WU=" 2"%'ZF1*HJ#Z='H5@FFF#_J_R=<.VZZGW54Q[GR^
M-H\;5EZ:BK*V.MI95GU"!2\C!XI7DL3ZO"&)^NH>LL6[ #!IT6O9Z:FGY4Z*
M9GZ?#/G)*"-\G4Q1F2D@5TCH7F=S=!$B-4,RD./&REF;4!I4@J%ZS!?,G]O1
M=+;>.0 !@_+HP1P&(ZHV-C,P=H83(YS(I/55<.1AK!64$TDG!J'IZJ%XY7U"
MR>%%MJ'Z=(]IOJ6=M/ >O2PV20C4H!/V#H"\]W_V-0O/'18[:^'BEC6QHL2]
M>)##K5O)]]+5J_D7]971]%!'LSBLHY5JQ)^5>B2[W*6/ 7'GCI)U/RI[?CIC
M%19#"4:GR-42P;6QX>0A00S>2G<?3TFY)(/U%N5<6VPKGNQT@;=Y0, =!U7_
M "#[0FBD2JW-4% 2B1PX6@QY(4^I;T])!)ZC>UW-KFUB3[6+M\3>1Z0OO$X\
MQ^WIBG[FWO-%:LRPK*=&:%H\A04>45& 4$*E13L-!XX(*_6X/&F_[L'R_E_F
MZJ=WF^7[>F2I[+RQC=!CMIK%*RHXIMB82B8'DG7)!0PR\L &(<D@_P!+ .QV
M8!Z2R;@ZY(0_:!UBEW_MJ3Q"OZ_VU.B0&/SP5V<IIK@D@'QY<4P4WNUH-5])
M$@()-OIV0D*S#CZ])TNXG/<H)\P *5^73E0;JZR>1A)M'=/DJ9 JK3;\A@2)
M78,?VYL#5NUCJTN*D\$ @@#WH6[_ ,3?SZ5H]JYJ01\APZ4D&7ZG>&,5$6_\
M#)J0224U5BMW@!RY>T(3 R,!;\&RD@'@W6K13(.T@CY\>EC+9T\Z?RZ%3:-#
MU<QDG':N0Q>,E@\DU'N[8=5+$\DTGI1?X/7Y8Q!(60%@5(]2GZ78GN(Y":D#
M\NCJRBA!!5C3TJ>A4Q>R:*KKJ&FV7V5LC=&-K)X!%C*S,R8AEDE<*H@ARM)C
MZCQ@AR (W<@(2#>_LNUNIH:]'MLBEN/V=#YWAT#3T76N&S=52-CMW8 !\Y54
M.FMI:B"KB4/(1Z)'6&0*?)958%C];73?4,CYJ!]O5;A-+T(P?D.JP]V]?5$L
MTWA--. L3-/22*KR'01H>,D$&XU<!KWN&))L=VU[05'2&ZVQ2*BGV= 7DMK9
M>BJFCEQ]3$ND?M-"8CZ"--[@"P8_U(/.DGV;I<JZY/1-^["*]--1M/(UMU@@
MD:I8RJ4$;$:E)%A9-18$6 L1]2./;9N%'#I1'MY'^K_9ZZBZ;WA6Q"IJ,<<=
M0@%GR&4FCQ4"@*22SU#(3<#A51F-P ">/=?K#_Q73R6%>/68]9[%H$7^)]@X
MJ>I( DCQV+GR:67Z:9-5,3<VN1$>-0N?H63.S]/_ $ZCI(;NV+LJHI(6PV\<
M14UP71)3U[-@=88J 5>J5*9%)-@'E4BQY]W1VZJ8?$P,^71>=T;8R.'D,%;1
M34LI"20M,A99496*NDB^B1&MPRL018@D<^S.*XH #TU)9E?+H,*@RPLQ4M&\
M9],EM+ M]?\ >?\ ;^U':^:#IA 8SY].%%NK+4\\<1K%9-2*):F98M('&HRN
MZJGUMZF"GVGEC!.*<.E\-R>!KTL<EDL35T^BOKL')/)&B-^Y%,H?Z-^["YO9
MA^%^M_5[9(*&@]/+I<45QW?X*]!1EX\3#(Q;^'O9N)%TL+G@"[%B+<VY-O;_
M )#IKPT3A3I#5\S2#PTM;04L8U<K,JM;_@UCQ_K6]W1M)Z]JIY5_U?/I(U^'
MD,?FEJH71GX*S>2]OKR+FWMY7#8SU5I#Z=!SE(8_*?$Q8"P!2(VX/UN>?=76
MO2BW?37_ "FG28JH".2&/) _%_Z^TKKT<0G4*X_R=,,_]D?GG_>?;72V/J/[
M]TYU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U(1@(K$7.N(K_ (%GL3_L0![TQP1]G2N$
MTTU]?\O7U7?Y>/\ V0!\&O\ Q3SXS?\ O%83WCGO7^YD_P#S6E_X^W4X;;_N
M/%_S33_CHZ.'[+.EO7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5+'\XC_CZ_P"5#_XUE^)O_N37^Q/RSPN_
M^>.?_GWHDWKC!_ST1_Y>J'^K-OT];LVGJY%G#R[DWT@,8)U!<WD[GZ?3^O(^
MA-_<G[=<F*UBS3L''/6/&_V?B7\^*_J,<8\ST/FUNKLUN. _P#"5M?3D+++5
MRTJ4M,@ )&NJE\<""P^ODYX!L&!;<FYMPJ.DMMMBUKIS\^ABVYUYL##5 3=>
MYTBRS/'!!A=GTC9>JUE&NDE5)+'10LRK^E))W8FYLJZ_:"6Z=L]&*;<@((P1
MZ=+:NZNZBJZM9JZKW33N(F;QU5?02S'60P$I3&*$YOZ?,6'%V)Y]I4OY> '^
M'I[]VP,:M_DZQ?:_'S:N.\4FT=V9VN2!M5=5;M-! NO]+BGIZ**>1TUA1KG)
M)M=#>YW5YOZ/V5ZM+911"B</Y=9J[=755=2P4V,VY4;3E"I#,!42[CA>VHF2
MH%7-4B4@ZTTVT\W(2Y]ZT-JXG]O5="]!C%E\+3S5D./W1E*69)#HHX\;#C@&
M>0F\8IWCBY^M[G2+*H"^I#&I'55B0^?0C[>S>&F^VB^ZS,M:J)'*M9F*[2JB
M,E EI?#'X@" RNP#*=-ORCF=A7)_;TJCA0&E >'IZ]&.V-A^N-U5FO,5\@_;
MF6LK*K(U,LH+/IB5[NP\40\C*2Q9@J!M:LY]HGD8>9_;TM-I&<CCZ#I99W:G
M16W)J=<5&^=T7DDJ!1T5) %B"&Y5::29P2 H#S1#2#^='MA9&(XG]IZ]X07B
M!UPI,EUHX/V>U\52H*:%1(,;#62.4!_<8S+INQ!)*Z1] %^H.R6/GUO0#Y#K
M+F]MT&X(::CH8-N8O%U%.YR4DF @@J)"RH$ITD>.41P.^LNRRJQ $5GC:16K
MXACZHT8/3U@(<MM/4^&J\;3T\K*W[E%35L1,"HJWD,1F;QJ%TACZ1>RK>_NK
MS&3'3?@BOE^P=+IY\7G28=P8^C2JK7$[93#5S4GCTHRKKBT%#$I8C2&#7M?\
MDT5M!KU::T\Q_+IB/5E745H2CB.3I]6M9J>K8*5'T9E9M48N]C;Z&XY^I<^H
MKTG6'.:UZ$_;71U76^&K,-934](RNS1(B)'I'(&HL[L 5("(P)7EE''O0EIP
MZ?%1CHT=)U_BZK%40D7[JHA@@!-;*L;GQ(+GB,:2Y%SQ;^G%@$SS'5Y]6-@T
MGEU K.G]HY PS5%.TLL8'"A&,9(!)1_%KU7 )]8^GX]I_JC\_P!O39L*\<?9
MTF=Q[9ZJV?2E<I!7%TIIJDTT53-*66(<WUR"-;&PY=0H_45 )%UD:3IF2S5.
M!-?D>BU[LW;TY)]Q#2SXVOAA^XCEHJO-XY@0+J1XVG)="1R!!<W 'JL/:V,:
M,]4\ <#_ )\]%ZR6Y_CA1U#M7==XNIC8/&),90)4Z22&##_(13 DJ1>]_K_C
M[<\9WX$_M/\ GZT;9%[CQ_U?+H$-Q=Y[7V]73_W&ZXQ5#1PE?X=49NBIZR>)
MHS>X1(#!&J\E X8@6OJ)(*J.W,F6)KPX^75&O",=!?E/D?%7UDM=N+86#W)(
MZ3(Z5[HD6AP+HM/!%#3JE@OZ43Z!1R;E4MIIPI/Y=(GO%'Q =)^;O7:-:SQK
MMW+[$CE$,,R=;QT&,UH&<!YY)HUJ)Y26 (:HTV9ETV#:GH[1VX5Z86YCXXZ;
MJ>3KW(R?[@^UX\)52*"L'8>V*NEBNQ9O55X=<N"[W&HFD1" ;Z1Q[=:!AQZV
MTJG(.>G3(=)[PRI67$T7678\4"G52[(W535U6XB5SQ1?=T615@M_^4 <D"UP
M?=4NG@( _GTDEMA(""*CSIT7O<>PXL5724N[MG[MVF$DD#M-!XK*222L-93Q
M"7QJK@ 5O( !8D$@PCW!B,L*^G^H]()=N0@BASCY9Z1==UK@Z\K)B=TT/D+M
MY(<U02X*3^BA&#5=,XYY)J%N;^D6/LSAW5EJ/\_17)LJMP_P=)RLZAW8"ST&
M'J,XR,@F7 O3[G$>KZEVQLM:B:B5-B1;DDC\[_>J^O\ ,])9-C<?"*]!_EMM
M9.E^X6:DFI)8IC#)#,I25&-N!&ZJ=0O<V)N0P%["R^WNT?/2"[VF0#ATGCA:
MR(1R.75-10: &'I)L"KCDGDBP_V_U]OF=0>)_;TBBLM."#48-/7ISI]O5CN)
M1&UP;+&BZ@2H_M$@DEOI8_7^@)/MIKFAQ_AZ>6P!-:-U/CV^:4R1%)WFC=[K
M(A)NAU$,6742& )!-^+D?2]3<ZL?Y<=*/H/MZG4--6*OCTO+<N(U>Q&L<&P*
MA%LQL;K[9>13Z#I1##+'C)]/ET_0UM71/"_E>#[.2*TBR&*SQ7]9964AB0?H
M1]>#[23!!3 _8.CNW>5"*U^63T;7K7Y+=A8REH<#6N-P8AEIL=IKI'0Q4Y72
M(99;SPS0>,"RSQ2W6R (0"I7<VRRBHXC/0EB!F'?^1\^G'M';VR-W00;@Z_/
M\)RSPM59W;]+40T<<94!HWI*9QH:Y476G;E;_LI8CV71R-!@#ISZ<1G))_/H
MJN83=.,,@DJJVE.HB05$;02@1WL6C= 3_3]-R.0;7/LR@G#BA.>F&C93@#]F
M>DC7;IW=!$J)G,NL<HMY8*MZ:X;\>@I_MK?3GGZ^U.D>O5=#J. IT%>YLI6S
MS1U61FKLC4,)&62>=JAV(!_+:CJ%R+G\>U"=)YV95P*?9C_!T$M?'E)YI98J
M:?S21,Y\4;*8U:Y'/X%A<CZ#\^U0*#I)1AZ](RNHY7,D4YDFED&@)2$NU[&X
MOR+FW]?P?=Q,HZ=",1TUBLW7AJ&6D:FR$F":SR8_,4+U=$]P=+,DJ:([CZ,"
MC7Y7^OO?BHW _GU6K#%/VBO2)J8\)DVDL),+42LV@JS5=(#<<:BIFB!!)N[R
M 6L6M]+K*4P"<?/K9B$BU( /V=(W*X')T>EVH?O(VYCJ\?-]Q&^FP:TB"PL>
M+LL=[< _E09 >/2<6S*<9Z1LY2,R6290&7602P-R!].#>_U-O>Q1L]*06]!^
MP?YNF^6>,L/(9'C+&PE35>__ "$/^(/N]*=>J3Q%/RZB-C*)J>:K-/5OICM%
M%$>6/Y_#V!_X*?\  >]D]: IPQTGJO[RGAT)0PT:*OH:J8%O5S^E@6!Y^ND#
MW9!GJ]2?\W_%]!SDU!()J(W8?58X[#Z_ZR_G_#V\?MZ<0$>7^K]G23K&4$7/
MY/%K?7_C?M-(:'HWM0=/^STE*@^NUN>3?_7/M-TOBX=1_?NG.O>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NLH_1%_C4 '_ %@+@?[ \^Z/P_/_ "#I^'BO^F'^7KZL'\O'
M_L@#X-?^*>?&;_WBL)[QUWK_ ',G_P":TO\ Q]NITVW_ ''B_P"::?\ '1T<
M/V6=+>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NJ6/YQ'_'U_RH?_&LOQ-_]R:_V)^6>%W_ ,\<_P#S[T2;
MUQ@_YZ(_\O55'1U9CL/U!MRJBP%!)D),OOXG)Y$&MNYW%DRNB%R(U%XUL"I4
M\WN"01.C, H%?@3_  =1!N]$NI33_1#_ )>EAN;?&[<JU)!6Y666@IZ=4AH4
MC6CA1$7\*I1"2S&[$6(X'Y!,X%7CY]$\UPTIP*#Y=(V&HEJ*B(HQB\<B$2Q<
M*&.AOU*5OQ9K7OZ;V%N%) IGIM:DXZ4&5J,C4ZY%DJ/(Y&JH@1D(2%;"Y)^A
M"WY-_P"G/M/&%U=.E7 X=-'DR$U/X$=R$A;QNX+ 7 ]2_0Z@1?46N1;CV]0#
MILLYZ9UEK(9UBC+H8BX67[?TZS8@LQYT*H>WX'O: >?29@].N&/\LM6U36ZI
MW_S*24TC#4D04\@C0I!^A%F/U<MZ0-EU'6XEJ>A3V[4O#$*&2F@^W-1#XI9;
MPA6D4@N+"W&HFP4\@_TO[+YCD]&$6".C#;&Q-;CZK[Z.%YJ&3Q1%PA>.Q978
MJ0P'D.D+<<V;FX) 3G@.C:,<.A*R6(FE<B1%_?=8@5:Y M:Y)7Z ?BUK@G_'
MVEZ<9=74FAPDXE=?"\Z1^/2GAU\W-B?ZCGZA?I[LK4Z]X1;AT)5"U8M&*:>@
MBL6+!3$R,J6)'Z;D.A8$FW!'U]Z;/7A;GIQI,SM"!BN8@IJ,W5$!JYJJ0 D_
MJ );5&%&JX-R>/K[K3KW@:<]*:GS>'GE5L'CZ2K$2>833TQ+DA=04*ZD@K=O
MSR#]>/?NM%:9Z%';&=WWD(DHI&EHZ"1X33LB+CXD^FE65"LC *=5R2O!)O[U
MPSU3'0MK09I%I8JZJBJRK$Z8&,3 ,2%Y=F*'0Q^B#\?6USK6.MT!S_JX]*BG
MW+BL&D$.0R5'$VIXY:6G9JF4LURHMJ:0^E1]1]3Q]0/=2!)@=/))3ATW3]HX
MHR/'%6M0P4WD2H^[II)I3)*VE2BHI4.!8VLUQ<$CW3Z=>F+QBWP=$&^2.[LJ
MV8DGQE7/6XVMH#(9Q(49O(6TPOJ(=054Z[K9K_X#V[&OA]((H6<$MYD]$ W/
ME97%XYI(2NIU$8T A"PY*V(L0;?2ZGVLC.KK4JA13^?04UN3KHH@\TE0=;Z8
MBLFJU[V-F;4+"]B";?FUP2OA5:=%S/0=):?,9<R,1/,(PTH5/(205XO8Z@;W
M'^W/%O:K%<=(M1)-.F6JJ8'\CU]- AGMJ:,F"3D D KJ0CZ\B,<@@A@?:F,<
M>F9(_$I7@.FFIQE+4VEII?%)9#%'(%-K_3U(4#$F_.E0/H0&! =&.F)+1?(]
M-4^V\['$E1'2F>%Y5"3QW>,B,WL77Z%0#^K_ !/U]N+.*T;IKZ5_+J#4MFEE
MCEJ(S)5-HBA>2==)\(].GUWU:@AN"..?J?=W:%A3_5Z]..'AZ%+;O<O:^T(O
MM:'==948W1H.,SDJ9^#1':Z1></)3 A0#]O)"UB+-?U!CZ.*3@>J+=- :G/#
MCT*-%W-UWN&!O[\].;5K'<^.3)8"J&'E]9 D"")(ZF0D6_5E+!A<7^A326;I
M\)/1JLT-PO=@_LZ:ZVK^.M=/'6461[-VA4+I$,?VU#N.&-N?5'JK&J[@DV/W
M0/)(10#=CP9O3K2I"/A/4;)2;3KV6&+M^BSN/TSBFHNPMC9.J,0"KJL(J3-4
MZ7D5/4)='T=@&#*'@DR>O6O#1_B84Z;*?;_3D^0D3<&?VXE&DL;SR[?QF4#:
M67U&&-Z2ABNEBQ"HA!9OU$( T99AZ]>^BMW\QU.S&%Z94)'@ZRBKTCE1ILA4
M93,8N6/PDH?\F7;55'I<7?4)6/I*_6S#:R2OZXZL]K R]M/]1Z2+; VO)4K/
MC,OM[,050>)(WW$*'3K-@[_=4V-8:[CCCDZ@%!)]OI<N!0])$VM&.H]/L?5^
M8FI1/@]FP9*5Y)$DKL)DHL\@:0MH4"BFJU67]0U,PY7\L0#MKTKTK7;E/#I+
M9'K'.T$M2E;M#)TYFC3UUCR1/&TGX%A'& 58,P=/386:Y8^]"]5>)ZL-O_EU
M#FVGN5E@B@HIHXXU\1@I!&60V4,H".VHVL;O]6NY)!.JK7B28)_8>E45N> Z
MCP[)WE%4SU:8[+@M&K:_MWU6&E/46&AS8@$!> !P 02T9E_+[.G3;,N>GNFV
MUV'60K1QXG(91!'Z*>HQZUL:W^EPZ2,MQS8*!_07]Z\=?7ILHP'0B[8Z;I"P
MKNR,;M3!X"QJ996E2DE#.@T^.2-C3H5)!TEBPM8H.0/>.3Z];2'Q!7RZ+_OK
M8&QJ'*5YQM51-B5J:HTCOD(IE: &ZDRB:1"=%B?VU '-A?2%=O.W6C:J>/0
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MO?NO=91^B'_J)_Z)]T?A^?\ D'3\/%?],/\  >OJP?R\?^R /@U_XIY\9O\
MWBL)[QUWK_<R?_FM+_Q]NITVW_<>+_FFG_'1T</V6=+>O>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ6/YQ'
M_'U_RH?_ !K+\3?_ ')K_8GY9X7?_/'/_P ^]$F]<8/^>B/_ "]5J_'3(=;4
MW2VWJ?=':O4V$)S/8#5N'S&_,51U\#Q;CRX59J-ZCSQ,2 P#JMU-PMB#[$L3
ML0*BO:GV\#U&NZ6OB32\?[2M:?+I:PY/H"OJG>L[HZSCI@DB^:'>>+@;4K>@
M '(!F%F<GBXX!-S;V[J;^'^?1;]!JXU/RI_L=/U//\62K&?O'93R*R"!*;>V
M"46LP9BK58 TW'+,;VXM]/?F9Z</Y]>&W*. 8'[#TY4N4^+]*\E.O>>RVC=K
M**G?> DL(RQ^J5-F+6X]2_4#VT-0_"?V]._1?,_L/^;IKK<G\<%ET4O>&RI%
MD*IZ=[X%#;7=M1-7,A8@D<CBP/U]NAV]/Y]:-B.%3^S_ &.FYIOCO)H$/>6R
M%8%C)]QOK RLVG@"ZU<85K_4@$ _V6'NVIOX3TQ^[!Z-_/J?CO\ 9:^9*KN+
M9<,D?FC:&;>^W+W56$12+^)A/$S:2"0K"]R+CFNIOX3^WJ_[N \C^P]+2BI/
MC&B([?(_K.GBU)(T$V_\ T@!MZ6*9(D*ED'Z?I?DW]LMJ)^$_MZ=%H *4;]A
M_P W2PILA\<,=XI*?Y/]:SPQE46FQ^^<2X'E.D$C[QFN 2+ A%!+,"!<O(:#
M*GI2L908#?LZ&K;V_OC-68J6DR?R+ZL2LI&C'FG[&P-.QUI86'\0<L%! )(4
M:B;<?1J123A?Y]::-CY$?[4_YNLU5O[XR8YX@WR8Z@$;)8LO:.$D>Y&JY$>2
M LOTL+7/NGAGTZTJ./7]A_S=(W+]P_&'2RQ=Y;#K2UB3#V#A%UV8'4X?(V)-
M@+$VL.5XM[V(F\A3J]&'K^P]1L=\@_C!BF=GW]UUDJA:@2P-/V1@Z5 H8^,/
MX:PAW72NHA0I(^B D&WA-\NM,&/K^P]*&7Y<=%0N/X5O_IK&(BZ$GD[ PTL@
M*M>Y*U1U!KO<\7! %Q[]X+_+JH1AG_)UVWRPZSJH];]Z]64FFT<2T_8>(NO]
M3I^Y52--U!/]DFWUX]X+>?5@K'_HG_8Z$#:GR>Z>BAC.3^1'6+I/51)!3'LK
M!TB1QEO4=,56B@DMR;#\WN#;W7P/D>ME&IP/^\GIPW)W[T%E,K+CL;WSTQ2X
M;'(E?55O^DG"LTDD0\A#,:P22,K"R(O#$  \\-Z'&=-.D6AS^%OV'_-TE,I\
MB.H\^*-,%WEU#"7,WW#UG9N"QJP>:P>5VER+*[LJW6[MI'!'Y]VHW\)Z]X;_
M ,+?[R>D5F^YOC7A\#D:#+=_]%[ARKTU1%38BB[.H*RECDD5PC5%5135!9$U
MAQ%$I9B"#+"?6MA#7-#7JS%B*:3@>A_S=$\K=\?'ZM$PIN^^J3.4&EZW<%-2
MPFXX"2I42S6(/U:DB_KI47TJ%C91\/\ /I/):-*/,?*G0;;DRW7=-2>>F[1Z
MBS5+$XD2;"=E87*, 02&-.*M*R*P)YDIE'UN0?;R K@KT@>P<&@!/Y'H&:W?
M_6[2K(.Q=BBRS!F.ZZ%C9 -(LL[, "> ;7!_/-EB-I\CTEDMI%- I_9TF:[L
MCKW]V!-^;&8AGTRQ[FH) /H2$U3\J"O^Q^G]/:Z)ZUJ*=-M X\C^P],B=C;*
MC9PO86S-#-+K0;GH=).GAC:8GU?\1[NW=Y],R0N."Y^SJ7C^U]EXQHG@[$VA
M!H=E,2;HHC=5/(8&6UR2;<F_U(/T+3)7TZU%%+J^$_LZ6"]R=5Y6+Q9C=FPF
M82!QIW'CX;E4LA#^<E=-CZ3_ (<GVE:(D_YNE/TY)[A_+KBV3Z>W' L-)W!U
M]M^IF:.G-+D\[0E&(2[-Y8YBB!@#I9K&]S<$#WX3F'&D]4EVXRB@!_9Z]!MD
MSM#'HP/8?74RV*2BGWM1%77U#6@%2ZWT ZOTBX92&//LPM]P#\5_.O1;)LDZ
M\/\  >D6^Y-E4S1Q'>FT(KMH#G=V/L+@ $$U&E18?@<_2W!]KQ<CY=(OHY@V
MFA^VG61-V["A(6JWKM&R.)8#'N>D?1R2;H*@JS%=7U%^1_K%,64^?\^G6LI/
M,']AZ=Z??6Q)9EE&]]F^D!_5N2@4W!'TU3>F^FY_VWNKD4ZV+>4?A/[#TKJ+
M?VP%A.C?>R"X_:17W90I<. ' *SWL1^#:XX]L$>AZ,+>WD*BJG]GS/RZ?J;L
M#K<JY_T@[.IWN[%ANN@;4I*DG2:C\ '^MQQ[;(/2Q;=Q^$_LZ>,9V?LFAG6N
MA[0V+%-$-4-1C-V4N,JD1=++J(JT8NI#'T$AC8 V)]M.M>(KT_'$Z'@?V=&4
MZH^3?6N*SD$6]>QMG5^ ".7GH>Q*3#5RLY95UR"K8U"(5+$ +PWJ 3Z(9;?T
MQ]IZ,U#..%/7'_%=&XG[-^(&Y(:=J[MOK.H^YGGF1JOL3"53_LJP\AG$T<JW
M9=48LC -?2NI]*9X&'"G[>KBQ8T(K^P]81NSX=8^.M2C[-ZPF=8S*:^O[,P^
M2 ,BLVF.-JP"ZA#;2VH&P!N;EHQR)_Q?5KBRD7U_WD])N3LSX[XEC(O??5IH
MXF$OVXWKC)EM$&-F1LG*A8WM<(.0 />I'G [1U5-OD.36GG@]5Y]S]R];9/.
M92?"=N83/4CU$BP25NZ:2 E)/4415JN(4/I34J.RA6L"?9O:1,ZC70=)BIAJ
M ,$4X=$TW)V#M6:4.N]MM/XY3I(W!2$G\#U">]Q_C<>S:)!'Z=%UP#Y _LZ"
M?);DVM/K\.Y]OD_0'^-4Q_5<_P"K](YO<?ZWM9',%\^D4D+OP!_8>@ZR>?VW
M&9%_O%@)7_U?\5IC:_U'IE/^/M3K0^?2?Z=AY?RZ1];EMN-J(S^%8,JG]O+T
MZ_IM]3K/'^M[<%P ,=7^GH,CI+UF8P1:4KF\2022&7*0%OQ^=8'X][\4,*U_
MGUHQ%<4_ETFJO,X98RJY/%O9E+,N0BU>G@ G7S]3^+>U"2(1QZ9:%SP'24J\
MQB=$FC)4'J4:-5="?]>]F/M])E7SZ:^GD' =)FLR=!("HK\:IN5(2NC/T_Q+
M>W5G0\3UHPR?B'21K:VB)(6NHR!JO_E2?G_6;W=98SP:G51"PX#I,U-72C41
M5TQ&EA_GUXL/]?Z^]ET_B'5Q"YX<>DO/54W]FIA!7Z+Y%-^?^)]U,JG\0/3R
M0/Z],]35QF_[BV;\*_\ 3\V!]M-)4]&<(H,J?V=,<LM.7;U_DFX-OK[9+J//
MHP313AUC\E)_JA_R=[UK'7M0_P!1Z]Y*3_5#_D[W[6.O:A_J/7O)2?ZH?\G>
M_:QU[4/]1Z]Y*3_5#_D[W[6.O:A_J/7O)2?ZH?\ )WOVL=>U#_4>O>2D_P!4
M/^3O?M8Z]J'^H]>\E)_JA_R=[]K'7M0_U'KWDI/]4/\ D[W[6.O:A_J/7O)2
M?ZH?\G>_:QU[4/\ 4>O>2D_U0_Y.]^UCKVH?ZCU[R4G^J'_)WOVL=>U#_4>O
M>2D_U0_Y.]^UCKVH?ZCU[R4G^J'_ "=[]K'7M0_U'KWDI/\ 5#_D[W[6.O:A
M_J/7O)2?ZH?\G>_:QU[4/]1Z]Y*3_5#_ ).]^UCKVH?ZCU[R4G^J'_)WOVL=
M>U#_ %'KWDI/]4/^3O?M8Z]J'^H]>\E)_JA_R=[]K'7M0_U'KWDI/]4/^3O?
MM8Z]J'^H]>\E)_JA_P G>_:QU[4/]1Z]Y*3_ %0_Y.]^UCKVH?ZCU[R4G^J'
M_)WOVL=>U#_4>O>2D_U0_P"3O?M8Z]J'^H]>\E)_JA_R=[]K'7M0_P!1Z]Y*
M3_5#_D[W[6.O:A_J/7O)2?ZH?\G>_:QU[4/]1Z]Y*3_5#_D[W[6.O:A_J/7O
M)2?ZH?\ )WOVL=>U#_4>O>2D_P!4/^3O?M8Z]J'^H]>\E)_JA_R=[]K'7M0_
MU'KWDI/]4/\ D[W[6.O:A_J/7O)2?ZH?\G>_:QU[4/\ 4>O>2D_U0_Y.]^UC
MKVH?ZCU[R4G^J'_)WOVL=>U#_4>O>2D_U0_Y.]^UCKVH?ZCU[R4G^J'_ "=[
M]K'7M0_U'KDLL.N-8R#<-QS^?S_K^],PZ<B?O4>I_P O7T"?AI_.U_EB=4?$
M#XI]6[^^37\!WWUM\;>C-@[UP7^ACL'*?99?9VU\7CLE2?=46TZFCJ?MJRFF
MC\L%1+#)IUQ2.A5C"VZ<J7]Q<S2)%56ED93KC%0SD@Y<'@?/J8+'?;2&&-&>
MA5$!&E\$* >"]&2_X?T_E+_]Y8?^P*[+_P#L-]H?ZG;E_OG_ *J1?]!]*OZP
MV?\ OS_C#_\ 0/7O^']/Y2__ 'EA_P"P*[+_ /L-]^_J=N7^^?\ JI%_T'U[
M^L-G_OS_ (P__0/7O^']/Y2__>6'_L"NR_\ [#??OZG;E_OG_JI%_P!!]>_K
M#9_[\_XP_P#T#U[_ (?T_E+_ />6'_L"NR__ +#??OZG;E_OG_JI%_T'U[^L
M-G_OS_C#_P#0/7O^']/Y2_\ WEA_[ KLO_[#??OZG;E_OG_JI%_T'U[^L-G_
M +\_XP__ $#U[_A_3^4O_P!Y8?\ L"NR_P#[#??OZG;E_OG_ *J1?]!]>_K#
M9_[\_P",/_T#U[_A_3^4O_WEA_[ KLO_ .PWW[^IVY?[Y_ZJ1?\ 0?7OZPV?
M^_/^,/\ ] ]>_P"']/Y2_P#WEA_[ KLO_P"PWW[^IVY?[Y_ZJ1?]!]>_K#9_
M[\_XP_\ T#U[_A_3^4O_ -Y8?^P*[+_^PWW[^IVY?[Y_ZJ1?]!]>_K#9_P"_
M/^,/_P! ]>_X?T_E+_\ >6'_ + KLO\ ^PWW[^IVY?[Y_P"JD7_0?7OZPV?^
M_/\ C#_] ]>_X?T_E+_]Y8?^P*[+_P#L-]^_J=N7^^?^JD7_ $'U[^L-G_OS
M_C#_ /0/7O\ A_3^4O\ ]Y8?^P*[+_\ L-]^_J=N7^^?^JD7_0?7OZPV?^_/
M^,/_ - ]>_X?T_E+_P#>6'_L"NR__L-]^_J=N7^^?^JD7_0?7OZPV?\ OS_C
M#_\ 0/7O^']/Y2__ 'EA_P"P*[+_ /L-]^_J=N7^^?\ JI%_T'U[^L-G_OS_
M (P__0/7O^']/Y2__>6'_L"NR_\ [#??OZG;E_OG_JI%_P!!]>_K#9_[\_XP
M_P#T#U[_ (?T_E+_ />6'_L"NR__ +#??OZG;E_OG_JI%_T'U[^L-G_OS_C#
M_P#0/7O^']/Y2_\ WEA_[ KLO_[#??OZG;E_OG_JI%_T'U[^L-G_ +\_XP__
M $#U[_A_3^4O_P!Y8?\ L"NR_P#[#??OZG;E_OG_ *J1?]!]>_K#9_[\_P",
M/_T#U[_A_3^4O_WEA_[ KLO_ .PWW[^IVY?[Y_ZJ1?\ 0?7OZPV?^_/^,/\
M] ]>_P"']/Y2_P#WEA_[ KLO_P"PWW[^IVY?[Y_ZJ1?]!]>_K#9_[\_XP_\
MT#U[_A_3^4O_ -Y8?^P*[+_^PWW[^IVY?[Y_ZJ1?]!]>_K#9_P"_/^,/_P!
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M />6'_L"NR__ +#??OZG;E_OG_JI%_T'U[^L-G_OS_C#_P#0/7O^']/Y2_\
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MPWW[^IVY?[Y_ZJ1?]!]>_K#9_P"_/^,/_P! ]>_X?T_E+_\ >6'_ + KLO\
M^PWW[^IVY?[Y_P"JD7_0?7OZPV?^_/\ C#_] ]>_X?T_E+_]Y8?^P*[+_P#L
M-]^_J=N7^^?^JD7_ $'U[^L-G_OS_C#_ /0/7O\ A_3^4O\ ]Y8?^P*[+_\
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M?^_/^,/_ - ]>_X?T_E+_P#>6'_L"NR__L-]^_J=N7^^?^JD7_0?7OZPV?\
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M_P! ]>_X?T_E+_\ >6'_ + KLO\ ^PWW[^IVY?[Y_P"JD7_0?7OZPV?^_/\
MC#_] ]>_X?T_E+_]Y8?^P*[+_P#L-]^_J=N7^^?^JD7_ $'U[^L-G_OS_C#_
M /0/7O\ A_3^4O\ ]Y8?^P*[+_\ L-]^_J=N7^^?^JD7_0?7OZPV?^_/^,/_
M - ]>_X?T_E+_P#>6'_L"NR__L-]^_J=N7^^?^JD7_0?7OZPV?\ OS_C#_\
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MX?T_E+_]Y8?^P*[+_P#L-]^_J=N7^^?^JD7_ $'U[^L-G_OS_C#_ /0/7O\
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M -Y8?^P*[+_^PWW[^IVY?[Y_ZJ1?]!]>_K#9_P"_/^,/_P! ]>_X?T_E+_\
M>6'_ + KLO\ ^PWW[^IVY?[Y_P"JD7_0?7OZPV?^_/\ C#_] ]>_X?T_E+_]
MY8?^P*[+_P#L-]^_J=N7^^?^JD7_ $'U[^L-G_OS_C#_ /0/7O\ A_3^4O\
M]Y8?^P*[+_\ L-]^_J=N7^^?^JD7_0?7OZPV?^_/^,/_ - ]>_X?T_E+_P#>
M6'_L"NR__L-]^_J=N7^^?^JD7_0?7OZPV?\ OS_C#_\ 0/7O^']/Y2__ 'EA
M_P"P*[+_ /L-]^_J=N7^^?\ JI%_T'U[^L-G_OS_ (P__0/7O^']/Y2__>6'
M_L"NR_\ [#??OZG;E_OG_JI%_P!!]>_K#9_[\_XP_P#T#U[_ (?T_E+_ />6
M'_L"NR__ +#??OZG;E_OG_JI%_T'U[^L-G_OS_C#_P#0/7O^']/Y2_\ WEA_
M[ KLO_[#??OZG;E_OG_JI%_T'U[^L-G_ +\_XP__ $#U[_A_3^4O_P!Y8?\
ML"NR_P#[#??OZG;E_OG_ *J1?]!]>_K#9_[\_P",/_T#U[_A_3^4O_WEA_[
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M /L-]^_J=N7^^?\ JI%_T'U[^L-G_OS_ (P__0/7O^']/Y2__>6'_L"NR_\
M[#??OZG;E_OG_JI%_P!!]>_K#9_[\_XP_P#T#U[_ (?T_E+_ />6'_L"NR__
M +#??OZG;E_OG_JI%_T'U[^L-G_OS_C#_P#0/7O^']/Y2_\ WEA_[ KLO_[#
M??OZG;E_OG_JI%_T'U[^L-G_ +\_XP__ $#U[_A_3^4O_P!Y8?\ L"NR_P#[
M#??OZG;E_OG_ *J1?]!]>_K#9_[\_P",/_T#U[_A_3^4O_WEA_[ KLO_ .PW
MW[^IVY?[Y_ZJ1?\ 0?7OZPV?^_/^,/\ ] ]5A?S)OYMG\OCOW<'\OBNZE^0'
M][*7H_\ F&?'KO+M&7_15O;!?PO:VQIZM\KE-.3VW1M6_:K*A^VI!/5R7_9I
MY"#8]V/EN]L_J/$CIKMI8U[XS5VTT&&-*TXF@^?17N>\VUQX.AZZ9D=NUA11
M6IRH_EGK;=JOB-\4:ZIGK*WXQ_'NLJZJ>:IJJJJZ8VY42225#%Y))'?&EG=W
M)9F)))))))]QH+R4?C?_ 'IO\_0K,2GR'[!UA_V3WXD_]XN?'7Z ?\R3VU^/
M_(9[W]9-_OQ_]Z;_ #]:\%/X1^P==?[)Y\2/^\6_CI_Z)/;7_P!;/?OK)O\
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M.O?[)]\2?^\7/CI^1_S)+;/Y_P#(9[W];-_OQ_\ >V_S]>\)3Y#]@Z[_ -E
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MGQU_]$GMK_ZV>_?73_[\?_>V_P _7O!3^$?L'7?^R??$K_O%WX[?^B4VU_\
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M7_UL]^^OG_WY)_O;?Y^O>"G\(_8.O?[*!\2_^\7?CK_Z)/;7_P!;/?OKY_\
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M #Z/K'_T L5_]2>_>,_\1_:>O:!Z#]G7O]"?3/\ SZ/K'_T L5_]2>_>,_\
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M>@_9U[_0GTS_ ,^CZQ_] +%?_4GOWC/_ !']IZ]H'H/V=>_T)],_\^CZQ_\
M0"Q7_P!2>_>,_P#$?VGKV@>@_9U[_0GTS_SZ/K'_ - +%?\ U)[]XS_Q']IZ
M]H'H/V=>_P!"?3/_ #Z/K'_T L5_]2>_>,_\1_:>O:!Z#]G7O]"?3/\ SZ/K
M'_T L5_]2>_>,_\ $?VGKV@>@_9U[_0GTS_SZ/K'_P! +%?_ %)[]XS_ ,1_
M:>O:!Z#]G7O]"?3/_/H^L?\ T L5_P#4GOWC/_$?VGKV@>@_9U[_ $)],_\
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M#]G7O]"?3/\ SZ/K'_T L5_]2>_>,_\ $?VGKV@>@_9U[_0GTS_SZ/K'_P!
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MC/\ Q']IZ]H'H/V=>_T)],_\^CZQ_P#0"Q7_ -2>_>,_\1_:>O:!Z#]G7O\
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M/V=>_P!"?3/_ #Z/K'_T L5_]2>_>,_\1_:>O:!Z#]G7O]"?3/\ SZ/K'_T
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M']IZ]H'H/V=>_P!"?3/_ #Z/K'_T L5_]2>_>,_\1_:>O:!Z#]G7O]"?3/\
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M)],_\^CZQ_\ 0"Q7_P!2>_>,_P#$?VGKV@>@_9U[_0GTS_SZ/K'_ - +%?\
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MH^L?_0"Q7_U)[]XS_P 1_:>O:!Z#]G7O]"?3/_/H^L?_ $ L5_\ 4GOWC/\
MQ']IZ]H'H/V="=[;ZMU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=:XO\ZK^;YW__ "Q/E3\!MN]?==;>[1Z([6PO
M?G8'R?VLF'DK-SIM/I2/!5>9RVV:A:V!4J-O8*NR^6J(6I)UE@H',K4U.D]1
M'[KW5E/S<^8\G6G\L7Y!?.?XP;EV9OC^[/Q@W%WYTKNNH@.Y,'DXUQ0R>)JY
M(H9J=JFBJ8WC9D6>-RI*ZD8<>Z]T9K9?<VWZ#XU['[[[FWALSK[;TG3>SNS.
MQ][[JS5)LO XJ/)8BER&0K:RNR%1%1X['P/+(S23U*QQ(/6]A?W[KW33T[\P
MOB9\A]O[MW9T+\G.@.Z-K[!CFFWSN+JWM_;^_*+#1T\'W,DF5J<9D*F''QI3
MWE9YWC41@N3I!(]U[HC_ /*__FI]>_S&-Q?-':M!E^FL%NWXU?,#NGI'8NQ-
MC=LT._<OG^O^KX\!1XOLJ2F1H:E\)N;+Y#))2UE/1?PT"-*2*JJIHI9I/=>Z
M.9FOF[\,MN=R4OQVW!\L_C9A._*VN@Q=+TKEN[]M8_=3U52CR14JX"7))E/N
M9(T9DB^U\C*+JI!%_=>Z&'L_MCJ[I+9>7[([E['V)U/U[M^(39S?/9&[:#9&
M(HU-[&IR.2J*:DAU6-M<P+'@7/OW7NDQTC\C?C[\E]LU>\_CIWEU%WQM''U[
MXK(;FZ=[&Q'9-#3U48)--456'K*R&"H %_&[J^GU6L;^_=>Z576W:O5_<VUH
M=\]/]D;"[6V349+,X:#>'6V\,=OK%/6;<JI:'(4B9#%U%52-4T%;!-3U$0F+
MP3QO%*JR(RCW7NB<_P Q[YW4/P*Z0V]O#!]<9;O+O?N7LS:/0?Q@^/\ M_+0
M8.MWEOKL*1XL3C#75-XL=C85CEJ:^L=&2GIHF-B[Q@^Z]T30==_\*&*?;*]H
MGY+_ ,N/([_BIDW!+\4U^/.ZZ3;4C"TK[>C[%.Z3FUE,=X$R#8#Q^?3(\0AO
M;W7NC0_!/^9CU1\M_B=O'Y'=FT^&^+6X>@-Y[_ZA^8?7_:^^<7CJ;K7>744P
MIMRX[+YZ>:FQPQ=.S1U%-7S- DE++&TJ0S++%'[KW1F!\S?B!_%>W,$?E1\=
M$S'0&"BW3WKC)>Z]MQ3;,QDZHZY'=,;9(-@* K)&345H@B&M;N-0O[KW0J[V
M[9ZKZTZ[R?;W8_9G7_7_ %/A<519[,=H;VWGCMJ;=I*')M"E-6U.;KZF#&P4
ME0]1 L<SU*QR-)&%8EUO[KW1&^R/E5V9MK^:-\4OB/@Y=LS=.=T?%+Y&]T[I
MFDQ9JLDV5ZLRVUJ+$FBKUG$<5%)!FZIID\#F1EA9)$ <2>Z]T=_#]P=2[BWY
MO/JO;_:/76<[/ZXQN&S/8?7&'WMC,GGL#1[C$IQU7FL/!4OD,735X@F-/+4T
M\23B-S$S:6M[KW0(;:^?'P:WGVJW1FT/F1\7-U=SK6SXT]4[=[[VMFMP_=4Q
M024HQ%-E)*YJI#(@:$0&4&]U]+6]U[HVGOW7NJFJC^8'%UO_ #%/F#T;\@.R
M^H.H_B[\??BG\:NY\9OOL'+T6PDI<OV]F-T8_(+DL]DZZ"B:F:/"T@I8=$;^
M5Y!JE+QJGNO=6-]6=S=0=Y[)HNR^E>U.NNW>NLB9EH-]]9;UQN^L/,:=5>18
M\EBZFJHV>)70NHFU("-0%_?NO= KMKY\?!K>?:K=&;0^9'Q<W5W.M;/C3U3M
MWOO:V:W#]U3%!)2C$4V4DKFJD,B!H1 90;W7TM;W7NA2[K^0_0?QLVM%OCY#
M]V=3]%;,J*Z+&4^ZNW^P\3UQCY:F<J$IXJO+U=)!).Q9;1JY;F]K>_=>Z?NJ
M^WNI^]-E8OLGI3LWK_M[KS.>7^#;ZZRWCC]]XBJ,! D6#(XNHJJ25HV-G59B
M4/# 'CW[KW2URF5Q>#QM=F<WDJ##XC%TL]=D\KE*R/'TU/!3*7DFGGF9(H8H
MU!+.[!5 )) ]^Z]T6;J+YS_"OY ;UR76_17RY^-'<O8.'2HDR>R.K>\=L[]R
ML*TC2),S4&+R=55:86AD$A$1"6]1%Q?W7NEAV/\ *;XR=//OB+MCY$='=:5'
M66!VYNGL:DWYVO@MIS8'&[QDJX</7YB"NKX)<=29>:@KHZ&6=(TJY*>>.G,C
MQ.%]U[I8=4=Q]1][[,Q_8W2':/7G</7V5>2+&[XZOWGCM^XB=X0K/'%D<74U
M5(\D8="Z"74NH:@+^_=>Z7];6T>-HZO(Y&KIJ#'T%-/6UU=6SI2PPPTJ&26:
M:60JD<4:*S,S,%5022 /?NO=%JZ/^;7PU^36>S.U?CC\L/C?WYN7;U''D,Y@
M.FN[=M]F5E+3RLZ+434V&R5;*E.SHP$I3QDCAOI[]U[I2=C_ "H^,73LN]*?
MMKY%=&=95/6^%VUN3L*DW]VQ@=HS8+';TDJX</79B&OKX)<;1Y:6@KTHIJA(
MXZIZ:H6!G,,@7W7NI>/^2GQ_SW3%9\A]K]W]/;EZ/I<//FAV_B>S<-6;5,$6
ME1(^XH:N7%11&62*,N:@A7=5(U$*?=>ZIM^)7\V;=7\P?^6UU)\K^H>V_A'\
M;.]]P?(':^T.X>MNYNZ8<CB]I87+]G9;;M%MJOF1!DJ?>^\-G8^GGV[%68VB
M7*9*J@DIX$HY54>Z]U=MVYW1T]T!L;)=G=[=J]<=+];X:>@I<MO[M;>V-Z^P
MU-+E95IZ6&;)Y:II**.:JJ'2*&-I@\LC+'&&=@#[KW3'U-\COCYWUL*L[4Z0
M[SZA[@ZSQSY*/)=@]9=CX??&%IFPP<U:U&3QM94T<!I5C=I1),IC4%FL!?W[
MKW08Y#Y]?!?%9OKG;F2^9GQ6H<]W!@L9NCJC$U7R!VI#/N7&YM%DH<A@HVRP
M.5HJ]'5J6>F\D=2#>!I+'W[KW1M??NO=5!_,;^;/U5\1OY@7P+^%V[-T=%X+
M;GR@F[^J>[>S>PNY<;L^78,'6NTAE]ITU;0U,D,%)4;YSM9046/FKZV!:@I)
M3T=/55%1&\'NO='L[Y^8WQ(^+-3MVB^3'R?^/OQ\KMWP5]5M.@[I[BV_UC49
M.+%-&E5-CX,SD*.6LAI7FA6:2)'2)I(U<J74'W7NAXV_N' ;LPF*W-M7.8?<
MVV\[0T^3PFX-OY.',T-935:AXJBEJZ9Y(*B"52"DD<C(PY!(]^Z]U)RF5Q>#
MQM=F<WDJ##XC%TL]=D\KE*R/'TU/!3*7DFGGF9(H8HU!+.[!5 )) ]^Z]T6;
MJ+YS_"OY ;UR76_17RY^-'<O8.'2HDR>R.K>\=L[]RL*TC2),S4&+R=55:86
MAD$A$1"6]1%Q?W7NE!WK\N_BE\7C@5^2GR7Z#^/S[I,PVU'W3V]@.L6R IK^
M5J)<UD*)JE(B+.T894/#$$CW[KW0Q46]=G9+:4._L=NW;-?L6IPW]XZ?>M%G
MJ6JQ,F.$9F^_3))*U&U%X09/.)C%H]6K3S[]U[HN6P_GO\&>T\7+G.M/F9\5
M>P,+#O?:G6CYC9GR"VGN6E_O%OR=:7!8(5%'EIHFR^;JF6''TBN9ZV4B.F25
M^/?NO=#[0]E]<Y3?VX.J<9O_ &3D>T=I[?P>[-T];4.ZJ"KS^,Q6YI*B'&Y/
M(8>.=LC1X_(34E4E-434R0SO#*L3NT;@>Z]TELYVWL7)5/</7NQ^U^JCW%U5
MLNFS^\-JUV],?4U>U1NV@K*G;^2W5C89I:_#8JO%)//#-54L:5%/!/)!Y%C>
MWNO= ?\ 'CY$XRB^-7QHW3\GODC\3<YVEVYLF&H/873W:%!'L3>.7Q>*J\WE
MJCKVMR4U)-F\13XFAKJY6BC>2.@IIJJ8+%%)(/=>Z6V.^:?P\R_2E;\D\7\J
MOCID/CQCLC5XC(=YTG=.W)]HP5E XCFI)MQ+D3B8ZN.0A6A:K$@8J--V%_=>
MZ7O2_?\ T5\C]H#L#X^=S=6=X[&-=58P[PZCW]BNQ,8*FB8I-3M78BJJZ99X
MF!#1F0./R/?NO="Y[]U[HKV:^;OPRVYW)2_';<'RS^-F$[\K:Z#%TO2N6[OV
MUC]U/55*/)%2K@)<DF4^YDC1F2+[7R,HNJD$7]U[H5]S=S=/[*W_ ->=4;R[
M7ZUVEVEV[_>'_11UKN;?6+P.?W/_ '1IUJ\M_=[#555%D<U_"Z5UFJ_LZ:;[
M:(B2;0A!]^Z]U)R/;756'[(VYTWE^S>OL7V_O';^7W9M'JK([SQM#N3*XK ,
M$K\GC<'+4KE*['T3D+45$-*\,+$"1U/OW7N@@S/S<^&>W>XZ?X[[@^6?QKP?
M?E76P8VEZ5R_>&V<=NN2JJE9XJ5<!-DTRAJI$5F2'[7R,HU!2.??NO=%^[-^
M4O:.T_YI?Q6^(&).W/\ 1%W%\5ODAW'N_P"YQ#3909?JC+[7H<6*2M$ZI!2-
M#FZLSQFG=I'2(J\85P_NO='KV%V7USVKA:O<G5^_]D]D;=H-P;AVG7Y[86ZJ
M#>%%!E=I5<M!E<9-58Z>H@CR&,KH9J>KIVD$U-/&\,R)(K*/=>Z3^ [XZ.W7
MUG6=T[6[FZHW+TYCSN 5_;. [$Q&8VS!_=*LGQ^5\V>IZR3%Q?PS(4M335>J
MJ'V]1#+#-HDC=1[KW2,Z(^7GQ2^4?\=_V6KY+]"?(!MK^#^\L?3';F![,?'B
MJMXFK4PU?6/2K+>R-(JAC<*20??NO= U\7?D7-4;$Q5-\E?D]\-]Y]E=B?(G
MN_J[J.KZ([2H:C%9E-GYC)C&;3H5KI*6HR>^\'A*+1N#'TD4TE-705@"B&*Z
M^Z]T;G>G97776XVPW8F_ME;"7>^[L/U_LQMZ;JH=K#+Y[<7D_A^$Q9KIX/O\
MO7>&;[>C@\E1-H?QQMI:WNO=!7WO\O/BE\7/X%_LROR7Z$^/[;H\_P#=J/N?
MMS ]9OD!2W\K429FOHWJEBM9VC5@IL&()'OW7NAQV_N' ;LPF*W-M7.8?<VV
M\[0T^3PFX-OY.',T-935:AXJBEJZ9Y(*B"52"DD<C(PY!(]^Z]TGJGL_K2C[
M&QG3U7V'L:E[;S6T\CO[#=6U.[:"#<=7@L/51457FJ7"-4#)SXFEK9X*>:L2
ME:GCFDCB>17=5/NO=8<1VOU;N#L+=_4F![*V!F^UNO<7M_-[^ZRQ&\<=DMPX
M.BW:CR8JLS&%AJ7R6,I<G''(U)+4TT<=0JLT+.%)'NO=>V]VOU;NY^P(]J=E
M; W._4^XLAM#M--O;QQV:.VLMB:2"OJL7N 4U3*<-D::@JJ6IEIJSPS1P313
M.@CD1C[KW00='_-KX:_)K/9G:OQQ^6'QO[\W+MZCCR&<P'37=NV^S*REIY6=
M%J)J;#9*ME2G9T8"4IXR1PWT]^Z]T]=I_+;XK=&?WN7NCY*]"=32; HMFY+?
M4'8_;V V7+AJ?L6>KIMOSY6+(Y"GDQ\.<J*"OCQ[SJBUCTU0M.9#!*%]U[HJ
M7P,^7F^_D]WI_,6V=G\ILS-]>?&WY,;0ZSZ3S6SJ5"M9MW<^Q-M[ICJZFNBJ
M:B#)O/4YJ8PU,.B)Z;PZ58ZI']U[J/\ -K^9-\?^D>BOFS0=/?)?XTY[YB_&
M_P"+?R#[@P70]7VE@MQ[@I<OU9M#(9^C3+;4ILK%FC3QRQ4<E1"8XG,#@ED5
MP_OW7NA*_EX?+K#_ "P^+'QJWENGL'J[+_([>?Q0^-/>_>76NR<_1+7X*I[U
MVQ1YF"JJMOI6U63PN+R=0U<<<:I=,T4+B*6;QNWOW7NC8;*[7ZM[)R6^L-UU
MV5L#?V7ZOW95;"[+Q6RMXX[=53MW.T,<<T^%SL%#4SRXC+0PRQ.]'5+%4(CH
MS1A6!/NO=%4[)^0U7NS>7Q!RWQM^3/P[GZI[$[]WGU]V=_>SL^BRV0WA2[.Q
M><BK]M=92XQZRDRN]<3N#&'^(41G5J:CI,DLH2>#2GNO=#)W%\N?BI\>-R;.
MV;WY\E>A.D]W=AR^'8>U^V.W<!U[D,RPFAIC_"Z/+5])45P%1401$PQN!)(B
M$ZF4'W7NB.?RH_FOV]\TI/YB[]L#9GVWQ?\ YG7RD^)/5<FS,/)B4DVCU <,
M<-+D&DJZL5N3=<A,9ZE#%'*-!6%+&_NO='(V?\W?AEV'VUD.A-@_+/XV;V[P
MQ4N0@R74&TN[]M;BW+!)B2@JXI<)29*;(I+2EU$R&GU1$V<*0;>Z]T:'W[KW
M1:M[_,WX@=:9%\1V)\J/CIL;+0]E4W351B]V]U[;V]41;NK*.DR,6UYH*K)1
M2P[@?'U]!5#'NJU7V]33S^+Q31,WNO=)[X[[][/W7VI\N\+V!VY\;^PMK]?=
MT8O;G5VUNE-S-F]P[1P\VW<772X;LNG:-%Q>ZY*ZIJ:J&!693BI:*4G4[$^Z
M]UBQG\P/X'9JK[,H,1\U?B;DZSI>BR&3[?@H?D3M&J.UJ;#SM2UE1N'1ER,/
M!1U2-#4259B6"8&*4I(-/OW7NBZ=Y?-G<'4'\R#XU_'S-;MZWVI\:NQ?B!\E
M?D%V5O/=T]/B!15/4.4VM2XZL_CU3604-!B12YNJ>I,JE6*PN)8U5Q)[KW1S
M.HOE1\9._P#9.=[*Z,^0W2/</7NUHZF7=.]NLNTL)O?%8M:*.6:8Y*NQM=4T
MU (H8)I'^XDCTHCN;*I(]U[H@G\LK^:[UG_,)S'S:P?]X.DMJ[@^+ORX[OZ<
MVCM#:/;^/WIDLUUUU/#@:;']G5,6NGG& W%E:[)BGKH:,8Q5B2ECJZF:&6>3
MW7NCK]1_-KX;=_[VS76O1?RP^-_<O8FW$K9,]L3JWNW;>_<Q2)CI&BJ'GQN+
MR5561QT\J,DC&'2C"S$&WOW7NC&Y?+XG;^)RF>SV4QV$P>$QU;E\UFLO6QXV
MDI*3&QM-4U554S,D-/3T\*/)))(ZHB*S,P4$^_=>ZUS/Y=O\SOM;^83\W/E5
ME-N?-CX7;1^*?QF^0_>W5VV_BO@L5B-W[]WQL/J'$4E'!VS2;K7>&JFV=D=P
M9>AJXLI2[?J<9+! ]$M1&[^<^Z]U=ULWY??$_L7?NV.J^OODW\?]]]E[VV!C
M^UMF; V;W%M[<^8R^V,M"*FEW%C,=0Y">KK\)4TQ$T5;!%)3R0GRI(8_5[]U
M[IARGSG^%.$[G_V7',_+OXRXKY C*TV";I#(=Z;8H]V+7UE.M5#0OMZ3)KE8
MZV:E=)D@:E$KQ.DBH5=2?=>Z%/?/>W2'6&7&W^R^Y.JNO,\=F[A[&&$WSV'B
M-I5?]WMHS4M/EL]]MD*RGF_@V,J*ZBBJZW1]M325$"32HTL8;W7N@MPWSF^%
MNXNF<W\BL#\M/C=E^@]M5DF-W%W-C^Z]N56V*"IC<QFEK,VF1..IJIG&E89*
MA9')4(IU+?W7NADZK[<ZK[SV/A>S>ENR=B=M]<[CBEEP&^^MMV4&]L16+ Q2
M3[;(XV>II)FBD5D=5E)1P4<!@0/=>ZK._GE_-KN?^7C_ "VNZ/E;T!%LZ;M'
M8.XNH\9@HM^X*7<>+,6]MU8C#5OGI(*NAED84==,8R*E=,@5CJ *GW7N@LW%
ML#_A05M3:V1WAM?Y2_RW.V,]A,5-G*#K'-_%S>?7M/FWI(C,<9_'*??5?)CI
M:H QQ5!HWC20HTH$>KW[KW1O_P"6M\_=G?S!O@5TO\VQB*3J_';^VSGI]]X'
M+Y=31X/+;#R%;A]P0C(5*TRR8V#(8ZJ>GJ)5C+4K1/($8L![KW0P=1?.?X5_
M(#>N2ZWZ*^7/QH[E[!PZ5$F3V1U;WCMG?N5A6D:1)F:@Q>3JJK3"T,@D(B(2
MWJ(N+^Z]TY[W^9OQ ZTR+XCL3Y4?'38V6A[*INFJC%[M[KVWMZHBW=64=)D8
MMKS0562BEAW ^/KZ"J&/=5JOMZFGG\7BFB9O=>ZR][?,;XD_%V3%0_)/Y.]
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MOW7NN?\ PH.EHG_X3==ZQSY&BHA6]2?"O[&6I:1EFDI^P>N*I((O#'*S2SI
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M?B)</1C.QS9"DQSXFDCIQ7S+3PA ??NO=3/YJ-.W0?RZ_E1?/Z@6HHL5UO\
M)^O^'G>F5IRJP+L?YL8Y\!2566!%SC\/O>BVS+&Z'5#/4!R#$TI7W7NJ6OB_
MWQC_ (V?.*C_ )S_ &=N:O3HC^:7NC^9_L/<^<J*M,?BL?M+X@QP93I2M"U4
MC&2#);(ZHW(8*V ,U5+DHC%%]E+3B+W7NHO:W7G9FS?Y2/\ *VV-VA39+!TG
M\X#^;Y\?>T/YA_V:U.TVJ\!\Z-W9?>V1VUDY!*E50TTF,_N_CZR266(R"@>&
M5(A4M /=>ZL3_GP_'#I'XK_"WI;Y2?$[H?K?JKY0_#WY*_%K_939NFMN8_J;
M(U$NZ-VXG;=9L2&HP\-$]3@-PX3(5M-5XR3RTDT2ZIH&1&]^Z]T[Y+X=?''Y
M8_\ "@3Y>S_)7J78O>NUNM?Y?GQ1J=N=:]K[7HM^[:_B>[=P;Q@_C=1@\G#4
MXZIR^.HZ2KIJ&IEIGDI8LA7"$HT[-[]U[H+MI;YW=\>>I/\ A4OV'T@YVAO/
MIO>_8VY.L:[ TL$?\#JMD_'O;<V-KJ."2*6F PAIXZF*-X&BM3A&0I<>_=>Z
MR8'X,?";<_\ PFBQ6XMY]4]<XZOW#_*XB^4F^NZHMKTM?N==]9KK$[OS>[:C
M/14E3FZS+OG)JPU%Y9IJB$R8]TDA<P'W7NB^?%SL3;7\OW-_R6_FMN^K.W.C
MOE)_(ZPGQX[WSM14QT>,@S_Q2ZZQ7:VSZVOD<?L5]7@*;>5#3S<QF*%HY;,(
M2WNO=%0^*?>79G\I7K#Y,]P]D5.>J>U/YGW\KBF_F7[8H\G%)2B;O_?&\\KC
MZC;-)C)6GRE/7U<W;/7D$%)&DLLJ44GW!%6K-)[KW5I>]/BY1_"O#?\ "9CX
MN4_V[U_3GR7&V-U5E+3"C2KS\G4&]*O<5<L0DE\8KL[4Y"<+YI"HD"^1[:C[
MKW2@_DX=7=8?+_LK^<KWS\J>L>O^Z>ZS_-6^4OQ4?(]K;1Q6]ZG#]<]+4.W:
M/;&S***NI)%H<+CHZ[(1-'%'&*R1&FJC-4J\I]U[JI*#.Y+X1?R4_P#A21C_
M (89O.XREZU_FP=\].;.SF&;(25^%P>ZJ_JC:6Y$I:N,4];%+A,1D<Q319 /
M^UX%KEFE55E?W7NC4_(OX<_+3<W\OG#] [%_E%_R^_B7@NJ,#LC>_0WRDP?\
MP3#X7(]>[GVE4TF2Q._*7+IU=AIWRDF143UDTF?B.2:IG6JJ)?N'+>Z]UMP]
M1UN[,GU1UCDM_3XBJWUD.O-EUN]*K;]9%D:"3+5>-II,C)0U%.6@GHWK&F,,
MD;&-XRK(2I'OW7NM>?X&_"7XO]]?S+?YSG=O>_2_7?=>\]A_-KJW;_6#]J[0
MH-^4^U)<-U]M/,2Y;;4&2@J8L-FLA5R8_P"YKJ5(ZJ1,;0)Y0L"CW[KW5?\
M\UNT.QNHOB?_ ,*=]S]9[GS&Q<KEOG?\>>O=S=@8"FJ:VKP6VNT=N]4;=W/D
MX8:-DJY#'@<G7Q-X761%E:164IJ'NO='*_G[?R__ (%]:_R0>ZYMC=0=0]1+
M\;^OM@U_Q_W_ +,VUBL!E*6KJ,MB,/#019F"!:O()NZDKIJ"N62HE.0^\::4
MO.$E7W7NA ^4'QXZE^2?\Y+^4IM/NO9V&[#V3L_X(?)?LP;&W31+F,/DLCM6
MNV*N+&6QTVJDR5-05U5#7PP5,,L(K:2EG,9>&-E]U[KGL?JWK;I__A3MO3K[
MJK86T>N>O^Z?Y(]/V+VSL/9>WZ7;>$W%GL=W-)@(,SE\32118^MR46$IXZ%:
MB2G,HIC+#JT33"3W7NB%_#'XE[!^0W\O+_A1+TCB=\]5_&+<'9?\WG^8-T=M
MGNW<=/0;0H</C$J^OJNAVW69%5@EIML9&IIDHIZ*&0QB&HD\-/)+I1O=>Z$W
M<NZ\ET9VW\(J?^:W_)[V;\;L-T1\CNHMJ?&O^81\ ^VL=D]J4&[-SQ'&XVES
M>)PD6"WMM[8^8K7I:2NHLN)L=D)E2&JH9X5A%1[KW6W37T%#E:&MQ>4HJ3)8
MS)4E309''5],E9!405B-'-#-#(K1RPRQLRNC*59258$$CW[KW6K?_)BZ[Z_P
MO4/\_7.X?8NSL3F\!_-I_F@[%P.9QFV:*@JJ+"8[$X!J?#TE1% DU-BH&),=
M)&ZP(3=8P??NO=(SX _''JCXB?\ ">2D^<OQZZ7V(WSBHOY:G<O;6(^1\VRJ
M',;\;)9':^3R-)3#<$E/)F)\5@8:7'4]!C!4_:QTF.I*:.$:![]U[HT?PC_E
MR? SL[^1CTI@>Q^BNI-Q4?R,^$.Q.].]^TMP;=Q^4W%D-Y=G[+I-P9_=]=NF
M>-\N-P8_,5,\L-<]>*BA--%%&\:0*B^Z]U5'\ -KU/S\[B_X3R;D^;>U).RL
MU@_Y<OS&WM7X'LVI;>T.Y&Z@WM@L#LO-[BCK6E3-O5XR#";@3[U:B^16EJY-
M=1"LH]U[JR#J/X1?%*?_ (4,?,$S=%]<2;>PWP=^,G<6.Z].U*$;7CW?N#,;
MIVW+NL[;$ PS[B@P=-44=/D&HS4T\.0R@BD4Y"I+^Z]T8+^3_LK:'5/RY_G;
M=4=:;:PFP^L]L_._8NX-M["VIC8L'B<?5[ZZTVO79:6AH*=4IZ05M6!(Z11K
M&+*J*JJJCW7N@S_X5;?]N0_D_P#^'G\=/_?@;<]^Z]T+>Y_AC_.U[+V?5["S
MO\W?H[8&V=ST%/B-P;KZC_E_4>(W1#C:G2*R/$UN3WWD:*@KJNE\D"U0HVEI
M3(9Z8I/'&Z^Z]TA_F+\=/@)_+K_E/]#?!K?VTNZ>S>CJCMGI3HCJ[HWK#-T6
M*W;W!O[=^>ES5#MS*37QF-JTW?GHJRNS$<DE)1O$LL5E@"4[^Z]U5_\ S%HO
MD*G:7\H+LW>_\L+XV_R^,1@OYMOPKZ]Z_P!\[0^06W-U=GKC=Z9"JAR&V6Q6
MR-NXO"4.W\I04A7)4L&[LO&%@ID-&\9DJ:3W7NCZ? WX2_%_OK^9;_.<[M[W
MZ7Z[[KWGL/YM=6[?ZP?M7:%!ORGVI+ANOMIYB7+;:@R4%3%ALUD*N3'_ '-=
M2I'52)C:!/*%@4>_=>Z;<)OS8_8_S)^>^Y/@5_++/\P/LUN\UZ3^4?RJ^4?>
M.T.N]C83<W5F,HJ2KZ_VS4YG$;IW.V)VS35-.L]#C-KFD:JD9YIW9HYG]U[J
MG?8W8?<70'\B3^?9A]ET^W/CQ7;-_FT=P]%UV Z%W#7[\VQUGM3L3</5^"W=
M0;+D@2BJ7P..Q^:S4<*TU%CG43RSBBH)0U/#[KW5LG\_;^7_ / OK7^2#W7-
ML;J#J'J)?C?U]L&O^/\ O_9FVL5@,I2U=1EL1AX:"+,P0+5Y!-W4E=-05RR5
M$IR'WC32EYPDJ^Z]TI=Z;1P/RD_GY?%?X[?)39V$[$^/?QZ_E''Y7]%];;\Q
MT6>V]4]DYK?V'VQ5[D?&5BR8_)Y;%83]NE66"62@:'[R$1._D]^Z]TONP^M]
MI?%;_A0=\&#\7NO\)L''?-?XK_*[#?,W:G7:Q;1P]7C^A:2@R^R=Y9C T(AH
M*G-0YVK.&AR+4HJC!5R0B8QK*A]U[I#_ ,D?X+?$[M'XR_+S?W;W0_6/<&Z>
M\?G%\ZMF;URW:.SJ+?,W]W=O]A;AQU-MRADR452^.PJ2-7UIIJ4PQM75U55L
MIJ)3)[]U[H:_^$OF?SNX_P"1W\*JS<&9RF<K*&/OO 4=7EZ^7)2Q4.V^R]X4
M..HXY)G=UI:"AIZ>FIH@=$%/%%#$JQ1HH]U[J^?-?\6;+?\ :LK_ /K4_OW7
MNJ ?^$L?_;C+X:?]K/Y*?^_5WM[]U[I)?R\OB3\>>UOYEG\[7NWMCJ?8O:>]
ML1\N-D]6[6F['VQ2;VI\-BZOKC:E?E%Q5)DHJFEH9\W)/2I7S10)+4PT5)#+
M(T4*H/=>ZU]=Z;@[(ZR^"'S)^(O0^TH\CTCOG_A6%V3\*9^D8-VUG6^WHNL\
MI64=?%UY#FZ:.HBV7M//9G'8V@JI5I9*6*"MK-5+,U7*LONO=6S?*?XZ_.//
MI\/]W;0_EC?R_/Y?&\_BC\@>G\_TQ\@-C_.3 XN?$8FAJ4H,SL6DQ\76^T*?
M)XG=NWWJ\:^)DRH@FO&RP/)&MO=>Z,ODOAU\<?EC_P *!/E[/\E>I=B]Z[6Z
MU_E^?%&IVYUKVOM>BW[MK^)[MW!O&#^-U&#R<-3CJG+XZCI*NFH:F6F>2EBR
M%<(2C3LWOW7NG#O3=W2U5_,S[9VM\4/Y>NX/YAWS&^/_ ,>>F.K.R(=^=I[0
MZRZMZ;VWO:*JR^V<-15.YZ?(OB,IN&DCEJZL8;;N0K)J98XV_;5XH_=>Z*U_
M*_Q>^]G_ #<_X49[%WMTQTU\::VGZP^(F]\K\?OCKV#)V!LO"YC?_7&\ZW)5
M]).,7M^G&;S0%+499X]N8XO57O'4(L=94>Z]T+O\L3^7S\&-_?\ ">_K' =A
M=1=9;NPO?'Q,RW9/<_8NY<)29C,29N?%U$C9-L[,KY"CJ]GFAI:7%O%51MBH
M\92QTWA^W%O=>ZJ]W_W!\K/DE\4_^$OW1N\>G,3\L,'\A]N]Q[Z[;Z1[T[,J
M.O<!V5D_C'M>F?8-/O3=-7C<]35=-/C)*G.M1Y#$Y#^-5D$"RHSWF'NO=6;U
MG27S:KOYC?\ +_\ DOD/@M\+/Y?N;V9O+='5/:.Z^L_FCA]TY;L3KS>F.,>0
MV:=M1;&V8NX7P];'09:@7S54]'-3WIXD\C$^Z]T=W^5LRGYH?SP$#*77Y^[)
M9DOR _56R@"1]0"5:W];'^GOW7NM7?Y8X':N8_DM_P#"E[<CT>W-R5^%_G[=
MXY7:FY/X:M9-0MN/LWJ-*HT%340)/3224\STT[PE4E4.JO+ RL_NO=;-O\R/
M:^V=E_+/^1GMK9VW<%M/;F-^?^_?X=M_;6(I\%14_P!YU?OJHF\%)2QQ01>6
M>661],8U2.SM=F)/NO= -_*8ZHZ[^5'R@_G)_)3Y2=4;([+[_P!L_P R?O?X
MA[5KNT]G4^[*K ]5=08K;\.T\%B(,U'5?PW#96DK9JJH%+'#3Y25ONG612FG
MW7NFSY'_ ,OGXW;G^".;^&O\O3Y"]%42=-?S*,)VMA.@N].S:3/; DW]M'<J
M;ORG062H\?":G%X.KK:^*>/ )1U55!))"[QNDYE'NO=(3I#M#";:_F5?#^K_
M )A7\IZO_E]_+[.TO<?1/Q8^2_QP[>Q._NL]^1SXOSUFWMR-M(XMTBJJ*&MJ
M\!BMRT%8]+(6JH4I:P.U-[KW6TG[]U[J@'_A4=_VXH^<W_ELW_OXNOO?NO=!
MA\GOCWU1\D/YR/\ *8VCW1M'$]@['VI\#?DMV1)L3<](N7PV4K]IY#8?\+7,
M8V75292EQ^0J*?(0T]3#+ M=1TE08S)!&R^Z]URV)U[L7HC_ (4][NVKTILC
M;O6.U.T_Y)=+VOV-LKKO%0;.Q6?W/@>YY,'19O(XZ@CAHJG+T^(I8:**K>G,
MT<!=%:TLNOW7ND[_ "$/C1T1\N?Y9N9^1_RNZ-ZU[:^1_P X.S_E#D?F!N?L
M[8M-N+-U]7C]^[HV_!MVLGR\=5E,?C<)BJ"DBH<;YXTQX.J%(Y"7/NO=74_
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M "7_ ),$WQ0Z1SYW-_?CY 2_/S8'<Z[?7%8?(5N/8[:PV*ILEDADLK34./\
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MK<6W<Q@RZP97!5U?09.FI:MJ:>KI9O)0S1S4E34021E9+CW7NO?)#^7KT/\
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M<R];[BZ^-'C5Q#4N&FDIJ^@J<578Q(Z7(8^OH*NDKX!HJ8W)+^_=>ZY?&/\
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M*BV-A3N*2:I6EI9:? Q;GKL%CZZ=ZJFPN0W!5XIY0J5])74X,!]U[HQ/=O\
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MY:OQM^4/Q$[FK,[UKVS\S_@I'MKL'K_-5VVIJG'9WM'!XK,XFM5#25]'*/\
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M/QJV0G9F^-S)BFI_XIDZ2@FK<;CJ'!82"JCJ,ADLCE:.C@@#%99) (C[KW2
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M.RN!ZTP]='(V+K>P,Q797'0XF?.RQF/&XVDCK\Q5"]2N/%"DM4GNO=$LV?\
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MQ.7GZ[ZQWIM?)U.)K*9!3U%%3Y7"UU'KCGJ$>>FF99BI$<?NO=8,'B,7C_\
MA('/145!2TU))_*UW#EWIXX0$-5D\74U]14:;6\LM;-).S?7RL7^OOW7NAY_
MFNTM-1?R9?B1145/!24=)VW_ "K:6DI*6):>***GWKL9(XXXT 5(T4 *H
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M)ZGL?<.>WY55.'QN)W('G_A]0-J53R4U*W^5AHC))[KW58WQAW#B]R_R,/\
MA2KF</VKNWO'%Y_YA?-S=V [CWW0TF/RV[</NO:&R*K#[IJH\?!2XW3N"A,=
M;"]'1TU))!+')2TE+3O%3Q^Z]U<5_.'V]@J;^3S\9=N0X?'# X[NS^6'AZ'$
M/1I+3Q4L.]MF4BTZQ.K((A2LT6FUC&2ANI(/NO=#A_-E_P"RK?Y(7_C2A?\
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M0O\ \#CF_?NO=.DW6&S-X_*7YW=B?RS?YK^\?Y;?>^RODOFLS\V/B]\C>O\
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M>63IJ>F7,[PV_*M/744K^N3%5,<*(BI3Q>_=>Z*#\@?^R4/^%:?_ (EC-_\
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MGQNXMH[PP=-N3&5]/(0Q@K*&LBFI:F(LJG1)$RW -K@>_=>Z!'X_?#3XE?%
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M=?\ 7.UJ'96%QL5=435<T=!B\;!345)'+55$\SK% @:61Y""SL3[KW0#]M_
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M:ZCZ#V/BNLNC^L=A=0]=X/R'$;'ZUVG0[*Q5.TUM;Q4..@IZ99)-*ZW\>IR
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M;R+9;;N.[>ZXQ/8$>/J9%T//0C)TM2:262.Z2-$4,B$H^I21[]U[J9LOXO\
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F7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>timage_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_002.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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M5R/QW[<GZ=S^W_DS1[_R\=?/LW?LL>/KLW2X@XIH)*G$USY)E@^]$:R"-0Q
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M5V!'EVI&ERRU=/7"@3!MC&)"9QLTPQYIC(+5)%Y/&!)[H8E_*E?*M?\ B_\
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K0?\ YH_\@O\
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M<?)_^5GT3\@^MOE!)L!-R=E=J8K?NU4Z^W/6[HA2'&8*EH)'J :*CB=?N-(
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M_P F_P#&_;GA]>ZD>W.O=1_!_M?_ ";_ ,;]M^'U[J1[<Z]U'\'^U_\ )O\
MQOVWX?7NO>#_ &O_ )-_XW[]X?7NH_MOKW4CP?[7_P F_P#&_;GA]>ZC^V^O
M=>]^Z]U(\'^U_P#)O_&_;GA]>ZX^"E_HO_4P_P#%?>Z+U[KEX/\ :_\ DW_C
M?O7A]>ZD>W.O=1?!2_T7_J8?^*^Z47KW7+P?[7_R;_QOWKP^O=2/;G7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>ZK^^?WSSZ5_ES_'W+?)CO^#><O6^&W'M+9TJ==8"'<F0%;O.:.."
M04=3+%%%I9Y&]<HN !_:O[K%$(Q4U-<=7)8&@H*9-?D:>7V]4A_]!AW\H_\
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M//\ [1_R=_QKVYXG7NO>?_:/^3O^->_>)U[J/[;Z]U[W[KW6?[@_Z@?\E_\
M&O;?U7^JG^SUO'7#SP?UC_ZEM_Q3WKQ(/4?SZ]3K)Y_]H_Y._P"->U/B=:ZD
M>W.O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M)?-9(T%,+6NU_>F>@Z;C34>BR[N[ABQ#5MN+_CW;7IZNXU4Z,QMVK6NV]@<O
M?TU=!09$_P#(="%/^\@^VE; /^KATZXHQ'Y?SZ57MSIOKWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][+^O=<-8_Q]W^J/\ J_XOKW4;R?X?[S[2
M=>Z]Y/\ #_>??NO=8_N8_P"O^]_\4]^Z<\/K#]Y_M*_\E>_:_G_/I_Z4_P"K
M_BNO>=/Z-_MA_P 5]^ZIU[[S_:5_Y*]^U_/^?5_I3_J_XKKWWG^TK_R5[]K^
M?\^O?2G_ %?\5U[[S_:5_P"2O?M?S_GU[Z4_ZO\ BNO?>?[2O_)7OVOY_P ^
MO?2G_5_Q77O.G]&_VP_XK[]U3KWWG^TK_P E>_:_G_/J_P!*?]7_ !777WH_
MHG_)?OW37A?;UW]Y_M*_\E>_:_G_ #Z=^E/^K_BNO>=/Z-_MA_Q7W[JG7O.G
M]&_VP_XK[]U[KJ>8V_ L#JOR!_QO_C7MX3_2GJ@&>N1F4?AO]M_QOVQ!_C/3
MA6G7-/TC_8^VH>'34G3+H_RKZ+IT?ZC_ 'W^]^W=,/\ J/\ L]6^F-*T_P!7
M[.G;SI_1O]L/^*^]]6Z]YT_HW^V'_%??NO=>\Z?T;_;#_BOOW7NO>=/Z-_MA
M_P 5]^Z]U[SI_1O]L/\ BOOW7NO>=/Z-_MA_Q7W[KW7O.G]&_P!L/^*^_=>Z
M]YT_HW^V'_%??NO=>\Z?T;_;#_BOOW7NO>=/Z-_MA_Q7W[KW7O.G]&_VP_XK
M[]U[KWG3^C?[8?\ %??NO=>\Z?T;_;#_ (K[]U[KOR?Y7ILFG3_O'^M]?]]]
M/>OT./5J'3UBED70"2OZN>?]?_'VH,4U/T>'S_V>FA. <_ZOY])C*9G#82 U
MF2S-!B:0B^FORO\ ";6/Y%C[)-PW6#:E_P <N/I_YUZ5I:,QHJU/0</W1B*^
M4T^S=L[HWE,+)]]08_\ AE(0?^FV<*1^?Q_O'L+2>Z%G=?HV=;H_ZOMZ-8>7
M7CRY"#YY_P W3?\ ?]MYL!Y?[I;*I@ .!_>BK(Y-^2;_ )]H9MQWS<CV?HP]
M."RLK/,P+']G^&G3-F-O0TE/][OSM/<%- WT R-'M>DYM_QQ8V'^P]D5[<PP
M8O\ <O\ FST8VTY_XB68^VG^?H/FV]B]U0>#K_;FZ\M?Z;LSVXJO%4E*1<^;
MGB?BY]DWT#;K_P DRW_U?RZ]]5$W]JP^P"I_P_Y.C;[6QV2P6W\/B<KFER^0
MIJ$+75U<034ZK\W/T !_VWXL3[G3E^RFMX?UN@E.ZR,2 ?R\NEGY_P#:/^3O
M^->S7ZEO]5/\W2+K']W_ ,V_^3_^->W/#Z<\/J9[;Z;Z][,.O=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO= GV74^&DKQS];W_VP]W)H*=:(X'JGGOC
M>E?1O5B*J_-?<V_K^/\ >O=&ZN'ZN9Z:E2KZBZPK)N?-UWLRO((O^O$TE_\
MH;WLY1:^@/\ +JIJ)7 _B;_#T+/O77NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NF_P!I^O=>]^Z]TX>U'7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NHU1]4_P!9_P#B
M/:.Z_P W^7K?EU%-62+!(S_B2#[H;LVX_6/2GZ4?ZO\ BNI7W!_U _Y+_P"-
M>[_5?ZJ?[/2;'7#[O_FW_P G_P#&O?O#ZOX?63S_ .T?\G?\:]J/$Z;ZQ^3_
M  _WGV5]>ZCRO_0*/\2/I_QOW4OIZ4"+7U&GG3@?7ZV'/^W/MO\ QCY]7"G_
M %5Z[\LG^J_W@?\ %/;>L=*] ZQB83\#_#Z^VB9SUH+HZ:?,O^^_Y%[=UCKW
MU77.[_Z@?\E_\:]T^HA_U#KWU74MI2/JEA;GU?T_V'ND-Y!<?V/3E*=</*?\
M?^2O;OU!_P"&?ZOSZ<T#KEY7_P!2?]M_QKVD_>4'3=#UWY_]H_Y._P"->W?'
M/IUN@]>N'W%-_A_U+_XU[OXPZKUQ$M%4@^#2#R?S?_8^[F05Z\%(&>LW']#_
M +?_ (U[WK'3/C#J-[9\?Y?SZ44'KUGGJ#!]5LW^O?\ WKWOQNM  ]=05OW
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M/^J6WM!/[A[?!Q\7K0Y=NSY ?G_L]>_TZ]>_\[NO_P#07JO_ *C]V_UQK/\
MY1[G_LF'^?K7[CD^7^]=8Y>]>OD6W\8R%)_A_=FK;_>Z?_??['VXON'8+_H%
MQ_S>BQ_J_/K;;!='T/Y]9XN]>LYE(.[,=2,!]*O%5F.^O^)((]V_K]8'U_U?
M8.G&Y=O%\J_F#_AIT]4O9_6U23X=[;7 _I_$:0?7VMAY[L%_XE'IK^KUUYVQ
M_GTYIOG9LM_#N? G^MJZC/\ Q'M1_7C:/^4P_LZ8_<=TO&T/\_\ )U';L'9\
M7^?W;M,7^G^_DI/^C?;7];[#_?\ $?SZN-KN6_"_YJ1TSS=P]<48YWM@YR/H
M*'(_Q@_[P;?[S[8/.]C_ ,I!_GU8;+=-^"GY ?X.F27O3:50 ,1C]V[@:XL-
MO[<K+?C_ !'^]>TD_/D'^^)'_P!)C_/TZFR/YD#[37_(.HT_8&^\J2V"ZNKJ
M:"UC7;LKAB5_U_ ;V_Y*]ED_.[W'_$"Y_P";U3T\FSVZ<9 ?DO2;R,V]ZZW]
M[.T\%LNET\4&TR .!_RN5MC_ +W[#UQN-Y<?\3[:#_FX3T8P6*+\,1;YFG^K
M^728BJ.E,'7>:7,?WUS%PJK7K5[[J?\ B![00?NJPRGZW_57IV87CBDPT#Y4
M4?Y>EP=];OR4*TNT>K<_46!(K<XHVO2\?G^EO]C[/[+>[D?[C6'^'I$]E; _
MXS(/L&3_ #ZD?W7[8W(6&X=VT&UJ;\4&Q,:/N3;_ *;:RP%_SS_L/9I;65_N
MF;FX_P _3,]S:66+=:X_%P_8.G_ =3[1Q%0<G-1_WAS%M0SF[LE_$ZKZ?TL1
MP?\ 'V>[;L-GM?227=GO*4P/11_J_P G0L:J2G_R4*21R+_[X^Q%-<PW'10+
M<G(I_J_+J3K?_5?\FK_Q3VY^\X/]5>J_3?9_/KLJ?R1_L3[=@O8+;KU">N):
MX'-Q?V["_P!3UKZC3Z?ZOSZD03NQYTFXO^1?_C?M;]-]O^K\NDV/GU-$]APN
MH?\ !K?\1[9M[BGV=>*TZE>S+JO7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW4?S_P"T?\G?\:]M^)U[J/[;Z]TX>U'7NF_VGZ]U(\_^T?\ )W_&O;GB=>ZC
M^V^O=.'M1U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NHWW!_U _Y+_XU[1_5?ZJ?[/6\=8/;G6NG#VHZ]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T O;/_ "N
M_P"#?\5]^?\ R?Y.MCCU2#\B)/W<K^/S[T17KPZO4Z1_YDIU%_XC/97_ +J:
M;WZ/R_+_ ([U4_"_VG_CQZ&3WOK?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW3?[3]>Z8\GG,/MZ'[O-Y6BQ4'^JK<B4'^V/)]E4FYP6O
M]K< ?R_P=*UMC(<*3^70;R=W;",_@QE57[@JBMB<%MBKR1'UXX(_']#[#YYY
MLO[#]7T_L_\ )7I5^[).) 'VM_L=+#:>\L1O.@6MP\>1IH%K6H$%?06O_##J
M( ^B\<W)X_'LPVCF6#>?[+Q>DL]NT'Q4Z$3V+>DG7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1JCZI_K/_Q'M'=?YO\ +UOR
MZ)CF,%A\+O#*5/8#9ZC3/YG^(X#LG'9.KQGVWDTZ<=^31Z0& _U[\V'N!+C:
MX+"\\?<OJ#\QX_V]"NW#2)2/3CBM%_;T(5)/V=M%A4XJM_TF[=*L#09$4N,R
M? _W567\%<?]C^+>Q'9[W>[?_P .AZ8:UBFX]K?G3\_3I783MO9.;04-14_W
M?S?'^X/.$XBIX_V/ (_Y%^?8IVSFRSOA7_<;_FKY_M/1=+MKH<9'J,C_  ="
M1<S<E?\ >OS_ *__ !3V>+)#<_V$_P#J_ETPT&GB.N?Z^?I^+?7W;QOI>M?%
MGKE,#ZOR./J3_A[2M>=/QD'_ %#II M[2S7?3_#INK<WCL<+5];CZ2F_(R&3
M(^O]-7_%?: [S9P?VT_^K\NGUM&;X02?4"G^'H/<CW+UYB)S!/NW UDU^:''
MY$Y2J_V\( M_K^R2;G3:K?/C]/IL]V?PG\QCIAD[LAJQ_N VAOS<*_ZD[=_A
MM)^?]W5@8_[S[#4WNK"/]^?\X^E_]7".)4?[:I_E3IKJ>SMV2 -3]<4&*_K_
M !_?M)C;_P"M]/\ B?\ 7]I/]<RYN?[&#_JH>EB\O6Z\6K]EITWGLG?T@Y;J
M:D_ZC>P-?]/Z'_B/9>.?-PN?]]_[W_G/3IV.T7^+_G!_F'7/^_\ OUN2.G*O
MF]SO3_>?U>V!SM?_ -'_ )RCK?[FM/\ EX_WAO\ *.G2+M'?D0)GZYQ^4_!.
MU-Z4N1_I^/\ ;?CVOB]PKVVQX%M_SEMS_GZ1_N&-A4.1_ID(_P -.LD?==#"
M ,SL[?>WR.0%VX,C]?Z_9!?]\?9I_KG00?VT$G31Y<:F&4G[2/\ #7I[IN[^
MLZL&&?=]!2M]0*[%5N*_WD,OLPL_<7:KG']C_J_/I,=DNTS0G[*?Y>GZG[ V
M#(/V=_;5MQ]*^B_/LR'.EA_O\?ZORZ;;:KL?A;\O^+ZAUW:77./YEWKA/I?_
M ('C_HTC^OM%_K@;2?\ B4?Y]/\ [FN_^4;_  ?Y1TFI>^=D%1!ATSFX:C_J
MP[:JUM;_ %S[+KGW$L/+I?;\L77XJ4]"0?\ )TE:WN[/S+:CV[@<#3\_Y?OG
M>E)C?_5>"W^]>R"7W&K_ &'3B\LA?B)/^E4_YCTEZCMG-5Y;[WM_8VWPP_X
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MRM/V<.FBMH-^RF^:Z=V'GQ?G[#<5&GT']:VG]E\^T;A;?VUIT^M]:'X;MO\
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M44]3*#;CE3<'^@_VW'L[V#F.+>\>?^4=%=W8FRXY!R"#@CH2?N_^;?\ R?\
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MM>$/]0Z]YO\ :%]^\4_ZCU[PA_J'7'[A?]2O^V]^\4_ZCU;Z?K#]VW_'./\
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M/Y?[/4:7=6!B6U3G\#2F_P!5RR$_[RZ^_#?XE_XO_8ZK]&?X3^SI/UW9FQZ
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M/4W;%5S]#C+?3_8^U'T&Q0?Z!+^WJK;ING\<8^T?[(Z4$9ZRHOU=+;[-P?\
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MYRFXJS)_]:_^*>WV&[W']M;_ .K]O556Q7\;'\A_T#TW5^V>TLW3Z,FG4;P
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M[,XY.?[.2#_[TWMK]Y0>G7OIW]/Y=8O[T;;_ .=OM[_S[4O_ !7W[]YP?/\
M;U?Z-OG^P]28\[@IB+97''Z_IS-OI_AK'O?[V@].M&U<>1_9TX1UU).EJ<_>
M$6))LW^]@#\_T]NPWL SP_GTP4;K-Z_]I_WGVI^H'S_U?GU7'SZ]Z_\ :?\
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M/7OIQZ?S_P!GKWW2?T/OVL]>^G'I_/\ V>NONE_U/^\_\:]OTZU]+U[[I?\
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M(N;EC_M17K$V'[-R?[V=[!.WZ9>30;7VR,6/]A-6\_[Q[*Y4W"7-S<&#[/\
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MJ#_RHT%7M@?^J52!_O'M%#R:\'!+?I8=WD(_W(NQ^S_*.H?^C[/XTFVPZ_\
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MB%%%UMNBJIE +UN2%)M>EYO]/O*L"W^N/97_ *X<'_*/)T__ %?;^-1_,_R
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M[_8>ZTZWX!^?\NB^]CXK=D.6HLS1UV[*K:1H0N0Q^TLG_#*JEL/^!A_Y7?\
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M@O\ Q#>TG]:[ ?\ $G_CW^;IX;+=^2-^Q?\ /TWR=P]=D '>V#Y_Y48ZH?\
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MKG_DH3^-_J^SHRM[2X7_ '%0CY_\6>G##[RV7B8/L]B;2K<^5'+;5VUJ'/\
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M/_/U:3F!#_Q#@_U?LZQMT+AY5O6;R[(R9 MZ]PJ?]MS[5?ZV<)_MKNX/\O\
M(?\ !UIN9BO"U0?E_P 5U/A^.?6# ,U-F\F;_3);AK#_ -"V_P!Z]ZA]J]L/
M^_>D9Y@F_H_L_P!GITH^C.JL:"L.T<'657T!R$A_%_I8&_\ MO9O#R!M-O\
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M@'1A;[;=77PH?V'_ "]%:W#EMH[?SE5NCJK?NU,3D<L@.X-I5N2_R6J/%R"
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M;_8R*/L'4\8/.[?I_-#L_I;9GU_R[/;D_B=[_P!+DB_^P]L&T_=W%$L_\/\
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M'LS_ '/?#_EH2?MCZ2"^M1CZ2GY=>'4O;,\_^1]S+5'ZF\E6/^*^UIY:O_\
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M_!_L]*#=6Y_XA#_JK_FZQ?P#?\7_  '[DR-_Z9';=.H_WF_NWU-U;_\ $O\
M.J].":U/_$/]AD/^;K#+2]CQ'U=P8_@D?\>Y3GZ?ZU_=_P!X7/\ REQ?\9_S
M=.B6U;_B'_*3_/TP5^2W#3>FL[NH:7^G^X[$2?Z_]HV]IY]S1/[;<O!_YP?Y
M.E4<-M<<+.OYM_EKTBJK,;0K+_Q7LC?V?J/J*# B_P!/^H,_[U[*I&MI_C?Z
MGHRMX;E?["V"CYG_ &.L4.)VM,1-BNL=X9X$<5^=QJK?_P [:AO][]IQ#;VX
M_P!P)#_V4?Y.E1:X/&2T7Y C_-UDJ]Y#$@10;;ZZVZ> :%=R7JK_ -?!14_T
M]W_>\UG_ &,:]6_=WU?&YFZBKOWL7(F^*PN/^WL!;'8VKN/]C-[3MO\ NH^!
M#TKAV:U_T>X_P?Y!UU_'>XUGN])7T=N-5!MRCR'^V]O-N6_'XNJSV&V ?HX_
M,CK/1;AW+-6TE)DM^YO;]357H*(9_KVEQ@J;?CR7('X_H!_3V[9ROJ\#ZHP_
MD/\ #TC:SMQ%J%K$<U/>30_9TK<Y2[JV_C_XEFNUEIJ<?ZG9U,?^)]B*YVB?
M:/UOWD?V1]%5O,DG:+1/][;_ #](P;LSP^N_=PU5-^<A_HI)I?\ ;D^RR3<[
MPGX_&_X=X0_S=&LL"T_W&I\M9K_AZXKNB:J%YNR-J'_I@S^RFQG_ !7V6F3_
M )>O^<W5/I O"U;\F/3!E(L/F!X*O>/5!!/-?0[>;&U5+_U!$B_^]^TOT]M<
MS5-U;P_\W.G$AN(QBV<_:2?\/0_Q]B=?FGHX?[]4)/U)^_Y/^Q(_WL^Y8L^;
M;&PA_M[?_G*>@LVWW+$]I_WGCT'79NZ]L9&@PTU'N;'9:#%5_P!_G<!09*PJ
M:4VM;\7A_P!X]A;FCFFSN(:?5'H]VO9[]2?\6IC'#'3;C\QAL90464V+V2:,
MWYV_G\G_ !2DY_ZS0G_8>R';-[^DAI9W72FYV2]NSWVO[,=*_#=[X05'\-W-
M]C@*\VO6T&2&3I:G\6\X%R#Q];_Z_L3V//\ 9_V-Y].G_-S_ (O_ %>713<<
ML-Q6I^1%*="5_?\ V=("3N+"TOTL%R=&WL71;UM,'ZPGB'VR=%D>SW5*:6/V
M _[/7?\ ??:W_/2[:_\ /_3>[_UCVW_E,7^73G[JW#_E%E_8?\_7#^^NV/\
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M"=W$U.9!R(%=09*K^YI:8?6C^]_K$;?GV*N7^0G2'P9O\ORQT77>^S7![?\
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M<'2>Z/QS1Q4F5/\ M[#V4R[X_P#Q-L)?\'^3JWT]M^"11]M?\XZ;Y>S]J_\
M*1U-N87^A79(7_>B/=!NEG_OBX_[)NGA8N/QC_>A_FZX1]E;88_Y!T]OF_\
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M;B\' _D /\O3HO=74>%/V5%N*A"#C[' 8NW]/^.)O_MC_L?;HYTL-L_L:_\
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M^/75E-/Y:.DS#5'_ (<0_/\ AI'^^Y]V7VWV\XG+?L'3,W->X'_?7[#TH?\
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M:/8V3M]3C]G50^O^/'/MY>=/^4?ZG_G&/]GI//L94=Y0?G_Q73G3=F[ID_X
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M?HMM86M!0VU<U].I-'O7/T0$4>5V/NFG87M0;B_AI_V/E)^O^Q]HI;_P_/\
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MF_N\6X6P_L(/^J/3_P!#<CB__5;_ &.H\1VK+S2]6YVI ^I&S+_7_7M[O]5
M/^(DG^K\STF <<;H?[U_Q74ZEAGEO_"^GP0./]R I,9_MK 7Y]OZIO\ 0;4]
M6\8>=W_AZ=4'8%)3\T>T]ET_U!-LB3_A_J?]]_C[UX5Q'_OO_G+_ ,6>D_\
MBUQ_$?RI_F'21K-P4\\WV<W8^X-T5^D_Y!L;;?\ "SQSR0?^*_GVCGOOH_[:
M[_ZI^+_AZNEM]./]Q:?:?]GIO_NAF,T!X]N5]- ;_P"7;YWI69/_ -4XC_O?
MLNAVB6_^SI1XHC\ZGY"G^'IVI^JZ>47K<R3:U_X%C*3&?\3[5P\FU/\ C,_3
MC;MC_%Q^WI01]7['B'GK,3D"?R?XJ#_O7/MW^JNSV_\ ;U_P=-?O_<6^&G^'
MIGR6/VGM[5-C-]5NUJBX _A^X_XD/SP:/_8?[[\;NMKL]L_6AG_ZJ9Z86-[S
M!4'[5ITH8MY;^JM@?Q<49RV97('[$#'?PS[FE_YV?@_XGV)3N4ES8?I?ZO\
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M?]<>U@]NX_\ 1]S'\^DYY@@_#9_M/_%]9TZ(VA(OFSVY]]Y[_4_?[NK" /\
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ME63_ )2?^J_1/-NV[VW\/\NGBGVA\9(_\UN\_P"QW)_V#]F\/)/)MQ_Q(/\
MSD_V>DQWK>!^ ?LZ<O[N?&0 :]RT56Q_Y7]Y5@''^V_WOV;V_*7*FW_V/\KF
M0?Y.FI]SWAN(_P",CJ13P_$VA!G)V/5'ZVNV5_/XX_WBWMXVW*]G_JDZ3&?<
MKOA_D'^?J=!OKXSXWFAHMOUS'Z_9[8;)C_;F#D_[#VJBYFY>V\</VV_B?Y^F
M#8W[^9_WH#ISA[CZN0?[B-E9W*GGG ==7_WL_P#$>WFY\V.+^QMQ_P!DPZW%
MLM[<_$W[7/6>3N6LK !BNI^S*NW'%!_"O]Z7VG_K_#/_ ,LQ_P"?3AY;IDWB
M_G2G74/<&Y*86FZ9WL(6'ZZ.*F_XJ/:P^Y;M\=A+_J_+K7]7K<?V,J?ZOSZE
MQ?(3;%),(<]A=T[7)'!S^WZQ_P#>;\?[;VIL_<15_P! EZ:/+EPV593]AZ$_
M#=B[*W32G^ [EP=<5'_*^$M?_;$G_6/L76'-VV7V8)X_V9Z);K;I8OB4]+.'
M[3FVC5I]5OT_7CZ?G_C?LVA^G_XO_8Z2&O\ JX]9-%)_QT7W?Z4^G5OJ6]>N
M/GHK7(4G_??U/NDLT%MY?Y.JA3TDLQO+9^#@\V9W%@L6?Z5N5$@X_P +JW^\
M>R6;?=L@_P!'CZ5K;R-P#'[ !T&5;\@>L:;]F@K<EN*I/!_@6-J\F/\ 8%AJ
M_I_O/L@O>=]O3^PJ_1[8\O7EQQH/V?[/3:O<V8R"A,#U%O?+J.?\OH/X ?I_
MS?U?[W[*6]P+B3_<:PK^6C_!3I1-RVEK_N1*J_GXW7)]X]WU:DT/7>T\2H_.
M:WA?_K0U_;$V\[Q<?V5I'^;?[/5HK/:UP;H_E#_L=0JC<G>=#^_6X7K*DIS_
M ,K^0JC]/Z7;V4#F3=AYVW_5/K7[MLGP"_Y'_8Z1^2[WWKM^>^9PW6>4)_Y0
M=J[@_B=4/]YX]E:>Y=[93>!X%M_J_;TMMN5X[P5!<?Z84_D:="'-W[LZ."EA
MJ,)NZIS1H/O:W!8[;O\ %*JE'%X9@=.DW_H;GZDC\#)/<RP\&L\'^\1XZ+)>
M5KHG!%/(D]1AW)G)?^++U%ORJ)_.2Q])C?\ >Q_Q/M!!SX3_ &%A)_SBK_DZ
MLVPJOQR+^T_Y^N-1O_M.N0FCZ;%$!Q_EN]*7%_7_  N/Z#WJ7F"YG_Y9O^;I
MQK"S3C=D_D3UU_>GO/\ Y]_LW_T(%_XK[W^]]T_Z-MO_ *OSZ3?0P?\ *4W[
M/]CK.NZN](QQUKM!?QQGE'U_VY_'M2-XW.VS^[;;_5^?6C8V[_\ $MO]7Y=<
M&[$[9@'[W2K58_Z8=PT;?[S8^V/ZW7]O_;V'^'J_[MM#PE_;UR':/8L?,O3V
M=^EO^/DI#_T3[4?UUN?^43^75CLEK_RE@?;_ *AU(_TJ[_E'_,G,[_0_[^.D
MMQ_K+[5GG?<+G_EFC_G(?^@.FOW-:)PO!^SJ*F]>YJX6Q75E!B_S_OX=QW^O
M^N1_O7M!_7#?+G^R@T?ZOGU[]T6*Y9Z_8*_X!T\8ZN[@_@6XIZ^CV9_>K[W&
M?P*BA%7]E]I<?<>:;_5Z-6GG]7UYM[$5O/OG[KE!_P!R]::<<.X5_E_+I$UO
M!]4*%M-#4^?^K\NAN]R)T5= #V%VK0;&SHP57AS6J,>M<6H\E_"R=7//^O\
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M_P!OP/8>N+'F:W^ -^W_ #]+H+GE]Q^N*?;U ,??%/\ \76IWP0> ,+D-O\
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M*Y^?;F#^VM;C_LI/2A-MMFP+H5^0ITQTW<68SD_@PO7%=E;?3[#(4G^2D?\
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MK4Y^IKMQ!?I_7[(K]/9S!8WE?T;#P?\ FXG^7HMFFB_%*6_('_)TYC%?(;(
M^;<>Q,#3\V3&8^IR9-K'_8?[$^SB/9-[N/\ 1XT_;_DZ:BNK%."D_LZQ?Z*-
MY5P#;C[<W6X NF/P0I-L_G_7M_O'M0W(UY=?[D[F!^9Z?BYCC@'^+V0/S(KU
MCAZ7ZAI 9LSGJO/5/ZO]SVYK_3^@ 'MVVY/V7;_[>X_ZJ=(KC>KA_A6GV"O^
M;I74-)TKM56FQC[&V_5?05X>D9O]@01_O8]F<=IRZ.'\STF)OWP=7009>DV_
MBL]ELWLOO+ ;8@W!7-75^!KEH\E3?<O]0"38"_L"[YLMEM\WC65QH_;Y='EA
M<LZA9(BU, B@/\R.H:[_ -X45Q!VETQDH/Z9"V+_ -Z%O91+S9>O\=W'TZ^V
MQP_VUHWY$].*]L=@P6BA;I?*7^GV&]$]OP\];E;?Z!'_ #_S]6.U[:WFX_+_
M #CI1T_8O9]:?VNM]NY8WM_N/[#IK\V_VH^UT'/&\#_B+_U67_)TV=AVW_E)
M(_YL2_YNI_\ ?OM&"PEZ?R(/TOC]WTEO]X7VN_K?NG_*+_QO_9Z;.UVIXW8_
MYP]>C[%[ '_-'L]]+6.=I5_XCW;^M5]_T;?^-'IGZ&V/_$S_ *I=<!V!V5,1
M]AT_5V^G^7[CI#_A_0#_ 'CV]%S%NUQ_8[;_ ,<ZT;:S3C>#\AUR;/=Y50_R
M+KC9^-'UO5[A#GC_ (+Q[5B7?[O_ (B?]5/\YZ>,.U1_%=,?L_V!UV^,[_R:
M7EW%L7;%-_J,715.2)M_L0.?>QM.\W4/]O3ILW>UQ?A9C^5?YTZ4>/VGOBFP
M6X,9+VFU3NK)-BYZ7-_PVE!IEI2&9/!]")4#+]0+'\\V/H.7]V_=LL/UWZVM
M?U_(9&2>(^718U[:&Y4^'V@'M\S_ #I_JKT-_N1N@]T7SLOM'#;.W#28RLV;
MF]P9*JQPKB:''_Q,#@6 Y/T^G_$"WN(^>N=8-FF^CE@\8?/TZ%6S;.UZM0U,
M^O09R]GYC+@_PWI2JREOS78N]K_U/N.)=\;=/]QMM_P]" ;5!9XGO/V'ICJ-
MC=F[U 63KCKG:Q/Z3_#J7[KCZG\G_??T]E;\N[KNA\'P/!_8.E]ON=GMV=;M
M_O1'3]C>@JE<?24>>S6&M2WO74&VR:GU<?\  Z8 ?[S_ +#V=6WM+#NGZ,UP
MHZ1W/.0M"2HE/YXZ4M'\==ETI_RJNW=5?G_BXJO^]M[$<7M=':?Z/+^SJK<[
M7UP."CI\@Z&V/36\-=NW_#3N.K_XH?9Y)[>6_@_Z)_D_P=%TO,-R?X?Y?Y^N
MY>E,0O-%N+?M+]/^ .XJS_BGM'_4#_EX'5?WU09"_P A_EZ8JGI6M(O0]I;Y
MQ@-O36Y$90_[>X'M//[?3>=W^WKR;T&_XB*?L_XKK#%UOV[BP)\+VFE92K_R
M@Y['GB_^!'LIAY2W[;\)=:_V]+CNVV/F>UI^SIZI\CW=@_\ BY[:VCNQ2/3D
M,!D!C.#_ %,O^]>S*U/,5M_N3!;]%M+&3_<=F'R.>G&3L^HH^<SUSOS$SV&D
MX[%T>5^G]3"!_CS[-#S9-M_]O8?ZOV=,KMVKX)%/VU_RD]2(>Y=CGBOJJW$?
M]1FV:S%GG_6/_$>U47/=M<9F'@]4.RW*_#GISI^S>OZ[_-[OV^+6MJR3,#]>
M/I_Q/M<.=]J3_1Z=4_=UW;?AKTI8=S[=E%H-RX&L_J#DJ,?\0/9@G,%AN!_M
MZ](Y[2Y7\)'Y'IPADIYU(@KL96-S]5M]?]8WM;W>*6R_Y2/\_3C:O0C_ %?G
MTZ&_YO\ ['VI\:$_V/30Z:)\?1UH'WF'Q]61_P [#&<_7_$V_P!X]L36*3_\
M1^M?43@=I/\ O724J^M=A5X'WVQ<(;'Z_P )T_[T![*_ZG[?/_Q'\/\ /_9Z
M5#>[M>#5_9_FZ9)>F]B1\XNEK\4?Z8+<M7BO^AA_O1]I9N3K+_4>K_OZ3U_:
M*_Y>H7^C+)48$&#['WWBEM]/XD<J./\ EJ+7]H!R<\_]C?W/^K\^GSN5OYHA
M_*G^3IMJ-N=[8]1_#-]X/<%,; 8_<.VQBSS].&!'^\^RR?;>8MN_1A_6_P!7
MSZNLUC)DJ5^8-?\  >N"9+Y#47$^T-BY0?U_B0QO^]FWM@7',4']/Y4_S4Z>
M9+!N#,/LJ?\ #7IQ@WAVI"H;(=1)4J;@-A-RT*VX_+"Y_P!Y]F<6_P"^-\=A
M<_SZH;2R4?H2 ?:/^*ZF+O[<5);[[JC=UOI?'Y.DRG_7?V[)SM>VO]O:2'KT
M.TI<?#=J/RZ:<;W#2Y;[R;&;-WY5K2UHQ]<*#&4;?:U-O^H@V]NV'N#]?FSC
MD?SFZK<[+H^*Y QC/$?LZP9+OK;.+F:')8;=M+4VM_P 5/K_ (6]D]Y[EV9_
M1^C_ ,/3R\JL1BZ%.NJ;O"FJO^++UOOK+ "Y)Q][?[W_ (>]Q>XWUG]C;_SK
MU4\K_2?$ZC_5]O4X;U[.S"WHNJQBP/JV>W)2-<_FU^?Z?3V^.8MVN,)!TG&V
M6:9G>OY'J?X^Z*P _=[#V];\8[&5>5)O_B ;7]KH?WM>]-M]':^I_8.L_P#<
MS>]4G^YKLO/$#C[';]%1XL$7_!U?[W[</+E[<?\ $N3[.KKN<:\+44]34_S_
M -GKA#U#LVJM_&*W/;AM<6S>YJO)_P"PL%'^]CW3^I%L?]S>_P#P]7_?UR,*
M /LH.E70]?;%P@OBMH8"E-R+G&LW^]D^SRSY9V^W_L8">BUK^[?BQ_(CIX.#
MP7^Z-L4(^G+8ZB//^W]F Y?L+C_BNF_JK@<2?]Z/^?J?%$8.:;'_ &'^-_\
MB/\ ??GVL-G]-UK46'KU-LO^KO\ ZX]U@EG/_$?K>.->L9E-S<"W(Y;\_P"%
M_=Q<0G^WZ;-Q\NL']+LH'Y%C_P ;]WA$'_*1_+IXV_R_GUAEL3?@7_H+_2_^
M]W]J)YIIO[']:G3(_P 3X]-V9RV(P6/^]S57C\5CJ0^BOR UDVYL./\ B/\
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M/^\@C_>?8GM+ZPM^%OT5M979XN#_ +8C_!T_#MS9L%A)A-U8CB_^Y#956/\
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MBVX@/KS^&'LJFY _WS?];7F?^)5)^P_Y^F>HZF[5Q(/\ [;K:NUO^![?6_\
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MT_PU>_#DS:I_^(O^'_-UL[M=CA=?X/\ /TP5?2?4]6 :?:5'3'^M _\ "O\
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M>BD[N'_/KJ$C^@JN;_ZU_;PGWW_5C_)U6E@/XCUP:'NACQN/K&F/ ]./J?\
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MF*VSMK"_M8[;U!B[V]5#C=7U_P!C[.[2WMK'I$;JX;S_ &]*.)JF 6)'^O\
M[X>UO@?+_!TE$/V_RZSPO4"WJ M^?K]?]A[]6O6OH1_JIUSM5_X_\DC_ (I[
M<T_,=-_3_/\ P=3(I7^G']/]]?VY],.F1'7U_E_GZETGW(^OT%_J2/Z_B_\
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M_5^SK<^YP7.0I_E_EZ4=-A]XTE/XH-P4=)3GZ?8;;'^Q_/L\M-IN+'_1Y/\
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MG_BNEAWF8<?\(ZZ@Z]VL!R:ZZ\$C)?\ &_Q[;/)=N_5?W_<7'IU)_N7MFW_
M'(7_ .UC5V_WKV_%RE;])SO%P,_Y#TY0[,V^G"X?'?X_?F_U_P!;\?[#VI3E
M.QZ33[E<4_S9Z>8,!B*4$0XF@IJ<6X_AEC_M^/:W]V6D'^@=,&Z+>9_U?ETY
M5.3P^.-YJS&T?'T"$?7_ 'G_ 'GW:5$L/]'Z+_!N&X#^73)_?O:40 .X\>.;
MD8Y!_L?K[22[U;?[_P"G!M]SZ?X.HDG:.W(;"(9NK^O..V[66Y_PMS^?:7^L
M$,'^H?Y^G?W<QXT_;_L=<!VQC "(=M;MK)Q8V_AH'_(O:";G1>KKL<PZYT_8
MN8K"11=;[EK+$<UH_A7UO[<AYINY^-K-TR=F'_*5%T\+N3L:7_,]>8.F'U_R
MW<"M_O0_Q]K%W&^_Y1_YG_*>D$VW6P_&3]BC_-T%6_<MVL]!5&/:.U$YYMN+
MG_;7']?;*7&]2?Z!;]4>WL[;S;]G537=E5V2TM5JPNTZ0#_CKD!^/]C;\>S)
M;Z]?^VA3]G16RV\_PDGJY#I[M'96-ZIZKHLON*AI,M2=<[0H*W4#?[K^%4XN
M/K_9]EZ<][=P\?\ YP_+ID;%)J) \SQ^WH3G[HZ[BY7=M"OT_LUO_%??G]P=
MK_W_ --2[!='@/\ !U(C[HZP_P">GDY_IBZIO]O[U#[G[/\ Q_X>G/ZL;C_R
MC_S'4F/N'J^7_,[EI>?]5B0?I_OOZ^W)O<[:_P"/I/\ U=NS_P 1C^W_ &!U
M/A[AZRN+[OHOS<Z3_O'!]N0^X^U7&(9H^FVV"\]#_/J%D^[NL<+BLMF<CNO
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M\Q7EL?C-/2B_] ] %O'K4;,S6(H8,MC\BFX*UJ.AJ:Z*3;J4@Q=O\[6$SR$
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MM0I][&Q[C_RD_P#&.M?O+;_*T'YW1_S]=#:V\1_G^R\C_KG;*#_XX'^'M_\
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MXKM6IQ]*<>:P9VJR$V,I>?\ E%M%*_/^'T_P]A_==XO3=?2PWY^E_C\,:?\
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M[N.7D_W\?VR?]!=)?WL3_P 1S_QG_-U!R&$WFM.)J'>QB!%M55ZA_P!9&?\
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M\<,E,!_O%/[V$WK^)O\ C/\ T#TS6U R/\/^?K,E!ON"<0S[QQE-^=)Q5/\
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M&8G_ 'D'V_\ U,VC^!/VR?\ 0?3'[VNA^)OV#_-UG;IOJZ8<;$Q=P;\S3?\
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M_9ZM]6_I+^UO^@NN_P"$8S_G48;_ ,]U#[;_ '-MG]'_ +)NO?4MZ2_[T_\
MGZ[_ (/C?^=/A_\ SVT/M_\ <FV?T?\ LF/6OJ7])?\ >G_S]=_P+$_\Z;#?
M^<-'[I_5[:_^4=/^-?Y^M?O!O^&_[TW_ $%UYL)BH_TX?#CZWTXZB]U_<6V0
M?Z O_.+J_P!6S?[]_P!Z;_/UU_!</_SJ]N_^>_'_ /%/;W[FVS^C_P!DW3'U
M1])?]Z?_ #]=_P (Q/\ SIL5_P">VC]M?U?VSU@_YQCJWUC>DG[6_P _63^#
M8K_G3X;_ ,]U#[5_U:VOT@_U?GU;ZMO27_>F_P"@NI/\"Q7_ #J,/_Y[Z/W[
M^KFU>B?]DQZ8^K?TE_WIO\_7'^#8[_G4XG_SUT7O7]7;/U7_ +(A_FZ]]2_I
M+_O;?]!==_PC&?\ .IPW_GOH_P#HWVW_ %:LO]\C_LA7_-U?ZE_^&_[VW_07
M79Q6+X Q.+Y_!H:,?3_8^VIN7;'_ 'RO_9"/^@>M_O";_AW^]O\ ]!=8OX10
M?\ZG%?\ G%0_\5]IOZMV'^^%_P"R$?\ 0/6OKY_6;_>V_P"@NHG\'QG_ #I\
M3_Y[:/VI_JSMG_"/V?[/3WU;^DO[6_Z"Z]_!\9]?X1B/K;_BVT0]M?N+:[?R
M3_G$?\_7OJG])?\ >F_Z"ZY?P6C_ .=/A?\ SV4'_%/;?[HVSU3_ +(1_FZU
M]:?27_>G_P"@NN?\(H/^=/B/_/70_P#%/;_[FVWU7_LGZ]]7_1E_WIO^@NN'
M\%Q/_.KVW_YPX_\ XI[U^Y]M_H?]DO6_J6_AF_WJ3_H+J1_!\;_SI\/_ .>V
MA]V_=&V?T?\ LG/37U;>DO\ O3?Y^N?V6%_YTVW_ /S@IC_UP]M3<O;;/Q1?
M^R$=;%VW^_I/][?_ *"Z(S/G]L;+^=%76YFV,Q=3\:EH&6AQX8?N9)2?\Q;Z
M@$7!_IR/Q!^T[E8\M\WX) $'E;#S4^M>A;]+<[KR]2M3XWF?GT;=.^^LH2/+
ME\XW^OMNJ'_$<?CWD9+[F[/;_P!M7_5^?0,/*.YGAI_E_FZP_P"S =91?\O?
M/C_R7*H_[W[9_P!=/9_4_P NKGDK<CY#]O\ L=8JGY)]<QC]BFSE3^!_N./X
M_P!=F]E<WNMM7J?Y=67D^\'&G31-\G-I'F':V=J2!;B2_P#O:D'VFF]UMJ(P
M?\'5EY.NQYC]G397?(?;V7'A?9E9,*K_ )0*O[-_K_P8'_>O9/?>YFUW_P#Q
M&)_WG_(.C"UY-N(_^) _+5_GZ#&'$U.6S#;YVM5[!V9%358-!M[*YZ@=ZFI'
M^?(\D,D5&Q_IH_U@/9)9V5CO-U^\8I5B*?Z 2P;]FH#]HITY=?XF/"8.:CX@
MK4 ^T?Y,]#!%V/O['T_^48+"YFF!'.&[%QDGU_Y9QJ?]Y]BU.:9; UOY;:2#
MTC%NH_XQ&AZ*Y-MLYO@CG5O4K*?\,G3\G>,BQ#[_ *QW-#.!9A2?:Y*_^/I*
M?7_6]WF]T; BD!(_9_E'28<KW!\Q_/I58[MO'9#:^X=R?W3W93C 5^-I#0ST
M3?>5 R3(-4 U:M,>K4YU_I6WT/L>VO/4)V.:_J<.GI6I=?ET2-LK"Z6.HJ0<
MTP*?+HPON:.@OT"V]=KY?<=>)Z#?^X,!C?X<6-!@EI4^AYO,2#_L>>.+\>P!
MS#LO[QF_M]'1Q878B'P FOG7I''J3$SB^;W'OS+-:X%?O6K/'^M:]O897DJR
MD_MY[G_C?^7HS.\M9X54'Y _YNIL'3G6I-SMX5K?UK,C6Y3Z?ZP/M3_4^SX?
MXS_SE_V.J?OV3U ^P ?X2>G"/J/8<7_, X$_X>8#_B?=OZHV'K_J_9U0[Q<G
M\1ZD?Z-]@_\ /*;6_P#/;2>W?ZN[?_OO_JGU;]\77_*5_A_S=<9>K]A2#_CP
M\%?^IQS?\:]Z_JWM]QU0;M=#\1_:.H(Z@Z\F \.TZ&F_VJAR5<?]Z51[\>4+
M/TZNF\2+^*OY#_)TWR]3;+M^S0[BI#]"<?N.K/\ M[CZ^V_ZFV5OPGE^W_4.
MMC?)&_A_WG_9ZD#JC;\!O#N3L>D)O;3O6J7_ 'OVE_J7#<_V&K_5^72S][OY
M^ ?R_P!GK(>MJ6(VA[)['I../]_&#]?]=A[M!RA3_B1=]4;=M7&.W/\ J^8Z
MA_Z-LE%?Q]G=C'GC_<K1GZ?[;WZ'EV\']A<GKQW)6XQI_J_+J+/U#B,I3>'/
M;PWUGJ>__%OK:_F_/XM8^TNY<A?OC]&>XN='Y?Y^K)OS1?"B#YY_S#ITH>G^
MMJ*F,*[2H*QA_P KP.3'!_X,1_OK^S6TY%VR"'P8Z],G>97-86'Y8_PUZ4M/
MUILJE -)LS!TH_QQM&?I_A?W>+EBRM_[;IG]X/YD_P ^L[UVU]NT_@FK-O8D
MGAB,K18?_>;?T]J_ LK#_??_ %3Z:[Y.%?V'I.5W;.P8++/O&AJQ^!CHOXF+
M_P#3G3S_ +#_  ]E<O-^VV_Z/_6/K0LY#D#]IIU%_P!+NU9K_9T.[<O]?^+?
MMNJ6_P#O)]MGG2P_T'HS7:;GSH/S'7/_ $I4Z"T6TNSJH?7U;<!Y/^N![]-S
M]"Q_6S^S_)TF_<)7BRC\SU@/:<! $^T>T*/_ %MM* /]Y_XCVG'.'_".G#M)
M/!D/79[9Q$8O+BM_4O\ B-C51M_MV_UO;G];+4?VUO<].G8KD\&0_:1_FZY?
MZ7=H_P#*CNO_ - [,?\ 7SWK^MMK_P HX_EU;^K=W_$/]Z'_ $#TF<UOKI[+
M4_\ N;PGW1_U5;LFK3_H6G'LGW+?["X/^X\7_9-THCV:[7@3^3=!ID]R=+XP
MBHV[5[_V_5"__%B-5BAS_0S7/'/L)2[YMVV?V/U/1DNQ;E=_%H/VYZ]B.P]T
MS5]+#M_?="V%/-=6]EFBOQ]0#%^]S_KC_'VEVKF7<+J?]'_JMTQ=;(UL,@U_
MH5_V.A!B[AS.%/\ EIV)N&FM_P #,%OC4+_\L*TDW_XGV-+CF2\V3]:;OZ0P
M[.E[PU#Y$#_)USH_D=LRKJ/'487.4U2+W88P93_K2?=[?W3LY_[:"3K4_+;C
M@0?Y?Y^E*G;^#F%\;MG?N6'Y^QV]6 6-K?D^UW]<EO/] _8>DG[@GM?B91]O
M3%7[X[2K@8-K]9Y"B! M6[OK]7T_I<#VAO\ FS<S_N':_P#.:LW2JUVJ%?BN
MA_M0!TDFV_W1F[S[HHLC5T]@304.]1M>EX^G$)''L+BSWG>?]S/^J/Z71J9=
MLA^#^8U'IYQ.V-T[>'WN-ZJVJ]1;_@>=QZJK_P!Q_K_L/9S!LLVW_P!C:?\
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M''=^5@/W6Z]EXRG_ .F#;]7?_>;6_P!O[.+.TWBY_P"4=/\ FV/\@Z3$VD?
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MO@_ZORZHVY.WXC^T]=_W=VQ_SS. _P#/=0_\5][_ '%9_P"H?[/5/KV_B/\
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M/F1IYMQNO2H_;UF[^[7EZDVE1Y+$XN@SF[]S9K'[6V7B/J:C)5XY:_U,,/\
MO?NON'S1-MEC^C]OY=:V+;!NUQ1B0 *D_+/^H]!3%T+W#EJ#^.[C^2N],7O.
MKH#7U_\ !J&FQV#IJC_C@:4']Z'^ME_XK["-IR5N>YP^,-PN$E]#QZ5'=[:T
M.D6BE0<9J:?LZ7'4/9.\Z/96ZZGO+$T&TLMUWFTP]7NFNQHQN.R5.WTRU'P
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MI$5'<>U2O@PQW!NBH -SM+&+D?\ K.3X?]X]DLW/ULO]C6Y_GT8#E^XGRU%
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MH,S;A<W7$G[,?YNE[%^_2W_QXL/Z?\C]J8HK(?Z!W]4J3Y]< 8_R"/\ 8>S
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M!_M]!_WKV6R\X[5Y7:?L/5EV.[_Y1?Y]0#V]AJM?]PVV=^;@_/\ D6WZQO\
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M?K_K$^VY.=;8_P"C]++?9+@>0_;U@D[+VB>31;N'XXV_6?\ %/:;^MMM_O\
M_P '2K]S7/D!_O1ZQR=D[.4VE6MHS^?O\96?\5O[:_K;:'_1S_+I1^Y+\< /
MY=>;L'94MB-QFE/]/H?]ZM[40<QVT_\ H_6SL]P,Z:]<CO':,UQ!N3' _C_<
ME;_B?^)]K(=UL?GUL[?<^G\NLD68Q,@_9S..JP. #D_Z_P#%/:V*Y2X_T?\
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M;YR^1VQBQO!VHJG.5-:,=7[%K"LK4@D-@DFEOI];^TVW12&Z6+5IJ:'TR/\
M8Z2^XEGMEQLIWJ"W!(\_E7_,?V](S<O8'??SN[[SW3'6>^<MMCJC$U6==6DK
M*F@I1BMN3FG&4R24 -35U=2X_P FATDWX''M_;8;[<7$23\3BI-/\O\ EXT'
M2V+:=DY$VS]Z;I;B6;&!2IQ6@K3J-VQUE\DOY=FX]M[SVQVMD]X;4W+5G$U2
MRUE1]O\ <+<&@R./JY:BYJ0?V9B""#<'WK<;6_VF-98Y])(-"OIY^F//I3RS
MN6S>ZGU$)MPE,T(&#ZCH[7R<^9>Y=H_%[K/M3KVO-'G>\J*FH-LBHH@/X2(*
M<3Y&13;F6F:W@/X%S]>?;UXM[:VZ35P2:_[7_9(ZCCD[DZWWC=+B"8?V'S_B
MX?X,U\_7HHNS?@9\ANX.J%[RS7=^XD[ W)ACO? ;3?,9%WJJ:OO4T[2UQG(C
MJZJQ(O3<_P!?K:G[LOMQ@,GBCY5RQ^?0NW3GG9MHOA8PP'P?]$H!0>G^H?\
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M/\/0CWJ.SY6Y1@\:"EU-_J^5>BN]R]&[OV7\NL9TM7;\J\QNG.9[9JTN^_\
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MSD_;TQHKZ?RZGQ_?RCFL'U_LK;_??[?VSXT7EXG3.G3Z=9]<O_*SC_\ >?\
MBOO7C0_T^M=9H9JGCA1;_:?^-7]N:_\ FITT8:>G4CR^;_E")M^" /I_L?\
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MG/YC_..IT?868I!_N:Z\W]2<CU4.-.4_WF(>[0\XS6_^YEI)TG;:5;X;M?\
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MJ%;UFZ_V>0/];VR)Q_RC]*@/GUR_UR.?]A[<N)I[G_B/^P=.@ >?7O\ */\
M:?\ D[VU^C\_Y=;Z].S7MZ>!]3S:_P#Q/MT7)@ST@^F_U?ZAUR LOY_4WU_V
M'N]K/]2.G+KJ"0O-1/D+"QX( '/]1_L??GO7MSCCU: 7!\NFVIW7MR@(,^YL
M#2BUS_N1HQ_O!4'Z^R*?FVPMO[:>V_ETK6PN9> 8_;J_R]-3=A=>1V,V\=I_
M^?"D7_>Q[1_ULV?_ )2S^SI3^X]R_P"45OVG_/TV5'9O7)-AOW:A_P""U]O]
MZ]T'-NS)QNH_V=/+M6YV_P#Q%/6"7L[J^(6&_,+?F]Z__D?MF;G:P_W_ &W_
M #DZO]#=\=)_R]!GOW>FR-QX=:'$;BK:K<5)7XVOP*[?QE;DJH56+%H3_KDW
M/_&_8.YDYLMMQ/\ B_ZTW_">E-K87,/]N %S6N!GJ92[Q[.CIZ09WK&NJJDT
M-JUZ+<5(W^PL#:_NT._[H(O&G@Z-Y+*U-0C@9\Q7KN;=/9TH_P DZLHJ0?TK
MMZD?7_8W]HGW+<KD_P"XD7[.O06VW*/]RR?R'^;ID?)]UM.?'M+KBDO^*S<-
M6YY_UB?:2==\/^AV_P#@'\ST:Q?NU>-R_P"0!_P#J#4R]VR@$0]94Q/U&O*_
M]%/?V5.V_P#\%J/]7R'2R%MH'^C7!_,?Y^FQLAW33B\FW.N*BU_30U]7[2&/
M?!^"#_5^?2P-MS?\26_D.H,F]NRJ( Y+J\5(^H_NMN"DR7^OQ,"?:8[Y?6W]
MM:_ZOY]6%K;.*K=4^T$?Y.N%/W'LZ:?[3/KD-G5YM_D&Z,=58S_K-_F?=H>:
M8O\ 1?\ /_@Z>.UM2HS]E.A"I<IAJG]W&9?!9<G_ )4LG27_ -N?]?V?K=6]
MQ#X\+TZ*IEG!H;8_SZCUV[ML8_\ XN.X<%BQ<\#(4C<'_7'M!>\P6]K\?2BW
MV^XNO[ 'H/JGN?8XG\&*RN;W=4G\;7V_5U]K_P"W!_VW^\^T[\PI/_N/!7_5
M\STO@V:Y _6I'\B0/\ /6$[R["RAO@.M6I8/H:W>V?\ X;?_ %Z*'VT-SW #
M]*#_ "_YNK&U6O<Y_P!J!_L]9OX-V]67%9N[:F"LI_R#";>_BG^Q_>!]MG]Z
M7)^/1_+IL2VB?\1R?F3UX;(WE-8U?;F^"!?BAH,3B_\ HOV]_5:6?];]X/\
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M/^E/0T?S0=U8O>O5716Z=M[QHM[;5SVYLG6XG-X[&_PLSDXI 9&4_FZG\7L
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M-W4N+WSUSL7&;<K>OV2\U14;>IS2PFF8#3(:KQB]_H +7]KHMZ@LH*'5J4T
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M>'^A !_/M9O4=G&(&B%!0<1YU_S5Z"WLGNDVVWL]C??VTW#[/VGAT'^+ZO\
MY;AZ,Q?:.:WYV#_?.GQ%"F=ZPHNQXQECF? ?N:(4!C_S=K<ZR?K^>/=H;;;C
M I+'5^5*>OP\/0]5N[CFZWWRX@AMQX>37Z<\/+'1\?Y=VV^@!L_>^[>DMK]J
M8'"[ASN-QF7':E;'D5GGVP2Z_8>-4]47DO\ U\]@.+^S""TL9(J*N3]A_P
M^?49>X=[NGC?[L[@/HX8(/YU)].K)Y,'A#?_ ""XX^F*][_=]OT"_K;CK%+M
MC 2?\NC'_P"Q(_X@#W3Z%3_H'^K]O3WUUQZ_X/\ -UW_ '0V_P#\Z:A_VW_2
M/NG[CMO]\=>_>L_K_@Z:I]IK0S-5X&L_@500 P;FE-_Z@\7]^DVR:OZ/A];-
MZ&%&S\NNT_OO".!@\L?H /\ <:?Q_KCWH17Q_P"4;^0_S=6_Q8?Q?S)_R]<_
MN]Y_\Z'"?^?"H_XI[:T7WI;_ ,_\_5? @_C;^7^;J;&-[2_\HN"I[?2_W?\
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M%8;"X3#X7;NUL6F$VOMZCBPN%PU)$8EIJ?'FP -N23_M_P#8^\WK6%;50JX
MQ2E!U'MQ<&N>G#]KR^/_ #\W^/LP!!/2+KWPLZ'R'S^_F>=+=:XV&LROQ[^!
MFYL;\CODANJG!^SFW71F0[5VAY#Z9Y144RR31?J,/WC+]0?>-_O'SDMM#]%
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M!_3QF_\ L%O_ +W[(MPAT_ZOMZ769J.H?D_P_P!Y]EWU)Z4^.?3J+J_VE?\
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M_P" ?8-=4TY_.;H*3)?\2?8NL_<+<X.,VO\ U?/HE;8+4^5/VCI5Q=L=G8X
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M#IWBV=OK<W^4;YW;_"L/47MM78P&,O<?2;)?YT?B_P#Q7VHBV&\W?%_/X/\
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M$_\ &Q[M^Y;8]._7W/\ J/39)U[MD_\  -:^C_Z@,E5D?\3[T=BA'3AO"?\
M4.L<FSI8["CW=FZ3_@V1_B7_ %NX]M_N4C^QZ4C< >(ZQM@=QV].[ZP:3:W\
M/I!_7_#@_P#&O;#[7<0?Z/\ ]4^GH+J$^0_:>FW(86O$(^\WSD*4-<^@4F,-
MO\0/\?=9[.::'^W_ )]*8I!*?A_94]!/'0X*7,TF-R>8H,KC_P UU</^!57_
M -1W^O[!.WV]I;W'^-]"-KAOIZKQZ&6GPV AIAX<1C[F]A_K?ZXO;_8^Y%AA
ML?\ 0>B/Q[CS/7?VV-A_S-$O^P;VM#L?]]_ZOSZ<,TY'^K_-UG\<'_*H?^25
M]W\*'TZUJ/\ %UFCCIOJI!XL=1M[;\+Z?_8Z;Z[\#_U7_;G_ (I[WU?6.O>!
M_P"J_P"W/_%/?NO:QUPT'_#VYXHZOT@=^;1P'86UMQ;+W53BNP&Z*6/;V5I*
M"O\ X;I@K?I:6'@D$_7F_P#6WMM9"O;<5_U'_8ZI9S?NXB>WX^517@*>OSZ"
MCISH+I7XYT.<QW55"NWZ7=59CZK,MG-SSY@ 8VYX6OED!')YY^O)X]IXK^QM
MSV$D_/&.C3>-\ON8P#><!6E,Y./MZ?.W=E=1=W;-J.O.SH:'+;7EK:"N1A7U
M./'W6.73:*KI TD?'X^EC];^[7U_:R@,ISZ^?3.UW6X<JS_6V6/ET@>C>F^@
M^@6W"G5U)F:.DW.OBGI1N3)[@IZB?'7O:&H0<\_U)_Q ^J.XW"QB.F593C]O
MG\NEV_[KN'-8$\\XJ#6N 0#^9]>@JWG\)OB'O[<U5N3)]79_%5N145M0NT:S
M)8*FJ*G)?2U)!,T:J3_1K#Z>R^ZN]IG:M+FGHL8-/D*UZ%&S>X&^6$/@Q3K_
M ,W\\/GCHP/4'7'4O1>'_N[U#UYDMMXBJ1:NND:@!J:BI'^[:NJJ[554%_HJ
MC@G^OM;:;LE>Y"?MZ#&\O>[U_N;<C&,<!^S%>@_Q?QFZ4PW;]1WEBM@[J/95
M=7Y"N3+-G)S3?=9%C%5C[<5XIN";VU>[_O!]7B?3&M:T^?2S^M5Z;+]U&Y'@
M</\ 5P_P=&"S;R;JPM5M[,[';(X+-T24V9ILRU&M-44^2OICEA '(_'N[[JY
M73]+_DZ#]I:06\WC_54(X?(TZ)I2_P O[XQ8G/4^X:#H_P"YJX:O[JAPNX.P
M)LA0>?\ I]@JAR!_0M_O'M#MMO);\+5CZ]W']F>ATW/NY7X/C;@!\_!R/S..
ME]@OBCUGL_MF/NK:76=;@M]UWWU=43T6_:Z2C5MP@B;_ '%:#0F$ GTZ[?U]
MK(KJ6.Y!6V6@-::QT03<T2[A9&">ZD.*?[C&M1\Z\>H?<_Q/ZC[TSU+N[L'J
M@S;K>E;'-E]J;VJ-KBII\=:WW0IT;[EAP..;$?T]I;I;J]FJ]L@-/+ACS^W[
M*=+MEYJN^75\&RNJQU\QD5\O*G'SKU[<GQ2Z@W3UUL7JW<'3><J=B]<B:NVM
M38GL6=JF#S6+WDCE^YK+D7X''XM]/=+J62X'T_TU!Z_;TQ!S)=V$_P!9!<CQ
MOLH,?LITL]W]3=7;ZZFP?2FYNNMV+USMREVQBJ'!BMJ3SM;7]C>KB!JO4&:_
M%O\ #V[/O$MVHCE6BC([/]7KT6V5]-LTQO8+@&<_9P_U =+;J+:G5'2NR(.O
M-@XZLV_M2AK*RMIZ;-K4UA^XW#4B2J'ER!%@  !_KW^M_:FVW2,KX<E?\/\
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MS9]4NG:0]^2/6E<_ET[SBH%_!I-R3_K?[S[6PVUG<3?K5Z>:7&*==1\CD <
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MB^]]>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>]P]>ZK_W1C,KDOG"(,-E_P"
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M:?\ 'U_G_EZ+9+-_WJG"M#CRX'_5]G1K_<X] ;H%=U]C;1VUE#C<MF5QM2:
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M.AIM_+-Q=?'3_#T&.7['[1RES"VU=K0$@7H6_B=5_P 3].?Q[C;=O<>]O_\
M<:L/Y4Z%^W<K6J?V]6Z0U37[UK!_EW8FZ23:XH128T<_\L2/80N>:]WD_P!R
M+G\\]"BWVC;[;^PM1TFZO"15!M69C=.3O>W\0W#5'_BAY_U_88O=SO[S_B4/
MR'1E!]/;<+<=03M;;K6(Q5!4\6M7?>9+_>O94V[7P_U =+((:]9X\1C*;_,X
MFB_UACC[I7ZC_57I3U)J:BAI?^!O\.I1;\<^V RV_J>GC!/\NF?^\VU*4@_Q
M?!7_ *%/;?CCT;KWTUQ\O]7Y=8O[Z;>_YVE#_P DC_H[WKQAZ'ISZ*?_ % =
M/%!E,3E/^+;6454>/^ /^/MPU\^F_"IZ]3))/]A;_??[?W[IGIJKL#@\D!-5
MXBA6H_Y7K_PO_>#[=CCN(_,_9Q_R=-RMX_2BQ&YNPMJ?LX?+?QW#G_EQ;J_X
M$_XC[S_C?L<;=S_>[=QQ\QPZ([_EJVO,TH>E]0=^X^EL-U[2S>!'(-=0?[DZ
M;C_EB!_MO<C[7[G6]Q_;D'\^@K<<H3_\1STK(.[.KI8?+_?6EA(_-:*MA_MB
MP]B>#GVPB_L13]O^0=%QY2O[<\"?V?Y3T&^Y^XLEF+8KKLUP@J;D[VS= /MN
M?^5*#_=H//L$<P^XRSXA^RGF>CS;N3)E_6N*5]!T@:#&4..?RG_*LA5_\#\Y
M7?[DZFIOSP/<,37O[TN*#]G0[I]-#UFSN4GQ<0FAI!S<<^SX+J\^FX,'I$RY
M7*2\?=V_J:#VR9/]1Z-(;?I/9?S24/[QK?\ 6&0]E%_)C_8Z6+:=)(MC8N/N
M_K;DBWT_V'L+DN>CF**'I6[,CR\N4I9HOO/X1S][]]_O/MZSU?YNBF^\#H6O
M9YT'.O>7_:O]X_XU[KH'7NLNL?X^Z:#U[J)44=%4_P# NDHJG_'Z?3W4,1TH
MZ9IMF;68>:#$FF4'_@?0Y'^&?[W[JKW&V?V)_*E>K3'ZGI[IIMQXZQPV]]U4
MT(L!15F1_B5, W^(]B2WY\W6TXC]E1T4W&SVMSY"OV9Z4--V#VK0'PPY;:N3
M_P"HW;O\,_ZTCV>P^Y]Z?7^1Z+#R5:GU_:>N='WQNN2#+#.TO7=+-C*[[(T-
M;GZK&FI_Y8\S>Q?M?NI+#"*6Y/Y?[(Z+;GE 0^9_*AI^WIPH/D?6U7_-/LW4
MV/-909$BF]F9]Y/IO^(0Z2'DT'\7\NGK_3YE?TTG7F<OQ?[[)4GY_P!A_P 3
M[13>[L-Q_8VS_E7_ &.E(Y)QFY_ETP2]V=FU-1>BV508"$@_Y=I_B=5S]?\
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M'^W^OLENO=R[N/[&T_ETO@Y*4<;H^O4.JW#V=E0!DMWT.)I--OX=M+'7^O\
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M7]]/-Q_ETR-KM@./6/[;>A'-7@Z07_-!6>W=%R?]0Z1^#;'U_;URG7?<(O\
M[]2K_P!8?PSZ_P! /ZW]HYX;B"3S'2B&TMO&_P!1ZC1[DSE ;9_:%=]O^:_
MC^*'_;\CVKAWN6#^UZ<.W*<#INR-!B=UU/\ $\-F*$9 _2AKN/\ 'Z^RS<4?
M<9O&,_2A8H;,4ITSR;:W7%Q]KB:OZ?\  #) \>TT"[B?[&G[.GS<)_PW_5^?
M66/;FYIC?[3!4G^OD@/][/N\$%]/QKU4W%MU+CV/E)1>MR^/I*<6'^18[_??
M[Z_MZ7;)O]&GZ9^J!X#IPH9Z>+_</LVD^Z^U_P"+A75_-+]/]M6^[6%S]/\
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M?[&WTY]HV&CS'2V&W^HZSG*[DJO^ >U*X7'UKLB?][M_Q/NTLPG\_P!G3AA
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MU83+9!Q1-:UM0/\ O'T_U_K[;%O%'_Q703^H^F_XOK)&:?S^ "QM>U_]3?\
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MR)_P$=/D796WI91#5_?8NHMR:W&\?Z_U!^GLVCYSL6Q-T73[-<6XQTN,9N7
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M^GK>5K?_ %5Z;OX1N.@XQF8_BOU_W'YVP^G/^>^GM)]/-;_V/2CQU;B/V?\
M%])O^_>>BKJS##;OW.1I> :'(W_WKV40\PS?V5>E)@'&O3__  W/9^_]X+8G
M#<??X+'C_@5_RWFX_K[6Z)I^'2?PU3A^WI4QTU-2PF&AO24U*?\ (/8BAMX;
M?I*9Z\>F3=F+K\KB1186K^VJ!;[_ )M]T3_OC[+-SL[R<_H]/VS!>/06G#55
M!P=O5U+R>*+V$(K1H/[:OY]'>J%N%.NQ#EI0!_!Z\_\ D.]J-?\ OF#KPE]3
MTY1X;<4I'AQ'_G=D?Z^_0V'[P_1\#^76C?!?/I6X#:E1BISD\G5FJR!_XM_V
M%N2/9OLVP?N^;'19=76L4Z5?L0=%?7O:CKW7+]G_ &GVGZ]UFE6VK\?3_??U
M]NZX;?I-X)Z1>=R-=2UU'0_=G 8:J/&=&,_ISX?81W"[_>(_7'Y='Z+IX9ZD
MT.U]IM_EGVARE4/K75N3&4_5_K>UMALMG'^K\?22X#6^.'3DF!P,-1:'#T-(
M..#C?Q_R/V=PV\,'^@=-FY)\S_J_/IUCO";6_P ?I_O7_(_;WT</]MTQ7KCK
M;^O^\>]^,>O=-^5S=!A8/-6#_@8+T%!CS;B_/Y/M-NFXPV_2NUL">D;-O;*V
M/V.(H*3C_E-R)/\ Q/L*MN\UQ_8=&L&T <>F[^\N[)/^4RAI?_(</>_WI>=.
M?NH#_4>N$>X]UQ<KEZ 6'U&._P"-?U]MB>\N/[:<]4_=RC@/]7[.E%M?<&6R
MU?5XS)?858I* U_W]%P;#_6O[-MLW:\W/]&;I'=6"VHJ*]+2IB@FI_!-1_>T
MX/UK_P#'V:2V_P!9TA\;Z7I-3;7@I1YL!55^ G_/V)O2<_\ -F]S[3C9O ZM
M^^*\1UR_W^E&!_Q8<J3_ (_PFUO;'C2V?KT]1;OUZ\-T?;6_C.(KL4/P+_Q2
MEX_P-O?HN8'/]MU[Z2 \#TX4>1Q&;I_##64%3:]J"UO^)]JYKS;;[CTG&WNG
M395;*P,QM!1U^*J.3_D.3OQ_MO:8;)#/_P 5TK_>+#J#_<3$_BJSI'/TR8_X
MI[8_JM]/UO\ ?/V=38]E;:A_S]'D*K\_Y=D@/;O]7SU3]\4Z?*6AH,?:&AH\
M?2<\F@_J?]Y]F5OM\-GQZ:GOS==3(_J?];VI>;Z;I-%W=<9):>+]Z:]-^?K_
M ,:]HOK3Z].F#IAJ=S8&$>"CK#E<C;_@!0_[D_K?VQ=[I#!#^MU=;0DXZB')
M;EJO^ .W/M/I_P 7[)?\5L/:2/=9KG_</IZ*V"_$?V==&GW;/^_][@L3?C_(
M,;;C_6M_C[=>'<KS^VZ?A*6N!TWU&"KICJR6X\]5\G_@$/X9]?\ 7]L'EV:;
MA/TJ\4#RZ;IMG[;\'AFQ/X_3>U5_U.^GLKN.7XO7I1#N)!Z8I=H4'^9AR^<I
M#_VL?9+<;0;?-!T;P76KICJ=JV_X#[BW7P.;Y"UB?]C_ (?U]D5]9_(=&T%_
MTPR[?RD=O!NS.C_&MQU)_P 5]D[14\A^TGHPAGKTU2X_>,9M#N&AJS8?\#L=
M?V7W$">E.C6"XK_J_P _35+4;OH/\_BJ+)'_ *8<@,9_O7LLF96X'^5?7I9X
M76"3<BQ'_<CM_.XO_7/\2^G^N!^?:4$G@0?]7V]>\'J91[CP=>?#%EZ&UQ:A
MK?I_O -_;I!'EUHPGIT&C_=7V'^PM?\ /_&_>YM/SZ8_5_U4ZR?O?[3[UX2_
M/^?6_P!;ILJ\Y@L9Q69:CIO];(^V@6/ET_X/V]-*;H@DJ/\ <=B,WE!]3]EC
MOI_L9K^W89<9('Y]7^GITM<+OSLF!O%C?L<!3WX:MR%O]YBY]B[E7GB]VMO!
MS^71%N_+5M=PU/\ DZUW_P"<)79.J_GE?R&ZC+9(UF1_B^ -36_XKOV;G_D'
MD>\[_;^_EW'8]4W&A'^#K%'?;,17I5< L:?[SUM74N4K\KOVLQE165QIZO(9
M,V_B7!(^MK_T_P ?>.]CS%-?;Q]/<]2W/MPVW;A/ !BGEUJ-]-_S<OYK'SPW
M'\COCQ\*_BQ\;,AW?TAV[OBDW'W3NREBP^VL/L_;=<^'Q-"9,WDS#)NC.Y"&
MJTL6=2NB0!23IR.3D';+1XII/., #&3^R@ _;U$\7,U[>2X)X^K?;Y9KQ^0X
MTZL&[6_F0?-WXY_)+^4!\5.V.MNC=D]@_.C#32?*+&X&DKLHV KX<NM :;;\
M\65FBAOCO")B'D'W/D#6L?;B<L6DUE<K9?BJ!\R/MZ:N=WF6:)Y_P?Y@?\N.
M..E/_,L_F%=M_&?Y)=1? CX+]3X;Y._/#O2"CSM)C=T0238?9V#G9G@R62E$
MD4=FBCJ:]GJ&^RH:(BU^$8-;/[3VH;Q[K]G1_><^W#KX4&!]M/MX?/TS7^9
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MGZ6#;3Z=1_[\X_\ YU6<_P#/</>X>883_8GIH[:?,_SZ[_OS@A;S"OI3^/\
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M3UB_W^DW_.BI;G_IKRG_ !7Z^]UW*?\ XC]>&CU/7A0;LDL!N.@N+G_(,?\
M\:_U_=R+W_1NG/&0<!_/_9ZR#!9R8_Y=N^N^GUH,83_O?N_[NF_W]T[J'I_/
MKC_<[$37^\^^ROW7T^^R=OI[I-L%IN']M/TS]45X4Z[.Q]LQVAHZ48D@6_R+
M)59_WOVT=AAM_P"RSUOZHGCUE_@N=A/^XO<5:#_TW8[^)^W8K*;_ $$=:-PO
MGUAU[MI/\_24.5IOZ8_)_P *O_6]N?\ >/>IOK(>MC0>'\^NO[T4\?&4I<]B
MOZBNQ]_;D7,/T_\ ;6_7B*\"/]7Y]2:F7;6ZZ?[.:MQ]4>?KDO\ *_\ >?Z^
M_2P0W_7@6CZ9_P"X,SG_ "+*U](/K8>RS]PI)_8S]/\ UDUOQ'6&78(^G]XZ
MR_T-\8?]]?V\.6;GTZ]^\X/]1_V>LM-L/%$D5M77U7TXL/=9N2X9_P"VN.DO
M[U/D.E518Z@QW[.,HS2 V^OL]MMMALX?!ZU<,;HU/4O0?\/:GZ:7I-X9]?\
M5^SK+[9Z>ZP6']1_O/\ Q3VKUP_ZO^*Z3]9?7_M/^\^V?J8?]\=;U-Z_X?\
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M /\ AZ$O;%'"_P#*P:>*0$CKS<0$%OJ!F)?5_L#?VTT/97^D.B22<GFNE/\
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M_%^8)_MDZ&;X*]C;(R/QKVCUW3;HP-3O3&;=W<U1M=JVT\'V53PLD?YU&6_
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M)_Q;_BGM)+-:0?VT_285/ ?ZORZ>H<_@H3ZJJ@/^&F__ !/NW[WLQU7Z=O\
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M\W63%9W%Y.;_ "2LM/P31UYM4\#_ 'CV7-54STJ$/Z^>G&26",_O_P"24W'
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MO^*>UD.VV=OTF-V3Y]3J;#X^(_L4M >;_P#%M]O^!9M_8]6,Q/'K(];!C_\
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M?CG^=/+/08]0_%'I?IW?V:W7LM]U4&>SU%7T=5'N#><U;3?;UR_=5=S&H+6
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M4_R])*H_E_?&,;)I]EC9^XJ&G&3_ (ZN7QVXYCG:B>_AO-6E= AL1^QQ]/\
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M,K8=M[9-?)!3;CKA75+??U2U7$B\+_L/]YY/M1/=F!B!Q/\ J_P=-[K<B_\
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ME_L]$7^;_P R=A93XI?+[:^%PV:R-'F/C?\ ('%8[.$4N/IE:KVKE:*]@-3
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MN3HZ#-?9[9-(M)2TU>+T@EK)ENWW8L3_ *_L2<Q^_6Q["G@P?K#(K3T%3]I
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M9C4ZC2@\OF?D//\ S]%AS,N1QJ5+UE,?]QE8:.LMS!3SG_=7E^E[?X^P.=K
ME\ DU K_ $F'K3\NA[M][X$'Z/\ HW0I=W=#;LZ:@V'79VHI,ABM[;7Q^1HJ
MRC!M3Y TP^[Q_P#B1?\ 9/N4>;_;BYY/@@NI1VW.?6JZJ@G[/,^8Z!_)7.DF
M\%H!6L1H:_X?LZ1>S^KLOOO']F55)546(S/5^V&W17;=RY&/-138X_O1"]O$
M0/\ BGY]A[;=FDW9'D![5J2RY()/EZD4Z/[_ )F_J[,)<O\ 5&@].!.>D'A<
M!E=U97!8?%4W@KMT9FAPV(JJO_<?3SECX1R?]A[+K:T,LY@)#4!)7)*DG'1[
M>;G#M$/C?P="OWGTKG^E.PY]A9*I&;AJ*),SAJZC/%33/<@_\VN+W_WQ]B3G
M3E"7D:]%I<4J"H/^V^7GPZ#?)_-0YNL9[@>?ET.7072%?OGXW?(3<M+N>BQD
MVYJ+'T5#0&N%!3G^X%2,C/\ >?T^Z4>D_P!?<C<F\AMOO+E_N1E/^+9(;C@"
M:F?3RZ G.O,,MGOMJE"? /D":>-CR_GT2!*>H:E^[^V/V[UG\)I*S_E'^X_Z
MB;^X02!F-:\.YAYT]-/#J9+N\AM_TOX\=#;WSTGE^D=R[>V[ELG1;A_CFU,%
MFZ,T36X:G\55'_K>8'P?U%C[$O,O*]QRQ(B2=NM#+J_TS:A7[*G5\OGT$^3.
M8X-UL[B>6N+DC]F.G/K+X\[X[2ZV[-[&V]]B*39M*M%2TE;7:?XE4T5JJO"D
M\7I*3GZB]^/9CRQ[?W?,MG+>H.RW.MB -2@K@"OR[O\ BND_-/.:[#N@L8S_
M +D&@_;0?M..@-Q6-R&?K,%CL7^K=&9H,+1U=7Q3_<9&HM]?]?V$=OV\WEUX
M)H&%30?%I"@#_#T*[W<H195_@_XOH7N\>E-T]-]E_P!R*JH_C462HZ',[:S-
M%_GLA39$^*_B!-IKWXO_ +'GV>\X<H7/)<G@7B!3FH_ !\0(J21Z4Z#/)',X
MWJW^H>?%:$'B",$'I*X?K6JS75F^>TL?DZ*&/8NY<#A\SAZL?Y1]OE.!5?[<
M?3_7_I[9M^7+F[M!>FC( ::3^(C@/D#CI1><T0;?<"QSIG!-?+!''YFO776'
M76;[.[!V+UQCJ@XRIW+7JHK*L?\  >@/^=JHOIYOV1^R/S[IRWR_+S/>-:P@
M L0/Z)?C0U]/Q4X]+>:.8H>6[?Z@UF %>L'8'7>9ZQWUNK8&7%+49#:<P%95
MT8(%13GF*J -B+@CZ^TG,.SR[1.;::H)J .*@UX#Y'I[ESF$7L%O?#@7!^?1
MI/B)M!<7VCB:O*+19.FW5TGD]^4E&?\ E'_W)_9_T^O[)_V_N2/:/:(;K=E@
MF'PJ5KZX!_;BOY] 7W%W\S)<$?[]'5FPV_MJ,<8FB_'_ "[2/^1>\NUV^SC_
M $88-?4/37[6^2>LW\,Q_P#RI8__ ,]H_P"*>W_IK?\ Y0/\/3'[TN?XCUG%
M%0?3[.@'_D,_XW[M^ZTM_P#0.J"YN#Q/^'K')%CX 9Y_X?2V^MO\?]A_A[I]
M98)_H'3@%Q<^?^7J&,WMBFMYLO@J0\_12WT_UK^T_P!9#\^M_3$\!_+_ &.H
MV2R.T]P4XHZRKP53;\C)'\?2][>V+CZ:^AZ>MQ<)U!QT.>Q__'F[Y!I_K]A7
M?[D_I_L+>VX)KRW_ +*?K;6:O\2_X?\ -TH*?>O86*ETUNW*'/TO]H8+(G&?
M3_6_XGV(8>;MR@3O@_;T5WNU1O-2 _M%>A"Q&_$K-@[LR9VOFH)\-D<;3#!M
MS53G(U=,?(!] 8P"?]8'W)5IS4YY?GOO X,G_'U\^@S)83#<T%13/ECX3\^C
M<0?V_P#D'_B?>0,?4:=%"[L-?%N'[B3<B8##''XW[PQ_\">?>-/O'_N;!XU/
M\G4G\D4\,T%34] '%E-I4EYL7MVNS]01Q7Y!OS_K?\;]PY%?Q6_]E^MU(1L6
M/''4Z3>&<\'[.)H*7_J.R%_=9MYO/]!@Z9%HOF:_MZX/O+<O!-'@?]@/=7W/
M<KCIZ6V3K"V[,K]:W$8'+4W]"+?6_P#2WOR[G,/[;Z?KTUJ/*O2CH\+M3-4%
M)DX<2],:J]<?L?\ <9_MO9]:;7;7'ZW10UU$O:?\'4W^[U?2_P#%KW)G:3\'
M[_\ W*<'VY%MLUO_ &/6C(#QZB'*;LQ0'\3P^.RE,3_P/P7_  *M_P L?;,V
MX7FW_P"ST_K1\5Z=\9GL3E;_ &59:I^HH:__ (%?[#CVJMMQAW#^VZ3QQE.G
MJQB-N/I_K_7V:"?P.M@5Z8:W<> Q_P#D_P#&/O*B_P#P QX_B@_V_P#O7LJE
MWDG]'IT6U<T_U?LZ;OXUG,CSC-NU_P!1_E^>/\+^O^O[1?O28?\ %]4^E XG
MKO\ A>Y:O_BY;B^T_P"U#]?^IW_&_;TWUK^76JK;>74B#;6"Q_\ ETU%]V+C
M_+L\/XH.?];V[<VD-O\ VW6H'8\/Y?EU%J=ZX&C AA^]JA<?\ ,;;_D?LM&_
M6]ITL%G<774'^_%_\SB:W[:]K:OX6?\ >/;9YQ3_ %'IO]RP?+_#U'_O[7?\
M\W_ZTC_Q7WK^L,W^^.G?W:/XO]7[.N<>^?'_ ,#<17FGX'^0DY3V]+S;-!P@
MZT-M!\_\(Z6L513UD%'6G_*J:KQWT!_WWT]B.)TW/I!XT]ITTU&V\3+/YH2<
M3D>+5] MQ[*_W0?P=/C</]_]8$3=V/\ V!]AGZ<?\I__ !;*KC_;6]MZ[F#U
MZWX-L>F*KW-N.EG\-9B*# TXM_EU>/XG?_;WM]?:/]XS7(_6Z4: .'4VCPV)
MS1,V3S SX'_5S_R7_J3]?;GT,,_^CGKWAE?(#I81T4%(?!1G'TA/U/XX]F=M
M%;0=)9S/7K/Z_P#:?]Y]F'U'_-+]G236?3_5^WKJ3P_X6M[KXOR_U?LZWJ_U
M9ZX5=33T5.*V>QIJ,\<_TY]ZN+OZ/IRW7ZKI"5.^#)_Q9L37U9_YV%??%_7V
M')N9II^/^?I<-N _U$]-51NK<THM ,%2 7^F,'Y]E@W:\'2T;<I^?^K[.HYW
M!NR6 _[F6_\ /=_QKV[^]+S_ (7_ "Z;^E4>1_G_ )^LL>X]V0\C,41_ZC<=
M_P ;]L?6S?[_ .E?T*^@_P!7Y]+?:>5&;H?-6_\  JEKUH * ?\  N__ "+V
M*-OW>;<_]7#HDD06?3Y(_P!";W_H?9I+;>G2=9Z=0ZG$XBJ'^6XF@JO\/X:1
M_O7M%-8PS]66Y(\_]7[>F@[0Q,-1;&5E=BO^H')W_P!AQ[1R[1_OGI0)J\>L
M$V.W-]OX?XM0;@IQ_P N_.XZ_P#OO]]_A[17UM+UNVN!TF:7;>(JJ_\ A==2
M5NULC5?\ 30Y'^*TM5?Z?[Z_LIALX:>O3AN"/GT]?W&IX['^\5;^/[5'[-/Z
MLS7?ZU.M_O(6N.LL>P\>+&;+9VJYY!'\+_XK[U_58P=.C>/LZ>:':VV:,":&
MC_R@_P#*?7G^+?7C_#VNM]M-K_H'1;/NQN?/]G3][/(?\7_XC]5X^?6+QG_#
MW37]/Z=->%J'42LK\?2\5E9CZ3_6O_Q/MG]XP_[_ /Y=:T$\!U$IMQT-?/X<
M-1YW/VY_W XW3Q[OX/U/]CU4W>@=U!]I'3]2[=['R_\ P!V<^*IK_3/9+_K@
M?:VSV?=9_P"Q@_YS5Z1/OUHG%OV4Z?H>I-ZUIOD]WX#$#\'!X_3_ +Q-;V);
M+V_FG_W,N/\ +T7W',RC@I_/INKOCQ4F<9+&]AYPY"G%J'[_ /XF_)_VWM+?
M>T@'ZT$_^?I3;\[:NUDX\?/I"9Z@W=M(D;FQ-?5X[@C.X(_Q2D-_I^Q_K>P-
M>;/?[9^CT)[#?K6^X'\C@](Z/*8K*7FQM90U7^\>PW]7,//H2:!U#J8K\?\
M(N?9 ]Y]?-X)Z7PC2*_ZO/I/RQ_[ '^OLBG+T_S='</@=,E3%:P_/]#_ +[_
M %_91)-3/1P!3I*Y/)8N@@_W(U=%2<_\ /K]?:!5BN>'2P ])QJ:@S,Y.)V9
MFLZ!]31;?T_U^O/'M7;\MWMUCP?YU_R=.MNHM,EA^>/\O3Y%L;>4G_%OZ?K$
M_J7-*/Q].?9A![?;K=?Z#^P'I&_-UK'Q8#[3U-.U]^TG^?ZPSM+^0:!:5?=I
M.0=UC_XCR_SZ<AYCL+G/U(Z3M7EFQTP&<Q&Y\#/P!_&]O50'^PM[03\NW]K_
M &UK(?SZ6+>V]T.VX'Y4ZDTF7HJX^;&U=#50'C_7_P!?V3%?I^..E/3A(X!_
M5:W^!_WU_;&N+IOP#_JKUR^A_>^G)_K^?>_%_P"4;JWG_C'77JD_U5[_ .M[
M>[DZ]^A<]-U91T5=#X<E2D4Y''WWMEC3AT[;\/\ 5Z])S$39E\D<3M.FS.^,
M?3 BNHJ,?Q$4Q_ZB_9_9\MW6XYBP?LK7JES?V,8JQ ^9P*]*&JS%7BOV<[AM
MT8*XY^_V_;C\'S6]WCY:GLIO'EMATFAOH7%%N0?SZYID*&IOXJK^GUY]GDL!
M3I7_ &_#J94HDW[,Y^[_ *?3_>_=QI'27]8^O3'4[8Q5?!X3_$*7G@4//^^_
MV_LJW. CTZ6P7G35_</%$_OY;-6_ZC[^PA,)_P#0 .EHW/K/%LK C_/&NJK\
M7_B/]/Z^TEO$+C_BNMSSSCI]HL7BZ'_@%34-+S_7_C7M3]03\/1?-G^WZF@_
M4Z?K]1[5O<?3_H].305Z:ZS/8RBG-']W]U7U0/\ D5#;)5/^'X'MP0O)-X/\
M^ Z3T@MQ7I1XG;'8>=!.(VF<93#G[_>]?_#>#_2'\^QA8^W^X7?G^0Z(;GFJ
MPM,G^0Z7U'T=O*N8+GMZT5*; _98/':AS_268CV-;7V9$?\ :S?M/0:O.<!<
M' /2@I?CYM^H!_B^X][Y1R18C< QX_QXO_Q/L1Q^S6TD_P!M<?X/\/1?'SG?
MVXP%'[3_ (.FRK^,6REF\])N#>U+4TMOLRV0&2^O^L#>_M//[16'^@T_9TO@
M]P[\<0/G7'^?IFR'4/8V#].*RF$WA0?44-</X94G_C?U_/L/;O[:7=MFW[OL
M\NE,?.B76)P1^6.D755]1A)Q%N+;V<P%1?\ Y3L=_%*4_P#3Z_L#W&Q7.V_V
ML(/\CT=P7T%UD$'I[Q>3Q>3L*/*T-58W_P AR '_ !KWJ/PA_HW\NFLCRZ5S
MXVGKX!]Y1T-53?2]?Q_MO]]^?:RQTSS_ *'ZO15/-.!G'7HMF[:E-_X50?UL
M#_R+CV<V^WC_ $: ]%\US/Y'KDN.ZXH"3+2T8J1P*"A/\4'/^)]KI+.UM_\
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MW0^P_B'_ !=/]N/>X;Z%_P!&6#JAMC;94]/LFT,#](J.OQ53<_\  ')?PO\
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M #14Z%[O&L?'_ SX]83G[_<N=@KR;WXQO\1%O^LP]R3S;=3#EG98/^(]'/\
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MW)LVBVGG_A/U_B6'W\.!V]G*VMA'_*3N?*T,TTI^O((]C'F7EVWV?]S-"?\
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M*.+J_P"(E/CB?XMG=^;RKJ\6^E1_'<?1K_A](![A2PBCBO+&4_Q#_>?&-/Y
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M!&*E@/S_ -CK#7[*W'D#Y8>K3]R%_LY&DQ=5;_6AOQQ[HW)MY/\ V/3<N]V
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M_D=#_$!D_P!5O\/Z'^O^'L \S<@)8V_C6_Z.>C?;.;IWN MQ0@^?#^70?87
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MZ_\ :?\ >?8DT'HI\4]8?;O3?7?]3?VV(?'Z]U)/FOQ]/S]/=Q$]OTV#,?\
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MTZQ?Q"NE'[.&K?K?_+^/][/M&6/^JO5P/+K/]G7S#_*:M:3Z6%"+_P"]^V?
M Z\9J_ZCU(CQ%##;S &H_K[<BABZUXW3GQ&OYTC_ &/U_P!Y]K?TO]5>M<>H
M\T5!6668+4V_I<_[U[;DQQZ;%3PZ:9,/3D>:A^_I2;7./!_WW^\^ZBW(_P!7
M^QUKQ^N:TV5IC>&K^[I[6 8<\?X^V?#(Z>U5/^?K/'FX!>&M_P E(^E_\?\
M6]N13]:,%.'4K_)9?\;?T)'U_P!C[5_7Q>O3?T_IU%J<ECX/\_66)_*GGVGE
MNJ]/ T%.H_W.0J_^ E)]H0?KD%/^]#VW]7X_#KW#K+]OEC;SY;[>WT%!CM7^
M\\GVF_=XFZ;)QC/4@8NI/$F9R#?ZW'_%?=?H*?ZCTU6G6)<0/QF:^_\ MO\
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M!]Y/54([6VGC1^:ELI1I60@?U(8?[R?<S>V>R3\R\HSV$WZ>G4WV&@)_90]
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M+"?*YW)82AN +8K;;" 6_!)(-_\ 6_Q]A+EC_')O'G_U8STNW _2@(,T /\
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M.,746Z)03/OFAI#_ -6_;GM;#[=W)_T?_LV_V.DIYNMAP0_[T/\ /UVG3F>
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M5X K_P!Z_)_$-A:_/]?K[+(X:_VO&GGT1;3R[+NLW@P_9^?0$;N_F$=#;57
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M]G>>1RKM>\2,/\:D5#XH!^*NDT^TC\^@#SELO[WW#;93\+$U&*'S_P '0?\
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M#1M_<6'W1B:/-8RL:KQE7<,A/Y'^V]R!L]_#?P_K]!N2R,;%?.F.E!/^@?\
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M^+ZSPYO:<7TJK_3@<CC_ 'W^W]ETF]=)YV)ZD4FY(<W44>,VSAZ[<&2JR>*
M_P *I?\ J:/\/^(]TMKZYOYO!MN_I#</ @K<&G0G8;J;=V<(FW=EVV]3'C^
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M\<>G^'J0FWL?8B5<C5V/X5B.?Q_OC[6_N^;K7C#IW@I::E!AIZ3[4$#Z ?\
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M%#+L$T+S>3 @>G^H=+)YQO,%_3_1I/ /VZP.C=_RQJ=(.M>\.Q:L?<U]?N=
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M:*K;-MYX^7^U&>@BDIYMS=3_ !-Z?HW^ZRVZ>Q]P[CJUI!?[:#<F4&-I ?\
M$VJY_<7K?#=[.#:8L$L14\2<?YNA1*QCN=PW \(544_TNHG]M1^SJ1N*M6*7
MYK9>2I!FJLS@]L4?'/@R&X-7'^PQP_/LF"_0BZB _B)^;!B?\!'2F&+]X?N&
M+\_^,]'I[*HO[D?RO]M8ZDIK-GML;0?(W /&Y*V*NE/_ ":OO+WF"V_='M=;
M-$?]R&J3]EQU#^R-]9SFP/\ H3G_ ([3HK7=]5!-\7/AOTU@[U6Y=U/!N$T@
M/_.V;PH/]<SU[>X:YU>*+EC9;3^#ZNXK\YF)Z'/+=SX&\;U?>7:O[!TW9"2A
MI>S_ )W"O%X,)U;N7!T/XL5KL;C82/\ 'V$H4^FDO?%^+3I_,D ?X.O(QN(=
MM X$C]FACTDJ'S+C?@+3;EM3;47<N1RZW_HV[#JO;FUEB_V'MNTA\2XLDEK7
MA^1GS_@Z,4W'Z(;C$M*T_GIQ_AZ.1U:R[T_F7]L9B0::;:6V\Q1M;GC&4=!0
M"WU_/N?.4+?]X\]7A'E;3-^RWC'4=;A<?NOE=8O.:X7^9)Z2'PXWEC-G9'YP
M;]S2F#%88UN7JJ"I /+5F=('YX)]/Y^OL/\ M9O,6R#?KR7)T!12I))-S0?,
MU;RZ,N;+ R?NRW'\7'T $1_R4Z+OM7'5F&^ O<FXJ^G6"F[![3VQC\-27YOB
M1$Q_V')M_K>PM:P?0<F23 U\:] )_P!+HJ>CYC]5S,(?]\(W\R.E5C"^YNZO
MAML2+_*5ZFZOV=N7<WY\&FGJ<^W^VIS2>PP[_OU["T/X+;2OSSXQ_P!7SZ<O
M;?\ =]ON,_K<D?X$Z+:U0K?&[<:)8Y3L'Y!8[[SB_&VL74RG_#DY,?[;V$4,
MJ0K7X4_PTI_AZ$96NZ5\_HC_ #/^QU:358?^!?+W:."#?:_W?^*.W:$V_P"K
M7D1?_>?>1%SLWT&[[:L/^@P?X1U&NTR>)M]U.<UG;_#T9$E+"]Q_CQ[FR9NB
M$1=9O:;ISK#X0/I8?ZR^TNY7)G_W#ZTLH\^@JQAH=N96L&[*/_<Q55]OX[7_
M .Y2UN+V]@U-RAAF_5_9T<1*6';T*E-6C(0>:BK&JJ8?\ZZY]C"TFMKCHM;Q
MQ_J/7+6G^I/_ "3[7Z(>F_!_U?ZAURUC\%A_K >V##-_H,_5Z@<1UW_E%A;Z
M_P#&_P#>_:J'P=?6O]%ST(&!^X_N/OK]-OXS@[_Z^JGM_L/K[&NU>%_5Z^_Y
MK6__ %?7H.3_ /);C^QO^.GHV7O)7J)^F2M^AO\ ITI]/Z_X7Y]AK=N'Z/YT
MX=+K6OS_ ,O0 [WW?F&SW]R=H5=!19(4'WN?SU=;_):7Z?7_ )7?]]Q^(PYM
MYL\.']V6?]MT)+"Q$X\1ZT\@//\ V.D;_<*@F439G<FZ\_DB.*VOW%68H?[>
M$'P_[?V'/W?-*?!FZ/\ Q!:\ !\J==+@\_MS_+=D[DSP^T-A@<]DOXI2U0_Q
MM_P#_P!C;VG2ZFY<_P"2;U26 7V9 /M Z'K9NY,?O+;&,S-&%HC64'JH_K]K
MIT^>$_[;_>!:WN6>7]R_K!")N@;>PFW8K_/U_P"*Z67LVZ;Z][3]>Z][]U[H
M'<5^_P!U[P'T!V'ML_7_ *::@^P;8YW:X_U>?2^3%DG^F/\ @/0Q>QUT@ZP3
M6NM[_GZ?[#VP/'_T#K8Z3N;W%M_;].:O-9>AQ=/<\9#)%OK_ +223[3[QNEG
M!!6\Z<BM&8T4'[0*?X3T@X^Y^LIJFXW/27YYM6#_ (C_ (CV&/Z\V=S-X!G_
M $>EQVN11P-?R_S="'C,IALOCC68NKH*J"LX_B&.4#_BK?[<_D^Q/#?PC_<,
M^-T@:U8'-13RZ<O;_3?3A[]U[KWM1U[J+_RG_P#(/MGR_/JOE^70.]2$00;\
MH?K]EV=N0W_V#?\ %/83Y*_L)_\ FH.E^\=Y1AYH/Y]#)[%T?2:3J/[;Z;Z[
M%B?43SS[OX\UM!^AUL@>?6:>]EO:_JM_O'O4/@=>ZBQ:N+9$DD_0"_'^QM[;
M$WU'^^^O$?+J7X/]K_Y-_P"-^[PGZ;KU>O+;_4_T_'_(O?H?&N.'5WZD>]=-
M]1Y^"A_U_P#B/>X!]3^AUZM.@8[D2:FP6&W/  :G:>=VSGVMS:E:K_=!_P!X
M]A3G-?#3ZW_?/^STMVR7P(BGDU0?MH/\G0O0S>9>/Z\\V_U^/8JB'U,/C],M
M1.L^K_:6_P!M[MXOV=;ZB5,/^2"F^@ YL?ZV'_$^Z2?XO%/TEM,GHLW7<8H]
MM?PR<$5&)R&2H,[S_P I1K./]XO[AGEJ7Z>'PO\ AG4A&A-?48Z7WL1^'U76
M.F#<9@EP&Y()K?;C;^1M?_"D ]E6]#P+.?K=J22/R_P]"CUT*H]?;-^XO]Q_
M \=H/_5$?K_MA['_ "D?]UD$'0#W$CQ&/V]+[V==4ZB/]/\ 8^U,/3D?3!NG
M_CW\K_X;N:_]PA[*=Y_W#N/]7EUJ'^T'^F'_ ![IAZK_ ./!V?\ ]J/&?[V/
M:+EG_<.W_P!7KTHW#XV^WH2/8BZ2=>]E_7NBW9\:^W\M-5 6I-J8P8,?3C*5
M7^6?[S_Q/N,]ZIN&ZF'H8[.2MF"/,Y^P T_R=*'VIN)O Z<G-:=8%_X%'_67
MV])!]1!UZ8YZB=1@Q9?M+&Q6_AZ[IQU=0_G_ (O%+^_;^O ][Y%G^F^H_P!7
MKT6<R MHKQTD']HZ'KW(G1+TW?D_ZP_XGVS=_P!AUL<>FM_T_P#(?_$^T^X_
MV/Y?YNE*<>@0Z;_X]3+_ /AV;C_]R_8)Y8_T?H37_P :_8O^ ]+RH_L_\M'_
M .)]FT_^0=*8N'^KY],-;_G?^01_O:^R\\/]7SZ7P=!YOK 0[LVUN#;DW$.=
MH!1#5QRH/LGO[/\ >%OX(_U9Z.+"X^EN QX\?Y=%IVMFYIX#@LUII=W[7'V.
M:H2+_2]ZR'BW^6?\3^/<$75U^[9O!/G_ (>I/C'U U0TH>E4_P!O;S?B_!']
M?^*?[Q[;0/\ \7UZ?QATB)+[S[!VM@,8?N*#;.<_O1N>M86^V_AES24G^^_X
MCV]L,'U-[6;_ %<.JWY^CMC3S%!]O1J)/Q_L?<U] +K)[]THZ][]U[K''^?]
MA[]TGZ!SI ?\8XIHO^57-Y^P''Z:N_L+\K']"W_U>0Z-MY'^,G[!_EZ&V5C%
MZN/I;_;_ /(O8J_M^B<'5T G?CS2[2PU*2/X?E-[X&@SC#_E6^Z/'^/T]A#W
M"/T$!^PG\Z='_+HK/^7^K_!TV5ITT-8#;_BWK_OO]A[BZRM_J3T+FAI_+H'8
M).#]>"+?X?[[GV=P24Z%, IURCE$.X=NU"\355?D:$_[#C_>C[>VO,IZU>T
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M</;W5.H!!'U_V_MFL-S_ &/5OMZ:J_,8;$TWDRE504E-]?\ +\HQ_P!L#?\
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M^.>TMH]/;WGWMMZKVC'NG9V-V^SY"$X##BE<RPA2UBH!''YY^GL\W':Y+E%
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MR2\'AQKY4X$Y.JG^$=/^U7-^U\O;7<P7\X!8G2*@$@ ?Y03T;/Y^=2[DW?\
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MZFN+C5J8G/H12A]?GY=,O67;N+VGU1WQU9F]OTV;QO9F$2KP];1BU2N:B8&
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M^\/8.R<!%Q/@:T;VSE_I2TN-/[/^PM;_ &/^/LXV6P_>-] 8?P8_9T0;K/\
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M^K\^I:;FS]6;T6TLZ;@\5WJ^GNDMU,/[&#I@(OF>NOMM\URDS5F"P$%Q_P
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MP@NR)J=+;;FVZF/J_L;&R[EK:BEGR>V7I:WG[J!(ZF)G3_IXMU^GY]R)M6V
M<O7T/]*W_P"TM>@Q/=5WN(_Z:H\O@/1Y?>4?41=,E;/:P!YT_7_6M^/8<W"'
MZG/SZ6V@Z"[>NRZ7=V-I1%5G%YK%5YR&"SIM_DM4WU7_ 'P]@[?^7OZWV?C
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MW7O?NO= [W+GIJ#8]3AJ"XSN\;;7PM #_P I.2_'^\_[S[).:+W]+]'X_/\
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M /%/8H_T;HB_#_J]>G^DAO<_U-@W^M]>/:U3P'15,M"?]7IUBSW_ ![>Y_\
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MT[UM0((:4:@3]$'];?[W_A[>5'3_ (OI---!;=1L'M6HG[/W#3U%J9AM7;C
MGZ#75V^G^LWL,V;_ %%^=?\ JR.BS<>8 EJ##GN-/V'HPE'@<=1?YF@)(MRZ
MV'^\<_[Z_L9P0Q1_['0$O]XN+G_5GJ3EIFH\)6S0V^ZI,?EAP/\ >?\ B?;.
MZS?3V<_@=([1=; 'U'^K^71;^MJ<Q[<Q%8+&IW ?X[7UWU^ZJ\L3Q_KGCW$F
MTPPR6WC?ZL=2%,WT\9'IC[.EHRWY'!'LT@GZ0$>1Z2>_J2GJMMY>:X^XQ?\
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MC8_=4PLC+28R<V<G7/+<IC8:4X >3#.13^8QGRIT)+.]^K&M:E3_ "_;Y?\
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M?[V/;,T/U'6U:O07;OZXH-RSC.0U==B]Q4Z_Y%G, -0-_P"MK\_UYM[#V_\
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M04V0W/G,ANG-T/T^V_O-:T-OK^/:78]MT</Q]*+VX%RWV8_9T+(FI9N(>?\
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M .3W6/R4IMVY+K:/<]3B-H3XZERU9FL&E 6FR),G&@D#D?3^GM;9S+<'4@(
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MVN@%I0\:^0^VA/1YO/MONO+X\>:A3T!J3]@('1KL-^Y]W63<5%57Y-:^Q^@
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M=XT.!%4+$9!<[4"<'_:@I7_6O_0#W.?LDH%S+6E0&I_SD8GHEWH4B/\ IO\
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M\*X\QY_MZ#4=%["/$)SU)3'ZT-!N2K:D'Y^MO8:FY!LKCA_J_ETL7=9?E^8
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MGLDGCXZ<MS3J/[OT]UF_'_(7_$^T_P#HW7N@PA_X_#)?]J3&_P#N8?9+9?\
M)4N/L'1D_P#N.OVG_ >EC[.NJ]>]^Z]U KZ"#(05E',3]M5T/V(%K_UO_MO:
M5X/K8?\ 5\NJPS4./6O^'I TU3_"9SALR136(%#77'^54O\ 0_T/^Q^GL(^)
M])T>U^KR/V?/IWDK((:<RBIHA=KZS;_B/]C[4^-X^?Y=.B'/ ]-&._W\65I)
MHN,-BB<A]Z/^4JI^GUX^G^^_'MNU_P :EZ9O?\5'S]!Y#H3?8KZ)>O>U'7NL
MT7Y_X,G_ !/M'<<(/]7F.FI.'^KY](C*'Q;DV[4R#AADJ+C_ !'_ !OV5[W^
MA=P _P"K/1C'0J:?;TL?8@Z1]>]^Z]UW&-,];/R?^->Z?Z#_ *O3I$XH>M<+
M!X7%_)?^8[N;$=IQ-F<!C]W[TPC;=R1T0STW7.LT&//^IIK*%_P'/L*QZ]PN
MQK/Q$</G44!^P?LZRM2^O>3>4?\ $10?[^IFIR3]M34]68]U_P N3H+MG.;:
MJL7+4]:+0T@HJU=@8ZFQ8J:>_P!7'@!#4M^1S]1Q[7MRV]XQD4Z1QH<TIY]0
M[LGN_N6WV^?ULXS3/14_YF_QTCQG5777:6%J\OG<AUPN/V+G<[6C[ZH-#7*6
MI)IC>_[=?K%^?\\HO[27^T&W"B3A3H;^SG-2[G?7&V3T'C&N,9\^DI\E_E.F
M]?Y?G4D$&8>'>/9IH=E;KHZ:Q_X\$6S;$_AI_#%_L+B]O:C<;SQ-O13QJ2?L
M\J_G3J_)/*@V[F>X/^@P^OKFM/RQT+%!MW,?&+^6#FJS$"IP>]=[8P9C<593
M$-403=CU,%* .+@4V.4WYN"?P?:RX@^BM01\3-G_ $OI^8'\^BJXOASESA^O
M3P!PKZC-?VG]HZ8/Y9?Q_P"I]S]+9_L/=VQ=N[WW-FMV5>VE7=%%]\*:@QU+
M QIP)&%VEU?[Q_K^TVRVBWBEBNH@X'EZUZ,/>'F"]VW<A907!A@\.N./$C_9
M/1L^E_@CUST3W+E>XMI9K>^/;*)GFH=EJE+_  RAIL^"/M7;Q_<M%1W_ &/\
MK!-@;^SF/;Q X\'R./7_ %9ZCK>/<>]YAL/W7/D>9KBH\_3B/RZK=Z7"G^;+
MO1?HH[5[H%Q_RRE]DKO7> /Z9_PMU+E^-/(?C>BQ?X!T%_R5WYB-T?/K>&4[
M2V]N+?FQ]B[PFP%%LC;M(*RHGQ^W*0JM)%3G@7J%\TYM^2?K[1[A<QM=DR $
M5RI-, TXYICH2<C;6+;E>D4XM9YABY\JD?+Y]8OEUV!U)W1CMI5O1_QJ['ZG
MW;@:HTN9RG^CM\%3U% :8>*.V/8C_@5JN_\ K?CVYN>CM9$TXR-2D5_8,])N
M0=KFY;EN+?<]PMKJ%^']K_G^?5U/0NY=PYWIKJW>6YJ7+0Y#=^RMMU.Z'S%$
M:&HI\AC":.2>4D?\IO\ M_S[27$/T489LBI_D3U!._*(KZ>"&E5P,\00#PZ,
MC'()%$T/^5#Z?@?[WQ[M%=>O2$@4Z:<KD;7QN,_RG+U7UL?^ W^/^^_U_:&Z
M'CS=5'KY#^?2WQ='!0XRBH:<6IZ96(Y_K_QKV-H(O!7/1%.=4W3E[4=5Z][]
MU[KWOW7NDIN/_BX;2_[7H_\ <4^P]N7]O_J]!TH@X'[/\IZ5/_*/_P @_P#1
M/L0])?/\NN7OW5NN,0M2 ?[6W_$^VIC]0>F!T&RVH,U5T<IO3Y3_ "_'_3\_
M7_>O84O8?H;CH104>"OSIT]^U'2WJ/45T%'#6UU0+T](01;^O'_&_;$H_1Z0
M#CTH]E4<U!A**&72:CBN-_P<E_R/V?;8#X/Y_P"3HDOR"_\ +]G2R?Z?['VJ
MM^/^KY=(>O0?2/\ UV_XGVMGX?M_R])U_P _^7IX7ZGBWX//^I]Z']C/+TQQ
M(Z1>TW\N7WA4?4-GACR?^U72#V%MH43TE^7^?IZ[-*?9_E'7'<^#KX*_^\&W
M_P#*\E1J*&OQ_P"K[JE_Q_YO#_?6]L[_ +9X'ZW5+.ZJ*'_4>FFFW;@I[P?=
MBDJ2#]_19 G&57'^M:Y]E9WV&#^VZ.C:,>'Y'CU%GSQR0&)VFHRN:-Q]]0\T
MM-?_ ([37(]MM+]7-X4/269?I15A3Y>?0R[6P=/@L#B,?%]*,*03_KGV/]MV
MS]V0^#-T$[FX-VQ8<.E=3Q:K?BY!O]?;]OB;I%<<.LWMSJG05[__ ,U6?[#_
M 'I?;;</SZ3R>7Y=4F[V_P" VZ?_  YMW_\ N4/9+L_^XH_YJ=.;QQ'V#H].
MPB(]E;5_PVQ@ /\ 7-)3>X YB;5NL_4I[=#^A^9Z5FJ8GZ 'V%82@F_L.E_A
M3>O7'R2_CZ_B][>ZSZ:=57QO^*KTVU=5!)/]I#_N4GJCQ0_3_??[[_'V47$7
MUX\'JTL.G/0T[7H)\5@Z7&UH/W-*2;\_\B]R'L5O]/#T$]RCU'I!=V_\R@[4
M_P#$?9W_ -QE]A7W-_Y(EQ_IA_A/1ERS_N?;?ZO3HVWQ7_[)PZ5_\1EMC_W&
M/O*SV7_Y5W;O]*W^'J&.=_\ DJ7?Y?X.M>W^:K_V_O\ Y!O_ %$_(O\ ]TTW
MN6A\'053@G^K^'I4?&K_ +BH/Y@__B@G1O\ UMVG[NW!O]*/^?>F!\*_:?\
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MZ/&PX+)?&CKG>F1J*0F1ZC*[QH(\UEZMK?VYLA5R2,+<.X7Z6/MMA2E/2O\
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M@<'_ +>7;(_WB.'V&_&#4IY5_P *]/Z<-^7^!NI?>O\ W%/_  <_\9U]S_\
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MK"I]OE=QX^FJ@O\ P"L<M5<_C]@\?[[GV2[CS#9;?_;7!Z?3;Y'^%:_/@/\
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MMKW)H .)..D5_I#[%F;53[$P%*2+#[_<>JJ_U[_;<_['V&_ZX;P/UOI^CO\
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M3U<GD@J8?ZX_)@_\A&W_ !7V6RYAZ71G21]O^;H'^CI;=98V#B^*S.=PI/\
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MX.K?%UW[KTHZQD6-K_[Q_K?[;VX(9C_8]>K3I%[BW?MO:$ EW!EL=2W'JH%
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MC[IU[K!4?3_D/_BOO9X]+(^FL14\7_ ?_6)!O[UT]PZD^_=/=,M1^E_^0?\
MB/;R<.GGX=8?=NE77&5=(7^OJO\ [Q[+WGK7KW0?90B@W+AZS_E&RIR."*_3
MZ'C_ 'D>RZ>$B;I?"=2D?8>E9^^Y_ !_V)_XW[.I8J\>M87KKWKJW7O?NO=8
MY**GR$'AK*450_(-A]?Z<^TTD/C]4\71P/3)'LO!13^:##T/]"?]?_8?\1[+
M_P!S0_ZJ=*/KV^?[.GV*-8;+!2BF@_V ^I_PO[-XOLZ3X../6;Q_X_[Q[9\?
MJ_47P)_5O]N/^*>U'7NLWOW7ND_N/$393'_LL/XC2@5U#:W_  *QG^-_Z\>T
M>^VWC15ZO:W(7_5Z]3L/E(,K04U= +@D<7_H>?;>VWD.[?K?Z-UZ=2E1Y=/'
MA8_E?]O_ ,:]JYIY9O[;I, /+J,;3PB#\E_]?Z7_ .*>_,:4ZW,./5%/RB^.
M/?71?R-I_DYT'M7)[UPN6R_]YZK%X:@.X)Z;(96FT9&"LH0/*M!7$N+'^SQ_
MA[+-RA>VN/J4R*U5N/ UR,_SX]9 ^W_-NU<R;8=EW7]&2E#Q&/D?7[.'2-W]
MOWYO_-K>NPMO8/JG<O1V.VY5,JYK;\N3V[34]176BFR%77Y!Z>QI8K7IRW ^
MG^+/B2[P%"@5X  &GY\:?;TMVW9N7?;&RN)KBY^K)'K'4@>@''JYO<G2\>\.
MA*[HK<F4J=P)7]?G;$.YL_>OGJ*F.E\2Y"6:UQ5"LL +_BWT]B.2!+>V8QX-
M ?SX]8[[;S##MM]!?0T_M3CT'I^S/V]:Q_Q[ZMW'VKW]UUT/EZGSXO ]@9U-
MRTRG[^"GIL)4>7.-%_7[A* G_C9]@S:X/%N:'&JGV\/\@ZS;]R>8+?;=E%]8
M_BK^9]/VGK9V[OZIQ7;W3^Z>K:DK2TFYMOPT]#6G_=%2A(HY3_04DQL?\#[%
M\D?U1\,>1QUA9L&Y_NZ]^NK]OS'5'W4F[?F9\$9]U[$7H.MW[MVMRYE<SXW)
MG%C( ^(5F(KZ I<RV_S(:Q_(]A^&6YVY3$BU#>1!.1@<#QSQZR+WFSV3W8@%
MQ]?]-/&*>0JIX@U!Q\CT97X2]8?*'>/>>>^1/<]=OC8.TZ^NR&8DV169*JQL
M&2R&1)CYQ?!IL70Q_7S"UK 7_#FWVK24\:@4&IQ2OR_U>70&YYW3;=MVO]S6
M?ZT_ 3>@_P!GY>?0:]/=9=FI_,YWEV"=@[SH]C9'LCM.KI=YQ[9J_P"%B#)0
MOZOOQ:(*0>.?R.?;-K;LUR&' ,2?RJ?\O1Y>;W8)R7] 2/J*0^F?+A]O2@^6
MWQ][OZK^2\7RF^/VV*W>4=37T.Y,WA</0MDZRER+TYIJL-3+<R4%?1:K'\\@
MV(]J-Q1HI(KE*Y[@2,>O#[?Y'I-R+S79;IM7[EW/M&5-#FG#B//R^WJ'E?DE
M\]_DGN79>U>HNL-P='TF,J=.5RM50M_#^.;UE9DZ(_[CZ,'_ #!8R@?U/NEO
MN=Y*VL$ G@%Q3_5^SIX\I<K\EPF>><WF,UX_R\_LZNHV[B\IC]O83#9[)KN/
M.TF%Q]'FLR,>,>*BI(;RRBD^EI01]/Z<<6]G4L<UTJ>-GJ!);Q;B:<K^F*U
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MQ]__ +EN/]?CVDGVZ&?KRN5^&OV 4_P] ;V7L?8^)VO53X_:6"ILS65^,PE
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M"]O\>/\ ??[W[176YPPS=4%J3P'2/V-GL%%BC][EZ 9"KKLC7?8?Q'Z_Q/\
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MF;WET5\8%K,]O+=^\.C:D]?U^4P^!88+;,KS#R(<QN^>.3(5)DB,A262J*,
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M )K'^9Z&/_='F_W1_7_??[Z_L3=,=)S([LVW05!@K,M0_<$_\ *$_P 4^GM
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M_'V+"]G;>1_XS_GZ0AB_37)B</-_P(V_1U5C:PQ:_P#1Q]HA96=S_P 18/\
MLF7_ *#ZN7<<'(_VW^QU"FVALN0 S[?V[.?IZ\32@_X<!/;K\MV;?VT%L?LC
M'^<=46YDMN!8'[3_ )>L/]RME1W$.V]L @\?[BJ<?[R$]M?N#:_]\0?[P/\
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M0PZ-;F[C"!I8QJ;.,&G[:\.A)\/;^.B6.LAV)F(#8_=TU=E,:W/_ "R@=?\
M>?8D>7=[#\:R_P"]_P"1>D?CPS9[A\J*?\/3U+7[SOSMS;K6%O\ B]U)^O\
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MZ8_09A9,=5<'\^%)1_C]?:>:VNJ5U#3Z9K_@Z\&7T/Y<.L\^X,C2$BKVY/5
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M[?NJ_P"QE=5DX_X)[93:KK<\7; _9J_R@=;^H51513YGKC+LI:5EEVQ6_P
MJ#:YM>EJ-5N&^I_K]+^]IL4VUTFM)Z?;_L5ZTUX'PPK_ (>I-1G,SA%)S>&F
MK#IN:K;2RY"G'^!\R0@?\E>VY-RT?[E0ZOF*T_F!UI0'PII]N#_AZ[HM\8C)
M2?;0U,4<QY--D&AT\?X"4M_O'M^'=K6?\)_XS_T%U9K,CSZ6$4 G'^3G0#QS
MZO\ >O\ 'V90-$/[($?L_P A/2-O\5QQZZ^U/^J7_;'_ (K[>\?K?C'KWC'^
MT_\ ) ]M>%+ZK_J_+K7U0^?\ND[ELWBL->:I>EC)Y_:,?Y_X.Z?T]I9[Z,?V
MLK'_ 'G_ "MTX!Z#IM@W>,F0V+Q.=E%@!]U?'4W/^,'F_P!Z]HANE<0X^W_8
MKT_]'IXD?ED_M/6=J;=]<!XZG;F)I^;BG62O/_62.(>WO]VMW_8NJ?;K_P"@
M>M52VP:G^77HMJUU1?\ B>X\[+_U"$8L<_\ !"WT]IVVV:;^VF)_U?.G5_J@
MOP@=.%-LK XVH,HI&KY[7O6#^)6OQ>S:?:V'8K2O#_!_GZ0_6,1Y_P NGPX?
M%5,)AK<)2U?UY&-4_P#$W_WGWM=IM/3_  ?Y^F9KAJX)Z:6Z[P#?O4E.N'J/
MRV$R#XX'_DE&_P!Z]IOZM"W_ +$B']O^4=4^M/GGKC!'O#:JRU+9*'=F 1+I
M#*LARL5_J$*(\<Q%_P"TR_3VBD3<=G'QK<?;JQ^Q3U53'>&E"I_D?]GKR=L[
M3FY#5US^3)3?_5!]J&Y[BMO[92?LT_Y6'37[G8\"/Y].F)[%3*TH^SVQN]@!
MZOOL<M!]?^"-4>V+?FBSN?[)&'VE?\C'I*]BRC+#_#_FZ=ZNMWU4CPXK%[.I
MP.+9:NK,C_3GBDB]JH[S<;LTA('VAO\ (IZJUJD>6)/V=87VIOZM).2WP8*<
M#_@'M[&@'G^I;0?I[;GVK<;\?K7%?EW?YNDHN8TR%SZGH/-Y]<;;H(#DZJ*L
MW'DJ;D5^;R+9.]_]= +^WH^2XE'CS35^RG^4CJR[@QP!2ORZK![T?UY2_P#4
M>QAM7A7,/^*BFCUI_D)Z)9YCY]7(]24E/)U!UI#6A:RF/76S;K7 ?\ZBF(_W
MU_:+ZE]X@'V>?^QTF629';A\1_P_9U.J>KNOL].)J_9V&AJ/J#+0#%?X<Z"W
M^]>P==<J[;-_:P?ZOSZ6/N$D8H"3_/H*.T>K^N=K[,W!F,7B:C&Y&FH0*$C*
M3<:OR=4H/TO] ?8*YSY-L+7:? AKK]32G^?^71[L_,%U>2#413SQ3IUZTZ)V
MO_!Z7(;J@7(9;) 9'[:KNJT]*/K!9PCZO]=0/\?=.4_:^V6#QKLUKY"H_P (
M'3.]<T7%:)2@Q7S)Z'C%;)VO@*:V*VW@*5@+W&/_ -?_ !O[D_;.6+;;LPP1
M?F#_ )N@K)=W$QRQ_(_['0:_)>HA;XZ]S74W'5&[QS].*5+?G^O_ !/L)^[\
M(M^7=Q_1'P+Z_P 7V=&'*<!&YVAKY_Y.G?XM@?[+=TP">?\ 1AM4'G^M/S_O
M%O8I]GC%<\K[=4&FD^G&OV]$W.%5W2ZZ,_[EOH-=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U3Q_-N_F58#^6]T%M[<.-V=6
M]C=U]V[KGZGZ%V/1UE/#CZG<U>B/]UFE^Y7)M@L:SI/7M04%94BPA:%(ZAI$
M6[9M3;S<43)9@B+G+'%< X'$T!Q7IN6X\"*AX#+'SIG^9X=:94'0N>[9["W5
MW_\ -G<\?RI^46ZZJ?*9S=N]8'RFW<!#"?\ )L+M;#3JL%#24R!5B!@B<JJE
M1'J-LN>5N1;+8XXWD&MZ"KTHBGY FBC/S].@GN>XRR82@'IG_57SZ5'6V]$_
MEV?,SXP_+KI"G_N)MG=G;FSOC[\F.O=GJN,QFZ-L]J5\=#'.V++QXYLEC:PQ
M5$4DLL:I+&9%.M0 &O='EB*>U,Z454(210.(; (H: @D5/H.%>E6V77U,A4\
M:"E?(@FG^KY]?2(I/]V?\@?\3[Q2DZ%4G4SVLZ;Z][]U[KWOW7NO>_=>ZT@/
MY[_:&1^5W\Q78/P3S>1S\7QT^*746![[[2Z_^^%-1;OW1OJ2V%%?%"95FH<1
M2>$B.98R)IJDQI949Y@]G]B2_D:XDII [AD:BY%*TI@:N'17NMSH0Q^;5'EP
MX4S\Q7]G59W8GQ#Z$["Q-'44&R<7U9NS$&&?9W9?4D2;'W%A:C'\T551U5&L
M;-'$;?MF1>?I+[R)W'EBVO8Q"RK4<&  (/D<#Y_ZCT$[;=",>7H>MAG^2E_-
M+[?[([%/\MKYJ95M[_*#86P:[?O6GR!H&@Q^.["VC1,AUYE*]Z:O?>.+1I15
MM04-93U(CDDJ:J.6*9ZC$7G'DJ7EB8ZF4HP)% PU)PKE0-0X-3!^7#H;6-]]
M6-+C& 13@<4I\C_+-*];2_L(=*NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[JJ?LG%[@S/SZ;';8_A?\1F^.T2K-FED
M>E@MD.3^S'*W^W4<GW@=[F;++NON#2-J?XN.-?X37@#U._+>Y"RY;U&I'C'A
M2O''GT8+&=$'(S_[_K=U;G)N?]Q-&?X91@_TL+O_ -8Q[DK:_:>$_K74]7^7
M^S3H,[AS@9L(N/7!_P O^7H9=O[%V?M> _P?;%'2M8M^YC ?I:W]L>Y+MN6;
M'8\Q _R_S]!RZW.YO\%@!]N?\'2T\%+_ *@?[Q[$GZW^H'_-TAZY?=?\&L?]
MI'O=PLP/ZQK^W_*!UX4\NN?M)JA]#_+_ #]>ZB2&FG/VU2K5U^ QL?Q_@3]?
M;LW^^>O 4X=!)N3H[9N=J/O,72U^T,R!<U^&!QJ_["Q8W]Q_N7MO8[E_8_XM
M_J^?1YM_,5Q:#)#@?SZ#2;J_LO#1>2DSN%W%CK6T5<=3CZNP_P"H>"=;<?ZK
MV!MQ]O=UVY_\4D0?:)#_ ((ST)K;G*.[F[@1_O./^-=/6WI<O+U_V#"=NU\.
M6ILIMW'C&RI/XIF>HA3R1*8O+H0,S-:/](/XO[$FU6NX?N*^BUK]3KMZ-1J?
MVR_T:_RZ+[B^3]Z17'EW'RK\)^=.CG^\DNHMZ;JKZC_@G_$>P[N7]O\ L_P=
M*K;@/RZ@>RGI=U'\'^U_\F_\;]^Z]T$6 93W#OJ+FU9M/;==8G_5"H'^\$^P
MG9"FZS]&$Q_Q)/M(ZS]F;HR^W=K^;&$_QG+U^,P5"00+5>4 )(_WW_%?:CFR
M^^CA\;KVQVPNVH?+/[.D!A]GXC#7G<C+9JL_X'Y[(?[E:JJJS^+7_P!]_K^P
M/8[29/UINA5')]-C@/3A0=/=10X_(0^&LI*"LIK\_P 1QA'^]$^U?[KADZM]
M29\YZ:]@O_=/>QV92<[4W#CVR&"H3S]K58DG[R$W_K;_ )'[MRA<?0WGT715
MNT =/$/$>?J.C#?3D^Y5A_QCH-'.>G#VSU7KWOW7N@B[AIHZOKC<0@)^[HJ(
M5Y!'_.IX_P!]_P 1[#'.D!_=/C=&&RMINP/7_+T(F(J?XECZ.LY'W>/Q.0_V
MQU'V)K85@_9_E'2"Y&DD?,C_ "]//M3UKJ/Y_P#:/^3O^->_=>Z!S>/8];39
M1=L;2Q-!E\^5#9!JXWI<7^/\L*_7_ @_ZWL&<Q<P36?Z-E37T;[;8"Z&IR0/
MEQ;_ "](Z2;L^93--OS'TH N*"AVW1G_ 'B?\^P6;S=;D^-X_0A&WVJXH?S)
M/4VD[ WKLV]1NRCQ^XMN,=60S^"QQQ=72W_Y7:/@?GV9+S?-M/\ N9B'HHFV
MA)?@J#Y DD'H?8*REDIJ"IIQ_P #V4#C_;_U_/N4/%^H_L.@]FI!\NG+V[U[
MKWOW7NH\W]A1_4_\1[23?[_ZV.@CZG.FGW_ UP:'?>Y;D<_0$?\ $^PMRE^A
MX\/2S=#\)]5'^'H5/8LZ1=>'/T]VO/\ %\]6'05=M9W+XW 45%A:X4E?NW/8
M[!4-;8'[092QG!/!^OL(<]W\VUP_H_CZ,-FMENFJW!14_.G#I.X;;F)VW3?:
M8RC'VS ?Y?8-551-B9YY^!;V$K';O#BZ%<;F+B<_M ^73C+%][3B"<#[;^MO
M]M[,WL+/</\ <R#IB"X(X'I.;$4;5WM6;8I!;;NX,"V=H*$\_:5.,YF_K^1_
MO7M)RR\UI>?1?\X>B[>X!&FOS!H?LZ,S[EKH-=>]I^O=>]^Z]U[W[KW7O?NO
M= IV5$D>X>L,HG-/!OD?7_J[T=Q_T5["7,_;>6_VU_P=&FU]Z.OJE/V:AT*/
M]O\ Y!_XGV/?]!Z(^GKV7]*.N@;_ .!'U'O<\%.O=,F0QF.S%+64>2HONZ2K
ML:_'UQL+6X((_P!;\'VW>0P;A#X,W3L;%*%3]A&>@L?H_9B3_P"XIL_MV"US
M0X7<59C:7C_&W^^_'L+OR/92'A_J_GT90<P26ZU)%?4KG_#TL-L]?;6VA8X>
MC6GJ*T_Y=7UJC)554"/^.Y8_7\V']./9EM?+-EMG]A ?S_V.D=W?R7WQ$'[,
M ?MZ6QBL I?\@VT^S^#^V\<=):XIU@]L]:Z</?NO=-E8/MO\J%_J+FW]/^*^
MV;N:N.K#NQT%O3<7^_"IOQ]Y6[DR/_)%:/\ BGL/<G?[A7'2W?&I(?L'^7H9
M?8GZ0=-D_P#F5_X/_P 5]OP<3THZBDZKG^BK_O9]H%A^F\?_ (=_L=.P'_5^
MWHL6[=I9O9V=RV?V=2C<&W<^179W:N/(-535)X^[I/\  _[[\'W$6];#^X)O
MT.AIL^[B90KFA& Q_%\OS\QT'E7V+MR$CS4F;IJC_E0.VZH57^P/'Y/LCO-S
M2Y_MO\/0Q4Q#T_E_DZ;Z#;^Y-]9S$YC,XFOV_M# UW\0H*&OXJLG4\>$S0V_
MR.'_ &%O>MGV.;<A_C']CU:3<5LP1;GN/\NAXF/(_P""-^/\?<EM+#!#X/13
M "<],[_7_8>TW1G!P/3+,3!35D]A]U;ZC_&W_%?:(1#QL_\ #.E'V<.@2Z5M
M+M[=F1AO?-]A;PKQS_6J^G^\>PGRA^O9S5_Y2!_@!Z/-X%' ]%'\^AA3Z?['
MV(>D73/GL7!N#"93!5__  &SE%DJ2LO_ -7.W^/]+^VMRL#N,'@^?^H]:MG%
MI,". R.BO[0RU1CP=B[C_P EW-MC_(A]X/\ @53#_@)5P_C_ (U]/<+WO^ZZ
M;PY?\U.I$M)OJA4<#_AZ7@:G/[\_/] &_ _V_M#-<K;XZ=$$QZ056QWMOK:F
MU<,J5/\ #LYCMT;HK*'_ ("TM-C/\U%_3_*_9AL=M-N4]3]@]>FKZ;]UVY/J
M,?;T;T_4_P"N?<T0\!U'G77MV7_)U[H).\:/[SJ;=\'!JJ/"K6DW_P"=7;_8
M?D^R_F:+ZFV8_,=&W*9^FO[?[:?ZOV]$6@F\L'F7@7L1_B.?<9K+3K):48ZG
MH^GZ_P"\>[&;I-5>AAZ4D^XW_A83:WV61_Q^ES_Q'L2<N]\DYZ W/W^+6(Z>
M]II!%F.SJ7)DG+TW8>1:K/T_XN)_R3_K%[ NXJ?KC3TZ#D3?H6Y'H.E]XF_U
M!_Y*'M'K'3?TO6.6*F^VO./K>W^Q_'MJ4_40]7J.G;H/[C_1QM__ (XZLE]E
M;_E6^[J/#?\ QO\ \1[F+E44VTRS= GF'_<FG^KRZ&TN?R/Z@^Q#6'_0>BXK
M7K'[;ZWT#FYU$?<W6,P/%5@]XT /_!;G_>_8>NYM-_;0_9_EZ,K;NV^Z^1'^
M?H;-8_VCV,JGHD^G'^K_ (KJ72BQ;ZW*J3S_ %]^$U.J29-?]7GT\1CRJ8/R
M/S^/Z^U$<U.BR< UZ+9UY*=>[)IP/XS4;WW!_&S_ (XRK_:XXX^S_P /<-PM
MXE^-70ON8/IX/T/04Z&"EEJ .3S=>+_ZD?[[\>SVVFZ(;@UZ<Y(X<C05E%/8
M4U5CQ06'U_VW^\^W;E?&_MND%O!G'0H])U=17]9;2EK!P,$Z@GG\CG_;>Y5Y
M&O/J+ S=1CO"Z+HT\Z="U3,/3]>-5_\ 8W]B\P_3]%7'J7YT_HW^V'_%?=.O
M=!)OJU5V-U33CZ"LW+D 0;<?:7_XCV$=T'U.\V/V]*[+LB>GH!_AZ&*+Z#_7
M_P"*^Q?%_N1<?ZO+HN/^K]@ZS^]=5ZB^,_<:["UKVO\ ["]O]]_K>W?%/@_3
M]7\J_ET"7<\512T6W-W _P"3[3SYK,@/^F7)VHYA_O/^\^XYY[L_J? O/^4;
M_+T;[,PJ4_B '[!7_+UZ*7SW\(N;\G_6'^P'LM9[,?K?]6>CZ:!C_L]<KTW
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M13!A)Z=5M/\ :O:]_I_KCWA*W=PZ&C=W#J=[6=-]>]^Z]U[W[KW4>?\ L?\
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MU[VUX'7NO>U'7NO>_=>ZZL0..#>_U_XGWH_XR:S]_6^'#K@L8--8?J^IL/\
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M_P#T=[3[E_N+^8_P]4M_]R>@SZ4/_&/,,W_*H<IC_P#DNM'L@Y27_$+G[/\
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M_BK_ .KY]+MC.F^MOM'^&G5:>(K#+14I_I0XXV_UO<6,O;^9ZRJ_T;IW$O\
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M3&$45_\ 8>S+V]M_'$\W\?\ L_Y^B'?9PI5?1:?F:'_)T,_L?>+]G150^O\
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M7FV4G]&#HREVR@JQ'\SU(I-_T,=0(<UB:_ 7/%?7#_)?^I__ !KVJ7F[Q/\
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MZ^XW]T_^2)N'_- ?X1T>\I?\E*T_U>1Z<OBG_P!DZ]-?^(QVG_[BGV(?8_\
MY5?;_P#3'_#T4\Y_\E2Z_P!7GT:+W+_08Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z2N3R"XW'Y?)#_*6IL;E*\+8 ?[B0?3_ $X(
M_P!X]TC(,IKZ?YNJ@5H/F.OFF_">5\KTWO+?55)*^7["^1_R"W?N"68W=I*W
M<50Q+_FY55!_Q]YJ>W\/TUC E:E@S$GYGA^5 .@=O,VG]@_G_P 7T<+4+^*_
M[W]/]]_C['_15TL_Y;'1T_S-_F\;!J5I7K^F/Y<>#RO:&_LUS]K5=B;WC:EV
M[B@0K1&?%IYJD(>&6GE+C\C'#WBYC$:1VD=* FII_HC"@_D/3\?'U%>SVVHG
MU84'V>>/]6>M]UI]1TZ;?F^K_C7O'&YSG\O\/1]3%>I7M;UKKWOW7NO>_=>Z
M][+^O=:C/_"E?I#(]=YCXC?S+=IT<N1Q_P ?MPUG2G?]-BP9?#L;MZH44V3;
M2A"IBLNR$FX!2J/]E>9-]NN8SLU[&)!EV,;BO%&XTJ0,<?/Y<>D.ZV^K4<YR
M*^; 4/"O^KCU6!#64M9%0UV-GIJW%5M-25&-J:?CSPUG^;D]YGH0PJ.'0&(I
MTF.Q\)#N'8G8&$KQKH-P]?;TQ=8?K9:K'2H?]YO[:O(M4;CR*D'\\=,6UQUM
M$_\ ">S=65W?_)X^#6;S]0)<C3=:[BP;51-O\EV-NC<.(I5)_P *2A=1_A;W
M@5S'%X5_/&/,_P @2.I+M^W57Y#\](ZO#]EO5^O>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZKCJ_^WATG_BLX_P#=X?>(?,/_
M $\1O^:7_6'J7+7_ )5H?;_EZ/)[R$Z ?7O?NO=-_OW7NO>_=>Z</?NO=>]^
MZ]TW^_=>ZG4_Z4_Y"_XGW[KW6:+_ #-5_P!1$?\ T.OLQ_T#JC<1^?\ @Z6G
ML3]$73=5?4?\$_XCV'=R_M_V?X.E5MP'Y=0/93TNZP3#5HM^=7_$>VYI?I^M
MCH$^L7.6RN_-Z@6IL_GOLJ!1S_DFV/\ (OI_2Q/L)<LI]3<SS=&.XS!+=4]!
MG[3G_/T,'FU$V N%(/L:S14_;T5_4]!%G^JE.7JLSM+,5VU<CE"&K,?1C_):
MHC\S0V%C_O5_8#O>2)W_ %K+X_ET=6N^K;@+)W <">(/^KSZ8DZV[%JOV<KO
MS&XFFL;UV"Q_^5?GC]ZQ^H]HH.4KRX_W,_;TM;?D [5)^1/^7H5=H[2Q&T*
MX_%4P:,A?XCD3;[FJJAS^]^;6/\ 6W^PO<9;=R_#L>(>B"6^:]-6_('@!_GZ
M5(%^![-9IOI^F^'4_P!UZKU&F^D?^L?^(]WFXGJR^?V=1*V,/2_;V'%S^?\
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MZ][]U[KWLPZ]T!_:EJ;-=.9D7'\+[#QU /ZVR5)/%?\ Y-]@[F(_K6UQ\O\
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MV-OY$AMLB_;_ %?GU>3W5YK;'[F'Y2(/^?>E<OS4_F$?G^55VT.?I_?9Q_\
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MD?\ *SC1P/\ 7TD_['W%=ON7T^YF'Y="&6(M OR8G\C_ +'1@=:\?6QOS?\
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MI*_<N6S78.7I[_Y=N?(?Q&EI?I_RABU+?Z\7_P ?:?\ JTO^C_J=/-O,Q%(
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M]]S[>B'U'2+K-3SV ^H^A!^MK_\ $>WHA7I <=)7<V^MK8&!AF]P4%-56O\
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MMC<=C\73M0TM&U)2&X(TZ1_K<\^WE3Q.'4?3S&ZR3T\(?J1^/Q_C_MO=I?\
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M!_M?_)O_ !OW[P^O=2/;G7NO>_=>ZC^#_:_^3?\ C?MOP^O=>\'^U_\ )O\
MQOW[P^O=1_;?7NH_OW2CKWOW7NGCVHZ3]>]^Z]U[W[KW3/[3]*.IGVG_ #<_
MY,_XW[;\3IOQ.J0?YZBRI\3.M%&D1M\GNGW  _Z::O5_O%O8\Y#>."ZD$O\
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M,/V$?MZPKN_?&UE(WKMG^+8TW S^U/\ <ER0;7H[>:Q_UO\ >O:&3?;W8?\
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M1/\ 0+)_9-^1J.A)Q&=P^;IS78.JQ^4IJSAJ_&Y0I]/\+7X_U_9WMU_9W_\
MN'TFDM&4]U1\B"?\'3V;?V;V_H?9D1-;XGZJ,9'4_P!UZIU[W[KW7O?NO=>]
M^Z]U[VHZ]TE\I7XW%TU=5Y*K^TQE&-&0KJ\?6UK6''U/^^X]H+N]_<Y\2?\
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M^MTL79W;N;M'SQ_D_P O3)-MWL?>EJC=&779.$%].#P63'W0O_RO9,_6]O\
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M- ;U7_4[_'VG3;Y9_P!7K<S!109ZE3;1H!#2X['4GVJZ?OZ"OH2!4BI'Y/\
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MCKWAC_J/^2Q[]XA_U?\ %=>\8>HZ]X8_ZC_DL>_>(?\ 5_Q77O&'J.O>&/\
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M^']/]]_OOZ^SBY!N./7K>WITU2RK)ITAM0/%Q_QL_P"'NL<=?T>EW2-W!NG
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M^QO^.GJL?!?M'^$=::O8HU?\(O-C$_5=L[4(_P!AV+4>VZ_X3_EZN14'\O\
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MQT%.'3A[KUKIKD^B_P#!O^(/NEY_8'\_\G3P_P!7[3T%W2__ #+'$?Z^4_\
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MR#:3S_M[^Z;EM4-X?\<ZJEV;+*](H]:Y?"6_N3O#/XJ J?\ (*T?WHI/]?\
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M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4>?\ L?\ (7_$>VY.O=4D?SU_^R5.M?\
MQ97I3_W)K/8@V/\ W(?_ $C_ .!NH<]ZO^25;_\ /;:_]7X>K=X*7]BQ+<L1
M^G_6]QS>P4NNIYVY_P!#^?0<YSK6@JJ^KS>WZZOVIN*JN:^OP7/W(_Z;(/K-
MS["%WRU#<?K6?Z,W0@6^*@!J%?*OE]G32<OV=MD'^.;:Q^]:8$WR&U.*H7^G
M^1RC\?ZW^Q]E_P"\=SV__<SK1$<G E?MP/V_[/05]B=L;'FHO]R.7R.!J?\
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MVEL_,SA1497"8ZNR%_S:D(_/^(]R+LES^]]N@F_U8Z"<ML(G(Q2O^$]/-9*
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M@E^G_M^C)=+;$\>[=A9?=^/-3B-RUWV=%AZT7O48^F^[I*F7Z?FW^\>S?EY
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MD?MKT,O4&],EN/99&;_X^C!5N0VMF#P?\IQXXF_I^]Q[GGEB_P#J;?J->8+
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MV'LTGE\^A_M^U#;13IN\=JAF_'/Y_P!]^/?H^CNN*]>AD_RDP?4E.?\ 8_\
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M_.+HZMMUM-L6N@!O09)_S?MZ&O9_3&Q]HJ9X<2V6K_K]_G ,K5<?[2I/Y/\
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M2_:48Y_Q_P ?^)]G&P1&?<89_7J*=V(2V-?/ ^?1LP\S4UQR?Z7_ -M_OO\
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MEA\NDA&,\.H%=%B\'B#GMSY#$[>P=*M)BH]R;CR%)C:8U.<.B*'SSF]VO?\
MI:]^ ?9Q:;2\HU_;^WH@OM[@MB;<9K0TH3C]O2 [Q[HZ$^+VP*_M7Y*=G[7Z
M:ZZH-P8S:AWOO9U%$F5SC,(*)&\;N?(RLY-K!1>X ]F.T<OM=2PEC0#B?\_1
M-N7-,5B"% )X\:8/GY\>@N^./8747<F&W;W#T1V-MSM;J;?6ZIJ[;F]=MRH:
M*O;$1+3Y(*;+_P I\:KR 2&_QL =;[)+L5[>PC_1>!^63_EZ%%INW[[MT)IP
M/G45) %"/LZ-#&\W-^+_ $/Y_P![/M7X1@_1'1@0#UZ28QB['\VMQ[9UGKP'
M70(()/%N#?VHE'T_#JP&KCTA=\;&P>]\)_"<K3 0<5U%6T0_RFFJ>?\ *XAS
MQ_OK?T)]XV>+<(>G-OOVLC4'_9'^H] I)LWMO#@4L%7M?>$%*2:&MK?NMM9,
MC_F]?]K_ 'GW'M_RO,?]QZCH566\6S9GJ/V$==TG5.^MX3>+?.3H\5MHV-9A
M=L$_<Y&P_P U5Y#Z"C_'X]NV7*,\O]O_ *O]7SZ<W/F2!!6W&3Z\!3Y?\5\^
MC-T=-BL50T='1TII8*6C^RHZ&A%_M=7U_J1^/<KQ6L.VP]1^=5V:_M^?3GY?
M]J_WC_C7MOI_M_U5ZRPRD@'@W'^]?\3[]%Y=-$5ZFTM1:]P;$?T_XCV_4'I&
M(BO05=IO/B!M/L*"_P!QL7-XT5I_Y6L;DO\ (\C%;^H(]A[G$_06D%]%_P I
M'6K(!]5K_$/Y^1Z'S'UPFB-73G]BL%R+?@_T_P!O_A['+2$"":+_ $;H@ELP
M25/$=/\ #->_%K?4?[US[<5J=)IH>I%;24V;Q59B\F/NL=E<>*&KHCP/MS_3
M^AY_WUO:JZMS?P>#_JIT5+%H:HQ3(/SZ+M@LS/M@5FRMR\;AP ^QH:X\?Q.E
M'_ .L(_J./S[B3:H)OK/!FZ&UK:C=!K7@?7\/K_J\NL-3D)\C/5SR_\  CZ+
M;Z6_Y%[&$/@VO0I@LOI_\G2>J0<E6TF&A]1^^^_K_P"S]M2C_'_'CWNUF^NF
M\'IRX[14_P#%GH69KW'BM?T^QE%T'ATOMG;*.;O6UM_X: +BX/W=^?Z^U$4'
MB_J= ?F3??I!]/T.E)34V/IC3TYO2F]_]]P?]]_7VO9O$FZC6XN/J>@UVX15
M]K]D5'XI:#;>.O\ X\?]&^PAL(KO-QT8R=L4?SJ?Y'H7N5HN/59?Z>Q(9?J/
M[;]'_)TA_%TALYV9LO;P:#([CQ[5&D'["A_W*U7U_,4'T/\ L/9;><PV>W_Z
M/TH2P>3@OYG _P _2.?M+(5+#^[VP\Y5>G_@=7'^ZM+]/^;OU_WOV&)_<2:G
MZ-OY]'*\O ?$X^RE3_J_+J*VZ.R6MX-N;2I>"/\ <AD:O+?[T?98>=]UN1_8
M60_[*/\ *>G_ .KEJ,EF/^\_YNN7]Y>T8P0,/M"IL+:@E7BO]Y/MH<T7]M_;
M>'_S9ZJ=CM'X5_D?\_7.+L_+8JW]Z-BY"GI['_<C@G_O/:_];6F]FUCSU#;?
MVV/]7V])Y^6Q(.QJGT./\G0GX#<F W30')X3*T%52GZDV&FW]>0;6_I[&EG?
M0[[^O#<=$SVK6!H0?RZ>=)'UO?V:C<O]\]-TZ8LIN?;^*)_B>:V[3?T%?E-?
M'^\D>RP;W9;=-_N1U46;2#"G_5]IZ"_:F2H,WV?OO*4-;0U--2X';]#05^/Y
MM<5/_$^P98[[]?NT_@W'^H8Z/[J,Q6:@CBQJ#\\]#@(-5A_9_P!O_L3[D-H8
M+CH/7+4ZX& P<DWT\V_K?B][GWJ'_$.FNBX;FI?[G=AM65P^TPO8 QI^]O\
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M[KW7O?NO=>]^Z]U&J/JG^L__ !'M'=?YO\O6_+JDG^>?_P!DG]:_^+.]*_\
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M2_\ ^)'^K\P.FWM+E.*D?:*_X#T_B191PHM;@ZB/H?\ 6]F;)]/TP)Z?ZO\
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M4G_*PZ_[*KNO,50?(+M/:M!E,IM^K[CV)LZC&&K4Q)94J\935U5#D,G1,6U
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MW2O:R/$ ]0P_9T*%))YK5)&D5JA0%Y^@]B#;9OT>DS"A^SIT]O=5Z;_=IO\
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MW::WO:?H_P#5[_5_+I#=7:PJR @M0Y\E'^K]O1D!#<*H^ER1^>3^3_A_OO\
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MMM?':@M-:_'\P2" -.=- ?3(QU>UB<'08;'4F,QU'08O&TE"U%0T-!8TM-3
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MZ0P-C[BCFW>3N$Q0"FF@'^ESZ^M>NA/W?.0_ZG[=]5/4M<L9'KPU,H%!3T4
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M9 LH"4RQQMJ+)[TS:S4>O^'_ (OIZ.$DD'.,FE. K7CZCK/_ #R^K.LMF?\
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M?NO=>]^Z]U[W[KW7O?NO=5Q5//\ ,5JQ_7XT*/K_ $R8]X@;Y+]-[B_\V?\
MK >I8ML\L?[?_G\=#'G%7=7>F(Q,Q^XPG7^".<K?S_E61Y@X_P!M_MO8UW(_
MOG=?IN/1(GZ-D;@8+&@_U?8.AY! '%@H_/+7U'_8?T]RI-#$_1+_ +E_ZO\
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M]Y]O>,>GL_+KE[9ZMU[W[KW63R?X?[S[KH'2?H*MIK]KO#?6&'(%?C\[C_\
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M/;1_QC^QZ9Z ;MB:NRV?V%M_;0QYS-)6Y+=H%< *0TV.;@S6_P"*>X[YL?\
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MZ!JT''KUG_J/]]_L/;?B=>JO0,?)C_LGCN7_ ,1/N[_W&3W'WN;_ ,D7<?\
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M;NN67(=@=OY[GC-T6#'^MBJ2W_$CV/N4_P#&-UG/^K_5CHDW#LM57Y$_X/\
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M_D-3T-1C$ZF"8#\'B_\ OA[$<LI_T;I'0=(;/]=;%W +YK9]#DZCZ^F@$?\
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M5%GIAL=9/)X*?_+:SGZ$CCZ_[S[]X,USTT.WH.=UO3[IIZO$UI'\/J@#]?\
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MT)LQC(IH/2ATJ-+7-I"=#C_5QZ;'%/M'V\">MGKVFZMU[W[KW6D]_.C^=?\
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MBAH:8SCY^728V)\A?C;W#G\]M/IOY$=(]J[SV]1Y"NW+LSK/L*@WQ7T=-C9
MDTTE+2>J,:[$W) O?D<EB?9'LH=7^H=/;=S;#N!\%@1PSZDFGV_MZ'2#$U,U
M/_$YV%)3"U#]_7?[?Z?D7'LKL=C>//1Q/OMO;X_P=1)[1S&GG !X(M_OO]]_
MK^T2VO1G#<5%!^WK&E/.XNMR/I8_[[_??U_'NZV]>/3DDVGAU[[=?]1_R=_Q
MOW;JO6=/I_L??I^O=9E=8P/*UN?Z'_??[S[JL&GK39X=)/-9$2*(8P/M_P C
MZ?[[\^U$,'IT;65G3)Z35.:C@BP)O<?\:_V_^\>S!8?7HUG(/#I.[I?%BA7&
MUE(,I/56-#0#D_[?V5;Q=0CK5@#4?SZ]MK9=;ES20YZJKLG!3&WV0'^3<?3G
MB]O<?W=]-=0^")^K;C>"U)( SY^?1@\1A<=B:<0T-)04A'_.OQM_I^?Z7/L/
M%5@FSU'=[/.W2F7$8C(TZFLHZ&II[_\ *?C;?U_/%O\ ;>U<DAN.BJ:<K_L=
M)'.=74-7!?;]778&HI*X5U!0462!I?NO^6/]?:;<=OGW#^Q\^D:3:?BSTH]G
M[KGGF_NWN2E&-WAC.:Z@T_\  KC_ (&T9_/^^_V"C;-PTGP)NDUTE1J6A4_Y
MNA5A^B_7^U>WU_/^^Y]B*'QNB]N'67VYU?KWOWB_/IOP^LGC_P ?]X]UUCIO
MKWC_ ,?]X]^UCKW7O'_C_O'OVL=>Z]X_\?\ >/?M8Z]UY5OZF]^EEID]>Z\;
M7(_ _P"->]>+]/#U[H+]A2OD,WV'N &_W.ZFHJ+_ ,E@^'_B/9)LN+BXF_9T
MHO0? 1?Z.?S'^QT)T:#_ &%_9Y)+YGII^/7'W7Q.K:!UD\?^/^\>[:QTUU[Q
M_P"/^\>_:QU[KWC_ ,?]X]^UCKW7O'_C_O'OVL=>ZXZ&_I_O/MS6>O==M$""
M+A@?\+>VBXZNK>1Z#'=$G]X,_MO:=Q]K_P ?9G;CZ4N-_P S#QS[*.8A_CD$
M$/X^G(OTU9S_ *4?:3_GX]"=JN?I^+6]G</Z'#ICKOQ_X_[Q[IK'7NO>/_'_
M 'CW[6.O=8_=?$Z=T#K)X_\ '_>/=M8Z:ZXO^H_[#VXG'KW31E<+0YS'U>,R
MG^54%4>+FUO]M[3W=IX_^?IQ&(-1UQZYW#6HM9LG=%9]QF=OV:@R&D7RF+-K
M36:_]!]S];V_VPWY*Y@^L_Q/_1N@ON]G]-^HHP>(]#T,L($%]=AJ/IN+W_K]
M/<E3'ZC^PZ*SGK#[IU[KWM/U[KWMW0.G-)]>@M["WCL[!;?JL?NJJBU9:@&/
M; T+?Q2IJ0IX^E^?]B!^?]8,\W;_ &-K9W$,GY>#TKVJRDNF!<>=:M@?RZ#;
MKGM"? X&CHM\X;.;?Q](#0X_=E=B[TM53'_,^<D?T/\ 3_>_81Y*YO?:[/P+
MGHUW?:(%<FV(/RKD'HPV,RN%R],9L968W+4HMJ7'IIY/^%_^(]R'%NEGN'^C
M]!HVC)Q%/M_V#T[7']!_O/\ Q7VK\:'I3UUYF_HO_)7N]?F?]7Y])?J/E_AZ
MR>/_ !_WCW7I[Q.N6B?^D?\ MS[O1NMU7K'9?]5_O'O?A])?JSZ==NWD*@B_
MZK?ZW'OS/!:_VW5K>?5CKA;\'_>O=?&_WST[Y=-=?F<=B*;S96LQM*2?KD1?
MC_7O[I+S%#;YO>K_ $9D/;7\O^+Z#BN[8@R=2:#8V'R&]\BU@!0@XJDI+_\
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MB:E5"OJ753@&U$5/ ]9S_<\Y^VW:Q?\ +MY.+8[B8O!F8T \(9/V*14T!-.
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M[I_\1'N__P!Q8_8!]T/^5>W'_F@/^/='?*O_ "4K3_3'_CO3O\5?^R;^EO\
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M^KS^71Q?<TP6T-%R?3Y?,^0^9ZI2V_\ \*8?Y/F;WG%LF7M_MO!8ZHD_AO\
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M]'UQ;FV)#?9^1ZC9[*@@4,%EO;\?T_XT/:Z&*G2JRLJYZ2L$>HVO]/\ B?\
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MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZH[_GM?\
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M_P":"_\ 'AT=\J_\E.U_TP_P'IZ^*G_9.73'_B,]D_\ N(?9[['_ /*K;?\
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MPKL[<U'*?^/KH<;GJ"XO_P 6P_9S<?[S]/\ >_<4[A =OWR>:;\?0KVDZ[,
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MJ#Y5]A=K?)CNN@_TA[GW7V7NW$[.Q&YKY&AP^&VI7/24V,IZ67]D%00  -(
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5'?\
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M7Y#_ &.L]/F<SAAXZ3+5D$ -EN0I%O\ &W(_WKVFLK^YC/82/7JTFU6]R*S
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MKJFGIZL7@K2P_-C[=^M@N.FWMRO3)N/;./W-0_95I'^2C^(4%?0?\"J6J/\
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M38G_ (CWX0FYZ]T"V8J:?<':FVZ"C(JJ;9'\2SN<-_\ E+REJ*CAYL 00/\
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MMWBM34$@4ST*X[;R@^G56^OZ?\6]O^*>]'G.:W_T"7JG[J!_&O45NP]Z5/\
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M8EMQRTT8_1<R1_\ &2?MTBG^#H5[+[J07DHAW.W^ANS6B,5U&F32CL#C-.(
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MO=2/?NC#J*#^#]?=X9J=(2/,=93%;_6'XM_Q4^[RB'JX@(_U?[/77B;ZK?\
MUN/Q_@#[0S64-QU;P3UQ]F'3'3E3_P#%MR'_ "TI_P#H9?;R_P"XA^S_ "CK
MS_[E+]A_P'I?>QET'^@^S^)Q^?Q]7ALQ2"KQ=7CQ0UU#6G_6.H$7O>XY_/\
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MN#]UD,?15X_/VV3JS;_;W_XCV&N;)OT<=*]L'?\ M(^VE.N$9 )AA-P 3?\
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M/_O+2\?B&LM]U8?ZWLM_<D^V?[BW/^]8Z./W[;[GF_M?S@X_X.NAFN^J)?\
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M+/X8?\RFSG_B3NRO_=U4^\9=H_W'_P";B_\ 5I>NXW-7Q6__ #S#_CW1PO\
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M'_F@/^/=.<J_\E*T_P!,?^.]//Q3_P"R<>F/_$:;6_\ <0>SSV+_ .56V_\
MTQ_P]$W.?_)5N_L_R]&?]S'T&>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z;_ &GZ]U73_,9^1F?^,WQJW#N?KRF%7VWO;*;9Z@ZC@B34\VXM[U#4
MN/?GU*],B-.I'%R./K[/>7[-;^;0WPU#-]O^P.@![E<RS\J;6;F#,[?HP#U)
M- #\BS $XQ7HO_Q4^,6V/C5U]38IJ^/='9V\4.=[K[/S@_B62W#FZ_\ X$35
M%3;_ (!BX\+$^H\_6X(HO;YD:G%1D$YJ2?MX?[/4:;#L%OL\% /UWIXYP"Q
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M\Q7@PW;>9HIP+;LP.-SU#>W_  *QO_(C_O7N2++QMNW_ ,'_ $'Z;_9'0<D
MD@%/)J'[.'0J:/\ %OK?_??X^QG_ *-X/17J^74OVYTMZ][]U[KWOW7NO>_=
M>Z][]U[K'_R@_P"^_I[5>?Y]%_4VG_XM]?\ Z]/_ -#CVN'^XI^W_+UYO]RA
M_J\CTO\ V*.@_P!)S,?I;_EE_P 1[(+O^W_/I9:\!]A_R=-%7#][3?;U%Q2U
MH%B#_L1_M_\ >_97<6D/^@>?1DITGYCH&Y.LLAMJ=J_K',' T]V%=M.O4Y3%
M50_US?[.]_R!_A[!DW+,VW_[@?\ .'HR%^)/]RQ7^EP(ZR+V?FMO!HM\[$SN
M+:VD9W!D[GI;M:W)O;\_U_UO=(=ZN[?$]O)_J_ETTU@LGP.#\CC_ &>E%C>U
M=@Y-?V=W8-V/XR"?PK_HH ^S6'FW;V_MI_#_ "_S=>;:+M."D_8:_P"'I-9?
MLF3/3U6$Z_492I!M6[LK[#%TG^  %JW\_P!>/IQ["^\<^)_8[9^<W2^/8YH^
MZ7'HHX_['4'!;7IL9.<G/5_Q;,U8_P OSE>+57/U'Y_V-^?8(DLH=S_7G^/H
MYBC-N-(X>@X=+OW?JG7#^S_8^O\ OO\ 8^Z>7ZW^K]G6_LZY^[]:Z][]U[J#
M*":8P_6PL;<_3VW>'Z^'IU!0U'0:8@_W*S%)MB;_ (]W+&VTZYA_P%-_W\8?
MR/\ ;_[S]"-A]!-!#_J_U?ZOM<IXH)\QQ'KZ'_-T)>L_U_-KV_XU[//]R/T>
MO:*=3O;G2;K@_P!/]C[M#PZ]T&^X-[3T>0_@N&Q'\5S--_P/O_P%I2>/WOZ_
MGV%MTY@^CF\'HPM;+ZH5)P:4]3TS_P 9[$_SO^_2M];?Y8!_O7U]D)YCEM_[
M'_)T8C;5\Z_RZQ_WFW[2"U;MW!92FN/50Y3^%GV<0\ZRP?[[Z:_=:G +?ZOM
MZ5^W]W4.?_R*(UU)D*0?Y?@ZZPJK#\<_[[_6X]G5CO/[PFZ*[BT,8J:?;Y=>
MW/MP;AH*2&"K^TR5)D/O\#7G_E%JOZ7Y]ZW"*D/C=55@A)/IGY@=-VT]ZT^?
MFJ\;64G\+W5BU^QSN"X-ZG\>$D_[#WK;[[_B-/U5[/0/J :KQ!^72AS>)Q&X
MJ"LQ>4I&J:=?H0/:J2WAO(>FA<FU->@YFV[O';XO2#^^= W-J[_<9E/\;$@?
M>C_8>P1?[!<'H^M]SMVX]I_:,?.G^;J#)N*6D ^\VENJDJ&^M%_"K_\ $_[S
M;V5&RN:]&(NX6&"*>O\ J/4B@VYE-P3TN9W+2G$[<Q8^_H<'7&]54U/_ !WR
M(^G_ %3V^O\ 7Z>Q/M7+D,WZTW'I!<;@%JJ')Q4< /E_GZ4T1JNR:D[>V^:[
M^[PN=V[L/%O^F*CM?\W_ !_O5S(7+>SWF^3?\)Z".X7XV\$M2OX0/\)Z&<=4
M];S4ZZ=GX(7M<C'$_P"\ W_WOW-</)FV4_W'Z!_[RE!^+^8Z3.9Z<PI1<CM"
MI&RLT5&JMQ^/_P EJ3;Z5E&; W(_)'_$ /[I[9V4OZT'Z+]&%IOKVN'[A_,=
M)LX_M+$J(YMMX+=5-8 UN"R8QEC_ +5#6'\?X?[ ^P#<\C;K9?\ #NA%!O=I
M>^9'R/\ L=81E]S1#][K3=O/Y_B-)_O?W'M)_5W<+C_B)+T^US:C_B4O[.N?
M\8W/_P ^UW=_R1B/_JCW;^KNX_\ *&/]7Y]:^JM/^4L?SZY0[>[*W+/X:BCH
M-@8\\C(-DQD\IZ?^.'^Z80?:^/DK==P_1_L1TBN-VM(@34N?2F/]7KTW[PVS
MB-A5NP:B %L-2UNY:+(5M>+_ .597C[RMG'U'''^Q]VYVY>_JAX'T723:+TW
M6O5QP:#T].EHCW_J;GV&/]Q^A0R])_<N)I]Q8FLPLQ)-61:O(_WO_'VBW.Q_
M>735M<&T-:_E\^@QQ^8GCG_@&?MBMPTJ_E;TM3_S>HQ^/]M[C)T^FZ%$$NK(
MR#^W\^E9_P VO]]_OOS]/;=?JNE6!GKWOWZWR_GU7'^JG2.J;;PR/]V\:#4X
M^DKL?_>RO' MC3<T=OK<\?G_ (K[66=B9YO#Z+[R81C0>.:?F:_Y.E+@!_>#
M=V8W!P,=M_\ WZ>!M_RM'BL]C2W'CWG1%='PU"CSJ3]E>A0(/"V OS];_3V;
M>%]/UOKTTWV_]2">!Q_3VJAAITV2"*GKVL3C_!?]I_U7^Q/]/>O!ZL%T]<?N
M&_U?_)O_ !KWKKV@==I]?]A[W#U;K#)" MS_ %^HY_WP]Z\'IU6KU&D@L+@$
M@?[5[3^!TZ)<>O33-& ?V3]>+@\^TSP_+I;":=);,5N,PE!4YK)U5%BZ#&42
MUU96UM\;2_:F_P"?Z'_6_P!Y]^^C\3]-O]7ET^C&X_1A\S]M.JS-[=F;U[@S
M^3R77J-LW87^X^AP>_LW0_?YF?\ A=5YO-A*'@T<,I_W?,"?]L;";E;ELV\?
MBSG_ %?Y_P#57J9.7N7(K2 ?6"I]*T'#S/\ J/RZ0^1ZLP>8G.1W;4[F[$R_
M K:[>.X:K)'C^D?_  %_V'L6O&PX]2%M=I#MV(  .  _U#_!TRU74W77A\1V
M-MRGX%JNCPU,)_\ ;\^TDZ'_ %5_S]"J&;S'[":#_!TG<=L6;:+?<=>;OW=U
M[7GG5M'/U0@-OZT-25I?\/K[I'XL9[6/3%WM5EN(I/;Q?ZO]7IT/>Q/EGN79
M=728/OW&BJV\H-%1]K;;QW^X^GU?3^/8X ?9 ?\ ':G'B_ O[,+;<))FH_'U
M\^HFYH]L/IH?&L/M\ ^GR/\ GKT?^CR>*R^)I<MALG1YS$9.C^[I*ZC'\1IJ
MC_$6O^?:[3J^'_/_ )NHFU&#$X((P?(@'TX]9)8C&2"+D_[#Z?\ $^REEITL
MAFIUBJH T!2UK<BX_P"1>WJ"8=/5KU%6*"#B*D_-Q9;?[S[1_3#I0*],.?S=
M!MC%93.Y:J-/C\71"LK*VLY'/^M;_#\?X>V[R_-@GBS=4MK#ZJ< ?9_AZ+PW
M;79.Z)S4;/VKA-MX( ?9Y?>:U J*G_6I8K'_ &['V +CG>^N<0?RK_Q7\NAS
M!RG8VG^Y))/F!2@_P']IZP#?7=V.5JMEV#N*FX#4-'CZC;M2?]A_Q4>V(^?-
MP&9R/]7V =&(Y:VE@1 )A\S0_P"?H4.N.SJ#?XRM*<95X3/810<SALUS44XX
M_/\ QP_VWL6[9OIWG'^KTZ".Z;5^ZJ&M0>!\CT*+Q^D\\CZ?[&WL3V?^?HL;
M..@/[,L=Z=)U$AM_O_Z]0/\ #^&5 Y_V_L+<PK^NI^W_  CH[VB3_%[I1_"/
M\O0Y6'G\WYT?T_L_T_U_]]_C[$OA_H_S_P O1-UQC^@O;[;CZ?Z_X]^C\7IJ
M:G^K\NDSG:[:,<=51[DK<'_#ZD"U!FVI0/\ 8^4V/LNO#9?Z+TJMTN"017^?
M08P=.=?5B_Q+8^7S6S,A4V++LO</\/IC_K4I/VG^]^RO^KMA#_N!V_;Y?ZOM
MZ.3S)N Q? 3CYBO^7_)US39O<N'L<5V7A<Y#S_D>]MHE*C_8U=)]?>I8-TM!
M^C<_Y_Y@_P"'I+]=M]V>ZU(^8;'^$5_9UV<[WSC>)MG=>Y\&W_%BW?4XWZ?]
M15/_ ,1[=AW?=+;AX'[#_GZ;-KM]S^)OV _X!UFFW;W7/^S#UAA:0C\9#L$M
M_P!<1_O7O4N\;K=_A/[.K&PVZU_XD?RZYI3?(')P"*:JZ]V?3CZJM#5;BJ?Q
M^"8@?=PNZW>/\G^P>F6FVVTR Q^PT'^'ID@Z(RPR-3O5>Q\Y2=CFUMR_PVDQ
M]-QQX?X>?\[]/];_ &/M(O*\IF\<3CQ_V=+9N9@%%L4_Q?AIXX'SZ?HMZ=C;
M298NPNOZW<2TX)_O/UZ/XE3GC_=N/EM5P_Z_T_I[6F^GA_W(R_\ J_U>716+
M&VDI],1&/0\3]AK_ )^E1BNX^M,F! -T4&,F/UH\TM5MFI&G_&K)_P!Z/M^W
MYKL./CE/V]);C9+\?AK]@'2MJ=Y[>CQQJJ7+X.K%K'[#)4K?[S]?8EAO+>Z7
M]'_-TFM-OGGFH:_S/^?HG.]M^Y#?DU5B,!45N,VTO^1YC,\?<Y&W'BI/IX8?
M^;__ !OVW)((_@ZF;9.5_I,S@5\AY#_57IGH\?!2T])24E,*2GIO^4+Z_P"M
M_MO;/0N\J]/<5+!#^E>!_7G_ (U[UTBZE10B47 _WGW<(>J&<CI\I:6G'^O;
MBW/M:MOY=%<UQTIJ2D@_PM].3_7_ !_UO=H+?_?O11//TE-IY+-?'+*5.=P=
M)69WJ'*5OWN]-DT;$U&&L?W<MB?I>E%O\NI/]O\ 7@MW+:M6$_V>@#S!LPW:
MG@T#>1/ GT/^0_F//JQ3;.XL3N_$8G/X&KQ^1Q&>H36T5=1K;[FG0$'BWX/^
M^%C[ S6?A/HZAVX_Q68PGR_D>E?X_P#'_>/=/#ZKUZ3\?['W2;KW4SWKI/T!
ML1_B&[MW93Z?:UV/P8_/_%KL?^(]Q9O3_K?ZOLZ$NWPA5'S%?VY_R]*&/Z#_
M %F_XGVC/'I;+_DZP>]^+]G3W7$>KDVO;_7 %_?IOU.DX/U'7+K$:-I4I-OM
MZ3(9&AH#;_E%-7;_ %SS?W('+7ZEGCH/WX\!L_;^=*=2]A]<09_;%)N?"YJM
MVIF<G7Y*L:NH7!^ZIA63D":#\7N/]X_KQ(G+/M]9[[#];\$_^3H*7^\&S8QD
M!EQ@C@:#I5CK_L-0?MM_[>?\VKMF*#_O%3?V?'V]W:7]$SQ_S/\ *AZJ>9;0
M\5;\B*?X1U.7JO=]4E\CV15+;^Q@]O46,'^-^90/;\'M;3_<F?IB7F-0/T$_
M:Q/^'IUCZ0V9*+Y9LENJPM;<%><A]/I^!]/]?V>6OM;86O&O[.D4_,MS/PH/
MLQTLL3L+:&"%\+MW XQN/51XP-_MB+<^S^WY1LX/^(T?1<^X._%B?V=)O>_7
M"[CBI,OBZX8/=6+0?99P ,"+&\,P%R8;6'YX_'LAYMY$AW_I78[F8#0BH/ET
M$$NXI\0IP?8^&_A$]6%M7Z?XGBZH6!'[WX_UO]O[A'=MO_=9\&\KT-[:<7F8
M_+]HZ@)L7;=6//MC,UV"/Y_@&3_B=+_U)!^OY^@]AY]ILKG^QG_/HQ@W&1/B
M /VXZQIUY4Y$+#FMW5^3QQ'-!08T8S[K^OF\'U_'NJ\N"VKXO3L^Z'!TT_/A
MT)M-0TN.IZ2BHJ,TM+2'_(OL>>".0?\ 7_Q]B.SAA@_S]%9.JI)^VOEU($PL
MHFT_<VMQ_4>W_P#FCU8#TX=!QG-Y5$D-;C-HT393-TM#DVKZ\'_)L7_"_P#E
M=E^E_P#FW[+G3]X_[A_K?]8NMR.(S5^W./Z1/IU(ZYH_M-I4DTX-7496^>KJ
MXG_E*R?'^W]L[7#]/#UN].INA!_W=_R#:Q_/JM[-S%X_7O+\N@U[%?[J';F%
MM>FR><_R[G_E%Q=YK?[:WL*<T7/TX\+I?M4.2?0#]IKUQ)/X5/\ 6(]@F%/I
M_7H\,-?]7^QU[W[K77.;Z-_P1/\ >Q[O#Q'5#\72<S)^TR^W,S!S4TF?QV/]
M(M_DN4_9\/\ L>?:BS?5/^SIBZ@JI'R/0[<(/S]?<C?#T&_CZ#3>N2GJ_L]I
M8:K%+D=P'[$UZC_@+2C_ (&S?U^@Y]I]PF^H_1Z>C735R*TS3U/ETK\;0T&*
MH*+%TA^UIJ7'_8C'_P"O;G_>_9CML7T\/3;5<U.<U!Z?O;W3?7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7 7L#87_P_P"1^Z>-]/\ V/\ EZ]T@L)(-I]B
M4E+"RTF$[ _B.JA;TC^)XOG_ !%JS_?<>SWD2XAV>]I_O[I'ND7C1UXE*9]
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M\$ ?[ #V&/ZY[G<04_33_5\^C<;%$AXD_.@I_@ZS4O;=?A)[;YVV<53'ZYW
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M/=G77:&W/[R;7R,G^XNML&>*6FFB+E164<ZM1U,8.E)+&[(1=O2* CY_ZO\
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M?G_BO_%?:6ZLS?P>#U4/X9!\SY>N.D]L_/U\HK-O[@_X^#;_ /P/!Y^ZI?\
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M8X6U#=)..JA_U60 &W^/_(O8EN?;J\M_['HIMN8(FXBGV9'[.HL-'VC";?W
MH/\ $'<E%_O5_93)RMO;?Z!_J_;TK.YV7\7_ !D]95P_:M6WC:AVEM* <C[_
M "!RM20>;7@N#[O;\B[[>']:O[.JMO=E:Y!)_P '\^G?'=186IG^^WEN7.;T
MJ/QCZU3BJ87_ .F*(7_QO_M_K[&VU^UUG9_KS]$]QS"UQVH H^6?\W0R4F+Q
M^)I*.BH*844-'ZSCZ#U#U?2]K&U_\?Z>Y&BL8+?'^'HB9V?I2>S'IKKWOW7N
MF?VGZ4=>]^Z]U[W[KW6;U_[3_O/MKZ@?/_5^?3./GTVY3#XW-8VKQV5I$K<;
M6:C745<2!];\?BWT/U_V/M/>6<.X0^!/_JSTZDC1M5>/0'U?5V9V_JGV5N,C
M&Z5;^[^X/]RM)ZO^.$X_RR(@7^G/N)+_ -L_ _5LY_\ FU^?0FMMZ$F''YC!
MZ3LVZ\G@BL.\]M5VU:GZ&O:^3Q?^'^6?U%_^*^P+?Q7-G_R4(-'1W;S6]Y\9
M##]C=/%=08+=-!2"LHZ'<%!5&VL"W_$_BQ_(]E"6$-W_ &W2N",VM0,4Z2TG
M7'A_XLNY,]BJ<@?Y !_$_P"G_';V27G*L!\NEZ[RWR/\NL(ZY@JB8<UN3.Y2
MFYM1 ?PNEX_Y8\>_0\MPV_\ H_7AO!K@#[>)ZE;BJZ#:.!_@VWZ:AI<CE+4&
M$H*#G_*<G_N[Z#_#VKO5AM8?!AZ9CE-VVHGYFOIG'2IP.%I]OXC#XR,V.)H+
MCC^O^?\ 9G9VE8?!Z9=]9)/F:?YNH.X-VX_;,%*)[5F2JR!0T-"/\JJK?UXY
MO[9OMZAL.KVUH7K_ )>'2"?(;TR_[L^8H-JTM[&AH!_%:KC_ )O?6]_]];V#
M+WF>\OOT8/\ -T;PVB+Q%?V4ZPG;)E%JW<6[*L \#^\=_P#; CVA-U>C/C]+
M/ 7R4?LZQB#<F 'WN S&0RM/Q]]@\\?XK]U?_CA-_C[M:[A-;S_K],7%LL@_
MP$8/0J[>S]!N'#4V3H_^ U65O?\ 'Y_I]?<DV-Y]?T1W*%#GI\T-_3_>?:KK
M>L]=R4ZRFVJ_Y_(^O^P/NA;_ %?ZCU5)]/ET'^]MW;;Z_P 'E=T[GRE%@\/C
M: )65=6-1-S<6_)_WW^-JP6;W,G2NQLYMQF 7@?3JN[<^4W7\CJZDR&Z*2IV
MATUBZP5NUNO@?X;49JW^:J\U_P!,I_Y4K\?[N_!(ZV?8V$7ZO4P;#L,&Q^A8
MBA;C3UITKFQD ^@!%K>SR=?!Z'L-Q08\^F&KH.;_ %_XW[2NG1Q%<4Z34M%;
M\_ZW^\>V&7R/1I!-TP56.'XN1_3VF=.C2&XITG:K'"4>(\CZ@GVFF7P>C6&<
M ?+I ;:S/8'1V;J<IU(PJMO5%6M;F>I*RO\ ]QU3;B67#\_[B\A_BO[,W^MQ
M[5).Z1ZSA?7_ %?ZOMZ"?,_*-ES%#XQ_MJ<:9_/U_+]G5FW579FU>W]GP;PV
MG4"HBGM15=#6M>HQU1CK-5T%5$.6JZ7D@VO]3_KF46DK1?\ 5Y?ZO+K&K<]L
MGV.<B?\ XOYX_GT) AN:H?ZF_P#C^/\ ??GVFN[?P.O"?^74?0?\?]L/^*^V
MO$Z?\4?ZCT6WY T_EIM@X^95_@]3V!C5K--OMZG_ "8_:?UX,MOI^1?V"N=C
M2"'CY_X!_L]"GE#+LV*Z1_IADU_U?+J$T(E%D_X$ "U_]M_M_<>VZ]N?]7#H
M533?KT'670?KQ?3>_/M-X79THK^OTC,,#1=P["EH_ID\/N_"YA1_RK8P7AO_
M +$?[Q[$G*LU+R#\OYU_R=)=]&JU8>A!'\O\O1NM/%K_ $"G_>O<J1?VOYGJ
M/"V.@'[5A\&;Z=EY_P"9I(M_\<GC)C_Q7V&=_/ZUL/E_E'1QLG"Z^P=#?H/V
M]O\ >?8V_P!#Z):YZ 7MS>>9Q/\  -F;4 IMS;F_B6K,@ ?P[&8W_.U5OIR;
M_;W_ -[]@?F[FF;;E\*#_5_J_P '0AY;V];N8M<9'IZD]!CB^M-KPP&MR%*N
MY<M4FU;FMSC^\5145/Y'[QM_L>/<:';VO_\ &):CY#'0V_>&G] 4 'EP'6.7
M85/AY_XQL"IJ]CYVF%Z+^#DM35/Y\-72&_\ Q3VQ!N-YL$WAPU_R]-&\%Z/
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MDL\_KTI:2@+?4?T-O;X73T47%S7IZAAT_P!;W-A?_D?]?]]^%BKT43STZF^
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M?7\,=(X'^ ]A=_:[Z?\ W%N!T9P\PKPN%_WG'6/^Y?9!/[V[]IGZ<C;E4?\
MXX]L#VMW$_Z/_AZ4'FFT'X3^T?Y^FC-].;GRE%HK.QZRLR6F[8_^'_PO&5/]
M(9O +$$#_7OQ;Z^Z[C[1SW$/Z$_?TS'S6J'X,>I-2.N.*W3CMD8\;7WOLP[
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MZ]U#G_W;_P @?\1[W#T\G#H-=T9G%8O=/7,V3K:+$4])75^<KC7<VIL727_
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M_)$W'_F@/^/=&?*?_)2M/M_Y]/3S\5/^R<NF/_$9[)_]Q#[/_8G_ )57;_\
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MR=._.7P@="&9\F&#?4@R77B]O8DY-WW]RW'B-E&RPX54\1_+Y9ZAGWP]M?\
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M#N>W_P!O/XW2VL4OD5)_,=91V;4T0MN+:&[L59;WH,:,I_C_ $L+_P"M[O\
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M2HOJ::I'T!/U(/\ C[CAX_H^A:DWC_S_ #'2ELW%M M>WU/U]I(DZT8@>L(
M'T]VF'3_ ((Z8-P99:+$UE2+-4L@Q]!1?UJ<ISR?J1_3\>T%V2Y@$WG_ &5/
M0=(KF+P.'#SZ$/"T7\"VUAL;D6^V&)H-5=?U6_V/^O\ X^YBL+4BS_5QT%+A
MM;D@UKPZ>>KL?_>+/YCL!U-/C*C')@MO!CI^YI8#JDJ[WX#D"PM8<_TYE3V[
MV V?^.?9CH+;_=>*!&..:_*OE_/HP'VG_-S_ ),_XW[E?Q.@UXG6/VYTWUQ]
M?^T_[S[:^G'S_P!7Y=6Q\^I7@_VO_DW_ (W[4^'U7J1[<Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4;[<_ZL?\D?\ &_:/Z7_57_8ZWCK#/'%.
MIAJ-/@TC^V4O;^I_'^W][=(KGSS^SJPJO[>@4W3T[M_<N3_O!15N0PFXS9C7
M4Z?Q%/S<F"36G)_H1[ &[>WL9_L2?YGHZLN8#&-)H1^P])M\+VMCH/LZFCVI
MN6G*\S4N2.,F(_X(UEXM_J?<>R>WVX[;^M !+]G1T-YA<^8/V'K!2X/M/(0"
MD&/V]MVDTDB>OR(R<UB?]3!Z+_[#_>?;UORGNTTM98"/G^SI0V^VB9#5/H/]
MGI#[*VO#3;PW3FEFJLHV/TX""KDC6F62IB'^6"-4TA@MN+_CV!8]@FMMRGEF
M_ET<?5!D4#'G^70PS$0"W-[WY'^\>S+QAX'C?C].DM/+RZ ?;S_Q:KR.ZJJR
MSYIP]*@.D08[\,UN&8_U(O\ GW$5Q/\ 4?VV/6G0SC@\,4'D*?,GR'2JT+_3
M_>?=-9Z5>".LVO\ WVG_ (W[KI/SZUX/71D O_K#_>??G\_SZ;E&GIGP32XO
M?]7CF -#NK'?>!OJ14XOFP/U %OI[$W*M]X,W13N4.I-7I_@/0N+:J6R?Y+<
MC3K]7T_U_<CC](_K?R_U?+HA_P!QAT%W:';6T^G\%_'MS5 2HK8WQN%PN.;^
M(9+)3D_M4>/HQ;S5-R;\D?X>WH-N>X?I98;=-NDU /\ (!QZ(G2XO<N_]ZT/
M;79]&E!F,3$:?8^R<-_E$.#I$_S,>0J(],V0R7/^;#Z?ZCFP'^W[1&K>-)7R
MX5ZE_:=K_=L'AJ?F2>)/R^7SZ%G0?\/9CH/0DZ:YX+_3_$>ZD4Z4PS=,M72V
MY'*G_'VG(IT8P3UQTP5%);_D=_;+)3HTBEKTGIZ4C_7X%S]/]C_O'M*R]&L,
MW3#4T9 L>+?B]_J/;#K7HTAFZ89Z( ",<"P^I_I[1SP4Z,H+BN>F/K#<C=4=
M^;?W,9D3:_:S4/7FZB\8E6DR!8/A:U78AQ&) ()TU!;W:U_9G9CPY-'E_J^7
M4=^Y.SG<MO,V?$7N ^P4(I49]/M'5M<V/;[DSFX_4+CZ&_M2ZTZQUAEZ:IZ;
MPB][_3ZG^O\ L/;(M#Y_ZOY=*C?T\QT&W8VQH=^[7S.V)*K[::6%ZJ"I_$$U
M';[5W']I6O<CZ<>R;?MO-S!^?^?HTVS=OI9P:?ZC2O1;\+O T=6,#O"E.WMY
MT<20UE/5<4]0D?TJ:-@;RB3\ &WN$I+*6TFK)P_GGJ3H9A<BJY'RZ>JW*;:P
M]#55F3R>.Q<%.; 5F0%Q_MN>?>Y9?%^#JR@VU/%_EURZEPN5W1NG-=@Y6GK:
M7!KM_P#NYM..MHOX;.Z2?\#*UE/#)SZ 18_T'L9\FV.F7QC_ *J8Z).:[T:?
MIXJ5K4^>2>C/>*/_ %/^\G_BON2-!Z"/0(]N0?O]4R$V%+VGMM2/I]:0?GGZ
M ^PGOXH+4_TS_DZ-]GES=?Z7_/T,S0_LVO\ 1;?[;_??T]BF$5%>BX-4TZ*_
MVK03T':VRLK);^'9W:^=VP*S\?<7%7'Q^+V ]QGS>FF0^+_J_P!5>AERK=U6
M@\B#_/\ V.GW[.XN+@$<7_Q_WQ]A-=O_ 'DGZ71C"?IINNY,?!+8 G[D6 &J
M_P#QK_?<^]Q;M<6W&$K^=>MB[%SPZ9=@T(J>X\[44/\ E,.&Z\HL/EVO:U7)
M5&2FB']"P)^GU]B?D^"7ZOQR,%/+TQ_E Z*.8=Q MA#YUQ^P_P"2O1JHX@;V
M//T%S_OO]Z]RC$M#T!O&!ZEZ!_C[W].?]7_%=,^*.L?VNJWU-_TCZ7M]?=D'
MGTU<3TZ<(:0*+*>#^?K_ (?U_P")]NL-7226?ZGJ?%2DU(FA))  _K]/:M$Z
M2S3>75=/:V9D[#[-K*F'RIM[KW(S[9VW3"-0*RLG_P"+A6SRV\B1@V\2A@A_
MI_5*XHY5_P#8ZG;V\V@[7;":7!(J<Y ^SK#''_A_C]?=O (X5Z'@N"W3C!2<
M6YO_ (?3C_??[ZWNRFO22:6O3A3P?3ZV'/MP"O2::7SZ=8*4\Z>+6%S[4+ :
M](9IL=*6GH_ZW/NXB/15/<=.L2_U9. /H;^WBA'1=XHZF>]IQZ;ZD>U&@](M
M9ZD0?V_^0?\ B?>Y.J=!/CJS-]([KS6^-LTDVX]C;FK*:O[3V?3QK+7TQI6/
MBSF*E8"24P$#[BA=CI_%@;@/;UL3!O%C/G_J_P /Y>?0;WS9XKV'2V" =)J:
M$GB#_D/GQ'5A^T]V83?FW,/N?;^8HLKM_,4 K:"JHP;U!_H ?T\@_3V!+JV5
M/AZB&:WFLFI,*$?Y>E/'';_"P ]^Z: KT'>Z]H5%7D4W%M^J6FSE#3AXVK@&
MIJB$_P"ZU/.EN/K?_8^P=O>P*P\:*I''/1I:W<E-)X$TP.!Z31RVZJ2335[*
MW$M9;]>.>ER,'/\ M2F_^\^PLNP3*:C_  ='+7D;X)%/3(/7H<9OS,P^!*2A
MVGB +&>L/\2J+  _HX7Z_P"TCV[9\M2S]4;<8T/F3\NE-34NV^NL!)'3FNC6
MP4R1C^(35]0M_3&E]*"Y_LJ![&EG9P[%^L:_/SZ)9IGF.:'T\J#^=>A ZWV5
M6T%55[WW3:'=FXJ6GJJJCC;QTU##2@B*F!M^Y(@_SQ8DC\6^ON;N2>439CZN
M8_JS>7\^'0'W;=!<#PT^%<?,]#;[DOH/=.'M1U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>ZC?;G_5C_DC_ (W[1_2_ZJ_['6\=8:R&*I@$
M3PF>G('"2:?\!8A@3_M_=KB#Q^K*VD] OO3IO;&Z[5;>?&YME-31Y6.K95-0
M/P::9G6UK>FWT/\ 4>X\Y@]O;/>P9HF97]"3_EZ/+;?[B 4(!'V=(2JSNY]I
M++0[ZQDZ4B>J?=>WZ!LC227M_G!<?:\<>H'_ %O<:;C!<\L_HO"9:^AI_@IT
M)K>[2XHRD5' -CI18C.4>XHB<97T.7@^I./8WX_US_K>R!;GZWXOTOMSTH+"
M+/29W+U_A]QUL>06IK<;EX@!'51 3Z;?3RP/J ^G^'LJON6XKG^R)X_;T8VF
MY-$,4/RX=,$&U>QH/VZ?+[5R4'_5PQM9BC_O'LBGY8DM\?ZOY]+?WRIR01^P
M_P""O6*3K_<>X$-)NG<T+T1L?X;@,0*93^>*RJ! ^ON^W\JS+_:#IN;>%CRJ
MT^9/^3H4,9A<?@\>:.CAFBIS^7<R'G_%B?8RAVSZ:GA9^WHJGN#='/\ +H.<
M\\V\,_%LV!;8C"3X_+[GR' T2,?VJ!#^'/\ JAS_ (\'V37L/[WF^DA_V>EJ
M'PAK/$U '\Z]"GX((@/%_J"?U$^SZ+^Q'25:UR.DUE]V;;P*F+*9FCIG-B<<
M;FH/].-5O]X]HKS>8; ?\7U1;1G..'KBG2?F[,IVC\5-MS==:O(^[.,&,'/^
M$X(]D1YH3SIT:?N2<'B*^F#_ )NH)[(PU++Y<UA,U@(OQDZV.U/_ +%N?=UY
MA#\!_J_9UN7;FM_,'Y>?^'H4Z6>"HI?-3-]Q3DFQ''T^O]/H?8II]0/T<]%;
M'.<'K)I3_4G_ )*]VT#KVL]=:%_I_O/N_A?+K?B==Z4_U)_Y*]TT#K6L]>T1
M_P"U_P"\>Z>".O:STA-R[DGH*VBQN I#EMTU'./IOI!27X\]6PL1#[*;K>81
M^C7I0(M0);X?/U/[.O;8V92XB6IRE?*V0SM82:S),QI8H_K_ )B--*2<_P"J
M!]NV6S2C]:8<?Y?LZ;DNM6%P!FG&O[1CI?$$G_$\<\?3V>S0F$YZ8Z]:(?DC
M_$_\B]NS3"?JPJ.@YR^U)(LU1;VVQ4IC]Q8P6C^\_P IHJP/Q:4->2'ZD>AE
M_P")]D\$]WMTWC0@?F/\_6YHQ= H^0?R(_9QZ?J7NJG,KXFNV_GZ;>#(3-MB
MAHAD@^FW,<X %M/))-O\/8VM?<5#^A**/6E*=$-QL<L0U @J!75UFJJ#L7?,
M+T>3IJ?8VWL@29(H(1F\C6%1>Y#7@HQZ1];>SJ6SN^9(@6 BB'"HJ9/LKPZ0
MPSQVO])AZX _U4Z$S X&AV]00XW%QRQT]*O@I6G9G,U21^M[ZBB\?06'U]BG
M:=LAVF+PJFOV])9;QI34TS\N Z4G@_VO_DW_ (W[6=-=);=5-/+M?<=/16,S
M8/*BAU>KZJ?K_7V2[T*V=Q_J\^EEHU'7_34/VT/0#[$EIYME;<:*Y@^S740;
M_I_SW/\ @;>P%:K*R_HT/V]"V6GA&OKTK]0_WQ'_ !7W[ZZ'_5_Q72.C=(SL
MBTVR]Q$?B@_B%_I_RF^RO<-M^IF^LBSTJKI-.C&8LZ\;12R'34?P_%DC_8\"
MWT_K[E[9;OZFS@J.@C<C2QIZFO4[P0_ZI_\ ??[#VL\<^G6N@DZ['V.X.R-O
M,;FFWB,[J/%Z;<]^?]< 7_WKV#.39/H[V<]*+^7ZI$8>:T_,?\5T,W@_VO\
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MF'$C'F_!]E=SS)MVWR&"Y<JS<5(-,XRPX?X?/J4N3/9SFOGZW\;9]MG:%?\
M1M):IXX!&?\ !UJQ_!GY=]"]0?S%^Y?D!V-OEL#U/O>H[YIMK[N?;F2KWD_O
M7FZ:JQ9DI8:1)T'VOJ:]/_P8?2\$\J7MGMN\2SW!;PU)90--:,6%<$GKJ_\
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MHH],HC<JMQ'R;^[DJ02!P%1U41LA",<$CR_XKAUIT?"CM?YM]/?+#N#^8O\
M+W^3Q\^>[OFQW%49?#Q9WKRAPVP=C[5VHB*F,P>&QJR1S9&J2BB1:FNRE1-,
M%$;JFH/+/X(]31&K]C8K^77C*@ 9G4*!3BN<_P"F'5UOR?Q7S _F_?RS.TL)
MLGHOLKX(?)#;W9F-R_5_7GR7BPYGW!/UJM+D8FF>.DJ*6##YA:JHI(JE(%\=
M1$',K1%BJ<Z8Q2A6AP#Y_M Z4#7$M:@@C)%,9^1/13>^OEC_ #??GA\<=R?
M[&?RI.T>A.[^W=F3=2]L?(GM;?&#CZVP-)E8C0Y_<.*E@1JG,*814BC@A,I5
MGB+1SGCV_4E/A.>)S3IEA5M.H$#@HI7(/H2?]6>E;W#_ "^NV.E_F_\ \)X]
MC]3[(WKV;TU\']I;SV!V'VW0X])*2@I<1M9<?25N597?[1*ZJ)T^B]C9;VU%
MLX_+B:8ZOK5BN::JT%<^5/MX=6M?S8?Y?6V?YEGPF[3^+V4R<&W,_5O)N[JK
M<XK*K[?'[DVX_DP]16QP.6J:*6:>2"I1D=44R,%UQ@KJ)Q*E/,9'7GKJ!\B
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M;3>3V<O\NA_#.)55QPI0_*GETLZN(3P5E%"0&J: @&]_Z@?[W[+9;2D/[/\
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MZO\ >/S_ ,B_I_OOSIET].P3UZ::BDU_ZQM_C[;(KTOM[GIDJ*$#Z _UM?\
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MLK*NU'CJ46R '^'NDUP3U1;>OIU%V-M>?<61_OYNBB%(  =IX'($DTE*2/\
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MUU8VC'T_WCV]>6=D/['I2':O^RW26K=B;8-2*W%T=?M_(@ FOP'^XRQ_J?\
MD?M+#8>O6PIX$@_SZ1^:FW1MO=6W<]N4C/X>CH<C@J[.T7-524V2^G\4_I8G
M_;^R_<[VYM[VW\?_ %#JUM';2(RH*&H-#P)%#CY?9T-T=33S*# 0;7'^M?V?
M1M0=4*D<>@_WM_P!K?\ 6?W>/A^?^7JC_P"K]G52WR&_55_['_B?9[8_%TD_
MT7]O^ ]%;_EO_P#;TS&_^*Z[U_ZW4WO)':O^20GVC_!UBQ9_\KM<_P#-%_\
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MH:^9'4'_ 'K]M@YGY,&Z7H)OK2Y_M_6*J"IQ6IU&N> '6UY%IFC-[VUG^G/
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M?/[>Q2\?_3=9B\OC_$;<?\*_;7IXEN/2?4>2?Q];GV5!?$Z-O'^G'6,?5_\
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MC[$UVQ@'2#CUS]UZ]UQ#7%[?FUO=9C]/U[CTR9_<&*VU1')96K^UIAQ_K_\
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MT'_#VW4=+M8ZR^V]!Z:Z][IU[J//_8_Y"_XCVY'U[J/[<Z]U(\'^U_\ )O\
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW25S?_%GR_\
MVK\E_P!#-[I/_9'_ &W2BP_W)7[5ZTL_A=_S*G/_ /B3.S?_ ':U/O&3:?\
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MGV])!TEGG].E*D(_H"1^2/\ D?O>CHH\;H"M]]>[AQ>9;LSJVU-O"FM_&=M
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M6^O]OV_ZO\'4<^XN^?1VO@>;$ ?Z4"I_U?/JR^66_)N;G_??[#V=-,3PZQ_
MKU',U3#^+\_7_>/]M[9\?I6%!Z4E%N.JI1X)K5MSI-_]Z^A]K[;=:]%]Q9!C
MZ=+:DR-+6J?!S_B!;_BGL^@W#5@]%3VI3..G3V9],=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=1Y_['_(7_$>VY.O=!GO386(WA3T-1/\ ?8G,
MT8 PF=H%(JJ0@7_%_P#&XY/]2.;@[F#E*'F//^K^?1I9;BUCCB/,'SZ ^IK:
MW&#^Y?9M%CUH:K2*'==Q_#,G?Z7M_P  JS_&YN.>;W]P9S#M1VX?33P=#2TN
M1(?J8SGT\Q_L=1I^OJ_&G_?N[CR%+2GD8[/XS^)_[$_CZ^P._)LV[?[C3]'4
M&]B<?XP*_9UA.S=[7\,VX\#_ $M_=P_\4]U_JG>=.?OE/0_ZOSZECK2&3_CX
M,Q7;@/\ 9H+?PJEY_P"6-Q[5V'+4UO/^MTU/O>K@*?/SZ$.CHJ?'04=%1T9I
M*:E/V%!_#R#_ +?^GT/L1>##Y#HJ9N-?M-?3I Y/-5^ZLA68#:55]K34O^0[
MJW8H(^U_Z8Z+_IL]E%T/J/['I4 (\L*G\*^I]3\L_ETML+@\3MZ@I<;BZ04M
M-2_0_P!?Z\^S';K3Z?CUIW9ZDD=/OM7TUU[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=<'^G^Q]VAX=>Z#/?LPR4&'V73<U.ZJ_P#W($?\JV,M][S[)-TN3=35/3EG
M!]-5J\!0?G0]"/!'30P^"+_,4E^+7^G/LXBIU6I!^9ZD>]]5Z][]U[KWOW7N
MO>_=>ZQFUR/P/^->W?%^GAZ]TEMUP"NVSN*A%Q]W@,E]3_3Z?['CVFE[(?'Z
MLI$Y%/4=(+9=5-O<XG<U<+X[ 4&.P.U1I_Y2N!690_X\#\?0?['V5;?N<^]?
M;U>6W%A4 5K4M\QZ?YO*E>ADAB$2V M_ON?9U=U7/39/6;WKK77O?NO=>]^Z
M]U[W[KW7O:CKW00=K;:FRN!J\UC#_N9V_1-6G\?Y+S-X?Z7%O84YBLZ6?C0_
MZO\ 57I3;2A6"GS-/M(K_FZ$';F7@S>!Q>9BN(,G0"N/^^_U_9KMLIFAZ;N!
MI8CTH.G[VNZ:Z][]U[KWOW7NO>_=>ZX:!_C[MXPZ]T'N\)/\AJU'T%A;^MC[
MVEMX_7I;BE!U2S\EL#68;,97<.T"9%DYS. '--6_B\1'!JO]A[<@M9+6:D?[
M?3K9;ZI<]%^_EIY.ES7\T'#9&C]%(?CKO<'D?M<4_P#7^AM[RHY:?1LB?:.L
M48X/^1K<U_WR_P#QX=;;GO?4N]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)S,_\ %HRW_4!6_P#1?ND_]D?]
MMT]8_P"Y"_:.M*KX6?\ ,J<Q_P").[._]VM7[QFV[_<?_;I_U:7KN3S/\=O_
M ,\X_P /1Q/^4;V]Y_GT&.@_ZA_[>I? W_J%[A_]ULWLVV'_ )*5K_S5?_!)
MT%/=7_IW>_?Z5?\ M(MNMICN'_F578O_ (C_ 'G_ .Z>?W.<O^XTG_-)^N3G
M+G_)2M?^>N'_  ]:<OP:_P"R9]E?]K+=O_NYKO>.EC_8#_FY_A7KM]SW_N:O
M_-&U_P".+T<0_J7_ &/MR/H*OPZ9OBU_V]H^-'_B#.YO^M;^SOE?_DJ_\VC_
M -6INHO^\1_T[Z7_ )[F_P -IUM=T?Z)/]C_ +U[GU_\W^7KDS!TX>V^E'7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1Y_['
M_(7_ !'MN3KW5('\]M4?XJ=9EO\ O)3HY3^/^4FM'_%?8IY6C\>9S_PM_P#C
MK=0K[XDKM=L/^7ZS_P"TB'JSJOZHT5-5D]F9C^Z^2G_RJNHFME<75$BS'[,?
MZK_!?\ /<$;Y[=Q;I<?503TKQ%1Z_+K(O;^8/I8?IW6M.!ID?GTVRX[MBB;[
M>;$;0JF"_P# _'Y2JQ/UO^?MA?\ IP?8*@Y3WVP_W&A'[?\ 9Z-_WGMC?[D$
M_8<](7>D78=+CJ&E.6P>*K\_6C!X#'X.,Y V/,_GF(%H:>_(^H_/L*\W\M[K
ML4,^OXY^C+:MPL[LU@J0HJ2?+I&;HVSCMM[<JL;B[^?ZY#(5W_ JJJO^;PN>
M/\?;.Q["FT)^O\?2^\EGEBQP\NJ>OD%=Y*K_ %R;_P"^_P!?V.-J_P 6Z()#
M]2.KV.H<QAL3TCT]/D\SCZ5O]%G77&1RA%O]Q-.?H.;<^Q5+NL5N/[?I!):E
MW:BGXF\OG]O2GJ^U-CWN<N:[CZT/WO\ O-S]/];V6R\X[-9_VW3Z[#)<C&/V
M=>_TM[5^D-#N"KM>PH,8!_M_][]M2<UVW^H]*8-CN0.(_/\ XOI+;ARF?W[0
M?W>PVSLAB::I6_\ ',XIQ?VH'UL/K]/\3_M_9#N%Q-O</Z,'2I+9=O.IFKC@
M,U_+I<;!W/496G_AF3+4FX\0IH:ZAO\ ZW[_ /K^Q-RGO/U$/@S0=%]_:!3J
M!P<U_P G2)^2O_9/?<O_ (B;=O\ [C+[#ON;_P D3</^: _P]*>4/^2E:?;_
M )#T[?%7_LGGH_\ \1IM?_W&'L4>QW_*JV7^F/\ A;HFYS_Y*LGV_P"1>C1^
MY>Z#77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T5#Y/\ Q6Z+^8O4^=Z$^2W7U%V7
MU)N2NPF8W+M2IRU;A8JFKP&06NH-4V)JL?D/1/!$YYY!%G-C[\"!AA45_.O7
MF4N:KC%/E3\^@9^4?\MSX3_-[9O5G7GR=Z9Q_;6U^I:G_C'6,EWIF]LC$21T
M(HC*DF%RN,F?_)J>*W^U*I^I-[>)2@;-.'R_8?EUYD5ZE32N3@9\_,?/HFU/
M_P )SOY--/605=%\.*&DJ\=78ZIH&'>79(O58W47%WW818K8!@#_ *H7^AKK
M7T_F?\_5?# \_P"2_P";J]6GIQ " ?=%6G5R:]-M;04V3IZR@K2M52U-!]AD
M0#;D F]A]#ZF/^'^W]Z.?V=6#:34?;T6CXR?%;H3X?\ 5T/2WQVV#3==]9T&
M9W=N6BVG1UU?E4@J]Y5YR&2+3Y>HK:IUJ:W44 !]*+]3<FS$$4 Q]O\ J]*=
M54,AJ>/EZ4_+'G7IOB^'OQ\C^4-9\QH.N\<WR7R?5L'3U7V9)E*]IO[K4M8*
MTXLTGF.)\OWR*1:BOZ0;<-JM45U>?^?_ %4ZUI8+I\OL],\:5^?4;Y4?#[XZ
M?,_KVBZ@^2VQ:'M+K2BWEM3>\6U*C*U^$@DR^U)9),<9I,76435<:@S(T4G[
M;AV#E2UET*#!X5]?R\NO-J8U7T/E7%:^=>C9T5%1XFC6AH5^TI:2[$L1:UO]
MC>]Q^/>@*=;)U=$^SOP=^,VXOE5M#YJ9#K2%_DUL#9N8ZXVQVS2;DR&#G&&R
MHF\M!-CX*LXC(&%IIXPU7C[QJY5+A5 <\5&.KS^W_9ZJNK3I\OL^?V<.CL^Z
M];Z][]U[HKFR_C%T)UMVWVKWKU]U/L3:7</=PQ?^ECL;$8(1YK<)VI&#0_Q&
MJN6=J9E5@&A74P0F[6/O8(4D@9/\_P"?6F#.H4G _EY>G1+JS^27_*4R^0R&
M5S'P(^,^4RV7RN4S&5RE?UM2))+/DZYIJAG$:+&BZF=0;  7^GJ]ZU#T_P /
M^?J_;_%_)?3HT/QK^$/Q+^&V-W?COB_T3UKT70;TRN-K=YT'6^(3;HRLV-B:
M&B^X*@672S$*EEY)^ES[V9$_"/Y_YSUI0Z_$:_D!Y9X ='3]ZZUT67>GQQZ<
M[#['ZQ[BWQUUM[<_9W2=;F:SJG?&6Q"25^W_ .^R"EK_ .&R1N'1I(5(E 6S
MM9E YU:-&H3Q!QY>?^3RZ\NI 5!P>/GY?Y1TJ^T^I^N>Y=A;CZM[*VYM[>W7
MV_,7-M[>FU,[C&RE#E*+.HD9@J #&98I"H;6KW6PY N?>U8**'()S_J]>M2(
M9#J7!'I3TSTZ;&V%L_JK8VT.N>O\/AML;.V9MO%;:V/M;%T_VU)0T&+HC1T%
M!3IK#)'&"S%R2Q!(+ :;-@:<?LZ<9M9)/GQZ0>3^-'1F=[PVI\F<SU=LC(]]
M;+V=E.O=J=GOB4BS&/QF?1VK,;'6!F>&C=)) ZE-8#$*0MA[>U MJIG_ %?X
M.FM+!=%<'U_R8Z,O[KU;KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MJY\C_P!O#<A_XK6O_NS'O#W=?^GEC_FA_P!8NI=L_P#E6/\ F_\ \_='(]Y!
M= +J1[]T8= SV :C+;HVWM^H(_A_^Y'.Y 7MSBV/Y]@CF"7];P?]7#HRV3M4
MM]@_:>G^.JL/JXL?Z_U_V/T]U^E^FZV+FOKUQED,_%W_ *_[[GZ>[^%]G6C<
M?;_J_/IHS5'!F\364=:>:G'<'Z7O[0[U9:[,>#TIM&,[5].ECL+)SY79^'FK
M0*N=: _Q 7MQB#]/]?Z>Q5RS>?O#;?&_&G1%N"A'],_X>E?[$4'2'J13_P#%
MOR'_ "TIO]['LQ'^XGY_Y>O'_<H?9_DZ$#V;]!_H*-T_\7X?]JX?[V?<.^XW
M^YD'_-/H7[!\)^W_ )^Z9O8!Z$/7O?NO=>]^Z]U[WKZ<?ZO^*Z]U&TC_  _Y
M(_XW[]0=;\'I.;CVQ@MV8@8S(TEJ< @"UOM2/Z_CBW^M[8WNP^OZM:W)C-1_
MQ?09X/<V<V+D*39^^*K[K'58'\"W9;_)OZ>&L_V/_&OP0165Y-M\WZI_1Z77
M$:S N@SYBF?RZ'/ZBX/)O[/99?'_ %H>B_ACH!]D_P#%B_?M]P*[<9KO]?[O
MW%LDWU/]AT*XZ@_LI]M.E6]])_KZ;_7_  ]H+7_AWKTHCX8_U<.N7M7XOV=.
M=<98OI;_ !M?_??[[GVS+_C'Z$/30-,GKEUDQCP590\FEQ6=R5%0G_IE!'_%
M?Z^Y&Y8?P_T?Q]!W=(OIVK\OY@]*K-YJ@V]05F2R=::3&TG' _VW^/LYN[B&
MS_1FZ)UD-YPZ4'6&!K(*:NW?GJ5:',[J6@=: $)]I2XO_@'1W_V_X_/]?<R^
MWO+,NT0^+.<T_.@Z"^]7@<Z5X#^9/0[>Y0Z#W7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3/6UM%1
M#]X"QM_9!^O_ !3VBN=S-N?+^?\ GZLEIKS_ *O\'2-K-QU55^Q"!0D77Z?[
MQ]/]]?V'+K<?J.CJVL@/GTR^3_#_ 'GVDAFZ6=%;^4W4^9[&VSBMY=? /VOU
M=6/N79>@V_B5*1?(X*;D>JNI.;"][VX%_:2[A^LRG'H6<I[Z-BOJ7%-+5!\J
M'@#_ )/V=%1V+O?';QQAW%B?O*6 **'-X:L!6HQU1C?^!E+57MXJJE'T_K[*
M89(K<]9*3J>!ICS]?YG!Z%P'RC]CBWU_QO\ [?\ H?9M_;=%=:==0L;?O_7B
MVKG_ %_=Q%Z=:R/]7^?H!N],Q5G'X+8>*J%QU=O:NR%+F*ZC-_\ <-C_ -W(
M#_ RW\']3;_'VBNKG0O^K/1SRY8"ZG+'-*$5I\72(IZ>AH**EQV.I#3T-/\
MY'1T=);_ &Y_WW'LC9-?4F0Q?3_X<]3D'C%CQ?Z?GVWT^17J%/!#4PU<-93?
M<PU0_P LHJW_ ')4W'/M43TF'^KUZD=5Y:NVANVEZ]FJJRIVGN>DK:O9HK+Y
M#^'56/\ \[BQS?[7PG]CGV8V<NOM_P!GH%\Q6/@CQ_.HU4Q4>OY?['1HO9KT
M#>D!V-NZ;9VWA-C:3^([GSM;_!MEX8 $U&1R1_H+&\/_  (G_P ?]O[:?_5]
MO5HE!/I05)Q@#_5CK+L+:4.RMO4V(8_<UP_B&:W-F[_\",EDA_E=7S^1]/\
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M7]W]U-U+O "A46I:D&F^L/UN>!_O/)''L)^YG,?T&P7*3<? 'YY'1IROM?\
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MDM3J5[;\/ICK-1P^2>P^@ _Q_P!;_??[X.(E3TGFGH/LZ?XHH(8!P--N3_Q
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MLM.U%]U_"LA?_BWYT_PGGVML.9X9.DESMKV=32OV9/\ /I<^);7O_P 3]?\
M"WU]G,WZ_P#8],:SUS9K^E?:F**F!U3I"[_S,^#VQ534?&2JS]A1?G_*<G_R
M/CV0;S>>!%TJM$U-G_4!T\[4P$.V\!B,+" W\+H>?S_E)^O^]GVLVV+P(?\
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M)<= Y_+CD"?S6L=)^%^..Z+\?X4QX_Q'^O[S#Y?D_P!TD?\ IA_DZPQM;?\
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M)"UQ>5($HJ*\0,FF0,>GG6^7.8BFRV.J\1D-%5CLA0Y"AKZ*]BU/DQX!8&W
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M)'(UM!0[H!-9E\LB2 :G@9U%,=#MJO\ V1[DCD3E>>SGFO9ZAUJ@C(H== H
M'$*H8\<DD\*=8$?>8]\=FWW8[?E?8*30"8S7ER#75GC6F*TX5(%/7K8>AF#5
MK @WY''^/N55.>L$Z8KT[>WNM=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U'G_L?\A?\1[;DZ]U23_/9_P"R3>L__%ENDO\
MW(J_8JY8_M7_ .:;_P#'6ZA;WP_Y)=O_ ,]UG_VD0]75T'_ 8_ZTGL/3?#_J
M^?4Q6_'_ %?+IS]M=/\ 0(]IX')9G!IEL3Z=P[6J_P"/X&,@$U7\+)_R,FX_
MX&VXX-^/Q[C[GK9!N]AXM<PU_9T:;9*(KFA&&P?E7_-T7'>>7@S>VQD\8/\
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M(Y%4^3B^O^M+S[6Q<Y>Y!X_2?]DR?Y;GIH[5RQ%P,WY$_P"2#J;!E?YC\O\
MGF^,U)]/U#)_[S]?9S!S![AW'#Z'_LF3_K?TA,'+(_Y2_P R>N?W?\QO_CK\
M:/\ DC*_]'^U7[\]Q_XMM_YP)_UNZ2:>7_\ ?%Y_SE/4C^)?S'/^.GQH_P"I
M&?\ ^*^W/WU[D?Q[;_S@3_K?TWX?+W^^+O\ YR'KW\2_F.?\=/C1_P!2,_\
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MD/\ UKZE?Q+^8Y_QT^-'_4C/_P#%?:K]]>Y'\>V_\X$_ZW](?#Y>_P!\7?\
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M,UC_ /SY7_WCV9_OX_/IO]VD\>F!4GW]4BAHJ2NI-J4G-?77_P"!5C_NB_\
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M4_G_ *A^/]C?V72RFN,?ZOGT.K'E>W7R+?,C_(!_DZ:X:+=5/^[CNTNP:6O
M)'WN2I\G_P!8C![TD[#/^QTLGV&W;!44_P!7V=*/"]O;FV9/30=BBESNVZK_
M ",;^P]!_#S37X_W*X_Z'_EO_O?M7'>>3=!^\Y6!!^GJ#DT/^0Y]. ]>C54\
MM/54_P!Y"/NZ:K"VL?QS[4-^AT"YL?LZ!GLGK.?<5;2[NV;E/[N=DX1;X?,D
M%::IIQ:V/K^/\KIK?G_;^U3'TZ46K:11LKY^M?4=)W9_=U3D,+5U6\NNMSX7
M^!YFOVWE\UA]O5.\L=39''<UE_MO\KI/J/\ /?[?Z^ZQ3LF:8X$YZ3WYAM31
M6!)%0*@$C^=1]@'3])W[U*:?Q?WL=OK>A_AF5%3<\?7[>_\ O/O79!U3QD_U
M4ZD8[?VY=VR_8]1=2]F[YF^G\9J]O_W.QG(L/]R&6!M_L;>TZZY_B0_ZOS/2
M*;=;?;!_C5PH'I6O\@!T)VW_ (J]J=BS+5=Z;TQVU\%4('JNL>M:T7J*7Z>+
M(YJ_E7Z?2DO<<CVV]MH[YOSH?]0_P] ;=?<U/[';Q4C@S#A7T'^>G1W-D[,V
MWUY@:7:^S\#2[:P..;50X3!8\XUB3^2Q^H_QXO\ GZ>S.)4MT[/\'447VZ3[
MK<5G-?G6H_9_Q72@U^8$,/\ ;'_?<^]>,>M=8O:'K77O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=9:2>I )@XL;?TM_P 4]JH;GZ+AU4VWU?'I6T.Z
M2H*UXL""5T+]+>SVUW<CHNN+$>72QIZVFJ+B WMR0%M[//JCZ?ZOV]%9%.IO
MM;UKKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZC5'U3_6?_B/:.Z_S?Y>
MM^715Z>D_N;N[+[7R!%+CLKD,CGMID?2J_BEOO*,<_YZ#C_BOO''?K#^KUY_
MCG^XS]#^PNO'4,N2*!CZ4R#]G2V1A*/K_@+#3_K\7M[1>'#;^71@T5,]2-8_
MQ]L>".O= SOZ09S.X?::V_AHH/X]GC]/\E!_R*#Z?CV!N<=R\?\ U?ZO+HWV
M1=()_(?;7)_;U-%C_DY_U-R/]B+?C_6]A9/+H_@Q7K)[]TJZ@9#'X_+T_P!I
MD:,U=/\ 3@<\_P"^_I[JZF>''3,D=#4'J3L3*UT-;5;2RE9]R*0C(8*NO_P*
MI?H.>?\ ,?X'_#V,N7-V,$/@CH+[I8  /^WY="LZ@3><7N+"Q'Y]C:.+Z?\
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M?SZ4_NJ-NN<6X.P\429UP>ZJ?Z'[+_<75?T^OT_WOVML^8)CTP=H1O4?X/\
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MA8'(=?\ 9%&V@[8SF0XJ3R/-BJN_BRM+?Z<V/XO[1>(]NVEQ3_)U-UI<P[G
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MX_XI[..FM9ZYZQ_C[MX(ZIUS]UZ]TW??4W^8^]H=7TMQ_O6KZ>V/JX?]5?\
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M?>/'+TXM=KMC=.?PRG2/S-#^RG2@H_YL.T).GANX;!D':AJ?X*>OQ7)I]?\
MR\#5:=7V'-M-_P#D+W5^2?I[CP]0T5X9_;7TZ76WWE=NEVCZT0M]32NF@U?9
M3U^=:=)7I3^:[5;@WQ0;8[IZXPNV=OY2K>EI-Z;:K3*,?4/<$5\-0[ @<_NV
M5>3_ %-UU]R,;6 2+(#G"/Y'YU_P\>BSEC[RRWFY&RW.U>*@_P!R(:,AXXJ,
M@_:*?/H,M\_S:NUY]W5$/776FT*;8T%3:C@W+7U#9*OM].8Q:F/T/T'].1[9
MBY*\& RER&K@$$D_YN@[S)]Z&\CW,6=C:QO!3+A@N?2@4U^VHZ.=7_S%>O\
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M+KLRD[7:/<$9"1T\OFQ _G^SIUVS_-?V_6=/;DW!N7KIJ+MC#U=#3T77M+D
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MMV?=?WIT2;E:_0\?/^?^#I0^S;J_7O?NO=>]^Z]TEL_5> B>W^27 )/'Z?\
MD7_&O:2]NH8D_6ZMMUN;BXZ+QU52C<V>W=V7.3_N3KLC@\"#]338T7_'] /\
M/>//+:?O::?<IO31T,KZ?PU6,>5#T8#V,>B/K@+C5>UK\GVI\;Z;'3I X==W
M_%Q_M[^TW@_4?T.MUIUW^?H??A"+C_1^JUH.'2=RFU=LY>W\3Q6"J.0#]YC
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M37A]3/>^G.O>_=*.O>_=>Z][]U[J)8?X_P#)/_&O>_&FZ0_L_;_L]25_M?\
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M8_[E=R?\6>QO_#L-_P HE+%;Z>0#SSV_WCV4SRM(W4K[=8PVD&GR'\SQJ?\
M5Y]*CVFZ/NO>_=>ZX>3Q_NQ<@_BWOW6B*]/G2N2_@6[MT=?M_P 6G*4/]_\
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M;]DNP;ZALYA-V:<MU(/N1[57&U[H+7;AX_U%? U<%('R_P GGT#6&ZYV3/\
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ML/;XN:.BS]80.;XP$?[SS[8GWV$?[/32;6PXT'Y]<4WWD)!_N+V=GZN_'^Y
MG$?[U[3_ +\A].G_ -U^K4_9_FZ9LG_??.4]=%E1@=IXZ_\ EXKS_%:O[0?2
M]_\ B?;&X7FYW$/Z_6[+PX_AJWI3 K3]G[>HFU-VP8+_ "')UE=5;=:U!@L]
MIO\ 2_\ QK_BGNNU7EY_H]='3UY%J^&E<$CU_P!7KT,,<M-4'[BFO]>1^/\
M>/8SA\'HC-1UB][ZUU(]^Z,.O>_=>Z][]U[KWOW7NO>_=>Z][]U[K'_R@_[[
M^GM5Y_GT7]3:?_BWU_\ KT__ $./:X?[BG[?\O7F_P!RA_J\CTO_ &<=!_H*
M=U?\7\?]JL?[V/<*^Z']K;]"[E_X#_J\^@?['QV0JL#292BI/NLAM^O&=&//
M_*3_  S_ %N;?[[^GN*>8(/J8/\ 5PZ%=C.$8BO' ^72;QV1H,CCQ74E9]W3
MU7'T_P!];W&T5SX_]OT+FDIP'4R;Z"U_S_C[5M:3'^QZ<E(\^N"_I-Q;D?BW
M]?>K:&:XZW :=)S*039O+8?;$!O45M>,A7GBU+2XO_'_ !Y/M?;V/U$_@]%N
MXW C6O\ J)/^?H=IIC*!P1<\#_#W)/\ R3X>@F ">DYE-XX'%S_9?>'*Y*UO
MX%@A_%:H_7_C7M/$/J/['IY03Y4^9P/V#_+UDPFQ\MNVMI,YOBC_ (5A*3(+
M7X#:835>I^OWN3N5!O:PI[_[US)O*O)!N/[?H+[GNZQ"B9/ GY>@Z,E#"+ D
M>CFPO>]_R?<T6]O]/T%2>I?M5U7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>ZA/4B$?Y1I*GZ:1?\_T/'M&;K_5_J/6S3RZ2]?N8
M1,(*!16-?]0!_P![%O\ ??[P4W^\&WST8VMCKX](N>KJJX_<U(U7//YO_O7T
M]D%S?_4=&=M;:13KC9_ZC_??[#VA\'IW6>L,)\'/^P^OO76@:=9?)_A_O/MS
MQ.M=8_;?7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[K.#?VLBEIU[K@+6))^GT_P!]_7V['=B+JUQ_C?4W0_\ A_MO
M^-^[:STS]-_J_P!1ZPU5+3Y'&U.,KC]Y!E* 4-<P.FU)EP1_Q7W6Y/B&GKQ_
MP]/6P^GR/(U'VY'52^W,;/TSV%GNC-R\5&"89KK3-@@C(;=R52#$;V!-7BN8
M)_\ 6L.!["\L'@'N_P W63FP;A_67;P\'^V'HP'^K^70]<_<?F]_\?\ 5?7_
M 'W^V]GOBP^#T_FO2<WK0U>2VCNO'4@_?R.U\]14%OZ/2%1_O)]Z-3_/^5.G
MH&"L*^1!_;4?X>BB;'JX:K:&VIHO[.%HZ'C_ *M]*(?^(]D,OP=3#:5,)_U?
MZN'2M7];?['_ 'OWJ+_+TLZP:Q_C[MU[K/))]/#_ +'VVS^G6@/7KEU]'][W
M-C#2!;;<V!D6S O;_CX:C_)8?\>:;\>S6T>K#H$\W3?XN?F13]@Z$/?Z#.]I
M]1;8%_M\=69W?]</I_Q[5+]K2?\ JW4GVL=:-T#+6:EN6]:#^=3_ "Z%_)9"
MGQE%5Y&K%\?C:+(5M8/\<=R?Z_2S>WM&C]G^K_#TSX7U&!YD ?GG_(>B6X>?
M([FK#V-N;_*<]N2U9AJ2Y'\.QW_*+24@'YY_?_WG_$E=VKGJ4MMVR#;1H'E3
M\SYUZ57M-T?=>]^Z]TRY[ T6X*+Q2U/VM?2D5F%S-$?\IQ]0+6EB-^?I[<5]
M'2:6+QS@?EZ]#OTWO:LW7@*RCW!JI=U[1K?X-N47TT]3.1^U5Q \>+(1?O\
MLYBD^J7/^H]1)NMA]%/C@>%.('^QP'0M^[],:!U%JI?%3B9A8$76Q]IC*1UZ
M #ATG'^O^P][Z,^D93R-0[QRT)T_[E<)CZ[D?\I.-_9_WKVW7'^KCTIH2/+B
M?V'I94D'DJ-,P  N #[4*E>D,TW2N]M]%G3554=#D*>JH\C2_<T%50_8UYM^
M<G^?]]]/:N7IG-<'/^'HEDD$_6M;3;-W;4_;8FGO2[-WE5@FFR-,>8HI9?\
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MTRCYN:M3\@#^SIYZ)QV-QOP<^:&^ZD_=9G=.:QNU35D7L4DIR2/KQY:E@?\
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MU_Q_UO:JW0W'^,]-SQ4/C>?4KR_[5_O'_&O=NGM ZZY_J/\ ;?\ &_:G0?\
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M?^O^\V]J(=X^G_1O.O-9ZA5,_93I>Q3">T]VN>?Q^/8FA?Z_$/2,V]./6/\
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M\<U+_$+20_UJ_34>W*5;_5_J\NM2$1P*M?(D_/-/\)'0S[[QT^9VKNG"4?\
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MS_ET$'.IR?(U'YANG[VNZITF=ST0R.!S%'+]:K!Y*B_VXX_VY]I;R(B&>O\
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M%$.S=H;Q^^ZVVU29^ER.0S.'QP!U4@B-\A5Q0,/H/T@W/(]I(Y5BO&8?V;C
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MG\NBH="8'LC8/R6Z-[,[$VC5[;PV*Z)HJ3>.9S!IL93XXX^D-)IR!8C[2_\
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MIWG_ ,6RK_Z=?]"^S!N!_P!7ITG'Q#JGCY)_YRJ_UZ__ 'L^W$^.?\^KR?V
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M(XMO6WFN9')Q7S_BQ_AZD/>^;Y]SY?V6TMO]&TD5\A$NL_X*?GT(>Z\+/O\
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M\P'1][BV_P"Y[GE_;/XFX?Z5CTE][XF#:'R7^8>T8K"BWSL+>.<L#JY?[?,
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M'NS9M&_U>?0MC_@4G^P_WOV)[7^P_9TQUR]EW7NN(_X!'_77_B/Z^U<']O\
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MO&4)L+X3'$?3_"*F_P!;\>WZQ+CHN\=[DU-?V]/#=X]6Q']G==%]/[.-JO\
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M ):]1KS%;W-CRR=W\[S<5:GH&D5?Y*.CW_$:"FW1_,+WMF(2:BAV%UO18>B
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M;8BN0S4X'\O\'3QTIWOV7U9M#LG96T?\IP>\=GG[NCK*$FGQ]1(/#_%/\/\
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MW;&ZLW'AH>ONT.C0>LZJ3"T/\&W)UUV'U'+]M_$,<T;4]92U-%4P?<1->]1
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MB! >DK)^/]C[0="Z/KWD_P /]Y]^Z]X?0T[5QW\-PU#!;_*JV_-O\?\ D?\
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MT8O_ ))GLF;G_6X]EFV8@ITLN#4@_P"KATHD^G^Q]FD7'HN?CU+]M].]<?\
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M[]^_OF?]7Y]>_=?V]>_OG)_RI'_;G_BGOW[^^9_U?GU[]U_;UU_?*H_Y4?\
MH;_BGNO[^/K_ *OV];_=8^?[?]CKO^^<G_*D?]N?^*>[?O[YG_5^?6OW7]O7
MO[YR?\J1_P!N?^*>_?O[YG_5^?7OW7]O7O[YR?\ *D?]N?\ BGOW[^^9_P!7
MY]>_=?V]>_OG)_RI'_;G_BGOW[^^9_U?GU[]U_;U[^^<G_*D?]N?^*>_?O[Y
MG_5^?7OW7]O4.LW)65 'A/V(4?UO_P 1[8FWBO3B[93I/>3_  _WGV4>)TJZ
MQ^V^O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4#
M(?\ %OK?]9?][/NY^+HQVSATEO=.C?KWOW7NGK&2::BLGFL!_#@+#^GU][;]
M/IN?_&>'KT!=;7_Q*LJZ[G_*ZXG@?[U?VTR>(G4B[)!]-#3Y=8?;?1OTZX:@
M_B69HJ<V)%N3S] /]O;W>-O$?HIW6?Z6#H?Q?@6(/^]W^G^\?X>WV_23J&IQ
M]5/UD]UZ:Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z]#-4P\T]P?\ #G_>/?NMBO2EIMTU<(^VJ*,UC?[[ZW!']?Q[/X=X
MITA;;*\*CK/_ 'HK?^5+_DU_^*^W?ZP'U/\ J_/IG]UCU_EUE_OG)_RI'_;G
M_BGNO[^^9_U?GT[^Z_MZ]_?.3_E2/^W/_%/?OW]\S_J_/KW[K^WKW]\Y/^5(
M_P"W/_%/?OW]\S_J_/KW[K^WKK^^51_RH_\ 0W_%/=?W\?7_ %?MZW^ZQ\_V
M_P"QUQ_O>W_*DW_);>W/ZP'U/^K\^F?W9US_ +YR?\J1_P!N?^*>Z_O[YG_5
M^?3O[K^WKK^^51_RH_\ 0W_%/=?W\?7_ %?MZW^ZQ\_V_P"QU[^^51_RH_\
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M_/KW[K^WKK^^51_RH_\ 0W_%/=?W\?7_ %?MZW^ZQ\_V_P"QUW_?.3_E2/\
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M]WJG7N Z^CV+VC@J9%JQD1C:2)EQVXJQIM JZF4)#4M8&.@8%]C6@)JI %:
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M>EQVT*!*^LD0_P!J1@X46_/]2;>[O,""?0?YNJI:F,A1YG_8ZI3_ )/_ /.
MW;_,FS_<6Q>W^A:#X]]B;.VOU[W;U%M\9:KSJ[CZ[['4Q8G=*BKIJ$%+(C!4
MD4,DP8(I!]M&7!J , CCP_U'K<UN%H5)(R#PX^G\NC(?S&?GYN[X/]@?!;:.
MU.OML[VI?EQ\G]N=$;DR.X<S58.JQ%#DX)9SD*4P))Y&<Q @'0!I8$DV]NL/
M"*@9J:9_+IN) 58DGM (I2GG]O\ J\^A _F.?S#NHOY<G4L6\=Z4%;OOL[?>
M07:O0/0>S8GRFXMZ[BR3**"@H<>5E:2D9Y%6NK0GE46%C*T:&A<,*TJ?(>M?
M]6>GH[<U] .)_9_/TZ+#VS_,Z[M^&OPEZM[U^<?QLP5-\K_D!OZCZWZ>^&_0
M6XIMR5V3S^\70XG"5.3K(E4Y*.(A\P8]<=,0])"M6[,L>A,=%:"K' '3SPJ'
M(8F@&2>''\OV] )F_P";S\^/B)N?JK<G\T/^73LSHGXW=N;YVWUT>[>FN]XN
MW8]HY?=T^BA&[,9#"4AIYV24%XD0J\;W+2+I9E:J14T%?(UI_,]7E7!'ADD
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M?Z?0_P"P]OF7KR<:]5,_(\_O50E^OT_W@^UB3=G3<J_J]%#_ )>,9_X=.L+
MK\=M[-SQ^D4Q_P"(]S#935V-#\QUC%9?XSSS<C_A#_\ '^MI+VCZE'KWOW7N
MO>_=>ZX8_P#XN'^P7_>O;;?!^WI1%_;?ZO7K63_X3%>KXT_.P?\ @R_Y& _\
MAC'?\4]LJWA5/](_RZ57<6I!]@_D.KB?GG\2.KOGC\5>T_C-W%0P?W:WCA,A
MD<3N/'HTM5@,QA4>IQ6<HAZ0M?CZQQ)H)L^EU(LVH7D41I5OF?\ 5^?5;:8L
M_AK]E/4&G5$G_"<'I'+=M]?]A_S*_D7V#D.\OE'D\Y/\*]I[MW'BFT[>V/\
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MK]J>D'4:*(2 DEKZC^?;2KJZ>S7K6@_X5/1R-_+MZ/ OI/\ ,!^-P//Y,.X
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M'_C_ +Q[]X?7NO>/_'_>/?O#Z]U[Q_X_[Q[]X?7NO>/_ !_WCW[P^O=>\?\
MC_O'OWA]>Z]X_P#'_>/?O#Z]U[Q_X_[Q[]X?7NO>/_'_ 'CW[P^O=>\?^/\
MO'OWA]>Z]X_\?]X]^\/KW7O'_C_O'OWA]>ZQ^V^O=>]^Z]TA=XG_ "*NM_@/
M]X/MZ*&G6D;(KU4A\D/^!%7_ ,''_$>U</P=6/\ ;=%,_EV?]O3$_P#%:]Y?
M]"TGN8K'_DCI]L?^$=8L[=_RN-S_ ,T;G_C_ %M&>TG4J]>]^Z]U[W[KW4&F
M0"?[D\6]']3]/=&XUZ<B;%/]7EU55_*O_EY[D_ET]9]];&SW9N)[0;NCY,=I
M_(7'5N%VXV)2EI-\QTZC&2%JBH/F&E6+KJ5?4%+!K^]1UH14&I)QTKF<%@PJ
M*"F?+_#U:1748K,?643#[3[R@RF/ )_.6^EK7_Y'[T1C]O\ /ID-0_93^75:
MW\K'X(9_^79\6J_H#/=E0]F5=;W+VKVP-P83;LFUJ9%[)K7K%IF65I6+QII4
MC@!FTK^GW2):U2M:FN*^?ET]<2!HPP%,:<_+I/\ ?W\OG-=S_P SKX9?S!J'
MLJCV]@_BEL7LKK^?JZNV=62U&6_OK25D(GIJT5#BE6!:R[,T TZ 1J:X+,*:
MT6/^$%:&OGT^TN@NQ'$ZJXIZ?ZATI?YH/\NWJ3^9E\6<GTEOK(S[0WI@,Y!O
M7I[MO#P/D*_:VY,.#'!DE,;)-]K+$OV]8RNI*6D]110+% ^#QX@^G^KS^?5(
M&*)J&0:5!\_]5<?+JN3YG_R?_G=\Z/C[\+NE^UOGILK,9GXW>7<_:,^=Z6ES
M&,["S^VJNVW<ON#!/6M!7-1X<JE325$4T4\[33G4TP?WIQ'$JC4,5)]*G_8Z
M=@D9V8A3GY#_ #X%:_['0S;4^&O\[W;N1V9'F?YN/3V3V)MG+;<&3V1A_A'L
M["Z\5B7(GQ%,]'1(M!YJ "%2&544A+@'VY''Y4&/Z*^7Y=-SD$_VK&OS;/YZ
MO\_5^GM3T5]88/T'_@Q_WH>Z)PZN_'JISY$4(Z;^6,&_ZEOMMB?(3"X_;V:R
MP_X#TNX=H66E\X%[?=4Z@V_Q/]/;'AT;4>'^4?Y^C2*XTG3YDF@_HGH0W)IC
M5RU@-+!2T7WU;6UQ_P" WMKP?]7ITOX\/^+Z9OA?AY^Q^Q^V_DK-3(-LU]%0
M=.=:"M%_NL=@ZI1D*^WXBJ:H*;V^I(]J0#J)\J4%?2N>BEF\15;SJ6;[:8ZL
MO]O=%_3A[]U[KWOW7N@&I9/[G=BYK"S#_<;O8C/8$_TJC_P-@X_KS_O'M-/'
M4$'SR/MZ.[*?P9 ?-<'[.EU65L&-IZVNKKT<%(;9!;?U_P!]]/:>-*9/1A--
MJQZ])CJ^GGR$&9WK6THI:G=>1_B&/4$'_)L5S#_O?^Q]JT'AU7UX?8.@\6^H
MI+Z#/Y]#-[>Z2]5J?S._C9WG\J_A%W3TC\:NT]Q]-=X9RAQ^8ZXWCA=U5>TD
M_B.SZ],@F(J\G1B2>GH,W&7H2 /'J1+V475EI"]64T/^;_5BO2Z$*R"-A4>8
M]*_ZLGCGJC3O3IW^;-_-APWQ2^&OR,^#M%\2^HNEN[NJ^U?D]\@-W]JXKL%-
MR?Z+_-%*NRJ/%L*VI3+Q2R,SSNRK)+&Q8JATLZBRBBT I4^M.E$:^$S*[5)J
M N< G_5]GV]6.)\'N\^_?YUNY/FO\C]@[;I_BW\;OCM_HC^(N$R>XJ7> R^9
MWKJ;<6X:W%AI%Q[A):Z%Q4)^XAIF/D:SBG@'31Q@"@X&O^KCTY]0&[T.6-32
MHI]G^#Y]&5_F'_R_>I/FI\,>_?C=B>MNNMK;O[ Z]R]+UWN3'[7H\6,=N+%-
M_$L%*]330 4PCRM-3FH_U,$E[CD^WVMA"I4 5\CPSQZ3P732L&8DCSS7!^7Y
MUZJ:WG\&_P"9=\A?C7_)&QO:O6&!Q_=/P=^46V\GW\@[/PTU]M=>TJ8K'[AI
M)XY/\LJ*['4L9-.DDLY,2L%/EY8$:ZJ$"JGNSY?ZATND?5&I!PX[30_Q9_P_
MSZME_FQ_R[]A?S+OB[N;IS,UM#M+LS;U<W870'9D#?95>W]WX/\ ;H:Z.>+_
M "C[*K'^3US"76B!9%#LB7TL8C337AP_U?ZL])OJ27K0T-*_ZOE_@].J=_DC
MUS_PH&[[_EC=9?%).GMI[;^151N'_1Q\ENT]M?(O!XFLW+L7:]#'X6Q>6#R2
M8G([M/FI<HX5RAI-:A5KBC;"ZP$ SP)J,C]O^K\^KHRQ OJQQ TG!_9^S\Z=
M";\7C_.)^&W5&T>@_CC_ "6?A[U?U)M"=(,?@\1\THLE/53Q3?Y;E\C6?8M4
M97*32-JJ*VIU%VTA@51$300R#2:4K_$!G]O3US,%)9%;53^$G[!PQ^0KULMT
M$E5)CJ6?(TOVV1-#COOJ#_BY::CZ@<?4@_FX_']+^UXX9^6./1&U*X_XOI2^
M]]-]8(_^!3_\$C_WOW0?%TZO ?ZO7JF3^>/_ -DJ=9_^+)='_P#N76>S[8?[
M5O\ FF__ !QNH@][/^23;_\ /?9?]I,/5MJ_YJA_X.__ !/N"+_XY/\ 5Z=9
M2;7_ +CVWV#K+[1]/=>D0!1=OS_3VYX?6P*] -VI_P 6:J_U_>H.'^KY]-GX
MNJ5>_P#_ #F1_P"#_P#$>S!/]7\^F_+J\SIC_F4G5'_B+NNO_=13>RRY^'\A
M_DZ6?C;_ $S?X>A0?]?^P/\ Q'NJ<.G+CC^S_!TT5'&9VQ!_7(BO(_WKV7WA
M^HN>EU +<_LZ7WL5=$'7O?NE'4/*_P#%CKO^U?F/:>]_LI_M/^3K=K\8ZA;<
M_P"/=PW_ % -[1;/_8P?ZO3IR[XG_3?Y.GGV:]-=<'^G^Q]^Z]TP;PA$^WZP
MT]B:33D#S<<W_P!C^?95O<=,=.VDXKU"BJ?O*>CGIQ8UI _WOVCL_P"RZ6'J
M4_U_V'M3TR_'KA*?!SR>2/K_ %Y]IQ_H_3E.'76RHO'A?/?_ (&Y#)+_ %_4
M!_O/M[EW_</\^DTOQT^SI4^SKIGKWOW7NO>_=>ZY>!/ZM_MQ_P 4]M:SU[J#
M+2>9S8GZ$_[<_P#%?;%V:C\NF0/\/0:;KZUP&Z29LC1D5%+_ ,6^OH/]Q=40
M/^;QX_I[#.[<G1;Q^L_1_%O9AQ-_GZ+GT[A-P8/Y!?(&AI\HN<JZ;:_4'_%^
MO]T=='7&X_Q_V/\ M_<$\C<J/MO-EQ##/_%_DZ$^][M;WEE;$B@)/#[>C$[S
M[;VYU7M?+]A]IUV,V'LO9M!)N#=V]]TY*@P6&H::+]OSU%=5!RBNU@H4%C?C
MZW&1=C<S33>%%PX_MZ <]L&% 17_ #?X.M#?X\_&OO7Y>=R_+_HC^7[V#U)N
MGXO;?^0F\<[6_.#([BJ:!L'B.]IJK<]91XS:AITRF8W/C5FJ*."H2!<=KT,'
M"!W&6,WO)%REMHMC!+XI0D,-&D @8IPJ/6OECH"-R]^]I5+C)\L?Y*^O^H];
MM'Q;ZBZ<^(70G5?QPZ=Q&1CV/U;L_';5Q-*^+"U]9)K9ZK(U(N2:O,Y(_<U;
M7*LRJH6UO>*=[OTKWHE<4D84 Z&@V,K"8C_AQ0?YAPZU0/Y@O\O+Y(?!&F^4
M/?OQ,V1L7L[X4Y7&]E]QR;4W3OVDZ\R_5N3S8:IRE'2)6RQ1YO;.0KV6KH:6
M'3,D[FC=7)5CDE[8^\<C6KV-Q%*6050,*%30UR:U7AVT&:YST#=SV!89UE;X
MOEFOG7AQZOH_DS[DZ<R?\O+XW];?&GO[KWNO;O4'6^WMO;NW%LW(M/5T6X<_
M))F:VCR>**KD,+ :BJK"GW5OTL5)MQ"'-UGN%[>2-*:K(H44/Y_Y3T*]IFM[
M9"7&2?/(H!3_ "#'$=6Q4>R::LJ/-FZZORRV_P"7A91_O9/L+;=RA/!^M-T8
M-N@I1:#H'MW8G'TGR)ZFIJ&U+2TG77:A!M:P%51_['_C7N.N<]O@',>W3?,?
MX#T;[9?D[5=USD=& ,)AI?\ )_J#_0#\7/ ]RE*XZ+1/3J,DC0J >&TWTC@?
MT_XK[ONFZ0&.W1.D3R,)S#!_J\^LODI[B?GZ_P!/Z?7\_7V\\,-_T[<&G47_
M "6?Z<?U_P"(]HIH_P!^?HWEO;=G5A.+/*D]8OMO"?\ )ZX49_KJL?\ ??[#
MWKQ?J/UNO#&.N/FR,'(+ G^O^'NO6@1\^I7W)_HG_)7_ !KVN\8]4QUZ:J\0
M-["P_/X_XW[3"XT=*?%^FQUP-42"!<WO_O%O]]^/;SW<-S^MTS;@KCKO[NIG
MM3M?_"WU]MQ>-;_\H_6L'UZX&@$Q_?O6CD$WM[HGC0?HS=*(*$U'4R./P_X$
M>],U>DG6&2/S7!'N^%'7N'6"*F\/_ <FC_Q^OOV!U;57CUD^\J/^4B]Q];_X
M_P"Q][\;KS'K+[?\8]5ZX>0?T/N\S?0?H]7%QJSUE_X#57] ?][!_P!XM[9_
ML(?]7E_L=>\^N7D_P_WGVQX?5.L0-_:B*6G7NI/MSQ^O=<J?]2?\A?\ $^W/
MP_ZO7I/T[P2_Y'7 GZS0D6/^UK]?:@3?XF3^7\^JD#ZG_5Z="/[&G1#T&6Z?
M^+JW_:L/^]CV#=X_MOSZ/=L^$?;TR>RGI7U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW2?SX$.&!-P21JYO]"/Z>T\O'_5Z=&^T?Y>D-Y!_4
M?\D_\:]Z\3Y]"SP?L_U?EUBM2P?4G_8\^[^)7TZ:\ =!;+5?=Y*MJ++ZF/'^
M*C_C?MA7\1!^74@P0?30].$_X_V'_$^Z0=>/#J;AJ45>9HH"/^!F14V_V'M9
MX?B)CHIW6?Z2#HP8_P W'_P8_P#$^_1]0Y-QZ</;G3/7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW0<[Q_X!5G-_]JM;_>/;T+UKU98<]5+_ "//^4U?'^^%O;T?ZZ=:']OT
M47^7A;_AT-DO_P!RX=AC_;?;>Y:L9/\ =,A_YI_Y.L6MN_Y7"Y_YHW/_ !_K
M:0]L]2IU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UA\Z?T;_;#_ (K[IK'5
M]!ZS>[]4Z][]U[KWOW7NO>_=>Z][]U[H+NR.M]E]O;3R>Q=]X&AS&W,XP>KH
MZIM#7 /[T)M^S60$W_V_]2/=) "-)&#G_5\^GX@Q.I30C_5^SHE/_#?F!G-)
M@MR=W]Q[EZPIE9J'8%7G*3P+3\D4E7D(HC6S4=[<A%'^M[T6'FS$>G^R.GA,
M>(1 WK3_ "='\P6"PFU,)B]N;<Q='@]O8.C:CPN%HV.,IJ6FQAL22+GZD'D?
MXGFY.E4**#AY#APZJS&0U.2?S))Z>_;O23IP]^Z]U[W[KW2;W#MS$[HH/X7G
M*-JNG'(8'^H_WO\ V'MIT#BAZ41RE,CH/:/JZ"LG0[JW)G]U8ZD&K'XS(,%I
M?]O<C\>]>"$^$D@?LZVUP9_[4 'U'0S>WNDW7O?NO=,_B_VG_>?^-^_=>Z>/
M?NO=8?.G]&_VP_XK[IK'5]!Z]YT_HW^V'_%??M8Z]H/6;W?JG3?[]U[IP]^Z
M]U[W[KW7O?NO=>]^Z]U'_P!W_P"^_P!3[;_%_J].GO+\_P#+U3)_/$_[)2ZT
M_P#%E>D?_<RM]GO+GXO^:<G_ !QNH>]Z_P#DEV__ #W6?_:3!U;:G_ 7'?\
M!A_O9]PO>_[DR=90[?\ V%M_J\^IWLNZ5=<'^G^Q]^Z]T _:G_%IJO\ 6_XG
MVW'U9O+[.J4._C^YDO\ !K"W^M[-)(OTNDO5X'2-1!-U'T]X:PW/7W70(_\
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M(OUC\@J?J#XE]%TE%2UN^^T]Z[3J,+L+KEEU3Y"9W9;FWJ_AP%A8CGZ#\Z8
MY8]VX.7N7#91_J73.:^845Q_J]<_:-]RY.:XW*X:?"VP!)]33_#\^C!]"='Y
MW8-7ENR.ULY6;S[UW^FG+5C-JH,=32?YK$XJ(#0:0K8<7%N  !<RI[/^WDVW
MTWZ_!$LI_5!XQ?-/GZ]!C>=RAN_TTH$4?F3\_0#^?37N'YA;1I]P93!;&ZX[
M0[<Q>TJQ*/<VZ.M<"<CC<=48Q3Y81*/^!:P\V,) (_V_LNO??B%KT"TMKFZA
MQXLK&G^ &G\NEEGR<VX0>,]S#;DUH.-?YC_+TOZKY1]84W40[MAR61RNP&KJ
M&@K!0XP#*4U7DJH4GAK*75H/VJ_YZYNQ^E[>SK<?>+;+*S&Y+_9DT ]?2GK^
M71;!R]=&Y^F.#DU\J#/3!LKY1;*W1!OW*Y#:.\=D[(VKM<[RHNR=XX$4..R&
M/) ^ZHP%'))XM]1_MO93M'O!%O4(O/ \*W/E-QXTX#IZZY::S(4$%J@$*<@T
MJ<FG#CPK3H-IOG%MN##TN[:_I?NO&]<U#"L/9"[2!QY@)M]WJ\_W?VA_IY+>
MR.?WWC+077[OO/HJT$]34FM,=],?;]G1I+R)6H%U#JID8Q]OI^SIB^8/?TVW
M,)U%!LRMWG-3[KW)M+=M9G-F41KZ:IPGW+ 8[[L@-]W7D$_:7*_X^P][U>YG
MB0[=-:4B32>)&,5]?*G2OE;E?ZXW6L!-&,^OGBG#Y]"7/V#U/N?M'X\[GRVW
M^PJ;L'<^%W=6=;4-:*G;HI*;U&O_ (M2@W-B2?7]5M^+>QW=\R;1O5W974]O
M_C MQ4UX^ 2/3.>B3]QR.CR(RZ0:,*5X@'&<8/\ L=<<S\P-CPY+-[/VGLKL
M+LSL'96:R&%RVS]M;?TS4_\ ##IFK%*5#0FC/ X'_%3[=/?G;+>]%E8V%[)-
M%FMO$:"GV3D^7IU:VY0N-.NY=-+4-2W&OY#CBAKGH3NH_D+L?M_;N6SF H\U
MA1M2JK\-O7";HHACZC'5&.4D-5D?7@6M?\&]O8BY/]QK+G"WGN(O\5^G ,WU
M&9,_9_JKCCTGWGE>XVBX%N2)=1[:>?[?LZ!"K^<&R9XLGF-I=5=O[PZUP=8M
M!6]K[4V@*_'_ .XRQE,=QKJN/PS#DW]A"7WY@'Z\5C>M:UIX[)2 ?;5Z#\R#
M\NC(<ASU$!D@%P03IKD_ZOD.C#5O>G65+U2O=HW32_Z/32#+-E]'KJF)-_#^
M!77'_ :UO^('EWS_ &$&SP;SI/T]::?,MPI3C7HD7E>_-T=N_P!%IQ]!Q_9C
MCT!N)^;&S37[;I-X];=J]8;:WC6&BVSO/LC!?88V:HM>$Z;VHQ->_IXL;_3G
MV!MO]][.[O((;N"XB2;/C UB^=._-*>5>C<\GSVX;0Z,R\5&&%<YR<^E:=#;
ML?M_9N^]W=C[/Q=#FZ?=?569?"[GHJV@&-##)$K%6P@$^:CD8"X/];_X^Q[R
MOSO!S/=7-B>P6M:?MIT27>RW%@+:YP1<4_P?ZL]!+V_\F<!@Z+N+;&VZ3>=9
MO/K3;%#5Y>NVS@!N*EIJK>E);'D,;V%'Q43\"YU&Y M[ O/7NK;[-9[I9H9#
M<5.20!%D<2:4SY]"7E_E6>Z9'G*H)#P.":5K3UKY#TSTA_CW\CMJT/QJI=V]
MH9+>] _7.*P./W=N_>./5_XU494N0N)G+:\OY0+&]R!:X(Y!7[:^ZJP\N_4W
M(D_0)TR25/GPID_D>M<Q\JSV5W]$M#JX4\J#S]/R'2EPWS,VF]=@X]Z]6]O=
M6;<W96_:;:WKO[!&@QT]1DQ_DAN+?:BKY-YAR/\ ;^S/;O?.SO+G3/;>!JJ?
MU37A^7R]3UK<N2WL8&E@NH;@BE0O$?;0_LP.A.[5^1>WNK<W@=K0;>W+O_?^
MYJ'(5F$ZZV)0#)Y%8*#_ #M66 )BIC8^D#\<\>S[F_W:@Y;\"WMX)+N:;SM\
M#/11LG+<V[UN)BMO$#QN,@G_ #]0.I?D9M?M[-9_8KXO='7/8>VZ+'U69V'O
MR@&/R+4^1_56*UE_;4$'20+WX]F/(_N=#SE<3P>!<6D\5:!LC'KT[O?*$^RP
M+/47%N?]'@IT8DX;STUYZW)UA/YM]/\ 8W_/N3?H?LZ#/U73U28C'Q8;*Q?:
M?Y+4UE(XXO\ YJ16_P!@+^UHM?\ $STE-R?J1_J'0M>QMT'>@OW7_P 79_\
MJ!/^]^PCNW#_ %?/HSL^'^KUZ3_@_P!K_P"3?^-^R7HQ\3KW@_VO_DW_ (W[
M]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q
M.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#
M_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^
M3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\
MC?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW
M7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z
M]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]
MK_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-
M_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-
M^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>
M\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW
M@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO
M_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_
M (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[
M]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q
M.O>#_:_^3?\ C?OW7O$ZC^_=.=2/!_M?_)O_ !OW[IOQ.O>#_:_^3?\ C?OW
M7O$Z]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z
M]X/]K_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.O>#_:_^3?\ C?OW7O$Z]X/]
MK_Y-_P"-^_=>\3KW@_VO_DW_ (W[]U[Q.FS<_P#Q;LA_K_\ 1OM/+_9_G_GZ
M/]C_ +?H.>++IN03:Y/-_P"A]^CDZ&DT-.FG,U7V6.KJBWU ^O\ K^]Z.RG2
MJQAI/GH+<6-=<@/XN;C_ %O;8.K_ %?/H=7_ &_LZ5>DQ,1_K7MS?_;^](:?
MZOLZ)X!4=+OK>@^XJ:RN'_*)CC:_/Z0?]MR/;M-#] WG"_%O;C]G0M^#_:_^
M3?\ C?M_J,O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?O
MW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/
M]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW
M[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>
M#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^
M-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3K
MW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW
M_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$
MZ]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y
M-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[
MQ.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_
M^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=
M>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_V
MO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?O
MW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/
M]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW
M[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>
M#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^
M-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3K
MW@_VO_DW_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW
M_C?OW7O$Z]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$
MZ]X/]K_Y-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$Z]X/]K_Y
M-_XW[]U[Q.O>#_:_^3?^-^_=>\3KW@_VO_DW_C?OW7O$ZF>/_'_>/;?B=.=!
MQOC_ ( UG^NWM7#TX.(^SJI+Y&?\":K_ 'W^I]N0?&>J6W]L.BA_R]/^WHS?
M^*Y]A_[U![EJP_Y):?\ -O\ PCK%S;?^5ON?^:-S_P ?'6TI[:ZE+KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[IO]^Z]TX>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZP1_\
M"G_X)'_O?N@^+IU> _U>O5,O\\C_ +)1ZV_\65Z2_P#<NM]G>P?C_P":;_\
M''ZA_P!Z_P#DEV__ #W6G_:3!U;G'%_D]"+?0F]O\">1[A+=/]R)!UE!MY_0
MMNN/@_VO_DW_ (W[2=/^)U[P?[7_ ,F_\;]^Z]XG0)]I?\ :S_@O_$^ZP?Y3
MT\WE]G5*'R"'BDR7^N/]XO[-EXG[>D8X?LZO-Z9VYALETQU5/-1-]T.J^NOH
M?K?$TY)MQ]?]\?93>[?^J/L'2A+HAV_TS?X>A/I=MX>D!G^S/W-(.1D3;Z_[
MQ[9AL81QZ6FZ+<.GYA=2/S?_ 'NW_%/9C'%].?\ 5\^D-R:_ZOLZQS3$&PM>
MW)^MK_\ $^U2KYGIKJ;[2=&'7O>KO^P_U>O3:\3TF-K/X:>NH2=7VM?_  _Z
M?C_8_P"M[0;6*P]*+DBM?G7I3^S#IOJ)H'^/MSPCTBUGK"_^;_Y#_P"(]V@X
M_EUY^/4P$,32V'+<'_'C\?TX]L7D/U Z?4TZ8I=NX:8><4>-4#GAO^)]IOW3
M#_HW5O$(X=.D4=+0TP@@#&EYY!'MV%/I^O?45SGK)]/K_B2/K[4_V_ZW27Y=
M2O;?2[KWOW7NO>_=>Z][]U[K#/\ H'_!A_O1]^Z]U&_!_P!<?\3[<DZ+[+_)
M_EZ*]U\P;Y3_ "+@)M]WM3H:Y_P%)D![@OE*^^GYKO(?^78_\^]">[@K8(?1
MW_X\>J9_YEW\JKY9]U?+D_*OX<;LZ63*=J]4['ZC[HV=WGD<ABZ2FJMC3U#8
M3<>+?%TDT3^.*HT55 Q9YGT:39PJYI>V_NU;\M6XM9$56TA2K5I@8(I]OV?+
MS$;7VWR7,A#5H"3C[>'[?]D]60?RSO@'M7^7CTAGMFU.]&[3[I[1W)ENS>_^
MX<ABTQ4VXMR9:ZP)!3H%EI,-BJ>-:/&T;KJTJ9+'5=0?S'SA%S3/-*UQ&?-C
MV?IM_.GR'2K;ML:WB&"*8 SGA7SX^M. ZL]^[H[FX<?Z_P#R/V'/WC#<?\2(
MNC$@CH#N[^G^N_D-U3V'TKVK@Z'<>P>U-J9W9>[L+4RJDD^)W31I S*2#_E2
M3HIIK_E1^1RL&_+920O'/56J*9^T=,7%F93JID9\N/ _[/6J70?R!_F7+V-L
M+HC>'>_3N\OA7L;LS9&Z3VM4RY3'=G5NU>O<JN1Q>TLAB_"<><H\L5+"^5^Y
M$?C83JC2#29FW#WQADVT6:R0M*0$<>(HD !!!.:4'[.B']QRF74 0:>E03GT
M_P"+ZW%,C5@G\6K22>+ 6'U_ _!]P1-OL*0UF^FX="I8_IL"O1<M[1P'Y"]7
MJ>!_HW[#O;GZU5%_M_K[A7F2:']^VOVC_+T+;(G]V7?VC_!T+OBJ@0;^GFQ(
M_P ?^1>Y*NM7@]$=OXX/0==Q1?\ &(>S](-O]'6X";_XTJ?\:]@7WEF/]7[K
M1_:>"*?MZ.^6:?56O@</&ZJ^ZA^(\/8?Q@VIV5MO.YD=U55/3[EV%N"NK]*T
M"[8)%+B:3GBEX)N1]1]0 ;XM<N>RQW[9H]TM9B)M9!05 .?,?Q?X/+J2]RYS
M%GN_TMR!I(SYUKY_9T='H'O&M[PZDW=CIZ),/W-M''Y[;>^=MF/150YH4E3"
MM2/3>]41:WX8'_&\S\E\\S<][5?0,3%=K$8DCR RFHKFGS!^8(\N@7S!L8VC
M<%:(ULRP)^5"#3''.>BB_$O;O?F;Z@H:7K3OS9FS<9MJMS]'F=KYKJNER%1C
MZ@U!-8:^K9#]5%S<_2P^@XA+VYM-RW.SN(8K\VW]H?AKB@%02IP?+TZ%G.LM
MI:W(+VK-4 5#$5I7R##/^'H/MWX3'4'Q8^2-1C.P<9V>-Q=[;2J\Q5;:VW5;
M<Q]/D?N:%L@HX$-N;?Y/QR/\/9?N.V1;+R_+%]2T^FXP2GR:G&GKY^G2^QC,
MFYK']-&OZ#"AN030D>A\J?SZL6^0>]=N]7_'C*9[,[,H=\8F#:FS<>NV:U;X
MRH.1\$%(U78C_)5*FWUY%O\ 'WDIS7N47*W*EO/#!%+7POTO3%?+Y=1IM=B=
MVO3 &*T+Y\^)K2OSZ*EW#2_(REZ"W+N#LKMWI[:6QJG8U4J;+V%M1<A]T!2@
MT>(I*^J'/(_Y1R;?ZW(QUYLO][FV53+<0&"2E(28*\?D#3]OVYZD788-NGW$
M0P6K^.)#W$D#YFE17]GV8Z<>SYX3\7OA*%O3V[)Z,&HD,#J#\V^HX_J?9WS:
MT,_+FTN\5/!;_..D^PVY&\WD,T.NO\N'0U=OKI^9GQ5LQ%.=K]L<_P#5+)[%
MG/M_X?,NT>#_ ,HZ?]6#T&]I@^IVR\K_ !?SQTV_%&$1=J_,>L2DO4U/=?\
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M/:W:.1K*RGX&E?4?Y%'1/>;N\JT)'SP.(_XKH;[?3ZFS?\0?<BR,Y_1\9O\
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M*1R::_\ 7T_\3[C:W]B]A=19CQF'G^LM8_F*(*?F#T+'Y[W,35JHX?AX^?\
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MGW6":6*(;@P^++!5#"]A]#<?0EV?;9X,DCII9XVH(P17[/\ /T=OC^A_V_\
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M5_WW^P]I:GJ2? Z"G)3^>MJ%N+DD#_6^O^VN;>W=7=T.+*']$#IQVW_P//\
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M#E#HK#!39'[,50H@0 "'M9VY;013@^H_V/\ +U:*8R1UQ\0'#U_XK_!TK?\
MA-'N/^6CN/8/RG;^7+US\JNNMO)NSKZ#M2+Y3[FV]FI:J?\ A]:U!_"$PM=6
MA1_G#,&C-U_*BP+6]Q2RBB</R^?V=>V]$:FNG$\ :^7K7RZ'S^8!_P */_@'
M\ ^SLWT9E#V3WKW1M:2?&]AX/IV#'ST.WLG"S"3&YC,Y:II4_B4/C?7%2^66
MG/I12_I]LC9Y!'I)S_EZ>>]+>@'V5-#_ "'V=.7\NW_A1)\#?YBW9]!T=MH[
M_P"A^[-PU3Q;(V/W+'C*6EW.,>?*E'AL[BZF:G.1G))2AJ6A=C'IIT4?ME'+
ML,D7 _ZORZO#N)>OG^61^1K7CGB>M@5A5Q?7G\<BWT_QXO[)_$Z-S/7HHOS"
M^9'QZ^"G1>X>^_DKOJ'K[8&+JFPT%0I?-9?)Y#(QF2'#8C'TFDY#)S1JS'2X
M6,7)-@?9M;;;+<9;_4>BNXF\(T4CR)]/Y?R ZUQ,?_PL7_E]U6]H,/DOC]\H
M\9LYZW[#^^,E+MJ6MI(E]/W0P]-E"[&]QH2H$][DII]0,8]B4'I+]:Q''/I0
M_P">O\NME?I_Y3?'KOOH'$?)_K/MK;6Y.A]P;)R&]/\ 2:<F^+I*.CPAMD8<
MQ'("V*.)%_OTJM3T@(8EU*GV43;5<12UXCUZ71WL0%*9QCU^SU^7#Y]:Z7>/
M_"O+^7/UEV1EMC[#ZK[^[YVS@ZJ3'/V3L_&X';&%KHJ25P:K#QY>MCR.0U.M
MU>IAI$D'Z%5B1[-TV35Q_P W2=]Q1N/^"M3^T4_8?7J\_P"!7\Q3XL?S(NI1
MV]\7]]U^9I<-F*?:O86SMT8YL)N+;M=5+K3'Y;':W(CKF!6DG!^RJR-"N9 4
M""[VMK<5'Y];6ZBDP1GR]#_F_P!5*]:57\L+_N+:^5/_ (L9\]/_ ';9CV>[
ME_N,?S_R]%L/]I^S_)TV_P T[_N+)ZC_ /$J?"#_ -YO >U-M_N./L'^#KUS
M\7^KU;KZ,U5%_N0R'! .4'U_P^G^V]A.[\_L/1]9FH_U>G6'Q_X_[Q[0]:Z]
MX_\ '_>/;W@GKW7O'_C_ +Q[]X)Z]U[Q_P"/^\>_>">O=>\?^/\ O'OW@GKW
M7O'_ (_[Q[]X)Z]U[Q_X_P"\>_>">O=>\?\ C_O'OW@GKW6/W[P3U[K)X_\
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M>F?^?>=H?^<>(_\ JOVWH7_5_P 7T[XTGJO[3UP_X<RZE_YX#L__ ,X\1_\
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MYNN/_#C74G_/-]P_^<F(_P#J_P![_=5Q_J'^SUKZB/U7^?\ FZY?\.-]2?\
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M_7/^M[,8'KTCFD"X' 8'3IM?OF+X\YX[DRV*S.>VAN=&P>Z<?ACI^WJ1_P
MYAY1]1^/I[O>>OKQZ8C7%*T(R/\ +T*'_#EW2G_/#=H?^<6)_P#JWV5Z&^?^
MK\^C#4OJO\^LG_#F?3G_ #[WL[_S@Q'_ -6^V_!;Y]:^H3U7]C?YNO?\.5=-
M?\^^[3/_ %0X@_\ QY[V;=9_7K7B2#S7^?6#_AR+I#_GV':/_G+B/_JSVF^@
M7U_D.M^/)ZKUF_X<OZA_YXCL_P#\X,5_]7^W?I4]#_+I_P 5_P")?Y]</^'*
M.FO^??=H?^<>)_\ JSWO0O\ J_XOJGB2?T?]7Y=<?^'*>H?^??=H?^<6)_\
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M_?1-W'MSMS<':-TP[8/^$_Q;7_N.;5.OW++J_P \+@?@^[\R<Q'F#P>S1X$
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MP\'_ .:<G_'7ZASWK_Y)EM_SW6?_ &DP]6^4_P#P&/\ P8>X=W/^TZR>V_\
ML/\ 5\NN7M-%QZ?ZD>V^E'0?[MQWW4!XOQP?]X]V7K<ITGHC787339:HJP*2
MU_K?U?3VX'KTR\.GH#:CXZF2T_VK6_UK^W8FZIH _P!0ZA_[+F?^54_\D_\
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M*1TXR@?ZO]CHW_5W61P4='?\FW^W]W$M/]7^SUH)JZ-U]C_N(^WY_P!5>_\
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M=GX3)_'L5];@*,E*[.9[(Y1J.AHUDUU4M%CXXTJ7('A<A2#-B@Q0?LI7[?\
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M4XKO!#":D?=-%&5$;>T#7\0FH3G_ %<>GWM#HU#A_A^8'^KAGCU2K\2MQ?\
M"D[^37LC?WPYZJ^$61^0?6;[AS.6ZRW=0[-R?:>*Q57F]:3UVV<O@<A1QU5)
MD'2*K6AR,4QC#!C"@E-S,2QS"F#7Y=(G4J02>'S\O0US_EZO1_D._%/^:UU;
M_I&^0/\ ,W^1O;F4J>QHYVV%\8-[[Z&]X,?-F*^+-5NX<X U8N.R5,$=<9CX
M:N.:E#-?QI98BC=)P!C_ "UZ7VT;L:./\&!Z#_!Z4_E63\ OY>7S<ZK_ .%(
M/R'^6V_?CAVAM;XY[G[M^8^[,#W'EJ"E@Q-3C=[9.OJ,-5>;[@*4R,<T0!5C
MJ+'1>P+K+R[3PBV2*GR^WI-';25TU - .(XXZA?S#/Y=OSC[0_X4B=8?*O87
MQP[7W;\=<3V)\3,C6=S;<P5+/BJ6BV7@\/39257CF,8&-DI9U;BRE!K/JU>[
M0W2^%J_U8IUZ2WDD:AI4UXGU)]<];TDTOGJLC/3_ $X XM["=S+6?_5\NCRV
M%!_J_P!7ETW^Z],=>]^Z]U(]^Z4=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=1_?ND_4CW[I1U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U']^Z3]2/?NE'
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]J
M.O=!_O?_ (!5G^P_XCVROG]G6Y/B'52/R/\ \_5_['_>_:R'^TZ8;^TZ)_\
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MGO+\_P#+U2]_/"_[)5Z\_P#%D^C_ /W+K/9]L/!O^:;_ /''ZACWL_Y)EO\
M\]UG_P!I,75P$'_ =O\ @X]PMN?Q_P"KTZRBV_\ L/\ 5\NN_:6'I_J1[WTH
MZA2TWF'/NZUZ3])ZIP$$GT/^\?U]^U \>M@D=0/[K4/_ "I#_;?\;][H/E_J
M_/K>L]>_NE1?\J(_VP]^TC_4#UOQ&]>O?W2HO^5$?[8>_:1_J!Z]XC>O7?\
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M/_E1/_)/_&_==7R'3_A'U_EU[^YE'_RHG_DG_C?OVKY#KWA'U_EUC_NE1?\
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MU[W[KW7O?NO=>]^Z]U[W[KW7O:?I1U[VHZ3]>]^Z]UR^W;_4?\G?\;]I^GM
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M(Z.V_N[8766YOD9W#NVAV+TELO9FY:S["HIEHTTU-?4U3Z(S2TS6J?7]""2
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH_^[_\
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M[IBZRQLD/B$G,XI*G<+5;0_5POD!*<6!]/LT_=:#UI_J^?2$7K^H_8?\-/\
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M7RZ"SYE_]QBNS_\ Q8/XO_\ OOMN^WA_8_L_R=.#^V_)O\#=&@_X5T?%C/\
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MHW4O:1Z?ZOV]!AN_JCK3L5::GWUUMMO<])3 _9S;NP%-DF_'T,I!_P!LHO\
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M_=>Z][]U[J/[]U[H-.W?^//KO^H_&_[TWMB?@.A5R5_N=^7^;HC+R">9I1]
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MQ<C^@VGFNYGE UF&0<,Z0U3\_3K85_V=/XD_]Y.]+_\ H>X__K[[3?0R?/\
M;_L]27_6"P_WZO[#U$_V=;XD?]Y-=-?^A[C_ /H_V[]"_P#J(_S],_U@L?\
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M/YC_ #]>&_V'G,GY"O4G_9UOB1_WDUTU_P"A[C_^C_=OH7_U$?Y^O?U@L?\
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M_P ^TP7_ %(3_BGO?]<KO_?DG[3_ )^J?ZPNP?\ *!:?\XX_\W7+_9,NL_\
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M)QO_ "J_[U[]I^W_ %?EU[2?7KW^@G&_\JO^]>_:?M_U?EU[2?7KW^@G&_\
M*K_O7OVG[?\ 5^77M)]>O?Z"<;_RJ_[U[]I^W_5^77M)]>N'^@;&_P#*J/\
M;?\ &_>M'R/\O\W6Z'UZ]_H&QO\ RJC_ &W_ !OW[1\C_+_-UZA]>O?Z!L;_
M ,JH_P!M_P ;]^T?(_R_S=>H?7J3%T+C>/\ )E'Y /O>FGK_ *ORZUI/KTKL
M'U'1453S2FY_ Y]V0Z.K1GP.ATV_@Z?'0>%O^*^]+U=FU&O2\A_8^G'^OS?_
M %[>]$UZKUD]ZZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1_?NO=2/
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1_?NO=%#^8/_'O;,_ZCMS?
M^XB^WX?A_+IK\1_+_#T:O;7_ ![VV?\ M08O_P!PQ[8N.'3D'$_;_EZ<??NM
M]2/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U']^Z]U(]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UR/_ H_\@?[
MW[>M/[?K5WP'^KSZ$;V,NB#KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z1^:_X%+_
M ,LU_P!Z'L-;K_;_ +/\'2^R^'\CTS^RSHQZC^_=>ZD>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[J/[]U[J1[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[J/[]U[J1[]U[KWOW7NO>_=>Z][]U[J/[]U[J1[]U[KWOW7NO
M>_=>ZC^_=>ZD>_=>Z][]U[KWOW7NO>_=>ZC^_=>ZD>_=>Z][]U[KWOW7NH_O
MW7NI'OW7NO>_=>Z][]U[J/[]U[H%N^?^98U__4?CO_<L^VKO^T?[>AO[9?\
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M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K'X_\?\
M>/?NO= -VW6=D8E#F=I5G^X.F(-?0?PZCR0O]?-8?2]O]?WZ6L:^(G^?_/T-
M.3[*PNIOI[C_  D=%'W)VQNK=% N(S==]WCQR!_#?]?\?7_>/9))N,TG:_60
M&U>W=A:?KP?ET'COKF _IQ_M_:(RZCY]2"HT#KWM/U?I_P!L;KR6S*LYK"U7
MVM>R?8:KV!U<$'_7Y_V_M8D[AM*<>@WS#R]#S'#]/.,<>A\V+OSN'?V0\-#F
M/M,=I(KJ_P#AU&II:4<G_;6)^OM;"\EP_P#A_P '4+\T\H[1RU!P_P!G_53H
MZL4-3#2^">N-95&]@/Z<?X_\1[-X^/4+3YZR1_G_ &'OW5.LGOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J/[]U[J1[]U[KWOW7NH_OW
M7NI'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>ZC^_=>Z][]U[J1[]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J/[]U[J1[]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH_OW
M7NI'OW7NH_OW7NI'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[J/[]U[J1[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH_MR+AU[JH;H;_M\_\WO_
M !7+IK_XS]R8_P#RKL?^F_R=0#LW_*[7_P#SR1_\??JYZ>,#_*;7%C<6_P"(
M_P!]_L?8-I]3U,OT_E^?^K'4:8TD%JFI%R?H!Q]/H?\ 'VY#!7KW' Z)IV_\
MYOA[T1F:G;G:/?\ UOMG,Q'3E-KU.8;(9.ET #1]MCON:J  FQ -Q;\7]DM]
MS/9[8R1SW&HC!T1NU/S I7\^I5Y*]F^:>?(;B\VG;KFY3^,$?/R/$?E^SH>>
ML>P]A=K[3P6^>O=Y87>>T,]1FLQ&\MMY 5\-2X%[R2F[+_AJ ;CZ6Y]F<3+N
MD!>*ZJ&-"H!!!\Q0YJ.H_P!YV&\Y4N/H=SMI(9X/]_'&?L^SH4W]-FJ2=!_3
M;Z_XW_']/K[<6#PC0XZ03O\ 3"HZ+KW?\B^@N@<3AI^\.W-D]=TFX)C%A3NC
M)'"?>3QK8O!X[D*+DW*_X&PX*&>_LMI;Q;DNC<=**S'[0%!/^3H6<I^W^^>X
MA\':;;ZT_D/RR1GI4]5]N=7=O8"7/=3[^V3O_;\J?;X_/[.W/3[LA5C:VM*=
M5()^O(%_K>P]N1WMKN@+JVH#BH%"/M% >B?>=@O^59OH[RWEM9O6;S/VUZ%S
MW?HNZ+9\P+?[*5\E>/M0>D^P/3_Y!*C_ 'KZ>Q-L'^Y$7^F;_)T!O<'_ ))%
M]_S0'^7H OY8]W_E_?$PW''4N'-_KR:F;_BH]D7-C4O''RI_QCJOM3+_ ,A^
MV^Q#_P!5AT?R/\_[#V'NI+ZR>_=>ZC^_=>Z][]U[J1[]U[KWOW7NFNL_X%O_
M ,&'MD>7^KSZ]UC]UZ4=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U']^Z3]%7^7'_ !9MG_\ :PW)_P"XOM1;\/\ 5\NK/\;?
M8/\ #T9W!_\ %BVW_P"&]C/_ '";W>?A_J^73D?'\^I?M)TSU(]^Z4=1_?ND
M_4CW[I1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW62+_@2O^Q_XGVIM>'[.DUW
MT+GL;]$'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TC\Y_P "%_Y8C_>O89O_ /<@
M_;TML_A/^KTZ9_9;T9]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1_?NO=2
M/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1_?NO=
M9)4U?\"#_D@/]>?]ZX_XI[H7\7JHM_I.'1)>Z^DI<<:K>&TZ1?L"%K*[!47U
MI2_/EYX-P/\ ?6X+KJ _Z'6G'J>_;3W%&+&Y(KPJ?/HJT4_E'[QYO_Q'LKTU
MZR#^'TZREUJ%\L0^V7B^H?T]T_L^'5"!;BAZ6G7&RLMV)GA145.M+CZ6,M6Y
M$L!]L!^?]Z_WW'M^*UDE?1&#T%.=N9+?E*W$\YJ>(^?5D6U=GXC9N&I<)C*2
MU/2@A&(XJ_\ '\7_ *V_V'L11P^$FA,]8A[KOG[\G^HGQZ8X=*B+U7OR#];<
M_7_;6M;V[)^KT5P?XKUC]TZMU(]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=1_?NO=2/?NO=>]^Z]U']^Z]U(]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4?W[KW4CW[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U']^Z]U(]^Z]U']^Z]U(]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O;D7#KW5/OQX(J?YS'SKE/TI_COT11W MPQC7F_^'N3K
MO]/ER+_3_P#/J]8^\O'ZGGG<?^>*'_JY<]7.3_\   _\&C_XCV!>IRZ#WL2E
MW!7=<;RI<#4K3[EJ]GYW^[U:GI^UR#05'V1O]"?NEX_VWT ]UN[9HXI!%6OA
M,4]=87HVY7G@M[^V^M_L_JH1<#U@,@J>M*?X@=5=:[TV%E-R[]VCCMR=N8[=
MNZ,%V+F-X+_>3(C)4]0+C747 ]-B1Q?ZW/)]X_6MI%=2UNT:3]61BJDJM2M0
M: Y-:UXYKUV^YHW.7;_IHK(>#;"UA\#&:@9JQK7)^7D.K7_Y'6\JW9V>^4_Q
M(R$D>GK#L.'?FR**L2\8PG8+>*9%O]6*M1O]./,?I<@R1[;7PCAN+"8GMHYK
MZ1$(Y/VT7]ORZPC^_#RL9VVCF>(4$Y,$K#UX@#[.[]G6Q=/.4&08<AE4_P!/
MKS8?X\?[Q['[_I_3CTZP$G/T^?\ 5FG6H9\F:K$?+#^8[WQEMV8FAW9UA\>,
M/C.F,'C<\3F*?^(1V7*%";67[\9$R<7N;BQO[A?F1DW[=IHV9A';H<*Q!$<5
M4&?FVIA_EZZ[>Q7+X]M.0K<Q )>[I2Y%Q2F#4D4_.+5UW\)-DTW6/\T[J/8W
M1T-7M3:N4Z\WGN;MG;6/KJK(8NIH/M)_MU,1*@WJ11<<#Z6L226N3U8;H@M"
M0.U)5.6TZ2S GB01Z\#FO6_O)[G!NWMK--NE))A(WTU*#/8*_M)_P=;A5/\
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MO/OW7NO>3_#_ 'GW[KW7O)_A_O/OW7NO>3_#_>??NO=>\G^'^\^_=>Z]Y/\
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M_P#7+?-OVM?^)-U%"1\CD_Y>M3'X9XC(Q]2Y#L;<=0M1G^XMW9CLW<M76$L
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M3M+:58:3^ZIHA!24$MI:JJ(NJQD$FY(\(!Y^EP/-?'>+KP[2"FIP$ (+.0M
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MJ5N+GV(>>C#S1##?)#W"BR \=+4U#\C^WHLY0/[JN9K"7[,?;C^8_81U9?\
M)_Y2]4?$SJR3MON:NRM#@XLEB\#@-O8#%IELGG,GDP6I<9BJ5_1/-.GJD9B
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M$9KP/$\2*GY#Y]$.Q<UZ++6T$BE:'2U-7P@4Q6M/E7/EZW@?'3Y(]3?*[J;
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MD1?Z9N@1[@XVB_\ /_%P3_/H#OY9M/-3?R__ (GTL^DU'^B/$:;BU]4$M_\
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MS".L^X^@?Y@/R4^/O2_5^)^->Z\7MG=><Z@[1?<D^5P.]:EH:G%UM%42/+/
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M@-K:^G;P_P!LW2<_E[Y6ASGS@_G'5V.F>6C;?NTX5FAC-.0M#C\O'<+(J&X
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M5K_@S\8_BC\3?B[NL9++=/S;ZW/4;GKIJ'*51:>OGQF*J*E89Y_&04F2-P.
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M#)@OF;\=<PA@?==?@[\E<YMZJQ8X_H49O]Z]ELO*TEKC13[0>CJS]Q-HN?\
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M[V&\AB$;/QI@,#W GY\.A'MVZ37\4MHH-%(P>*D?ZCC_ &.J[OA1\T]P=4_
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MK?JONR:CION+V9H:C2- _22 /]?Z^U')47C\N70_H/3_ 'GIKF1@-WLOF?\
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M5_\ MMO^VCK"W\SKMVE!AS?\NCY24TP)O0T\U+77OS]+<^])L5#V7:?;0_\
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M_K\>RC;=V;9H/&42'7Y$5_P]7O;&&X;]4T\L$CJ*FRMD1#!U0V5LQ:[9IOM
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MM;]V:R#F]_K[$&I88M34+>0\A_G_ #Z+W=I256H'F?,_YNK)1)Y;3?T87/\
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MVOV[_<@?ET67OP?E_GZU+/Y6'_;U7N+_ *@ODO\ ^[J;WEK[C_\ *J6OV/\
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M=>_ )>JH,CKD#_FIQTGSTDT(RI(J%V&)&I[ V_K;C_C?N'0LEO\ ZO\ 8ZS
M-_;GT'7 ?\ Q_P M%_WH^V6E\O\ 5QZ5W/77M1TDZD>T_1AU[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1_
M?ND_7O?NO=2/?NE'7O?NO=>]^Z]U[W[KW4?VHZ+^M=C_ (41?\RZ^+W_ (</
M:G_N#C/>37W>/[>[_P!(W^#J'?=O^PA^U/\ CK=71_#W_LDGXP_^()ZZ_P#<
M"+W!//?_ "59_L/_ !P=2/RY_N+#_P U&_P]&.G_ . X_P"##_H4^PE%Y_9_
MGZ$]S_E_R=<?>^G.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NLT
M'_ N@_V'M1;?ZOY=)+KH4O8XZ#77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T@LY_
MP._V"_\ $>PYNO\ ;?LZ--KX?ZO7IL]E71IU[W[KW7O?NO=>]^Z]U[W[KW4?
MW[KW4CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW4?W[KW7O:?I1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U'B_L_P"Q_P")][GX#I"G'JN+^:#W[+TC\9J_;&!RYQ6^NZJYMDX2J2]Z
M;$0 C+55P>"],13'^JU##C\G&R6?B_GCI!=SZ4!/!<G[?(?Y>BI?RU>C8.O.
MGV[1S%+_ +^SM@RPT(K6 %/MG'6% EOZUM=:8?X+_C['Y C35YL?^,_[)Z"\
MLWB/I\EX_;_L#_#U95[3]4Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@@[RZ:V_WY
MU;NSK/<!6DI\])_$,%G&/IQV2QUQ05+?U61=0/\ KW]K8"$<H?/@?0]6-68,
M/+B/4'JJ+X(_)K<?PP[IW%\<>[]6#ZZW#NE:+*1UHU4^"SM58465M<!L7F!I
M6IMP8R)Q^E?8;W6P+MXC8_P='-E=AE")QI^T>8^W_+ULQB$P'[<\CZ\_X7]@
MZ2(=".W8]=^_=6Z][3]*.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[J/[]TGZD>_=*.O>_=>Z][]U[J/[]TGZD>_=*.
MO>_=>Z][]U[J/[]TGZD>_=*.O>_=>Z][]U[KWOW7NO>_=>ZC^_=)^I'OW2CK
MWOW7NO>_=>Z][]U[J/[]TGZD>_=*.IV/_P"+ICO^#+_O9]K;/^VZ+=SX?ZOG
MUJ4?RKO^WK'=/_!_DM_[NY/>6_N'_P JE;?ZOQCJ!>5O^5AN_MC_ , ZVPZC
M]3_\@_\ $>\/_P /^KUZGSK-[;Z,.O>_=>Z][]U[KWOW7NO>_=>Z][]U[J/[
M]TGZ][]U[J1[]THZ][]U[KWOW7NO>_=>Z][]U[J/[]TGZD>_=*.O>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>ZC^_=)^I'OW2CKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWGJH+&P!
MN;?["WNT<OU/Z/26X%,]4"?S+OYKL?54V7Z!^-.5I<AVTZC;V\>U**1JVFV]
M41 *<=CV !J=PEK^KZTMK+:HN5E_DSV[DO*BX/8/C49I]GS]3Y=8A^]?O^O+
M0%CM0#7;@^%(P.DL>&HCU\E&3GRI4JGPD_E@UV[)J?O3YATL^1R&3JSF<%U!
MN>K^\EFJ*_G^)[LD()DD^O\ DUP22?,  29!WSF:VL5_Q+S-==>X_P"FX8^7
M$^?42<B>TUWS"XW+F(B1J&EI13$G"GD=3@>>% .!6C=; %/!04E%20XK_):>
MFQ_V..H<<+W)MS_O _Y'[CU[AYW\9^'62D,$!@I!G/$]1??NJ=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U-_<?\ )M^/=?%DCZ44M[GS
MZJ/^>O\ +:P_?]/E>U>F,5CL7WRV-TYS$A?L,5NJ"3DES<:LI?DU-Q_6?U7U
M"W8.8J$P70_3.2.%/F/G_(^?KU"'N7[5?UE'U6VE4OU!5'.1,/X7 ()7&#Q4
MY%14$*/Y9W\SK/;"W'3_ !'^6T^7QM-09,[0Z[[)W(O\.R>)J%!@.WMP>4V*
M6(%'4D7C/^> 06!1SUR!'"!?67"M)$/%#Z'Y>G^7R5>RWOG>;7?-RQS(NF8
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M?\5U[KD1X3:86/T]MS3UZWUF@AJ'-R0%!O>]_P#>OI[?,)C^+_5^WJ^H6_\
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M\5/D3T-B/BW\>L/F.]NI\7E\;T_UO0UU!D-]XO%U5+4XS'1D+8S7M<@&]_\
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MXI?-/ ?&SY<[U^3^0V96[HHMXKV4DNR\5G8,5-$.Q,BU45\\B26%,&/]F_\
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M $LH /\ MQ]/8HM^7I9TU_R?M_P]1_N/N/:;?-X!K_S9/B_X.DO_ +,[UO\
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M:7:^PM^Z8MK[D:KJZ12:^@;_ (&'_D(#Z>RBXY>FL.]H^A7L/.%GS!^A%/\
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MGF_>_P!Y]O\ 1=UA]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T'F_\
MLGK[J':TV\NR-U8?9^VJ$VCR61C,K5E_K#10*/\ +)OZG@>W'I2I-/\ +UM'
M:,T45/\ @^WJLG?'SA[H[6%9COCWM2CZPV2S<]I]B40R>2J- L/L<<0U/1'Z
MBR*3_5O>NZ3Y#U/'IQT6/*&I]!PZ+;7]14^\:\9[MG>F]>U]PU)U5U=GLY4O
M3'^GCI6NY_VX]^,NO+$M\Z];$0CPH"_(=+W#[-V=@;I@]K8/&D?G'XNF8B_^
M)+>VPH'52Q\S_AZ5@,,?^:IJ6G'T_3[UP].GN/KUC>.&3B6EHZG_ *HO>O\
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M4G-.BX_+#HZH^2?QM[@Z*H,]B=IU>_\ ;E%MO'[@R6*.5Q\/VTB. (1RGZ2
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M8O;N3:IFG\=S4'%13A3A^?6R /\ **MJFW.HFY_Q'^V]X\CQAU,]MGK'X/\
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ME1_,]:\_\I3;4E9NCNC?-4;2_P!U=M[:3_J(W'6)D'_WB,^Y.1:QN?D!^T]
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MK\NL/^@+=O\ S_S?/_)+_P#%?;?]=X?]\Q_M'5/]:V]_Y3;K]G6;_0-N4_\
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MSY"2QV\YZLW@";VX,48/M;M^)S]G^3I-N/P)]HZJC_E/BG_T6=P51_X'C?\
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M][VI]JXFK8\KB]C6D9@!?AJR9%_UQ_@2 AS#+I0GU-!^71YLR:G5?0$_F?\
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M:<?4]&JLW^H7_;>R_P"K'RZ.OISZGK"WH83"Q''/T^E[>Z/^IV=/6_\ BO\
MC'12_E[\O^KOAYU;ENRNPZN/)YZ*1%VEUW29.C.4SLX_524; ,54-_RD@W/T
M^IY-MNLI;IM"Q:%'!_,_YJ>O0>Y]YOL.1[8W5S<^-*P/Z'F3Y**E06;@J^9^
M70L[/W]E]U]18WM+%8&OJJ_,]<T6]:'9M#D-(-7D*8U?\.\O''I)M^?Z>T%[
M9I#((YAQ-0P]3GHWVW<)K^U^K!I2.G@^@!IU7D_S=^<)03-_*U[UQ]0  ,<.
MP=OHIM;^RRZ_]X_XCV>G9K*7_1X_LU'_ * ZC8<^[W;&G[DO3\ZP?]M'0F?"
M_P";N>^7^Z>V=L9#H7<755#U##BL#D-TU^<I-P4LN2B95J,1 $4 U%,22MF:
MUM-KV'M#?[;'"4!9#4#(-?E3[>C7D3W!'/BW++;SQ^&Y4AP%KYU%&:HS3TK]
MAH738'\SSY!]P4N[LGT]\ NV^T<!M?<N?VA6;HPV_,;)!YMMUWI_SE.PX1OJ
M38ZASP1[?DV9+81DRQ*)/,$_;FB_ZOLZ#UE[FWF\_5B';;Z;Z4Z:LL:AR"0=
M.J521@&M "/G4 R'2_RA^578?9> V)V+\!>U>GMIUIKS7;]W#N[&9F+'"BI.
M9)4ALH$FFUBPO] #Q[NUC9PP@K)&P/XJX&/F!T(MBW_<]UF,5QM]W;'% _AF
MN1_ON63U_EY=#_N/&U'3W9&VNP,"#B]I;SR[8#>N$('VWJ!$4W %N#]?\?\
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M_+HMTGRUJ?I#L7'BP_&XV'_17M48?E_J_9TP+D^I_9UB_P!FVR?_ #PN-_\
M0A;_ */]N?2=>^J/K_+KW^S:U/\ SP>-_P#0B?\ Z.]L?2?(_P"K\NM_4_TO
MY'K!_LV69'^8V+M__7_B%9_T=[?^F^76OJ/Z3?L'7O\ 9K\M_P \=@/_ #XU
MG_1WM/\ 2'T_E_L=6^J'J?V=8_\ 9KMQ\^':&WN?^F^L/^VN3[L+91Y=5^IF
M/F?Y=>_V:G=?_/([>_Y)J_\ H[WKZ5/X?\/7OJ9_4_RZQ?[-/N[_ )Y3;_\
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M_P!Z_E!67G_A&?/^/]VZ4_\ $>_5'^JG6O#(\Q^T]=_WC^4'_*KGO_0;I?\
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M?VGKW\.Q_P#SIL?_ .>NA_XK[]0];J>N7V&/_P"5/&_^>FA]ZZ]4]>^PQ_\
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M[W[KW7O;O@P>G6ZGKWOW@P>G7JGK)Y6_HO\ R3[IX<'^K_B^O5/6/WKPH?\
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MOW7NO0RWL5/^'_&C[3SP?4=;!IUS\H^EK@?F^F_Y^G/^]^]^-JZ5 ?5]83*
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M^'^P/]/Z>VK8=_\ J^72FY:D&/MZUC/AQ3GIOY[=@]7,QI\?)D.T]CL6 /\
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MB]A;%P>P<)2XO%TM^?\ +J[C[FHJ0/I[PXE4(U7XUP.AYO&YS;OF'I:Z1$.
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M(Y^#:?QS[XW$U4*>3'=3;TJ OU_SD**3]?ZV]FFRCZF\!\\]!_F6X^DVN<G
M$=2?LKU6'_PGAP(7;?RKW@W'DRVPMLCFY'V=)49$_P"O_G /=O=C$T*>BJ/Y
MGJ+/N5IXFU[E<\-5S*?^,)_GZV0!]3_K_P#$#W!L?706YX_G_D'7?MSI+U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW4*<5+5/VUP;_4?2]Q?ZV)]V6Y\./JT,OT]QTC-W]8;"W]^_N7
M9OWLPX_B 88FK(4?TA!'^\?[U[.]OWZ;;OA?_)T#-XY)L]Z_M8/RXCI!?[+'
MU5_7<O\ Z$=7_P!&^UO]=;[Y?MZ(?]:/:_63]G77^RR=5_\ 9R?^A)5_]&>V
MOZ[7_P#1_;UO_6BVS_AG^\]>_P!EHZI_U&Z/_0BJ?^C/:C^N]]\OVGKW^M-M
MGK)^P=>_V6CJG_4;H_\ 0BJ?^C/?OZ[WWR_:>O?ZTVV>LG[!U[_9:.J?]1NC
M_P!"*I_Z,]^_KO??+]IZ]_K3;9ZR?L'7O]EHZI_U&Z/_ $(JG_HSW[^N]]\O
MVGKW^M-MGK)^P==?[+/U;_J-R_\ H1U/_1OMC^O-]\OV]>_UIML]9/V#KW^R
MS]6_ZC<O_H1U/_1OOW]>;[Y?MZ]_K3;9ZR?L'7+_ &6?JS_4;K_]".J_Z-][
M_KQ<?/\ ;_T-U7_6HVWY?LZRT/QNZ=HIC*<+7Y;CZ9G(562^I_%K>VAS7-+Q
M_F?]CIZU]I=GM\C^0 Z'*CI*&AH**@HACZ6GH[ T./8&Y)Y_-_I;V';J9[A_
M$?\ 9U(^UV4&W0^!!7[>O$'_ !HK'GC\G_C0]TB[.GO]Q^LL9,O,X%[D<C\?
M['WJ6/Q.FKV$W/3+F<)B-Q4%9BMSTN/R>-J^4HJPV/\ L./9C'?N@T+TDWW;
M(-W(AEQ3TZ!EOC/U&O[]-@]R49Y_R"AW#5XKG_7*GV=1<S36G]HB_MIU'!]I
M-F@'Z%O(?F17KO\ V6CJS_4;F_\ 0BJO^C/;_P#7*X_H_M/6O]:G;?\ AG[/
M]GKE_LLG5?\ V<G_ *$E7_T9[I_7NX_H_P"]=/\ ^M!MOJ_[/]GKA_LL_6MO
M/IW5;_PX*O\ WU_;7]?;OY_M/5?]:BRX4'[.NS\8>MOK_OZ+_7_B_P!6?^(]
MO0\\7?S_ &];_P!:FR/D/V=<O]EHZN_IN;_T)*G_ *-]U_KY<?+]I_S=>_UI
MMM]9/]Y_V>O?[+1U;_V<W_H15?\ T9[>_KQ<?+_>O]CK7^M/MO\ PS]@Z]_L
MM'5W]-S?^A)4_P#1OMG^OEQ\OVG_ #=;_P!:;;?63_>?]GKW^RR]8_ZG='_G
M^J_^*>WOZ^WGS_;UK_6FL?0?LZDP?'+JB&4RS8FNRM4?TG-;AJLC2C^MB;#V
MGN.;;BX/?_,D]*XO:O;%_M?V #_8Z&JAI8,5!145%0XZEI:-N3CS<\_@_P"P
M_P /8;NMQFN7Z'.UV'[N@J?]7^'J7[;Z6=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]UR@_P"!-%_P;WZV_P!7\NJ3\?\ 5\NAF]CCH-=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW2!S__  ./^^_'L,;UY_GT=[9Y=)WV3=+>O>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZQR?C_ &/OW7NL?M1U[KWO
MW7NO>_=>Z][]U[KWOW7NN"?3_8^ZOPZO:]:T?R!1.H?YLIR<P^VQ>8[)Z^S>
MFUK4F^Z*.DE/_)+GW(6V3=@/S'0-O.R0C^B1^8K_ )NKS/'X;>;FJ^A(]J.B
M\]8O?NM=>]^Z]U[W[KW7&6."6#PUUZO&U?\ P/H!_A_Q3WOJP^75"E/L^;H?
MN7LOX]9$ZL=B*[^_'5^0K%(^YP>Y0)D?\?YJ(J?]O[W,=+'T!J/LZ>1**(_R
M-/7H1?=>O=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW4/(Y:@P]!7Y;(B]+@:2MJ^/^K?\ ['^I]T)I^5>K@5QZTZ-7
M_+MV!78GIG-=M9VE,.?[RW57;UA!%@<?A3X\<W^LTQ;_ &P]J154U'\1K^0Z
M2LFI](_" /S/5A/MGK77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]UQT+_3_>?;WC'KW14OEU\B8/C?U-4YZDK*%M_P"[TR.T^O*9%U::I#:H
MR?/T;'_I7_$^W3)X:5\S@?Y^GHU[Z'@,G_-T77^4C\9<C!)G_EGO8"2LS?\
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M/[A;R[,Q&$S"L_\ 8;'F:0Q/8CAY%(^G!]N_2@#I/]8YX YX?/HT<<U/,3/
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M *!_EQT#V?Z*?;^_]74?8E[B]/7C_<;)-8_\HCZC;^H!_K[=WFT_>$;R'A4
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MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K')^/\
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M3VSU'528/<M'3X[<]$^#=L*,C3Y&F\GB+TC0U)N1^^#,;WO:Y]@G:[N]Y4W
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MA'IY9\JTX?/H<.QMW;:W-\#=TTFS\[@\]/M[JK9.!W(,+6?>''5&FG_:EO\
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M_C9U[D>Q*>EW,V5PR4&:I,U_E\&4GV[5>))9CR;CQ_G^G/Y]EW,X;;MP<0U
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M2Q%E&G52,SD\_0D#CV$>8N;Q"Z_1ZD2)-"=W<%\^'J23TGFDF;^SXDU.//\
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MRP_VYM_O?O1C4>9_+KP<GRZ<]M[C[/[(O#TUT9V/O9K?\7S+X]MO8NG)//\
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M5D?_ "CG_5^777_#<VZ_^?E;7_\ 0?J_^C??O^ MNO\ E*/[3_FZU_P5J?\
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M_7_8>V4X=7FZX>[]:Z][]U[KWOW7NO>_=>Z][]U[KWOW7NIZ<EOZ@'5_OO\
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M[?;83-\X_P#BN@WN._7.Z?V]U-^T_P"STJF+2 \+?BX/^^M_OOS[$$$DD?\
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M_=>Z][]U[J/[]TGZD>_=*.O>_=>Z][]U[KWOW7NH_OW2?K/(=(L!Z@H_WO\
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MZ][]U[J/[4=)^I$=_/\ [$\^V_"^HKUXT7H>?Y9/7,G;G<>_/E;DJ8KM[8,
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MO9'U/7NJ5_Y\)'^R7;3D'T3Y);*DM_@<;D;>YQ]A3_NZ_P";%?\ #U$WNO\
M[A/_ *?_ )^3HR'\J:7P?RY/BU_X;>]/]XW%F?8;]U[;ZWF*[_YI_P#/S="7
MV[.G;+?[$_ZMKU8I[C)./^KTZ&4/'KWO75NH_OW2?J1[]THZ][]U[KWOW7NO
M>_=>ZC^_=)^I'OW2CKWOW7NO>_=>Z][]U[J/[]TGZDQ_\"*#_@G_ !3VJM/]
M7[.O7?\ D/\ A/0S^QMT'^O>_=>Z][]U[KWOW7NO>_=>Z][]U[H.MQ?\7/\
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M_0==83;^0HL-W14]>4PRBS5,KJ,?Y8V:[ D64WM<F_N=O:OG#9=LM)!?)XH
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M>M@GX0=>]N=4?%WK3K_OVNJ\QVO@Z?=S;I-7N3^_=6D^1SDLL5JP,P<_:*>
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MT_N;M"DOS_E=5Q/ER/Q<U#_T]H+C<$MO[/"_L'^STK@LB^3\7[6/^K\NKO\
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M?ZO\O1C223<L!P?[-O\ 7]AF%4^CZ/3!!J_U?Y^N)_?O?\_7\WO_ +;WZ?\
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MFX[6Q/\ O-YQ:WLY_JSN'^^'_P!Y'^?HO_?$9_T5?]YZ[_TW]$_\_P!NF/\
MT:V*_P"O_O7]5+__ )1W_P!X'^?KW[Z3_?R_[R>N7^G;HS_G^_3'_HUL3_U_
M]M_U3W#_ 'Q/_O0_S]>_?2?[^7_>3UW_ *<^A_\ G_'3/_HUL3_U_P#;G]5-
MQ_WQ-_O*_P#075?WM'_OYO\ >#UW_ISZ&_Y_STU_Z-7$_P#U1[K_ %5W'_E'
M;_>1UO\ >\7^_6_WD]=?Z?>@O^?[=._^C6Q'_7_W7^JVX?[X?]B_Y^O?O=/]
M^K_O)Z+-WO\ S#/B'\><)4Y/<_;>V]VYI*,U&.V#UON"GWYF<JUK*TDU,H6$
M7/*U$A@(!L+\>S[:_;F]W45D1ODH(+?RZ*;_ )RM=GXC3\R"HI]A/^#K7@ZP
MP'<?\X/YL5&_MZXC^$=1[-J\<=V0J",?@MOX&IUTFU8*H+_E&?R0NLO%V8LY
MLH8C)+>KNQ]HME^B04GDQ3Y?P_Z8^?4/6$<ON%>?4C@*TX&K>9X\!YC@*4ZW
M"$C@I?V*.C^UIJ/_ '&X_' ?6D/UMR;<G^I'^/O#>YE\2;7+UD/ /IQX'GUA
M]L^*>KZ#U[VWU3KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NI$HX^Y
M/]?K_K<_[[CW6.3Z?IZ?)_U?+K5/_F:]#=E?##Y7X[YP]"L]/LS<V^:;=U7D
M^)(<'NQ6_P MQV5 N/X3G%)9=0L\<\R\V-\O_;[F.UYIL1L^X^9[1Z-YUSP/
M^H]05S9M Y9NC?0\0M#Y:E\C7U'\N/5O7Q:_FF?%GY#83&TVY]U87H_LZH/W
M&X^O]\5[8&)ZJQ\QQN1<&DJZ5K+Z7%R2?H!<PWS3[/[GM%UJC=WC_P!#2,A2
M/L)P?]6.AQM//]G?+^I6+'$C/YCC^S^?D=\=^=#_ ([VZB/_ )57%'_>/N/8
M+@Y8O8?[:WF_WI?\_0J_?%J>$S_[P?\ -UD_TY]$_P#/^>F/_1JXK_ZH]Z_J
MGN/_ "CR_P"\K_GZI^]HO]^O_O)Z]_IVZ,_Y_OTQ_P"C6Q/_ %_]U_JGN'^^
M)_\ >A_GZW^^D_W\O^\GKW^G;HS_ )_OTQ_Z-;$_]?\ W[^J>X?[XG_WH?Y^
MO?OI/]_+_O)ZZ_T[]%WY[XZ7!_\ $K8G_K_[:FY3W \+>?\ WI?\_6_WS'_O
MY?\ >>NH^\>B9O\ FN_2U_\ Q*^)'_QQ[]_5'</^4>X_WH=:.\Q_[^7_ 'GH
M1<1EL5GJ!LU@,M1;APBB[5N!R=#E*47_ *K#[176VR[<*W< (^6>E5E??4FG
M _,$?X>L_P#C_L+7]E_@_P"^>E%?7KOW[JG7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U(]^Z4=1_?ND_7O?NO=>]^Z]U(]U\8]*.N?DXN!?_ &/_ !KW
M28?H_H]6!SGJMWYZ_P O3K?YH;;_ (VPAV5W7M^C7^X_8D$OZA8!:#,Q$$ST
M4H!L1Z8#;P7 M['W)W-UYRX2MR:*1Q\N/ _ZL=0=[I^SFV>Y$"WB+6]0U1OQ
M+4<1_E!K7SR 10#TC\EODY_+.[6J?C_W]M;*Y7KB"L-6VW=(K6I8<A:V4V;7
M2EONJ<\VI5N#QS3?43>\-ES<E;2HD!RE:_FI_9Z _;UAAL6_<T>SVYC;-XI)
M9$52=1E>!"D:B2 012A(J".W'6QSU+VYUGWILK&]A=2[OH]T;6ROUK*4#[JE
MJ1_RB5=&+BDJS_4&Q_K[ ^X;5+M;:9$J/\!^8\NLJ-HW6QW^W%QM]R"#P*FJ
MD?(CCPZ%7BY'ULMP?]B+^RX3:>E5^A)_9_EZAM]>;Z>+^[+_ ,)Z?G^?^K]G
M6+WKJG0%]Y?&7I7Y+[>.U.V=DT6Y8J8 8G.6&.R&/%[D4]?%>J3Z_E#8_P"\
M+K??I;'OC>M.!X$?GT0[]RKM_.:FUDM0RGBK"H-/\!'D0:CR/52N^_Y;WR5Z
MFE,_Q_W]BNX-I4H_R;9?9O\ D&4I[\>&/(LPM;_@T'^L/8[L=^,\7C3$,/G@
M_P";_!UCKS'[$26=P!9MI 'PM5AP P:U'_&OMZ)]N?>/9'6<HH>\_CGV_P!;
M:F*"KCV[4[EQEEY_X%QA6_W@\_X<^S5)H+S$$A7[01_L?SZB?=['=>7 +:]V
MYF!_%"1*M/7MHX_->/J,]0Z#Y"]1924*>PZ"CJK\'(+4XBH_Y.O^/\?=;BW$
M/^H])D21S36*^F*_LK7J;)WIU%%_S4W:0_Q.6(_XCW7Z:OK^SHO:Y9>,J?FX
M'^7I.U'R)ZLGE\>)W'E]Y5@XHZ7;.W:G<PXX/*Z?=X]M$'V]+09=QRA+_P#-
M,%O7T!'0J[.VC\L.WYO%T_\ %O<V)Q]0FNCWOV]_OS*?T_XCT?BWZ_\  <^]
M3SV\?]O<L?*M*#]K4_R]'VU<C;_NG^XEA'&/(RR"M?33%XAQYU(_PT.GUG_*
MFGW77TVZ/EMVU5;Z^V5JT=7=<G^[^&M_QRJZJXJJN_TM:$_D,/89ON;Q /#M
MV_)?\_\ FIU-?+_L7:0-]5N0,AS35A!7^B":X'XBP^0ZMNV)L/:/5>TJ;9?7
M&U,3M#;.(?52X#!T7V4#G_:F-BQM_B#_ +86"NY7C7+U( 'R_P!GJ?-LVR#9
MX!!#Z4H. 'R'ETN='U$-_P#7^G_%/:'7_'T_]/\ \H_4#W;KW7O?NO=>]^Z]
MU[W[KW7O?NO=2/?NO=2])!(!_P![/_$>ZZOJ/[;I_P ?T'13_E#\M.I/BKLT
M[GW_ %*Y//9''UR[6Z_Q#:,IDQ]+NUCX:2]K3_4D<?0^SK;MFEW"Y\-,QG@P
MXG_,.@3S=SIM_*5HUY>'2J\8N/Y >9/I^W'5!FQNL_D__-V[QJMP;CK8]N=/
M;4J1C*G-,&_@NUZ>X"T&$L;Y+<$I) 4-=KCS_P!J,"7=M]M^5(=%K_;Q\3^%
M%]!_JKY^G4 ;1RIO'O[N)-R%&TQ_"@_M))!BI(K2AU<#2G:03J'6U]\?^@^K
M_C9UQB^JNI<,V VO@9!*S9!$R&1R-1'Q55M=4CTU=35+P  !_A:P7'K<^8).
M99 TF!7\S\SUT+Y:Y1LN4[$6]B!0"@I@ >0S4_ZO6O0XQ$/>Y^O%QS].?\/9
M,DGBGH4PP?2]8/>^F>O>_=>Z][]U[KWOW7NO>_=>ZD>_=*.H_OW2?KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZD>_=*.NN+7)'^
MO]/?I8/]_=;!IU3=_,;Z[[UV9\@/BI\Z^C>L6[YI_CKAMY8/?'3V%C--D9:#
M<[S2#-8N&/4XF,<I.M0WC90>0K 3!R/N<5Y;2[?JT>*L57\R&%*CYXZCSFUI
M=ODBNHH/&)..'H,9('$<*BN>H.#_ )QGP5[RP.X^F.^COWHN??6$R6R]U;?[
MGV;/B:51N"F$553I70MI0J5!]42\C\#Z*IO;3=MIN/JK4Q2F(4*@Q'\J]-0\
MTV;PB*8A"Y!!J033/!L'\NC)563Z'_EN?!/);CZ^R.?WKTQT_L>OS6QZ'(;M
MBW579&3=E6HQ=!39*(1B>&MJZMFCT+<4]V*WO["EJ;SGK=?#;5;L6_5 ["1Y
M9^?1Y-+9[%MU(@/V' 4>AJ< 4R:D]%DVSLW^<YVMLG']XT_R+Z4ZPW#N#$G=
M.V/BQ4=2OG,=#1U_[U-C\QG7\DRU;@BWDF=N0'<$-I%-T-DVF'Z:&!UE45\8
M)7Q/D1QK^70?GBO9W\6&<D#!B\P?V_X*?8>A4V-_,NV]7?R_]^_,??&R9=N[
M^Z<KMP;-[)ZFQM:T34^\=NU$>.AQ-,I.N.@R%0YD==;$0JP]5O99?<A26>ZQ
MV4,I5)=,CI7.IL4_;^SHQBYAIMWU<]:$$@TKVBM?6I%,'SZ+_!COYT>X>H1\
ME*#O?IS;6Y)MIKV#A_B5BNI(JZE?%"G-5%A),RVJI.3-/RL/E:0J1=@;@'SW
M/+5ON'[L>!Y'IJ$NC&,TU<:_ZJ](&MMU,/BF<4K34:\>%<&G'SQ]G2\[D^<?
MR2P6W/Y;^;BZY/0^Y_DWV[B]A=V]=[^VG]UD*2C@BBCFIZ5:A"](CB1G@E"J
M;,.?K<GV?E:VN9;]J>-&NE64\1BO_%=/76^W1$(KX5 2*'SR?(T.>/EQZ-1_
M,O[X[*^+_P 0.R^X^H:K$8[?VS:C8N+Q-1N.CCW%2A:K+QTLA2F8,JO=!]01
MP2+&Q]A7DC:H-WOWT\4I2OS('1UOVZ2V5H%8"C G&*D G-./1)_EQNQ:KYP?
MR=]][OJJ/%1OC-^[KW-6U(_AM/3E<)2UM;-8V6*+\C\6M[DSE_:H8+/<(+>@
MS(3]NBORZ!VZWA^JLYIO72/7S Z&3ISY2?(KYG_(C(;H^/4.(Z_^"'6N1BP.
MX^V]P;':NR?9&0QO$L.UC.D;T&, -UK ZF!#KD;40GL&[ELVW\NVVFYE N!_
MH9XJ:?A'I\_]0/[3=9=UD\:(5M6%10F@'Y<?\O\ ,BMT[\DNV=\_S$OEO\8M
MP93!OU1TOU3U[NGK^FHL(BY**NW7]H9GGJPHEG)-0X;4Q%R"  #[UN7+<%SM
M$,\,W?.Z$'S[@34\:^GY]*4W=9+F9*9AX\:'+#AY?".J_?C%WO\ S,OG?U[N
M]^O>V.J^@MO===A;^VGFNVJ;JJ+<=?N&NI*A7@Q>/Q"LE/14V,H3%]S5HBFH
MD8!B]S86[GL>P\GRJVX1RW&N)E+F4N5H>%"7H/GZ_9T1P;ON&]Q7'TXS7 -0
M!3%:^9_;Y\*]&Z_E^?)KOOLG>'RD^-'R?79F;[E^+N?HL=/O[:>.3'X[<&.S
MU%54]-4O3HB*[+Z60F($@V(!!N'.;-EL8A97EF!X5TR@E>#!A4'TK]G1AM&]
M2K-<6DE0(?G]AQ6I\Z$?(]+[^6'\B.S_ )4_%V3M/N')[6R.\*#NK?VT8S@,
M!'MZE_ANV*^!*<-2Q*NL))*0MUX!M<GV5^X&P6_+6YV\< %?"=<>CPTZ.=BW
M!=VB,JUI0<2>.H^OV=-7Q4^3/;O;?R?_ )A?4F]:[:]5L[XU;OP]%U='1[>3
M'U5+#64M;+-]]*JJU9=8QJUZKM>UK^S#=]A@VZ.UD-*3,H'K0@G/1=9;G+*D
MD2UK&,YXX4_ZJ=$<^,/=/\T+^8!U)/NO8?;O3_0&)VANG=&RZKL0=91YC*[I
MR>,JTE$,M&BO38[#XV)X*?SB-!+*0#Y&)L)-VV+:^5[J)9BKT4R TTU(-.&!
M3_53HEL]QO=YA/@@FOD2: 9^8-<''IZ#J=\;/D;_ #-_G#MG<G7FTMY=2_'C
M<O1FZ\YLGN7OR;8T6\ZK/[BQ\T@I:7;^ 6(T-'(*5&-;-&FHJ-<1 ]/NN\;;
ML>R".X\)P96THNFM6 X!O+U))\\=.6\^[;AEO#4$5"U- ,>I!(]*\/Y]&E_E
MZ_)WOCLR+Y8]+?)J'$[Q[G^).^9=MY/>.PL>E.-Q0U5*TL*F@1566L5Z?T/I
M^C?0<DA_FK8X+$V=_;0@Q3L%*/C0"*@@>O1QRUO%W^M#*1XJC\O(USPP?\/0
M2=>8W^;W\K<'D>V(NYMG_!S 5VZ-S4NR.E,WTLVYLS+2X^M$2S;AJJD-+3H[
M>C5SJ8'T*.?9E%:[%L/C1K!<7,\A/=6BD?,D@?LZ*?#W:](D\>&,"E3Q_P !
M'[/+A7K#U'\H.W^]_AQ_,HZS^0J[/R_;OQBVQV?U-N+>NP$3'X7,Q/A*RHIJ
M\4L:QI3E&IWLRHH96!TJVHLNGY8MMBW&SN(M42R_%&*A6[3Y>O'IN+?9=X6\
M\085@<\1\+?X&&/+.3BA</@GM?\ F9]L?#KH_(]'=U]9?&WK;8VPH<'UEM;-
M]?+V%7[N:CJ6>IRN<J:B.<XJ@KJUBD,<0*DKI*?5V,>;)MBVZ]9+B,R!EQ(9
M-16F,DD4!/I]G1=RU'N*V7Z@U/C53'EY 4S3-/*O'R%HG\O?Y7[T^3?7V]\3
MVYMG';-[]Z [%R?37=.W,&BQXUZY69%R%$@NH2MEC9'L2+K<'U ".^>=C7DY
M(YH%\1+IBKBM17CCY=#7EK<I;YOUL"(5'KC]GVCJP'\_ZWL"&&&W_L>A(*MQ
MZ[]M]5ZD>_=*.NX_^!%!_P $_P"*>U5I_J_9TGN_\A_PGH9_8VZ#_7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]T&^Y/\ BZG_ +5I_P"AC[#V^<3_ *O(=&NT\#TG
M_9!T9]>]^Z]U']^Z3]2/?NE'7O?NO=>]^Z]U[W[KW7O?NO=1_?ND_7O?NO=2
M/?NE'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U']^Z3]<-8_
MQ]Z\;ISP^N?MCIOKWOW7NO>_=>ZD>_=>ZC^_=>Z][]U[KWOW7NO>_=>ZC^_=
M*.I'OW2?KWOW7NO>_=>Z][]U[KK\C_6/_$>W).KGX>NC^I?]C[;B\NMQ]<O?
MNF^IL=54P?YBN/%N+W_XU[]6?JQTG_4.@P['ZAZF[9Q\=#V=U[L'?E!5Z")L
MYA*:NK %^@^_1A,";^U,&X7"\17JCVL4GPDC^0ZJ8[Z_D\;,W)]QF/C?O!MH
M9HH*U]@[]?\ BV, 8V_R3)@??4(YX#).?]J]B?;]Y$/Q8/SX=(+BR,WP"H]1
MQZ),.ROGY\)!2X#L?;V<R^S*#G''?4?]^L!Z_P XS<5,66F)M_QT'^(]BF/<
M5NAG(^>1^1Z#D]GX65(KZC!_,?YQT.NW_P";7M+[(KO#I?<T5:6_RL[:WE#5
M4YM_M-9&_M4KTXRM^1_S]7:WKP8?F/\ -UDS'\W/9=/!;;G1.8J9B?KN?>45
M)_O%$D=C[:9J\)#^9'6A;^K ?8/\_035G\S?Y#;HFEAZ_P"IMK4L?^KH\;E]
M\D?ZWDD'^]>]F2-N$G^$]>$3KQ)/Y@=<!\V/GM3G[^3J[_)O]JZ)R7VW^\QV
M_P!Y]M>.OH/]YZMX0X5_XUUFI_YH'R$V_,L.[>HMD5/VW]E<;E]B'GGZQZ?]
MZ][%Y&.*J?VC_!UHVCG@6_:#_DZ54/\ -V0_\"NA\:9Q^:/L-8Q_[C'V[X\7
MF_[#U3Z?^G_(?Y^DCGOYF'R [(/]W.F^KL'@<ID[4='687'5W9&4-OHL+R:V
MO_K+[3&2.#!DI_,].+&\N8R33[ /SX=*?K+^6W\J?DMN:G[(^4.Z-Q=>8ZL;
MUC=U6V?W/5D?[IH\:Q%/B_\ #65 _$)]E=YOL+-H)-3^9Z,[;;FI1@#]F%'Y
M]7G=$_&WIGXW;?.(ZJVO28$U:!<SNK),,MF\A:_%3D4"K$IO]!QQ_L?8-N[X
MW HH_P _1Z((U-6/V#R'Y=#=[+NM=<?]BW_)/_&O=O&EZO0?ZO\ B^I7NO5.
MH_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NN-K'@_7ZWY^GO4/Z_3C?/HKOS!^56P_B#TQF>W
M=YTU3G*L^7;NQ]GT]TFRN=K0Y@I%/UTQ_P#*3)?DBW)-B..0^3Y>:KF*W6M!
MP'FQ/ =$',N^P[5"9N  J3Z#_5P'6LEM3K3^8#_-WWAE-\9_=$>,ZJH<O70'
M(9&MK]N;(Q,D*W^PP6.I@?XW54Z@>:1$=R+&I/.HY073<M^UJ^!;Q-+<9P-.
MG'H/Q?,_MZA:Q@W3G:43L=(/D*EB/F:CS^P>@Z-E3?\ "=Q'I:5<M\I,-3S/
M<:*7HQ9?Z_D95?8;/WAVF'BFT(_YMC_H+I9+[/17@I<3%O\ ;+_T#TX_] [M
M)_WEEB__ $2"?_7[VU_P0@_Y1&_WC_9ZM_K,1_[^/^]_]"]9_P#H':H_^\N,
M9_Z(M?\ Z^^_?\$"?]\G_>!_GZ=_UH8_]_-_SD7_ * ZQ_\ 0.[1V-_EICS_
M (?Z"4/^]9[WK_@@5_Y0V_YQC_H+JW^M#&/]&;_G(/\ H#KC_P! [\?_ 'EE
MCO\ T2$?_P!??>O^"!7_ )1&_P"<?_0W7O\ 6?C_ -_G_>Q_T!UB7_A.Y327
M,GRHH!)?Z'I! /\ ;_QG_B/;G_! +_RB-_SC'_0739]J)O\ ?Y_WL?\ 0'0I
M=5_R .H=OY2"O[-[WW;OFA@)"87:>U:?KR&HX_W;72O53 ?3_,(W^N/J"J]^
M\-N#&L5N$_8O^!R?V=&5G[16RC]6;Y9:O^ #^9ZN^ZDZCZOZ1V;@NM.J=EXK
M9>R=ONTV+P&-H#) [,!>>8EF>LK"5%IY&L!;^@MC]N.^S;\XO-P42%> '#^?
M4L;?ML.T$P0'C_(>@I2@^70@W'XY'^'/LI\;Q_[;I;PX=8/;?3G4CW[I/U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4R3\?['VW'THZ36XML[8WAM
M_)[<W7B\)N+;^<I<A39K"YFB.2IZFFR1NL4T:D69?ZWO?G_6-+'=KFQ!5::B
M,U%?\G2*>R@W ZIJU&00<]4F=V?R(_C?OZNJLGT]O[>O44-1JD7;^3Q=/OO!
M'G]-'-*Z5],!S^N=C_C[G+8O?/<K:/PY=4I]%RO\\_X>HSW/VPL+S"HI^R@/
M^ C]E.B^K_PG5IY>9?E;"/S8=*J;?^M;V+D^\8T/&TB_W@?Y^@W_ *T\A_T=
M_P#>Q_T!U(_Z!V:;_O+K'_\ HBT_^OGNO_!"M_RB-_SC'_075_\ 6A3_ 'Z?
M^<@_Z ZZ_P"@=JC_ .\N,9_Z(M?_ *^^]?\ ! -_RAM_SC'_ $%U[_6A3_?I
M_P"<@_Z Z]_T#M4?_>7&,_\ 1%K_ /7WW[_@@&_Y0V_YQC_H+KW^M"G^_3_S
MD'_0'6)/^$\5%_WEIC1_6W24;?\ R>]W_P""$;_E#;_G&/\ H+JQ]H4/^C'_
M )R#_H#K%+_PG?I!?_G*O"'Z6MTK%_O'^YWWK_@A4K_N(W_.,?\ 075O]9Y#
M_HQ_WL?] =%3[5^#WSL_EEM+W=TSVQ5Y7:&* J=Q;NZQJ*FACQ\!L0FXMKU(
M6%J%B5N&5HS< F_'L2[;SAL7N0YMKR#PGXM04_WD>?15N6Q[KR?;&6WN:D<
MXJ/RH1_(@]7O?RY/GEAOFSU9609W%8W;O=&Q8Z&D["PF 014DD>;?32Y7'K<
MZ:.H;AQ_NBH(<<,?>/ON=R".3KZ81 +&/C4<)/L^74D\C\U_UAMU922S?#7R
M-.'S^7J.K%_<6]2%U(]^Z3]>]^Z]U[W[KW7O?NO=>]^Z]U(]^Z]U']^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=1_?NE'68'5?CCVY%+X'31%.I#+4.A0C6K6N+WO_ *_N
MLMQ]8_AOCTZN8Q;S^/#Y\>BZ?)+XN]/?*WKH==]Q;6:OH:6%JS$YVE08_*8R
M=[,:K'9 J%I8[@\$_4W]1"V$.R<RW?*[B.(<,@CB#]O0$YYY&V[W&M6M=R =
M'%&1L@C\J9'D1D'(H>M83N?X@_,3^6-O^7MOIK<&0W9U'%'HJ-[X?&F)#3OQ
M]IOK!MJ*6/TKR+7M;Q^YZVOF&SYA4ARS35^,?Y!_GQYU'6"W,OM/O7M)<"?9
M/#%F%IX!Q4T_T9J5(&2&2C#@5*@GJQGXF_S5>D>]8L5L_M-L=U+VC.!0T JJ
MPI@\C?@?PW(BYI_KS#5$KQR038)=RY:EBHY':>!_"?S\OS_;T/.0O>/:N;2;
M;7IN5^*,D:Q]G\7Y=WJ!U:IS.?ZD_P"Q^OL)\>ICX=<4^O\ L/?INK)QZS?O
M?X7XM?\ WW^]^Z=G^B=6_7_XC_G_ *CUW>8']U;?['^OOWB)^#KPMKC_ $<]
M9O(!:"Y^V_4<=S[4PS36_P#FZ;(!^WUZ"C,=-].[HN,[U'U[DR .9MBTN2^G
M^*'GVNDW*ZE^!C^T=!Z7EJSF_P!R((_^<9Z8D^-WQ[IIC+#TATU_KC8U,?\
MHKW[][SC\3_L'20<G;5_RCVO[?\ 8Z$3;^QMA;48IMC8.U]N$@G5A<#2X_\
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MM1.]?UG&&7TBU?"#^?QI!'^^/L9[W9^'MMG*WD8_YK7HNVMQ]=>";A3_ "=
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MB</#?_#T9\GP 6=S3_?G^5ND]_)C?_(/GD4DII-'S:["BTTW^U4DXXX_-_\
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ML?GFT[$<?\%_I_L;F_GF\A^SK4=FA'Q-7[:?X!T.V/QE%A(?%A<-CL33F_\
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M-]A_S?LZQRFN><O:2]\&]\.:Q)'ZBTB@B48SDM6OD0P/X6&:6L] ?S3?C?W
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M3Y#KCUIU+U=TUMV7;O46QL-LC 9;-Y3=59@MK8J3$0U66RBA:ZM#2$E71 0
M %  XL![*;RXOMRCI.-(KP%*=.;?;0V458C4\,\1UQVUU#UKLW?.\>T=J[$V
MQ@]^]G/BWWWO?!8E\?D\U_"CJA^^;Z7N!KT 7)-[\>W+_>IMQMS;W4J@Q_%2
M@KC'35EMT1F\:I(\@<TZ1.]?BI\9.Q=Z8[L+L'H?J3>F]<?<Q[EW3L/$UE5(
M?PSH\BI5$_U8?TL/9I:\T7T$'@6%TC1C 8J"?\_28;)&LWC5(^0/^JGY=+G;
M/5/7&TMU[[W[M[:&U,%NCM!<2O9>9H,6:&KS?\+IFHJ491#_ )]50N6T $\D
MW-S[+;KF1;Y45I_M/#5]O5H=LM+"6>6*O=D#C3K/UKU9UOU#MNFV/U'M;:G7
M>UC59?<DN"VMBGQ-&]3F5 JZQFD+$31H   ; #Z  #VWNV\1WR_4$ #I[;C%
M%^E'4GA4CB/3KW7W4G574HSW^B_9.UMA_P!]-T9/?FZHMKXZ3$C)Y+*>F7)U
M?DU&.KCU.1'?C5P+&P<WK>KC<^(I4U-,5/'JMG90V-/#-:"F?]61U&V?U)UA
ML3=W86]-D[)VOM3=W:&X*#<'8NZ\+C'P\V:K<<QDDFKE9B*E&<L6T7!):Y]5
MSNZYC.YJMK=* J_V9'XOM]>J6=G%833U)[O(\!C_  ^7V=!I6_##XDUN]?\
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M(]^Z3]1_?NE'7O?NO=2/?ND_4?W[I1TX>_=)^H_OW7NI0_16G^BC_>O;33>
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MJ;O'MK,_S;?E-T7DM\9O*]*;,Z"V1NK;.P#2T[4>*JZK^#-+4+&T'G&EYFY
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MO/\ [1_R=_QKW[KWA]>\_P#M'_)W_&O?NO>'U[S_ .T?\G?\:]^Z]X?7O/\
M[1_R=_QKW[KWA]>\_P#M'_)W_&O?NO>'U[S_ .T?\G?\:]^Z]X?7O/\ [1_R
M=_QKW[KWA]>\_P#M'_)W_&O?NO>'U[S_ .T?\G?\:]^Z]X?7O/\ [1_R=_QK
MW[KWA]>\_P#M'_)W_&O?NO>'U[S_ .T?\G?\:]^Z]X?7O/\ [1_R=_QKW[KW
MA]>\_P#M'_)W_&O?NO>'U[S_ .T?\G?\:]^Z]X?7O/\ [1_R=_QKW[KWA]>\
M_P#M'_)W_&O?NO>'U[S_ .T?\G?\:]^Z]X?7O/\ [1_R=_QKW[KWA]>\_P#M
M'_)W_&O?NO>'U[S_ .T?\G?\:]^Z]X?7O/\ [1_R=_QKW[KWA]>\_P#M'_)W
M_&O?NO>'U[S_ .T?\G?\:]^Z]X?7O/\ [1_R=_QKW[KWA]>\_P#M'_)W_&O?
MNO>'U[S_ .T?\G?\:]^Z]X?7O/\ [1_R=_QKW[KWA]>\_P#M'_)W_&O?NO>'
MUA6126-C^/?I?/KTG5)W\QB*GE_F(?RAYYX:.>6D[<W:(?&UAI2KQMOZ_P"]
M>YTY,SLMS_IY/\G4><V ?O&S^S^?AL/\'5X<,O\ N36YL/XF!_7W#$Y_5ZD#
MUZHW_EH3XO#?+3^<9FLA+1X^FH/D=29&LKLIR%&,_C<TLE4.>;_4?U/N:>>K
M5KJPL;=!XOZ(S]C<>HQY4FAMKR]GF]1C/^^X^'Y]*5_YN55NFCRV]>G/@S\K
MN[.A\-79)JSNW X['8ZBJZ?:_-34XV@EAFKLA3 <N'J>!^K3R/9:_MMF%GNH
M;>0<8E4 &GH$()''_4.C27G4SU$<-QI/#ABOVL#^8&3PKUQ^8'SUV?O_ /EM
M[C[OZ I>V=QXKO/:F\.O\+O+K[ UN-DV9DC3>2LGW01Z,*M%*H@>I5R)%8Z3
M:]Z\K\EK)O+17(A/:@#*N9#G+9Q3S]>K[[S)]#MOUL1';5J'@1\OV>?#H0O@
M'\M-D5OPHH]V]B;6[%ZBVI\:^K]E8O=_8W;N%.'H\[3PXR1I\IAJH!CE\?*X
M U #SAE'+&YISYR=-%N4%O:21$2J 2HH4&D'4.%:_P";UZ5<O[]JVTWTV=1)
M ]*'SKPIZ](#_AW6KJ<(.U$^"'RSJOB_-3&:?OJGPE+2TYQU])RAV_XVJ3CM
M6J6WW@35Q<6TFMU[:';XYK<W2F<O6E!3[:5K3I(O.8:$>-$OA>GG_GKY<*TZ
M1G\WO?VQ^Z/Y=O7796QMP8?>NQM\]X=([GVUG*75DZ>6DRM;(BAPWJ1T964@
M_2Q%O:ODK;'V*_DMV-5\+!\N/^STEYRWCZ^P@GAXTSZ'N7.#]G1[_DM\W.L_
MC;N+K#KO*8?>G;/;_;U9C(MB=+=:4M-NO,2P/^K(N\L\;46)DN0CRJ7-K6%F
ML%DY&N-Z8WD4S0"W^%5 -?V^7K_Q=!'+O?T4$'"DQ-221_D_U?X4MV[V%\>J
M/YH?$'9O9?2F1S/R(WCMS?=9TQV/]I0Y,[.AI:*09''S9!*GQL5F69B61M&K
M@"]O;^TV-_>;=-=PCM=V+GT X]);J[A6ZBAE8:1Y?Q'&>!I7'2;[K_F2]4](
M]V[P^.TW6G;V_.X=L[:VCE=K[(Z]P9W34[NJM\1)*,=@5"L2*&.02U\U2C10
MPAPBZ@ SVW<A/=V_[P61C%I#!0*UJ/+[.)KPZ;O^:XHY19PP**DY.* ,14YI
MY>5/*M*]-_0'\Q[']K][4?QK[H^._</Q6[LJ\-5[@V7LWLZ6EK8<S14*LTD=
M'DJ>GI7AF<*=+:=)LPO>P-=RY1&U6!N[0F5.,BD89?.AJ:]-VG-)GF^CEB$0
M]12OEZ5'GPXY'V]&&ZE^5VR^Z.\/D9T1M_#;PH-U?&7*X+%[NRV=Q-'+B\A/
MG.%.+C !A8N+KZC<<CV27_*\VTP1W2U\*<@,#P[LBG1_;;U!?78BJ/TP>%=6
M ./\NL^1^5VQL9\Q=L_#6IP^[O[^;TZMR/:]-G:".E3;WV&*N1!-<?>/6^)&
M4D$68 @D$ :3EB:YLA=FNHKJ'I3ATW^](+>[-MB@.GY\0/LIT5_?O\TOKO:?
M:_:GQ]Z^Z+[V[I[^Z[W>=L4/7.RL!!'-GG>F-779A9A))%186F(<K)6+*P!4
MVTWT""U]OH[B)GO)!'"/QOQ(XUJ< ?/HL?FAGE6.$J&(K]@/ =(+:?\ -ZZW
MSM'N7;69^/??FUODYM_=L6RA\1XL*NZ\[E<G6PM4D4,LFFD3'&5 *RMFA\M-
M<Z P-@:-[;W-G%KB,0V\&FNE6K3RS2GJ?+_"CBYTA8^!X0-U2M>&*CT_8*&G
MK\AI^+/\P/#_ "0[-WC\?-^])=A?&WO_ &9AJ7>]=UIVA)'D$R>'J@&DFI:Z
MCB@@ED*.C*'B*L.;F_LEYEY'M^6;5-T@>*X645*O0U!X%2!0_P"KCT:;)S.U
M]-X,QTBM*C%./')]#YX_9TF.X_YDNW-H]M[IZ#^/7QT[F^8?:O63*G9F/ZG=
M,=A,1551TRT^1RM;]Q))7))=2A"+<6#7X%]DY(UP+=7UY' \_P 6G6 *_,G\
M_P#9'1?>\UG;UGBLH/%'D.W4?0=Q %?MK_AZ$CXB?S!-J?*;L?>_3&7ZJ[&^
M.W>O7^(I=PYOK#LRGIJ*44-34I')74513Q00SS*&!TM#R#?D D4YTY N-DM8
M]T,D4\>"S*M"5/F",4^VG1I8[S]5+X(.H'A3/KCS]/*O53'QE^75'\8?DU_,
MLVEM/IKLCY!=Q=D?+'/[AVIUOU1C(#42T.VH*M*O)Y/)U*3T./QX$QB*O$W!
M8DK8,)(W_EQ^8MOLYGEB6W\&I51Q% *U- !_AKT!-CWL6U[?5(72 <FO%%X"
MHSCU\J]6U?$CYW; ^4NX][=:3=?;ZZ&[YZ\HJ.NWWT]V; :?()3U9_<K::\8
MER-(@T%BRJP!!52+DQ7S)R3=<MVS7:NSQD59FPP!\QZCH8;!S+#NU(98 17!
M'#[*YI]H)X=6 Q2?UX_U^;_[ >P+,D,7]CT+?'-UQZP>?_:/^3O^->Z]5\/K
MWG_VC_D[_C7OW7O#Z]Y_]H_Y._XU[]U[P^O>?_:/^3O^->_=>\/KWG_VC_D[
M_C7OW7O#Z]Y_]H_Y._XU[]U[P^O>?_:/^3O^->_=>\/KWG_VC_D[_C7OW7O#
MZR>3_#_>?:CIOHG/S2^8_6WPHZ<;MG?5)4YO(Y"JDVWUQU[A[86;*9>G7]R,
M@(PIJ2F+**NI!O"Q"KS[%'*')<O.]P;:7@,4'$FG#_.?^*Z*M\W:':8O&'VD
MG- ?]6!U3SL_YO\ \ZKO?;*=U=,_%G8$75D]$),7C#M+^(SY&D4Z+4HR>8I\
MCD[,I!F2!K$'F]_<R-RARQ9/]+=7*!3D!J5(_.,$]1=%S3OUZ/&AMB&]"WGZ
M5&!^?1S/Y>O\T"E^7.X]P](]M;-AZL^1&UZ+(U];MI%JABLLFW%)KO E1>KI
M,ACU#M+CYF*. UROX!'./M\^SK/>QBL2CL7R\,?#^ST_U 9\M\S"\F%E=Y;%
M<Y%?/YCY^70#_+S^:%\L^G?F?NCXE_'_ *4ZP[,K*.GV<^TH\A3YBKSV1J,A
MBHZ^H+-#4T\#N#(UQHX_U[DB3DWVMV_?]M%[?LL:$ M)4AC45\CT0;]S==V%
MV+.SU5()(J-(%2,U4XP/V]!AO3^:C_-"Z8P,W8W=WP VSMKKBB8QY/,5.)S^
M'$)R(_:5\B];5FF/-P/%_C;VNA]NM@YFO/I8;T2,.(=J@5X?@-/V=);[G;>-
MK7QY;<F$9PZL?V 9_+JR>G^>N.[%^ >_/FYT[A42MVWL?=.6CV9OH"JCQN>V
M?)$*J@KA3:->N*0.M0EC] UB?<?6_)\T.]G:;K()+@'R*^1Z&7]:;>YVP;G"
M>U0,CS4@GSKG&1UU_+P^9.YOEE\8=S_(7N3&['ZSFV[OG=6$ST^ULC54^*IL
M=LREI:K^(5D61>87#,%!!N>1QQ[MS;R<FTS_ $EB IJ:TX4'GTURQS$-UB%W
M=U-5J >.6(H* ?X.B5;$_FE?)/Y:?*S)])?!OJ;JW/\ 5&#2E3/=K]H0Y662
M+%H0:O/U?VK(8Z6H(OC*;3YYKA?4YM[%%][?6'*VT&]OF4W!%6#5_:!CCY=%
M$/-TF_WG@VA.CT4@9\AP-3ZGA_ENK['[%PW5776].Q]RS?:;?V'L3=&Y<W5)
M8>2CVC3!HU%P3>O+ VOS>W]/<5V>W#<9895X $_L'0\W"[.TV?B3>9 ^63_D
MZUXOC3_/ [J[.^0/1FQNY^J^I-D=6=L;OJMHTVZMO19:EK($SU4M+2SK)42/
M3 4]8:6.I](NHYL;$3YOGL_:V=FVX1,OB-%J#"M0:8P<<>-?7CU%EO[@O)NL
M%I*7U$%A4X(7C3&./KQ/6S&(JF*,03\U6H6LW^!]XMIU-4YKUDA>IFO#87/Y
M^O Y_P!;VHAM?U/!ZT;BD%?/_4>J'?DA_-@[NI/D7O#XR?"+XW4_?^Y.KYLC
M'OC*96#)9Y)*G%$C(4]!1T+QE:*@:\/W/G-Y1?@'F>.7O;/;I+6&XW2[T-Q3
M)H/D!\O6O42;QSS?"[\';;<TA _$J<?F1DFE<"GEZ]&W_EU_S!\/\YMK;NQ6
M:VG'UKW;UIDJ*AWSUW357WE%)15S!:;(8Z)KD.GB6GG@G)6EETOJN2/80YZ]
MN)^7Y(Y;:7_%Y2 [$UI7S'^K'0AY8YI@WK_<C,WSX@@<#^VM?/HG'R%_FT]T
M-\A]]?';X,_&^D[YSG6=36T^]-Q9*DR.<5ZC;UDKQC:+%O 8UIIP8?N_N"9Y
M@K0Z>/8VY9]K[)+-=QW:?2S_  DDT'V4I^VO1'=\XRM-/#:$C%: A>/ $FOE
MY</V8.-_+L_F [?^<6R=WPY?:L76O;W6-?CL?V)M.HKC7I'#7MI3(X^HD+,M
M._\ P'^WL123%7#<V]@;GOD%^5KJ&YBEUQ*:1,<D$_Y/ET)>6>8?WK#X(KG]
ME1G(&/G7\O+K#_,'_F*["^$W7<U)B,EM'?GR(SU,*+KWK*?*MEO K']RNS@A
MT?8XVFHR0JZU-02&L1<JYR)[;7_.%WXM08C\;5RW^Q_AZIS)S;;[/!X\0(E]
M>%3\J?/)/E_A';X1=\[L^2_Q5ZD[ZWOB<'A]T;\Q&9R.<P>UA4QXF%,15U=$
M#31U9=4;_68@W(_K[)N;-AM.7)Y(X!I+BI \J&F*]+N4=V_>R>+-P%*$T-:@
M'Y?ZORZ-X#R/I_3GC_>./8*MI)INA-<0?2]<//\ [1_R=_QKW[I/X?7O/_M'
M_)W_ !KW[KWA]>\_^T?\G?\ &O?NO>'U[S_[1_R=_P :]^Z]X?7O/_M'_)W_
M !KW[KWA]>\_^T?\G?\ &O?NO>'U[S_[1_R=_P :]^Z]X?7O/_M'_)W_ !KW
M[KWA]>\_^T?\G?\ &O?NO>'U[S_[1_R=_P :]^Z]X?7O/_M'_)W_ !KW[KWA
M]>\_^T?\G?\ &O?NO>'U[S_[1_R=_P :]^Z]X?7O/_M'_)W_ !KW[KWA]>\_
M^T?\G?\ &O?NO>'U[S_[1_R=_P :]^Z]X?7O/_M'_)W_ !KW[KWA]>\_^T?\
MG?\ &O?NO>'U[S_[1_R=_P :]^Z]X?7O/_M'_)W_ !KW[KWA]>\_^T?\G?\
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M\_\ M'_)W_&O?NO>'U[S_P"T?\G?\:]^Z]X?7O/_ +1_R=_QKW[KWA]>\_\
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M!UW1TD )Q\=+3U QM3X5(0>0B9-)NI8D^UFVR;H]C9PV4*6C$+_C&D+J%/(
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M/7NO>_=>ZP^=/Z-_MA_Q7V]X)ZW3K-[9ZUU[W[KW6+[*I^W^XNWVE_\ B?\
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M#Y4_S7E@CQAWRWR;>FJ0PO/!@?N9PQ^A_P C%3K+#\V!L0/9'[@6Q.S6$/\
M91^%0^H%,=&W*D<)W2]-?2OV^&O_ !?[>GSM=EE_G@_%)=J38]MU0_%[M%NW
MHJ?D?PYX\D,8,CIOR:8@0?T]!/M+M,K'EF6.?CJ?5]@)IT_>2S?O2'P?A)Q^
M93_+7JY(7L@%CRUR?</M#U(DW=U-]M=-]>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]UA@_0?\ @Q_WH>]0]>ZU:_Y[]2-R?*GX<=>Y>3[;94FV\-+-
M4R\07WQN:*ER##^MH%4'C^S[RL]C$$-KN3)\8ML_F0/\'4-\[VW[SN[;[*_;
M11C^9ZV@Z7&0;>I*7;^&H\?38?!4.+H\%0X^UZ:FQ7,,)O?GZ?DV_P ?>-=Y
M>S7<-'X"7'4N6-D+>SK"<FM?F?7K5Q^5U+3=6?SZ_C_F]B+2X/,[SWKT1D=W
M4%$W\,$S[]I_X=F%-_TKD:>1_/\ CUF_O)3EVXDW'E.Z1^XI4'YUJ/\ !U!'
M,%R(.9[0$YT>?&BU(_80/V#H+?G5V5O3I[^=)E.R^O.OY^T=Z[3;8M=MK8^&
MCJ99LE/5[;:G2(+2 L6CIB!87N1^>?9]ROMJS\LA)7*Q!2) ,$U4@])MYOIX
MMY5(.!4G_C;?EY=/O>W\TKY4?,C!;O\ A/M[XO83K7L7MFJCV;G:#-;P?^**
ME7*LS4#IG5Q]-1U4\@ _SBWO:(7M9!R][?V'+TIWF"7QDC&FA?@#QX@#/_%>
M72^_YTO-U;Z(VSX!.JBZ0.%>TDFG^KSZL,IOBKG?AS_)M^1G46\,ECLAO*JZ
M_P"Q][;TJ<0PRE%2Y/<<U)"F.BG4E?)3P)XFD^E[@$BQ,;CF7^L?,4%Q'%X)
M".28_,D''0KGV@66U30CAP /&F3_ (>'6N%M3NWY [E^)&X/B3U;A=P'JW:.
M<WQWQWC6[85JXU% OV<439%A?[;!8XHI\7"U50P9KM A7(Z_Y6VS;MQCNKB1
M?&:BA!_#6O[.H<@W2_>Q^CM@/  T FF*U./VT_+'GUM _P ES,?'[)_#C$Q]
M&8.AP^ZJ'+QT7>U+7UOWM>VXCJ_RFLEN?\DJ:/R#'644XCUAKD,QQK]W;>_@
MW61;@#Z=J>!3B$Q4G[?+Y?/J9O;>6WO+)9X"/T:^+GTXC[1Y_+/"G2 _GL]W
MGK?XEX3IO$U<T.X_D7NYZ?(8O'V23^";-9LCE X!U:JF5J&G'T%HS]>;/^R_
M+K;K?3S7/P0-I'V#)_R=-^YVX@V)A%?UA0?:P_S ]5Z?/GXH;2ZN_EN?#C,;
M%W%MNH[,Z"6&EW?#@,_2Y.J$_;).3KPXA-U.,W%X(OI^?K]/<A\K[G/O.[S0
M2_V+?//;Q_*O01YJV^';+.*>W%/-:@T[<#]O$];!OQL^4&T>W/AYL+Y2[LW'
M2X+;]1UG)N#LC<63B\T&,RFTJ5:'/O5*+EKU-,C*.22UP-1(]P+S-RX;?>)+
M2W- S!B> %./[.I4V+?89]M^KE%?X1YT.1\O//777W\P;X0]F[WVQLO8GRDV
M)NK=>Z*Y*#:FW,+E*N&2JJ9N! CM"+!F-A^3]!?VH7DG=MH07$L1:,\%!SU4
M\T[;NH/@3C'$A@:#JE7^09'_ '@[T^;V[J^=Y-SR5>"6JR"^JHD_B6Z,Q63@
M7^NJ:B6_']/<M^[%M+9[=;KX-3J7_"W0#]O=Q6[O;@ X#L"/L%*?SZ=?@]5/
MM#^=I\VMO[9IQ'C*Z@[G=\91FX'CK:#((HO:^FKDDM_B!_K>[[^LL_+%N+B+
MBJU'VE\?G6GY],[-,L.[3^ <Y/V8%#_/J#_PGWBILMV;\UMX5WCESTVX-C4#
M-5V^X^WSF4S51,1?^@1;\?GVS[SQ?26UC9&&L#1@']L?6O;R'ZF]N37.MOY
M4_P]3?Y>=9-M/^<W\WMO8.&G3 3?Z5GK(*-K4WB&?HJE0.1P*N6.W^P]W]P$
M-SRI T@]3^=1_GZIRC<3Q<P7-L?X8J?FK ]/_P#,8_EX]$]"_&3YK?)N!<WO
MWNSL?=E#N=MV;NR?W*[;I-Y[LHR*+!THLT3F,24[53DRVMI"^JZ;VOYSFW"]
MMK"SD\*"-%-3Q%0* ?Y_\_2OGC8HK/:KF5^&IJ\2250BM?\  !]OEU8Y_*45
M$_ES?%R3D+_!=XA@+_4;@KK'^G^\^XV]U1%/N=T(N-17_>CT->1ZBU@^Q?\
MC@ZL9')_UCSS:UOI;W&<DTSP_H]#NW47)SU*]ZZ2]>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW39H'^/OW7NG+PG_'_
M &X]WUGI[P3UW[ITSTW^_=>ZFZQ_C[]U[KG[]U[IO]^Z]TX>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NL%T_VO\ VWOWA)TY_B_^H_[/7KI_M?\ MO=M,/\
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ML;:*8Z//;EK,@D1?=^5"AA4R,KW_ #J_)O\ J)(2;Q#JMS\A_FZ?AETRBO\
M%]O\7^K'6^PO]K_@Q]A2TZ.#QZ[F^O\ L1_O7NR<>G9N/6HK_-C^)W\VO^93
M_,:V=\4-G9;M/XU?RR<1C:/'YWNS:F32GQ67>CQIR6;RV5HJ'+#(Y*J%8PQF
M(I*T1TUHV=73]T@2VE\EC;"I-/3/1'/%)+(3C5\B*Y\O\]!\_3JK[KO9GRR_
MD)?SG_B/\/\ 8GRJWG\E/C_\I\QUNNY=A[DFKZ*.OH.P\K/A7-1A!5Y&.BS>
M/F7[F@JJ:0NSV5@ 9![72I#?1:^(I7TZ3*9(VS4'(%36A'S_ .*ZN-_FP_R[
M_P":_P#S+?F[L[IG#]M?[+5_+$V_A:;^,[QV)OTO455=B<>*K)9/,[;BJ<;/
MD,G+E!'CZ"$E**+QFH#@M))[0;9<6]O2$&F<^?Y\?]7KT_<"21=5*L?(<3\N
M'#\_RZJZ_E,[P^27\NG^>CG_ .53L;Y1[A^77QGR5!NF@WQ&N6K<K0XJ2BP!
MSG\22!'R";?SF"KU\%<\%0U.3(8R[%E9C.]C73@^8R,5_P"*_P _35O+(AJ1
M0TX')'_%\/S]>M^%_I_L?8$FZ/>JPNW_ .;O_+XZ#^1F[OBKW9WOB^N.Z=F;
M8FW_ +TQ&;V;DZ'%T6.7!'.DMFXHWQKNV.6..X<W9@%OP&.SL[@TSZ?GTB6^
MC8 J 0?GFE:>E/Y]%G^+W_"B'^5K\L^]L;\?-@=C=@;.WSGLBF"Z^K.V^O\
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M3HXT[/M_TO\ QFO1XOCO\4.G?C'TK1]!]>8#[_9-1_>==T9#=T?\7GW1-N=
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MD?PXU7]V,)DMP_>[0W!4A[HU.5!S>T:M?PP\D*&]E;D?7^Z0^XFT$2R*)T]
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M>U^U_P!MTGFXC[5_P]:,?_"/R33VY_,^ !]<^S +?]K;<!_XCV)MR6J'[/\
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M;N7IWK'"?&J64[BVWV!BLL*RNDEW/1YYACQ0T\T?C I/#9I4.MP"UC8/[;?
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MVR>U.N^RY=ZT&QMZ;?WC5==;TS?4G84>"RT65.'S^&IGDR&%K5 LV6Q[.WF
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MK$RQ211AZJ"J,3P/H1CHF_?M]LLL'B#XP<$U'#YEOL\J5^WH/OGWN?MO8O\
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M(]=<]&HML4_P>756.\_Y)G\IW??8$_9NY/@?T?5[[K,A%E<@]!1Y'%4M95Q
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M42$&@HC!##N;37!H/V8'\NK+8HL0))R0,DGC]O"G\^J3<5WKOW^:SAOY"GQ
M[^R^6;J;Y/=+]I?)?Y=XJ@S55C6["D^,<-90XO"Y26!H3)C\C7;?>LK8BQ8O
M4!QZ%0J972?3]_G3C^9%?MQCCTE@I0H/7'#S533APJV1\AU?5\G_ .4A\)?D
MGT?3=*8#J#K_ ..6;V__  2MZ3[AZ ZOP^P]P["R^WJQ1C\G@Z_%M _ALK7C
M:716)I5G72A4G6]S]O'Y_;0YZ7BW=>ZM>/$TICB*C!_EU8GLG$Y/;NS=K8//
M9S*[TS^V-L8;;FX=YY#^&K6YRMP./,$N7K3&6'W616U0NHWLH)))))=)TJA
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MM^MZF7XBXSLOJK ;_P ?UKNFARG]RH/X!D\8V73^&UF+BBTTU=IE,CJ_DCU
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M):X' 8QUSR_1W4V?[9VAWYEME8;,]S[$PF2VAMSL:KJVCR>+QF05EJJ=8O\
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M,]ZF<'[K\6']?]O[#?'HY%!CRZQ<4X_/U_U[W]I^G>J+_D6^K_A05_+8N?\
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MOA,ELO"T2561I]T1UD'CKHJV4.E$E/51.LU6SPTU8?VR_$0*@BOIQX_EU24
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MJ VQ_*9ZPVU\'?E7\&Z?LCL.3KWY=]P]H]J[[W74RXM,CC*OM&JQ61JQ03>
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MVWOVB\>]:O=<4M,E,,2S*'CQ%$@:K56IGFOJ^H]-GIO<68V5U9"-2[8B0YU
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M-A+4R9.CV7V;\F]IT]6X^]FJ(<3BTI8FM_P4 W_ )_'L<<W;A#<[MMK>-P1
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MPHYX_P!]]/:6XM_'].'5T?1T%U;!54-4:<VO;^MP?Z>P+):5Z%%M<@CKTO\
MG&_V'^]#VWTHNNL?OW23KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>ZP+%Y@;'_ %/U]M(>M@T/0B8'%FCI?N*H6JN1]?\ ;?[?V--MV[P,]$U[
M=ZL#I5^SGHOZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NF7,
M8>FRU,M/4,HLME8\?3V730_4]71]'0>5>/J:.JU3F^H:@0;\?CD?['_6]A6_
MMO"Z%%K<_5]-WG3^C?[8?\5]HNO:#UUJ;_5'_;#_ (I[=T#I[PA_J_XOK#K/
M^'O?@GIFB]3?;/5.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[K#YT_HW^V'_ !7V]X)ZW3K-[9ZUUCAA\_\
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M:#U[QCU[T?[5_O'OV@]>\8]9O=_!/3/77F/^/^V'NF@]/>,>N_=.F>NO,?\
M'_;#W?0>GO&/7?N_@GIGKKS'_'_;#W30>GO&/6+T?[5_O'OV@]>\8]9?,?\
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M_E4A_P!X_P"CO?O#@]!_/KVL]<OX?1_\JB_[9?\ BOOWT[?ZCUJIZX_8T?\
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M5(?]X_Z.]^\.#T'\^O:SUR_A]'_RJ+_ME_XK[]].W^H]:J>O?P^C_P"51?\
M;+_Q7W[Z=O\ 4>O5/7'[&C_Y5(?]X_Z.]^\.#T'\^MZSU[[&C_Y5(?\ >/\
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M_H[W[PX/0?SZ]K/7OL:/_E4A_P!X_P"CO?O#@]!_/KVL]<OX?1_\JB_[9?\
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M_*I#_O'_ $=[]X<'H/Y]>UGKWV-'_P JD/\ O'_1WOWAP>@_GU[6>O?8T?\
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MCKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U'\_^T?\ )W_&O;?B=>Z]Y_\ :/\
MD[_C7OWB=>Z]Y_\ :/\ D[_C7OWB=>Z]Y_\ :/\ D[_C7OWB=>ZD>W.O=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TW^T_7N
MG#VHZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW01[^W]MOKG9NY=Z[SJL7AMK;(P>8WAN;,9! :2DH]K4Y
MJ:NJ0#2=9.K2+W-FM=N&\JZ@3Y#-?L'5'<Q,%'$XI]N.M?7^4)_.=[4^??>&
M^^GN_.J>ONF3N7J^+Y'?$U]GR5F/;=77V0S>4QL]5D#D:VK_ -S-)*: S"E1
M;@UA9218K9;7Z>$S,!PU+\QPK_J'2"RW(7DWTZDJ0=+U -#\J&GEZ^8ZV3/X
MJG_'-?\ >/\ BOM+H/2OQ3Z=$5_F,?);>GQ'^#OR5^2W7."VYN;>?4'66;WE
MMW$;I6>7#5552RQ1/%7K2/'5-I21F52P!(YX!LY A8$ <.'[0/6O3=U<K:H)
M6.,UIQ% 3TIO@YWQNOY+_#7XU_(3?V)PV%WGW7T7UEV;N3![92NCI*>LWAB:
M>OJJ?'+5 U*4I319?ZW-V!N6RAB*CU K_J_+J\5P+R,R#R)I^WY_;T=;S_[1
M_P G?\:]L>)THZ]Y_P#:/^3O^->_>)U[J)49 4]M84W_ *?\C]ZUGK86O5<&
MW_GMMK<?\Q?>O\N[%=>;D&[>N.A-N]\;P["K:FB.(6DW34/24.*H*,LU3)Z%
M"R-XZ<W)]'H9F5BW4J33(%2?MX>72,WC"81$]I8JOS(I7\^'E3_)8]_$?\(_
M^2_:36>EE#UZ:N%+<58!X'Z1?W[4>!Z\!7KW\1_PC_Y+]^UGKU#U2W1_/WMB
ML_G4YO\ EPML_8@Z7@^(B?(<[Y\5<NY#F*'(45)]F93)_"OX;:HT!/#8K<:K
MDAE>@TU?*M?/'\ND?U:F;Z8$UK2GX:$D?;Y=74>T/2OJI/\ G"_S LY_+A^*
M5#W7LOKR#LWM'?\ VALWH?JG:N0G;'XRJS_8=/4S4L^4<,LTU!!%153.H<:B
M =0L;K(4^H%*5R !\S_Q72*\G%H"]:4!8\. \LXJ:X^?0P_!S<'S^S_5VX\A
M_,#V3T%L7LN+>*?W4PGQWS61SF/.$FH8/^+@,I).XR8KQ/HU2%2Q0,!I2_@M
M6X 9X#[/S^75TE80C42<4S]OK0>N<=6"FM%/(*8CD6 -[D?\;]I0Q&.EFFHK
MU.\_^T?\G?\ &O=O$ZKU#_B/^$?_ "7[UK/6Z'K']_)_SKI/]N/^C??M0].K
M:1Z]<_OAX_NK&WTMS_OO^-^]:LUZK3-.IE/4"<$@>[JU>O$4ZJ=_F9?S'\%\
M!-D=8T6#ZTS??'R#^0O8]'U/\?.B=H92/$Y#<N<K6C1_\L:.3^'8_'2/&:J4
MD3)(RK=068*;.$3*#2K,: 5Z27UZ8":8514FE?S_ -D\.J\-^_S6?YD?P<FV
M+V;_ #+OA'U'M3XN[^WAMS;.X>V/CCW!5[WKMAS[MJ0E$=RXVH>>+)4R N7E
MHEC@^JK(3=3>*W6>,$'M.#3B/YD](7W&XMZK/%0@$BIP:8Q55_PUKCH\'\QO
M^9G%\1H>C^KNB^L*CY-_+CY89],#\>.I,/N(XFGFBI$U56>S&361DQF#H5<)
M(XD4.!(7D4+,1I+<-1B.)&D#A]O2B]W#Z;5%&:D@U)X_8./YT!^RG1<>H/YG
M_P O^HOE'TI\4OYHGQ2V!T9D/E"^2V]\>N^NC>P5W]M/+;BQ"QR_W7R23^:>
M@RLT1BCAUU"1RO\ H0)(7721<*-3B 13CZ<2/\W337\B.RSQ5K0D&IP?.ND4
M\N/&HI7H3?F]_,[[AZU^5FUO@+\'_C?2?*CY=Y?851V?O*+<6[XMD[5V3M]W
M'BR.YZM0TC&KD,<D$,<L,D@>-/W&<(MXXP  &(\SF@'\QU>XN948A81(1@#S
M8U H*!C_ "IC)!I5!= _S0_DYLCYA=3?"/\ F6_%_9_0'8W?^-W!6_'[MOI[
M?S;^V/N?);9CUUF&(KC-D</DWA7]N-ZC69%)>-4J"_O1ATF@.HG@1P^SSSTW
M;7DDA*SP^$!Q'G3&<A?MX4^?EU)^0'\TGY,[K^7787P:_EI_&?9WR#[8Z+V[
M@JWY$=N=M;]_N;L?9E;NA@U)AY5IQ'69/+R'2?#%/J3U1QQ,B%C58 V"<CB3
MP'RS3_/TY<7<BFD$503@?B(H<X#</R'"AXT5'PE_F;]P[\^6FY?Y?7SO^.-'
M\9_E51]>CLSKRJVGO6+L':&],%0F05=9M^M#^='HI4D8TKO-XB50B-J;2;SQ
M%<D:6XCT/\^(ZM:W7CMX3'4M=)QD'RJ:#CY>?GPZO7]EO1AU2C_,L_F:[O\
MB+V'T5\5_C)T3E_DQ\W?DI_>:KZSZQCRJ;7P])B-L1NM;N3<F4D9=.-A$5PJ
MR1I&J5$DDJ^  F4$#$C%:U('V>9Z+KR\%LI5"0P(!(%<GR&* ^GK3%3T07M/
M^8Y_/'^%6V4^0OS:^!?Q?W=\8-MTU)/V_D/BQV7DJW<NV:+)5"QR9#[;)93(
M?>)CB 9?' R:F#O,"%/NOTT)%.TC%=+5(K_JX]4:\N8&+LA#&NG6 %-!FN
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M3LC?7R'[_P -TM1XGN!LC'0O+D\5,],!)CJNG.IJM6+'R "PL#ZB5,*"15)
M)/K7RIZ'HKOKU[!F"%@!Z4\Z^O[/LKQX=%V7Y$_\*9J61ZS,? +X YZCBAJ/
M#A-J]\UE!4Y&3C25>KW6U-< ']:_DG_6J8M>3I_8./[>M3RW"THC^5:N0!]G
M:?\ )T;7^5U_-0F^>%;W]T_V_P!)9SXX?+7XO;IQVW.ZNG\CE4SM-HS$@2DK
ML97&.$:)+%%IGU#U*09#,=&[NV\.H4'M-"/\H_U?Y:*=NO/'TM*P!8 @\>(K
M0\/LK^?"E;L//_M'_)W_ !KVC\3I9U#_ (C_ (1_\E^]:SUNAZ]_$?\ "/\
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M.MP.R=+K%G,T[MHQ5$M#$K-4QDIH X,:W;*%B0:#&3\OM_+TSTM#I" XJ<U
M^?V?GZ]:Y^Q>PL]_/ _FE?'KOKI/"9?"_P N7^6GO+=&=V]WMGL/_#SV1V'N
M"&2 0X /&!_"L8C46F5[DZ%>4H]9!$'&K& R@_)O5N./Y?ZCT@,W[SE=&/:
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M_9NU.TG\2-3),8ZJY 9/?IF\*01 &M V* "M#@<?V'IB9W6S-Q-(.)!%:L:
M@]U*$CU*GUI3'4+^8/\ +'Y<]P_'#_A/QVQTQV?5=9=\_*#LW8]%G,U202+A
M*W.[APV$HFK<G@@RT>3I5JWJ*REHI25#.%":2%%8^)4FA)_S=6W&9I8[>6,5
M4+4#SR"<?9\_2G&AZ1G\ROXP_(C^4-6?%7Y6?$7YU?*+M+NSMSO3;GQZ[3C^
M5/8)[5V[NJJ[,$M/25E5A$AH(33XW)U =(2;HD:K$P,.KW:$B9":&I.D@T(;
M5C_#ZUZM<V<B31,L@P*KD@K0U/[0*8 XU^72M_F;?$WN[^5EUCU-_,+ZN_F
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MBI_H+&HF5DO?\>U]B]9*5X.OY\?^*Z*-^FI U!7])Z_[SD_EQ_+H/\Y\^O\
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MO[2^1&/I_D+L'M6AW37[9[?J<'4XENK\!B\?1?W1D2-S@?OU ;(BS?>NX*@
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M<>\AEOF'WNG9;=0[KAV[C:=%IL;MS,5T"4F/FR#B5966JA #1EQ)&OJ\QIJ
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MN/VKTYN7^^^T\!LC:L+U6.6#,^29<H)X'H_%)!(Q5(1K=Q.2C<NI-7"H'D<
M<>/G^73]C#&^F4@Z9" 2P(8MPK2N/3T\QFM:7^G/E[\8_P"93NGNCY!_S(/Y
MI^_?BSMT=M;NV?\ '/X>]0][MTHFV=N[6JE%!N/,24=#5_Q;-9%U\B/+"/6C
M.[\JOMZ<-!6E:5H%!X#UX$=%2SVM^ TL@KIJ6-:L2/M4_P"3TJ#TK.MN]NXO
ME3U;_,Y_E;=)_/'<_P KLK\>^GML?+WX+_,3:/8<HW764NU:JCK*O:.?R>-(
MK\_6XRJD@H3.TA\DDA61"GVP2B2(AIPH**P\O0?/Y=+!(?#8HWB!B69:D!B
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M) 12:T0,[R>WRG@Q#)"T H.))SGR_P /29Y!=3RI2KQY!/#2!Y$&M/V9\SY
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M^[B196JQHIX\"13Y'[/Y])S&;3N6,N^/,@$$TI48% ?/T))X5$/J,[L^0?\
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M !T[RGRGQY[SZMS'>F,@ZEW#5UNRJ'&08I:JNW<@H!_=J.!XY%D-61949BP
ML*NRD_F3^7RZ]]/*(8@2:Z *9P:?B K3'K05^>"?G_A01T/W?W5U'\)L7TOU
M%V=VKEML_/;H/?.\L1UML7);W;%XC!UL,];E<BN-IY6@QM$@;RSNJHMR"RV)
M]WCET@C^F#TIN+;Q'B)\D*GSI4$?EQ_U#I2?\*,^C^XN\OY?6.VATMU7V3V_
MOH?)'X^[C?9O5NR\EV#7K0;?SE/49"M;'X^.J=8*6&.225_&%&H$M^IO;<,P
M0\?Q _D.KWUL)JG^@PQZG _P_P"?HL/S]V;\F_C#_-'^ ?\ ,7V%\4._?E!T
M_M'XT;V^.O;.V.@>O\CV/NC;S9H+-'DFP.-CGJYETUQ]("K(\4T=UF!L[XB!
MJ<1IIQ^7^K\^DDB3(%D7XRZM2A/ D9_;FM*#\@0*^8F\OF)_,)_F#?RFNW]B
M? 'Y?=9?%KXN_-/:%3N'?'>'167V-N.>IWG48RIR&;JML-%)7X'9>#H<8@DR
MN3CIT-7+(H:]HU;5D04'P@US2IJ*<.KW!F>6-P.YAI- =*E65JD^G:1G!J*<
M,G_^.71G=6#_ .%#?\P7NW.=2]F8KI;>WPWZ6VKLSMO+=>Y'%[:S>4P4^$:K
MQ>/SIACQM760B*7RPI.S#QR%D6W/G?5C^BH_93I^U@\"1G_INWG2C"@I^S_5
MCKC\JND^[MP_S]OY8G=&!Z@[2S_4?7G0?R)P>_\ M'#[)RV7VSA<AN?%;@BH
M*7+YR*&3&XV>JEGA\2O,/7(J@&X'NRLH.G--)'KDU]>D-W#,\Z2T![JX\@"O
MRP/M]//JO?8/QEK_ .7-\VOF#@_DI_+#WI\V?B3\GNU,UWUT3WGT]\1J?Y;Y
MC9\NYWU5^V,QAZ7%YK.4D"LR)&VFWH:6-0C:A:212"M13BIQ7[/(]7ME-E,'
MCBH7PX[J<":U&!2G\QQX ZWP PW:G<WSPW=VMUU_*^V7\&/A9U=L2HV_L?=O
M=?Q"QG1/:FY=S9Z)Z>7(8FFEH,;FL+A'I99%J%DD<E5T2%GJ)2*N^KNJ*CAA
M03^S_/T^BA6"K&0I.1J:@H?F<_L/D17RV7O:?HQZUS_YB72O=>]OYPO\GOM'
M9'3W;&[^M>KZONH]F]A;3V-E<O@=N+EZ>F6B.:RM/$]/CA5!61#4.M[&VH>U
M,;CX3^W\^BB[MRTJ3 $\< <.WSI_+HS/\W?^72W\P/XT)C]BRS[.^4?1^=/<
M/Q>[+I+XZJQ&Z]H,LZ4C5)L?LLR(TIM6M0"E--J*PN32TN?"D.LX&4(\B/\
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M7K+X:;'VOWCL3)8')4F!Z-V*N%H,\*7*Q15+P564JZ642(C">;&HX/IXOXZ
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M%+3_ )T]8]N_SG/Y6?8D?6'QJ^1/Q/[WZ\[8P/9/2?4ORDV/3]1;AKMP=-5
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M"NHNC%YI$>H=AQ-"%!K7I/;0/;!52,TTT9=1 %*9KP\_\/D,VA_RI,#WQO\
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MO>T?2CIP]J.O=-_M/U[KWOW7NM>GY&?%/YQ;=^>W9_RR_ES?+;J>JW=N[9>
MV=\B/B/\F,UDMW[=BJ,'CZ4X3.8NAQ,ZS;>R-;BX\=?R46MXF;1(T+M&IF@
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J=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>timage_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_003.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
M0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI
M_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^
M?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_
M]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B
M?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3
MW[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW
M7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\ 0;TI_P ^?ZM_]%_B?_J3W[KW7O\
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M=>]^Z]T0#^;%_P!NLOYEG_B@'S(_]]UN/W[KW5;7_"53_MQY\3O_  YOD?\
M^_)W7[]U[K8D]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]UI8?\ "B3_ +?<?\)S_P#Q:WJ__P!^WUS[
M]U[K=/\ ?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW54O\ ,+^7?SC^
M&.[MC]K]-_"K)?-#XCP;7K(^_,+TYG1'VAMJNI)ZF5,S@<#*'BW-BOL?$M11
MQ(*E9560300^5_?NO=5\_+_Y/_'W^?+_ "U^\.C?Y>G;VS][?(&GRW6N\\Y\
M5.ULG)U%NBM7JK=6-S.7V?N/#5\]'6TE+E:?%U=')5Q//CO,51JO06=?=>ZJ
M'3X?_*[Y?]@]&=/;!_X3>_'[^6%EMF?(GHOLO='S4PN\=N8VIVUB^J-P46;R
M38Q\5@,36Y6?(T^/DIHXZ>IKP\DT9=5!^[A]U[K?8]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW1 /YL7_ &ZR_F6?^* ?,C_WW6X_?NO=5M?\
M)5/^W'GQ._\ #F^1_P#[\G=?OW7NMB3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT6 ^I]["D]:+ ==:U_K_O'O>@
M]:UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]
MH/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>
M_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O
M'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_
M[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^
MO^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U
M_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKV
MM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z
M]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6
M.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>
MUCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/
M7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:
M#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'O
MV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q
M[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^
M\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K
M_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?
MZ_[Q[]H/7M8Z]K7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K
M7^O^\>_:#U[6.O:U_K_O'OV@]>UCKVM?Z_[Q[]H/7M8Z]K7^O^\>_:#U[6.M
M+'_A1&0?YW'_  G/M_WE;U?_ ._;ZY]Z(IUL&O6ZA[UUOKWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>ZIE_F=_S,/D#\3^T^A_BK\*/AQEOFM\NOD!M7L+L
M;$[&;?%)UYAL!M?KIZ2EJ\WEZ^JLL@FR-?3P0PM4T<)"3:ZV.4TT-1[KW5,.
MV.L=I?S6?E[D?C/_ #1/Y;6Z?Y7_ /,FHNF\C\C?C]\N/BUVM!C<[E,7MK(1
M8:JJ8MRX'[JBK<EB:S(1L:?(5>2=(=5C0N\)E]U[H^.TMT_SQOY:&[MM;.[A
MPF%_F\_#&LW'B=OKWILJ"/K?NG9N-R53)",AN?"#[FDW918V%XGJ)Z;[JKDC
M22HJ:VG4:/?NO=;(_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ(!_-B_[=9?S+/\ Q0#YD?\ ONMQ^_=>ZK:_X2J?]N//B=_X<WR/_P#?D[K]
M^Z]UL2>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NH=3+XV4?U6_P#ON/;\2ZATGF:AZC_<_P"/^^_VWMWP^F=9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7
MM9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S
M_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]M[]X?7M9Z]]S_C_OO]
MM[]X?7M9ZTN_^%#<GD_G;_\ "=$_D?*[J[_W[?7/MF5=-.E$+5KUNL>V>GNO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JA'^;1\7/A'\LN_P#XW[+["^?.
M_OY?/SLVKM/=5?\ 'GLOJ7N,=,;DS6V]VU#09?"4DU5/0T^;A-=C(YVI:.OC
MR$!0,2*:I=9?=>Z$O^7=_)GV7\(>[=S_ "H[%^77RO\ G/\ )/<G7%1U)@^V
M?E'V94[X."VQD\A!E:S'X2GJ)ZN6-LC64M&\\T^0J;+"%I$I%J*S[KW7NKHF
M954LQ"JH+,S&P 'U)/X ]^Z]T7C87RU^,_:G<F]/C[UAWCUKV-W'UMMV#=/8
MNP]B;JI=VU> HZN>&FA_C)H))X<94SR5$9CIJB6.I="95B,8+^_=>Z,1[]U[
MH!/E7VINOHOXO?)'NW8>S:GL7?'3O0?</:FS>OJ..>6;.Y7KW;V1R^.PT2TL
M%34M)E*RCAIE$--+*6E CCD>RGW7NM8WXP?"BN^6_P#+%PW\S#M?^:/\U\?\
MM>T.I*SY-2]^;&^3^1V-LWK[*;<I#7#:E%L:CDI]G1[:P4M!)09>BK,=++4,
M^1"U$'EA\/NO=&$D_F\?)#$_\)T^J?YA^1V2B?,CN+8VV^I^O,'D\-#A(LGO
MG>>\*K86$W-'C:OPT\E%E$IUW)!3J!35%+(@C*TL@=?=>Z:/DM_*T^0WQ'^&
MN^?F-T%_,$^=N\OYA?QRV)NSY*[OW5O[NS.]J;4[(KMFT%9G-Q[+R'63U$>V
MAM_*TR5=#AZ2@Q\510M'CRDE5+"?+[KW5]?PU^1F*^7GQ/\ CG\H,-BI<#0]
M]=-=?=HG 3-Y&Q\^[L;3U=7CR]V$GV-5)-!K#$/X]0)!]^Z]T97W[KW1 /YL
M7_;K+^99_P"* ?,C_P!]UN/W[KW5;7_"53_MQY\3O_#F^1__ +\G=?OW7NMB
M3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]TT9&0)*@()O'_P 2?:B&I'2&Z?21]G3?YQ_J3_M_;U#Z])?%^?7O./\
M4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_
M &_OU#Z]>\7Y]>\X_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]
MO[]0^O7O%^?7O./]2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V
M_OU#Z]>\7Y]>\X_U)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;
M^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_O
MU#Z]>\7Y]>\X_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0
M^O7O%^?7O./]2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V_OU#
MZ]>\7Y]>\X_U)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;^_4/
MKU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_OU#Z]
M>\7Y]>\X_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0^O7O
M%^?7O./]2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V_OU#Z]>\
M7Y]>\X_U)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;^_4/KU[Q
M?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_OU#Z]>\7Y
M]>\X_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7
MO./]2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V_OU#Z]>\7Y]>
M\X_U)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;^_4/KU[Q?GU[
MSC_4G_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_OU#Z]>\7Y]>\X
M_P!2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]
M2?\ ;^_4/KU[Q?GU[SC_ %)_V_OU#Z]>\7Y]>\X_U)_V_OU#Z]>\7Y]>\X_U
M)_V_OU#Z]>\7Y]>\X_U)_P!O[]0^O7O%^?7O./\ 4G_;^_4/KU[Q?GU[SC_4
MG_;^_4/KU[Q?GU[SC_4G_;^_4/KU[Q?GU[SC_4G_ &_OU#Z]>\7Y]>\X_P!2
M?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?]O[]0^O7O%^?7O./]2?\
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M\Y_U(_V_OWA?+KWC'KWG/^I'^W]^\+Y=>\8]>\Y_U(_V_OWA?+KWC'KWG/\
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M]YA_A_MC[]H/7O%^?7O,/\/]L??M!Z]XOSZ]YA_A_MC[]H/7O%^?7O,/\/\
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M]H/7O&'7ON&_U?\ R;_QKW[0>O>,.O?<-_J_^3?^->_:#U[QAU[[AO\ 5_\
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M7OV@]>\8=>^X;_5_\F_\:]^T'KWC#KWW#?ZO_DW_ (U[]H/7O&'7ON&_U?\
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M1'_S3_Y^;H)=;?U_WCV(- Z!?7M;?U_WCW[0.O=>UM_7_>/?M Z]U[6W]?\
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M&U<1UUBOBGV%A>N\;)M>FRU'MRLZ\VY4U&ULI04#&&-:C;V0H:"JIO'+ ZO
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M#VY64G4ORMS&Y]^=-;PFH7IXEW9M:C%!DH8Y]&BJI<G282*ED'D+TU92TBA
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M^+_SQZ!WC@>CMIY+%[>W1VM#-GL'L^GW/2XK&9.GW7C)L8*C&Y'^#TE+5RK
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M5D&,R&.KXY8H3+X//#4/H6NCN(N80T[).N8V0!3Z')H:>>:_M'D>K,*8]/\
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6FO\
MSCOYW>!W!V#\E_B5\7?Y9W4_\RZB^%FU]T[I^5O:/R#Z[B[7ZWZ_R.SUF:JB
MKL0]#)'5M@ZRAJ5KFDS>-D-50U-'2>2:FGFI_=>Z,%\4_P";;T7\5NZ/Y5WQ
M+S/P7ZK^+77'\S;X/?&'O' ]T?';K&FZ8V/'VWWK1BMKMGT.%BHEIZS#K5Y+
M%1+5)G:W(T%9EZ&&OAFBJFKT]U[K:F]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW1 /YL7_;K+^99_XH!\R/\ WW6X_?NO=5M?\)5/^W'GQ._\
M.;Y'_P#OR=U^_=>ZV)/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW1>NX/^+WC/^U4/^MTGL7\N_P!DW^F_R#J,^=_]
MR(_^:?\ S\W02>Q#T"^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NF7<FX,3
MM+;N?W5GJI*'!;9PN4W!FJZ3],-)AH)*FIE;_".&-V/^M[V!7K8&HTZU4.E.
MD/E%_/AK.QOD1WO\@NQ?C[\+EW?G=C].]#=8UOV[Y*EQ!5:B;(1NYQD[0*\<
M<]=5TM?)4UAK(*:&BHX(T<332Q;'2-$5Y10N["H4\0%X'YXIY5J>#A8+PK3Y
M8)^WC^S_ %$A7S+_ )$/R!^)NXO[V=0XGL_Y;_&+)56,.\MJ=3UZ[5WY'#2L
M9?MJN@BQ.X:>JBBE"/#D*;"9!8SJ:HQ],%620QL]^CNP!)ICD%=+,*IG_; C
M'S ^?EUH?*M/,5X_RH?\/^'H3:7XW?(WYW]8]<?";XU_RSE^!WQWVQOF'?G8
M?=WR"QN2S^>GR*TZ4\^13.YK!8+(U-5-3#Q2TM!25$U0$I*=JG'XY)(_:<7,
M=@YGEF\:0@A50C33.#0D4\_*G&A/5B:U\A_JX"O'Y_SZ._O?^2;WS\*.HJSN
M/X'_ #:[SC[?ZBPU;O>IZ\S#1XW [F7;\$U768^CQ=),:2*6K_R@PTE?%D:>
MHD?[>:2/R&I5$-YCO7TW$2:6P64$.O#-<DT^5/\ )UY6K@5^0)J/\G[>A-ZM
M^'7Q!_GF_''K#YD]I;8W7TU\C*N&KV1VEO/I+.4NWI:W,=>RM1^2KIZ^@R=!
M513PBEJH)#2+70P2PT35LD=+'9M[N;8Y7@4AE!P&%11@#\CYYH:5ZTQI3]H]
M1G_/U65\K_A+OK^1QVSM/YB];'8WRMZLWY3;WZEFI^_]HQYBOP^=W]B:YUFK
M/ RQ3O64]/6LE; T$DT KL=4QQQU8EF,[6\&_(;=_P!,BC#1A2JGA0GRK@>H
M!\J=># =V?GG/VUI^W_9P9#X:_\ "=:G[%ZEQ_:GRB[L[#ZUW9W'B8-SY'J?
MH>+&;5I<;C-SZ*Z#&9*:JH:VEFG$<B&6C@QR4E&X$$;3B,2%/=\PZ7"Q*K*F
M T@+,2//B*?X?,^@\6TU&<\:&@^SH8OE1M?)?$G>O1/\H#^51B*;I;M/Y-XB
M?L'N3O%LM6S[BI,'2-D8EKZG/HKU4%2U/BLY-)- Z344$,5/C(:5JV-O:>V;
MZH/>71+A"%5<49O2GH*@D4S4DUH0?#N'[?7 _P!G@,_Y*(WY*?\ ";[<NZ>O
M)]X;!^7'9?<?R(PV*AJ@G>YBK\7G*FEU234M/52RU=9B%J6T^$5-371!O3.^
MAS+&Y:\Q>$U#&BH>/AC2P_G0D?E^77M8;C7Y5-0/Y?ZOGU7]\I]H=^_(?:VP
M^LNW/Y,W=NQ_EAL';FVNLMF=X?&N'(]?[<J:+;<9H\9'5X>DVAGMM3XW&1Q4
MR*:?.1)%"&$%?CZ2%(2OLVCMBS)<J8V)9ED%6)_-@23G(&33!ZL3_DID8_/R
M^PUIT;?XH?\ ";'>&Z=GP=F?+?O7>75_<&:J8MS8K:W5M51YW(86KD;[E*C,
MYRH^XCJLNE41)(M#(4C==29"5VU(GN^9*'1"BE *=P-".& "*#Y'R].'5*@9
MR3QK6G^?]O1U?@IWE\H_AA\]Y/Y6/RY[5K._=M;_ -CY'L;XO]S[@FJJK,2T
M>/AR=4E#735+U-3]M4TF$S:&*JKIS1UM"*>EJ)Z>IA"H+R".\@^JA711M,BC
MX:XR/V@4 \_D2?-0_P"'Y_8?\-?]0V+_ &0]-]>]^Z]U[W[KW0>]K]K]>='=
M=;M[9[7W5C=E=>[&Q$V;W1N7*ES%300D*+1Q))///+(R1PPPQ233RND4,;R.
MJF\<;2L%45)- !YGK8&K ZUD.RO^%---E-\5VU?BY\/MV=IX:D6H>DW#N_=D
MN&KZQ*64J\\>W\/B<O)3TF@(ZR29/R'R 2P0,A5Q*G+11-4TJI\J5 _,LHK]
ME?M/5U6IH*G[/^*/0Y?$3_A1QT+W/OS'=7_)#JW*_&+<.7RYP6,W?4;J7>>W
M%JI)(X8H<O4R8_$UV"9IG>-GEI)Z6'1Y*FJ@1F\;%[R[);KKC82+2IH*&GJ!
M4U'V&ORZT$KCS]#_ *N/5WWRD[WC^-OQO[B^0L.VTWW#U1U]F]^Q;7BSHV^N
M27$1>5:=<B*3("F686M**.8 <Z&]DMM#]1(L=::F"UXTJ:?+K2K7^?\ (5ZU
MD/\ H*I_\ 0_]F@__1W[%/\ 53_AO_&/^A^J]"IU9_PJ-Z:S^<HJ#N#XL;]Z
MTPU5D::EGS^R^R*/M04T$[(K54]+48?;,S)#J=G2$RR%%_;5W(3VGGY6E3,;
MJV.!!4U]!\0_:1U8 'SS]F/]7Y=7Y]V_*O:76GP_WY\PMA4V.[>V5MCJ.J[?
MVM2XG<0PE/G:%:5:NG6+(BDK_M%J(W7UFBE:,W#1:@5 ?AMS+*L1[26"FHR"
M33ACAZ=>"YI]O\A7HOO\L#^8?_PY#TUOOMO_ $0?Z&?[D]FU?7/]W_\ 2!_I
M$^Y^UQ6,R?WGW?\ !,%X=7\2\?B^VDMX]?E.O0JK=-O_ ';((]6JJAJTIQ)'
MJ?3JO1??YEG\ZSI_^7WN[;O5N V+!\@^X*NU?O78V*[ 78T6W,?40^2EDR61
M7#9U?XC6LT;14/VJR"G)J9GB1Z9:A_:]F?<JM70HX-2M3Z 5'YGJQ6@K^SJP
M_P"(/=';_P @^C]K]N=R] M\:\YO.-LM@^L<COV3?>4@Q<__  #JLL9,!@/X
M;5UB?O+1&"66&%XON&BJ#+30EUU$D$A1'U@8U4H"?EDX^?GY8ZT13HL7\T#^
M9AM3^6MUIUYN^OZ^C[<WEV9O&LV[MOKM-]Q[ E>APE(U3E,N:ML7F9&I\?++
MC8&5<>P,E;#JDCXU*]KVUMS<J#I %2U*_8.(R?M\CUX#IS_EC_S']I_S).H-
MX]B8K8,G5&[.O][OM#=G7E1O"/?#0Q5E+%5XW)0UZ8[%-)29"-JF-0^/B99Z
M2IC&M$25Z[GMQVV0(3J!%0:4^7#/IZG%.O$8KU91[+NM=>]^Z]U3%_,2_G2]
M*? W?^.Z2P_7NXOD!WQ68_'Y+(; VMG8MM4F+&;:(XZFRF4:CR<T61R,,OFI
MZ6GQ=5+XO%),(4J*9I3C;MFDOU+U"(#EC\N-!\O.I _GU8+]N>&*UZ3O\OG^
M>'TS\VNTY.@MZ]8;A^.'>-4^7CVWM'<>YH]W4&4FP0F>KQ]/DSCL-4P9B"""
M61J2HQ46H)(L4LDB:#O<=E>Q42*0Z&G</*O"HS@^1!/Y5'7M/[1Q'1T_GS_,
M'Z/_ )>?5F,[$[<.7SV:W7E9,'U_UQM40R9;-5-*(WJWA^XDB@IJ''PRQR55
M5*X2/7%$@DJ)X(94=C82;@^B.F!4DX '\_\ 5\J]: KGRZJ!Z1_X4L=4;M[+
MVSL_Y!_&7>?QUV;O(8Z3 ]EMOX;_ *6.FR\DD5/DLA1R[>V_-#B&9/554LE<
M%LY$;+&S>S>XY<=$+1.)"M=2@4((\ADU/R-#^>.K:/R]*BE1_J_+Y];,=-4T
MU;34]91U$%725<$532U5-*L\<L<ZADDC=25='4@JP)!!!!M[#?5.JH_YG?\
M-BZP_EOX79-#)M&D[H[<WOD?+2]3T._(MDU%'A88YO-FZ^K&,S4E+ U2D4%-
M&V/O5.9C'(%II?9KM>UMN;$ Z5 RU*Y].(S^?5M.*_L^?^K_ #='T^-/<O\
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MEAAQTL;>Z]U]$WW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$
M_FQ?]NLOYEG_ (H!\R/_ 'W6X_?NO=5M?\)5/^W'GQ._\.;Y'_\ OR=U^_=>
MZV)/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW1>NX/^+WC/^U4/^MTGL7\N_V3?Z;_ "#J,^=_]R(_^:?_ #\W02>Q
M#T"^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDKOO:5!O[8^\MB95Y(\7O7
M:FX=I9*2*^I:?<='-1S,NED;4(YF(LZF_P!"/K[V#0UZVK:2#Z&O6JE_+S_F
M"[9_E++V1_+H_F X7<W7E5U7OG<>Y>M.TMN[;JMV8K(XG=TJU:EH*%:BO>FK
MYFEK:&J@I9E*5$U)6I1U5&5E%-_8-N]+FWHVH ,M0"K 4\Z#&/\ "*@]78#_
M #?,5_/H>M^?S</DO\].U9/C9_)^V3#'4XW&+F]_?)SM[ P8^@Q-&Y2-9Z/&
MY."L@I(1/(L8>NQM75U3B5*7%%(C4E.FTQV"^)>&E3VQJ06:A\SZ?8?,9!QU
MX ?[.:</VU_U9\DINKY9_P X/^5A6[:WY\]EZZ^87Q@W#GJ/!;JWYU)2TM-D
MMNS9(CPK%4QX+:;I)*1)XER6*DHZB4+2)D*266&]UM+3="5MM4;@85_A;C7S
M8U_/AY')ZT*$9_EQ'^2G0K?)O_A0O\/Y>B-UXWXQUN_.SN^M\[>R6U=@[0J>
MN,IA(\=E-Q0-2TM5E):I:>*ICIII5<4]!/4S5$BK"IC5S,C,'+\Y<>* B#+-
MJ7X1QI0GR]13UZVH /&OI0')_ET1+^6?\V:S^3E5[U^$O\Q'8^\NK,=N^IP/
M?NP=UXW'OO>/'C?F+I*6LHZN#'R5,ST+28I8@]!%4"#*09&&9#J,R+]RL_WS
M2XM:-2J,/A-5.#FE<$<?*GV#Q&,G_**>G[:_ZN.?^9;\XJO^</)M'X/?RZ]A
M[S[5I-O5F4[UW[N[)4@V-%D(MA8ZK@IJ*DI\H]+-'1+-DT5I:X4OFR+T-/#&
M01*VMMLOW,?J+JB_@4#N-6\\5& #ZXK\J^ P:'CQ^ST_;3_56AX/BQ_PH4^)
ML/1^W,!\L)M^=0]_]>8:FV=O_;"==Y3/0Y/)[7A6EGJ\<]%#4&B-7+$3+29#
M[22DJ3+ 6EBC6ID17/+\P>L(#H<JP9>!X5J1Y>8P?Y=:8 GT^6<?X>JFL]\X
M/DCN;YHO_.ZVY\>]UM\.NM=WXGX\Q09.JH**KFVWDZ"IQ4T4EIIF^]:KR3U+
M5,(DH*?*5%-C#63!9"306,2P_0EQXK5D\RH8>7YJ//RJ:<!U8</E2GS.>/Y'
M_5QZN.[?_P"%'?P=VWU5+N+I>#L3MGMK*X\1[<ZMKME5NSA2U]7$3"N;R=4A
MHDIH9M*2_P .FR$KMZ8593Y5*8N7;AFHX"+YL6!%/L!K^VGVCJH45XU^RN?Y
M=!%C<7_PI/[*VQC?D!C^P_COUG'-C'W%C?B]6[?Q.-R-1!-JGCH9XJ[;N5^W
MGJHA&BQUF]H*B %5DDI9_,0YJVV.J4E;/]IZ?9D?S7K9 !IC^=/]7V8Z$SH#
M_A0]\:Y]MY?:GS2V[NSXW_('K[(Y/:G8&UL9L[*[SQ53E=NS24E:N.-##65V
M/E%3#*LE'7(/M7O$*RJ"F8TGY?FJ&AI(C %6J%-#G(8C^7\N'6BH'G^7_%=
MU\-]Q;@_FJ?S9*?^8IMW8>XMD?&#XH]=5_4'6F8W(T5#69W*34N;2&&HAA,Z
M&=/[VY6OGCAJ66DC7'PS3.TS([MX/W7:?2L07D8.P'!1CS]>T?S^1ZV5 %?R
M'S^?V>7^H@;0OL-]-]>]^Z]U[W[KW6IU_P *B>[=SXC9_P 8_C[BJJHH]L;U
MRN^.SMX)!520BLEV8*"@Q%/*B%4E@A?)9"9DD##RK3R*%:($BKE: .[R'BH
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M/D4:E @K<3&3+.K1E5UOK4W)=>Q+;WC"0=OB5('\!(;%*>1ZL2"?V9/K3/\
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M:@BIH9C&TL0JIEN(;,;\MV;23>-2BH#GR+$4I^PU_P"+Z\!09\^'[>/\J?\
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MJ>FECAJYH#!+HBEHZJ%]B.8;:JDJZ\5![2WS%>!I@GA\Z&KGP\.!\\X^6/\
M5PX=;:/\QS>6UNQ?Y7'REW[LC.X[<^SMY_&7<VY]K[BQ%2M92UM!FZ!:BEJ8
M)4)5XYH9$8&_T///L*;>I2YC!%")%!!X@AAU5!0_D?\  >M:_P#X3]_RTNB_
ME'2[_P#D_P!^XV@['P'6N]JGK7:G3^<QB5F(J,@V+HJ^HRV820LF0BA@R44=
M-2-'XA,'GF\A6)5$W,6YR6Q$,9*U4,6!H>)%!Z<,^O#A6NA@?ZO]7^K]@/54
MO8/\A'^:=,U(-Q9OXW[UE,XHE,B+GNO-WU3:8M4GEBJL[M"J6ROJ22:IH^33
M4V1=?;@T\P6GEXB?974!^5 W[ ?73U;A]A^W!_GP_P !^?6X-\I_F%L/HWX2
M]D_,#;.?P>Z=L8_JE-Y=892DKTEHLU7;PABAVO'#,JRAX<CD:V@4D1OIC=F*
M$*P]A"VM6N)EAH02VDXR*<<8X"M?LZJHSG_53K2)_EH8G^:%MC=F_/F'\-/C
M]#W-F-YR[JZ[W%V/O/"T6;C^[R-5C\SF/M!5Y?%2?=SS&D,U1&KJ0TD(8'S(
M!MNILV"P3.4"T(5:\*4%>UO+AY]."IJ2!G.33_*.H/\ ,IP7\SO-;\V5\SOF
M-T(>E=P;>GV=U[M[L39V,I,+3_Q# 3Y',89YDI,QEF3(0LE28JAA&I6&*(DL
MD8.]J:T"M;PN7#5)5J\" #^%?+RZT:BA &/0U\_M/6SY\@,S\K?YGW\M/XP]
MH? SM2OZ<[;WCO#9N]>Q,GMGMS+=4O!%M_";DPVZ,"<KA5BJZF&GW3)3::>2
M)(YEIHZDHK1QCV&;;PMKN76X76 "H[0<U!!HQQ4?X>JE<\0//U_P#HN'\OKX
M(?SBNF?EYU'V5\J/E1O#LCH;;?\ ?W^_>R\K\JMV]DP5O\8VQFJ#%^3"Y,_8
MUOV^9JL=.OD_S+1"=/W(D]JMPW&SGA9(HM+&E#H04HP)R#7A7K14#S'\_P#-
MT0O^59,G2W\^CY-=>;Y=<)G=UYGY5['P,&34T;5=3-N&+<5(81=E/WN)Q<M3
M#Z],D1!1F+(&6;I^MMT3+D#PZT\J*5/\\?;U=A4D_G^T@_X#TR_S[,53=_?S
M9_C9T9@*NIS597]:=$=39C#8^J:1J;([]WEN"=XPD0G:">7&9?&2,WAUZ#&Q
M1D5+WV)_I[.63 (+D$^=$%/Y]:09%>''\JY_P=/W\\'7U)_.'^)?=&ZU?'[%
M3%?'/>;9ZJB:.E6'KG>=:V53R)K+-1P0Q2R@+K5)XSI(92U-D_5LIHURW?@<
M>Y !^T@]>&=/IP_G7_+U8'_PISWKAZ?X4](;0@S42Y?=WR3V_N2@H*:M7_+,
M7M?:^YHZN;2KWFIX:O*XDW"M&'>)B0VBZ+E=:W#&G!#^1++_ +/5:&A/Y'_5
M^75EG\G_ *[J>KOY:?Q$VO64M31U-9UG+ON2GK"_D7_2IE<CNA20\<3*&7,!
ME7395(4,X =BO=9?&N9&_I$8]%[1_(=;<4-!Z#]M!7^?56'_  J'_P"R7?CC
M_P")\KO_ 'G<E[->5_[=O^:9_P"/+UX?"?M'^ ]7+?RTO^W>_P *_P#Q67IK
M_P!T5%[)MQ_W(E_YJ/\ \>/53T=[VCZUUIH_\*F$<=H?$"4HXC?8/;")(5(4
MM'D<,6 /T)4,I(_%Q?ZCV,>5.$O^T_Y^ZN?A'VG_  #K8>^>/S.3X&_":M^0
M%-M>'>>Y*''[&VGLK;=;-)34E1EMSI'%3M72Q$2I14T25$\H1E>01"%'1I Z
MAK;[3ZZ58JTK6I]  3_DZ\%J37@,G]M/\O51/QWV3_-Q_F0]$8KY&=F?S!\!
M\4>BNQJ+,Y+#;6Z4V%2P92+#X.JJJ.NJ6R%%+B\ABS(U'4&-GW-5S1I9Y5B8
M&'V;W+VFW.8UB,C*?B=C2OV 4('V"OV9ZOP\LXP!7C\R30]%5_X2S_\ ,U/E
M[_XC_JK_ -V.7]KN:^$7^W_Y]ZH/A/VC_ >L/_">S:^.K_YD/S3W?4:GR.V]
MB=BX;&QLD;QJNZ=\8Z2>8:D,B3HN-2-&5U_;EF5@P86:WR0BU@3R(4_[R@'_
M #]TY*,L?Z5/VU_S='6_X4_XG-57Q(Z$RU)254^#Q/R$CBS-3#&SQPRY+;V8
M6C,Q!L@?Q5"JS+;4=.H%@'3\KL!<,/5#3Y]R]-CX3]H_R_Y^K/\ ^5WVMUAF
M?Y:7Q9W=A]S[>H]J["Z#VGMS?&3FR4-)!B\AUW0+0Y_^(.[*M(T-;254LAET
M^AA*"8W5F*MSC9;F0$&I=B/L)J/V@]>*DD>=0*?LZUO/Y&^Z=M;Y_G)_*G>V
MS)$FV?O#9_R:W3M2:*%J97QNX-\X.KH66-E5HU:EFB(4J"HX(!%O8DWQ#'8P
MJV"#&#]HC8=>;B?]7GT >]MC_(3.?S^>X-I]7=W8#X_]^YKN[M-^L.S]T8 9
M&DI8-R[<K9<90FEJH<I%)-D]K5:T4#/"4EEFC,*0O)#&CT<D:;:I9"Z4&I=5
M/Q\:C/Q=7H&.3^$<!7@!\_\ 53H\GSO^ OS6W]MGKS97S_\ YLGQ6QNUJK<]
M?G>NJ?MG%8_K""3)8NE^VJ9::NBP^)+&*FKP)$>I\=I%9EU*K*7V&XQ0L6M[
M9BU*'2[-BH\J'S'7J*1Q-,?A'S_I=2OYZ^P<MU?_ "N_Y=W767W=B>Q*SK[+
M[!V54;_V[4MD,=E_[O[&J:2#(4=2US-35L-.)89&8M(AUZFY8VY>D$MW(P%*
MJQIZ5=33\NM-P/'B./'SZV%/Y:7_ &[W^%?_ (K+TU_[HJ+V0;C_ +D2_P#-
M1_\ CQZ;/1WO:/K76F3\7]KX[<?_  I?[=KLCJ=MH=C?(;=&/@T1R1O4KMJN
MQ\?E#HW$2Y!Y4*E66:.)@UE((LGD,>UH!^(T/^]LW_/O3["M3Z*O^!1_EZV2
M/YD'S.3X&_%+>OR IMKP[SW)0Y/ [3V5MNMFDIJ2HRVYYC%3M72Q$2I14T25
M$\H1E>01"%'1I ZA_;[3ZZ58JTK6I]  3_DZ:1:\> R?\'^7JF?X[[)_FX_S
M(>B,5\C.S/Y@^ ^*/178U%F<EAMK=*;"I8,I%A\'555'75+9"BEQ>0Q9D:CJ
M#&S[FJYHTL\JQ,##[-[E[3;G,:Q&1E/Q.QI7[ *$#[!7[,].</+., 5X_,DT
M/15?^$L__,U/E[_XC_JK_P!V.7]KN:^$7^W_ .?>J#X3]H_P'I&= PPS_P#"
MGC.I/%',B]Y_)294E02 /3]=;JDC8 @C4DBJRGZJP!%B ?>V_P"23^0_ZNCK
M<O'\E_XZ.K _^%05)"_Q#Z!KVU>>F^2%+21V;TZ*W;&X'>X_)U4\=C?CG^OM
M#RO_ +D-_P TS_QY.JUQ^8_R]$A_FI8G-57\D#^5CEJ2DJI\'B<3TO%F:F&-
MGCAER6P:Q:,S$&R!_%4*K,MM1TZ@6 =9M# 7\P]3)3Y_J#JWD?R_P'_/UL._
MRN^UNL,S_+2^+.[L/N?;U'M7870>T]N;XR<V2AI(,7D.NZ!:'/\ \0=V5:1H
M:VDJI9#+I]#"4$QNK,'MSC9;F0$&I=B/L)J/V@]:*DD>=0*?LZUO/Y&^Z=M;
MY_G)_*G>VS)$FV?O#9_R:W3M2:*%J97QNX-\X.KH66-E5HU:EFB(4J"HX(!%
MO8DWQ#'8PJV"#&#]HC8=>;B?]7GT >]MC_(3.?S^>X-I]7=W8#X_]^YKN[M-
M^L.S]T8 9&DI8-R[<K9<90FEJH<I%)-D]K5:T4#/"4EEFC,*0O)#&CT<D:;:
MI9"Z4&I=5/Q\:C/Q=7H&.3^$<!7@!\_]5.CR?._X"_-;?VV>O-E?/_\ FR?%
M;&[6JMSU^=ZZI^V<5C^L(),EBZ7[:IEIJZ+#XDL8J:O D1ZGQVD5F74JLI?8
M;C%"Q:WMF+4H=+LV*CRH?,=>HI'$TQ^$?/\ I=;/?Q/V)D^K_C#\>NMLQO'#
M]AY#8/3'6VSIM][>JS7T&87;>(I*2+)44[7:>EK(H4EBD)8R(P<LQ.HARXD$
MLC,!2K$T]*DFGY=-OQ/'\^/1@?;/5>O>_=>Z][]U[KWOW7NO>_=>ZU*?YX/_
M &^M_P"$]G_BVW47_OV>O?84YC^)/L;_  CJ1>1O@E_TR?X&ZWMO8:Z'?7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ,_\*A_YKO\P/\ EN4_QWPGPSK\
M5L?:?;FU^Q7[%[9K.JH-^U&'R&'K,5!B8*2NRD-;@<?/60U-<5CJL?-)*8RT
M.DQL??NO=:]'Q7V]TU_-LFII/YEW_"E3=^+RN?Q>*I-S_&?*#/\ 36)6?+L#
M3T=%E][G;W7=0Z2JZ3QX_;546FT,SA&@DF]U[K<%^"?_  G;_D_?$_.=:]X]
M-]53=Y]D;%J]O;CV%WCVEVC4]HR1Y3;5539"ASM#18^:BVA#E:>NI*>H@JZ7
M!1R4\BWIFB5F#>Z]U?Q[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NB ?S8O^W67\RS_P 4 ^9'_ONMQ^_=>ZK:_P"$JG_;CSXG?^'-\C__ 'Y.
MZ_?NO=;$GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[H*(N].HI^Q).IX=_[>D[#BDDA?;"U1\WEBC\S
MP"33X&J4CNS0B4RBS70%6 !B>XFQR;J=D%];F^%1]-X@\2H765IPU!>XK74!
M4TP>A$W*.YI9?O$VTOTQSXNGMH3IKZZ:XU4I\^A7]C/H.]>]^Z]U6O\ S#M^
M]0;#P>R\OV/O';^QJFEJZQ4RV5\L]554]0$48_&8ZEBGR6;KI)VC=:>CIY33
MK>6I-/#*)3B']Y_V)O??R;;=OVB%5N;>5WN;^4%(+:RD6A0MIK)(SA72)2=.
MDF0QB168HWCF"SY=C\:[D6,'"@U+.WDJJ 68_)03\J="]MK;VTOC/\=M_=R5
M&)RV)SN ZIW/V'N6IW934J9*FBV]C)\G]C+!2U%72TS1"%1)3Q5<ZF8:6GFT
MHPDOV+^[SLWLE;F"QK<7D^E+B^D4"27.%09\*('(0$DX+LY (>OMQ%G:27<@
M*".)Y6#4JH52QK0D5%,T)SY]:S.Q>XJK.?&OX_Q='?-'Y.[H_F2[Y[ @HEZX
MQW;&Z<YA'IZ_-UZ14^;BS@.WTBI\1'0RRAJEU>6_DAFI_+,N54L 29S)%&+<
M#XM"@\!P*YR?]0ZQ@L-V:XVVT6RW"[DW>63$8N)Y(R#(V)%EK& L=":\2/Q"
MIZO;[1^2'6NV?E]V#49U>Y:O>_PT^'&]NW]\0[<[$DPVQ:V#)4])5MCZW!(Q
M%;G9XYXGHY)H/&%9)'BEFI*-X Y#:N\*TT4EE""H[Z_(^0]<_P"7J;=RW^VM
MMSEU_4:[&QDN)-$A%N5:ATL@/=)056JTIG)"T"FF_G*XNEJ>D*[=GQ&[YVYL
MOY"X9INJ-ST\^/SLV<RBHD"XK%XZ(QRU#U&6EIZ*GDEFIVF$\%8(5I95D]O_
M +C)UA9$)C/<,B@]2:>F3Q]./14ONM&AMFELKI([M1X$E$;Q'(%$"AJU+$*I
M.FM0WP=W1A.A/YAM?W7D_DKL.L^,W:VQ>[OC9C:+)Y;IS(9+'Y7(9?\ B:S?
M:T^/JT,%(M1.\4>AG;[62&>"IAJ9879D37.V_3B-O$4I)6C"M!2E:XKY_;QQ
MT>;)SQ^^7NX#:3QW%F%+0,8RSZ@Q4*0VFII@DA2"I#$$D)_JK^9W@]]=R]@=
M.;[Z [.Z8JNH=@Y_LCN#=.\LSALKCMKXS!47WVO,28JKJ_MIJB,H(X6;RG5J
MT:02-S;48XUD5U?4VE0NJK'A@$"O3.V^X,=[=RV<UM-;FWB,T[R-$8X4 U=Y
MCD<*2,@'-,\.H?57\S^D[&[6Z)V9F?C5VUUWUS\GZG=<'0O;6Y\GBY(LTFUX
MC-]Q48>GE>MQM-5H$,+22,SK+#-&DE.[S1VFVDQ([!T+1TUJ*U%33C2AIY]-
M[;[AK?W-M"UI<117GB?33OX>F0(I:I4,64,!5:BI!! I4@G?Q/\ E95]+_'_
M .;_ /,$W9M'>7:6SNQ?F3N.FH:3;F6IVEH]I4=2M+B:VD6KE$7\.I,AF31^
M-65_K,UT5G9;>67CRPVRD*1$*UK\9%37YD#_ "=!;EKF=MIL-QWR=9)XI+^3
M1H*DBW5A&A4%@-*LQ'EYL?7H_P!_PX_UQN;>'9&!Z>V5N'MS:75&P=J[MWGV
MKALM18;;T.0W\(/X)@(:RJ;54Y"K:LHS,8HV6F0U.L//3-3N7?NMU"ER%+$@
M*:ZJ+Q-!Y8_/[,]#I.=[>[GFBM4>98(T>292HA#R@%(PQ/<Q# F@(4$U.H:>
MC1_'3O3'?(?K2@[%QVWZ_:WW-2M+5X+(UD=?+3R34E)7)')+$J+YDIJVG6>,
MHK0U F@.KQ^1TMW;&T<H37YCSR1_D_9T(-FW1=X@6=5*5IVM0D5 :AIY@,*C
MR-1Y=#M[3=&O7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1>NX/^+WC/\ M5#_ *W2>Q?R
M[_9-_IO\@ZC/G?\ W(C_ .:?_/S=!)[$/0+Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>ZC5M%29&CJ\?7T\570U]-/15M).@DCEBJD*21NIX9'1B"#]0;>_
M=>&.M4G<6P_Y@'\BF3NG=7Q\V[UY\@_Y>>8W-7]C-AM^;ICP==LULG-!1PTK
MO49*CR)KZA7H:(34T63AR!IX)&IJ6LF\3B99(-\TB0E)L+4+4/\ .@&/Y4]2
M.#HHW[#BM*>?G7'\_P#+6;W=W9_-%_FI4&.[AWY\<.Z]^?#C:&6;+OU%\>J"
MNV#A<C%B7D$DM'7U=%GZS<.3A,926K&/R:TKB9:6FH3*R@SBAM-I.A9%$IQK
M8:M).. H%_,CYDCK8'RQZ5 )\_M_9Q\L])C+]D_%SXX;2ZP^67\L7O+O;H#Y
M04V_HNL^POAMV6?[_5F0=!^^TIIZ:*GR&'UR>)8ZVGG6JE=!!%C<C2M&=I'-
M=,8KM5=-)83"@"BE:@T'I\CYFJ];(XT]>&<FO BI-?G7Y<>K>MW=P_SY/GWU
M-0]#T/Q+V3\5=I=L[8.![3[FW(U7LFI&+S,(CK5BH<OEJO,8>EKZ=YH9Z6'"
M5^2T2A8I:<+))[*DBL+%RYD,I4U5 ,&GJ:4/K6H&.!X=5PM#P^=0?V4X?G_L
M]*G:/SFVS_+UQ^P_Y7G\O7X^[S^<G>/4<5;!VYN3#22X'$)G\E435NX999*6
MGR,TD\%;*\<WDEAH<9'X:-J^HGIIHHVWLC?UNKAUB5_AQ4D"@% *8I^9I6F:
M]>*U_P!7 <>)_P!7^#JL'Y3][][_ #O^46U.@/YKFY#_ "[>H-B;0W[OK:.W
MHNO,G'1U.8H\9*M%5?=ULE<,M/4D2I'5+4&D:.*;&T"19"N#2&EK"EA"9;/]
M9R0I^0)_A%#Y#''SX#K=!PIC[1G\^'G_ )^C!?R^/YF/\U3:?0DN"Z]^)&;^
M:WQ_Z:HY]L[+[4CVQF-J923#[0UTT-#3UD J4SC4=)# D5/#BZC(TZCQ5,D[
M: B?<-MM3(-4@B=J%D^(*30^5-/'S-/2@Z\16IX_.H%>.:'_ %?GT8#?>=_X
M>$EZ\^9GP0RM3T!_,?\ A/54V*W3TQV%7Q4$];C34U$\5!_$VBAAJ*1*V7,4
M\#5,%/!.M774&5@I%GBD"9 =IU07 UPRBH9<_P"V'E7A7[ 17S\!I_;YC\B#
MY_ZO6M P^:G\RO\ G;=:]!U^+[.^)F)^,=+D%3:^\OD1LG"5FYEH_O6-.\M%
M54^6SN.P#U1U(E4[5#@N&H)(IS!('K+;K*:3ME+^80C23\JD"OV"G[.O #B!
M_,$?L K_ (>JW>RNA/@WF]L[/ZF^)L/R<_F)_.+MC9D?96XNV=@[@FVUB\'E
M-QI]VU178F;#Y7(5$U)5U$4F2IZRI2:)F*U67HZIVCB,([FX5B\VB"%3IT%0
M=0'D/7 XC'H".M@#RI7R-<_:34 ?+^?KT:SJ3^;)_-C^!U9MCXJ?(WHV?L?>
M6;JL5M[J6;Y"4F1P6:F;*2045'!!N6.KAH=R8U*J>%#435$TD<C/#+D46,1P
MIYMIM+X&:&32H!+ "H %3\."O X_8.JTKQ%?*H(%?Y$?ZL]7-?R]_@I\J\M\
MI=W?S'_YBF0VY#\B<]M239/5?46U*N#(T&S\95P_:SN7IYZVDI9Q1&HIZ:FI
M<E5*L=;75%;435M4P@)[^]B$0MK>N@-J9FXN?Y8^T>0P*9J6_P %,?M_P]7N
M>R7JG7O?NO=>]^Z]T'O:_5'7G>/76[>INU]JXW>O7N^<1-A-T;:RH<15,$Q#
M"TD3QSP3Q2*DD,T,L<T$J)+#(DB*PO'(T3!E-"#4$>1ZV#IR.M8_L[_A,I14
M&^ZS=OQ=^7FZ.J\-4-5-C]N[OVE-G*_'BL=]<$&X<3EL5--2B%Q&J2XWRA4_
M=J)S(642IS*733-$K_.M ?M!5A7[*?8.KJU#45'V?\6.AP^(G_"<;HCIK?F,
M[0^2/:F4^36XL1EAGL?L^7:J[/VXU7%+%-%+EH)J_*UN=*S)([I+4T]--Y/'
M44TRJWD8O.8I+A=$:B-:4-#4_8#04'V"OSZT'IGS]3_JX]7@_*3HB/Y)?&_N
M+X]0[D38D/:_7V;V%%NB+!#<"XU<O%XEJ%QPJ\>*E81:T0K(01QK7V2VTWT\
MBR4KI8-3A6AK\^M*U/Y_S%.BJ_RP/Y>'_#;W36^^I/\ 2_\ Z9O[[=FU?8W]
MX/\ 1_\ Z._MONL5C,9]G]I_&\[YM/\ #?)Y?N8[^31XAHULKW3</WE()-.F
MBA:5KP)/H/7JO3K_ #)OY<W7'\QOIW$]?;GW">N]][-SL>?ZZ[5I=N#=,^*:
MJ,<>2I): UV,^^H,E2HJR0_?PZ9HZ>H#%H CUV[<&VZ36N011EX5'[#3[>K!
MJ C_ %5Z!_I+^61V'U?_ "^NX_@#N_Y6'LS:^_=N[JVMUSORJZ;? U.U*'>"
M,U31_8-NW(#+T<58\E13Q??41B,LL7D:,Q")R?<5EN%N%330JQ756I4UXZ12
MOV'UZWK_ ,!'\J?RZ$O^6!_+P_X;>Z:WWU)_I?\ ],W]]NS:OL;^\'^C_P#T
M=_;?=8K&8S[/[3^-YWS:?X;Y/+]S'?R:/$-&MJ[IN'[RD$FG310M*UX$GT'K
MU3KW\S/^6ML#^9%U5M79F;W8G5W8.P-R_P =V-VK3[0CWG/14^158LMBY:)J
M_%25%!DXHX'=%R,.BIIJ6?UB)HI/;9N3;:^H"H(HRUI7T\CD?9ZCSZV#BG1!
M,[_([[PW+\*MJ?!?,_S"9*WJ;9G:T_9>!J6^-4L=7'3O35*Q;>D\?8B)48:#
M)5M;D8XYO(4JY%*D)! L:Y=ZC2X-P(LE:4U^?\7P8-,8^?J>K%JCY^OR].K@
M/A5\6-L?"WXR]6_&_:N7.Y*3KW$UR97=<F+.%?+Y/.UE1D<GDWI&JZYJ45=;
M53-' :V<4\7C@61DC7V47ET;R5I3C4>'H. ' < *=5)KUA^;7Q3VQ\U_C+V=
M\<-TY@[9I]^X_''#[NCQ1S<F(R> K*?(8[))2"KH35"GJJ:/R0_>PB>%I(6D
M59&/OUG=&SE65?PGAZC@1P/$8KY=>!IT ?\ +'^ N[/Y=G4&\>ELK\@I.]]I
MYK>[[WVFM1UQ)U\V#ER5+%3Y*EA5]Q[@6:DK)*:FG6-/MEBG-3*5E>I=E4;G
M?C<9!($T&E#FM:>? ?9]@'7B:CJRCV7=:ZI _F,?R5>OOFEV9C?D1U/V?D/C
M=\BJ,8_^-[RP>$DRU'FWPJ1Q4%95QTM=C:RAS%%#%'%'D*>I9VACCCEAD,<4
MD9SM^\M9*8V42(?PGR^S!P?,4_9GJZM3UKZC_5GI-?R^_P"1]M7XF]WGY/\
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MT_EQZ\S:C^0'[ !T83^9_P#R\/\ AR'IK8G4G^E__0S_ ')[-I.QO[P?Z/\
M_2)]S]KBLGC/L_M/XW@O#J_B7D\OW,EO'H\1UZU8VO</W;(9-.JJE:5IQ(/H
M?3JO09_*/!?%'X:_RT>M/CW\TJ?=G;706)VMUE\;]Q;LVAL&:2=*O$XR7^';
MDDI*>MJIL"L55B$D@G2LJ&IZV2D@5IFE ;=N9;NY,D&'+,X&H#B:TS0'!R/,
M5Q3JZY/Y>=:?R'5'GQ8_E,?RW.Z,'D^Z-L?S(=SY_P"*4.<-3N[J;=$>-Z>R
ML;;2E6=Z?=60K<I (H?$H=9AMFCD,#B>DJ(]22@ZO-XN8&"/$JRTPU-6&_AX
M_P"$BN".G #2@#$?(FA/[!_GZ9?Y">W,!FOYKGRVWIT]B81T9M_97>-+M+(X
MR!X*&EQ.ZM[8D[8I8A)^X@J,922-!&WJ\5/(3RA]N[\Q%G"KUUDH2#QJ$(:O
MYG/39'$_.F/]7RZO%_F0?R=.J_GKNO!]R[=[#SG0GR(VU1XG'T?9. Q(SU-7
M0X*99J+^)4"5>-J36T(#)25M/DH)H 4\BU"0Q1H1[=NS[>"A =&K53\Q3CG\
M\&O7@^*>G ^8Z)AUO_PGTW+O'M+:G8GSO^:W97RQP^R!3QX;8^9.7J_/%3.)
M%HJG,YW.Y>KAQ3,B>6DI::$RCCSH 0RR7?\ 2A6WB6+5Q9:5_DJY^>>MZ@/4
M^E>'[,_ZN->ME6CHZ3'4=)CZ"F@HJ&AIH*.BHZ6)8(HHJ50D<4:* J1QHJJJ
M@    <>P[TV37J3[]U[KWOW7NO>_=>Z][]U[KWOW7NM2G^>#_P!OK?\ A/9_
MXMMU%_[]GKWV%.8_B3[&_P (ZD7D;X)?],G^!NM[;V&NAWU[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=5._P SW^;]\$_Y7^%VMA_F%7[SRN6[6VUNO.[&
MZQV3UG-O^JW!3[.DI(ZRG1ZEJ3;]/+YZRE1%R.6I(V9M1<(K,ONO=:,_RZ_F
M&_RL_P"8SF\KM_X9_P#"=C>W<G8-7D*G.YO?'64E?TCN&"OS+.(*JLP/3>,S
M29A\C(:QY?XAD"LDRF4+-.3+%[KW2B_DZ?R6_P">5U7\SN@>Z<1UQVO\+_C+
MM[Y+=/=H]P[2W#\A).NH\OM';^Y<?D,YMZJVWC\Q/FL\:C;]-/0O!E,4L-6C
M""JE"O)I]U[KZ;'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z(
M!_-B_P"W67\RS_Q0#YD?^^ZW'[]U[JMK_A*I_P!N//B=_P"'-\C_ /WY.Z_?
MNO=;$GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>ZK;^=/S$K.FZ=NJNNS-!V-G<3'69+<;1%4Q%%D-:H]*6%I
M<A.%?0PND"^OF0J%Q'^\O]X!_;B/]S;54;A/$':8CMM87+*&6HHTK:3HXA*:
MFJ=(,Z^T/M@O-+?O&]H;6-RJQ5S-(M"0U.""HKYMPX5ZH9CR>2AR4>9BR%=%
MF(JY<G%EHZN1*E:E)/*M0LX82B<2@.) ^L/ZKWY]\NEOYTG%T))!,)/%$P=A
M*)0VO7KKJUZN[575JS6O68K6\;1^$54H5T%"HT%*4TZ:4I3%*4ICJ_'X1_,Y
M.Z*6EZP[%G2#M3&4,CX[*B,1Q9ZFQ\9:2:R@)%DH(E+3Q@!)5!GB  DCBZE?
M=P^\*/<F,;/NQ"[G%&2L@%$O8D&7  HLRC,B8##]2,4U)'AM[L^UAY48[A8B
MMH[#4E:FW=C0#.3&2:*>(/:WD6&/YN?)O_93?C]N3M'&[=GWEOFNR6%V)U7L
MFEII:V3+[FWA*:?%T0A@(J)T#"6>6*$^:6*&2.&\K(#F!M]G]=*$KI&2S'\*
MC)/6-'-W,/\ 5BQ>Z5#))58X8E!)DFD.E% &3DU(&: T!-!UJ_;@_E@_S7OD
MWO-_D3VK0X:F[%R]50Y^@'8_8&/IJZF6DE:IHJ6GQD KJ;%TM*UO%0R+ L&K
M0\*-Y !DF\V-FG@I4K2ATJ:&HSDT)/SZQRG]MN:>8[@;E=&-9JAE$LHU)I.I
M0%59%51Q"U\\BI/5^7REF^5_>?\ +Z[;Z]I>@<UMOY,;MVQMS8V7V11;EPF3
MQE8F9KZ*'.9'#Y>/*-0MC9\8N2:.&JJ(*V'4D<T%S&\H6L_!M[E6+UC!U!J&
MN!4 BG&M.%1\^IQYG&Y;OL4\$=N5NY(Q$8@\90ZV579'U :=.HC5I;@"H/1%
M.R/C%\F/D[@/AK\><-\,S\:]@_'W-=89+=G?&^]];6S.4^QZVQHQ[45%3X2L
MK,C/]T&EG :>0U%6*=YS3JDL_M?#=Q6AEE,OB-(& 158"K&M3J '0.W'E[<.
M85V^QCL3:0VDD#O<2RP,X6!=.A1$\C&M:U)RP!-,GK%V;\<_E3V)B/YNV^-L
M]-[MJ>Q/D9V/UCU#U#B\NM-MI\AM'KS("CK<Q2RY&HHHGH:_!4].(]4RFZI=
M7.I#:&ZAC-LK,-,89V(J:,V0, \#U3<^7]SO8]]GA@;QKR2&W@1BBZX(J1LX
M+,HHR$D5(X#'ET;[>/Q1[-K/E!_+'VYA]F/)\>_A]UEN&HW3NH9&ECIHLU38
M&#&8FF%+]R*NIJHZS"X^5913F-%GD<REF9&0QWB"&<L>^5A04\M1)S^?0JO>
M6KAMRVA8D_Q6QBEUMJ&D/X*QQ@+6I(*@@TH 3FIH0&DZR^>?5.7_ )C7R!ZA
MZ2K,EWQ\CN\]N;!Z<@R&X,%*<=LK9M/EX*;=R+-DTI&EDHVH8XJ6HEUQ50@>
M2GDACE212)K:8012/V1H6?#9=B"5P/YCR\^B,[=O6V-NU_:6];J[N$BMU+Q4
M6WB5E6;+@5(/PL:@TJI -7CI[XF=C5?P2^2OQKP_QWW_ -0=Q]C]>5&1W-W%
MVUO;;N;R'8.Z\N\M15?=5F*RN:GI::26.2$+53+'#%5EM<DTE54&DUZOU,<Q
M=656%%4, BBF "J_R].E&U<L3'9;O;DMI8)YH6USW$D+-=3R!M3,T4DQ&<'5
MP#8J:GI ?&+I:GV#L7=&XZ'^7W\A]H?)_IOXH[ZQ.V=^=H[TK=^8E]QT&*_A
ME/AMAQ569RD<+9RHJJAU-+CJ=*2C$\$4CI+HG<NY_%;29D,;R"H5=)TUK5J*
MO#YDU/2/ES:!80M*NUW27EO9.(WGF\6/Q0FD1P%II=.LDT*HH"U%:&A==I](
M?([:?\OGXV? 'KSJ?=&)WCW_ (+<"?(7M'=.V3)A]BX+?>4K\EF4KFE"PR[@
M:BJ&HZ6D1A+%X0[O#42TLK^DN8I+J2Y9A1"-"CBY4 #[!BI/6[38[^SV&TV.
M"%@]RC"ZF<#1;1RLSR5_BDHQ1%'"E21@DRG\JKIC?O1'5'>_Q7[>ZBGP^)Z_
M[@WA#MG?.4VE#2XS?NWMTO+##D7EO+%DYO'1E9%EYCH9J&F9?VF54N\7"W4B
M3(U2RK45-48>7R_SUZ/O;79Y]BM)]MN8=*Q7$HCD*KIN87)HYH34T%"#P72/
M+JU?!;?P.U\9!A=M83$;=P]-)4RTV)P6-AQ--&U;*\\S)!3I'$C2S222.0@+
M.S,UV8DE#,7-223ZG)ZDF*)85TH HSA0 ,FIP/4FO3O[KTYU[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]T7KN#_B]XS_M5#_K=)[%_+O\ 9-_IO\@ZC/G?_<B/_FG_ ,_-
MT$GL0] OKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM?/_ (4I4F_*
MC^7U@)]J&J_NO0_(3KZH[.6DD$?^XJ3'9V&B:I!8!Z09^7$ J S?<-3.!I1R
M#_EO3]3W<=+:?]-C_GVO5AP/^K%>KMNBJ_JC)],=65O14VW9NFI-A[7CZQ.T
M_",<F$IJ2*+'Q4JP?M1QP4Z)&8P 8V5D8!E(!)+JU'7754ZJ\:US6OG7K3"A
MSUK=5_4/2/2/_"D7%YSL# XK;&([OZQ?L_II\A2)28N;?F<Q?\+J*F$B&*F2
MNKZK&9^93*\CR9>J1T?[FHID @\9Y]MTC\$@#9SHXBM3ZD#'I\CTYY5]1_@/
M^;K9'[P[8VKT5U!V1W!O7,8[ [:Z[V=GMTY'(Y2;PQ#^%T[R11<7:26HF$<4
M4:*TDLCI'&K.RJ0]'&96"J*DD #YGJBKJ-.M>S_A,KNSKC<'QZ^1ZM6X^L^0
M>1[ZJMT=FUU?61U>9K\+F,3C3A:R9C%'.:#^*?WB"JTDVFK:JE:1?N4C40\R
MQF.5!^ ( N#04)J./'AZ8I]O6V)85^9_;UB_X4^9+J=/BYT/B<ZN.E[GJ.ZY
M*[KH1RPQY"+!TV'KTW+(0\;S-BGJ9-OI,B-'JJ_L7+E86C??*X?QV(^'1W<:
M<13\_2OE7K0X'_5G_57J]?X;Y/I_,?%3X^9'H$8A.GI^I]F+L2+"Q^**.DIZ
M..-XI%,<,BUL-0DZ5@EB2<5:S_<*)_(/9!<!UD82?%J.JOK7/7GX_P"KAY=:
MZU7\@/C]TY_PI&J)=H9W"[5P?9&P3TCW3FZ:LCI,;-OC<6,%5'!.Y5(4GJ<E
MC]LT50$9O]RVLSN)ON @@%O)-MM34Z7UJ.)T#!X>A).?*IX=7^1XZ?\ +7_!
MP_(=;./=5=UAC.H>SJ_NR7!0]0TNQ-TR]F2;FTF@_@:T<W\2%4'X:)J7R@J
M68D*H+$#V'(PS, M:U%*<:^5.J+6N.M>W_A,ATK2;9^*G;O>62VM#0[C[/[@
MK]K8/=%13C[BMV_L/'8X(M/(5U"B7.5>7C8"2SSP.&4>)&(AYGFUSA <*HJ/
M1B2?\%.O'  _/_)T(O\ PI+JNK9/@_M'!;FCH*SMG+=U;17I>@AB^YR9J$BJ
M1F7IXX[S_9-C&>*8Z3$U1)1HP,S069Y=U"YJ,*%8OY#33_/3K:@D'\A^=?\
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ME<Y-EJW$0UE89&$-358_.T]#6TMF2-7JMLU,Z*BO+)4R^H'O[ZCG6EQ"CL:
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M5S;8QFPL=0T4Z5& JJE*"&3KG;U:5@JH99:LU(FFDI'BI8+"0CT_U5_S]:*
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M\3FTDCR%+CL]08R@Q:5XE_>%75T^/:O<2'R(*Q4E"RJX#F^72W4_932@""G
MTKP^5304\AUY_P"?G]I_U?MZNN]D_5.O>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K4I_G@_]OK?^
M$]G_ (MMU%_[]GKWV%.8_B3[&_PCJ1>1O@E_TR?X&ZWMO8:Z'?7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]T1[Y\?S%/BE_+3Z83O'Y7]@2[0VUDLNNW-H
M;?PF*EW)G=P9-HVF_A^%QD%GJ9DA1I)99)(:6G0!ZBHB5E+>Z]UJ^9W_ (6Y
M?#FGRABVS\,ODQE\+?BOSNY]K;=JO\XX_P" =/6Y2+_-"-O^!WZV9/HHD?W7
MNK7?Y:'_  I)_E]_S,NU:3H+98[,Z*[US461GV9U[W?B<;C4W&,5#]S40X+*
MXK)Y.@J:Z*G663[.>2EJY(XIGIX9DB=E]U[K8']^Z]U[W[KW1>OEG\<-F_+_
M .,O>WQ>[!K<EB]G]\=7[OZRS6:PJQ-6X]=T4<E/%DJ(3I) U9CIVBJ8!+&T
M9EB02*R7!]U[JC;IKL_^>3\.?CEMSX24_P#+SVM\L.S^GMLX;I7HKYM8;Y-[
M9V=L3,X#!"+$;>W1O? YZO;>M#DL/AXX9LM1P0U4F1GIV6EG0U(D7W7NE[B?
MY(V0K/Y*&\?Y;.\^WQD/D'V%-N'O3<G?>-\V.I8^WLSN5=[PY>F6DAHZA,-2
MY^"DHR5IXYWH$>58XZAE5/=>Z"3NO=G\\GYF_%;=7\O;>O\ +[Z_^/\ V+W1
MLG-_'[Y%_.7+?(K;6\^MX]K;AB?"[GW1L_:N+KY=Z5M9N7!SU$F.Q=;%3RT,
ME44K9-5/);W7NM@+XW=$[,^+_P ?NE?CEUVE0NQ^C>K]D=6;7DK&USS4FR,=
M3X^*IJ6NVNJJA 9IFN=4KNU^??NO=#5[]U[H@'\V+_MUE_,L_P#% /F1_P"^
MZW'[]U[JMK_A*I_VX\^)W_AS?(__ -^3NOW[KW6Q)[]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+UW!_Q>\9_VJA_U
MND]B_EW^R;_3?Y!U&?._^Y$?_-/_ )^;H)/8AZ!?7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW22WSL+8_9VU<QL;L?:&VM][,W#2M1
M9S:N[L)3[AQ]7$_]B>DJHY8) #8BZ$J0&%B ?=D<H05)!&01@CK8-.BA]<_R
MRO@%U/N^EW[L+XH=/8;=N/JUR&+S%3MS^/M1U",S)/0Q9&2K@HIHV8E'@BC:
M.PT%=*V4R7\\HTM(Y'H6-#]N<]6\0_+\@!_@'5)6T<)\U/Y(G<7=.!ZM^+V[
M/EO\"^YNQ*[L39M'U4E95YK:E5DH41HJF*AH,K/2O24-/3T4S5-#]G71TE%+
M#74D[34WLY=H=Y12\@CE1=)U_"X!]2>.:^N3BF>K8;]OEQ'Y8QZ>G0>?(3:_
M\Q'^>MFML=??[+MG?A%\4^LZK-[WI<_W?CZ_[O,[C@QM12XJ7P5-%B:VM$D=
M;+3Q_94+4=%#/733UM74)34C/6TEOL57UB61@!1#V@5SG(\OMX8IGK1 &/GQ
M\_V5^?KT,G5?\S+^8S\-M@8GXV?)C^6QWAW7V9UGA*39NRNS^KQDLAB]RT^%
MA>#'/4UF-P&=HJB84U/%Y:JCJI9)0&>:B@G5PZ>3;;:Z;7%,B*34JY 9>&!4
MBO'Y>E3QZL1JR:_ED'_!3_5CRZ&7X$?![OSY"?(OO'^8+_,EZRVWB<_W+L>H
MZMZZ^,^ZL73;CH\7MG))2QR?Q3&5HK%I@M%2I2Q4M0RU#O49&IK:>*6>(!F]
MO(X8UM[<DA6UF3(+/\N%*?Y!3A4Z9M/#[/6@KZ^=?V?X!91LG^6#_+[ZZWG2
M=@[/^)73>+W9CJT9'&9&;;?\7BI*A6UI/245;)44-++$]FB>*F1HB 8RI ]E
M[[A/(-+2.0>(+'/\^J^(?E^0 /\ (='P]H^J=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M:E/\\'_M];_PGL_\6VZB_P#?L]>^PIS'\2?8W^$=2+R-\$O^F3_ W6]M[#70
M[Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM0'_A4!T]V/M;M[^6Y_,:JO
MCC'\N?BU\'][]@9/Y*=+3H^0ABQ^Y:K;U=!E*ZB,-7 V(9<-**JHFI9*2&:F
MHDR,<E%,^CW7N@XVW_PL6_E&4.'IJ*J^&WRWV\:2".&DQ&V^GNLJZCB54'[<
M;MO_ !VA%?4H I0-(#6!.D>Z]U7KN3Y6];_\*"?YKO\ +:W%_+S^".Z.GJGX
M?]]=>]U_([Y1[TPF-VK7Q;8VIN/%[B3'9I]K29''K'%+A,FV$^^RD]74Y*KD
MAHEH(9,C-+[KW7T3_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MT0#^;%_VZR_F6?\ B@'S(_\ ?=;C]^Z]U6U_PE4_[<>?$[_PYOD?_P"_)W7[
M]U[K8D]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=%^[=C+YK&$?\ZL#_K+)[%G+[A(V_TW^0=1ISLM;B/_ )I_\_-T
M$WA;_??\C]GWC#H&:#U[PM_OO^1^_>,.O:#U[PM_OO\ D?OWC#KV@]>\+?[[
M_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_ )'[]XPZ
M]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^
M_P"1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.
MO:#U[PM_OO\ D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?
M[[_D?OWC#KV@]>\+?[[_ )'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]X
MPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_P"1^_>,.O:#U[PM_OO^1^_>,.O:#U[P
MM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO\ D?OWC#KV@]>\+?[[_D?O
MWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_ )'[]XPZ]H/7
MO"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_P"1
M^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U
M[PM_OO\ D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D
M?OWC#KV@]>\+?[[_ )'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H
M/7O"W^^_Y'[]XPZ]H/7O"W^^_P"1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO
M^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO\ D?OWC#KV@]>\+?[[_D?OWC#K
MV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_ )'[]XPZ]H/7O"W^
M^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_P"1^_>,
M.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_
MOO\ D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC#KV@]>\+?[[_D?OWC
M#KV@]>\+?[[_ )'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"W^^_Y'[]XPZ]H/7O"
MW^^_Y'[]XPZ]H/7O"W^^_P"1^_>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO^1^_
M>,.O:#U[PM_OO^1^_>,.O:#U[PM_OO\ D?OWC#KV@]:DW\\1"G\ZW_A/7?\
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MF_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\
M&_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?N
MO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U
M[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[
M7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;
M_P ;]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;
M]^Z]H'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]
MH'7O!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O
M!_M?_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?
M_)O_ !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_
M !OW[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW
M[KV@=>\'^U_\F_\ &_?NO:!U[P?[7_R;_P ;]^Z]H'7O!_M?_)O_ !OW[KV@
M=>\'^U_\F_\ &_?NO:!UJ#_SW4T?SL/^$\8O>_RTZF_%O^:L]=^R'>>*_8?\
MG0PY7%%D^U?\!ZWF/9+T*NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JJ/
M^8Y_.9^%7\K#<?5VV/ECE.RL5D>X<)N7/;*?8NP9-Z12P;2GI*>N$[15,34\
MD<E;3:0R6</=22K >Z]U6Q_T%[?R</\ GK?D+_Z(JK_^K??NO="ATA_PJ7_E
M1?(/NGJ#H/KK<_>E1V#W?VAL#J#8D&7Z9J<72/F>RLM287%I5535;+34[5U;
M ))2I$:%G(-K>_=>ZV,_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]T0#^;%_VZR_F6?^* ?,C_ -]UN/W[KW5;7_"53_MQY\3O_#F^1_\ [\G=
M?OW7NMB3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]T%^^8P^1I"?\ E2 _Y/?V=;8VE#]O^0=!+F%=4J_Z7_*>D3X5
M_P!]_P C]F7B=$'A]>\*_P"^_P"1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_OO^
M1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?\ ??\ (_?O$Z]X
M?7O"O^^_Y'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O\ OO\ D?OWB=>\/KWA7_??
M\C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_??\C]^\3KWA]>\*_[[_D?OWB=>\/K
MWA7_ 'W_ "/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_ +[_
M )'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O^^_Y'[]XG7O#Z]X5_WW_(_?O$Z]X?
M7O"O^^_Y'[]XG7O#Z]X5_P!]_P C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_??\
MC]^\3KWA]>\*_P"^_P"1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_OO^1^_>)U[P
M^O>%?]]_R/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?\ ??\ (_?O$Z]X?7O"O^^_
MY'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O\ OO\ D?OWB=>\/KWA7_??\C]^\3KW
MA]>\*_[[_D?OWB=>\/KWA7_??\C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_ 'W_
M "/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_ +[_ )'[]XG7
MO#Z]X5_WW_(_?O$Z]X?7O"O^^_Y'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O^^_Y
M'[]XG7O#Z]X5_P!]_P C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_??\C]^\3KWA
M]>\*_P"^_P"1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?]]_
MR/W[Q.O>'U[PK_OO^1^_>)U[P^O>%?\ ??\ (_?O$Z]X?7O"O^^_Y'[]XG7O
M#Z]X5_WW_(_?O$Z]X?7O"O\ OO\ D?OWB=>\/KWA7_??\C]^\3KWA]>\*_[[
M_D?OWB=>\/KWA7_??\C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_ 'W_ "/W[Q.O
M>'U[PK_OO^1^_>)U[P^O>%?]]_R/W[Q.O>'U[PK_ +[_ )'[]XG7O#Z]X5_W
MW_(_?O$Z]X?7O"O^^_Y'[]XG7O#Z]X5_WW_(_?O$Z]X?7O"O^^_Y'[]XG7O#
MZ]X5_P!]_P C]^\3KWA]>\*_[[_D?OWB=>\/KWA7_??\C]^\3KWA]>\*_P"^
M_P"1^_>)U[P^O>%?]]_R/W[Q.O>'UI\_SZ4"?SL?^$\%OS\L^J/]X[:Z[]D^
MYG45^P_Y.A3RZNE7^U?\!ZWC/97T(^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[JO3^9/_ "U?C;_,Z^.F[>C>^-FX:HSTN&RDG5/;$&-A&?V?G'C)HLIB
M,AH-3%"M2L7WE'Y/MJ^G#05$;JP*^Z]U5Y_)_P#Y..Q^LOB%@NGOYF/\M/\
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M]4^G7O!'7OM%_I_O/_&_?JGTZ]X(Z]]HO]/]Y_XW[]4^G7O!'7OM%_I_O/\
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M_C?OU#Z]>\/KWB_VG_>?^-^_4/KU[P^O>+_:?]Y_XW[]0^O7O#Z]XO\ :?\
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M[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M_?O%^?7O!/7OMO\
M#_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M_?O%^?7O!/7O
MMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M_?O%^?7O
M!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M_?O%
M^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /]]_M
M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V_P /
M]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$]>^V
M_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y]>\$
M]>^V_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]^\7Y
M]>\$]>^V_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _WW^W]
M^\7Y]>\$]>^V_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_  _W
MW^W]^\7Y]>\$]>^V_P /]]_M_?O%^?7O!/7OMO\ #_??[?W[Q?GU[P3U[[;_
M  _WW^W]^\7Y]>\$]:6__"A^/Q_SM_\ A.@/Z_*[J\_^Q;ZY]MNVKIZ--'6Z
MI[;Z<Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NL4\\%+!-4U,T5/34\4D
M]143R")$2(%G=W8A515!))(  N??NO=4.?.O_A2-_*N^"XSVW<IWA%\B>W,'
M45F-FZA^,PI>S*V&MQ]2M)4TF2S:U5-M;$3T4QD^ZIZK-I6Q+#,J4DLZ+"_N
MO=4_?%/^=)_.N_FX?*GX^Y#X;_"Z/X]_R],/\BNH).^>VLGCX-SU61V;@-UQ
MR[PHQO/<R8O U3U&WJ*KII\?M["396DJ&,:UVNIIBONO=;M/OW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z(!_-B_[=9?S+/_% /F1_[[K<?OW7
MNJVO^$JG_;CSXG?^'-\C_P#WY.Z_?NO=;$GOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM+#_A1)_P!O
MN/\ A.?_ .+6]7_^_;ZY]^Z]UNG^_=>Z][]U[KWOW7NO>_=>Z][]U[I'[PW[
MM/85-1UF[,K_  FFKYWIJ23[&IKM;QKK*VIH9F6R\W8 ?XW][ KUHFG2!_V8
MWIG_ )[+_P!=[*__ %#[WH/6M8Z]_LQO3/\ SV7_ *[V5_\ J'W[0>O:QTJ=
MH]L=?[[R4^(VIG_XKD::ADR4U/\ PJMH=,,,D43/KJ::%#9YHQ8,6YN!8$C1
M4CK88'H1?>NM]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6GW
M_P *MOA9_,\^66SNAJOX08?M[L7I#:&U^RZ#Y$=/=5]F288Y:;+S8R?%5=;M
M!<E1C=:TL%'6Q(L='6U,+3Z8H-$LK#W7NM>_X(_)G^0'\:^FNW>HOEA_+][>
MZ#^=.)Z@WAMQM_?*S 5_R3AAW4<56##3T.-.'QTFS\J]3-0UD4J=?4DE&\B
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M=J4">*S@D#230'$;V\^\A[A<\"RW)>3S^Z;ZXAB2Y2_42QQ2S+%XY1X_$>)
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MXN)=)O81&0!XGAR*Z,?,*Q 8#YL@(KYYK8OLW:U!LC:6VMG8N:LJ<?M?!8O
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M2VHA#'[W5]R]QY%V;9;7;Q"OUFSPK/*T0>5HQ!&@0,2**/$9AZ,:CSK?[O\
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MS&&E@BIXC45$E7)I@4*NN65GEE>P%W=V=C<LQ))]X;R.96+&E2230!14YP
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M6C_/GJC9O9'\O[Y@=.YR@-)LK<GQ/[OV@]+B4AIWHZ;^ZN1BII*'RQ3P0U%
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MXR;[RB-12R2I1@XFE=\<9312U+35;Q^>34M@U.JE:]=CX7;<;9Z;1J]_[IR
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MOW7NO>_=>Z][]U[KWOW7NO>_=>ZUDOG1_P!E6]P?]K7 ?^Z;'>SBU_LQ^?\
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M.PLOU^FT-J]>[<V3112Y&&DADR(J-Q5M34R.M#)62(6,9CFA'E6:-Q(XY 7
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MS9>#(04;XE(T#/5+DZ2HF#4VAHYFA3SA8$DD35EE]/DP(/V4ZW>835P*D$=
MAG/@#V5#\%/CEL7:%#M_=/=76/<&Q_E3V3L7L"J%-C=Z;AFDJJ_.X+,U#IXV
M+&O^SCEG4120TJQ3:/)YHW!=#Q&)J 05!'$#R/39MSX:@<00Q!\SUB[VV#\Y
M?EOG?C3-N'XA;!Z(VSTO\B>J.RL_-EN[\#O_ #\U+MJ1VJQC9,5%%108:GBE
MF\D#U!JJF=*1XZ=$C>WHWC@#48M52.! S]O7I%DFT]H%&!X@G'5UWLOZ7=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW6EA_P *)/\ M]Q_PG/_ /%K>K__ '[?7/OW7NMT
M_P!^Z]U[W[KW7O?NO=>]^Z]U[W[KW3=E\3CL[C*[#Y:ECK<;DJ:2DK*66^ET
ME%B+@AE(^H8$,I (((!]^X=>X]$'WO\ %3=V.KIY]D34NXL3([O34=55QXZL
MB!/$;F8QT\H4&VL2H6L;QKQ=T/TT4/2?V[\7.S<K6QQ9NFQ^V*$2+]Q5U>1@
MR3Z+BYBBHY9@[V)L'DC!L;L.+[+CK6@]'XV)L;"=>[=I=NX*-_!$S3U57/9I
M:B>4 /-*0 "S6   LJA5' ]M$UZ= ITL?>NM]>]^Z]TA\-UEUMMS?&]>SMO=
M>['P79795%M;&]B]A8;:=!B\YGZ?8\51!A(,UEH*=*_*PX>&KJHZ%*JHE6D2
M:5(!&LC@^Z]TT=B=)=,=O56VZ[MCJ/K#L^NV<NYTVC6=B;!Q6]9<4-[8Z;#Y
MH8V3)4E2]",OB*BHH:T0E/NJ.62FG\D+LA]U[J?D.INJ\OMC9VR,KUGU_D]F
M==Y78N>Z_P!HY#9F.K<7@J[JZHIJO;-;AJ"2F:DQE7MVJHJ.;&34T44E!+!#
M)2M$\2%?=>Z3-3\<OCW6[ZW]VC6=$]-U?9?:VQGZQ[0["JNL<+49S<FVI$2)
MMOY[*O1&NR^$>**)&H:N>6F9$13$510/=>Z%' X'![6P>&VQMC#8G;FVMN8G
M'8';VWL#CH<10T%#B(4IZ2BHJ2G2.GI:2EIXXXH88HUCCC541550![KW06[B
M^./QYW?ANUMN;LZ&Z8W1M[OC(XW+]XX'<75V#S=%O.KPU/14E'5;KI:FAE@W
M%44M)C<=##)D$J'BAI:>-&5((E7W7N@1V/\ RV/Y=/6.[]N=A=:_ 7X5=>[^
MV?EJ3/;2WQL?XL;%VGF,774#:X*W'9.@P5/6T-7"W,<T,Z2(>58'W[KW1U??
MNO=(I^M>N9.QJ?N&38&RG[;I-E5G6M)VD^U:%MQQ;<R-=!E*C 1YLP?Q-,)/
MDZ6FJY*$50I7JH8JAHC+&CCW7NLE)UWU_0;[S/:5#L79U%V=N/;6%V9N'L:D
MVQ14^>K\/MN>KJL=BJW+I ,A58V@JJ^NFIJ66H:""6HGDB17FD+>Z]U@PW67
M6VW-\;U[.V]U[L?!=E=E46UL;V+V%AMIT&+SF?I]CQ5$&$@S66@ITK\K#AX:
MNJCH4JJB5:1)I4@$:R.#[KW76YNL.M-Z;FV%O7>/7FQMV;RZKR>6S?6&[=S;
M2H,]D]MUN?HWQ]=5X&OJJ>6JP]56T$DE-/+22PO-3LT,C-&Q4^Z]TN??NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UIV_)S_ (2U?(OY!_)/Y"=]X/\ G,]U
M]787N_O#MCM[$=9XKI7.Y6EV[2]E9ZOS5/@J:JA[?QD533XB*M2DCE3&TB2)
M$'6F@!$2>Z]T02'^3MVQ_*H_F/\ \M+=7RA_F==\]R?'OM[Y2=?;6V3N? IE
MMF,O8NS\OB]P;:VQN[ 93=VX:>?:6\$Q]=C)JNER$LT,TL7FIA 78^Z]U] W
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$ _FQ?\ ;K+^99_X
MH!\R/_?=;C]^Z]U6U_PE4_[<>?$[_P .;Y'_ /OR=U^_=>ZV)/?NO=>]^Z]U
M[W[KW57.0P6$JOYL5+1U.'Q5125/PUJJ^HI9\?#-')/+NF0M,Z,A5Y6))+D%
MC^3[C&6WC?FD JI!L"2"H()\9LG''Y]0V\2MSV%(!!V4FA H3]9Q^WY],?R&
MWSTM#\R=MIL[X[]D?)GY2=:[)QRT^%PF=CQ>W=O4%6L\],U9_$)GQE+5A,GY
MTF- 0C2TY$XF$:JUS!?V8W=%BM9+R\A0412!'&M"16H8 C6#6E 6!KJZ3<T[
MCMR\Q1FWL+G<=SMX!01R!;>VC8L1K\658E<B0L&"%B-/=4*.@3[[W7\D]Y?)
M/X0;O[BZ.VAT5M^E^0^U=O[3I:;>U'OS<E7+F)X36+5UV/1((,6*6,J8!I+R
MR@NK@*4(]]N=RO=RVZ:[MH[91=(J#Q%EE:K+6K)^'AB@_.N"#F>^WB_W;9[B
M_LX;.-;](X@)UGN6>16U:F10JQZ%(*@DLQ%<+T9O8%/!5?S2OD735,,5133_
M !EV%#/!/&)D=):O&!D=&!5E87!!!!'!]B+;U#\T7:D5!LTJ#D$5AZ&>V@-S
ME? Y'[MMO^KK=-_\N#"8::;Y@U,V(Q<M3C?FIW$F.J)<?$[TXA>D*+"Y0M$$
M(%@I%OQ[U[>6\;&_)5:KN$VDZ144"\,8Z2^TD2-^]S08WN^H:#%&3AZ="Y\T
M^ZMN=)[.IL/L[9V"WE\C.WZJ7:O36T(=N4F:K*K*5NF(Y2IBE3U4.-,B22-*
MP223QPLRHTDD9OSCNT6SQ!8HTDNYSH@30K,6.-1J#A:^8-30<*T/O<+FA>6K
M81VT:RW]T3%90A [/,13602O9'4,Y) X L*U&3X3?$^7X_;!RF:[,FQ^[^^^
MT:ML_P!M;ODD&5UN\C24N*IYGBC4T= K+J\<21R5!=T40K3I';DWE4;# SW%
M'N9CJF?CYU"CC@>?&I\R .J^W/)+\JVK27K+-?W)\2[GKJU-4E4!*KVH#045
M5)J5100HC_/_ *-SO<G3M-7[1HI\INOKS*R[CHL12Q&>:LHZB$Q5U-3QKZGJ
M-(AF1%!:3PF)%+NH]Q%]Z+VUN?<3EVM@I>YLI?J8XE%6F30R2(H&2Q!#*!EB
MFD9;K*7V9YNAY6W0K<L%AN4$3.314<,"C,?):U4G@-53@'K75DCDAD>*5'BE
MB=HY(Y%*,K(;%6!L000001<'WR,DC:%BC@JRDAE((((-""#D$'B.LX58. 0:
M@Y!' CH<OCMT=N3OSLO![.P]%5G#)6TE7O'.11-X<?C4>\\LDMBBS2QJ\=.A
M(,DQ5190S+*'L_[97?NEO4-C"C&!71[R8 A(;<&K5;@'< K&.+-\@Q 0YXYN
M@Y-L)+J5E\0JRP1D]TDM, #B0"06/DOSH#M/Q11P1100H(XH8TBBC7Z*L8 4
M#_  #WVS50@ & !0#Y#KGBS%R2>)-3]IZR>[=5Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ(!!! (((((O>
M_OW7NBN[K^$WQ+WMFIMQ;D^/O6-;FJFJ^^K*ZGVW%B6GF-RTE2M']O'4.Y8E
MS*CZSR^H@'V>V_,^XVB"..YF"@4 UM0#Y5)I^740;W]W_DCF.Y:\O=CVR69V
MUO(;2)6D?U<HJZR?/56OG7H;]B=<[ ZOP46V>N-E[8V-M^%VE7#[4PE/@X"\
MA):1XZ>.,22N22SM=F))))/LKN[R:_<R3N\C'BSL6.,<23U(/+G*VV<GVJV6
MTVMO9VZDE8;:&.",%B23IC514DDDTJ223GHK'8?:.Y<-\@<G%B<<<[-M;!=8
M]9=?[5J]P2[>QU5N+O.MR59D<GEIHH*HK2XC#;=IFB84<\H#U<4"&2I&G2("
MOVU)/R'I^9Z.2W=^P?M_XKI.87YK9G([6WAGJSK"FCR.S.T.O.L:S#8C=$N7
M^YGW;O?*;,JYZ25L;32/XI,6U33QM3JTOE6%RA4R&QMP#2O$$\/1:^O7A)\N
M! _G3IA_V>ZNCZ^VANV?;_3<69W+LK<O9)PG^G0) ]!M\XZ%=OT=7+@86J-[
MU.0K9Z(8Q:=HXYZ1]=3JFBB&_ILD9P0*Z?Y\>'SZUXN/+A7C_JST"W2/?N?Q
M7>W96*PM-F=\9_?4^[*K:>V,WEJJ@IZ+$X;MKMB3+Y:K9XZD44&*PT-'"L8B
MURSF@H%T*ZO$Y)$"H)Q2E3\]*=51\T]?^@FZ-%)\L]V9"AZ(I]J]:X#)[I[V
MV+U'NC$4&;WQ/@:*BJ>R\%NC.S4\]7#A\A-)%1P[9DBC=:0&:2=2XA5"2SX
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M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UI8?\
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M-X(F8/+XD(9]*G2INUA[]U[KV2R>.PV/K,MF,A18K%XZFEK,ADLE5QT-/!#
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MG!JJJ62Q1'\0=858CRS%(EY;B2O:?VWO/=#>8-NMT8Q:T:[F .F"W#5=BU"
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MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZTL/^%$G_ &^X_P"$Y_\
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MN1JVKGR>#V)E\_6[1Q<T59)-+31P8=(*-G(I(8%2)8_=>ZM_]^Z]U[W[KW1
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M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM+#_A1)_P!ON/\
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M\@NU=W=P[Y@PM-NK>M3CJK+P;>HY:"C5L914U!'X(9IZF5 8:6,MJG:[:B+
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M4\NC)NP1&=@Q5%9B$0R&RB_"J"S'^@ )/T O[3R.(E+&M "30%C0"N H))]
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MH%E$NK4"P*I&=>.UM1"U!8$ZB>E<]ZC>&891&B@52C5K7/!:'\S3B?/J^?\
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M:2RQQHJJ&"@#@7+$M/(9#5C7J0>5.3MNY*MVMMMB\*-G,C#6[EG("U)=F/
M 5H.A4]TZ$_7O?NO=>]^Z]U[W[KW5(-;V/W#U5_,G^1,E?MONC=VRMX[8[+H
M,/B^KMB9'?NB+,=?] GJN7(Q8R&=L3C/[T;8^1L%!DZYZ?&4V2J<A!4UE/)D
M*=']U;%/]7S_ -CI$;>V;\GJNKV/3=K5WR>["P.UNW]E=M;SWM6T>[-HU&)G
MK,W,<=@DV\M!E&RT..Q&82#^);5R,M"E/CFGSV(H<M*6]^ZKT%.6Q?\ ,0[&
MSGPHSNQJ'> [@VWVON+.]LR]U;0WC7[=VIOS)=&=TX6LS$U1D,53XW$8F&NS
MC8^GBP,=?M.HK)L"D-7>LC;*^ZL,5_U>8Z$#:>WOEWV%F/GI78O<7SHZ?VY@
M.O%W1\>:#-8:?$Y>NW-A>FNH9:8RU57A*M-S9.CWM2;GII8:"IFQF2JOXC1F
M*MHHX(8/=>-!3_5YGH<:'L7Y-]D;5Z^ZSCQ_RYZX[ PG>NZ<;VQOBGZNRN A
MBPTW=^U_L#C\SF<178/,8NKV!4Y Q5%(M=!2XA*P5$M%/#9/=:Z4.;3Y6]8;
M"SVZ=MY7Y/\ 9F>E[H[RZSI-KUSP53XW8^-W+54>VLW$)MJY:NK(<%AXER/\
M13'9;<>?HO/34CYC(SXF%/=:Z*AMJ/Y&82L[VW5N6?YP9;>L'26>P/QJW7MS
MJ3>>.ER><Q^Z-Z97:..S)K\755OV="^2I(X?[UU:8P4$Q;<9C_8$/NM]6I?R
M_FJ:CXZME$AJ8-M;B[O^3V[.O/-7C)P2[:W9V/NG(X.LQ4HEG/\ =[(4%5%5
MX5#*1#AYZ&%%BCC2&/W7CT=;W[K77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6EA_P *)/\
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MGVT=LTN\QUO0[MHJG-'$UL,-1#DACDF-4:*6"H@D67QZ&21'!TL#[\'#</\
M5BO^#/3$O+M_!:_7/;S+;^(8O',;B+Q 2"FLC3J!!!%:X/3#D_E1\:\+DNT\
M/E^]^J,;E>CZ"CRG<6.K=\X^FFVQ3Y!HT@FSD;3AL;',\T2HTX0,SJHY('OV
ML?ZOMI_AZ4Q<H[I.MNZ6EPRW1*VS"%R)V%21&0.\BAKIKPZ6FU.X^I]]=;KW
M'LSLG8^Z.IVQ69SG^DC![GH\EA!1[=,ZY"J;)Q3-2)!0M35 J':4+"8I!(5T
M-;VH4KZ<?E3I!>;+>;?=?13P2QW&I4\!XV674]-(T$:JMJ%!3-13CT&TOS$^
M*<'76UNW9OD7TU#U=OC=$FR=G=@2]A8R/$9/,0M4*^,H:XU IZFN1J2I!A1R
MX,3W'I/OQ8#\N/RIZ^G1H.2]W-S)9BRN?'AC\66'P9/$CCQWLNFH7N&2*9'3
M)O\ ^=/PRZIWGF>NNS/E+T-L#?>W9Z2FS^T=W]H8C;^0HI*Z"*JA2JI:JJCE
M@:6FGAE76HNCJWT(/NX!/ $_8">E&V^W^^;S MU:;?>30O4I)%;RNC4)4T*J
M0:$$8\QT8##[]V+N+9T/8FW]Y[3SO7]3B:G/4V^<-N*CRF'DH:-7::MCR<$T
ME$])$L4A>43F-0C$L-)M34"*U%/7RZ#D^WW%M,;:2.1)@P0Q,C+('-**5(#5
M-104KT&W3?R?^.7R'GS]+T1WCU7V_4[6AQU1N2FZZWOC]VR4,>7,RTLE4E%/
M*T"5#4\XC9@ QC8 DJ?=N'&H^T$?X>C3?.4]SY9"'<;2XMA)J"&>%X@^FE=.
MM16FH5IZCH=??N@_U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW6EA_PHD_[?<?\)S__ !:WJ_\ ]^WUS[]U[K=/]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW12^V/F_\;^D/DC\
M?OB;V5O7(8'N[Y/TVZ*OIS;T>T<ME:2O3: 05GW66I*.;&8LF6:"&'[RJ@\\
M\T4,6J215/NO=9/FA\V_C=_+]Z1KOD/\J=^2]>=5T&Y-O[1;-4NW,ENVHER.
MYY'2CI:?'XFEK*ZHD<132-H@(2*.21RJ(3[]U[H:-L]J;5W;V%V=UCB8]Q+N
M?J/^Y?\ >Y\EM7(8G'M_?VADR%!_#,G4T\=!E[4\;?<?9U$WVLEHJCQR$*?=
M>Z$CW[KW7O?NO=>]^Z]T!/QJ^274?RXZ:VUWYT5N"KW3UCNW+;\P>#S==@JW
M;<LM3UKN'*[6S$;4>0@IJN,4V:PN1A5FA"RK&)8B\4B.WNO=#M[]U[KWOW7N
M@(^2OR3ZC^)/3NY>].[\[DL#L';%9MO$S/@MM9'>F2K<CO/)4F&PV*Q6'Q%-
M69/*93+9:OHZ2EIJ>EDDDEE7A4#,ONO=+;JGL6@[;Z[VGV3B]L=@[,QV\,4F
M7H]L=K;$R76.XJ..1W18LMM_,04N4Q-40FHT]5313*K+K12;#W7NL7:';G6G
M2VW:'=G:N],%L7;N4W9L_8>+R>>JOMDJLUV#DJ;$83%TR@-)45V4R=734]/#
M&C/)(X %KD>Z]T(WOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H']Y][=:[ [9
MZ7Z2W/F:JB[$^0'^D;_1?B(L155D5;_HIQL67S?EJXHGIJ+[:AFC=?/+'YB=
M$6IP1[]U[IZZP[<ZT[JV]D-V]4;TP6_MKXS=N\=B5FX-MU7W]&,OU_DJC$9J
MA2H $<TN-RE)54LQC9D6>*2/461@/=>Z$;W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=4(_P [O^5-_+H^=V ZX^0O\P_Y*=F_&78'QKPFX]NT
M&]]K=J[.ZKP@3LFNQMTRE5NS:^X$FK)ZRCI(*..":%Y9)#$L4TCH![KW5 OQ
MC_X3P_\ ";#YF;MKM@?&#^9G\E>X]^X[&56;J-C;7[_ZV3,M14!B%16P8NKZ
MHIJZII*=IH1--#3R11%U$C*6 ]^Z]U:7\>O^$BG\MOXU]^]'_(O8O=OS?RV]
MN@>X.M.Z]G8O=G9.PZ[%5.5ZKS5%G<?3Y."CZUH*N;'S5=!"E0D%=3S/"76*
M>%RLB^Z]UM.^_=>Z][]U[KWOW7NJ/_G-_/&^.'Q0^7_Q&^"/7]?MCO#Y,?(C
MY4]%]$=C[(P.YPJ]?X3MK-XW$3Y?/5%+%5)!FXTRM)/18B3143Q$S3FF@>&6
M7W7NK2/D_P#)'JKX@_'_ +7^2_=V<;;_ %?TYM#([QW77P1+4U$D='I2"CHH
M&>/[G(Y"JD@I:2 .#-4S11 @N#[]U[JDW<O\W?\ F$=*=2;=^:'R:_E65'77
MP5S&4H\KO'+[,^0T'8_:VQ=F9Z5TQN]=U;$IMNQ43T7@:BJLC146>DJ\53U+
M/5@&DJ![]U[K8-VMN?;^]ML[<WGM++T.X-J[NP6(W/MG/8R85%-78_/T\=71
M5E/(.)(*FFECDC8?J5@?S[]U[I]]^Z]T0#^;%_VZR_F6?^* ?,C_ -]UN/W[
MKW5;7_"53_MQY\3O_#F^1_\ [\G=?OW7NMB3W[KW7O?NO=>]^Z]U[W[KW6L[
MVI\&.H=X_P UOH3I3>TV;^0^0WCLKY+?*OY:;J[*FBR60R6)W30R[,V/@JE:
M*"DI,5@-N7-)BZ:DC@,9>26+Q$P^-/HR0:FM 37UJ3_-5^RM!04 RIV?G^^L
M>3KR_@TV:QRV.W;=' "L:21N+JXD&LL7DEH&D9RU< U%:G/_ )I>P*WJK^3G
M\B>MZK=F3WM!LCKW9FV<'N+.TZ0Y"7%8G=F$AQ$.1EC8I6Y"CQBTM/4U@2(U
MLT3U;0PO,T:[T: H)K1X\^?]HO0&]G]Q7=N>+"Y6-8C+<,[(IJ@D:&0N5!':
MK-5E3.@$+4TKUKD?*_Y%?/+=7\ICICIWL_X;T77WQ?P.Q_CO1[/^0L>ZTK9,
MI1[=H*1,!5-0BI<H<U L3E?"#'KL0MC[4+0R_%^)B!I85-&Q7AY_RZREY-Y7
MY<L^=;N^M-T,U\\M^9+/PR C.[F1=6D?V9J*US3JTOX\\?S_ *EOQJ^ '7NF
M_%_]^MM?Z?[8^V8?[(?Z<?\ 5H=0[S-_T[7_ *G4_P#U=GZ)]\@B&[U_X47,
MI!'^A[K!=0-^5R&$!'^N#<6_K[\.,?\ IF_ZNKT.>6A_NOY)_P">FX_X[+T4
M[X\]5_/";X@;:^,76\F?;X?_ #$Z^SOR@WWV/#C9)H]MX_I-\Q2[UV_%7!Q3
M4C9N?#8 M!(+U)DHHXU\=3D=>IILLY J&-%\FT$@,3\J9]:**BN1CS/OG+G[
M]EWB["?O/;+A=OAM]0'U#W/AFWE*TJ?#$DN1PHQ.53I0;F/_ &(W_EUD?G^8
M3N3_ -R]Y^W)?BE_TDG_ !U>DUOGW!W[_I2'_CMKT9KN;MSXA]-_S@/YE>Y_
MF+\?JCY"[&;86P8=O8"'J:A[17'5\.V]JRM7225Y6+!*].CP_?B1&C,EM0][
M<E0E#Q+BFH+4EA3B17SX5.>@IL6R;WOO(^Q0['>"SE\>XUL;EK;6IGG 4:36
M0@YT4-?3K'USO/?7Q._X3G=MYW(5<&&JOE=W!N;;O3U!0;BCS I=O=K-CL7D
MJ'RPR2^*27%X#=C-"[)-&TI-0D<WDC&E&MZ<:L 2/Q%%%<>52A'5MSL+?G3W
M2MXE!<;?;QO=,R%=<UJKNK4('XY(<C! [210]/OP7WO\7_C+_-1^(.T/BUV=
ML;=O7'?GPZVYTIW9/LW(_P 3@&_L/15-5/-5$7M7Y;+X3$2"0 *7K:A4M&Q'
MNBEBNI@:@BI8'\8H0*^6H*?3/2;W"V_>.;>3MRN-YMYHY[/<WNK7Q5*GZ.1@
MH"U_"B2.*>BK7/6X][=ZP=Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[K2P_P"%$G_;[C_A.?\ ^+6]7_\ OV^N??NO=;I_OW7NO>_=
M>Z][]U[KWOW7NO>_=>Z(#\W?EUN#XZ1[5VSL7$XBOWANNDKLK-D,]&]53T5%
M22+"A2FBEA::HJ)3(%9I!'&(FNDA8:,7_O'^_%S[0QVMMMT44EU=!WUSZFCA
MBC*K70C(69RQ"]P4:23JX=3-[3>VD//)FGNW=882J:8Z!I'8$_$0P"J*5H*F
MHR*9KC_X<J^3/_*WL?\ ]!,?_5'O$;_@RN</2P_[)G_ZW]3E_K#;#Z7'_.;_
M *$Z]_PY5\F?^5O8_P#Z"8_^J/?O^#*YP]+#_LF?_K?U[_6&V'TN/^<W_0G1
MI?B7\_>P>S.U,+UCVEB]NU,&[C5TF"S^ H'Q,M-64T,M0D=3&9Y8IH)UB,:E
M$1TD922ZDZ9L]B?O3;ISOOD6R[U#;D70<036Z-&4E1'DI(&D<,K!" 5H5:E0
MP)*Q[[D^S-EL&W/N&WO*##0R1R,'#(6"U4A5(8$U-2017@>-NOO.WK&GKWOW
M7NM:K^;5U!NKM[YX;2DZUIVF[HZ8_E4_)[Y,]#,F4J,,W]]/CAW?T%O# TPJ
M*;]Q8\I4XDXZ8%61H*R56 !U+[KW1*_YZ_<6T/G[\)NXNV.NZNBSG2GQK_EX
M[!^3U%7)BI:^+^_'SCS&#Q6U8Z;+,8Z7^(;?Z\HMYK6P10F:.+<E+YS#Y5C/
MNO=70/N#O3O+Y&_S=.B,%\B=T=.)U)MOXBY#H'>U)44\=+LK);JV/D,SD*V2
M*6+PU>)K\A31ODX*KR))3F7QF&41RQ^Z]T!O\I[YT]V?S&J[N;Y<]A[LVULC
MKGX^[:Q/1N-^+O4^[HMTTN4W5C<-2YS<G9F1KQ%!4U6!W.*Q(MDT[ZJ:7"H,
MN[35%7":7W7NB,]3_)3Y_?(SX>;;^;75.#_F39WY?]H;4B[RZJVOM/&['?H.
M:EK:B7*8KKI=NUV81JG;=;BS%AZG/U.*7<8G9LC%D*=T33[KW5E?6U5W7_,#
M^1?S:H<Q\AOD!\5-O_$S>/6?1'5?7W16Z<;MV>DW!NWKC:^^<ONW=,>1PV1A
MW)74V0W9'046-KHIL(L&.=IZ"JFG:5?=>Z>O^$_6W,ML[^51T;M'/9;'9[.[
M6[B^<^W,UG,12FBI*VKP??G9]-4U=+"99S#3U$T3R1H9Y-*,JZWMJ/NO=$%^
M1';7R@Z=[0^2N[?EUW'_ #"_B3DL'\B,_F/C;\N^F>O(?D/\:<%UQ15H;:D&
M]MB;=GFJ:>B&WT3^]U3N>GHI_P")5-9-CMP4E+!0?;^Z]T?7YM]W;>K_ )(]
M7=1O\D_E=F:&O^/V2[-7XG_R].L<QF-WYN;(5[KC][;HWU@X*F3:&TFBH9J#
M"4M3G\)29;(RU7FJ\@E,(8/=>ZI2[1W]W#\DO@YNG;':O;/R7IV^)G\__P"-
MGQ4ZZJ.S\]MN+?,NV:G=W3N8QHW[68'^+8G,;IVQ5[GKTH:U)Q/&L5,,G'-7
M1U0/NO='_P ]W9W?V[\M?EAT)D<A_,MW1U1\(J[I;X_]>UWPXRFU,'D\OGZ_
MK_ [HS&^.P\Y5UVWJG+9ROFW#31TV,CIC@C'2/4SX]I:IHD]U[H)OFQ3?*7N
M#^67\/\ (?+S(]R]8=X['_F;_%/K'*U;#![%K]V8C_3A@L3M;?&:Q.)I:K#T
M6>KMO18S*)!1>*DH<K-4A:<1!::/W7NCN]B?,W>/\O#N/YZ[/[SWCO;MKKO;
M7Q!VS\T_B.=YYF@S.9RLNR:=-D[QV!0K!!C9ZVNEWD-G5=.&9G>HW:((Y(XD
MACC]U[JSWX@[4[EV3\8.B]N?(G>]=V-WS2];[<K>X]X5\*TQJ=RYN$5V9BAB
M0!8J*BKZF>EI$L"E+#"I (/OW7NM;#87=_S0ZC_E:M_,SW-\NOD)V[\ANZ=R
M0_&WK_J6MJ=OYCK[;$7;/=M#UOM[=%!MF3 TE5E-YX+$+-7K)79J2CJ\E734
M%1$^,AH!2>Z]T>?I3._,'8'R;^-L/66T/YE^Z^G-\[@W1LKY:4WSD;9VY,12
M4V4PF1K</OO U>,S%?D\'7X[<E'04-1B,;]KAYZ#)R.*%):.*HA]U[HJ?3O=
M'R4ZJ[&Z /SL[O\ Y@7Q'^5.6^1.-VUVGOCL+8%/WS\6.PHMU9P4)V;MF7;E
M2=N[!QF=2II,;M2NR%3A,_150IILD,O/)615?NO=7&_&SMCL7=_\P#^9;U=N
M7=F3R_7_ $__ +)M_HTVM5>/[;#_ .D#95?D<S]KIC63_<A6Q1S2ZW?U*-.D
M<>_=>ZI1^$_;G;/RK'\CCL/NSLK=>Z.S-];J_G;[1S'9$4U-C<PE/M/+[MVQ
MAY::6&F6GBJL5AL;CX:>0TS6-/&\HE?66]U[I,_$/9/RYV7_ "M)LM\5\]\C
M^TH<C_,X^4=!\B=E]7;ZVYANPI.MMH=M=FTN;7K'(YY<7B\=NK.9G^ 29::2
MMCJIZ!LFV)J*#("D9?=>ZM=_EG]MX??V[_E)U=A?DK\M=PG;*[%S-!\9?G/T
M[D]A]L]8'<\65I:JO7<V="5>]-G[AK*/7B)VIZ^&AJ:&MBBR];3SPP4WNO=6
MC]1[&S/6G6FR]A;B['WIV_G=JX&DQ&6[.[$:A;.9R>GOY,CD_P"&4>.QPJYV
M)+BFH8(5X$<2* H]U[H1??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6DU_P *
MK<'4_(OYJ_R/_@IN3=.XL-T[\B?DNV#[#QF&>.)7DWWNS8>SJ?*1WY?(XK%Y
MS/)3%K+&*N2U_(UO=>Z*C_-Q_E1?&K^3%\GOY3GS&_E^TF^NH)Z[YC;+ZM[!
MV_4;\R6]C7/75%#4Q55-69NLKJFD-?B(MPT%?3B.6CJ8:I (Z<(Z57NO=?03
M]^Z]U[W[KW7O?NO=>]^Z]UJ2_P T#X-?%KX'T'\D/K3XN]3X3KC"YK^?1\%,
M]O#-">HW!G=PY.2JRPDRFXL_D9:K+YJO>['RU57)HU,L2QH=/OW7NCT?\*-\
M10;M^!O5W6^?GI8]F=J_//X0]=[^ILA!%44M3AL[OF@>J@JDFLAI]<$,CC6@
M(CTLP0L#[KW5I'SDV?MO?'PD^7FQ=TXJ'*;3W3\7>^=M9S#F22C2:BRNU<K3
MS0K)3O%- 3$[!7BD22,V>-T=58>Z]T3_ /D/Y_);D_D\?R\<CE9?-54_QKV7
M@(GU,UJ;:AGQ=&GK9S^W1T<"VOI%K*%6RCW7NK:O?NO=:2W\TS_A4S\)LMU)
M_,:_E]0=$?*:/M;)]<_+SX;P[NEP6TO[O+N&MQFX=DKDFF&[3DOX,,DPF+C&
MFI^V]0IO+^U[]U[JT7_A*I_VX\^)W_AS?(__ -^3NOW[KW6Q)[]U[KWOW7NB
MF9;;&]J[YJ[8W-1_*^FPVQ\-T%5Q9'X8TV+Q-159>HFS%;%+OJIJ)JILO#0T
M[U.+HD:"@6):BF$9JU6HGIYJ&A(SGC2O$<.'V^?'_*,8;RWCV)X3MY:9KP$;
MF6D"QJ(E(MPH706.EW-6K1JZ>T,#0YG,XG;N'RNX,]DJ+#8/!8VNS.:R^2J4
MHJ:EI,9$\]34U$TA6.*""%'=W9@JJI8D 'W8D**GH)P0O<NL<:EG=@JJH)9F
M8T  &2230#S/55_\MG;><[EW7\A/YC&_<57XO,_+'<=%@.C<)F*22DGQ'5/5
MSS4&URD<I#P-N>19<O4+XE2;R4U0A9) Q;C%3J_U9I7_   >G;7SZESW0NH]
MDAL^6;=@R[<A>Z=2")-PN*/-PX^%B)<XTL#0UZ.K\MOCAM_Y=?';LWXY[JW%
MF=I[?[/Q>*Q>2W#MZ&"HK*9,5DJ+)*T"5*20,SR42(=:$:68CFQ]V==8'E0J
M1YY5@W^3H"\F\T2\E[G;[I"BR/;N75'KI8E&3-*'\7ET2?MSXA_&#Y0?R_,'
M\+J3Y-8J3JSX_P" ZLVGN;M/9^[=NYRJQ_\ H6HHJ>,YN19)<;CIIHJ4R5"R
MB+Q^H@*H/N@D#=RLM5))/$ T(-<XX^O0MV#W*O>6N8I>84MT::X>XD\)PX3_
M !IF8Z?Q$#50<>BF=Q_%[XB?*_M+.?(# _)_.?%+>WQ);JGHK:/R\ZK[NP6,
MQN[,?FMEX?.4-3-5RQTU!%50IG*S'K]IEB:F*)UF>6+QTU,EBN%8, RA5*C4
M353V*:@@K0T-,'H\Y7]UMPY6M9=MFM+>^M+MY)WL[F)V$<AD(.FAJ!5 V0:'
M(H:DQ*7X+=$=5[&^9/Q1HMZ[N['WS\H^HOC]VAVU\NNW.XL50Y3/_P"F'?N9
MP%%14M768JHQU,8)Z"2JI"T]7-FZZOCHRZR?:RK9IRKE<=HC8$FB]SG@,\2M
M>)+$T].G;[WBW'<=PV_<A#!##MKR+:6,$;+!&%C6M0&J:B@)P%"X'&M@G2>R
M_BE\=/B%6?"FF^4?7M?MWK7K;M'9&Z=R[A[&VUC\OC:',Y7+T&6K,I3K5)3T
M#8K*5U312--"D<55#]O,!,'3VX9$*L"Z_C+&H%*DU\\4)IT!.8.:KOF/>VWQ
MX LLD\4XC4.8RR!" *Y((0'C6AQT4P_RG/B[N3X@?''X:4'R>S=;M;JCL7.?
M*_8VZL;E]N5F3SE E15_=5BQ(KTTVWZ67<M,CUM/&8T:6F#S S*&N6UU[EJZ
MM7YJ: D9\L9R/V]#Q/?'<8=ZO=\^EA\2\M?HI(SXFA%(C%0:UU?I<#\_3H>^
MLND/AMLKYH_('Y1P_)_KC>>\?F-L;;>SLGU'F=^[5K\;/CX-OX#(1_PVF6H-
M7DH<AMZ/'5Y5O+')CZY*D!J::*1J>,CD#6A%" *C.JC'SSBA^PUZ">Z<]W^X
M['8[*8?#CVZ5Y8YD$@DUO)(<G@*,Q (H01Z]$L;^5]\&L?\ '_KG:65^==)4
M_$[:'RTKN_MF8W/;^V74[:ER<ZPTL^TH\Q,_V]30_;QSQ/")VFUU%3(5$DTF
MK1D4#69%H1I)J*&M!QU?%BG^3H=GWVW1KZ:^6RA%Y-MXL9)E$HDTBI\6@.'K
M0UX=JCR%!-[[^,WP:[!^6O54\65ZD^&&;^'N?Z([LZ^[!V%)LWKJDW[7=PY#
M)5=)@ZJGEH*".LCH3L> P-%75,DR9&=8XH@"9F_&2-VC&E!I3C0!BQ-*<,C3
MCCQX=!KESW/W?9K"]M92]]'N$,EO(EQ)-*8552-:5<T/ZV<#X1^5[@(8!E((
M(!!!N"#^1[7]0_UW[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[K2P_P"%$G_;[C_A.?\ ^+6]7_\ OV^N??NO=;I_OW7NO>_=>Z][]U[K
MWOW7NO>_=>ZHN_FJ?\S:ZW_\1T__ +LZSWS8^_%_R5]M_P">.7_J\>LNONZ_
M\DZZ_P">D?\ 5I>JN/>#W60W7O?NO=&;^&G_ &5!TU_X=?\ \:U'N;ONX?\
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M"M-G)%W-GJO<HJDRN#IL,U%D<9F*M:C'U=)!3STDM/33(YGB\K>Z]T&/5_\
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M%6%'57HR,IP11@Q[@5 ::_:/W*MN2?&M[U7,4Q5U>,!BCJ-)JI(J&%,@U!'
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M:Z(W5UATYTUGMB_?];= [KZ+WOU)MS^\^9I?X3E/C5D,;E-DU7WD.0CKZ_\
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M:+?6+IZ;"[RWO/ELOBSGMRYFNP53C,3#3XW/R8FFIZNM6AHC4_<5'NO=%1Z
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M&#_[&O?NO=>_X:V_X4O_ />]38__ **&#_[&O?NO=>_X:V_X4O\ _>]38_\
MZ*&#_P"QKW[KW7O^&MO^%+__ 'O4V/\ ^BA@_P#L:]^Z]U[_ (:V_P"%+_\
MWO4V/_Z*&#_[&O?NO=>_X:V_X4O_ />]38__ **&#_[&O?NO=>_X:V_X4O\
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M4V/_ .BA@_\ L:]^Z]U[_AK;_A2__P![U-C_ /HH8/\ [&O?NO=>_P"&MO\
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M .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\
MHH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38
M_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\
M][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4
MO_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_A
MK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=
M>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:
M]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_
M +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38_
M_HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C
M_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O
M_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2
M_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\
MAK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U
M[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QK
MW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/
M_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z
M*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-
MC_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\
M>]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]U[_AK;_A
M2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O?NO=>_X:
MV_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8/_L:]^Z]
MU[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#HH8/_ +&O
M?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>]38__HH8
M/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#][U-C_P#H
MH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_ (4O_P#>
M]38__HH8/_L:]^Z]U[_AK;_A2_\ ][U-C_\ HH8/_L:]^Z]U[_AK;_A2_P#]
M[U-C_P#HH8/_ +&O?NO=>_X:V_X4O_\ >]38_P#Z*&#_ .QKW[KW7O\ AK;_
M (4O_P#>]38__HH8/_L:]^Z]U5]W%_+V_F*[8_G;?R/-I_S%/GKA_EGF,_W;
MOCMGJW<& V4FWVP<'Q1DPG8&0QDL8Q^-65-Q5.-H*?R6=H5#N.0%/NO=?0;]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW12_EE\,.F_F-MG"8+L^'.8W*[6JJJJVMO'
M:=;#09*A&0\7W4"M4T]7334M7X(?+'+3/RBM&T<@U^POS1RC:<V1JER&#(24
MD0@.M:5&0P(-!4$?90YZG'V/^\%O_L'>37.S&&2.Y55N;6Y1GMYM&K0Q$;Q.
MKIK;2RN/B(8,IIU7Y_PQ5\:_^?K]X_\ GPP'_P!8O8$_UEMO_P!_W'[8O^M?
M64?_ "<GYO\ ^C;L_P#SCO?^VSKW_#%7QK_Y^OWC_P"?# ?_ %B]^_UEMO\
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M;B^+WPBZDZ/RF;IZWN"'8>3W3VWOM*!*-LKV+VK+5;AWCN":-$%WKMV9;)5
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M$T./Q^%A>HJZVLJIV2&GIJ:".2221W"HBEF( ]^Z]U4!M+_A0!_*YWCNW:6
MH>\=WX?:'8._:_K#KWOC>'1>]MF=:YW/8^6J@;'8S?V3P-+MF9WGH:V..5L@
ME/(T$FB4C26]U[JYU65E#*0RL RLIN"#]"#^0??NO==^_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+!0?,;X]9;Y>Y;X+8G?M-
ME/DOM_HVH^1.X]AXZCFK5QNV(,QC,&)\A6QJU)1ULU;F,>T5'+*M3)3RBI6,
MP^OW[KW77RS^9_QC^#762=N_*?MS;W4VRJS+P;;P4N3AJLQD,QE*N.2:'%8+
M#8VGK<OF\G-%#*ZTM%0SS:$>0J(T9A[KW17_ (Y_SA_@C\F.XL1\>MJ]A;YZ
MX[RW3C7S.Q>J_D/TQNSX\Y?<=+##-/)+MR'=V'Q,6;:*&GGD>*DFEG$<;R^(
MQ*SCW7NK0/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=)'?V_\ 9'56R=U]D]E[MV]L/K_8N!R>Z=Y;TW;E
MH,#C,7CL-$T]76UU94O'!34U/$C,[NX4 ?7W[KW50>)_X4&?RM\GDL%)5]S]
MA;5ZVW3N&3:VU_D+OSXZ]@;$ZUKZQ6>-5@WUEMMTFWTIY9(Y%2JFK(J4Z2WF
M$95V]U[JY6?.X2FPDVY:G,8JGVY3XJ3.S[@GR$,5$E%%":AZQZMG$"TJP R&
M4R",1C66T\^_=>ZIXE_G_P#\K2+.4<+]];H7KBOW8=BTOR/DZ,WQ!U6^66=J
M5J5>QY-OIM-HTJ5:)JM<F:$,"34Z06'NO=7*4E72U]+35U#4T];15M/#5T=9
M23+4Q2Q5*AXY8I$+))'(C!E920P(()!]^Z]U(]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=5 _,C^>[_+#^ _=^4^.ORA[_ ,IL3MS"X';V
MY<KMG%]2;OWTL%)NF'[FA:2LP>$R%$DLT&F3Q&H\JHR,R .I/NO=#7\!OYJW
MP>_F;?Z5_P#9,^U\IV?_ *$O[B_Z2/XEUQN3K_['_23_ !G^#Z/[P8K&?=_<
M_P  RE_M_)XO$/+H\D>OW7N@6[9_GI?RXNI>P>Q.MI.T>Q.U,WTY65F-[FR_
MQ^Z WQWW@]HU.-DDBJZ;<&?VK@<GAZ*JHWAG%3"*V26F:*1)TCD71[]U[JQG
MH+Y"=)?*;JG:W>/QX[-VGV[U/O2"IGVWOC9F2&1HYS0RO3U,#W"34U925$<D
M-133Q15%/,CQ3Q1R*RCW7NAC]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO= +\I.A,7\IOCKW-\<<[O3>O7F![MZ^W
M#UMN#>/75=3XW-T6/W5"U+7-CJBKIJNGBJ)J22:'5)32*%D;TGW[KW19NQ\C
M\,?Y4O\ +DEP79?]U=H?$[XX='476[;=W#!3U7\?IJ#&_P /BPWVDP?^-Y[=
ME1K1XF26:OK*J62;7KE?W[KW16O^$[73/;O17\I+XR[.[FVKF-@;BS$G9?8V
MV^NL_75E;6[?VWV;N7*YS;F)J!7VJZ>2'$UU-(8)K2PB4),J3"1%]U[J[CW[
MKW7O?NO=>]^Z]TU9W.X7:^#S.YMR9;'8';NW<5D<[G\YEZR/'TE%18B%ZBJJ
MZJHE98H*>G@CDDDD=@J(K,Q !/OW7NM"+^>53;P_F,?RXOEQ_-/[#_O/@OC5
MUGGNINJ?Y8O5.6IZG;PJ<-F>Q=NXG=O=65I&=&JJSL"$246WUGC\=/MM$J8X
MS+D?.?=>ZWRMD?\ 'E[0_P##7P'_ +B0^_=>Z5'OW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJL_P"=C\>=[_*G^5?\S>C.N^R]
MN]1[LW;UEC\K1[WWANA-D8A*?K_.8G<>1Q>6S$U514V,Q>X<;B*O$U=34U I
M(J>MD>K62F$L3^Z]UKX?*W^;]\4/EC_* QGPVZV^/.]=F]F?)+K;:'Q3Z^PG
M8^R(>NNH=J[B3P8A,M3=M91H^NZS";>JJ(U>+J\=FZF:L9*-:>/RRG1[KW6W
M)\6NN-T]._&3XY]1;YWLG9>]NK.B.HNN-X]C11M$NX,KL?;^/QF0S:J\DKJN
M5JZ6:J :5R!+8NQY/NO=#O[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z+[\I^O>\.UNA=_==_'+O&+XV]P;LBV[C-M]WML>D['EV_2G+
MT$F;J:/#UTD5'4Y*? IDZ:B>5]%-5S051#>'2?=>ZUD?Y>_PBZQ^!'_"D/?O
M3W7&Z.S^Q,AN7^2S5=H=K]L]S[\K^Q=T;OW=N7N7;%'E=R9G(5TT@%770XRB
M4PT\<-.BQ*1&96EEE]U[K8*[P^ O4GR$^8/Q1^8?9F;W?G-P_#K'=C_Z)>KJ
MBJIIMJ+F.RJ9*2?<M90/3-/49S'PQ0"AE-3XJ=D69834)#-#[KW50O\ / W5
MM7Y ?+/^53\'>B<=1[Y^;FV_G!T]\KZVMVU5S1Y#KCK3JIJJ;=&?SE=1*SXG
M'9N*2GAAIZF1(Z]J<%(Y*B.B#>Z]ULP>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)?\^_A'L#^8;\;-Q_
M%KM;>78.SNM=Y[EV1F]Z?Z.,M%A*S+4>R<G3Y9<)5SRP3L,5D:FDIUJUA\4[
M1K:&>%[2+[KW1-_YW'</QG^-'\K3Y =9=D;6VSF:7N+I_</QG^.'QYP^+UUF
MYMV;SQCXC:>"VSAZ")JPRXNMEHJM7HH/)014HGA*2I#?W7NJM/YEN0WS\0/^
M$ZGPH^*7R2['R?4>\N[Y_@[\'.]]ZKEQ65&&Q>YH8J[>]//DJBFK($2BVGMW
M.4U3--: Q1RQB2172.;W7NA=[?\ YF/P]K/A)7]6]C_RM/G)MW^4+NOKI.DH
MOD%2]&8_:VU:'8U72C%8_<]+M6#+0[]P.W(P*>HQF6.W*:H4?:Y"DC\S0!O=
M>ZV#_BYMSI[:/QMZ&VS\>MR#>/0V#ZCZ_P =TMNE-VR[]2OVK3XNF& JHLU/
M+/-E()<7]J8JEYY'ECTNSL3<^Z]T._OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[K3/^%GR\WE/_ #$/YWG>G1?\N3Y%?.'?V\/FIA^B\_G]
MKU>T=C[=PN ^(F"_NABX4SV\<Q0455E<I5)D:D8['P35<="M!-D!3^:CCD]U
M[J^?X*_/;HS^8+M+Y"]:;%V7V1\4?D=TY6UW6?R'Z![#VW0[+WULFOS<-;!B
M\H$IFJ:*OHJE%FJ<97PO+!(5]2H3I;W7NA%^*_QI^+?\HKX0P]8XW><6U.B^
MD<5OCL'LGN3MO+TD-=7R9FMJLMF-Q;IRBQ4T-77S-/XRXA0>.."EIH4C2"!?
M=>ZK>_X3F;>S&2Z/^;7R-P77V5ZG^-WS"_F ]]_(CXC[ RL-5BO'L7<K4=+1
MY>FQ52D8Q-%FJBCFF@@BC2'QJ&IE^T-.S^Z]UL2^_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@#^4OR2ZP^'WQX[?
M^3?<V5DQ'6G2^R<KO7=%13JLE1,E"%2FH:.-V19LADZV2FHZ2+6/+4SQ1 @N
M/?NO=:F'Q=^5GP=_F)=M]>_S#_YM?S^^'.W*/9>8FWC\,/Y;.0^2NVEVUUQ$
MTODQ.Z]_XZ?(Q_Q_LS[<\I5P+#C0^F2E2I2.GH/=>ZV]NE^].F?D;L''=J=!
M]I["[EZTR]9D\?BM^]:[HH]Y8BIGPLSTU7%!D*"6>FEDIJB-XI0LA*2*R-9@
M0/=>Z%7W[KW7O?NO=>]^Z]U7E_-%^&?9GS]^'^]/BWUCWTOQXJNPMP[/DWCO
M";:$V^*?)8# 5J5N2VW78^GRN$GGQN=\,%/6QKDHEGI#-2SK+33S0R>Z]UK+
M_P _[XT_S-.G?Y/W=\?>GSM^//;7QWV;4_'W;M1TMUI\(J?I"H:FHMY;;H<+
M!C\U#O/++C:;%5(HI/$N.=9((#3CQA]:^Z]UME_#'9OR*V-T)M7"?*#NK:'?
M?9C6R$>^MD=5)TY0KBJRFICC\>,,F3R_[U$@=9*@UK&=FU:(Q9![KW1JO?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=42_\*-MI
M;UW3_+&WE6[>V5O'LS86PNZ_C]V9\B>M-A&9\GGNMMB[FHZ[=V/ABADC,\(H
MD2HJ S"-*>"6>4JD3,ONO=2OF_\ /C^4WNG^5;W-5Y/N?X[=H?'?L?X[;NV%
MUQTUUYOW!'*;AJJS#5M)@MH[6P='5QUU)N2.NI%IZ.""GAGQ=53&9C2_9221
M>Z]T;/\ E!['[CZU_EA?!G8G?])N#&]N;8^.?7N,W;A]UR2ODZ#12AJ#'9 3
M 315F.QC4=--#)ZX'B:%[LA]^Z]U8[[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[K79P'_<5AO?_P 84TG_ +_##^_=>Z77\ZC^
M;?\ [(C4=(?%GIG>G3&R/EO\L:FNAVAV3\@]W46S]C]<;9QCM%D=];KJ:V6*
M)XT:*JAQ5&S#[^L@F2-:B2 4=3[KW0=?RS.P_P"3/\-%S-+M3^9C\9_D_P#-
M#Y-[KP\W>_R5WY\C=L[LWUV)N3-5"P4&.IU3)SRTF*@J)XJ7$X:C'CC01!_N
M:HO._NO=;&/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NB#_P S'^8%U7_+)^('9'RP[5I)\]3;6_A^WMC;
M&H:Q*"KW'N7<I>/$86FE=7$7F:.:>IE$<AIZ*GJJGQR"$H?=>ZH#^"O=O\O7
M=7<N!_F4?S1_YH7P:[?^=E=A".I.I*'Y,;6J]@=#XO,*Q?";)QC9B:GDW)-
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M+TM9!!/"9*=C%-&DJ:716'NO="!!!!2P0TU-#%3TU/%'!3T\$8B1$B 5$1%
M5450     +#W[KW67W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW6.6**>*2">..:&:-XIH94$BNL@(964@AE8$@@BQ'!]^Z]T2W
M:_\ +:_EZ[([1B[MV=\'?B9M;MVFS59N2D[(P'Q]VKB<S!DL@7:?(T]?!BTG
MIZ^9I)2]3&ZS.TDA9R9'+>Z]T=;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!U'U!U+%VM/WO%U=UU%WA5;$'5U3W+'L
MG&)NN3;*UR9,;<?<0IAEWP0R4<=7]@:PTGW*K/XO*H<>Z]T$'<_P;^%'R/W9
M3;^^0WP^^+??.^J/"4>VJ3>G<_Q^VGVCEHL;CY:B>GQ\>1SF(KJQ**">KJI(
MX%F$2232NJAI')]U[H.\!_*]_EG[4SN%W3M;^7=\%MM;FVUE\;G]N;CP'Q(V
M!AJ_'U^&F2HHZVBK*?;\=12U=+41QRPS12+)%(JNC*R@CW7NCT>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z!KNSXY_'SY+;<QFSOD;T3TUW_M'"9N/<N&VMW9UAA.U<;29*&">E3(4M#G
M:&OI:>M2EJJF$3QQ+*(II8PVB1P?=>Z++_PT[_*R_P"]:?P _P#2-^NO_L<]
M^Z]T=;9&QMD]9;0VYU]UOL[:W7VPMGXBCP&T=D;(V_2;4Q&*H,<@2GHL=C:"
M&GHJ&D@0!8X884C1195 ]^Z]T67$?R]/@;@.XD^0F"^&7Q=PW><68J-Q0]MX
MKHG;./W F1K$:.;(QY6+&I5ID)4>0/4K*)VUOJD.IK^Z]T</W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW16^_?@_\-?E5D\+F_DM\
M5OCWWUG-N4TU%@,[VWU#@M^UU%!4D-)3TU;DJ&HJH:>1E5FB241LRJQ4LH(]
MU[H6FZ9Z>?JVLZ-;JCK5NE,AMBNV17]/ML7%G:T^%R<+T]3B)MO_ &O\)EQ=
M1!(\<M*U(8)(V9&C*DCW[KW12O\ AIW^5E_WK3^ '_I&_77_ -CGOW7NC+=)
M?&WX[?&?!9?:WQPZ$Z6^/VV=P9<9_/;<Z2ZMP?5-!6UXACI_O:NCP-#04]35
M_;PQ1>:2-I/&B)JTJ /=>Z&GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U5'_ #:=\?S7=A]0]99/^4ITWUOW5W!5]D2T/9NWNS<I
MM[%4=+MIL962+6P/N+=6TH&J5RB4406*NFDT2.3 5'D3W7NM2C<G\[K_ (4Z
M;1^:VTOY=NX?C?\ $O'_ #%WUBHLUM7I_P#A6WJO[JFGQ-=G4E_O!!V9+M:"
M^*QM;/IFS<;CQ^,KYGCC;W7NKO>D.ZO^%/63^'OSDW#WA\1/CQM[YA[9_P!E
MG_V1K8N'W+L6?%;B_C6Z*N#LW^,34O9]=C8/X1M=:2HI/OLQC-<S,M-][+>!
M?=>ZO3^%.9^46X?BOTGF_FKM3 ;%^5.3V@M7W;M#:U3CJO'8[,25-1JI:.7$
MY+,8]X(Z?[?28<I4J?S*SZO?NO=&4DRN+BR$&)ER5!%E:J(STV,DK(TJ)$4.
M2Z0EA(Z 1R<A2/2W^I-O=>Z]-E<73UM/C*C)4$&2JT+TF/FK(XIY575<QQ,P
MD<#2W(4_0_T/OW7NI_OW7NFZAS&(RCU,6,RF.R,E$ZQUD=#715;0LY8!91&S
M&,DHX :U])_H??NO=./OW7NM0+^>/_.3_F.?#3^:)\4/@'\',7\?\G+\G^I>
MBIMM0=P;-JLO+)O'NKL/=NRZ.)\E%F<?#1XQSB\0&+T[>(F:5G92%7W7N@V^
M1_SV_P"%5?P.ZMS7R4^0GQ8^!W9W1774E'GNV'Z\EGKJW%X6DFC6JJ'2DWI2
MU\4,JRZ#508W(BD(%1/3B!)-?NO=;-?\N;YN[&_F,?#/I'YA=?X/([6PW;6"
MRDF3VEE9#43XG,;3R-9A<WC3.8X15Q4>6Q]8D-0L2K40".8*FO2ONO='*;,8
MA,C'AWRF.7+2H9(L6U=$M2RA6?4L!;RD:%9KA?H"?H#[]U[HH_\ ,$^:O7W\
MN[X?=T?,CM';NZ-W;*Z9QFUZFOVQLU*=LC7U6]L]BMM8NE@:JEAIXDERV9H5
MFE=[0P&24)(4$;>Z]U#_ )=?RMRWS@^%'QW^6>>VCC.OLEWSLN;?!V1BLK)G
M(<9'5U]=%342ULT5/)6RP4M/$)9_MH!-('E6"!&$2>Z]T=7W[KW7O?NO=<7=
M(D>21UCCC5GDD=@BJJ"Y))X  Y)/OW7NH6.RN+R\#5.)R5!E*9)6@>HQU9'6
MH'4*Q0O$S*'"LI(O>Q!_(]^Z]U(JJJEHJ>6KK:F"DI8$,D]353+3QHH_M.[D
M*H_Q)]^Z]UPHJZBR5-%6XZLI:^CFU^&KHJA*J)_&Q1M,B%D;2RL#8\$$'D>_
M=>ZE>_=>Z;Z;+8JMJJJAH\GCZNMH25K:.FK8YY82#IM+&K%XSJX]0'/'OW7N
MG#W[KW6GG_/=_G/_ ,R3X2?S,/C%\$O@CM;H[>&0^2'2W2V2VAMWLO:/\1K\
MAO7N'?\ N_9V/Q\65J=Q8/&4-)5OB</$K54D4,,CRS3U*1$F/W7N@![3_FT_
M\*B_@'L]_D-\ZOY;?QTSWQKVGD(&[(K]E9W$U%?34N0>*FA8Y+9O8V\3@HA5
MRP#[VMVS54REV1Q=D:/W7NMMKX/?,CJ'Y^_%OJ/Y9='5.1?8';. DR4&*S<<
M<&1Q.0Q<\M#EL+DXX9)H4R&)R5/54LQCFDAD:/RP220R1R-[KW1G&SF%3(KA
MWS&+3+/;1BVR$2U)U+K%H"_E-T]7Z?IS]/?NO=.GOW7NF<[AP"Y'^$-G,.N6
M\BQ?PPY.$5&IAJ"^'7Y-14@@:;VY^GOW7NGCW[KW3=!F,14UU1BZ;*8ZHR=(
MC256.@KHI9XU0J"TD*L9$ +H"2HL6 _(]^Z]TX,RJI9B%5069F-@ /J2?P![
M]U[IJQV?P68>2/$9K$Y62%0\T>.R4-<R*QL"PB=BH)XN??NO=.WOW7NJ.OYY
M/\ROLGX&=.=%]7_%T;1ROSB^:?>NQ^AOC-@-XT:9JAIY<KE,=3Y?.5^/\T4M
M11TOW^/QZ%4D$=;E*25XI8XY(V]U[HE?RS_FQ_,7X-?SK_@#\">T\UL'<OQ/
M^4>R>F<5G>R\GU;+29NNW3O^;,;-D%%D\=4TV,I%DWG1X:KJ8?X8PH:3( RF
M*E>%U]U[K%_PI+_G8?(K^57/\6=@?$[$=?9KM'N.F[3WMO8]A[4GWE2T>W=A
M1XZ&!HJ2DR&/J(Y:FJJJV0SES%'#0SZ@;ZH_=>Z._P#%'^:O5]R_R,YOYH>[
MX<-4[^V5\7^Z^P^Q,'M_&G$4C[OZ/AS='6T%'1U%1-X(,AE\2GVJ253@PU,)
M:0AK^_=>ZB_\)]OF_P#+O^8I\#ZCY7_+U.LZ7.[U[CWYMSJVAZMVM/M:C.V=
MBQT..>JJXJFMKY6KYMQQ9^)K5!C%/3TY4!WD ]U[J[BAS&(RCU,6,RF.R,E$
MZQUD=#715;0LY8!91&S&,DHX :U])_H??NO=3W=(D>21UCCC5GDD=@BJJ"Y)
M)X  Y)/OW7NH6.RN+R\#5.)R5!E*9)6@>HQU9'6H'4*Q0O$S*'"LI(O>Q!_(
M]^Z]UKB_*S^:I\H^G/\ A0/\+?Y9FSX^M/\ 9<._>I=O;YWU4Y7:,]=N-:RO
M3?[RI0Y09".GIZ=CMC'#2V/D8!I[."ZF/W7NMDAF55+,0JJ"S,QL !]23^ /
M?NO=0,CE\5AXDGRV3Q^+AED\4<V1K8Z)6:Q.E6E906L"; WL"??NO=9Z>IIJ
M^FCJJ&JAJ::HCUT]722I4(P;@,CKJ1A_0\CW[KW5$7\KS^8WW1VG\T_YAW\M
M+YEYW:.3^2_Q$[1J=U=3[DV[@Z7:)W7U7NI*"7"9">@@=(WS&.ILCAI\C)!1
MP4^G,T<<:,89)']U[J^;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW6BK\C_\ N-7^)?\ XBW$_P#OIM\>_=>ZNL_X5'?]N*/G-_Y;-_[^
M+K[W[KW6JI_-C_[A4?Y+G_B7=E_^\OV5[]U[H7OY[G\IS _$+^7QT'_,[V;W
M[WQO/^8&O:G3N5^07R<W1VWFJ#)9V?M3"Y2HK*W;U#3221[9?';B;&C%TM#5
M4L5#BO/ 99Y(X-7NO=1?YLG\KO![-_DV=,?S?.U^Y/DAN_\ F<YF@^*?<_8W
M<6[^QYXI:>O[HFQ]6^W,=BJ1:>@VU2;/J\U%_#3BHZ62GGH0ZOIF=1[KW1A/
MYUO\U+Y,;*_DN?R?=E47<NY-B=H?S&NB-C[E^1/R#PRR4&2.&V1M;9DNYG9\
M28JZGFS^2W;2556*"F#3T]-64D:QI4>)_=>ZID^1W;_\G7X$[3^/GR5_D8?-
M;Y"4GSFZ5W5M_$;[I=\[-WKC\9V%M_(Q@YF3.19? 8;#4T9K*2D:7'4\T5%4
MTTLT?VK5,-+4P^Z]U]0KX[]PX3Y#?'_HSO\ VU8;<[RZ=ZR[AP 6*:G'V79F
M$H<U2VCJ8XJA!X*V/TRQ)(/HZJP('NO=:!?_  IQA[AJ/^%$O\L&#X\56V:'
MO^?J7X50]&UN]%UX:'>,G>6_EVS+EAXYKXR/-&B:J'A>\ ?T-^D^Z]T/7\TW
MJG_A53NWX1]W4'R/W7\8MY_&[';3R&YOD#M+XLS8K#;GR.TML)][F8/-D\'#
M4M014L+U-3'0.:J2*!D\53"TE+/[KW1].A/YH7QOZ!_X3$=@_*;^79L/.]8T
M?Q:V4W0V'Z[WK58[=F8V[V)OC<>$PCY7-55-'0T.<FGR>]:+<LE2*2G^]@J=
M3T4$I>CC]U[K5+ZJD_DA]E?"'>/=?RP^?'R?;^<GORGW7W!1=NQ8#L/.#;F]
M<'53U6U<6M938"6@R,4PHL6M;D'R;U$$L\K8ZMHDIJ?Q^Z]U9U\G.Z\A_-D_
MX2@UGRK^16_-V[I^1O\ +W^0NU]D5>X<8T.,AS^;K-S;2VK#/N=*O'3R9&5M
MA=C451)+05E-Y,HD=1+,P%51'W7NAQ^(/\BWIS=W_";_ .1';/4&9[>W7\A?
MFQ\7NN>_LAM?<6;PF1QE+N;XK9?.[CPN.VI34^#QU71C.QM7XV<5V4KF9*H>
M*6G(+GW7NBV_*+YL]C_/;_A/C_)_^"W6%119WY)_*WY"[:^(^:V]79:7+U-5
M2_$VKBPE!4UM2L1EITJ9<CUYDZVIFC<P123%C,JM4#W7ND;OO^8)N[=/_"5?
MI3X68^IW7EODQNOY>-_+PS6RXZ27;N=IZ3K;.KOFCQ,E(T5//+%%A:G9^WWC
M1%\OW#4M2\DL=8C>Z]T-_P#/)[0Q/POQO\I_^17N'O#>_P ;OAEM_P".'4.\
M_FYVAU]C9\ADLWB,UF,I@<JAI<+#6U%?(]5MW<^0DH?X=/1U-=D:.:HCJ(Z<
MJONO=$EW#\U_Y6'\L#YE?$'Y*?R0_E3W/)UWE=VX38?SKZ)[$VUOB3#9G:%#
M6TK2YF1L_AL?+6UKT-5E],,(J7HZN.FJ<?! K5,-3[KW1\/Y]OS=Z;^0?\ZC
M _R^/GE\@^SN@/Y9?Q<V_L?/=TX/K3&Y;*S[OW-NK:M!O2C$U/@:++U-0LKY
MG!8Z.6?'D8V.#(STOAJ9XZ@^Z]T$GP$^<'P:^#/\ZKXP=5?RDODSVEOK^7O\
MVMP;3ZF[RZ'[,V[NZ&CP.^-]3/MS 5>);<.-H:Z:HJ,I)MZ1:YH9Y(HI*RDK
M*HT?V_VGNO=&^_GF=>=F=N?\*?OY9/5?4?;&[NC=Y=D?$7KS8TO;/7\-++G<
M)A-U;K[IH=TU6&>LAGIZ;*-M>?,14M48F:DGD2JBM+"A'NO=%G_F\? CJW^1
M_P#S&OY3G?GP)WWW;L7<?R)[=W)B>V(MR]I5^[YLQ)U]NG84F3GK\A6:ZVMC
MW;!NZ>++4M1+-13?;Q21TT;/+K]U[KZ,OOW7NM /^?I_W%-?R5__ #')_P#!
M%;R]^Z]UN-?S-\=L/+?RX?GSC^T*BKHNO)_AI\F#O*OQT23U=-CX=FYF2HJJ
M))(:E#7TJ*9::]/+_E"1D1N;*?=>ZT'?Y;W\PKOK^7I_PF#^6?:?5N;RN [%
MWI_,-R70'QYWC7XVIS\>!G["V9L_)9VNQT;B6FHA18['9^>BFE6.BCS4_D85
M%2[4TWNO=6%_&S_A,)T9\D?Y:76GS2W9\DODI6?S"N_>@]B_+[:G?M5V(<A%
MB-P[TP5!NO 4DE/-"F2K4I5>CBJ:Z7-?Q'[DRU--5P*D$4?NO=&$_E4_S!?G
M]_,,_P"$^/S7CV9F-W;R^<7Q^P79'1G5O9F'RGDW-N-7V_C,KC:Z*I;Q2_WM
MIL?DJZD@J!(9YZFGI*H2FKE?3[KW6K[T)E?Y%VY^G#TU\[]H_/SX.?S)<-/6
MYCL+YGU=1G.UJ>CWA19A:X9*LVRN1I\[#5UJ-'--2OM-*J(O4:<S]TE/63>Z
M]UML?S7OGON7X ?\)\>F-S_$CY?[F^46?[@S/7WQ6ZL^:S9:GR6>JJ#+X[<>
M3K\]/7PSB09REPVU\ABA5G5D*:M>*:IO7135'OW7NM4G>];_ "2.G/A'L3O+
MXD?/?Y-8_P#G-=<TFT.XY.V8ML=@8Z'.;URSQ3;IP/GK-O4N*H\>OWV3CI:X
MURSU)AC.1J:Z&IJ8I?=>ZOG_ )K7RI^9?\P3_A/S_+N^4_4^W.T.Q=A=C[BH
M)OYA&UN@6R6T:S-4778RVUMR4E2M)25E=2;8KMR8C,K4L*"LH()'HZB6.II8
MHW;W7NJW_B#G_P#A.MVA\AOC-V!\.ODW\U?Y.GR V'V%0)D3V+75&\<3O!(O
MLZR"@J=SG.Y_#8C'U-;2)#,<G44=!6QO4T57BI$FI)4]U[KZ9,#^2&%_+%-K
MBC?S0"R/J .I!J>RM]1ZVX_)^OOW7NM-#YO9K*=L_P#"OW^5QU!N>K-5L7J?
MXZ[FWQM7!5$:U5/#EX=L=K;GFR"1V0I55%5@\*A<NVG[&G=1=2I]U[I/?\+(
M>NMR;$Z__EX_/SK^&K7>WQ@^259M:GJ_MFK*&*3=D5%NG"U.12/1*D5+EMD>
M*-EJ(5)K&B9C)) 5]U[H*.M*'8G\Z'_A3=V3V%6X_P#O1\:?B-\#Z?9]!7T=
M?#F<;E(^T]HR8X4-42CQA3E>TMUSP0Q2?N-B?-(VEIZ<^Z]U2'MSY@9CXB_R
M,/YLG\K3>N^:Z#MSKK^8/LKH;;U&E \)DQ^Z\I7S;HI*16UO2T#R=3;D:J#F
MT3Y-(B_DK$!]U[JVC^;QWAV[_*D_DB_RC/Y=?5>[ZKX^[F^377$X^079&Q!4
MTDN+HMOT>WLYONEBGQ[)E0^7W-OXSU4E+#YZRGI:V#T_=&-_=>ZJ3^1W;_\
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M-.VXYZ62MI*.*AHF$./7$K65M>V1R50M-1Q^Z]TT_P T/^6?\\^K?YG75_\
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KZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>timage_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_004.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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MZ]U[W[KW7O?NO=>]^Z]TL=H516HJ*,GT2Q^9!^!)$0K6'^*OS_P7W[KW2_\
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T$N<).6KK
MDG]\CG^@50!_O'OW7NFGW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UF@-G:W'[-2/]O3R@^_
M=>Z5F\6/GHE_ AE8?Z[.H/\ T*/?NO=(WW[KW7O?NO=>]^Z]T57Y(_-WXJ_$
M&?:U/\ENY-O=0'>\.3FVE4;IH-QB@SXPSTJ9:''9/'86OIWFIOOX&G@\HD19
MXW9 LB$NQPO-\ )^S/26ZO8;( S.J \"QH#^WHS.'R^*W#B,7G\%D:+,83.8
MZAR^'RV-J8JS'93%9*FBK<?D:"K@9TEAGAF26*1&*LK!@2#[:Z4@UZ<??NM]
M%*VI\[/B1OOOW.?%S9/>&U=W=^[9KL[CMR=:[:I\]F\QM^KVPO\ OXTS57C<
M/4T5*M"]H*N6>J1(IR('83$1ETPNJZR#0\#Y'I*E]#)(85=2XXJ#5A]H\N/1
M:_\ AZ_^5;_WFKU-_P D[L_^QKV[]%-_ W[#TC_?UE_O^+_>U_S]>_X>O_E6
M_P#>:O4W_).[/_L:]^^BF_@;]AZ]^_K+_?\ %_O:_P"?IYVY_.-_ED;OW#@=
MI[9^876&:W'N?,XO;NW\/11;KDK<MF\U708W%8VDC.W%#2SSU,<48N+LX'O1
MLY5%2C?LZLF]6DC!5FC))  #BI)P!QZ'/Y'?/CX>_$7<.WMJ?)+OG9O4>X=U
MX:;<.W<9N=,WY\MAJ>NEQL]?2OC<3D$*)/"T;!F# CZ6();C@>;X%)IQH*]*
M+K<(+*@FD5*\-1 K3TKT7/\ X>O_ )5O_>:O4W_).[/_ +&O;OT4W\#?L/27
M]_67^_XO][7_ #]>_P"'K_Y5O_>:O4W_ "3NS_[&O?OHIOX&_8>O?OZR_P!_
MQ?[VO^?JS#;FX<-NW;V"W7MROBRNWMS8;%[AP63@65(,CALU0P9+%U\*3QQ.
M$F@J4D4.JL W(!X]I3CHU!KD=//OW6^O>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NBV;2^8'QIWUW[O+XM[2[<VWF_D#U[C:W+[TZMI
M8LNFX]O8S'G""KKJ[[C&PT_C3^\=#ZDG?4*J,K<'VX865=9!H>!\NDRWD3R&
M$.I=14H"-0&,D?F/V]>[P^8'QI^-NZ^L]C=X]N;;ZYW=W)DIL1U?@<W%EY:[
M>F3@R6%P\U#AEQN-KE:1:G<5##I=D]52EN#<>2%I 2H) XT\NO3WD5LRK(ZJ
M7-%!(!8X%!Z\1^WH=MS[GVYLK;F=WAO#.XG;&U=L8FOSVX]QYZOIL5A<'A<5
M325N2RN5R5;)#%!3P10M)++(RJJJ23;W0"N!TH9@HJ< <3U5;UY_/-_EC]K=
MP;=Z-Z]^0E?NG?V[=UKLS;<.,ZB[FEP>8SLDTM/"*7<)V"M)]H[Q$C(/(M*(
M_P!]YEIP90L?;YHUULM!]H_S]$D',=E<RB&.34Y)  5Z$BOGII3'&M.CR?''
MY;?''Y=;>W!NSXV]L;<[;VYM7,Q;=W!F-LQY5:+&9N:AAR4>-GDRF.QY,O@J
M(Y2$#65U)M<>TTD+0FC C[>C.VO(KU2T3JX!H2I!%>-,?;T8OVWTIZ][]U[K
MWOW7NO>_=>Z][]U[KWOW7NFC"9_!;EH3E-N9G%Y_&"NRF,_B6&KZ7)X\Y'"9
M*KPN:H5K:*6>,S4=;05%'51ABT4\$D,@62-U'J4ZT#7AT ?3GS ^-/R![ [/
MZKZ:[<VWO_L'I?)56([3VOA8LN*_9.3H\WD=N5-#F7KL;21+(M;B*JGTQR27
M:![7 )]N/"T8!8$ \"?/I/#>17+,D;JQ0T8 @E34BA].!_9T9/VWTIZ][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z:,SG\%MVGI:O<&9Q>$I:[*8K!T-1EJ^
MEQ\5;F\]D*?$X+"T;U<L0EJZVKJXJ6CIH]4DTTJ11JSLJGU*]:)IQZ=_?NM]
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1;,%\P/C3N;Y#;E^*&![<VWE/D3L[&R9
M?='5--%ESN/"8R+&8?,O75S/C4IEC^US]%*&%0;BI0"[&WMPPL%UD'2>!\ND
MRWD3R&$.I=14I4:@,9(_,?MZ,G[;Z4]>]^Z]U[W[KW7O?NO=>]^Z]TCNPNP-
MF]4;%W=V9V)GZ/:NQ-A;>RN[-X;ER(G:@P.W,'1RY#+Y:M%+#42>*"&!Y)-"
M.=*FP/NRJ7-!DG@.J22+"I=B  "23P &23TENC^]NH_DEUOA>WNC=]8CLCK7
M<51EZ7";OP2UJXO)5&!RM9@\O'3_ ,0I**4F"KQ\T#DQ@:HS:XY][>-HC1@0
M?0]4@N$NE#QL&4UHP-0:&G'[1TCNFOEM\<?D)O;M7KGICMC;?8&]^C\S_=[M
MC;F%3*+7[&S?\6SF"_AN9^^QU'&)/N]M5\%HGD&JE?FP!.WA:, L" >%?/JD
M-Y%<LRQNK%#1@""5.10^G _LZ,7[;Z4]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T][<8KF:/\ HQF4
M_P"(:GE_XFQ]^Z]T*OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z"3.?\ %VK_ /EN?^A5]^Z]TU>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NLT'Z
MV_Y8U'_N/+[]U[I5[Q_X$T?_ "PD_P"MGOW7ND=[]U[KWOW7NO>_=>Z(5_,E
M^"6Q/YAWQ6WST%NO['%;H>/^]'4F^:FD%3/L#M##TU2-NYQ2JM(:2<5$N.RL
M,9#2T59.B%9?&Z*+6X-JX<?F/4>G1;NVV)NT#0O3.5:E=+>1'#\_45'GU2A_
MPGM^<>^]LU^_?Y3?RPIZO:??'QJK=R4/4U+N%VCR.5V?MW(RKNKK4U,S,E3/
M@I)_O\++!)(M5AZ@FG'VV/$DB_<[<&DZ?"W'Y$_ZOV]![E7<77587&)(<+@B
MJ"@_E44X54@BN3U9!_.C_F/T'\O?XK9*?9V0IY_DEW5%E-@]";?AFIY<IC\M
M44T=-G>S7QLD-8TM+MV+(Q3QJ8)(YJ^>AI7TI.SHEL;7ZI\_",L?E_L_[/1M
MO^[C:8*KF1^V-?,L<5H*D@5K\S05%1T%'\BO^6;5_"+H2O[C[IH*ZK^7/R5@
MHMV=I5^XIYJ_/['VY5RRYC!]=3U55453_?F6NDR6XI]0EGKIQ!,TBT,#^[[A
M=_4M1::5PM/\/3/+>S?NN(O)4S2T:0DU(.33B>%34^9KFE*&2_X90_E6_P#>
M%74W_)6[/_LE]L_6S?QM^T]+?W#9?[XB_P!X7_-UK$]2_!GXEYW_ (4;=U?$
MK+]';0KOCCMS:N5KL)U+,V8&V<=5P] ["W1%/"4RB5)*Y#*U%4 U0PURGBU@
M#>6X<6BN&.HG)KGBW0-M=MMWWF:$QH4$8(32-(.F,\/S/[>MH_;G\G+^61M#
M<.!W9MGX>]887<>V,SB]Q;?S%%+NN.MQ.;PM=!DL5DJ20[C8++!/31RQFQLR
M ^R<WDK"A=OV]#1-EM(V#+#&""""$%01D'AUK_?\*%-I;<W]_-2_E8;%WCB:
M;/;1WKD^M]I;IP5;Y?L\UMS<?R,Q&'SF)J_#)$_BJ::LEADT.K:7-B#S[,]K
M)6*4CB!_D;H*\V1K+>6:L 07H0>!!>,$=7T?\,H?RK?^\*NIO^2MV?\ V2^R
MWZV;^-OVGH4?N&R_WQ%_O"_YNO?\,H?RK?\ O"KJ;_DK=G_V2^_?6S?QM^T]
M>_<-E_OB+_>%_P W5F&W-O8;:6WL%M3;E!%BMO;9PV+V]@L9 TKP8[#86A@Q
MN+H(7GDE<I#!3)&I=F8A>23S[2G/1J!3 Z>??NM]%AA^:'Q7E[=[5Z'D[RV)
M0]L=&[*K>Q^WMHY?(3867KS8F-@VS59#=FY\MEZ:AH*:A@BWEC))9VJM*I6(
MQLH8J[X+A0U#0X!I@G_4.DHO83(T6M=:C4RU%5&,D>0R/V]%'PO\[W^53N#L
M4=6XSYE]=G=+UZ8V.KK\%V)A]BSU<CP1QK3]IYC9E!M>1&:H4+-'F&C)O9O2
MUGVL)E744-/Y_LX_RZ+X^8K*63PEF0M^>DUIP:FDG/ 'HUWR:^;WQ/\ AOMK
M&;K^2W>6RNJ\7G(9JC;]-E)Z_,[DW)3TX0U%1MG9NUJ#.YC)1Q^5/(]#0U"K
MK6Y%Q=B*!YS1 2>E]Y?PV"ZYG5!\SD^>!Q)^0!/29^*W\PWX7?-DY.'XP_(#
M9_9^5PM-)6Y7;$=+N+:.]:''1U/V;Y6?8N_<)M;,BC\I5/N_L?"2Z6?UK>TU
MM);_ !J1_@_:,=-V.Z6^Y"L#JU.(%0P\L@@$</,9Z.5--#30RU%1+%!3P123
M3SS2+%###$I>6665RJJJJI+,2  +GVQTOZJJ[*_G@?RJNIMW5&Q]W_,;8DVX
M*2IEHZK^Y&V.S>T<'2U4%4U'/!4[MZPV-O#$QLDB$.&K1I U&R\^UB6$T@J%
M-/G0?X:5Z);CF*RM7T/,M:TQ5J&M,E00/SIT??I'Y!]'_)39D/8?0?:NQNV]
MF2SO2/GMC;AH,[345='?R8[*PTLK3454H%VI:N.&4 ABEB"4SQM$:,"#Z''1
MI!<1W2ZXV5E/FI!'\NEYO/>NS^N=JY_?78&ZMN['V5M7&U&9W-N[=N9QVWMM
M;?Q-(NNJR69S>6J*2FIH(Q^J6:1%']?=54L:#)/D.KNZQ*68@ "I)-  /,D\
M.JU=J_SMOY5V\^QTZJP/S)Z[;=LM?_#*>?+8/L+;6RJNM,T%/'#1=G[EV;B-
MLS^1ZA%B>'+NLG.@MI:RIK"95U%#3^?[./13'S#92R>$LR%OSTFM,!B-).>
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M8U1"K6(QXU%7#"X4-0T. :8)_P!0Z3B]A:1H@ZZU%66HJHQDCR&1^WHFL?\
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MD43K*ET)<M[,IKK;\R2/V="638;*12AAB (I4(H;\B "#\Z] 9_*(^$/S*^
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MDRTN5O(DE7@ZAA7B*BM#QR.M>C_A6-_V0[\??_%K<+_[Z'MGV:[)_:M_I?\
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M6Z G-/\ N=9?\U!_U<CZW#_9)T.^O>_=>Z][]U[KWOW7NM2/XS_]Q4OS,_\
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MHX''4,-4Z22UF2VYV9'EHHH?*JIC:M2[%%+;O?UK>-UX+@_;2G^3_!UK8?\
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M7G7,+3C(15$NJ>EG?3(H$ND:%07;1,P\$$"F:UX_F3T(MGBNXHR+QU=]6"H
M&F@QA4\Z^7Y]4#=K[%H?YGG_  HWS/0'?42[@^/'PNZ_FS>-ZKRC5%1@]TTV
M VSL7*9.ER%/!6TL87*;J[!H:K)7285>.Q,-!.C1G4ABA-G:ZU^)S2OIQ_S?
MSZ#%Q&-ZWCP9:&.!-00Y#$A#GAYL*\00M",];:&Z^E^HM\];5O3F[^LMB;AZ
MHK\1)@:GKG)[6PU1LS^$2P2TQH*?;QHQ30HJ3L(O#'&8R;H5:Q]DJN5-037U
MZ'+Q)(I1@"I%"" 00?EUJJ_R>:?(_!O^<I\\OY:^S\MDLAT!68K,]E;(P>0R
M$]6=L97%Q;!W-M&2.2LJ*EI9QMO?YQ.1J2WFJFQM)+*?VK XOO\ &($F;XOA
M/SX_YOY] K8/]UNX7%BE?#H)%!/PFB8]3A@,G\(Z+KE/BKU_\OO^%/WR"ZY[
M:H*7<75FUX,'VCOG8N0-6<7V%1[*Z(ZBDVYM3,PTT\*3T/\ 'LAB<A6TE2LL
M%3!024TJ%9;A_P 8P6:E>)) /I4MG]F/SZ0_0KN&^2K)E55793P>B1T!SPU$
M-0U!I0CK<DV#T#T5U3G<EN?J[IGJSK;<.9P>-VSE\UL'8.UMG9'*[>PU34UF
M(PN2JMNXK'-/34DM9,]-#*66(RN4"ZFN0%RV"3^WJ0TA2,EE4 D $@ $@5H/
ML%33[3T+GNO3G6&HIZ>KIYZ2K@AJJ6JAEIZFFJ(DFIZBGF1HYH)X9%971U8J
MRL"""01;W[KW6@-_,%Z1^2?\G7YD=J]:?!_-?P+J#^9_L;)]>]:[:QN1I<57
M[5RN>W;A\3E=F[?JSE,4V-R.WZO>#4NVLT\U.E-0;C5?,\]/42*)+61;^,&7
MC$:D\:BE?\F?L^?48;K!-R]<LEI0+=C2BCMT/4#!J*4U=IJ -7]'K;H_E>_R
M_-C_ ,N;XL[5Z8P?V69[#S'BW;W5OV&"-)]Y]B9"G05H@F\,+_PS&(1CL1 X
MNM/")'O433R2$EW<FZ<L?L ]!T.]GVM-H@6%<GBS4 +,>)_R#T  J>K%_:;H
MTZ(5_-,_[=M?.S_Q5+O+_P!][G?:FS_M4_TR_P"'HLWK_<.?_FC)_P </5;7
M_"8G_MU]B?\ Q/';O_0^W?:G=O[<_8/\ Z*N3O\ DGQ_:_\ Q\];#7LMZ%'7
MSH?Y9'57\SOM#Y(_/*+^6QWOU]T?D\-V'3R=O5&_6Q(BW'0U^_.TEV5#C!E>
MK.SAJI9*3*-+H2CXG6[2<!!1<O"D<?C*3VXI]@KYCJ*-K@OI[JZ^BD2.DAUZ
M@,]\E*51^&?3JZ/_ &4W_A4G_P!Y]?';_DK:'_W*'M#X]E_ W\_^@NC_ .@W
MS_E(B_8/^M/5E7\M'IG^;SUEV)V/D?YCWR.ZR[MV#DMET5%UWB=AOA#5X7=\
M><IIZ[(UZXOISK-O&]$KQ*6GJA<_YM2=7M'>20.!X*D<:U_XL]'6S6]_"7^M
MD20$#1I %#FM:(GR]>KD?:'H^Z(5_-,_[=M?.S_Q5+O+_P!][G?:FS_M4_TR
M_P"'HLWK_<.?_FC)_P </5,7_"8;XA=0X+X=R?+',;5P&Y^YNS-_[WV[AMWY
MK%4>1R^P^OMFY6'"P;2VM5UT$[T*5>3HJ[)U[TC1?<&:!9+_ &Z>UV\3,9-'
MD*8]33B?\'1!R78I':+/2KL6&HC*J&(T@^0J*T]37HDG_"B'XO\ 6^7_ )CW
MP!H]H4#==;@^64E!TYVGN'99IMOU68Q>3[(VOUV,S,M+0RQO7MBNQ*S'U53/
M#4>>EB@@FCDBB",HVN4B*2N=/< <YH3_ )!T6\W6:27EM2JF4F-V4T)4LJ_9
MP<CAD8-1UMV[9^*GQOVATG_LN.W^D^MJ'I"3;+;1KNMAM+#R[9R^#EHIZ&KA
MSE#+2.*V:H2KF>IJZDRSRR322R2-*[.20RL6U5-:UK7->AZMK&L?A!5T4TZ:
M#32E*4X4ZUKO^$Q6.K.ONS/YK/0]!E*FIV)U#WGUGCMJXR:S14M8<_\ (?9N
M5RBR2"29I:NCZ\Q,<ODEDXHT(LQ<L;;MW+$YXE37]BG_ "GH&\G#P9;N!?@2
M4:1Z9D7CQX(.)\ND#_PI"[TVYW/\EOA5_+CR/96"ZTZ_KMXX'MSY![VW+FZ+
M;.W-GX[<^2GV=M7+Y//YJHAH8VQ.%3<F1:*HCE#M7487UMH;>U1F-'F )(%%
M %<_X?3\J]4YNN5N9H+)G"*S:Y6)TT48&3C^+!KD+U<OV_\ +O\ E+=M?&'?
M7Q2K/FQ\2\1UGN_I[)=-T6.H.[^OH8MN[?DVP=M8"3%QP9^+0V,6*GFI0I 5
MJ=/P+>T"6\Z,'"-4&OPGCQ].A%/N5A<1M$TT.EE*D>(@P13^+JI?_A+E\IQ'
MMCY$?R_MV[HP>>SO3.[\SV?U7D<%F:'-8#/;)RF9AVQV+#M')TB1+5XRDS45
M'E:6K3R>==R/("L:J/:[>(<K* 0& K7B#\_3'^#H/\E7O9):,P8Q,2I!!!0F
MAT^HU9K_ $AT)/\ PK&_[(=^/O\ XM;A?_?0]L^];)_:M_I?\HZOS[_N(G_-
M9?\ CDG5UW\O;X1=/?!KXO===-==;1P]#F)=I8*O[8W8V+BCW#V3V%D,/2/N
MW<6YZNI\]1(LM2\L=)132R1T=*L5)"%BB4>RZYN&N7+-^7R'RZ$^V;='M<*Q
M1B@ R?-F\R?F?Y# P!UKF_/7K[;'\LC^>3\$?DI\?L+C]@[*^7F=I=D]P["V
MS3U&'V[E*[<6^L-U]VIFDQ= ?M?'5T>_,+FEQ\%/&ARV*-8_[M1K4TMB;NV=
M&SHRI_(D#^1'Y_+H);G&NS;I!/$ !.2DBC )+*"WG_$IH *E:DU)Z47_  H&
MH=V=)_/[X$_.#MCI[+=]?"OJ/#87;F[]CHD=7MW&=@TV_P#=6>S<N5@K(IJ.
M*IR=#DL#/CHLAXZ;(3;=%'-(J!B*[;26-X@=+MP/J/3_  _MZ<YHUVEU;W;J
M9(8ZAE ':Q/Q9]<4KBJ@5%>K%]O_ ,VW^3?_ #">I]P= [^[:V5L[";]VG-M
MG)==?(G;7^C&/$0YF@?$THP^ZMP0';<.0HFF5J*;&9MIJ>6..6%D*HX2-93V
MQU:3C-1GA]G1Q#OVW[HIB\1:,-)5QHKJQ3N !_*O1X?Y;GP6ZP_E^_'V7IWI
MWMSL?M_8&X]W5W96*S._\]M?/4>.J-QX;!T-;3;&?:F"PU/3XFI;#+7K K50
M-153SB0M,Y+-U<FZ;4P -*8_R_/I=M.UIM$7A1L[+4L-9!I6F!0"@Q6GJ2?/
MJP'VFZ,^O>_=>Z3>\O\ CT-U?^&WG/\ W657O8X]:/#K2R_X2P_"_I/LJF[X
M^679FSMO[\WQUWO/ =9=5T^YL;!F,?L6>7;XW+NG=>/QM?'44QR54N5H*6DK
M3'YJ6.GJ%A=1527/]ZG92(P: BI^>>HYY$VZ*1'N6%7#:%KG2-()(^9U4KZ8
M'$ULP_X4T_'/JS>/\O'.=Z5>S,#%V?TCO[KBIVQO6DQ]%1[A@P&]-U8K86?V
MS49*&F$L^/J!G::H:D=] FHH)5L8[,DVB1EF"@X(-1]@)Z.N=+5);)I& U(5
M*MYC4RJ?R(/#[#Y=#YO#=^X=_?\ "=S,[RW;DI\SN;<7\K%LEG<Q5L9*S+92
M;X\(*S)ULK$EYZAU,L[\:G=FL+V]M*H2Z ' 28_WKI7+*T^TEV-6:U))]28J
MGKK_ (3E_P#;I#XZ_P#AR=Z?^_Q[ ][W7^W;_:_\='5.4/\ DGQ?\W/^KC]$
M-_X5G_\ 9)'QC_\ %C*W_P!]GNOVIV3^T;_2_P"4=%G/O^XJ?\U1_P <?HYW
M_"@+_MS#W!_Y;?\ ^_=ZU]I]K_W(7_;?X#T9<W?\DZ7_ )M_]7$Z4W\A;X>]
M.='?R^.BNS\9M';N5[:[_P!C4?8W8O8]?AZ&JW1EJ+/S5TNU=GKF*JGDJ8\7
MA\5+3T,%"DOA\@GF"!IW]TW&9I)6!X*2 /+_ %'SZ>Y:L8[6TC8"K.BLS$#4
M:BH!/HH- /(=46?-WX5=([Z_X4==/?'^GVZNVNJ_D7B>ONS>YME[<F7!;>WG
M/M[";LWWN;!U>.Q],(EHL[/U!12Y.%$5I:F>:J22*I=9XS*WF9;1F\U)"GTK
M08^?<>@QN>WQS;S''2BRH'D X/IU-0CA0^&M1Y\>.>MLKY6?%?HGLWX;=R=
M93JSK^DZY?J+>-#MO;=!M+"X_"[,R6+VM5/M?.[6QN.I*2.@JL54XZDJ:&:D
M$+Q/2QE&&D>R2*5D<,":UX]#R[M([F%HG4%2I%*8^5/2G$4X'AU3!_PEXR^[
M-X_RPNV-L-N>KQ\FW/D]V[LO8N36EIJI]FT.5ZGZ<W3')0TK" 3"'+[PK\B$
MF<ZI)V4L$TA3'>5"S ^J@G]I'^3H+\CR-)9%2?AE95^0*JW^%B?SZ&SX<_&3
M^77_ "5&[*?O7Y@],;B[][:WK6;IF[,[PS.R-H=Q0[0EI\?]CMBAP]?NO<>3
MEC%94561R65@$'WDU<C5"*L$&EF:67<*:5-%%**#0?ZO\G1A8V=IRX&URKJD
M8L7E90[<,5-":5J?F>JHO^% 7\P'^5?\N_C8VR^G-][8[>^4^R]\[2RNQ=Z[
M4ZZWC2/A,'4/!#O/%S=HY3:V%HZW'56,J09<?3UU;":JEIF>-:BD0Q+MKMIH
M'J00I!K4CYTQQX_ZJ=![FS=;"^@*(ZO*I4H5#&E2*T8#205XBI%0/,"EQ&;S
MF9W+_P )RZW.[@RE=FLUDOY50J,EELG4RUN1R-3_ ++ND;U=?6SL\DTSZ 9)
MI&9W:[.S,22A "W5!_OW_G[H0.YDV@LQ))M*DG)),7$]$]_X3%_#KIK$_#MO
MEEGMH;=W9W+V3V!OC;V#W;GL11Y7*;"V!L[*082#:NU:C(05#4(J\E15V2KI
M:4Q&<SPI)?P"[V[S,9"GD*8]33B?\'2'DNQCCM%GI5V+#4>*J&(T@^0J-5/4
MUZ![_A4YTSL;K[8WQ8^7G7VU\=LOO3#=WQ[*G[,VQ3T6&SN0I(MM9C?>UFS4
MM)%')65.-K]GFHQE5-K:G\DZ!K2@>W=F<N6C)[2M:?L'^7I+SQ$L,<5R@ D6
M0 ..-*,P^VA6HKPSZGK;?V[6SY+;^"R-45-3D,-C*VH**$0SU5%!/,40?0:I
M#8?CV2''0[&>GGWKK?6:#];?\L:C_P!QY??NO=*O>/\ P)H_^6$G_6SW[KW2
M.]^Z]U[W[KW7O?NO=>]^Z]T ORFZ0_V9?XV][?'K^\_]RO\ 37U1OGK'^]_\
M%_O'_=G^^FWJ_ _QS^ ?Q; _>_;?>^7[;[VD\FG3Y4OJ#L,G@NK<:$&GV'I+
M>VWUD+Q5IK1DK2M-0(K2HK2OKT W\MCX1?\ #>GQ1VC\8?\ 2;_I>_NKN/>N
M?_OO_<O^X'W_ /?#<=;N#[3^[7][-Z^+[?[SP^3^(2>33JTI?2'+NX^J<O2E
M:8K7@*>@Z3;/MW[IMU@U:].KNIIKJ8MPJ?7UZ/G[3=&?7O?NO=4\;'_E.?W,
M_FP=A_S/_P#3[_$O[^82MP_^@_\ T6?9_P *^[ZQVSUQ]Q_I+_TCU7GT_P!W
M/O-']WX;^;PZAH\K+GO-<(AIP-:U^9\J?/UZ(8=D\&_>]UUUKIT:>&$%=6K/
MP^GGU</[0]'W5&'\U;^3%D_YEG</3'<6$^5-?\=,STSM*?;N)7%]2U&_<G/D
MSNB3=%!N3';@I.VNN)<?/2RE!"(HY75XQ(LJD  PLKX6@8%=6JGG3U^1]>@W
MOO+YWEXW64QF.M"%U&I(-0=2TI3HBW_0.9\M_P#O=?\ (S_T7?9G_P!U][5?
MO6/_ 'RO[1_T#T5_U4NO^4Z7]C_];NO?] YGRW_[W7_(S_T7?9G_ -U][]^]
M8_\ ?*_M'_0/7OZJ77_*=+^Q_P#K=ULA_&/I_.?'_P"/O4/2NYNQLMV[N'K/
M8V%VEF>S\[15F.S.^\CBX/%5;FR=%D,_NJ>.>J<F219<C6M<F\KGGV4S.)&+
M 4J:T]/\'0PM(3;Q)&S%RJA2QXL0*5-2>/'B>AU]M]*.JD>L_P"5G_HZ_FI]
MS?S,_P#3I_&/]+FRYMH?Z$_]&/\ #_[O^7:77>UOXC_I(_TA5WW=O[@^?P_P
M"F_X%Z-?[6N1<]YKA$-.!K6OS/E3Y^O1%!LO@WTE[KKK0+HT\,(*ZM6?@]!Q
MZ/'\NN@?]FH^,G>/QR_O9_<3_3/USN+8']\?X#_>?^[?\?I&I?XM_=[^,[>^
M\\6K5X/OJ75]/(OU]IH)?!</2M"#3[.C.^MOK(7AK36C+6E::@16E17CZ]!/
M_+E^&/\ PW_\2.NOBS_I(_TM?W R6^LA_?K^Y_\ </\ BW]]-\;@WGX?[L?W
MIWGX/MOX[]MJ_B,WD\7DLFK0KEW<?52%Z4K3%:\!3T'2;:-N_=5NL&K5IU=U
M--=3%N%3Z^O0#?.#^6)_LY?RV^#7RE_TW_Z./]DP[&V[O_\ N+_HU_OA_I)_
M@'9>Q^Q/X3_>?^_^U_X/Y?[F?9^?^'Y73]SY?&WC\3N6UY].CI2NL4K6E,$>
MA]>DVZ;-^\IX)M>GP7U4TUU=R-2NH4^'T/'H\'R:^,O3/R^Z9W;T-WSM*#>'
M7F\((1649FDHLIB<I12>?$[CVYEH/W:+(T4MI::IB-P;HX>)Y(W312M"P930
MCHTNK6.]C,4H#*PH0?\ 5@CR/EU01M3^1Q\\/CQB\GUA\/?YO?;G5W0.0JIF
MQ6PMS;%JLSE]F4=5+'-5Q[?RN-WM24T,\DC2SR3X>CVZ)';U)J+2$Q:_BE[I
M(@6]02 ?]7Y]!F+EVZLQHM[MUC\E9%<K@#!)'\@/\O1]OY<G\G/HSX ;CW%W
M'7[VWE\B_E'O>CJ:;=_?O9H495?XMX9MR1[0PLE;F9*!<E/$9:RIK<CEJZ4,
M8GK#$61D]U>M<T6@51P4<.C+:=BCVLF34TDK?%(YJQX8'&@J*\2?4F@Z-;\[
M/@?T-_,*Z1K.DN]\7D?LJ>O&?V7O/;E1!0[QZ^W9%2ST=/N+;=;54U9"6,52
M\-32U,,T%1$Y21-01T9M[AK9M2_[!'H>ENY;;%NL1BF%0<@CBI]0?7_BCCJE
M_ _R.OGQ2[4IOCYG/YQW=\OQ0IY#CIMEX':&9QF_:K92OH79%-NBK[(R3TM&
MU,?M33FHJZ%$]/\ #GA_8]KC?Q5U>$NK[>W]G#HA7E^Z \(WDGA5X!0)*5J!
MKJ3_ )*8I3HV?PH_DF=9_!/YR[[^6'3O:/VW6VY.FX^G]K] /U_/'4[5I_X?
MU?!7;ER/:M3V#DY,K5UE7UY49"LUX*C,D^6D;6/'^ZU/N!N(A&PR#4M7CQ\J
M?/I5MW+B;9=-<1M160((POPTT9U:C4G14XR3Q]1/_F*_RL_]G[[S^&W='^G3
M_1/_ +*3O2MW?_=K_1C_ '[_ -('WF\.N=U_P[^,?Z0MF_PK3_<#[?S?:Y*_
MW>O0/%HDK:WGTRNM*ZA3C2F"/0^O3VZ[+^\YH)=>GP7U4TZM7<AI74*?#Z'C
MT8O^8U\,?^' /B1V+\6?])'^B7^_^2V+D/[]?W/_ +^?PG^Y>^-O[S\/]V/[
MT[,\_P!S_ OMM7\1A\?E\EGTZ&:M+CZ60/2M*XK3B*>AZ5;OMW[UMV@U:=6G
MNIJII8-PJ/3UZ%?XY= ?[+_\5>GOC+_>W^]O^B?I;:G4']]OX#_ ?X__ '8V
MI2[8_O#_ ';_ (SF?M?/]MY_M/OZG1JT>9[:RW++XKEZ4J2:?::]*;.V^DA2
M&M="*E:4KI %:5-.'KT2_P#E,?RQ/^&N>I.SNK/]-_\ IR_TC]C0;_\ X[_H
MU_T9_P &\.V<3MW^$_PS^_\ V#]Q?^%^;S_<0?KT>/TZBHOKSZQ@U*4%.-?/
M[!T6[#LW[CB:+7KU.6KITTJ%%*:F].F_^8]_*&Z5_F"97:/:E)O7=OQW^4'6
M\,46P?D-UE&HW#3QX]ZBLP-!NS&P5^$FR%/CJR?[NAEI<CC*VG?4L%;''(Z-
MZUO6MJB@93Q4\.M[ML4>ZD/J:.5:Z9$PPXX/"HJ:\0>-"*FI!=P_R-OFI\C*
M+"=;?.#^;-V[W5\?,)7T-96]:;6V0VV<EO,8BJBJ,4VY,YD]V96"6>-HA,E3
MDZ'.R1RJ'C82 2A0+^.',485O4DFG1<_+MQ> )=W3R1U!**BQZJ&HJ034?+U
MH:U'5TN7^!_Q>S'PZG^![]:T%'\:WV+'L.EV;1SS&LQM-35:9BAW-1YJM^]G
M.<@RL29M,M.9IVR"_=2F20MJ0"X</XE>ZM:]'S;="T'TQ4>'I"Z?D.&>-1QK
MQKGCU2CU7_)#^?GQ8I,EUI\/_P";EOKJSH*JS59F,3LK<73U!NO(;9?(L\U:
M,?!5[MDH%EFEE:6IEQT.&CGE8S/ ).28/N$4_=)$"WJ&(Z#UOR[=6 \.VNV2
M.M0K1JY%>.21YYP /SST^]T?\)LNENYNE]PX?<?R7[9W7\LMY]@[8WYO#YC]
MP8Z?M7=V4I\#C,YB:S8V/V0^\]JQ4>$JH\ZTP@&5EG2:DI#)4SPTL$"5BW1H
MF!  4"F@8'VUSG''_/U>]Y2BO(B&=S*Q!\9^]L$X JH"T)%!0<.-!U=WF/C=
MB^Q_B1/\4>\=PGL#&;FZ.@Z6[&W?MS$2;"GW.LFT(MK9;=>$PK9G=1Q51,\9
MK:> UM>L$NE2\J+8EXDT/K7%#45S3^6>A&]L)X3%+W:DTN15:U%#3)(K]IIZ
M]4Y?R\?Y(?>?\OWY&[/[!V[_ ##-^[[^.^T:O?\ /+\;*S8^XL'M7=$&\]L9
MO"4)RM&G;N5P]/7T59DJ3)ODZ;#&2>;'*HCA2=Q&876X+=)0Q@,:=U?3\OY5
MZ#NT\N2[3*&6X=HAJ_2*FE&K3\9 (-#4**_*IZ-M\!OY6?\ LCOR>^:'R/\
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M+#N[;FP:$5F;R,U.L$24>Z>L&Q-:?+:EIZ^GKJEHX7/L\ ^JM J\4.1Y^?\
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MR_E<9;N'^:=\>/YC\'<^.P.-Z+V5A=H3]22[%J<C7;E.*'9JOD(MZ)NNCCI
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M;%I$5:&JQS>.28%RS(\:JWNVME95 [A0UK\QC(]>BK<-GBW*2*5RP,+:ETD
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M>^27\HSX_?*OXA_'_P"&7:_:/R&J>O/CC5[6JME[TQ.Z^O(.T<VNS=F9S86
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M4]2E?41R+?7WH@CCU96#<"#]G2U]ZZMU[W[KW718*+L0HNJW) %V(51S^22
M/]?W[KW7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K-!^MO\ EC4?^X\OOW7NE7O'_@31
M_P#+"3_K9[]U[I'>_=>Z][]U[KWOW7NJ4/\ A0ON#/[6_E2?(+.;9S>7VYFJ
M/<?22TF7P62K<1E*45/=6PZ6H%/D,?-3RH)(IGC?2XU*Y4W!(]F&V*'F4$5&
M<'/D>@[S5*T-A(R$J1HH02"/U%'$=!YMG<>X#_PG#J=U'.YD[H_X;:W;F_[R
M?Q2M_CW\:'5^:K!E_P",>?[C[KS?N_<>3R:_5JU<^]E1]52@IXE*>5*]:$K?
MNG74ZOI=6JIU5\*M:\:US7JG#^55\-_E'_-H^'&T-L_(KY4=P=4_"[I#)]A=
M9;7V5U?EI*7?G?N[]Q;NS/8F\]V=A[JW1)GX:R@QJ;_7 T<-909" I2&*&*"
M2&IDJ5UY,EC*="J6-#D87'D!3.*UZ#^R64^_6BB>618AK6BMWRDL22S'5VBI
M733RKTE_F5\6NV?^$[/;GQV^2/Q&^1O;.[?C9V!V.FW^R^G]\YK%M4YVLQ:8
M[-YW ;BQV%QV$PF4AS>%Q,\%-DUQ%%5X^:B0K*2\+I:"8;J&1U 8"H8?ZB>)
MZ9OK-^3WCF@D<PLX62-B#4G)( "BI5<&@((&2#0;17\T/YUT_P #O@YV'\D\
M%28_*[UK*3";2Z<Q&:5?X?DNQM]I)'MJ?*4)K**2HIL=!'59BMHX94DEI\=+
M&K)J,B%%I;_4R!/V_8./KT--ZW']UVSS@5(%%'D6.!7(Q4U/G2O5$_Q:_D<[
MZ_F.=([+^5?\T#Y>?*+=O8/=V,H>T=H]?[*W;MG$8W8VU=U8ZDK=KRUU#O78
M^],?1U57CYHYSB\-BL3!1131TX#-&X!A+N M'*PHH Q4BI/Y@\/V]!FVY:?>
M(EEOYI2ST?0I"JH(QVE2 :<: 4K3YD6_C%U'\_\ ^59_,>ZU^+>V\Q\COF)_
M+M[WQ<4L&[<WMO.[YAZ%R%<:K$19'<FXL;1Y6GV^V(K<?2FO.O%8VOQ^2\\5
M/]["R0-3/%=Q%Z*CJ> QJ'V?\6<?9TLLX;O9[Q8*R36\@)UMW&-@/-O(8'&@
M-<9!J4_^<EVY\JMC?SQ/C=M+XH[MS.+[3[$^..U.KNO<9+F<O#M#$[T[PK._
M>G*??V6Q--%DJ4-@TW:N9^^GH:E:<XN.>5&C@(]J;&*-[=C(!0-4FF:#2:5Q
MQX?GT6\P7=S#N<4=NS5:(*%J=(9S(NHBA!TUU&H.%ZLN^ ?\AW*?"GY1;.^5
M.;^:7:?<.ZX]O[G7M+;=;CLYM?'=C;RSV$DQ5!E\[FZ?L#*U&3H*!LA5SK09
MJ*N\T_V]09(S"8Y$=SN'U":-"@5Q3R'[//'"G1UM?+?[MF\<S2.Q6CZB:.U
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M+99 TDGP+Q^9]/\ 5ZCJ_,.ZR6QCM;:GC3&@/'0M::B,GUS2E Q\J= CA_\
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M+:]#!A'87.J&0Z5[5\A\5%/'UX=1GS'M8BO+<>)*?&E-:O7PZNGP8[::L<>
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MZ1<PVKW6ZPHCM$6CHL@K4$>(<4*Y\L'SZL"_X8K_ )B/_?0!\T?_ #A[Q_\
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M,G-5U,6/R-#N6CJ8Z6>>I>FE::F,]0(1/(@OK7Z233Q'$'Y="+8-V_?-N)2
M&!*N!6@84.*^1!!\Z5I4TZM)]H^CKK4C^;/_ '% _P OS_Q"^S_^M?R5]G=O
M_N&_^F_Z!Z VX?\ )<M_^:1_P3=;2_<'_,I>T?\ Q'6]O_>:R?LF3B/M'0W?
M@?L/6M;_ ,).?^R'?D%_XM;FO_?0]3>S?>_[5?\ 2_Y3T"N0O]Q'_P":S?\
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MCJ7-97QA")LQB)L9F9#H4%ZYP+Z3[*+Z#Z>4KY<1]A_U4Z&?+^X_O.T20FK
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MRR6MVH66,!NWS7%:Y85%0:@T(.!@UV*O99T*NO>_=>Z][]U[KWOW7NGG;_\
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M_BB2YO=I&8 $F@X#R'3*6\<;,ZJH9J:F %6I@5/$T\O3K6$_D&?]O//YS_\
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MFDHZ1?"E)+F.VC,<-26^)CC%/+A_J]>G;;;+K<KE+J^"((ZF*%2&H:\6.17
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M)R&?Z[W[@L33_=Y7-;+W3B<92^6"#[G(9'!UU'14_GJ9(8TUR3*NN1T47NQ
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MGD?=S$%5)%% X.*UH0:8^7IQZIMEX\DLUM(=30E*/0+J61-0K0TU"AK0 '%
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M.#_FC'_QP='U]INC/K3P_D-_]O?_ .;O_P"'KW'_ /!/[@]G>Y_V,/\ I?\
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=9H/UM_RQJ/\
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MII_,9'<AE57KV%82FC@45JGB:D](=AO9KU9C-34EP\8"\%"A, T!.:Y.3\N
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M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW029S_B[5_P#RW/\
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MO_=5S_QM%\Z/_F7>S#</]#_YI)_EZ#?+G_$K_GLG_P"?>AI_EF/+V7A/E/\
M+JM+S/\ +#Y6]GY[9E6\@F23I7I":D^.?4'V51?]REJZ'JZHS5.Z@1L,P6BU
MQE9I4]QVZ5QVJ/VGN/[*T_+HRVVL@DE->^1J ^2I^F*<,,$U?[;HO/=O=G<_
M\S3=.]/B7\),_4]??%K$9G*=??+;YT4@1_XM0TXI*?=_1_Q-D'W$.3SE5%53
M8[+[FEC-#CXI)6IWFG\ F=B5;;OD%32JI_@+?+S XGY#BDNI9=S)AMSI2I66
M8<<<5C]6\BW!<TJPH+=^G^I=A=#]7;#Z:ZNP4&V>ONMML8O:6T\) SR"BQ&)
MIU@@\T\A+S32$--43N2\LLCR.2S$^TCN7))R3D]',42P*$0450  .  QT)'N
MO3G7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6:#];?
M\L:C_P!QY??NO=*O>/\ P)H_^6$G_6SW[KW2.]^Z]U[W[KW7O?NO=:_O\^OY
MU_+S^7ML7XX]T?''<.U:79&Z.Q,[UWVEM[=&S<3N$Y/)S8>GW7L_^%9BMIY9
M*$S4FW,]!46\E_V7108WU&.W6J7;,K5K2H(_9_EZ#/,VZS;-''+'I(+Z65@:
MFH+"AKCX3Y'B/3-[VS=U8K?6S]J;VP4RU&$WCMO!;JP\Z21S)/BMPXNERV/F
M66%G1@T-6C!E)!O<$CV7D4Z$H.H5'6NA_/%_F??+/XD]T_'_ .._PBEVM7=G
M[GZI[>[N[0P^6VEB]Y9@;"V;BZW-8>LQE'EIH8H4@H.N]WUU0D8EGJ!1(D*Z
MU5)S/;[-)U9Y*@ @ C J?R/J.@GS'O5QM\D<-J%9V5W92"3I45% "/(-ZDTH
M,]6A?RI_EYF?G'\$>C?D)NYZ1NPL]C,[MKLM**BIL=2?W[V3N3*[7S=;2X^C
MO%!#7C&Q9*GAC-HXJU$-F! 27D'T\C(. X?817HYV6__ 'G:QSG!8=W^F4E3
M3)Q48^70"?SPOGIV!_+[^&5/VAT[E\-B>X=Z]K;-Z[V'+G,!2;FQZBII\QNC
M=%358FM/B,:XO;-3")7!"2U$0'J93[=V^V%U)I-:4)-,?ZL])>8]U;:+8RI3
M6655!!().3PI^$'H.N\\O_.OW%\8/@UN;XDY#IK)=T;JZHR.Z_EO-V!C=B8B
M@IMW;HP?7&?V=B=KX[*4]-!%%029'/T4PI5-Q3PM*\C$.WHQ &8/KI7MI2M,
M\?Y=;NCN!BB,'@Z]-9=>JFJB_#3RK7C\NJM/E7\I?^%)'PSZ0W5\A>\LC\9<
M3UKLVKVY19RNP.$ZSW%DX9]U;BQFUL0(,307ED#5>7@5ROZ5)8\ ^UD$%K<,
M$7Q*FO&GD*]$>X7^[;9"TTGT^E:5TAR<D+YD>9Z4WQ\[X_X4Q?)WICK_ +[Z
MHK/B_D.N^S<*VX-J5N8Q?6&%R51C175F/\E7BZK]R%C)0R>A^;6/Y]UECM(F
M*GQ*@T/#IVUN=XO(UE3Z;2ZAA776AS\^KX/Y<?\ PXY_H][!_P"'(_\ 1S_I
M'_OG2_Z/O]&G]U?X-_<G^"4GW'WO]V./NOO_ #ZO-SH\>G^U[+[GPJCPM5*9
MU<:]"/;/JM!^K\/5JQX=:::#U\ZUZL6]I^C'JJ3X*[P_F;;A^2WR_P 7\TMD
M8S;'QYP6[<K3_%'+T%%UQ3U&Y-J+O[=E/CJS(S;0SN6R#2?P.GQ4H_B4-(Q,
MSED\FI467"Q*JF,DL1W#.#0?(=$^W2WCRS"X150-^B12K+5LFC'RIQ X]6M^
MT?1QU[W[KW7O?NO=>]^Z]U1A_/O^>'R&_E_?&/J3M/XWYO;F#W;N_OC'; S<
M^YMKXW==%-MRJZ^W[N*6&&BR:E8Y?N=O4S"5>=(9?HWLQVVU6[<JU:!:X^T#
M_+T&^:-VEV>!9(M-3(%.H$BA5CY$>G5SO7.7K]P=>[$SV5F6HRF;V;MC+Y*=
M8HH%GK\EA*&MK)EAA2-$#23,P5%51>P 'LO84)Z$:FH'2R]ZZWU[W[KW7O?N
MO=>]^Z]U5)_-W_F7C^6+\>=O=HXOK,]H[W[%WD>OMB8>OR_\$VKC,U_!<AG9
M\UNVKIUFJY*6"GQTA2DHT62>33$9Z96,RK+*T^L?36@ J3T2;]O(V2$2Z=9+
M!5%:"I!.3G% ?+CCY]&N^<_:^\^AOAC\H^Z.O*RDH]^=4=#=G;^VA79*@ILI
M0P;CVIM')YC$SUV-J$\4\8GI$,D3 *PN.+^V;=!+(JG@6 /YGI=N,[6MO+*M
M*I&["O"JJ2*_LZ*O_)B^5_<GS4^!NPN_^^,MA\SV-N3>796(R-9@<#C]MXL4
M&V-W5^$Q4-/BL:B1J5AI%+L=3,Q))M8!Z_@6VD*+6@IQ^8Z1[!?ON=JDTE-3
M:JZ1088CU/IU:K[1]'/7O?NO=>]^Z]UIK]I?\* /D'\8?YM':'0O=E?M?.?#
MG8W>&;ZWS-#B]EXNCWGM3:56L%'C]UP;@I/%/5MB)JM*NH@D#M44\4L:_O,C
M [CVQ9H ZUU4K\C0GH"7/-;V.X-;RA?"#!:@49=2@U))I0$YQP_GN+X?+XK<
M.(Q>?P61HLQA,YCJ'+X?+8VIBK,=E,5DJ:*MQ^1H*N!G26&>&9)8I$8JRL&!
M(/LDZ'0->J6_Y]'SC[_^ 7Q!ZX[C^.68V]A-[[E^26T.L\K5[EVSC]U4$FU<
MSUAW#NFNIXL=D@8TF-7LVA99AZ@J,HX<^S#;;9;MRK5H%)Q]H'^7H.\S[K+L
M]NLL6FID"G4"10JY\B/X1U9=L_L+=&:^)VUNUJZL@.],M\>,)V%69"*CI8Z<
M[HK^MJ7<E161X_QF%4^[E+B'04 ]-M/'M%3NI\^C]6)0'SI7^756_P#(0^>'
MR&_F _&/MOM/Y(9O;F<W;M#OC([ PD^V=KXW:E%#MREZ^V%N**&:BQBA9)?N
M=PU+&5N=)5?HOM=N5JMHX5:T*US]I'^3H/\ *^[2[Q TDNFHD*C2"!0*I\R?
M7J\_V7="3K7;^87\QKY/]-_SJ_B#\(-C;AVO1]!]Q[<ZJRN]\17;/Q&1W#55
M6Z=V]E8G,B@W+4QM44Z20;6I54)^@ARI!;@RBM%>W:4UJ#0>GE_GZ#%YN\L&
MY16BZ=#IJ-0=5?U.!K_1'ET:S^=Q\PN[O@Y\(*WO7X_Y?"87L&F[5Z_VJE7N
M#;V/W-C6PVXOXTF3@?&9)6CUM]I&4D%F4KP;$@LV$"W,@1JT->'R'2WF#<)-
MLM6FCIJ!6FH5&6 ]1Z]5-]-=L_\ "G/OCJ;KCNKKRI^+5;L3M79>W-_[/J\E
M0=78O(5.W-TXNFS&(GK<;4_N02M!5H7B?U*38\CVKD2TB8J?$J"0>'ET36UQ
MO%U&LJ_34=0PKKK1A45_;UB[>^5/_"E;X;;)RG?/=74/QT[<ZCV1#)G.Q*3;
M&)VMF9MN[4QB_=9C,Y*EV%NK;N7@I$@$CSY"GAKHJ18C/4HD*,6W%#:SG2I<
M$X%:4K^S_-U6ZO=WV]#+(D#HN7":JA1DG)'EZ T].KX/Y:_\P7K?^9%\:L1W
MQL;$56S\]C\M4;+[1Z[R%8F2J]B=@8RBH*_(8NGRL<%(M=CZBGR5/6XVO$,!
ME@G42Q05$<\$2"[MC:.4.?,'U'0AV?=$WB 3(*>3*34JPXC_ "@XJ"#0<.K
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M=85"I<W:J, "8  ?(!.K8OCETA_LNO4>W.I?]+W>7>O]W:G.U/\ I,^1N_\
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MT?\ 6K1_PK&_[(=^/O\ XM;A?_?0]L^SG9/[5O\ 2_Y1T".??]Q$_P":R_\
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M"<U_F?\ #^72\;M?['*B7^B2.0T\5:#2309P@H.)JM:$D$TIUM[JP8!E(96
M964@A@1<$$?4'V2=#KKOW[KW6B'L_P"%G7WS\_G7_P X7XY[^$5%-G>G>ZL[
MU_NMHWDJ-A]FX3N;XYG:&\*58B&98)*N2GK(E_S]'55-/<"6X$/CFVMHG7R;
M]H[^HW&WIN>ZW<,G!HL'S!!A((^P_P";JQ3^0A\W]]]6;RWS_*!^8<Z[9[U^
M/N7W%AND'S-5ZMQ[:V_YLCG.M,?D*F2,UC8^F+9K;CQI:HPTDGC"PT4>M+N-
MN' GC^%LGY'_ %?SZ->6=R:!CMUR0)8L)Z,@%0 ?,@9' Z?+!Z6O_"KS_MW=
MTS_XNCUW_P"^.^1?O>R?VI_TA_PKU3GS_<-/^:R_\<DZNVZX_P"R"-A_^*A;
M7_\ ?,T/LK_'^?\ EZ&"?V8_TH_P=:OO_":_YP?$3XP_$+NS9OR$^1/573^Z
ML[\D,MN;#X#?>ZJ'!9/);?FZQZUQ467I*6J8,\#5.+J(1(.-<+C\>SO=[=YI
M 54GM\A\ST N2]QM[2U=99$0F4D!F"FFA!7)^76Q3_P[G_+)_P"\X_CG_P"C
M%Q'_ $?[*OHIOX&_8>A?^^[/_?\ %_SD7_/UK2?*7Y!](_)7_A1K_+V[!Z"[
M0V;VWLFDP_2NV:K=&Q\Q3YS#P;@QV].W:ZNQ$M93$J)XH<K32O']0LZ'\CV:
M1Q-%:.&!!KYBG\/01NKJ*[WJW:)U<>'2JD,*_JFF/MZM7_X4[?\ ;K[+?^)X
MZB_Z'W%[1[3_ &X^P_X#T=<X_P#)/D^U/^/CJR7^5G_V[:^"?_BJ71O_ +[W
M!>TUY_:O_IF_P]&NR_[AP?\ -&/_ (X.AO\ E7WITS\<^@>T.U.^]R[=VYUM
M@-GYT9I=Q5,:1;A^[QT]'3[3QN/M)-75F3DJ$HJ:AIHIIII)UC1&+6]M11M*
MP514GATKN[F.SC:24A545)/^#[3P &2<#K6?_P"$E&P-]X?HOY=]DY:3(1]=
M[Y[,ZTVSLFBJ8*J&A?<>P-N[LJ]]YG&R2A8Y1/%O?"TDLD5[/C]#&Z64WWMP
M74#B!D_:<#_5Z] OD*%T@D<DZ6<:13%0,D'SK4#Y:>MN;V2=#SJG+^;I_-'R
M/\OG:O56P.G^O(.X/E;\D,Y5;7Z2V#7Q9*IP-/40UF(PW\?W#18>>BJJWR9#
M<5#0X[%4U31RULTKA:B)8)&]K;*T^J))-%7+'SI\OV=$.^[S^ZE5477+*=,:
M^1.!4\, D8J":^62")9#IO\ X5+;KHAOVE^6?PUZVEK:6FR0Z6Q^VME5E;BY
M"L<TF!.3S'QFW["9?68Y&.[*A+J=%1]&*D26:XTN?G_Q3#_!T6/;[W(P82VZ
MC'8 :?SC8_L;[.AL_E ?S6OD#\H^[>]_A!\W^L]O]:_+#H#&Y',U4^VJ*IQ=
M'NG&[:W-2[5WK0YG$1UN:Q\%;C:G.8J6DK<7D)J3)TM<U12Q)#3^:HI?62PJ
MLD9JK?R_U9\L=*-AWV6_EDMKE DT8J0*T(K0XS2E5_$=5:C'0/\ \RO^<)W_
M /!'^:)U)T7B,"O9'0FY>@Z7=57U%MW:V)G[ WYVWO.F[FVGUMM_#;MFCDJJ
M2"KW+AMMQU/ACG9(!4&.&9F$+WM;!;B$O6A!I7RH*$_RKTUNW,$FVWT<% R,
ME: =Y<ZU4 U RP49]3TF-]8O_A4AN/ U'?>W-^?%WK>DI\=#NF#XB[8PO7N>
MWA/1TSRY@[/J,GO#J_=R35\L++05"P[\I2S):GDAF.OWM#9CM(<^6O@/2N#^
M? ]-3)O<GZJM"@ KX(R3YZ22AS^$D.!Z4X]'Z_DO?S0<]_,DZ8[$':NT<'L+
MY"=#;GQ&T^TMN[?3)4>+RE%G:"KDV[O&EP>8DJ*K&M5U6!RU%58Z2>I\,V.=
MA(%E6*--?6GTC"AJK"H/1IR_O)WB)BZZ)$;2Z^A]:'(!H<'@01FG1:/GS_-4
M^4F;^8V._EI?RN=A[3WO\D:*!:GN3M7?E''6[.ZIII\70Y6JBQL>0K*2@U8B
MER]+69C)UL>2ACDE3&4U!5Y%S%&[;6:>'XTQ(7R XD_ZA_Q723<][G-R+.R5
M6E !D9_A133YBM-0).:< "> %=E]O?SXOY?G5V\>U/F]D.B/G)\:JW 9C#]J
M5?1N-Q6"[1Z>P>XL3-A(]X4M/B>H^DZ>HHJ">I2:M\F/RT81V,U310!JF!P)
M;73 151O+5\)^7%L])_J-SVA#)=Z)XQ748Q21!3C33&"H\_/-:T'3A_PDY_[
M(=^07_BUN:_]]#U-[MO?]JO^E_RGIKD+_<1_^:S?\<CZVE_9-T-^M6C_ (5C
M?]D._'W_ ,6MPO\ [Z'MGV<[)_:M_I?\HZ!'/O\ N(G_ #67_CDG3;UYW/\
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MFC5M:C[F4!?4P)UM@U13 _P_Y&Z W-!T7MDPP?$(J.--<>/YG]O2R_X5G_\
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MP?\ [K*7V3GCT-APZ4GO76^M13^6=_W$I?S0_P#Q$W=O_O[OC1[.KG_<./\
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ML?'2Q@K'410E;FTNU2U)%"O$-4 4XUR>JVG-UHR*KZDD^$QZ')##%!I7.>'
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M/RR_[BD_@+_XKLO_ +R'RO\ 9Q!_N$_^F_RKT";_ /Y+EO\ \TC_ ()NA_\
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M_P"*>_=>Z]_!\I_RH57_ %*;_BGOW7NO?P?*?\J%5_U*;_BGOW7NO?P?*?\
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MG_X*OHWV8;5_;K_MO^.GH-\W?\DZ7_FW_P!74Z,A_)M_[=8_ _\ \5OZ]_\
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MO=>_@>6_Y4)_]LO_ $=[]U[KW\#RW_*A/_ME_P"CO?NO=>_@>6_Y4)_]LO\
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M"?\ VR_]'>_=>Z]_ \M_RH3_ .V7_H[W[KW7OX'EO^5"?_;+_P!'>_=>Z]_
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MR?\ RWG_ ."KZ-]F&U?VZ_[;_CIZ#?-W_).E_P";?_5U.C(?R;?^W6/P/_\
M%;^O?_=:?;%Y_:O_ *9O\/1ALG^X<'_-*/\ XZ.K+O:;HTZ][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>ZH!_X5'?\ ;BCYS?\ ELW_ ,&'\???NO=?(%]^Z]U]J?\ D>_]
MNA?Y=7_BJ75'_N@A]^Z]U:C[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z36\_^//W9_X;6=_]U=5[]UH\.M>+_A*Y_P!NJL;_ .+"=Q?]
M"[6]F6[?VY^P?X!T&.3O^2?']K_\?/6R%[+>A1U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>)MR> .23^/?NO=)S(;FH*/4D!^\G'&F)@(5/
M^US6(_Y)#?XV]H)]P2+ [C\N'[>E\&WO+D]H^?']G2(K\UD,@2)9BD)_Y1X;
MQQ6_HPN2WT_M$_X>R>:[>?B<>@X='$-HD' 5/J>/33[3=*>O>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZET==54$@EI9FC-QJ6
M]XY /Q(AX/\ L?I^/;L4S0FJFG^#IJ6%9A1A7_#T(&*W)35VF&ITTM4;  G]
MF5CQ^V[?0G_4M_L"?9W;7ZS8;!_D>B2YL&ARN1_,=*7V8=%_7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=:F?_"D[^:-\/J?XD?(C^7=M_?==OWY,;YJ>J*7)X+8V-@S6U^LZC9?<VP.
MRLM1]E;MER%%2TE8:/8]33C&4/\ $JZ&IJ*=:NFIH9&G0YVFT<R"6E%%<GSP
M1C]OV= CG'>(%MWM-59&T=HSIHP;N/ 87AQR,4->A?\ Y"7\WOX7=K_'3XQ?
M!%]X9SKKY)=8]7X/KRDVIV/B:3"87L[*;8H(ONY^L-UT&4R]%6M*LUX,;728
MW)2F&8PT4D41E+6XV4D3-(1522:CRJ?/_53Y]*N6M^M[N*.V!*R(BKI84U:5
M )4Y!^S#8)I3K9M]E?0MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZH!_X5'?]N*/G-_Y
M;-_\&'\???NO=?(%]^Z]U]J?^1[_ -NA?Y=7_BJ75'_N@A]^Z]U:C[]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z36\_\ CS]V?^&UG?\
MW5U7OW6CPZUXO^$KG_;JK&_^+"=Q?]"[6]F6[?VY^P?X!T&.3O\ DGQ_:_\
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MJQ)^ >7<_P"I1!<D_P"M[;EE6$58TZ<BB:8T45Z0.3W/4U>J*CU4D!N"X/\
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MX'Y=1QN/),=O!))$TC."610*C37"T +$T\Z_EUL"?RZO^$[7SC^67:&U:WY
M=3[]^*WQWQ^9AJNPMT=M8"NV-V3F,)CJPC([:V!UMN2FH\O_ !&N$/@@R.2H
M:6AIXY35AZHQQTE2KN]TCA!"'4WE3('VG_-]F.B79^4;F]=6F4QQ@@MJJ'8
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M/_CS]V?^&UG?_=75>_=:/#K7B_X2N?\ ;JK&_P#BPG<7_0NUO9ENW]N?L'^
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MZ][]U[J@'_A4=_VXH^<W_ELW_P &'\???NO=?(%]^Z]U]J?^1[_VZ%_EU?\
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MRG_RN?\ U&7G^"?K*[F?_E4_^H2U_P ,/5RGO,#K%'KWOW7NJ:^I/^RRH_\
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M/<;[AM]IO>\QP<N)*J$QZ2=9TN#5I!K)8(N#5CBA/"G4@6%[=;/M+S;^\;.
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M+C<'C*2NFHZB./,)A(:W(5L:1I4YXQ@4L/NO= [_ ,(E/^R%/EO_ .+:1?\
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M3(4,<B,5='JX$=&'!5E:0$$?T/MHSHIH64?F.G1 ["H5OV'KA_%L5_SL\?\
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MZJ!^2_\ V5C2?]K+KG_K3B/>)?N/_P K;'_I[/\ PIUE'[>_\JR_^ENO^?\
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M]U[W[KW3?EO^+5D_^U?6_P#N-)[9N/[-O]*W^ ]/6_\ :+_IE_PCJIWX#_\
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M([.S$DCN9"6/$]'B((P%' ="M[KU;KWOW7NO>_=>ZI][$_[+AQ__ (EKJ_\
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MCH,?-5204<LD6E89&'NO=4:?] 5/\K+_ )_Y\_\ _P!&G\=?_N5??NO=>_Z
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MEEU14;?43XK&X[(]?;IHLKO39L,,-/33U$.,CQ-%#*X6*NJ 96?W7NFG8_\
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MO59.658(*<Y!:=*J>0VCAHZJI6&&9V/"K%(Y)( N2![#=ISQM%]*(8KN!G)
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M4QV%H*K*9:MIL=CJ*(S5595RI#3PQBPN\CD"Y) 4#DD@ $D#W>*)IF"H"2>
M&3U22585+.0 .). .B'=K_)K)YPU."Z^>HP^'N\,^X"&@S&23])- I"M21'D
MAO\ /,+&\7J4CK:N6U@H]Q1F\E_"OV^I_E]O0%W7F1IJI;U5>!;\1^ST'\_L
MZ*2[O([R2.TDDC,[N[%G=V)9G=F))))N2?8K IT%2:Y/7'W[K77O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]T8SH[O&KZ]JX]O[@DGK-EUDY_#S5&WJB9[O6T2#46@8MJJ*=?\
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MO]*W^ ]/6_\ :+_IE_PCJIWX#_\ ,X=R?^(US'_O4;.]XH^PW_)8F_YXY/\
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MOKC=NWLO3;CP^0[8WQ@:^1,]7TM114Q;#8F48M'BD2>KRT$OBC:NMQU55.'
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M7XA?"S^9O\-Z_J_LWY#;)ZMZ?S_9^U]QUG>'7.[.J(_NMS[5J,G51;=@WIN
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MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK,^?'\UCXP?
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M=?1XZE5E1JFOJH*.G#N;(AFJ'C6Y_ OS[]U[IC_OOLO_ )Z_:_\ Y_\ $_\
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M+^<K_P \'T+_ .CXVW_]1>_=>Z]_T")?SE?^>#Z%_P#1\;;_ /J+W[KW7O\
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M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z$':-'XZ::M8>JH?QQW_XY1$ZB/\
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z36\_^//W9_P"&UG?_ '5U7OW6CPZUXO\
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M6QLAU_V5L%MT24T%-,QI:7);NQ\=7)J18HZDRO\ MH[)[KW6F_\ *7^?KO\
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M(SX6@6*-@+,WFC(!X8'GVQ'RKLLYT)*"QP LZDD_(9Z>?F;>(06>$@#))@D
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M,.[-C;8Z$QN7QV P\]?59O;E%3[&S>T:A8<@9XHFACJH(E1>58*J'W7NA?\
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MK4J\<+&G"I>,GU\^B2_R;NZ>H^G_ /9C?]*?9.R^O?[Q?Z(?X%_>_<.-P/\
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M\R_Z _\ #QWK_P"Z3"^PC[;?V\W_ #37_CW0J]P?]QXO^:G_ #Z>BL[ ^?\
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MZAS-)!45%)@/DWM:/)&*">H%'2Y7K'M6F@KZRH4.(HA/#%3^24@-+4QH#J8
MP_['2JFZRJ2 6M7I4@5(EB-!ZFE3]@)ZEOWJB9]JB8 D+<H6H": QRBI]!4@
M5/F0//I;_P#";?<5!F?Y>^;Q=*LZ56TOD3V/@\F)Q"JR5-9MCKW<\,])XYY6
M,)@W#%'JD6,^2.50I50[(_>FW:'>=1I22WB84] 73..-4/KBG2OV>N5GV<**
MUCFE1J^ITR8SPHX],U^WK6Z_G88FMWI_-S^1>W-N(N0RVXL_T+MC%4Z.%%1F
MJSH?I_!PT9=K '[IO$Q/ (/N;/;&9;3ERWDDPJ+<.W^E$\S'^74,^Y$#7G,4
M\299VMT7_3-!"H_F>OHA@!0%%[  "Y+&P%N68DD_XD^\..LNNM;+_A3K_P!D
M=]$_^++8S_WUW97N:_8S_DIS_P#/*W_5V+J'/>S_ ))D/_/4O_5J;HSG_"?/
M_MV9UC_XD#M[_P![K)^R#W=_Y+L_^DA_ZM)T>^U'_)#@_P!--_U>?J[+W&?4
MC=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TJ
M]JX[[BJ:MD6\5(1X[CAZAAP>?]0.?]<CV9;;!K;6>"\/MZ+-RGT+H'$\?L_V
M>A%]GW1%U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=$#_F>?/?9G\M#X5=Q?+S>6WI]Z/L"@Q>,V9L2FR'\
M)EWSV)NW*TNWME[9ER_VF0-'2RUE<DV0K%IZAH*2"HF2&9T6)_=>Z^>?N+_A
M95_-@R>;RE?@MG?$;;.&J:ZJFQ>!BZHWMEOX7023R/1T4F4R/:KRU#QQLJ/.
MPCUE2P1+Z1[KW3%+_P +&/YO$D<B)0?$Z%G1T6:+I;<ADA9E($L8F[-F0LM[
MC6C"XY!''OW7NMTO_A.-\F_GK\N_A)VOW?\ S"EWZ.T]R_*[?7^C0[XZH@Z@
MI&Z-?J3H[)[3'7^WJ7:VU(JO;R97)YV*BRBI6&>9*A9*N>6*0K[KW5_WOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J@'_ (5'?]N*/G-_Y;-_\&'\
M???NO=?(%]^Z]U]J?^1[_P!NA?Y=7_BJ75'_ +H(??NO=6H^_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDUO/_CS]V?\ AM9W_P!U=5[]
MUH\.M>+_ (2N?]NJL;_XL)W%_P!"[6]F6[?VY^P?X!T&.3O^2?']K_\ 'SUL
MA>RWH4=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T&6ZH]&6=O^.T$
M,G^V!B_H/^.7^/L/;D*2_:!_F_R="';36+["?\_^7I.>T'2_KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z!_OK#'-]3
M;P@1=4M#0Q9F(VN4&&JX,C4L+ _[HIY5/^!/LVV*;P;J,^IT_P"] @?S(Z*=
M]A\>UD'H-7^\D'_ .JI_<I=1;U[W[KW7O?NO=>]^Z]U[W[KW11?F'\X?CQ\&
MNN)^Q.]]X)C7J(:K^Z6Q<(*7)]@]@9&F5+XK9^W9:NC\S:I466KJ9:6DI]:M
M45$2D$L3W"6PJQ^P>9Z?@MWN311]I\AU4O\ +CL3MO\ G+_R[\?G_P"6_G-R
M8.&?MZKV9W;UIO#/8OK3=&?P>,VF]3F=AY/+PY:MQL\&K=&'KYJ0Y-*:KII@
M'=GC-.R*=VOXJQ>M"#CRX?SZ6P*MA+27TJ#2OGQZ9?Y<O_"?WJ;X_O@NV?ER
MV![O[BI)8,IB-@0Q25?4.P:L0KXA5T=:D9W)7PNSL)ZZ&.BC8J8J1Y88ZIM6
MFV+%W/D^GD/\_5KO<VD[8\#U\S_FZV.8HHH(HX88XX888TBBBB18XHHHU"1Q
MQQH %50     ![->BGKG[]U[KWOW7NO>_=>Z][]U[KWOW7N@_P"U>M-K]Q]<
M[QZOWI2&LVSO;!UF#R<:$+/ )U#TN0HG8,$J*2>.*JIG(.F6%&L;>U-G=O8R
MK-&:,C!A^7^0\#\NF+JV2\C:*055P5(^1_U8ZU4=\=(?+K^6OW&^_P#9L><D
MV]BZBHBP_9V$Q$V5V'N[:TLT$DF'WO0Q&KBI/.NA*B@KVB=98S-1RL8HJH3;
M;;E8<X6_A2Z0YXQDT=6SE#Y_(BOHPS3J'KC;;[E.<RPZB@_&!5&7!HX'#\Z>
MJG%>ANS/\Z_Y(U^W&QN+V#U+@MP2TT<$FYH<=N6O$$WB*S5F/PM?N*:%)"UF
MC6H:JC7Z,DGX+H_;BU5ZM)(5K\/:#^9I^V@'Y=+W]P;ADHL48;S:K$?D*C\L
MG\^DY\2/@?WG\N>V8NZ_D-1;FQO6^0SR[LW=N/><=3CMQ]H3^4U(P^W<?4P1
M2FCJ&B2":L$<%/#37CI&9T2-'-]YGM=BM_IK,J7"Z5"96,>I(/'S J37+?-O
M9>6[G>9_J;P,$+:FUX:0^@!&%Q0X TX7Y7,_S1:>"D^ _=U+2PQT]-30]64]
M/!"BQPP00]P==QQ0Q1J %554*H L +>P#R4:[I"?^:G_ %:DZ&_.'_)-F_YM
M_P#5U.B _P BC_N:7_RB'_S7O8I]S/\ B-_S>_ZQ=!GVZ_XD?\VO^LO5MORY
M^-6V_E3TKN/K+,FFH<WI_C6Q-R30B63;.\:"&7^&5]PK-]O,)'I*Y%Y>GGD"
MVD",H#V/=WV2X69,C@ZUIJ0\1_E'H0.AQO&UIO$#0O@G*M2NEAP/^0^H)'6L
MO\,._-W?!3Y09#;_ &-1Y#!;:K\N>NNZ-N5":I,:M%7RP46XTC5BLCXJ>9JF
M*6(N):6:=8BPG4F8>8MLCYGLA) 0S >)$?6HROYTI3R8"OGU$_+^XORW>&*8
M%5)T2CT(.&^P5K7S4DBN.K(_YWU929#K3X[5]!4P5M#7;HW=64592RI/35=)
M4X#!S4]33SQ,RO'(CAD=20000;>PA[;@K<3 \0@_X]T+/<$UMHO^:G_/IZ.[
M_)[V_E-U?#GIO;V&@-3DLKN3L2EIH^0BENP=RM)/,P!TQQHK22/_ &54G\>P
MW[@7"VNX3R.:!5C)_P"<2?S/ET?\BV[75C!&@J6+@?\ .1_\'0Q?SU/Y:>.[
M ^,. ^0G4F!%;VK\:\%5G?CT%'3KE=^]12S397<U?7276267;U3-/EZ6,NPC
MHY\@B*[>%0'_ &NYZ:TW!K6Y:D-RPT5)TQR\%IZ:Q12?,Z230'H1^Y7)"W>W
MK<6ZUFMEJU -4D7%J^NDDN!F@U "IZ)!_P )^_YE^#ZE.X/AMWONB#"]?5D6
MY=_],[IS-5%3XO:N7I*.LW%OG8]74SN@BILC'33Y6@' %8M3&-4E;& )?>'D
MEKPKNEJM7[8YU J6&%1_RPI^6GT/0>]HN<EM@=LN6HO=) QH .+.GYY8?/5\
MNJY>E,-F?YLG\V^CSNX\;63[6[<[HKNQ]Y4%90QS_P &Z-Z^1,A3;7S/V]:T
M45]O[;H-N+4>>1145,1'F9E1QINDB^WG+GAH>^*$1(0:5GEK5EJ*X=FDI08'
MET#=L1N?^8O$9>R2;Q7!4&D$5**PK3*JJ$U.37/#K=V_X;5_E]?]X7_&G_T3
MVR?_ *T>\7_ZZ[Q_RFW7_.>3_H+K);^I^T_\H=K_ ,X(_P#H'JDG^>__ "U.
MA=G?$.@[\^.'2/7G56<Z4WE05.^X>M=G8S; W%U[OB>AVQ63Y:FP$%(M2^-R
M;8N>&2>.7[>"6L96C1Y2TG^U'.]Y/N7TE[/)*LZ$)XKEM,B L*%B::AJ%!2I
MT\:#J-?='DRTBV[ZJS@CB>!@S>%&%U1N0IJ$I72:-4@T ;@">A#_ .$V?RI_
MTC_&[?GQ>W'E!/N?H'<;[@V;33M,9Y^K>P*NIR!@@::>;R?P[.KD!+H$:QQ9
M*DC"_5BB]Z]@^@OTOD%$N%H_"GBQT!X#%5TGYD,>EGLYOOU]B]FYJ]NW;QKX
M3U(R2>#:ABE!I%.MD_W"W4P]$J_F&_%,?-+XA]O_ !_I*REQNYMS8BCS&Q,I
M7.\5%0;[VGDZ3<>U_OYHXY62FJ*C'"BJY%1RL%3(RJ6 'L2<H[\>6=QAO*$J
MC$.!Q*,"K4^="2/F!T'N:]C',=A-:5H76J$\ ZD,M?E4"ORZTO\ X7_S!/E+
M_)FW5W!T3V9T!49.#=-=0Y_(]8]A5E?L7)[>W=01386+>6W=P46(S<==09"F
MI%@E:)*FGJ11024M3&$E,V3',W)]A[FI#>6]P 4!3Q8QX@9/BTLI92K*37-"
M-1J#BF./+G-E][:O+9W-N6#$/X;MX95OAU*P5]2L!3%1VX(S48OY9GQ@[^_F
M5?S!XOFYW3M*OI^I,1VI4=W[VWI48JIQ>S=R;NVUEHZS975VQ35-_E\5+6X^
MCIZF-'J$IZ#'2QU<WW$D*3EG/&^V?)&S?NFU<&8Q>"J5JZHX[Y'XT+ DC@2S
M J* T,^2MEN^<]X_>UTA$(D,Q>E%9T("(O D*0*G(HA#&ISMO?S#?BF/FE\0
M^W_C_25E+C=S;FQ%'F-B92N=XJ*@WWM/)TFX]K_?S1QRLE-45&.%%5R*CE8*
MF1E4L />/7*._'EG<8;RA*HQ#@<2C JU/G0DCY@=3WS7L8YCL)K2M"ZU0G@'
M4AEK\J@5^76E_P#"_P#F"?*7^3-NKN#HGLSH"HR<&Z:ZAS^1ZQ["K*_8N3V]
MNZ@BFPL6\MN[@HL1FXZZ@R%-2+!*T25-/4BB@DI:F,)*9LF.9N3[#W-2&\M[
M@ H"GBQCQ R?%I92RE64FN:$:C4'%,<>7.;+[VU>6SN;<L&(?PW;PRK?#J5@
MKZE8"F*CMP1FHQ?RS/C!W]_,J_F#Q?-SNG:5?3]28CM2H[OWMO2HQ53B]F[D
MW=MK+1UFRNKMBFJ;_+XJ6MQ]'3U,:/4)3T&.ECJYON)(4G+.>-]L^2-F_=-J
MX,QB\%4K5U1QWR/QH6!)' EF!44!H9\E;+=\Y[Q^]KI"(1(9B]**SH0$1>!(
M4@5.11"&-3G>S]XK=9.=:V/_  IU_P"R.^B?_%EL9_[Z[LKW-?L9_P E.?\
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M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H/MW4I2J@JU'IGB\;D?\=83P2?\58
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MQ^18?X".L$/QYZ<@8NFS(6)4K:;,[CJ5L2#<)49B50>/J!?_ &Y]V/,%X?\
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MW]NW^D/_ !Y>@?SM_N*G_-5?^.2=7-_RH?\ MV3\ O\ Q4/H#_WVFW?99?\
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M )IQ?\>?HTWQP_YD9UC_ .&O2?\ 6R;W*7M]_P D2R_YYT_P=1QS[_R6;O\
MYK-_DZ&SV,>@CU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJQ?\ "NO_ +=N=)?^+O\
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MT=P=H[KC/^?HZG"8%6ZUV:9Y'+@C1DJ&954VO%9?0"/>V[4'^KY]:&3U9/\
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M3VMO/<--CZO<^1V=M7,[G?:>":*IW%EQB\76Y*EQ6.HM1;[BM-$8*4, 'D8
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M (<(RO\ SZW'_P#H65/_ -8/8]_X(&3_ )05_P"R@_\ 6GH$?ZQL?_*8W_.
M?];>O?\ #A&5_P"?6X__ -"RI_\ K![]_P $#)_R@K_V4'_K3U[_ %C8_P#E
M,;_G /\ K;U'J_Y@F=EI:F.DZUQE+5R4\R4U5)N6HJ4IJAXV6&=Z8X2'R!&(
M8IK75:UQ>_MN7W_F92$LD5B#0F<D TP:>$*T/E45]>KQ>QT*L"UVQ4$5 A )
M%<BOB&E?6AIU7[D\GD,UD:[+9:LJ,AD\E535M?754C2U%555$C2SSS2-R69F
M)/N ;JZDOI6FF8N[L6=F-2S$U)/4XVUM'9QK%$H5$ 55 H%4"@ Z$?IWMG.=
M-[RIMV8>+[^'[>HH<MA)*N2DI,S0U$3!:>IECCFTF.4)-$^AM+1CBQ((CY.Y
MLGY.O!=1#6M"LD18JLBD8!-#2AHP-#0CT)Z(.:^6(>:[0VTITFH9) H9HV!X
M@$CB*@BHP?LZ.'_PX1E?^?6X_P#]"RI_^L'N7_\ @@9/^4%?^R@_]:>HJ_UC
M8_\ E,;_ )P#_K;U[_APC*_\^MQ__H65/_U@]^_X(&3_ )05_P"R@_\ 6GKW
M^L;'_P IC?\ . ?];>D9V)\V,CV!LG<NS)>O*+%Q[CQDN-?(1[DGJWI!*R-Y
M5IFPU.'(T?0NO^O[)]_]ZWWVRFLS:*GC1LFOQBVG5YT\(5_:.C;8O:%-DO(K
ML73.8G#Z?!"ZJ>5?$-/V="S_ "^?^+%V;_VMMM?^X>7]BOV _P!Q[S_FI%_Q
MU^@Q[X_V]I_S3E_X\G5B7O(/J"NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[K5B_P"%=?\ V[<Z2_\ %W^MO_?#?)3V
M?<O?V[?Z0_\ 'EZ!_.W^XJ?\U5_XY)U<W_*A_P"W9/P"_P#%0^@/_?:;=]EE
M_P#V\G^G;_">C_:/]Q(?^:4?_'1U8%[2=&/7O?NO=>]^Z]U[W[KW3ECL569)
M],$=HP;23O=8D_UVMR?]I%S_ +#GVH@MGN#VC'F?(=)Y[E+<=W'R'GT(V+PE
M)C%#(/-4$6>HD U?XB->=(_P'/\ 4GV?6UHMOPR?7_5PZ(;B[:XXX'H.GCVJ
MZ2]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U1Y_PH7_ )B.YOY:_P#+:WUVUU[C
M,'DNU>VMZ[>^.?5YW1@*?=&U\7N3L+!;MSV<SF>P%?%/25<='MW9.<GIJ:NC
MEI9:M:>*IBFA=X9/=>Z^;1\)/Y<_\[_L;8C?(CX'].?*C:FP>RJ@R0]A].]@
MQ]!8O?,6%K\@D%3B1#OCKMLA04E3454=+-20RTL3F6.!E(=1[KW1[/\ AO3_
M (5C_P"K_F1?^EM9/_[H+W[KW6[+_P )N>F_YA?1_P '.U=I_P RH]VGO3(?
M*[?.X=J?Z>>TI^V]W_Z)JOJ'HO&X+^&[DJ-X[W:#&_QC$Y[PT(JXPD_W$OB7
MS%Y/=>ZV"??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5 /_"H[_MQ
M1\YO_+9O_@P_C[[]U[KY OOW7NOM3_R/?^W0O\NK_P 52ZH_]T$/OW7NK4??
MNO=>]^Z]T2'Y\_%K/?+'IC';&V?7[:Q.\L!O3$[IP>3W569.@Q$<4-%E,5EJ
M2IJL/AL].!+!E"RHM.09(HRQ4"_N\;Z#7JK"O2"_EV_##=GQ$VSV0O865V=F
M]X[[SN%9:S9E=FLEC8-L[=Q]2,932U.=P&W95G-5F:YY42!D*"(^1CZ4W(^O
MKRKIZ2_\Q3X+;Y^7%=UAG^M,[LC [@V;2;DP^=;>U?GL=39'#Y2;%UN)6AGP
M.W-R.9*:>GJM2R1Q@BIN&NMCN.31QZTRUZ,S\+OC]E/C+\?-I=5;BK\+E=U4
M-=N/,[GR>W9:V;"UF5S><K:R#^'S9&@Q<[I#1_:4Y>6",LT+,%"D 5=M1KU9
M10="5\@>O\SVMT?VOUIMVIQE%G=];"W+M;$5>:FJJ?$T^0S.,J**EFR,]#19
M&9(5>4&1HH)F O9&/'NJFAKUXYZ*!_+K^'_9?Q&V]V?B>R,YL;-U.]<UMO(X
MI]D9//Y*"G@P]#E::I7(-GML[:9'9JY#&(UE! -RIL#>1P_#JJKIZL?]M]7Z
M#'NS9>4[)Z9[<Z[P=1CZ3-[^ZQW[LO#U66EJ(,7393=.U<M@\?49*>CI:Z9*
M=)JY&F>*"9P@)5':RG:FAKUHYZ)=_+K^'_9?Q&V]V?B>R,YL;-U.]<UMO(XI
M]D9//Y*"G@P]#E::I7(-GML[:9'9JY#&(UE! -RIL#>1P_#JJKIZ0VVO@QVU
MAOYA]3\MJK<774G7$VX-V95<+!EMRMO84^>ZQS.RZ-&QLFT8J#6M5D4DD'\2
M($09E+. AWK&G3_JX]>TYKTH/YC?PN[2^7W^AS_1KGM@8/\ T>?Z0OXU_?G*
M;BQOW7][/[C_ ,._A?\  -J[FUZ/[LS^?R^"VN/3KNVCT3A*UZ\RZNF#YR_#
M/Y"_)G:G2>P=@[JZOP>TNML DNX8-U9W==%/FMYC&T6%@K*2'$;%SP--24U+
M,*>1Y878UTH>(:4)]&X3CUYA7JPOIGK3%].=4=?=78<B2AV-M3#[?^Y  -?6
M4=*@R>4ETQ0CR5=4TU3(0B M*3I'T#;&IKU8"G14_P"8'\0<Q\N>L]K879N1
MVSA-_P"RMTG+8+*[LGR=)B&PF5HGH=R8>:KQ&)SD\?G,%%4*5II 7HD5M(8L
M+QOH/6F75T0G?'\L+Y-=HX/X[[=WWOGIR>CZ=VN.O<Y78W=&]_XED=DP;PKL
MMC(L,U3UGX_N:3&5_P!A )EC0?:Q%BUV;W<2@5IY]5T$]3NQO@;_ #!:_!_Z
M!]N?([#;J^/-X<9B(MRY_(8;(TFUZ&97QF'W13T>UZ^LFCITB1$I(*VLIB(T
M 2) J1^$B\:9Z\5/5D/QO^'/7O0?0&5Z+J]&\Z;?%)F1VAEZNG>C7=]9N/&#
M#92&*E6>9J:DCHU6EI8EE+*J&0L9I'8MN^HUZL%H.JZ\1\ OFU\7=U;JJ_AU
MWIMA=E;GJ(9I<3NM*"',20TL\W\/ILOA\]M+<^)GGIHJMH_XC3O2R2#61%""
ML?MPR*WQ#JNDCAT*WQX_E]=PGY!4GR@^779^%W]V!AJR')X/";:\M3239G'4
M8QN$R67KFPNW*>GAH$B6:DQ^.HE0RK'(TJA)(9=-(*4 ZV%S4]6^^V>K]>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3)N/;.V]X8:NVYNW;^
M$W3M[)PM3Y+!;CQ5!F\-D*=@0T%=B\G3U4$J$'E9$8?X>_5IUHBN#TC.NND^
MF>H(ZV+J7J/K'JZ+)/-)D8^NMA;5V3'7R5%5)73O6IMK%8P2EYIGF<R!B78N
M;L2?>RQ;CU5(U3X0!]@IT)WO75^O>_=>Z][]U[K#45%/1T\]75SPTM+2PRU%
M34U$J04]/3P(TLT\\TK*J(BJ69F(  ))M[]U[K1X_G,?\*U]A=74V\/CG_*Z
MR>'[+[-,-9@L_P#+>HHZ#-]6[%JV>6DJWZ:Q.2AJJ;=.1AT%H,S5P28528Y(
M$RT3'1[KW0;?\)I?Y77\RZL^8E1_-N^9V^>S^NL/O_;N]EGVKVAE\I+V]\H/
M[];7GPF,S_8>W<LLM1CMM8UZBFR6&3("CJ9)\51-1TT>,6.2H]U[K>_Q&WL!
M@!7# X/#X092OGRF2&(QM%C1D<G5-KJLC7"CAA\T\AYDFDU.QY)/OW7NG?W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TR9?"P91-7$54
M@M'.!^H?B.8 <K_3\C\?D%)=6BW(KP;R/^?I7:W;6Q]1YC_-T&=725%%,T%3
M&8Y%_KRK+^'1OH0?Z^P]+$T)TL*'H0Q2K,-2FHZC>V^G.O>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JGDX.DRWS8KL-
MG,139.@KNS,J]9BLK015M'644U/5UL;5-#5Q2I)$T964:E*E;-].?>(WT*7?
M.S0SQJZ-=R%DD4,K*49A56!!%*'(^?64XO&M>4%EA<HRVJ:71BK*P8+@J00:
MXP:UQU9Y_H8Z>_Y]1UK_ .@+M?\ ^M?O)7^INS_\H-G_ -DT/_0'6/'];-U_
MY3;O_LHF_P"@^O?Z&.GO^?4=:_\ H"[7_P#K7[]_4W9_^4&S_P"R:'_H#KW]
M;-U_Y3;O_LHF_P"@^L4_2?3D\,T#]5==(DT4D3-!LO;E/,JR(49H:B#&QNC
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MKW\8RG_*_5?]36_XK[]U[KW\8RG_ "OU7_4UO^*^_=>Z]_&,I_ROU7_4UO\
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MXJJI,@8J:D6HCHZC RAXJN1/=>ZV8?A_\$OB+\!NO*GJWXA=%;.Z3V?D*_\
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M]Q3_ -!'+K4?["99#_O/M*^VQMPJ/L/^>O2I-RD7C0_:/\U.FR79I^L%</\
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M.\U!M3:E!,ZZG;2)*NKD @I( T\[!0 U;>W:Y;2O^P!ZGIS<MRBVJ(RRF@'
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M,L*/55"4$\\LCL(Z>FIIZF4B*%S[2V]NURVE>/\ (#U/1QN.XQ;7$9I30#
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M%OS%=6T:QI83:54*,OP H/\ 0>J]?YHGR#_F$?S%LC\<][;8_DX?-;XY=O\
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MG:V*P1EYZ@_A .3C_5]G3;[_ ";A<I!84=0?UI"IT@5I@U'H:>1Q0TKT-O\
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MOW7NO>_=>Z][]U[J@'_A4=_VXH^<W_ELW_P8?Q]]^Z]U\@7W[KW7VI_Y'O\
MVZ%_EU?^*I=4?^Z"'W[KW1[]XY3[_)&FC:]/0:H18\/47'W#_P"P("#_ (+_
M (^_=>Z2/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[HI?R"_P"/EPO_ &HQ_P"Y]7[=3ATT_'H _=^J=&U^/O\
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M^]B]?]-]3]Y;*K.M-H4&\<[GNQ\7L*EVX]-DLS%A:+$0U.V=^[DJA73O))-
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M !=*_P#ZBI?^AC[]U[IM]^Z]U[W[KW7O?NO=:;O_  J+V$>U?D5_+ ZO%?\
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M=5/Y)122!&:.WIM<$@$G1&E-%!)]!T,I[B.T77(P51Q)-!G'1,?^'K_Y5O\
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MX_%UMN>R3H<]:HGQ-_[BD_GU_P"*[-_[R'Q0]G4_^X2?Z;_*W0'L/^2Y<?\
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4 _\
M"H[_ +<4?.;_ ,MF_P#@P_C[[]U[KY OOW7NOL7_ ,EW_MU!_+]_\5>ZN_\
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M>_=>Z2^3WKM3#5DF/RN<H:&MB6-I*>=V61%E19(R0$/U5@1[L%)ZT6 Z;_\
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MVOELYM"?JV@Q)QO7N+^XP&$H]BT&6BJ?'UM0G749NJ35+.?'9HQ%M[MGB$1
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MCIH7@R=/25V;R/DE>]3'1TL-H,B]DX]5?AU;/[>Z9Z6'7_\ Q^^U?^UYC_\
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U0#_P *CO\
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M\(CTZIK'4N+^:S\5H,E0X_<2=J[,BKW*QY+=/7.1I*&-5=$DE=*"KR52R)Y
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M](T+6O\ EB. /\3;W[KW2YP^V%@9:G(Z))5(:.F!U1QD<AI6'#'_  ''^O\
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MBIVAB2>F,E.#.MW1I(Q0JSPPU9J'2?#%!Q\^J#NST;O^8> OPM[[50 !M7&
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M -&^_=>Z]_",7_SKZ3_J1'_T;[]U[KW\(Q?_ #KZ3_J1'_T;[]U[KW\(Q?\
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M9TF2G6:2<3.Z^[APK5'#JI4D=*_YV?%+Y"_)7:?5>P^L=\[#P.S-LP2U6_\
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M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5
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MRB[EDD,#!5U)]T]3=B3ZM2WXL/=>ZV%_?NO=?!\_V:+Y,_\ >17>O_HW-_\
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MW[KW7O\ 9HODS_WD5WK_ .C<W_\ _9![]U[KW^S1?)G_ +R*[U_]&YO_ /\
ML@]^Z]TSYKY!=];EI8Z'<7=W;N?HHJA*N*CS79.\\K2Q54<<L*5,=/79J=%D
M5)W0. " ["]B??NO=)C_ $E]C_\ /?[V_P#0JSO_ -7^_=>Z7D7R>^2D,<<,
M/R&[RAAA1(HHHNV=_1QQ1QJ$2.-$SX"JH      ]^Z]US_V:+Y,_]Y%=Z_\
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M]Y%=Z_\ HW-__P#V0>_=>Z]_LT7R9_[R*[U_]&YO_P#^R#W[KW7O]FB^3/\
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M;F__ /[(/?NO=>_V:+Y,_P#>17>O_HW-_P#_ -D'OW7NO?[-%\F?^\BN]?\
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M[]U[KW_0$'\9O^\Z>]?_ $6&P/\ Z[>_=>Z]_P! 0?QF_P"\Z>]?_18; _\
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M"#^,W_>=/>O_ *+#8'_UV]^Z]U[_ * @_C-_WG3WK_Z+#8'_ -=O?NO=>_Z
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M!69#!8_LOL+;VS*W,T%)4LD<LU+'FFGBCD(5F0*Q )]^Z]UO\?\ 0$'\9O\
MO.GO7_T6&P/_ *[>_=>Z]_T!!_&;_O.GO7_T6&P/_KM[]U[KW_0$'\9O^\Z>
M]?\ T6&P/_KM[]U[KW_0$'\9O^\Z>]?_ $6&P/\ Z[>_=>Z]_P! 0?QF_P"\
MZ>]?_18; _\ KM[]U[KW_0$'\9O^\Z>]?_18; _^NWOW7NO?] 0?QF_[SI[U
M_P#18; _^NWOW7NO?] 0?QF_[SI[U_\ 18; _P#KM[]U[KW_ $!!_&;_ +SI
M[U_]%AL#_P"NWOW7NO?] 0?QF_[SI[U_]%AL#_Z[>_=>Z]_T!!_&;_O.GO7_
M -%AL#_Z[>_=>Z]_T!!_&;_O.GO7_P!%AL#_ .NWOW7NO?\ 0$'\9O\ O.GO
M7_T6&P/_ *[>_=>Z]_T!!_&;_O.GO7_T6&P/_KM[]U[KW_0$'\9O^\Z>]?\
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MUL#:75?5>TL)L+KG86$H]M[,V9MNC3'8#;. QR>*@P^'H(O3#3PKZ8HELJJ
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M[&QU5?/'222/+4U-)24T4;U%94T].CRCW7NM>/(?\*O\MLNA/;W;7\GCY_\
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K1W^)&%P_\
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M&DK:3S*$EIR?=>ZR_/S$8K^91_PJP^(?PH[$^RWM\?/A!U=1=B[YZTS5*T.
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M87<G^D]J*(I][48"BWGC.LTJY(XF>3[2CKI*J41LD$$TK1QO[KW5E'_":_\
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MSG_@KO\ ]G9__5']^Z]UJV_SF_YI'_#NORQV[\H?]!G^R^?P#I/:'3W]Q_\
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M/B]C[ZVKF*RA7-X:ODRK?<4E$] B)41H(YF#'0"C>Z]UIJ?'SX-=U=O_ ,V
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M\*N-J?)+X,_S+.L_D[TEW5VKL+87R8VMB.S=KXO"=A[F7;>"[OZ1KMO8+?\
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MY-CXZI7*4,0Q^:BCR+5 J:*FJ4IY14U<T/NO=7H?\)QOAC\E?@9_+4V[\?\
MY7];_P"BKMRA[D[7W75;2_OAL+?/BP&Y<ABY\)7_ ,>ZWW3O#&-YUIW/B6M,
MB6M(BDB_NO=:LO\ PPK_ #8?^']/]G5_V5/_ )QE_P"'?_\ 9H_])?\ IS^-
MO_,B?]G/_P!+']^?[F_Z8O[P?\>__N0_AG\*_B'^Z/M/N?V??NO=?1\]^Z]U
MH2_\*:?Y+7\S#^8/_,*V7WE\0?C7_I=ZMQ/Q>ZYZZR&Z/],?0.P?M]Y8'L#M
MS-Y;#_P3L_M39>1?Q4NYZ&7[A*1H&\^E)6=)%3W7NMES_97.]O\ A@O_ &2K
M^XW_ #DU_P - ?[*Y_HT_O-L[_F>W^R8?Z)_[C?WR_O#_=__ (^#_<?_ !/^
M*_P__=_W?VW[WOW7NM<'_A+_ /R9_P"9-_+M^?7;O=?S%^.'^A_K+='Q W]U
M;@MR_P"F#H7L#[[?>;[HZ W9C,%_!NK>T=[9"+RX_9.4J/NIJ2.G7[70\JR2
M1))[KW6]Y[]U[KWOW7NO>_=>Z*!_,)ZMWWWC\!?G#TIU;@O[T=F]P?$#Y+=6
M]=;:_B>'PG]XM]]@=+[UVGM'!?QG<60Q&/I/N\AEZ>G^ZKJNEIXO)KFECC5G
M'NO=:@7_  E__DS_ ,R;^7;\^NW>Z_F+\</]#_66Z/B!O[JW!;E_TP="]@??
M;[S?='0&[,9@OX-U;VCO;(1>7'[)RE1]U-21TZ_:Z'E622))/=>ZWO/?NO=?
M-EVK_((_FUXW^>;MSYBUOQ.\/QQH/YL.'^2]7V+_ *=OC3)XNDJ7Y?T_:4^]
M?[HQ=R29UM."C-=_#5Q;5YMX12FH_:]^Z]UL3_\ "E/^2GVI_-:ZFZ9[#^-F
M9P<7R)^-C[YIL-L3=F:BV_MSM/8N_4V]5YO 4N;J:.HAH\W1UFTZ6;$RU4U'
M1R)55<55*I:GE@]U[JE?X4]?_P#"OKKGHO9GP"Z[ZSV=T3U=M_"5.R-H]_\
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MK:&R]F_S1>LML;3VKMS#4D5!A]O[;VYA/E]0T=#14D$"0TU)2PQ111HJ(JJ
M/?NO=*7_ (;3_P"%DG_/QOG_ /\ IV+8W_W9'OW7NMJ3_A2]\!/F!_,)_ER=
M"=&_%#JJ7N+N+:'RFZM[,W?MN?L#K79$]'M3 =%=\;0W!GIMQ=H;UV=CJEX\
MIO7'0-#!6S5$AJO*D;Q1RR)[KW0Z_P#"<;X8_)7X&?RU-N_'_P"5_6_^BKMR
MA[D[7W75;2_OAL+?/BP&Y<ABY\)7_P >ZWW3O#&-YUIW/B6M,B6M(BDB_NO=
M:YWPW_DA?S0>J?\ A0LWSDW]\8_X#\6S\VOE)VZ.T/\ 31\>LI_QCSL:N[BF
MV;N'^Y6%[9R.XO\ +%W50'[3^$?<Q>?]^&(I)H]U[K<T_F+?!'JK^9)\1>U?
MB3V[4UV'P>_Z&AK=N[PQ$2SYK8&_MN5L68V9O;%4[S4ZSM15E.GW%(\D:55+
M)/2NZ),S#W7NM#_X]_RWO^%0/\ECL/L[9'P8VMC>X.H-^9#[VNJ]G;BZAW[T
M_O/(4D4V/Q.\X^N>U]P;=S. SJ4D,$=7414-$9EC@IIJBO@IH0GNO=#E\$?^
M$Y'\QOYQ?-S%_.S^=IDZ.GP0W;A]\;[ZWWEF]C[P[)[UJ=K4\-+MC8^7V]UM
M45.W-M;5'\,I(JRA0HS4$+X^#'TZU JJ?W7NOH6*JJH50%50%55 "JH%@ !]
M /?NO==^_=>Z^9'V7LR/^5K_ ,*[]A[MS^'R>&ZW[B^5E'V5LW)QU5%5Q56S
M/G5A=S==;FW#3JE5 \.-Q&Y>SMPT%1!*JS)!AI1%%.OA,_NO=?0=_F$]6[[[
MQ^ OSAZ4ZMP7]Z.S>X/B!\ENK>NMM?Q/#X3^\6^^P.E]Z[3VC@OXSN+(8C'T
MGW>0R]/3_=5U72T\7DUS2QQJSCW7NOF2=*?\)]O^%*GQKW5D-]?'3HKN#H'>
MV6V_5;3RF\>E/G)\<.J]U9+:M=D<5F*[;60W#L7Y.X*KFQ\U7@J&JEHI)FA>
M:C@E9"\,;+[KW1DJ_P#DE?\ "J[Y/TE=U;\B>P_D))UQE<?-_$X/D=_,=Q/9
M_6^05ZN@ADQ5?M;:W>O<%3,TBOYR),.T12E8,XD\4<GNO=;3?\B3_A.CL/\
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4=>]^Z]U[W[KW7O?NO=>]^Z]U_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>timage_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_005.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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M<_V'N_ ;?A\N*QD^>RGR!HSD9H# \P-&DB,L,2P>Z]TC_BM\O?CS_)4^:_\
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M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZIV_X4"?]N9_Y@W_ (@JI_\
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M .0]%MZV4RG4.;GS&YL3N?:^7W?14KT>-R&+SN(\=3*(Y98A(*NF]U[JSO\
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M0OO#?/75/L+K/?VV<IN?)S^#<L*Y(8MEW13U3253P9BJ:G]U[HR>T?Y</>&
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U3M_P *!/\
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M_)7[IS,N V]\X]C[2R<>D@]O[.[0Z8PTL;@VDBW7V?LC:VTCZ@04->)5M<J
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M;L_^4'\]-S;2^/G1^UMR8;I*HJ\1N#;G4^P\)G,55#<^VXQ4XW+8S 4M?0U
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M)7RXJ/(4+Y2"$5,^-2K@:OAIR8P)Y:-9#41PDS)9BH7UCGD>_=>Z]D,GC<3
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MO;G77;F4[MSU958W+56Q^V-Y;CV]M R0YBDT4=-BZ\U\=HQDX7J)G,_NO=;
M/076W:/\BW^4I\O]QY[Y-R?,[K/X^[8[5[:^'R;FB$%5LGKF+;<=+U7TKE]W
MTV2R5'N3 0;IAI6-504])24XKJB.BHXJ=:>G3W7NJ._Y;?5/\C?Y!=(8GYB_
MSAOFU\9OE-\[_DM0YK>G8F,^1?RXIZ*/HK;VZ,W7Y/ =0[7Z\;L7!1[0DVSC
M98W:*H@:;"U$\M'COM*1!&_NO=&-_E5_*'HCX8?SGZG^5U\+?EE@_E%_+H^5
M71V>[E^/FW,+V='WICOC5WGM6@WONC<W4NU>Q<?G-POBMMOL#K#,UU5C<C*9
MG6IQ,S/]R\T^2]U[HY/2_P#W%Q?+C_QD-MK_ -_-\8_?NO=4TXC^;ATQ_*+_
M )F'_"BSM;?>.FWQVYV)W#TCMOX]]/TCU%+)V%O/$4?;4^1K,YF(X)8MO;%V
M@F6I*C,5IO/XYXH*:.6HGB7W[KW6PY_*3_ETQOE,7_-;^979VT_EO\_/E#LW
M%;VP_;6W,G!N/IOHGJ7>V'@RFTNK?C/3TU35X"BVQCMM9)86S-)JDJHYYD@E
M,4]3-6^Z]T7GI?\ [BXOEQ_XR&VU_P"_F^,?OW7NO?\ "O;_ +<X;M_\6%Z*
M_P#=KFO?NO= G_PI&KNTJ2I_D>4?2G8==U-VKNGYH;8Z^V1V9C,?BLIDMBYG
MLK:FTNODW/CZ+-4.1QLM=B:?<TDL1DA8QR*'0JZJR^Z]TD?YK'_">3^7;\=O
MY;WR3^2W2>U^U-L?+_X];&S'R+Q'RLR_>W<.YNV]Z=E[.R.,WEN3=&]9<UO.
MMVO59W>4^+GE:JHL;0S4&1J#5TCP3-*TONO="Y\#?Y-?Q=_FA?"[I3YO_P T
MW^__ ,SOE1\INI\-OFJW_N'MOMC8V$ZEV5G@M3L#874FR.N]X[1VEMB#;&V*
M/'&OJ)**JFRF8%94U#RK65"S>Z]TJ/\ A+MN;?6T.H_YAWPOR^^MU]C;,^"G
MSQ[7Z.Z3KM\Y6.NKL1USBZFMPV,VS'D*>AB^TQ@S.TJO(&&&E2GIY\E-]O"D
M9$2^Z]TD\/\ RI?A1L/L+O+Y5?\ "A#Y0_&+Y#?(7LKM/=F6ZS_TP_(7.=:]
M&=-]*YC[67:7777W7786\]CT"5<-8:L1P?:U4%/$*>.D+U J*JH]U[JMSXC;
ME^"?Q&_X4:_$WJ'^3K\@\/NKXJ?*_J7L[ ?)GIC8/8.]>S>HL!OG";*[7WMA
M:_!;KS6X<OB<KDGEV;AZBCA2>OGP:0542S+3Y):>+W7NC;_SQ^@=Y?*3^?;_
M ">OC_LCM3=W2U;V?TE\A\#NCL38-<<5O;&=4Q;=[)RG=F%VIF!+$^#S^]NG
M<?G<'2UZZWH9<DLZI(T8C;W7NAS_ )DG_"?CX0_'_P"%W8'R8_E\]?[J^)7R
MY^$'5>\.^NF.VNH-[]AUV]=SUO4.TLEN[*[5W;!F=QYP[OR&\\1AJBE2J,?\
M1^ZG6/7)2R3TD_NO=73_ ,I/YC93Y^?RY/BA\L-Q_8C>G9W7#TO8O\-HI,9C
MI.SNO=QYWK+LFJQV,E:1\=C,AOC9M?4TL.IU2FFCT.Z:7;W7NK%_?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
MIP_R\/YTWSF^2?\ /_\ E%_+Q[.W+UY4_&SJ3M[YO;0VCA\-UWB,1NM,'T5V
M)NK:_7\&2W9%++7ULU+C,9":F32CU,J:F-BP/NO=;CWOW7NO>_=>Z#_MG-Y_
M;75G9>X]J48R&Z<!U_O+-[:H#*D(KL_BMN9*NPU&9I(IXXA4Y&"--3(X75<J
M?I[]U[KYM_\ *$^(OP:^3G\F[^<I\QN\\3M+Y!?/K;/4OS.WE-D.S8?XSNKJ
M5<3\=<OV#LKL_:N*R5?54\^Y-Q=C5M?DY-TQT\=5'70+2*8S3L]1[KW0Z?S"
M.D_BCNC_ (2E?R^.\>V*_&8KY/=5];=>[<^*<D^[*S'9?<51OSN;'4W;VT,;
MM)LFF.W#02]:X^MS-9**.2HII,+3/YD12C^Z]UNJ_P IK>>^^Q/Y8GP WUV;
MD<AFM];K^(?06<W!G,M*)\KGYZ_K;;\U+N#)5/ZJJOSN/:&KEE;URR3%V]1/
MOW7NK!_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U3M_PH$_[<S_ ,P;_P 054_^]5MGW[KW5L>R
MO^/-VE_X;.!_]U5+[]U[I3>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[IBW%M?;.\,7)A-V[=P6Z
M<+-+#/-B-Q8C'YO%RS4[B2GFDH,G3U5(\L$@U(Q0E3R+'WL$C(Z]2O'IHWSN
M_!]7[%SV\LI15AV]L_#OD*RBP5'!+518RA5$9*"B>>CI]%+!SIUHJQH;?2WO
MP!8T]>M' Z3W47=/7G>&V(]T]?9M,C3+XX\GBZE5I<[@*QU+?8YO&&222CGN
MK:'4R4\X4M#)(GJ][92IH>O @\.A5]UZWU[W[KW7O?NO=:F_\Y3HWY,_!+^8
MCT)_/>^(W5.X.]=J[(Z^EZ.^=_2>RX8)]WYSJ%A-08W?^)QM+@<CELC14.+K
MH5R5;&\DF'GV]B)Y8_X9_$IZ;W7NK'NC_P#A0]_)W[SV%C-\T'S;ZIZTEK8H
MQD=E=VU]1U3OG;]>5O-CLCA=UP4<%>U.PL:K&SU]!)_NN=_?NO=4&_S9/Y@_
M47\[;MKX3_"C^5YM#MSY7[GZ/^:_6'R"[;[:VIU[G=N=+[)VCLBBWMM[(IE-
MX;WI]MFF@FAR-35P9.IAIL/61T@BHJJKJ)XHO?NO='Q_X5 YZOZ87^4C\P\O
M@,WD^H_B1_,KZ<[3[@S&$P^1S3;9VYBLYMS=%/79"GQ\3>"DR']RJBCA>62%
M9:^>FID8RU$:GW7NC/?/K^==\%-P_"_NK9OQ'^1O5WRG^37?'3V_>L/CYT9T
M=FZ/M+L3/=A]A['S&(P==N/96W*F3+;8VQM!*]LKG9\K_#XZ/'T-0'=9%T^_
M=>Z*]_(([.[8Z5_X33=?]N]&=3+WMVQUKA/E=O79?3PRM;A:CL7([=^0O:F3
MJ-KXZNQN*SF0_C.1QM/.M#!#2S2558(H% ,FH>Z]TF]M?)7_ (3?_P VOXW[
M8[R^=F(^!'4/R%W%L^FQ_>.S>U.P-H]#?(C8._L6)H=U;<QF]?XMUCW%NW$8
MS</W,F+K*:685-/*K,BR/+$/=>ZK\_E2_$K>/R?^'W\__P")?PXWEO[=W\N/
ML2LSW7'\N/-]N9>M@VOE.TJ.GW_G=P1[0R%? <Y1[*J,ZFVH,CD7HECK(9(*
MF2-L@,A&/=>Z'+^3WVG_ "&\A\/=A=$?S"/C?_+/^-?SB^,-!4=)?(?:WS&Z
M3^,VQ>PMS[DZ_GJ,/0[^J-X]N;(P,N^LOO'!4M/5Y%Q55E='DWG25Y@8JFH]
MU[H\/\O3OK^7U\D/YH6^M@_RWOY8?PJ_V7CXO["J,EN;^9+U-T9U3UO78/N'
M<.-R&#_T>]09?;/5&+J\Y'G\-F9:5ZVBRU/]SCDR$EGI&@-7[KW772__ '%Q
M?+C_ ,9#;:_]_-\8_?NO=%-_EQ?$SX[?*C^=5_PHZP??G5.U.R()LOLCJJBK
M-P8^.JR> V7W5B^S</V51;:KWO-@*_<E!MRA1JZF\=9"*9?%(@+AO=>Z&+^3
M9W-V=_*_^9_97\@_Y<;ISFXMJTLF=[:_EG]U[KJL5'1]A=*922LS59U$*E!1
MRG<..\%?74M($D%-DJ'-T<;1TB8>*7W7ND?WA\DNKOY>_P#PJ<S/=?RPW)1]
M.='?*K^6_C>G^O\ N'>4-7B^N4W1B]][ S]92YC=]3'!A,/]C7=32TM5))*T
M=&V2H3/XEJXG]^Z]T4__ (50_P SKXY_*KX)4OQS^%W9>U?DW!@NU>M^W/D;
MV/T]4P]@]7]0=;X^;-;6V1C=R]C8*HFVMC-Y]@=H;EQ<6.H8ZBHJI*2@K=<2
M !Q[KW1X/^%#/_,Q?^$]_P#XTIZ _P#=[U5[]U[JXG^=U_VZ)_F+_P#BI?<'
M_O+U?OW7NO?R1?\ MT3_ "Z/_%2^G_\ WEZ3W[KW5,/\@2OWCBMT_P#"BK*=
M>40R6_\ &_S%/DA7[&QQ@6I%?O&CR/;=1MFB-,X9*@56:C@CT$$/JL?K[]U[
MJNC^1[@/Y(W;G179??\ _-J[*^,V\?YDFYN\>RJ7Y(TG\Q/L_;6V=XX;)X'<
M4T>W<;MSKCN[<&W\#544>"$"U<U#C9I8*T38N5HTH8Z2'W7NE+/\BOBKW3_P
MI1_E)0?"3J/9_7_P[ZFVMWMU/UEVQUIU=3=9=(=U;[I>K>Z4W^G3E;A]O;?V
MAO+;&P\GE,3A6J\:)E_B;S+J,3T[/[KW1O/YVGRYVY\&?Y]_\H;Y,;YH=Z9+
MK3870WR)INU8-BX;+;DR^/ZTW3ANP-K;PWE7;<PA.1S>V^L<7F&W5DXXXYWA
MHL))4)%))"BGW7NCE_S=?YW/P0H/Y?O?'7/Q=^4?6OR5^2OREZOW9\=/C_U9
M\7-_8[M3M:?L#O'!9'KK$9O^%=;9+)9_9E;M@9YZ^F-8*2LJ*ZG@I:2.:KJ(
M(9/=>ZL@_DW_ !"W'\$?Y9GQ%^,&]J&/&=@;#ZXJ<UV1C8ZJ"O\ X5V-V;NK
M</:>^L(V0II)J>O_ +O[GWI4T"RQN\31TJ^,F,)[]U[JS/W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TG=V[OVIL#;.<WKOK<
MV V9L[;&-JLSN3=>ZLQC]O[<P&(HHS+69/,YK*U%)C<9CZ6,%I)II$C0<DCW
M[KW5>/5O\Y3^5?W3V%C>JNL_GC\;]S;^S63_ (+@=O#L''8B7<.7:26&#&;<
MKL\,7BMPU];+$5IHJ*>=ZIBHB#ZTU>Z]T5[XX?R(?BS\2/YC/<_\TC:?;W>^
M7[:[8W;\A>Q-V[-W9DM@576&(J._]Q9K>.\H<-0X7K_%;MBH<'5Y61<>)LG4
MRK"@$IF>['W7NK#_ (G_ #_^&GSG_O\ ?[*/\A-A=[_Z+O[K?Z0/[D5&2G_N
MK_?;^\?]U/XG_$,=C]'\<_NCDO#HUW^SDO;B_NO='"]^Z]UAJ:B"CIYZNJFC
MIZ:EAEJ*B>5@D4$$"-+--(YL$CCC4DD\ #W[KW6A;\D/^$RWQ"_F,]H=H?+/
M^4!_,$ZAP>S]W[OW;0]D[#VSDX.VNJ=J;^W=B*:MWIMK9_8/6>YI<IL_";AP
MFZ9:BKVU6TN1C@ILIX8'AQTD-)#[KW00=8?\)2.L_BK'LCY'_P XK^8=UGAO
MC_U7/L_%YC9VT*K.XW9%3,VX*>IP77%7W)VM%AI,)L#,9JKJ:66DHMN4E76)
M6/\ ;RT,\GE7W7NM_OJS='76]^LNN]Y=09?;N?ZHW5L?:NX>L\YM&6GFVKE]
M@YC!T.0VAD=MRT@%,^"K,!44\E(8P$\#+8 <>_=>Z7GOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZIV_X4"?]N9_Y@W_ (@JI_\ >JVS[]U[JV/97_'F[2_\-G _^ZJE]^Z]TIO?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7%T21&CD571U9'1U#(Z,"K*RL"&5@;$'@CW[KW
M1(,O\-*+;W<&W>WNB=WS=2U29>";>VU:*D:HVQN'#&H2HR=#0X^*6&&@CRB(
M8Y*5UEHT9DFA2&2(:W/$JNEA7TZIIH:KT)OR:^8WQ8^&>SJ3?ORH[[ZPZ)VM
MDJJ6@PM=V'NG'X6KW%D8('JIL;M?"/))G=TY.&EB:5Z;'4U3.L:EBND7]M]7
MZ(Y\=?Y]/\H;Y5;RH>ONE_G%UAD-YY:OAQ>%V_O_  G8W2-=GLI4A?M<;M[_
M $W[)ZZAW!D*IF"1043SRR2>A5+<>_=>ZMW]^Z]U[W[KW1#>S_Y6W\MKNC>&
M1[![5^!WQ(WWOK,U4%=G-X[AZ!ZSK-S;@K*6".E@J=PYL[<7(Y^:.DACAU5D
MDY,4:(;JB@>Z]T:3J7I/ISH/:%%L#H[JGKCIW8V-1(Z'9_5^RMN;$VU3",,%
M:+"[8QN,QXD.HDOX];,Q))))/NO=*_=.U-K[YV]E]H[UVW@-X;4S]')CL]MC
M=.'QVX-O9O'RD&6AR^%RU-5XW)4<I4:HIHG1K<CW[KW19>EO@%\&OCAE<[G>
M@OA_\:>F\WN;&383<&9ZVZ3Z[V?E<QA*F&IIZK"U^0PFWZ.KJ,/505DJ2TI?
MP2)(P9"#;W[KW0Z=4]0=2]$;'Q/6/1_5W77376V!ER4^#Z]ZIV3MKKS8^%GS
M.2JLSEYL3M/:.,P^!QTN5R]=/55+0TZ&>IF>5]3NS'W7NBO=G?RQ?Y<O=6^<
MUV;VW\$_B1V-V)N2>&JW)O?>'Q^ZNSNZ=R5E/#'30UNX<W7[9FR&=KDI88X?
M/5R32^&-(RVA$4>Z]T<?:VU-K[&V]B-H[*VW@-G[4P%''CL#MC:V'QVW]O83
M'Q$F*AQ&%Q--28W&T<18Z8H8D1;\#W[KW1;.]_@9\)/E#G\?NOY&_$CXY=Y;
MJQ5+)0X_<_:?3FP=[[BI*&7Q%Z*+.9_!5V4%'>!"(C*8U*W 'OW7NAQZOZEZ
MLZ1V9BNN.F>MMA]3=?8)/'A=C]:[1P&Q]I8I"D:,,?MW;5!C,32%TB4,4B!;
M2+D^_=>Z@472'2V-[<R_R QW4'5]!WSN#:$77V>[MHM@;3I>W,WL&&MQ>2AV
M1E^R8,3'O+);0BR.$HJA<9-6O1+-20.(]4497W7NL6R^B>C^M]\=C=G==]-]
M5;"[*[AK,=D.V^PME]>;1VMOCM*OP_WO\(KNQMV8/#T.?WO68O\ B51]M+DZ
MBJ>#[B305UM?W7NF?LKXT?''N?>/7O8G</Q_Z2[7[ ZCR<.:ZHWUV5U5L3?6
M\>L<Q3Y3&YRGRW7NYMT8'*9O9>3@S>&HZQ)\;/32K54L,H821(R^Z]UF[Q^.
M/Q_^36TX]B?(KI+JGO39L-6E?3[8[:V#M?L#"TE?%)#)'7T6/W1C,G3T5:KP
M(?-$$D](%[>_=>Z#;$? SX/X'I[)_'K$_#SXP4G0V<RE%G,[TR.A^L)NK\]F
M\;D/XKC<UG=BU&V)MM9K+X[)_P"44]354TL\$P#HRD CW7NA6[#Z"Z)[=J>O
M:SMCI7J7L^KZCW+C]Y]4U78?7&SMZU/6.\<3)22XK=G7L^Y,-DI=E[EQDM!
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MY2_RT_YD'\N#:/R+V'@<OF=R_';YP;M^*>:K=@Y^;$4./R;[>F[<RF$J-O'
M;_V-6TV3QM!-D:J3"YRDKL9YYI9T6/W7NMKK_AD7^43_ -ZZ/B7_ .B?VO\
M_4GOW7NC2_&GX1?$3X;_ -]/]E6^.?4O0/\ I&_NY_?O_1;L_%[3_O9_=#^/
M?W7_ ([_  V&+[_^ _WHR/VNN_B^]EM^L^_=>Z-+[]U[IHW!G,;MC YO<N9G
M-+A]O8C)9S*U(C>4T^-Q-'-7UTXBC5I)##2T[MI4%C:P%_?NO=?-?Q?77\T_
M_A61WCW7V-MWNBE^./\ +XZO[!_N1MW9>[MP[B&RL!2B,;EVUB(NJ-FU,]#V
MQW%3XQ,5D<YD,K5T=)1/6QBDK%C2"E]^Z]U![A^"W\W/_A+GE-B?,7I?Y)X7
MOWXFT>]<!MGLO9.#R>^,%U]EJK=4]6)<%VOTGF*S(X3%8[<#4*TN-W/C:VIK
MJ+)5$2AJ=Y$2H]U[KZ+WQR[RVA\F^@.E/D7L 5:;)[SZLV)VQM:'(1M#D*7"
M;]VUC=RT%#D8F2-HLA00Y$0SKI%I8V X]^Z]T,_OW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZIV_
MX4"?]N9_Y@W_ (@JI_\ >JVS[]U[JV/97_'F[2_\-G _^ZJE]^Z]TIO?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW05=N]*]=
M]X;:.V.PL%'DZ:%I9<7DZ=_M,Y@:N945ZW"Y-%:6DE?QIY(R'@G"*LT<BC3[
MLK%34=:(!X] 3\;.DN[NB]RY[:6;[%QF^NBX<2XV32Y&2M7=N"RGWE(U+30T
MLE%/34>)BH!41S0I6M TOBEABB+2I[L[*PK2AZTH(^SHY?MOJW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=)+?^T*#L'8F]=@Y5@F+WOM+<>T,DYB%0%H-RX>LPM8Q@9XA,%I
MZUCH+*&^EQ>_OW7NOFU_RL?YL6Z_^$U_97RB_EP?/GXU]G9_9R]T9GLNBW;U
M:F&_OD,[48;;.PX-U[6VUOK+[2VQOKJ_LC:.R*'(8[(19NBEIW@T%)S+(*3W
M7NEA_."_X4(P?SJ.I]E_RTOY=WQ9[QK,A\@.SMBQ[@J.SZ'9])V%N^JVMG*7
M<NU]D;.V9L7>&]\'C**7<^.I<GD\YD,W'!0T.-?R0I"\U53^Z]UOR_!;X[U/
MQ(^&/Q9^,=?EH<]E>B.A>KNL,[G::%Z:ES6X]I;0Q6*W'EZ.E>IK6I*+)9V"
MHFAA,TOBB=4UMIN?=>Z-9[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ=O\ A0)_VYG_ )@W_B"J
MG_WJML^_=>ZMCV5_QYNTO_#9P/\ [JJ7W[KW2F]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW14/DKTYVUOR7;
M6]^ENT,QLG?&QTJ9*';[Y&J@VIN<2N)/'D:8/+CDKPA>-6J::IIYXW\4H1/6
MMT91AA4'JK G(ZC_ !I[X[#['K-Q=?\ ;W6F9V)V/L>D@?+UXH*B';.>0S)3
M&HH99/+!35C^6.01PSU-/41.9H9/'Z%VZJ,J:@]>4DX/1M_;?5NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@4[W^2/0'Q>VA2=@_([N7K?HS8E=F
MJ7;=)O/M3=V%V/M>?<%=35=90X1<]N"KH<8,K6TM!/)# 91+*D$A4$(UO=>Z
MH%[1_P"%,OQ&V3_,NZ,^&NU-X?'#?OQ?[.Z__O9OWYRXWY-;77KKJ;<0Q7:5
M=_<S-TM'@LEM67(-5[(Q-/JJ-PT4@;<$'[5Q&LWNO=6??\/(_P IS_O9#\*/
M_2D>J?\ [)_?NO=$E_DV?SNG_FO=Z_.3JNGZFVILG:GQ:W%MBEZX[!V?O;*;
MRQW;NT=Q;Q[2VY3[LG3(;=P46#BK\;LK'5M'%&U1Y4KY;M:($^Z]UL ^_=>Z
M][]U[K2;_G5_\*$/Y0N,['SOQKWE\$MI?S.]]],9RMP>9S&\X=E[1ZNV/N^A
MR=7A=T;5VIVQG-G]A;TGS6#5*D5SXG"_PIZCQPI62R"8TWNO=%Z_E+?\**OY
M+G6W:5'M.K_EJ==_RR<[OFIH-GP]Y]>':':VVQC7CQ])CH^S>RZ;KGK?LW;6
M#J<A+(*AS193'4^D5=94(KS2P^Z]UOQTU33UE/!64<\-5254,532U5-*D]/4
MT\Z++!/!/$S130S1,&1U)5E((-O?NO=9O?NO=>]^Z]U[W[KW5-W\XO\ F<;J
M_E]]>=(]=?'_ *ZQ?<_S:^9W9]/T=\3^KLW5/#MR3=M9/A\=DM_;UIZ.MH,M
M7;-V;D-SXJ*>GIIJ9JBJR5.DE12P>:HB]U[JM_Y%[M_X4??R]^C-W_.CL;Y(
M_#+YG[*ZVQ.#[&^0?Q#Q72D/56,ZZZQV[0FK[2J.D.XL=%MO>&ZZG#X_S54M
M3N(U$RQ4QJ:6@J63^%57NO=7<[>_F+="YK^7)C_YFU:=P8+H:I^.?^S&9#%U
MM'!4;PQ.*@VZ^7R&R)**CGFH:S>%'FX7PRK#.]+/D%'CF,++(?=>ZI(Z(["_
MX43?S&.G<1\[NC.^OB9\*.JM]T^XMZ_&?XA;VZ:H^T9^VNL,C3D]>9;O3M[(
M4>;W/LZIS\$*55)4;=%)Y8J@5$]'%$\=.ONO=62_R;_YF&\_Y@_4G;>S_D/U
MC0]$?-WXA=ES='_+7IFBK('HL1O&FBJEQ.^]LXTY?-Y/&[)WO/B,E#1K/4U4
M:UV*K8Z:KK::**KF]U[HE./[G_F+_P T[Y??/O9/PV^;-'\"_CA\ >RLK\6M
MK9C;O0W77=&[^]/E)MNFE/869[$_TP;<F&!ZYZWW#0-C8\?B%3^*PU/W J)E
M\;+[KW1_OY-OSO[$^>OQ2W/N7O+$;2PGR0^.O?O;/Q-^1U+L$5Z;'K^VNG*W
M%_?[CVA'DHHZB/!;FVYN'&UH56DACJ99HT8",QQ^Z]TB_P"7S\CN]OG+\M?F
M=\E,9V1F*+^7_P!5[LF^)OQ5ZVH,/M:/;?<._.L*_3WQ\FJS<DVU5WME<=_?
M,2;<VVE-F%PTM%3U4DM+)4QQ31^Z]U<M[]U[KWOW7NO>_=>ZIV_X4"?]N9_Y
M@W_B"JG_ -ZK;/OW7NK8]E?\>;M+_P -G _^ZJE]^Z]TIO?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=%!^2O<_=G2.7V[NS:W6N.W]T[3X]Y-_3429#^]F%JTGJS)4QU--734
M]!AXZ#Q2>>7'30K(CK++&'C(<15;!-#Y=58D'ACH6.E^^^M>^< ^<V!FA4ST
M24W\<V_7(M)N';TU5Y?##E<?KD"QS-!((IXGEIIBC:)&*L!5E*&AZV"".AF]
MUZWU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW14OF]\.^H_GQ\6^WOB?W=15$VQ.V
MMM28B3+XV*B?<&SMPT<\.4VGOO:TN0IJNDIMR[.W%1TU?2-)&\,CP^*9'ADD
MC;W7NM(_>W_"+?)4WS)ZSP'7W>.X<E\#ZO:OE[<[ W-NG:E'\CL1O0T.]F%)
ML?:E#UR=DY#;RY&#;RF2K=9_%/7$"\<-_=>Z.K_T!*?!3_O+?Y:?]2NGO_M>
M^_=>ZOL_E6?R@?B7_*-V/V/L7XX5N^]V[H[4RN!S_9?8G:F9VWFM_9VCP*YR
MEV;A6.U]M;2Q.+VM@?XEDC1P142F2HJ*B2221SZ/=>ZM<]^Z]TB>R\/N'<77
M._\ ;^T<F<+NO.;)W5A]L9A6T-B=PY/!5]%A<FKW70:#)3Q2@W%M'OW7NM(K
M_A)#\*OBGM_;/S'PGR9Z4ZXJ?YC'27R1R/7NZMB=PX/!;B[(ZJZEPVR=FMMV
MNVQM;<@R5/@J/-=B5.YX:K,XJ$'(+1TRO4201TOOW7NC#_\ "L[XT_ :D^$F
M*W#0]4=2[?\ GKNCM+J_:GQJAZUVCA<1WAV><GO*DH=X;0EQ6S<?#N7?6TXM
ML9O(30P5D533T^9EIA3E*JH59O=>ZV4OY</6/:O2WP"^&/4G>535U/;_ %Q\
M9NF-G=C+7USY.OH-UX'86$Q^5PE;DI))6R-7M^>$T,E1K<3/3EPS!KGW7NCI
M>_=>Z][]U[KWOW7NF#+[4VMN"LQ&1S^VL!G,AMZMCR6 KLOA\=DJS!Y&&6*>
M&OQ%36TTTV-K8IH$=9861U9%(-P/?NO=:G_\^3YO_P Q!^HODQ\9\9\#-\=*
M_!+=7\0Z?[J_F.5-9'WJ^(Z4S]/%C^Q-[X#XW;&I\/O/ [?FQ=1/0?Q?)UST
M@AE>53#>*<>Z]T$?\VV3XX[:_P"$G>V=K?"OMJ;N#XST>W/BOLC9?9+ZJ?);
M\Q6V^]MG/GZC=>*FH<;5;>W0G8. G?+8B>FI:C$Y6FDI)88G@:,>Z]UML?'7
M 8C:GQ]Z*VMM^A@QF!VUTYUC@,)C:90E/C\1A]DX3'8VAIT%@D%)14R1H!]%
M4>_=>ZUF?Y?FZTV1_P *J/YU?2-)#-]IV#\<>@>YIIJ?Q18^.MVGL'XN^6.I
M@<25,E?//WW.R2(ZQ^B8LMW0+[KW0U8?I_\ F*_RK_EW\_\ =_Q#^$%)\]/C
M9\^>T\_\K=G4.U.^NN^G=\])_)O<^.0]A;=[-7M_,T<.8ZZ[$W77/74M?AGJ
M&Q%+3&/P LD(]U[HNN0Z>^0W\L?^6A3_  RP&Y=GUO\ -2_G-?+[LZ2NJ^M9
MLD=J==]D?(^6AF[Q[%VM+D,@N9BV)\<NB\"DC5\3)'!ES%.H82F23W7NK>]I
M_*?^55_*3Z_Z._E_[J^6'071=;U/U[M?;& V/O??>%Q&Y4HI8&G?>&^XUFEB
MVU7[XRLM3E:FLRLE*M7/523AV5]1]U[JV'&Y+'9G'4&7Q%?197$Y6BI<EB\I
MC:J"NQV2QU=!'545?05M+)+35E%64TJR12QLR2(P9200??NO=3??NO=('M3L
M;!=0=;;[[4W11;ER.W.O-J9S>.<H-F[9S.\]V5F*V_CY\G74VV]H[=I*_/[F
MS<U/3LM-044$U553%8XD9V53[KW6K%_.:_G!?%WOG^5W\T.G]F=<?,[$[HW[
MU%/@\+DNP/A1\D^O-F4E8VXL#5"7<.]=W=>XK;>W:#QTS U%9411!RJZKL ?
M=>ZVM=E?\>;M+_PV<#_[JJ7W[KW2F]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UT0""" 018@
M\@@_4$?D'W[KW0=[0ZCZUV#GMQ;EV7LW"[9S6[#$=P56'IVHX\@8':5+T4<@
MH*8&:1G80Q1AY&+-=B2=EB10GK0 '#H-.U_E+UETIO[:^P^PTW)AANO%?Q6C
MW<N)CJMH4:?>U%!]M7UL%8V32IBGIP9O%22I3I-$\C*CEELJ,PJ.M%@#0]&
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M=>]^Z]U[W[KW7O?NO=>]^Z]UI)_\+7<=V+4_';X'9%J7)57QPQ7R"WX_=/\
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M<A645=(:6KIHC[KW0V]\Y?\ E =C?\)TNB?E1UW3_$CHO^9#TG@^@<;MC/\
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M3<FP=UP8[(Y+,Q9"@AW%M3)8G+Q45?$H6:)9@DJBS CW[KW0,?\ "L266?\
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M52U/24M%CJ34\T\A2-$0LQ !M[KW2DSWR7[U_G[_ "/W5\?_ (*=X[^^./\
M+!^,&_*#&?);YC].;LJ]E]T?)SLW%+!F,?U'\?\ <&,FAS>TNN:53%55><TH
M,E R36DIGIZ>K]U[I?\ _"G#=F_OBA_)K+_'?M'MKJ?.[+[>Z'VAA-\;1[4[
M QG9)P?W.5H:R'*]DQ;B&^<[5YB&(-D*BLKYYZ^0L\[R.Q)]U[JPWY>_RR<+
M\^3TUOC._-C^89\8:W976U#MXX;X;_)"DZ5V[N_^)_;Y>3.;XQ]9L'>,N?W#
M32R-%#4^:+1 Q4J2=7OW7NM4OYT_#/=.*^:'5'\L3^65_-(_F^]Z_-O<572;
MO[_SW:OSORNY.B_BATK3BADS&Y.U8NO=@[+W#/N^:ES%'/!C(LE!)3Q5=()5
M>;(T,,ONO=6T?\*&U[@^"?\ (CV5M#J3Y)_(#_2+U/OOXY]=3?()NS]T83N[
M>ZTO\3Q^>SFZM_;9R&'SM=D-TS1-+6WF/FU 2&0@L?=>ZVJ/?NO=:S7_  F/
M[B[<[CZ1_F%Y'M[M/L;M3(;2_F6=Z;,VK7=D;WW-OBLVSL[%;2ZWGQ>T]OU.
MY\GE)L+MK&S5DST]!3-'2PM*Y1 6:_NO=5D?RG.A/E]_-_V9\J]C?(OY_?*S
MJSXD_&3YM]X[.V_MWX^=I9K:7>/<.^<EFDW)+BNTNZ-V2[XRS]1=;[4RV/H<
M+MJ@I*6@_P K:2R3TE/.ONO=8NK>G_YBWQO_ )J_:?\ (LZ+_F(]^UWQ<[IZ
M@V=\E?\ 9@^W-S4_8WRD^/\ TMAL7DL=O/;72FZLO3Q8/ [YWYO6FI,$]73T
M$-!08R4Y*DH*>O$DS>Z]TK?G/\7.VOY"_P @OY>ORM^,7SZ^;G;76/=OR^Z]
M^-?R/Z8^6'<+]U[=WO@.PH(ZS,;@IHJ/$[0QT&4JMN[3R;/)+C:NLI\I+35%
M'4TL<)I9/=>ZNY_F;_'K^99\Q?D+\;_C?\>>V=V?%'X"Y;"[LSOS#^2/3?8&
MU-L?(7*Y!*6N?:_6?7<56*S=FWZ.IFQU+&V3H8A&[Y29JK5!1)3UONO=4Q_S
M;_Y:> _EC?%/?_S6^&/\T;YI=+_)'HNGVCN6EVCW9\Q:K>VV^]:B3<^ PV0Q
MN:VIN>C%3N#>]?@\G42X^A$%5B<C41I2RT*13-/#[KW5D?\ ,.[YS_RD_P"$
MR?:GR1W7C:/#[I[U_E]]7=K;FQ>.8OCJ'<6^<-L#<.<@QY,<)% F4KY?"I4%
M8M(/(]^Z]T2[^6O_ ";.R?FG_+M^*?<WS4^=?S3VQN;=?Q9Z/PWQQZS^,'>>
M7Z6ZI^._1VU>O<-A^B<IB=JX_$U%#N_M/<&PZ/&9O/97)12QRU]6U.B/'!'.
M_NO=);XO=A_S#.SS_,S_ .$^&^?F;NA?EI\:I/COE>B/G+19/*TW=M?\2-^=
MF])9CM;+9JM6O7<5=OG:O1O8-'#39/\ B39-JO<)@>N5Z>"L?W7NMF7YG_$+
MX4?*S8>+J/G#U7UEV3UQU"^<WI0UW:]?-B]J[&,^.C@SVXZO('+X?'X^%,92
M!9:BIDT11*>5!:_NO=5=?'#^5S_PG3^7NQ]S=E_&3XQ?$GNSKW9V\\OU[N3>
MFPJC<.7VUC-XX+"X'<>6PC9@9^.BJ9:+!;HQ]4TL+R4YAJD99#<V]U[JI/M?
MO/\ X1F=.]H9_JG<?4O1>?S.ULNN#W!N+KOIKO?L785'D$D6.N2@WGM"DRV&
MW-38PM^_/B'KX2RLD;R2*R#W7NMF[^7A\9/Y;W3'7.6[>_EL]?\ 2FW.L/D-
M0;6R67WUT?E'S6V^Q*38\NYZ?;1J<E_%\K"U1M>JW1EH&@_:GI:BHGBF19%*
MK[KW5AGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+!W7\(OA?
M\E-U8_?7R+^(GQ@[^WMB=OTNT\7O'NOH+JGM3=6-VK0Y'*YBAVUC]P[ZVGG<
MO1[?H\OG:ZJBHHYEIHZFLGE5 \TC-[KW0/\ _#3O\K+_ +UI_ #_ -(W^.O_
M -KGW[KW1K^H.D.EOCYLV'KKH/J#J_I#KZGR-?EX-B=0; VGUKLV#+91TDR>
M4AVQLS$X7"1Y'(O$K3SK ))BH+L;#W[KW1<^V_Y:?\O3OOL.H[9[L^$?Q8[6
M[*KC$V5WMO[HSKK=&X<ZT-Q"^XLAEMOU4NXY(E.E6KON"$ 4'2 /?NO='.QF
M,QN$QU!A\-CZ'$8C%T=/C\9B\924]!CL=04D204E#04-+'%34='2P1JD<4:J
MB(   ![]U[I&]K=5[ [PZWWKU#VKMNFWCUMV+M[(;3WQM*NJ<A28[<VV<O$:
M;+8'*28NLH:R7%9:D9H*J 2K'4T[O%(&C=U;W7NG38>Q-F]7[(V?UKUWMG#;
M+V!U_MC!;+V3M#;M##C,!M?:>V,92X7;^W\+CJ=4@H<7A\5114\$2 *D48 ^
MGOW7NB9_(?\ E;?R[_EEV92=R?([X?\ 2';W:%)28W'MO7=VT:>IS>3H,.R-
MBZ'<,U-)2Q[HHZ!$$44622JC2"\0'B)0^Z]T>;#8;$;=Q.,P&W\5C<%@L)04
MF*PV%PU#2XS$XC%X^".EH,;C,;1104=!045+$L<,,2)''&H50  /?NO=.7OW
M7NO>_=>ZIV_X4"?]N9_Y@W_B"JG_ -ZK;/OW7NK8]E?\>;M+_P -G _^ZJE]
M^Z]TIO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7!8HT>2
M1(T624J975%5Y"BA$,C  N506%[V''OW7NBY?(C9OR W+0[<R70/9./V5F<!
M/7U.3P>8HJ&7%;J65:04<<M94X7,/!+1K'.HBD0TTQF4N8R@<70J/C'56KY=
M!MT?W9\CJ[?E)U;WQT;D,)624-?4)V7MF"IFV@300/+",E)3'+X56R.D1B6#
M(*5G=%-.BL3'ME2FI3^76@6X,.CL^V^K]>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=:JG_":_\ YGU_/A_\:H]P?^]EV5[]U[I4?\*]O^W.&[?_ !87HK_W
M:YKW[KW27_X5?_\ ;CQ?_$N_&O\ ^/\ W[KW3'_.EDQGQ%_G/?R9?YFW:+9+
M$?&O:,_:OQD[@[%J*C(5.SNJ\KOO;.^L/L7,[HI*FJJL'MVBRZ]M92JGR4-'
M#,])@9?N:@BEHEB]U[JZ#^9C\ZOC[\2/@!WQ\AM[=A[)K\!E^GM\8OJ>AI-P
M8;*Q]O;XW-M;*XO9.T]FK35DL6Y1GLS4Q+-)3&6*GHA-42E88G8>Z]U5'_(J
M_P"X7KK;_P 5Z_F!?^_[^4_OW7NC!_\ "7!$3^13\'65%5I6^3+R,J@&1Q\P
M._XP[D %V$<:K<\Z5 ^@'OW7NJQ\G@\Q_.)_GD?/#X6?+[Y4]S=2?'+X4X#:
MN-Z9^'73';.2Z8B[[H,]B\9_>_>^^OX54KF]]T- ^1I:RJDAT5%-3YF@BIY:
M>G-0M5[KW5:'_"D3X/?R;?Y9/PTVKT'\5.G-G8'YB]M]L;4S29&I["W?V9VK
MM7K#:N/S%3NO<&;K=[;LW-5;.V_G\@M!CH:.DAQ\60GFDE1'%-.1[KW5I_\
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M3?<U4E_'34_F=/-426]*+=C^![]U[J9[]U[J&V1QZ5R8MJ^C7)RTYJX\<U5
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M7NJ&_B?_ "$L)\X?C/UQ\Q?YD?R1^7>^OGI\@=FGNO!]F;5[MW+U^_Q/';^
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M_L?8_4&[.R]D;8[1[-QF?S'7&PMP;DQ6&W1O['[4J,/2[EFV;B,C4T]5N63
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MV^%WRW^!/R)^,_P!["@^6G>'R*^-?9]/6X?:N&W;M':O1O1<VSI:GN;O?O\
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MX6GP> KQ644<\$M-B*LZ%II\;4U7NO=6;?S(OYHM'\ OEI\/.I?DSU9LZE^
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M%+59'*_$[XH56!Q5=%.DVYMQ4_\ ?;/TE9 8Z[%QT]09'G+:O=>Z:=D_-/\
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M X=J2&?X0]E3314S8^G,$4TR_(V-998XB S!5#$7L/?NO=/W^@_^?+_WGU\
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MO9?_ -TA[]U[KW^@_P#GR_\ >?7P _\ 2'>R_P#[I#W[KW7O]!_\^7_O/KX
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MD/?NO=>_T'_SY?\ O/KX ?\ I#O9?_W2'OW7NO?Z#_Y\O_>?7P _](=[+_\
MND/?NO=>_P!!_P#/E_[SZ^ '_I#O9?\ ]TA[]U[KW^@_^?+_ -Y]? #_ -(=
M[+_^Z0]^Z]U[_0?_ #Y?^\^O@!_Z0[V7_P#=(>_=>Z]_H/\ Y\O_ 'GU\ /_
M $AWLO\ ^Z0]^Z]U[_0?_/E_[SZ^ '_I#O9?_P!TA[]U[KW^@_\ GR_]Y]?
M#_TAWLO_ .Z0]^Z]U[_0?_/E_P"\^O@!_P"D.]E__=(>_=>Z]_H/_GR_]Y]?
M #_TAWLO_P"Z0]^Z]U[_ $'_ ,^7_O/KX ?^D.]E_P#W2'OW7NO?Z#_Y\O\
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M -Y]? #_ -(=[+_^Z0]^Z]U[_0?_ #Y?^\^O@!_Z0[V7_P#=(>_=>Z]_H/\
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MNO>_=>ZUMO\ A61_VY0[]_\ $E_'K_W\.U??NO=7_=+_ /,G>I__ !&FQ/\
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'KWOW7NO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>timage_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_006.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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MDO6][ ]C?6EJ!X5O Z!JU,C&.74Q(P:D8(X\>! $>3VTJW5K<7!/B32JQ6E
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MZWF2.Q-T$*.-(*2!L$N%/\)(S4''^3H#?A%_,^_FQ_+[<O07?^9^*?2G4O\
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MF/R&U\SBQD6E2G>NPV8I*#)P4\[P3+%4&E-/,8W$4KZ3[;W+9[G:&"W$92O
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M0?B !"YI4XI4,[YN9LK0S1$$L%T,!J7N(SBHX$D$XK09K0G9Z^^>_P 7LO\
M$;&_+W<?<%#M7H[&8^/';A[)[*V_ENM%.0QDB4%3&N/SN/QN5FGJ<C>*ECCH
M&>L=D%(DNM+D[[5.+CZ94U2>2H1)Y5XH6&!DYQY]&"WT1B\8MI3^)P4\Z<&
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MIGCGT\Z=+K^8;\V=]_S!?^$[_=_R8WG\?:OX[T>ZNR.I,5L_;]9OAM]#,8[
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MZ"7/U5&D=)4YJ2*F5JZ6!%ADJ3*\2A"H]Q+=3&YE>0A1J9FHHHHU$FB@\!G
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MJFQT5"NY<M%3T\$=?59"HR6(FJE%'&DM14*XCCT*@&5P/\=CA9 LDFV&)$&
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M+_A3//''(Z)4_P JP05"J;!T7?"2!6_J!)&C?ZZ@^]_\L'_J-_ZP]:_Y:O\
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MGO.(MH6MXS-,B)"OA") Z$ T!!\1,T X5Q0UST5<MF>19G$<;,TC>)K8HP-
M2*>&V*D_G4=7??\ "?/X^]H?'#J/Y,;0W)O_ ./6]NIMU=V)V/T]COCGWW!W
MUA\"NY(:FGRV%-9!#&M**1:#%A"7+5+>61T217+A3F^^CW"6)U60.L020RQ^
M&SE>#4J>-?RP.C_E^T>SC=6*%3(60(Q=5!_#D#A3JW+YE=C?(/J7XW=C]@_%
M?IVB[][YP']T/[B=2Y'(_P *ARW\5SV+HLIKJ#4TGC^PPU3D:P?Y0FIJ<+ZK
MZ6#^VPPW$RI<2>%&:ZGH6TT4D8'J0!^?1K>2R0QEHDUN*46H6N0#D^@J?RZH
MG_X<7_X4%_\ >GC97_HPU_\ LD]BK]R[/_RG'_G"W^;HC_>6X_\ *(/^<J]+
M#KS^8%_/BSV_]C8/?7\IK9VT-DYK>&V<3O'=D.^/OWQ>*R-;!#D,BL";A=YF
MHJ1YIA&J,7*:0"3;VU/M&TI&S)>EF"DJOA,-3 8%:8J<5Z<BW"_=U#6H520"
MWBJ: G)IYT].MD7V#.A%U2O\JOFEWQ\A^W=Z? /^66,?-W#MJ2FPOR<^7F;I
MS6;3Z@I<IZ9J2C(1H]P;]:#S"GH(F,='.I6H82Q51H!)8;=#9HMW?5T&IBA&
M'F(]?X4KQ;B?P@]$]W=R7#&"UIJ% \ARL5?^//3@O#^(CS/Y\,?A[U/\&^A]
MN]$=2196MQ]#69#<N\=Z[FJ_XEF]S[BW"5DRVX\Y6'U5.2R,RKJ/Z(84AIH0
ML,,:@JW+<9-UF,TE*F@"J**BC 51Y #_ #G/2ZRLTL8Q&E<5))-69CDDGS)/
M^JG5:O\ PHRQ%-N#^6)O; UCSQ4>;[J^.V(JY*5E218\ENW&PR-&75U#A7)4
ME& -KJ1Q[.N393#?JXXK',PKPJ(G/1;S'&);1E/ O&#3YR*.FC^>UTIU;D_@
MU\=^LIME8"+9>W?F-\1=D;:PU+C((8L;C<KEOX!/34"B,I3QOB*JHIBJKI,3
ME2I''OW*UU)%=.ZL03!<$FIR1&S"OY@'[1UO?+=)8%5@"/%A %!@&15_P$C[
M#TT_SV\5BL%MG^50<)B\;B/[M_S7?B1BMNC&T$5$*"EBI\YII:,1HHIJ9?M*
M6T486/\ 9B]/[:6?Y28DWE?.RG)^?P],<P"@MO\ GJA_Y^Z$WYS]T;.Q/\P3
MXP=:=$_$3#_*[^8AMCJ'L#L?KS,;X[4EZOVUU[LK<,TN(R6<KZF6/(TLE7E*
MF*:EC6GP[UI5= J8P\,<B7:[5FLY9)9C%;ET1@JZVED +!0*K\(R:L /F>E-
M[.HN$2.,23!68:FTA$-%))HQ%> H"3\AT1#M6L^9-9_.M_D]9[YC;?\ BKLG
M<E>OS'Q^Q=N_&_-[BW57PXJ'8TGF.Y\UGZ7&BK$]552)04])C8X8=-<[33M5
M>. YM1;+M5\+8RL/\7U&0*HKXOX54MZ9);-1@4R5W!F-_:F8(/[:@0LV/#XD
MD+^0IBG$UP9SX<?]EA?\*$__  ]^H_\ WW.7]E.Y_P"XUA_S3?\ ZOMT96/]
MO=?Z=/\ JTO2[_D+=5[!P?\ )JZ#HJ?;.)JJ?M3:?<.XNQ4KJ"&7^,S[@W%N
M&BG7(:(T^ZB&.AIZ)!)J(I8HXBS:;GW-]P\NYS$GX655I7 50!_@K]O6N785
MCLHP/-23\RQ)/^']G5(OW-14_P#"/NH-343U!AW33TT)GE:71'!\A852-=1.
ME$'"J. . /8P  YHQ_JK:UZ#=2=BS_JI.!U8E_.)_P!,VX>[_P"2+UWUWMKJ
M;=^#SW:N\-TX_:_?M?78C9&1WSLK;N!;9M/GZK&PU5:' K<S]C!'2R"JJ7\#
MJ\;. '.6?!2WOGD9U81HM8P"XC9^^@)4>2@Y% >CO>_$::U5%5AK8T<D+K5*
MK4@$_P 1&#D#K!_, ZW_ )H_<NU>A<C\DJO^59\;VZM^2_5&_P#J/N>F[_WK
MM3+4>YL75.T&'Q-9F]O1TT\V>I4J8&H1*OW92,V+0H5UM4UC;-)X/U4FJ*16
M3P8Z%2O$TE- IHU:8IUN^2ZG">(($TR(P;Q'J"&X"L8J6%5I7-:=&)VOU_M3
M='_"COMC=^?Q5+E,SUU_+8V+DMG25E/%4K15F>W;'0S5T&N-GBK%H7J:=)$=
M2(JB="&UC2EDG9-E2,<&NG)_VL:T'V9_D.GEB#;DSGBMNH'^V=O\W^'J;!24
MF+_X4GUS8RFAQS;E_E'09?<9HP:?[^KHNS5HH:FL"FT\\-'2TT".P)6**-!8
M+[N<[$*^5[0?(&&M/V]4X;K3UM:G[1*1TE>M^]]_[T^7?SKJOY67PBZ?W+N#
M&]NX_K7Y6_+?Y%=ZY79N.SN]NO*62FDPV,Q-'C]P9J>AV^DKQ'[<TE&&:\5.
MJO'))J>T6&W@%_/( 4+PPQQARL;FNHEF106(KYDCCU:*X,DTIM8D)#!9)'?3
MJ=0,"BN3I!IF@!X=%_\ Y<R=LTOSK_GY4W>C=.Q=NU777QDR?8='T##DJ7:2
M9.KV-N:::/&#,.V3J)*;[CQUE54+')4UWW53X*83B"-=OWA_0[?X.O16XT^)
M341XJY-,"O$ 5H*"II4I-IU_5W?B:=5(:Z:Z1V' KDTX5Q4YH.'1P_Y"W5>P
M<'_)JZ#HJ?;.)JJ?M3:?<.XNQ4KJ"&7^,S[@W%N&BG7(:(T^ZB&.AIZ)!)J(
MI8HXBS:;DMYON'EW.8D_"RJM*X"J /\ !7[>EW+L*QV48'FI)^98DG_#^SJB
M_9-1E\[_ ,)W/Y96RL\SUG3787\Q?9'7_P B7KZMDIX]D3]H;TJ)8JJ1G @H
M!EJ3#@MRL;",!1?4HMNM,>]W;@T=+9VBI_OSZ=/YT+'RST'K;5)MENI%5:=%
MDK_!XS?/U"C[.ML'YT;'^$M5\:'@^:\.TMJ_''KO=/6>=H\M79G(["I\!E,%
ME*.DVW/C<AM^>BR6)DAK9J>FC:DGB @D>&2U,TH]QYM<ER)O\5U-(P<4 #%@
M5.H$$$'%>(^?'H8WRP^'^O0("IJ3I (84-013-/\'5&-77_-K<7\^/YS;B^.
M.Q/BIOG?W6OQS^.NV^K)?E5N?<>UI,=L/=&(H,AD*G:7\!H,C/.M5N:KKDR4
M\JQM"\RTZL!/-&121:+M%NLKS*&EF9Q$JL#(" -6ITI1*4X\3T15N#N$QC6,
ME8X@I=BIT&I-**U>ZM>' =&.Z<ZM^9S_ ,WOJ'O?Y-;C_E_]2;]S'QH[ V!O
MOI_X]]T;AR&[=[;9IGJ:G"YB;;N>P]#-DX<%G($C-<)CX:=/#<B%$""YGMAM
M[Q0?4./%1E>2-%2-J$$:E=LL*8\Z5Z5PQS&[627PE/ALI5'9F85!!H57"FN?
M+5\^K9/G]GM][6^"_P Q]R=7R92#L7 _%_O;+[)J<)3&MK8LGC]LY.6DFHX0
MKF6KAF57A41N6D50$<G22/:$22[A66F@RQAZF@TEQ6IQ04Z,MP9T@D:.NH1N
M5H*G4%-*#-<]%&_EF]4=#YO^37\9NO:G;.RZWJ3L'XDX:I[2Q34%)4X^NK-Y
MXAI]WS9%7"P35+Y6;(FJ:5M23(P=E,=U,-^N)5W.9]3:UG;2:FH"M1:?8 *?
M+I)M,*&RB2@TM$NH4%#J7NK]I)KU0OL;<.]=K?\ "1/<U=UO69>"LK&WUMO+
M5N.I+U!V_NKO"HQF=22-3,(X*K#557#5$,XCII9CK"J9%&4R))S,!+2E4.3C
M6+<%<X_$!3U/EY=!J)F39#X=>##AG29B&QG\)-?3UZV=]Y]0_'&I_EW;@ZBJ
M=O;,B^,D?Q7KL9!C(Z:FI\3#MZFVVT\%="P6.&)H852LCJETNDX6I5UE ?W'
MD=S,+H2@MXOB:JYU:]7^?H9/#&8?#(&C12GEII3_  =:_P!\=^J>X_DG_+;_
M )+^Z=L_*'I;IGY]=-UG;V]OB;LKOZ09+'[\P^TI<QB4QLN*9VRTYQ^SZ?!R
MMD*''5\E'3EI(TC>IBJ8!G?30V5_>J8I'MGTI,T>#$696K6FGXP0%)%>%<4Z
M#=JDMS:6I\1%F6K1A\AP%9:4J">T@DBM/SZ.;UY\E>_MI?//XC[%_F@?!'I_
M:W?_ &!2=C]:_&'YF_'??C;KP;U7\+EK,WB'Q%?4/G</2UM*H0FIEE/DJ5T4
MZPFHGB*9[&"2UFDL9W,:E6E@E72U-0535:JQ!;Y4SZ@=+XKJ5)XTNHE#-54E
MC;4M:%F%&HRU"_.O10/@_D/YC>2^<'\W;L3XY];?"K=G8LGS4W1U[O[/?)G>
M>Z]K;IH]N;.,U-L?'X^#;V,R,2[9DP4$+4TKS(U5)"Q82+3Q,IGNRV0M;-)7
MG"_3AE$:(R:V8ESW.G=JJ"*8%.D5@;GQ[ED2(GQB"79E;2JC1\*-C3D9XD]&
M2^-G3';6#^7/\S;>7S([>^#G2V"[U^)N/7Y*]6_&CO7(U-3MFJI,<:./L+/8
M[<6.Q3[?CJ-L5E?++DII-$TH6H=B7=_9=>SQR6]M';+.Y25A&\D:C54J?#70
MSZJ-Y>6KY]++6-TFF>8Q(&C4NJ.3IIJ&MM2K2J^?]'Y= K@-N?S(OA[\(DZK
MSO3OPL_FL?RR=M=-QMA\UUENV7JS=&3ZYIZ4Y(Y*IIZEZG;^3CBQO^4Q+CVK
MZJ=8TF%=/.Y=5LSV.Y77B!Y[2Y,A+!QK19:\ 1I=<\:C!/  =)8ENK. )IBN
M(0@ *G2S)3B0=2G'D#G\^MA_X?=H=9=T_%?X^=I],;=R&S^J-Z]1[&S'7VS\
MK M/4XC%&@ACI,3,B35$8?&1QBF/CJ)8SXKQR/&58@_<+=[2>2*0@NKLK$<"
M02"> X\>'0BM)EN(DD0$*RJP!X@$5 \^JH/FOM#K;>?\\#^4U1]DKBZF+#=4
M?*[=.RL7F$BEAJMP[=HJ.HQBA)3I>HI-,]93V!99Z6-T&I00?[9+)'M=WX=:
M%X Y'DI+_P"6@_.G15>HCWUOKXA9BOS;L_R5/Y5Z47\TB&EPGSH_DR;PV/%1
M4O=];\O-P;'2NH8 <E4["S6#D&]::3QM'-/BZ>CDBDDUNT5.\IE"$NX=O8R6
MM;U6KH\%6^0D$B!#]N3\R*CJ^YXGMB*:O%(^>@QL6_+ /VTZKU^#^0_F-Y+Y
MP?S=NQ/CGUM\*MV=BR?-3='7N_L]\F=Y[KVMNFCVYLXS4VQ\?CX-O8S(Q+MF
M3!00M32O,C54D+%A(M/$RG.[+9"ULTE><+].&41HC)K9B7/<Z=VJH(I@4Z+;
M W/CW+(D1/C$$NS*VE5&CX4;&G(SQ)Z-%\5NJ/DELWYF?S)^R.^MW_"C:VZN
MWOBQB,IVQ\<OBQVYE]V9"BW'@*#Q8C=V9V]F<7CJO&#,82HJ5DJVU?=S,DIU
M-*[^RS<;B"2UMXX1,P21PLDL:J"ITDH"K-72<T\J]+K**59Y7D\(%D6J1N6(
M(J-1!5:5&/G3Y=#]_P )[>LMD;/_ )3GQ3RV$V]C(<SO"'L;?NX\R^/IS5U6
M4R&Z<_2"IEG2)'>2GH(X:.%B2Z4L:1%F )+7.-PT^Y3ZCP8*!FE%4#_9/SZM
MRY"L5E%3S74?M8D_ZOEU=!GL%A]T8/-;9W#CJ7+X#<6)R."SF)K8_+#54>7A
M>GJ:>9?[44\,CHP_*L1[#"L5-1@C(Z.R*XZT^*+NGL'XX_ /Y4_R<,%GJFI^
M3&W/F=COY?/Q[:6KJLKD9M@_,BHJ-Q[?W'6"()54U/#LZHW./*MJ>D2&DC$B
MIH7W(S6RWMW%N;+^D8/J9<!5\2#L91Y'5(%^9U<.@>LQMK>2R4]XE\!,EB$E
M[E;U&E"?EV\>C#?S7.HM\]0]E?R*OB7\?]G]3[BZPV#V+NC![)V?\@,G7X[9
M>1W;TWMS T6QHMRUU!#69"2JDCFS+TR"GE:NK96282J\ED>P7"7,5_<3LX=D
M4EHP"^B22LE 2HI72#D4!Z4;K"T+VD42J45C0.2%U(G94T8\*TP:D#IZ_F =
M;_S1^Y=J]"Y'Y)5?\JSXWMU;\E^J-_\ 4?<]-W_O7:F6H]S8NJ=H,/B:S-[>
MCIIYL]2I4P-0B5?NRD9L6A0JSM4UC;-)X/U4FJ*163P8Z%2O$TE- IHU:8IT
M[?)=3A/$$":9$8-XCU!#<!6,5+"JTKFM.C-=J]XS5W\SWN':GP-^&&QN]_FI
MUAT9L':7R/\ D;W)W/6=:[<VG@=X/%EL#MFE@6ES=355-:GBK)TQN.I=7/ED
MG=)?&C@M--BC7<S1P/(S11HFMG90%9LL@ 'PU))]!3I1)<:KIE@C5Y510[LV
MD*K$D+4*QJ>- *>IZ+5\7G^20_X4+YZL^5E)\=L)V]G/Y761J<CA/C349RNP
M\&/C[#QL>.I\ID-P)3U^5SHIZ599I_L::%:8T4$4++3?<3&5]X V0"W,A07@
MS(%!)\$UH%) 'E2IS4US0(;;Q3NE9= ;Z;@E2 /%QDTJ?.M!Z4Q4CW_+DZSV
M3E_YK/\ .Y[%R^ QN7W52]G_ !VV)CZ_)T$%::;&9;:M955]-3F2)I(TR,L=
M+]ROD*2K3P J-!U(-YN&_=]C'Y!)6\\DRD?RIC[3TLVZ%?J[I_,M&OY",'_+
MG\NK_%4* J@*J@*JJ+  ?0 ?@#V$^C[KOW[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=4J_\*'-I9+=_\H3Y9P8BCK,A7X"'J#=OVM&H8_;;<WUMJHR,T@/^
MZ:3&K65#D$$+$3S8@BKDJ58=S@+&@)=?S:-U'[20.B'F:,RV,H7- I_)74G]
M@!/0B_R3NV.O=]_RJ_B-E]M[JPM91=>].X[8V^7;)0(<1DM@>6DR=/D1Y#]D
M8O 9QYBA:EDBJ+".124O-%N\.X3A@06D9A\PQJ"/M!Z4;'*LMG$5-:1J#\BH
MH?V$=4W_ /"<6LQ6_OG7_.4[?VO*V9V5NGNNCK-J[JH'6JQ]92[OWCO_ "D#
M05,1DIYS-2+2S(8Y6'C<."5=6(HYX!AL[")L,L7<IP00D0R.(R"/R/1%RN1)
M<7;KE3)@C@>Z0X/G@C]O0?\ \B'972^Z/YMO\WG)[YP6S<[VEMON3LN?JV/<
M='3Y&MIL?D]_[LAW+4XR*H5RA!&#BJ)HP'2.58]029PSO.$DB;;8!20AB752
MM"1''IK_ ,:I^?3?+B(U[=D@:A(:>M"[UI^P5_+I+],[&ZAPO_"A3^:9TALC
M<&)ZB^-&^_B5VGMWM_(;0SR;%Q&$CWAM38[;HR354#4M)B9\7NS*9-A/YZ;[
M*J>18YHR2CWO9';8[.5AKD68:-0U$T:72,UJ"%&,@@#'6K5%&ZW,8[4:+NTG
M2*D1U.*4-6.>().>@PZCZ>_FS_"?XI;\V!\7L=\&_P":C_+<GR79$^8BVNV#
M[*QU?B8)*B7/^6*DRF%S%34,Z5&NGI<EG#25(TTS21JFI^[NMMW:Y$ES]19W
M5%XU%&H-/X33RS1*C../35M!>V$&B#P;F"K<*&JFNKS .:^;9^6.AP^4'RJZ
M.^7'_"9_N3?/0G06V?C'MG9O;W6O6^Y.FMDXV*APN,SN-WOM/+5\V+EAHL?'
M6TN1BS-+5M/]OK\TTL,SO/#*Q3[;MTVV;_''/(96*NPD8U9E,3@5J2012E"?
M+&*=.WUY'?;0[Q((P"H* 4 /B*33 !&:U'^&O4W^9KD=]T/_  F&^#E-M 1'
M;^8V=\+<=VD9%E)&!BV[-5TY3QD(&_O/2[<%Y04TZ@!Y#&1K8 AY@GUUJ'N-
M%*?%J(S\M.KAYT\NO;N7&SQZ:4T0ZJ_PT'#YZJ?E7HY7S1ZC^&M%_P )RH9L
M?MKK7&;"Q?Q-Z9WCU-N#&4U-2SG>%=3XBHQE52UVG[V3,93.U$L5<3(:BI^X
MK8:NZR5 ]D^T7%T=[!)8R&=ED''MJ0U1PH%K\A0$<!T:;E# -M8#3H$0*9\Z
M K0^I-/M\^/6MWW[E=\S_P I#^0;LI:##93J+<'<_P P\KNK#[RK)</MBOSN
M)[9J:3$T^X\E$JMC:/\ AF3SZ>1:F-S23Y"50QIM48^MU0;EN3U(D$404KEP
MIA!8J*BIJ%_.@J*]!"0N;*R6@*&234&PA;Q2 &-#04+?E7!IU;U_,I^,G\Q'
MO^N^)]5V+L3^5=\-.TNI>S*;='QZWUA?D1_<C*Y&;:,<%8,%BXLQBZ9,A245
M1#C:[[:G60P&!&"*CN2$MAO[';_&TM=S(\965?"6@#&FHTD-.) )]>A'NUI=
M7GA5%O&Z.&1O$))(%:"L8] 2!Z=;E%*]1)34TE7 E+5200O4TR3?<K'(Z@O&
M)-*>0(UP&T+JM>PO;W'!Z&'6HE_+YPNU.R/^%&W\SJM^0^%VWGNUMGXG<_\
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M2I!"J*5K@#C7/3>W!Q>7'B%"VB+5H4J*]_&K,:TIDGA3HVW_  F_VY@\9_*
M^-E=08JAIJO=^<[ZS.YIXJ9$:NJJ??NYL6DU20MYG7'X^B@!>Y\4*)^E0 QS
MTQ.Z3?(1T^7Z2'_+UOE44L8_]O\ ]7&ZH9H8%A_D8]4;)KH::EZ-JOYQU%LC
MNBBDJ#08^CV(N\<A//!.JH43')E8\7<%D5&*L"2 I$0<MNCR5/B?1:HR,L9/
MIU_.M"3]O164 L52@T?5:7' !/J#_*M!UN _,_!_#X_%C?=#\T,9L6/XIX*D
MV?5[UI-V4U1!AZ6'"Y7'G#:8\8%JHUBR:8](4IP-5Q$5:)G0Q]MK7 G4VI;Q
M<Z=/Q5((/\J]"R\6$Q'Q]/AXU:OAP017\^M=B1/G+NG^>9\R,[\*JOX<56[=
ML_%CXRTG37^SK4>\YHH>L\_M[!U-9-LR3:Z-DH0VZ9JG^(FM76TE44U+ZT(U
M0V*;3 MUX^DRS%_ *?VH-!KUX^"FFGSZ#+BZ:_F,'A5"1!?%#?V9!)TZ,_%6
MM?EZ#HPVU^F/YA&2_FS?"+NWYH=W?RMNO>Q-K[$[MVA0]8?'#>N_-O;T[ VG
MF<+D7J:&+#[LQT@W#!M[)!<C$D==3K1JM75,)C$JJDEN;$;=/%:1W; M&Q>5
M8S'$P:E:H>TL"5R#7 Z41PW?U<4EP]NM!(NE"X=U(K2C#-" <<,GK91JS4"D
MJC2*&JQ3S&E5K6,@4Z ;D"Q:WU(']?8''0HZHA_X3D04DO\ +BI\_EXHCW%N
M?Y$?(?+?(BNJ8(X<G4;Q_O%415+YG0JO_$5Q28D,KBZQ^, !-(]BOG0CZXA/
M[-8X1%DD"/PU(I7RJ3^=>B#EL'Z4%OC+R&3A4OK8&M// _*G5-G<-/CM@?R]
M?^%(6,^-^JCVO2?//$X0P;1C2KAIL9GMQ[5I=W4=,D"M'%C(8ZG,4TBQIHIJ
M(2"Z1Q%U$MC6>^VPW/'Z>HU8ROBF/TSA:>I]:]$]W^E:7W@?[^-:9^(1:_7&
M6KZ?*G6VMU[LSH6/X9[-V1!AMG?[+6_QRP6+.)2DIQ@WVA4[=CUDQD&G-%+B
MV:1F-PRL79B26,<RRRF<N2WB:R2:G5KU<?6M>A@D:",* -&D  4III_@IUK8
M_"SJ+:_R:_D ?$SJSNSY-T/QIW/5_(NM;XA]L=@U%%KDW5LW?6X)-F8NGQN4
MJXUS8GDCR$%/005+LE/$# 'AI A'.[SM9;S/)%%XJB/]9$K30T2B0DJ,<<L1
MQ-3T%]NB%QML2/)H);]-VI74LA* !CG@*+Z8'0[?(3Y$_/SX@8[JO=7\W3XK
M?$/YC_%?8?>/7^2Q/R+Z(6HCSNS\])+-08/==1M'.4W^5Y>)ZM_$N+QM,L$C
MR11U1D>F\B.SLK/<2R[=-/#*T; Q2TTR"FID#H1B@_'@TS3R47%S<68#7D<4
MD8=:.E=2&M%;0P.:G\)J*XKT 'PUHOYH^5^=G\WS=GQ(J?@%+OX?-3=6UNR9
MOF52;[;=<&VL-/6IU]#B9]FH].-L/M] E,D]I2U-J8O92IAN3;:+6S6X^IT_
M3J5\$IHUDGQ*B3\6KC3'#I'9K>F>X:'P-7C$-XH;5I &CX/PZ3BOS]>CL?"#
MIGY@[=_FY=Q=R_+'NS^771]K;Y^(>-VWV9\=?B%O7=T>=KX<#G,2VW=ZY?;6
MZL>E4ZTE.9<<^3_B)6.*:EIDIP9VD8KW:YM'VY(K6.YTK.2LLRII&I#J0,AI
MF@;33U->E^WPW"WC/</!5H@"D1;4:-AB&%<5(K7T'5^/8G_,O]]?^&=N;_W"
MG]@U.(^T=",\.J;/^$ZF!ZYQW\HWXVS['IZ)ZC<E;VYE.Q:G[>&.HJ<]_>W-
MT=7]^(QZW@HJ:AIH#(-;4$-(3<$$BGG5I&W.;Q/(J%]-.A:?M&3\R>B+EE46
MRCT>8-?75J-?V' ^5.M<7N!]]_\ #<7R@V)UC4[?QOQ??_A0WN396W4W332G
M94.P'EK*FDI\@M&J3-LB+<J;>FJ%H7OY5=82DA<,,[8Q"]B=ZF7]V!NT_J>+
MHS3C1]%:5^1].@Y,)3;.BTT?7%>X=GAZ_/A5==*T^8]>KE/F;U#_ #K.TOB'
MW/U3\D]R_P C[8/QSSG755AM[;I:M[>VQ3[>QU*(C292BJZ^AJ<;C:C$3QTL
M]'+)220PS11$Q.HT$.[9<[1;7,<D OVD#@JM(26->% 037@0,GHVO8=QFA=)
M3:!"I#']04%.-2*"G$'RZ#+^8CLBLK/C=_PGAZX[2WIL7O26K^8WPAV5O/L#
M96<?>FW=VT]1C,=0U.4Q^3J(8'R^,S=*QF2J>GC-7'-YC&ODTAW8W N-R:-6
MC'T]R51AI9.ZH!&:$<*>75=U!,-F'8.?'@JP-58T-2#Y@\:];6JHB?I15LJH
M-*@<)>PX_ N;#\>X^Z%O5/O\[OI'=G87PMJ^\^J(6'?/P>[ VA\QNG:R**:9
MON^FYC69:FDCIY(IIZ>?!FOD:!7!EE@@ ((! BY7NEANA%+_ &<ZM!)P^&3
M-34"C4-?+HGWN!I(-:?'$1*G'BF:4!%:BHI\^BM]<=O;8_FC_P TWXX]C;"J
MUS?Q]^!WQ%VO\DC31UK2PMV5\SL3#+M['Y.E,:(*G"[5C>KB,CK/25T,T>B,
MF=2OFMFV+;Y$D%)+B8Q<!B.W/=0_-R!C!ITFCG7=+M&0U2*(2<3EYAVU%/)
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M5Q\.+IZ..."*E2G$$<*K$L810H9:5W8N6)8DL6))8L34DGC6N:].+&J*%
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MBG6&EFJ/OEJ8:QI9*P92+)VKTK'F>H^^45+.TMR0BNZ3K<"[UGQ0VK6<FO\
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M,[LS-_O$U^4K1%CQ&D8TI'FO:/6O$DDGS/3EIM\=H&I5F?+LYU,^*9/IZ 4
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MX(+=OW:3;?%T!3XT3Q-JJ:*_$BA&?MJ/ETLO+!+WP]1(\.19%I3BO &H./\
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M_P X9/\ H'KW[VM?]_1?\Y$_S]>_X<L_ER_]Y_?"?_TJK8O_ -?O?OW!??\
M*-/_ ,X9/^@>O?O:U_W]%_SD3_/U[_ARS^7+_P!Y_?"?_P!*JV+_ /7[W[]P
M7W_*-/\ \X9/^@>O?O:U_P!_1?\ .1/\_7O^'+/Y<O\ WG]\)_\ TJK8O_U^
M]^_<%]_RC3_\X9/^@>O?O:U_W]%_SD3_ #]>_P"'+/Y<O_>?WPG_ /2JMB__
M %^]^_<%]_RC3_\ .&3_ *!Z]^]K7_?T7_.1/\_7O^'+/Y<O_>?WPG_]*JV+
M_P#7[W[]P7W_ "C3_P#.&3_H'KW[VM?]_1?\Y$_S]>_X<L_ER_\ >?WPG_\
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M>_X<L_ER_P#>?WPG_P#2JMB__7[W[]P7W_*-/_SAD_Z!Z]^]K7_?T7_.1/\
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M_<%]_P HT_\ SAD_Z!Z]^]K7_?T7_.1/\_7O^'+/Y<O_ 'G]\)__ $JK8O\
M]?O?OW!??\HT_P#SAD_Z!Z]^]K7_ ']%_P Y$_S]>_X<L_ER_P#>?WPG_P#2
MJMB__7[W[]P7W_*-/_SAD_Z!Z]^]K7_?T7_.1/\ /U[_ (<L_ER_]Y_?"?\
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M_P X9/\ H'KW[VM?]_1?\Y$_S]>_X<L_ER_]Y_?"?_TJK8O_ -?O?OW!??\
M*-/_ ,X9/^@>O?O:U_W]%_SD3_/U[_ARS^7+_P!Y_?"?_P!*JV+_ /7[W[]P
M7W_*-/\ \X9/^@>O?O:U_P!_1?\ .1/\_7O^'+/Y<O\ WG]\)_\ TJK8O_U^
M]^_<%]_RC3_\X9/^@>O?O:U_W]%_SD3_ #]>_P"'+/Y<O_>?WPG_ /2JMB__
M %^]^_<%]_RC3_\ .&3_ *!Z]^]K7_?T7_.1/\_7O^'+/Y<O_>?WPG_]*JV+
M_P#7[W[]P7W_ "C3_P#.&3_H'KW[VM?]_1?\Y$_S]>_X<L_ER_\ >?WPG_\
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M>_X<L_ER_P#>?WPG_P#2JMB__7[W[]P7W_*-/_SAD_Z!Z]^]K7_?T7_.1/\
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M_<%]_P HT_\ SAD_Z!Z]^]K7_?T7_.1/\_7O^'+/Y<O_ 'G]\)__ $JK8O\
M]?O?OW!??\HT_P#SAD_Z!Z]^]K7_ ']%_P Y$_S]>_X<L_ER_P#>?WPG_P#2
MJMB__7[W[]P7W_*-/_SAD_Z!Z]^]K7_?T7_.1/\ /U[_ (<L_ER_]Y_?"?\
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M_P"\/?\ V8+M/_[-_?OZ\;I_O_\ ZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\
M)P_[P]_]F"[3_P#LW]^_KQNG^_\ _JG#_P!:^O?U6L/]]?\ &Y/^@^O?] ZO
M\G#_ +P]_P#9@NT__LW]^_KQNG^__P#JG#_UKZ]_5:P_WU_QN3_H/KW_ $#J
M_P G#_O#W_V8+M/_ .S?W[^O&Z?[_P#^J</_ %KZ]_5:P_WU_P ;D_Z#Z]_T
M#J_R</\ O#W_ -F"[3_^S?W[^O&Z?[__ .J</_6OKW]5K#_?7_&Y/^@^O?\
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MP_\ 6OKW]5K#_?7_ !N3_H/KW_0.K_)P_P"\/?\ V8+M/_[-_?OZ\;I_O_\
MZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\ )P_[P]_]F"[3_P#LW]^_KQNG^_\
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MS?W[^O&Z?[__ .J</_6OKW]5K#_?7_&Y/^@^O?\ 0.K_ "</^\/?_9@NT_\
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MK_)P_P"\/?\ V8+M/_[-_?OZ\;I_O_\ ZIP_]:^O?U6L/]]?\;D_Z#Z]_P!
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MZ#Z]_P! ZO\ )P_[P]_]F"[3_P#LW]^_KQNG^_\ _JG#_P!:^O?U6L/]]?\
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MKW]5K#_?7_&Y/^@^O?\ 0.K_ "</^\/?_9@NT_\ [-_?OZ\;I_O_ /ZIP_\
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MR\W/_.7_ &.O?] ZW_@TG^8I_P"C7_XW[]_7+_ESL_\ G#_L]>_JY_R\W/\
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M *-?_C?OW]<O^7.S_P"</^SU[^KG_+S<_P#.7_8Z]_T#K?\ @TG^8I_Z-?\
MXW[]_7+_ )<[/_G#_L]>_JY_R\W/_.7_ &.O?] ZW_@TG^8I_P"C7_XW[]_7
M+_ESL_\ G#_L]>_JY_R\W/\ SE_V.O?] ZW_ (-)_F*?^C7_ .-^_?UR_P"7
M.S_YP_[/7OZN?\O-S_SE_P!CKW_0.M_X-)_F*?\ HU_^-^_?UR_Y<[/_ )P_
M[/7OZN?\O-S_ ,Y?]CKW_0.M_P"#2?YBG_HU_P#C?OW]<O\ ESL_^</^SU[^
MKG_+S<_\Y?\ 8Z]_T#K?^#2?YBG_ *-?_C?OW]<O^7.S_P"</^SU[^KG_+S<
M_P#.7_8Z]_T#K?\ @TG^8I_Z-?\ XW[]_7+_ )<[/_G#_L]>_JY_R\W/_.7_
M &.O?] ZW_@TG^8I_P"C7_XW[]_7+_ESL_\ G#_L]>_JY_R\W/\ SE_V.O?]
M ZW_ (-)_F*?^C7_ .-^_?UR_P"7.S_YP_[/7OZN?\O-S_SE_P!CKW_0.M_X
M-)_F*?\ HU_^-^_?UR_Y<[/_ )P_[/7OZN?\O-S_ ,Y?]CKW_0.M_P"#2?YB
MG_HU_P#C?OW]<O\ ESL_^</^SU[^KG_+S<_\Y?\ 8Z]_T#K?^#2?YBG_ *-?
M_C?OW]<O^7.S_P"</^SU[^KG_+S<_P#.7_8Z]_T#K?\ @TG^8I_Z-?\ XW[]
M_7+_ )<[/_G#_L]>_JY_R\W/_.7_ &.O?] ZW_@TG^8I_P"C7_XW[]_7+_ES
ML_\ G#_L]>_JY_R\W/\ SE_V.O?] ZW_ (-)_F*?^C7_ .-^_?UR_P"7.S_Y
MP_[/7OZN?\O-S_SE_P!CKW_0.M_X-)_F*?\ HU_^-^_?UR_Y<[/_ )P_[/7O
MZN?\O-S_ ,Y?]CKW_0.M_P"#2?YBG_HU_P#C?OW]<O\ ESL_^</^SU[^KG_+
MS<_\Y?\ 8Z]_T#K?^#2?YBG_ *-?_C?OW]<O^7.S_P"</^SU[^KG_+S<_P#.
M7_8Z]_T#K?\ @TG^8I_Z-?\ XW[]_7+_ )<[/_G#_L]>_JY_R\W/_.7_ &.O
M?] ZW_@TG^8I_P"C7_XW[]_7+_ESL_\ G#_L]>_JY_R\W/\ SE_V.O?] ZW_
M (-)_F*?^C7_ .-^_?UR_P"7.S_YP_[/7OZN?\O-S_SE_P!CKW_0.M_X-)_F
M*?\ HU_^-^_?UR_Y<[/_ )P_[/7OZN?\O-S_ ,Y?]CKW_0.M_P"#2?YBG_HU
M_P#C?OW]<O\ ESL_^</^SU[^KG_+S<_\Y?\ 8Z]_T#K?^#2?YBG_ *-?_C?O
MW]<O^7.S_P"</^SU[^KG_+S<_P#.7_8Z]_T#K?\ @TG^8I_Z-?\ XW[]_7+_
M )<[/_G#_L]>_JY_R\W/_.7_ &.O?] ZW_@TG^8I_P"C7_XW[]_7+_ESL_\
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M_F*?^C7_ .-^_?UR_P"7.S_YP_[/7OZN?\O-S_SE_P!CKW_0.M_X-)_F*?\
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M ,Y?]CKW_0.M_P"#2?YBG_HU_P#C?OW]<O\ ESL_^</^SU[^KG_+S<_\Y?\
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MO?\ 0--N7_O:K\R/^I]1_P#9%[]_78?\H=K_ +QU[^K1_P"4FX_YR?['7O\
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M-N7_ +VJ_,C_ *GU'_V1>_?UV'_*':_[QU[^K1_Y2;C_ )R?['7O^@:;<O\
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MDW'_ #D_V.O?] TVY?\ O:K\R/\ J?4?_9%[]_78?\H=K_O'7OZM'_E)N/\
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MH_\ *3<?\Y/]CKW_ $#3;E_[VJ_,C_J?4?\ V1>_?UV'_*':_P"\=>_JT?\
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M)4ZE5KM(.>>9#<R6TS<7M8R3ZDEF/#_3=!?E>,0)/&O!;B0 ?(!0/\'6S/[
MW0HZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>ZU^_P#A37LN#=/\IWL[.34T<\G6W:G2F]*65X]9ADKLY#MTR(?&
M^AC%GY([ZH_2[+K.KQN,>0I"FYQC^)9 ?GV,W_/O0<YK758N?0H?^-J/\O5T
M/QVWS2]G_'[HOLNAJ8*RB[#Z<ZQWS1U=+,M1'+%NW"4-?')'(A9'1TJ RLK%
M2"""0?85NHC!*Z,*%692#Q!!(Z/X9!*BL,@@$$<""*]#'[8Z<Z][]U[K64_D
M[XQ>J/YMG\]#ID3SI3;@[GV-W+C,;-)&$B3=>5W9F93!$AB6.(1[KHXQHIS^
MU' LDA*(9!US+)]5MNWRD"HCDC)'F$T(/^.D_:33H+[*G@7MY&"::T>A]7#,
M?\/[ .MFOV!>A1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1*FOH*.2EBK*VDI)
M:Z84U%'4U*0--(?I'$&8&1S_ *E03_A[]U[KNMKJ+&TTM;D:REH*.'1YJNMJ
M$I8D\C!%U2.51=3,H%SR2 .3[]U[K+!/!500U---%44U1%'/3U$$@E1TE 9'
M1U)5D92"""00;CW[KW46DRN+R$]934&2H*VIQTO@R%/25D=2\#W9=$R(S-$^
MI'%F -U8?@^_=>ZG^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NJQ/YT&QJ7L/^5?\X\!64T%5%C^BMP[Y
M2*HA6=1+UA-3;E@D"N" \,^)CD1K:D=592& (/>6)3#N%N0:?JJN/1CI/[0:
M=%>]QB2SF!S^FQSZJ-0_81U/_DX[T@W]_*X^#&<IJF.JCH?CWLG9;2Q2>4"3
MK:-]NRQD^26S0RXIXV&H:64KHCMXUKS+&8MPN ?]_.?]Z8M_EZWLK:[2$_\
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M-#2ZY*>&.HCD;(30!YE]U[IWZ_\ YBW>&VN]NE.E/G#\*:_XATWRBSN<V?\
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M'\/K<XQ'^;NJI)=92I'/*P6XL=P@/$PB0?\ -O6W^'3T&-\)ANK24<!*4/\
MS<TC_!7K9H]@;H3]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=:]'_"D+IZ+?GQ,^,?;.=.?/5OQ=^?7QN[F^14>"@KZJW661?*;2WS
M-5IC;U28^GP^Y7DKI0CJF.6L65?#)(Z^Z]T&?\SU?AGN3/?RI8?A?5=$S?,F
M7YN=!5WQ!J/CY4X./)Q;&IJA*GLR8C"$(=A)L.*N;)I/IHF(I5 :?QHWNO=#
M)T+F=D_%?^?'_,^Q_<&[<%L*3Y_]!_!/O#HC);SS$>W*+.+\9L!N+8>ZL5B:
MJLBIZ.LRF+D?'5=311UDE5%2U"51C,$A,/NO=*#^74N)[N_FI_S>?F5UKEJ'
M=?0^?/Q+^+>Q>PL-5#)8S/[AZ!VU6S;S?#UM/)+0Y#'8:NS./Q[5$<KWKHJR
M$!!!JF]U[HA?:_\ PE@_TI=I=E=F_P##J7S3VE_I%W_O'??]U=O5'AH,9_>[
M(U.0_A]"G\:711T7W'AA72+1HHL/?NO=:]'\^G^4QV!_* Z!Z6[CZ]_F)?+G
MN3(]I=P5'6==A=Y;MK=NPTD,.%R&4%5%)0Y>5Y)2]&L>E@%TL3>X'OW7NOIU
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@U[DE[3AZH[&FZ.I]KU?<<>S=PO
MU?2[W:5</)G5II/X8F4,,D4PH&J_$)]$BOX]6E@;>U=@(#/']3J\+6OB:*:]
M%1JTUQJI6E<5Z3W?B^$_@:?$TMHUUTZZ8U4S2O&F:=4L_P ?_P"%&O\ SQ'\
MN?\ \Z]Q?_7CW(GA\H?Q;E_U1_Z!Z!FKF3TL/^JW^?KW\?\ ^%&O_/$?RY__
M #KW%_\ 7CW[P^4/XMR_ZH_] ]>U<R>EA_U6_P _7OX__P *-?\ GB/Y<_\
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M\&<]2YR/&OH,].*3Y"25"52I_G(UIH8W8.#98XWXT(1[KW4O^0,V<KOYRO\
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB3?S _Y?\ \=/YE?QMW/\
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MT>=P&0V]456.R..J)46KIY-8FBJ(XIT]U[I#_'GX&=TTGR9P?S,^<GR2VO\
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MU[KWOW7NO>_=>Z][]U[K2P_X6V_]D._$+_Q:VM_]Y#.>_=>ZV<OYAOS4VY\
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MUN7>,2'-R3T$.WJ;[=J6.F4M75F3EEIXJ6.);U%1/$B?K'OW7NCE?R^OF_\
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MA\&\W+A<J^273&LCQ[.W=C98ZDM(_CAEC<(J*S>Z]U4WTA35FS*_X ?SOJC
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M%>EH=V3U-'D:*'Z&1<?N7#Y:25M-U>NC!-F4"5?>&Q22YM]SA_L[N!3J]64
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MW?BX:2CI*FJB&>J6B\"3S2CW7NCG_P X#XR=V]_?$C;>1^).S<%NSY5?%[Y
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M\=),Z/!)3&26/W7NB ;)ZU_FZ[]^6?\ +_[:_F?=&=O[_P#AQ\<^ZLMN#I'
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M%DUI+U$?NO=63]Q;QW=_*_\ B;\&NJ?CKT>.^=B[1[?^&'P<W''7[YI]DUN
MVAO66BV%3;R2!X*RJW%D*7,R8".;'4D3U$HKIZ^>6*CHZRIB]U[HZ/R4^.G5
M/RVZ,['^./>.$R&X^INV,)%MW?.!Q>X:[:L]71QU,%68%R&,J*6NIU>6FC#F
M*="Z:HV)1F!]U[K7C_F%?R"^OL]UW\>,;\2]N_*'L'/XOYD?&3,=IXG>GSU[
M"RE-C.N]O9P5.Z\O01;M[ @HH,EC:&*(TLM!JR\+$OBU%2J.GNO=6Z?)OMC>
MO\O;H7XH[?\ C_TCF.^]GS?)'XM?$W=46\.XZE\SMW:?;V5BVC!NV3(9HY;.
M[SR>/S59@*>6E#SUU0E9-D*J>.DHZRIB]U[JQGW[KW6O=L#IGY[_ ,I[L/O;
M:GQ;^-5)\X_@!W=VWNSNOK7K+K7L[ =5=D]09WM&66MW+B:2@WC48_;.Z-CS
MY<BIQT=-EJ>OH9:J=9Z:6G1YW]U[H@VQ.M?YNF^OE[_+\[C_ )GO27<F^/A]
M\<>W\[D.C=O]<XW8W879E%OK>L-!MS9F\N^<=L6O?!OA,1%7Y.<9+;5,O\,D
M*56>HZ:G:L=/=>ZO*_G0_';N/Y9?RO\ Y>_';X_[/_O_ -Q=H[!P6$V+L_\
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MA*?W[KW5K_;_ &M_,OZY[4Z0^2^Q?CONSNCXY[Z^-='M_OOX";;W9UYC=_;
M[$K*J#+0;BQ&YJ^KQF(W7!#23U.#RU"N[S2H]-#D<5%/Y9M7NO=,'\M[XV?(
M6B^4'SV_F$_)?J? ?&S>_P V\ET/MK:'QOPNZ\;OG)87:_QRPM=B,5F-[9G#
M:\17;QSQR,SS04=55P8RCAIJ,5E2X?Q^Z]U<=[]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[JDG_A1-L>KWO\ RBOE'_#Z85>0VA-U%OB"$R)#:+ [SP'W\H:26) 8
M,9-6R6];.$,<:-*Z>Q5R5,(=SA+&@)=?S9& X>I('1#S-&9;&4+D@*?R5U)_
MD#U8%\!]_P W:GP<^'?8]4?\OWM\8>BMQY1?*U1IK,GMG&25D?D<!Y/'5&9=
M9%VMJ_/LDW6W^DNIHAD)+(H/J%8CHTL9OJ((Y.&I$:GI50>C:>T'2KKWOW7N
MM9O^4QC:3JS^<K_/+ZFIU-,=Y=B=9]SBDD=F9VW%6[ASD\P\H>70TV]M7ID6
M,"10J:/&$'/,4AN=KV^0^2RI^2E$'\DZ"^SQB&^O%'FT;?FP9C_-NMF3V!NA
M1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW6EA_PMM_[(=^(7_BUM;_[R&<]^Z]T;[IZ2;?'_"H/Y+5E
M0S5=+UGT!11X99R*8TJ1[+V+03A!';S!JS,UQ'D+^F8MQH0)-.XJ+;DJVI@R
M7)+>=3XD]/LP@X>GV]1M92&;F:<'(2W 7Y#3"?\ "QX^O6TC[A;J2>M3SM61
MOY</_"A3879VI\/T=_,(P-/MO<<XA\5)'E]]S4V+K(]2EAYH=YX_ 92JGD11
M%3Y24%E0NXG&Q'];N4Y(.,VWN77U\-:MY^7ALZ@#B4&*TZC&Z/\ 5_F!)3B*
M\70?3Q,+P'GJ"$D_QG/'K;#]P=U)W7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T@NU-G9;L3K'L;8& WUN?J_.[XV+N
MW:.$[+V4\,>9V[6;CH*BCIL[B34QS4PR6)GF2JIO-#)%YHD$B.FI3[KW557\
MNS^3/U7\#>^.\?EONKO?NSY>?+OY XRGV_OGY!?("OH\AE(L7"]+(^.QD=-"
M#24T_P##\7&RM4RK%34%%24JT]+3K"?=>ZN2]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TWY;$XO/8K)X
M/-XZBR^%S./K,3E\3DJ5*VFJJ7(QM#44]1#(K1S03Q.Z.C*5=6*L""1[]U[J
MGN'^11\'&EH=M9G.?+/=GQ[Q&1QF2P7PSW;\Q.PL]TW1'"5K5M'2P[ FSAQ<
MF(I7,<28J<S8O[:-:=J-HFE63W7NKCJ:FIZ.G@HZ."&EI*6&*FI:6FB6"...
M!0J1QHH"HB* %4     6]^Z]UF]^Z]U[W[KW7O?NO=>]^Z]TGJW:.U,EN3 [
MRR.VL!7[NVM09S%[9W16X>GJLCCJ;<WVW\2IZ&M>-JBDAK_LJ/[A(I%6;P1>
M0-XUM[KW2A]^Z]U[W[KW2>SNT=J;HJ=N5FY=M8#<-7L_/Q;KVE4YO#T^5DQF
M4@IZFDCR./>>.1J.N2EK*N%9XBDJQ32H&"R,#[KW2A]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=%U^7__ &27\HO_ !77NS_WFLG[]U[KYI_PIW/-
MAO\ A-AO?!4TL2ON_P#G1Y?'5L4D#2%J3%]+[8KW:-_TQNM734/U-RI8 $7*
MR][*VXEW9W/X+:1A]I>)/\#'J//<R<Q;<JC\<R*?L"N_^%1U]-GX\[?7:70/
M1NU45D3;/3W6>WT1J;[(@8;"T5, 81Q$0(_T?V?T_CW%NXR^/<2N?Q2.WKQ8
MGH>VR>'&J^BJ/V #JH?_ (4.?%\]_P#\OG=6_P#"XRLR.]_C-GL?W!ATQYB6
M1\0"N.W/'*94-Z2EP]3)DY0DD;DXU"&>WADD'VFWK]T[ND;$!+A3"U:_$>Y*
M4\RX"BM1W'AQ /\ <#;/WAMSLH):$B44IP&&K7R"DMC-0/L)XOY8?R>7Y>_!
MGX^=T5N6FS&\*S9-#M'LNKJE\<S;FV(/X5FIIEU-8UU72M6(=1U0U,;<:M(#
M/.6R_P!7]SN+8"BJY:,<?TW[T_8I /S!Z/.7=S_>]E%/6I9 '\N]>UO^- T^
M71]_88Z.NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I%[$['
MV#VAAZ_<'7&\MM;ZP.+W/NS960S6T\S!GJ6++[$R-1B,UC7J*9Y(A68K*4=7
M2546K7!4PRPR!9(V4>Z]TM/?NO=!]V5L+:?=?5_8O56YZC(S[-[-V;O7K3=4
MVU]PU&WJY*/<])58C)+0Y3'RQ5F-R$"2SK'44\\=12U"!XW26,$>Z]T1GX"_
MRF?A5_+9KNS-Q_&?8FY:?L#N.H@G[.[2['WWD^R-Q9=:>>6J6*?(9*:011-5
MSS5$HAAB-1.WEJ#*Z1E/=>ZLG]^Z]U[W[KW2#[([3ZQZ;VK4;Z[>[&V'U5LB
MDR.%Q%5O'LC=^/V-BHZO<=7#08ZEDR&4J*6D2HKZZHIZ>FC,P>>>6.&)6D=5
M/NO=+SW[KW7O?NO=>]^Z]TF=Z;UV;UOM+<F_^Q-V[9V%L39N%R&X]W[UWIGJ
M7:V(Q6.Q,;35=?DLE72P4=#14L*,\L\TR11H"SL%!/OW7NG' Y[![IP>&W/M
MC,XG<>VMQXG'9[;VX<#D8<O0U]#EX4J*2MHJNG>2GJJ2JIY(Y89HI&CDC971
MF5@3[KW3K[]U[I![ [3ZQ[8H<_D^K.QMA]E8W:F[]P]?;IR&P-WX_>4&-S^T
M91!EL'D)<=45,='F,7.1'5T<S)44SD)-&C&WOW7NEY[]U[KWOW7ND3OWLOKG
MJK"TFY.T-_[)ZWV[7[@V]M.@SV_=U4&SZ*?*[MJXJ#%8R&JR,]/!)D,G730T
M])3K(9JF>1(84>1E4^Z]TILMB<7GL5D\'F\=19?"YG'UF)R^)R5*E;355+D8
MVAJ*>HAD5HYH)XG='1E*NK%6!!(]^Z]U3]%_(I^"DKT>V,_6?*'>WQYQ.1P^
M4P'PPW[\M=_;QZ9Q\FWZMZV@AINO*[-S89L?0SF$T]!,LU!3K3P+#2H%;7[K
MW5QL444$4<$$<<,,,:10PQ((U18P JJH "JH   %@.![]U[I&8[LKK_+[_W1
MU5C-Y;<K>R]E;?VQNS=FPX,K"V6H,5O62NAQ&3J:#5]Q'C\E/B\E%3U'C\,L
MM)4Q(YD@E5?=>Z6_OW7NO>_=>Z][]U[I@S>U=L;EGP%5N/;N#S]3M3.0[GVO
M49G%09-\=DJ>">FCR%"TT;FEK8Z>JJ8UFB*R*DLBA@'8'W7NG_W[KW7O?NO=
M,&;VKMC<L^ JMQ[=P>?J=J9R'<^UZC,XJ#)OCLE3P3TT>0H6FC<TM;'3U53&
MLT1614ED4, [ ^Z]T_\ OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>ZIW_ )D?SFQ'4-+V?\7^Q>COGGLW9';G
M1^Y,=A?F_P#'+XR5GR,VGMVKW12ST$\%9'A?XCD:'.8X2K410UF!DH*J.X,S
MA)XE]U[K7&^(7P;^)O;6U]H]6?$S_A5A\V=O8G;6 I<1L_HG%?)'*=%Y##T&
M)TTZ8ZDV-EMR8#)8N*A8K$:5,1$*<V0HEP#[KW6[;T5L'(]4](].=79?L;=?
M<66ZVZKZ]V#E.W-^9-\UG-TU&SL11XZ?<>:K)9JB6KRV<EIFK:N9ZB5I:B:1
MVD<L6/NO="I[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK:_G'?\ ;IW^9#_X
MI-\E/_>3RGOW7N@!^!7=YZ _DB?R\-[8[;TF\]ZY;XA_#[KOJO8<-6M ^=W9
MV5A<%A=O8LSOQ34LV2K(7K*BS?:4,=55E66 J3+:MO\ WE,(RVE0K/(_'1'&
MI=S3S.E3I'XFHHR>DE[=?21EZ5)*JJ_Q.[!5'G05(J?(5)P.M13Y<?"SY;XO
MY.?+G!]G;;Z]_P!)O=W=>[-W8A\-V7M?;V/RDFY-V5>9.1@I<AN-ZK;V-R4%
M0*JAAS$U/4&"6*-B\UP9^@Y[V>%]ITSE5MHF60,DC-'6U$:ABL8#&N"5!%<X
M'44ORKN,D>Y5BJT\B-&0R /2X+DBKX%,T8U\N/6V_P!=]+_.3HWX2= [4SF4
MZ;[ZP>U^@^C=J;T^)O<_QXJ-SU-'7;8P.(IUP5'N79F0R5,]/A<G2H'K:O9V
M;(6G^X1Y9-#F*-VW?;;N_N)@LZ%[B5DN+>3BKR,=1CD522RG@)(^-#T/-NL;
MRVM((ZQ'3#&KQ2K^)8P-.M&( ##)T/\ +KW27R7V/@\S49[<W\JO>/76ZMC9
M;*X;)[X^-/1<7;\.)R%#3*U53B6':VT]VQU1I*GU14VWII&29(E\AD(]E4[?
M7-X4-X[JQ I<EH0<XU5DDC K3+. .)H.C) ;9/$EA52 2?"_4X>E$1B?D%J>
M%.C]]=_.OXE=F9NGVAA.\-H;>["J W_&*>T6J>FMX(4N&#[2W9!A=Q*%(8:O
MX:4:Q*,R\^TMUR[>V:&1HF:,&GBQTEAK_P U(BZ?\:ZM!NUO<,$#@.17PWJD
ME/70X5A^SIA[)_F _&CJ3=U3L??E=W?C<_!N--HTYQ7Q'[<W905N2FC>:.DQ
M67Q&QZ_$9B26**5XS0UU0LBH[(S!&L_9\KW=_&)8O *E=7==VJ,%!I5E>967
M/\0'EZ]-7&]P6KE'\6M:=MO<.I-*X9(F4_D3T97K/LG;';FS,3O[9L>[(MNY
MI\A'0)O;KW<'5N2OBZF:DE\^$W1C,/FJ1?-!)XS/CXQ-'IFA+PR)(Q1>6CV,
MABDT:EI71)'*N0#AHV=3@YH30X.01TOM[A;I!(FJAK34CHV"1E756'#S&>(Q
MTO?:7I_KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HBG\S_ &74=@_RYOG)M2BHY<CD:[XK
M]X5N*Q\"-))/68+;U?D*.*-5L6EDJJ6)4'T+$ \7]FNQ2B"]@=C0":,D^@UB
MO\ND.Z1F6VE5<DQN /4Z33HM7\A'L*3LG^4E\.,S4((:O [/WEU[/ )!+I7K
M7=.<P-,Q988%O-18^FEMH8IY-#22NK2,8<WV_P!-N4ZUK5P_^]J']3PU4_S=
M(^79O'LHFI2BZ?\ >"4_G2O5P'L-='77O?NO=:R75&.CZJ_X5(_)2..IF@I/
MD=\&,%N-<?Y8TA:JP<.R:36D2F$&33L^LDU%9I=4U0UPDC&,=7$GU/+\50/T
MKDJ#YT*N_P#A?Y<!T%X4\'=WH3^I &(\JAE7_ O\SULV^P+T*.O>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>ZTL/^%MO_ &0[\0O_ !:VM_\ >0SGOW7NC>_ U)<U_P *./YDV<"29:BQ
M/2>Z<2V8"FOBIJF++=94D5,:CUI#.L-)60I'K#A(9HP-,;A9KYE81\G[>G F
M>NG@2*7))IYCN%3\QZCJ--G4MS'>-0D"$ GR!/@4%?7!_8?3K:2]PIU)?5"W
M_"A_XL57?'P4K>W-JT%14=C?%'<4?;.(JL>1'5# 58CI-TQQR$J8HJ6D%)EI
M65P^G%#1J:RM)_M-O8VO=!!(1X=TIA8'(UG*8]2W8*X[S7H$<_[8;ZP,J5UP
M$2J00"%&&S\AW8S51]G5@W\M[Y5TOS/^%_1G?33I)N?/;4BP'8\"H(3#N;9S
M-C,Y^VI;QQ5-=3255.";FEJ(&-BU@$^;=C/+FXS6GX4>J'UC;N3\]) /S!Z/
M]@W0;S9Q7 XLO</1U[6'[0:?+H\?L.=''7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=$@_F&?*;*?$GXS9[?&R:+%9ON_L3=VP_C]\9]IYHR?:YCLG
MO;*4^W=GT-4(8Y930QY2M2KK=$;.*&EJ2@+A0?=>Z5.Z>[.J_@Q\>.O,M\O?
MDG1$X;'[1V!F.W^S6I*#*;OW/70K&YH\3A:"G%;F,S5K/+#C<3B+JI,=-2K'
M& /=>Z#K ?S/?@KOGHCN;Y"]??)GJO<'7O0M DW:N2KLQ-MJ;;<^2<P8R/<6
M,R5/29C"1Y.J*)325=!$E0I\D+/&"P]U[HM/\K7^;)U!\T?Y?U!\L^XNX^C-
MG;PV'MS,;P^5&/PNZ(<-A.NTS&5S4^)H,O4UU2XH%BP5)36-35&:33KEM+)I
M]^Z]T8GH7^:U_+N^3G9^/Z8Z/^5W6>]>TLUAO[Q;:V4[Y#:]9F: ^6U9@1F:
M''1YZF989763'25*M$IE4F(:_?NO=2N\?YI_\O'XW5FX\5W9\M>H]B;@VEN[
M/[%W%M*KR\V6S=-E-IXN@S>5IVP>/IZO+NF+P^4QM;5SI1-3TU+5033RI'*C
M'W7NC3]8]Z],]T=3X3O?JGM#8V_NF=Q8.LW)A^SMM;CI<CA9:'&F4552:]9/
M!%'1M!.M1Y'0T[Q2),$>-P/=>ZH-_F4_SP^@8/A]O/</\N_YG]<Y/Y!8SLSX
M_P!+MZMP&#H]R#)8'/=E;:VQNJ7 KN?"U."W)2P4F2J*2KJ,<M8:!IDD,E/+
MXI![KW5R7R:^>/Q ^'%9M'$_)7OO8_5NXM_19&HV1L[(RU.<SV7AP]OO*G'8
M'%4U?F:REI-0\\\5"T,0N9'4 V]U[I1=!?,7XN_*;J&M[Y^/'>.P.W>I<7%D
MY<SO'9N8&0BH#AH3454.1IBJ5V.JH(!Y'IZFFBG"$-X[,I/NO=!/U?\ S.?@
M%W7VTW1O4WRJZH[ [/BZH@[RJ]N[9S$N2CIMIU-#1Y-,W5Y)8/X51TC8W(4%
M7::NCE%-403F,12HS>Z]U5'_ #*?YX?0,'P^WGN'^7?\S^N<G\@L9V9\?Z7;
MU;@,'1[D&2P.>[*VUMC=4N!7<^%J<%N2E@I,E44E748Y:PT#3)(9*>7Q2#W7
MNMDGW[KW5=/<_P#-,^!W5'86^.@-P?*[JS;G?&V!3;=R6UYJZ6N3"9W=%,S8
M/'9W)I2SX+"9#)3M$E+39*NIY*B9E@2-Y&"'W7N@G_E.?,C=7;O\HKXU?-'Y
MF=O[;_O%FNI=V]@=U]R[P@P?6>+AAV[G<U32Y&O7'TN(P6,IJ:AHX5=HZ6"*
MR:F!=F9O=>Z'SX\_S/O@%\K>PH^IN@?E)UIV#V75X&;=6'V/#4UFW<EE,53W
MUY/"TN7I,?)G,:%#.*K'BI@,:M()#&K,/=>ZQ][?S0_@#\9NQ,EU1WA\H>N]
MB[_P$.$J=VX"?^(9S^ 1;D!>@EW+58RBK:+;,57"KS1OE:FC5J='J ?!&\B^
MZ]TZ]W]L19'?7P8S76WS%Z\ZLV'VQVS+/%M>/;>([%A[GPV3VMDJVBVWMO,R
M"?\ AS@M39I*_'3>2:DHI%#&F>5A[KW3%WC_ #3_ .7C\;JS<>*[L^6O4>Q-
MP;2W=G]B[BVE5Y>;+9NFRFT\709O*T[8/'T]7EW3%X?*8VMJYTHFIZ:EJH)I
MY4CE1C[KW1I^L>]>F>Z.I\)WOU3VAL;?W3.XL'6;DP_9VVMQTN1PLM#C3**J
MI->LG@BCHV@G6H\CH:=XI$F"/&X'NO=$9Q?\Z3^59EZ#<F8I_G-T/2X+:V/;
M+5NY,SN.7;V+JZ6+*TV#EJ<+DZ^FIL?N*GILM64M+/)BJFL2GEEC$YC# ^_=
M>Z>N^>_=[_&/YT_%NDWGO26L^,7S57*_&G&[=RL-,J;7[;VW25^Y-J5>.J(J
M%:QJ3?>"I-PXVMAJ,A)#%7XS#O1P0M5Y"27W7NK(_?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M%U^7_P#V27\HO_%=>[/_ 'FLG[]U[KY??Q-KI(_Y!F%QHJ-,-7_-^[DKGI-0
M&ML?TQUW&DFGZGQ"J=;C@>3GZCW-?L<M=PN#_P N]/VR)_FZC/W1/^)1#_AX
M_P"K<G7U@,901XO&X_&0N\D..H:2@BDEMJ9:2-8U+6 &HA038 7]PLS:B3ZF
MO4E@4%.FW=FUL#OC:NY=E;IQT.7VQO#;^9VMN/$U(O'54&X*:2DK*>0#ZI/3
MS2(W^#'W:&5K=UD0T92&4CB"#4']HZTZ"12K"H(((]0<=:L?\BS=63^'GS:^
M='\KSL/(Y.@7$;XRF_NE,=G)U/W4>V&>*HJH0K%&GW%M*IVWE$554FFI)795
M8%5FWW-A&_[;8[W$ =48CG*XHQR!_M7$BD^I ZC/DF4[3>76UO4!7,D0.3I^
MVIXJ4:GV_/K:\]P=U)W7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5
MI?S=_DQV!\5?@1W+OOIQ%;O+?-3L7H'HN:5UABI=W_(3.8_9^#R,TC,HCBQ-
M5EQ7,UF_X# :'OI/NO= 9\C_ )#R_P L39'\NSX"?&'9W7^7[*[_ *S+]$=.
M[W^1.\LELS8N%IND=MQYC/9_>6?@AKZ^NSF60AJ+'"J2OSN4J9@E5Y$F<^Z]
MTO<'W;_,XK-D_*'J[MSXS?'C ]S;&ZMHM[=(]W;$[:W1_HDWA3YJ>JIJ['55
M=4[:GW=M?<N(HJ9ZEZ5<5DX&,],8JMXUED'NO=$-_D9][?([JO\ D8=>=Z=E
M=.MW/M[8/3.[-\=';)^/6:W!W%V;OQXLYN2IRM/F,168''14^X,CFV"4D-!7
M9</ [U%14>4&,^Z]T+_>O\P#^9G\+>NNK_E/\P/CQ\,L?\:]T[^ZLV/VQUQU
M%V]O/+]B;*_TS9S%8/$U$-9E]MT6W]V5&-FR)?*4L-'C#&RF.DFJHXVJ6]U[
MH8>Z/GA\SLI\Z.\O@#\/?CATOO7L'KGX_=,]\8KN?OOM#+;#V7BZ;L3(9K'U
MM'N*+!8C-Y^JKGEQM/\ PJGQU 5J5:MDK*JA2BC^\]U[H..O?YQN:ZW^._\
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MQ5LV.VI'DMI8FJKJ-MQ34]9CZE,.)X4^Z\-;#,8M0BD60J??NO=:2GRB[O\
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M*DI2M, HW6V-[@SJ4.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI
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MV(IV"-0I(22H /NO=',_GY&E3XE?'JHC%&=TTG\R#^7W4[ 2:H%/4-F$[(Q
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M"39N>JXX<S#DJ%*:>&JD3$-#/5RPYI)4HX9EN]W&S;9%%#XY2VN[=I));%U
M>!X!3_<E0"IC)*$U>H4,E-1 $.V'<;V224PZIK6542.Z5B4E$IU?V!)!U@!P
M"%H6TO6@W4_A9\6<M\-<#\-^ALIM0;0BV]VS\D,OB*"3NF/OB::FW+M6JK6J
M*C-P[!ZXA25JN6JC6E3;Q$44<;FKF>5DBBWG+>UYBOC=AM6I4!/@^  5730+
MX]QY 9UY-<#H9<N;8=GM%MR*:2U/U/%PS:LMX4/F3C3CU/5N.]L+N7<&WJK%
M[1WG4[!S<TM*]/N>CP=%N*2%89%>1%I<@DM*_F0%"7C)4,2MF ("_1WT4''?
M"R>J?/XWL3MJ?M#9N\.P*SLK=^T=R=7;<HUJLK7P4T#U5'D**E@R6'JD6CIF
MAJ*&IAG@D0/'(K$DUT]6U=.XP/R(^.+&39]7GOE!TO#)J;9&Y<M O86 IE"W
M7#9NK>"DWA1PJ'*TN4F@REM*IDZPZ8??LCK>&^7^#J@GYO\ >W\NGM#OO'[A
MW/\ !^KS?8&![NV[GNYMY;[VICL'D]RX7;>)J,;-CIZ.:L?)03$M0H:7)4M#
M-']BJR1JIC8C';N;[S98?!BNI=!B8(D;.JPNSZN#:17B3IJ.[C6HZ(KKERVW
M*3Q9((BVL$LZHQD 6G$:L<!G..'#K8H^%^>ZWW+\9.J,UT]U/4=(]75V&R$F
MQ.M*B?$3''X[[^K$+*,'DLM00I6>JI6#[S[B#R^&KAIZF.6",/;E,US,TCR^
M.S:6:3OJS%0376JFJGM.*$@T)%"3&TC$,814\,+50G;0 $@4TDBA J/.A%0#
M4 T/M#TIZ!CMOXY] ]]T*8_NOI?J_M6GA4"D??FQ\=N::F*@A9*.IJJ>2HHY
MDU$I+!+'(A-T93S[7V.Z7.V'5;RR1'@=#LM1Z&A%1\CCI-<V4-X*2HCCCW*&
MH1P.0<]%];X-TFSUF;X]?)3Y/_'H"L&0I-N8;L>+N+;D<@0I]NN ['H=X4]%
MCG:S/38R;' $?LO#<W,AS!XO^Y,%O-VZ:F,Q/QK75;M"6;YOJ^8/21MLT?V,
MLL?=J(#!P<4I242 +\ET_*F>D+V%GOYF/3&R=]YBB3XC_)+'83:&Y\OBMS"'
M<GQSSE!+CJ.HDIYJC /+O;";D\#K'-*B;BV\)E1Z>/Q&59XE-O'M%\Z@_50$
MLH*_IW"M4Y[_ -!D]!V2TXFO LR-?VX/]C*.XU[XF44QV_JASZ]T?RZU6-@_
M\*6?GYN??6R]M9_%?%S;6"W#NS;F#S6XVZHW%DQCZ3+5D-/4UIIH]X1R5 I(
M9'E\2R*TFG2K D$3K?>S6U6T,DB-=,R([*OBQC454D"O@FE2*5ZBBS]R;^XF
M2-E@4,ZJ6T2&@9@"?[7RKUNV]4=_]%][XO\ C72G<G5_;.+"L9:SKK?>,WBL
M1CTZEF%!4SM!(A=0Z2!60D!@";>\;K[;+G;&T7,4D3>DB,A_XT!U-%M>PWJZ
MX71U]48,/V@GH7?:'I3U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW6LM_PGHR5+M/N/^<7\=8',;=._/?=V22B162*.+<>4W/@D
M,8UO#S_= JP2[ *FMF4QV'/.49:*QF/![5!7YJ%8_P#'QT%^7)!KNHQQ6X<T
M^3$@?\=/6S3[ W0HZ][]U[K63_GFQY+KSY\_R-_D#0?:P8S;WRXJ>M=V5M2
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M(/+&R(M84J)51M:!'1+^-2Q .>9.=I]RMWM$18XIYWNG'Q-JDDU!=5!A=(R
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M1^(DQ.6IF$U/4J(LO/JAE6ZR+X:FG>X)&F1#]&'N8_=Y3&U@C"C+:*"#@@U
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MQ4VZJVGIMW[[3$15>,V_'62TKP?[D(9$5L8/NUB]^Z]T=;YA_P O'?6U]F_
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M"/4F]>]^Z]U[W[KW7O?NO=$9_F _\RGZ:_\ %YOY?/\ [^K8WL2\J_[D2_\
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M=<[;JLIB=F;3E29:/$8[/T])7P9?(LB5<$#QBAEUM)&?=>ZK;I/E!OWX>_\
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MZ]U[W[KW7O?NO=$YZ+ ;Y1?.96 96WAT.&4BX(.PL5<$>SF__P!Q;7_2R_\
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MN+L]ML6ZR6UHFB-5C(74S4+(I.79CQ/KT/>3]QFW7;XYYVU.Q>K45:T=@,*
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M6MI>Z"3B*'.@D>:^1_$M&]0%7*G,8WZ"C]L\?;*G @C&H ^1IP\C4>53<![
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MFJ=A9?\ BU?]_1[BG:=H2ZY"-:2H:$3P&-BWMF^Y=MHHHKI&GCA>98F$Z 2
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M[J;L/JE<3V5F=\;FVE0U6%Q^T^FMW[UI9EGK4TJ<KA\'78F*4?;3%HI*Y)$
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M+"MI\;L.B^05?EZ>BI*L!%H:>6@K,$II(H0(@LE,[-$J+([D%F]U[H<>B?\
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M5!;W7NMQ3X(57=U;\)?B)5_)49$?(2I^-/2,W=AS*11US;IDVWCCG'KUI_\
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M>CZO+_E,?]NU_A;_ .(%V9_UJ;V3\\?\EB\_YZ)/^/'HTY9_Y)UM_P T(_\
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MM%,H=&P585!\_P!HX@\0<CK4U[ ZC^8'_">[N?)=U]!-NCY!_P N'?.9H_\
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MML;<F#WAL[=6*HLYMK=.VLI#F\?7T6102055'5T[R05$$R,&1T=E(/!]P=/
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M#Z12G^0'^7H!^X[4VQOG)&/YD_Y.MCK^6]0)COY>_P ':=)&D63XE?'JO+,
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MW<NZDJ)8:C*/0P5607"X>@I*[(U_VE)-524]*U/31M43Q>_=>ZI(_EN_S/\
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MJ6C3)U&' 6JGVY45D<+5#K(LHEQDQ&2I#'*&CG@B-6X2YP]OKGEC]>,^/:L
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M&ABK^A=S['2:>>.F5I>S7@VW!"&E>-2]1-EHXD4,7=W5(U=V5&/>68C-N%N
M*_JHV,X4ZC^P"O17O<@CM)B33]-A^;#2/VDTZS_R;ME0[!_E;?!G!04XI4K_
M (_;-WJT8C6*[]DK)N*22R11 F:3*M(3I);5J9Y&)D:O,LAEW"X)_P!_./\
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M_P E:]_YZ[G_ *O/T)N7O^2?;?\ //#_ -6UZ.)[#W1QU[W[KW7O?NO=%O\
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M?\*TK_22@_ 3C8Y^&/\ ,(^+7SRV@VY.@.Q:/+9W&8^AK-X]:YQ/X'N3!/6
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M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU4O\
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M'#JS\3]IZ-1[WU7KWOW7ND#V/U=U]V[MN;:?9&T\/NW!2R+4PTV4IM4E-41
M^*LH:E"E305T!.J&IIIHIXFLT<BL ?>B*];!IT6]<;\A_CDE\+4;D^5/3=+8
M?P#+UM,O8^"IDT7^RR50]-1;WIH4\A$-:])E[ #[W)2D(?<.K8;Y?X.DSW5W
M#UQW+U/UOG>O-S4F;BH?EA\1Z#.8J6*7%9/%U<796VA)0Y?%5:09'%5T;*0T
M%5312#]04J0QT37KP%#^1_P'H^GNW5.NB0HN2 !]23;WL"O6B:=</-%_QUC_
M .2Q_P 5][T'T/[.M:QZC]O7O-%_QUC_ .2Q_P 5]^T'T/[.O:QZC]O7)71O
MTNK6^NE@?>BI''K88'AUR]ZZWU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5='\W;=R;)_EA_.W,O+XA
M6_&;M+:(;2S7._\ '2X%5LJ2'UMD@M]( O=F1074ZY<37?VX_P"'1G]C _Y.
MBW>#IM)O^:3_ ,U(Z0O\D78%/UK_ "H_A%MVEB>&+(]0+O\ 9)&=B9.U\KDM
MTS/ZWD;3)-F78 ,% ("*BV17N:IS<;C<,?*0K^2=@_DO3>Q1"&SA _@#?FW<
M?YGJU'V'^C;KWOW7NM9?X>TU=V?_ ,*4OYF79LU9)/@^FOC;UOU#AZ/[?2()
ML]1; =QY0(6(%5ALX^EXI-1J#HET0QZASN3+;[%:1@9DEDD)K_ 77_ R_L^?
M07LE,VZ7#DX2-$ IY,%;_"#^WY=;-'L#="CKWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM5S_A53')-\
M<OBA%$C22R]^[@CC11<LS[<K0 !_4D^Y<]EW$>[2,QH!:RDGT >+J//<M#)8
M(JBI-P@ ]24DZ-%_(VVZ^:G^5'<]7K>7=.[]M;=HG>,@JT9R65KKO<ZFD.0H
M+BPTZ+DMK&F(V?Q69O4D_M->I(D&@*OH/]C_ "='F_F3?#*'Y7]-/D-H8^,=
MX=9I49WK7(0RQT4M8MT>LPDL[E0(ZU$UTY:1!%6)"VM(WGUU85ZU&^@])G^6
M7\UT^276S]8]BU4N.^074%#383>.,S,C05N7H\9II$S?BF5)34K,O@R269H:
MK3))H6KA0>4UZ](FG[.K0?=NF^J(=[HV?_GJ=2Q1WKX-I=6UCY&.9O32C^Y^
MY)HM D(# 5&0I7 B#6>0L>5D*T/Q=/#"'[?\W5[WN_3/7O?NO=>]^Z]U6G_,
M)^!='\J,#C>Q>N:Y=F_(WK>F6IV/NFEJ&Q?\1CQLAJH,9654.F:"2&HU24%4
MKZJ2=VO^W*Y2K+7IR-].#PZ#C^7I_,&G[:9OCE\DYGV;\H-EUE5MPT^X*'^
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M;LI#"(UGEKLUMC(QIY'5JF10/$<?N[E3G#-O*UA.WX'HL>KB31B4-:T"K(G
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M'+)LCL?&4<<F3Q$TA#,JLVG[G'U! %12.XCE%G0Q3I%-'HBO5T<IPZJ/Z_\
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MI-1C,UCH<K3R:?IKAG22-K?BZGW9':,U4D'U!H?Y=:90PH<_;U5G\F?Y)_\
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M[TOU'M3H?J_9_4>QVRK[4V1CIL9AGS=8N0JVCGJ)JEVGF2*%'<RSR&XB4 6
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M5-73QPO#M3M;=^$ID:)/&LL5&F<:EBDTA;A(0CL-;HSO(SG-O[I;[;J%%SJ
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M]BQ[]U[KW_;6'_X)-_\ 8L>_=>Z]_P!M8?\ X)-_]BQ[]U[KW_;6'_X)-_\
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M?_@DW_V+'OW7NO?]M8?_ ()-_P#8L>_=>Z]_VUA_^"3?_8L>_=>Z]_VUA_\
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M[KW^S$?\+4?^\#_BE_Z&'5O_ -N;W[KW7O\ 9B/^%J/_ '@?\4O_ $,.K?\
M[<WOW7NO?[,1_P +4?\ O _XI?\ H8=6_P#VYO?NO=>_V8C_ (6H_P#>!_Q2
M_P#0PZM_^W-[]U[KW^S$?\+4?^\#_BE_Z&'5O_VYO?NO=>_V8C_A:C_W@?\
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M;W[KW7O]F(_X6H_]X'_%+_T,.K?_ +<WOW7NO?[,1_PM1_[P/^*7_H8=6_\
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M^_=>Z]_LJO\ PLY_[V6_";_T ]E?_<_^_=>Z]_LJO_"SG_O9;\)O_0#V5_\
M<_\ OW7NO?[*K_PLY_[V6_";_P! /97_ -S_ ._=>Z]_LJO_  LY_P"]EOPF
M_P#0#V5_]S_[]U[KW^RJ_P#"SG_O9;\)O_0#V5_]S_[]U[KW^RJ_\+.?^]EO
MPF_] /97_P!S_P"_=>Z]_LJO_"SG_O9;\)O_ $ ]E?\ W/\ []U[KW^RJ_\
M"SG_ +V6_";_ - /97_W/_OW7NO?[*K_ ,+.?^]EOPF_] /97_W/_OW7NO?[
M*K_PLY_[V6_";_T ]E?_ '/_ +]U[KW^RJ_\+.?^]EOPF_\ 0#V5_P#<_P#O
MW7NO?[*K_P +.?\ O9;\)O\ T ]E?_<_^_=>Z]_LJO\ PLY_[V6_";_T ]E?
M_<_^_=>Z]_LJO_"SG_O9;\)O_0#V5_\ <_\ OW7NO?[*K_PLY_[V6_";_P!
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M*79>ZMG[IVBTAQFY=K9N!7EQF7HUFJ(P_CEAF@FGIJF&>GFEB;W7N@'^-_\
M+>VETMW5!\F.W/D'\A_F7\B\+LG)=:[ [3^2V>P5<=I8'.2129*@VIA-LX#;
M>!Q$^8:"'^(Y 8^7)5J(L,U8:91"/=>ZL>]^Z]T77Y?_ /9)?RB_\5U[L_\
M>:R?OW7NM8S_ (14_P#;K+OS_P 7_P"T_P#WW757OW7NMOWW[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UIV_\))?^ZN7_ (O56_\ R;]^
MZ]UN)>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM.W^3I
M_P!Q(/\ /D_\AW_N^H??NO=;B7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7N@1[\^2WQ\^+&R5[(^27=/671FQ),E3X:GW5VCO*
MAV91SUE4K/%1TTM=-"*FKD2.1EAB#R%59@NE21[KW2IZG[>ZJ[WV%@.T^E.Q
MMD]L=;;I@EJ=N;[Z\W-1[NQ-:D#M%(:>NH99Z>1HI4>.11)JC=61PK*0/=>Z
M$7W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T@,KVKUOA.R-H]/9;>VW*#M/?N
MW-U[OV=L"?)QKE<CBMC24$.7R--1W,ST6/FRF/CFFTB-9*B)-6IP/?NO=!3\
MB?F3\3_B-2;;KOE!\C>F>@J?>-5446U#VOV%C-E/DI*/1Y_LHJZHAEJ4I_)&
M9G1&2$,ID90PO[KW0[;5W7M??6VL%O/96X\%N_:&Z,519W;6Z=LY:#.X[(46
M3C66GJZ*MI9):>JIIXF5XY8Y&1U(*D@^_=>Z?_?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]T2W>/\Q[X ]>=S'X[[[^:'QCV?WFF:QNVY^JMQ]U[?P^;@R69\'V>-J:
M&>O26ER-7]U3>"EE"3S>6/QQMK6_NO=#)WY\EOCY\6-DKV1\DNZ>LNC-B29*
MGPU/NKM'>5#LRCGK*I6>*CII:Z:$5-7(D<C+#$'D*JS!=*DCW7NE3U/V]U5W
MOL+ =I]*=C;)[8ZVW3!+4[<WWUYN:CW=B:U(':*0T]=0RST\C12H\<BB35&Z
MLCA64@>Z]T(OOW7NO>_=>Z][]U[KWOW7NO>_=>Z*Y\C/FY\/OB'-M:E^47R:
MZ0Z"K=[BM?9^/[6['Q>RZG)1XQHDJIZ*FK:F*>HIJ5YX5FF2,Q0M(@D=2Z@^
MZ]T,S=J=8KUN>XSV-L7_ $1KM8[X/:2[MH&V[_!1!]U_%QFA4'&G&?;?N_="
MI\'C]>O3S[]U[H)_CM\R?B?\N:3<E=\7_D;TSW[3[.JJ>BW6>J.PL9O5\;)6
M:_!][%0U$TM,E1XY#"[HJ3!6,;,%-O=>Z,K[]U[KWOW7NO>_=>Z][]U[KWOW
M7NNF954LQ"JH+,S&P 'U)/X ]^Z]T&/5W=?47=NR7[)Z@[*V3V5U]'E=RX-M
M[;+W'2[@Q7W>S:N>@RL KJ:22F9\?6TU1#/:0B.2-U8W4^_=>Z!_H[YV_"[Y
M,[VW1UM\>?E5T#W7O_9<-14[GV=UEVIAMY9&DAHY1!-4/24-7-,]+%.RQO,B
MM$DA",X8@'W7NC7^_=>Z][]U[KWOW7NO>_=>Z][]U[I#]D]F=>=-[%W-V?VS
MO?:W6_7.R\:^8W=OG>V<I]M8K&4D;*AJ:ZNJY(J:FA#NBZY)%6[ 7N1[]U[H
MM72G\Q;X$_)+?=+U?\??F/\ &SNKL>NQV2R])L;J_N+!;VRLE+AT\E54K0X^
MMGJ#!3QD-(_CTH"-1%Q[]U[IYW5\]/A/L;O/&?&3>7RP^/FU_D)F:O&X_&]-
M9WMC"XS<4E5FE5J*D_ADU8M2E96J\9IZ=T6:<,IB1PPO[KW1M/?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]UQ=TB1Y)'6..-6>21V"*JH+DDG@ #DD^_=>Z*)U!_,!^
M#?R![1S/2?1ORY^.O;?;F CRTV3ZZZ\[<PF[,NL> 8)7R145%6335,5$[ 5#
MPK(L)XD*^_=>ZG=X_.WX7?&;>VU^MOD-\JN@>E-_[TAIZG;&SNS>U,-LW(U<
M-9*8(:A*2NJX9DI99U:-)G58GD!17+ @>Z]T:J">"J@AJ:::*HIJB*.>GJ()
M!*CI* R.CJ2K(RD$$$@@W'OW7NLOOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJG?YYO8,'6G\I[YJ9Z:4
MQ'+]8X[KZ ("S._:6<Q6VPBJLL3$6RK%O40J!W9)$5D80\J6YN=QMU'E('_)
M 7/_ !WHHWZ80V<Q/FA7\V[1_,]"W_*=V>-C?RSO@G@?MQ2O-\7NG]RST_B$
M!67>^'ILU-K0 6D,N0<O<:M9;5ZK^TW,,GBW]P1G]:3/R#D?Y.G]I71:P@X_
M23_CHZL']D_1AU[W[KW6LW_+AIJ7L?\ GY_SENY#''4U>Q=N]4]+P5[*"\<9
MAQ./F@5FD,@1GV+"&"H4)A6Y2R*PXWIC%L]C'Y,9G(\JAC0_L<_MZ#&VJ'W&
M[?S B6OG0KG_ (Z/V=;,GL#]"?KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z)7\V_Y>'P[_F,[
M&VAUO\RNH/\ 3'LO8>ZWWOM/#?Z0-T]>_:922CGH&JON-JYO!U<]Z2IFC\<T
M\D/JU>/6%8>Z]T=3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!
M7WCTGUC\D.H>Q>ANZ-L_WSZH[9VIEMD=@;5_C.0V[_$,7G(S%54OWV)JZ')4
MOEC)'DIJR&9?JDBGGW[KW24^+GQ<Z)^%W1.QOC1\:-C?Z->DNM?[S?W*V5_>
M;,;Q^R_OCF,AG\E_N2S^0RN7J?N<OE:^?]^OE\?E\46B%(XT]U[H?_?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T3OXD_ /XD_!7_2[_LJW4_\
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M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T!FQ?C'\=NL>U.Q>\>NND.K=C]R=O?\
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M;-;#W+V#42R! [GLW<F:W!&6,?!"09*&-+^H1H@;U ^UO-MQ]3N4[>CZ/]X
M3_GWI/R_"(+*)1YIJ_WLE_\ +U;I[#G1QU[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$!^3_\
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MMOX*NS&*&"R]9AL9597"+.M2*.IJ($>>E$BV604\I:/4!9M-QP??NO=:'/\
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MCN/K^#^\>W'N%=HW3.XG'LLBHS(0&"M:Q]U[K2 ZW[R@_FB?$O\ X3-_RO\
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M,K@,30XV?';4I):&2"CKLB))JV0+4B*G#5/NO=2_YBW_  G7[2^9/\Z;H/\
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MV7MFAW_E-J4_66RMNR[PH#2XW"4C8/;QS=3A<=*\TDF0K,=5Y"8RD+!'%'%
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>=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>timage_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 timage_007.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
MA  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$" 0(" @$" @(" @(" @(" @(" @("
M @,# P," P,# P,# P,# P,# P,# 0$! 0(! @," @,# P,# P,# P,# P,#
M P,# P,# P0$! 0# P,$! 0$! ,$! 0$! 0$! 0$! 0$! 0$! 0$! 3_P  1
M" *>!M$# 1$  A$! Q$!_\0!H@    8" P$             !P@&!00) PH"
M 0 + 0  !@,! 0$            &!00#!P(( 0D "@L0  (! P0! P," P,#
M @8)=0$" P01!1(&(0<3(@ (,11!,B,5"5%"%F$D,Q=2<8$88I$E0Z&Q\"8T
M<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D@W23A&6CL\/3XRDX
M9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9FJ2EIJ>HJ:JTM;:W
MN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$  @$# @0$ P4$! 0&
M!@5M 0(#$00A$@4Q!@ B$T%1!S)A%'$(0H$CD152H6(6,PFQ),'10W+P%^&"
M-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58WA(6CL\/3X_,I&I2D
MM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'U^?W2%AH>(B8J+C(
MV.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H # ,!  (1 Q$ /P#?
MX]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW1%?YB/SPV+_+F^.TWR.[%V3NS?VV:?>VV-DS8'94]'3UWEW2*G
MPSJ:Z6"G:.-J>S@RJ;-=;D6)KLVTOO<XMXRJL02"U:=HKY G^72'<;]=LB,S
M@D @$+2N33S(Z%KXA?)/;OS!^-G4GR7VEMW-;3VWV]MN7<^&V[N.:">NI85J
MZFE5*EJ9Y*<RDTQ8A)&4:K!C:Y3;A9-MT[P.02C%216A(]*TZ>M+D7<2RJ"
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M]U[K%//#30S5-3-%3T]/%)////((D1(@6=W=B%554$DD@ "Y]^Z]UJW?)/\
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M=9ZJ0Q4=-Y%-141!EN86.US[EJ\%"P0%G;\*@ G)X# -!Q/D#TDN;Z*SH)&
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MN&C4Z43+N16@J0!Y5)I@5' GRZ5[OO";1$'859L*M:5-,^N!YGYCUZI/S?\
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M^(X8XPV %)."3@ 9J#/?=X?;?#CA4-)*:+J^$9 SD<:@#('F3BA)#VG\N_\
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MJ.@ZBI]O9C'_ ,/-30O5;?GP&4KL?-))>E6HR^,F"QQ2Z?-'2RD:TBD\:[D
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M5584V8F-/49Z"!O&\M#D8ZI4:&H#)[KW1#JW*9S"?'+M'_A-)MW)?8;WW?\
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MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T7+Y>]O[[^/\
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M6DB@H85C@1(!65^1FCIHZJBCM(Y'R_L=K]!)N-TK2A"0L2DJ#2@J2*'BWV
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M_+DWONA((<+W'_+E[@Z:Z\K6B\A.X>O:WL;<F1C=W58Z=3A\E"D;K(SR23>
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M 'OW7N@X[CZLVGWEU'VCTKOR@@RFR.W>O-Y]9[OQM3"*B.?&;ZQU3C*Z)D)
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M*J:FB_334\"V4((.?[^S4Q'1)0D!W#%P/M#"M/F"?4GI7/RE:7+"3N2M*JA
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M$_N!=T;PHX(V?+.B'436M>YB"<GB#Q/1.O*5N2OB/*ZK@*S]H%*4P 1Y<".
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MO_/U[^]/_"J7_GV_P?\ _.[&?_7_ -^T<O\ \5W_ ,8_Z!Z]JW?TMO\ C?\
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M ,^W^#__ )W8S_Z_^_:.7_XKO_C'_0/7M6[^EM_QO_/U[^]/_"J7_GV_P?\
M_.[&?_7_ -^T<O\ \5W_ ,8_Z!Z]JW?TMO\ C?\ GZ]_>G_A5+_S[?X/_P#G
M=C/_ *_^_:.7_P"*[_XQ_P! ]>U;OZ6W_&_\_7O[T_\ "J7_ )]O\'__ #NQ
MG_U_]^T<O_Q7?_&/^@>O:MW]+;_C?^?KW]Z?^%4O_/M_@_\ ^=V,_P#K_P"_
M:.7_ .*[_P",?] ]>U;OZ6W_ !O_ #]>_O3_ ,*I?^?;_!__ ,[L9_\ 7_W[
M1R__ !7?_&/^@>O:MW]+;_C?^?KW]Z?^%4O_ #[?X/\ _G=C/_K_ ._:.7_X
MKO\ XQ_T#U[5N_I;?\;_ ,_7O[T_\*I?^?;_  ?_ /.[&?\ U_\ ?M'+_P#%
M=_\ &/\ H'KVK=_2V_XW_GZ]_>G_ (52_P#/M_@__P"=V,_^O_OVCE_^*[_X
MQ_T#U[5N_I;?\;_S]>_O3_PJE_Y]O\'_ /SNQG_U_P#?M'+_ /%=_P#&/^@>
MO:MW]+;_ (W_ )^O?WI_X52_\^W^#_\ YW8S_P"O_OVCE_\ BN_^,?\ 0/7M
M6[^EM_QO_/U[^]/_  JE_P"?;_!__P [L9_]?_?M'+_\5W_QC_H'KVK=_2V_
MXW_GZ]_>G_A5+_S[?X/_ /G=C/\ Z_\ OVCE_P#BN_\ C'_0/7M6[^EM_P ;
M_P _7O[T_P#"J7_GV_P?_P#.[&?_ %_]^T<O_P 5W_QC_H'KVK=_2V_XW_GZ
M]_>G_A5+_P ^W^#_ /YW8S_Z_P#OVCE_^*[_ .,?] ]>U;OZ6W_&_P#/U[^]
M/_"J7_GV_P '_P#SNQG_ -?_ '[1R_\ Q7?_ !C_ *!Z]JW?TMO^-_Y^O?WI
M_P"%4O\ S[?X/_\ G=C/_K_[]HY?_BN_^,?] ]>U;OZ6W_&_\_7O[T_\*I?^
M?;_!_P#\[L9_]?\ W[1R_P#Q7?\ QC_H'KVK=_2V_P"-_P"?KW]Z?^%4O_/M
M_@__ .=V,_\ K_[]HY?_ (KO_C'_ $#U[5N_I;?\;_S]>_O3_P *I?\ GV_P
M?_\ .[&?_7_W[1R__%=_\8_Z!Z]JW?TMO^-_Y^O?WI_X52_\^W^#_P#YW8S_
M .O_ +]HY?\ XKO_ (Q_T#U[5N_I;?\ &_\ /U[^]/\ PJE_Y]O\'_\ SNQG
M_P!?_?M'+_\ %=_\8_Z!Z]JW?TMO^-_Y^O?WI_X52_\ /M_@_P#^=V,_^O\
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M /SNQG_U_P#?M'+_ /%=_P#&/^@>O:MW]+;_ (W_ )^O?WI_X52_\^W^#_\
MYW8S_P"O_OVCE_\ BN_^,?\ 0/7M6[^EM_QO_/U[^]/_  JE_P"?;_!__P [
ML9_]?_?M'+_\5W_QC_H'KVK=_2V_XW_GZ]_>G_A5+_S[?X/_ /G=C/\ Z_\
MOVCE_P#BN_\ C'_0/7M6[^EM_P ;_P _7O[T_P#"J7_GV_P?_P#.[&?_ %_]
M^T<O_P 5W_QC_H'KVK=_2V_XW_GZ]_>G_A5+_P ^W^#_ /YW8S_Z_P#OVCE_
M^*[_ .,?] ]>U;OZ6W_&_P#/U[^]/_"J7_GV_P '_P#SNQG_ -?_ '[1R_\
MQ7?_ !C_ *!Z]JW?TMO^-_Y^O?WI_P"%4O\ S[?X/_\ G=C/_K_[]HY?_BN_
M^,?] ]>U;OZ6W_&_\_7O[T_\*I?^?;_!_P#\[L9_]?\ W[1R_P#Q7?\ QC_H
M'KVK=_2V_P"-_P"?KW]Z?^%4O_/M_@__ .=V,_\ K_[]HY?_ (KO_C'_ $#U
M[5N_I;?\;_S]>_O3_P *I?\ GV_P?_\ .[&?_7_W[1R__%=_\8_Z!Z]JW?TM
MO^-_Y^O?WI_X52_\^W^#_P#YW8S_ .O_ +]HY?\ XKO_ (Q_T#U[5N_I;?\
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M ._:.7_XKO\ XQ_T#U[5N_I;?\;_ ,_7O[T_\*I?^?;_  ?_ /.[&?\ U_\
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M]?\ W[1R_P#Q7?\ QC_H'KVK=_2V_P"-_P"?KW]Z?^%4O_/M_@__ .=V,_\
MK_[]HY?_ (KO_C'_ $#U[5N_I;?\;_S]>_O3_P *I?\ GV_P?_\ .[&?_7_W
M[1R__%=_\8_Z!Z]JW?TMO^-_Y^O?WI_X52_\^W^#_P#YW8S_ .O_ +]HY?\
MXKO_ (Q_T#U[5N_I;?\ &_\ /U[^]/\ PJE_Y]O\'_\ SNQG_P!?_?M'+_\
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M /SNQG_U_P#?M'+_ /%=_P#&/^@>O:MW]+;_ (W_ )^O?WI_X52_\^W^#_\
MYW8S_P"O_OVCE_\ BN_^,?\ 0/7M6[^EM_QO_/U[^]/_  JE_P"?;_!__P [
ML9_]?_?M'+_\5W_QC_H'KVK=_2V_XW_GZ]_>G_A5+_S[?X/_ /G=C/\ Z_\
MOVCE_P#BN_\ C'_0/7M6[^EM_P ;_P _7O[T_P#"J7_GV_P?_P#.[&?_ %_]
M^T<O_P 5W_QC_H'KVK=_2V_XW_GZ]_>G_A5+_P ^W^#_ /YW8S_Z_P#OVCE_
M^*[_ .,?] ]>U;OZ6W_&_P#/U[^]/_"J7_GV_P '_P#SNQG_ -?_ '[1R_\
MQ7?_ !C_ *!Z]JW?TMO^-_Y^O?WI_P"%4O\ S[?X/_\ G=C/_K_[]HY?_BN_
M^,?] ]>U;OZ6W_&_\_7O[T_\*I?^?;_!_P#\[L9_]?\ W[1R_P#Q7?\ QC_H
M'KVK=_2V_P"-_P"?KW]Z?^%4O_/M_@__ .=V,_\ K_[]HY?_ (KO_C'_ $#U
M[5N_I;?\;_S]>_O3_P *I?\ GV_P?_\ .[&?_7_W[1R__%=_\8_Z!Z]JW?TM
MO^-_Y^O?WI_X52_\^W^#_P#YW8S_ .O_ +]HY?\ XKO_ (Q_T#U[5N_I;?\
M&_\ /U[^]/\ PJE_Y]O\'_\ SNQG_P!?_?M'+_\ %=_\8_Z!Z]JW?TMO^-_Y
M^O?WI_X52_\ /M_@_P#^=V,_^O\ []HY?_BN_P#C'_0/7M6[^EM_QO\ S];0
M'L#]";KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBG4?S=
M^->3^8E7\#<1V'29GY.8OJ"N[QSVP\11RY%<9@*&OHL<TF2KHE:DH:Z2?(T3
M1T<LJU+P2K.L9B.KW[KW2F^4WRR^/WPLZ@S7>GR5[&Q?6O7.&JJ+%KD:REJ<
MM5U^1RI9:+$XC%T$-3DLOEJYU98*2DI9IY-+,$T([+[KW19?B_\ S8OAE\L^
MW9^@>O\ ='9.R.[?[L2;TPW5O?G2.[>@,QF,33$K45^#IMV8C%?QB&D(O.*5
MY)(D(D9!&"X]U[H9OF#\[OC'\%=J[3W/\B]^U6WJGL/<D.SNM-C;4VIE>QMT
M;FRDI351;?VU@:/(9G*2P)(CSM#2-' K*9736@;W7ND;\0?YDWQ,^;^X>P-B
M]([QW71]H=61XZLW[U!VUUEN'I3=F.HLN%^TR3[?W1C<7D9L94,VA:J&&2%9
M/VY&1V56]U[H^/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[H(^^.]NJ/C-U#O[O;N_>6)V#U=UIMW(;GW=N?,SB&.&GH
M$+:(D_74550^F*G@C5I9YG2*)6=U!]U[K/T7W1L'Y&],]6=^=5Y&LR_6G<NP
MMK]E;"RN0QDV%GJ<1O*CBK\?/+25*1U%-)+33QL8I461"=+J&! ]U[JNWO;^
M=G\ /C_V?V3U'N+>_:F_]U=+>&/NJLZ+^/F]N\\1L^>59'>CW)F]KX/)8K&5
MU/%%(\]/)5>:G52)D1P4'NO=6.]0=Q]7=^]8;,[HZ:WSM_L7JSL+ TNY=F[W
MVU6"KHJZBJP2LL;D*\;(0R21R(DL,BO%*B2(RCW7NJL=V?S]/Y9VT-S[JQ%5
MVMV3G=E[%WK_ */=[=\[+^/.^MZ];8K*0S14]3#5[\Q> JMMB&AGF1*FHCKY
M*>(W)E*J6'NO=7!8#/X/=6#PVY]LY?&[@VYN+%T&;P.=P];'D:2LH\I$L]-5
M4M1$SQ3T\\+H\<B,5=6#*2#[]U[IV]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=%]
M^4_7'=';O0^^NM_CYWM4?&?M;=AVMC\'WC1;+H^P:K T4>:QTV=EH<5D'CHI
MLE6;?BRE'1RRMII:JHAJ[,8 I]U[K5O^#?PEZK^!'_"E9>E>KL_V-OB7,_R?
M\[V7V9VGW!O*HW]NK=^[-V]I4L>7W+N#*5&GSY&O6BI581111(D4:JEPSM[K
MW5@/S?VB._?Y\G\I?J#=\57ENL>@NB?EE\OWVG/61S8NMW)1#%[9P60R&.G7
MQ5%1@*N>"HH9E#ST\TKF+Q1/4F3W7NI7_"@S!5&RNI_@]\PMDQRXKN#XF?S$
M?B[GML[LQH@IZHX/M',':FX\!4U$B/*<-GH<I21U<* ^4QQ!U,7D!]U[J+LS
M:([N_P"%*'>N]=ZQ5>9P_P */Y<W3VU.H\1D*R.OQ^+S/R'W%D<EDL]1T<JZ
MJ/,56.HZN@>I@75)2J(ZB4JM-''[KW4K^9M@JCJ7^:Y_)*^4&PHY<+NS??=?
M='PU[6KL<(*5,_M7M?;#Y2AQN7;0T]7%A\CB:FNH4_1'.7<E9!$R^Z]UL#^_
M=>Z][]U[JN#L_P#F[_RV^F.P=W]5=H_+3KG9G8>PLY6;;W?M7+4F7^YH:['G
M3-3S>+&R1%T-N4D92+$$@W]G%OR_>W2"2.&1E85#!:@CHOEW6V@8H\J*PX@L
M 1T8OXT_,+XT?,3;VX]U_&;MW;7;VWMHYF#;VY,KMJ*KBCI*VJ@6ICIY/NZ:
MF8NT#*_I4BQ^M^/:.]V^?;F"SHR$BH#"A(X5_ETHM[N*[!:)E8 T)4U%>/\
MEZ,I[1]*.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUDOYZ7\M[*=^]"?S
M ?EE\DODIV=V1U)T3\5^W=]_$/X>8!8]A;+VIG]M=?*LNZMRM0O][O?<:;BI
MLE78V2L>.#&0U"TR13)Y+^Z]T?/^7%O.OZX_D7_$#L/%1+-E-A_RU.L-YXV%
MG$8>HVOU]3UT*EBD@4-) HN8V ^ND_0^Z]T''_"=CIG%=8_R@_BEEJR*IR^]
M._ML[F^0W;.[=PS19?)[AS7=&7R&7DR&7K;R2Y"<XZHH:<25$DDY@AC6=C*'
M]^Z]U3[AM[;U^'7\OO\ X4_=!=;9+-;:V=\:^_>]JOX_T>,R@PLNTL5\MMOT
M>2:@P,M$BOC:+#RYB6KH%BD62.25G#15#/+[]U[K9+^#GQ0ZLZG_ )<'QP^)
ME5LO#U_7=+\7MA;#WUMC*8^DGAR\NY=OTXW'-DHZ=?M:FHS%=55TU4Z@K)+,
M[@D$'W[KW1%_^$X^7WE3_P M/$]/;TS.7W!/\6OD7\F_B]MS*Y^ICJZUL+U!
MN[(4N*IZAX56.^/I9DI(U0LB001)&1&J*ONO=7P>_=>Z+K\D_EI\<_A_M'";
M]^2W:VWNHMG[DW'%M'!Y[<D57+#49*:EJ:U*1/M*:I<2M2T=3(-2!=,;<WL"
MLLMOFW%BD",[ 5(45(%0*_S'2>XNH[0:I65030%C05XT_ET5K8?\XS^67V=O
MG9G6NPOE_P!:;FWUV'NO;NQME[;H*;+K/D,MNRLAH,=0PF7&1QB6KK*B&)-;
MJNIQJ8"Y]KI>7+Z!2[P2!5!9B5P !4D_8.DJ;Q:RL%66,DD  ,*DG '5E_LE
MZ,NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NM;'_ +NQO_,*/_S5O?NO=*O^:#NVF^&O\TS^5]_,4[*J
MO[O?%>FVSWY\,?D;V?5+6G';.?N:GIJ[966S4M-!)3T.&K=R4ZTM36UDJ4E*
M DDK(0CCW7ND-_.1[WZN^;.[/@+_ "W?B]V+LGN_MSNKYF]%=Y]IT?5VZ(]\
MP;3ZLZ"R$N;W#NG.5F$:OI,7$]7%CX*%:UXUK)?*L :2)2/=>Z4_:/8^WO@5
M_/\ 3W-W]N#&=<?&S^8I\+]F=)[,[AW76SXC 4G:?0^=EJ*+:^5R<L:8;%39
M;;554S4+UE7&:BH_R>G;6[HWNO=-7RN[=V/\^/YQG\L#X\_&;=^W.W]N_!W<
MG:WS*^6N_>OLR=U87:JUNW_X-L/"U>6QHJL/_&L[D9ZQC0O4BJCI=$X58I')
M]U[K9*]^Z]U[W[KW1"^P_P"5W_+S[9WON?LKLOX?]';VW[O7+U6?W7NS<.SH
MLA6U];6F\M34S.=4DKFUR?\  #@>S6#?+RV01QSRJHP%5V  ^0!Z0R[9;3L7
M>*-F/$E%)/YD=4M_\)=MOX7 =:?S :7#8VEQM/0_,C+[?I(:5/&L=%@<>%HZ
M91^(J99I0@_ 8^Q-SW(TDEL6))-K&23YDEJG\^B7E=!&LX44 N'  \@ M.MI
MCV!.A1U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5;'\Y'_ +=.?S(?_%*/
MDC_[RF3]^Z]T@?Y8FR(^S?Y)?PGZWFJ?LXNP?Y=73^R):NY'B7=>PZ2@:2X#
M$:!4%N%)X^A]^Z]T2'^1_P#.7H7H[^71M[XL_+;N3K'X\?)#^7<=^=#_ "4Z
MW[<WM#L&MQ$'7^5RD^%S4$6?>AJ:_!9;;'V%32UM+%)22D2PT[?M:![KW11_
MC3\;^T/Y@_\ +5_GN=\;2VSF,4O\TKN3OS?GQ!P^X*+(8"JSNTNML1!C>OLI
M+2U]*E52+NBIQEHP8V0Q,CQVA9/?NO=64?#G^<A\)*'^5_UI\B.Z>_NO.N=S
M]$=%[=V?\C>J=U;F3#;PP6^>J<32XK<6UI-L9)X=R3YF7-TTD-! :!IZ\3TT
MD(E$ZL?=>Z4G_"?;IGM7J/\ EH=;YWN[;%=L?M'Y$=D]U?*;=&R<I'505.)7
MO?<==F,;25,5;%#5PU!Q#X^:2.9/+&\K)(=8;W[KW5U_OW7N@*[]^,?Q^^4V
MV,1LOY%=1[)[CVG@,]'NC#;?WUB$S5+39&*GJ*1:R*)SI6H6FJJF,-]0DCC^
MT?:JTOIK!B\#LC$4)0E214&F/+ Z8N+:.Z&F55< UHP!%>%<_;UJ=_S5OB'\
M8_BA_-!_D:4OQNZ0Z]Z7IM\?+K951NZ'8."CPBY%]O\ 8?6JT3503_.-3+65
M0CO^D2O_ %]R/RUN-QN&W[AX\CR:8#IUL6I6.:M*^M!T#-[LXK2[L_"14K**
MZ5 K1XZ5I]O6YS[B[H==>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!K_ *&>G_\ 2S_I[_T4=:_Z=/[D
M_P"C3_31_<7%_P![/[N?=_?_ -W_ .\?VO\ &/X)]]_E'V/WGVOG_>\7D]7O
MW7NE1NW:&TM_[:S>R]][7V[O79VY:";%;CVGNW"4VY,9D*6I%I*:MH*R*:EJ
MJ>0?JCEB9&_(/OW7N@/Z ^&_Q+^*0SH^,WQIZ+Z"?<YC.Y*CJ'JW"]?S5XAT
M:$K)\91TTU3'&44JDCLBL-2J&))]U[H2^V.GNIN^-CYCK+NWK/87;O76?1$S
M6QNRMI4&]L35>*^AIJ#(P5%,\D9),;F/7&WJ1E8 ^_=>Z3/17QI^/'Q?VO5;
M)^.'1O4O1&T:^N;)Y#;O4G7^+Z_I*FI<L?N*F'%TM,M3.-; 22AF53I!"@#W
M[KW0V^_=>Z][]U[KWOW7NM7_ /X3&_\ ,N_YAG_B\&[O_<&'V..=_CM?^>2/
M_"W09Y:X7'_/3)_S[UM >P/T)NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ36\MF;/[%VGN38/8.U-M;[V+O+"9+;6[]E[RP5+N?$Y7&YF)H*S'Y+'5T4]
M'7457 [QS03PO%+&S(ZLI(]^Z]U[9NS-G]=;3VWL'K[:FVMB;%V;A,;MK:&R
M]FX*EVQB<5C<-$L%'C\;CJ&*"CH:*D@1(X8((4BBC54154 >_=>Z+WW/\%_A
M;\C-ZX+LCO[XF_'/NCL';24L.#WKVATUM_?&4IXZ&1)8(5KLC05%0T$,D:M'
M&TC1H;Z5&IK^Z]T9Z@H*'%4-%B\714F-QF-I*:@QV.H*9*."G@HT6.&&&&-5
MCBABC551%4*J@*H  'OW7NBK;K^!'P?WWW#3_(/>OQ!^-&[>\J6KILA%VWN/
MI+;F9W#]S1!Q!5/E:C'25DE7"'/CG>5I4LNAQH33[KW1M/?NO=>]^Z]U[W[K
MW6JG_/9_[>D_R"O_ !;3!_\ OQ.K/<B<G?\ )/W'_FA_UCFZ!W,G^Y=E_P U
M?^?XNMJSW'?0QZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NM7__ (3&_P#,N_YAG_B\&[O_ '!A]CCG?X[7_GDC_P +=!GE
MKA<?\],G_/O6T![ _0FZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU4_Y[/\ V])_D%?^+:8/
M_P!^)U9[D3D[_DG[C_S0_P"L<W0.YD_W+LO^:O\ S_%UM6>X[Z&/7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ_P#_  F-
M_P"9=_S#/_%X-W?^X,/L<<[_ !VO_/)'_A;H,\M<+C_GID_Y]ZV@/8'Z$W7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW6JG_/9_P"WI/\ (*_\6TP?_OQ.K/<B<G?\D_<?^:'_
M %CFZ!W,G^Y=E_S5_P"?XNMJSW'?0QZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z;VJF#,
M+_1B/I_3_8>U(A!'2)IR#2O\NN/W;?U_WC_C7O?@CK7U!]?Y?['7ONV_K_O'
M_&O?O!'7OJ#Z_P O]CKWW;?U_P!X_P"->_>".O?4'U_E_L=>^[;^O^\?\:]^
M\$=>^H/K_+_8Z]]VW]?]X_XU[]X(Z]]0?7^7^QU[[MOZ_P"\?\:]^\$=>^H/
MK_+_ &.O?=M_7_>/^->_>".O?4'U_E_L=>^[;^O^\?\ &O?O!'7OJ#Z_R_V.
MO?=M_7_>/^->_>".O?4'U_E_L=>^[;^O^\?\:]^\$=>^H/K_ "_V.O?=M_7_
M 'C_ (U[]X(Z]]0?7^7^QU[[MOZ_[Q_QKW[P1U[Z@^O\O]CKWW;?U_WC_C7O
MW@CKWU!]?Y?['7ONV_K_ +Q_QKW[P1U[Z@^O\O\ 8Z]]VW]?]X_XU[]X(Z]]
M0?7^7^QU[[MOZ_[Q_P :]^\$=>^H/K_+_8Z]]VW]?]X_XU[]X(Z]]0?7^7^Q
MU[[MOZ_[Q_QKW[P1U[Z@^O\ +_8Z]]VW]?\ >/\ C7OW@CKWU!]?Y?['7ONV
M_K_O'_&O?O!'7OJ#Z_R_V.I%/,92P)O8 _3_ (U[;D0)T]#(7KU*]L]*.O>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NM7_P#X3&_\R[_F&?\ B\&[O_<&'V..=_CM?^>2
M/_"W09Y:X7'_ #TR?\^];0'L#]";KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K53_ )[/_;TG
M^05_XMI@_P#WXG5GN1.3O^2?N/\ S0_ZQS= [F3_ '+LO^:O_/\ %UM6>X[Z
M&/7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW2'J*H+43@GD32@\?T8_X>S1$&D?8.B&26C'
M[3_AZP_=K_7_ 'C_ (U[MH'5/&Z]]VO]?]X_XU[]H'7O&Z]]VO\ 7_>/^->_
M:!U[QNO?=K_7_>/^->_:!U[QNO?=K_7_ 'C_ (U[]H'7O&Z]]VO]?]X_XU[]
MH'7O&Z]]VO\ 7_>/^->_:!U[QNO?=K_7_>/^->_:!U[QNO?=K_7_ 'C_ (U[
M]H'7O&Z]]VO]?]X_XU[]H'7O&Z]]VO\ 7_>/^->_:!U[QNO?=K_7_>/^->_:
M!U[QNO?=K_7_ 'C_ (U[]H'7O&Z]]VO]?]X_XU[]H'7O&Z]]VO\ 7_>/^->_
M:!U[QNO?=K_7_>/^->_:!U[QNO?=K_7_ 'C_ (U[]H'7O&Z]]VO]?]X_XU[]
MH'7O&Z]]VO\ 7_>/^->_:!U[QNO?=K_7_>/^->_:!U[QNGO"3"66>QOIC7\?
MU/\ K#VEN@ !TNL7UD_9TH_:/HSZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU?_ /A,
M;_S+O^89_P"+P;N_]P8?8XYW^.U_YY(_\+=!GEKA<?\ /3)_S[UM >P/T)NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NM5/\ GL_]O2?Y!7_BVF#_ /?B=6>Y$Y._Y)^X_P#-
M#_K'-T#N9/\ <NR_YJ_\_P 76U9[COH8]>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= K7U
M[K7UJ@FRU=2OU_H[?X>Q'%$2H^P>0].@/<7)61A_2;_"?EU$_B#_ -3_ +?_
M (U[<\(_Z@.F?JCZ?ZOV=>_B#_U/^W_XU[]X1_U =>^J/I_J_9U[^(/_ %/^
MW_XU[]X1_P!0'7OJCZ?ZOV=>_B#_ -3_ +?_ (U[]X1_U =>^J/I_J_9U[^(
M/_4_[?\ XU[]X1_U =>^J/I_J_9U[^(/_4_[?_C7OWA'_4!U[ZH^G^K]G7OX
M@_\ 4_[?_C7OWA'_ % =>^J/I_J_9U[^(/\ U/\ M_\ C7OWA'_4!U[ZH^G^
MK]G7OX@_]3_M_P#C7OWA'_4!U[ZH^G^K]G7OX@_]3_M_^->_>$?]0'7OJCZ?
MZOV=>_B#_P!3_M_^->_>$?\ 4!U[ZH^G^K]G7OX@_P#4_P"W_P"->_>$?]0'
M7OJCZ?ZOV=>_B#_U/^W_ .->_>$?]0'7OJCZ?ZOV=>_B#_U/^W_XU[]X1_U
M=>^J/I_J_9U[^(/_ %/^W_XU[]X1_P!0'7OJCZ?ZOV=>_B#_ -3_ +?_ (U[
M]X1_U =>^J/I_J_9U[^(/_4_[?\ XU[]X1_U =>^J/I_J_9U[^(/_4_[?_C7
MOWA'_4!U[ZH^G^K]G7OX@_\ 4_[?_C7OWA'_ % =>^J/I_J_9U[^(/\ U/\
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T3W.54JYK, '@93(
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MV=NK;>).4SW8D5,-KX>KU%4>5(VF,XC*/+X'ECCTH5+NRV8+S[T%J>MEJ#I
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MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1-,[_Q>\S_ -K7(?\
M6Y_<D6G]DG^D7_ .H+W'_<B7_FH__'CTU>U'2/KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z@5&5Q=)J%7DJ"E*?K%161PVYMSJ86YX_U^/=
M&E5.) ^TCIY+>27X58_8I/\ @'3)4;YV;3%EEW/@]2_J6/(Q3D<VM:-F-P?J
M/J/;#7T*\77]H/\ @Z5IM%U)PBD_-"/\('3'/VSL" LISZR,H_3!CZJ8'_69
M8"G_ "=[8;=K=?Q_L#'_ "=+$Y:O7_T.GVL@_P +5ZB_Z7-K3?\ %NIMP9=O
MPF-PTDI/^MK,8^MA]?K[I^]HC\(=O]*I_P M.G/ZLW"_VAC3_3R ?X*]=?Z2
MYY>:/8._9U;A'DPGA75_0L'=0/\ &_\ L/?OWD3PBE/^UI_EZ]^X OQ7-L/L
MDJ?\ Z]_?/?$]C1]95Y5^(WK<[!1$%OIJ1XK@<B]V'Y%Q:_OWUD[?#"?S8#_
M "=>_=5FGQW:_P"UC9OY@]>_C':]3Q#L_ XSZB^1S0K!_K_Y/(#;\_ZP_P!;
MW[QKIN$:K]K5_P '7OI=MCXSR/\ Z2/3_P >'7M'<51^J;8F/7]),25DK?UN
M PD4_P!.2/\ 6]^I>-YQ#_>C_GZ]7:T\KAOM\,#^5.O?W?[0FMY=_P"/I?P5
MI=MP3?7Z\R*#<?CZ>_?3W3?Z*!]B _X>O?6[>O"V9O\ 32L/\'7?]RMYR?\
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MZ]UJI_SV?^WI/\@K_P 6TP?_ +\3JSW(G)W_ "3]Q_YH?]8YN@=S)_N79?\
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MZ-MXC.XG+461^.^_-L]J/+5P4;['Q52N%9W=C#*4:6>(1JE@_AB9)+,ZR("
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M_P!7_%=>^_7_ 'W_ "+W[POEU[ZL?ZO^*Z]]^O\ OO\ D7OWA?+KWU8_U?\
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M"8N;9K3>&WBW&AVN9)]&JHTRNS-&305!#%2:"HS0'I+_ !KZ _V7G:>=VO\
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M1]K\2.(:K*0:4+ZOPG[1HL9)LS#?*+>=#UQ)K@7;C8ZI8I2R?JI0(\M' 8V
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:J?\]G_MZ3_(*_\
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MG7OIO]7^H]>^Q_VG_D[_ (W[]XG7OIO]7^H]"#U]3^&LR!M8&FB'UO\ VO\
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MO=>]^Z]U[W[KW7O?NO=:J?\ /9_[>D_R"O\ Q;3!_P#OQ.K/<B<G?\D_<?\
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M:+$XC%T$-3DLOEJYU98*2DI9IY-+,$T([+[KW19?B_\ S8OAE\L^W9^@>O\
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M+D88^1^.7'MLSH.++^T=/K9S/P1S]BL?\G4&;>&TX+^;<^WT*C44.8I]5O\
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M-A]PY/&U,&%RM132T]5%408_)/35$D;TLRR+&5:*0$H?=>ZT_MT_S]_YMO\
M*_R-1L3^;I_+,J.P]JX21,;1?+/XR5]3@=MY=$MXJQJEZ3,;8JJNM5D<T_\
M$<!407TRXR%[Q+[KW2N;_A:[_+3&#%0GQO\ G*VY?M$<XEME;!2A\YMJC_B
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M3*\24>#I:8*4M8J$B4 BPM;Z6'OU3UZ@Z?H:>"F4I3P0P(6+E(8UB!) %[*
M+V ]ZZWUF]^Z]U[W[KW0-]MT_G_N_P $Z/XK_P G?;?XC^GL1; Y7Q*?T?\
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MW,F&WA@M\]4XFEQ6XMK2;8R3P[DGS,N;II(:" T#3UXGII(1*)U8^Z]TI/\
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MOW[@Y,_Z.%U^P_\ ;'U[][<S_P#*';_M'_;3U[_9P?\ A2K_ -ZY_B]_U/\
M_P!,OOW[@Y,_Z.%U^P_]L?7OWMS/_P H=O\ M'_;3U[_ &<'_A2K_P!ZY_B]
M_P!3_P#],OOW[@Y,_P"CA=?L/_;'U[][<S_\H=O^T?\ ;3U[_9P?^%*O_>N?
MXO?]3_\ ],OOW[@Y,_Z.%U^P_P#;'U[][<S_ /*';_M'_;3U[_9P?^%*O_>N
M?XO?]3__ -,OOW[@Y,_Z.%U^P_\ ;'U[][<S_P#*';_M'_;3U[_9P?\ A2K_
M -ZY_B]_U/\ _P!,OOW[@Y,_Z.%U^P_]L?7OWMS/_P H=O\ M'_;3U[_ &<'
M_A2K_P!ZY_B]_P!3_P#],OOW[@Y,_P"CA=?L/_;'U[][<S_\H=O^T?\ ;3U[
M_9P?^%*O_>N?XO?]3_\ ],OOW[@Y,_Z.%U^P_P#;'U[][<S_ /*';_M'_;3U
M[_9P?^%*O_>N?XO?]3__ -,OOW[@Y,_Z.%U^P_\ ;'U[][<S_P#*';_M'_;3
MU[_9P?\ A2K_ -ZY_B]_U/\ _P!,OOW[@Y,_Z.%U^P_]L?7OWMS/_P H=O\
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M[]K/7OI^O?9C_'_;_P#&_?M9Z]]/U[[,?X_[?_C?OVL]>^GZ]]F/\?\ ;_\
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M:VS]M0G*9O:V6Z,V5N5):>@5I9Q]GU[EL=N653&K:OMI=8 &FQ^ONO=;3/\
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MOOWC'KW@CKWVT?\ 3_>_^*^_>,>O>".O?;1_T_WO_BOOWC'KW@CKWVT?]/\
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MO>_=>Z][]U[KWOW7NM5/^>S_ -O2?Y!7_BVF#_\ ?B=6>Y$Y._Y)^X_\T/\
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MJ839_P#*D^+&T-A]9E)J:OFQE)C\WC!3YGL7.X'.K$<SD:R:K2&#&SS&:O\
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MYRW!;6;R%+R99QKH&:)E\4!M..W]('U(KCAT2\M33[WO<T]RJ!K:(PG14J)
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M>-I7E::94D5F2AD(#J"2"=:TK3X:4] /MEC--OMU=2*X1(TBB+(P5JA*E6(
M(!5JTK\7'J7_ #3/C=\FMJ_.#X>_S+_C9T_E?D=)\?-O5^P.R^E]NY+PY>3%
MJ^>GCKL52&.5ZJ6>GW%EH7^WBGJ8ZA* K2SQ&5HJ\E[Q9S;9=[->2BW^H99(
MIF6JZP4[6(X"J*16@IJR#2MN9=MN8[ZVW*VC,W@ADDC# -I(;*@X)[FK3).G
M!%2 '[FZY^8'\Z/Y _&[%=@?%+L[XB_!;H?>4?8?85+\BL1%MS<>ZLA$R+-1
M18&JB2N"2TT$]!3D1?:QT]95UM3-,YI*0&>WWEA[=VMR8KF.ZOIT\*,VY+1P
MJ<UUB@)K1L5-54"G<>D-Y;77.<\'B0/!:Q/XCB<*))6& -&2!Q&: AB<X'3[
M\,7J/D?_ ,*!_GYWD*VCS.S_ (W];0=*[>FIRE4E%DH_X-@&@AD%RI:;#;O:
M4ZBPEEDC!">D-\P@;1RI86VDJ]Q*T[>6I1K()^T/'3Y 'JVSD[CS!=SZ@5@C
M6%:4-"=-14>C(]?.IIY=5JX/^6;B_A]V'W?UK\G/Y4/?GS[Q.<[%KZ_XT]Y=
M%]D;L6"?$9&Z4-!N:+;&6HX<,HM%)55E=1+-!4O5C_**,4L[#*3G63?H8);'
M<X+$K$!<P3Q1BCKQ:,O&^JOX54\ O!B0 TG*T>U2RI=V,UT&E)@EBD<U5N <
M*ZZ:>;,.).2 ";.=N_RFLYNC^5+\E.I-K?&'K7XA?(WY%P[(WC+UGL_M7<G9
M4=1+TWEHLUMO&9O+;HSN<2CK*P?Q& PTU::6C>L6::1I?-'""I.?/!WVWN9+
MF2[@MRZ"1HHXNV52CLJ1JM:5!!(JVFF!3H4)RB)=JFMXX4MI9@K%%D:3NC8,
M@9G+>E#3 J2*]!IT_P#(G^<;GNF?BQ\&OCS\)=\?%/?_ $=B.L^LNV/DSW)M
MN');1DP76%#%BA)CAE\3_#:],I2TD4]<^/JZZJ#ZX,?9IXZJ-;N.U<OQW-SN
M=W>)<QSF62&VA)6;7*Q;NH:KI+474 #Q;@5*6QO]W>&"Q@MF@>(1I+/* T6A
M !V^3:@,Z22. -2& W?SPNJODSN+>G\MG?FQ.ENU?DWU9\>^Y3V+WQ@NG-H_
MWBS>0J<%D=H2TS+AZ"*>KA;(4-'GTA>"%Z2!YG%48U%.6+O;6\LHHMPAFFBM
MY;B Q0-,Q5 &66M6.,$I6N33MKGI9SO;W3O9RQ1R31PS"298U#.2K1THHR:C
M7PP*YICH-?YM/P@[/^3W:_PP^>,/Q)WM\A=CX3JC [3^2?PX.]I]F[JHL9D&
MK<W30T[8>LI:N7+XRKS^0@K%QU;))]Y1T:>*HHFJ9(U?(?,\.QV]YMGU26[M
M(7M[OP]<1<40UU*>U@@*ZEH 6.&H"GYLV&3=9K:]\!IE5-,]OXFAPI!84TL!
MJ4L:Z6R0HRM2&7X"_!'I_L/Y5[+[?VE_*"W!\/\ I/J2;$[XVWV+\FNWNQX-
M[MNS:]6U1CI,7L[);HFHWA@K(::1'K\<]/&L1JEGED>"E]N<U<TW=M9/;2;J
MMU++5'CMHH##X3#-95C4U()!"FOD:9/5.7^7[::Y6=-O:WC2C*\\DOB^(":4
MC+L*"E06^1'20_EXT?SR_E9Y[Y-?#^@^ 7=/R+3>W:FX-_=&=R[=R%)B=KY!
MC2IBZ.?<FYZC_</C**MI*'&U3J]6E?3N]3$]%Y"H1[FV3;.=EMMP-[#;E(DB
MGA96,BT)8^&@[FH68#\.!W=4Y=CON5VGL_I99@\K212AET," HUL:!> )XMD
MT4TZ-9_(%^-???6N#^8OR)^3_6N[^MNX_DSW919RMH-\;>J]I5=51T,=;FY:
M^'%UZ15]%3U>5W1D%*SQ)*6@\<BAX"/9+[I;S:WKVEG92+)#;0: 5(8!JA*%
MEPQ"Q+D5&:@YZ,>0]LGM5N+FZ0I+/-K-015:%@0IRO<[8-&\B,=;#GN*>A_U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TQ[FVUM_>FW,_L_=N&QNX]K;JPV
M3V[N3;^8I$KZ2NH,U"]-5TE5!(&CFIZB"22.1&!#*Q!%C[]U[HF?P!_EZ]"_
MRUNGLQT)\:\AV>O563WID]^4&UNQ]^3;^3%5V<A@BK4Q$M3"D]#159IHII*9
M9##]R9JE46>IJ9)O=>Z/1[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NM7_P#X3&_\R[_F&?\ B\&[O_<&'V..=_CM?^>2
M/_"W09Y:X7'_ #TR?\^];0'L#]";KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB
M>=R_*RDV!N"JVEM/#4NX,OC&$68R&0J'BI:>86+4Z)& \\B ^LB5%1O3ZV#!
M;JE>J,].DA@OE/U]V'@,UM?N3;D>,I*JCO?'QU&4IJLHRD1HD:FJI:E7TO$^
MME!4L98V"AME*<.M!Z\>@?Q_Q^R&^\NU;UOLS<N&VEYV:#+]J96/'Q2JWXCI
M*2F2M>,&^AUEE!L!(][@VU4X]5TUX=&QQ7QK@R5/01]G;XW#O6GH(X(Z7:^/
ME_NOA($IP D<5%2E=*Q@:0T;0W'U4<6IJ].KZ/7H?=N[.VIM&F6DVSMW#X.!
M4"$8V@CIF>UN9)%7R2L;"[.S,?R3[J37JP%.E)[UUOKWOW7NO>_=>Z][]U[K
MWOW7NBA_-"?)Q=7XJ*C,ZT%3N['Q9?PWTF-*>J>)9;?[K\Z(POQK5/SIO=./
M5'X=5=^W>FNK:/B3496?IG%C)&5H(,QFZ?#-+S>D24'TFY)1:EJA1_2UAP![
M:?CTZG#HS'NG5^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM=#Y6_R8NV4_FM?'C^:G_+RW
MYU)T7V!CZ^IH_F1UWO.?*[9Q786+JJBECKFC7!8C)HV6W!B)<A!D)JJ'Q_>T
MN*RJ))713RO[KW6Q?[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NM5/^>S_P!O2?Y!7_BVF#_]^)U9[D3D[_DG[C_S0_ZQ
MS= [F3_<NR_YJ_\ /\76U9[COH8]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2<W9NW;^R,'6;BW-D8<9BJ);R32F[.
M[ Z(HD%WEFD((5%!8_ZP)&P*]:)IT6S';=W?\B*NGW#OR*NVIU'#/%5[<V''
M(U+5Y98[-'5Y.12"L#\%%4_I_P UIXJ)K5T_;U6FK[.F?Y.=$9/=F*VYF^O\
M7!)4;3QLF&DVU0(M-KH0WDB^SC&F/73N9;QBS2*WHNR!6\K4ZTZUZ)9M/HCM
M/=N8AQ,&S<]B$,ZQUN3W!BI\-34ZW&MI'J$CU,@Y\:!I#] I]N%@.J:2>KA=
MLX&EVMMS!;:H6>2DP.(QV(IY9  SKCHDB#O;C6^G4UOR3[8.>GACI\]^ZWU[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T7GY3]/=B=\]([MZOZK[WW;\:][;@D
MPLV([@V/CCE,EC&PU;!6Z885KL:SPU9IU@J46MB,M-)-#K7R:@:;+?Q;;<I-
M/"MPBUU1.:*P((X@&A%:@T-" :'ATAW*UDO(6CBD:%S2DB@$J00>!X@TH1YB
MHJ./1:_Y='\N'KW^7EL[LK'X+?N[.X.RNYMW4^\NT^V]\TT--DLI44$<JTT&
MF-YYA303U>1J?\HK:J=ZFMJI7G8.JH<\V\WS<V21ET2*.%-$44==""N>.*D
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:J?\]G_MZ3_(*_\
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MXFE1;C4T>H+<:K$CWX@CKP8'H2)ZB"EADJ*J>&FIXEURSSR+"BC^K,Q"J/\
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MIK'IL[225=48'K9!3Y;'UE.SU$\PD4LY^9>;]GMMWL]2QPDQ2VX-4AR "
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M/F9^/JI&<TIRXG[PWN^O5KH4" &F&8:%-#\O"X>C XQ4"_YCOQ(^/&QOFO\
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M ,V]'CM_8]VU'JND=#A3T]/200TM)!#34M-%'!3TU/$L,<:1 *J(B@*JJ
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M^SHRFU-H;<V1AJ; ;7Q5-B<93#B*!;M(Y #2S2->2:9K#4[L6/ O8 "I->K
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M*WHGL3O#"[@S/9&Z^N,IM&#+&MKL1@*V3$:U$SXK;N.W!.^1R-EIHY*N$1S
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MNYF*O!"0XAHJMWR Z:BIU4&E=).HTZ7P\R*R2W$T4D-O&H*RRC29*LP[4(U
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M>_=>Z][]U[KWOW7NO>_=>ZU?_P#A,;_S+O\ F&?^+P;N_P#<&'V..=_CM?\
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M/N3,XW^,T>/S%51S1XRNJZ.X^ZIJ2M:"66&X\J(R7]7OW7NM+/O/^8=_.8[
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MW EC8KZ+8]UOQ?N(VD=7C:0D!H]4A%&..#* *^1 ^$T?O@5O;+]R?/O^8_\
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MZA[+ 64B]GKJWM]X_7(#/$Z1$T_M"R&F3Q*A@/6M//HT]R8)I]M/A5(616D
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MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6JG_ #V?^WI/\@K_ ,6TP?\
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MQ3S9'(5M5#0TZQ5%<:(JJI+3N'<D'<G;]?6LRV-DRQ&[GC5Y M7 9@M QKI
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MJ'FF2VFB$HDCMUBE+A15P225*NQ()9N-/+'2#E789-@2>)]!1YVDC"$FB$
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M2U5.M32T]69*6(X'M3NAE: M;B0*&1&F :7%3H4KJ.DU!8A4JIHQ%"2\\_6
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MO_9.W#O'>>QNK]_[PVCM$/X_XKE-LXFKK:#&ZM2:?OJN"*&^M;:[W'U]M[?
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M=YU90N2JA774=-:"K5KZ*3^$]"E\[^I.D?F3\U=G8SXU_.Z'X[_S,?AIL.'
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M!ND]GO#\R+)<37ZV8#GZ>%98D("\&D!;4P)-"IH#0G@1T<CXZ?S+?EYW-_)
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M/A6Z:F>:0U94)C6IH* T RP)HH(Z%/-N_P VVF"TBDCCEG/?,^D)$@H&:CL
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MU#$_V2[)J0G@F%E_(]W7&>J-G'1D:>G@I*>"DI8D@IJ6&*GIX(ET*B0J%1%
MX"JH  _I[IU?K-[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
MU?\ _A,;_P R[_F&?^+P;N_]P8?8XYW^.U_YY(_\+=!GEKA<?\],G_/O6R_N
MW<=%M#;.=W1D3_D>"Q=9DI4!TES3(2D2D\:Y7THO^U,/8( KT)2:=!'\=-MU
MN,V(VZ\X ^Z.R<E5;VS=05(8KE6+TL8)]0C$!$@4DZ&E< D>]L<]:4=#[[KU
M;KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NM5/^>S_P!O2?Y!7_BVF#_]^)U9[D3D[_DG[C_S0_ZQS= [F3_<
MNR_YJ_\ /\76U9[COH8]%CZE_P!__P!I]F=LRVFQ>.J$ZXV5+^I338@B2LFC
M_JD\QC='!_W9*O%K>[' IU1<FO1G/=>K]>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=:O\ _P )C?\ F7?\PS_Q>#=W_N##[''._P =K_SR
M1_X6Z#/+7"X_YZ9/^?>KZ/D%42[JK=@=,8^1_N-^[@@K]Q>%RICP^WF^XJ&:
MWT+NFI"38M 5^I!]@I<9Z$;9QT92&&*GBB@@C6*&"-(88D&E56, *H'X   '
MNG5^LGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>ZU4_Y[/_;TG^05_P"+:8/_ -^)U9[D3D[_ ))^X_\
M-#_K'-T#N9/]R[+_ )J_\_Q=;*7>.\9-D=8[GRU(T@RU72#!X-81JD-9FS]O
M$T8_M/"':4#F_C/!^ACU14]"]C0=/75FS8]@]?[6VJL:)4XW%P-DREB&K*O]
MZK:_]H&HDDTD_P!D*/H![T34]; H.A ]ZZWU[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]UJ_P#_  F-_P"9=_S#/_%X-W?^X,/L<<[_ !VO
M_/)'_A;H,\M<+C_GID_Y]ZOGZO WQW)VMV3(/+CMOS4_66UI2-2A<3:3(,A^
MEFGT.I%R5F8<#Z@DX%.A&,FO1F?=>K]>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6JG_/9_[>D_R"O_
M !;3!_\ OQ.K/<B<G?\ )/W'_FA_UCFZ!W,G^Y=E_P U?^?XNMA/L@?W[[LZ
MPZZ6\N*VE'/VAN:,#6I:@8PXY&_'$]PP/U2<'GZ&/1@5Z%QR:=&9]UZOU[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6J!_P )X-X)
ML/X]?S-MU&14GQGS*WM_#M8N&JZNA@@I%(^I#5,D5_Z+<_0>QSSL*O:_\\D7
M^%N@QRV:+<?\],G_ #[ULR=&;1;975NT\34(RY*IH!F\P7)+FJS9-3(LA/U>
M(2+$3_2,<GZD$,:GH2J*#H6_=>K=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6JG_/:('\TG^062; ?
M+3!DD\?3L3JSW(G)W_)/W'_FA_UCFZ!W,G^Y=E_S5_Y_BZV%.A!_>S</:O;<
MUI%W7NE\!MV4F_\ N+VNHAA>,_33/= UB07B)X^ICUL8Z%RYST9CW7J_7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]T73Y3?++X_?"SJ#-=Z?)7L;%]:]<X:JHL6N1K*6I
MRU77Y'*EEHL3B,700U.2R^6KG5E@I*2EFGDTLP30CLONO=%E^+_\V+X9?+/M
MV?H'K_='9.R.[?[L2;TPW5O?G2.[>@,QF,33$K45^#IMV8C%?QB&D(O.*5Y)
M(D(D9!&"X]U[JR7W[KW7O?NO=>]^Z]UIU?\ "?\ C;=N,^575P4RT.>_F#[V
MW3N*(#@T6T<;#*8I#>PCGURCG^VJV]5@1WSKAK4_\ND?^%N@MRWD3C_EYD_R
M=;BOL"="GKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>ZJ8[V_G9_ #X_]G]D]1[BWOVIO_=72WAC[JK.B_CYO;O/$;/GE61WH
M]R9O:^#R6*QE=3Q12//3R57FIU4B9$<%![KW5CW3_</6'R ZRV7W-TOO? =C
M]7=B8.DW)LO>NV:O[VBKZ.L!T2Q,0KHRL&22*1$EAD5XI421&4>Z]T)/OW7N
MO>_=>ZU'?^%$M154G\P+^275T,DD5=2]_5U11RPB[K+#O7K1HV46/J#@$<?7
MW(O)O^X&X_\ -'_K'-T#>9?]RK/_ )J_\_Q=;4_6.TTV-U_M/:P1(YL3AJ5*
M\(+ U50/-5N/^#U,DK?['W'9->AB!0=+OWKK?7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]UKW?-_:([]_GR?RE^H-WQ5>6ZQZ"Z)^67R_?:<]9'-BZW<E$,7MG!9#(8Z=
M?%45& JYX*BAF4//3S2N8O%$]29/=>ZE?\*#,%4;*ZG^#WS"V3'+BNX/B9_,
M1^+N>VSNS&B"GJC@^T<P=J;CP%342(\IPV>ARE)'5PH#Y3'$'4Q>0'W7NM@?
MW[KW7O?NO=$NWU_,;^ W6.\-Q=?=C?,GXU[&WSM'*5&$W1M#=?<6#P61Q]92
M&TM-64=36QST\R&UT= 1_3V9P[+>7*AXX)64Y#+&Q!^P@4Z12[E;PL5>6-6'
M$%U!'Y$]:NO_  GK^4GQ*Z)R/S?WEWM\CND^I4W5\B]TOUV_8O8^*VF,O29(
MI/45N-^]J8?NH(HUI09(]2@5"\^KV-N<-KN;MK8112.5MHPVE&;2>[!H#0X/
M09Y>OH(!.SR(H:>0KJ8"HQD5.>/6R_\ \.K?RT?^\]/B7_Z/C;G_ -</8._J
M]?\ _*//_P XG_S="+][VG^_HO\ G(O^?KW_  ZM_+1_[ST^)?\ Z/C;G_UP
M]^_J]?\ _*//_P XG_S=>_>]I_OZ+_G(O^?KW_#JW\M'_O/3XE_^CXVY_P#7
M#W[^KU__ ,H\_P#SB?\ S=>_>]I_OZ+_ )R+_GZ]_P .K?RT?^\]/B7_ .CX
MVY_]</?OZO7_ /RCS_\ .)_\W7OWO:?[^B_YR+_GZ]_PZM_+1_[ST^)?_H^-
MN?\ UP]^_J]?_P#*//\ \XG_ ,W7OWO:?[^B_P"<B_Y^O?\ #JW\M'_O/3XE
M_P#H^-N?_7#W[^KU_P#\H\__ #B?_-U[][VG^_HO^<B_Y^O?\.K?RT?^\]/B
M7_Z/C;G_ -</?OZO7_\ RCS_ /.)_P#-U[][VG^_HO\ G(O^?KW_  ZM_+1_
M[ST^)?\ Z/C;G_UP]^_J]?\ _*//_P XG_S=>_>]I_OZ+_G(O^?KW_#JW\M'
M_O/3XE_^CXVY_P#7#W[^KU__ ,H\_P#SB?\ S=>_>]I_OZ+_ )R+_GZ]_P .
MK?RT?^\]/B7_ .CXVY_]</?OZO7_ /RCS_\ .)_\W7OWO:?[^B_YR+_GZ]_P
MZM_+1_[ST^)?_H^-N?\ UP]^_J]?_P#*//\ \XG_ ,W7OWO:?[^B_P"<B_Y^
MO?\ #JW\M'_O/3XE_P#H^-N?_7#W[^KU_P#\H\__ #B?_-U[][VG^_HO^<B_
MY^O?\.K?RT?^\]/B7_Z/C;G_ -</?OZO7_\ RCS_ /.)_P#-U[][VG^_HO\
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M /.)_P#-U[][VG^_HO\ G(O^?KW_  ZM_+1_[ST^)?\ Z/C;G_UP]^_J]?\
M_*//_P XG_S=>_>]I_OZ+_G(O^?KW_#JW\M'_O/3XE_^CXVY_P#7#W[^KU__
M ,H\_P#SB?\ S=>_>]I_OZ+_ )R+_GZ]_P .K?RT?^\]/B7_ .CXVY_]</?O
MZO7_ /RCS_\ .)_\W7OWO:?[^B_YR+_GZ]_PZM_+1_[ST^)?_H^-N?\ UP]^
M_J]?_P#*//\ \XG_ ,W7OWO:?[^B_P"<B_Y^O?\ #JW\M'_O/3XE_P#H^-N?
M_7#W[^KU_P#\H\__ #B?_-U[][VG^_HO^<B_Y^O?\.K?RT?^\]/B7_Z/C;G_
M -</?OZO7_\ RCS_ /.)_P#-U[][VG^_HO\ G(O^?KW_  ZM_+1_[ST^)?\
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M>_>]I_OZ+_G(O^?KW_#JW\M'_O/3XE_^CXVY_P#7#W[^KU__ ,H\_P#SB?\
MS=>_>]I_OZ+_ )R+_GZ]_P .K?RT?^\]/B7_ .CXVY_]</?OZO7_ /RCS_\
M.)_\W7OWO:?[^B_YR+_GZ]_PZM_+1_[ST^)?_H^-N?\ UP]^_J]?_P#*//\
M\XG_ ,W7OWO:?[^B_P"<B_Y^O?\ #JW\M'_O/3XE_P#H^-N?_7#W[^KU_P#\
MH\__ #B?_-U[][VG^_HO^<B_Y^O?\.K?RT?^\]/B7_Z/C;G_ -</?OZO7_\
MRCS_ /.)_P#-U[][VG^_HO\ G(O^?KW_  ZM_+1_[ST^)?\ Z/C;G_UP]^_J
M]?\ _*//_P XG_S=>_>]I_OZ+_G(O^?KW_#JW\M'_O/3XE_^CXVY_P#7#W[^
MKU__ ,H\_P#SB?\ S=>_>]I_OZ+_ )R+_GZ]_P .K?RT?^\]/B7_ .CXVY_]
M</?OZO7_ /RCS_\ .)_\W7OWO:?[^B_YR+_GZ]_PZM_+1_[ST^)?_H^-N?\
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M1_[ST^)?_H^-N?\ UP]^_J]?_P#*//\ \XG_ ,W7OWO:?[^B_P"<B_Y^O?\
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M_P"<3_YNO?O>T_W]%_SD7_/U[_AU;^6C_P!YZ?$O_P!'QMS_ .N'OW]7K_\
MY1Y_^<3_ .;KW[WM/]_1?\Y%_P _7O\ AU;^6C_WGI\2_P#T?&W/_KA[]_5Z
M_P#^4>?_ )Q/_FZ]^][3_?T7_.1?\_7O^'5OY:/_ 'GI\2__ $?&W/\ ZX>_
M?U>O_P#E'G_YQ/\ YNO?O>T_W]%_SD7_ #]>_P"'5OY:/_>>GQ+_ /1\;<_^
MN'OW]7K_ /Y1Y_\ G$_^;KW[WM/]_1?\Y%_S]>_X=6_EH_\ >>GQ+_\ 1\;<
M_P#KA[]_5Z__ .4>?_G$_P#FZ]^][3_?T7_.1?\ /U[_ (=6_EH_]YZ?$O\
M]'QMS_ZX>_?U>O\ _E'G_P"<3_YNO?O>T_W]%_SD7_/U[_AU;^6C_P!YZ?$O
M_P!'QMS_ .N'OW]7K_\ Y1Y_^<3_ .;KW[WM/]_1?\Y%_P _7O\ AU;^6C_W
MGI\2_P#T?&W/_KA[]_5Z_P#^4>?_ )Q/_FZ]^][3_?T7_.1?\_7O^'5OY:/_
M 'GI\2__ $?&W/\ ZX>_?U>O_P#E'G_YQ/\ YNO?O>T_W]%_SD7_ #]>_P"'
M5OY:/_>>GQ+_ /1\;<_^N'OW]7K_ /Y1Y_\ G$_^;KW[WM/]_1?\Y%_S]>_X
M=6_EH_\ >>GQ+_\ 1\;<_P#KA[]_5Z__ .4>?_G$_P#FZ]^][3_?T7_.1?\
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M_P"<3_YNO?O>T_W]%_SD7_/U[_AU;^6C_P!YZ?$O_P!'QMS_ .N'OW]7K_\
MY1Y_^<3_ .;KW[WM/]_1?\Y%_P _7O\ AU;^6C_WGI\2_P#T?&W/_KA[]_5Z
M_P#^4>?_ )Q/_FZ]^][3_?T7_.1?\_7O^'5OY:/_ 'GI\2__ $?&W/\ ZX>_
M?U>O_P#E'G_YQ/\ YNO?O>T_W]%_SD7_ #]>_P"'5OY:/_>>GQ+_ /1\;<_^
MN'OW]7K_ /Y1Y_\ G$_^;KW[WM/]_1?\Y%_S]>_X=6_EH_\ >>GQ+_\ 1\;<
M_P#KA[]_5Z__ .4>?_G$_P#FZ]^][3_?T7_.1?\ /U[_ (=6_EH_]YZ?$O\
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M=6_EH_\ >>GQ+_\ 1\;<_P#KA[]_5Z__ .4>?_G$_P#FZ]^][3_?T7_.1?\
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M_P"<3_YNO?O>T_W]%_SD7_/U[_AU;^6C_P!YZ?$O_P!'QMS_ .N'OW]7K_\
MY1Y_^<3_ .;KW[WM/]_1?\Y%_P _7O\ AU;^6C_WGI\2_P#T?&W/_KA[]_5Z
M_P#^4>?_ )Q/_FZ]^][3_?T7_.1?\_7O^'5OY:/_ 'GI\2__ $?&W/\ ZX>_
M?U>O_P#E'G_YQ/\ YNO?O>T_W]%_SD7_ #]>_P"'5OY:/_>>GQ+_ /1\;<_^
MN'OW]7K_ /Y1Y_\ G$_^;KW[WM/]_1?\Y%_S]>_X=6_EH_\ >>GQ+_\ 1\;<
M_P#KA[]_5Z__ .4>?_G$_P#FZ]^][3_?T7_.1?\ /U[_ (=6_EH_]YZ?$O\
M]'QMS_ZX>_?U>O\ _E'G_P"<3_YNO?O>T_W]%_SD7_/U[_AU;^6C_P!YZ?$O
M_P!'QMS_ .N'OW]7K_\ Y1Y_^<3_ .;KW[WM/]_1?\Y%_P _7O\ AU;^6C_W
MGI\2_P#T?&W/_KA[]_5Z_P#^4>?_ )Q/_FZ]^][3_?T7_.1?\_7O^'5OY:/_
M 'GI\2__ $?&W/\ ZX>_?U>O_P#E'G_YQ/\ YNO?O>T_W]%_SD7_ #]>_P"'
M5OY:/_>>GQ+_ /1\;<_^N'OW]7K_ /Y1Y_\ G$_^;KW[WM/]_1?\Y%_S]>_X
M=6_EH_\ >>GQ+_\ 1\;<_P#KA[]_5Z__ .4>?_G$_P#FZ]^][3_?T7_.1?\
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M_P"<3_YNO?O>T_W]%_SD7_/U[_AU;^6C_P!YZ?$O_P!'QMS_ .N'OW]7K_\
MY1Y_^<3_ .;KW[WM/]_1?\Y%_P _7O\ AU;^6C_WGI\2_P#T?&W/_KA[]_5Z
M_P#^4>?_ )Q/_FZ]^][3_?T7_.1?\_7O^'5OY:/_ 'GI\2__ $?&W/\ ZX>_
M?U>O_P#E'G_YQ/\ YNO?O>T_W]%_SD7_ #]>_P"'5OY:/_>>GQ+_ /1\;<_^
MN'OW]7K_ /Y1Y_\ G$_^;KW[WM/]_1?\Y%_S]>_X=6_EH_\ >>GQ+_\ 1\;<
M_P#KA[]_5Z__ .4>?_G$_P#FZ]^][3_?T7_.1?\ /U[_ (=6_EH_]YZ?$O\
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M=6_EH_\ >>GQ+_\ 1\;<_P#KA[]_5Z__ .4>?_G$_P#FZ]^][3_?T7_.1?\
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M_P"<3_YNO?O>T_W]%_SD7_/U[_AU;^6C_P!YZ?$O_P!'QMS_ .N'OW]7K_\
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M\W0>V79;:_$OC*6T3.B5=^U12@PPZO6_Z!U?Y.'_ 'A[_P"S!=I__9O["_\
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M +-_?OZ\;I_O_P#ZIP_]:^O?U6L/]]?\;D_Z#Z]_T#J_R</^\/?_ &8+M/\
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M-3$M4ZG'!B. 8#JZ7_H'5_DX?]X>_P#LP7:?_P!F_L,?UXW3_?\ _P!4X?\
MK7T=_P!5K#_?7_&Y/^@^O?\ 0.K_ "</^\/?_9@NT_\ [-_?OZ\;I_O_ /ZI
MP_\ 6OKW]5K#_?7_ !N3_H/KW_0.K_)P_P"\/?\ V8+M/_[-_?OZ\;I_O_\
MZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\ )P_[P]_]F"[3_P#LW]^_KQNG^_\
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MS?W[^O&Z?[__ .J</_6OKW]5K#_?7_&Y/^@^O?\ 0.K_ "</^\/?_9@NT_\
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MW?O*I,ID*<2_98G=E#CJ>T,$2Z8*2)/3?3J))OOW-^XV5Y-%%+1$D8*/#B-
M/F4)_:>M;7RY9W-M'(\=69%).MQ4D?)@.K _^@=7^3A_WA[_ .S!=I__ &;^
MRC^O&Z?[_P#^J</_ %KZ7_U6L/\ ?7_&Y/\ H/KW_0.K_)P_[P]_]F"[3_\
MLW]^_KQNG^__ /JG#_UKZ]_5:P_WU_QN3_H/KW_0.K_)P_[P]_\ 9@NT_P#[
M-_?OZ\;I_O\ _P"J</\ UKZ]_5:P_P!]?\;D_P"@^O?] ZO\G#_O#W_V8+M/
M_P"S?W[^O&Z?[_\ ^J</_6OKW]5K#_?7_&Y/^@^O?] ZO\G#_O#W_P!F"[3_
M /LW]^_KQNG^_P#_ *IP_P#6OKW]5K#_ 'U_QN3_ *#Z]_T#J_R</^\/?_9@
MNT__ +-_?OZ\;I_O_P#ZIP_]:^O?U6L/]]?\;D_Z#Z]_T#J_R</^\/?_ &8+
MM/\ ^S?W[^O&Z?[_ /\ JG#_ -:^O?U6L/\ ?7_&Y/\ H/KW_0.K_)P_[P]_
M]F"[3_\ LW]^_KQNG^__ /JG#_UKZ]_5:P_WU_QN3_H/KW_0.K_)P_[P]_\
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MT#J_R</^\/?_ &8+M/\ ^S?W[^O&Z?[_ /\ JG#_ -:^O?U6L/\ ?7_&Y/\
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MP_\ 6OKW]5K#_?7_ !N3_H/KW_0.K_)P_P"\/?\ V8+M/_[-_?OZ\;I_O_\
MZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\ )P_[P]_]F"[3_P#LW]^_KQNG^_\
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M!U?Y.'_>'O\ [,%VG_\ 9O[]_7C=/]__ /5.'_K7U[^JUA_OK_C<G_0?7O\
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MU[^JUA_OK_C<G_0?7O\ H'5_DX?]X>_^S!=I_P#V;^_?UXW3_?\ _P!4X?\
MK7U[^JUA_OK_ (W)_P!!]>_Z!U?Y.'_>'O\ [,%VG_\ 9O[]_7C=/]__ /5.
M'_K7U[^JUA_OK_C<G_0?7O\ H'5_DX?]X>_^S!=I_P#V;^_?UXW3_?\ _P!4
MX?\ K7U[^JUA_OK_ (W)_P!!]>_Z!U?Y.'_>'O\ [,%VG_\ 9O[]_7C=/]__
M /5.'_K7U[^JUA_OK_C<G_0?7O\ H'5_DX?]X>_^S!=I_P#V;^_?UXW3_?\
M_P!4X?\ K7U[^JUA_OK_ (W)_P!!]>_Z!U?Y.'_>'O\ [,%VG_\ 9O[]_7C=
M/]__ /5.'_K7U[^JUA_OK_C<G_0?7O\ H'5_DX?]X>_^S!=I_P#V;^_?UXW3
M_?\ _P!4X?\ K7U[^JUA_OK_ (W)_P!!]>_Z!U?Y.'_>'O\ [,%VG_\ 9O[]
M_7C=/]__ /5.'_K7U[^JUA_OK_C<G_0?7O\ H'5_DX?]X>_^S!=I_P#V;^_?
MUXW3_?\ _P!4X?\ K7U[^JUA_OK_ (W)_P!!]>_Z!U?Y.'_>'O\ [,%VG_\
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MP_\ 6OKW]5K#_?7_ !N3_H/KW_0.K_)P_P"\/?\ V8+M/_[-_?OZ\;I_O_\
MZIP_]:^O?U6L/]]?\;D_Z#Z]_P! ZO\ )P_[P]_]F"[3_P#LW]^_KQNG^_\
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MS?W[^O&Z?[__ .J</_6OKW]5K#_?7_&Y/^@^O?\ 0.K_ "</^\/?_9@NT_\
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M +-_?OZ\;I_O_P#ZIP_]:^O?U6L/]]?\;D_Z#Z]_T#J_R</^\/?_ &8+M/\
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MP:.SP->G4_Q:@*UU5X?.G5\'_0.K_)P_[P]_]F"[3_\ LW]A7^O&Z?[_ /\
MJG#_ -:^CW^JUA_OK_C<G_0?7O\ H'5_DX?]X>_^S!=I_P#V;^_?UXW3_?\
M_P!4X?\ K7U[^JUA_OK_ (W)_P!!]>_Z!U?Y.'_>'O\ [,%VG_\ 9O[]_7C=
M/]__ /5.'_K7U[^JUA_OK_C<G_0?7O\ H'5_DX?]X>_^S!=I_P#V;^_?UXW3
M_?\ _P!4X?\ K7U[^JUA_OK_ (W)_P!!]>_Z!U?Y.'_>'O\ [,%VG_\ 9O[]
M_7C=/]__ /5.'_K7U[^JUA_OK_C<G_0?7O\ H'5_DX?]X>_^S!=I_P#V;^_?
MUXW3_?\ _P!4X?\ K7U[^JUA_OK_ (W)_P!!]>_Z!U?Y.'_>'O\ [,%VG_\
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M4Z2-#&5D#T&-0&HJW,)9&6:FIZWW7NAO_EL_RV=G? C9V^=S;FWSFOD)\O\
MY"9J'?/RP^6&^8?]SF\,YZV2GIT9Y?X1MG$>5X<9C(7\5/%ZFU2,2/=>Z)Q_
MPG@SLV-^,/RPZ"SZ28_?_P 8_P"8_P#,_K#>F"K*&3&U$#YK<[[FHZGQS'R2
MTE=3YLO3SZ$25594#>,NWNO=8OB5G&[3_P"%!'\U#>>W ^0VAT3\5?AU\<,_
MG8*%DI?[Q9<Y+=LV/BJUU0U530P54BU*ZA)!):%T&@$^Z]U?][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK=P.X/Y>'\Y#J
M#>&$SFR-C?)_JWHWY#[KV#NK9/;6Q)D_@6_NK:6IQ=;Y\/EH8*NDKJ2BS=7'
M#-)3IY(:EY(2T;JY]U[JLS^5K29/XJ?S:?YA_P#+3Z3["W?OOX/]/=*='=V]
M<]>;KWS4=@1=1;E[!\"5&P\-5Y!ZG(T6'R6/G?(4V.>L:&CAIXF2,5%1533^
MZ]T+G_">#.S8WXP_+#H+/I)C]_\ QC_F/_,_K#>F"K*&3&U$#YK<[[FHZGQS
M'R2TE=3YLO3SZ$25594#>,NWNO=8OB5G&[3_ .%!'\U#>>W ^0VAT3\5?AU\
M<,_G8*%DI?[Q9<Y+=LV/BJUU0U530P54BU*ZA)!):%T&@$^Z]U?][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MJJ_YX>QMQ]C_ ,HS^8+M7:>.JLMG9?C5OS.TN-H:62MGGCV?''F*F.&&)7DE
ME:EH)]"JI):PM[]U[HT'PR[KVAVQ\'OC%W]1YS'1[.WG\9NINQZK-U#+CH*:
MGK=MT-96M4AY'%+]BWG2='D)@:-T=KH3[]U[JL3_ (3?3Y3<_P#+DR7<E905
MN/Q'R,^7/R_[ZV:N0Q4F$EFPV^]\9,4=3]M( 8HZ@TDLD84LAC9"K,I!/NO=
M7W^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MBO?-?=/QWV9\2_D+N+Y;T<^0^,-'U7NNG[YH8,/EL_YMK96G:CS$<M)@D?+S
M4ST<\HG%*ID6'R-PJL1[KW01_'/XK_R\*SX/]>=6="=(=)9+X1[^Z?Q^3VGM
ME]NP;CP^7VQO['K7?>Y&KRQJZ[)U&2I:HSU=;7U<U=-,[S54[5&I_?NO=5G_
M /"8?*[BJ/Y>G9^V8,S7;FZ"ZV^<7RDZX^&NZZ_+/G3D^JMM5^/_ ()4PU<L
M\LD]+'FIMQ4\)9(0(X%1(1&J._NO=;%OOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[K6Q_P"%&_\ W1G_ /&UWPR_^3?OW7NA
MC_X4>U>5VG_+HQ/=-#CZW(8GXW_+WX>]_;Q3'XR7,20X?8.^,9]Y4_;PV>2.
MG-5%))ZT41ARSJ!J'NO=6:?-;N?9_4WP;^47>^4SF/79VSOC-VUOZ'-(4KX*
MB&GVW75-%]NNI4JVKI&@CIXP_P#E#RQQJ;N/?NO=%B_D>;&W'UQ_*,_E];5W
M9CJK$YV+XU;#SM5C:ZEDHIX(]X1R9BFCFAE5)(I5I:^#6K*"&N+>_=>ZM4]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6MC_,S_P"W
M^W_">G_S(9_[P5![]U[JS?\ FI9SX%8KX;[TQ7\RVB6O^(F]=U=>[*WY#51;
MD2D6NS.7IFP,M;6;5EI\KBZ>',PT;BN^Z@AI9EBDEGB ##W7NFKYK_$KX,Y'
M^7+WOU#V5U/TQM+XO;*^.&]9:2.CVOC,'C-KXO96#J*K'9?#3PTX7&5&$--#
M54=3 1)'+$CH68V;W7N@C_X3_P"[NYM]?R<O@9N?OM\C/V)7=1Y&E2MR]2U;
M55>W<-N#,T6RZZ>9YZF2:6NV93X"H:1Y=;F74Z1L3&GNO=7$>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB?_-7X-?'[Y\]4
M4/4_?F$SQBVUNS"=A]:=B["W#-LC=VS=S;8D\N-W)M/<%*#58?,T3WT2J'C=
M24FBEC)7W[KW16?CQ_*)ZIZC^0.T?E5W=\A_E-\Y^_NK]OYK:_2>]_EWV!C=
MZP;&I-RK&N2FVOA\1A,'BJ'+9%$,=1DGI9JUX2L0E14'OW7NK9O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T
M2+X5? CI_P""7^S,_P"B+<G96XO]FK^4/9ORT[#_ -(^8Q>7^SW'VM]K_$:+
M"_PS#8?[?"0_:1_;0U/W=4EV\M9-<:?=>Z"_Y?\ \KOIOY6=O;,^2^W>S^]_
MB?\ *_8FU:WK[%_);XK[UI=@[EK]M9.99Y]M;@CK\;EL1N'"B8&6"&MQLKTL
M^F6GEC*V/NO=+3X0_P NCHWX,/VINO9V=[-[A[V[[SV/W+WU\FN_]V+V#OO=
MM5B(%IZ&'(95:6B@IL5C8@4HL=1T=/1TJ'2D1(#>_=>Z/S[]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUX>P/^$X_0V^/D9\
M@?E)AOY@O\UOI_M/Y,[YK-\]IU/1GR@V[U9253F:HDQV,1,=L!:F3$8"GJ&I
M,73U-74M24BK$LK'6[>Z]T:'X;?R?ML_#3N[&]WXW^8'_-#^1E7C-O[AV_'U
MK\KOE;3]N[1E&X81"U9-AH]LXMGKZ0 M32_=CQ,2=+7M[]U[IX^1'\HOJCMS
MO_=ORHZ1^0ORE^#'?_9^!P^V.[=]?$3L#';*AWS2;<5TQLNZ<-E\+G,179;&
MJVBFR4=)#6I$6B:9U;CW7NC2?"CX,_'_ . O4]=U-T)AL^8MR[NSW8O9?8V_
M]PR[VW=O+<VZ)3+D=Q[LW!4*M3F,Q5M8-*ZHB(JI%'&@T^_=>Z.#[]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZIT[B_DR]2[
MM^0'8WR:^./R<^7WP*[3[L0R=[K\0^R,5M# [TK0R.F:SFWLU@,[C?[P1NCD
M9&EBIJAS/5-*9):J:1O=>Z-;\&OY?/QX_E]["W+L_I&EWMN'<_8NX%WGW-W;
MW!O&?LG?6^<[X_&^:W5N"I6-ZZM<&1A'!3TU'$\DSP4L332E_=>Z+Q\B/Y1?
M5';G?^[?E1TC\A?E+\&._P#L_ X?;'=N^OB)V!CME0[YI-N*Z8V7=.&R^%SF
M(KLMC5;139*.DAK4B+1-,ZMQ[KW1I/A1\&?C_P# 7J>NZFZ$PV?,6Y=W9[L7
MLOL;?^X9=[;NWEN;=$IER.X]V;@J%6IS&8JVL&E=41$54BCC0:??NO='!]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW4:MHJ/)4=7CLC24U?CZ^FGHJZAK8$JH9H:I#'+#-%(&22*1&965E*LI
M(((/OW7NJ(LQ_P )^?CBV(WIU#L#Y2?.KIGX8]CYW/YW?'P1ZJ[W@V]UM4+N
MVIDK,SB*"&7"U.XL)MO,5+EJO%4&>@I9%>HC18XZAU]^Z]U=AUMUOL+I[8&S
M>J^K=I8+8?7/7NW,3M'9.S=LT"8R@QN-P<*T])24L" *D4,2*!]23=F+,23[
MKW2V]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=,&Z]J[:WUM?<>RMYX+%;HVAN_!9;;.Z=M9VBCR=%D,=G8)*6MHJNGE5HIZ
M:JIY9(Y8W4JZ,5((/OW7NJ'J3_A/;TMMK9V5Z)ZT^=/\RCJKX<9S,-6Y'X;[
M+^2L V>F.K9(9<CMJAR.0P-=O"AVSES"PK:./<A>85%81.KU4C^_=>ZNQZ6Z
M8ZO^.W5&P>CNE=FXGK[JKK#;6/VEL;9V#1Q3T-#C5LD8>5Y)YY9&+R33S2R3
MU$SR3SR232.[>Z]T)_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[HD7S5^!'3_P [?]EF_P!+NY.RMN_[*I\H>LOEIUY_HXS&
M+Q'WFX^J?NOX=19K^)X;,?<82;[N3[F&F^TJGLOBK(;'5[KW1I^R>M]A=P[
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M8%1EZJ>>,U%4^3SM2\J1PP&67W7N@-_DI?RG?DM\$/EG_-/[E^1D'562Z_\
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MQ[OVC_'\.LR0C)[ RE7A<S1$3Q0R"?'9:AK*68%/3+"ZW-O?NO=5/]M_S/\
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MXZJ?$&'&YZH.-DILI(9!.E&/=>Z%W<WSH^0F"ZV_EB;HWA\>H.@>ROF+\O\
M:/QN^0?2G:LS[LR&TH:[8W96X,F,)E,17T5%5U!RVRL>V/R$L513SXNI9I:"
M*IE I?=>Z4?5O\R;H7:WQK^,797RI^37QPEWY\A]B[MW3L[<'16+W1'MG>9V
M/D:"@R4VP\1EHLCNBNCBDS6$C6C?[BMEGJE6G6=2&]^Z]T<CX^?)+HWY5=>I
MVI\?>Q\'V9L89W,[5K<KATJ**:ARVW'6+(8C*8^N@I<EB,M02,BU%%6T<%5
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M!M==];*VML+:N>[DSF2P!FI:=]PTN!V;B\_F9-NP2UE*)\K]A_#X%D#S5,:
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M9ZDJ,10;RJ^P-R82FS]=#A'-([[4J8IZAXZ<4Z-(&3W7NK6M[_+G>N,^1_\
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M R?3-=/C-TTE:W@\FO!U]-405)CCD19(W 9M)M[KW3IMKY+]$;OPG<^X]O\
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MNK,-T;W1D\?ANJNUGW-%6X/.U>5Q.5SE-3X^OIO-!-+-B\)EIE74"?MI8O\
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M.#!U&UZ^LJZVCAFQ,,\U+'!6S/.;>Z]T0G ]<=RS]'?R.?DJ1\_OCUL'XH?
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MV5W9UM5UV3_AT#5]2XQF#H:NHJI8X@L-'323SE88&=/=>Z2NYM][@^%O;O\
M-TVYV1\7_D'\@%^9&]J[N[IG>G2O455VO@\[B_\ 1#MO:=1L7=VX*1&Q.QJK
M;M7MVL(&YI\=CY<9DH:JCJJLFKB@]U[HV'\G[M6AQWP#_E>=)R[+[-GRNY/Y
M<O1_8]/ORCV)656T:6GVY@MNT,F-R&XU7["BSM4^0AFI*"5A/54T=1/"'CIY
MBGNO="A_-#^7_=/Q%Z*VWDOCST;VAW+VYVQV!B.L<!F=A]&[K[^QFQJ7*1RS
M9/?.Z<#LVBK<WD,7@J.)VI\?3B*3)U\E+1^>FADGJH/=>ZJ2_P!$.R^X_@UW
MGLWXR=6?.3LWY4[3[W^+_P Z.]>SOEI\7MW_ !YW7W/N;HO?>W=S5M!CZO>^
M(VYBIJRHP>VJO&X+"8MXL7@H1CJ"&*EIG5I?=>Z//U=O'(?.O^9;T-\H.N^J
M^^]A] ?$7XK?(;8F4WEW_P!&;I^/-3F-[?)K,;(*8'"87>.)PV;R*;>PVS:R
M;*UZ47\/BGJZ&FI*BJE:J^V]U[I)_!3NO:O1?6WS<^1^^L5OK)]2?)G^<UW#
M@>G_ .[FU)MQBEBW3N#:G3F.S+Q+*R4>W\SOO;>2KOOU=85CR,55)''++,/?
MNO=&4_G3=7;Q[J_EC_*7JO8.W=];JW7O?#];X;&87K/$56<SSJ^]-N254^,I
MJ*GJZEJFCI(YZ@.E/((5B:9UT1L??NO=%-J?BQDOY17R/ZQ[J^%O5'9.\_A9
M\@JG8?2/S<Z'V'3YSMG,8'/T<<E#MKOF@H$_BF<S.4J99(<=ONHC6HK<E3O2
M9RL\TU#55(]U[IMV5\$M\_(3H[Y\X,T^ZN@_D'MG^:K\E/E!\*^Z=P;7K<#4
MX7<>+3#OMG<]"*F*GER>U,ZGWN-R2Q%Z3*8FIKZ0F0,0ONO=$N^,7QK^;>]O
MA?B/DGNCXW;CVA\NOCC_ #L?D]_,$RWQ4S ?;$FZ,?O3-;FQ^ZL!M;)YM<=2
MUAJ,-NW+U&VLG)-'C\G445(IJ%IZLSQ^Z]T=?YJ?(G<?\SOXX;_^ _QE^,OR
M_P!M[R^2$>&ZJ[E[(^0_QAW7\>ML]9;8RU=3ONG+Y3+[MH,50Y[-4N)@K(L9
MCL#/E6K*Z2G8R)1:ZCW[KW2KBR>Y/Y8'SB^6?9.\>G.^NU/B)\WH.A-_[7['
M^/O2^X?D+D]E[YZ@VG3;&S6"W9@MIT63W%#A\[A<)M^OQ>2APTU+'5K7TE5/
M')-11GW7N@;^;^]_ES_,'_E]?S%:*@^-?;G670&\,?T#L7XF;2S'5F;VKW-N
M=J/=F'J-Y;PJ=M/-5Y'!X8*U-_!*2LV[2Y1(Z&LR=;&*::GC3W7NA%J?BQDO
MY17R/ZQ[J^%O5'9.\_A9\@JG8?2/S<Z'V'3YSMG,8'/T<<E#MKOF@H$_BF<S
M.4J99(<=ONHC6HK<E3O29RL\TU#55(]U[IVZ*[+SG\JG=GR@Z5[UZ+^2V^NE
M.U/E3W9\H?CKW[\>?C]NCY'4-=1_)/+3;GR>T=RXS96.S6=V[N7;V?J\E2PR
M5F)BQ^1H&HYX*O[C[F"+W7NBW]U?"KY-_/+H3^<UW_'U)N/I;?WSK^/W5W07
MQ2Z)[9-/MG<LFW?C13Y?(4&4W52+43P;>S&]\]FLBE+05-2LN.HXZ)L@()II
MXXO=>Z6_S'^4&[OYF?Q\V?\ "CIOX?\ S;V!W;VKW;\4<YV[/WG\7MR]1;7Z
MXQ?2_8VT]];IR&;WCFZ>CVMEUHX=LST=%#@\QE)<I/-"U LU.S5">Z]T>7^;
M-L'??8.Q?@]2;"V5NW>]5M;^:O\ RY]_;FIMH;<K-RR8[!;,[&Q=;F,U7I10
MS-1XG$T<;SUE9*$IZ6%6EGD1 6]^Z]U:O[]U[K3HV!VA0[P^'/\ .U^"G7WQ
M6[VWE\@OEE_,(_FX]4]99S9?0F:W#M#<N9[9WAG=OT6YMP;^QV,FVMMJ/9K2
MT:US;@R]%50T>+IY*-*B-Z9/?NO='DZ2S^XOY;';/SRV'\C?CU\F?D!EOD]N
M3I_LSJ#L_H_XY[G^0.-[ I\+U1L_8%5LK*Y/;F,R5-MC+8S.[9RG[6XY<9CC
M092*KAK7B-6(/=>Z+]\ .KNX?Y1^Z^F-V?,;IWO;L+#[X_EB_%#XYT_8?0'3
M.Y?E)-LG=7Q]SF]LIE]@Y?'[(QN?SN/I,A2;MPQH*^/'OAZBHQE1#)5P/'3"
M;W7NG/;?Q4^2M-T'\&!5=3]B=?Y#LG^>M\F?ESB.O_[M55=7=7[!^0FVN_Z[
M;;[HI\8*N';:8^3<6(-8KRQQ45?D8J*5UJWT-[KW12OCW\7NV:7X[?#WX"]G
MY[^;QG^W^B^W?CMBMY_&? ]%[!ZUZ@VU/T/N_&Y<;^Q/=$_2#8RLV312XU,W
M1&E[#JMRY2*08R=#DYZJ-?=>ZLTWAN;+_#+M'^;5M'M?XS?(WOS(_.O?DO;G
MQUK>EOCON3O+&[SQV4ZIVML9-C9K-X+%5N(VG587,X/(0L-QUN-Q\>-JTKUJ
MVA:H,?NO=&8Z%ZW[$Q/\@GJWJ/*;"WIC>UZ'^4MMSKVMZQR&UJZCW##GX>I(
M\<^#EPLD"Y*/,+D/\F-&U,*D5'[)C\GI]^Z]T7;^7O\ R8_B7D?A-\$\Y\B^
MM_D+NS?E%\8_B[NSL/HSOWY(=J[@VKC]V8O:N#K:NAR?5V>W0^U:/^!YM)!#
MAZC;JTF-F@2&*CA--&D?NO=!?T__ "\/DG\ZX?GC\G.SODQ\@_A]M_\ F#[^
MW[U5E/C;4_'GKK,5,G3_ $]!7=?;)HLU'V7L?/;GP[YS$Q9G.&BI*C&00OGI
M*B*F%9+-7U/NO=)WKS>/R6Q7PN^._P =_GI\"\Y\ROC9\=-T=T_#?YNT^X?C
MIN#N'>M?6?'Z;'4_4O<6S=O9(S/OG9FX-O0BHRN0Q%#F,G!DZF*:CJGDH\DJ
M^Z]T+O\ +,ZRV]M[YM[FW9\">G_EK\</Y<DGQWSF'[3ZQ^2>U=[]6;4R/9=5
MGL54[:J^K=E=B!,_A%Q>"7<,>;J<?1T.!J!4T%-#%45=,[4ONO=')_DN]?[\
MZS^$4FV.Q]D[NZ_W*WRJ^=&X%V]O?;=9M2N-!NKN3?&2Q=<*2OAIZ@T>2QU5
M355+-X_'44TT4\+/%(C'W7NI_P#,!V!OO>'RD_E&9_:6RMV[IP77?SBWGNGL
M#-;<VW69NDP6,J>G^R<='D<S4TT,L.,H),A64E,M14O%$U1/#"',DJ*WNO=%
M@R?9FY?Y>7R8_F5MN3H/Y.]O#YG;VV3\B?BUDN@^A-P=S4>X,Y'USM_8^2V1
M7Y' T5=C-I9BASFUX)UJ=QU.*QDF.R4%0M<RTM=X/=>Z+A\/>G-Y_P G'=O0
M6Y^_^M^Z>P-C[Y_E@_%;XR;UW/\ ''IC<WR1_N[V;\;<KNG*Y'!5N+V;B\OG
MUQN?@WI*N*RC8A:!I\94PU512O/2)+[KW5J/\I[IWLOJ7XI93+]P;1RO7?8G
MR#^1WRG^6&<ZWW 8OXGMV#Y*[^SV[,1A<NE.\E/#FJ#"Y'')D8(I'CIJ[[BG
M2258A(_NO=5,_)'XU=H=B?#7^<]UIE.C.Q]U4_=W\ZCXQ;OV_LYNN,IE7W1L
MN'-_%9,UFL;1"BD?,;<@HL)N+[NM@BFHXXL?D#-*JTE3X_=>Z.YVCN:K^%7\
MT+N#Y4]J=,][]@]&_(OX=]"=.=>]G=!=#;G^1D^UL[T-N+>N1RVU,OA=EXK-
M[BP])N6#=.*K:"K_ (6<9/44=1#4U-//' LWNO=$,V_\3.](^EOY<M5O3X_[
MWH<?NO\ X40]B?.>'IW(;)DW'5=;=?\ :'^FG<NV)MT45''74FVFPU3E<+43
MM*\<6+R=93P/+'6A1[]U[H]*]%[DB^1_\^[=T?3F<C7OOH+X[X#:&YTZ]J$&
M])=M]0;@Q$U%C:T48_O')05,T5$\,,M08)72F95=@A]U[HP_Q1WUO7XN?R<_
MBIOW?74/=&^.RNC_ .75\=LCNGHO;.R<CEM^Y+<&S>N\(E5MF'!2PC)_WCGR
MD+TDE//"LL-27^X5/');W7NJ^/Y>/>N,[J^3&TOD=\O>H_F]E?G'VE@,EL;K
M[%;N^!W;?5_571^V]P1C(5^SML9W<NV,?AH:JK^SA3/[KR%1%7;@JX8:6#[;
M')08Q/=>Z"+L#&]K=0?"[^8C_*;P_P ?OD;O/Y&?)[M[YJ8+XX[KVYTAN#.;
M!SFUOG?N3,YC'[MRG8=%CZK9NVL=M&CW971;@@RF7I,G!)BJ@T=!5&JQXJ?=
M>Z>_EQWWF.P>YZW^7_W;TM\_=L_R^_CMLWK/9G9V2Z#^$W:O:51\@J^CQ=,U
M5MU-U;2V_74N%ZLQZ)3P9B.EK!D=R5)J,:\M-AHZE<E[KW1V?DA\B>D-Q[2V
M'U1\F/Y>G<79G\N_M[HK9N[>NY<7\2MY=Q5./W-M&OE\&QMZ]2X?:];N/9<]
M+C8</6X2HJL3]JL\5335;XNKHZ9*CW7NC ?RENO.Z.KOA9M+:7<^#WGLP0]C
M=VY7I;K7LK)ME]R;2ZQSF[<O5];[5STTDU3*F2P6SY<52M32U,DM#&D5#*5D
MIFC3W7NJ&*?X_?RYSWK_ # H_G?_ "J/E%\A^Z-^_.[Y#;AV1O[:7\OWL_L^
M+-;3W++CEP!Q&\\+AHL+]O-,*TP3C,PQQ:O(U1&A#CW7NC3_ !%Z2^:^R>Q_
MY/N1[WZW[(SNZ^J_B_\ S;\/-3;UFDWC4;6PF^<]UA/U'LK?N[*<5&,_O+_=
M''T>.>:IK6EJY<?67FK)J6JJ7]U[JO+*X;Y2]N]%?"3;-?AOGU!O[J/YG?!+
M<_>WP6ZO_E[8SXU="].T&Q>R,%-FH\'5GK:'-;LP&W9J>7[*7;_8F<_8<YFL
M$>&@J&B]U[HP?R1W!W'UG\!_YSOP$I?B'\ONQ?D7W9\A/YA':G3]-UE\=-S[
MUVON/9?RAW77;MQ>Y,=O.EQYVPQQV*S<\-5BVR8S,F2H9Z"AQ]9/+2"H]U[H
MQWSD^*??59\GZ/I/I[J_?N0^/W\XCJ+H[I?YJ;ZVYC*Z3%[$G^+]91ONK,9Q
MJ5(TP];V1TY69;:E/72S12/D,3B:4L["#[?W7NG;YJ]/=E=)?S+L]\EZCL[Y
MV]$?'WM+X;=.]%;)[*_E_P#QTPOR6JL7E^E]P[IR-3M'=6WY^KNTL[A<9DJ;
M<-%68>LQV(I<;+40UM/DJE9DH%;W7NF#X+_&+LCJOY)?RP-RIU'\K-N;*.VO
MYSW8V[LC\D*+#9?/8:I^16[^K<UB)MTG9VV]N[7V95[UDILMEJ#;YH*:HHQ)
M54;H:FDJHH/=>Z//_(Y@W/LWX25/1G8/7':G67972'R4^8^%WKA.S.L\UL&.
M8]@=N[ZW=B*W!UF4HJ6CW%B:W!9[&3QY#&SU5&S2&,3%T8#W7N@A^,?QZH^[
M?C7_ #H/@IV//5U>[=]?,SYV8/<TV4DJ8)WQ7RYQ]/O#9.5BDE?FGI]O[GQ5
M/3R12>%),;)$H3PM&ONO=%2^/7QO^57S&_E3_/[N#O#JC>O3_P V?E1B]M9O
MJSKSLG9U1M[/;<S_ ,%]I;;Q77$;05M&:V6*7L[:&8W#CZAJ$^6+,I41PR"4
MM-[KW0C;7^&?R1^6O\H'Y";ER6QEZ;^;WS%^166_F%X3KKLW$UFVI,9N7KS?
M.$W#UCM'=-/6QP5U)HVAL39N&KXY%B-*SS:60Q^4^Z]T9O>'\TONGLWKVEZS
M^*7P;^7>)^<FZZG$;4AV-\D_BUN_8G7^Q,E/400YC.;RWY4+B=HYC:^!B-5.
MC8#=574YM8X(\4'-5'(ONO=%_P !WWD?A9_-L_FC=B=P?'?YE;WVA\@>J_Y=
MM%UAOCX\_#/L;O7"9BMZ<VMO.#<<-/D-L8/+T5,]'59W'QB.:NU!W>,N6AD(
M]U[HX/\ +ZZY[DW[\H?G#_,'[@ZQW=T3BOE%3_'WJ7H'I7LK%0X+=V.V-\<,
M;F1'G=VT%/65T>-R^Z-P;GS51#CVF6HH<=!115<<=4\RCW7NBI]W_(CKWXT?
MS[=[;][!Z<[@W[1UG\H/HG;])O\ Z3Z*S_R R^WS5]R]G3''38?:.*S6YX*#
M<DT%,&J:?'O1I4T%*E>\0>GD7W7N@-^'/Q"[CV[\ROY<';O:?1.\]L8&I[&_
MGO\ RIVYM_.;0EJDZLI/F!O'8>4V/M_.U4$4U!MW<5=MS(YJU%)4QSB9\G21
MZVI:E5]U[IA[MZJ[=^/GS9_F-[AW]VI_,YZYVI\NM[; [2Z5'P0^+.V?DOMW
M?M%0]?X'9\VT\_7Y#I[LJOVQN?$UV%J:40Y?)XG!R8RKI:JD<M_$FC]U[I$R
M]!O\0\;\6H:;#_S3OA/V1MGX#]%=383N'H_K6+^8Y0;HI-@5>=JH^I.U=H;4
MZXW'M]<]LALR4I,@E!A:/)T^0J*>@R$D>/E\'NO=)?;?6GS$ZO[AZ,^67RJF
M^8OPJ_TT?RXOCUTWN$_RS/BU@.\8-J;MZDSVZ\K7['W)LT=8=JY;:=!DZ/<>
M/K\<<5C*?%1Y"/)4%?5"6#'A_=>Z'# ?$;>^(^-7\I+!4W1?R?R..I/YY#_+
M#>>V?D9@L'OG=>!Q&Y\?W-FDWGNO&[-VQ@]O;(HJO/9+&Y:.C;$TPP%9DZ2C
MJ)(<@!$GNO=<_P":5\=.].R,S_/F'6W2G9F\&[<_EG?";;G7DNUMA9')ING-
M["W!V?5Y;%822"F9,[F\;CIJ$RT5(T]8B3TL?BO/ K^Z]TFNXNUN\^[.V?F@
M-M8WY]?&3%=XX':^X?C;UE\0/Y=%'@,KW?C<UUOAZ2ERO:G9F_>LMST.V]R4
MN4ILCMZ6DSV4VJ^&Q5%21S^5/MZ@^Z]TJNKMG]H=.]/?\)>=^[SZ0[Z_A/QV
MVUD>O.^<5M[I/<VY\UL[)]F= 9O8V,&Y<#0XR?,86D3<U;!25=75T45-17,E
M7+%'9C[KW08_!;KKMSX==._R2/E+WA\=/D)ENONCO@W\E/C-W#M+:/1FY.P-
MZ=:[D[CW!MC-8C<61V%C,;5;Q_AU=0[9R.*KIZ#"U-31FJI&J8%HYI)XO=>Z
MF[@^/G<7=GR3Z^^55-\<NV<1T3W_ /S]_A_\DM@=>;[ZBRF)R^)VQT7\>MS;
M.R'9NZ-L5=&:[9U'F-XXRBJJ>?+T=#5PR''3U24]144R>_=>ZN)Z2Z_WGA_Y
MO7S[[&J]D;GQ6P-[?$3X%8/!;\J=M55#A\OE=H9?MO\ B5'291H5HJ_(8NEK
ML9]S%'/)-315%+Y51)8M7NO=%O\ Y<_=>U>N=S?(+-;EQ6^JC;OS]_G"?-?'
M?&?)X_:DV2Q-.G5^ @PE=4UE;Y7AQ6/W)6]8;RRE!,"$K?/<1I432*?=>Z'C
M^9[M/>=!O+^7Y\E\'U[N[N797Q$^7&0[8[6ZDZ[P9WGN6LP^Z.OMZ;13/[=V
MY%_ENY,KL^NS]+E/X?0++DI*2*KDH*:KJHHJ:3W7NJE=];\RORT[0_X4993J
M_P"/G>FT<SV%_)JZBV9L'9>_NILCLK>6\:[,[/[WI<764^SYZ==S0563J*B+
M%T-%7XZ#)U!HX]%((I:8-[KW1FOE#2=G="8W^6!M'9FTNU/CET9L7XI;EZYW
M'\HOC%\($^6?:.PLK18?8M/BNO\ "8E-G;ZJ]EX#=%!C,C_%:L[)JXIJC%8^
MD>6CFCB=O=>Z)KU5\9>]YOA]_-7[4S.S_DX.^^@?YBF _F,?$W>ORQVSB>M-
MY[NJ.@.OM@Y6AR,U1A<'@=N4T&^<)B]Q[=JX:/'4S4%'DZK$9B&"OAR$ ]U[
MJ['^4AMC<V<^.>Z_E]V3MF?:W;7\PKMS=WS"W1A<D'^^QNW=[QTN,ZRP-8)
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MGD\;A,=7YC,Y"AQ&(Q='49#)Y3)U<=!34U/2(9)9YYY62*&&)%9G=V"JH))
M'OW7NIWOW7NO>_=>Z][]U[KWOW7NDG4;]V-2;WQ7657O/:=-V1G=L9O>V$Z^
MJ-Q4<.<K,-MFJH:+)9>EQ+3"OJ,9CZW*8RGJ:J.G:"":KIHI9%>>)7]U[I6>
M_=>Z26T-_;%["I<U7;!WIM+?%#MK=NZ=@[CK-H;CH]RQ8_.['K)<=F\+6R44
MTZ4N6P^0@GI:ZCE*U%)41O!/''*C*/=>Z5OOW7NO>_=>Z@U63QM#4XRCKLA0
MT=7FJR7'X>EJJN.GDJZB"GGJW@ID=@T\R4M-4S,B!F$44DA&A&(]U[I.]?\
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MU>&2.5E\%(^I8Y&6XC<K[KW0VNZ1(\DCK''&K/)([!%54%R23P !R2??NO=
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MVU/18S*-M#+8Z;+4LF/3$ID8)8J"HC@D4U<WNO=+/ [;^1/1O\Y3JC(_(CY
MT'R3VSA/Y5'S,W7M#='^BO$]6[A@?$]B=/U&X*#(4^"ECPM91?MXYL9)'CZ:
M>-6GAJY:QT6H/NO=%!Z#_FT_-#L_:OQQ^4^'A^3?:M1WUO[J&?>?PFVO_*[[
M)H>O\#L+M;-K25-=M;NG^Y\7\5S^U,%E*3*5><K=QU&W,TN-J8<?C,<M9#.G
MNO='2^#7RTZ>^)/1GRPW-W$G:CXO=?\ -^_FG8+#KU3T+OCOVJ^XI>W=U5#F
MJH-B[>W%74-.(U-JBIIXH"Y$8D,C*I]U[HNW97\U?NSO3OCY(XCH7LSY*]#=
M;_'M^ML+TYB^L_Y5O9?RW.^,SOO8&'WJ\_9]13;,KJS9N-A?=&)H_P"[-+)@
M=T4_VDM775\ JXZ*+W7NAZ[X^=GS<R'0GP%[HK^IODK\2.L^[NHMR;Q^8N[>
MG/BM/\EM\]:;PHZ? KA]N5FQLMB<EE\=MJNJ9]R/4Y23:5?4PI1T<,B43U/E
M;W7NBNY'L'N+Y,_++^0AV@OS,ZI[<DG^1/SXVA-OWI#J#^[V-JY>O^M>Q)9J
MC)87<:_Q;;VZ:[:L4&#SV(G418W(BHK*%(&\42^Z]TX?%/YD?,_N3J7^15U1
MTQO/I#X^1_.CXU_-+LKOC<.U^BL2:;"+T7+LZLQLFR=L4ZTN#HJR27/5M,(9
MT^R45;Y"HBK9:1*.K]U[KVZ/F9_,XZN^'?S?^6V]ODUU5G8_Y9WRH[1Z7K-C
M8#X^8R%>W=L=.[CQ*U^5W=5RU$3[9W#EMOYM(*>GVXE'145=1_<R25L-4:>F
M]U[H>OGE\W.\]E=Y?)#877?S+R_7.3Z8VYMW(=3]*_#WX*[F^>V=DR$VUERU
M5_IQK*79N:QVS::OKZ^E?'XBARN&KFQ,,&6?-.E;)2TONO= !\8N[NW_ )!?
MS+?@I\UM[;_@V[2]J_R!=T_)+=_5VV-DX^>CIZ?([JZKJL_MV@KZHO7_ &>1
MSM0F3AJ))&JZ7P+0K-)3R.3[KW23Z#_FT_-#L_:OQQ^4^'A^3?:M1WUO[J&?
M>?PFVO\ RN^R:'K_  .PNULVM)4UVUNZ?[GQ?Q7/[4P64I,I5YRMW'4;<S2X
MVIAQ^,QRUD,Z>Z]U&^>O:GS9^9O\I3^9S\JL%WQL/KOI/&K\R>G-L_%FJZ;H
M\M!4[&^/^YLQL?+Y+,;IFJX-QP[YR_\  <ID:0T\L6*H_+34,V,K"'JC[KW6
MPG\VNWMY_'WX ?+GOKKFHH*7L+I'X>=]]O;#JLK0+E:6/,]:[*RV9Q<E32N0
ME33I744!DB8@2("A-C[]U[JN?:'?WSN^/6=_EH=B?)OOC87=^V?G_OW970W:
M_3^T.H*#8V.V/NOLKKW/;UP^4V-F:8_Q[(86BJ]L5V/R$.=:MEJHZN*NIY<7
MX&HYO=>Z*?\ 'CYT_P RV+^5MT]\_P#N/N/IS?W;GS/R'QSZ2Z)Z8HNDH-H[
M1V3F_D-V+1;(PF]<UE:3(_QW<&G%Y&#*Y'%^6CI'J0*&CEI(B:EO=>Z>_P"9
M1VW\I?C7U1\KOB+\@>^<9\I-B?+G^4?_ #2.P^O][5/4N&ZCSVU]R?&O85/+
MF*":+;[IC,EMO-8S=D340EHUKZ&HHV2:MKTGU0^Z]T-G57;OS=^(%#_*QR_R
M [WV!W7UU\S<CUS\:NP>G,!U70[&H=A[AW#UGFMW8++;-W!3ZL[DL%CWVG5T
M&5&>%9+41U,>1@DQHA:CD]U[HF]5_-2^2^VMT?&3LW%?+*H^0[]H?+'H#I+N
M'JCI?X([JJOCI2[?[QWI#MMWV1\@<AM#%293+8JFS./-/F)MU5F.S-72&&GP
M=$]2T,?NO=&1ZWZW^:?8'\R7^>!-\<ODWLOXX;<VUVS\/LIMQZSJ#&]K5.=W
M;_LO>P6>DW,,TZ0T>S8*2+$ADQ<M)EJB2>K9<C1I3Q"?W7NBC]C_ #ZW7\W/
MC5\U-Z9?KW8.R\=VO_PEMWC\F,E'0[1I9,]2[@W]-W!A,QBH]S30)F*G:T,F
M!6:@H7E%.KR25FAIIV?W[KW06?-_L3L7L_\ EQ?SS^O*#)[*V'@_CWU%_+YH
M4R.VNK\.F6W/A=T]&; S^0QFY,N8DK\C/_$<Q:CKI)GGH*2FAHJ<+3ZU;W7N
MCO?/_P#F"]X? WY0=J;;Q6/V!VSV)@OY>GPIQVT>S<GT6N4S]5N[Y*=];GZ]
MERE?1[3ICN7.8+$4T,64IMI8J5!7Y!)*:D\537B>/W7NC!?"CYF?*/</RII.
MB,W6?*?Y0]/;YZ7[(W__ *;_ )!_RZ=Y?!.;9N\MEU]#)0[9EK\GM';.V\OM
MW<^-R52F-44LN6QTN)85U=D_O5DB]U[H(?A=\\?E=NOY#= =>?*WOO+=']V]
MA;AW'M_O7X1?)WX>UG2N*%6V%RM72T/1/9N,H9,1O&HQV1I::2]=NG-'+8E*
MJ>!**;1I]U[HPO\ /,V'O??75/PGH=M=F_W'P=1_,T^ .VMP8&;86(WO3Y&J
MWAVGM2CQ-?4+E8Y $P%1YJC[0 T^0$A@K%:$ >_=>Z+I#\IOY@.X/A%\J?YB
M^P>^^MMG=?\ Q"S/RF@V'\5*KHG$56*W9M/X)93,[?W VZ,^L\.<Q&Y-YML_
M.5-",,]'CL']W14QH<JD$CS^Z]T/F?\ D1\VODS_ #&=@=!?'+N[9GQU^,T_
M\N7XW_.'=^5S'3-!VONFJR_:>_-V8J+;5,^0K*:@I,;E\%ARM;4&.2HI9*1&
MH=#U,LB>Z]TT_P#"@.OJ,5T/\#LI2=>9#MVKQO\ -R_E]5]+U1B#C%J]SR4>
MYZF1-O4IS551885&:911Q_?UD%%KF'W4T4&MU]U[H.9^O>V^[OE]\0/D]5_R
M[YOY:O4OP=RG=G;G=O>/9V[^M:#.[@P&?V7EL1+LS%XWK7/;BDJL)45%13Y3
M*S9:NI*6!<=3FGAJIV81^Z]U3_\ '3YU=&[ [U^-'\U>NH^X<!WA\S/F!V#M
M_P"8T6X/C-VAM'!8_I#Y9/B-K=2QU6_<SM:AZ^KX.NHMK]6UGDI=TU-,PR&?
M_@[5SUBF;W7NKP^Z.I.^=L_/3Y)_*WXE]3?#3^8<N[MC],=)=\=%]E]QT'7?
M876M=U;CZO(4^ P&6FPNY\-2T&Z<7N*FRU1B,PN(D^ZDIZP2RTM8)8/=>Z(%
MV-N3X^UWP4VCLWHSI?M?XP9W87\^GX<1]^?%CMZOIZ^JZ_WUOWMG9NZ,OBL&
M<=5U^#&T<I#F:3,8@XBLDQAAR#FF$+>2FA]U[K:J[.VEG-^=>;SV5MKL'='5
M&=W5MS*8'&=E;(I\=59G!RY.)HADL4F7H<EB_P"(4H8O3M58^IA24*[PR!=)
M]U[K5=V%M23X0_"S_A3=@?C[N+L*FRG3O8':F:VAOG>.^,KV7N?^*Y3X_;'R
ME?N'(9_-5%?D\AEY,E75N0DJ9YFT3,2BQ0HB)[KW1V.Y>G.I_C/V+_(-S'Q_
MZ_VMUUFZ#ORE^-L;;'P\.WYJ[86_.D-]5^;Q&1FHTC_B>-_B6WL#E9(JKRJV
M0HZ>N!6IC\OOW7NB=YWK_8W97\ES^<I\C.P-LX2H[\J^^/YH';7^E:IQ$5/N
M3&[H^+&\=RXSK>JQ^6BCAR>+J]G4FSML4V*:&>)J(4J-'8O(7]U[J_/OC_2%
MV7_+_P"P*W#[TJ>L>PMU_&2?<-9NJ#;E#NB2CGJ< E?E(!05Z&CD^\A%72$M
M'>$3&:,"2-+>Z]U1;_*GW'\N.R>G_BO\+^E/D7MWX_[)Z:_E;_ ;Y/[T[2P_
M0&U]T;CR^2^4FV9*?;FUZ6BR$1P8PVVZ#9]>^2RU10U68S$]9#&:BA:F:>?W
M7NA5W9_,1^=V_/C3\3=M=4;FZ<V3\J]V?SB-^_RLN_>S:[KF7<NV*FBZ?A[1
MI-P[TP&WI\D9J6HJ*7:&/S-'02962*.K5L?+4RT;O*WNO=75[JVSE-G_  [W
MUM'Y(?)R@IZ^AZ4WW@.T_EGF,9ANDX*"/(8VM@J=VSP1U,."P!Q=/,*@M]U'
M2Q-!Y2T:DA?=>ZUT]_\ 76[_ (D?"7K[I/Y[_P N7J'?WPE^-U!TUEZ?YZ_R
MY.T*2DW!MJCZ;R>)R.)[2K-FUV*PN[<3,LM!2Y;-3;?SF=;0^04QUM)(6F]U
M[IPIOFGNCJK^;C_,G^.W4$PV7N[Y?_+/X#[-P_RDWEL>LW-L/9E/E?CGM.MH
MEGJ41<=D-W;I&-J:';F,J:R"FGK726JET"&EK/=>Z/AW1_,#[V^(V8_F5]5=
MHR4O9'8G4_6O1_;G\OVIJ\3CMM5&]X?D?%#U]M[;%:U'2T=!49JC[HHYJ.K>
M.B6*/'YC%RR%59TA]U[K-G^P/YCV]OYC>P_A+M#Y,=<=7=?]:?RZOCI\G>_N
MR8^A\9O[-[@WQGM_;MVQE,9B::KJ:/&8G [DH]O53S,(9*BA%-"*'0]1-*GN
MO= I\=_E7V+'_)O^&WS.SW?V'^-DNYNJ<93R=1]"_&O:&63=^\>P\[54.W-K
M;+VU+3QPT^8S61:*CH:"BC5)9IFJ*AE1)IU]U[H1>H.QOG#L?Y6_RG.J?F]D
M^E]Z=V=^=5_S$^S>RJG;_5V$^\V>-C8WK)\'M3 ;A@I8YHVHX,W51YRLHDIH
MLQ4JHT?9TU,GOW7NC9?++NOY![A^97QJ^"?Q[[)Q?0=3VITMWQ\D.TN\ZC85
M#V1EZ7!]-9+:F!HL!M?&YE9, F2RV6W;#/5UE=25JTM%1M'%2--5)/![KW51
M&P_E3\AO@#\</YR7:.Z,ALWN'Y)C^;IU_P!*;>W;@.L<Q-B:G(=U;'Z'VMA-
MQ3;+P55DLWDZK&X?*4M?4X+%U1GR>1@?&T#TPJHFA]U[I6UO\R7YD]2;1^6Z
MX7.?)SY%;0V?_+R^9/R8VC\A?DG_ "T]X?#)=A]C="X&ISF"P-8<KM/:VV=R
M;7W!!-)]A3&!\K2/B'BKZ_)??K+%[KW0L[[[!^=>S.EOY8&Z/D-W9TWVEVS\
MT_G-\:L)-2T_QGV_1XOJ[_2+U'V'N"KI=FOD'RE565V*S>-H_M,U6 9$0?=P
MW2&L:*/W7NA,Z%_F%?(_O+:W\N;HSQ[>VU\P=_=Y=W==_/""+"TLT. Q/P*D
MR&'[2RE#CIM:TM)N_=8VC18>;0KPTNY::J2%#"Z0^Z]T1S=?\VGYA;[C^2G>
M_2M;\BZC*])]X=]=9]$_"_K;^6)V-WSL??N-Z"W-/MYX-S=OX;:->:?=.[9<
M'E!35&&W#0XO;4M=!3Y6BRTE#4._NO='1RO>7S=^<,W\PG)=%=P;8^+FP/B=
M'#TQL_IW?G2-+O:LW7N/*=88#?.=FW_6Y*IH\IAL9&=W4F*HZ;"R4%3 ])/7
M5-75"1:-/=>Z.3_*PQV:R_\ *!_E]XG;>X9-H[BR?\O;XT8[ [KBQ<&;?&5M
M;U]AXZ7(K150-+6-13M',()@8I2GCD&AC[]U[K7P^ 6;^>^S<#\ /C!\;ODQ
MUWU]BOF=VI_.LW5W1VIN7XV;>W9F\##\4NY<A34>4P\*2T5/E\GF,UGIP8LJ
M\U)14U?)'!&R4=-$?=>ZN*VSV%\^?ECVY\S]E=*_*'97Q\POP>WOL_XY[9GK
MNA,/V+)V#OFDV)MW>&<W'O"/)5<38;:U54;GQ])2XO!ST=6D<-35'+GR1T\/
MNO=%6^,_S[^;O\RSNGHK9G2W;FR/B+UIVG_*=Z,^:6]<M0]4X_N#<.-WSO;?
MN^MG5^-P2YTC%/@IY-OQ2O+70S2QP4<<,%.)LC+64/NO=-?2?SE_F)2?'3^6
M]\W^[>Z>I,IA?DY\P.EOA[VW\9>O.F:>AP/VG:N[\AULFZL=N>NJCN:/<*YV
MBI\S+%JBQ:4T\V-CQ[M!'63^Z]U8#_/:RLF"_E1?+?.0XO)9N;#8?JK*Q87#
MTYJZNL;';[VM,M+2Q#F6IJ"@CB0<L[*/S[]U[HHWQ'W=OCOO^:!NZ?\ F:]5
M9#J3Y+[/ZPP/='\MSH#-[EH=X;-P.P=TTHH]SY;$U%)JHLMW=@\B7Q^[*C7/
M_"*"HI(=O2MC*NMK:SW7NB1]7;_^<OQN^)7\X_YG].?(+KS:&POB_P#S1?YF
M?:6V/C]6=-4F\*?>=!LKLBOK]RT6[MP5U0N5QL^4'WU)C3@S2"A6.GJZF2O>
M:6EA]U[HZ'S8^=W>.#[9[ZVSUQ\Q<QUCD>K=D[/W%U+T=\/_ (,;E^?6>-?E
M-HQ9NJ7O*NI-F9G';.IZVOR5*U!B*'*8:N;$PP99\RR5LE)2^Z]T&'PZ[/[I
M^5O\U+^7E\K=T=AT>UW[Z_D19+O/<?6F V5034%(FZMY=3MF]OT=?4:\A]A7
M[@K8LG%42.U92B!:%9I()')]U[H.=K_*O^81O+^2IB/YB?R>[=Z+[/RW?,GP
MUBVM\=F^,F"J-K8&GWYWOLS:XSE149*>OJ,UF,EMRO%:T513+28S*-#-CXT-
M&CR^Z]UME>_=>ZU=^P.P.Q?AQ\_?YYOS9S.\J7M\?&'X1_%#N' =:Y7KO!X(
MUU-EZ#N^7;NVES]/32Y3%46%FHUCJ*VG#5&1@E9JU93!$![KW1T*SN'YR?$/
MM#^7_EOD;\C-D?)#8GS<[JPOQI[+V!A>DL7U;'L[=>_=E[CW9A<MLG(XZLGR
M%7MVDJ]KUF/JZ3-S9*KFAJ8:R*O@DB:GF]U[I0_R6.T/G1\HOB9T_P#,WYB]
M\;#W:OR'ZJHMP;:Z-ZZZ8H=C8W;P@RE9%0Y@YT5E1E<GD,WB8::>MII(XZ.F
MJ)C'1HL<6J7W7NBA?S5?G9\BOBI\F_DX/CSB.EX-^=?_  *_E^;QV!N7?77M
M)6UDV3^0ORGJ.M\KC,OGH:>7,MMIL+(YBHXV>.CJYI\A#!)4L/?NO=&]VIWM
M\LOC+\ZJ7XY_(KO3 _*#K7LSX2]X_*O$Y3&=+8[J++[:S?QZSNU,;E</C(\/
M55462V]F:3=(DI(JXU.3I)Z;1)D:Q)?3[KW5:'=>\/G%\D?A=_+2^:W:7R Z
MZK^MODY\\OY6G<&X_C%ANGJ+$T&TL%V3VSM#*[5H=L[ICJQG\AF<6U3B(,Q/
ME6JZ>O'W<M'28O1&A]U[H\V[/GW\B<+_ "Q/YJWRII<YMB/MGXG?(#^8]U_T
MW73;7IFH:;&_&7>^=P&U(:VB-HZ^1*'&TRU+R-KJ9&=B5+*%]U[I3X'MSYW?
M,KMKYGX7X[?(C8GQKVY\.-Q=>]-[#P>8Z8QO9HWOO;+]>[<WWE,CO2JR<T=3
MB]I^?=6.QL%)@UHJ[Q4U37_Q,M-'20>Z]U78<_\ )7J?OC_A13WQV/OKK+<O
M8?7O\J3XT=K;HZMH=B8[?VQI\XG6?=.9QN%CJ<ICZ"LW!M7;=;09&CB:LQE-
M)G<?6:LK3)(H0>Z]T?SKCO3Y6_*;N;:/Q7Z-[@VM\3]I=)_ 7XD?(3LSL';/
M3F"W[EL[N#Y)PYF##8/"8?,1_P!W<!M;!TNT\A)5"+'35%0]7!24DF-CI3)-
M[KW19.O_ .83\]?D5W/\)/BKM/LCJ/J/?V[.T_YLGQS^6W;F,ZL7=4-5DOY=
MFX-H86AW3L;!Y*LJ:>@J=P)E)6^QKZZIHZ)J^660Y$8Z"EK/=>ZL_P#Y</>O
M>_94GS)Z6^1.\]O]I[_^'?RTS?Q^H>X,#LV#KR3=&%J]H;0WCB<CE<)1RRXZ
MAS5/3[J-'5FB\5).],)X:>G$AB7W7NBR0;Z_F+_);YJ_S-^GNH_E'UU\>.I/
MA[NOX\[9Z&B@Z*Q/964R^?[)ZFVUO3*46\ILS(L3;2BR68A91C9*++S"IJ(D
MR=%'20&;W7NJ\/B]W/\ )C^8S_,8Z:^172O:6W/B/+WK_(>^,/8W;&8H.NZ7
MMK-4>3J>WNSH(L5MFFW"#@XL:V5&2EGJZ^@JYS2PTL-/"KU,M73^Z]T.N,_F
M2?(G>/Q;^+U3V7\H>MOCYV!NGLOYK]+=U;SZ2^/.<^0W:N[J_P"*>],CL+'9
M;J;J3'[?WI31TN0J:6+)[@KLAC\I0X,R4M&E%-%D!44?NO=/?0_\P7YZ]K?!
MCYX9[K/;.^.^?D%\5OE_ANB]C;ESGQAJ^EM^978>9I]@Y[*;DKNH\TV":7>^
MW=K;IS,]+C!'CX<U+14<D-!&*D4LWNO=!KE?YM_:O37QS^3N]-K_ "2HOE+O
MC Y?XK;!ZGZ^[V^(.Z.@.X-C[@^1&\6V;D,AOCK7$X' 5&\-N4+U5-6X2';^
M'IZS*55'587[J::I@JXO=>Z-K\&/F1\E]S_+C#]![LRORK^2G1V_NHM_[ZKN
M^^_OY<6\O@[4;(W9L[)4#TVW7J\EM+:^W,WM_<>*R=6,9&*>3+T$V(9*ZOR?
MWRRQ>Z]T/?SBS4O8OSG_ )7GQ(R3!NO=Z;][Z^7'8^(JL=!6TN97X8X?#5&U
M,7.9I5*_9;[WAMC/QZ()2)\% 6""SCW7NJE\[U_L;LK^2Y_.4^1G8&V<)4=^
M5??'\T#MK_2M4XB*GW)C=T?%C>.Y<9UO58_+11PY/%U>SJ39VV*;%-#/$U$*
M5&CL7D+^Z]U>-3?S">E=E[GZ-Z5[0I^[XNZNT]H].56C:WQ=[*W[MZ+(=IPT
MD=.M?O# ;2R&T<6B5DY^Z>KS-/'0Q?OUIIX/7[]U[JN[&?&?%=(?S[/COV+7
M=G=N=O\ 9?>WPJ^=6?WIN_M3>+YB*DH,!O/J\X#;>V\'21T> VUM[;U+DZF"
MGI\?C(9JIGDK,I45]?++5/[KW0$8G#?)[OGYQ?SI,WL#XU_%/O!M@;]ZOZ!G
MS'RQW3EX'R6R\+U=M_,TO66TZ?%83(G;]+49'.[CR];E*DO!+69VF_R.K\$D
MM/[KW5@>V>[=S[C_ )(&V?D'_+HPN;V5N3#?![ ]G?&78G9]9)VM74O^CO!0
MU]'M'*UF;K)Y\U+-!C9<,U9/7^676*E*B.31(ONO=%-F_G09&+YJT6\O[S=<
MR_RQIOAYDLHV\HG@&2;MFAZTIOD"8CE7(1*)^H*A?'2:B?NA(TBB30OOW7NF
MGN;^8;\P-B;&_EM]"]BY_L7I[OGY9_&;L/Y*_);M?H;XBY;Y=;MV>NWH=NM!
MM3:VP]LX'<N.CK*;)[PI:.ISN5P]?C*2'%%):6KJ\I#+%[KW0;;B_F[_ "XV
M9U)@.M]P[,[IQ.^M_?.NB^,?6'RMW=_+Y[)V[GLYUW-L:MW_ %N]<7T=)A*?
M<6<WEBX\9D-N2T]%CUPQK8O[P/3QXV.3&'W7NBV?-WYF=\[Q^ GSIZQ[EHOD
MQV_U!TYN?^65VQUC\J>ZO@MN[X>[ASSU_P @=A4VY]H9+;>2VOMC%YW/XB7&
M4=?256!P=)#54N42C:B%31M-4>Z]U9ECOG)\W._?A]\H_EY\;]JY6KW?MSMZ
M#I/8?PWHNK(,QOWK_&;#WC08?>^>W3ALM)C:_/\ 94>V7K\YC=MQ5E-COMVH
M*>/^+RU"S2>Z]T.O\L_Y5;A^06\^\]A;D^5L/R)Q.U=K=>9S&[ [K^,N1^)?
M<VU:C/39BDS5/O3:55@]NXG(;<K)*:C7$9"@PT0$D==35$U8?%*/=>Z4_P#*
M.W%4X[JOY2_&CRFHVY\'/G5\A_BMUH\=+%2PTVS,;_!]Z;+PM,L+,HIMJ[6W
MKB<#$#I98\6H**NF_NO=+O\ FW?)'NOXD_ KM;O;XZR[0B[EVYO[XR[5V7_?
MZA?(89W[:[4V5M"MBR,<22S)3S8W/5D9EBB>6 L)XD>2-5/NO=$[AR?\SK_9
M\MP_!BJ^<NP'V=N3XA87Y8P=\T7Q=P%+NS 9:DW36;1KMI8#!2SU.VI-M5D\
ME!D4K,N<KE8$AFQXDD,ZY&'W7N@$^!?SO^<_\SG(8SJ7;?=&SOB_ENANA!N;
MY ]N[.Z<Q6_,GO+>=1VAV;UK1+@\-N2:NPVW]L"/JK)9.L7PU=9/+DX:.GGQ
MRTIEF]U[H0]M?S'/E9VOU-\:.B,%F.M]A_++MG^8Q\G/Y=?:??\ 1;$DSNW<
M=_LG,>]LCN;>FV]L5E=+!_$]RXC9\"XS'5^1J*2AK,A*\IKX*(13^Z]T4'M/
MY)?*+^71\G/YLO9&]-];:^2/<LG3G\G_ *@Z2W\W3U723-3]Y[Y[5VOC\IN;
M9VSGEGW#F<!6Y3+5;8[ 4M ^=6FHJ*DIJ*>K:1?=>ZY=]_,CY+[G^-7\Q3H/
M=F5^5?R4Z.W]_*C_ )A&^J[OOO[^7%O+X.U&R-V;.V9E'IMNO5Y+:6U]N9O;
M^X\5DZL8R,4\F7H)L0R5U?D_OEEB]U[JY; ?S!_CO\?]H?'OI+?=/WE4]B9/
MH_I"HQJ;.^,'9&_< 3NC#T45"M7O+";5R&S\6ID ^YDKLY3Q4,9\]<]/!>3W
M[KW5.W0?\VGYH=G[5^./RGP\/R;[5J.^M_=0S[S^$VU_Y7?9-#U_@=A=K9M:
M2IKMK=T_W/B_BN?VI@LI292KSE;N.HVYFEQM3#C\9CEK(9T]U[HRGS<^</S
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M5'8&X-O[6S=+@L!%5;AQM)!A</D<3G3%2/DI<LL%=!2I[KW0S])_+OYO?/\
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M+,[6J\!M2ER5%3UNUQ-09:CVQC(9EGGIC#*U.91[KW5Y/P;_ .WA_P#.R_\
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M#+1RUDM32'9V-^R:"NIT3RU/GCJ-47A]U[HLO<G\M[!=@=O=G]Q]1_*#Y/\
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M)H<I60;LVANJ7!;DBPRQXYLS@IL9D)J.&FCGFE>CI)(/=>ZF;]_EO[$K=O\
MQOHN@>\OD'\2=X?%;KROZ?ZN[%Z=W/B-WU\^T\S3X^&NP6Y*+L+![UPFY8ZJ
M;$XVL-=78N3*Q5L!GAKXQ4UL=3[KW0:8W^41TOMG%_&JJV1W5\A=G]I_&[Y-
M]N_+5.\Z#-[9R.Y-X[O^14&5I.Q*C=T=;M>HP,]/O&CS-?!4IC<+C31Q,B8U
MJ-8P/?NO=+CX_?RN.BOCE_L@W]S-Z]M9?_AN[J'OOICIW^\^7P]5_%L;\A_X
M!_&*C<OVN$H_NJZD_N[1_9M0_81)Y)O/#/J3Q^Z]TX]A_P LOH_LGXQ_-+XJ
M9G>/:M'L+YS]J]G]N]J9S&9?$1Y?&Y'M>?&5&0@V_-+A9J*FHH'Q5.*=:RAK
M95#2>2:4E2ONO=)C?W\KS:.[NU?D+O?:_P GOE-T[UQ\N:R#,_)_H'JK<NU\
M1@=W9)=O4NU:G(#-U^U,EOO;$^1P./QU+5_W?W;BM8IDDA,$KR._NO=<>JOY
M5G5'2V]/A3OGKSN;O7$Y+X6?%VN^&F-H*JMVODZ/?77E9)AZE<+O6";;#"1X
MLA@<55"HP[8F5Y(2DI>)C&/=>Z3FS_Y1O66S*K8^RL?\EOEC4?$WJWLO#]L=
M8?"2;>^WJ/8>$R6VLL,[B<=%DZ/:]-V%6[3P^659Z+;]9O:HQ,*I%1-328Z&
M*B7W7NDE\B_Y,'57R#VOWWU'3_*7Y<])_&;Y*Y[=6^NV/C!TQNC9^%VM5;FW
MO5OD\OFZ*LRNR\QNG%IE,V_\5KL72;BBP];D-;U5!+35%72U'NO='"_F&=8;
MS[7_ )>'SDZ8ZPP-9NWL+LKX7_)CK#KS;%+/!!49/,[QV/F\5B:".6HD@IDF
MK:ZIIXE:26.,,X+LBW(]U[HKOPW_ ):-+UIB_B;V!W?WG\D>Z\U\;NJ]J0]&
M=(]V[AVYE<!UIF\IM>+!Y6?&OA]NXO.9W+4-!4Y'%T=9N#/9J>AHIYXJ:4-(
M9C[KW0Y;?_EM_'K%?R_]E?RXLQ5=@;KZ0V!L#:>Q=L;JR.Y8\+N^CFV!6P93
M ;BHLWAJ3&IC]RX3+TE%7T5;24< AJJ>*01%0R-[KW015/\ *;V%OG!=V1?(
MSY-_*#Y2;_[@^+_<7P]P_;';N4V7CLMLO8_>N-.-W)3[2H-J[+VYMNFS.35*
M2:JRM=@Z^LJI*2E2>1Z:,T[^Z]TY=._RINL^M]P]3U?8/R!^3'R6V)\=-J5^
MT?C/U'WSNK;^6P>QHLM@9-KU%=0SX3;6"SV<S"[>J*S'4M=G<UE*BAI*JH2E
M>.24R^_=>Z"7&_R4NN(NN^FNEMQ?,+YF[OZ+^,G:72_:GQ@Z<RFZ-DXK$;+J
M.A<]39K;U!]QBMC8_,[NQU+3TJXQ8]S93,&.C=IH&BR<=/D(/=>Z$KL;^5+M
MO=OR ^3_ ,A^O_F!\Q?C_N7YDUW6Z_(C;/3V[MI4V'S&+ZPVAC-ET&,H8<YL
MW.5>!D;%XYI'R>.K*?,+-5U/BKT@6DAI?=>Z4>X_Y3GQ?RM)VSA-M3[\ZWV?
MVM_+9IOY6K;)V/D\;38[!==4$NZI*:LP@KL7752;E@&[:]!4UE35TKB&G:2B
M>03/-[KW3?N;^4I\=-W]6_.KJ/.;O[>GVU\_]F].[-[:J8,]B::KQ,?1VPL#
MU_A:K;<BX7QTU4<=MS'UE1]]%7PRUQE(B2D<4J^Z]UDWO_*@Z-[CS&Z-T?(#
MLGNWN[>.]OB+U-\1]U;QW+GL-M;)30=*[RS&_MO[YHJG;6"PLF'W[0[GRYJX
M:^A:GI8'I*-H*&*2.1Y?=>Z$'I+X T'779U1W-W+\G?DQ\P.R*;K/<'36T<O
M\@,YM?&T."VUNV:CGRU)08+8FU=EX2HR65>@HQ59:NH*S)M'$(8:J"&2>.7W
M7N@DZP_E.;'V%O#H.IW5\H_E7W;TU\3=_#LSXN?'#MW/;0S&W-FYG'8W*X;"
MU2YC'[.QN^MQG;.(S62H\5_'=VY)HHY%DJFJZJ-*@>Z]T=7Y)?&G9/R@V_U;
MMS?.9W3A:+J;Y%=!?); 3;3JJ2DEGS?QVW-0;JPU'6&LHZU'Q577XZ&.M2-(
MIWIV=8*BGD*RK[KW1(]^_P HKJG>N6[@V[COD1\HNO\ XP?(K?FX.RN__AAL
M?=NW*+8.YLKO:45.Y5%36;7K=[;>Q6[:SR5&<QF$W=CJ&OFGJW,$9K*OS>Z]
MT<[;GQ7ZZVI\HL]\K<'6;@H=Y9WXT=8?%?\ N?!+10[?I-N=2[BW/N3%S4=*
ME$M;%D#5;JKH)6->U.::&F2*FB=)))?=>ZA?*?XE]??+?'=$XSL+.[RP4'Q]
M^4G1/RTV@^S*VBHGJMP?'[*_Q?$4.2-=05XEPU54>BLC@$%2\?$-5 WJ]^Z]
MT_\ RP^..V/EY\<NWOC+O?=6]]F;([LVC5;"WKG.NLA1XK,'#YB2(92AIJBO
MH<E30QY:@6HH:AC1N_VU3-X6BF\<J>Z]UUWW\7^I/D5\8NR_B-OO"RTW3?9W
M4^6Z<R6*V_)'0ST&*R%!]A32XN2:*HBIZW%!8)J*1X95BG@A=HW"E3[KW1*]
MQ_RJL+#N2B[,Z2^8?R[^-?>&9ZXZLZW[P[@ZGSVS*FJ[/7J'$PX7$[@WU@L_
MLS,[4JMVK00)$V6QN"QDYBTTQ!HXH*>+W7NE!3?RH_CW!T?@.EZK>O=6=KX?
MEGU/\V.Q^Z=S[NQ^X=[;Y[ ZDSN)SM+D]UY2HQ#4,]/6/@\;0R4M#BZ&GI<9
M!%0XN/'Q11!/=>ZLZ]^Z]T4K8/PPZ>V-F/F7D:@;@WOBOG3OZ;?G=NT=[5-'
M7XL_>[+PFQ*O$XZ&EHJ.>/$UF%P<)FCJ:BIF:::<B=8RD:>Z]T 70/\ +)VA
MTOVAU/V/O'Y(?)?Y)T?QKV[N/:7Q/V!WUN+;F9Q'7-%NB@7#5$^-EPVVL+E]
MPYR/;X;$09G<64R^3@QLU5 E3KK:V6?W7ND]VE_*>ZL[2WMV?]UWQ\B]J_&_
MOSLFC[@^0_PPVMG]O1=?[UW$LU%49*HR,M;MNMWAC<7N>?'4DN?Q&*W308S,
M.*@U=*WW^0%5[KW5E.\]HXW>^R-V;"R,E30X?=^U<[M&NFQACAFAIL_22T4K
M4Y>.2))8XI6,>J)D# 75AP?=>ZK3;^5%L+:6"^.O^R^?)7Y-_&'LSX[_ !9Z
MS^&D'<O4N4V=DLMN_8/4M%!283';TQ6Z=G;BVIE:['2QU-71Y"GV]1UE#4UM
M<*.6"FJI*8^Z]T)V _EI_'O:6P/BEUWM;(=BXK%?$SY/U?R^V]F:C<L&=R^Z
MM\9S$[SQF:RN],E7T-3/EI<]-OK-U]<\'V<K5O@\,D-+&:9O=>Z.WO[8>S.T
M]C;RZS[&VUB-Y]?]A;6SVR=[[0W!1KD*'*8G=%++19''UD#^F6FK*2>6*1#P
MR,1[]U[JIE/Y->T*[;>*Z4WC\V_G7V)\-\/'A,9#\--[=E[:RFU:S"[<>.2C
MVKF-P1[0A[#S.TX?#!&V/JMXN:FEC6BK9ZJC,E/)[KW0^;__ )8/QO[.A^=U
M'O*??&0H/G[DNH,_V'24^3H,:=JY7HC:6#VGM3,;%GI\9'4X7*X4;=Q65I*F
M>:LDI\M"M1"8X56G7W7NBA]J_#S,?*;^8_\ "'*=@]*]V5.P?Y:>V=U9[<'R
MR[AR^UZ&A[9S6>H=HUVU,;C\5M^L>;-C#[LQ,.Y*^LK]O82+&9W!4PQE+*E8
M*A/=>ZM*Q_QIV3C?EIN[YBPYG=+]C;S^.O77QIR6WY:JD.$CPG6>Y=T[IH:R
M" 4:URY6:NW;D(YW?(/ T$5.L=/'(LLDONO=5J-_)!ZPP^SO@_L_K/Y@?,KJ
M.+X =?[JV+T5E-HYCKS.R>;>33K6[BR-%N;KO/X<[G^QJ9Z"+(T>-HY8*&6:
MGBT+43F7W7NC/=:?R\:;:?='0/?_ &C\KOD_\E^T?C?!\C,;UYG^ZJG8E./X
M=\E\;LW'YC&UD.TMC;6BFI<<=ETM3CRJQS1U%=7_ ',U5"U-%2^Z]T*OR@^'
M>WOD?G.L^Q\'VIVG\=^^^F?[T4G6/?W2<N!_C^/QF_11+N#!5-'NC![DV[E\
M%F_X;C7J*2OPM0JU%'2U-.T,\(<^Z]T73KC^4A\=]F_'CY1?'/>^_P#OKO7!
M_+KN^?Y'=K=B]L[[HWW=%O9\?M>F@W'@LU@,3@A@\CCLGM+%Y?'M2TL:8W(
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MFS6WJ#[C%;&Q^9W=CJ6GI5QBQ[FRF8,=&[30-%DXZ?(0>Z]T-?>'\J?H;O\
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C^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>tlucid_sig.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tlucid_sig.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5&7\S'_ (4)_P O3^61E*_KO?\
MO/*]U?(&@D6"OZ#Z..$W+N_:DTD..JXQV5F*_+8W;'7328_)Q5,=)7U7\6GI
MW$D-%)&=?OW7NJ?-J_\ "D7^:OW5TUV/\N^C_P"3)24WP\ZCV_NSL+>7:_:/
M?3;1QM;UQM+%OGLED]J;GWAMWKG';ORE+AZ.4M%M['[AEGJY(Z6G@EGTQS>Z
M]UL>_P K;^8_U/\ S4/B+M/Y5]48/)[-2MW!N#8?8/7.<RN)S6<ZX[(VG]C+
MF]KY')8>0TU9!4XG+T&6QT[Q4E158C)TD\M-3O*84]U[JQ/W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4)_S;/\ A0I\
M,?Y5(J.N\L:_Y!_*2IH):G'?'WK?,8VCEVN9\9/78?)=Q[WJDKL=UMA,G,L*
M)%'2Y7//'4)418N6FU3+[KW1ZOY7/S![(^?'P=Z3^7':/2U/T#G>Z:+<VXL1
MUU3[EJ]UQP[+I-W9W"[-W*F6K\'MZJDI]X[?QD&4IPU,H>EJHI$)21??NO=6
M!>_=>Z][]U[HDGS'_F._"'X [:7<GRV^1W774,E7CZS)8+:.3RCYGLK=M/0/
M2153;.ZRVW!E]^;H2"?(4Z2R4>/E@IS.C3/&AU#W7NM6+Y/?\+8OC/LW)9'"
M?$OXE]H=Y"DR!HX=[=L;QQ'2>UZVD6GE+YC#X/%8;LO=F1IGJPB105T6%G>)
MF=_$RB-O=>Z+#L;_ (5&?SP^^,W@]W?'/^4AA>S.GZT1^2CV-T#\N^WLWFRK
MU4TYP?9NQ<[1[7I@]&T(4' 5NAHW<ZED5(O=>ZMO^#7_  IEH.R/DCL7X7?S
M(_A?W!_+D^1W9]5@L?ULW9>-W9C=E[MK]UUHQ.SZ;,X?L?9_7^_>OSO+.)-0
MXJIEI,KB:FIBTR5\#,$'NO=;4_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ1]5V'L"@W=C>OZ[?.SZ/?F9@J*K$;)JMS86GW=E::EIFK*JHQNVYJU,S704
MU&C2R/%"RI&"Q(47]^Z]TL/?NO=>]^Z]U[W[KW4>KJZ6@I:FNKJFGHJ*BIYJ
MNLK*N:.FI:2EIHVFJ*FIJ)F2&"G@A0N[N0JJ"20![]U[K3Q_F1?\*X.EOCWW
M#_LNGP%Z<A^:?9-%FQM7.;]_CV4QG5/]\:FK_A5!M'KFFVSB\ONCMW,-EV6"
M26B-!CY)&2.CJ:UG8Q>Z]UM)?%#-?(W<GQOZ:W'\N=O]>;1^2FX-BXC.=P;2
MZII<Y1["VIN[+(^0GVO@H-R;CW?E]6W:.HAHZMY,G6QRUT,SPR&%HP/=>Z&3
M=F[=K;#VUG=Z;XW)@=G;/VOBZS-[EW5NC+T&!V[M_#8^%JBNRN:S64J*7'8S
M'4<"%Y9II$C11<D#W[KW6LG\GO\ A7'_ "I>D<9V-0]1;A['^4/8>S*@XK;N
M V!LW-;5V+OC-QY"3'UJXWM'>6.H\9%MO&M"\LF5IZ*N@JH-,E M:CJ??NO=
M;$WQU[BC^0W0O3G>\&Q=[=90=P];;.[(INO^R,=3XC?FT*;>."HL[38+=>,I
M*JM@H<U0P5JK-&)"5/Z@K75?=>Z&;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:3_P#PHO\ ^%(J?&AMU_!C
MX!;VI*KY# S87O'OK;\U+D*'I!+Z*[86Q*NU115W:\RWCR-8 \6WD)B35D2Q
MH?=>Z*5_)3_X3N=<[3ZXR/\ -%_G4G$4NW7P^3[?P72'?>16FV_A-N5-MQ5?
M='ROK=U587(Y7/)-)51[6RFM(XIA+F1+63MCJ/W7NB<?S;?YMO?/\];OS9/\
ML#^6#LO<E5\6,ANS;N&QN.Q. R.V*OO3)8/,8V3&;_[ Q\^.I)^N.A^O:^&G
MR%)29&"E6D^W3(Y%(YXZ:FH_=>ZWR_Y5G\O_ &C_ "R_A!T]\3=M9.FW+F=J
M45=N/LW>U-1-0)OKM7=M1_%=Z[CBI9)9IX<:M8R4&.25WEBQ5#2QN2R$^_=>
MZL1]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=)RDWCM'(;DRFS:#=.W*W>&#H
M:3)YK:E)G,94[DP^-KW:.@R&4P4-4^4Q]#6NA6&66)(Y""%)M[]U[I1^_=>Z
M][]U[KWOW7NM13_A1=_PHDH/@-B\Y\,_AMN'%9KYH;BP\2[^[ IACLWAOC#@
M,U2K/2F2DG6LH,EW1F\;.E1CL=4QO#B*2:*OJXW,M)!/[KW6L%_(._D3]M?S
M8.Y?]F]^5DV[J/X<[>["K=S[VWCNJLR=9O;Y;=BTV>DRNYMF[?SF6EFRN2V[
M69[S+O+=3R22M*\U!1RODGJJG%^Z]U]57"X7$;;PV)V[M_&4.%P.!QE!A<)A
ML72PT.,Q.(Q=+%0XW&8ZBITCIZ2AH*.!(H8D54CC0*H  ]^Z]TG^Q.Q=A]1[
M%W9V=VCO#;G7_7>Q,%D-S;RWKN[+T6!VUMG;^*@:IR&6S.7R,T%'0T5+"A+.
M[@7L!<D ^Z]U\_3^;Q_PKUWMN/,;MZ$_E:TZ;0V92.^'RORZW3B1/O+<TJ?>
M4^1;IW8V:I'H-J8,GQ&FS>8BJ,E4J7,5#0E8YY/=>ZH[_EJ?R3OYA'\[7L#,
M=Y9_=NY]L]19S/U2]C?,KO\ JMT[\R&[\WCX7Q]=!LY,YEH=T=T[IQT]!'1U
M+#)4]#1-'XJFOAD186]U[KZ$_P !_P#A/9_*[_ERXC%;DQW4^$[M[=H:K&FH
M[]^3,6WM\[DI\W45U51XK^YN"R./I>O>NI369W[*D;$8VGR=2I@CJ:NLF1)/
M?NO=+_\ FW?SJOBE_*/ZGJ'WA6X[L+Y#9G R#IWXT;4R='2[CSE2:>2#$9?>
M$T"5*]>=:4<\:_<9*>!Y9(D:.AIZJ>T7OW7NOFM]+4OS7_X4)?S;-D9'>^Y\
MO6]H=F;MVWN+?>[=D5&3VWMWX[=#=>Y'%MF\EUU'5S;D.Q,%L/%S6PD1>H>J
MW)7PO/)/75\T\ONO=?9 ]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TG
M,'O':.YZW/8[;6Z=N;AR&U<BN(W108/.8S+5NV\L\*U"XO/4M!55$^'R+4[!
MQ!4+'*4(;3;GW[KW2C]^Z]UQ=TB1Y)'6..-6>21V"(B("S.[,0JJJBY)X ]^
MZ]UIT[L_X4D?([Y&_P VW9/\O;^5ST5TGWMU12=@3;([&[C[(I.QZQ\]C]LO
M"_:6_P#9>9V?NK X79W7.P(J.OC@R^0H,U%GI(X7I42.>F^Y]U[K<8]^Z]U[
MW[KW7O?NO=>]^Z]T7KY0_*SX]_##IO=/?GR:[1VUU-U;M&F>;(9_<-2YJ<C6
MF*22DV_M?!T4=5G=W;JRIB*4>+QM-55]6XM%$UC;W7NM'GY#_P#"@_\ F*_S
M7.P>TNA_Y1>UJ/XF_&WJ_;66W?W9\T>W<GC=M9;8?5>+H6J\GV3V1V!6T>:V
MC\=-I:,9D32P8],SNNOIZ;S4<T,T=120^Z]U1_\ R3O@K\E_Y@'\W#;G8O5?
M=O8N\>O_ (T]\XGN3M3YM9B+>E+F]R;/V!O*.?:TT=5N^NEW+%O[O/$X6*DH
ML3DZF>LHJ"JJ):R*:GHJB)_=>Z^N7[]U[KWOW7ND9V)V+L/J/8N[.SNT=X;<
MZ_Z[V)@LAN;>6]=W9>BP.VML[?Q4#5.0RV9R^1F@HZ&BI84)9W<"]@+D@'W7
MNOG._P Z_P#GC=M_S&>B>[\?\<MU[L^,W\M7;>1J.K<3OC);:K<?VW\_>WWJ
M(/+UO@,<^?PTF Z9QV#<9G.PO-'44.$,39B":MR%%M\^Z]T\?\)&/Y0,/<?8
MTG\SSOO;<-7UIT[N&NV]\7=OY2-Y(-V]Q8K53;A[3GHY$%/4X3JT3?:XEV\J
M2;CDDG7Q38E"_NO=;['S&^9WQU^!?16ZOD1\F^PL9L#KS;$$J0":2"?<>\,^
M:6IJL;LO8F :>"KW3O'-BE=:6B@-R%:21HH(Y94]U[KYTW\W+^:SWU\Q^O,'
MWU\K<7E>I/B]VA-4[C_EZ_RXZ7)3TF9[PP>W\C11XKY;_-6KH*B"JJ>F:&MU
M5&W,0IIAN_*HD.(08FBKMPU/NO=0_P#A,/\ R+U^<G9>/^<?RBVG62?$GI?=
M\9ZXVCF:6:EQWR'[:VM64]7X9X:B)?XYU)U_DXT_B^B]%F,K&<6[RQ4^5IA[
MKW7U"5554*H"JH"JJ@!54"P  X  ]^Z]UW[]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>ZU,OY_/_"A^F^%$^0^#OP/EA[,^?6]'QNV,IG\#BJ7>V*^/%3N=X:7
M%T$&WEI<M3[W[ZS7WD*X?;STU134#U$55D(ICX,=6^Z]T)'_  G_ /Y-/<'Q
M0J]R?S"?Y@>^=]=F?S#?D'M:JQ=?3;TWQFMVUG3/6^Y:O'9ZOVIN/(U>1JXM
MQ]E[BKZ"FERTCR5%'AHZ>.@H-!%9-5>Z]UM"^_=>Z][]U[KWOW7NO>_=>Z!/
MY'?(?J/XG='=F?(OO;=E+LKJCJ7:V0W;O#/U$<E1-'0T* 08[%8^ -5YC<&;
MKI(J/'4,"O45M;/%!$K/(H/NO=:WO\D'^>)\YOYOGRS[XIG^,/3?6OP2ZKQ<
MTU/OVFB["/:V(W#EP\>Q-G97==9NS)=?[RW1G(J2?(9"EH,/C%Q5"H#2S%H)
M*CW7NMJ[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:EG_  I:
M_GS'^7_U_4?#GXK;BA?YD]L[<>7=.],75TTS_&SKK+0HL><*+(\L?:N\Z2=A
M@862V.I!)DI2KB@CJ?=>ZU4?Y*_QY^(_QIH:'^;%_-$RE+F=J8G.5\OP;^*2
M4T&]^]?F!W7A<O34=5OK:75-9/%6[KVSM+=N1I*+&5]<\>(GW%,TU944\5%&
M]3[KW5PWR ^.W\]W_A2-ONAI>P>O<G_+<_ELP;E3*[0V5W#%E<)N++XO%UD\
M%!NK=O6'DPW8_;N_!)2&LH5R-)MW:L*RQ-15%P*R;W7NMJC^5[_)Z^'G\J'K
MJLVS\?MK56>[*W524T/9O?>^5H\EV?OYH!3N,<]?!!%2;7V?3U5.LM/A<:D%
M$DG[LOGJ2\[^Z]U:G[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK/_F[[H^=N
MU_@=V^?Y;VR*W>_RQW')MG9^R/X7+MM<SM'#;ESU'CMX[YP46[,KB,'+G]N[
M;DJ&H6FD=:6KDCJ3%*L#1M[KW5)7_"=/^13\C_@SV=V+\^/GCOW(Y+Y6=Q[%
MR&S*3KG^^4^^\QM/#;MS6'W/O3.=N]APYO,X_?F_L_D-OXY%@IYZRDQ_V\LK
M5=7-.GVGNO=;<OOW7NO>_=>ZUT/^%"G\[G;7\JWH1>N.J,A19KYK=YX#*P=2
MX0P09&CZMVT=>-R7=&\:>=)J(18FID,6"Q\ZO_%LHA)C>DI:LK[KW6I%_(S_
M .$\?;/\S[>Q^<'SV?=^"^*VZ-S9K>KTV9R&;PG:WROW/G*Z7,Y/-X_*HE+E
M<-UQE\O72SY#<23Q5F4D+18X^N2MI_=>Z^FYU_U_L?JC8^TNL^L]I;?V'U[L
M/;^+VILS9FU,7283;>V-MX2DBH,3A<+B:"*&DH,?04D*QQQQJ  /Z^_=>ZC=
MF]E["Z9Z\WKVQVENO"[&ZYZYVSF-X[VW?N&MBQ^%V[MK 4,V1RN5R%7,0D<%
M+2P,;"[NUE4%B ?=>Z^35_/A_GU=J?S5NS*WK#J^LW'UM\']A9J3^XO73U$V
M-RW;&2QU2#2]G=LTM--XJNLDDA6;$8>0R4V&BTN==8TDH]U[H]G_  G=_P"$
MW^1^:TFV/FM\X]NYK;?Q,HZRDS'4?5%4LN(SWR3JZ&KCF3/9SRQ"MQ/1J/"8
M]<?BJ]R$D4TD5$IGJ?=>ZW'OYLG\W_XO?R,^D>G-OU?3.?W=N;L+";NVY\<^
MB^K<=B-D;'@QW5N+V_'7#<6ZI:5L+L#96%J-T8FC(H,?ELE>M5H,?+%'/)%[
MKW6AO\A?^%2GS@^0VX=R;TSFR]A[?W'A<O3Y#XW;>QE;6Y#IOX\Y"@K:VKQ'
M:4O5&:Q];3=W_(?;K2TTF(W%O'(Y+;6#KJ..NQNV:2LM,/=>Z)A\'OY6G\R?
M^=KWGG>R,-0[TW'B-X;G&4[A^8G>M3N)]BPU3U<=!E9AO')0U%7V'NK%TE+X
MH<)AS4STZ0Q0R"CIM,B>Z]U]0?\ E0?RBOC)_*2Z/J>M.E*6JWAV3O1J#)=T
M]];KH,?#OSM#.4,<OV=(5HU:+;&P=NO4S+A<#3R20422R2S2U==/55M1[KW5
MJGOW7NO>_=>Z:L[G<)M?"9?<NY<OC-O[=V_C*[-9W.YJNIL9A\-A\932UN2R
MF4R5;+#1T&/H*.%Y9II76..-2S$ $^_=>ZTBN\O^%0GR9^1G\QOJ'XG_ ,G_
M ./N)^0W66&['I<1OS-9S;^4RF=^0>#H\O24F[\CLVLCKL30].]68+#FIFBW
M/E/*6?Q5M0M/1QM35?NO=;Q*DE02I4D E6TZE)%RITEEN/\  D>_=>Z[]^Z]
MU0M_PH8K?YGN0^%6/ZU_E>;$WKN/L/M+>-9MSN3=_6N4PN)[%V+T[2;5S62R
MJ[+R&3S^"K\/F=V96&GH6R&.,V0@IO+%3B.>HBFC]U[K0L_DY_SL-F_R5MN?
M(9I?BMV1W[\G>\]XXG$]F3;X[>/3FT-B;?ZVGSJXC!' ML+L?<NY]]/N7<>7
MERM3D(\3)3F:.G1+PS25/NO=6%]I_P#"V;YS9V-8>F_B=\6^MPTP,]3OVL[2
M[8K13""$>.C;#[MZIHH*AJM)&,DM/4)X7"",.OE;W7NB =\?\*B/YPGRVV#N
M[X^P;JZVV90=U8,]8U>/Z%ZDJ<5V!E:?==8,95X79^9K<YN_=%#G=U4E:<2#
M0,*LQ3VI3%4LLP]U[HF'PHZG_G9?#CM:K[J^%'Q3^<.Q>U*K:F;V'4[JVK\,
M-_\ 8-7_ '8S-7A<KF\2F.W7U!O'$4S5%1AZ-WFCIDJ41=(D5)'5_=>ZV-NK
M>Q/^%NE=E<7E<5MWLW+4HKZ.:IP7:6P?@-M7%9:GHL@AFQ>4&],7M+,8N@R/
MC,4TM+54%5]NY>*>/TR+[KW6WM_+(["_FW[MV=6X_P#FE?'OXY]6;D@PM-DM
MO[OZ0[1&:S.2R53+1RS;6WKUOCWWGM7$U^,I*V1),KB=UU='-443HE((WBJ)
M/=>ZM3]^Z]T0W^8O_,7^./\ +'^..XOD7\B]Q?;T5/YL1U]U]B)J5]]]N;[>
MEEJ,7L?8^+J)4^XK:C1Y*NKDTT>+HU>IJ72-.?=>Z^;GMJ@^?7_"G_YG;N[>
M[_[&7I+X9=%+7;D[%WGD<C)COCU\1>G*8U.7J<!M./+2X[![C[7S6#IG:IR5
M9:OK_%]U7RP8VEIZ>#W7NC5)@-U?S6-Z8;^37_(YZVR'07\K_J_<E%E/DW\I
MLI@LC!4=ZYC%RTM-D>ZOD%NZ"FP^3WI-7KCD79^SY9X<AG)*>"66.AQ]&HPO
MNO=;^O\ +Z_E]?''^6I\<=K?&SXV;6_A6W\5IRV\MY99:6IWWVOONII:>GS7
M8786:IZ>F_BNX,K]LB1QHD='CJ..&CHX8*2"&%/=>Z._[]U[H*^[>[^I?CAU
M=O#NKO/?^VNL.K-A8MLONS>N[,A%C<-B:,21P0J\LEY*FMKJN:."FIH5DJ*J
MHD2*)'D=5/NO=:"7=/R5^2W_  J$^1V]NM=H[GW!\2_Y)GQ+R\O87?W;&36'
M#5NX]N;3I*K-)N'>516&;&YCL/-8S$U%5@,"Z5.+VG2,<ID8JNIA@CF]U[JB
M./;&4_G:?S-^@OAG\3]L93J/XC;+K8NEOC?L9)<SEZ#I#XJ;"J*O.[[[>W2U
M7!6/4]E[]QM'6;DSM?D2]3D]QY"EQTU9*L=*X]U[KZ5ORK^97P2_D.?!WKO"
M[GF@VOL+JW8F*ZT^/?0VV<A2U_9W:$VU,?18^#%;<I,M6BMRM5Y)TK,]GZ^4
MQ12U#U-9.]1.JS>Z]UJ!?(?L7?>Z=I8S^>-_/*HES"92I8_RLOY11RLN+VEG
MY] K-J;Y[+VKEZB*OCZ]Q,E939?<%=4T<F5SL"Q/5J*63%81_=>ZK5_E@_R_
M_E)_PHP_F![\^1?RESVZ).B,#N6@W#\C>V*&)\/AUI8#2MM+XV]-)*\]/A:I
M]NHE-24M(LT&VL! *BH83S425ONO=?5AZVZWV%T]L#9O5?5NTL%L/KGKW;F)
MVCLG9NV:"'&8';6V\'1Q4&*Q&+H8 (X*6DI854?5F-V8LQ)/NO=+;W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]UIO?\*)/^%%L7Q*3</P5^!FYH-P?+G.+_=_
MM'M7;GBS--\?8LD%@_NMM80I5097N_)).$"!9$V^KAG5JYHXX?=>Z=O^$ZW_
M  G[RGQ6J:#^87\]*"7=OS-[!@KMT;!V-O&1-S5W1T>[V;(Y/>N[LGE37U63
M[]W0E9(U55>5I<+%4S0^1ZN:H:/W7NMPOW[KW7O?NO=5K_S*OYCU+_+5ZE;N
M[=GQ1^3??W6&+HJFOWOOGH?&=69?;?6%-#645!3S=@P;K[0VOO7&TE?49"-E
MK:+"9#&T\*2O55-.55']U[K4Y[/_ .%Q.-ARD])TQ_+QKLCA46,TV?[/^1%/
MALI4.64RQS[1VIU/G:2C5$5@KKFYRY8$JNFS^Z]U7]V1_P +3/YE6XJ]_P#1
MMT3\0.ML)X(EC@R.T>U-^;A6ITK]Q-+FJOM? X:2!W7]J-<2C1JQ#/(;$>Z]
MU5[\QOYP7\V+^<UMG#_'+>T>3[+VGM[.UO9\W3/QHZ:RJ-F)\=X:#'9C=>*V
ME!N7=.>P&RFR92B%5,]+!45BRS^6H%-)%[KW0L_R^&_X4F?$O:^9Z?\ @7T%
M\W^J-F=B;KJ-^9ZG3X:++MK*;G&UZ*C_ (MD^P.XNFLCC,0LVW=O014T,F4I
MJ:60*L$;5$]I/=>ZNDZU^6W_  K\Z0["Z]Q7=^<Z0HJ;LC)5.WMG[0^9^[?Y
M>'4F(W%7QM39/+Y/#0X??74?<F[*G:^%I9ZJIH\+49">.@%1(M%*\:%/=>ZW
MG/B-O+Y.;\Z/VQN+Y=]7=5=2=UU-QF]N]+]FUO:W7F1Q[T=#58_<6$W!D-OX
M&JQRY(U,BOCB^32F,-TKZM'63W[KW1F/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U2
M'_/-_G#]??RF/B]7Y[%UNWMQ_*OM;&YC!_''J_)EJY9\S%$E-6]E;OQ-)/3U
M8Z^V++5QS5 :6F_B=7XZ&*57D>2+W7NOG&?RH/Y>_P @/YZW\PS.UG:N\MRY
M_:2[H3N[YG=Z9MY:O,28#-9V6IJ<!CZN$TE-!OKM&MII\9A88_'!C::.HJXX
M'IL:U.WNO=?7&ZQ^./0?3&&VE@>J^F^M=BX_8NV=N;/VFVW-F8#'9##;;VEA
M8]N;<Q=/EH*!<HT.)PD0IHB\S.(B02=37]U[I<]@=@;'ZHV/NWLSLS=NW]A]
M>[#V_E-U[SWGNO*4F$VWMC;>$I):_+9K-9:OEAI*#'T%)"TDDDC  #^OOW7N
MJ/OY>O\ PH!^/G\S?YK=G?%GXN=(]V;BZOZWZ^K=ZR_*;,8@87861J:++P8N
MGH,AM.OHX-Q;/QVZ!4ZL'-E)*?)9"2GJ4?'4ZP-(?=>Z-!_-@_FS?'+^5'\?
M<UV7VIG</G^X-P;?SYZ$Z#@R\=)N_MS=V/BAIZ6(10PUM;@MB8O*Y"E_C><>
MGDAH*9R(TGJG@IIO=>Z!?^1M\Y_Y@O\ ,-^.&9^27S3^-G4GQ]V+O#(4-5\<
MJ[8$V^\/G>T-FRS9:6NWED=B;WR^ZZO$;/DIFH(L-ECE$;<#)4UD-%#0/13U
M'NO=8/YK_P#/P^%'\J.B_NAOS*UO='R3R= U9@?CEU?DL14;HQ<,M)!5X[,=
MJYRIGDQW5>V\C'60M3O61U&5KXI/+0X^KACFDB]U[J@_?ORV_P"%#7S(Z?S?
MS*[6[XZ%_D:_R^\/05>:CW%OO&4P[3W%MO)XVB&VGPF-W/MG<W:>[]T9K*A*
M?#T\$FQSF):]OLJ:L<4D9]U[HMO_  E,^;_\V/Y6?.K?6#[2^1'>'?\ \3<'
MU]OC=O>%9WAN'</9.%VSO'-QX^DZXQNP]W;HDR-;LO<M?N&$24V#H:N#%MA8
M,G(M$'5)4]U[K;[_ )K/\V7XV_RFOC_4=N=SU<V[.P-QS?P/ISHK;%;1IOOM
M#=,\=2\943F2/:^Q<+'2R5&8S]8GVM'#%X8$J\C/14%5[KW5>W\AC^;!_,4_
MFPU7;/<'=GQ4Z0Z7^'>!KLE@^LNRMJY+L2CWANS>=//CT?9V&HMS9//8OL+'
M[7I_N3F]Q01X&BAJY*>CIZ:>=*T4ONO=;*'OW7NM5G^;I_PJ9^+/P#S6;Z-^
M,>(P/R]^36'KLKA-V08G<_V72O3^9Q4K459CM\[RPT-?4;NW?C\HKP5&W\*R
M/2R4]1%75^/J(TAF]U[K6%^7GS?_ .%++]*P_/#Y.?)C<OP9ZAKMR;2SO1_5
MT6XMM?'C<?:F6;,055#M/K#HC;=%D.W]_8#$TT*Y#+)OE),35X:0M5U%53R>
M,^Z]T=_^4-_*"^0O\ZCY)9/^;Y_-P;(9[I_>.?I-S]9=59;'28"E[Z3"E(-L
MTU-MM2G]UOC%L^EI8Z:AI%_>W1XB6DEIGJ:FO]U[KZ#U;7;1Z\VI-79&LVYL
M;8VS<'KJ*RMJ,9MG:FU-MX2C"AYJB=Z+$8/!XC'TX%V,5/3PI_95>/=>Z)Y\
M-/Y@G1GSVR7=.0^-='OK>'3W3VX\1LF@^1%;MB;!]-]R[S>KW71[UQ'2.<R4
M\&5W]B>MY]O4J9+-1446&JI,K3C'U-8JS/'[KW6E'_PL4_FG97<F_MO?RM.H
MMP-3[0V/#MCL[Y53X^8@[BWMD::BW-U7U?634U;IDQ.TL-4TVX\A330LDV1K
M,8ZLDE P;W7NJL/^$V_\E _S.._*[O#O7#3-\+OCON3'IO:F,Y@_TQ]H4L>*
MW!BNFX-,,DAVY'B*R"NW/*KPS)CJFGIH6$E;YJ?W7NOJ_P"&PV)V[B,5M_ 8
MR@PF"P6-H<-A<-BJ2#'XO$8G&4L5%C<9C:"ECBI:*@H*.!(H88U6..- J@
M>_=>Z+?\M_A9\6_G9U7-TO\ +/IC:7='7K5QRV/QFXXJZDRNV\Y]E5XU=Q;-
MW7@JW%;KV9N*/'U\T"U^*K:2J\,SQERCLI]U[JK[I?\ X3/?R6^D=V0[SP_P
MXPF_LQ2-(:.D[HWYV/V]M.G21H6,<VP=\[JR^Q,LJF'TM7XVK=0S -9B/?NO
M=&Z^??\ ,L^$/\I/I#&;I[[W5A-F0?P:OI.G^@^N\?A6[&[#_@,4$1P?6G7U
M+48FDIL/CIJNG@J,A4-0X3&&HB%34PF2,/[KW6E[N/\ G7_S\?YQV[-Y4_\
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M9(] ]<9MZ6OH>J\/4 M2)O+)4]-3U&Z*VG'IJR<;!++2TK5%9[KW0Z?S=_\
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MXQAP'FDV_05<DC@9.:*EK8?=>ZW+D1(D2.-%CCC54CC10B(B *J(J@*JJHL
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M?RF8LGL_L3N1_EE_.?[>Q$6;[R[<GWGE=^;>^"F,W#01S0T^T]X962;/;O\
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M'6[XW[F&J=P9T4\D[FFI3+'CZ!7*4E/!&='OW7N@@[D_DN?RO_D+\G*GY?\
M=GP]ZP[*[SR6/H*'/YC=(W!7[/W;/BXH:7'YK>O59S2=8;SW%3X^!*4U^4Q%
M74S4L<<<KR+##X_=>ZLZHJ*CQM'28['4E-08^@IH**AH:*"*EHZ*CI8D@I:2
MDI8$C@IJ:F@C5(XT541%   'OW7NBF='? /X5_&KLC??</0_QBZ;ZN[5[,RF
M6S&]NP]J[+Q=)O#,UF>K)\CFD7/RQ3Y'%X_*5]3)-/1T<E/222,6:(GGW[KW
M1O/?NO=$ ^:'\K+^7_\ S"YL)7?,+XR[)[BSNV\?'A\'N^7);OV-OW&X6*O?
M*1X.F[!ZTW)LW>PP29"62441KS2ZYI3X_P!V35[KW0W_ !H^'WQ<^&^SZW8/
MQ:Z&ZQZ)VIE,BV7S.-ZZVMCL%+G\LT,--_%-QY2&-LON+(I2T\<*3UL]1*D,
M:1JP154>Z]T8JIE>"GGGBIIJR6&&66.CIFIUJ*IXT9TIH&K)Z6D6:=AI0RRQ
MQAB-3*MR/=>ZU%_G3_)%_F-?SIOD'0;X^=7R8V!\3_B'UWGJH=(?%/I5\IW%
MO3&8)XYJ:KW=V!GZZ+9G74/<6YJ?2DV1@;<='BZ61J6DC\:RO5^Z]U?9_+L_
MEE_$W^6#TQ!T[\8-C?PR3(18Z?L/L[<C4F6[2[8SV/IVA7/[[W/#1T0JF22:
M9Z7'TD-+BL<)Y%I*:%78'W7NK O?NO=%V^5OQ3Z*^;'0^^OC7\D=DP]@=1=B
M4V/AW%M]\CD\-5K58?*4><P>7Q&:PM70Y;#YG"9G'P5--44\R.DD8!U(65O=
M>Z$+I_J/KKH3JW8'2W4FUL;LGK/J_:F&V5LC:N(B,5!A-NX&BBH<?1Q:BTL\
MOBBU2S2,\T\S-)(S.[,?=>ZU$/\ A:3\9M]=H?"OXV?(K:&,W#F\-\:NX=U8
MSL2BQ,TTF+P>S>Y]OX:@CWQGL8DZQSP8;=FP\7C8ZKQ224G\:?E(I9F]^Z]U
M8_\ \)7L[0Y?^1K\/,?2.6J-KYGY)8+*+=?VZZH^47<NYHT%B2 <9N*G;FQ]
M7]+>_=>Z.7@?Y)_\K/;OR>W5\PZ+X9=3UG?6[MV4^_J_<.>I\UN7:^+W[!7+
MEGWQM7K'/YC)=9;1W=59N-,A)D,;B*:J_B*FK5UJ7DE?W7NK.\OB,7N#$Y3
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D[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>toruka_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 toruka_logo.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &2      04  DE$_]L
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MLOE\[73. LN2KJO)5+R.=*JC5$LTA)+6 '^L/<C06MI91Z+:WCBB X(H4?R
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M[-]JV+=-ZD*;?;%E'Q.<(OVL<5^0J?ET%^9><N7.4H%FWS<5C=A6.):M(_\
MI46II\S11YGHK&8^;>*BE9,!L'(5L'JT5&8SE-BY0;C26HJ*@RZ-<7N!.+?U
M/L=V_MC<,H-WNR*WI&A8?M9D_P '4+7_ -XJQ1RNU\L2R1^37$RQG_>424'_
M 'KH*MY?+[?^X:&;';>QV-V?%4(8YJZCFGR.9564*PI*Z=:>GI"P+>M8/*MP
M4=2+D^VWV[VFSE6:\F>Y8&H1@%3\U%2?LK3U!Z!7,'OQS/NML]KM5I#8(XHT
MB$R2C_2N0JKYY"ZAY$$5Z SK_KW=/:>Y4PV"AEJ)I9149;+U7E>CQE/*[--7
MY*ILQU.0VE;F29_2H)O[%.[[O8[%9&YNF 4"D<:TJQ'!5'^H <>HVY6Y5WKG
M7>%L-N1F=FUW%P]2L:DY>1O4YH.+' \^K>]C;.P?6NT,=MK&.L6/Q%-)+5U]
M24B>KJ6U3Y#*5LA;0C32:G-VTQ1@(+*HMCQNFXW6];C->SBLTC45%S0<%5?L
M&/F<\3UG?RYL&W<H[%:;19'3:0(2\CT!9OB>1SP!8U)\@,# '0*;U^6/6FUJ
MB:@P_P!_O*OA+([X80Q8=)%^L;9>J=5G!XL]-%41GGU7%O8FVSD#>[]%EN-%
MM"<CQ:EZ?Z0</L8@]1WS%[W\G[++):V)EO[E<$V]!$#Z>*Q ;[4#CY] S6?-
MW).)10=>4-.Q6T+5FXZBL"-_JI4AP]"9%/\ J0R'_'V)8_;&$:?&WAB//3&!
M^RKMU'\_WB[M@_TW*D:FG:7N"U/M B2OV5'V]%B['[<WMVE5Q3[GR"?94KM)
M087'QM2X>A=E*-+%3-)+)-4%21Y9GEE )4,%-O8XV;E[;-BC9;&$^*PH\KY=
MOD3@ ?( #\^H<YMY[YBYTGCDWBZ'TR&L5O$"L2'A4+4DM3\3$GB 0,=&F^,7
M059'68_LS>=&U-'36JMIX6JB*U$E1P8,_6PR &&* 7:D1AK=[3>E5C+@/GCF
MR-HYMDVV343VW$JG%/.-3YD_B/IV^9I-/LY[8SQSVO.',%N4"]]C;N*-J\IG
M!X ?@!R31\46N+YJ[GI)JK9NSZ>:.2KH4R&=R<:D,].*L04>+1R+Z'E2&H8J
M;'3H:UF!-O;.QD5-RW%U(C;3$A]:5+?LJ/Y]4^\-O,#R[!L,3@SQZ[F8#BNJ
MB1@^A-'-/2A\QTX?"3#SK3[_ -P2(!3338/#TLM@2\]*F0K:]+VNHCCJZ8\'
MG5S]![:]SKE2^TV@/> \C#Y'2J_X&Z4_=UL)5AYGW1E_19H;=#_24.[C\@Z?
MM^76'YMX>4_W!W B7A7^-X>I?U>B5OL*VA3]17]Q$J#] ?1]3^+>V-RO^[:T
M)[NR11\NY6_9CJGWBMO<KRQNBK^D#-;N?0G0Z#TR _[//RQ_"C<E(DF]=I3.
MB5E0,=GZ%2P#U$, EH,B #:_V[2TY%KDAR?Q[W[F64A&V;@H)C&J%_D31E_;
MW?LZI]WC=X%/,.Q.P%PVBZC'FP%4D_WFJ?M/IT>W*9.APN-R&7R50E+C\71U
M-?75,ALD%+20O//*Q_HD:$_X^XK@@EN9HK>%"TSL$51YDF@'[>LE;R[M]OM+
MF^NY0EK#&TLCG@%4$DG[ .J.\E4U>ZMRU]9!3M)7[CSM54PTL>DL]7F*^26.
MG3]*ZFFJ H^@O[RAA2.PLHHW>D4,04L?1%I7]@ZYQWDT^][S=7$,1-S>73.L
M8XEI7)"CRK5J=7?8O%Q8_"8["D(\-#BJ/%E5NL;14U)'2$+8(0C(G' X]XP3
MSM-<S7-3J:0O^9->NC-G9I:[?:V! ,<<*PT'"BJ%^6*#JD*NI:_:6YZNC<>/
M)[9SL].PE0C36X>O:/UQW!L)Z?D7]Y/1/%N-C'(,P3Q X_A=?\QZYSW,-SL.
M]3P'%Y9W17(_'$],C[5ZN#SN$VUW=UI%3S-JQ.ZL3197&UD6F2HQ=9)"M11U
M4=PNFJH*ABDJ'22 \;6!8>\=K6YO>6-[9U'^,02-&ZG@P!H0?DPR#]A'6>FY
M;=L_N)RBL,AK87L"30R#XHV(U(P]&0X(^U3Q/53.]]C;KZMW.^'S<$^/KZ.=
M:K%Y6D::.FKHH90]-E,16J(V90Z@@J5DAD&E@KJ0)_VO=+#?;$7%JP>)AIDC
M:E5)&5=?]0(R*CK!WF/EO>^2]X-CN,;17,;:X)XZA7 -5DB?' TX94X-".AY
MV=\O^P<!1PT&X<=C-X14\8CBK:IYL;F'"KI055;3+-2U6@ >IJ?RN;EW8F_L
M*;C[=[1=R-+9S26[$U*K1D_)30C]M/0=29L'OSS1M=NEKNMI#?HHHLCDQRGT
MU.H96^W1J/F2>A5PWS:Q4LR1[@V%D*&"ZB2JP^;I\I+8L=3+15E!B5&E;6'G
M-S?Z>R&Y]LKA5)L]U1W\ED0J/]Z#/_@Z&NW_ 'B;&20+NO+,L47F]O*LA_WA
MTB_X]T:?8?:.R.R:1ZG:>;@K9H%#5F,F#4F6H02 &J<?/IF$18V$J:X6/"N2
M#[ FZ['N>RR!-PMBJGX7&4;[&&*_+C\NIIY:YRY=YM@:;8]Q61U%9(6[9$_T
MR-1J?,54^1/15_E!T-6YBHG[(V70/5UQB7^]6%HXR]15B%52/-T%-$A>>H6)
M0M5&MV9560*3Y"1WR-S7%;(NR[G*%BK^A*QP*\48G@*_"?M'IU"_O)[97&X2
MR<V\O6Q>ZT_X[;QBK/04$J*!5F PX&2 & KJJ3OK[M+>O6&0DK-K9,P0U#H<
MAB*R,U6(R/CN%%91,R$2H.!+$T4ZBX#@$@R-N^Q;9OD*QWT%6'P2+AUKZ'T^
M1J/EU ?*W.O,7)MT\^RWFF-C^K;R#5$]/XDJ,C^)2K>5:=&DHOFYE8XXADNO
M<?5RA+3O1;BJ<?'))_JXHI\1DVA3_:2[G_:O8%E]L8"6\'>'5:X#1AL?,AUK
M_+J9[?[Q=XJH+KE6)WIW&.=D!/J 8I*#Y5/V]"_L[Y<];;BJ(J+.PY/9U5*Z
MHD^26.MQ!9SI16R5%>2GY_4\T$42 W+VO8.[E[?;U9HTMJR7,8R0F'_WD\?L
M!)^70\V#WSY0W:5+;<5FL)V( :>C15/_  Q/A^9954>O1HZ:IIZRGAJZ.H@J
MJ6IB2>GJ::6.>GGAD4/'-#-$S1RQ2*059200>/8%='C=HY$*R*:%6%"".((/
M ]3+%+%/%'-!*KPN R.A!5@<@@C!!'F.LWNO3G7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW0*=Z=M4_4^T374X@J-RYAY:';E#-=HVJ$16J<C4HI5GHL9'(K, 1KD>-+
M@,6 FY6Y???]P$3$K91T:9AQIY*/Z3?R%3Y4ZCWW(YXAY'V(W485]WG)CM(F
MX%@.Z1AQ*1@@GU)5:BM15/%#O'LW=6B,9/=6Z\]4LQ+/YJJID"EF9I)&2"EI
M*:%/R8X((EMZ47B>F;;=CL*G1!81+]@'[,DD_:2?4]83)'S!SCO>E/&O=[N7
M)R:LQX\31551]BJ!Y =&QVU\*L[5TL-1NK>-!A:AU#R8[$XR3,O$&!M')735
MN-@29+C5HCE2]P&(]7L 7ON9:QR,EAMKR(.#R-HK\PH5C3[2#\NIPVC[O.XS
MPQR[WS!'!*<F*",RD?(NSQ@$>= P]">/0FX'X8[$H9TFSVX=PYY4)/VD(I,/
M2R\\+/X5JZPII_XYS1F_-_Q[)+OW)W652MI9PQ$_B-7(^RM!^T'H8;9]W[EB
MVE63<MSNKH#_ $,:8E/VZ0S_ +&'1I=M;5V[L[%Q8;;&'HL+C8>5IJ.+29'L
M 9JF=R]15U+ #5+*[R-;DGV!+V_O-QG:YOKAI9S^)C_(#@!\A0=31M&R[5L-
MFFW[/81V]HO!(Q2I]6.69CYEB2?7JN'Y)=ZUV\LU7;*VQ7R4^S,14/25TM)*
MRC<V1IY"M1-/+&0)L/2S+IIX@6CE9/,2UXA',O)?*L6VVT6YWT0.Y2#4@8?V
M:G@ /)R.)XCX<9KB7[N>Y-SO^XW/+NS7178(&,<K(:?42*:,21QB4X4<&(UF
MO;I#WJ_H'?7:,:Y+'PT^&V[Y&C.?R_ECIZ@QNT<R8RFB1ZC(R1.A4E0L(<%6
MD#"WLXWSFW:MB8PS,9;RG]E'2H]-1.%K^WY=!7DSVOYDYS07=LBV^TUI]5/4
M!J&A$:@:I"#CR6N"P..C%S?"%/M!X.QG->!=C-M<"DD-F] 5,ZTT(N1ZKO\
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MN]P;KW1D@ J*#+4U4Y"I'&HTPTU)31* !Z(:>!/[*+P+%6PV3;M(TPV$"?D
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MQ]WD\6VV6%R(M(EFIYDDZ%/V4K3Y@^74]^P/*MO]+?\ -MU"#<F0VUJ6_"H
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M6B=HJ6B6P8TP9I);Z9?& R/&_,W/L*Q26.Q.6E/:UQP"CST5R3_2X#B*X(R
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M)-19&GC5Y9WPRRF2>ER"BY6G#&&4#3&J-8/('+//ERL\5COD@>%B%6<@!E/
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MW[KW7O?NO=>]^Z]U[W[KW56WR_R4M9VRM$TC-#B-LXBDBBNVB-JF2LR,K!2
MODD^\%V%R0J@GT@"=?;N%8]@,H7NDG=B?L 4?X.L,??F[>XYW2W+DQP6<2*O
MD"Q=R:>IU"I^0].C1?$+ TF-ZI&8B1/O-QYS)U55/I_=,6.E_A=)3,U@3%":
M61U'(#3,?S[ ON'=23;]].Q/APQ*JCRJPU$_::@?D.IF]B=M@M.2%OD4?47=
MQ(\C>=$;PU7[!I)'S8^O1I_8$ZFCKWOW7NL4\$%5#+35,,513SQO#/!/&DL,
MT,BE)(I8I R21R(2&4@@@V/NRLR,KHQ#@U!&""/,'UZI)''+&\4J!HF!5E8
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MDLI-69_<>:J8*2F@IX2[NS,(J/'8ZB@73%"A;3'&B_4DF[%B94M+3;]DL!#
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M_=.4+=-JW"W-YLJGL7522('B$8U!3ST&F>#*.C5I\Q.IS1_<M2[N2?\ ./\
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M'@SCU8\54_M/R%*X_>XWO/%LLDVR\J-'-N2U6:Z/='$>!5!P>0>9-54XHQJ
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M_LY0"S+3^,^:?TCD'C4<(M]W_;'9;/;[CFO97ALW0CQ[8E4CDKYPC 64_P
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M,AHL+!+$VJ\$QQ%+135,!#6*RLX8?6]O;5CRIR_M[K+;;:GBC(9RSD'U&LD
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MSD;X_+8]X:V@KZ*:4054 E8T>6Q-8%AE:%I824<!)(Y$*L%=642[MFYV&^V
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ME*B1FD>;%O78)GD8$&21<)5X^.5R6N=8:YY-S[/[3FSF*R4)!NDF@8 DTO\
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MD*,D T!ITJ^G^V,QU-N9<M1*U;B*X14VX,,9"D>0HD<LLL)OHBR-'K9H)""
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MRDTLF1Q]?BI3)$;^2DFGB@,FGZAXR1;D&WLWM[S;]QC;Z6ZAGCIW!&5Q0^1
M)_GT%K[:=]V">,[AMUU9SANQI4>,U'FK$"OV@]&@Z:^4V>VY5TF [$JZG/[<
ME:.GCS<Y:HSF%U,J+-4SDF;+4$8),@DUU*CE&:PC8#<R<B6EY')=[/&L5X,F
M(81_D!P1O2E%]0./4R^W_O3N>U3P;7S7.]UM3$(MRV9HN JS<9$'G6KCB"::
M2>O?&P=F]L;<AH,Y!%D*&>)*[#9G'S1_=T9J80T.0Q->@EC:.>)E:QUP3+;4
MK "T6;7NVY;!>--:N4E!TR1N,&ARKKC@?L(\B.LD^8^6-@YWVE+7<HEEMF42
M03Q$:DU"H>)Q44(SYJPI4$=5^;W^)'8^WZB67:XI-YXJY:-Z6:FQF6BC%S:I
MQU?4I%(XX ^WFF+?72OT$N;9[@[-=HJWVJVG\PP+(?L917]H'V]8N<Q>Q?-F
MURN^RZ-PLN(*%8Y0/Z2.P!_VK-7T'0-UW4':>.BDFJ^OMW)#$Q622+!9"I1-
M(8EV:F@F B 4^O\ 1].>1[$D7,6PS$+'N]OJ/ %U'^$C/RX] "YY"YUM$:2?
ME:^" T)6%V ^?:#C''A\^@[DCDBD>*5'CEC=HY(Y%*21R(2KHZ, R.C"Q!Y!
M]G (8!E-5.01T%'1HV9'4JZFA!P01Q!'D1U:)\6]_;%S>TUVG@,12[8W#AXE
MJ<QBDE:9LRQ6*"7<,%7-_E%8)W"K*CEGIB5CN8_&Q@OGK:=TM=P-_=W#3VDI
MI'(131Q(C(&!3RIALGC7K,WV9YGY:W+8QLFUV"6>Z6XUW$ -3+P!G#'N>N P
M-2F%^'226+Y7=;4&RMYT.X<+3K28G><595R4D**E/29NAD@_B8@1 %A@K$K(
MI@O_ !T:33Z0 !SR#O4NY[;+9W+ZKBV(4,>)1JZ:^I%"/LIY]0Y[W\HVW+_,
M%MNVWQ!+'<%=V1115F0CQ*4P X96IZZJ8X#U\,MUSY/9^X]IU,QD.V,I3UE
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M?#"DT\F*GRR?KM'K[%]F;-RFVLC%']Q)$]3A:UE!DQF:ABD%#6QM^I4#N4E
M(\D+NMQ>_N)]CW>?9-Q@O86.@'3(O\2$]RG_  CT(!ZR<YRY6LN;]@O=GNT7
MQ2I>WD/&.4 Z''GQ-&]5)'GU3[M3/Y'8F\<-GX%EAR&V\S#434]PDCBEG\5?
M02$W 6JI_)"_^TN?>1-_:0[KMMS:,089HB WVBJM^1H1U@;LFYW?+',&W[FB
MLMU9W 9TX$Z6I(A_TRU4_;U=_3SQ55/!54[K+!4PQ3PR*;K)%,BR1NI_*NC
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M%F]%%3_+K1( J30?/H)?]FT^*O\ WDS\??\ T<W7/_V2>WOH[S_E$E_WEO\
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MM' BO0FM[B*YC$D1QYCS!]#T=3V5]/\ 5 ?_  ID_P"W3G:O_B3ND_\ WO\
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M>.-W2G@;L7#TRS3LH*PQ-4U$<89K O(J_5@",^0#_P BBQ_TLG_5MNB[=?\
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M8RR)3-#()>5=_?E_<UN&!:S<:)T'$KY,/FIR/7(J*UZ17UH+N H,2#*D^O\
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M-3U%%#V7N6JEKXT7R0U>*Q^,JT=EF4+!?N+O*7VYQ;=;O6"U!#^GB'XA\](
M'R.H="G9[8Q0&9QW/D?Z7R_;_@IUM.^X[Z-^B^_+3_LE7Y,_^*^]S?\ ON=R
M>U-G_N9:?\U5_P"/#JDG]G)_I3_@Z^.3[ROZ 76_+_PD:_[),^4W_BQ.)_\
M?:[<]PC[G?\ )8L/^>8?\??H3[)_N-+_ ,U/\@ZVT_<:]'/23WWL39O9^R]T
M]==A[:P^\MB[WP.3VQNW:NX**'(X7<& S-))19/%9*BG5HYZ6KI9F5@>1>X(
M(!#D4LL$L<T,A69&#*RFA!&00?(@]:9592K"JG!!Z^8;_.<_E1;O_EH]]O/M
MJFRFX/BYVOD\ED>E-[RI5UCX)E K:_JK>60D1XX=V[8CD;[2625FS&+C6K4^
M9:R&FR%Y0YF3F"S\.<@;G$ )5P-0X!U'H?/T..!'01W"Q-I)J3^P;X3Z?(_Y
M.JY_BU\G.W/AYWMU_P#(;I'<4VW=^]?9B*OIKEWQ6X,1-^QGMH[EHE=%R>V=
MSXMY*2M@)#&*37&T<R1R(?[IMMKN]C/87:5B<8/FI\F7T*G_ #'!/22"=[>5
M98SW#^8\Q^?7U6?Y?7SMZA_F'?&[:7R ZHJXJ2HJU7!]C["J*R*JSW6/8=#2
MT\N=VAFPBQO)'&9TJ<?5^.-,ACIX*A536T:8V;SL]WL=_+8W:]PRCC@ZG@P^
M1_D:CRZ&=M<1W,2RQG!XCT/H>M<?_A5[\V_[M=<]2_ [9>:5,MV354G<O=5+
M230O+'L7;.2FINM=LY*-HI2D&XM[4-1ERJM%-&^WZ9N8I[,//;3:/&N[G>94
M_3B'A1$U^-AW$?Z5#3_;=%6]7&F-+93W,=3?8.'[3_@ZT@-F[0W+V%O#:FP=
MF8FHS^\-\;DP6T-J8*D:%*O-;EW+E*7"X+$TKU,L%.M1D<I6Q0H9'1 SC4P%
MS[F*>:*VAFN)GTPQJ7=O15%2<9P!T'55G94458F@'S/7T[.E/Y!_\M'874'6
M.R^Q?B]UYV9V!MC8FU\+OGL++U>[5R&]=X4&'I(-R[FGCI-PT-- N8S*S3QQ
M)#&L4;J@'I]XZ77.',$]S<31;G+'$[EEC5L*"<*/D!CH8)M]HB(I@4D"A)''
MY]"?_P ,>?RH/^\)NJO_ #KWK_\ 97[3_P!:N8_^CS/_ +UU?Z"S_P"49/V=
M>_X8\_E0?]X3=5?^=>]?_LK]^_K5S'_T>9_]ZZ]]!9_\HR?LZ]_PQY_*@_[P
MFZJ_\Z]Z_P#V5^_?UJYC_P"CS/\ [UU[Z"S_ .49/V=:9_\ PHQ_EK]?_!GY
M$]:=B_'[8<.Q/CUWMLYJ7'[;PYR=5@=G]G[ 2BQNZ</35%=)6O04NY,!6XW*
M4\<]2\M15MD6C'CB(26.0-_GW:RN;6^G,E["U0S'N9&X?,Z6J"?(%1T0[M:)
M;R))$E(V%*#@"/\ ./\ +U3U\(/E)N?X6_*_HWY-;4%5/5=5;YQV7S>)HWCC
MFW+LC()-@NP-IJTS+ C;HV5E*^@5W-HI)UD%F0$"S>]LCWC:[S;GI61.PGR<
M94^?!@*_*HZ+[6<V\\<PX Y'J//^77UM/].G5/\ H,_V9/\ OIA?]"?^BW_3
M1_I ^\@_@'^C7^ZW]\_[U?>^3P?P[^[?^4Z]5M'O&/Z6Y^J^B\%OJ_$\+PZ'
M5KKITTXUKBG0VUIH\34/#IJKY4XU_9T+7M/U?JD_^:K_ "1_CQ_,JQS[[I:F
M+I;Y/8G'I2X7N3!8F&LH]V4E'3?;X_;G:^WXWI3NK$4T:(E+712P97'JJ+'-
M+3*U)(*^6^;;_EYS&H\6P8U:%CP]2A_"W[0?,5H0AO+"&\%3VRC@P_P'U'6@
MA\S/Y4'SK^"61R;]Y='[AGV'CY:CP=R]>4]9OOJ&OHX&I(UR$V[\31!MK154
ME:BPP9^FQ%=*0VF#T-:;-IYIV3>0HM+P+.:#P9:*]37 !-&X?A)^?09N+"YM
MJZXR4_B7(_V/SIU7-[$/2/KWOW7NI%'1U>0JZ6@H*6IKJ^NJ8*.BHJ."6IJZ
MRKJ95AIJ6EIH5>:HJ:B9U1$12SL0 "3[TS*BL[L @%23@ #B2>M@$D "I/5_
M/P _X3L_-_Y>YC"[G[@VQE/BCT5)+15F1W;VAAYJ+L;<.+>67[FEV+U75/2;
MB%<\42E:O.)B<?XYUEA>KTM"0-OG/NT;:CQV+BZO,@!#V*?5GX$?):_,CCT:
M6NTW$Q#2C1'\^)^P>7Y_SZW^/A1\&?CK\ >G*'I;XZ[/_@.&,Z93=>Z,M-'D
M]\=A[D\(@FW-O;</@IY,ID62Z0PQI!14,)\5+!#$-'N$]UW>^WJ[:\OYM4M*
M*!A5'DJCR'^'B:GH2P6\5M&(XEHO\S\ST;_V6]/=>]^Z]U\W[_A4G_V]#D_\
M5VZD_P#<[>?N>/;;_E7I/^>E_P#CJ=!;>O\ <M/^:8_PGJO3^3C_ -O1_@U_
MXL%LS_K;4>SOG#_E6=W_ .:7_/R])=N_W-M_]-_D/7UC/>-G0SZ][]U[IFW%
MMW [OV_G-J;IP^-W%MG<V(R. W#@,S1P9'$9O"9>DFQ^4Q.4H*I)::MQ^0H:
MAXIHI%9)(W*D$'W969&5T8AP:@C!!' CY]:(!!!&.OEK_P YC^6;G_Y;/RIR
MVV<%05U5\=.U)LIO'X^;FJ*BJR#1[<6HA.8Z\SF1JE,LFZ>NZVM2ED9Y)9*S
M&RT=8[^2IDCBR+Y1YB3?]N4RL/WC%19UI2I\G ]&'V4-12E*@_<+,VDQTC]%
MLJ?\GY?X.D3_ "E/YC>[OY;'RMV[VE!]YE^G][-CMD=^[+@DE89SKZIR,;ON
M'%TJWCEWAL*:5\CBR0#.1-1F2.*LE</<T\OQ\P;:\(Q>1U>!OZ5/A/\ 1>E#
MZ8/E3JMA=FTF#'^R;#CY>OVCKZI>P]];0[/V3M+L?8&X,9NS8^^]N8?=NT=S
M86ICK,5GMN9^@@R>'RN/JHB4FI:ZAJ4D4_6S6-C<>\<)8I()9()D*S(Q5E;!
M!!H01Z@]#)6# ,IJI%01TK/;?6^JO_YHW\K/I+^9YTY3;.WQ/_<;MO9*9&LZ
M=[HQF-CR.7V7DL@L)KL/F,<:BA.YMC9Z2EB^_P <T\+ZXTFIY89D#$0<O<Q7
MG+UYX]OWV[4$L)- X'[:,/(^7S!(Z27=G'>1Z'PX^%O3_8Z^<M\W_P"5I\TO
MY?\ G\E3=\=29AM@T]9]OA^Z]E05>ZNH,_!+44U+13INVCI53;E775-9'%%0
M9J+&Y%Y#98&6S&>-FYFVC?$06ER!<D9@?#CB30?BH!6JU%.-.@K<V-Q:D^(E
M8_XAP_V/SZKP]B#I)U[W[KW2AVGM'=F_=Q8K9^QML;BWINW/5)H\'M?:>%R6
MXMQ9FK$4DYI<5A,/35F3R-2(8G?1#$[:5)M8'VW--#;QO-<2JD*Y9W(4#[2:
M =656=@J*2QX 9/6W+_*2_X37=A[MW1M'Y!_S$-N?W(ZYQ%32Y[;OQDR+J^]
M=^U$.FIQS=L"CJ3'LO::R!'GPK,V7KK-!5I0H'2:+.9_<"(1RV&PN6E/:UR,
M!1Y^'7)/]+@/*N"#RQVEJK+="@'!/\_^;K>GQ^/H,3046+Q=%28W&8VDIL?C
ML=CZ:&CH,?04<*4]'145'3I'3TM)2T\:QQQQJJ(BA5   ]P^2222:DY)/0BZ
ME^]=>Z+[\M/^R5?DS_XK[W-_[[G<GM39_P"YEI_S57_CPZI)_9R?Z4_X.OCD
M^\K^@%UOR_\ "1K_ +),^4W_ (L3B?\ WVNW/<(^YW_)8L/^>8?\??H3[)_N
M-+_S4_R#K;3]QKT<]>]^Z]T7+Y8_%CJ'YG]";^^.W=^".:V-OW%O3-44IBAS
MFU\[3AIL!O+:M=-#4)CMS[8R6BJI)6CDB9T,<T<L$DL3K=NW"ZVN\@OK.33/
M&:CT/J#Z@C!Z;EB2>-HI!5#_ *OV]?*S_F"_ [N'^7?\CMT]!]LTGWE- TF<
MZWW[0PR)@.R^O:RKJ(<'NO$LU_MJMEA,&1H69I<?D(I82TB".:7)'8=\M=^L
M([RW-)!VRQ^:/3(^ST/F/G4 &7=K):2F-QV\5/J/\_KT,O\ *?\ YF'8O\L_
MY(XSL/%'(;CZ8WM+C=M]\=9Q5)6#=&T!5-X]P8:"5A2P;ZV4:F6KQ4[:/+>:
MCD=(*J5@CYHY=@YAL&CH%OHP6@D^?\)_HMY^G'RH7;&\:TE!XQ'##_+]HZ '
MY_\ RSW%\X/E_P!Y?)7//5QT?8&\ZW^Y6(JWG+;:ZVP03 ]>[>$$U761TU3C
MMIXZE^\$++#-D'J)E1?*1[7;#M:;-M-G8*.]4K(<9<Y8U %<F@^0 \NFKN<W
M-Q++7!/;]@X?R_GU<?\ \)A?AB?D!\XZ_P"1.Y\6E7UW\1\!%NFF:IC9Z6O[
M@WK%E,'UQ2"-X##-_ :"ER^;#I*LE+78ZB)4K)P%/<;=A9[1'MT;?KW+4-/*
M-:%OF*M0?,:NE^S6_B3M,1VH,?:?]BO\NOHQ^X*Z%'7O?NO=>]^Z]U[W[KW5
M3/\ .Q^%G^SP_P OCN/K_!8?^+=I]<T?^FOIN.&)9,A/OOKZAR%7-M_':IJ=
M&J][[2J\GA(ED<0K/D(Y&YC4@1\J;M^YM[L[EGI;,?"F]-#8)-/X31ORZ1WU
MO]3;21@=X[E^T?Y^'7RK?>2O0+ZV&,?_ #3-\9'^01N[X;Q[AEBW]M#Y%===
M$5=?+69%<S6_%[L? =H]MXZCH*TR 3_PS=?5E5MFK@#&"+;M934Q0"1;@!N6
MH5YXBW,I_B[PM<@8IXR%$/\ Q\/7^+HV%ZQVMH:]X8)7^B03_DI]G7TH/<#=
M"KKWOW7NN+HDB/'(BR1R*R.CJ&1T8%61U8%65E-B#P1[]U[HD7:O\M/^7YW;
MD:[-=G_#?XZ[GS^4#C);E/5FU<-NFO+PRT_DK-T;?Q^*W!4S)%*=#O4EXV"L
MI#*I!K;;YO-F@CM=TN$C'!5=M/[*TZ8>VMY"3) A/J0*_MZ VD_DC?RI**I@
MJX?A)U$\M/*DT:5?]ZZ^F9T-P)Z*NW)4T=5$3]4EC=&'!!'M4>:N8R"/WS/_
M +T>F_H;,?\ $9/V='&Z:^(/Q4^.WKZ(^.'2'454PM-D^ONL-G;6S57Z4357
M9S$XBFS%?(4C4%IYY&(4"_ ]EMUN.X7Q!O;Z:4CAXCLU/LJ33I](8HL1Q*O^
ME '^#HQ?M%TYU[W[KW7O?NO=>]^Z]T$^\>A.C.Q,RVX^P.E^I]\[A>F@HGSN
M\>NMG[FS+4=*&%-2-E,UAZVN:FI@[>.,OI2YL!?V\EQ<1+IBG=5XT5B!_(]5
M*(QJR@GYCIJP?QH^..V,QC=P[:^/_26WL_AJN'(8C.8/JK8F)S&*KZ=@]/6X
MW)T&!IZVAJX'%TDB=74\@CW9KJZ=2KW,A4X(+$C_  ]>"(#4(*_9T-OM/U;K
MWOW7NO>_=>Z0^^.L>MNSJ.AQW977NQ^PL?C*EZW&T.^-IX'=E'CZR2(P25=#
M39^@R$-)4R0DHTD:JQ4V)M[<CEEB),4C*3@E21_@ZT55OB /V]!K_LI?Q5_[
MQF^/O_HF>N?_ +&_;OUEY_RER_[TW^?JOAQ_[[7]@Z&7;.U]L[+P>/VQL[;N
M"VGMK$QRQ8O;VV<1C\%@\;%/435<T>/Q.+IZ6@HXYJJHDE81QJ&D=F/))+#.
MSL7=B6/$G)ZL  * 8Z??=>M]>]^Z]U'JZ2DR%+44-?2T];15<,E/5T=7#'4T
MM33S*4E@J*>97BFAE0D,K JP-B/?@:9''KW1#>R_Y5_\N/M[(UV9W[\*OCID
M\UE'>7)YO%=:;?VEFLE/(\3R5>0R^SZ7 Y*MK6,*@SRRM-INNK2Q!-[??]\M
M46.WW:X6,<%#M0?8":#I.]K;.27MT)/$T%?V]!;COY)?\J?%UD-=3?"+IV6:
M#R:$R,&Y,O1MY8GA;S8[+;AK<?4620E?)$VAK,MF4$*#S3S$PH=YN/R8C_!U
M06-F,_3)^SH\/3WQM^//QZH)\7T/T9U%TU05=S6T_6'76TMC#(,2I:3(R;;Q
M..ER$K%1=YFD8V'/ ]E5U>WEZ_B7EW)*_K(Q8_S)Z4)''&*1QJH]% '^#H:_
M:7J_7O?NO=>]^Z]U$R&/H,M05N+RE%29+&9*DJ<?D<=D*:&LH,A05D+T]915
MM'4))3U5)54\C1R1R*R.C%6!!(][!(((-",@CKW0$?[*7\5?^\9OC[_Z)GKG
M_P"QOVH^LO/^4N7_ 'IO\_5/#C_WVO[!T)6Q^L>MNL:.NQW6O7NQ^O<?DZE*
MW)4.Q]IX':='D*R.(01U==38"@Q\-74QP@(LDBLP46!M[:DEEE(,LC,1@%B3
M_AZL%5?A 'V=+CVWUOKWOW7NO>_=>Z#W??4?5/:)Q;=F]8]>]BMA!6+A6WWL
MO;>[CB!D32G(#%G<&-R!QXKS0P>;Q:/+X4U7T+9V.::&OA2LM>.DD5_9U4JK
M?$H/V]!__LI?Q5_[QF^/O_HF>N?_ +&_;GUEY_RER_[TW^?K7AQ_[[7]@Z]_
MLI?Q5_[QF^/O_HF>N?\ [&_?OK+S_E+E_P!Z;_/U[PX_]]K^P="5L?K'K;K&
MCKL=UKU[L?KW'Y.I2MR5#L?:>!VG1Y"LCB$$=774V H,?#5U,<("+)(K,%%@
M;>VI)992#+(S$8!8D_X>K!57X0!]G2X]M];Z][]U[KWOW7NO>_=>Z][]U[HO
M[?$WXKNS._QH^/[N[%G=NFNNF9F8W9F8[<)9F)N2?K[4_67G_*5)_O3?Y^J>
M''_ /V#KC_LI?Q5_[QF^/O\ Z)GKG_[&_?OK+S_E+E_WIO\ /U[PX_\ ?:_L
M'1@O:;J_7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]TU9W,4FW<'F=P9 3&@P6*R.8K13H))S28RDFK:D01L\
M:R3&&!M*EE!:PN/:BUMI+RZMK2&GBRR+&M<"K$**_*IZ1;E?P;5MU_NEUJ^F
MMH'N)-(J=,:EVH,5-!CHM?\ LX74O_'#=O\ YYJ3_P"NOL:?ZW7,'\5O_O9_
MZ ZB/_7YY&_AOO\ G$O_ %LZ]_LX74O_ !PW;_YYJ3_ZZ^_?ZW7,'\5O_O9_
MZ Z]_K\\C?PWW_.)?^MG1J?8#ZFGH+,_W!M+;>_<)USD$RQW#GQCC0M3T<,N
M/ R=3/2TWGJ6JXY([2T[:K1M86^OL^M.7=PO=INMYA,?T<.K74D-V@$T%/0^
MO0,W/GO8]IYFV[E.Z$_[UN@ABTH"GZC,JU;4",J:XZ%/V0]#/H+-B]P;3[#S
MFX-OX!,LM?MHLN1.0HX:: E*N6B/VTD=5.TO[T1^JKZ>?9[NO+NX;/:V=W=F
M/PI_@T$D\ V<"F#T#.6^>]CYIW'==KVL3_4V9I-XJ!1ABG:0QKD?+H4_9%T,
M^@ WM\DNN]@[GR>TL[%N)LKB?LONFH<935%*?O\ 'TF3@\4TF0@=_P#)JQ-5
MU%FN.;7]BW;.2]XW:Q@W"U:'P)-6G6Q![6*FHTGS!ZC#F+W;Y4Y8WB\V/<EN
MOK8-&OPXPR]Z+(*$N*]KBN./25_V<+J7_CANW_SS4G_UU]K_ /6ZY@_BM_\
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MW91S[,=KVB_WFX^FL("\@%6/!5'JQ.!_A/D#T0\Q\T;)RG8?O'?+P10$Z44
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M:[_W6GV8>V?_ "4-S_YHK_Q[HB^\/_R0N7_^>MO^K9Z.3C/^+;C_ /J!I/\
MW'C]QQ/_ &\W^G/^'J?K3_<6V_YIK_@'6*KPN&R$HGK\3C*V<((Q-5T%+4RB
M-22J"2:)WT*6-A>PO[M'<W$*Z8KAU6M:*Q _D>J3V%A<OXES90R24IJ=%8T]
M*D$TZ(WT_B<74?*'MVAJ,;CYZ*GQ^ZV@HYJ.GEI8"FZMN(AAIWC:*,HCD#2!
M8$C\^Y0YBGG3D;EZ5)G$I>*K D$_I2<3Q/6./(EE9R^\_/5O):1-;K#<:495
M*BEQ;@44B@H#T>JBQN/QJNF/H**@21@\B45+!2K(P%@SK B!F XN>;>XLDFF
MF(,TK.1PU$G_  ]9)06MK:AEM;:.-2:D1J%K]M .@Q[X_P"9/=@_^&]4?];(
M?9YRK_RL6T?\UA_EZ!WN5_RH?-/_ #R-_DZ0/Q)_YDYC_P#M>YW_ -RE]FWN
M!_RL<W_-)/\ !T&/8[_E0+/_ )Z9O^/]#%V3N.IVCL'=VY:)0U;B,#D*JAU*
M&1:[PM'1R2(U@\453(C.O]I01[#FRV2;ANVWV4A_2DE56_TM<_F1T/>;=VEV
M+EG?=WMQ6X@M7DCKPUZ:*2/,!B"?ET5'XL=5[?SN"K>S-W4,&Y,WE\S7QXYL
MS&,C%3)326K,B\57Y(JG)UV0>0M+(KL@C!4AF?V/N>]^N[6[BV3;Y3#:QQJ7
M\,Z2:C"U&0JK3 I6N?+J$_9;DO;-QVR?G'?+=;O<KB=Q$;@:PH4T=Z-4-([U
MJQJ104()/1FMU]/];[TAIHLYM3%,U)44\\-504T6,K0D$RS/2/5T*P3R454
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MB>A&I'4,IHP#"JD&A (\Q7HLOS"_YE+!_P"';AO_ '$ROL;>W7_*P-_SSO\
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MSVEU(%8NN@&XL;_T]RI[:AFBYA5/C*Q ?;2:G6-?W@FC2ZY$>:G@B2Y+5%<
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M_P!Y#;_O(3D?_E5MK_YN?]7I.L%?>3_IY',?_4/_ -HL'0!^Q9U&/5V75/\
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M']RQUC'U:/\ #W_F4L__ (=N9_\ <3%>X+]Q?^5@7_GG3_"_69_L-_RHS?\
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0O]*/\'6?W7ISKWOW7NO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>tproxy_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tproxy_001.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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M5G_\]O\ [=S]D?\ A\[4_P#=W3>PM[8?\ENW^R;_ *LR=8<_W:7_ $]K;_\
MGDW+_M#EZI1_EO\ _;J3^:C_ .&T/_='5>Y$YZ_Y6/;?]-!_VD'KH?\ >Z_Z
M?A[<?\]"_P#:='T_?\)W?^9L?*S_ ,0-#_[LA[K[T_V5I_IY?\$?19_>O_\
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M3]^VC_E;[W_GE3_CMIU[VW_\2EYK_P#%6M_\'+?5FO?W_;^#^7?_ .*KP_\
MN/VI[ FT?\JC??\ /4O_ !ZTZPX]KO\ Q&3GG_Q9#_U<Y:Z2_P#PI-_YD]\8
M_P#Q)6<_]U=-[>]F/]SI_P#FA_UD3H[_ +HG_E8>8/\ I76G_:2_1'L[_P!P
M\FS/_%EY?_=]EO8AC_Y71O\ FG_VJ+UD;MO_ (E;=_\ 2A7_ +0+;KWP4_[<
MP?S*O_#EB_\ <' ^_<Y?\K/MW^EA_P"K\O7OO,?^)"\@?\\__:Q>]#?\L/\
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MJ/D/_P ?'_PFS_[4G6?_ %OZG]D.S<.9/^HC_M<ZA3VH_P!Q??W_ )J\P?\
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MF_[NYZUG_P#A/S_V7T__ (A#<?\ [D8GW.7O%_R2T_YZ8_\ JW+UV&_O3/\
MIV"_]+BP_P"K5UT$/\OK_M[QU?\ ^+![H_ZT9_VHYK_Y58_\\]K_ ,>AZ'/W
MI?\ IPNX?]*/;/\ C]CU?Q_+N_[>G?S6O_#EQ'_N;7^XEYH_Y(>T_P"ENO\
MJXG7+[[U?_3E?;7_ )Y[S_JW!U?/[CCKF=U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW15_G3_P!D2?,;_P 57["_
M]Y++^S[E7_DJ6?\ SU6__5U.IK^[7_T\;E7_ ,638_\ NYVO6J)W?_W#^?#O
M_P 7#R?^]]I^YYVC_E;[W_GE3_CMIUV[]M__ !*7FO\ \5:W_P '+?5_'\XG
M_MU+WO\ ]J387_O<[0]Q+[9_\ERV_P";W_5B7KE]]P+_ *?;LO\ S5WG_NS;
MIU2C_(H_YE/_ #+_ /Q V,_]UN]_<B>\/]KM_P#IYO\ #!UT/_O,?^2W[?\
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MG/8[WC_E;['_ )Y7_P".WG68_NI_XE3R=_XK=U_VC\U=,G\H_P#[)'_G#?\
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M/_='UM[W[>_\E3>/^>H?]7;KI?\ <A_Z>5[K?]+^V_[3>8.O=W_]P_GP[_\
M%P\G_O?:?OVT?\K?>_\ /*G_ !VTZ][;_P#B4O-?_BK6_P#@Y;ZMA^6W_;V_
M^59_XC_(_P#N-E?<8<O_ /) W3_36O\ U='6#/L5_P!.*]R/^>VU_P"KMMT]
M_P N[_MZ=_-:_P##EQ'_ +FU_O7-'_)#VG_2W7_5Q.D'WJ_^G*^VO_//>?\
M5N#JD#^?3_V\.WC_ .(UVO\ ^Z\^Y7]H?^22?^:\G_'8^NC_ /=B_P#3JK;_
M *6.X_\ 5X=&4_X4!?\ <B?_ (@W(?\ R"]A_P!E_P#B;_IH/^LW4/\ ]UI_
MSN7_ $M[?_M=Z4OR$_[=@?R?O_$WX?\ ZW93V7;7_P EG>?^>:\_X^G1)[6?
M]/D]T_\ I3WO^"VZL&SO_<03LS_Q4:7_ -Q\M[#,?_*JM_TL/^L*]8M[;_XB
MW=_^+2O^&VZ]_),_X_#^8]_XMSD/_<K,^_>X/P;;_P!*^#_!U[^\1_W Y"_\
M5:W_ .K=MUKM_P X_P#[>4?)_P#[7>W_ /WD-O\ N;O;/_DB6W_-[_J_+UU@
M_N_O^G0<O?\ -*__ .[K?=&H_P"%#O\ V75M/_Q7+ ?^[S='LA]F_P#DER?\
M]3_]6H>H4_NI/^G:W7_2_O?^T+;>C4?(?_CX_P#A-G_VI.L_^M_4_LAV;AS)
M_P!1'_:YU"GM1_N+[^_\U>8/^.<S=&HZ0_[B(?F)_P"*Y8S_ -YOJSV0[O\
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MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NBK_.G_LB3YC?^*K]A?\
MO)9?V?<J_P#)4L_^>JW_ .KJ=37]VO\ Z>-RK_XLFQ_]W.UZU1.[_P#N'\^'
M?_BX>3_WOM/W/.T?\K?>_P#/*G_';3KMW[;_ /B4O-?_ (JUO_@Y;ZOX_G$_
M]NI>]_\ M2;"_P#>YVA[B7VS_P"2Y;?\WO\ JQ+UR^^X%_T^W9?^:N\_]V;=
M.J4?Y%'_ #*?^9?_ .(&QG_NMWO[D3WA_M=O_P!/-_A@ZZ'_ -YC_P EOV__
M .EQ=?\ :1L_0+_\)^?^R^G_ /$(;C_]R,3[./>+_DEI_P ],?\ U;EZD7^]
M,_Z=@O\ TN+#_JU==&4^/?\ V[ _G _^)OS'_6[%^PGNG_)9V;_GFL_^/OU#
M?NG_ -/D]K/^E/9?X+GI2_(;_LC7^17_ .)*VK_T-AO;6U_\E'??^:%]_P ?
M/11[5_\ 3P/>3_I7;K_VM=6?_P ]O_MW/V1_X?.U/_=W3>PM[8?\ENW^R;_J
MS)UAS_=I?]/:V_\ YY-R_P"T.7JE'^6__P!NI/YJ/_AM#_W1U7N1.>O^5CVW
M_30?]I!ZZ'_>Z_Z?A[<?\]"_]IT?3]_PG=_YFQ\K/_$#0_\ NR'NOO3_ &5I
M_IY?\$?19_>O_P#)$Y;_ .EQ)_VCCKVRO^X=3MW_ ,3S3?\ O8[8]^E_Y75/
M](?^T1^O<P_^)9;9_P!*>3_NT;AT+WR'_P"/C_X39_\ :DZS_P"M_4_M/LW#
MF3_J(_[7.@-[4?[B^_O_ #5Y@_XYS-T:C_A1U_V2/TQ_XL;2?^\SN7V0^S7_
M "4Y?^>5_P#J[#U"G]TK_P KYNO_ $H)O^[CMW597Q[_ .X>WYT_^+48C_W9
M].>QWO'_ "M]C_SRO_QV\ZS']U/_ !*GD[_Q6[K_ +1^:NF3^4?_ -DC_P X
M;_Q3RJ_]YGL'WOW#_P"2GL__ #U?]9;7I?\ ?K_Y7SVL_P#%IC_[N.Q=>[O_
M .X?SX=_^+AY/_>^T_?MH_Y6^]_YY4_X[:=>]M__ !*7FO\ \5:W_P '+?5F
MO?W_ &_@_EW_ /BJ\/\ [C]J>P)M'_*HWW_/4O\ QZTZPX]KO_$9.>?_ !9#
M_P!7.6NDO_PI-_YD]\8__$E9S_W5TWM[V8_W.G_YH?\ 61.CO^Z)_P"5AY@_
MZ5UI_P!I+]$>SO\ W#R;,_\ %EY?_=]EO8AC_P"5T;_FG_VJ+UD;MO\ XE;=
M_P#2A7_M MNO?!3_ +<P?S*O_#EB_P#<' ^_<Y?\K/MW^EA_ZOR]>^\Q_P")
M"\@?\\__ &L7O0W_ "P_[=J?R=/_ !)6SO\ W6R^R39?^2QO7_-"^_ZNCJ-O
M9'_I[WNK_P!*[>/^TE>CPYW_ +B"=F?^*C2_^X^6]AZ/_E56_P"EA_UA7K'+
M;?\ Q%N[_P#%I7_#;=$-_P"%*/\ S,KXK?\ AC;F_P#<_%>QI[)_#>?;!_@F
MZR=_NA?^23S)_P ]>W?]6;KH/_G%_P!N./Y=G_B0Z/\ ]U.\_;W)O_*T[A_I
M9_\ J_#T)ONV?^)(\]?\\,__ &E[3T&O2'_</Y\Q/_%P\9_O?5GLVW?_ )6^
MR_YY7_X[=]#+W(_\2EY4_P#%6N/\',G1J/D/_P ?'_PFS_[4G6?_ %OZG]D.
MS<.9/^HC_M<ZA3VH_P!Q??W_ )J\P?\ '.9NC4?%O_N(#^>'_BN4?^]=3^R'
M>?\ E4+'_GJ;_CUWU"GO-_XBUR9_TOW_ ,/,W597_"C/_LMOJW_Q5?"?^];O
MCV._9O\ Y)<O_/4__5J#K,?^Z9_Z=SN/_BR7G_=LV?ID_FL?]D*_R:__ !7+
M,?\ NCZV][]O?^2IO'_/4/\ J[==+_N0_P#3RO=;_I?VW_:;S!U[N_\ [A_/
MAW_XN'D_][[3]^VC_E;[W_GE3_CMIU[VW_\ $I>:_P#Q5K?_  <M]6P_+;_M
M[?\ RK/_ !'^1_\ <;*^XPY?_P"2!NG^FM?^KHZP9]BO^G%>Y'_/;:_]7;;I
M[_EW?]O3OYK7_ARXC_W-K_>N:/\ DA[3_I;K_JXG2#[U?_3E?;7_ )Y[S_JW
M!U2!_/I_[>';Q_\ $:[7_P#=>?<K^T/_ "23_P UY/\ CL?71_\ NQ?^G56W
M_2QW'_J\.C*?\* O^Y$__$&Y#_Y!>P_[+_\ $W_30?\ 6;J'_P"ZT_YW+_I;
MV_\ VN]*7Y"?]NP/Y/W_ (F_#_\ 6[*>R[:_^2SO/_/->?\ 'TZ)/:S_ *?)
M[I_]*>]_P6W5@V=_[B"=F?\ BHTO_N/EO89C_P"55;_I8?\ 6%>L6]M_\1;N
M_P#Q:5_PVW7OY)G_ !^'\Q[_ ,6YR'_N5F??O<'X-M_Z5\'^#KW]XC_N!R%_
MXJUO_P!6[;K7;_G'_P#;RCY/_P#:[V__ .\AM_W-WMG_ ,D2V_YO?]7Y>NL'
M]W]_TZ#E[_FE?_\ =UONC4?\*'?^RZMI_P#BN6 _]WFZ/9#[-_\ )+D_YZG_
M .K4/4*?W4G_ $[6Z_Z7][_VA;;T:CY#_P#'Q_\ ";/_ +4G6?\ UOZG]D.S
M<.9/^HC_ +7.H4]J/]Q??W_FKS!_QSF;HU'2'_<1#\Q/_%<L9_[S?5GLAW?_
M )4^R_YZG_X_=]0I[D?^(I<J?]+^X_[3^9.O?\)Q?^R1^Y__ !8VK_\ >9VU
M[][R_P#)3B_YY4_ZNS=>_O:O^5\VK_I00_\ =QW'J@?<O_;Y3<'_ (TUJ_\
MWZDGN6A_RK'_ %*_^U3KJ#M7_B/L/_GO8_\ R6QT,O\ /I_[>';Q_P#$:[7_
M /=>?91[0_\ ))/_ #7D_P".Q]1]_=B_].JMO^ECN/\ U>'5PWR,_P"WI'\H
MG_Q$,O\ [KLC[BO8O^2#NO\ I[;_ *NCK +VD_Z<M[G_ /2SB_[2(.DU\</^
MRT_YY/\ X8U=_P"X6<]N[[_R2=F^VX_ZNQ]&_NY_T[OV?_YZT_ZOV?1O/Y$G
M_;N?K?\ \/G=?_N[J?9?[G_\ENX^R'_JS'U!O]Y;_P!/:W#_ )Y-M_[0XNM:
MGXL_]OE=H?\ BYN=_P#=WE?<Q;]_RJ@_YX[;_!%UUZ]ZO_$?+G_Q5+'_ +1+
M7KW\P7_M[QVA_P"+![7_ .M& ]^Y4_Y58?\ //=?\>FZ]]UK_IPNW_\ 2CW/
M_C]]U?QG?^X@G9G_ (J-+_[CY;W$L?\ RJK?]+#_ *PKUR^VW_Q%N[_\6E?\
M-MT1#XU?\>;_ ,*.O_(__P"Y7;OL9[UQY;_YL_\ :GUDS[O?[G>PO_4!_P!6
M^5^K:_Y.W_;J7HC_ +4F_?\ WN=W^P%[F?\ )<N?^;/_ %8BZP:^_P"_]/MW
MK_FKLW_=FVOK5Z_DH?\ ;S;XT?\ DY_^^_W7[G?W-_Y(=S_S9_[2(NNSO]XE
M_P!.<Y@_ZE7_ '>]MZ9-R_\ ;Y3<'_C36K_]^I)[V/\ E6/^I7_VJ=+]J_\
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MO2_[]?\ ROGM9_XM,?\ W<=BZ]W?_P!P_GP[_P#%P\G_ +WVG[]M'_*WWO\
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M]YOJSV0[O_RI]E_SU/\ \?N^H4]R/_$4N5/^E_<?]I_,G7O^$XO_ &2/W/\
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M_P"(M<F?]+]_\/,W597_  HS_P"RV^K?_%5\)_[UN^/8[]F_^27+_P ]3_\
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M /;RCY/_ /:[V_\ ^\AM_P!S=[9_\D2V_P";W_5^7KK!_=_?].@Y>_YI7_\
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MK_[5.NH.U?\ B/L/_GO8_P#R6QT,O\^G_MX=O'_Q&NU__=>?91[0_P#))/\
MS7D_X['U'W]V+_TZJV_Z6.X_]7AU<-\C/^WI'\HG_P 1#+_[KLC[BO8O^2#N
MO^GMO^KHZP"]I/\ IRWN?_TLXO\ M(@Z37QP_P"RT_YY/_AC5W_N%G/;N^_\
MDG9OMN/^KL?1O[N?].[]G_\ GK3_ *OV?1O/Y$G_ &[GZW_\/G=?_N[J?9?[
MG_\ );N/LA_ZLQ]0;_>6_P#3VMP_YY-M_P"T.+K6I^+/_;Y7:'_BYN=_]W>5
M]S%OW_*J#_GCMO\ !%UUZ]ZO_$?+G_Q5+'_M$M>O?S!?^WO':'_BP>U_^M&
M]^Y4_P"56'_//=?\>FZ]]UK_ *<+M_\ TH]S_P"/WW5_&=_[B"=F?^*C2_\
MN/EO<2Q_\JJW_2P_ZPKUR^VW_P 1;N__ !:5_P -MT1#XU?\>;_PHZ_\C_\
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MR"6,K';V@D8.I5"K,2&-:*1Y@TIY]1+[F<Z[-<^[GMI=QW]D\%KM-HES,MU
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MON]S/MMW]VCE#:XKNV>\AWQI)K1)XFN8HR>8^YX0YD1?U4[F4#O3/<*UR?\
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M$)S%_>#XE?+?&*:8/,<.=FUQ6:RWC43[CQVN('5:0E6-@?&+D+[KW1N.L_\
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MWZW=6Y\[D7$=/18_'TTE76U<\AX2&FIH7D=CP%4D_3W[KW7R%-CT6Z_Y_/\
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M\K7XQ=2YW#S8;LO>>U!WCW#25B1)51;CW>L>5GH*OQ*H-1A,?)28IKER/L0
M[  ^_=>Z)C_PJU^&LORH_E1;][!P%,\V^_A_NRD^1N'6$HK3X6EAJ,3NNED9
MXI#]O#@\E)DV56B9I<9 /(5#1R>Z]U\F#W[KW6X?_P (VOFF.F/G9V;\0MSY
MC[79WRYZ\_B&TJ2LJ76%=Y;-2KR5(E/ P:%9LCMZIRJRN"CRM2TD9,FF-5]U
M[KZ=/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ=O\ A0)_VYG_ )@W
M_B"I/_=KC/?NO=?&0]^Z]U=9_P )TO\ M]7\ _\ Q*64_P#>3W#[]U[K[)GO
MW7NO>_=>Z][]U[KWOW7NOB:?SD/D%C_E'_-*^=/=6%D@J=N[@^0V<VWM/(4U
M0U5'68;;$B;6PV0CE9$(3(8O"T]2L8!6$2B%&=8P[>Z]U7-@\'FMSYK#[;VW
MA\IN'<6X<I3X/ 8#!T\M76UU;5RI3TM'1TM.DD]355,\BQQ11JTDDC*B*6(!
M]U[K[37\F+X'S_RXOY<OQX^,N>%/)V3C<!-O[N:KIF21'W=N2=\KF*9)HXXE
MJ(,.T\>+IY=(:6FH87:[$D^Z]U:5[]U[KWOW7NOE _\ "M+Y>UWR._FL[KZA
MQN2JY]@?#[8N,Z9PE 74TK9VNACW#NBOA122M0]5D:?&SEK%OX3$-("@M[KW
M6L+[]U[KZ27_  BE^+4.S?BC\G_EWF</-3Y[N_MVEZDVCD:JQ$FW]FT*551/
M2 ,=,-7G<_4P3$@%I,:HMI0$^Z]UNS>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM7C_A6
M5\[XOBE_+.S/1&UL\N,[:^;6;;IS$4]+)3?=1[0H_MZ[?-:()P[24=3CGI\)
M.R(6C&;5T>*0(X]U[JHC_A%'\)5+?*'^8/NK$N'3Q?%[IVLJ%F46/V&X=Y54
M2LZP2J2,)313"-V5EKH5D2\R/[KW6]AW7U'LOO[IWM/HWL?&1YC8/</7N8ZS
MWEC)1<38W-X^HQU8J_E9/!4,48$,CA74A@"/=>Z^%S\B>D=W?&KOON?X];]A
M>+>727:&=ZMW&S1/ LM5@\E4XZ2IBCDNPIZHT_FA:[!X9$=696#'W7NA8^ O
MRLSGP>^9WQL^6&!AJJN;I#M;&[NS.+H51YJ_"F0TFX<9$LDL$?DRF!JJRD4M
M+& 9@2ZVU#W7NON/[6W-@MZ[9V[O+:V3I<UMG=N"I-S;<S-$VJ&KH*^GCJJ.
MIA;^U%/3RHZG\JP/OW7NGWW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW08=V=Q=?_'GJ#L[O?MC,S;=ZQZ>V+E.R.P,]3TM57/1
M8?#4<M?D*I*.AAJ*RJ:"E@=Q%!%)*]M,:,Q /NO=45?]!5?\CS_O+'<W_HN.
MR?\ [%/?NO=>_P"@JO\ D>?]Y8[F_P#1<=D__8I[]U[KW_057_(\_P"\L=S?
M^BX[)_\ L4]^Z]U[_H*K_D>?]Y8[F_\ 1<=D_P#V*>_=>ZN$^'WS'^/OSQZ-
MP/R/^,.\JS?O4.YLOD<'A=S5V*RN&DFJ<35R4-<AH,S1T%?&(:J)T#/"JO;4
MA9"&/NO=&@]^Z]UTS!068A54:F9N  /J2?P![]U[KY>/_"GW^>1%\Y>TJSX0
M?&#=E14?$KH_>$@[ WA@YW2D[#W=C97@:6-XG"5^T]O5"NN.8ZJ>OK V4C$T
M,6+J![KW5(W\J#^67W%_-2^6NS_CSUO2Y+#;(HY8MS]Z]KQP"2CVEM:*4+55
MTK.1%+DJUA]KC*2Y>IK)%+*M+#5SP>Z]U]D_XP_&GIOX>]"]9_&SH#9V/V+U
M/U/MN/;FU\%0J-3>IYJNOK9K!ZS*92MEFK*ZKDO-55<\U1*S22,3[KW0\^_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ*^8 O
MWEDO_#>Q_P#UJ/M].'3+\>@-QJ#T?[Z_O?5>E]C8^$_Q^OOW7NE]CH_H?K<V
M_P!M_P B]^Z]T8/K_LK<FU!%2B=LIADLIQ=:Q(0#\02'4T/^L+I^2A//NI4'
MJP:G1K*?L3 5&U,SNQ7ECI,!C9LCE*68:98Q#$\I3\JQ<(0A4G4;#Z\>VJ4Q
MTYJKU5B^?R6[<_D]R9B83Y',UK5M4P^@+6"H@_$<261!_915'X]O\.F>/0N;
M=C7]LV_I_P 5]^Z]T/&W:>-M%P/P/]Z^GNK&G6QT,N.Q4,M,6)0:4U<G_>O;
M/3G'I%[@I(D60*![L#U7I;=<[A6HPE=1ULUCM_U&5R3:F(9D)^I/CT.O'T4*
M/>W%#U9#CH.=\]R5C+-0;34TD14H^7G7]UOP?#&P(C'^U,"WY 0B_O83UZTS
M^G13<S+45D\U55SS553,Y::HJ&9W=C^69B6)_P 2?;G3?0>9&/@_X,??NO=(
M')1_KY_V/OW7ND#DD%VXX(][Z]U?#LS_ (\_:?\ X;5!_P"XL7M.>/3XX=*7
MWKK?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T7SY8?(W8_Q$^-/>/R<['ET;,Z/Z
MTRO8F8IT95DJSCZ5Y*;'TY8@&KR=7XJ2G7^W/-&HY(]^Z]U\C[^5/T#OC^;[
M_.7ZS7N2ECWK3=G=Y97Y2_*"IJ($J*&;"X_(2[GS]+4T];)./X;FZUH<*D;&
M;QC(0H5=%/OW7NOLAJH4!5 55&E57@ #Z #\ >_=>Z2>_MC[:[-V+O7K;>>-
MAS&S^P=I9+8^[,14!6CJL9EJ.:@KZ9U=61DGI:AT8,""&-P1Q[]U[KX8_P Q
MOC9NOX>?*GY _%[>@G?/]&=KYGKN2OG4(:^EH*R1,;E$520(,MC3!6P_3]J=
M+@'@>Z]TG_C'W[O/XK?(GI#Y)=>SSQ;RZ-[2PG9^"AAJ):5:J3#Y""M?'U$T
M-W^RR<,3TE4A5TEIII8I$DC=D;W7NON>=-]K[-[WZDZP[LZZR<69V%VYL#$=
MD[-RD+(RSXS-T$&1HI+HS+J-/4+J )TM=?J/?NO="3[]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>ZIV_X4"?\ ;F?^8-_X@J3_ -VN,]^Z]U\9#W[KW5UG_"=+
M_M]7\ __ !*64_\ >3W#[]U[K[)GOW7NO>_=>Z][]U[K6Q_X47_SI^NOY<'Q
MEWCT/UEO*&O^</?^QJO;W6NVMO2Q25FSL1DXY:*JWSF#ZUQXIHC,N&CE4RUV
M157BBDI*.OE@]U[KY,V(Q&6W!EL7@<#B\CF\YF\C!B,+A<1!)4U=75U,BPTU
M+2TT*O-45%1,ZQQQQJSN[*JJ6('OW7NOHX_\)OO^$X&Z/B_NC;WSY^?6VJ"D
M[LI* 5GQZ^/=<%J'V>]0J$[IW.;>(;J$6J+'X^-I(L7%))55+R9.2"+$^Z]U
MN[>_=>Z][]U[K#45$%)3SU53+'!34T+5%1/*0JHB*6=V)X"JH))_ ]^Z]U\(
M#Y0=OGY"?);Y#]^F*O@/>'>>[>WS!E @JD_O+G\AFM%2(Y9XQ.OWMI LDBZ[
MZ7868^Z]T!GOW7NOLJ?\)X.GJ+I+^3)\#=M4GW#R[KZEE[AR%156\DD^^,QD
M]V\Z8X@8X8<Q'!#Z;^"**[R->1_=>ZND]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?)(_
MX4^_.3(_.+^:EOSKC8]=-N+K'XH$?&?K/'84M4K79VEJ=6[JV"&*+5)5U6YY
M)<:OC:43T^,HWC/KTCW7NOI4?RH/AG1? '^7K\7OBTE-%#N/877$&3[)FB9V
M\^[,[++G=T2AY6>0Q#-Y&ICA!-HZ>.*) J(JCW7NK#_?NO=?+8_X6&?#J#H3
M^9'M;Y(;<Q4./V=\S.KX=TY&:*1R)-X;2^UP.X0L)&B%'Q$F"J6*']VHJJB1
ME#DL_NO=:EWOW7NOK:_\)7?F;_LU_P#*>ZNV3G<FE9V%\1<U4?&O<D+ZA(<1
MC(8*W:$X5F<_;IMJMIJ!&! :7'3@*H6WOW7NMD/W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UQ=TC1Y)'6..-2[NY "@"Y))X  ^I]^Z
M]U6Y_.._[=._S(?_ !2;LK_WD\I[]U[K1[_X3(_R6_@+_,T^+_R&[0^6_7>\
M-Y;OZ][[BV%MBMVYN;-8.*+&MM[%Y Q208RJ@BFD^ZJI&\C@M8A;V 'OW7NM
MEG_H$Q_DJ?\ /B^TO_1@[L_^N/OW7NO?] F/\E3_ )\7VE_Z,'=G_P!<??NO
M=>_Z!,?Y*G_/B^TO_1@[L_\ KC[]U[JZ/X7?"[H3X ]";?\ C3\:=OYG;'4N
MV,SD\]AL-GLG69>HBJ,O625]<375\DM5(LE5*[JKN0@.E;* ![KW1K??NO=:
M6'_"I_\ GDQ?'#8NX/Y</Q4WU)3?(?LG 1P_(O?.U:A//LO;&2@$G]WHJF,L
MU)N3<U!*IE"Z9Z+$SB93%-74DT?NO=?.OZ)Z.[3^2_<77'0?26S\KOWM7M?=
M=+L[9.U<-&7EJ*NJ>VN1@-%-14D0>HJZJ4K!24L4U5421P0R2+[KW7V0_P"3
MQ_*OZM_E/?$C;G1^UGQFZ>V]S"'=OR#[:IX!'-N+<;QG7' S(DZ8+#+(U)BX
M'LRP*U1*OW554L_NO=6N>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[JI3Y;Q)+WGDUDJ8:5?[O8X^2<2%>(CQ^U'(US?
M^EO\?;\?#]O3+\>@EP>(H*B31-N;!T"JEQ)5QY(J?K]!!CYFX_Q ^H_QMOJO
M0T;>V;M6I\(J>T=JT[E#)(B4F::WTL TV-IT8\BX!_K:]K^]5^76Z?/H=MN]
M3["J3&9.X-O3$M;P0)%$S?3]+5%6IO<FPT&_!_J/=2Q].K:1Z]#G@^E-C*B3
M1Y;(YI5L6:*H@\1N/K^S'J%SS^OW4N>K!!TQ]]XG&[.Z'WZF I!2+/'013W>
M1RXFR5#3R%F=RW^:D;B^D?TM<>_*:GKS"@ZK@VY4 :/Z\6]N]-=#KMZK4:+D
M?U]^Z]T-^!R2H$);_>?>B*];!IT)U-N )%82#Z<_[XGCVUIZN#3_ %?YNDWF
M<PLBOSR;WM[LJ]5)ZG=1U0J]RYNB=?)3U&"=IA_9-IHD"G\W99&MS]+^]OUM
M.A R?4&R:Y6;PUV- !8O1U!L/ZG_ "@3 #_>/=-9ZMH'0.;AZ>V%3Z]79N/Q
M#7Y3)-22M^/["U%.Q/\ K#_>O=@Q].JZ1Z] 1N'8.SJ,2>/MG;$VD@_\!,@W
M!)!_X"PU=R#^!?CDV'NP/RZU0>O0(YW 8BG%0T&]MLUWC)\:4\.95G'XMYL3
M$HO].6')_IS[W7K5.@FR]+!&I=,C1U# #]F):@,;\?62!$X_Q;_6]V'6NKS]
MF?\ 'G[3_P##:H/_ '%B]ISQZ?'#I2^]=;Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NM(;_A:!\\8-@?'SI/^7OM#+4YW3W]FX^ZNX:*GGB,U/M+;=;HV_355,&\
MRPYS=,+U,$I4(7P$R L;Z?=>Z3?_  BM^$8VGTY\COG[NW!>'-]LY]/C[T_D
MJV",2C;F"D@R6YJNCG*&4T>6W U'22!75348)PRL41A[KW6\[[]U[KWOW7NO
MF3?\+,OAJ>H_G+U'\PMNXJ.GVI\LNM/[O[PJJ.G< ;PV.E)C9YJN=5\ ?(;9
MK,0E.K$2R&@JV&I8R5]U[K3@]^Z]U]3_ /X2$_-=OD;_ "V,C\=-SYF*N[#^
M%F_Y=@0TL]0)JM]F;A\^;VK5RIXHVAABJ_XMBJ=+RA8,5':0!A%'[KW6US[]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZIV_X4"?\ ;F?^8-_X@J3_ -VN,]^Z
M]U\9#W[KW1Q?Y?\ \O<O\"?F)T7\O<%LC'=CY;I#<U3N2BV3EJV7'TV0:IQ=
M?C#%+6PP54L"JM>9 RQ.24"VL;CW7NMR;&_\+F,M%"RY?^61CJZHU767&]QR
M4B!;#@QR]75C$ZKF^L<$"W%S[KW6:M_X7,UTE.ZX[^6'24M62/'-6]S/41@7
M&J\4?55,S$C@?N"QYL?H?=>ZK2^6/_"PK^9KWKB,OM7HG;W3GQ$V]E*5*89_
M8E#/N'=D0U'[@19O<+SXJ!9T]"O3X:"IA%WAJ4ET2)[KW1*_Y7?\F#YE?ST-
MX]G]T#Y"[)Q6W]N;[AP_>7<W=N?K]S;TJ,A5T*5<54F$$U1F\S+/#H6.JR59
MCZ2<QU$<-=+-230I[KW7T1OY7/\ ("^!O\KA,9O786U:KN7Y(Q8XT>3^1O;$
M<-3E86D,OF&W,8NO&;6@=)6B+4:M72P6AJZ^J7Z^Z]U>%[]U[KWOW7NO>_=>
MZ#3NBIJ*+IWMBLI)I*>JI.M,[4TU1"2KQR1XNJ='4CD,K $'\$>_=>Z^"E[]
MU[KWOW7NOMY?RE::"D_E7?RU8J:)(8W^ _4%2R)]#)-U_M^:5O\ 7>61F/\
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M_-X]H=E[IS.]^PNP=RUF\-Z[OW#,U179+)Y"=ZJLK*J9N7FGGD9V/ %[* H
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M[U[.P^SL%N[/;DS>'K,=L2GK:7'+%C<C-20-%#D,AE*D2/'&#(6J&!:Y55'
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ME=&;JJ,'M+!X/'YN+!U$45#M^I5LC35&X:FOFD,F5F!,-;3KI6,!00Q=%O\
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MJOXINO TU7P]'AEZTTUU5'\5*>749W?W?]FM_9B#W%$U[^\I-Z.W- 9(/H1
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M+ BWOW7NC4^_=>Z][]U[KWOW7NO>_=>Z][]U[JG;_A0)_P!N9_Y@W_B"I/\
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M?\U(O\$G4;?W77^X'-G_ $OC_P!6WZ,IWY_V0+_)(_\ $W]?_P#N/[#^V?\
M)4WS_GFW#_JX.H?]L?\ IY_N]_TI]^_ZN]&\SO\ W$$[,_\ %1I?_<?+>R./
M_E56_P"EA_UA7J"=M_\ $6[O_P 6E?\ #;=>_DF?\?A_,>_\6YR'_N5F??O<
M'X-M_P"E?!_@Z]_>(_[@<A?^*M;_ /5NVZH'_F"_]O>.T/\ Q8/:_P#UHP'N
M6N5/^56'_//=?\>FZZ@_=:_Z<+M__2CW/_C]]T/G_"AW_LNK:?\ XKE@/_=Y
MNCVE]F_^27)_SU/_ -6H>HS_ +J3_IVMU_TO[W_M"VWHU'R'_P"/C_X39_\
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M_J_9]&\_D2?]NY^M_P#P^=U_^[NI]E_N?_R6[C[(?^K,?4&_WEO_ $]K</\
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M_P#5B+K";[_O_3[=Z_YJ[-_W9MKZU>OY*'_;S;XT?^3G_P"^_P!U^YW]S?\
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M /SUI_U?L^B&YW_N'DV9_P"++R_^[[+>QI'_ ,KHW_-/_M47K)W;?_$K;O\
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MNO(__*S;C_U$_P#:2G2O[IG_ $__ -P?^HO_ +N4'2:P7_</)O/_ ,67B_\
M=]B?;LG_ "NB_P#-/_M4;HWW+_Q*VT_Z4+?]H%ST?+Y'_P#9:?\ (V_\,:A_
M]PL'[!>Q?\DG>?MM_P#J[)UC%[1_].[]X/\ GK?_ *OWG3I\./\ M_G\^?\
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M_P#B+7.?_2_3_#RSU[^4?_V7_P#SAO\ Q8VJ_P#>U[!]^]P_^27L_P#SR_\
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MVR^PNO=S46\=E[LP4GBK,=D\=4)54=93O8@203QJP# JUM+*RD@^Z]U]F/\
MDR?S.=D_S4_A-L7OG'RX[%]O;95.OOD5L.E*J^'W91P1FIFAA#,RXG.0E,AC
MGN5\$YIF;[BEJ$C]U[JV+W[KW7O?NO=>]^Z]U\Z?_A:G\(:K:W<'QQ_F";8H
M"-N=I8 ?&_M6:+QK'%N+")79C;-5(!&LLM3F,$U?3EB[JL6$B4*E[O[KW6B_
M[]U[K<)_X1Q?.2DZ+^<_8_P\WAEFI-H?,?9,<^R4J7J&ACWMLV*OR5%!'&JO
M2TW\6V]4Y5)9G\9FGI,?3!W=H8S[KW7T[_?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW5='RR_FQ? ;X/]W=/_'/Y+]]4'7_<G>:4E1L'
M9=-B,]F)VI\AE!A<?69*3"XS(0X:BKLF)8()ZYX(I3353*Q2FF9/=>ZL7]^Z
M]U[W[KW7O?NO=:FO_"O?YUGXW?R[\/\ %_:.:%#V7\U=W_W0R$%)/XZF#8^W
MFILIN:H 5';QU]:^,Q3HQC$U-75@#L(GC;W7NM9W_A'S\,(_D'_,@W)\E-QX
MR&NV1\+.N'W92/*YL-X[M6MP>VD>&VF6./&0YRL5B?VJFBIF"DV*^Z]U]2SW
M[KW7O?NO=>]^Z]U[W[KW6N]_PJ(^'8^6?\H_N[.8B@@J]^?%2MIOE/M*:61X
MM%'MR"JAW8K-&KF1!LZOR<ZQ,/')44].6*%%D3W7NOD4>_=>ZV)?^$O7S4_V
M4#^;!U#@=P9HXOK+Y58ZH^-.]TK*QZ>B2NS,L%3M2MDA)^VFJH]ST5'1122:
M6A@R-7XW7R.DGNO=?73]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=5M?SCO^W3O\R'_Q2;LK_P!Y/*>_=>Z^+RW37:"]-Q?(3^YF7?I>
M7LV3IH]APB-Z"+=$>*BS8PM04D:6FK)\3*:FG$R(E3'%4_;M*:2J$/NO=6G_
M ,DG^;WV;_*3^4M#OFG_ (ENSXW]HU5#M?Y)]4P2'_+<3',PASV*C8^)-R;<
M$\L]&6TK51-48Z62&.K^X@]U[K[#'4G;/77>_6.Q.Y>H]VXC??6?9>V*3>.R
M-W8*3R4M?CZV)9H)XVX925;2Z.%DCD#1R*KJRCW7NOGX_P#"K/\ GD4_9V8W
M)_+ ^)V]WGV'M'.F@^7V_P#;4RF#,Y?'S!AL.EJHRQDH,-71!\R8R!+D($Q[
M,4I:R*;W7NM1[X%?!_N[^8E\H^M/BKT)AVK-W;]R)FS6XZN*5\9MO!4NF3+[
MDS4T2D4V,Q=.;DDAZBH>GH:825E730R>Z]U]F_X&?"'I7^7A\7NL_BOT1C)(
M-I; Q0&6W'D$A7);AS,ZJV5W#EWA1$DR.4J09'"@1PIXZ>%4@AB1?=>ZUK_^
M%K.+R-5_+5^.N3IJ.HGH,5\V\,N2JH5+)!]QL;?B0M*1?0DCKH#'TZRJ$ZG4
M'W7N@'_X1![LVO5?&WYT[%IGI!O3 ]X;7W9FXU;]\XO+8&KH\6632/VA5X7(
M!6!/J+@A; M[KW6\9[]U[KWOW7NO>_=>ZA9/)4.&QN0R^3J8Z/&XJAER60K)
MKZ(H((VEFD:P)TQQJ6-@>![]U[KXIO\ *>PTO8G\X+^7XO7>T?X/CYOGWUWO
M?%[/BK34C%X3$[XQF>JX!75[QRUBXC"T,Q\DA,]0(.%>>14;W7NOM?\ OW7N
MJKOYX7_;H7^8K_XJENO_ -P']^Z]UH!_\(ZO^WO55_XJEO7_ -S]M>_=>Z^J
M;[]U[KWOW7NOCO\ _"F'_M^'\\/_  YMF_\ OMMF^_=>ZV@.C_\ A&=\+.TN
ME>H.S<K\L/E#C<IV-U=M_?>2QV/AVF:>"HR^)I,A-# 9,*\AABDJ"J:F9M(&
MHDW/OW7NA1_Z DO@[_WE[\K?^I&T/_K'[]U[JRW^53_PG+^-W\IWY)YWY,=1
M]]=W]F;GSW4V3ZBJ=O=C18%:!*/*9+"Y.6JC.,QU'4?=1S82)4NY31))=2VD
MK[KW6Q%[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU[/E)_P!Q ?P/_P#%<I/]
MZ[8]RWLW_*H7W_/4O_'K3KJA[,_^(M<Y_P#2_3_#RSTP_P I?_MY-_-O_P#$
MWYS_ -[W=GNWN%_R2=G_ .>8?]6;;HS^_-_TZ/VQ_P"E/:?]V;:^JBOY]/\
MV\.WC_XC7:__ +KS[D'VA_Y))_YKR?\ '8^L[?[L7_IU5M_TL=Q_ZO#H;_Y_
M'_'X?##_ ,5HA_\ <I/9)[,_!>?\U(O\$G4;?W77^X'-G_2^/_5M^C*=^?\
M9 O\DC_Q-_7_ /[C^P_MG_)4WS_GFW#_ *N#J'_;'_IY_N]_TI]^_P"KO1O,
M[_W$$[,_\5&E_P#<?+>R./\ Y55O^EA_UA7J"=M_\1;N_P#Q:5_PVW7OY)G_
M !^'\Q[_ ,6YR'_N5F??O<'X-M_Z5\'^#KW]XC_N!R%_XJUO_P!6[;J@?^8+
M_P!O>.T/_%@]K_\ 6C >Y:Y4_P"56'_//=?\>FZZ@_=:_P"G"[?_ -*/<_\
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MO'L[]WO^22/^:\?_ !V3J2?[SK_IU5S_ -+';O\ J\>K&OC_ /\ 9-G_  H
M_P#$E=E_^XNZ?8%W3_<_8?\ FA8?]7%ZQ']T/^5O]DO^E=R[_P!7=NZ)1\B_
M^W"'P!_\6-W/_P"[KM#V,]G_ .5OOO\ GE3_ ([:=9'>T_\ XD_SK_TH-O\
M^T3ESJ_C^>)_V[7[R_[7>T/_ 'K\)[B7VQ_Y+=M_S>_ZL2]<OO[N'_I[^S?\
MTMT_[M5YU1%_*'_[(D_G-_\ BJ\7_O)=J>Y9]P_^2IL__/4?^KMKUTR^_?\
M]/&]J/\ Q9&_[N?+?3)_PGB_[+JW9_XKEG__ '>;7][]Y/\ DEQ_\]2?]6IN
ME_\ >M_].UM?^E_9?]H6Y=>^.G_;A#Y_?^+&[8_]W75_OV\?\K?8_P#/*_\
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ML#_W6[:]DFT_\E'??^:%_P#]7&ZC;V4_Y7OWE_YY=]_[2;_HX>"_[B"=Y_\
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M6''LS_XBUSG_ -+]/\/+/7OY1_\ V7__ #AO_%C:K_WM>P??O</_ ))>S_\
M/+_UAM>O??K_ .G7^UG_ $H(_P#NT[%U1%_.O_[>;?)?_P DS_WW^U/<L^V7
M_)#MO^;W_:1+UTR_N[?^G.<O_P#4U_[O>Y='7_X41?\ ,V/BG_X@:;_W9'V#
M/9;^RN_]/%_@DZQQ_NH/^2)S)_TN(_\ M'/0H_(;_LC7^17_ .)*VK_T-AO9
M-M?_ "4=]_YH7W_'ST"?:O\ Z>![R?\ 2NW7_M:Z/#@O^X@G>?\ XJ-%_P"X
M^)]AZ3_E55_Z6'_6%NL<MR_\1;M/_%I;_#<])K^0S_W/G_XLH?\ Y*>W?<C_
M )9__/!#_EZ-_P"\Q_YTO_Q7E_ZP=65_#C_C_/GS_P"+PY#_ -]MUG["F]_V
M%C_SR'_M,N^L1/?S_DE\E?\ BH0_^3!S#T>'V'NL<NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NJ@?F5_S.[)?^&_C_P#K4?;R<.F7X]%EHYM) ORIN/\ ?6]W'5>EK05(
M])OP?K[UU[I:4%7^D7%Q]/?NO=&&ZUP>%BISOG?,OVVTL;.4HZ$B\V6JTL12
MTT9(\D2&WF;] _0S*"[)4GR'6QT^;R[5S6^:L"=AC\+!)JH,-3-^VEA8/*;#
MRRV_) "\A%6YOY5IULM7I1=24YS6^,' 1JCHYVR<S#\"G4R(3_KRA!_L??F-
M!UI14]"MW)OI6K%VGCY@8J4K-F'0_JEX:.#C\1BS-S^HJ."A]U0>?5W;RZ$#
MI[)K7;+C4L ,=D9Z-K_@'34?4_BTW^M[J_'K:''1><7ORHQ&ZY-QPZG2IR$L
MU;!?_.PS2%Y$^MKV-U)^C!3^/;E*BG38-#T+'=HILIM+ [HQ\BU--'4A8YX_
MH8:N/4&/^L\2"QY!:UOK[JF#3J[Y%>BJ4NY,CA:Z#)XJMEHJVF?5#- ;'_$$
M<AE8<%2""."+>W./38-.A*S.<Q7=&*CC*4N)[.Q5,4HH VB'+Q*"Q@B8_HJ0
M=1CC8_J)"L5<^*GP?9U<G5]O14<E.\+RPRJT4D3M'+'*"&5@;%6!Y!!%B/J/
MI[OU3I$5]5>]C?\ I[]U[I$Y"I!N+\#D^]C'7NDP[:V+?U/O77NM@'9G_'G[
M3_\ #:H/_<6+VP>/3XX=*7WKK?7O?NO=>]^Z]U[W[KW13/G;\K]G?!OX??(?
MY8[YDHCANDNLZ_=E#C:Z>.G7)Y<H*3;^%CEE=$%3G,[4TF/@%[M-4HJ@L0#[
MKW7Q8>G>N^X?Y@7S,V'UR<OE-U=V?+OY!4V.S^[Y*,U<TF8W?G/+F=PUU+1+
M"OVU+)6U&1K600PPT\4\K-#"C,GNO=?<+Z?ZKV;T9U-UETKUWBXL+L+J38&'
MZUV7B8 %6FQ>#Q]/C:"$!0!=*:F0$_DW)Y/OW7NA&]^Z]U[W[KW7O?NO=>]^
MZ]U1K_PHS^&;_-7^4Q\E=JX/"IF>R.E,1'\E^K8XJ22MJ_XCLU)ZW)TV/IX
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MU]PK^7+\M\-\[/@W\8OEAB'H!4=Q]48[.;MH,;*D\-!N2E5L;NG%K*D<(?\
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MY97R:^/&T:7[OLR7;$'9/4<"K&9)]R[5JX<YC\?$T@*Q/FTI)<69."B5K-<
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ML^4G_<0'\#__ !7*3_>NV/<M[-_RJ%]_SU+_ ,>M.NJ'LS_XBUSG_P!+]/\
M#RSTP_RE_P#MY-_-O_\ $WYS_P![W=GNWN%_R2=G_P">8?\ 5FVZ,_OS?].C
M]L?^E/:?]V;:^JBOY]/_ &\.WC_XC7:__NO/N0?:'_DDG_FO)_QV/K.W^[%_
MZ=5;?]+'<?\ J\.AO_G\?\?A\,/_ !6B'_W*3V2>S/P7G_-2+_!)U&W]UU_N
M!S9_TOC_ -6WZ,IWY_V0+_)(_P#$W]?_ /N/[#^V?\E3?/\ GFW#_JX.H?\
M;'_IY_N]_P!*??O^KO1O,[_W$$[,_P#%1I?_ ''RWLCC_P"55;_I8?\ 6%>H
M)VW_ ,1;N_\ Q:5_PVW7OY)G_'X?S'O_ !;G(?\ N5F??O<'X-M_Z5\'^#KW
M]XC_ +@<A?\ BK6__5NVZH'_ )@O_;WCM#_Q8/:__6C >Y:Y4_Y58?\ //=?
M\>FZZ@_=:_Z<+M__ $H]S_X_?=#Y_P *'?\ LNK:?_BN6 _]WFZ/:7V;_P"2
M7)_SU/\ ]6H>HS_NI/\ IVMU_P!+^]_[0MMZ-1\A_P#CX_\ A-G_ -J3K/\
MZW]3^R'9N',G_41_VN=0I[4?[B^_O_-7F#_CG,W1C>@?^W\'\Q#_ ,57F_\
M<?JOV1;O_P JC8_\]3?\>N^HC]T?_$9.1O\ Q9!_U<YEZ>_^$XO_ &2/W/\
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MT3ESJS7Y'_\ <0E\-/\ Q!I_]UG9'L";/_RJ%[_STK_QZTZPX]I?_$5N;/\
MI=+_ -I'+_0&_P#"F'_N2G_RH_\ \H7L\]DO^)O_ %#?]9^I-_N>_P#G;?\
MJ0_]YKHGG=__ '#^?#O_ ,7#R?\ O?:?L_VC_E;[W_GE3_CMIU/7MO\ ^)2\
MU_\ BK6_^#EOH2O@[_VXX_F)_P#B0ZS_ -U.S/93SE_RM.W_ .E@_P"K\W0-
M^\G_ .)(\B_\\,'_ &E[MT-_RJ_[)%_D1_\ AV; _P#=;MKV2;3_ ,E'??\
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MJ4**DE?B4 >9 ''.#UDIN7W-?=#:-J.]7'+NX):JCR/VQ-<1H@#,SVJR&Y0
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MRQH),)XE*F+42 /%"5) XD=&A9E16=V5$12S,QL !R22>  /93U#0!8T&2>
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MJI:&EJ:VMJ8*.BHX'JJNKJG6.***-2\DDDCD(D:("S,Q 4 DD >_=>Z^8_\
M\*9_Y_6&^<>8R/P0^'>YAE/B9L;<L-7VWVIBV/V_8NX,55":EIL4ZM:HV9@Z
MV%)Z>H(TY7(11UL -%2T-36>Z]U-_P"$671<^]?Y@_R![XJ88)L+T7\:)MO4
M[R(&>+,[RS>/@H9(V)]'^XG"99&L+D/:X&H'W7NOIM>_=>Z][]U[JF+^?-_,
M@H/Y:/\ +R[6[1P.<H\?WOV91R=/_'7&F1/NFW'EX)(WS$,+$L\.V,?YLF[%
M3&98*>G<AJF,-[KW7R(_B?TLGR2^4WQJ^.TE=4XN/OOO_9O2TF3HFC6:G7=.
MXL;@S/$TR20K+"*[6I=&0, 65EN#[KW7W8=O8#$;4P&#VOM^A@Q>!VWAZ; 8
M3&4PM'3T='"E/301C\)##&J*/P /?NO=/'OW7NO>_=>Z][]U[KWOW7NO>_=>
MZ^:3_P +4_C)A.N?FG\9OE%A((:*7Y-=,Y+9^[((44?<YGKRKQU.V2ED!U/-
M+@]SXNCL198Z"*Q-R![KW6E[[]U[K?\ ?^$:O\S';6.QW9/\L/M;<]'B\WDM
MP5G='Q;&6F5/XBTU+Y-X;7HPR(#4TR42YJFA#O)-&^8E"JM-ZO=>ZW^_?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6U_.._[=._S(?_%)NRO_
M 'D\I[]U[K75_P"$27_9#OR]_P#%K8/_ 'D,'[]U[J_[^;Y_*TZG_FP?$O<?
M1&]9:7:O9NWC+NWH/MH0++4;;W)'%:(RBQ>?"Y55%)E*8$&2F?RPF.K@IIHO
M=>Z^.)\COCSVU\3N\^SOCEWKM6JV7VQU'NB;:F\=OU7J"3(J305--+8+4T&0
MHYH:NCJ$_;J:2>&HC)CD4GW7NOH*_P#"53^1N_1NT\!_,P^5VS$I^Y=_89JC
MXL;"S\0:;;&VLC2^-]W5D$JWIL_N.EG>.A2WDH\2YE9A-D7AI/=>ZW=_?NO=
M>]^Z]U[W[KW7SY/^%*/_  G-W[7;]WY_,-^ 7757O'%[QJZG>/R8^/FQZ5IL
MK2Y69I*G([RVWCH2TN2ILE*S397'TL9J8:DO70130357VGNO=4=?RG?^%(/S
M6_E>X.EZCJJ2@^3_ ,8:+_BS=)=EY*IHJG;]S(SIM+<L5/7U.%I9Y'#244]+
M7X]2&DIJ2FGFGFE]U[K:]VG_ ,+8/Y<=9AZ2??/QE^;.W<^].C5V,VGC-B9J
MCCE(/D2*NK-]X&::-#;2[4D1>Y)C2UC[KW1%?F=_PM@J,OM+(;8^ WQ6RVU=
MTY2A,$/;7R9J:*H.*=F17>CVC@*JKI:VH6(N89JG,"".81M-05<0>%O=>ZU=
M_BO\0?YAW\];YBYNIQF0WUW)V'O7<$><[S^2/9<E3-@]LT,LBAJK+9(JM)20
M4M/>/&86B".T424>,HTIX+0^Z]U]:[^7-\ NE?Y:?Q2Z]^*_2--+4XG:T+Y?
M>>],B@3([GW'6+&<MN#(V>0+/6RHJQ0JS1TE+'3TD)\4">_=>Z//[]U[JJ[^
M>%_VZ%_F*_\ BJ6Z_P#W ?W[KW6@'_PCJ_[>]57_ (JEO7_W/VU[]U[KZIOO
MW7NO>_=>Z^.__P *8?\ M^'\\/\ PYMF_P#OMMF^_=>ZN\ZC_P"%JF[NJ>J.
ML>KHOY=FW,Y'UMU[A=@QYJ3M"JIVK%P^-IL<*IJ<;"F$!J!3>0QB1]&K3K:V
MH^Z]T(7_ $');R_[UL;9_P#1K57_ -KWW[KW7O\ H.2WE_WK8VS_ .C6JO\
M[7OOW7NMP7^4Y\]:[^9E\%NI/F5D>L*3IVK[/RFY<=)U]19=\['1#;^Y<MMY
M7&3DQV):H-4,9YR/M8_&9/'=]&MO=>ZL=]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6
MO9\I/^X@/X'_ /BN4G^]=L>Y;V;_ )5"^_YZE_X]:==4/9G_ ,1:YS_Z7Z?X
M>6>F'^4O_P!O)OYM_P#XF_.?^][NSW;W"_Y).S_\\P_ZLVW1G]^;_IT?MC_T
MI[3_ +LVU]5%?SZ?^WAV\?\ Q&NU_P#W7GW(/M#_ ,DD_P#->3_CL?6=O]V+
M_P!.JMO^ECN/_5X=#?\ S^/^/P^&'_BM$/\ [E)[)/9GX+S_ )J1?X).HV_N
MNO\ <#FS_I?'_JV_1E._/^R!?Y)'_B;^O_\ W']A_;/^2IOG_/-N'_5P=0_[
M8_\ 3S_=[_I3[]_U=Z-YG?\ N()V9_XJ-+_[CY;V1Q_\JJW_ $L/^L*]03MO
M_B+=W_XM*_X;;KW\DS_C\/YCW_BW.0_]RLS[][@_!MO_ $KX/\'7O[Q'_<#D
M+_Q5K?\ ZMVW5 _\P7_M[QVA_P"+![7_ .M& ]RURI_RJP_YY[K_ (]-UU!^
MZU_TX7;_ /I1[G_Q^^Z'S_A0[_V75M/_ ,5RP'_N\W1[2^S?_)+D_P">I_\
MJU#U&?\ =2?].UNO^E_>_P#:%MO1J/D/_P ?'_PFS_[4G6?_ %OZG]D.S<.9
M/^HC_M<ZA3VH_P!Q??W_ )J\P?\ '.9NC&] _P#;^#^8A_XJO-_[C]5^R+=_
M^51L?^>IO^/7?41^Z/\ XC)R-_XL@_ZN<R]/?_"<7_LD?N?_ ,6-J_\ WF=M
M>]>\O_)3B_YY4_ZNS=(/[VK_ )7S:O\ I00_]W'<>J!]R_\ ;Y3<'_C36K_]
M^I)[EH?\JQ_U*_\ M4ZZ@[5_XC[#_P">]C_\EL=/?\Z__MYM\E__ "3/_??[
M4]Z]LO\ DAVW_-[_ +2)>D']W;_TYSE__J:_]WO<NM@SY)_]O?\ ^5K_ .(A
MW+_[H]P^X1V+_E7]T_T]I_U>'7*KV@_Z<+[C?]+/;/\ M-L>@>^.'_9:?\\G
M_P ,:N_]PLY[4[[_ ,DG9OMN/^KL?0]]W/\ IW?L_P#\]:?]7[/HWG\B3_MW
M/UO_ .'SNO\ ]W=3[+_<_P#Y+=Q]D/\ U9CZ@W^\M_Z>UN'_ #R;;_VAQ=:U
M/\OK_M[QU?\ ^+![H_ZT9_W,7-?_ "JQ_P">>U_X]#UUZ^]+_P!.%W#_ *4>
MV?\ '['KW\P7_M[QVA_XL'M?_K1@/?N5/^56'_//=?\ 'INO?=:_Z<+M_P#T
MH]S_ ./WW5_&=_[B"=F?^*C2_P#N/EO<2Q_\JJW_ $L/^L*]<OMM_P#$6[O_
M ,6E?\-MT1[X\_\ 9&O\]3_Q)6ZO^ALS[$.Z?\E'8O\ FA8_\?'61ONI_P!/
M ]F_^E=M7_:KU:[_ "=O^W4O1'_:DW[_ .]SN_V%/<S_ )+ES_S9_P"K$76$
MWW_?^GV[U_S5V;_NS;7UJ]?R4/\ MYM\:/\ R<__ 'W^Z_<[^YO_ "0[G_FS
M_P!I$779W^\2_P"G.<P?]2K_ +O>V],FVO\ M\IM_P#\::TG_OU(_>S_ ,JQ
M_P!2O_M4Z7[K_P"(^S?^>]D_\EL];"?Q[_[B$OG3_P"*KXC_ -UG3GN)-X_Y
M5"Q_YZG_ ./7G7*_W4_\16Y._P#%DNO^TCFKJI3XZ?\ ;A#Y_?\ BQNV/_=U
MU?['N\?\K?8_\\K_ /';OK.7W8_\2?Y*_P"E!N'_ &B<Q]7\;?\ ^W',_P#X
MS*R?_OMJOW$I_P"5G_ZFG_:UUR^W+_Q) ?\ GPH/_)@CZH'_ .$\7_9=6[/_
M !7+/_\ N\VO[EKWD_Y)<?\ SU)_U:FZZ@_WK?\ T[6U_P"E_9?]H6Y= '_+
MZ_[>\=7_ /BP>Z/^M&?]JN:_^56/_//:_P#'H>I,^]+_ -.%W#_I1[9_Q^QZ
MN:^.'_9:?\\G_P ,:N_]PLY[BW??^23LWVW'_5V/KGO[N?\ 3N_9_P#YZT_Z
MOV?1#<[_ -P\FS/_ !9>7_W?9;V-(_\ E=&_YI_]JB]9.[;_ .)6W?\ TH5_
M[0+;J_CY5?\ ;HKL?_Q3*E_]YVC]Q+R[_P EJW_Y[(_^KPZY?>R7_3]-O_\
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MI?\ A/[_ -SV?^(-Q_\ \G?;7O1_Q"_TT_\ UAZ*/[TO_G3?^EO<?]J77O\
MNW0_\KE_\NWOW_.[?[7_ +4NO?\ L6?_ %*/^\-T<WY'_P#9:?\ (V_\,:A_
M]PL'["&Q?\DG>?MM_P#J[)UCS[1_].[]X/\ GK?_ *OWG3I_PI"_[)NZ _\
M$WS?^Z'(>UWLU_R4IO\ GF;_ *NQ=,?W1_\ RN&]?]*=?^TVWZ(OLK_N'4[=
M_P#$\TW_ +V.V/8DE_Y75/\ 2'_M$?K)'F'_ ,2RVS_I3R?]VC<.@U_E3_\
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M +LNL_:[>_\ E4+'_GI/^&[Z8]_/_$7^2O\ I<0_]6.8>JS?^%#O_9=6T_\
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M+=_^51L?^>IO^/7?41^Z/_B,G(W_ (L@_P"KG,O3W_PG%_[)'[G_ /%C:O\
M]YG;7O7O+_R4XO\ GE3_ *NS=(/[VK_E?-J_Z4$/_=QW'J@?<O\ V^4W!_XT
MUJ__ 'ZDGN6A_P JQ_U*_P#M4ZZ@[5_XC[#_ .>]C_\ );'3W_.O_P"WFWR7
M_P#),_\ ??[4]Z]LO^2';?\ -[_M(EZ0?W=O_3G.7_\ J:_]WO<NM@SY)_\
M;W_^5K_XB'<O_NCW#[A'8O\ E7]T_P!/:?\ 5X=<JO:#_IPON-_TL]L_[3;'
MH'OCA_V6G_/)_P##&KO_ '"SGM3OO_))V;[;C_J['T/?=S_IW?L__P ]:?\
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MF3_I<1_]HYZ%'Y#?]D:_R*__ !)6U?\ H;#>R;:_^2COO_-"^_X^>@3[5_\
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M'92E@:BFF4 3@JCMXE0)]KEDGVN]CE),2>#)'J)HMP950::GXFC,E0.*BIX
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MQPQ"*/29W?R<:&]U[JPO^=C_ "IZS^;U\5]G?'/'=]5?Q^K=F]TXWMV+<O\
M!7W!15XH<3F\4^-KL8F6PKNI&9^XBF%2?%+ H,3Z]4?NO=:O>/\ ^$,^3DA9
MLK_,YH:.H$I"18_IN2I0I9;,9).TJ1@Q:X*Z"  #J-R![KW1G<'_ ,(BOB)3
MI,-R_-3Y'Y:1EC%.V#P^V,<$(#>4NM1!E#(')70 4T6-S)J!7W7NA&A_X1/?
MRZ5BB$_R=^:LDXC4320Y'8J(SV&IE1MCR%%)Y"EF('!8_4^Z]TVY3_A$S\ )
MO!_!?E7\P\?IU?<_Q2;959KOIT:/%M2A\>FS:KZ]5Q;3I.KW7N@$WO\ \(=^
MH:^GA7K?^89V1M.J6N:2HFWOU[B]PQO3%6TQ)%0;JVRT<X8J3*9'4@$"%2P9
M?=>Z#_:O_"(/.;;WSM?.G^9I4?P; [GH,Q/7[5ZRFPV=6&FJ89Y9,76_Z0,E
M%C,FBHQI:DI4+!,(YC&^DQGW7NM_3W[KW7O?NO=>]^Z]UI7_ #L_X1U=<?*W
MY==Q?(?IOY=T?QAZ_P"W\^V^:KJ2GZ[&YHL9FZU5ES+X^HBWEMB*''9'(&:K
MCI_#_DK3/#&S0B-8_=>Z@[3_ .$1WPPHXH!OKYD?)[<<ZL34R;3H-J85''B4
M 1I68W/F,B>[DEGO&1'8,#*?=>Z?<[_PB6^!=13LNV?EE\N\15&GD5)LZ=F9
M&,2E?V7,=/MK%L8T;ETU@N.%DC//OW7NBL;R_P"$-N%GR61JNOOYDV4Q>';P
M_P (P>\NJ8J^I2T<2U'W.5HNP<;%+JE$DD>C'1Z4*0MK*M.WNO=;;W\J[X(C
M^6G\%>E/AD>S:CN";J=MP557O^7'?PB.LGW!N;,;DF6FQ?WF1-%34\F6,2HU
M3,S%&E9P9"B^Z]U85[]U[KWOW7N@\[4ZCZL[SV-G.L>Z.N=D=K]=;FIC29_8
M_8F+HLQBJM+$ 3T-?#/3NR7NC%=2-ZD*L ??NO=:M?S-_P"$>?\ +F[^J<UN
MGXT[K[*^&>]<F]361XK;+_WKV:*JHD,QD;;N;JHLI30I(Q$=/09JBI(8CXX:
M=$5 ONO=:[/>?_",7^9/L3)5DG27;?QH[[VU''JH))\GE=J9J5M3C3+C,GC:
MO%0^@*01EY!<LIL%#-[KW1>.JOY3O_"I#X>Q8O#=$; ^8W3N&Q&3.5H]L]*=
MMX)<(9HIUJY/N,5M[?D^'JX9YY"TL,\,D-46D61)09%]^Z]T9VGS?_"R_)T-
M-M>.'YUQ05!CI8JFHQ^UJ2<6=74R9B6FAJ8AJ4:Y)*E05NKL4)!]U[H,MS?R
MH?\ A5M\Q:C)8#N^H^5V9V?O-9J/<U%W;W9B*?;2T\BR)+#/MH[WEC%%+RGV
M]+BW0Z]1B\;,_OW7NA4Z=_X18?S%-V9&-^Y_D!\5>GMNO3,TDFWZS<>Z\PDP
ME153^'1X+"XPQ-#Y',@RNH,(T\1UN\7NO=6P].?\(B/BYB,?3#Y _-GOWL'*
MZM58W3F#V[LZG +.?'$,VF^I"50JOD8C459_&H<(GNO=6A[*_P"$H'\DK:M)
M!39WXX;_ .RIHM7DR&]>Q-\P32WU6UKMS.8" :-0MHC3](U7]6KW7NKPOC3\
M7^A/AYU'@.A_C3UKA>INI-KU%368/9>!EK)H(9JV9JBKF,U?4U=7--4SNTDL
MDLKN[LS,2Q)/NO=5>?SR/Y/V9_G%=)=,=0XCY&-\?!U-VI/V14557M^3<E#E
M/-B*K&)'+0QYO!M%5TGW#&"?RR!8Y:F/QWE#+[KW6O3L7_A#CLFCR J.S/YC
MNZ=QXM\=I.)V+UA282HCJR\+:_XAD-\Y^.:F2,2IH^RB=V:.7R((VBD]U[HT
M&-_X1-?R^8H'7,?*?YDUU29BR38VIV321B.RV4QR[0K69PP8EM8!! T @EO=
M>ZC9C_A$Q\!)XT&W_E=\P,9,$D$CYB39=<I8A?$56#:V.*JAOJ!8EP0 R6)/
MNO=%DWM_PAPV?5UQGZY_F0;EV_C4QP5<5O;JZES$\E6#(2YR%!OS!QPTTBF-
M0GV<KQE7?R2:EC3W7NKI_P"15_(4R'\FK=/R,W;E_E!2_(.K[XV_MS;M-C\;
MM)]L0XN/!5.6J9)I7EW'GFKI:MLDJH M.(%B<DS&8"+W7NMC#W[KW7O?NO=$
MH_F,_#N'Y_\ PE^0OP]F[!RG59[PV=#M^DW_ (B*:IDQM31Y*AR]))-24]=C
M9*Z@EJL?'#6TGW,2U=')/32,8Y64^Z]UIC8[_A#1FI3+_%OYFN+HE '@..Z>
MEJBQYU:Q+V=1Z .+6+7YX%N?=>Z,%L[_ (1 _&^AH\8G8'SN[NW/7Q4S+F*G
M9VT\#@H9YO5I>F@K<AN)Z2,>FZ/+4L;&TBW&GW7NA?H/^$3?\O..F1,I\I/F
M;65@)\D]!6;(IHB+G3IADV;5.I"V!O(;GD 7L/=>ZX9'_A$U_+WEIPN(^4WS
M*H:KR F;(U6R*J/18W7Q1;/HVU$VLWDL.?2;\>Z]T N_O^$//2V1A"]7?S!N
MT-GU'\2\IEW]L+$[D3[31(/ (\=N7:C"I\A0^?64TJR_;W<.GNO=,G2__"*W
M.]0]Y]2=J#^9%%F<3UAVEM_L)Z7$=838C*5,>%RE'DGAI*O_ $@Y&+&UDOVQ
M2&HT5 @<K,8I-/B/NO=;X_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HD?\RO
MJ'L3Y ?R]OFST=U'M[^]O:7;OQ<WOUSUYM?[NAH/XAF<QMZOH<=1_>Y.IHL=
M2?<54R)Y:FHA@CU:I940%A[KW7S=ND?Y('_"IKXSX/,;8^.&R?DK\?MM;ARP
MSV?V]TC\A]C;4H:ZN$*4XK:RDP/:U!3U-6*>)(A-(C2>-%35I4 >Z]T-7_#:
M?_"R3_GXWS__ /2L<%_]N3W[KW7O^&T_^%DG_/QOG_\ ^E8X+_[<GOW7NO?\
M-I_\+)/^?C?/_P#]*QP7_P!N3W[KW7O^&T_^%DG_ #\;Y_\ _I6."_\ MR>_
M=>Z]_P -I_\ "R3_ )^-\_\ _P!*QP7_ -N3W[KW7O\ AM/_ (62?\_&^?\
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M&%-1YO#QYM?K]B(>YE\+#]W^'!X?@?3ZM,FO1X?AUKXM-5,UI2OE3'4_6_\
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M@Y"NEQ9JL;+DC5&=,,T>,CACC3[MM J8ZDBRZF;FZVXYLN+B:TG98]5FD21
M!J,(2"NOO))-,T*_*G0WYA^][OW,F\\L;W-:;>LW*L-O!8HBW'A3I;>'H-P&
MN&9B?#&KPVC!J: =&+^,GQEV=\6/CMM#XV;)SFYL]M#9E)F*/'9O=3TLF2D7
M-9;)9BH,STE+24I,51E)$CTPK:-4#:F#,Q=ON]2\P7;WDP57DTU" A1H14%
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M0K3O)MV .)::5],DUG!*%#>YY_O+K<HMT9(1+#&8U4*_AE2)!D&0M7]4\&'
M8XUEKF/[]/,W,O/VU>X<UCM:W^T6<UE!;I'=BTDCGCOHF:16NVE+@7\A!651
M54J#1M1QZ+XR[.H?B8_P_CSFYGV"_0M1\?#N-WI?XQ_"JC!28!JSR"E%%_$%
MI93(&^W\/E )A*>CV'?WU+]?^\:+XGC_ %&FAT:_$\2E-5=-<4U5IYUSU ,_
MO#N%QSR.?3#;B]&])OG@ 2?2_4I>+?".GB>)X6M=-/$UZ,:Z]W1./A3_ "C^
MB/@SV[D>X^M>P^V]T[@R>QZS8<V-WS/AI:-:6MJ\?622JM!AZ"<5"R8Z,*3(
M4TL]T)*E1%S-S_><U6ZV]PD*JL@D!C5PVH*R_BD<4HY\O3/4_?>(^_3S-]Y/
M8H]@WBQVNV@CO(KU9+..[64R0Q3Q!29[N==!%PQ(T@U"T(%04=TQ_):^/'2'
MR4V_\G]M]F]SY3>NW=Z5^^*7!YNHP;8MZG(I6)-%)'!A(*OP(*U] $X8$+J9
MK&[FX>XE[N6W_NYTA$>B--2J^ND94C)D(KV"O;ZT Z/_ '!_O">:_<;D^;DN
M[V_:8[.>T@LVFACO!<B.W,15@7O'CU'P5U5CH:F@&*&AV/\  CK'8?:?RU[9
MQ>[M^5>=^86(FP^_L?7R8\TF-CFBJXBV'6.@CFC=5K'_ .!,E0+A>+7!(+OF
M&:\M[:V94"VNOPR VIM;!CJJQ!RN* ?GU#',GWFMXYGV3EG8I[:R6#E:59;)
MT6<2SD-$]+@M,RD5B']FL>"?D0$%7_*BZ/K/A7B_@W)V!VJO6F)WZW8$&Z4F
MQ'\=:J:KJ:TPO*<2:#P>6I8<4H?0%&J]V)HO.]TNZ'=M$7C$:=.E_#IX8CX:
M]7 ?Q<?ECH>P??<YDM_<23W)%EMO[PELQ9&W*77T0C$4<.H+]5XNK3&#_:TU
M$FE,=''[#^.^U>R/C7F_C!E\SN&BV;GNKHNJ*O.XUJ9<FM#%114(J(WEIY:4
M59BB#7,+1ZB3X[<>P[9;B]C=)=H%+I(LH!KI+*VH T(-*CU!^?4 \J>ZE[RC
MS=#SC;Q0/=P;B=R2&02&W,QF:;2P5U?1J:E X:GXJYZ)Q\.?Y471_P *<GVE
ME>N>P.U=S3]L;"?K_.1[VFQ$J4]*\AD\U)]AB:$K."2/W#(EO[/L1<S\[W7-
M8C%PD2^$69?#5Q4M2M=3O_#Y4ZG[W_\ ON<R?>)AVZ'=[+;;<;9>"]A-FETI
M>32%TR>-=3U7'X=)^?24^'W\G/H#X8=UXOO/KSLCN+<NY<5@LA@(<5O2HPLE
M"T61@\$KLM#AJ&H\B+RA$H%_U*?:KF3W"O.:+?Z:=(576KUC5PU5!'XI&%,^
MG1Y[]_?[YI^\+R[)RWNUAM5O;R303F2TCNUF#P-J4 S7<RT-<]M?0CH;]F?R
MZNI]D[%^96P<=O/L2JQ?S9SN=S_8U76RXTU&+EW!'D8ZM,(8\<D<<<2Y*3PB
MJ2I(*IK9^02F?FJXN)K29ECU620I$ &HPA(9=??4DTS0K\J=1OS!]ZW?.8MR
MY4W2:UL5DY1ALH+!46XT7"6+0-&;D-<$L6,"Z_",0()TA<4"K>_\H_HC??P\
MZ:^%N3[#[;I.N^D]\9#?FW-S4$^&&:JJK(U6?JY8JV23#R4+4Z2;BG""*FB?
M3'#=R0Y<SMN?[RUW*7=%2$RS1B-E*OX84",8 D#5_2'%CQ..%!ORY]^GF;EK
MG[=?<.&QVMK_ '>SALI[=X[LVD<<$=C$K1JMVLH<BPC)+2L*L] *KI./\L_C
M+L[Y@=%;MZ"W]G-S;<VMO"KQM9D,OM!Z6/(1MB\E292$0O6TM93@23TB*^J%
MKH6"Z6LP#NQ;U+R]=)>0A6>/50."5.I&0UTLIX,:9X]0#['^\.X>PW,MKS1M
M<-O/<VBW"QQ70D:!A<6\MLVH0R0OA925HX[@*U%02A_&K^4WT9\8.J/E'U%L
MOL#MC.X'Y7=>KUQOC([GGP[UF/HUQNX<8)L2U)B*6&.I\.Y*AKU$=0FN.$Z-
M(=7$6\\_WF^3VUQ*D(:UD\2,(KA6;5&W=61B16,<"///I/'N]]^/F;WEWOEW
M?MQLMLAGY:OC?V:6T=TL4\IN+&XTSB6ZE8IJL(Q2-HVTL_=4J5B?"G^4?T1\
M&>W<CW'UKV'VWNG<&3V/6;#FQN^9\-+1K2UM7CZR255H,/03BH63'1A29"FE
MGNA)4K[F;G^\YJMUM[A(559!(#&KAM05E_%(XI1SY>F>GOO$??IYF^\GL4>P
M;Q8[7;01WD5ZLEG'=K*9(8IX@I,]W.N@BX8D:0:A:$"H/MD?RC^B-B?#SN7X
M6XSL/MNKZ[[LWQC]^;CW-7SX8YJEJL=58"KBBHI(\/'0K3O)MV .)::5],DU
MG!*%/7//]Y=;E%NC)")88S&JA7\,J1(,@R%J_JG@PX#'&ON8_OT\S<R\_;5[
MAS6.UK?[19S64%ND=V+22.>.^B9I%:[:4N!?R$%95%52H-&U*SLS^5]TQVCM
MOX6;9S6^NSZ"D^#M'!1=:SXN;%"3*+3G;A0YSRXN592?[M4^K[44H_<FM:Z:
M$MISI=69O2J1'Z_5XU0_;K\6NBCBG]J::M7 ?.I'R?\ ?*YAY,N^;;NWL]N=
MN<'D?<!(ER5MS)]?7Z;3<J5_Y*$E/%,OPI6M&U&!^9'Q(V+\UNF:CI'L7<.[
M=L;;J=S4&Z),ILIZ..N$V/,IBC#5U'70")S*==XBW LP]E7+^^R\N72W< 1G
M4, '!*]RE372RG@?7J+O8'WSW/[O',*\Q[3!:W%PMO-;B.[65H=,X4,2(986
MJ-..^GJ#T6/J/^5%T?TY\6^]OB?M[L#M7);&[_KTR&Z=P9F;$-EJ-UBHX;8^
M2#$P4:J4HD_SU/*;EC>U@#C<^=[K=;^'<9$B$D 4(JJX0Z'9QJ!<GBQK1ACJ
M8N>_ON<R>X'.FS<\7=EML=[LB:+:"%+H6LHURO\ JA[IY":S'X)$P!\R9_PU
M_E8]*_"7_2[_ *-]^]I;G_TR;1AV=N#^^\V)E^V@A^[T2T?V&*H-,Q^\>_D\
MBFRV46-Z\S\ZW7-GA?4)$O@EBOAJXKKTUKJ=_P" 4I3SZ3?>!^^ES%]XS]U_
MOBRVVW_=5R]U!]&EROB._A5$GCW,]5_16FG2<G)Q3W_#6/2O^R1_[(E_?WM+
M_1E_>[^^/]ZO-B?X]Y_XK_%_%Y?X5_#_  _<>G_@)J\?&K5Z_?OZZW7[T_>^
MB+QJ4TZ7\/\ LO"X:]7#/Q<?ECKW_!I<Q?ZXW^N9]%MO[Q^F^E^FT7/T6CZ;
MZ6NGZGQ=6C/]K35FE,="AOCX$=8[\[3^)7;.4W=ORDSOP]Q$.'V#CZ"3'BDR
M4<,5)$&S"R4$DTCLM&G_  &DIQ<MQ:P!;:<PS6=O<VRJA6ZT>(2&U+H8L--&
M &6S4'\N@7RW]YK>.6-DYFV*"VLF@YIE:6]=UG,L!+2O2W*S*H%93_:+)@#Y
MDR?G+\$>L_GKL;9NPNS]U[ZVGBMD[K?=^.J]A28^*HEJ'HYJ+QS-D*#(1F$1
MSL;*BMJ ]5K@N\L\SS\J3M/;K&S,AC(D#$4+*V-+(:U4>?Y=-_=O^\MO/W8]
MRNMTV6VLKF6[MA:R+>K.T:QB5)JJ()X#JJ@&6(I7%<@(\5_*NZ3Q/PDW+\%(
M-^]IR=9;HWC'O2LW5+-B?X['41Y/'Y4112C%#'B$SXY%.JE9O&SC5JLP7-SM
M=-N@W;1%XP%-.E_#_LS%PUZN!K\7'Y8Z'-[]]3F.^]QK?W+:RVT;C;VK6J6P
M2Z^B9&MI[6I4W)EU:)V.)0-0!I2H+%\=_P"4?T1\;>HOE!TYM#L/MO-;?^5>
MQZ78>]\EN2?#/64%+2TF=HTEQ34N'I8$J&CS\Y8U$<Z:HXK( '#J-YY_O-\N
M+:XE2$-:R>)&$5PK-JC;NK(Q(K&.!'GGT,_=?[]/,WN]OO+N_P"X6.UQ3\MW
MDE[9QV\=VL4TDDMG*5G$EW(Q0&R0 1M&:,^:D$>WO_*/Z(WW\/.FOA;D^P^V
MZ3KOI/?&0WYMS<U!/AAFJJJR-5GZN6*MDDP\E"U.DFXIP@BIHGTQPW<D.7];
M<_WEKN4NZ*D)EFC$;*5?PPH$8P!(&K^D.+'B<<*>Y<^_3S-RUS]NON'#8[6U
M_N]G#93V[QW9M(XX([&)6C5;M90Y%A&26E859Z 572/6^/@EUGOSYH]7_.')
M[KWU2=D]4[2_N?@]K4$N/&#J*?P9RG\E7%)025[3:,_.;QU4:WCB]-@X<IMN
M9Y[7;9=K58S%-()&8AO$!!C."&"T_2'%3Q.>%(QY<^\KO'+/M[N/MQ#;6;;?
MN=U]7-<.LYO$D#V;TC99UB"UL8\-$QHSYR-*3^>/\N+J/^8%_HK_ -*>].Q]
MH?Z)/XY_ O\ 1_-C(ON/X]_!_NON_P"(XS(ZO%_!8?%X_';7)KUW72KY6YRN
M>4?%^F2)O%T:O$#FGAZZ4TNG\9K6OET??=G^]KOWW6_WE^Y+2PNOWG]'XWUR
M7#Z/HOJM'A_3W%O35]6^K5JX+2F:ACNS^4?T1N_X:=9?"2O[#[;I^N.K.S:C
MM/";GHY\,,W/6U']X==/52/AWH&I1_>.HL(Z6.3]N&[FSZU=MS_>6NY2[HJ0
M^+-&(V4J_AA0(Q@>(&K^D.+$9..%!AL?WZ>9M@]P=Q]QHK':VO\ <MO3;IK=
MX[LV:0Q_0@-&HNUE#_XA'4M*R]S]N5TOO4W\J[I/I_XE]V_#[;^_>T\CL'O3
M-R9S<VX\Q-B6S%))+3XNF9*&2#%042H(\3$1Y:>4ZGD))!4*GW/G:ZW6_AW&
M1(A) $"*JN$.AV<5!<GBQK1ACHLYY^^IS'S]SSM'/UW9;;'?;-"D-O!$ET+6
M14DN9090]R\A-;EJZ)$% N :DJOL3^6[U'V1UM\0^L,OO7L:BPWPUR.'R77M
M=CI<8*K)282"@IZ89EI<;)%(DB8]#**9*8DLV@H+ );;FNXMIKN=5CU7B2I*
M"&HHF8LVCO!!%<5+?.O1'RK][7?>4MWYHWF"TL'FYKCNX[Y)%N#';K>/-))]
M.%N%92#,='B-*  *ALDB=2?##KZC^9V4^;L>YMY-V/ENMUZQGVN\E#_!%HEC
MID$Z1BB%?]U_DRFYJ3'RW[?TLC;?IFV\;;I3PQ-X^JC:]>DI2NJFFA_AK7SZ
M!\_W@=UN/;Z/VY-O:?01;@=Q%P%F^L,Q,ATEO&\+P_U#CPM6!W= C\YOY772
M_P ]]X[(WIVAOOM#:60V)MF;:^+I=A38F*&6&>J:K>2H&1Q60<RAVL-#(NGZ
MJ3S[-N5^=KKE)9%MTB;Q"I;Q YII! II=/7-:]2-]VW[YO,7W8;"\V_9;/;K
ME+VX2XD:]2Y=E9(_# 3P+F  4R:@FOF.H_=O\K'I7O;XQ]"_%?<^_>TL5LCX
M^>#^ZN>P,V)3*UGV]!-CX_XA)48JHI&O#.S-X8(;N 19;J=;5SK=;/?3;A&D
M1DGUZU97*#Q'$AT@.#Q&*DX_;T[[<_?2YB]L^<MZYVLK+;9+S?/$^IAG2Y-M
M%XDZ3GPA'<QR#N0 :Y'[:UJ<]0*3^5%T?1_"O*?!N/L#M5NM,MOU>P)]TO-B
M/XZM4M735HA248D4'@\M,HYI2^@L-5[,+-SO=-N@W;1%XP&G3I?PZ>&8^&O5
MP/\ %Q^6.E,_WW.9+CW$C]R39;;^\(K,V0MPEU]$8S%)#J*_5>+JTR$_VM-0
M!I3'0O[X^!'6._.T_B5VSE-W;\I,[\/<1#A]@X^@DQXI,E'#%21!LPLE!)-(
M[+1I_P !I*<7+<6L 5VG,,UG;W-LJH5NM'B$AM2Z&+#31@!ELU!_+H!<M_>:
MWCEC9.9MB@MK)H.:96EO7=9S+ 2TKTMRLRJ!64_VBR8 ^9,GK#X(]9]5?,7N
M+YJ83=>^LAV+W5M2?:&XMLY23'G"TM//48&H:2BCBH(JY9E;;\ !EJ95M)+Z
M;E-#MUS//=[;%M;+&(H7,BL WB$GQ.)+%:?JG@HX#/&K?./WEMYYUY VKV[N
M+:R2PVFY6Z@N(UG%Y)(B7J4D9IVB*TOI/AB4]J9P=0#?-;^4?T1\YNW<=W'V
M5V'VWM;<&,V/1[#AQNQI\-%1M2T57D*R.5EK\/7SFH:3(R!B) FE4L@(8L;<
ML\_WG*MNUO;I"RM(9"9%<MJ*JOX9$%*(/+USU)GW=_OT\S?=LV*38-GL=KN8
M)+R6]:2\CNVE$DT4$14&"[@70!;J0-)-2U210#WR2_E']$?)SK;XR]8[S[#[
M;P>%^+764?5FR:[;$^&2JKZ*.@PN/%1E6JL/51/5&+!PL3!'!'K>7T6*!/;-
MS_>;'/<W$20EKJ3Q) ZN55M4C=M)%(%9#Q)/#/K[VC^_3S-[-[OS#O.W6.US
M3<Q[@=QO$N([MHX9FFNY], BNXF":KQQ21I&HJ]U029>]/Y3?1F^/A=U'\'L
MEV!VQ2];=.=A5/8^W]TT,^'&<J:RJGW/4/#62R8B2@:F5]U5(41TL;VB@NY(
MD,GK;G^\M=REW14A,LT8C92K^&% C& ) U?TAQ8\3CA1GE[[\?,W+?N%N?N/
M#9;8VX;K8QV$]N\=T;..*--O0-&JW2RAR-MCJ6E9:L_;E=(]=@_![K;L;YE]
M0?-O+;IWQ1=C],[';8>WML8Z2@&$J:5O[QWEK8Y:"2O:H_W\M1S%51I^W#Z.
M'UE-MS-/:[;+M:K&8II!(S$-X@8&,X(8+3](<5/$YX4C'E?[QV[\J>WVZ>W,
M%O9O8;M>"]GN)%F-Y'(/H#IC99EB"?[KX\-$Q[GSE=/OC;\'NMOC'W+\FN[-
MF;IWQG-Q_*7?$F_-[8O<\E ]%054F5S66,6*6EH*6=*<3YR9 )Y9W\:1#7J#
ML_MYYFGWRWMK>58PMK'X<90,&9=,:]U68$TC' #-<>GO=S[QV[^\FP<O<N[C
M;V<,'+EF+*SDMUF6::-;:TMM4YEFE4OILT-8UC&IFQ0@ H?RJ_DI_'7Y;]][
M\^0F^^S>ZMO;K[ _A?\ %</M*IP4>/A_A6&QV$@^W2LP=94CR4V-C>37,]Y&
M<KI72JB'8O<R^Y?M$LX8X&2/50NLA8ZW9S73*HXL:8&.IX]D_P"\0YM]B^6+
M+E7;-OVB>VL?J/"ENH[QIV^INY[QM9BO8DP]PRK1!V@5J:DBI\U_Y5W2?SGW
M'UWN7LO?O:>UJSK;9S;+P\&Q9L3%'/3M.:@RU(R&*KV:;5P-!1;?V2>?99RO
MSM=<IK(MND3>*5+>(KFFFH%-+I_%YUZ!'W=OOJ<Q_=JM+ZSV:RVVY6_NA=2F
M]2Z=D=4T )X%S  M..H,:^?3_O7^6CT_OGJ_XC=4Y+?'9-+A/ASG<?G^OLA0
MRXL562EQII3 F9:3&20R1O\ :+K%-'3$W;2R\636_-EQ;S7<ZK'JO$E24$-1
M1,26T=X((KBI;YUZ*N7OO>[]RWO/,^]PVFWM-S5#<07R.MQX4"7/B:S;A;A6
M4CQ#I\1I *"H/0M4GPPZ^H_F=E/F['N;>3=CY;K=>L9]KO)0_P $6B6.F03I
M&*(5_P!U_DRFYJ3'RW[?TLB;?IFV\;;I3PQ-X^JC:]>DI2NJFFA_AK7SZ!$_
MW@=UN/;Z/VY-O:?01;@=Q%P%F^L,Q,ATEO&\+P_U#CPM6!W=0/A]\(.N/AC_
M *8/]'NZ=[;F_P!,^^O[_P"XO[Y24$GVU7_E%XJ+[&AHM-/_ )0W$OE?@>OZ
M^[;YS!-OW@^,J+X$*PKH#"JKP)U,V?6E!\NE/OQ]XO=OO _NO]ZV]I;_ +IL
MA8P?2+,OB1#11I/&FFJ_8,KI7/P]#OUAT_@>JLOW%F<)DLOD*GNKMF?N#<4>
M4:$I2U\^#P. :FHA%#$RT:TNWX) )3+)Y9)3Y-!1$+[J^>[2)&  AC,2TK4J
M9)):FI.:RD8H* 8K4F-><>?+KG6WVJWN(XD7:=L7:X#&'!DA2\O;W7)J=@9/
M$OI%JH5="H--0686?:+H#]>]^Z]U[W[KW7O?NO=>]^Z]TR[CVWM[>. S6U-V
MX/$;FVQN/&387<&W<_3PU=#74=3&T512U=+4))!44\\3%'C=65E)# @^W(I7
M@8.C%64AE920RL#4$$9!!R".'1AM.[W6P745]8S2V]Q!(DT$\$C130RQL&1T
M="K(ZL 592""*@]5S;:_D]?R[-J;_I^QL7\=\5/F*/)MF:'#YG+9VOPL-0S.
M^H86MR<^-EB5G]$$L,E/'9/'"FA;"V?W WBY@-N]RV@J%-%C5R!3BZH'S3)U
M5.:DU/66.\??V]U]\VMMHGWV40O&(GEBMK*&[>, "AN8K=)@Q [G5UD:IU.=
M1K9A'&D2)%$B1QQH(XXXP JJ!8*H%@  + #Z>P=UB S%R2222:DG))/0;;"Z
M>ZZZQSO9>Y=D;>.%S7<&\O[_ /8E8:NNJ?XAEOM*>A^Z$=74SQ4G^2TL2>*F
M6&'TZO'J+$JKB\ENEC20U$2>'&* :4U,], 5[G8U-3FE:4Z%O,W/FZ\X6VWV
M>XS^+#M=I]%8IX4,?@6WBR3Z*Q1HS]\KG5(7?--5  ",;R_D\_R[NP-W[JWY
MN[H.JS&Z][;DKMW;GR\F[][QM59')54M96U+1P[DCAC:>IF=RJ(J*6LJJH
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MB3[UU[KG##-4RQP4\4L\\K!(H85+.S'Z!54$DG^@]^Z]T8/K[XO]M;]F@E;
M3;4PTA#29G=*O3#03]8J5A]W,6%RI$8C/%Y%!!]U+ =6"D]69]/=#;+Z=H6.
M)B;*[DJX/#E-TY!5$\JW!,4" LM+3%@#XU)9K+Y9)"JD-EJ].!:=#;[KU;KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[K')%%,ACFCCEC;ADD 8'_7!N#[]U[IJ
M?;FWI&+O@L,[M]6>E@)/^N2E_?NM4'7'^[6W/^>?PG_G)!_U[]^Z]0=>_NUM
MS_GG\)_YR0?]>_?NO4'7O[M;<_YY_"?^<D'_ %[]^Z]0=>_NUMS_ )Y_"?\
MG)!_U[]^Z]0=>_NUMS_GG\)_YR0?]>_?NO4'7O[M;<_YY_"?^<D'_7OW[KU!
MU[^[6W/^>?PG_G)!_P!>_?NO4'7O[M;<_P">?PG_ )R0?]>_?NO4'3A38^@H
MO^ =#1TGIT_Y-$D? _'H4<>_=;ZE^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH&3
MRN,PM#/D\SD:#$XVE4/59#)S1P01@D*#)+*R1H"Q %R.2![]U[HL>_/F'T_L
M^.:#$9&HWSEDNJ4>W%_R<-^/)7RA:?0>?5#YS_M//NX0GJA<=*'XY]L;M[DP
M.Y=U[@PV*PF(BW!_"]M4V/\ ,7,<<*//YI97(G*M(@#JD8+!QI%K#3"G6U->
MC%>Z]6Z][]U[KWOW7NO>_=>Z!*M^1G2^.W8VRZS?6.ASD58<=47CJ#2Q5 ;2
M89:X0FCC=6NK$RA48%'96&GW;2>JZAT-H((!!N#R"/=>K=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=0\AD<?
MB**HR65KZ+&8ZD3R55?D)4AAB6X&J261E1%N0+D@7('OW7NBS;]^7W3VS8Y8
M<9EI=\9901'1;7 D@O8Z3)7OII0A(L3$TSCZZ+>[!">J%P.G/XW]P[I[IQ6[
M]QYS"XO"XBASZ8K;\&.\S, (%EGCGFD;3.\8EB.M$C'J/H M[\PIUM37HR7N
MO5NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z3>[=G[:WUA*G;F[,33YK"U;I)/15
M!=1JC8.CJ\3QRQNK#AD93:XO8D'8-.M$5ZH6WOCL*F_]T8G944T^!3=-5C=M
M1!FF:2!:EXJ8([$O('4#06)8@C42U_;PZ8/5Y74^QX>N.NMI;-C5!-A\2BY%
MXS</62DSUL@/-U>JDD*\FRV%[ >V2:]/@4Z$/WKK?7O?NO=>]^Z]UCFC:6&6
M)9'A:2)HUE3]2D@@,/\ %?J/?NO=4@Y#XS=UTV[I=K)LG-5\CU[4\&X(8V.-
MDC+V6I:OYIXHW4AR'<2 7#)K!7V]J'3&D]72[7Q51@ML[=P=75FOJ\-@J3%5
M-<?K/)3T\<+S'@<R,A;Z?GVT<]/#'3[[UUOKWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z8MR[9P.\<)6[<W-BZ;,83(
MJBUF/J[Z'\;K*ANI5E9)$5E92"" 0??N'6B*]49=XX/:VV>V-\;?V7 ]-MS#
M9?\ A]'2R2O,8I(H8EJXA)(S2,L=8)574S,% #,2"2^.'3)X]6^_'399V)TY
MLG#S1&+(5>,&?RH< .*C($U3(]O[4"2)#_K1CD_7VTQJ>G5%!T-ONO5NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z!+Y#[__ -''4NZL[!/X,M6TG]W\"RFS?>5H
M:)'3D>NGB\DX_P (CP?H;**GJK&@ZK+^(VP/[[]PXBMJH#+B-E1_WKKF8'29
MH65:&._TUFK9) I_4L3_ (!]N,:#IM14]70^V>GNO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJI^5W?
M.^(>SLGL_9F\,WM[![8I8,=5KM^H>D::M*B>HD:> I4$Q^182NL(#$UE]3%G
M57'33-GH_71$>ZUZEV3/O7*U^9W'D<3_ !:MK,D2T^BJD>HIHI&/K9XJ:2-&
M+$MJ!O\ T%&X]77AT+GNO5NO>_=>Z][]U[I-;RW)2[.VGN3==8 ]/MW"5.8D
MB)MY#3PO(L0/^JE90B_U+ >]C/6B:=4<]7;;J^T^W=KX6OO6/N7<_P#$,Z[W
MN\"N];D&)O\ 5J>.4_7ZD>WC@=,C/5]0 4!5 55%E4<  ?0 >V.G^N_?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW05=Z=JXGHSI?M;N7.4\U9BNKNOLOONKH*;3Y:D8RAFJTI(=;QIYJJ2
M)8H]3HNMUU.HNP6[=9-N5Q%;H0&ED2,$UH"[!030$T%<X/0U]MN2I_<CF';>
M7[9@DNXWUK9([5TQFXF2(NU QTH&+M0$T!H"<=4G=/? _O;Y9]!;=^7O8?S)
M^0^S?E/W'@X.YNLAL?-S4&SMKT]? ]=M_#0;?"N6Q4]+)1R5:I-&Q\<85G(J
M7K9!W'F.UV*Z>PBLK:2W@9X'\6,-/+I8*[F7!#U#:"!10WPX73T0Y^^\MRU[
M'<SS\A[5RIL5WRYM4TFT[A]99I-NNXO XANKA[NHI.KK,L)*,!J:H'Z:PC%B
M_P"8YOG;_P#*AW5\L-Z8>AI>_P#KJFKNGL_A9$BJ(#OFCS:[7@JZBG22GB\+
MS30Y.KIT<!(_/#"TH6,R(1RE%<[ZFW0N3!(4D5S56,#1"?%0W<$JJDC+4) J
M0 %=_=+VW=?>^VY'VZ9VV2_:'=()@6C?]S2V9W)D1F60Z@BO;12,IU/H=PE6
M"A1O'^79\C.KNAJKY0;5^9'R5S?S<V1M*I[<W)#GLZ:O:V:K(:1<ED-IC 31
MQ1QXY%2IIJ)6E$0EG8RPK 8(:53!S797MP+66SM4LW98@5CTSQ)4@2>(-3%Q
M4%Z@Z@M *EBPUV#[UO*7.?,R\FWW*G+\/*-Y<Q[9 8+/PMRLXFE,$5]]4C,S
M3'5').0A8K& KZ];RF][;^?[[3_E@I\Y<'B:&DW;NCJ/$93;.W6M6TM+NG.R
MTN)2G?5)2FJHL3EZF22:YC>2FII+)Y"(R3[=RK]7O7[J9NU9Y$9_A)CBU,Q&
M'HS*ATUJ 2*FF>H*Y%^Z\-]]Y?\ 6VN97:VM]TNHKBX_L9)-NLEEN2XHLNB2
M>WC"IAE621:G2"W10MX_R[/D9U=T-5?*#:OS(^2N;^;FR-I5/;FY(<]G35[6
MS59#2+DLAM,8":.*./'(J5--1*THB$L[&6%8#!#2G$'-=E>W M9;.U2S=EB!
M6/3/$E2!)X@U,7%07J#J"T J6+3KL'WK>4N<^9EY-ON5.7X>4;RYCVR P6?A
M;E9Q-*8(K[ZI&9FF.J.2<A"Q6,!7UZWE-[VW\_WVG_+!3YRX/$T-)NW='4>(
MRFV=NM:MI:7=.=EI<2E.^J2E-518G+U,DDUS&\E-3263R$1DGV[E7ZO>OW4S
M=JSR(S_"3'%J9B,/1F5#IK4 D5-,]05R+]UX;[[R_P"MM<RNUM;[I=17%Q_8
MR2;=9++<EQ19=$D]O&%3#*LDBU.D%NBA;Q_EV?(SJ[H:J^4&U?F1\E<W\W-D
M;2J>W-R0Y[.FKVMFJR&D7)9#:8P$T<4<>.14J::B5I1$)9V,L*P&"&E.(.:[
M*]N!:RV=JEF[+$"L>F>)*D"3Q!J8N*@O4'4%H!4L6G78/O6\I<Y\S+R;?<J<
MOP\HWES'MD!@L_"W*SB:4P17WU2,S-,=4<DY"%BL8"OKUO*-WR.^=N_<[\"?
MC/V+T>:3:7>OSBW'L_IOKR= *V';V<W0&BR]4C,8VD&)EIZBFIIO&[K4R4TK
MTQ42*J+:.68UW.Y@N:R0V*W$TH'8TJ6YH /BIK)6HKA=5&K0]1W[3?=IVS;?
M<WF#:>8]5UL_)]ONNZWRYA>_L]MHT"4&H+XX>.21-0!B$JK(#I) /O\ ^(_;
MO\NOK"F^9?0WR=^1?;F]>GI,=F>_-@]Q[B?*8;?.$DR$46:D,$T9;&54$,Z-
M'(6JFAI*4&,/5J\M09;7O5OS9/\ N^ZMK6!9R5AE@A\-X)=-$':>]2PH5-*E
MZZ@  LG>U_OGL/WKMY;V_P"9N7MAVNTW7QXMEOMJL!;7>SW@@9K8:D;]:-F0
MADI$'EE.HK$0D9V?YA/RDWEU[\;>JU^/N4CQW;7R[['VKTGTON.:))UQLN[U
M\O\ &&37;734(*0NJS>.KGIG\4B*]@[RGL\>X74AN03%:PRW,R E6=81\ -#
MQ8@'AVZJ$&G6.WW6/9C;^:^;MR/-,9DVSEC;]RWC=K<,4-PFU]OTX.G@\I!<
M$IJB20:U8CHDW?\ \1^W?Y=?6%-\R^AOD[\B^W-Z]/28[,]^;![CW$^4PV^<
M))D(HLU(8)HRV,JH(9T:.0M5-#24H,8>K5Y:@1;7O5OS9/\ N^ZMK6!9R5AE
M@A\-X)=-$':>]2PH5-*EZZ@  N1/M?[Y[#]Z[>6]O^9N7MAVNTW7QXMEOMJL
M!;7>SW@@9K8:D;]:-F0ADI$'EE.HK$0D9V?YA/RDWEU[\;>JU^/N4CQW;7R[
M['VKTGTON.:))UQLN[U\O\89-=M=-0@I"ZK-XZN>F?Q2(KV#O*>SQ[A=2&Y!
M,5K#+<S("59UA'P T/%B >';JH0:=8[?=8]F-OYKYNW(\TQF3;.6-OW+>-VM
MPQ0W";7V_3@Z>#RD%P2FJ))!K5B.B3=__$?MW^77UA3?,OH;Y._(OMS>O3TF
M.S/?FP>X]Q/E,-OG"29"*+-2&":,MC*J"&=&CD+530TE*#&'JU>6H$6U[U;\
MV3_N^ZMK6!9R5AE@A\-X)=-$':>]2PH5-*EZZ@  N1/M?[Y[#]Z[>6]O^9N7
MMAVNTW7QXMEOMJL!;7>SW@@9K8:D;]:-F0ADI$'EE.HK$0D9GOGCWIV#V%D?
MA]\3_CMO[+=;;G^<.4J\OE>TL O^Y+"[&P^(AS>8GQD\4\<E)E:ZCG'VTT>J
MT<%2OEIV:.7V3<K[=%"EUN-S&LJ62I2%OA>:5_#36*=R*02PJ*X&02.H;^[/
M[;[7RO#S3SQS791;A;\GQQ1Q[;.?T+O>+NZ:TMUF5D82012(3*C4JSQ'3( R
M=%_[%Z8W[_*U[$Z*[QZL[X[R[6Z![![9P/3/R0ZV[NSPS,<$>>/V5/N_'U3P
M4XI:JGK]=14(L9,U1.L2R0TCLD!E;;A!SA#-;SP6\$\<4L]O);Q>'J,8,AB9
M5-&!045B05"U.IB=4H<J>X.U_?/VK>>7-ZV;9]LWJQVR]W;8=PV>R^D9VLOU
MGL)45W\1'BI'&Q8:(XRY5Y@"YG/YC':?:65WM\7OA+T=OG*]8;^^7>\,M2[J
M[,V^I&1P6SMM4"Y+/RXR=)HIJ3*UE.Q%-,@)$=/4KY:=VCE!7RI8PK%<[E<(
MLJ6:1E8F^%YIGT1ZA3N12"6%17M&02.H>^Z?R5LMEMW,7N+S'9Q;C9<KVMJU
MMMTY_0O-UW"<V]J)E*,LD$;"LJ$BK/$=,BAEZ+'V+TQOW^5KV)T5WCU9WQWE
MVMT#V#VS@>F?DAUMW=GAF8X(\\?LJ?=^/JG@IQ2U5/7ZZBH18R9JB=8EDAI'
M9(#2VW"#G"&:WG@MX)XXI9[>2WB\/48P9#$RJ:,"@HK$@J%J=3$ZIAY4]P=K
M^^?M6\\N;ULVS[9O5CME[NVP[AL]E](SM9?K/82HKOXB/%2.-BPT1QERKS %
M[Z_<<=<S.J?OF5N'LSY,_,3JW^7IUKVMO?I;92=25?R*^1F_NLYOL=P38>+)
M+B<3@\5DU=VHFFKRCU>J$QM'44Q)G5):60=[!#%L^WR;O-%'.WC+;01RC5$'
M*&1W=,:J+0)W8-214*1GE[ ;5L_L_P @[C[J[OMMGN]W^](MAV*RW!/&L4NF
MMS=3W,\) $@6(%8:.&#1R80E)51&S=E]A_RXOF1T)U;A.V^T.VOB7\O,AF=D
M4N [?RW\5KME[OH:3^(8S^&U\B))-0Y2)%I(X-"'2LLL\LT\41F<N+B#FG;Y
MIFBBANK01M6"/0MQ"SB-M2CM#JS!BPX@Z0H J!%S!S#M/WLN0-ZWJXVS;MLY
MFY7CM+MIMKM?IH=WVN:7P)O&B4E5E@9C,TE2*E41$1FT+?YE;A[,^3/S$ZM_
MEZ=:]K;WZ6V4G4E7\BOD9O[K.;['<$V'BR2XG$X/%9-7=J)IJ\H]7JA,;1U%
M,29U26ED;V"&+9]ODW>:*.=O&6V@CE&J(.4,CNZ8U46@3NP:DBH4@.^P&U;/
M[/\ (.X^ZN[[;9[O=_O2+8=BLMP3QK%+IK<W4]S/"0!(%B!6&CA@T<F$)254
M1LW9?8?\N+YD="=6X3MOM#MKXE_+S(9G9%+@.W\M_%:[9>[Z&D_B&,_AM?(B
M234.4B1:2.#0ATK++/+-/%$9G+BX@YIV^:9HHH;JT$;5@CT+<0LXC;4H[0ZL
MP8L.(.D* *@1<P<P[3][+D#>MZN-LV[;.9N5X[2[:;:[7Z:'=]KFE\";QHE)
M598&8S-)4BI5$1$9M"W^96X>S/DS\Q.K?Y>G6O:V]^EME)U)5_(KY&;^ZSF^
MQW!-AXLDN)Q.#Q635W:B::O*/5ZH3&T=13$F=4EI9&]@ABV?;Y-WFBCG;QEM
MH(Y1JB#E#([NF-5%H$[L&I(J%(#OL!M6S^S_ "#N/NKN^VV>[W?[TBV'8K+<
M$\:Q2Z:W-U/<SPD 2!8@5AHX8-')A"4E5$;-V7V'_+B^9'0G5N$[;[0[:^)?
MR\R&9V12X#M_+?Q6NV7N^AI/XAC/X;7R(DDU#E(D6DC@T(=*RRSRS3Q1&9RX
MN(.:=OFF:**&ZM!&U8(]"W$+.(VU*.T.K,&+#B#I"@"H$7,',.T_>RY WK>K
MC;-NVSF;E>.TNVFVNU^FAW?:YI? F\:)2566!F,S25(J51$1&;1+[5QV^/Y@
MGSH[:^,,7;W9G5'QE^(.UMO5?:6/ZEKWPV3W=NK=%/)74U!5Y6%Y7.$IL=%+
M#)$T:,)X:DHI9X*J#=IX?+&V17IABFGO&F6(S*)$ABA(0D(P \0N:@G4 H&,
ML"QR5=;;]USVVVSG)MKV_<^8.:;F_3;I-SA%W;[7MNW.L+RI X4?4O,RNKZF
M'AM'4T$D3J#XJ)VO\./F?D/@QO3M/??=O2'9O4%1W+\>-\=IUR5N?Q57BJX4
MV<VU5502,UR&*5JP.J0QPHL*PP#RS^)G>S;[[8#<HHXX)HYA!/%"I6)E=&9)
M%%>SX"I )U$:C3S*_>MMC]_/;Y/<G;MMLMHW?;]T3:=]L]MA,-C<Q7,)DMKQ
M$);PC5!"5)=G8N7?M34G^U<=OC^8)\Z.VOC#%V]V9U1\9?B#M;;U7VEC^I:]
M\-D]W;JW13R5U-05>5A>5SA*;'12PR1-&C">&I**6>"J@>M/#Y8VR*],,4T]
MXTRQ&91(D,4)"$A& 'B%S4$Z@% QE@33DJZVW[KGMMMG.3;7M^Y\P<TW-^FW
M2;G"+NWVO;=N=87E2!PH^I>9E=7U,/#:.IH)(G4'Q43M?X<?,_(?!C>G:>^^
M[>D.S>H*CN7X\;X[3KDK<_BJO%5PILYMJJJ@D9KD,4K5@=4ACA185A@'EG\3
M.]FWWVP&Y11QP31S"">*%2L3*Z,R2**]GP%2 3J(U&GF5^];;'[^>WR>Y.W;
M;9;1N^W[HFT[[9[;"8;&YBN83);7B(2WA&J"$J2[.Q<N_:FI/]JX[?'\P3YT
M=M?&&+M[LSJCXR_$':VWJOM+']2U[X;)[NW5NBGDKJ:@J\K"\KG"4V.BEADB
M:-&$\-244L\%5 ]:>'RQMD5Z88II[QIEB,RB1(8H2$)", /$+FH)U *!C+ F
MG)5UMOW7/;;;.<FVO;]SY@YIN;]-NDW.$7=OM>V[<ZPO*D#A1]2\S*ZOJ8>&
MT=3021.H/BHG:_PX^9^0^#&].T]]]V](=F]05'<OQXWQVG7)6Y_%5>*KA39S
M;555!(S7(8I6K ZI#'"BPK# /+/XF=[-OOM@-RBCC@FCF$$\4*E8F5T9DD45
M[/@*D G41J-/,K]ZVV/W\]OD]R=NVVRVC=]OW1-IWVSVV$PV-S%<PF2VO$0E
MO"-4$)4EV=BY=^U-5QOL"]8#=(/L7M/K/J';TF[.UNPME=:[8BD$#[@WWE*+
M$T?D8@)$M17301/-(Q 2-27=B%522![4VEG-?N(X$>1S6BHI=C05.%!.!GH3
M<J<E[QSW="QV2QN]PN""1!9V\US+I&2VB%'8*!DL10"I) ZF['[!V'V=MVCW
M?UOO7:>_]J9&_P!AN79>1I,I03:39A'5T4T\#LIX8!KJ>" ?=+BWDM',<JLC
MK@JZE6!^8(!'2;F/E?<^3[M[#=K2YLKF/X[>[@EMYDKPK'*J,*^51GRZF8+>
M.T=T568HML[JVYN*MV]5"AS])@JZEJY:&<M(@AK(Z>61Z:4O#(NB0*UT<6NK
M6HT;)0D$5X5%*])]QV*^V=(I+NWG@2==<+30R1+,E%.J,NJAUHRFJU%&'J.H
M&2[%Z^PV1R>'S&^]FXG+X7&_QG,XO)92B@J:2C_;_P KJ8)9TE@IOW4_==53
MUKZO4+^$3,*@$@F@-#D^G2FTY6W2_BCG@L[J2*63PHI([>5TDESV(RH0S]I[
M5);!Q@]$(_EJ?*#+_([K#L'-]A=B[9W-V(>]MXT6/P./J:*.:FP&-KH*+&"E
MQT$GE3'QTZIIETL)7<RO(\DK.P@YEVI=IF1$5@I@MW):N7DB5VR1_$3CRX>7
M63/WN?9R#VFWFRMMKL;BWL?W-M3O-)'*5DO;B!IIM<KKI,I<M5*@J%"A0J@"
MRGV'.L2.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[JK#^8QVGVEE=[?%[X2]';YRO6&_OEWO#+4NZNS-OJ1D<%L[;5
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MHZBF),ZI+2R(]@ABV?;Y-WFBCG;QEMH(Y1JB#E#([NF-5%H$[L&I(J%(C[V
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M2R4<E6J31L?'&%9R*EZT0[CS':[%=/8165M);P,\#^+&&GETL%=S+@AZAM!
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M#,HL"PN1?V*[LTV6V_YZKG_JW;]9G<\'1["\L@8#<R[PS <&80JH)]2!@$Y
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MB6)WCDCZGW')')&2&5AAZPAE(L001<$?3V"+;^T3_3+_ (1UA][:J'YCVH$
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MWR^'5T?5?RHR017#%@=*GZ\F8[H_XY9'S_<1-?\ J&N.NR\)U<\\JW!_M?\
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MDJ.2BKZF1(F7QN[1B6I1YGE+#W=+SF-KUI+2*]BA1Z01)%(L2Q(:(#&H*'M
MJ,@\.'6?WNES5]X,\XW%[RQMF_V.TV-VT&T[=;63Q[<-OM)/#MU>VC!AD$D4
M:EP=2@,5C8(%H,?PEVUAOG]_+L[_ /B=V+O(]CXSJ7M?<?1/6_<-5,E9-6T&
M'^UR.R]RQRJH<FD%5'''^ORTD"*9'$KHI?S&S\I[K;WT"")Y(8;IX0"JQO("
MLL=":T)5JC%-6D 4'0!^\5NUQ]U[W7V3GC:;3Z"7<]LL-ZO]J5&B2&>Z\2#<
M+,J3PD,3,WPZ)9#11H4DM_7.\>_?Y@5;TA_+4[?P>X=OTWQ?SCU_SWW17ZU3
M<-#M')"DVIBZ2HF JJD[A^W@J)YW2,3EDR$#.L)0FEU;6W*@EWBV8'ZE2-N4
M?%$95!E9M)HIA#&-15CJPP''J6>;-@Y8^ZY'N_N]L,T$S<Q0A.2K=*%K&7<[
M?Q+Z:14.A/I/$DBC0,Q2A@D"E]0-[_,A^.W1FXOE#_+>_CG56RLHN]N[SUGN
MQ*NBB9:_;V.Q!>APU0MM+XZD=B8H+!$)) Y-P[RKNUU:6=^(I9$"P"10KL-,
MAGA4L*'#%30GC3'4$?=*]UN9-HY-Y]^EW*\B^DV<;A;:)F!AOI[M5DN$-:B9
MP &?XB *G ZNCVGM/;>Q-L8#9>SL)C]M[4VMB8,#MS;^)C$5+145+&L-/2T\
M2^F.&&)0B*.%4 #@>P--,]P[22$LS$LS,22S$U)).22<D]<^=[WN[YEO)MPO
MYI+BYN97FGGE8M)-+(Q9W=CDLS$EB<DFIZ4/MOHKZ][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[IORV4HL'BLEFLE,M/
MCL1039.OJ&^B0P1M+*Y_X*BD^_=>..M?K>^ZZW?.\=Q[OR6O[G<&8FR3Q%K^
M.-W/B@5K?I@A"QJ;?I4>WP*=)R:]6@=!_'TR247:G;&-BK-U5-+3KM3:E8@-
M+@Z&GB6*@C^W8E?/#3H@B1P33@!F!J=3HVS>0Z<5?,],7SXJL8FP]CT4L<1S
M-1NZ2JH)3;R"EAHYDJU7\Z&EGIBW^*K?\>]IUZ3IR^".$J:'K+<F:G5DBSF[
M72B5A^J.EIH8VD!_(,SNG^O&??GZ]'T>#VWTYT ?;?4F;[9W+L['Y;/0TW5.
M(,F5W-MND\D=7D:Z-A]K&\JW0TF@F]BC)9[:GDCDI[ TZJRUZKM^7O85#NCL
M*GV9M]:>#:W6=(VW*&FHE5(!5^@5OB1 %1(/%'3!0+*8&*^EA[<04Z;<U/5A
MOQGZR;K#JO#4%=3>#<6?_P!_'N,.+.D]0J^*G:_*FEIA'&RWMY1(P_5[;8U/
M3BB@Z,#[KU;H!/D9VV.H>NJS+4+Q'<V:E_@NV(9 &TSNC-)4LA^J4D0+\@J9
M/$C</[LHKU5C3JMOXP]7OW#VA+DMR^7)X';KC<VYY:TF0UE1+*S4]/.SEC(:
MN</)+JOKCCE4F[ ^W&-!TVHJ>KGP   !8#@ >V>GNJ%Z//F?O*FW/BI0OW':
MJYO'RH=0M)EQ/&0PTZE(8?TN/]?V_3%.DXQU?1[8Z4=>]^Z]U67\J>O>O>J-
MF2/00U^?W[V3N5I:C<^[*@5M?'24Q%34_;2%$6$+(\$!9$61H9"DDCKZ2ZIK
MTTPIU&^!NQ369_=G8=5%>#"T2[;Q#L.#4U6F:I=3^'AIXT4_[34'WYSUY!T=
MOY!_;?Z$^S?NU#Q?W1JM ()_=T_LGC\K-I(/XM<\>VUX]7;AU4K\:'F3O;K9
MH"X<YUD8Q_70U-.L@X_LF,MJ_P +^WFX=-+QZO,]L=/]>]^Z]U3Y\U-YC<G;
MSX&GE+T.R</#A](-T-5./NZIQ_1@)8HF']8?;R"@Z9<U/3M\<>JLKW/CL9A<
MT*G&]2;-S$V:S<%.S1G,YF?2OCUBQ AH4ABD93>*,?MZ)*DNFF-.O*-75L..
MQU!B*&DQF+HJ7'8Z@@6EHJ&B18XHHT%E2-$ 554?0 >VNGNM?&JH?X]O&HQN
M'A5?XSN9Z'%T\)U ?<51C@12/U :U _K[4=)^MAKVGZ4=>]^Z]T7KY!]\XKI
M;;B^!:?);TS,3+MW"RDZ5 NK5M4%LPI86X"W5IG_ &T( D>.RK7JK-3H.NA^
MC<K69!>Z.Z'FW!V'G2N2Q.,RRZEQ4;'7"YA8:(ZH*1XX@H6D6RJHEOHVS>0Z
MTJ^9Z=?F/V-3[.ZJJ]MP3*,YOYSA:6%2-2T:%)*^8C\H8],'_!IP1< V\@J>
MO.<=%X^"?7/WV<W!V=7P$T^#B.W-OLXX-74('K)5-OU04K+'];$5#7%P/=G/
M54'5GGMKIWI&]A;>S.Z]E;CVWM[/OM?+YG&M0TF=C0R-!K*^2P5T93+%JCUJ
MP>/7Y$]2CWL&G6B*CHC/R7Q^W^C^AML=/[5LDNZLL)\S6%56:M2A$4]753Z2
M3Y)JO[4*"2%B7Q*=* >[KW&O3;=HIT3'IW;VY-Z;FDV'M7535V\Z=</ELP Q
M%)B1*E1D'8 K97$,8;D&10:<&TY!N33JH%>KJ-M=9[-VML:'KN@PM)/M@4#4
M-?1UB(_WGD73/-5^D"6:<\NQ'] NE54!FOGT]3RZP;#ZEZZZR->VQ]KT>"ER
M=A75*25%1-(JDLJ>:JFGE6(,;Z%8)>QTW ]^))Z\ !T(OO76^BZY#J.IS7;U
M?VGV1G*')[4V?112]>;?]:4] R1B6KK:Q'/B,T4J%U>[:SI=O&((D%JXH.J:
M:FIZJ8[E[ E[.[(W1O EQ15]=]OAXFN-%#3@0THTD#2S1('<6_SC.?S[= H.
MFR:]6 _%/I2:6BPO;F_:8U.2&+BHNNL+5@F+'8^,$PU:QO<+-4%FEB(^GD>H
MYEGU)1V\NKHOGT!_S?[(3<>^<9L''R*^/V/ TV2D0W$F0K$C=T-B012TZHH_
M(DDF4CCWM!3K3FO2=^+'3%=VMD9:C<(G7K#;>83)Y.B!9(\GDDB"P4K$6$B0
M0NS2-RT<<K1II-27&V:G6E6O1A_F]V+1X#9^%ZEPRTT,^X!#DLK24ZJJ4^,H
MI5-)"L:@",35<*E-(LJTS+8!A[J@KGJSGRZ9_@KUB]-29SM?)PLK9%'VSM@.
M/K"DBM75(^H(>>-(486(,4ZGAO?G/EUY!Y]6)^V^G.O>_=>Z*%\B_D)7;*JZ
M3K3K:(9?L_/O%2C[=5F_APJ"HA'B-U>NJ X,4;#2B$32 J45[JM>/5&;R'2J
MZ&Z!HNLJ23<VZ9DW+V?G;U6<W%6DSM3M+<O3TLLFI_JQ$LU]<S7O9 J#3-7K
MRK3H /G=V+3)CMM]84%0KUD]6-T;@2,_YN*-9(J*)_\ &9WDD*\$".-OHP]V
M0>?6G/ETM/A!UQ_=[8>1W[7PA<EO>I\6.+CU)CJ1WC0B_*_<5/D8CZ,B0M<\
M6TY\NO(//H[WNG3G7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T7/Y>=0U_?
M?Q>[[Z<Q!@7.=@]6YC;^WFJ@IC&2>DD?&^340%3[Y(KM]5'J'('LSV2_&UWD
M%R02(I8Y"!Q(5@2/S ZE?V*Y[C]L><MEW^<,8;'<K6><*2&,"RJ):4\_#+4'
MGP.#U75\5OYH?QCV5\*=FS=X=J8/9/<G0?7T/6/9_4FZZF&GW=49[:U,,/.E
M'AFE>LR$F3FHA(KP(Z1O*5J/MVCE2,6;UR5>S[@XLX'DAF?Q()(U8P^%,=:5
M<@ :0P!U$4IYBA.5_O5]S/G'F'W#NUY:VV:\VK>KYMPVW<[:-WVM++<I/JD,
MEQI$<0A6;20Y!(2J>(&5F*WB_B/W!NS^37V;E:7;U;A/D+VUVE6_.F/;M-',
M:Q<D^:HLG314]/,B/35TVV<;$888T7]YD0J7DDN;/OMM!O\ $';Q+6"-;'4:
M &(0M"S$K6JZW9JU-5X'A29KWWTV#8_?_;H))TGV+:]NAY.,[,@B-LMG-;.S
M.A8/$MY</K=F/8"0:*M#;]I?S:_BUGOA7G>RMA]F;6S'<?8'6<V V=T50SQ5
M.ZH]V9:A:CIL;58&!ZFNCAI<G.!).4>GDB0F&:;R1ZR6VY"OTOQ;SQ.L22?J
M7!4B$1(:LX=@JTT@D5(/E0'J#.3?N,\Z[;[A0[/N>WW,.U66X+-=[R\;Q[:=
MLMIA*\R73K'$2\*55*B16-'1-+:0[[8^$W8>VOY+>U/C]L[&U--W+U%LC#]Q
M4N&Q_DJ*E=R4>:_O=G:6D,O[OW@FK:](%0?Y[1#&HC(7VJM.98;KF%KVXS!+
M))&:]OZ#HT"ZM/DJ%=7G@YKGH5\D_>)VK>/O"7/-6XR*VT[I>7>UM*^F.,[?
M-:':[9Y N/#T10,Y/X*NQU9Z$3M+^;7\6L]\*\[V5L/LS:V8[C[ ZSFP&SNB
MJ&>*IW5'NS+4+4=-C:K P/4UT<-+DYP))RCT\D2$PS3>2/6EMN0K]+\6\\3K
M$DGZEP5(A$2&K.'8*M-()%2#Y4!Z"G)OW&>==M]PH=GW/;[F':K+<%FN]Y>-
MX]M.V6TPE>9+IUCB)>%*JE1(K&CHFEM(=]L?";L/;7\EO:GQ^V=C:FF[EZBV
M1A^XJ7#8_P E14KN2CS7][L[2TAE_=^\$U;7I J#_/:(8U$9"^U5IS+#=<PM
M>W&8)9)(S7M_0=&@75I\E0KJ\\'-<]"ODG[Q.U;Q]X2YYJW&16VG=+R[VMI7
MTQQG;YK0[7;/(%QX>B*!G)_!5V.K/0B=I?S:_BUGOA7G>RMA]F;6S'<?8'6<
MV V=T50SQ5.ZH]V9:A:CIL;58&!ZFNCAI<G.!).4>GDB0F&:;R1ZTMMR%?I?
MBWGB=8DD_4N"I$(B0U9P[!5II!(J0?*@/04Y-^XSSKMON%#L^Y[?<P[59;@L
MUWO+QO'MIVRVF$KS)=.L<1+PI54J)%8T=$TMI+?W7\;M\_$W^7;\ -_8C;^1
MJ=T? _M#;G?G;FV,*&J*PXW(U=7E-\TT#SR1-:.LRCB=2T<2TZS'5'%$I4VV
M_>(^8MWO4D(I?QRV\+/VA6JO@%@H/#PT'F:\:YK+?MY[N;;[Y>Z_.NV7$T:V
M_.>W7^R;7<34CB%Q!'%;[8[A%892V70:,YD*89F((O?/[YX]"=Y_$_(=&?%[
ML[9_='=?RRCQW5/7VPMF5*5^0IH\U5TJ9*HS=%3K-4X5:7&&<,*N.&1)2&"Z
M8Y&1%RSRU=;9?+=WT,L$%J3/)(Z% ?"[E52VD,6<*H"DUKCH"?=?^[1S/[;<
M[Q\R\Y[==[3M'+)GW.^O;N,P02-9QR-"EM)(42X,DP2GA,ZE:BM64%0?S#.H
M<ST/\7_AMVAUSB\CF:#^7?V7L;>&>P^%!J*NHV9M^@APV:C@DGECE=?LX83,
M9)%!IA-)+(N@N$_*MZ-UO;F&X*ZK^*:(,V%%Q*PD1B%'^_%%*#B1BF.BK[JW
M/5O[F<Y\U;-N\D<4G/6W[Q:0RS'PXDW:^G:[MF81JP'ZK,$"J:2%%53724_\
M_OGCT)WG\3\AT9\7NSMG]T=U_+*/'=4]?;"V94I7Y"FCS572IDJC-T5.LU3A
M5I<89PPJXX9$E(8+ICD9%'+/+5UME\MW?0RP06I,\DCH4!\+N55+:0Q9PJ@*
M36N.C7[K_P!VCF?VVYWCYEYSVZ[VG:.63/N=]>W<9@@D:SCD:%+:20HEP9)@
ME/"9U*U%:LH*@_F&=0YGH?XO_#;M#KG%Y',T'\N_LO8V\,]A\*#45=1LS;]!
M#ALU'!)/+'*Z_9PPF8R2*#3":261=!<)^5;T;K>W,-P5U7\4T09L*+B5A(C$
M*/\ ?BBE!Q(Q3'15]U;GJW]S.<^:MFW>2.*3GK;]XM(99CX<2;M?3M=VS,(U
M8#]5F"!5-)"BJIKI*?\ G]\\>A.\_B?D.C/B]V=L_NCNOY91X[JGK[86S*E*
M_(4T>:JZ5,E49NBIUFJ<*M+C#.&%7'#(DI#!=,<C(HY9Y:NMLOEN[Z&6""U)
MGDD="@/A=RJI;2&+.%4!2:UQT:_=?^[1S/[;<[Q\R\Y[==[3M'+)GW.^O;N,
MP02-9QR-"EM)(42X,DP2GA,ZE:BM64&-\N-JTOP:[+_EI_)9(\@.COC/MN7X
MK=QUV*CDJCC]OYC!4F!PF2JF9Q4S8Z@K8C+(6+2>58 BRS2B*2NPRMS)%N%H
MU&N;DK=15QJEB=Y'50HIJ=';3P''@,AWV+WI_O(;1S_R@Q0[QS!.O,FU)(RQ
M^/?6EY+>W,,84:%EEB?2H%%TEZE474L#Y_\ ?W2WSD3X_?!SX[[^V?WAE.[N
MYL#N;M:HZ\KUR=#A-CX*9LGF*K(9'&&=,?5,8H@D9DCG4*ZL(V>(.[RUMEUR
MR9MSNHY+?P(9%A,B:"]Q*IC0*LE-0&HLU 0 N1TJ^Z_[8<Q?=O.]^Y'-=E=[
M/'L^TWMOMHOH#;S7>\7J?36Z10W.@RH-3EF"LAP1J :@H?S$\K/\<_E#\(/G
M3E8\C_HEZRSN>Z6[WKL7 9FH,1O&D6BQ>3JPC+(V/H,E(\LH%V$JP+$DDLHB
M=#RK$-VM+S;5 ,TJQS6]2<O;EF910'N:-F \N-?4 S[J5BONQR;S?[;0Z/WG
MN$-ENVS)(^D376TRM--#'4$"66$:%K0%2Y8JJZE"_P"?_?W2WSD3X_?!SX[[
M^V?WAE.[NYL#N;M:HZ\KUR=#A-CX*9LGF*K(9'&&=,?5,8H@D9DCG4*ZL(V>
M(.NY:VRZY9,VYW4<EOX$,BPF1-!>XE4QH%62FH#46:@( 7(Z&?W7_;#F+[MY
MWOW(YKLKO9X]GVF]M]M%] ;>:[WB]3Z:W2*&YT&5!J<LP5D."-0#4M6[[^3O
M4GQK_P!&O^E;+93%?Z6NP*3K#9'\,H:BM^XS-=_P%II?MU;[=);']V33$MO6
MZ\7!6W;3/NOB> NKPHFFD[E73&E-1[B*TKP%2?(=84>V?L[OONY^\/W)%'+^
M[+&7<;SQ)HX?#M(?C<>(1K*U'8M6/D#U6_\ ('?.(^&7\T'K_P"2/9^3.VOC
M[\G>@6^/^Y-ZU**F,P^[,/DAEL949BHUJ((:C'0""&9@V@25#.%@ADEB%>U6
MIW_9Y+.!==Q;S_4JHJ7>&1%B<( #4A@C$>G#.#EK[7<MS_>!]FK[E'9HOJ-\
MY>WL;W;VBDM<76V7=O\ 2SI;I0ZF25O$= 173&%)=U1V/NKMKK7YW_.WX7=,
M]#[GV]VWL'XT[VJ?E+W5O[955]]AL?5XF&)=I4<.8H/+1U-5+E23)"DQ1@RI
M)J"3(CUA8W'*^W7=Q<J\,EP@M(4D72[J[!ICI>C!0BA=6GBPH0<]&7M[R-O'
MW:/;7FSF#F:WGVN]Y@LX^7-ILKN+P;N>*Z=C?R-;SZ9$18!17*5!J5I5"7SY
M [YQ'PR_F@]?_)'L_)G;7Q]^3O0+?'_<F]:E%3&8?=F'R0RV,J,Q4:U$$-1C
MH!!#,P;0)*AG"P0R2Q,[5:G?]GDLX%UW%O/]2JBI=X9$6)P@ -2&",1Z<,X)
M;[7<MS_>!]FK[E'9HOJ-\Y>WL;W;VBDM<76V7=O]+.ENE#J9)6\1T!%=,84E
MW5'8^ZNVNM?G?\[?A=TST/N?;W;>P?C3O:I^4O=6_ME57WV&Q]7B88EVE1PY
MB@\M'4U4N5),D*3%&#*DFH),B/6%C<<K[==W%RKPR7""TA21=+NKL&F.EZ,%
M"*%U:>+"A!ST9>WO(V\?=H]M>;.8.9K>?:[WF"SCY<VFRNXO!NYXKIV-_(UO
M/ID1%@%%<I4&I6E4)?/D#OG$?#+^:#U_\D>S\F=M?'WY.] M\?\ <F]:E%3&
M8?=F'R0RV,J,Q4:U$$-1CH!!#,P;0)*AG"P0R2Q,[5:G?]GDLX%UW%O/]2JB
MI=X9$6)P@ -2&",1Z<,X);[7<MS_ '@?9J^Y1V:+ZC?.7M[&]V]HI+7%UMEW
M;_2SI;I0ZF25O$= 173&%)=U1V/NKMKK7YW_ #M^%W3/0^Y]O=M[!^-.]JGY
M2]U;^V55??8;'U>)AB7:5'#F*#RT=352Y4DR0I,48,J2:@DR(]86-QROMUW<
M7*O#)<(+2%)%TNZNP:8Z7HP4(H75IXL*$'/1E[>\C;Q]VCVUYLY@YFMY]KO>
M8+./ES:;*[B\&[GBNG8W\C6\^F1$6 45RE0:E:50G-M/M?9GP7_F5_*G;G?6
M[,9USU-\S,-MWN3J'?\ NN6#'[?CS.#HWQFXL;59":6.FI*ZHFJA*7EM&T<5
M/Y)(Y)HEFK)M\G,FT6S6D;22V;20S(@9Y"DKF6-@H![0=:^M?EP;WKDC</O(
M^T/+EWRQ:R7^Y\J37VU;I96RO/?-:7LPN;29(D5G>)%C*46K!FDTJRHQ1PZ^
MWYM#YO?S3=M]M=35]%O?I#X2=*9;;U/V=AGE?&5N]]X&>@J:7&UD2BER=/#@
M)) 6$DD0=6D2^J&1JW5M+RULS6\X:.:]F1C$P 86\%2"P/<I:1L5 )"G-*CI
M+S3RU?\ W<_9>XV/?$>SW?F[=K6=MNF51<1;/M6F9'FC8ZX6:Z"T!57*T4\'
M4-^T^U]F?!?^97\J=N=];LQG7/4WS,PVW>Y.H=_[KE@Q^WX\S@Z-\9N+&U60
MFECIJ2NJ)JH2EY;1M'%3^22.2:)9K2;?)S)M%LUI&TDMFTD,R(&>0I*YEC8*
M >T'6OK7Y<%6]<D;A]Y'VAY<N^6+62_W/E2:^VK=+*V5Y[YK2]F%S:3)$BL[
MQ(L92BU8,TFE65&*.'7V_-H?-[^:;MOMKJ:OHM[](?"3I3+;>I^SL,\KXRMW
MOO ST%32XVLB44N3IX<!)("PDDB#JTB7U0R-6ZMI>6MF:WG#1S7LR,8F #"W
M@J06![E+2-BH!(4YI4=)>:>6K_[N?LO<;'OB/9[OS=NUK.VW3*HN(MGVK3,C
MS1L=<+-=!: JKE:*>#J&_:?:^S/@O_,K^5.W.^MV8SKGJ;YF8;;O<G4._P#=
M<L&/V_'F<'1OC-Q8VJR$TL=-25U1-5"4O+:-HXJ?R21R31+-:3;Y.9-HMFM(
MVDELVDAF1 SR%)7,L;!0#V@ZU]:_+@JWKDC</O(^T/+EWRQ:R7^Y\J37VU;I
M96RO/?-:7LPN;29(D5G>)%C*46K!FDTJRHQ1PZ^WYM#YO?S3=M]M=35]%O?I
M#X2=*9;;U/V=AGE?&5N]]X&>@J:7&UD2BER=/#@)) 6$DD0=6D2^J&1JW5M+
MRULS6\X:.:]F1C$P 86\%2"P/<I:1L5 )"G-*CI+S3RU?_=S]E[C8]\1[/=^
M;MVM9VVZ95%Q%L^U:9D>:-CKA9KH+0%5<K13P=1=1[ '7/7K7SZVSGQ^^'WS
MZ^8O47RZVGUSM+9'R1[#/R/Z#[A[:H<=+AZ^7+(9]S8ULUDH9(* P9*H(2*:
M2&.*2&4&RU%&9Y,OK6YYEVRTN;,O-);Q_2SPQ EXPC-X3:%R0R8+ 'ADU#4Z
MD<W[9S1[^>V/*N_<BW-]=WFP6/[@WK:MLEG6Z@6U;39S?3V[*TNN%!5T5RP9
M>)CF"&BZN^3_ ,?NU?FUMWHKXF]+=)=E[)V5LBJWUW#\C-D4..6@VY4GSPXF
M@PV3QU!-2Y'(5M0(U;3/"GB>9X)IVIJF.,CO>7;C;MO-W>O)"[R".&W=2))
M "[L&92J*.!TM5J A003#'.?LQS1R1[=S\R\\;KNVWW=W>1V6U;#>2SF>_C&
MAYY;B&XF1X88T)()C<ZPBND8DC9@=^1V&A_F;_,Z3X>)4Y,_%#XH8Y]X_(S.
MX&>: 9G>^0IIZ/![;CGC>!DDP\<TM29(S-'Y(JV&98Y$@9C3:)CR?M_[Q4@7
M=R=%L"%;PX%8&26A##N(\, Z30EEJ*TD#VEW!ON=^WPY^I&.9>99!:[##,B/
M])M$$B2W-X597!%P46(*VAM+1.A96< 8?Y7_ &[O3;5+V;\ N]\O_$.\_A[D
M$V_A,S4#QG<FPYPC[;S-.AO=:2DFAI774[10-0^:62HDF;VAYQLHIFCW2U73
M!=@L4&?"G7$B<?7N4T4$$Z5 '0!^^3R+MV[OM_N?RS%X>S\THT\L*G4-OWE*
MB\MV/]-U>5310S^-H18U0=!]_*#[HZMQ^![X^+\^[Z*G[JV1\J>R*NLV+7*8
M:^IQL>6B8Y:G@NY^Q620P.SE'CJ(WC9;&)Y7N=MKGC-O>%#X4MI::7 )4-X"
MKI)H!J[":5^&A]0!1]^WV\WJXN=EYR6U=MIO.6]@5+Q.Z".<VA7P'>BCQ2$\
M10M0T;*P-=06ZSV ^N>G7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U3O_,3RL_QS^4/P@^=.5CR/^B7K+.Y[I;O>NQ<
M!F:@Q&\:1:+%Y.K",LC8^@R4CRR@782K L222RB)QSRK$-VM+S;5 ,TJQS6]
M2<O;EF910'N:-F \N-?49Z_=2L5]V.3>;_;:'1^\]PALMVV9)'TB:ZVF5IIH
M8Z@@2RPC0M: J7+%574H7_/_ +^Z6^<B?'[X.?'??VS^\,IW=W-@=S=K5'7E
M>N3H<)L?!3-D\Q59#(XPSICZIC%$$C,D<ZA75A&SQ!UW+6V77+)FW.ZCDM_
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M:/;7FSF#F:WGVN]Y@LX^7-ILKN+P;N>*Z=C?R-;SZ9$18!17*5!J5I5"7SY
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M/W]N>W7ERT^U[C97%Y/8RV5TYEA9[B*5H8M*. YD=!@LM4*L5-L'Y[X;KO\
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MK<%HH$5II!<:E0H"&8>]J*]58TZ*5\,.NJG<>5W%WGO!ILIEJG)5%#@*NO\
M4[U,MVR.0N1RY\G@C8<"]0MKA;7<^75$%<]'9[-[%P75NS<KO#/2 PT,7CH*
M%6"R5=4X/@I8K@^N5AR;$(@:1AI4^Z 5Z<)IU2C0Q[H[X[9I8JZH:?<._-Q*
MM54(I*4\3&\C(A:XIZ&DC)5;\11 7-K^WOA'3/Q'J]K"X>@V_A\5@<5"*;&8
M7'0XK'P#^Q#3QK%$M_R0B#G\_7VQT_TY^_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z #=/Q3^,V^.P:+M?>/0/4&Z.RL=/#5TF]\[M_&562$U
M-(LM-.U5+3-))44TB*T,KEI(B 8V6WLR@WB[MHC!'/*D35U1K(ZH=0H:J" :
MC!QGSZD_9?>SG#ES:GV/;]ZW2WV^175[.&^N([<I(I5UT+(%"N"0Z@!7![@>
MA^ "@*H  %@!] /Z#V6]1B37H :#XI?&7%=F-W+C>@.GZ#M9JMLB.P*3;V+C
MRJU3H\4E6E6M,)8ZN6.1E>=2)G5B'<@^S)MXNV@^F,\IAX>%XC^'0'5336E*
MYX<<]2?<^]G.%[L_]7YM[W1]MTA/H6OKEK8QA@P0QF324#*"J$%%(! '0_\
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M,H:]DJ722HC2IIZ>.2&*HD16D2,HCL S*2+^S*ZWB[O8UAFGEDC6FE'D=D%
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M%!4L230"@^72;FOG#=N>KU]QWJ\N;ZZD"A[B[GDN)F"*%4%Y69J*  HK0
M =0.T.G^JN[-MMM#M[KK9G9>V#.M6F$WKCJ7(P1S+^F:%*F.3P3K^)(]+@<!
MK'W:TO9MO<202/&XJ R,4:AXY4@YZ4\F\^;W[>7?U^PW]WM]QI*^-:3R0.5/
M%6,;+J4^:M4'TZG]=]9===1;7H]D]6;%VEUWM#'R2346V=EX^EQM%'),[232
M"FI(HHO+-(Q>1R"SL2S$DD^ZW5W+?.99W>1S2KNQ=C04%2Q)- *#Y=)N:^<-
MVYZO7W'>KRYOKJ0*'N+N>2XF8(H507E9FHH "BM    !U [0Z?ZJ[LVVVT.W
MNNMF=E[8,ZU:83>N.I<C!',OZ9H4J8Y/!.OXDCTN!P&L?=K2]FV]Q)!(\;BH
M#(Q1J'CE2#GI3R;SYO?MY=_7[#?W>WW&DKXUI/) Y4\58QLNI3YJU0?3J?UW
MUEUUU%M>CV3U9L7:77>T,?))-1;9V7CZ7&T4<DSM)-(*:DBBB\LTC%Y'(+.Q
M+,223[K=7<M\YEG=Y'-*N[%V-!05+$DT H/ETFYKYPW;GJ]?<=ZO+F^NI H>
MXNYY+B9@BA5!>5F:B@ **T    '2X]I^@YT&G:73/4G=^WTVKW#UKLCLW;T4
M_P!W38G?&,I,E%#-8#S4XJHI#3SV%O)$4>W&JWM59WT^WOXEO(\;<-4;,C4/
MS4@]"_DSW WSVZNOK=AO[S;YRNEI;.XEMW9?X6,;+J7^BU1\NLW674/5?2VW
M1M+J+KK976FV?.:M\)L?&TF,IY)F_5-+'211":=OS(^IS^6]^N[V;<'\2>1Y
M'- 6=B[4'#+$GIOG#GO>O<*[^NWV_N]PN-(7QKRXEN) HX*#*S%5'DHH!Z=3
MME]9];];_P!X/]'?7VR-A?WMSLNZ-U?W+Q-!B_XGDY_\_D<A]C3P?>U\UOW*
MB;7*_P#:<^ZW%W+=Z?%=WT*$36Q;2B\%6I-%'D!@=)^8><-WYM\#]ZWUY>_2
MPK;6WU=S-<_3VZ?##%XSOX<2_AC2B#R ZZ/6/6QW^O:YZ]V.>TEP?]V%[*.)
MH/X^,;J+_P /&9^W_B(H=9+>#S>*YOHO[]]7+X7@:W\/5K\/4=&NE-6FM-5,
M5I6F.O?UQW<;7^Y/KKS]W>-]1]!]3-]%]133XOT^OPO%ICQ-&JF*],.-Z)Z5
MPW9N4[IQ'4O7.+[=S=&]!F>S<=AL?#G:N*18HY$J<I'3K63ZXX(T8O(69(T0
MDHH =?<;B2$6[2R&)358B[&-3G(4G2#W'@/,^O1G=^Y7,.X;/'R]/N=_)M<+
MAXMODNYWLXF!9@4@9S&M"[,** &8GB2>A6]HN@3U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=-F9PN&W'BLA@=PXG&9
M[!Y:E>ARN&S,$5525,$@TR0U%/.DD,T3CAD=2I'!'NRL4(()!&01@@]+-OW"
MXVF=+FUEDAFB8/'+$[1R1NN0RNA#*P\B"".@FZE^-GQ]Z&GS-5TMTOUEU;6;
MA")G*W8V&H,=/5I&SO%%//30QRR0PM*YCC+>./4="K?VNOMVNMTT_4S2RZ:Z
M?$D=]-:5IJ)I6@K3C0=#CGGW<YI]S%B3F'=MPW%8*^"EY=S7"1%@H8JLCL S
M!1J8#4U!4FG0@[WV'LGLO;.3V9V)M';6^=HYF'P97;.[:*FR%#4+^!+2U4<L
M+E3RI*W4V*D$ ^TL%Q):N)(F9&4U5E)5@?4$4(/06Y=YEW'E"\CW#:KJXL[J
M(ZHKBVFD@FC/]%XV5A\Z'(P<=);J?HWIOHG"U>W>F.KMB=783(UG\1R6/V-C
M*3&I55&A8A/5&FBC:IG$:*@DE+L%4+>P ]O7NXW&Y,'N)9)6 H&D=G(%2: L
M305)-.&>CKG?W'Y@]R[A;OF#<;W<9HT\..2\N);AHX]1;2GB,VA:L3I6@J2:
M5/2IWOL/9/9>V<GLSL3:.VM\[1S,/@RNV=VT5-D*&H7\"6EJHY87*GE25NIL
M5((!]LP7$EJXDB9D93564E6!]010@]$O+O,NX\H7D>X;5=7%G=1'5%<6TTD$
MT9_HO&RL/G0Y&#CI+=3]&]-]$X6KV[TQU=L3J["9&L_B.2Q^QL928U*JHT+$
M)ZHTT4;5,XC14$DI=@JA;V 'MZ]W&XW)@]Q+)*P% TCLY J30%B:"I)IPST=
M<[^X_,'N7<+=\P;C>[C-&GAQR7EQ+<-''J+:4\1FT+5B=*T%232IZF]H=/\
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MK7K%3[O_ +)W'O?S.FQ/-]%;PQ3WFZ7CHS+86%F-5Q*P H"*K&FLJGBR(K,
M>J[]V?)S^9?\.*/97?/S1POQXWI\;L]F,;ANX<=TQ!E(LUU^<M6I1T]://Y!
ME:.E9X%F$;UCR5,[TT3!%@J9A5;[+M',+/:[8UTMR S0BX,92<(FHKV :'-&
MTU[:+4D%J+E7L?LY[0>_TEWRS[>3;[:;_#%<2[4^[/;-:;W]+"97C[-/@2.%
M<H6$2K'&)'R7C2Q#YF_*W#_$_H"O[=I<)_?[<V>RV.V/U%LC'SQH^XMR9QC'
MB*"!]6J2-E62JF\(>4TL$S1(S*!["NP;*V^7(AU:$"M)+(02(HHQJ9C3T&!6
M@+$ D5KUBI]W_P!D[CWOYG38GF^BMX8I[S=+QT9EL+"S&JXE8 4!%5C3653Q
M9$5F /5=^[/DY_,O^'%'LKOGYHX7X\;T^-V>S&-PW<..Z8@RD6:Z_.6K4HZ>
MM'G\@RM'2L\"S"-ZQY*F=Z:)@BP5,PJM]EVCF%GM=L:Z6Y 9H1<&,I.$345[
M -#FC::]M%J2"U%RKV/V<]H/?Z2[Y9]O)M]M-_ABN)=J?=GMFM-[^EA,KQ]F
MGP)'"N4+")5CC$CY+QH=7YP_+;<_Q_VGU7M/H_:V&[-^17R3W@NP.A=J96H5
M<:\WACJ*[/9+QU$%1+A</331/4-"Z@-/!Y)88G:50]RYLB;H\DMRS1VUNGB3
MNHJU"0JHM01K<X75C!.:4./'W<O8VS]T;W<;[F.YEV_8M@M3>[U=1(3.%UF.
M*UAU(Z"YN'5EC#@X20JKLH4E>PGR<^='Q2[KZ:V;\](>C=Z=.?(S=]'UGM+M
MSI.#(TO]V]W9" R46&RM-610M+0UE5KIX*CQ']B UD\\6F>!#B39=MWJWFDV
MLW"RVZ-+)%<&,^) K4+HR  ,HHS*?72FJE3,VX^SGMM[V<N[KN'MD=XM-UV&
MUEW"ZVS=WMY/K]K@?3)<0/"S!98TTR21ZOC?P8T>J.QJ/G5\KMW?'/;G6>R.
MF=GXKL3Y*?(G>W^CCH[9F;F$= *F.-)LCF\JJ3T]2^'PL$L35)B9;// ))88
MV:12;ES98]U:26X9H[:W3Q)W45:A(547!&MSA=6,$YI0PM]VSV2L/=B[W#<N
M8+J6PV#8K3Z_>+N%-4WALQ2&V@)1T%Q<LK"+6#A'*J[ *2KX3Y.?.CXI=U]-
M;-^>D/1N].G/D9N^CZSVEVYTG!D:7^[>[LA 9*+#96FK(H6EH:RJUT\%1XC^
MQ :R>>+3/ AS)LNV[U;S2;6;A9;=&EDBN#&?$@5J%T9  &449E/KI352IFG<
M?9SVV][.7=UW#VR.\6FZ[#:R[A=;9N[V\GU^UP/IDN('A9@LL::9)(]7QOX,
M:/5':Y7V ^L >JX/FA\JNZME=G]2?$[XC[6V1NSY.]R8JLWH<EV/+*-O[4VM
MCI&BJ,YF8:*05[+65$<M/1E49&DAF 6>98Z:45[!LMM<0R7VX-(EM$RQTB \
M6:5P2$0N-':!J>IP*8[JC+3[OOLIR]S#LVY\\<]7-Y:\O;5+%:>'8(OUVY;E
M.H9+:W:93$#&A62:I#!73**6D0.^C/E!\K>I?E#M7XB?.VCZOS&4[FPN5SWQ
MV[OZDAJZ7&YR7"QB?(87)T52J_99*&A'W!.B.)7DCIDDJ3-"Y4[ALME>V37^
MV&4+"8UN89BI>,R85U90H9"W;PU8U$ <!7[D>S7)//')ESSW[:/N,4>TRVT.
M^[1NCQ27%FMVVB*YAEC/ZL+2_ITJSD*TC+&$=0(GS0^57=6RNS^I/B=\1]K;
M(W9\G>Y,56;T.2['EE&W]J;6QTC15&<S,-%(*]EK*B.6GHRJ,C20S +/,L=-
M*FV#9;:XADOMP:1+:)ECI$!XLTK@D(A<:.T#4]3@4QW5 4^[[[*<O<P[-N?/
M'/5S>6O+VU2Q6GAV"+]=N6Y3J&2VMVF4Q QH5DFJ0P5TRBEI$#OHSY0?*WJ7
MY0[5^(GSMH^K\QE.YL+E<]\=N[^I(:NEQN<EPL8GR&%R=%4JOV62AH1]P3HC
MB5Y(Z9)*DS0N5.X;+97MDU_MAE"PF-;F&8J7C,F%=64*&0MV\-6-1 ' 5^Y'
MLUR3SQR9<\]^VC[C%'M,MM#ONT;H\4EQ9K=MHBN898S^K"TOZ=*LY"M(RQA'
M4")\T/E5W5LKL_J3XG?$?:VR-V?)WN3%5F]#DNQY91M_:FUL=(T51G,S#12"
MO9:RHCEIZ,JC(TD,P"SS+'32IM@V6VN(9+[<&D2VB98Z1 >+-*X)"(7&CM U
M/4X%,=U0%/N^^RG+W,.S;GSQSU<WEKR]M4L5IX=@B_7;EN4ZADMK=IE,0,:%
M9)JD,%=,HI:1 [Z,^4'RMZE^4.U?B)\[:/J_,93N;"Y7/?';N_J2&KI<;G)<
M+&)\AA<G15*K]EDH:$?<$Z(XE>2.F22I,T+E3N&RV5[9-?[890L)C6YAF*EX
MS)A75E"AD+=O#5C40!P%?N1[-<D\\<F7//?MH^XQ1[3+;0[[M&Z/%)<6:W;:
M(KF&6,_JPM+^G2K.0K2,L81U#Q\C?D]\FMZ_)P?#+X08WK.EWYLS9])V!W_W
M'VLL]9B-JT&4T_PS&4U!0R&:;/U=/(E9'%/&R/#)#9!$\U33TVO9[.WL_P!X
M;D9=#LT=O%#17E9 "S%G4@1J2$)6IU5QVT8O]I_9OD_E[D[_ %P/<>3<&L[N
MZELMDVK;2D5UN4UM7QIGEF72MK&X,+/&=0</G4J1R.GP^^5??N1[PW]\,_FC
MMO8F ^1NR]E0=J;1W9UB:H[>W?M:>K^SER-"*I5DIZB@K'6!XY%A>;3,RTT?
MV\Q]UW[8[:.V3<-N:1K9Y#"RS:1+%,%U:6TX8,O<"M0!@FM*I/?GV3Y8M.7+
M+W ]O;B]GV&[NWVVZMMQ$0OMKW)(O&$,OA$JZRQ@R*REU2J@R$R)TU_(WY/?
M)K>OR<'PR^$&-ZSI=^;,V?2=@=_]Q]K+/68C:M!E-/\ #,934%#(9IL_5T\B
M5D<4\;(\,D-D$3S5-/;:]GL[>S_>&Y&70[-';Q0T5Y60 LQ9U($:DA"5J=5<
M=M&5^T_LWR?R]R=_K@>X\FX-9W=U+9;)M6VE(KK<IK:OC3/+,NE;6-P86>,Z
M@X?.I4CD=/A]\J^_<CWAO[X9_-';>Q,!\C=E[*@[4VCNSK$U1V]N_:T]7]G+
MD:$52K)3U%!6.L#QR+"\VF9EIH_MYC[KOVQVT=LFX;<TC6SR&%EFTB6*8+JT
MMIPP9>X%:@#!-:52>_/LGRQ:<N67N![>W%[/L-W=OMMU;;B(A?;7N21>,(9?
M")5UEC!D5E+JE5!D)D3IK^1OR>^36]?DX/AE\(,;UG2[\V9L^D[ [_[C[66>
MLQ&U:#*:?X9C*:@H9#--GZNGD2LCBGC9'ADAL@B>:II[;7L]G;V?[PW(RZ'9
MH[>*&BO*R %F+.I C4D(2M3JKCMHROVG]F^3^7N3O]<#W'DW!K.[NI;+9-JV
MTI%=;E-;5\:9Y9ETK:QN#"SQG4'#YU*D<CI\/OE7W[D>\-_?#/YH[;V)@/D;
MLO94':FT=V=8FJ.WMW[6GJ_LY<C0BJ59*>HH*QU@>.187FTS,M-']O,?==^V
M.VCMDW#;FD:V>0PLLVD2Q3!=6EM.&#+W K4 8)K2J3WY]D^6+3ERR]P/;VXO
M9]AN[M]MNK;<1$+[:]R2+QA#+X1*NLL8,BLI=4JH,A,B=6;^PAUAWU[W[KW7
MO?NO=>]^Z]U[W[KW14OB!\F4^5O7N\^QJ;:[;2QF"[@W%UKA\9/.*B>2GP%1
M%1_=U,BJL8FJYA))H0:8D9(]4C*TCFF[;8=ID6)F#$Q125'#]6-9 ,^@8#[>
MIK]]O: ^RFZ6NTO<"YDFVNPW"614T(KWL9FT("2=**574<LP+44$*#6^ROJ%
M.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[HB7SJ^5V[OCGMSK/9'3.S\5V)\E/D3O;_ $<=';,S<PCH!4QQI-D<WE52
M>GJ7P^%@EB:I,3+9YX!)+#&S2*(^7-ECW5I);AFCMK=/$G=15J$A51<$:W.%
MU8P3FE#DK]VSV2L/=B[W#<N8+J6PV#8K3Z_>+N%-4WALQ2&V@)1T%Q<LK"+6
M#A'*J[ *2KX3Y.?.CXI=U]-;-^>D/1N].G/D9N^CZSVEVYTG!D:7^[>[LA 9
M*+#96FK(H6EH:RJUT\%1XC^Q :R>>+3/ AS)LNV[U;S2;6;A9;=&EDBN#&?$
M@5J%T9  &449E/KI352IFG<?9SVV][.7=UW#VR.\6FZ[#:R[A=;9N[V\GU^U
MP/IDN('A9@LL::9)(]7QOX,:/5'8=OFA\JNZME=G]2?$[XC[6V1NSY.]R8JL
MWH<EV/+*-O[4VMCI&BJ,YF8:*05[+65$<M/1E49&DAF 6>98Z:4NV#9;:XAD
MOMP:1+:)ECI$!XLTK@D(A<:.T#4]3@4QW5$:_=]]E.7N8=FW/GCGJYO+7E[:
MI8K3P[!%^NW+<IU#);6[3*8@8T*R35(8*Z912TB!WT9\H/E;U+\H=J_$3YVT
M?5^8RG<V%RN>^.W=_4D-72XW.2X6,3Y#"Y.BJ57[+)0T(^X)T1Q*\D=,DE29
MH7*G<-ELKVR:_P!L,H6$QK<PS%2\9DPKJRA0R%NWAJQJ( X"OW(]FN2>>.3+
MGGOVT?<8H]IEMH=]VC='BDN+-;MM$5S#+&?U86E_3I5G(5I&6,(Z@1/FA\JN
MZME=G]2?$[XC[6V1NSY.]R8JLWH<EV/+*-O[4VMCI&BJ,YF8:*05[+65$<M/
M1E49&DAF 6>98Z:5-L&RVUQ#)?;@TB6T3+'2(#Q9I7!(1"XT=H&IZG ICNJ
MI]WWV4Y>YAV;<^>.>KF\M>7MJEBM/#L$7Z[<MRG4,EM;M,IB!C0K)-4A@KIE
M%+2('?1GR@^5O4ORAVK\1/G;1]7YC*=S87*Y[X[=W]20U=+C<Y+A8Q/D,+DZ
M*I5?LLE#0C[@G1'$KR1TR25)FA<J=PV6RO;)K_;#*%A,:W,,Q4O&9,*ZLH4,
MA;MX:L:B . K]R/9KDGGCDRYY[]M'W&*/:9;:'?=HW1XI+BS6[;1%<PRQG]6
M%I?TZ59R%:1EC".H>/D;\GODUO7Y.#X9?"#&]9TN_-F;/I.P._\ N/M99ZS$
M;5H,II_AF,IJ"AD,TV?JZ>1*R.*>-D>&2&R")YJFGIM>SV=O9_O#<C+H=FCM
MXH:*\K( 68LZD"-20A*U.JN.VC%_M/[-\G\O<G?ZX'N/)N#6=W=2V6R;5MI2
M*ZW*:VKXTSRS+I6UC<&%GC.H.'SJ5(Y'3X??*OOW(]X;^^&?S1VWL3 ?(W9>
MRH.U-H[LZQ-4=O;OVM/5_9RY&A%4JR4]105CK \<BPO-IF9::/[>8^Z[]L=M
M';)N&W-(UL\AA99M(EBF"ZM+:<,&7N!6H P36E4GOS[)\L6G+EE[@>WMQ>S[
M#=W;[;=6VXB(7VU[DD7C"&7PB5=98P9%92ZI509"9$Z:_D;\GODUO7Y.#X9?
M"#&]9TN_-F;/I.P._P#N/M99ZS$;5H,II_AF,IJ"AD,TV?JZ>1*R.*>-D>&2
M&R")YJFGMM>SV=O9_O#<C+H=FCMXH:*\K( 68LZD"-20A*U.JN.VC*_:?V;Y
M/Y>Y._UP/<>3<&L[NZELMDVK;2D5UN4UM7QIGEF72MK&X,+/&=0</G4J1R.G
MP^^5??N1[PW]\,_FCMO8F ^1NR]E0=J;1W9UB:H[>W?M:>K^SER-"*I5DIZB
M@K'6!XY%A>;3,RTT?V\Q]UW[8[:.V3<-N:1K9Y#"RS:1+%,%U:6TX8,O<"M0
M!@FM*I/?GV3Y8M.7++W ]O;B]GV&[NWVVZMMQ$0OMKW)(O&$,OA$JZRQ@R*R
MEU2J@R$R)TU_(WY/?)K>OR<'PR^$&-ZSI=^;,V?2=@=_]Q]K+/68C:M!E-/\
M,QE-04,AFFS]73R)61Q3QLCPR0V01/-4T]MKV>SM[/\ >&Y&70[-';Q0T5Y6
M0 LQ9U($:DA"5J=5<=M&5^T_LWR?R]R=_K@>X\FX-9W=U+9;)M6VE(KK<IK:
MOC3/+,NE;6-P86>,Z@X?.I4CD=/A]\J^_<CWAO[X9_-';>Q,!\C=E[*@[4VC
MNSK$U1V]N_:T]7]G+D:$52K)3U%!6.L#QR+"\VF9EIH_MYC[KOVQVT=LFX;<
MTC6SR&%EFTB6*8+JTMIPP9>X%:@#!-:52>_/LGRQ:<N67N![>W%[/L-W=OMM
MU;;B(A?;7N21>,(9?")5UEC!D5E+JE5!D)D3H-]__)CYK?(_Y!]Q]*_ J#I/
M:.QOC;6_W1[2[I[H2LKX,EN_PO.VW,+!C?NECCH)H_M,C)+ \U.YF>T;QT\5
M4JMMGV[:K6*?=#<&2X >*&#2I6#5I\1S(/Q"K1A<$ 5:C546<K^S_MY[2\K;
M5S#[FMN]S>;^GU6W;3M)BA>WVO6$%W<-<>'4RJ3+;*CA) $%6#R/$/?P8^67
M8/>51W%TE\A-H87K_P"4GQJW%1;<[7V]MEI7Q-?29.F:IPVX<1)*TI^SRT$3
MR>+R.\2F)W$:U$2 MYCV./;!#<VKM);7*LT+. '!1M+HX'XD) ) TMQ7SI&7
MWD?8_:_;=-JYBY6NIK[ESF"":XVR>X"K=0R6\@CN+2<*%_4@9E77I"N=0748
MV/0";_\ DQ\UOD?\@^X^E?@5!TGM'8WQMK?[H]I=T]T)65\&2W?X7G;;F%@Q
MOW2QQT$T?VF1DE@>:G<S/:-XZ>*J,K;9]NVJUBGW0W!DN 'BA@TJ5@U:?$<R
M#\0JT87! %6HU5DWE?V?]O/:7E;:N8?<UMWN;S?T^JV[:=I,4+V^UZP@N[AK
MCPZF529;94<)( @JP>1XA[^#'RR[![RJ.XNDOD)M#"]?_*3XU;BHMN=K[>VR
MTKXFOI,G3-4X;<.(DE:4_9Y:")Y/%Y'>)3$[B-:B) 6\Q[''M@AN;5VDMKE6
M:%G #@HVET<#\2$@$@:6XKYTC+[R/L?M?MNFU<Q<K74U]RYS!!-<;9/<!5NH
M9+>01W%I.%"_J0,RKKTA7.H+J,;'H!-__)CYK?(_Y!]Q]*_ J#I/:.QOC;6_
MW1[2[I[H2LKX,EN_PO.VW,+!C?NECCH)H_M,C)+ \U.YF>T;QT\5496VS[=M
M5K%/NAN#)< /%#!I4K!JT^(YD'XA5HPN" *M1JK)O*_L_P"WGM+RMM7,/N:V
M[W-YOZ?5;=M.TF*%[?:]807=PUQX=3*I,MLJ.$D 058/(\0]_!CY9=@]Y5'<
M727R$VAA>O\ Y2?&K<5%MSM?;VV6E?$U])DZ9JG#;AQ$DK2G[/+01/)XO([Q
M*8G<1K41("WF/8X]L$-S:NTEM<JS0LX <%&TNC@?B0D D#2W%?.D9?>1]C]K
M]MTVKF+E:ZFON7.8()KC;)[@*MU#);R".XM)PH7]2!F5=>D*YU!=1C8]6">P
MQUBYU21CODW_ #%?F/E^TNP_@M2?'?97QVZXW76[(Z\SW<:5U;7]@Y#$3K!D
M:NBGQ[5%'28.?4YI)AXRSQPQO/\ NU)HI!?9]IV$1P[F;IKAU6258-"BW5UU
M*I$BU,@[=0P &/$J-71.[]GO:CV"@V[:O<I]]N]]O[:&\OH-J,,,.QP749DA
MCD6X"2272T7QD.H!6=@G9&)CU_!OY7M\MNH,GN?<&U3U[VQUOOK)]1]W=<LS
MN,+N?#.BUM-#(Y8S4LD<L<D;AI I9X&D>6"0^PYS%L9V*<1AA)')&DT$@%/$
MAD%5:G%3@@@T-1Z$$XV?>/\ 9'_6,WZ.SM;GZ[;;^SM]TVB_ "_5[==@F-V4
M4TN"K*RD*30.%"NO1%,=\F_YBOS'R_:78?P6I/COLKX[=<;KK=D=>9[N-*ZM
MK^P<AB)U@R-713X]JBCI,'/J<TDP\99XX8WG_=J31"-]GVG81'#N9NFN'59)
M5@T*+=774JD2+4R#MU#  8\2HU9)W?L][4>P4&W;5[E/OMWOM_;0WE]!M1AA
MAV."ZC,D,<BW 222Z6B^,AU *SL$[(Q,<KXD_-G!]]_'7?7;W96&@ZEWCT-F
M=P;-^26SZZ0B';68VM"U3F;5$S!7H4HP)UD,CI'^Y"\K202D$.^<NR;5=);Q
M'QEF6.2V=0:S1RX0A>(8G&DBM1C!!, >^?W=KGVQYKL]AVB5MSM=YBL;O8+I
M%[]PM-R81V_8HJ)3)6,II!;M<*%=>B*;<^2/\V/OWKNO^7/0G7WQ\V_T7-53
M[BZNZ WY'D9-Y;HVQ2-/KJIZ^!S14^4KUI5^RBCFIXI%G=AJ6*G>L$<^T;%M
M<WT-U+<F9:I-/%H,$4U0*!2-;(E2'.&JO:.[MR4W;VC]C_;#=4Y%YGOM\GWE
M56WW'>[(VXVG;MQD"418G42O!$9#XS,DCJ8P* O(L-EWQ]^7/6??/Q3V_P#+
M.EK$VSL.HV-D-W[R7+.$_@CX-:I=P4]5+*(E\>,GH:@>8A8Y846H0^*16(3W
M78I]JO6L&&J57"*%[M>NA32!7X@P(''-"*XZQ"]TO8O>?;+G:?D:1#<7JWD-
MK:^$-7U@O#&;5D5=1K,LT9T9978QD:E(ZK1VY\D?YL??O7=?\N>A.OOCYM_H
MN:JGW%U=T!OR/(R;RW1MBD:?753U\#FBI\I7K2K]E%'-3Q2+.[#4L5.]8+)]
MHV+:YOH;J6Y,RU2:>+08(IJ@4"D:V1*D.<-5>T=W;E[NWM'['^V&ZIR+S/?;
MY/O*JMON.]V1MQM.W;C($HBQ.HE>"(R'QF9)'4Q@4!>18;+OC[\N>L^^?BGM
M_P"6=+6)MG8=1L;(;OWDN6<)_!'P:U2[@IZJ641+X\9/0U \Q"QRPHM0A\4B
ML0GNNQ3[5>M8,-4JN$4+W:]="FD"OQ!@0..:$5QUB%[I>Q>\^V7.T_(TB&XO
M5O(;6U\(:OK!>&,VK(JZC699HSHRRNQC(U*1U6CMSY(_S8^_>NZ_Y<]"=??'
MS;_1<U5/N+J[H#?D>1DWENC;%(T^NJGKX'-%3Y2O6E7[**.:GBD6=V&I8J=Z
MP63[1L6US?0W4MR9EJDT\6@P135 H%(ULB5(<X:J]H[NW+W=O:/V/]L-U3D7
MF>^WR?>55;?<=[LC;C:=NW&0)1%B=1*\$1D/C,R2.IC H"\BPGGVQ_,!ZASW
MP0;YXU$572;#Q^PI]QYK;1DBCK(LS2538F;;L4E28(GK)L^HH*5VTI4-+!+'
M=)DN'IN5;J+<_P!U4!E\0("*E=+ ,'.D$A=!UG%56M14$=8W;Q]UW?ML]R_]
M;)2KWKWJ6\4^EFB:UEC%RMVPCUL(UM3X\H%6C"NK49&H0[,?)/\ FX=>=3TG
MS0W]UW\<LET=3XMNP=Z?&_ #*0[NP^SGCCJDKCDZC_)Y,K1T$TD]:C2E84IU
M?[77+/3TPBBVC8KZ?]WP2W(F8B..X<1F"2:I6FA1K",0 AJ3W=V%JV2^W^T?
ML7S7OC>WVUW^_)O#2"QM-^G^F?:[O=0S1F/P8^]8))45(6"U9I"#+1$DENIZ
MQ[%VMV[UUL7M/8]<V2V?V)M.@WGMJMD1HGDHLE2QU=.98G"R0S".4"2-P'C<
M,C@,I'L 7=K)8RO!**/&[(XJ#1E)4BHJ#D<1CTZYZ\X<J7O(F[7FR[DGAW5C
M<SVEP@(8+-;R-$]&4D,M5.E@2&%""01TN?:?H-]>]^Z]U[W[KW7O?NO=%2^1
M/R93HSL+XP]<P[7;/9/Y(]P)UK39.6<108NGAI_O*VKDC"F2HF:$>.! 44.W
MDD8JGCD--OVPW\<\H8 01"0CS:LB1@#\WK]@ZFOVK]H#[D;7S#NS7 ACV':S
MN#1A-3W#O((8T!K15#'4[&I*C2HJVI36^ROJ%.O>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[JF7Y@[X&[^Y<MCZ:82XW9=)'M:FT&ZF>,M+6DC\2+52O"W_+%
M?Z>WD%!TRQJ>K+OCOL8]?=0;.P<\7BR550?QW,!OU?<UQ^X9'MQJ@C=(?]:,
M<GZ^VV-3TXHH.AL]UZMU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW1"_YH63K,3_+[^6-50R>*:7J.NQCMSS#6R04=0O!'ZZ>=U_V
M/-QQ[$G)ZAMUM*_\I$1_8X/63/W-;..^]TN64D%0-U@D'^FB#2J?R9 ?RZ'_
M .+NW\5M3XT_'O;.#I_M,1@.D=JXG&T]RQ6&#!T,::F/J=R%NSF[.Q+,223[
M*=SN'N[F660U9Y'=CPJS,2>'S/47>\FZS[[S=O=[<MJEGW?<99&I0%Y+R9C0
M# %3@# % ,#K64SM1/D/@%\O.E<A*\^RZ#^;]/U;#14_[ 3!U6XL16R4, BL
MT2"N22=26=E:4@$!4M+O^X>YV5S'B0[.)B>-9%M9E!-:C@JBG#'S/783;HUL
MO<_E;F*$!;M_:U-R+MWEKR/;[N%9&U5#'P]*$4 (45&37:LW_A*',==[UVW/
M!3C&Y79>2PDU,8P8A!/0S0-'X@54Q^-K:00+<<>X7C8HP8<00?V'KBERUN,F
MW[I:7:EO$CNH)@U:-K297!KG-16N<YZU@X\]D>P/Y"OQEVSN:IGKL=N'OW"=
M59PA_&\V&INQ\I'34ZM$(_']O34M/"AY:T*N27.KW,MXHVSFFYDA[2D,\R^=
M)#9&0G->+,33AFG#KLC-ML7*GWF^8;RR54DM]EO=RAQJ"7<G+]N[N0VJNMY9
M'(X5<BFG'6SYO_"4.8Z[WKMN>"G&-RNR\EA)J8Q@Q"">AF@:/Q JIC\;6T@@
M6XX]PU&Q1@PX@@_L/7&[EK<9-OW2TNU+>)'=03!JT;6DRN#7.:BM<YSUK!QY
M[(]@?R%?C+MG<U3/78[</?N$ZJSA#^-YL-3=CY2.FIU:(1^/[>FI:>%#RUH5
M<DN=7N9;Q1MG--S)#VE(9YE\Z2&R,A.:\68FG#-.'79&;;8N5/O-\PWEDJI)
M;[+>[E#C4$NY.7[=W<AM5=;RR.1PJY%-..MGS?\ A*',==[UVW/!3C&Y79>2
MPDU,8P8A!/0S0-'X@54Q^-K:00+<<>X:C8HP8<00?V'KC=RUN,FW[I:7:EO$
MCNH)@U:-K297!KG-16N<YZU@.@,U6=E_%?\ D;[9W?(^5QE'\Q<RSQ2FWD.T
MLSG&P*NJ!5,5%#H@T,&\D:6<G6]YEWY1MNY;TT/;6T4'S_W(-MXG&OQ:V/RK
MBE!UV3]T["/D[G;W@N[ "*1N5;45 KI_>EM8BZ(J2=4C%GJ"-+-50*"E[7\R
M+$TN:^!/RXHZM(Y(H>B-P99%E76/+CZ&2O@8"XLRS4R%3_98!K&UC''*3%-T
MM"/^4F$?MD4?Y>N:OW2;Y]O]SN6)(R03O5A$:&G;-.L+>N"LA!'F*CSZK-[%
MS59VKUE_(6CWI(^67=/8VQM[[B,QL:O*X7:-'54U5*$"1D25;/))'IT,':.V
M@D$4P*-KN-Z6#M"13Q*.-(WNHXR,U_":5X^?'K+_ )5L(^2-Y]YSMP$7TUAO
M-E!05\*VN]UDB=%U$G$8"JU:B@;C0BS+^9%B:7-? GY<4=6D<D4/1&X,LBRK
MK'EQ]#)7P,!<699J9"I_LL UC:Q"W*3%-TM"/^4F$?MD4?Y>L0/NDWS[?[G<
ML21D@G>K"(T-.V:=86]<%9""/,5'GU6;V+FJSM7K+^0M'O21\LNZ>QMC;WW$
M9C8U>5PNT:.JIJJ4($C(DJV>22/3H8.T=M!((I@4;7<;TL':$BGB4<:1O=1Q
MD9K^$TKQ\^/67_*MA'R1O/O.=N B^FL-YLH*"OA6UWNLD3HNHDXC 56K44#<
M:$69?S(L32YKX$_+BCJTCDBAZ(W!ED65=8\N/H9*^!@+BS+-3(5/]E@&L;6(
M6Y28INEH1_RDPC]LBC_+UB!]TF^?;_<[EB2,D$[U81&AIVS3K"WK@K(01YBH
M\^JS>F,U6=J?+'^3?G=YR/ELEA?Y?F4[!IJB8_KS5;MNBQ5;72(H2)GJ(;OI
M" )(59>40@4[BHVVTW:&'M0W\4-./Z:27#J*FIP4&:UQ\SUE_P"X-A'R3R1[
MJVNW 11R\[VUBR@<+2&_N+F.($DL K "M:E:@_$:F?\ YW,E7C/Y?V_-WXJI
M^QW!L'L79>\=M9)45Y*:O@W-CH(*B+7=5DC%2Q!*L"+J5(8V+O;B);G=XHG%
M4D2='%2*JT$E1BASU#O]W3''?>Z5E83KK@O;'=K2XC)(62!]NN'96I0D'PQP
M(-:$''43N(4^\OYLWP'DR].)(-L?''?V_P# 4NIBD&1R%*,?-(1PLEJ5[+=>
M'59!ZD6S&W3-;[+>A3_:7%HCXXJ!-(!\NY0?Y=.<@,^P>QW.@@:AN=^V2RG:
M@J\$$C7"CU'ZBU-#D$KP)K+_ )W,E7C/Y?V_-WXJI^QW!L'L79>\=M9)45Y*
M:O@W-CH(*B+7=5DC%2Q!*L"+J5(8V?\ ;B);G=XHG%4D2='%2*JT$E1BASTW
M_=TQQWWNE96$ZZX+VQW:TN(R2%D@?;KAV5J4)!\,<"#6A!QU:[BJPY'&8[(-
M&(C7T$-88@;A3+&KZ0;"]M5KV%_8'..L([R#Z69XJUT.RUX5TL17^754O6]%
M39K^<W\C\YD8_N,CLGX:[5VMMR5B;04F3S,60K%"DE=<E3$"& !52ZCAWN,+
MF9H]A@B'PO>SNP]62*%5_8'/^H#K-CFRZ?;_ +OVPVL1TQW?->Y7,XH*O+;6
MG@1FO&@1SC@30GX11M_FJ9&LVKO?^6SOS$2BGS.&^?FTMMI,JKK>AS<=33Y.
MF$C!M$592P&*2RDV8,I5D!]J>285N4W&-Q4?NZ=Z5/Q1M&ZG'HP!_P ..EOW
M*;2/>]NY^VRX&J*7DG=+@@DT$UFT4D+T!%3'(P=<TJ*$$$].76]%39K^<W\C
M\YD8_N,CLGX:[5VMMR5B;04F3S,60K%"DE=<E3$"& !52ZCAWNFN9FCV&"(?
M"][.[#U9(H57]@<_Z@.D7-ET^W_=^V&UB.F.[YKW*YG%!5Y;:T\",UXT".<<
M":$_"*-O\U3(UFU=[_RV=^8B44^9PWS\VEMM)E5=;T.;CJ:?)TPD8-HBK*6
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MH5,;V3IDX8R.A/\ O+$9]?4#I;[+6D>]>Q_N!#.*_17?+E[;DDTCGDO&@9@
M0*M$&C)-11N%5!Z<O@)14V0^9?\ -4WI51^7<-9W_MS9DU:Q)MC\+@IXZ"%
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M!K7T\,DA#,8X:^5)U50I#QVU%78>U.R0K/L>Y:A4QO9.F3AC(Z$_[RQ&?7U
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MW[KW7O?NO=5+=[T5-N#^;U\&*/*Q_<TVR>@.Q-Y[>A8G3%D*N$XN:9EOI?\
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M[A[NYEED-6>1W8\*LS$GA\SUS!]Y-UGWWF[>[VY;5+/N^XRR-2@+R7DS&@&
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M>2@.E'65I%!/JRR$@>@J/.C/W@-O/-'M1R!S'::I(K2WW/8[TJK:+:Y@NA+
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MXVFAIY-U4[;=QE#/*A44E89'@K '+%XO&!'9RX<VZ0[?L-VS 4NI[>%,@']
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ML/FJ\1T];%K:2GJ)<;+2U#HX7F4E1HTDH^?;46^Z3.I)2;3/&Y% Z3*'JOJ
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M/L4C/%H9773)'(@>.1*@Z64_,<10CR.3T$O9+W\WWV'O)[C:A;7%O>1"WO\
M;[^ 7-A?0!M02:(E3C.EE96 9EJ59E(<_%7^7SU=\7]Y[F[9J-]]M=\]X;LQ
M:[>R7<G?&7.<S<&+7PG^&4,S11BFI&DA5V)\D[?H:8PJD:K-[YIGWM%AT0P0
MH2PAMX_"C+G&LBIJU,5K0#@!4U%OO7]Z7>O>7;[?8ULMLV79[:0SQ[5LMJ+.
MS>Y.H>-*H9M<E'*CX4'$)K+,1&^5WPYZD^7^V-N8?L27=>V]S;$S#;CZW[-Z
MZR#XK<6WL@R!&J<;7(DBA9 J%XI8Y(V:..0*LL44B(]EWV?8I&>+0RNNF2.1
M \<B5!TLI^8XBA'D<GH)>R7OYOOL/>3W&U"VN+>\B%O?[??P"YL+Z -J"31$
MJ<9TLK*P#,M2K,I#GXJ_R^>KOB_O/<W;-1OOMKOGO#=F+7;V2[D[XRYSF;@Q
M:^$_PRAF:*,4U(TD*NQ/DG;]#3&%4C59O?-,^]HL.B&"%"6$-O'X49<XUD5-
M6IBM: < *FHM]Z_O2[U[R[?;[&MEMFR[/;2&>/:MEM19V;W)U#QI5#-KDHY4
M?"@XA-99BZ_*_P"!G5?RLS>TM_5V[.SNG.Y]@44N+V9W5TIEY,)GZ2CG?R2T
M,LZ+(E32,Q8JK*)8C)+X98Q+*';V3F2?8PT:I%-$Y!>&>,21,R@@&AH017B"
M*XK6@Z0^R/WF-Z]DK>ZVR*VV[==JO762[VG=[5;RQEE0:5D"L5*2 4J0=+:5
MUJVE=+Y\2OA+U-\0<?O"HV?E-[]@=B=D9%,KV5W'VMD/XON;.RQ-*:=*RO\
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M22?D  6^^7WB=\]^);5;^.SL;&PC,6W[5ML'TNW6:L%UF.+4YU.5!9F8T^%
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M?>)WSWXEM5OX[.QL;",Q;?M6VP?2[=9JP768XM3G4Y4%F9C3X4"H H8_E?\
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MFW69KBX8O(YJS'S\A@4   H , 8&.L:?<?W&WCW8WFYW_?KAKF]NF#22$!5
M50B(BJ J1HJA410 H'VGHB'=W\J/I_M;LC>W9FR.Y/D;\<<EVQ,\W<N"Z%W*
MV(Q6Z'DC\<D^0H)::J@%1,-1ELI@E9Y)'IS+))(PDVSG6?;X4ADAM;E8Q2(W
M,(D:(5+45@5-*GS)I@"@%.LEO;G[[>_<D;1:;/N.U;#OT>V@#:IMZV\75SMR
MAM06*59(VTJ:::G6@"JL@154'MZ0Z-ZQ^.O5VV>F^I-LTVV-A;4HWI<=BT9I
MGD::1YJFIJYY2TM75U<TC232R$L[,?HH  ;W'<9MUF:XN&+R.:LQ\_(8%
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M5W?.^OCI\)?C+#\BMW]-XF#(=U;PW3G(-NX'#5M73FMH<#33U8B3(96NITT
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M%?P];^*I+ZHT0*]:AH3+:ITUWUUMWITEM'Y ;&SD%1UUN[:S;JAR=2R@TD<
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MD:2(+9HZQ:8:'D^QM76UNKY(KHKW1^$S112&FE'E#4!.H58 JM&J?AU9K?\
M >\C\LW<'*W-'.<6W\TW$49:RCL7GVZQNY@AAM;F\5_#UOXJDOJC1 KUJ&A,
MMD>W?EMTGN3XMQ?,*CW*1TL.O:CL:ORR1F:HIJ>B245]%)3P&1FR=%5P2T<E
M.A9Q5QM"+M["<VR7,%Y] R$3^((@AH*LQ 7)H*-4$-P*D&M,]8D[M[&\Q;1S
MH>0I+?\ W;?71V"1$Z$DDF*^%('?2!#(CK,LAHOA,'X=5I/_ #._EUM[9N%^
M36__ (!YO;OPRS50M?+O.@W'25N[L=MZH>$4.YJ_ )&LJT-7'51R>+Q*L:13
M.]4(7I9YQ;_4ZQFD-G#?H]V* 1F)EA>7.J-92U*@K0$@!B5 R2%R\7[G/(NZ
M[A+R?M?.T-QS7$I1;1["6':[B^0/XMG%=LQ4R(8V77J.LL@6/6)42Z;:NZ-O
M[WVQMW>>T\M19_:V[<%2;FVWG,:ZRT]905T$=5254$BDK)#44\J.C#@JP/L
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MND^UW+7N//S%<\TPW5Q:;)RY?[T(;2X^FED>Q:)R@<JX[T+J*B@8@GATGO\
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M3U#U--5QH^JER449NH8O&['A@ YNVW;5L26HEBN)'GM(;ABLZ(H,H-0 8'-
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M[I;@[3#>;M BK.5N-%E;W$L59=)J=42ZC3(J,=";_HH_FW_]Y:?%?_T *_\
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M'[=_EF=NXVDHFW#M_P";N%ZW6OD35.N(W=3R46:IHF!0A:FEI!]7"B1(F97
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M49.9@CC*@$O@D@]3?Y/N-@J^H?DMV94-)/N7MSYL=B;PW)536+>5:^"E2%7
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M9\[KMT_+'LXNYM1C+?K>D"L@VW]_6@B)#%05">-X8) /=FF>CM_RPZ?&4O\
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M X@9'G-7M8G),OL'"G/K;RFW?UUF,+[)]&;D7HV>B*_U@9?":)IR=*ZM:IW
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M26G:L:O:>N+M&[B,4Z!E36IDDV3;[&^V7;?KKOZ8*+OPP())BY-QW90XI1:
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M4,]37#IK*YA(*:,RNZ8U%R4RJBD,28:1_I<CZ@&UB(>4Y1#NEHS$ "XBJ2:
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M4E"F1@266Q#RU0:*!4 4ZY%>Y4-I8VN+ZK9KX @&*6UE(\V4F6(T'R,@)/\
ML=5]KHVYK]D^>((BOCV6Z['NLL8/<\$DSV[%5\@AU.6J112.-*\OYV4C9OX4
M_P"B3&U-(F[N^>[MD]4;'HJLD"HR53G*?(1H2H>18UCQSL[JDA4"VDEA[?\
M;I_IMS6Z8$I;PW$TFD5(187!XT\V &1DC/5O[NT#;/<0;],KFUV7:-WW.\9!
M4I;QV4D!.: DF<!064$GCCJVNBI(J"BI*&#68**ECI(3(;MHC0(NH@"YLO/
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MW!10$*KI(O\ #1.TEV1D?QJ$:SD*+F3Z7ER&)P09[Z29#3!2*%8F/^]-08/
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MYG<&<IMP44!"JZ2+_#1.TEV1D?QJ$:SD*+F3Z7ER&)P09[Z29#3!2*%8F/\
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MFKJ^(\2F/]EJV;_WT=?^M^J_^V[[5_OH_P#3-_\ 5'_MSZ.O]=Z^_P#""_\
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M9 6K,Q9B>-6I4TKUC!]XOWH@]X-[MYMIMGL-IVJQM=JV:S9@TL%E9@Z6D9
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M'JH=/B1.Z:J&FJM#2G596R^]/YOW5&U\-TSNGX,[![SWGMK'0;5QWR%V_O\
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M.J-;)M[-?QJEJS7P4E;53?;S0K)JCU2S5,9D%-3G4\NU\UD75Y=-:7!51/\
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MJTZ]0M?ZVO>U[>_=:\-JTH:^E#UQ^ZIO^5B#_DM?^*^_=;\%_P"$_L/68$,
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M>'PV)@EG@QN/C]#2(CZ9)(T9(X(U2%6M^W]=U6."WA6WMXJF.%6+G4U-3.[
M%V-* G@H 'F25>_7WAHO=:TL-@V+:H-BV#:R[V6V02M<,UQ*H$EQ<3NJ/-*V
M0K,*JK$$NQ9RGOE7\%MR=N=L;9^3'QT[VS?QC^3.U]J2;$FWWB\719K&YS"2
M3I.,=G,36Z8JH4\BWAD8R(OI\D$IBIVA=V3F--OA:TNX%N;9G$GAL[QLD@4K
MJ1D/;4&C8-0*8S4U]E/O)6?(NQW')_-FS0\P\OW%RMZ+*2YFM)[.\5&C\:VG
MAJR%E-'4 $YTN@9PZA^'OPIK_CON7L?N3MON+</R*^2G;T5/C]]=M[@I(L9#
M'C:.1GH\/AL3!+/!C<?'Z&D1'TR21HR1P1JD*M;]OZ[JL<%O"MO;Q5,<*L7.
MIJ:F=V +L:4!/!0 /,DJ]^OO#1>ZUI8;!L6U0;%L&UEWLML@E:X9KB50)+BX
MG=4>:5LA68556()=BSE/?*OX+;D[<[8VS\F/CIWMF_C'\F=K[4DV)-OO%XNB
MS6-SF$DG2<8[.8FMTQ50IY%O#(QD1?3Y()3%3M"[LG,:;?"UI=P+<VS.)/#9
MWC9) I74C(>VH-&P:@4QFIK[*?>2L^1=CN.3^;-FAYAY?N+E;T64ES-:3V=X
MJ-'XUM/#5D+*:.H )SI= SAU#\/?A37_ !WW+V/W)VWW%N'Y%?)3MZ*GQ^^N
MV]P4D6,ACQM'(ST>'PV)@EG@QN/C]#2(CZ9)(T9(X(U2%6M^W]=U6."WA6WM
MXJF.%6+G4U-3.[ %V-* G@H 'F25>_7WAHO=:TL-@V+:H-BV#:R[V6V02M<,
MUQ*H$EQ<3NJ/-*V0K,*JK$$NQ9R%O>O\O[M"O[TW;\D?AS\H<S\5.SNTL;18
M?N+'C 8W<>"W M LD5-D7QU?ICI\M#%)I\Q675ZFC^WDEGDE6[7S/#%;):;A
M:K=Q1%VAK+)$\9>A8!DK5"1733B:UX#H:>VOWH=FM>6[7E'G[EV+F3;MNDFE
MVI_KKBPO+$SE6>(305+0,RUT=M,:O$5453!_#7X@X/XD[+W51S;WW%VSVMVC
MN8[Z[F[AW<--?N#,-&(_((/+.*.@I@7%-3>64Q"1]4LC,6]E6_;VV]RJ0BQ1
M1KX<,*?#'&"2!7!9B22S'+$UP* 19[_>^]S[Y;C;2+9P;9MNW6_T>T[5:YAL
M;0-JIJTIXDKX,LNE=9 HJ@ =%\[U_E_=H5_>F[?DC\.?E#F?BIV=VEC:+#]Q
M8\8#&[CP6X%H%DBILB^.K],=/EH8I-/F*RZO4T?V\DL\DIKM?,\,5LEIN%JM
MW%$7:&LLD3QEZ%@&2M4)%=-.)K7@.I3]M?O0[-:\MVO*//W+L7,FW;=)-+M3
M_77%A>6)G*L\0F@J6@9EKH[:8U>(JHJF#^&OQ!P?Q)V7NJCFWON+MGM;M'<Q
MWUW-W#NX::_<&8:,1^00>6<4=!3 N*:F\LIB$CZI9&8M[*M^WMM[E4A%BBC7
MPX84^&.,$D"N"S$DEF.6)K@4 BSW^]][GWRW&VD6S@VS;=NM_H]IVJUS#8V@
M;535I3Q)7P99=*ZR!15  Z+YWK_+^[0K^]-V_)'X<_*',_%3L[M+&T6'[BQX
MP&-W'@MP+0+)%39%\=7Z8Z?+0Q2:?,5EU>IH_MY)9Y)37:^9X8K9+3<+5;N*
M(NT-99(GC+T+ ,E:H2*Z:<36O =2G[:_>AV:UY;M>4>?N78N9-NVZ2:7:G^N
MN+"\L3.59XA-!4M S+71VTQJ\1515,'\-?B#@_B3LO=5'-O?<7;/:W:.YCOK
MN;N'=PTU^X,PT8C\@@\LXHZ"F!<4U-Y93$)'U2R,Q;V5;]O;;W*I"+%%&OAP
MPI\,<8)(%<%F))+,<L37 H!%GO\ >^]S[Y;C;2+9P;9MNW6_T>T[5:YAL;0-
MJIJTIXDKX,LNE=9 HJ@ =2OBA\:-W?''_37_ 'L[OW'W3_I6[=R'9.!_O#2U
M--_=V@K+>#;])]SF<OY:.BYT-']K'R=-,GNN\[I%N?@^%"L/A0)$VFGZKI6L
MAHB=S5S6IQ\1Z8][?=VP]V/W1]#L]OM/[MVN#;Y_ DCD^OGAKJNY/#M;6DDF
M-0;Q6QF1NB<;X_EL=X;2[ [2W'\*OF?N/XL['[WW%4[M[2ZS;;6-W!00Y:MB
M2*LR>WI)YJ6?$SU6C4_A:.96TB.K2**&&(06G-MK+%''N5FMTT"".*3QI(6$
M8)(5].H,!6BX%!BAJ3U/W+?WN>6]\VO;K3W#Y3@YCO-FMX[7;MP_>%Q8SM:Q
M.S1PW019%G6/51=89"*ZHBS.['V^+'QGV%\2NF\%TYU_49C*T./K:K/;@W3N
M27SY/-9C(2^;(9;(S !7JJJ2PLH"I&D<8X2Y#&\;M+O=PUQ+I!- %0:41% 5
M54>2J  /YDGK&3WI]W]S]\=_FW_=%BC>1(X8+:W71;VEK NB*"%<T1%]34L6
M8Y/1"=\?RV.\-I=@=I;C^%7S/W'\6=C][[BJ=V]I=9MMK&[@H(<M6Q)%69/;
MTD\U+/B9ZK1J?PM',K:1'5I%%##$)[3FVUEBCCW*S6Z:!!'%)XTD+",$D*^G
M4& K1<"@Q0U)ZR;Y;^]SRWOFU[=:>X?*<',=YLUO':[=N'[PN+&=K6)V:.&Z
M"+(LZQZJ+K#(175$69W8]GQF^+/6WQ>Z.QW16T%R.XL"7KLAN[.;N=:JNW!D
M<JS/E<CE7(T335Q;0R@:%A5(@"%N0SN^[R[S<-<RZ0QTA50:415 554#@%
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M<*YZ)F^\O[@-N"[L>8-U-XMN]HMS]7+XPM7E29H@]:^&TD:.5X%E!XCI,?\
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M@5(16(%2!4^>.I.6W!@< M.^=S>(PJ5DWV](^6J8:82R?71&9G0.]O[*W/\
MA[T%+<.F;+;+G<BPMHI)2HU,(XV?2OJ=(-!\ST[^]=(ND_F]V[5VS-CJ?<>Y
MMO[?J,Q*T.)@S=;34CU3H8U=*99Y(VG96F0$(&(+H#^H7LJ%N )IQH.C3;]D
MO=W61[2WGF6( RF**201@AB"Y16"@A6H33@?0]*#W7HKZ][]U[IAR.ZML8C)
MXW"9;<>!Q>9S+!,/B,C64\%55DMH IJ>6199R7.D!%;GCZ^[!"14 T'$]&5K
MLUY?0R7$$$TD46994B=XXQ2O>RJ57&>XC&>N.0W;M7$Y;'8#*[FV_C,[E]/\
M)PN0K::&KJM;F-/MZ:219I]4BE1H5KL"!R+>_!"14 T'$TZM:[)>WL#W,-O/
M)#%7Q)4BD>*.@U'6ZJ56@-34C&>E![KT5]>]^Z]U[W[KW7O?NO=>]^Z]TGX]
MV[5EW!-M.+<VWY-TTT0FJ-M1UM,<A&AC28.]&)#4HIBD5[E -#*WT(/NV@TK
M0T]:8Z-&V2]2U%Z;><6[&BW!BD$+'45H)-.@G4I% >((XCI0>Z]%?2?HMV[5
MR6;KMM8[<VWZ_<>+B:;)8"BK::6MIT1HT=YZ5)&GA57E1274 %U!Y87L4(%2
M#3UICHTN-DO;2W2[EMYT@D($<SQ2+$Y() 5RH5B0I( )P#Z'I0>Z]%?3#CMU
M;8R^3R6$Q.X\#E,SAF*9C$8ZLIYZJD(;014T\4C2P$.-)#JO/'U]V*$"I!H>
M!Z,KK9KRQACN)X)HXI<Q2O$Z1R"E>QF4*V,]I.,]/WNO1;U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=4$[H_G#_*W ;FW%@J#^4S\A<]0X7.U>)HLY
M25^Y!%6Q4U1)#'5Q!.LYD$=0B"1=,D@LPL[#U&4[3D';KF))&W:V1F16*$15
M0L 2IK<C(K0X'V#KI[LGW">1]TLX+F7W,V*!YH8I7A>';]<+R(KM&U>8$-4)
M*FJJ:C*CATQ?\/._+C_O4'\C?_/AN;_[5_M1_K=;9_T>+7]D7_;5T9_\F^^0
M_P#PJ.P?\X=N_P#+BZ]_P\[\N/\ O4'\C?\ SX;F_P#M7^_?ZW6V?]'BU_9%
M_P!M77O^3??(?_A4=@_YP[=_Y<77O^'G?EQ_WJ#^1O\ Y\-S?_:O]^_UNML_
MZ/%K^R+_ +:NO?\ )OOD/_PJ.P?\X=N_\N+KW_#SORX_[U!_(W_SX;F_^U?[
M]_K=;9_T>+7]D7_;5U[_ )-]\A_^%1V#_G#MW_EQ=>_X>=^7'_>H/Y&_^?#<
MW_VK_?O];K;/^CQ:_LB_[:NO?\F^^0__  J.P?\ .';O_+BZO\V_DI\S@<)F
M*K'S8FIRN(ILE48NH),E-)/"DKT[EDB8O"SE"2B&X-U4\")6%#3KE[N=HMA<
MRP(XD6.62-9%I20(Q4,*%A1@*BA/'B>/3O[UTAZ][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>ZUI_Y 7_9$GRP_P#$D9+_ -Y+'^Y@]X?^2I!_SSI_U=EZZ]_WHW_3QN6_
M^E?;_P#=SN.E/_(;_P"W;/R5_P#$W[R_]X+9_NGO!_R5H?\ GFC_ .KTW1/_
M 'F__3W-@_Z4^U?]WG=>C!_R!_\ MWWBO_$O;F_Z'H_9-[I_\EJ7_21?]6UZ
MBO\ O/\ _IZ<W_2LV_\ X[)U8-\Z?^R)/F-_XJOV%_[R67]AGE7_ )*EG_SU
M6_\ U=3K%O[M?_3QN5?_ !9-C_[N=KT1[^1)_P!NY^M__#YW7_[NZGV(?<__
M )+=Q]D/_5F/K(W^\M_Z>UN'_/)MO_:'%U<3[ '6 _7O?NO=5H?SB/\ MVU\
MH/\ PWL'_P"]7@?8OY!_Y+%K_P U/^?6ZR_^X1_T]WEW_GHN_P#NW7G7OY._
M_;MKXO\ _AO9S_WJ\][]S]_R6+K_ )J?\^KU[[^__3W>8O\ GHM/^[=9]67^
MPAUB!U[W[KW5*/\ /X_[=]Y7_P 2]MG_ *'K/<B>UG_):B_TDO\ U;;KH?\
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MT?\ //\ ]8K?KKW_ 'B'_3N?;O\ Z5X_[MFU]"+_ "8O^RN/YOG_ (L;C_\
MWINT/;7N+_R3-G_YY3_U:M>@I_>"?\J'[7?]*";_ +MW+O2L_DF?\?A_,>_\
M6YR'_N5F?97[@_!MO_2O@_P=$']XC_N!R%_XJUO_ -6[;J^?W''7,[IDW+_Q
M[FX/^U)5_P#6B3WL<>E^U?[E0_\ -6/_ (^.M=?^01_V01\G_P#Q+N>_]XS
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MP>\/_)4@_P">=/\ J[+UU[_O1O\ IXW+?_2OM_\ NYW'2G_D-_\ ;MGY*_\
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MGG\C_JKY&_W*_P!(G^CK;S?[\[^)?PC[S^+]EU&"_P"+A]AD_M_M_P")^?\
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M?=8^Z/\ \$OO6[;1^]OW;^ZXU?Q?H?K/'K.\--'UEKH^'574_&GSZ5/\P_\
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M?^+<Y#_W*S/LK]P?@VW_ *5\'^#H@_O$?]P.0O\ Q5K?_JW;='-_EX?S /\
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M,>G3]7::*4K6K5X4''HCW\^;_N0S_P 64'_R+]G?MO\ \M#_ )X)O\G61?\
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M)316IU47KLO^8A_H[_F$]2_ _P#T0?QC_2CMNGW#_I4_O!]O]C]Q39JI\/\
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M -UNX?:'F;_E;X_^>FQ_P0= W[S/_B4&R_\ 2XY1_P"K]ATF/B9_W#V]R?\
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M<N_\K?)_ST7G_'9NB/V,_P#$J=U_Z6',/_:/<]<OYA__ &X@^)W_ (C7I?\
M]Y2D]VY5_P"5MF_YKWO^&7K7W5/_ !)GF3_I8\V?]W&;J/\ S7?^W,/P\_\
M*5?^\'DO;?MY_P K%-_U$_\ '^G/N/\ _B0?-'_C2?\ =X@ZD?SL/^W5/P__
M /$E=?\ _ON-U^W/:;_DLW'_ #0E_P"K\/3?]W1_T^OFC_I7;W_W?MMZ1_\
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MR1MV_P":#?\ 5B;K7W'_ /IRGN1_TKMT_P"[#<]1_P"99_V^>_EK_P#DF?\
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M=_.Z_P"RG?Y3G_B>,Q_[T'67MKVX_P"2;N__ #S#_JU==$?]W/\ \J9[F?\
M2EM?^T'F'KW\VO\ [>-?RB?_ !/&(_\ >ZV9[][>_P#))WC_ )YC_P!6;GKW
MW&/^G3>Z'_2EN?\ NS;MU"_F;_\ ;VC^5O\ ^'3A/_>QA]I^3?\ DA[K_I(_
M\#]._<Z_Z<=[C?\ /-<_]VM^DM_,L_[?/?RU_P#R3/\ WO,O[4\H?\J[N?\
MJ_ .CO[H7_B/G/\ _P!33_NSVW4CYY_]OW_Y?G_B-=J_^]7O[VYR]_RJ5_\
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M?Z\+_P#*!)_SE/\ UHZ]_P G*[__ *83?O\ >I/^V#KW_#&&S_\ O8Q\:/\
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M (O+Q)ZS$^X+O5YS#[V;%>[A/-<W$IW0R3W$KS32$;%N*@O)(S,Q"J *DT
MX#JN?OW_ +AU.J/^U+M+_P![$>Q-L?\ RN+_ /-:Z_ZMR]97>UO_ (EAN7_-
M?=/^[6W5Q'P,V5LWL'^7;\3]K[]VEMG>^VJSHS;4U7MW=]!2Y*AE>&DAEA>2
MDK8IJ=VBD4.A9"58!EL0#[ ',\SV^[7;QLRL+F>A4D$5D8<10]8$?>9YAW#E
M?W7YEO-LN;BTN$WG< L]K-);S*'E=6 DB9& 8$@@'()!QT<+-]6=8[EV?CNO
M-Q]<[#W!L##T]+28G8V;Q&/J\/2Q4$8AH8J;&3T\E%!'1Q*$@5(U$2 +&% M
M[($NI8W\178.226#$,2>.0:Y\_7J!-NYSWC:+]]UM+Z\AO96D:6\ANIX[J1I
MF+2,\R.LC&1B2Y+$N35JGKVX^K.L=X[6QNQMW=<;#W5LG"_;_P 'V?N/#X^N
MQ5)]G"U/2?;8^JIY:2#[6!C'#HC7QQDHFE21[]%<R0-K1V5C6K*Q#&O'(-<]
M>VGG/>-@O9-RL;^\MKN77XMU!=3PW,GBL'?7+&ZNVM@&>K'4PJ:GKV[.K.L=
M^[=QFT-]=<[#WIM/"U$-7AMK[LQ&/R..I)::"2EIY::BK*>:F@D@III(HV1%
M*1.\:D(S ^ANI;9BT;LK'!*L5)!SQ!'IU[8^<]XY9NI+[;;Z\M+F5766XMKJ
M>">19'61E>2)T=@SHKL&)#,H8U(!ZQ[MZFZKW_@\3MC??6?7^]=MX!XY<%M[
M=N&QV2H:)HH33Q-24E9334],T=.QB4QHI6,E!93;WZ&ZEMF+1NRDX)5BI(X\
M01U?8^=]ZY8N9;S;-PO;2>8$33VUU/!-*&8.0[Q2(S@L QU$U;)SUKR?\*1H
M8:;ICXO4]/%%3T]/V+FH8((5"(B)BJ551%4!555   %@.![EOV9_W/G_ .:'
M_61.NJO]T;(TO,7,+,26.WVI))J23=.223Q)\SUL1[VZQZV[+BQ<'8W7NQ]_
MP82L.0PL.]L3095*.H("F>E6OIYQ3S$* 7CTL0 +\>XCAN)+>IC9EJ*'2Q6H
M]#0BHZY2<O<X;MRBTC;3>W=D9D\.4VES-;&5..ES"Z:ESP:H^75 7\_'_C]O
MY=G_ (FO+_\ N7L_W)_MI_8[E_SQM_QU^NH/]V/_ ,DWGO\ Z4]O_P!6MTZO
M^W9UEUOOW(;;RV^NOMD;TRNS:QLCM#)[LQ-!D:C%5#O3RO/C9JRGFDH9GDI(
M'9X2C%H8F)O&A$8Q7,D 94=E#"C!6(##.#0YXGCZGKE]LG.&[<LQ3P;;>W=I
M'=(([J.VN9H$N4 =0LRQ.@D4"1P%<, '84HQKKO?SK?^RV_Y87_B2(__ 'K=
MI^Y9]N?^27N__//_ -8KCKJS_=W_ /3N?<3_ *5Y_P"[9NG6PYN/JSK'>.XM
MN[OW=USL/=.[-GU$57M+=&X\1CZ[(XN6"=:J&7'5M53RU-%)#4HLJ-"Z%95$
MBD. ?<3174L*LJ.RJV&"L0&'#(!SQ\^N5.T\Y[QL%K/8V-]>6UM=*RW-O!=3
MPP7"NAC998XW5) R$H0X(*DJ<&G7L]U9UCNG=.!WSN?KC8>X][;5\7]V-X9[
M#X^LRN-\,S5$/V&0J*>2KH_%.[2)XI$TR,76S$GWY+F2)2BNP5OB4,0K?: :
M'\^O;;SGO&S64VVV=_>06ESJ^HM8;J>*VGU*$;Q8D=4DU* IUJ:J #@=4#?/
MS_M]I_+B_P##6Q'_ +T6Y_<G<M?\JUN7^GC_ ,,?73[[L7_B.O/O_/3/_P!H
M6W]7_9/K+K?-;SPW8V8Z^V1ENPMNT8QVW]^9/$T$^9H*<&H804>4EIWKJ6$&
MKG(2.55O-*;?N/>,5N9$0Q!V"$U*!B%)QDBM#P'[!UR^M.<-VV_;Y=IM[V[B
ML9W\2>SCN9DM)G[!JDA5Q&[?I)W,I/8F>T4H.[>_[B+/BS_X@?(_^\;V/[E;
M:O\ E3[S_GI7_JY:==/.0O\ Q$[F3_I=0?\ =UV#I([Z_P"XD7IC_P 1K5?^
M^OW7[=V[_E3KK_FNO_5ZVZ/.6/\ Q$?=_P#I8Q?^3#M?4?\ [N2?_*>__,J]
MM_\ .G_]1/\ UDZ<_P#81O\ J/\ _*CZV(H>K.L:;?57VC3]<[#@[,KZ<4E=
MV)#B,>N=FB6GBI!%+EUIQD)(Q2PQPA6E($4:1VT*H$4&ZE:,1%VT U":CI!R
M<"M/,_MZY32<Y[Q-MJ[,]]>-MZ-J2Q-U.;-&+M)J6 OX0.MV>H6NIF;B2>J$
M^H?^XBSY3?\ B!\=_P"\;UQ[E;=?^5/L_P#GI;_JY=]=.>??_$3N6_\ I=3_
M /=UW_J_'&=9=;X7>>9[&P_7VR,3V%N*C..W!OS&8F@@S-?3DT[&"LRD5.E=
M50DTD!*22LMX8C;]M+12US(Z"(NQ0&H0L2H.<@5H.)_:>N8=WSANVX;?%M-Q
M>W<MC _B06<ES,]I"_>-4<+.8T;]5^Y5![WSW&M)_P )/^WR7\S/_P -K"?]
M"X;W(',/_*O[7_IKK_JZ>NA_WBO^G >WO_/1??\ 'KKJZO ]6=8[6W3GM\[8
MZXV'MS>VZO+_ 'GWA@</CZ/*Y+S3+43??Y"GIXZNL\LZ+(_ED?5(H=KL ?<?
MO<R2J$9V*K\*EB57[ 30?EUSSW+G/>-YLH=MO+^\GM+;3]/:S74\MM!I4HOA
M1.[)'I4E1H444D#!Z]MSJSK'9VXMQ;OVCUSL/:V[-X5$M7NW=&W,1CZ'(Y26
M>=JJ:7(UM+3Q5-;)-4NTKM,[EI6,C$N2??I;J6955W9E7"AF)"CA@$XX>77M
MVYSWC?[6"QOKZ\N;:U55MK>>ZGF@MU1!&JQ1R.R1A4 0!  % 48%.O;4ZLZQ
MV'EMP9_8_7.P]FYW=M1]WNK-;4P^/QU7DY?++-Y,A4T=/#-6R>::235,SG7(
M[7U,Q/I;J2<*KNS!110S$A1@8!.. X>G7M[YSWCF6""UW&_O+J&V73;17-U/
M/%;KI5*1)*[+&-**M$ %% X =44?R8O^RN/YOG_BQN/_ />F[0]RI[B_\DS9
M_P#GE/\ U:M>NE?]X)_RH?M=_P!*";_NW<N]*S^29_Q^'\Q[_P 6YR'_ +E9
MGV5^X/P;;_TKX/\ !T0?WB/^X'(7_BK6_P#U;MNKK]D]8];=:192#KGKW8^P
M(,W6#(9J'9.)H,4E94 %1/5+04\ J)@&(#R:F )%^?<?37$EQ0R,S4%!J8M0
M>@J30=<\.8><-VYN:-MVO;N],*>'$;NYFN3$G'2AF=]*XX+0?+K7&_X3L?\
M9/?R[_\ #OQW_NDK?<N^\O\ N?!_S0_ZR/UUG_O8?^5JY9_YXY_^TR/H6?\
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MQ/1;/YA__;B#XG?^(UZ7_P#>4I/9YRK_ ,K;-_S7O?\ #+U+WW5/_$F>9/\
MI8\V?]W&;J\GK+K[8797QLZ-V]V-LC:&_P# 1]7;7R4>#WMC:+*T:U,6#I4C
MJ%IJZ&> 3QI*ZJX74H=@" QO%<MQ);3NT;,AU,*J2II4^8(ZYM\W<T;GRCS;
MN]UM-W=64YW#<(S-:7$MM*4:[D)77"Z-I)4$K6A(%1@="CNSJSK'?NW<9M#?
M77.P]Z;3PM1#5X;:^[,1C\CCJ26F@DI:>6FHJRGFIH)(*::2*-D12D3O&I",
MP+$-U+;,6C=E8X)5BI(.>((].@=L?.>\<LW4E]MM]>6ES*KK+<6UU/!/(LCK
M(RO)$Z.P9T5V#$AF4,:D ]>WGU9UCV/B<=@.P^N=A[\P6'J%J\1A=YX?'Y2D
MI94B:%9*:FKJ>>&"186:,,BJ0A*@Z21[]!=26Q+1NR$BA*L5)''B".O<O\Y[
MQRE/)=;5?WEE-*I666TNI[>612P<AWA=&8%@&()(J >/7M]]6=8]I4M!0]F]
M<[#[%HL54/5XNCWWB,?EXJ:610CRT\>0IZA(9'0!69 "1P3;WZ"ZEM23$[(3
M@E6*DC\B.O<M<Y[QR8[R[/?7EB\BA9'L[J>U:10:A6,#H6 .0#4 YZHO_GS?
M]R&?^+*#_P"1?N1?;?\ Y:'_ #P3?Y.ND?\ =G?\[I_XKS?]9^@U_G]?\SA_
MEI?^)*W5_P"[3KCV;>V/^X.Z_P#-!/\ JW<]#+^[!_Y5[W!_Z5VW?]HV_=*[
M^=U_V4[_ "G/_$\9C_WH.LO;7MQ_R3=W_P">8?\ 5JZZ(_[N?_E3/<S_ *4M
MK_V@\P].O\W#_LO_ /D\_P#BQM+_ .]KU][K[>?\DO>/^>7_ *PW72'[BG_3
MK_=/_I02?]VG?>D[_,W_ .WM'\K?_P .G"?^]C#[9Y-_Y(>Z_P"DC_P/T9_<
MZ_Z<=[C?\\US_P!VM^K^<]U9UCNG=.!WSN?KC8>X][;5\7]V-X9[#X^LRN-\
M,S5$/V&0J*>2KH_%.[2)XI$TR,76S$GW&*7,D2E%=@K?$H8A6^T T/Y]<P=M
MYSWC9K*;;;._O(+2YU?46L-U/%;3ZE"-XL2.J2:E 4ZU-5 !P.O9CJSK'<.\
M,+V'G^N=AYS?^VZ>.DV[OG,8C'U.8H(HI)IHHJ+)S4[UM+'%+4S.BQ2*%>61
M@ 78GRW4J(8U=@A-2H8A2<<16AX#]@Z]8<Y[QM=A+M5K?7D-E.S-/9Q74\=K
M,S*BEI(4<1N2L: EE)(50<**4&_(_P#[B$OAI_X@T_\ NL[(]RKL_P#RJ%[_
M ,]*_P#'K3KIU[2_^(K<V?\ 2Z7_ +2.7^LW;W_<19\6?_$#Y'_WC>Q_>]J_
MY4^\_P">E?\ JY:=:Y"_\1.YD_Z74'_=UV#H4?\ A0S_ -D);;_\6'V__P"Z
M?<GLO]I?^2N/^:,G_/O0+_NJ_P#IYD__ $H[[_M)L.B\?S7?^W,/P\_\I5_[
MP>2]F/MY_P K%-_U$_\ '^I4^X__ .)!\T?^-)_W>(.I'\[#_MU3\/\ _P 2
M5U__ .^XW7[<]IO^2S<?\T)?^K\/3?\ =T?]/KYH_P"E=O?_ '?MMZV!,IUE
MUOVALS:>)[+Z^V1V)BL?04F1H,9OK$T&7IX*C[01>>&'(4]1'%-XW9-:@-I9
MEO8D>XEAN9+5BT3LA."58J:5X8(ZY;6'.&[<FW]Q/M%[=V,CM)&\EG<S6SNG
MB:M+-"Z$K4 Z22*@&E1U35_/<_X\_P"%/_BW.(_]Q9O8_P#;CX[[_I7W'^%.
MN@']VK_N?S=_XJUW_P!7$ZNKWOU9UCV9_"/])'7&P^P?[OU#U6!_OOA\?EOL
MI9?'Y9*3[^GJ/MI)/"FIH]);0ER=(M'\-S);5\-V6HH=+%:CT-"*]<\^7><]
MXY0\7]TW]Y9>.H6;Z2ZGMO&5=5!)X+IK U-0-4"IIQ/7MY=6=8]C56 KNPNN
M=A[[K=J5$E7M>LWEB,?E)<;+,T#RRT$E=3SO1R2O2PL[0E"QAB)),:6]#=2V
MX(C=E#88*Q 89XT(KQ/'UZ]L'.>\<J)-%M=]>6:7*JMPEK=3VZW"J'"K*(70
M2 "1P ]0 [ ?$:Y=V=9=;[]R&V\MOKK[9&],KLVL;([0R>[,309&HQ50[T\K
MSXV:LIYI*&9Y*2!V>$HQ:&)B;QH1Z*YD@#*CLH848*Q 89P:'/$\?4]4V3G#
M=N68IX-MO;NTCND$=U';7,T"7* .H698G02*!(X"N& #L*48UH._FU_]O&OY
M1/\ XGC$?^]ULSW*WM[_ ,DG>/\ GF/_ %9N>NGGW&/^G3>Z'_2EN?\ NS;M
MU?AG^L>MMU[DV]O+='7NQ]R;OVC(LVU-U9_$T%9DL6Z2B9&QU=44\E51,DP$
M@,+H0XU#U<^XHCN)(E**S!6^)0Q ;[0#0_GUS#VSG#=MEM)["SO;N"UN@1<V
MT-S-%!< KI(EC1U20%>TAU.,<.L>>ZLZQW3NG [YW/UQL/<>]MJ^+^[&\,]A
M\?697&^&9JB'[#(5%/)5T?BG=I$\4B:9&+K9B3[VES)$I178*WQ*&(5OM -#
M^?5]MYSWC9K*;;;._O(+2YU?46L-U/%;3ZE"-XL2.J2:E 4ZU-5 !P.O9CJS
MK'<.\,+V'G^N=AYS?^VZ>.DV[OG,8C'U.8H(HI)IHHJ+)S4[UM+'%+4S.BQ2
M*%>61@ 78GRW4J(8U=@A-2H8A2<<16AX#]@Z]8<Y[QM=A+M5K?7D-E.S-/9Q
M74\=K,S*BEI(4<1N2L: EE)(50<**:\?R7_[B$OB7_XC?'?^ZS>GN6=F_P"5
M0O?^>@?\>M>NJWM!_P"(K<S_ /2PF_[2-HZV(:KK+K>MWQCNS:WK[9%7V3AZ
M-L=B>PJK$T$F<I:=HIX&@I\L].:^"%H:J:,HDJJ4FE0C3(X,3"YD5#$'8(34
MIJ.DG&2*T/ ?L'7*:'G#=K?;I-GCO;M;"5Q)+8K<S+9R.&1PSP!Q$S!HT8,5
M)JBFM5%.GZQZVDWQ#V=)U[L>3LFGHSCX.PGQ- <XE.8F@,"98T_WZPF!VCT"
M4+XV9+:21[U]1($\+4VBM=&HZ:^M*TKUY><-V3;CLXO;L6#/XC6(N9A9E]0?
M48-?A%M0#5TUU &M1UY.L>MH]\3=G1]>['C[)J*,8^?L),30#./3B)8! ^6%
M/]^T(@18]!E*^-52VD >_?42%/"U-HK71J.FOK2M*]>;G#=GVX;.;V[-@K^(
MMB;F8V8?47U"#7X0;42U=-=1)K4]8X>K.L:;?57VC3]<[#@[,KZ<4E=V)#B,
M>N=FB6GBI!%+EUIQD)(Q2PQPA6E($4:1VT*H&S=2M&(B[: :A-1T@Y.!6GF?
MV]7DYSWB;;5V9[Z\;;T;4EB;J<V:,7:34L!?P@=;L]0M=3,W$D]>H.K.L<5O
M7)=E8OKG8>-[&S-.U)F-_P!!A\?#FZN)EB1HZG*QTZUT\;+!$"KRL"(XP19%
MMYKJ1D$1=B@-0A8Z0<\!6@XG]IZ]<\Y[Q>[='M$U_>26,3!HK)[J=K2)@6(*
M0,YC4U=C55!JS>IZ]A^K.L=O;PS78> ZYV'@]_[DIY*3<6^</B,?39BOBEDA
MFEBK<G#3I6U4<LM-"[K+(P9XHV()12/-=2N@C9V* U"EB5!SP%:#B?VGKU_S
MGO&Z6$6U75]>364#*T%G+=3R6L+*KJ&CA=S&A"R. 54$!F PQKDPW6/6VW-U
MYW?FW^O=CX+?.Z(VAW-O/#8F@I<MD49XY&6NR,%.E95JTD2,1+(X+(C'E01I
M[B21!&S,57X5+$J/L%:#\NJ7_.&[;K90[9=7MW-9VY!M[26YFDMH" R@Q1.Y
MCC-&8551@D>9Z]@.L>MMJ;DW#O+:_7NQ]M[OW=(TVZ]U8#$T%'DLH[RF9VR-
M=3T\=56L\Q,A,SN2YU'U<^_27$DJA&9BJ_"I8D+]@)H/RZ]N?.&[;U:06%Y>
MW<]K:@"VMIKF:6"W 72!%&[LD8"]H"*,8X==[;ZRZWV9G-S;GV?U]LC:FY=Z
M5C9'>.X=MXF@H:[+5#S2U#SY.KI:>*HKYGJ)Y92\[NQDD=R=3L3N6YDF55=V
M8***&8D*,"@!.. X>G7MWYPW;F"VM[._O;NYM[1!':P7%S--#;(%5 L*2.RQ
M*%15"H% 55%* =..U]E;-V1#EZ?9>TML[1I\_G:C=&>@VO04N/2MR=4(UJLC
M5K211+4U]2L2"6HD#2R!$#N=(M669YJ:V9J *-1)HHX 5X >0X=)=XYAW#F)
MHFW"YN+IH(4MX3<323&&WCU%(HS(S:(DU-IC6BK4T J>E-[:Z)^O>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>ZC5E928ZDJLAD*JFH:"AIGK*VMK'6*&&&)2\DLLCE
M4CCC12S,Q"JH)) 'OW7NF#96]]G=D;5PF^>OMT8#>VR]S40R6W-V;6JX*_&Y
M"F9F5*FBK:9Y*>JII"IT2Q.T;CU(S*03[KW2H]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2.W/V'L/962VAA=X;SVOMC
M,]@Y\;4V'B,[74U+59K)F&2H-!BJ::1)LA5K30R3/% KND,<DK@1HS#W7NEC
M[]U[I'4O8>PZ_?.6ZQH=Y[7K>QL!@*;=>>V+1UU-+EZ'&5DLD%'7UN/21JJD
MI*R:*1*>65$2=HY1$7\;Z?=>Z6/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND;1=B[ R6^,SUGCM[;3R'
M8NW,'3;EW%L2AR%+-E\?CJR62&CKJ['1RM5TE+5RPR)!++&B3-'((RQ1K>Z]
MTLO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]TC=L]B[ WIF-X;?V?O;:>ZLYU[EX]O[\Q&W,A2UM
M1A:^:!*J*ARL5-+(]!6O2R),()PDOB=)-&AU)]U[I9>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND=OGL/8?6.#3<O8V\]K[%V_+E:/
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MWV^3<KV>XCJ%EFDD4-0-I=RPK0D5H<Y/6)OOQSK9^Y'.>];]MPD%M?[C=74
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M7NMLG^1[_P!NA?Y=7_BJ6U/_ ' 3W[KW5J/OW7NO>_=>ZJN_GA?]NA?YBO\
MXJENO_W ?W[KW6BK_P (J?\ MZ;WY_XH!NG_ -^+U5[]U[KZ??OW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[J@W<GSZ_FU8W<6>QV#_EJ?QG"T&:JJ+$9BV73[NEBGDCIZG1]UZ?/$JO
M;\:K>Y&MN6]CEC1I-RT,54LO@,=+$ D5'&AQ7SZZ;[/]V/V-O+2":Y]P/!F>
M&-Y8M-NWA2,BLZ5\/.EB5KYTZ9?^'!_YOW_>L+_><O\ _57M[^K&P?\ 1T_[
M-W_S]&/_  +7L-_X43_C%O\ ]:^O?\.#_P W[_O6%_O.7_\ JKW[^K&P?]'3
M_LW?_/U[_@6O8;_PHG_&+?\ ZU]>_P"'!_YOW_>L+_><O_\ 57OW]6-@_P"C
MI_V;O_GZ]_P+7L-_X43_ (Q;_P#6OKW_  X/_-^_[UA?[SE__JKW[^K&P?\
M1T_[-W_S]>_X%KV&_P#"B?\ &+?_ *U]>_X<'_F_?]ZPO]YR_P#]5>_?U8V#
M_HZ?]F[_ .?KW_ M>PW_ (43_C%O_P!:^K]-NUF1R.W\%D,Q1?PW+5V&I:S*
M8ZS+]O4RP(\\.ER77Q2LRV8DBUB;^XT84..N8VZ016MS-% _B1I+(L;U!UHK
MD*V,=P .,9Z>/>ND'7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TGMW;4V[OS:>Y
M]C;OQ5)GMI[SV]6[4W1@Z]=4%;CLC32T=;23+_:BJ*:9XW'Y5B/?NO=?'4[%
MV_VM_(&_G5/4XO%U63J?B5W[%NW8PF:H@&Z>O,LC-!&E7/"@\FXMDY2;'5LL
M:S14U;+611O(U-J]^Z]T,?\ )@^,>_\ ^<I_.=PW8/>43;JVY%V=E/FA\I\@
MZ224532T>83*IA-%6E<GV&=W%5T6*^TDE#KBI:H02AJ8$>Z]ULC_ /"J_P#G
MB]Y?&G?^!_EX?#CL7-]4[RJ]C4^^?DCVYLJ<TF>HH,RKG";5PN3@E6MPE5+C
MT_B5?54XBJC!5XV.DJHU:L1_=>ZU)]X;8_G8_"_K/I7YV[QW/\TNF>M.U<C0
MYOJ?N^LW?F##D)JZ'^+X_P"]B3,U-33QYBEA:HA@RU/%'DH%D*QU$6L>_=>Z
M^B'_ "1?YM^Z?YH7\LGMW?/8U=3XOY5_'+;V8Z^[DR6W%3'_ ,0J/X%4U^W=
MX4,%)(!CSF*:.19%C$*IE,?D&I88:7[=1[KW6K%_PES^>OSG^0/\V78G7'?7
MS0^6/=W7E9TSO7*5>P^W>Q=X;EPTM52XU)*6IDQ>9S%;0O/3.=44C1%XVY0@
M^_=>Z.__ ,+!_F3\O?C+\GOB%@/C=\JODC\?<%N7H;,9C<>$Z0WSN?:=)D*N
M+<+PQU5=38'*4$-74QPCQK+*K.J>D,%X]^Z]T8K^9!\F?DAM[_A*G\+>_<!\
M@>[L'WKNG"=35>YNZL/NO/4V[<C+D*>L-?+7[C@KTS%9)7$#[AI:AS-8>0M[
M]U[K3E^/^0_G<?S':?<&R>@^R/G[\I<5UI')N[<L%#O3=V3QV*DJ(XXD^YR&
M2S*4,=?5QTQ^SHVG-5.(ZAJ.![5!]^Z]U]#O_A+;U!\L>JOY=&Z9OF)N'O.H
M[)W7\C]SM@]@=]5&=?*;5P^%BQVW_P"&1T>?FDJ:"*HS&,R%9HB6*"19XY41
MBS2/[KW6P5VSLJL[)ZK[+ZZQ^Y=Q;,K]_=?YG95#O#:&0KL1EL3-E<=4T,63
MQ>6QDU-DL9D:!YQ/35=)+%4TTR)-!(DJ(P]U[KYB'\A_^9Y_,$V3_.;^/W0/
MR^^7GRC[,V?O'?NY?C=V;U=WQV'NK=..I,_48[*8_%I%19;.9#&)E:/>%'10
M)4(DC>-IX8G'GUCW7NKL_P#A8C_,'^1?QA'PFZ.^,??O;W06Y=XG=O:W8>X>
MD]V9O:N6J:&A_A.(P='55.!K:"JGQTU159*0QRR&)IJ:-@A>+4ONO=!1M#^:
MS\H?Y7W_  G"Z&[^['[@[8[J^=_SZ[,W/D>D-S_(O<F5WQ7X'#O4R44>X4;<
MF3R,G\%Q6V,/0U=#CXV:E7+9VEJ*FC=:C(*_NO=:K.U=L_SL_F=U=W/\]-I;
MH^:?=/675N5K<GVMW?0;PS#)CYZ"&/*U_P!G3G,P5LT&&I*A*B:+%TTD&-IB
MK,E/"@T^Z]UMK?\ "4[^>)WC\E-^YW^7;\Q>Q,UVIO"BV+4;W^-G;6\Y_NL[
M64^%5#FMJ9G)32M69JIBQ[_Q''U50):H4])DHZNJD5:-$]U[K4A_G3]@_.K?
M?S2[/A^:LW?LV-VOVCO? _'%N\L5D\8G]RH]UY(4/]VWR5%1_?X7QK%XZB$S
M1.-)$K7!/NO=71?\)].]OYT]7\P?Y??6>YJGYOC^7DE7_"*:/([7W#%US_=6
M#;N6?$A<VV&3%G$&KCI_!)]WXI'\:!VU 'W7NAB_X4T?SS?DSN[Y:;M_ET_"
M_LCL#J[K;IS,4^Q>UMQ]25=30Y_>N\Y?MWJ\-2Y'%NF6BQ.#JI!BWHJ=X6K<
ME'7)4I40)2CW[KW5(F\-Q?SS_P"2YVOT]VQVMNCY1_'?<N[Z4[HV71[[W--G
M]O;BHZ4HE7C,YC(\QE\+7+$M6HJ,;D46KI3-%.(:><03+[KW7U-/Y7'SQVM_
M,G^#O1_RWV[C(-NY3?N#EQ?8FSZ9Y)$PNZ<1.^.S^-BDE1)):5*Z!I:21AJE
MHYJ>1K,Y ]U[JP3W[KW7S#_^%3/S/^8?2'\VW?NQ.EOEA\E>H=CT_2^R<G3[
M-ZOWWNC 8I*FIQCM45"8[$Y6DHUGG8 R2",,Y +$GW[KW5+GR%V]_.?Z6ZXZ
MM^;'R0W1\W]@[![^SB5/6?=F]MW;BIY<E7R4TN2HB",Q_$\5-64%/)5XU:J&
MD^[HX9*C'B6GA9T]U[H:L'V[_/L_G&S;@W'L#>WS ^3-!\>.OZ&EW&G6F3J\
M1A\=38^CDCIWDH<958C%97=V4B2>5C'%5;@RS&0@5*1(D7NO=6B_\)6/YL7R
M?VS_ # MA?"GM[N3L3M3H?Y*XO.X;!X#L3+5>87;FZ,;AJS/8_(XJHR51-44
M,.0CQ$U!/30-X9I:J&=HO)%K]^Z]U:S_ ,*B][?SJ:7Y+?'GH3X8;Q[QD^-O
MR/VHV-V3LSXIX_*X_<-5N[%S6SV-W-N'"@Y1J,T,]-6P*U918XT1K#4TK#'5
M-8_NO=:CGR=Z;_G7_P KO(]6=A?(_<?RT^->1WU75,G6.ZX>PZJK^YJ<8*6>
MK@^\V[N3)PTE1"E3"S4M8\,LR,Q6&1(YM'NO=;F-?_,A_F$_,S_A,OMGY2_'
M:O[DK_GG@>Q\1U'NC<GQ[Q%57;CS%1@MV08[)YBGQ.#QLO\ Q=MO20U612GI
M130S25)C6*)%6/W7NOGP]&[S^6VVOE/M[>WQ[?M]/F#2;ZR>2VR_76-KJW>?
M]X9HZX98TN,I:2HKY,CXY:O[B-:=G0>8LBZ6M[KW5QGRJ^1O\_K=OPDKL3\H
M*S^89)UAN+=F[\1WS#VKM'=%!B/[K04&Q)L.<])6X*FIJ'%G)SY#P3RM"DLP
MF02.8=*>Z]U7+_+[[7_F<]5Y_LNJ_EI3?*.+<F8P^.I^US\8L#F,[4FAAFJF
MQ?\ %X\1C,D]/!YWJ/ T@0._D"EB"![KW7T#?FK_ #?OD1_+2_D-?#7LO?YW
M=6_S$ODIU1B-A8F7M^A>/-X?<'\+^\W5NS<.(RD,,K5& 62&(4L\!'\3KL?'
M44[4OG4>Z]UHW[8V3_.^^7_4';G\PG;&Y?FAVWU/UQFJW*=C]ZTN\\H@I*B@
M"9"ODQM&^<ILC54N'2H6648BDEIL;'P13I$53W7NMPK_ (2H?SMNZ/EQD=Y_
M 'Y@[ZS'9?;/7^R#O_HKMO=TTM3G,U@\;)3T68P&>KI$,V3RF*%1!54U=4R2
M5M73M6"KDDDI4DD]U[JG'_A4S\S_ )A](?S;=^[$Z6^6'R5ZAV/3]+[)R=/L
MWJ_?>Z,!BDJ:G&.U14)CL3E:2C6>=@#)((PSD L2??NO=5O;$^*'\_WNFMZ8
M^2%?'_,1QVTN^^Q\%C-N?(C(YG>;/2?QW+4F-H=QU*09-<SCL*KUD<]-7R14
MU%+2Z):6<TY1_?NO="]_,?\ YD_\R7^:5_,+S_Q=^.W8W=@VEMOM7(=!_&[H
M#K'<5=A3FHL%7SXVGSN?T9#'P97<F6CHFR%=65\C)0(\R1R04D$DA]U[I1_%
MW8G_  HP^!/SR^-71%)F/EET;V-\@>S\9LK;M!VG75>[^NLW'43>7*R9!),C
ME]G9J+$X>BJ:RO%/4C)45!!+-#-2,8YO?NO=?6*IUG2G@2IECGJ4A5:B>)#&
MKN% =UC+R%%9KD+J;2.-1M?W[KW3'O#=FW]A;2W3OK=F0_A.U=E[<KMV;ERG
MBGG^VQ^.II:RMJ/!31S5,WAIH7?1%&\CVTHC,0I]U[JB/_H*._D4?]YS?^PR
M[B_^U][]U[KW_04=_(H_[SF_]AEW%_\ :^]^Z]U?][]U[JG;_A0)_P!N9_Y@
MW_B"I/\ W:XSW[KW7RC?@%T[_,6^1N\]\=#_ ,N^B[USFZ-W8&FW%V=MOIK.
MS;=IJG&8B2=*.;<63;)8C&QT-/4Y%U@2NJDBDJ)E6-7FT >Z]U9C_*%_FC_.
MW^77_,PZUZ8[B[4[:R_7^:^1%)\;/E%T-VSN&NR-!035.=&ULM6B'(5-=38_
M.[4R$CU*STS1&=J1J*:H^UGD(]U[K?@_X4,?S8,S_*I^%$6Z.JUHJCY+=];B
MGZQZ,:OB@J(,.\5(:G-;LJ:2H#15<& IW@CBB9)(WR-=CUGB>F,X]^Z]U\WW
M;&R?YWWR_P"H.W/YA.V-R_-#MOJ?KC-5N4['[UI=YY1!25% $R%?)C:-\Y39
M&JI<.E0LLHQ%)+38V/@BG2(JGNO=;A7_  E0_G;=T?+C([S^ /S!WUF.R^V>
MO]D'?_17;>[II:G.9K!XV2GHLQ@,]72(9LGE,4*B"JIJZIDDK:NG:L%7)))2
MI))[KW6L[_.@^>_SVZR_F[?-W8_4GS)^6>RMN;5^1E7CMD;$V-O_ '=1XNB"
M+1M3TF/PU'E4H8X3,WIIXX/&Y8KH.H@^Z]T.O\NGX+_SS,;_ #"O@%NWOR@_
MF ]/];]K=^;=W=NCL_>>8W>(I,)1RMN3-8_<4@R<E1B:G-X?%U-*U)F5IY)7
MG$<].X8QM[KW1TO^%-'\\WY,[N^6F[?Y=/PO[([ ZNZVZ<S%/L7M;<?4E74T
M.?WKO.7[=ZO#4N1Q;IEHL3@ZJ08MZ*G>%JW)1UR5*5$"4H]^Z]U2)O#<7\\_
M^2YVOT]VQVMNCY1_'?<N[Z4[HV71[[W--G]O;BHZ4HE7C,YC(\QE\+7+$M6H
MJ,;D46KI3-%.(:><03+[KW7T)\SVQO#^?C_(-WIE?C7C-@[<[E^5'5$?6V<V
MKOW*U^-P>W]TX[<%!1[LIY\E38?+UQI:)*.JJ\=:B=JV)J*.1Z85#U$/NO=$
M5_EE_!CM[_A-O_*S_F2_);Y!T?3_ &+\@12S]E82FZPR&3R&)KL7MS I2;,Q
M.3KZ[#82NA#[JS62-4D4+I%23K+'*TK.D?NO=:5VP-T_SM?YT/>O:^\>H-]?
M)'Y#]C8:DDWQO'![.WD<!A=N8ZJJ!'3T>+QU9GL1AL/0-)^W1T-(%>;Q2M''
M-)'42#W7NMB7_A,=N[^=%MS^8EOGXD_(7?'R#V]\?>DNNJ[>7R$ZC^4E+D\G
M)CVJ1)B=J0[9JMP2_P 1PTN4RL+STLN.G?%UU!0Y&405)$4\?NO=?0G]^Z]U
MJ[_\*^O^W.>YO_%BMB_];\A[]U[KYY7P0^.?\UOY6['[)Z\^ &$^26[NM.OL
ME_I#[-V]U-N*?;^!AR=321P0U%89<OB,=D<Y/18T)2TRM45[11-]M"5+W]U[
MJ[3_ (2[_P W'Y4[!_F$=5?#GMCN/?W;'QY^3LN3V9'MOLW.5F57;6XXL569
M3#9?!29.2IFI7KJO'KC:FCAEA@J%KON622IIH%;W7NMDK_A47_.>[-_ER=2=
M8_&_XM;D&TODY\C\?7;BR?85-'!-5[0V90RBBDK:".<LL.:S^2:2FH*HQ3+3
MPT.2D7Q5:T<R^Z]UH92;"_G2?[+:O\RE]S_-U_CW-GS)_LS?]^-P,_W7\0;$
MG)O,,\<^M(<HII/XFT(I#4VA^Y\C!3[KW6VQ_*\_F]_*;^:)_*,_F1?%_=W:
M^^\9_,#^,/QCS/9W3G=O764GVUNK=&(H**>NQ4\>4P]7CZJ#<..S>-AQ=?61
MM2QU5-E,>9VEEDKY7]U[H"/^$A_\Q_Y3][_-CY$_'_Y/_)SY"_(&CW7\<#V+
ML$=Z;WW'NR+&5^VMP8NDJX<9#G\G7BCGR%#N)Y9F@"&2.A D)");W7NJ2/EI
M_/%^>-%_-2[L[GV7\Q?E!2=";'^:5?G=G]&;)[$W=0;.K-G;7W7X<;A1MY,S
M_!'HLO@\9&E=":84M7)45#R0".9H_?NO=;'_ /PKW_F)?(/HRE_E];,^(WR2
M[?Z,@[,VSO#N'=NX>C-VY[:V0RV-==L4FV5JJC 9''S3X\B?)2JDQD1Y=+1Z
M&B?7[KW6PO\ R!8^\:S^4E\/=Y_(WMGLKNOMSM39N1[<SN_^V,[E=QYFHH-R
M9S)Y3;\$N4S5975TL5+MVHH8T1I2B:2$55L/?NO=&:_FAY[N[:W\O'YB;C^-
M;[\C[]PO0V=R/43]7TU36[A&>BIBV/\ X/244-155->9@!%%'%(SGTA&O8^Z
M]U\9;LG>?RVR_P M,GOKM1^WS\SYNVJ'.Y63=F-KJ?>W]](ZNEDQYFQ<U)%D
M%S?WJ4_A@-.)6E\:K&20#[KW7T(/^$V_R:_FC5>:^<^_/YL>?^6^$ZKZHZ9P
MV^]JYOY5;>SN Q]#!0RYVLW+68Y\MB<:E2]-CJ2*2I\?D:.-4)"A_5[KW6J_
M\O/YI7\TC^>'\VI.M/C1N'O:BVQNW=&1H?CC\4.G<S48*"EPM$LU7#5Y[['(
MTE!D,U'C:0U61R60J7@I9#.M+)3482(>Z]UC^('\TO\ FB_R/_FTO7'R5S_?
M%9MG:>Z<?C?DA\4NY<M4YJ&KPM5XZF>KP(R&0JJ&@S#X^K^[QF3Q]2E/5OX!
M4RU5"SQM[KW7UMMC;UVQV3LG9_8NR<O2[@V9O[:V/WKM'/41)AK<7E:2&NH*
MN$D F*II)XY%/^I8>_=>Z:.V=E5G9/5?9?76/W+N+9E?O[K_ #.RJ'>&T,A7
M8C+8F;*XZIH8LGB\MC)J;)8S(T#SB>FJZ26*IIID2:"1)41A[KW7S$/Y#_\
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M_'SUU302!VH_O]MS3O4Q-=J>.65=0*EA[KW7V-_?NO=:N_\ PKZ_[<Y[F_\
M%BMB_P#6_(>_=>Z)Q_PB2_[(=^7O_BUL'_O(8/W[KW6KO\!/^XF[K_\ \:;[
MQ_\ >GW'[]U[HZO_  LVZ&W)L+^91U9WI-CV797?_P <<;28C+ZF*RYK:.0K
M<;F:/2W"O28ZNQ$IT^DBK4_JU7]U[J[[(?\ "A7X;2?\)[U-+WULVD^:5?\
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MM_7O^3LWMS_T;N9/^R/;/^]QU[_H',^;?_/TOBO_ .?O=O\ ]@_OW^O)M?\
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M%A3H]G\S3?VW^U/Y>VR.S=J5*5FV>P>Q^J=Z8"I0WU4F3W+A*RG)/'J$<P#
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M1 JVH# J3,]#Y>J^57R^^47SGVCL/?6R^CL=\/&^.&P-P[[QLF(FW;625O\
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MAI<+!1?[\>@NE1B:J7]VK_>_<A\'NO=7[^_=>ZU6_EW_ #[OF7UU_-"^1O\
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M-D1YFERN&QE)D<C4UD--79G#F*B2HKG9H:B!FJBK>;W[KW2W_DG_ #)^3?\
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MCLQ/G\OF-[X/'8I:(8NII$Q5/4[6@JLAD)JF)*2@EK*F0+'2:F]U[JO;"?\
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M3HSM+/\ R0^%_8OQ*[^Z1[&R75.[]B[KCK(,#G<GCHRSU&V<KD*:)IJ19_\
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M\I#CMVP_'?X+#YO=Y5<*J,93;D@T8RI2" R23?<0;[ZXQH>%RR1I44_KDT3
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M9/1YC1"/_*C#[]U[J!\"/^XP_P#FV_\ BE$'_0OQY]^Z]UN2^_=>ZTVOGO\
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MG^7E!) N;U_=G&KOGN(2&&_H^P$38WPZ/V?MS3?;_L:/?NO=;"7\U3YF5/\
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MK36E32M*GCTF?^@:;<?_ 'F#A/\ T!Y__LJ]J_\ 7L'_ "A_]G'_ %PZ.?\
MD\!:_P#3+2_]SA/^]9U[_H&FW'_WF#A/_0'G_P#LJ]^_U[!_RA_]G'_7#KW_
M "> M?\ IEI?^YPG_>LZ]_T#3;C_ .\P<)_Z \__ -E7OW^O8/\ E#_[./\
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MBNL@!(#K72P]1J -/M /RZQ(YWY?M>5=UN-OLKZ#<H(7"QWUL'6"X!16U()
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MDES'8[;L5FMU=W<T<LBO-+(L5O:Q",=T]PY*QAF501W,H(/2LZF[SI^Q]_\
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M]_LBWPD_[PY^*_\ Z+W:7_UH]^_K5NG_ "F77_91+_T'U[_@E/<;_IJN9/\
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MN[L*OQ5W=\G?BYV/W7N#N_;G8O2=0M7NC"-N2>"JK<=EMO\ @DGK%HYPRK4
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MY'W_ &_>KVREYIYDB@VJ/;;&Y%S)M>UI.9;N2Z>-3&KS^$L0B#UH492U)EC
MW9OSB^-?PO\ YCW\SB3Y![YK=I/V7N?K1-I4^.Q&7RKS#"[4K#7/(<;0U,<"
MJ<O3A-;!G.NRV6Y.Y>6K[F39=M%G%XGAB[UG7&@&NXP.]U)^ UQ3AGJ2]_\
MNX<W_>$]I/;U>5;);H;?;\PFY9[JUM@IN]SB\,#ZB:,L3]+(304';FIQ9'\>
M_P":%\,_E)V9C>H>ENQ\SN;?>6QU9EJ+%UFW\[CXV@H8&J*ES4U]!3TZZ(U)
M"E]3'A0?8.WCDO<MAA\>[AT)J"ZO$B;N-:"B.Q\CY4ZQ']U/N:>X/LML[[]S
M%816]E')%$TBWUG.P>9M"#1!/(YJ?.E!YGHH'5G\RK&?#_*[_P#CG_,@SO8N
MTNP=E[^S,W7'=F9P&2R6)WSM6JK)*S$5M#/@L9,?N**FJ$I9D6 Q1!8HY)_N
MUJH(#R;DN3?TCNMG5)$:-/%A$J+);RA=+!A+)6CLI9#7()P%"DSOSE]T*?WY
M@L>;/:2&QNK&[LK07^T17UO;W6S[E'$L4\<JWMPG9*\;2QL7#-5V6/PC$[B+
M\(LIB/D7\S_DE\V^I]G[AVAT!O;JS;W4FW=Q;@Q3X9M]YS'5+UM=NF&DGBBJ
MIZ6BI/!CHJJ4 RA6C(#PO'"@YAC?:;&WVZX96FCEFE95<2> CZ%$9*DJ&+(S
MLHX5!XL>@E]XNRN/:?V_V#VZWRZ@NMZL]RO]SG@@N5NQLUI<1K#'9,Z,R*\D
M@DN'B4T0D-P<,Q1_A1\=L]\H/Y'NV>K]EY2+!]CQ;FS^^.KLS.ZQ1T^X\!O>
MORN*$DKQRK%%4STWV\DA1O&DS/8Z?8CYJW1-GYHEFE77'^FDJYJT4EJD;TH5
MSI8D9&:=3M]XOW6M?9O[Q]SO.XQF:P-O96>XP@%F>PO=G@MIZ*&0LR))XBKJ
M&ID KGHS^#_G'?%C;^UH=G_,C%[WZ [\VQ1I1=B=0[TVGF\A_N3IPT4U1BJF
M@QM;0U..JY$:6DGD>$/$ZD$K9V)#[=W]VQ?;]%U 3V3)+$H((! 97=65@"-2
MD5!QU#6X_<"YUW:\-_R!)9[YLMPQ>QW2TW*S@_Q=Z,J3I/<0RI-&K!9HPKE6
M!!S@,WPJH-W]B=C_ ,R/Y?-U-N_J7ISY([:VK0]-8W?M)%C,I7TFT-JY;#5N
M1;%*QEI*.LD:.>G9P%E64Z&?0S'7,\T5M:6&WK(DDML)S,8VUQJ9Y5D"AAAB
MH%&I4 XJ>E_WB+NPY5V?D+D,;G:[GNNP3[D^ZR64K7%M#+NFY6UW'")R-,DD
M:ADD"DZ2N:5  F_ WIS9?R"_E(=+=,=A4(K]H]B=,UNW<J@ \D)ERF1-/64Y
M/Z*NAJ5CJ('_ +$T2-^/:7F6^DVS?;BXA-'CN6=3\PU<^H/ CS&.@?\ >8Y^
MW#VN]]-WY@VI]%U8[O%<1'\+:8(-4;>J2(6C<>:,P\^JW/B!W?VS\9-[_P R
M7._(]Z>H[+^('Q@VGU<F:ED8G<'\ .<I]FU\KU$TSO-N"FK,;9WD:28SK-(!
M+*T8%G,.U0;M%MRV.$O;F>4+3$+2_3K(@HH[8V5N   &*@5.6WOS[<;'[P[;
MR#;<HAEV_FGF+<]Q\$* +$WWT+;A$H1$ 6U>*YPJA4"%%JJAB;KXP_R9/A?N
M7X\]-[I^0G2V7W=W?N[K[';P[2S^6W7NZGJILUEH%R-;'418[<,%%YJ66J,#
M-$@$AC,C%W9G8LW7W)W*&YE2RG"6ZR,L*K##I$2DJE-45::0,'APZ@[WC_O!
MO<+:.:MULN5=VBM=GM;Z>UVV"+;-K>-+.V<P1%#/8O)I=8PX#'M#:0   !(_
MENXRA^-/?OS1^ U+'7T&TNMM]4??'0U!E*AZAAM#=U+ T]%22SR2U,])@\A'
M%3M+(\CO//(TKF8N6+>;9FWJWM-U;27E1H+@J*?K0&@9L  O&RF@H,8 '0/^
M]M>R^[_+/*?N?(4>ZW"SEV;>GC0(#NFUR.%DD5%5%>YA8R!%"JJ(H10@ "A_
ME1?\!_YAW_C3SM3_ *%P/NW/?_+._P"E7:?]9.BW[[WQ\C?^>\Y;_P -[U S
M?_;\K9W_ (S2E_\ ?B97WL?\JQ_U-/\ M5Z4[?\ ^(W77_GP%_[L5OT&77W>
M6)_E;=J=T=*_)3'[KV_\7>SNV<GW'\<^_,=BZS)X/'_WEG2JRNS<S_"J*:HQ
M]5C\BTDM,[I+Y8GED=HX_%=R;:SSC##/9:6N8XDAN+?4%D<0KI25-;=X**JN
M%H0P%%.JO0MYH]MY_OG;)M/,/*#VT_,6W;9;[5ONRO<16]Y/^[XS'!N%O]3,
MJS)+"JI*JE-#JJJ&8MUAW5W!B?YJG>?QUV7\>,?O#)_$_P"/G;F/^0O<W>>9
MQN0PF,S66P'G&W]JX2#*T=/59%I:R1WR"R0Q"*$B52DL41E<CV]N2+>Y:\\,
M74\+6T4 9)'1)=.N5RC$)V=J9)8DXTUZ=V7D*?[E/+>^[AS6]K'S+OFUS['M
M6S13P7EQ:6U]H^KOKEK:5TA"QJ%MRKL7>JD%&?28/8G_ &]^[[_\4DVE_P"]
M/7^R2X_Y(L'_ #V7/_5FVZBOF3_IQ&R_^+=NG_=NM^JXOYDW4>]/CE\GNM]S
M]?T,9^/7S3^376^:['Q(9Q#ANQ]M;BIJJ/(4D?E\43[GQ!J'G"Q7J)J:>660
M>&!"+^4[F+>+&9)32>RM;LQ&@_4MY874J32OZ;L"M6P'("\2,M/NC\\;=[L\
MF[A9[HY_?G*7+W,$5A+1=5WL.X6$L30R'3J865QH$9+T1)455.MV&S![B;KD
M%U6E\-]>U?E]_,HZVR44M-DZCN+:O<^,,XM]UBMT[5IX(9X&'HDBAK,-40-;
MU(Z:9 "5N*-['BV-A**$"&6$_)X[B1R#_M9D/IG' ]9=^_E-ZY#Y!W>$AHUV
MK<MIDI_H=SMVYR2,K#B"T=Y$XKA@U5X&A!.I/^R2OY^O_BR7R"_]T=5[&>Y?
M\E/8O^>7;/\ JZ>LH^>O^5Z]E?\ I0<C_P#:9'U;S\#O^R(/AW_XJ]L+_P!Y
M;%^P%S5_R5+S_GJN/^KK]8(?>9_Z>/S5_P"+%O7_ '<KGHU_LAZA#JC;(_&_
MI/\ F2?/;Y59;OG9U?V#T[\5]M;9^//7U%#FLMC:-]S2??YW=50G\$RE#4"K
MQTU5%13B0Z''CU!FA7Q2-;[W=<G[;;BTD$<MTTL\GZ:,WA K%$"9$84)21A3
MA6N*YZ/V7NYS']T?VRY<@Y8NX['=.9+C<-\OG-I;7$HV]?!LK%#]9;3+X<HB
M>9-.5[J4#G4@N^_B1\?OY9'='P_^67QPV-DNN=DT_=@Z7^0L"YK-92EFV_O.
MD;'4^3K6SN3R)IJ?#5<7E'B:-))I(?)=TA*JK+F.\YSMKJQO9%D80F>W)1%8
M2P'657PU6I>,N,UX8IGH3>VGOKS3]\7E[FCD?FZ\CO[L[0=WV-C:6EM(E]M,
MHG>&,65O '>XC8KWABJ*^F@+U.%\(P&^8G\TE6 (/>FT 0?H1_<^#@^PSOW^
MX6W?\\\O_:5/U GWB33D+VZ_Z4VZ?]W:7JN3<'4F]?BQ_-(^*W06)HD_V6/L
M7Y![A^2G18+.1A,CD-JY*@W=MJD5I76.@I:UZ:KAA1(TACJHV'DDGF*B^.YB
MWK9+J\8_XS#!#:S"@_43ZB)HI"0!W:4,9J6)T FF*Y9;7SOMWO3[+\R<T3N?
MZPV&QV'+^\87_'+>'<[:>PO'(4$RO&LD+N69G:)@=*H@-_'R/_[)X[Y_\0QN
MC_W1UWN+[/\ MH_].O\ QX=<PO:C_E:=F_Z6NW_]I</0%?RV?^R!_B1_X@O
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M0Q5O!X43Q(R)19*#2I"T&!3&.DI_PY!_*D_[U7;:_P!O@_\ ZE]K/ZB\Q_\
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M]WCY2W0,/\4N>(_T&3_H'HZY;^Z;[F6VXVLDG+.\*J7,#,QLI0%595)).G
M%3T17_A.C35$'P@[)EG@FABK/E%G*FCDE1E66,;6V7"9(R0 Z"6)T++<:T9;
MZE( T]XW#;I& 02+9 :'@?$F-#Z&A!^P@^?63/\ >QS)+[CV"JP)3EVS5P""
M58[CNST:G Z65J'-&!X$=7Y>XGZYA=>]^Z]U[W[KW6)H('8L\,3L?JS*"?\
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M*2AJ%1-:QJU!(74UHC0!E"( Y)< "Q)^I/\ 6_Y]E74*:CZG'#Y=<@ H"J
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M]7]Z<A_>;P_WRT?Q#[N;[W3X?V=/W.NVCT6_3Z;>YSV_^N/@1^!I\/PT\/\
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MGW(]A^8+6_D\;^JF[[1>[:\O?);P;K*]C-;Q.:E82[>,8P0I?-*A:9_Y0O\
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M-Q56!I)%*BW-^P%US]ZK3^:__94_\LG_ ,6,W%_[Q.7]B?8O]Q-P_P">:/\
M[2[?K+K[O/\ RI?N#_TH;'_N\6?5EGL,=8B]>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?-Q^)5'4?RSO\ A7?V#TW_
M !#$XCKSOKN/<VT$CKJ3[,R8;M3#/N[:.*Q\RQQPEZ7<-=B*8LK/#5?:O&X^
M_P!"P^Z]T^?S_P" ?S'/^%&GQ*^ F+_O%NS9_7D77?2G96U\4QHX<>-S9$;P
MW7F4KK!W^VVAGJ.2J,1U(M#]O3R+6,ZI[KW6XK\Y/YS_ /+>_EI[HVYU5\F.
M\*?:F_LCA$R=#UKLC#Y3/Y*AQB+"D%17TV(I*B+&0RK-%]M%4/'/41%IJ>&2
MGAGEB]U[I0[(_G%?R^>R_AKVC\\>N^\J?>OQ]Z3I5J.V:[ XW)/G< [5JX\0
MY';DM-%F(I)*AB8&$#0U<*M44<M1!:0^Z]UH3_\ ">;^;E\*_P"7S\K?YA_;
M7RFW_NW;6U/D5D*&KZVR>%V_E\U/6F'<FX\G,]5#04\\U*WVV2A>\P4LS,OZ
ME;W[KW7T3_FK\^?B?_+TZN@[>^6?;>'ZPVIDLFN$VY2RQ5-=E,O6M)#&:;$X
MFABJ*^M:$U$;5$J1^"DB835<L$(,@]U[HNWP,_G0?RZ_YDN[=Q]=_%7O>'<_
M9.V,&-SU_76[<5E-O9B;&>5H),ACZ7+TM*,G3TTRA:D4KS24@D@DJHX8ZJF>
M;W7NF7YS_P [_P#EM_RZNQ*#J/Y-][283M"LPR;AJ]B[,PN7W#7T%'*8OMY,
MD,525$%#+4K,DD-/+(*J2 _<B#[?]WW[KW1BOA'_ #&OAI_,4V9FMZ_$;NW;
MO:--M6:&GWIMR..IQ^<PCU$M9!2ME,+D8:;(4U+6S8^J6DJQ&U'6_;3FDJ)U
MB<K[KW1W68*"S$*JC4S-P !]23^ /?NO=4(=M?\ "F;^3CTSVKN;J+=7R=KL
MIG]G9R;;NX\YLO:^Y,SA8*JE56JQ#E*#&RP9"*G#6$M%]Q%4.K14CU$H*>_=
M>Z,9\JOYV'\OSXD?&SIKY<[R[3R'8WQ_[[W=4['ZVW_TA1+N2"JR5'#6RUE-
M.D-1!)234;XZIIZF*4+-2U<$M+4Q13HR#W7NE%\T?YO/P^^!/QWZ&^4'R!K^
MQZ'JOY&MCH^N*G:F#;)US-E,&=PTBUU&E5$U*6QP)8ZG"R H3<@GW7NM1+_A
M6EV]M3='R*_DT=VXZOR='UUNG8M5VK3U%5!/]PN%K<_L?-1R3T5.)YFF6D\;
MO#&LKF1 J!W"^_=>ZV>OBW_PH=_E0_,'O#;_ ,>>G/D36'LK>==_"]AT>]MN
MYW!46;JF6!H*2AK\C0PTT595FH6.FIZQJ6>HG#4T4;5($)]U[HR'SL_FV_ _
M^6QN/K7:GS#[=R_6>;[<QE=E]A4N,VONC</WL&-GI::L8MMW#Y44[135D("2
MZ'DUWC5]+6]U[HE'7'_"GC^3!V1G-SX:G^5DFS8=LX"MW-_'NP]L[CQ-!7TE
M#3T]1**":7&O))6S)4!*:BECAKJJ=7IJ>GEJ0(F]U[H4_B7_ ,*"_P"5I\U.
M]<7\<NDN^\C-VCN6:6FV;CMY8#+X:CS4T24[_;X_(UE,M']U.:@1T\%1)!-4
MS(\%.DLH5&]U[JGCYW?&_P#E#97_ (4>_&C='=._/E9A?G!V!N?K/LK$]8;)
MH*"?8>>W#@_M\=LG*9+-3R')8J""#:M)%7T=*JQSBCCD!C>>I,_NO=4;?*7^
M:A\0,E_PIYZI^?2;XW6_QHZ8K,9M+>FY)L'E/OJ.JP>TLQM[)0P8@P&NGCBS
M,^E6BC9) S3(2I+>_=>ZLZ_X4S?S;?A?\O?Y3W2.T>B=^[NS>6^4>_:+NKJB
M#)X#+8R/(;<V7NC=.S\_-5O5P1+1RTNX<1*D=/4:7F5$GB5D*M[]U[JU[_A.
M1_-*^'?R.^*GQ>^ O5>]=S9?Y*_'+X=8S.]J;7R&!RE%0TE-@:G"8')-3Y>I
MITH*UHLEG:1%6&1C(KM(MUC8CW7NC!=T_P#"E3^3OT-V]N/I;>WRCDR&YMGY
M9L'NG-;$VUN+<&$HZJ*))JB)<MB,;5T]?]LD@#M0_=(TP>FB:2IBEA3W7NKJ
MNONR-@=L;!VKVGUGO+;>^^M]\;>I]U[0WQM:KAK,9D<;51":GK:2LA=X9:>2
M(Z@P;CD&Q! ]U[K5*_G$_P __P#E:=E?#;YZ?#+KGY#UF]>Z-V]$;KZWVTVU
MMN[@J\%7Y>2EFI5IJ3/0X]L?4T\TJD)5QNU%)"15K4-1'[CW[KW0I_\ "/N6
M2;^4#3332/+-+\G]\2RRRDLS,R84LS,;EF8FY)Y)]^Z]UM"9K-8?;>&RVXMP
MY7'8+ 8#&3YK.9O+S1TU)1T=+$\]35551,R104]/#&TDDCLJ(BLS$ $^_=>Z
MH=7_ (4X_P F ]M-U#+\L4I:]=UG9IWS5[;W)'M858KOX:9GSS8P4D6-%9]:
M]]-$M.#D&G&._P K]^Z]T#?_  J_R%)DOY(W=61Q==35^,RG8W7-915]!*LL
M%13R[JQDL,L4L;-'-#(I5T9258:64D6/OW7NC!_R-.T.N^EOY#WPI[4[9WGM
MWKSKG8_0U7G-V[SW74QT>/H*5-Q9A3+43RD*NJ1U1%%WDD=(XU:1U4^Z]UUT
M-_PI)_D_?(SN7:?16P/D_)C]Z[]ST.U]D5>_=N;AV_B<GD*H.U#21Y;*XZFH
MZ.>O*B.!:UZ754O#1'36SPT\GNO=7-]G]H==]*]?[K[5[:WIMWKSKC8V)?.;
MNWINRICH\?04J%5,M142E575(ZHBB[R2.D<:L[JI]U[JE3IS_A2[_)R[Q[9V
M]T[M#Y1S8K<.[LRF!VQG-][9W'@<)554RN]*CY;*8VGIL<E2B'3)7_:QQ.4@
MJ6@J)$A;W7NM3?\ X4G_ #V^.N__ .<Y\+*G;NZ=P5-!\#-_8?:7R*CJ<77Q
M#%9'"=@4V<R@H$>,#*J,9$KB2EUB4JL8)<!1[KW6YCLG^>I_+=WY\+.POY@F
M+[>W71?%OJWN&+HG>F^,IM+<JU5-N2>FP55#2IA8,;49>HA>/<=#^_%3O$&E
M8,P$<A7W7N@)Z]_X4T?R>>U>TNN>H=A?(?=^>W=VGN[$[$V@AV)O2DAERV<K
MJ3'8VDD%=@Z:J3[BKKZ=1*(6ATR&3R&.&=XO=>Z,_P#.[^=3_+F_EP;QPG6_
MRD[W3;O9.<Q?\=CZ^V?B<KN'*TM ?$(ZO)08FEJ4QR5!GC,$=0\=141EIH(9
M((9Y8O=>Z'OXE_S%/A[\X^D=Q?(+XR=Q8CLGKW9D56V^!2T]92Y;"2425,D\
M&4PU9!!DJ5V2DF:G<PF&MC0S44M1"5D/NO=569+_ (57_P DNBQW\0H_DSO3
M-6J! U'C^N]^Q2Z;H'D4U^WZ*"41&1-:1R/, P<1&,,R^Z]U9AMKY"?#3^9K
M\$.WMY]?;Y/<'Q7[BZFWCU9V74;8^]QF47&5>$K,=N7$2P5*4>2Q66&+K&,6
MM8G*34]73N\$T$S^Z]U1G_PE?ZJ_ED[,V%\P]V?R[^RODSVO59W>>UMO=M;G
M^2&*QF$FIX:&GSU7MW'XF@Q1-/(L,61K'JZE_7-*Z:5BC58E]U[H]'=O_"E;
M^3OT'VWN/IC>?RAER^Y]GY5L)NG+; VWN'/X6CJXD26IA&6Q>.J*2O-+'(-;
M4+52-*'I86EJXIH(_=>ZL#[;_F1_!CHWXT;9^8/9OR8ZSP'QTWQ0_>["[&IZ
MJ3()N!A3U-4U'@<=CH:O+9G)QPT52TM#24LU7#]O4":&,P2A/=>ZKFZK_P"%
M-W\G#MSLS;W5>!^361P6=W3GH-M87,;TVQN'%X=ZNJ#_ &PGRL]!]K1TTI0A
MJJH:*EIR5%5- 66_NO=4&_\ "OUF/SK_ )0J%FT+D\LRK?@$[QV:"0/I<@"_
M^L/Z>_=>Z]_PK]9C\Z_Y0J%FT+D\LRK?@$[QV:"0/I<@"_\ K#^GOW7NMG;9
M_P#.R^$F[_YA-7_+%6I[<VW\J:?=^<V53X?=FVIJ/"U55@<5D,W-+2Y@5,L,
ME)7XO&RST,I114!HH[)+((_?NO=<OF3_ #K_ (3_  :^4O6OPW[CJ.V,KWQV
MWAL'E]C[<Z\V\<I3U+[CR];A,3CVKGK:2"'(U-=1?YEB-,<],Y:TP ]U[JW'
MW[KW5*'R4_X4+_RH_B3W=V7\<N\OD'N+;'<G4F1BP^]MI46R=Z9!*>JGIJ2K
M@A7*46!FP[B6"N@(E^[$"%PLDJ,& ]U[H,L)_P *=OY,>:ZLKNTW^5,F&AH,
M[3[<;8><VYGX-S35-12"M5J;$K02&IHXH;K/5QRM2T\P6GGFCGE@CE]U[H[W
M\O\ _FQ?!S^9KCMWU/Q+[8FW;FM@I3S[PV5N;&5^$S-%!51PO%5"CR$,0K*1
M7G2&6>DDJ(H)RL,[1R21*_NO=)OX8_S>?A]\\?D1W]\7^A*_L>I[4^-39"/M
M"FW=@VQM#"V,SAV]5+1UAJIEK",BI"E5 :,:[@6!]U[KKX9_S>_AY\[_ )#=
M_P#QAZ&R'8T_:7QH.17M*#=^$.-H(&Q><;;U6M'6FJF6KMD58*54*T8\EP+
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M\)/^?I?*C_S][2_^P?W[_7DW3_?5K_O$O_6_KW_)V;W&_P"C=RW_ -D>Y_\
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M-7)S8+KW"5M)15M52Z:P8^6H53.E/+!+(JA!,JEPWNO=%_\ @C_*F^*'??\
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MH1H#0*O_ &:7_A0'_P!X'?'/_J8/_ML>Z_N;E#_E.NO]Y;_MDZ)?]9C[K?\
MTV>_?[R?_+9ZAY#Y:?S]\505V4R'P4^.5-08VCEKZVH9RPCAA1I)'(7M=F(5
M%)L 2;< GWL;+R@QH+ZZ_P!Y;_MDZ?M?8_[KU[*D,7.6_L\C*B+II5F(4#/+
M0&2?/'5CW\M3YK5?SP^-J=P9G:=#LS=NW]\5_7&],/AWEDQYR-#2X_("HQYJ
M&>H6EJ*'*TS:)'D:*7R1^20('8&\X\LGE2]-MJUJ461&( )5B1D G(92/G2M
M!6G6)7WO?N[I]V;FX[!!<O=VT]G#?VDLJJLW@323P:90E%UI+;2#4H4,NEM*
MUTBP+V%>L7.O>_=>Z][]U[H/NTNU^N>DMD9?LGMC>&%V)L7 R4T67W-GY#'3
M0-654-'3*[!68M-55$<:@ F[ FP!(4V=G+N$@A@1I':NE$!9C0$F@'H 3]G0
MIY,Y)W;W$W&+:-CM9KV\F$ABMX%U2.(HWE<@5'PHC,:G@.E7@,]AMTX+"[GV
M[DJ3,[?W'B:;/8+,8]Q)!5T=9"E12U,$@X>&>"171AP58'\^V'0QDJP(()!!
MP01@@]$FY[;<;-<RV=W&T4\$LD,T3C2\<L3%'1@>#*RE2/(CHFNX?YD_P2VG
MG\YM;<GR>ZPP^XMM9BIV_GL16U,RS4M;1S/355-*OVYTRP3QLC"_#*1[/H>5
M-SN$62.UG96 96$;$,K"H((&00:CJ?MJ^Z-[E[Y:PWMIR[N4L%Q%'/#*D2E)
M(I4$B.IUY5E8,#Z'HSG5_;G5_=FU:??'46_]I=C[2J:B2CCW!LZN@KJ831&T
ML$CP._BGC)&J-PKK<$J 1<HN[*:P<Q3H\;BE5=2K"N1A@#GRZA[G+D7>?;R]
M;;=]LKJPNE56,%U"\,FALJP#@:E/DPJI\CT6/</\R?X);3S^<VMN3Y/=88?<
M6VLQ4[?SV(K:F99J6MHYGIJJFE7[<Z98)XV1A?AE(]F\/*FYW"+)':SLK ,K
M"-B&5A4$$#((-1U,.U?=&]R]\M8;VTY=W*6"XBCGAE2)2DD4J"1'4Z\JRL&!
M]#T9SJ_MSJ_NS:M/OCJ+?^TNQ]I5-1)1Q[@V=705U,)HC:6"1X'?Q3QDC5&X
M5UN"5 (N47=E-8.8IT>-Q2JNI5A7(PP!SY=0]SER+O/MY>MMN^V5U872JK&"
MZA>&30V58!P-2GR854^1Z$3VFZ"G11\M\]?AG@>S'Z>S'R4ZEQW8T66&!J-N
MU65A7PUY=8OL9ZS_ ( 05@E81F"2=91)^V5#@K[.8^7;^6'ZA;>8Q4+:Q&Y7
M2.)K3@*9/#J<K'[LWN!N>S_O^WV#<Y+ Q&87"VSD-" 6\14_M&CT@MK5"NGN
MK3/1N/9-U!O7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6J)_/C^57RN[Y^7/Q2_D=_ SL3*].
M]K?*K R=D_(SNW"/605.WMBH^2_R:&MH/'5TL4E'@LG69!8)Z>:JCCQ^-6=(
MLE,&]U[H4>I_^$DG\F[8FQ,!MK?_ %/V?W;N['421YWL?>&]]T8JKR-1:\LO
M\/VQE,+B:2$O?QQ1TY9$TJ\LS@R-[KW0C?\ 0*I_(\_[Q.W-_P"C'[)_^ROW
M[KW7O^@53^1Y_P!XG;F_]&/V3_\ 97[]U[KW_0*I_(\_[Q.W-_Z,?LG_ .RO
MW[KW7O\ H%4_D>?]XG;F_P#1C]D__97[]U[KW_0*I_(\_P"\3MS?^C'[)_\
MLK]^Z]U[_H%4_D>?]XG;F_\ 1C]D_P#V5^_=>Z]_T"J?R//^\3MS?^C'[)_^
MROW[KW7O^@53^1Y_WB=N;_T8_9/_ -E?OW7NO?\ 0*I_(\_[Q.W-_P"C'[)_
M^ROW[KW2/W]_PDP_DM;MVCG-O;8Z.[-ZMSV4H)*7%[\V=O\ W=69'&S.C+'4
MTU-N+*9S#S/$Y#:*FBFC:UF6Q/OW7NBG_P F[O+Y4_RX?YE'8?\ (4^9';-;
MWEL-NNI>W/@9W%N60G)5N#IZ2;)/A(ON*ZJJTQW\)H,DR4$KR'%U>$R$-([X
MV6F9/=>ZW!/?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ_?\*Y/C@_=G\I#='96.BR
M[YKXN]N[<[?9,)#YY9\7732[2R5//$+.<?$VX:?(5+K_ )A,>*E[Q02 ^Z]T
M7'_A&-\:HNMOY?O<OR/R.!HL?N'Y(]X/A\;F8)1-+D-N;*I#1T$CL/3 (,[E
M\U!X5)TM$7>TCLB>Z]U1!3=\]X?\)B?YS_R\WEOGX^9?M'H7Y$4VZ)=C8O$U
M\F(H\SM3*[B@SVW<UCLM58_*J^3P=4\%!D(=1BBEJ:V _N&E,?NO=']_X3*=
M#?(;YG?S.?E[_.=[JZ^K]F=?;RK]X0["R>42>..MW7NK+F'(8G!%WB^XQ.T\
M/!44%0\L,C1RO0P+.\T=8??NO=5 _P OK^9!WO\ R4OG[_,=ZPQ_Q(R'=7?'
M>?:<W2^T=H[BRM3MZ#&[DI-Z5T>'GJXVQ=1+DL7E/[PPO$$GH?N%EHC'5)%6
M+41^Z]U;E_PIS^.O?'Q(_F2?$#^<+UUU?%VGU?M0;/Q7:\T5&)Z)=T;8S'AI
M,3GJ:;[V.##[OP]5!0TK+"9#*E9":E9FHF'NO=&O_EM_\*#E_F+_ #WZHZ)Z
MJ_E*XK;W26X<.(MZ;VVO38[<&:VO6R:98-XY3*##8+#8S:>+JJ&LHI4=/N:E
M_%-1U39$P8&I]U[HN/\ ,@_X474&U^^?F5\'?YBO\I>C[N^-F'WWE,7TMM_L
M,5>V,W)A\?))@\/N6L_C.,RZ-'N+)X^NR.)S>*.-GHZ2:G-$U:RBH/NO=/G_
M  BNZ,[:P--\Z?D1D=C[DV=T-V=D=N[(ZVRN:I5I*7-9'"5^X)<BF/<OYLA'
MM]*M*6>0I]M3U$\E/3325'\0C@]U[K=4^2?:6Y.D/CWW=W%LSK?=?<6\.L.J
M\[OK:G5&Q:2HK\QN/)8S&U-70X7'4=*DE54562JHD@1(4>4Z_P!N-WLA]U[K
MYB7\S7^?!L+^8W\2LUT9\P/Y:6S-N?//9LJ[6VK\I=M5#T,FW:O$5L3[CBI\
M378^?.TU/))35=#4XB?,5E'"\O\ $&*U5+%"ONO=&9^;_P %?E5LC_A*]\#9
M=]=3;VQN9Z8^16:[LW]L_)01462VGM'=DFZ/X5E\OC#Y)*:DE>MIFFA_;K(Y
M<M3U5?'!.*Z%/=>ZJN_F=?SJ-[_S"/A1\&_AQD^G*+8>)^(&T-OXS=O8F:KQ
M4YG=^X\+MN7:?\5IZ"&.@I<+C)Z:EFGJ:58:YEK9Q$*NFCITCK/=>ZM0_P"%
M/&Y<GL?:?\A?>&)@HI<SL_X=8_<N,ILL&^V:JQ]-L&JA2I"RP/X&EA D DC.
MF]G0^H>Z]T6'YV?S _D-_P *</DC_+R^.W4WQ4DZD[!ZZGS6)R#T.1;<V+2?
M=>1VV=Q[EJEJ<3C1#MC"8;!8RNDCJ#(T:2U4+O4J]/++[KW5J_\ PK4V_1;3
M^8_\F7:V-,AQVVJ.JV_0&4DL8:/=.RJ:+4222VB,7-SS[]U[I]_X5 _]OKOY
M-7_:QV9_[]FG]^Z]U[_A4#_V^N_DU?\ :QV9_P"_9I_?NO=>_F?_ /<7Y_+D
M_P"U=U7_ .[3='OW7NBX?SU^Z]\?RZ/^%+/1GSQS?3>X.RMF8?KW:6^-HX"C
MFFQL6X::GPM?L[+4E%EC05].E?05<]VB$4I5I*195C6KC?W[KW5C_P#.4[K[
MZ_F7_P#"8O:OS(S_ $D.NL_N[MC$]]9KJW:DM3F?X#L>CW;N+!87(RUPB67(
M))@I\;E*VL-/211QU,TKTU+%"R)[KW1??Y17S.[2_G ?R^>T?Y+^"^.&(ZUV
M?T?_ "R<MLW)]Y[IS517QYK?-)EL=AM@4O\ #HJ/$OAL55S4]765SB:NF\F/
MGIXI:8Q+)/[KW52'\NK^<KO7^2?TSWS\#_DM_+KQ_;7=.SNULMG]LCLF3'XV
MIVSDIZ#%C*8K+QG;^4J<EB:2"%<M%X*I&?SNJU24E;!4T7NO=;EFSZ?M#^;?
M_(;[SQ><^)%1\4>\?D/T5N';M#UI58ZGVY0[CW!B:=*G!9_#1E9JZCVYN7)T
MD(HI<A"\T49>2(Y+'BDR-?[KW6AIT%_."[D^&_\ *M^8G\G[=WQWK*K<':F[
M]S4R;]WU/582HVAA\WCH,7N;%56W:K&X^NDR-/F,2&HVJJF.5*G(5,$U.[4M
M+13^Z]UNI?\ "/A6'\GR@)! ;Y-[W92?R/'A1<?U%P1_KCW[KW5@G\_7X2;\
M^?7\KOY"=(=2X./='<.'CQG:_5>V'.ELGEMMUL=9)C:8^: ?Q#(XHUE-1!Y%
MB-;+3K->$R*?=>ZT@?A!_P *'MR_!KX5[-^"&3_EQ[+[9^3G3^;R/76UNR>R
M8*4+#%/N#(Q1T>=V[#@H,GDLCALO4+B(HER5&9 (TGG%52.*[W7NMB;_ (4
M]AU_;W_";2K[8S'QYW#\4\]V3G.M-X[@Z"W;14N/R>W:RKW7CS-35E)2QP^)
MI2HFC%1!2UH@DB%?14-:)Z.#W7NJU?D[\!.V/FO_ ,)4OY;F[>B=F5G879WQ
M?Q4W9\VS\1&\V2K-L5F2W%C]Q-BH$DC-16T/^1UKQ$2:Z.FJQ%$]1X+>Z]T
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M_MDZ$'^M/]Y__IM=@_[E]I_Y;G7O]F+_ )"'_> /R-_]"?-?_;0]^_<_-_\
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M6Y'[]U[KWOW7NO>_=>Z][]U[KWOW7NF;<.W=O[MPF2VUNO!8;<VW,S2M0YC
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M_P![CJ^/ X>FV]@\-@*)YY:/!XJGP])+5%6E:*FA2&-I&140R%$!8JJ@F]E
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MPP_A^LF5NYP$%"M([F:>HIZN"*II9X:FFG020U%.RNCJ?HRNI*L#_4'V">L
M98F@8HX*L#0JP((/S!R.LWOW3?7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ2[L_[C$>L?_&;M1_UI
MW#[]U[K;:]^Z]U[W[KW7O?NO=:Q/\IK_ +?N?\*(_P#P[.E?_>=W#[]U[H_'
MRC_GU?RGOA=WMOGXT?)?Y6?Z->[>M?X9_?797]QNR<S]E_&</C\_C?\ <E@-
MG97$5/W.(RM+/^Q52^/R^*71,DD:>Z]T7_\ Z"COY%'_ 'G-_P"PR[B_^U][
M]U[H0.I_^%'G\F/O'M/K3I3JWYD_WH[-[@[ PW5O76VO]'G:M%_$<[N#(TV)
MQ%#][D=C4F/I/N\A5Q1>:JGAIXM>N:6.-6<>Z]T1O_A3[_W1W_\ &K6PO^NG
MOW7NMJ+W[KW7O?NO=>]^Z]UIN?/7_N,0_E)_^*35/_6OY#^_=>ZW(_?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M5$7\LG_A07\./YJ/R6[?^,O0NS^X]M[EZVVC7]B;9W1V!CZ.FQNY]O8W+T>'
MJLE0BFKJFLQS^;*4,T=-7PP3O!4'4J30RQ+[KW5[OOW7NO>_=>Z][]U[KWOW
M7NBK_,_YE]#? ;X][Q^3?R1W%E-M]7;+GHL?75.$Q]3DJVIKLG5Q4.-H*6EI
MD/[];63)$LD[P4L6KR5-1!"KRK[KW4;X,_++;/SI^*/37RTV9M3.[(VEW;@J
MO<^V]L;GEIYLC2T464K\?3??-2%Z9*J>*C$TD<3RQPO(8EFG""9_=>ZD_-#Y
MF=#? 7X][R^3GR0W#E-N=7;*GHL?75&#H*G)5M379.JBH<;04M+3*1YZVLF2
M)9)W@I8=7DJJB"!7E7W7NHWP9^66V?G3\4>FOEILS:F=V1M+NW!5>Y]M[8W/
M+3S9&EHHLI7X^F^^:D+TR54\5&)I(XGECA>0Q+-.$$S^Z]T;'W[KW7O?NO=>
M]^Z]T3/YV?/?XU_RY>A\M\B/D_O"?;6QL=F<?MZAQ>#A2NS>5K<C5Q4L5-B,
M7YH9J^6!)'J:@(?V:2">=O3'8^Z]T)'Q3^376'S*^/75WR<Z7FSM1U=W!@7W
M)LV?<U(:"N>ECJZFB+5-&9)3 YFI7LI8G38FQ-A[KW0Q[MW;M?86U]Q;WWON
M+"[1V=M'"U.X]T[IW'4PT>/QV/HX7J*NMK:NH>."FI::"-I)))&5$12S$ >_
M=>ZHXV5_PI@_DU[[[=Q_3>)^59QV9RVXVVKC=U[HVQN;%;=>K62:$-/F*_%0
M08^C:2!_\LK134D::)9IHX9(Y']U[J^6*6*>*.:&2.:&:,2Q2Q$,K*PNK*PN
M&5@;@C@CW[KW5)?R>_X41?RF?B-W+N+H7MOY)R3=C;,K#C-[46PMO9[<%'B:
MQ&F6>BJLCBZ">BEK:-X)$J8*62HEIIU-+.D=7: ^Z]U;%TEWAU)\D.K=H=U=
M%[^V]V;U;OS&_P 5VKO+;,IDIJF-7>&6-E=8YZ:JI:B-X:FFGCBJ:6>.2"HB
MBFC=%]U[H5??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M1>_E9\FNL/AK\>NT?DYW1-G:?J[I_ IN3>4^V:0U]<E+)5TU$&IJ,21&=Q-5
M)=0P.FY%R+'W7N@._EY?S(_B_P#S/NG-R]Y?%3.[IS&R]G]B575VXX-Z8J7#
MY"FRU+C\9E'1J29Y-=/)19:G>.9':-V,D=Q)%(J^Z]T7W?/\[SX(; _F%8O^
M6-E]Q]BUORDRF\\#L!<=AL!+/@H<IN/%4.:Q]/-FC41PC109&!JAD1Q#(6A;
M]Z.1%]U[JW?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5+L'^<!\7^W/YEFZ
MOY7W5%+O3>/='6.S\[NGN#>4E&<?MW!5&":@BGPD$U7HK<OE?-D8A(U/3K01
MIK*5LTJ&'W[KW5K7OW7NO>_=>ZHB^0/_  H+^''QT_F>[&_E:[PV?W'D^V-U
M;NV?UWG.QL%CZ-]N87<._*7'UFVL;4B:NBR=8E1!FL8]14TM-+!3"M +.]/4
MI%[KW5[OOW7NO>_=>Z][]U[K7M[6_P"%07\H+I;M'LGISL#N;LK&[\ZFW]F.
ML][8ZDV+N>JBI\O@<C4XK)015,% \%1'%64LBK+&S)( '0E2#[]U[J7U5_PI
MU_E%=T;FRVT.O^X^R<IGL+UGO3MNNI*K8VYJ51A=@;.SN^]RS++44,<;34VW
M-N5TT46K7/+&D$0,DB*?=>Z'7^4;_.P^-O\ .%Q?=\W1VP^U^M-P="Y/#1;N
MVSVE3XY9)J#<*9(XG(4=5BJ_(4D@EEP]9%- SK+"T2-9TE5O?NO=7)>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM5#>WQ;^\WGNZL_P"@@S9>T_N]
MSU]3_=9]_>(XSR5<K?P\Q?Z3X/&:._A*^./3HMH2VD3?8;QH@C7^KYEI&@\3
MP*^)11W5^D:NKCQ/'B>NV'+?O-]/MUK'_K'W5UIMH%^J_<NKZG3$H\75_5QZ
M^)3774U=5=1XE,?[*E_X46;)_P#1A?\ Z5?:O]]_^&V?^<'_ &Y]'7^O9_YP
MBZ_[D?\ YC77O]E2_P#"BS9/_HPO_P!*OOW[[_\ #;/_ #@_[<^O?Z]G_G"+
MK_N1_P#F-=>_V5+_ ,*+-D_^C"__ $J^_?OO_P -L_\ .#_MSZ]_KV?^<(NO
M^Y'_ .8UU[_94O\ PHLV3_Z,+_\ 2K[]^^__  VS_P X/^W/KW^O9_YPBZ_[
MD?\ YC77O]E2_P#"BS9/_HPO_P!*OOW[[_\ #;/_ #@_[<^O?Z]G_G"+K_N1
M_P#F-=;6VTZ?[3:VVJ7^+IG_ +;;]'3_ ,>B?R+6Z*:-?NUDUR:UJ;>0-K;4
M&OJ:]S [<3Y9X>G7$C>I?'O)W\,PZII6\$C28JNQT$46A3X:4%*<!PZ4'NO1
M9U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=4 [O_ )W^]JSL
MKLG9WQV^ '<WR)VGUKNZJV7D=^;<R-?&LM71SS4[NU'B-G[DCI8*@P&2F\U4
MLTD)#O#$UT$J6?MO!X$4M[N%O;-*BRK&P4G0X!!J\L1KFAH" 1ACUU#V#^[E
MVV#9]OW#FSG;:=BN=PM8KR.RN((&*Q2HC@>)=;IMY=EUA9-$117!"NXH2T_\
M//\ RW_[U"_(S_SX;F_^U?[?_P!;K;/^CQ:_LB_[:NEW_)OGD3_PJ.P_\X-O
M_P#+BZQ3_P Z;Y84L$U55?RB_D/34U-$T]143Y/<B)&B L[N[=8!515!))(
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MJEZS(5E1796KK:ZHFJ:ARQ,DS6%E4*BJH5WM]+N+^),=3:40$!5 5%"* %
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MI:*E01P0FIK9ZFKGT(+:Y97<_5F)]@N[NY+Z5YY3J>1F=VH!5F-2:  "I/
M#K$CF_FW<.?-TNMYW67Q[R]GDN+F;1'%XDTC:F;1"D<:U)X(JJ/(#I<>T_0<
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NM27=G_<8CUC_XS=J/^M.X??NO=;;7OW7NO>_=>Z][]U[K
M6)_E-?\ ;]S_ (41_P#AV=*_^\[N'W[KW1/_ .:__-=_D0_&KY^]]])_,S^5
ME_LQWR3V7_=;_21W-_HYZRSW\9_B6R]N9;#_ .Y7<.=H\Q5?P[ U]#0_Y1"G
MB^V\,6J".-F]U[JNW_A]+_A,%_WI$_\ 81=,?_9-[]U[HQ/Q!_G,?\)T>T?E
MG\7NL^D?Y/?^C+NCL3Y$[)V+U#V1_HNZEQ_]WMT9?<N,Q^ SGW^-W#/D:'^$
MY:H@JON*6.2IA\7D@1Y553[KW5CO_"GW_NCO_P"-6MA?]=/?NO=;47OW7NO>
M_=>Z][]U[K3<^>O_ '&(?RD__%)JG_K7\A_?NO=;D?OW7NO>_=>Z][]U[KWO
MW7NO>_=>ZTO?YC__  K-W/\  KYL_(KX>T7PAV[V+#T?N:EVU1=C5N_JK'/D
M#58O&9(5#86/:%6J& 9 J8?X@HD$1(GC9PH]U[HY7Q$_X4@[.['_ )67=W\S
M?Y8]&-T=M'JKNX=#;,VALC*39>IWQG),3@ZZ*GPB5U#0&$_=Y:6*1S)411T]
M#5U3NK4\T">Z]U5ST3_PM(DS7:W7\/R3^".3ZM^/'86Y4Q'^E'8N>R.:K\52
M.STT]?#0SX"CAW.F+R">.IBHI*:H>#S2P0-50)05/NO=;)O\UW^<)\>_Y5WQ
M?VU\@=VTG^EO<O;0>D^/?6&V,A!2-NR=:&*N-7_$VAK%HL#2PU5*U771T]6T
M2U=-XZ:9I5'OW7NJ!?A#_P +"L)W5\E>L>DOE9\1S\?]D]R9BCP.T>U=OYRK
MKTHI,K4T])AJ[(8W(8JC-5B*^>63S5--47I5C!ACKR[+%[KW5@W\Z7_A1QU]
M_*[[;VQ\6NI.F*CY+_*/-XN@S^XMJ'(38_%X"ERZ5/\ !Z:H>DHJZMR6<R<D
M<#1X^%82E)50U1F=GAIIO=>Z?_Y*?_"A_8'\UCL;L'XY]C](Y/XS_)C9&%DW
M=B-H2Y";*XG/XBF^VBR)I*RHQ^-J,?FL74SGRXVHC9YJ-?OJ::01UM/0^Z]T
M2K^3;\Z,%WA\]?YNW6OQ_P#Y?OP^Z#[HZCV_OC,XKLKK#&5])E-\Y_%;NK,5
MC:7<LWW&J'&Y3)Q1U=9!0F!7J7:90);/[]U[HZ7\@?\ GI[W_F_57REPG:_4
M77_3F<Z!@VSF-OS;$K<E4T67QN:;.0U\\CY73+"V-FQE,3PO[=9&7"D$>_=>
MZ#O^4'_/^[+_ )FGR(^7E'N/I[JCJGX9_%[KK-]C3]\+799,G)24^5B7"MDJ
M&N8P44,^WH,AD*N1E1HS2!%C4LZQ^Z]U6%V[_P +4:BC[0WM+\=?@7D.TOCM
MLG)K1+O_ '=N*OP^4KJ>1%^TK:N&DP&2HMNKD*B*IBA@J&JG6.-:@L\ADHXO
M=>ZV?-A_S@/B#OO^696?S48L[FL!\?L+LBHW#N3 [A2EI,_09JFJTQ3;1EIZ
MBIBHVSU7G)8:"A_R@4M:]525$%0U)4Q3M[KW6A!_-B_X4U;R_F=_$'MKXJU'
MQ Q'5.P-Z;TP>;VKV-2[FR&4J(CMO,8W)SP3QR;>HZ2KE<20(P#4GC2ICE?2
MYCIYO=>ZWDO^$\W_ &Y=_E_?^(<J/_>AS7OW7NBE?\*SO^W*G>G_ (E+K[_W
MK,=[]U[K5_\ Y=W_  JTWW\&/B/\;/C''\(,;V%U;T)@8NO]S]E)NK(4D]>U
M3DI,E)-$XVW-18ZJ6GKJA5I'%46>&-EG=)6,?NO=7X_S3_\ A21V-\->N_@C
M\D/B[TAU1WG\:/G)U16;SVIF^P<CE<9EL?F<-64T6<P]7/CI)\1 ]!'E*2GE
M#NS15D599IX8RT?NO='3_G=_SMY/Y7WQ3^,G?W2^RNO^Y-R_)O>-.=F;9WS7
M5M+35&UO[O29BLR](^,)FEE@FKL2ERP@$=6UV,C0AO=>ZMA^#?<O9_R+^'WQ
MP[_[DV=A>O>Q>[>I,/VOG=CX!*R.GQ46X*5<KCJ$I7RS5B55/C*JG2J65M0J
M1,-$8M&ONO=:=/\ PK6_E*[&JMD]S?S;YNY=YOOS'?Z/^JZ7IPX^C.&6E:LI
M, :@9 S&L$FF=ZC0(PGD)'Y+'W7NC,=0?S7Q_*"_X36_RU/D'0].'N[='8'V
MW3FU-J565.&Q\%15UN\\U/7Y&N2CKY_##1829(X8H2\L\D=WCC5V'NO=$Z_G
MG_SB]Q?,S^0#\8^U-A[<R?1-?\U>_9ME=E[*GJ:JIDEQ6PYJ^KR5'C,E%3TO
MDHJS/4F)JA),L6NFCFIK37UO[KW1=/FO_P )[_C%T%_PGKZN^;.P]F;WQ?S7
MV-U;L/Y$=P;QGW!D*B3)4F\9\<<OMV?%O5OMNCI=GQ;EBDBJ<=14U7/'AOW:
MF=ZF5W]U[JZO^77_ #'.S*#_ (2Y;I^4]?O&BJNY_C)\>]\]1;=WI505;14V
M6V])4X;8TU5$(3-.^*H:_#1U!B5DE>G=E;2Q(]U[JD/_ (3X?R%_BW_,U_E]
M_*3Y(?*O#;WS_;_8?8><Z@^/V^WW#E:;^[51B,%1U!WA3TN.K::#,5=3G<V8
M)Z?-I7TY7$ QP1K4R/)[KW1R?^$6_?\ V'0R_.OX3;ZR-1'B>L\WA^U-H;-R
M1DEJ\+D&J*W;>ZHI*A8Q2O%,]'B8U1&!62FF8)XY%M[KW6]S63O2TE54Q4E3
M7R4],\\=#1^/S3,BEA%%YI(HO)(1I76Z)J(U.HN1[KW6BIV__P +'^TL;V;V
M9MCIC^63O?(;1ZDW2^V]\5/9&9KTSN*\,LE)4_W@QN'PE30[>R5/D*>HIFHI
M*VJB,E.X6N))">Z]ULJ?R=OYJFQ?YN'Q5F^06V>O<IU+NS:>\YNN>S.N<C5M
MDH:+*04='7+48S*FBQW\2Q=73UJ^.8TT+I/%4TS*W@$LONO=&P^=7R7J?AM\
M._DA\J:/9\'8%5T'U-ENSH=DU-<V-CRC8NG,_P!DV06EKFHQ/;3Y13S:/KXV
M^GOW7NM)1O\ A;7W!FZ<9#:G\MO;9H<'&V0W:5WYELJL=+HJ=!>I@V=CH\61
M+'&3+(E7&T32&RNF@^Z]TM.R/^%L6:J,W]YT3_+WR.:V%AL;35VX\GV#NB=*
MHEZ5Q4E'Q.&FI:"C3*JT$%1-Y6FIXFGD@IYI#20>Z]UN-_R_?FSUE_,1^(_4
M/RZZEHLEB-I]IXVM$^W<R;U6+RF)R59ALQC97,4!G6DR=!.L,_BB^YI_#4B*
M(3!%]U[HY?OW7NO>_=>ZID_X4,_]N7?Y@/\ XARG_P#>APOOW7NM1;_A&W\O
M!TAWC\N/C#V?D\C@]E]A]$4WR7VW+F)T^QI7V=Y'R,E'3LXD5\E@,[)5SRQA
MT:/%(LIBDC42^Z]U4C\ OD5N3Y<_\*-OCE\F]T+E(JWO#YZKV'14>5ECF:DH
M:_+UKT./AD@O :7&TP2EA$32(J0A/+*RM(_NO=?02_G8_P ]?IK^3UM;8."J
M]BU/=GR)[;HYLUL3J>EK_P"%TM+AJ6KBHZO/9O)"DK6IJ42O*E'3I%Y,A/3S
MPK+3)%+4Q>Z]U7Y_*J_X5/;2^;GRDVS\0/E#\:ZGXJ]G]HUL>(Z?SM+EJO(X
MS(Y:6*KFAP>3@R&+QM7C:FMC@B2@J0TL=95U"TAAIV$4M1[KW1I_EK_.S[=^
M.G\[+XP_RL\'TOUQN+KOOR#9U1ENT<M69./-8\;DJ\K35*T]+#(*&4TXQH:(
MN!<R$,#IY]U[KWRU_G9]N_'3^=E\8?Y6>#Z7ZXW%UWWY!LZHRW:.6K,G'FL>
M-R5>5IJE:>EAD%#*:<8T-$7 N9"&!T\^Z]T0#^8M_P *QMV_!7YP_(3X9XKX
M,X3L]^F-U4FTL3OV3?M70SY.:NQF,R$4HP<.SJVSQ-D='VXKU\PB]-1$TBJ/
M=>Z'C^5Y_P *8ZK^8"/DYU7O?XO_ .A3Y+=)_'C<W>NP=JT61R.6Q6Y'VW0R
M5%3AIXYL9C\AC<@9'IY(H0TSU-/]YI,+TJ&I]U[K3&^,?\W#Y4]'?S=OD5_,
M/V7\2Z3>_?O<E/NF'=WQ[>EW&\>'&>JL7/7%8*2%LTGV#T,:CS(+>7]RQ*^_
M=>ZWM_Y@7\_?/?R\O@1\$OE1V#\/-[[Z[(^9W3.VM[UFW*&N_@6U=J;AR>V\
M#GLOMW+92KILCF8,G3IE:EL?128]3618ZL66LII86]^Z]U7;\-?^%;NY^V?E
MKT[\:?E9\%,U\?<7W5O>BV!AMYX_*9:6LQ=5F*NDI,/75N%RF"I9*G&R2U:F
MNDCGB^SIU-6AJA> >Z]T.7SI^;'5O6__  H\^%7QDS/P1^*?9?8F^,3L>FPG
MRSWMC*F;?FWX\U79N-/X;.DHHFGQ)HV>@GEB::F,T@B= 3?W7N@I_F+?\*QM
MV_!7YP_(3X9XKX,X3L]^F-U4FTL3OV3?M70SY.:NQF,R$4HP<.SJVSQ-D='V
MXKU\PB]-1$TBJ/=>Z.5_)*_X45T'\U#NK?GQA[;^.\GQR[TVKLJ;?NWZ;&Y.
MLRF,RU+0U%/3Y.CD6MQF/J<7DJ9*N&HAB=ION(%JR3":134^Z]ULX^_=>ZT1
M/^%2/\HS^7I\9_A)V5\U^D?C[_<KY-]G?*O%Y3?'9?\ >O>^2^^GW;5YO*;@
M?^#9?<M?M^F_B%>3+IIZ&)8/T4PAC]'OW7NCM?R+/Y4W\O/KG^7I\2/YF6'^
M-6,KOF)1_&O<^^*[L?-[FWK64==5Y/#;GV]E8ZO;%1N27:<E+D<%65%%+#_#
M!$J2M)$B3A)5]U[J;_PF@^=76WR)^,'SH["ZN^#?QD^'E'T[N>AS>0VI\<J.
MKH(-R5,F#S&4$N7J:QZFH8TWVI@I5%XJ6*6188U4Z??NO=5=P_\ "VOMS=*)
M0;*_EL[>?-QS"LJ88-^Y7.-]E%)!]RQI*79F+>*\+OHG\\BI(JK)#I8-[]U[
MI9;J_P"%L6:S.%V3%TU_+WR.6W4=MP9+LY=R;HGJJ&FKHID.4I\*,;ADJJB@
MIJ-D=:RJ%.PFF\4E*(HEJ*KW7NMB+X+_ ,]7XT_+7^6?VE_,>WWBZWI;;'QR
M7(X?Y%;*>9\H^*S6-QV-R2T.$JGI<=)FDS$>8HH<<?! 9JV<T7J:(RO[KW6O
M)'_PM>S([#FW!-_+RRT_QB3?/]VQO*BW34?QU:)*P"24-)@TP4F:_@\L5<N-
M:HA43LM$U:(7&27W7NMX;H?N_KCY*=,=8]^]0YQMQ]9]N[+H-^;+R\L,M--)
M0Y"!9XTJJ6=4GHZVG+&*III566GJ$D@E59(V4>Z]T+/OW7N@.^2OR)ZK^)70
MG:WR2[MS_P#=KJSIS9U5O3>&5CC::;P4X"Q4U) OJJ:^OJI(J6DA7U35,T42
M\N/?NO=:1Z_\+8<K)V,^7C_E[U[_ !LAWO\ W?GW@N[*DYM<>:M(UJ&8;?\
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M#_3?_P )_/\ O#OYA_\ GS/_ -M/VN_='-__ "FVO^\+_P!LG0@_UM_O2_\
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MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK\_P A[_N?3_Q9J3_Y)>Y*]QO^6?\
M\\$'^7KJ)_>6_P#.E_\ BN1_]8>M@;W&O7+OI%]D?\R[W[_X9>4_]P9_=X_B
M'VC_  ]'_*G_ "5+/_GJM_\ J\G5'?\ PG,_[(D[2_\ %J,W_P"\EL?W*_O)
M_P E2+_GE3_J[/UTB_O9O^GC;=_XK=G_ -W/>.K^/<2]<ONO>_=>Z][]U[IK
MS6<PNV\;4YK<.8Q>!P]'H^\RV:J(J6FB\DB11^6>=XXH_)+(J+J8:G95%R0/
M=E4N: $GT&>EEAMUQNLRV]K%)-*U=,<2-)(VE2QHJ L: $F@P 3P'4^GJ(*N
M"&JI9H:FFJ85J*>HIV#QR1N R.CJ2KHZD$$$@@@@V]UZ32Q-"Q1P592596!!
M!!H00<@@X(/#H.ZKN7J"AJJFBK>U>MJ.MHYWI:NDJL[BXY8I8V*21R1O5!TD
M1P596 *D$$ CVZ()#D*W[#T*8>0]\N462/;K]D90RLMI<,K*PJ""(R""#4$8
M(Z7N/R./RU'3Y'%5U'DL?5IY:6NQ\J30RK<C5'+&S(ZW!%P2+CVV13H-7-K+
M92-%,C1NIHR.I5E/H0P!'YCI!57<O4%#55-%6]J];4=;1SO2U=)59W%QRQ2Q
ML4DCDC>J#I(C@JRL 5(((!'MP02'(5OV'H2P\A[Y<HLD>W7[(RAE9;2X965A
M4$$1D$$&H(P1TO<?D<?EJ.GR.*KJ/)8^K3RTM=CY4FAE6Y&J.6-F1UN"+@D7
M'MLBG0:N;66RD:*9&C=31D=2K*?0A@"/S'4SWKICI*+OS8[[G?9*;SVH^\XX
MA/)M%<C1G*+&5+AS0";[L(4!:YCMI%_I[OX;:=5#3UH:?MZ.CRWN*V8W VMR
M+4G2+GP)?IRU:4\73HK7%-7''2K]TZ)>O>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM27=G_<8
MCUC_ .,W:C_K3N'W[KW6VU[]U[KWOW7NO>_=>ZUB?Y37_;]S_A1'_P"'9TK_
M .\[N'W[KW6SM[]U[KWOW7NO>_=>ZU7?^%/O_='?_P :M;"_ZZ>_=>ZVHO?N
MO=>]^Z]U[W[KW6FY\]?^XQ#^4G_XI-4_]:_D/[]U[K<C]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7S\OCKL_:6\_^%HGR0H]X;7V[NNCQ%1N/<>*I=RT--71TN0H^
MM,,])7TZ544JPUE*S$PSH%DC))1E)]^Z]T/_ /PM>7^ZGQ1^&6U]KXG%8/:N
MZ_D9N/=6Z:3$T--#%4Y>DV[3PT=9,\<*D5IIZJI3R7$DD>I&9D!'OW7NJ;/D
M1\=/^%$W\P;X.?%3XP;@_EV;0C^-72> VUN;X^YOJJ@VYB\BV%IMLMB\6C9&
MHWI5-48_*8RKAJZI&A1ZJK@I:F4B2*Q]U[J7_.LZX[&VTO\ PG@^)WRCPN2Z
M]&R_B?M'K[LS9M>RM/M^67=&,V[FJ..NIZJ::U%A\92P@Q5C72GA?S,X27W[
MKW7TE=P_%'XU[L[,Z7[EW+T=UGG.T?CIA*S;G1>]\EB:66NVK15\5/!40861
MHR*-1#2HD+(-=,AE6G:(3S^3W7NOF>_(;?\ \[,=_P *>?EKV#\'^GMI]]?+
MC87;^ZHNK]G;VQ]%50QXV@VVN&.0CIJK*8.&HJ\=MMR*>62H:1(],L:L8XRG
MNO='V_E]_ _^=/N_^?-TC_,B^9/PHK>H:?<._P"KRG;^\-G_ ,$H,%BHY]C5
M^V*BLI\71;ER52CY=6TUI(J!-45]74LJ/()(O=>Z&+_A+]_V^N_G*_\ :QWG
M_P"_9J/?NO=5=YGO5/Y*_P#.@_G/;%7<";<I^U>@>W]F=6U-+35$>)P]?OO%
M4O876*Y+&TM-+YIJ.:IQ5%'5Q\'[F;A36RI'[KW1KOY8'0VX>DO^$N_\VSY2
MPX6+%[[^3-%6;=I<]Z:V;*;/V^U!B3+4+*DD:Q-4[CW! \1U+H5I9/4[*ONO
M=5Z?RT?^'N]Y_P LSO3XS_ _X5]>=R_#WY(Y_=.V>SNPY<7AY\]49JOQ5!BJ
MUX<E7[KQLU+D,%2PT<N-<T12DG2.IC#NSLWNO=&%[!^*/S7_ )??_":[Y9].
M_*#J+<_0N7[#_F&;,SE#MG.3T%6<IAZW TD=57%J&OR5/'Y:[!4L#!6B(%'"
M?&'8RR>Z]U8%\P^M>M,-_P (R_BW6X';FWJNIQ5/LK>6-S4]!#]U19K</8%1
M/N*>EGE\T]/45-5755/-+'(AGA)0JD3"%?=>ZV:O^$\W_;EW^7]_XARH_P#>
MAS7OW7NBE?\ "L[_ +<J=Z?^)2Z^_P#>LQWOW7NJE^U>LNN%_P"$4.WLB,/M
M;:-70=<;3[*I\U18X(\NXJCN3&XZ6KD^Q@,LF3S=)6S8QZN0$Z*QON913B1A
M[KW5?&Z_C;6]\_\ "/#I[LI,/E!N#XB?)+.=IXJDQ5&U5.,%E-XY3 98!*CR
M5,./G?<L.9K)X'18HJ=ZBPHD>+W[KW5=64[VW+_.1[)_D/\ \O\ P^+KEI^B
M^K,%\<.P*3:DDHJL,#NZ?&9/,4^1J8C&*2@ZOV[M_)R>*262.H2IHI'>JIX_
M?NO=?7&QF-H,-C<?A\5204&+Q-#%C<;0TRZ8X*>"-8H88U'"I'&@51^  /?N
MO=:WO_"L[_MRIWI_XE+K[_WK,=[]U[H7_P"2=T5TS\C/Y$/P.ZN[ZZNV)W!U
MWD^I_P"(UFSNP\9296@-52;ES,U'6)!5Q2K#6T<P$D%1'HF@<!XG1N??NO=4
M<_\ "RSH_9G4?P?_ )?.UNG.O=H=9]/=7=S[BV;@MF[&HJ'$8C%C(X**JI:6
MAQU(L$,?F-!52L(8B682S2'468^Z]U:G_,V[BV%D/^$N&ZNSX,NIVIV)\".K
M*+;%3I8R35&YDV9C\93F)09$F-77QI,I%X-,K2Z%BD*^Z]U37\"NMMTU'_".
M#YG0PT<4C[L;L#L'#E9H-#XS%YW!?>SM*91$@@&"J_(&8-&8G1@'4K[]U[JT
M'_A';OK;>;_E$9?#4F0A2NZV^4F\\'NR.I(C%-)48_;V;BD8N0/MVH<E$1+^
MC6LJ7U1.![KW527_  C[9.P/YAO\S[NC;+?>;$S6UV;'Y!_VY2-P;XK,MC#)
M3/IJ(//1T,K#R(MRCJ/5&X7W7NMY3YA_(K%?$;XK_(/Y.YK!5&Z*#HGJ3.=F
M-MFFGCI7R,N*H)JFFH/NIKQ4BUE2D<+3N"D"N96!"$'W7NOG1;*^2/\ PH\_
MFC?&[YA?*GX^[HV?M_X9Q2[VH>TNNL!2[!VOAJZ&HPLF0W;B:#%9*B6OS4E+
MBJT55365E342UDE;]O/E,G5PU,-/[KW5SW_")+_LAWY>_P#BUL'_ +R&#]^Z
M]U?]_/"_[="_S%?_ !5+=?\ [@/[]U[K3;^%75NPLY_PCH_F!Y>HVOAJ3/9?
MM;(;AS6X\92T]/D:ZHVSNS8.2PPK:Z.(5-5%1S4JHB2.P6%I(DTJY]^Z]T)G
MQ5ZLZXK/^$8?RIS#[)VU3YK=&3S^[]T9W&TD5'7Y/)[=[1Q$F#K,E74JPU=?
M-C1C::*'SR2 4\*4I!I[Q'W7NKW_ /A)Q45%5_)7Z*EJ9YJB1>S-^TZR3LSL
M(X=T5\448+$D)%$BHB_14554  #W[KW6R5[]U[KWOW7NJ9/^%#/_ &Y=_F _
M^(<I_P#WH<+[]U[KY7/;?5?9GQ>ZK^)/RUV5FIJ'$_++X_;KZ[_B9FC61#38
MF?KS?& BID"3&AR6RLW!!45!9V*9FHCC^VFBIYC[KW5@_P#+?^+U;\7?YOW\
ME"FR^0^^S7?>'ZU^3E?%")!304V[\CGYL(E)YXXZCQU&VZ3'54OE%_NJBH$6
MF#PHGNO=75?S/L-@^X?^%>OPTZX[86ER>P</F>J*+%XK(Q 0SQ4])4[AI<=.
M5"/5T=;GW9'AE9X9!/+"Z-')*C^Z]UQ_X56XG ];_P XO^6'V]L T>+[;S6$
MVQD,Z])&KR/)@>P57;^3FIV#Q259,T]/'/H\Q2B@CUD4T C]U[H1?YH3JG_"
MOO\ ER%V5 :#JE 6( NV5W0JCG\LQ ']2;>_=>ZY?S/_ /N+\_ER?]J[JO\
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M/?O]9S;/]^W7_.2+_K1U[_DU=R'_ -'?FG_N8;=_WJ>O?]!!ORX_Y\;\//\
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M:_[?N?\ "B/_ ,.SI7_WG=P^_=>ZV=O?NO=>]^Z]U[W[KW6J[_PI]_[H[_\
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M9[K*#<X@2K&-J<KCYZ:CR#TCE4K(J*K>.:2G8JLZ(T190]Q[KW7SPND/@/\
M\*E/ACT+\@?Y;7Q\Z8..Z)[ESN;3=.\MN9'9E723Q92"/!9JNVUNK+Y."JPM
M)N/ 44+E/%2UT4&EZ>GH,Y+,C>Z]U8E_+H_EA_SBOB5_(U_F3=!=?==[O^.G
MS;[3[EPV\>EZ+!;JVW3YK(X""#:]/N-,+G\/FJVCQ.3K</19*DIG>KHZD2E?
M#- [Q3CW7NC?_#SX>?S;)_\ A/\ _P PCXX?-#&=C]A?)/MS;F\<7\=^LM\Y
M^FSNYHZ#)X>BAAQ;Y"7)U=-24M1F!4-1TKU<<-*A=DCAA=7D]U[H+/B'_+;^
M<'7O_"8/YA?"/>7QYW=@OE1V#N_<E;LWIRIJ<2^0KXJ[+[4J*62&HBR$F.59
MH:*=@7J5L(FU6-@?=>Z77QP_EX?-#9O_  ED[Q^#&YN@MUXGY8[EI-V4^"Z7
MGJ,6V1J6R._:;*T0CJ(Z]\;:?'@S FI 500Q5@5]^Z]T6+#_ ,O_ /G/]3_\
M)P^BOB_\7MF]I=-?++:7RRS6[NY^KMH[AQ6$W-D-C5N2W)514U)E(LG'25%-
M-D:O%55520UT;5-)'+#*LT0GI9/=>Z,_\F^Q_P"97_+\_P"$QE!G?D=W=V5U
M[\WMJ9W#X+_272YULIN[&4%?O0287'5^=%17O6UTV,$-%52//4/'1S-&SQO%
MIA]U[JUS_A/%FOE!OS^5OTIW1\O>T>TNU.X^]<WGNRVRG;5<U=D:+"/DI<3@
M:6G)5%@H*O&XJ/)PQZ0R_P 0;R$O>WNO=&+_ )R/QZ[>^5W\L?Y@_'CH3::[
MZ[@[2ZSBP.P]HM7XS%_?UD>8QE68/XAF*S'XRE)@II"'J*F&.XL7!(!]U[K5
MR[._D;?*/LS^1E\#?C)V]U?4=4_)SHWYQ;>HMQ[=67;6ZZJBVAOW<M%LO-U<
M-=@LKF<-'30&OQN=GD%3*$H<9+#60QAY/%[KW1L_F)_*7^9N]/\ A0O\"/F'
MTET'!7?"SX\;2ZUVKN+L:'<FSZ&/#TFU)LVE33)@*S/4NXZE:*DGIE7[7&RJ
M^H"+5I?3[KW4K_A1U_)D^6GRD[QZ _F,?R\WJ,Q\FNBZ3#8'+[$I:W'4=:&P
M&:ES.WMW8 Y>2/'RY;#554_W,1<320TM$:2&HGC*'W7NB&_"/^4)_."_F%_S
M/NH/GY_./Q4O76W/CK-@<]0T62;;E+7[A;;=965V$VIBL1M>L>+&8>/*L*_)
MR2QQTM1#5U4,'EJJRK,'NO=&,_X49?RE?YAW<'SW^,?\R+^7ILN/M;>?5^#V
M[3/MO%-A(,MMK=6RLU6Y_;VX@N8KJ-<OCYYI*1(J4)/%355'(]5&:>MD]^Z]
MU7E\3/Y8_P#/O[=_G(?$7^8'\_>B-]9R/ =TX/='979>?W#L-*7"8+&5-6M/
M2XW;^*W-)48W%44#*8J*EQM,RO+++)2M/+/55'NO=6M?'7^7A\T-H?\ "IOO
MWYS[DZ"W7B?B=NVDW'3[=[HJ*C%G'5356PL9BJ<)3I7MDE$V0II(5+TR@LM[
MZ2K'W7NO?'7^7A\T-H?\*F^_?G/N3H+=>)^)V[:3<=/MWNBHJ,6<=5-5;"QF
M*IPE.E>V2439"FDA4O3*"RWOI*L?=>ZKN^='\LC^>E\8OYS_ ,HOF_\ RQ>O
M:W/4OR#ER>5V=VQ@)-F5T4-%NW'P#,8;(X_=S?:X^OQ^:H@89IH/ JBAJ34F
M%JM8O=>Z'3^<#_)A_FFY3L3^7!_,#^)&2K^__EY\<?CYU[L3OII:_&+N(=B;
M'ICE1ORG.5KEI,_0YK-R315F.^XJ$AG$)%-5XZMKWI/=>Z(%O[^7=_PH_P#G
MI\^_B!\R?F[\:LKEZ'K+MC8Z1TV)RW7^$H-J[6P.Z<?F,BT.WJ?<,58C--+6
M5$SNE3D*IXR%:2D3'+[]U[JYKY^_R\/FAVO_ ,*7/A#\T>O.@MU[H^+_ %A2
M==T^_.WZ*HQ:4&.;$U^?FR(E@GKXLA(*2.MA9S%3N/7Z22K!?=>Z]\=?Y>'S
M0VA_PJ;[]^<^Y.@MUXGXG;MI-QT^W>Z*BHQ9QU4U5L+&8JG"4Z5[9)1-D*:2
M%2],H++>^DJQ]U[KWQU_EX?-#:'_  J;[]^<^Y.@MUXGXG;MI-QT^W>Z*BHQ
M9QU4U5L+&8JG"4Z5[9)1-D*:2%2],H++>^DJQ]U[K<;]^Z]UKX?\*9OB5\B_
MFG_+.J>E?B[U9G.X.T9>_-J;ICV?M^:A@G./H(\M]Y5&3(55'3". SI>\@8E
M@%!/OW7NC*?RP>@>XND?Y,OQ_P#CMVIL/+;-[JV?\8LQLC<G7^0:GDK*7*R_
MQD14;/3334SR2&>/24E9"'!#6]^Z]U2__P )EOY>'S0^$_Q$_F)=?_*7H+=?
M3^\>VZNAJ.N<%GJC%U,N66+;&<HI#3MC:^MB4K55$<9$C(;NIM;GW[KW2%_X
M3S?RV_G!\1/Y?'\U;J3Y'_'G=W5?8W>>T*FBZFVMFJG$SSYN5]D;DQBQTKT&
M0JX$8UU7##:62/U2*3Z>??NO=+K_ (3[?R\/FA\2?Y5G\RCHGY%]!;KZN[:[
MCJ]UU'66RLS48N>HRZU_7,>'HS324%?5TJF?)H8 ))4(:Q8!"&/NO= 1_*!_
MD<_)7=7\FW^8A\!/F=UON3XP;_\ D%W#2[RZFS6Y)**L:DK<7A<'-ALPPP^0
MJA)CQF<6:6N@$J2S43U,( $RD^Z]U7STG\//^%9WQ5ZD/\NKH#;VXMB?'S&[
MTKZ;![QV9DNOZ>&GHLAEJR2OJ,1O%J^'.X;&9.2I;-2)!4TE8"6CO%75-;0U
M/NO=6[?\*$/E/_,;^"W\J7X+MF_D_4;.^:^>[/H-I=R]H_&@56)H]Q9*GP&3
M>IQ\"21+)+1NDB33S+34:5=?2)404..AJ$Q\7NO=;&?\L+"=U8/^7W\1O]F.
MWGOK?W>^XND<+OSM;<7958:_-C-;BIQG:O'U]394>3#-D1CU"*J*E*H46%S[
MKW3?_-$^#.'_ )COP9[W^(^1W ^T,IV/@:>LV5NY2X7'9_$5U-EL1-/XP[M0
MSU=&M-6JJ.S44]0$1G*^_=>Z^?Y3_P K'_A374_&I?Y2,O5=3#\,E[2_B06?
M([$3;T<9W N1:L_CT5=_%)L N1)W%]F3)+]U>5*<Y8+2CW7NK;_YOO\ (W^2
MFU/Y-W\O#X"_##KC<OR?[ ^/_<55O/MK,[<EHJ-JNMRF$SDN9RZ#,Y"E$...
M8R8IJ&G\KRPT24T14B)F'NO=#Q_PH)_EX?-#Y;?RK/Y:_1/QTZ"W7VCVUTY5
M[4J.S=E8:HQ<%1B%H.N9,/6&IDKZ^DI6,&3<0$1RN2URH* L/=>ZVG_BEM;<
M&QOB[\;=D[LQ<^$W5L[H/9VUMS86J*&6CR&/V[CJ2MI9#&SH9*>IA>-M+,MU
M-B1S[]U[H?/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:B&^OYF7\LC#
M;VWCB,Y_*WZ_S.:Q6ZLAC<OEY,=M-VJZJ"KFBJ*EGEQ/D<SRJSEG]1U7;F_N
M=MOY)W^XMXI(MQ94:-&1?'N!I4J"!08% :4&/3KNQRS]SOWDW';;2XMO<6]A
MAEMH)(HA<[HHBB>)&1 %N-(TJ0M!@4H,=)7_ (=$_E:?]ZI>O/\ SV;/_P#K
M3[5_U#YB_P"CFW_91<]'G_ 7^]?_ (4F^_[*MV_[:>O?\.B?RM/^]4O7G_GL
MV?\ _6GW[^H?,7_1S;_LHN>O?\!?[U_^%)OO^RK=O^VGKW_#HG\K3_O5+UY_
MY[-G_P#UI]^_J'S%_P!'-O\ LHN>O?\  7^]?_A2;[_LJW;_ +:>O?\ #HG\
MK3_O5+UY_P">S9__ -:??OZA\Q?]'-O^RBYZ]_P%_O7_ .%)OO\ LJW;_MIZ
M]_PZ)_*T_P"]4O7G_GLV?_\ 6GW[^H?,7_1S;_LHN>O?\!?[U_\ A2;[_LJW
M;_MIZV]MG5M%D]H[6R6-H(\5CLAMRAK:#%Q6TTT,M+%)%3KI55TPHP06 %AP
M ./< ,*$CY]<(-]MY+2^N(I7,CI/*CR&M9'61@S&I)JQ!/$\>E'[KT5=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=4'9X?-CO3^8G\BN\_A\/C1-AOCCMBC^'M+7?(FI
MW1)2&I<4>Y]R/B:3;L!2+(096=:.JEF?7X8H46X=ECDVV.U[?M,%MN/U6JX=
MKO\ Q=80=(+P(&:4U(HK,H%!WG[>NG.UGVZ]MO:C8N6^??ZP"7?KB7FEDV*/
M;EE$8,VVV8GDOWJT30QM-$J+36[DY +/OPNJ?DG\>_YB7=/5ORO'4=+G_FCU
MW3]\[3?H^7*G:S9[:Q_A&5I*&'.0PY&/*5F*!KJ\$RJPBBD#V;1"SS&+#<MK
M@FV[QJ6DC02>.%\71,6E0DQDKI#:U7@:FA' DL^\)#RA[I>U.T;UR/\ O1H>
M4[Z39;H;PMM^\?H]RK=P22-9L\)@CGK! >PC4RE:C4XP_P H7_CT?G=_XTM[
M0_\ <;;/M+SYQV__ *5=I_UDZ GW[_\ <[DS_P ]_P N_P#5S<.LG:<N-[B_
MF^?%C;>VJN2NJ/B-T3O;L_LBIH0LE/1S;RI8=N8K%5<PU""NEBE%8(&TR-3L
MDB@H7(9L7;;]BNF:E+N>WA2I[B(-<KL!Y@$JI/"IIQZ:Y*6;D'V(YCN[M0B\
MS[SM&W6"N2LDJ;3(]_/-&IH6C5E\$N*J'U*:&E<?\H7_ (]'YW?^-+>T/_<;
M;/M[GSCM_P#TJ[3_ *R=._?O_P!SN3/_ #W_ "[_ -7-PZR=IRXWN+^;Y\6-
MM[:JY*ZH^(W1.]NS^R*FA"R4]'-O*EAVYBL55S#4(*Z6*45@@;3(U.R2*"A<
MAFQ=MOV*Z9J4NY[>%*GN(@URNP'F 2JD\*FG'IKDI9N0?8CF.[NU"+S/O.T;
M=8*Y*R2IM,CW\\T:FA:-67P2XJH?4IH:5M&WSO'#=>;+W=O[<?WXV]LC;-=N
MW/'%4T];4BBQU++6534]'3))4U4RP0L4AB1Y)& 1%9B 0;!"URZQK2K,%%2%
M%6-!4L0 ,Y)( XDTZPSY<V&XYJW"UVRTT>/=W$-M#XDB0Q^+/(L2:Y)"J(NI
MA5W(51EB ">JV_EKT[\5OEG\6=S?,''I18;>%)\>9>RNF?DE025N)S^WH\70
M5NX,'40U4511U=(E'73.T]*61BTDT3:9;,HJV7<+W8KP6)U,OU'AS6A(>.5B
MPC=2M'1B::0U#2@(X#K+;V.Y^YU]CN=+?D.77-:MOB[?NW+[K%<V5\UQ/#97
M*-&R2QR&2- (Y0& "HPJN";GX;=B;N[;^*'QT[.WZ4DWEOOIO;^Y]QU*(8A4
M557C8)9*L1DG0*PMY[#T_N>GTV]DV_6:;??7%O'71'-+&M<G2CLHK\Z#J#/?
M[E2QY%YWWW9MLJ+6RW6^MK=2=12.*X=%2OGHIHKQ[<YZ,I[*>HBZ][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NM27=G_ '&(]8_^,W:C_K3N'W[KW6VU[]U[KWOW7NO>_=>ZT3*3^915
M?RIOYUW\YK?.^?AU\KN_=L?)+?/7='LS,]'[?:JI(O[K[=J!6O-55AIZ>9)9
M,RD:&!Y-+PRJ^D@7]U[H[/\ T%E=;?\ >KG^9%_Z#%!_]6>_=>Z]_P!!976W
M_>KG^9%_Z#%!_P#5GOW7NO?]!976W_>KG^9%_P"@Q0?_ %9[]U[JK'^9#_-O
ME_FQ=G_RT^L^L_@K\SNFY>F_Y@VQ.V]S[G[;VT8\<<='D(<?*!+CVJC"835"
M5WE"1+$CDN+>_=>Z^A1[]U[KWOW7NO>_=>ZTW/GK_P!QB'\I/_Q2:I_ZU_(?
MW[KW6Y'[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z*+\^.JN\>]OA?\ )GI'XVY_:.U.ZNXNG\QU;LG=.^<GD\-C<8VX*9L3
M79%\IAL3G,I0U5%C*NIFHY:>BFD%8D O""9X_=>ZK0_X3Y_RD^Q/Y1WQ1['Z
MO[NW1U;O;NSM;N&HWWNC<74,V0JL1'B*;'T=!@\8E;EL+@,C5RTK)6U,CS4B
MA'K6AC9XXE8^Z]U?3[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z*#\W_@U\>/YAO1M3\=/
MD_MW.;IZLJ]U8_>53A]OY6MP\[UV+,S4;FMH)(JE8XVF8E%<!S8-<<'W7NAY
MZ@ZIV/T3U1UGTGUEAUV]USU#L'$=9[#P:N\OVF'P=!3XS'4[2R%I)GBI*:-6
MD<EY&!=R68D^Z]T(OOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z(!\^/Y9/Q%_F78#K#:_P N-DY[?6 ZBW34
M[QV;C,-F<AAXUK:N&&GG:J./FA>KA>&$)XI"8[%KJ2;CW7NC^111011PPQQP
MPPQB***(!555%E55%@JJ!8 < >_=>ZY^_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJB\Y_(]_E[[CS>8W#ENO-[U
M&5SV5J,SDYTW1F4#U%5,\\SA$J%1 TCDA5  O8 #V.;?W(WBUC6))P%10JCP
MH315  %3&3P'GUG5MG]XY[J;/;16EO?VBQ011PQJ=NM&*QQJ$45,9)H% J22
M?/IJ_P"&)/Y<_P#S[??/_H5YO_ZI]O?ZY^]_\I _YPP_]:^EW_)RWW:_Z.%I
M_P!RVS_ZU=>_X8D_ES_\^WWS_P"A7F__ *I]^_US][_Y2!_SAA_ZU]>_Y.6^
M[7_1PM/^Y;9_]:NO?\,2?RY_^?;[Y_\ 0KS?_P!4^_?ZY^]_\I _YPP_]:^O
M?\G+?=K_ *.%I_W+;/\ ZU=>_P"&)/Y<_P#S[??/_H5YO_ZI]^_US][_ .4@
M?\X8?^M?7O\ DY;[M?\ 1PM/^Y;9_P#6KKW_  Q)_+G_ .?;[Y_]"O-__5/O
MW^N?O?\ RD#_ )PP_P#6OKW_ "<M]VO^CA:?]RVS_P"M75N^'Q5)@L1BL)CU
M=:##8V#%42RL680T\2PQAF/+,$07/Y//L DU->L$;Z\?<9Y+B6A>5WD<@4&I
MV+&@\LGATY>]=)>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB]?&SXU[&^+^S-R[/V3E
M-R[BEWKV1F^V-Y[KWD]#+E<KG,]4"HKJNLEQU!C:9V"I'#':!2L,4:$L5N3/
M==VEW=U>6@T11PHJZM*1Q*% &IF(X$G.6)/GU*?NY[N;E[R;A;W^XQV\ M+"
MSVRTMK43+;6UG91^'''&L\UPX%2SMWD%W9@!6G43N'XO[![G[4^/G<V;RNZM
MN[^^-N[*W<^Q<MM2:BB^YBRE-'293$91:N@K6GQ>0IXE25(6IYU%S%/&68FU
MCN\MA!/;KI,=PBK(K5_ X=6%&'<I&*U%"<=/\A^\FY^W^R[WR_;1VT]EO]M#
M;WD5RLK>&UM(98)X?"FB"S1.Q*EQ(A_$C4'1%\M_)WZOJ]S]@;CV[\L?G+UU
M3=D;^R_9&>VGUSO;'8G#IDLW625M8T%#!MW2%\CA%:1I)3&D:O(Y6_L3Q<^R
M)''&]G82F*-(E>6W+R%8U"BK&3T'E0>@'62=C]_?>8+*QM+OEGDZ_:PLK6PA
MN;_:)[FZ-O9Q+#&&D>_K6BU(4*NHL550:='6^+_P[Z)^(6W]PX;IW;=;3Y3>
MF27,[]WUN>JDR>X,]5HTSQSY;*SCS5'B>IF:.-0D,;S32)&LDTK.&]WWZZWQ
ME:X>H0:8T4!8XUH!1$4!5PHK09H*\!UCO[R>_?,OOM=07&_W"M':1F*RL[>-
M;>QLHB$!6"!.U*B- S9=@B*S%44 E.6_D[]7U>Y^P-Q[=^6/SEZZINR-_9?L
MC/;3ZYWMCL3ATR6;K)*VL:"A@V[I"^1PBM(TDIC2-7D<K?V)(N?9$CCC>SL)
M3%&D2O+;EY"L:A15C)Z#RH/0#K(BQ^_OO,%E8VEWRSR=?M865K80W-_M$]S=
M&WLXEAC#2/?UK1:D*%746*JH-.CK?%_X=]$_$+;^X<-T[MNMI\IO3)+F=^[Z
MW/529/<&>JT:9XY\ME9QYJCQ/4S-'&H2&-YII$C62:5G#>[[]=;XRM</4(-,
M:* L<:T HB* JX45H,T%> ZQW]Y/?OF7WVNH+C?[A6CM(S%96=O&MO8V41"
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M(R3Y\>NWO+ON=[OP[?:I![9;1/$MO"(YVM%=IHQ&H60M]0-1<48GS)KTFO\
M9>_Y8'_>X'N__P _$W_UK]J?WIO/_1FMO^R-_P#H/HX_UT_>3_PEFS_]D0_[
M:>O?[+W_ "P/^]P/=_\ Y^)O_K7[]^]-Y_Z,UM_V1O\ ]!]>_P!=/WD_\)9L
M_P#V1#_MIZ]_LO?\L#_O<#W?_P"?B;_ZU^_?O3>?^C-;?]D;_P#0?7O]=/WD
M_P#"6;/_ -D0_P"VGKW^R]_RP/\ O<#W?_Y^)O\ ZU^_?O3>?^C-;?\ 9&__
M $'U[_73]Y/_  EFS_\ 9$/^VGKW^R]_RP/^]P/=_P#Y^)O_ *U^_?O3>?\
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MV/\ ^@A!_P#8U[]U[KW_  UM_P *7_\ O>IL?_T$(/\ [&O?NO=>_P"&MO\
MA2__ -[U-C_^@A!_]C7OW7NO?\-;?\*7_P#O>IL?_P!!"#_[&O?NO=>_X:V_
MX4O_ />]38__ *"$'_V->_=>Z]_PUM_PI?\ ^]ZFQ_\ T$(/_L:]^Z]U[_AK
M;_A2_P#][U-C_P#H(0?_ &->_=>Z9=P_R</^%#/;6&R'7O;7\^9<5UYN>G;&
M[IJ^O-L5-+EOM7XD2FEQ<6UZVT@]+HF2I@Z$H[%25/NO=76_RK/Y2/Q<_E*=
M+93K#H.CRNY]Z;XK8<QV_P!W[V2F;<6YZNG\PHH9WIHHH*'#8I*B5,?CH (:
M<2332-45U35UE1[KW5H_OW7NO>_=>Z][]U[KWOW7NO>_=>ZT5_\ A;%WU*W7
M'P7^'V*I/XG+OWLS,]Z;B@H7,V0IY<+1Q;9V[]GC(Y(WKI,@-R9J-22$1H%B
M ,DZO%[KW10?^$B.Z]X?$W^9S\\/Y??9-+AJ/=&6V37X;>$V/JY6T[RZFW-/
MB9L5#!/' U5!!3YW.,:A8TT-3V/D2HB:/W7NK+_Y@OSN^8/67_"G'X-?$?8/
MR$['VK\:^QZ3KFHWQTWB:M4PN2;)Y#/Q9 U$!C9R*N.CA64*ZA@@N.6O[KW7
MOY@OSN^8/67_  IQ^#7Q'V#\A.Q]J_&OL>DZYJ-\=-XFK5,+DFR>0S\60-1
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M=W_^B_I_?OW9NG_1\MO^YA)_FZ]_K8^Y_P#X5[9_^Y]+U[_3Y\!?^])'=_\
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M3EJ*2MHJNG>2GJJ2JIY$EAFB=HY(V5T9E8$^Z]TF?YIG\B?,;1[#^07\V?\
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MW_EC>?ZP1\OR2<L7VXFTN;"0Q,#>V*-;7=9$2WC+0JX9D;4H4U!5!B_E"_\
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M+^-?R\W!\\L+V/5=&=FTG9F:V6NPJ^GGR\U/5U55)3G.56]*W3+*U1ZJG[!
MY!9J82,\C^Z]T(7_  H1_D;_ !1^0/=&#_F [F^>O5W\O+?FY&Q6RMV;B[:2
M@@Q6YMP8BC'\$K\15+D\-F)=V183%+3BEIY:MYJ?'T\]-%3O35357NO=4*_\
M)9NBX!_/$W;E.G-X57<72GQ_ZEWO3Q]UIAZ[$46<QDD%%MK%9.&DJ*K)G%ME
MYJ^&HIZ&JJDK$IBVNEIWAGIJ;W7NKJ?GG_PD+I_D?\M.Z_D/\<_F&O0&S?D#
MNK([]WMUIF=OY#*FCR^>FK*O<)I:RGS]&M;C,A7ULM1%1R1TZ4T<DE$C-"R2
M1>Z]T?;^2K_PGLS/\H[N?Y"=JY+Y84W=\'>/5O\ HUI\=M[:53M6IQ/^Y6+)
M??Q5E3NG<LDTH$>F,-ZT>SM+*;W]U[JIWM;_ (1?;J&^]W5?Q\_F.[OVSUKN
MVNAEJ<)V9@ZRMS<E*A6>6#,9/#YK'4.=JY,BT]9]T:*BB628A:(,IE?W7NK]
M?BW_ "'_ ([?&K^59W)_+$CWYN[=]!\B]M9<=U=W3P1T^0K-R9:BIJ:/-8C$
M33UU)B*'"R4%+)C\:)IXT,#25,]155-553>Z]U6U_*&_X2YY7^6Q\TNO/EUV
M!\M,;W0.GL1N9.O=B8';E=B(5RNZ,!)MBLRLTTV=J8H"F)JJM&A\%2)_+37D
MC:A26;W7NMO7W[KW7S^NY/\ A&!WYW!VWV=VOE?Y@G7"Y#LC?^7WQ515^R<Q
M4RQG*5\]8(7G;<2F4P+,(PUE%E%E46 ]U[HY?\I[_A*WVA_+>^?_ $'\T-Q?
M,/8/:>&Z:_O3]YL/"[2R.,J:_P#O%LK<>U(_%73YJKB@^UESJU#:HGUI"T8T
MEPP]U[HFG<G_  C [\[@[;[.[7RO\P3KA<AV1O\ R^^*J*OV3F*F6,Y2OGK!
M"\[;B4RF!9A&&LHLHLJBP'NO='+_ )3W_"5OM#^6]\_^@_FAN+YA[![3PW37
M]Z?O-AX7:61QE37_ -XME;CVI'XJZ?-5<4'VLN=6H;5$^M(6C&DN&'NO=$Q_
MX35]%0=[_P [K^:#\TI*2@EVOTENO>6V\(\U-(:AMR[[W;D8*?+QU4T2".6K
MP>$S9JHE)D+UX,H4",R>Z]U] CW[KW7S^NY/^$8'?G<';?9W:^5_F"=<+D.R
M-_Y??%5%7[)S%3+&<I7SU@A>=MQ*93 LPC#64646518#W7NCE_RGO^$K?:'\
MM[Y_]!_-#<7S#V#VGANFO[T_>;#PNTLCC*FO_O%LK<>U(_%73YJKB@^UESJU
M#:HGUI"T8TEPP]U[HS'\YK_A,9UE_,Z[R3Y0=1]TTWQS[JW%1TV,[73+81\W
MAMP_8T7V5#DTCI\ACZC&Y2."*GBJ;?<05<<$;JE)4M55%7[KW1B_Y)?_  GZ
MZ>_E#U>^NT<GV(.^OD?O_$R[0;L63$)B:/!;>DJHJN3$8BF>JKJEYJV:FIVK
MJV26,3BF@2"DI5%0:GW7NJF_YB?_  DP[N^=GS6^1'RR7YQ["V?C^Z>P:C=6
M#V=F=HY7(SXF@,<4-)CVJTSU/'+]O#$!=(HTN20O))]U[H-OB!_PCJ[>^,?R
MT^+OR3R?SDZWW;COCU\BMD]XY#:M#LK)TL^3@VGN7&9^7'PU4F?FCII:V/'F
M%)6C=8V<.48 J?=>ZWEM_P"VYMY;#WMM"FJ8J*HW5M');;@K)U+)$]=1S4JR
MNJV9EC:4,0.2!8>_=>ZUO?Y8O_">O-?!WX0?S"/A9V?\E,9V/B?G9LZIV3-O
MG8.!FQ53M^GK=M9C;L\ZTE?D*Z.MFC&4$Z*7C1_&8WL&U>_=>Z%#^1%_(GK/
MY.#?('-;C^1*][;H[P7#8E8\)AIL%BZ"@PLE?-%*:6HR62DFKZJ2NLS!E6-(
M].J76/%[KW6Q![]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>ZT\]]_SL]H[8WQO+;3_ ,O;XW91]O;KR.#;
M)U'VJR5)I*R:G,[J=ON5>8QZR-36)/J/U]SOM_M.][;Q3?7.OB1H^GPB=.I0
MU*^,*TK3@.N]?*_]W/?;WMEI>CGC?8Q<6L$PC42%8_%B1](/URU"ZJ T'#@.
MDI_P^?L__O7/\:/]O2__ &.^UG^L\_\ RGR?\XC_ -;^CS_DVI?_ /3=[]_O
M,G_;?U[_ (?/V?\ ]ZY_C1_MZ7_['??O]9Y_^4^3_G$?^M_7O^3:E_\ ]-WO
MW^\R?]M_7O\ A\_9_P#WKG^-'^WI?_L=]^_UGG_Y3Y/^<1_ZW]>_Y-J7_P#T
MW>_?[S)_VW]>_P"'S]G_ />N?XT?[>E_^QWW[_6>?_E/D_YQ'_K?U[_DVI?_
M /3=[]_O,G_;?U[_ (?/V?\ ]ZY_C1_MZ7_['??O]9Y_^4^3_G$?^M_7O^3:
ME_\ ]-WOW^\R?]M_6XELS)+F=G[3RZ4=-CDRNVJ#))CZ,6A@$]+%*(8@  (X
M@VE1864#CWC\XH2/GUP.WZT-A?7,!9G,<\T9=OB?1(RZCQR:5/S/2E]UZ*>O
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NBH?$?XQO\8]I=E4&7WO_ *2-\]O]U;A[Q["W
MM]A+C%J\GGIXB(8:&7)95J>GHJ.G@@C45!5M#2:4+L/9SO6[_O=XR%T)%#%!
M&E0:+&,DD*E2S%F)(K5J5-.IM]\_>$>\-]M\L%I]!9[7M%CL]C:>,MP8K>R1
MNYI%M[;6\LDDDC$Q@C4%J0H/4'O+XK-VQ\@OBW\B]N[\;8>\OC?N#,&K@_AS
M5\6X<!GZ-*+*X28KD:#[-VC0M3U)6I6%W=FII+BUMOWCZ*UN;1D#I<+'FH!2
M2)]2L.UJX+ C%0>/2GVX]ZAR1RMS'RG=68O+7?H+72WCB%K&]L9C-!<K6";Q
M ":21@QEU  D7S(MAOY:/R_ZXW#V]4=$?S(*_IW9?;7<FX>YZ[9F*ZQPU>8,
MAN"K$\Q?(UFX&JJF6*FB@I_+^V&2!2L48](%#\W[;=QPK=[=XSPP10!S>2I5
M8ETBBJE!4U-,Y)R>/62NX?>^Y"YMM-K3F;D)-UN]LVJQVE+N3F*[@UP6,6A:
M0Q601%9V>33W$%S5FX]'1^)OPIVO\8<GV!O_ "_8>_>\^]^VY*<]E=V=GU)G
MR5;!1F0T>.HJ8.\&*Q=*9#HIX2>%BC9VBIJ6. -;UO\ )O"QQ"..&&*OAPQ+
MI52P4,235F9M(JS$FN?,UQY][_O#7OO'#8[7!8V6S[-M@D_=^T;=&$MX7E"B
M261R \\[Z1JD?S+,%#22LY+L-_+1^7_7&X>WJCHC^9!7].[+[:[DW#W/7;,Q
M76.&KS!D-P58GF+Y&LW U54RQ4T4%/Y?VPR0*5BC'I E?F_;;N.%;O;O&>&"
M* .;R5*K$ND454H*FIIG).3QZR&W#[WW(7-MIM:<S<A)NMWMFU6.TI=R<Q7<
M&N"QBT+2&*R"(K.SR:>X@N:LW'HZ/Q-^%.U_C#D^P-_Y?L/?O>?>_;<E.>RN
M[.SZDSY*M@HS(:/'45,'>#%8NE,AT4\)/"Q1L[14U+' &MZW^3>%CB$<<,,5
M?#AB72JE@H8DFK,S:15F)-<^9KCS[W_>&O?>.&QVN"QLMGV;;!)^[]HVZ,);
MPO*%$DLCD!YYWTC5(_F68*&DE9SJ^R'K'KHLGRE^.K?)3:_6FVEW>NS/]'G?
M&TNZFK6H/XA]V-KY#[\XT1_>T/@-=^C[C5)X?U>&7]/LTVG<OW6[OIU:X9H:
M5TT\:-H]7 UTZJT\Z4J./4P^S'NL/:.]W"\-K]7]=LVY[3H\;P/"_>-N8/&K
MX4VKPZZO#HNOAK7CT9OV5]0]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1*_GQ\!?CU_
M,CZ J?C;\F,5G\EUW-O'%[[IY]J54-#DZ3(XEY?#-15L])6"E::FJ:BEE=(Q
M*::IG2.2-G#K[KW7?PD_EZ?$'^7=UYD^M?B1TYA.K\+N&N7)[MRZS560S.9J
M(WJ)(6RF8R,U3D*F&E>LJ#2TOD6CH_/,M'3P++(&]U[HZ?OW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NDYM_9VT=I???W5VMMS;
M/\4F6HR?]WZ&EHON)%U:7G^VBC\SKK:S/<C4;'D^_=>Z4?OW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJS\K\
M!?Y6^4R>1R>7Z>Z$JLMD:^:NRE55Y8^62HFD:2>22^5!\CRLQ:_Y)]B:+FO=
MH5")<W 50 H#L  !0 ?(#K+RQ^\_[S64,<-ONV]+%&B)&JV_:L:*%4+2WX
M ?+J!_PWO_*F_P"?+?'S_P ^Q_\ KM[O_6_>/^4JX_WMNE7_  5'O9_T=]\_
MYP'_ +9^O?\ #>_\J;_GRWQ\_P#/L?\ Z[>_?UOWC_E*N/\ >VZ]_P %1[V?
M]'??/^<!_P"V?KW_  WO_*F_Y\M\?/\ S['_ .NWOW];]X_Y2KC_ 'MNO?\
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M )<W7O\ 9A]Q_P#?-GA/_19S_P#VI_?OW,/^FD_[./\ M\Z]_K46O_A?9?\
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M>20Y\CH!X>M.!Z2^TTR;9['<]R70(2\W+EJTLV*U5KN"[:ZE"D\&6 5:F=)
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M?[W%_P!:.C__ )-,^W/_ $<>9/\ LLVS_O3]>_Z",_FW_P ^M^*__GDW;_\
M9Q[]_K-[7_OVZ_WN+_K1U[_DTS[<_P#1QYD_[+-L_P"]/U[_ *",_FW_ ,^M
M^*__ )Y-V_\ V<>_?ZS>U_[]NO\ >XO^M'7O^33/MS_T<>9/^RS;/^]/U[_H
M(S^;?_/K?BO_ .>3=O\ ]G'OW^LWM?\ OVZ_WN+_ *T=>_Y-,^W/_1QYD_[+
M-L_[T_7O^@C/YM_\^M^*_P#YY-V__9Q[]_K-[7_OVZ_WN+_K1U[_ )-,^W/_
M $<>9/\ LLVS_O3];DFSLQ4[AVAM7/UJ015F<VW0YBKBI0RQ++4TL4TBQJ[.
MXC#N0H9F(%KL3S[QK<:21\^OG]WVQ3:[ZXMHR2L,\T2EJ%BL<C(": "M!F@
MKY#I2>Z]%77O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]TDM_9ZLVKL3>NY\?'335
M^W-I9+/4,-8&:%YJ.CFJ(EE5'C=HF>,!@KJQ6X#*>0W*^A2P\@3^P='G+.VQ
M[UN5I9RE@D]S!"Y0@,%EE1"5)# $!L5!%>(/6I%M7^?1_,4WU]__ '(^/'1&
M\OX5XOXG_=7:6^<C]MY_)X?/]IO";P^;PR:-=M>A]-]+6'ESL-A9T\:8I6M-
M<D:UI2M-2BM*BOV]=T]\_NRO:;EG1^\M]WFT\35X?U.Y[/!XFC3JT^+M::M.
MM=5*TU"O$=*[_AZC^:C_ -X@];_^@!V-_P#95[2_N[:O^4I?^<T/^;H@_P"3
M>GLG_P!-3?\ _<[V'_O6]>_X>H_FH_\ >(/6_P#Z '8W_P!E7OW[NVK_ )2E
M_P"<T/\ FZ]_R;T]D_\ IJ;_ /[G>P_]ZWHPGP/_ )PGR[^1_P TNKOC+W+U
M9TMLC#;NDST.YX\'@]SXW.TCXO:V9SM,J#*[GKHJ=I*C'PB02TKEH7<+H9ED
M6M_LMM#:M<0.S@4TD,C*:N%.57/GY\>HL^\Q]PGD/VE]O-QYQY>W+=KR6U%D
M;<S7FWW%G*+C<;2S<DVVWPLP"3N5*2BC@5J 5.R5DLGC<-0U.4R^0H<5C**/
MS5F1R4L<$$27 URS2LL<:W(Y8@>PDS!14X'SZY%6EG+?R+# CR2.:*D:L[L?
M0*H))^0'00[R[VZXP^T-U9?;W8W6^5S^*VW79+!XO^+T$_W-9!2RRTT'@@K%
MFF\TRJFB-@[WTH0Q!]IY+I%4D,I(!H*CC3[>AUL'MONU_?6T%U8W\<,D\,<T
MGTTR>'$\BJ[:GB*KI4DZF! I4BG6L?\ \/4?S4?^\0>M_P#T .QO_LJ]C?\
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M2*5-2AQJ23;%855@PJ,@@C!'3O\ \/4?S4?^\0>M_P#T .QO_LJ]M?N[:O\
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M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UK5?''^<_P!V?)G^?7WC_+,H.O=E]?\
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MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T&_<G_,H>U?\
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M (3>_P#,WODS_P"(WP?_ +LZKV>\X_VD'^EF_P ,/71S^]P_Y(7+W_/?>_\
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M/;+VSL_-561W-GJ[-T1:";/;<RM6&G--!K!F2")(VDO -<H]U[JK?+_S:/\
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M]LG7O];?[TO_ $U?*W_9./\ RV^O?Z;_ /A/Y_WAW\P__/F?_MI^_?NCF_\
MY3;7_>%_[9.O?ZV_WI?^FKY6_P"R<?\ EM]>_P!-_P#PG\_[P[^8?_GS/_VT
M_?OW1S?_ ,IMK_O"_P#;)U[_ %M_O2_]-7RM_P!DX_\ +;Z]_IO_ .$_G_>'
M?S#_ //F?_MI^_?NCF__ )3;7_>%_P"V3KW^MO\ >E_Z:OE;_LG'_EM];GVR
MY,3-L[:<V!IZFDP<NVJ"3#4M8;S1TC4L1IXY3KDO(D)4,=;^H'U-]3C4]:FO
M&O7SW[^DT=_<K<LK3">82LOPM()&UE<+@M4C QY#ATI?=>BGKWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[JA'Y:_-;XU]<?S2^I<?\A.QTVCL3XG](Y7=&)6CI,WEFDW_
M +U6FHTIZJ@P=!7Z?L-GN*F*6I T/6+XU!8/[D[8.5[[<-EE:SB+O<SHAKX2
M#P(*N2&D93W2E00OG&:GRZZ<>QGW=N<.;O9?<Y>5; W5YS+O%M;2EY+.V"[)
MM!DE+)+>30U\6_'ALL5:B$ZC04Z4O\I+Y*=0[Z[?^</1W3>\I]X=7TG<,WR'
MZ:R-9355 3B-W^.7/8ZEQ]?2T-=34>"SQ6%1)"H8U(D!;6))$_/6QW.WP65Q
M<QB.1H/ E4$-W6YT(Q*LRDO%IX'BIP.'1-]^;V@W[EC8>3^8^8+1;7<7VI=C
MW6-)(YQ]5M6I+69Y899HWDN;7O.ES3PBM!ITJ*W\H7_CT?G=_P"-+>T/_<;;
M/M-SYQV__I5VG_63H%_?O_W.Y,_\]_R[_P!7-PZG?)-:]?YL?\MR3 +*:ANM
M^V8][FFM_P 68;?3[/[GD-X%RS(4_P";VFU^1[3[/X?[DW'Q./B67A5K_::Y
M:T^>C5^723VB,)]D.?1=4H+_ )9-GJK_ +EF]?Q-'EJ^G#5_H5^74'^4+_QZ
M/SN_\:6]H?\ N-MGVHY\X[?_ -*NT_ZR=*_OW_[G<F?^>_Y=_P"KFX=3ODFM
M>O\ -C_EN28!934-UOVS'O<TUO\ BS#;Z?9_<\AO N69"G_-[3:_(]I]G\/]
MR;CXG'Q++PJU_M-<M:?/1J_+I)[1&$^R'/HNJ4%_RR;/57_<LWK^)H\M7TX:
MO]"ORZ-C\]JNNH?A!\O*K&N\=9#\:]ZF.6)S&Z [=R"R2(XL5>.,LRVYN  ;
M^R?E= ^YVBL 0;F $'((,JX/4(_=D@CNO<;E>.8 H=_VBH(U!O\ 'X" 0<$$
MT!KY=58=8=2?-RO^$'67RBZT^5N<Z[W#LSH3";XZB^-6,Q>+DV*-L87!4DE#
M@\OY*5,ADJ_,XBC\LU9)(OAJJID@6**.-D%-[>;?!N,MI=6XE7QY8YKG7*MP
M7,C R+20H-+&H4J=0'<223UF?SESS[=6GN-N/)F\\MPW\%UO5Y9[IS!)<W*[
MR=PNKR59+F"DK0PQV\\NE(0IUQ1 R%G9@;F_CGV[#W[T+T]W5#C?X,.T>NL3
MO6;#ZBPI)J^CBGGIE<\NL$[.BM_:50WY]@C=+$[9<RVS&IBD>,D<#H8K7\Z=
M<_\ W7Y%;VQYFW3EUY/%.W7]S9B6E/%6"5D5Z>190&(\B:=#1[0=1]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW0;]R?\RA[5_\ $;YS_P!UE5[9N/[-O]*W^ ]"SD+_ )+NW?\ /?9_]I$?
M6MG_ ,)J?^YTO_*<_P#R^>QUS?\ Z#_S<_Y\ZZ\?WOO_ #J7_4^_[PW6K7[&
MG7:3J^__ (3K?]EL=H?^*M9O_P!ZW9'L,<V?[CK_ ,U!_P =?KF)_>P?].ZV
M[_Q8[3_NV;OT+O57_<1WE/\ Q)&\O_?89SV60?\ )%/^F?\ [26Z 7.G_B),
M?_/!M?\ Y,5GT"/SE[PPWQM_GD[U[SW!A<GN+#=;;HV=GZ_"89XDJJE/]&VW
M8!'"\[+$K:I@;L;6!^IX]K(+)]QVH0QE0Q-1J) [9]>2 3^'T/4C_=O]M[CW
M>^[;:<M6DT<$M_;[I"DTH8QQG]_WSU8("Q%$/ <>MG7X)?-?:/SPZBW'V[LS
M9FX]C8O;G8]9UO/B=SS4TU1)44>,P^3:I1Z1FC$+QYA$ )U:HW)X(]A&^V^7
M;7"2Z:D:AH)84)(\U7.#Y?GUQO\ O+?=WO\ [L^^P;#N-W;WDD]A%?K+;+(J
M*DMQ=6X0B4 Z@;5B2,48>=>BS?S3/Y;V[_Y@W^@O^ZG9NV^N?]$?]Y_O_P"\
M-#55OWG\?_N]XO#]M+'X_M_X*^O5?5Y5M;2;J]JWAMIU:8P^O3Q<I337^@]:
MU^74P_<M^]Q8_=8_?/UNW3W_ .]/W?H\":.'POHOKM6KQ%:NOZL4I2FDUXCJ
MN+K7K4_R"3F>W>W<R._\7W^*?K?$XGK>G_AE1CZC&>?)O4U+Y.=HY898V* (
M0RL+FX/#US<S\T3HB(B%$D;ND8@@M$/*+!&/+.<BF<L^<.<#_>?F'8=AA_<D
MFR>)?RRW\GU"3I<>';A$%O&"K*14DX(^?&W#Y%_S'MA?'/XC=$_+O/==[OW%
MM?O?^['\&VEB*BBCKZ'^]&V:[<]/]U+,PIW^UIZ%H9-!-Y&4KZ0?:.WVJ:ZE
M:!-&M-6K4S!>TA30A"3DXJ!CTX=8,>T_W2=T]V>>]YY$M;ZU@N=F_>/C7,J3
M&";]W;A#M[Z @+C6\P==0PH(.>BU?S'^Y\5\B/Y,'97=V#PV0V]B.R]L;'W1
MC\)E7CDJ::*;L'; 6*9X;Q-(-/.FXYX)]JM@0QWRHU*JTJ&AJ*H'4T) Q48P
M.I>^Z/[?3^U/WA-OY<N94GEV^YWBVDFB#+'(R;)N-2H;N SBN>B\=)?]PZ&:
M_P#$1=@?^_!W+[>W;_DIK_S6MO\ CT74J^Y'_B6,/_2TV/\ [LFW]:AWN1^N
M\/6WC_PG#_YD+\B?_$NT'_NFB]QQS5_N8/\ FC'_ ,?FZX/?WMG_ "M&Q?\
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M"4Y83>.NI7"$5,&OW7NA(_F?_P#<7Y_+D_[5W5?_ +M-T>_=>ZP?*FFIH/\
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MZIZ]^];K_?TO_.1_\_7O[M;<_P">?PG_ )R0?]>_?JGKW[UNO]_2_P#.1_\
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M;8%)DZ2+'4DFUJC$;<DJ4KQ).U3A,SD:RL4PH$".FE#+Y&;W7NA/_P"$_O\
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M7:&[)*;-8/<.%<1Y+ YS'NTN+S>-E/"U-)(S(Z-Z*BEEJ*67]J=_?NO=:?\
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M2K[![-S&-P.'HZNK9:3&I/D\O44M!%-5Y">&"G220&:>2.% SNJGW7NM5/\
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M]]UN9]Z5[B_CN-P-QM<JQ26,FW0K$L.W1-&KP2.)6D+.RE42_;LOO+I/I?\
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MN&\<IV'[SW6W^D^ELOI;F\\?Q;VV@E_0LWCG?1!)))V,-.C6U45@3^TG\L/
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M=!/_ "E/B=U-\'/^%6/SL^+G14.XJ3J7K#X8J=D8[=61J,K64=+F\5TMN-Z
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M?//0G?S.O^R /E=_XB*O_P"AH?;%I_;P_P#-:'_JZG0-^YU_T]#EK_I:0?\
M/W5:G\@_/S;4_EY?(#=-/3Q5=1MKOS=>?@I9B525Z/8^SJA8W*^H*[1@$CD
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MS2E.M1/YR_\ 9;'S"_\ %I>P?_>MR_N1]M_W'B_YII_QT==WONV_].ZY6_\
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MN_/LO[#P:?%X?#4Z_P!?E3]'L/I-_5:X>.GBZXXFK\%*-,*?CK_+K%E></\
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M0VUQLCO_ *7ZG[RV6*E*P;0[AVYA]S8OS1O'*DO\/S5'6TGD26)'5O'J#(C
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M.VKLO;6 VAMC#P?;8C;FUZ.GQ]!2QW+>.FHZ2.&G@342=*(HN2;<^_=>Z?\
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M2PM]RD*J6+,Q2-B22:$D]'G_ )7?_;E#^8E_Y5S_ -]-M_VDWG_DHP?\VO\
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MQ?3&S:2DI*TT;I1O45B82FI8FJ(]2HK2J6T<*;"WL%QPW.ZNQ17E90NHEUJ
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M<K15-!G-OUU/!]R]'E\1*C5,,KTUI87B\T%3&=5---9M/NO=4R;T_P"%>O\
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M_9M_I6_P'H6<A?\ )=V[_GOL_P#M(CZUL_\ A-3_ -SI?^4Y_P#E\]CKF_\
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MBCGRL<B--)2Q55+M^AJ869(2=4<\3^FP:YL?7&UV&W+X\BZ0C(U:R-1@RZ<
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MM'+BLO)&\*@Q/XXBR%XXW3W7NJK_ .?_ /*S?W;?QQ_X35?QSIG,?(+ ?(/
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MMO&E1)1N*C:)A15<-9&S1S-+#-5+,ROBZ%*>*2K]U[JS/W[KW6HY\N/YE?\
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M!\NC'=J_]Q'>+_\ $D;-_P#?88/V7S_\D4?Z9/\ M)7J).2__$29/^>#=/\
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M_P#";W_F;WR9_P#$;X/_ -V=5[%W./\ :0?Z6;_##UW0_O</^2%R]_SWWO\
MVCQ=;;GL(]<+^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[H*>[^\NHOC9U7O/N[O?L#;G5W5/7V);-;O
MWMNJ;PTE' &5$'I5YIZB>5UB@IX4DGJ)G2&"*25T1O=>ZUW\Q_PKL_DTXS)5
M=!1;_P"^-PTM-)HAS6'V'DTIJ@:0=<*9"6AK%4$V_=@C:X/IM8GW7NFW_H+Z
M_DY_\]-\BO\ T!9__KA[]U[KW_07U_)S_P">F^17_H"S_P#UP]^Z]U[_ *"^
MOY.?_/3?(K_T!9__ *X>_=>Z]_T%]?R<_P#GIOD5_P"@+/\ _7#W[KW1]?@U
M_/Q_EA?S">Q:+IOH/ON:@[BR\,D^W>K^T\1D-M93+>&*>HGBP[U\0QV6JX*:
MGDFDI:2JFJ5A1IO#XTD9?=>ZN3]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJA?\*B<=%V/D_P"3S\<]US5M
M;T]W[_,KVIM/MG9\$TD$.8Q[UF+QGV]2T3*[(M+FJL*+V5W60#7&C+[KW6R9
MM7XQ_&_8NVL#LW9O0/2^U]I[7Q4&"V[MS!;8PM+1T5'31K%3TU-3Q42QPPQ1
MJ%55   ]^Z]T_P#^@WI3_GS_ %;_ .@_B?\ ZD]^Z]U[_0;TI_SY_JW_ -!_
M$_\ U)[]U[KW^@WI3_GS_5O_ *#^)_\ J3W[KW7O]!O2G_/G^K?_ $'\3_\
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M.:@D*5,RMZ/=>ZUD?Y '_<,S_/'_ /#7[V_]\!B??NO=7_?\)4O^W'OQ1_\
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M  U^]O\ WP&)]^Z]U?\ ?\)4O^W'OQ1_\.CL?_WX^ZO?NO=7_;W_ ./+W?\
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MVW9N"AK\/CZ67(9'"U..QL&4EVE6_:5V6FJHY:C&5#S!U5I6C6,+[KW1'O\
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M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6JC_ ,*3_P#LH/\
MD+_^-3MH_P#N[VM[]U[K:N]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6FY_P +8/\
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M]U[W[KW0-_(@]XKT-W&WQF793_(=>M,T>DT[&\O\!.Z!03_P49;PD2?8FO\
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MY+^(_P .K_X1]E_%OLI?X7_$M?V_W&AO!Y_%^[X?+IUZ/5IOIYM[]U[JL/\
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M9K*YNNTU.#R](TDAK9XWJ!.J&,HT,?NO=77>_=>Z][]U[J@CY-_S4?D'TO\
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MTL\BZE7'[JWGMW YI2NI3>?"U]7"A!],DBN0P4J?=>Z'3^2EU9L3;?\ )O\
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M'[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM"K_A2MV14_ O\
MF/U?R6H*NLQM#\[/Y1G:?PP7(8@5$531[AA6LCAR!GICK;RC+86FB*@&FD05
M$CI&HDC]U[HLW\TS:&Y?Y-V%_E?=L86DR&.SG:O\E#L;^7?VGGL/2N4I]T#8
MD]5BZVF,<J0TE:F^=ZP51DD#M)244SE9Y(Y'3W7NMC'KOH$?&3_A*UOSJ*;"
MG;V8H?Y/'9&]MVX:0)Y*?.[MZUW+NW.QS&,E6G3+YNH5R"PU @,0 ??NO=5X
M?RX59O\ A&WWF%!8_P"RG_)!K#G@9S?I)_U@!<_X>_=>ZLQ_X2X;HVTW\D'X
M-[<7<6";<*/V=&V!6KIS6AE[;W[4LII?)YP5II4E(TW$3I)^E@3[KW5>O_"<
M_P#[? _\*4?_ !=>O_\ ?H=Q^_=>Z]_PG/\ ^WP/_"E'_P 77K__ 'Z'<?OW
M7NO?\(GO^W<WR<_\77R7_O"[&]^Z]U[_ (1/?]NYODY_XNODO_>%V-[]U[KW
M_")[_MW-\G/_ !=?)?\ O"[&]^Z]UM_;V5FV9NY5!9FVQ7JJKR232RV 'Y)]
M^Z]UJ&?\(MMT;:QW\L7O/"9#<6"H,U6_/_<GV>(K*NGBJI?N.O>KXZ?Q4[R+
M+)YY()%CTJ=;1NJW*,![KW43XK?]QG7\RK_Q2C _^\1T#[]U[KWQ6_[C.OYE
M7_BE&!_]XCH'W[KW5;OSC_EG?&+Y9?\ "H[Y#] ?/'M3L+ISK3Y1] X'NKXZ
M;FZPS&$P>1RV>H]O;5P$&*GJ]R;=W!CFAF;;.YHTACA66>:CI3'4JYDI)/=>
MZO)_ER?\)U_Y6GPB^;6T_D;\9/E'\A^T^_\ XRTE?75_7.[MZ=>YNAQ\6\]M
M[AVM&^X,5@-C8G+TRU&/R%;+17JZ;5/ DA\L*O%)[KW6S][]U[K2;_DT]K=8
M_#[^?O\ SWOCG\BNP=H]8=G_ "0^0T_;736-W55K0TV;QU5N3>6]H::EK:U:
M>F;*/MK?..K$I-8EFB6KDIA/%2RR#W7NI'\YGLWK3Y>_S]_Y#?QS^/?8>S.R
MNSOCKW]#W'W#C=K5JY"GPF,I=R[0WM)2UE7CUJX(<L=M[$R-9]FS":*"2BGJ
M1!35D,[>Z]UL\_*O^8_\,_A-V-T'U7\F^[-M]4[O^26Y*C;G6L.XB\5)_DT1
M,V0RV095HL/B4J6@I#5U4L<?W55 A.@RR1>Z]UJ1_P#"F_;?QLZC^4W\NWY?
M?"";8'_#F&\/D[AO'B.G<Q1TV3WG0TWVT>)K,]'C)T22>IRRT6'3(5#Q25='
M5RT<LE33TX6F]U[I+_S9\/\ -#^8M_PH_P!@_'3^7GW)UYU9W?\ R^_C+1[S
MV]O/M=)5P.WLY5B'.YO(J4VONS[NOJ\?N_!4BZL?44Z30(MX)X9']^Z]T!G7
M^R/YD7\KW_A1%_+Z[I_FA?(7J+N;?'S>I:GH;/\ :/343-C\MCLE2KLK#X?,
MI_<G9?@J<7N*LV]4FHCHBB014S3UA@CGB3W7NM]'M7Y=?%SHOL/KSJ3N7Y!]
M0=7=H]N55/0=6=>[ZS^-QF9W'/5UR8RE@PF.JZB*JR<U1D94IHXZ=)'>=TB4
M%V4'W7NC$^_=>ZTL_P"<5O7:'Q'_ .%,W\G[YI=_[EQ/7GQSR/Q^R/3M1V'F
M6E6DH,I15?8]#6S9&01&*DQU'+V7A'J*IG\=-#+-45)A@A,I]U[HRW_"K[Y>
M?&RA_E&=A]-4W<_7>>[.^0>^]FT'5>R]L9:BR>0R4.#W1A]RY7(K34,U1)'B
M:''8TB6M<+3+45%'3&7SU=/')[KW5LO6/=76/\K#^49\6=X?,O==-UYM_P",
MOPYZOZT[(JZ*"KK97SV*VC@\$V+QE(E.E965E;E8#3TT;11,S,#*(5#E/=>Z
MJY_X4"57\KGYO_RA^ROE%N#L7HC?NX]H=7R[P^(7<& R^-.X%W#7&!J';^,F
MA=\E+%F:I$I\EB)$*J8VEJ88)Z(3T_NO=60?R$]]=O\ 9/\ )]^!6\.](LLO
M8=?TO_#WJ\[5/6UE=@\=F,IC=I92HJI)9I9I,OM.CQM:6=R_^46<*P*CW7NB
MH_\ "JQ6/\CWY8$ D+N?KAF(_ _TD;5%S_07('^N??NO='W_ )5&6VQN[^55
M_+TVCC=SX2KR<W\NWJ?&Y"CQU53U%33#_1Y@*&=Y:>.4R(:>HU1N&"Z95,;$
M,"![KW6A9_))_D.? #YW83Y?=9?-SOWO3J/Y<?$CY'9?JO>'7'4NZ=GX:@3
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M&X,E4;XES&1Q+YN2CPE9GJC;U>9-O-D*YDQV/A%-%"\RZ(XC[]U[I9?S]/\
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M .>S>'_VKO?NO=>_T)_\*Y?^\O\ ^47_ .>S>'_VKO?NO=>_T)_\*Y?^\O\
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M';.[6Q]%25A;>6/IZO&X_(TU=B*W%U3U63I<XT537U*T-!0)!&\_NO=6-_\
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M)258IF%_=>Z![Y#=L?S'?YUG\SSYC?!3X-_-W</P$^*7\OBFI-F]G=M]329
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MS&3U"J[Q19+/Y&CIF9%9[2G0"UA[]U[K4[^-_P 0?^%(WRCZ$Z?_ )IO7/\
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MI:;Y =+C?D\4D%20L)W!@HI:226LVSDYQ>*0,\E'*WV=5:0123^Z]U=E_P!
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M#1U]7F-NT&(CP?ASAI*+'T-7-6T"::DQ4M/$[.^B&-2%'NO=43;0_P"$D/\
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M5>5SW9W9<*YC)/A*FAR-36XBEQ<T%"!4I"D>1KO)'*SQF/W7NK"/^$N=9/\
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M1&#'T:I"K([/[KW1]/\ A1I\C/CJ?YA'\MG^6/\ +3M[>'27\MS8_7%-W_\
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M2(8<OF*Z9+&RBH\85507]U[J]3^;%_VZR_F6?^* =R?^^ZW'[]U[JC'^1/\
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M<V\U3N.FVSB*J+;6,RVXZA/N=JFC7[.G9*=L[]Z7BFHXZNA]U[HCGQ3^4/\
M*M^%_P#/#^"T_P#)>^0&[,I\7OF-5+\9/E9TEEJ'LO\ A=)F,Q608O9=3"^_
M\1196LFK,_E*6:GG$U;_  UZ>M62:DH:^6*3W7NC:_SL?B[U[\TO^%1'\M3X
MQ]LY#=N/ZR[5^$]#C]^)LBO?%Y"NQ6/S/>F8K<.*^(&>GHLY#CVQU<8BDS4-
M54)#)%(RRI[KW7NO/BET]_*(_P"%47PH^-OPGQNX.ONB?E1\/LCE>S.O<IF<
MMEXI34T?9X,:UF7K:^MECCRNP,9D(Q+(_CE$T47CC?CW7NC5_P B[.XSX/?S
M/_Y\GP&W3G\3C]G;'[.3YC];[?BC%//3;<R#560R4\%->\L-'M[<>V()2MD5
MTC9 %G 7W7N@Q_X3_;_R'37\M'^<%_.AWILRBHM[_(/MGM/Y,46+II&K9JK&
M[+QF:W#2XT5#I"9(CNW-9BD5F$6LKYIBBD:/=>ZH"^,-5_(#^2GPG[;[8_FE
M?,'LJ;^:]\A]P;RWUG>R*S%=NUTVU,K)6U=+MJ..#:VU*O8V3I*R&CIZ^:*1
M:Y8(*XT$+T(IHZ>E]U[K9)_EV_,W?'S1_P"$J'S9SO:&[\AOSLSH;X<]_?&S
M>6ZLS]R]?5# =:Y+)8,U]74W;(UL>UL[BXY:L/(9V4O/(]7]P??NO= ;\#_E
MWNWX-_\ "/*O^177F0K</V5M_$[]V7UOF\<D,D^.SN[NX,QM3'9:):F.6F+X
M:;,_Q "9&1OMM&AV98V]U[HN4O\ PGM^*7_#!,?\PF/(]J'Y_+\.5_F(M\A1
MNG,"H:N.%_TEMCSC6KCC;+AF^V^\$8R9K%%=]UYB83[KW1M?FA\N]V_.3_A&
MYNCY%=AY"MS'96X-@]>;+[(S>12&.?(YW:/?6T-J9'+2K31Q4P?,S8;^($0H
MJ+]SHT(RM&ONO=$UW9_($^$]7_PGCP'SVVW2=GK\T\-\),#\O#W;E]TYBHD+
MT&#H]QS;>CPQK8<#3X:@PD9Q>.,-(E;30TU(_P!S-+&_F]U[HR7S^_FT=QQ_
M\)7/B-WIM7L+<D/>?S H\'\3=W]I8L&GRGFP?]Z,9OO)&H>"G^WJLPNPZVAE
MGIT60/D7GH7 5*J/W7NJ2_EUGOY!7Q5^-_0W>W\GKY?=BTG\S3XQ[PVEN?'[
MM3%=P4HWS/!)34>XJFO3=VU\;M7&(5DFK'IJ4XVEJJ,56-EI:E*E8/?NO=?3
M>^.?<&(^0OQ[Z([^V^T;8'O'IK:_<&$:&.>%#2;FPE#FJ8K#5*M3$IAK5LDJ
MB51Z9 &!'OW7NM6?_A:M_P!NLN@__%_]K?\ ONNU??NO=$&_G/?R/?BI_+=_
MER;#_F$_#3)=N;"^7/QR[$V#OK='>F?W3ELSEMT5N8R=!C:C+Y*FR-5)BJ3+
M'/Y&GR&O'4E-"Q\\$M.\$O[?NO=//_"CK+8;YU;H_P"$QV=_O%N#:VWOF-GZ
MC+?WLV3(U#E<;1=A5'0$W\1Q$M53ZJ/(4<&7\U*TT%XIDC,D-U*>_=>ZV"NO
M/Y=WP1_D/_'+YO?+[XE=:;PP.7VW\8LSO?>./W#N#*9XY4;(Q&7SN.IH1E9I
MQ23UM82DAC:*!BZ%U1(P5]U[K7J_E7?R&OCC_-E_EC[R^>_S$SW9W:7S@^:&
MY.Q-X[6[NGW#74;X#(8O.YC:^-=<12U$&$R$;9G!2U,L593-"E+,E%2)2000
ML/=>Z0W5'8O8/\U+_A(U\G,#V;N#+;N[>^!&[ZH8W>FZ46KK*S$]=# [SI9W
MG15>22GV'FZS"BHD8U)^U\]4TOD>2;W7NA]_FN_,O<GRI_X34_RV=F;-FQ>^
M^V?YA.\>IOCIF):*J\43[@VP97S\GH1T\XWUM&FHIJ=BHA>ID;633A']U[H3
M_P#A6[U)MSH'^2%\(>B]H4E+0[5Z;^5_6_5VW:6C4I$E%@>INR\73A%/JL8J
M4&YNQ)NQ))/OW7NA2_X4K]C[E[(Q_P#)]_EAXC=^[-D;,_F'?)[;>S.Y\SM&
M>.FGEV]2979FW8J!Y)8)TE1Z_>:UZ1NDD'GQL#5$4BA%/NO=5=_S<OY47PU_
MEB_S)_Y#TGP[V;NSK["=X?,G'P[WVKF]Q9G<%$:O:V^>HUI<E2'.5E?54E97
MIGY5K DP@D$%-XX8A&0WNO=6D?\ "M;Y:0]?=>?!7X3[B[6W+TETI\S.]Y9/
ME=V9M:GJ)ZB@ZUVQ7;;I<W$\5'0Y+(U4);<JY%Z6BI:F>J&)^U>">*H-+5>Z
M]U05WI\F?Y'O\OGY2? _YA_R/_D;O;#;NV#W/1;)^6?6%9C^WI,=GNM\B%.X
M,C7/OS!TOW1>G@>GFH**I?5/-1UM%CXZBA6=/=>ZO1_G;8[&_P PK^>/_*R_
MD]]FYW>E%\8\WL3-?);NK:NUZ]\;'N*JIL;O7*4=!4SPI]P/#C^OYJ431LLL
M$.8J31RT]5:>/W7NB1U'\OKXV?RWO^%7O\LCI/XI[?W+M#JG>7Q^RG;T>SMP
MYK)9U,7D,AA>ZL/54N-K,Q45F13'R)@HJ@135$S+43U#A],@5?=>ZW__ '[K
MW6K[_P *(M\?R.,%6]"2?S88>S^RM_;%P6<W#U'T)TEDL[!FLM091J:*IJ:Z
MFQ.6P5#% :K%"*BJ<ADJ!1*:F..8QM.%]U[K7E_E!]X?!#'_ /"C?XHT?\I#
M ]I]3?$WY%_&[=&U>X.INU9\Q-D*#.46S=\;JJ\4\F3SF>>I6CK-LX2=91DL
ME3K*:E::H8-=/=>Z&_\ FF[5^*[?\*.=]Q?SQL=V+4_!#LWX\X;;GPXW115>
MY<=MK$5D=+M6,RU&0VY+19"+&TF;&XQE1"\WVU=D:2KK0E 8Y(_=>ZW$?Y7W
MPB^&_P '/CA/M/X*YV3=G0'<.]JKO7;&Z4W*V[**LCS5'004YQ&:%14P5&&C
MI*&(4IA<JP+S2O-4RSU$ONO=6.>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KY[O\BG_ +BK_P";G_X<WR3_
M /?XX3W[KW6\Y\J?E5T1\+.B]]?(WY(;^Q?775/7^.^\S&:R!+S5$[W6DQF,
MHX[U&2RV0FM#2TD"O+-(0% 4,R^Z]U\\AJ?YZ?\ "N3YR15;0;K^//\ +.Z"
MW7)3PU+*TN,V]2$1M+&KV%!N7M7/4$T9909*?#TLZ$A*/3_$O=>Z^A1\;?B%
M\>/B9\<]H_%'I'K3;^VNCMG[;EVS#LZLACK8\E'5A_XG59IJE'_BU=F)99):
M^:H#FIDE?6-!"#W7NM>/Y2_\) OY8?R![0R79O7.X.\/BU%GJA:G-=:],UF$
MDVJLA>5YIL7C<WA<E58=YS(H\,%7_#X5C5:>AANVKW7NK8OY:O\ )O\ @W_*
MMVUDZ+XT=?9"O[%W+0KCMZ][=F3P9;>.6IU,;&C;(1TM'2XS&M+$DC4.-IJ.
MEDD1)9HI9D60>Z]U29_/[_X3NUGR@S62_F!_R\(WZU^;6R)X]^[MV-LZ9L0V
M^:[%21UE+FL'74LE.V&[!HW@$D%2CQKDIHXO)+!6A:J3W7NA#_X3[?\ "@FG
M^<5/2_!_YP54/7/\P#KF&HV[CLCN*G7$1]D1XA9(ZXBADCIUQ>_<6M/(<OB!
M'$*D139''0I&E=0XSW7NKP/YL7_;K+^99_XH!W)_[[K<?OW7NM?C_A%/_P!N
MOOD'_P"+[;D_]]YUA[]U[K<&]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:&'
MQI^9WQC_ )1W\^S^<IF_YGFYLOL'-]^[SHNP?C?W7F-G9_-H-K9#)Y?+4.*Q
MK8#$9?)K2OA<EC,:*JG@-))-@JB"IGCGA\?OW7NIG\CWY(=5_+O_ (4_?S*?
MD=TAM_<&W.I>TOA;D\QL&FW-B_X+5UN.IL]T=CX<W_##:2FI=Q?9G*TAE5)Y
M:6LAFGCCFDDC7W7NC/?\)S_^WP/_  I1_P#%UZ__ -^AW'[]U[J)_P )WZ&F
MR?\ -S_X4O8VL0R4F0^9F4H:J-25+1R]F]RQN RD%258\CD?CW[KW1(OY'/\
MS#XU_P B_;?ST_EI?.RO[/VSW7UG\P<MN[K7$;8VAE\O/O>3(8/ [>I*/#T^
M)BR+4==EX=N4-;1K7R4]'-39.E:"LE/FT^Z]T>C_ (1/?]NYODY_XNODO_>%
MV-[]U[K<E]^Z]UIM?\(GO^W<WR<_\77R7_O"[&]^Z]TD_P#A1#TYU]\;_P":
M1_+C_FO_ "&^/=-\COA-M[;-1\:?EOM7<>WL7NW;V*ADDW%%@,IE\#E:2LI:
MEY/[ZU-51F:)X36X*EBA:GR$U(T_NO='5^!'RU_X3H?,+Y?[,Z;^"WPC^/&;
M[?VI@Y.Y]L]R[0^.&'VY1;<R6WJRDJZ"5,]-M''Y/ 9B"9/NJ&O>.EITJ:>*
M*GKOOY::%_=>ZKH_FV_(3K7X&_\ "I?^7C\S?DW5;BV+\<-N_#;*8S)=C46'
MRF5@-14X?N/;;4]-#C*6JJ*VIH\EN/&_=P4Z2S4T%93U$L:Q31,_NO=&C_X5
M'1T/SH_D2=7?*+H3^\&X>K\#W'L'Y9XRJ;%5*U59L_+X#<>W:3)5%(Y2JQE/
MXMYTE=(T\>N"%2E3%"QD:'W7NJ6?^%%7\Z[X1?S(OY;7QCZ/^+V<[#W3O[:?
M?FTNUNT4R^VLQB\;M@T>P]Y8?^!UV5R-+2T=9EJNLS4AIA0M4P30XZNF$P5$
MU^Z]U:3_ ,*._P#LN7_A,?\ ^+7U'_O7] >_=>ZW3??NO=:;7_")[_MW-\G/
M_%U\E_[PNQO?NO=>_P"$3W_;N;Y.?^+KY+_WA=C>_=>ZV)OYL7_;K+^99_XH
M!W)_[[K<?OW7NJN_^$O5#4Y/^0Q\<\;1H)*O(5?:5#2QL0H:27L#=T: LQ 4
M%F')X'Y]^Z]U3K_PD/\ GU\<>@.I=X_RSNULSO/:GS/[:^;N[]U;0ZAK]N9I
M)!1TNP=J4^1_B.0DHTQV)JL7)LO+"JI*R:&J0TX187DD1#[KW6^;[]U[K3:^
M*W_<9U_,J_\ %*,#_P"\1T#[]U[KWQ6_[C.OYE7_ (I1@?\ WB.@??NO=>^*
MW_<9U_,J_P#%*,#_ .\1T#[]U[K<E]^Z]UH2Y3YN?'[^5G_PJN_F4=\_-C.;
MJZJZL[8^)V)VGU[N:FV]F\PN5JLEC>F\A1R4<.)H:N>>BD&U<I3-5(C4\5;2
M2TDLD<T<BI[KW1IO^%+N0CRW\P7_ (3696&&HIXLG\R,ED(J>K"K*BS;VZ#D
M5) C.HD4-9@&8 @V8CGW[KW4_P#X4Y?]O&?^$WW_ (NOF/\ WNNA??NO=)/_
M (40].=??&_^:1_+C_FO_(;X]TWR.^$VWMLU'QI^6^U=Q[>Q>[=O8J&23<46
M RF7P.5I*REJ7D_OK4U5&9HGA-;@J6*%J?(34C3^Z]T=7X$?+7_A.A\POE_L
MSIOX+?"/X\9OM_:F#D[GVSW+M#XX8?;E%MS);>K*2KH)4STVT<?D\!F()D^Z
MH:]XZ6G2IIXHJ>N^_EIH7]U[K9\]^Z]UI7?\*(>G.OOC?_-(_EQ_S7_D-\>Z
M;Y'?";;VV:CXT_+?:NX]O8O=NWL5#))N*+ 93+X'*TE92U+R?WUJ:JC,T3PF
MMP5+%"U/D)J1I_=>Z.K\"/EK_P )T/F%\O\ 9G3?P6^$?QXS?;^U,')W/MGN
M7:'QPP^W*+;F2V]64E702IGIMHX_)X#,03)]U0U[QTM.E33Q14]=]_+30O[K
MW15OGO\ ]QA_\I+_ ,4HG_Z%^0WOW7NO?/?_ +C#_P"4E_XI1/\ ]"_(;W[K
MW1)O^%-._-U_R[?YD]-\MMD1U]-B_P"8#_+%[,^&VXZO #[:OI\Q'CY\0,O#
M6"2*\E"<QMB0LK+44\5(\D3,X@C]^Z]ULF_#3^7I2XC^0QUW_+VRM-3[0S7:
MWP0RFPM[RXY@#0;G['V]D,AG*L2LDBR3T>?W#/)K9'1FC'H:.R>_=>ZU1/Y6
M_P QOY)7P8^)^;^(7\X/X+],;:^=7Q>[&W3M'>L/;'1.#WONC<\%5EZ[.8\O
MN!MMY(234461&.ICD:^.G>BIZ*:CJGQ[PM'[KW6TIVNWQ.SO\@?YQ]J?##X\
M[3^,G2O>O\N_N#MZEZVVML2AZZ?[^OZPS5%45N4V_C\=C('R3P8Z"G-<(Y4K
M*6FI9:6JJ*+[65O=>ZI1^#'Q*W=\W?\ A'7DOCWUWB\AG>R<WB=^;WZZP.*:
M-:G(YK:/<.7W70XJ#S,D+2YB3#&A42$+>I!#(X5U]U[HN3_\*%_BDW\@>D_E
M\4N.[4J/GS4_#L?R\'Z!CVQE3.E7_ VZW_B9R1H5QCQOAU$ZT:2-E!5NM$:8
MRAIQ[KW1P?FO\0MU?!C_ (1P;I^.78.-K\+V3MWK_KK>?9>"RDD4M1C=P;M[
MXV=NO*8B9J<M3:\+4YEL>?$S)_DM_),Q::3W7NB?5_\ /W^#-9_PGGPOP'VM
MD>T,C\U\W\),/\-*'H63:N:%3/D:[#4VTGS--F8Z&HV_48JJQ\AR=$D=8U=4
MPS4T"TL=3(RQ>Z]T9KY__P HCN9O^$L_Q1^.^U.MMU5?R"^'E)@?E3NCJ3 G
M[[+-D,R^Y<AO_%>'R5)JZC#KOS(UTE-2.SM)C3!0^5?'3S>Z]U,Z-_FI?\)=
MNU]L?'K C^7;\;<G\@^WZ[;>S]S=+;.^,&W,K7X/-962GI<B7J:79JT.6HL?
M4/)(/X2];55$(7P4;2L8D]U[K=,VCM3:NQ-J;8V/L3;. V7LC9NWJ+:FS=G;
M5HJ?&8O$XK'4T5'CL9C<=2104N/H*"DAC@IZ:&..*"%$BC1$4*/=>ZU(_P#A
M:M_VZRZ#_P#%_P#:W_ONNU??NO=$;_F__P [;XF?S0OY;>Q/Y>_PAH>V^TOF
M+\GM^]>[(J^A*[:V6Q64VW58G)X_,U='DZZOI(\'5U<65Q<5 W\/KZF%-4M7
M+41TD#N_NO="?_/;Z?Q_QZ^1?_"3[H'$JBXKH[NK&=/XQ8Y)9E%/MG._';"P
MA9IV>:4".B%GD9G;]3DL2??NO=;@/S'Z)3Y0_$GY.?&]ZM\>_?'06[NHZ;)1
ML$:EJ-P8&OQ=-5*QNMZ:HJ4E 8%#HLZLA*GW7NM)[^55_/M^.'\J#^6!N_X(
M_+O ]I=:_-WX:[G["V=M7HZIV]75,N<K\KG\MN6@C&5@I9,-C5@S.=G@J&KZ
MA%-/ M52M513PQ^_=>ZN"_X3-_R^MQ] _P G"KV+W[M+-[:S_P U=R;H[:WE
ML?=4:+54>W=RX7'[6P]--1E;4ZY+;F(AR7AG!G09$QU(C=?MX?=>ZU=?Y06V
MNQ^]/YC7\NW^55V1CI\KMS^4-\N^_.W]\23EH<94G$9/%5>*JVH3(9'K\?V#
MA71$F5A!%D1HD;RU2#W7NK_?^%JW_;K+H/\ \7_VM_[[KM7W[KW28_X4X[,W
M-U+#_)M_F;8[ 9[<NP_@+\F<#N'MW%[=IDJ*E,?7Y?8NX,95^2>IAI:=?OMF
MOCT\P$<U7DZ2.2:( !_=>ZKB_FY_S5?A[_,X_F._R%JGX?;KWEO[;?3/S,H_
M[Y[OSVVLWM_'C(;EWQU!)%AZ-LY14$U;D,9#A3)7^&-X(EJZ,I-*)KCW7NK8
MO^%6GQIS.8V;\!?Y@E%TY4=_;%^ ?R-3='R(ZF>AHLKCLEU]EJ_;N6R\N<Q=
M?!4TU;A5J=I08ZL62.6F6FR\TE="]$DTM/[KW4#X\?.C_A+M\K^^.BOCA\??
M@%\:.R.S>\LH<1!0XGXNX".GV[-]C)57S\\^S8C'3K.BT\M71I645,6:IJZF
M"BC>I'NO=!/_ #P]S8_^79_/A_E6_P V_M*@W/+\9J7KO*?&[L_/;:QKU[8:
MO:AWY025<@$Q:=IL)OYJM*2&+[AX,-7/2K4U!6)?=>Z*;7_/OXY_S&O^%7?\
MK_O#XLYO=.[.I-L_'?*=5T&]MR8/*X"+,UN/Q'=N3K*S$TF:I:'(S8V%\R*,
MSRT\5ZREJX@I$6IO=>ZW^/?NO=:./R^[\Z=_EM_\*F-P?+C^875Y;&_&CN/X
M<T&)^.79M?M?*9[';6R%'C=O8JK2DCQ>/R5=45--E<-F&J&H:>>JI!N&G,L<
M=/.)3[KW0$]9_./XX_S!/^%='P/[Y^*T6X<CU#3="[NV%C>P<[@:O;T6[*W'
M=:=R3UV=QM'DJ>CRDU DU=_#//6TU/4-4XZIC\7BBB=O=>ZN2_F3_P X'^2)
MN#LGY&?RX_YH&QMWK0]8U-'0+5]@[#SF5QF7DRF$IZALQLC+[=@KL]AZ_&/7
M34:Y-$QLJU%/+)05<L>F0^Z]T6K_ (2#0]AQ='_/,[6J-^S_  '_ -FIEA^"
MY[)^]_B9QZ39S^\$B+,B8\4\E$V!^X^Q B_C(R_E59@_OW7NMP?W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=?-'_EP_+WX^?!G_ (4=?SHOD;\FNPL;USU=L[<7R1BJ,E5AYJNOKIN\,.:/
M$8BAA#5.3R]>T;+3TT*L[!7D?1#%+*GNO=2<5!\VO^%=?SRDGR]3NGXZ_P L
MOXX;@\STU+^[!A:*8@)34[%'QV=[4W-1\M-():+!T3.X22!(J;+^Z]U]#GXT
M?&CI'X?]([ ^.WQVV!ANM>I.M<,N'VQMC#JQ^K&2IK:VID+U.0RF0J7>HK:V
MH>2IJZF22>>1Y'9C[KW0[>_=>Z][]U[KWOW7NO>_=>ZU#O\ A0W_ "!)OE%%
MD?YAGP$QF2V'\[>L9J7>^Z-L=>2-C:G?O\(DBGI\MBYZ66FEQ_86%$"ST59"
MZS9$0)3.36+23+[KW1+?B?\ \*$<?\[?Y47\QOX4_-;(T>P_GML/^7IW5A<+
MFLU$F+I^S*?%];[F6KEBI&2"/';ZQT<#ME<4J1K5+'+D<=$D25U#C/=>Z-[_
M ,(I_P#MU]\@_P#Q?;<G_OO.L/?NO=;@WOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[H$^W/C3\<OD!4;6K.^.@.D^[*O8^43-[*JNW-JX+<DF'K8VU1UF+?,T
M%:V/JD;E98#'(IY# ^_=>Z$;%;*V;@LE)F<'M+;.&S$U F*FRN*H*6GJ7I8U
MA6.F:>&))6@1:>(+&6T 1Q@ !%M[KW2 ZY^.?Q\Z>WAV5V'U)T3TUU;O_N?-
MMN7N'?/7.U\)A,QNS)/55E<V0W+D\90TM;G:UJW(U=09ZV2>4SU51*6\D\C-
M[KW7NN?CG\?.GMX=E=A]2=$]-=6[_P"Y\VVY>X=\]<[7PF$S&[,D]565S9#<
MN3QE#2UN=K6K<C5U!GK9)Y3/55$I;R3R,WNO=<=T?'#X\;X[.V?W;O7H;IC=
M_<_7H<;![<W1M?!Y#<^#$B&*08?/U=#-E<9KC8HWVT\=U)4W!M[]U[H2=O[5
MVOM.FFHMJ[;P&V:.IG^ZJ*3;]'3T44DND)Y'CIHXU>32H&H@FP O8#W[KW3]
M[]U[H&ND_CG\?/C3MS)[.^.71/370&T<WFVW+F=K=)[7PFU<;5Y)X(*5\A54
M."H:"EJ*UZ6EAA,\B-*8H8HRVB- /=>Z$W<&W=O[MPN1VWNK!8;<VW<Q3&CR
M^ W!2P5M%50D@F*II:E)()XR0"5=64V''OW7N@XZ<^/?0?QUV]+M+X^]']0=
M%;4GG-3/MGIS;6%VQCWD9Y)&D>BPE%0TS.9)78L4N6=VO=B3[KW6;M;H/HKO
MBEP-#WCTMU+W+1;5S$6X=L4?:VW,/N*+&Y"%TEAKJ"/+T=8E'6121(Z31!)%
M9%96!4$>Z]T(<F!P<N$;;,N&Q,FVVQG\$;;\E/":$T?B\'VAI"A@-+X?V_%H
MT:/3IT\>_=>Z!K8'Q4^+W5&!R6U>K?C=T'UKMC-9L[FS&W-@;.V]AJ"KR1$P
M.0J:/'8ZFIYZXBHE'G=&EM))Z_6U_=>Z=.R_CA\>.Z-P=:;L[BZ&Z8[8W5TO
MF6W%T[N;LO:^#SN0VGD'GQ]2]=MJMRE#55."K&J<30RF:A>"0R4=*Y;53PE/
M=>Z&?W[KW0-=)_'/X^?&G;F3V=\<NB>FN@-HYO-MN7,[6Z3VOA-JXVKR3P04
MKY"JH<%0T%+45KTM+#"9Y$:4Q0Q1EM$: >Z]U[I/XY_'SXT[<R>SOCET3TUT
M!M'-YMMRYG:W2>U\)M7&U>2>""E?(55#@J&@I:BM>EI883/(C2F*&*,MHC0#
MW7NA%W9M/:N_=J[EV+OK;6W]Z;)WIM^MVGO'9V[**FR.*RV*R--)1Y#&9/'U
MD<U)7X^OI)I(*BGGC>&>%WBE1D9E/NO=)KJGJ#J7HC8^)ZQZ/ZNZZZ:ZVP,M
M3/@^O>J<)C-NX.B>LJ9:RL>DQ.(IJ.@IGJJR>6>8QQ*99I'E?4[LQ]U[IAV_
M\=OC]M+LS<7=6U>B^G-L]R;OB$&[.VMO[8PE%N;*(HE"ID<]34,>5K443R6$
MT[@>1[?K:_NO=#'[]U[H&L5\<_CY@NY]R_(_!]$]-8;Y#[TPD>VMX]\XK:^$
MI]Z9;&Q08^FBQ^3W3#0IG*^BCIL30Q+!/4O$L5'21A0M/"$]U[KV*^.?Q\P7
M<^Y?D?@^B>FL-\A]Z82/;6\>^<5M?"4^],MC8H,?318_)[IAH4SE?11TV)H8
ME@GJ7B6*CI(PH6GA">Z]U[%?'/X^8+N?<OR/P?1/36&^0^],)'MK>/?.*VOA
M*?>F6QL4&/IHL?D]TPT*9ROHHZ;$T,2P3U+Q+%1TD84+3PA/=>Z&7W[KW0.;
M_P#CM\?NU]V;1W]VET7TYV5OKK^5I]A[TW_MC"9G+81W616?$9'(T-368UV6
M5P33R1DAV!X8W]U[KCV=\<_CYW;N/K?>/<W1/37;F[NF\V^Y>H=T]G;7PF?R
M6U<E)/054F0VW796AJZK!ULE5BJ*9IZ)X)6EHZ60L7IXBGNO=>[.^.?Q\[MW
M'UOO'N;HGIKMS=W3>;?<O4.Z>SMKX3/Y+:N2DGH*J3(;;KLK0U=5@ZV2JQ5%
M,T]$\$K2T=+(6+T\13W7NA-W!MW;^[<+D=M[JP6&W-MW,4QH\O@-P4L%;154
M)()BJ:6I22">,D E75E-AQ[]U[H..G/CWT'\==O2[2^/O1_4'16U)YS4S[9Z
M<VUA=L8]Y&>21I'HL)14-,SF25V+%+EG=KW8D^Z]T+_OW7NF?<&W=O[MPN1V
MWNK!8;<VW<Q3&CR^ W!2P5M%50D@F*II:E)()XR0"5=64V''OW7N@XZ<^/?0
M?QUV]+M+X^]']0=%;4GG-3/MGIS;6%VQCWD9Y)&D>BPE%0TS.9)78L4N6=VO
M=B3[KW6'/_'/X^;K[BVC\B-T=$]-;D^0&P,(=M;#[SS^U\)6;QPF-/\ $;X_
M$;FJ*&3-8VB/\7K[P4]3'%_EM7Z?\IFU^Z]U[/\ QS^/FZ^XMH_(C='1/36Y
M/D!L#"';6P^\\_M?"5F\<)C3_$;X_$;FJ*&3-8VB/\7K[P4]3'%_EM7Z?\IF
MU^Z]U"[P^,'QI^3>.P.'^27QXZ,^0F)VK6S9+:^+[PVE@-V4^-J*B-8JBHH(
M,]CZ^*CGGB14D>)49U558D #W[KW0W111011P01QPPPQB*&&(!515 "JJ@ *
MJ@6 ' ' ]^Z]T!N_?BW\9>U-^;9[4[/^.G1/8_9^RQ(-G=C[]VCM_,9[$B5%
MBE&,S&0Q]1D*#R1(J-X)DU*JJ;@ >_=>Z%7=6T=J;[VIN38>]]L;>WEL;>6W
MJS:.[]F;JHJ;(XG*XG(TTE'D,9DL=5Q34==CJZCFD@J*::-X9H7>*1&1F4^Z
M]TF^J>H.I>B-CXGK'H_J[KKIKK; RU,^#Z]ZIPF,V[@Z)ZRIEK*QZ3$XBFHZ
M"F>JK)Y9YC'$IEFD>5]3NS'W7NDA'\7?C/%V[)\@8OCMT5'WU+2&@E[NCVCM
M\;O: RB<PMN48_\ C)A,X$F@U.GR#7;5S[]U[JM'_A0MT+W%\GOY0?RPZ'Z!
MZ^W#VGV]V+D>M\7LS8FUHUDK*Z6G[8V+75)7R/%##!24-+/4U$\KQPT]-#+/
M/)'%&[K[KW0U_P OCX$=;=&_%GX/P=V_'?HM_EST!\6=E]1;D[1? ;>RFX\9
M78; 8Z@R%#0;M6CER#4L532Z0:>I\+A%9+J%/OW7NK-_?NO= 1L[XL_&/KOL
M;<7<'7_QSZ(V+VWN]D?=O:6SMH;?QFX\H8XF@C.1S=%CX,G6E(6,:F:9]*$J
M+*2/?NO=#O[]U[K6H_X5(_"SY+_/CX.?&_X__%/J_+]I]EY#YV[9W!6XZ@DI
MZ:DQ>)@V'V5256:S&0K)8*/&8FDJ*ZGCEJ)I%7R30PH'FFBC?W7NKU>N_C#T
M!L#=8[:P70O2NVN\<UMVCP^\NW-N[8P=+N;)>"$(T==N"GH8LK71!RY EG<>
MHFWJ/OW7NGWL[XY_'SNW<?6^\>YNB>FNW-W=-YM]R]0[I[.VOA,_DMJY*2>@
MJI,AMNNRM#5U6#K9*K%44S3T3P2M+1TLA8O3Q%/=>Z&7W[KW0%[T^+OQG[([
M%VUW!V)\=NBM^]M[,##9_:6]-H[?RFX\3KC$+_PW-UV/GR=#KA41MX)DN@"G
MTBWOW7NAT]^Z]T!.T_BW\9=A=N;L^0&Q?CIT3LOOG?M-4T6^N[=I[1V_CMW9
MJ&MFIJFLBRVY*/'PYG(Q5=114\LRU%1(LLD$+N&:)"ONO=.W=?QZZ"^2FU<?
ML7Y%]']/]_;)Q.X(MV8O9W=>V<+NK%4V5@IJNC@R=/C\[15])#D(:2OJ8$J$
MC$R0U$\2N$FD5O=>Z$+-[5VON7;E?L_<>V\#G]I93&G#Y/:V;HZ>KQU32%0A
MI9Z&>.2FFIB@"F)T*%>--O?NO=!CUW\:?CEU#M; [&ZFZ Z3ZOV3M7)U&:VQ
ML_KO:F"PF*QM963)45=708_&T%-24=355$:RS2Q1H\DBJ[LS $>Z]T,E724M
M?2U-#74U/6T5;3O25E'5HLD4L4BE)(I8W#))'(C%65@0P)!!!]^Z]T#'5'QD
M^-O0^2W-F>COCYT?TSF-ZY.?-;RRO5&T\#MVIRU94NLE35Y.?$4%'+7U-1(B
MM)+.SO(RJ68D ^_=>Z6W8_6'6G<>S\OUYV[UYL;M38&X8/ML_L;L?$T&<P]=
M'R/'68S)T]515*6)],D;#GZ>_=>Z;-F]*]-]=8O:.$Z^ZEZSV)A>O\-'MS8>
M(V;@<5BZ7"8^$2"*@Q%/0TD$6-HXA-)H@IUCC76^E1J:_NO="9[]U[H)NXNA
M.B_D1M==C_(#I;J;O3925J9%-H=Q;<P^Y\6*B-@T<XQ^;HZZD$T;*"K^/4I
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M'_Z]^_=>Z]_P^M_PJO\ ^]1FYO\ TFSO'_Z]^_=>Z]_P^M_PJO\ ^]1FYO\
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MQ87Y)8L8BHQ(VEBXLOGZ^!PY>MQ6/HY2)*@PP,M1#4TS0K-3RJ/=>ZI*V?\
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M905^\^@:JCJH20I,513RI(I(!TL+@>_=>Z>/^%/$,-1_,3_X3AT]1%'/!/\
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MD%T)V#V'OGJ+87=_4.]^U^L/!_I*ZPVAN7#9+<.WOND,E+_',+15LV2Q/W*
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M$8G,#$5E7_#<G!_NREJ/'.G]I![]U[H6O?NO=>]^Z]TF=Z_\>;NW_P -FO\
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MNR*W!=:O24M?F:RH[!R.)HX7R5;!6Q4-/2&J>9]-)++-Q&DD +,WNO=63?\
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M#/#35-7)25#3R^!_=>Z^M;!!#30PTU-#%3T]/$L$$$"A$1$ 5415 5550
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M-15N,JL7]]6-254LV0I:>)ZAJRH!]U[I-?RR.B^F_P"6'\J?CQ\-_P"8_P#
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M8UIXUB1!JU>Z]TJ?Y_\ _P ?I_(X_P#&ZW1/_N7EO?NO=4__ "$^*?QQ[_\
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M7NM^OW[KW7SW/GA_W&7?%#_PY^K?_>7D]^Z]U]"/W[KW7S&/YHFQ^FOY<O\
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MR*T8Q6-Q^$ASLDF46KJ8JFEBQU8_@:T0?W7NMF/_ (2I?]N/?BC_ .'1V/\
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MA*RKDP]#.RR31018S*9[*4<<$3M%$E,JQDPK"%]U[JNSX_\ RLZ:_P"$_/\
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M^[I_F#5GSYZJ[FH<?BU_NAD:N*@I/X)4XF3=DIS<"T<$ZO+]U2I))+#(:=#
M"WNO=;,?5G:NQ]K]9=>;9[&^1O4>_NP=N['Q6"WQONBRN+H(LUEZ2A@I\CEH
MZ%\I6/1)DJN.2H$!GG,/D\?FDTZV]U[K6DW1_(UZTW'_ "^OFC\'5_F,=*4E
M9\M?GI/\U*7LDXK'O%@HIY,6_P#=V3$_WT1LC(O\-M]Z*NF4^3_@*-'J]U[J
MQG._"GJC,_S3]F?S(A\R>GJ>@VG\&Y?ATW4);&M-/+)59:J_O ,Y_>)4CC'\
M3"_9_8LQ\>K[GU:5]U[JL'#_ ,A#J[:WP/\ B!\9=G_S)^IMK_(7X9?*K+_)
M+K'Y.XBAIH D>:JXJVNQ']WH=\QVE>>AH=-5+73A$IY$6G"U#@>Z]UN XV:6
MHQU!/-4T59-/1132U>-O]O*S1JS24]WE/@<G4EW<Z2/4WU/NO=:0/\BW^4?V
MY\J/Y9GPKRGR ^7_ 'QA_AAD-^9'N[=7\O7.[5P<&%W!787?]?F=J5]/NBII
MX-Q4VS\T*.ERU1C_ !U5/DWJ?O*6K@BEC]^Z]UL)_,K^5[V#W9\C*/YA_#[Y
MM=I_ 3Y.93K>CZ8[5WILK;^&WI@MX;5Q^2_B./I<QM/<4L.-&9Q3R5$=!E8W
M$U/%4/&\<T0\9]U[J+\ROY5N[?F/_*\W1_+FWU\R^SMR;JW9D,-E,Q\J^X,!
MA]Q9^HEQ6\:+=NBJPN"FV5CYH+4G\/I56:.2FI1"99:N2)C+[KW2T[B^!.8J
MOYA6ZOYGFW>U<L-P8+^6QFOA;@NCL!@97KIJP[HRF]*7<E%N.#,K.M7YZI:.
M''1XLN9%6H2NU,(![KW2U_E)]2]_]*_RZOBOLOY5;_[A[*^1]5UQ'O?N;</?
M.=R.XMT4^<W'4U&=J,)D<EE*NMJF_NVF03$Q1&5A%'1*ERP9F]U[K-\@O@-_
MIV_F#?R^OG;_ *5_[K?[(EB^T<;_ *+/X%]]_>K_ $D[4_NQK_CG\9H_X'_!
M?^!-OX?D/N_\S>E_SOOW7NBV;(_E ?W-^-'\W3X[?[,-_$O^'4?D!V_WI_?#
M^Z7A_N)_I6QXH/X7_#_[S2_WH_@-M?W/W.)^^_3]O2?J]^Z]T">U?Y&/873&
MX^G-Y?%+^8OV_P#%/=M)\2NKOB-\N,QUAL?9M=_I2QO5.TH=I8#<5#'N:/.'
M9&YC0P)&E8'S+4M)'#2069'J9/=>ZF;H_D*[6J_Y+-9_)OV7\EMP8#;;[GCW
M)C^^=T;7ILQ71$=A)O\ FAFV_29S!P3AYP]$C+70Z$99F61E,;^Z]T?/^8M\
M!O\ 9_,+\0\/_I7_ -$_^RJ?.O8'S5^X_@7\>_CW]QHLY%_=K1_&<-_"_P"*
M?QF_\1U5?VWAM]C4>2Z>Z]UD^/\ \!T^.GSL^:7R]V3VO4ML+YLX?:.4WU\?
MJC$R^#&;RVK1S8U]UX_.-FY(@,WCIF6MHABHW>H6.<UK)&D ]U[HTGR5K.LL
M?\=._*[NJJQM%TY2=+;IJ.V*S,O#'21;:3!US9QZJ2H*P)3KC!,9&D(0+<N=
M-_?NO=4>_P#";'X=XOJW^2SU#@NT-OX_-9#Y@8',=O\ 9M%D?)4#)X#=-*N%
MVY154DZK))2GK^@Q4*P_YF&-FBAN@U-[KW2W^+G\C.HZ)[GZ+S_:OSB[K^37
MQC^%V=EW-\"_BCO_  V'H:'KS(2TE10P5>8W'1RR9#?$V#I*EHL&:FGHABH[
M*@FT@CW7NE7\A_Y.'8._OF;W)\M?B[_,"[K^$=/\L]GX3:7S-Z_ZKVWMW-5&
M]3M?#RX+;F1P>>SYJ/[E9&BQTK1SS4U!6&HN\L7VM3+//+[KW27V_P#R)]K[
M)^)7\K;XD[,^2.?I]M?RS/G7AOFKC=V;GVS3U]=O'^%[PW1N^;;4\-)F\53X
M/[JHW,].F17[[P1P([4,[.0ONO=7Y^_=>ZIH_FZ?R>=G_P V!/C-_'NYLQTC
M4]";[R=5N?([=Q557U>Z=E;D@H:;=NQGJJ/<6W9\72[@AQE,LE7JK%B"$?9R
MZS[]U[H5_GS_ "VZGY;[IZ.[SZ)^2.__ (4_+GXU8_.;?Z:^0/6^+QV>IX,+
MN2CCH\QM_/[2RKP8G<.%G\$$T4$LD+TT\0D@E0LU_=>Z3?17\I'JCJ?X:_++
MXK;X[8[3[RWA\ZH]W93Y7?(_?L\2;FW-F]X8=\'5Y.""G_R+$TV+Q_BCQM!!
MJIZ98@&\GDD+>Z]T%G7/\FMY?Y;%7_+D^4?S![;^1V$P,F#AZ,[FPF*QFQ<[
MUO2;+CQL77L.TX\//6LE3M+^$TTHK*VIJZBNE-0)W6FDCIH/=>Z'OX<?"7Y@
M=$[HW;NOY-_S2._OF1-EMI5^R-J;6RFT-C;,P.(I:FJ@J*/+/0XG&Y&LR.Z<
M='!XDR,E;'!,LTWGQ[JT:1>Z]T4WKS^2]W/6?(#H'L7Y@?S.._\ YM]'_$;M
M''=V?&3H/M/:FU,=4XS=F(H*FCQ.<W;O+'(^3WG78F:I-71RO38^6*H1&DDF
M!E$ONO=7KY_"8[<V!S>V\O":C$[@Q%3A,I #;73U<+P3I>QMJCD8?3\^_=>Z
MUN-J?\)R=K;-_DW[G_E3X'Y0#&;OW+WK3?(63Y78W8JT]5#N*DS^(KX*U-KQ
M[P$WW<6W\-!ADJ%SJ2HBI4*=$8I#[KW5C/\ ,1_EG8?YT_RW,Y_+KV[VFG1F
MWZW [(VU@NPH]OC<*X^CV3EL'D:6)<(N:P(F%5!A%IQ:NB$/D\@$NCQO[KW3
M#\I_Y8VXN\/GM\?OY@73'RLWQ\7^U>K^JS\>NVZ':V QN?CWUUU_>%]T+M;S
M9:J6+;,CY>>8RY*DIIZUH)C'$T$L4$\/NO=+SIG^7I_HB^=G\QWYJ_Z7O[P?
M\.!;7ZVVW_HT_@'VG]TO]'NSFVGYOXS_ !NI_CW\7U?=:/L<=]K;P:JG_/>_
M=>Z5'\KCX,?\-K_!/HSX5?Z4?]-'^A?^\W_&2_X)_=S^)?WCWCN'=G_%F_B^
M=^S^S_COVO\ P.G\O@\_[7E\,?NO=%/[[_E#;ZWA\O.Z?E=\5?GMW7\(ZCY=
M;6P.T_FELCK7;>U-Q#>T>U<+5X+;N0PF3W/2UK;(S-%CZKQ2U='351E7RO''
M3U53/5-[KW0=TO\ (GVOMWX*_P MWX-;,^2.?H-M?R\/G7@OFKC=^[GVS3Y*
MNW7_  ?<V^-S3;:GI*3-XBGP_P!W4;U>%,BKUG@CI$9J&=I3X_=>Z/!C_@-]
MC_-8SG\SC_2OY?XS\%$^%7^A+^!:?'HWQ1[S_O+_ 'E_C)UW^T^S_AW\*7]7
MW'WWI\!]U[H#OYF_\K?/_P RGMCX6U>\.[\7M'XU_&/MZ'N+LOHB7!9"NEW[
M6P55&\-)592GW)BZ;'TU/24TD,)DH:UD>JFD]2%H7]U[IMZ._E2YCXX_S8_D
MA_,6ZC[IP>W^K?EGLR'$]V?&U]NU325>=@AAE_O%29\9]:2"JFR\!JY%;%.U
MJJMC25&J9';W7NC7?S"_@ILS^8+T)C^GMQ[XW/U/N[8O:6W>^.D>YMDT]#59
MC9V]]J5356#W!CZ?(PS4L[PB:>FGB/C::DJ:B%)X6D$J^Z]T47XI?RF^SNF/
MFC1_/SY&?/SMWYA_)"3XI5'Q4S.;W9M':&U,3'C)\_#N".HP6'VY2QTV'IJ6
MLA9XZ28Y!FFJ:J>>KF,JI'[KW068?^2EVYO#NKH7<GRY_F>?)/YD_''XL]SX
M+Y%=#_'7M';NU,=64^]=LQUR8',;HWQA(*7*;ICQIKF=*=Z2C64^2.H>:":2
M$^Z]U=IVSL:M[/ZN[%ZWQN_-Z=75^_MD939M'V1UQ-34VX,#)DJ*:C7+X2IK
M*6MIJ;*X\S>:EED@E6.9$?02H]^Z]U4/\>OY1':.U_EQU#\N_FA_,'[D^>>[
M?BUC]TXSXB[<WSM;;6T:39HWEC*7#YZORDNW?7NW,56-I?"*FI6FB6\<WVIJ
M((94]U[ISV1_* _N;\:/YNGQV_V8;^)?\.H_(#M_O3^^']TO#_<3_2MCQ0?P
MO^'_ -YI?[T?P&VO[G[G$_??I^WI/U>_=>Z:NS_Y-V0W!T1_+^PG27R_[$^-
M7S"_EU?'7%_'/J'Y?=?;?Q]=%E,1!M+%;6S5-N+8>7R%5B\GA\RV)AKXZ":O
M>2@J /#6N=4C^Z]TJ]B?R=]B;*^ WS3^'V0[T[#[+[:^>F(WEEOD'\M.U*:+
M)YO*[QW7AVQ-/N)\)3U=!1Q8W;XCI318:GJJ:%8:<PBJC>9YQ[KW1?M\_P @
M7KW=OPC_ )9GPQQW><>U\=_+S[GP_:F:WUCMH)??M'?+3;WPCXR/<M.=NQ[Z
MK<O--5SFLRJQ R)/35_E+CW7NC_?)_X#?[,A\X?Y<GS,_P!*_P#<S_AO_*=G
MY+_1O_ OXC_>W_2/MO%;?T?QC^,T/\!_@W\,^XO]CD?N_+XK4VCR/[KW7OC!
M\!O]EO\ G#_,;^9G^E?^^?\ PX!E.L,E_HW_ (%_#O[I?Z.-MY7;^C^,?QFN
M_CW\9_B?W%_L<=]IXO%:IU^1/=>Z]_, ^ W^ST9KX-YC_2O_ *+O]DQ^=>Q/
MFK]O_ OXW_>3^Y,M7+_=K7_&<1_!_P")_=6_B.FN^WTW^QGU6'NO= !DOY27
M\0WU_.PWK_LP'A_X>(Z3P73W\,_NIJ_T=?P7KG<_7_\ $?-_>1?[W?<_WC^_
M^W\>%\?V_P!KYG\WW$7NO='_ /AO\>?]E)^)WQO^+W][_P#2!_LOG2>V^GO[
M\?P_^%?Q?^[V*I<9_$?X9][DOL/O/MO+]O\ =U/BU:/-);6?=>Z)1\A/Y8.Y
M>TOYCG2O\QKIKY:[^^-F^-F]0TOQZ[RV5M?;^)S<'8&Q*/<O][$VZ:_+3D[9
M%9E5B2LK*2EGJ9*6)8Z5Z*H_RKW[KW27R7\I+^(;Z_G8;U_V8#P_\/$=)X+I
M[^&?W4U?Z.OX+USN?K_^(^;^\B_WN^Y_O']_]OX\+X_M_M?,_F^XB]U[IKVK
M_* _NSN_^2INO_9AOO?^&?.I]U=8?8?W2\?^D3^\VQL!LO[[R_WFD_NE]C_
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M]%43:501Q4]/45-1)#3033)[KW1JL5D8,OB\;EJ994ILI00Y&G2< .$GC65
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M7=/R\W'O+?OSJVV^<&S]C5\NPMKPO@\NE+LO)85JN)-NT4A^XW!CY-.9I;P
M")JKW7N@3^;/\QWY3[;_ .%-W4?R8Q7\L?Y ;H[9^,NR=Y=#]2_%C'R;C&XN
MU-N4%'VUM^F["VZT?7]1DEPF1QN;J\O$*/$9>E^VQ=0%R4L1DJ:?W7NMS_N[
M^;1UE\1/Y;?7?\P3YI=7;Y^.V;WYLO#UB?%K*EYMY1[NS-))50['IH,Q0[;J
M)\M3""9ZEZFCH?MJ:GJ:JHABCA<#W7NB)?!__A1KM?Y#_*38GQ&^6_P;^1W\
MNWLWO6LJA\9Z[OB.M_A6\H%\?\-A\^4V_M>JQV5S#&2.FBBIZ_'O4K%2)E9*
MJJIX9/=>Z.%_-A_G4_'G^4)FOC%C_D#UWVIO+%?)G*;EH\;G^MHL;/'@Z?:L
MNUDR=9DJ>MKJ2IG3Q[IADBCI5FD<4\RZ0QC#>Z]T1KXD?\*4<%WG\V^O?AQ\
MCO@%\F/@T_R KQB_C)V!WQYZ:3<]2ZS>"+)X3(8'"-AQ7SI'2TDM!6YR&6LF
MC@DE@U*Y]U[JP3^;+_-ZZ?\ Y56Q.M'SO7F\N_\ Y!=^;@GVA\>_C;UM((\S
MN;)0_;P_N3K2Y":AH/OZ^CI/+#15U5+45<4='0U<@=%]U[K5!V3\\,I_,(_X
M5&?RJ.W-U?&CN;XB]C;(^-V1ZD[0Z*[RHZJDRV)SE'A>ZLW+]K)6X_$5=?B9
MJ+/TQIJN:@H9)2) U+$4M[]U[K9.Z:_F);#WS_/T^6W\O"B^(76&U^Q^H/C;
MA=XY[YE8^IHFW9N;%C#;!SU%MO(PIMV"O7&8Z??TJP))F*F&-J8RQTZ-4L(O
M=>Z"/YG?\*0^C_B)\U^[_P"7]COB5\IOD!\DNJ\'AJG9^V.F\?19--WY/-;9
MV_NV'&8N"DGK,S */"9N2IK*A\?((H\?5F..8F%9/=>Z'7^41_.WV9_-$W+W
M5TMO+XY]C?#SY6?'^"++]D?'[LNK>OJ(\745;4<=;25=5B-N9(RTDK4Z5]/5
MXFB>EDJZ94-0D@E]^Z]T#W\PK_A0EL[X?_+,?"GXZ?#GOGY_]][)Q=%O+Y!;
M7Z"^Y=ME[>J(H*FJJC'CL'N*KRF5H:2NHII*5X:&AC6L@CJLO2SMXO?NO=&+
M_E3_ ,['HC^;5O7Y)[,Z9ZA[FZPJ/C1-AH]RU';L.,I)*X9RKSM)2BGHZ&OK
M*FEFA; S&HBJ5B>(R(EBP<+[KW5Q^5JY\?B\E7TU'+D:FBH)JNGQ\%]<[QQL
MZ0II5VURLH465C<\*?I[]U[KYC7QD_FL_,KKK^?3\Y/FWM?^4+\FNS/D!W-\
M>8MA[\^!^ EW4-X['QJCJL#<.7>GZRK\T:)O[LT%A4;>H(O]S=)_E)M#]W[K
MW5M__"JGN7 ]6_)S_A/9\A.R\;E]L;8ZZ[WW/W+V!AX89*FOQ]!B-P=%YO*T
MR4[)3RU%924]/*@C*1.\B:2J$V'NO=6(?$C_ (4HX+O/YM]>_#CY'? +Y,?!
MI_D!7C%_&3L#OCSTTFYZEUF\$63PF0P.$;#BOG2.EI):"MSD,M9-'!)+!J5S
M[KW5F'\T7^:YT1_*UZXZ_P _V)MK>?;O;_=F[EV'T%\=>JTBJ-T;MRGDIHIA
M1T[EI(Z&DDK::*:=(IW^XJJ2EA@FJ:J&)O=>Z*=_+'_GR;+^=W>^9^'O?WQ4
M[J^ 'S-QNT)=_8GH;O053?QO%0M-)*^%KLEA-L9.:MI\<J5LM-58BD+TYJ):
M-ZR&BJIH_=>ZOV]^Z]UHK?\ "@9.J9?Y_'\J2'^8FE!)_+8GZLEIT&[I)8ML
MC<<F6W"F:?+RTLD51'1QY5MFMF6G84 Q0@-5>E^]!]U[K8JZ7_DH?RQNI_EC
MU7\]_C=TOA>K=^[*V!6879-)TIE:G%[,KDR\#PIGY,/B:B/'Y*K;%5=13HQ9
MZ&HAJ%GFIIZFGHZB#W7NBA_,W_A2#TA\1_FQW=_+\QGQ(^5'R"^2G5N$PU1L
MW:_3..HLHF\,IF]M;?W;!B\5!1S5F9A^SPF<DJ*N=L?((H\?5F..8F%9/=>Z
M&_\ E._SQ>M?YF>_>V/CUO'H#LWX<_+WI+#)N7?_ ,<^W9O-6C'&>"EJ*K'S
MU..P63F..J*RE2LBJ\30RP?>4K!)$EU+[KW2 _F2_P _/:GPM^0<OPX^,OQ%
M[M_F)?+S![0BW]V'TYT(:KQ;6Q4QHY(FSM;B,%NW*4]:]%70U1@CQ,B10U%$
MU3/3BM@+>Z]T=K^5[_--^/\ _-3Z:W5V9TYB=X]?;RZPWC)U_P!T=)=F0PTV
MY-JY9?(T$==#!))%+1Y"*&1J6I0@.T-33RI#5TE53P^Z]T17^93_ ,*!]C?"
M?Y#S?#7XV_$WNC^81\N\)MF#>._>HNCWJ(H-MT-0M+41QY:NQ>#W7E%R!Q]7
M%5M!#B)HX89Z0U-1 :I+>Z]T)WQ]_G7=(_,K^6_\W_F)L7I'>V*W3\-.J=_Y
M+O'XM]VPI05*Y?:>U<GGYMN5=>*6MI9J'+0T1I9932M-3%Y4J\>CH(I/=>Z5
M?\LG^8/UWW)_*!VM\[-K?$^#H7K'9NR]\9N@^+'QHHZ7,-08O9&;SF.EH-KX
MR@QFVZ6JJ:V+$//#20TE,/)+X4UD:W]U[JJW=G_"J_<_56=H-[=[?R<OGSTE
M\0\G74^+I/DEO^@K<?*:FIDA6.,X?([8H-OOJBD,BK#N>6:2R+'"Y<$>Z]TD
M?^%D>[]N]@_R@OBQOW:&2AS6T][_ #:V/N_:^8IK^.KQV2ZP[0K:*ICN =$]
M-,CK< V87]^Z]UM];(_X\O:'_AKX_P#]Q(??NO=4 _\ "JW_ +<>_*[_ ,.C
MKC_WX^U??NO=$R_X2V_,RGV)_*M^1O3GR(K5V5GOY96]=T93?V,W%5HM5B]C
M9&AK=[4N0K!/(%IJ,5T6?BIY0QI'IZ-'AE9-6GW7NJ1?^$M':>_>]OY]?RL[
MW[-Q64PF]^]OC;V'W?F<9E_/Y(UWAO38NY*0PM410R2T,M%DX9*.4(L<U(T$
ML(\+I[]U[K<&_FG?SI^K_P"6[NSK#H;9_1_:/S(^97=F)JMP=8_%;HX/+FI\
M;31UA&3RCTE#F<C0T-5-0U$=.:;&5]1,*6MFCIVBHYV7W7NG/^5/_.:ZD_F=
M5?:W5U;T_P!F_%/Y9]!PTD_='Q>[G1DS.-AJ1%%)7XZ>:DQE5D,;29"3[2=J
MF@Q]93R/3-54-.E;2F7W7NFS^:=_.GZO_EN[LZPZ&V?T?VC\R/F5W9B:K<'6
M/Q6Z.#RYJ?&TT=81D\H])0YG(T-#534-1'3FFQE?43"EK9HZ=HJ.=E]U[K)_
M*\_G2]5_S*J?N?KR3I/M+XR?+OX[8J')]P_$[N!'CSE(DL2*:G%SR4-!69"@
MAR3BBF:HQM#6T\LE,U3CX4K:3S>Z]UI7?&3^:S\RNNOY]/SD^;>U_P"4+\FN
MS/D!W-\>8MA[\^!^ EW4-X['QJCJL#<.7>GZRK\T:)O[LT%A4;>H(O\ <W2?
MY2;0_=^Z]UM[_P U'^9/L_XD_(3^3SU[V#\*^NN]-T?,SO9L'M'<W9E32PY3
MJ;-#(=?X&7,8)*[;.4J&S$4&_IHW>&3%3A:1H#*%J7\7NO=#;_-A_G4_'G^4
M)FOC%C_D#UWVIO+%?)G*;EH\;G^MHL;/'@Z?:LNUDR=9DJ>MKJ2IG3Q[IADB
MCI5FD<4\RZ0QC#>Z]T1KXD?\*4<%WG\V^O?AQ\CO@%\F/@T_R KQB_C)V!WQ
MYZ:3<]2ZS>"+)X3(8'"-AQ7SI'2TDM!6YR&6LFC@DE@U*Y]U[JP3^;+_ #>N
MG_Y56Q.M'SO7F\N__D%WYN"?:'Q[^-O6T@CS.YLE#]O#^Y.M+D)J&@^_KZ.D
M\L-%754M15Q1T=#5R!T7W7NB-?#C_A23UQ\G?E_\?_@7V-\'_E9\7/E#W+C:
MP[GVAV[24U'1;8KZ##YO.3TTSY./"Y[(4<U#A2U-5_P>E,S3QAX(2DH3W7NM
ME;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW1 /YL7_;K+^99_XH!W)_[[K<?OW7NM>G^75_*,^5?S4^"'\OZ'YO?S(L
M_P!R?R^O]"?6_;FT_@9M'K?:>V*62EQ^-Q64VWMG=&\Z MF-S8/$QQQQ5$=7
M"\E<\:3M)!,NL^Z]U)WIN[?77OSM_P"%?F]>K)LC0]A[2^"G4F<V1782,R5=
M'D:7X]962DK*2-5?5444JB>(:6&N-;JPNI]U[HH_Q/ZN_F;=\] ?R%FZ,_E'
M[<Z+ZR^'_:?4?=T?S:V_W1U1E:G=?7F1PJT78534[-1<-N+%1[[QN8DRN0H6
MJ:O)4SQO024T]>1-%[KW1N_YB'S#^:'S5Z@_G0X_XA?''X+I\/?AULOMSXG_
M "E[9^055N7_ $H;GR>T]@UC;FJ]BTV)Q*XO'5.RIZNJ./\ XP]33Y!XJ=Z.
MJI?*_B]U[I8;;^"7R8[_ /Y='\A7YO\ PNS'5F<^67P$^'^&R77W2OR!B:;9
MN]L-O7KS;V#W!BJJI1TDQ>8@H*)!BZDO'3I.X\\U,8X*F#W7NBM_S$/GED?E
M[_+/^#%=TU\0Z+:&X\=_.]V7\9/F#\%8,EM_"X>NW]MG(Y?/YKKG);I>B_NU
M08K=N[),=4MFJR 0++4Q5=<'TU*2>Z]U9)_+\ZT_F3[D_G =L?,KO[^7%COY
M>?Q\[7^#-%TMO_:.%[2ZY[#IMP;[VQNVGK]M[AG.T7Q^1AK4VUD*W'1B3'/!
M%!3N9:QGGIX8?=>Z$3_A0E4U]1M?^5#M#**TW4>__P"=)T/M;N^AJ$UX^MP#
M9'*U)HLO<-&<;+54\<CK(/&TL,-S<*&]U[HF/RK@W+UK_/7_ )@^X?CYM?#T
M';-'_P )E-][QV!CL)304@K]VTN_8!A))_ ]&):B6KHJ.#R/+&_CCC3S(J*5
M]U[HL/R!ZVZSV'_PEL_ET=D] ;#V%)W]L7-_'_M7X\9&AHJ*.NF[7RF\\-+E
MC#5H*6<U]?D:_+)5D5$+N/*))@$U#W7NMX'W[KW7SE,3M7;6 _X194'96!P.
M)P?8F*[W@WKC=^8:".ES$&8I>_UQ5-E(<G L=9'7T^-1::*<2"2.!5C1@JJ!
M[KW6R9\<-KXSL?\ X4-_S7*ONS9NU,YE.O/B)T?L;XWR[BI*6LF?86:QV1R>
M[FITJ#4Z*>?>QF@J0JP!O%$KQ.&$LGNO=:]??=#+C?\ A,A_-;V9C<'A\=TM
MU-_-JW=L3XH#%QQ?;)L&'N;9LU*U!HD=8:9,Y6Y>G01I3CQQ@"(J?)+[KW7T
M)Z#'8_%TXI,904>.I58NM-01)#&&;EB$C55N?R;<^_=>ZT8OE?U;1;\^=7S4
M_DG28RFP&W_G[_-$V!\T9\323T]'+N+8^6Z>W'O_ 'O78M:>K-;3O#V'U=34
MV8K#!&R+4%DD26MIJF+W7NCB?R%^PLY\UOE3L3Y1;QK-W9+/?$?^3WU9\*MP
M0[CIJZACI-]56^-YIOTST%7%31TVX14]?4L5:R1!WA,!8B%J=??NO=&3_P"$
MI>PMC4O\F/XO;TI]F[5@WADMY=BUU?NN+'TBY*:9-];FQJ2RUPB^Y>1<?$E,
M&+DBG581^V-/OW7NM?Z2FIIO^$0-/42T\$L])VDSTLTB*SQ%_D:4<QL02A9"
M5)!%P2#Q[]U[J['^>?O+NW8W\Q;^1SM3HKXL8SY:4--V'W/VC@OBW5;BV]L/
M#;KWC@=E8Y<%45&Z-R455@,7D-K4=?D,K1)/&7JY$DI8 :F>G>+W7NC'_P F
MGIOYZ;&^6'\T'NOY3_"^D^"O3GRPWOU[VYU#T3C=^['W[1T.Z*+;]?@M^U]/
MD=FSQ6FS\]%CJ^I:JQ]&"\D<4)J'@J)Y/=>ZR?S=\:V\?YCW\@SK?L# 83/?
M'3.?+7L/>&]H=Q113T9WSMW88JNLX7AG=HI)9*^HR<D(,$G[T*6EA:PE]U[J
MM'^8MA(-A?.G^??MOJ7;&WL'UCV!_P )[JOL;Y!2[=@@IE/8=%69S%;5>KBI
MVA5JVLV?+7,SM#*[1PQEIH[A)?=>Z=ODVZ2?RY?^$AC1NKJ/FS\)D+(01J78
MU&K"X_*L""/P00>??NO='N_E^X3#/_PH-_G_ +OB,8SX_;_QAJZ!FIXB8)9>
MK!+++"2EXI))/6S+8LWJ))Y]^Z]T5;LO:_;7\B/OGY ]]]E=2=.?*S^4Y\MO
MG$?D_P!I]GY>"A3LKIC?F^LYC*=,G4P9!)*;<.V,3GH*%J!Z0??4SWJ-=+5J
M6K_=>Z178^>WMM?YO_\ "PK<?7%1DZ/?6#^!O4^4VM7856:LIZN'X\Y:2.HI
M @+_ '5/I,D14%A(JE02 #[KW09]X;'ZWPG\N_\ X2+YW9^U]JT.1G^=OQ"^
M\SN)HZ9*IJK*;?@R.X(WJTC$Y-7G$>:J0M:2IC#R NBD>Z]TF>L-W?-K?7RK
M_GT;9V+_ "8MH_S!(>Z_F;N7H#M'LS<W<W7&PZS'[1P>VZ3;VR=OG"[PQU?D
MZFB;:\D.7IJN&6.F+UWV\86>@<K[KW6RG_)JZK^2W1?\L7X?])_+W9!ZX[^Z
M@ZVGZPW9LLY?$YW[+'X#-93%;7'\4P>0RN*J//M.EQLVFGJI5@\GV[Z)(GC3
MW7NJ_/Y?N$PS_P#"@W^?^[XC&,^/V_\ &&KH&:GB)@EEZL$LLL)*7BDDD];,
MMBS>HDGGW[KW57O4NP-C9S^75_PKFW'F-G[9RFX8_G[\K8X\[745-+6*N'QK
M9/%(M4\9G"8[(S25-.H:T4TCR( SL3[KW2/A[<^6,?RK_D#YKJ_X.TO\Q7=&
MP_Y!VU^VNM=A;X['VSL1_P"]NYL7MO$[VW1'G=ZT^1H:[+XO"T6,26%8S6U*
MY9JI9=-%,1[KW5U'\D;I+YI]2=L_S,-W?)CX/XKX$]4_)'OW;7R)Z2Z5P>_-
MF;[I*?.9;!56*[!,%9LVI%/3K-6X/%UQ,]!0:S7F"%9Q222#W7NL7<-'4[L_
MX4I_%G;?8FWL-F.M=I_RH-[[QZ;FSM/#4*N]:_L6DQVZ&I!,9 M7#M>GH 66
M-&$,\@$CABJ>Z]U1S)E]U=8?R@/^%7"=.[?@AJ*/^;'W3L"' 8)8Z."CVOEM
MS[.V[N,010^**&DQVTJZND\* (883$JZ2%]^Z]T:G:W5W\S/N7O'^3GO#9/\
MCO97PWZ\^$/<NUXW[]VMWSU%NUEZBS>#7:>[:%,5A$P65J*27;U:,H$@DK9I
MWI3!'1S2U9<>Z]T(?9>U^VOY$??/R![[[*ZDZ<^5G\ISY;?.(_)_M/L_+P4*
M=E=,;\WUG,93IDZF#())3;AVQB<]!0M0/2#[ZF>]1KI:M2U?[KW2*['SV]MK
M_-__ (6%;CZXJ,G1[ZP?P-ZGRFUJ["JS5E/5P_'G+21U%($!?[JGTF2(J"PD
M52H) !]U[H,^\-C];X3^7?\ \)%\[L_:^U:'(S_.WXA?>9W$T=,E4U5E-OP9
M'<$;U:1B<FKSB/-5(6M)4QAY 712/=>Z?=^;1VIN+Y!?\+2\IG]LX#-Y/ ?"
MS8LV"R65HZ>HJ*)A\?.P:W5232QO)3DUF.I)SXV6\M-3R&[PQE?=>Z%[X]_-
M'Y/U7QU_DZ_RZO@ETO\ %/L_Y;Y_^4YLGY89?LSYM5&X!LW9>S:.@PNT*5H*
M7;E#-F\GD,W44]90K'15<#420T[SPSTLK!/=>Z*E\.J/>1_DY_\ "I*@[7VU
ML/;G86.^8GRCFWSM#KIY:G;.(W%'LVA&4I=MR5<%/.V(H<A&\5!+)##,U+%
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MOM@;9WS7]?[1DAJ>OCFILYDMS;?H(XO%BLJK8T>!*N*2/RQP^Z]T!O\ +O\
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M/B,?3A.="4\",;@7]U[IH_X3F(D7\W[_ (4G1QHL<<?S5KDCC0 *JCL_N,
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MOC)V1E-J;JH-M"+#05&.K*E8*W#Y05T&!HTJ):K&RS,([I)&X5E]U[H0L/\
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M;MG_ ,[Z7_K[[]U[KW]]=F_\];MG_P [Z7_K[[]U[KW]]=F_\];MG_SOI?\
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M?#+#@MTX/)34[UV%R-7X9FIY8 DXA5P*6IIJ[(T=28S40U--[KW7+^6C5_\
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M -K[W[KW7O\ H*._GK_]YS?^PRZ=_P#M?>_=>Z]_T%'?SU_^\YO_ &&73O\
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M_M?>_=>Z]_T%'?SU_P#O.;_V&73O_P!K[W[KW7O^@H[^>O\ ]YS?^PRZ=_\
MM?>_=>Z]_P!!1W\]?_O.;_V&73O_ -K[W[KW7O\ H*._GK_]YS?^PRZ=_P#M
M?>_=>Z]_T%'?SU_^\YO_ &&73O\ ]K[W[KW7O^@H[^>O_P!YS?\ L,NG?_M?
M>_=>Z]_T%'?SU_\ O.;_ -AET[_]K[W[KW7O^@H[^>O_ -YS?^PRZ=_^U][]
MU[KW_04=_/7_ .\YO_89=.__ &OO?NO=>_Z"COYZ_P#WG-_[#+IW_P"U][]U
M[KW_ $%'?SU_^\YO_89=._\ VOO?NO=>_P"@H[^>O_WG-_[#+IW_ .U][]U[
MKW_04=_/7_[SF_\ 89=._P#VOO?NO=>_Z"COYZ__ 'G-_P"PRZ=_^U][]U[K
MW_04=_/7_P"\YO\ V&73O_VOO?NO=>_Z"COYZ_\ WG-_[#+IW_[7WOW7NO?]
M!1W\]?\ [SF_]AET[_\ :^]^Z]U[_H*._GK_ /><W_L,NG?_ +7WOW7NO?\
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M\YO_ &&73O\ ]K[W[KW7O^@H[^>O_P!YS?\ L,NG?_M?>_=>Z]_T%'?SU_\
MO.;_ -AET[_]K[W[KW7O^@H[^>O_ -YS?^PRZ=_^U][]U[KW_04=_/7_ .\Y
MO_89=.__ &OO?NO=>_Z"COYZ_P#WG-_[#+IW_P"U][]U[KW_ $%'?SU_^\YO
M_89=._\ VOO?NO=>_P"@H[^>O_WG-_[#+IW_ .U][]U[KW_04=_/7_[SF_\
M89=._P#VOO?NO=>_Z"COYZ__ 'G-_P"PRZ=_^U][]U[KW_04=_/7_P"\YO\
MV&73O_VOO?NO=>_Z"COYZ_\ WG-_[#+IW_[7WOW7NO?]!1W\]?\ [SF_]AET
M[_\ :^]^Z]U[_H*._GK_ /><W_L,NG?_ +7WOW7NO?\ 04=_/7_[SF_]AET[
M_P#:^]^Z]U[_ *"COYZ__><W_L,NG?\ [7WOW7NO?]!1W\]?_O.;_P!AET[_
M /:^]^Z]U[_H*._GK_\ ><W_ +#+IW_[7WOW7NO?]!1W\]?_ +SF_P#89=._
M_:^]^Z]U[_H*._GK_P#><W_L,NG?_M?>_=>Z]_T%'?SU_P#O.;_V&73O_P!K
M[W[KW7O^@H[^>O\ ]YS?^PRZ=_\ M?>_=>Z]_P!!1W\]?_O.;_V&73O_ -K[
MW[KW7O\ H*._GK_]YS?^PRZ=_P#M?>_=>Z]_T%'?SU_^\YO_ &&73O\ ]K[W
M[KW7O^@H[^>O_P!YS?\ L,NG?_M?>_=>Z]_T%'?SU_\ O.;_ -AET[_]K[W[
MKW7O^@H[^>O_ -YS?^PRZ=_^U][]U[KW_04=_/7_ .\YO_89=.__ &OO?NO=
M>_Z"COYZ_P#WG-_[#+IW_P"U][]U[KW_ $%'?SU_^\YO_89=._\ VOO?NO=>
M_P"@H[^>O_WG-_[#+IW_ .U][]U[KW_04=_/7_[SF_\ 89=._P#VOO?NO=>_
MZ"COYZ__ 'G-_P"PRZ=_^U][]U[KW_04=_/7_P"\YO\ V&73O_VOO?NO=>_Z
M"COYZ_\ WG-_[#+IW_[7WOW7NO?]!1W\]?\ [SF_]AET[_\ :^]^Z]U[_H*.
M_GK_ /><W_L,NG?_ +7WOW7NO?\ 04=_/7_[SF_]AET[_P#:^]^Z]U[_ *"C
MOYZ__><W_L,NG?\ [7WOW7NO?]!1W\]?_O.;_P!AET[_ /:^]^Z]U[_H*._G
MK_\ ><W_ +#+IW_[7WOW7NO?]!1W\]?_ +SF_P#89=.__:^]^Z]U[_H*._GK
M_P#><W_L,NG?_M?>_=>Z]_T%'?SU_P#O.;_V&73O_P!K[W[KW7O^@H[^>O\
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M +7WOW7NO?\ 04=_/7_[SF_]AET[_P#:^]^Z]U[_ *"COYZ__><W_L,NG?\
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MO_VOO?NO=>_Z"COYZ_\ WG-_[#+IW_[7WOW7NO?]!1W\]?\ [SF_]AET[_\
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M_><W_L,NG?\ [7WOW7NO?]!1W\]?_O.;_P!AET[_ /:^]^Z]U[_H*._GK_\
M><W_ +#+IW_[7WOW7NO?]!1W\]?_ +SF_P#89=.__:^]^Z]U[_H*._GK_P#>
M<W_L,NG?_M?>_=>Z]_T%'?SU_P#O.;_V&73O_P!K[W[KW7O^@H[^>O\ ]YS?
M^PRZ=_\ M?>_=>Z]_P!!1W\]?_O.;_V&73O_ -K[W[KW7O\ H*._GK_]YS?^
MPRZ=_P#M?>_=>Z]_T%'?SU_^\YO_ &&73O\ ]K[W[KW7O^@H[^>O_P!YS?\
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MSAZX_P#0+R?_ -?_ '[P^O>)U[_H#R[=_P"\X>N/_0+R?_U_]^\/KWB=>_Z
M\NW?^\X>N/\ T"\G_P#7_P!^\/KWB=>_Z \NW?\ O.'KC_T"\G_]?_?O#Z]X
MG7O^@/+MW_O.'KC_ - O)_\ U_\ ?O#Z]XG7O^@/+MW_ +SAZX_] O)__7_W
M[P^O>)U[_H#R[=_[SAZX_P#0+R?_ -?_ '[P^O>)U[_H#R[=_P"\X>N/_0+R
M?_U_]^\/KWB=>_Z \NW?^\X>N/\ T"\G_P#7_P!^\/KWB=>_Z \NW?\ O.'K
MC_T"\G_]?_?O#Z]XG7O^@/+MW_O.'KC_ - O)_\ U_\ ?O#Z]XG7O^@/+MW_
M +SAZX_] O)__7_W[P^O>)U[_H#R[=_[SAZX_P#0+R?_ -?_ '[P^O>)U[_H
M#R[=_P"\X>N/_0+R?_U_]^\/KWB=>_Z \NW?^\X>N/\ T"\G_P#7_P!^\/KW
MB=>_Z \NW?\ O.'KC_T"\G_]?_?O#Z]XG7O^@/+MW_O.'KC_ - O)_\ U_\
M?O#Z]XG7O^@/+MW_ +SAZX_] O)__7_W[P^O>)U[_H#R[=_[SAZX_P#0+R?_
M -?_ '[P^O>)U[_H#R[=_P"\X>N/_0+R?_U_]^\/KWB=>_Z \NW?^\X>N/\
MT"\G_P#7_P!^\/KWB=>_Z \NW?\ O.'KC_T"\G_]?_?O#Z]XG7O^@/+MW_O.
M'KC_ - O)_\ U_\ ?O#Z]XG7O^@/+MW_ +SAZX_] O)__7_W[P^O>)U[_H#R
M[=_[SAZX_P#0+R?_ -?_ '[P^O>)U[_H#R[=_P"\X>N/_0+R?_U_]^\/KWB=
M>_Z \NW?^\X>N/\ T"\G_P#7_P!^\/KWB=>_Z \NW?\ O.'KC_T"\G_]?_?O
M#Z]XG7O^@/+MW_O.'KC_ - O)_\ U_\ ?O#Z]XG7O^@/+MW_ +SAZX_] O)_
M_7_W[P^O>)U[_H#R[=_[SAZX_P#0+R?_ -?_ '[P^O>)U[_H#R[=_P"\X>N/
M_0+R?_U_]^\/KWB=>_Z \NW?^\X>N/\ T"\G_P#7_P!^\/KWB=>_Z \NW?\
MO.'KC_T"\G_]?_?O#Z]XG7O^@/+MW_O.'KC_ - O)_\ U_\ ?O#Z]XG7O^@/
M+MW_ +SAZX_] O)__7_W[P^O>)U[_H#R[=_[SAZX_P#0+R?_ -?_ '[P^O>)
MU[_H#R[=_P"\X>N/_0+R?_U_]^\/KWB=>_Z \NW?^\X>N/\ T"\G_P#7_P!^
M\/KWB=>_Z \NW?\ O.'KC_T"\G_]?_?O#Z]XG7O^@/+MW_O.'KC_ - O)_\
MU_\ ?O#Z]XG7O^@/+MW_ +SAZX_] O)__7_W[P^O>)U[_H#R[=_[SAZX_P#0
M+R?_ -?_ '[P^O>)U[_H#R[=_P"\X>N/_0+R?_U_]^\/KWB=>_Z \NW?^\X>
MN/\ T"\G_P#7_P!^\/KWB=>_Z \NW?\ O.'KC_T"\G_]?_?O#Z]XG7O^@/+M
MW_O.'KC_ - O)_\ U_\ ?O#Z]XG7O^@/+MW_ +SAZX_] O)__7_W[P^O>)U[
M_H#R[=_[SAZX_P#0+R?_ -?_ '[P^O>)U[_H#R[=_P"\X>N/_0+R?_U_]^\/
MKWB=>_Z \NW?^\X>N/\ T"\G_P#7_P!^\/KWB=>_Z \NW?\ O.'KC_T"\G_]
M?_?O#Z]XG7O^@/+MW_O.'KC_ - O)_\ U_\ ?O#Z]XG7O^@/+MW_ +SAZX_]
M O)__7_W[P^O>)U[_H#R[=_[SAZX_P#0+R?_ -?_ '[P^O>)U[_H#R[=_P"\
MX>N/_0+R?_U_]^\/KWB=>_Z \NW?^\X>N/\ T"\G_P#7_P!^\/KWB=>_Z \N
MW?\ O.'KC_T"\G_]?_?O#Z]XG7O^@/+MW_O.'KC_ - O)_\ U_\ ?O#Z]XG7
MO^@/+MW_ +SAZX_] O)__7_W[P^O>)U[_H#R[=_[SAZX_P#0+R?_ -?_ '[P
M^O>)U[_H#R[=_P"\X>N/_0+R?_U_]^\/KWB=>_Z \NW?^\X>N/\ T"\G_P#7
M_P!^\/KWB=>_Z \NW?\ O.'KC_T"\G_]?_?O#Z]XG7O^@/+MW_O.'KC_ - O
M)_\ U_\ ?O#Z]XG7O^@/+MW_ +SAZX_] O)__7_W[P^O>)U[_H#R[=_[SAZX
M_P#0+R?_ -?_ '[P^O>)U[_H#R[=_P"\X>N/_0+R?_U_]^\/KWB=>_Z \NW?
M^\X>N/\ T"\G_P#7_P!^\/KWB=>_Z \NW?\ O.'KC_T"\G_]?_?O#Z]XG7O^
M@/+MW_O.'KC_ - O)_\ U_\ ?O#Z]XG7O^@/+MW_ +SAZX_] O)__7_W[P^O
M>)U[_H#R[=_[SAZX_P#0+R?_ -?_ '[P^O>)U[_H#R[=_P"\X>N/_0+R?_U_
M]^\/KWB=>_Z \NW?^\X>N/\ T"\G_P#7_P!^\/KWB=>_Z \NW?\ O.'KC_T"
M\G_]?_?O#Z]XG7O^@/+MW_O.'KC_ - O)_\ U_\ ?O#Z]XG7O^@/+MW_ +SA
MZX_] O)__7_W[P^O>)U[_H#R[=_[SAZX_P#0+R?_ -?_ '[P^O>)U[_H#R[=
M_P"\X>N/_0+R?_U_]^\/KWB=>_Z \NW?^\X>N/\ T"\G_P#7_P!^\/KWB=>_
MZ \NW?\ O.'KC_T"\G_]?_?O#Z]XG7O^@/+MW_O.'KC_ - O)_\ U_\ ?O#Z
M]XG7O^@/+MW_ +SAZX_] O)__7_W[P^O>)U[_H#R[=_[SAZX_P#0+R?_ -?_
M '[P^O>)U[_H#R[=_P"\X>N/_0+R?_U_]^\/KWB=>_Z \NW?^\X>N/\ T"\G
M_P#7_P!^\/KWB=>_Z \NW?\ O.'KC_T"\G_]?_?O#Z]XG7O^@/+MW_O.'KC_
M - O)_\ U_\ ?O#Z]XG7O^@/+MW_ +SAZX_] O)__7_W[P^O>)U[_H#R[=_[
MSAZX_P#0+R?_ -?_ '[P^O>)U[_H#R[=_P"\X>N/_0+R?_U_]^\/KWB=>_Z
M\NW?^\X>N/\ T"\G_P#7_P!^\/KWB=>_Z \NW?\ O.'KC_T"\G_]?_?O#Z]X
MG7O^@/+MW_O.'KC_ - O)_\ U_\ ?O#Z]XG7O^@/+MW_ +SAZX_] O)__7_W
M[P^O>)U[_H#R[=_[SAZX_P#0+R?_ -?_ '[P^O>)U[_H#R[=_P"\X>N/_0+R
M?_U_]^\/KWB=>_Z \NW?^\X>N/\ T"\G_P#7_P!^\/KWB=>_Z \NW?\ O.'K
MC_T"\G_]?_?O#Z]XG7O^@/+MW_O.'KC_ - O)_\ U_\ ?O#Z]XG7O^@/+MW_
M +SAZX_] O)__7_W[P^O>)U[_H#R[=_[SAZX_P#0+R?_ -?_ '[P^O>)U[_H
M#R[=_P"\X>N/_0+R?_U_]^\/KWB=>_Z \NW?^\X>N/\ T"\G_P#7_P!^\/KW
MB=>_Z \NW?\ O.'KC_T"\G_]?_?O#Z]XG7O^@/+MW_O.'KC_ - O)_\ U_\
M?O#Z]XG7O^@/+MW_ +SAZX_] O)__7_W[P^O>)U[_H#R[=_[SAZX_P#0+R?_
M -?_ '[P^O>)U[_H#R[=_P"\X>N/_0+R?_U_]^\/KWB=>_Z \NW?^\X>N/\
MT"\G_P#7_P!^\/KWB=>_Z \NW?\ O.'KC_T"\G_]?_?O#Z]XG7O^@/+MW_O.
M'KC_ - O)_\ U_\ ?O#Z]XG7O^@/+MW_ +SAZX_] O)__7_W[P^O>)U[_H#R
M[=_[SAZX_P#0+R?_ -?_ '[P^O>)U[_H#R[=_P"\X>N/_0+R?_U_]^\/KWB=
M>_Z \NW?^\X>N/\ T"\G_P#7_P!^\/KWB=>_Z \NW?\ O.'KC_T"\G_]?_?O
M#Z]XG7O^@/+MW_O.'KC_ - O)_\ U_\ ?O#Z]XG7O^@/+MW_ +SAZX_] O)_
M_7_W[P^O>)U[_H#R[=_[SAZX_P#0+R?_ -?_ '[P^O>)U[_H#R[=_P"\X>N/
M_0+R?_U_]^\/KWB=>_Z \NW?^\X>N/\ T"\G_P#7_P!^\/KWB=>_Z \NW?\
MO.'KC_T"\G_]?_?O#Z]XG7O^@/+MW_O.'KC_ - O)_\ U_\ ?O#Z]XG7O^@/
M+MW_ +SAZX_] O)__7_W[P^O>)U[_H#R[=_[SAZX_P#0+R?_ -?_ '[P^O>)
MU[_H#R[=_P"\X>N/_0+R?_U_]^\/KWB=>_Z \NW?^\X>N/\ T"\G_P#7_P!^
M\/KWB=>_Z \NW?\ O.'KC_T"\G_]?_?O#Z]XG7O^@/+MW_O.'KC_ - O)_\
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MSAZX_P#0+R?_ -?_ '[P^O>)U[_H#R[=_P"\X>N/_0+R?_U_]^\/KWB=>_Z
M\NW?^\X>N/\ T"\G_P#7_P!^\/KWB=>_Z \NW?\ O.'KC_T"\G_]?_?O#Z]X
MG7O^@/+MW_O.'KC_ - O)_\ U_\ ?O#Z]XG7O^@/+MW_ +SAZX_] O)__7_W
M[P^O>)U[_H#R[=_[SAZX_P#0+R?_ -?_ '[P^O>)U[_H#R[=_P"\X>N/_0+R
M?_U_]^\/KWB=>_Z \NW?^\X>N/\ T"\G_P#7_P!^\/KWB=>_Z \NW?\ O.'K
MC_T"\G_]?_?O#Z]XG7O^@/+MW_O.'KC_ - O)_\ U_\ ?O#Z]XG7O^@/+MW_
M +SAZX_] O)__7_W[P^O>)U[_H#R[=_[SAZX_P#0+R?_ -?_ '[P^O>)U[_H
M#R[=_P"\X>N/_0+R?_U_]^\/KWB=>_Z \NW?^\X>N/\ T"\G_P#7_P!^\/KW
MB=>_Z \NW?\ O.'KC_T"\G_]?_?O#Z]XG7O^@/+MW_O.'KC_ - O)_\ U_\
M?O#Z]XG7O^@/+MW_ +SAZX_] O)__7_W[P^O>)U[_H#R[=_[SAZX_P#0+R?_
M -?_ '[P^O>)U[_H#R[=_P"\X>N/_0+R?_U_]^\/KWB=>_Z \NW?^\X>N/\
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M]FD_X5I_]XO8#_T'-C__ &0>_=W^JG7J+U[_ &:3_A6G_P!XO8#_ -!S8_\
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M0>_=W^JG7J+U[_9I/^%:?_>+V _]!S8__P!D'OW=_JIUZB]>_P!FD_X5I_\
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MF;:=ZU:W=;>!-TUBT5.FN;-OG9&P_B!D<)C8HT"223(66-3TZ@H.A8_F$?\
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MBR5-540+)-,ZQHD:EW)-E55'T4 6'N,>8+9+*_N(8AI1)Y405)HJNP J22:
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M<23+E7>20QEB5CC[1(RQ^%?\R_Y 8#O7#= ?+M\GD(MU[B@VC393=6(7$9[
MY:N,,6/IZZGAI:$O0U,\J+(:B#SP^99S.*="GM+S=[?6,ED;_:2*1J795D\2
M.1$KJ969F[EH:@-0A2 -7$,?>K^X7R7O7*$_.?MH(HFL[:2\:*TO#>;?N%G
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M.4J9(?,O[M-+IX$]+,'AD ^DB,/Q[Q\O[*3;9Y+>44>-V1O2JFF/D>(/F.N
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M45W"23V>5@I\<"2R'A#[B+E_9I.8+R.TCQK;N;!T(,LV2. !-*Y- ,GKD_\
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M%!U](GL-R)O$?W<8=HY?MT;<]SV;<!"K-'!K?=[BYI*TCO$ 4M[@.CLU=,:
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M6VXO%X_#1+-#221:M;>:^1I:J379+>3QZ3X];,^Z+HV\2!10A(@YK74V@&O
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M&[4_]Z+ ^Z>?Y]6'P]?28^4O_9,GR,_\01N__P!Y_(>W3PZ:Z^>]_P )4_\
MMZ/4_P#BM.[O_<W;_MM./3K\.D?_ ,*A_P#M[#OG_P 0SLO_ -ULGO3\>O)P
MZV@/^%!G_;C#(_\ E*O_ '9X?VX_#JB<>M>?^5NS)_(9_G6E6925P2DJ;<-2
M0 CC\$$@_P!0;>VQP/5FXCHQ7_"/G^%?[,!\S/-K_C?^AW;7\/MKT_:_QJL^
M\O;]N_F^UM?U?73QK][3KTG1#?\ A4/_ -O8=\_^(9V7_P"ZV3WI^/6TX=?2
M!Z=_YE%U9_XCC!_^ZRE]O=-="/[]U[KY"^_>G)?D3_-/WG\?H-P1[3G[T_F
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MJZ?)4V)QT]>D%#5TS3P2R5S1+#"REE+R+]1[U7K=.OF:5GR/_FW?SG?E+N#
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M/%?S-<A%_I&F3P49.=*MG!]RG[H=W]Y;>3=7P>#8;"1#?SBJO<R?&MI ?-W
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MJSC(\@5Q_ICUE[_>N>W%COW*&W<W0A3=65Y%:^,@#"6QO4E8 LIH569$:,Y
M\1Z?'ULY>\?^N G7O?NO=>]^Z]UHV=-1+W__ ,*[^SM[[5KJ+.8#J'/[@EW9
M6TLEQ"=J=2Q=>U$"M!&R>>AW,\%+,CE-)CE5W,HTNW^+IS\/6\G[<Z;Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I>=8_\?UM[_J(E_\
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M&ELBHE]6JO3;+IZUFO\ A*G_ -O1ZG_Q6G=W_N;M_P!U3CU=^'2/_P"%0_\
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M5IIY"T#I/3A&H5ZWT?;O3?7O?NO=>]^Z]U[W[KW6IS_)>_[+%JO_ !$.;_\
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z7G6/_'];>_ZB)?\
MW'F]U?AU9./1U/;/3W7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T&?;O\ QXN4_P"HBF_]R(_=
MDX]5?AT3OV]TSU[W[KW4/(8^@RU!78K*T-'D\7DZ.7'Y+&Y"))J>HIYD:.:"
M>&16CEAEC8JZ,"K*2K @D>_=>ZHC[:_X38_RH>U]XY3>D?36[NKZK,U9KJ_
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MJ#H+K"KP^V^[Z$8SN#*Y[+9+(9?<-,M'64$-/69*2I6>GIZ:ER-4L$5']M'
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M-023RL7ECO+$SL6C6&Y!E+EKW1N=C@%O/&)T04C.LHZ@<%)TN"H&!@$<*D4
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M"I% .J'W?/[S_>?:_:(MCYDV\[Q%:QK%:W27/T]XL:4"QREXIEF"J-*OV.
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M:QU[0>O?]!<G\M[_ )\G\W?_ $&]A_\ VR??M8Z]H/7O^@N3^6]_SY/YN_\
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M:QU[0>O?]!<G\M[_ )\G\W?_ $&]A_\ VR??M8Z]H/7O^@N3^6]_SY/YN_\
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M:QU[0>O?]!<G\M[_ )\G\W?_ $&]A_\ VR??M8Z]H/7O^@N3^6]_SY/YN_\
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M:QU[0>O?]!<G\M[_ )\G\W?_ $&]A_\ VR??M8Z]H/7O^@N3^6]_SY/YN_\
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M:QU[0>O?]!<G\M[_ )\G\W?_ $&]A_\ VR??M8Z]H/7O^@N3^6]_SY/YN_\
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M:QU[0>O?]!<G\M[_ )\G\W?_ $&]A_\ VR??M8Z]H/7O^@N3^6]_SY/YN_\
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M<7_>&GRM_P#1=[O_ /K/[]U[KW^R'_.+_O#3Y6_^B[W?_P#6?W[KW7O]D/\
MG%_WAI\K?_1=[O\ _K/[]U[KW^R'_.+_ +PT^5O_ *+O=_\ ]9_?NO=>_P!D
M/^<7_>&GRM_]%WN__P"L_OW7NO?[(?\ .+_O#3Y6_P#HN]W_ /UG]^Z]U[_9
M#_G%_P!X:?*W_P!%WN__ .L_OW7NO?[(?\XO^\-/E;_Z+O=__P!9_?NO=>_V
M0_YQ?]X:?*W_ -%WN_\ ^L_OW7NO?[(?\XO^\-/E;_Z+O=__ -9_?NO=>_V0
M_P"<7_>&GRM_]%WN_P#^L_OW7NO?[(?\XO\ O#3Y6_\ HN]W_P#UG]^Z]U[_
M &0_YQ?]X:?*W_T7>[__ *S^_=>Z]_LA_P XO^\-/E;_ .B[W?\ _6?W[KW7
MO]D/^<7_ 'AI\K?_ $7>[_\ ZS^_=>Z]_LA_SB_[PT^5O_HN]W__ %G]^Z]U
M[_9#_G%_WAI\K?\ T7>[_P#ZS^_=>Z]_LA_SB_[PT^5O_HN]W_\ UG]^Z]U[
M_9#_ )Q?]X:?*W_T7>[_ /ZS^_=>Z]_LA_SB_P"\-/E;_P"B[W?_ /6?W[KW
M7O\ 9#_G%_WAI\K?_1=[O_\ K/[]U[KW^R'_ #B_[PT^5O\ Z+O=_P#]9_?N
MO=>_V0_YQ?\ >&GRM_\ 1=[O_P#K/[]U[KW^R'_.+_O#3Y6_^B[W?_\ 6?W[
MKW7O]D/^<7_>&GRM_P#1=[O_ /K/[]U[KW^R'_.+_O#3Y6_^B[W?_P#6?W[K
MW7O]D/\ G%_WAI\K?_1=[O\ _K/[]U[KW^R'_.+_ +PT^5O_ *+O=_\ ]9_?
MNO=>_P!D/^<7_>&GRM_]%WN__P"L_OW7NO?[(?\ .+_O#3Y6_P#HN]W_ /UG
M]^Z]U[_9#_G%_P!X:?*W_P!%WN__ .L_OW7NO?[(?\XO^\-/E;_Z+O=__P!9
M_?NO=>_V0_YQ?]X:?*W_ -%WN_\ ^L_OW7NO?[(?\XO^\-/E;_Z+O=__ -9_
M?NO=>_V0_P"<7_>&GRM_]%WN_P#^L_OW7NO?[(?\XO\ O#3Y6_\ HN]W_P#U
MG]^Z]U[_ &0_YQ?]X:?*W_T7>[__ *S^_=>Z]_LA_P XO^\-/E;_ .B[W?\
M_6?W[KW7O]D/^<7_ 'AI\K?_ $7>[_\ ZS^_=>Z]_LA_SB_[PT^5O_HN]W__
M %G]^Z]U[_9#_G%_WAI\K?\ T7>[_P#ZS^_=>Z]_LA_SB_[PT^5O_HN]W_\
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MO=__ -9_?NO=>_V0_P"<7_>&GRM_]%WN_P#^L_OW7NO?[(?\XO\ O#3Y6_\
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M\-/E;_Z+O=__ -9_?NO=>_V0_P"<7_>&GRM_]%WN_P#^L_OW7NO?[(?\XO\
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M .L_OW7NO?[(?\XO^\-/E;_Z+O=__P!9_?NO=>_V0_YQ?]X:?*W_ -%WN_\
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MO_\ K/[]U[KW^R'_ #B_[PT^5O\ Z+O=_P#]9_?NO=>_V0_YQ?\ >&GRM_\
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MI\K?_1=[O_\ K/[]U[KW^R'_ #B_[PT^5O\ Z+O=_P#]9_?NO=>_V0_YQ?\
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M )Q?]X:?*W_T7>[_ /ZS^_=>Z]_LA_SB_P"\-/E;_P"B[W?_ /6?W[KW7O\
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M9_?NO=>_V0_YQ?\ >&GRM_\ 1=[O_P#K/[]U[KW^R'_.+_O#3Y6_^B[W?_\
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MXE=8)BGNO=$A_P"@@3^3/_WL&Z*_ZF97_P"MGOW7NO?]! G\F?\ [V#=%?\
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MJFHJS;YI(\PDDN3R]+XW$!AGI95K:>6:D*S'W7NJ]?\ H+._DJ?\_P!.TO\
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MF*JD@\YGEHJ?+4E,E:\,=-+-)!!))4QTZ-5/"M/:4^Z]T0/_ *"SOY*G_/\
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MV7V%EL1E<?(LU/4TM3V#V?-3U$$J$I+#-$ZNCJ2K*002#[]U[HGO\C#^7/\
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M5]=-204M%A<_O3,R4>:J9:J6$1P;?R5%'DIF1M9IJ:HC19998X9/=>ZV-/\
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MM535,1T"2*?>M;##D)/6Z-CJ3$/&(GDJ5?W7NMQOW[KW6H%_PM6_[=9=!_\
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M%9WR)W/\A9,'U9UM\T_CK14^U.W=QY...B$-?B\#6&KKQ4:304%9N;9DN)U
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M..W!@LC]DE7CJW['+XFIJ\?5_:9"DGI9O%*_BJ(987TR1NH]U[K52W'\BO\
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MAO+:G0'0^<WKM_Y1;(RL.8VAN+&)A:&EJW\JT5+%1RR9O*208QJ6JR=-E:&
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MG55\.J7;5'\Q=\R=2'Y>YK;&&I#7/VKOP97^"/N6OH8YZD4ZT_W"P%V5/$7
M!6_NO=;SU#WC\<N^?BOV]N#XN]S=-=W]:;2Z^W!U^VX^C=RX7=.'H*V@VX)S
MAY:_!UU?205M+CZRDE:F>03)!/3R,@26-F]U[K7#_P"$5/\ VZR[\_\ %_\
M=/\ [[KJKW[KW1,?Y#GRH^-?\OSY[?S]L'\P^].LNALWN7Y*4^:VWB.P,I#C
MY\D-L[F[2J<G18Q*HQ#)9=TW11+1XZE,U=7,*C[.GF6GD8>Z]T5?^3ILK.;<
M_P"$QO\ .TS]='3RX3<U3O6DP65HW\D%2V+V5A:6K,3E5UHKNC*PNK*ZF]]2
MK[KW547:?P&Z^Z5_DJ?RIOYM?5.P-OR]@93O/>FT_E"^ZZ7,;GQVXIZ'L?=E
M'LJ>MP==D)MO4&,I,5M27&UD*P8^"O:2C#5:5\H-7[KW6Q1_PHV[,V;W;WE_
MPF2[=V##%%L3M+N"MWWM6B6(0B''9;.=!5M-2O3:4^WDIH9Q%) RJT+HT3(K
M*5'NO=48?S+/Y?\ /_+R_G]= ]>;7Q%1C.B.WOEQL/O_ ** AI(:6''[BWMB
M/XEAZ-*2G@6*#;N2I7QL4<A>4TU/3U,KM)4LS>Z]U]7?W[KW6EA_PHD_[?<?
M\)S_ /Q:W:__ +]OKGW[KW3%_P *U-L[?WK\O?Y".S=V8B@W#M7=OR0WIMG<
MV RD8EI:['U^Y^CZ6MHZF)O3)!4TTKQR*>&1B#]??NO=%T_X4*?![XA?#/YQ
M?R)?]E4^.G5'0/\ I(^5N7_OY_HQQ-/B_P"+?P?=_37\+^^\ 'G^P_BE7X=7
MZ/N);?K/OW7NG3^:-A_B;G_^%9'Q2Q/SDFZ4@^+=7\4F_P!*$OR)KL5C=G#Q
M[)[3EPG\8K<W44N+AON)* 4GFE777?;1QZI6C4^Z]UN"_"+L_P#EVUG7\70G
M\O/MWXE;LZYZ?I9:[_1?\5]U[6SU%MR#-Y.OR4DT]!MS)5_\-BR>6J*R</*J
M+-.TY4LVJWNO=:QW_"VW_LAWXA?^+6S_ /O(9SW[KW1(OF5A?Y8?57\['^3E
M7?R@-Q=34^^]R]V8>C[=H/A=E*7,;5J,76YZFQD K*K;LU?B%:KI8Z^FRT,5
M0D46-6>?(Q1(S5!]U[HU<?='6W\MS_A6?\B-T?(63!=5]:_-/XZ4=-M7MW<F
M3CCHA#7XS UGW=>*C2<?05FYMF38G4#X5GH(YV81FH>G]U[I7_RE-T;<^<?_
M  I4_F@?.SJC$19SI+8?5D/46,[7I,@9(LCDH(MJ[6QABH1;32YK#[6JJB!W
M53'%C4U+]Q45 C]U[KG_ "UO^XOC^;Q_XJEEO_=ST3[]U[KW_"VW_LAWXA?^
M+6S_ /O(9SW[KW2M_P"%A'6^[,-U+_+S^:VT:*HJ*[XB_**I%161QU\L5&FX
M4PF9@J:LT-)6K24BUVQ8%>JGC"(S)#&S5%1#3S^Z]T4#^?[\L.@/YPW:G\G[
MX3_$+LC$=R4O=7:])VUV50[1^\J)\)BMQ?PK#XO^)BGI"*&LI:";-M70S5--
M-CQ'$]3&D4PGA]U[I+?SK/B/3?.'_A0%V3\=H\*^=W7N7^4SFMP]94=/4FBG
M.Z\#BMV9G;L<-:L<K4HK,G114<[:)$>EJ)X9HY8)9(G]U[K5A[)^(N7VO_*S
MV_\ -WL:ER1WYVY\YO\ 0-M&7*PA?%@]J;)R4^4GHJO7(U;0Y+)3TD*:6-)3
MG$^*A2-#*&]U[K[5'OW7NOG4_P M/^5_\/?YE_\ .F_GLX?Y=;$SF^\7TO\
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M^:S49*&>GR,^1Z9FKX*HSM(DS2]O-*DC5+R5)=7)#&5VD)!ULS7)]U[JYO\
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M#;HSUTJTTBQ@M0$T!8$T!-. /5"7_01U\1_^?,?(W_SDVS_]DON6/]9K<_\
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MWIJ^K33IU<&K3%??/'^8[U'_ "_?]%?^E/9?8^[_ /2W_'/X%_H_AQDOV_\
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M:I5F_%&@IVGS_+J.?O!?<.YH^[GL']8MWOMKN(#<PVOAV<EVTWB3+(RFDUI
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M#:69=0-F(Y]Q/(AB8J?(D?L-.N8W,&SR<NW]SM\K*SVMQ-;NR5TLT,C1DK4
MT)4D5 -.('5)79O\_P"^+75G9/8/6.;ZC[^K\UUSOC+;#R]=BJ7;K4LU5B*^
MHQ]1+3--N&&5J>26G9HR\:.4(U(IN!)MA[3;CN,$=PDML%EC210SRZ@KJ&%:
M1$5H<T)^WKHKR;_==\Z\[;18[S;;GLB0W]G;7L22RWXD2.ZA2=%<)8.H<+(
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M^[?WW=V%U^\_K/!^A>X?1]%]+K\3ZBWMZ:OJTTZ=7!JTQ7WSQ_F.]1_R_?\
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M=\Z\[;18[S;;GLB0W]G;7L22RWXD2.ZA2=%<)8.H<+( P5F%:T)&>AX^&?\
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MIXK2N:5Z_P#01U\1_P#GS'R-_P#.3;/_ -DOL6_ZS6Y_[]M?][E_ZT]94?\
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M9OQ1H*=I\_RZC/[P7W#N:/NY[!_6+=[[:[B W,-KX=G)=M-XDRR,II-:0+I
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MZ3]Y?N2[L+7]V?1^-]<]PFOZWZK1X?T]O<5T_2/JU:>*TKFE>O\ T$=?$?\
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M[JX/XF?)K9WS Z*VEW[L'![FVYM;>%7DJ/'XC=Z4L>0C;%Y*KQ<QF2BJJRG
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MD*0M$.:5H,]5$?\ 01U\1_\ GS'R-_\ .3;/_P!DON0_]9K<_P#?MK_O<O\
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MSP?H7N'T?1?2Z_$^HM[>FKZM-.G5P:M,5]\\?YCO4?\ +]_T5_Z4]E]C[O\
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M?32QZ]'B/HU5TZVTTU&H5_[(M\)/^\.?BO\ ^B]VE_\ 6CVO_K5NG_*9=?\
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MPY^*_P#Z+W:7_P!:/9M_6K=/^4RZ_P"RB7_H/J3O^"4]QO\ IJN9/^YYN?\
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M]15UE95U&+DGJJNJGD>2661VDDD9G=F9B2<Q<R;C H1+JY55 556>4*J@4
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MFECUZ/$?1JKIUMIIJ-0K_P!D6^$G_>'/Q7_]%[M+_P"M'M?_ %JW3_E,NO\
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MZ.NI&96HPJI*FH)'0"?[(M\)/^\.?BO_ .B]VE_]:/9M_6K=/^4RZ_[*)?\
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M"JDJ:@D= )_LBWPD_P"\.?BO_P"B]VE_]:/9M_6K=/\ E,NO^RB7_H/J3O\
M@E/<;_IJN9/^YYN?_;5T/>Q]@;$ZQVU0[,ZUV5M+KW9^+>:7&;4V/C:/$XVG
M:HF>HJ&@H*"&GI86GJ)7ED*("\CL[79B24W5W+>N99G>1S2KNQ=C0 "I8DF@
M  ^0IU&/,G-&Y\Y7C[AN]W=7UU($$ES>3RW-Q($18U#2S.[MI155:L:* HH
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MAS\5_P#T7NTO_K1[-OZU;I_RF77_ &42_P#0?4G?\$I[C?\ 35<R?]SS<_\
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MX?8FUJ6LHZREE6>FJJ6I@Q234]33S(LD4L;*\;JK*P8 ^WY>9=QG4H]U<LK
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M !PZEG;_ +PG/VTV\5K:\R\P0P0QI%##%O.XQQ111J$1$1+D*B(H"JJ@*J@
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MH!GY#H5<K>\?-W(UK]#LF^;QM]MK:3Z>QW.]M(/$< ,_AP3QIJ8**M2IH*G
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M%YI=&GR/=!?;K=;GI^IFEETUT^+(\FFM*TU$TK05IQH/3H%<X>Y7,?N'X/\
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M:/$XVG:HF>HJ&@H*"&GI86GJ)7ED*("\CL[79B24W5W+>N99G>1S2KNQ=C0
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ME2:%VCDC97CD1BCHZ$,K*RD%64@$$$$$5&>BQ_[(M\)/^\.?BO\ ^B]VE_\
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M7=KN&S7EU872!E2YLKB:UG574JP62!T<!E)# -0@T..@(_V1;X2?]X<_%?\
M]%[M+_ZT>S;^M6Z?\IEU_P!E$O\ T'U)G_!*>XW_ $U7,G_<\W/_ +:NA[V/
ML#8G6.VJ'9G6NRMI=>[/Q;S2XS:FQ\;1XG&T[5$SU%0T%!00T]+"T]1*\LA1
M 7D=G:[,22FZNY;US+,[R.:5=V+L:  5+$DT  'R%.HQYDYHW/G*\?<-WN[J
M^NI @DN;R>6YN) B+&H:69W=M**JK5C10%%  .@\[!^,?QM[:S_]Z^U?CWT?
MV9NG[&/&?WE[!VG@<SD/MH2YAI_O,E05-1X(C(Q2/7H4LQ4"YNKL][O-N3P[
M>>:)2=16.5T4D@"M%8"M ,_(="KE;WCYNY&M?H=DWS>-OMM;2?3V.YWMI!XC
M@!G\.">--3!15J5-!4X'29P_PN^'>W<OBMP;?^)WQIP6>P62@S&$S>'V)M:E
MK*.LI95GIJJEJ8,4DU/4T\R+)%+&RO&ZJRL& /M^7F7<9U*/=7+*P*LK3RE6
M4BA!!:A!&"#QZ.=P^\)S]NUO+:W7,O,$T$T;Q30R[SN,D4L4BE'1T>Y*NCJ2
MK*P*LI(((/1BLACZ#+T%=BLK0T>3Q>3HY<?DL;D(DFIZBGF1HYH)X9%:.6&6
M-BKHP*LI*L""1[)@2IJ,$<#U$UK=2V,J30NT<D;*\<B,4='0AE964@JRD @@
M@@BHST6/_9%OA)_WAS\5_P#T7NTO_K1[/?ZU;I_RF77_ &42_P#0?4R?\$I[
MC?\ 35<R?]SS<_\ MJZ%3K/HKI'I7^-_Z'.G.J^I?[R_;?WC_P!&>WL1@?XA
M]G]Q]G][_"J.E^Z^T^[G\/EU>+S2Z-/D>Z"^W6ZW/3]3-++IKI\61Y--:5IJ
M)I6@K3C0>G0*YP]RN8_</P?ZP;KN6Y_3^)X'[POKJ]\#Q='B>']3+)HU^&FO
M335H7572*>[,Z*Z1[J_@G^F/ISJOMK^[7W/]W/\ 29M[$9[^'_>?;_>?9?Q6
MCJOM?N_M(/-XM/E\,6O5XTMZQW6ZVS5]--+%JIJ\*1X]5*TKI(K2II7A4^O7
MN3_<KF/V\\;^K^Z[EMGU'A^/^[[ZZLO'\+7X?B?32QZ]'B/HU5TZVTTU&H5_
M[(M\)/\ O#GXK_\ HO=I?_6CVO\ ZU;I_P IEU_V42_]!]#7_@E/<;_IJN9/
M^YYN?_;5T9S'X^@Q%!0XK%4-'C,7C*.+'XW&X^)(:>GIX46.&""&-5CBABC4
M*B* JJ J@  >R(DL:G)/$]0W=74M]*\TSM))(S/)([%W=W)9F9F)+,Q)))))
M)J<]%US'PN^'>XLOE=P;@^)WQISN>SN2GS&;S>8V)M:JK*RLJI6GJ:JJJ9\4
M\U14U$SM)++(S/([,S,6)/LYBYEW&!0B75RJJ JJL\H55 H  &H !@ <.I9V
M_P"\)S]M-O%:VO,O,$,$,:10PQ;SN,<444:A$1$2Y"HB* JJH"JH   '2FZ^
M^,?QMZES_P#>OJKX]]']9[I^QDQG]Y>OMIX'#9#[:8H9J?[S&T%-4>"4QJ7C
MUZ&*J6!L+,7F]WFXIX=Q/-*H.H+)*[J" 16C,16A.?F>B;FGWCYNYYM?H=[W
MS>-PMM:R?3WVYWMW!XB A7\.>>1-2AC1J5%30Y/2_P!]]=]?]I;<J=G]G;%V
M=V-M&MGBJJS:V^\919?'2RP.)8)):'(05%-))#(H>-F0E& 92"+^TEK=RV+B
M6%WC<5HZ,485%#0J014&A^707Y9YKW3DN[7<-FO+JPND#*ES97$UK.JNI5@L
MD#HX#*2& :A!H<= 1_LBWPD_[PY^*_\ Z+W:7_UH]FW]:MT_Y3+K_LHE_P"@
M^I,_X)3W&_Z:KF3_ +GFY_\ ;5T/>Q]@;$ZQVU0[,ZUV5M+KW9^+>:7&;4V/
MC:/$XVG:HF>HJ&@H*"&GI86GJ)7ED*("\CL[79B24W5W+>N99G>1S2KNQ=C0
M "I8DF@  ^0IU&/,G-&Y\Y7C[AN]W=7UU($$ES>3RW-Q($18U#2S.[MI155:
ML:* HH !T'G8/QC^-O;6?_O7VK\>^C^S-T_8QXS^\O8.T\#F<A]M"7,-/]YD
MJ"IJ/!$9&*1Z]"EF*@7-U=GO=YMR>';SS1*3J*QRNBDD 5HK 5H!GY#H5<K>
M\?-W(UK]#LF^;QM]MK:3Z>QW.]M(/$< ,_AP3QIJ8**M2IH*G Z3.'^%WP[V
M[E\5N#;_ ,3OC3@L]@LE!F,)F\/L3:U+64=92RK/355+4P8I)J>IIYD62*6-
ME>-U5E8, ?;\O,NXSJ4>ZN65@596GE*LI%"""U"",$'CT<[A]X3G[=K>6UNN
M9>8)H)HWBFAEWG<9(I8I%*.CH]R5='4E65@592000>C%9#'T&7H*[%96AH\G
MB\G1RX_)8W(1)-3U%/,C1S03PR*T<L,L;%71@59258$$CV3 E348(X'J)K6Z
MEL94FA=HY(V5XY$8HZ.A#*RLI!5E(!!!!!%1GHL?^R+?"3_O#GXK_P#HO=I?
M_6CV>_UJW3_E,NO^RB7_ *#ZF3_@E/<;_IJN9/\ N>;G_P!M70J=9]%=(]*_
MQO\ T.=.=5]2_P!Y?MO[Q_Z,]O8C _Q#[/[C[/[W^%4=+]U]I]W/X?+J\7FE
MT:?(]T%]NMUN>GZF:67373XLCR::TK3432M!6G&@].@5SA[E<Q^X?@_U@W7<
MMS^G\3P/WA?75[X'BZ/$\/ZF631K\-->FFK0NJND4]V9T5TCW5_!/],?3G5?
M;7]VON?[N?Z3-O8C/?P_[S[?[S[+^*T=5]K]W]I!YO%I\OABUZO&EO6.ZW6V
M:OIII8M5-7A2/'JI6E=)%:5-*\*GUZ]R?[E<Q^WGC?U?W7<ML^H\/Q_W??75
MEX_A:_#\3Z:6/7H\1]&JNG6VFFHU"O\ V1;X2?\ >'/Q7_\ 1>[2_P#K1[7_
M -:MT_Y3+K_LHE_Z#Z&O_!*>XW_35<R?]SS<_P#MJZ,YC\?08B@H<5BJ&CQF
M+QE'%C\;C<?$D-/3T\*+'#!!#&JQQ0Q1J%1% 55 50  /9$26-3DGB>H;NKJ
M6^E>:9VDDD9GDD=B[N[DLS,S$EF8DDDDDDU.>BZYCX7?#O<67RNX-P?$[XTY
MW/9W)3YC-YO,;$VM55E9654K3U-555,^*>:HJ:B9VDEED9GD=F9F+$GV<Q<R
M[C H1+JY55 556>4*J@4  #4  P .'4L[?\ >$Y^VFWBM;7F7F"&"&-(H88M
MYW&.***-0B(B)<A41% 554!54   #I3=??&/XV]2Y_\ O7U5\>^C^L]T_8R8
MS^\O7VT\#ALA]M,4,U/]YC:"FJ/!*8U+QZ]#%5+ V%F+S>[S<4\.XGFE4'4%
MDE=U! (K1F(K0G/S/1-S3[Q\W<\VOT.][YO&X6VM9/I[[<[V[@\1 0K^'//(
MFI0QHU*BIH<GI?[[Z[Z_[2VY4[/[.V+L[L;:-;/%55FUM]XRBR^.EE@<2P22
MT.0@J*:22&10\;,A*, RD$7]I+6[EL7$L+O&XK1T8HPJ*&A4@BH-#\N@ORSS
M7NG)=VNX;->75A=(&5+FRN)K6=5=2K!9('1P&4D, U"#0XZ C_9%OA)_WAS\
M5_\ T7NTO_K1[-OZU;I_RF77_91+_P!!]29_P2GN-_TU7,G_ '/-S_[:NA[V
M/L#8G6.VJ'9G6NRMI=>[/Q;S2XS:FQ\;1XG&T[5$SU%0T%!00T]+"T]1*\LA
M1 7D=G:[,22FZNY;US+,[R.:5=V+L:  5+$DT  'R%.HQYDYHW/G*\?<-WN[
MJ^NI @DN;R>6YN) B+&H:69W=M**JK5C10%%  .@\[!^,?QM[:S_ />OM7X]
M]']F;I^QCQG]Y>P=IX',Y#[:$N8:?[S)4%34>"(R,4CUZ%+,5 N;J[/>[S;D
M\.WGFB4G45CE=%)( K16 K0#/R'0JY6]X^;N1K7Z'9-\WC;[;6TGT]CN=[:0
M>(X 9_#@GC34P45:E305.!TG,%\,_A_M?-X;<VV?BE\;-N[DV[E:?.[?W!@M
MB[7I*Z@KJ29*BDK*.KI\7'/2U=+/&DD4L;K)'(JNC*R@A^7F3<9U*/=7+*P*
MLK3RE64BA!!:A!&"#@CHWW/[P7/N]6TMG><R[_/;SQR0SP3;SN,L,T,JE'CD
M1[EE='5BKHP*LI(((/1A\ACZ#+T%=BLK0T>3Q>3HY<?DL;D(DFIZBGF1HYH)
MX9%:.6&6-BKHP*LI*L""1[)@2IJ,$<#U%%K=2V,J30NT<D;*\<B,4='0AE96
M4@JRD @@@@BHST6/_9%OA)_WAS\5_P#T7NTO_K1[/?ZU;I_RF77_ &42_P#0
M?4R?\$I[C?\ 35<R?]SS<_\ MJZ%3K/HKI'I7^-_Z'.G.J^I?[R_;?WC_P!&
M>WL1@?XA]G]Q]G][_"J.E^Z^T^[G\/EU>+S2Z-/D>Z"^W6ZW/3]3-++IKI\6
M1Y--:5IJ)I6@K3C0>G0*YP]RN8_</P?ZP;KN6Y_3^)X'[POKJ]\#Q='B>']3
M+)HU^&FO335H7572*>[,Z*Z1[J_@G^F/ISJOMK^[7W/]W/\ 29M[$9[^'_>?
M;_>?9?Q6CJOM?N_M(/-XM/E\,6O5XTMZQW6ZVS5]--+%JIJ\*1X]5*TKI(K2
MII7A4^O7N3_<KF/V\\;^K^Z[EMGU'A^/^[[ZZLO'\+7X?B?32QZ]'B/HU5TZ
MVTTU&H5_[(M\)/\ O#GXK_\ HO=I?_6CVO\ ZU;I_P IEU_V42_]!]#7_@E/
M<;_IJN9/^YYN?_;5T9S'X^@Q%!0XK%4-'C,7C*.+'XW&X^)(:>GIX46.&""&
M-5CBABC4*B* JJ J@  >R(DL:G)/$]0W=74M]*\TSM))(S/)([%W=W)9F9F)
M+,Q))))))J<]%US'PN^'>XLOE=P;@^)WQISN>SN2GS&;S>8V)M:JK*RLJI6G
MJ:JJJ9\4\U14U$SM)++(S/([,S,6)/LYBYEW&!0B75RJJ JJL\H55 H  &H
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M7<ML^H\/Q_W??75EX_A:_#\3Z:6/7H\1]&JNG6VFFHU"O_9%OA)_WAS\5_\
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MQZ]'B/HU5TZVTTU&H5_[(M\)/^\.?BO_ .B]VE_]:/:_^M6Z?\IEU_V42_\
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M ,[2H_\ .:H_Z]^[:#U76.O?Z7=B_P#.TJ/_ #FJ/^O?OV@]>UCKW^EW8O\
MSM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.
MTJ/_ #FJ/^O?OV@]>UCKW^EW8O\ SM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2
MH_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_ #FJ/^O?OV@]>UCKW^EW8O\ SM*C
M_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_
M #FJ/^O?OV@]>UCKW^EW8O\ SM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\
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M ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_ #FJ/^O?OV@]>UCKW^EW8O\
MSM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.
MTJ/_ #FJ/^O?OV@]>UCKW^EW8O\ SM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2
MH_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_ #FJ/^O?OV@]>UCKW^EW8O\ SM*C
M_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_
M #FJ/^O?OV@]>UCKW^EW8O\ SM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\
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M ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_ #FJ/^O?OV@]>UCKW^EW8O\
MSM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.
MTJ/_ #FJ/^O?OV@]>UCKW^EW8O\ SM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2
MH_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_ #FJ/^O?OV@]>UCKW^EW8O\ SM*C
M_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_
M #FJ/^O?OV@]>UCKW^EW8O\ SM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\
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M ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_ #FJ/^O?OV@]>UCKW^EW8O\
MSM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.
MTJ/_ #FJ/^O?OV@]>UCKW^EW8O\ SM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2
MH_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_ #FJ/^O?OV@]>UCKW^EW8O\ SM*C
M_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_
M #FJ/^O?OV@]>UCKW^EW8O\ SM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\
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M ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_ #FJ/^O?OV@]>UCKW^EW8O\
MSM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.
MTJ/_ #FJ/^O?OV@]>UCKW^EW8O\ SM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2
MH_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_ #FJ/^O?OV@]>UCKW^EW8O\ SM*C
M_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_
M #FJ/^O?OV@]>UCKW^EW8O\ SM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\
M.:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_ #FJ/^O?OV@]>UCKW^EW8O\ SM*C_P Y
MJC_KW[]H/7M8Z]_I=V+_ ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_ #FJ
M/^O?OV@]>UCKW^EW8O\ SM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\ .:H_
MZ]^_:#U[6.O?Z7=B_P#.TJ/_ #FJ/^O?OV@]>UCKW^EW8O\ SM*C_P YJC_K
MW[]H/7M8Z]_I=V+_ ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_ #FJ/^O?
MOV@]>UCKW^EW8O\ SM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\ .:H_Z]^_
M:#U[6.O?Z7=B_P#.TJ/_ #FJ/^O?OV@]>UCKW^EW8O\ SM*C_P YJC_KW[]H
M/7M8Z]_I=V+_ ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_ #FJ/^O?OV@]
M>UCKW^EW8O\ SM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\ .:H_Z]^_:#U[
M6.O?Z7=B_P#.TJ/_ #FJ/^O?OV@]>UCKW^EW8O\ SM*C_P YJC_KW[]H/7M8
MZ]_I=V+_ ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_ #FJ/^O?OV@]>UCK
MW^EW8O\ SM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\ .:H_Z]^_:#U[6.O?
MZ7=B_P#.TJ/_ #FJ/^O?OV@]>UCKW^EW8O\ SM*C_P YJC_KW[]H/7M8Z]_I
M=V+_ ,[2H_\ .:H_Z]^_:#U[6.O?Z7=B_P#.TJ/_ #FJ/^O?OV@]>UCKW^EW
M8O\ SM*C_P YJC_KW[]H/7M8Z]_I=V+_ ,[2H_\ .:H_Z]^_:#U[6.IV,[,V
M?EZ^EQM#D)Y:RLE\-/&T$R@L038LR!1]/R??BI'7@P/2^]UZMU[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6NI_P *L?\ MR!\
MI_\ P[>N?_?B;8]^Z]U\C+W[KW7O?NO=>]^Z]U[W[KW7O?NO=&6^%_\ V6)\
M3_\ Q9;8G_O4XKWL<>M'AU]E+V_TQU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]TL^O/^/VVY_VL5_Z%;W5^'5DX]'=]L]/=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UKJ?\
M*L?^W('RG_\ #MZY_P#?B;8]^Z]U\C+W[KW7O?NO=?0'_P"$\W_">_\ E[_-
M7^6AM#Y1_,7J#<O9?8?</96[9]F9O'[JW/@(Z#;V$R3;7@I(*3!YB@HZATS.
M$R-09ZB%Y&:81,3%$B^_=>ZT6/D+T[F?COW[WC\?]QUB9#</1G<&YNG<]7QQ
M&!9ZW;.:K<+53+ 9)3")9Z)F"%W*7TZVM<^Z]T#_ +]U[HRWPO\ ^RQ/B?\
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MXJ*&;[>6KP57!61+( "4:2GDD17 (-B;V(-O?NO=/?OW7NM/[_A1/\Y?GO\
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M=6L&^C _0CW[KW3?E=^[&P5%6Y+-[SVGAL=C1JR.0RN1HZ>"G -B9I9IDCB
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M;;CU?_[OU7I'1]B=?S9A=O1;ZV=+GWJOLDP<>3HFK#-_QQ%,)S,9?]HTZO\
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MA-'$]0-OT$+3-)$_VU96(AU^/WLC2*=>4ZCUKW]G=)]5_!KI;XC_ #%^+/\
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MWO;<!U5./6V]\1/^R3_C!_XKQLK_ -YK&>[CAU3JD7_A5!_VZPK/_%A]G_\
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MIOFWO;^8#M"B[!B^0W8-=FJ_<E9D,R9\1(V?B\->L6,-,JQ)I"^/3)="HNS
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MW/\ -+K/Y[[VHM^R_('J5<.FSJS&9AJ?$QK@Y:J:A6?&"G99QKK)?(2X+A@
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M\5E%SFWJAIJFAR.+K%*$U&.R5#-3UE-Y?&BSQ!S3U**L=3#-& OO9%>M TZ
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M&:_\Y9_^O?OU1UZAZ]_=O<7_ #H,U_YRS_\ 7OWZHZ]0]>_NWN+_ )T&:_\
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MNWN+_G09K_SEG_Z]^_5'7J'KW]V]Q?\ .@S7_G+/_P!>_?JCKU#U[^[>XO\
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M9_\ KW[]4=>H>O?W;W%_SH,U_P"<L_\ U[]^J.O4/7O[M[B_YT&:_P#.6?\
MZ]^_5'7J'KW]V]Q?\Z#-?^<L_P#U[]^J.O4/7O[M[B_YT&:_\Y9_^O?OU1UZ
MAZ]_=O<7_.@S7_G+/_U[]^J.O4/7O[M[B_YT&:_\Y9_^O?OU1UZAZBUVS<MD
MZ*LQN1VMDJ['Y"EDHJZBJZ*62*:&5#'+%+&T95XY$8JRD$$$@BQ]^J.O4/4;
M"[ J-MXG'8#;NR9\!@L12)C\3A<+C6I:2E@C&F."GIH(8X8(8U%E1%55'  '
MOU1UZAZ<_P"[>XO^=!FO_.6?_KW[]4=>H>O?W;W%_P Z#-?^<L__ %[]^J.O
M4/7O[M[B_P"=!FO_ #EG_P"O?OU1UZAZ]_=O<7_.@S7_ )RS_P#7OWZHZ]0]
M>_NWN+_G09K_ ,Y9_P#KW[]4=>H>O?W;W%_SH,U_YRS_ /7OWZHZ]0]>_NWN
M+_G09K_SEG_Z]^_5'7J'KW]V]Q?\Z#-?^<L__7OWZHZ]0]>_NWN+_G09K_SE
MG_Z]^_5'7J'KW]V]Q?\ .@S7_G+/_P!>_?JCKU#U[^[>XO\ G09K_P Y9_\
MKW[]4=>H>O?W;W%_SH,U_P"<L_\ U[]^J.O4/7O[M[B_YT&:_P#.6?\ Z]^_
M5'7J'KW]V]Q?\Z#-?^<L_P#U[]^J.O4/7O[M[B_YT&:_\Y9_^O?OU1UZAZ]_
M=O<7_.@S7_G+/_U[]^J.O4/7O[M[B_YT&:_\Y9_^O?OU1UZAZ]_=O<7_ #H,
MU_YRS_\ 7OWZHZ]0]>_NWN+_ )T&:_\ .6?_ *]^_5'7J'KW]V]Q?\Z#-?\
MG+/_ ->_?JCKU#U[^[>XO^=!FO\ SEG_ .O?OU1UZAZ]_=O<7_.@S7_G+/\
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M7_G+/_U[]^J.O4/7O[M[B_YT&:_\Y9_^O?OU1UZAZ]_=O<7_ #H,U_YRS_\
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M&:_\Y9_^O?OU1UZAZ]_=O<7_ #H,U_YRS_\ 7OWZHZ]0]>_NWN+_ )T&:_\
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M@%5]WCFH<C-1XVNI,5CFJ<?7XO+B-(ZY/N(I(*01*&DJQ[]U[JO'^7G\^/\
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MCL/9.ZJZFJH3E*ZH?#4F"$$DRK"SG;^VZNKR,*ZS3U%12(DAB-Y/=>ZVWO\
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M)2QFGH]EU-#3TV0J\@DDN3CQ])CJAZN>*H:*F?W7NCA?%G^<W@?D!\,_G?\
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M6N'JONZ:(KI44U6U)COO5Q]-[KW1N?YL'_=JE_XOIT7_ /*%[]U[H<<]WO\
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M3*5L,]#A9I*173+[;>NRT1DET&G6&:IK=6)6C--D?=>Z&;^2I_V^/_X4G_\
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MXW;]S&Q\9V3CJ&D-%1T&]J;#E*BNA@A$7[M%44%5*8(1/42QJ4;W7N@FR_\
MPG:_E^S? C?_ /+BV?7=^]9_'GL;Y$0?)O.3[0W)0U6X(MQ08_%8M(J7)[CP
M>?@CQAHL-2HT+TLDMU9Q.&=B?=>ZN9[;ZFZX[WZSWSTWV]M##;^ZR[)VW5;1
MWOL[<$?EI,ACZR,QSP2K<,IL=2.A62*15DC=)$5A[KW52/QA_D&?!OXI]T=<
M=U;*W1\K-ZUG1N:FSOQXZY[6[,W#F-H]?2U&+;$3Q[7PB24BK3S4<TX>/(2Y
M -]Q*AO$(8XO=>Z8OD9_PGJ^!GR5[@[*[>W+NGY9[#7O;=\F]_D5U;U9V=G\
M9L_L&NDA$)_O1AJDY!V@0JKQQX^HQXB*+'%H@'A]^Z]U<EU9U?L#I+K;8G4'
M56U<5LCK;K/:E#LG8VT<(GCI<?C,=3I2T=+""68B.&, N[-)(UWD9G9F/NO=
M5M?.?^3-\._GOV?@N]=_U?=?3'?>%VTFQ:KN[XQ[KJ=G;CRNW1.LLNWLS4PT
M]92Y/&5,8>G?RTYJ4II7C@J(;1LGNO=#%L#^67\3>H?@9V5_+FZ:VAENI_CQ
MVMU/NWJ;=DFT:M9-PRQ;UPU7A,[G&RV6I\F*K<4M+6%HZJL@J8HVB@C^W:EA
M2G'NO=#?\0/B[L#X4_&?ISXJ]69C>.?Z]Z1VBFS-J9GL"HHJK,U%*D\TXDR%
M1CL?BJ&6HUSL"T-) E@/1>Y/NO=!%OG^7MTQV/\ /_I7^8QN_<_9^6[A^/?3
M^6Z>ZGV%+68C^YN*BSG\3CRN>BQYPAS/]XZRBRTU')4#*BG-*(H_M-2:S[KW
M4;Y!_P NWI;Y'?,#X=?-O=6Z^U-J]R?":?<1ZSI]B5N'I\1EZ?<U+%1Y&AW-
M3Y#!9.NK*1:9)4A6BJ\?(@JJ@M(Y:,Q^Z]UF^+_\O+I;XF?);YO?*?KG<_:&
M:[!^>^\MN;X[@P^]:W$U.&QM7MB//1T$>VJ>APF-KJ.GF7<-3]PM;5Y!W*0>
M.2+3()/=>Z;/@K_+<Z-_E['Y-T'1NZ.T\MM#Y2=]9;Y$;HZ]["J\+683;^:S
M>I*^DVO3XW 8BHI,3)2K34PAKI\A*(**E4U!997E]U[JO*3_ (3(?RN&[=KM
M^P[<[QH>HLIOH=I93X6X_>57!TS4;F%8M4,U)L^.E%1Y%B1*):)<@N*3'HE$
ME L"A??NO=6/=:_R[^DNL?GEWG_,2Q^X>RMQ=Z]Y]287HV?#;HJL/)MO:^U\
M(N+*8K:5#18.AR./I\A58>FJZT55?7"2I5GC$*MH'NO=8Y?Y=O2Q_F,4W\SB
MBW7VIB>^%^.Y^,V7VACJW#KM#)X#^(29):FOH),%+FGRT=28=,L65B@T4E,I
MICID,ONO='7W;M/;6_-K;DV/O3!8O=&S]XX&KVONK;6;A2HH\ACJ^GDI:VBJ
MX) 4FIJJFE>.1&!#(Q!X/OW7NJ3/CA_PG=_EU_&#O/K[NS8]-W_NG']*[BFW
ME\?>B^T]]93</7^P,S5-4R567VQ@*Q/.N0J9JD3/)D:S(::F&"KC6.JC\Q]U
M[I2_+K^05\!_F)W9O#OO=G^GCJ/>O;-/!COD%0?'C>5;M3#]DT-/3R4Z4.]L
M7!!4T^1A975I9*?[.IG>*,S3R R"3W7NAI^2/\H3XA?([XQ_%SXA-1[ZZ3Z,
M^('=FV.]>G-L]'5F,H'BR>U*+-T5!19";.8?<'WF.K!N"JGKF"QU]55$5#5R
MNTQE]U[H5.V/Y>72W<7SR^*W\P[<VY^T*'NGXA[-W1L?K;;&"K<3%M>NI-VX
MC,87(R9RBJ,)59:IJ(*7-SM3-2Y*C1)4B:6.9%=)/=>Z!_!_RA_C9@,S_-.S
ME'O?O"2K_FZ[1?9GR1CJ<E@3'A*5\#NO;QDV.%VTC8VH^RWA6.&RC9E//%2M
MH\:2QS>Z]TC>W?Y)_P 5^Z/Y:/5O\J[=&_\ Y T'Q\ZDDPTNV]XX#*[<BWE.
M<'5U=92??9"HVI582022UKB;Q8F'4H0)XR"S>Z]T9+MC^7ETMW%\\OBM_,.W
M-N?M"A[I^(>S=T;'ZVVQ@JW$Q;7KJ3=N(S&%R,F<HJC"566J:B"ES<[4S4N2
MHT25(FECF1723W7NB8?*3_A/G_+X^5O=V^^]=S0=\]5YSN>K@JOD7LOH/>M?
MM;;'97VT<RQ)O/#4T,T=8/++]P\E')0S2U*^>65WEJ#-[KW1C?E1_*;^*/RK
M^.7QA^*F4AWSTUTM\1>Y]I]W=.;:Z,J<3C?MZ[9F-S&*Q&,JVS&%ST<^'DI\
MW.U4J)%633+'+]ZC>7R^Z]T(7;'\O+I;N+YY?%;^8=N;<_:%#W3\0]F[HV/U
MMMC!5N)BVO74F[<1F,+D9,Y15&$JLM4U$%+FYVIFI<E1HDJ1-+',BNDGNO=&
MX[.ZWV=W%USOKJ?L3%2YW8796TLAL;>F$AJJRA:LQ>4I9:.OI?NZ">EK:<5%
M-,\9>&:.0!CI<'W[KW50OQ<_D#? WXI=_;#^0^U:_P"1?9VY>EH9*3XY;-[W
MWUDMT[:ZTIYJ&.@FI]EXNJBC>BBDBC##[R>N:&32U.T0BA6/W7NA?H_Y/'Q-
MP_\ ,'S_ /,CVUFN]MI]T;TGI,OV%U]MK=M33;!W)F<?2QT>-SN>VV*=I,A7
MXZ",FFA:K&.BJ':M%#]]HJ5]U[I.?-_^29\+OG;V[3_(#?%3WATMWE/M>+8&
M[^UOC)NRIV=E]S;;CEB:7;VY6BIZRDRN,JJ>(4LQ:!:LTNF%*I!#3F'W7NC$
M;5_EG_";9OPCR/\ +LPO1V!3XE9K:M7M//=:U%16O)7+73?=U61JLN*E<L^<
M>N"U:9):A:R&JCBG@FB>&(I[KW17_A'_ ",?A'\$>YZ#OWKNO[\[5[(VAM.H
MZ[Z:R/R'WC5;JINO=M544,,FWMDT4E-1TV)QRQQ.D;RK55D4514P1U2P3O$?
M=>Z[V5_([^'6S/A%\P?@+)G^Z=W]*?-7NO/]_P#9>5WCD=OU&?Q.X\ZFW2M1
MMFKIML4>-HH\+6;7H*S&BLH*^2*J1FGEJ8RL2^Z]U9IT+U%0= =)=3='8G>6
M_>PL1U#UYB.M\1O;M*LI\CN/)TF&H8<?2U>;R%)18ZGKLG+3P(9ZA::'S27D
M9=;,3[KW5=?R5^$_;>-_F*?%_P#F/?$JFVC4=A4^('Q;^9NPMY9:IQ%#NGJ3
M(U,E=#F:*6&DKX7W9L;,B.LHXF@C.3IB:&:LAC@@'OW7NA+QG\KKH#%?+'YQ
M_,6GW?W"_9OS^Z;Q?2'<>"FR&%."QN)Q&VL;M:FJ-LTJ[?7(4>1?'XN*262N
MK<C":AI'6!(RL2>Z]T$G_#*GQ8_X:>_X9U_O]\@/]EE_Y[G^*[<_OW_S,G_2
ME_Q<_P"ZO]W_ /CX/\G_ .++_P 6_P#:_P"!/^5^_=>Z4GRY_DW_ ! ^9FQO
MC]M[L6J[DV+V-\7-E0[!Z,^2'2>Y7VQV%@L?%CH<:Z19FDHWH*@SQP+*Z5%!
M+"DS2M!%"D\Z2>Z]UGP?\G'X8[.^ O='\NKK_%=@;"Z;^0<>0JNWM^X;+0UN
M^LYE<K44U17Y_([BSE!EXZ[,S?9PQ"6II)HHX(TAB@1%4#W7ND3\B/Y'OPU^
M2OQ\^'?0^\<]W[M',?!#J[$=2_&OY$]5[GBV_P!BX7&XC"8G K,V8I,6<145
MM=2X2DEJ&.+$2U*-)2PTJR/&?=>Z$3X1_P H#X<?R_.X.W.\?CY1=L-V!WGM
M.CVGV=D^T-VY7=C9-:22&H>NGJ,Y)5U[Y&NJXGGJ9'J&1GFE2.**$111>Z]T
M1O=G_"7G^5[NZJ[+QE0GR;P74G8NXO[YT/QPVGV)E<;UYMC./6M5U.8VSMJF
MA2*EJZF-C2>.KEK:2FI"(J&FI&2.1?=>ZL,[C_E?_'WNSMS^7;W)N/<_;>%W
M#_++FR,G0.'VSD<1'C<DN3Q^V\;+'NN.MP5?69!(:?:])XC0U.-8.]0TC2!X
MQ%[KW6'X]_RNN@/C7_PX#_<7=_<.5_X<?[<W7W-WA_>S(86?^%93>'\7_B<&
MU/L]OT'V-!!_&I_M4K_XG,FF+RSS:7U^Z]T$$/\ )=^#^!_E<X'^5KOG%=K=
MO?%_K(Y;=>W<GNO(T\F]X,C4[FS>\QD:+);<Q.%@_BE'D<U504JT] BS4;"B
MJHJM)JCS^Z]UK[_RG_@SUAVW_.*Z?^9?Q3V3\Z*[XI_#GX_9G%9+Y@_.RLSY
MW'VUOG=&"R>V:*BQE)N6BH)3M_ ;:W!4%6Q^/QL4=33?O1+#-1BJ]U[K=USN
M$Q6Y<)F-N9VBBR6$W!BJC"9G'3Z@E12U<+P5$+E2K!989&4V(-CP0??NO=51
M?##^2W\3/@AL'Y!=7]&[O^1=1L'Y [;R^RY-J=A[O?.T&SL-FHJA:[&['HZF
M@6EQ$<L]3)52SU$==6U=1XWKZJK2&"./W7NH?_#*GQ8_X:>_X9U_O]\@/]EE
M_P">Y_BNW/[]_P#,R?\ 2E_Q<_[J_P!W_P#CX/\ )_\ BR_\6_\ :_X$_P"5
M^_=>Z&?Y3_RL_B5\Q^@>EOC_ -WX'>&2H/CM#AY.D>T]K9:3";VVU7X.AIJ"
MCRN*W!C(J=Z6N>.CADF"PBFEGBBE-,&AA\?NO=*;X'_R[.A?Y>FS][[<Z<SW
M=&^]Q]IYVBW5VSVKWWN[*;MW-N?*T&.AQ5-DLI55;Q8Z*J6AITB/V-%1QLBH
MAC\<4*1^Z]T?'W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5 /\ PJ._
M[<4?.;_RF7_OXNOO?NO=:W?_  AV_P"9M_S#?_$<]>?^[/=GOW7NOHA>_=>Z
M][]U[KWOW7NO>_=>Z^-C_.@_[?I_,S_Q<!?^M^-]^Z]U]D[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=?-Y_X6[?\ 96GPG_\ %=<W_P"]+)[]U[K:^_X38_\ ;D7X
M%_\ AD[G_P#>^W9[]U[J\CW[KW7O?NO=>]^Z]T0#^;%_VZR_F6?^* =R?^^Z
MW'[]U[KYWO\ PC@_[>YYO_Q4;>?_ +M]I^_=>Z^J#[]U[KWOW7NO>_=>Z][]
MU[KWOW7NOC8_SH/^WZ?S,_\ %P%_ZWXWW[KW7V3O?NO=>]^Z]U[W[KW7O?NO
M=:@7_"U;_MUET'_XO_M;_P!]UVK[]U[H.?\ A$M_V0;\L_\ Q;G_ .4W;?OW
M7NMT/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=:3_P ;]N?SV?A)W=_-TW]\5/Y>73FY>O>T_P"8?V!\LZK<GR2SL]#F
M-[[0R&;R]70X'K_'8?+T2#*28R]7%D*^62FCDJQ3?93U ,7OW7NMF[^6=\[]
ME?S*/A9TQ\O]D[>J-F1=DXJII=U;%JIWJVP6?Q59/C,UBEKGI:'^(4]-7TSF
MGJA!"*BF:&8Q1,[1)[KW1\O?NO=:8W\T#Y0Y_P"('_"F[XK]S[;^-/R&^663
MH/Y5)P"]/_&# S;DW7.E?OCM"-Z^#&4X,CT5"%UU,GTC0@GW[KW5U'RF^068
M^4_\BOYU=\9_H;NWXR9???P [Z^[Z/\ D7AY<!O+"?PO:V]L-'_&,1.!+2?Q
M*+'+7TFK_.T-533#B0>_=>ZHXV5\N?D3TC_(X_D:_%SXB[_Q/4?R(_F!;LP/
MQZPG<>0@I:V?9FVAD*ZHW3NJAQ]8\5-53XF"HI2_D==$$LOB(J6IW3W7NC[_
M  G[7^3WP?\ YLM-_+![O^7^_/G'\??D7\7:KY$?&SN/NZJQU7O+";DP-=44
M^Y=IU>5H@TV;@FHZ2IR2>;QBDIFHX:93XZIY/=>Z*UTU'_,>_G8]B?S ?DAT
MA_,;[<^$'7_Q/^56Y?BS\,.H>H%HVVSDLML^@IGJ,[V+:-I-S4.=@S%',U+,
ME3#1RU#O3B=:.!)/=>Z 7_A0S\0.Y-W?)G^1KENSOF7WA3]D=P_)_K/XK[MJ
M>F:RJVOMK;^Z5S6,7)=K[ P!K:_^Z^]:FLS!D@JEJ)9((Z+'QAR*9??NO=6(
M_P \'LOY._RK/Y*.U*GX^_*[NK/=U]5]F;1Z_P#]F2[+JZ;/;QSM'7UV2^ZE
MSU9EZ>OAR%7/ Z1R2R1DGQ(R!"JA?=>Z>OGCVY\J_FO_ #:=F_R@OCI\G=_?
M#7J38WQ K?EI\H.[.C)Z:'?N3BK,M#M[&;;PF2DC:7;?VLV2QU4U5!(M3(M9
M(]E6G@\_NO=(7X;?*7YC=#]M_P VK^5Y\IOD1EOD!V'\2/C34?);XG_)3<HH
ML=O+-;-RVW99C)DH:1F:MJ=L96NQ].^08F9:UY1(QAEHE7W7NJ3Z'L?^:A1?
MR'>M?YY<O\V?Y19;MCK'=DD^)Z$R*8E-E5^!G[D_T:U%#N*BIJ2%MU9&2O5:
MZ.KROW'VM"SXVD2!;2^_=>ZW_.HM\'L[J?K#LDTPHCV%UYA=\&C"Z/%_%L;3
M5_BT^2;3X_N--O)):UM;?J/NO=:\7S$[#^6?\PG^;1N3^5E\=_EGV'\-/CQ\
M9_B_2=X?*OMKXZU=%!O[)[BW/)3Q[>VK299C]]MG1C,E29))*==;P>=YB#/C
MF3W7NBF; WI\O>[>M/YV7\FSY5_,7MO,=H?!G9>$[4ZP^9/6-7#MC?FY-E9?
M!C>=/@LTM!I$D4M##0T&4G#S-6T.7JZ.H;TQ23>Z]T.W_"2?XY9SKW^5_P!7
M_(:L^0?>F_<)\A://TN'Z"WQFIJW9&P6VMV3V!B9Y=CX=SX<-)N:2]=ER@_R
MNL_>;GZ^Z]T]?\*]O^W.&[?_ !878O\ [EUOOW7NL7_"KR";9GP@^+/R:VY%
M%+V/\5/YA'77;.Q*&)/\LR<\<6:B.%HI@LK4\M56"CJBRP5)/V(7P/?4GNO=
M&+^6_P K_D-U[_/_ /Y4'Q1V;VAF\'\>>_\ I/M+</<'5]/#1/0YNMV_L_>N
M2P]3/+-2R5L$E%6X^GE'V\T(<PHLH=!I]^Z]U5?\0>M/YCG\TCY>?S;=N5O\
MW+Y5?&;IGXC?S(-X]8=5=?=.P8X54<&+W?N%L72/EW:EJUV_C\=004O\)8S4
ME8@(K$DC!CD]U[HTG9V__E1_-$_FE?-WX=];?/+M?X ?%[^7'MG8N$ES'Q_K
M<=2[FWMOS=%*^;BK,MEZWQU*87$RXRKHJC$I)+#6Q4UJIA][+'%[KW1<\-_/
M*^5O1?\ )?\ Y@F_>V,QM+L?YT_ ;Y9Y;^7_ $7:Y2BCH=RY8YFCQ.+WU4XF
M&G2D6IH:2>OE^S1)J>NFQ,<TCI'5U"4_NO=6P_"#^7I_,K^,W>O4_:_:?\U'
MM/Y/]<;QV!7UGRYZ1[\Q<63I&W948^B6@;K66FJH%V=BZ*O5R\2:X/'!)>DG
MDR+R4?NO=41?%C^7KOC?G_"D[^:!M&D^?/S8V17]&2=9]^Y;=VS=WUE)D-ZT
MV;QVT-T1;'WA*LNO*[(PT.17#4&-=],&(I::D5M,8/OW7NK%M^;E^8_\VO\
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MI!_\*8=QX/X9?S5?Y-W\QS)9;)8''[-W!5;9WO/CJ2JJ_N\%LW/46:R5$!3
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M;<KI(3<B.JSN:I)K%64ZD#L."""+7!]^Z]UJL_#W^9;O3^0A\?/YB_\ +/\
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M>*PTXQ]3%!15=+65,]08/+54,$JRGW7NK)OB;_,^^?\ %_,?V)\!?YD?Q?\
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MNO=>_P"@JO\ D>?]Y8[F_P#1<=D__8I[]U[KW_057_(\_P"\L=S?^BX[)_\
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M(]\_$G8F1ZT^/W8%5N#<[2X+"Y7$UN"R%))0_P :_A>:DJ<7D*B%JG*TU=5
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M296# 9'[RARM5%KKJ&JDB\NN!XI$C=/=>Z3W4_P&^)G1W^S5_P"B[JC^Z_\
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MS_A5TKO#O$Y%LSD=W9*CJ5I\E7/)3RMD,U@X*J+;^<R.NEC(JLA0U-0OK"R
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MLU\/^]-P](Y/LN@H<7OFKP%%AZQLA!C)*F6ACE&7QV16,4\E9,RF((3Y#J+
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MIJF&*HIJB)H*BGG4.CHX*NCHP*LC*2""""#8^_=>ZU1/^%!.\^G>T/C=LO\
MD.?"WK':6\?EGW[F]DTW7?2'5N,I:+!]5[0V[GL=G9-R9C^'0)CMI8J*@Q9I
M$B6)9!CZNHG6'PZ/+[KW2@^1FV*/=_\ PH&_DL?#?=&<RFX=L_#'X1;J^3,E
M%G*=:JBSF9GQV8V7AJ^1FK%"Y7'Y#:29(5#TA:%HD2%F:JD:E]U[I5=Q+C?C
M[_PJH^(&XMMF2A'SV_E^[NZHW_B<1 L4=5E=C_QW=5/FLI*M3"*MY,5MJBH8
MF>&:6'[2) 3'+JIO=>ZHQW3V9L"O_P"$^WR!_E%[EW_MK<'\TW*_/JIZ-R70
MV3O1[PS^\ZWY 8C<S;EI<+40PUTN%R.W)3*,I!$]$L>N$S!TDC7W7NKF?EA\
MENFN]/G;4]H_([=S3?R]_P"1ED</G.P:BAQ[YR+L7Y/[DIEQ.W<%CL>**>HR
M^2Z^AKU>GAI6%1'GZ^-9;0AF7W7NKG/@A_,OZ,^?C=E[<V3L/O\ Z%[EZ:FQ
MY[6^.'RMVI+LO?N!I,PL\N$R=;A7J\A ^-S$%.\M+/3U4PT:1,(9&">_=>Z8
MOYN'SUR7\M[X,]I?)C:VQCV;V71Y'$=>=/[!99I(LGNK<F0AQ>(CJ8J9TJYZ
M6G>9ZF6"G/W%0D!IX62259$]U[JH++?,'^<7_+*[P^$FX?YE':WQZ^3OQL^=
M'>&!^.N\<+T[M6/;F6ZFWONFD08J@Q-;"*9=R[=I*BFJ9:BIKS-73Q0UAA6,
MK2Q/[KW1#NM.B?YB-;_PJN^0F*P7SIVSA=Z8CXV47<>\]TR=>[;GCR_1[=B[
M'J(NG4I)*(PT5='CJJAI/[S1*,JQHFG,WDGDO[KW6TY_-)V9WMOWX!?*';OQ
MR[DQW0_9K=69'*Q]AY3!T&XHEP]!"U;N+%?PS)PSTK/GL%3U>-2H*^2C:J%5
M"RS0H??NO=:W_P#PGHZQ^6^"_D;[U[.[ ^36$WS\1M\?%'N2@Z%^,U/M3#XZ
MNV1E:'=N_P"GSE?/NJFI5R^X(\WD(*ZJ$59.Z4@J4AA71&FCW7NJW_A/\B/Y
MO_P)_D _&[^85TAWO\:H_AI\?-V9S&O\4LOLXU><W1A-Q=U97;^1R6X=V54T
MU939*#>.5J8**FP_\/BCQ,J5%2U551:#[KW6S)_,)_F'?*3(]H?R[?A3_+P.
MP]G?(O\ F([7R/;,O=?:..ES>'Z]V%AL'!FLCF#A_$G\0RL\$LJT"UD4=))4
MTJTDR*]8C0>Z]TM_Y67S:^5^^/D;\T_Y<OSXEV%NKY2?"NLVWN/&=W]7XQ\+
MA>P-D[MH16X;.?PB1@E#EJ=7A7(1TD8HHIZC[6(M)2R22^Z]T)?\\GY^]G_R
MU/Y=7:_R?Z9VIA=T]G8[/X+8>T'W1!-4XG%U.?R,="<QDJ>"6!YX:*(MX8C(
MB25;TT<A,;,K>Z]U[^7+M;^:=B-UY#<GR\^:7Q.^:WQ=W[U9!O7JKLGIS9Z[
M<W <[DL@E3#34\N(F@V[4[.I<(Y%+5&*LKZ]Y(6EEI/M9'R/NO=:9W\KCMS^
M<%\5_P"1AO#YK?$OO/XU;(^-'Q=[BW!N^NZ)W;M$YO/;Z@ER&.I-R/G,W6S@
M8NBQLM='+14V)>@K*E::025B$JD_NO=;KO=6_/F]\LOB#\4^Y/Y<7<OQ\Z#;
MO_:.W.V]_=H=[;>R6=;#[+W-M!L[25^V\7))34L^7AKJJB3[;*P+$T,KO))
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M4'5]!WSN#:"]?9[NVBV_B8MW5V 2:EJ4P=9N2.D7,U.'2HH::5:.2H:F$E/
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MQ!6UM'&OVHBIY*6BJJ0O%D*2L+NS>Z]UL/HB1(D<:+''&H2.-  JJ!8  <
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M\K/X4]P]Q;SSG8?9_8/3T6X-Z;UW)*)J[(ULF0KT:HJ) JAG*(JBP "J%
M'OW7NB@]J_*_Y#87_A2-\:OAIBNT,W1?&3=W\MFO[LW+U)##1?8UFZ8MS;_Q
M\>7EJ#2G(F5:/%TL8C%0(/V$?Q:[L?=>ZUG?CYOK^:YWK_)([B_FW9G^;U\K
M,)V5\:-[9?-=7]38=,2FWJZFPM=C,?E8MW$4JR;H^]BR$S4=-7I/04<D43&F
MF+$Q>Z]T?C:'>7SX^+_=G\BGYP]N?S!^]^_=I_S?=[[/V?WU\8,M1XRFV)@#
MV=A<57;6I=H8)'2EPM)MNKW=$E751%<C5B@AFDFJ$O1O[KW0T;TQ/SN^?/\
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M]S[>>LC,7\4P.1B99*'*4H):GG4WCDLUC:Q]U[K40_X2 ?$K<M-\3\%\QO\
M9J?DI4;8R&[M\]8?[*/4[@J'ZM@F6LQ;?WDI]MZQ3Q;C+06-78L5DE6WKU#W
M7NJ=?Y?'3_SHZ\_X3^]H_P PSX^?S).^>@XOBSVGN'>_5GQPZ[I\;1[2JQ29
M+%T>XY=U_P"32S[JJ<FM?))24^26IQ]*\$(-.^H/![KW6R1\UOYB/R-^1_\
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MOG-8_LW![!==RT$*013XF<5U/NBEQS1E*#+QT)BDD6C2:7W7NC"_*:M^4O\
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MOQ=#%B]LXO*4Z/%29VFI-MTS5<,['[9GK \C?;(U1[KW12NX_P"71\H>C_\
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M5#Y3+9*::.*CQLD<4X%?35,9]U[K:4_D _\ ;FK^7Q_X@6G_ /=ED??NO=$
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MGNT*'MW<N-WAF]^[EW?B,=)BZ'[S.5*3/1T---4U50U-1Q1)&)I75YV#RF&
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MDX*"#:/8;8^GK:@8G/;AW)6F&JJ4\=,OABI::G1*JHO[KW5J'\G;LOL;=_\
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MDPXO+93"U./GCD\TRXRKJ*>*H$C+4#W7NAX_G%_"S:OQ"Z]_D3?R^OC-W/\
M)'I_JO>W\Q^DZ;?L+:F\*RGWO08K>NX\6LIHL_#'$!-M^/+"+#>6GECI(J.B
M5XYVA9Y/=>Z!K<_\KKJ+J/\ GN;/_E;]5]U?*[87PG^6WPK;Y;?);JW"=A9X
MU.\=S4.X=XT$_P#%<W45$V5\67DV[23Y"6&:*JJ?W(&G$+*J>Z]T+G\M?)?+
M#9'\OC_A07\+/A]N_L[=>^OA%\KNTNB/A#'D\K+D<_A\-CWKL/CL+@*B<"2"
MOI:/!R38]4<1C)5(:"*%B=?NO=++_A.EU9_+9[/R?3G??1OR5^4NV_Y@G5O6
MM1A?G=\8^S-_[EISNC?,V$I,'N+<.Y=H9>?5G\?C,G'-)BI8)):*C,D$>1IQ
ME*&G%%[KW6R%_,O^2>Y/A]\ /E[\F-E_PP;XZ=Z&S^[-AMFH)*FC7/+1O3X1
MJJGB*O/3)E9Z<R1ZD#H"K21J3(ONO=:B79/\OGL'X^_R=>J_YXW4ORR^3=1_
M,UH^F-@?-+L?MG=N]<I68C=6'W14XW/5NS<O@9S)CY<#B,-N65:6C1$CFE@>
M&3]BK9$]U[I-_,CX-?"7^8-_/)_E&[YW?LK/YOKC^;%\1\O\G>]J7&YK.8TY
M:?']29/+[5FH#YX*[!Q4U-A<:'@B\+2B)A4JSR2ZO=>ZWY\=04^+Q]!C*0,M
M+CJ.*@IE<ZF$<*+&@+'ZG2HN?S[]U[J9[]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>ZK?_F^]#=E_)W^65\U.A^G,!+NOM+L7HW)8O8NUH):>&7)9"!X*Z#'P
MRU4U/3)/6&E,,1DE1/(ZZF ]^Z]U1_-\4_DW_-._X3JXSX,YSXN=M?$#OOXZ
M=,=9]5=98OY,TD>(FW;N7JC&XBAKJRBH9ECK,3@=PKB*BBH*ZK$+EZO[DQ/C
MXTFK?=>Z1GR!K_YE?\[$_#;X1]Q_RW>W_AYU3U1W]M/N#^83V[WR,9)M7/1[
M2IEGJ=N[(0ATW7BMP2UDKK+3&6..I%/35#&"GK9#[KW6XDQ(4D*6(%PJVN?\
M!<@7/^) ]^Z]UI4_S=LQ\XOYH/3&8^%.:_D:=Y[!^8\79U%+T7\N:NMVWEMC
M[0PF*W=CIZG/TW9%&5CQ=1G,)3O!4X9:@L$J7J8I*QZ1%]^Z]T97YN]5_,KX
MB?SA/Y=O\P#9OQ3[V^>.R\!\"/\ 9(NU(OC]3PU>7HMTTU1NG)#/9%ZQHJ>E
MQF6GSB%JO(-CZ*$),9:T5#4])/[KW0K_ #=ZH^7OPO\ YK.P?YQ'07Q4WW\N
M^LNQOAM+\5?E;T#T<:>KWY@S39*FW#2YS T+K%+N=7GQF.I?MX(34_Y'*OI2
MJ@\'NO= ATI_+>^6/\QG*?SB_F%\PNH%^)&^OYA'QPB^(_Q)ZC[$%%DMP[+V
MIBL=&U'D=PO2IY:-,KN#%XC(55#=*@U%/4N0B1X]Q[KW0G_RW_EM_-=ZNV+\
M'?Y<6Y_Y3G9NU]S?'/%;<Z+^1/R4[0S5-CNLDZ]VQC*G!T.>VEN7'09"/-[B
MEH,722#'P158,@$,C11U\592^Z]T7[<7\JB3YD_SPOYY.:[X^/\ V'B^LNYO
MAAM3J;XX?(W<VWLK3[=CS.;ZPV/M_+9':6<K*(X#)YK#55"T4C0-4RTC055.
MZH&J(V]U[HG'</7_ /,$^0_\C[^5KT/VE\//E3'\FOAA_-7Z_P"J^T-GML+=
MU37MLW8^#WQ0XG>L)6BKCD]J4^$R.,HJC<%-++B)*Z.015"))$GOW7NKH/F;
MTAW3NG_A1I_)V[PVSU!VAN+I;K'HOM[$=D]OX+;^6J]K[>J\GLG?-)CJ7.;@
MIZ23$XFHR%55P0TT=5/$\\LT4<2L\B ^Z]T3+IB3^8I_)$[%^?\ \?>H_P"7
M1W%\Y.I_E=\I-T?*;X<=L=$&D.(Q><WACXHY-O\ 84/KEVWCL/#AJ&&2O=8J
M>9X'$ 'WL*P^Z]T4_P"9_P#*F^6?0?\ PFAH?C-#U)O;O?YF=I?+#&_)KO\
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M\7CH*FNK:@HC,(X8G<A2;6!]^Z]T1_Y$](=TYO\ X2\[?^/^%Z@[0R_?,/\
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M9E%TKF_D9T1A^Y,DK/CNI<IN_;]/N:<)*E.YAP,V03*RA9Y$C)6 VD94/J8
M^Z]TK-X]T=.]=9"?$=@]L=:;%RM+MU]X56,WCGL7C*B/$Q-,DN4DAK:J"1,=
M&]/*K5) A4Q2 N"C6]U[H.=X]GR=Q_&#L?L/X;]T]&[@W#G^K<W5](=T39*D
MW%L2'-C&5!Q.4R-?AJFIIJO#4E:8I:IH9) (%8Z7'H;W7N@$Z7^1[?&/X=]
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M]Z](=/\ PZZ&_EY1_)>O[!WS44V#F&XJW=.R,<*K-;ES&3AQE)C*2AS=3%#
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M.#NKJ3K_ &1B^R\7O'9>T</086DI*3Q83'9G:F0QT4='3M31I#BJVJK*J@(
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M2IJ\UEC$ *O)5,]9,\L[#R2-(=1-A;W7NJQOE?\ "GXN?#C^5G_PG?\ F_\
M&WI[;757RBW1\C_C;F=[=O[8>KILOGIMZ[ R&\MQ#,UD50E36QU>;QD+1H9
M*:G:6EIO%!*R'W7NECW[\ROY5&Z?YX7\S;(?SILS'O?KSHK$;1^-_P +^K=Y
M[9W1N;"8JD7&RS[ZK*2@VSCZZ"ER#9B&*H2MK0*ICDG^TE5*9$I_=>ZM8_X2
MI?(##]D_&OYH=&]>[_W'V1\=_C%\VMS;1^)&>W3%4QU4'5V8M7[6H3]_#!E!
M&!#45BQ5R?=4WWIIF\<445/![KW1]_\ A0Y\CO\ 99/Y/7S4W?25%93Y_?\
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MV>RLGCKJW X_$]HX[%T\E7#HDDEHMM5M+0K4M_E$GVXEFDEJ#)-)[KW5T?\
M/*^(/Q1_EQ?RT)>A_A'U%COB_3_S%/EMU'\/NX-T]635ZU]?A%DW)F@,E55F
M1EJ*J$T&/R%),K._WD>0J*>K66"HF(]U[H+OGG_+U^&_P1_G'?\ "=[_ &4O
MHC9W29[ [?WQM;?;;026/^,P[2H]D+A:K)!Y76JR<7\>K3/6L/N:HR@U$DAC
MCT^Z]T1_M'YA_P G#NG^:Q_-]SO\Y?>F4W;2;0WH?A-\3-@YW;F]<U!M'![4
M&3P6],O@7VS05E)B,K5[CH4GHJVT5?3R_=U%/-:L<^_=>Z+YW'\E<W\B/^$C
M-5@\_O\ R_:59\9?GK0?&3';^S<$U/-D<-AJJ'-[;=8ZE5JA!!MO<E!!$L^J
M:*.)8)6+Q'W[KW6^E\-/Y;?PC_E]4^ZH?A_T#MCI>;?>W\#MK>^1PU5E*RJR
M]-MI<B,0^0J,I7UTL]7"<M5M-4DBHJWE#54DQBA\?NO=%N_G0=N?R^.N?B9C
M=K_S%.OMR]W];]G]K[>PG6GQYZ[HJ[*;KWOO'&Y"'+X3"[=QN.KL94555/4T
MBQ2I)5TU+-#,:*JE,=8(9?=>ZUN_Y;>^NBU_X4>]54WQ/^#W?7\MGKS?W\NK
M.8WM;XU=Y[*EZ]R&0S-%G\[5Q9^';PJJFGGQE90T&)$%9'I5ZFDJX] ECF=_
M=>ZK3^'G\NCX<=A?\)<?F-\QMW=+;>R_R>P&Y]Q9O;?=%2T[9G&?W:S&#@QU
M'CI6D:*BH)8)IHZN")%6K69S,698FC]U[JX;<%?@?YH_S_\ ^$^?Q?\ EIC'
M[ ZE;^4EA?YBG:O5-:U0VU]U;OW7M22@H_XI0R5LK5L>)KL'-/&*GS,L,\U*
M998:^M5O=>Z'/^4G\>NFOBM_PHL_G0=%_'_8>'ZQZDVCT7U;D]K;$V\)%H,<
M^>V[M#<62CHXY'D,%-)ELM52QPJ1'"L@BB5(D1%]U[JV;^?]_P!N:OY@_P#X
M@6H_]V6.]^Z]UJ-9SL;^;/\ )3XU_P H3^37\D-P?#WXU?#C^8]\;-@XCI?O
MGJ;';JR&[*[9.R-J;;SF'PNY)<CN1\='N3+4\&%AK*:BHZ:GJ*VNCA\T5#+/
M"?=>Z-;_ #)>[?Y<_3'\Z/X\_$_^9!D12?RW_@;_ "[L+BNCNC,C@,UG=M3[
M]K9:7%XV6NP6V*"JEK%BV:J)&:N$X^G.*BCCCBDG85'NO= K\*?YAO6/0_7G
M_"CS;O\ +3[-W,OPZZZZ+Q_R6^#T4>-KZ./96X=TXDX;<LN$H-RTU-E:"EH=
MTY2G6"FJHWID7$QU-- XFE-7[KW0T=W?RH_B]U5_PG*Z5^?W3FV&Z]^>W7'Q
MTZW^?%!\N<;5Y#^^59NK<)P&ZL\F1R@JQ+74\M/G*FFI(Y_)%321TU0J%TD,
MGNO=*CM/K#X^_P U[^?3_*BW!\G.LX>R^K^\OY%VS?DW5=?;G>:CAFK\GD>P
M<_0KDH<55Q*ZTTN3+24R3/3-(@5O+$+-[KW1F?EA\1_BOV!_.B_E5_RBQU+B
M\'\%_CG\5.P?F9'\9<>:C^YN9SFXLYNNEHUR5 ]8_P![]CF,55UY$ZN *RII
M5)IJ^LB/NO=<OY572'0WPV_X4+?SM.J>F]I[;Z;Z*ZV^/?6FZL;MK'N:?$X6
M#*[9VENG-21&>1EHZ!<ADZNH":A#3QMXXPD,:JONO=4G?S7NX?Y0?9GP=^6N
M]?@=_+ ^4V&W%G.WZ;L'KG^:.O7&4I^OJK=-7V=AZG=*4'8-;EYJ['XRJIZG
M*8V@I'IZ:FAK/!14U%3_ .3R>_=>ZLX[F^.G3'SK_P"%"?\ *VV?\L-AXGNG
M9^5_DD[6[8SVU-VF62@R>:ILOV)5PSY*G21%KH!5U+3/3S%H97"^5'4%3[KW
M26^*FV=M="=-_P#"QOX:=48.BVET!T/UOO/>G5VSJ-IV7%S;PZJ[0@R='"9)
MFC6@@I]K8^*E01B2.*+1)+,HC$?NO=6E_P NOIWX2]D_\)]?@WO?YZ]8=4=D
M=&]!_&^J[ARTO;^/@R6-PR8TYEJW)Q4]0&3[M:'RQ1Z%,K^0PQ M+I;W7NBS
M_P AWXS_ !^Z>ZO^;G\[/N'J3JSXD]1?*_$9FMZ=ZMQV/@QV$V)\?,#XWIWK
M:-89 N1WB</!D,FM/)44V3-)0UU+'&]>:6/W7NM?C^9GW-_+)VY\/NM.T_Y<
M?\J7Y>?$O=?4W?VTNU/C5\^>QNLZ[!;0W?%B,C)4!H-Y5&;R%7EX<J6BR&.@
MK4&N.G1M-#-''2GW7NKT/EC\+/B;W#_PJPZ-Z[[3^/G5O8&QNWOY:5;W+VAM
M7=>*IZRBSVZH-R;]Q<&?R<$RLM5DX<;B**FCF>[)!201K98E ]U[HR'S6QE!
MA?\ A3E_(MPV*I8Z+%XGXV=RXS&T4-]$,$'7V_XH8DN2=,<:!1<G@>_=>Z*!
M_*,_EZ_$S^=)\8/G'\]/FAL(]W]Q_-/Y-[ZPFP-]=@&=,UU]M+$+!2;2Q.WG
MI*^2GQ%3AVJ'=I*'QK)"E+0R>>GI09?=>ZJD[F[>W9\S/^$SO\IG"=\;AS^_
MJ_%?S=ML_&_<.?S4Q%=6X"AQ/9]#C:=JR)_/*U%MVOIZ%*A]-013JTC22@SR
M>Z]U=;6?%OX[_P N7_A2G_+!Z]^&G46TNC]C_)WX==F==]M[6VJM2E'6T^W,
M!N3<5#7",U!+9::NVUCQ5U,YG-2D >534VJ![KW6W][]U[K6-_X4(#%][?(;
M^2__ "[-\U>X4Z6^8GS4K-U]VX'#5,U-3;@P/7<&"J'VYE&IZF"66BR=1N>-
MM%F6.6".L0I54E,WOW7NBO;,^(7QL^&?_"K;X[;!^+O4&T.DMB[Y_EB9CL[<
M&S=BP&DQC9N?.[VPD];3T08P4AGQ^!HE>.%4C:2-IBGEED=O=>Z*;_-3[N_D
MR]NT?\TW)]._RR?DE\K>]*_9>]\-VK_,*ZGZYR&Y.OMB]H8/9<V-Q4T^[ILN
MJ;=I<+D,;0U66J*&CAH7227(R-7+-,Y]U[HMW=W2G47=WQ,_X2:]C=M=<;1[
M!WSW1\C^K?C7VUNK=-(E96[CV'1;IQN/I]JY>HFUR5N&2EJZA#3R$H?/,2+R
M-?W7NK ?Y]F__AC\:?E?_)W^"GR&2#IS^59LX;S[P[UZ<V3BLK-@,@,-3NNQ
M\748G;D%1EZK&0[BCF@-%3I]LJ9*26HC:.&-Z?W7N@'_ )=WSJ^#_6W\XSY/
M4/\ *6W#+%\(^X_Y<.?[LWETYB<!FL!M[&]L; %96)58S#;CH<?5T _NY0 R
M&C5*&H?*2(X>2GB%+[KW1=>O?Y>WQ,[J_P"$L_<O\Q7MOJ;#]@?-SLT=C_([
M<WR5S\M7)NJ7<U%VMF]O"7^(_<W%#546+#5-$JK1SSSU%3) U5*\Y]U[K=8_
ME._]NLOY:?\ XH!TW_[[K;GOW7NM?#^;[WA\3^ROYW_Q3^-GR^[GV#T[T%\=
M/@5VOOK=>4[8R-'1;<RFX^X,+D.OZ;!U<=6P2HJ(<(4R"H+R/'=5 C$^KW7N
MA/\ Y"/R&G[P_P"$ZW8^R\SN&#<.\?BWL#MWXW;GEADAF6&/&XK(YS!4\-33
M7I*ZCIMM[@Q]/3U5,\L$L<(4322QS$>Z]U1_U!_+7^*V;_X2?T/SRVIUOA=B
M?-K9)W#W[@_DY@35Q;II\AL[NC+X2FIZ7(PU<$]'3MMK#I2P) \<=-5^/)*C
MU,9+^Z]T?GY;;,Z<_FA_S9O^$WB_)78:=B=4_*;^7]E^]M[;#SDM10QUT\O7
M6:[ Q\%<,76QOXHLU24TE13)4/!.B/2S>>FDD23W7NC*_P X_P"-_1_Q+[2_
MX3F=$?'/KK"=4]1[2_G#;3R&W-C[>:H>DI)<SOG YK(M$U7/4U&FHR60GE"M
M(4B5Q#"L<$<4:>Z]T-W2_P#W%Q?+C_QD-C?_ 'L^L??NO=;0?OW7NM,'N>'Y
MI=%_SC_Y?W=_\Z3^X_;_ $!G.[,CT;_+VS_Q4RKTVT=B;_W3-'286NWYMK*;
M:H,[F,WF*0TJ?=QU@HL?/1R540E@@\2^Z]UN?>_=>Z:\YF\/MG"9C<FX<G18
M7 ;?Q=1F\YF,E(L5/24=)"\]34U$KD)%#!#&SN[$!54DFP]^Z]UJ;=<1=M?\
M*/ODUUE\A-PX:LZL_DQ_#7OO_2%\>\)E:8P;C[QW[M:>IQ\.Y:U)PM3BMK8N
M5ZJ!(=,;>.:JH)A-725?\(]U[H=/B9+7'_A4A_-6BWN,+_&%^#W5_P#H2-4F
M.&2_N>*'91W!]D\*_?&@_O>[_=^8ZC,*,/>%*'3[KW7OC;%7#_A5/_,4EV@<
M+_<UOY<.QO\ 3(,0^.,W]\#7;&&V?XHB-_$17_W52IT7&D41I3/97H-7NO=
ME\EM\]N?\*(?D/V;\ _CW4R]>_RG/C-V]1[8^<'R86(')=E[LVQD*;*_Z/\
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M12M6K1"2HJ(Y?=>ZA?%#_A.%\C.I_GU\>OY@OR=_F:[X^6W:72>6&1JJ3?\
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M&%K\O'N*OAK,GE:>)&HZ2L6%90]1*B1RR+[KW1)L%\-/YU?\MW+_ #&^./\
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M<%-4X^EH8:?$0QX]8Z?QB;W7NJ6/Y<W1?\X'YT?R)_CO_+WZ6ZL^.FR/A/\
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M#&T.4H,H[:GJ*RFB)IL?)JGCCJ8)_=>ZY_"_X)_-[H?K'^:3\YN\,5L'>?\
M- ^>>TLKN/;?4/5.76EP6"?:NU<IB^M=BT&Y,O4QT"U$E2]-#49*9HZ6 "F\
MM1(E-)._NO=5._RSL3_PI!_ED?$'8'Q%ZT_DS=*[[PFR\WGMQ5^^MS=Q=<4F
M1RU9G<S6Y1YZR&C[!%.'I:>HAHHRMR8*6(MZKCW[KW5^W5W\I3X']V]=[,[D
M^6W\L7XE;1^4G:^WJ;L;Y$[8_@>%SAH=ZYJ,9'<M,V:IYJ^#+219>IG#UD=3
M.E2UYEE</<^Z]U0-\7>HOF+_ ,)^OY G>7<E/\<.N^L?YC&XOD!MO 5N&S,>
M%WE5;HQV3WOB\#MB@JWV;G*V/,S4M!N/*#&TD-:9X):B0^+ULC^Z]UNG==P[
MTI^O]CP=D5V/R?8<.T,;'OS(XF!::DGS(HX1E):6F26=:>FDK?*8HQ+)HC*K
MY)+:S[KW6M1\F?B9_-:Z3_G1=U_S0/A-\=^B_D5L'='PTQOQYFZT[)WQ3;5R
MN=\57@<E5TV%GEC>EQ^2BR>%IGBFR4D%%)3Q5<;2QR24[GW7NCB?RJ/Y<_=O
M3/3OS?WA\]:W86X?D?\ S*.[-R=M=^;1Z[DDK,)@,)FJ"7%8[9U-75%QD8\7
M0U56/(J^&-*E*-'JEIC65/NO=5C_ /"3SXS;^V9LCYE_(#M7?=7V?D,5VG2?
M WI3>7C@CQ=1L/IK[ND@J]O") YQ.1R68>(,SR:GQVIG>;S2/[KW6WY[]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>ZJ=_FD?S/4^ >*Z5ZSZFZ7W#\I_FA\K-Y2]?_&7XT[1J8Z2?*5-/
M#Y:_.9FL<-_#=MX?7$*NITG295>1J>CAK:ZC]U[HV'PFE^:%5\>]KU_S^I>C
M<;\FLED\E7[NPGQT.3;:N/HY*R4XFAI'R\E16O4T^/\ &*IFJ*E#4&3Q5$D>
MD^_=>Z-E[]U[K6-_X4([]_FQ_#_I'NCY_?$/^8'M[I+X_P#2VSMF8BM^-#]9
M['W'D,GF,YO'%[7J\NFZ-RX/*U-*K'<5-)]MHDB"43"/0]0S+[KW1W_Y:6+^
M>?4'3F=^07\S/^8UUO\ ([KOM#J[9^_^OY<ILG9G6E'L85M'4Y#*C(Y;#TF*
MILFM='D:*$/5,J0M1EHE7[AQ[]U[JU;K7M7J_N?:6-W_ -/=D;"[7V)F8A/A
M]Z]:YC'9W$5:,JNKTV2Q=154<ZLC!@4D8$$$<$>_=>Z?-U[NVIL3 5^Z]\;G
MV]LW:^*\7\4W)NNMIL=04WGFCIH//65DL-/#YJB:.)-;C7(Z(MV90?=>Z0>T
M?D#T-O\ WSG.L-B=V]1;V[*VQA:;<FY>O-H[DPV2SF.QU:6%'7UV)HZV:OI*
M*K*D0SRQ)%+8Z&:Q]^Z]TR[=^4OQDWAV/D.G=I?(SHC=/;N)C27*]6;=W?M^
MNW'3+()&C:HP=-D)<G"LBPR%2\ #!'(N%:WNO=4CX#^=CL>;^>5V]\&=Y_)C
MXC[1^(G6_P 4&K-N[IK]R[?HZG)=Q/N[:>)J-I56XJW.&CEW#C:>KRE,-OTR
M0UJ20SFI@EEIB8O=>ZLGVG+\SL7_ #">^\UV#\@_C96_ 6GZ'PE1UAT;CZ1:
M??\ MW<M)]O)GLYG<B_C*XNH$L[O+-/-2FEEQ<5/1T$]-7UF4]U[JDWX0?S8
M^XOGW_-'^1V'VY_,3^'W3'Q ^.??6<Z<ZM^)[0;-R6YNZ\!@Z#)25V^=N[HJ
M<RV7J,9&,--EH:W#+48]L5(PFA0(*U/=>ZVG?[T;9_@/]Z?[Q8+^['VWWG]X
M_NZ?[#PWT^7[SR?;^/5QJUZ;\7O[]U[J939?$UF+CSE'E,=586:C_B,.8IIX
MGI7I].OSK4*QB:'1ZM8;3IYO;W[KW6O-_+B_G5;-^6_\QC^8_P#&_?OR2^)B
M]6]8=C;!Z^^ N.V?N/ 15>_X:^GWC)N2MP-;)FZN7?-:9*#&^;^%>2"D5H@L
M$1G+2^Z]TO/B)_-EKM\?._\ G ]/_++LSX^]%?'[X-]K=8=2=);@W9D*':\4
MTVZ5WJE<^9S>>RRT]?E<K68FBBIXHC3QK98H*<RR.\GNO=7LXW.X3,X:CW'B
M,QBLKM[(X],MC\]C:B&>BGI9$$J5,-5$[02T[QG6LBL4*^H&W/OW7ND/UUW7
MTUW ^XH^I>V^LNT9-GY9\#NV/KK/8K-MBZZ,D/19$8RKJC15:$$-#-HD'Y7W
M[KW0F^_=>Z C*?*7XR8/LRBZ5S?R,Z(P_<F25GQW4N4W?M^GW-.$E2G<PX&;
M()E90L\B1DK ;2,J'U, ?=>Z5F\>Z.G>NLA/B.P>V.M-BY6EVZ^\*K&;QSV+
MQE1'B8FF27*20UM5!(F.C>GE5JD@0J8I 7!1K>Z]UWL_N;I_L/KF/N'8':_6
MN^>HY<1-N"+M+9^=Q>3VXU!31-/45RYRBJI\8U'!"IDDF$WC1 79@H)]^Z]T
ME<;\H/C1F=[;7ZTP_P B.B\KV-O?#R;BV7L#&[MP$^;R^/A=8Y:[%XJ+(/7Y
M"CBD=5>:"*2-68 L"0/?NO=+?LKM7J_IC:62W_W#V1L+JC8F&B,^8WKV5F,=
M@L12(JL[/4Y+*5%+1P*J*6)>10 "3P#[]U[I+;MWE5=A=#[[W=\<>S>JY]P9
MKK?-5'47:F3GBSFSZ;,_PZJ7$97)28RK5,AA*'(B*6L2"H1I*>.5$E1B&'NO
M=%\^'F]NYNL_A[T95_S"_D5\>-[?(&LICM??G</7]5C\)M7/9IJJN^SI\;)*
M,90564-#3:*D4=)113U4%5)38^EA'AC]U[HQ&R?D/T!V77;\Q?7/>?3V_P#)
M=65+T79V.V3N;"Y6?;DT<2SR0YZ&@K9Y,/+' PD9:L0LJ$.0%(/OW7NJ1OY5
M'\Z39WS>^4WS^Z;[/^0/Q5QJ==_+W+=)?!_8FS=QX.');ZV;A)<VD.YL''/F
M:K(;S;,45#'725F,$E (;/2Q1Q:G?W7NKG-W_*_XM]>QULN_ODIT#L>+';O3
MKW(2;OWCMW&+!GY9S2QX.8UN1@$68DJ085HVM4M+^V(R_'OW7NGZK^0O05!V
M1@.FZ[O'I^B[?W7AQN':_557N;"Q[DR5 1"174&#>M&4K*,BHB_>A@>/]R/U
M>M;^Z]TH^RNU>K^F-I9+?_</9&PNJ-B8:(SYC>O968QV"Q%(BJSL]3DLI44M
M' JHI8EY%  )/ /OW7NI]!V!L/*[,;L;%[VVCDNO5PTNXVWY09*CFPPQ]/&\
MT]><I',U"*.&&-GDG\OC1%9F8*"??NO=!SC?E!\:,SO;:_6F'^1'1>5[&WOA
MY-Q;+V!C=VX"?-Y?'PNL<M=B\5%D'K\A1Q2.JO-!%)&K, 6!('OW7NJ6?D3_
M #I-G='?SLNI/@;O'Y _%7J_XJXSXJY'M/OGL7?FX\'C:S&;^FK-P4V,V=F<
MYE,S#C-OSQ8RBQV2CQTD<&2J%KZ>4N:2:))/=>ZV$:*MH\E1TF1QU735^/KZ
M:.MH:ZBD26&:&5!)%-#+&622*1&#*RDJRD$$@^_=>Z#'M/OGHWHNDPU?W;W/
MU1T[0[BR<.$V_6=I[BP^WHJZMJ)HZ>"DHY,O64B555/431Q1Q1EG>21$52S*
M#[KW5??\XS^8SB?Y</\ +O[E^4VT=P];9'M+^!T. ^.VV]UY"C:'<>X<WD:#
M'4KXVA^^I*C<,6&HJZ7-5=-12-(<;054Q*PQR2+[KW43^3EVGW?W;\6&[2[R
M^?70/S_W'NO/4V2;=WQ[Q>U\9CMD559A\;EZWK_*':E95TE3F,!_%(=;U2TM
M>*>6F^ZI@[>>H]U[I(_);^8AW-TQ_.0_ET_R]=N[;ZLJNDOEQU3V)OOLW=>X
M:/*ON>@J=H[8W3F\>F$KH,W2XBEI9:G!P+5"KQM8[0M,(Y(79)(_=>Z;OY=G
M\Q?O#^8W\I?EON?JC;G45+_+)Z"W.>D.H.X4HLQ5;K['WM0I229W+X?+IG(]
MNQ[,QWD=83'C*F6L2>CFCKDU3PP^Z]U1]\#^W_\ A1!_,(V-\M/DC\?/YDO3
M=#COCQ\Q=^_'O9_QE[CZJV,N.SZ;8HL1EJ*GJ=U8/;-+F**&HI]P04L; ^82
MT_EGJ]$C$>Z]TK.]O^%*GR8VG_)&Z!_F(]8]1=!T'RAR7S2/PN^2?5G8]!N2
MOV]A<SCMM;PSF1DHL=0[CP&<Q5=6P8?$5T5)6UM2U!!D)J24UCK%6GW7NK\?
MF-_,HV?T'_*<[!_F5=?5VS\K1U/QIQW;?2-/NHSU6(R6?W7042;-QU=%155!
M6U5-49O+4<-5#!44U08A,HFIF4RQ^Z]T1/J'^=YO&A_X3[8G^<+\BMB==/VM
MD-N[HAH^L>LXLKB]O9'<5-V7G^OMJ8ZF3(Y'<&5I*6J>BHILC*U54,B?>5$0
MC0)"GNO= 3M'OS_A0G\8]Y_"#O;Y,CJ_YB]%_,7M7!;&[S^,WQQZVR*[AZ:I
M=Q8MJNDR./RN&@FK:W$8>""6LS5=F9:JGI)X9*%)C#54]9![KW6U7[]U[JFW
M^7I_,-[I^6?SY_FX_%CL;;'5^%Z^^!':>Q=C]/YC95%EJ;,Y*DW/!O*2ODW+
M45V;R5#65$+;>IOMVHJ3'H@>?R1RZHS'[KW7OYJ'\PWNGX/=V_RM>MNI]L=7
M[AP?S=^=FU_C#VM5]AT66JZO'X#-Y;"4%55[>DQN;Q,-)F(X<E*8I:R*OIE=
M8R]+(H96]U[JR[Y%;KS^Q/C[WKOC:E?_  K=&S>F]S[KVWE/%#/]M7X["5U9
M1S^"ICFIYO#40H^B6-XWMI=&4E3[KW6F9\4/D7_PH][._E?83^;KLCY]=%?(
M3;E'L/>_9>;^'G:O4FU\?+5XK8>Y-P8;+)1YK8^$P>5R.4GIMLU%334D,]#Y
M1,*993/XW/NO=;:'\OCY>[>^>WPK^.7R]VWC*/ TO>'7%-N;,;:Q]6*^'$YN
MGEGQFXL-'6^.$U2X?/T-91>1HHG?P7DBB?5&ONO=#/VW\A>@N@:#'Y3O?O'I
M_I3&9:KBH,7D>V]S87;<%3//*L$,-/-F:VBCFEFF=8T1"6=R$4%B![]U[I=T
MF\]GY#:B;[H-V;:K=CR8EL]'O*DKZ63%-0HAD>M7(I*U&:18U+&82>,*"Q:P
M)]^Z]TBNJ._>B>^:'*Y/HWNKJ7N;&X'(RXC.9#JC<>'W%!15<,LD$U+5RX>L
MK(Z>HBGADC>.0JZNCHRAE('NO="U[]U[K6S_ )6'\\3?WSU_F;?/KX2]@;(Z
MTV9L'I"NW'F?BCGMIT.<BRVY]M;0WO5[+S.4S62R&4J\5735,ST-1!'04=$(
M2:V FJ^UDE3W7NDO_-K^1_\ ,CE_FN_R\/Y>_P $_F)C/B-C?E9TWOK=>Z-U
M9C8FS=[4R5^T\;GMP)/)3[DPE?6CST6":D5*:JIXU:99G1RA#>Z]TH_AA\V?
MYCGQM_FA[>_E1?S.NP.G/D5-WAT%7=W?%?Y7=;8#^Z59GIL*^2DRV!S.&HZ2
MEP+9-,=B*^JEIZ&.-Z"*EIYGDJX<G&:7W7ND?N;Y??S5?YE/RU^:W5?\K?NS
MI'XN?';X";ZAZ5RW:O:6SH=SU_8W9F*EK#N3;,+9/[JGQ6VZ2>E%%-6T]$*A
M8GBK:2JG6LB^U]U[JU'^6K\K_DGWG\#MN]\_//H3.?%[O7:%'FZ7M_:69QU7
MBJ:IAP(>8;FQ5#722U,&+RV."SJC2R(LRU"0RR0+&[>Z]U7G_("_G8]F?S7M
MB_+2O^0W7_7'5'8_Q^W9AMQX;9W6E#G:6,[$W1BZNNP%75RYO*9-\IDC)BJP
M2U5**2GFA:CE2B@6>,R>Z]T,O_"?_P"2ORU^0_\ *^V?\NOY@G>)WYO'MC>F
MYMXX'=&[<'M/9M)A=G8NN_@&/B:+;V'V_0/25%7AZS(I6U49DEBK8],K4RP$
M^Z]U<7U3W5TYWOM:#?'1_;76?<NRJEM%-O#JG/8K<6+D:U[)D,155E(YM^!(
M??NO="9[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+W4_$OXPUO=\OR5R'0'4.2^0,C4LB
M=R93 8VJW%#)1428VEFILK44\E725$&/C6E6:%XY13J(=?C&GW[KW1A/?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T23YQ? +HK^81L/;?5_R$RG
M;L?7^"S%3D\IM7J[=N9VK39^"LHWHJC%;B.&J*:7*XB1'#FFD<+Y$5KVU!O=
M>Z,MU)U)UKT-UGLCIOIW9F#Z\ZOZXV]3[5V1LK;<7AHL?04RZ8H(5)9V)-WD
MDD9Y9I&>65WE=W/NO="+[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>ZK@^-O\ *G^('Q@^1&__ ):;1P'8._ODAV#35N(J.WN[]T9G=V5Q
M&)KZZIKIL)MQLO4S4^"Q*O5-$D5)$CBF58#(T9D#^Z]U8_[]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7N@I[RZAP/?O478'36Z,_OG:V [%V[-MO*;CZSR]5@<_11S%3]QB<S1%:K
M'5L3*"DT9NIX(()!]U[H#/A3\!OB]_+[Z[W!UO\ &/8-1M6AWKNNHWWV'NK<
M61K\YN+<F:JF9I<GGL]E9ZK(Y*I <K&'D\<09_%&ADD+^Z]T<GW[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(S8O7/7O5
M^'J]N]9[#V9UWM^OW!D=V5V"V+BZ'$4<V5S%9-D<MDY:7'P4\$F0RF0J):JK
MJ&4S5-1))-,[R.S'W7NEG[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z2/8&RL/V3L/>W76X7K8\!O[:.2V5G),:ZQU"T>5HYJ&I,$CI*
MD<PAG;0S(X5K$JP%C[KW0:_&/XS]+?#KH?KCXU?'C9D&P.G.J<1+A]F[6@J*
MFK,*U594Y*NJ)ZNLFGJJJLR&2K:BKJ9I9&>6HGED8W:WOW7NAX]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW2,VQUSU[LG,;VW%LS8>S-I;@[+W F[.Q\[MC%T-!6;@
MRL5'38Z/)YNJI8(I\KD(\?1P4JU%4TLRT\$,(<1QHJ^Z]TL_?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW2,WUUSU[VAAZ3;O9FP]F=B;?H-P8[=E#@M]8NAR]
M'#E</60Y'$Y.*ER$%1!'D,7D*>*JI*A5$U-41QS0NDB*P]U[I9^_=>Z][]U[
MI/[LP']Z]J[FVM_&,SMW^\NWZW ?W@VZT"9"A^\II*?[RA>JIZNF2LI?)Y(6
MF@FB$BJ9(I$NA]U[HLWP5^%/3'\O+XN=8_$?H([JJ.M.K8<C_"\MONJIJ[-Y
M"JRV5K<SD:_*UE)18ZEGJZFNKY3^S2P0QQB.&&&.*)$7W7NC<^_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NM+/Y,4'SQ^5W_  IH[TV-\$NWNMNE]V_%/X"X/JK=/=W;F .YZ;85+NM,
M9NYZS:NW*MOX9D]U9B7<5+3+)4Q2T2X^2O%0'FIH(S[KW5LW\I#YT?+3?_R%
M^:_\M?\ F Y+8&^OEK\$ZW;&1J>\NL:.#%XO?6UMUXN#)XG+U&&AAHX<=F%I
M:FDGJTI:6"D!KTACAB:G)F]U[J^;W[KW5 /_  J._P"W%'SF_P#*9?\ OXNO
MO?NO=5R_(K:NT_G=_,>_D=?RT>ZVS&?^,NQOY?-'\Y>W.H*DO'@=YY&/"5>$
MVI1Y,TM7!45*8K([;EGFAG1Z9Z2>:E"2"NG,/NO="O\ &GJCK[^6W_PI-SGP
M\^+6(?JWXO\ S+_EWI\CMS=#[;9SMO'[UQ6Z,YBX,OCJ*>5QBK8W;54GCI-,
M)^_:,P^.. T_NO='#_X5'?\ ;BCYS?\ E,O_ '\77WOW7NE5\+O@I_*X_EL_
M"O#?+>CZ3ZWZ9HYOA#11?(GN7*/DJZNR>V<MA\-G-R4V4EJJJLEK4RF0HX9/
MMXHR\LJ0T]-& 4B/NO=:A7S+[-_EQXW:?\N/=W\M_P#EA_+?X4939WS]ZQR/
M4WS2[8Z_R&W<'V)M QYMYACM\56;RE9N6IR=;#C,C3+6N]144,=3+>%8YX#[
MKW5RW7_P4^'6]O\ A5;\K^N=V?&_J;/[&HOY>U-\EZ/;&2Q-/)20]@5N^-@3
MU6\8HR/V]PSSY2KD>M4B8O42MJU.3[]U[HT756,H,U_PK0^9.&RM+'6XO+?R
M>*+&9*BFOHF@GW?UG%-$]B#IDC<J;$<'W[KW1-_Y&G\N[X:=J_(3^?-MK<7Q
MWZFDDZU^?7;7QCZ@R\F%I)9]I;+SR[WVA7X'!:E'V6,EV]72T34\95&IV,1L
MI]^Z]T2J#N_M#>'_  G:V-_*>?<F2J/E;F?YGE-_)US4V %0WV$F.WRV[&ED
M8)0UE3MNEP=-!B9&2-7FIF--4QB,593W7NM^WKGK#9W5G5.P^F-HX>BQG7_7
M/7N+ZPVQ@*2*."GI\-B,;!BJ*CB@@6.&&"*BITC6.-51% 5%"@ >Z]UJ*_R3
M/@]\0J/^<;_/#6D^.G5%*/B+\B.K9/C$:;$T\9V(:^G[#>M_NT44'%K5G'T_
MF6*PD$**X*BWOW7NDQ\#OY>GPX^>'\XW_A1$ORSZ*V?W2VP>WMD;5V'+NU)9
M3A8MVT>]US57C0LBI2Y23^ T1@K57[BE,1-/)'Y)-7NO=5B[%^8^_>JO^$AF
MQ-J2=I[EV!/V_P#,VK^&.-[!QQKJNIP^U<GFLIN[.06BDEJA0_P+%Y2E:"E\
M1>EE^TB4-*2WNO="]U9\QOY./2G\U?\ E#9S^3/O3);3H]Y[Q7X1_+38.$VU
MO3#0[NP6ZSB\)LO+YR3=&/I*7*9:DW)6//6UP\F1J9/M9ZB?12+?W7NOH.Y?
M+XO;^)RF>SF0H\1A<)CI\OF,KD9%AIZ6EIHFFJ*B>5R$BAAB1G=V(554DD >
M_=>Z^;)_->[A_E!]F?!WY:[U^!W\L#Y38;<6<[?INP>N?YHZ]<92GZ^JMTU?
M9V'J=TI0=@UN7FKL?C*JGJ<IC:"D>GIJ:&L\%%345/\ Y/)[]U[JSCN;XZ=,
M?.O_ (4)_P K;9_RPV'B>Z=GY7^23M;MC/;4W:99*#)YJFR_8E7#/DJ=)$6N
M@%74M,]/,6AE<+Y4=05/NO=(_:.R]H_#_M;_ (5P_P OWI''2;/^->U_Y?\
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M+-1Q8'(;HBR4%:^1QE+5R9"EF25:BEA(T^_=>ZO1]^Z]UK<_R]_GS\L^\?\
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M!\!_-N^(G\S_ .!G3/5?R.J=I?&W)_$?MKK+M#=E-M*#%8^IR&YLO0[D6NG
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M9.LK<+MG,9#&14Z015-5&]97T(@AE2"4^7A$D==!]U[K5?\ C?\ !_XP9?\
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MEZ&MR.-J\K55;BKJ<8&EH,7$:F2'6(/=>Z"+YQ_RL?F$?G./YF_\JKY"]/\
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M\CMRXH3C)]A',TV8K<G5XU*DU2XZJA@_A2$U4U;%0B.22:IF1UE]U[I 8O\
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M4ZSV;\=OY3]?N+#[HVKO[)9D9^MP%7B=C8K"18+[7"Y.FRN12+:T[UTF1K*
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M[\HRM4Y6OI:.&"LR50T<4$9FKJA'F?1%$FISIC1;(/=>ZUG^[/Y;'\YWK?\
MFQ?-K^83_+R[5_EY8#:7RVVEL79;X#Y05._*G+4]'M/9VUL).9:' ;1JJ&EF
MERV#GDB:/(5(>E>(NL4K/''[KW7OG1_+8_G._P POX"]2]4=^]J_R\J?YC]+
M_P Q' _*'9VY-A5._,=L [)VYLO+XW'T%89]HUV;GW,=TYNHEEB6C2B?'>.U
M8LZF)O=>Z.I\3-E?\*"H._\ 8K?.[L?^5ENSXHR0YBF[9V[\?*7L'^]U5'-@
M<I%B(\4,_MVBQ#(-P/0M6K43(&H%JEC#RE$;W7NJV\]_(=_F0=/=?_)KX)?!
MKYY].=7?RQ?EAN#/93/;+[;VYE,[OS8.+W/%3P;@VKL\Q*,36X/,4OW%+/Y:
MS'2) QEB5<C55=?)[KW1I.PMD=Z?%+YV?R+?Y:?PZ[5WMLCXM[)Z6W_G?DC@
MJ/\ AA?.[7ZYQNV1B:K,5-;1SU6O,;@JA25"XYXI6?*2%A' HFA]U[K88WIM
M/#[]V=NS8NXHI)]O[TVU7[3SL$)"N]'D:66CJD5F5U#-!,P!*D _4'Z>_=>Z
MU)4_D3?S7MM?!;LW^5%UW\^OBS@O@4T>3CZPS>8V'F:OL?(8_-[JK-U9';>X
MJE*R'#8G'C(532&OH/O:NI,\\(AI*<1H/=>Z.[LG^4'W_L?YK_R/>_:?L/I[
M,=9?RP/@Y5?%CN-)JG-4N=SV6/665V/39+;.-7"56/EQTF0K(IY179*CFBI_
M)ICFD54D]U[I3+_)[WGO_P#F*?S@?D#W=N3KG(_%O^9;\7]K?';;^V]I9#+'
M>.,&-V3MW:V6K,G33X6EQ-$4J<5/44$E+DJUC_D[S1Q,7C3W7NJM.W_Y /\
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MO="1_L[OQ$_V6?\ V<S_ &8SJ7_94O\ O('^,4O]U?\ CX/[J_\ %VU_;?\
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MC@I:2DVMUQ!34\*#A(H(8U1%' 50/?NO==_\*M<)AJOXO?R]LC58C&5.0?\
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M^WL78_\ XI-N_P#]ZS8/OW7NOJ0^_=>Z][]U[KWOW7NO>_=>Z^5E_P +%?\
MM[U2_P#BJ6RO_<_<OOW7NOIA_$#_ +)+^+O_ (KKLG_WFL9[]U[HQ7OW7NO>
M_=>Z][]U[KWOW7NM+#_A;;_V0[\0O_%K9_\ WD,Y[]U[HX__  D%_P"W.>V?
M_%BM]?\ 6_'^_=>ZVB/?NO=>]^Z]U[W[KW7O?NO=?'?_ .$SW_;\/X'_ /AS
M;R_]]MO+W[KW7V(/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U\K+_A8K_V]ZI?_%4M
ME?\ N?N7W[KW7TP_B!_V27\7?_%==D_^\UC/?NO=&*]^Z]U[W[KW7O?NO=4
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M,WWE,)MY1FJ3;&;R!2MK9**3&S*]3545+1SS-%#354\\JQGW7NC?_.7^<?\
M$'X%=G[=Z,["H>[^X>]<_M>/L"IZ9^,^TJS>6X,3MAJM:2;<V:IZ>6EIL;AZ
M7]R:0R3_ '+PQ2-3TT[&-)/=>Z.C\5/E7T3\UNB=C?)'XW;YI.PNI.PJ2:?
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MC,=19=5RGW>/:KFKL@KPFFH**5D3W7NK9_F'_*D[C[6Q7P&[S^*_R!V[\?\
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M?B'W%\0^VJO)8?;':F&IUH=T86QK<+F,96T^5PN8I59D65Z#)T<,DD#,L=3
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MHIJ<MO+*1,8(%M%%JBIXD.E1=8HU/"*![KW6X/\ RG?^W67\M/\ \4 Z;_\
M?=;<]^Z]T?\ ]^Z]U[W[KW6H9OO^8A_-;_F.;#_F(;X^ O4/P*VO\#OCQNSL
M/XO]CQ_)ZJWBW8>]IMO;=B.Z<CB#MX28"@\V R=,V-BK4TQ.56IGK5!IXO=>
MZITZ8EDR?\M7_A(6,E(^0#_S;JJ@<5Q,H,$7R RE/%"?)JO%' BQJGZ5C54
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M7[?$35\T=2U16U*3&:9\@X90H50J@7-R?=>ZK2_Z @_C-_WG3WK_ .@OM_\
M^J_?NO=>_P"@(/XS?]YT]Z_^@OM__P"J_?NO=>_Z @_C-_WG3WK_ .@OM_\
M^J_?NO=>_P"@(/XS?]YT]Z_^@OM__P"J_?NO=>_Z @_C-_WG3WK_ .@OM_\
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M&8V2VVCESO+$;KQTF,DQ_P#%US^); _94M=D0LAH\DLIK.8D$;"7W7NM;O\
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MI?M?=>Z-3LO^6Y_=#^;CVY_-._TS?Q'_ $J?$*F^*G^@K^[OA^P^WS6V,O\
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M<S;TIRFZL73UH>>BHBV.IJ2L%/5B.1Z<(_NO='A^6O\ )AQG>V6^+W=7Q_\
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M:?@%_,<^#/\ LQ_]]?\ AP'?O;^]_P#2C_<_^&_W2_TK;*Q^S_M?X)_>FO\
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MQH_X2N[_ ,=TMMK?&1^1_P D_B9OWY&X*'I2BR4FZLCN'?.'J6V7+B(L6O\
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M*JJJ5_=>Z<>X?^%+G\N;I[?WR#ZOFP/RN['WQ\6>U,OU=WOB>J>NLAEH-NC
M9JIP.;W'D,I)54F(I]M8VOHY==3)5)42QK>FI)W94/NO=6$]M?S0OA5TG\'=
ML?S$]_=M"@^+>^=LX/<NQMV4F-R,V1S/]XQ'_!\?C\$M,,K)E:@NWEI7A1Z1
M8:F:M^W@I:F6+W7NBG?%W^?I\'OE5\E>G/AYMW;'RAZG^3?=&'RF:Q'3W?W7
M^2VMDL5%B<!E=S3#,RU$\]!']QB,-4RT\E'45L$Q"()@S6'NO=67_+C_ +)1
M^3G_ (KUO3_WF\E[]U[K0'^%7\IC8=%_PGVVC_-^^*7:G=7QH_F&]0=;]F?(
M#)]K]>[DR,>/S^(ZVWYO$56W<GA))_L/X?5;=VK!^W$J135E-"];#6P/44TW
MNO=;AW67\VGH';G\J+X^?S-?EAN_%=5[,[%Z?VYG]X1XV&HJWEW57P?:Y#"8
M+'Q1&LR%1)F*6K6GAC0L*>)YG80Q22K[KW0E? S^:M\5OYAN7[*V3U .U.O.
MY.GHJ.N[-Z"^06VZO:6],/0Y%5DQN3J,1523I+CZZ*6*2.:">70L]/YQ"9X0
M_NO=%$W_ /\ "CC^6AUSWIN#IS,[F[ER6SMD]C'I_L?Y4;<V=D*WJ7;6Z_N8
M*3^ YG>,<@$=5Y)68ST])44*1032O5JBHS^Z]T<7YY?S2_BO_+SH.N*7MZ?L
M?L/LSN=:UNE^A_C]@9]V[UW8,=3K45;X?$TTL$!IXHW0?<55334Q9P!-PVGW
M7NO='_S5?AU\A_B!WI\U^L=W[HR'5'QGV]NK.=\[<S&%K<=NS:\^R\1/G,_B
M,IMVM6&KAR]-CZ=GCA!:.<E1%*W)'NO=5U8'_A4C_*PS60ZSKJNN^2^U>H>S
MLH^UZ/Y*;QZYS6/Z]QF>5U7^[^4SLK&?^)B(M/(U%25M'301R2U57 B$^_=>
MZ-G\)?YV_P ,?GA\A-P_&+JS%]_[ [7H-AR=L;+QG?.RZ_:D.\-I1O1Q?WFV
MN]7++-4XN62L A%;%0U4ZQ5$L-,\,+R#W7NM=K^4M_/EZ?\ B'UE\X,7\ULS
M\QN[-VUW\SCL+<>[.T-N[9W#OG$;%V94XG:>&P-;N?<554BGQ6&.0PE;1T6.
MH7JZN'Q@ICHZ>2.1O=>ZVT_D/_,'^(OQ>^)])\V^V.XMOT7QOS> P^X]F[^V
M_P"3)KN*#<%.E7@H]OTU(LD^6J,M2R":GCA4DP"2=]$,4LB>Z]T%/P,_FK?%
M;^8;E^RMD]0#M3KSN3IZ*CKNS>@OD%MNKVEO3#T.159,;DZC$54DZ2X^NBEB
MDCF@GET+/3^<0F>$/[KW1*-E_P#"DG^7CV9W9MOX_=9;?^5'8G8V8[]I?CIN
M*#:>P*N;';:S62R:X3$5FXLK-6P8^EQ.7SA:@I9:>6JG,T<DDM-%2+]S[]U[
MJ_&OII*RAK*.&MJ\9-54DE-%D:#Q&>G9T*K/")XIX#+$3J3R1R1Z@-:.MU/N
MO=:4?\TO^4)LG^7E\(>]/YEM%_, ^7N6_F.]1YFAW;M#Y8[^WG51U69>OWG1
MS4FQ4P-/)%0MB:N.L98Z*,/3BK#54E/_  Y9*!?=>Z</^%!7RF_G';-_EH?'
MCY,=>=E=9?$[I+?74'4V;[XH^L,YO'!]Y4'9FY*-\CFL'0YS#14N"IMG4%1]
MO!)]K4TE=/)'5QS"6CD2#W[KW6ZO[]U[IISV-J<S@\SB*/,Y/;E7E<348VEW
M#A/MS64$D\+Q)6T@JX*JD-52LPEB\T,T6M5\D4B70^Z]UH_?S5OY-FR_Y<GP
M5[3_ )E.._F)?,[*?S%>F\A@LS0?*/=VZZU9=SUN3W50PKM"+"4@J)J/#5E5
MD#/3TJ54T5-- L]8[XY*J/W[KW1VOYE7?/RK^6M/_(__ );U-OKL7XH=B?S-
MMM4_;OS4W=U#D(J+<6$PFT]EXC=&[-GX?(4].R0O75E5D ]5"Z11MC*>*>GK
ML=655))[KW22Z6Z-D_D9_P Y?X9?$/X]=F]MYS^7Y_,HZQWIMK'= ]E9ZHS5
M#L;?FRJ(YQLWMUZN&22.++35=-#40H\#RR9:LJ*N:J6CQL%/[KW4_P#F+?R'
M^H\?TO\ -?Y]]_\ \PGYG9WY*=9;;W]W_P!']\9C<\N.HNMZ.DI:K)8G;V&P
M>&IP?M'HJ6GQ5:,<:6:O5C_#Z6BG>&-?=>Z.U\/OYG.Y.E/^$_G2'\QSYWS9
M&HWUMWX[R9O-ID:NF?*[SKJ?*Y#![)D6H 2)\OOZD@Q=6S,+QRY%Y*C_ #<K
M#W7NB1_\)I^_OGKW)\H/YOF!^?W;&]MX]H;0W#TUNQ.J<KN#)Y3;G7U5O*@[
M%SV1VSMC#UE?6T.V8\?"U%05U%1GT3XY(*B:JDI5G;W7NMMWW[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]TS;BW%M_9^W\[NW=N=PVU]J[7PU5N+<VYMQ54%%C\=C
MZ*!ZFMKZ^MJ7BIJ2CI*:)Y9II72.*-&DD954D>Z]TACWCTH-O]4;L/<'5HVM
MWS7XS%=&[E.X,3_#]YU6:QL^9PU-M.L^[^VW%49;#TLU=11X]ZAZJCBEJH \
M$;N/=>Z%+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T5
MS"_.+X5;DZ?W?\A=N_,#XN9_H+K[.0;8W]WAA>P-IU6S\'DJF7'PTV.S&YH,
MM)A<975$V6H8XX*FICE=ZVD54+5$(?W7NAUVGOS8?86 VON?8V\]H[XVMOO:
MT&]=E[AVGD:/)X_,X2KB@EILOBZNCFGI\CBJJ&JA>*J@>2"1)HF20K(A/NO=
M=;(Z^V%UG@H-K=<;(VAU_MFE.JEV[LC&T6*H(R%5 8Z2@AIZ=#H15X0< #Z
M>_=>Z5_OW7NO>_=>Z][]U[KWOW7NO>_=>Z2.7Z_V'N#<F!WCGMD[1S>[]K12
M0[8W5E\;1U.2QR2R1RRI05TT+U5&LDL,;L(G0,R(QN54CW7NE=[]U[KWOW7N
MO>_=>Z][]U[KWOW7N@B[)^0/0W366V?@.W^[>HNJ<[V%E!@]@87LG<F&P57G
M*U@Q%'AZ;*5M+-DZHA&(BIEDD(!]/!]^Z]T+OOW7NO>_=>Z][]U[IIPN>P>Y
M<>,MMS,XG/XMJRJQZY+"U$-53FHHJJ:BK(!- \D9FI*RGE@F2^J*:*2)PKHR
MCW7NF;</8.P=I9S9^V-U[WVAMG<O862FPVP-O;AR=%15V<K*: U5128>DJ9H
MJC)U-/3*9I(J9)'2(&1E" GW[KW2O]^Z]TU97.X3!)0R9S,8K#)E,K3X+&/E
M:B&G%16U;^.EHX#,Z":JJ9#IBB2\DC>E%)X]^Z]TZ^_=>Z2V]]\[)ZRVAN/L
M'LC>.UNOMA;/Q$V?W=O?>^0I,3B,504Z%ZBMR.2KYJ>BH:2! 6DFFD2-%%V8
M#W[KW3]05]#E:&BRF+K:3)8S)4D=?CLC02)-!403(LD,T,T;-'+#+&P9'4E6
M4AE)!!]^Z]U+]^Z]U[W[KW7O?NO=-&(W!@-P?Q/^ YO$9O\ @N5DP69_A%3#
M4_:5T*1R34=3X7?P5423(SQ/ID570LH#"_NO=8\/N7;FX9LY3X#/X3.5&V,V
M^VMRP8>K@J7QV1C@IZJ3'URP2.U)6I35<$S02A)1%-%(5"2(3[KW3W[]U[KW
MOW7NL4\\%+!-4U,T5/34\33U%1.P1$1 6=W=B%5%4$DD@ "Y]^Z]U#Q&7Q.X
M,3B\]@<ICLW@\WCH,OA<UB)XZFDJZ2IC6:FJJ6IA9X:BGJ(762.2-F1T965B
MI!]^Z]TX^_=>Z][]U[IIR^>P>WH:.IS^9Q.#I\AEJ3 T$^7J(:9)ZZOJ(Z2A
MHH6F=%EJZVJE2&"%29)I76.-6=@#[KW3M[]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z9*3
M<NW,AG<UM>@S^$K=S;;I*.OW%MVDJX)*Z@@R/W'\/FK:1)&J*6&N^SG^W>5%
M6;P3>,MXWT^Z]T]^_=>Z][]U[IHR^X,!@/X;_'LWB,)_&,K!@L1_%ZF&F^ZK
MJE_'34=-YG3SU50YTQ1)JDD;A5)]^Z]URRN=PF"2ADSF8Q6&3*96GP6,?*U$
M-.*BMJW\=+1P&9T$U54R'3%$EY)&]**3Q[]U[KJAP.#Q>0S>6QF&Q..RFY:R
M+(;CR5#3PPU&0J(*6&B@GK9HT62KFAHZ:*!'E+,D,4<2D(BJ/=>Z=O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW2#[/V-UAV5U_NO9'=&SMA[_ .J\[B7BWSM#L_'X_*[?
MK*"$K4R+EL?E89\=44D30K*PJ(VC4H'-M((]U[KOJ_<G6.[^NMD[DZ6S^P]T
M=297;-)-UQGNKZK'UNW*G#K"L= V$JL3)+C)L8M.BK3FE8P"-56/T@#W[KW2
M[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ^?.K_N*%_D>_\ BO7=?_O ]@^_=>Z>
M/Y(T2;C_ )E__"A;>_8F*P5)WK'\W\9L&ICBF$E9'U]BXMPTNP933M551IJ;
M*X>F6=W7QBIFC9'1/M(Z>G]U[K7P[+IH\%_)F_X51[,VE1T-'T]M?^< *;K:
M+%E13(O^F[8=++#3QI)H2"'%T.+$96) 4( 9PH6/W7NM^_X?4]/2?$KXNTM)
M!#2TT'QVV5%!3TZJD:*-M8P!410%50/H +#W[KW51G_"H[_MQ1\YO_*9?^_B
MZ^]^Z]U7K_/T_P"W4?\ )7_\7T^./_OM]Y>_=>Z,9_,<^-'S1_E^?-/N;^=U
M_+[VQM7O[';WZ:QVW_GC\1MW33TN1S^ VAC\?30[EVADU6I:FR.+P>#I?)30
MPLX6EFFAHLI-5R4WOW7NBL[_ /E3U3\__P"<C_PFD^1FQ*'3\>NTNC>Z>Q-@
M8'<7VWDQ6YZ#:>X*:OQ-1%3U$]%'E=N[CV]0T;&"Z?>4BB*20(@3W7NMFGY>
M][]9?!+XS?)_YD9G8E/D(.N-@U?:>]Z':L%)29/<M;BZ"&@QE-55I1?+43"*
MEH8ZB<R?;P!=*LD8C/NO=:-7\ZKOK^<9\C_Y/^POD_\ )K8G\O\ V!\*N]-S
M===U=*;6Z(JM[_Z3=IPYF$9;9+Y"HRFK;TYEPU:8ZUJ-TE6:19(8Z*-6I3[K
MW5Y?='_<7%\1_P#QD-DO_>S[.]^Z]U8K_/7^+$GS#_E/_,_J#&8_(9/=M!U5
M-VSL"CQ+1)539S9%1!NN@I(#.KQ$Y-L0U!(K %X:J18Y(I"DT?NO=4T?!SMJ
MO_FP_P U_P#EV_('.TV)KME_ W^4GM[O7<E/3U+5+T/<';].^&R%'4L&*S1K
MA*5JFF21(Y(I*-:ARSR1)%[KW1:_B7W[_,;V;_-$_GO[K^,G\K;:_P XMQ[P
M^7,'5/9V<W!V_LK8<F%VKMJ+.8G9&/\ X7N=GFK:/<6WA][)+"!$^E::8%Z4
M*GNO=+SXI=Z?/'^2/_*^Z+^)/8WP]V=M7YB?)_\ F0Y/XZ_!/ISM#>&&W+M3
M%XS>M3A<QA<YNK-[/S.2EJ:#%;JS-72&FBJ*3(3M$M4[4:.DK^Z]TVT$W\RB
MB_X4H?R@J3^9%'\0E[*J>E>X:/9V>^&4NZUP^2V[_H[WY5FCSL.ZXXJTU^/R
MZNR>,?:LK1LB>6-II?=>Z/1_PE1BB'Q6_F'SB.,32?S=>UXI)@!J94VYU\44
MM:Y5#(Q / +,1]3[]U[J^;YO[IWKL?X6_+W>O6V-.8[%V?\ %[?^Z=@XA7$9
MJLUC]J9:KQ5,)&*K&9ZZ&)-1("ZKDBWOW7NM$#X[=>?S1OEC_P )]>O_ .7[
M\??Y.VV.Q?CSVCL^3<.Q?E72]\=;4%;6YN+?<^Z)MRG:^6KJ#)TE5#G:66CD
MH:FJA=*>-J-V$ \7OW7NK7^Q*+M&+^?'_P )K*+OW;<&V>[J3X![X3N3:GW5
M'DDQF[8.H]WG/425U#/5T%;]AFDGC2IIIIH)3&)8)70HY]U[I$U&9WWM'^<7
M_P *GJWJ.%QOK&_RTMM[KV+AJ,^**IW-3=)[>JL3(\:2TZ-4/DIS^X71]4\I
M\J&1V]^Z]T 7;V,V-3?\(@<4^R*;!'&R=;['R=?-AC'(ASDOR(V\F?DDD4O_
M )<,LU7%4W.N.42P$*$*#W7NC6?//_LN'_A(I_Y-/_O(=.^_=>Z@?RJL5B\@
MG_"KF*OQN/KH\C\Y^],;D(ZR&.59Z?\ XR!_D\P=6$L'[C^AKKZFX]1O[KW5
M6G5N;SNX?Y2__"3?%[MKJO-[&R'\WJEH-V/GII)XO#B^[=V8O$4DKS2&U+28
M1ZNF@C_1#31B*/1&@7W[KW5[/SHIZ=/^%1G\D.J2"%*FH^.W=$4]0JJ)'6/8
M78AC5W U,L9D;2"2%U-:US[]U[K8$^7'_9*/R<_\5ZWI_P"\WDO?NO=:T7\J
MCM7%=(?\)$_]*N8CH:FFV;\4?D3D:3'Y&3Q0UM=)OWM*FQN/>32^C^(Y&:"F
M!"L;RBRL; ^Z]U3[O;;'=W1W\MS_ (2B=6]==$0?)1\[\AL]\G,-U+N7<>+V
M?3[AWE79]-];!V[-FLJXQM%3Y)-YU_BDJ0T4\5*L$H+501O=>ZM-@V%_.,[4
M_FE8#^8EVW_*_P 5\+MM;<^ O9OQM[5W9A^Y.OM\?=PP[=W1NC9M:U'@<Q1Y
M;[L;P3'4%Z>DF80RQRS3PP4@:/W7NCN?\)?-@]<;@_D2_$C'9/:VUMPT^X-V
M[^W1O'&Y:DIJR&HS.-[7W1_#:NK@GCDC:MHJ;%8UX'9=<?V]-(A!1"/=>ZKX
M^77;OS%Z]_X5 ;MW;\4_A;B?F_VKL3^5WC,%LSK'-[^V]UX,7MZMW72S9/<]
M)FMSL:&IFI<EE:G&FAAM42QY&:H4>*GG)]U[I.;5^.G\P_:&V?\ A3'\P_EQ
M\)\9\*>N_FO_ "W-T;BQ.P<1O_9>^H/[S[6ZPW/C*UQ5;6RLU0\F1:MK\G+-
M4T%,JRUCPK)*P9Y/=>Z*E\]:"AC_ .$;?PA,=%2(8LML&OB*1H-,\N<W$)9E
MLO$THFD#N/4P=[DZC?W7NKEOFO4U.%_X4_?R4J;#U$^)IL[\8NY-O9NGQCM
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MJS3Y7_SU._OBAD.U.Q-V_P GOYDU'P[Z-WQD=C]H?)K+9C:^,F0T&;CP29C
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MNJ>; T]!7I/434K]AT:2Y &?8<%2:6G>KB>6I^ZJ33BE+TM48O=>ZL&^6O\
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MS6YZ'>&V-UY/<6>H8LEMM,KD,M'MB#'*15TZTM,*?3Y5I1%+[KW5S_4>P_\
M17U1UCUA_%?X[_HXZ\PNP_XYX/M?O/X/C:;'_=_;>:H^W^X^W\GB\LOCU:/(
M]M1]U[HH7\T?X,?\.4?!/O/X5?Z4?]"_^FC^[/\ QDO^"?WC_AO]W-X[>W9_
MQ9OXO@OO/O/X%]K_ ,#H/%Y_/^[XO#)[KW1>OGU_*?\ ]GC^*/PK^,7^GO\
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M7O?NO=>]^Z]U[W[KW18.Z_F[\+_C7NK'[%^1?R[^,'0.]LMM^+=F+V=W7O\
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M&ND>FD5J>224,\3:5M[KW2/^?'\I_P"*G\Q#+]?[Y[9?M7K'N[J:@KL5U?\
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M5#E_XCC=M8N?^]\51M^JJ*_33[6I&3^'38JTDE06U*\:1>Z]T6OY5_\ "?\
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MT5\$$E&M/&)*II33B"2I]U[HRG>7\[7XK]4?"[XA?.G9N(WGW7TU\SN]=M=
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M)522Q,Q@6$&4>Z]T;'W[KW7O?NO=>]^Z]T53X>_-+X]_/'JO*]W?&+=]5O\
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MO976FY\[L">MJL-.V+H^LZ>E_AU1D<?BJV:GCHEAC#34D#DH;I^3[KW1W_\
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M6[[VQ-'DMA0TVYC&V;S.2KGW'C(LG4UDLM#%)3SQQTM-%(:Q?=>Z,KW-\O\
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M-IZ_["M$$DT'WE"TY@F\4DD?EC;QR.EF/NO=41=Y_,#^9K\W_P"8I\JO@O\
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M4S[IVYB]I].[/DVS'USN/;.(Q<LV/P=>S5N;S&-.1R^/ J,O4U<E2M55_P#
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ME]N#&Q+/'&R[FK:?&8RL@@GJ:DP4>0PFWZ*II45@#2RPR,&E>223W7NB]?\
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MECZ7.8+&Y7*45=-BL/M2@H*#*"9ZO3E11-!!2Q/++[KW6V/\N/\ LE'Y.?\
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MNP??NO=%Z_X4,_\ 95W_  GO_P#&O.P/_>DVI[]U[KW='_<7%\1__&0V2_\
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M_P"DNP>T=@F4[%[)WOM3 Y;/X7SQI%/_  G,5]!49''>:)%23[>:/6JJK7
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MYL3EJ:M7=_\ >)LTL"T4L-']@F.\E/YS4,WNO=7:_-'^9K\O]L_*WJ[^6Q\
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MQV],W4[UR=/)O3^YD.<V[2.E/0X''4F;1L5)'7IE)ZNN*5*"DHFN/=>Z1O\
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M7FER,%1 /(0DDONO=;%/\@'_ +<U?R^/_$"T_P#[LLC[]U[JN7Y*;EVYL/\
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M6V:&NV7D<I)M+>N4@BRN(QI\=)3/1TM1-#D1-]XO@56]U[JL7M3Y2]%=@_\
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M@R$%+'-+4)CIJS&U5%45^)%1-)*:"K>>B,DDCF L[$^Z]TB*O^4/_+=G^/\
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MM:G@K34QUT,^,HX*:JQ\K+4T,K)%/+ 8XO=>Z"_X^?&/;_S%^4/_  HDV/\
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M+U3V/34U7L^OQ)CIJ6GJZ%I,55/,(@_V4]2*1V1!!&ONO=41_ 3^8Q@_@/\
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M\T==C<SN#?-544\JV*GRQR:)5>"#W7NKJM^[N^;?\U#^85_,0ZCZ4_F#[[^
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MS74M4L,57/C:9S)"(YT,*^.5+M?W7NB$_-SM_P"2'R$_GE[I^!._?YC/>/\
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M[4V\N[$PV/JLFF,P6W,)@Y0V/DR5?4R4SSFLTLU'5RSTI5J%Q/[KW20^-_\
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MH&6Z]V?C$GJ]T9'<7W%%)38C(8=JE5:*K&D00U=8%EAAC\WNO=;J?OW7NOG
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MA5>.F8&C^UJF-3$6]U[JZ+I?_N+B^7'_ (R&QO\ [V?6/OW7NJU_CCTWO'Y
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M]U>=_+K_ )[_ /+S[:Z+_EO=(8+M>7-_)#O?8>WNFJKHW8N,RN;S&U]R8';
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M_8+[]U[KW_0$_P#RX_\ O)KYL_\ GSV)_P#8+[]U[K2B^6'Q*V)\$_YSE?\
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M7O\ [A[.]^Z]U]=?W[KW7O?NO=>]^Z]U[W[KW7O?NO=?.Q_X7#?\SK_E]_\
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MBSDN4E^RG2:=*6CECGEJJJ.DIY:A?=>Z)5\1/YZN0[@^4W5?Q(^8?P(^1?\
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MUN=U');OJY1W,N3I]]D#ML>1?[TMCDQSBC,Q(A-74MI8.5/NO=+2M^)_>WS
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M-RRP0U@EE>DJLMOS*FGULBQ0.(Q"J,J1>Z]T>_\ X4^M!L[K;^5/WACJ:/\
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MS;X%=C?)C^9KVQ\D.V>T/CYE\GT[7]C;AW%LRNPN/@VOF-H[I.,RD6)PN+S
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M0UK#.UX8A$DJE JB33RTH3W7NE;_ ,*CO^W%'SF_\IE_[^+K[W[KW5>N\O\
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MDWB<P0RU%-&LKN[*ONO='R_DJ?\ ;X__ (4G_P#BPO47_N)V?[]U[J@'I?\
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MNO>_=>Z][]U[H@'\V+_MUE_,L_\ % .Y/_?=;C]^Z]U\]W_A&/\ ]O8NQ_\
MQ2;=_P#[UFP??NO=?4A]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7R*/YQ?_<2)WG_
M .+C]>_^X>SO?NO=?77]^Z]U[W[KW7O?NO=>]^Z]UJ!?\+5O^W670?\ XO\
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M,47W7NMQWW[KW6KY_P )YO\ LJ[_ (4(?^->=_\ _O2;K]^Z]U[^2I_V^/\
M^%)__BPO47_N)V?[]U[JD/X4_#'M?YT_\)'.R^GNB\$^[.W-N_)O.=M[)V="
MQ2?,/MS/8RJR.-H[7$F0J,,]9]G"1:HJUA@NAE$B>Z]T9?X0_'W_ (3=?(7O
MOX\=9]-_RH?FK@/DK-NNCJNR\5FD[W@QW4.>QF+7<,4N^LED]^_PRFHQ714T
M-.RK6)+]S32U,44,O/NO=62]+_\ <7%\N/\ QD-C?_>SZQ]^Z]T57YTT_P =
MNC/Y\W:O>7\V3XX;D^1?Q%[7^)6V-@_"'-YGK;*=G;0P>?II*)<]MAL#2T.=
MI&W1E,M39*KII#0^>**LC%HHY_N']U[JN3X\;8CP?\HS_A4'F<%T1OWXX=9[
MV^0.;W=TYU)V%MFJVC6X3:M9F:N7"8?^!U$,*X_^#X]XJ)Z:'5%2O"U.K6C]
M^Z]T(F]OE#M[^:O_ "UOY1_\FGH#H?Y$Y[N@8[X_TGRG?=NT<U@\-M'KC:.V
M*6CR.]SGZA::@J,%N&GI#6X:L@G*5U")%@;^(2TE-+[KW1H?YU_PO^+^ROYN
M6V/G9_,B^+7:7R2_EN]L_$Q>K]Z[NZE;>3R=<[_VW7"II=P;EBV1E\/F(<"^
MVZ9H$E,TM,[U=4[TK344+M[KW1OO@]\(/Y9W<?P@_F;R?RM?AA\A/BC7_(;X
MZ;Y^(F)[$[[@[&ABWO2YO9E8N,S>V<;OO=66-5A(LME3"95CH:HS4[QS")'3
MW[KW6N#\GOFS1=S_ /">+H/^6)LKXV?+BN^6?QYWW@MI?(#:W^CS<@QVSGP&
M4S%;3'-9)J%4IZO.4592RTM$4^Y0R2+.D8C5I?=>ZV/O^%#^X)OCY\Q?Y'OS
MSWIM;>V8^.?Q0^3&\L=WIN38N*J\Q585=Y)L:FPM3+24J$M3S2X6J2VL32RB
M*GI8JFJFB@?W7NDW_.[[.P?=/;O_  FQ[;VQB]U8;;78_P#-0ZSWEM[&[WQU
M1A\O'0U^>VE44AR&*K E9C:F2G='>FJ$CJ(=7CGBBF5XU]U[I%'Y#XG^1_\
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MF#UEUK6XB6DS^ZJ7KW.9/"[BQ='CEJ'JHZJGJZ?[^)84JJNJ@Q[T]'235-5
MOOW7N@"[9^7U+_PH/^4_\MCH/XS=#?)+9/0_Q8^2V,^:7S-[4[=VY5;?Q^V,
M[L5)J6FZY2J=:BEK-T"OK:NAJPDJ^,S++2"I2&N>C]U[HO'\S'^95\.^G/\
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M@7'^11_W@S_[$WN+_P"V#[]U[KW_ $"X_P BC_O!G_V)O<7_ -L'W[KW7O\
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M^Z]U[W[KW7O?NO=>]^Z]UI8?\+;?^R'?B%_XM;/_ .\AG/?NO=''_P"$@O\
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M:_:]>TM/+49:-J:?(U,^W<QCUJ*R-K5;:GJ/\I:H4>Z]T?OM_P")&W_Y1O\
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M];$I,IIG\=)GZW+[PQ5/"\Z^?)&CF@A0K#$(/=>Z^A][]U[K6RZ=[+[&JO\
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MRU-NC&T6_-QXM\M5T&=J)JBI:NIJW,SU=$U2*B*"H6(^)DC">_=>Z$+^8_\
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M4N9[ &8J<<E1'C9ZRDVP,A3257B:H*A(%G5:4H/=>ZULHNX>K(OY<:?S;_\
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M&]<U@,!D:O,=<; @UY.AHJ@05-/13RRU<=/H6&6KD\M0LJZXW]U[JQ[_ (3
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M/=_X1C_]O8NQ_P#Q2;=__O6;!]^Z]U]2'W[KW7O?NO=>]^Z]U[W[KW7RLO\
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M]C*::HA@F$=4\=+/+[KW6Z[[]U[K4GZLP?S+_EE_S%?YIN7C_EH=\?/*A_F
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M0U6]-I[\VI#!A,)DL?A$I34UF$KJ=EDFD"U"1-6Y>KK*F@AH:2*K]U[HQ/\
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M^VWE[]U[K[$'OW7NO>_=>Z][]U[KWOW7NO>_=>Z^5E_PL5_[>]4O_BJ6RO\
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M +&O?NO=>_Z ZOYO7_*U\4O_ $-:_P#^QKW[KW7O^@.K^;U_RM?%+_T-:_\
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MR51CRT<F"R-1M>%\75TLU#5RT]2(VK()@T=,X:FB]U[HWW6O:O5_<^TL;O\
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MO^'A^RDVS]NT1B\JYG+?<^/23+I^T-%8MZ"+>,DB2WNO=;.OOW7NM7SYU?\
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MKWOB:K(9Q9ZF+)(9L9AY98Z./'TD@I%JUIJB "8"L'NO=7!?([XU=2_S3?\
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M1K\WNI,)1U@CKQ65"4FY,775]3#4>2F>"MJ*8(ZUTW@]U[I4?'CIKK'^7?\
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M^-'_  ES^0-+T!T_L/J&E[+ZJZ%[!W_3;#H(J"/+YRIWYU6M1EJY(0%GKYU
M$DS#6X50Q(46]U[IO_FP?]VJ7_B^G1?_ ,H7OW7ND'_.<ZYVI\=OYN&S/G[_
M #$OB+N#YK?RN-V_%NE^.KU6+QIW)1=1[E;-4U;-N/)8%GC2&*01SVJ2\1GC
MR50M,\M?1TM)/[KW5T4W2WP8WM_(Q[DZ:^$,^V8/A5O+X6]CT74V2VK-55T%
M+3Y/$;AKIZ]ILM*^2FRU%G9YJFI_B,AK!71R"M8S"3W[KW4G_A/1V-N;M/\
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M_(Z^.>?^,W\KSXJ;3WQ)F:GM/L;9<OR'[@K=R!!DI-T=BUD^\,K'7B-4'W5
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M..*1E]U[H6<E\N/C/B_CC4?+V?NS8-5\9*7:R;VF[MPU:N0P Q3S)3_?+64
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MC[%[#6HRFX\KBJKE*;(46%DR>$R '^4,@B1BD!"R^Z]T7_\ E/\ 1W3?<O\
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MIV=MZMJX:W;V1Q]:XJ5J*W)2L979S+CY:>MJJ8>Z]T?C^9W_ "S.Y?E5V?\
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M5'-5Q;FA6%:*KR".JS^22(K&)/=>ZU7?YJ?P?^;/\M/^53W'\ '^?'QPW_\
M"BH[6P-/\7/CC%@9Y^\-ZUFX.R:/<R;0GB1H:2DI,15RR;B>JQJ5LV0JJ26G
M6FH*:I6,>Z]UOW_'C:N8V)T!T9LC<,*TV?V;T[MG:N<IT+$1UF.PM%25* LJ
M,0L\+ 753QR >/?NO=:B??6S?F]O'_A4+\H?^&_^WNE^H^^=L_RO<1N0GY!8
M6NS.T]Q8@9S95#/MW*-BF.4Q"RY&NHJ],A20U,L3X]833R15$EO=>ZL&V_\
MR1^Y]I?RLOYB/QBKN^]F=Q_.+^8[N_/=P]T=Y;T@K,%M5MU9RKH9EH:6+'8_
M+Y2CV_C8:64Q'[6>5JBIJ'CIZ6F>&DIO=>ZN0^(?QVR?2OP0^+_Q,[9;;6Z,
MSU+\2-E?';LM]M2U-1A\C58'9N,VUF3CYJNEH*R?&5<M)-X'FIJ:9X'5I((7
M+1K[KW6NR_\ (?\ YE&QNBM[?RRNCOYAG5.TOY4?8&ZLU72T&X=JUE5VWM_:
M^=S R^4V)BZZ)5PV0Q64FJZUZJOJ*N"H:65P*<TU5-3)[KW1\?DW_*)W=W;V
ME_*<Z/VEDNL-K?RR/Y<.4Q?8NXNL<OE,W4[RW/N79^)_AFQ:4T?\%DQ-3B\>
MM.OW]7599:JL3(Y(/3,VAIO=>Z%+X!_R].]_@A\Y/Y@^Z-I;FZHR'P#^8V_X
MOD?L#KNGR&63=^T>R*]*<;L QC[>_A,N S\LL[K(F;+4<5!BZ:GQJJ]3(GNO
M=52]-?#W9?8'_"L/Y2]M[8W/D-R[!^-?1&#^0V]=GK6R#%[<[=WSM+%[)I84
MQT3B":LR.SJ>HRTL\BM(D\D09OVJ=4]U[K;T]^Z]U1C\\_B)_.2[?W[W5B/B
M7\[/C9M;XR_(_:<77.Y>I^]MB5%1D]@8RIP4^&SN3V9F,8M>^=RF5+B9J7+"
MGHDDD=X? R-]S[KW0+?*'^0_5[Q_D[?&G^7!\:>WL#L[M?X;;]P/>_2':^_J
M.9,17;\Q,^X:[(5V8HZ.+)O246:R&Z\I*1]KDEI6FC9J2L\6AO=>Z'WY=?RT
M/DI_,,_EN;:^.ORT^0?5^.^:&S^SL5W[LGOGI[;4\.T]O;PV_75;84X["Y&;
M^(U%#'A:V>@J)Y94J)9*F>J6)(M% /=>Z*A6?RJOYJOR.^:7\NSYC_.?Y>_$
M?=<GP9W[E=P4G470^SL_AZ&2GRB8J+(Y"GS62J9JK(9G-KBZ9JF*:EHJ&C-'
M$E&A%1.R>Z]T.G1'\LGYI_&'^;7\L_E[TU\@NB8/AS\Y=T;=[&^077&Y<)E*
MC?R9+:]'7P8[#X&I*2X6GH*FKS60FJ<B]0)OMY5I(L<LRQU\/NO==?(_^61\
MV>N?F]V[\^_Y57R1Z2Z9[%^4>V=N[7^5/2OR9P.2S.SMQU.W!#C\9N>AJL,)
M,IB\OCL.9M--%&D%74F0S5$(K:B1?=>Z&'OKX+_-OY!_RC/D-\*NZ_DWUCWY
M\M^[=FYO#1]U9G -LC:\,F4S:92AQLM%@:3-5,>-PE(/LH:J.B>HGBBA::G$
MFMS[KW18_F?_ "A_DG\B_P"6%_*<^%>R=[]'XOM/X(]F=$[S[=S^Z<EGH-OY
M&EZPZ]RNT\_'MRJI-M5V1K*BLR-=')CUK:''I+3!WJ7I)0(6]U[HS_8/\O+N
MG=G\\WHS^9KCMS]7P]#=9?!.K^,.>VE6UN67=TV?J-P;QRJ5='01X23#28<4
M^X:96EDRD53Y$G I2JQO)[KW1/?^&H?YFWQ/[5^1^&_E;_.+HSH[XI?+?MC*
M=R;LV'WIM*KW%G>L]PYZDE&<R_77A1\9D7K:U*;Q4.4:GHZ:&&$@2R02?>>Z
M]T:'^;__ "XOD5_,)^-'PSZBZ][)ZGE[&^/OS-Z\^1_:&]NS!D]O4&;Q^U,#
MN?&9J3%T.$Q>Y6ILKDJW-13T]$^BDCC\J-7)XXQ)[KW2A^27\O+NGN+^<G_+
MF_F';9W/U?0]+?$/JSL/8_9.V,[6Y:+=%=5[MVSNG"XZ3!T5/A*K$U-/!59N
M!JEJK)4;I$DK11S.J))[KW1:MF?R^_F1\&_YE?SK^?W5/>G3-9\*_E9!C^]?
MD;U+7[?S5?V1-7;%PV5EH=O[7,%/68T0Y"JRF0>2L$CU3QSQT--B_N!%6Q>Z
M]TJ_^$Y/Q^[+ZS^#F_?D-WYLS<VP_D5\]_E'OWY>]O;5WE ]+D<9-G<U-0XV
M@>EGBAJZ:"2CQW\12*J!J5DR4WE*76"'W7NJ7OBYUA_,K[#_ )N__"@^7^7'
M\C.@NC<[3=\]?[7[2QG?^W:_,4E=29J#>B4&?PE?C5J*C';@VE#19"2CIIJ6
M>BR,E>(ZMX%@23W[KW5@_P F/^$_/8F0_D;;*_E4?&7MS8.?[6Q';6.[AWSW
M+WM+D\+CL_F9LM7YC<-;(,'B-S5]-KFK5I\?"\-0ZTE/ E562S*\\GNO=7C_
M ,P?X1=8_P Q7XA]Q?$/MJKR6'VQVIAJ=:'=&%L:W"YC&5M/E<+F*569%E>@
MR='#)) S+'4P"6EE/BF?W[KW5*>U?Y._\R3Y$]H?$7"_S/\ YP]+]Y_%3X']
ME8?M3J78/3.V<ABMP=@9[;='#!M[-=B5=<D5/25E"3-#-%0RUJ55-)/KD6>M
MEEB]U[H]'S,Z"_G19GN[=>_?@7\W?B_M/J#?FV\3M8]&?)+8U75)M*6"-J?*
M[DV_N#$+DJW+9>I5C41T5?##C6<)!)&MFJ7]U[K7J_G(?R[\'_*Z_P"$RF#^
M).+WY5=GY7;?R8VUN[>N_9Z1:"+(YK-9?(5=8]'0"6=J2AIT\=/ DDTTICA$
MDDA=R%]U[JXKJ'^5M_,&[6^<_P :?E5_,U^8/2G>FS?@9#G3\6MB]#;5K=O/
MN',Y[&4V.GWCOV'(-+34.7A$(D6BQLE7 )Z6CF@JZ:,UE)4^Z]T[=Z_RQOGI
MU#\U>]?F?_*G^471_355\PJ/ P_*3I+Y,8')9K;53F<.5HX][;?DQ"R55/G:
M?%R3LM'(L5-654T_W52$GC:D]U[HX7R#_ET[@^:?\L7,? ?YG][/V]V7NWKC
M'X?=OR5V_MZEP,TNZ\/6T^5Q&Z(=O4=8*2-J/)4=.:BFCG@CKH%GB;[=*IU3
MW7NBZ_"#X<_SB]A=V]4;@^;G\P[J[?W0OQXV'7]>[2ZQ^/VV9*"K[(2HH*"C
MH\SV;4YS'F&FR..:F:2-<3JE,L:R)71+5U\,WNO=)KHC^63\T_C#_-K^6?R]
MZ:^071,'PY^<NZ-N]C?(+KC<N$RE1OY,EM>CKX,=A\#4E)<+3T%35YK(35.1
M>H$WV\JTD6.698Z^'W7NF'Y3_P L#Y\T'\RO>G\PG^6Y\G/CST5E_DAT?B.A
M_DYM_O':^1S3!,*J0T&[\)#C]5-FL_1T>.QE+2TU>]###%3R^6KJ(912I[KW
M47^7U_**^9GP2_EV_*OXL[(^<.T]M?*/O;Y2YKY);.^56V]H+E(<7493';*I
MI4K=MYF=:*HJ<A-M>I6J!,],D%<0D4Q32?=>Z=?BO_+&^=>Y/YAO7G\Q?^9S
M\B?COVSV1\<.K=P=-_&O8OQHVYD<1BZ6ESOW]'5;FS55EXX*L9FNQ.4JXIJ&
M):BEIVJ"M/5,D9,ONO='R^ OQ[^<'1.:^5%;\R/EQ0?*/&=H=YU6^.@,?18P
MX_\ N?MB;SLF&<F*$ ?NPQK2Q>2GIQ2^6.9VJI4C]U[JQ;W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=!!V]T!TIW_#U[2]V]7[+[4HNJ.S*#N7KO'[YH8<C38K=.*I:^CQF=IJ:H
M5X/XACX,I4BFD='\+R>:,+,D<B>Z]T+_ +]U[KWOW7NO>_=>Z][]U[HN.&^)
M/QYP'RCWC\TL9UU OR<W[U91=);C[4K<EF*NH.U*"KBKZ?"46/J\A/A\31M7
M01U$_P!A24SU4T:2U3S.H(]U[HQWOW7NO>_=>Z][]U[HI^Y?@I\/-Z?)+#?,
M#>/QRZKW9\F=N8ZAQ>W.Y-S8R*OS&.BQJU"T#T$E7Y8:*II%JI!%40QI4+<6
ME]":?=>Z-A[]U[H*<%T9T_MGMK???."ZXVECNZ.S<)C=L[[[0BI(VSF1Q>(C
M$>-QDV1<-4)C:2VM*2-DI_,6G:,S,TA]U[H5O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]T7'I_XD_'GH3M3Y"]W]4]=0;9[8^5FZL=O/O[?,^2S&2K=PU^(I9J+%>1
MLMD*Z.@HL;2U,L=+0T*TM% )9#%3J78GW7NC'>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MN@IZYZ,Z?ZBS?9FYNL^N-I;+W-W/O67L3MG<F#I(XLAN+-2KXSD,Q7$-55TT
M47[4 E=DIH0(:=8H@$]^Z]T*WOW7NO>_=>Z][]U[KWOW7N@I[=Z,Z?[]PFW]
ML]U]<;2[1VSM?>N.[$PFV][4D>0Q\>:Q#228S(24,X>EJ9J"64RPB9)$CF"3
M*OECC=?=>Z%;W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:]7SV^8/SY[>
M_F/;._E.?RY>Q.K_ (V;[I/BO5?+?O3Y2]H;>CW7/B,*<TNW\9BMM;?K(:G$
MU-:^2GI/N9:^)XC%6 Q,DE*T=3[KW0T?R;OGM\B/E3%\R/C5\SL9UO1_,#X!
M_(&3I7M?-]4AH,+N/$UZUDVV=T4V/DEEDQPRZ8VM41W576G67Q4TKS4E/[KW
M5UOOW7NM='^>Q5_S7N@NJ>Y_F_\ #+^89MSX]=$=!=%4N;SWQTJ^L=E;IKLU
MFJ;*5*5V3AW+N3#92IH164E?20K3Z7AC^S+J@>=S[]U[H;?Y-O\ PXID?CEL
MWY<?S!?GSL_Y+=<?)+XS[#[WZ\VF=A[0V'_<(9_"0[DR"Y'+[?QN+BRZ?9Y2
M""2:H$<41I#+'&@F8+[KW5MW5?>?2?>N*R&=Z1[AZL[CP>)R<V%RN9ZKW#B=
MPTE-64TTE/44E148BKK(8:F">&2.2)V#I(CHRAE('NO="G[]U[H",7\I?C)G
M.SJCI/"_(SHC,=S4D:S5?4F+W?M^HW/$CM(J/)@(L@^517:)PI, !*.!RIM[
MKW3GO[Y%_'SJG^]/^E'O;IOK;^X^!&ZMZ_W^W/A,/_!\6S0(N2RG\1KJ;^'T
M#/4PJ*B?QQ%I8P'NZW]U[I:XWL+8.9V0G9F(WQL_*];R8*7=$?8.-R=%/A&Q
MD,;S39%<M%.U :&**-W>H$OB5%9F<*I(]U[H.L;\H/C1F=[;7ZTP_P B.B\K
MV-O?#R;BV7L#&[MP$^;R^/A=8Y:[%XJ+(/7Y"CBD=5>:"*2-68 L"0/?NO=*
MG>/='3O760GQ'8/;'6FQ<K2[=?>%5C-XY[%XRHCQ,33)+E)(:VJ@D3'1O3RJ
MU20(5,4@+@HUO=>Z351\G/C91]04GR#J_D)T?2]"9#&_QF@[OJ-V8%-H3T=F
M;[J'<K5XPLE-I1CY5J2EE8ZK ^_=>Z6N+[2ZRS>SJ#L3"]C;$R_7^519,7OK
M%Y?'U&'J5=M"-3Y.*H>BF#N-(*2FYX'/OW7NGW,;JVOMZ@I,KN#<F!P>+KYX
MZ6AR68K*>FIYI94:2*.*:>1(Y))(T9E522RJS $ GW[KW2-[1[OZ6Z/QN,S/
M=/;W5_4&(S>5@P6&RO:.X,3M^FJZZJFCIJ6CI9\M5TD515U-1-'%%"C-)))(
MB(I9E!]U[H1:&OH<I14F2QE929''5].E70U]#(DT,T4BAHY8I8RR21NI!5E)
M!!!!(]^Z]U1?_/?_ )I>X_Y:'3?QMJ.JM[=*X3MGOOY5;8ZLS.-[.JJ22OQ>
MP:FFS%1NK>..Q,N0I&:##5%'04DV1J8I\;0R9&(52&26!6]U[J+_ #9OYLL_
MQO\ B%\8_D#\%^P^A.\\1\E/G-L[XG)VMMC)T.\,#18[,T^YJK.5N'J\)D9<
M55YJBDVX:1%FDG@IY)9#/3R/$(_?NO=7&]>=]=&=NYK>.VNJ.Y^I^S]Q==Y,
M87L# =>;CP^:K<%6%4<4F8I<;65,^,J2DB-XJE8WTLITV87]U[KCO[OSHKJG
M<&T]I=H]T]2];;JW[7?PO8NV=_;CP^'R&:J1'+,:?$T61K*:IR,_B@E?QTZ2
M/HCD:VE&(]U[H65964,I#*PU*R\@@_0@_D'W[KW5'_\ .%_F#?)3XV[F^(/P
MR^!>U>O]U?.GYZ=CY#:/5N1[5$S[;VIM[ 4\%7N;=>6B@]<RX^GJDDCCTS'P
M0UU0E+72TL=#4^Z]T7/X5_-K^8Q\9/YCVU?Y7'\UG?O3O>F4[^Z9JNU?B/\
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M'OW7NJP/YS'S5[3_ )=O\MGY'_,7I3 =?[H[-Z?_ +G_ -VL%VE2Y&MP4_\
M>#?NUMK5OWU+B<KA,A+XL?FYY(?%6PZ:A(G?R1J\4GNO=&VZW^06S\CT_P!
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M9P335\=#7U,"S+9A%/*@-G8'W7NKX^I_CAT1T5_PF%[8W5TYU1LGK;<7>O\
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M\)4S4DST]7#3Y7#U59032TM1&T4RI*6CD5D<*P(]^Z]U25_./_FVS_ /OO\
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MQ]Z)VG_?GM[M3J.;;&PMH_?XS&??USUM%,L'W^8K,?C*6\<3G745,,?%B]R
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M;\ZZWYA)MM[SV9N2%:G'Y/'U*Z*BBK:=_1/33IZ9(VNKJ2K J2/?NO=:G_\
MPD$^,?Q\A_EW;:^5,/3^PXOD=5]J[ZZ^J^Z8J")=PRX,56/MB9,B )WH 8D(
MA8E-2*UM2@CW7NJI?@U_+T^''R"_D_\ \_OY1=P=%;/WQ\@>K.^_D;_HT[5R
MZ2OEL -B[ Q6\]O+B)O)IH?%GJ^>6I,2JU9%(:>I,D*JB^Z]TMOFC\P]H5'\
MFK_A.ST+\L>VMY;.^/7R=S^'ROR\W#B!G:VJS?675 Q=#EL)6R8AJC/3MDH\
MQC@HIF,@J8HJE4TTP1?=>Z'W^6=\ROY;V(_G_=?]??RE=V2X;XI_-3XI9C:G
M;G2.V]M[DVYM^B[)V/1YC<M!G:7&;BH:)*5JC:>$>&]!%'%]P]7).7GK6]^Z
M]UO/^_=>Z^8_\]?DA\=^]\-_/A^4K=_]?;8^86%_F&]5K\-NM=V9?$Q[C_A7
M0M?_ '63<NU**MD#DU>'SN0J@BJPE2CFIHHYJB25)/=>ZOU_X4S]S;>^1G_"
M>SKGY ;3JHJS;/=VY^H>V,%41))&#2[AHCE808IE6:%T2J"M'(JR1L"DBJZL
M![KW11>XU_F=_P T3^9K\=/Y0?\ -AK?AMT1UUUGC\7_ #!<SM+XQXO<U;0=
MG8O 5\N-AVP]5N?<.5-0*B"7+K+&\,--"E+5U$D57-!2!?=>ZL2^6C2'_A5[
M_*Q&^):Z+:,7P,W\_1XIU@$4F]7H^T(]S)4/$AJS%_='P$"H84PF$/VQ\[3A
MO=>ZVD_?NO=?,?\ GK\D/COWOAOY\/RE;O\ Z^VQ\PL+_,-ZK7X;=:[LR^)C
MW'_"NA:_^ZR;EVI15L@<FKP^=R%4$56$J4<U-%'-422I)[KW7T>/CAW-M[Y&
M?'OHSY ;3JHJS;/=W4.W.V,%41))&#2[AP]'E808IE6:%T2J"M'(JR1L"DBJ
MZL![KW6NI_/T:3_AQG_A.8F[9:Z#IH?S"9Y]P2T*P7_OG'E>O#UZKMH:O6%\
MB:U9?':F,)E-605IV7W7NMI/W[KW6@W\-/Y='PX^7V__ /A4)VI\B.EMO=E=
MB[ ^9W>.V.M]WYMIVJMMHF3WUF4K<&!((*'*+D88I15B,S6B6+5X6DCD]U[J
MRW^7G\FOBW%_PEDZ+["_F3U]))\:Z_HW='QW["Q-",B:S*X?$[ZW1L';V'Q,
M='5#*-FY\=B*-8'I9H6@GC-5$])##JA]U[JH+ ]B?$VE_G&?R0LW\)?Y:?RB
M_E?SY+M3>NR>P*/OSKV;K[_2!MO(8?;U+AJJ@=<IDHMQBEIZO*)7S-))+&:N
MC>::?RPLONO='4^"G\N+X5?/K^<[_P *#*_Y?]#[=[R;JGNK8N!Z_IMSUF6@
M@QD6ZZ?>3YN:"'&Y"B3[ZH_NW0"*J8&II5CD6EEA%1/Y/=>Z77RJ^$OQ'[7_
M .%5/0_6797QVZHWQU]VM_+-J^WNR-F[DQ%-58_-;GI=Q[\Q-+G,A32*8ZC(
M4V,P]#2Q2L+QT])3Q)9(D ]U[H%OYL?RB^ F!_GN]7=)_P TG-,?@+\2_@U3
M[@ZPZ8RF"SVX=N5O9FXLC'#!55^&V]1U]7D+;5FM&U<CT4!Q<:*J2SO]Q[KW
M4;^3G\EOCYN+L'^?U\:_@WO3,[B_E[T_1TGR+^+.UJZ@RF/H]NU.=V?DX-[T
M6+H\]34N;Q]"V<J(Z6*EG7P"/&I/3*HGEEJ?=>Z-Q_PEO_EM_",?RY_A/\^)
MN@=L5OR]KMP=D;E/>%=592;)PU,.[M\]?Q)3PO7G'P4B;6IEIA3+3BG$Q>N$
M8KV-3[]U[K:H[*ZUV#W'L'=O5O:6TL)OSKK?F$FVWO/9FY(5J<?D\?4KHJ**
MMIW]$]-.GIDC:ZNI*L"I(]^Z]UI=?\)O=D?'WXV?R0>]_P"9=!TOLZ7Y(=)[
M/[NW+4]OXS&4DFZ*G";6PS9P85:R=HA44K'&)HIII%@:14UE;:A[KW0?]/\
M\J+XN=N?\)QNV?GUVYME]_\ SVWO\>^R/Y@>0^7>2JLC'O.#=V"7/[FP\=)E
M$K6GIJ*GI,-34LU/&5IJB<SUQ@CGE4Q^Z]UM5?RD>]]Z?)K^6;\(>\NR,S6[
MD[#W[\=]OU>^]RY)(8ZC)YBCI1C<EDIT@M")<A64<E0Q144F0D1Q7\:^Z]UK
M(_S=_EK\$X_Y^'7_ %9_-=W)-7_!GXP_"E=Y;!ZDS6#SNX=OY+M/=.54"NR6
M&V[15U5D&?;-02KUL;T4#8R-%5)9W^X]U[I;?R!.S/A_\A?EC_.+^#'QNG7M
M[^5EO2#:O<_1G4>\\5DJ?!T$&Y:'[7?^%@Q>X::FS%-B*G,U$=&*&I4TS0XY
M9:= M1-+4^Z]TJO^$H?PL^)O9W\JG-]F=@_'SJW=_8/<.[-_=#]I;QSF*IY\
MAG]F2Y+#54NV,I4LODJ\++48^G=Z5R8F,*:E('OW7NJX_P"5K6=7_##_ (3$
M_,S^8OUUL;;NR?EU)B-\?'W%_(O;5!"F[8:3=FZ=J;9P](F4"-4+2T&:R%#5
MQB^F&6EBG%FB!'NO=$MW/\P_Y,WQ1^/?\K[NG^7[VMEL9_,:^*?;>R-U_*#?
M>&VKOO'Y+L'#9BD=NW:#-9/.4$>*RL-7E)2:..HFJ?MJ#S4&.TQ37'NO=;*/
MR)ZKZ[_F-_\ "E7'_$;Y5;?@[9^,_P ./Y<<_P @-F=%[J#/MNLWEF]S8'$U
M>9R-!'*J9.0XS<L"!:D-$K8^ +"+2/-[KW2P_FO?RMOA9\1?Y%WSIZUZFZK>
MHV;LBKSWR=ZOPN_,ED<_#L_=>6K*:C-1M*/*5%1'M^GHL=52TE/%2+'^W+/+
M,TU34U,\ONO=62?R1OCAT1T5_+2^%>ZNG.J-D];;B[U^'74?9W<67VA11T<V
MY-Q5FP<+4U>:RQB %7DJF>LF>6=AY)&D.HFPM[KW0Z?S.NTOAMU+\&OD%F_G
MW5(OQ7W'LN;K_LS#1"L:NRT.<(H(,5B(\;+!D6R]7/*OVCTTD4L$BBJ$T"P-
M-'[KW6F#@>Q/B;2_SC/Y(6;^$O\ +3^47\K^?)=J;UV3V!1]^=>S=??Z0-MY
M##[>I<-54#KE,E%N,4M/5Y1*^9I))8S5T;S33^6%E]U[KZ&GOW7NM(W_ (2E
M?RRO@OVQ\#NNOF9V=\>-H;\^2^V?D_E=P;1[5W)+D)ZS#U>S\AC:G;LN+@%8
ME%2-CJR%:A2L-Y)O5,9 J*ONO=5L]6_+[^2;W]VG_-BW[_.9WA5;G^3G=GRJ
MWOU5T9E-Q[4WIGZG9'6>%@&-V:^UZG;6+K<;@JK&U,\\*F-EKG..BEJC**AY
M*CW7NA;ZO[[[,WE_)O\ Y(G\S7?F\FRN_?Y9_P#,=H^HNS^U-T>$5R]4Y?<1
MV[E**HJS!)YZ8X$8/$U$S@5$D"-5/,]8C3R^Z]U<+E>RJ&N_G3_SD/Y@%;29
MR?;7\IC^5]C>E]N5SP)+15&3KL'F.U\I+1$B3SSX^&GJZ8PBW-5(TD966!F]
MU[K5*C^2O\I:/^4PG8"][;D/\^F/M(?+!?D;)MS?K[F_OV-Y?>##MNAJ$X-L
M=_=#_)C":HXHY/\ W)F$U''OW7NMA+^;WB^J?YD/R0_X2MS]P[:?=_47R^H]
MU]A;RVI/+4X_[_';FVWTSN(T<ST4E-4TT<WG595B>-@A9 RWX]U[H]G\Y#^4
ME2XK^4WO7XS?RP_C[MS:^U<?\EMN_)[N;XN=>?<4O^DW$X>GC@S>!@JGJVK:
M7)5)QN&KHWI)!4RG"14M,IFG&KW7NN'\M_Y._P HO:WQ'_F"?-+^7?T+AOB[
MW!TST)D=T_,+XZU.+J,3N;:N1Z^V]N;,45#D-OU+/2K"*B.OB6JH(UI:ZHIY
M8JE5KZ:H@A]U[K4$C^2O\I:/^4PG8"][;D/\^F/M(?+!?D;)MS?K[F_OV-Y?
M>##MNAJ$X-L=_=#_ "8PFJ.*.3_W)F$U''OW7NOIY_%7N*'Y#_%_XW_("G$B
MT_>?0FS^XH%EC$3!-S;>QV:4-$ HC;36BZ@#2>+"WOW7NM37^<YUSM3X[?S<
M-F?/W^8E\1=P?-;^5QNWXMTOQU>JQ>-.Y*+J/<K9JFK9MQY+ L\:0Q2".>U2
M7B,\>2J%IGEKZ.EI)_=>Z";^?YT%_+H@_P"$]G0'9?P9V1UMF.E^L^Q,'B?B
M]V!@ON:^KQ.%W9G*ZNW124V2RCRYA*G*Y6"^56L<ULE7 5K29XVM[KW5EO\
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MO=>]^Z]U0#_PJ._[<4?.;_RF7_OXNOO?NO=:W?\ PAV_YFW_ ##?_$<]>?\
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MX9YLUL_*YBFHOXO1)5T:5,,\D^/DJ$JG@?Q>)_=>Z%S,?%C^=K\XOGA_*?\
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M7;4>Z]M1Y-=P8RKVUN&4QT..SW\1I:6%_OY8Z/124K7 :IU>Z]U9%\&=S_S
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M=>Z.!_PC4_[=*[Q_\7)WC_[SNRO?NO=;8_OW7NO>_=>Z][]U[KWOW7NOC?\
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M_>B,QO[M#J[&=G]O]P[8K>P>E<K'A-U8E)(.K)/N\'EI:2OCH*Y#& LK4\H
M+#0;\>Z]U<?L/X.;:^ 7\O+Y@=.;6[^^4?R-Q^Y=A]@=F3;W^6VZJ?=^Y*6:
MLV/#BVQ5%DJ?$X9(,) F&2HAIC S)55-9*96$P1/=>ZU6_M:7_H!5\WVU/Y?
MN/NO+H75Y?\ 9OO!Y-5K^3P_MZOKH]%]/'OW7NC]_.%5P_SA_P"$B7\( Q>F
MBW7C5_AW[%J:39G44+TX\6FT#PS21LGZ2CNI&EF!]U[H>OY,&/H,C_.*_P"%
M*L&0H:.N@J>^>I\?40UD22I)3ST?9RSP.KJP:&8*!(ANK@ ,#8>_=>ZHPP<>
M3Q7_  D;_FK[*IZ."EZPZX_F"3['Z%DIJF2KCGVA3]R=0U,$J5,M55-.BYNK
MR<2R73R",2%79FGF]U[JU_X-Q1[B_P"%&'6#[VH<=.VP_P#A/QL.7J"HK=+2
M0M-E=F)4STFN1S'4%,UFX3XQ&3 \UU(9W?W7NN:?'7!?(7^>G_/?^)6SZ#&T
M_47RC_EA;?POR"R^#J(EJ<3V3EL5@L9M>6)))9(*6NFPN3KLH^JCGC-1%'43
ME3.\=5[KW1%/A=O3=O\ ,(@_X3A? C?N#HJ+_9+]R=B]W_*G9E;4>6MQTOQY
MRK[)Z[2H6-R$IZJLA%'50.C),T[1QR""!S-[KW0P]&=_?S!^K_YZ'\]+>?P^
M_EV83YU[WK-\=8[)WI5YGM+:?6]1M+ T.WJ^FV^E/_>EB^9@W)1XV%Y!2G31
M_P ,@$X'W-.![KW1#_F#\;?G9\1/Y%G\VO'_ ">^,E+\5=O_ "G_ )F>W/D'
MLWJ7$[LVONVEQ&!W-N#%Y"?'PU^U,M7TC4V)R."P]#&\\-)).(TE%,BA1'[K
MW5D?S(ZY_G:_/-_Y>FW#_)9VG\9,1\*_E[U]W_L[M#!]^=4;I:BP.V"()\13
MT%/E<1.E'+$E%5EZ:620G&PQQT\C.C1^Z]UNI^_=>ZUF/YR/\J+!;M@[5_FO
M_P OKL_*?%[^8M\==D9C?N6[#ZRKJ:#%[Y@VGCYI\G@=U4,SMB7R[T% U)]Q
M5+X9S'#1YN*II8XVI?=>ZKF_FP_,+)?/K^2=_)1^6^=P:;<W-V__ #-NIZO>
M&(IXIH((\WB,;VGM_-R4<4Z)(M!49;$U$U(>5:FDB9'D0K(WNO=6#?\ "CR*
M/.]D_P CG8VZJ''9'J;=G\X+K2+L2CR^EJ295KZ>CC@JHWD\3T\V,R.2637&
MPT7&I S+)[KW4O\ G;4JX/\ F?\ _">K?'7&-PU=W]/\T\OL9(9I5CJINNZ^
M+;\._IVB^YI3/#A\-52U$+,S>&:5DCBF-2\$WNO=)[_A,]MS![YZ4_FUUG9&
MW\#GMZ=B?S;NW<!V[C<U%#6C(43XK;,C4&2BG-0M70M693**$E,J2>:H!+ZG
M)]U[HJ__  J$W'WKUO\ ,[^1#D_B-LVAW-\@\?V#W#MSH;::TY:D7/Y"GZIQ
M&'=J>#QHE'C9JM*AP3'!'% QE:.!79?=>Z.__P ):LG@<'\">X>A-P8BFQ_R
ME^./S/[*ZW^9.;F>6HR6XM\?QZ>I.XLIDJA1596>7%O3XQ:J<F9QB6#A2O/N
MO="W_P *CO\ MQ1\YO\ RF7_ +^+K[W[KW11_C[_ ")>ZOE/U%\6Z[^8S_-%
M[Q^8_P 8MO;2V5VML[X@XW:&'V+MHO!B*:IQ^*W+6X_,9BIW-C:&"6.G4-%1
MS%4D82H9V">Z]TK?@934]'_PI]_G=4='!#2TE+\=.DJ:EI:9%2..--@=>JD<
M:* J(B@!5     %O?NO=4#X#_N%Z_GX_^->:W_WOOCU[]U[K9-_FTY#>^U_^
M$T/;<G56,IY,R/A%UQ@:JAA"Q1Q;=R$VS<=NN1%6:F513;5J<A*JAB"4 $4U
M_#)[KW5J?P*ZXZ:A^#'P'I]D[;V?F-F=??&K86;Z=RL4<&12A6;95)1Q93%5
M\OGE%368VOG1ZR.3S5$=5/Y)7$\FKW7NJ4_Y+U#15W\XS_A2G%6T=+61S=]]
M3T,T=5&DBO!/2=G":%@X(:*8* Z'TM8:@;#W[KW5:7\H+^8H_P#+B_X39[.[
MBI-@1]T=C[X^9>?^.?074V9KA1T&8W3NG(-/1X^JJ925IL:E/39"MG1=(E\<
MB:XC,TZ>Z]TH?E-/_-3/\X7^0#+_ #-\?\)*+*U7R#["K>GJGX:2[P/CAJ*'
M8PW!BMS)NH-:3'L*'[.2CFGCE%16K)*X2-F]U[HU_P I-G?*W^01\D_EW_,4
MZ.Z[PWRK_EI?,3MZ#N3YM=))+]OO78.>SF1F3,[MP-15M-#E,35U^9GDDIW/
MVZ?<0TD\>/HH/XI![KW05_S+/DEWKOG^>#_**[E^&WQ;P7SFH$^ 6XOD=\5]
MC9+?6!V'29VKWM#G(LOEX,ON&3^'-)A]H0XS(10,&>4U"S0^NDU)[KW1R/Y5
M?27\RNF_FX?.3YG_ "N^ &,^$74'R\^/&VXMPXS&=F[(W_%4;]V54X+#XEHU
MVUE)*Z(Y7;]1DZF9WQ\5.D].Q>=JBK'D]U[H^7\_[_MS5_,'_P#$"U'_ +LL
M=[]U[JFWX+?R.^Y_FA\'?@'D/G1_,\[U[^^&&0^.W5/<>R/@QM7:^*V9@:"A
M;:.(R.#VMGMP4.6R5=NK%8&EEIZ2.26EI)Y/MS4H:>>4-%[KW1ANUL;C\-_P
MK1^&^'Q-'38[%XK^3S6XW&X^C01PP4\&\.S(H88D4!4CBC4*J@6"@ <>_=>Z
M)U\C?YAW\TK^9A\#_P"9A\A_B'U-\%]F?RP-N=1=S=1Y[(=T5^[)NT]Y;=PF
MS,K1[AW?MXX02[=I*I,5(LV,I,@D-JFG$$LU3 4E'NO=%)ZVABKJ;_A%3'6Q
M1UD8K>T6$=4HD6\-3U\T)LX(O$T:E/\ 4E5*V('OW7NKCNBJBHQW_"M+YH8G
M'SS4.*W#_*?P>XL_C*-FBIZ[(46Z^MZ.CKJR%"L=364E)4RP0S2!I(H99(D9
M4=E/NO=61?SSJ?/U7\H#^8E%MJ3Q9%?BYN2HJ6TZKX^&F$N66WCDMKQ25"WL
M--]6I+:U]U[HBM%_,1V5_+/_ .$WWPM^6,>PT[7FP7PCZ:V!M/8'W IJ/)[D
MS&U,)C)8<E5.LS08^FK%JYJO1')(R0O#$@9U*^Z]U4/_ #$<C_."_P!G1_D2
MY/\ F68GX(8G"Y/^:3UQ5=657PXFWK'E\755^Z-M19S [B7=#S02TDM$80K4
M4\RDQRQSSU*R(8_=>Z/?\S.C/G?_ "=/F'\Q?YM7PPVGL?Y2_$#Y+8JA[-^?
M_P :MW5"XS<V#I]H4&0DGW-MG*/Z):''4M;D*QQIJ7ACJ:J&;&U,"P5E%[KW
M6R;\4_D1UW\M/C=TG\E.IEJXNNNZ.NL;OS:M%D(EAJ:2GK(%9J&IA0F..IH)
M@]/*J$H)(F"$K8GW7NJ#/Y0DD^6_G=?\*-\ENR&&3=5-V;TMA<1)5<SC"1X+
M>E/3I'=F/V[T-'C=0^EEA%E%E'NO=:RV>R68P7_":/\ FYXG;U*L6&S?\\O+
M[?W'%3#1'#C87ZLKX $0JHC7)8^B15L5!*V L"/=>ZN*^9'7/\[7YYO_ "]-
MN'^2SM/XR8CX5_+WK[O_ &=VA@^_.J-TM18';!$$^(IZ"GRN(G2CEB2BJR]-
M+)(3C88XZ>1G1H_=>Z.AW1_W%Q?$?_QD-DO_ 'L^SO?NO=%Z[0_[B-?YJO\
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M<3_M]C\!O_$C9S_WB]S>_=>Z^R![]U[KWOW7NO>_=>Z][]U[KWOW7NOD]?\
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M;\]^M,3NG?'R;H=PX;,4M51T>5[$W/\ W:F;*MA:#:]7"<!48V*"GQ=3,*2
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M%E:O7AXX1(M+6K'4(9O=>ZV0_F#\_?AQ\!=GXO?/R^[_ -C](X+//41;<@W
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M_GAWU\'^U=Y=/TW0'?:=18O#9+^]6TZ266>**AJ<BT38#.>04JC(M'D1"E%
M::E@GUSM[KW0!83_ (3M;)V1_*6^7G\JW8OROW\^-^6/R H>_P#(]]=D[>I,
M]E,56TN7Z[R4U+-BJ/+X&/+_ '<?7\<;U#5M-()JZ6H97$2PR>Z]U=K-\:-@
M;H^*,'Q#[4I8.QNMLET/3] [ZAJ86HUS&+&"CP5;)X4GGDHGJX%:1 DSO3NR
ME)69 _OW7NJ<?B?_ "']Z?&KM/X\U.X?YGOS)[F^+GP^W"^ZOB_\6L[+1X6'
M#U4E)D:'[?<>Y\+405NZ,/34E?X:7'"DQU+3TXFH0CXVJFHC[KW1V/A3_+<_
MV3[YD?S)_EK_ *9O](G_  X9V'M'?G]P/[N_PC^Z']U8MT1?:?Q7^.Y/^/\
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ME)_)#^%&YJ7 82FW)E*?LJDR>X*>E@2NJ(D[@WZJ13U:QB>:-%AC 5W( C0
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MU'3UNWL;DL_4#?7<..JL#5T=3BL73U3"/^Y-5!4H9D":S'(YO]N#[KW1[/\
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M/4_5W6/\D3_A-WVMUYUQL79O9%!\B?BUE(-Z[>Q-!39!JC<76.4W)GI9JB.
M/4OF,]CJ:OK#+K^XJH4EEU,+^_=>ZLSCP&W.\_\ A6'OK;G;NU<+O? _'K^4
MI'N+IS%;PI(,A1XS)Y#>FW*>MRV.IJV&6&GKIJ/=63HY*B$"5H6>)I"@,8]U
M[I@_D.[%V9UI_-G_ .%'.R.O=JX#9.S<%\@NIX\'M7:]+#0X^C2:/M2IDCI:
M2G2."GB:>9W"1JJ*6.E0./?NO=#5_P *E=S[C@_EN[!Z?Q1W-1;6^4?S5ZR^
M.W:NXMKU$E-+BMM9.KR6:K*N>04]1"U//6X"DHM%1HIVEJXA(9/33S>Z]T7'
M_A0'T%TQ\1=K_P G;O?XS=3;2ZJ[2Z-_F8=6=%=<5'5./IL-D'VA78O<-15;
M6$^-IUJ:G&59P--3O3.LT3I//&\;K4RI+[KW0G_!7_N*%_GA?^*]=*?^\#U]
M[]U[JO+^6'B\9E?Y 7_"BY,ICJ'))1?(CY<92C2OACF$-33],[=DIZB(2*PC
MG@D :.1;.C"ZD'GW[KW5Q_\ )XZ"V_W'_(!^/?5N&JVZQW%W[\),[U3D>T]C
M0P4.?Q[;A@SV)3+4V0BB$_W^->K%33R,6*31(X%Q[]U[JOW^4GVI@/Y=7=/Q
M=_E ?S&?AKU]T_\ )C8<FYZ/X(_-79F"QU7MCL>GK9<G)7_8[A6E3(XG<^1H
MLK-!5HSWJVDBBR24==6445;[KW0J]1;#V-7_ /"M+Y<XFOV9M2MQ7_#3N/W!
M_#*O'4<E/]_)O/K3R5OA>%H_NW\KZIK>0ZVNQU&_NO=&?^?_ ,_&H_G/@/B5
M\0OY8&#_ )F/SAZ3Z<F[#WCE-T9C:6T<;UQM3=4N.,U&N[=U4%;%%DL_]KC9
MGQ\;TGW%.U/*LL[120+[KW6MY\<LOG\E_*=_X56IG^L&Z)K&^6F[,O7]!I54
M5;%LFOJ\[.*[:\=5C%CQM2<$\"8XSTBK33"C1X%$6@#W7NC(?S$>I^KNL?Y(
MG_";OM;KSKC8NS>R*#Y$_%K*0;UV]B:"FR#5&XNL<IN3/2S5$< >I?,9['4U
M?6&77]Q50I++J87]^Z]U9G'@-N=Y_P#"L/?6W.W=JX7>^!^/7\I2/<73F*WA
M209"CQF3R&]-N4];EL=35L,L-/734>ZLG1R5$($K0L\32% 8Q[KW16_Y:NQ=
MF=:?+G_A6MLCKW:N V3LW!)MN/![5VO2PT./HTFVOW-4R1TM)3I'!3Q-/,[A
M(U5%+'2H''OW7NJG=]X3$;E_X2P?R)MN9_'4N7P6X/YLL6$S>)KD$D%525>^
M/D1!4T\R'AXIX9&1U/!5B/?NO=7U_)#9&R>AO^%/'\H#&=+;*V?U=C>U_B+V
MIUUV%C=CXN@QU/D\+@-I[SRN&H9H*:G2*-,=78VE>%XECE"01P%S /%[]U[J
M1_*&ZMZO^4/\Q3_A0EV[W]U%M3>^^IOFD?B\:;L?'4N55=C[5ILK@,93009"
MD)AH<[C,;233!5\=3##1C5*E/'(WNO=/_P#PD)_[<X;2_P#%A=]?^Y=%[]U[
MK!_--PF*[S_G\_R*/C5VMA8]V]%)A>W.[*K8VX46IP63W+@MH9?*XBIK<=/&
MU%6U.(K-NT;Q&82F):B1$6-:B3S>Z]T<W^:9TMT]\,OY;O\ ->^17Q<ZAVET
M[W=W/\>,K5]D=A]54<>&S-?4KBFP--D7K*")9J=\/1Y"HJXS!XM%0]36:DJ9
MYJD^Z]U3O\H_A%\8<?\ \),.G]XX'K;96S=_=<?"GJKY9;,[1P6/H*;<%%OK
M+4^V-Q9C)09D0BN2KSE9EZRCG82^1H:GQ1D-'#H]U[K'VM)C_EI_.>_X3)[K
M^1'66)SE9VU_+[SG<N_.MNS:*/*I2;D/5NX-W0K7TN4I$$N1P6Y((:F*2:GC
MEAK:2.<1Q31KI]U[H7?A;\;_ (_[A_X4Y?SI,+G^E>KLWA=K?'[K&;;.&RV#
MQU128]]S[%V))N&2BII:=X*63,-4S?=/&JM,)I58E97#>Z]UKZUN5K\A_P (
MV,325E0T]/@OGTV*Q4951X:=]P5-:T8*J"P-563278LUW(OI"@>Z]U?Q_.4^
M*_QHV_\ S5/^$WW5N Z"Z?P76N3[>[$V5D^O\-MW%4N&J</MZ+K6?"8NHQD%
M+'1SX_%RU$K4\#QM$GD<!;,P/NO=/GQ:RG^@S^??_P **(>K-O8W 8K;'Q%Z
MU[.Q.S]JTE/202YJBZSVWE8I88:>F98ZBIR&2JY'T1L)9JF221)'(]^Z]T$G
M\J7X7?&WY"?\)?.P]S]O;!VGNC?_ ,C>M^\^X^U.X=U4=%D=R/NS"[HWOC\/
MNA\WDHJBL_BN'CVY0U$,\DI*RQO(Q/FF+^Z]T03;V;G^66U?^$9[?(G9 W33
MYO<?;^PL_MCLV)LK'E\;LW.;$V]@:^NBR5.OWM-E<;M^AR$*RI)&T,T6F2HB
MTRR>Z]U=+\6</A>K/^%5GSNZWZWP>#V1L7L7^61M[M?>FU]LT5+24E=N+&[D
MV#BZ/*O'#$OBJ8Z'*U<;>(HDQF:29))0KK[KW6QG\ANJ9>]^@>\>CX-V9_8,
MW<O3VYNJ8=];4F-/E,*VXL+6XA<MC9P"8,ACC6?<4\@!*31HP^GOW7NM5S^4
MGVI@/Y=7=/Q=_E ?S&?AKU]T_P#)C8<FYZ/X(_-79F"QU7MCL>GK9<G)7_8[
MA6E3(XG<^1HLK-!5HSWJVDBBR24==6445;[KW0J]1;#V-7_\*TOESB:_9FU*
MW%?\-.X_<'\,J\=1R4_W\F\^M/)6^%X6C^[?ROJFMY#K:['4;^Z]TJ.MMG;6
M^4'_  J&^9M5WGL6/=-#\(?@UL?:7QTP^^8HLCB$;>$.'S>9W5BJ&OHS%35T
M4V=R&'\],SK8UBRR-*RQTWNO=5:=G9O+?"[Y _\ "M3I#XQ4&5Z\ZJPWQ2V-
MVSM;;W7<DF.Q6V=P[OV/C/X_7X>DH8OML175(W973M-2_;RB/'1BX%+$]-[K
MW6P/_*O_ )?'PIW#_+&_E1;@W'\:NG=R[BZ_Z!ZV^4&T=R97!8^2NH]]YW:F
M/SV1W#]V(1-/7OE\I+4 S-(%GBI9M/FI*9XO=>ZT^?YT/R2^2'3?\VK^?5U9
M\8MH;FR^Y^__ (V=7XOM??>V619-J=;[>ZPZ\RN]<E(7C<1Q9"C>'%R2ZHVC
M@KIO XJVI@?=>Z^@_P# _$?'[!_"WXKX[XJ4=-0_'%.AML573-/3S&H;^ U.
M)IJFA>JJ'9Y:C(2I-Y*V65FGDJVG><F9G/OW7NB"?S9/G;L+H+?'Q5^+.UOA
M31?S#?F;\@MW9/>_QD^-N9J<%B<92S[6QM6^3W77[BW)15^,PTF+Q536M3.(
M6FD\=2#-1QJU2ONO=4Q?RJMX=P[Y_P"%'?S5Q/R ^&>&^#.ZNP_Y9U-GNW_B
M[C<YMS=N%K,GB-W=>8G%[A.4V]3PX;*"OP]=+8B+5'YYX9&F(\TGNO=&G_X2
MI;3VL/C1\^\^-M;?&=Q'\VGMG$XG-"CIONZ6E&VNOU%-3U/C\T%.%E<"-&5+
M.XM9C?W7NMGC?6]=L=:[)WCV-O;+4^!V9L#:N0WKN[.5=_%18S%4DU=7U<ND
M%O'34D$DC6!-E-A[]U[KY^/\V#YH[^^7O\H_Y2]G='?R4\1T1\ ^V=]8GL'8
MWSLR6X=AXO<$^;J>U\#+D-W5^P*3'0;EC.\<N:S&O615%29CD5JI*N6FDD1?
M=>ZWO/BI6U>1^+OQNR%?42U==7]![.K:RJG)9Y99=O8YY)'8\L[NQ)/Y)]^Z
M]UK4_%KI+ISM_P#X5'_SG:SMCJOKSLV?9O0'3]3M,]@8;'YA<;+7=>==P5<U
M%'D*>HCIYZB!!$\B*',>I-6EF!]U[HV7SH^<N,VG\TMF_"SX2?RK-I_S%OF)
M\>.C/[V9B+(Y+9NR,%U;LG<)QD2XJCW)N3'55+1568AHL6PQ=.:-)*3[9XY)
MO"].ONO=4B?RY7K-S_RX_P#A61#O+I^CZ:J:3?WR"W6_0%9)CLE#L/,OL??;
MSX"FJ:"-<9+4;;FIXZ!*NB1(7^S22FTQZ+>Z]UL=?\)\]K[:Q?\ )_\ @5G<
M9MW!8[.9GH6G_B^9H:2GAJZJV3R)'W-1'&LT]B+^MFY]^Z]UIL]/;GW'!_PE
M.Z3Z?Q1W-1;6^4?\UK&_';M7<6UZB2FEQ6VLGEI<U65<\@IZB%J>>MP%)1:*
MC13M+5Q"0R>FGF]U[J_7_A0'T%TQ\1=K_P G;O?XS=3;2ZJ[2Z-_F8=6=%=<
M5'5./IL-D'VA78O<-15;6$^-IUJ:G&59P--3O3.LT3I//&\;K4RI+[KW6VE[
M]U[KY_&$_P"R&/\ A8Q_XO\ ]C_^]MF??NO="+_,1ZGZNZQ_DB?\)N^UNO.N
M-B[-[(H/D3\6LI!O7;V)H*;(-4;BZQRFY,]+-41P!ZE\QGL=35]89=?W%5"D
MLNIA?W[KW6^%[]U[K51^#VP]CUG_  IY_G8X^KV9M2JH,1T/TQDL30U..HWA
MI:F;8VP)Y:BGB:$I!/+,[2.Z!69V+,2Q)]^Z]TR?%#I_JGM'_A4?_.EK>RNM
M]D=@5.V/CIU)!MR3>>+H\G]BN5ZYZ\I,E]JM9#,L#5M(O@F9 &>$M&3H=E/N
MO=5E_$KNO>?0_P#PF3_G<)L-<S'CNHOFWVC\=.K,/M0-!-@-M[KJ.M<)4K2S
M4P2I%-B_[YY&ODFD=Y(X?+^X(HT5/=>Z!'MGL3*YOX3_ ,K;9GPH_DE_S7>O
MOD%\ >Q^N>XMF?(&BZ(K<?2[IHZ&B2;?6K<&W8ZS)5E)V#7R)E9G6)8:ZH2&
M2<B)F5O=>Z^C7[]U[K4>_E0_'[HCNK^<[_PHTR?<G2W5/;-?MONKKC;6WZKL
MO;V)SK46/SM/OV3-45+_ !2DJA!2Y9\-0FKC2R5!HZ;RAO"EO=>Z,E\J/YBF
M?WY\Z^]_C_\  K^4-MG^9;WG\5ME8/8_RQ[<WIN?9&Q8=O4&8&0R^'V?C,GN
M[%5]3FEG9\A)+%$\42544R14U<=4D/NO=:VO6&:RF0_X27?SEL)682LV=B-E
M?S,$VQM/KJJ>)UVOCV[ Z"R9V_#]N3 L=!D,E57$9,9E>1D)5A[]U[JU;Y]]
M6]9?'C<__"5/>?1W76Q.K-TM\M.K>K9LULO$8^BFEP&[*?9E-N+'3F*G"SQY
M2.NJ#))(&F66>:>*1)Y&D/NO=&>_EH;!V!\D/YX/_"AG>'>W7FT>R<]L#/=2
M=';+7L+&T>6%!M2MP>ZJ3(XNBCR-/-]OCLO'MG&S5,,06&=D1Y1(2']^Z]U4
M1\,^PLG\:?\ A-3_ #[,UU7BLEBY,)_, [.ZDVY0;-\D$N,QFYJ'J'9$TU*:
M<K)3TV(Q69DG=D(\5/ [7 4D>Z]T&';/8F5S?PG_ )6VS/A1_)+_ )KO7WR"
M^ /8_7/<6S/D#1=$5N/I=TT=#1)-OK5N#;L=9DJRD[!KY$RLSK$L-=4)#).1
M$S*WNO=?1K]^Z]U[W[KW5 /_  J._P"W%'SF_P#*9?\ OXNOO?NO=:W?_"';
M_F;?\PW_ ,1SUY_[L]V>_=>Z^B%[]U[KWOW7NO>_=>Z][]U[KXV/\Z#_ +?I
M_,S_ ,7 7_K?C??NO=?9.]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7S>?^%NW_96G
MPG_\5US?_O2R>_=>ZVOO^$V/_;D7X%_^&3N?_P![[=GOW7NKR/?NO=>]^Z]U
M[W[KW1 /YL7_ &ZR_F6?^* =R?\ ONMQ^_=>Z^=[_P (X/\ M[GF_P#Q4;>?
M_NWVG[]U[KZH/OW7NO>_=>Z][]U[KWOW7NO>_=>Z^-C_ #H/^WZ?S,_\7 7_
M *WXWW[KW7V3O?NO=>]^Z]U[W[KW7O?NO=:@7_"U;_MUET'_ .+_ .UO_?==
MJ^_=>Z#G_A$M_P!D&_+/_P 6Y_\ E-VW[]U[K=#]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=-6*P6$P25T>#P^*PR93*U&=R:8JGAIQ45M6_DJJR
M<0H@FJJF0ZI97O)(WJ=B>??NO=.OOW7NO>_=>Z][]U[H/.LNHNI^E=O56T>F
M^L.O.I=J5N>K-TUNV.LL+C<#CYLGD9?/D,C+18JFI*:2OKYOW*BH9#+,_KD=
MFY]^Z]T(?OW7NO>_=>Z][]U[KWOW7NO>_=>Z2&/[!V#EMY;AZYQ6]]H9/L+:
M.-H\SNS8F/R=%-F<71Y$.<?5Y'%QS-745-7"-S3RS1(DVEO&S:3;W7NE?[]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>ZCU=72T%+4UU=4T]%145.]765E6ZQQ111J7DEED<JD<<:*69F("@$D@#W
M[KW43"YK#;DPV)W%MW+8S/[?S^,@S6"SN%GBJJ.MHZJ))Z6KI*J!Y(*FFJ8)
M%DBEC9DD1E=&*D'W[KW3G[]U[ID?<NW(]QTVSY,_A(]W5F$FW+2;6>K@&1EQ
MU-/3TM1D(Z$R?<O14]35P0R3JAB26:*-F#R(#[KW3W[]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[IDP^Y=N;AFSE/@,_A,Y4;8S;[:W+!AZN"I?'9&."
MGJI,?7+!([4E:E-5P3-!*$E$4T4A4)(A/NO=%4^7_P Z.A_A#!T,>ZZK=DF2
M^2O?F$^-G46W]DXULI7Y'=&X!/\ P^%H%EA$-(9(!').S:8Y)H5(]=Q[KW1Q
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW4>KJZ6@I:F
MNKJFGHJ*BIWJZRLJW6.***-2\DLLCE4CCC12S,Q 4 DD >_=>ZB87-8;<F&Q
M.XMNY;&9_;^?QD&:P6=PL\551UM'51)/2U=)50/)!4TU3!(LD4L;,DB,KHQ4
M@^_=>Z<_?NO=>]^Z]U%EKJ*"JI:&:LI8:ZN222BHY9$66980IF:*,D/((@ZE
MRH.G4-5KCW[KW4KW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M_P#(7I3:OR4Z"[P^.F^LAN#$[)[^Z?W-TIO'*;3EIH,K38K=6%K<%D*C&3UE
M)7TD.0AI*^1Z=YZ:HA28(TL$R!HV]U[K5B_Z J?Y67_/_/G_ /\ H4]=?_:J
M]^Z]U[_H"I_E9?\ /_/G_P#^A3UU_P#:J]^Z]U[_ * J?Y67_/\ SY__ /H4
M]=?_ &JO?NO=>_Z J?Y67_/_ #Y__P#H4]=?_:J]^Z]U[_H"I_E9?\_\^?\
M_P"A3UU_]JKW[KW7O^@*G^5E_P _\^?_ /Z%/77_ -JKW[KW6UETMU7M[HKI
MWJ;I':-9F<CM3ISK3 ]5[8R&XY()LA/C]O8NEQ%%-7RTU/1TTM;+34:-.\4$
M$32EC'#&I"+[KW0E^_=>Z][]U[KWOW7NO>_=>ZJL_FG?RA?C9_-UV-U1U_\
M)+>_>.R<-T]NROWCMFIZ0R6 QM5/59&CCHIHZ]\]MG<L4L"Q1 HL4<+A[EG8
M>D>Z]U2K_P! 5/\ *R_Y_P"?/_\ ]"GKK_[57OW7NO?] 5/\K+_G_GS_ /\
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MF?KA/(C7E9JMD9N41!Q[]U[HBG_0%3_*R_Y_Y\__ /T*>NO_ +57OW7NO?\
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M>3+[G&UZ_ 1;F[3S34F K1L\Y:JS!I=\4*B*KQM#3>6*K4U02.%Y_=>ZL_\
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M:\Z4V-7=8=-=2=:92MI,CD^O.L<#L;(Y"@#B">?$XJDH)IH1(JR"&62G+)J
M;21J -Q[]U[JKKXV_P O+NGIW^<G_,9_F';FW/U?7=+?+SJSKS8_6VV,%6Y:
M7=%#5[2VSM;"Y&3.451A*7$TU//582=J9J7)5CO$\32QPNSI'[KW02?);^6A
M\U]L_P Q?>7\QK^6S\@_CUU5OSY"=18;I;Y/==_)7;.5S6&R4."%-3XS=&+F
MP-135TF:H<;CZ*FBI9I*>%A3'RU;12^!/=>Z3GP"_DR=K_'GI'^:OT]\J/D/
MM+OK*?S.MX[QW#OCLC8N$J=O3_[_ (Q&?Q>?K*G$?</3T%75R9R2J6GHZIX8
M&8PQ2Z8TD;W7NAZ_DR?"SYY_ KH)/C3\MN_>A>XNJ^HJ$[(^-%%TUA,A09"#
M!KE<I6_>;JR&1IJ/[C(24M530P4E+ T=&D<RSY#*RNM6/=>Z(Q\2_P#A/_N+
M%_R0M]_RG_F1O_8$V[MV=DYKLG!]F]$U.4RV/PF2DR%'D]O9&#^.8C;=75RT
M=52::RE:GBCGIY)8$J!Y/(GNO=/NQOY1?\QSY&]^_$W>/\UWYI],=^=%_ _?
MM!V=TGUIT9MW(X:MWMNK"P4O\$W;V)4U<5'!%DJ.KB+345$*JCJ(U=-425M9
M$_NO=;,'OW7NM7O'?R3_ )44GQN_GW]/2;_^/S;F_FE_)_=O=?Q^KDRNXS0X
M?%9[<60R]'3[QE.U!48_(1TU6BS)C8<M"L@8)/(H#GW7NA3^9_\ *'^2?R+_
M )87\ISX5[)WOT?B^T_@CV9T3O/MW/[IR6>@V_D:7K#KW*[3S\>W*JDVU79&
MLJ*S(UT<F/6MH<>DM,'>I>DE A;W7NMC'W[KW5 N^?Y8WS6V-_.)WM_,7^'W
MR'Z,V!U+\IMA;3V%\Q-A]J83)9;/O3[2CP&-@FV:(8GH%KJ_!81:>.>IJJ2G
MH9F>>:@RQD44_NO=#1\;?Y>7=/3O\Y/^8S_,.W-N?J^NZ6^7G5G7FQ^MML8*
MMRTNZ*&KVEMG:V%R,F<HJC"4N)IJ>>JPD[4S4N2K'>)XFECA=G2/W7N@,_EV
M_P FW<O27P0_F$_"+YD9SKG>VUOFY\K.R>VQ/TUD,K4BBVQO7 [7Q>/66IS.
M"PLM)N3&U>#EJ0(H:FFA=::2.IF.M$]U[KE\)/@M_.;^-&Y?C_TGO_\ F'_'
MO>WPA^,LU'C-NIC]@U51V3O7:]#1Y/&T.SMTU5=-%B\118J@EH5I<E05537R
M/2Q-4!_"_P!W[KW6P'[]U[JFW^7I_+R[I^)GSY_FX_*?L;<_5^:Z^^>_:>Q=
M\=/X?95;EJG,XVDVQ!O*.OCW+3UV$QM#1U$S;AIOMUHJO((X2?R21:8Q)[KW
M1;MZ?RN/YA'17SZ^5?RR_EM?*OXZ=5;*^?U5MW(_)G;/R,VCD]QY';F3VSC\
MC346=V5#BJBCHLM4R5&2J'-%DYJ.!/O*AY9JKQP1K[KW14L!_P )_/E/LG^2
M+\^OY:5-\A>F.S_D#\N_E?1_(_"=M;IBS>W]O*JY[JO)Y"/,BBQF>R%/75$6
MPZZ5?M:2HA,]73PW2,23)[KW1Z_FY_*Z[_\ DI_PRG_<7=_3V*_X;@^3/6_<
MW>'][,AFH/XKB]G_ -V?XG!M3[/;]?\ ?5\_\%G^U2O_ (9"^J+RSPZGT>Z]
MT GS*^!WRQ^*WS>^1?\ ,E^$7SK^*WQ ZY^4_6>+QGS/H/EKBYZ[&8N3:&+G
M@@WUMIUE6FK,KC\?"A3'U4U!2+)-7U%1-5B>*GA]U[HMW_"<CX:4/R#_ )*/
MRYZM^0U;E-[=3_/CY4=I[MQ6\S2R8C*9O;F4Q.V=HC<ZT<T17%Y*HSFUZROI
M41JB.!E@82,0R+[KW1[OA)\%OYS?QHW+\?\ I/?_ /,/^/>]OA#\99J/&;=3
M'[!JJCLG>NUZ&CR>-H=G;IJJZ:+%XBBQ5!+0K2Y*@JJFOD>EB:H#^%_N_=>Z
MV _?NO=>]^Z]U0#_ ,*CO^W%'SF_\IE_[^+K[W[KW6CA_P )L?YO7Q6_E+[\
M^6&Y/E#B.WLMC^Z]H[3P>SUZFQ&/RTB382LSE16&M6OS.'$*,F1B\91I2Q#@
MA; M[KW6V-_T&5_RE?\ GCOF3_Z!VW?_ +-??NO=>_Z#*_Y2O_/'?,G_ - [
M;O\ ]FOOW7NO?]!E?\I7_GCOF3_Z!VW?_LU]^Z]U[_H,K_E*_P#/'?,G_P!
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MY2O_ #QWS)_] [;O_P!FOOW7NO?]!E?\I7_GCOF3_P"@=MW_ .S7W[KW7O\
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MO:.IDFA']Z-L[EW-N;;16:G(FC+9O$4R-:ZO&[Q2I+!))$_NO=#M_*![I?\
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MGR%#4/322+#6T54CQ5$+D2PRJR2*K@CW[KW1(_DM3SU/_"2#;D=-!-42+_*
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M;W7NJW?Y;7S'_E?_  E_EZ];]@=*_(7Y5=M_&/O?YKY/J7:O</R$@W#G\O\
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M^P=L;:HMOX7/XVIVKC9X*7%U>5R.+:CF6U15&BEFR4=,U",C71S^Z]T"&/\
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MS.;0W5@]MQR[*V_]Z<SGWRF2HJ.G)@F^TDD+F:&!9IE]U[JZK^7?_-6^+O\
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M4M9BHLU!D=P9VO?$41QSXZ>*7SX]J]=+W%U24Q^Z]U41_P *-/YJ>&D^&_\
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M'D:&;0?)#)!,C)<-[KW5D?QC_GP_!;Y4_*3 ?$G:-)\@^N>Q.Q<+-N7HC/\
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MDYG\U-#-4-)IFBDJ*&&0$1^Z]UN\^_=>ZI!^5G\_KX5?$;N+LOIO>?77S$[
MJ^C,W%@?D#V'U)UCF<IM/8DL^+I<Q!)N/.5DF+B6FGH*VGDCEH8ZY72:.5;P
M-Y??NO=&D^0G\U?X7?&WXI]1?,;>?868W-U)\A),'1= 476^(KLSN'>M=N.E
M^]Q&-V_@H8XZR>OJ:8,S1S> 0E3',T<I5&]U[J;\ OYF'07\Q;%]F/U#L_Y
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MJ[;3?,^%7;<^\TH:499\<LOG6@?(B+[QJ)9_W! 9/$']875S[]U[K6@^"O\
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MN^RJ$PBC5LG3P>:UY&HA4B'P!UKIZJI^Y9)1 GNO=!9L/^7#5='?S#?YB/\
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M0PF)R>9Q..RFY:R7'[<QM=40PU&0J(*6:MG@HH9'62KFAHZ:6=TB#,D,4DK
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M2BZ*KN^^EZ/N[)4S5F.Z<J]TX./=51"KQQM+#MYZX9>6-9)HU++3E0SHI-V
M/NO=#1[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z)?\WOE3V-\3^N=J;IZJ^(G>_S*WQOG?477^ ZWZ*&*26EJ
M9J"OKTR&>KLI60)B<&J4#QRURP5*02O$)E175C[KW10_Y=7\V?(?,[N_OKXF
M]^?$GLSX/?+CXY[-PO8>_NG.QLUBMP4E1A,T$\62PV=Q\./_ (C34IGI?/*:
M**$"LIPDKOYHXO=>Z)^W_"BJ@W/N_.[[Z._EX?+CY"? 7:'<2]$;G^<_5$%-
MDJ*HSKY2AQ,=5MC9=)35.9W1MYJFLM]_35$<C.:>".CDJ*J.-?=>Z.I_,!_F
MQ8[X@=K=1?%CHCXU=G_-SYK]Y[.K>Q=A_&KK&LI,'+1[<H?.C9_=6:R<%2FV
ML545-+/!#++1S%I::H5D0Q@/[KW3GU;_ #=^E\Y\#.Y?GE\A>J>[OB!M;XZ[
M@S6R.Z.MN]L+-09FCS^%K(,:<7@YI$@HMSG)Y2KI\?034;Z9LA(:&58*F*6-
M/=>Z*!TE_/YGS_<?QWV1\MOY?GR4^#G47S.SM'M_XA_(;MFMQ>0PFY*K*4M+
M/AJ+<5/110/L[)YEZH)24LTU:SHT50[QP-,]/[KW2[^6?\[?<G0OSMWO_+JZ
M,_E__(3YB?(["=*TG<&TJ'J?*8>AQ-5'6003*-Q9+(H1M3"TYE\$^5ECK$6J
MEHJ6*EFGK8D7W7NB;47_  IOW)NOI[LK?G6G\J[Y3;YWW\4JO*K_ # =DC-8
MN@P_44&WZN2FSNO=,^,>/=%?21T=?/%104%%,8**:6L-!$&D3W7NCR_++^>G
MT[\:?CO_ "^ODKM;H'NGO_:7\Q+,X?#]3;+ZZ%!#NF"?-T..K:&B&)K95@R&
M6F?("D2DBJHUDK%6-)S'()5]U[I7_ _^;Q7_ "D^4_9?P=^27P_[9^"GRSV3
MUU_IMVOU;V9E<=N"FW)LE\BN/CS./S6*IZ6D2MB>>G-30Z9%1GGCIJNK^QJV
MB]U[H./FO_.+^1_Q/WUWN-I?RD_ECW/\>OBX\M?WM\F9<SM_;6$BQ%/@*;<%
M5G-HT52F2J-W8VBHZI3521R4:TGCG%28IX)8%]U[IQ^4_P#/=Z4^.OQT_E]_
M)K:'0W='R#V9_,/W%C-N]5;/ZU&.3=-/4Y6FH9Z>A&)K)EI\CF&GK#1I1QU<
M0DK4$*SZ'\J^Z]T^_"3^<1N/Y)_,'LOX'?(GX1=P_"/Y/;6ZLJ.]NOMD=DYG
M&9^EW-L]<A'0TV07*8BEAI,?7R_<1F6F4UE-#*E93+7SS4CJ_NO=#'\9?YM7
M17R.^$/R1^<-1M'>_4^T_B7ENP-O=\];;X;'U&XL!D>N<><IF\?518BJKZ1Z
MR6C,<E-%#+,9A-$%N[Z![KW5=/S\^;/P"^5/\M#^7U\L?G!\(^SNS.EOE%\O
M]F8WHOI;<&0QT.5Q.>RD.[VVSN'/OBL[%CZC 93#8>IDJ*'[BL$]!DX8:RB,
MWF@@]U[HQ7RK_G6[IZ.^=787\NWHCX ]]_,+Y&[8Z,I.ZML4'5V:P.,Q57#5
MI2,JYVORVD[;Q-.]2(9\CXJ\BHDI8(J.:2J4)[KW0Z? [^;YT?\ ,WXE?(#Y
M3;RV5O+XO?[*)N?=&S/E9USVI::LV;D-H8Y<MG ]73P0K7T]-1%N5@AJ1-%-
M!)2QR*H?W7NJINP/^%1.:ZKZ Q/RZ[#_ )37S+VE\3^TMPT^.^.O=N9R>VXZ
M;<M%/'(5K,W1!FEVI)624\QQB&3)4N5ID2JI*XQR #W7NML7W[KW6OG\BOYZ
M&]^N_G5\F/Y=WQI_EP_(GYD?(CX[;1P.\)3UYF\'B-OUE-F]LX#<PERN6R$4
M\FWZ:"'<$-(DC4U9)55:&*"!BZCW[KW2EHOY^70N5_E1]T?S1\;TSV?%3?'7
M?M'U)W?\9L_/0X_=VWMU3;NV]M.JPU;)+JIXGICN6ER"-+'%))2MXY8*>J$L
M$7NO=+GX:?S<^Q?DU-V!V7W)_+Y^07PD^&^T?C;/\D<+\L_DAD,=18W(X^@%
M)/DJ:HP\%,9,:@Q=4V2HJDUDZ5=!2U4SQTI6!:CW7NB>XG_A2?@8*38GR![(
M_EZ?*WJO^6SVGO>FV#L#Y^;E?&R8QYZG)5F,CS&9VG!&<CA-L334R&#(O63-
M4:I(XJ4S1I'-[KW5JF[OYDW5W7G\P7J;X [_ -F;HVME_D#TQDNX^AN]:NJQ
MC;.W.N&B:HRN!I*D52U4>;HJ.">K>,Q/":04\PFO51QCW7NBI[2_GD]6]B?!
MSYA?S"NNOC;WIO#XZ_$WM#(; I,O1O@X*O?F-PV1I:+-;NV@E1D(Z.JVYC::
MNBJWFFJ8W=(JZ"-#5T;P/[KW0]?+7^;%T=\5?B1\8?EJNT-Z=SX;YA[TV)L#
MX^]?=82XULMN#)]@XJ;,X.*GJ,E5T.+AA^Q@=I)ZBH@@5M"&022QH_NO=6F(
M7*(9%5)"H,BH2RAK<@,54L ?H2!?ZV'T]^Z]U0+\A?YXF[]G?*/Y"?&GX@_R
M[?D7\\Y/AJN)?Y>[UZ@R>*Q_]V'S&.R&1I*' X6IIZW)[PRY7'31"BIQ2R23
M0U44#3/ %E]U[JG_ /X4-_*_Y,9;Y+_R-<]LSX)=DUFW\5\GNK_DWU10[SW1
MA<-E]S]AUV8QE6G2^0QM-#F:3;NX*)::BAJ<N*W(T$4V19(XY5I7>7W7NMGK
M._,7N_87P5P/RM[#^"W><_>-7BL9_>7X5=/5N*W9NW&Y7*9J+"QX^'(R'!46
M4IZ62HBJ*FJIX;I2EYHZ>5(V/OW7NB5_$W^<QV%V[\OH?@M\L/Y??<WP:^1F
M\>I,WW7TG@=\[EP6Y<7NW"X::=6@I\IC:>A^VS$U/33S/2Q05B4XI:E9:@:(
M6G]U[JBS^2+\NOFQ6?SC_P":Q)E/Y<.Z\>?DO\ANM8/EH6[!Q50>AOL:7?46
M,&0"8+5O=,H*RH"FB_AZTRT3%RRR*4]U[J]KYC?SKX^@_DIV7\5_C+\*_D!\
M].S/CGU]2=L_+ ]'S4-)0["P-73K71025%9%4'-;IGQSI54N$IE2HJXV98)6
ME@J(X?=>Z%?MW^<G\<]C_P I_)?S<^ML#N7N7HRCP.WLQ!LO#ST>/SGW&;WE
MA]D5>*K#,]32T63P67RCI6Q%I%O2RK$[J\<C>Z]U7-E/^%+V2Z]W!TC5]Z?R
MJOFSU+U1\L]L";X?[TGDP>4SF_=R24T3T6VTVK3/$^(DS5;78^EQDTE?/-5&
MOAJI*&GHU><>Z]U8?_+G_FLYSYJ]V?)+XN=X_$#M/X2?)KXSXK"[PW7U;V3E
M\;G8:W;NXGJ6Q&4H<MCZ>BC>0TJ4\E5$(&@A>K2*"LJS%,R>Z]T2C>/_  I
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MM#*KEZ/=6[,O44>?V_NC.8RJ>F!A2=:.?PU,$%,6,)]U[H$\W_V0Q_PCG_\
M%_\ KC_WML-[]U[JX3NC_N+B^(__ (R&R7_O9]G>_=>ZII_F!9/=?Q%[F_G6
M?RK>N<_MW8F7_FM_(SHWL;XHX:.226KK*CN?<ZXOM(PTT_E)H:JIH*JAF2)1
M%1P%4IFA,U,D'NO=6G?\*2NK-I]&_P O7^5%TKL.@@Q>R.HOYFW1G6>T,;3(
M(XX,9@ME;[QE#$J D*$IJ5!:Y_US]??NO="1TO\ ]Q<7RX_\9#8W_P![/K'W
M[KW53O7E%G:_X5?\+(8-NF05\?S=[?K:@Q?7[&FW!N>IR@/I;TG&13AN/TWY
M'U'NO="-_-^SFW\C_P )&_Y?\N)K\?)!+T_\<L/&*=XP)*Z@VC24V2A501KG
M@K*6H$P%V#QR%N0Q]^Z]UO/^_=>ZU=O@O44Z?\*C/YWE*\\*5-1\=NEY8*=F
M42.L>PNNQ(R(3J98S(NH@$+J6]KCW[KW5#'<D=54_P HS_A6%G,5)#-UUE?Y
MQ9CV;/1J/MWEC[VV9-5- P070T-5CR!J("E2%6]V]U[K:2_F)T>XZ[_A.GWO
M!M8NN33^6K0UE4436?X=3[1QE1F!I$<M@<1%4@M8:!=]<>GR+[KW5=OS%WYT
MG#_PCWZZJ]P9#;==M[,_R\^E]A[;A"QSK/O:GBV=0Q4]-&ERV2QVZ*":68J-
M=.])4SRZ5@E(]U[HOG\[[$=F[J^"'\D;X?[1H\WN[^;KNK;>U<QUINC8%>^(
MR6(7;?6,$/:^8EJHJ"G)P^3F*))CRM$:R.*6:*";^'2T$ONO=7#_ ,HK:7Q3
M^9G\@OHWHOJ3:\&&Z3[+^*&9^.O96TZIBM33[CJZ+(X+?LU=4TE+BY)<E7;D
MJ*[)-7P0TSSO4I74XB,D97W7NM>S^65N?=/S8[V_D?\ \O'L_-[<R>>_E*UO
M=7;GRHZ]H *I:;,=7;KCV7U4]8&7R4]9AJMZ0PZC&)(I7J9(3Y:94]U[K?\
M_?NO=:K/\R+X3?*3X&=U?*;^=1_*U[ZVCM[)C8]7V9\^OB7VI']]M/?6-V1B
MJBNKZ^BG@+3X_.T.-BJ)Q3!J:H^XDGDI<A *NIHJSW7NB[_S-?E#B_FKC_\
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M6U6&G;%[BVO3TO\ #JC(X_%5LU/'1+#&&FI(')0W3\GW7NCO]T?]Q<7Q'_\
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M4;Y:&I99H8I)GQL;QQI_#VA!B/NO=#CN;^3!\2]P]?\ \N?K"DW%W9M?9O\
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MD?RN_P"7_P!6_P PW?V]J'Y.8FO[7W-VCEMU2=.= [%J::CS6Z9]J5>6HJ?
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MYL%DUIQ'N#;&:H%IHMR8*GJ:N"">KCI:<0R5-*)$4U$8]^Z]U;1[]U[HC_\
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M-58C<^,Q<U14N=PXNAF6KVK+D9(I7Q(\F4I,G#!'5TM88Y5*>Z]UN7[T^?\
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M>V]@1AUP,6X*O);0@<9FMW;_  ^DF"U,"+12P2),DH1T5)/=>Z+Y_,V^</\
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MC65&(]U[H\7OW7NO>_=>Z][]U[KWOW7NO>_=>Z)WWC_,*^"?QEWO_HU^1/S
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MKW59'\GW)8*+_A(Y_,!&4K,?X:?ISY(4,B3LK>.MJ-G5BXZ-UY*3RU4T'B!
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M<>^OML%6X7"5E=1SU%%D8ZZ=:PR"22GJX(64"!2?=>Z1O\K3_MP)_P *-_\
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MB_\ VJO?NO=>_P"@*G^:;_S_ ,^ '_H4]B__ &JO?NO=>_Z J?YIO_/_ #X
M?^A3V+_]JKW[KW5;7_"9[_M^'\#_ /PYMY?^^VWE[]U[K[$'OW7NO>_=>Z][
M]U[KWOW7NO>_=>Z^5E_PL5_[>]4O_BJ6RO\ W/W+[]U[I^ZW_P"$<?\ ,W[0
MZ[V%V7@.]/@C1X+L39>+WUA*3,;G[ CJXJ3+T,&0IHZJ.'K"HA2I2&H595CE
MD0.&"R.H#'W7NEI_T!4_S3?^?^? #_T*>Q?_ +57OW7NO?\ 0%3_ #3?^?\
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MMLX6/'5\60CHJ2.6*N>MFHA]U&TH5D,#^Z]U7K1?S]-^9G^1W\A_YH-)\?\
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MX&_''J7N#YN;I^.:_)WO&O[KS5?B=A[#VZD\6/85,M T>5RE579@_9PI!(#
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MJ6MK<!O"OK_M,9FLBE55TT$LF.HZ")#D:04XK6CFU>Z]TM._?YH/SU[!^?\
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MSN/H[X2_$.N^&WQ-P62[#SV\^W=\9:HW9OO:F&VQ%N',9;;..POV,& EQ?\
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M_P#%)MW_ /O6;!]^Z]U]2'W[KW7O?NO=>]^Z]U[W[KW7RLO^%BO_ &]ZI?\
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M/Y9VY>I?YA78^YNWOC]O[K#8FZ:O)4U<N/,?9$V5WCN/#5\>'S=+1F! D<E
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MTS!%+2O14;K [3SM)))*6]U[JIOM6CV1_).[W^)GR@_E/_-3;_;GP?\ GO\
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M5PK'4F:(P3&.59(V0./=>ZUJ/Y>>Y>S_ .6G_-PZV_E,=3?*:3YH_P O_O\
M^/.;[IZ5P.9R&.SNY.E!AH\G604%9FJ*<F3:^2_AYHZ-"/%*]90&FHZ,T]94
M9#W7NB5?R[>U.LNLOY'G_"C_ *T[#[#V1LOL"G^1GRGP[;.W)E:&DR#U6?ZO
MP^W<)!#333K)/+EL[1ST-(L0<SU4;11ZF%O?NO=!]VC.O7O\H3_A+/\ )?==
M358[I7XZ?.CJ_>/<^?9&./Q&*_O'45YR^4D#>*EI::##U$0FE7QAZA8O(CRH
MDONO=;N.S_F!\6NPNZJOXZ;#^0'5&\^[Z+KBG[=FZVVOFJ*NR)VU55)I(<O$
ME-+)'/2^?0'\;N\234TLJI%4T[R^Z]UI#_ ?_N#;^;7_ %%]A?\ N]P/OW7N
MMPC^4[_VZR_EI_\ B@'3?_ONMN>_=>ZI#^=FZ^V/FS_.\'\L7L#YN?(/X*?%
M'K/X/I\GL1D/B[NVDV#N7>^Z),[0T#TU9N2J@K354%)05M7*E"87@3^$S5)@
M,J_<1>Z]U5?\ =N;?V;UG_PL?V=M7OG=_P G]O[0^+DVU,7W[O\ S-/N+-[H
MCQO6_?-$<CEL]2(E/F:_7 8IJQ1_E#QF5BS,6/NO=9/GQ_W!M_"7_J+Z]_\
M=[GO?NO=7"?.K_N*%_D>_P#BO7=?_O ]@^_=>ZIZ_E?=%?,R7>_\TGJK8O\
M.NP'\L[<O4O\PKL?<W;WQ^W]UAL3=-7DJ:N7'F/LB;*[QW'AJ^/#YNEHS @2
M.2@2&@2M2I85Y/OW7NE!_-&^$NT_@)_PEOV_T7U]\G,#\O.NLE\H=M=K]?\
M=^U,5!B,5DL3NC(U63IAC:>FW#N>GEH]4CRI41USI,96<(G(/NO=6R_SJ_\
MM\?_ ,)L/_%A>W?_ '$ZP]^Z]TE?Y:79/7_QM_GD?\*$]C=[]A;5ZTSG9&<Z
MH[UV5)V)D:7#QY#:V,PFZ*K(9*CER4\*U-!B8=TT$<\T;-'#JLQ3257W7NJ%
M]B9O$;E_X2P?SV=QX#(TN7P6X/YLLN;PF6H7$D%525>^/CO/35$+CAXIX9%=
M&'!5@??NO=7&_P V#_NU2_\ %].B_P#Y0O?NO=&%Z7_[BXOEQ_XR&QO_ +V?
M6/OW7NJ-OY8?QT^5F9^,GSKZ!W)_/@VI\!\;T1\@NR=C?+SX[=I]3;!RTAAR
M(EBR^],CG-S;IP^3?$;OI(ZG3,!X8C33Q03N(U<^Z]T=3YM_$>?X)=>_\)9_
MBC+WA%\D*;J3^:MM&CPO<]/BH\)#F<7E>P\5GL1]MC8LQGXH*7'8O*4]! Z5
M]0L\-*E0&02^)/=>Z/KW1_W%Q?$?_P 9#9+_ -[/L[W[KW3!_)QW7M;:_P#.
MC_X498/<VY,!MW-;H^0_42;:P^=K*>DJLB33]BH!0T]1)'+5DO74RVB5_540
M#ZRQZO=>ZVHO?NO=?/BKSV%_,C_EU_S4/YC'RW_F@_*SHCMKJG_33U;M?X*]
M<]@8?:O7V"I,5MS(4^$ZYW7L^2&L_O#4[KEK#BII(Y:>IR4<RPI+4U""7W[K
MW3MF_P#LAC_A'/\ ^+_]<?\ O;8;W[KW5PG='_<7%\1__&0V2_\ >S[.]^Z]
MU6K_ "X^X>M>F/\ A.__ #H_B5VWVKMW!]\?'&J^3?1F_L3OO)T=%E,KG<MM
M3(8_%5=+35-;+5U+9[-U$E! &+S2Y&"H@'D(227W7NMBG^0#_P!N:OY?'_B!
M:?\ ]V61]^Z]U<)[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z![KCY ])]P;O[7V'U9VALWL+=O1>YHME=P8?:-;%7MMW-2K,W
M\'RDM.7@ILK"*>3STA?[BF("U$<3,H;W7ND/TE\R?B_\C^R_D%T[T=W1L_L?
MLWXK[Y7K;O\ V=@'G^[VWFF67_(ZD3P0QU*I/35%+)/2/44\5=25N/DE2NHJ
MNGA]U[HS/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@6Z4^
M1G17R/HNP,GT-VKLOMO$]6=F5_3>_LQL2LCR%'CMSXNDQ]=D<-)60:J::KHJ
M;*TK3"%Y$C:7Q,PE21$]U[H:??NO=>]^Z]T2+YD?S(?@_P#R_*;9-1\P_D5L
MKI*3L:M>BV1B\U%DLAD<CXIJ>GJ*F'%X6AR>1&/I):N$5-:\"TE,'#3SQJ"1
M[KW1S,/EL=G\1B\[B*E:S$YK'09;&5BJZB6GJ8EFAD"R*CJ'C=6LRAA>Q /'
MOW7NG'W[KW7O?NO=>]^Z]T%&R^^.CNR-]=B]7=>=S=4;][,Z@JJ>A[:Z[V7N
M+$93.[7GJ_**6'<6(H:R?(826I-/+XDK(H6D\<F@'0UO=>Z*O\Y_YH_P3_EK
M_P"B[_9U>\_]"_\ IH_C?^C3_?L[QW'_ !+^[G\(_C/_ !Z>WL[]G]G_ !VA
M_P"!7@\OG_8\OBF\?NO=</AC_-0_E]_S":C+X_X?_)W8W;^?P%$V4S&SDI\O
M@L_!2)-X&K&V]N;&X;-FB68A34"E,-WC]=I$+>Z]T_?-'^95\&/Y>6(P&7^8
M_P C=E]+?WKC>?:^ KX<IE\YDH8IX:::IH-N[>H,OGJRDIYJB-9IXJ-X8;DR
MNBJQ7W7NC"=#_(#I/Y/]8;>[H^/7:&S>X.J]UB88'?&Q*V*NH9WIIGIZJ R1
MG5#54M1&T4\$JI-#(K)+&C CW[KW4G9??'1W9&^NQ>KNO.YNJ-^]F=055/0]
MM==[+W%B,IG=KSU?E%+#N+$4-9/D,)+4FGE\25D4+2>.30#H:WNO="O[]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NH62R6.PV.K\OEZ^BQ6)Q5
M%+DLIE,E*D%/34\"-+////*RQ0PPQ*SN[L%1068@ GW[KW0;])]Y=0?)#K7
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M[W[KW7O?NO=4 _\ "H[_ +<4?.;_ ,IE_P"_BZ^]^Z]UKM_\(;?^/R_F3_\
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M-3@7JL=72T-3HD,51YZS$TDTT\B-432P(\LSMJ)]U[I@V#_*U^"/6'PVWO\
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M'J\K/@,=]G0XJEBUT-#2R2^+7.\LCR._NO=(#&_RW_AAA\C\W\KCNFOMZ_\
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M[*V5M_#;3V?M/#4VW=L;8V[314=!CZ"CB6"EHZ.E@5(:>FIX45(XT4*J@
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M$T,]=C*BDDI*V6KJ8I*2:03R13PLGNO= _V]_/'^<>>SGS:[V^$_PCZP[L^
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M5[6Q%9GL-4XVNI(=OXO<6Y98/[OY:3*S4DU/54CO*526+[::1X7A]U[JB?\
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M*'LVMQV.K0YM%DJ3""A2MA152"K$T ,AC,TONO=7:_.K_N*%_D>_^*]=U_\
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M$_\ U)[]U[KW^@WI3_GS_5O_ *#^)_\ J3W[KW7O]!O2G_/G^K?_ $'\3_\
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MI$?+#^?%\GMW?R9/Y?W\P#X;8/876W?'RA^9FW_B]OO:'8^/7+X2FR#8_?\
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M'3 SP0T_CEEE$_IA;W7NK3/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW56?\
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MPXG%UDL8_BG^XW<]6_DIQX@<=)(9O')3?=>Z]T('_"5+_LE'^89_XUY[9_\
M>;Z[]^Z]T7K^07_VZC_G4?\ B^GR._\ ?;[-]^Z]U4]LC"9;87_"?_\ X3P?
M-^; 9W/=7? _^955]W][S;?A>IEQ6THN]MZU-9EY::*-YY((:S%TU+>/4RRU
MD0,;*Q>/W7NMP;8?\RSX2?S&LYW]\-OB/W0W<F]ZKXQUVZ,KO[8&,R=7M+'4
M^Y(*["4M'5;HBI'QU!G8994E:AJ6AG:-CX%FEIJR*F]U[K28^"G27\LK:/P.
MW?TQ_,F_FW?S*_@UWKTIF-[]0_)OX&[1[*;";>AAJ,[F"U!MOKT[&W"^>QNX
M</D(WR,5&^1@K*ZHR$TH6GJ /?NO=71_-+X]=6_%+YN_\)-?CUTEN?=V].H^
ML.P>T,)UWNO?=125>7K\3+2=9UM)4UM10X[$4DLDD54"IBHZ=0FD>,$&_NO=
M;$'\RWNSX#]1?'%]N_S(*W:5-\:N]]XT/2.9I]\8VOR>*DK\K'45%$U=_#::
MIJ<73T\E%Y!E+1)CIA#4O4TP43)[KW5"O_"?_>^*Z]_F$?/[X6_"[Y%[J^5_
M\J7JWKG;_972F\]QY*HS5#L/=V8GH/+L7;6;G@"9/$2T=1D'8P2K!$<9 3%+
M73Y&LJ?=>ZV>?E/CJ[+_ !B^1V)QE-+6Y+*=#[OQV/HX!=Y9Y]O9&**)!^6D
MD8*!_4^_=>ZUB/Y 'R.Z-WQ_PGDJ/CIM#LS;.XN\.D_C7W=E.V^M<7*\N2V[
M3YK>'8^2P\N6C$>BD7*4&0AGI-; U$9D,0?P3^/W7NJ\O^[%'_??]YA^_=>Z
M,_\ S4<IL#=O:?\ ((^/7SLWUG=A?RGNU_C_ %5?\CI)\SE=L[6RN[,3L"EJ
M]IT6Z,_BIJ&6"&GR\>-:F62KB6)9JNI7Q>)ZB/W7N@Y_DC;;^ &R_P#A1W\M
MMF_RS<S0YSXH[7_EJ5V.VW4X3-Y[<6*CRTF^^K*S.0X?+[BK,AD*S'QU]4UG
M%1- 9S.8I'!+'W7NC>?\))/D'TOMOX/5WP9SO8>!QGRYZR[X[#RF_.@JHRC<
M&-HJ.NQD55D)Z81&,XV&IJ(Z=JQ'>F^Z;[3R_<@Q#W7NKYOYK&\>\^OOY;WS
M6WO\:9MP4O>6U_CQN/,=?5VTX'J<K2U,-$[3UF,ACAGE;(T=%YYJ8I&SK-&C
M)9@"/=>Z^<-\^>OOY)N%_DZ_&CMWX^=FX[>W\T_N7!;&S?R,J*??6[]P;BJ\
MYD<<N5[).[<%6Y>KPN,2#<D$AB>6DIY9IO!-"]1J\OOW7NMO?NC_ +BXOB/_
M .,ALE_[V?9WOW7NBG?\* >A=D8/^:]_+W^6/R0^0?RR^*/Q%W_TAE_B3OWY
M/?%3<;[8K]C;D@R>=SVWVR>83#YDXW$[GESWVM=(T!C>FHC-(\,5#*S>Z]T>
M/^2]\1?Y:V'^3_R.^7OPI_F)_+_Y^=J;>V%#\6^X-V_(?>U%O/%I1Y&7;VZ\
M?)0Y9=F8&IRTE(N*CIZ6J@R%714P?)4GC$]S%[KW1S?Y_P!_VYJ_F#_^(%J/
M_=ECO?NO=:P/RI^7WQ7_ )@?\EC^3O\ RK_CCVI0]O?*/N')_'SH;?/5W7JS
MU&=V>FS]L4>+WEELY2&DE:@H\-44C_OS)X7IO+DD:2AI:B5?=>Z.#_-.A^*W
M=/\ /;V]\?\ ^<9V!-M+^7%MOX'-VA\;]K[]W3GME;(RG8XS]%29"KFRV$KL
M*:G-1XJ7+0\UGE5(J2G5E^X2";W7NB__ ,A3N;^7E\8NQ?\ A1=VGM7<,-3_
M "WNLMQ=28?;^8SL&:W/35&R%?M/!0PBER45?F\WC9UE\,$4L<\T](8U$;J0
MI]U[IQ^,F[/AW\8/YT_P@V;_ ",ODIDNU_C;\WYMX;B^:?Q2V)E,CG=D;.H*
M+%4=5B]Q0TM1 9MNUC>2H<05<AJL?_#HZ%C3T=9#2#W7N@:SOQO^+?1W\V;^
M:KUM_,!_F2_S /Y;([?[JG^7GQXWAT=V6NP-G[_VUNVJKLEDDEJY=LYBGR&8
MVS7UJ8VD@\L<QIXIJ:&*9J*5S[KW0R_.CX)_&WH;_A/KLGOG^7CV9\BOEMT9
ML'Y\[._FIP;B[GK8J[<&4B>C39N>2H-'M' 5>.Q5+%4'(5WW&.^YHYQD*^KG
M>!71?=>Z%KYV_P P[X<?//\ G%?\)VY/B;WEM/N9]A=O;XW3OV#:S2R/A(]V
M4>R#AJ/)EHUCILI(<!7">C+&>F,0\R()(B_NO=;JWOW7NM*;^43_ ##_ (H_
MR6OBQ\W_ (&_-3?+=*]V?"SY);ZW!L/8.^$J3F.P]JY9*:LVIE-N+#0PTV5J
MLU)"\?BI2RQP/35TI@IZ@B'W7NJT=[?'7L7XW?\ "<O^3=@NU-LYG9F\>R?Y
MS.R^YI-K;@41U=+CL]1]EM@Y)H JO3?Q#"4U)7+#(3,BU2B812:H(O=>ZV!/
MG5_W%"_R/?\ Q7KNO_W@>P??NO=;'7<NR9NR^H.U>N*:84]1V!UMG=DP5#,$
M$;Y7%U5 KERD@4*TX-]#6M?2WT/NO=:2'P)_FJ?&7X"_R"^W/@S\@]QGK_YZ
M_&C!=O\ QXJ?B5NBGK(=TYC=>[]R[KR6WHL?204T_P!WBIIMU015-=3F6&!(
M)YBQ0P&;W7NDQVE\9=U_#_XE_P#"13H3?>+S>!WOM_\ F2;&WIO+;NX_&*[&
M97>>_P#%;UR.+J4BCB6&3&5>X9*4Q,#)"(A%*\DJ/(WNO=;[_OW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZU&?^%%O3E+\@_YE'_"?+I:OWUV)UKC
M>Q^Z.W=MY7>O4V4FPFXZ*DEBZK:K_A.6I_W\?4U-,CTYF3U(DKV!/'OW7NGK
MX0]4X_\ E7_S_-T?RYNBM_\ 9^1^(ORL^!B_*S"=3]EY_*;CCV]O.BW3F<=5
MU>'J<A+-+3ME(\-E*JNDF9YJN6K3SSR"FI(X_=>Z+7\*/@]#_/XZZ^7_ /,=
M^0?R6^0M'OO<WR4WEL?^7C4]2[MSFVL5U=MS;,/V6W,KBL(BTZT^5R+5[Q9
M5"R22TL?E+0UM95,ONO=&;^&GS@ZN^:W_"=39_<G\S7Y=;\^/&'Q6;J.INX_
MD9U?G\SM?=>2FVCN?R8ZGHZG#Q5>5R^<W/MVCIZ?(4E#35TF3>:LDBI/(WBA
M]U[JM?\ EC_(+X!=;_ST_ASU9_* ^0/=&_/BK\INF.R=K?)3JSLG*[[:BHMW
MX3 ;AWM2Y]<;O.FHZBHR>0.%I?\ + D\8$E8L,Z2R5</OW7NA;_D/?RW>LOG
MO)\AOE]\DN[_ )7;LWI\5_YLNZ\9T=L"DWYD8MH8?^Z:;5SS2K@YHZE)&W%#
MFFQ.6 D038>"&CI_MB997]U[HQO4'Q>V]_.V_F7?S6>QOD;WQ\B<;U_\#._:
M/XG?#C9_3F[LUM!=@Y_ 465Q>Z-W8T8UJ429R;+TLS0U4HE,JU%5#.9Z)*".
M#W7NC!?\)"?^W.&TO_%A=]?^Y=%[]U[H7OY^W<?;>5RO\NC^7/TGW)N;HC<G
M\R/Y5+UOV/V+L6:JH-P4O76VTQL^\UP>7AAFCQV0E7.4*QAK/5'_ "8_Y+)6
M,ONO=$GJOCSB?Y*?\W7^7+T'\8>TNX7^&_\ ,[QG8_4_<G07:FY<MNC'T6Y,
M#08^N@W/@9*Z2:IQV9RN8W)2-53L91('KE<I',C4WNO=%N_D0_RNOAYL'^<[
M_-@R.V=D;CHZO^6[W9LK ?%"2;/9688:EWCA.QL5GHZ]9:EES9J:*DC1&K1,
MT)!>(JY)]^Z]UN.?)[N.C^.WQK^0WR!R,:RX_HOHW=O<==$Z22!H=L8#(9N5
M3'$KRN"E"05168_1038>_=>Z^?!\FOY?>*WW_P )PNQOYN_=W?GR+[.^<??U
M'M7L[M;>&3WCEO[OYW#9SN/#X?$[3R6UQ(F&FPF!ILE'D:*G6!(Z'+PJ]#X:
M2*&G7W7NKO\ YH=E]C;0^7O_  E'V9M+?^]MK[/['IL]1]A[4V[E:^BQN>AH
M=I]1R446:H::>*ERD=')42M M2DJQ-+(T84NQ/NO=%*^/?\ +LZ]_FI?S:_Y
M[&PODUWK\K\=UE\=>_\ 8=5UOUGU/ONOP6$@R^=&[*NFSTN/:*MIGRFW9]N*
M^)8(L-/)6UDKQ32/$T7NO="O_,:[9^+?RI_G+9GX#_.?YFXGXQ?R^OAE\3</
MN?-=7OV$O7<6\>S-S?PZNQ-%E,D]92565I\1M;)4F0ABCG1Z6:EIV&J.LJ@_
MNO=![\0_YK^^/C)_*B_G1X7 _*&A^4.6_EE=J3]<_$?Y&Y3)+O"KRVT.P\F-
MO=39/*Y>F\M-G9H<P\MY BTT7B:E<BDI@R^Z]U8%_+<_D<87K#$?!3YTGYA_
M+V#Y?9'9VWNVOEUO"LWMD-PX_M!<UMZ>NFVEFZ?-I+#-@,57Y80T<TD#U1HH
MI7)3)319"E]U[JKC;G\HGX1=J?\ "HCY3=)[PV)NNKV'A_B>OSWQU'2;BRT%
M1'V9E-^[+K:O,?<QU D>D:IW!6NN/;51+Y%40Z8T4>Z]U8/\I^NQ_-[_ )W/
M;G\NKN/M7L;%_!OX+_$[#;\[=Z-ZQS>7VP=X;^WPF/K,?#N*KHA#)E<11[;S
ME/4*L4ZI!-%' FHU605?=>Z*UU-V)W%\4=D?\*9/Y5%=WGV;VEUS\*O@[N3N
MKXG[V[%RM;D=WX#$[OZ@RVX)L2=PZDDDIL*^4Q?V-O#+33K4R0W6333^Z]T-
M_P#)#_E=;/K/AC\3/YH%-W#\FNVOG;7_ !LW9D>M,AVWOO)97:]#59_&YW$4
M.!7!U0>#^ TL[T]0D$LCA:Z&&M)\D,(C]U[HBW\BCJGX:]Z=Q;(G^57R6^9?
M2O\ /.Z)[YRFY/DUL'L'L'<VW:WL.'&;@SF1Q.WI,=5U'V6X=K)B*NF-?BZ&
M6*I>2&=IXI,)7%*WW7NM\_W[KW6DI_.?S'\AC)?(SY+T7R=^?GR/_P!GA_NY
M45O4VR]H;L['RFV.J-XTFVCBL-3XJ/ XZOVOMNNJ\M3B?(4E756I7J)6JH<?
M33>1_=>Z*K\KODAWY\DO^$T/\E+L#/\ <W:>U>T>T/Y@FV.A]W=K;5S^3@W)
M5T&$G[JV1!7U68%2*VLKYZ3 4M9,]1))Y*Q!+(790WOW7NK#^J_CCMG^5!_P
MH=^%7Q^^/'8_?NYNJ_Y@GQ>W]/WGMSMS>F7W$*_=FU,+F,]'O2O?(O.,EFJZ
M/:E/2EG6)J999_M98Z>1Z1_=>Z+#T'\5</\ SAMB_P Y+^8_\B.^ODYB>W.E
M_DCV]\>?B4>KM[YK;^.Z]VILK:F)R=)1X?$TDB4OAW!2UU'!FX)@T&0-*U0\
M,5945%3+[KW5TW_"7'_MQ1\&?_*F_P#OXNP??NO=%X_GU5(SW\Q#_A.SU?NV
M5L=U)N+^8#6;_P!PYA[QPG=&U:O8LFRL3+//Y,;;.5N4JZ;[:6%JJK37%12P
M-YF;W7NLG_"H>-L5U-_*SWU@X5J=_;4_F]]5Q[0I8P[SR&;&[IK)$BCA9*IP
MU;BZ($1,K:B@!#E#[]U[HDFY?@YM#^9M_P *)?YN_P =?D;W5\E\=\>^MNE>
MJ=P1],]6;UR>!P66GRG7?7\3Q9:BB,U-/10RR35(@2-%DJI3+(6]2O[KW1R^
M]UW+\=_Y_7\ASXJ=;=D]ITG2.$^(G9&Q<IL_*;AR=3#N"GVKUQO:FP];NB,U
M"4^X,M"U#%4-65D4DS58-2"LIU>_=>Z#[!]E]C9[^=%_PHTZUSF_][9GKK8O
M\O[:E9LC8.5RM?483#39#J3:E37RXK%33O0XZ2MJ)7EG:GBC::1V>0LS$GW7
MNJ5OY(_R-'SAQO\ )R_E*[7[GW-U/UK\7L#VC\OOE)1[/RN3PF2WUFZ?LK>V
M1VWUQ%68VMHIYL;_  #-)E,I3DO#4T%3-QYJ-"GNO=;*_P#/<S'\HRD3HS&?
MS3?EGW+U-M$XG.4&"^-_4.Y=Z4U-O:FR;4<9R.Y-J[)I:^MJ\=ACCIHZ:NGC
MI:<2SS4K54K,E*_NO=$8_P"$W^^^F?D75_SBOA1L[?VYOE1_+OV+V=M2I^/$
M/==9F<S]QL3LG%;MI:S;%12;BB@KJ;$PTFV887HIZ>GD,LE4:J!:B68M[KW1
MEO\ A2K#VIU=\._B7!USB^W,'\%^N_DSM.D^>6W_ (TSU6,SE/U!C5AIZC'T
MTN-FIIZ3"I21R0FSI3Q5(QS3LD*,R^Z]T<W^2ET?_+ZZYZ5WSV5_+6^2O:O>
M7QN[?K<)48+8&^=[9G<F*Z_EQ..>%\'A\!F3'7[2JJLU1J<C35T R,DOB264
MT=-0P4_NO=$D_P"%>W_;G#=O_BPNQ?\ W+K??NO=%L[@^*V%_DG?S2OY4?:'
MQV[S[^RG6_SW[MR7Q0^9>#[IWAG-VS[YW)G*3#8S:>Y<B*]:W7EI,O6I)-5*
M8/M7I*2.(Q4-17+[]U[I53]#XS^>#_-Y_F<=)?*KM/M^/XE?RWJ'KSJWIKHO
MJ7<>6VK03;JW-2Y'*5F[\N]%+&^2S>(S.VJP4<KJ(HU-$$5UIR]1[KW1C_Y)
M'?6]MG[/_FF? 'Y6_(K<.^J/^6/WYD]AXGOC?V8JJ;.TG5.>H<Q4[:R6:W;(
M:54KJ"DP.1F-2DJ38W2(]2004;'W7NM9_P"17=W\J'X\=J?#KLW^4U\]/E)W
M9\Z]M?.?KSKWY"]C=E;D[#K)-_;)D_CD6:J\I59W%XK;N;H%RU/1TA6A7[:2
MFR3F**>"43K[KW5P7R4^'^VOYC?_  I1^3'Q$[S[A^1.V?CKC?Y;6([7W+U?
MT]N_(;=QVXZF+*[/P:XW.T\(F@J\2YSHK985C1IJNAHC)(T,<D4GNO=*GM[X
MK[*^8_\ .(Z1_DS=A=H=^?[(I_+\_EC8ON9>NL'N_*XK(;UW=3;@VUA,=FMY
MYC&FDJ,UD:.')8S(P5""GDILE2SS4KP)65=/-[KW2L_X3I=.4OQ\_F4?\*#>
MEJ#?78G96-ZX[HZBVWBMZ]LY2;-[CK:2*+M1J3^+9:H_?R%334SI3B9_4Z1)
M< \>_=>ZLP_X4-_,WM/X+?RJN_\ N/H_<(VCV]GJ_ ]3;$W:D<CSXN;<F5IZ
M+(9"B*6$.2I,(*V2BF<A(*L0S$2,BPR>Z]U2I\Y/@_%_((V7\/\ ^9#\<?DG
M\AJO=NV_D9LGKS^8>_:V[<WN7$=G[?W#2_9;DS^5PL_W+SY:"3'JE(E/9H()
M4DA#5-% S^Z]TDOYJG\KKX>?('_A2;\!.N^S]D;CS.UOGCU9O_?OR1HZ+/96
MCDRN2V3U_N%-O2T4U+4Q2XE*5=KX\21TAB2?Q,90QED+>Z]UO!8Z@I\7CZ#&
M4@9:7'4<5!3*YU,(X46- 6/U.E1<_GW[KW6C/T'\5</_ #AMB_SDOYC_ ,B.
M^ODYB>W.E_DCV]\>?B4>KM[YK;^.Z]VILK:F)R=)1X?$TDB4OAW!2UU'!FX)
M@T&0-*U0\,5945%3+[KW16-T=E]C=2_\(OOA]O/JO?\ O;K/>%)WYF*.DW7U
M]E:_#9**&H[I[/CGBCKL=/3521SQDK(H<*Z^E@1Q[]U[JT#^9A\>W^:O_"DO
MXN_$7?/=_P A^L^C-U_ROWWQOK:_1>[<EMALTU#O#L]&HJQZ1VA-+7JD,=6?
M$99H(4A\B@*R^Z]TEOYGF*Z7^%>]/Y0G\D_"_*+>GQ*_E];WJ]^]B_)CMG=&
M^9L)N"3:F!:LSF#VK5[\K)J84&$RV4GK<4D!Y9?X314[11TR1S>Z]TI?Y3/>
M'17QC_G'[Z_ES?!CY98_Y/?R[NXOAO3]\]4;?I][-V!3=>;VP&3.*K]L8/.)
M7UJ4%%48>DJ*ZJQ\NJ0)/C)%>-4/W7NO=!'\%/@?!_/TV+\L_P"95W_\J/DI
MM#LW>/RDW9L_X![BZBW;G,/CNIML;;IJ3&83)83;JO0QTV2R4<S1Y.+7&:J"
M+[G739"NK)??NO=0_P">[_+F^//:?\U?^17LWN%M^=I5GREJ=R_'7Y#;RS^7
MEI,IN?"; HMF-A:B9L0F.I,=DYJK<N2J:NHH(*8SRU)&E8HH8X_=>Z-U_,9Z
M\?'_ "@_DO\ \@[H+LOLGH3XD]K;?W;G>XCUYFLG1[KR.R^MMNU66PVU$W.)
M/NX\?DH,-D:>K.J6HF<TLLK 0VJ/=>ZY_%'KJ;^4#_.\ZJ_ES=1=L=E9KX,?
M.?XI9GL+IOI3M'-9/<QV?OO92Y*MR%)MZJJEDDQ6)FVY@ZB8B:0I4/,8)',M
M+1!O=>Z)/_(>_EN]9?/>3Y#?+[Y)=W_*[=F]/BO_ #9=UXSH[8%)OS(Q;0P_
M]TTVKGFE7!S1U*2-N*'--B<L!(@FP\$-'3_;$RRO[KW2+^6&VOCUV7_.V^8G
M3?\ .G[M^3/QVP>_:?;-1_*6[IVKNS-;3V9MRABQ61HLM6X;*4QFV_CL\U16
M4MJG(P-1C(1Y&GKVU5E)%4>Z]UO#]4;.Q_7G5W7&P<3NC<V^,7LK8F)VICMZ
M;URM5G<QEX,?004D63RN:KIZFLRV1KTB$]1632R2U,KO*[LSDGW7NM17Y ?$
M[:'\PO\ X4L?)WXD]_=C][TOQQH/Y:>)[1W'U-UEO+.;;Q6?JXLQLW"K19J#
M&54*5>-;^-_=R06 FJ:2D:4M'&4;W7NFSX<]H=L=1?R[O^%+/\OG='=.^NQJ
M[^6OM'N+$] [VW'DJZKSV(V)N3KS>U9LNE_C3Q03FIH9=N550H6:22AJ998(
M6CHXJ$>_=>Z,9_PGW_E==-UGQY^!G\T#?_</RF[:^5%?U%E\C19#LO?>4RNW
MZ''Y],MB)L#2X.H#Q?P>E@=*B&"21].0A@K2?)#"(_=>ZJLZE_F+_)GXR?R!
M_P";AWGMGN#>N4[MI_YLF\OCIU!OK>V2R69K=MXW,4?7-++%A):RHG;'?PK$
M3Y*;&(K)34=8ZSI$[?M2^Z]T:+YR?!^+^01LOX?_ ,R'XX_)/Y#5>[=M_(S9
M/7G\P]^UMVYO<N([/V_N&E^RW)G\KA9_N7GRT$F/5*1*>S002I)"&J:*!G]U
M[I3?)3X?[:_F-_\ "E'Y,?$3O/N'Y$[9^.N-_EM8CM?<O5_3V[\AMW';CJ8L
MKL_!KC<[3PB:"KQ+G.BMEA6-&FJZ&B,DC0QR12>Z]UMR=$].[7^/72W5/16R
MJ_<F6VIU#U_B>N\#F-YUAR.8K:;$T4-%'79:O,<7WN4K!#YJN<1QB6>21UC1
M6"#W7NM+WYU?RK?AK\G_ /A43L/I/N/8^YMP=?\ R8^!51\H.W,;09_*T$U;
MN^AS&[]NTM93U5'40ST-+%B=L8^+[6!DA9H6E=6DEE9O=>Z.Y\P^O'_F/_SI
MMD?R@^P^R^R=K?!/XP_R^3\B^T^INM,UD\!5;ZS-7EL9M>CQ>Y<K0R035N(H
ML=G,9/'3QV36E9JD+U%J?W7NA,_E(93?GPM_FD?/_P#D]YGN?L#MWHGKWJC;
M/RV^'\';&2K<_G\!MG*-BZ#<F#DS4\:J,?CLOGJ*"FI9&U&.(540+SUI'NO=
M#I_PIE^-G5'?G\H[Y';L[+P^1RN:^-F%/>O4\U#6U-(E'N2F1\+#5U$=/(BU
ML*X_,U<?@FUPEI Y0NB%?=>Z*'\9/@Y\>?B'_P )FODUV!T=MS-[?W'\NOY-
M60^0/=TN5RE;D8J_=.5Z KJVNKJ2*LEE7'133Y&4_;P:($&D1QK;GW7NJ"]Q
M?%' ?!G^2)_+9_G*=5]R?):K^6'7_9>RLQ)_$M]9A<-+M#(9^O:JZ\QN,$CT
M6%VQ(,73AX8H)4J!YTK(JF&411^Z]U<__-D[PZ(^3?\ .0V3_+H^=7RSH_C'
M_+OZ?^&<_>_:6W9M[_Z/J3L'>^>RHQ=#MK.YQZRC&1H8,+64];38Z)D<K3Y&
M5I'5[4_NO=#;_(#^2^,IOEY_,Q_EW]9?)YOEW\3/CAG-I=L_#GMS(;E.\JR#
M;>[<>:C-;:3=2553!E<7MNOGI**!1IDIJN+()(SZQ%3>Z]U8[_/^_P"W-7\P
M?_Q M1_[LL=[]U[HJ?\ (8^07\RG?7QX^'G5?R"_E_;7Z-^'VT?@9L6+IKY3
MX[LG:^X:W=L.-VSM6AVM)-M#&UTN:PIW)@7DR4@JH5-$T7VDX29U'OW7NF+I
MWLOL:J_X51_*SJ>IW_O:HZLQW\JK';RQ_6D^5KWV_!F&W;UM3-E8<,TYQT62
M-//)$:E81.8Y'37I=@?=>ZJM_P"$U'\M#J_YF?%7HC^8!\D^\_EKV7W/TO\
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M#[KW5@V;^16>R/\ /&_F1=[U?9^ZT^._\I[^6!C*/?/6IKLE'MI]X9JES/8
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M6;:VS30/F)*',96DCBQ<<D(JZ^2:U/3O"::HJ_=>ZK.^;/Q,^5&Z_P#A)_\
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M#G-TI!G,EO+L>3[*7(TE&^*AJZ2FK*:HGII*A:A(*F"7QZ98RWNO=6;]/?S
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MQ<]0U#-5X2#+4JRJ:ADBBDF%/(:@T\J^Z]U$^$_:_P GO@__ #9:;^6#W?\
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M#)Y/;[P'E,ZF(GK(HJ9A^[7QQTQ*&02)[KW1N_A#\??^$W7R%[[^/'6?3?\
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M9&MV#18O=F,Q?\!Q&/R,.-QODBI9X,?3+7RI.L)@M![KW5L/R\J<'_,SJO\
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M?XS)_85R5M;,T'W^'K,AC*JT<J'73U,T?-@]P0/=>ZU7O^&8_P"93_T#4?\
M#?\ _LMW_.7'^SD?Z5?]$O\ ?#87_%@_B'G^_P#X]_>G^[/^:]7@_B/W'X\-
M^/?NO=7Q?S0/AC\E?D3_ #*_Y(GR Z<ZW_OAU'\0NY.QMU_(C=O\8P&/_N]0
M9ZGV(F*G^PRF5H<GEONFPU8-&,IZV2+PWF2,21:_=>Z9OCC\$OD!M[^>)_-N
M^4_:75PH?B?\M.@^N.MNK]^G,X&<9^7$[*VC@]PT9Q%%E9]P8W[>IQU9#Y*V
MBI4E\?D@>2-XW?W7NBA_%CXX?SW?Y7'4=;_+U^(/1WP]^2OQYVMNS=&2^,/R
MQ[FWC58*3:N'SN<ESOV6^]HT2QY;-9!<AF:V=#AD$%TF\DFDTT,GNO=;46".
M;;"8=MRQXJ+<;8JG.X(L$\TE$M:84^[6CDJ$BG>E6?4(FD1)&CTEU5B0/=>Z
MUWOYCVW8?@I_-3^&/\W_ "D=#C_CKN3KRH_E_P#S<WC6SRQ0[1Q&Y<Q'5["W
MG7<?;0X:'=-3%0Y:KF=(Z6(4/HD:37#[KW6'OKXG?S$_C)_-B[:_F0_ ?I7I
M?Y;;(^8G0FV>G^X.M>S=\'9E=MG*[=BH*/';@QV2JZ;(4LVWCCL32//2T44M
M1/-+4LM*LFFID]U[I"_RT_@Q_-?^'W5O\W'L/-;?^*>&^:7S!^4>2^2G2Z5.
M;RF2ZXGRF7K\CD,FE4U+2C<--BC+6S)1PSQ0U3(].)Y8&$TD7NO=)S;_ ,/O
MYK'SR_F8_ _Y<_.7XV?''X8['_EX5VZ*T9SJC>,>[LUV56YW'8^*,4"T3--B
M]M1UE(##3922*JI8YLBK1U7W2,/=>ZV9^Q=C8+M#K[??6FZ(6J-L]A[-RFQM
MQ4Z<%Z'+T4^/JT!/%VIZAP/]?W[KW6D7OC^6+_/G'\K7LW^2/A^F_B]V%T!M
M#<%++UY\O=P;]^QR>Y]L4W8T.]\;@L;MN05=;B<G05]-#+*V3,%'2XL'&4,U
M9-%"Y]U[JX[YI?RWOEKGD_E:_,?X=5/6*_.+^6WL5=DR]6=MUDL&UMWX+/[3
MHMM[KP<V7H5>2CKZ>%*I*&I1EIV6KJ&D:ZP,ONO='N^!G8W\TKM'/]A[L^?W
MQR^./Q<Z^K-M86+J3JGK/=M3O'>%'ED:L;/2[ES%(K[9GHIXY:9:5*&37"\,
MBN9TD$WOW7NBC_RO_AC\E?CM_,K_ )W?R [CZW_N?U'\O>Y.N=U_'?=O\8P&
M0_O#08&GWVF5G^PQ>5KLGB?M6S-&-&3IZ*27S7A201RZ/=>ZK<^/G\K7YW;'
M_DF_SCOB-NCHO^%_(;Y5?+_LGM+H3K[^\^SI_P"/8+/T/7\.)KOXM3[AFP>+
M^[DPE:/#D:RDJ(O#>:*,21&3W7NAD^?'\M_YG]U?R@_Y*OQ=ZSZ:_O+WK\2>
MW/CCN?Y![&_O%M2C_N_0["ZPS.W=V3_Q/(9VDP^5_A68JXJ?1C:NLDJ=7EHT
MJ(%:0>Z]T9+YJ_$/Y_\ 07\Q&3^:/_+4V)UA\A\_V=\?X^@?E)\3>T,_!M1M
MQ0865:K;>=VYN&L:/&T>8IFB@IG%9)'"M/ \:ZOO))*?W7NCF'H;Y9_-W^7-
M\@OCI_,)PW2?4G<7R+V7O7K\47QYKLEF<5MW$9M*J/:[553EH$^^S>$26$UC
MT^JDJGIQ+%XO*T4?NO=:Q7R0_ES_ /"A'Y1_RO\ JS^59N_XW_$#;FQ/C#7[
M7VCC.[J;L-9J[?F#VA2-1[8DPN.\4HP]/C:(PP5TF56CJZR2G#T]#3QN5;W7
MNM[CW[KW5#O6/PQ^2NWO^%%7R*^=N8ZW^S^*F^_Y<E#T-M3M/^,8"3[K=D.Y
MMB9"3%?P.+*ON.#31X:LD^YFQ\=&?#H%07DB5_=>ZK<^(O\ *U^=W6'_  FD
M^4G\OW?/1?\  _EUV-4;RDV;U+_>?9U3]X,KE<14T!_CU'N&HVS3^>"EE;]_
M(Q:--I-#,H/NO=;(W\O;JW??1WP%^#W2G:6"_NOV;T_\0.M.K>Q=M?=4=;_#
ML[M_9>%Q.7H?O<=45>/J_M,A22Q>:EGFIY=&N&62-E<^Z]U4%_,:^'G\P? ?
MS;OB)_,_^!G3/5?R.J=I?&W)_$?MKK+M#=E-M*#%8^IR&YLO0[D6NG F>F2I
MW$R5 I(LE5D01Q18TK-)5T_NO="9\G/AC\INR_YZ/\IWYGX'K>CS?0/QOZ-[
M+VKWYV3C\O@Z2GPV8W%LW=^+QL$&%K\O'N*OAK,GE:>)&HZ2L6%90]1*B1RR
M+[KW2>Z1_E\]ZO\ SIOYQ/R&[AZN:A^(/S2^-FP>G.O-^KF<!.<]]GL3:NW-
MRT8Q%'E*C/XTTTU%6P^2NH::.7Q^2!Y8WC=_=>Z 7X8=(_SY_P"7OLS8'\O;
MJCI_X?=\?&CJSL.5.JOFCVKNZLQ<]#URVY:?(R[=S^SL<DF<J-SOC*VNAH:J
MCBDH*-5B29IOMHON_=>ZVBEU:1J #6]04W /YL;"X_V _P!;W[KW6N/W_P#$
MC^8O\7?YL_;W\QKX'=(]-_+#9_R^Z(VWTUW+U?VEO=ME9#:V8VVE#0T&>H,A
M64M?328 8_$4K5%)1Q2U,\\E25I5DTU,GNO= E\%_P"3M\L\K\:_YUW2?SWA
MZKV%O'^9UW?N;M'%;CZ6R<F=P=#7[C;+Y#^)4$%6E-DHZ'&9^KAJ*:FK4BJ9
M*9$24I+Y-'NO="S\!]N?\*$NM\A\/OB9WGUI\1=@?';XK8_'[,[F^5--N6?=
M]?VCM+#X>KQ&&Q6#P+34N?Q6>BBIZ-ZW*9%: 5%4(JX(\*UF)J?=>Z3':/Q.
M_FR? OY__-+Y1?RT^H^B_E3TI_,+CVYN+>_5O:^[O[K5^P=_XRFGQDFZ8TK9
M:7'Y+;Y6KEKJ^&DE?)Y!9%I$CA..IGK/=>Z&CYP_R\?Y@/RT^%OP9WU7=P=*
MQ?S5_@UV=M[Y)[?W9A*2OQ6P=P;GQZK_ !?;E8(6^[CQF3A2&.HGBBI*>NEI
MW0T>/HJQH:;W7N@XZ)^'G\R_YM?S(_C7\_\ ^9?U?U!\4]A?!7:.Z<-\=_CC
MU/NB#=U?F=S[GI9,-EMRYK+TGGHX,344D4%724Z3)5J:>@AJ84*5HG]U[J;_
M "]_@-\L^CO^@@+_ $H]4?W7_P!G;^6_:_9WQA_W.[:K?[SX/<O][OX)7?[C
MLS5_P7[W^*4W[.6^PJ(?+^_%%HDT>Z]U7)V=_*._F%;A_P"$N7QU_ET8?X^_
M>?,G8G<E=NO=?3O]Z]D1_:T$W:.^]QQS_P!X9=RIM6?5ALS1U&B')R2#S>(H
M)XY8D]U[I>?S)\[\M]K_ /"H'XG;E^%6P^I^T^Y\#_*K?)/UGW%EZK XW/85
M=Z]I+E<=1YFFIZE<;F)(W1Z.:H44JR(14-H-F]U[H]OP1_EE?*/L*M_FM_*/
M^8KC]D].?(;^:_L2GZ;KNHNG<P^:CZ\V/1;+J-I8^CGSU-,(:W<L=)61QU4F
M/JYJ37C(*NDJ8_NVIJ3W7NJO.Q_Y=G\][>/\HG/?R88?C1\.SUUL"+"[:Q?R
M>3LB6&HWE@,-OF@W?C(,'MG^%F7$Y6"KHX/OJK+RTL4U)#4)3T[5<L3M[KW5
MG>R_@%\L-O\ \Z_X#?*^NZOA;X\]&_RAL1\5^R^RJ?.;>:.@WS15N[I)\,F)
M.57<%8@CR=,XK*>@EH2)0/N=22*GNO="]_*_^&/R5^.W\RO^=W\@.X^M_P"Y
M_4?R][DZYW7\=]V_QC 9#^\-!@:??:96?[#%Y6NR>)^U;,T8T9.GHI)?->%)
M!'+H]U[JKOK?X9[@SG_"K#N2CQ^\)\G\<.G=K1?S),IU]AHJ=<=BNR]X;/QG
M7<,69?QM,V8R$OW>>I@&4B"-&51JJ'F]U[JT3^:!\,?DK\B?YE?\D3Y =.=;
M_P!\.H_B%W)V-NOY$;M_C& Q_P#=Z@SU/L1,5/\ 893*T.3RWW38:L&C&4];
M)%X;S)&)(M?NO=>_E?\ PQ^2OQV_F5_SN_D!W'UO_<_J/Y>]R=<[K^.^[?XQ
M@,A_>&@P-/OM,K/]AB\K79/$_:MF:,:,G3T4DOFO"D@CET>Z]U5/\:?Y&WS&
MW?\ \)V-U?R]^W<'C?CA\Q\%\A,A\@^FAF,[B<I2T68QF8HLCAGFS6S\KF*:
MB_B]$E71I4PSR3X^2H2J>!_%XG]U[H&N_P#?_P#,U[I_G%_\)^L3_,!^/?1?
M0F]-H=J=B5.SMC=2;NI]TYG)QX['[<GW7O'-"B:3%8?"9>FP]//AJ.*IGJD6
MFR:5:QRI'$/=>ZWG_?NO=?/2_E8)_-UWQ\.OYGOQW^ O1?Q]WQU'\D?Y@?</
M4>?[U[ WDVW<YUMG,OMS;U#G\[48F6GD_C6(; 5&-3&-CA4U]-E//-/0S4JK
M?W7NKD/YA/\ *'^0D7\J_P#E1_!7XH;2@[TW1\-/F)U3V#VIE:3(X+;<,N(V
M]@-Z1;NW3#'N3,T$7AGS^=69*"&HJJ[15 1QSB*61?=>ZML_FZ? 6O\ YDWP
M<[*^-.V-\?Z,^S)<MB>R>G-_NTR18O=>VZU,AB9:B6E#5=/35#+)2RSTX:>G
MCG:HA5Y(E1O=>ZJ$R?P\_G'?S-.]/A#@OYE?5OQY^,OQK^"G>.#^16\LITYN
MF/<64[;WMM>FC;$9#%T4+51VUMZIFGJ8*BFK6IZV&*>N\1D+T<L7NO=++NS^
M4[W;_,T_F'?/#N'YQ=?576_QLVU\2*_X8_R]J7)9C;F<F^ZW-35HW#VK0XW%
M9+,?P#*TU87%-]]%25U315E+!50$41BC]U[JPC^51U?\NI_Y9^T/BO\ S*.I
MIMF]N=?[-RWQEW145.>P.Y:;>6SJ:C;%X7<,-=A\[N!V-=MZICHJM<DU+72U
MM)55$E%#!40!O=>ZIU_X2>?&;?VS-D?,OY =J[[J^S\ABNTZ3X&]*;R\<$>+
MJ-A]-?=TD%7MX1('.)R.2S#Q!F>34^.U,[S>:1_=>ZV]JDU IYS2)#)5B%C2
MQU+,D;2:3H$CJDC(A:P8A6(%R%)X]^Z]UJ.?-+X;_P [K^9]1]-?#3Y=_'CX
M7]<]3];?(C"=U[E^>73.[ZQZQL5B*_)0K1;.VU5$;JP.[)<1.@J*QHX:*5F'
MADIM;14_NO=&M_F-?#S^8/@/YMWQ$_F?_ SIGJOY'5.TOC;D_B/VUUEVANRF
MVE!BL?4Y#<V7H=R+73@3/3)4[B9*@4D62JR((XHL:5FDJZ?W7NE;_,0^&_SK
MQ?\ ,!^'/\U'X3];]5?(OMCI+HG,?'#NGXX[]W,^T*?+8;+35U7!D=L9C(?=
M8S&U=+79JM:H>H_>:"&ECTUH_;B]U[H$_A3_ "\/YB.5^?/\U?Y<_-?8_175
M?^S^_&'$=3;4H.E=SS[AQ^(J:+;F+VW2450];0T61DGQ^+H85K*K[805%=%5
M24J?;/3ZO=>Z&3^0Q\6/GU\5?AE7_P OSYR=!=3;"Z?Z1I-U;+ZY[#V7NZ#<
M-?O^GW?N;.;DR5<U%0L!@L12KN">DIQ5K#D*JP>6BH1 &K/=>Z*_\6/CA_/=
M_E<=1UO\O7X@]'?#WY*_'G:V[-T9+XP_+'N;>-5@I-JX?.YR7._9;[VC1+'E
MLUD%R&9K9T.&0072;R2:330R>Z]T<#^9)\,OE?\ (O\ F(?R+/D%L+K/%;KV
M-\0^S]_;L^5&Z,%F\-1T6W%SU#L%*2:CI,YD<;FLU2U-5AJ\1"AI*JH2.%6J
M8H3)&']U[IUZQ^&/R5V]_P **OD5\[<QUO\ 9_%3??\ +DH>AMJ=I_QC 2?=
M;LAW-L3(28K^!Q95]QP::/#5DGW,V/CHSX= J"\D2O[KW5<?Q@_D;_(3M;^4
M;_,V^!ORDV^GQY[)^1O\P_>?R8Z!S\V4P.?@6E%+L.KVKF:QMNY/,0PX_*9#
M;]70UE+*T61AI'FD%/%(U.[>Z]U9K\2^SOY^>X>T^G.O/E5\6/A5UEU!U_6_
MPOY!]]X7?.0S>1WW1QX-XX<AL7;^/22? 5DF8EBDJ$S:HLG@J8XE@A>"63W7
MNF;K'X8_)7;W_"BKY%?.W,=;_9_%3??\N2AZ&VIVG_&,!)]UNR'<VQ,A)BOX
M'%E7W'!IH\-62?<S8^.C/AT"H+R1*_NO=%\^$7\L7Y,8G:W_  HGZI[WV6.I
MMN?S*?DQW'6] ;O;,8#*#);5W_3[RQN/W 8<-D<M48L"#.P3?;9&"GK$OIDI
M RN@]U[H@.Z]_P#\R;^6A_PGK^1GQK^7G0W7'4FX-B]:1?![XH;CZ<W;'N'<
M6_,AOS/93!',P46.J)_X-]CMVO:JHXTE;*UDJ/,U!B7A^W'NO=;#O6OQGI?A
MM_)TI/B]!+!4UG2GP*RNRMQ9"FA%.E9FX=F5LN>KUIP\OA&0S<M54Z#)(5\N
MEI9&!=O=>ZU%?Y<W1?\ .!^='\B?X[_R]^ENK/CILCX3_(;)[HAR?S3R>ZI3
MN#;FU*+M[.5VY\#DMD%(J[(9O(9ZDR'V4E"TE%48C31U=1CZF?[B/W7NMASN
MK^7QWQ%_.C_DY_(3J'K%LE\1/A9\:=^]-]C=@OF<!3G!&LV'NK;FVZ4X>KRE
M/GLB:J:MHH3)04-3%%Y-<[Q1I(Z>Z]T8K^<9\!>[_F=UO\=^S?B;O;;&QOF!
M\)?D'B?DO\?)]]O4Q8#,5N.*BNVYFYZ/_*H<=EX8XQ)I]$WA^UG*4]1+)'[K
MW1-NB?AY_,O^;7\R/XU_/_\ F7]7]0?%/87P5VCNG#?'?XX]3[H@W=7YG<^Y
MZ63#9;<N:R])YZ.#$U%)%!5TE.DR5:FGH(:F%"E:)_=>Z0'\SSH[^>/\V-A?
M(OX!5'Q8^"V^?C9\@=^RMUQ\KGW954T^Q=IT6:QF5Q*[@VME(URF2WE31P.E
M/D,12M312(6DCU*DU3[KW1,/YAFPOD;\9OYRW\@7JSX?XG9G=_??0?PAWAUS
ML+$]YYBLQF/W33;8V'N/%YM<GG$CK:JERN6VY15S4M5,LB#)R4[U;>$S./=>
MZM._EZ? 'Y9]@=\_S _G9_,VVCU]UKVI\\^K,-\=\!\9>N,Q'N&/8G7N.Q$F
M/KL57[BI7DQU=DLM(\3S"B::!9Z>:J6H;[T4M'[KW0#_  PZ1_GS_P O?9FP
M/Y>W5'3_ ,/N^/C1U9V'*G57S1[5W=68N>AZY;<M/D9=NY_9V.23.5&YWQE;
M70T-51Q24%&JQ),TWVT7W?NO=&\_FT?!+Y4]N]Y_!?\ F"_!!NO,S\L_@;N[
M<#T74W:N0EQF"WGM3=^.CQF?P_\ %(X_\@R:4JS14TLCT\!BK:IY9#)#3QM[
MKW0Q?%/!?S0_D-TY\M$_F)[7Z$Z C[UVO4;.Z$^/?5]4-PY78]#D-M2XO)'<
MV\J&JFQ.;EJ:^H$RQ4M//X'6H9:R2GEIZ6G]U[HMO_"?;X[?S#OA5\4J'X2?
M,CHOJ?K;KKXVUVX,3U#V?LG=E-N/(;Y;<6[<SNRJR;4-&VC"8FA?.2TU.*Q8
MJ^J*AIJ*B$(:L]U[JFE?Y6O\[/I+X._-G^4#\?/C]\5\_P#%'M'M/<>\^HOD
MMO'?Q@KSL[.Y>EJ(MI4V#,4F4&Y(J?&0R35N3CBHX#4S0Q55<4BE3W7NKT9=
MJ?S9_AU\%?Y<?77PYZ1^,W?>[_CI\3]J=2_*CH[LW=%3@LIF<IMW8N P]/3[
M&W*%AV_2RTN9QM4KU.2E^VJ898P(XP?N8?=>Z*[\".IM[_R@^B/YIG\S/^8N
MG4O0N<^37:#_ "0W/T#U%E?O-M[6CHX\F,/M['2W7'UN[]T9O<#44ST7D&1K
M&H0)7)1(O=>Z-M_(;^(?9?QB^&>X^Q>_L!#M;Y*?-[O?='S5[SVM')/*<)D-
M[525.-P3FH5)4GQN&AIC5Q,"8:^>LA\DP02O[KW0_P#\W3X"U_\ ,F^#G97Q
MIVQOC_1GV9+EL3V3TYO]VF2+%[KVW6ID,3+42TH:KIZ:H99*66>G#3T\<[5$
M*O)$J-[KW50F3^'G\X[^9IWI\(<%_,KZM^//QE^-?P4[QP?R*WEE.G-TQ[BR
MG;>]MKTT;8C(8NBA:J.VMO5,T]3!44U:U/6PQ3UWB,A>CEB]U[HY7Q/^&/R5
MZT_GR?S4?F?O;K?^"_&KY(=-]7[4Z7[)_C& J?XS7[=VCL[%YF#^#TF5GS^.
M^SKL551:ZZAI8Y?%K@>6-XW?W7NA1_E$_+WY5?,RN_F ;Q[^BV;2]9=+_._?
M'Q?^-O\ =+"S8PY# ;*R$U/49>JK9ZVK&:><U=/2FIITAIA4T58B@R"5(?=>
MZ&[^;_T'VU\H_P"6?\Q?C[T3M/\ OSV]VIU'-MC86T?O\9C/OZYZVBF6#[_,
M5F/QE+>.)SKJ*F&/BQ>Y /NO=5 _/C^6_P#,_NK^4'_)5^+O6?37]Y>]?B3V
MY\<=S_(/8W]XMJ4?]WZ'876&9V[NR?\ B>0SM)A\K_"LQ5Q4^C&U=9)4ZO+1
MI40*T@]U[K:A]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T
MU9O!83<N*K<%N/#XK<&$R47@R.&S=/#5TM0@8,$FIYTDAE4,H-F4BX!^H]^Z
M]TZ*JJH50%51I55X  ^@ _ 'OW7NN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]T5#(_"GX]9CYHX3Y_9?:==DODSM?H1/C;M7=M3D*S[/&[7&7
MR^;GBI<4DJ4)KJRKS50LM7+'+,( D,)A5IO+[KW1K_?NO=>]^Z]U[W[KW7O?
MNO=$F^/?P*Z9^.'R7^8ORUVIF>PMU=S?-W<VWL_VQF-^5N/JJ:@I=JXZ;%X+
M";<IZ#%8TT&(HJ2=@5J'K*N8K$9ZN40Q*GNO='9]^Z]U[W[KW7O?NO=5P?&W
M^5/\0/C!\B-__+3:. [!W]\D.P::MQ%1V]W?NC,[NRN(Q-?75-=-A-N-EZF:
MGP6)5ZIHDBI(D<4RK 9&C,@?W7NK'_?NO=%9^(OPS^/WP=ZVW#U;\=MGR[4V
M]O/LK,]Q[YK*^KGKJ_-[IS[P-ELWD:F=CKJJF.EIX52)8J>&GIX(((8HHE4>
MZ]T:;W[KW7O?NO=>]^Z]U[W[KW2?W9@/[U[5W-M;^,9G;O\ >7;];@/[P;=:
M!,A0_>4TE/\ >4+U5/5TR5E+Y/)"TT$T0D53)%(ET/NO=%F^"OPIZ8_EY?%S
MK'XC]!'=51UIU;#D?X7EM]U5-79O(566RM;F<C7Y6LI*+'4L]74UU?*?V:6"
M&.,1PPPQQ1(B^Z]T;GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW3-FMN;>W)%20;BP6&ST-!6ID:&'-4L
M%4L-0@8)/$LZ2".9 Q"NMF ) /)]^Z]TU=@;*P_9.P][==;A>MCP&_MHY+96
M<DQKK'4+1Y6CFH:DP2.DJ1S"&=M#,CA6L2K 6/NO=!K\8_C/TM\.NA^N/C5\
M>-F0; Z<ZIQ$N'V;M:"HJ:LPK55E3DJZHGJZR:>JJJS(9*MJ*NIFED9Y:B>6
M1C=K>_=>Z'CW[KW7O?NO=>]^Z]U[W[KW16=V_#/X_;\^6G5'S:WAL^7/_(+H
MOKK+=9=0[EK:N<4V H<]]W'F:FCH(VCIWR61HZV:C>HG$S1TKR10"'S3M+[K
MW1IO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=-&=V_@-T8V;"[FPF(W
M%AZB6*:HQ.=IH:NF=X)4G@=X*A)(F:&:-)$)4E'576S*"/=>Z=_?NO=>]^Z]
MU[W[KW7O?NO=(S8O7/7O5^'J]N]9[#V9UWM^OW!D=V5V"V+BZ'$4<V5S%9-D
M<MDY:7'P4\$F0RF0J):JKJ&4S5-1))-,[R.S'W7NEG[]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNM8/_A1WN[O5-\_RA^C.EODW\A_BY1_*C^8#A/C[V1O7XX;LS&U,R^&W+683
M#S,9\35TJ5DE"F0DGIHZI9H%G 9HR"0?=>Z!&OK?G)_)/_F+_P N?J+?G\P3
MOKYS_!?^8#VGD/CEG,+\K3%N+=VU]XUTN.I=M5-%N>2>?.3I69C-4BJ0%Q\-
M''7PUE,KMCZNG]U[JX_MG^>/_*9Z-W3N_8W:7SDZ;VOO;K_M*HZ8WML[5E*W
M*XK<5'D)<574==CL=C:NLIZ;'U\,D577M&,?2%'>HJHHU+#W7NAR^7W\S'X(
M? @[4@^7?R6V#TKE-[B*7:NVLX,A6YFL@EJ8Z,5J83$461R\>.BJ) LU9)3)
M2T]I&GFC2*1E]U[H47^9/Q:'QJJOF+3]Z=>Y/XOT6W#NVK[MP=:N0P4>/6H6
MDDJ7J:%:A@(*IO#,FGR02!TF5&1PONO=%FZ3_G)?RO\ Y'=Y8+XW=(?-'ISL
M;N;=&%ILYM?:."J*WQY-*JEEK4H\=E9Z*'#5^8BIH)'J,7!5R9*DT,M520N-
M/OW7NAP^8/S]^''P%V?B]\_+[O\ V/TC@L\]1%MR#<!JZO)Y1J1%DJEQ.#Q-
M+D,WE6IU=/(*2DF*%XU:S2(&]U[H2_C_ /)[X]_*KJRA[L^.O<&Q.W^J:^2>
MGCWOLNNBJ:.*:E -5359)22AJJ4,#-!4I%-$"#(B@CW[KW13NA_YPO\ +'^3
MO=];\<.AOFATOV1W-3U[8S';.PU94Q#,3QT9R$D>VLE64M-B=U>*C1Y9#AZJ
MN6,13!RK0RJGNO=/WR^_FM_R[_@5N#&[0^6?RLZVZCWKEJ.DR5'L2I_B.8SX
MHZ^=Z:DKY\%M^ARV6I<=--%(!5S4\=,%CE=I0D;LONO=$O\ YNG\Q^39O\DC
MY)_/K^7GWSLW<5=1XG:U#U5W5L@8_.44#9CLC;&S<T\$5;#4TBY&BI<G6P>.
MI@,M'6*#)$LL.D>Z]U;3\8\YF-S?&SX][DW#DJW-9_<'1VT\YG,QDI&EJ*NL
MJ\#CYZFIGE<EY9IYI&=W8DLS$DW/OW7NM:OY"_SF^[?BM_PI%ZY^#':/9-#_
M +)!W#UCMG9%%L[(8W 4J8#>6ZZ$R8;<'\<CPIW#5BKS=/#C9*6HR2T,462D
MJB@:EC4^Z]T>+K'YG?)7</\ PHJ^17P2S'9'WGQ4V)_+DH>^=J=6?P? 1_:[
MLFW-L3'R97^.18I-QSZJ/,UD?VTV0DHQYM8IP\<3)[KW1S_E!_-I_EP_##L[
M ],_)SY<]5]4=H[A:#[?965DKJVLHXZJ&6HIJG-+BJ*O3;U%40PLT53E&HZ>
M2Z*LI:2,-[KW1]-J[JVQOK;6 WGLO<.%W;M#=6(I]P;9W1MRJAK<?D*&KB6>
MEK**KIWD@J::HA=7CDC9D=2&4D'W[KW3_P"_=>ZU;<O_ #*/YG[?\*!OAC\'
MNVNE,3\2OB#VC%VZV$VM39S9.^:WM?";7VEO2NV_O*LRM#15&9V8C5V"H:R'
M#Q2T%5%Y9*;(25Z @>Z]UM)>_=>ZJ&_EE[JVCT[\5/D-O'LS^:93_P P#9G6
M7?V^]P]B_)3LBJQ./I=ATU,E-FLAM++5<51)!CDVU0U:5=1%/-%34"U?V]!2
M8[&0TE%![KW0[_$O^:G_ "\_G3O'<W7GQ1^5G67<&_=HBNGS&RL4]=C\LU+C
MJE*.LR-#C\S18ZKRN(BJ)8U&1H8ZBAD66&2.H>.:-V]U[H\VYMR8/9NV]P;O
MW-D8<1MO:N#J]R;ARU0':.EH:&"2JJZAQ&KR%(8(G<A59B%-@3Q[]U[JJF@_
MGS?R?,KO#KC8F,^?O0^1W)VM++3[/AHJFOEI1+%6+0>#+Y)*!L9MNHGJ744T
M67J*&2JC/GIEE@_<]^Z]T?'Y*_*OXY_#KK6J[@^3_<6Q^E.N*6OCQ(W-O>K%
M.E163*[Q45# BR5>0KI4B=DIZ6*:=D1V$95&(]U[H!>J?YH_P"[R^-7:?R\Z
MB^3&R>PN@>C]H5>^NW]W;:I\O45^V\;0X^7*U,N8VP,:-U450M!!)*M))C15
MRA&6*!W!7W[KW5('_"=C^=+M/YK9?Y+=#?('Y1YGM?Y8;W^7>_\ LCH/9F5V
M[F:2->H:#!;47"M05='MZBVSB:&FJ(,BRT%144^1,C2S34S/.'D]U[K:Z]^Z
M]U5%N/\ GE_RDMI]V#X\Y[YW='TG::Y>;;]3CH:BOJ<335]/6+CYJ"LW12T$
MVUJ&MCK#XS!49&.6ZNVC2CLONO=&&^37\QOX-_#/<FVMH?*;Y,]8]&[BWEM.
MLWQM3';]JI:7^(XR@$QJ:BCE$$D$[AH&CC@1S//,8H((I)IH4?W7NE=\1/F]
M\4OGGUI-V_\ $;NS:?=FP:/*?P/+9/;RUE+58ZM\,=2*/*XC*4M!F,35M3S)
M(L-92P2,C!@I'/OW7NB2U'\_W^352UVS,=)_,'Z$:HWYF9,%@Y*>HR,T$$\2
M,[/FJJ+'/3;<HR%.BKRTE%22-98YF8@'W7NCD?);Y\_#/X<2=9I\H_D?U?T=
M'W)%DY^L:W?]>*.ES$>&3'29.2EK-#4HCI$R]$6:21%;[F((6+6]^Z]TA^I/
MYG_P$[Q^-O8'R_ZV^3_763^-'5>ZZ[8_87<.>-?@<3BLMCA2-4T%2V?HL74>
M=DR%(].$B85D=722TAGCJ8&D]U[K-\1OYFWP,^>$>[_]E*^3&P.YZ_844U5N
M[;V$&0HLQ14T%1)2M7/A,O18[+R8Z2>(K#61TSTM0"C032)+&S^Z]T,FQ/EO
M\9>S^A,]\I>O>\^MMX_'/;&#S>YMP]TX#)T]1MVCQ^VXZF7/5D^21C3I3XB.
MDG:J<MIB$4FHC2;>Z]TF=[?.GX?=<?'+$?+K?7R*ZMVO\:=Q4D%=MKN3+9*.
M/#92.J>1*3^%36,F3DK#$YIHZ5)9*A5+PJZ\^_=>ZX_$7YT_$?YY;"J^ROB+
MWOLGN_:>,G@I,Y-MIZFGK\7-4Q>>GI\QALE3T.9P]1-%=EBK:6"0A6LMU8#W
M7NB ?S*OYTOPK^(O7_RQZ6P?R^Z>VE\[-@?&#?F]^J.M\H7KWIMX8S:59D]L
M8O)2FDGP%/F:[)RT)I,-D*J&LR(E5(*6=6/OW7NAX_DS]R=G?(7^5]\-.[NZ
M-XY7L'M3L[JC^]N^MY9KQ"IR%?4Y3(M+,Z01PT\*@ +'%#''##&J10QI&BJ/
M=>ZKK_F8_P RS<WPO_G,?RP>L>S?D;B>B/@SN[IWM+LSY&4^XOX?28K(UV-V
MCNV#;QR>1DI9,G*(\S%0I0T%/,%JL@].B4\]2T"CW7NK2NL_YJG\N_M_XU[B
M^8&POEIU/D?C=LS-4>W-\=I9BIJ</28#(9"6D@H:+<%)F:7'Y/ U59/7TT<,
M60IJ9Y'GB5 3(H/NO=&([B^4?QV^/?4]#WKWAW-U_P!5=.Y*3'Q4'9&^,C#C
M\1*^63R8U5JYV6,M6IS$+W<?3W[KW0\(XD1)%#!74.H=65K$7%U8!E/]00"/
MH1?W[KW6M_\ \*7/YB/RM^ _Q3Z7'P?WE3[)^1G;?;>4JGS PV!S]5!L79.S
ML_NK>M;28S<5#D\9:ACI:"6IJ)*2;PTGG"!)I8I%]U[JS?:GR7E^1G\K&B^6
M>SLAEMNY3MGX,S]SXNNH)?M*_%Y2OV1+DY!'/1NOVU=C,BSH'@<>.:+5$_I5
MO?NO=:D?P9^*G\R+NG^3)@_YKW4W\YK^8=C_ )/X[J[LKM:AZC[9WQ4[QZ^R
M(Z^W/N_%KAGQ>[J^>BAFS./VO&$K,@]134M5.TDL1IM03W7NKD=Z_P [[=6V
M?^$[&TOYKT.&VW4]];[ZLIMDX'#)2/!ASV4^XZO8>0K(\=4U/F?#X[.XVNR8
MI!,[2T=*85E97\OOW7N@LVI\$_YY/Q8[#^%7R6ZZ^?7>'S:WGV?V5M[&_P Q
M#XS][9'#4NP<7MNJQ<U5F\CLJBKJK'T^V/X*(9:&*/$TJUE=E)\=6S0FDAK*
M23W7NAG_ .%+G\Q'Y6_ ?XI]+CX/[RI]D_(SMOMO*53Y@8; Y^J@V+LG9V?W
M5O6MI,9N*AR>,M0QTM!+4U$E)-X:3SA DTL4B^Z]U=9\,OD!C_E9\2?C3\E<
M8DL%/WIT=MCM":CJ!&LM-4YC#TE;64DJPEH5FHZN66&01DH'C8(2MC[]U[H;
M-\[YV9UCLS=78O8NZMO[&V%L;;]7NO>6\MUU<%!C,7C*"!ZFMKZ^MJ7CIZ6D
MI:>-I)99&5$12S$ >_=>Z([\6?YK_P#+J^:^Y-Y;-^+ORPZR[:WCL*DR64W'
MM#%'(4.6%#B9UI\ADZ'&Y:AQ];E\1!*Z 9"@BJ:*1987BG=)HF?W7NJ$?Y4G
M\_?ICY*?S2?G]U%V7\P,SOCK+O/M?K_8W\K_ &34[3W+2T%9C:6FWDVXHZ**
MGVM2G!SSO+C&J:C<9HJBJ*Q!995@*Q>Z]UL#_+W^9_\  3X%9C:^W/EO\G^N
MNFMS[S6";;NU,L:_(9::GJ:H445?)BL+19+(4F+^YNKUU1#%1QB.5Y)T2&5D
M]U[HSFSN]NE^P>H*#Y ;)[5V!N?H_)[6FWO1]M8C*T<NWFQ%/')+4Y)LJ)OL
MXZ2ECAD,\CR*L/CD$N@HP'NO=%,^+?\ ->_EU?-3L[='3/Q>^6?5W;O:&T4J
M)\ELW"25M+5U-/2)!)55F&_B='0Q;AQ].M3'Y*O%O64R$LK2AHY ONO=5T_R
MM?Y@G9'9O</\\S>OS [MQ=!TW\+_ )V[IZAV+DMS?88C [-V)L^NW%10AVAB
MIX1:EH4FK:VH,E34RC5+*RK$B>Z]TS_SVOYD6\.B/@=\./D7\.N_<'M?K[Y)
M?.;KWJW<7=>"-"])6=>9C$[OS&7J<;E<A"T6/I*T;>@896 QNM'Y)::I1)1-
M[]U[JSSXJ_S2_P"7S\W>Q]]=1?%7Y4]9]S=D==4\M?N;:6VY*V&I:CIWI(I\
MEBSD*.CBS^(@FKJ>*3(8MZRBCEE2)YQ(=/OW7NFCY0?S:?Y</PP[.P/3/R<^
M7/5?5':.X6@^WV5E9*ZMK*..JAEJ*:IS2XJBKTV]15$,+-%4Y1J.GDNBK*6D
MC#>Z]T7?^=_\S>Q?C5_)S^3/S#^('9V"H-[8W:NR*_J?MC;J8S.47V.[=][1
MV_-E,8U1'6XRL\V%SD[TDY26-)&BG0,47W[KW1B,S\\/C?\ #KX/?'OY#?-?
MO[;G5FWMR]/;3DJ]V[XEJZS)9S,U6VJ3(546/QU#!79K/96=4FJ'AHJ:IJ&
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MVLHE2F:6G26CE6-T(:"'W7NC2?/_ +_Q^U?YC_\ (GVKV-\2ODS\S^KOCO\
MR[:;Y.8/H+XZ;2&]ZS.[JS>*FP%#D#MR9XZ:K_N;+MRCRLE0#Y:.1Z*0$)(0
MWNO='._DL;B[/RO\WK^8WO\ V?\ R^_G#\'OB'\L.FMO=V4&VODWUOD]A8*C
M[$VW5X?"9N/'0K"< <INK^.UN7815#UE28:Z65?'" GNO=52_&KXWY;Y,?\
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M5V;RF*G)EIFIW@IJET:*HE6@H3'[KW0=_-G^29W!\G_YQGQJ^=6W.RNM</\
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M]G;GR&]^JNFN^<]\;.AZNIK9)J'#9+=VX9M^=FX+%T*N:6DAP.=6BH4E1 9
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MHJW+-NZ'/T^X-G95ZNLH),)'AH\.:?;U2JRQY26I\CP TH5I'C]U[HL'1O\
M*'^2?673?_"@;KS/;WZ/J\U_-;[,[FWG\>*K$9+/24N&I>Q,5O&APD>]'FVU
M3RXZHI9=PTYKEQD>72-$F,#U)6-9/=>Z"SY-_P D_P"5'='\@CX[_P J[:^_
M_C]0?(/J2?:TNY-XY_*[CBV;.,'DLG65?V.0I]J56;D,D5:@A\N)AU,'#^,
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M6D18I)XXIJ>&<""OKT: RR03T_NO=(/^6S_*\^7WQC^??S&^>_R]^2O4??\
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M1X7:F!GP6/DVO@7R^?Q0CK:*JKGEI9JZ6G8X^ PHONO=)WY;=G]T_*;^7_\
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M8H*.=)X40I-"![KW57'8'?'R%^*W\@;^4IU)NSY9[WZYW_\ S//DEMZC[_\
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M.]LQ-49"*KH=Z;HVED=Q56?J@M1!DJC:6R:^MDR$IEGHW>2I\TT\ J&]U[I
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M[KW7SH_^@U;^:;_SX/X ?^@MV+_]M7W[KW7O^@U;^:;_ ,^#^ '_ *"W8O\
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M%GR=ZLSO<F\=P46VZ'"TC[+P63P%;!L_&TE;_%\WMNN%=-7RY6.FAI(FIJ>
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M*+*/=>ZIG^)4$--_PFV_X4&TU-#%3T]/\^NWX(((%"(B)C.J51$10%554
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M&?<N5K1'C\=1J&R#K5T%%-59;(^3(5?NO= M_((^6WR>^;_3VY_D7\B?GO\
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M;JT&WL_2[=QFWWP-948J68TD%52Y/<E/4O44XCF+T0=C(9:A*CW7NF7X&?\
M9</_  KK_P#)6_\ >0[B]^Z]U5+L+<>=WI_PG_\ ^$\OP@&Y,_MSJ_Y[_P R
M.MZ([\CVY,]+-EMGS][;TIJ_"RU<4B5$-/45>4IJEA$59WHXPTBQAXY?=>ZW
M0_BY_*;^"_PJ[_W=\BOBMU >C]U;XZIH.HMQ;/V%E,I1[4J:&@K#6)D)]MK5
MG&U.;E98D:NGCEF58V:(QS55;+4^Z]UII=%]1]9=G?\ "='^>=G.P=C;;WAE
M^H_YFO;O9'661S],E1+@L_%@>M<?%E\:S@FFKXZ&OJ8%F6S"*>5 ;.P/NO=;
M<7\D;XX=$=%?RTOA7NKISJC9/6VXN]?AUU'V=W%E]H44='-N3<59L'"U-7FL
ML8@!5Y*IGK)GEG8>21I#J)L+>Z]U;5[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB ?S8O^W67\RS_P 4 [D_]]UN/W[K
MW7SW?^$8_P#V]B['_P#%)MW_ /O6;!]^Z]U]2'W[KW7O?NO=>]^Z]U[W[KW7
MRLO^%BO_ &]ZI?\ Q5+97_N?N7W[KW7TP_B!_P!DE_%W_P 5UV3_ .\UC/?N
MO=&*]^Z]U[W[KW7O?NO=>]^Z]UI8?\+;?^R'?B%_XM;/_P"\AG/?NO=''_X2
M"_\ ;G/;/_BQ6^O^M^/]^Z]UM$>_=>Z][]U[KWOW7NO>_=>Z^.__ ,)GO^WX
M?P/_ /#FWE_[[;>7OW7NOL0>_=>Z][]U[KWOW7NO>_=>Z][]U[KY67_"Q7_M
M[U2_^*I;*_\ <_<OOW7NOIA_$#_LDOXN_P#BNNR?_>:QGOW7NC%>_=>Z][]U
M[KWOW7NJ ?\ A4=_VXH^<W_E,O\ W\77WOW7NM=O_A#;_P ?E_,G_P##9ZI_
M]RNPO?NO=?0B]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=5;?/+L7^;/U9OW9V[?@3\;OC1\K.F8MB5E)V1U#V
M+NV;9V]JC<)JKT53@LOD%@VQ!C$HR!-'63223/K513:4DE]U[K6!^9/\OGY!
M?"#_ (3U_P Z#?\ \GX^L]K=P?-3Y8;2^3>:Z:Z9J)JO;&RH,OW+L&6#!X^J
MD$<4S0/42H1"ABBIXJ6%9Z@QE_?NO='$VA\0_P";=_,AH/Y5_3OS%ZA^,?3G
MPK^&V\NM_EEN3O#J[=E3F,CV9/MK;LL>U,7A]MSPQU^!F%)4M39M<C!##;(M
M58VL=J0T,WNO='T^:OQ#^?\ T%_,1D_FC_RU-B=8?(?/]G?'^/H'Y2?$WM#/
MP;4;<4&%E6JVWG=N;AK&CQM'F*9HH*9Q621PK3P/&NK[R22G]U[H[..Z*^5'
MS7_EZ=\?';^8QA.F^I^T_D9L_>O7=;0?&[(9++T&W<#GDJX-N-)59>&):W<&
M#AGB-2\1>AJY:=9%"+-) GNO=5E? OKC_A01T+C_ (A_!S>?77PYV1\:OBA5
MXC9F^OE^N;EW--OSKG!4M;C<9MG#;-2IQV<Q&=CQL%'&<A4_8Q1NM+,!-''6
MT<_NO="K!_+]^16YOY\WS'^5.Y]A3X/XC=\?RL)_BE@>XJ7,8&663<U=F-F-
M48^/!PY?^\D,D%!C:V9:F6AAHR8 BU0DDB#^Z]U5)B?Y=7\]/KG^53VE_)3V
M)\<?B'G.I,)C<[@]K?,'.=AR4LNZL!N3?&1W=4X_%[2CH)J[&;@BDK98Y9\J
M]-0Q4\T<=/)530M*?=>Z._\ )_\ EI_,?=73?_":3KS9/5]!O+-?RZ.Z^BLW
M\MJK%;@V]2TNW<;L;%;'H=QY&F?+Y3&RYVGI9<)5F./&1U=7.D8,5,QD16]U
M[K:2]^Z]UK<_R]_@-\L^CO\ H("_TH]4?W7_ -G;^6_:_9WQA_W.[:K?[SX/
M<O\ >[^"5W^X[,U?\%^]_BE-^SEOL*B'R_OQ1:)-'NO=5R=G?RCOYA6X?^$N
M7QU_ET8?X^_>?,G8G<E=NO=?3O\ >O9$?VM!-VCOO<<<_P#>&7<J;5GU8;,T
M=1HAR<D@\WB*">.6)/=>ZM>^>?PL^<'5W\PW9/\ -F_EN[1ZM[P[8'QJK?BS
M\A?BWVUFEVU'NO;4>37<&,J]M;AE,=#CL]_$:6EA?[^6.CT4E*UP&J=7NO='
MS^+6.^<G?_1O>^VOYE_4_P ?.IY.V*O)[1V7U7T)G,GGYL=LO+8./&5F/W-E
MZN)*&MS;5,E6XJ,>13/#,B^*)H[-[KW50GPPZ1_GS_R]]F; _E[=4=/_  ^[
MX^-'5G8<J=5?-'M7=U9BYZ'KEMRT^1EV[G]G8Y),Y4;G?&5M=#0U5'%)04:K
M$DS3?;1?=^Z]T87^=G\+?F5W7W!_+/\ FE\'>NMD=U]T?R_N]LUNVLZ.WSGZ
M/;E)G\+NX;9@R<D.5R$U%2PSXY=NHVIZA&2*:6:*EKYHXZ*;W7ND[_.D^(/S
ME^>/PL_E\[<V;TKM7/?(3KSYX]8?(CY!]?[(W+AJ?$;<Q6(V]O&#<,F/S&Z,
MA@TS=-AZ[,4U,AA'WE;J^XAH53R)#[KW0C=8_#'Y*[>_X45?(KYVYCK?[/XJ
M;[_ER4/0VU.T_P",8"3[K=D.YMB9"3%?P.+*ON.#31X:LD^YFQ\=&?#H%07D
MB5_=>Z+1\./Y4/?F4VC_ ,*%NE/DULV;J/8W\R/Y==F[KZ&WI!E=OYAZW;6Z
M:O<SX7<RTF(R>2GH# ^0I*K[/)1TE9QXY((V#A?=>ZH%_FK;&_G*]<_RB?C?
M_+C^4_1/Q9VEL'K;NCK[XP]0=C;+WPN7W1VU5X^";'['H=I[?%OX7#CZ*-(\
MG4Y<T$LQI1+'24L<@5_=>ZVXJKY>_*K.?SS:7X);2BV:/B7L?X(4WR@[6S!P
MLU1F4S^1W'E=MXO$?QW[U:.@2L=:>LBIFIGJ9X:.L:,^(2/#[KW5R/OW7NM5
M[X#_ ,M_YG]*_P H/^=5\7>S.FO[M=Z_+;MSY';G^/FQO[Q;4K/[P4._>L,-
MMW:<_P#$\?G:O#XK^*YBDEI]&2JZ.2FT^6L2G@99#[KW5OW\H#H/MKXN?RS_
M (=?'WO;:?\ <;M[JOJ.';&_=H_?XS)_85R5M;,T'W^'K,AC*JT<J'73U,T?
M-@]P0/=>Z*!_.3^&/R5^5GR"_DY[XZ#ZW_OYM?XK?S&]G]\]]93^,8#%_P !
MVGB\WM^LK\KX,UE<=493P4]#._VV.CJZQ]&F.G=F16]U[KW9WPQ^2NX?^%%7
MQU^=N'ZW^\^*FQ/Y<E=T-NOM/^,8"/[7=DVYM]Y"/%?P.7*IN.?51YFCD^YA
MQ\E&/-H-0'CE5/=>Z*WL'XI?S</Y5W>'R[VU_+RZ%^.7S ^*'S'^2&:^3NU(
M.V-Y?W-S76FZ]TT:C-+F(Y BY_:\$F,HJ:GBQ_DR,D24Y=HS]U.ONO=&@_F1
M?R_OFA\\/@S\2<O)NGHW9/\ ,P^(';FR_ECM6KVM-EAUSD-^[85S7XF&:NIV
MRT&%KI)!/3/*@DCJJ>GADG6F>:;W[KW0P_"S)_S=._>Q.U\K_,8Z8^-GQF^-
MF6ZF/6F ^/'7N7&\MR9;/25=93Y/=#;IQU>*'%X3(XQ],>/E%74F.2ENM#40
M5;5/NO=5F_%CXX?SW?Y7'4=;_+U^(/1WP]^2OQYVMNS=&2^,/RQ[FWC58*3:
MN'SN<ESOV6^]HT2QY;-9!<AF:V=#AD$%TF\DFDTT,GNO=72?-?=/\SS9FS>E
MMV_!?JGXO=S;NP]=-4?(OJ;MG/Y;!'+TK8Z/QTFQ\U]M%24=2F3$NFIRK)&(
M?$'I9"\AA]U[JK[^71\$OYBNR>_OYG7\R+NO87QZ^,_RE^<G7>#P'3/QBV_F
MI<_MK:^7V_@5HJ+)[RS&&BJ:.MJ9\C34TU:<<*O[B63)3I+&*E8A[KW02U_P
M\_FZ?S!?G7_+V[6^>OQO^+'Q=V9_+H[5_P!+66[RZ*WA+FLIV/D!!BZU<9MF
MB267-;?VI693&QQY#'9AT:6(RKKJH@OG]U[I;[1^)?\ -E_E^?-[^8-NSX.]
M$_&CY)='?S$.X?\ 9@<-V-W9ONMVS4=<;IJX:R7)KN/')0Y++;@P0R.1F^TH
M\2CNM-%"J2T@9H%]U[JM;=G\D?\ F*[=_P"$X,W\NO#]0;;WY\JXOF%'VTFR
M-I[KVS#128)ZX5+5:9O.93"XD/%'^N%YUF)%D1Q8^_=>ZWH/?NO=:;/\CKX9
M[@V;_.9_FF;DK]X3[LZ)^"^^MU=&_&#$XZ*GCP>%G[>W5/V#N'%T92/RMEMM
MTE-#CZ\ZS9ZME(6,011>Z]U<K_*)^7ORJ^9E=_, WCW]%LVEZRZ7^=^^/B_\
M;?[I86;&'(8#960FIZC+U5;/6U8S3SFKIZ4U-.D-,*FBK$4&02I#[KW1HOYG
MOQCWI\S?Y?GRS^+W7%=A,;V!W+T[D=J[*JMR324V/_BH\=5015M1%!524]-/
M4TR122+%(8U<MI-O?NO=5Z?$OX<?+SY'?R;=P?RY/YAG4&Q_C#D<7\9L3\/=
M@R]?[BHMWUTV,VKMVDP.)WMDY:"HGQ-/5U-9C*2NBQL,\I1([SSQRU#4E'[K
MW5:6]OY?7\]'YB?%3I;^4%\IMJ_'#K7XB=95>S]K=S_.'9.[FS6X-_;*V56P
MR8/'X?;56L^4HMRQQ8>@FK*O)T\5/55:P3ZP!5T[^Z]UN*X7$8_;^'Q.!Q,'
MVN*PF,@Q&,IM3-XZ>FB2&&/4Q+-HC0"Y))M<DGW[KW5#?\RB#^=)O2O^1OQ]
M^/\ \2/A7\H/B3\D^NVZGV1FM][KEPF<V4N8V_4XW/Y7>V+S IZ#<N*2O;ST
ME)B5DK(B\:LU0I;[;W7NBY=C?R1?D9M7^5S_ "VND_COW'M8?.K^6!V+C?D'
MU+NS>M5DGVOG=PG*5N:S^U:RK 7)0[:J9Z_[2E73&C45'!0RI!2S.8?=>Z6'
M1/P\_F7_ #:_F1_&OY__ ,R_J_J#XI["^"NT=TX;X[_''J?=$&[J_,[GW/2R
M8;+;ES67I//1P8FHI(H*NDITF2K4T]!#4PH4K1/[KW4WXD_ ;Y9]8_*G_A1A
MV1OCJC^";+^=_P# ?]E2S/\ '=M5/]ZOLMN=DT%3_D]'F:BKP?BJ\_01_P"Y
MB+'ZO/J34D4S1^Z]T3_K7^2S\TL[_(C_ )=WQ^^RVQT)_,:_E[_)'*?++JG:
M^^LMC,I@FSU#V;O;<6,P^7RVV:O-XYJ;*8;-4=;%+2U$ABJHZ>GJ9*=35B/W
M7NKF?@5O'^<3VEW)OK?OS\ZA^-OQ:Z'H>OZ;:6R.A.O,LF\]RY#=%/D:DU>[
M&W1CZ[[#&86NH0!'CIEJZ@QO2ADH:B&L:I]U[JIOX=?RE?F10_R>OYOGPG[7
MV+A.H.Z/EW\N>U.SNC*7<F>PF1Q]?B,YA-D#;F1K:_;5;GX\;39')8&H@DBG
M5:VG53)+2HK1L_NO=6]_R<=M?-_KCX1=.=(?.#HGK[H+=?QVZUVO\>^OL#LK
M<U)NFJS.#V9@J3;\&Y,O5XV>IQE!4YE*".:.AIYIS!'^Y-*DLQHZ3W7NK5O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T
M0#^;%_VZR_F6?^* =R?^^ZW'[]U[KYLO_"4_Y0?'CXD_S)]^=G?)GN/8/1_7
MV0^)6Y]GT6\.QJ^+'4$N4JMR[+JJ:@2HF(0U,U/0U$B)]2L,A_LGW[KW7T2/
M^'POY0O_ 'L5^*7_ *%=!_T?[]U[KW_#X7\H7_O8K\4O_0KH/^C_ '[KW7O^
M'POY0O\ WL5^*7_H5T'_ $?[]U[KW_#X7\H7_O8K\4O_ $*Z#_H_W[KW7SDO
M^%2?R7Z!^5W\SNF[3^-O;NQ>Z^N5^-^T]LMO/KRNBR./&0HZW/O54?W$)*>>
M!*B(NOU4.M_K[]U[KZFGQ _[)+^+O_BNNR?_ 'FL9[]U[HQ7OW7NO>_=>Z][
M]U[KWOW7NM+#_A;;_P!D._$+_P 6MG_]Y#.>_=>Z8/\ A,'_ #,_Y?OQ7_E:
M;?ZG^1OR]Z)Z7[)I^\]X9Z?9/8.>I,?D4HJV:B:DJ6IYF#B&H$;%&^C6-O?N
MO=;#O_#X7\H7_O8K\4O_ $*Z#_H_W[KW7O\ A\+^4+_WL5^*7_H5T'_1_OW7
MNO?\/A?RA?\ O8K\4O\ T*Z#_H_W[KW7O^'POY0O_>Q7XI?^A70?]'^_=>Z^
M9A_PF>_[?A_ _P#\.;>7_OMMY>_=>Z^Q![]U[KWOW7NO>_=>Z][]U[KWOW7N
MOE9?\+%?^WO5+_XJELK_ -S]R^_=>ZWB?B__ #I/Y3^U?C1\=]K[C_F!?%["
M[AVWT9M+ Y[#9#=%#'44E;1X#'T]533QE[I-!/&R.IY5E(/T]^Z]T.?_  ^%
M_*%_[V*_%+_T*Z#_ */]^Z]U[_A\+^4+_P![%?BE_P"A70?]'^_=>Z]_P^%_
M*%_[V*_%+_T*Z#_H_P!^Z]U2K_PHB_FI?RY/DA_)V^8'2_0WS0^/O;/:^\_]
M'_\ =7K_ &1N"CKLID/X=VCLG+5WVM+$QDE^UQM#45,EOTPPR.>%/OW7NJV/
M^$-O_'Y?S)__  V>J?\ W*["]^Z]U]"+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1:OE]\2^E?G-\>M
M]_%SY$X3+;EZ;[+K,%4[TP&%R%5BJBL3;^XL3N>BIQD*&2*LIX9<CAJ<3&"2
M.5H3(B2QLP=?=>Z'O;>W<)M#;N VEMK'08?;FU\+2[=V_B:75XJ6BHH(Z:DI
MX]19O'!!$J+<DV47)//OW7NGKW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5;&4_E
M/?#S=/S4IOGMV-@.P^V>]=NYU=S=7T':6Z<SFMJ;(R'V..HI:S9^TZFI.&P]
M1/)C(ZUG\4I2O9JN Q2I3F'W7NCZ4/7/7N,WWG^TL;L/9F/[-W7M^@VGNCL6
MAQ=#%G<EBL7+53XS&5^7C@7(5F/QT]=4R4M/-*\-.]1.\2(TLA;W7NEG[]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z)-\(?@5TS\"=L]UX#J3,]A;MR?R&^0^Y?D]VUO?M
M.MQ]?F,INC=,E.^0<RXS%8:B@H(%IHTIJ>*E41C7([2SRRRO[KW1IMB]<]>]
M7X>KV[UGL/9G7>WZ_<&1W978+8N+H<11S97,5DV1RV3EI<?!3P29#*9"HEJJ
MNH93-4U$DDTSO([,?=>Z6?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+=\R>D,O\FOB%\JOC=@,WCMM9WY!?
M&[?/2&$W'F$EEI,?5[LVQE,#35U5'#>:2FI)J]995C];(K!?41[]U[K0*_Z
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MP-1#DMLP8F3<V#6C3*4DE5+DL?214D4\<U2\41U^_=>ZLMQW='4>6ZAHN_\
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MA5\'=ZU?2GR"_FF[DBSX[LCIZ*MJ-B=>X7&8G<.ZJZDIZZ"=),U4XS(LM(?
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M<DWGBZ/)_8KE>N>O*3)?:K60S+ U;2+X)F0!GA+1DZ'93[KW5 F5[$W?L?\
MX2_?S+NL=J5M7B]C[8_G&YSX_;:Q&)_8CQ6SQ6[#W*<2LD*"62BERTDH?SN[
M.M4T#.T6B+W[KW5ZG\\3XX=!])_*C_A.4>H^H>N.OI=K?S-.LNJ<%D-F8?'8
MV>/;>/W)L]J'$>6AIX"]!3/"KQ1&\<;ZFC52[7]U[I9[.ZPZV[-_X5Q?(_\
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MEN= ](]IY7_A5IGNQ^J-@;WSU1\S>\]F'.[FQ=)5UT>*%7OVO%%3UDT35-+
M*X+4 0O&?.D<M_)%&R^Z]U7K\E\K6;\_X1>_#'>.[Q19S=."[<&R<-GZJEIA
M54N*P_:V_P#!8ZB@ECA1HXH,3BZ6G-K-*L*O,TDA9S[KW7T5,#MK;FU:)L;M
MC 83;>.>H:K>@P-+!1P&5E56E,5/''&9&5%!:UR% )L![]U[K6$_X5:X3#5?
MQ>_E[9&JQ&,J<@_\V;JK"/7U%/$\QHIMO=A234AE9"YI9716>*^AF52RD@>_
M=>ZS_P#"C+;>W\TW\G?XER[<@QG07R5_FR=<;.[KVEM]1C\1F,2^2I:.7$92
MEI(XJ>JIZU<M+4>.4Z/-21S^-Y(8Y(?=>Z;OYM'5W7WQ;_FJ_P AGY(_'OK+
M#[/[1WY\J*OXF;\Q'5=#388YO8^XZ?%8JJERT6*HO)6X_9M#DJRL5)$-/%3R
M3+*\*+'-#[KW6TID,?09:AJL9E:&CR>-KH&I:['Y"))H)HG%GCEBD5HY(V'!
M5@01P1[]U[K5I_X2I;3VL/C1\^\^-M;?&=Q'\VGMG$XG-"CIONZ6E&VNOU%-
M3U/C\T%.%E<"-&5+.XM9C?W7NB>?RW.@>D>T\K_PJTSW8_5&P-[YZH^9O>>S
M#G=S8NDJZZ/%"KW[7BBIZR:)JFE@%<%J (7C/G2.6_DBC9?=>ZK2[%[PW3FO
M^$]W_"=[8G8&U>SN[^O.Q_GU)MSM7J'JZA_B&9WSM?8G9>]</B.OZ+!TWV\.
MX:[)XQ:>EQN/G)%97TE'))KJ46=/=>ZLOQO;W9/R(_G5_P K7Y+_ !B_E'_S
M(/A#M?8=-N_HCY7[O[<Z;RFQ-N9;9^<Q4=/MJ'*U6%CJL5-C,#6R5E0XR9AB
MAF3&O 6D@B:G]U[K=C]^Z]U\K3YE_P P?X>=U]=?SW<SN'LK*;9^:'R5^>&S
M-S?%P8BASE713;0Z8S,&*VS64^X<?1U%%B<A5;>J<H89!-$7J4I5:2&F\<H]
MU[K:\_GC]\XWY1_\)=>T/D?BA41T?>?171/:9IJM8UGIYLWV1UE7U-+4+$\D
M2U%)4SR0RB-W021L$=ELQ]U[JE[M_H3Y^]E=_?RB/Y:W\S[^8IG.V?Y>7SSV
M!B]Z[3P75.RMG[*E;*;1PE-DL3L#+5^+Q=#DJJ!9*K!4\=?)55KR5-;'(M#%
M50PUJ^Z]U<[_ #",92;/_P"%'7\@VHJX8Z;82=6]P;,VMB$E>.GIJ^'9F=I(
M1#&;1(5?(8U1I)>3QQQN++&#[KW6T1_$* 5XQ7WM)_$S2'(#'>1/.8 XC,XA
MU>3PB0A2]M.HA;WX]^Z]U\['^9]\]?A7N;^9=_/1V[\F-]S[8W8GP!B_EU?$
M.>BQF8SE#/GH85W3F?XHV)H<A%BUH>PJ.G@>=TUP1&;QH\HG ]U[K;6_D%?(
ML?*#^4)\&NQ*FNRN0SNWNGH>F-TU.=?RULF1V%5U6SIZBIF\LS3/7IA8ZQ97
M<RR15$<DP69I$7W7NJ_/^%'X?'=M?R+MUY:0ML7;_P#-VZ[&ZZ1YGCBD:3)X
MZIA:0"T0*4=#6J)&8-&';1PSD>Z]UL]S9"@IJJBH:BMI*>MR1D7'4<TB)+4&
M)/)*(8V8/*8X_4^D'2O)L.??NO=:H/Q0Z?ZI[1_X5'_SI:WLKK?9'8%3MCXZ
M=20;<DWGBZ/)_8KE>N>O*3)?:K60S+ U;2+X)F0!GA+1DZ'93[KW16?Y0?S2
MZ#^!W\DK^95O[Y,;;GWO\<>D/YD7:?Q\V9TGBJ"EJ_XGB<YCMF+1[,IX*A5I
MY:2OK\_6M/)72.D5-+.9':**.'W[KW1>_F5W3\N-R_.7^1!G>\/Y2.VOY7XQ
M?\QG86V.IM[[&WKLG=#9K;6X]P;<QF;VC64NUL7BJO!"+&F,-3U4*++%-*JT
M]*T9$ONO=60_%KI+ISM__A4?_.=K.V.J^O.S9]F] =/U.TSV!AL?F%QLM=UY
MUW!5S44>0IZB.GGJ($$3R(H<QZDU:68'W7NE%_.@V!L2@_F]?\)M<#0[*VE1
M8.;NSM#;DV&I,;1QTCX['4'6$./H&IDA$+45!"3'3P%?% ATQJJ\>_=>Z 7^
M=)W7MSKO^=[_ "N=@[M^'/R*^7/3?QJ^-VZ_DMM;XX?&+9D6\)<ON?-Y#,X&
MAK8]K$PT4Z[-FV[1Y62= )**1Z*0661@_NO="O\ R6-Q=GY7^;U_,;W_ +/_
M )??SA^#WQ#^6'36WN[*#;7R;ZWR>PL%1]B;;J\/A,W'CH5A. .4W5_':W+L
M(JAZRI,-=+*OCA 3W7NF_P#X2+_'OH;*_P K+;7;>6Z7ZKR_:E3\D-TUTG9&
M7P&+JLZ)L/4T"XF2/+5%+)71-C-(-+HE7P/=XM+LS'W7NMM?(8^@RU#58S*T
M-'D\;70-2UV/R$23031.+/'+%(K1R1L."K @C@CW[KW6K3_PE2VGM8?&CY]Y
M\;:V^,[B/YM/;.)Q.:%'3?=TM*-M=?J*:GJ?'YH*<+*X$:,J6=Q:S&_NO=(7
M_A/=\:.BOFM\"/F_\@/D_P!.;=WAVI\[?EYV;-W^_:]#29?+XVDCFBIZ+;/W
MV1H8:Z"GVY)4U$].LBQ24]9/-,BP 11P^Z]T:+_A*5V#O+?W\EWH*#>-9F\E
M_<+?F]>OMK9+.SS5#R8:BW%5U%##3R3KJ%#COO'H:>)6>."*E6"(I'$L,7NO
M= %_,KZWZ^[9_P"%+G\D?8_:.Q]I=C;+KNC>V<U6[2WQCZ3*XV:KPVU-[9K$
MU$U#713TTLV-R^/IJRF9D)AJ:>&9+21JP]U[H ?YYF\]A=%?S2?Y*_3\'Q&[
M+[^^-_5\/:?R%'PR^*6SJ7.3[GW-)2U5925V-V%2K28K+5N!R],^:K)70R4]
M+/EJS]4]1Y_=>Z4O\OC>/:O:W\_S=7R5ZI_EL?/3X,_%KY ?!^?KKOS'?([J
M_+;#V]E-_8'+&NQN<JDIXI]M3U<F%IJ2AHYIIDKFDER2(@2HE-1[KW0U?R3M
MG;1I_P"<A_PHP:GVKMR!MJ?(/J=-KF&AI5.-$]'V<LPH-,0^S$RJ XAT:P &
MN![]U[JIW!]N[JZ/^#__  L(W[LN+.ON&7^8IOSK^GGVVTL=92P;Q[ RFT*Z
MOCD@(EBCQU!G9JJ:12/'##(Y("D^_=>Z!SMGL3*YOX3_ ,K;9GPH_DE_S7>O
MOD%\ >Q^N>XMF?(&BZ(K<?2[IHZ&B2;?6K<&W8ZS)5E)V#7R)E9G6)8:ZH2&
M2<B)F5O=>ZO7R.U]O?(C_A5WG=H]U;:H=\[1^,/\J<;^Z1VUO.".OQ5!F\EO
M+;U%6YS'T%9$])'7RTVYZVF>I16F/@B!E_R>)(?=>Z,1_./^)/QE^-G\E+^9
M-M_H?HOK'JO#;GVCFNX\YC]GXBDI(Y]SY;)XT5N8LD?[=6T*I!&4TK3TL<5+
M L=/&D:^Z]T?+^43MK;F"_E>?RZ:["8#"8>MSWP+Z;K\Y68JE@IY:V<]>;?<
MS5<D,:/4REY7;7(6:[L;W8W]U[HC?_"H[_MQ1\YO_*9?^_BZ^]^Z]T5C^?AE
M\3C?^$QN:HLDL)K-P=.=!XC &4C4*M-S[ KW,=^2_P!A0U(-N=!;\7]^Z]T2
M;^9?W-+UG_--_DH=:]Q_$_Y/_-;97Q:^"$OR#3HGX^[2DWOD-P;UR-'5[9AR
M4FVZQHDJWV?5[8I<M-4/:HHY7HI#82,K>Z]T:O\ DL;B[/RO\WK^8WO_ &?_
M "^_G#\'OB'\L.FMO=V4&VODWUOD]A8*C[$VW5X?"9N/'0K"< <INK^.UN78
M15#UE28:Z65?'" GNO=%8_E$_,3X]?!;^3Y_-U[^^3^V*O?W4=%_-<[8V/F.
MLJ&D@KI=TS;BV]UWB(-NBGJB*)H<G]RR5#5+"".F$TDFH+H;W7N@&^97=/RX
MW+\Y?Y$&=[P_E([:_E?C%_S&=A;8ZFWOL;>NR=T-FMM;CW!MS&9O:-92[6Q>
M*J\$(L:8PU/50HLL4TJK3TK1D2^Z]T(_SJKM[](=Q_\ "@#X'[9K</M%OYB7
M=OQFKNA9?$]2\L_>.5I=G=C5\>--13FMFG:@KE(B:,B: O)(?)&L?NO=(7XV
MPXSLC>/\I'^4'DZ+>>1E^#W\[7O^OS,66^XJ!2[<^/OWV^=KO75%3+]V,;7T
M?8%#14$A#TTT$4D"R*/MXY?=>ZN#^0_\P;+]L_-SY)]2_!3^33@/YD.]/C?C
M\5T3\R?D)N7<.Q-EK24ZOD*Z/8V'R&Z\;4S[F?&RUF3\U&M1&*>L,J_:R1S)
M4>_=>ZU99ZVKJO\ A&Y105%1+-#COY@)HJ".0DB&)LW-4&.,?V4,\\CV']IV
M/U/OW7NMFG_A2SLCK3X?_P D_P"0N$^,/4^PNAZ;L_/=<=(;JJ.E<+CMLM)M
MBBSRST^)K9<+2TDD^)2E2HH%II&,/V^1JZ?3XJN>.7W7NJL/E?VON3NC<W\J
ME?@S_)"_FH_$[LWX._+38N2H^S]T]$Y/:E"O6M/'_#MSX&LRNW%KJAZ;*&*B
M:LCJX_LI:/\ B/W4A6>2.?W7NM^/W[KW6H?_ "YN_NMOBM_,3_X56?(WN"OJ
M\=UETQV1UGV!O.HQU.U54M1X_&]I2M!2TRV-15U3A88(R55Y9$5F126'NO=4
MY?SA_E?WYW%_+!ZR[8VC_)<VS\$_B@>U]D]U_#KY;[7WCL&KR]+'))+6;>K)
M]HX+%T.;P+[HQ=:U6)&=XXY2D;O7!Q5K[KW5O?\ -%[CW)_+X_F8_P P#O?"
M'"X';_RO_D4[GSVV\K6LR_>=I=>YM=NX)I(FD2.K>CQ>>HD,:_N/',@5HUCD
M\GNO=4\X_K"IZ#^'?>7\@G<DN^<UG^XOYF?Q'V912K!4J&Q7;^S-M;TW/E:.
M"IJ99*+#T>;ZWRDU0E+),E#65(630OW$R>Z]U]'^CHZ7'TE+044$=-14-,E'
M24T(LD<42A(T4?A410 /Z#W[KW4GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW5&_P#PI([+['Z?_DM?,WL;J3L#>W5O8.W?]'7]W]]]<Y6OPF9H?N^U
M]BT-7]GE,9/2UU+]U0U4U/+XY5\D$LL3WCD93[KW7S(^C?D'_.\^3TVY:;XU
M=W_S5/D-4;,BI)]X0=&[E[<W:^)2O-0M"^27 5N0:A6M:DG$!G""8PRB/5XW
MT^Z]T83^Y7_"FG_GDOY['_G!\@/^O7OW7NO?W*_X4T_\\E_/8_\ .#Y ?]>O
M?NO=>_N5_P *:?\ GDOY['_G!\@/^O7OW7NO?W*_X4T_\\E_/8_\X/D!_P!>
MO?NO= [UK\T/YJ'7'R]ZEZ=[S^6/\P'8>[\3WEM3;V_NK.V-]]C8O)4RU>7Q
MKR4.8P>8RL%5"M31U"EH:F "2&525*.+^Z]U]H+W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=:$W_"R;Y1?)CX]=P_!>AZ!^1/>O1U#N?K7>M7N6CZ?W=N#;,61EILI
M@$II:Z/"Y"B2KDITFD6)I0YC#N%(#-?W7NM8?K^O_P"%%';.S-O=C]5UO\Z?
MLSKS=M ,IM3?G7\G>69PV3I2[1BIQ^4QS5-#6P%T9?)#*Z:E87N#[]U[I8_W
M*_X4T_\ /)?SV/\ S@^0'_7KW[KW7O[E?\*:?^>2_GL?^<'R _Z]>_=>Z]_<
MK_A33_SR7\]C_P X/D!_UZ]^Z]TG]V4__"C_ &%M7<N^M]0?SN-E[)V7M^MW
M9O'>.[%[WQV*Q.*QU-)69#)Y/(5@AI*#'T%)#)/45$\B0P0H\LKJBLP]U[JZ
MK_A(_P#,'Y;=]?S/-_[+[S^4GR+[GV=2?#W=6X:3:?;&]]S;CQD5?!N?8\$-
M='09C)UE*E9##531I,$$B)+*BL%D8'W7NOI+>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KY-G\]WYL_/+9'\Y#YH=2]+?+CY<[0VY1=LXC ;&ZSZOW[O+'T4,E9MS
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MKCY>_#'MS*_(CHSY']*FOS>'V[O==_[NW5@*^"',X[;]9EJ 8S<:05M/44D
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M$^BDCC\J-7)XXQ)[KW1R_P"8_P#!/8'\Q[XB=F_%7?\ G<KLY-WK1Y[96_\
M C57;=W)AZJ/(8/-4R:XC+]I61*)HA)&9Z9YX1+&9/(ONO=%9^#_ ,??YRVP
M^VMMY3YT?.?XX=M](];;*KMB8O9'3VQ:FDS>^Y9J7%I0[KWCF<B:/^!Y^@J:
M2=C3XE*BBG6:4R<SJM+[KW5QWOW7NM4.B_DA_P RCI+I#YB? /XC?-?XP]>_
MR]/D]6;ZS&W\5V%L/*Y3?VV*/?%)-1Y/9%!+1UU)@TP-71.*.7*-YZVGCDEJ
M:*@AFTH?=>Z$W=O\DKY&R="_R(>F-K=G])Y2H_E7_*G:G='=FX,_4YW')G\)
M@=Q8_+5,>UJ:GP>4:;*S4U(ZQ05\E#!Y2JM6*A+K[KW5P_\ ,?\ @GL#^8]\
M1.S?BKO_ #N5V<F[UH\]LK?^!&JNV[N3#U4>0P>:IDUQ&7[2LB431"2,STSS
MPB6,R>1?=>Z*S\'_ (^_SEMA]M;;RGSH^<_QP[;Z1ZVV57;$Q>R.GMBU-)F]
M]RS4N+2AW7O',Y$T?\#S]!4TD[&GQ*5%%.LTIDYG5:7W7NKCO?NO=:YWPP_E
M#_)/XZ?RPOYL?PKWMO?H_*=I_.[LSO;>?46?VMDL]/M_'4O9_7N*VG@(]QU5
M7MJAR-'44>1H9),@M%0Y!(J8H],]7*3"ONO=8<S_ "/=^=B?RFO@G\.]R=V;
M=ZC^9GP%R^"[6Z,^1/6,55G,)A=\[?R%764E3'39:AP]5D\1.LT>M9Z6!TJ(
MH9_#*(/#-[KW2O\ B[_*X^;&]?G5UC_,*_FK?)?IOO'M3XT[*S6P_BWU'\<,
M-D\/L_;TF;CJ<=D=TUSY1*2JKLWE,5.3+3-3O!35+HT51*M!0F/W7NG/HC^6
M3\T_C#_-K^6?R]Z:^071,'PY^<NZ-N]C?(+KC<N$RE1OY,EM>CKX,=A\#4E)
M<+3T%35YK(35.1>H$WV\JTD6.698Z^'W7NK]&U:3I(#6])87 /XN+BX_V(_U
M_?NO=:N7RS_E1?SG?FEU_O;X5?(#^8U\8]]?!CM#?5/NO?&^TZYJL7VJF+QF
MZ:#<F'VQ0T5))+MQJ.BEH(-%?+D/O@U/''4&L@DF4^Z]T9+YW?RJOE!N/Y-?
M"3YJ?RU^Z>D^F?D!\1.F*KXQ5F+^16(R62PFY-AU2?;4M-7U>$BDK9)L'#6Y
M&HIZ4TZQU%9412)5X_0[R>Z]TJ_Y1/\ *Y^2GP*[Z_F&_(+Y0?);8OR7["^=
M6\=F;WR6Y=F8"?;C4]9MP[S>N^XQK2STE/#-_>>&*EBIY&6.*E.LW8>_=>Z7
M_P#)3_EY=T_RX.DOE/UMWAN?J_=6<[P^=F^/D]M.KZIK<M74E/@-RXG:M!04
MF1DR^$P<T68BFP<YGBABGIE1X3'52LSK'[KW7OY*?\O+NG^7!TE\I^MN\-S]
M7[JSG>'SLWQ\GMIU?5-;EJZDI\!N7$[5H*"DR,F7PF#FBS$4V#G,\4,4],J/
M"8ZJ5F=8_=>Z(+\7?^$_6\J'^1GV'_*;^67977%/V!NWL;,]E;7[6Z4DRN=Q
M6#RK9*BRNW<@L6;QFU:VN^VJ:/QU])XZ<3TLLT$56C2":/W7NCJ_!SXH?SBM
MG]^[0[#^?7\P+JCLWJ/I_K.OZNVCU'\>]MRXY-^RU28T0;P[$J,O001TNX*=
MJ1V$&)C*(^EJ>MIX*K(TE7[KW08_$G^3;N7:&)_G6=:?+#.=<[MZ>_FD_*S?
M/;>U*'JS(96;*8K;&ZZ_.U5(N6;*8+%P8_<F/&2@F04CY"FBJ8=25,JHI?W7
MNN7PD^"W\YOXT;E^/_2>_P#^8?\ 'O>WPA^,LU'C-NIC]@U51V3O7:]#1Y/&
MT.SMTU5=-%B\118J@EH5I<E05537R/2Q-4!_"_W?NO=#CV#_ "\NZ=V?SS>C
M/YFN.W/U?#T-UE\$ZOXPY[:5;6Y9=W39^HW!O'*I5T=!'A),-)AQ3[AIE:63
M*15/D2<"E*K&\GNO=>_EZ?R\NZ?B9\^?YN/RG[&W/U?FNOOGOVGL7?'3^'V5
M6Y:IS.-I-L0;RCKX]RT]=A,;0T=1,VX:;[=:*KR".$G\DD6F,2>Z]T"_\G/^
M6-\UOY8&X>V^AL[\A^C-]_R^:??NX]^_'S8>W<)DEW[%49^7&O##N++5L4='
M34.*CIZA?!!+DJBLJ'CJFKZ:G_W')[KW5_7OW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z"
M#M[H#I3O^'KVE[MZOV7VI1=4=F4'<O7>/WS0PY&FQ6Z<52U]'C,[34U0KP?Q
M#'P92I%-(Z/X7D\T869(Y$]U[H7_ '[KW04]<]&=/]19OLS<W6?7&TME[F[G
MWK+V)VSN3!TD<60W%FI5\9R&8KB&JJZ:*+]J 2NR4T($-.L40">_=>Z%;W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U0#_P *CO\ MQ1\YO\ RF7_ +^+K[W[KW6N
MW_PAM_X_+^9/_P"&SU3_ .Y787OW7NOH1>_=>Z][]U[KWOW7NO>_=>Z^11_.
M+_[B1.\__%Q^O?\ W#V=[]U[KZZ_OW7NO>_=>Z][]U[KWOW7NO>_=>Z^=C_P
MN&_YG7_+[_\ $6[\_P#=MMSW[KW6V+_PG[_[<S_R^?\ Q!4?_NUR?OW7NKB?
M?NO=>]^Z]U[W[KW1 /YL7_;K+^99_P"* =R?^^ZW'[]U[KY[O_",?_M[%V/_
M .*3;O\ _>LV#[]U[KZD/OW7NO>_=>Z][]U[KWOW7NO>_=>Z^11_.+_[B1.\
M_P#Q<?KW_P!P]G>_=>Z^NO[]U[KWOW7NO>_=>Z][]U[K4"_X6K?]NLN@_P#Q
M?_:W_ONNU??NO=)G_A$__P!NX_DU_P"+LY/_ -X38OOW7NMR/W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW05=V=&]0?)#K7/=-]\]=;5[9ZJW368RNW-
MU]O>E2NQ.1?#9:ASF-6NHY;PU4--E<;35'BE#12-$JRH\99&]U[H3**BH\;1
MTF.QU)34&/H*:.BH:&BC2*&&&)!'%##%&%2.*-%"JJ@*J@   >_=>ZD^_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JO3Y__P SWXJ?RSL1
MT_N#Y59C?&!P7=N]YM@;0R6R\#6Y\I70103RFKI,<):\1+#.&'@@J)7TLD<3
MR%$?W7N@]^!W\X#XF_S!>RNS>D>L\9W7U%WOU3B!NS<'1_R6VO/L[=-1MUZM
M*.#<N.QL]35_=X::2>F8MY$J:=:RC^\IJ9JB-3[KW14-E_\ "DG^7CV9W9MO
MX_=9;?\ E1V)V-F._:7XZ;B@VGL"KFQVVLUDLFN$Q%9N+*S5L&/I<3E\X6H*
M66GEJIS-'))+314B_<^_=>Z,1\W_ .=?\,?@EV[#T!OBB[S[I[RI=J0]A[RZ
MI^,FT:K>&6VOMF66!'W'N98JBCI,5BZ:"H6JE#SM5"E*2I3/YZ83>Z]TO9?Y
MOWP//QF^/WR_QG:V2W#\?ODKV[BNB>O=][>PN4JDI=U9B6JIZ3%;CIDIQ4[;
M>.IHIH:B7()!!3RJBRRKYH#+[KW1@^[OFST!\?>_OBY\8^Q]P9NF[E^8N8SV
M&Z,VQA<965ZUS[9IZ"KS4U=54\;4V*IJ.ER,<HDJGC654F$/D>)U'NO=$ _E
M\S?!;87S)_G$Y+HSO7Y ;M[=Q/=^'[*^;6U^[,EE9]L;,R==C\]]D-J_>T\-
M#_#&HL'6_N12U4E)CZ3'XSRPT-#0TL/NO=9_B)_/N^#/S7[RVGT?TW@/E%3M
MVAE,GBNC>V][=;;@QVR-]OA*&JK\R^W<ZL=2T46*2@JXJILM3XOQ3TTL1%S$
M9/=>Z</CC0_#,_SG_P"8+7]<]W_)'=?S-H.DMB8?Y!=*[NR.6;KK;&&GQ6W\
MC@ZG;E#+308R?(9&BJ:&8L)JQJ!YLFE-]G_$:Z.?W7N@V[:_X4=_RU^GNX-W
M=8YK+][[HV9UIOJ3J_MSY-=?;'RF8ZNVEN2.IIJ7^"9K=5.^HUK35.D&AI*V
M &*0-,K>-9/=>Z.%\V_YKWPU_E_[)Z [+^0.\MRMUU\EL_%@NK=Z=:8>JW11
MU0GI*7(0UQ3$?<5DU!/0UB3PO2053SIQ#'([1H_NO=(#X,_SEOB+\]^[>R/C
M=UYA>^.H.^NM<%+O.KZF^2VTJC9V;RFW4JH*6/<6(HZBIJGFQM0*NEG2.H^V
MKEIZJ&6:BB'D$?NO= +V7_PHI_EZ]9]W;TZ?GQWR@WWMWK+L=NG.T/D1U/UO
MG=R]=[>W<M=18P;:K<UBQ/D:K+RY"NCIHHL?CJU9IQXHG=Y:=9O=>ZO:1Q(B
M2*&"NH=0ZLK6(N+JP#*?Z@@$?0B_OW7NJ/?EK_PH*^!/P[^1?<GQ)WWBODCV
M#\CNE\9B<GE^J>E-BUNXJ[*C,X'%;DIH\-4I4TN-D:+$YFFDG>LJ:*"-B\?E
M++8^Z]T*_P EOYTWPW^+>Q?C5N7>U!WKN_L'Y:];T7;?27QNZKV?6YSLJOP%
M9CHLJU?6;5CFAEQ2T-$\CU25DT+QM35D2K)+23HGNO=&V^,/SH^+GS ^,U%\
MO>C.U,-GNA9,7DLIFMXYD28O^"C#1O+F8,[3UZP2XF?%11M)4K.%58M,ZL\$
MD<K^Z]U3CE/^%4O\K+![=K]]YF#Y9XGJVLW')MSK#MS)]7YZGVUOMJ:Z9&IV
MCDYBBU$6*J4DIZN+()CJR.:&55I74!V]U[JS'YY_S-^@_P"7M_H_Q7:6QOD9
MVKV!VO09?(]9]5_&[8N9WAG,U'@A1ME!3/3I2X2FEI17TY9*S(4S:9!);QAG
M'NO=)#XX?S??AO\ */XG_)/Y@]<93LK&[ ^(6)W+DOD9LG?6W*S$;NVQ+M/!
M3;BS%!5X2=F$U=%CJ>3QK3U$T3U$<E-Y1-%*B>Z]T!?P]_G[_![YW=\]7="_
M&W:ORBW?5]K8C,UN,[4R6P,AC-E8VNP>/JLK6X7+Y^MJ(A3Y-J"BGDB,,%11
MNZ+3?=K53002^Z]U6A_-C_X4,?$O<7Q"^?/2WQ?WQ\G<7V#M7;&2Z9V;\N>M
M=J[BH]@KO^*N2FJ]KX;L'&,)Z/.)2QL\588J;'U%/4T\]#DIXY0X]U[H5]7P
M_P!P_%/_ (3$;\^9'?'R9V)VZ=N=+I\9$ZJRV:6AWAV'N7K_ &7C4H=[O10U
M<DU/6U%;&KUT\E.XI:G*T<M6*/*5\-3[KW1UOE5_/[^"WQ*^1O=7Q&W9M[Y-
M]G?)'H[ XW<6X.I^B=@Y#<U?D:?);?Q>Z$;$U$,]/CBE+ALO3SU4U;4T5/!Z
MU::Z&_NO='C^-'\PGXI?*[X@1?.KK#LJ"A^-L&W<YN;<^]M_02X,X"FVRU4N
MX3G(:T(:#^$?93/-)J>!H56H@EFIY(Y7]U[JK'#_ /"GK^6IEJS:BS8/Y<;?
MP'9W8U'UUTAOO=7669Q^ WXU7(M-_%]K96IE2GGQ-+7.M+4?>FAKHIFU?9-
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M>5H,K1[)W!5WCR5105*^"1*B*D+U!2"'RRR1HWNO=+OYT_SM/@]_+P[[VO\
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MJ:BGQ5=34-8YJPU+)154-+54U;2U,<4GOW7NG#Y;?SQ_A?\ #CY&;P^)._\
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MTIM/,;MSV?SJXZLRHQ5!28V T\=7)0T$\L8JJBF618I"C,(I2GNO=%4^/?\
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MO=&.R7S9Z Q?S1V]\ 9=P9NI^2^X^CG^1=-M:AQE9+0T^TTR5=B#7UF76/\
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MK9-W_P#S$OC]\$_@M\7N\_EEV#N5JSLCK;9&V-KXG$4E?N3=V\MT97;]!/\
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M>8SF>GB?;&4>AW7LW&93-5]:D=%C\-48G(TF+I1%'1QKD*AEM5);W7NK$?\
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MDJ8DO_>@4U,DSQ2M*A\9!%+%)2^Z]TG_ /A*C%$/BM_,/G$<8FD_FZ]KQ23
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M6G2."")?PJ* /Z>_=>Z?/YU?_;X__A-A_P"+"]N_^XG6'OW7NB];-_[?K_\
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M?"/LFOW3%J+Z<C-U5O62N769)BVFI9Q?R/?ZZV_4?=>Z!?Y==N_,7KW_ (5
M;MW;\4_A;B?F_P!J[$_E=XS!;,ZQS>_MO=>#%[>K=UTLV3W/29K<[&AJ9J7)
M96IQIH8;5$L>1FJ%'BIYR?=>Z-A_*P^(7SWR_P [OYM7R!^;/PFI/A5TY_,2
MZOVICYM@;=["V7O5?XWB<35;?RS0UVU<I/4BHR4>4R.3>HJ:"F5)JQHDDE=6
M>3W7NBW_ !F['^8?_"<[=_0OP0^7&TME?('^5GVG\ACU1\3/EQL\Q4>XMF9S
M>67RN?@Q&[L,Y8SF2OJ:VM<QQ_LJ*RHI,C51(F.I/=>ZW(O?NO=:/O6W_,PO
M^%O?_B!9_P#WU_>7OW7NB]?./_<%_P (\_@5N'!_[AL_MG<_7FY]N9S%?Y/6
M8_)#/;A89&AJ8=$U)7!I'(GB99;LQUW8W]U[KZ _OW7NM7SNC_N+B^(__C(;
M)?\ O9]G>_=>Z5N?_F'?S2OF=\Q?E[TI_*JZF^"])T_\$NS8.C>\.S?F97[L
M^]WENBD:K&5V_MZ#:(D;&TV)JZ6MI9'K871W=)XZB(M+3CW7NM:WXR[4J<%_
MPF9^+_S2Q..SN6W)_+C_ )KV)^6E#1X!5DJ9<;CMX8G%Y*F42*PCA$F6@JV?
MTK&U*LDK"$2GW[KW6P[\7:[,_(/^9?\ SX?GMM#^ [@H^C.B=O\ P@^,VX*+
MR?<)/A]FG=V[*(R-)$8?]_0<>TA22(EF\9T& R2>Z]T#G\G'8O2N7_X2=[CQ
MV_Z+;E-LC>'QV^0V:[EK:IXX$,M-N3L"F&0K:@6:&LHL1C*!H9R1+"E/3/&0
M8X[>Z]U6)\D\COS<O_":;_A/U)VOB:2DSC?S%^M,#28\!9(IMM4/^F'';3ED
M4SU2L:[:5/CII%+#U2LIA@Y@C]U[KZ%"JJJ%4!54:55>  /H /P![]U[K66_
MGP1KN'YW?\)^.O=_8S!UGQ]W'_,#J\]OBISTPAA;=^(AVV.O\>]ZJ))DR557
MY)? T,J5,D<5,[*LS0U/NO=-G\VFEAPO\]S_ (3O;HV50X\]CYG>/<VVMUU,
M15*F3;<> V[$1,XDA=H:>BRN;>%68J6:90CW:-_=>ZP_!7_N*%_GA?\ BO72
MG_O ]?>_=>ZV@_?NO=?/6_X3_?RS/F5\U?Y9=')MG^;!W/\ &+XC[Y[.WCLC
M?OQ>ZBV5ASD*V&\-/E9J/?U1FDR&.?,>5?,@QTR+$KPV<2EA[KW5B'\V/XE=
M)?";/_\ ":7XK]";8_@'4W6'\UK8>$Q-!D&6IJJV2IW5MJKR61RD^A!69'+5
MU3-4U<A15>65@B)&$C7W7NC/_P#"CR*/.]D_R.=C;JH<=D>IMV?S@NM(NQ*/
M+Z6I)E6OIZ.."JC>3Q/3S8S(Y)9-<;#1<:D#,LGNO=2_YVU*N#_F?_\ ">K?
M'7&-PU=W]/\ -/+[&2&:58ZJ;KNOBV_#OZ=HON:4SPX?#54M1"S,WAFE9(XI
MC4O!-[KW2?\ Y,&/H,C_ #BO^%*L&0H:.N@J>^>I\?40UD22I)3ST?9RSP.K
MJP:&8*!(ANK@ ,#8>_=>ZUU]UU^\]M_\)3/FUL#;U!!3]/;3_FO93K3K&:FJ
MI:J.78%)NK:V5I)DJ)*Z<U*KN_S0JY%I @E,32$U;^Z]UL3?\*=MN[8V=_+Q
M^'F>Z<P.UF[=ZC^<W4J_#+"0R1T\4N=ABR$.)PU $J*)9*"?&TUWA$\,0CIH
MIC)&:>.1/=>Z$#^9-\'OGQT=\\\?_.0_E@T^Q>X>WH.C(^A/DE\2NS#X!O'9
MU'6TF2?^Z^2\M.*?+L<92'PF>!UGHJ>:#[S748VJ]U[I+]B?\*"<;OC^7M\)
M._?AOT1MS</R._F _)*@^(_2O47<-4\6V-J]@S91*"JJ-SU>,^TK,AB,=EIJ
M26$T7VL]7%5PSF6C8/I]U[HA-!-_,HHO^%*'\H*D_F11_$)>RJGI7N&CV=GO
MAE+NM</DMN_Z.]^59H\[#NN.*M-?C\NKLGC'VK*T;(GEC::7W7NCV?R5/^WQ
M_P#PI/\ _%A>HO\ W$[/]^Z]T87_ (5'?]N*/G-_Y3+_ -_%U][]U[K50_GR
M=7;Q^#W1M=V7U[M^HG^/?\X[X-]*[ [@CH5;[?$]K]1Y786ZL7EZEVD9(AF-
MH8RKA@AC5//4RY.J8,T<CGW7NKKNYHH]Q?SC/^$NVV=Z4..K=A8GXA;XW7MQ
M,GI:,;BAZHDJX9%1Y&1:BEK\1AYJ=A&K^=8RKNRJ(_=>Z,A\A*5=M_\ "J7X
M!9+JW&X:?<W8O\O??>)^3[PRJ*F#:% ^YZC:^3FIQ4P_OS;KHJ.A24QSO) F
M@QB.F2:G]U[K9O\ ?NO=$ _FQ?\ ;K+^99_XH!W)_P"^ZW'[]U[HO7\@'_MS
M5_+X_P#$"T__ +LLC[]U[JX3W[KW6E#\C/CQ\H?DM_PJ#^2NQ/B7\V,Y\#NQ
ML3_+/P.[<UV]@-FXW?$V1PD&?V31U.VVQ.4RN'IZ>*LKZ^CK35K,TD;8]81$
MRSNZ>Z]U8MO_ /E8=:?R\OY7'\Y7L*7MCM'Y,?)WY*_!_MS<GR ^3/=,\<V>
MS\M'UUNG[*C@AB+QXW%T?W#^*F629A=5:9HH:>.'W7NGC^7#E-[[._X3']?;
MBZ?Q-'6]H8+^7+OW<O7.)90D57N2##;IJ\5'+IGI+_=918A(WFA)U$F9"=8]
MU[HHGQ,V-TJG_"/3?-%B:';55MK(_P N[N+?.7FCD2I27>L*[QR$D\TSM*3D
MZ/=M+'$J$ZJ:6GBI8Q&L$<:>Z]T0O%3YO.5__")UMYTD,E;'M_>5+303VE4T
M%#B^K8<')9Y)@&&,IZ21>1H:VE(BH1/=>ZMIWW%)A/\ A6WTP^UZ2G1=W_R>
M:J7L>:EMJ=8M^;L2":IT.MY ^+Q<0UAOVUBLOZ&7W7NF+_A,C@MJ[Y_EN?+K
M<7<V"VI#V=W!\W.W:GYD8LRI4)%G:B/'Q9?%Y!9*FN^WI:;&3J8Z<RO'X9S4
MAI&JI)I?=>ZKS_E6_P O3<_\T/\ X3.](=%P;[7J?LOJ'Y4;G[T^)W8]2LU3
M1XW<>WMQY]J*?(TL4TGEH*BJSV:I)5,3"'S+6)2SRPH9?=>ZM^^!?\X;LV;(
M_-7XT_S/>G,-T#\U?Y>/1-7W[W-E=B5$%7M[?G76#QYKZG>^V07$D-/&M3$\
MM-KDIXSD:8K+3U$E7CJ#W7NJ%?YIGRX_F[?.[^2/\@?EUO?IWX)=/_RU>[H]
MJ9W;77N-R&[:WN7'XU>VMKPX+-RU2(VSZN?*Y^FA-4G^32#'UDKFF2ICN_NO
M=6"_/9WD^<G_  D6DD9GD=MTN[N222=H]/$DD\DD_4^_=>ZW!O?NO=?-C^-/
M3&_MO?RY?DE_,\^/^'BR'R)_E7?SV>T?D/%14YC@J,]US4;<ZUH^QMM25D@>
M.FHZC%+%6U,SPU+QT-%714U.T]4#[]U[H0?ACVCO+<__  EH_GG=J=1861LA
MV+\[M[9@XC*E/+3;9W12]+1[F:4QU,,9J*#:62KY?3(ZF2(6CJ!^S)[KW5N'
M\Y_8W2N)_P"$I&V:#9%#MI]G;-^/?QZRG2=3CY$J8@]1G]@4HK*"K+2M53UF
M$R%>\E1K:2H2:>61W+NS>Z]UM*=#U^X\KT=TSE-X1^'=N2ZHV[7[IBU%].1F
MQ%')7+K,DQ;34LXOY'O]=;?J/NO="O[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NM4G_ (4R=6YON[M_^2#U)MW<6_MF93L+^9/A-KIO
MKJUM&X]O0U-1A$J]QX:<P524F0V]2>7(Q5,D4D5,U-]Q,IBB?W[KW5DGP5_E
M'U?QA^3W87S>^2?R\[>^=GRYW?UO_H-VSVOVACL=@*/;>QH\E_$8<)BL!B99
MZ-:R:2*$UE<7 FE6HFIJ6B-?7)/[KW0H_P JG^6Y_P -D]4?(;K#_3-_IM_T
M\_+W=ORK_CG]W?[M_P *_O3C=NX_^ _;?QW/_??8_P  \GWOEI_-Y]'VD7BU
M2>Z]T77Y<_R7<EV[\H-\_,?X<_-_O7^7IWQW9M+'[ ^1V5Z@H:#,XC>V+H/#
M!%55>(KJFA%#N6#&Q?;4F6BF9Z,A*B* RFH^Y]U[HZ7P5_ER?'OX!?%*3XF=
M3TN=W%M/<57E]P=J[TWO-'4Y[>.=W! E-F\[GZN**%*BOK:6**G!5 L5+!3P
M+Z8@3[KW10OY+?\ )AVQ_)[V?\@,'1]YUOR*W3WKO/#Y.;?^:VX-O5]#M[;>
M-EQVW=MS 9[/_?QXI:NJ9)T>DBM/XXZ.%(UO[KW2TZ"_E-0=+]\?S:^Y*KY'
M;OKJ7^:A78.:KQVP,/'MK.=?18G';MQTK8C<4N6SL>4R,\>ZC)3U9QU#]G+2
MJXAF,@,7NO= !TI_(UWC@ODO\?N^/EM_,@^3_P Z-J?#O.G<WQ-ZG[GH\73I
MM_)&AIZ5<MN;-TTU16;TS5-/3)44]?/%1SH\<8E:<B1YO=>Z-[T;_+83IK^9
M_P#.3^9!)W&NZ8_FAUULKK^3I5]N"D7;J[0P&W\$:D[A.=JQF1DA@O,8CBZ+
MP>?Q>2?Q^23W7NJV=Z?\)M<!4#LWI+I7^8)\I/CS_+P[PWQ5[_[:^!NP(,7)
MAIJJMJJ.IJ<;MS<4\@K-N;<J?MF2HQOV=9'4(T*R2:( C^Z]T>GY;?RBMA_(
M2I_E:XKJ[L2B^/G7'\KWY%;-[KV+U[CMN'.0YS%;,GPC4.V$JFSV(?#>6GPJ
M1'(/'DG#2&5Z69P0_NO=+[>W\ML[Q_FX=2?S31W0<8>K?B#5?%,=&+MT3&N^
MYS.Y\O\ Q\;G.<C%*8_[R>+[(XB8'[?R?=CS:(O=>ZKU[@_X3[=E]\PYOI7M
MW^;=\WNRO@CN_?)[!WO\4]^Q8+)9'(U4>>@S]'C1OS1!64NW:*K@4PXQ,88H
M)$@GI&II($]^Z]UL:[>P&'VI@,'M;;U#%B\!MK#TV P>,@+%*:CHX4IZ:!"[
M,Y2&"-4!8DV'))Y]^Z]U6MT5_+<_T*_S0OG#_,D_TS?WE_V<SKS96P_]#']W
M?L_[M_W/P&WL']W_ 'B_CM7_ !C^(_P'S^+^&4/V_G\?DF\7DD]U[I ?/G^4
MU#\L>\^O?F%\>/E%VE\%OFOUGL*NZMQ'R!ZIH*+,PY?;E8TLJ83=6V\A/24F
M?QU'53R3P1-40E9'#EB\-*\'NO=&3Z-^#&.V%\1=^_$CO_O7NGYI8+MVDW70
M]K[Z^15;25F4RE-O/[H9K&TJT=+3QXS#(*R84-&AE%"KZ*>18DBCC]U[K1H_
MF/\ \O;#[9QO0G\F;HO^:U\EOFGV36?)W";(Z7^$<.,QD^.ZAVJT?WF=W#V7
M5XXO-E8]NT&2%3C(YI<-#2T4[R4=%'14LTJ^Z]UMU?-3^4;E_D)\MMI?.WXP
M?,CMOX*_*K']81=#]@=@]=8;#[GHMS;(_B4>1GQ-7A<\R4E-D04 IJY6D2"2
M.EGEHJIZ2$#W7N@@^/'\AS;/QUZI_FP["Q_R][J[<WC_ #6NIZWKKL'MOO*@
MQN8R^#KZO [[PQSLHQTN%3/SF7?4U3+3EJ!'6EBIXI(%<NGNO=69? ?XD0?"
M+X7= _#ZIWQ%VS3=(=>KL&HWS/B!ATS""HJ9GG?#MD<PM&DBU)0PFLJ!87+G
M58>Z]U13N;_A,E]UU_WM\8.N_P"9I\K^I?@+V_NZL[#P?PXVGC<')C,%EZ_(
MG(5%'_&ZEWJ:_:<;I"(<*E-1J9(14UE7653O*WNO='K[Q_DV8OMG8?\ )SZ\
MP?R#K]HX7^4;V9UGOO$565VQ'EJK?=+UO1[:H:?'U+PY[$1;>J,K%MQ3)5)'
MD4@><E:201A7]U[H<>BOY;G^A7^:%\X?YDG^F;^\O^SF=>;*V'_H8_N[]G_=
MO^Y^ V]@_N_[Q?QVK_C'\1_@/G\7\,H?M_/X_)-XO))[KW04?![^3EU[\6?B
M!\VOAEVSV=)\C.L_F_W]V%W!ON2#!R;2EH,7V#@,'@:O;\'ASV=FDJ<?%AC-
M#E(YZ:3RS(T=+ \ >3W7NM3[YB_!T;6[Q_E^_P K+HC^9_WQ\_>Q^G?G1M.3
M:/Q!GQ&+CQ'2_6^W*6:3/YG>E9C?(*W,X&*JIACYZFIQL=/B):^FI<:!)'(?
M=>Z^BS[]U[JC3Y<_R7<EV[\H-\_,?X<_-_O7^7IWQW9M+'[ ^1V5Z@H:#,XC
M>V+H/#!%55>(KJFA%#N6#&Q?;4F6BF9Z,A*B* RFH^Y]U[H:NIOY1W1_QZ_E
ME=_?RVNC-T9_;F-^1'4/8&R-_=Z[TIXLYN#*;G["VY5[>R>]L]!%-B4S&0AC
MG@*TXGI%:FHZ>C6>%4$H]U[I.?\ #3__ &)J_P"&D/\ 3W_S07_0A_LP/]UO
M^KE_$/XG_=3^\?\ T[^V_C'^U^?^S[]U[K-\EOY4G^S$?R;=N?RD_P#3U_<_
M^[_Q_P"I^B_]F _NM_$/-_HOKMFUO\4_NI_>.A\?\<_NEH^V_C#?9?=ZON*O
MP:9O=>ZA?,C^3]LWY9=9?#:'"?('M'XZ_*'X(8JAI/CY\KNG8*6'*T<L&&HL
M1D8,AB*N6:*NP>8^P@FJ,?\ =QL='VS5;TD]9#5>Z]TL/B1_*TQ'2G17R:ZH
M^4GR/[D^>VY_F?4U%5\F-Y]V3-18O*BKP<.WZFCV_M.BJZC&[6Q[T,6E5IY9
MJI56GA-8T%%11T_NO=%P^(W\EKM_XF]B].4N)_FK_-'>'Q)^..?3<'1GQ+K!
MA:*DI%$66IC@]R[E2.IK=T[4BI,F(:7$R4M)%2)"OAD!2E^U]U[HU.]/Y;G]
M[_YN/4?\T[_3-_#O]%?Q"J?BI_H*_N[YOO\ [C-;GR_\>_O/_'8OM=']X_%]
ME_"9K_;^3[L>;1%[KW5H/OW7NJ?_ )\_RFH?ECWGU[\POCQ\HNTO@M\U^L]A
M5W5N(^0/5-!19F'+[<K&EE3";JVWD)Z2DS^.HZJ>2>")JB$K(X<L7AI7@]U[
MH2L7\">ZMJ_R_P#N/X=[=^>/=V[^X>X<5N>DJ?EYW_0TV[LYB*C>%1*^8DQ.
M&H*_;$=-1TT%54KB:05XCQDLJ/$TD$$=+[]U[HF6^/Y"NQJ3XJ?RV.D_C7WO
M_LO/>7\LKL7']G=2?)5=I?QJ7,9"<M6;XI<S@*7<VW9SB=_YOQUF2I(\QI\<
M2T3O44[/J]U[I?\ S"_DRY;NSY4;@^:WQ)^;G=?\O[Y'=I;#QO5WR%W+U#B\
M;F,5O?"8[[:GAEKL1D*BC^UW#!C*9*.DR8J9FHUAI)8Z=GAD^X]U[H4.T?Y.
MG0_;G\KBG_E9;S[3[UW)UW0[?QM-0]S;QSLN=WBN9Q>6BSE-F'J\K]S3&(9*
M,J,<D<5%!0N:&DCIHUB>/W7NB@=;?R$NR(_D;\+_ )4?*'^9]\D_EOVE\*-V
M5F5Z[QN^=O[?Q>W3BI6ITIL=38RCFJ*VBKWI*:-,GDY:^MGR<L%-*T=.E.L#
M>Z]T-O8?\MS_ $*_)7^;[_,D_P!,W]Y?]G,^&XV'_H8_N[]G_=O^Y_7E#@_N
M_P"\7\=J_P",?Q'^ ^?Q?PRA^W\_C\DWB\DGNO=4&_R;_P"2;O3YS_RF?AFG
M?/SH^4>WOA9V1FMP]H=I_ &EH<?1X7,56'[+SIP;8S<A6GSF&VQFJ3%P92IH
MDBJ15UE;_%L?644W@E7W7NMDS^89_*FPWS/W7\;N\>F/D%OOX7_++X@19:B^
M/'?G6V,H,W#BZ#-4*XZOQ.3VQDI::@R^+DI5,8A$],_CDFA:5H)I(F]U[H-_
MA!_)GC^(7SO[1_F#[V^:'R#^6'>'<7Q^DZ(WO6]WTV#35'+E-JY,UM$^'I:&
M*AI:8[5A@I,?'!X:>"5QY9'4.WNO=3_Y?W\H3+_R]ODI\B.R^MOF7VYN7XS]
MY]G;@[MQOP\RN'Q5)AL1N[<_BCRN9J\]2S?>YGP45+34E!3_ &M%#!#!&]6*
M^JCIZB#W7NE#\3?Y0^P?C_/_ #2<1VIV'1?(3K;^:#\C=X=W[YZ\R.W&P4.#
MQ>\:C-2UNV'JDSV6?,^&#,-$,@D>.<M&)4I8F8!/=>Z(UM'_ (3;8 U'4W3W
M>7\P/Y1_([^7S\?]YTF^>FO@EV+3XH8:GJ**HJYZ7&;DW#"[56Y=NTB3I#2X
MYJ*D2F@6:"*005!B3W7NK)MY_P MI=V_S<.H?YIB]RC&+U3\0:GXI+T0NW/*
M*X5&9W/EQG1N?^.Q?:A/[Q^'['^$RW^WU_=CRZ(O=>Z2_P 8_P"7#5?#;Y)?
MS6/EY0]N9#M*M_F"YG ]A4?66(VRV-J]K2[3Q^[4CQ]+D4SV3?<=1DWW&!&R
MT>-,3P*HCE,UXO=>Z1_\@7HKY#=$?RON@\=\L<MVID_D9V)/F>U^SJ7NFKW!
M5[DQCYC*5'\%Q&37<Q&7H*O'[<I\?'4T4D<2TM6:B-4<AII?=>Z%K^:M_+<_
MX<VZH^//6'^F;_0E_H&^7NTOE7_'/[N_WD_BO]UL;N+'_P !^V_CN ^Q^^_C
M_D^]\M1X?!H^TE\NJ/W7NO;+_EN?W0_FX]N?S3O],W\1_P!*GQ"IOBI_H*_N
M[X?L/M\UMC+_ ,>_O/\ QV7[K7_=SQ?9?PF&WW'D^[/AT2^Z]U[^7G_+<_V0
MSM?^81V?_IF_TJ_[/?\ +W<'RK_@?]W?X%_=7^.Y+*Y#^ _<_P =S'\<^U_B
M?C^]\6/\GBU_:1Z]*>Z]T9'YS?$'KGY[_$WNWXB=KUN4Q>QN[-K1X'(YK!K3
MO6XZJHZ^CRV*R=(E5'+3O4XS+8^FJHQ(I4O"!<?J'NO=5;;L_DK=N=F?RC>V
MOY7W<O\ ,2[+[GW%V4FR\3A/D?V+M&DJ1MK"[)SVT\QC,'C-ITNXZ22II'BV
MN87J*W.5&0>:M>IJ*RI6"&F]^Z]T.ORP_E/_ .S0?\-4_P#&>_[C_P##9/?6
MQ>[_ /CUOXG_ 'V_N7_ ?]QG_'QX_P#NW_$OX'_P)_W*_;^;_,3^/]SW7NLG
MSY_E-0_+'O/KWYA?'CY1=I?!;YK]9["KNK<1\@>J:"BS,.7VY6-+*F$W5MO(
M3TE)G\=1U4\D\$35$)61PY8O#2O![KW1U/AI\:MS_%+I:GZMWE\DN\OE7NB?
M=F7WMGNV^_JVDK,Q/69NMDKZJEHTHZ6FBQ^%IZB5_LZ$&5*1&,,,@A6../W7
MNFGY_P#Q/_V>?X:?(3XC_P!_O]%W^G?84FR/]('\*_C?\*\E335'W7\)_B6(
M^^M]OI\?WE/?5?R<6/NO=%@[7_E'=(?(+^6A\>OY<7>&Z]QY^D^-_4O7^S.N
MN^]C0I@=Q8G='7NW*/;^,WO@(GGRJX?(31P3L:9IZM4IZN>D:>4'S'W7N@6^
M(W\E[)=0_*S:/S7^8OS=[R_F$_(3J':61Z_^/6<[=Q^/PN)V7B<B*FFEGH\/
M05%<E9N*;&5+4U5E'FC-4[RU+TRS& T_NO=&)^%/\MS_ &3[YD?S)_EK_IF_
MTB?\.&=A[1WY_<#^[O\ "/[H?W5BW1%]I_%?X[D_X_\ ?_WDOY?L\;X/M[>.
M;S7B]U[KVR_Y;G]T/YN/;G\T[_3-_$?]*GQ"IOBI_H*_N[X?L/M\UMC+_P >
M_O/_ !V7[K7_ '<\7V7\)AM]QY/NSX=$ONO=%_ZC_DT?Z+.K_P"<]UO_ +,?
M_'?^'=]^]I;W_C/]S_M?]'O^DK';GH/M?M_[TU'][/X+_>/R>3RX;[S[?3XZ
M7S:HO=>Z/_\  #XG_P"R,?#3X]_$?^_W^E'_ $$;"CV1_I _A7\$_BOCJ:FH
M^Z_A/\2R_P!C?[C3X_O*BVF_DYL/=>Z*Y_,%_E:_[.3W'T!\J>F/D]V=\,/E
M]\;<9E=K=>][=:XW%YV.HP.;XR.%SFWLP4HLM1V><TZO*D<;U4[315 **GNO
M=)#X!?R@Z7X._+3Y*?,;/_+?O'Y3]M?*79.'VOV3G>[Z7#"M>IQ0HBM9#58>
MGH8$IE%(*>DHEI4BH:%::CC=UIA))[KW35_+2_D_Y;^6=VGW!/UO\S>W]Z_$
M_>>[,YO3JGX:YC$XRAV]L_(;@?'O65'\5@GGK<LU(M$\-%!%#C:&&*=I9J.I
MKP:Y_=>ZR?R_OY0F7_E[?)3Y$=E];?,OMS<OQG[S[.W!W;C?AYE</BJ3#8C=
MVY_%'E<S5YZEF^]S/@HJ6FI*"G^UHH8(8(WJQ7U4=/40>Z]T7'<W_"?W,8[>
M/REP7QR_F1_*?XK?$OYD;HW-V5WG\7.K\=MVH%1NG=%/%2Y.MP^[LK#59/#X
M>LIE:&LQ\=.\U3!X8!D(8:>)![KW0GO_ ""OCWD?Y6O0_P#+*S7<7;:0_&3L
M*M[>Z+^3FT#1X;>FW-U5&[=P;LILQCS"D]+"],^XJBA94TN].%FAFIJU(*F#
MW7NC#?R__P"6UVE\2NT.UN_OD5\]?D+\Y>]^U-I8SKFIW%V&D.V]M8S;^$K*
MZIQ5-C]FXJMJ\9_$HUK")\A-++(\K5,U-'1FOK5F]U[HK70?\BS_ $'_ ,FW
MNW^4G_LTG]Y_],<VX9?]F _N1]E_#OX]74%;;^ZG][ZO[S[3['1_Q>(/+KU?
MMZ=+>Z]T,?<7\F#K+NCX@? CH#)=W=D];]__ ,NCK;:.S/CM\S.EXH<%NC&5
M^V]M8;;F1K:>AGJ,G%#BMSQ86"6MQ3U4Z^B&/[N3Q>23W7NAQ^"?P1[S^,&8
M[)WS\EOY@WR)^>'8?:>U</M'.1=ITF)P6S,;!AS6,LVW=E8U:NFP]56M7S+5
MR"LF-5'XUJ!+)&)??NO=5([F_P"$R7W77_>WQ@Z[_F:?*_J7X"]O[NK.P\'\
M.-IXW!R8S!9>OR)R%11_QNI=ZFOVG&Z0B'"I34:F2$5-95UE4[RM[KW6Q;\8
M^D,7\9?C9\>_C=@\[7[HPOQ\Z/VGTAB-RY6*.&JR-+M/ T&!IZZIAA)BBJ*N
M*@661$)17<JIL![]U[JM7YJ?RC<O\A/EMM+YV_&#YD=M_!7Y58_K"+H?L#L'
MKK#8?<]%N;9'\2CR,^)J\+GF2DILB"@%-7*TB021TL\M%5/20@>Z]TGOA!_)
M/VE\+C_,.J8?EY\F>WMS_P Q>BQM/V9VKO.IQ--O/$U-#!N^&;+8W/4="(7S
M%2V\:B1*AJ)%IGIX/#$ O'NO=!STI_(UWC@ODO\ '[OCY;?S(/D_\Z-J?#O.
MG<WQ-ZG[GH\73IM_)&AIZ5<MN;-TTU16;TS5-/3)44]?/%1SH\<8E:<B1YO=
M>ZO0[$Q.\L_L#>^"ZZW;C-@[_P SM+(XK9&^LUBVSE'ALM44DT6/RM5ADR.'
M?+08^K>.=Z,5U&:E4,/W,&OR+[KW1'OY7/\ +QV?_+(^)>WOC7M[?-=VYNN?
M=^:[-[?[MS>.3&9/>>ZL_6&>NSN2IA6Y.43K1Q4M#%YZVLG%+14ZRU,SJ7/N
MO=5O=9_R$=S]6?R7^VOY1.V_FI)2U';&]:G<&1^1])U\89*?%U^?PN9R.&_N
MK_?B3SK7TV*DH)9_XQ&#!5N?!==+^Z]T='Y??RL-N?*K:O\ +@ZTINUCUGU+
M_+Z^1&Q.^4V)0;?7)+NR/K['+C<)@?N7S-$F!I33F6.6;P9%O#*T:1HP$GOW
M7NEUTA_+VJ.J_P"9)\R?YBFZ.Y3V+F_D[UMLWJ/876\NWOX<-A;?VO1T\=;C
MJ;-?QRO_ (S#GLG219"4?88_PSAQ^_KU+[KW35_+S_EJ8/X.[#^7^U=V=H'O
M_-?,_P"5F^?D[V?N*LP7]WHA_?:.E@FV]'1IF,S++2T44$MZEJH//)4S.(H%
MTHONO=$-^,_\@O??Q5RN*ZVZJ_FJ_-C:'P@V?VC1]L]?_$K9/\$Q,U#64^?.
MXZC$UN^/%696MVUD:Y(Q5X^GI*#[E&JS4SSRUDDB>Z]T=W97\LN.L_F)]N_S
M$/DAW7+\A]V9/KMNEOB[U9/M[^!8+JC9]9'-'G*''VSN7.>S6?$S_>9>6*BF
M*U%7#'"E--%#3>Z]TZ?RE_Y<V2_E;?&/-_%B/O0]Z;$I.XMP]A]6UM1ML[=J
M=OX7/24]2-N5%]P9\9AZ2O6HJ/O[TC2FJ932H$4GW7NGW^:Y_+[J/YGOPYW1
M\/F[HJNBL%OG>^V]Q;NWA0X(;@GJ,;M_+4^8;&0T39G"Q0RU=520,E3)+.D#
M1AC23FP7W7NK$<3BZ'!XO&X7%TZ4F,Q&/AQ>.I8^%B@IXUBAC4?ZE(T '^ ]
M^Z]U3I_, _E&9;Y@_+7XY?-WI#YA]J?"GY&=$[+K^H\MO_J_"XK-3Y_960?)
MU$N#:/*30TU+4P5>6JI*>HJ8LE2Q&>1_X:U2(*F#W7NI?SI_E$TGRB[?ZJ^6
M'Q\^5/;_ ,)?FUU!UQ/U)@_DCUQ34F>.;V[,LC+B=X8#)5%+!N2D@JII*B-9
M*J$F61FD9WCIGI_=>Z&7^6Y_+(ZK_ER;7[;GP6_^P>^.]_D7OH=D_(SY)]O2
MP3[FW=E8_N?M%J7@4)3XW&FMJFI*4-)X7JJES+(\S-[]U[JROW[KW7O?NO=4
M _\ "H[_ +<4?.;_ ,IE_P"_BZ^]^Z]UH4?R OYUO6O\F_.?*3+=B='[X[HC
M^0.*V?CL3#LO)T&-...V9MRRS-4&NBE$PJAG4"!+:?$^J^H>_=>ZV3O^@WSX
MS?\ >"W>O_H4;?\ _J3W[KW7O^@WSXS?]X+=Z_\ H4;?_P#J3W[KW7O^@WSX
MS?\ >"W>O_H4;?\ _J3W[KW7O^@WSXS?]X+=Z_\ H4;?_P#J3W[KW6GC\E/E
MWM_YZ?SAW^7>U=G9GK_;_=WRCV-N3&;.W!405=90I33[=QABGJ*94@E9GH6<
M%% "N!]0??NO=?:5]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7SL?^%PW_ #.O^7W_
M .(MWY_[MMN>_=>Z:_Y;_P#PK0Z$^#OP<^-OQ-W/\0^WM]Y_HWKY=F93=V!W
M!A:6CKY%K*NI\\%/44SS1(5J NER3<$^_=>Z.W_T&^?&;_O!;O7_ -"C;_\
M]2>_=>Z]_P!!OGQF_P"\%N]?_0HV_P#_ %)[]U[KW_0;Y\9O^\%N]?\ T*-O
M_P#U)[]U[HN/S%_X6&?'GY-_$7Y3_&W"?#/N;:^9^0?QQWQTAB=S93<>#GI<
M=5;LVSE,#3U]3#%2K+-!22UZRR(A#NB%5()'OW7NJ\_^$8__ &]B['_\4FW?
M_P"]9L'W[KW7U(??NO=>]^Z]U[W[KW7O?NO=>]^Z]U\?3^>GO.FZX_X4 ?+#
ML.LHI\G2;#^2>TMYU6-IF5)*B/%X7:M<\$;L"J/*L!56((!()X]^Z]UM"?\
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M'/08ZGFW5A*#<4>W>NY,;)12R2S;JAJZRNCR)E:"@.("S4LKU,+Q^Z]T'/\
MPH(^3OR![!_E1_ KO+Y*?%+?GQ'[,B_FQ[%FWM\9L?N*DWGE7QV#PO8];0Q0
M9+'T>$H<Q+F8\?3U=-3>)$2I,,;OY8O(ONO=7!?#;^<IN;Y#?-NL^"OR'^!O
M?OPA[4W1U!4]_=&2=N9+$9(;GVG2RT\,DU?3XY(C@,UY'J"<>DN16%:.=:JK
M@J-%.WNO=1/F-_.OCZ#^2G9?Q7^,OPK^0'ST[,^.?7U)VS\L#T?-0TE#L+ U
M=.M=%!)45D50<UNF?'.E52X2F5*BKC9E@E:6"HCA]U[JS?X>?+3IKYS?&[JS
MY3=!YN?-]8]L8$YC#&O6.*NHJB">6CR.*R=/%+,E-D\5D*>:EJHA(ZK+$Q1W
MC*.WNO=1OF)\C-Q_%;HO.]P;3^._=?RDW#CL_AMLXGI[H*BI:[<%;4YO*4N)
MIYQ%55-,L6.I:BK1ZRH42FE@U5$D8IXII8O=>ZKC^$W\XG=/R ^7V:^!ORQ^
M$':WP+^4,73U3W[L[:&^]Q8;=6+SFU(,E)CQ6TV9Q5/0)'5,(W=H?!)$C4];
M#]RSTUY/=>Z+@W_"BJ@W/N_.[[Z._EX?+CY"? 7:'<2]$;G^<_5$%-DJ*HSK
MY2AQ,=5MC9=)35.9W1MYJFLM]_35$<C.:>".CDJ*J.-?=>ZL&_F-?S1-D? 1
M.@]C8/I?M'Y1?)SY5;MJ-G?'CXR]1I3T^=S4M)2?=5V3R$V0TC#8+&F2".MJ
MV@GDIC4"62F^V@K)Z;W7NFKXA_S2\3WAT3\FNV?E%\;NY/@/N7X833P?)?9W
M>,/W>+Q8I<#'N&IJ]O[JI*6FH-T4,= ^H-!!!5,KTTAHUBKJ)Y_=>ZKUVC_P
MI$PGFZG[D[P_E\_*/XZ?R]^_MW4FS.GOG=V%48I\-++75=524N4W/MZ!!5;7
MVY6"&.6ER,E;5)50O)/%$8(?+)[KW1H_G7_.B_V3[YQ=7_ 'KOX6]]?+OO7N
M;X_0=[=>X_I6MPT,4R566W1BHZ*O;)R0ICZ*G.UYJBKR;NT%-!,C&)RI!]U[
MHC&$_P"%+V_]Y;,[BHM@_P I+Y;[L^0_Q(R&1D^<G2T.9Q$&.ZSQ.)8?>Y([
MH;'R2;AGJ(Z7)G'4,6)I:FM_A57(1!2F*J?W7NCO?*K^>KTA\:?Y<_Q%_F18
M_I7M?M?K;Y>[[VML/:'7&V),=3[DQ]5N;;^XLYXJB*26>CJZS'R[;J*%X*>9
MA-4NGBF,?J/NO=8?BO\ SI<WVU\T]K?"'Y4_!+OSX&=C]V;&R'9GQ7R7<^2Q
M&0I]\8G%TPJZRDJ%QR1)@MS0TT55/)B5FR+4\5,?NJFGGGIH)?=>ZE_-G^;1
M\G_BUV+V_@^L/Y2'RP^1?4'QXI%SW<OR#H<SM[;V!&'7 Q;@J\EM"!QF:W=O
M\/I)@M3 BT4L$B3)*$=%23W7NG7Y&?SONBNC/Y6?4G\UK;W6.^NS>G^W9=NP
M8K8-%68W'YRBESLM71STM;*9*['"LPN2HIJ2KCCF=/+')XY6TC5[KW0<](_S
MQ-S[Q^:O4'P[^1_\O'Y)?#2I^56WLIN/X@;Z[DR&'JGW='B,2<I54F=Q&(2I
M&T,D CQ-3&MR3T[/2-6?;?=(%]U[HT?QE_FU=%?([X0_)'YPU&T=[]3[3^)>
M6[ V]WSUMOAL?4;BP&1ZYQYRF;Q]5%B*JOI'K):,QR4T4,LQF$T06[OH'NO=
M5Y?S&?G'\"OD7_)BZ.^>OSJ^%':'9WQFW[VMM;LO8_0V4R&.@W/15LE=FL?M
MK/R3XO.4^.\&2QGED>F^_82XG*O35D0E>HI$]U[HS?SE_G+1_"[YN]5?R\NM
M?A)WS\K^[^V/CU3=U=<X7I2KPU-"8I<KN?#0XZN&3DA7&4-)_=66:KR+LT%+
M3RHQB<J0?=>Z'7^6-_-#V_\ S#^K^]-Q;KZ/WO\ %'MWXM=I5O3OR-Z8[+KJ
M3(/M[,X^CCK*IZ?+T\-$*[&I^_$)YJ.BD,E+,WVXA,4LONO=53;T_P"%/E/@
M>F>Q_F+M'^67\LM_?R_=N[I_N)UQ\P*3(X+'X_<>4BSQP-3/58"N5,E@,!+5
M:8J+(R/5-/7NN,JJ3'U8=4]U[K9MZKWW!VCU?UOV;2XZ;$4O8NPL/ONFQ-1(
MLLE+'E\?3Y!*=Y55%D>!:@(7"J&*D@ &WOW7NJ5?EI_.PW?T5\Y^P?Y>'0/\
MOSO?YD?([:_2%%W7MS'=99S!XK%55)5K2,W\:K\G&[[>QM+]SXI*[PUQ-3)2
M4T5+))5CQ^Z]TI.LOYY'379_\MKY.?S!*'ICLO;>=^'&?S&P_D7\8]US4U'N
M7 [GP5300Y##??/$:.I7PY&*6&I$:*Q$E--'3U4%1%#[KW3Q_+L_FT=O?/[>
M6*RE9_+@^2/QB^+6Z^@AW=L3Y5=YUM%2XC,&&:@AJZ""@BHM$=)5+D4K,-7M
M76R^+AJLDE+34\0\GNO=$ZSO_"E# K0[M^0G7O\ +S^5_:?\MCKWL"LZWWI\
M^]KMCEQJU-%74M#-F<1M&6+^)97:<4DTGFROW=.(7C2G:G-4[PP^Z]U9CWG_
M #5.C.B>S?@%@,O@-P[JZ0_F+9BDVOTE\I-IU6.FV=2Y;+4,.0V[19>6:HAJ
M85W/3UE,<9+"LRSZYRXB2F=F]U[I-==?S8]B=U=A_P Q[972?17;/9V%_EMX
MZLH-^=@867#Q8G>.Z<?CJNOR&S-FU$U:(ZO.4,F-K*2I%4]-%3U*4HF>.*MA
ME'NO=-N3_G+?&?%?RG*?^;Q/AMWS]%5.T:7/P[%H&HI]Q'(U6Z8]FKM[3'.U
M#_%H=P2?:S_O?;PE)99)E@C>4>Z]U9GU%OJM[1ZIZS[,R.T<SU_7=B; P^^:
MK8FY):2?(X5\MCZ>O;%9&6@FJ:&2OQYJ/!4&FFFIS-&_@FFBTR-[KW5//R^_
MG,[DZ3^8VX?@_P#%+X(]Y_/CN;J/KG%]O_).GZ@R^&Q=/LO;^7C\M' OWB5L
M^6W3-3U%!50X9DH6JJ.OBGI:J8QRQ+[KW5/G_"G_ .4?=^\?B%_*TSVT_B7V
MEA=D]I?+3KSY 9%M_9?'X3,XK=5/A,[4;<ZHSV#IUR<4>9ST&1K*J2K6LFI\
M9-AC%/3R2SQ-%[KW6PG@_G/\F<'\$*SY7=W_ ,M_OK9O?%!N/^[U3\).H\UA
M=];L;[K/PX3%5E-E5CV[05E)5154-=4F"%Y:.F:4F*8P26]U[HL7Q-_G,=A=
MN_+Z'X+?+#^7WW-\&OD9O'J3-]U])X'?.Y<%N7%[MPN&FG5H*?*8VGH?MLQ-
M3TT\STL4%8E.*6I66H&B%I_=>ZHL_DB_+KYL5G\X_P#FL293^7#NO'GY+_(;
MK6#Y:%NP<54'H;[&EWU%C!D F"U;W3*"LJ IHOX>M,M$Q<LLBE/=>ZO:^8W\
MZ^/H/Y*=E_%?XR_"OY ?/3LSXY]?4G;/RP/1\U#24.PL#5TZUT4$E1615!S6
MZ9\<Z55+A*94J*N-F6"5I8*B.'W7NA7[=_G)_'/8_P#*?R7\W/K; [E[EZ,H
M\#M[,0;+P\]'C\Y]QF]Y8?9%7BJPS/4TM%D\%E\HZ5L1:1;TLJQ.ZO'(WNO=
M5S93_A2]DNO=P=(U?>G\JKYL]2]4?+/; F^'^])Y,'E,YOW<DE-$]%MM-JTS
MQ/B),U6UV/I<9-)7SS51KX:J2AIZ-7G'NO=6'_RY_P":SG/FKW9\DOBYWC\0
M.T_A)\FOC/BL+O#=?5O9.7QN=AK=N[B>I;$92ARV/IZ*-Y#2I3R540@:"%ZM
M(H*RK,4S)[KW1*-X_P#"D#:F/F['[JZO^!OR>[N_ES=+]@U76?:O\P+84^)?
M 0UU)D*#'S93;VW6U5VY=JP2UC&?*PU<"1A8M,$HG!C]U[HUO\P7^=?U5\':
M_P"!5/LSHSM+YCTO\PZFS%=T/)\<*G&5U1D(*"GVC4XV;'4]3+''EH\]#O&E
MDIGBF1%BCDE9BI7W[KW3A\ OYMNY/F1V?\L_C;VI\+^U_B3\L_B;MVBWGN'H
MS?N:QF;3,8G,I538*?'9O'4M/&:BKACI34(*62G@:NA6FJZ\)*R>Z]U03_PG
MI^6WS3KOGW_,OVQDOY?&[7V;\A_YCN[MT_*+LV?L#&3KTAG&J=RSG:-;C_X(
M:C>1QU:JXP5E%+00!8Q,(4A 0>Z]U9Y_.=>?Y6_S$/Y-W\LNAILADMJ[H^0-
M=\YOD'!C) Z0[8ZMHJFHP]+EZ812QC#[@KCD:,RU)CA-7%30PB6JDB\/NO=-
M6ZO^%$N_\KV;\V.KOC1_*L^5/R>KO@3W9N3K'O7=^S\SA*+!08K:F;RF)RN8
MHZEJ6NKZO+3PX>HJZ'!04<M551+9IX0&D7W7NC3]\?SU_CMU/_*NZO\ YL&R
MNO=Z]L]-]GYC#;?IMA8ZLQV.SN-K\C5UV,R&/R#N];0I78++8^>DJXTE>-GC
M9X99(RC/[KW4WJ?^<=FGZ4^67RA^:/P8^0_\OCXW_'+:&"[ V7OCY"R4Z9??
M&,W&:FGQE%1;?CI*?^&[J?(T\='+AOO:R6"HK\7'+.LE;XXO=>Z!+I+^?S/G
M^X_COLCY;?R_/DI\'.HOF=G:/;_Q#^0W;-;B\AA-R564I:6?#46XJ>BB@?9V
M3S+U02DI9IJUG1HJAWC@:9Z?W7NAW^;'\W_</Q]^6F/^"OQ3^%/;?ST^4M!U
M%#W_ -E;#Z\SF'VQ1;:V=+E*3&&OJ<IEHJL5>1U5D3QT4<"JYJ*.-JF,U.J/
MW7NI'R@_G)X7XH_RS=B_S(^U/B/\@MDT>[MSXS:N4^-O9G\,V_O?#3Y+(9#'
M1ODJ=IJ^GI@ST'W$<,Y@J_M9XFJ:>DJ1+21^Z]TA?C?_ #M<IV1\S>L?AQ\H
M_@9\B?@MG?DUM[*;M^'N[.Z*S%5Z;VH\/CTR=929:AQ2LNT<ZM()6^PEJJ\(
MR0PSU,-35TT$GNO=.'S&_G7Q]!_)3LOXK_&7X5_(#YZ=F?'/KZD[9^6!Z/FH
M:2AV%@:NG6NB@DJ*R*H.:W3/CG2JI<)3*E15QLRP2M+!41P^Z]T:_'?S6/AS
MD?Y<K?S1QONIIOB[#UXV^:NNJ(H?XO#5I6_P<[8>A6H:/^\S;A(Q"4@FT/7N
MB+,8G64^Z]T53X5?SCNS?DUW[UCTOW3_ "T?ES\2<!\B]D9'LSXR]M[T@CW!
MA<]@L;0TE?)/N?\ A%#&VQ*V:&I'C@KGGAO)1+)5)+7TT;>Z]U1!\7OF-\XM
MN_\ "DK^9MN#:O\ +BWEV3G>PH^M.I.TMD)V'BZ*3KK8N-H]J8O%=@O-/@9U
MS-+G\'%#N%<+314U33??FCDGDJ(Y)G]U[K:>Z?\ YBG7/<G\PWY;_P NG![#
MWMB^Q?A_L7:N^M[[]RKT'\$R<.[<-@LU008I(:B2N,E/3YU$G-1%"HDB81^1
M6##W7N@.^//\YKXX]Z?#3YD_.#*;0[$ZOZF^$?;N\^GNTJ+<:4%7D:ZNV5BL
M)E*R?"Q4-7)%4Q9)L[3TM"DSP2R5'IE2%6#>_=>Z#GX(_P W/O[YB=G]0X#>
MG\J[Y5?'[H_Y'[(J.T.@OD[E,KM[<&UJW;:8.FSE#DMTM2-0/M6;-P544>-H
MU?)55:9HIH8S3)6S47NO=7A^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NB ?/'^6E\8/YD-+TCA/E/C=^;JV3TAV/)V/2=<[?W!
MD<3@=QRR4$U'_#=U4%'(@R>.CG:"KB,;4]9%-3+%'5K1560I*SW7NM>WX4]
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MO=>]^Z]U[W[KW7O?NO=>]^Z]UJ^?\*K?^R4?Y>?_ (UYZF_]YOL3W[KW7O\
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M8RESFU\UNO&Y&"*.L>BK:S8CU+)'-''*(*J"=7A1XZA?=>ZK4_G0[]Z2R?\
MPE)VM6[+R.UXMH;W^/WQZQ'1])0I'2Q/+3Y[859]CCJ1EB>GJ*+ XW("2F$:
MR4\<%1')&GCD"^Z]TZT..W)B/^%.7\N+$[R<R;OQ?\C"@QVZW*&,MDH,YV%%
M7$H8H2EZI7])CC(^FA?TCW7NDA\#/^RX?^%=?_DK?^\AW%[]U[JH'<T\--_P
MET_D*5-3-%3T]/\ S=*2>>>=@B(B;\^0S.[NQ"JJJ"220 !<^_=>ZV$_YO*U
M&4_G=_\ "<C'[2E@DW73=F=UY?,1TX#S#")@=F35#OZ'_8>@I,EI/XTRL"MM
M0]U[HFN-[T_FM?S8NL_YF/R?ZE^?FR/A'\8_B?VQV?\ &K#?%"/J[;N[?[S8
MG9>W:?)Y>KW1NK-5-'F<949_%99:>62F5DI)$D:C@I9(VGD]U[JKONC_ +@F
M?B/_ .+"Y+_W]G9WOW7NK_OYU?\ V^/_ .$V'_BPO;O_ +B=8>_=>ZII_F!9
M/=?Q%[F_G6?RK>N<_MW8F7_FM_(SHWL;XHX:.226KK*CN?<ZXOM(PTT_E)H:
MJIH*JAF2)1%1P%4IFA,U,D'NO=6G?\*D^K-I]&_R%-M]*[#H(,7LCJ+L+JOK
M/:&-ID$<<&,P4$F,H8E0$A0E-2H+7/\ KGZ^_=>Z$CNC_N+B^(__ (R&R7_O
M9]G>_=>Z*5\3\/OK</RB_P"%DF ZOG:E[+SFS\3A^NZE1<QYVIV'W1#B) /%
M/<ID'B-O%)]/T/\ I/NO= #VYN[96Y_^$0>.GV?7XV6CQ_7.QMHY*"E04[1Y
MK%_(?;M-F8)(&6-_N?OZ>HE9BMYT;[I3)%*LK>Z]UN8_$?\ [)1^,?\ XKUL
MO_WF\;[]U[K7]Z9EBC_X5R?+-))(T>?^45C8H%<@%V&\>LW*H";LP1&:PYTJ
M3] ??NO=5/;Q@GK/CS_PL?W1M&KPM1TCE^^Z'%;67 11I3G>-#69E^P)_)'3
MH)IYZRMQYJ&\L@>H6672IE:6?W7NMD/H3&=AYO\ X3L]+X;J*M3&]KY?^2UM
MS&=89%U#K3[AJ.C:.+"S%&@J@XBR3PL08)@;6,4GZ#[KW56WQ/W[TDO_  CS
MWQ7XW([7HML8_P#EX]P;"RT82.ECCWO4C>&-:FFAD6(C*5V[ZR.2-B-=5/41
M5,1E6>-W]U[HMWRSS.#PG_"5W^7'T]O7 Y?>'RE[^V[TYLCX,X/:M4V*SL._
MJ^OI<IM#*XG(K3*V.DQ6V"P:H)@CJ/-'0_?0OD(JKW[KW5HW_"96KZ^C_E]=
MF=*Y# M1?)KIKY:=E=>_/2'<!CK*[,]EOGJELEF,A5&@H!D8*_#FBI86>-S%
M%1FAEEGDI9)7]U[K7@VMLNJJ:_9/_";RNS6WZ/%;=_GP9/+U?7*22UU37?'/
M#X*3M)*:O6K:6K>FK5J/NTJ'=9):B,1-+(D-2TONO=?161$B1(XT6..-0D<:
M !54"P  X  X 'OW7NM;G^:;\#_D/U1WEVA_.,_E>]Q;5Z[^8'6?3IH?DYT?
MOJ&"JVCVIM;;6-IZY*'.)'+334>X*;!XZF2DEFEA,\-+0115N,T"J;W7NJZ?
MYQ_S)QG\P7^3E_)I^8>+VG5;$'=G\T+JG,Y?9U4TT@QN6QV+[1PF:I*>>H@I
M9:N@BS&,J11U)B055+X:A5TRCW[KW5S/\[SYS_(WXF[/^&_2?Q.RNU=@=Y_/
MGY=;;^)6U>\]ZXV+-4&Q4W!4P44NX4PU4CX_)Y"FFK87@AK ]+H2=I()](0>
MZ]U2=2]&?,WX_P#_  I4_D\;,^9WSFHOG;NFNZ<[BW!LC?C; P?7U?AL9-UM
MV!#48JJQV!K:VFKZ=J^GEFIJJ5O,=4L9(C2..+W7NCY_R5/^WQ__  I/_P#%
MA>HO_<3L_P!^Z]U7C\/*3^<)-_-0_GJ8CX,[G_EKX??<WS$I<EVOCOF3'O\
M_O'4;489O_1E+B5VICYXY<)!MFHT2F;]-7*Y2\4T;O[KW4+Y9_!'Y*_R[/\
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M0W3\GW7NCO\ 2_\ W%Q?+C_QD-C?_>SZQ]^Z]U[_ (3S?]E7?\*$/_&O._\
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MVU1;8FWA0KN3;]/A=WXZK.9KI=OT4STL\51#>>,2R5,E541BI'NO=7W]T?\
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M!!+A]TXV;&2??;1WE1-2FI3!UN5GR24\S4TL-,U97!J&1G)@]U[HE6?_ .%
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MH_9?\OW;6*V?\G/C_G,GLVOP?8557;:CH:+$;DIXY**LR;[9FS#34$\%=3+
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M;.[\?25)HJJNVO7TN0ACF"+(89):269$E".K:20VEE-K$>VGC:(T8$?:"/\
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M:KFA$K(&4L%N5!!-KCW5(FE^$$_8"?\ !T5[-RWN/,99=OM;FZ* %Q;P2SE
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MCUG:,*9%A:KFA$K(&4L%N5!!-KCWI(FE^$$_8"?\'2+9N6]QYC++M]K<W10
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M_=>Z][]U[KWOW7NN.I2Q0,I=5#,M^0#< D?4 E3;^MC_ $]^ZW0TKY>OV?\
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M4C_=_?\ 3H.7O^:5_P#]W6^ZW+?@Y_V[R^,/_BJ^VO\ WG*;WC5S3_R5;O\
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MG_B2L'_[JZGW[WG_ -SH/^:'_61^O?WNW_*P\O\ _2NN_P#M)3JJ_P#GT_\
M;P[>/_B-=K_^Z\^QY[0_\DD_\UY/^.Q]9K?W8O\ TZJV_P"ECN/_ %>'6U!_
M*G_[=X_%/_Q&H_\ =A7>X'YS_P"2M=_\UY/^/'KBG]]?_IZO,O\ TL6_ZLQ=
M'-[/_P"9:]A_^&-EO_<"H]AR/XA]H_P]8^\H?\E:R_YZ[;_J\G7R^/>=O7V;
M=7-?R%O^WAVSO_$:[H_]UX]Q;[O?\DD?\UX_^.R=<]_[SK_IU5S_ -+';O\
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M_BQM)_[S.Y?<2^S7_)3E_P">5_\ J[#UR^_NE?\ E?-U_P"E!-_W<=NZ*O\
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M2LY_[JZ;V"/9C_<Z?_FA_P!9$ZQ _NB?^5AY@_Z5UI_VDOTI?^$WO_9-W?\
M_P")OA_]T./]M>\O_)2A_P">9?\ J[+T4?WN'_*X;+_TIV_[3;CK7B_F@?\
M;P3Y8_\ B7J__H2'W+_MY_R1;7_2-_U<?KJQ]S#_ *=9RU_TK(O^//UO)?\
M<A/_ ):'_P#*9[Q3_P")7_-W_G_KYMO_  97_C3?]Y7K1M_E?_\ ;P3XG?\
MB7J#_H2;WE9[A_\ )%NO](O_ %<3KZ2?OG_].LYE_P"E9+_QY.OHG>\0^OE$
MZUSO^%(7_9-W0'_B;YO_ '0Y#W+OLU_R4IO^>9O^KL776/\ NC_^5PWK_I3K
M_P!IMOUIX>\D^N^O6\E_('_[=]XK_P 2]N;_ *'H_>*?NG_R6I?])%_U;7KY
MMO[S_P#Z>G-_TK-O_P".R=:T7\X__MY1\G_^UWM__P!Y#;_N<?;/_DB6W_-[
M_J_+UV"_N_O^G0<O?\TK_P#[NM]U65['?68_7T??YA/_ &0K\OO_ !7+=_\
M[HZWWA=RI_R5+/\ YZH/^KJ]?)#]UG_IY7*W_2_VK_M-AZTTOY*'_;S;XT?^
M3G_[[_=?O)7W-_Y(=S_S9_[2(NOH(_O$O^G.<P?]2K_N][;U9K_PI9_X^/X?
M?]J3?'_6_:OL">R?"\_ZA_\ K/UAQ_<__P"XO-/_ #5V?_CFY]&H_P"$XO\
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MWDK[F?\ )$N?^;/_ %?BZ^@C^\!_Z=!S#_S2L/\ NZV/7T"_>)77RW=:K_\
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M441VO^2WO?>'8OP)V'O'?FYLYN_=.9WUNN;)Y_<53+5U4Q&=K%0-+,S,(XT
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M=3?W:[4KNL_[N7S^>\_V>(P>5^]^\_OMAO'Y/XSXO#X&T^'7Y6\FA!9SEO\
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M%&8Y/63WWM;S;/<^QV[GO8K6*UM#>;IR[+% NE%.US^/8.U,:Y=MNX%;\3-
M[&HH>AU_F.G>0^.D P$'8U1L@]I[8'?L747W?]Y6Z]_B2'="XG[!ER&MJ4(M
M3]J?-]D:G387(+N6]'U0U>'JT2>%XVGPO&T'1JU=OQ<-79JIJ[:]1M]T\6']
M:S]4;!;O]W;A^Y3NGA?N\;W].?HC/XX,5 ]3'XOZ?C"+5CHJOPBZ_P#A/-VU
MLOL/^6MW7MC =?0[<R$'R'Z"@S&X:Z3,TD]#!3X'+G [BKY,CA<QB\C3Q++7
M-"%J86FAEUSR^7V?\S76YZ&BWF%S)J_0F9$0J0Q+J'1*2(0QHH:BG25(6JM-
MGWC.:/<5-DN]J]WMIN9KXSPG8]Z:UL85M94F>2Z@%S8P+%<V\T4C%8 Y,3A'
M2B+HZ17>/96[:;YG9[Y>T&[<S1]+?$'NS8OQ!WAM^&5$QE52;RHYH]YY.H1F
M\;38C,[TVR \F@J,?.JD70OZPM$:P%F8U,MS#/=I)G4H@)TKP\UMYQ08/B(3
M\.#_ -N>4+&;V_AY$DM8GW;FC:-YYHM9RI-Q%)M,JMM\*$"H6>WVC<^U:@_4
M1D\#I47\W?\ OI0[P^(.]-B9?-X_.].93?'R!7'85Y5.4AV'C<+NBLQ<T<4D
M?EBKJ#&SPZ3J74X+)(NJ-F.36C_7BD5&$ZI;AGI2(SL8Q("0:%"0U?0'(.05
M?<6.WW%CS/M^Y10R0[K%M&Q^),JD6S[S<76W1SJ65M)BEGC>HH:*:%31AA_F
MX;\R&_NH^G=H]<;JR6.Q%8(/DYN?)8$N/O-MXBOP&%QE)-/&0D=/E,SO.BG'
MJ)E6BD500"RM\IJMM)+)+&K]IMU#GX))5=M87S*K$X]%+*3FE;?<;Y<BY8WS
M=+[=K:.25=?+]O'/0^%?W4-[=S2*C99H;?:ID..QIE)/ %)[VZD^)/<G\Q'Y
MMT/RVW9CL/1;1V?U-)UK1YS?N6V;%JR. S9S34T>/S^%2O9C14/E+"4P^BVC
MS'686]]=;;M5JUFBDO+="0FWBF)">!IS)&]*:FI2E:]'_+O///'M_P"U/*4O
M(UL\KW5WS*-P>+9;7=6I!>6?TX<SV5V8@/&GTTT:^ZNK0* UC=SF+:>T=L]8
M=D;I[#^.6R_YRO4FS_C]O;)YFIS:SX.H;%56;Q./STTTT^9P=!FJJJIX)'GJ
M%*ZXC-)I-E_TP,]9XDCG;:[MYXQ&L>F55N C&, !'*+&U J\0U*FO0^NMEUW
M]S=[S86UCOUW[5<SW6]V<=I':%+R,7<=M/+:HB+;W,MM%%(ZK'&0=+Z%U9M-
M_FE5=50?R^_E+6T-344=92];F>FJZ5VCEC=:^B*O'(A#(ZGD$$$'Z>PCR@BR
M[I:JP!!GC!!%006%00>(ZPP^YC EU[I<N1RJKHVX*K*P#*RF*4$$&H(/F#T2
M/I+KG^2[ENS.L:?JCL_%[B[87=.,R&Q\+0]E;_KII\Q2SQ5=*HH*C<,M+4VJ
M(0S12QM"RAED0QZA[/MQN-^B@<W,!2+25=C8P( K=OQ"!2O&@((->!KUD3[B
M\V?>#L=GW!M\VV2#;#;7$=Y,_+VRP(EK*C1.?%2P5TJKT#HP<$@J0U#U=3V!
MO3#=;[#WMV)N.9*;;VPMHY+>F>J)'6-8Z+%T<U=5.SN0B!8(&)9N !<\>P);
MP/=2+$@)9V"J *DLQ   '$DGKGMROR_<<V[G:;5:*6GO;J"TA4 L6EN94A0
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M/<:/>;[9>6+SW"M+>SYJ?FV%+5!866VW]SL.F#Q9+N"S@MP46\5$M7= 3_C
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M%W: D#N"&.Z+ 'YT'VD#TZ'OM9;[:_MMN4FZK_BR\W<L+=.J_J+:-!NIG"D
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MOUU7;]$TZ5ISD^%/ED'CFCE6#^*L?VED4B/TA@WJ]G:;M;Q;F+Q;>/PA:!A
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MO[R6Z^A?K<M_X3B_]DC]S_\ BQM7_P"\SMKWC5[R_P#)3B_YY4_ZNS=?/O\
MWM7_ "OFU?\ 2@A_[N.X]4V?SZ?^WAV\?_$:[7_]UY]R'[0_\DD_\UY/^.Q]
M= /[L7_IU5M_TL=Q_P"KPZIE]REUT(Z^E3O/_LCK=G_BM%?_ .\M+[P:@_MU
M_P":@_X]U\@7+_\ RO=M_P!+Z'_NX+UHV_RD_P#MXQ\6/_#YJ_\ W293WE9[
MD_\ )$N?LB_ZO1]?23]^K_ITO,?_ #R0_P#:9;=7I_\ "DW_ )D]\8__ !)6
M<_\ =73>XJ]F/]SI_P#FA_UD3KFK_=$_\K#S!_TKK3_M)?KW_";+_F3WR<_\
M25@__=74^_>\_P#N=!_S0_ZR/U[^]V_Y6'E__I77?_:2G55_\^G_ +>';Q_\
M1KM?_P!UY]CSVA_Y))_YKR?\=CZS6_NQ?^G56W_2QW'_ *O#K:@_E3_]N\?B
MG_XC4?\ NPKO<#\Y_P#)6N_^:\G_ !X]<4_OK_\ 3U>9?^EBW_5F+HYO9_\
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M%_- _P"W@GRQ_P#$O5__ $)#[E_V\_Y(MK_I&_ZN/UU8^YA_TZSEK_I61?\
M'GZWDO\ N0G_ ,M#_P#E,]XI_P#$K_F[_P _]?-M_P"#*_\ &F_[RO6C;_*_
M_P"W@GQ._P#$O4'_ $)-[RL]P_\ DBW7^D7_ *N)U])/WS_^G6<R_P#2LE_X
M\G7T3O>(?7RB=:YW_"D+_LF[H#_Q-\W_ +H<A[EWV:_Y*4W_ #S-_P!78NNL
M?]T?_P KAO7_ $IU_P"TVWZT\/>2?7?7K>2_D#_]N^\5_P")>W-_T/1^\4_=
M/_DM2_Z2+_JVO7S;?WG_ /T].;_I6;?_ ,=DZUHOYQ__ &\H^3__ &N]O_\
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M_P"5AY@_Z5UI_P!I+]:BOO([KN]UO;_R)/\ MW/UO_X?.Z__ '=U/O$[W/\
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M?R_:M?UWNO=.-7<-+CUV;U'C:6?+5]?D&\8EBI&FHXI2D<1EJ)"^M8(F>SZ
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M4H$9U=MN3MDO"+2+<=5V6*@Z"(&<?A!*@&IPK"0ZL:5)('2GE[[H7LMS5/\
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MLQ_;O^[FMO;SG,[M=;U:;M9;)*=T7:;.,3;Q="S83PP2VI8H"[HJ,NHB8TC
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MZ<^,=5U=U#NG<.VNFOFAUIV7D>O>C-N39"KI<%M_*5&0R#X_"8>G 5(H8R%
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M/MNX^\.V[E;W=M+:))R@7NHYXGMD%MMNT)-JE5R@\)HW66K#PV1@]"IHI?\
M1YN;_AG_ /T?_P!QL[_I(_X;9_N=_<C^&5'\;_C?^B_[+^%?PWP??_Q7[_\
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MS"*MB:":.'RJQ1P0+OUG'$)8HYK;6H6:18EEA=PX".Y"ZU=Y"P9E)4C3720
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M#_VI-C_];]U>S[WLX6?_ %$?]8.IK_O@/]Q>5O\ FKO'_'-LZVN_<#=<1.M
M_P#G7_\ ;S;Y+_\ DF?^^_VI[RT]LO\ DAVW_-[_ +2)>OJ"_N[?^G.<O_\
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M2;WE9[A_\D6Z_P!(O_5Q.OI)^^?_ -.LYE_Z5DO_ !Y.OHG>\0^OE$ZUSO\
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M?]9'Z]_>[?\ *P\O_P#2NN_^TE.ME;W#O7(7KYZW\VS_ +>,?*?_ ,/FD_\
M=)B_>6_MM_R1+;[)?^KTG7U2?<5_Z=+RY_SR3?\ :9<]$RZ8_P"9P]4?^)*P
M7_NTI?8CW_\ W!N?^:$W_5MNL@O<7_E7MT_Z5U[_ -HTO7T,_P"83_V0K\OO
M_%<MW_\ NCK?>(G*G_)4L_\ GJ@_ZNKU\J?W6?\ IY7*W_2_VK_M-AZ^<%[S
M1Z^M[J_C_A.9_P!EM]I?^*KYO_WK=C^XE]Y/^27%_P ]2?\ 5J?KE]_>S?\
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ML,]8P=>]^Z]TB^R/^9=[]_\ #+RG_N#/[O'\0^T?X>C_ )4_Y*EG_P ]5O\
M]7DZJO\ Y%'_ &[EZP_\/3=?_N^K/8\]S_\ DMW'V0_]68^LUO[RO_I[6Y?\
M\NV?]H,/5C/R([_ZX^,'4&\>ZNU<J<7M'9U!]Q+'!H:JK:F0Z*3'4$3O&)ZZ
MMG*QPIJ U'4S*BLP!^U[9-O$Z6T"ZG<T ]/4GT &2?("O6)OM5[7[O[R;]:\
MN[)%XMU=/I6M1'%&,O+(P!TQQJ"SM0X% "2 :6_B?\=^T/YCO>>W/YB7S%Q
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M=<V]ON5!KN;[;BZ-XC'07D9HX_J%JY_5BO0H+2BIY?Y%'_;N7K#_ ,/3=?\
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M_BM%?_[RTOO!J#^W7_FH/^/=?(%R_P#\KW;?]+Z'_NX+UHV_RD_^WC'Q8_\
M#YJ__=)E/>5GN3_R1+G[(O\ J]'U])/WZO\ ITO,?_/)#_VF6W5Z?_"DW_F3
MWQC_ /$E9S_W5TWN*O9C_<Z?_FA_UD3KFK_=$_\ *P\P?]*ZT_[27Z]_PFR_
MYD]\G/\ Q)6#_P#=74^_>\_^YT'_ #0_ZR/U[^]V_P"5AY?_ .E==_\ :2G5
M5_\ /I_[>';Q_P#$:[7_ /=>?8\]H?\ DDG_ )KR?\=CZS6_NQ?^G56W_2QW
M'_J\.MJ#^5/_ -N\?BG_ .(U'_NPKO<#\Y_\E:[_ .:\G_'CUQ3^^O\ ]/5Y
ME_Z6+?\ 5F+HYO9__,M>P_\ PQLM_P"X%1[#D?Q#[1_AZQ]Y0_Y*UE_SUVW_
M %>3KY?'O.WK[-NKFOY"W_;P[9W_ (C7='_NO'N+?=[_ ))(_P":\?\ QV3K
MGO\ WG7_ $ZJY_Z6.W?]7CU<G_PHZ_[)'Z8_\6-I/_>9W+[CSV:_Y*<O_/*_
M_5V'KG__ '2O_*^;K_TH)O\ NX[=UII>\E>OH(ZW2/\ A.9_V1)VE_XM1F__
M 'DMC^\:?>3_ )*D7_/*G_5V?KYZ/[V;_IXVW?\ BMV?_=SWCK7L_G'_ /;R
MCY/_ /:[V_\ ^\AM_P!RW[9_\D2V_P";W_5^7KJA_=_?].@Y>_YI7_\ W=;[
MK:@W!_VXY@_\9E8S_P!]M2>X''_*S_\ 4T_[6NN*>V_^)('_ ,^%/_Y,$G6J
M_P#R</\ MY1\8/\ M=[@_P#>0W![GCW,_P"2)<_\V?\ J_%UVL_O ?\ IT',
M/_-*P_[NMCU?Q_PHZ_[)'Z8_\6-I/_>9W+[B7V:_Y*<O_/*__5V'KE]_=*_\
MKYNO_2@F_P"[CMW15_\ A--_Q\?S!_[4FQ_^M^ZO9][V<+/_ *B/^L'4U_WP
M'^XO*W_-7>/^.;9UM=^X&ZXB=:!_\Z__ +>;?)?_ ,DS_P!]_M3WEI[9?\D.
MV_YO?]I$O7U!?W=O_3G.7_\ J:_]WO<NJK_8\ZS6Z^F/V[_V3#V?_P"(&S7_
M +SU3[P8M?[9/].O_'AU\=_(O_*W[?\ ]+BT_P"TV/KYG'O.?K[$.KO_ /A/
MS_V7T_\ XA#<?_N1B?<4>\7_ "2T_P">F/\ ZMR]<X/[TS_IV"_]+BP_ZM77
M5E?_  I-_P"9/?&/_P 25G/_ '5TWL$>S'^YT_\ S0_ZR)UB!_=$_P#*P\P?
M]*ZT_P"TE^E+_P )O?\ LF[O_P#\3?#_ .Z''^VO>7_DI0_\\R_]79>BC^]P
M_P"5PV7_ *4[?]IMQUKQ?S0/^W@GRQ_\2]7_ /0D/N7_ &\_Y(MK_I&_ZN/U
MU8^YA_TZSEK_ *5D7_'GZWDO^Y"?_+0__E,]XI_\2O\ F[_S_P!?-M_X,K_Q
MIO\ O*]:-O\ *_\ ^W@GQ._\2]0?]"3>\K/</_DBW7^D7_JXG7TD_?/_ .G6
M<R_]*R7_ (\G7T3O>(?7RB=:YW_"D+_LF[H#_P 3?-_[H<A[EWV:_P"2E-_S
MS-_U=BZZQ_W1_P#RN&]?]*=?^TVWZT\/>2?7?7K>2_D#_P#;OO%?^)>W-_T/
M1^\4_=/_ )+4O^DB_P"K:]?-M_>?_P#3TYO^E9M__'9.M:+^<?\ ]O*/D_\
M]KO;_P#[R&W_ './MG_R1+;_ )O?]7Y>NP7]W]_TZ#E[_FE?_P#=UONJRO8[
MZS'Z^C[_ #"?^R%?E]_XKEN__P!T=;[PNY4_Y*EG_P ]4'_5U>ODA^ZS_P!/
M*Y6_Z7^U?]IL/6FE_)0_[>;?&C_R<_\ WW^Z_>2ON;_R0[G_ )L_]I$77T$?
MWB7_ $YSF#_J5?\ =[VWJS7_ (4L_P#'Q_#[_M2;X_ZW[5]@3V3X7G_4/_UG
MZPX_N?\ _<7FG_FKL_\ QS<^C4?\)Q?^R1^Y_P#Q8VK_ />9VU[(?>7_ )*<
M7_/*G_5V;J%/[VK_ )7S:O\ I00_]W'<>J!_YQ__ &\H^3__ &N]O_\ O(;?
M]RU[9_\ )$MO^;W_ %?EZZ@_W?W_ $Z#E[_FE?\ _=UONMTC^7M_V0K\0?\
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M];L?W$OO)_R2XO\ GJ3_ *M3]<OO[V;_ *=SMW_BR6?_ ';-XZ,;_P *6?\
MCX_A]_VI-\?];]J^R+V3X7G_ %#_ /6?J(_[G_\ W%YI_P":NS_\<W/HX?\
MPG,_[(D[2_\ %J,W_P"\EL?V0>\G_)4B_P">5/\ J[/U O\ >S?]/&V[_P 5
MNS_[N>\=:HGS$_[*X^4W_BQN]_\ WILG[GGE?_DF6G_/+;_]6DZ[=_=__P"5
M#Y;_ .E!L_\ W;K?K?5^<?\ V[R^3W_BJ^Y?_><J?>)G*W_)5M/^>J#_ *NK
MU\QGW;O^GJ<N?^+)MW_:?%UII?R</^WE'Q@_[7>X/_>0W![R5]S/^2)<_P#-
MG_J_%U]!']X#_P!.@YA_YI6'_=UL>OH%^\2NOENZU7_^%,/_ ')3_P"5'_\
ME"]SQ[)?\3?^H;_K/UVL_N>_^=M_ZD/_ 'FNM5_W/'7:SK?5_D=_]NU^C?\
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M<H5@:>3 -1AY,"/+H:\_>RNW\K<^V/+EE=RW6U;G+M$UA?T42S[=NPMV23X
MGB)XKHW:5$D; C!'4CX/_+7)?);XL4G>W:&WL5UQNS 5N;QO9VV\>9Q28N3$
MRR5,<J&K=YUAJ<%+1UREW8-'4!XW>)D<VYAVA-HO&MX'\9*(8Y*4UAE!X G(
M:JGSJI! -0&_O&>Q\/M#SH_+6S7$E_:S)9R;?<.$\2X6Y14(/A@+J2Y66 @
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M_P"KPZIE]REUT(Z^E3O/_LCK=G_BM%?_ .\M+[P:@_MU_P":@_X]U\@7+_\
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MXVW?^*W9_P#=SWCK7L_G'_\ ;RCY/_\ :[V__P"\AM_W+?MG_P D2V_YO?\
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M #K_ /MYM\E__),_]]_M3WEI[9?\D.V_YO?]I$O7U!?W=O\ TYSE_P#ZFO\
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MW_3H.7O^:5__ -W6^ZW2/Y>W_9"OQ!_\5RVA_P"Z.B]XT\U_\E2\_P">J?\
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M=/\ \T/^LB=84_W1/_*P\P?]*ZT_[27Z]_PFR_YD]\G/_$E8/_W5U/OWO/\
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M;_IW.W?^+)9_]VS>.C&_\*6?^/C^'W_:DWQ_UOVK[(O9/A>?]0__ %GZB/\
MN?\ _<7FG_FKL_\ QS<^CA_\)S/^R).TO_%J,W_[R6Q_9![R?\E2+_GE3_J[
M/U O][-_T\;;O_%;L_\ NY[QUJB?,3_LKCY3?^+&[W_]Z;)^YYY7_P"29:?\
M\MO_ -6DZ[=_=_\ ^5#Y;_Z4&S_]VZWZWU?G'_V[R^3W_BJ^Y?\ WG*GWB9R
MM_R5;3_GJ@_ZNKU\QGW;O^GJ<N?^+)MW_:?%UII?R</^WE'Q@_[7>X/_ 'D-
MP>\E?<S_ )(ES_S9_P"K\77T$?W@/_3H.8?^:5A_W=;'KZ!?O$KKY;NM5_\
MX4P_]R4_^5'_ /E"]SQ[)?\ $W_J&_ZS]=K/[GO_ )VW_J0_]YKK5?\ <\==
MK.M]7^1W_P!NU^C?^UWN_P#]Z_-^\3/<[_DMW/\ S9_ZL1=?,9_>/?\ 3W]Y
M_P":6U_]VJSZTTOG3_V6W\QO_%J.PO\ WK<O[R5Y5_Y)=G_SRV__ %:3KZ"/
MNU_].YY5_P#%;V/_ +MEKUND?R4/^W9/QH_\G/\ ]^!NOWC3[F_\ERY_YL_]
MH\77ST?WB7_3X^8/^I5_W9-MZM0]@/K"GKWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NHU91T>0IIJ*OI*:N
MHZA=$])61K+$XN#9XW#*PN ;$'GWZM.G8)WM7$D;,C+D,I*L#\B*$=5R?&W+
MY;;_ &;_ #0L]@,%4;ISN$^0D>7PNV:1@DN1JZ;K#:,U-01,;A9*N9%B4G@%
MP?8EW90\&W@F@-LP)]!]9=9_+K+#W;L8-SV;V\MKF9;>&78VBEN&%5@CDYCW
M57D8#B(U)8CS ZK!VAV-W/L'OCX"U797P^^05)W-F^[>Q.S^V]P9&';B-NS<
MNY-A9;'Y/^"+39F9ABMJXV6-*6*J,<T6#QD,:">I4HXPEM+::WOS!=P-$MO%
M'"@\?4D274++JU0@:G85;35?%D)[5-1F/OO*?+W,W+7.J;/S3LC[5#L^Q[=M
MD"-N!_=NWV&]VL\/U/B6B#Q[V96:5HM2-?73L?#B-09JCRV.VW_*R_F,8C/U
MD=+D]L[U^0VT<[!6$+)#D<IN'<;8Z*0.$(>M7+4<D)L/(M1$Z AUN5PCQ-[V
M]ER"-L((R*+%;JW["K ^A!!X=1!+92[M[T\B3VJEH[BTY%N82F0T%O8;>)6%
M*XC-M,KY[3&P;(/1^OD)UWNS=_\ +^[;ZOPU))-O;,_%+*;2H,<2VN7(MM>6
MG6EY4MKFG'BY%[MS;V&-EO$L]Q@G?X$N(Y&I_"LBL?Y#K&'VKYKL>7_<_:]Z
MN& M(>9+:Z=\46 ;BLA?B!15[N/ETH.C^]^KY/AGUIWX-Q8JAZRQ/1&,W;E,
MM++%'#14^/P\)K::9F9(XJBBE@DIY(R05F0QVOQ[9O=MFBO'M"I,HE:/2!4E
M]6D 4XU/"G'RZ*_<7VTWF/G^_P"6#!(^XR;S<6L<05F>:2:Z81LH )99 ZNK
M"M48-PZKFW'BY_F-\]NA=W;1[(^0'QIH]\?RU*GM/'5VR)L1B=T+15N^\&\&
M*RJUE%N"B2GECKXYY8HP7\T$!$P571Q; PV3;;F.2."XT7\<9U&1HB5BN!J4
MQO$Q^'!)H0>%:4RRVB\3V#]LMZL+^PV3F!K/G^+;G2[6ZN=N,L.SWH:> PS6
M,A8&%D1FHNAWJA)4A?\ 0W5>0Z0_F@[_ ,#N'NKMGNHS?R_\3N63>7=E;C:S
M)4D#=AYF$T,4^,Q>(ITQT'VC3JK0LXEGG9I2K*J)MTO%OMGA9(HH0+V<:8O$
MTD^! :GQ))#7-.-* 8K6H8]S.=(O<7V:L;JTVG;-IISM=VXM-IBN(H)7&QV;
M^*RW-S=.96\4(2'"E40!002Q+J[%?+_O?XU_)7N[K?X\[.SN-^0/=_\ LW/5
MG;>1WJF.S])0[%KL8=B)3[4GVW4>0?P7:5.H@GRD3U KZ@B2A\J1TYZK[?ME
MW;V]Q/*I@A-I,@@#H#,)!/\ J"<'M>>0!A&0-*XDI5L@K:]Y"]M.;M@Y<WC?
M+N&39-H_JQN6V1[0;BRDFWB&X&YE[Y-PCH1<;I*?$2U98_ C&F?26D,%FY=P
M_,/YS?'O?O2W>N\^@_[_ '\LN;LVGWCL6@Q5;62TE9OC!F3#5%-G*2MIXX5J
M:Q'E*HLRRTBH) ID#%D &R;;<Q7,,<QCW".)D=I H98K@$@Q.A)&D@9(H>'"
MD6[:EK["^VV^;9S#LUIO7T7N"FWM:WDUU%$LL6T7H%PCV<T+EM$3!:L4*2DE
M20I#]\4\Y3_'+>?S@WE\NM\;K[+^7/Q]Z\?*[J[3W08EI,UU/2I7YO;=3M+%
MT5'30XRAJ:F*9,E0H:R=,PA#54@DAC1O>T_>RVD>W1K';3N5CA#$E;L^&D@D
M9V)8Y30QTKX96@!U]%GO9MS>[-ARAM_(EG;;?RQO=\(K;;;?49;3F60P6EXE
M]/-+(TTJ(T9MIV\&-K,@B)2LA)6'QOS&Z:^,?Q[[WWW\==G82DZ)[S_V=3LS
MM/$[VCK\[74F]*[)U.^(*C:O]W*?QHV%W741M"F6EGIDH8#YZQHG6<XU[=N-
MY/;03R-X\ LX4: *A,*QB#]3QR>YX(ZL8@#J:JQ@U6:5O.0/<#G'?.6=LWV[
MF;>=G_JEMVW2[08+.*7:8;:/;66^^ODJ?J=LB;6UHB2&>3].$,#'9[\6\SB<
M/\V/GOM*MKJ/^-=D9#8'?NQ9-0#9;:U;M"CP*UE+J57EAH<IAIX);7$9DB_X
MZ7(/W8&:PLI #I19H&/I(L[S$?[Q.A'KGTZPW]YK"?</;SDN^C1_!L(]ZV6\
M%,6VXP[I-?&-Z$A6D@O(W6M-6EOX>C9;,[_V5O[NOMWHW;-/F,CG^DL1@J_?
M6XX%IGP\%7GTK9J;#+4QU+S_ ,8IJ6C%14P/ HBAGIV\A9RBE$^W26\$5P]
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MEL;U;:8M)("\FW7$BVNA 3]/- *?I]Q^J[_M[IM?_P 9Q9[_ -^;MSV21?\
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M*.XFW9[>6!)I1N-EX==OM+=#&$=T$\A,E6$<=F?P;[ER_<GQ-ZKWKNFFJ/\
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M4XR3,UR459D:S*5T5#6SQ0+),D$&H2+&9+L0W=;U;K"\%E;^")0%E=Y6FD9
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M9S_W5TWN*O9C_<Z?_FA_UD3KFK_=$_\ *P\P?]*ZT_[27Z]_PFR_YD]\G/\
MQ)6#_P#=74^_>\_^YT'_ #0_ZR/U[^]V_P"5AY?_ .E==_\ :2G55_\ /I_[
M>';Q_P#$:[7_ /=>?8\]H?\ DDG_ )KR?\=CZS6_NQ?^G56W_2QW'_J\.MJ#
M^5/_ -N\?BG_ .(U'_NPKO<#\Y_\E:[_ .:\G_'CUQ3^^O\ ]/5YE_Z6+?\
M5F+HYO9__,M>P_\ PQLM_P"X%1[#D?Q#[1_AZQ]Y0_Y*UE_SUVW_ %>3KY?'
MO.WK[-NKFOY"W_;P[9W_ (C7='_NO'N+?=[_ ))(_P":\?\ QV3KGO\ WG7_
M $ZJY_Z6.W?]7CU<G_PHZ_[)'Z8_\6-I/_>9W+[CSV:_Y*<O_/*__5V'KG__
M '2O_*^;K_TH)O\ NX[=UII>\E>OH(ZW2/\ A.9_V1)VE_XM1F__ 'DMC^\:
M?>3_ )*D7_/*G_5V?KYZ/[V;_IXVW?\ BMV?_=SWCK7L_G'_ /;RCY/_ /:[
MV_\ ^\AM_P!RW[9_\D2V_P";W_5^7KJA_=_?].@Y>_YI7_\ W=;[K:@W!_VX
MY@_\9E8S_P!]M2>X''_*S_\ 4T_[6NN*>V_^)('_ ,^%/_Y,$G6J_P#R</\
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MM?[9/].O_'AU\=_(O_*W[?\ ]+BT_P"TV/KYG'O.?K[$.KO_ /A/S_V7T_\
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MF#_J5?\ =[VWJS7_ (4L_P#'Q_#[_M2;X_ZW[5]@3V3X7G_4/_UGZPX_N?\
M_<7FG_FKL_\ QS<^C4?\)Q?^R1^Y_P#Q8VK_ />9VU[(?>7_ )*<7_/*G_5V
M;J%/[VK_ )7S:O\ I00_]W'<>J!_YQ__ &\H^3__ &N]O_\ O(;?]RU[9_\
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M[GWV\_Y(MK_I&_ZN/UW#^YA_TZSEK_I61?\ 'GZW#_YA'_;J;NG_ ,5\Q/\
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M1_)0_P"W9/QH_P#)S_\ ?@;K]XT^YO\ R7+G_FS_ -H\77ST?WB7_3X^8/\
MJ5?]V3;>K4/8#ZPIZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@]V;U9L7K_<'9&Z=I81L7G.V]V1
M;WW_ %IJ:N?[[)PXVAQ$=0(JF>6*E"T&.@C\=.L41*%RA=F8J9[N2X6-'-1$
MA1!0#2I=Y*8 KW.QJ:G-.  Z%._\Z;ES1:V%E?3>)#MELUG9)X<2>#;O<371
M2L:*SUEN)&U2%F[M-=( '6Z>JMB[TWMUAV+N/"OD-W]-Y3*9GKK*K4U<(H*G
M,XFIP>1D-/!/'35?W&,K)8=-1'*L9;R1A)55QZ&\DMTDC0T650L@H#J5760#
M()'<@.*'%.%1UO9>==RY>V[<=JM)=%KNL5O#?1^'$WC1VMU'>1#4Z,Z:9HD>
ML;(6II8E2002WA\(_C9OOMM.Z]R[$JZO>4N8QVY,U14V8S--@LOE,.(UQ&5S
M>W*:OBP67R6,$,?V]354DLJ^*'4S^"'QKH=]NH(/IU<:*,H)1"ZJ]=2K(5+H
MK5.I58*=35'<U9#V'[Q/-W+6Q'EVTO%6T$4]O$[6MI)>6MM=ZC/!;7<D+75O
M#-K;Q(HI50ZWH!XCZC8>RCJ$NB%9S^67\+-Q[ZS6^LMU"9CN?=7]^=T[#BS.
M=BV?E,U9 <GD-GQ9%-N5-2YC5Y U'XII!Y)HY'9V81Q\V[A%&L:RT\-/#231
M'XR)4]JRZ/%49( #X':,8ZR9VW[X/N%M.VP[;!NFGZ:V^CMKTVEFVZ6UI5OT
M8MP:W-XB#40M)M2*=*,J@ &H'3O72]N4'>B;>$?9V,ZRGZ=H=P15-6L<>W*C
M)TN8EQZT"SC'<Y"CAD$W@\ZA/&LHB+(2<7TH@-MJ_3:192M!EU5E!K2N Y%*
MTSD5IU"W]?=V.Q/RV9Z[=)N";H\!CB+-?1V\EJLOBE/%_LIG4IK\,UU%2P!#
M-N3X_P#5.[-][L[,S6WJN7?&]NF7^/\ N+/TF2R=+)+M22LK<@V.BCIJR&&E
ME%9D9Y%K($CK5+@+4!40+9-QF2)8 W8DAF52JD"0A5)R"34(HH:KCAD]&&U>
MZ&][+MEML]O.HL[3=1O<$#06\BKN0BA@\5C)$S.OAP1J87+0D DQDLQ*ZV1L
M;:G7&R=J=<[+PU-@]E[)VU1[0VQ@H"\D=-CJ"FCI*6G#S-)+*(X(E4O(SNYN
MTC,Q)+%Q</=R-+(2SNQ9F/$LQJ2?M)Z#7,7,=[S9N-SNVX2M-=W=Q+=7$S4#
M23S2-*[T4*!5F)HH"C@H  '0+=2?$+X^]&;AVWNCJ_8T^V\SL_KO*=3[9F;+
M9FLBHMO9C<*[IKL7!35V0J::.G.:430VCU4T8%-3M%3 0^U]YO=U?JZ3/J#N
MDC]J M)&AC5B0H-=+&IKW$EFJV>I"YY]]N:?<BUN++>;P7$5U?6VY7 ^FM8F
MFOK6Q.W1S,\,$;E_IR4?NI(Q,D@:4Z^L?=7P^^/?R$W NZ>UMBSYW/ML6JZQ
MK<CC<MF<2];MZLKJ7)5&&R Q.0HEKZ!ZZCCE$50) C:PFE99 ^K'>;G;ET0O
MI'B+*!I4TD0,JL-0-" YR*>7H*6]O??CFGVMM?HMDO!##]9%N*(]M:W(BOH8
M98$N(OJ89C%*(Y675&5)&FM2JD#CNW9>UM];,W)U[NO"T>8V9N_;57L_<6WY
MP5@J<;74TE'54C",H5BEII6C]!4J#Z2" 0@@G>V=9(R596#*PP5934$?,$5Z
MCG8N8+WEK<+?=;&5XKNUN(KJ"=35X[B&194D!-:LKJ&S6IXUZ+7V1\%?C1VK
MM+J?:.[-E9FW1N&AV]U/N[!Y_/X[<N%HH:-<>*6#<U'DH<Y/3RTBA)8ZFJF2
M4@22*TJJX-;3F&[LGE>-U_7-94:.)HG.K6*QLACP<K11IR%H"1U+O*7WDN;^
M2;[<[ZQNXO\ =Q*T^YVLUE93[?=RM,9];6<UN]LK+(2R-'$A0$JI"DJ17Z-^
M/O3_ ,;MFOL/IG96/V;M^IR<N=RYADGJJW)9&=46?)97)5LM1D,GD)UC0/45
M,TLA540,$15"/<-SGW63Q+AR[ !5K0*JBM%50 JJ*FBJ !Y#H$>X_NCOWNWN
M W/F"[>[G6-88JA(XK>!"2L,$,2I%#$I8E8XD50232I)+_@>IMA;:[*[ [>P
MN$>D[![1Q&$P6^,Z:JKD%92[=2N3$1"EEG>CIOM5R50"T$4;RZ_WFD*)I:>\
MDDB2!C5(V=D6@PT@0,:TJ:^&O$D"F*5-2S<N>-SW?:++8KB;58[=+=SV</AQ
M*8I;XPF=M:H)'UFWCP[,%T]@6IJ4C?\ _+#^&/9N^]X]E;MZXW7/O#?V>DW/
MNS(8?>F]L7%5UTR1QR5!HL9N&DHHG9(D4B.)!90+<>SNUYLOK.)(4>/1&-*!
M[>WD*J6+4U21,U*L3D^?4Y\K_?&]P.3]LM=GL;^V%K90K;VR3;1M%RT4*LS!
M/$N+&61@"['N<FI/0N; ^&OQYZR/3;[0V;E*6;H'-;AW#U3593/;@R4V-J]U
M4$^-SDDDV1R=5+D!6451)&J5C5"4X(-.L3*I"&?>[FY,Q9E_75%E"QQH&6-E
M911$4+0H#V@$TS6IJ!>9_?[FKG#]ZB^NHV&]PV,&Y+%965NEQ%MTR7%L L%O
M&L7AR1JQ,(C,E*2%@2")>_ND^M.S-V]6;\WCMULAO'I7<T^[.M-QT=76T55C
M:NJI7HJQ1)15%/\ <T=;2.8JFDJ/+33J%\L3%%(26]]+:I)'&U%E4)(M 0RA
ME<<0:$,H((H1ZT)Z!_+/N'N_)]CN.V6$^BUW:W2VW"!HHI8[B*.59HS25'T2
M1R*&CECTR(:Z7%34KV\OY97POWWOS<'8.<ZIJX*_>6=&Y]\[;V_G]PXO;V>R
M(F%0]9F-NX_*4V&KY:B90]0)*<I5,6:I24NY8X@YLO[>-8UE!T+IC9HXGDC6
ME $D=&= /PZ6&G\-.IEV#[X/N#RUMD&UVVY*R6D/T]G<3V5C<WUE!H*".WNY
M[:2XB5%-(],@,0H(BE!1?]^]5Y7M7>7QLZPH-MO1=1[)[$IN[-_92D2*&@1=
MDB&;:FW(8XYX9%EK=QU-'7!(XG@%%AZJ&8H)H4E1;==BR2:75^HT9A09K28%
M9&RI!'AZD-2&U2*RUTF@7]LN=(>2K#?MXDG#;G=V,FT64;%GF)W?6E]=L61U
M*QVD<T!+.LGC7D3IJT.5'SLWK/97<6Q\WUQV)AVS^SMQ?;?QC$K4U5(9?M*R
MGKZ?_***:GJ8_'54L3^B1=6G2UT+*2^WN'M7$D9HPK0T!X@CS!' ]1ERAS?N
M'(>XP[MM4O@W4'B>%+X<<NGQ8GA;ME1T-4D894TK44(!#/\ Z$NKO]-/^S#_
M -T:'_3'_HY_T3?WV\D_F_@'\0_BGV'@\OVG_ [U^;Q?<:?VO+XO1[>^OF^G
M^EUGPO$\71^'Q-.C5]NG'2__ %Q-Y_J]_57ZI_W5]?\ O/Z2B:/K? ^F\75I
MU_V?;HU:*]VG5GI&[<^*O1.TY^D*G ;+DH9OCE7;AR/3SG)Y:7^$S;JIJRDS
MK,)JZ09#[V#(3J!6?<"'7J@$3*A5T[K<$2KJQ.JK+VKW!&5U'#%"@.*5IG%>
MC_=?>GF7>DW=+F[#C?4L8]T'T]LOU*;=)%+; :85\+PW@C-8?#+Z:/J!(*PW
M]TGUIV9NWJS?F\=NMD-X]*[FGW9UIN.CJZVBJL;5U5*]%6*)**HI_N:.MI',
M5325'EIIU"^6)BBD,V]]+:I)'&U%E4)(M 0RAE<<0:$,H((H1ZT)Z(>6?</=
M^3['<=LL)]%KNUNEMN$#112QW$4<JS1FDJ/HDCD4-'+'ID0UTN*FKA-U-L&H
M[9HN\:C!M/V;C>OY^K\;N&:IJV6GPM3D(LI4TL%$9S0125-;!$TM0L(J9%BC
MB:4Q(J"HNY!"8 ?TRXD*T&74%02:5P&( K05/J>DJ<[[G%L;\N+-3;Y+U-PD
M@$<8,EW' UNCM($\5@D;N%C+^&I=F"ZB3U@W7T[UWO7L+K#M3<6!>KW]TY)E
MGZ\W%35=;2RT2YVC6@RL$B4M1##74M;3QQZX*I)H?)'%*J"6-'7<-[+!%)"K
M4273K6@(.@ZE.0:$$FA%#0L*T8@N[+S[NO+VU;ALEI-ILMU%L+Z!HXI%F-G*
M9H&!D1VC>-V:DD11]+.A8HS*0^^0GQ,Z&^45)MJ/N/939O*[)K):_96[L'7Y
M##9S$2U 1:C^'YC$55%D*>*I6)!-")3#+H1I(V:-"JK;=YN=HU> ] X =&57
MC<#AJ1PRM2N"02/*G0I]K?>_F;V:>X.P7?@QW:JEW:S0P7=G=*A8IXMO=1S1
M.4+'0Y36E6"L Q!2NSO@O\7]B[-P>Q-O];LN#P?;..[R>;)9;,UM?DMU8B4S
MXW+9S)U60FR&<:CFTO%!733TJ&.(+ !%&%<N-_N[F0RL_<8VA[4156)@0555
M4*@()KI K5J_$:G._P#WD.<N9=PFW*ZO_P!:;;9]G CMK6&"#;;E=$T%M#%
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M0J:BLKYZFLJJBKKZR:9Y)I78E[ A0JAB[NY+Y_$E.IB%%: 810B@    *H
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M)?\ GE?_ *NP==0?[IG_ *>-N/\ XK=Y_P!W/9^M+?WDMU]"_6Y;_P )Q?\
MLD?N?_Q8VK_]YG;7O&KWE_Y*<7_/*G_5V;KY]_[VK_E?-J_Z4$/_ '<=QZIL
M_GT_]O#MX_\ B-=K_P#NO/N0_:'_ )))_P":\G_'8^N@']V+_P!.JMO^ECN/
M_5X=4R^Y2ZZ$=?2IWG_V1UNS_P 5HK__ 'EI?>#4']NO_-0?\>Z^0+E__E>[
M;_I?0_\ =P7K1M_E)_\ ;QCXL?\ A\U?_NDRGO*SW)_Y(ES]D7_5Z/KZ2?OU
M?].EYC_YY(?^TRVZO3_X4F_\R>^,?_B2LY_[JZ;W%7LQ_N=/_P T/^LB=<U?
M[HG_ )6'F#_I76G_ &DOU[_A-E_S)[Y.?^)*P?\ [JZGW[WG_P!SH/\ FA_U
MD?KW][M_RL/+_P#TKKO_ +24ZJO_ )]/_;P[>/\ XC7:_P#[KS['GM#_ ,DD
M_P#->3_CL?6:W]V+_P!.JMO^ECN/_5X=;4'\J?\ [=X_%/\ \1J/_=A7>X'Y
MS_Y*UW_S7D_X\>N*?WU_^GJ\R_\ 2Q;_ *LQ='-[/_YEKV'_ .&-EO\ W J/
M8<C^(?:/\/6/O*'_ "5K+_GKMO\ J\G7R^/>=O7V;=7-?R%O^WAVSO\ Q&NZ
M/_=>/<6^[W_))'_->/\ X[)USW_O.O\ IU5S_P!+';O^KQZN3_X4=?\ 9(_3
M'_BQM)_[S.Y?<>>S7_)3E_YY7_ZNP]<__P"Z5_Y7S=?^E!-_W<=NZTTO>2O7
MT$=;I'_"<S_LB3M+_P 6HS?_ +R6Q_>-/O)_R5(O^>5/^KL_7ST?WLW_ $\;
M;O\ Q6[/_NY[QUKV?SC_ /MY1\G_ /M=[?\ _>0V_P"Y;]L_^2);?\WO^K\O
M75#^[^_Z=!R]_P TK_\ [NM]UM0;@_[<<P?^,RL9_P"^VI/<#C_E9_\ J:?]
MK77%/;?_ !) _P#GPI__ "8).M5_^3A_V\H^,'_:[W!_[R&X/<\>YG_)$N?^
M;/\ U?BZ[6?W@/\ TZ#F'_FE8?\ =UL>K^/^%'7_ &2/TQ_XL;2?^\SN7W$O
MLU_R4Y?^>5_^KL/7+[^Z5_Y7S=?^E!-_W<=NZ*O_ ,)IO^/C^8/_ &I-C_\
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M.L*?[HG_ )6'F#_I76G_ &DOU[_A-E_S)[Y.?^)*P?\ [JZGW[WG_P!SH/\
MFA_UD?KW][M_RL/+_P#TKKO_ +24ZV5O<.]<A>OGK?S;/^WC'RG_ /#YI/\
MW28OWEO[;?\ )$MOLE_ZO2=?5)]Q7_ITO+G_ #R3?]IEST3+IC_F</5'_B2L
M%_[M*7V(]_\ ]P;G_FA-_P!6VZR"]Q?^5>W3_I77O_:-+U]#/^83_P!D*_+[
M_P 5RW?_ .Z.M]XB<J?\E2S_ .>J#_JZO7RI_=9_Z>5RM_TO]J_[38>OG!>\
MT>OK>ZOX_P"$YG_9;?:7_BJ^;_\ >MV/[B7WD_Y)<7_/4G_5J?KE]_>S?].Y
MV[_Q9+/_ +MF\=&-_P"%+/\ Q\?P^_[4F^/^M^U?9%[)\+S_ *A_^L_41_W/
M_P#N+S3_ ,U=G_XYN?1P_P#A.9_V1)VE_P"+49O_ -Y+8_L@]Y/^2I%_SRI_
MU=GZ@7^]F_Z>-MW_ (K=G_W<]XZU1/F)_P!E<?*;_P 6-WO_ .]-D_<\\K_\
MDRT_YY;?_JTG7;O[O_\ RH?+?_2@V?\ [MUOUOJ_./\ [=Y?)[_Q5?<O_O.5
M/O$SE;_DJVG_ #U0?]75Z^8S[MW_ $]3ES_Q9-N_[3XNM-+^3A_V\H^,'_:[
MW!_[R&X/>2ON9_R1+G_FS_U?BZ^@C^\!_P"G0<P_\TK#_NZV/7T"_>)77RW=
M:K__  IA_P"Y*?\ RH__ ,H7N>/9+_B;_P!0W_6?KM9_<]_\[;_U(?\ O-=:
MK_N>.NUG6^K_ "._^W:_1O\ VN]W_P#O7YOWB9[G?\ENY_YL_P#5B+KYC/[Q
M[_I[^\_\TMK_ .[59]::7SI_[+;^8W_BU'87_O6Y?WDKRK_R2[/_ )Y;?_JT
MG7T$?=K_ .G<\J_^*WL?_=LM>MTC^2A_V[)^-'_DY_\ OP-U^\:?<W_DN7/_
M #9_[1XNOGH_O$O^GQ\P?]2K_NR;;U:A[ ?6%/7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=('M#M#872^P
MMQ]G]G[CI=I;#VE2QUNX]QUL<\L5+%+/%31N\=-%/.RM/.B^E&MJN;*"0HM;
M62]D6*)2SL:*HXD^@Z$W)O)NY^X.YP;-LT#75[=,4@@0HK2,J-(0#(R+72C'
M+#A09ZSXWLG8N7ZXHNW<;N?&5?6F1V6G8E'O&-F^S?"240R29(,RAA3FA/FN
M5#!?JH/'O4EM)%(864APQ0H1W!P=)!'K7%/7IN[Y2W*PW9]BFMY%W".[-B]J
M1^JMVLW@&&@--?B#1QI7SZ+IN[Y^_#_876W6_;^[^[]OX/K;M[[[_1ONNJH\
MLT&5_ATHAK?"D>/>>/P2&W[L<>KZIJ'/LSM^7;Z[F>WBA=I(_P"T0"K+Y9'4
MK[#]V'GSF?=[_8;#:)YMPVOPOK[99+8/;>.NJ/46F"G4/X6:G T/2@Z)^:WQ
M5^3.9R.V^B^[]E=A[DQ6-;,UVW,9)/3Y!:-)8X9*M:&N@I:J6FBFFC225(V2
M-I(U=E,B:J[CR_?;0H>Y@EC4G2&="%+$$TKPK0$TK7!].BSW*^[SSM[/V\=W
MS+L]Y8V\L@B2>15> RE6<1^)$TB!V5&95+!F"L0#I-#1>R?J&>@QZG[FZN[S
MVY7;NZDWGB-];;QFY*W:-?E\,9/%'DL=((ZVE;RQQ-KA9EY *.K*Z,R,K%3=
M6<MBP2961BJL PH=+"H/V$&O0PYVY WGVXNTL=\M);.XD@ANDBETZF@G75&X
MTLPHP!\Z@@A@"".F_N_OSI[XW;#KNS>\-_87KS9-!.M&^7S'FD>:HD5WCI:.
MCI8JBNR%9(D;LM/30S3,J.RH0K$.[=MD^[S+!;(TDC<%7_"2:  >9) 'F>E?
MMS[8[_[M[FFS<N64U]>2 L(HM*A4! +R22,D<48+ &21T0$@%A4=)?X^?*WX
M_?*?#9K-]$=D8W?$&VJ_^%[FQOVU?C<GC:C5(@BR&)RU)09.CUO"X1I8%230
MQC9P"?;VZ;-=;*X2YC*%E#*:JRNI (*LA96&>()]#GHY]T_9/FCV6N(K;F6P
MDLVN$\6WD\2&XM[B.BG5%/;230R4#+J"2$K4:@">EQBNYNKLWVMNGH_%;SQ%
M=VQLK;=)N[=.R(3)]Y18VO95I*J6\8A*2F1.%=G421EU42(62-9RI$LY5A&S
M%5>G:66A(!]14=!N]Y WG;MDM^8Y[25-MNYY;6VO#I\*6>$$NB]VJJT/$ '2
MP!)4T;<7W[T_FNZ-R?'C&;ZQ53W3M#:\6]=P]?Z*E*RGQ4_V8CK=<D"TTT).
M0IP?%*[*95# &]KMM\Z0"Y*-X3/H$E.TN 3IKZT!-/ETLO/;'?MOY?@YJFLY
M5VFZN6M(+ZJ&)[E/%)CH'+JWZ,E-2@'2:$]3<QW9U9M_MC:'1F7WEC:/MG?N
M K-T[2V0R5#U59CZ!96JZM6CA>"*&(02<RR)K*,J!F!'NJ64LD33A28T959_
MPAFK0?::'I-8>WF];GLEUS)!:R/MEE-%;7-W5!%%/.5$<9JP9F;4N%5J @M0
M'HI2_P UG^7I_&7P$WRBV)192*O?&SQ9.GR])'%-&YC=)JBIQL5-"$=2"SR*
MH(Y;V=KR;NKH)%M9BI (*H34'((I6O4Y'[D_NH;<72\NWKQE!(IC:VE9D8!@
M52.=G:H(("J3\NC@97M[K7"[HZMV9D=W8N/<?=?\0/5=#3^6H3-C%8QLS7O1
MU-/'+2Z(<6IJ0SR(LD8O$7/'LBCM)95=U4E8P#(?X S!!7[6('VGJ!K'D7=]
MQLMQW"*UD,&T^!^\7.E#:?4W M8A(CLKU:8B.@4E6^(#IJ[L[XZD^.>R6['[
MKWI0["V3'E:?!R;@R,-7/"M55:_MXF6BIZF53+XV 8IIN "P) +EAM\VYR"&
MW1I'()"KDD 5/[!TN]O/;3?/=C<1M/+UH][>&-YA!&T:N8XZ:V!E>-3IU"HK
M6F:8/0 =5_S'OA+W;O\ V[U=U7W_ +8WCO[=DTU/M[;=!1YB.:J>GI9ZV94>
MIQL$"^.EII)#J=19"!<V!-+WE7<=NB::>WE1%IJ9EH!4A17[20.I0YU^Z9[B
M^W6US[UO>R7-I96P1I[B22V*1B21(EJ(YW;+R*N <GTZ./G<YB-L8/,[DS]?
M3XK [>Q51G,WE*LZ8J:DI(7J*FHE:QM'##&SL?P ?9"B%R% J2: #S)Z@+;=
MNGWBXBM+5&DFGD2&*-15I)9&"(JCU9F 'S/2!VSW9U9O+J.+OC:V\L;F^I)]
MK5>](=[4*5#4[8RA2=ZRJ$1A%5:G6FEUQ^+RAD9-&H6]J)K*6WE,$BE9 V@H
M<$-6E.A-O'MYO7+^^'EJ]M9(=S6XCM#:.4$@N)BBHE=6CN,BT;5IHP-:9ZSX
M'N/K+='4\'>>WMWXW,=3U6SYM^P;TH!,],V)IZ>2IGJQ&(ON?V887+QF/S*R
M-&8Q("OO4MI+!*8'4K(&T%#@AJTI]M>F]SY"WC9M[;EN[M9(MR6Z6R:T?2L@
MN7=8UCJ6T=S,*-JT$$,&TFO06=M?,[XQ=$[0Z[W[VUVUA=D[1[9QXRO7F;R5
M+DY(\G3FEI:T21+344\L5Z6MADTS+&UGM:ZL LL-DN]T=HK>)Y&3XU45*YIG
M\\=#3D;[OW./N7?WVV;%MDUY=;:_AWT,<D :W?Q)(J,9)4![XG6J%A4<:$5?
M.B/E=\<_DW3YF?H;M_9O9;;>6)\]0X&=A64:3EQ!)4T-3'!6PPS-&ZI(\01F
M5E5BRD"NY;-=[00+J&2+573K4J&I2M"<&E16G"H]>B[W*]DN;/9UXEYFVN[V
M_P ?4(7GC_2E*4U!)4+QLRA@64,2 02*$=*/LOOWI_IS<766U.S=]8K9^?[D
MW0NRNLZ#)I4G^+95I*6%**&6*"2&*9Y:V%%\SQJS2 *3S9BUV^>^5VA1G$2%
MY"HKH0<6/R'F?+HIY0]L=^Y^M=PO=GLY;J':K8W>X/&4_P 6M@LC&1@SJQ4+
M$Y.@,0%)(ZF]O]V=6=";5IM[=O;RQNQ]KUF?H]K4F5R25$BRY"O9DI*2*.EA
MGFDFG*-8*AL%9F(5216TLI;YM$*EV"LQ \E45)^P 5/2;D7V\WKW,O6V[8K6
M2\N%AEN6CC* K!  TDA,C(H5014D\2 *D@=!5WU\V_BQ\8-Q8;:??/<."ZXW
M#N'"_P!XL-C<M2Y.9JBB\\M-YT>BH:J(*)X'0@L&!6Y6Q!*W;=@O=X5FM87E
M"D!B@K0G.>AM[9?=VYT]Y+66]Y9VJ>_@@E\"62)X%"2Z%DTD2RQFNE@:@$9X
MUKTJ>B/E/\>/DY0YO(="]M[0[-BVT\";AIL!,XJJ'[H2FE:KHJB."LIXZGP2
MB)WB5)#%*J,3&X5O<MFN]G(%U#)%JKIUJ5#4I6A.#2HK3A4>O1+[E^RW-?L[
M)#%S/MEUMYN Y@:=!X<WAZ=8CD0O&Y36NL*Q*AE) #"HC=E=E;%Z>V+N3LSL
MS<E!M#8NT* 9+<>X\D)##2PF1(5=UA265R\LJ(JHC,S,JJI) ]H[:VDO9%BB
M4L[$!5 J23Y#H)\H\H[ESYN5OL^SV[W5Y=/X<$$>G7(^DM0:BJBBJ222  "2
M:=*3!9S$;GP>&W)@*^GRN!W#BJ?.83*4AU15-)5PI44U1$UA>.:&174_D$>V
MG0H2I%"#0@^1'13N6W3[/<2VETC1S02/#+&PHT<L;%'5AZJRD'YCHLWR*^<'
MQ9^*-?@\1WQVUC=F9W<=')D\3MRCH,OFLF]'"LKS5\F.P6/R=;38^)*>4FIF
MBC@/BD57+H5]G.T<N7N^ZOI8BX6@9BR(@+$ #5(RKJ)(HM=1\AU,'M1]W+G3
MWOCFGY9VR2[A@98Y9WFM;2W$KE56(37L]O&\K%U B1F?N4E0#7H>.N>R-A]N
M[,P78G66[,+O?9&YJ7[W![EV_,L]-4(&9&TL.5DCD5DDC<+)&ZLCJK*0"NYM
MI+.1HI59'4T96!# _,'J-.:^4MSY&W";:MXMIK2[MVT36\Z%)(VH"*@\0005
M855@05)!!Z9^I^YNKN\]N5V[NI-YXC?6V\9N2MVC7Y?#&3Q1Y+'2".MI6\L<
M3:X69>0"CJRNC,C*QM=6<MBP2961BJL PH=+"H/V$&O2[G;D#>?;B[2QWRTE
ML[B2"&Z2*73J:"==4;C2S"C 'SJ""& ((Z;>O._>G^U]Y=H]?=>[ZQ6YMZ=+
M9R+;G:.W:1*F.HP]9.]7'##4"H@A5Q*]#.%>(R1DQ-9_I>]QM\]I''+(C*DH
M)C8CM<+0&A\Z5%?2O2SFKVQW[DG;]NW7=;.6WM-VA:?;IV*&.ZB01EF0H[4T
MB9"58*PU#'4+(_([I+%;Z[#ZSKNP,5#OKJ?KQNUNQ=N)%5R38G;ZQK,<C4M'
M3O$5\3JXB1WG96#"(@@^_#;YC&DNAM#N8T;R9Q2H'S%1T_:^U',5[MMCO$=E
M*;/<K[]VV,Y:-4N;W45\)-3AJZ@06(" @@M7HNFS_P":+\ =][DQ&T=M?*#K
MVIS^>KHL9B*3(C(X^.:HGD6*&$5.1H:2E6261U5 TBEB0!?V<7')^Z6J&22U
MF"J"6.@D  5)-*X XGRZEC?ON9^Z'+-G+?WG+M^L$*-)*Z>#.4C12S,4@ED>
MB@$DA30#/1NL#VAL+<^_>P.L,#N.ER._.K*7#5N_]N1QSK+C8MP05-3AWEDD
MB2"1:Z"CF9/$\FGQL)-#6!(WM9(XUE92$<L$;R8I34!]FH5^T=05N?)NY[/M
MEEO-S R66XM=)93DH5G:R>..X"@,6!C:5 =2K74"M1T#/??S5^+OQ?SF"VWW
MWV[A.M\UN7%/G,%0Y>ER<QJ:6.9H'EC>BH:J*R2J5*E@PX)6Q!*_;-AO-Y#&
MUA>4*0&T"M":TK]M.I ]L?N]<Y^\MO-=\L;7-?Q6\@AF>*2!?#D90X4B66,Y
M4U! (^=0>I_0'S!^-GRFJ-TTO0/:V%[*J-E0T=1NB/$4^0@-&E>U2M&TAKJ.
ME#>=J28#1J(T'5;B]=SV.\V;3]5$\6NNG6*:M-*T^S4/V])O=#V&YN]EUMGY
MHVV;;Q=F5;8RO"WBF$1F2GA2R4T^*E:T^(4KGH1^V.YNKNC-N4.[NV]YXC8N
MV\GN2BVC09?,F3Q29+(R&.BI5\4<K:YF5N2 B*K.[*BLP1VMG+?,4A5G8*S$
M**G2HJ3]@ KT$N2>0-Y]Q[M['8[26\N(X)KIXHM.I8(%U2.=3***"/.I) 4$
MD#IP[0[0V%TOL+<?9_9^XZ7:6P]I4L=;N/<=;'/+%2Q2SQ4T;O'313SLK3SH
MOI1K:KFR@D:M;62]D6*)2SL:*HXD^@Z2\F\F[G[@[G!LVS0-=7MTQ2"!"BM(
MRHTA ,C(M=*,<L.%!GK'N_M;KS8?7L_:^ZMTT&-Z[IZ&BR<FZXUFJ:8T^2FI
MJ>AFC^TCGEECJ9:N$(R(P(D#&RW(K%;O,_AJ"6SCSQD_X.K;%R7NG,NZ#9;*
MW>2^9Y8Q;$K')K@1WD4^(R!2BQ.2"1\)'''1=^X/Y@_PVZ!W_D>KNX>]MM;$
MW[B:>EJ\CMW*TN6>2**M@CJ:61I:;'STY66"56!$AL#9K$$ VL.6K_=(_&MX
M))$J1J1:BHXC[>I7Y"^ZUS_[H;6F\[!LUQ>V4C2*D\4EN%9HG*. 'F1ZJRD4
MTY\J@CHQG67:?7'<^S<5V'U1O7;G8&R<UY!C-R[6JHZNED:%VBFBUQD^.>"5
M2DL3A9(W!5U5@1[++NSEL)#%.C1NM*HZE6%145!H<@U'J,]1/SAR7NWM_N$F
MU;W:7%C=PZ?$M[F-HI5#*&4T8"JLI#*PJK @J2.D[GN_>G]K]P[*Z!W!OK%8
MKN#L;!U.X]D;'JDJ149*CHTK):F:GE$!I"88Z"H8HTJR:8F(0BU[Q[?/-"]P
MB,8HRH=P*JA8T%3Y5)H/GT:[9[8[]O.PW?,]K9RR[7831P7EXI0QV\LIB5%<
M:]?<9HP&"E:L!7J;V!W9U9U7N'K;:G8&\L;MK<?;^Z1LOK7#U:5$DV6R9$9-
M+3K!#*%*^5-4DA2)-:ZG&H>ZP64MTKO&I98UUN1P5:@5/YFG2;E?V\WKG2UO
M[W:[62X@VNW^KOY5*!+:WJ1K<NRUKI-%6K&AH#3HLF^OYFWP3ZSWMN7KG?GR
M*VIMK>NSLY/MO<V!KZ/-&2CK::0Q3P221XQX"8W!!979".0Q'/LXM>4]ROHU
MFAMI71A565:@CY=3%RU]SWW*YQVZWW;;-BNKBTNH4GMYDDM=,L3C4K -.&R/
M(@'RI7HVO6W9O7W<.R\+V+U;O';^_=C;BBDEPNZ-L5,=523^&5Z>=%EC)"RT
M]1$\4L;6DBE1XY%5U9037=G+82&*=&C=::D=2K"H!%0:'(((]0:]0=S=R?NG
M(6X3;3O5K/97D!436UQ&T4J:E5U)5@.UD971A565@RDJ0>FK??<W5W66X^M]
MH[]WGB-L;D[>W(^T>ML1D3)Y<ODDC61J6FT1NH<*Z<R%$+.B!M;HI]!9RW*N
M\:LRQKJ<@5"K4"I^52!TLY;Y WGG"TO[[;+26XM]L@%U?RQZ=-M 6*AWJP-*
M@_"": FE%) G>TW0/Z(]N_\ F2_"#87;,_26[/D%M7$]@T.9CVYEJ8TN6FQ=
M!D9?,(\?DMPT^/EV_CJTFGE#0U-;%)&T;I(J/92(K?E/<;JW^JC@8QT+ U74
MRKI!94+!V4:A5E4J/7CUD;L/W1_<;F;8AS'8[)<RV+Q-/&WB6RW$T":-4L-J
M\ZW4T8\1#KCA92&!4D5(.3FMP87;N RVZ<WDJ3';=P6'GW!E\Q4-^Q!14L+U
M-14NXN/%% C.6%_2"1[#ZH7(4"I)H!YDGJ -OVRXW6YCL[>-I)YI4ABB4=[R
MR.$5 /XF8A0/4](3;/=G5F\NHXN^-K;RQN;ZDGVM5[TAWM0I4-3MC*%)WK*H
M1&$55J=::77'XO*&1DT:A;VHFLI;>4P2*5D#:"AP0U:4Z$N\>WF]<O[X>6KV
MUDAW-;B.T-HY02"XF**B5U:.XR+1M6FC UIGJ;U-VWUQWIL# =I=2[LQN^-@
M;H6H;!;FQ0E6&H^TJIZ&I 2>.&9&@JZ:6)U=%8,AXM8^_7ME-MTK0SHR.M-2
ML*$5 (Q\P01\CTQSQR-NWMMNDVR[Y;26=[;Z/&MY=.M/%C29,HS*0R2*P()!
M!'0(Y3YU?$S"]59'N_)=U;=@ZHQ/8<W5-?O9:;)R4B;@@1I)<<!%0O-(RHA/
ME1&@;Z+*20/:R+8;R:86ZPN9602! .XH1J!IZ4S]G4B67W;>>-QWN/ER':;A
MMREL5W)+/7 LILG("R]TP4 U':2''FHZY]'?.CXC_)+<L^S.DN]ME;\W;3T,
MF3.VJ-JFEKI*>'1YIH*7(4])-4QPAP9#$KA ;M8 D7W'EV^VA0]S!+&I- S*
M0M37%>%<''6O<?[MW/7M'9KN',>S7EE;,ZQ_4.J20B1ZZ59X7D5"VDZ0Q%?*
MO0Y]8]H;"[EV5BNQ>LMQTN[-EYNJKJ+%YZCCGBCEEQF0JL57H(ZF*"=6ILA0
MSPMJ07:,E;J0Q+KFUDLG\.52K *:'C1E#*?S5@1\CU&W.')NY\@;A)M6\0-;
M7<2PO)"Y1F5;B".YB-8V=2'BF1Q0G#"M#4=%2["_F8_!?JG>VYNN.P_D/M?:
M^]MG963![EV_7T.;::DJHK:XG:'&2Q,1<$,CLK @JQ!O[.;/E/<K^-9H;>5T
M855E6H(K3'YCJ;>5?N@>Y/.^W6^[;5L5S<V=U&)K>=);4)+&W!@&N%8<.! (
M.".C/=/]R]9=^[ P_:/4&[:'?&P<_-54^'W)CHZF*&=Z*JEHJI52KAIYQX:J
M"2,ZD )4D7%B2F^L9MME,,Z,CK34K"A%0&%?M!!ZASGSD#>/;'=)=EWZV>SO
M8!&TMO(49T$L:RI4QLZ]R.K"A.#G/76^^YNKNLMQ];[1W[O/$;8W)V]N1]H]
M;8C(F3RY?))&LC4M-HC=0X5TYD*(6=$#:W136"SEN5=XU9EC74Y J%6H%3\J
MD#KW+?(&\\X6E_?;9:2W%OMD NK^6/3IMH"Q4.]6!I4'X030$THI(Y;T[CZR
MZ[W=UKL3>V[\;MS=?<&8JMO];8C("8'+5M% E344L$JQ-!',L,BE5E>,R,P2
M+6Y"^_0VDMPCR(I98P&<C@H)"@GY5('6N7^0MXYJL;_<MNM9)[;:XHY[^5-)
M%M#,YC1V4L&*E@02JMI ):@ST\9SL/9FV]X;'V#F\Y!0;O[)_B?]R,*\<[/7
M_P 'I4K<EXY(XGAB^UI9%D;RO'J!LFIN/;:0LZLX%0M-1]-1H/V](-NY6O\
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M;?\ -[_J_+UU0_N_O^G0<O?\TK__ +NM]UM0;@_[<<P?^,RL9_[[:D]P./\
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MZ;V"/9C_ '.G_P":'_61.L0/[HG_ )6'F#_I76G_ &DOTI?^$WO_ &3=W_\
M^)OA_P#=#C_;7O+_ ,E*'_GF7_J[+T4?WN'_ "N&R_\ 2G;_ +3;CK7B_F@?
M]O!/EC_XEZO_ .A(?<O^WG_)%M?](W_5Q^NK'W,/^G6<M?\ 2LB_X\_6\E_W
M(3_Y:'_\IGO%/_B5_P W?^?^OFV_\&5_XTW_ 'E>M&W^5_\ ]O!/B=_XEZ@_
MZ$F]Y6>X?_)%NO\ 2+_U<3KZ2?OG_P#3K.9?^E9+_P >3KZ)WO$/KY1.M<[_
M (4A?]DW= ?^)OF_]T.0]R[[-?\ )2F_YYF_ZNQ==8_[H_\ Y7#>O^E.O_:;
M;]:>'O)/KOKUO)?R!_\ MWWBO_$O;F_Z'H_>*?NG_P EJ7_21?\ 5M>OFV_O
M/_\ IZ<W_2LV_P#X[)UK1?SC_P#MY1\G_P#M=[?_ />0V_[G'VS_ .2);?\
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MVO[B;WD_Y)<?_/4G_5J;KF;_ 'K?_3M;7_I?V7_:%N75AO\ PI-_YD]\8_\
MQ)6<_P#=73>P5[,?[G3_ /-#_K(G6*?]T3_RL/,'_2NM/^TE^M17WD=UW>ZW
MM_Y$G_;N?K?_ ,/G=?\ [NZGWB=[G_\ );N/LA_ZLQ]?,_\ WEO_ $]K</\
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MJ?\ 5V?J!?[V;_IXVW?^*W9_]W/>.M43YB?]E<?*;_Q8W>__ +TV3]SSRO\
M\DRT_P">6W_ZM)UV[^[_ /\ *A\M_P#2@V?_ +MUOUOJ_./_ +=Y?)[_ ,57
MW+_[SE3[Q,Y6_P"2K:?\]4'_ %=7KYC/NW?]/4Y<_P#%DV[_ +3XNM-+^3A_
MV\H^,'_:[W!_[R&X/>2ON9_R1+G_ )L_]7XNOH(_O ?^G0<P_P#-*P_[NMCU
M] OWB5U\MW6J_P#\*8?^Y*?_ "H__P H7N>/9+_B;_U#?]9^NUG]SW_SMO\
MU(?^\UUJO^YXZ[6=;ZO\CO\ [=K]&_\ :[W?_P"]?F_>)GN=_P ENY_YL_\
M5B+KYC/[Q[_I[^\_\TMK_P"[59]::7SI_P"RV_F-_P"+4=A?^];E_>2O*O\
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M<&$0L9QNNY1*P?1+X$021SH+F(WRE/UO_-%WK\CUC$,6W^WNKOCUONN7R?\
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MR,61VD>T:@!5EC#/,NKU#+%6G$-QH<C_ .ZIRO>>R._;I;76J.[NMXO.5 0
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M<M'$\BBV"FVK5$:A_5G-,GM1M/PDY<_=AY1Y@Y/Y8Y>:SVO<[RQYJWN\_?\
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M+N/W[KW1 /?NO=>]^Z]U[W[KW7O?NO=>]^Z]U]?K_A+C_P!N*/@S_P"5-_\
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M1?\ JXG7TD_?/_Z=9S+_ -*R7_CR=?1.]XA]?*)UKG?\*0O^R;N@/_$WS?\
MNAR'N7?9K_DI3?\ /,W_ %=BZZQ_W1__ "N&]?\ 2G7_ +3;?K3P]Y)]=]>M
MY+^0/_V[[Q7_ (E[<W_0]'[Q3]T_^2U+_I(O^K:]?-M_>?\ _3TYO^E9M_\
MQV3K6B_G'_\ ;RCY/_\ :[V__P"\AM_W./MG_P D2V_YO?\ 5^7KL%_=_?\
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M]+_=?^TV;I[^=/\ V1)\QO\ Q5?L+_WDLO[URK_R5+/_ )ZK?_JZG2#[M?\
MT\;E7_Q9-C_[N=KU\V?WFEU]=O5[O_">+_LNK=G_ (KEG_\ W>;7]Q-[R?\
M)+C_ .>I/^K4W7,W^];_ .G:VO\ TO[+_M"W+JPW_A2;_P R>^,?_B2LY_[J
MZ;V"O9C_ '.G_P":'_61.L4_[HG_ )6'F#_I76G_ &DOUJ*^\CNN[W6]O_(D
M_P"W<_6__A\[K_\ =W4^\3O<_P#Y+=Q]D/\ U9CZ^9_^\M_Z>UN'_/)MO_:'
M%UJ=?S0/^W@GRQ_\2]7_ /0D/N??;S_DBVO^D;_JX_7</[F'_3K.6O\ I61?
M\>?K</\ YA'_ &ZF[I_\5\Q/^]XGWC9RA_R6+7_GH3_CW7 K[J__ $^S:/\
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M_9;?S&_\6H["_P#>MR_O)7E7_DEV?_/+;_\ 5I.OH(^[7_T[GE7_ ,5O8_\
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MN#:LMZS$5M(*6FJ89\[MS*KJI_N%C$M+/-3_ ',2Z;H;;<H_HI;28,>Y98&
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M++(DXF5ABFE: @UK4$5X?GU?ECW<3E+E:TVVS\=-RL^9X-^AF4*L*I;V:Q(
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MV*Q51D*67+,D"23) -"&7R6.LTW+<MGW*7ZF07;/X<*F(+#&A,44<7]IKD8
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M8SWEGS1_R3+O_GEN/^K3]?3G]X#_ )4/F3_I0;Q_W;KCKZ6?O"SKY ^J!_\
MA1G_ -D2=6_^+483_P!Y+?'N6O9O_DJ2_P#/*_\ U=@ZZ@_W3/\ T\;<?_%;
MO/\ NY[/UI;^\ENOH7ZW+?\ A.+_ -DC]S_^+&U?_O,[:]XU>\O_ "4XO^>5
M/^KLW7S[_P![5_ROFU?]*"'_ +N.X]4V?SZ?^WAV\?\ Q&NU_P#W7GW(?M#_
M ,DD_P#->3_CL?70#^[%_P"G56W_ $L=Q_ZO#JF7W*770CKZ5.\_^R.MV?\
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M8>N?_P#=*_\ *^;K_P!*";_NX[=UII>\E>OH(ZW2/^$YG_9$G:7_ (M1F_\
MWDMC^\:?>3_DJ1?\\J?]79^OGH_O9O\ IXVW?^*W9_\ =SWCK7L_G'_]O*/D
M_P#]KO;_ /[R&W_<M^V?_)$MO^;W_5^7KJA_=_?].@Y>_P":5_\ ]W6^ZVH-
MP?\ ;CF#_P 9E8S_ -]M2>X''_*S_P#4T_[6NN*>V_\ B2!_\^%/_P"3!)UJ
MO_R</^WE'Q@_[7>X/_>0W![GCW,_Y(ES_P V?^K\77:S^\!_Z=!S#_S2L/\
MNZV/5_'_  HZ_P"R1^F/_%C:3_WF=R^XE]FO^2G+_P \K_\ 5V'KE]_=*_\
M*^;K_P!*";_NX[=T5?\ X33?\?'\P?\ M2;'_P"M^ZO9][V<+/\ ZB/^L'4U
M_P!\!_N+RM_S5WC_ (YMG6UW[@;KB)UH'_SK_P#MYM\E_P#R3/\ WW^U/>6G
MME_R0[;_ )O?]I$O7U!?W=O_ $YSE_\ ZFO_ '>]RZJO]CSK-;KZ8_;O_9,/
M9_\ X@;-?^\]4^\&+7^V3_3K_P >'7QW\B_\K?M__2XM/^TV/KYG'O.?K[$.
MKO\ _A/S_P!E]/\ ^(0W'_[D8GW%'O%_R2T_YZ8_^K<O7.#^],_Z=@O_ $N+
M#_JU==65_P#"DW_F3WQC_P#$E9S_ -U=-[!'LQ_N=/\ \T/^LB=8@?W1/_*P
M\P?]*ZT_[27Z4O\ PF]_[)N[_P#_ !-\/_NAQ_MKWE_Y*4/_ #S+_P!79>BC
M^]P_Y7#9?^E.W_:;<=:\7\T#_MX)\L?_ !+U?_T)#[E_V\_Y(MK_ *1O^KC]
M=6/N8?\ 3K.6O^E9%_QY^MY+_N0G_P M#_\ E,]XI_\ $K_F[_S_ -?-M_X,
MK_QIO^\KUHV_RO\ _MX)\3O_ !+U!_T)-[RL]P_^2+=?Z1?^KB=?23]\_P#Z
M=9S+_P!*R7_CR=?1.]XA]?*)UKG?\*0O^R;N@/\ Q-\W_NAR'N7?9K_DI3?\
M\S?]78NNL?\ ='_\KAO7_2G7_M-M^M/#WDGUWUZWDOY _P#V[[Q7_B7MS?\
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M_5V;J%/[VK_E?-J_Z4$/_=QW'J@?^<?_ -O*/D__ -KO;_\ [R&W_<M>V?\
MR1+;_F]_U?EZZ@_W?W_3H.7O^:5__P!W6^ZW2/Y>W_9"OQ!_\5RVA_[HZ+WC
M3S7_ ,E2\_YZI_\ JZW7ST?>F_Z>5S3_ -+_ '7_ +39NGOYT_\ 9$GS&_\
M%5^PO_>2R_O7*O\ R5+/_GJM_P#JZG2#[M?_ $\;E7_Q9-C_ .[G:]?-G]YI
M=?7;U>[_ ,)XO^RZMV?^*Y9__P!WFU_<3>\G_)+C_P">I/\ JU-US-_O6_\
MIVMK_P!+^R_[0MRZL-_X4F_\R>^,?_B2LY_[JZ;V"O9C_<Z?_FA_UD3K%/\
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ML;7;+2.6]E&X7=M:6]S+"42&WU7+HLA>65&:$$L\228TAB"^?"G^47\5>O\
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M_NY[/UI;^\ENOH7ZW+?^$XO_ &2/W/\ ^+&U?_O,[:]XU>\O_)3B_P">5/\
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M3?\ F3WQC_\ $E9S_P!U=-[!'LQ_N=/_ ,T/^LB=8@?W1/\ RL/,'_2NM/\
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M_P"2U+_I(O\ JVO7S;?WG_\ T].;_I6;?_QV3K6B_G'_ /;RCY/_ /:[V_\
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M7_$W_J&_ZS]=K/[GO_G;?^I#_P!YKK5?]SQUVLZWU?Y'?_;M?HW_ +7>[_\
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M LS$*JJ"2230  9))P ./6I/M7-]G[J^=/;?8O\ )2P>[:W;F9RU3%\CLKV
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M()86S4D$A% 3^D0_ 5]!T,]X]E=M@]UOZIQ.Z;/)N4<\=P2[,O+\T:[DL]2
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MN^\D['NUMO?,G,-C<[M:;#:VMP=HM+A[1[Y[N\2U'BSQ1R2PVT(+/,\2ZQ5
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M$;C<QPL2%9AK8"NB,=SM0>2H"Q^0Z ?LCR"GN?S9MFR3L4M[BY4WDB@UAL(
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M&\-A:V^X7<;1@E&86BW,BD@'L-&J%4O_ ,P?D_VYUE\I?AGTOU7/C:3;&_\
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M7;@HH\C1QU$]%58^0ST4Q$<ZFFK) %8V#$-]1[]U[J_#_H+I_G,?\_#Z*_\
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MZ]_PFR_YD]\G/_$E8/\ ]U=3[][S_P"YT'_-#_K(_7O[W;_E8>7_ /I77?\
MVDIU5?\ SZ?^WAV\?_$:[7_]UY]CSVA_Y))_YKR?\=CZS6_NQ?\ IU5M_P!+
M'<?^KPZVH/Y4_P#V[Q^*?_B-1_[L*[W _.?_ "5KO_FO)_QX]<4_OK_]/5YE
M_P"EBW_5F+HYO9__ #+7L/\ \,;+?^X%1[#D?Q#[1_AZQ]Y0_P"2M9?\]=M_
MU>3KY?'O.WK[-NKFOY"W_;P[9W_B-=T?^Z\>XM]WO^22/^:\?_'9.N>_]YU_
MTZJY_P"ECMW_ %>/5R?_  HZ_P"R1^F/_%C:3_WF=R^X\]FO^2G+_P \K_\
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M#*_\:;_O*]:-O\K_ /[>"?$[_P 2]0?]"3>\K/</_DBW7^D7_JXG7TD_?/\
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M_NY[QUJB?,3_ +*X^4W_ (L;O?\ ]Z;)^YYY7_Y)EI_SRV__ %:3KMW]W_\
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M/^I5_P!V3;>K4/8#ZPIZ][]U[KWOW7NO>_=>ZTLO^%,__;TW_A.[_P"+7_\
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M 'IL9[RSYH_Y)EW_ ,\MQ_U:?KZ<_O ?\J'S)_TH-X_[MUQU]+/WA9U\@?5
M_P#PHS_[(DZM_P#%J,)_[R6^/<M>S?\ R5)?^>5_^KL'74'^Z9_Z>-N/_BMW
MG_=SV?K2W]Y+=?0OUN6_\)Q?^R1^Y_\ Q8VK_P#>9VU[QJ]Y?^2G%_SRI_U=
MFZ^??^]J_P"5\VK_ *4$/_=QW'JFS^?3_P!O#MX_^(UVO_[KS[D/VA_Y))_Y
MKR?\=CZZ ?W8O_3JK;_I8[C_ -7AU3+[E+KH1U]*G>?_ &1UNS_Q6BO_ />6
ME]X-0?VZ_P#-0?\ 'NOD"Y?_ .5[MO\ I?0_]W!>M&W^4G_V\8^+'_A\U?\
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M .XO-/\ S5V?_CFY]&H_X3B_]DC]S_\ BQM7_P"\SMKV0^\O_)3B_P">5/\
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MKE]_>S?].YV[_P 62S_[MF\=&-_X4L_\?'\/O^U)OC_K?M7V1>R?"\_ZA_\
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MQ>-JNY[2]N;>6Y;6TE9GBD5I#J=FJY)U,3Q)Z4/7/4O5?3V&EV[U-UKL+K'
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MV^B0$.HC60*%<$ZU "M4Z@:GH7?[G;2_O>>P?[L8#^_9VW_<[^^?VD'\4_A
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M88MYVZ26662PG1$1$N2SN[$*JJ"S,0 "3U]!WWB-U\L75(W\^SJCM+N+X?\
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M&5-*$<.JF/\ 9%OFW_WAS\J/_1>[M_\ K1[DC^M6U_\ *9:_]E$7_0?6<_\
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MF_V%EL]O%-<V\;KXM4>:-&%9Y"*AF!%001\C7KZ,ON'^]_)?)_M3L>W;MO\
MLEE=P_O/Q;6[W6QMKB+Q-XW"5-<4TZ.NI'5UU*-2,K"H(/5;/^R+?-O_ +PY
M^5'_ *+W=O\ ]:/8T_K5M?\ RF6O_91%_P!!]9=_\$I[<_\ 35<M_P#<\VS_
M +:NOH7=HXK*9#XZ]BX2@QM?79JNZ5R^*HL11PR2U4U5+@JB&.FBIT5I9*B2
M5@BQJI=G(4 DV]X:V[!95)X:U-?S'7RH\F7D-KS38W$LB)$FZVLCRLRK&L:W
M:,79B0H4**EB: 9)IU\]'_9%OFW_ -X<_*C_ -%[NW_ZT>\ROZU;7_RF6O\
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MMKJZMV#NN*&&&+)4SRRRROB52.*-%+,S$*J@DD >S_>^9MMELKA5N[8L890
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-Z]U[W[KW7O?NO=?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>tproxy_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tproxy_002.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     ! !+     $  0$L     0 !_^X $T%D;V)E &0      04  DE$_]L
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MO_OW7NO>_=>Z][]U[KWOW7NJFOYXOQ6^0WS2_E@_)[XZ_%O*2TO<F]L#C*O
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M<;1[SRG2G=6>J]Q;3W?M^IG,;I54JY7)X;(4U0:26F-913"NH9DE2&IIJA&
M]U[KZ&/\P7YN4_R,_P"$]G>?SH^-F[MX]<2]F?%*C[,V7GMK9.?'9[;F1ER&
M.@R./3*8N>*:FRF$R*56/J)*:8#S02A'*$$^Z]U\V_XQ=@?SK_YB6Z,Y\>/C
M9WY\Z?D;FI\2N[=T[/B[*W*]!3T-$S0I592OSFXJ7%4%+YJOQH*FIB2>=HD5
M9)EB"^Z]T;W^4+_-'^=O\NO^9AUKTQW%VIVUE^O\U\B*3XV?*+H;MG<-=D:"
M@FJ<Z-K9:M$.0J:ZFQ^=VID)'J5GIFB,[4C44U1]K/(1[KW7URO?NO=>]^Z]
MUH\?\+?/^R9O@M_XG7='_O/TGOW7NC__ /"07_MSGMG_ ,6*WU_UOQ_OW7NJ
M>_\ A8Q\JOE!\?/E%\/\-T)\D.^ND,1N'H/,9//XKJ#>&X=M4U=4Q;BDBBJ*
MR#"Y&BBJ9XXO0LDBLRKZ00./?NO=;'/Q'^;^.^+?_"?SH'YU_(K=.XM^S=;_
M  DP?96[<UN[*O4YC<N<J*.&FQF/FRV5GDEJ,ON3.U=+00RSRN\E551@EV8
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MMV__ .ZFD]^Z]U\GK^3I_P!Q(G1G_BX_87_N'O'W[KW5J/\ PMV_[*T^$_\
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MP_<?84D-+Y_#Y)?%Y?%JT:WTWTZFM<^Z]TJ??NO=:F'Q@_X2Y_[+?_-&P_\
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MF3;(_=_=?WTVO]IX]7C\7BGU?K\B_I]^Z]T?+_AL[_L4+_PU3_IK_P"Y4O\
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M_P#C_P#I#QOF^Z_A-_/_  Y/%Y;>&31=_=>ZVZ_?NO=>]^Z]U1Y_.^_DS?\
M#RG6?1?77^S(?[+C_H6WWE-Z_P 8_N?_ 'O_ (E_$L?%0_;?;_WIVO\ 9^'Q
M:_)Y9]=]/C6VH^Z]T/\ _*"_EL_\-3?#G&?$O_3/_IY_AW8N=W__ '__ +N_
MW6U_QJ2G?[3^%?QW<6G[;P6\OWA\FJ_C2W/NO=$ _G=_\)\O^'D>VND^TO\
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MY/A34=R_/+HF/HWM6#MC+;5VJL.$RFVX]R;;IZ/&55%GX\%EY9ZRC3[VMJZ
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MK95%XJ*&HD4ZE'OW7NM !?YIG_"FIOC=)_-W/:3I\+T[5^R6!J'8G]W'A_O
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M/^6^(%/N&J^4%/TOUW%T5#M2BH,CD#N2?)[E@QK4U'E*6MQTK)-*&8U,1@1
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MX&_(/?>[*G%;QH-K]?=<;>VUL%(X*:+:V$RF8KZO+9';AGQN/5Y:JIGJ9:^
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M]BU.M*P6=JF.L!S) 0C^'@UX)I+3>_=>ZI=SFV\[@/\ A';M:MS%/XJ+=?\
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M\)H=P_S8/F(ORJQWS P?2%-%U#ANL(]C9'8U3N%S)B)<I,*TY"'=N$"B9\B
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MA,/MK;F*Q^"V]M[%4^#P6$Q,*4]+1T5)"E/2TM-!$JQ04]/!&L<<: *B*%4
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M7S4$6%&%RF:RV4R51DW/@CH*;',WIL @<L2;6]U[JEGL#_A;+D*+L3>J]5?
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M3^%EH*+)J7K]X;?Q^<J319)EH9?L-M561JKSZHX_#Y6231XV]U[K5)_EW?\
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M-@C05R23->9JTH%58M3^Z]UM?^_=>Z][]U[KWOW7NO>_=>Z][]U[K6!_DO\
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ME FVL/E\B\V:S& -514,7FJ)):RJR5.*?R"U5$ B'W7NCS=H?)[^>?\ !O\
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M5N<JM"UNX<=5X[*8VKH:O)1F=J^G99155-0]0*B%=<$GNO=6+_R5?Y&'3/\
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M,K-2[=J:C$[LVD]-E\I1M.F.DGQD!E,57,I>FB>8)(D<LH;W7NMN+I;^9?\
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M1_:1!3Y=3*I60NK.&]U[I ;2_E\_"C9/QTJ_B-@OC5U8_P 9JW--N.?I/<%
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M79?=GQ^^/^R.K>U>X_NCV?O?;GWGWN:-;D?XM5-6M45<\;M/DB:AB%4^0FQ
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MT6]MR?&W9N"GH8=MUB;4J*W#+0[J-9B*O)R563S^#KZ6&6AGIH:&,T\[Q9!
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M:TU4S+4QN(/VZJ4GW7NKFO\ A057]@Y'_A/;_)9D[6HMWXWL2CK]L87==!V
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MNPR^"VWO#MNAW!DL;^Y!33TF-7#54$\B71)8<O&].Z,0PFC=2-2&WNO=8O\
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MLNQ-PUOD\..W/AJRFS>VZRH,1$OV:9K'4ZU:I=GI'GCLVO2?=>Z^<)UQW?\
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MR2(LT8=2R$AE# D"X]^Z]T]>_=>Z][]U[KWOW7NFC/9_ [6P^0W#N?-XC;F
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M)!-+&\D*R2"-E#O?W7NM[[W[KW7O?NO=%A^0'S7^('Q1R6V</\F_DYT3\?\
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MKV=4"1L=LC96Z,76Y"N$4#U;MC88Z@G)H*2)Z@-2F8-3H\ZDQ(SCW7NM+?\
MX4O_ #?V#N'^;/\ RXNLML?)2CR'4_QT[2VSF/D5L'%YZ;^!;8W-BNPZ6:MK
M-QXQ)A14^6H,+$&,\T9EBI;Z'",U_=>ZWJ_CE\J?CC\O-D97LKXP]T=?=Z;!
MPFZI]CY?=O6^0AR5#3YBFI*&OJ,=+/"2B5<-%DZ69HSR(ZB)OHP]^Z]T$?\
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M?'8^'=.0W))-LK:N0.RLS1;@6%))CC\9629N40UK)&DDE1I24L54#W7NM_\
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MJ?YO?&;?_96>K_X5M[:&V=W8BIJLG5-&\T5/B]-3X\E-401/+ E,\K5$*--
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M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?.Q_X3,_\
M<1?_ #2/_$6]V_\ O]-A>_=>Z&/_ (5 _P#;Z[^35_VL=F?^_9I_?NO=%C_X
M4'?&?%_,G_A2I\5_BQG=VY78F"[WZPZUZZSN[,%!'4UM%0U^5W*E9)2PS21P
MM4/3!XXS(6C5G#O'*JF)_=>Z!3Y+_$#;7\A7_A09_+VV;\1-Z=@_Z/=_R==[
MRJ*GL>K2OJJO';IW7E]C;JV_45-!CZ&"H?(4F.JO&PA18/XC3A_&D;3/[KW1
MPO\ A194=A_S$_Y['PI_E6#?&X]K]/4D&T\#E\9BW:*&GK=XU+Y7<>YTC)JJ
M>OR-%MF"!*1)Z94B>E:,2(E7/*ONO=%2^:GP_P #_P )U_YV7\OK>/Q#WQV:
M.F>RYL!GLC1[RKTR61JZ2IS\NU]Z;;K_ +2GP]+74-;BJJ.6%V&J&2L#"(24
M<4L_NO=8.]_@!L+^9C_PJS^5GQ3[3WONW8G7.X=Y5.\=Y9#8R4_\4K*+ ;#P
M.2.,I)ZM9::B>MEB134R050A4%EIV?2R>Z]T8'^2ATK'_+Y_X5 _([X1]5[B
MSU5U+AMI[YV-20Y>KEEGJ<%'B,5NS"ID0ABI:O(4YBHQ-/X$U31.T"01R&+W
M[KW7T8_?NO=?.9_GZ9[^090?S1.Q=^?(&/YC=R]PC;>/PW>G5?Q6K]KXC::;
MJQ5.N(FERN:S2RY*;/+B4H(:NEQ@I:2&HQ;I55\F0%9CQ[KW0&?\)3=W=<TW
M\[SN_!?&Z7L#"?'?=706^)=C[?W_ %0?+G!TV9VW/C(,T*2;^'UE="4C:2H6
M)&=X@\4=(DDE-[]U[H!OY<?\H_J?^;O_ #</YEO57=?:W9/6>P>I>U.P.QZJ
M'JN/&KE,I5S]AY#%TT*UV6ILE1445-]R\CDT-2\H/C1H+ES[KW0T_P#"C?\
ME]==?"*F_DS_  )ZBW9N"JV=MC;_ &!MC&;_ -S112Y66HW5V%B,G4Y2NCIG
MI89ZJ&IS+'3$8(RL2)$((PB)[KW6TA\$_P#A.Y\6_P"4M5=_?(;J7MON3M;L
M#=/Q#W/T]F#VE_!A1TXK4HLK7U^(@Q6/H&HA4S8:*,0U#ULD<19%JK-+Y?=>
MZU1/Y,_QQ7Y1?R#?YZO7<$67DSFW7VMW-M@[>A^YR+5VQ<7D=V_:T-/8M439
M6DP\^/:%+23Q5<D,;*\BL/=>Z@=?_/RGQ'_"23N#XU5>0?#[J/S:H?C)M6CV
M]6N:F3!9VLA[;EJ:O0[RT-/7U6&SU)40L!'40?M\1UH5?=>ZLMW/\=?Y=_Q[
M_P"$O?P[V-_,-W;N_:&4[>W6GRJZSJ/CC28Z;>N7S>8J)ZF-\!3YB:GQ<T57
MUOD*7&Y&NR4J4*&KIY+25<F.I)O=>ZU)/F7O7^6,,?U!6?RX]A?+KKS>&T<K
M54W9>9^2&>Q&2;,Q4T=(<;E,=4[;7%-C:NHF\YJ$B@@5E*-#'0&+34>Z]UM1
M?\*G\GD,W\E/Y&^9RU7-7Y7+[,BR>2KJ@WDFJ*C/[%EFED/Y>21RS'\DGW[K
MW7T+_?NO=>]^Z]U\^7_A9[M:3?/RO_E>[)BR;X67>&!W1M:/,QQF9J1LAN3:
MM(*E8A+ 93 9M8021ZM.G6E]0]U[JN/^>-_*OV#_ "#.VOY<_<OPS[6[4FW9
MNJMS&=R._NQYZ>H^TW5L&OVM7)DUAQ6-IEIZ'(_QZ-UH5$SQK13!7J"X,?NO
M=60_S!MQG>/_  K&_E9[N-.*0[JV)TUN,TH-_%]]4[CJO'>YOH\MOJ?I[]U[
MH ?^%5OR)V[W+_-T^-GP]^07:^\^KOAUTEM7:^2[8JMI4E165%''NNL&4W-N
M"@H8!7+D\T-O14E)0++1LE//!<AXYZCW[KW5<W1/>_PN^%7\\/X7]B?R@.W.
MVMW?'7=N[]H;![ 3N:#+45;)%NO//M[=VU)X30XA\I3U&*,%9CYZF"6D@R%1
M1RNOEQGW ]U[JT;^?IGOY!E!_-$[%WY\@8_F-W+W"-MX_#=Z=5_%:OVOB-II
MNK%4ZXB:7*YK-++DIL\N)2@AJZ7&"EI(:C%NE57R9 5F/'NO= 9_PE-W=US3
M?SO.[\%\;I>P,)\=]U=!;XEV/M_?]4'RYP=-F=MSXR#-"DF_A]970E(VDJ%B
M1G>(/%'2)))3>_=>ZK7VOLWX9;I_FL_-7K'^=_NSY-=<U^Z^U=U[>I.W.NZB
M"FEVKN:;-U=;'E]PT63P62JJS"2T(6.CFHZ>>#_*()UI*NAJ%K:/W7NMK/YD
M]>=6?R7_ /A-+VKM3X-=ZP]KT/R<[!_AN,^46RGIY&SU'O\ R1IS6TE7CLI/
M!%]MU]AH-OQU5/4OH: U<<4<S&)/=>ZTN\SL/^4?#_+%HMVT/?G>^=_FKU&>
MCW!F>NY<37Q[(^RJMP+12X6*NEPBP?<4&W&7*2UCUS^>M2IHX[I+3F+W7NOI
MM?\ "=CY-=A_*[^45\5.QNULVVZ-^[<Q>8ZFS&Z)9*R>;(0;5S-=A\5/5U&0
MDFKJK(IAJ>D@KJF:21ZJMBJ*GR.LRL?=>Z+/_P *SO\ MRIWI_XE+K[_ -ZS
M'>_=>ZT_]Z_R+^C-G?\ "=C$?S::+L;M?<GR1K*7;_8=5@1)24^WJ+!93?%+
MLA<72T,5)/7O/CEK(*Z2NDK+,D$J+3TZ,K1^Z]TJ/YCW?.^OD)_PF0_E);H[
M&S@W-NC9OR?W)U*V?(D#3X_;..W9C<-'+Y51C-C\-%2T4C :7>F9T+HRNWNO
M=;!W\LS_ (3Y_%G^7ALKH;^;4G<O<_;/=G4_Q<S/R)RNT]SPX>';$U=G>NLC
M//\ 88^EIDRM/)04N5F2(U.3K1)(!+:*3QM%[KW6FK\1=R?RTOEIO_YC]\_S
MD?E+\AMN]Q=GY2;,=.5O66'R63,^<S,^3K\IGLW]OC,RJT..J&HX*+%Q5$,8
M@DJH]06.ED3W7NK7_P"1E\B_E#OW^3=_.O\ B#U!F-R96JZTZ4I^V.DL+@VR
M5=F<1%N%\G3;YHZ!$2<-3Y/$8X34U'C8$D-8N2G%.:JO5Y/=>ZK]_E-_$K^3
MU\ZNN:SH;Y/?)[N?X??/O,;YE;JWM7<5?AI>NL^F1_R?$8F.GJJ2DF@R]-4Q
M%WAJ<G1-55-12_:9&I:5\73^Z]UM:_\ "L;M2?X1_P J7XP?"KX\5&1ZVZZ[
M%W;B>F_L, TB-_<CK_!P24^ >KCJ(98X9ZE<8\S:9#4I2O#*/'/*3[KW6EK\
MG<!_*EZJ^*7Q)W[\$_D;\AMW_/[;.:P65^0T.X:#+8/"TF0.-FRU;EMJY 8G
M$S4']W-R4T-#0^&L:KF@EAK1*LU/*\GNO=7(?\*(NT=V?-KKG_A/]V=O3,T6
M/W[\B_BVM3O+=&$II12C-9FNV929/*T5'+)!.M++D'EJH('DCD6-DB=T<%A[
MKW0??S4_Y8'7?\C7^8'_ "M*WXL=C]D9^IWAF,%O',;GWQ61KD9=T;;WAB(Z
MRL@_A<5!#1XNLCK*5HJ+3+XV29)YZJ-PH]U[H:/^%)7\O_X]]??SH/B#CMO4
MF\!3_/[?V'WK\A/O<FTK35NX-_PX#('$'PK_  R+^'-IC0>30]GNQ]^Z]UOI
M?R\/Y</QJ_E@=*[GZ#^+-#O3']?;N[1K>W\Q#OK+/F*LYFOQ.$PM0T=2\,!C
MIC1;?I L6DA7$CW]=A[KW09_SB_B!T[\TOY?7R Z[[LI]R5.V^OMCYCO7;\>
MV*XX^;^/;4P&8KL0T\HBE,M(M0UY8;+Y  I8"]_=>ZTQ?^$G/\J'XD_,/9^X
M?FCW-CNP*KNWXD_,?;>?Z@JMN9IZ#&15&W*7 [KQIR./6"1:Y%RZ R*73R1?
MM\#GW[KW0*=[_ #87\S'_A5G\K/BGVGO?=NQ.N=P[RJ=X[RR&QDI_P"*5E%@
M-AX')'&4D]6LM-1/6RQ(IJ9(*H0J"RT[/I9/=>Z,#_)0Z5C_ )?/_"H'Y'?"
M/JO<6>JNI<-M/?.QJ2'+U<LL]3@H\1BMV85,B$,5+5Y"G,5&)I_ FJ:)V@2"
M.0Q>_=>Z4'_"?B#?=3_,[_G^TW5KU$?9U1UQVM!US)2%5E7//V#E%Q!C+ J)
M!D#$5)X!M?CW[KW5 _\ +0Z;_E9]];_[PZ/_ )KO<GR%^-'?>XMW"GZQ[\6K
MHJ/:V(R='4O397%[WH,UAWR5#6UF1F!DFJG@@C@IZB*HJ<)/"LU7[KW7U<_Y
M?/Q3ZV^$GPP^._QBZHSM'N_9_6/75+3C?M"$$>Y<ED6DR^;W.!'45<8&X\S7
MU61"K/.B+4K&DTB(K'W7NBT_SMY/AG/_ "U?D;M_YV[RR>Q>CMV8&#"46?VO
M$E1N*+=$50F2VO+M>CDDA2MSU'EL?'6112214WAIJB2OGI\='5SQ^Z]U\K+Y
M7;D_D]2=$X; _!SK_P"=.%^0>#W715-;V5\D\QM2KQV7Q,R5,U<C8S;4=%%B
MLA13_;I T*RHB*\3-7,XR$?NO=;-_P#.3^6?9^U/^$TG\H?K?&[PW)CZOY*;
M&VC3;ZKJ67S-D<-M#;,533XBMJJQJBL-,E;-CJA'63[AI<?3EYROE$GNO=5<
M?SEOY(/3W\M3^7U\!/DOL?L7L[.]H?('';?P'>^T=Z&DDQB;BKMJ56YJRLPB
MP46-J<=24=0\E!'25:54W@CAD:H2?[HU/NO='-_X4R[6DWS@_P"0-LF+)OA9
M=X?$7$[6CS,<9F:D;(0]?T@J5B$L!E,!FUA!)'JTZ=:7U#W7NB+?SEOY+O4_
M\OOY_?!3X8=([YWE7[*^3NPMH8W=':?830Y'(R;ES.^:[;.8JOX3028FFCQ%
M'31XZKIJ))(Y&EEJ(FKVTQR0^Z]T8CYX_P M7K[^2C_.0_E1[*^,78'9>7P.
M]\[UOO7+[LW7E8USE7N2+LA\5EA,F.QU%CX=N55-!CV6A597F5Z^GJ)=#0R#
MW7NK+/YG_P#W%^?RY/\ M7=5_P#NTW1[]U[HD7_"I;^'8;^=OTIF?FMA^Y]Q
M_":?JW:E7C,#U?414.2K-N4;U0W/3;9KLE2R8<Y;^-23>:%Y$ETRQ+-48^.J
MIJQ?=>ZO=_DQ_P N'^7ET]UW\U_F;_*2^3VXODKG>U/CKDNI>G<;N^6A;='7
M.<GI<CEJO#Y/PP8Z2&MS64IL"8158RDD2GQ43K-7Q5+5#>Z]UI7_ ,M#IO\
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ML[MS,BMQ>'I\=69.&6# I@!]S/+51RR-6TY6D2$QSS>Z]U3W\7?C#OCY2_\
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MN[XS8_IU.H\7D<EOS=$.RMN[,-/2UE%C:3%;0I8\0KU.0AQ1I)I)F+QT,+>
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M'1[;R<N#::MQ>X9MJ;DB2.H0SS)09'%5*T4DU7B:19/=>Z:?C%\K_C+\T_\
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MVKZ;K/9,'7U/7/\ 6:/"Y[8F-24\+S(M,&/ ^OT'OW7NA'_X5^?]EV?RA_\
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M\FKY9;<^='_"IS?/RTVAM+/;%VKW;L_>NZ=N[5W1)%)D:6BBV-1T%-]ZT $
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MQBJ%;0QXRI65GJVIBLM!$D! B "*H4 @'W[KW7MN?R_OAKM+Y19[YJ[<^/\
MLC$_*G<_W0S_ '93?>?QBJ%;0QXRI65GJVIBLM!$D! B "*H4 @'W[KW1Q/?
MNO=$R^0_\NSX+?+/=V+W_P#)'XH]']R;\PU%2XW'[VWK@:*IRZTM#+//14KY
M(1I634M'-53O!#)(\433SF-%\TFKW7NG/IKX!?!WXZ[^/:?07Q%^.72W9#8*
M3:_]^.K=G8' Y3^&RK DF/%9C*&FF%$R4L*F ,([11C3Z%M[KW47H'^7]\-?
MBUVEV7W9\?OC_LCJWM7N/[H]G[WVY]Y][FC6Y'^+535K5%7/&[3Y(FH8A5/D
M)L0"1[]U[KWR4_E_?#7YA[NZYW[\F?C_ +([BWAU'Y#UKGMU_>&;#&6JIZV1
MJ/[:KIT1GJJ2&0DJQ+1IS8 >_=>Z-EF,1CMP8C*X',4J5V(S>-GQ&4HI"RK-
M35,30SQ,4*N!)$[*2I! /!!Y]^Z]T5[XI?!7XC?!S$;PP'Q,Z)V7T9ANP,E2
MYC>6.V8*I8\A54,4L-+/.*JIJ?7#%.Z@KIN&YO86]U[I!9K^6)\!=Q_)JD^9
M6<^+O6N3^3U!NNBWS1=QU4=8V5BR^.CBBHJ^,?=BE6HIE@0J1#;6OD(,A+'W
M7NC1=P]*]0_(/8.7ZK[SZSV/VYUOGI:>HR^R.P\929;&3S4=1'5T=0U)6Q2Q
M"IHZN&.>GF4"6"9$EB=)$5A[KW1(<1_)J_E0X7"_W>I/Y=WQ"J,3][_$!3YG
M8N!R+B3]W3:?(4=54".,SRF.+7XXC+*8T4RR%O=>Z%OY!_R[?A-\J\]U7N?Y
M"_'38':6=Z/HQC^I*_<"5:' 0K-2U"QXY*6JIXH56:B@8>DV\48^B@>_=>ZI
M8_G9_P G+Y!_S/\ YT_R[]]8:'JVL^)G0F6A'R+Q&\\G54^2KL;6;GQ];F:?
M'XV&GEBR,CX*A>* 2RPHLT[*_DC>1/?NO=;.ZJ% 50%51I55X  ^@ _ 'OW7
MNM(W_A4#\0.^OF=_,*_E4=9=%]*;H[IGIL/N3*[XQV*QQJ\50X>+<>VJBLFW
M!63)_"L;CIZ6FFCUU\L,$S_L!F=PA]U[K:;Z(_EN_ ?XP[]E[1^/GQ"Z!ZB[
M%>EGH8-Z;)VWCJ3(TD%3%#!4T^/J5A,F-IZB"GCCECI#"DD:*CJ54#W[KW3I
MOW^7]\->T?DILOYA=@?'_9&Z?DSUU_#ALCN+)?>'+8T8AYI<<M,4JTIU6DDJ
M)60&(@F1]0;4??NO=#EW'TAT[\AMB9#K#O;J_8?;_7F5JJ>OKMF=C8NCR^.>
MII)5GHZL4U;%-''64<ZK+3SH%F@D421.C@,/=>Z!SXY_ OX6_$2ORN7^,GQ=
MZ1Z0SF<HOX7E=P=>[?Q]!D9Z/S-4"A;(QP_>B@%0[2BF$H@$K-((];%C[KW3
M/\A_Y=GP6^6>[L7O_P"2/Q1Z/[DWYAJ*EQN/WMO7 T53EUI:&6>>BI7R0C2L
MFI:.:JG>"&21XHFGG,:+YI-7NO=.?37P"^#OQUW\>T^@OB+\<NENR&P4FU_[
M\=6[.P.!RG\-E6!),>*S&4--,*)DI85, 81VBC&GT+;W7ND#VW_*R_EQ=[[Y
MR79O;WPE^-N_.P<UDTS>=WAFMJXO[_(5L<20)6Y&HB@B?(5BP1I&)ZCR2Z$1
M->E% ]U[HYFQ-A;'ZMV;MKKKK39VU^OM@;,P\.WMH;(V504N+Q.+H*9 E/1X
M_'444%)1TL*"R111JBCZ >_=>Z)/7?RH?Y9^3[)F[=R'P1^+-9V'59E]Q5>X
M:C9F$;S5\M9_$I*V>D-)]C-529*]8TKPLYK":HG[@F0^Z]U8#%%%!%'##''#
M##&(HHH@%55465546"JH%@!P![]U[K7;_P"%3&QM[=E_R?\ MC8?7&SMT]@;
MXW/V_P!>XW;6S-DX^KRN6R%0=U4#BGH<=00SUE7.51B$BC=K FU@??NO=9?Y
M2G\EGXF]9?!WX=Y'Y7? GH&#Y>;*V$E9V)E-Y[:PF0RBY@9>>NI*K*%4J*2M
MR<5/#0N):A9*B%X8E<I-#I3W7NK?/E1\)?BG\W-J;8V/\K>D=G]W[1V9GFW1
MM? ;P%4:>BR#4TE&:N)*6HIOW?MI7C!8D!68 "Y]^Z]T8?:FUMO[&VMMK96T
M\73X3:NS\!1[6VUA:348J/'X^GCI**EB+L[F.GIH4C74S-91<D\^_=>Z*EW_
M /R[/@K\J-XT?8?R)^)O1/;V_P"AI:6BI]\[SV]05.8,- TKT$,F3$25L\-"
MT\IITDD=8/+*(@@EDU>Z]T8+9/3'4'6O6N/Z9Z\ZLZ[V/U%BL0^W\;U?M/#8
M['[?AH90PEI(\/2T\6/6GF#MY(_%ID+,7#%C?W7NB:[;_E%_RO\ 9^^L-V3M
MCX#_ !4PF]-N9"FRNW<O0;,PJ+CZFBG6JH9J&D^U-%1R455&DU.884\$T<<L
M6AXT9?=>ZL(R&/H,O05V*RM#1Y/%Y.CEQ^2QN0B2:GJ*>9&CF@GAD5HY898V
M*NC JRDJP()'OW7NB(==_P JS^6UU)V)CNV.M/@W\8=E=AX6OARN!W/@=GX:
M&7'55,CQTM5C(Q2FGQM31Q2-'3RTT<4E/&S1PLB$K[]U[I;_ "4_E_?#7YA[
MNZYW[\F?C_LCN+>'4?D/6N>W7]X9L,9:JGK9&H_MJNG1&>JI(9"2K$M&G-@!
M[]U[KWR4_E_?#7YA[NZYW[\F?C_LCN+>'4?D/6N>W7]X9L,9:JGK9&H_MJNG
M1&>JI(9"2K$M&G-@![]U[I>?(WXD_&3Y>;9PVS?D]T5UEWIMK;F4DS>WL5V3
MBJ7)+05<U/)235%$\Z&6DDGI97BE,3)Y(SI?4  /=>Z6G3/1O3GQUV%CNK>B
M.L-C=0]=XFJJ*^AV;U]C:7%T"U-9*U165;04D<:RUE9.[2U%1)JFGD8R2N[D
MGW[KW0J>_=>Z)'L;^6O\ >M.XS\@]@?#OX\[1[I&?J=U4_8V#VOBX,E392L>
MKDJ<G1R+!HHLA,V0JM533K'-:IJ ' FD#>Z]T\;<_E_?#7:7RBSWS5VY\?\
M9&)^5.Y_NAG^[*;[S^,50K:&/&5*RL]6U,5EH(D@($0 15"@$ ^_=>Z]MS^7
M]\-=I?*+/?-7;GQ_V1B?E3N?[H9_NRF^\_C%4*VACQE2LK/5M3%9:")("!$
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M=VSMOMM7;6X-XQ51J:3'/4R59HXY*6JIBT J9I) KZM+R.5MK:_NO=#!WO\
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MOISJCOK8F9ZO[KZYV9VKUWN#Q',[+W[CJ7*8ZH:"19H)'I:N.6,34\R+)#*
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M -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\
MA];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U
M[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W
M_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%
M5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>
M_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_
M /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC
M-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_
M (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z
M]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G
M>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\
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M (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\
M]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W
M-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\
MA5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW
M7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X
M_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>
MHS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6
M_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?
MNO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z3
M9WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_
M -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\
MA];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U
M[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W
M_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%
M5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>
M_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_
M /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC
M-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_
M (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z
M]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G
M>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\
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M (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\
M]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W
M-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\
MA5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW
M7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X
M_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>
MHS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6
M_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?
MNO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z3
M9WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_
M -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\
MA];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U
M[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W
M_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%
M5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>
M_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_
M /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC
M-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_
M (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z
M]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G
M>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\
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M (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\
M]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W
M-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\
MA5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW
M7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X
M_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>
MHS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6
M_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?
MNO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z3
M9WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_
M -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\
MA];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U
M[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W
M_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%
M5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>
M_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_
M /7OW[KW7O\ A];_ (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC
M-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_
M (57_P#>HS<W_I-G>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z
M]U[_ (?6_P"%5_\ WJ,W-_Z39WC_ /7OW[KW7O\ A];_ (57_P#>HS<W_I-G
M>/\ ]>_?NO=>_P"'UO\ A5?_ -ZC-S?^DV=X_P#U[]^Z]U[_ (?6_P"%5_\
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MJ_X6R]4Y+-1[8^9WPKW[U8T-7#C:[>O1N;I]QQQ3&5H:MZW;>=IMNUN/@HB
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M$IMU[5R\6=C2DR.52DKZ%4K%BETSU<=315'W"R3I[KW1YO\ A1;\]/E5V_\
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MTNV*[8_1O9&5I::"LEC2BDJL]F<C6XG3&CH9:V84U'ZGG=((=*Q^Z]TJLO\
MS+?^%ANQ*&3=&>^#NZ-PXK'2(*G#XCIO^,SS>9Q"@7'[;JILS,J/(&8P+^VJ
MF24B)7/OW7NDKC/^%9/\W?XLU4,?SR_EN;2@P]5/#CL6<UMK?_4V3FJ?#)))
M&]9N$[BQ]1+-$@E2.''0E LK6=&41>Z]U=]\-/\ A6]_*\^2^0Q.T^Y*W?\
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M,T4X-#LY43:E,L4D">&6>CK*Z)0ZBM*RR!O=>ZV"MO[<V_M/$46 VM@L-MK
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MOH(^_=>ZT%/^$OW_ &^N_G*_]K'>?_OV:CW[KW7O^$@?_9=G\WC_ +6.*_\
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M4F6Q4.*DSLN3Q\6$BQYRTN8DFC6E6E6/S-4M4%A"*<0C69"V@)ZKZ>??NO=
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M@<M:0V'U]^Z]TQ=)?)#X\?)? 9;=?QQ[ZZ7^0&UL#F#M[.;EZ2W3@]UX^BR
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MS30-5T>&IX*G+5D*.KRT=!/&C*[J??NO=45?\);/Y6N2H=I97^<)\O1EM_\
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M:NY=]Q>"9JJ7^#8RKJZQ8/N7CB9XJ;<VX\W"I*(TGB\KJ-2*ONO=52?R /\
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MCS==6Y:"@SF*H<QF:?175;5M;+)CXMF9X4\]9.DAIJYJ>:6>1*8R>Z]T*?\
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MF (-F(Y]^Z]U/_X4Y?\ ;QG_ (3??^+KYC_WNNA??NO=)/\ X40].=??&_\
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MCQOAU$ZT:2-E!5NM$:8RAIQ[KW1P?FO\0MU?!C_A'!NGXY=@XVOPO9.W>O\
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MNT>)HXXX:/%TF$AITQM/CJ6*)$AIHX5AB1%5$4* /=>Z1/3GQB^-?QU_C_\
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MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@8RWR/\
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M1P??NO=>]^Z]T1KNO^63_+O^1NXY=X]Y?"7XP=F;RJ $J]Y;GV7@9<Q.H9Y
ME1E4HDKZB,/*[!9)64,[,!=B3[KW00[,_DG_ ,I+8-=0Y+;G\N_XHFNQM3]Y
M0U.X=HXS,M'+Y1,L@_C,5>"T<@!CN#XP J:5X]^Z]U97@-O8#:F(H=O[7P>'
MVW@<7 *;&83 4T-'1T\8^D<%-3I'#"@_"HH _I[]U[K4F_GZ?R(]Z]O[Q/\
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M=3;%I:'%8K+0SFGK%K)5IY\-F\1!5TU ^,J*N:&KFK:ZJ-0J0>Z]TKOY%OR
M[YW]_P )T/YT'9N^^[>W=Z]D;(VUW7)LOL'=NY,SDLYB&H.B\9D*%L7EJRMF
MK\>:*OD:I@,$L?AJ&::/3(2WOW7NB(?'[^5/V'\ZOY%NZ_YIWR _F"_+[>'<
M?QVZO[3[O^.FPLAN&2JP.WDZRK=Q9 I43Y-<EFJG-Y+(X:OGCR=+64$U,E31
M4RAHZ%6?W7NMR3_A/_\ *+LOYA_RD/B'W7W)F\CN?L^HVYG.O]W;KR\K5%7E
MI=I;HS6V:7)UE1(3+45U=CL53S5<LGKDJFF=BVK4?=>Z,G_-B_[=9?S+/_%
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ME]Y5H+4^5I8],5*!$"DIG]U[HVW\W;OW8?\ ,(_G&UW\J'Y%?/;&? _^7_\
M&CH9>POD+GSO#![&?>^[LUC<564^W#G-T5D6!R,D6-W3C6IZ"2EKECBI\Y(]
M+-(HDH/=>Z4?\E/O[;OPB_FT;Z_E)]-_/;;?ST^#';?0P[<^*&\EWK@=X5&U
M<Y@Z5Y*O9]'DL#656+2>/ XK(2UF+I%I8DIZ.AR4%!1K+5^?W7NMUJ>>"E@F
MJ:F:*GIJ>)IZBHG8(B(@+.[NQ"JBJ"220 !<^_=>ZT!OA]\*-Y_\*A.P?F-\
M[_D[\P?D-UITEU?\EZKJ7X5]:=.545%0;<7"T4&7H,F^/R]/74]/54N(SF*D
MEDI5I<A55T]=-+5TZ^"-?=>ZOX[ WK\D_P"2#_(R[AWI\@?DX?EWW_\ 'K8%
M7B>M^U=XXVK_ '<KN+,4NWMC8NM2HR53E<W1X;(9:D\\]34K4R4L<JNZ10JZ
M^Z]UKA/_ "9OD=%_*[3^>W%_,+^5X_F2_P"RX#YPR9],O?%':KQ'?!P8E$"Y
MM0-L,*IHS5'$?<AJ;^&_8G4/=>Z'7^='_,J[E^3/_";S^7/\VNN.S]Y=1]L=
MM_*;;6U>ULYTYE,KMB5\UA=H=M83=5%&V/KHZV+$U6X]O/50TLLTB&):26\F
MF.3W[KW10_YR/P)[Y_DO=8?%_P#F?=)_S%OEIV%\S^V^RZ'K?NGL??.2HI*.
MOK,GM?,YYY,7C31R^+ Q5%!511XC)SY6FBAGA6/28;M[KW2__FB_R]=U?\)^
M\G\+OYFG5_SH^7O>'=V:^3>W^N_D?D^RLS#6'=..7%9+/96FB5EBJZC&Y"##
MUM*:'+5]>-%7&PJ$EC,Q]U[K=A_F;?*JB^$OP"^6/R?J*^CQ^4ZLZ9RU=LIJ
MZ?[9)]S5\0Q.UJ,369EDK=Q5]% FE68M(-()M[]U[JC#^2!LK%?RL?\ A.9N
M3Y6;FQ"TV[-W=0[X^=NZ(J!Y)9J\U&'D.S*>+[QDA26MVWA\,J1*(J9:BH=O
M4TDM1+[KW6K+3]*Y7X5_RD/Y+'\VB/$;^I>Q=L?S-=V]T]@5E+)4_?9O'9O+
M8]:>>ODK2)53*XKIN**DO+%15M/E)Y9A/]_Y&]U[KZ#?\WG*T&>_E#?S#<YB
MJA:K%YGX+]A97&U2@@24]1M#(S0R &Q >-P>>>??NO=:,7P6_G8_S(/A[_);
MVOT'T-_*S[GW3U%L3KWL.FVW_,#FQN\:W9E)#FMW[MS&6SK"DV;_ '?>/:]9
MDZNCD9L]X(ZG'N]44*34R^Z]UM9?\)T.AND.AOY+G7M+TEVYL[O!>T:?=/;O
M:G8.QZ>KHZ%]W9*!:'(8G[7)04N4BGVY08NAQ#M6P4\]1]B*K[:FBGC@C]U[
MHA__  C(R+X?^4K\ELO'&LTF*^=.\LC'"Y(5V@ZTZME"DCD!BMC;W[KW4S_A
M&545N\?@G\P^XMSU\&9[#[,^>N=J-ZYV58UK:V9-G;,RAJ*D1*B".6NSM9)&
MJHJ"1Y]( X'NO=-78-?1],?\+-.BJ7:N)Q<$GRS^#];0=D55$RQRRS8[:&\J
MR&KJPL-YJKQ=:8NG 9@?MUA;R601'W7NMQSW[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:^_\ -_\ ^$\'Q&_FHTM?V50.
MGQV^6E/2'^'=Z[,H(9J?.-'"8X*/>F'#4Z9NF%D"5<<M/DJ<(@2IEIU:DE]U
M[K5#VOWA_P *%?\ A-+E&V%V=L7+_)'X0X2N:+!5.?\ XEN_KJ+'PI2P(<!N
MBC/\:ZXNK*D&,R HJ0S+43Q8FJN]2_NO=7R?$[_A8Y_+5[@Q='1_)W;';_Q
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M2IAO[KW0'?R /^X9G^>/_P"&OWM_[X#$^_=>Z/\ _P K3_N#P[^_\4H^5?\
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MM_\ V1M?CTE6AW>NXQLI^MFJ),"LK5T>+T(<D,BP%&:4H^L2.*?W[KW5;/\
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MX];(Z1^(&?DR> J8LHE7MO:O]\95QE#65&=QK87-8.NIU;)04@J/XE,]-]S
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M_P#>P;HK_J9E?_K9[]U[KW_00)_)G_[V#=%?]3,K_P#6SW[KW7O^@@3^3/\
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M[!NBO^IF5_\ K9[]U[KW_00)_)G_ .]@W17_ %,RO_UL]^Z]U[_H($_DS_\
M>P;HK_J9E?\ ZV>_=>Z]_P!! G\F?_O8-T5_U,RO_P!;/?NO=>_Z"!/Y,_\
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M_J9E?_K9[]U[KW_00)_)G_[V#=%?]3,K_P#6SW[KW7O^@@3^3/\ ][!NBO\
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MMGOW7NO?]! G\F?_ +V#=%?]3,K_ /6SW[KW7O\ H($_DS_][!NBO^IF5_\
MK9[]U[KW_00)_)G_ .]@W17_ %,RO_UL]^Z]U[_H($_DS_\ >P;HK_J9E?\
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MN/OW7NO?] F/\E3_ )\7VE_Z,'=G_P!<??NO=>_Z!,?Y*G_/B^TO_1@[L_\
MKC[]U[KW_0)C_)4_Y\7VE_Z,'=G_ -<??NO=>_Z!,?Y*G_/B^TO_ $8.[/\
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M_P#KC[]U[KW_ $"8_P E3_GQ?:7_ *,'=G_UQ]^Z]U[_ *!,?Y*G_/B^TO\
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M&#NS_P"N/OW7NO?] F/\E3_GQ?:7_HP=V?\ UQ]^Z]U[_H$Q_DJ?\^+[2_\
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M_/B^TO\ T8.[/_KC[]U[KW_0)C_)4_Y\7VE_Z,'=G_UQ]^Z]U[_H$Q_DJ?\
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M2I_SXOM+_P!&#NS_ .N/OW7NO?\ 0)C_ "5/^?%]I?\ HP=V?_7'W[KW7O\
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M?)+JKY?="]:_)/H_+9+.]4=M8-]Q;)R^7HJC'5,](E5449DEHJM(ZFG)FI7
M615:P!L+^_=>Z'CW[KW5=/9W\W/^65TMV!NWJGMOYO\ QXZX[)V'FI=O;RV/
MO+/TU!D\;6PD:Z>JI*C1+$]B&4D:71ED0LC*Q]U[I"?\/A?RA?\ O8K\4O\
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MVGQN.V5@L=DZ*ER=51T5##3R5#)%F,8U31K%+2P4:5#TL=.8(XE3W7NM7?\
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MW3VDY1G0*24)*]RAA0LJG@<XX]8/^^GLGNOW?>89.6]YEM)KF*&&9I+*2:2
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M?G96)W;F]G[/JL;29/&['@HZG).V4R-+BZ<P0U]?C*5E2HJT:374(1&&*AV
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MX]*:_<K<FW7-WB_3-$OA:-7BLXKXFNE-*/\ P&M:>7'KWW;ONF<Q_>B_>/\
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ME5DN9X;>-G)"!YI%C4L55B%!85(4FG $XZHJ_P"@C/X2?\^M^5'_ )Y-I?\
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M/_O3]7J[.W/0;WVCM;>>*AK*?%[NVY0[GQL&05$J$IZ^EBJX4G6.26-9ECE
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M]?C*5E2HJT:374(1&&*AV 0AW8MEEYANDM(2BO)JH7)"C2C.:E58\%-,'/4
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MX+=ZA6 :L8 / D9Z*%\POYN_QM^$W;PZ6[5V1WAN#=)VK1;N^_Z^QN!J\?\
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M8.>H ]E/9_<_?CF2VY7VB6UANKM;AHY+QY8[=1;V\MRVIH8;AQ5(F"TC:K$
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M8A06%2%)IP!..J*O^@C/X2?\^M^5'_GDVE_]G'N5_P#6;W3_ '[:_P"]R_\
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MS9[>/2W56R.\-O[I&U:W=WW_ &#C<#28_P"VH'ITF3RXW<N6J/.QJ5T+X-!
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M6*JQ"@L*D*33@"<=45?]!&?PD_Y];\J/_/)M+_[./<K_ .LWNG^_;7_>Y?\
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MK0YH3]O70KD_^Z_Y^YUVBQWFUO\ E](+^SMKV%9;K<5E6*ZA2= X3:I%#A9
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MZ'<G:>_\-USM^MSN'VO%0PUV<R--C*26LDI]XU4\=)'/5(TK1PRR+&&*12,
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M7_AO;X*_]X@_'+_T$,'_ /47L"?UKW3_ )3+K_G/+_T%UAQ_P4WN5_TU._\
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M!_K%NE_N7TWB?3_77<UUX/C>'XGA^,[Z-?A)JTTU:%KP'7NV/CWT5WQ_ /\
M35U!UQVM_=7[K^[7^D##T.5^P^^^V^\^T^]AF^W^Z^S@\NBVOPQZKZ%MZQW6
MZVS5]--+%JIJ\.1DU::TKI(K2II7A4^O7N2/=/F7VT\;^KNZ7^V_4^']1]#=
MS6OC>#XGA^)X+IKT>*^G573K:G$] [_PWM\%?^\0?CE_Z"&#_P#J+VO_ *U[
MI_RF77_.>7_H+H>_\%-[E?\ 34[_ /\ <UO?^MW1M<7C,=A<;CL-B**FQN)Q
M-##C,7CJ)%CAIZ>"-8H((8U 5(HHD554 !5  X'LA9BQJ<DY/4'7EY+N$SW$
M[M))*[22.Y+,[NQ9F8G)+$DDGB3T6+<7P7^&6[MP9W=>Z?BST)N'<VY\Q5;A
MW%G\QM;#U%975];.]35UE542TC2SU-342O)+(Y+.[,S$DD^SJ+F7<8$5$NKA
M54!559I JJ!0  -0 #  X=3%M7WD?<'8K6&QLN8][@M[>*."""+<KN.*&&)!
M''&B+*%5$10JJ  J@ "@Z4?7'Q&^+G3^YZ?>W57Q[Z=ZZW?2TLU#3;FV7M[&
M8ZN2&H3QSQ+4TM-%*(YDX==5F'U'MF\WR]W%/#N+B:5:@Z9)7=:CSHS$5SQZ
M*>;/?/G/GRS;;M[WS=;^U9E=K>[OKFXA+H:JQ261EJIR#2H\NA3["ZWV!VSM
M3(;%[/V9MGL#9F6D@FRFU=WT4&0Q]0U-/'4T[34M2DD,A@J(DD0LITNBL+$
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MK_IJ=_\ ^YK>_P#6[H8NI_CWT5T/_'_]"O4'7'5/]ZOM?[R_Z/\ #T.*^_\
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M_K7NG_*9=?\ .>7_ *"ZG'_@IO<K_IJ=_P#^YK>_];NABZG^/?170_\ '_\
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M4  P .'4R;;]Y3W"V>WBM+3F3>X8((TAAABW.[2.**)0B(BK* J(JA54
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M5E95RO/5553/)2-)-45$\C22.Q+.[%F)))]G47,VXP*$2ZN550%55GD"JH%
M  U  , #AU,FV_>4]PMGMXK2TYDWN&""-(888MSNTCBBB4(B(JR@*B*H55
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M,K*1D%2 01P(Z*5_PWM\%?\ O$'XY?\ H(8/_P"HO9]_6O=/^4RZ_P"<\O\
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MZJLK*N5YZJJJ9Y*1I)JBHGD:21V)9W8LQ))/LZBYFW&!0B75RJJ JJL\@55
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M2,RM0Y4D'!/1<?\ AO;X*_\ >(/QR_\ 00P?_P!1>S?^M>Z?\IEU_P YY?\
MH+J6?^"F]RO^FIW_ /[FM[_UNZ,=U[UOL#J;:F/V+UALS;/7^S,3)/-B]J[0
MHH,?CZ=JF>2IJ&AI:9(X8S/42O(Y51J=V8W))]E%U=RWTAEF=I':E7=BS&@
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M0 #  X=3)MOWE/<+9[>*TM.9-[A@@C2&&&+<[M(XHHE"(B*LH"HBJ%50
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MP#*2&H<@D''1=?\ AO;X*_\ >(/QR_\ 00P?_P!1>S?^M>Z?\IEU_P YY?\
MH+J5O^"F]RO^FIW_ /[FM[_UNZ,=U[UOL#J;:F/V+UALS;/7^S,3)/-B]J[0
MHH,?CZ=JF>2IJ&AI:9(X8S/42O(Y51J=V8W))]E%U=RWTAEF=I':E7=BS&@
M%2Q)-  !\AU$W-/-NZ<\7K[EO-W<7UW*$$ES=3///((T6- TDC,S:4556IPH
M & .@Q[+^)WQB[FW+_?+MKH#J'LG=G\/BQ7]X][X#&Y*M^U@+F&G^YJZ>640
MQ&1BJ7TJ68@7)]K++>[W;4\.WGFB4G45CE=%)( K16 K0#/RZ&/*'O?SC[?V
MGT&Q;WNFWVVMI? L[ZXMX?$>@9]$4BKJ8* 32IH/0=)?;OP7^&6T=P8+=>UO
MBST)M[<VV,Q2[AV[G\/M;#T]90U]%.E325E+414BRP5--41))%(A#(ZJRD$
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MP=6_^A!B?_JOW[KW7O\ 3ETI_P _@ZM_]"#$_P#U7[]U[KW^G+I3_G\'5O\
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M$_\ U7[]U[KW^G+I3_G\'5O_ *$&)_\ JOW[KW7O].72G_/X.K?_ $(,3_\
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M"#$__5?OW7NO?Z<NE/\ G\'5O_H08G_ZK]^Z]U[_ $Y=*?\ /X.K?_0@Q/\
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MK?\ T(,3_P#5?OW7NO?Z<NE/^?P=6_\ H08G_P"J_?NO=>_TY=*?\_@ZM_\
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MB?\ ZK]^Z]U[_3ETI_S^#JW_ -"#$_\ U7[]U[KW^G+I3_G\'5O_ *$&)_\
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M5O\ Z$&)_P#JOW[KW7O].72G_/X.K?\ T(,3_P#5?OW7NO?Z<NE/^?P=6_\
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M;UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\
MV<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]
MB%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F
M?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\
M0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7
MM9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]
MG'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\
MV(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_
M +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T
M#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=
M>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\
MV<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]
MB%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F
M?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\
M0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7
MM9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]
MG'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\
MV(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_
M +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T
M#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=
M>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\
MV<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]
MB%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F
M?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\
M0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7
MM9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]
MG'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\
MV(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_
M +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T
M#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=
M>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\
MV<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]
MB%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F
M?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\
M0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7
MM9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]
MG'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\
MV(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_
M +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T
M#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=
M>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\
MV<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]
MB%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F
M?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\
M0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7
MM9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]
MG'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\
MV(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_
M +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T
M#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=
M>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\
MV<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]
MB%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F
M?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\
M0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7
MM9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]
MG'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\
MV(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_
M +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T
M#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=
M>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\
MV<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]
MB%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F
M?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\
M0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7
MM9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]
MG'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\
MV(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_
M +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T
M#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=
M>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\
MV<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]
MB%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F
M?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\
M0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7
MM9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]
MG'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\
MV(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_
M +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T
M#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=
M>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\
MV<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]
MB%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F
M?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\
M0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7
MM9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]
MG'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\
MV(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_
M +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T
M#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=
M>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\
MV<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]
MB%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F
M?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\
M0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7
MM9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]
MG'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\
MV(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_
M +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T
M#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=
M>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\
MV<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]
MB%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F
M?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\
M0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7
MM9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]
MG'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\
MV(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_
M +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T
M#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=
M>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\
MV<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]
MB%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F
M?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\
M0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7
MM9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]
MG'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\
MV(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_
M +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T
M#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=
M>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\ 0.3_ "9_^\./_8A=J_\
MV<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7M9Z]_P! Y/\ )G_[PX_]
MB%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]G'OV@=>UGKW_ $#D_P F
M?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\ V(7:O_V<>_:!U[6>O?\
M0.3_ "9_^\./_8A=J_\ V<>_:!U[6>O?] Y/\F?_ +PX_P#8A=J__9Q[]H'7
MM9Z]_P! Y/\ )G_[PX_]B%VK_P#9Q[]H'7M9Z]_T#D_R9_\ O#C_ -B%VK_]
MG'OV@=>UGKW_ $#D_P F?_O#C_V(7:O_ -G'OV@=>UGKW_0.3_)G_P"\./\
MV(7:O_V<>_:!U[6>MCGX@](=7_&[XV=2]&]+[8_N9U;UOMZ3 ;+VO][D,C]E
M2?>54_B^]RU779&H_=F=M4]1*_-M5@ &V%#TXO#HR/NO5NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@S[=_P"/%RG_ %$4W_N1'[LG
M'JK\.B=^WNF>O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z.KUE_QXNWO
M^H:3_K?+[9?CT\G#I=^Z]6Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z#/MW_CQ<I_U$4W_ +D1^[)QZJ_#HG?M[IGKWOW7NB^?*[Y
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M;V_VGTOO.LGISF:."LI:+-XQZF2EAIX4R.(R&N%9%AC$GV\=0(U$H44(H>K
MZAUL[?\ "GSYE;DF^ GPCZ8I*FLQF4^7$%%W5V3#C_%]O+B]N8?#5ZXRI)5&
M,51N'<5)5PB) ->+NYC&E)+N<=40=!Y_PG;_ )-/Q.^1WPXW3\HOEOU%@^W\
MGV[O#,;*ZNQV8K<I'38O;N&ECQ]97104E311PYJLSU/61"H'EDIZ:DA^WEB:
MIJXV\JUZV[4Z*%\>/^$_O\RCIW^8Y1=B]+[(QVRND?CQ\JTW1UIV[V'NBCQI
MSFUL)N8S4BQTN/\ N\]/)E,##X:D/CHZ2H$TL9D>GDNV@IKULL*=;_':'8&
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M\GV=85I*BHIZW%9 12?;5<+E6:.2*9()XWB78:O6BM.M%[_A4/\ ]O8=\_\
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MHZXO3S4<LU(,_1QR0/'J:5\]MBBIFB?QE#*7)+1B-]H:'K3Y'6P?_P *^/\
MLCOXN?\ BRTW_O+9CW=^'54X]:X7\M7^>WWO_+$^-^_/CYU!TOU)OT;S[7R7
M;U-N[LB7,O\ :5^0PFW\+]N]!BZW'?=4<,>WXY;"HAD9I77R* I]T#4ZNRUZ
M+UL+KOYA_P \?^8%FLY_#(\YVIW;NO'Y7MC?6#QLD6W=HX.EIJ/$ID:M/,5I
M<9A<-CXH*6"6I-36&".FCDFJI06U\1ZW\(ZN<_X5J82DV7W'\%.N\*TL6U]C
M_&_(83;]#(0?%#3Y6GH4-P!=FIZ&%6/T] L![L_5$ZVC_P"0UM?%;1_E&_";
M%X=)DI:SKK);HG\[:V-7FMS9W,5QU6'H-972Z%_L)I2Y"W]W3AU1N/5NONW6
MNJ2O^%#O?,_0_P#*?^2,N,JZ2DW#W!%BNAL&*NY$L>Y<A%%FX457C9I6VO3Y
M,IS96 D971&1JL:#JRBIZT!N@OA!)VQ_+&^=WS*FQE9-7?'+M7K3#[.KL:)'
MDDI\A4Y3'[NIJB,1.GV<,&X,+6.ZD.C4ZNSQPI(L[0&.G":'K9R_X1^=Z-7=
M:_,3XSUB+$FUM\8'O3;S^2YG.?H),!F08=($8I1MO&6<,WD^X*E4\0,ET/57
M'6YY[<Z;ZJK_ )WW_;I[YQ_^(9D_]V6/]U?AUL<>M)'_ (3M?RTOC9_,6[M[
MZA^3V/W+N?972VP\3EL9L; Y&JQ$.1K<W65M,LU=7XZ6GR2PT,5 Q2*GFA\D
MDJM)(4C,<E$6O3CFG1(/G%U-+_*P_FM=C[+Z7RF0,7QA[RV[V=U/45T\AJ(:
M*>EPN]<%15-4K>69J6BR,%)-*3JG".[B[E?=2-)ZL#J'6SY_PKES-)N/XN?!
MO<- 2:'.]GYG,T1/U,55MVCGC)N ?T./P/=WZ;3CT$7QT^1^Y_C#_P )1=Z[
MUV/E)L+O;>.[MT].[9R]).U-4TK;KWQ-B,C4TDT;)/'6TV$GK9:=X2)8ID29
M2OC++ZM%ZW^+JNC_ (3M?RG.C_YC&\_D'O[Y/8?<FX.GNE\1A]N87:V$KZS$
M)E=P9YJ^8RRY''SP5HBPM!C-3P1N@DDKJ=W<I&T<FD%>MLU.B,?-GIO=/\GG
M^:QN' ]+YO/I'\>^T<!V[TEGLK,R5%7A:N"ASU!15L\'C^\A6&HEQ&0.A8ZQ
M8:I9(O'*T?NI&D];!U#K9._X5I[HQV]_B7\#-Z8AM6)W=V%E-T8MM0:]/D-M
M4-7 =2W5KQ2KR.#]1Q[N^:=43CT6S^4!_(E^)/SB_E@[J[\['BWED?D+VC4[
MOV_UAN:FRM918_:E9AIJG&8B6'&4<T--E?+70">J^_$RO&_AA2$H97\%J.ME
MJ'JLK_A-7W;G>H_YK_2VV:"JDBV]WOM;<W46\*82.J20-A:O/X]C&MTDDCS6
M"HPI8>E7D((N?=4X]6?ATLO^%0__ &]AWS_XAG9?_NMD]^?CUI.'1X/YM?\
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M.W.S]@[NV'N*"GR^T>P]GU^T<[3>F2*JQN6HI:.J3\I)'-35##\AE;^A]O\
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M)Z*E_*#_ ),.]OYMDO>.YI^]8.B]F]256*H*W=]=M]]U5>8S.9^^J#2PT?\
M'L!XUI:>C\U342U).JH@6..4M*T7E75UMFT]%5[9^+-9\)_YF]%\6:_>E-V)
M4]._(W:.WFWK24+8R/(K/687(1SB@>KKFI&\=8JM']Q, RFTC"Q]Z(IUZM1U
MMB?\+!?^R>OAM_XF;<7_ +HZ;W>3JB<>K#?^$R/_ &Z-Z;_\2/OG_P!Z:O\
M=DX=:?CU7E_PL%_[)Z^&W_B9MQ?^Z.F]UDZVG'HRW\C;_N'RW/\ ^&?W/_UN
MS_O8^'K3\>M=_P#X2I_]O1ZG_P 5IW=_[F[?]U3CU=^'2/\ ^%0__;V'?/\
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M#VUU7U[L3K#9F.IL1L_KC9F+V'M3$T<:10TN-P]#!CZ&GBBB58XHX*6G1%1
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M3^1[WU[INVGLO9VPL0FW]B[3VULO 1U#U<>$VG04N.HUEE(,D@IJ.*&$22$
MLP6[6Y)]^I3KW2E]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW1U>LO^/%V]_P!0TG_6^7VR_'IY.'2[]UZM
MU[W[KW7O?NO=>]^Z]U[W[KW1 ?D]_--_E\?"_L6CZE^4GRHZUZ5['R.UJ;>U
M#M+>#5RU4N*K*BKI::N3[>BGC,$U305$:G5?5$X(%O?NO=%T_P"@@3^3/_WL
M&Z*_ZF97_P"MGOW7NB)_S0OYW7\J+N7^7#\ZNI>K_G!TWO/L?LGXH;\V1L7:
M6(DR1JLGELGMO(4E!0TXDQ\<9FJ:F5(TU,HU,+D#GW[KW7S"/A[NS;FPOEM\
M6]\[PRU+@-I;+^1FR-V;ISM=J\-%CL=N;&5E=5S:%9O%34T+R/8$Z5-@3Q[]
MU[KZ\?\ T$"?R9_^]@W17_4S*_\ UL]^Z]U[_H($_DS_ />P;HK_ *F97_ZV
M>_=>Z/)\5OFQ\5?F]M;<V]OB?W9M#O#:>SMP+M7<V>V::IJ>CR+TT=6M)*U3
M34Y,QIIDDLH:RNI)%Q[]U[HTOOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7N@S[=_X\7*?]1%-_[D1^[)QZJ_#HG?M[IGKWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HK.V?@Q\
M)ME[]H>U-G?#SXL[3[/QF:DW)C>Q]L]?;2H,]3Y&9I&EKX,Q2XB+(15LK2N7
MG682L78EB6-]4'6Z]&F][ZUU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO= ]V9\?NDN
MY]P==;H[:ZOV;V1FNI<O4[@ZWGWI119&+#Y"KCABER%)250DI%KPD""*H:)I
MH/5X'C+OJ]3KW0P !0%4!54651P !] ![]U[KOW[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW1U>LO^/%V]_U#2?];Y?;+\>GDX=+OW7JW7O?NO=>]^Z]
MU[W[KW7O?NO=?."_X5H_!OYK?(_^9ML#?OQX^'WRD[YV+1_$':VV:S>G3'7^
M[-T8F+)4^Y][U%1CY,C@\174<==!!5P220-()4CFB=E"R(3[KW6L'_PT[_--
M_P"]:?S_ /\ T3?8O_V.>_=>Z36\OY:'\QWKK:>Y-^]@_P O[YM;$V+LW"5.
MYMW[TWEU3OO%XG%8VBA>HK,ADLC6X&"CH:&D@C:2:>>1(HHU9W95!/OW7NB=
MX' YS=6<PVV-L8;+;CW+N/+4^!V]M[ T\U975]=63)3TE%14E.DE155=542)
M%##$C222,J(K,P!]U[H]/_#3O\TW_O6G\_\ _P!$WV+_ /8Y[]U[KW_#3O\
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M'7O^@JS^:/\ \JWQI_\ 01K?_L@]^UGKV@=>_P"@JS^:/_RK?&G_ -!&M_\
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M!U[_ *"K/YH__*M\:?\ T$:W_P"R#W[6>O:!U[_H*L_FC_\ *M\:?_01K?\
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M@]^UGKV@=>_Z"K/YH_\ RK?&G_T$:W_[(/?M9Z]H'7O^@JS^:/\ \JWQI_\
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M&M_^R#W[6>O:!U[_ *"K/YH__*M\:?\ T$:W_P"R#W[6>O:!U[_H*L_FC_\
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M]^UGKV@=>_Z"K/YH_P#RK?&G_P!!&M_^R#W[6>O:!U[_ *"K/YH__*M\:?\
MT$:W_P"R#W[6>O:!U[_H*L_FC_\ *M\:?_01K?\ [(/?M9Z]H'7O^@JS^:/_
M ,JWQI_]!&M_^R#W[6>O:!U[_H*L_FC_ /*M\:?_ $$:W_[(/?M9Z]H'7O\
MH*L_FC_\JWQI_P#01K?_ +(/?M9Z]H'7O^@JS^:/_P JWQI_]!&M_P#L@]^U
MGKV@=>_Z"K/YH_\ RK?&G_T$:W_[(/?M9Z]H'7O^@JS^:/\ \JWQI_\ 01K?
M_L@]^UGKV@=>_P"@JS^:/_RK?&G_ -!&M_\ L@]^UGKV@=>_Z"K/YH__ "K?
M&G_T$:W_ .R#W[6>O:!U[_H*L_FC_P#*M\:?_01K?_L@]^UGKV@=>_Z"K/YH
M_P#RK?&G_P!!&M_^R#W[6>O:!U[_ *"K/YH__*M\:?\ T$:W_P"R#W[6>O:!
MU[_H*L_FC_\ *M\:?_01K?\ [(/?M9Z]H'7O^@JS^:/_ ,JWQI_]!&M_^R#W
M[6>O:!U[_H*L_FC_ /*M\:?_ $$:W_[(/?M9Z]H'7O\ H*L_FC_\JWQI_P#0
M1K?_ +(/?M9Z]H'7O^@JS^:/_P JWQI_]!&M_P#L@]^UGKV@=>_Z"K/YH_\
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M]!&M_P#L@]^UGKV@=>_Z"K/YH_\ RK?&G_T$:W_[(/?M9Z]H'7O^@JS^:/\
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M'7O^@JS^:/\ \JWQI_\ 01K?_L@]^UGKV@=>_P"@JS^:/_RK?&G_ -!&M_\
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M!&M_^R#W[6>O:!U](K^41\@.P_E1_+:^(_R'[7."/8?;/6;;KW3_ '9IFHZ
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M]U[KW_0%3_--_P"?^? #_P!"GL7_ .U5[]U[KW_0%3_--_Y_Y\ /_0I[%_\
MM5>_=>Z]_P! 5/\ --_Y_P"? #_T*>Q?_M5>_=>Z]_T!4_S3?^?^? #_ -"G
ML7_[57OW7NO?] 5/\TW_ )_Y\ /_ $*>Q?\ [57OW7NO?] 5/\TW_G_GP _]
M"GL7_P"U5[]U[KW_ $!4_P TW_G_ )\ /_0I[%_^U5[]U[KW_0%3_--_Y_Y\
M /\ T*>Q?_M5>_=>Z]_T!4_S3?\ G_GP _\ 0I[%_P#M5>_=>Z]_T!4_S3?^
M?^? #_T*>Q?_ +57OW7NO?\ 0%3_ #3?^?\ GP _]"GL7_[57OW7NO?] 5/\
MTW_G_GP _P#0I[%_^U5[]U[KW_0%3_--_P"?^? #_P!"GL7_ .U5[]U[KW_0
M%3_--_Y_Y\ /_0I[%_\ M5>_=>Z]_P! 5/\ --_Y_P"? #_T*>Q?_M5>_=>Z
M]_T!4_S3?^?^? #_ -"GL7_[57OW7NO?] 5/\TW_ )_Y\ /_ $*>Q?\ [57O
MW7NO?] 5/\TW_G_GP _]"GL7_P"U5[]U[KW_ $!4_P TW_G_ )\ /_0I[%_^
MU5[]U[KW_0%3_--_Y_Y\ /\ T*>Q?_M5>_=>Z]_T!4_S3?\ G_GP _\ 0I[%
M_P#M5>_=>Z]_T!4_S3?^?^? #_T*>Q?_ +57OW7NO?\ 0%3_ #3?^?\ GP _
M]"GL7_[57OW7NO?] 5/\TW_G_GP _P#0I[%_^U5[]U[KW_0%3_--_P"?^? #
M_P!"GL7_ .U5[]U[KW_0%3_--_Y_Y\ /_0I[%_\ M5>_=>Z]_P! 5/\ --_Y
M_P"? #_T*>Q?_M5>_=>Z]_T!4_S3?^?^? #_ -"GL7_[57OW7NO?] 5/\TW_
M )_Y\ /_ $*>Q?\ [57OW7NO?] 5/\TW_G_GP _]"GL7_P"U5[]U[KW_ $!4
M_P TW_G_ )\ /_0I[%_^U5[]U[KW_0%3_--_Y_Y\ /\ T*>Q?_M5>_=>Z]_T
M!4_S3?\ G_GP _\ 0I[%_P#M5>_=>Z]_T!4_S3?^?^? #_T*>Q?_ +57OW7N
MO?\ 0%3_ #3?^?\ GP _]"GL7_[57OW7NO?] 5/\TW_G_GP _P#0I[%_^U5[
M]U[KW_0%3_--_P"?^? #_P!"GL7_ .U5[]U[KW_0%3_--_Y_Y\ /_0I[%_\
MM5>_=>Z]_P! 5/\ --_Y_P"? #_T*>Q?_M5>_=>Z]_T!4_S3?^?^? #_ -"G
ML7_[57OW7NO?] 5/\TW_ )_Y\ /_ $*>Q?\ [57OW7NO?] 5/\TW_G_GP _]
M"GL7_P"U5[]U[KW_ $!4_P TW_G_ )\ /_0I[%_^U5[]U[KW_0%3_--_Y_Y\
M /\ T*>Q?_M5>_=>Z]_T!4_S3?\ G_GP _\ 0I[%_P#M5>_=>Z]_T!4_S3?^
M?^? #_T*>Q?_ +57OW7NO?\ 0%3_ #3?^?\ GP _]"GL7_[57OW7NO?] 5/\
MTW_G_GP _P#0I[%_^U5[]U[KW_0%3_--_P"?^? #_P!"GL7_ .U5[]U[KW_0
M%3_--_Y_Y\ /_0I[%_\ M5>_=>Z]_P! 5/\ --_Y_P"? #_T*>Q?_M5>_=>Z
M]_T!4_S3?^?^? #_ -"GL7_[57OW7NO?] 5/\TW_ )_Y\ /_ $*>Q?\ [57O
MW7NO?] 5/\TW_G_GP _]"GL7_P"U5[]U[KW_ $!4_P TW_G_ )\ /_0I[%_^
MU5[]U[KW_0%3_--_Y_Y\ /\ T*>Q?_M5>_=>Z]_T!4_S3?\ G_GP _\ 0I[%
M_P#M5>_=>Z]_T!4_S3?^?^? #_T*>Q?_ +57OW7NO?\ 0%3_ #3?^?\ GP _
M]"GL7_[57OW7NO?] 5/\TW_G_GP _P#0I[%_^U5[]U[KW_0%3_--_P"?^? #
M_P!"GL7_ .U5[]U[KW_0%3_--_Y_Y\ /_0I[%_\ M5>_=>Z]_P! 5/\ --_Y
M_P"? #_T*>Q?_M5>_=>Z]_T!4_S3?^?^? #_ -"GL7_[57OW7NO?] 5/\TW_
M )_Y\ /_ $*>Q?\ [57OW7NO?] 5/\TW_G_GP _]"GL7_P"U5[]U[KW_ $!4
M_P TW_G_ )\ /_0I[%_^U5[]U[KW_0%3_--_Y_Y\ /\ T*>Q?_M5>_=>Z]_T
M!4_S3?\ G_GP _\ 0I[%_P#M5>_=>Z]_T!4_S3?^?^? #_T*>Q?_ +57OW7N
MO?\ 0%3_ #3?^?\ GP _]"GL7_[57OW7NO?] 5/\TW_G_GP _P#0I[%_^U5[
M]U[KW_0%3_--_P"?^? #_P!"GL7_ .U5[]U[KW_0%3_--_Y_Y\ /_0I[%_\
MM5>_=>Z]_P! 5/\ --_Y_P"? #_T*>Q?_M5>_=>Z]_T!4_S3?^?^? #_ -"G
ML7_[57OW7NO?] 5/\TW_ )_Y\ /_ $*>Q?\ [57OW7NO?] 5/\TW_G_GP _]
M"GL7_P"U5[]U[KW_ $!4_P TW_G_ )\ /_0I[%_^U5[]U[KW_0%3_--_Y_Y\
M /\ T*>Q?_M5>_=>Z]_T!4_S3?\ G_GP _\ 0I[%_P#M5>_=>Z]_T!4_S3?^
M?^? #_T*>Q?_ +57OW7NO?\ 0%3_ #3?^?\ GP _]"GL7_[57OW7NO?] 5/\
MTW_G_GP _P#0I[%_^U5[]U[KW_0%3_--_P"?^? #_P!"GL7_ .U5[]U[KW_0
M%3_--_Y_Y\ /_0I[%_\ M5>_=>Z]_P! 5/\ --_Y_P"? #_T*>Q?_M5>_=>Z
M]_T!4_S3?^?^? #_ -"GL7_[57OW7NO?] 5/\TW_ )_Y\ /_ $*>Q?\ [57O
MW7NO?] 5/\TW_G_GP _]"GL7_P"U5[]U[KW_ $!4_P TW_G_ )\ /_0I[%_^
MU5[]U[KW_0%3_--_Y_Y\ /\ T*>Q?_M5>_=>Z]_T!4_S3?\ G_GP _\ 0I[%
M_P#M5>_=>Z]_T!4_S3?^?^? #_T*>Q?_ +57OW7NO?\ 0%3_ #3?^?\ GP _
M]"GL7_[57OW7NO?] 5/\TW_G_GP _P#0I[%_^U5[]U[KW_0%3_--_P"?^? #
M_P!"GL7_ .U5[]U[KW_0%3_--_Y_Y\ /_0I[%_\ M5>_=>Z]_P! 5/\ --_Y
M_P"? #_T*>Q?_M5>_=>Z]_T!4_S3?^?^? #_ -"GL7_[57OW7NO?] 5/\TW_
M )_Y\ /_ $*>Q?\ [57OW7NO?] 5/\TW_G_GP _]"GL7_P"U5[]U[KW_ $!4
M_P TW_G_ )\ /_0I[%_^U5[]U[KW_0%3_--_Y_Y\ /\ T*>Q?_M5>_=>Z]_T
M!4_S3?\ G_GP _\ 0I[%_P#M5>_=>Z]_T!4_S3?^?^? #_T*>Q?_ +57OW7N
MO?\ 0%3_ #3?^?\ GP _]"GL7_[57OW7NO?] 5/\TW_G_GP _P#0I[%_^U5[
M]U[KW_0%3_--_P"?^? #_P!"GL7_ .U5[]U[KW_0%3_--_Y_Y\ /_0I[%_\
MM5>_=>Z]_P! 5/\ --_Y_P"? #_T*>Q?_M5>_=>Z]_T!4_S3?^?^? #_ -"G
ML7_[57OW7NO?] 5/\TW_ )_Y\ /_ $*>Q?\ [57OW7NO?] 5/\TW_G_GP _]
M"GL7_P"U5[]U[KW_ $!4_P TW_G_ )\ /_0I[%_^U5[]U[KW_0%3_--_Y_Y\
M /\ T*>Q?_M5>_=>Z]_T!4_S3?\ G_GP _\ 0I[%_P#M5>_=>Z]_T!4_S3?^
M?^? #_T*>Q?_ +57OW7NO?\ 0%3_ #3?^?\ GP _]"GL7_[57OW7NO?] 5/\
MTW_G_GP _P#0I[%_^U5[]U[KW_0%3_--_P"?^? #_P!"GL7_ .U5[]U[KW_0
M%3_--_Y_Y\ /_0I[%_\ M5>_=>Z]_P! 5/\ --_Y_P"? #_T*>Q?_M5>_=>Z
M]_T!4_S3?^?^? #_ -"GL7_[57OW7NO?] 5/\TW_ )_Y\ /_ $*>Q?\ [57O
MW7NO?] 5/\TW_G_GP _]"GL7_P"U5[]U[KW_ $!4_P TW_G_ )\ /_0I[%_^
MU5[]U[KW_0%3_--_Y_Y\ /\ T*>Q?_M5>_=>Z]_T!4_S3?\ G_GP _\ 0I[%
M_P#M5>_=>Z]_T!4_S3?^?^? #_T*>Q?_ +57OW7NO?\ 0%3_ #3?^?\ GP _
M]"GL7_[57OW7NO?] 5/\TW_G_GP _P#0I[%_^U5[]U[KW_0%3_--_P"?^? #
M_P!"GL7_ .U5[]U[KW_0%3_--_Y_Y\ /_0I[%_\ M5>_=>Z]_P! 5/\ --_Y
M_P"? #_T*>Q?_M5>_=>Z]_T!4_S3?^?^? #_ -"GL7_[57OW7NO?] 5/\TW_
M )_Y\ /_ $*>Q?\ [57OW7NO?] 5/\TW_G_GP _]"GL7_P"U5[]U[KW_ $!4
M_P TW_G_ )\ /_0I[%_^U5[]U[KW_0%3_--_Y_Y\ /\ T*>Q?_M5>_=>Z]_T
M!4_S3?\ G_GP _\ 0I[%_P#M5>_=>Z]_T!4_S3?^?^? #_T*>Q?_ +57OW7N
MO?\ 0%3_ #3?^?\ GP _]"GL7_[57OW7NO?] 5/\TW_G_GP _P#0I[%_^U5[
M]U[KW_0%3_--_P"?^? #_P!"GL7_ .U5[]U[KW_0%3_--_Y_Y\ /_0I[%_\
MM5>_=>Z]_P! 5/\ --_Y_P"? #_T*>Q?_M5>_=>Z]_T!4_S3?^?^? #_ -"G
ML7_[57OW7NO?] 5/\TW_ )_Y\ /_ $*>Q?\ [57OW7NO?] 5/\TW_G_GP _]
M"GL7_P"U5[]U[KW_ $!4_P TW_G_ )\ /_0I[%_^U5[]U[KW_0%3_--_Y_Y\
M /\ T*>Q?_M5>_=>Z]_T!4_S3?\ G_GP _\ 0I[%_P#M5>_=>Z]_T!4_S3?^
M?^? #_T*>Q?_ +57OW7NO?\ 0%3_ #3?^?\ GP _]"GL7_[57OW7NO?] 5/\
MTW_G_GP _P#0I[%_^U5[]U[KW_0%3_--_P"?^? #_P!"GL7_ .U5[]U[KW_0
M%3_--_Y_Y\ /_0I[%_\ M5>_=>Z]_P! 5/\ --_Y_P"? #_T*>Q?_M5>_=>Z
M]_T!4_S3?^?^? #_ -"GL7_[57OW7NO?] 5/\TW_ )_Y\ /_ $*>Q?\ [57O
MW7NO?] 5/\TW_G_GP _]"GL7_P"U5[]U[KW_ $!4_P TW_G_ )\ /_0I[%_^
MU5[]U[KW_0%3_--_Y_Y\ /\ T*>Q?_M5>_=>Z]_T!4_S3?\ G_GP _\ 0I[%
M_P#M5>_=>Z]_T!4_S3?^?^? #_T*>Q?_ +57OW7NO?\ 0%3_ #3?^?\ GP _
M]"GL7_[57OW7NO?] 5/\TW_G_GP _P#0I[%_^U5[]U[KW_0%3_--_P"?^? #
M_P!"GL7_ .U5[]U[KW_0%3_--_Y_Y\ /_0I[%_\ M5>_=>Z]_P! 5/\ --_Y
M_P"? #_T*>Q?_M5>_=>Z]_T!4_S3?^?^? #_ -"GL7_[57OW7NO?] 5/\TW_
M )_Y\ /_ $*>Q?\ [57OW7NO?] 5/\TW_G_GP _]"GL7_P"U5[]U[KW_ $!4
M_P TW_G_ )\ /_0I[%_^U5[]U[KW_0%3_--_Y_Y\ /\ T*>Q?_M5>_=>Z]_T
M!4_S3?\ G_GP _\ 0I[%_P#M5>_=>Z]_T!4_S3?^?^? #_T*>Q?_ +57OW7N
MO?\ 0%3_ #3?^?\ GP _]"GL7_[57OW7NO?] 5/\TW_G_GP _P#0I[%_^U5[
M]U[KW_0%3_--_P"?^? #_P!"GL7_ .U5[]U[KW_0%3_--_Y_Y\ /_0I[%_\
MM5>_=>Z]_P! 5/\ --_Y_P"? #_T*>Q?_M5>_=>Z]_T!4_S3?^?^? #_ -"G
ML7_[57OW7NO?] 5/\TW_ )_Y\ /_ $*>Q?\ [57OW7NO?] 5/\TW_G_GP _]
M"GL7_P"U5[]U[KW_ $!4_P TW_G_ )\ /_0I[%_^U5[]U[KW_0%3_--_Y_Y\
M /\ T*>Q?_M5>_=>Z]_T!4_S3?\ G_GP _\ 0I[%_P#M5>_=>Z]_T!4_S3?^
M?^? #_T*>Q?_ +57OW7NO?\ 0%3_ #3?^?\ GP _]"GL7_[57OW7NO?] 5/\
MTW_G_GP _P#0I[%_^U5[]U[KW_0%3_--_P"?^? #_P!"GL7_ .U5[]U[KW_0
M%3_--_Y_Y\ /_0I[%_\ M5>_=>Z]_P! 5/\ --_Y_P"? #_T*>Q?_M5>_=>Z
M]_T!4_S3?^?^? #_ -"GL7_[57OW7NO?] 5/\TW_ )_Y\ /_ $*>Q?\ [57O
MW7NO?] 5/\TW_G_GP _]"GL7_P"U5[]U[KW_ $!4_P TW_G_ )\ /_0I[%_^
MU5[]U[KW_0%3_--_Y_Y\ /\ T*>Q?_M5>_=>Z]_T!4_S3?\ G_GP _\ 0I[%
M_P#M5>_=>Z]_T!4_S3?^?^? #_T*>Q?_ +57OW7NO?\ 0%3_ #3?^?\ GP _
M]"GL7_[57OW7NO?] 5/\TW_G_GP _P#0I[%_^U5[]U[KW_0%3_--_P"?^? #
M_P!"GL7_ .U5[]U[KW_0%3_--_Y_Y\ /_0I[%_\ M5>_=>Z]_P! 5/\ --_Y
M_P"? #_T*>Q?_M5>_=>Z]_T!4_S3?^?^? #_ -"GL7_[57OW7NO?] 5/\TW_
M )_Y\ /_ $*>Q?\ [57OW7NO?] 5/\TW_G_GP _]"GL7_P"U5[]U[KW_ $!4
M_P TW_G_ )\ /_0I[%_^U5[]U[KW_0%3_--_Y_Y\ /\ T*>Q?_M5>_=>Z]_T
M!4_S3?\ G_GP _\ 0I[%_P#M5>_=>Z]_T!4_S3?^?^? #_T*>Q?_ +57OW7N
MO?\ 0%3_ #3?^?\ GP _]"GL7_[57OW7NO?] 5/\TW_G_GP _P#0I[%_^U5[
M]U[KW_0%3_--_P"?^? #_P!"GL7_ .U5[]U[KW_0%3_--_Y_Y\ /_0I[%_\
MM5>_=>Z]_P! 5/\ --_Y_P"? #_T*>Q?_M5>_=>Z]_T!4_S3?^?^? #_ -"G
ML7_[57OW7NO?] 5/\TW_ )_Y\ /_ $*>Q?\ [57OW7NO?] 5/\TW_G_GP _]
M"GL7_P"U5[]U[KW_ $!4_P TW_G_ )\ /_0I[%_^U5[]U[KW_0%3_--_Y_Y\
M /\ T*>Q?_M5>_=>Z]_T!4_S3?\ G_GP _\ 0I[%_P#M5>_=>Z]_T!4_S3?^
M?^? #_T*>Q?_ +57OW7NO?\ 0%3_ #3?^?\ GP _]"GL7_[57OW7NO?] 5/\
MTW_G_GP _P#0I[%_^U5[]U[KZ O\KWXM=@?"?X ?%OXJ=J9C9V?[#Z1ZV39V
MZ\SU_45M5AJBJ6MK*DR8^HR./Q5=+!HJ%&J:D@?4&&BP!/NO='V]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U6U_.._[=._S(?_ !2;LK_WD\I[]U[K
MX[/P/_[+B^&G_BUO7?\ [U^']^Z]U]TOW[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]T!?R=Z#VO\ *GXZ=Y?&G>^6S^!V=WWU5G>H]T9O:KTZ9.DH,_CJ
MC&5=10/5T]72I610U+-$TT$T8<*7C=;J?=>ZUD^HO^$='\OSIKMCK#N#;GR.
M^8V1W#U3V'A>R<%C\WD=DO1SUF"R5-E*6&K2#95/.U++/2JLHCEC<H6"2(UF
M'NO=;<'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JNSY
MP_S8?@!_+>S?7VW?FAWY_H:S/:>*K\UL.C_NMO7<7W]-C)J:"NE\FU-N9V*E
M\$M7$NFH:%WUWC5PK$>Z]T9OXS_)OHKYB])[)^1?QK["QW:73/8E/55&T=Z8
MVFKZ):G[*MJ<=612T.5I*#)T-32UU)-#+!54\,T;QD-&.+^Z]T0'N/\ GO\
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M)MS*9^FVS'DX8:NB7.5%!$YBJ9J"HCJ_M:9*JJ2FDBD>%?- )/=>ZN2VUN3
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MN0AHTGFTEEI*"!BU7DZ^4 ^.DHXIZF7Z1Q,??NO=!M\&/G!TE_,-Z#HODO\
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MGJ:JIG>.&GIX8U+O)(RHB@LQ !/OW7NJL8OYZO\ )]FW6FS4_F(_&(9=Z_\
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M"%OZ^_=>Z6O>_P#*/_GX?)WM;=7>/?\ \-OE;VMVYO?['^]N_MV4---D*_\
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MP^Z/'&;,1C,;D_XM+I.OP8V541W95/NO=:BO\A/_ (42[5_E)?'[OSX\]O\
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MHJ7XQ]DY9+),\]/BH=S[00J%M-J@?<(9V(9!%"@U*P\?NO=-G\^GXF)\(O\
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M%6GC0;6@F\4/[9DD8D>A/?NO=;7/OW7NOE3]O]0]:]^?\*S=Z=-]Q;/Q6_\
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M1\=>G.VL%\V?E%UWL3=V]NP5J&R.'I,AEZ;;EJ&.)##4I3IEI:F..8Z/,/H
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M9L;"IBB8O6Q*&D7W7NM\3W[KW7SM_P#A<'6[V_TQ_ /'5=16IUS_ *,][5N
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MY$P?)?\ D]_"7>)GK)<OL;J__03N"/)3">I2IV%65.U(&FE'ZVJL;BZ6J4L
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M^-V[D*""?,T^/6(5>5D:[U?EGQM+B8G%.ONO=:</\K':NU>E_P#A37UUUO\
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M4U\>*W'4MM.MRN!H,G45]=65D5#N>IJJ BIE1Z>99<?/=*9IY/=>Z^@__/\
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M>QV/S==E]Q8%)MV9:2NC26O23<M<S5%9$]5,KGPH[2"GA9?=>ZM"_P"$@O\
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MSZ7=^U=M[JIJ/X]86HI*?<E#2UT<4C;DC4O&E5%*J.5X)4 D<7M[]U[H;?\
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M0&20PQX[(RQPDG2K/USFP[!;V#.(U!(Y(50?H/?NO= -_P (B?\ LK3YL?\
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M;;1V[L/8VV_YAKTFW=G[2HX,?C*"&2FDG:"BHJ9(Z>EIQ+*Y6*)%C2]D55
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MOW7NO>_=>Z][]U[KWOW7NO>_=>Z^;S_PMV_[*T^$_P#XKKF__>ED]^Z]UO\
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MC?[RUN[FQ=5CZ+'YZ>):ZOE2&IKZ=Y:GP8JI$<:R>Z]U;/\ +'J/X6?S)_\
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M^T%^7.X.L=D_'_N#)9&D@BH8<1LJ7$M79\Y(54BUW]\(,!'3O31J)H16UC5
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M]/MG(*?/R=3;6S^3[ H:G(5V5PU\]50QTL.0Q]-5)BY'RD],7AI()A)42R2
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MZJDO"S429'(RR#'T$LM/'++34,=+!-+'')-&[QQE?=>ZJ?\ ^%>_R"P/5/\
M*/W!U!6TCU^?^47<VU.O,,L*Q.]%!M[)P[YK,DPD976!)=M4U"[QW97R$8(*
MLP/NO=8?^$AWQ;JNB?Y55+V[N#'5]#NOY6=OYWLM4RU.U-40X##3?W6PE,$D
M E:DDGQ-?DJ=R%61,EY(PT;K(_NO=;3?OW7N@ ^4_P :NM/F'\?.TOC-W''G
M9NL.X=N?W5WG#MFK^QKGH_N(*EDIJOQ3&!V>G4%@A.DD"Q((]U[K7YB_X2$_
MR=(I(Y5VQ\ART;B11+O>5U)4W&I'QS(Z\<JP((X((]^Z]U<3\%/Y7_P>_EN;
M=SN!^(?1V'ZXK-V1QP[OWGD*O(9K<.5BAEDFAIJO-YBJK:\4,$LKR1T<,D5'
M'(S2I3B5W=O=>Z5OS=_E[_$/^8KUA2]2_+OIW"]I[9Q-><OM;(M/5XW,X2M8
M(&JL-F\9/29/'/*(T6>..8054:B*JBGB]'OW7NB._#/_ (3U_P K'X,=N8CO
MGI[H2LS_ &_MB66HV;O7M;,5VX6PDTLOE%7B<=4O'AJ/(P, *>N6C-=2I=:>
MIB5G#>Z]U9)\J?B5\=_FSTWN'H/Y/=88/M;J[<A$]5@LNU1!-3521RQ0Y#&9
M"BFILCBLE!'/(L=523PSHDDB!_'(ZM[KW5(VT/\ A)Y_)8VQ59:HR/0_9&^8
M\C%/%1T6[]][G\5 *A3&YI#BJ[%RNR1G3&U2]0T1M+&5G E]^Z]T=/K;^1W_
M "[>E_BI\DOAGT[U=N_KCH[Y81TB=S8K%;JS^1KZPT6@0/29'<%=F)\>WCC"
M-X=*E23I#V<>Z]T*7\N/^59\4?Y6.TNS-D?%*A[ Q^ [8W'0[JW9!OW,MF9#
M68^FEI('II7IH'A0P2D.OJ!(4C2;W]U[HU_R1^-?1OR\Z7WQ\>OD=UU@^U.H
M.Q<:,9NK9^>\R)((Y$FIZFEJJ66GKL=D**HC2>DK*2:&JI9T2:GFCE16'NO=
M46X3_A)W_)2Q=5EJG)_'_L?=4>1E1J*CS?8&[X(L>B *(J3^$93%R2*5 #-5
M/4RL?49"Y9C[KW5ROPR^$OQP_E_]*TWQ[^*^R*WK[J>CW-7[OIMN5^7RV;=*
M_)F)JV7[[-UN0KF65H5(0S%$YT*H-O?NO=&O]^Z]U4G\]_Y'W\N'^9%O&@[.
M^2G2$DW;=!BOX$>UNN\G6;?S=71+&(HJ?*/1/]CF!31J%II:ZFJ)Z11HI984
M+*?=>Z%?X#_RI/@G_+0QFZJ;XC=(X[8VX-]Z$WKV%G*RMS>X\E#&8VCHI,OE
M)ZFHI<6DD22#'T?VU#YAY_MO.3(?=>Z"+^8S_)-^#_\ -*WYUYV-\K<;VCD=
MP]8;1GV5M0;$W ^&ITHJFM>NF\T4=).9IFG?]1:P50 HY)]U[JT3K_96%ZUV
M'LGKG;AK#M[8&T<;LK G(2"6H^RQ5%#0TOGE"())O! NM@JAFN0HO;W[KW2N
M]^Z]UKU_)G_A,=_*\^6O?O:WR3[AP?>=;V=W)NZHWKO2IP.[Y*&B:MJ JO\
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M_P MD=NYZ3'@ZHJ/(3XZ9*3,0TS<TW\0IZIZ0-(E*\,<TRR>Z]U/^!_\EO\
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M]U63W]_)R_EP_*+Y/;=^9?>OQS_OS\DMIUVW\E@.Q_[W[[QGV\VUIHJC O\
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ML:YZ/[B"I9*:K\4Q@=GIU!8(3I) L2"/=>ZU]O\ H$%_DY_\\S\BO_0ZG_\
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ML</C]\>AW'V)W#FJY#]_D:VAV)E<;C,+C8%.BBCQN]H_N:JIE$K5,#Q14PB
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MRKRG:V<PHJ)<ICJ6:MPVYX::@R:K"\*PG!/%0U=!*^7AJ9ZF.E]U[HUO2?\
M-/\ EA\_OY)OS3[QZB2N^-G\R?X;X3=&TNSMO;(P>,SJP;SV!!#N"LAPN"W+
MCMR4552[LQ%+-0BBEAJZJEK):JEI)WFIZ6LD]U[H7_AW_-CWCV+_ ,)[LC_,
MO["RT&ZN\NJ_C-OBOWQ6Y&GQ>,3+;]V:V7Q%&\M-C:.'%4,>X<K1T4ZQT](L
M44=:JI2\>'W[KW1B?Y"O<7S#^1W\LSH_Y%_.+LFN[-[I[RKLUO['9:MP^V<%
M]MMA\G/0;;@BH-IXG#8SPU>/H1DDED@:J9:\+-+I2.*'W7NAH_G(_P#;IS^9
M#_XI1V1_[RF3]^Z]T0#_ (34;+VMV1_PGV^(?7V^,'CMR[-WMM[MC:NZ=O9:
M))Z6MQ]?VUV+35=-/%(K))%-!(RL""+'W[KW5>/_  E.[1V_\>>I?YN7Q7W3
MO7,UG7_P+^5V5W:^;W VN*BV]44VX,545:,%CCC$O^CFJK*B&)(XUED>81JT
M[EO=>Z"_;?\ ,5_X4;_/CK'LS^9S\!\7\:NL?@QUIN/=3=8?%WLC'4&0W;O_
M  &VT:"JK:N5L=7U4U=32P5!:*AW%M\-705%)3I6PQPR5/NO=7#[B^>6T_YE
M7_"=7Y@?+S:^!?:%5V'_ "Z>[<=OC9+R-.,+N3$;%W3C,[CH:ATC:JHTKZ9Y
M*.<JK34<M/)(D<K/&GNO=:Z/PT_F0=\?%+^0;_+/^(OP-JWJ?YB_S?[SWSLK
MH:"CQ=#FFP.(I>U\\,WN.MH<KCLIB%IB)5HU>NIWABADK\A8QXNH>/W7NCI?
M\*VMI=I[$_DD?#+9_>/:\O>?<>WOF3L;&]H=O28K%X)=PYY.L^TCE,E!AL-2
M4.-Q='/5E_MJ:&$>&G$22/-*))I/=>Z.AV9\\_F9\L/YN'0/\MO^7;W%4=0=
M-?%786,['_F2=ST&UMN[CB>&>'$U<.R:&JW/@\M24&5GI-&/AFHV29*S)5DK
MK,,#5P#W7NC&_P YC^9A\E_C=VA\2O@'_+ZV=LO=_P \OF_N"JBV1FNR!')M
M_:.V\:X&0S^1@:=&FE=8ZF2+5%40QTN/R,S05$\5-25/NO=%/^#/\P?^:G\2
MOYAG4?\ +'_G.5_3G;F6^4>Q<EN7XR?*GI2DIJ.GR&9QGWM=5X3*0X[";8H9
M(330M1HPPF.J*6I2B\GWT.0:KA]U[H&OEA_-/_G,;W_G1?+;^5#_ "\=K?&.
MOAV#UEM[=.R=\=L4,M-+M2DKME;!W)E]Q9:NDKZF#*K'DMQRX^DI(\9.1+7T
M<DL$T-+.6]U[K8B_ENX+YZ;;^*NT</\ S)]Z;#[ ^5M%GLM#NW=?6\&-I\55
MX]*QTP\L:8G&8:A\\M"J23^.BI@)7=1$JJOOW7ND+_.&^6&3^$7\LSYC?)7;
MN6_@6\]C]1SX3KO,"%JAJ7<^YJNDVKMJI6%;ES39S-4LIU QHJ&27]I7]^Z]
MT07^3A\6NU^GO^$__56UOBAO3;VQOE=\B_CCF?D'LWMW?L4-310=@]A4,^9P
M&9SBRXC.I5TN(CJL;3R&;'9 O342^2FJ261O=>ZU<?Y#72_\Z#<O\PC^8S'\
M:_EO\>^OLEUE\RMJI_,WJ-WXV@F3L2>+>_88R3[.$O6.<%"M1)0[G,?@7;%A
MD:.RQ:$%#[KW1\OYWV>^3^W/^%/G\M_(?##9VR-\_)VH^#M+@>H\+V54&EV_
M!797+=ZXRIS&9E26&5L;MW'5E3E9X8F,U1'1-!"DLLB1O[KW1T?@!_,6_FS?
M'/\ F[[6_E4?S=M[]+=QYOY+=49#N7H[L7J7%T%!!BFAH\YD*3&TU5C<#M=*
MS#20[2S-(17X^6O6OBA KYHGTGW7NC(?S0_YC/S]W9\\-A_RB_Y2-/U=MOY0
MY7J&H[Q[R^0O<D5-5879&"DBD&/AIZ:>DS,1KF,E+--)/A\DH-?BX8:259ZN
M6E]U[IT_E.?S'OG=)\SNYOY3G\V'"]<U'R[ZMZPH^Y>JN\.IH(Z?"[]VPHHZ
M6NJ9H*6EH*%*YI:A:N&:GH<9'(HKZ:7&T4M @J?=>ZV2O?NO=:X7:?Q:["S7
M_"HCXT?)]NL=QY+I_:W\LC+8R#MFJQ,E7A<?NZ+<6\<1+B8,JL#08K,28'<<
M<B+))'-4TM16)"9(ON$C]U[K-_*<^-W9?4_\WK^?OVENO8&]=K]>]K]N]7U_
M5>\L[AJK&8G<GGQN[LKG9<+53QK!E4Q-7D((*FHIGDC,\I\A64M&ONO=58_'
M+Y"]!?&O_A7+_-=WU\B^\.G^@=DY;XD46T\7O'NO<V%VKBJG*STG0=9!C*?(
M9VMH*2;(34E!4SI3I(9GAIYY50I#(R^Z]U(VQV9UM\[_ /A7%TCW?\&=\[>[
M-ZA^.GQ0JZ3Y*=N]8R_<[>R$ZX#>F+\:9:B3^'YY9JG=.!H4F6::)GIG,,CG
M':4]U[KG@_YGO_"@'YZ_-'^9U\)/@#2_$W9..^(GR/W3U_B>]]\XZ*EJMN8#
M#[QW9MS"4+0Y0[DHLSN#/0XE)%J),/+20C'59FBB-5!I]U[JTW^8A_,U^77\
ML'^6O\6O])&UMF]X?S2ODIE,/T)M/:^WX*=MO5._*Z$MD\LM#02XPUF+Q\DD
M%/304JQ?<UM7012B"&:9X_=>ZKXV_P#S%/YX_P#*I^2_Q=QO\Y?+?'_O/XH?
M-#M9>KJ;L'INDQ%)6=;YG)/2I144U5C</M2F>BQGW'GJ$K8LI)44$-=-396>
MHI!#+[KW1U?YTGSH^;/\L?YB? 7Y/8WMJ>N_EC=D=DT?1_RUZBJL!M=X<+75
M;U03<0W&=MUF[H8WQ-3-D8Z:"OCA>JP I"R1Y%E/NO=)[X]?S"/F/\_?Y]O>
M?1GQB[RI]N_RS?@9LJGP7R!H,#@=F9>FWGO-ADJ&*A@W'6XNMW%CFKL])4QA
M\?6)3-0[5J@BP3UPGD]U[IT^7_SO^6/6W_"EK^7-\%MD]OY#!?%+NSXM2]@=
MH=1Q8S!S4^6S"+W.5K9,G48R;.4S [7Q?[=/6PQ'[1;Q_N3>3W7NIW\T/^8S
M\_=V?/#8?\HO^4C3]7;;^4.5ZAJ.\>\OD+W)%356%V1@I(I!CX:>FGI,S$:Y
MC)2S323X?)*#7XN&&DE6>KEI?=>Z=/Y3G\Q[YW2?,[N;^4Y_-APO7-1\N^K>
ML*/N7JKO#J:".GPN_=L**.EKJF:"EI:"A2N:6H6KAFIZ'&1R**^FEQM%+0(*
MGW7NBL?.[^8Y_-G^4?\ ->[C_E-?RC]Z=%?'G<OQHZ;H>T^SNX>ZZ&@K*G+R
MS0[4KJR'%G+8+=N/BI*6/>&.I$@_@SU,LBY"I-2D"0%?=>ZL!R.S/YH?>'\F
MC^8KU-_,(V1T_7_+/.] ]M=<]5X?XU>=X-TTC;'JEVW52)42/2KDLWFY9($A
MIT@3[<0&2.FJI)H8/=>ZIR^9/PB[KS/_  DS^)/QUV)T1V#D>\=JKUYO2IZ4
MVQM+(G<<66R^Y:^JS256"BI4R&/KZ>3<534Y.HE@#*XJI:K2)995]U[K<F[(
MZ9V1VYTCO?X_]@XV'<G7G8O6-?U/N_&5R*RUF*R>,EQ58CJ05#24TS6(_2UB
MI! /OW7NM</_ (2F=P=A5/P\^27PK[1W)!NK<?\ +W^66Y.@MO997G:7^[LD
MTE120R>>>I_9@SD&82D".(XJ(4]*B!:8/)[KW6TG[]U[KWOW7NM7/Y=[7_X5
M5;K[)[9WM\<NX_Y?G1/1?6N\LSENM-BTE-_$L[O';&-J9'QD>5DW#L_=D5-7
MY;'Q*\\<-?AC#*\D25$06.0^Z]TNOY?'\Y;N3YF?R)_EI_,%R>!V)AODY\4^
MJ^W:3/4^,H*M=MU6[-A;';>6$K/X;-5M.:&LH<CBWJZ>.K*F4U,<4L0LD7NO
M=4R;1_F7?\*:OEK_ "\:O^9OTWG/B#TM\=^@L+NC?N^J''X:BJL]V%B=E5M?
M4;BJZ?#YG&[ICQ^$H*2EFH9(XLCALE(^-K:J"I"STQ]^Z]UL>]$_SA-I[W_D
MDT'\W#L':U'1O@>B,SO#?/7V"F--!/N_;V4KMK5.$Q\M9)*]-2YG=5"L-$97
MED6GJX&)F?\ 7[KW6I+_ #$>\/\ A0-\F?Y-_>GS"^6%;\8:G^7M\M<'L+=>
M/Z;VU3T5%NO8&$;L#:U;M'.8QJ3%Q55;1;FR=-CA,F1SF:JUIZ]9?M,9IDAA
M]U[K=C_DW?\ ;IS^6]_XI1UO_P"\IC/?NO=9?YLO\PS;7\K_ .#O:_RRS6W5
MWIN#;K46T>L=C22"&/,;HS4_VN)I:F7R1/'CZ<^2LKFC)G%#2U)@2281HWNO
M=:V&Z/YB'_"B3^6M@NG/GU_,FH_C?W!\%NY=V[7HNV^D>JL?0TFY^K<9N"G_
M &_#-1XC&U(R:O4*6CJLMN>FDK($QYJJ$52U(]U[K:V^6FZ?E5D_BMNC=W\O
M.AZ9WI\A,]B,3E.HH^\):^GVO4TF1JJ,U-;4R44E-4AX,/42U=,C,J2RQI#(
M 'X]U[K4K^3OS\_X40_R;MX='_([^9%W'\.?D!\3>ZN\L7UINWKKJ+$1BHVS
M3RQ5N0R$.,JJ79^T\TM6<-0U<]-+45>>B,M/''(H,C*_NO=7P?SR?YH>]_Y9
MWQPZ[GZ'Z^H.U?EA\GNU*7HGXV['RZ-/1',5: S9.LHXJJDJ:^*C:6GIX::*
M1/-75M&DKI 96'NO=$Q^$VY_^%,_2ORZZ=V1\^-M?'GY8?&3O6JRU=OW?/41
MP&(J>J88::*>"&6JHL3M1:Q8)G6&&EDILU-7*9UCRGDB#^_=>ZIB[NR/\P"+
M_A5]_,:V]_+6PO4<_P C]\_&C:VU&WQWA,4V[M# 'K?I?(9'<E3 D53+75*U
M&/I<=2P+2U@^YR,4TM+)3PS%?=>ZN&_DJ?S(_P"8+N7YW?+S^4M_-*W!UYV+
M\H/C9L6F[9V]V[U]CJ#&19;&3R8&>II9TQ.+P&*JH3CMWX>JQLL.*H*@TQJ1
M5I+*GD'NO=;2GOW7NM2[YF?S$OYLGS4_F&]]_P N#^2YD^GNG8OAYMJCK?D;
M\H.XJ3&U\!S]7)2.,'C/XAA]VXZGCC9Y:$1R8::LGJJ7*-KI(**.:7W7NAH_
MEK_S*/GQ\S-A?S(?Y>G>M#UGT)_-U^'^PL]M?9'8M!!3#:-?E<MB\C0[.WA+
M0-3[AB:FP^X&H*JO,>,JZ"JH*N@J(:"7[F:@3W7NM=/_ (3Y]/\ \X+-_P R
MSY\2]*?*KH3:&*ZI^<VRI/YK5-N+'4,K]F4\&_M_G/)L@R=;Y0T#UL=!ND0_
M;OM32<E16:#QH:#W7NOI*^_=>Z^:W\V>F_YR5;_PINZCV3LSY8_'_$_-?>VR
M=Y;J^$W;V0QM"VW=G]52T?;57B=M;BIFZTJJ>JS=+M.ES-%+++A,W(:FKIW.
M5E95JZ;W7NK*_P#A5AM_Y!;4_D3?!K;7RNWSM;LWY)X3Y>;#QO=W8.R(8J?$
M9C<<767::Y/(8Z&'#[?BBI*BH!:-4QM"H4\4T7Z1[KW2.^2'\RO_ (4&?RP,
MM\7?FW\Z3\9(/@KW7V!@>L,W\3^M:.BR63VG1Y/'S9L4U=G$PU/FCNRDV]C*
MT1S0Y_)XJ:LI9@U'XVB(]U[K8$_G7_S0-V_RZ?CAUA-\?=CXOMSY8?+/M+']
M#?%;964*/C9LWE%3_<OD$-;0M445%]Q3Q11),@FK:VBCF>*F>>:/W7NJG=@_
M/_\ G;?RPOEK\6>O?YRN=^/'??Q?^</:IZJVSVYT71TM+5=?;ER[TD6'Q$S8
M_;VUQ4XZBGD!GCJJ*OGDHY*JJAS53)0_:2^Z]T:K_A0'_-7^:O\ +C[;_EK]
M<?#'9'5_9&X_E_V+NW9&<V)V'1R2SYFMQ63ZYH,#B,7DOXKC*?#RY.?==33R
M5,_DC1I(96T+"VKW7NJJ._?YH'_"CS^6C\I>G>C?E70?#GY/;P_F QU&Q_BC
ML#8,"XW!;;WE7Y#$[?Q%)_%(<1MS*55/C<UFZ!ZRDR=56+5P5.B+-TEC-%[K
MW1E>HOY@G\[7X&?S/_AU\6/YM78/QA[5Z<_F#[CKMH]<5?45)0T$.ULLLE)0
M4%%C<A!@-N5M1,<WD<=2O39$9)IUR"&FK?,JQGW7NMR#W[KW7O?NO=4!_P Y
MC^9A\E_C=VA\2O@'_+ZV=LO=_P \OF_N"JBV1FNR!')M_:.V\:X&0S^1@:=&
MFE=8ZF2+5%40QTN/R,S05$\5-25/NO=%/^#/\P?^:G\2OYAG4?\ +'_G.5_3
MG;F6^4>Q<EN7XR?*GI2DIJ.GR&9QGWM=5X3*0X[";8H9(330M1HPPF.J*6I2
MB\GWT.0:KA]U[H^O\R[;W\^7?O:&&V-_*]WS\,.D^EZO8-/6Y[NCN]*RKW13
M;B>NJHZJBIZ"? [MQ/V,%%'3312MB*@R&:9&(:) WNO=$W_DM?S+/GWV%\Z?
MF!_*F_F:5W4^]ODQ\5NM\=V7C>UNI*!*&GS./63;\&2>M^RH\9B9C/'NW#55
M,T&.Q;+YJF-Z3]NT7NO=!)\Q?YBW\VOYL?S$/D'_ "XOY,&0Z;Z8H_AUMZCJ
M?D)\GNXJ3'U\;YZIDI6;#X_^)8?=>-I8EE>6@2%\-45=1/29.;RTL--'(?=>
MZ,3_ *5?YFG8O\D[^;C@OYHW1.S>JNZ>L/BCWEL/;&_M@U-$,7OO$4O7.X@-
MPTV+I:RJ:AA::Z13::>*NB*314E,5=#[KW6M5_+J[8_X4"]5?R6-G?(?X.[@
M^.'3GPE^'M%V!V9FZ;==)C<WO+L3&X;<N=W+N^K^SR>"SE/1X/'M/5T'B@JL
M'DF&,JJB&I(EIY&]U[K>>_E5?-L_S%?@!\;OE_5X7';:W%VKM*JAWSMW$>44
ME'N'!9;(;=ST5&L\DLZ4+Y7%3RTBRN\GVLD)9W)U'W7NB:?\*+/DM\M_AO\
MRS-[_)_X:]P573'9/4G:6TJO<V?@P.V-PI6[?S>3&V*C&ST>Z\)G:&&-\IFZ
M"H$\,,52LE,D:S"&6:.7W7NJS?\ A0W_ #K?DM\1?CS_ "X]V? ;L>FP._\
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MW5/GR:_F-_\ "C?^7-0]5?S#OF?MSXN;@^$78^\]OX3?WQ1ZII:6MS6Q\;G
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M6&EV9D7R&*PJC&92+ X'+LU%E]S8AJ],K49J-J&9GIZF*56;W[KW5T/\[?\
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MV;2K75T]+/BF=J&9G7"*%KID58:?W7NMOG^3-_)AW+_*R7YBOV'\SL_\U_\
M9O\ <6$W+NN?=^V:G!M39?&-NI-Q9&NDJ]Z;Q;-Y/=,FX$&1J933U#-0)]R]
M4SKX/=>ZTG.QMU[Y^.'P]_F-?\)^-JXO(/V;V!_.1V+U9TWA-S9)C%-M#=-;
M59# UM*Z&MD:"7(=?;:GGC98](W!'4MJJEFA/NO=?3TZ.ZEVMT'TMU)T;L>C
M@Q^S>G.M,'U?M:BIE*)'C\#C*;%TBJI9V'[%*I.IF8FY9F))/NO=$J_G(_\
M;IS^9#_XI1V1_P"\ID_?NO=$ _X34;TVMUO_ ,)]OB'V#OC.8[;6S=D[>[8W
M5NG<.6E2"EHL?0=M=BU-74SRR,J1Q0P1LS$D"P]^Z]U1O_)GZAW=\A_Y2O\
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M+YB2F5D@DS&>RM179K*& 2/XA4U4B0^23PK&'8'W7NM:#_A.?_V^!_X4H_\
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MVZRZ#_\ %_\ :W_ONNU??NO=)?\ X6/?]N?OBI_XNOL;_P!]?V?[]U[H#?\
MA5/U7OG>7;O\B#<.)[4S_06TJCN6LZKE^1NWY94J.N\[N#)]8SXW=5*(<IA:
MB/(8NFQ=5DZ>2"NHGU8@WK:1EAF'NO="!VQ_PE5^:_>]!M/$]Y_\*$OE+W+C
M-J;MI][[%QO;&U]V[B@QN=I(9_M,OB8<QWI61T>6I:>2;Q55.$J(XVET2*K/
M?W7NEE_PIR_[>,_\)OO_ !=?,?\ O=="^_=>Z]_PHP_[? _\)KO_ !=>@_\
M?H=.>_=>Z]_PHP_[? _\)KO_ !=>@_\ ?H=.>_=>ZW$*W.X/&5$%'DLSBL?5
MU(#4]+6U$,4D@9M(*)(ZLX+"PL#<\?7W[KW3K[]U[K0P_GP_&;N'N_\ X4??
MRZ]J;-^4F_OA#/WW\5#UKU1\LNOI:W^*;?S6+J.SIJ[$8Q<=N3:F06HS#9>C
MQ<J0Y.E62+/V'W1::DD]U[H[/5__  F;^5^#^77Q&^4O?_\ /"^0WRHS7Q.[
MHPG;NT=K=P[8W)DZJ?'XS-XG)9_ XW+9KN3.RX.CW-2T$=!D)8:::-XI$^XI
MJI%6%O=>Z*,/C?N'_A1%_-J_FE] ?+CY)?)CI_XM? ;?='U+UE\>>G\I18>+
M(M2YK-8;^/5%+F,?G<5.E95[7?)BJEQ\T\J5]%XI:>*-$;W7NFC^1Q\:L1\/
M?^%._P#,?^-F![3[*[IPW57PAK</C>R>X,A%E=RU\-3F>C,BD65R$,4$53/C
M16_8H4BB58J:-!''IT#W7NC5_P#"=:FJ.N?YN_\ PHRZJ[ TT':&>^4U%V)B
MJ"MD1ZFLPO\ ??M6LERD3.WW$E+50;IQ%1KT\K5P&;1(RJ?=>ZV!OYI>?P6?
M_E8?S/'P6:Q.:7$?!;NS 99L34PU(I:ZEZ\W&E515!A=_#5TSG3+"^F2,\.H
M/OW7NM>_^5I_W!X=_?\ BE'RK_Z&[-]^Z]T?_P#X2I?]N/?BC_X='8__ +\?
M=7OW7NK)_P":MT55_)?^6U\X.D,51TF0W!OGXT;L@VC1UQTPOG*'%5&3P0D?
M2_C49BBICKTDI;6 2OOW7NM(G^6SMY_YQ.?VCUQCZ\Y'9?Q#_P"$Z^:^(5,7
M6.:? ]D[AK\_LRDGBB2-GBJZW!4FM!("7H:: QQG[@2GW7NEO_(,[@E_F(_S
M#OY4B9!*BIP_\K7^5=N?%Y>@C,\]/0[K7=VX^O,?]Q4O'%&)<ALG+8&N@I_4
M(V@81M((&,?NO=6,_/?_ +C#_P"4E_XI1/\ ]"_(;W[KW7OE3_W&=?RU?_%*
M,]_[Q'?WOW7NE1_PM6_[=9=!_P#B_P#M;_WW7:OOW7NDO_PL>_[<_?%3_P 7
M7V-_[Z_L_P!^Z]UM^[(_X\O:'_AKX_\ ]Q(??NO=4 _\*K?^W'ORN_\ #HZX
M_P#?C[5]^Z]T37^8[C<CE?\ A'%UY2XN@K<E4Q?R\_BODI:>@BDFD6GHLIU!
M65E0R1JS""DI())YG(TQ0QO(Y5$9A[KW2 ^?-=13?\(Q-@-%5TLJR_#+XWT,
M1CD1@TT.^.KUFA6Q-Y86AD#H/4IC<, 5:WNO=2OG[_W!B[$_\4H^-7_O;]5>
M_=>Z(!_/%_[A3_Y,7_AT=&_^^/[!]^Z]UO\ FR/^/+VA_P"&OC__ '$A]^Z]
MUJ5?\+5O^W670?\ XO\ [6_]]UVK[]U[HQ__  J&SVW:3^0GVG%75V-^XW3F
M.JL;M%I9(2:FK&Z<!D66C+->64XNBJI?VM3&!)6MXP[#W7NJEOYK>R-]=+9C
M_A()OCN^L:HVST1N7J_9'>&[<M5O/2TF=H)>C:S+35U1D3 7.0I\!D)C//I:
M5**9JKQZ5O[KW1TO^%F44>\_@K\/.D=LTL.;[?[0^>^ BZ[VK3M *[(+'L_>
MN(GBIO+(C!'RF?QD+'B(230^5U.B_NO=/W\^/<M+\(OYA?\ ))_F0[PJ**/;
MG56X-\?'CM;=,TUF67.[9,.%>>:=5+8\_P 1S<M1-*R>&/4[6ULR>Z]U2EUU
M@<C_ "_/AM_PG=_FR]KR-'F<A\X>Q]R_(3,2%Z=J[#]W5-=(=P5L\--(7JX]
MD;:FJQ&B!)HY! J:5:3W[KW6QO\ \)<NKMS4O\IJO[TW%+5TG:/S>[^[(^1^
MZ<U5I-3R-7UV5EVO3U<0),L5+*-N"L@*<,M09HRPD#M[KW6L!_(0_E-?-/Y>
M]$?([$]-_P X7Y.?RX=P=$_)_*=;]I_&3IW^\LM/_%HL-A8GW-D$V[VILVE6
MNKIZ6?%,[4,S.N$4+73(JPT_NO=; O7'\G'>7\IS^5__ #X\QO#YL;F^9.1^
M5OPN[$WKF\IN7;=5@)Z#/878'9ASN7JIZK>F\),SE]RSYZ(U]5(U/4&3'Q_<
M253,O@]U[HV/_"5+_MQ[\4?_  Z.Q_\ WX^ZO?NO=;$WOW7NM.7XJ4E3UO\
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M(9<KFY\-',TN.RF.CC5VBQU2D.1HJ6:L."SE/,*.A/NO="M_-^^:>+_F(?\
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MVK3M *[(+'L_>N(GBIO+(C!'RF?QD+'B(230^5U.B_NO=(O_ (4K4M;0_/\
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M'XK?]QG7\RK_ ,4HP/\ [Q'0/OW7NO?%;_N,Z_F5?^*48'_WB.@??NO=2?\
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M.ZO"X_,5:-'2SUD2]]B6DAJ' BEJHSD*75$K%U^YI[J/-'J]U[J)\])8I/\
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MR51]YD:/YAY"EKZO6\GEGCWKT&DLGDD D?7("VI@&-[D GW[KW3I_P *<O\
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M86@V9O;,X^E?0TF(P6_]K9;+3,"R(\6/H*26MD5C^BF8H&E"*?=>ZH'^&/\
M(*^9WS4_EV?'??F)_P"%!_RKV]\>>\OC'@HJ_P".BX_=V8V?@,-58*"BR6P9
M*(=VT6%K,+MT)-AGISCJ6F,-*8FH:9+T\?NO=8?^%$/PMRG\O#_A.?\  SX:
MY?N.O[]J^D?GA0XJ+M7)8J3!R9"ERF![OSU#3+B9<SN!J&GPU%E8L;!&*^=/
M!1QM&((RM/%[KW5O_P#PJ&SVW:3^0GVG%75V-^XW3F.JL;M%I9(2:FK&Z<!D
M66C+->64XNBJI?VM3&!)6MXP[#W7NBV_SH_A[V#OO_A,W\::G,QY/,_(/X+]
M"=*=SU>>QU;/_$(\AMW:V'VWO/(+D*AZ:JF%+C<I7Y*1Y"L\C4:3!#4I&OOW
M7N@?_EC=KT/\W?\ G_UWS[CPM%5=;_"S^6MUKMO:M?7SF>KI=X=B;7AS$].\
M"+]O3U6.J=W;TQ\^F69%EH1+&6:>\'NO=;L'OW7NM*_Y^[:[+_F__P _#??\
MHGLOY!]\?';X;?'KXL4_9NY=K=.5T6(GWYD,CC-M9*KE:2LAKL=D8=&\8Z*]
M715<$"XNMC2F\DDDH]U[HE/0G\O_ *__ ):G_"KG^7/\9NK>XNZNY=AT'QJW
M1NK;=?WOE:+,9C!TM5UGW+11;=IZC'8_%44&*HH\<L]-!%1TZ1_=/ICLP9O=
M>ZL(^,M+4XK_ (6;?S$)<I3SXV+<OPAPE5MV2O1H5KXH]F]&0O)1&0**J-)J
M"JC9HM0#TTZDZH9 ONO=1/BE+%-_PLX_F5O#)'*@^%F$B+1D, T>R^@D=202
M-2.I5A]0P(/(/OW7NLGP(_[C#_YMO_BE$'_0OQY]^Z]U[_A3E_V\9_X3??\
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M\1_AGWN-^_\ L_N?+]O]W3>73H\T=]8]U[H$_P"5Q\&/^&U_@GT9\*O]*/\
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M(RS5=742S33U,LC>Z]T&O\N?^4E_L@7S!_F4?*__ &8#_2S_ ,.&]V5'</\
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MM>US]??NO=:UOS/_ .$VNSN\OD_OOY6?#CYO_(?^7)OKO3-PYCY*8+H,UO\
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M?[+3_)XW_P#RG/\ 9@/[Z_WYZ3[6Z>_T^?W4_AOVO^DX[F/\1_NK_>2O\_\
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M(ZUVC+@ZJ27+8=]OUM#EL)F(ZNH9FK,C2YK'05T_GU1ULGFBJ4>">6-O=>Z
M?^4-_*1S_P#*TVMOW ;G^:W>WR^?<^'PVS]E8[M#ST>W]E[?P$N3-!B=IX&H
MS.?&(2:GKH(JSP524\_V-*8J2F2-8U]U[KG_ "5/Y1L7\G[XW=I?'F?OR/Y(
M0]F]T57;DVYY=IC::TJU6!P>#;&-CCN3= JE PWE,YJ(PPF\1@'CUR>Z]T43
MX"?\)R-I?R]/F'+WWT_\X_DF_P ;\5OC)]B;.^$J2U%+M1<GDL97XF-]S5)S
M573[J7$TU32G'S38RFKXY,=225%=5,@(]U[H1_YH_P#(/VS_ #!ODCL'YC].
M?+SNKX-_*':.T:?KG-]H=0QU%4V5P5/)5%8@E%G=M9''93[6NFI?NX,AXGIB
MD=11U C7W[KW3[_+K_D!="?RYOE[NOYG['^0WR*[A[2W[U!4=6[V'=-?C\J,
ME4Y&3;U9F=PU&0^S7+39/)Y7 _=,)JJ6.+[J6%042(K[KW4?^:U_(@VI_,E^
M1/1WRXZ_^5O;_P ,?DGTUM1.MCVIU%#/45E?MI*[(UBTE,]-G,#58;*PIF\I
M!%D:>H8M#7-%64U9!#!"GNO=<OEO_(U@^3N:_E!Y*G^66\<"O\J7=5-N>7+=
MA[>&[L_V9+!D>O<C/4YO-C<6 _A>6R,VQ'>KK?M<B9I\E).808"E1[KW5@?\
MQK^79\>OYGGQIS_QG^16.RBX&JRD&Z]E[UVPU/%F]LY^DCGBH\UAYZF"IA2=
M(:F:GFCDC>*II9YZ>1=,FI?=>ZI\^%/_  FEV)T%\F^N/E+\N/FU\@OYA>\?
MC]EGK_C-MCN]*A,+M%8'BEPTLE/D\_NFHR%?@JB,5-(]-/C:%*Q(*H8U9::(
MCW7NCP_S.?Y27_#CGR,_EO=__P"S ?Z&_P#AOGNRL[A_NE_=3^\/][ON\[L+
M-?P[[_\ O)@_X!X_[D>'[C[?(ZOO?)X1]MXY_=>Z]_,Y_E)?\..?(S^6]W__
M +,!_H;_ .&^>[*SN'^Z7]U/[P_WN^[SNPLU_#OO_P"\F#_@'C_N1X?N/M\C
MJ^]\GA'VWCG]U[JY+W[KW5!O\TG^1+MK^8%WOL+Y@=&_+;NSX%_,G86T(^O:
M?O;IDUE0:["Q33R10U5%C\]M?)P5]/#6U5/'5T66I"\$_BK(JN.&G2+W7N@\
M^'?_  G#Z.^)OS@Z7_F$Y'Y;_*[Y!?)+K+$9J/>6Z>[LI19@[QRN<VUN#:=1
ME<O5U=-4YF-J3"YR.GI(5KG$<>/I!)),QF:3W7NC1]5_RDO]&7\YWY*_S=O]
MF _C?^S#])T'3W^R^?W4^V_@_P!EA-@8;^(_WL_O)4?Q#R_W&\WV_P#!J;3]
M[X_,WVVNH]U[KW5?\I+_ $9?SG?DK_-V_P!F _C?^S#])T'3W^R^?W4^V_@_
MV6$V!AOXC_>S^\E1_$/+_<;S?;_P:FT_>^/S-]MKJ/=>Z*=\_/\ A.SMGY9?
M,^H^<WQS^;?R!^ W<V_L70[6^0.0Z)6=9-UXBF2"FK$I*['9W;M?A<GE*&CI
M(*B:67)X]S1TT\F)DF65I?=>Z-;_ "L_Y*?07\IWL#Y.[ZZ0[4[B[!'R=KL3
M4Y[$]L5./KFQ<>%K<]64<=+7TU%2UM9(W\?E2>>L>::8Q1R,PD:0O[KW5RWO
MW7NJ;?Y)_P#*2_X9W^.?9W0'^S ?[,5_I&[LJ>X?[V_W4_NC]G]Q@L%A?X=]
MA_>3<_W&C^"^;[C[B*_F\?A'C\C^Z]T*'\TC^5!\>?YJG5NR]G]M93=G6W9O
M4.YCO+HOO_K22*GW-M/(224KU@HII5*34&1^QIS4TS%+RTU+4PRP55+!-'[K
MW12?Y:'\C3,?!GO"+Y/=\?S#?EQ\Y.^\?LVOZ_P>9[,S.9QFW:7$Y&77/3R8
M"KW)NBKR( CA9(JS*3T<=3$M9'1I4I3R4_NO=7\>_=>ZK;_F;?RT.N/YG74&
MQNLM]]N=V=(YSJGL>#MWJWL;I#++C<CB=Q4U)58^"O>*6*6*J,5%75,49!AG
MA\\C05$19M7NO=5D_!#_ (3E8KXV?*_9'S*^6WSS^1G\PON+IF6M_P! ;]R'
M(4N/VT*N(Q0SS)D]S[MR&3KJ(35#PE*NCH1-,M0<>9X(I![KW0H?S1_Y!^V?
MY@WR1V#\Q^G/EYW5\&_E#M':-/USF^T.H8ZBJ;*X*GDJBL02BSNVLCCLI]K7
M34OW<&0\3TQ2.HHZ@1K[]U[I]_EU_P @+H3^7-\O=U_,_8_R&^17</:6_>H*
MCJW>P[IK\?E1DJG(R;>K,SN&HR'V:Y:;)Y/*X'[IA-52QQ?=2PJ"B1%?=>Z*
M#W-_PEMV+N7O[Y-_+7XW_P Q'YA_$_Y-?)'MW<O:U1V%UQ4P0TF(7=N?R&XL
MU@4I<!5[4S.0P\U=5P%(Y,Q&Z_94[.\C:B?=>ZM<_E7?RF^B_P"57UGV!MOK
MO=.\>WNV^[-UIOGOKY!]FF*3<6ZLE%]RU.*AX];0T%'+75<T$#S5$@GK*N>>
MHGGJ))&]U[JISY$?\)A<CO\ [3[1WC\;?YJWS<^+O7'?O9V7[.[VZ6HLAD,Y
MB<U4[DJI*O<:4S4.Y=JQPRY6:IJ2TV3I\S83:98ZB-=#>Z]U<M\</Y6WQ9^,
M_P#+VRW\M?9^'W%FN@MW]:;DZY[(K=P5K'-[A_OA1U5'N7*UE=2K3?;9'(+6
M2&)J1($HU6&.D6)8([>Z]T1;^4G_ "(IOY5O9^Y-WTGSP^17R%ZT@VUF=I=1
M?'S>*MB]G;6I\WD,?DZO)C#IF,ICZO<K3TE0IR-'38I'CKZL/2%Y6=O=>Z'/
M^7/_ "DO]D"^8/\ ,H^5_P#LP'^EG_APWNRH[A_N%_=3^ _W0\^Z-Y;D_AW\
M4_O)F?[P:?[V_;_<?9XV_P!IYO"//XH?=>Z)X?\ A.'LW;?\R/>OSOZ:^;_R
M0Z*Z\[;[MI/D'W=\6.MY)Z3%;MS\&>7<=509;,QYJ..LVGD\G/7M/B*O%58C
MCR-13T5324X6'W[KW1J?YN_\EOK_ /FI-TIO_&]]=D?%3Y+?'.LK)^G^_.M(
MGK*BABKI:6HE@JZ"+)X2JF--54:3T<])DJ"IIIFD*S,DC(?=>Z+!\1?^$VO3
MWQA^8?Q\^>.Z?F1\K/D5\E.E\771[GW5W#D*7)4^Z\A78K/8-JRM.07)9FA@
MI<1FDIJ6ECR<JQ"B@=I)&DF+^Z]T:[^<1_)KV%_-IVQT56OW?O?XS]\?&?=E
M?NSI/O/8M(^1J,7)E#C):V*;&QY7"23D5N$QU72U,%=2UE%44@:FJ(UFJ$E]
MU[HLWS&_X3^5?RT_EA="_P N?*?.KMFISW3GR('R'W#\HN\,*^_]S;HK6H-Z
MT4M#7P2[GV_-'%$N\%CI)I,A5/34>.IZ0K-J\T?NO=69?/[^6U\>OYD?Q/G^
M)_R*I,I/@:3[',;+W]MC[>GS>W<_C:62EH\[AY:F*KABG\,TT,T,B215%+43
MTTEUDU+[KW52'PI_X32[$Z"^3?7'RE^7'S:^07\PO>/Q^RSU_P 9ML=WI4)A
M=HK \4N&EDI\GG]TU&0K\%41BII'II\;0I6)!5#&K+31$>Z]T>'^9S_*2_X<
M<^1G\M[O_P#V8#_0W_PWSW96=P_W2_NI_>'^]WW>=V%FOX=]_P#WDP?\ \?]
MR/#]Q]OD=7WOD\(^V\<_NO=>_F<_RDO^''/D9_+>[_\ ]F _T-_\-\]V5G</
M]TO[J?WA_O=]WG=A9K^'??\ ]Y,'_ /'_<CP_<?;Y'5][Y/"/MO'/[KW56W\
MPOI.;Y9?\*BOY6G5>2VWB\ELCXO_ !'F^9V[JZODD8LM!N_=E/AU%.L91FH]
MVX/",NIPCBHDU@B)8Y?=>ZVV_?NO=4&_S2?Y$NVOY@7>^POF!T;\MN[/@7\R
M=A;0CZ]I^]NF365!KL+%-/)%#546/SVU\G!7T\-;54\=719:D+P3^*LBJXX:
M=(O=>Z#SX=_\)P^COB;\X.E_YA.1^6_RN^07R2ZRQ&:CWENGN[*468.\<KG-
MM;@VG497+U=735.9C:DPN<CIZ2%:YQ''CZ0223,9FD]U[HT?5?\ *2_T9?SG
M?DK_ #=O]F _C?\ LP_2=!T]_LOG]U/MOX/]EA-@8;^(_P![/[R5'\0\O]QO
M-]O_  :FT_>^/S-]MKJ/=>ZL8^3WQGZ8^8O0O9?QJ^0>SZ3?74?;& . W9M^
MI9HWLDT551UM'4):6CR6,KZ>&LHJF,B2GJH(9D.I![]U[K6ZZ'_X2W0]5]F[
M$EWW_-1^=O:/QBZ:W9A]W])_&2BS62VY3X6?"RBJHXI\Q0[BJJ31%6HLD4F&
MP^!J*=0RPS+(PF7W7NMKY0%4*+V46&HDGC^I-R3_ (GGW[KW5-W\SG^4E_PX
MY\C/Y;W?_P#LP'^AO_AOGNRL[A_NE_=3^\/][ON\[L+-?P[[_P#O)@_X!X_[
MD>'[C[?(ZOO?)X1]MXY_=>Z]_,Y_E)?\..?(S^6]W_\ [,!_H;_X;Y[LK.X?
M[I?W4_O#_>[[O.["S7\.^_\ [R8/^ >/^Y'A^X^WR.K[WR>$?;>.?W7NC8_S
M#/Y?7QY_F8_&G<_QB^1^$KJO;&5KHMR[1W;@'BAS6V-PTD51#0;@P=3-%/%#
M7TL55-"RR1R0U-+/44E1')!/(I]U[JH?X0?\)VLQ\9/D5UO\@^^?YG?S6^74
MG0NY)\S\?NNMS9O,X+"X.F:G^RI:+)H^Y]P3Y6**A9Z>IBI'Q-!70M]O4T!I
M#)32>Z]T<?OS^4E_IP_G#_$G^;'_ +,!_=C_ &5KI.3I[_0'_=3[W^.ZQV&/
MXC_>K^\E)_#+?W]_X#_P>KO]C_GO\J_R?W7NK9=_;#V9VGL;>76?8VVL1O/K
M_L+:U?LG>^T-P0K44.4Q.4I9:+(X^L@?TRTU923R12(>&1B/?NO=:H=/_P )
M.MIX+>63V7L/^9W\W^O?@IE<Q49Z7X8;5R=7#31RU62-=-319W^._P )>A\.
MF$&HVY/7LRK439"::Y/NO=7%?S+OY1W2_P#,V^)'4?P\[-[0[@V%L7ISL? ]
MC[?W;MNOAR^X:RHV_MK/[8I8<KD]RPY:?(M44>X)9JFJF+U<]1&DDDS%I-?N
MO=50[&_X2J=60=M=;MWW\^/EG\H?AIT?N&@W+TK\(.W*R>LVWB'QRM#38ZKJ
M:G,5N-J,(E)HI?M*#"XJ1Z16II:F2"5T/NO=;!GSMK.G\/\ "#Y=5??,< Z-
MH?C+O<]JTYBDE!VZNVLDN4BB@@5II)7HM:PQPJ96D*+$#(5'OW7NM?G_ (1\
M_%F;I'^5O7=XYJFDBW%\N.YLQV%1FII#331[>VZW]U,/3LS2/)50R5V,R==#
M*5B5HJ]1'&R 3S>Z]UM;^_=>ZH-_FD_R)=M?S N]]A?,#HWY;=V? OYD["VA
M'U[3][=,FLJ#786*:>2*&JHL?GMKY."OIX:VJIXZNBRU(7@G\59%5QPTZ1>Z
M]T'GP[_X3A]'?$WYP=+_ ,PG(_+?Y7?(+Y)=98C-1[RW3W=E*+,'>.5SFVMP
M;3J,KEZNKIJG,QM287.1T])"M<XCCQ]()))F,S2>Z]TJ_P":/_(/VS_,&^2.
MP?F/TY\O.ZO@W\H=H[1I^N<WVAU#'45397!4\E45B"46=VUD<=E/M:Z:E^[@
MR'B>F*1U%'4"-??NO=/O\NO^0%T)_+F^7NZ_F?L?Y#?(KN'M+?O4%1U;O8=T
MU^/RHR53D9-O5F9W#49#[-<M-D\GE<#]TPFJI8XONI85!1(BONO=!-\[?^$Z
MFUOEO\\LM\]>G?G!\C?A3V%V9MJ@VE\@*3H1YZ>NW-1X[&46)B_AV;I\WC)<
M U318C&)60O39&AJ6H4G:B6JDEJ&]U[HTG\R3^4#3?S ^^?Y9O=%'W^W35'_
M "Y>W)NT*3:+[5&XFW;%)F=@9:/&G(#<>!&!,:[%$)J!39 -][Y/ OVWCG]U
M[IP_F<_RDO\ AQSY&?RWN_\ _9@/]#?_  WSW96=P_W2_NI_>'^]WW>=V%FO
MX=]__>3!_P  \?\ <CP_<?;Y'5][Y/"/MO'/[KW0@_S3_P"4I\?_ .:KUSL#
M =F[BWGU/VUTON9MX]%_('J]X8=Q[8KI7IGJ8X7E7_*,?5R4=-++ )()%J*6
MFJ(*B":%7]^Z]T3[^6;_ ,)_>OO@U\@I?F3\AOE/W'_,!^8M+MB?9NT>ZN\$
MGCCV]0U"5%))+AJ')9K=.5BR3XF=L>:FHS%0L=++5QTT-,E7*GOW7NC =^?R
MDO\ 3A_.'^)/\V/_ &8#^['^RM=)R=/?Z _[J?>_QW6.PQ_$?[U?WDI/X9;^
M_O\ P'_@]7?['_/?Y5_D_NO=6)_+'HO_ &:#XL?);XT?WI_N/_LQ'Q_WET7_
M 'U^Q_B?\'_O;MS)8#^*?PW[S'_Q#^'_ ,0\_P!M]U3>?Q^+[B'5Y%]U[JDR
MI_D"SS?R1,?_ ";(?EW-2QTF]&W95?(B/8K::B,]@3[[%')L\;T4:%EE2E#G
M-,-42U7CO:!?=>Z(9LK_ (3&_P QGK7:.W.O^N?^%(7S7V!L/9V'@V]M'9.R
ML/OK%8C%8^E014U#C<;0]]04=#1T\2A(H88TCC4!44 6]^Z]UL4?.7^7+T+_
M #%/B)-\1_E!'E]UXB.@Q^0V_P!EXUEAW!A=SXRBDHZ3=F)J*G[T0Y0">H65
M9ON(JBGJ:FDJ1-#/(&]U[JJ/X0?\)VLQ\9/D5UO\@^^?YG?S6^74G0NY)\S\
M?NNMS9O,X+"X.F:G^RI:+)H^Y]P3Y6**A9Z>IBI'Q-!70M]O4T!I#)32>Z]T
M<O\ F[_R;^JOYK^T^I*S(=L;W^./R#^/>XY]T]&?(3KJG2KK\-45'@E>"IH_
MN\9455(E?14E;$:7(8^LIZNDBDIZR(-,LGNO=%"^(?\ PF^ZQ^-/R]^.7SR[
M ^:WRL^3?RDZ2P573;PWKV_70U])N[)UV*S^%FKJA,K)FL[C*.GQN<$-)1)E
MZD0"DA:2>>22=Y?=>ZV2_?NO=4Q?SB/Y->POYM.V.BJU^[][_&?OCXS[LK]V
M=)]Y[%I'R-1BY,H<9+6Q38V/*X22<BMPF.JZ6I@KJ6LHJBD#4U1&LU0DONO=
M"]LG^5CU%-_+FR/\N+Y+=D=K_+_8V[,3E*?L3MSNW(M6;OR^0R.9FSE-EQE)
MC5S4V0P%8U.,1([U$E''0T:-),(CJ]U[JF7I?_A)WU5MOM+KBI^3/SS^3?S!
M^*W1.XJ+<'1?P^[.5HMMXM:-"O\ #LLTV;RV-K\5.RQK+38O$X%):=&I9O+!
M*Z^_=>ZVUT1(D2.-%CCC4)'&@ 55 L  .  . ![]U[KE[]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HG'0_P)^,7QM[]^
M27R?ZIV3F,9WC\M<Q29OO3?&<SN<R\F4EH9JR:DCIJ3)Y"JH<12TYK71*>@A
MIH5B2"$((X(E3W7NCC^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z ;OSXP?
M'[Y2XSKW!?(GJ;9O<>WNK.SJ/N39&V]^TJU^,I=R8_'97%4.3EQTQ-%7/2T6
M:K%CBJHYH%>59A%YHH9$]U[H=T1(D2.-%CCC4)'&@ 55 L  .  . ![]U[KE
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@/\ DE\=NK/EGT?V'\=.[L5E\]U-
MVKAEV[OO X/*9+"U%=0"HAJ7I/XEB*FBR-/!.].J3+#/'YH3)!(6AED1O=>Z
M>NB^D^M?C;TYUGT'TYM[^ZG5G4.S*#8&PMNFIJJQJ3&8V!*>EBDK*Z:HK*J4
M1I=YIY9)97+/([,Q/OW7NA6]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW1-?E!\^OBY\/M_?&KJGO+L(X#LWY==PXCI#H+8
M>+HJNOR.;S.7RV,PRS>.FB>*BQ6/J\Q2?>UM2\4$(FC0-)/)%#)[KW1RO?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW13_ )G_ #=^,W\OWI+(_(+Y6]EX_K+K
M>DR\>V<95SPU%76Y;,U%+65E)A</CZ2*:JR&5JZ;'U,L<,:\10332M'!#+(G
MNO=&AQ61@R^+QN6IEE2FRE!#D:=)P X2>-94#A690X5A< D7^A/U]^Z]U/\
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M]U[J?[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB@=I?.[XO\
M3WRCZ$^%N\^R*2/Y._).GJLKU?U)BX)ZK(2XJCHLY73YS(-&GV^,Q&G;M?#%
M/42(:FHIY(*9)GCE$?NO=&_]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5<^P/YI7Q0
M[+_F&]O?RQMKY7?,OR:Z4Z^I>P]VK6X66';\L,\%#5U-!0Y8REYLAC*/+8^>
MH\E/#2NE;$E'554T-9%2^Z]U8Q[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[HH'Q!^=WQ?\ GCA^U=T_%3LBD[:V3T_V=+U#N7?6$@G3$56;@QF.RU1'
MB*N=(_XI1PTV5@'WD*FEE<M]O+,BZS[KW1O_ '[KW7O?NO=>]^Z]U[W[KW5<
M_P TOYI7Q0^!'<?Q,Z,^0&5WS1[Y^978,G7G52[2PLN3HZ6:.:AH_O\ -U"R
MQ&DQ[Y3*T%"OVZ5=5YZR.5J5:**KJJ?W7NA.^<WSZ^+G\N3I*;O[Y8=A'86Q
M),[#M/ 0T-%5Y+)YG,5,4\]/B<1CJ**6>JK98*6:4WT0PPQ2SU$T,,;R+[KW
M0S?(+Y!=-_%;IS?7R ^0._L)UAT_UMC8LIO+>^X6<4U)'4U=/CZ2/3$DLT]3
M6Y"K@I::")'FJ*F>*")'DD53[KW4GH/NS8GR3Z3ZI^0/5]3DJSKCN?8.+[+V
M)6YBF>CJI\1F*2*NQ\\])(3)3234LR.8GLZ:M+JK@J/=>Z%OW[KW7O?NO=>]
M^Z]T4;YM?.CXQ?R\>CJSY#?+'L>'K?K:'<-+L[%5,='6Y*ORN;KH:JHHL/B<
M;CH*FLK<A4T]%43:501Q4]/45-1)#3033)[KW3#\FOYA7Q5^(57\;<)WQV%)
MM7>'RZ[&QG57Q[V)24-57Y?<.8R55BJ/1%3T4<T5)18^;-T0KJZJEAHZ8U,$
M;SF6HIXY?=>Z.O[]U[HFOSF^?7Q<_ER=)3=_?+#L(["V))G8=IX"&AHJO)9/
M,YBIBGGI\3B,=112SU5;+!2S2F^B&&&*6>HFAAC>1?=>Z-#OG>^T.LMD[Q[(
M[!W'B-G["Z^VMD-[[WW=GYDIZ#%8C$TDU?DLC6U#D)!24-%3R332,0J1HS'@
M>_=>Z!+XC_+CH_YP](X3Y%_'+<E;O'J#=&X<YM[:^ZZRBJ,>,@VW\Q6X*NJ:
M>FK$BJUI'K\?,('ECB:6,+*$"NI/NO=&6]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=%.^:'S>^,_\OSI'(?(/Y6=DT'6G6]+F(ML8VJFAGJZW+9B
MHIJRLI<+A\?2QRU60RE538^IE2&->(J>::1DAADD3W7NC18K(P9?%XW+4RRI
M392@AR-.DX <)/&LJ!PK,H<*PN 2+_0GZ^_=>ZKV^:7\TKXH? CN/XF=&?(#
M*[YH]\_,KL&3KSJI=I867)T=+-'-0T?W^;J%EB-)CWRF5H*%?MTJZKSUD<K4
MJT45754_NO=6,>_=>Z][]U[HG^/^=_Q@S7S/R_\ +^V_V/2[B^4^U^L)^W]\
M]=X6":;^[^%C_@;0/FJW2M)1UM?#N*@GIJ/6]3)33I4F)(&21O=>Z.![]U[K
MWOW7NB:[6^?7Q<WO\V=\_P O?9W81W+\H>K^GI>[^S-F8JBJWI<#ADKMO4,,
M.1RC1)0KE:H[GH)XZ**26=:63SSK"CP^7W7NI7RH^=_Q@^&69Z)VMW[V/2[6
MWK\F>SZ#J#HG8M'!-69?<F:KLGB<44HJ2!3IHL?59RA^^K)FBIJ1*F$RRAI8
MD?W7NC@>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB@4
M'SN^+^9^9V6_E_[?[(I-Q?*C:_6,_;V^NN<)!/-_=["1?P-H),U6Z%HZ.LR$
M.XZ">EH_(]5)33+4M$D#1R/[KW1O_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U7/\
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M?R\*+XA=8;7['Z@^-N%WCGOF5CZFB;=FYL6,-L'/46V\C"FW8*]<9CI]_2K
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M]I'3[;GC;3(9/)+%9"NLK[KW5.6,_P"%7/4F,[EZWINX_@3\M>@_AAW5G:+
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M[V?!4XK%YRHJS24]#EZ;!5V"I:&;;$]-,E:];2Y^KJH:-EF;'$%@GNO='_\
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MF4HZ'<6^NV,Q24N2I-3_ &V0IX*Q8ZB+4WCF5TU&U_?NO=;N_OW7NM/?%_\
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MV)\A,6F(KX,IB:>DJ*]Z)S)>MQU.*Q(FJ6BIRE3'44TD22T\JK[KW5'?</\
MPJWZQVOV1V'D/C[\ OE3\K_AETCNZNV9W9\W>K8W&U\;4T4,+&?$:,-783(4
M4TT\?CFR>=P?DII(:R!9H9X?)[KW5R7R!_FO_&OI7^657_S5]KQ;F[M^.$>T
M]L;QPM+U^M+#EZZFW/NC#;2B@$&4GHX:2OQ64S'CR%-421RTTE+54[KYX]!]
MU[JC#<W_  KLZ]Q,/6?;N%_EJ_,G)?"G=4M'C-\?+7-P-C<9BLE4)X:O&X6
M8:MV_N6IQF52>@G#;AQK//2U'VR3A4$GNO=']_X4$?,+=NQ/Y0G9>[OC_P#'
MG>WRMV#\N.H<OUUG-Z=</D?M-D;)W;L3.9+_ $FY8X_;^=5]OXRG2G,OW3XR
ME/W49DR5.=(?W7NJU/\ A)Y\Z_D3NCXR_'?X)Y?^7]W3M3XZ]<]=]A[RVM_,
M#R3YP[*W-7S]B9G+28/'I+LNFP0JZ>MSU9CV\.XZJ3S8FIO KF6&F]U[K<Y]
M^Z]U[W[KW6K]\J_^%&7;72/;'9FQ.EOY-?\ ,$^0.Q.CM_979?<'<U3A,OM_
M!T4.#K&H\KE<3/CMJ[NI,C01-&[P2U=5BX9XO%+YXXY5<>Z]T;"H_G(XOY"_
MRC=V_P QSX3?%;N7Y2YDU8V%-\6,&*F'=T&2?-T6"SD4QV_AMX2,F#H,@<PT
ME/1SQS8]$DD>E5Y'A]U[K68_X2*_.OY$]7;0Q_PIVA_+^[I[8Z"[I^7FX]Y;
M]^=6VWS@V?L:OEV%M>%\'ETI=EY+"M5Q)MVBD/W&X,?)IS-+>  1-5>Z]U]#
MCW[KW7S6_FS_ #'?E/MO_A3=U'\F,5_+'^0&Z.V?C+LG>70_4OQ8Q\FXQN+M
M3;E!1]M;?INPMNM'U_49)<)D<;FZO+Q"CQ&7I?ML74!<E+$9*FG]U[JRO_A5
MAVYO;OS^1-\&NZ>R.FMT_'C?O9WR\V'O+=W1N]S5ME]J5];UEVG-48/(M7XK
M!UIJZ!V,<GFQ]')J'J@C/I]^Z]T9GK[_ (50];XKN?H?8/:GP&^4W2GP\[HJ
M\3L3J/YN]GP5.*Q><J*LTE/0Y>FP5=@J6AFVQ/33)6O6TN?JZJ&C99FQQ!8)
M[KW5^_\ ,4_F%_'S^63\9]R_)SY%93(+MW&Y"';.S]F[=^WDS>Y\_61S24.#
MPM/4ST\4U7-%3S3RNSK'34D%153$10N??NO=5+?!_P#X4:[7^0_RDV)\1OEO
M\&_D=_+M[-[UK*H?&>N[XCK?X5O*!?'_  V'SY3;^UZK'97,,9(Z:**GK\>]
M2L5(F5DJJJGAD]U[K92]^Z]UI5?\*_7J(\__ "EG[MBSDWP"3Y3US_*:'#?<
M!7D$VV3"LIQ[)EA7-LO^]0H/LF6:WWNDB;[<^_=>ZN!V3_)*_DS]Q[S^)GS.
M^-?3/76V:7J'/TO;O4F]OBSF)<-@-SZ42HQ-1EI\!5(N8@Q]?##5Q,LT<K21
M/25CST<U522^Z]U!_F4_S]_CS_+*^6/6_P 0>S>BOD#VMV)VOTQ1]M;*J.G*
M+&Y):VHRV5W1@<'MNFH)*^')U.:R^:VU]I"L,#QAZZF9GLLNCW7N@\_ER_\
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M5.6I-D[0S=?3+=TQ.:["VKB\G#?E4CKZ2J>CD)!O'4.JZ7977W7NM;?K=?\
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M$R^R_C=\+/Y@NR]OXW,;Z^ 'S2VOV*)JF1J:=</E*NEE>"*JCCDDCCJMT8+
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MIZ#^&[DJ*)H9&404D<-)%&PD6%?=>ZP_&7=^X_DST1_("_E5[KGJ<KV)\?\
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M>?S)'DBCD>G^%F"FIW=03&YV+T'&70D75C'(RW%CI9A]"1[]U[KOXF1I0_\
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M5#Y!/=>ZW4??NO=:;7SW_P"XP_\ E)?^*43_ /0OR&]^Z]U[_A1A_P!O@?\
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M(H51] H ' 'OW7NA,_X2X_\ ;BCX,_\ E3?_ '\78/OW7NK_ +W[KW0=]O\
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M=(?RC?G9W3ORL_AVQNH?DGNWM#>>0NH\&)P'66S\MD9KNRH/%1TDC79@O')
MY]^Z]UBZ,^6/_"E;^:KU/E_G9\0]\?!WX\_$&NR>[</L3X^=G4;561W3B\7)
M5XFH%?7MM3<>0:HI:FFGC6:',8"*6JCDU0M2Z WNO=%Q_D%_]PLO\ZC_ ,N.
M_P#@==F^_=>ZO6_X2I?]N/?BC_X='8__ +\?=7OW7NC_ /\ .1_[=.?S(?\
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M1!_,<_X3@2!%$C_-7+HT@ U%5WWT.5!/U(4L2!^+FWU/OW7NMR?W[KW6G/\
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MIA<M15^%K\U@JBMHXJRCR-.HGF1)D2.H0,LD8]U[JMOH#XU?\*LOB+LG:O\
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MI_'MLX'[7#8W8>^\+6UGWVYLUAL;-X<EF:.'Q15$D[^;R1Q-%'*Z>Z]U9/\
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M<CCSF\5EJ]9<EL2AJZ.KQD=:ZK5O23X\I"U3)[KW1I/YX/\ +X^9/S!^7_\
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MK>>QLG@L-@*#+948BF,#5DJ--7US4T)KJZLG>2"C$8C]U[HX_P#PG]^)_?\
M\)/Y5WQ\^-_R>V#_ *,NZ-CY[>M;NC9G\5PN:^UBR^]L_E\>W\1V]DLMBI_N
M,?6PRVAJI#'K\<H2571?=>Z)Q_-7_EJ_/?'_ #CZT_FX_P I7<'7]=\KMH=5
MR],=P?'_ +5FIJ/"[XP$,=7)1F*JJ:K&TLE;+K@I)Z:LR./A/VF,JX*ZDEI)
MON/=>Z.9_*RI?YU^>SO9?9_\UO)?&;8^W-V;:Q=#UI\<^E:):C([=R-.[RUE
M969RBRV4QPBJ8JAH9Z?[_-&::*&2GJZ*&%HZSW7NBA?.J;_A3-TS\D>YM_?
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M8)-'JU(Q4@, ;'Z>_=>ZH8^$?\BW$=#_ "K3YY?,;Y==T?S!_F%AH:NBZX[
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M:NFH,?04TE;75U;(D4,,,2&26::60JD<4:*69F(55!)( ]^Z]U7/\9?YN_\
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M*"NARE=D\;)/4%8$;-4&*C>>2.-'8NM_=>ZOP[9[8ZXZ*ZTWOW%V_O'"]?\
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MFR5 V,RF<PF1IX7>,RI2Y&6H@2:)JB&(-Q[KW2\^;O\ .I_EZ_R[>ZL#\?\
MY8=N9OKOLC<W43=W8:BI]O9K)4<V"\^X*2 _?X^CJ*5:^LK-LUM-3TA<3S3^
M"-5O41:O=>Z##^6]_/U_E[_S1>R=Q=-?'S<?9.U.V\%CZW/4'7G<V%@P]=F<
M502K'493#34&2S&.JH$5TE-.]3%7I"WEEHXU271[KW6MYV'\\?C?_+C_ .%7
M/\T+Y*?*+=62VQUWCOB+M;:>-I\!0S9+*9;,Y#8W1$E%B<70PZ?/6SQ4L\O[
MDD,,<,$TTTT<<;,/=>ZVE/Y8'\Y+X8_S:MM;YRWQBR>_\%NSK.2G??O4_;^,
MI<5N/&TM;-4PX_(M'C<EFL164%<U+)HDH\A4&(Z8ZI:>5UC/NO=%D_F!?\*2
M/Y:G\NCMS=70/:^7[J[*[NV)445-O?K;I7:ZU=5BFKZ2"OIA4Y#<>2VQ@I"]
M#4PU&F"NF?Q31D*2UO?NO=6&? +^8W\4OYF/3V1[L^)V^J_=NU]O[D;9V[L1
MN''U.)R^&RBT\-7]GD<?5*&0R4U0DD4T+S4TREO%,YCD"^Z]U4%OK_A6Q_)M
MVAL_#[LP?97<W9L^7W6^V6VAL79==%F*2.):%Y\M64^X9\!318J)*X%76H>>
MH,-3'24]1)!(@]U[JS3YA?S<_@[\"J#XRY/Y5]CY[JRA^6='5U_4U55X+*5T
M0BQZ;>DR$F9EQU/5PX:.A3=% 9GJ&5%#2LK,L,A'NO=5V=/?\*MOY.W;>ZNS
M=MU?;G8W4>.ZYV[D=TT&].X=MR8S%;HI,93?<SIM@459D\I59&= 4I,=645#
MD:V8>&DI)I61&]U[H6_@A_PH^_EJ_P POY&?[*YTSN#MK:/:&7:K7KI>W\!3
MX?'[N^QIGK:E<!4TF5R<@G2DBEF6GR,6/J9$AE,<+E;'W7NA5_F2_P ][^7]
M_*RW;C^L_DAN;LO.=P9;:$._,5U)U1MV?*9:?$U-144E-6"LR,^'V["E144=
M0D8FR<3%H)05&GGW7NA,_EI?SA?A1_-<V_O#)?%G=6[X]U==4>/R'875W9N*
M_@^X</#E!,*26:*&IR&,K8&EIY87FQ]=60QRII>0:XB_NO=6C^_=>Z][]U[K
M3:^5/_<9U_+5_P#%*,]_[Q'?WOW7NK=OE[_PH+_EC?![NSNSXY=_=M[PPG=7
M0^W\7GMV[%PVU\S6RUC9K&X++XR@PU:*>/&9'(5..W%23F,5*)#&*AYY(DII
MV3W7NA7_ )8'\Y+X8_S:MM;YRWQBR>_\%NSK.2G??O4_;^,I<5N/&TM;-4PX
M_(M'C<EFL164%<U+)HDH\A4&(Z8ZI:>5UC/NO=!U_,P_GS_R_OY5FYL/US\@
MMR=A;X[BS6%AW+'TST=BJ3,YZFQE1,(8*[(OD\I@\)C8I[/)%'4Y"*IFBB>2
M&"1=!?W7NC?_  *_F)?%'^93TY-W=\3NPVWIMC%YIMM;MP>7I)\9F\#DU19?
ML<QBZD"6FED@9989$,M-41G5!/*%?3[KW1WO?NO= A\EN^]G_%?X]=V?)7L'
M&[ES&Q>ANKLWVUN_$[-AI:C+5.-P./GR59!C8*ZLQU'-6R04[+"D]53Q-(5#
MS1J2P]U[KYWO\AK^=U\4_C#_ #"/YC.3W[U_\A,O!_-*^96U:_X_)M#%;;J'
MPZ93>_8<E.-XBMW9CUQ[(N_<?Y/X:<L 8:S27\<!J/=>ZW>?YE/\W7X6_P J
M?9FU]S?*?>&XSN+?PK&Z\ZHZWQZ9?=&<6@0-5S4='-54%!34D+R1Q-55]91T
MOFECB\VIB![KW7?\M?\ FZ?"S^:QLO<VY_BOO+<1W'L-:1^Q.I^Q\>N(W1@5
MKU8TDM;1Q5-?055+.\<D:U6/K:VE\L4D7GUK8^Z]U9O[]U[K03[#^>/QO_EQ
M_P#"KG^:%\E/E%NK);8Z[QWQ%VMM/&T^ H9LEE,MF<AL;HB2BQ.+H8=/GK9X
MJ6>7]R2&&.&"::::..-F'NO=;3'\LS^<E\)OYL&#WA5?%_<F],=O+KREILCO
MOJ;M;%Q8C<F,I*QWBI:QXJ2MRF*K:.66-HS-0UU4D4FE)C&TD8;W7NGS^93_
M #=?A;_*GV9M?<WRGWAN,[BW\*QNO.J.M\>F7W1G%H$#5<U'1S55!04U)"\D
M<355?64=+YI8XO-J8@>Z]TY_RW?YL/PS_FI]?;CWS\4][YJLRNQ9*&#LGJ[?
MU",3NG;DF2@:>C&2QZU%72S4\YCFB2LH*JMH)9Z>HABJI'A<#W7NK)??NO=?
M.S_E^_S7/B-_*B_F9_\ "B3LOY3YO>3R]A_.W.83K?KWK;&)E=PY^HQW9/;U
M1D!0P5-7CL;##11U,'FGK:VD@1ZB"/RZY54^Z]UNJ?R[/YD_Q;_FA=%OWU\6
MMQY^NP.*S?\ =;>VSM[T*XS<.W,O]M!6'&9BBBJ*RD$WV]0CI/1U5713#5X*
MJ70^GW7NBO\ \S/^?!\!/Y5&XL!U_P#(;</8>].WMQ82+=%'TWTABJ3,9^#%
MS5'V\.1KVR>4P6%QU/.ZRM"E3D(IYT@F:"&0*-7NO='2^#OSV^+O\Q;I*G[^
M^)_8T/8&PQG*C:N<AJ::HQ^5PV6I5C>?&9G%5B1U=!5B&:*>,.ICGIYH:BGD
ME@E21O=>ZUH/^$3W_;N;Y.?^+KY+_P!X78WOW7NK.?EG_P *2?Y7OPT^5U/\
M0>UNP.P\OOS&9M]M]H;TZ]P<>6VOL>O6.)Q2;FR'\0IZYJC5+XI8\3195Z.5
M)$KUI"A]^Z]U6-_PB>_[=S?)S_Q=?)?^\+L;W[KW6Y+[]U[K7-^2'_"IC^4Y
M\9?DAD_C7NG>O;V^LSM7<U5L_L;LSJG;4>7VEMO(T)$=735];)E*/*9)J>HU
MT\C87'954GBEC9@4/OW7NKK,I\JNAZ#XL[@^:-%OW'[G^-VW>DLE\B*CL;:,
M<V1AJ-I8G#5&>K,E14]/&U55,N-I9'6!(_.SKX?&)?1[]U[JA+L;_A7+_)UV
M(O74F$WIWKVM!OVH R4O7.S9 =LTWW]10-6[BAW#D<!40QH:5JC[>ACKZ]J5
MH9XZ-UGA#^Z]UL4]-]P=;_(#JKK[NWI_=5!O?J_M/:=%O?8N[,8)%AKL;7PK
M/33B.9(YX7*-:2*5$EBD#1RHDB,H]U[H2O?NO=?,X_X5$=C]K]^?S0NZMR=1
M[ARU!MO^4=\9>N]X9O+T]&TE'BMS[FWWM,P2053QO2C)U%3O_"L%E+K(F&J(
MEB+4\Y7W7NM_O'?-;K-?Y?47\Q"LI\]G^HZ#XA/\P<MC]HT\+Y6HP5)L]MX5
MM)CZ/(56/@_BAHXI(8J>JJ:9!46BGFA =U]U[H'>@_YJ/Q\^1?\ +:W?_-(V
M3L[N7%_'_975W8';65V?NG'X2#>,F-ZW.=&<@I\?2;AKL*];5?W?J/L4?+)%
M+KA^XFIM3^/W7NA@_E_?.;J7^8_\5NOOEYT?M[L7:O6W9-?F\=@\)VM28RAS
MD3X'-Y# UAJZ;$9?.4$:25F.E>$QUDI:%D9Q&Y:-?=>ZJ8[$_P"%47\H?K+Y
M&;V^/&X.S^S*Y=@4.3&=[NVQMMLGL=\KB7J$J<!05U'72YS(Y&1J=A!/3XF3
M%3LR)%DFD8)[]U[HZ^\/YRWPXV[_ "SMR_S8MM-VKVC\4]MUE/0?[\?!Q4VY
M:V2??%%U\XH\/N;(;=B IL_6CRFHJJ>]-%+-#Y6\4<ONO=+#M_\ FH_'SI7^
M63B?YK6Z=G=RU_QXS/5VQ^VJ79NW\?A)=Z+C=_93;^(P\$F.J=PTF#%;35.X
MZ9JQ!EVBCB2<P35#+&DONO=*;<_\SOXF]>? '87\R?MG=.>ZF^.'8O5^W.TM
MO+O.B63<+1;JI*>KPN&_A.&J,LM3GJD521FGI)ZF)&620U'VT4DZ^Z]T1CX
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MVML#([)I>T.JZUL=N#!R5T#1)D,96*"T4\+$:@"I>,O&'0OK7W7NM.SY\?\
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M(S?9E/DJGKC8^Q\%7YG*YM<2*;^(&E,:0XNG%,];3HS5E;2H&GB&JS7'NO=
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MY\C<9\;=L;U[>V!FMU;CI-H]<]D=L[:CQ&U-R9*N;QTE)05T.4KLGC9)Z@K
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M*&=9:#:.:K]P=S?Q?!4BQ6IK8N>G2@,L2J)8Z.'^PB!?=>ZR?\(O.F>HMU?
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M]U[I0?"G&8[87_"QC^9[M'9E%3;9VMF?AWB\SD]OX9!!1S5=;MOHK,U52T"
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MX&#%PY-WH1)DZ#:%;5TU)F<345>+BCKI,%61H)*-HI<?596."26'W7NBK_\
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MI/=>Z??^%L/_ &[F^,?_ (NOC?\ WA=\^_=>ZV)OYL7_ &ZR_F6?^* =R?\
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MW)N6GBG6DCA6:8Y?;^.E$DI<JE+H"FZM'[KW5,O\R+Y-?-+YX_!G8GPQV/\
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M?;?1/<O5NP.Y_EY6[EZ>WSV-M?-X3#[LQK]C=KURY#;63R=#2T6=HFHLC25
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MHRE5E]\[KVU4TU/@\32T$=369RNQV.I<;A8I(4D>ODHEDIXTCEBA3W7NC?\
M_"</J?M/H[^3'\-NK>Z^M.P.G^S=K_Z0_P"\O77:6&R.W\[COO>U=\Y&B^^Q
M&6IJ3(4GW>/JX*J'RQ)Y:>:*9-4<B,?=>ZM][:WI5];]5]E]AT&W=R[OKMB;
M S&\:+:>S,;79G+Y2;&8ZHK8L=BL1C(*K(Y3(UKPB&FI*6&6HJ)G2&&-Y'53
M[KW6I9_PG"_E%[5S7Q$[J[O_ )I7P8ZVWQ\D^^_E!N#>\%!\R>K,95;LH,.E
M)C8GGGH-Z;=2OQ'\8W"^5K!%!$E/-"]/4*6\FB/W7NI'P"^)'=7\O7_A2?\
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M+8F>;&UE5MNJ,XII/((:>4%XF:-C[KW15.SL5_-G_GP_*CX6]2?)7^6]NO\
MEY?%GX:_(NC[U[^WCV565.3CW/D,,::2*BVW49#$X#^(0UM%]U04[8P9.CC>
MODJZJN<4D=._NO=&T^;'QS^0>Z_^%5O\L#Y$;7Z)[EW)\?\ 8'Q#GVUOSO/
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MMW<V<R6*QE/MG-TE3'MO+2U"UV32C\;QT$[SN@,<;'3[]U[HR?\ *S[U[_\
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M,HM!DI:2;;6<SV7FRE9+A*4YK'5T4E=215^+"TU3+[]U[JW'XB_&CO3XA?\
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MBIJRL2*-9YXXUEE6.-9'944#W7NM[[W[KW7SQ?Y(OS[ZJZ6_G,?S=NU_G/\
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M[BQ]-E_!5O(E'++CO*U7!'6O#**9I8T%08IO#Y/%)I]U[JG_ /X4F_) U/\
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MC!E92592""0??NO=(_LCL[K?IS9>=['[<W_LOJ_K[;%&V0W'OCL+*46&Q%!
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M'R*V#B\]-_ ML;FQ78=+-6UFX\8DPHJ?+4&%B#&>:,RQ4M]#A&:_NO=7(?\
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M=A;HWY_)QZ[H]S9.LRD?7_=>]=B[<:MFFG>'')74^56$//)(X1:S+5#*@(1
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M$2Y."7;?V>*H*VCDV]ES38]'DE62I23[LM!+']O+[KW7T%OY4WR.W/\ +?\
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M9>9^2&>Q&2;,Q4T=(<;E,=4[;7%-C:NHF\YJ$B@@5E*-#'0&+34>Z]ULH_\
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MZ=A43R4D)]U[J\/_ (0_?]D_?/?_ ,3'LW_W29?W[KW5I/\ PK._[<J=Z?\
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MUMXX1,C/C*:JH*W#3O!6QP-)+"T[0F62IQ\D-3[KW6SQ_)Q[E_D__P R6O\
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M.DI_NL=4;!W/BZ.K@*BH7(4V"GFR%(Y+(<N)R=-1 J>Z]ULY?!_^71NC/_\
M"5G,?&;:>'H<OVS\G?C+N7O;%8_:Q6D&=S.=G;<NT*:*>2.56J,GA\=A:,U$
MBE9';79(R ONO=:VW\M'^?7L7^7E_*7^8/\ +S[0V!V=!\DZBNWMBNA*ZAQU
M/_"L?/O'$C%546=>HR<593U&W,NM1D-"4ZK6+.E(&@:-ZEO=>Z-?_+I^&_:O
M57_"6#^:OV]NK9NXL%7_ ";Q4F_=F87*H\<]5M+9DN,!W E++3P2TU'.RY1T
M+&034U&M9&Y@J(A[]U[HVO\ PE6_F\=.8OJ'XH_RE<!U7VUN'O[<?9'9.Y]U
M[[^WH8=H8+;L%%FMZIE)JZ*LJLE//5M F+B@>BIXA62J9*M%:!*CW7NJ5-E4
M'P[_ )3'\Z'YK]8?S8/B(>\/CEN?/[D7KEMP;:IMQU$$&4S\&=VMO'")D9\9
M355!6X:=X*V.!I)86G:$RR5./DAJ?=>ZVP?Y!GRF_E"_,ONWOO<OP4_EX8GX
MB=K=.X5!B-Z0[8I*2JRNR<Y)!3!J_+89)\5B,I4Y:BFCEPS5E2)HJ9:F@JZ\
M4V0%![KW6P1\V/\ LC/Y;_\ BL>_?_>5RWOW7NM13_A$'_V3-\Z?_$Z[7_\
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M;44>+IJ[-K6&+)Y 4D;55;2T0I&9J2*6E>H)""K@%W]^Z]T+WP"^478'>O\
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M8RDR&0IL?C]PT%3EMQP[>H:B'(9*KJ5G7_*F,K/2PM34GNO=;J/\C7^9T_\
M-9^".UN_MSXO [?[GV7NJLZ@[ZP&UTJH\9'N3&TM#7"MQL=8HF2BR^(R=%6"
M,//'2U$U10I4U/VAF?W7NKB/?NO=?/%_X5W9[$;6_FC_ ,L;<^X:^#%8#;FP
M<7GLYE*F_CIJ.C[$>HJ9Y-(9M$,,;.U@38&P/OW7N@(_X56?/WX+_P P7=/P
MHV=\(.P,3WWW'LC);AEW9OOK2AS3+%09@XF+#882)CXWS-<M;05%3''$D\^/
M5C]N <C.I]U[JPK_ (4'_P Q+^9-_+1P/\JOIKXM=Y[HZOW9O+XT# ]K[?P6
M#VWN"KS6XL'#M3%1HG]X,!G*@U9J:BHC18%!F>0:XY6T@>Z]TF?C3\WO^%!/
M\O;9'RF^:O\ -PH^Q<KT)L3XLU69Z>ZSWU%LL1[D[+W!N#:^(VE05"[3IZG(
M;=AHEJZ^NR4,OV$L%*LZ_:LL4:4WNO=5HK_-,_X4U-\;I/YNY[2=/A>G:OV2
MP-0[$_NX\/\ >!<5]@NWUI#EQM\9 G;OWC:9_N5*_<_Q?36'W7NMFKY-?+?Y
M5?S*OY!&U_Y@WP+[+[+^-WR2V1MI^WMZ[2ZMJZB!ZQMK&OQ78&VQ')05]1D,
M>D4<^:Q*QPFKJEI*&&.935S!_=>ZU=^QO^%-_P QMV_RL?CW\<MB]Q]HX3^8
M1C>^<OA^VN[<-%&V<RNT*%A4;:195B0#)YRLS+8^9(89JE5VZ6JDA7+TCS>Z
M]U;;_.D[M_F8?RU/Y-/\N>KS7S)[UH/F1OGMYYOD=V;29ADR<U7F-MYC-R[7
M>:)%A;'[;D^WH(PB!99*)JG]<[D^Z]T<?^=!_.P[R_EX?RW_ ((XCHRM;,_,
M'YB]'8.OA[-W!2+E9<%21;4P\F5W"E-54]30U^X\AF<M *&*KCF@<I6S2T\O
MB5&]U[JH+ ?S8_Y\_P#)U^5/Q@K?YO>X9-X?&WY%P??[FV7NL;9R550X-I\<
MF8KL17;2I)LC2[FV8M7&\F.=YX*D5 IJL$U5%7TONO=6Q?\ "F_^<3\K_A+N
M#XL?%CX1;GQ/7O8OR-Q?]^\KV[4#"LRXYLO!BL7BJ&MSVK$8NGR%2)FK:^;Q
M&&#Q/'64J"9V]U[IV_D_Y'_A2CL;YVT/2O\ ,BK:+>7Q>R76>8[ W'V9NFDV
MWG*&84$<-+C:?:NZ-G-214>>R.6S-%JHLDSH<5C\C418P2E:X^Z]UMU>_=>Z
M)E_,)SWS VK\.>]-T_ W$;.W%\I]M;2.>ZSVSO6B>O@R;4L\,V2H*"G6KI(F
MSM3BEJ%Q7W!EI6R/VR5,$L+NOOW7NOGX_)OYL_\ "HOX,]8[8^5?R3^4VW<%
MMJIWI1;9RNPL9E>I=QY"BR$D\DT,>;VWMFDRE)CX,C!12QR"WVU-Y!!+'1U[
MP1CW7NKEOYU'\X?YI=9?R?/Y9'S>^+_9Z?'WM7Y3Y3"5W9LVTL9A\M13+7;+
MK\G74E%#N?$Y3PT!RU-YJ8F)*I80D<KW\@/NO=!?_)[[,_X4K]H?*SXU=]_.
MC=7:F _E\[PVIG.S.PMR;[QW7]'3UV AVCFLAA1/@L-CX,WACD*]\<Z3-C\:
M7AB$L;ZI72J]U[HCM=_->_X4"_S>_D#\I]]?RL:O,=9?&_XPH:Z#8V!CVO0S
MC$?>9=L.,E-N.E?)YG=NY,?CI9I<?3%D@^S:"FCIW?\ RSW7NMC'_A-G_.&W
M_P#S3/C3V)M/Y$56 K_E1\8,OBL#V/N;;E,E'3[FPF9BK1@MRRTM-3P8JFRM
M348BO@R$&.O1AX8*N*.DCKHZ.#W7NMD;W[KW5"W\]_>?\XW9G4W3[?RF:;9L
MM5N;=U9MWNK+U46VX<_AH1##78K)09C>V0I]I8O;L\5)74>2J*F..JAJ*C'&
MEK(2[^_=>ZU;^L?YI_\ /5_EY?S(?B+T1\\OD)LOO+8?R"WY@,-G-G8VNVEN
M3$5F"W%GZ3 S-19W;6-:;&YK$S&4TL0GBD\YB;(B;'S1,WNO=6A?S!?G=\P>
MLO\ A3C\&OB/L'Y"=C[5^-?8])US4;XZ;Q-6J87)-D\AGXL@:B QLY%7'1PK
M*%=0P07'+7]U[KW\P7YW?,'K+_A3C\&OB/L'Y"=C[5^-?8])US4;XZ;Q-6J8
M7)-D\AGXL@:B QLY%7'1PK*%=0P07'+7]U[K6$^3/5'\X"/^?A@NO:_M2A/\
MR7,[EBJNCM_OE,"T5%AY\)E*G;L,E>,><1&U/M4/ PFIY&5CI=GD(?W[KW5M
MO_"C':'S1V'_ ".?Y:FU/YA>[J;??S!Q7RMW9_I>W7256/K8ZKS_ -^ZG ::
MG%4U'02^#:\V-A/BA328RCZI%=F]U[HB>2_F8?\ "C/^6UUG\*ODIW[O_<>W
MOC5VIBJ#$=)=7]D8S:7V&9VUM^CQSTM#F<7B,,N3P,57@):9(Y)$H<E4TI:K
MIU-4DE2GNO=;2G_"@/\ GG;\^!GP[^-&1^*=-0XKO_YO;3_O;L/>6X:>GKJ?
M9NW'Q%!6RY@05U-+B:O,O4YBEAH8ZV-Z4B*LGF@D6 1M[KW5#6*_FV_S_?Y0
MOR(^+VY?YJ5;E^PN@ODM3Q9>JZRW6FU:ZO."-9BAEY,34[<ISD<;NG;%)7H?
ML)92&DJXH<C%*9*22+W7NK,O^%1'\T[YX?"3M/X(XCX'=]Y_KO!]\]?[ASV7
MQ.U<!MO.2Y^>/(X"+#-31Y_;^;G6:2'(.D4<"+Y#*H>*1@H'NO=+K^4/5_\
M"C&'M7OW>G\TG/=F[6Z#@^'&ZMY;%H]VQ[&$E3O&1\.<.8DVQ'+6X"LQ]$N1
MJ7I9FH)$=Q$:5HT1*7W7NBZ_\)]_EI_,X^?'\MW^:C'0_)CL7M+Y:8 XC;'Q
M?WEV3EZ:1L%FJ_"926G:"JR,,M'30&KBCDE,L<B'0-2./2?=>ZJG_F%_)_\
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MX?=N(W%!BZ2'#C)[2R-92Q0S0::JLI6G%7 U303UE7[KW5.E=_->_P"% O\
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M7A\LE-D,1A<W%FL7!'N;$92/^'',XP55#.L:S24<E.S2G6X/NO=9OY,N]_\
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M&&3/9V/$;:VQ@?XO$V'@K\U-35'W]7.0U%23TLD,U*\AJ(O=>Z(M\$?YM?\
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M=;0W5'#E-BYS ?Q@;Y;:NY,94U,0?'D5BR[?KOLZB@A2LI*2>M2:FQT/NO=
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MOVY5YVCH\'E1EC5Y*7;.+3PM/]JPJHHIZA*7'0MX(O=>Z/Y_.J_[AH_Y%O\
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M*DU#YZ_'M(AC=U337T%3$Z$ADEC=757# >Z]UNG_ ,K3=FUH/Y'7PVVI-N3
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MNL'_  CYIJ:B^<G\W&CHZ>"DHZ2JP]-2TM,BQQQ1Q[OW@B1QH@"HB* %4
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M(\I_#'-&*P*1Y6:M,'C_ ,@;W7NK0?YD?_"<O*?*+(_RV=N?%WM;8/374?\
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M$F*QKYVNQ,^+QE-N#:U3EZ^;+XS%FI>I$4&6H9GJ4AD6HB5'BD]U[JNWI/\
MX1AY&A[=ZZRWR:^>V:[2Z&Z]S='6-UAL_#93'9+(8V@UR18:FR]3GIDV[3SU
M#^N:B@>:& S14IAJ)DK*?W7NK</YTG\CWM#^9OWS\'^T^J.WNLNHML?$F.>"
MOVUNRAR4\E?%)F<'D88*#^'QM#31P4^'\0UWY=;*%4W]U[J7\M?Y)G;OR+_G
M9?&'^:9@^Z.N-N]=]!P;.I\MU=EJ/)R9K(#;=7E:FI:GJH8S0Q&H&2"Q!R;&
M,EB-7'NO=>^6O\DSMWY%_P [+XP_S3,'W1UQMWKOH.#9U/ENKLM1Y.3-9 ;;
MJ\K4U+4]5#&:&(U R06(.38QDL1JX]U[IB_G2?\ "<CJ[^:?VAMCY*]:=P3_
M !G^3.*PU/M;=^\H\9-EL;N7&4,%1#B_O::GR6-FH<MC3,B"NC:9IZ*&.ADB
M4)!44_NO=,_\F;_A.=2_RO\ O+._*/LGY;]B=\=T9; 9/;=/AMN+6X#;+0YD
M0/E*G/02Y*OK-U5<M9$]53+5-!2TT\HJ)J:MKZ:BKZ;W7NB/_.;_ (2/9_OW
MY.=Q?)3X]_S =]];9'O;=N;WSO?"]H8RIRU;%D=RY2KR.;AAS6&RF':KPTL4
M\-)2T,M'&\%-2PI45=:?4ONO='&^*G_"7SH+HC^7_P#)_P"'&^?D5VWNW?\
M\Q,M@\GW1WIL81821:3;&87-8' 8S#UDN8@&'-4I&8:245>9\CEIZ)(Z&*B]
MU[JIK"_\(J.QZK<&W]M[\_F4UF7Z2QF92NRV$PNT:^+(3Q2U<=1E&Q]'6[FK
M,3BZS(I'997^]$$[)4S)6B'P2^Z]UO0=)=.[#^/73_6/175^,J</UWU#L7%]
M=[+QU;435E1'CL31Q45+]U65#/45E6\<(>>HE9I9YF>61F=V)]U[H2JBGIZR
MGGI*N"&JI:J%J>IIJA5>.2-U*O'(C JZ.I(92"""01;W[KW6C%W5_P (T\E4
M=U=GYCXG_/;-=!_'KM3)Y!:CJK)X/)U]9B,+E!$T^W6JJ#<.-@W+B:2=7\,=
M:M.\U&M-254DE1#)D:CW7NK"?Y7_ /PFHIOY?VQ_GIU=NWY@[E[*V9\XNCAT
M37Y;K7;Z[/W'MO',N:IZBMH,G4Y?<M)/D'I,R51VHTB22/4T4B.8U]U[JJK<
MW_"*KLD9S-;<V#_,FEP_368W!49%<#F]H9*6IBIVUT^.6HH*;=<..R%9C\<R
MT\D[20_=*A")1QR>./W7NMS7X)?"_J?^7U\5>I?B7TM+GJ_8_56%EHTS^ZY_
MN<IELA6U,U?E,K7R@*@GKJ^IED6&)4IZ6(QTE+''3011K[KW1NO?NO=:X?3?
M\DSMWK3^>_VU_-OR/='7&2ZU[&@S5/1=2T5'DUSE,,EM2BV["TM9)&*!RDU'
MYG"G]#Z5)9>?=>Z]\2OY)G;OQT_G9?)[^:9G.Z.N-Q==]^0;QI\3U=B:/)QY
MK'C<E7BJFF:HJIHQ0RFG&-*RA"+F0%2=//NO=8?BE_)$[5Z _G5?*7^:#N?N
M'K+=G6/R%HMYXZBZEHJ')#+4<6Z*G%30BLGJ(CCZA8DQS),B\-Y/26 (/NO=
M5/=U?\(T\E4=U=GYCXG_ #VS70?QZ[4R>06HZJR>#R=?68C"Y01-/MUJJ@W#
MC8-RXFDG5_#'6K3O-1K34E5))40R9&H]U[JV[^1M_(3R7\FWL+Y'[QJ/DW0]
M^X_O;;>#VYCL7#M23;LV*3"5V3JDDFJ&W!F$KWJ$R 0Z8J<*T98 A]*>Z]UK
M&?\ "A_X][/^:'_"C[X[_%WJ&LJ/[Y=F[,ZNZ[[^K=FK3_Q/"Y6NR5=/4Y6I
MF=3' V.Z]J<-6*9C(T4,:R+3R"2))_=>Z^DMAL1C-OXC%8#"T<..P^$QL&(Q
M./I[B."FIHEA@A0$DA(HD55N3P![]U[IR]^Z]U\^7_A9]M0;\^5_\K[8[5JX
MU=YX'=&U#D'B,X@&1W)M6C\QA6:G:81>;44$L1>VD2(3J'NO=&F^$'_".G;O
M1OR5ZL[A^47RPI/D'UGTIGJ;<FTNI,%MVKQ<64J<?6QY;'T^1J*O,UL=!AES
M#5%35X^".H6M6=HFFB+S2S>Z]U9Q\M?Y)G;OR+_G9?&'^:9@^Z.N-N]=]!P;
M.I\MU=EJ/)R9K(#;=7E:FI:GJH8S0Q&H&2"Q!R;&,EB-7'NO=7D_)CXY]4_+
MCH3M/XV]W;?3<_5W;VU)MJ;KQ1*K($9DGI:RE=TD6&OQM=##5TDI5A%4P12:
M6TV/NO=:1U)_PB<S$>_Y,/4_S"ZS_9=7WFN?EVG2[1J5S$M$*Q7:%HSN(XA<
MF<4@HA7:'M-:M^W,:C'GW7NK*?\ A1_\>NJOBA_PG?W#\<>D-N+M3JGI[<?6
MFR]F84R--*M-3[KQY>>JJ'_<JJZMJ'DJ:NH?UU%3-+,_J<^_=>ZUZOY<7_"4
M/=?SE^*OQL^4M9\UL=L#JCOW"4O86[.N*':E;4U])_#\C68T4\3-N!*&NJ_M
M4KUAK9/!X#6DI3:%EBG]U[K>/[O_ )1?P_[P_EQX#^6-F-K9+"] [%V9B=O=
M:9'&S YK!93! OC=R05A5?/F'JWFFKG8!:\5=;#,!'52#W[KW6K;UG_PBOW+
MCM_;8@[8_F-9_-],[7R)JH<1U]MBIQN;:&6.-*U,:<CG\GBL%55LM-2RK/X<
MA'"*>.&:EKPJ2+[KW5N7\X'^1'V=_,3[8^ .\>IN]=J[!VM\*\"FWZV#MZ3/
M9_.9V&#)8"J@DFRY-355=<U/A+5%96RRU%342F:5F<NS>Z]UL8]A[<JMX[ W
MSM&BG@I:W=.S\GMRDJ:K5XHY:ZBGI8Y)- 9_&CR@MI!-@; GCW[KW5$?\@+^
M3?VG_)YZW^1NQNT.X>O^WZGNO>^"W7B*_85'D:..BCQ-!74<L-2F156=Y6JE
M9"A(L&!L;7]U[K5C_P"%#_Q[V?\ -#_A1]\=_B[U#65']\NS=F=7==]_5NS5
MI_XGA<K79*NGJ<K4S.IC@;'=>U.&K%,QD:*&-9%IY!)$D_NO=?26PV(QFW\1
MBL!A:.''8?"8V#$8G'T]Q'!34T2PP0H"20D42*JW)X ]^Z]TY>_=>ZH8_G8?
MR)^I?YOF"Z[W7'V%/T5\CNHZ8X;9O;5'C5RD-9A)*P5LF"R]*M30U300U#3R
MT-1#4 T4]543-3U8D\8]U[H@?\J+_A+-MWX,?*? _,#Y*_)NI^3O9?7SQ9+K
M/ XO$U.,Q]-EXXI88\QE:O(9/)5V2DH(S :&G40+!/3)4/-,C+2Q>Z]U%_FJ
M?\)6MH_-OY4;@^7OQ=^1T?Q5[%[(K)LYVMM^HPE37T%;G*K0M;N''5>.RF-J
MZ&KR49G:OIV645534/4"HA77!)[KW5B_\E7^1ATS_)_VKV%G*3?59WA\C.WU
M3&[^[CR-"<9%#A:>KEJZ+ X?'-65[4U,LKI)75+3>3)5$,,SQ4\<,%/#[KW0
M,_RD?Y)G;O\ +I^>?SC^7>_.Z.N.PMM?+&?.U&W]H[1H\G!78@Y;>3[GB6LF
MK(TIYQ%3R>%C':\@U :3Q[KW7OY)G\DSMW^5G\A_FGW-V+W1UQVAB?E)/1U&
M!P^RJ/)TM1BC39S-94K5O71K%.'BRRH#&19HR;$,+>Z]U[^29_),[=_E9_(?
MYI]S=B]T=<=H8GY23T=1@</LJCR=+48HTV<S65*U;UT:Q3AXLLJ QD6:,FQ#
M"WNO=5O_ #?_ .$?6U.XOD=V)W5\/?E4WQEV+VWDZG,[QZ9R.%KJVDHY\K+6
M/GZ;$Y*BR],1ALDE:R08^:E,-#'Y*<-4T\R1TWNO=7W?R>OY3FSOY2/Q]W'T
M_@.[>R>\]R]A[EI]Z=@;GW=)+189<E!1)0_[]O; K*^GP5//&FNID:IJZVLD
M\8J*MZ:EH*6C]U[JV[W[KW6N-_//_D)YG^<EOWXZ[RQOR<Q/0%/T3M?.[<J<
M;DMH3[G.4_C=;C:KRJ\.Y=OFD6G7'Z2O[AD\EP\>GU>Z]U6)\(/^$=.W>C?D
MKU9W#\HOEA2?(/K/I3/4VY-I=28+;M7BXLI4X^MCRV/I\C45>9K8Z##+F&J*
MFKQ\$=0M:L[1--$7FEF]U[JY_P#G4_R,>F?YOVU>OLY5[YJ^D/D;U"C8WK_N
M3'4+9*.7#5%9%65N!R^.6LH&J:=I8WDH:E9O)C:B:>>.*H2:>GE]U[JM_P#E
M<?\ "66J^$/RKV)\NN]?F]V!W'OCJG)0Y?9.V>MH,CMNFK*JGI)L;"-P96HR
M]?D*_"_PUH:>3$1+#'/'3+3U-748R:HQDGNO=&Y_FW?R3.W?YBWSS^#GR[V'
MW1UQU[MKXG3X*HW!M'=U'DYZ[+G$[R3<\JT<U'&]/ ):>/PJ9+VD.HC2.?=>
MZ.S_ #??Y2?2_P#-T^.E#T_V)G9^NNQMA92IW+TIW+CJ&/)5&WLC5P)!613T
M#U%&<AB,FD$'WE*E33/*U-3.LZ-" WNO=4!?!W_A'OM3IGY$];=R_,#Y5_[,
MOL/I_)PYO9W2V)PE;045948ZIIJG"4V4R%=F*H_P:ADIRU3CX:415X=(6>G@
MCECJO=>ZLD_G9_R3.W?YIGR'^%G<W77='7'5^)^+<]949[#[UH\G55&5-3G,
M+E0M(]#&T4 2+$LA,A-VD!L IO[KW6P]NK:^W=\;8W'LK=^&H-Q;3W?@:S:^
MZ-OY6,2TM?CLA3R4E;1U,3>F2GJJ:9XY$/#(Q!^OOW7NM%[NC_A%F*_M/>M1
M\:?G9D>IN@=Y9MJVCZUW9M_(Y6OQ-%>FJ*6AFKJ?<-)#N(8W(TRU,4M2E+)*
MJP1,8IX/O9?=>ZVT?Y;_ ,"]C?RV?BELKXK=?]B=E=HX7:V3R&X:S=O9U>]5
M42U^5G^YK(\;1ZVI<'AHYK_;8^FND9,E142U>0J:RMJ?=>Z/=[]U[K72_GN_
MR$,;_.*K.B]^;6[PI^B^V.E<;EMI-D<UAVS&,S&#RC1U<=-41P55'5TM5C<G
M#Y89$>2-X:BJB>(.T4T?NO=%\J/^$XF[-K_R6.U/Y7>P?DAMS.=H=T?):G^2
MV^^\=\8O)PT$N26NP+2P?8Q5V4JY73$[<HJ7SAX5J9EDJW@A:5XS[KW0Z=S_
M ,DSMWL_^1!U;_*0Q_='7&,[*V%!@*>O[:K*/)M@YQAMUS[BD:&C2/[\&>&1
M85# :7NQ)4"_NO=#_L_^2[UGO?\ DX]4?RHOEAFZ#?E-UYLQ,;%V;U^L]))C
M]P466R.3Q.X<)]VJSQ34GWOBDBE&FHIY*JDDO#.]_=>ZUZ>L_P#A%?N7';^V
MQ!VQ_,:S^;Z9VOD350XCK[;%3C<VT,L<:5J8TY'/Y/%8*JK9::EE6?PY".$4
M\<,U+7A4D7W7NMZ_9NUJ'8^S]J;*Q=;G<EC-G[;H=K8[([IKZO*Y.H@Q]+%2
M0SY'*5\L]=DJ^6.$-4553+)/42EYIG>1V8^Z]TI/?NO=:X?3?\DSMWK3^>_V
MU_-OR/='7&2ZU[&@S5/1=2T5'DUSE,,EM2BV["TM9)&*!RDU'YG"G]#Z5)9>
M?=>Z]\2OY)G;OQT_G9?)[^:9G.Z.N-Q==]^0;QI\3U=B:/)QYK'C<E7BJFF:
MHJIHQ0RFG&-*RA"+F0%2=//NO=>^)7\DSMWXZ?SLOD]_-,SG='7&XNN^_(-X
MT^)ZNQ-'DX\UCQN2KQ533-454T8H933C&E90A%S("I.GGW7NBQ_S5_\ A+3L
M[YO?*+._,/XM_(Z?XF]M=AU#9SM?%/BJW(X[*9\?: ;AQ]109?&U6'JZF.F9
MJV&-)$JJR3[\2PRB:.I]U[H\W\DO^1;M7^3_ (_LO<,GR)[$[R[-[;Q%)M[<
MD+>?#;0H:"@JYJNB6CVX*VM6MR\(F\!RE7*76!7CH*3&I5Y!:SW7NJE?F_\
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MR4%+GHL=MVMP:O2XNAJ,A-123O5B4H]3*(U4KK<FX]U[H5OYNW\DSMW^8_\
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M^Z]U?K_-18?\,.?+1;C4?Y?]8P7\D#;5-<V_H+C_ &X]^Z]UK8?RPZ2EK?\
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M)#^=A_PGP^0ORH^76V?YC'\MONS$]%_*MZ?'4?9%/ELQD-N&IJ\+CCC\1N;
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M=U]QY#';9JL]#!MW)XS[YU=Y]4@GK(H(5EFJZQJ>)9:^NK:TSU=1[KW6R_\
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M#_%C@O\ 9CFVQ_QCS[L5AH@OWXR)W)]H6_=%?_!/X=]N?.:L1W/OW7NBR?\
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MF-RY=^K=HTN/H=H8?+Y"HGEK34134H2.6>CAI5D'NO=')^/^PMD;X_X6@_S
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MS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\
M7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[
M0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:
MSU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_
M $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;
MA_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT
M^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_Z
MS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\
M7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[
M0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:
MSU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_
M $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;
MA_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT
M^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_Z
MS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\
M7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[
M0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:
MSU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_
M $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;
MA_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT
M^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_Z
MS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\
M7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[
M0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:
MSU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_
M $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;
MA_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT
M^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_Z
MS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\
M7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[
M0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:
MSU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_
M $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;
MA_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT
M^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_Z
MS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\
M7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[
M0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:
MSU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_
M $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;
MA_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT
M^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_Z
MS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\
M7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[
M0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:
MSU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_
M $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;
MA_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT
M^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_Z
MS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\
M7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[
M0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:
MSU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_
M $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;
MA_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT
M^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_Z
MS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\
M7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[
M0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:
MSU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_
M $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;
MA_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT
M^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_Z
MS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\
M7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[
M0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:
MSU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_
M $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;
MA_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT
M^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_Z
MS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\
M7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[
M0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:
MSU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_
M $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;
MA_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT
M^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_Z
MS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\
M7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[
M0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:
MSU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_
M $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;
MA_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT
M^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_Z
MS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\
M7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[
M0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:
MSU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_
M $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;
MA_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT
M^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_Z
MS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\
M7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[
M0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:
MSU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_
M $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;
MA_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT
M^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_Z
MS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\
M7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[
M0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:
MSU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_
M $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;
MA_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT
M^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_Z
MS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\ 7WW[0.O:SU[_ $Z;A_YT^&_ZS_\
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MZ][]U[KWOW7NO>_=>Z][]U[H*=O=Y].[M[0WETMM7LG9^Y>UNNL139SL#8F
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M#?=7O+#28R2,ST=57J::#S5$E2%IJ.1FT@&^E0&)X\&U=>(IT3*I_P"%)_\
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MU<='V_D"_P D#^Y.<^%7\UG_ &9W^)_>[,S^[O\ 0-_<OPZ?[P;>W)M'[?\
MO1_>R6_VG\2^[\G\('E\?@T1Z_,NT7SZTS5QT13^59_, ^-'P _F;_S.NR/E
M)OG,[3VYNW>&\-H[3.+Q.5S$U77IV)7Y*6FC6@IJB.G(IX9I@9Y(5D8,D1DF
M8(V@:$];(+4ZW$.L?F!\(/YH/Q/^0?\ HOW]5=F],Y7KK/\ 67=V HH,AA<[
M1XK-X*NIZZG>EK(J.MI9*[%R5"TM5'>)I8Y4BF\U-.D3E0W5*%>JG?\ A.KM
M'^6UU9U?\P.ROAMVMWIN_#PYK!)W5OSY)T6+V_#C<=B:3.5^*BI8:)UHTIJ.
MEJZV6MJY6!9BIM%&@1:IU9S7HWD/_"B[^4M/OT;!'R,R<<[9TX!=S2[6W,N(
M,OW?V*R_=_POR"F:IM:4Q!1"?NFTTH,XWK'6M!ZN@VCN[:N_]J[<WSL;<>#W
MALS>&#I=S;4W7MFJAKL=DL=70I4T==0UE,\E/54E53R+)%+&S)(C!E)!!]VZ
MKT$OR6^3W1?Q!ZES_>'R([ QG7/7&W"L-7F*^.HJ)JBHD#&&BH*"CBJ*[(5T
MX1BD%/%)(55Y"!'&[KHFG7@*]5_?'3^>U_+&^3_9N'Z@ZZ^0L.+W[N7(QX7:
MN,["Q.4P%/E*^:IIZ.GH*+(Y"FCQSUM755<,-)"\Z/6S2+%1"HD#(NM0/5M)
M'1D_FG_,F^''\OS&[:K/E!VW1[+R>\7;^Z^TL51UF6S-9#&LS25:XW'0U%1#
M0I]O(GW,PB@>913Q.]0Z1-LD#K0!/4GX6?S&_A]_,$PFZ<Q\6^VZ'?55L:I@
MI]Y;6R%)6XG,XT548DI*BHQF2@IJIZ*I6ZQU42R4QF2:G,HJ()HH_ UZ\13J
M-\TOYDOPW_E^XW;=7\H.W:+964WBS':VT,71UN6S5;#&)3+5IC<;!43PT,?@
MD7[F<10/*OV\4CU+QPOXD#KP!/0)=:_SJ?Y=7;O1?<WR"V!W@^;V;\?\)#N7
MM;!G$92GW!C<=45%'2PUZ8.HIHJVOHS/D((WFI%GCAE?P3M'4!HAK4.O%2.M
M._\ D6_S0?B/\'/DM\Z^SODAO?<^WML]\5U'5=?Y#$X/*9>:K\6?S^0E:HBH
MH)I:9OM\A"UY0"68C]2GW1#3J[ FG5TGS.Z"_E<Y+^?C\?-Q]M;U^2N(^86]
M]Q=>]@8SKK:-%13;+S6=P_@H-HY'(9>:0Y#&0PP[:I8JVEIE5)A2I("CS5!F
MV1GK0..KV_FG_,C^'7\OS%[:K_E#VU2;)R.\I'&U-IXNCK<MF:Z.)96FJH\=
MC8*B>&BB$+J:F?Q0-*!3QR/4O'"]R0.J@$]=?"W^9+\./Y@6-W'6?%_MRBWK
MD]GLIW3M'*4=;B<U112"%HJM\;DH*>>:AD^XC7[F 2P)*WV\LB5*20IX$'KQ
M!'1<^_\ ^>?_ "T?C'W!V%T+W)WGG-M]K=85R8O=VV:7:&[JY(*F:FIJJ"%<
ME1X6;%-YHJR&TAJ1"I<+)*A#6\6 Z\%)Z'+X2?S0OA;_ #"I=U4'QA[5DW7N
M+95#%EMR;0S^,R.&RD%%++]NM:E+D:>#[JE6<K'+) TH@>2 3^/[FG,O@P/7
MBI'5@?O?6NJB?D!_/0_EI?&+M_L'H7N/O'.[=[6ZPKX\5N[;%)M#=M<D%3-3
MTU5#$N2I,+-BF$L-9"1)]R(5+Z9)$((&BP'6PI/0>XC_ (41?RFLMUO6=D-\
MDGQ,5%F8,"VR\S@,W#N&6>>E%6K4^,%$YJ*6**ZS54<C4T$P6":6.:6&.36L
M=;T'HU'Q"_FG?"[YR[0[%W9\=>RZS=$W5.$;<6^=H9C&UF*S5)1K2K5&HCHJ
MZ.%:V !A$\M-)+'#.5AG>)Y(P^PP/6BI'6'X5?S1_BO\_.O>X>S?CU6[]R&U
M^CFB3?#[LP[8R<--0U>01:2&2HD^X/V]')<W0!BJWY)'@VKKQ%.G?X$_S+/C
M'_,@VYV-NOXU5^]JW#]6YFAP.ZYM[8EL2RU&0@GJ:<0(\\QE014[%V](4V'-
MS;P;5UXBG14.SO\ A0I_*FZG[)W#U?N3Y$5N1S>U<S-@<_F-I;<S^5Q,-13*
MK50BR-%02PUT4 :PEI//'.X:.E:>0%?>M0ZWI/54G_"EK^8'\5>VO@!UOU!U
M/VO0=A;A[TW=A>XNO<ELV.>LP^0P.!R.8Q.6\V2B7[:EK<=EH#!/0U!CJ8:B
M)XY(DEB=4JYJ.MJ#7H_/\A/^8]\5>^_C7\=/A-UMN[<.4^0/0OQ4Q^9[)VY7
M87)4E'2P86HQ&%KV@RE1 E%5F.OS-*BK$[%U=G6ZHQ%E->M,*=7E=PLR]2=I
M,I*LO7.;967@@C&55B#^"/=NJ]:#_P#PG7_FE?#O^7OU'\E\+\H^P=P;8SO9
M?8^VZ_9^.Q&$RV5:>CQ^/J:*IG:HIJ9J.*.D>KA4Q-,)A&=:Q&)&8-(:=.,I
M)ZWH_C%\I^A_F/U)A.\/CGV!CNQ>NLY,]''E*2*II:BEJXEC>>@R-!6PT]=C
MZZ!949H9XD8QR1S)KAECD=P&O5"*=5Q=M_\ "@7^57TMVEGNI-W_ "-DKMP[
M5R;8?<>7V9M_/9S$4M3'&DL\:Y/%X^I@K?MTD =J/[A&E#T\;25$<L2:UCK>
M@]6Z;$WYLOM#9FV.Q.NMTX+>VQ-Z86GW'M/=NV:F*LH,A0U48EIZJDJ86>*:
M&5&!!4_X&Q!'NW5>E9[]U[JE_MW_ (4"_P JSI7M#/=3;L^1CY/<6U<B^(W)
MD]E8#.9K$4E3$BRU$0RF/H9J:M-.CC4:,U*M+JIHFDJHY($KJ'5M)ZLUIOD?
MT/5]&I\EZ?MC8\G03[6.]!VQ]]$,,,:K%&J&JB0J%)@86B8"9:@&G:,3@Q^]
MU\^M4\NJR^HO^% O\JONKM'!=2[1^1LF.W%NC)C#[;RN]=OYW"8BKJ9$>2GC
M.3R5!3T]%]S&AT-6FF59-%/*T=5)%"^M0ZWI/1V?F9\]OB[\ -E[3[!^5&_Z
M[KW:>]]T-LW;>2H<+FLV9\BM)-6F!H,)09"HA'VU/(_DD18_3IU:BH.R:=:
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MH\=O']U!>_\ G!;EILGIQ30=(7</2?R$_P"$Z_\ ,Y^,&V-E=^UW:^PNXZ7
M5>ZLE1XDX:BW!MVKW+58K+8"NV^V>R?AJ:35++!*]1-%!+50UU.SU*200:^
M];KJ'5AO\Q9F/_"I;X$ DD+C^ME4'\#^);D-A_07)/\ KGW9N/51\/6SU\T_
MYDWPX_E^8W;59\H.VZ/9>3WB[?W7VEBJ.LRV9K(8UF:2K7&XZ&HJ(:%/MY$^
MYF$4#S**>)WJ'2)KD@=5 )ZD_"S^8W\/OY@F$W3F/BWVW0[ZJMC5,%/O+:V0
MI*W$YG&BJC$E)45&,R4%-5/15*W6.JB62F,R34YE%1!-%'X&O7B*=%A^0_\
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M4SM44U,U'%'2/5PJ8FF$PC.M8C$C,&D-.G&4D];T?QB^4_0_S'ZDPG>'QS[
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MS%=AJ>IKJK?]5C_)6U.*EI<FZ4\,C-&D-5 NLWE$J@*/ 5/7B: ='L_X4O\
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MR.-JTK!7R3TZU321K"1!F:2J@6GT*#CU<YX=;"/\^7XH_##8O\FCXU=A?';
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M/B-KYW#-654RQPB:IJQCQ-*^A2TCLQ%R?>SD#K2\3T5#^=-_+I^.?PP^$O\
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MR6XWPN$AFJ<758V4X["8:DGAIZ=5LIBHO6%@*S44:CU8F@Z&+^31MF?X0_\
M"@KY=?"[85=D1U1FJ'>6TZ+#&:\(QN&DAW+MB:K23SO49#'8^0THG$D?-35'
MQJLWBC\N#UYC4="7_P )T_\ M[I_-@_ZC]V?^_-G][7B>M-P'0<?R-O^WC'\
M[/\ \,?LC_WNLC[\O$]>;@.BB_R$?Y:'Q7^;/QN^?/:/?6T<CNW?'6.UCM+J
MJIEKZB"AP577;?R]>N;BH:9H4K<G2U=+"T8K&J*4(A4TQ+LQTHKUMFIT/_\
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MF:HEI<(M%3::F;<%?04,L[5LZQT]3%,M*YFU4_D;RZVZ^?55WP+_ )E'<?\
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M6V_/4)CZZ)A%&9Y:B'1''/1S1>^ ]>IJ'6RA_)5_F.[J_F)9;O#<V>^"N/\
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M'=.WZ^KJ:7)QT&8HZFFERM,ZTZJL I)M,XBK8WT>TUZV.X4ZM._EF_S4\O\
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M?S&ZIV#\:Z3K2J^,^T^LI^D\;49A\O6[PWCC*6MR6XZ6&<P8:.C/\#IH(\5
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MDJGCBA>IDIZ*&")YWB@C1I"I<I&BDV10/4IU[IDJNF^H:W>"]AUO5?6]7O\
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MB&%)9#(P!;4QU$ FY]^Z]TU[NZJZOW_78S*;\ZWV%O;)X12N&R.[L/CLE/2
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MJ5Z]TM:.CH\=1TN/Q]+34-!0TR4=#0T:+%###$H2***) J1QQHH554!54
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M. 5$[+&JM(X=VCC]U[JP'W[KW7O?NO=>]^Z]U[W[KW5>O\NG^8GUQ_,CV/\
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M0S1JE1U-UCD</GBLLVG[B)ZF>CAB*H$"4OEBDFAJ(V'NO=40_'C97SL^*?\
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M%!655(J^%9)Q+3!:=Z<+[KW6RU_+Z^$'R6^)F:[?W7\D_P"8EWQ\[-P]OT>
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MNGJ[(SK524D5-M_M;9>9VVU;7/&&:2FHLY%01HJH79ZTPAHXYY94]U[JY?\
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M1?S^_P"%:/Q\RDRTV,[VRVSNF\C4,TBB.#<^UNW\),Y:)DE4+'7$W1E<6NK
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MHR7\OS:/?M/64FXJ3K2637CRU+D7:NAH98FIR-0\,E:*Z6!Y5D,A]U[H9?\
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M,/XQ;.Q:9O?/8?59R77N%DG:E%9N/;>2Q^ZMO4GG$D2QFIS6$I8P9&$)+ 3
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MML;QWMU7%-+BMZ1X#$>3';A$U6E(D=.\34=5)1/-D:"<(D$LWNO=)/\ E8=
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MN%BK8HIJ_+8G-;<H4JXBR+&%KV=7CIXUJ_=>Z''_ (3S?]E7?\*$/_&O._\
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MN\A]K)E:GST^V,UF<5@THGD 5Y_OJJO>IJ:BM8^Z]T$'P-^)_P#PGR^0=?\
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MU[KWOW7NHE=7T.+HJO)9.LI,=CJ"G>KKJ^ND2&&&*-2TDLLLA5(XT4$LS$
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MV9Q='D0YQ]7D<7',U=14U<(W-/+-$B3:6\;-I-O=>Z5_OW7NO>_=>Z:*S<&
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M+WLO(8NGV_C,AB:.MJH8:6@IZ6:7,8?)3T+T$.2CJ8/]R$L$ I'C,T\'NO=
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MKQ]ENW -M/;FYL9A<%3OD*Q,9++1+C8<C*M#2"IGQE))-]UX(W'NO=$XH?\
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M'4^8P&6QF<Q%9K^TRF'GBJ::7QR-%)XYX'>)]$J,C:6-F5E-B"/?NO=:GO\
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M4&XH]N]=R8V2BEDEFW5#5UE='D3*T% <0%FI97J87C]U[I+?\*)>[^_^^_\
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MP3;KWSG*>'PL*>KRTD%)30P22T\<DL=)2TR3/'&90XAA$?NO=:,&YH-RR_\
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M(CFA>7IO P1I+$]GC:2>-HU# %I%9!=@0/=>Z+[F_P#LAC_A'/\ ^+_]<?\
MO;8;W[KW5RO_  K-BWX_\KO9TVTWV='M2C^:'6]3W$W84=7+@AMOR9B. YE:
M**6<XH;IDPQK HU-2B58]4S1HWNO=!EN3X%?SW?E5\P_Y;_R2^4G9W\HN+:G
MPS[[I>W<7D_C95]GP;AR&S\Q/A:7>^/QC9O;5905Z97;U.B4R>>DIVJC2M-5
M)&0P]U[K:_\ ?NO=:!N/ZLP.^_YDF]OY*>>KL[N;;67_ )YN_/YANX-KQO5?
M;8O9,G3*;ZQ(R)I70T^'3<6=HDIX:H)15U?&%45$LDX]^Z]T+W\@7=.^?DU\
MX_B7LKL6DV[45O\ )]_EJ;Q^->]$HVFEJ<3V+D.W-P[&I*82.$C,4O6NU*5U
M_;BE3RR!C*DRB#W7NG+XD?\ 9,'_  L\_P#$]?*3_P!Y[L[W[KW5O/\ *Y_[
MAO.E/_% -V?^ZW<?OW7NJ#/^[%'_ 'W_ 'F'[]U[H^GSS_[+A_X2*?\ DT_^
M\AT[[]U[HPO\E3_M\?\ \*3_ /Q87J+_ -Q.S_?NO=>_X2$_]N<-I?\ BPN^
MO_<NB]^Z]U[_ (56_P#9*/\ +S_\:\]3?^\WV)[]U[KW_"O;_MSANW_Q878O
M_N76^_=>Z]_.K_[?'_\ ";#_ ,6%[=_]Q.L/?NO=5X_#RD_G"3?S4/YZF(^#
M.Y_Y:^'WW-\Q*7)=KX[YDQ[_ /[QU&U&&;_T92XE=J8^>.7"0;9J-$IF_35R
MN4O%-&[^Z]U?C_(E^"/R5_EV?"_<_P ??DSNKH'<^;KOD/N?M3K6+XV5>;K-
ML8O:VY*7#5L.+IWSV%P59$\&>&5ECB2&:%*.:E"U,LAD">Z]T1C_ (4/2Q0?
M*G_A/G//)'###_-UV#+--*0JHJ[CVJ69F) 55 N2> .3[]U[I1_)^"?,?\*E
M/Y9PZ_J\*,_M/X%=D97O^*FBC>O.SJB/=U)MN"KF^WE=(!N^LBFIU,D14FH(
M8+.8ZCW7NDM_PF?W!AMM=._S<,3V/FL'0[_V/_-O[>W!W#)E&BIWHZ-L7MN(
MUN161(/MZ%JW%98J9$CC4PU/I70X'NO=5C_"+L+I#J[_ (2Z?S(-_P#R,Q6/
MW/\ %7M'O_MZB^*G7E'&V.GEQF<K,/A-CXBA_P!QDLN.K8NQ(*JMBJ?#6G&1
M+]W(1'1O3P>Z]T='_A*A15755%\\_CI\D\%N/%?S'-I=@;$WS\B,QOVL&4S>
M2V9E]B8:3KRE?)FF626' 4K5D4L#U5<T536/4BI:.NB1/=>ZVT,5O+:&=SFX
M]LX/=6V\SN39\L$.[=OXJNI:BNQ;U49FI4R-)#*\]"U3$"\0F1#(@+)<<^_=
M>Z4GOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JGS^8G_);^/O\R3NOICY!=C=]
M_+WH7M/H?9N2V/L'<WQ6W3A-K545)EI9GKI)*VNVKG<BE1-%42T[-35-.CTT
MDD4D;AVO[KW0^? '^6'\2?Y:^U]^X7XV;2W"=U=M9^/=/<';_964J-P[QW7D
M(A+XZC-YRK"R2I'+43S)3P1T](E355=2L GJJB23W7NB3]E_\)T?Y=G9N^>\
MMRU<_P F]E;$^1N9R.\>W/COUAV3N';W7.5W+DF>6;<\VV,=+%&^6AJ66:&*
M29\;&\<:?P]H08C[KW1D^U_Y//PT[D_EU[7_ )8>\,5V#_LN&PL72477V2QV
M81=T8.JQU155..RE#EIZ.HII,A1/6S*IJJ.IIY8G:*IIYXV=6]U[I;2_RM/B
M7N#X.R_R^^UL-O[OSHFM26HS&6[QW%D<_NZNR4E:^03-S[IDDAR4>8I*EQ]K
M/3M *6%(Z6GCCI46#W[KW06_"O\ DR_%'X.]P#OS9&]_E'W!VYCMGY/K?9V[
M_D;V)F]U';VU\K60UDVV\-0$T.+BQ,+4M-'"M135-0BTT3M4/4>2>3W7NK:/
M?NO=5(]7?"3MWXQ?S2.Y?DKT(VT*GXD_.G8<6>^5_7F6K:JER&W.T=KJT6&W
MGMJFO/15L&\<=6S4N9IEBII15P)D)*J4>.G7W7NFKJ+^2?\ %?I?^6CVE_*N
MVOO_ .0-?\?.VY,S+N3>.?RNW)=Y0'.5=)65?V.0I]J4N$C$<M$@A\N)FTJ7
M#^0D,ONO=++L7^4/\;.S=A_RR.O,]O?O"DPO\J3=VPMY_'BJQ&2P,=5F:KKN
MCP5#A(]Z/-MJHBR-/51;>IS7+C(\0\CO,8'I@T:Q^Z]T,&V/Y>72VT_YBO8O
M\S7';G[0F[Y[-^.4'QASVTJVMQ+;1AP%/D\%E4JZ.@CPD>9CS!J-O4RM+)E)
M:;QO.!2AFC>/W7N@?ZZ_E#_&SK+8?\S?KS [W[PJ\+_-;W=OW>?R'JLODL#)
M58:J[$H\[0YN/9;P[:IXL=3TL6X:@T*Y./+O&Z0F=ZD+(LGNO=$MRG\G'=^"
M^3'\G'KK86=BSW\O7^5A@MQ[]\';&0H,CNS<.^YXYO[H54U%C\)B\:\NVZ^"
MFKHL@J0>)RZ04BRWJ/?NO=6O_.7X(_''^8ET95?'[Y-;4K]P[.7<E%O;;&:V
M[628S.;>SV.$RT.<P&5A#2X_)T\53/#K"NDE///3S1RPS2(WNO=$P^(/\C'X
M8?##Y$;0^66P=S?)7L?Y%[8Z[J^MLIVMWSOJOW7D<]25L,E--59E:R".E^\%
M*8X8UH8J&DAC@B\5*K&9I?=>Z1/R)_X3U?R^/DM\A>W?D1NU_D1LK(_(BE(^
M1/5G4&_,KMK9F^ZU(DCILKN7#T"+45-;2,KS(D%73T<M3/455525$\\LC>Z]
MT"WRQ_DK56<^+O\ +B_EL_%*'%XKX']!_+ZD[O\ DSB^VLN<GD<OM&CW#E=U
M5>VD@EH7_CHS68W%7%DF>G@IDBIBZU(01^_=>ZV$=W;FP6RMJ;GWENFM@QNV
M=I;>K=S;BR-45$5/04%-+55DTA8A1'%3Q.S$D"P-S;W[KW6N-_PEG^/^U.O/
MY?W8?R/VQL&IZUQGS>^46]N]]E;(K:9:>3";+ILK/M_:&$BL-<M#24F,J*FE
MD/HDBK?)!JA=))/=>Z3W\[OJ;K?Y@_S+/Y&_P^K]G-N'?-'\@=S?)[>6YJ:G
MCJ?X/UYLRCQN6S.+R :_V^-WGD\/2TAED B,U"D2EYWBC?W7NMEK=VYL%LK:
MFY]Y;IK8,;MG:6WJW<VXLC5%1%3T%!32U59-(6(41Q4\3LQ) L#<V]^Z]UKC
M?\)9_C_M3KS^7]V'\C]L;!J>M<9\WOE%O;O?96R*VF6GDPFRZ;*S[?VAA(K#
M7+0TE)C*BII9#Z)(JWR0:H7223W7ND]_.[ZFZW^8/\RS^1O\/J_9S;AWS1_(
M'<WR>WEN:FIXZG^#]>;,H\;ELSB\@&O]OC=YY/#TM(99 (C-0I$I>=XHW]U[
MJV7^:+TO\H_DO\5,Y\9/BY7;2VI7?(K<V/Z@[P[3W+DY:&JVCUKEG>/>N9V_
M1Q4=3_&MP2XA7Q]'1O+2(&K6J34*:<*WNO=&[Z$Z0ZZ^-/2G57Q]ZCP@V[UE
MTUL+&=<[(PYD>:2+'8JDBI*<SU$K/-554JQ^2>>5FEGF>2:5FD=F/NO="W[]
MU[KWOW7NO>_=>Z(=MC^7ETMM/^8KV+_,UQVY^T)N^>S?CE!\8<]M*MK<2VT8
M<!3Y/!95*NCH(\)'F8\P:C;U,K2R926F\;S@4H9HWC]U[HW_ &+L?$]F]?;[
MZVSU1D:3!]@[-RFQ\U5XAXXZN*DRU%/05,E+)-#40I4)#4,8VDBD0.%+1NMU
M/NO=5R]<_P G?X7[)_EM[;_E6[LV_O#N_P"+>UXLQ_#SV[74DNY/N,ONC+[O
M.07+X#&[?BH\CCLMFIA15%'34TD4"1QR&4F9YO=>Z8_A7_)E^*/P=[@'?FR-
M[_*/N#MS';/R?6^SMW_(WL3-[J.WMKY6LAK)MMX:@)H<7%B86I::.%:BFJ:A
M%IHG:H>H\D\GNO=)GY"_R+_@]\C?D=OSY-9VM^176.\>Y\;3XCY%;4Z"["W!
MLO;G9-+2TJ4<$&\\?A)J>HK46F30_P!I4T1F+/).999'D;W7NIVW_P"1M\!-
MO_!F+^7C%MGM.L^.M#VJ>Z\'3/N_,T>=QVY1,E1!DJ7-8J;'U#FEG4R0Q5"S
MPI(VLQEDB,?NO=*;X+?R<OB5\">TMW=^;(S?>_>7R'WIMN38^2[^^4V[:G>>
MZH, ]4E6F$H*R6FHJ6BH(C##$&CIA4R0P11SU$OK+^Z]T7CM;_A.;_+F[5[2
M[$[ *_([K/9W<^?K-U]X_'3IGL+-[9ZXWEE*Z6FEGKLYMO'E)%E+T[$1T%51
M0$SS,T3.(6A]U[J\S!87';;PF'V[AX9:?$X'%4^%Q=//--4.E-2PI! CU%3)
M+43LL4:@R2N\CD:G=F))]U[K4W_F%_R\(?GC_P *._C_ $/8VQN\X>B]E_RM
MX<IDN].H*[/;:DVGNB'??97\"FH]WXDPT]#G1+5!J>DEDE,T;.[4LL2,R>Z]
MU<1T)_)S^'OQN^'GR@^&W6@[5& ^9FS=S;6^2O>&[,ZF:[&W35[LV_5[<RNX
M*_/Y*AJ*#^,+25]144Z)CEQL-=/457\.9ZJJ$_NO='$^('Q=V!\*?C/TY\5>
MK,QO'/\ 7O2.T4V9M3,]@5%%59FHI4GFG$F0J,=C\50RU&N=@6AI($L!Z+W)
M]U[HAM+_ "3_ (KTG5'\RGIZ/?\ \@6VS_-+[@S?=?R!KGRNW#78?*Y[*567
MK*?9THVH*?'X^.IJW6%,E#EIEC"AYY&!<^Z]TLN_/Y0_QL^1?Q!^%7PKWMO?
MO#%]6?!'=W7&\^HL_M;)8&#<&1JNL-L5FT\!'N.JJ]M5V.K*>LQU=))D%HJ'
M'O+4A'IGI(@86]U[K-\\_P"4)\5/YAG;/1/>G;N<[TZZ[=^/L=9BMG]A?'S=
ME1M++5>%R"5*UNW\C7TU-45:XRH-7,Q>ADH:]1+-%'6I3U%1#+[KW5GN+QM'
MAL;CL1CH5IL?BJ&'&T-.OTCA@C6*)!_@J*!_L/?NO=5'?,K^2)\+?FW\C,5\
MJ=_Y#OWJ[N1MGQ=;=B;@^/&],AL\;WVQ"DB)MW=HH8Y)JS',C1K(]'+0UDT5
M-2P354E/30Q+[KW0E_%S^43\'_B/\2>[_@YUGUYG,S\:OD-NG.[K[/V%V)EZ
MO,&KEW#A,1M_(00UTABK::G7&X.D$!23SP3(:B.<36=?=>Z)#C?^$SO\NB"D
MZYH-P;L^8_8&.Z6WS0[SZ,P_8?:F>RN-V3#CY?/38';6'G48>BP8F2%F1Z6:
MK;[>)#6>,RI+[KW1Q_GG_*$^*G\PSMGHGO3MW.=Z===N_'V.LQ6S^POCYNRH
MVEEJO"Y!*E:W;^1KZ:FJ*M<94&KF8O0R4->HEFBCK4IZBHAE]U[J=\Y/Y1WQ
M'^>\G5VXNR$[4ZH[=Z1P51MGJ'Y!_'/<4VTM\;?Q]53M32T5'F88*N*>E$3O
MHAJZ:IBC,L^A *B<2>Z]T9;X=?#?I+X+=,TW1?0E'O&GV:NY\IOC*U^_MP9?
M<F6R6;S=2U;E\K79+,555,U7D:MFFF$0AA:5GD$0>21F]U[I,_/'X'=!?S&^
M@JOXV?).DW97=85V[,;O.KI-F9)L56/68II7H_\ +$BF=85>8LRJ 6( )M<'
MW7NBD_$?^1W\'_AS\AZ;Y/[)/>?:/:6TL#4[.Z1JOD-O3*;SI.M<%64OV53A
M=B0Y,&;%T<E,\\0EJI:ZMCAJZNGBJXZ:HDA/NO=*OYM_R<?B'\Z.U]N?('>6
M0[PZ/^1&W-OP;-3OOXM[NK-D[IKL%#51U+83*5E+%4T^0H)D1J<M+3FICIY7
M2FJ(&6)XO=>Z%O8G\M;XS=6_ _M#^79UK3]A[0Z#[=ZUWQUKNS(?Q^LS&Y='
M8=%DZ3<V7I\QN/\ C*)EZJ3+5%5&9*>6CCJFU_9LA>)O=>Z1,G\I+X;9W^7E
ML+^65V9M?<W<7QNZWVQ2[<VO5]A5T W-!+0U%15467BS.$HL*E)F:66ID"5%
M)34RM$SPR1/#),DGNO=)+X+_ ,F?X>_ ?M+<W?.P*SNWN;O_ '-MV39)[R^3
MFZZG>.Y<?M]I_+%@,55304=-08VFC2*G0QT_W3TT,<<]3-ZV?W7NA9Q'\M+X
M[83^9#NG^:-05G8"?(K>'1$?0.:P+5F,_NJ]!%+CBF9%"N(7+_W@%'BX*'S-
MDVI/M%*?9>73,ONO=)3XP_RG/BC\2^T/GQVOU@G8M7G?YC6\ZC>G?.,W1E*:
M6@HGJY]QU570;62AQV/J\1CZBKW5D)RDM15S(\D213QPT\,2>Z]T+_P(^ WQ
M\_EN= 4_QL^-%#NZAZV@WEE=]E=[967+U[U^8DC>I+5,B1*D,<4$4,4<<:*$
MC#OY)WFFD]U[HZ?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[HN'RQ^)70'S>Z-W?\<_DQU]C>R>J=Z)$^2PE:\M//3U5.WDI,CC:ZF>*K
MQV2HY/5#4T\B2I=EN8W=&]U[JN#X3_R"O@-\&^\L1\D]F1=W=T=W;/Q5=MWK
M+?WR3W7+NJHVCBZWS1C&[;IUH\=0T,%%254]+2S20S5D5/45"_<LU1,[^Z]T
M;W;'\O+I;:?\Q7L7^9KCMS]H3=\]F_'*#XPY[:5;6XEMHPX"GR>"RJ5='01X
M2/,QY@U&WJ96EDRDM-XWG I0S1O'[KW6H]_.-_E<?"OK_=W<WQ2^$?07SW[7
M^8_R]S>'[*V3\:=AY'=</06S\ON7-5HK>T<K)'34N!I#20XVMIDIZO)5='1-
M!2QK04./ADD3W7NMF:E_E#='YVD_E(YK?F^^V#OC^43UM1;+Z6.TZ[#P8O.S
MIMK:&W:R;=,%7M^KJJV)H]GTTD(H)\65:6<OK#1K%[KW0][8_EY=+;3_ )BO
M8O\ ,UQVY^T)N^>S?CE!\8<]M*MK<2VT8<!3Y/!95*NCH(\)'F8\P:C;U,K2
MR926F\;S@4H9HWC]U[HB/9?_  G1_EV=F[Y[RW+5S_)O96Q/D;F<CO'MSX[]
M8=D[AV]USE=RY)GEFW/-MC'2Q1OEH:EEFABDF?&QO'&G\/:$&(^Z]T9/M?\
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M=1MC&/33P9"@K<9"U.E+74]+& !]L?%3^'W7NKTU 50HO918:B2>/ZDW)/\
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MP=3M[+YJ3-Y>GR8J,U#C*A8Z.2IIYZ6F6"GB6D:GB\)]U[H-^R?Y1GPDR?\
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M9BBV95XFDK\E45314"5GV<$<-J"BHT952/QZ(H4C]U[JCG^3'_PG?^.?8OP
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M*50'1&J1JB+[KW16_P"8#_+!^*G\S/#]0[>^5.)WUF\'TIO:;?NSZ#9.>K,
MS5U1%#!+]U58_P =<8S# %7P3P2)J9XY%D".GNO=(?X)?RB/B;_+^[#[([IZ
MTK.YNV^^NTL2-I[C[Y^2NZ:K>6[8MNQU25=+MB@R=3#3+1X2E:"F0(D7W%0E
M%1??5-6]+$Z^Z]T"ORZ_D%? ?YB=V;P[[W9_IXZCWKVS3P8[Y!4'QXWE6[4P
M_9-#3T\E.E#O;%P05-/D865U:62G^SJ9WBC,T\@,@D]U[H9^\/Y0?Q$[QZN^
M&O0%93[^ZZ^-OPC[-Q':O7/QUZRK,72;4S]?@F#XVFWG#DL-E<KF:"-Y*EYD
MAKJ.6KDKJN:LGGGD22/W7NA+S7\NCI;(?S$-I_S,L'N_M;8W?V$Z1J/CYO';
MNSZS"Q[4WEMJ6:>J@@W5CZW 5V5J*J@K&IIZ>HH,ECY->.Q\<WF@@:&3W7NI
M'QO_ );WQD^*OR=^5_RYZEQ>]*7N#YF9^#<G<E5N#-5-?CON(:BHK&7%4,H"
MT,4];5RSLK-,8R_BIS!3*L"^Z]T?3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$O^>G
MSTZ"_EP]!5/R3^2=3NZCZQH]W8W9534[*QIRM:E;E3.M)_DBSP,T+- RLRL2
MI*DK:Y'NO=4C_P#07U_)S_YZ;Y%?^@+/_P#7#W[KW7O^@OK^3G_STWR*_P#0
M%G_^N'OW7NO?]!?7\G/_ )Z;Y%?^@+/_ /7#W[KW7O\ H+Z_DY_\]-\BO_0%
MG_\ KA[]U[KW_07U_)S_ .>F^17_ * L_P#]</?NO=>_Z"^OY.?_ #TWR*_]
M 6?_ .N'OW7NO?\ 07U_)S_YZ;Y%?^@+/_\ 7#W[KW7O^@OK^3G_ ,]-\BO_
M $!9_P#ZX>_=>Z]_T%]?R<_^>F^17_H"S_\ UP]^Z]U[_H+Z_DY_\]-\BO\
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MWR*_] 6?_P"N'OW7NO?]!?7\G/\ YZ;Y%?\ H"S_ /UP]^Z]U[_H+Z_DY_\
M/3?(K_T!9_\ ZX>_=>Z]_P!!?7\G/_GIOD5_Z L__P!</?NO=>_Z"^OY.?\
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M@OK^3G_STWR*_P#0%G_^N'OW7NO?]!?7\G/_ )Z;Y%?^@+/_ /7#W[KW7O\
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MA[]U[KW_ $%]?R<_^>F^17_H"S__ %P]^Z]U[_H+Z_DY_P#/3?(K_P! 6?\
M^N'OW7NO?]!?7\G/_GIOD5_Z L__ -</?NO=>_Z"^OY.?_/3?(K_ - 6?_ZX
M>_=>Z]_T%]?R<_\ GIOD5_Z L_\ ]</?NO=>_P"@OK^3G_STWR*_] 6?_P"N
M'OW7NO?]!?7\G/\ YZ;Y%?\ H"S_ /UP]^Z]U[_H+Z_DY_\ /3?(K_T!9_\
MZX>_=>Z]_P!!?7\G/_GIOD5_Z L__P!</?NO=>_Z"^OY.?\ STWR*_\ 0%G_
M /KA[]U[KW_07U_)S_YZ;Y%?^@+/_P#7#W[KW7O^@OK^3G_STWR*_P#0%G_^
MN'OW7NO?]!?7\G/_ )Z;Y%?^@+/_ /7#W[KW7O\ H+Z_DY_\]-\BO_0%G_\
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M_P#KA[]U[KW_ $%]?R<_^>F^17_H"S__ %P]^Z]U[_H+Z_DY_P#/3?(K_P!
M6?\ ^N'OW7NO?]!?7\G/_GIOD5_Z L__ -</?NO=>_Z"^OY.?_/3?(K_ - 6
M?_ZX>_=>Z]_T%]?R<_\ GIOD5_Z L_\ ]</?NO=>_P"@OK^3G_STWR*_] 6?
M_P"N'OW7NO?]!?7\G/\ YZ;Y%?\ H"S_ /UP]^Z]U[_H+Z_DY_\ /3?(K_T!
M9_\ ZX>_=>Z]_P!!?7\G/_GIOD5_Z L__P!</?NO=>_Z"^OY.?\ STWR*_\
M0%G_ /KA[]U[KW_07U_)S_YZ;Y%?^@+/_P#7#W[KW7O^@OK^3G_STWR*_P#0
M%G_^N'OW7NO?]!?7\G/_ )Z;Y%?^@+/_ /7#W[KW7O\ H+Z_DY_\]-\BO_0%
MG_\ KA[]U[KW_07U_)S_ .>F^17_ * L_P#]</?NO=>_Z"^OY.?_ #TWR*_]
M 6?_ .N'OW7NO?\ 07U_)S_YZ;Y%?^@+/_\ 7#W[KW7O^@OK^3G_ ,]-\BO_
M $!9_P#ZX>_=>Z]_T%]?R<_^>F^17_H"S_\ UP]^Z]U[_H+Z_DY_\]-\BO\
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M_>7ORM_ZD;0_^L?OW7NO?] 27P=_[R]^5O\ U(VA_P#6/W[KW7O^@)+X._\
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M0_\ K'[]U[KW_0$E\'?^\O?E;_U(VA_]8_?NO=>_Z DO@[_WE[\K?^I&T/\
MZQ^_=>Z]_P! 27P=_P"\O?E;_P!2-H?_ %C]^Z]U[_H"2^#O_>7ORM_ZD;0_
M^L?OW7NO?] 27P=_[R]^5O\ U(VA_P#6/W[KW7O^@)+X._\ >7ORM_ZD;0_^
ML?OW7NO?] 27P=_[R]^5O_4C:'_UC]^Z]U[_ * DO@[_ -Y>_*W_ *D;0_\
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M]^Z]U[_H"2^#O_>7ORM_ZD;0_P#K'[]U[KW_ $!)?!W_ +R]^5O_ %(VA_\
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M>_Z DO@[_P!Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_]2-H?_6/W[KW7O\
MH"2^#O\ WE[\K?\ J1M#_P"L?OW7NO?] 27P=_[R]^5O_4C:'_UC]^Z]U[_H
M"2^#O_>7ORM_ZD;0_P#K'[]U[KW_ $!)?!W_ +R]^5O_ %(VA_\ 6/W[KW7O
M^@)+X._]Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_P#4C:'_ -8_?NO=>_Z
MDO@[_P!Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_]2-H?_6/W[KW7O\ H"2^
M#O\ WE[\K?\ J1M#_P"L?OW7NO?] 27P=_[R]^5O_4C:'_UC]^Z]U[_H"2^#
MO_>7ORM_ZD;0_P#K'[]U[KW_ $!)?!W_ +R]^5O_ %(VA_\ 6/W[KW7O^@)+
MX._]Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_P#4C:'_ -8_?NO=>_Z DO@[
M_P!Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_]2-H?_6/W[KW7O\ H"2^#O\
MWE[\K?\ J1M#_P"L?OW7NO?] 27P=_[R]^5O_4C:'_UC]^Z]U[_H"2^#O_>7
MORM_ZD;0_P#K'[]U[KW_ $!)?!W_ +R]^5O_ %(VA_\ 6/W[KW7O^@)+X._]
MY>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_P#4C:'_ -8_?NO=5"?SOO\ A-3\
M9?Y7'P7RWRJZK^0/>W8V[,?VCMW8D>VNP8MOKCFI\S)4I-,QQN,I:GS1" :+
M2:>3J!X]^Z]U;W_PB2_[(=^7O_BUL'_O(8/W[KW6Z?[]U[KWOW7NO>_=>ZU
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M_>7ORM_ZD;0_^L?OW7NO?] 27P=_[R]^5O\ U(VA_P#6/W[KW7O^@)+X._\
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M0_\ K'[]U[KW_0$E\'?^\O?E;_U(VA_]8_?NO=>_Z DO@[_WE[\K?^I&T/\
MZQ^_=>Z]_P! 27P=_P"\O?E;_P!2-H?_ %C]^Z]U[_H"2^#O_>7ORM_ZD;0_
M^L?OW7NO?] 27P=_[R]^5O\ U(VA_P#6/W[KW7O^@)+X._\ >7ORM_ZD;0_^
ML?OW7NO?] 27P=_[R]^5O_4C:'_UC]^Z]U[_ * DO@[_ -Y>_*W_ *D;0_\
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M_0$E\'?^\O?E;_U(VA_]8_?NO=>_Z DO@[_WE[\K?^I&T/\ ZQ^_=>Z]_P!
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M>_=>Z][]U[KWOW7NO>_=>Z][]U[K5W_X5]?]N<]S?^+%;%_ZWY#W[KW1./\
MA$E_V0[\O?\ Q:V#_P!Y#!^_=>ZW3_?NO=>]^Z]U[W[KW6H%_P +5O\ MUET
M'_XO_M;_ -]UVK[]U[I,_P#")_\ [=Q_)K_Q=G)_^\)L7W[KW6Y'[]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NOD]?\ "NG_
M +?,=A_^(*V%_P"ZJ3W[KW7U,^C?^9*=/_\ B+=O_P#NII/?NO="E[]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>ZU=_^%?7_;G/<W_BQ6Q?^M^0]^Z]T3C_ (1)?]D._+W_
M ,6M@_\ >0P?OW7NMT_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?.K_ )M^Z<O_ #S_ /A07\??Y9O7.5KL
MG\=?BSN:IV'V=F, 6:F@FH?'FNV\LU92O4)33TE+BX=MTKU B$68I5IU&NK'
ME]U[KZ'>W=O83:6W\%M3;6-I<-MS;.&I=O8##T*Z8:2BHH$IJ6FA6YTQ001J
MB#\*H'OW7NGGW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U3K_/=_F#4W\N#^6[W;W+A\Q'C.X-]47^A/H")=)F;=FXJ>IB@K
MHE+K?^ XR"MRS7NI^Q$9!:15/NO=50_\)!/Y?#_&WX+;B^86^<,]%VA\T\O%
ME-M"L65)J38& EJ:7 KXI&*QG-Y&2NR>M%7[BBEQCDL$2WNO=;='OW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7N@M[R_YDIW!_XBW<'_ +J:OW[KW7RS/^$BW_;YCKS_ ,05OW_W51^_=>Z^
ML+[]U[KWOW7NO>_=>Z][]U[KY%'\G3_N)$Z,_P#%Q^PO_</>/OW7NOKK^_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K5W_X5
M]?\ ;G/<W_BQ6Q?^M^0]^Z]T3C_A$E_V0[\O?_%K8/\ WD,'[]U[K=/]^Z]U
M[W[KW7O?NO=:@7_"U;_MUET'_P"+_P"UO_?==J^_=>Z3/_")_P#[=Q_)K_Q=
MG)_^\)L7W[KW6Y'[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NOD]?\*Z?^WS'8?_ (@K87_NJD]^Z]U]3/HW_F2G3_\ XBW;
M_P#[J:3W[KW0I>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM7?_A7U_P!N<]S?^+%;%_ZW
MY#W[KW1./^$27_9#OR]_\6M@_P#>0P?OW7NMT_W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5<G\V;YT8?^7+\ _D+\
MIJJ6E;=FT]I/MWJ3$U:&5*_>6:/\-VW3/$+&2FBR$ZU578C314]2_P#9L?=>
MZUR?^$=GP.RNT.C.Z/YEW;U/7YCM;Y6;@K=B]:;FW+(:O)/M3%Y-I]PY9ZNH
MC:M:?=.[H&^Y>2:0U(P]-4$?N:W]U[K=1]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U\[K^>CO'>/\Y[^>I\9/Y2O4
M.>KCU#T!N!-J=F97 O*%I,Q6Q1YSLK.O(%K*&2?;&U<?#CZ+STI\&5BKJ5I"
MM:4'NO=?0;V+LG:W6FR=G]<['P])M[9>PMKT&S-HX"@&F"BQF+I8J*AI(AR1
M'3TL"1K^;*+^_=>Z57OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7N@M[R_YDIW!_XBW<'_NIJ_?NO=?+,_X2
M+?\ ;YCKS_Q!6_?_ '51^_=>Z^L+[]U[KWOW7NO>_=>Z][]U[KY%'\G3_N)$
MZ,_\7'["_P#</>/OW7NOKK^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[K5W_ .%?7_;G/<W_ (L5L7_K?D/?NO=$X_X1)?\
M9#OR]_\ %K8/_>0P?OW7NMT_W[KW7O?NO=>]^Z]UJ!?\+5O^W670?_B_^UO_
M 'W7:OOW7NDS_P (G_\ MW'\FO\ Q=G)_P#O";%]^Z]UN1^_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KY/7_"NG_M\QV'_X
M@K87_NJD]^Z]U]3/HW_F2G3_ /XBW;__ +J:3W[KW0I>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NM7?\ X5]?]N<]S?\ BQ6Q?^M^0]^Z]T3C_A$E_P!D._+W_P 6M@_]
MY#!^_=>ZW3_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=?/E_X4S=S=A_S+OYHGP[_DK?'C*Q34FT=W8O(]E5=/HGA@
MWINFF,LE97T[_;ZZ;86P6DR3&*J5I5RF0IW034\1/NO=;W_0?2>P/C9TCU+\
M?>J\6V&ZXZ6Z[Q'66RL=*[2RICL+0PT%,U1.Y,E152QP"2>9RTDTS/+(S.[$
M^Z]T+?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[HAW\S?YL[9_EX?!?Y$_+7<0IJJNZRV+*FP,'5"1DRN[,HZ8K:N+<0QRRK
M3UF=K*9:F1484])YZEP(X7(]U[K5Q_X1Y_"S<F6VU\E/YKW>,=7G^T?DEO'+
M];]9;LS;0R5-;C4RHR>^=Q#Q7"R9W=D:T;,PBE5\35A4$%0&E]U[K=_]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW06]Y?\R4[@_\1;N#_P!U-7[]U[KY9G_"1;_M\QUY_P"(*W[_
M .ZJ/W[KW7UA??NO=>]^Z]U[W[KW7O?NO=?(H_DZ?]Q(G1G_ (N/V%_[A[Q]
M^Z]U]=?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=:N__"OK_MSGN;_Q8K8O_6_(>_=>Z)Q_PB2_[(=^7O\ XM;!_P"\A@_?
MNO=;I_OW7NO>_=>Z][]U[K4"_P"%JW_;K+H/_P 7_P!K?^^Z[5]^Z]TF?^$3
M_P#V[C^37_B[.3_]X38OOW7NMR/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=?)Z_P"%=/\ V^8[#_\ $%;"_P#=5)[]U[KZ
MF?1O_,E.G_\ Q%NW_P#W4TGOW7NA2]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:N__"OK
M_MSGN;_Q8K8O_6_(>_=>Z)Q_PB2_[(=^7O\ XM;!_P"\A@_?NO=;I_OW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HK?S9^5O7
MWP=^)_?/RP[/J(H]I=(]>5N[GH'EBADR>1LM+A,'2O-)%%]_GLU44F.I59U#
MU-5$I87N/=>ZTUO^$E'Q=[#^2WR$^8W\YKY(4LF9WGV!O?,]?]5Y[(I46J<_
MN"I.:W_F:".L61XZ2A@J:'$4$\-1*JQSY:@8J:9@WNO=;YOOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM O_A4W\B-
M_P#SL^=/P]_DG?&NNBRN?&^<+NGM6GIW+0)N_=,7@V]2Y/Q2EXJ;:^U*R?,U
M8:.PILI%,"6@LONO=;P'QB^/>P/B=\>>F/C5U;2/2; Z1ZYQ?7.VO/;SSPXV
MEC@>MJB.'K<A.KU-2_\ NRHFD<\M[]U[H=/?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T%O>7_,E.
MX/\ Q%NX/_=35^_=>Z^69_PD6_[?,=>?^(*W[_[JH_?NO=?6%]^Z]U[W[KW7
MO?NO=>]^Z]U\BC^3I_W$B=&?^+C]A?\ N'O'W[KW7UU_?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ[_P#"OK_MSGN;_P 6
M*V+_ -;\A[]U[HG'_")+_LAWY>_^+6P?^\A@_?NO=;I_OW7NO>_=>Z][]U[K
M4"_X6K?]NLN@_P#Q?_:W_ONNU??NO=)G_A$__P!NX_DU_P"+LY/_ -X38OOW
M7NMR/W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=?)Z_X5T_]OF.P_P#Q!6PO_=5)[]U[KZF?1O\ S)3I_P#\1;M__P!U-)[]
MU[H4O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6KO_ ,*^O^W.>YO_ !8K8O\ UOR'OW7N
MB<?\(DO^R'?E[_XM;!_[R&#]^Z]UNG^_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NM$__ (5X_+_>7;F_?B5_)X^/LKYOL3NG
M?>!W]V7@,=-)$];D,QD_[O\ 76VIVTBG9*[*SU&0FB=RT;PXJ<JBLC/[KW6W
MK\"OB)L?X'_#[H'XF]?I3R87IKKZDV]DLQ!!%3MELS+JK,_FYHX51149G-5-
M562?4AIK%FM<^Z]T;OW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]T ORD^1.P/B3\=.Z?DOVE6_8[#Z2ZZR?86X"G^=G6@IWD
M@H:86.NLR-5XJ6F2UWGFC0<M[]U[K2'_ .$J_P <-]_-SYM?,C^=;\CZ!\QG
MZGL'.[5ZGK,GJJH8]W;KOD-SU.+>M2:IIJ?:VV*ZEPM!XI52.BRD]&HT4^A/
M=>ZW\O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW06]Y?\R4[@_\1;N#_P!U-7[]U[KY9G_"
M1;_M\QUY_P"(*W[_ .ZJ/W[KW7UA??NO=>]^Z]U[W[KW7O?NO=?(H_DZ?]Q(
MG1G_ (N/V%_[A[Q]^Z]U]=?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=:N__"OK_MSGN;_Q8K8O_6_(>_=>Z)Q_PB2_[(=^
M7O\ XM;!_P"\A@_?NO=;I_OW7NO>_=>Z][]U[K4"_P"%JW_;K+H/_P 7_P!K
M?^^Z[5]^Z]TF?^$3_P#V[C^37_B[.3_]X38OOW7NMR/W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?)Z_P"%=/\ V^8[#_\
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M&-5CJM.Q-^5#4?F58)*G STXNQQZM[]U[KZ.:(D:)'&BQQQJ$1$  4 6  '
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MVB>DK0BP!Y9HZ>.'W[KW5PE+2TM#2TU%14T%'14<"4M)24J+'%%%&H2...-
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MB?\ V=>_=>Z]_P!!L'\N/_O&7YL_^>S8G_V=>_=>Z]_T&P?RX_\ O&7YL_\
MGLV)_P#9U[]U[KW_ $&P?RX_^\9?FS_Y[-B?_9U[]U[KW_0;!_+C_P"\9?FS
M_P">S8G_ -G7OW7NO?\ 0;!_+C_[QE^;/_GLV)_]G7OW7NO?]!L'\N/_ +QE
M^;/_ )[-B?\ V=>_=>Z]_P!!L'\N/_O&7YL_^>S8G_V=>_=>Z]_T&P?RX_\
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M?RX_^\9?FS_Y[-B?_9U[]U[KW_0;!_+C_P"\9?FS_P">S8G_ -G7OW7NO?\
M0;!_+C_[QE^;/_GLV)_]G7OW7NO?]!L'\N/_ +QE^;/_ )[-B?\ V=>_=>Z]
M_P!!L'\N/_O&7YL_^>S8G_V=>_=>Z]_T&P?RX_\ O&7YL_\ GLV)_P#9U[]U
M[KW_ $&P?RX_^\9?FS_Y[-B?_9U[]U[KW_0;!_+C_P"\9?FS_P">S8G_ -G7
MOW7NO?\ 0;!_+C_[QE^;/_GLV)_]G7OW7NO?]!L'\N/_ +QE^;/_ )[-B?\
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M"W77_P!M7W[KW7O^@U;^5E_SX/Y__P#H+==?_;5]^Z]U[_H-6_E9?\^#^?\
M_P"@MUU_]M7W[KW7O^@U;^5E_P ^#^?_ /Z"W77_ -M7W[KW7O\ H-6_E9?\
M^#^?_P#Z"W77_P!M7W[KW7O^@U;^5E_SX/Y__P#H+==?_;5]^Z]U[_H-6_E9
M?\^#^?\ _P"@MUU_]M7W[KW7O^@U;^5E_P ^#^?_ /Z"W77_ -M7W[KW7O\
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M -M7W[KW7O\ H-6_E9?\^#^?_P#Z"W77_P!M7W[KW5-7\]S_ (4C_!S^9_\
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M"W77_P!M7W[KW7O^@U;^5E_SX/Y__P#H+==?_;5]^Z]U[_H-6_E9?\^#^?\
M_P"@MUU_]M7W[KW7O^@U;^5E_P ^#^?_ /Z"W77_ -M7W[KW7O\ H-6_E9?\
M^#^?_P#Z"W77_P!M7W[KW7O^@U;^5E_SX/Y__P#H+==?_;5]^Z]U[_H-6_E9
M?\^#^?\ _P"@MUU_]M7W[KW7O^@U;^5E_P ^#^?_ /Z"W77_ -M7W[KW7O\
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MO^@*G^5E_P _\^?_ /Z%/77_ -JKW[KW7O\ H"I_E9?\_P#/G_\ ^A3UU_\
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MUU_]JKW[KW7O^@*G^5E_S_SY_P#_ *%/77_VJO?NO=>_Z J?Y67_ #_SY_\
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M]JKW[KW7O^@*G^5E_P _\^?_ /Z%/77_ -JKW[KW7O\ H"I_E9?\_P#/G_\
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M/77_ -JKW[KW7O\ H"I_E9?\_P#/G_\ ^A3UU_\ :J]^Z]U[_H"I_E9?\_\
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M/_O)KYL_^?/8G_V"^_=>Z]_T!/\ \N/_ +R:^;/_ )\]B?\ V"^_=>Z]_P!
M3_\ +C_[R:^;/_GSV)_]@OOW7NO?] 3_ /+C_P"\FOFS_P"?/8G_ -@OOW7N
MO?\ 0$__ "X_^\FOFS_Y\]B?_8+[]U[KW_0$_P#RX_\ O)KYL_\ GSV)_P#8
M+[]U[KW_ $!/_P N/_O)KYL_^?/8G_V"^_=>Z]_T!/\ \N/_ +R:^;/_ )\]
MB?\ V"^_=>Z]_P! 3_\ +C_[R:^;/_GSV)_]@OOW7NO?] 3_ /+C_P"\FOFS
M_P"?/8G_ -@OOW7NO?\ 0$__ "X_^\FOFS_Y\]B?_8+[]U[KW_0$_P#RX_\
MO)KYL_\ GSV)_P#8+[]U[KW_ $!/_P N/_O)KYL_^?/8G_V"^_=>Z]_T!/\
M\N/_ +R:^;/_ )\]B?\ V"^_=>Z]_P! 3_\ +C_[R:^;/_GSV)_]@OOW7NO?
M] 3_ /+C_P"\FOFS_P"?/8G_ -@OOW7NO?\ 0$__ "X_^\FOFS_Y\]B?_8+[
M]U[KW_0$_P#RX_\ O)KYL_\ GSV)_P#8+[]U[KW_ $!/_P N/_O)KYL_^?/8
MG_V"^_=>Z]_T!/\ \N/_ +R:^;/_ )\]B?\ V"^_=>Z]_P! 3_\ +C_[R:^;
M/_GSV)_]@OOW7NO?] 3_ /+C_P"\FOFS_P"?/8G_ -@OOW7NO?\ 0$__ "X_
M^\FOFS_Y\]B?_8+[]U[KW_0$_P#RX_\ O)KYL_\ GSV)_P#8+[]U[KW_ $!/
M_P N/_O)KYL_^?/8G_V"^_=>Z]_T!/\ \N/_ +R:^;/_ )\]B?\ V"^_=>Z]
M_P! 3_\ +C_[R:^;/_GSV)_]@OOW7NO?] 3_ /+C_P"\FOFS_P"?/8G_ -@O
MOW7NO?\ 0$__ "X_^\FOFS_Y\]B?_8+[]U[KW_0$_P#RX_\ O)KYL_\ GSV)
M_P#8+[]U[KW_ $!/_P N/_O)KYL_^?/8G_V"^_=>Z]_T!/\ \N/_ +R:^;/_
M )\]B?\ V"^_=>Z]_P! 3_\ +C_[R:^;/_GSV)_]@OOW7NO?] 3_ /+C_P"\
MFOFS_P"?/8G_ -@OOW7NO?\ 0$__ "X_^\FOFS_Y\]B?_8+[]U[KW_0$_P#R
MX_\ O)KYL_\ GSV)_P#8+[]U[KW_ $!/_P N/_O)KYL_^?/8G_V"^_=>Z]_T
M!/\ \N/_ +R:^;/_ )\]B?\ V"^_=>Z]_P! 3_\ +C_[R:^;/_GSV)_]@OOW
M7NO?] 3_ /+C_P"\FOFS_P"?/8G_ -@OOW7NO?\ 0$__ "X_^\FOFS_Y\]B?
M_8+[]U[KW_0$_P#RX_\ O)KYL_\ GSV)_P#8+[]U[KW_ $!/_P N/_O)KYL_
M^?/8G_V"^_=>Z]_T!/\ \N/_ +R:^;/_ )\]B?\ V"^_=>Z]_P! 3_\ +C_[
MR:^;/_GSV)_]@OOW7NO?] 3_ /+C_P"\FOFS_P"?/8G_ -@OOW7NO?\ 0$__
M "X_^\FOFS_Y\]B?_8+[]U[KW_0$_P#RX_\ O)KYL_\ GSV)_P#8+[]U[KW_
M $!/_P N/_O)KYL_^?/8G_V"^_=>Z]_T!/\ \N/_ +R:^;/_ )\]B?\ V"^_
M=>Z]_P! 3_\ +C_[R:^;/_GSV)_]@OOW7NO?] 3_ /+C_P"\FOFS_P"?/8G_
M -@OOW7NO?\ 0$__ "X_^\FOFS_Y\]B?_8+[]U[KW_0$_P#RX_\ O)KYL_\
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M_O)KYL_^?/8G_P!@OOW7NO?] 3_\N/\ [R:^;/\ Y\]B?_8+[]U[KW_0$_\
MRX_^\FOFS_Y\]B?_ &"^_=>Z]_T!/_RX_P#O)KYL_P#GSV)_]@OOW7NO?] 3
M_P#+C_[R:^;/_GSV)_\ 8+[]U[KW_0$__+C_ .\FOFS_ .?/8G_V"^_=>Z]_
MT!/_ ,N/_O)KYL_^?/8G_P!@OOW7NO?] 3_\N/\ [R:^;/\ Y\]B?_8+[]U[
MKW_0$_\ RX_^\FOFS_Y\]B?_ &"^_=>Z]_T!/_RX_P#O)KYL_P#GSV)_]@OO
MW7NO?] 3_P#+C_[R:^;/_GSV)_\ 8+[]U[KW_0$__+C_ .\FOFS_ .?/8G_V
M"^_=>Z]_T!/_ ,N/_O)KYL_^?/8G_P!@OOW7NO?] 3_\N/\ [R:^;/\ Y\]B
M?_8+[]U[KW_0$_\ RX_^\FOFS_Y\]B?_ &"^_=>Z]_T!/_RX_P#O)KYL_P#G
MSV)_]@OOW7NO?] 3_P#+C_[R:^;/_GSV)_\ 8+[]U[KW_0$__+C_ .\FOFS_
M .?/8G_V"^_=>Z]_T!/_ ,N/_O)KYL_^?/8G_P!@OOW7NO?] 3_\N/\ [R:^
M;/\ Y\]B?_8+[]U[KW_0$_\ RX_^\FOFS_Y\]B?_ &"^_=>Z]_T!/_RX_P#O
M)KYL_P#GSV)_]@OOW7NO?] 3_P#+C_[R:^;/_GSV)_\ 8+[]U[KW_0$__+C_
M .\FOFS_ .?/8G_V"^_=>Z]_T!/_ ,N/_O)KYL_^?/8G_P!@OOW7NO?] 3_\
MN/\ [R:^;/\ Y\]B?_8+[]U[KW_0$_\ RX_^\FOFS_Y\]B?_ &"^_=>Z]_T!
M/_RX_P#O)KYL_P#GSV)_]@OOW7NO?] 3_P#+C_[R:^;/_GSV)_\ 8+[]U[KW
M_0$__+C_ .\FOFS_ .?/8G_V"^_=>Z]_T!/_ ,N/_O)KYL_^?/8G_P!@OOW7
MNO?] 3_\N/\ [R:^;/\ Y\]B?_8+[]U[KW_0$_\ RX_^\FOFS_Y\]B?_ &"^
M_=>Z]_T!/_RX_P#O)KYL_P#GSV)_]@OOW7NO?] 3_P#+C_[R:^;/_GSV)_\
M8+[]U[KW_0$__+C_ .\FOFS_ .?/8G_V"^_=>Z]_T!/_ ,N/_O)KYL_^?/8G
M_P!@OOW7NO?] 3_\N/\ [R:^;/\ Y\]B?_8+[]U[KW_0$_\ RX_^\FOFS_Y\
M]B?_ &"^_=>Z]_T!/_RX_P#O)KYL_P#GSV)_]@OOW7NO?] 3_P#+C_[R:^;/
M_GSV)_\ 8+[]U[KW_0$__+C_ .\FOFS_ .?/8G_V"^_=>Z]_T!/_ ,N/_O)K
MYL_^?/8G_P!@OOW7NO?] 3_\N/\ [R:^;/\ Y\]B?_8+[]U[KW_0$_\ RX_^
M\FOFS_Y\]B?_ &"^_=>Z]_T!/_RX_P#O)KYL_P#GSV)_]@OOW7NO?] 3_P#+
MC_[R:^;/_GSV)_\ 8+[]U[KW_0$__+C_ .\FOFS_ .?/8G_V"^_=>Z]_T!/_
M ,N/_O)KYL_^?/8G_P!@OOW7NO?] 3_\N/\ [R:^;/\ Y\]B?_8+[]U[KW_0
M$_\ RX_^\FOFS_Y\]B?_ &"^_=>Z]_T!/_RX_P#O)KYL_P#GSV)_]@OOW7NO
M?] 3_P#+C_[R:^;/_GSV)_\ 8+[]U[KW_0$__+C_ .\FOFS_ .?/8G_V"^_=
M>Z]_T!/_ ,N/_O)KYL_^?/8G_P!@OOW7NO?] 3_\N/\ [R:^;/\ Y\]B?_8+
M[]U[KW_0$_\ RX_^\FOFS_Y\]B?_ &"^_=>Z]_T!/_RX_P#O)KYL_P#GSV)_
M]@OOW7NO?] 3_P#+C_[R:^;/_GSV)_\ 8+[]U[KW_0$__+C_ .\FOFS_ .?/
M8G_V"^_=>Z]_T!/_ ,N/_O)KYL_^?/8G_P!@OOW7NO?] 3_\N/\ [R:^;/\
MY\]B?_8+[]U[KW_0$_\ RX_^\FOFS_Y\]B?_ &"^_=>Z]_T!/_RX_P#O)KYL
M_P#GSV)_]@OOW7NMP+:.W*79^U-L;1H9ZBIH=K;>HMN4=35Z?+)%0TT5-&\N
MA43R.D0+:5 N38 <>_=>Z4/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ*_GG_-3NG^7Q_+4[O^5?Q]
M;:B]J=?9_:&.P!WM0-DL;X\WNW"X6M$]&M12M(?LJ^7QD2KIDTMR 5/NO=:#
MG_08;_-__P".OQ=_] FH_P#K][]U[KW_ $&&_P W_P#XZ_%W_P! FH_^OWOW
M7NO?]!AO\W__ (Z_%W_T":C_ .OWOW7NO?\ 08;_ #?_ /CK\7?_ $":C_Z_
M>_=>Z]_T&&_S?_\ CK\7?_0)J/\ Z_>_=>Z&/X[?\*TOYLG:7R!Z+ZRW-/\
M&M-M]B]Q[8V)N!\9LR>*I%#E\W0X^K-/*V;D6.<05#^-RCA6L2K 6.QGK1QU
M]#K_ $R;V_X[X[_SG7_BOMS0.F]9Z]_IDWM_QWQW_G.O_%??M Z]K/7O],F]
MO^.^._\ .=?^*^_:!U[6>O?Z9-[?\=\=_P"<Z_\ %??M Z]K/7O],F]O^.^.
M_P#.=?\ BOOV@=>UGKW^F3>W_'?'?^<Z_P#%??M Z]K/7O\ 3)O;_COCO_.=
M?^*^_:!U[6>O?Z9-[?\ '?'?^<Z_\5]^T#KVL]>_TR;V_P".^._\YU_XK[]H
M'7M9Z]_IDWM_QWQW_G.O_%??M Z]K/7O],F]O^.^._\ .=?^*^_:!U[6>O?Z
M9-[?\=\=_P"<Z_\ %??M Z]K/7O],F]O^.^._P#.=?\ BOOV@=>UGKW^F3>W
M_'?'?^<Z_P#%??M Z]K/7O\ 3)O;_COCO_.=?^*^_:!U[6>O?Z9-[?\ '?'?
M^<Z_\5]^T#KVL]>_TR;V_P".^._\YU_XK[]H'7M9Z]_IDWM_QWQW_G.O_%??
MM Z]K/7O],F]O^.^._\ .=?^*^_:!U[6>O?Z9-[?\=\=_P"<Z_\ %??M Z]K
M/7O],F]O^.^._P#.=?\ BOOV@=>UGKW^F3>W_'?'?^<Z_P#%??M Z]K/7O\
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M/7O],F]O^.^._P#.=?\ BOOV@=>UGKW^F3>W_'?'?^<Z_P#%??M Z]K/7O\
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M/7O],F]O^.^._P#.=?\ BOOV@=>UGKW^F3>W_'?'?^<Z_P#%??M Z]K/7O\
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M/7O],F]O^.^._P#.=?\ BOOV@=>UGKW^F3>W_'?'?^<Z_P#%??M Z]K/7O\
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M/7O],F]O^.^._P#.=?\ BOOV@=>UGKW^F3>W_'?'?^<Z_P#%??M Z]K/7O\
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M/7O],F]O^.^._P#.=?\ BOOV@=>UGKW^F3>W_'?'?^<Z_P#%??M Z]K/7O\
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M9_;==U3#@:B""#&5%'3S?=OF,[APID-=&T9C\B%0Q=DL+V+:>JA=75<6PO\
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M'69S=%%'B)X*V3*54.TZ$ULF?R,T.7DJS4RLM0CB']NID)KQ'#JPQY]''_G
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M?]G7_P"J/_XY[]XG7O#Z]_H$_P"SK_\ 5'_\<]^\3KWA]>_T"?\ 9U_^J/\
M^.>_>)U[P^O?Z!/^SK_]4?\ \<]^\3KWA]>_T"?]G7_ZH_\ XY[]XG7O#Z]_
MH$_[.O\ ]4?_ ,<]^\3KWA]>_P! G_9U_P#JC_\ CGOWB=>\/KW^@3_LZ_\
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MU[P^O?Z!/^SK_P#5'_\ '/?O$Z]X?7O] G_9U_\ JC_^.>_>)U[P^O?Z!/\
MLZ__ %1__'/?O$Z]X?7O] G_ &=?_JC_ /CGOWB=>\/KW^@3_LZ__5'_ /'/
M?O$Z]X?7O] G_9U_^J/_ ..>_>)U[P^O?Z!/^SK_ /5'_P#'/?O$Z]X?7O\
M0)_V=?\ ZH__ (Y[]XG7O#Z]_H$_[.O_ -4?_P <]^\3KWA]>_T"?]G7_P"J
M/_XY[]XG7O#Z]_H$_P"SK_\ 5'_\<]^\3KWA]>_T"?\ 9U_^J/\ ^.>_>)U[
MP^O?Z!/^SK_]4?\ \<]^\3KWA]>_T"?]G7_ZH_\ XY[]XG7O#Z]_H$_[.O\
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MO] G_9U_^J/_ ..>_>)U[P^O?Z!/^SK_ /5'_P#'/?O$Z]X?7O\ 0)_V=?\
MZH__ (Y[]XG7O#Z]_H$_[.O_ -4?_P <]^\3KWA]>_T"?]G7_P"J/_XY[]XG
M7O#Z]_H$_P"SK_\ 5'_\<]^\3KWA]>_T"?\ 9U_^J/\ ^.>_>)U[P^O?Z!/^
MSK_]4?\ \<]^\3KWA]>_T"?]G7_ZH_\ XY[]XG7O#Z]_H$_[.O\ ]4?_ ,<]
M^\3KWA]>_P! G_9U_P#JC_\ CGOWB=>\/KW^@3_LZ_\ U1__ !SW[Q.O>'U[
M_0)_V=?_ *H__CGOWB=>\/KW^@3_ +.O_P!4?_QSW[Q.O>'U[_0)_P!G7_ZH
M_P#XY[]XG7O#Z]_H$_[.O_U1_P#QSW[Q.O>'U[_0)_V=?_JC_P#CGOWB=>\/
MKW^@3_LZ_P#U1_\ QSW[Q.O>'U[_ $"?]G7_ .J/_P".>_>)U[P^O?Z!/^SK
M_P#5'_\ '/?O$Z]X?7O] G_9U_\ JC_^.>_>)U[P^O?Z!/\ LZ__ %1__'/?
MO$Z]X?7O] G_ &=?_JC_ /CGOWB=>\/KW^@3_LZ__5'_ /'/?O$Z]X?7O] G
M_9U_^J/_ ..>_>)U[P^O?Z!/^SK_ /5'_P#'/?O$Z]X?7O\ 0)_V=?\ ZH__
M (Y[]XG7O#Z]_H$_[.O_ -4?_P <]^\3KWA]>_T"?]G7_P"J/_XY[]XG7O#Z
M]_H$_P"SK_\ 5'_\<]^\3KWA]>_T"?\ 9U_^J/\ ^.>_>)U[P^O?Z!/^SK_]
M4?\ \<]^\3KWA]>_T"?]G7_ZH_\ XY[]XG7O#Z]_H$_[.O\ ]4?_ ,<]^\3K
MWA]>_P! G_9U_P#JC_\ CGOWB=>\/KW^@3_LZ_\ U1__ !SW[Q.O>'U[_0)_
MV=?_ *H__CGOWB=>\/KW^@3_ +.O_P!4?_QSW[Q.O>'U[_0)_P!G7_ZH_P#X
MY[]XG7O#Z]_H$_[.O_U1_P#QSW[Q.O>'U[_0)_V=?_JC_P#CGOWB=>\/KW^@
M3_LZ_P#U1_\ QSW[Q.O>'U[_ $"?]G7_ .J/_P".>_>)U[P^O?Z!/^SK_P#5
M'_\ '/?O$Z]X?7O] G_9U_\ JC_^.>_>)U[P^O?Z!/\ LZ__ %1__'/?O$Z]
MX?7O] G_ &=?_JC_ /CGOWB=>\/KW^@3_LZ__5'_ /'/?O$Z]X?7O] G_9U_
M^J/_ ..>_>)U[P^O?Z!/^SK_ /5'_P#'/?O$Z]X?7O\ 0)_V=?\ ZH__ (Y[
M]XG7O#Z]_H$_[.O_ -4?_P <]^\3KWA]>_T"?]G7_P"J/_XY[]XG7O#Z]_H$
M_P"SK_\ 5'_\<]^\3KWA]>_T"?\ 9U_^J/\ ^.>_>)U[P^O?Z!/^SK_]4?\
M\<]^\3KWA]>_T"?]G7_ZH_\ XY[]XG7O#Z]_H$_[.O\ ]4?_ ,<]^\3KWA]>
M_P! G_9U_P#JC_\ CGOWB=>\/KW^@3_LZ_\ U1__ !SW[Q.O>'U[_0)_V=?_
M *H__CGOWB=>\/KW^@3_ +.O_P!4?_QSW[Q.O>'U[_0)_P!G7_ZH_P#XY[]X
MG7O#Z]_H$_[.O_U1_P#QSW[Q.O>'U[_0)_V=?_JC_P#CGOWB=>\/KW^@3_LZ
M_P#U1_\ QSW[Q.O>'U[_ $"?]G7_ .J/_P".>_>)U[P^O?Z!/^SK_P#5'_\
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M\3KWA]>_T"?]G7_ZH_\ XY[]XG7O#Z]_H$_[.O\ ]4?_ ,<]^\3KWA]>_P!
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M_H$_[.O_ -4?_P <]^\3KWA]>_T"?]G7_P"J/_XY[]XG7O#Z]_H$_P"SK_\
M5'_\<]^\3KWA]>_T"?\ 9U_^J/\ ^.>_>)U[P^O?Z!/^SK_]4?\ \<]^\3KW
MA]>_T"?]G7_ZH_\ XY[]XG7O#Z]_H$_[.O\ ]4?_ ,<]^\3KWA]>_P! G_9U
M_P#JC_\ CGOWB=>\/KW^@3_LZ_\ U1__ !SW[Q.O>'U[_0)_V=?_ *H__CGO
MWB=>\/KW^@3_ +.O_P!4?_QSW[Q.O>'U[_0)_P!G7_ZH_P#XY[]XG7O#Z]_H
M$_[.O_U1_P#QSW[Q.O>'U[_0)_V=?_JC_P#CGOWB=>\/KW^@3_LZ_P#U1_\
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MTU129O$Q5OD^SER^W<M3X_/XF.J:&58FJZ.$2/%*B$O%(J^Z]T-73GR$Z/\
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M\J.%=5< V90;CW[KW3[[]U[J%DLECL-CJ_+Y>OHL5B<512Y+*93)2I!3TU/
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MQ_I+I?K/Y'])?&>M[RVY6==S^5AD:"B@KZG&Y*GQ^4S.'KJ(TV1@*U%'6Q+
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M:G<VSESZ8>J9WEQU?3U$^.S&,>22"E>?^&Y>CJ:99C#%YTB6=8T615'NO=5
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M0YC-;GS<.&K_ .%_</B\=D*;<=56U]92U30T>&QLNA#%$9I6@:>J]U[HVO\
M-E_G7_/OXQ=W?"OX(?%3XW]4U'SA^3W3^&W[N_%;QR297;N.W)F%R%&FS-O9
M2LKML0U<])F,;(KY#)0TM'44\]*J24TIJ&IO=>ZM@_E)?(K^8U\BNHNTLC_,
MA^,.UOC3V9U]VE-U_M6GV[_$Z5MQ4E-31U%1EOX;D!40KCQ]S!'2U]%6U%+7
MM]P%BI7I71_=>Z-W\EOF[\1/AO\ W+_V:GY&=2] _P"D;^)?W$_TI9BEQ/\
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MV5@*+''95135%.DM3D-X0869UR5._CPE56+H%2M/4-[KW5R/Q7^7/S2^'O\
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MVOXK DR\JL[JX>)Y$;W7NJ__ .455U7\QW?7\YC^9]M.JW1*_P I<3BOA_\
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M?V%6]++*D%6,?DZ2I,3$.(:F&0C3(I/NO=+'_A/-_P!E7?\ "A#_ ,:\[_\
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M3C_*^WK\B3\K=V?";H_<'>TN6EW#6[NR>/FDI*O)S5,%8^6K]OFI_NWD,O\
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MGJ'HX)#8S?;+$]4R1O5M.\<;+[KW33TK_)K^"OQ_^,'R6^'_ %KL?>N/Z/\
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M_)S_ .>F^17_ * L_P#]</?NO=>_Z"^OY.?_ #TWR*_] 6?_ .N'OW7NO?\
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MA[]U[KW_ $%]?R<_^>F^17_H"S__ %P]^Z]U[_H+Z_DY_P#/3?(K_P! 6?\
M^N'OW7NO?]!?7\G/_GIOD5_Z L__ -</?NO=>_Z"^OY.?_/3?(K_ - 6?_ZX
M>_=>Z]_T%]?R<_\ GIOD5_Z L_\ ]</?NO=>_P"@OK^3G_STWR*_] 6?_P"N
M'OW7NO?]!?7\G/\ YZ;Y%?\ H"S_ /UP]^Z]U[_H+Z_DY_\ /3?(K_T!9_\
MZX>_=>Z]_P!!?7\G/_GIOD5_Z L__P!</?NO=>_Z"^OY.?\ STWR*_\ 0%G_
M /KA[]U[KW_07U_)S_YZ;Y%?^@+/_P#7#W[KW7O^@OK^3G_STWR*_P#0%G_^
MN'OW7NO?]!?7\G/_ )Z;Y%?^@+/_ /7#W[KW7O\ H+Z_DY_\]-\BO_0%G_\
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M_P#KA[]U[KW_ $%]?R<_^>F^17_H"S__ %P]^Z]U[_H+Z_DY_P#/3?(K_P!
M6?\ ^N'OW7NO?]!?7\G/_GIOD5_Z L__ -</?NO=>_Z"^OY.?_/3?(K_ - 6
M?_ZX>_=>Z]_T%]?R<_\ GIOD5_Z L_\ ]</?NO=>_P"@OK^3G_STWR*_] 6?
M_P"N'OW7NO?]!?7\G/\ YZ;Y%?\ H"S_ /UP]^Z]U[_H+Z_DY_\ /3?(K_T!
M9_\ ZX>_=>Z]_P!!?7\G/_GIOD5_Z L__P!</?NO=>_Z"^OY.?\ STWR*_\
M0%G_ /KA[]U[KW_07U_)S_YZ;Y%?^@+/_P#7#W[KW7O^@OK^3G_STWR*_P#0
M%G_^N'OW7NO?]!?7\G/_ )Z;Y%?^@+/_ /7#W[KW7O\ H+Z_DY_\]-\BO_0%
MG_\ KA[]U[KW_07U_)S_ .>F^17_ * L_P#]</?NO=>_Z"^OY.?_ #TWR*_]
M 6?_ .N'OW7NO?\ 07U_)S_YZ;Y%?^@+/_\ 7#W[KW7O^@OK^3G_ ,]-\BO_
M $!9_P#ZX>_=>Z]_T%]?R<_^>F^17_H"S_\ UP]^Z]U[_H+Z_DY_\]-\BO\
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M_GIOD5_Z L__ -</?NO=>_Z"^OY.?_/3?(K_ - 6?_ZX>_=>Z]_T%]?R<_\
MGIOD5_Z L_\ ]</?NO=>_P"@OK^3G_STWR*_] 6?_P"N'OW7NO?]!?7\G/\
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M_)S_ .>F^17_ * L_P#]</?NO=>_Z"^OY.?_ #TWR*_] 6?_ .N'OW7NO?\
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MA[]U[KW_ $%]?R<_^>F^17_H"S__ %P]^Z]U[_H+Z_DY_P#/3?(K_P! 6?\
M^N'OW7NO?]!?7\G/_GIOD5_Z L__ -</?NO=>_Z"^OY.?_/3?(K_ - 6?_ZX
M>_=>Z]_T%]?R<_\ GIOD5_Z L_\ ]</?NO=>_P"@OK^3G_STWR*_] 6?_P"N
M'OW7NO?]!?7\G/\ YZ;Y%?\ H"S_ /UP]^Z]U[_H+Z_DY_\ /3?(K_T!9_\
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M^@)+X._]Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_P#4C:'_ -8_?NO=>_Z
MDO@[_P!Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_]2-H?_6/W[KW7O\ H"2^
M#O\ WE[\K?\ J1M#_P"L?OW7NO?] 27P=_[R]^5O_4C:'_UC]^Z]U[_H"2^#
MO_>7ORM_ZD;0_P#K'[]U[KW_ $!)?!W_ +R]^5O_ %(VA_\ 6/W[KW7O^@)+
MX._]Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_P#4C:'_ -8_?NO=>_Z DO@[
M_P!Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_]2-H?_6/W[KW7O\ H"2^#O\
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M_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_]2-H?_6/W[KW7O\ H"2^#O\ WE[\K?\
MJ1M#_P"L?OW7NO?] 27P=_[R]^5O_4C:'_UC]^Z]U[_H"2^#O_>7ORM_ZD;0
M_P#K'[]U[KW_ $!)?!W_ +R]^5O_ %(VA_\ 6/W[KW7O^@)+X._]Y>_*W_J1
MM#_ZQ^_=>Z]_T!)?!W_O+WY6_P#4C:'_ -8_?NO=>_Z DO@[_P!Y>_*W_J1M
M#_ZQ^_=>Z]_T!)?!W_O+WY6_]2-H?_6/W[KW7O\ H"2^#O\ WE[\K?\ J1M#
M_P"L?OW7NO?] 27P=_[R]^5O_4C:'_UC]^Z]U[_H"2^#O_>7ORM_ZD;0_P#K
M'[]U[KW_ $!)?!W_ +R]^5O_ %(VA_\ 6/W[KW7O^@)+X._]Y>_*W_J1M#_Z
MQ^_=>Z]_T!)?!W_O+WY6_P#4C:'_ -8_?NO=>_Z DO@[_P!Y>_*W_J1M#_ZQ
M^_=>Z]_T!)?!W_O+WY6_]2-H?_6/W[KW7O\ H"2^#O\ WE[\K?\ J1M#_P"L
M?OW7NO?] 27P=_[R]^5O_4C:'_UC]^Z]U[_H"2^#O_>7ORM_ZD;0_P#K'[]U
M[KW_ $!)?!W_ +R]^5O_ %(VA_\ 6/W[KW7O^@)+X._]Y>_*W_J1M#_ZQ^_=
M>Z]_T!)?!W_O+WY6_P#4C:'_ -8_?NO=>_Z DO@[_P!Y>_*W_J1M#_ZQ^_=>
MZ]_T!)?!W_O+WY6_]2-H?_6/W[KW7O\ H"2^#O\ WE[\K?\ J1M#_P"L?OW7
MNO?] 27P=_[R]^5O_4C:'_UC]^Z]U[_H"2^#O_>7ORM_ZD;0_P#K'[]U[KW_
M $!)?!W_ +R]^5O_ %(VA_\ 6/W[KW7O^@)+X._]Y>_*W_J1M#_ZQ^_=>Z]_
MT!)?!W_O+WY6_P#4C:'_ -8_?NO=>_Z DO@[_P!Y>_*W_J1M#_ZQ^_=>Z]_T
M!)?!W_O+WY6_]2-H?_6/W[KW7O\ H"2^#O\ WE[\K?\ J1M#_P"L?OW7NO?]
M 27P=_[R]^5O_4C:'_UC]^Z]U[_H"2^#O_>7ORM_ZD;0_P#K'[]U[KW_ $!)
M?!W_ +R]^5O_ %(VA_\ 6/W[KW7O^@)+X._]Y>_*W_J1M#_ZQ^_=>Z]_T!)?
M!W_O+WY6_P#4C:'_ -8_?NO=>_Z DO@[_P!Y>_*W_J1M#_ZQ^_=>Z]_T!)?!
MW_O+WY6_]2-H?_6/W[KW7O\ H"2^#O\ WE[\K?\ J1M#_P"L?OW7NO?] 27P
M=_[R]^5O_4C:'_UC]^Z]U[_H"2^#O_>7ORM_ZD;0_P#K'[]U[KW_ $!)?!W_
M +R]^5O_ %(VA_\ 6/W[KW7O^@)+X._]Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O
M+WY6_P#4C:'_ -8_?NO=>_Z DO@[_P!Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+
MWY6_]2-H?_6/W[KW7O\ H"2^#O\ WE[\K?\ J1M#_P"L?OW7NO?] 27P=_[R
M]^5O_4C:'_UC]^Z]U[_H"2^#O_>7ORM_ZD;0_P#K'[]U[KW_ $!)?!W_ +R]
M^5O_ %(VA_\ 6/W[KW7O^@)+X._]Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6
M_P#4C:'_ -8_?NO=>_Z DO@[_P!Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_
M]2-H?_6/W[KW7O\ H"2^#O\ WE[\K?\ J1M#_P"L?OW7NO?] 27P=_[R]^5O
M_4C:'_UC]^Z]U[_H"2^#O_>7ORM_ZD;0_P#K'[]U[KW_ $!)?!W_ +R]^5O_
M %(VA_\ 6/W[KW7O^@)+X._]Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_P#4
MC:'_ -8_?NO=>_Z DO@[_P!Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_]2-H
M?_6/W[KW7O\ H"2^#O\ WE[\K?\ J1M#_P"L?OW7NO?] 27P=_[R]^5O_4C:
M'_UC]^Z]U[_H"2^#O_>7ORM_ZD;0_P#K'[]U[KW_ $!)?!W_ +R]^5O_ %(V
MA_\ 6/W[KW7O^@)+X._]Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_P#4C:'_
M -8_?NO=>_Z DO@[_P!Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_]2-H?_6/
MW[KW7O\ H"2^#O\ WE[\K?\ J1M#_P"L?OW7NO?] 27P=_[R]^5O_4C:'_UC
M]^Z]U[_H"2^#O_>7ORM_ZD;0_P#K'[]U[KW_ $!)?!W_ +R]^5O_ %(VA_\
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M>_Z DO@[_P!Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_]2-H?_6/W[KW7O\
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M_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_]2-H?_6/W[KW7O\ H"2^#O\ WE[\K?\
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M]^Z]U[_H"2^#O_>7ORM_ZD;0_P#K'[]U[KW_ $!)?!W_ +R]^5O_ %(VA_\
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M>_Z DO@[_P!Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_]2-H?_6/W[KW7O\
MH"2^#O\ WE[\K?\ J1M#_P"L?OW7NO?] 27P=_[R]^5O_4C:'_UC]^Z]U[_H
M"2^#O_>7ORM_ZD;0_P#K'[]U[KW_ $!)?!W_ +R]^5O_ %(VA_\ 6/W[KW7O
M^@)+X._]Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_P#4C:'_ -8_?NO=>_Z
MDO@[_P!Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_]2-H?_6/W[KW7O\ H"2^
M#O\ WE[\K?\ J1M#_P"L?OW7NO?] 27P=_[R]^5O_4C:'_UC]^Z]U[_H"2^#
MO_>7ORM_ZD;0_P#K'[]U[KW_ $!)?!W_ +R]^5O_ %(VA_\ 6/W[KW7O^@)+
MX._]Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_P#4C:'_ -8_?NO=>_Z DO@[
M_P!Y>_*W_J1M#_ZQ^_=>Z]_T!)?!W_O+WY6_]2-H?_6/W[KW7O\ H"2^#O\
MWE[\K?\ J1M#_P"L?OW7NO?] 27P=_[R]^5O_4C:'_UC]^Z]U[_H"2^#O_>7
MORM_ZD;0_P#K'[]U[KW_ $!)?!W_ +R]^5O_ %(VA_\ 6/W[KW6J-_(QV;1=
M<_\ "@3XI]>XVKJJ_';$^2V[]FT%=7:!--#B\-NJABEF$:JGED2 ,^D!=1-@
M!Q[]U[K[!'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K5W_P"%?7_;G/<W_BQ6Q?\ K?D/
M?NO=$X_X1)?]D._+W_Q:V#_WD,'[]U[K=/\ ?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UIN?\+8/^W<?
MQE_\79QG_O";Z]^Z]TIO^$5/_;K+OS_Q?_=/_ONNJO?NO=;?OOW7NO>_=>Z]
M[]U[KX[^RO\ N)IVE_XW8H/_ (("+W[KW7V(/?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7R*/Y
M.G_<2)T9_P"+C]A?^X>\??NO=?77]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:N__  KZ
M_P"W.>YO_%BMB_\ 6_(>_=>Z)Q_PB2_[(=^7O_BUL'_O(8/W[KW6Z?[]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NM-S_A;!_V[C^,O_B[.,_]X3?7OW7NE-_PBI_[=9=^?^+_ .Z?_?==
M5>_=>ZV_??NO=>]^Z]U[W[KW7QW]E?\ <33M+_QNQ0?_  0$7OW7NOL0>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NOD4?R=/\ N)$Z,_\ %Q^PO_</>/OW7NOKK^_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NM7?_A7U_P!N<]S?^+%;%_ZWY#W[KW1./^$27_9#OR]_\6M@
M_P#>0P?OW7NMT_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=:;G_"V#_MW'\9?_%V<9_[PF^O?NO=*;_A
M%3_VZR[\_P#%_P#=/_ONNJO?NO=;?OOW7NO>_=>Z][]U[KX[^RO^XFG:7_C=
MB@_^" B]^Z]U]B#W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U\BC^3I_P!Q(G1G_BX_87_N'O'W
M[KW7UU_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6KO_PKZ_[<Y[F_\6*V+_UOR'OW7NB<
M?\(DO^R'?E[_ .+6P?\ O(8/W[KW6Z?[]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM-S_ (6P?]NX_C+_
M .+LXS_WA-]>_=>Z4W_"*G_MUEWY_P"+_P"Z?_?==5>_=>ZV_??NO=>]^Z]U
M[W[KW7QW]E?]Q-.TO_&[%!_\$!%[]U[K[$'OW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KY%'\G3
M_N)$Z,_\7'["_P#</>/OW7NOKK^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM7?_A7U_VY
MSW-_XL5L7_K?D/?NO=$X_P"$27_9#OR]_P#%K8/_ 'D,'[]U[K=/]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW6FY_P +8/\ MW'\9?\ Q=G&?^\)OKW[KW2F_P"$5/\ VZR[\_\ %_\
M=/\ [[KJKW[KW6W[[]U[KWOW7NO>_=>Z^._LK_N)IVE_XW8H/_@@(O?NO=?8
M@]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=?(H_DZ?]Q(G1G_BX_87_ +A[Q]^Z]U]=?W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]UJ[_ /"OK_MSGN;_ ,6*V+_UOR'OW7NB<?\ ")+_ +(=
M^7O_ (M;!_[R&#]^Z]UNG^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K3<_X6P?\ ;N/XR_\ B[.,_P#>
M$WU[]U[I3?\ "*G_ +=9=^?^+_[I_P#?==5>_=>ZV_??NO=>]^Z]U[W[KW7Q
MW]E?]Q-.TO\ QNQ0?_! 1>_=>Z^Q![]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z^11_)T_[B1.C
M/_%Q^PO_ '#WC[]U[KZZ_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K5W_ .%?7_;G/<W_
M (L5L7_K?D/?NO=$X_X1)?\ 9#OR]_\ %K8/_>0P?OW7NMT_W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=:;G_"V#_MW'\9?_ !=G&?\ O";Z]^Z]TIO^$5/_ &ZR[\_\7_W3_P"^ZZJ]
M^Z]UM^^_=>Z][]U[KWOW7NOCO[*_[B:=I?\ C=B@_P#@@(O?NO=?8@]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=?(H_DZ?]Q(G1G_BX_87_N'O'W[KW7UU_?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW6KO_ ,*^O^W.>YO_ !8K8O\ UOR'OW7NB<?\(DO^R'?E[_XM;!_[
MR&#]^Z]UNG^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[K3<_X6P?]NX_C+_XNSC/_ 'A-]>_=>Z4W_"*G
M_MUEWY_XO_NG_P!]UU5[]U[K;]]^Z]U[W[KW7O?NO=?'?V5_W$T[2_\ &[%!
M_P#! 1>_=>Z^Q![]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z^11_)T_[B1.C/\ Q<?L+_W#WC[]
MU[KZZ_OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[K5W_P"%?7_;G/<W_BQ6Q?\ K?D/?NO=
M$X_X1)?]D._+W_Q:V#_WD,'[]U[K=/\ ?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UIN?\+8/^W<?QE_\
M79QG_O";Z]^Z]TIO^$5/_;K+OS_Q?_=/_ONNJO?NO=;?OOW7NO>_=>Z][]U[
MKX[^RO\ N)IVE_XW8H/_ (("+W[KW7V(/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7R*/Y.G_<
M2)T9_P"+C]A?^X>\??NO=?77]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:N__  KZ_P"W
M.>YO_%BMB_\ 6_(>_=>Z)Q_PB2_[(=^7O_BUL'_O(8/W[KW6Z?[]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NM-S_A;!_V[C^,O_B[.,_]X3?7OW7NE-_PBI_[=9=^?^+_ .Z?_?==5>_=
M>ZV_??NO=>]^Z]U[W[KW7QW]E?\ <33M+_QNQ0?_  0$7OW7NOL0>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NOD4?R=/\ N)$Z,_\ %Q^PO_</>/OW7NOKK^_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NM7?_A7U_P!N<]S?^+%;%_ZWY#W[KW1./^$27_9#OR]_\6M@_P#>
M0P?OW7NMT_W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=:;G_"V#_MW'\9?_%V<9_[PF^O?NO=*;_A%3_V
MZR[\_P#%_P#=/_ONNJO?NO=;?OOW7NO>_=>Z][]U[KX[^RO^XFG:7_C=B@_^
M" B]^Z]U]B#W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U\BC^3I_P!Q(G1G_BX_87_N'O'W[KW7
MUU_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW6KO_PKZ_[<Y[F_\6*V+_UOR'OW7NB<?\(D
MO^R'?E[_ .+6P?\ O(8/W[KW6Z?[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM-S_ (6P?]NX_C+_ .+L
MXS_WA-]>_=>Z4W_"*G_MUEWY_P"+_P"Z?_?==5>_=>ZV_??NO=>]^Z]U[W[K
MW7QW]E?]Q-.TO_&[%!_\$!%[]U[K[$'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KY%'\G3_N)$
MZ,_\7'["_P#</>/OW7NOKK^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM7?_A7U_VYSW-_
MXL5L7_K?D/?NO=:L7_">O^?U\6?Y1GQV[RZ?[ZZE[_["S_:'=,?9.%R/45)M
MVHHX*-,'CL68*ILSN+#3+4^:C=K1QR)H*G7JNH]U[K8"_P"@V#^7'_WC+\V?
M_/9L3_[.O?NO=>_Z#8/Y<?\ WC+\V?\ SV;$_P#LZ]^Z]U[_ *#8/Y<?_>,O
MS9_\]FQ/_LZ]^Z]U[_H-@_EQ_P#>,OS9_P#/9L3_ .SKW[KW7O\ H-@_EQ_]
MXR_-G_SV;$_^SKW[KW7O^@V#^7'_ -XR_-G_ ,]FQ/\ [.O?NO=>_P"@V#^7
M'_WC+\V?_/9L3_[.O?NO=>_Z#8/Y<?\ WC+\V?\ SV;$_P#LZ]^Z]U[_ *#8
M/Y<?_>,OS9_\]FQ/_LZ]^Z]U[_H-@_EQ_P#>,OS9_P#/9L3_ .SKW[KW7O\
MH-@_EQ_]XR_-G_SV;$_^SKW[KW7O^@V#^7'_ -XR_-G_ ,]FQ/\ [.O?NO=>
M_P"@V#^7'_WC+\V?_/9L3_[.O?NO=>_Z#8/Y<?\ WC+\V?\ SV;$_P#LZ]^Z
M]U[_ *#8/Y<?_>,OS9_\]FQ/_LZ]^Z]U[_H-@_EQ_P#>,OS9_P#/9L3_ .SK
MW[KW7O\ H-@_EQ_]XR_-G_SV;$_^SKW[KW7O^@V#^7'_ -XR_-G_ ,]FQ/\
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MQ/\ [.O?NO=>_P"@V#^7'_WC+\V?_/9L3_[.O?NO=>_Z#8/Y<?\ WC+\V?\
MSV;$_P#LZ]^Z]U[_ *#8/Y<?_>,OS9_\]FQ/_LZ]^Z]U[_H-@_EQ_P#>,OS9
M_P#/9L3_ .SKW[KW7O\ H-@_EQ_]XR_-G_SV;$_^SKW[KW7O^@V#^7'_ -XR
M_-G_ ,]FQ/\ [.O?NO=>_P"@V#^7'_WC+\V?_/9L3_[.O?NO=>_Z#8/Y<?\
MWC+\V?\ SV;$_P#LZ]^Z]U[_ *#8/Y<?_>,OS9_\]FQ/_LZ]^Z]U[_H-@_EQ
M_P#>,OS9_P#/9L3_ .SKW[KW7O\ H-@_EQ_]XR_-G_SV;$_^SKW[KW7O^@V#
M^7'_ -XR_-G_ ,]FQ/\ [.O?NO=>_P"@V#^7'_WC+\V?_/9L3_[.O?NO=>_Z
M#8/Y<?\ WC+\V?\ SV;$_P#LZ]^Z]U[_ *#8/Y<?_>,OS9_\]FQ/_LZ]^Z]U
M[_H-@_EQ_P#>,OS9_P#/9L3_ .SKW[KW7O\ H-@_EQ_]XR_-G_SV;$_^SKW[
MKW7O^@V#^7'_ -XR_-G_ ,]FQ/\ [.O?NO=>_P"@V#^7'_WC+\V?_/9L3_[.
MO?NO=>_Z#8/Y<?\ WC+\V?\ SV;$_P#LZ]^Z]U[_ *#8/Y<?_>,OS9_\]FQ/
M_LZ]^Z]U[_H-@_EQ_P#>,OS9_P#/9L3_ .SKW[KW7O\ H-@_EQ_]XR_-G_SV
M;$_^SKW[KW7O^@V#^7'_ -XR_-G_ ,]FQ/\ [.O?NO=>_P"@V#^7'_WC+\V?
M_/9L3_[.O?NO=>_Z#8/Y<?\ WC+\V?\ SV;$_P#LZ]^Z]U[_ *#8/Y<?_>,O
MS9_\]FQ/_LZ]^Z]U[_H-@_EQ_P#>,OS9_P#/9L3_ .SKW[KW7O\ H-@_EQ_]
MXR_-G_SV;$_^SKW[KW7O^@V#^7'_ -XR_-G_ ,]FQ/\ [.O?NO=>_P"@V#^7
M'_WC+\V?_/9L3_[.O?NO=>_Z#8/Y<?\ WC+\V?\ SV;$_P#LZ]^Z]U[_ *#8
M/Y<?_>,OS9_\]FQ/_LZ]^Z]U[_H-@_EQ_P#>,OS9_P#/9L3_ .SKW[KW7O\
MH-@_EQ_]XR_-G_SV;$_^SKW[KW7O^@V#^7'_ -XR_-G_ ,]FQ/\ [.O?NO=>
M_P"@V#^7'_WC+\V?_/9L3_[.O?NO=>_Z#8/Y<?\ WC+\V?\ SV;$_P#LZ]^Z
M]U[_ *#8/Y<?_>,OS9_\]FQ/_LZ]^Z]U[_H-@_EQ_P#>,OS9_P#/9L3_ .SK
MW[KW7O\ H-@_EQ_]XR_-G_SV;$_^SKW[KW7O^@V#^7'_ -XR_-G_ ,]FQ/\
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MR_-G_P ]FQ/_ +.O?NO=>_Z#8/Y<?_>,OS9_\]FQ/_LZ]^Z]U[_H-@_EQ_\
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MKW[KW7O^@V#^7'_WC+\V?_/9L3_[.O?NO=>_Z#8/Y<?_ 'C+\V?_ #V;$_\
MLZ]^Z]U[_H-@_EQ_]XR_-G_SV;$_^SKW[KW7O^@V#^7'_P!XR_-G_P ]FQ/_
M +.O?NO=>_Z#8/Y<?_>,OS9_\]FQ/_LZ]^Z]U[_H-@_EQ_\ >,OS9_\ /9L3
M_P"SKW[KW7O^@V#^7'_WC+\V?_/9L3_[.O?NO=>_Z#8/Y<?_ 'C+\V?_ #V;
M$_\ LZ]^Z]U[_H-@_EQ_]XR_-G_SV;$_^SKW[KW7O^@V#^7'_P!XR_-G_P ]
MFQ/_ +.O?NO=>_Z#8/Y<?_>,OS9_\]FQ/_LZ]^Z]U[_H-@_EQ_\ >,OS9_\
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MR_-G_P ]FQ/_ +.O?NO=>_Z#8/Y<?_>,OS9_\]FQ/_LZ]^Z]U[_H-@_EQ_\
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MZZ_^U5[]U[KW_0%3_*R_Y_Y\_P#_ -"GKK_[57OW7NO?] 5/\K+_ )_Y\_\
M_P!"GKK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T*>NO_ +57OW7NO?\ 0%3_ "LO
M^?\ GS__ /0IZZ_^U5[]U[KW_0%3_*R_Y_Y\_P#_ -"GKK_[57OW7NO?] 5/
M\K+_ )_Y\_\ _P!"GKK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T*>NO_ +57OW7N
MO?\ 0%3_ "LO^?\ GS__ /0IZZ_^U5[]U[KW_0%3_*R_Y_Y\_P#_ -"GKK_[
M57OW7NO?] 5/\K+_ )_Y\_\ _P!"GKK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T*
M>NO_ +57OW7NO?\ 0%3_ "LO^?\ GS__ /0IZZ_^U5[]U[KW_0%3_*R_Y_Y\
M_P#_ -"GKK_[57OW7NO?] 5/\K+_ )_Y\_\ _P!"GKK_ .U5[]U[KW_0%3_*
MR_Y_Y\__ /T*>NO_ +57OW7NO?\ 0%3_ "LO^?\ GS__ /0IZZ_^U5[]U[KW
M_0%3_*R_Y_Y\_P#_ -"GKK_[57OW7NO?] 5/\K+_ )_Y\_\ _P!"GKK_ .U5
M[]U[KW_0%3_*R_Y_Y\__ /T*>NO_ +57OW7NO?\ 0%3_ "LO^?\ GS__ /0I
MZZ_^U5[]U[KW_0%3_*R_Y_Y\_P#_ -"GKK_[57OW7NO?] 5/\K+_ )_Y\_\
M_P!"GKK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T*>NO_ +57OW7NO?\ 0%3_ "LO
M^?\ GS__ /0IZZ_^U5[]U[KW_0%3_*R_Y_Y\_P#_ -"GKK_[57OW7NO?] 5/
M\K+_ )_Y\_\ _P!"GKK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T*>NO_ +57OW7N
MO?\ 0%3_ "LO^?\ GS__ /0IZZ_^U5[]U[KW_0%3_*R_Y_Y\_P#_ -"GKK_[
M57OW7NO?] 5/\K+_ )_Y\_\ _P!"GKK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T*
M>NO_ +57OW7NO?\ 0%3_ "LO^?\ GS__ /0IZZ_^U5[]U[KW_0%3_*R_Y_Y\
M_P#_ -"GKK_[57OW7NO?] 5/\K+_ )_Y\_\ _P!"GKK_ .U5[]U[KW_0%3_*
MR_Y_Y\__ /T*>NO_ +57OW7NO?\ 0%3_ "LO^?\ GS__ /0IZZ_^U5[]U[KW
M_0%3_*R_Y_Y\_P#_ -"GKK_[57OW7NO?] 5/\K+_ )_Y\_\ _P!"GKK_ .U5
M[]U[KW_0%3_*R_Y_Y\__ /T*>NO_ +57OW7NO?\ 0%3_ "LO^?\ GS__ /0I
MZZ_^U5[]U[KW_0%3_*R_Y_Y\_P#_ -"GKK_[57OW7NO?] 5/\K+_ )_Y\_\
M_P!"GKK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T*>NO_ +57OW7NO?\ 0%3_ "LO
M^?\ GS__ /0IZZ_^U5[]U[KW_0%3_*R_Y_Y\_P#_ -"GKK_[57OW7NO?] 5/
M\K+_ )_Y\_\ _P!"GKK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T*>NO_ +57OW7N
MO?\ 0%3_ "LO^?\ GS__ /0IZZ_^U5[]U[KW_0%3_*R_Y_Y\_P#_ -"GKK_[
M57OW7NO?] 5/\K+_ )_Y\_\ _P!"GKK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T*
M>NO_ +57OW7NO?\ 0%3_ "LO^?\ GS__ /0IZZ_^U5[]U[KW_0%3_*R_Y_Y\
M_P#_ -"GKK_[57OW7NO?] 5/\K+_ )_Y\_\ _P!"GKK_ .U5[]U[KW_0%3_*
MR_Y_Y\__ /T*>NO_ +57OW7NO?\ 0%3_ "LO^?\ GS__ /0IZZ_^U5[]U[KW
M_0%3_*R_Y_Y\_P#_ -"GKK_[57OW7NO?] 5/\K+_ )_Y\_\ _P!"GKK_ .U5
M[]U[KW_0%3_*R_Y_Y\__ /T*>NO_ +57OW7NO?\ 0%3_ "LO^?\ GS__ /0I
MZZ_^U5[]U[KW_0%3_*R_Y_Y\_P#_ -"GKK_[57OW7NO?] 5/\K+_ )_Y\_\
M_P!"GKK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T*>NO_ +57OW7NO?\ 0%3_ "LO
M^?\ GS__ /0IZZ_^U5[]U[KW_0%3_*R_Y_Y\_P#_ -"GKK_[57OW7NO?] 5/
M\K+_ )_Y\_\ _P!"GKK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T*>NO_ +57OW7N
MO?\ 0%3_ "LO^?\ GS__ /0IZZ_^U5[]U[KW_0%3_*R_Y_Y\_P#_ -"GKK_[
M57OW7NO?] 5/\K+_ )_Y\_\ _P!"GKK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T*
M>NO_ +57OW7NO?\ 0%3_ "LO^?\ GS__ /0IZZ_^U5[]U[KW_0%3_*R_Y_Y\
M_P#_ -"GKK_[57OW7NO?] 5/\K+_ )_Y\_\ _P!"GKK_ .U5[]U[KW_0%3_*
MR_Y_Y\__ /T*>NO_ +57OW7NO?\ 0%3_ "LO^?\ GS__ /0IZZ_^U5[]U[KW
M_0%3_*R_Y_Y\_P#_ -"GKK_[57OW7NO?] 5/\K+_ )_Y\_\ _P!"GKK_ .U5
M[]U[KW_0%3_*R_Y_Y\__ /T*>NO_ +57OW7NO?\ 0%3_ "LO^?\ GS__ /0I
MZZ_^U5[]U[KW_0%3_*R_Y_Y\_P#_ -"GKK_[57OW7NO?] 5/\K+_ )_Y\_\
M_P!"GKK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T*>NO_ +57OW7NO?\ 0%3_ "LO
M^?\ GS__ /0IZZ_^U5[]U[KW_0%3_*R_Y_Y\_P#_ -"GKK_[57OW7NO?] 5/
M\K+_ )_Y\_\ _P!"GKK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T*>NO_ +57OW7N
MO?\ 0%3_ "LO^?\ GS__ /0IZZ_^U5[]U[KW_0%3_*R_Y_Y\_P#_ -"GKK_[
M57OW7NO?] 5/\K+_ )_Y\_\ _P!"GKK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T*
M>NO_ +57OW7NO?\ 0%3_ "LO^?\ GS__ /0IZZ_^U5[]U[KW_0%3_*R_Y_Y\
M_P#_ -"GKK_[57OW7NO?] 5/\K+_ )_Y\_\ _P!"GKK_ .U5[]U[KW_0%3_*
MR_Y_Y\__ /T*>NO_ +57OW7NO?\ 0%3_ "LO^?\ GS__ /0IZZ_^U5[]U[KW
M_0%3_*R_Y_Y\_P#_ -"GKK_[57OW7NO?] 5/\K+_ )_Y\_\ _P!"GKK_ .U5
M[]U[KW_0%3_*R_Y_Y\__ /T*>NO_ +57OW7NO?\ 0%3_ "LO^?\ GS__ /0I
MZZ_^U5[]U[KW_0%3_*R_Y_Y\_P#_ -"GKK_[57OW7NO?] 5/\K+_ )_Y\_\
M_P!"GKK_ .U5[]U[KW_0%3_*R_Y_Y\__ /T*>NO_ +57OW7NKWOY7_\ *_Z"
M_E-=!;O^.GQTW?W!O39.].X,AW7E,IW7D,+D<K'E<CA=OX*>GIY\%M_;E(F/
M2DVY3.B/3/,)GG9IV1HXXO=>ZL?]^Z]U[W[KW7O?NO=:J?>/_"03^6KW]W5W
M!WOO'N_YR8W=W=?:.X.V]U8[;.Y=@PXVGR6Y,M5YFN@Q\-5UG6U45#%55KK
MDU1/*L059)I7!=O=>Z"[_H"I_E9?\_\ /G__ .A3UU_]JKW[KW7O^@*G^5E_
MS_SY_P#_ *%/77_VJO?NO=>_Z J?Y67_ #_SY_\ _H4]=?\ VJO?NO=>_P"@
M*G^5E_S_ ,^?_P#Z%/77_P!JKW[KW7O^@*G^5E_S_P ^?_\ Z%/77_VJO?NO
M=>_Z J?Y67_/_/G_ /\ H4]=?_:J]^Z]U[_H"I_E9?\ /_/G_P#^A3UU_P#:
MJ]^Z]U[_ * J?Y67_/\ SY__ /H4]=?_ &JO?NO=>_Z J?Y67_/_ #Y__P#H
M4]=?_:J]^Z]U[_H"I_E9?\_\^?\ _P"A3UU_]JKW[KW7O^@*G^5E_P _\^?_
M /Z%/77_ -JKW[KW7O\ H"I_E9?\_P#/G_\ ^A3UU_\ :J]^Z]U[_H"I_E9?
M\_\ /G__ .A3UU_]JKW[KW7O^@*G^5E_S_SY_P#_ *%/77_VJO?NO=>_Z J?
MY67_ #_SY_\ _H4]=?\ VJO?NO=>_P"@*G^5E_S_ ,^?_P#Z%/77_P!JKW[K
MW7O^@*G^5E_S_P ^?_\ Z%/77_VJO?NO=>_Z J?Y67_/_/G_ /\ H4]=?_:J
M]^Z]U[_H"I_E9?\ /_/G_P#^A3UU_P#:J]^Z]U[_ * J?Y67_/\ SY__ /H4
M]=?_ &JO?NO=>_Z J?Y67_/_ #Y__P#H4]=?_:J]^Z]U[_H"I_E9?\_\^?\
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M_P!JKW[KW7O^@*G^5E_S_P ^?_\ Z%/77_VJO?NO=>_Z J?Y67_/_/G_ /\
MH4]=?_:J]^Z]U[_H"I_E9?\ /_/G_P#^A3UU_P#:J]^Z]U[_ * J?Y67_/\
MSY__ /H4]=?_ &JO?NO=>_Z J?Y67_/_ #Y__P#H4]=?_:J]^Z]U[_H"I_E9
M?\_\^?\ _P"A3UU_]JKW[KW7O^@*G^5E_P _\^?_ /Z%/77_ -JKW[KW7O\
MH"I_E9?\_P#/G_\ ^A3UU_\ :J]^Z]U[_H"I_E9?\_\ /G__ .A3UU_]JKW[
MKW7O^@*G^5E_S_SY_P#_ *%/77_VJO?NO=>_Z J?Y67_ #_SY_\ _H4]=?\
MVJO?NO=>_P"@*G^5E_S_ ,^?_P#Z%/77_P!JKW[KW7O^@*G^5E_S_P ^?_\
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M?_\ Z%/77_VJO?NO=>_Z J?Y67_/_/G_ /\ H4]=?_:J]^Z]U[_H"I_E9?\
M/_/G_P#^A3UU_P#:J]^Z]U[_ * J?Y67_/\ SY__ /H4]=?_ &JO?NO=>_Z
MJ?Y67_/_ #Y__P#H4]=?_:J]^Z]U[_H"I_E9?\_\^?\ _P"A3UU_]JKW[KW7
MO^@*G^5E_P _\^?_ /Z%/77_ -JKW[KW7O\ H"I_E9?\_P#/G_\ ^A3UU_\
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M[]U[KWOW7NO>_=>Z][]U[K7;_P"%5?\ VX\^6/\ X<W7'_OR=J>_=>Z^>O\
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4NO>_=>Z][]U[KWOW7NO>_=>Z_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !"*]E@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  0BO98[;I;VNX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2@,Q$(9?17+?G4U:*H1M+HHG!<&"XBTDTS:XV81D9+=O[VYLMX@^@,?,_/GF
M&YC61&E"PN<4(B9RF&]&W_59FKAE1Z(H ;(YHM>YGA+]U-R'Y#5-SW2 J,V'
M/B"(IMF 1])6DX896,6%R%1KC30)-85TQENSX.-GZ@K,&L ./?:4@=<<F)HG
MQM/8M7 %S##"Y/-W >U"+-4_L:4#[)P<LUM2PS#4PZKDIATXO#T]OI1U*]=G
MTKW!Z5=VDDX1M^PR^75U=[][8$HT8ETUMY40.\$EWTB^?I]=?_A=A7VP;N_^
ML?%%4+7PZR[4%U!+ P04    "  0BO98F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M !"*]EC"B>/!5P0  ,X.   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MK9=M<^(V$,>_BL:=Z=S-)+%Y"'DH, ,DZ3%M<AFXMJ^%O6!-9,F5Y #?OBN)
M..3&$5QZ>1$L>_>OWZY63_VU5$\Z!S!D4W"A!U%N3'D=QSK-H:#Z3)8@\,M2
MJH(:;*I5K$L%-'-.!8_;2=*+"\I$-.R[=X]JV)>5X4S HR*Z*@JJMF/@<CV(
M6M'+BQE;Y<:^B(?]DJY@#N:O\E%A*ZY5,E: T$P*HF YB$:MZW&K;1V<Q=\,
MUGKOF=A0%E(^V<8T&T2))0(.J;$2%'^>80*<6R7D^'<G&M5]6L?]YQ?U.Q<\
M!K.@&B:2_\,RDP^BRXADL*05-S.Y_@*[@,ZM7BJY=O_)VMMVNQ%)*VUDL7-&
M@H()_TLWNT3L.5PF[SBT=PXN$;'OR%'>4$.'?2771%EK5+,/+E3GC7!,V%&9
M&X5?&?J9X8U,*TRR(2.1D5MAF-F2J?"CC5GKQP8[L:9QNA,<>\'V.X(=<B^%
MR36*99"]]8\1KB9LOQ".VT'!>ZK.2*=U0MI)NQO0Z]01=YQ>YU#$>V&2/]&(
M3 T4NBEB+]AM%K3SYEJ7-(5!A!-#@WJ&:/CK+ZU>\EL MUOC=D/JP]V8S&#%
MM%$4N1]H 4V489W1;#(BX^G7QR^CV?WHA$P?)F<!O/,:[SPH6V?SV[9LI J[
MST^[\2B T:LQ>N'HD"%S''><KIHXPOY&51# N*@Q+H[$N &=*E:^-X?",M]R
M($SKBHH4-)%+\HE]]@5%.2<ZI\J_=F.:RJ+ "L:5(GTB3!#8I#D5*R!8W01H
MFGL':_]554_TK<,G)E)>94RL]G0;["P.9%;?()PWP&H_3;G4UGG)!-+BT^<3
MU#P:UP:YX$"J4EIR4"G3#M5J+RN[A) U5;;N]1[#FQB;3(TD9:70"-6"<6G)
MCXGJA%!<'S&PCT662O$,RNUD+]9S4 RT%QN31]R+0"D,8?Y=N@\.9UF[NIZ1
M%+\R8<!E!!.Q .P?N\?68HN!,HW;J5]-W-JG#<6%SQ8M-NQ6YZ%P:MI.UCG#
M/FUZ:(H1EE1L;69*)3?;5]<8V[K$G;:RPT20BBIS1K"0+8PF0I*,+9$3L*21
MR*P!?-)#230Y-;@?8JH7\",I"53N.Z/[TT@D*JD0SP?Z>JTCZWIHEAR#^M.F
M3&,ZW5SY'U'^\&SY:)U\-W5"^^%EO0-<'K-=3W!.*,KQC)'!AOP!VZ9-(*R4
MX-]5<M$[#QUZKFJLJV.P[AC'ZIS@I%U)U<@4EGF0XA27 3Q3X]J!:7-Z ;Q6
M\GH,38X!G!=V81U76%"@&\]B!W0.;.2MO7-QZQB@VP+4RM;T[ZA@<C+Q2V C
M65AP2;D.HK5?T=K'H$U%*E4I_2I^@E,!AX1@I4]DA<6'-2BSQA/9 ?6;VR;(
M>.^*85/B+E(:IRKVY6\;]=OZLC;R5Y17<W_3PP,]9E03#DMT3<XN\(BH_.7)
M-XPLW85E(0U>?]QCCA=.4-8 OR^E-"\-VT%]A1W^!U!+ P04    "  0BO98
M/$U+5J0%   R&0  &    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;*U9VV[;
M.!#]%<(MBA9H8I&Z.A<#K87%[D/1H&EWGQF)CHE*HDM2N>S7+RG9LBV.%*?K
MET2RSPQYAL.90_KJ4<B?:L681D]E4:GKR4KK]<5TJK(5*ZDZ%VM6F6^60I94
MFU=Y/U5KR6C>&)7%E'A>-"TIKR;SJ^:S&SF_$K4N>,5N)%)U65+Y_)D5XO%Z
M@B?;#[[Q^Y6V'TSG5VMZSVZ9_K&^D>9MVGG)><DJQ46%)%M>3S[ABY0$UJ!!
M_,W9H]I[1I;*G1 _[<M?^?7$LS-B!<NT=4'-OP>V8$5A/9EY_-HXG71C6L/]
MYZWW/QKRALP=56PABG]XKE?7DV2"<K:D=:&_B<<_V890:/UEHE#-7_2XP7H3
ME-5*BW)C;&90\JK]3Y\V@=@SP,&  =D8D&,-_(V!?ZQ!L#%H0CUMJ31Q2*FF
M\RLI'I&T:./-/C3!;*P-?5[9=;_5TGS+C9V>?Z8%K3*&;JT'A=[_J&B=<\WR
M#^@,_;A-T?NW']!;Q"OT?25J1:M<74VU&=B:3[/-()_;0<C (%^H/$<^_HB(
M1P+ ?#%NGK*L,_<!\_1X<W)H/C71ZD)&NI"1QI\_X&]12\DJC:A2)F074#A:
M!P'LP&[E"[6F&;N>F+VJF'Q@D_F[-SCR+J'@G-)9>B)G!X'SN\#Y8][G"ZI6
MR&00RNP#^U7S!UJ82((9U;H*&U>V>#W,_7#FF>5_V(\-@(H#'Q^B4A<5D" (
M.]0!FZ!C$XRR^:I73)HMNI\,$)'62[0W>!S%/1HN!D=]$BZ&A %,(>PHA*,4
MO@M-BR,HA,[0?A3%7H\$@(K#&>G1<%$!B68SF$C4$8E&B33MZDPLSVK%6A[H
MW9N$8'R)3(>45//J'B(6N7'O+XT+(4$/D[H8/_!A1G''*!YE="/MQ/5SLU_L
M5EF;9JL_HHIIB$CL)EF/AXO O05,70@9V"-)QR(Y8H\,)U;B3JJ7+XN7(2D
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M-Q.TR^,NZ'BBQ:[8%SP)C;N,XC#!G2-((\#[&R'TZXG9:E1[T>4/4$L#!!0
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M#0"#KEJ4,L/&)C!:&^\<81KCUIX[Q]Q/S-9V.\<XMM7::7KCR$F![M19SU!
MBHR7GY=ZMFXGOJA3M#6_,*=+LV/>%^U'V2W\DR][%_&%W<7BA$I@*T(9@Y%8
M*2W[@7+ 2:X.O&?"Q?&I;B/10@&5 /%\2P@_#F2 NBGS_@)02P,$%     @
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MMQBEF$H!\?N&$/YR(U_0GBU<_0]02P,$%     @ $(KV6)+4"E-U%0  )4\
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M3(<("2>38)I6^O2SA>UNV=$Y4O;ECZYX337S:B\"^I!^'JY"8SU'ALB7)Z2
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MBS?>XJW&/7]V:?)<>[C%.R&+1%R:PNMBK(I8*W>RZ\&"#N[&%;F+0"YZA-Q
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M4>]Y_9P?LJK\HO_\60BLH _%*X/E,!)YF#E&:JR+@@RT1)I!+N1@ +D59JJ
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M=E06_F=!%ULT+$#G*TT[MWU@ _U5>?X74$L#!!0    ( !"*]E@ (@- ZP<
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M1++2Z'5E+'@E?&^J-JT'=5S!M(UX9RJ,\-U8N7< 9_C!H;RW>XTUE["/B !
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M W;/+IG-_\,CP73Y]I["=&L^TW8[/(:CVG3L+;.3[ U KFSTGB,MFY!9X67
M]&MZE?(RO$'8WQ[>P_P@[2TMURJUP-'9](>G!V&[V7WQIN'W">?&>[/BCTLE
MT;_I!EQ?&..[+\0@O6#ZZC]02P,$%     @ $(KV6!!EGH; %@  R%D  !D
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M9I2F4\%9KLG-71NXN6MR9'B2=+8U*VQ 5Y"-1I/S(J8'[-.WB8#^L3@41U!
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M!/8ZFLVTXM",B<U<;'ORITU [M"Y?/TR].^=R)2'MBNW*EBN NX0S^V6A:L
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M='/[9DYO*]1N <T?%<6LZ3@#W6MM_0502P,$%     @ $(KV6)3,2-[P @
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M;H$_$Z"L *[G4IKUP&[0_YXDOP%02P,$%     @ $(KV6.8ZJ\,A P  9@@
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MR03[FFD&SN;#Z<H/>4OM<&3TRS7.Z&!( /]G6KOM!QGHIO[Y_U!+ P04
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M PVN7IO6R=;8VXT6M?/&G=#&:=VR-'<A2!M@WN="Z./&)NAOU_074$L#!!0
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M?/^58+\CV;9X;W['I&1IL;DA."9<%ZCS:\;D\XY^%5]]JUG^#U!+ P04
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M,?HYO4FHC0-*,Z$T"TJSH30'2G.A- ]*\Z&T $631=C8.(Q#;VXYMC<)]6E
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MZG0X%$G"-#Y(K0CE4S(47#,^!QXQ4.1X!)JR6'TAIV2,2VZ:Q4#$C%QE.I-
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MV"?GIPO\]@%I)N#]F1#Z96":Y>IK*OP/4$L#!!0    ( !"*]E@L1A@Z8@0
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MYCP_"=/B+WDJTPZ'/>)OTBR)JF!Y!U$0E_^]YZH@M@(LZT" 5058.P&F<R#
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M=]_G<W+760CYH"8 FCSF&5==;Z+U],SW53*!G*HC,06.3T9"YE3C5(Y]-95
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MXVW)'\C^-^@"FDB^E)1,_47[SM:Q4+IEG%0=6'A0%77[B9^Z1!P!!(\>X'4
M;P@(7@#X'< ? L(7 $$'"%Y[PZ0#J-#M-G:5N!AS'$TIV2,JK06;7*CL*[3(
M5U'+0EEQ*IX6 L>C58XI7,I49VA)*E%_#"L%W\; <5&R=^@2K41Y9ML2$%FC
M/TA]F6*67Z 7H<F37(, ?E[%Z.V;=^@-*FKT*2=;ANN,36TN/)?WVVGGY:+U
MTGO!2Q]])#7/&4KJ##(-/A['N]X(@2U2UN?-.^1MX8TR?L3T"OGN!?(<+] X
MM'P]W-?%,PZ/(1V%)Z^'>R/)\/LB\A6?/UI$"U4)]_BKZ",<S2G%]0;D^N)0
M$1D2\J,E;@J.R^(_R"[0O");8?WW[X(2?>!0L7]TY='>'^COE\WTCC4XA9DE
MNB4#N@,K^ODG-W1^T4ECDBPV2988(CL1,>A%#,;8HT]$B(*@54K['6WQ$X67
M/T"[R'5%[>^.<WMNXSD#F_C<)KP)3VV2<YO)Y-GF),!)'^!D-,!?H08J0I0U
M.,]$+RT8IUC^3NF"'>7ZUHHS21:;)$L,D9T($O:"A#^X;80F131)%ILD2PR1
MG8AXW8MX_9UMH\6'HVU#8Q/Z@[9Q;C/QAFWCW";P?'W;N.D#O!D-\$&D#-,T
M5T48PTZ\6S>R/'6ACC)]:[V9)(M-DB6&R$[DN.WEN/W!3>/6I(@FR6*39(DA
MLA,17>=Y['"^LVV,$^@=1#H).J+C=XG '?06C8T(==!<=$;^L+O81[-8!72C
MAF"&4EEZ[1MU?]H/VG,U7@[.%^[=TM6<QW(P5[/?,WT[U8NA8E/4#)6P%E<Y
M5]?"4]H.RNV&DT9-@H^$B[E2+7/ &5!I()ZO">&'C;R@_W=%]#]02P,$%
M  @ $(KV6!\3JSYC P  I0X  !D   !X;"]W;W)K<VAE971S+W-H965T,SDN
M>&ULM5==;]LX$/PKA'IM4^#.HB1_);4%U':*%F@.08/>/1SN@9'7EE"*5$DZ
M3OY]24J1)54A&L-YL46*,]P9<8G=V9Z+[S(%4.@^ITS.O52IXL+W99)"3N2
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M9H%^O^%</0[,!G5G&O\$4$L#!!0    ( !"*]E@X!"G&>08  /(D   9
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MLD0/P/=SSM7FBYZ@ON8T^1=02P,$%     @ $(KV6 ,,9T%P P  M@H  !D
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ME;#=.*OH@^*?1&Q9+E%*-Q#9N9O ^(KJ[%7=*+XOCR]KKN P5%[NX+Q*A3:
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MN'P".%N"3[]RNE&3*L%;1"2FB7@'+L!"W6O+/"& K<"1\@OP?8' VS?OP!M
M,_!MS7*A*L3$E6J,^DIN7([GXVX\_I'Q?,'\$@3P/? ]/^R S\UP1.(*'G3
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M0=QN'X9]8*2S)502-9*VT_WZD92LV#(CI"B!?HE)ZIZ'=_><S[I,]X1^83D
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MX)CLQSW8.[QXCE9K+E\8D]$&K? +YG]MGJAX,DJ4193@E$4D!10OQ[U[>!=
M7RID$G]'>,].[H$,94[(-_GPVV+<,Z5'.,8AEQ!(7'9XBN-8(@D__BM >Z5-
MJ7AZ?T#_G 4O@IDCAJ<D_AHM^'K<\WM@@9=H&_-GLO\5%P&Y$B\D,<M^P;Z0
M-7L@W#).DD)9>)!$:7Y%KP41)PJ6<T7!*A2LJH)[1<$N%.RZ"DZAX-15< N%
M+'0CCSTC;H8XFHPHV0,JI06:O,G8S[0%7U$J!\H+I^+?2.CQR<L:47PKJ5Z
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ME*_92B&*V_T.4['R@> 5TS!B&#S1*,2M*<JM^B?>.OV!5R$H%QJ>"=D5=NH
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M+SB\Q?:2RW)AF/_H=MF+8[\SMFZDG&/;5_59\VK_,GS_(O_#+U!+ P04
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M.^KMS]0[Y=,NIEO/=8WO?R;5^?QLO+W^LKQNHH3#"\X!_FN^_P)02P,$%
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M;"ORZ?D2)WHT\WF946ZR51V7I-XZTKDOB$)=I;NB_?/)(>XP[:[\ZORNS+G
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M<' N>&UL4$L! A0#%     @ $(KV6.VZ6]KN    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ $(KV6)E<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    "  0BO98PHGCP5<$  #.#@  &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ $(KV6#Q-2U:D
M!0  ,AD  !@              ("!F@P  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( !"*]EA/>?>\=@,  )<.   8              "
M@702  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  0BO98
MUMT%N5\$  #R$@  &               @($@%@  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ $(KV6"2<_5OM @  H D  !@
M     ("!M1H  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M !"*]EAQ P0!_@8  'DS   8              " @=@=  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    "  0BO98&'3J>_$&  !G*   &
M            @($,)0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ $(KV6)+4"E-U%0  )4\  !@              ("!,RP  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( !"*]EBF<T.(Z@,  *\-
M   8              " @=Y!  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    "  0BO98)2D ,QL$   :#0  &0              @('^10
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( !"*]E@_-8R%
M,@,  )H)   9              " @5!*  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ $(KV6/9P)#*K P  OPL  !D
M ("!N4T  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  0
MBO98J<4T<[ +  "G*   &0              @(&;40  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( !"*]EB.)_TEL 4  #8/   9
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M970Q."YX;6Q02P$"% ,4    "  0BO98$&6>AL 6  #(60  &0
M    @('6A0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M !"*]ECRK_ML8P,  +D)   9              " @<V<  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ $(KV6)3,2-[P @  J@@  !D
M             ("!9Z   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    "  0BO98YCJKPR$#  !F"   &0              @(&.HP  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( !"*]EC&$'=DY@4
M +02   9              " @>:F  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ $(KV6+ZWR:?\!    0P  !D              ("!
M ZT  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  0BO98
ME,A,@IL"  !I!P  &0              @($VL@  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( !"*]EB,K4J+<@,  -$0   9
M      " @0BU  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ $(KV6-;40K0N P  $0T  !D              ("!L;@  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  0BO9884U-ZI8"  #-!P
M&0              @($6O   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( !"*]ECU43"/*00  +<9   9              " @>.^  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ $(KV6#7XAHCW
M @  T0H  !D              ("!0\,  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    "  0BO98A<)BX!$-  !NF@  &0
M@(%QQ@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( !"*
M]EC\VJ_)4 ,  %D-   9              " @;G3  !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ $(KV6"Q&&#IB!   _QX  !D
M         ("!0-<  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
M    "  0BO980E&T58X'  "S2   &0              @('9VP  >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( !"*]EA1Q5D/X (  %T'
M   9              " @9[C  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL
M4$L! A0#%     @ $(KV6 ?"F^J:!0  ^"   !D              ("!M>8
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  0BO98G!3,
MMVX#  #K#@  &0              @(&&[   >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;%!+ 0(4 Q0    ( !"*]EC^V W'DP,  +H0   9
M  " @2OP  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M$(KV6!\3JSYC P  I0X  !D              ("!]?,  'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    "  0BO98. 0IQGD&  #R)   &0
M            @(&/]P  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( !"*]E@##&=!< ,  +8*   9              " @3_^  !X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ $(KV6/]4:80'!
M#0\  !D              ("!Y@$! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    "  0BO98C*U*BW(#  #1$   &0              @($D
M!@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( !"*]EBN
M+J.S*@0  +<9   9              " @<T) 0!X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ $(KV6.F,'-G[ @  1@H  !D
M     ("!+@X! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M  !*%   #0              @ '4(@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( !"*]EB7BKL<P    !,"   +              "  5 F 0!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( !"*]EB,.-ET&@0  $P@   /              "
M 3DG 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  0BO98DBR@EK@!  #G
M'   &@              @ & *P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    "  0BO98C$_JC[H!  #N'   $P              @ %P
L+0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     .  X #\/  !;+P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0001013762-24-000530-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001013762-24-000530-xbrl.zip
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MAW&?![X^795U&U#AZ,X+6>G.9C=0($NW#5@=T5TL(WG7.7,=C_U0+^6Y.IV
MJIR[H!_BY-=([.\IY!.AR-0O]\J!B!9=?JIN$2EV:B0!5B=;@V(DA@/9YTS\
M^&IX J/G0=_@C#8L2Y['0W9G."0FOD!FS*T6A")H93=5W3FJW!VW2GO;&)9K
M'&PT.J.PI3ZF$W'NQDG)<X8DOG:R)!=2Y2P-<XB#Z9"Z\@CI-;%AL0(U[MS;
M9!3LLSI6UUTBFR\C#PN]]#Y'+MT<60VT#,_8^0+ZL;#8MB%T^0U6=M'F-?0X
MSKL\_4#=V *L+B\>L97BN$)79B7.L+ GLK*]+)9!5X'4R*BX9:QP_I46ITYO
M%14+Y$QE(E3'Q=&#D!X?NY0\80ML/192^#'5 !2?-D848S^IUL.V76 W:U>)
M=,<#X;W,I8//RACT#U-FO3+Z9TI[KFVM9])S9_6S%_8=(*N51'LS7>$F>@ZT
MZC-/NKH%FO$Y<6KWWE?,?P$]  DN7!HY+0E+'A0@#%Q"8CY;GU]RE<H#5[<F
M>]0<"]=V! 8 _);@3'B,4_GLM454(%-YH)KK@PHW*3.QJJV/IFJ!9F0NE"HF
MDQ<+%8Y %42=B4G6*1!A.G!J95S'!2YC343I<NC2.:(6DZ&!Q"3"@TWY1N+1
M'Q;!9"#=ZIS2QOE9D9WW]UQMVYW[W\\KK%^XO2Q*+R%9-J/QYEAD[R^=XF^Z
M/%<TY9>HTK\/73@SI\6I_6Y,>L4"&;Q,A&JK=^--[C&523&&37E>KD^1\,):
M:,D*D<S+@*B<R_TQN%AC<"E]!>X,_?,C(M5C2M7N"F %SE3G%$"GNXDF6MBT
MP?6TQ'=M6F1&+.P4.5F?#[\FOH5^P@."J[1 %YL8'KV8R?Y1ZUH.\$KE7VVS
M=O@84[G3+++?Q)$T7> BK^?9V'4J'WQ5-)K[[% R@MJVO;QDS,/69ESXAV5R
M\B-]IKSB:"% %2;SSR!T%*X^""'^2>_>%)MD2' DYW7A4C]>,Z%$N(*\#.\O
M$:#L!ER7JU^8> I+0UCCS(5XX!J+?V*K.'$X'N'7CEFT^-3G>,-\29A V4A9
M%='+5B#6,!>.B-R086*;I@=@Z+)0OE<"G/:(#JS-@0TO,E51F$H-O'2@&Q [
M?B*B[YXC<WR^"!S2(LN95P2U%]6@)CH++V&"YB!.[%#O ?5A>493#-5-!H_]
MZ1PUKY8[02159W]<,+0=6+7IB3533.'64BAFXI1P9'><%IZ(WYY&-F8K3[(8
M$N6!J#X89X,W82([<A(> @0B=L4*(ETFP'P;N(YU2_&%)PXJ_(JH/"59$ %S
M@50>;":4 <D4_)%BB),$I(4NPE,<^&ZPE,B31>)VAL+H7TZ4VB\6B25CAB,[
M<L4038-,XVU=P=+,@O31I;/J"-D]3&?@J;%VNUD,^;9 JM)17Y$+9O#30>D<
M9#S_$ZQC.5%J,K%XP?MSM\C6) ]$Y5I=7(\QPSU49MB$,]U@C(P<>0U;L?0Q
M"Y[V4)3I.E8#GEA^'JZ)*0<!-L.'-N8<@O=B2+L+9.T(A+<I%8Q5-3#--@C@
M9(VOV .KZUC-*SP<4KQLX8>'HGA=>2"JY9N[4-\37S:!NOTQH1QC1YS2*(AP
M6?A4JW>LXAS>+/WSH"O7I[!29H!5DCEPB+B; JI=8TL$3DUX)Q)05^X8.> 0
M??9@0D,3HTA)$/:I&*/P7/AJ[R!VW6-PV^DZ45Z<:V9R(]6=3M%<WET<27.A
M%+-;WI3M7^4K"?XO4$L#!!0    (  Z*]E@FV58?/@L  %1^   5    86)I
M;RTR,#(T,#,S,5]C86PN>&UL[5UK<]HX%_Z^O\(O^V7?Z5#(K91,TAU"2IJ$
M!"9 -^G.3L>Q15!B2T22N>37KV0@7&SYAHQAIY]*7*%S_#PZ1T='1^+DSY%M
M:0- *,3H-+?WL9C3 #*P"='3::[3RE=:U<O+W)]?-.VWD__E\]H%0(#H#)C:
MXUBK8KO?,J#6)CJB74QL[0]F_U_+:SW&^L>%PG X_&CP-M2 !%#L$ -0\4#+
MYWF'LRZK!(@.C[4;C+0KQ]+V][7]XO%!^7BOK'7:5?['_N'D*[^=6!"]/.H4
M:%QO1$]S"Y)&C\3ZB,E38;]8/"C,&N8F+8]'XL%2^^&!VWJO7"X7W/]];TJA
M7T/>[5[A_J;>,GK UO,04:8C0PB@\)BZ#^O8T)F+9*A>FK2%^"L_:Y87C_)[
M^_F#O8\C:N8FN&G:"<$6N -=S=7\F(W[X#1'H=VWA$+NLQX!W=.<_@AQ7B!8
M/)AT\;MX\I/\K&)$L05-@?V9;HE7:?4 8#E-=-VYNUQZ"9T8XGO]GDYL77!8
M$*T*TDX*KJ+J-;WD@],&+<8_VP E5W:U'ZZO<EVK.NW5+#Q,K.1[!P)-)>J)
ML6LZ%L#=FL,< FX@@K9C<T.V(1- T','M/5'T6$,I6-TJPKHN<@)E6U]=,9]
M4Q>R"F,$/CI,B&.XX9 ZIK1+L-WH"]?%S9.N\X:)Q174V>Y<FUO 3- %A "3
MZ2.=4L"HCDP+\I869!"L]:Y1>U=I[=''4C&E,5J<O(]X&T.W#,=R6:QSW:=O
M(/I;RSLNH0-&#" 3S'T[EVMA8ZF-)2863&9?M/1'8)WF')I_TO7^SXI+3-7A
M/"&V#+-0DG(MW2FFJ]-'=YZ9?K$@\"\ B]'9$Y<1EPW_ON=$QU92.+,*<GW:
MUU<'#G1+8%YA59V0,0\WONN6 Q0K'TWFC.UEOBMD^>TXQS/M^$?/$%B>PZ<M
M"M2Q;;>W/.03S>S[PCN$L,=P;.0P,0'A,5Q.&P+XU&/BX\3;QN:JP7J I#FJ
M? 0L#:VMY,$/E2GH^RN@KV'&J=CO?"!DAZP?I/YHK@[AI"YG.@.CISK@H?2=
MZ+'1[5#@2E4]H@-ES8?$=N$?@I!D="?AHDDPE\7&33X-,N[-A"?KBVGW5CD5
M@:*VQ,WXD1$,T92+ U6V,7=FMQ@9:7OY!1E;ZHHD@$QA/_3 G@3T^CQP3F=>
M]1&PQABI& 9V>*C1U,<B+DXIP/07DG%0)F=J:?J2 *0P%/O*ETYX#/B:RA++
MB-1'4+B\S#UH-&XB *<R>)NX#\,@S@9("A%6^+(+!(4A)I_PUG2]Z?G<;.<V
MGU=<Q#L XW0"[IG <7H!1JB\;7)6X0&X+V(R+Y60HQ;#QDL/6[Q3*B),-E9,
MBH^ ==)&\_R<R(%@), "R%!OQT&2,HY&Y)PMY8F"H%(8DC3)-"?LJI5&WLY/
M0K9+Z&@,^"(CM=^DYH!1:L![NL]T0HL^[)<A4;Q4KI@F%)KJ5E.'YB6JZGW(
M=&M!KNHE4;C 7;"&*+@I75[? :9#!,RO.D'<]5$>7#JVXX;_YZ +#:@Z_H@@
M<!>(BH+;E*@CU7D0/E.E'I&$BMN>9$,@'))H/BB,WZV7\FLEST&?%%:V9[\H
MWK/U%)LL K>X;;O66NGKJ \051[.>OM/;*Z3HB^+TU@Q;8@@9:+G 9CVK%CQ
M,&F9AB12UA:'<2A>8?8:=]JC@+^#V",^!P-@87?3(!UR@F5E.]E%XB8$+*4I
MP9D^$S\BZH+2LO$%"5O"@?>=?=,><ZJ\-I%?(\*X!2PUU)?[SCS#Y/NJOF O
M-I.ZH"1H7R(&"*!BT]+-ZDX$*89=(B3CV"T4?1DV"O?6W7YO,<(K5I7&KH.?
MF&Q=3OCXE\+C313D%R;BU./+>8&P++!,[OU$WTV"!Y#W=#;N4!'-OCN"BL'#
MD33V0F((_N7:(PWMF#PNCOL5H!1F@,]!GP #3L#@4:Z-"8-O[I^*"0F2E+WG
M7X.<0 @5;_D$5GDM2DYIWH@K?L?M+C[<DH1UHNT]/M^ ,R[7%*>S>/=I6*5$
MR$X;I PX:88Z::AL$#$LSL'DWTNT4D2D/&H.D[?CUA8!4$GN6@U]\CJCU)D,
M$%UX/['Y]U\WWX_^^?O>Z#NC!W14-M]*@Z>',>J<.\.+$BF7KO>?.^TQM4H#
MXZUH7;$":X&KM]+!RVC/J+/BCUIMOW5=&(S.J@_%@=DB#\/7L]J@>35\LF@)
MGA6JI=>G*PN"#D+%V\I1HPK+A]>W^+G1JU[7V=-=MU3O?6[>WNOWI==QK:Q_
M:ET-2O:W]B$\;+/:P#BHE3J=RU;IC71&1?/^Z/7Y:-CX5*^\5?^ZKC3W'L:#
MJL7L'^<M?:^RUWSN7=A#\\)N?+AW[DN=ZMO1<[WZ0EY R;IY.G#03?,#^@P[
MY6_GK]5OQ5=][P[9E<=1_;XX^$YONDC_8+4&G<;]]8?N^8<7:#L_O@W?QH=&
MS>@^?/]&NC]T>OJ/5FW=B0.G_QV;"!JE4_/XI"+GY6N-*Q5>LY7P?)[<H,W$
M5"?SI:UJSQB+B^G(**D8&1<Z1&(ATD MW0*-[E*U^WNIN^J]A&A"=WP*C KM
ME,[/GG2'&DMW!]*TM#"5LTR11&:Z/:3:8/T@G;)8]DE:J21R7H*X22X]4O];
M#EB"["PU4_1/1*K*_UVB :!9Y/_\!"?.__&PWJUQ;..*P7T; =)S4ZJK$J,+
MWLZ5< #_2U6,,0"6[=HE/2&^<LCYCNM+H#'-E7/1RP\66C8!@=CT6IQA.::;
M\C=Z.GH"=SSZ_=KM D/UX-BP\EE7]V3#U4IV.[)K#MGL_ 5@F)-06L,L$5R#
M2$=&!K.3G^!?HR,&2=)ZZ[0V4>-<8R3;6DU4MPIXP 8D9W9FT^:Y\JK\R&+7
M.!X74<0MA[ ]!-8 W&#$>LK/TB55(]N#=S&'Q5(=;V+@99-:FO0_ )VTAS@C
MUF?2LR[7W@#=[T KG7EC2>?D9N7(YO*S7?YOC.D)UHK/+<71H(8=DB'9KOC,
ML[";HGL"MGQC.?VP*?F=B9)P*F'B<:+$M YBJHOZ1*.OE/4RII,N[X"!>31L
M3<IX))(JK 9,<1Y '"1Q>*_C^?=Y")[6ZRK1+>.9-F2$K.1:57*BL%A.HIE[
MK(@OX\2=P=9[FS1V0&-)WWG&Y;@JJ+AV[RB5"*Z8SPYU5Y]M?#X]!\X;^5PV
M)[G[-$F_F:Y[(I"5'#!9,*30!"<WT+QKL2'3\TC--L9=W^*\,"H]U2V16G63
M6)=H=>10<0G !$++PL/I%>T;X#6.0MMNMBJQEYX<5SH<^(,JUP2ZB5+WA-]F
M6/>1N^/D^B'I+1'+IWH*.\$%Y[(\;[)1YAG9%T3]:1.)D,2>TM/??#G*^W6O
MB^YB,M2)25O.XS,P^,3+APDDZ9S<6$N9C./08/Z7#W*L![KB*]@\ZG!?3:"[
ML!<W0KFK?.'!%_5*F_DH*NPNWY$ 5GRBQZ/$N]->DIO25!A7^NYR&P:KHHRM
MNTI:%>Y_4T&DE63$KC)/N(8S$PL9I<L.KVX8FT-HB6L]+A'C 3#D)I]*;60L
MT=FN'M>PK4 \98L&5<YR]FP:)2\>^>+Z3(-FZG\FK(JIZB1U*BKN[,A0PH_*
M4RW)-=R:<;(+SEX%W)(C*VO/QG1I1\]3FQ9Q(O;VL@.T1,7#>[Q$Y?2K_G="
M?$5D75@;]-[!TRE1?Z_/YG.K$9.GNTE10'9T7\F9+*^1SNUS _:S(BW3/&A$
M* +Y6OS=G;7*[%8]Z((N@;]*%3ZK!/2T;:MN.0%QX$G+7A9D;NH\45SINT-H
M8GP#+N3:@F+R8L NPZ]R\MAO=@=L'7( 2:-;@Y23*&KCLGA7?T4RC\Q3+T>4
M$!!X.ZV?"9Z\_ZJY\,/_ E!+ P04    "  .BO98F>@^ N$^  #$Z@, %0
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M<(/<%'N9YFW\49!3!6959).SRSJO_GC;.[? ^555,4 SC-(.S"2K0[YHF"L
MC+JHY>P[,[R4= J/.16)P#3>RU.HEAFA^ 3*/S?=XYM$+J:881LTFJ2 ACRY
M0 ?R_B9DFBK]H-ZOF_"+O@Z3/%LF./R* E"^[0$;P1F3D4OZM&V+1V=IFO?"
MGQ+0 )Y[M!E3T4B>H&B+*],\HXW3:8?Y'EA3AS9&_C2H)4]-[/CFT]/=I )Q
M!(I.B7#2/)".+ .^CD20!A$.5>40]QX2I8E8X0W(-<2#,@9[CDLA:2*(+9;
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M$($X/GJPG?#32'[KQTR3OJJ1FOXCD:J9RR]YRR]YRX[SEM/#=:,A?6]IS&V
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M8T0^+:3X#2'R(<'DLV6"](Z^TUQ4J9@UDH=[YZQ*'A30\2=F(<VEW!TL;.N
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M-'4M3N7M4<W&6Z[NHV2-T SAA]!''+Y$;)&03G6_1GZRB,.OA"U,2[#9<^=
M@\QM8]=]ZKD=C&!'I-O$T<$\=2"1;!^^;I6?KB:UG\5$IZ!91G0;7?Z\1!9@
M0KL($I@193"8'>"8UN5'2'"0$48<B"!#V\6PP&P,I6'M"J*NP"CE\>SV>65]
M,KN<6^#\$HUEM\DPU4'L1ES[A&)B)D9T=F.P(G2BQBLQ9%%I?H%,+%:#Z7)
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MYJB$#/H5I<$(S.#O 1NT5AAZT=T+/D=$^&J.HIDWO+?*T/FC2@R561"6KFB
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M"$\9RN]@INH((+ELY&.DUUHYV49"L X$%TF,UA<>_HRRTSP.8";J<( ,@EU
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M]: 5[[N]3W%3(&N]*4#[AON>W58="H)*\3(!,:"IL;;S/F@286O,96I2!2;
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M>X/3, EN<G)&Z5/_4$#^(R^">^:.RJ^,Q(?-O3@BD4_C0)_$[U1(_/H$^=T
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M0CQ%$\]&/ 7(J8IG6 V=O7AVL%Y!/&4D,A1/F +^!YKYR8M *5\3^&GHYSB
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M9 "K+.56R'N9UM4$H24V9A%^_B,."GC$6!"A#*"J<_B$;[!?I/2M^O3%CXH
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M91+#Y1^S^VUVF^1>Q/^=5GI*\I]Q?HW]Y"$&7R>OY4?6IW9PMNW6L;(JR;Z
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M,OAJ1%#&\EXY%-+'Y*0E=PR<$O!DED66X1SJ'55UB$.<_>1%!7MEC*+DN9U
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MJ&&\7/V0/'IQC+/OBQS'9(8'[DLOC'_3.%J&SF']X!F(L$0@=]^B$BQB<"$
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M;8&&0JQ>;I>B+L4N!+YC14(9[Z6 G3=:L[1/D=A#AFP%A3[W,#B( 4*[,FD
M"NV]+EI64RY29=_9#>WMB@:XKGLBLFJ4<&Q>XGRY.DO2%0Z)*3<LG&('OPP.
M+JT<<)03TX:;Q?']9C"5M ,QU$EOU4 1&?=<N#J1\!^*X %LK RJHOO4&%NN
MV'=Q<)G$$?P(IEH2=YC*TCL5-QFU<^KIR)_J"4%XZ/?TDVI25,_JVNH9FXJJ
MU[#AG+(J;/OI.@O?+]8%]>J<X%7HAQW.LOU<I=]S@U$Y^LN9)2ZUUR?V<ZE1
MQ:*91DZR9(UOO9=KJ%7DDYL^E2;RB^,4!V&>57W/I*\$JQ7VZ:'/0%$'%^2Z
MH";$ _H'!I0>'Q0JV?KN^O5HTT#$4TT"6O:4='ITRBMU=E)@B'2C!7O'\I0!
M0$0ANGT=TB: ME],3D7WD0[G\1,Q1AJO\X81#C4D+L+!L0Y67[-&/(.48C8L
M>^4*2VJ7LZK*E/ V]EE4FK+JT:@V^FVR\,DM,*VS%@"GG(\1E->K9!! 4Y8P
MZO#) \HF<C1Z?!BE6^6IOF+A Z\FO=RG<;/ #H)9XWY?EKU0>1JH7?[<J\ O
MK;H@K@,F]->N'CZC0,(9A%@LBOPQ2</?],,L=B-=WT2[UZ4:<;%/":NWQ"HU
M'DS&CF)3=54"9EJ>OOA103,;R@K@@'U=NN! &(SI=L?MK5-\C1"0XG.(G>2<
MWBR6PWFH9",_GN'DVD=IB?3J:GPJMMLTUP3:;N\%1D?QS^45JF=9JGJ_10GK
MI[+$%BR5G^B&LV<J-RWE9OE!1ZR1KTG,ESX:V$WB'*H*.)FR'QW?T.H=8>^O
M4+U+Z3J%/N]AHM4(@HRVX:VJ#_;%J]/OZS.?EF049U<YB1T0KT4<-]"U;A=O
M X*ZCY(V:>4#P$%5#'-VEU_9FCI=^\+U6V $C>+Q7II1/,(.6^PC]_%(/+*M
M>*3V2FQ5^E!N^BYTK%:#R[<J2'JNQC.7>07!H7=598%M%ZLZ65Q&CO5[:T2!
M8Q)7S1P"Q[K=-+WKMYOE<)]?)/%#CM,U.9-N""+0K69-D+R'IVPF.?*LAWMB
MF,/X-[=D$#V<*0CZ3ZATQJ#LOP([R8-06:B(7SHDLEXL.0K)9;PL9=)]AE0?
MUS5:1$5BW=1*;B]"Q(>.U5HOX0ZF0[I)6*.A&RAQ=0Q"D&Z/DT!Z'2I+NC?&
M$FU&:WPE*2HA( #AROFLN$*>/5I$L9WT!X4EEZL[&E^%\^4]B\\YCT]?_$>X
M,)TEJ>397QJ_!"#?)*LW!"A+]$(56!3&J *,5H2C>\$4NU@*U]%-YF01ACT-
MI;(M,U&]J:C(3N0[K2YEG5;G$!4]><M5R\7C)+*C4"6G(YA)4#/';95ZR=I$
M&TZ1()9+Q-&J/JRW!-=FY7B'D6A3E86,RKX;W#AB/.ZSQXVR[%Z7D#T*E'"X
M@?;*+4,N%AS3$-/9DR79VD^M8M45,!HA*LAY=,1"S?7W[SE5&MK=@L<)#<I@
M!AC4IV<AJO"3_&;-#:&= @[*(-[R'RJ./B=W;NE2Q7?N'LK8O'.70?TX$/OR
M2[^P83S20>4==VQCJBU2Q"L=\MC=7^2"D\+N/\'LOUQYK-)RZGO#J""@WU<P
MOH1;PTZQ5@;F;%XVU-<L<;%K4<SF-I1$")^%L1?[8U:/JR&^HNIQ'500\=F4
MEG9KL0=!R*K(0A36>5Q*8+?;;#>(AJ>](;NUWJ.")DM.5&W7NH0:MI\0MJ[D
M5QZT2E]D6?@0TZ=JM;LX&X9VX[INX+;OWSUK:EV\E6C0..F4BAS7_NNZV (M
MI5$?I%P5IJQ5AZ.UVUG]8Z!-1HA#";/RLGM*G7*FMU 8^2V.\JSZ#2V53,LD
MCX2,57TQ#%=9:>6^</*Y'/SCB$WC(64X/2T^4YZN-U&RQ9@^U+'@F9Z^6GV&
M.0,RE]Y\TO4)WUZZB6$_D-FDK)"HBUL=U8K3]91-?62]^>KP94# M2$Q'65%
M,C4U'ZT*I7JZX<#+A"A1<^Z7B0XJ:%PF>FEIA>'PW+D@HAB .)[@S$]#*H'2
M^T/U+>(^=L,E&>K[K[GRY;FH SAI[L*>'[>L[<P*S\TKD:7E:J]P9?4&G?;L
M=,HFZ='B6'!L-GNY"'\MPB"DG4R^3\"Y!EQ+8\6V]_5PFE=. : 20E?7>]OW
M:L55MN[76M2QK.).\";%/JLI0M!;K),T#W_S*I4KXA8_Y("<*IL(4_5#ZP)P
MX^D;]R9-@L)W=^8HK%,<<]=#%FOE&@8$C!@$B]C>4B9Q(EI!(LZJ=9,?JM^5
M+T:-HR .CG",5V'I<6B=%>",T*KU#3_7?RAG/&C:!R !U:P'2&I&P-2N?3\3
M4%.\S:?BFBW_]5U,_T4,@?(J\D$F-?67=>NT#TZCQ-J8MW:Z;'%6+EIE!D.R
M]K+%C[C *=03_@&O5BG>GN!/GW#:4R^'#D5L+#5LJM&(#7>O?156U^*),D6L
MG9 M*7FOO@7>SVL+O._? N]M;X$6!E^KD_?K>9'WZW[R?NW =_>]%\87298M
M8[!E=FTA:=YV;]$G&(U^#^._1.3T/@FS3=G+A'9\J;IGLI3VF11^4ENQZ,36
MH97E['9,2Z9>XPW<%>('=KM33&TM!Z-Z]'PS7)76*72*J!/(W=DA?8-I*[=W
M\U)N[_J5F\V'"3$&A^KD/9P7>0_[R7OHX.R0UOBXR_"JB"["E=2/W%/NA %
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MQK<E@FW!7-;P;M'<^ ZDL86'P0:D2=N/CI<+>C =+6?:2KXC*]#_JCX$I=E
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M)/(N]\U+64%MK_B6.:1LJ+KIQV+CH*L_E/=\M_.V7W,2GEE+D!F*INNMI.D
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M@R=*HPJ^BAIS)C 7G]O-=I$OM\KG)D>AKMX4^FW$0G94U2$)I,'$ZX) 7[R
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MA0;Z/=_PS>>WQYH+H]&>@DO8VDKE&4H/:-\%%X=]&^OG6XD_2S>!>2O$'#_
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MMY4L=,A+L]8I^<;\0?S&U"JKSD[M-54#-**"30>G[CJ:X9IPC:2-F>ZR%!#
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MRT^""5"EKS!^@H'A%!5(;"<QZ$7'FCC7XI)[$"H&LLC&'Y4D7XV>E+!K'H)
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M#2%\A%F<(;?_2!)C&O'!##$E=!J%-'3\!?97EY&)_$)P^NSVMI+2B-RU%5Y
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M^?F]3*^)XU-&4&F'^::@K I@.U9-5;AZ/(-Z&]/9U!-T&YX'_HI!VO"Q?>N
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M4N#*V=1^,'MFL)01U[D(OR</2[*<+V&0K2J>#"G,7;\BZ#3B&2B_"Z\]5#G
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M9N.FV^JWFCU6;U^PYN^-S_7VIR9K=*ZN6KU>J].FQ[X8_A@N-'"=$KLH-\I
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M0DT*G\4=K4 *#\H'!YH4:E*XB!0>'.\=G!P='9Z<YA#$_<!;67D\6D9Y/"_
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M]JOR<FO$3)0^S(1>(-,_XCC'4AR_C)YM6T468,DEE<+AH,*B<C#BZU$>-6,
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M 6J'L=APD$,$DD#0"F"08=[U6_1+WG;?_-+\-N33@-V/N<>9/^5#:X3RIOT
MHG7 X7PQ'FGDVK9[#U?$+ >A@@*1F.&8P+QLYL(C7NJ7(<QD6 XWX5L8P/+9
MU'._/<#2C(!/8&/[\#=.%H0^,UVX5YB,W:)GDX]&\#4+7)H8'INZ/HSC<:!0
M/JR0C)W^U+8"9G)_Z%D#,<LU/6G80NYONS(D^T"$5,U=@038LH;89P&Q0.<
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M=G5(J@Y)?51(JHY)W;F8U.V%I&HV_1W9M!(=0?8'M9Q4'V!:;<,WC;^E1%K
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M1^XP]$6LK0D+M-TICNVX\)$-+!"(;ZTA&>7@="5I!6Y@ $^X9Z2NHN:H"&@
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MQ!HHZIAN/$2)77 ^97W/@!FB[ZXQ,V%*9NZZ>6?Y+DYQCB&NL L'#B>T ZM
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MT2U-]/S 5FH3XR^0*8.'92C@#,53!9)DW*ODU[)0JY\HD94O4F,#,VI.%I%
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MY$V$@X[EU;=47GT4RZMC>?5-RZMCK==^UGH%6'!)<,.3I:I'@,6WW]I6!#[
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MP=X].DI1SCU.C64F;N?[&BR5"\3!659=HT\J;)YN:-EY$W2HS"B!A!,3$(:
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M*<&. T: 2L!"R_2Y+JJUF:CB[A"B69KY:V]1[9YK F-^?4Y8SG86V] LA'<
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MV4JTGSB,GV1]R*( WQFD!15HPB?. S;\WH_:!^R,96N#31FD%-#?=>5H07N
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M:J6-'PT7UFI-H!]PYF_+^0%7:>ADJ57V>P<6 Y$D[. ONBPJ[+/\E"8G(""
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MDS/I/"]*D#5=X?,,C->+A,\7;?N<+,(E#G2LL$%;,VSLEDC,0?+?[O&J:,;
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MR:\F(#TDMMTXT%01:*.[+F!YM]@6'T>6TJM(OO3HJ G+V\/?'/+C%C#S41?
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MKT/-:SC3*IN@W[;Z3KX7 O8CV!C/' #+Q2KZ>\A#(,1H=1XF(#E0&V2X*0.
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M0MM4NC^\BN<_D1G:CJ_&FRXO;W598+J>Z1"!7F.Y[6V7VSZ+Y;:QW#8:&_<
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MJO4*;$/JS$!"TK4A@?HEE(TV.!$<+$8IJWJ^IYIAO$_YTE?T( ,](ZD#&SE
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M!;#2&0]+,SNG$OI%O% Z0_XECA"M'#25#BVM3LD#V*M*)QD^SH_6JN;/AR3
M\,<$T1+3%8IVN%Y/@R<^#:3L3>FAQ:S.@@U1QRIK^0&H83((3#3B]WS-7")<
MEI8,X, 'VKPFYX?E:1[%-K.YA7'L OXFOWD[,E6"L<\Y/;PEOI\OK1QA,4=B
M3LB9I(7)/G#9G<409X>X8]H1F@=%%7+*0CFK:)FM$?<3M6[I9DC;)^59U'H<
MPS!IHO,6P?7(L$R^7)B[62<UO69%:%T<PF7@^\8O85(N32UUK@>@ACP([R/
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MHG^OQ(R_IT6RVNAJHX]AHRISZ7R$W1Q\ $UYSKH8?$A]2E0OF;9$0NG%[3=
MJV/HG:=@J,(!E-\(;^IA(J\I?2.Z&RMEI^G0])_MJUS;U5D2Q$!-QL\:T^W>
MGF_+'?6 \ MF!JQRX]\ [P,DQ];U=U -^FGP;E-.+_CWMVU.PD;^WW_.#WDG
M*WN3]SU$8W+X67X,7G=M[F*GI:N[08A']U6Y6]?MNFY_T;-%F.D6@'DI &6U
MQ=46'S=6)?A2114KE-<%(H!*U][50?S2U7ZD=HI%06FS!L]'7AXXVN50$[5F
M_[;<-@Y6:]=Z$Z=YZ@A,L%KO:KV/5?$B8([RNXDC,@Y 0^B8]IKB5_YD]P<]
M673H35VK]4_$>*9D%M/(G[W'6]![(_<UQNN.4(O*%&21P82"$=W$"> E8KP)
M"= M]ZPP10B#.CBU@=?;^G.9J;.8O<./@"!#VZB80Z@>^^W(G-6Y6D0M>5?$
M=16+HRPDBHX)R1,&IL!-0 RZ:VY=#<Y9(<]4TJ2^+:6MRL*^&8L%QE?IEQ2:
MN,T=?HP:G=_)!#_%DO9;%W$OC-N'="3AK3:S*L_T3'7-B-78WCU;X+O:B&1I
M_-30IC-8?PK.T$Z9 ,>1J25AA,F'L^UK 9*YM;A];]>$[&;YQD!?ZI>^DS0N
M]O0;;\(,J*]*]MNX*9VQ;;0&,4>(:?P<QI9F@HCY>Z:""O9]LQ%"*K*>5OA9
MV@?+RHMCG'^8;*278P>!P*U\].0B+#I@E]:&N]]&PQW@;0$4FF_>'!T%Q3^V
MC5^!/F1XZ0VUZP2$&4"IJ@*/7B3:EBBL9L"D=-^G<&+OJEVW^<%6%4 J4'87
MWC'PH<9F[ 7A$],O$:$ BEBA!S?5#@:LK$UP3THK^.+9\Z]DN[S0\CX2*/&;
M'U\*;OCC)6L,W+YS5K@(:F=Q*/_[X-?Y6P7"#VK6$KI?;*'Y#CNT=B;;7PD
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M H<>;U%$05IJQM;]<^8YLEB+5ZS=1$U3.Y]XVRW_K0U-=?$@D_7#V2\L(WE
M74<\4CS0#-P@_XM,&>YS^XN8]_T6BOS%K>!7V(WG>JBJ!H5D.ZJJR?X\G<$X
M8[83+1E_D2CPSTJE3#^ZJ[OT1(CMQ"69&@*7"#>U(E&]$7+96+EMRU%AY+Z8
MWP"?Y><<^6E<S\2%J7UR4XN)\[%MB?P$RD479\-RHH!64U44,M].M&JQ!1.S
MF_ ;J8*Z33VTTXUK\5G'+9>T<N*@+XAHO-^0!B+M0'I7:QM%@FX*T&IFJ5_7
MV-,@+^/NYG?B+@MD[0'$0XD*ZZ4O!]W9A6YSEH)R%[(?O6E@D((_,8#JU\_'
M):O]/(U\A=\U_GNH3N>YC^%>,Q>MC1+/'/%W?F/ZST^O7GQELU?J<<YG:T9\
MG./4#:XXHC+^[(NKW_]^E,-YN437GBGU:W%F 5"\^NGG5VD::ZU7?/#UBM3A
MBSP 4?99P6G_&O(6@07#IF8,A0%]/G8ZYDCD$1Z.$Q:)*&)HI:$C^+J1WG\@
M^*[&_G^=L^0C98_P)>^F4OH(I_403L_P"Q*YV,]V-<55E(I=^KBA;4328I&.
MQ,@.#760P&Y=;'$*\2' :\-95V'I[>&T\*'$XPI]@U63Z-<B-O[UUP+B@-1
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MI>3YZ?0;4U.7O:3"V<O31TUHAM:8Z]? '%]J-A?:2;0 9.OK7CT;8%*D>/0
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MZ$]6O(S<.NND4BZ .VR+LH*T:PKY5PBVE9%2,)@_9K$KH@V@N:M9O&-U!3\
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M4>E55E+)&RN;T='[M$[IDPCVBHK_=2X5:BW'ZFZW$CW\>C"J<5H>+>$')#&
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M=207HS2R)UU#^V8WA'H+KUS.3VI.**YCK?&FJ\P?N$/7(V/8>\];:EQ3.Z^
M ?(3& K:X&_#5Y&*:1+D2&BDX_V1'B*YI^W"NR+/AJ=L B 9M?:E#2(S/8#4
MMD<;2TAX*FL.D:!4^2RQSR4T3HVV*RVE35-@%&<& O6B,'9AA0KQ$H\=6F?*
MFZ;Q"UF3$BT#:WCGD-5G#IKXUK$C)J=HGZQ/!-MQ"G<1*9D70 P3-R*2 [I=
MNI(VM64Z(#R,L@&M2>"GP7+!5K+%TLQ#RX(HA(B5!LYDDXV4!-<(5VC78C:?
M98FTC9@V!MQ@K2.#*>FY/%ERUP2:]U:[D@=]6,WAOQD>9H*"^0/?'],5'PJ"
M^M92V\J[L5K6PSB#"#]26&A<NNO-^0[[IIT@25837$WP@2;H"%8/9Y5B\1!L
MVUJEP7N#;IN[<W(AKFX#9P#SRU/LRWLF0;\*/=OC#],?K+:[VNZ#;+=U>X&1
M:F.7<FZ*IQEHX8E,66*\^/4B_1Z8"0($<37*U2A_UIF>$F )&'(E;%N-['%V
M/N&82:TL)#XM[$4Z=9 B3['0:;1M6D-":B]+P9Z_(P:JE-1F%AVYVO5JUP_T
M1MU;3C?_<V#@V&I*JRD]R)2(#,'%BHK?FSJW8Z6@U:A6HWJ043&@7^@AM9=K
M? H&K<(D([[2DZYF]^ ,-*1&G!21@3@)FYK6D5>"C@^>H.,G)Q!MJJ26;<&5
M>]4#FZ%PR51$:LR?+%URTZ(Q%\?NT1'34AH)WRF6PP+0 P<F<GPD#R>%?NHC
MND?-!7B#H=:6@Z+90 308CBT=LY5NY6XX^F*O:^,D87VDQE; P9JP<0(_Z/I
ML\R(QE2"5QO3I^9B.E:1-V.$E3:Q+K!J[O(C%E-D)U-80]"?9&YC6C_B[>6J
MQUCNZ-EJ?_#>E$>(1KFV9C""MN3LSHP&1<,T'O3"W)0;7SN7_ Y!9"3AX[B+
MUNW]]3G+N!U*8D*@6U<\#J.(.@VG_1LSOH,:%W5QNHK(_ZF=W+_TW.[1.3^<
MXXEDF;K13'('5ZTB5\H(5&%=$G!E<,Q8QV_=-415M;N)=0'>$*J3?T"K5AI@
M9 3H\N_0LTI6W82^_  Y8HO0D2*4$+M5YK62S2GN)T+HFLYT#_"<8DQ2[ICD
MEV=VV)65=6W&>.QFC,_79HRU&6/U8WYY5M;S+DO@F3SO9UQM_BB]@G3>J?=Q
M!R0L$D<M#O[T<+$^\\\Z[$T7_,0!67:WKS9_I?;0<?J!_:.-\R=E<W(*\P?K
M7EN29(2_8O#3]-F(X5Z:+Z*OOV(PGZ81GUQG@@U/79Y%YX[MO2/_,$*!3#@8
M +?JLS&1%W5CC)S(VS)?=JG>TUN.?K)$>H2#9E9DMR]AQ]Y]7!,6'WK"0DV1
MI4PIGANU/K]UVKQ5NVJ-Y)^6AT<Z;R;[?\BS^*F[\0]<G=(99)Z5LD;+2&6E
M8M*K-+G?'J!:0GM'(UU)[AW54&Z=D41A*9.JZ6*7F_)+B/ KG:@@G;PM"Q -
M'T@))P5PSS=$& +K3"-Z/;*D%<C_EX22X,C<M4,9#ESB.J=V$#72R*I&AW=7
MHGWG;5E5-%R[&_03UM?Z>^D>.AQ=SR?BQB\6#"-=)?;1<3L9VB#\1($]KA86
M >)MB"U+,96Q[GZ_B=T/^9VZ&>$FX+GMT(3#W5[' 539/=J9J+?0VSQLJ+\Y
M20\9P2_H#*0%03VN1&=N6G:B![ANHT_<U5TTCEL98V*1@31G>"RQ%5A!><.<
M(S,:R'WFFKM&K#1E*XI/'*#LF .?>-NGS7/7:.<*D)V7/[X6\BYKKZFOS^R%
M?GX,E?V(')DY #<5,1GQ[JB2$,KI.8U70G&3HZ^EE\69DR^-5N?_Y"2Q&R:"
M\[J6"'PT]"FOHQ,&RO%]DTD24:?17 TM"FN!O1]&U3E'GC<WMEW%/*^6=;TC
M2]L_\?'BRN_?(,5,E#$ASL]J+(=SMWEUXED7[NKE,=:^[_G2<Q#G]%9!7*?H
M%_9VQ,TL^F'K#@" RU#,7(EXK]2YT&F T$<2""<D._RDCJFP71H$S_.^=J.\
M,G>43U^'N:[Z?+^G/O$2G,Z#M-3B<[,$9.LMF.\5/FOH-F9S./HP&EP"MWE9
M28-E%H8%79X2B5F3FV<%;(SVB;2YM[:Y.K@".!$P$- Q+>B58P@(/K^VA<=5
M$H&8V^6==-8& _G7@$0&+0@[^ ?GX#,=J%.;&CR!LB^['"RT/ASTWV0Q$+]7
M[P?E%XQ292@/N-U-W53-]2GY$J:P+=_B&RAI+]@[H &&\_NN:=]BZH_8NEFO
MD',NQ^8.=&A#SW]7@^[SP]'QCG27$UU:3R/A1XKW0R%6UP9RR/,M<*]'0^4W
MT^>/Y S!9DXI%5>,O/UL%<3;:JI'#VJ'G-'$&>OEG3TO8LJ)$DSM<"0N6.YY
M9V44M7+FY(S)+>]]1+(1IN8^KRR2UDFH'QL)B*5])Z7K7=Q]J"5>>T)!CN9N
MG>2=_"OE91W-.-UP<" 6/A09O42DPE2I%D &VQ-WLN3]33;J6.E2_G$B*Q=6
MONW)]#LC-VB9+!N_TU2]F:4LN')QU6QBXTS<JZG_NP1#,I$9Z@C+QW'!88JH
M-M8.M>$."93*IK?<1$Q#NUC5?S4_#30%3!_LMT50C=A%4-);W#;5[6BG.96N
MPNC_:X9E.TA4=9W?:4APQQ\M=[ 7%$;]*-("AV'35T%#;!(&TPKB/1BJ,<^U
MPNHMM75*ZYHPG5(:-;*=PBWZH^%&?<FMPNRTMU"X;+B;)-!A!W*"A'R;^,QA
MY&K?M OSP:5?E!?SIK]SQYXVF&#91(42&/Q"X?.^L;BGPSHQZ83"4ZDP1S.:
M3:?3$+J33Z9TLRQ-P6]?-+N![C*J X_.SL!HF.YWN+CW86DQ@3'@)B8R:2#Z
M1 87?J9\6Y<;=?; K!"^^Y%HFP/)T<IIKQ*<V'4*8K7@]A\=)6*R9)+10-^9
M=\)54O+>M41AN]2<N9RKG8L$0IY!83%0._&F0#ZH5#9H;X.Y=4/7LWR;H7RY
MVOS]*'F=9L=!#$^35 =(M0TV?&"%V: WS"O"JDIY(R+IGO'VC22N[A2B=U</
M2!RQ-<B(A:!F;;5?@8X/%EZ/AA5EGE*+++L@U):LGM&64[OKAK5?*-CA[C_>
M)HU#EUZZJ8T#5)W$MOF*KB4^V3TR/?[#%42^&OF#C!SJTT(,1;.>4P8#?AD$
M=B20,Z$F\C=KR\)J;0_?4F?4<+@^)(S/1F& (9EYJB#FA._$.Q>W[FM\>[7&
M7]\:QT]=>]?N-VNBI%(,;29MY8??VSI_-XG.CC[T;=.MD1-%E!40PV4F2(VQ
M13Y2J=%-E+B2;Z]XST?'>_Y^Q7NN>,^UD/^A%?+_!B@;G?>4RP-II2E'6H7T
M#MG*E 4X]J@$FEMI05#=41.O=KT[4OF)RZ%"!@OOGOV,^4Y1SJ5F1#;+VGJ5
M5B1(:<.?AOAMW9B\G%0*S%-1IHX+#'UXX<O?=D4=/#'JH.S.S\NV;!;9J4EB
M43,@0OKA3?NF1)7U=+7Y6[,AX+.!!/2;:T>B1(Z;@F)QA'M^&+'4R35P/XC[
M#M36M, Q$I"DS#5-SQZPU,EOA"-6"+H9C-8IM;-)/WI'K[UVD2O[S/!0*MY6
MFD<RX6U8-Y>T>R6IVHLZ+=7O1+5\:&O>+/C-,A"YHP!$/^V!L 96HUZJN*W)
MT@\@EOHMADT@0(=5VG+O".Y"!1K!T% 98BNUULLJ%[88.5H :SYJM=H'\J-9
M?! C>DG,G<"T?IO$0=6C!0&:ZP&N:U!;53[4?NN=ZS]8K7*UR@=9):4#@*YI
MEMI@( JPK51'4,O91>*;2,+IHD89%%%C&0HN?YN#5=\F7F>ZX>$F23V* 08!
M%K7:_FK[/X<IRQ@;6C5V!IDZ;4JTCL6RCQQ1SOR='6 4WMOHB#*"9$:\67O3
M74L*J_D^U'S%IS4.@@''SA.<+/+GH+(?$5J$S",=FIF&G34Q\OB)$>3-:B,D
MAC)/8Z7,]0]830.@TPQ7)_ZB8],J3C)G\:@EB.N9Q('N=.<Q6^\!IT7IU-\0
MV*F2Y70HX4+(TH<DZE27BL%T\PC0M;GL0\])OXY=T@E"=7K0JD@Z.:C<G\\-
MB:6@E] S1E724,0/LFPKN]93[EXZ=Y39I3*T/_>IX<_U^4+' )V KM6> <R@
M]XZ:HJ3LC/\E-;?P7D#::^WFY7>"7_X_-V4E.5X<=Z0 I[VHM"4"-S1JR ]]
M!-3M5+9=K^$V$KX+#]FCJ;5WA3[ER(OCV^#1K2@XH5%KM,%<_O:Z(O@UXVK0
M-2!G@RVY\&D-S)2_9L\0OV24EB'F_F9H_B+%MF[7EEM&DJ-!BN,VZ_GZX41'
M$75_^9U;!4YS2Z)-/[#9"VG98I4][E) ?-FI[F6Y9^PX2TU"W]/YM0NKH4FD
MJ=VZ"KT2.. (CPY)OHZN(X\F"IC&>T<9BL?,_Y&5^P0&3@X-S10@0 6U+H@&
MJ@Y \);L&7?(WSJB#$,35P0""_B<Z+A$[M&]*_F]@V^_>DY/WLAZ<OWF;=W<
M^3G,^W'VK#G"41IJ:F#FA<6;1'W*R(*5=F9,>\>5%"PSS.^K'_[Q^MN%=?W\
M*UW2WD^#:N2XP9,>[L;_G\C@WMUX[T<//-VB^&@3C._<F^1M"T%'P?7JS_;2
MC!2E*5M7'K8^QA6R@G/[YBR+B>@ZFLT-76+B?/KG\>N&-PRNS-5(R%#?'7";
MQI,,2R(3@4TJ#;-0L-_'@N)G^)Z(C!I?<%U,3[283(E^=N5(4T3KT-Y:L&XE
M<?+"8,M]\-$H6#$%F#3:B-W_2B"!7I<VXXV6)7"]EY?Q";%W:)HD( %_A.Z1
M5D@F?$C@ XM2E$>)BP(83QQ:/L:X%5;'<&:\WL>;B]F>8MR%H]$Q,1"N%!R0
M++"#\JD6=OMP+7Q]2ZIX8?T*XZ0<,L?0N:E'J_=_CS>GSB_$7-JW]+"$N(_Y
M8E1^3'2JS1RT8#E!#V&S[1JFB?27JYO:N,Q7F^^&%DLLVQR'K??/-Y!)'>J=
M;"2MNX9_(WE>&X=9,A.YH$A4*_&NR*?ZAY((E,&W1.QU;,M=0("0'31(DG@/
M*'19W>;5, 6)^&7N^C6H^_"#NN\8YB!\MPO2*+1S(!^ <H/X?U@T.!:#,RL]
M^#:X2U9)IDLDTC.HI!H,B[:H-?1[\M#O_?FZ-5R']ZP;A20@J?V2@"3O.>_$
MQE0XM#S!"J=7G<^)7O; !N?"9 <Q%)/<7.PO%3ID/L.H%Y_=O<J[-\JRD',/
M0MXJJX9-;M#6ZO=K>'0U,Z.0:Z8>JJ5DIBP*?$3P4;![)6=T-X!3("VW,>,'
M&KKPY-;[^EVCCAKAKKHH>IV>.I+V8ZZ42EK)9"ZV_FWW)5$;[^DX\@_'STP'
M[\HUO&+/'QM[_L6*/5^QY^O1_LMS#<\!6\>H.Y-%*1I.QR/983(,A+5%N<?E
MR7&C1T=R+H+H(DT@X+P.AU:('4.B1MQ'XHHI#Q)_)6>B@0\+17^(<L5?B.]P
MM7E90</#!W"W8#_<*2N,M^"2>1D0DR[D@B12#;GCL4")!$JS7HK>_SM#XB#4
M,>>\&EL]8=J4Y.2>DDTN%\[6!?7X;,=SL@Y2PS>U=PJ7R=#SPOUK )P]R>,I
M2OQ"-J9C?D(J9@;D&G,:2SXO+3 1S""!PC%+DJRP$3F(U'DEW4ZMAX'GS2]Q
MK1&31\T!X6I_3YW=DZF?B,;<3XSU,"L*5!4+=G2&LM>_H120M#(#^D%IA1@M
M#8YA.K<8P>$(8+:[BOLMUB:$%7WU(/150C/%NVS, 'Q/ ;$0/_)_^.!J-;75
MU!Z$4VW+6_@!-RZO>K1>=<398V&F3$J^Y!' %",[I:%?7?&GJUD^''^J?7[O
MXXFNKMX3N'K?4Z>K9LS)\1&*,"*SYM2-GP_A>!P5; +YF*G2ND/GJEOQZJ5!
MW&CRO4<D M@-*"/952O;D#P&!Q1X51$!^3<Z!3V?'M7-H 84:"QE-Z1CU@_+
MX'W9$_S(OKF#@@-!?H 7]?$5XQ_^ CC71C=3/;(?N'-FZ.H=CF#2WMWDW938
MFE(%I3=1XO--/D&)^QW*S(2[VH%J32!8U>!$*+5PN[*CKZ=U62X-9S/.+^.U
M,;!6GM+@PZXV;^">O.>$V5-&W1HNOUO1"-'60.3J_^S'F5$S.K>Q3$X)%!;)
MR%1_Z?3>1D1)G!GGOW9WU2GF@ZR)!)KM=0-Z"L'5KE]:40U1/^B$0A6IE-(4
MY\B\Y6-%N&A3$CV2=DJ4Z#7,\<L<R6FWOS<<XM\F2$C$0!6!<55,>+HG3L-)
M?4P*@,O]B$G98)_>S[(E;ZI-_"$'=";JY85_)A?S\U(Q*]SB X-;_-GL:JTC
M78.#MT0"M2ILE6G^JY/0HH_0.4M)X!4W\80R5H&HWT@Z$9ZA9D S^6@I$PJ^
MN2T;HU00I9@HVT#3&ULKC-+P9'MZ@-\FWA0#SH ]$V!JQ[<PIRUC,:*O]JJ!
M?$O74?G'U2PF4KGKLA.V<A)Y)E/&)>VYW9VZWAW.HU<)]6\O=\A/F<@N>^O+
MU,OB!S8\N\%%OFD8:DBQ-955PH9+VV4Z#_'80<4*]/+E@?54QEYG7)D!3C&+
ME<L/X*5G4NFQ4[-P<Y4^"7=0;+YQ*0DHXX_8PW#P%]X&=9C@C]%;LL%HF@H?
M7K?Y077/($E#@@0#T0WR12!10_@_A):N[KA:%R[!U3QOST3>[6I_X%=<GPM?
M$;^;)WGD($<J???NB%:QR)G^Z6?//OKF8[:J'QG&*/OA&]5>(]D?A/TTI/(V
M(\Y]>AEK,3)G78+LH5.8O?#"H9C&KZF,0@*"$=>B=NBM0^ "^O5!U8/4C,*;
M6(<:W3)[Q^6>/G_'FD':)<&K8&&)$O8FMJ9( %2FS<?J?A<.(Y,R/E]M_IB#
M\GSY*[18)5SSC^#>[="F[Q]S\Y%_7$;[^?_ZF$0^:C5A^"O4K?_BZM/_%;I
MR(V#Y;&?1L.?W M:&XR<2I](HY9X=T&/"0Z)(MT0L08(HC251#Z->53_065J
MKS8_U)O_]@_DYX^-Z\6+;//BV?,OL\1,[LS^U0TP_1"9C482X^0'!I>@A>3_
M\149X;?>3F!@<AO_9Q\(01S"CP<W2AX=0-?[I:N:9^!]5LN_?\.+?I3#6/?$
ME>_=0G='Y6_M%O7O_N[$6@[87WZG7N'0?<SLXF^)2*UA_%C0FZ#?TAOMS;_A
M8!(^S4 W53WJ=1W4(T#AW_FW4/(L/ ]MMEOG:J,#P'U&84O'U\@Q#4V?]%A9
MLD+#W-RJ9QP(?KC-B<B _!E0H,79AZ8Q7)T[9("X<^]R\-QA'6TZ:!?1/D(;
MF;KT^9(R<4:6+NU/%O@MNV79V5&-9W(B+I(.!G1P+>V&GNET8M(AS"]"[\%G
M,8E9">2/&J/8S-?0]RE<NS<P&5H3XI/!/0#%H0_GJ(\U<7M@ZHS54 LP82A$
M2&$VF1%@F3FE6WOD5\QE+4UX*<>_[.6D'**=<7J@\^)!2Q^W-1!NE/6 _IT(
MRO!CR-UI$Y5N!>S$JK@7MOFY.PGHFWL\C_Y=KC;?+SL#=O53\9C/$CW?.^:0
M#&O5.WD(A=4C0R[ KUV5S:K3,YE<P) I$]3MRI"\HE0?&Z7ZY8I275&JZVG[
MRZ-4_Q1=JJFC%,Y.;@Z40((%29J0(RCT0#L3H<Z%R]*/SFH2FH ^<PTM]_!Y
M:UW%4/IAP2G1UN[<M7;CD8_0'%7JC7)\(^DV>!RD DXX*G$HYA%3<NZ][FT$
M ,=D[PH2>HW>A_HNE&\@ZEQVHH,LW,1AWS>[@>5!8Y_^S32!F40/:%BY(8;=
M*6#R"!5@[SY37[2YIO6J*#^ENF^QQYO;5>#]-Y, (!00F_=(V9_)R0O<6$/%
M]/7(/\I[Z1&:YB*2YQ?WD *F,9=NE#Y<P7USX#X;85T$T<HVEV-M9M9T]O#"
M3R;2QR<.4BEBGZWO_IP,?^P IAV$IF)'-A_8<-'/QE8:XV>R1RS3;E)@RV.Y
MKAP9)[?X2O=O*R7;);8HIH!4KD?6.Q%L],2,NYORV/$E=[2-KS6K#[YF-:86
M"!P!LE%*Z[RBN>9;@94CPFT##P%1 !@U ,K-<)&@UQYV4LM)E: 8>""YOY@2
M-!B!M13VE%BEJ3Y$M!"! 54J?9[TM%P#W>):4S_S>U,SM.KMD!IZ7_+V)+SA
MY!ZEG4N9;#;X:(8C7&%":4KE D.*]BB%L!_H;'!YNT@Z1:1WT</0\E[0DF:1
M*,G0&LI<,V06_T.^',L5^*#4'XU-*]G2A$0&'<CD9_*H*<C"%?$19O7IZ93C
MVSF=-L>78]\-I]BN'<J@2]4Z'>BHC-P112#>1"%!^;6(7ZEF<A8?:CI_?B T
MAZ44&E!<IY-#":TF,VZJ3-2!H[FOV&P6.6E.X:P1%13*:7&I9PP4X:P<]>_<
M^HGQ;](,W>2+J>N6YKY'ZA ZJJ&EO#HE[>C#<:(HL78UK)C>GT]23\O5+X6"
MV4*/1"PSU_-IA54LJ6P47LA54@@K=7:+96]RMPP<"^:OFZ.W1>\-KET5JZD_
MR-2W0PGFHCIB[")S6CS2RWK?YOX@&:B(HESU)O& 2C]YF"@=1C+]62K];LRE
M/\.8/TN>LQKY:N0/,G*E8+/L,HCD);FT2->T"MZLMO=S;2_O_=:WZXW7OWGK
M3M&E7YO/5N-ZL'&5!46,)^MD+F:I&ZN20 B)W)L@EQ3 A;4F$#_X!**R9^SS
MLJ)H.C$ B<XIZMZQ<&EB#-VFF1<TH)Z),M1K8IV)X)H%A=4:JF>!>X[N(0(&
M(0\MJ*]+[DNW.PZ]2"[!=#F"-R*3H=%.*G(JR%KV 0ECO5#.?]77:^KRZ5*7
M/]13TE+U^UW'O8ASIJDA]"49P'L,B7H'N*@3Z';1K<DIKW%\P7#10R0ZBI9+
M5:1=Q'^9?KV9VY8=(0QK*CE9WS)T])W+Z,+Z*9>KV=N8LXWY>W!F4U\6_1<1
M0O?Y6WKED[5\LQ:I#<S16#3[V7- Y5261&:5HYIYXCMRC_&BUZ(TFVNBT,T,
MRX:'W&0'5;J$(L+9]-_L3K"@.YMM"C_$;9(47<I[QQ1JK+;UA)*&%;P&+OG%
MLVS<+=:YO$5UM!ZINP6IM<V=(UID4LE210!NX-.8-DW,&C(KPW]$G*^RT7;#
M%@R70C NV^YESR4(#^[ D^,@,X7!]ST.X@3V$8J0F)<>%W9CCL>&.3..Y='!
MVYDWQ%$J'28RO9T4_J^QK%K"OC?6[J/\,8-^E\X+&O.S)\;FN^FK3@N]1B2M
MZP:TR-#JP%UZ5/YW0\LF8C"M15D-TB;1W$GEEGZD]-E4([[Q)SPU)"P_!U4^
MXL,PR1L7AI@!K7#;/A/@R355RTO.A@MIG/38M+W)M 04D/121+XYOUX!%,><
M,@EUMDFDS1=(K^?6+164\-S1R5SI3U=@Z6,!2[]:@:4KL'2-5C^T:)4.W:#,
M8EI^\N/1_X3,9TZ+W(@JA38V;:.*;4C^!.1SJ%3^4.Z<&[,A:$>0E/+(U:1V
M19+**/RI=Y*@&E@Y4_,PU^+C%IT4X?YKB/F$I*'1\V(@<["9Q%3*Y8:T15/D
MYM5[;-!?V*%--#7"TT:Z"N?M;^3>&O8.4HZ1^,GF<$C@K%5!%X6I(%;D-^OF
ME@%ZD#D:R,2[U5?@FG1AVY\61"D"Z')>A=W0IL8 !OCL0@3$6$%XMIZ]J(EM
MABJ)J6W+'F2Q)2TES$TCQEB>/1E*'9O9YR"U K3!(U;)N[)C1#0:UZN(.MU'
MJN'"!PL-W7J7 PJO$01YW(DT-W?^MV%7*?OI5I+L))-)U*TJI 3R &U5_UIA
MTI(BB]FX.<X$KC60OTW)N! \KRG>#_[0?#U*&<F"J$)K)!$ZV(P'9*G(RCBE
MH%V6W"6K$E+S>1?N:8@(Y:"Q-([J5BW1)^V>=024X"/LLV>?J1/T)F^WN9^X
MA93I#^\J%P#U+W<]_[[9:X_]LQ>Z679A.P.I^Z L#JE<BVS2EQM@'KPUTH?9
MRZ%9=LB$G5S>9JKX%P4T#<I1-)R1:^@";\?/?*12,(%U/82_8P_]SIL%#\OS
M9PNC^?_H2'++!3J!XIN,>DWB6]@6B=%AZS\HC_[W[IW;#90G;B"EZ5K)+^OG
M\3WD\RQ*)S)",C:</&";H/28GE5 I/E03#P%_->^S8?B2F7*N(6)3GD^1036
MFF^Z [[=]7Y_H!&:N142[82YM;ED3E\"LSO)CH_?H5M^"3HEV2=P-4O[B-2<
M/%@D1^!'+.O;IA)UA+D+4@_<V>8,5L6KD.6[!AMA[Z:#;H15YZG8"L=*X#O)
MR(5C_LX;'4R< YM[AF7$,O$RW)\9'#)H.AQRZB6 \@0!? -U"Y6*>2ZA;IG7
M@6:-!'MC53B3#'77('\)J+"R O51CM/>-V;]R+TF-CMM23JX?M1X$XT@'UUG
M<Q@Z; ?[2HF!]KD:?93.U%2_:?(SQ4DCPA3'C:Z[=?:(#.I-' N4+?MS5YMO
M'/M]LJ.5-6Y,*55O)*%YD99,^O0=#;_LJ^+LAB>PPZTC.QY8>TEDF:68H1I8
M]$JT2L6HHRPX7%C#*8(..Y5X+5SO(E>*&7NTR/&HV^?TOL0V%XU3X-HM(P\>
M]R!"CCY$&7B**.%>WC1-8;JG:)/I#+O)#FJ+/;^QVYR:05X9K G\3,+"1_KE
M#$F'Y(<&Y$*S<MW IV=]5 Q7Y+Y131;UA?U,_A 9L*(E4*5[![($[PGI&8,_
MZ:1S UJG'1.2B*>,04^"8CRYLA2CX!J53DJ:3=HICTU5ZFJ/V\/E]O5>8.#Q
M/G#P]J,L-]VFX&94WN^Q99,182B:'04UI)9)*R2:R[EI*RF%PB=R;&KDI@-:
M72JQN:-0AXAVR_80N7@C?&&Z$]Z[#YX]]=/]\3$O?B=;.A>6C/_21X:3AUZ;
MNC#"K(9@^Y<(!FC>J3&H9%&?3=6PAR63YG^ZQ_Q =<\>9AR@UO<$IGS,V.ZU
M,Q*H:UCZP8>EK^)V"-:K*K_KT@[M5(FJ0D-3#"*E\*^[Q<Z?PW[KM2"(LQF/
MV> 5O@L(<*OF;CX+0H\WGP19(]DGBF0Q&B7TE_TF0HT%&?-** 1%;2FCDWV@
M7&T[T/>L:=%Y5= <!WI70RP@'@2?\4EQ.G)+XDZ!!7P2>A3^";M>.N\T/^?C
M/+3HH3O-7QTLA4R\=TGA.[E@RD,6MD@+:IG@/1:(4?U/@%S'0!A_.D )?MYX
MTG/ZT) C UKQ!=3("VY0Y [Y^:4MG9T)=9QE<S <$"^>/?\"83*]!^ N?=F#
M%Q.S]#?__*\&24G_=[/MD,?()I+?MV4G/WBM)^)/PO+\JBGHD'G^U9>_I_;&
M_ "_A,7+\0M\(: LKH>R(%]-],1F+BB,FI;4P#^DL((Q' A^'EA'3$UA]D6X
M?S5:"T][]*NY^U$\PODKA+EB@D2>E3!#"&[YQ<S8CPH13  )Q7.^+1&#%$P^
M 3H.YJ+ 1H2.3>%P4T83)J<]]XK2",<<]#KKRJ%"YFF?[)7ULMMCPX2B_EMM
M0*8B(K6%@]JAIWWOO5B8 *:"P"D)L<DB=DQV@G"Q\5*/ 63AJ$M:XG\+E.&P
MX^P(R"0(K4O*L!I]J'CD"8VG^$OS0O S[YQ-\@NV%[JIEU09L5&&D(&$"N3%
M^7*!)WA.[3+2&>,Y9%#.H7I6NK@5U?,05,]GSU94SXKJ62/!#RT27,J/#^,#
M P=UQ'\BNR"%A/V^ _*>SQ.<QK XCA*T!<4@--1/,8FQ-8)[0L%4<DA3NNY/
MGX,5_,6GDDFZR8N9R=Y\1#UQS[[^ZP]_H7\]__ICL(6U)_]<$*>B"Q-"XUT)
M3\C[B__YXMF75\_Y)GY&*@&&%Y.O77V6?(DE Q8 \CN0Y?5&>V!+ E+%?;9X
M=?;M)F_RG\\___WXL90COQ N81#"$YLZ!ZGD57L7"HG$K7<2ZUJREWYP/X=C
MCA3>T)<@D"NN-G\_[WB.BOS145/OVT\$/^GGSZ^^2!]4<.2%Y'?X0Q0Z._-@
M9&>SIH" 3D86XU(R&H<4R&!E>[1'.*!YME(MF'C7R3/&87OXXY1=$#GWH_[E
M,V;A'TUP$ABQ7Y_4WC_]\H6&8P@;,R:8/&KRGRR*?G;=4)5F(R8?<?X<18O]
M)[3T]]].+5^QDG]K2>3BM/DIAO(?C]C4;?E@0HBCMB3@JZ7P@)]9 P2:D4N7
M"F>=J41RH+?45B0?==ZPDH4DG(ET8CQ.FKD_YEUOJD:C5/7X5Z."* 7]&A.A
M #QL.Y"!^ZW _VC?3Y/_#($)E\V813LT.HAE2WOS3%,7Y>*IL@8X8,>-&CGZ
M5=ZRC4CEQ2#3Y,DC$R/K*'26H5O*0[QL-6,V( ;W6YVKI53;C=9]R 71[SBB
MDSU&+W*'1AKNV E,D9$@5D91#F0*V6,;B<4WH.S/C*CXTG%H2?V%]0,8KI@\
MX1R.3PW2Q,)4P8A2)_064@MV12@SY!6E;;H;Y[REB&UN44@":\\F5%\SJD&*
M\$7>L[I)HON59@Q#);&R!+:1%3>:?QB5F-Z.(?0D.6CZ6F,SS)+HT5H/^>"]
MX#?<ZN4WAA8H)RR,W<D?0Y_ QG9ON1V/5VQ1=NUP#(E7P'P*JL>&M=D8?&FT
M*MK]H_4D">'6'0?>YE=?^ E]8>G<3(0F$C9?KH539IL]A"A2)N@0*0A8/B7:
M2.T47TEVF&IE"1!<.RM%/52Q)"U_SU&NW'_121X3I$O -'4X60CA8!\N[N1(
M_-//!Y;6 EWD*:-_^3.7NGB#^9DK9.-&UR+O<T:S47,N,IO)_;#%U>SQ1'K$
M:<G#U.H(KD)]E8@-J=TZEVY'DN!)KN]' 2GY'4LO+22!63].;R6=ZJ>KS1LY
M\R>7C:#8>B-L+@080MZ4' Q_4^_LH')):Y\U0BPCI$#F[N ]$-\D$:LWC)!*
M"#KM\2JDRF"?U!N0VJ[?6\3-O/%W0U-RUW>9NIA*_:A?];O/=3O45&%1+6%D
MJ/WK@8/S<*R:D\/VQ?6IY6[\/GB$A!.Y^-N0/_%'.AR^71\XGFEK]-/["IOF
MPF5D*PVW;6G<_'F^](.X+O4W0A<-+[ YWL QVN5]B"H+UQW!Q)<Z@[JSJZ1<
M-L9@S"[OF64M?N/M4"&<"9W>\/?XS1@!R-2_?(P4U@ 4KR-S%($[?N?<^X>C
M(N"Z[S_1OH_PI51> PI-HQU,;$8 H_VD+APP@G9OM9=B;6C=KGE#O8;7RH$S
MQ13$QT I$7\)^-_XD7?F1:G(L6 A53$10Y"IE]VN:@B^90J9IZ/K%+36-@>_
M 5UM_MS<88EE877TB<"BK)Q!$9/GUJ,JC45]/K.KGEGX_0T*]6$-^QMVN_RH
MP"4!HUT/N=]+>Q?AJ%8&,E#A*ZTA]4GU=$*:]C]_.)8$Y>W&_IP9INBQ)1%I
MFJ:DF0H_#FS#%V]O2*  *8BBZP[!_T<:&=Z6[="IZ#SXYS_VKW C%,#!W>P:
MBB%(B=RQQE;G'^6@,U8*,LV_T5Y>W8><CK$-="M^>#GNHD5,DKK^&=X&6N!T
M&<#U$'9R<VP2F:I%$I!M^9CYA'\RW R.%)LH_E9!0)2BRZ9R]10'I[Z40#CC
MPQ:C4!-_/O9R<99"I6?V>W0W&VBMN^?C[Y[U:;R\(D64KJU(6M,ZUC[P'M'.
M^3VPT"IWVH?'0MTF$"+W\^"?7K0RQW%6C.:Y8X\2'J04X_^)8_<6@)UKW4[1
M^UG(R@B7(D@\U=<Y1>$M]UK1;TT4'O;CXKVR8B"&;:.^H0(QF>2D+?)3M6-&
MVAGJ0Q*:!CF"*B\/$4SLBHA:B)$CIQ:G2:I\IRSG0@0C_BFE(:8R-\#XT=ZJ
M)YFH\MWFNY.<4S*K0(W.>/R\N32UHIP[181/9G0: S"WNU'X %.1M"^4!/>8
M@?;%%M^8@&%L!36PK4F5#SNI\EULOR48_8F-E8Y6L4$L.S),HW-J*')4QLHL
M.@=[W+G X80O?V13?MJ,MO-KEG:>$&[YP#ZOL$(^CI(X_Q][;]ODN'%D"_\5
MAF/WAA0!MV?&EKW>B7#$:"39VFM9$S/6[L<G0!)LP@,"- !VB_OKG\J3F559
M0*'?U--J^=:'78^:)%ZSLO+EY#D-1PR:0_R&*>X!6.6=3$LW?/"6)H68K?Y.
M_#A1=IIK.T\<XWOB*M'82<1YXB<98"EU%D61W<E0/ZLOJHLB_=DH>EY0B;>>
M%D=6=_LY&E=+5 ?MR27V%$4N>/3).6W"R=\RD6R\W05@J5&&"M&?7B]_+?,\
M94388R/"7F9$6$:$Y<WOTPN(IA,"&B:CS>7V+:ZZN'1;7(1M^$(;NM_\_2VA
M53XO>+?C2$VFB=&#8# &U<)#T:I0#E8]KSL8;T$+Q15A,[0E:\EY4IT):=H>
MC\U<S,AD%S)!8/\R%0Z0P"%)_D.#ELQ;D]@]90#!M@T^"SNS!S=1(; >3WQV
M_(9#61ZO6G-_.]&5^3R,9YE@)IG,1=1' >S^%[[F;UL=5G[G4E?;JWS#4Y[Z
MIQD!Q<L__G$^D?&7;]^]T>&1K]!)0^NC]6/?0B%4]YO300:@M0Z8H'.:A^[2
M^O_8=M?<KY.'!!/C@5ZI.PTF;Z>\D6=3:WB_Q M#-ZH$R 6X ]S)4B&4C#Q8
M(QUX//-X+^OWR#RMD,*&.B[700[U./)I^''E?.!).<=X;.0MZ;1U?5N7M!&R
M(WPGZP?H.YTO>OON38%)\H.A+R&3_J^R/97]658#()0ON,%)OP''[6!/XQ:]
M5+"84Y?H"NCQ<+%I8^@TP-7+] 4I_^:N[3@2?@FU?L'3)AWAL"^]HE]?H?Y&
M97.7ET\Z'CSX3^P2RZ?%G-' ALM.A8EZL1:,JA_W2L")0$-VP>OC(_- = ,:
M *3CLG]%NLF#RU>Z<HMN/-!UG^M^@:.BB!=^3">AT)A939:&Z]W]Z7HU3XW5
MD1;K7?YERJE9&8PK"\$ET=^NZLYG8$:$K_2%!KQJ0&0W7KYOVF1@G\&D,%6D
MWQUE<:%F<;%ZHZK2@4E#<9+5CY7R.LRU D-O7XT\=$0]V[=T =RW@(I%:]N4
M7X[HG8.=NZ^\R#;58<F9FIDT43E>"=2-I8Q/K#VEI\=^FAY5,AP,@18Z<$3X
M0NG%"KJ;@[M_EV]$"6S@T1 )8!XSQ45)8(3>LO16)+C@:;GLGY_ /W]S0\W%
MU#0*E!#)5P5D+-O0UR?"N;BG^0,8#[]R(0][ZC]^\9O?_?XW7[]=?49?$ZB%
M_]A#V74IQ,?Q-OAG8)B;U5=T?>_"]07L;G3\/W_U[KT_-!;V; =Q5O9=>58R
M+T*1@]T1Z&=;NK$/(TP>%D$\U<>YCQA!<U1%$4M R:8K5'"2@Q2CG.L@\-O@
M7 S-/YI^BH2 ,0$3MKS'O.J=5-8X@O1 XHEMZ*OFFUG]7V=7V^Y@*V=0>)77
MRK,P193.E.[,9[!.>EP6=:],A+_INV&)V(U=@]Z3_OIS!C<[_[ZX%_G'+"7N
M@9KU4W93.S@KI$Z#S,ASL]0WLWA(6 :E_4GQ!/FY4YLJ!J"K16Z8TVTB8%M*
M5PN,G/#Z]JMQKVTW/59L+GU(8$+GC[F&/4QBNCSL$+?NKFH*0B:FQ^2*/C.B
MT"8B7:_Y@Z OZO"T1FN @$=VQHAV(D4=,H3G*;8+"LR"B]<%35Z7#&)?K^LQ
M;!4$]#-F8VQ4)LAU_=HX$"\8G2NEYIVX0N]4OG:&U!WJS>J-NT/D#5]__29,
M BP5]@.=]839!WA#<_RWW8&(G\07>;HQH_')H8M94K(B+E8?W#/XWZHGS T0
M3^761<@D3BTQ4E^QKV9P9BJ8Q,,Z5(3]J8<#K\&F<8F"!G7+3\^3,+CG@7=D
MKT:\4^K)^,"1%BH2DRD+U\2A)QLU'(7*_((GL>C:RPY#7]Q^W[M[J73FA(^J
M5V;N&3?,R8Y)<OR-WW#7BW<Y0S&HX-'$X4XVS85SEMANI#4PE4JO=Z9_RK&Z
M:+MT-']"T"K9+J1)Y#P-4(E<$ D3*"61HO%!X ,%"GJ/O8X7E=S#$*^1^)TN
M'.X'.9(?AA.S6CS_[ >:XW_8UY5[ ;O>164$@7+6[TF@:;2-PXRP^I% '(FH
M@9E3^L ["'&IDC<Q,3W-CIMN$[94I/^;<]X@GF"#",.5M"EXNAQ5ZM) ->@T
MT>".8&?BS+Y=-,;@E=3(R%>K@Z 5PE6!*FQ.1!BY*VDJ"V=S+O-T5">APF'N
MCZ]>Q/.<M#80T_SNWV7[J7L"#S;;:]X+P(?K$NH6H+C/>B:[^9PK&#BSIM;#
M3(?J2&9L"K^)S'H:$$]V2:6OU6A.08H66VDI\DD;C$I6#3T)P[T>;S-5.S#W
M8^S[_;,,R<#7/R1XF::; GB3\MI[@K7W=O+&?HB\M:(KDLT*3O?QJA8@05,)
M,-+/HXT2,@M=RU@)FTH(9[1'S!43U4FW_9<\JBJR(L;@-*;'CR2KG<S@^D&=
M"32;TQ.6<6MY G53XDC"#E2SS(#%I\BJ1/9S C57^)LYI5(WUX'$]1_N\0U;
M'\A]+:!,!NF!49>YMBIEF,4^1=XH;K@X4SSK!!&HPW1N9P'+E7ZU]T!XA0#(
M8+P">--/^#P2[ MN]V="?ZV^<X^G Q9?IGJ4<!=)N&54]( E:3!&Q7]37A8F
M;ID9<X=!Q;^:#SWYZ2RN&^EBX-98@B@[$T!EN,]CPWU>9;A/AOOD>.L)X#XQ
MBU,4E$QF?%S&PA,((8;?8T:I:\K)Z(,&(AJW<36T@,@2A_6W@;P1#.ED9!24
M4?9B8K; \F#%=7<N%^>QB*8J ER$.0M]&9"X$)?2->H8F_DUS)#MJG9KMG@K
M#CL-!/",E/&Q/Z0G'1)S":^>IZW_2\PEI"82EN[U5W]Z7P\?A]7[((W[K9V4
M?R>3\C"'[Y%9_A5EPN\@OC$LP??SX,DS&SSY-NA3AQ(&>:!3+050*%(, Y'+
MT! ;%;U'/YC+<?)(LM@L-$C#IRP49PM&5HVY%"G*2:&#(^ND8)XH\!4B)1[X
M11+*VGENY&GG1JA"-R1,"-PNS 3L/0A:(!47R&_205SM3P=8MD7A2)V,+ =5
M07\"VDUY8R8P8LO[H18(@Q@2U^&H4;!!.0-L:H.1*I2]WYUL?1H3(E:B8A@L
MM#D'34B9S([6BFZ8LE3FSX@O>Z(J?^/BR36Y)[!KEY65_;81U37WLEGL!?.;
MB+Y.(]/Z3]\DC--'1?\Y>U=?_O7_.SSK]]0X\^<?_MHM+I2:_U-:N?8S(D_X
M3PJ3;WRQO_N/$' _W;O]]2TO-]HTUVZ=5N-DP_2/\5=_ BSI]Z_Y-_(E?CNK
M5W\X_OC:/8-C4[K<OFZ=KW*7VG3(W[G,=_?_[S<M_,^V4LJU;7606N$-\K5S
M%_HZ6UZVO(=87MW^@T@VIW,@@6D@6U:VK =9%A4ZMGUY#6G/*;Z:(1BU^]Z8
M?5>VL(=9F(B1[WS"$1I6V::R33W(IFP6=NA:IBPKF?><L!F^->EI_;*I95-[
MD*FI!*7 D8;79%39F+(Q/<28N',5(6]"6;6Z5RZ9*TY/R;+I9XET,'%>-*S]
M%#K&20/KF_YG0;.IS&-I:><5 "_$JP*DA\B],(Y%C/C<36Q!-@?=]G%5'@CA
M"R16R9,"FTUU'/$+BKX*_:1I+A9I[P6E8ZNH1GC]QOO=B<#>S$@SO]FS;S-]
MA5HX(^.Y'"XE4SN"51^8@-LMA7;;8!"*>#4)<LAD!6Y+X01R7_ZO"\) &+JO
M#I1*$NRPW-:=4%13][PF>F*DF<JE9P0_J?F]\FUN3T6-[GAN(CVMZ[,(Z[20
M4;=+=8IX#)I@FI6.[Y$<"4$L1$ DV(DW 3N[N& \@"(FK">6A*\:@"8%LJ[L
MQ,XG8E!.E,I+?*5F368*>* YR0('K38+2N X47KS$S'FI/\M,W5):*@AD<'H
MI;.K$Y&'8&!<5D_A%Y0VN1(+:7J7GO^-ASBFL'1JPP&7KUY9;H#0I-%] PFB
M($_<'O7]1 I9M5YFO/$>D&LN:XJ5KMJKNN\ @Z4N6>KIR$WXE2U:GX8,GD5-
MXD--CT HY+J?#0/ 5(O(3DT,1?=>[=S3&5,XE[P_/:_]B68_- 7#PO1L(]P@
M7GVLSB%49J[56)HY920SE'/>67ZFG>580MN99O!V75-W<>#A 29A:RCU)T(U
M C_(^G0O"^!BJAH8%-+.PB"J@M(G1%/.X%@\F0_$PU1MM^J[<]G0*'4\RNU>
M9^7<=DL#=.?TE+J./QK'4_#4[I60EMV$HLD)W5/,7$,$SC_ZR!3%(.R(Z!1/
M.1IO1+NEOO'@E>3=S]YVI:_9[,M;(1+@";<QOK12.?#ELEB]B?_.("M_G3*&
M72%3&_Q4D3C(TKI(8>F. S8%HL9^$Z%02C-L&26:#?;QY]!D."HIAZ2V$=Q<
MS?,TZN;(7L)H(G\;3K2'YL]!&2G8@%CFL%>4,-4]_ F"A>MYY!R 6C'EATH+
M50S^$J:G46Q[\-P@WO-B1LS^ 3\->H#D5V555!/)&QW-G-$<*L0[7/!I$+JM
MB33.\E(5_C"-*NR$-^F CO4&<#G$H/X"YY?DB>,]!?R,._XFE?K,29R'E!XT
MI/3;/*24AY1R*OO\4EE;2 'U[G6K=9F^:R2Q8245SG%$:=DP\2_1$6CP>J>>
MDJW5=;V="0JA;D!I\.=^#Y,)<QU4"K7:G$/_3#FT)!2B&^F"$XF%0K"TU'"<
M#G 8;KJYI;"JZ+ Z';N)6+4YO@15DWJGIB*@26@:*2%N^]/EX!FN2*FPAC:;
MCH1[,3J)Y5@),ZRAB]4;.T= $56YJ4ZLMBFU8A/S>>(C8F>J*;$)<R]I,FOP
MY01!Q$N(NVW].I5U PDO/0T=4(FI_&2%^<Q7);H^!-<250L+@5_BFWW7\9(>
MJNICD:CV\M]]^*S,V.X9+<P/(KS7V4&Y#Z7QXA4N%*C*+\$YP5F+_>IF=A6[
M#BZ6"%F=6SM[4Z0&L2-+>E^K4*;2,$6/4!ZO&  _'LV6Z1RPS6(6?NLH"'*C
M=NMC_82FJSD:*"N6AI167U8L )7RO\0T :8.9]K">7EV1H/SH@Y5".>8BK,S
M^Q+7M-TC52;QN5.G'S08BS'ZWES9BAY4V:>?DAW BCW#XHT&'H?2OU3;%9ZU
MG+OEWC"R.]MDSCO D[ 'DC40/;-%PS$6@)>JW\"Y%Q?6720DF:HKB,.5BE?L
M1L6Q3MRMN^C3P"QCETPS*U-8I?'9?AXGA#+,\:&.7^2JP]G,".,\K1;'G=!<
M\]UD46@#&W[8*G8J^^O+RGDF*".Z'CB9P>[X<)=EI7.%R@R@H0]&V:1Y\5.8
M )K:J$72=K6E,(?VE[;D2PPAVPB"-%7YF'"5NPO159:!LWEE/&AE>%PV2Z J
M/!N,RN7@XWU>.8'%2W>R;'?9[AYD=Z3)<>HYJ%8>98XUX.DH_T2HT9M^2"+;
M/;48-.;\!T'3OFLHO>*L;(B*+N%+$BYGE'BVX(?'%#N3E%&$[Y,Q6' 9&Z21
M\D*]0D!@-BGP67K.S)X*-&X+(&!]W')+E+%^\>8G:CHU8PK655-75XI+*5&V
MJL9ZI-I%E"Q-*[NC*GTG0D^6O99FJ\\+P6OA2[K%O<)-!BS>&EX6GMA>V!DF
MV 9_+:;XL"NONMX6'S).[]DW-R)CO+&HH"_ZV%?"=NH-7'"H4D-6LGIF@8G&
M8=+U@ /<WFY7];D5\3.U(O1=4@(KG#OL9;AY4( RN^QI)&6YAR"C*,PJ) 3^
MBA,,;'P[*>82T6XKE'M1J5TY ZG,B:J_U<9)&6BH2FE%G9%9'J/($1&*30NM
M!0][!X]@]:-H-( L1#@"_WFBVC6+K"F_N"#7R14+WH=!B>/@"\ E> ,5)T./
M-.(T\JN)QUUY(9T0W,85M0M(!5;N*EKX_)O.#ZS9+KH,G-F+V 7 F+9XK!YJ
MS]_6(T,OD]X5 ]>];L56!,M/K*B!CH%0):O"@WNJSCBWD#"U--2I,GV]I$/.
M51&Y/R[31)33J+\8"4T:LB+&E\W97=!8A_ZL%/O1S:H)]<[TBD$4*!B=7LV
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M!>_ QLC[RE- NH40M2*X7TU-""^XONUP?1V9G=E&J>"($0TTAZ<][>25"OW
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M^WLLV771#NT 3RG'TQ"!B$UK?DHSSWO+];[B[)[_C9WFC/JRQT_OI./(&0:
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M4)LP#^YM=2KXM:[V9;,KA*(B"(05]OJFY47BN;GB$9ZP('=8L%Z U3NF^<S
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MBUGFR0]J?N6=F=+..$?(\^FB:<Q#Z0E7%@[I/N>-)/<(GRY#2R#-DAL1Z7!
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MUL(YO$5\-[/&5WT8H?&LTX/M: 2.2AD$!7<@S0 2Y9:[(?=3 ;L)SQHH D&
M+*M31Y\G,PAAZ<(%L3E T;NOHTF=\$=U55^?7+18N6MT/LLXB:]_4!^1MY0G
M&UG3B16FU">*T@0!*;<AF-D]GGQ'/$$%W&Y;[\[1I"13H4%@!+B,F/J?QWH3
MB4%-A5XSA,!CR*(0#T<RFSA+B\(7VE@W=>9HR&QI:'@Z;W<S0X!R0T7U[ 6>
M@.*!1 &WL0.PNU7:/.DC66X$8=<C)WDO_OJT4K*=VD@QV6>&CF?(T"'1H*K<
M-CJ#+W,[B#A4/IQ[+>,UK>L!&CP4(&Q].:E8??_^_[[Y]8L7+QG)S?_QBG'=
M6'*^D3X?> 86ULI#&J'', 6>"2Q^+NK6B9;\S68S\:^" A0F@L2@KV=S&$GB
M9)'207SS;1:XD ([N]0,6,US\9NOY)OJ]&L/Q *O]*'\!X.;94VHE)MF*].=
M$ML=)*H6*+H#=CE0_,V1SV8TO%R]<S%SQ8G=RVD81K0  %2=5U==<R+."E$U
MOM/C45IRY!1$X, B6*^^X&3JEL.\FAQFJ&CKB(Y3K&A&T*:A?+Y&2MWNP"Z=
MQ-[J+)F"<A.4,EOU;&]'"&N=U0+.IQYB6^W6;I%?\3.E @JXIYK=PNTU]<Z3
M?]\%:Q$(&A!^=\+%-=+YMW<]T:%KNTV#3(+,04#[&B ?WJS]U*.)['F9"4GQ
MA$#)JYVOJX8H60;F!+O?[5/.!@2@Y]T$OEZIVH6I-Z@B"5'OL-E7VY/4@&^/
M<T@TZ2"I_WGF&CB<"M7A"3/.HL<A8ZEA"UQ ("8:Y-62+M))CTRJJ_6 ^SV<
MD-:R?>$<MTU4P%*B,8)C7Q]@1_JR__:7=^%E@WIF[)UU-8B16VC_W=N\[F7'
M4S%YPUM,N[7<+=O3?2\$ E<NS'>6X@XGZ\;2VLV)'T:16YL,Z2[P?P5+B5FS
MC0TO,_3DF..I8P[OLV'H6FFQ$IF)A>_V%JB^*:F/?B>6O1 ]@Z"*83B("O_V
M)R(:L[B%? M)H#@WM/J'.\RPK8,,GX^.)'3P7FDNNP)DM,004FSG=759M177
MXRC=%64ZZ1'K18)0R00JM RE5,]E1SZ'Z*T?.J83,J$&SV6T9R^VJ7\.%&"^
M3I@*WG1T0ZNM4*1@GZ_;]U+E,)[X;$&CI80P2 ?FY\L+\:E4D&Z*I:;[PX2F
M.U()$KKNB^E>@<I$V,1IH(@&?:Z >O5R.T.5XOO>5#VK)7*Y(4)\3Z, #KR]
M :*)QDST4M\L; RS)P!XF&,RR,2Q:JC^>^*Q)!+>.:NNI)YF(K3CK;>(N<;@
M!<"#YD6@&9Y^<U7I8O5FLW%V[ [8G)6,+!:73#/3&95)]2A>YC(E+^S]PYPX
MCSH(1K4JEHVD"S&4;4R7;AGYL+?>+0FAZ/!.:4;DQB@OC4(!Z7W\9-[,S*B>
M(:./"QG](D-&,V0TE\6?6UG<[V<^3E'>VE@UV489EYV!7%"UTP7%);T> NNX
M[?G46L&^S2@]\Z2LY%W'=W1CT^(ZBQO)YUX;Q'U:6$Y'KJ"R#/VQKS>54I\0
MQ"E7UY\NP/X&61.9BA3(/37S,$K-1XQ):J*H2YD&2KGAP=UAKP5D'?,-LGV%
MR7YM"N8A,2F&&QBS0AR< 0_=H1KQ!ITGK9BAT%F4>[/N4KLV" ^&OZ@-BI1:
MY;$;2M\>$8U8G4%%1R0X<8.T/9>?CKP.Y0DIO6_48XK..EU:40'= ^$2.*IW
MP_?FD;'@0JQ^9$"GW#'S&487T:UPA=L]L,6W#\%6:)2BC,6N(WG#]-S<FPGA
MNGTA;YA3?/H!RXJ1E+Q$NAX^Y<EA0^F3W^M*.!XB0XP/2JQZ8,K;.J=70M%3
MJK.E )_B!^\MG!(ZOHD-A)%WF)G'C+J[N',W4[N5'-$D'=Y)*S7%Y'Z'^=/<
M1CP4BWYX8:YLXGTA.TDIEFP2VWMZW-4;7\VBE$[:^#V)C-<L(SK;#_[AS0#B
M&?Q2F_HCE3H)9,!27NZ:B%C>[PK :O*F<"-\B2<*;(VM/-)FZ=Z3>Z(R%^UM
M471T&>T1A(5YC4PV26.?&1SPW*.@-^V9H9[.(FO2N =3RR8"[?FBB3.\D]B8
M?/VFU8.R#WW>7=O"8!%76X?3\=C8K0KHLQRA/#423)4B;G^W5W7IG%[*:,+.
M#5 Q.;"N#VA1_^WA/(S50;&(XFD-6SDD@+VP>  :PEWR3C-.U=N#LH!%XJY1
M\N>K\O?B2^6VT(@.7(^!*BHX5AR[N!,+O$$D4ZEEA5[[H8J JU,YC(4U(4 7
MK_TD[$C,51NA+'PUB\OD<3MBI_=?;Q06)T5"J!X.5C=VV^&L$!>5FSBX?Z.J
MRB#:>'T:\0U 5RL2P]A0L/$_#!T-&#N^"C($O5V!.Y #H0H=%1Q'44(L5]06
M;B*$>"%Z5[Q?;25<_%$0%US/!2>W%'!E2R4 8.CP1A*7B#)2MLG;)_VFWK*(
M+U_.DOHW$!U:>CRUY8YB.K:^NY-P><7N$/0AII@AKR"2@@?@@78J -'U@AIA
MH>+[GGOEO-">9TK@:*WA((2)0K.(9Y-AZ*=MM*@PT66(^V= <&\QWD#X;()*
M]S5ELN-!.O<4JTV41>?/Z8'W+]!5A"M=,'WV"6E37W42C,LF!KT=:5=M75 O
M<W"XOWM?3_)5%/SG%.C!X\C;Z-TMT*ZYPP@8PJYS__86;SCV*(PH#1B/L$*M
MSR4*GL''LGQ*,R-X@TP.NPG]6<)7*N&XU5(&BQO\V$P\PIO<CG6U2J 1FG)=
M"3,609!-)I<#TV<?F$YT1.AM$Y1,M_YZV'3P[@F 7:2P59,."G;;=M:&GJ).
M8>H&YD<!Q*EV*\'%#O4161C$$ -<P;E6*S17-J=<7/O98"3W,I((I1F_T1XT
MNH@3?7%,07"=H,4H"Q9RZF2_6,?AI&_LOG\\]0,1VNC5O7,NZY(0^7S$-RJC
M,*P:*C1 !$Z+5 U)%#3PC=O5H:(1J'I@P8-RXX.%:*[+8V8%27A>5:U[>%75
MRTY(=W*@&80[@K:B8B+=9 W.>NK"<JQ-CWI#D43CCCM*R.ZNT$^%^''L1+ <
MY/#<<Z(9)]X%[?'K Y;QZG3LC"A7:C2\-:*J[@TVE=\)=4NA0? "M;R%._<#
M[M76HS,3S_UB]9?NFEZ7#.V% J>W+43GSMH/;$#K<J@34 OC<C1P]T_E!#SE
M'5^3"%UTDD5A/).'056^7$4OR/V%+9Y$,AL+2^;DC-"B]#HMDA^SR.65V^FY
MQY;<P4]C+5" GW3A,:=U>X,R?9!1@TCNOE(*@#/,BH@)A#E#U$8H+KCK)+67
MCK?X2 &+WN'W*4DW7V&-WI,"3.X+J92>4P=PB+(O+(.C;=$V0(GGDL38/3^V
M+D/,:*PG'<HCM"'5SLD'RC;&GN21UA6L'P5K6EWDL+B6JQ/"08$:&%LFI6?;
M89^A#KT"+-"7YYT%#I2H*V[+[!51"LE[0>7N9A.6)(%S-%<.5@EP==N<Y_P@
M+K4H^ZWZ])"DW/')F&N;Z;+*,@1AB([!V9B1,D+C"Z(:Q*,Z;CII)K++J*3'
M1B7]/J.2,BHI[^$_>0^/;"%P)04CL/*^04YNLZ\.?D#A2.C3<L-4*B&+%,Z$
MB'D=;5D$M5MJ]*X\9MAS_,C(D]]$SG?;P75SFZL14VWX[E<KTSR:9%!V#$D_
M9-;XT)/&4+,9G2#\,/1_J"8=PO2N!SB7RC/D@W,<^@1Q:!3.A*!4YT5E1+BJ
M/B)?U?C45%F"K2%HA2Z AZ"X+S=1N!D%//X'6K8+*!"?QYC*3NC[J<9)O44.
M?IZ<"$H*DP"8&T5Z,"9;H+Z _H8+#F/'_<GA5(\Z[<(I(<([V+0["$,N9N5%
M!>3KDY%$.V*-F8X"*]+O1N'Q(3%+XZOB81PHGH"C@D]28BJT9^ZC?<XU_B%5
MY.>*B+\@Z7WAT?'3+?2A1>D&32^Y?X*5ICO20974AJV"9R!6Z[XKMV&^E=P,
MTF5ZJ=6 -$-ZJXI\03? 2UH(:"V:(@"/-!W CG XEP2R';TX2>6OR[YEB->W
M7$OT*7-PKGY@ZJYUQC!,^E2E1FO@QND69.U2, FV0_"/ELVWF) X7 <*DJ8>
M1_I"C4F7@HOB"D6ZSE0EN>FSW/1Y-YG<3(YZU>U5UX#+;-54[261'RCBFA5^
M%2S "SUBP9.F(WV?(()<H^A.(]6M94S16));M$WMO*L%JQK&-7'P1^=L:HE5
M=MY+QD0-<M#$5I:B#$N 8KWO,_SXTDDF@$": TF54):FJNW.OCGU$1J0>KLK
M[J;.]: 5UBN*T*98A8W2DX9)#[N8P74,"\QD&\K=LR>+\K[DL5_>PVG#6AKZ
M7:#Y4RBV3A,FXPIO92?B+510PY+5@Q=&\2=!LWNZ&+"2IWE*LL2>MC);NKN9
M<\^L<[FL"F''L2',Q=:JJ""X5=8+WO\$>PRZ& %&$(BZVV"UC7AB0(=O>3:=
M XGXT9SG#(+JX2Y6WV"%EG0!^J 9->/Q(M*G\82(1"P1"<OX0NW\C>B Z83>
MTKQ%000S7RU;#E.Z<!79T]BD'+EI,9D6Q.JRZ=9T#<[,1F?R_II#PRE$[O'!
M:@6N,#1Z-"I1P<9QK#DEB;CMY%,(B.HY_42A8#Q_O4J5-R@Q&^!,H=$F7G2&
M^+;NT6.^<[;[%",ZIY[J($1C0Z2$NP#OZEJ$P""XF7J&V4(>U%R%RY\[A!)<
M,&XD[?0HS#@OX1#IH!Y$MNR<XB!D0N?60.EL\NN+U7?NMCKTKJ>,&9-6+Q[&
M",:N@?A5:]G?:1@$P]Y4Y'''&*.64=F<!PVJ,.=O,'#D6 1:U_ XA?"YSAO)
M+OR@[GFU%>)8< 34Z ;?.7C"J4@QPIVEH8="[UA0"XMD9?P<DQ<U:?C,$-0]
M:-"FI;M.X:>K755MU^7F(WWGX!S+B;B'%3OM_^ NP$B)4:](TR@TM#FJ1=8/
M9[NOQ(=2E;'>D+LAIGXF2:G\\)8>G>P76=_.Y6= BJS/RL"P$K[X!"<M3^;P
M6_4#06YMT1U3L, =^FVY9-!C]VOZ4"Q:] 'PF*A/89^8[)N@0 E_Q6,T_^F_
M0U*OV(OH?RF_!D(RDY7_3$ULH:L ODX%3Y4\!E-IS WM69^2J1Y%65H5HW]C
M$>G>SA(1].J1WTA %DW[!<[)N_-1W)DST& ,DS1\)CTS%_5J:>!P$=KB2TQ+
M3.4<R)GD+?!%,[UT5&PT+FE*D)$,06;DXLOO-YZ'Y$BP6'WYUS=+K._"]Z2A
MD>$7OP^WD.6J+BCB[JY33/FH<ET"S3R'3OMHW6Z+2H(B.!T^#(Y1*"4Q\.I]
M/<@3L/'G0M8$LTB(^\+]S_9H*LJ.LF%B9E1(CPUHE8["-Z,!=]?.9V_G\ZXH
M@/YGS%SL66-,F<%LLH75E%#POZA?V.5RK]J/.+E?_0DHM*LN4M/H'OGP;O.*
MC@\G8E8J TGBQXAX?L8SIBJ#IBSB4>LE_6IPR>MIF&DM6UN@A!$I7J"DK^FE
MT0KT)XSX["8G-8A[*F3Y+&=^/AEXC?CU1>8S>0=:(P;+4]!O)GN5>]+"*D4@
M;]]_GXJ\6'^=RS_\2W<_',)(^&%J<R'=;ZO+3M^ -A(19TS2KT/77IJ>ZHT7
M8>]2.T2H7SGK[D_UJ,C(L9='Z+L]_FBQAKR=>S#/7=+D;]]_:<8=1N9!35R7
M/<R$5"IS$674SV.C?OZ043\9]9.3GD^/^I$:$&TOC<NX\4\9X9!V.DFY]/0?
MOR'<-OYEHZZ!-Y]8 _G6&>-E-625NXG"O6VW"@2,"+0Q(O#:!Q7K\^2<M,<6
M7EZO[K><4+#.C<])RBTJNW/=&'?)8^><TO#:3@I*B0>!.8@/,<MGU9W\^2,&
MTT14=0Z5"J%8_'/7;5=O]3+>$1B)QI,CU2%E7?[S6\.ZW/4FK[#G(LDDR8WF
MTC>O1:!HT.;[\A,(I2L*4#!\61K@0/1UX!+Z[GB$]9Q0U/;QFYXQGK:,[I!"
M&R_UA&S"T^RZ+VS%)DT='Z(M>H'FHED;:1H+!^VDZ-CN=Z#3WM(KKKLM]^=!
M'>WC:RT4,H6.8B<H+G_-G-<NNJ//8A;?H%CD'K/[,YDTK!#-?RYFE5RM(O19
M_..NORQ;C8CUW;_][GO_ZLU\JHFPYXOAN^]CNS^4'QE>TU9T=> 3"-8@1+>)
MVW@MS2^[GM85?>'44HXLKR=T5E5AC N4>IL$"^G6C0BYA1Y#+GL]7=DKM'Q<
MCD5.@8DO$.+O9@5)AB>@&E#%]0!8<#T6JM;G$@H_IEVW;G,93UY]BS.J5 &!
MD7<5ZW!)^](?\BO*?3]PW_2[SB6]'6SRRZ[LMP&_XT58YU)L5DCP'B6;B]4'
ME+HG*IC)JLCL@6U/6  E,5FMV3,D:(/-YF+9#.;R&=/]9LE_SAJ&2VZ=KH+3
MXJ7LW0*4 "347/"AS].X32FB02:NUDLPSW#?-=O"4JU(VURJ6>2.!8>%\C^#
ML0AS%9ZG;;R3L$1;[>HQ8-T"2Z_9E2ZIGM:BJM'H3>C]EUOWJFL>W+NJ9*X2
MGS3HD+CKW[HW0:?;G7BGLH)D\^<;4Q7'C>M9J301)4EP$P2Y%WAPA+E,B2D"
M!XMO9M-%5H=C(QQHYJJ,)[]9Z2*N8">E$?PLL\*6HG*EXH;8(!A/C88>350=
MNBVV2QJN,I_S(44F4"Q$A<87294GV"ECY%) G@HU>$Y+@T"R:,PI&BGC]YX]
M?L\O/+_W#:$;29Z*^Q&(?&QK5'@7DMBYH5CN#QGT-V^\,6,?5O(U\]Q-;2\#
MS7Z.L5:+)K1V@3$707V;YJY11[W11*2/;+0(A%Z2,1C2'KFM(9)*/KG]SUN[
M0JL*J3S[++B]I)QXBE@V>;:VX6R"'^*7:"E<[PD^0'P%GF<8 8);377#*Z&C
M,&< ^\#?9Q*RTW4E#\P^IS:AC!M+L 2!!P W$@%6/3D3$X^9>YU7((J5VQ#V
M2BW)L[&SB?-"]I\IZN!P="\.T 1@.93+(&4'\]$3)B"SCB- %P_Q^$$Y1(/
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M]@T8OQ=52'4D9.PQS/EW?3&G"BIN4<=BU=QX%=#?\+/ V"*]8-R.W*]G90'
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MDCY6OH385YN3,-0NJA2+<U5Y:#S4P$W%%6=B>E&W8-FF;MY\D33'*(N9K;N
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M_9V;*QM!) 2&F91Q%2X'H_[D8EH-48MUWY4DJCG$UE_PK"A(+U&Z\&28(U0
M"/;"!Z-!^,$H"\#N7#RC=8BY&LXN#>@DG$S3"-FC>^%7A/0E.ONQ;&7NCSDZ
M3T<H+!A1K03^!C6G\Q&8!8H%?U1P5^NVBV8\3V&4$2#QJFNNG&7'6(YHU2T
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M9UT%7.IZL<G&8E!ZXK#43]R ,MN_)CP%<EGZ9M%R9%'L2@'8E9294+Y?9KH
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M'=S(.&S<[=#@D&JA2_$%= FQ99X/3#Q=\EK.*50*0_*K-L'8AB'TS=-E#<0
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M9!3AB(!=+7<[4$S2QC.--WW#'5\MJ;SP=@*SI(F8RE-\$HV]^!9>K+#CS,'
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MFQ]+(E$<;R:.X)AJOQ0%#&2MPHJDIQVC;$79NI%L.>,M9LZ,%*#Y E9-(%7
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MQ.Y%'$=++2.&"!6[Q+%MLA=U;'4Z5($=^YF$;L-GP/?0 <5^=<W@0#OM9I<
MI@KC;\3'F!FXR\R&&2R/?;[W TNC-%\RY3REX7D@QC!,Q+9#D^!N %J$V^;P
M8>%;<7E[F!XLO+.7:6:?3_ H.YX/GAKF98@2CC&Q8=2ZDS3L3(H+<),?D@=G
M#W<3D&L,(4V8IQ\7Z5,@P;Y ?[?6OBZXN@]ROF(O1&-1#77/S_2/Y%<DSA:1
M15/=S/O#G]=**H?^^*C 6W;? 3R_OI%[)XSR\35B)7DTJOLQ>7#N/%;@@./V
M=.M,A+91"H@%UUUKVY$G7R>_41W'Z$L0R<^#1WS//?!:R-"E>,H%"H#SXZFU
MS^'M7>6L BA@<<F_QB^P@R[W!=&^*(N7PYM"A:L)1^Y2>N_WZN[VVFDI;$P"
MJJVR#>'AU1%9_05@B4.IA>#"8OKV?N8'GF\K+^6M07^9P-M!@ 5 7\3(0@C[
M5?HE7^7_1&Z4/B[5Y"NU\=8V)6\N78A#4# Y926S8"##2F26 <4?9>OHLO63
M:J^5\@3L_(D(&/+/.A\80,.(CXG>SO9\4ZO2E?Y>*S;0+PJ@N5F"2=;Z7,L9
M_@0FWR+?#?)$".4%9(R+#4L9^R=Y[>9U625[*]E1_5F;NC48B'+[=: V&Y;+
M2;$\6)H4Q;:7# V'2WX*%!A6##35N"$#*01F#72EC2D'YN,7L*=#(#U5IPI*
MU?9N0&Q?:U6W>:/DRRZRW]:)]-9W6J8W]OLSY!8H5'8!YWDA-L,> =<U<2]*
M)8P%;I3S%;QPK@CR&(Y]W4"Y,2RN>MUOM6];SKOZ0F]S6N@W4=+[1F(2?863
M&9"3G!C I?F^20EO/_I^444J)[N??3>._"<'*<9;&Y6DR@".,00ASPP_*A1.
MQ$&9-,\S)F?DEPJ5,@=>WBY04XI4 ;F0-H>$A!90F@+BY,C':X3AM^Y-MQTN
MCYL2LX"I1T&'7\FPDR+_K+]]6549$1 9/CWW2^2#@)/B$2.Y544O?*/O4\E4
MGCRE'LQL$(&3(Z6OU,BHN\"R*;2FBS%)*J'1B91O063".%I>_XSZ8Y#8 G?1
M(B.TAP5C@B<#O5!D6^@?@F2-L[HNTN92:I-@%2.FZ&N;I\??=CW/:YD*V[*Q
M@)ARDEN5,%D&KR'9X%&WJ483D03K@GB_WJA%.*>4:G6OLFV->R9\G65[AJQG
M+28,!!:K6*V$+ 3JISG %-K<,+A!?M8!I6Q/,LY8HXUB5V0*:>%#B)(LW42]
M\G7URI/M>0!.S3*WFQ5#&QF!MQ/TBERT#;M#6J<($^F(,^2X%9-I! >I5+HI
MU1E;RIEEM>)>2_())Y&%W"<+5XTXZ:\OGD^/%Y5)]#&&+H1/K?#W[5_;:RFR
MW_1,GV30B*B3K),^)Z8C$:Z+PC/>9;E3, %<'<GYDU/7JOH(/8+2M=:_YE*/
ME-6H&Y-2;0@&G'#F32\X%]IV"6C!Y"SR-97;]*$HH$=BR63C<%TNQ-JQAB[Z
M#,(,4ZK"9(^S;GG$/1+2KG6%>,B\-":JI#=E TOM_B,%"O/EH;[B>2+#!\_]
M^*C_'"-OB-OWS9UL1TS9*REYX0HZ5W;.)'GOEFF[YVG9.V[< M3UI>+RY-BW
MT2@L"I5J-:OW!S@#L"-MH=8MM[L#96$Z<ZM-_58_[7A<J(#_UUO5E?/SR)@7
M\5>'QE\]B_BKB+^*CMU7P%]9/3_HC%SG:_0)M &X"E@ESQ8!SL/Q5, ,F<;G
M_ J=)IA/AS:'XQ1*SAE7"SH0F$QV8.6:#M!$T#D*HXH0;U%U]8*R$]P9<0GC
M'185#L#6XJ#]D*I40WQ&__J3W#D/KB;LNK665. RW1&45D0?@MPK)PGI;(S9
M!KR/>Z-TA>E',.?PM)9'WHS-GG0C3"ZE=QWB-S<)5,82:9^PK?-YUQ+^ /LP
M_*2LA7MKC0!NE/;)5BN5Y40=HE\PA9K24\D,;E[&E9[1?4A3LX WE$M*-BA8
ME#7)P!'YLHL@ H$P-XIPFA@Q/YQ&[N>+G<9\+V7EKWZG&T.59,$9&\0E29B\
M%*\5$U:-///9<P;6:#5S"?+VQ=VA1;H&&L2$FIOA<$@1R/?.O@2=QJE#I!=4
MI_:R>K6K-"<ZP*E<.L,%G;JL^1F*MW]9MT UN3";MS!L>(V[6LA  MG1<B,+
MDD8O'2I6=4NY"2WT,$V.8DC8D]"FF%J;\=Z;024AT,SE+;G?_ 1Z^J+"JG;*
MX"= #R$,LQ?3&-G"_#]NJ=1TB$VLD8FV:<GA$R[D,M6F9Z$ZHGO"*8&Y7MSB
MLM1^U,7&GB5W;=Z;9(JRS'UY'KK15MX=F@^*_FA8#U.B01UD9FXX8QXU_=@;
MAU1LQBW5SB0(9B^#?[M$(3,*6N2!^5RTE]#X01H4'$:Y'\9DMHD[=2!ZHV5)
MFZ7U\F9(SN@UUCE$F*,AN]<HV$L'PSPDFV.@]VQ"1PBK79AM,/JLEDN8O!H3
M7G=/0_N3R\TYS'795\N4%Q[]EM^1M&LV@7E/PSE/2HU@!9M8W&0@5!ADOCVA
M=I*\H1IX7\/L0[LW&[OZ:*;.;-Q,LDC*2879@XZ.$F"'T"+(*9$S-);'B4?C
M"$?C-8A>_T@D6I+S(OE;5W+;\YE?MLATI'"%8^WF>68."M6XT*@]>VS?_HQ3
MBGBH<.@KB(Z6#^RO*":JXO,<"8*E,&X3D ]8>W-A'Y#'2^Q4]S*F^/(\SZYY
MR)A:9R;?HV?TB./+ +.C'5WMY)@2O=#+X<-J1P"L+-A60>AG^@\7RDRI&%42
M] #H+3!#,^X2#AY: ;>>#&<%AT>[986034*0HRWDPK(WDZM/J!)8"DZ_TW=%
M/P&AZADTQN<T3LZP*J.:\LHYR)%"DS[T!T].S21$.W3/^JHX59";/I)774W@
M#ZDW HJHRD:1ASM6Q6$"(]!Z&<@5:)*RTV^YZAK,9;,C17 K(N[2QQ0^W5^X
M9D()Q%++^'JWLP,WPQW.-.S3MGX!CFP:2=!;$! .=J\HJ%;)X^=R#7U,;G ^
M+-] T\WQ9EF2833D=\/0S*J&7A 3,-&=T2,;+65H:<I@!AE&A.*MKW".S')/
M'9_\3K]HKZL;/VG8<KH0*]G9,;_1_VXZUR\4WF.)P;Q5@Z@;_8@@;<,)!H5L
MPR;A[F;A'R"=5G+V7_3_!VRU<"2)K##-AHD*4F'P>:FXJXNUH<]$!SD ),7B
M;QN/GL611[;YL0ZWBHV655[I,P%GUMD.J6M1MUE2:.DB"$2XJA61X\>U[[^7
MXV;<LX,IU%U%1AS:?31@+S%_]%+'9B]9];]]^W*&<O1:QW84MNG_TIO]]OVL
M][<&_HA2^[=T4<VUMS%RRO^ATBM#JGZ2O.\1NP37MQV@95LT][D]$8J\A.\P
MA<J;-[;ED6N;H#0@#92CW>OWS\&L9 !V=.X(KZ67<)OQ!'"P,Z'7--)BNN,C
MC'55QH-W+,=Z^$[9M?85J?/"R9J1H#F^1,![&D5_4?X4\!'U&!D.ZGM#AH,P
M<NHR^I*"%1RR]3B))./C,@&J$#_>E(&'^V"9\PPI&=-BHV/C87Z&$JQ]4\<E
M=\Q=.Q1(4<J/8U[&1/F8P-E ;N(?N8ZJRN0C1 5EGOQ255D-P1;U(7RHP&V=
M)>]/7MI6!/\GIA_A 8ZL;2GK31A42&3/H0-+#EL?B@I^5:.*AU,H)I<6L!WG
M\INB#+M,$:EC;V"!30 @*A%2TRB@N41/4?]A)"7EN_@SUV7S:,7J'C<71RS>
MP_<9U_9E=G/9N;9&3NR"!]:TI4>7,O=F;.^&NADV%/H!DQE7PSJ,8FMO'#OZ
M2^Z^8-/=U![<3CVF1!R)JQKK6_$2WK4:N0L)K-QF,CMQDKQH,"UO(AVY=4IE
M,NWUA^].'>Y4SF@6VFOSFW*&X21CK9R4H03]>U=$;(G9%#R0/H(IS+<<+=Q1
M+QCLL0ICR30(2UNF5W@ZW.H&([ I#&0[I6_Q7W@4TWKD'<'MY0U!3@NX#YP1
M+;V\J@X+,7W Y>+Q:-#=')XL@H_S66W<&KJMSJ?.K)'6EH,KXM*/S%P1&79H
M9-CSB R+R+#HI]_:3Y^ @I$0H$%@@[00D- JS=#0B,V'A"XZO3[/3PFT4=SY
M,5*T#+6XCOGOW-_JLOST;"X&B.33@>$)NU8.78_CJ.5+A&&MUHI 0EZ^<[)$
MR^19XAU@^ZWVKF-4>:=1Y5-?6)_:5,I8F,FERK3LTMKKL7HT*IU;BME87X)F
M*)B8M0;-N-#'10C N*U*NX#:,;M9^7\4MS.,DODCO.M(1P0\CC?;:\EG3D&1
M;$ZL;*/KU*^@I$1AK:9*/G""+1XFM7&3ZG6!4Y3">,_Q\&DBX!TAC$+/UQ (
M>KS9 >)K@:_UIQ^! C%M:C8FP^!K0 LMX#!LEI_<'R^5?I!2,K&B>*QD6"S^
M]NO$48-^'0T:UI$!_7E^.JE =R[<;U6R5$8QO:I(VB\_ (EW)V%@D7CZ$))R
MG*PV^S-AO+OM4AO&),@(KPH^S'MT+%X8MOU5U;20\JN9L%"X-TP+&;?[(MQL
ME2.:NB":+Y,RX'/;0QP3S NR"%2&&@,?@V:[,+1UYB9N?7I08^Z16>1[)!G&
M2LXT -VYDA396U.+!@C V+L=>SG2NXS,^0RJK3@M:Y+(\E+Z6%[[7DH&^@WJ
M^8!E+BGC4EN>TNWKC4KN^$H.2MV>&GLJ:NP0^@KA-!<@*P[#$I0O:J3*A=[+
MI*ZTFKVL&M9!+'=1%NZ#P;/20!;OG9W]=6;LW8VE@^HN5?49NX6_M# F\PH-
M#(#_2W#1 (!E<8&6K$JTDV7[S"RZS6#>PI17H6M&<?LJJB<H3WN4\R?%RP)N
MM7M>ZR<CF]]<*H7P&)$AFH"*W2D8?TYP"("X,?Q46F*0LL;4G;P&*FE.$4ZL
M9?*=?LK34_P_*E&%?RPK@U\\>R*_B#+ZE51B4$I%(;*F?#3M_H\I0WG3X-B;
MU(E!YUKJ/ P1A01)ZTBE(UKME2XLEY3K84](L,T X"7UZZ5X?4/U1NG3Y*,P
M[$SUR]]:=E?K0MCH:5JDS]5DNSD+ZF,<]D!N.6]C36F47W1;T]"Y1P\T'I6O
MI,YW/ U'H<3I@5GV )5 EU[AT[0YIL.<RLR+E(1@C =J9SM8$Y1=RL9]=W9F
M+$//)!@R-Y-=TU]_>KKUZ^))6[H;YR&@VA">\I!"L,^,;>'NY_4H4(+/M>3I
MO#;I4/1;JM:4V=47Z1S[[OS,LY(7T"?L_<Z_,.<K+T BR(;B&;$R(>J._NRT
M*<#]L1-'98TIWC@3/BT;I;I(%YM !SR!;7H;FU1S?:)00JQ.(JB@UK[@Y&IE
MZ/"B#E,B%59P\,7L"N?)@U4A+@$%;F&<C)+<;UY9,D\!1CC*-#K./HB^.2X%
M'QI^^()_:(!1/;Q7O8:I?7J[L3A*![?<!_*#BYWUK)KI+0T.KG[PD_,T@23X
MS)2QML"<3)8^W#7OR6@P(Q+JH__122'MNMWP/:T_N%$>.ONK@%\Y:.*FI#9$
MYY.'RX6SV,9DW(L>@8./.[VHJ^OVTC;D [D=]/MR8_K22RJ^(^W(#^-H6"V7
METC%ATDQGG3)[%>&<XMTR#K=$ UE:>AI);DNL_C@:P+)^;%/^K3K5@\>!>3%
M"@B@ID"1C3-RR'6L$^1L@>0"7=FUCN($%P<D>JONXM)R?(QD-W]TV*I\+H.J
MH0K&> 2N)5[:7:K$9#W)1?/'_G#9R,3B(9:1JUP@TH$GM,@O2ZZRSVN2?B=J
M%'9SS%B 0>29!V/#DDP(.TV=N*@-D;*"5 !8>"3PY[J[T7$3Q(UA8*J?8+6)
M$-.7+,VB!JA:RO8CW-"@'"49*Z8AG<0;[$_ES1RI#/C#Z+KO'#G1*T(.M=TL
M@V:/#NY.,8MKKDXBMUI$T!T:0?=]1-!%!%U,$1R^T^7MD$M[9L-8,12&>AM]
MOUW[F=V8*YP (&_>A.=8*^#(A( B[(Z K84 CU#R@7$ECI^;$4)G-'.143N_
MI>HRM+$\N1 -N8R51-^:7, 0@*09Y*:MO0S21F.]S5#8]N.BK7<;2_HQZ96M
MJ8<S?^%<7VBA%-.:;44@C[PZ(/:&)644"EY7]6<*WDS3BKTSNDL@/!R_A1\+
M/"QX(&@L!(@3E?'_UA4&NG'^*&8,CT(I1".X GE"['1VWHC\?>18^_J#"X"Y
MF\8P?B9XW9:&8L+EY*F;S&64 9=\P1P0_7(AKL/-T43I.5)7_E!"+%"%(U.K
MJI@7&P-E&EJAW[II0]013+HQ)!\81?W9P? =5(.9&6E#%R8%RR"IWW%T+P@!
MO*)7=7=AHOK7KR)VX9BZ)"02V%C8771-Z\WY&\?FW8&/8- (8ZY"TZ\Z".LI
M4#QV32@EDFE!LX)L+&R4QJ\NC?NQ.%D<Y_8:U\W*6Q9S3YCQ,8G2PE3PC*-=
MY8FS1>Z8A'[&:ULK=G =)-12N\BXOLM*.@KQ<0SL'EHS5(#R^8P@O4NOW:U(
MN<G [=4I-SO:%QI]%R*5-6S9B\NT*+0[2 1Z0KNJI14D&N 5/!02*CN*9D?J
MF!*H>)OQ\5J-GT^EAS7Y9'= GCQNTR'8<=D! F)%/*\PT6>.1, +O+"-N"A9
M/8RYS$A8+^815+>-?D?9=D^2WTNKDNBE.A$XUWD1=$SU2BX<AZN4WFLITG5#
M?ZJZ5E+6D3[D>"0YX8,:XLEY-GV*/87;*^C='Q^&JU6MZYPU=ADV"D!^;%9(
MC@:P-X1)8"O06F4;I?68GE'>[.(9V0!\7.:^,CKH-GY.2"1'7!ZO6:]'2^-1
M:R-Q]EA2 TYTB?M4AWO^XB$X+N-3.+F=<%;;*.MW]<GT-W>DLX.Y\<2"-WVY
MEU5YG=)<#/WK.6(W#3[%39JAB4!T'!2CB9 =1?#)Z<E9H)VQU^WD]C927UB=
M$ZZ ?F,'+WYW=O+]$S@2WYV?G#[ALU&0!Y1ZDQ93;3L*!Y!WH+V+)^-K58BV
MF8:)^LL#\4D/=8#(#NA+/SRVW1D#_EF^;#<&OP$1FH>201X+?;0.M6]09,GE
MU<(,W3$8H_<49CFP+SJJ$E?.^PQ\N*ZTB*NYVY4XCER$V2.65:.'SX/"F=\I
M2@A1M-)?A"= JZ+S)XZR@F@.X:M<E1#["C+*]X+Z'\ 4J9[%#;17R+/M<Z$Q
M?Z/;OCLF8$-^9;_W%',R7:L#337)]FP>.&^9T,107)6>TA^91QE^HPZPR)"O
MLGEQ4P'Z/\!3X0J-*.Z]N%K#91W/,KG\78U";A.O,G2C^])> 9<%M#$B?X3E
MONL;M $+Q!2[@U"PWXKE ;FN2YHR- WH8F$# # QMF=!H8R6\%AA_4CH'N ;
M.#O'#Q^/64O7$.XEW-;@S1R3NW\J8&>#1%@)F1P["X<ILT,$0<P-[6L(3JAM
M<2CWV<)X7+YFQ:5O<^"5[WL&PNUX(MWHFSC=&R.FYPX%*])'1O#K@<"O9Z>G
M$?T:T:_11!W11%4# OASMTCS6T6U1G;E7YHVN5]@3%R).6GKZ&WGPZ,I<L9^
M^6V?JQ0'D,VDM6FMRL:I<W)+X1S0FKGMLN8TG[V%?L_4B]6X&9*P:]HO6.H(
M&RO&F>,S"E+6[;J2YN$T<SMAI&YK^V80,FI^^-+[H6U@0BZ''C^4USE)WZ0H
M]^"OI%\\QUVEG1O?.#.9&-R-MJ U?_=L]N04!\/Q1?0SX MR^0+P]4!]K1RY
MM%T$DI?R2G#'.%T!"6%_\VB(,_TMX5)\55_K9XT>\)'PD/M$A#OE3^]G;0WC
M1 /<='(=)\F+EFJ+\@ [4\*X/';<FFN2HOT&P*G67H<@DM- V!:(F!:#(:5
M=#;@ X"_A"HJLT&];C3;1KVP3 78>ZQ=DHG^HWL13"@YO%<<5>U9]Y(T6# S
M*B C5DKT8)0\T%;JNE>G,F-OH'STV,W'58'Q[=Y&O]9[CSVB+O+7GV087*"?
M68<) ?IAN]6:^4JTM55Y.4MT3 DC[!K%M"[<G,L:G4E)O>UZTVH-L3"JT]%O
M.7X2TF7:P[1-Q?C>SW^D<_366?L+7CN_AIDPH,[=X;^@NG2<P?,5,4==?=G8
M4>3_I?^-(-FN\<DB<2"B3Q=YJ/("*,N$R)7PW(\=CQ8:[_LU!I<NLS^\ K.U
MSN@]]SR80H2?X<4/Z9#M>T"$V!'[BF])$#S!NKAK+HX7_Z8_K;'74"PNES-!
M!D$+M-(!PH%@;@9C/8(F'!G) M-W:'Z(&<BS'>S TTB1Z-(?\2RZ?F(4"+C$
M"H=*:C^9602$IK-6*X#P567/P4L+M&;<CK9LN3':XSG:H70BI3TG>S]50G%[
MJ044V)@^EMPTXA\Q1863*],:4 >,[C+OTP'!>'G<P1@@"XCQF)Q#7>#1O[SK
M87QA#Y,*$J_5O!Z013YV9\/+J^Z=X#3, ;NAT+!4%A<XSO8@[.X>I[N9FGV#
ML;CHMN'[&F=+]D>T3K$[11&]3T4 JU+ ?QFHE3LH/(_"R;<4%_Q^#?*AG/5:
MXSMIV7<J%$<1/4Z4+FIRVO'EZ1QW6=#]BBD 64. L*;7JXN'>1^\XJ%""G\^
M)?G:APM8;-<):"#"6+*JP.;385#!:*,;82M/#K9N#*!VC;9LH+6GD-J>'MP1
M\_!V/T)Q&K&!A4(RT'276@40 (UI>&&L #@(6G;'H%<"TJ&G'7%^>!/HH-*"
MX7XX0F07XKB[B]]F/=#X.*42IDWZZ6^FKIRB@[-MT91@ >GT2<2Z>:'76>0-
M"<I!Y;!6?U1F4(_HJW%+:UK"+_,52<QEWCAO#-Z5,^>J7Y?8=^]I(2P[1P H
M:[VI,GISHEVDY9W2=HYB@2A0B[W^3@M'Z\FI<UC@'9Z=AF;13"F8,0W 8?Q.
M<:MQP"("Y]OS;# ^W->W"0:.C^33N\/NN)4]U]4.>^_8.;EUD3M;?J%,'*^\
M'3H+XS?B^E'K2'8SGIGC1@/]I,EMBW:3A2_#!S#S4&QFW#,6T-'VW2!QPC49
MDWLQU*"^IS^>")3L[*Y4Q[_7W><493SUTT?$U*D@(Y2AG %B52)>9G )#)/B
MU"^=4+*1-O4['-=DB]]8TP'! &NJ%QLDS89K:CE0WE4EH8R),<?#FO5@_"['
M[#Q=?);^)_VVNQ;=#T/9'YDQ(SCPX.# LP@.C.# Z G<_7!I'C:H U2LG2)^
M2UA$)B+Y1EJ_0D8C+?2*LPU:9\8R% /ZD=2=V#)-1'(C_L<@S;F7!MQS3B'X
MK^R^]EECV#' M)!3G':Q^U.#*&$XH1?[3X_VA6W5>X>KO5'%B=H'@_PW]"12
MFX9./BQHUUT^53_N.THM$K-#R9IX<J[VX%>URS0/B]E1^\38-+DEA_)GEPK!
M.TFFNXTRJ)FHWDD,7&%$)ZF4X1Q^N-8?=2E9(&="4 -T^*T4N>/4R7L5]SP_
M2MP#4D%':11VB!\;!W^9M^Z4Z] D<D:91+DY/CV PV%UK"F!H=J6RN;:_4T^
M*FWN<K0';\K%2?* L7O\.6/I'LX&(M8CCW0F1PG?QLY3H[:/@7*G1IW9:8+A
M[^NGH^/R@"L$@CC7&]0M;%D"P?9A-)P,@I&'&7H4EJ_-3E&T2%NZOUY(P?C_
MTEOW0WP6;2]:QIMK%;" 7@" 94E' \&W" YE*R(/SAP?25O)?-6M7/>&HW-B
M%##9#&T^:$F]=,:VZ7BNW[1M-MXT6_:/R8-S7KF#ZS+S./B]@<,7XK^>)0\>
M!7\=<,Z"I.+^=*+'SAXZTUL"B0]8T,B +RN%9A32V$@Q\A>#$\7XMC^2"_S$
M69@PV,'B"!(2M?77M/+XAGH??;^K ["%"&RK_;?N//CW(4<^;P<<"J/N J)(
MW:2C'3_$8[:BXW O1='(VX1%=YT!P1?Z[H SV[PW!SCY[NGNMEC8#JR9I#%G
M/""][-Q&,!)>8I]&FQ8EZ*NZGOTJ9;.N/JM19<3.0^F\Z[2T<C.8TX=#GZ&E
M#V<^)Q_&KFC*BH-*NT?&"[X%A>9CTR"!AFUR03#FRPIW%+ZO*GQA:WFH@;H'
M;^@3+6HP*0._>K]<UN!J+K.2_O,J1W\V"-JQ^<MK#!OLQ+YM(U!_V'\&*E';
M\!&T*#"83+E:%SFXQ.WA1J!Z>3>XL TRC=,O.J@W-_+&$T='S5UHUFA*WAH'
MAX;D$;_>V.^;((YQ>E.)[P?+[7UZHS=BBK?I6^S8JQ=HM/M]K<\)Q65ONT6>
MV0X\ 1OJ3]:P M &6LG3&O@JG]PU3+3DG>W2DO?0J5?_*PQ[+8&_667(O7.3
MN:_N\-NY%.ZYCK%*/ZO!7%C+&XAB/Y%#\06?BQ%R(_T%I@:<0Y]+IH![GI(H
M>9TEML-$LBKC=1@#-(2]Q<P,9QS\#'A@-?K6V-\OH(&&U\>;##F>7K;*7@U;
M[[H:7)B&( S% EK]Y+7Z;\^=,KNK6DF'T/#IVI3-)/5P(<P6P6X/$^]/S]T-
MR>V^DWU'AO?Z.WJ[T;U7KFA:4+G3+FI$U77R%B*&$.1VJY4=98<#ZF!,05D2
M7Z)7OS%EP^'FNX5$9_NA4"2%1]IX)'7#,;XW,C3^(%_[CH\\QG<KK>JMQOB&
M?2#($%*<Z *>YQM)>^M_>!BOT<Y0."B%&T+*,GM3%!WNSMO- :[0%_3*C^[=
M3341%P;WB]QF$;YT>/C2>80O1?A23% </D'Q1GJJ:ADI^PZZN[E5:B+5&JR\
M6OKA/4NP;#Y,N!<T-NP7]TQ=[Z=3X:RT) YZ$T;3?>@$T13;MCI)G'0.OI6R
M AJ-B>>J5=O5I20U*&M(-GRP092'-G9T?!]BXNY; 2R,N5YF4+;C>/$;]T^,
MS3G/]?LO@Q.]IB!T452.4Z)R=.;CZ7*HF1@Y,A!YO$%[SW1N'ZVR<\,W:R[X
M^)=\WH"">]65)3W=?Z:K]8_)R[IK%Q!5O7W[WJ!EZ,MC8!F>N2I F:L\D.3N
MI9Q')Z[+_/.#C%HG1(T#X9C$N7@C,S%]H[:-.\<50ZXFN-QX0H]^0DVG%L;[
MW"N=.;H6\NYF'C#AN1=$8EJ!BU.5*)7:STF3NH*40S^A1I '%$'.1HCHS6Q"
M?T9G0BN*],L,6_L*2!)UF*.IUJIN-_#GIJNQ'@,+HU2&/\B<E0DFB?W2M'X*
MN6V4LJ-+V3.1,I(K(V;>^_EFI<P_+%',CBAF+R#%7TW)VI2/\3<%/<)0H'C[
M]B5S(%\S^_)+RI;/\*,';76A0!+(DV$C_]X8Q1<78+ZLN0_<ZV55%6HS0Y15
MHPK!"/:O,?-\C9!G,-O9-<"BK#+ITMW,NAO7.8Y^X(EHD;Q9\'"PUV-KWMT]
MP'@BZ,S4RO3FH ^QXP/%<WAL=7]V-L9]8$[CE'N_(V"C3WH@*053"A#LNU\3
M>R$"Y1$);[W=20"2!*K"UA:"RW,;IFDU@V7H+_)1L@0V#1;9NC8I1D+O*-5?
MQ[I8T6:K;]__N(H<$P7DF&=2^T6=KRD&,X(AVM#1<W[T):@24HM9M>BX<%F)
M1H9O^7*)@QKFZC(MEG(P^C;(D)?.Q,M!G1U%[OB*= M]WI1S8[W225V[8PN9
M21=@BJ!LKKDZ.E[O_K-3#6&:?/22=+(T-@P0C$=>HR]NW/PH<4>0N)]4>PU%
MZX#8D?1HWZI@N/E$"612R&S?0S\Z,U4+PO7M$&C-O"C+-$/HY_JL6&?J[6D%
MIK*XK*LR7R3-YQPYTP%9@K^:$088\3B6915UHI:27KZ:,W;>6DV\:I_N)G&B
MG:/J(OXL%H,/AXU]$?E6PV$K\>KZB*G&P9%,9SG1<S9+=W!JDG /<6T'W:=0
M[I_: /2O*SCPJ=.%'M(5\7Q_33KAW7+H[,*L$/YB)V96BT7:2--=>(8@\0X-
MP#E].7+I'1'5LYM3))FDL18[!L0)H-AQG-HV75Q"QKHA@/1E/L];8CUJJRB2
M]TPD?:49T+[8)1"8NTPEX\'U1AU> 1?3N&U!DO:"3(\C9"+I, -247UKT.S6
M$4(=;4LP]B[>P=FNBL/I$5-;\0J@1SY>4XBW2-@5$6\W0[P]BHBWB'B+EOC.
MTPVFG7A/7 ^ARS"2IU9?O<E(.$]&I5 PCI,GYV#GT$NF77Z'45O#51:NJ^!7
MI)ABB>OIEVGC1V8#C\ #K0-!+,P<(H=#75E</X#9M!,+>36D1N_W0!L@/<=?
M <]#VW^]H5JT) S+X;R0!871;@X*:55AGP\Z !ZX'1\J.IU'%_7STYN*N@P-
M$PZW$3&7EQS?[7'>;2A-M6U>[:$:C/>>&XJ:S,N\\LQ/9><P;%L\E(E,!I4@
M$R6FM+#1R$XAIJ(81]T/_&# @8.I4@<5K<VGU7GSV2FY4G3\D!+1, 72B^GE
M:Z A"^W";6PQ8N;$;IE^;ORP0XZZK8_HCP'UG@?:TXJ.PSV?U2G-JG4;& \:
MN %TYL)!0Y@)#O9CUNBRK3=DS$*[2&^:=\9KK74F53CCJ*%%^(*I "7^>JGJ
M%IM26W2Q7BD \AF^JO?:$R-AU#_[ ,>,WLS;7.NBU 2#'PF]\%/RVR@!XO]6
MK1.GO<0XN45#1?< \_>1AA^06&)9TS:@XZ#!&L:Z</<O6,\9F&$)1CG74ZMJ
M*2E&= 0%XN#."Z7VM@Z(HC(EC9QS5537U$!&079*4>F@$YEAE]1U3/_H]R3W
MSLUK8[5?"-JR/_=V*!:3W<GGY!!,=B?3F_Y96D<_8..O_L4RS?4">)*N=2BP
M#1+[N;%%D':MQP>%C8EZ%32G(MJ4(Q1_IX5$:#Z-K4@;1@1D?U3<YH!H6OG"
M^ #TE"U1$ >\CPW:T03U#$^X2Q.?I=,BFJ]H3KHABPAQ6'@<!EZ2C(E*!]4#
MWQ -BPN.BK56Q<EV^6R]H'Y0@6@-A VT.>CT&?GJ&,9R90)N-@?6>AD?84^8
MV"F?/8"(B/G1];O7&P0M[OSL6RT8&Q44!;!+(RGPL!%U'E?,\MX;'77%$71%
M^ CMHQIV\?:^II+X28J40AX!BSJ,"?<6^P&GC#4F#TV_,A9YVS;Q-I,#B)M,
M!Q":]1V'S/$>9YXK^2#M*3E3I\C;)&]NHD' M<23[RR'F^F%Z-+I?#*DTD&-
MB.[4T,<6]WR6/)CS^O&6@A.BNT[JVHFK]B[AO0+S##/[ %A,4376LDN:TF6*
M[,Z0;2)L< +N_6W(;ENRZ"MO\T[AM_CBO!=V51$9#+(PF)*1(0['L_9*L( _
MU<!M?YVDP.C!C.3@WUU5+?N-&$!HQ9L29P]6:!R1B_KYZ/F!1RZH2BAJO SF
MI+1-!+OF.V-,-Z"C)AH>/[I%N1>#HMQWY\^>G)Q.3R5; 3&>_O6M"WA1'K]&
M0ZVQ(\R'J&-G;)C^ V-$,-J8E$$"K[0LJTZ8@O:U)S,##=3OOL![O&20Z0<%
M'%F@NU[KS:7%/1\1H_]A 9J9ENUB *TP1C6\#F.S[B@]PHKZ$#D2QYJXBZ5W
M];%#;C'OT;*);X>.NOZ)XI_(U_$5A:Z]#%S[K5[DR$-V:WE ]R(7XB^$)&R6
M$'_!4'<F#R[EAZ51;8GU*2%?8EI/75R;:"8F3\K-[='ZXX80=-_Q;A=I49#S
MB\X("KU,R!7,O^,[##78K^?W4W?-M<=Q8\UU=NZHKN^_#^BNJRK/;E4E/AO<
M[S_^VY.NG_0#F*T=>7[W67M9E;"SSV(:[= 1@5@XQ ;(&IEI4WG3$R;=H;W=
M]NVE#8/IM1$M+&J$(=9@$H5"?4;A16$&C?KDD*J$(=4V*@Y"?:5-+PSYE6(/
M5R;@'Y'I*^*>#HY[>AQQ3Q'W% W?W0\J3)$$%:,@ERW8CK9U?-B3Y TT7J2+
M2W1N6\B#+O*&IR&X&;YCVLRVJCXS_(KY@EMD.EUW4DSA[)<-CT90+L!JK;3'
M#25>S):Z_KLM#..<WR2S'@2WGL\$M(QC1W!+[>0'R1Q+2E4,*/#/8H2S[Y8Z
M)?<?!LKRI[?_;W6O#TV1-_S#O^HX!D'>/U1="SOG?M9NUNH'@*%/GK+'SZUD
M'^^@_76+B^G%"_.N*%3;BQC,-O['?V.:_^F/]!O^$KV=Y/S9^LN/>@_T.=%6
M-$="D+_.BPHMI505=OU?$V+@__ODP?L&U/)8U/>3_!8@HQ^K6C@S[?T!G< I
M AD,_.$M&?"C>-\?\<8%/3L/69)O0-X]4R**=F8R*QFUO&_"4NI=D/I$SQ%4
M@QTI(.RI(2%!5N5U 9B?$<II%ZMKJF?=O%%_=F OC16P:]._^%M78%H3;DU4
MFDCQ#K\%*A']8O6_M"%]^NPODI;$J:[(5YW5^L9(*X_SZS'_+U:7,+_#"NK[
MR[3A).VYWA#]I N<M OJ@F-3P@)OACSHR0?%#&OZ>7Y3VHQ6F58(6DLLJA3\
M?OWG]W75*FB;U#NI0]/ZMQ?O%^?)@Q<_G9^>/329U:H3AOQ2Y2WQ>&O#AYW_
M%+GS#\$S43"-!+!)^ICA:JU;LU FX2*K5L#]GB[T?Y09HI%^C,HF*IN#*!N3
M')9R.9YSHJ#5UG&AUG8.0]4PA)Z;Q'L3!^B<51=UNF*(W7#J@,"RC$0C(#%=
MJA;/)I0G]&_UP:!JK','  + ><1)Y2ET<#O#G)=*97,=E3M<!N[BUFE["<F'
MF?@,<V>*)(\\!Y6#I4/V:DGA_-EI!=<2B1,[S@V,1  O(1[!> 0/<02S' Z#
MMFQ4Y^8YCV1+/3LGE6U#3>#*N RKUZ);Y M50GFH@3@10!)P7*^!6YK'01*A
M'TY )Y-%HSIX#$H._>0I@"6678'-0@ON!ZIXX"X01;1=K;P5T-&(Q^+>'(MO
MZA2$Y]6L\[4ES_.$S<X2BQ(7)>XF$D<6WDV[C8/ ]T(3#Y@(W'QB%-<HKK=/
M"XPW/)@Y5C,:^P!T$Y<5C?JBBB@ZO<%XWVV0$B<_S:Y2"V(*N/P8.)3$T<N^
M/];:"%J"_<;DD&#;7)-"[:8>3KHR27B'1G0!(ZL Z4R>BC,#38:>40:/@,(4
MQYO&0+J#;:$+S\>V=F3F,J9;GI)MQ>E XS%<QRM3S]S<>#XZ1<S')=]LI-A^
M$\2B,HK*Z"Z5T5P[;VJ9./-;3T[I<H*#5=O'N&)HPJVTC*2$K!ECW?U3XU8'
MZ7J0N?!6N^[F6A\E!5\#T?,0.V4C>/-O8D#IC::2QM,?3__=GW[Q0XP7,FUB
M;V);8<25<^Z*_,\NS^S(%'U#Z><PT[%KQ#9J6[AQAJW"8%-]D"_P_]4]!3)B
MGOG<"DOD;+2SO*3!7-@YG&"RTEVSDW"QJ 9O8X1C&(_P/"V$$':!/)GR*28X
MS56[\G-979>2K2ERRGOF,6J.9_]HEG_6G[&<0M>"@7.6%UH%F %A1BDP#'V2
MFY+#%?(*5E73NDXU_M"9E(N=:!<74"%HV8O&LB.5XTP3,B)C&CA ;AC1Y%K0
MTSI&\O?M"/5775:E^E<^5W9,]=8!WQ@=^AZIM7&.O;%F#CU%U\J-N:[4DNHY
MPP,_N]]E&W"5IQWDF:5>QJ9>,S"HP1P >.1N47 VA?&.W)81XWTSC/>3B/&.
M&.]HV;^J93=/E)?!!T*COQ5$/C)0SAD_QTD320M1G.D/#;##!)B_S.7O(!H9
MCE0?$"Z,7=3,O49:%(T9YKE:U^H2TN.8RY4$O6_=_368$1T/+=XEPD_O@<C^
M2\!1J"QJH%:,G0+_CBHD*YKDX?I^P"RWS1UU:TLNK)1\SB'>:W@(AM>,$5@4
M^L,)_9_:+H T(R1QH<V#9>E4!E6,*0+YAP"2;5T-HB >B=#@$6DHZ<?%2"8S
MP<0"F0>F9P:26@1\.<G1*-U1NN\$6U6DI0?^]W,$%LG;3R@ *A:R!S)UEZ<U
M^2,L*,>OPRA]("JNS4>\;)3FP^IJK-GDEQ5-!*,,5EXN"^8(7P&.O-51 79^
M5+4 NA'&G<LDSV!JB\K-4JRI4ZA,@TC"=?7I,$1,43O?'WG^IL1WQT2O=.AZ
MP$2ML14&GVX1<")-:S\B.K%>(87\%T.*AQ42P#!^R2'$+#;)=T_Z> U]@5)1
M$5(*NQ>$08!AW995.@@XD%ZIO+%/HK\_']SV_'1''K59_T)(.2*A>;<&A!>/
MV>YSI4!7'$T-MP.I<+7DOW%!5:\&<MB6] 1(W@9;8A9Q45=-0PUV*FOLMMZ4
M[BUJF:AE[KJ<-'.02*FDH":G@'MYKD&<+E $-YCWPB;JS$0W="9GTC'H!BTV
M8INA#PVZ7QPX*)Y;8.WL:M"'\ON@TA/HZ)ZY!N/:=FN]'+CLP.O UDS/'?8O
M6I47%?SUS6^O1M2  D2*HP?<R--=+_31FH;<M)2Z6B9=OJR6X%.G.?:,=IY>
MV8?_>3&RB-/3,[F_&:Y3-X VI9G4YZ?G3_#F-[GT>>_2C8*,JG?MJ/.BSKMQ
M8& LL8L,=U27S)M2,_F&/I 4$:..0K^JJ\ND9FK+T?KWT!^S"FCL=[WY+M*%
MJE42\ZL$?S;0K CRTFO&[WA:E9["/OO#>)CB8;KQ87*ZI,F!!><^_:RH*422
M]G[ZR$PJZ@47<\5F,Q4$=JV$44B.![Q= GS\EC99^J>6K$LT^7D+OCVV8]<C
M@;FTJ(K)(L2C&&UB.*>2,EP%'@H:V.<M6*"NCIC(>%9N=U8\)B)D] H2$,%7
M^STZGI/)LP]7:2;\N:#5H:Z0CK0P&5=]7[S4X0OB(Y1E4W$$>K <2\0#& _@
M<<"3X? R+\!^)04),U*DP^ASA<Q&@]X_&M>"QHW!RBNXBL.*2]DNQ&'J_6:,
MA[TFUOOJ[J)/<](H&(39;WF?6=X'(@PT)7J\8JOM8:RSQ#-T*R/F--QHGVH#
M%'>&15F?")I .$P-A7KA+4LEFCQW1*$, ]37+HF#<OO0/[!JR'._ ^W9N9#@
M,[E8ZI*6%1ODKL_K%17<K\'WT_9MOO%F,I@AQ[@>^)(^O^8)'-[]/=:C3UQ-
M-*;;G_<A=DW@C#0B/-OO7CS,,LUK<@%,_<#K)9P>=3B<Q>A"NG%A-YD7>?N1
MD#_);KTZV$C(.%;EZX]L#,R3G>[^&9GSZ@ZW=?,MP,+7DU)#ALL833LP\?8W
M]AN.9M1L9-H.E7M \EK_#JA'%ZJ)0,Y[8+__9;J*2/\6BZ[HU9%=.S SE1(I
M[=H$9]-B439S2**1 2P\^9:+L#P6*7<[9'^,$QAB=\[!NW.>QNZ<V)T3+62T
MD(=)'3D%.<$L)3#=C&OIQCP^2(%\T\S9SHEOI<9AO#;/.^E$/H1?:3L,^1S]
ME2'2BH%44O,;4%#$9.D]. ;?HL0C&0EY<^#FE2E6RDS)FL<K(-S;QZ_(1$J'
MD!;#9\AJ5G.]7ZGY(8/NO*$@XE.&H#[\%<G RL\SFLH L-UB0S,7_)B.AEV'
M&N+M@L;6PTC?JJ4[\G/3/?&T7:9,KH1@QB50N1>0CX6]ZGO,-TZ'> +SIM5B
MMPB-[,OQD]"AHO'F??4BK]\9Y/W2>[6PE)<CT$@9&CJ157G\?(>L2E11447=
MH@?1*)>:1LA"FR&6(=TQLN5@**\]:H/$#6H"PE7C#ZCQJM=WY9#(=R4$1HL<
MQT$OB R>AZ=R899N)D257B9GYF@\=\%4G0UDN)<T @.ZQ(B.BF)T E-X/+7]
M\>>":+ZA#MI1@8Q/Z/U(NX2+VT5Y/(G*(RJ/.T5C6,H;=-+IV"P5^CG?/7Y\
M.CL]/359VD7:& <(OK-.-QCA<A\!3GW9YT=<#L['6*L:LRH*'L;4QYV>YD_.
MQH"B<O_]6JG)FLJ3TWB XP&^TP:_72:E&])H?5C67=UT*=EXJOO*J>HS6G%_
M-@<S,\?1*#8S1&O,H%[\!W<SR64@5E\SH!AO3+$#-L7J=[BDPYC7D_EQ=QZC
MEEQJ7SQ[SJ%_EFZ:'BWL>/?2#;6#40DPW]LP;=L+!S3%Q-3ZOP^GUD\KCD=1
M<43%<9>*0X#T-],-?B@1T@U\]F=0,H&D!'D#^MCK<Y8N$$>,\U(]J(2^[U4%
ML_<HE[A=3Q@:">^O?;??AB%:7R'84@[S"MV*JBR5@Q'MY6+2"[T#./!KX]+$
MAP.=8^J;C_P*#ZE2(C(NJI7;]Q5Q/C&4M43VF.5&N&ZK^B(M\W^FYO1QU,"\
MFW""/]+9I#L^>OK\0?J0_IM/]\LJ4Y1#P!M XJ+-VPY'>/+A@B8@G"SIW4\.
M2_BVGP"#TM6;A*JJE)7PUG)VHE<S8O"E?^_!!2\6UC?U@T?R@Q1&98H:8C)@
MF[?U-3$^\(4J59V"LB'"[D5UH9]0)6WZ!0,M4%^@* MHN0: _-]//I[0HI8*
M.N>A&43K3_P%V !@XVFH*=P#01B?T%.VAO?;^ZMK2D+!W0&BMH!&?,>,;\XC
MON9'?$./^$D_XDO])A'DZ+2@L;<XH3_/=\GD1GS<$?!Q;SBQ4&D94U)S!%#J
MW+8R8LM$:1J?3)7098N8W6BN_$[H/&]N/.R_HO8P;':9)3 #&!TK<H.@%1%[
M77BF(=!D84,8CYEW1OWX(X/<."<.D(_V^P#5!"V@UG 'VA7],OTJW4AED/2X
M#&W&7*#SJ1GF[!A;2TFBA6Q9IRL5(]HHN@<276YL=3#[JE["*P/HB?%D1$)7
M2FV=6VAF,EL7EQAG@2F#-;5^JY=H=T"EDQ0$B#_TGM55$84]"OOMA7W&DZ[&
M>D>Q^8YE7V74K"<M=GZ':H]4&5MC:H5'!!,Z<Z5P]+>"GG8^/WF)9PI=+#A'
MCM_#1:'1-6%J!=%@6K@A:\0LT70@\8[4:ZNM"E+(<+(I'IMX; Y0[V0:-G9G
MI&HY*(/V2IPV*JX6A#@D:V**'U>8P0.@!, >T5/O#]BD-EIP_+&OC%*'U#J^
M-;](]@T.R5Q1^&PH)JJNF6Q$B^?F'IR;?TTXL(\A!/7-<*#M^7*_T@=[MMCX
M,<940TP<5Q,;8F[6$/,L-L3$AIAH :,%O&41?0XH-'(HOVC[U1#]._1VEN@?
M6I+=R4)S=,[N@6A^JU((1*\Y*-:K"NJ40D6'K55UB@#M=9TO# IS6*T+$5R7
M905E"BK66=>L'H5:11F.,GQS3>IPK[5J<8E<G2X-FU,E8\8X_>]>':W'(3<@
M5H8*7PW)8 $<Q-E)4:KO2JKA/4%.AJ0U7ZV!_$2:\4Q5PO33S<R4)"V4EIB6
M.&P-9Z* +6*Y]UX*Z+<_,,;JUL5E6L#4\8!B17 /92PW#MFFF^SQ83]V\!=G
M*/O=J6Y;&:8XIZ@PMU*@N?]80UE#GT/B,V,*3F=BN=,!XS 406]92>Q=W)N&
M(W$@N\43V&4*.O?+]G*W8092&@=M6>@-BW8T,O$,W\49SE0!K1*]\SOS?2<>
MT$#BW+2FBM '?<^2(O^S Z\(3FWH%/ON&)1%*B#%155A&>.I7DD?7<"9+G+B
MDT ?#LF_FJI #(F]($4T^8K!F5"&Y+XRO#"0[Q:[75,.M*/I\*G[2FZNN*G]
M4A52M-G8,5D\L$<?]'S>@?3',QS/\!W;86#,;ENU6I,C6<GY0L-$/B-']T@'
M :FI; 1NG!95J:0GJ4\800!D+0E.1_8L>9 SE-D#4J)1!]M(*$J9[(!&G)@C
M7/" ):9ON@5PNC!JC!@_ TJD?RH!@O:+*A=I74FP!BMSEZ9]:TM/0YYV#Q[A
MJ"7'TPYQX%O2>]O.2OSY*QSO*P @K596E:GU L+MHB%N4:@XT#2PM,;J,I"B
MIOHR+1#'MG9@%L.X$RW)90MZDF]HH<S]6T,P,,\K#)>KHKK8.*5EN*K>%MD7
MOUQ'CD\_U(6_+&$@X"PX:'@&]?!L#H^#22(W- < "=S5,@*XL3>/1IY)+#-W
MYB6P&,##(LK5P>JBM&BMY,@7:6HC1@YYKG41'=850LT:.FAW36JI=X]L79$O
M('$+RA7:CFK:GVN8F\!N("7$FD9O^H]#A'=4\U'-WU3-^\J]5J#W4"W!T,%Y
MEQ=XF/1Q7"Y)_Z%"-H-TNA)&CO?'A.NCT2U(IT$G7*45L@VJW( (FRS:JOH<
MV[ZB8-^E8*_ G+-H>Z:(YM?@0!OX3-P.*3%P7+'RB;&<D)ILN?:("N&("#<;
M^7&*/@$*6D>H^*&W(&_C";A?)^";$WA)]WHEBL!0F]$9:8,^G@$5MQT%R YK
MWL((CL,1I'T 4/%K@K+SHTE#'*SR<#=ZF6+(G&K?\3?H]_Y@_,;757VM_U/V
M-QB\'& !?WVKK9X=(!FZW<TNK \Y=P7V=S V#]Z+YD'H'X4+T8A1%[\.(BY]
M'#Z./=@)N%,J&E)/@(>$$5)E9J8OJR^7:==@IG@.#8@U!,@%-4CI;Y *<&D0
MDI5TMAYXA2?)FS(1W#]<Y1I:5IR.Q<#] D@6",L5Y!'3(2[ :#BRZE\L/*'!
MYVJ)^N'&>ZRC5]QC'>KC!+RN4<NNH&A3/N.T"3),_ E]R?E2QZ/:C_CL!WSZ
MU&FAXE!4OQV2="&";)1L!VZ;;(E+L8D+,AH[G5? DJ,7!BRY,#[,F7IT\R<V
M+1D7>HW R;=<*B2_I>42+:_\S:SXTXWO9PLGT$9_A=WF=O*-<'N-/[UCT"C%
MXI9[;$;ZSPYH]"MNP!\?AV;:1S"_@K/6\.S:H3S.S&7*4_/X"I%@=[WR/'0R
MD3>$*U6<*S9#1V?<:.ST" Q5]J_G]U-9SZLBN[&J/CMW=/7WWP>4]5659[?"
MCYX-[M<S]#_I!PA9X[%GI3DJR5NI60!;+8NLL?K1W!ZA5S^$>ARU%?VNL9!-
MY9._QP#%=:W6:4WZR^@M7 P3%TG.T<[QH**8F;INA0CFH>;:L2\Z63Z1(0&?
MB2TFC];"77T("=RF6UQ:T@WO >QB,-LC 9Z,;<>LZ&"NK+>VVEWY;.SJ!KD:
M,.Q8X8<ECF^!+:FE*^ O,$4YK^H_5[9:%ICLY=4:I]9!G2/Z"MS@._Z\R0-8
M$P<M(37 GOG#D^1% 7D'SOV'OIK$J2RQ">7@32C/8Q-*;$*)7L>MO0Y/%D))
M<[W/W4JJTFCGM;&L.<+U2\,(4TF+_\_>MS:WC239?M[^%0BV9\*.H"F2>ML>
M1LBR;&M;LC62QG=FOW2 8%%$&P38>$CF_/J;60^\".IER5TRS\3V6J((H)"5
M=3)/5E:FW#1N,+37F!NUV\VU3G*[-U:6,L\1N:%3I"]K'F>A[/PP;QZM-(*5
M438\MS9P]GI4]^IKAJ\K6>0[K[&N1LC7SV:![\D[!^X5PE0_*$PE'<6DY",W
M>B;)I-R?8\0['LK/'4W])-$33?XO]TL.=64^<R:)NZ6'<U-"*QJ/?4\J8NYL
MDV]''P8<P^:?-:]NYT&3RHTO1;-3W31L%8YH?"'Z/Q4R,\TF.2!&-E&>M9]'
M62SC57F' .-6-VW\W&++2!:Y&*HP/$LSF])<D+:-;A&P-;5-4YF+PGV0JGZL
MJW(;2L61R_'&:VIEW(7UW#4<][V2(F^95,:P!_4=U[1W4D$R1;%$$?ZDP9$@
M2*ZR$.R(L$0UPQD;7))L*V&U(G6BOYL_:R<_3XV/]3?;NCZMKH3 03L^.^+*
MOL6R+@*C&PN_%-"9\*J@21,I [-,\0NB*QG*,W7BVL7850Q0Y5FI#1Y-".7*
M&:ES[I*XQ:DF.(23L>O+8^URS8T#N0ID!5J?LZ(X)TJ.^[J:MOQ.2BR!?#E=
M_(33#F.72UT*7RX]A31R#3,2Y?7M6(,7IQVH_8-0NQ'3N+>VU!<3B%"D5D7>
MTXBWO$B7AF1E96PTB!)2^S9=$LM+_>NOE(%UOVBJ)N^43.C+%S04P3N=1<3Y
M8%\A0.E/M)A=<X7>3-B;TC32>J+%8:JILL=,,*8:/)VHP>YYLF2A&^IT-#7*
M8C^E8G7H!@8[>7D7\=H2*DK3\F%O[T3GO'W2RJX2^T9"'43D,J<7Y%=)\-1R
M<]509%S%CZ?YV@J-D9/W*=_#S0?O3#A\DXTXM::=MU9N2\'Z ?\DOKFJAQV_
M9*F:$F<$1YX89?$2X\</D1N]JD^.?LC-@I#BE-"A8D/&2!=. <.QKZ,OE4)*
MX8^1F?@VDVW:$[DK8+J5Q\84)O(._#X2Y\D#CPL-S87$+\%IFHLOB\U2._#L
M9DW-/;5;>$R\T&0N<(YG0YT8ZB>FXO&,':,\130O#&:BN1WGA*WI%>^(DN^;
MB/V(LW@3Y^CH1-Y?;O@M+F:SA(MEK?2<R0VO95FO?FDOC;QATYT6_,W"HU=O
M5Y?O-6\WBH1Z/;WV:BNO6+*W6W;*";_F>31'[-W<98)5UFU#5\3B]?/KR/5*
MR^_$>^1&C+>27(W\T&3)Z\DY2R( Q%_I\&B524I$(=\6"$>5DFF\^T"+E1>4
M<>L;S<$RUTIHDF'ZMS<WFBW[%$O[L_&7\K0=_FJA>5-9#5[4^;8"%[7[(ZN!
M*%]IK+T8I^$&_/Z:MY1VZ>-HJAX9?M?HLD3Y<*:>M#X/T''>9S%_Q-S(5'9D
M=E9NN>>'$S48/WR(H0R%Y])P^&%S+B(O4UH\(CX76@@>4[U41^74(:WB?,A0
M5&#'5>(L^Y,=Z7T:V'R($>NI'8I*KD!T(:0PBT0%:6"2^IE/3AAHN&ENZ*Y7
MRG/EFSMQ%A3KH$A,44$^+2#9.8&&Z,G(C':MW>^7 ,O=7:*W;4-YV5YRR.,A
M!*Y=Q9%Z<--1WK@IK:-I?[#8&,S/>ZA42WVFI'0,5X90W:0<!_'SZ*[F7DZ!
M85K_1I&7R4A)<?GUEM"TTYT;VUL*JJKV!O(R#JE6NO7*AGF-<5;DEMPWMV3!
MI#UXLLEA[1!&D6-H$HU,A*UZP*T$NO4-?QW@E^>QRE'%F$^A9;H)L^ZM-@M<
MCV_-47QRP60P0'96))^P;4*EC8%8),/\4&])M3=18>;YM8Z-C$;G[?5DYG>>
M6VQRZUR5\IA'X<O^5HEA+4V,,=W,6=UTQR]C FO9&E453#@(HCMI*2RK[A%5
M^K^XCNF_4]I^@GO^ Q3N-S&7%'"J&C*JJ0KF)F'U.L]]]*I\X+>R$5G=TJSO
MH)I.[\6^Y-0=R5V*_\U"H6[8[_8W7E>.[9K3::4CPQQ-C[Y)928;^JR_V]G:
M5%^G^0[TH_.GD4I6[]_68?&1.@W'AC4RYVU-QE/9[*I$TC%W=%4 +G@-Z?+/
MB_NVIK['@GO2KD35Y.UX"R6:"T9FF:;%.W!1F,D!)'P62>TVAZ.\S08/S##W
M8K#Z=''ARBQQO?3)5Q.P*-Y;W:!4&^%U^9"PF>9$-(A*\2S62A*WZ4X7\7'D
MVCQM=_H[U6F2&I@WZ@Q4L6OV6"O[SPT*H@XQ7YH.6I7G]#8Z-6U0H[FV6V"6
MRC/QLK"#_,X[X<F$;'6G]5[;H2>OJ[A(GBBH=I^T'[A@I2N+829TO\+%UY$=
ME?N=[D;QI0Y*&R.K[,&SRG:158:L,G!%>\XA5./@I\)-V!<S,4X5@0 +^^O:
M!]+-O8D\#2B/]WA^HE/UI,=Q*9K.LNDY9>-./&N)'Z9]G:8H&!?9J>I%0_1K
M(CC0G$U%S">+N4>5JBLCLSR"_%AQ]3Y$ WW9>\V0O+9V;=DI3<2RLU(+9Z3<
M94<!.\Z_@E2[8;=X"8Y3ZD0N&><UI_GET-7IK$J(56VBZ7P<]LB-P*0OIRAG
M7J58=2&Z[0PX)>%?Z0#@D-PY)YJ9[$Q5A2<MZOR42AKE!\'T$"]=71^YH8ZL
M/Y.Y%4K867$ <JB3"(HNM"#"/V#-[Y7T28?C*A.FUF:S]A;'7G,]9B(4!-$5
M:^5SO67E5D_\EE/>='#&, BNHLTA$U7'3FT>^%-6+%:H%RCHBC(4]RY#46ZU
MG1\*"WC_;9:?TBJR4C7&Y24139MG/[PD6)3J7.24RP-N*F_(U*ZH0:)'+\-U
MNRN5MI9BH\K#<..BTWUY/,403,]I#@P5&V*RJW7Q*CYG1^7U\$;E@GAJX+%_
M*2W6$D/!IK:(E\BW0T%'K,-[K\/[.B;EEN[+O)!%?P(:"XW]_BXB"[V>I9M-
M;D_,M7;SI-&I+#_IN%<$W7*?/>^FJW:C"H2'/D(?[ZV/$Y_-OW0G)#.5W3;3
M^@D:3\2R7DB-ANH4D/+^CE3HQF[0FOB:$R!%2=AVO?(\X7GNX\BK<H?'3=&8
M%MK^'?42R8*+U)=<,'3EH2>]-T_OF25I+,M\*JJIP%:[MVA0 [6[G]K=%+DS
M_>['_B@CS"0-'&4R9<FD=J.],-3PQZFA+) W5D'D,"IGWIKR;,4!U[\BGBQD
M C/O[;C#8.Z8,_P1ISDSE;N0_^@#K'+W9W$1F9R5>F4Y4URT&'N1S5&DHD0Z
MRX>>*<*)=&U*-]</5H7Y>;"+%035@!:G &L;:_M1US8G&7GZE&B>;/:7KN:\
MI@;QD O=+B'O6R!/<$2Q2I-:<F\Q'JO32^;N4^&JM:F#EB:T(X^EJZ5L%G"Q
M,LL$A@_CGGS&6L1:O#?+4.N,-R";.2[9DLR3Y$/:%_4E/L88L.Z:9.%Z!>OG
MU>KJI>XKE<V!VF5%R1W-["7!I@>%XAJBG7(1W.0%5@%6P;U701$=4C&F>37F
M4P2)\JA[6W=_T;UI5;.=_ A;T<V&TQF@FE#->ZNFWF[-%2JO*./$JA"U.FS!
M7WWW8?^(,;9HT&=V2K5CH7*>KR;58VBE^EZC\E'VZHW- 40W4*=5Z$?S'(9U
M(;Z6AI87@/;C2ME4/RYE8S>-S2VJ*1<DY)T(Y-:"LT]K3VX?[TLN$V-["ROK
M_BN+U2RIAOISC^:F?C%YL@]2<^S1P*??(ZE22;Y4[=$XZ7ER&#DG?%) ]N2[
MXK;$$W^6GW"I'LPC_5X,*^6]"YOR#V4FI,QTG<5<YZ_-[2#Y.^&-N9V&OO^1
MC2[R/3+VE)*D?+JP='#'R8O2%4=T:O2A4G@[/]XEO^DGA7!*-?=,]E#3V[TH
MB>2Z!Q6EJZ5-%*/D^\,(8"F BP<G[XU!,I4U-.3JC4*>3),Y;[&HK',..1?-
M1,=B)-N-TIJ(N+.Y^RVO0M\N>XJ<:%X\K@%;2@E+G&C(N:]<G.*"GBMO*Y,'
M9;8>EV2,DN3V VFLKZ3>&$L+2^OAEI;IJAEF?!A4U7BI;,(O^HS1D$24%U^1
MYDDU9%;U-P5TU2Y=K8\ZC$+Q\RBPC@[D/+M@\PN%?K66\OY"7H,K"_FPJR?7
M@.NIMLOR.+.LJ</U;-4-S?<]/_:R:2+/*^1ED]23"?L%^ZQ<#HO\5CZ*%'&1
MJ]?HH(&SS@]]UKG7Q5EGG'6&.84Y_2O-J=KJ)XOG3>0!*C^4#&A*?R]JF\@Z
M]/7&F(JE28HEZZ'D73XK!ZCBTHVKEO>YWQ&==KGVTB&#[*60.=$'E[PV$86P
M8;W\-$M#'><V74EN//V=1PZ*XR7EH&>ER%*I*XE:=IKQJ^28F1NG\Z+77'4A
M7$V$KNM(=S355?5]Z[EY KW>L2@>.*.@E)M::*S:<KKE'A.KMR_RD'JU80^'
MY-PX=E7)2+6)1>#.;1=**Z*(4:B%X\<F=B:[J>0!BV1A1;!EJ52OU(7>2J7&
M8$7L63!/;GU4B[(5F5_EXFQ^DNB#VTUYT<5BN:[ F[Z'K"JN?2;98[6>A5"^
MAJBO:5WT/0FC.@!?ZK'!E>^<]Z2*2BIG2^ZY8>ZF+M7-4_)2GW)YZ[O+ /F8
M (03RV-WE/>8:PK+3Z*\%D71PZMZ5K/\'8T_+'^>]J5]$,QH70-DR X',GP'
M,N@,T4*=VI7:L;HHK8X[EOK2F69UJ@U$6?,K*JX*#!5FD$L6J>JBLMU'V[1P
M4P! %M-S9ZXGD[R3.]Z61GL9<;V)(+AM A0MW080JY%%=Z3+$ZEF)7%TZ0;U
M9R]Q,K TL33OGXM8Y'%'0[G\7.>3FXS</QV>"',*2;J>$U,Y9FDB1E$?V)V*
MPLJ?DZ/LSD26^AXMZL/0ZW"I%BZ-%[&^<]^=>MG8TL8:B!Q4_/OV?;\2<YM$
MT6AI1D6QHZL].FZJRXT9754\'[7;'KMVVXTQ)C=((J=2N5#OX].WJLT6&*]B
M/_DJ,^)4M<? 'YK4_W(]B8:2CPO5MVO]477^,I))@5P_HEI/DO?(JT/75$9R
M=(,JF?LOY,:^UN,B$NN.+@770-4;&-JVFMZ081AEI0*7I0=HFQR+65:T]BQ5
M1,TKS14'&4I_+?R)XO"FYM^ZW:_^35S*#992EQ[5*"Y_I=?.4E'<HSYK:3A+
M)!C%I5\:VCD5>>9+_/&'F(/O>[,?/G7?-]R%&0=F C/OGT"K>8JT]ZI5'F_?
MFN['*N,\=QUN$[34C>JJH4OU_*8$_ +'QOXWU9/4$S/9CIR X(\L255W'^[B
M5&\YDJ?"%VVA;I6X?N^U)X\ ESIFU,YNI8:3F1V(S#1PO?^IA>62:SZZX$^G
M8N2KAB!%15Y33XG4<*$-NNRJY-/R=V.^AF<!F ),^0X_S!CR6/49NJXC4A[9
M*$4TH'W0OH=C 3J:G 4TZ=>D[+:+%.";4W_]<9'*6SF#4<Y,2I-ZSE-S_P09
MT,M;_UYB_P@KX#LS]9*O-Q'@(H#GEP)X4ZXT(G68NU($05MY8>6&%RI!@INT
ME3K&CET_T"=#S*D/S8DJ1^LKE;=X6TBW>RE=7B56; _$][MM[5MP3%OH.Q;^
M7[_PKTOD?7)HH-H6^N%E%%RJY5[O$VUX027$JY@4XX)J>3@>1W%:4_N%MCJ5
M;N5&IQ=NJELQ<I? .-/EO>@VQ=HL_Z$@D+4ZQJ7Z-+JCC%QHIMGT0IUCQ<'H
MVT2Y]"E*_MCTH92(QCG#AGQQ\D=H?I%Q;IVY.8I*8XAE8F7YH^JZ+YH1*1 R
M[^Z.IGZH4ULNY68AZ4\HN\ G2>3Y;M[)2+&\,H>3W>NO.SN$/HDX.W2_LT,]
MG!W"V2&X'' YOB]+IJA%FK=*EE:T2+<N\MB66'>3:U!J]UZ-9FH'6IKDDD\R
M<95'32SADNL#<UJ"D <AS'T*-I![$-P)4)+V:_R-MDRA=3GSSDUTS6"V_?JL
MD@PP#X4,$M=:0L&GMV"!/=6UQ#WT"C)?.P*A,I:+4Q#5+95BBY7\4UX3219?
M^CKVU)@\UL"393"!OE1JD%[H/NE1(B-NRRK^5ADY%@(6P@-$M32U2MQ ;456
M=A^'W-=/IV(N[JJQTGINIH-*L]CWBJ!5?1-S+ -@<@]/[F/DIY+RM9%7RUJ\
M7I=\D!E0#2<1FDP9,C>Q0NZ]0DPW!)60I_+YZI&$Y7O&!O9-E*::G:?N-A*)
M%_M#D1\,2G0,*?73@#Z5[]U]79'584H2]YHZ@_OR+TWZU!J<\DI_KWK'YGVB
MZ>:]U^K1?L)1GF_SXD#0FHGZ9$@__1'II^<R9S,6%Y&*=!?MQW0\VV<>.U)Q
MP"%GF4P(=#G2U29_.N5OR>.AE^H;NHNPK(\SG7)7'3[YGQ\9*4H F(;"U38=
MM^M:K+-;S:5N0QY$*3_UGGL.ZML-&P_+4V1YP8KAO./LF38G<L]<-3>(+F4)
M.?K1#>:);Y+H$E%J=J*%4EVU41QE%Q..I'I9DLBG,@:H ?V9B81'HOR_>K_R
MQ:@N7U/IE]Z^I<QK?<[5L6#52+&MFH5S*HPFA_+04Q8J%U.6?BB=CR_$Q_DW
M<NWHKM/+LID+O'*'),:.\]:4\)0(LD2RN8K5+K_M&V<T\_Y4\4Z]U3NZ1L7*
M8?'O5[?O3<M>Q,Z/?3M1<TA^U+TQL]<O@>;N;@-J7D;^Z+O"?KV%Y]6\B+?T
M DUV<=F[M@:?9WZH(>N(G%&2926AYGU>H7]O=.DGD6P24_W*6Z.N[XRZYCX$
M3.9CF\R]1+DK.9Z43W22C$1X8>"6W$NV!"/Y[6,W]B9JG?=VVTZ_V]]PGO/B
MU?[607'=D;Q.NTHOE'X0$6%LI!M)I5&]=E)59:=HZN JE6G:'*P'!R*ZHTRB
MD??+=2O2VED>FGJBUELSK 6M;#J\DG<OX_KYII_N8KIJ6T7=RF\R(X]$;E->
M^N*J;6Y3/[3* ]"E5C^'SA[QP$#]UE<2;CMYO$7:RH7TM<5!M[6 E70TZ$=<
MQ%6+AO<7APG?+TS).)"<QWX\56#,1V[('LW-:U[%W+4IS*6J5*%IG#=+L^V4
MJFA7DGVYR#4+^+O$R).E1\VC-#]7YEYJCJJ@G1]>-(2%\":;SG0)CC\S6EQC
MWRM%MV094OU[(F1:L-+*6/@A#-;#&:P%+'MP"R99 [%GN8W9K"CDA[EIZGH3
M5:]YC[#HF]+XMTH)%[F?ZK"=R%K),;F0QL&)Q9ATA)S#CM)3^C'*8NEN,@^H
MZ+)$-7?4-"#%&E3MEW0N\Z'D%D>AMN0ICQC/B[XA*KK#N>S*$2/^DHHJ;<E5
M.U\]O%]!VD<CER/H\#'@,A]:'%NQ'-1J8"GH%50300ZGUTJ_HW_5->2;Q&%>
MGRL$&%=>O@N'U'2MJNN0_682IMY[02MDR8Z&=,J;'JCR,[DC5SGY3!F82725
M%RAHJJJMTCW9!N>IG?P7]ZN0-U1SJTG)]9:3"Q?PMZ_\1'3@=/TPI^NP>58J
MVM7./:.(ZTRH9H3R_ @)L=JX05=T=T@+PVCJ>]PG+OXJU HHC&>IZ!0IVI5@
MEJE AW=#8U^NR :%T6<PJKQ-EO(07A8K7ESJ%5'4EZ?OM/G0"]-YQ?PFI"X)
M#M,BF'RO8/*I-$7RU/@H)FF@E H4[)$4C)OC< 3NO]P$4Q^!4-D3C&NJ\QL7
M]"JH:A[W+(>=V2^1N1DY*S''Y^I5@8H@*:>JIC)_0S#'YLB@3-B(Y1/S1$OU
MQ%"7-Y)U!O4X]5Z+" 0',NMCS!N%DK-"U"J+0S^9J'BW,C@Z"%>*L]+@;_,2
M6'98=H^P[')%5AU 96O9:W6Z5!I$;7'?5LGEMZ'%%FCQ3Y-V^$YM=.5)\UJG
MIX)/KN<<NZJ&ZJ@2?5Q2>(GONOERPTF#=I.;KXX+F','B^B--A](U7_X5/T^
M4O61J@^;"9OY2.Y@X>RI#/=RM==$,R7EZ2U^T^0AQ()S.F13;<ZTE!_'KF1?
MVN;J#,XZ\^-O\5AR$B;WL)1+.>+@PRAW5^%'6K F?C[U+_R\&ZJ75=="4:AL
M2?PBOYMY4$)Z++OWYNZFRM$TYV2@^%#\OUCQBP)_AR>?5:_:O(0*$!J*^NB*
MFOL',9\"I!DJ::DJX%$#:*@<5.X1L)'3VN.P%A?E_&&1U ]-J+*$61PZTV@D
M IEOK(HI<OK%7+BQ3!GY0WCY3K&LF9&HW>3*N=FKB9!;#1QPU;$I4W@P=GT9
M])+=9I.,&T#X)L&,GZB\"W[21>Q.D[9VR76+I,6-E,6@[HRN<,N9]CBGA/7U
MP.M+UI):5$:9^U#\*3_HH)I]R7,2U8N+99FDM!2%_*Y:GRI-++SDDP]YRR]:
M=(T>2Y[G-,MB3@%*FO.ED,+SHU)XS)&8:M*Q3IF3JA3'_J4\ I$N3_&9N-SF
MC?<':M5KPT2>R)!)?5HW8SZ?-%)?C_C($HUV)N20G4N>#YVEZLBTZ9):M8L<
M5]<CN':]N598Y42;=&8^?'+3MG:1B2<[?XRJFQSY#MMUF\7.<ZW+U<YWI;)'
MY3/EET*FS!7-L5ZT^7=5J8%S+Q>I+?_938K\-CTKRF#H5,9<_#*/3Q9AY#2Z
M4.;1\:@X'U!75LLS++7PVC7)Q:4>?5J6;34)RR9HK(O5E21;'I*::3EK-T^W
MJ3!<R0N3\J^=EU+&L_QAGM1^Z1=5Y-JE$TNU\YKJ2<;@5TM<\7HPN6'QI>^5
MVRD]+QP1\S9%$K6Z::F5+GT@BL8U*I]-UP600FM\F*GCY0E_EAIE#NG7).%L
MU0MV/4*^>T6S8[F701 ^SWLV)?ETWV)(,NG;B(RO"?RQKD[&,^N)4G$^'E".
MYC-7ANHKBRP5 7M&666$G/%)JCDWS8[K)VB72^1%QR&D,H5/VC6-SXU5FWZ-
MY<><-YO#S;Q4&D6Y@?+[\B^SR3R16Y-^J%9OD3&KA^NK14OFT11H,#IIVN!U
MG/=9S&\X)4@N#TX/X5I4-,<'9#4S590EC'BO7^6_EDIT:_VN'3,8BO2**[#D
M1P34-.:S*#^3V<F^JAA3N=KGHWBJ/:XH(\FU0RXMZ5JVMGH;UHYE.+L$565J
MNH2D5%3P7!;0I/OEAU0URN(D\H]P#]1L$5LBJ?.92S:1@>N;965,C42TN+;*
MY*DGE<M-RRA1ZXI_*UJ+\V^R DMDLOC9-@HO+Y98352GZY6I+%:8[E#I7G%3
M22F*Z\_*&!4WX* 7GI M*0LE,^6*_%S!!9.Z4I66QE2%=GDSIYS64*YHN)C*
M4+33].5I@MH+D':G%=];'\U01R-*OH)97G6/0!5/U7-6-KVBR'=NEW.?==L_
M(K]L0TQ30"D$_ENY6$W]'0H(UBN=L:G(7"IPWL@ZR=%3$H:;3ARP,R1GNWZN
MNN0+C.BYJDB5Q!T]DN* MB8E^EN%:Z6Z-'IL9V4AJT+FO)@\-Y%U+B]H3#E_
M7ZACQ9IALL3=HNYT$:\H127:QO,C]?'T:753;LN<X"_U,^>@A:1D7-U]L?5"
MK<;0_1O+IM&%"H@4U37SU\R+O\@7DB;:U(DIE26C!7')EI.5DD0L$ET9G,=U
MDL6TNDC:Q2;/<Y>MT%BJZ&-7OZB^SG&A-._RL_S.W]WI[+6S5SJZ7AS_W:^D
M)9V6]F[SY5XMJO%"=^H5JNUUWF9^G#%C3I/2_FX>E4HGJKY O]O?;NOS![+Q
M#WV+LVRK"DS7LZUUA*]<!HG2?,2"0VL\3>,@NBJ=Q(\E#DQIX#Z9V&2)?L@#
MA7GK74/SZP=YM/]SC7.F,4:?=TJX3&Y(G$UZ5$2:JD5^<B14^J(.%KFJE/58
MC.3QD,"],N5FV4J0!^2&7[F@K2?SC\M/,$<^] FQIL-/HTCHXT^C$1LY^4Q9
MC8$6@OM-2DL=6)%=FO11,U-G5KMD4UUGP"T5WEOP IVB7+[IYWH=T$DPRNL<
MJ7+@(W:&U8K70RR<?C5<2=:+\>J3QS+^*7.?)V[9X5-$81:S#]XD'"T37M]A
M,'_((\,+M:.,S=*^AIP41\4?$G/&3!\)4\K'G)1<Q(*&EF;"Z+B^( <:_IBK
MN>DE+_/&).;(*BF-AYFFUQZ;TYS,5]T9C4]L#C"5"%;EU%).B"H=$G2U=UU@
M2\=)9&,%6>,E7T:&]YNBZM?X.H>IDTS,'>22(I&;SI-NP.SU8E(Z.%VFB:J:
MEW+'EL=\\N6C;.<"U<IF/+RVC%HD0H<7QGPT>\DYYF4>9](4S* 'C"+"E ZJ
M-2,%],%30->1 HH44$05'BNJ8-S7O"^0C!3D-:G(P?$3W=<MJD0W#3G7L5M9
M@EA2DN+\O[S 4W\DQ]LK567Z5\B-A]3FV1G[EKE'S.]&KU.*K[;-GT;1E&.F
MGO1#]==*(QI&HWG^W5+LH.PY$J6*1O)9I9/%'O?B$Q67C;PQ<IS8,2\*P0ZY
MZ',T*[W%67%FF:WF@?'"]J/IU)<L1@612W6+BD><<7\]<CAUS:)\Y,9=7O*&
M_#7IJ"+T]@,6R7L.%97V1U7EF\; 6+L6U-(A4Q,I+<):)D"4\PY#"DM5;&ZH
M@6P.47+_#EEF1X>6-&_7_G?A<LO06AIG)JH;,[_1CRO=2%)D0V1+M0F37%7U
M!YQW02JM]P?RYR25WBA#8>ZE5HR?E@(0"T-4$1,=MR[YZ:9KGNGFM$@S\BKJ
M],=$E@4Q6T)7+E<<D@N+"VJ8K2Q>94R^5%]?$TG0.R^=99RQB-Y+\53'4!)U
M4=.=Q<8H&A2+6K^-#":J8^?7[B3*#N>54;!TREM/[<J.4\%IU"Z!GI]\(ZJI
M0-["&Y0+>103:O:P;BSRF$N@%/#4@\][>F;<E8JCL_(K:A=,%X#A9ECYZ$.N
M69.DL:^?9VY-G%,6+9'[LCS'.@HKGZ+RA#05:NB!I0XYJPB'?JFJ7'3UQGK-
MEFOTHJ:)"ZW'=,\Q^7VYI^*;*(Z,Z<XD@V:/2P9+52E+_?22C=GS4F4QH[$I
MEK:^+N,=4KUYBZMVA;%(ZNM-UV]4KY?JP@M?<?9B8";N(X.-,AC$_S]+Y>9Z
M%IBJE$H7>?RZ(I'<!@PU".B:?@7#K&S/U:4IZQT5)599J*G/CY1%<BJU?5F4
M.?:YNN8G"R*55=GX7=>W=IZ[+\S[RZ_N1R.11VK/><<]HT5T6KP#3\<T"RX*
M]98 !LO[(W)B9 7=>KAD,5Q1UA*#4?6B33=7MKNV:-/UQR1D8%CW<W;+]=OH
MEE4[OU#&L"W]2MVO4+:E'E=B9MKS4(ZTVI+GA3(BWU),^?0$__9G%J7&V1X3
M]5*KQ54;Z]S;K&TV^8K.A^8QY@'&8%;'J]K6FCI]^<9S%@8<>JS4=BR (G"O
M2DS!;&3E9F0X;TB4R+B6+X>2M$F2*T5>E@5Z+;O2:JC@8;6MF'+[]00L41+M
MOONF4F^]XIG9!?4#=<*K(:ZL/1KZ2KG4^,T,( >8>DDW=;^I*V^X/"![3;"\
MAHAW+ALVSI-N2:I\PUKKUFFY)!C+ISZ\:H17[R_?KN[8]-[EQJ8-Y<9NLZ50
M$8?$E6#.LYWO"H^$)TTOCTAO[#4]5;GGFA/3QR5/07^I<FY0O5$@<ZI5[EEE
MJ[A4I;,:>F=:GM?&+/*JY"%#M:04P94-X.5G[/K(30_3P#XVFWA&1;7OJR:J
MG,RM7"+IOLA3B77X,-^KMG0@.(FX,K7Q&I?[Z/6]<+D?K>N.FO.5- GJ/8O<
MIR4S6H4S/;\Z9VTJJYJQ/KNI;K?*TR'"I$B)"/-:@Q'GD@M.MZU4T\L3!W.)
M27I4VV<RD09V 8I4,BE;F7&H520G,-51,#MR_>4K_V;U;UI6Y8TA&4S@,94?
M#=_E![4.6#1 VL[+]%*9AE$A6EFR8,15%D<R427<YZ;C5J7BI<GOT 4Z[V#(
M&^K*;OQ@'2BG"#R>#E0JRS9MTSQ^)?3[94F<J" D^9VE *+. 4"!S1_<",08
M/DZ1K)>LG>43M7AFJAH#*PJ4<RZ_:,SD[SAGG$UG8F_R4=IZ-]S>]!6IIGK*
MV*$."+K#3,>3Z<\R2T3YUS+]A8-3FF09J]MT[DM&?MAG29QIED@<4\6$*UE*
M\ENZ\JX,*VHY*?],7^\&$5EZW:VMXL+FV::J+\6LF8.9075X;TJ2->./R()=
M%?Y5&K9!1J]VD2P7'')H55KK6SVZ?@Y.;2M$071AB$"Y='+)UU1>D[F)2BOP
M2)#R]8DP!$(5CI"I_KDX9 +&-7+0%8US/2N=)-75FBLE 77UO>:[E7J"#(7*
M6!H5,<K%=.0&7E%-1N:L%>.7RO29/(F)8](J7^.&/B\+Q:MT]IXH%Z0MY7Q6
MDYJO2TM 92JD)=PO+6$#:0E(2VA]7+?38[:_$\,-#C,W7KB3TVS:+Y1Z:/&,
MF]Q%;>_>+<O2@SO]P]SIM]4>*;6C4#0YVYV-K?6><8TY!)7[PO2\4C_?^LYE
MF[>8^6@"9XE,BU1^?2>=:__*R?>!U!Z@KI%LXBY*6_PI>5*<D4O^L:+/U<#E
M\ZJ#HD-N/KD]Q3:\C*5^DR.ANSSK;V^JQY)J!%)![WDXX(6*U$578>T1N]N=
MK=[?<N>.G?LEMQ[Y ?G<>6:YB1@V=7FM2J\J>Q6J>S[4\LP#6?<3*:E"'F>4
M]?V3?(,BO_/GK*C43CQB3@M8>IE+9=+OK._^6)&46ZBWR[W=BV.$S7G;"]M'
M2Q,E"B=]:8\@6*8'L$R]6;KP^P-9JI-8O'R?-S544'"@ELT7/HT!B_1#D[QD
M&,=LMS8X"":[*TO]P/^O;!M1L1[Y"9IGO>W-3K<"].:$V94Z6W -XD\9T@P"
MY4<!BX=J3+BOX5!QF&M:V5>>KYY2C(+@F BXE^790TK?Y(A"<1&EZA#Y=9)P
M9L2/I"6L_T'7^-$O>/=7(WSEI48_/-O8[-;NCA9J?RD\WJV#6OG$WYFI&WG(
M+7/=P#E16R"?QV,5P2OY^PB)_^C<\7BA=-UBY91Z Q->W;+ (LUN;Y<<&?XC
M1T[G:_35P-7;QVL\0G(8LW 9$(PC+RN=C1SZ$0F!;N8)0DM/'G^M5&V4^8!%
MD4>Z)0U#G_4^X_QO+J*O&T]V>]NZ)AF; P[*FH(8=5;"][AR59HYHY9'$"2?
M3J]ZP@=L=:(=YWU<J-UH\XW2*:^.LV>.@9FM8C7R<D:/"L?*J&F>*J0R#7Q.
MNS!9RKQI&!H;EE1ZO-"5*DHK*Z?E76"* Z1[Y>.MG#M9ZQM=BK&J6&YY +J!
M'8V#W6Z:QHG@N>17E>W0PR1E0?KA)9\-3?1<?*NF7*GH^1_9Z$+E$Y<JM8W\
ML=[WE.*^14BXVLZ#/.V8SR#$?';:R]\I+TU;"$I*6MK*LOR,%6<Q5C*ME%'7
MAZ-SQ#KAHP_R?#_KR'Y^%WT@64XDFI?956%NNVK/MI]*P;F]670A!"ML[,XD
M_B70+&C6@VC63%89.HX(UN0VLO2XN+PF- P:]A :=NF/F$"_]:/$DVU#@5W0
MK ?1K/_Z:>Q"F:!,#Z!,!$^Q"P\+BO70BK7O#ET:5NJR!81.0:<>HE'DX?X!
ML IZ]>!Z-0\198!>/;A>'7 D' P0>O7 >O4Q2B? *^C50^O5;^*_;NP<<67^
M,R 6-.L!-2N>)]Q0@FQA*KP)M I:]1!:-9\*1*^@68^A65R*#*H%U7IPU3IF
M*?F>\S$*1C+C$UH%K?INK3J)(SZM+;($\08HUP,KU_G$CT?.1S>>1B$A%S9T
MH%@/HUA?Z+7FWX!8=BE6?=2<>/U3:)L?S]QOG+]>RJ=/KBFC@>X>**-QOS(:
MFRBC@3(:.*'U.$7+Y)%(U5]K%G.-074TTU5'4ORBW9\ZPJ),P>T.IZKO5LZ^
MRJ.=/+AA*D:AK,@9^/0%79 V/Q8ZRP_/Z,/TH>X#0N9SV:%/FHTX"H+BX*>Z
MPI>MPY*T[4S],$N*=HCR!QX=/565P:\>V^*:K20#77CU7!;RO?[<CC.1U<Z:
M!)KDW7^?K:_7S[7R:)YMK>]TJK4?3-$N+D1V*4\3R]H(X;(YX^.TZ[W-3K]Z
M=W.B[J;1=YQ_)>:H;G^S(N5]LO(-B[I8-9L[?WLM^TB2$Z"5,<EF9 E:@W12
MF0[ZD(V$'Q15U;<?X6%.Z3GZ$)?L02>63I YO$U?#<MGF%U51%<5IZC<H:38
MJGVW;CM>G'JFERK*C#SK=[:K,^.'LD&HTLC4E(IX43X*7BL/TMO>[FQ4;Y)&
MSK/-[D9MUOEDFI^8*L-)?GZO5.YSZ:%)<US:B+*R@EU9K'!)4XC&\]PX6/UP
M!ZL7?<;Z"+[[:/5-,%$[02TK)YJG?8I>2K?AI70#6C4VTNN2*_BWW#4E/R]P
M9PFYB.8G\Z=7TLN5[JKS:[?;S2_1-RHYHM(K3IVN_H>=!J8=/+"X>52.<E?D
M)Z?1U7X49-/PY58^V(F2AA:FO!?=;)2[(?L%C:GXV%JPRLFN_D4-FP^^Z\]Y
MBDN>COY4*M7BQS2U3??FCXOOZN5CU':C])'4W/72!TIYRY^P]O#[UE!5W:QZ
MHZ[R*'@:R&!M$Q0[9NDR'9#_K3,](6JP.&LU5G)%&AY=R6J@)!UY*+G&7/2;
M:^[28A"BD;'H^:\MY8RJ.9J5INAW'NLC@\SN#\&8]6I\X"'8YG4 4X./BBWN
MWPU(WJM&"5Q.K8H9/%EKZ0AKB]96T\MTZP_H+CR@M I[G?X=%R%Y%ZEX23/B
MT<(*HZO8G36L+!/TP40U@^#2"=GH=7;6_VI8;,!$P.']@V^E67Y A#SD2H Q
MP/$G!$=R:7E6_]'JK]JDW6%RM@"4 ,K; .5!'JQY,XS7!K+VH5J"SY\=O[@&
M0.FG>' ?/KA=+%O7^WH11UDX>N7\NK]_</#^_>N;..+;)8M^8;7>>6DO7</K
M=U_#ZS^"\=UFR7%W-CLC0K<(Z\L[/^[VX.(><Z];!/:9M/77MM?Z&S>Z$$]=
M+Z]]H*7>P%.7^:,2'Z##CT"':Q*P@17 BK\"*WJ=[=YCB+<9/GZ7SY=??;)(
M\OC^O;SQK=W[.@*U!L]^>DRY@WYO=GK]Q[&%4.:'5^;68+/7ZVP^$H4$781#
M:)5#N+W66U_KKP.OX>Z!&JXT$BRO"@U4 "J !%J&&?;YS4:5@1E@?D]3@]=W
M-CJ-KC V#\$&5\$'W%KK;8(-PN\#&UQU)*AT0P 0  A  "V#"?O<9Q! $,"G
MK<&;.YTM[/R!ZZV"A[>[UMM8Z_<!UW#QP/56&@F6UB$$*  4P/LL@PS[O&;P
M/O"^IZW!ZYN[G1UL_($,KJH+V.NN]>G_>@!Q.'Y@@RL-!4N+AP,4  I@@Y9!
MAGV^--@@V.#3UN"-K2UL X+YK8:[I[8!0?S@XX'XK382O#O</\#Q/V ">-\3
M0 S[O&;P/O"^IZW!ZQOKCU;X!;N X(+6>X#K:[T>N"#\/G#!54>":_N> Q@
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M]H'V/6T-7J<90SU04,&5]0!WN2U@;QL8#K\/7'"ED>"W>)Z0?\%L,!7>!(@
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M/*N\ K#_ Q:TVBQH62,R& 20H"=A;V% [32@JZK4($%/2X.YV0OT%R1H=5<
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M-Y@G?N)$8^<D%I[@)SJG@I9R(IQC$5^(V#F/Z9U<CSV<Y,T:/W"@)[VTRFC
MO]. [9S9NZ^NRMSNE*:V_W ^97^C<"G7Z\]K#8XRSQ\YL;CTQ948.>E$.&,_
M=$//=P.'GCM-VDX:R<_IICQO_*,?COEE>;*<*S=Q9MDP\+U@[KB7KA_P8FSS
M9 ><[)#H9 =^B)SPJ9KPM#3ASHCN%5XX'*[EQ_VO&V9N/%?&J]_M[3C/8S$6
M<<Q#C!QZ(H_B[[_N]/O=UV?D)'LI_>56NB4OZKU^T7$:7CV-"+Z=62RF?C;E
M)WEN,G%&Q,KI?NK9PO4F3DIB%&G;<8.(1GWEIQ,GHNMCY\^,E,-/Z6TN^473
MV/>2#F_NTF#*+]PF$7I!QCHK'TSO+]2M69Q>$"6"%-.-!;_K. H"GKZ%]0",
MNR_&E;[FT9]$_/"H=S>UK$&>-&A+MCSDSY_I3K$_$B][^:B,@\/VDAP</?T>
M*8\[2\@?-S^9/[%S\\U)HH!6P:_=;C>_I.3Z.%JO'-8$IZO_X6V37^ZS,=/;
MN76V[O[')2ZIDKL<]NLF9[7W'<YJP[VO]6$W[N[#]N^\;]/K=C:V[^:Q5N3R
MB@ J)+UGG7=(.D3,PEP)JE)5VM#D\.KYKECCTA0]#OSL_A#T>00?5V/*S> C
M,:H&-?L3-\Z7=_]NH+,O+8>RF^_(IE1A93G_PVJS+,J$";EF^VJGL[7^5P,B
MT/"!T+"!\C\8')YE\:5_R4[V?C2E>\Z!A\##GVY"-KJ=K3L&ZH&'*XF')S).
M S $&/Z\$[+5V;AC+@/ <"7!\(L;9,)YEP=WWPSCM0&-T=$H^45,?"\0ZO-/
M(N6(]C['@^4'SY\YTRD'DWO;KY,7UT I3K;???>V]C6Z^CN"8<7ZI/LT+4Y2
M/1EO_9VQV,Z(^E-)6%I?Z_?6^MW^!C(.KM7B!_8:I&*O>M;2<G'?(V!T:]!X
MLGAQW1[<HX!%MPP41P>?_@^'7@$8=HK['A$5 ,;C L8'4F!6:>ZO[#S_Y"8C
M]\]7SH?3DX\O !V #GO$???X Z#C,:%C,=;0&CSK]4'50=57G*KW-D#583[M
M$C>HNF7FLS4XG$ZS,+H0X3<@!9#"&G&#HUN'%._].$F=_^=>2I9^,G%IO,[S
M]__O[2$X.J##(G&#H]L%'4T<O;<)B@Z*ON(4?0L,'<;3+G&#H5MF/%N#O9$[
MDR>.R>6^$-A6!W38*6Y0=NN@@WCZ])OS_--_S@[VCE\IU3WY^.$ A!W 89&X
M0=CM HXFPOYI[T$)>V\7C!V,_8DQ]EY_K;_-G'T=]A/VTQIQ@[-;9C];@_VY
M%T05JEYDM>[_YQQ9K0 0B\0-YFX=@.S-9H$O1LYQ% @O"UQ=3VX6Q6F!)'O'
MY]A[!Y+8)&Y0>;N0I''O'5OO(/*K3N1[.R#RL)YVB1M$WC+KV1I\$EG,V?$"
M0 &@L$;<(.P6 @4Q]>PKS4%SU._3T?F_P=4!(A:)&US=+A!IY.J-Z<$@ZR#K
MJT/6>VN]=9!UF$^[Q VR;IGY; WVW3@5"0T?2?) #3O%#>9N'6JH5FXN'VK/
MNQGFM/WTT]X^:#L0Q")Q@[;;A2"-M+V1JX"V@[:O$FT':X?UM$S<8.V66<_6
MX+<HCB/VO@$4  IKQ VB;AU0O(_%GQGQ\_F2+?;WIP?_!%<'B%@D;G!UNT $
MI>C U>U:#79P]>[:>@]D'>;3+G&#K%MF/EN#HRR\P.XZ ,-.<8.T6P<8>WX@
MXFA95OS>T>DG4'9 B$7B!F6W"T(:*7L7E!V4?=4I>V\+E!WFTRYQ@[);9CY;
M@T^1E)YSY [!UH$5]H@;;-TZK/CB)JK:W%N?JUXP5S]*1YV"L']Y>W0.P@X4
ML4C<(.QVH4@38>^#L(.PKS9AWUWK88L=UM,R<8.O6V8]6X-W//))EF";':!A
MI[A!W*T#C6.Z/DS=)=OLQQ_.]\#: 2$6B1NLW2X( 6L':[=K-5C!VG>PRP[K
M:9VXP=HMLYZMP<'A"3=HIU$ZS_=%?!D=BQ%<;H"&/>(&:[<.--[YXW&6^%&H
MH<.3Q-T-2M3]W?OWR) 'CM@D;E!WNW $&?*@[G:M!BNH._'V75!W6$^[Q WJ
M;IGU; W.1>P>3J<9FKP!*2P2-_BZ=4CQULU&[C=.CB\(^MM_GZ*Q&X##)G&#
MH-L%'$T$'07BP<]7GI_WP<]A/.T2-_BY9<:S-3B;S6.!;'@@AIWB!D^W#C'V
MQ$4@9$>W)67G/AP=@+,#1"P2-SB[72#2F ^/2O$@[:M.VG&('<;3,G&#LUMF
M/%N#@\#W_ BD'9!AI[A!VJV#C+WP@C/AB;1/Q8AFK437/WU #CS@PR9Q@Z[;
M!1]-='T;;!UL?:79^@:VV&$\K1,WZ+IEQK,U^'!ZB [L@ FKQ V*;AU,?'&#
MX+K#ZE^./H.H T1L$C>(NET@TKBOO@NF#J:^TDQ]G6@ZF#JLIUWB!E.WS'JV
M!OMNX/G'<H,,4 &HL$;<8.O60<6'V)T/LPOGBR]+S.4L_</IWG_ T@$>%HD;
M+-TN\&@L*8?L=[#T56?IVR#I,)YVB1LDW3+CR20]]I.IB_1W8(:=X@9;MPXS
MSD0BPFIIN;.#,VRG S=L$C>(NEVX :(.HF[7:K""J/?7^NM@ZK">=HD;3-TR
MZ]D:'(2!?TE^-Y@Z,,-*<8.I6X<9A_2TTNGTP^-3-%<'9M@D;K!TNS #'=K
MTNU:#5:P]-X:&K3!>%HF;I!TRXPG;Z>G$T%W<TYBX<EDUK9S&'H=X 9PPQIQ
M@ZA;AQNGKJ-.R@3.V3Q)Q92/JO_G[."5<WI\\ Z<'?!AD;C!V>V"CR;.O@'*
M#LJ^VI2]K[NJ]V$]83VM$3=(NV76LS5XYR>><K]]-%8'6%@D;C!UZ\#B@YCZ
MH>\T=VO[<'R.#NM $)O$#;)N%X)@@QULW:[58 U;WP9;A_FT2]Q@ZY:93W+
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MD[C!V>T"$G!V<':[5H,5G+V_UM\ 9X?UM$O<X.R66<_6X(L?NU[J-I2> G(
M.:P1-PB\=<AQEH4B\9/Z09OR2?>S,[!WH(A%X@9[MPM%&MG[%M@[V/M*L_<>
M.L;!>EHG;K!WRZQG:_#/3 2!WWAB=2])Z;W@?P-![!$W6+QU"++ODO3<:WG\
M_M[Y6^ (<,0B<8/'VX4C33R^CUUX\/@5Y_']M7Z?B7QC\<:?6VEA/JT5-XB\
M9>:S-?A/1F_MIW/T?@=R6"QN$'CKD.,DCE(1):GD\!7TR G\R?DA^#M@Q")Q
M@[_;!2.-%><WP-_!WU>=O_= WV$][1(WZ+MEUI.<<)'&T<(6&O+H@1V6B1L$
MWCKL^"0RHO!Q-!/5DG7[QZ^<3^>G)Z#N !"+Q WJ;A> -%%W,'<P]Q5G[L3;
MUT'=83WM$C>HNV76LS5X_X9T.332#"-YJ]: WM*-WZSQWP:UP_%'_I26P C
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M/%N#@[.S/7W@/?>]G8.30VR8 3DL$C?(NW7(<2K<8%H][3X+O!J!/STZ!I
M2"P2-_B[74#2V"T._!W\?<7Y>[\/_@[C:9>XP=\M,YZMP9D;T.BS9+%HW='1
M/L #X&&-N$'AK0./]X'XIH&C\;3[^Z/?SD#? 2(6B1OTW2X0P?8[Z+M5B\$2
M^M[;!'V'\;1+W*#OEAE/67+^K9M4BT8#,X 9UH@;K-TZS/@\B6O1OAIM__SQ
M%!7F@2(VB1NTW2X40;]WT':K%H,5M'UKK8=.<3">EHD;M-TRXTDN>.C1O4+R
MO-'R'=AAL;A!WZW#C@_GWQHWVS^<__L0K!W@89&XP=KM H\FUM[(5=#A';1]
ME6C[+E@[C*==X@9KM\QXM@8'(Y&XID(=N#H0PRYQ@ZM;AQAGJ0@"-S:8$49!
M=.&+YM9P9V\_GX._ U L$C?XNUV TM@:#OP=_'VU^?LF^#N,IVWB!G^WS'BV
M!GLTOM2MGW1WGH\[7SNNL[_^OW"_@2#VB!M\WCX$F<X"?S;QF= GGB]"C\3Q
M_--_S@XTB=\[^?@6* (4L4C<(/%VH4ACP;J'[>_>[X+%@\4_.1:_!18/ZVF7
MN,'B+;.>Y(./YN&W;\B5!U98)F[P=?NP(@C\/S.9LW,L1CQMC5OO>T?_W -K
M!Y98)&ZP=KNPI(FUKV/K':1]M4G[QEI_':P=UM,N<8.U6V8]6X-C$8N(_7#3
M*V[O\/B5<WSR$7XWD,,><8/#6X<<GT,OFHK18MI.M6;=\<$[0 F@Q")Q@\+;
M!26-V?/8> >'7WD.WT.O.)A/R\0-#F^9^6P-#J?3+/0]9^\#D )(88VXP=FM
M0XHO?IK7MEP\[^Y\.3\"5P>$6"1N<'6[(.2N2?*_R!]8W /YX\B_5!_F\W%Z
M^A$SL60FM(B7S(66%M%X7@STG_XAY?52>Z#C!E?N/'GM5$"$KJ4KDBCP1Z^=
MTM@Y,B#O4WD]N>"<JCSJWY1B45\LO8>C7\0I)B6_L#RCCIQ2FE$YH2=G-)TO
M3\5%%KATK1<%$;W(,'"]KZQU.2^NKNW?QT&63'Y*E=JAAQJEZC_"\N[7']8:
MO'&=22S&_VC]>OYYO]OMM08RLN9$8V>?7HPN3]ZLN0,Y$_2__WE#"]S,QELW
M\;V7/"<OW\?N]"Z *W'[C<2-)6$^^?-GLARQ/Q(O>_F]\] 6J=??<G4GW0G<
M64)J9WXR?WHE5XY< LZOW6XWOZ1D4IS22DN=KOZ'!_G+O1**=FX=C-S_N,3Z
M*[53*[?)+^A]AU_0<.]KW86-N[L+_=N["_>/5=:@[HK4/;IBQ2?42\D5"T4-
M#O6;:T L' GUUY;2\+H[L?_8YFOW7E SC(+178!FO0AX_ACK54<DPAIRDD,C
MU_V)&^?+NY^+>(D@RB_=&NP'42)&RJM^YZ;BS1K?>7 CL\%J:W#.'XGXF#5U
M+??!A"R?D'O$81\>$(&&#^K+EV;Y >'P+(LO_4N: 7+9IG3/.? 0>/C33<@]
MHLW PY7$PY-L&/@>P!!@^/-.R-WCY@##E03#+VZ0">>="'RZ@1@Y;X;QVH#&
MZ&B4_"(FOA<(]?DGD<K(GYM,U ?/GSG3Z=]_W>GWME\G+ZZ!4K2;1>+>RB3N
MK:_U43('>^F6B1N)>Y;MI;<&!R&;W6^59K/.43I"_1P ASWB1AZ?=<#QUH^&
M),E4'[Z3F%$_>'=Z\@G)?, 1B\2-9#Z[<*0IF6\3[!WL?<79>V\'[!W&TRYQ
M@[U;9CQ;@Y-W9Y4&DG-GGQX9Q6[J1R'  ^!AC;C!X*T#CX/1A:C$_1H+X!Z\
M^W  $@\HL4C<(/%V00E(/$B\58O!%A*/^K<PGI:)&R3>,N/9&OQ[HU[ $AUL
M@!N6B1O\W3K<V(L3-_2;6?O>V:<SL'8 B$7B!FNW"T ::]XVDA70=M#VE:'M
MO;7^!F@[K*==X@9MM\QZM@9G0@11TK"!!N  <%@C;O!VZX!C;Q;[7I9PXD[B
M^2+T%JO@[IV<'H*^ T<L$C?HNUTXTD3?=\#>P=Y7F[WWU[:9O3>NA)];9V$\
MK14WV+MEQK,U./:#0(2C"/P=T&&SN,'?K8..SY?NF>+MC5OOG[_L8>L=&&*3
MN,'=[<(0),R#NUNU&.S@[EW=;1;D'=;3'G&#O%MF/3GSU;WT+P7OH 71!8@[
M8,,^<8.X6P<;7T2<N#1?S2GS7\[V3L'; 2$6B1N\W2X(:>+MUW2>!6\';U\!
MWM[7!]U!VV$\[1$W:+MEQI,;O7PC]QM<'5AAF;C!U:W#BKU+/Z9;A#<7J-O[
M<@C>#CBQ2=S@[7;!21-OW]@ <0=Q7VGBWEM;[X*XPWK:)6X0=\NL9VMP&(;1
MI9O*#?<92M4!0*P6-]B\=0!R'(4)W<QYYU_XJ1LT\OCCLW<X\PX@L4G<X/%V
M 4D3C]\"C0>-7W$:W\.9=QA/R\0-&F^9\6P-#BZCL9@NUIT";@ WK!$WV+MU
MN/%)1.E$+-V _W3P^1S$'1ABD;A!W.W"D!]0:[ZW"^H.ZO[DJ/L&F#NLIUWB
M!G.WS'JV!J>1]U6DBVWBCM(1H /088VX0=ZM@X[#,$K%USIT./OTW!J//SP_
M^ T\'G!BD;C!X^V"DSL6KOM%_L#2YD^KD_ [W?VGG(,=>JB9A?[#S4)_HZ".
MZ_7GM09'F>>/G%A<^N)*C)QT(G@A9,(9B<"G%4:?T7/DY[-L&/B><RDFOA<(
MYWE(GF4T=CPWF;QPQG$TE=\Z$X'P4KKL)!:>X"$XIX)NE CG6,07(G;.8WI%
MUTO]*"17E(#.FSCTT04_BN_RK-OI*FRC60OH6TX:.<\V-FJ?=OB(E]/??$,@
M&1H-.<MF]"@O]F=IKB0UG$CX*Z79WB1D;@W2R9LUOM' H;^RCOKTBFZH)++]
MF \QXKV/V$E\;N(\VZP+C ?^K+==_S@6R8PFAQX0S,WN'5;7(ZXNUM DF]+G
M<Y)#RG.:3AQW&%W23$<D+G*R:(+C&7W.6CXDG7.\:#H+1,JZH)2,IXYFW T"
MJ1!NZ ;SA"XF):(;3DE7AG-'+F2U)F:QF+FQFU_GC%T_#D62.-',#_E3/[R,
M@DNZ!0L\RA)Z%$EAZH?RHL0AI:+1\,.F49(Z[FP61S.:FE2MB9C6^"7-DS,5
MZ20:)?R4,5T<>KX;Z/'Y2;Y\Z'+2X'P\]!&!@;E4/V?&!9:\+'!CQ_-C+YLF
MJ<L[S?*-8CD;I$H9006I5OX:2H T8R/20/ISX@D2%]D-OJV\97D\M*#,9)1$
MVU&B<T;T']_-3=/8'V;R5>?E<2E%Y#OS'\IW'1.:T3\>B<X?R<5+$^*G;8=N
M0]!&[Q<[4W<DG#\STJ/4Y17H_)&-+J:D0V5I)Z1D_IAD1:]>EC3]1H(3KGS]
MDG35@SO.GN?1PJ0E&LS;_!)7?CIA ?)'ZL9*(X2^(M&"H/4X4NK8UE(8$OX0
M7!,P\_W=T:6?T%?V3O?W_O[K3K^W_3IQAI$;CW@\(Y\@GN_6IF>X*;UQ4BCG
M-"/%(7TN"87>TR6\CP+1T6:"A\>Z+Y6.[EBY@U$?,^2Z>!U^RX@D;/[ =^-%
M4KE#<746D'M,NB)GEI9 OL[8]FG%I+43>;Q2,EK?<3 W\E/"^:STKN,<AF;Q
M\1?*HS9RE-,=9E,1\_(B?,VF,_6:/&J#Q#SOA"0D*M))?4=7%@@?9HDOERR_
M@Z WC*9D!.C?D:^7*'T>:<U*:?'2DZ>LE_0>RJ2ZL2#YSR,M1;HTC:. _\ZS
M*:__'&=?7;G"DFMA1=Z+UT8H6#BD-[3::-QR45]*W20IDVXK(Z;61)9F=!6]
M:!:DN9V?NG-6BD+/4[K3E!8W7Q+P^X[=RRAVY1(FL"8]O;@02:H&H]>_&J><
M!39,+(]V,7Q:,JY4++VFE%VE(1J1TG=&41/R$LJY?L(LETUO1'<:!W*2I%[X
M'FM4JE^D=#.&%>%E,0V$]9[>4 DC4*\:!:/: JV\AIK@)/5I&ODW$H4?,N1)
MT239\ ^M)QGI19RZ?IC2+8:"WW#H\N+,9@2%N:H9?:=1T3IF>&E6@AQTU1O0
MKWY<<A#4TJ<;=9Q/42B,VK25SA@MIPNESDD]9*>(?0_6=3D/R8P7YM GR"-U
M&==40KXJOS39%9;5R!^/Y6L;7S)*Y'+\0[J3RK+E0B/_BFQ*147U*U96*F$V
M/<2=1B2LA+U04E$CH-3]*A@&2+0&0)2)HEO>@'=T%8W\JUG[(^'YB?93);M1
M=Y7F4[F\[D4L!(.]'&8RD5C$&K@ D"5#K!:64I;\&7#;?A@I8M<Z,6SF%DHA
M$8/-1ME%H0]ONFXH/#=+C.:R97>4'R:7!7TK(K!D0TU>&P&%5*.A&TKU&_OQ
M5.J4ODF;=8B7M;&F#=<8Z&H73V1<\$.%62*\<"_DTW+XS%VW$NKI]>97P(^N
MH5N%0I([9>G4"J"'A>(B2MF%'"GC>L77A!<)JQK;->F6^8EROHQ#$/@2^_EA
M6:A_*9[79EB6!PQG@>L)[4W1=_-!)Y)&$?82SAOO5:,58_^B&=%O+<&:1T1N
M U-7+<VZZ/AVTOJ/QX1R$L 9_].8K3_?1_R9,?B51&3L+X^++XVNZ/%D'3(-
M#H;VZ<\2C=4D9X_<A&@J94E?;,MOY#9%FIU4HC&9$N&0ET7#<P)&/C90$[9S
M],+R-?DM):X4XY)BX.>F5Y$BC7/ADG+.)(LW;M"(9<C&*1H;$4Q<XX1[@B!K
M)(<P%O2F$L;Y73LZ3OQ]#YBX_$+*NM/$3OR94C!ID*3H;AB*]G:NG3D]_=I2
M)4)\E4PBCBX)HIL6$WLZ!?-1-I/G.[Z4_H)>_H6WQ3^ML4HJ6U[,;MGT%F.2
MSL$WXRKJ%]/OI!5%88X<B^%6YO$P%C_ 6)P00&1,AK7)/Y#X*97D2+!G3MB<
M7@GR-0K-4SIAUK9:L8WN ML@R;Y)G=OL0Y6^I7!;$KF4_ZJMED\,B-P*CBZE
M 8?T"KUQ&9E,[(VUB ?P;*?;;7>[73(;<^EW,XB[R83A1/J, :%&KEWE.W34
M>_"R(Z>9"3<]7[^DO+M1T:I/QL_L;ZIG&@5=&_F7*NZ;J^K1Z<>?4DL?(M:N
M@^A+HNU:6@Z]WS>'_],_I+PC4GL@S=R5.T]>.Y5M(KJ6KB#JXH]>.Z6Q<UZ8
MO$_E]>26BE.51_V;4BSJBZ7W</2+.,6DY!>69]214THS*B?TY(RF\^6IN."P
MS&M:!$%$+S(D%^"K;.79;8:]<9 EDY]2I1X)^'*5ZB^BWAO7F1 __D?KU_//
M^]UNKS60>96\N/?IQ=@3>[/F#N1,T/_^YPTM<#,;*@_SLV2V,C/S,S&SF SL
MR]X=IJ?ZJTG9A*E[.%-7T84BZ[%0@N=^X3H;\Y>;D[JI,>9%ABN6&Y47Z@MZ
M'V1NOE$+P.WIIS)C:9?,$!M.;?+\Z5"Z[NI*[6XKSS/*TLJ&3AA),;4&+Z/Q
MRYG,F=(;->K[[(&%AO14G\/BF8;^. ]#7)!7EZ2Y?T=^G R 2+;BAUZ025^W
M]+%B0\KM%",9HBC1A<"]4C%PA^,"N<?  G5CN6NF_ 3VA.4(VJ7PGV(,3&/8
MKRUMNZG;</C<94>WK>(D)8;&5"*>YJPU(%)(#S".3.[2ZB<:E^8ZEBL]F2L>
ME7Z%TO#+DC$17Q52=DUXN/SB1I-(_#4&>\&RD/JCHETRP%NZ6GE.BV[QQ[Z=
M*#$D%G=OC)!Y[ 8D=G<;4.(R(OO^?3O[]>>192BOK+?T KEHE[Q_^5TY[XB&
M1BPK9\JY4KW+=8GU[> ;+1))ESX37:+EEACRIK:9]0(& WI,!K15M0I;4@$.
MP\J.C.*HM!9II8_R2-*-<%'?)4F2C.^63 A"BB@*WY9N2##G?2VCR#5?D[<J
M6:(HY.R$TK"<,QJXT*;B+><QC,D](5 \,T\IJ5D>=Z[LQ9@=!1DZE(\9SN6W
MY/WE,#A P]_4+$O]@=Z6XPA3(1C,VDLNT?%C?H $5(F4%8&.*DM%Y$LE,DME
MXEXRT3-+K?I*"GGIQM60?)N#'56+KT;HUY=L=;@$RFS5@KG9:2J^SR&7&?W(
MC[C;"TC]T)M.-*Q9Q"XGRX[F<QSXGAJ,>1("(3\>!N[J$/!NS_6S*'6AM%U"
M%Y%2JMV=VE:HS\DNKC=IVJ+1\92RQN]5]F>*/RC71D50%("IQ;%D*9=NS D3
MD=Q+5%"@M5PYC<V7CTLI! HGK\$&CAZQSR/(Q7'U!H7TZ.C!W^9T8_J07VB-
M?I<@FC5$ S^N_V#UYR)>OO>3N3TU:M3K-KM!A_+=FYRALE2JSM YIRM(O33(
M^EEE$<"[^:M@[5\Y6ZL0LCJ0R*TIE4;0$$0UZ'*S%\3I+)XG B&WK^2&'"<+
MJ%MQLHO>86(D'14&F+Y(_DR6YDE G(G$>R/R#Y<JHX)3!+Z)F)"1W2$BU8T!
MW_=^3-!K1OS<?Z$Y,2<C13-#_5V/QL%;)A7'*W^WB@.F;'=H'JZ3*U3ZATSZ
MX(%QJI21WHDKG9!]/; 3^743Z);)4D&@=PF5.Y?*_4M]=6S2MO(P>,A&@S?<
M=*B[G:<2&5/3OL4 ]'A%_3W,IKT6#H_JN5\5FS16]Q5>_;79;H2U) 85,AA'
M01!=22=<.KR)2!.5@]B65\G!2'U9\+"4W\5_GXKID$=[L\\N6?T%K8 +UM4P
M*U^G1Q_I)"AI1670(0NU-LI]6_VCE,'_9L&\.4SC:/CK;;6=?K>_D5MMA3-B
MM"2ZXW(&R(4P2;C5><O-HY)5\Q%R^7-#N#(_-MWM\#DF#;$>R=^=)>*58WXR
M?WHEX_(RP.[\VNUV\TM*1Q*<4AP_=;KZ'PYS_G*?@^[]S5L?=-__N.3TB$)[
MM2_0=*ZD]QWG2AKN?>UQDXV['S?IW_ZXB9Z']7YG:_=N)TEJ&RFT_,BRL+UQ
M2#JT4$-1VVS1;ZZW6XJ#*.JO+14_KQ]'V?_X.X_UD>W\[@^)6JU7[>SCGVW[
MSA#5)W<JJ@[8\F-OJ[>4EITWN\6)KD<Z+6<6TK4'YE9OHNXP(1N=WAV/YSX\
M"C9 (-#O_ND!I5G^;D#\E_;AW@SC-1GWD3\8JLH_/__U!1 3B/G$)^H.$[+5
MV;IC_20@Y@HAYO_31/7EGJ:D#)('FH^J52>###I?82S_;F!6]R]LQ-EGP%G@
M[%.?*'BFP-F'P=DO-P(F'%, YI.?J#M,R'9GO0? !& ^I&-Z,\I>ZY;>NW9O
M?ZM8Z*[W]2*.LG#TROEU?__@X/W[UZM2SW?9O;L-=[K_OL9MUO$P&LV?;.J!
M%95]'R1M9#$W]K8^SE-?$O=Z8+/!7+)R_A*/YJE/R\/.P-TYWXJ)&ZO RFEY
MV!FX>X1YQ<2-56#EM, 68!5@%3SL#-P]J'.SN!^"E8.!@X$_-09^/J&W3_X_
M>V_>V\:QY0W__<RG:.1F!A+09K1ZO1- D>78-]X>29F\%R]>!$6R*'7<[&9Z
MD<SY]._9JKIZHTA9DDF[!I@;BVQ6UW+J[.=W H-:])LNL9CT&[>;O4#XMD[@
M+M2B;N;R)[V<'MU8/G/_;GL:> 6O_>Y^^'AWU[,9SV8VZ@3NP@?AV<S#L9G]
MP>%CSV0\D]FH$_"ZS&8QF6?[X9/'^Y[->#:S42=P%SXTSV8>CLT<#)X>^&PB
M[\M<TPNS%K[,8W%B_DM/)IF>!R_UIT_>F^E%\X:=@+< -DLT[^Z'SW:]H\&S
MF<TZ >_-W"PVLS=XMN>9C&<R&W4"7I?9+"9S^#1\TNUH\$3NV<S:GH#W9FX6
MF]D;/.TTF'P6IO=<?H^>RSNI@[0=0[Z7\D<OQ;^M$_#5+9[@OZL3\$6-GN"_
MJQ/P'-X3_'=U NM:JNA3?KSA_"T8SF_A"Q7\FJDH#X-W@Y<#;_1Z";%1)^ C
M9)OENMX/#W=V/)?Q7&:C3L G^VP6E]D=//91>,]D-NL$O"JS64QF;S=\^NS0
MLQG/9C;J!'RRSV:QF4.?[.-]ENMQ.=;"9WF:#N&L@Q.I5CQ.DVLU]U+82^&-
M.@&O[&^6%/9^2\]E-N\$O-]RL[B,]UMZ)K-Q)^!5F<UB,MYOZ=G,!IZ ]UMN
M%INY3[^ES[_TOLQOP9=Y!)]G>? ZO=)>'GMYO%$GX-7^S9+'WH/IN<SFG8#W
M8&X6E_$>3,]D-NX$O"JS64QF;S<\>/;,LQG/9C;J!+P'<[/8S 'HGC[STGLK
MU^!RK(6W\E]JE Z#=^K1'UI=^<X07OYNV EX-7^SY.^3</>Q;PSAN<QFG8#W
M6&X6E]D=//-,QC.9S3H!K\IL&)-Y'#[=]X$1SV8VZP2\QW*SV,S>8+<S+.)S
M+KT7<PTNS)IX,7$;7L7S)/'RV,OCC3H!K_9OECQ^YCV8GLMLW EX#^9F<9F]
MP8YG,I[);-8)>%5FLYC,4^_ ]%QFXT[ .S WB\OL#7;W^QV8_T'_0 \E?EH=
MR.O]!SX"MXOH@B.@SJ(K'$#-&T9.57,"SYYU',%5&HUOXQ)K'P&];Z=^_+M\
M(G?26_54%_#B*$V"7]*DS(.CBTSK*7S4:+;JW#&8[Y\PWV_E;M6.]JESLGMW
MY^K<.Z@\G?ON^Q[73_8Q'>R)&ET&Z20X.CT^^J]_/-W;??(B#T9EEL%0@?ZL
M1V4176EX8A*-L$@]RH&-9L4\*-) !9D]T2&=:*P+F'H8J#Q0<+!C/0XF63H-
M"C@(_ 7^-PQF99:7L*?X"<@ZF$!QJ6D&[3<&UU$<PWM&&C]LOQ&F_N/NX\-P
M9V<'SK4<_J5'-.XE3'0$9Q4E)4Q"3V=Q.D=2@_&*2WX7"("+-!T#::D$:0EF
MD:7E!<]&JRR.X/4POH*!LEF:J0+6D,%IJ1%-0'8M2+, )EJH""](E* P"\;Z
M2L?IC-XXUJ,HAQ_D@^ <1GZGLPNS+IAA7D1%6>@;WP*'CQLW2W--J\9)=F]_
M;OHW_?.G<73%_-+>J-/3U]_D9;H+,36"S=398B8)VL0.:@WP__*/ A6+Q@L#
M%5^K>?XBJ&E?\%OX19[&P+ #9^XPTH#&J2V/-).@OA_-)VE;^$%G'8$L)*@.
MQ?[0/=& CA1.E [TXQD<YZ-3?5'&"GX[2N,4%C*,U>@3IB[L[79SYTE<YI??
M)$G=$W^V)+77?!F(615<9GKRWS_\X_S#\<[.[@\_4R06[_LQ+(Q%I6(Y"?_W
M?_X)%]R<!D=N/Q 'I%CN!U"MLVBL'^VN<#SU/V<2T/5*UL8H62>5J//ZU8;K
M5XFKN"ASFB#Z51',LO0*+G=N=8^9HN= \TK&P5 G>A+!'^4,M ,%TB&;1HDR
M&D5#'TK+(ABI,M?!<&YU&M2U<M@!_A%\@1J'T<I0&R'E";8NAZ^W-*X3U+XQ
MO#;1.($XO=X.X"O\60[:(/LKQFI.VJ'5=G#P'JT*IP8+V]WGGTZ!-"[AIWAZ
M-P\@P/!WK'%UG0?K=;!YW2<0):.X'.OGK<OWR]L_IVM]\>(HEQ\^@DV(<'.>
M ZGD0';N=\5\II^/HWRT\*8>/)TMROJXI\OZ:+7;6N/ PS(&A;K!?>VNH@/N
MZ=[>XQ?\&WE(7$A[3V:?7\"6S&(%:E:4@%D ,X]34J68,)?_7\N\Z3]G8%D
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M+CHIXV *1YLFP!"+D,5FD.@+V&X-THO8\ 2^F&2J! *$L<B #>"W^@)T0_@
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M?6Q:LM8YTJC,2,KU6YRL9VO3;.!F <L6XRA"L1>D0!WCT)K'MJ4G\8C/Y/F
MIY[L#P[_T[@^JEXL3&!@12(-,H\Q!FUG.SHPKHT!JC]3G]:<&JT)C^)QHSPO
MR4 G7X-M)D/MZHHB9OYG7VX:\%WJF+@6F?]P--%5- 9!/0A.L'%.2]TQFQ$V
MMDO!YW%$++#&,DDI47&>!H0V20X%Y-'POMDLS1P7PF*?"YOIB@WUL2Y4A!V
MP(H;E7GN=)5M#9OWFO)%5,1WVM;2Z;U[JED<U!K[=73N/9/IMCI?5MUZX5HD
M*.9@QGC+@MW#?4L7JT@9SZ/N@T>AUV;,7J$P>*6BC+IB!Z_*9,PG_.9-2$V4
MS?W L_NH85+!:Y5=1PE]RU?2W*@P> GT_E9=<]^HWV*-C]7OX9)N!?SRO,R
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MYF=?EMO\I_-_N*<]^_5G<\/6(Y_FRT%3Z&H^*&[*+DL-C '<(W#*,99X"[2
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MQKFV (.HR OR4 = 1H]YC]C&8S324N!)H&\C7$1="ZGPB:R5$-FI,DL[A\T
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M%[-,W;87N>][T=7W0LI[?%^+-4T:W%2P&=_7PI/NAI+N&O:U""I08#P5.(@
MH?BH0@-)G^HK;$,!$+DHP-FO/YS7TFMO&,AW#?"7R'<-\.3XK9'C_78-\$3J
MB?0^F@8LZN7;:!_@NP?XZ_*=7I>E?$&^AX"G[(VC[(5P[AWMW6^+0MTE#II
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M.>&QN1"O;*L=)\5*IF64;!WG^OJ2D_&9M2(QS*NFUS_!WY1R4W+\W=D&)Y7
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MLPGO/)MPSV<3KG4VX2\JCT:/\$P>O<K45*]P)CYC\*$S!I<36%7-*%JHR5A
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M#]DZT0M?:?:@"C,=X1(:*M>JT+V'J9C$:U$V&G*0 0OPC%E5S2\7YBRP>MU
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M2"1'O"BLNUM]A,+J3@%J94OD=2/#X7$MWTB;17*5XZ7*JN[M=1Z^Y2(^S]N
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MM"N#X'<*.)M#KZ%[!),R*Q@UP/'_=@=>**Y-'1(OHYDCW7.3Z,F"C!5YK'7
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M?HY+"US*;HPB1?]*5U9=5V#WUMF%X4JYJ#91O1D[)4<SAD!MJA?C1-9J%3C
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MRR]!NO:XJ5 5-=2+7#!.DXLE'J7D&^G9F0YAHYVVGW&DAJ!.<C'%:)25[8Y
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MIL]5;O)JJ*%5<6F$=I-=XYZ>86WI,G3,#'"W'MQQ!WH'<0&0 B"M!4A^9]4
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M.5=^Y<>Y7P&^A)D2D@L:@#T ^]U;^TQR.9YQPZTEN O#>8'DW04>>A#<!?%
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MF!A$4T2XZH?AGF%Z*KCWC7(%P%];EFA+Q6=>IAN=+D5!TI@!_+\:^'NWTL(
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MM8B,LW =ZPXF*91,\1U[H4)N?6$<^ /.Z!F^KW+9L*Y>3],RD=&[3D9L::Y
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MX:\Q5OVF_7HED>1ZG 7CZK"(98>K*N$(U'S*]87AP+!](V6><]]*9&W]2VL
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MHJ**+2.O0@8%C-L*;U3G(D[GJO8<->M* %R$C@>BQLNK0[7Z1:+U[4%+Y>Q
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MD5=K=12]VWF],XH\!S)]16_]72%\O,D6>1YM_5$ 7'-/XK[U10?S,LUX!7"
M3[=WX/6X&$?O5*M325[0=3UZ^?A?6@''%X!'F+O (ZW@5'F=IGWP\FR3LIA%
M?V]R;:?;QW/OK""@RSV@RRN=%9=1BK<&X!F7*0$Z7AWUA+;-H(=[0>]$1_W=
MH[&C-BQO6I1IO2"\RL]A_5&FSP$:XJ+)*YU%@% %O%A&^C-0R;K"+V) M2:K
MX9P!OF&4M(;%Z1D,-Y^7!4 )(B<,&*NR7$1%4\,3553J:@XOIN,T2^M45SM+
MK=X?G\(%98=J7EW58<=<<X4O/([AC;[..RV2?]9/;_ 4$@TW.!/T4S4?K4.2
MSDFC=;:BPX3M9B!08XOM]ZI*U)]1V61PLHC;)<D63)5*VX@>.YSO[[[ NY]C
MV^\\UO35W@MI2-Z9'2Y^4O+MJGP! \F0V&*<'KXLFBR)TMD<:%$T3>EZ\+9@
MAO0B31JX2?U9EW%:T2!NXAIDK^1\AG^XY9F&Z3#7,G;_MK^9>'W3YE)M46??
M0^OGSWOP^J)(DW40>[F[E)VOTUP*07^-CJ2.8+?[105Z?(?T&*E(Y_01KU!L
M0$3>^^E%U4=EY)%H"S%,B$!G&*$#V]&E:DM!X\60K 12@8ICN$!L&A9=IO4T
M.H6?@$ PY7NRI;:WGOV\O76PS5\($SCZ#+)+?B[L_2"N1TBML?U8!=MI[26V
M/<IPIB:G-F9(JB8IMBI#N:'4\ 1]#\0_UE4E%%#A_FCK^(]['K96:R0\P)K>
M +FJD6S-&YBGTBP6=@\8& ]<'O"72O__[+UK<]M(DB[\>>=75+B[(^P(F,V+
M)$M6C^.59;GMF;;EE3RSY[Q?.D"@*%8;!#BX2.;^^I.9584; 8J4*8J4<F*W
M+5%@H2Z93]ZSKM%)($992,M,M#Y7?]XJB!JES;=ICPA'40M*]#SQ[_\!D%0C
MP'$-UF:/RD@) *D2("HXC&D&Q^*5-V,$2N)Q(4+,VE$07IL7:+E*4/O#@]^,
M)4EC.*]8IBY0 .X@_96$+K[N.XR'7U[I+31.A!,'/32E11A]P!4A0,"*4X[E
MM9(W#9L!LX8AC ZS\E[@%,UYDD!$=0/(QL</)RH!Y0)D<1B%+2JQ6[K)F31B
M!?1Z+"91J(BA:()1ZMKY3=TX#65\-Z(0,$:%E^CM96I(I3M!_2F6_\E4K%D]
M<&]:=@\.*)9_ 7_#/&- /5>S@!C*]$;*T*IW*+SU%ZW"H+<'#-P$/1WA"!=$
M8 $\8:>BM8]55UC5'.1HA.AS+8%0-=^C&R<D93),XRA("&.:H..XA'B)QA$_
M X71J6Q/AD946>N"S7+(YM.4Y4E0CYT2B=&JX.Q3RWRX/P%P#:FC\/BUWG3"
MYF(QQ3*=8@VEM1?+B?6AXH<3%[ G3O*=Q)U6N(^X4'T>43B;1!G 6#8D8H49
MPLLE3"F:H49.$P28BBLZXW\RV!MXEE9<FD7#R[46:134R)!1C0C#$)5"^J;T
M&V&9!@%4C&'(8-;\R%KHQS%V-^VYG6U=FOHJ\8(H06HP!%"2H9_R&>3/OX/G
M,[VY.*D3.+M9HFASW^<K 1L>=\X\<R'1G*%'SH%3M""P>KE?C =HBZ+L1&_A
M!1%O@FP.8FRBA6FOVP(]_[2P@R_\[WQS5QODO\T@QA/1)/M@I5X6Q[ C,#J2
M.\$CX1<8$C^H=PKS_EP%>2WR0N>Z6R3_@_9OX++S='IRC33+[HE,1:*^BY24
M3P !BRZ8 6.S86;2C?776RPZUX^F*7F0;F(<%]8\IBVW2%Y_+1E3:&9?NRH@
M3@/^*;F/DC7M7%TFW,AAHE"[2HVQ6G[-QQ0T$Z_I18K^TJ1./WMS<W/3<6,
M2!5U@  LR5CKX%<P#'5 (+<3+B[N^]K@QQIT,;LE8'W?!?Z_^8&"$[47"C<
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MJ?=AW6"[+>LFA_AMIO2GN.(^)T,Z6<J0GKL$K#"D3[0-;*QH$$^H4C>Y<D
MNBE9O(5:8XQK-\PHZ8 T<%1O>ONLHVZ #L_K8>5#Q\1XM#Y5\J3"+^2ED&A:
M@;*()UX/=.OP39?L,!W%JQ <['5&6%5V=/AE XGTND4J9JZ]:0VUHKW!^W+E
M-5 AYJ&!-G<M@VBJW3G24PF&Y3H"UOT9EE *IQ\Y)EJUS,)UP K(GL8UVF=]
M+T#Y1?_+4*8W4H:%.5UC0MB*7&]6H0>G"U8EO> *&.<*#<DB-M;TGN%,['=_
M<<@&[NT;&[AJ:<*.$%_@,\!*H&@:#1HLXV@(E./J<"7\+?(4,7"N8:/ZB7R/
MZK+975H*@$0:*P^?!;W5^P: H%*CC3K6G/ US_^LV^/ &$TXE -/?67D'$,_
M0-1,I@,ZR))EU.]:YP6E]\SEZ^2D4CG)1*)1O<X#O>LY#@:=P> 7.LF^YB+M
M#8CE!/8=3P$3,8Q)U30&G1J<S-0P69W_C,_#G.?/O8-]32YD= QA'R82_0VD
M@%C_B&5+?%\$R 4665"UNUHV"O>FE*Z5;R_,J_U;#/N;<!0:-K &-FQ0"TO6
ML!GL3VOH4B*?8S.' 'O5:(X3BN%KCC B*#/0513Y MFER$-".URG[VDZ<V-9
MMLOK7C6K8+PP3LLQ>N;SV##F%=8FACY+T)3)E6#<:V1.7V.V8EJ!Y.=NJV,0
MIU'R 3JX ^3[+_LM(L_+$'ATED,"7)#G*Y+R$]->P*)Z@\KX=/YB@;/"P>\^
M'YK9)>K[+=-KG)T?P=F@RY"F>2^S+#MT '0%J)%N&<8P'T@#@%>6NE:]G)F3
MEM(\-46/"TD5/.8A(G&.YK=G;.;H!F<\5I/&)#58IG:2U>@L)V<BJZ'4LLE-
M\ST3J<+_X-QHIU7N)C+H'&6!#]/&#W#>]/VQZ^>>+'LL^8G$TI]S8%7R9[0F
M=8W*49:V9.1%HY=3$- RM9EY7I2D2278I!.'QCJ"I,(DT[PQE"%P76J]=J?G
M;R].:,N>?V_DB@=A@5D+"SP0O=^,)>57HMX: -'1:$A(@-3*4!X0HT2RT!OZ
MW"I+#F6W*?HZX!,Z+XF8\&=<#@R9+X#&-D/KWUN&=_!K)-_MQZ12%V@7F7U:
M@8#D=V14F]8*7(>LA+/ #-?OGC2*E:&SL6&1G)HT'^C(39FR]!(IS($.<K.B
M%QWQ$7C<UV$/ _&8SJVW +8,QTPB6+L/7!Q+_9A!?OL]>%6!^7G0"+/E(C$/
M[158UV!0&LB*#+..[Z#'V 7#2;F41@Z?E#5KO<P6(7MF$>YCF,H 5X73^Q)'
M8'2G,('3*!R10:Y W*/+%P;_'(4MIT7&2VJ37DKF-S(NG71Y*: %1;Z-.=5E
MHDKJ\2:B'1WD1<5M3K*2B1: NHOD%I .C)Y[?/<$'?ARFEKXI;"P_NY)A4EQ
MGF4EH\A.IARO5ET%B7R4!6("5 "SSKR4,B(38!!Y!4>!87&R#$;PAU'L9CX!
M2$3\!M^E6<,'0$68J)A0,J<>!N40+,U00FR48Y\".%H63$ N@)*(:6EC-Y[@
M/,P:CV$G1AD0DP-4@',$E15&![ <N2K(8DFS@,4/%9TN$JZ,:<-0 -F!Q5_1
MT$;?X?DQ/*XK+X:89RNE2B:DAEVK*'"M< 6RR<"@ ^D/WP1*JOP1%X4?X\]
M?X#],YI*_D:D*)UJ:Y)V]<>47]H0W,P)#:>G-D76-&4Z'SK'4O L=R9T+#G]
M/J]JYD2%SHP@\EQ+V-J;T4)J6NO7:1GYE^#-N$4(>*$8=($. YD<P\"^-.8@
M>B90J,,>E34S>-LDBJ7^8F__%S-U:VXCHDX)1H[S),A\)F!U!_A6\G5H_P;E
MH(!9H$;* S *],[Z$LQUW!BB42#<#!B]97E(:FA%(I$350+1L6&V </LK.88
M;<O+6*3A@C8<8>).DV."/+ZW.'SAE:&GID!0,L_FB;33MU,?DO0*G7*@=0MD
MQ))XJ:CT:CX]A9*<]'PUAOS 9)IL5D2H[^@,J:4)9T#: G-'C2<$Q=HG&5^Q
M_V%7PA_-10=+!T!,C4)+!*2EMUAC\N 2X8U/K@UM:/]DKT2Z9B)HR[;D-5ZB
M]$A13B1H4%;]G8UE4TRPZR;8?]'!MRD\SMQQXH.@UZ2!QIT"'>'_J*2N+/[1
M$]NWR6NE"(EYU#J3R:)=Q=41Q:V!#$#6%I.TF"*0W)5,B\#.8/^7)K<2I<QH
M]?U'I]5LRC&!/Z9 H&80C@16 D<&-78U%+@@]^R"<\\X]^Q.N6>O./>,<\]8
MU/^PJ*]W3IXC@K4D<F@)]F@R.0J!O'VI'%:#XER.I\C.*^5RU+CRCLD<EAFV
M+YO#S(S3.3B=@],Y.)V#TSDXG>-!TCEJ<O91Y',8V;K9A([:1G)&!V=TW%M&
M1XW6'EU*1VU]"W,ZN&J8/;=K\]P>LN>6/;?//O2W\ZRWOV_>/-#49]#02>_E
M)2PT.'6G25,F3=/>)/B%EQY\HZG+WGFITX3I>G%"+F&TD-]K\_K_HGE]%OK<
MDFUCWC[4ZT=1$$0WU$*$>!YTVYMDY7;+3JZ,J!!54ZWPH'L[ID-O;36"!%!Z
M28MR)W.RH)F1E1>"8>[/)_(5:HA>3_-]I?1SCE0%N.0W1X#<^B67HR"4 J!L
MD&?V)_NGUR222;:*G[K=;OZ5TIT2HB3"4]$5 _PO MS?[G*I:J^8[&VWJIZ"
MSA7#:<*^_?U9\;7JM1^:RK5VT'0A2.\'+@1I&'OA/2%[J]\3TE_^GA!S)(-7
MG=Z*MZ[4U"G@%N HY#/0K%)SA4?3KAJEJ^%*5W/V%7P[_? GSG4KNPJO*N?N
MX4;C14*N)L).P<1N4$-:EEUO"#NIM7AMO_V5&6R+[SG"PP&XUH=SR(?3=C@'
MO<[^WD/C80,8,@[>W5U0N=I];=!X/M6-'TEQ6X"1=[XPOK_\C?$E^F".KL/M
M7J>WXKVGS-%/DJ,_9X4I%XW$;\/XUS>78%#%Y-#5OU.U0C!#R\W\#C97[*E$
M^O2[1H6$?G[^TPO]T)E^9+Y?_F)EZFEQ=-O]B[ND6+'6RS#,,+RM,)P_Q$#\
M2('X:1T4@R^#[SU9M66U5=(O7V+EZ9^>__R"P9/!<\</:H4#V>\,'CQ$PN"Y
M,^!IL'.J]-4P].L[-UVD<=[91]@K;E <NMXW3$X/_=?BI]/3L[/W[X]O\QN^
M;>'Z.79=F;=;F7BP.A,/EF?BNT<UE^&Y8>3/=C;AHE>J4+RGW+WY>TY[YE!L
M8++USCJ\_5K&RUU\=JO:L>MDO?"%6ZI![/J>WZLQM2RX_$DOHT=W%F?N7\#3
MP"O(][WN(4,&0\9#0D:_,SA:;7_K],X0\I 00J4>_>-'#R.K(,:KWH\C1LU0
M7F 9TY^8"1Z6"328/W(>8%&ZU;C#VO=NH49_;[_SJLNHP:CQD*BQN@]_:=30
M_N9'!1L;KNH%D/BU?_ K-B5;JW?\X,><XW]>R*ETT\?&).OTD2^&ET>Z@5L&
MXD]NEUD#W#$-L+M_N_KWY*B8L8(=KXP=:W.\/CG*9O_KT^.%Y?RO3X\56)2R
MVLUP48.+P[W.7I_1@M&"':Y;#Q</X'#M]=#AVFB9L\.5':[;M(&,Y:SY[0R4
M;X'FUW/V>SW6_!@MV.7*Z,$N5W:Y,B^PRY5%Z>[M,BO>NP47^T>=O25279\<
M'3-:L,MUV^!BXR[7@U\/T>-ZP!Y7]KAN^P8RE+/BMS-(O@6*7]\9# :L^#%:
ML,>5T8,]KNQQ95Y@CRN+TMW;95:\=PLN]O8[7?:X,EJPQW7[X>(ADESWT>7Z
M:JMZ[CY2+F&?*X/Y3N\RJWZ[I?KU]OK./BM_C!<[XW6] UX RX".(=.7#!SK
MLQE?,6[LLK>5>6+=/%&_PT&')+J#X\K5*)?95,:)%ZMIP1,UFDOPD=(6[H,@
M>O;F>>_%\[VE+XUZ@GS'\IKU>X:DNICN-#MNGC@9,UBP9W?;T&+CGMU>_]<^
M]B\8-*KQ[-IEU^Y6;2"C.:M^.P/F6Z#Z'0R<P:"Q%_@3)V2&"_;L,FZTXL:@
MYQP<-!98/7&*9L_N$^6)^_;L]MFSR_+ZH7>9U?M=@J1G;_J=_A&#!8,%>W:W
M'BT>PK/;VT//;F,#PW5X=F_UXCXV7EBG^[:9\G>6VFGD^R5X4KO+Y/ZR9P[%
MDOS7,:P^$2<=C=3_E)F,'?$EEHG"+P@W],7I6,F1. <=W$UA7\7Y:*0\&3_Z
M:S6W77P^G>UE)7NWE.S#)?I1/!WJ97#8,H\Y=Z#8)K!8N@/%TR'I'7&9,Q-L
MO/7$$^(!EIJL4C- Y'[KO?W.JR4*AYX.!3- L*]Z:Q#B ?I+] ^POT1CIMH:
M6OIROC'G&S\&P'YRN\R*W6XI=KWN(><C,%:PZY2Q@YOWL@>5>>&>/:A/CQ58
ME++:S7!13U'8Z^SU&2T8+=BYNO5P\1#->['#0W^?G:OL7-VF#63<9BUO9V![
M&[0\KLAFK&#G*F,'.U?9N<J\P,Y5%J6[N,NL=N\67.P?=?:XR3VC!3M7MQ\N
M-NY</?CU$'VKC88Y^U;9M[I]@,*PS4K>EJ'V%BAY/6>/;S)BM&#O*J,'>U?9
MN\J\P-Y5%J6[N,NL>.\67.SM=UCQ9K1@[^H.P,5#I*[NHWNU\?K"C;2P?:0<
MP?Y5!NZ=WF56\W9+S=OO\U7Q#!<[Y&#E2Y>V C=ZKQ@W=MFQRCRQ:Q>1]?@B
M,I;7#[W+K-[O$B0]>[/7:?;1/'$R9K!@)^ZVH<5#7$36QP8$@T8UGKVX[,7=
M0DQAY&8U;\N >PO4O/[ &0P:FW0_<4)FN& O+N-&NQ>WYQQP\Q+VXC)/;,J+
MVV<O+LOKA]YE5N]W"9) O>_TCQ@L&"S8B[OU:/$07MS>'GIQ>_?EQ1V"BGD5
M1UGHOQ8_G9Z>G;U_?WRK9_>Q\<<Z7;K-W+"S'$ CWR\3D"I>9H&7/7,HE@U.
M.QJV_R%'HUC.Q#OY[9N,'7$IO5BF;CQSQ.E8R9%XKT(W])0;B//12'DRYMLN
M^;9+UKNW $>V3^\>[#O[_4:Y^E0IF &"'>F,% V.]"-G[]42-OK3(67VH#]1
M9KAO#_I@)0_Z$V(X%LVLNS,(Y;I[I[M$8/OIT"_# WO)MP8?-NXEW_^UU]T^
M)_DCC26MTU?.P;B'1_$GM\NLZ^V6KM?K.8=<C,YPP5Y;QHV5FM\X1PP;[+ME
MEN#LY^W@.Q;7K-TS)''V,X/%MNPR^W6WVJ^[3/;SW^@']-SBIZ53P(]&492&
M42I'M2.@%= )"Z.T6A6VLF#]1'6'Q,M]V&Y1WB;1W^O@&8C2TL1?69*JT<Q\
M:'Y[+12N^*7R970%'#HV?S:+%R_M2&6*/!;%68LC_?<RG0@B%* 3(I,OET D
M+R_D51:X\;'PHB""Q0T#T*5A1_\L_0_WM&6__JQOV+II]NB^2+:_-UV4KDR\
M8@FW?V?"G<]8IO<:TAW,O9$:O&DMVVRK1:##Z?=C7R73P"7B"%0(KPXB.BP-
MUHO_:]3M\VFJHC 1US))81BQ=UC1Z<.(EO/LC3#/3V!7Q\$,'DU HPDFL(9$
M3*2;9+'TQ2B.)N*=].1D*&/]GG[/$?UNO]LQG-A&.)-'2CC=S5*-(9K^1HEF
M<+!FHNGM$='TF&@V232#C1$-G'I__Q=!ZQ$@/L5,NK$CTK$,UT1/G]R9(:4N
MD]+F26GO7DGI8XBD(N0US$5$(^$*#U9X)9%V/-B]. KPXY.+TQ-'['=_P5_P
M"UEHB"\9NS&<6I(-_Y)>*M((_JP2X=ZX,?TQ",10>M%$BE$6 *&YH2_49")]
MY:82?C?#9--(S\0+H@0H1?CP9WQ9DGGC^3DY8AI'UZ#" 7F,HQN8/M&\"VLP
M"W+C0"%'C,1S]4(O&3\'#FEFB)?(-V938)*A@B$3-Y[9!5?G%<.H=E@57D=!
M%F()%&B2\42%+K*G Z/ MPVKTMQB.7%A#?G>P5QI>7:R-/;2>]81E@]_]=6U
MUL)SCKRX^, FSYU,'K-; M8'!BC\O_F!+(+:"X4;W+BSI.9UA^_"-Y(H4'YN
MI)"QT^MJR^%V Z?VI#9QZ,&R?6,64K9-[!?O:IST#H[FT1U>^><HR)+QHR2I
MP_LQ1W*2ZM=?]NS-;ZX8QW+T]V<_?3T_[79[S]Z0!$6L.86%H1#^[5=7._#U
M__[K-^!Q>R Z5>J<$)>2I\X!K&) PY>]%4ZH^NO49% 5Q_ZAOYW'/8P"_\Z'
M3:EB]K2/CAJ.^SH"MOV1\^XU8$U]!D "92GT%I;T\A(6&IRZTR3?]EOV)L$O
MO/3@&_/[\^P-BFSQ3L5 (R"N3J/)5(8)2:9J>*C&Y[":[3SV[>3R5NU-,_I7
MT!Q&41!$-Z@[D(L,!#P\#)_&I%>,5.*Y 6GM0L*8?LU^&VBC?^  VL<IJ@\J
M'.%6X$F*&Y6.0:U(IKGN!9I*Z:A)I0-U(H13;U9[Y&0:1#,IK>KC&XI)K-KW
M>HY.&!AV&A@68L+\RQM"T2VO+[]FV1L7:EBD.:0Y09A^SB5=08/6(NJ"ZO-+
MKHJ!7A/ !H!*9'\ZSMW,7:N>B9^ZW6[^E5*(092TP%1TQ0#_BP+R;W?)8AX4
M8OFVC.73#RV1'[W=6JELB@GU?B FU##VPE#1WNJAHO[RH2*;W'S8V5LQBES3
MP@%S@>^0YT A3Q?EQ^BE-\25S'E7I.3IAS]QKEOIY%@5 N\A^+P(_VKH=CIV
MXP;5=0EX>?;FLSN1R^:Y/#VF:HL:;WGT^^D=U H'TNL,]AX:#QO D''P[EZF
M2A;.VJ#QO92)9K,S-P[!HOAM&/_Z)C(&Q1=7^=9QJ?]RZB9CPY;XZ_.?ETX@
M?'K\RL"Z(P>U_($<=GH#QE7&U5MQ58==-6:>8'PK$77 W*SYW&>@9J#>]8-:
MJ0SLH,](S4A]NW,@"O^3P21&RFJ_[^0(AK*_E3V?^A/4E.'$$M:#&5X?U4$Q
MO#*\KAM>3X) <]EY.I9Q&Z0R?C)^[OY!K7 @W<[>BB?"^/DD\?-KE+K!TIKF
MG9MG'? %$^N)*_,%$YNX8.(/^(,K?H]=E3CB4^==9VWM;)]*+]N%+]Q2C6+7
M]_Q> [C<%N$AVR+T#OK._C+MBW:<A!DVMADV5@]/UDF>4>0A403[._7ZQXPB
MC"(/J7RL[MQE&&$881AA&&$881C9.9)F&-EJ&%D]5,*PL:6ND#6$)S@4P:&(
MK0I%7+BS213ZX@]SY_7_1%$2R-E:PQ)[+Y[WND\F-,&B=UNVEZ,0NR5Z]_>=
M[A,(0C! ;,GV<KQAM_'BJ5CX#!C;LKWL$V3$>&0DS8C!B,&(P8C!B+$EV\L!
M@]U"B':O!9<S< SA2<00HB$<I#@S(833*+QQ9VN*'>QSW( E,,<-M@ARMD\"
M]XXX<, (P8$#!@PVZADPMG)[V0W(B/'(2)H1@Q&#$8,1@Q%C2[:7 P>[A1 +
MW!9<:<!1@L<6)7@'2_^'"1%\4JDWED&PIB#! 1<8L,3E0,&6H<[V2=S]I]'E
MB %B2[:7XP2[C1=LPS-@L->/$8,1@Q%C6[>7$8,1XY&1-",&QPD8(9;P6G"!
M 8<.GD+HX 0^CQ/Q(;J6:XH8O.)H <M=CA9L$=!LG]SM[7>YK( 1@L,%#!AL
MRC-@;./VLO./$>.1D30C!B,&(P8C!B/&EFPOAPMV"R$6N"VXK(!C X\M-O /
MUXN&XI/[\G^D"T>ZIOC (<<'6-!R?&"+P&8+!>V XP.,$!P?8,!@VYT!8RNW
ME[U]C!B/C*09,1@Q&#$8,1@QMF1[.3ZP6PBQP&W!]00<,W@:,0/<AO?!+ S7
M%"\XXG@!"UZ.%VP1T&R?X-WC< $#!(<+&"_8E&? V,KM9><?(\8C(VE&#$8,
M1@Q&#$:,+=E>#A?L%D*T>RUTM.!O] .& _#3TI'@1Z,H2L,HE:/:@=!JZ+B%
MT.>!G!/*8U&9@7ZBNE_BY3[,2Y0W3?3W.CA945JF^"M+4C6:F0_-;Z^%"F&O
M7BI?1E? IV/S9[,3XJ4=J4R>QZ(X>7&D_UZF&D%D U1#1//E$DCFY86\R@(W
M/A9>%$2PN&'@>M]@-_\L_0_WM&6__JQOV+HI^.B^"+B_-UWDWR?.L43<7Z.+
MG]YKZ'@P]\9G;Y[W7FA7O]E6"T>'T^_'ODJF@4O$$:@07AU$=%@:LA?_U[C]
MW\7F9H.WL4K2Z,81)Q>G)R1=7QTG0"[Q1,;B2RP3A?,5;NB+T[&2(W'V77I9
MJJZE.!^-E"=C1]RXB7"#)!*N\%4LO32*A9_%</@B'4LQDVXL)*S;%^^D)R=#
M&>MW#WJ.Z'?[ T<,LQ2^Z@-/I0(&D#B\&\X$DE"JHM -@# G4QDF+OZ*\Q-C
ME2"97,,<!$X@?W='U%>7KZLR"'XI%#)?3Z37(VC<%-^1CH4[C.!/&39T$CA,
MOWM<[,!I:3B[R:2?Z%\NLPD<[*SRF""^Z=!0/:O'M''5Y)%R57>S+&4XJG^O
M'/45*-V=1%F8)D#"4R >H/<*W9Q/B0!.;MS83PP!P N)1S29D5B";X\"(&3Z
M'$ ?N,]W4RE&KHI1L\B04O&/"7R-QD)*]B7LW03F[N.0KN<!=;@AL,:- BI^
MKT+X10$;G<!?8([(FY<I<#5]_VT$_S3_Z33R%;"%H=UHJCR]ZE>]0^=6^D]A
M%RL/.<!N7I#Y%AKD: 0K37!!$@3>Q,5-@^,>295F #X=@=N:+SJA 2.]CV;M
M"#[%=[/$#OT6)5@E6AI&1%#/WKR\],91(!-S<F; EF>GL?)@3/OL)/)E4$S+
M(DF236B0!&:@CR"M/ &3-].F$TU 'YB)(1PJ9A[@XY^!W_6N'8HTJJ%Q?GI)
M"JN<2!Q A;B1]ET*L2S,X!%->P+>]![X5 _9Z[8L[I]V60BH2V%UAR%K@Y U
MN'_(NKJ*Y17B2YCA:1.;C5W@/9"#24: E$TCDI.QIQ)9(F7#@5&6)H@7R'EN
MVBKCD<1RP?Q[["K-N[TC9V\?L,0- AP:C%-O+&YD#+R1!<%,7 -S2[\C/FIZ
M3\3/NK\HC7<YE<07@#$3E:92SJL)\/*^<*?3& #6)SUFZBKB&CTMQ$Z5>%F"
M?#N4071##Y7?@@^V#K'''+%)CMA[K!SQ/U&4!'*V"D\PX6V0\/8?&>%]LH1W
M&H4W[@R4N3$HF'C>,&I%_1B2=@B?6@,K<1BYF8%69:"#Q\I ]G)(RQ3[KUXQ
M=&\3Y;UZ9)27ZPS88%Q3W:%S='3$4,P,L11#'#XRABB@V&UQ=)AF.\;;85BF
MV^TZ!;OT^OB!G>5"YAF\8N9YLLQS]%B9A^I+-&_T:[RQ-\<:K,=LGO+PSO F
MTNO?@?0*<@/RR0T[@0&_*PPBC.)H<IL9:-SW& E[+X=QYL8S/7C?:<,E6.Z?
ML-S'DN]0(8K#^PD5MU+%(5'%1Y(!/1W A?.[5A2 2&O!3B .+8W"UDB'G$R#
M:":EE9+%.:>10-&C?"G2,<#)7<:X4:";#DOB44=Z,.J@XCR0B_&QVWP/+L:G
M@P#W8X[ WOYQ[YCS8\05J,1\\>4T2BBX_1K!&O:V_+=T-I6O42M82(U[APM1
MZIX(LAVG-$562&,(*I0LJA-KVZ@3^OH'QTVXUG_U@R*U >_,/V<N"+75J5@3
M<9&@4,3<4A<F%XN1)%G\LTY"F@_O,WENG#SKLZ:TK5VDV9-D83I,!4<!)>4Z
M2/RY>N%H5?.O2(6H3-Z.SB$L&V8)<RQ'O$F&9+$W=D'?T/IE\\R$F9%1-NO.
M:+2S8$R=6J#3*S!N#2*P*[Z C'-@SCAI;1KUZ(\3TGT3DS;1I,B8]8)I!1)(
MMFQ9"AQHMPLX'FB-(OL/L$BR &&=N%#4^7,@&KJ)HG00LU1*'*F/;IZE9(IQ
M%.#H$RDQ[\,I#=6ZKH-[6]:QU3)\K68DV=U(V,+NK[ZZU@F?.0#_<?%AJ_'W
MKKKG.C)M/8FYIHM3;3$A&A.?X?_-#Y1\6GNA<(,;=Y8<BTIV.'P7OI%$@?+S
M?%C*J^UU=9+J[;FTM2=U-BT]6$ZE-0LII\':+]XU#[;WJMMLS(R"+!D_2I*Z
M)_&<DU2_00J[8AS+T=^?_?3U_+3;[3U[0^X$!))36!CF/?WVJZM[5L#__NLW
M8'![&KK/R_GP+\  ZOQR?BWC&,#D96^%XZG^.C7]7UB!VPX%+E^1"AL71+I=
MA=BJ]0B:RD"*D9X$8N9V<Y-T*Y!%@703D$CJNU;-0(ZEXP3DE4+5*ZH(6RTR
MGV=A()-$"S'X7HL0HX&L!)L"*40^)B!/*.T2_<$S5$Y <,K0SU,)\6V?HXD*
M7<K6I.1L.(@HQAG\'@'AAY3[63BE\9'<?PQCX@B5M.3\T1=LM6P!T>^B@8*N
MZQ622.:-Z<*Z:;.K!VQ7,X7^@ E=ILB3#,BM'+=#TKT+4?;VF2B9*'\(-HGV
M&@WF!@E-PGPU\4]431ZA%4F;\99)^][<[$3U>6&-M*'NA2A]!WRF9(UC9!.F
M8Z;C!Z+C=4'YG=1F4E X&K^!:/QY*/[AAD4F!!@LE IAPO.Y"3YU9WC>E2A.
M&E'87GX'OL8_WB'*[J";/LF,R[Y"@.^L=[Q"B5^B0'DS!UT"Y+:@ZLFHR##]
M Y;M"JK6<HI/3]!WGPA,/W6*_*&+" @?L5K7$^2?OW-#)0-ATZ1+XURXLTD$
M)&]J7TK?*76\):8H_4%?G[=4GE]D:C+O'+[P=,1"UYVZJ:D7USE76!AJM*3.
MP1[Z;G2"E$/.%2^(J!0U?ZIR&)5QHQ::T56F=@TPLD@R<F]:AQ-6_":T/1[L
MHM+/&?=0'B:JO#<Q=;U4X$_/ZF",+4V^BB65E](WS8>_DSOK<Y3B0FR=* Y?
MG1\FA&'4K=<7\C^(0N39"F;P&;PU"'35ZE "OU @L6W5CJZFQ4>JU8)F$4XU
M_=DNS:D7M#3\P5)@\:=Z]57#EX@&2[$S?]5LT]*A(W]EP/VE;!<J58[,D6AG
MH?8")HS7&\N>ZCNWI[HE6)RODC$%B>>S?H$EI2[W!C9-47Q?*2]G#CS;B?M=
M3=3_(F&70Z]4W*Y9:7Y495..27KH:>4N-H.W9Q6R%\])&WGA$*GJ;]CX=P7,
M/W7>=6#9%22'C^AKJX LYD77\DM-3P\WT1YV)/$U^+"=4O"^U.V (L5DVA::
M5]JXF38#C5*GM55 J$U 14>DAZ%?,>4V&R)>4GYCC6/G!F_=!1#T&OGR3' [
M%*713EQ?6CBOI2G,+X!4.9T4CN2&DX6/&LG 6?ZP;38[#+F2<'V.*2%T +)"
ML>(?62CS+>B_Z(@OM3T85/>@G,J^]%X F"9&3[J?;5F-!^I+W,N7F([C*+L:
MBQ/0!()\6_;6MW3M$W^PI2](MKC@9 M.MKA3LD6/DRV>;K*%*Y0/!]X[@#GB
M!'(:^+#*X!L\^R%H<G<^>;IE:!&>7$? PNL!E.*%-;?;6UC!RY,@.'6G2<WY
MMO)&T Q  PX3-#)?9U/0L3S0!>&=I,6>_?>_/G[]O^+T_-.7L\^7)U\_GG\6
M7_XX^2P^?GY_?O&)/JA>3L,6T#U:0&AXZ'(*\OT0!"12:S*@!ZL03S%OF ?@
ML*B6S-0?5XPI^9],I;/Y:I2B>D._M/GZ+OHY1Y?^LYK3M]<%6?-++OM D 1
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M3;"G<S.(8"M1H"DB>XM11*Q1E@K=30H(1G?'?P[_8.M-Q,A0]/H5J,W;.[T
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M-\;Y$:\=_:;KVTV>H7'#K:Q1K+"P1%42>@(KORKTU?7E1O6@EZ(A&#G;9>2
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M_2&BN0H^T,8;FV"QNVF31D$9M-?H_-GMM.4DKD:+VS&B$$/;VAC:^N&.;S?
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MJG#\'^ <BF&%@-ZQ&1(MB$%BPM(-57VC5&[LXWQL#E7/,(O)CWC4]##EQ.$
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MT4S*O/>Y%X##(&L$B]2=$+XY9+:NPIJGXS%[RA,0 #@%MRHAQ^C9P%>#MI\
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MLYX93\U2F?CENHD8#E:,"XSUT7A[?Z=ES(1K\FC6H*K@BW"D,HSS5>OZW+$
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M.O"-;#R-]#,\#'@2X6:IFE*@60*"P>H"'H/V/N)A2E2X-?ZD&JR 3KX+T,D
MG7P0=/(H0"<#=#+<6T]P;^5XV$2KFSCANV1X F.1FTP\&W),%%OM&N6"5TWL
MQ:#.WYQ*79>N68*+I:G([\ 8)MY-6 KN%D0]-,)'HRL5OASKF+.(EK7B<@\L
M<J(:+,9YXGOU)<6WG7]+@Y]DKC\:+EZ/1$11CE)32S"(SIH:89S^4%S<G1O0
M^'!Y>G)^=?[^XNXH"&)+T 4=B6LH7HK$4^QUSS/!5!5N;SJY=6]YI\3,)G$E
M[>F@L%P;T:)(VE:+;TO:U;'BP#:#72+:9,8)H*1PT$2Y@T?3 R%+5:RKR]BD
MP;)ZU# <%K5!/K.F&+1IP\_(DDE&,Z6SAX3-\>TN$P :X0*[8EOI,&V'U2,1
MGJZ5O4ZKM#8%1;/;"GRI)(^-88<RIUWJ)?'I#.T'QVKK':LW3FSG0[I@]IK@
M7&TR76<.(%*,H!ZA7,;H_[/WMLUM&]G6Z%]!S3WSE%U%*Y)L)W9RSZV2WQ*?
MB1./Y4SN^70*))L28A#@ * DYM<_>^V7?@%!B7)LQ3F%+S..2 *-1O?N_;+V
M6F2"&%6)Q$J "SQZ<OS==6C<09C7  A_&X8R(_M&AC_M*!OK#G<'LIX(E-H?
M%]$[W%&#U53EOB#M'@1WQ\DM<*N(!V!WR70;Q>A/9S1%*B3E)@2V1R='J-_/
MA_8-&&@@8JH:\,(!A/.B*-V0XY#L*ZE'#]9+HUHT)ZFS=;5T749',/M6E0NI
MC\JQ%]<LV>O .8J%2:_\DLGY0A83""&*?\<]>=>&&3GWFV$*<0EF"[+@O56/
M8$Q #-\-KB+CYS-$ Y ,@_!!?W6!TG?DHP=>D4^#.=C._'$I(*0&A:>*@>3*
M L(<% -(A9KKWVO,GVO3RE6E5963>')2KB@&%O1\V!B-@0H[MZ(P\<I.*(,^
MD7%>\,LUKA')8;J\+::%IU&([#*%+MK6+XN@NU5$E'&11Q'.N-/SG__U^L4N
M5,I37T:E00#0K -'S:,%KV,TV[.<N\,EI%"''.:,#G2RE^UYL?+^P77EE/1I
MMUW]$99P]Y N834!E'7=M&L7O=VX.LMO3MXV [.2C6;LG_HVF; 23&N5%'9U
MD4CI[*>3M[/CK4L/+(4FVM<4C]9;Z0-<3O;TO&B5M\YL0CNNG[M:/YQ  *K*
M79$E;9G=I^?UX W+FT(U'0A@GW.2T@T[AL(2ZJ,3]=X8%AQL1O2*F:6Q5PB2
MA3 A)RQJ^)1;QY#['#R'?7/GURG C2W8%!D(X,D38SRCM/-$8Z6U"! S+D;Q
ML .<'XU#T3UXGOA&BW4/0CE\ T[SU/S=NI?\JR\'*$3'#,@7E@%YA;8_-HCO
M7$M!Q\RU8P+D[C!W 0\IFTG<L?E.:#)9"CF=-(7/V4D.IR)':"'O5.A:%VMD
M7K&=F12@=T!-?-.JM:%P-\2<7+Q",+V,V6NYQU RP-T63K#5/8_(\3=Q/6$6
M2N=)G:[QIY06=NY\9C:F=F-XGQR^&$.?$W? *&U/E<</,J-8:+%2W,RZXFH8
ML%!YH<GY .3)EV3=--&L[B73N%&<+S^CR+75EU$HZ2H[*7B:G72#T9CC+O!M
M#^-Z=Z;$F60G&9\:\@*_0@<@(JV\)/>]][EB#93)').@3E7L-"<9>7-APL?<
MQYK/%)CU>N&?/TRFAHHQ*LDO2X0.\7=UM:1#B.XQ"2^,3D]/U-?OM6:(J4Q/
MQ'08'+JZ27Z.#,SHB-VM(^9#Z,15F.7MN3I6] _W[W7!G,Z\X;'UWN3-[%S#
MM:-)=GS(;/Y2ETG1Y6SG4C?$O^7$@HE:#3-CTY*@;;%!'HJN_'B+U)%!H_1%
M++>P/.N57!2+LJ =->NT-BDVT"P;<[(PJ#B).?</EQ7@R+6LLOB QL(&,Y1F
M&OS>.LA^,*CB[%PI:V9%,ULO85/I=.<!,Q.;;"II(&C72^<M7&3_<'3D+;#4
M,"G"=LWLRE&/=8"@1NT+DF<4%S02:D#'*=UK92^$;#%;(&DZ973495-79U$E
M5\IX[NJ<QMSQ2\@O\J)DV['PWDMCWDO6UG5EHT3Q=V"@WTFZ!LLZ,BU"&.B/
M@>W$0@CF>N<?>E)\)@2G['7YA>B,XC5\[=L<^>I&T-4G!UT]'D%7(^CJ;S\<
M?YGO^G]%*'X[U<(?.1LCA\><9G7#?OO/TQ+TU9$<[9A.^=+3*2-'VY];JI34
M+0+E!1W.=:O5)DF%# #Y<OM)06ZI% TI!CA2V%[!SEY]60E@GCU%5)<:3E+
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MV68G17BY/<T#EBT%1"=Z[^:$TA1L5M+Q, FWC<Z1Z/G1^:9YD,*FR\NC( <
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MB*9/I)]F+S% ;\)]CIN674R"571L,SE@E';!_M&B$B.KNA4J"K]F?4PE13"
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M,RF1RKEY@H$]I^U5R)3.W;+J39(?K?^;]<-UHC]8EHS!\!^/2=N[2MH:BPB
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M(IND)XV+!%/Z2S=*0C*]-&3;F2"%IX<<)$E]"'>=&68U>I:O'JGL1@C4IX=
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M<UI8R_4RG]Z7&N<[EJLA"W\/J;T"QA8?:7Y0\BA(HST]_+NL!4WL+%6L#*^
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MS2=L:;-G\8$(745ZCGD=+CW)7H!6\3U;;/^WM]*IA 5^,K] QRI=\1GRU_1
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M-.@&6)9](MX>PQU$+(N[I_-*M<8VG"_DMZEY5G_D'=A9PF)EG%V-**0:.1_
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M%^)ZG2_-7)O59QI+278>O++1,X,.2CLC* Z)0M-S]@+*XIUBC1>YD\RR/JM
MH0C?WG,CXJ<"OY2F3[H^1L2"HK3RW8$KAI#1W7*."(TD?;C)B^VB;UK9'7PN
MQ^/4Y=L%P7VDCIA%?!%MF3T;I:/V*AH<,=Z,)4:HRO<9,>,6)Q9-M-MB24';
M5.Z]$<>U];+)UUT(.5!?C";Z^(@32\'('EAI.5=FH<0M"]&QZ>&T9OVX+K=
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M'[VCI=_M-=';D7'>']]7!^%FT+<0F6VH"?0-OC1ME6FK?-Q6:7*H, 2*"JC
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M%/&W)\3.?7<^S!U\^C)?T1IIBB6=;8IP?DXOG=9F0F;_^OFY[T? XF $&;U
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MLYJ=U<^N$R'=:7E.R_.CEN=P>1FHOLP;6,MG>=;,?H[F\%*Z31H+LN;,G,A
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M-K,U1;]H)%*):"UUC9%F@3HMLYZ;JQJO&-A?8SU7'"KS8X(_(8V$>20TA4I
MD O@^?QXXJMPU4YP$^S8I ($QU6%,1UHS4XR*[P%I'O9DDCF_[CYU[?26@(I
M>F$!J-D>>&,A%3P[[V0!<#FR;T0PM$ 3R+)$J=W4FX,WO )P:66II\&%+?WD
MEBY(6M"F"4>R@^0JND!7!>)U$-$6G;%,D*TABR6=]K*4X1)OT!5:R2>D:5X_
M!QZ:FRDO="]TT2.A?!1CHS C+Z]S;YI2"Q$M%4>%]$=OB?IF).A.]H%\.MPY
M!.'!SO?AU/APF%7$N%A.B$4^'K2/6R=D)ORC91O:CC0ZL8"AR'OWP9E=@\ZR
MJ,@\*+Y2UKDJGV%>74.U*5L>JHK.Z7OVQ4??C\C/^_;OSDA=0=J$,B3(%\BH
M,?\"7>?6"\D$D0O?*P&TG7<#J[O.KDVM!&7AONC"7>SD#?.F7\*L2*BZ'GH
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MY^#(35'(YX]"+@Z[PM><T-%&?Z1$AB7 %Q?G<UU ^#)D&[@$*^WD>_U.[,;
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MA,?$AAW'9/Z>7()5&RR]2PO&"IT_K\ ,Q6] [1P_'[]FGY_BO<?9F5N.'UF
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M=*&+]XX+G0V-C2'"C<Q'?_X>]PW\84]%P+,=/,2S@3UEC ^S_20HCX@:$$J
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MS_;'OO6LCMX1F/, STJ?]7O_K+^:OM'+0/0'IK[ .(G7Y<0J=KW13TJW[U:
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MYR09 C,A+G-[+XPQAW78P*H2[$VJ1AP(I![LIOS-RCR]FS#J\^=?)8[Z&[S
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M[6[==2\[CSH LWASQ:I^\W"(MW*(A[I*:/=? ]B$RRGE[H;JHR;]XI8^AM'
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M)V__^>K%X_WGH>AS:Y?&>R5<$; #;Q2HS3)5U&@N*6-TI^'7B =7V#CEP,#
M>2--5Q6]H5P7*A]G.T.U>'ZI(:(H Q?F2MAG@\]PA*&/#B/9&+&ZC<1,H]]T
MI0 :(&)J+Q42UF0U5;+ITAAW&J#<2#/;=JTR5V.D&UZEL^/W9R.S."G_^?A
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MMJ#Q1T;4?^S-?O\V_NA!J($,9>[?53HH'+1OY: %DJ9[<;/=J6\:CM$6[JM
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MGD9'[+5/[3"XF(6OR&#'E&27G,?7V:?HX4^/O.?K",&96C6^87-DTQ,JUXB
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M8H,*<OR)M6U/09E]\/KA[J,5QO#W3?].T[_/ GQ='O0O>C_]]-XRHMMW]-'
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MSM#CU%"=C1-J(,KRS*</RPR[*.7PFF@2!3X&1,#N]4FMC],<U/>A/( >L:!
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M'Q7W&:,;BD;TLXP"'!Q"ZS]$/O],23J:'Q)<]@()%4Z00M:\,(&A&2*B;\G
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M]8NC7T>_UU9;*>;+C5E\=ECTN* :J482?5[;?G-$ZHCT^D0:?5%Q-$M3*2K
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M^]]8]Z_1 GS1(H(52A *A?[4(+] !32.OD:MV.+1_QV][\\'L:1A,?.+3I7
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M[4$$LZ#7)/ "OYT0PVB6B^ TL-BBY=5U)'9?A/"9#^."9O];&7_QLR2Z*TQ
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MVF -9:M-EB,43VJ7MS3[YX6(@_[*;OD+_9MKO6F.]YD>2:)/'C+*H8CE$/L
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MB\-\'N>SU=F[Y%.K%WS_;WKR#CO61IP$T) K*NG0Y<<IN\J=>2%[R(Z*Y2F
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MT@R6F36G[!H2WR=A"TES^0GS.;1BFVOQ=41C((>EQ8PIT#*S.37Q5C/K8"?
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M2 >\!J1!E*EN 8@RD!?("WG-BH\V1!EX#;P&458/"T"4@;Q 7DAA5GRT(<K
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M6@3%Q0MP5 U)9N<<$*P5@D^MM@4(5\41(TRI%#CA7A&F:&L!]=CQ4&$*R@!
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M+RO9O(44X*(*7-!'"C(:$(-'4A-AD-&'ML"!9#2:0X"]-,?.7FI5@!,U<-+
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M_""J2H2+X#7M> W-*W:.:62;0UO7VP+0UO!!T-;(-E=\M*&MP6O@-8BR>E@
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M0+:@WHO+"(/V'@:A3*=^<$$U3B4#64!,'8C!(T%&:VL!R&B0%DBK &2*%]U
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M9HTM ,4,T@)I%8!,\<3P6=L"+OK!Y=1J6\ +9#0@!H^D'L(@HP]M 63T@[W
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M1SF$03$?V@)0S+J35CS;P3Q%5HM1^Z+3'-]HM;AG6FT4P$#Z F'P(M"OE;0
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M'+ZQ%K"+;3P%SL._CWZZO[ULM=I'Y[S:W? ?C$MZ,?IZ^-LOML W_>>_?B.
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M.*,*B_8764-H%KWD_--;\NG7EZ13S]&7S:!&E<=9\1J3+4$!3%4-4Y;9:9\
M4DJ[KO+62  >."3H:HV'5SUR@@8 C54-9\5+=Z"K@:E\.;EY?-("I)1V7=#5
MBH('#@FZNN[D! T &JL:SHK70T%7 U,Y3)U:9P"4THX+JEI1Z, =056CN$M5
M@D!Q%\B@TL.KGE)!. !-4S6<%2\R0X@-3.4PU35/V\> E-*N"T&VHN"!0X*N
M1L4<^A[M8-6#5\=9VG)UIS4Y?'7<O1_9GN%/'%82-WXTG'\FSCAT0A V"+N^
M:A)!&W1GU7"&VCA@:NO:N.XI#@!2VW5A(411\, A05?7G9R@ 4!C5<,9:N.
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MG43B!JI/6^Y03>PAB-])+0/X0:L@$G0".H$$T71X(4' &16;U&7DRX,?($%
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M*5GTDO-/;\FG7U]T3CU'7PZ#WE0>9\6K'+8$Q<XPM?GN*S"&C=?:.;/RUD4
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MP8-20*!Z$>@'2:"WP?2[+7Z\?W((=LZ49E<($@6)0H1N2Z)%-WM HCJ1Z'U
M-[0'+-]:BM'!@*6ET5#*?P__FH;12"1K@D1K1:+ULN6!-_3 FSKQY@VK<@$A
MUHP0H2H/M1L+=M2)';\$OL#2)U[QQX7DI2SV VG6C#3K9<L#[["#)W7BR:4J
M<O,TB,RF =K\E5PC-0<%'(JY;9N_VXD3V'RUR?EGPDX%"-]7_CB3E3=<ZXR3
M_3MRW<>\R/#V=G*$#-@#1^H>?'(?-[LX\U4EGIC1ZSBI&[2B#!:@4ZK//R 4
M$(J"D_NLV2DXN6O&$^!FE:<ON!G<7-G)?=)LH0&E2CR!&!*THBH6H%-4YI^=
M'SNB^U!B^JH\?2&SX0\K.[E/FE8;W*P03T!F@U94Q0)TBLK\H]9!26GM K(!
MMS#(8C9G[/--T:X2:W"Z=7A./SJ_<T+'#@9/O%_"T/GA>/Z$%:!6GL5!V,H,
M[SX#RV_\_ORCVA*'^FT2T=0W*TBV3P/$7-Y?X]RVV6JC<:XF 3T@L L(U"20
MAP149G@A ?7F#$C 5?.[>(;EK"$PMP_K#T^MM@6'"(<(APC2@$-4(JT5<WF?
M:R)6NX?YBS61^D( :R*0@+JE"R_A!W%T4J4(HO2=\]7'2[$#\1_>@@Q !CKI
M#0@(Q(-JSN\R\J\QE_<GABW3LDXQ?Q$/UA<"B <A >N;UXZ3;W-6BV-VY+JK
MG.M.\Y@M>_!4=WLX<L=N&+$#<7\XH''0N$Y*$=(/TD^A28T4=[TF\+%IG2+%
M'>%[C2$ #H?NTX]B<,X%SKE0<'+C!&'0L"[#B_ ;TJUBDQK9U'I-X+9Y?'J"
M^8OPN[X0 (=#]R&;6E6".$ VM8UL:I"!5GH# @("0J%)C11JO29PVS*MWC$F
M,*+ ^F( ) [AAQQJG V.C4-0A_+#B_P-Y&]4='*7D;\+GE _B@&M@%8@2:HS
MO) DX(Z*3FZDE(*&=1E>["9B(;IBDQHII7I-X),VMA(U"<(! # X5)_NPXN$
M4L432OM(* 49:*4WL!*'E3@%)W<9B:7@"?7C$M *: 62I"K#JVJJ(XZ+S<20
M2'\$G>@RO(AP($4J.KF1_J@83R#" :U4 0N0),I3#;@#W*'@Y$;Z(VA8E^$]
M4/HC<9(]^.Y$[[2E9F31*#^[]Y('B9E<_DQN6%U,8SW"<B!AKWV'D1<%;8@D
M206YX@!)D@.0 <A *PV"]3JLURDXN9$DJ1A/8 L1M%(%+$"2U#!)$@F1<*.@
M#L6'%]$,9$=%)S<2(A7C"40SH)4J8 &21'FJ 7> .Q2<W$B(! WK,KPX#U+O
MG!G0[V'R(#&!2YO ULDI9J\>03@   :'ZM-]>)'JJ'BJXQ"ICB #K?0&5N*P
M$J?@Y$:JHV(\@<U!T$H5L !)4L-41YP'F8DAD?X(.M%E>(LJEQF5\DS>T']F
M?M%H3Z)5HB7T/7>XCO I>LGYI[?DTZ^_=#OUG+:V0@FKMLKCK'@FYI:@ *:
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M>Q*MDH&A[[G#=:1DT4O./[TEGWY]T3GU''TY#'I3>9P53S/>$A0[P]3F^Z_
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M\]T)FZ\OV'R"S2<]&=?1D_&L;N2>3=?0D?&DYUVZD+ZI]T\+5_4I2['CYR1
M*M)P5:]-^\U7&@WZRV*P:>FSN#X6T*F[M!+&UQK$,H$P-Q&<_4I=:%,5-,(S
M QEJG<$ &<:S!>#+$5## *$I%!P)-OYMZ0I8L8:C!Z8! C(;/D76\)Y6WL8@
MW#VI,XA/=1)ZT76A/VQ[^_M%1[EMW>Q;C_-D[W+?M2G>P/9<H]60I1-2]RN@
M01=>,"'-D33_@>;9.?%L8X%VV[ERR#_@D%^M?LASY\HVX@H'*TQX1YAP7>WZ
MZL!M.NBOCD8G_/H'7N6@W9ETL)(SR0"%I*:I?X=;)TJ&&47H"2E@,@76P-H8
M=H1.N+[NK_W>6;V#LX'I!L4_1[37@*!:,X5&(WX_2),RUYJC5@&Y^J[(4D0/
MF+'=P!@82'O$J+I!*M3W*'?1&=1D&J<TB!>8%(,<H1EH' *)N$9$ /Q7K4=U
M"Z 4::M1WL3NAHTIJ8]\=^8"-]VNM&4'+B'*&V *7JA@HT%OIHW +MFM&VL0
MF.VN:A2-YL;:+9P$H2($0O5GJ7$:6E@WJ_ )GS9.@GS8PW)2\CF&"A$WB]8Y
MB3S_$4Q@4)/GSC5F.%]]J1!<^)9F^%]@9U7.PURVMWXTG?*I)#9HPK\041SV
M+FI$@>$SH"'2!-TWO%KT!O0XMUXDOZ7+O3.TMWC4BHM$FG5$0,V!K?*-DIK?
M6_,"C2TKU/TCJ'NX&1'7Q IWFBRTRA5/#[$PG(RLTY91+I!17'MN))0)ZOD(
MU(TSLCCL'0ERY$4G@0R_ W(GZ9,4\:RZ&QJ-KD+X::) ^"0_$+CG"CZZ0I D
M>#OPBAQO3<2;\M?#LY/>P>(-L;><49@X5 X[]-?#91]%L3A4*B14)$7&B&-8
M+!["2BUKOKB'JD&4+#M !P-+8F?5YN7H1D)<BECE).D3[Z\'O?YR*T M00V*
MZN7#-->X5WI#4(9FW%I XZ?B_A[T#I=[P>H;PAH&H<5G:7DU;A7B>Z9I@7>Z
MI_;WF2AP$^RN5"60CB7 JR,".;[HW7)CC&Y@-*#&4:_4:H$.R4*6)6R+SL\L
MQ%\;[8S5-W,6C@:;5YA/&CQ<PT*Q>"!<+"O6'#0QN&=_/3Q8EKBK+3[9"_?W
MYW?84F['DJ<PT0X^XJS<(FE51W.XVM&X%T=SN7N<39#/W<8VAEE@5C CF#F2
M'0XIB!)'K[##KH M]ER#BNFUBO3>J/3F.*&6M@^$</E5X]V1C33/62SKZN
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M!A?<G 8[QSX._@![G=QE'T$T95&HGO=7.)[Z/XW/3!"<-HC@A"!E'7"B[:C
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MNX@4=M:L?#TX(MSXZVBHC**2U?4?7-"7<H"L:\HN5*/@D*(QX?7Q^1$K7:#
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MJS"NNX=#CB0<(M;6[EA;G^8+TQ:$1>H1$0HM/J6PB&@ V[*]/]IT$1S)W=<
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M1X,8/X IZ?M,P8-YDZ?%@FEQ-%*J]Y)KS%," $^=.S>I;B)Z4Z-<+SVBK(M
M,PH3E:RG9;@13),M17J\=EPZWMLA6@QD<BEF&];<$W_3%ON;OA ]L<OQ4EMC
M;/F)$^I'L<5EW$PVAA!Z_2-R$!G68;U%5:*X6]4]E_"7F_RDI4FAIY-IA!8>
M1D0N?3!>%B3?\A=SY_+JM_],MOI,XBC7#SX'24L"Z06&.T#>N-\5LZEZ$4;Y
M<.$A'I\O[.BPH7/L;NC0$G@:E'&LB@:GMMOXC+/53E^V!9,.S^[9 *([R)2K
M) +9CII 2W:#JV'/7WTA,2&Q)4@,W=P!)>R25;Q(?:_75)*:C.HEQC61S:&6
M.IAY5(_(CO;ZT"@*&^SQ)9I\0KE"N7>AW#]*RQS72+05RVVC5U&P-J]@F=CE
MD.)Q;#R[Z8#L9N#D07(2W2&/T;L9*XK^7,/720$[&)/?+TJ<#\3C] "G_=8I
M+1NMH%A'^7Q4M+]:0+Y5D?+VW(2T$+N^D7\IR"M_B_:U<(U8N,#14IEWY%W:
M-Z4L%,?7OK/4%CU4;B:_>E?#Q^9Q?0O5_9N$<;,/0-ESNY28#-Q;5AV-?/:S
MP2_+N*C<7$YZH3N_(KWB"T2B'=DG5I#%$89V?1L#3A1L2\3%2C<)^\0I&G[1
MN[CXR:RY2)%!SZ4T+)PO)=OJH"SE]U:I6')M'^#:WBF7W%^03+[\S:\%$0*;
M JXPQ00OK:ETM_7M*XW.^V.\S$.E0JY:LQ*H-?^[DU"Y+E.[=/U:(>W*:QZT
MEI;X[!2'V]O.^YY'H^>VSY[F@]X@R".XIVO(O40-'\X ;J(9FSA"?:&=V\/Y
M,W/2O?9[+>I1M2NS:8P=2["P1>?:Z!S>;THK TLP#V$0#\ @OMAS6)[*37Y[
M(VU+?1^J*4G@1E6W'.1#*&B\^QAC8M%K2]DHG 9G&6 >(RD#]8L,UQ8?0_V
MI46WHN0[]W8M7-&9Y=XM_+&=.>Z;25-#2NR1A 18C1H,BS*P*=W+,1ZT.CA)
M+AI517^WE_@)G3]0C >U:RR-3P<PA$D*P611-=%5_#I/E$M,5B?9GG<7OLCU
M.H73WL*E>)R*D]!JN":EIYC$S5KF*F9Q)D&<7J5:ECKE/T)J#T!J']([L3MJ
M%%?"!TD1SY8V?B2TOY6A_5=8IO1<M_Z1*/\V7,O;HORD;E2E@I2"_IUZ@,-U
MU*VY[U,0@@H&?5ZGDR8;*,996EZQTV6!Z\E4,I+F4A1@CW'3R#78?)=)HK[;
M-A[DF5]#$9_9I#V<MLZ >%U?WYMJ?:8QG>G.?@6:&=PDG2:I+?2J1[NI>_ H
MCPW'.NV=GUY<]#RGXM8FD"T^@.74SCF5\)91C?_"V//2WEQ*#-9>8G F)092
M8B"ZP^9+#);RQL+OGZ-D,(Z'FJ] NVC)6W ?3T3#'?W6.M/:FR7BB[JE+MJ.
MU$YQ%5%IF\W5_'HH>76/1YA,G"+D3-ZPJY=X WF8*_M'U_&9]U;%@XN:'"YL
M8+>@K<MRF^![>X$&@VEFH5<5&0ORT77F-R@X*JFEN=_VUD'SK90M?\L)PW-#
M\QS]O.[-,H77NKNYK:(TG<^K3N41I^H#@TA,*GZS (6/NS//?NF%AGK"V!B=
M&WQB>7*LFX&8$@%_@;;<+'QVRY-KE<_59.M-1IIDN4<9P2,"J=77MWO/]ZDI
M&#?TY&IT7;10[5=;^8([X:H(NFK DFF*\K"6NEED72L>P.$X6ENLM/%*;SS7
MWYJ*^E4O""=>4%$3%</K B?E[3G]2X$U5;'H_481?&M>]=*K&!EZ=X+S-V.B
MI<*+82:%=W1@H]7P'F#UQ'"U"V:)%69J$D2PZ^U.&RI,)K !( T5T:+W+LVL
MO'=E$B(58Y3\*\);:")9C<9P9_=>F4'Q9JKL2A,5O!T56INS8.K;>/\'90[O
MR',-NVS-2P,JT.A::IZ/)A,51FP=ZZ@JD7CA+,&T(DWCL-KL>1Y<3^)J>P$;
M@<WQB>SM^9)"S2D1Q"2NL&$ AHXI8JDAOXQ'5;\9IWV5HF/-^[H<,8>IRBN1
M%[C]PRA V>@OUI6DU*$^E%.C+.A=$(?M WB&WEFL$:)&#66G2>1=E '1_LZW
MR;V3*L[5#37<HMNYL#/M?C,W8"E'T+QF4L/50W^B7\\Y2EJ:3/J+4I%6X:1\
MM>8S>6QJ1O]>2 B^VRO,!!X=25UO,D[=E1L-SQ?OY^+4JI6TTI:\J]7SK>B#
M-25<!2;U%::(L$@H34"/V(N2J.#?8[06]HPRL_:72\UJ-I!ODVTM7'K.5==8
MN<0PMCB&@6VL;9OI]7>%GC_ZHP<^>M='_=B/?B5/O2: AHKY/ADZY>%XJ(O/
M4[23!\ C:F"9Z;9@-='L=/RT->6ATE9F-)FJ$#6 O$ SJ-#7/:\L4+K3NB,&
MJ<9Y#=M,OW&^\%&.?QL;:+YW6I'\,W$JF=L;%V^FHR:^.-MTC[^FM7K_UG[E
M;?NES<NJ'U[-<5.IK(VL1V?4N[2%9WM5?8_R0NF3=;PD ]B<,M$:VRU1:95@
M^"*_]1Q@;M0/)VHVO_&XG@HKX=(R0[43%=*BP(PE@AH:D";?[*\S0!=%D!BW
M+-E7V,,O88U^I,LDOI-C"+3@PGHLT*DM=O%NL)[7^##;):^0IC;%7>:$I.UB
MPP DPVH>+;2-'K(HKX!Z,J7X";XWC6:%:.%? ;52^0[\M,.7,U.! 6KAXL.>
M]S$A7!]ERAGGTD_JL#CD,@B2!,UK!TAH02-36XFKW?9Z#7B#HJ2D%$'M#V:7
M9>4!B#+C(HNH8<]*Z_JJO1^L'W1WMH+SQ3DL:+LE:;([?^5?F9.KD+C^%0Q!
M_X@VUU?_5AW9"D>X?O'MH"O41Q?NXS5.O*B^&$?3W,+1W38(Z=L3]*TS>)AU
M ]NBOYICG=U[]%KRF+2]NU%O5 ^3U/E9$15E86!N%DU3MYM"!Q'M37VN09A.
M+7::==R;\&IM;$R8 L6@0UFI6Q!5!SZW[2MI0CI69-RQ.1W:K=R!3OP*6!H^
MMSQ3P77AEINWL;^.]#5#LY5+#GUN28HGJH0;[0@W^N*0UR79"2^]+[H%W.\L
M4SE/VP41?' E9;Z_8HTU:"!,LM0=:^<F0VQ.DJ$Y1<!1[\??TCUV?TQ! M(C
MG YX$V?YG>_N>0W#C1FJWX#LT24,4V1X!B]4@P\JK5XPSJ+1/SJ0![_67V--
M/+U3O%%M"YACIZ:W-C!59E_2U%DR+M>><7DN&9>2<2FB?_,9EQ29'T=JY*GO
M:EB2E9JB!XK]1 J[,Z$(O!5N .0/"(/%.'?CE'[@V[:K5U>9PHI!GZ0<:?\4
M=QU%(]"&=<35VSLYJ&*KRZ('&8$X+3-L>DMY7?QGSJD$-OMGZ(#I:M'7HEFC
MW#/:=4T@ZH@W1W.,9H#U]PU17I /,N=J5GC7S$DEY4 T-H8FEU\*?%L4X=U0
MA"_#:XH!?$@+;"7^F9.".9D3:=!5E#]1 ^8@9JO*V/'PZ$3GAVU>1=;ZG]'[
M CW[A&=/O3O",M,*9=V.5HJ*81$S)Z,&8";!3:>IU=M/S+G7ZAXU=FXGO'*\
M@W"CP\!HLE:+I91M:XH6J[QC7NF%C4]U0L?,9L)D[H%QVZRJ "P)V4NNL3+=
M\>TL>.LZ.$:':Q_7V&V6V!TV@/2K;W!S?^^\B<*%'B027:><@)+?*&9#%I]*
MQG1+&^@!.I8<)12.*ABDU8+%@C0T;1:7]?.@,V8*%L/0(KW6XD_FRF"'1C8.
MJYQ1)QY.W>"N.5Q%119$C&."=<($OV (-ZX^L1[SK-:-X(B>;2J * JUM5R7
M,3;<UXNG/%2OI,S<(66DN:^;:@;,O,%]$;*&YK:W+1U7.ZPWE"]SUB4XJC9J
MEFD4S44Q.E*;(]^\CRXB*@=:NP N0IS7">+E+3R$M2$X-YTD1_Z+/TL,9/JL
M<1">!2Y5;R384WA"A<X^Z$3&:+Z#EL_KT)EX-,_JN+,2.5YH<R!,X+*%H4BJ
MTI:E*GUAV<M7\O#@R.C&MR%<2.[2@W==<3)[[WIJO?DGK_B7\<PF]N:6 =KA
MG/PUS:54<D6LRZ?DCJK)T3#*AN4$C3:=N@&L21>JM]5(Z!+UJK&R_BUR9JS%
M,1D6)K9!<6@P%2.6B!1BY;5@1!7YI)N%KK$@T=M)((_.2 ,U#"C9VVM_E0E0
M25]Z:;U\I];+(%)9+>>"&X-*VJ:,$4XC%D-$NI9+M=<3X7A.81#7%K%(KAP<
M#2)'F^"JF\RE)[Z0]YW(F^JT;$F>4Q*S;@K50'#M\B"]2913%7=^8DL0=::@
MK89C(ZD2AJYG42<2V#OJ+@'=C*A3A]1C4:<ACES_(B7E<)*"D3OSQ2#.VVRE
ML_F.UC @#VB.\A4]I]Q.U3772)/7SEK^Q!8O@ZX=IS.E=]:#TV8%G[???FL1
MB='Y8:H*YY#%;,(%GNZ(',)<_&+:@>MICQ78 XY*0NY7>+/-P6(#AH\]L.9,
M5K69(=/F)7PD/$AXT%UX4%!PQ]L!&[Y%B[1M+<MU1*Y.=^YPD3C9P!3\[X[_
MS_L\\7F\8:TI!K/.7@N&E_%Z3T\[\@</]1;\?/136ZRDQOV8#9BVC8;;='-5
M<0,^1._?IAW&%;'HR6DE6DS![RH8$78I['(9=KF@H0&[<6WU=J-<K9M7B/T@
MQ'AG8LP#K+U'<:=\JQ;Z&#XKK@+\:QJK$/]+"OF(Z=9VT;;QCCWLK9W4U7;R
M$U6M9]S8Q7Z#V+M,BY'7QXXF&8?SM) UC?;G#8H]K DL<IO>VR&X2?Z:S']4
M7:(P"K+9OEPDN4AWNDB."<8@ -SF@=I9.!>"O*!LB=O@3X6NGE573*N&-5M9
M=W+JLJ6U]2<20@C[X0F[6W,ADC>5KQQX];6!9Y#,S+]\).M&S02%CS,<"7,J
M;-,9Z\'B'O&MJ'K-F32;CMQF@0GFXY;<F^:L$] S=O(R<5G.4$738C'I&?+5
MK>ZZ+HRWIQ%G:K<$V]?DC7*DJFN/O0_[OA$I<1K0G>;$-/CKJ@S@;A<*_V;M
MSVF@" 8R5A,%L9D=II95[>],"-)\60=7:1K<#G[<8*:35JAG>./R]J3)M)0\
MK+WDX4)*'J3D0?RJ&P%=U!DM_GRNB_6Q=@4;37ME@BT@J<!!N3D-#I7$_LF<
M>Z#3!]^B%%* H>U=I+=&-$O;OXZ4S3Q/AY'N*44RM?FH>.X?(AVK-2V*LBUU
M\E(*>A%0@LEMXK.OIX7J?">P;+#LQNW[ *H*E4GK%KK-ALQ1K9<8F2#=@]SV
MK.Y07=5K<V)G+9*ELT&K'M&UX-E\']JV*T 1XQZGYZ-!AH&H:J]4>-MNX571
M 6L*,=NR&<KLQ0*?$LL**$759+%QE^0X,#YO1X^T>:I5LVBGB89)7M6YM4/8
M,UP,&HG4 ,QIT6-^B7G(0ZHLZ.@W*\T9MZ8YXZ>TX)0&MS'C9;WMTS]-VR>!
ME_I1B*CS-7ZV&\D<)!1B$5\'44S:'>;FC,JBS!S_INEU5I/TQ,6P.D##X\Z\
ML@!A^S]*\Q_3(01[:O.T./L4]UPQOZL* 4TVD-NL3,]B6@[B:,C9+E1HCZ4-
M051_@^[>3:W61L$0RQNH4LJI-+2%#6@::T!GLK8-S(67FA+'6B=P4FJP[JF8
M49F(2G+KMJVG^ZOL6M>%X8# ,3FUM]Z?I&4@2C@2W>.!VEC6^M79!G5X.\H$
MJ!0.T3396^[Z(.5S_[IE.OIP'T!3&9+:I+417(HDC&?<LX( &!'7 G: ")53
M8?GA[@: U FK7F]"%#C?*\^5PM@W/ L[XFV8]#8S\;;NAGKW:Z1'.8J9&E .
M?8%6AW5'<\\P9A>U[:TVI]&/:-E>CK@%F3(WN4K;JT-V5* 73D-%!P&#D3LJ
MT(M%W18-GS$?5.VH[4<.R&KC)4X__SIZRTAW=;?>\S;Z $4LCFVY)KI8X0C@
MWB!M4;^4/"=DR-+V6;FM%((FY<08&'.@@C290V9VF\[HDC)3;5[UC30'O^CR
MM LQ78!GC]$F9<XUQ$31!1*%;JS)>&L=,Z*7*EP5UX6B.IQ7=F2HS9":7.1$
MM,3T0A]:*:IK;".G#VK[23$N"$L1W \DR(QE<PS,JRI<!/I)=.DO300VDT]1
M.WI!6/HUP<>-T[DK7XOH[:RUTR5U[:6YFG]0>NS,4>5]SI+!(>>YC?ZU+H3#
MWU,M3-T<JMWD+M> R,V'L-GC/"4 (5U+!=<P;U'P:@U@_5H'6+\-:X$517M!
M-/II%)?<K\F<,T$,L1'K@+\[.$EU#>N[[J+IOJNS0ELLRZVQ+"^-AX38[M_1
MPT!^PC<&[TL,R0>[\'\W58U</E(YK]I@%G17B-S:A$OTCF;W[7PSQWH2N TQ
MVFZ5T\6(#PRBQHTW]B)=W\'!6]NY0@.WQ''=GM4=[;@5?<+MZPC@)2SA+]W"
MK=D 8BZ1_26\UGVO[1C.6@AQLB4;#.CE<H^1"D 1):Q%S=/=.NBM[FL=_!63
M<\$L&A0&E>=!-JO&:6XB#G;MC&44H&:C/./99!,&MB".3&.!$?GU$U7@B\)@
M$I 6FT6Y=9)R.[Y$70%YDC%&K3,ST&"<#U]RG8Z9#)+N)&&';',R?KVVAY4<
M8US-$^BB;H/4=DG7-=VAEJ .9ECS)11--"6<J@OQC+>@YUTB<IB]<=K-8/JR
MV+40=3GKT=6/"U2H%CI+L]W8$Y';VRNW?V-]2Z3SPW8T: !C>9AKI:P3\T.0
MA\&?WFM]UW[G/B65>9_/)G!\)HIT^>K]QYZ.(,E5V]ZK]M5D&5]>D?L:6.5G
M=85&D6V'+_?O8=S(-N$[L$>1F:.P[8;F+NGK=#(ML4T9I<-^S<J\H,_0>_:A
M=[DH64[Z TNRW%V2Y8X.#B19[NDFRP5>%,*!G\$4\?V55%]E[)V4ZFWL9$FA
MO@P_62C6GU_&,>A>^6WB_;:-H!FPJ(%?O"BG:-@'N4)4HX^_?[K\_/[+QP_>
MQW?>Y_=___7K%_SKUX^_O7G[F?YDJ_[RT_NOE[]Y7X P_]N[_/#&^]L@^_F7
MCY__^=^-+T6#>+@T2W;*:$3GB&K5I[$JT%'^,2N_U7/(V#%.]0?7:F$C9QNE
MO@5&>5IFZ'2WG4<X<IS69G5IP,M[\+QNQ@3_2YUKBGF,ZM]UT!=(IIQ8?&33
MQ9=G\B$U37N[0.\.?>^(5G',>2E.KMP"R*DY/Z!IHD)N%/8CZ/(DU=%AIFTW
M+2(&I9-6.4XV%$FNK#Z#^>'_$;K?L<7WHW04@T%L2J*P 2:VQLYR4PB53^.H
M,!%,."GLYUO%7^$_KM<3>X!30IUQ>&%U5QE/-=)[A9^%OMN@)0Z+C(2A-:OL
M1@[=5!F*11$,Q^CNS+UU='U.$O6=">#OON?\ZU?/5C.':W[1>SVROX9A:P5!
M=&$6XJQ+1/*A7"!(-LPM \)\(B*WD>W0<7>0ZU0SJB^%SN<U5XP#\_5P8J,?
MO7W1'.),U?_QBB)656WBF[^__DWWZOTG=_LB%N_T^C(LLXOC4W<O-3\?W\0'
M$#"/IVT87MLD'/YHFGNWN/VY#R[S2R'A!_(B3( 4,PP?84Z%R4\9J.)&*2UD
M=2Y819TMQ%+1.7_I M#Q)_5SK\@FR%NI"Y==H]#J#8L0[GR^@T%%CB!SM/R+
M)A,51ESD6.\RVG4O.$18TR8>4*7 GU)S/IW6K&#&.E^>/IWQ1UZ8*D[(ISR:
MC#2J@5T4Q[5JS6?Y\OY9 M$0%*BN-6#@ND)#WVE:H)^;:VQO[94-C5=9/%&2
M%UFIH^<4WZ3Y5^E95KAC.SE*RK>IO9HD-([F_TM+4(HH;V<(@V"R&,XH"%GN
M:8"]4 ?E[:0XXF9G'MI?U%+BEIB^K[.**-7(;B,1H(T1:3IINS0#Q>B>C1I:
MHE(8EZ^#Q@AHT%K'HYI&!Q&RU:%VUBU'PCWOG:EPBA)4O'3@,O'&0#I5&B4G
MPC@[EBN>7:[SNW0X3+OKUZ#3_!L3+NFL7\-0[X!C>;_C--]7T]37QQ26#!2P
M+SHVS$#$R/+189^7NYPZ5)!#1,_Z0_J<'"3/R>'AT=\M;@\#ZG%PT#OXR3KE
MAK#Y8%RK%Y[YRWSU@OQ[Y*CS_@(:N'U$#^2XX,@?6'@'^C_H+D&'*TXTZY@E
M.VKHD\_IS>LT+B?)\V,[V3'OL?8)T%@P6&A%Z.O*@5OS+NKC8O=B_1N>=A\&
MU)^CD'%\//I3XN;S'X.L:1L;/ZY^J^6WD9K'SD<D.(^<#UAVNI^@.,/U7J,Q
M,0QB+0MYL/I !RP-\1B.SWMGAS^A^Y5U!W2$TO\=H6,V2E[.GUK#'PM7#^0J
M2EL/=L>CQ@)>VZYJK^TS[YIFAEN/WSYC-QR?T;3MB#:CX%P\B%/L:%H\K(O]
M_LE?P)_K_B<\F)^+4.Y1VSVJ#^3<K'[O\'RUBW4SC@KU''9^")<E26^R8-IR
M6XP-+ >RXH&<@.0Z^-&L3OC<6D.)SBG?F_&10KJ \\%?V2]WT4M.VE205\]0
M9<*7_>]G1QV7=NZVK7PU.^_@T>IW\&CY.]CX&3S]TM4?5[R%U36"@=KN$% (
MJ;3_09:YLWZ1OH-TN:'H_'R7J/Y!Y1GIM]R^M8 -?LRN@B3ZGT#7*'2DD:_G
MLITN;02\>FRWSGVLO_@:WD'MEUOX4+>P)F:G<^BW37!<]E\N=)IG\^[HNL.Y
MS25-7O-;38!'>XLJS6*%>[5NI9^NVD*-7_;?W?\[Z/A+\[6=96F;SOE;,O'V
MO(57=87R&LRJ%DSQ6R,I;I#OLQW?=%)T +[YX;;6&\VWOD^N5>[6U^AQ;3J&
MMX<_TZY@'O?]YTOMIMWG> $]@^]]%V5YX7U6HS(''0AG_3KMJ-GX$L3*5/HO
M>MGGC^\^5S^HWFNVY%]<M6E_X7.!>D@AV8!VX_<@&XYU"8GO'1X<'K>R_#NK
M8V=/SO9915J(,;3]:EA-[5J_;>0T;#(E(BV]FM9S&<_%-A+;Z%%<RN5MHT5)
M@\5-RB?$:7?U<D@&FZJ@O -*":UG]6EI[*8JFB MRF#]=4/7,.5=E,)0I/C&
MN23(6_,=X>/^@9/>"(_RA)T<R,7)& 9WFV/[3B^(:9 A.<-+_HKBJ8_%NSPO
MUBQ.5AY_KK%*]RO$X!2#<Y?V7PS.;3<XV53:30FP<.[P\7F;!#A=G4$O% #S
M$N!P=1%SFPBHR0#:EVI'G,57-0*\-;4B >S_1YF.7%X0<N-<\X\];()$.):4
M+=A:>T#-[SAOK-8*81]= HC.93HMF3YKIED*CN;X&!#$RZ2;5>W@VCT/=-!Z
MZK:U2$<>Z7XGVF9C G/[5"/L3&&;9<P?I"R[9N-C'#.O?J3[(\=QK3G$XC<T
MVT;X7I15%\>\J-Y"IM[D_/AP;["_=[AO?MOIC69KB$IUB6L*Q(54[:ZW:K<O
M5;M/MVI7<F4EI4QR9>_$A;8^ATQR9;<D-5-R9;?L0"17]C'Q.<F5W6+WHX2'
M=S,2M:%X\&OV:&TL!GPA,6") >_VS;M3#-@6ESO>Y)KW>)@F>91SVMBJ051"
M4%HNAMKSJNLLU+$-U/$6<^*J(O.@0DAO;1SINK;1ST\>>"R49_ 7Q##A <8J
MIA[/F<(:?],.UH$\T5^$ >.4T/,31/9A[!)ZA/J>VR;G]:[L$BN76/DN[;_$
MRG<B5KZ2I%PQV'R;H%Q%4LJ1K^/(NZ5?2X1]J\2?MX>Y"#=9!(\D&C4DQZ8Z
M<:1* LOBY_)]26F7E/8??^VW1S?><$I[H\?I)KP8_0-Q8X@;XU%<QON[,9H9
M9:Y^MK)ZUAS,IA4N@^9:Y4EZ_:.3^[P6!M.YDV[_Y$M,!B%R1P6BP6=L5J4X
M6+:+;C^DS=[.2Y\IM;E.'+)JJ]O4G3GCF9N@V+N58#O2:JNI+GQQE+1E>>K6
MT:/H.[=%K"$8$^9<'<%8HY7$E,Q)UA!P\FA*R'F^ETYUQXP*2,W $U-'SF1F
MNE<.S3M<X-]Y1&14Y*V&GHLK<MMNROMY*&&W]^NM%(V)<F'.\,N:<I>E9V"X
M]4[U']+DN2X@7G1!BW&6EE>(O>QT,:=I5;3O-CS?8$OS=T:LN)72K^NS>E/-
MRM1+][P:@[K3+M39D,-6$%R]QI1R+TXQZSJGZ[O$:]M>Y0RI>W=0F]\D+7RB
M&OB^(U,\LP;S30"?VK:J3N[X?$+X'#)@-6UJX[WDU%]40*!!C&8^PE+#%40P
MZI#:\,=<>-_&*%/;*?D*YIT8N(2EMPT[V9J75FB;W=3AZU_A>]54$1.>51GK
M\&N"U09>V/C"- JNM6<V*%2F.S/\>X38XO@H\?RXT?G?7W"=ZCO3QO-9GCA]
M%HC6;L&EC[0/!E%-$&&:)(4&8[VA+L35*37/C[/YG3D9.37-HFM8Z!6?(!^L
MV3M7-E4 L^A+(N!YE:A15*Q*9+[&98 -S5EY58S&F5AR1EY^E5+M@WZY:9(]
MF'D3%20-$ 9-:LT#I1\S8T:-&[.8+/2#KH;0/:_H$V1R5E+3([B91$H9"_>;
M* <=H$*MU<@6948+N .K&*A92H2>YECC ])A,HV)^^,F&[1OPYV;8",X+PO5
MX932>'NLBA1P]+@)U4KV&U4UK84[RQ^D@Z2+?D XP *T"C1'\.9H^%/OZ. G
M<[#P+I"O! ' 6.=M""P+]BM3DR!"'R(_3%J7RVGQF+'E.-Q(QG@%CG9I9@C3
M>P<2%LD&ZV (()#I2\)T$J;;H?V7,-VVQVPNX]@&:*P]L&)19IO/I5;I2I!%
M]K>MSI@FQS8.&.LSJN9$@[?SU9YW6PQJSO:NAZ&&* ;JDH=+&!5:QT9\5U_>
MP*O4XE)2L*12O08'LKUESRC*!4*0E"4#8$\5M96Q$%A-V0UYC4BD(M1#1+W\
M:Z&M9OVDM=PY0':O0DB!+Y5"R+L50AY*(:040DHAY-.M%Y)"R#MQH:TO$))"
MR"VINY-"R"T[$"F$?$Q\;H<*(?O]IYOA]&,2FAZE!;-IW]2S7_8H[V=$F(PZ
MDM =5=O'0,+>*\=GSB$4"B6Y010;IJ(@.$4BJ.46AQ[(/3*C^!L&MAB[.X@9
MI=.$4[Q!F<.L\EQC1MI0M./7<7TNYHTN/JJ&IR372U%Y]+TPI59B^&@5B7 #
MIPG,S ORC@;?VCND0CBCYX[N5'="#8(\LJZC>G\M/5>_-ED&BYV;*^YX=*VW
MG-BCV4QXQ 9[:)]UBR[3W6PN7D:]RBS.JOJ.N=Q10:BDU+C,I'AG*=RY>L0)
M.ZM%%+9UHBC-N4I%DT1&MF>[[Q\(:>ZMU!SL7,V!: 7WCUAMJ,[@ T=T,)ST
M?]PT2-(Y3%+<1G3SPZ>KFV])]8%<RW6!\51Q4=)^:_G1J.51(A7E^F"SY+U#
MK4@F)O.9OU*)M]<_T)@WZCNH<V9@$^/$K*,LG7 .#\9D\;\#5!U!ZR]=G7]!
MBJM/*5N@B6J(GK96N//YB_9Q[BQ\6QIME<CI5E*,\!U[)WKY$X6+RREWU"9&
M:?/'27NJ-M<9'@8%\Z5D;)Y;YD*9:3D,ASM,N9BPF2:C+TJ&.#YH[^:!7L7X
M[(DF"B="C8];#1Y1NE=4-T0+E_PD$2M+BY70Y4BVH[W*<<.C?-PE%R@'>(XA
M]AI93TNS[SSZ[AFF+>7@8IK)9=VD:?:ER,IA47(2WRMS1ZUN\M+[JM48YZ.W
ML:Y[VKCY=B3FFYAO.W]U&P7A[16N8<15->3Q+\:94@;OQF_D^K[&CUD-?>_7
M_O6>T4K=3][7<7!ZM<M;3< U/4"DF]*S01#':<'&F+%G4K#DAA899$1@J313
M##,0)DI0.%\%28*YO5VM84QD"&88.3\SS6$,SLLHA8G<X#?_"&"\;,;KZR,2
MZL&Q7S.XZA/,U1!+:UIGJ+][B"E:J-?V61;C*.N8)'_U$'/4H+R7A6T1- 2R
MP%\O?CM%\FYYM>\0&Z9=*R1#7=\4>*,2C&>S,T3\/)69"C*JDM5SJ3L);,2-
MMNV&BJ=P$+.%N(-<&]>8_OQL32<B/5OT%A08:+.%E+7PFKL8LQ"8)!?ET60H
MWJB/N$R**,8!HHS7D>=F%\(2E%\S E*(KA)7H=CZ8NOOTOZ+K;_M.@@;]!7C
MRL<!U]):_J-+T1=+&E-"4X>"QZXRUYQ50&N=*X=16NVXHP)"A4?FUWKJ+H]E
M,6)E:Z(\%!W$4IG]CB,2DF/E\&#R;K0Q7Y^[F>!S-'GS8JO"P=@@,:@PVK9.
MH#KI">932#_$A_)=.0YRT[UPU*@#JWNA%I?%(<F2L$^ON!9=?1_&94Z:,S=R
MR;'F34V##)-BZ%Q]5F><,C B*:)!2[!F'JQ)+S'K6GH1E>%Q(('SI5C'P(M@
M.P7HF?,#>U$"\[9ZR\)%[_MSJVSN J\:/C)E)4MG39EL*=@5MUT^)TSY#@N:
MVSYR*@8QE;T;';F!OUFY&L5-*&Y"X8N;=!-^9LFV>8_?\E5>CU;_%H_?SM]"
M['8UJ\2_!0V&2V2B:%IQ=?JE^!X"'Z<)2&'*\1T&9:Y8^.-G"Q(IFIC"T?=B
MUB&:X3LCE,DC=9-V_)#<3N:G4Y4-=:,92B6I\(=14:!F0;:U2VOWJ=:DZ/GB
M>=H-:RLT$DK*A%L%F0X\52>B"H09P8<]W9?(;0,D[A1QI^S2_HL[91<8O-M7
ME-K6Q88+-ITM=0G@VV(9TP.0>+UO>'QGCS_-4%?CFV#>J6G!)2&!*Y:,[V/^
MK0LMQJ8XJZUA55DUGP/8+D!N,=S7:ZO.%_?XNIDA=Q-CM(-F#"$=M7C&R,,/
M5SRV#?/@V6F935/NU09_8G,WKN2Q;B_,AR%YNP2.T++=9#Y+-QGI)G.G;C)'
MTDU&NLE(-YFGVW3A[EX'Z2:SS5T6I)O,P]ZC>9-P0^:V=).1;C+"YYK&^RYT
MDSEY<M%'"39NERV\R NVH>CBOX)AD PIDX%K)^<+$382;#R18*,$&W?O%MX>
M;.2\-#>XB"[9J^@:_91)6D0,)H'N1L[TL<&R*)NJ+&<?<GMAGX^0(^CYKK+G
M'!R5?^'0]QOG]3A2(^_M=S4LR7/\D2*EF0GK?<+%X9;TO"_H;G5S\*J$HM&(
M2QZ\<@J?PRM5-"UL#)%;?#NY>\V88M[S<%.O+6,R,%Z)ND&'+AP=>L[M8L;1
M-,<1RY@VE"*\NO"[5G'>DKWD6U"3441N8M '32:6FYFU4B$] V3@5*H8!($#
M(1H:[:?O*71HPQE4?0,"[\\RS<J)KU%3 II+RV ,:T;IFK/J[&NN:N^R+=00
M(?XOIKQ18I?%S9KB ;'''\4*?]>2XEDM+:PBSHWB 2?M#A^I>HCQ8<Z\FR"W
M!XBY>4.J0PV=9-'VI,_;\T:KM%$GW;0E5Q0K>@(. )F448E/2WQZA_9?XM./
M02<@V:C5 8YO.DH!BP#B<UF:1$-N_S>)<@V>9C*:5Q7"1@9'!?)1"J(2[X01
M:\]@\58*D]085CA?9*]3;2*,@^E4)2;N6OT0I1JH!I>6W:/(<?<B!]9+H@OF
MK+)K'9==.O@]1"PM*ZMQAS@D;/&E=&)4#<+/Q',=S/O C1O/M;BT$7Z3#8WA
M8D=E<)MSWN6%RV@,>_F^C_AQ8X*-G-<2>MZ_:NK1/56C6YKQZ*2#:M\7= ^:
M4W4ZU["DIE,?/4^](1Y(TE*(8HO]8#N^V^I7FYE1Z1C+U0/R"UC!F%GU-4]!
M;\Y@1ODT!GD6]KSWNG211DG2&M2HLPLJZ<P3,1M,.#GZ2("-XGMLGAW6_A1!
M419*2EP>@H>_GT_M7"XAQAL%45P54P!UET@#$;*$MLM%2,A :$AL]8M;4Z%G
M';4N#F/2-#:K#4/L-D^M@4-$S7>-V73A*M[$ZH.\N?1;*UGL8K7E:195T^9Q
M.E(O(O4BPF0VW%;&*C/>)0L;$![_UMK):]9.-N+3/16?KOAT=_Y:/OOE0VH@
MG;5B5@3?5-+I;S-9OIP)K-7.ED876I#./Z]S5#L<=#5,;/;]K38]IZ9[D6TB
M?C#Q@^W2_HL?;-OY*/K!-*?2V!?DII]BJ^.BL'XG9E_:.;:0?=;86HWYF4((
MR\U\^]$TBV T[6I#_EG]%ETW% L+7,ZHO7!X; 7[3=),\V*]&K"GZ+4^N=%@
M7UHK.6K5% R$&Y@HH-LQ&JW]*(DFY60.G)=*%F[2$O%ST:V!#HL@FU'%@O'9
M4' .9J/[+6EGA[,5^ ^V(P/JD]Q>Q\+MEV#UZ,J8HH,N*4Q+ G1SO(6;."](
MC,,QX !1J-%LV".I6QMR1RM'*[T9I_0+MC/U4%:V=;W"\4\6O/_Z\6R:4D\(
M2VK:,F5,8T)48><-TP3\\_2 ^6P8S*Q]R[&BO* UA/;MH8KAC7HX<KOZ+<4B
M%0UTV/LURC73-V=%D-+-UPA\L12<_(""DV,I.)&"$RDX>;IYV5)P<B<NM/6)
MV%)PLB7U#5)PLF4'(@4GCXG/2<')%CO\)%JY7;;P#R@X^3^4_+.1^..9Q!\E
M_KA[%VW./_"E)/->.S Y!PPS/_-:"-&$!-U>:S9CCIJQ!;D90GMX \K[M+YX
M[MQ<I8&R/](W90$Y%0, 89AR$DK7@]E\MVE_;C<A@_ -RL\R?>T6MAQ:T*)N
MUAD08$>Q10Y4-M/0UB_4$+]'%OM<@R^\U\F0 UXXQ49-JF+M1?A?\JO/I4'J
M%1CW>?O>475)8VT(%7(59"&WV1MY-V/NJ<21"TX :UD9Y5!&(W2;UYN"5SY\
M7Z.4<R&/^]XI5_/@MB(A8/Y6CK@<F2HPQJ"79.,I&&\)PC_2,DO<+SP'<I[3
MQV!YE!LI 64)*._2_DM >=L%XUN=:-/:B50'8-TVI-P*4,M&__;^=\VFJDY7
MP4HV<2BW33C5V.5"&>#?(JSP.]VI+N]Y_^;T\JK[/;V0@HW-=O2.>/>76&!C
M9:4%T:E&;%U'IO3'O.\LU[J7Y&Z6&_FD'">-D<6J"NRBP:Z@?TR" EO(4N_^
MFH2S$6H,='.G/_OBT,HFE%GP.?Q=<M18*P!6].OD9RW7)A2T;8$?P@_"++CA
M-MPJH9*&9DP7]KP<*G>?]=8.5)S>.+4;[RO-0F^:R1G'U>IJ5TM(%.3&JEYD
M '6A;.A\(5'?2KD8CJ\I#!TDNX0"0'*?,RH2> )#Z:2BH&(@J=^2^BVB;+.I
MWSIEZG>^F5RLXG"I37A=).E;G"Z[?R&KNS-Q[LY<;:C..=0)VR :;T$7];LZ
M:OA5+PU3!^D(<7)_U#HAHXS&'_BV9//J"CT&*%_KZ82C: 2RWZ &[)T<_+2_
MA*^E]C+C+JGW2B9EE(H0E:U2'#H:LJ21B]6_@_LO5O]CX,P^F\U@-[4Q+;1L
MAEDTJ!B73@=O\W'6^'L=PJX%/EJSRJ[&22U]EIJ]E'RGVMP4@1OT7&U/L1U%
MOOVJ0'?&76[(5&<S#PW)Z+O866)G"?/8J)WUP7(/M]C66%V;L++.Q<H2*VOG
MKZ-[<U!:N1)]OFZ5)1H9'&R.S#L722:.TS*;D^3PA5]9*;D.YS9JROQ.,Z?>
MOLYX.B-3J^O@IW+S)@-![Y8YW1HBX(XT7<AJ>O(8SW":/)I OPNT9C(!',6F
M,;U&Q1E]HL&3Z!."K7-JHOBHFU[>55=(@1K3XHC =NG,<&]#A5T#N=]/=P<F
M&+9#4>/C'8'"%M6/(U1P@)%CHOXSP7_QVKX@+>7TD._![PH@;E0.IT$$8[!2
M9PO':BO5"W,^LDHA<($,MS:@OEK8&BO(;#==7K<E<)UI\+4ZJ*(1N3=JK-E"
MTZ#2]@AKEHA_X89"//#AT:'9*J0;L<7%%M^E_1=;?-OE]STC\'5NWF[=MN@&
M\]8^"X,@T4CN$Q0^Z,,L$Z LY(=YI2A@_PL2Y?44*4Q3PL!FP[<;*C6QI>GS
MP6]3$6U-])HTOY>H:]41%@KROEO'7)?HM1)G+<Y-=?9=Q+J[UHW)=0'9DYKG
M'U#S?"(USU+S+#7/3[<T4&J>[\2%MKX64&J>MZ3$5FJ>M^Q I.;Y,?$YJ7G>
M8H^8A(^WRQ;^ 37/E^$U.>QU].LS5VA@M0$[_-TH\J<LG:9Y$&\&=D_BR!)'
MWL%[V1)'GD2,>4.N2';.\F6R$!L:6F]1]I;QV4[UI7.K@K4+&,N*P/K/*O]V
M6T;P) A5O0%T5Y7R7J2Q8Z9EEI>(OZ##C::1)07S])0K+ZEU".]%9H !98!I
MAS&O21<VWYJ5C!@VD3L0AAQ=%[ )R&/><91CY+S^I?;[ZI<;OWT=Y=#&!?!4
M=#2V%J_6@]_J ]>_,\[XO=;ZI/VYX#.V>H4GA^EDBIT]JX[:U?R&*BPQ#3I7
MA>[R.C]/749/#O#$DAV]VM2/"R++ USY=SJD%%RG$<>_D:;3<E!P. C?<)7B
MR</^E[ER;HH-HE"C5P/LJ -(N@N"0]]X\3,F9(?+5.=-[$)E" S)@94E;KTN
MD,?0#-<TNJ-D6$^(0"SX]L]EK'C:_>.@HY/"N>FBL*?3!2J Q P>W]=#X7+?
M?A_"2Z_TD)?#8E^R B0K8)?V7[("MITU?]! ?',1?PI*5Y]J@8H5V8@_%6BS
M2,OCK&D6N3S9:&BYI+=+>KO<O(VFMU_"%0RI%P)&9Y$\1IA50PK7^\2Q4S;B
MHK@0%X6X*';^:C[[Y6LS9=O@V^M&;(7Q'01XW2KW0AO*/"."MO9RH:7F)FN.
MCI+K>H?!%"]Y1]</WYKGOC=.;]0U-\@A?%Z>T81KTV*8ND9.9T-"]W]1["VA
MDCO3H$Z+<)/\U;42I]*Y2ECK;%:C%^@Z6G32?##%-R_>.3+;KP@8-W/P./04
MN+',$O,\/?4.?S[ZJ7UJ;D^]0N^>;_<(#+0PG1:-G8H2<BSEF/E2>28Z6OT9
M"LI4'.BLO1>5(XGS\*SNQ*?(I1-. KM& C2 .6D"AJ?3/(<K'IM6[!P*STO'
MJBXJY.""N]K9OD(K^-W8!3._@4TWS$O78T7/<HD[IO#7.]W487+J8^F=Q,&N
MG;%4'%6.G<;T[:SU)]KW!'L21\$@BG'Q(\J]3+AQ7AA,8%+8A ^.TL N%X0Y
MG*@K8"347A"WX"I+\]SY\"5]NF=FADQFDK#P73@SW_3WXYW5O7C8)RK6OEC[
MN[3_8NWO@F)3M_(;BHP;V:B7)QW7RI->5B$"E%F^:?!*X82;,8.\ZRXE4POK
MQ?H,-BQS^IFP"[@)RX6R]W;9;CO7SJL@[1U3&G/QC3I0I%?<M36@B E\9#)+
M/:H<@,\[_+DP8;P1RG;'+=)Z2Y9! +J"MX=S0O9_>/"2@LA8Z>;]RDNAS_LO
M]_VF/F(5!:V8D$JW2(O3BZ^?<<0J&J'2LX81PI1SA6H$ ;,QFIO1%U@U\EDE
MT,"EO&\HZ*QZTSQ6X\[FWH,%8=*-W*#7D%0Y:GN;YZ6B7]<U7:T<TF1@Q5X6
M)-]R[X\R01A VU*Y_MIF(\((5M.^DOF%U$)IH-;!!'..-%B(OM!%@NLD:;UV
MY$AX98)XKA?CG%8/'_ I/>RBQ0<G/CB1AP_G@V,+:!/>ML,#\;:)MVWG+^'M
MA:EP@?RF2Z&IMUJ5:*G>?NP[:@X7Q'FZ8,RY_*$%KJM:K2>K%Z>G'0KDH68.
MCH^J77>]S2MXJRHK_@3Q)^S2_HL_8=M9=^5/6(HM+].2KX73_DAGPYRMWA$R
M6,TRU[OU PUSP2B7>OT?4*]_*O7Z4J\O]?I/MZQ5ZO7OQ(6VOHY5ZO4?]AY)
MO?ZN'(C4ZS\F/B?U^EOL;9)8W';9PC^@7O^W: )?<\Y=XKW1GB5RE1A@A]],
M[M]&HG)]B<I)5&[WKN.\:Y<S3T9E'*N\\. I])1.L45H4=0[QOH:UH3S5]3W
M*"_(E1NP/Q@=CC1/QS.,"*?&[5NUD*=:7XR=#91-U8UGE*P;*],4@!*(,-^E
MV7M[+HL7/\0-&8[Q%:,H+(<1?5]BTG/N3*'G76+Z3I4[7V6 3]*PGL:+)&W*
M?-__W]9D[VHA38<N>6+I>*EG?986NO2?=@W#=XVZ?$J"OWUBS80@RD8:\C&D
MDRC7B>G#89E1CK^N?EYR=&K K^OVX3I0IX#:_MUMUCVIO=^)>[S@$B<6GOZ'
M76([A=4OL?=_W[]__Z1O<'5^][W!$M&6C(*MWW_)*'@$XHKRP5SU,7.%$ ?8
M;Y="_+L-Z)+.? @OWL550*;.)5ZP""-X"-H&__%&P:>8L(!MFW0&!4H"DXMN
M^TPI4Q,X*C,:S1;!<>4?_HMSP<:JK>:MF7-A2M H.X*[*-5^O-1F#ZI:/,[\
MH%E4F#S+:""XDWEJ%K] H#>J_NI-A)Q23#VVGN<\1-5*$KZQ$V;Y'8*?6G75
MB@KJ>YKH?)AJQ"55 "V<JXE8G6":<<V OT!\.SLGM0!2"R"29Z.U ._K=< ;
M\3@>BL=1/(X[?P$Y X!!\TSU/#>WU&8K-H2\"7*N'T1K%BSUF?Y7,:;:PL2B
M/W%33_T;%(@H)VUUP4 -4]SZ*+E.XVL"'/0YH]2.X\-K.0$?GJ0^E IU%=:[
M4+Y&1CL8*L69I3=CSKL?1M<(4CC,2-#"7T&(L$IYD7%Z*:D%UZ *15?\ ;>[
MY(<CY#V)%M7?]=_&:;(7F!+23_:]5>THZ#JH:S@:43#4+24J/1!W"U6-FLIJ
MFQ#XGH*5IC.EJAWSX)2YE@GGX.L=UV-87T+AF5X6J.,99]!M;R&=V P?)/P^
MI"0@'OPNQ&.""^UV6/7I5!-8S3B:^MX?H/(5WC6,468PZR(K\Z*:.[%R4(NP
MIZ1NMCC6.T'>*[V=E^X2S8[VO+??@0AR(A14L5A7A:?XYQ$E$"=:.23E+?"J
M@ZG48L2H-%4I%@&<]'PS+%* TU7-G!^2#VQ?3KB86@.E%7QRR"XO*5N/ZHZ!
M^P4\+2Y$Y4H76+QN=X*EHHW.%/AJ_5Y3LZ;,LFM6E$97JWIP:B66-[IZ 0.V
M.=XF]0UW8ZXC1M;Y6IU$;BI<>KQQ8^V<Y$XE\*)IF0W'J%OC$B:P;EI[E.1E
MQKN(/5-@!2.;C%TQ$N<6F..T-'L%P^1L!50:._;FR8@#Z*^=*\6G5U&(>]L2
MSY+=,)@&0QB+KI#I,)*6A<W;ID=L>CRBYY;4PA:?KMA+FM&),+=,RSB$G;E6
M]:VI&*@[33USFHQ=F;CPQ(6W2_LO+KQMU^.6<.$%TRF83.2*(V\>.T)0K:OZ
M+B"'Y[*?>=DQ0FG>+;>*=)_<>EU=EDCER/485H293O16AEFO%,\]U]/LGM@^
M*I#8$-HM\W'<4:!R7&5*MTDEA8']-#P=J[3HB?A5)S37<85J$<H..#[87MBH
MNBO/*+D$H0["FB#*6<#<*OJK\EOWL&I]8/K')S68:MV;NLU/YS="4,M[[2J]
M8R\P#5!6<=+!5W-*9XL^N]!]U^%"6[BHE]129-#64.06WU]MFCS!NWD#6P9:
MWC^X<'%<-%VK7]-U<-6]L'J'OXS7U_J[V:._<NR9E%$L'4>5UZB^438L)UCN
M!Y3O,T!NJP'9L!"7-"2-]6-OBF-"FA-:OX%8V7W3U>R^,0V6CU6KV<<1B7E_
M_I(6'O^XR\1#0D-;3"G7MG/L. XEZ+U=V9Q#]@:&"!M:.$50^.=O3&5H#N!,
M1U$A*,52]?CP58]G4O4H58]2]?ATBX.DZO%.7&CKJX&DZG%+BNRDZG'+#D2J
M'A\3G]NAJL?#HZ>;#K')[(>G'J*0B-"6;+<$@+8L /3LEVD<))5[$]V$W/3<
M.*<KKR7%>.)87=E<&G:<LM\0FYR9*'F'8]'Q*^H$6R>"8Y^%"P;RH;54K6TD
MC 09#ZMV8<.G51[(G..;6H6:(!!W;DN\ZDG.8K)A>0Y3L#_9Y(*8V(..6.U5
MWLP CC=+U,PF HR4RO>K! -8<:A&.CFIRFEQMKB62()QJ[E$DDX((=^+G(QU
M[=^G5G.=P;9&;HRS"S"1,3N2:X?3E2U?)<R0TYU@;LIIBLN-(YCAS$G;1X\R
M(Z46P3=RKC.D<BWG@S:FF@_%)#(UI5:OL1=,TA+#;IAOSDL+<?%1H>=1QD4T
M"0I%6+$PAP)#%PFODS?T#S@PHME0#;G)'^'%V. A9_(GJ4W3MX003"D=FRBG
M,4M^I*CU=QTXL3L-RDQ/F3-8BD(M)=Z6!M2= K0H]\?D_51Y-A2Z"3B>485P
M@B''C!CFEL&K@Z+$!K9SR 7N1P9YVD90[Q<>E=QWR7U_LA+[87+?7Q,R"O'%
MS\1W-F+N+>^'?K1:LV2_[_P5U-GO8:I8^I/<) G;V@K^"_7RU;DW'E^T(L(X
MTR?;_/>+:?Z+DC:'^5!=7J,Y<,_[MZGX<\=\Y7U(DXY^]?^B-O,&[6C1NZ.<
MD7["ME1I?.7O*KLR4MY!=5K_3#KT<8W=Q,J4WEW0''2V?0W%R6TY'7B4P8!3
M[;=/S=.3HC$WLR28)0C6@R7>G]O49G=%DO>[HA8C7A[)^Q4)MA*X8!TVV>'P
MS1;U*[!F!P_%X6:^R4]+IVYV*;^R!AC _]#C,_(Q%M2CTV0XA+,F"]A**#3Z
M,0>N0*.[0#M]WDKM>>\3"_WFL\N"D&F#+(XP5P[3!C$'D_*6+=S<9*+"B/T+
M)B^3'AO&*5>&:&3<@)-8VM=M >+* >CAO#08C8UXBX[XUS[<'33+>11OSZD9
M(B1F>(2Z"H1_E'E!'IZ100V@MX01GB/B'/"_\VD<@0$.,QG8?%Z3HY='<#D"
M!$+0@#71_[1WN*'%.FO99SP$Q&'HQ%J<3"*:GY&0Y$4P< YZ$](1T!:ENSI@
MEI@+2(G#Z+W(U)7.MJ1WP])IS>R28%T(C@O.$S;\<DCIL3FZ@[1SS6[KR8$/
M(AC_#[>;(8&U(RZOG%6ZN*NI !%EV[D6%0BR3:VL*R"8)QN11V-$GLN JQ.9
MUCX$>1C\J56#WX/LFRJL__!#H#$)^7-6MX!K,1W^OS3[II][^[V""3<)F\KY
M;$+/3^, ,9 = ._;8#TT-G(- CHD>D-\9[J3*>\[IRHK[83",[LF3P\A8)#O
M"U[';I]L'L6C ['#)W??4GB@K"@B%T0HD"&U#!DHSV)\+L6"J(=&16Q-3A/D
M"-D]+..@T&G#+7RGSF $JT.R5A\^:_5<LE8E:U6R5I]N<I=DK3[.;"[)6MV2
M)$G)6MVR Y&LU<?$YW8H:U6P.B1?8'M=O1M*$/C,Y?LC[UV4Y87W68W*/(@W
MDB5P(ED"DB6P>Q=OJ2P!TP8#VQ+C/<KX'J%KD7RU$NF52.\N[;]$>K>="[W6
MS59JB;>V14H5O_C\\=UG[](D[()ME(\IUI5B^"K)1R8!N!GWXKBA#LGLI;JJ
M($@:OVX!.J_'1BDQG[*P*0N)^IKD)7DV*4KKA&;FA]OW)MA[A'FJR:3F"=HP
MC0U7VUZ$3KR:XL+<:,<&LB*S1LO#5:S#H>J[RH;44J;(%[!T;*CCVW8W*YZ
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MXX-_EGZ]N^I5*FJI(\P :C@0E4!LJWRGR\ :_/-?'T'!X]F0X>NK_E] F41
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M*MV)V$HAU9/X^B)1)*DCJ=N^U#DZIH?-;=Q?*(2(KB2()(B;"*+PIYZQLXF
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M0V^,<PB%1*B(3\T!(^.#@22,#@+G O!=I]M"U.!7)(LXJA$D.R[S0V,85T^
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MO2L0&<\R^8FZG@G^#]<]GYU!G2;[Q T^ZG-/JF!559:DRVV<DDK&[I6,W;/
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M(YMU'S(]\Y3DLQ9/22ZLR<8,^_:SC@^6+QC(YE[LL!S)I1QA(+MA]S+3<XZ
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M6<$P*"VHB&&9P3(C3T3-@82BT.[6 @GK@-)&J=UL,BAE4,I,RO$"CA<<9+P
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MV->:=!H\1 X0\9C#(-E5E=9:;WU4W]$7Z8S-^LG@Y2-LR< QAA^ E-$U=O2
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M%"Z-W"2)5&(E@E2E=BKB;X=Q_9ZJQ #QU</J _K L95#U:9HABJ2($;%P\*
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MUR<R !6 Y:CC"B!]@''0B 2^I:PBN,-0/$M?"FG3W= XP"X]MJE, _47^3(
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M/S:FX/HT88Z^JU:A;Q ;.].6H,?YJKFX%+DWQ&B&(KR"]TS67P(:XC1H3"S
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M)_EYI^-2^[C^VCN54^-UG&&9- L\7\C1 F*M@U;0.'3$446!&I7J 9G:.(@
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M\E23GP*!T_Q7:2VRW.L!GNZ]=_$2 M3*I/< !FI[]+%R!K@@#HB078$R!#\
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M<,)[2]Y<V-3WMKD0T31$TZ2*IJ'C%ABP[+&Q?56$GQM(4:%:3%:G#W$EI90
M<2585=4@!I@!S)!)J.7=/'AN@BJBFDD!Y4+\1>[X"QHY@36J%(M9*UM#RD$8
MS.(393%"/IOY9FG>YDS.BJ44Y=;M@]XT4+!T%($EX,#NJQ#>@C: -J@$.P@V
M(=@DDU"C<DD5V5V= <M2N33-?\LN7S)1OH3P637#9^C'!2ZL6@AMQM^N5!.
M!M)FJ+"2P2/=4HO0CTME]8'K"XI0;7!"/R[ V-'I&?IQK4/%FZ#BJ&!30-\1
M@I,[!+=I/ZX&3!<8>$6"=!\\0G+-/&W1=YT@(;A?\.W\PQ<C-<I@!N9JS* %
M9H @737\X%*#=*:R1$)&]8%W"XI0;7 JCS4 QB2ITD6O,(GB=6JQ\C.P\CW$
MZWX1/_" 7%?4T_':0M=/1"4@OZZP@/30[P,OB8;'@I=3P:,./31?GT9YX2.S
M^1P]:LP^K];M15HPT.;'B^H:KZIDVJ,5:4M+0 V]LW0;U,#]R9R3?[,PF*T
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MI8*E0FNQ60&)@VHE#OKTA!_\Y ,^VTG:!\CRO.#1\FT&V@57358[.V-3'TG
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MTF&%XYG>@3_"#9;58F_3#@1PL3E<3!GS\8RAA>]94K8)0+%3H-@1-P>N %?
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M^[NF].=[L;\["#:O9'V+T>8I\]L?6N&$0IGK&>*O5F@/GSTV87#)6VM.6UI
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M*<USK7O7<V.71>]@4\''53*S0 JY[695A1LQ0LF  GP<N'(,N@!.(CW4 #N
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M4M7&9C#UTU_*JH,$YSK5NM=C%EHQS9;F,2MBD]374UWS6:P%@TE2;!R$W,R
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MZS@KD:!Q<;IU9^H=&B0?P40(/DM:#"/RXILNO2@.688H#P$I<3F0\OS K8L
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M!RMR;=%,WG&])&8.C#)8O")V>I5],_S)XB(4U.]I?QK HY1X(D19HGU@4]O
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M.J"G2D\OZ"F XB@D><<ER1#;_=!30SI^VA;\M&GHX*?@I]#?I6F(7\0//,_
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MB;B?92WX7_G/-J^83B+F:+1V"\JE0>?@%JICPU$1('=%0%6%&R71D@$%*HV
M*\>@"^ DTD,-L /8(:-PH_I9,J  )SDJ7$'UL[0!1G6/P6D<7B=JW8]L'#+;
MM7@*"A85;%PE([M!VDY9L) M6P<6OO=J9\AN>>>][:K&N6A.>[[3&P4D4_\6
MOZYTNJ-IU+H-E(:HYYE!3V%CP$O5GU[P4F#&L0GUCHN7(;O[X:5;E2QO34S-
M6K<)8@IB"D7=>:H ]<E('RB2/BC:$7[8<BI'P> DB9A&4\WB5%/^\]>.:1B_
MI[],RI-!TN#8J62B87/EM+E5%6HD'%21W9TE'*YS6_J%61&[X8^\'OP1L1ZW
MO47K?/%SS/R(K>;L-6I= SM4X>U!>V%YP%85A1A@!C!#)J%&&D(5V=U=&F(W
M=+59ZYHMT%705:@O]C$@$5'%1,3MT KI)A;O@&('(VX\L*<!3IMRAA:64T[+
M656A1HI!%=G=68I!F-8/W++V"X9U-<^L5>L:!NK&X)I!26%@0$H5A1A@!C!#
M)J%&)D$5V=U=)F$;5GI6ZYHZ6"E8*;1T]PD#[&9 $D&1)$*?GO"#S710YYGI
M2+-\1_-<Z][UT$T=+IQZ]A@=!N7N,%A5X48W=<F 8D?$';@"7 $G.9[I!2<!
M=ARK<*.;NF1  4YR5+B"*F1I X@-976B>7B=J'6OXR$CB4["D#[.0H>PK&#E
M*AE;'(8L>4ZNJM*]XU)D"''Y0OQF9T7)E[X=\BVD'UGZ[Z4O;&\_-;UB.VFT
M6C%(N]8]T]'L1$'_#<J[0^6=Y;VU[EL8(S!9E6 '."(!CH#)[KU^&4*\;R:[
M525S>52V4^NVSCN@LJ"RT-[UJ2QJG9&JJ$ZJHF?;)*=Q1.OSQ,49_ S.G4J&
M&#N&X-/))-1HE***[.XQ)Y$;V6^IC5W-BSOGS=?;\.*4]N*@K[ UX*>*3B_X
M*3#CV(0:/5-4D=U]9AHV(:@-O=9MF."GX*?05VQT0/:@HMF#,)EIM2YZI+#1
MV N>&-/NF<\&+K8_P&]3R_0B8R^Y4:VJ=&/[@W)"O,_M#Q>9X;UAGA4SY\MS
MK[*B4Q<)<3A9YMT9./M5>>\.RHSM$&"V1S2]R$BH#1\@M,A(J"N[^\Q(K,9C
M%]-7L]8]0W)";?H*U54C.8'M#DA8*):P8.FYXFE#]T"T:RJT=0<]@TLGJRF>
M,;N/).G!(Y=YS1C'RZQP%'BNLXHE7_>6+T=O9J-?W>8G'C.413:5S'U5]6S]
MM,F66K%'I8(Z'=56$4Y0"OYNSW=$(X#K_"R:M7WA1JW;T1MPAI6QP.7YT@ "
MV%6X!PI/KWS@!/< ,'9T>K9^$@KN =3I,#MU2O</FK6NB5R9.A88[H&D0( M
M0 IFU'!8\E89M?<$57X^JQ\"SYE,YX)WSM[OGBZEKU^Q6+.M:*@E$7-FCEPF
M._20Y>/X0[H@K/"[JVOU#^5WHX@<#CCR<^4[X- KE79:$4_I$TWY%@8/KL.<
M#T]_$%^Y]"=.=V]"5M;<9]6J=8UZRT2[;G4L<;G^-W  F[3@.AS1],H'6' =
MC@7:X#H@=P>]4NQDGYWY#F?"=SAOP7=0QA3#=Y ;"'!(T)'E^)35#.,(LGO<
M[&D#C^ZF#<)@I+G^ XMFDGOOD-V#BRXY+]BFCPH :', FF(*XQDK#G>XI$P:
M@&*G0+$C#P"X EP!)SF>Z04G 78<JW"7T>,-0 %. ES!]@)U0H_87G#P .2+
M[07S(I (0(+L2V[#C[=&2%EXE"US";_CF'<5S(K%ADIV$C'[Q/UY,G0=$JAW
M6OHO*94=GYP9OVM0PNV5L&,:)K10;FN'+?32J@]L&*AXM<$)5!PP=G1Z=CQ5
M^ON@XB:H.*AX-:P=J+BTZH,S8U1/02FK#A(D9$NO?A^XON7;+JK?X?$JQ0%0
M::9>14A5A1O5[Y(!!2K-@"O'H O@)-)##; #V"&C<*/Z73*@ "<Y*EQ!];N,
MH4=4OQ\\ #FI?A]GK:>T^Z>Y44@$(4'X);?C*+N1#B)52EE65<]0 ;].V4T#
M93<HNZF&M4/9C;3J QL&*EYM< (5!XP=G9ZA GX=*MX$%0<5KX:U Q675GU0
M :]Z&DI9=9 @*5M* LIA-HTA8KS[DDA&6;Z3_L#^3EQ:1'HP$E#P>F7G =M4
MG'T7SQ>7XL@6^)HRIGU6.7L,0JSDV<5\'QK_[^+9WMZP* Y=.V8._Z#G.]-_
M*%SYC98D<"[]U(A_S(PY_>XE?)TO?MHT3S_8C16SB\& V?&:9YBU<?[Q[NW4
MSAQ.(,*A3R*KK%Z 'DL/.\ 1"7 $]'@W.S(@Q!+1XZW.YY6:'W=PQB_X,2!A
M8WZ,S4'(RAQ;5J:_*(U2U^X9#<6GB=2"@?;$K!"T#SZCK*88A832X9ML5A[>
MZS'OZ5G%JX8ZE:I.R]WH0WG11:=XL2]\7NLVVO5FPX SK(P%1G&CI$  NPKW
MH.K@!/< ,'9T>G8\^XS@'LCE'IA2NP=-O=9MFO5F$[DR=2PPW -)@0![GY!E
MJW:6K8S3/^8GZ1C]=9*>P\8GN.$5)P$?/+('FGG:HOLY04)&8\$=\P]?C-[8
MQ U7MSFI;'3A92W./X!H\B3L=JE?T*Q#>N0MN3URH]9MM.KG>@,>N3+&N%2/
M'$" 2#<\!56G5SYP@J>@.(S!4Y Z=P=/05G->L53:$CN*IBU;E.O=UHZ7 5E
MK#%<!4F1 &=E(5%7G43=;3(>>VQ$GUE>FFT;>,&CYOJIA2,;\@X<$UZSK'8:
M1]D>!CBF3/AXQKPBXE92)@M L5.@V!$C!ZX 5\!)CF=ZP4F '<<JW&4T<P-0
M@), 5U#OKW88D:_H=W7CZ(W#ZTFM>^G3[5@4T_JX#LPL*+JLEA?%-M(!F&R)
M0!3;E!S,E+789JL#.9_U;>F!G"T<R(D#.:MA^%#7(JWZ(/@%5EYM< (K5QS&
MP,I+#N=7F96?@96#E5?#\(&52ZL^J#9'FJAJ:2([&#$MMGYJ(1LDOD/_V,Q]
M8,@9P3NML)&&=ZJX.8=WBIQ1:=YI&]XIO--J&#YXI]*J#W)&8.75!B>P<L5A
M#*P<.:/26'D'K!RLO!J&#ZQ<6O7!=B/5\TC*JH,$&_)FNA8Y;F1[092$C!\,
M0M DVABY_@.+8II0<8[(P/4MW^:_Q2$-+NV.%Z&U$3Q;:0T\V@BHM]VWJL*-
MUD:2 <6.J#QP!;@"3G(\TPM. NPX5N%&:R/)@ *<Y*AP!?7I,L8549^^?73Q
M"[,BYF@TJ2R.1/@P&+/0$L%$CW^F>:YU[WIN[+(H51"1T3)^3W^Q1HSN[&37
MTM!&L,O@]+*::E302(>"LJ4<44%3<O13U@H:'#PFU\%C^A;GCMWPAUP/_HA8
MCQ.9Z_O8<GWF7/H7/VUZQQ_L4Q!>Y[Q&4)XO&:MY6NW4L4:M:QI-'#FFC!U&
M08^D&(#@'9R$JH,3G 3%80Q.0LGI"%F=A'V4V9^CS!YE]M4P?&#ETJK/\M37
M+^('GMOB?RVL!CWA^\!+HN'W/N,G(AS+FDRE8CKTT'Q-S(W7Q!83-']1&K./
MJW5O&=,LVPY&8\M_XNF8JR"F.8H#[5-:X&UY-$=6+$K#HVSIWO_FN _I<DW6
MZ,O-YZ-<E3+T9-F:Y(K"HYX<,^F_[(>8P^K, S7+>[2>HAET>R>81(J/6F'L
M/) J[C/U>@*7M>GYF+U23$MZ8>$]M.Q%M.=%F7RQN**:6%):4;&@WVYI.4]N
MV(_$L^B[=N %]"+WG#V1 'XZ,<U<K.8H_%'*5#F:_B+M.I$I\Z6>O[>T8<B#
MCK_>7?=UW:AU10T!W]_1Y_%1H=R6"#7^PO_W'^])Q?/E2(L.KN__9'8LRA"N
MB3:$KL-.C#769_K7<5:@0 /C(= [TZ QB2%,I."SI+;W/O"<C==>E&;DBW]^
M/F?U'P)2XVV6WYB#/;,CH+DF#N7G4_V!7FDRV0MFI/CVM6[OIM_3/EQ>?_O<
MN_G:JVN75_W3]_?A;]VKZ[N+6^WN6OMT>=6[ZE_VOFBW=[V[BZ\75W>WXHHW
M?_A6XA"-<]Z^_XV/HIL#0!KXODI&M%#VB\ ]_]WU$^;T8I+)Z_"'Y;O_%B>J
MDP@+]!._]'SG6\@BOI6)_WH]F%BR9T/V<;+#B:Z^I7ER!\2"_;A'IC#A3_GQ
MC>YGNRSB4/3!"^R_3FS].Q_!=Y)Y%MG6F&8J#A,VFR78][B>4PAFL]5HUJ!
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M1)?4_07JI'?-KTJKKNO92]$3YK\5J1Z?_)F&#N).X@Y:9'DT\7M#B^:F:-$
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M+FP:EI#BW@&,W)&;*"KB+XR91"$[>>ZBR',&+AF^M9G&B%&1< Z03*$[-82
MG:!HM"?KAQGQ4ZWB$TZ)'X@X\ZC%7MND%JTG$(N/?/K>&2SYHSSZNLSD(JW
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M<&VAV>A/RL[4-2[*-2F*!SMS=49P%L4IX*%)Q[3K41A2P.<\AE/ .(AQ;B7
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M:E$5QV5MX!O3$.&3CD4U-"3;%>%YDPOZ68Q5]8))'E CL4A&X\NH7:U=3:>
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M:A?O8GZ6PWF9:_N=35CFT<Y)IZ; YW3--7(!<0H:E7@%KF,$-LV[30U%C@E
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MRSB.J MDX@;"J&&8 #'ORQ:".(K/R=8>-WK$BE]HGM>>W""B7I'X=(@6?+3
M4VK#(( 3Y9GDTY1OZG,_'21OQ"TXV"EV?1PE,1#%,Q"%ZL+DB#'S]+ZX(4"
M8E'L>@4F2Z48N;F0/,2$.@"17X/Z?&/CHD(/=^/<V;!==?6Z$I<O$[38UXQ1
MCYR@2P P0EA617&XL-*0:G:2+9@XDH\Q.=(!DTXL3=]X<1XCRQ.*8)""O27*
MSTB4URAB^HD4E9,Q.F<DW2F*C9JVC#2Y:3J765Q^RZ=D</$#Q5:DDDI,5DI@
M:;@U[@HSUKBM&*R2U)JF UH.D3YGG/4 RDVQ%*L$Z]:N9AS(%3^J&,UI_LHE
ME8="0L>FC'?34NM[Y]W5V>GE!^[5AW.7&J#AY8\%0<"4>]#D;S41I'DSW('
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MB()-P%_CV(<IX3ST9B;R<'FN!S\=.G<1:$4AG80\03T:'1L\R]MI&$ RP1D
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MT0=B<\>FR3QH. 0)%)' C+LNA#0[EUK=U5XRN"OSK F4RE/,'9C)C1J'QA@
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MX:@2GM1&\K&P](4ESQM,G@_7'%-4G;9HZ?+S2H@"G:U<TB,(L!03BN])?CE
MH&II.&N#CPFQU([$.E\H"82+AI#L/3-L+%BF]HFPL2JC\A.(QN-2DJWD]>(8
M?E&6O)83NSC*XW\R(H)$)/C<:;0.NXWNT6&=?"0C.'0F$D=O&+E(V!A#23HE
MXY)-Q'@>L*#XE"6E\&IP:#<.CXX;QX=[3P$'0[!EN59+O18^7D1A,^*7]A^K
MK6$'!.#BWDCD67-:=9!55V-,TJV.,YF*$2H$M<Q22SCC02H_.-$1?[3 \^S
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MH'U7GG[-AMG84Q0"2N55EK/IR#26I]U#G2Q1+'^I46W*6J4.K<[$M32P([^
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MI9EGD&8.BY=YJ*09(P^[75DMNR3.D Y;[AUJ7.A57@^A>,M:4!E067WL+^7
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M$_8S/K6=G[<AF$3]]]9O)R=G9Y\_?WC(=/@T@\NGV'-I7I[)M-WEF;;[2H;
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MB^ 6J'"H_JQVPMK6=S)YXX.5G;QU*/]N4HU%9 -40T3S[1I(9OM*W":>'7X
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MIK+2$[/>NZ;T^::N^Z:O2U5H-*2(2E >+E7U"!)%JA#,C SZ =7=Z!1Z$-V
MZV2( ]X6Y %8^\L\BW)GX57=D<2*^A[PQA)LOMEM'K30S)*WU0G-N=7"-?N'
M=(U:#T6."E V4!G#O^A1H"7?=/:+"%C%Q2.5FE8"D=/;I;C>GF6[E8/G\BTI
MPFD%HU$.87Q>]*5PP2[,KAQ7FY%NT[I>[G"?>FA$KM,YHU/$EPI>]7Z:C2C?
M!V4$%36H!/+L^:0:EEWTU)?(;X3A-[BY1S4S4UFV4APH'488R%)93=)?A<NB
M *&&A;#[Z2^&/2,]"=,VT_2&( &G>8YIDDIY7N?8'0LLGVT@A=T+<O5)NE:I
M))E2A_T8P])RKCB=BZJ=@I0  *@V"9&\@O"GD:Q"&SPG0T4G#[#2>@&E]26X
MSR+)J8K1Z2MSK!@0C F0_@@!OQ84F263FFX8*0_SI1>147A@V#Y96<40DY/[
M5$*179FIH,R!AQ0C !?ES?WT1FD@^H'(L\Z=*>IF!(=X,;FG=4&IUKN.&SK)
M**)2*KB;D@B)UR^ZO\>V H&@6?7=< <'0DK]5G.G7/E92NUI90 +UG;8C,=(
MJ^M)3VEBD;0$H&Z:)IT:;(8%..4831.I \P'$[)Z*)$20%N"OH(@LK9,)9AE
MJ5A*MTWFK[3=-;V5_5F9Z@_DG%(.AYFJT!-*U4SG J)O'\6;IFA9=IGFMN (
M(Z"D7I#(3!8C4* VK"Q20!L6^$)FFZ=B7+V/5 T/-DV:\QHL/BN8Z5PL*$%@
M;A1ID!-3Y4;)/&4'"SXU0<F$23A+BDYHIL2+PCYA0_0?I?F.DAWUK^7?-=.;
MB>A&A)1D$"PC2J!L)]#0Q$QCC"?393./R_:VS5QOU!4CD4^4DBZ .?Q$N&TJ
M"?P)^=ZT95A;%.N"&[D9^+*D]J8SP+F'&2<QK3Z):8^3F#B)Z?4/E9.8EDAB
MXCYC=>PSUGG6/F/7R6BD F371H[)<59__0U4E$-S#[C#6"U*3+]+ 'BF?,HS
M#XYMKV>QO:0%D0LH+^D'<"G:B<7\:&&1I[90N:^\+/G@70"__11I+ $=7FBS
MC WOU]])_U;HXGLT:F1:HK1'L.P%33:C."TS2HI&"/D%<E,1I1UT2U[>&=^+
M,W>"D6@PSY60UO%/+RXMZ#*2T>1U5-1':6E1,R?5TJV1/MYL=S#@ZDFG-&ZW
MM*H>]G1HFQE[4.DZ_ZP/U9PB1'/03)HEA'3C4G<5/9!&3JC1FW!G>TE*5N3B
MGQ&AZJ&[3 >HJ#65'ZFV$/=VV,\_-G5MY[(!\18RIS;;,^Q5Y0?W/D9X_;XY
M)4<6OLU8#<8@\ "RIE/J6[ "<:>:P5&DCTC2C;->$-)W!/>) ID:G#70R_DZ
MF]8EVMJP0FE^D]G>,)E#R,TKOE-#A=652UA&0B0#YGVIN$3%0[AAH8O]A=#/
M0 WR=((NAAWZ+M8II1G WD2[+#!T8FQF:-(?-VZHO%:EE@U^K'-IT08+11^H
M]<J-?K**?3$5^]EHE(.UT(8V2\LP/:H\1(8SO772]UTX1$<>(O8IQ)#[2#9H
M@>M @LCF8=C^("<;=<M+77,0#4'@>#*,E+;"HMOF] 8NUXUEY@7&8I4FPY4W
M2#7B83=(AHA?&$BU!J*OVAW!=ZG3%BD7$'>Y$%DQ[3P34#+Q7 5#5/BD+ZA+
M3I2^&Q/MBS?(U T@X\=W:S3Q1=J.LF'V94L;,#BZ/*:D;!@#/I(J,G22M8+(
M>B3@-?$]($SJ[":#]GWCRLNK?Q_/>(=6JZW?@/(EYUW945?F&<ZH(DZ=[1(:
MY#;2MJ(1%NKXR:@G4UF-W0@C7=R-[*02EMRL/X,4(P-5ZZ.;S^76D<+WF;@N
M[4N1AD-5_0^VZ2"H+1/P[%P]![4=").QE@PRX9(6JE!RU@]+PPHL>"YI*3'+
MX)BY8K.N/4S;\Z6190H=9A%XVC3=;;B0PGY8DL'.(*9B("8=@GFIAV">H(G!
M\.55-('*,H MB-(<#D_<8MX!2)*!H/Z!E(60>N,:AM6UL.(8"!U*11[O@[1S
ML-DW?"5P7%L;O2!Z9MU,ZA!].]6/(6N^8%%OHO+QJDG6:L+\ M4$ *@94=8C
M"#/<<^T1D!_GNS^D7VZDIGFD<@V,8#/U_T#);3A?IM/2]!(;EG!I)\N_Z-AA
M2 %TM!U%=KM\R1$J4)5Q-P0F VFOI&Y:F39]=Z.N%4W^&=ON^JD-K[+4C(+"
MK-6)7IA^*\R&)/5#B9>//-.I J5WI,UZ0'V!K_-19IWYO=9^RK?0M]P1Z!17
M9IW2TK'WZZW(ZE:IM$![1;0.U(Z6DL)7]&J$8@C78WH>(MRY-82S5BK3D';S
M&:ZJ=BLCJDM%).344HO+/$,*^UO14(B8=6 -=& OMLYU0C+KOY?5?[3[:3JX
M'L&MRH[=\C*?A[+%B\)JY]TB>J%<O,NFN6-[0O[&K!9K5N6^R?S2JQQ2@A,L
M[W^JMH$***+4ZVMA^I3,H!;A2#_7"X! DD@[LK/\Z_3K(Q$/2UN\<D#W^03,
M<J'::[,X1N;U(QFQ>'D5>*U0<Y0V%]0-L57="DB;M/A!M<(V*BZB8K%3=IX-
MU=92]%.1(>UE;Y(%HO3%Z.^AN$YN1$&:(EP25Z)6L@OFSS*ZJ!BZ^&R[H?4?
MTBA_"1N]MB.9I\4BX*5J'I4E/2L('4K5[\K!%=A=7B$ Z?+*1]KU=)+L*G+?
M#JB\5I7DID)$ENR1H7V?U4,H:2.%D$J(QJE"*!-0&F"="$8,;0-MO,6:P%]N
M+&_Y3AL=:A0"" L<P9&Z8G%V4I!$>IZ.KGI('Y7=UY5ATI!DE5FB DN-[S'_
M6=T#_0<N/HJ"[?+IW V1$XE7GTB\SXG$G$C\^H?*B<3<#?$%44ONB/,'*5EV
ME(%',A::!"JE5YRF\;G_36 3J3,'9O[)RTTX,TK0:6#_RCIS)#(Q-.C!1BO;
MQ!\G"B-AO7/QRL2?NK9I90D8,Q!6.;I"W"5M&5WRI2:DJBQ":9!A\:'RB)B]
M44*!S4ONA)?6YQMW'KHB1*?OI)'UWY*F%7:7P:BU#C> R49.X.RE=&X=+(GL
M+N,J\^7?3[' IZ\_1I4F?\^-U!>W]5BD]P$<(+R=^;=X,A;O\0CF\LO.04:C
M+\<RVP\@_9S!UDL\3\0%8RW=1LR)/^AT]CZ4YM+O/S&7OB2O7OWG*Q*M"J%0
MCY)V1UWW_R:!S/IT'1GRL*6_3P)P(U[GXE[(X122WPQ$[Y:U)&#29-)<CC0[
M^BJ#/B^GM,1;'7:&5=*7K;;U7Y.*WS5DH!?LXO\^0-UHHT:@;\ H*"?KQO0M
MIC@#D]W4?2F/*664AV^>)B&K=TOO:>@&-2Z3VK>$8=!30[Q[$_,B92^#BK:9
M$YD3G\J)W1)._#Z-PC)Z5>-*)%T"=<>2</T@FZY,&5X3XRM&VACUPI;-.;3K
MVD!6"FO-X"%S@I)+20.CH"]P8!*2"KK>A3%C4<6OJ&N<T#TI%9-F@):S45\H
M2)*/?LYL>Z6+4G(5*U)RZL9RDCH:6;A%!T\I&JHJ6>9\/^><S?J3X7* $#-J
MQ$(?/<#%#55?"FQM945#'-@#7\)1K!,]"].:&0N2#2$+,60[-L*V&)?F8$OE
M@RTG4\U#3HQC+?1^YA#,JS7#-RQ^E3LULX.W0A]IB=N,G+H9Z1@SLK( PSEV
MHLI!U!WI"8A6Y7.I TR:A FZ"!/D*>R+FYJF?6$/_UBV .]C5G0_=ZW\JZSH
MP%P6=3L 5HD>%>'*&HTH\%!R9<6&E-D>!EY!$,L.,A1,TH,$97BY+V3I6-J-
M;RAFI?KAEL8VC<_(B@)GG@!KX)=ED)1V\UWN"\)+TPT>O!C)) 2L$AK'4Y19
M0I>%_*C==TWKD\$1@2-UL6YN/Y.RU2*4Y@;Z!6W=DXN9SJA*,<4\=M=FG&PU
M3753JGA6:_F4T.5-F]2Z6DV_S@T3#QZ[AC16.[+UZ'*<A#EO(T">!$C5^OT9
M*U0>*V3D_TWA4Z"8*U4$_<U(EV?Y]XII6@M"\QRVUS[["&=0!F,]39?N$LF&
MDV@:"%TMD#6H!)[ON8,D=-20'FP_3;T;*$_=T38LI6Y$) ^HH2U8'4V9.&P.
MDRWK<SS]*E-YJ33(4AO,#>-%2]-$2U-?)5GG\U]U)FKZ$G8TG8F* 1>RQ5+S
M+ ](%)8R.AXLDHG_R#16%IC5$IA79LW@J5$SB"D#H>W$B@6.T<2W/4YQ>QWQ
M*:5)I%B6:J(*=5UI\6<4)WW=OR4KC45>S96$9@GY>I9Y5FN5KUQ%W@]\\8BZ
M4RUPU.P1.]>\EGJXS.Z>H[M\+%+4BD(LT66W"Q?,H;<54_E4FF^8<W8ZFOS3
MY^<+L_6TEI.KRW3$BI*4ZHOYO9_Q[;\NC0$MA:%#QOZ2^EGDG98HVV6.?6[
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M:&E1@D36,NZJ$NXI+T\ZZQ?9&!GB2,8RB$$]Z%+C1KTS9LS0UBM=5;X!RJ+
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M-R$\G..34'__08)SO^1E.: %N&Y68_@B'NKGYK+"<8?4$&T&VI9CSS(;3([
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MF7*?GW*_:T]*>CY*3<TEL'G6G+;1#/,&Z=YS ;7W;=/V2NV=2#B)G'..& H
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M,RTB@;333Y#CD- P(0\\=W@[%R6)BW/%%,DK.6(\2WZ>\:SB<A154@+H*R7
M*+TK+.1-J]G>-?@'/9+S5_\6GXFBR[$C@>[=OPD!!2A@P@!NC-:#W?\[B4@
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MJ\O)6YR\]?J'RLE;G+SUFI;']U*'EA%; RVL F;CX%ZDR2E3:'Y1'*+R730
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M8%\OD+DCRB=7H0CY%VJ?D42Z<(XZ=,Z  -?., !AK4& ?,",:U%Y9@WJK%$
M*BU?I8\*'W7L'2[ T=ESZ-Z#%43ZDQFWQU0R+#O3]Q\"; !=X(!PPUNX@$K0
M>W<7>$"3G@Q:#_"(8UW,%](1-#"_3.],1,H8])PP0))QBUP>OO%$XQ**Z<C*
M7-##<6CW28U2]NI8B%"]%A84*)T*SXIDV834NOAS/T 0D, 'GDQ%I()$&]<'
M*A6!$F:.QKE%P#G:(+=O 63HL\RO"]\- ]QZ4?1VA'%D24!><Y,H5_I_$42H
M53J\ABS-CK1_1.TFZOI9?MDB:(ATZ4"*JA)\C__I%U,^D(B.&=VTR@EBC01
M JFU-$3%_%3ISIW@#JJO@E)W9Y'N'9R/Y]GJS?2M<VN4E!RZT2Q6&80B+?AS
M,9,&$1D5?DS5K:9N9(W)OC>OFU)WWR!\2,*)-7&Q.YZ3@$Z>7:TJ^5EG:^+K
M2YL!_RQK/2)97OJ+J!WH,Y=_7'I2=!N-B]7?4P>K7!6\4(XQ!C;U\E"+T]R.
MA^H+A*24R%FH%@G\:=]\&GB5#];)L52;D_^VJN5!?HZ$D'""H,2\/%%N\L=Y
MHH_,$]WA/%'.$WW]0^4\4<X3?77K(^TD3NW> :V.X#K8"1FNEJ\'*+$<)=F
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M?A-AA_IVL&PW (+K)R'>%4P96%@,5&G9GF<E_IVLV%1[!O^RHJ3W-VP-[MM
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M\2"=+L J(U%D%V42"GZ&+T- *\KNK4WRMJ&6**86>H#!TL;I+%_60&'$+>
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MQ3,&6<BJL8DJZJ\4> LN6N_U^\2#Q02;/*FLDC,+_-?%V4HQ29&U798+)N+
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MU0PB+2(P%]=,+@<4=<N;[0@+U6=*W\X1N$8ZCM,97'9M4&9.*-<NWSY&O4L
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M+SZ[O_"DQSY/;H7@N<OBYK*H9KE9]+_X#CR&=EA<;@YXX8"7=FGSQPUXV<"
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M;K' J '2[]GCS*"Y':"YDM1?-U&R#F30W!0IT  =V!E\2B-JVSBTC558(+!
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MS4H05)[KN!=WA:F@["6QD,$8_IK-=,+E+UA.,%ANNYRH <N5Y;+8N\P NB4
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MKHS=?]U$R7J1,713I$ #]&)G<*!CSP_C-%(L#%@8,$ANL3"H <G<3YP!<4L
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M/6^[!^E!Q<\WC1Q^W# J$EC+(P/RO\0 <+0'R6O\,J/;@]]80-8*R-$+"$B
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M&HDW2$DOGU4#<Z!W+E.RQJUXZY#?/>J0*1W(NR\&FB&J +78K/;C%(I(]>9
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MD0XJ)U1MK96HK\IZNZMR,C! MU7W+RI;TP'65TE"Q47J"LN;:GJ+(2@'0'L
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MLT%6Y4R)-^5DC4)7(+S-.CWS/KRC+,'&/=6^FR74:DDHM,N;RGS=I>Y)1-Q
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MH>NRX=MI>0JP?^.4WB_-<:G@NQF8<?B2C2!IA>(>ZP:HP@!38##Q,2'344Q
MF^P!NU%ZBTXN7&H^A1?,Q.,=715I8A-CDJ*92E9)'7VB%[9KPF9C<@B$ELV.
MQ%N-\.^=B)FW5%PRJ,D@N\VG_N7W#!K-HJWQ*O9S4-U\[=7?86\%KJLWF-(*
M9+Z@D*]?8,]>V)B3WLS*AH$3/&Q>I7YFHI(O\S%\0^0CF2O=7R_39T08C!)%
M<'[QC_3*Y-TX#"/J745I1A[3Z8VK"5P#,MX"7AQPSS777 *O?,.Q)6"IO$"<
M7R<5?S[*$CFB-H^MAWAG#O% A&W,IU<"M!'ESB_,,B5!CU'3VE7)DS@J/J4Q
M)9&29[/!+.NHC-.\ %&+OX!PI?PK%+IE653T)V@(DGJ%(>(L6B[I0_L@[%XI
M'RAII""Y2T%+NXQN+B"?947Q@NNH0J9BBR$H0(:<YX\FI?K:>51)E\>T\FLD
MVCAOZ!<%<&H8\XSV?'82%O T^\'CH7:G<=D +RG2S%8 STJI-! ,.!;^*X//
M-<T2U;BDB;F/Y_3FR'[4 [\[!_[R?3!V?]-OD\M)\!,&-B[CHJZ/WA= (T5P
MCOHJ)H,%/R]1T$J-1>L<?J:>J)VDR9\YM?R7(C<WW;ZS(R13AJRD3GK=%KE6
M*VK3XE=@QAI,Z 5N#+P<4R!=)TH/B<5U[L/+E6QWB&QK[#8<U[B_[Z2N9(04
M2XR5?32_Y9012R@*E7.+D)"G>ACG&'&]3/B/3FN2M;XGZ-NIZ#XJI<N[7Y!&
ME-9-;?/2O-]0I4GSQH[;^0B4>80^$E36R"["<D[$#I($-Z\&LKSQD_4\,XYR
MW\PG6./</@/[77;&\2]GM-DKJ?:T6?^8D@]F'4D;6]ZRUC(;?4\-N3C: 3K]
M6T+O!TS.@U/?E%)AZGZI@H.X(**B[C9A,#:B?Q=)<L[8R/R0?8%M6QTI,HO1
M8J:/]%.0@WZ 9 C/3W/[R>:[NY^Q^BNQ'WY[_\;=GL"686YY,2\JKVJC*IH2
MGL1HH+/4E)U3TNWC0T:*W^J'H8+:2QP",UXY+XKD.L7N0))X;A+^'<4-.RO;
M)D,/\-"0W7;%K$8DC/Y9E_>,"ZS<*]A,P0]2)\T89!:=6:R, W.(3UN"(8/V
M%BAPQ1)!CN#1;EDK$Y<&/W[,B^NC17%-S,"AJZ(EA_OMCJ44X@+3+5-##,#K
MLI3ZC-D6_+7&%[,T:^?E1<U6SL&,:WP[/-(Z/XE-VD>4J==-OBC]G7&>$6W2
MM+MR_?WE^-B;;QYU"/1GEML9H>WE#4;KB>LIP>T,P?TO\#PJPAXKV874I'L]
MK3% ?+JK-&DHBQ^]5Y1;V'Y+X'/$A[.;@*&5A#%B[<$5^IZQA(!+'[IW<DID
M:2)$SIMFU"G8?%HQ"AT\'04%WT0C""8)$"RH>B5'LRKW-*_Z$K_J/<OU@6JA
M.>@]04RF5#F6&EJ"_AJP_<; F&X/[2/;X2L2==@I(;\]Q^'I%]KA;:W0+^.%
M29K,<!1@3.F#=G'%<G[EU.C@C2!XNPYUB0#%T5Y_=+L#!)DN5TTMW;Y@4P<I
M^Z:3GHM4G-MXJ8^GRO,X7*< 0G;Z9.*&BGPI9LNU\3[L8F^R&V<Z"?XQ,$'0
MAFKLT>W7Y0R:I"&/3,<O1P<$(U/RN;*'R@&34#..=A9) 9N(\"@E-X-BE(+>
M687;0%M#5S [PZ^,_<S]08HI]2RWO_%'Z14R P,MP<[?18#3I5U;I3EW9)Y1
MCD!EG(-Z\ 6M8N:B;D!CV)U<2Z=W2 CN6BVA=97T<TJ\9!-7;N@R43R(5XS.
ML,_ , 20]9%@L@P87>F*RV$XCX:O!PY09(V+.1/N,MV-UAA")]686 *6%,:=
MFXRCSRY^!-]075UISS().AMR-GD44\B9.LGA'V Y@<TVC^@#L")VMLB)=N%H
MX%#<LX>![#X['NWE@FRX65"E)1-%4*=AC)^!TV >3/"^33-QXZYEE&C!H!8,
M/G#!X',M&-2"054IQJ=2((PZ:HDQJ)BP\J/6+SCQ K4)SDFKT[G([:B<IBZ!
M;.7>9@T)!;1Q3#TK4XQV8-YF(AFB$6>Z8)"AXF&OR/49K5:@3*/&W8YZ2*B,
M)84TTAS5!"Q:A*?4&'UQ@12\W1L/HR[4 3!&76%:%HW KGE&  Z;B'K '&$H
M[71SMAHMDBQ%P7[7=F% W.1&._OMSMG\I<GJU%:VCNA@CJ<*9=2(P9$-3"[]
M?60$7Z_4.#$S,O3!^.]#!#^G%/$G(,H/HD,?,5@/\6X=8K137UL"V"&B7?FE
M]?>$N'YR<H:!5Z\F'HFY1^)/CI6HOPJB_H=@8Y^WT,Z[2.,6XMM#J+X7JKO2
M\T[2\U SMA&3;RGS9&C&BEK'H><0T=>;&G/KR>)I>RO;+$KVDW)G96/;5;5=
MY&P%VZHIL8,YWHD90!B)L/CL&57V<#1(5@TC=_0X?"[8+QI1V#7"'RVI?V@;
M)3+1_A*5'XTV=]D= GN+JSQ:^D)_R>]-,N<:8RE1Q':&+?YT&Q6BN!%WUJ!>
M0QA#0A9Y8./?MA4AAJV1I5(/0_'*@)81=1LDVFQ*S,2;DP/'^[F-8GD-M^FI
MTB]E5185A<X[5W"^HSRR,G7-\2@O6M2K$P^[_B6M5=S]XT:Y/2,Z<>/Q%EVX
M?*<?FBK%-(\1+5,OF4PLC3CB"5N@;+^_<-N*V&:O2+/C.OIH\BW97HBV/945
MH%$PM([I5\)!Z()55&$C*1R3<'?7(?N\N7!^%Z<M<Z4!W\>U -2!(Z^S&TIQ
MEF9/] 8U(?C!FD;8IBKBO""OB]M+Z0Z$'O-%<8UJKR31)0VU5Z)$)Z_/\CO8
M@2+AZ=BS$*SONZ<3<ZU2E%6%I'$;MXZ2 D"I=!*Y)]!R^M.&%#:VBE:NN4-<
MLP7< ,'W2G+S1\P>MF3C^;EWG?13K/Z(. _/J^?A(!$<5NG-X6'W<P#+;X9
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MJLS7<4PN) 5;Z@\$^$&WE2FOX"EM+@$96@)\:-/$?FB2N:E[]16]*D[$%G)
M3N'FHE>P %D17::P@-2J<5GDIH[<0K50D0@]1YAE]-RW);P+7G91-&CV@6'@
M<L;8F0#W)04MZP%E.-QPV2[5K7:+)0]]@*7$L.W@0.TX&"2N9<&R=;8D5T5P
M,V4W1 H+E?+R=,$>_64L2A=,ZJV6*P+I$PT\B !#.CFO^"VL?9+!\B+N)"P
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MM((;VTH:G#R] 9-NB7T'T&DI0)@R7.2A)6!">I(<@<Z""LVR67;VSB^KBH$
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MG,%^U@2 ^8LIYZ94\:CB4<7C7K.'T\F96H8J"?>!U$42OI[-$*#PRA!PMXI
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M1#6R3GFSG!JT@O#JC(:%#UO&R.O(*OT[8=-W1-[9B"QVW-G=6\$G(UK!OCS
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M<9.Q[VP]?^,PQ ,Y3:5IG;=HW;5A1W*6?C2RS.%0,HCPB>[,G3,])(L9BP&
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MI!^V<6NFT*K(Q,P5ZQ93D<SRH.)P:F[F,%=&B@DB)+?D2.JI?1)=3^ -!9R
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MIV^8M^#YC4IG,]<%(M+><<+VUSN?.;%SE:P?IML4.EB,[_$8E$Z?P4&WC/;
MG'7-4R15D\,,\JO"7Q\9.0UU@$5T??*%25]#RK43AG)W]D5]B@+07Y&3%<U\
MT1&+Z(9BY;!3F+.Y##W$5D-@Q#%;[+JXAOR(UK&%+6ANC1=L?(ETUIDU%?\
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M(QDI/-#H2:*-(G5((RE(P^TZR'"K9('A5.<<@?9W3@;;L('X^E4#TI$S7+E
M1W:ULDB+L+%'IP=S3D+CCV?*?;=QWQ/EOL1]_P%$AYV68+]'=+XFP6OQB^-I
MZ';&"_MVXV:ERTC+1K:!DR:NI0B<W]GV:[[!)L5MFV3KH">.W>UCWSG9TH7)
M=K$BO4<JU2/.!O%M</*XXQ08#(OF8.P<Z.;N)&B3?-GQ)KK6D.%G^]W([Z!E
M)EIF\KAE)J?'6F:B929=%>O%0VA8XU:H/E]*WS&YR.5C45&[C9R1Y'6X,&0H
M<>RM:&4\(<9(<,]"/74E+>-"HN/'-1_O#$_A;9#<%&8QF(^01P)<1-==MRI4
M#\UFA7ZQ6H)]75$.ED/GTJ[Z@$UQBV%] 6=;FF[6 PQ=%JN2DNW_7L#VYZB@
M@/UYSOXF;#[=>8#3D&IJ%<!1?LI[LZXW5C_6;9E%1'M(V0)^IW?1@G#E%U:A
ML4^[+IK,\Q5Y^08XPB0XQP='-YS20=D2WM.C5M]"$8Y;!^2#"6P8U3)Y%=DM
M-\M55MQ@Q)BP>0S06RP??/NZEYA1+TH7WH!)E 7FO6QP>;DV#;T(F)I:VTRM
M4S6U2"T^AU,:I14<R_?D<1Z1>JR55ULJK[Y\2[L:N;TK21#,,T89&XB)V,H)
MF'P9E9PSMK7_,3%2E#%%4[NGI""#$Y0@60]9?"@4Q&8T5R;"."28,)\%AW?-
MX,N@N):@T-3D1IH8XW>EUPS>?$+17PFF-DC,&:>X1^ZT2'S& :Y]5K]W$[SZ
M^\6;X #T]HQ?)+L99^[\J[3"1#K<DTMZTQ'QB;;5@Y]J )0'4Z%:V!R(IBA[
MZ8 .\[$TL4FE?E8<W!<]SXN72K<33+V7'_)T1)N%=<S4B]R5).'I62.O">@Y
M>*IZ9W?]R ZZU>R6BOYF5:=9E);!590UINT7<<NQM4P$;E]N.\,A:(<9E@<0
M7COE9U9W>P'$GB)C@ID,J?.6K64<.TY*;I3>*JM9T49G^RS)JJD\,59DU];W
M<[FC!YPZ8T3*[M2]WX?>@C*Z8?*U3-X=PO8M[KHSW=<,#JX7AE( * .H9',
MK7I*)D!#8FL:@64>5,9&F6.=9.1U?B*A>K$:*%YFQ-8DRIXA$EE;FCJ<NG O
M/A2ZG'=J-&8J5/CO=)@<-D^*PJHL#2V=C>I$>8Z%E#N*95:-D\D!=>S$*IY.
MGH]HW53CWZ+Q?^D69Q_6BM?FR)[$@\:^KS[4M3B]$@-OG50$C-TRH]MEH;#
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M$7!+23,CQR='9-UZ;HB,B_N\65JX]Z0Q#O])LDS;V*XWU$W;<B)< V^B"P<
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MB*V*4W @9(8)6.\<A*?W@&K-_:@9N9J1^] 9N:>:D:L9N>KX_1/*W5ZW_/]
MXJ%W</FZV.D#.&I=^?^E 4%74\^T&3PS:@.=[L,KL)2N4>_L]JI8\^YRRLX#
M.Z;1,."U<\C:>"L8CQ&JGAA6IC!IE!'B#*<E==)@*E1HYVE5E_8CZ]$>Z @O
M* $6<*U,Z\A>:Y-A6R]1RA$M465BU%TQ^@L+5751$ZYMRG8J_^:D-S#0H=^_
MP^'OR.Y:@\39!N)_%B0>%S.PE3^$AHG-/D+?DAA .OJWG.^?ZVO7N-.(*@!_
M+81RL:$>^E/H8U-WBM30;6B;"=M&YP*6CU_?6"; _";<"AWB\[++9H4#M9=6
M/1?+OTM#^QF2?Z8A^;60O"3@B!Q0%C2BT#>EMKEFI?V2XF[R+773D)1D5)>>
M/0V/CX_QOZ%4MF*Y!'ET:0?B2,>WX9-G<,?)M_:.MD5$6E6-Y-KV(<M;S%?*
M):.LL5F;QG9ZO&4>O3RUL)W+^FWM9!)1T?"V31EO^'QOC,]_DVYRN2OS=EU-
MVI>BEK&=+0*]@G)SI7G@)#CO/F$[EI0+FO8&[?KN;7\4+T?=]1?Q,[IW@A?U
M /J>X8D;3UI0_\BMX9F%0KRV.S-%07@'T(HAU[C7U,::-?RZMLVO?X%-.LD;
M6U%O#P.A5.(!:]-9.<F2-&Z79>DA2XOIT5[?#DI$TRKOTZ+X> 342% ZE90'
M.& S0C;U :O+8'VTV#.J-MT9>F:+!;/V7SZM;&4F(1%P 6?N&LQ(JNS5H=0E
MR(&"@5/&->VNI30SI$=O84&$.\*)N2G#H* -D9OU&WT>2DP"8P[P7UZTY1VH
ML\5QB0QGVF#L@YKU$**(03C/(==HRU!NYP5]%(H6M\&? CV4N)<\N VV)VCQ
M266MBOX1.3_.VP9(OH@:SIH6($F&2E=._P4XO:^--)V6\G0F+0H:*QNATS:X
M_[R<1T0-RC$04K559G01XONNQU,J'\RH\_T:B.CF6MERW57C.680TFD2_(KL
M[LZTEU9MZ0#UAG'9FASB!<5F1749Y&H.)6(+P[?0T.1=<=\O(VHAQZX5MGFM
MM<W7R,K=;XZ]>;FGS:BT"V1 @[T88/UFT551]O9_$K2(K;%O>"/31_ =JI5@
MYY4G'R3X2CD47ELZJ:>@^'CK<?-BYL"1X]KV'!)A2 UJ5TT9 XN'GY"\LXS^
M6&$7=!FP3=Q IE14X@#%:I@Y 0;+H,7*!O"Z2]N31X=A)Q3<6=3!0NLVL-U6
MN+$S#\''Z@U /+['="L<3\AY,;(,!EV6V+*B^^913.Y"GL6MI.$D87L,=@07
M>HV#3G>+@]JB_^RF4_:?W;C^0UQVW.ZW;?@RE+K4UZ2&=_L@S>.L(7(0-4O,
MP;[3WN6+H!+)A,*%D^QOQ\<@/EPE]$HO6U"^5'^R7=1&&?<>[0KW4]WZTLY>
M+]:TYI(-WF61&-AF +B[V%6-*]XI?M'UE;=^F$@"/_XI!9D8Y<YA3NP=OPDQ
MXPSD( 9__%@-873/^2.W!4(&88%_&)?O:$I)C)UNI_8*:V J&7P!L>'Y5"C*
M2]#IC(U($;DVA.=) _*\V#'?BO)SF^?O.Q=VMJZ9MK+5BS.O^68V^5D]%93\
M$KWY#,[!QHL[,FE5IIY[HSL,.U4\%Z,%5QUZ)(9=22\D"&.YS3,-$(Z+9*4D
M+H9!*S\I8FW3$^G,N>(/',MW--T^$?-IE;)'Z K?MN,-ZEU**+8U=O2RC<J
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M<_=&U]BIE2-#0H,+XZPFMRJR-+9=E5MQ!V\2-U4ETAJS_='^84(A&&H@8Y*
MTIN(4:D]Q2E>(,JK0'A<850/M M,?. ?VHG)#W1<1!_!R56FGXG4S4+E5E,2
MHL&0$FH_MG/&; *;GDK)3GL/%4-0<[G$()HG'? F2>NBE!IG3)*J.0^-?,54
M #//R1,(%^-Y@\7*8T;2LT[F:Q-]])NKLU),$8V5Z>J3=U2K8<TRBJ;T$6W9
M XT@+"7,/ QZN1]V2M(U"NBBR*ZD(]+0,CHUK=4.VT",K?;$3'O72!VF9^Q[
MWD7M$+7P<]Z6 VWVA3DFAAN>86\G07.WA.[!<V!D>E[ E^JWW>*W?:&ZS7JS
MP&EE<R0O2$B.RFOK%<+M?+[>BQ$M[!V2]::FOD;1ZZ-'L""Q[1BML7Q'? G2
M-S%_H"'M"\=J\9W%@.=J4N!#Z*2X*)J2$Y]_L-?Y()VU#Y?%HGPK2I:;*HMY
M=IKDP#;KU$,=ZRBH#$>=V(1?UY6#=!,N"!&8@!O030_706S/$X1# PV4,QB0
MN4\/Q9P/$6= 9$_,"8PVC>*Z:+*$I8]#(Q.0-7PQT=/]!.O=.Q!/)Z=C+"'L
MM8!,..%DZXZ12P;$1XR-X6HS1)DMEEO_&2JPMPCL;U5@;Q/8O^4)\VU@#V_$
M;Y:.3(!?ILS5M@B1VTKMG$LP)"MF"AP9A4'8*?HVG[!0#O'146<./;,E#.9-
MA(DSI%R#"026CVC]#'KP,<T]JT( 5,(@FE9%UG!;)U+>2: 1)CK^W.3R9S?!
M[H!JOZ+11<@L?=R,B#IL<,Q!O,\P,1D%J4?-@:-QM,AG&?MN&+G E-3A6-K6
MNB(K/Q88DL3E1Q(K+M$A59(MQD4#G8>1^/5RKW*Z:,U*J]:H>OW)=])G++ $
M9W9Z[2]P'-?=@,U& L-OOY.B"#1N02W&LS'#UW(&;:=ER)OH&I89'67^V\[6
MH47]9MF]UV*'6A]O L,V27=8MVH#0*?U-C!)IZ-=>L4@OCIY8"0LTR$0J=]/
M=A6-YML1G<D[ "E@?&QV* @$:X>'DV5;M\PM^:M:R:*5+ ]=R?)$*UFTDD4-
M*#"@3HX'^S>=/8@%M4M6TP>L$D%1=$YI%R,2N-UDC>):M"#T+\V+PL-W"VIY
M!\3M"OO8 -+U#'-&,(U;@ELVL88'H&L(299"$Z8B2XSCM'64SZDHU1L!G6SV
M:YNN@G7U?S3IBK3,1AJM$4+2C!OK6!3:UK?GA81\U'('J,!M>4##3FL/\8$-
M@<[49 Z>%3"D\;.",N5[!<-NXPBRB@A!6EGSH$  @9X:!+LQ-11)M)/MU D)
M?"+[BF2E2N,:#FW:+;L]\K%G9! P'\7@X?=R"*(O]#'ZAIL6J7]I&WL\4?9(
M[/&] 47]'9_\FY>@Z0NC&"V?=%XB.&*.7S(4+1\Z0EW$MQ)^=N-P ?TCAN5X
M-ZY)F//[8GJDQ57#1$$LHUP;\!X(*L3)\@V)-9B= X>;B88+K=JG$.9;+]MO
MO0IT0[=LW$',:]W$_9&K7=.[55[5)SW>2"\*P3"PP>^"X$/%IX!-MP<9ES!@
M?J,V;PC?C6ZH.N6LY$]I_G_VWJV[;2/;%OXK>-AG#'$,6%N2+XF3)\6Q>^=T
M.O%GIW=_KR!1I!"# !L7R>Q??VK=JE;A0E*.;$,)'M)M2210*%2M6I>YYL3L
MAYI=!'C2[0"8,&'0^83VR/'LQY>:&S0HKVD1H369DLNE\HZ22R,:4%SH0)H+
MSLR*]BG!Q4@7%W!(#L#K$ARB^XF%05K9 T*WPVCFOQ?E'1"J&DJ",WD<6:5[
ML0S]10_PJ_D QP/\)VO2<_!I6W603VC+S>C*N?_N#^7(+Z\>70->K7V^>* /
M+^>3A'TCN=0[I.E&4/9/;^>-,Z'&L4>Z<28(LSF1J=MADVO'8]&K/PX036I^
MFY_>1N\\-7:>K0 FD';\L>A,)5+.KA>B+OYDU=9-N262EW+=H.(F!D5GEPOD
M^2_])>LR-P1C(_ /Y<.!$PYY6%=E2LR6P8"1"=1\7.5MG=TBXRF#AB&5YF[)
M]U!,'8,'/B24RA6!U-%?)?D;N0K&95<<ES&%OD=B8#:,A2R[Q;O41M9YN=LR
M!*)HUW;FVXJA]5K5!74%%#*YZ_#:^ X @#7%U=5MAFDLD;T??BHWPX"F"N:+
M*84 @IWGW-B(@:J*WENF57<W<_E+ !0D&X%LT[S*D\.@7C$*NRS6M!"Q[<#3
M_G)GF^B1ZL]! YNB+,69_W&A?R7X2ATT0][4(]"SHC=[R#0#30"XCACX+YJL
M64?<""9"%@[$ZO1/QP#;W0+4EBH3B^!Z/]'S,30WS?W18^B1=<T-'T,!M?<!
M21'%8G:#Q0.[U67C$:C-;<Q5>0OZ,PW:8V3K-F11XA!:!M=A8C.6^F)H<.(4
M9D[D12TKGP/$ M#@>1F<B=G#VD+I<.G?55N=?!\<V,DJ2<TV6T'A/T^6L.I*
M4):N6Y3$K?2A(@.J/.$<G,_2!8R\U="+[%BD!R_NKSU\:<4 (.?+:%?XTA1F
MG34S%<3$&@V[HD(B&A2S\M.()^GI]67_L"T K%Z2%=*AY7:W<S$<<[TTK.'G
M[A)8[-N,G!&19:)RQ3!] JR^%B"OYJ-U&:!X2I2*!'.5#.:@)USL[XB+F?+Z
M=V65GTKY]==<EU^:65"O2VT."1\ 12*2-R-, (FQLD'':E:JO,<#)KW_B9$
M*::#Z@D5UYBFDJ#.M>X@?:0(3.N=F$?EG:BNV,-AZC6&J6-A[^,(67]81!.*
M5L6!R3Y[R'I:H+I = GNQ16JU!W'C01V8!@WLCB/_F5?!VA\XJDD#"W<KZY.
M(]=[_-UI!\C+^Q\@"(!\^L+NGS_/B9)]%0Y0 "JE3I^3S@G1+^@01%6<AL90
MPSK!Q'>$ODEAIZ(C)CF<O5:M%*)1*LQ7L>(>@7&LLYSIL.RAM@6K9*>Z )2
MM UH1J2_(<L(,I#DT37Q-S4SN'P&EW]V</GS&5P^@\OG(VWP2,N^M.A3XL4
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MG!:S53E@56Z^M%;LD>@VUGE&]%_#T^9GLZ$]L;(N*KS\,T>5$D?+EM##"-7
MA6W7S,Z:F8P,$J896!XH "+*Q?A<VM&N=)_8N,P!IX)1 ;HQM<.#X,;&C(PK
M9S!7)Y'7 VUQ4[7,GZL\Y\KG$A#$""0+;%^5<566C.RF\7G/SKKO\S$<\UU8
M@5J$BH9WD\M?E#LD6J7!XN".#C:3>HG@B.Q98IJ;,JU9&!O@%G9IXU21MP)P
MT4HHI\GZBXVK^[:U]D2/K'C 8?& R:0GZ8;#D'1QED7N9/=6>)]TR +QI!ZT
MV1SY1+\PS^6P?PN-5&'^/-3:AEF 4.OW-MWP8@3XR*JB)'UPS+DT^$C6"Z>
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M1%8WD!&Q1R[@0,[AW#N/GKVX?'D9G;TW.WM+>UWKG\?1Y<N7EU15P=.EQS7
MC%4^$7,X0\2-P!I,O,-QC; -_*%EQ&0%-R:KY!V"R1)J6GM.6]^HW!OB\P2
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M^2+:FZ2:L6-3@G?VVUJ<3#?;/#03>>X8:.#GVLX.XY8<7MJ1N)YYF"/,_+9
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MVG'[7:_7H$ #EWD%9OX:.L>'-.[UZ4=*[!K!7-G[V>=C,E+,5(C8_$*1CS^
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M"%31S!2U_[ &@?W#C'&=,:Z?&>-Z-6-<9XSK7TY(UJG6L/!W6JY:)*F@QN-
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M[P""HJ$ZJ;JW[R]N#L!346[N.!>\R##S80]H6/&]^3ZKL;,,0>X])C,I4HX
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MUG/>?>.[;_6%=Q^_*B;+"U4O_9+2%AJ)H_XL]"//SB]ARJ>3<C@UF6>MGB'
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MV1E</KK5V#.5(IL7A>B \U)]8P4";6P@??;T8A&MDMP ,ZB=LKWCC(  &F:
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M6$%C9.IR(N)062E39-\CO)OFNS+>6H^_4_MYHH&BBPXMB=J8#W89;0&7(*V
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MD8ZL!MW-VL7,,4$&X7QTUK"S ^)D +)LBZ8;]COYSWJA ,OZK@#TC*"LSOC
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M(Y+H_9M7T6L;K<!+P.;A(%'L32H:WF&-F$\._8D@!BD0#PFVZB.W:F7$!M_
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MH#DZQ+FQN3TSRT'T2K#"JKCIL>)VKL7QI7V#1P[\COUGNXK):\4E=\Y=+.@
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M%MDAD]H.ME&GW/5&4P<Z;M8 6M+GDMV"Z6+XO^<#@:DL*A23#Y@LNG"?-!X
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M0[HC:F.<'#\"X!&K.HM[HX?-X;_DPE9@>]["O:/+)Y<TY'#F,6:67F$&8,\
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M=YC^ZINWN,GKG+)9%;N@J$[&\%2KC)=1^TFG/3:TB792,.1BRE[3X0,4W2O
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M7*MW=?<Y151AG:Y5!X*D\;2\0]#6CFO59%Q$@5GXBTX79+0</G;Z'M/WI[0
MV@9:_16F!!9,AWRZ2?8/GSQ]W-?ZWJ07C-O\SP)LSZM5O@@ C # NP8 'D8
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M#[TEGU33KG39P.=FR?$[YDL_[>\?'L2]>.B].,),0O2H_ (+-%=UFYSL\8:
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M.#R@R+.+,5VG&;(N8.&KZQ":#A+G$<7P-D<C\ FC@P'K;I#R\*.5\-8=_,.
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MA".@%**:4XS@JW(-Q;DI0%OS/93.[62<Z%.\6;Z3EGD"R60"'O2/GRNCZ==
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MHYA4DZ4J1GV>X:+4ZEQ6"G:)&Q/T[B=PKO27\OH0P4K/$C&_*!3BBF]:K%<
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MR6X8$;D+!HK8AEI;L2N3#.]W94%]':VBHKZ03ZU U34=@V%YZ?+Q//R.I4>
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M8I)-Q7E#T3$V.BFJ',(A5FFN7-_A68 9""2]KHW/#!NI,=2W_\)SF'/?N_9
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MA\N\VY+$>JE$/*6%F] Q8,4-(4%;L9D&:GNP/Z4U9#G6D'6LK+@256 LB2N
M55YYK]?Z#HU+=2XQ9@KVBK2BK&"\ZDQJX\\T:K9UNRZZPH;&!]\*VN2$(BWJ
MQK<DBH/]<>5X_W<JQ]ND$/^JFTP515JJJFNPDI64JYC0V8UNE6^:W;,59'QD
M#80I$6[RMG*FRT;!,3>=.]D+[1H&L 010T=[MWM%J\@RU&<EH^&\NE4] %L\
M1-\4,+X5A^BD;#'2:^GS.=BP'3K5D92:YX@RI#+@#9+:20$46U>ESMB_O])-
M(_[15VG6:!C_E&S)@8O%QW.2CX0G[^SZN6HOR./AG:5AW54Z?QT"FE6NN%:[
MJ?RD?? S%@QPN&B.=+C(!QPPN&$.3SH' Y7)I\#VJC(=XV488P$I TMA8+.X
MM0>SEDPEBZ?%2JMH>J4%A1K-7L^2J_,%"3*IX2R+VBHI!O[-'E:S*I4-B#7
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M?*V[@HLS!1$[.AD&U,G-@6M((5'%0YKHO_)BYO0E.$T_LZ5C0GHU!;F5KQA
M?I9V<T>D^$'MYFC>R(FX_,CPB5_GH&Z6,2<& QG%##C^>)L?1IS(?WN &YO2
M&:&2BG9*L4K74XFJ+EICIKTLX50.]H<[^]JZ.E6!..\X*+9;3:XJ,1@EM]B8
M@"<,:P;RQKHB59*DSP3]'9@!% >&CO/V@V.^0_?%8T3F:?W@F2_A&9RK3&(K
M4S ]<B-Q. &+]2-<]R7_72+Q&)P#5J0R;O@ULH S[P8LWTS$MF#0.^0K9\9Z
M*?AYRRII($LVUQ'39N@*C&Y<X'0:1UC#A4GC><ZSDK"FBBJ.8-EA5;P*;PC6
M5:D%:/,6=6$Z517.M9M,L:JF-:E8F>4U4FW?3^(WTN*5O]%D9^UXM#"SY8LL
M=C#%O =KLS]H#N;]@W#G8"'O+TC6H%H!'68%172&/^*8&$:RX)"D\2W5O7GJ
M]O#PYN+PQ*\<FGZ6PK\C2?(DPI_8U-?V U6#I+S=9A^SJ"J'HJ]WZG'G.SQT
M;+J;/RLS?96J0AV0YCI:E4$*A"X"F35+>2K)9DO96MI5;/M6YA8OC5@LH(S#
M>F%9RV55HL2^XP#L!A_^#28L7+4/OVUS$2V6/8=I(BF-'66^Q8Z6D:!O*F5M
MW5*J>#MR.JL23@9;Z%6"FL0Z(OBEB>!727-%--2?IL]LS21 (PG9*)I<J]R(
MK ^JR*>"Q#PUM,C8B*B($;YUF8951?'P4=.!7+3^;=57EN$DO$22#8&%"E18
M\:TWW^8& $J;ZYBZ$0S+RBBJLZ6M''BJJ@D$XW*F0YYFD=,L"J0ICDU5*3_;
MJ.8"\16>:+TT^LD37AG^:=L+0="0O09+*V,3R[5)\93WW[!R\Q[%[)5RTLQ#
M H2*(8'"85H.[3Z-F#9O,3^R"D S/4I*J0N$ZBTDM;QO6FFI9KF%DO6U?EQ7
M#;2N= V>-(];R:..3@*4GG8H3;FS[*^Q6X@-B2$KVTQ.@5LP6LN<0V5%\ QJ
M?[J5QCXH"2MS(6OZIDZ-F^L6?1.%M^"@&@@D6CSZJM1B5-4H.*GCI(Z3.NU2
M)WQ\FR['D%"4CXT<P2VE,TIA*=OCX=C,WO!H9Z"BA,WXC.'%E4TO=_J_K<.-
M[#?:J3"5[,2JM=)>V/YQOMP.MEI&Y_JZW.E=]_3*)[496AISENZW]JU:VWI4
M:#N=@I,.!/XB5= 7(]94'.I1ZQ<R#%RM^Y'A[Q0!H0A-O6#DU'0<(KD=/ZW+
M3Z,GX*=Z9@+S"#N41P"-GG&>!1A%DO!7C7\3*N:FEC\J*!&UK(*71T 0D=6:
M)"8BY%0#0C-P]J+B4!//#QCR 5X76;4E8@^7F/Q4U1#O],DW=4SSH9>WIME&
M06*LL^7-IA@57<5$:2P+#9^P((?#EF@F)P*]C 46*.Z_T+DC9W4^C)RY>>3&
M DO")+IL9$39_#(C':/Z11$6#2B:!#/7'W*/;1P_KO/P38:':NJM9VA:P&"B
MQ"0=:O>TT13LL'*M"\K^4G<7\6P1O,*V3Q@2R<RW;"4&#K-NSL)/##5H2PT9
M!2&*:K *ZJ\.2$@Q*H;MG=*^'^U\;P0R<XS*F(-!S3R=!F':&F)]2*"R)%NA
MZDCU03%[6(G$1KPNQ)L[5&&:8(.B2FOJLX\?57E,OTK<I5DCJ:G@%KTK%<@<
MO&@K[ZA,".5@B"1)RR2P^Y"&DLU'L 9+T/T9%IAD$B?XL&V8R;!45D=[0<=*
M3;4/@.30*O;FH[GU/'2]5F6A/SZ'%R._1H7:RYQ3T2RZ]&=J"UQEOJO,?]S*
M_'U77>,J\Y^=&5.IMBVQW:;=_#GUQH+95_J+]8ZE\!Y8K:VH?*Q> *-Q8WE#
M$$ 9YA:Q2F>18E*U54M>3B6;8BDRN#&6D@9H+9M2I;1(TH*JA10J(KD"(D\3
MXO-0@M\?8\\A(VY,[5+;(,J"<H+8SH%=_Z=>DP F"4:DJF%J#S7,87$[FUTQ
M^P<L0^$2F;Q64E8+O?BZ(70N8*>:'!47(!1K?8^V-,C*\-O#C=O$.V"YUF)2
M5!.-). 7J-4,*9Q17Y5G<Z<N7'"3I24=-%.]'ZJ_YG[#X301K=N43K!E3$8C
M7Z%HUHZ?WWIY7DVJS!7"M:FOCF>58UD_R6%* 3>\#EY@(OY("?)#+1'<5,(]
MQW7-+Z_I7:N,7EYFMQ'%7[D>?-N=!0V$BTC2!<(LU(K.@.=NHS06E6!J.R*,
MUSJDLP&N&*,<DHA*2@+,"ST,/OD=&$2F5"VSGRTE83X2Q'50E-PK@0>FR$I.
MP!@HVSGI6 NOKI#49X=2H\[BFV3H/8=5 HE$K *LX5 ?:Z==[RS1[JLN6ZAU
M8\R#VUJ0NJ885A7]A25"[DZG*?;&6=N  <0J+UV'S<EJ>6I::W4.*B0G!25M
M8P&7Q1B.U'^X<1\Q*J.$,AH&UJ>6 +?/?N.DWJ5E'/+>1 5XRG!<+:X!^9=5
M,,IMY-_5=$"TO(#*FTESR1M)Z'HUS#F?I9[^8SE$,5 PNA]J]EL1<]@?WI*
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MJ)=:R(0E&NTR<C3"#:E*!FB"' ?TH_D)8I6QJSL+K&(#L"81L%<4!>R1*G%
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MX\AO6'WW]9%30'U20.]F;]HDOF-A)T%Z2?Z#5[LOUA0AC2CN'1R#] X/A#<
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M:WJZW2 J#=YN^QK@&9Y0C$71',7>SM"'ZS/T//_VFUT'NZR9E6]'*ZKW$!V
MH_$VC/)I+,!HCY(X2L#<B%,RS.V+5_^W(OXUL'$B)E)SNL5"7I1[;2?)NZY_
M#_=W\/(M'!:0)%$B8N^D O+&^\)%UEWO1.Z-HA@.WEU4C/EXR2"3A6 X<'/6
MV@\>W.%7D05C;_#"]_;W]@[Y=:IS2V^C3N9Y>2OCU/M59C?PUZMRR&^@.-+Q
M'_/?_G?FOW>IR$+:Y"@#ER7-\GZ*5UIG#P5KV]D-RWCFB3"=%G#0,IFG<8F?
MYPA>.TUS5'5%ZL%1 >5'URXZLBWW[^4&'>/KP#]%#S?)]T()*\F(\D [LU8U
MTTB$MU%./C[:(U%"7QK*O("?P5&"'_*V?: OPY]R'(\T!C+(+/?I4W! QR"1
M_Z,?**:X]> ETP[#5L,WV^X(R\$ 51 5]*< F 97J;YI/P<_R-#;];V[<00B
MN>(S(%E!]A3\50EY9CS@QNK-0<&@,B (Y7PU<^!H?7',8?H7B^S;?LMGE)&C
M* -6F (I;C(Q'>-V'&,F /CE[&\MVVB4,E%;6;F7P$4"!<+"TPZ[@OLZG+%X
M4-=F^EI@360XV#^0UL7,[>"J0F#O+6YDD19@(24M@\Y$'/,R^=><!YZ-83OL
MXPG?A^^-Q:W4)QSV ,YLA#/1<.^.CO;\O3W^ATZO\FS@ED>'1_I/'0/6?&0Q
M3.O O?Z,W:(#;PKKI"^S6&F[0V,*ZZ*;L/78'-LZ$3.4@?0.H3?*THE7P#;@
M>^%_?62Z- %>S;Q)"D9@3J-@?4\*D#K\BQ:CE90#!1C*G')0<%-D9R]D6I11
M/D:2Q""D<!? <,1\+ZP;9\C34\=J-;0QR4R_+$F\=.0LR#I_'WQ7"Q)/2%V@
M52H&O8V:+01\,*?'VGP?4*T!2,50)(%D3P6\%/K3_N&^ON(7F<@,'1[KRD_B
MKM-[62V&\PP8YK"W#,/R=2B#%.2/'(UPTV_)[?P>:T47=__0$\5W>;KW#[$[
MV?UY"O_ZIW<J<A"6":4,5^/C%P_!QP^3,G@ZSO['4M_C\$'7$H$Y$07M:S$%
M&-YG<2.]#VRF]<@Y:D 4N'(%5Z[PL.4*O^P,7+5"WZH5:L4*[T0>!3NX)SL?
M,G XU]B3GQ;HGM</IGN^->WU5,&OLW/O][/K\].K*^_WCZ>7IRLD59].T/O*
MD>VRNB)EI<NO,B@M,YW"^NC#R5 'K=JL=?B_C6+(5E/32'F.T_A^S/+8%0KL
M]W=?K5D,ZS#<7.GWAI+_:/?UD6LGZ4_5MD/=<1)DL\A_\&KWQ9HBQ#6/]%\,
M/4(KLS,_G\3\=*++:8Z-(+^S/?LF]!VNCI,AFT7^>UB?CS4ZSYDWSKSIU=EP
MHLF9-\Z\L<P;!\WBA,B&D?^Q[!L']N&J9QZW>F;?5<_TK7KF>V!]O'18'QN)
M]?'187TXK ^']=%ODCJL#X?U<0^!Y; ^-K'QR6%].*P/A_7AL#X<UH?#^G!8
M'PXI8LZ<?3)0#Q0)(0L$WA7<P@I@1#!+H,RH88VXK5L"\O';-.4#;9K'$YE7
MIZ^K TJ!3JR_LTQ6[J^JMF\MF?VP'<G=-"+7$D2C6OH;,N30O@#JG9I6>WQN
M+X4ZHXU$7[VM%]NT7W<RAO5N#?:W+3"4&IZ*AC2))A,9*E"2&LA(_;45^@#&
M$R>"DDDQ :,$Z608)02^ ]<A$LK68)LR1"%\@9_A>Z,2OSX5$;-/DB8$)L.:
MAA8X#_>"=GE:%H1Q,BHSE/*>8)P+U8)7Z[/+Z(NL$S08BL_<_A4N\^A[=%.E
MU8!<<$QW:,DOW@PLNIF/!_OX>2:2&ZGT8RA!"T[HA=4B6LS&%G6VB+)(D6DY
M!&6'QE*2I&425/>W[@+<4E(X7=^HR*0H)DHOCC*F#G@^3-%*8R/2B,R#+!KB
M?<$7N=N\4W@I836Y5,Q[-8VC/MI7N]YY.K<3<UA&!LK#',($+9Q$P;@8C[3E
MG7>]4SSK@25W,8JQ\C'.Y!06A%'O4"^N?NR 5\!& V:DL[EQ;'(1UY12GR E
M*G%-V^][95)$P")EEJ%FS=CR:8'[D5^#,<F@$4JYVMZ;[41%FY? &0FLN0W#
MJ['+-3EN[L*\M.QREO5L;),D;?^6S6I*F#5VQX8,&TJ9&&TR)^ED'('4-7[@
MJK).#--;Z0(M_8'$NM!@1=]O"=R"[Z^AO"VE3^>#K*WO_1K6J>ORQ5:%S]L\
M*6^_62\E?+^-Z[G@>9O]26X;6\UI7TZM0ZGK/4J=@S7L)<,<]99AEL$:?F^9
MXR .?R2(PZ,'78N#.-S,6EI7I/T41=H?'<1A_XJT'<2A@SCL%\2AW>Z,;&15
MV>HF,0=ZV.?&L^5M9H>O=E_N.]!#UU3Y+,A_M/MZ3?*[SNPG'57O,!"=0-DD
M\A_N[[Y<$]7$82!NG%1RD(B;:IPZ2>84R4:0_YLM4T=JQ^D;0?Y[F$S."7M2
M<Z<3#/3>ULZ+YVOM..OF\82.D_$](;>S7APG_QCD=M9)SZR31>"=#M'0%<L\
M1;&,0S3L7;',]T T?.40#3<2T?#LL1 -?U0 0^\!$/N\IX2H6URCMG\XW41$
MNGYBZ/0=0VX-%#_\:#CS;J.L* VBV#1+;Z.<H)#NV=G2SWWK>(M>[F&82@,]
MPSW5LR<$ [1%QU'_1<=@MZW[97!PC^X7"W,MH-[WXE[8?Z$Z$*,HQL.FKEX-
M_0_+7]ON>R\L0.QXJX,!>@T<P X 0,=LG5" C\%LZP,8M7#D@^%&OE*LLH6
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MS_L[>T</G.7[/DOATOWR]O?_/4]^^_N;M^>_OOG]MQ^_>Y<F/_[\W:DLX^@
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M<E]+I-X%;9_MX41C NLC@\BA%=0,,',DA\'7HA<7V+A/S8$-E7@$U_:K5N-
M+ 6@KU95M($CUHA.4[/TGUPDNZII['*--(YN*Z"O'.V2 Y%G/ "DH'KC@ 'Z
M+NDTPV#2PN&)DXEURTQ$,!,1W#,1P<N9B& F(I@1/2>;S6</Z0%[A;L2$SIF
MLF8+@W?$@XG]$>Y=%77% WM$]T<63NY&ILWFC9 >03ES2D7J0<==?FN:,#,%
M>5.0";9^P04[0)75V._M([JVL[8!/20EKN<5CR=;V<N_[H^S1X*'S8+!,/+Q
MZ?'/LN4QP_3'1?GB8M*1E]&PW63%$9JL<\M>B!<:+A]S:(<(#8"4Z1&T(0%9
MBYF8LYNH)6,^R71P*&@O*QZ9T4&$@)'>:*BE)GQ9P(.FX ;B.F*BP"0<%H!R
M&Q<&H8=GT%GSBH(83"VF72Z,TE ?9@QSJ.?[%N>75=T^0T0+]">HR@OZ8>VY
M\=U"">$]OA0[G.DD4XG#:1KRI39=43PCX"-B@[G9*:PO]CIE>1D]IJD<#A=3
MN6$E,,.=^YBS&AIO(W98QQ;7H>OY![1.3Z[L)T'+AAU*$."S-:85Z#20ZML3
M!,\E5C^M-H,N#%J[!A]J> ![J9W\Z(6Q*R,3P\W>&HE>^:9RA%/R87J5(@P6
M19W1Z&)$&=)GT\[1VI67N%8-=JJNKXBM4,EK2B @/;YQ88[7Z,"@U;[>X[@'
ME^Z AD#4_=5=#V8O4!&O@SJY'-@<^Z3N[ALN=6\M;SYC?,1.H5I=38^>Y"=X
M?6DHM%!Z+E=#\R72EU3"-*KC<+.S=WFUV9#P +BY89-)SQNCR3B>QJ>OFW _
M4TW19262Z6BD[_RAU%5OX0=O$]#VN\[.B^,L^$'D,K?O&E*FYVRAJ3XNM'3N
M$VNSHOFZH6]R8+A$&H(<:T2.L[E>WM[F0J?UY1>[]C:.ZE65KP/;[!D^X6.,
ML[.'-BS8]'EY.N1CO;A=-'C4WZ)2@*![T<&->@*$>^<#%1+V:C/R*V17-07G
M=WOYCI!$"F5HEH$[RL"KAY6!H#$%*J](UT*!^"P>)!Z_05<GK)A?FA7 E8U;
M/D[U?<?DRKB:)UG0:PO^'C/S+)(3^^MI.IY3;UJR(*L&]X,N86O-0THGN\KR
M(A-]Y4"U<)K9L.RL#5HD_],5>RM)0"'T\M5I\G/5@C7ABE?ABQ#,O:BPWC-F
M2Y 69&!W"N=#5A<Y&&_@+3'PC@S0P)X\C67,/?HZYTH$,DY\/(D9(UQ$R4'J
M@]9B<=<Y:_PT5'H*<$:>.R;CVPIF)@;VK*3OJ*1?/ZB2?D< AG<>-^H.#.YX
M%<5GYQ!?KP;B@8H*)]2-Y/SB JJU[;7S$Y1I3RE83WHZ<P.\$9J#<&O?P[H-
MM?Q2(80@N'8&67>=;1]Z_A@K09)O(1AFAV7O FK1(+I?&B7(L[TWW(2]1(<N
M]G12G6J*25$!<]5<N1^%9JW7$LWQ44^ZCF6#&DAQ8YAT97]'=@I4G\&GIF9(
MH?Y.?JVJ8D*;$!I1?HAD@T#^>FLM#>K.FI<KX"A'*_=_LK*#P,X9XE4 B[.W
M9H_"[%B!>/'\Q6MJ-4T"Q[%:"I ,/HQL,,8(,?NP$_+73KY'I9C-;]_BXWO[
M#]0"+\_FIE%''@EN&M6/A/*@W9]K0Z?$:N*R4B?";2TK176J-IPJ03L93PR:
MYORZ6WU17ITEC1UW8??XQ@L%HZG4'13#J]<(]%RMNCHB1(/R'-8LM[ZU0K>#
M7 ZYP,1O% O]QH>I(B&VVQ7Y3(Q=Q3Y!D/:P/D:SJO/EXZNZ3\Z^F) D>$M#
M[4.V_J-K6B*J;40FYH6^!]/P@!FH>FV+#+'_S5^BW R *CS["E)/E/QU3!'Y
MCUZ#]K+*9AAMD28*^$G?$O)'%\.I=J:4=B0$&=G5^564,)D!%P<*6S]_;^Q'
M53!*[ONDA.Z'*!_VJ!38:W#GI[.:Y'/<TKL=4&N@QNP]CG<Z73]D &.?SJ-L
M!JMY.K+7^0T[^R=?UP*IF[8MN'9XXU,T?$*/L$%0@WJ.K!4<\0*,6?-A!]HT
M!=-G8W)&X7E;"]E5]+Q=/3;HZJ-M()K VE4>>>H6:K$$Z)[;+/J--EYHT[DR
M\)OW#L:TA(MFW:WHEH%0!3_UQH7UL66WM)H_,%KF:%68E>;8=]6FS8@-D&"%
M@F**L))2T0[OB[K!].ND4D^9S'53=K6R#_1\IJ11\$AU&%,BG;EY OYLK2M<
M;8\7&*G8A^6IRI*U"/JD>E)>-KA<[33YL8101,X "&5$^-5;FR*_0L#/B=T/
MQ%"(%-J' AC,>E$-L28N8NC'IUM6;] >=Z+G2I*YDN2!*TE>S94D<R7)[ V=
MC!",?$[>T)0K24Z3WNB4"4?VVR%"9A5V&+Q0.74%4<SPDQ0@[$%;<VK[O<H*
M4ZZS&D.>I\DYFR%@6*1BXU#(C\&IMRXC23^JCB2UMD_3MX[9J$=B:_,A)\8R
M9#-$HJ$K&D_ "0B&/T(=UM6.R9@ &PQ846>^$.@49L2X6\1T.V*!5&_,4/@U
M[G9!E$BN@6%OL(#8H3 ?&-F.@0![M2K&I#3I&LD2NO(@]%@]TEA%"ZM:=8AU
M'P/>)GM!.H[4&^8*H]&(9./ YO1G:TCBY'G0BGEQ1<<U($Y$?@=D@T3XNE!1
MC;]^(6$W'"ZLL(/2!.><W;E[%I\YA7.[%([L#9Y2VEDG';P1[(YZ5W6;K:UW
ML&EYV9&T@JO=1)Z@\@-R*-[]P2_YO7+RQ<FX4+Q2JFVAW,4AJ1;_M>#HAXS.
M'E//HMT <3>%<V$&@I)OR)D+8?X]!E(X:@&5:YQ2N5'S>+9^@>7; >P]'KU7
M7E*R_O,: Z@"7!CYSZXB+S%I]E;];"&E&2AF'<N 2#.>P (:2:_E^\<BN9ZD
MG;6^]X+=">FDW[(/2+'U&8!_4('Q9<-1N_@:]S'-S6C3*JD=BD-U?0S1V?/T
M^7/Z'TL<C]%]U!IC*WM5MYQ:$@LA&->C"J%/*@?($>[ V/(4W;+V0C;CS:HA
ML"Q$VCJG;[F[X7A'P^'#PV=F[EEX:_JFS]^5)?T*E_//5?GLC93F?2^UR&!@
MF++!\WHZ)2$+M?"Z*@K7&<@1#SVCAN\GKN^[Q\ZC.3A(NA9\E0Q/XI_%#,U*
MK<>H3@Y21=QL:+C4VUNL4)IM'_67+U^CZA;.ZY[O/+L.MW,=.+80K*$OAQXK
MP=_D==-B_;6N>H!6E2/;<O,C<RB>:?(++K%H$KLN.5 =]TI[?S+9VDD@Q02V
MV8=\VVV//?&'CRM?3</#%+=X!Q_[RYF8$G-)Q1U+*KYXT)**\_4V+ZWO5/=J
M<.;;_2D74?AC4=5#IV("^]"K>H.D+H_;A(%?@O#2%S2'Q 8LYZL,X!O(M<+A
MC'ZK,U!NM=E65X9L[S6S*U@E7Z5#;XDI!K)5&(3-["/_J&H@([FJ6GQJ5V9E
MOJVLU0[]:UJ#8> &FQ=#.;*C2NS#DK.BJ="3<WT5>>HX5\_>TO<L5$U@'7B3
M%/:AF*0=(T&&5UD'O9^%Z"61+AR<JF]A$/;B","B)\C!@E^#%VR58R']'8&N
MI<%B!FL60/<?>Z, ^2SCK1LI\_-.F^JU99>[/RT8X@XBQ"U>F3R\#,@N]<K
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MX2<?>2)WW*Y*:9@V&4')C<Z_L7TG[AWW1B. \W;7,KQ[H#1];(2GR3\YP%5
MU=L '+4KL4\D QT@-@B^YYH*]1'/#5_BZ)IF.1&V,C_\X>4 G[A%64%J$P]:
M&-P<,JA\@[PFL4H8UDUYSA3.I$I\:M4[C#+]#0BI3Y.WYN(T >G]\IOD[!16
MZ-D90/Y> ^H/@BM-A3#?2O?E4_#R#0<KU0O3Y&2_(%RXM02;H3&%0$D/[:(/
M;DR&#2Y%$= A1-A76,!TZYDE?FK?+8B*[U\XU'RK\=S9"F@?U;7B:.RP3! C
MM-!&V9XS(J7VXPN77@6^^!"2HHQ/XEWVZ,UBUH:N?U6$,$R#0#=ZF$L$VX=1
M;XESH_LIC5@=:&_9!1N)X230%]*HR(%)'B_*]\7S2840K[.<*W)</*#:*7G$
M;5$. "M+D!IWOQ#3RVACS1B.RA%&;J[*^;I;'"&NQ<GT>7BT%.I3/ XI!^ \
M20+74H3A(G]9NHL+JT.Q#(OS&89\6]3>*THC6$6(4,;P4TA U@2=JJ%*! "+
M-9*&%56#G9B1B%1%&D,BG!1.2MWMY!1"\4A7ND@W1++@PK,7B/U59@W>:G=I
MCM3J3Q($_ 0H!;\//:8X@3LA^3Q-SK$ BMH%-VGL[&'#8@DLC4P'(DE69L4<
M/#;6Y#]Y,-:$AIZ^0-+#T:?QCL?8.][^3<>14_O)TECSFWHQI_9)>0T%!0T4
M-:BDQ(XSI8[)N(:=([0A-T$<(%64@0[7GPI''CD:D"#!$K^&0--FV[ALUY'W
M&/GNSG6YU;;&5CW4>V[A!O>*#KS\E>OI(A5?;HG&NJY35AN"R:V=8&GV]ETP
M]:YH76-(:[0#1SK]C L )2;4S?<T^0?7]0;<"O"U;?@'O\ 9&11C+=HV'7!@
MVRN^I2[;.3"-%WOVO7WTD5CJR<F1N<- &P:-T /MPG60T+"6I:2<V*+ DLJP
M4]A%7=FKJC0717Z!/<(J:AIDAY18'P;.?K=R3!<Z34:3S(&V M@19Q;L&='Z
MP(C6+V9$ZXQHG4W6SYN=4?$H3Y#_^D=A?&H8Z^E#E](]@J.L.H+KX&?0XR(H
M(D5#A)Y!\8'8<K">)Q7GHVT(L47"C?1)JP&#(FZEA)C&:",I\J0'LI'Z^2*[
MAKL_)$SND3,$/;I3;Y<X6YG82H!.UK,S,)F(VF'$<B$_R(8-H\,CCLF_K9E6
MKT-TU@#H&D%[FWR [J7'EAF7'YH1J@FT.,D2EV\D%.=)59P^HN9<[MG2Q0>7
MV=;9IFI)O!V'^!-,;HE?43'S-?$-QWLB[!'2.7UFU;H;J]:7#\JJA1[ W(O\
MR=-H_8;ZZIUIH=$<A?LC:.JD+D!.G[)B4ZQ_/1!WUGA=-*!Y=1NP84*M70T,
M,*H;@0J^>\W\VP%<$)8?1#V=@L1*UEML2AXC2E!W8^A3$^ELK&Y\B@K>7DL[
M#(I31K>&I)YXUXJ]$QQY!2D=F86/35'.-AXQ[ 6DXS-IC##X(.A$X>[!_F+W
MJ:Q<QD'1Z@P^F7N*"5&6OXK]!L5#W@0@[!.%EG]KFK;.5X26Q_(69DEUL8VB
M8_P^T<_7^%_DI.<>'9XMDT-Y@2WCRW@W6"! 'QQMK\Z5-"G&3=Q>I2( KH.(
M PP$%"7.&%%B<X6WO'W#113ZD^'BS;"N#-67Y\C!Y2TL)4$0T_3P! =RD_)D
M?RB[,L<3C<.Q,HQFDSV;T@3>#=-W#.BSN<C8YUS"TR04&4U_3NI^.I)6Q!Q@
M%2$U">(-X10KERT&_7V[#^E[,>#[A2[$!5 4EJ[[#5*OGUA=AL+LOH1^I%(%
M (DZ^_*;YD#">1;!)YS.>TOY'3PV[WPUY:3$\#QPU4FNL!-.64E^"A,1NAHT
MQJJ-W,C(^RG>M%@0/EET5;4^"69%K6SS@EFU&&VF1T9DI.1)\S#L^R#91())
M'(V# X&@@&ZQX"Q,K)(%XP+O4E.N5=Z.Y^Y-#\EMV=?A //&V[W.U]>0D,<*
M!&F2L^=P04[GE*:/8_W.SJ:U;'"8'\?"3:MQBX*<)Y2''4!W]?BHYYO^269!
M[-7R0TT8;NN+4<_Y"9UFO/LV?H!C3>GE2ASH3>7-7^QO,=!2?(Y?WRU^_=6#
MQJ^Y=]BLGYYP[/J_J?H=_%2,7OT*##*34E._'5>C+V2Z_;I\9MOA!ILK0%9)
MMS47NEX&W0P.AF /1<0E8YJLZAQI+#R9P<#')1H,83F)BJIWN;94$!G.2]"^
MQL4/L-"IO+!*#GY*DYW=I.R"LI%V4A#R@&BR6X<+XQ>(FH7JLBA'A1P3*VBT
MF!^:CXQRZ"188GL56!>1NC5C@@&Z W!L^.PYMD.:"52.]W#:P:76 ?=LK+/?
M(B#9M6.R3C.TU*92+/1  ?P:MH)%4.C*GM>N@!/W89=+U/U@59LT'T3W]C)?
MYHQO*++KB/K;!<=R!JM"=U?L"U+9+=I3')X+-R3P1D\7@?&59%)%: =II(/;
MRYO+%;ZZT_Y]<>SVV=?ABC.*J^FL.-D];2\G=," JCS95$"8)(N-40RIJL>M
MA*4&-&I57DAG$]/$$&1$@GCR%@JD@J:Q!XSV+; L.?UB#<K5)6HZ#*GJ[C3N
MM,N^:\V";[/?QXI,Q](TV+(OB "5?HH2_YV5T2V4$6N+B')N1_UC:]-S(/KE
MJZ(JI+98,M 83008#9>5!OB;([;Y /9([WJDK>3M.9^3:&*YNH<SU\0^R$#W
M($L5\U-<F@)5(&5?\9?<L'OH6YE+K=(1 &ET6>JMJ2\T,EZWZJ;FL7AQYQP'
MC4N>H?OY>&&V3/V&<0N=VTA_62X1S]U-1%5/_% I$C_<XR;J/>O:CJO1OWAE
MS?*/'O^G&SMIQP%N26^1B@;,<@P%(]UC1%(4ML39FO:R6M]@A.JR"RAEKFMS
M51$\@=H4X1E#&..RKMX;C%/O[% @*,]E%5LHG:"+V![VK+A)OM P5ZVOO.*F
M@FVD8,+J/$6L65W#\,>3]K#<KCAFM'^V)F_'U] X]%TRUS7,=0T/7-?PY5S7
M,-<US!&SSQL^\W.5O#5%E:T3C)I-*YK/P5Q%)*/ G5'5(G7%4<4!FXI9UH)O
MNX"/.&?199[> /5W90VE(TQA,R(RBSCX!(R\P:5O'<F+S'<259!]5QFJ#;4Y
MT_:4,37#(;!I">DH/U=$R>7XNAY%EEX\H*\FM-:I^-A2Y]4&)%5C$5-7OJ7C
MG-91:5C1[*JF,0V&);%=( >U_T/>8#VL)7IEC&%R[9RQ.A]6A-0EJZVHU^Z
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MMREID1/12F#:#2=3^F>#"*M[\NKW4U8A:OI JS9HI0<])EWLN'G$'2$FE>C
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M"]_3SCF.K:C'$)H4FRH,54(+Q[U0<@$9$S?]D;Y-X,P%C:\I-1P>:RUJ7C#
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M65?F2(^ S&GMM;%Z?IUOL*RL5=D>_[MVOZ.Y2'G6SU6RJ>E,!#7/X5Q%.PV
M [2M3BC64@UWIE[\A#C6'YG4]XJ:PX&>\%T&G$Y=H1'H*NMZYUV+U!C\1/@
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MW\X'N@P%93JKJBNMR/0F*:6"V?6F*SQ4$<4T*SP$<UBLE-#J%<%N,FWC*:S
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MJB=2]: @-MLRWQ#+$"00$[LU6^3/07+2L2$X]E)N6\_:(K6?W%A=5%,?W]I
MK>P W]CU)>,CUEV+<!+*,-:FH#PDWZ%::U4<L>/08<!DAG<T&\Y07[@2^E9!
MD$#=U44&V\0[V+3$ 0_7M]%D] *PV!C3+"B (*)U$C;J:;HM*79(#H:(!3CG
M^7;AW%RPOZ5C!9\;R>;"-;O" (4]5B5?JLZ]I4RF$!J%3\/311AXSQIP#7="
MUN'D@8\6T"#+C$_!)'&Q:3)9!&A<<T4.51\'*K!*U^N$MWH+,,;1XQ&<2+69
M5+?M6'E]L$J$57C? C24=P3Y[=Q)Q\&IXV^'E%Y22R'I<>%0%4.XCT3ZSM0M
M/0U?^6-I;<X=.^&H'K[=8]@>S%-2)2R? &2%10/3!7U:$';[WT7*6B]K6U(Y
M&.C2=8=15^!^W)[:F[-J))WB.NF*^H%Q4'^G2ND_^XDM:F'0@?B#*,+9Y+FK
MR7/_;.CO0&',5.B!TOJ1Y#[(2H55&GM/.00%_(9@F7"K-BHOA0DZJ_5RH*XK
MX/XL4*2ZTI16*ZV,8,KA@0&0D?B)64Y)H[B2$'P$.55VSXG <C\R/D_K!UDU
M'IG*\ U0!Z#C[&8^@')"8X >Q J(@M[H%HNYX5]!5*2P-!N@FUQE)>O90T_D
M4)MKO2->><RZ*J-6%3"(Z!??+T?@0;Q_#I\_/EV,.$!K,]H&_%A(==G;%;$+
M:[/-\G+M;;T@Q=MKND8?=^V=\5R048C)R5EGWE5GWC_=\^_EIL-C.L,Q0Y2[
M1/A0[-9."2*FD)?,KK>URP**+4$><'_!%J-E+0X12K@)6 C(RG5N?: >*G.
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MF1%K'TP :'WWE-F%H58K)M]%3;[-&V#5[:S;!T3_?ADV88)<55QGO=,H1QH
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M*KZA;P%$2A4]CKT<^E@LNP:B+@TA!AKMI PZ(4$!W6SWCHIC-M+Z]K,@0AG
MI4X;7>@&K"D@@F[N;PTV5EA1KXFDV9E5OLE7@Q#<RG>%U\XVA42%)Q##JH>_
M32THK^PJ:VZ*@)J"\._X+/4EXL.'(("5,[B('8C<]9GLVJXV26$N\L:_5[T$
MR3+0EF^ZW:[ 2C[2*@F2-S94VJO?'#[A.-E_>7O9]WW3;V'T8-OV?I_UCU$2
M9P]]3EF(7CYHQW=*!>9%WLZ-%0]HZ0<RFB84,ITP"OPT.;>JJI^T1IOE(H?*
MFSAP+8F=(SH'@'%TB:'NQO[G&MH-C! I8\.<%BAAFS9Y^=SS'2,?<+[=6EU(
M53B>\V @JA[T FGCML=6,3^J .OK"1V4.0=QNQS$*!1$T,R-)I]V&>TCB,5]
M\A4M@Y?/GZVIR8[.NAXCG)PIP3QVR?45#D$=IW/M<ZK5JJMI=D"Y/"JM8798
MYKME1N9+<*0PI/F1"W Z5$X(*[NNT.M"K,VA>1_0;9 FNO'[0^M&'0?'<O7I
M$6[=;"*,F@C+3T]Z\NETV<]5^>SWTW>G_C!/2)F=1B*&W3:):;W15.O$'@4-
M]&@N <?Y21_W+/D-^W_[)"N:&YX,PO)[F:,>:*D"6-&\V[6%+^%K6$[![63)
ME,OTRR^?G]F3='*V.#D/$B2+A2]!0[^1^T=[\4?&>*U PN9^' $*/R^H'N/6
M+T?&PTOK$7BO,N:&5Q7-P1(J9GD$J0\2RX]]>9!C/IK#$93SR8^EZ_R&"DUN
MX4=7K'\VK5J[X9I\WW-2U\G;.^89M-,,JYA/*'J)72VAS28($UR%;/V"R*5\
M>OS1B4WCD7U?X%5(6VV%I#2;G)"L1M?RCW7]LNJ8NF5T+4CK@"0#M,^.O"P-
MVQ8$K#!4+H$/*."8DZ>",B6+H#!F\"6[3F1B!-7=^!DNGL\\O\'N:-#MD[QR
M5Y^_5_Z3K[N9D#J@8S["2,%.+?6PL:Z /=8@)+YPJJR&O Z6$JG"SL9ZG6")
M5D!F 0*9!NZWKVC$QZ4DD?V7AK GWZT%&AAC!H1N)1#*EOJB4IN=D<=ID)3&
M.JS#JYR?6EW;;<QVL/O\-L]BZ;P+^Q\JK\%PL/>OHH_:I?TK^"M5L=9%:JXU
M*6A'L?9).^$+=U73F 9)*0$WR.J;G]U6+79?WB[1';BJ,.Z[ ZP??-01;V+U
M*QQ'SWERT[38%SEB9MBOABKM>GNNO33,?T?S]$5S.$:Y"F3N\CFZJ4[&H"K1
M/7.'/5JMZLZ@3YI1)VR<A+25^LN+U^GSY\_MX:CMC0*6&0Y3U^RQ3S<([,2Z
M0>(091H1:*E)Q)\D1[GK4$NMO! T';3L\EPXT??TD<*PP3ZA3MBAQS@ @!\#
M' JKC<ZSM+>DUYYS!J,Y@U</FC,8"Q4?W*U7]V&A3-L@^2T@90(>I"UGS"B<
M MUES:K#8OX>E!?%!3C[>G]1-1)6^% T6QS]$?&:?JMY&APUB@.'$/4Y0(4)
M9]!J6I,A+I.3D#4_B)P1\55+O+H+5TJ,>@GN)M#$V'@O*V81OZ.(OWY0$?]5
MQPEF^2;Y/A\*EV/S^)$@[)(Z;%I7$-C6.(0Q5+O_0U[BG;D&SZ]%60+;%)S8
MM2D,Y/@7R*H-_2$1J(?8H=;<B,,A2@^LXM>QEUY**@-S?@?\ N3;&M!9$"Q>
MU3G9 9DG\NVL7-?YOXCAH23+&*]PGKP=X-9'7H;;?PMA.%, >D//1^;MD#'.
M75=EOO+-/(T?NWW'RJP!P7 O@>M9W8RJFR\>5-T$IV@.>'QJ&,*Y<AF"$E>6
MM2;0:H^V%FA*J6J.2>BU1L/,)?;00MME>UA_J]W6'5.P;;.U<11,.^!%S?9>
M-X;J^*0=9_WLJ<@%/5H5&\?%P7 E06L&(M!E(R\OA^H07>+U[#\PV(LY3_1T
MX7EGODIQ+OR8"S\>MO#CY5SX,1=^/#E?!3P,4S;DQY^$/8#L/0#R9H\ UX'[
M3QZ'[ >_Q"H%>UGDUC\PE&QUGL80H";T/J*+9:%+HM6%"""Z_,HTO>MN_(Z:
M$6"W0X UEYB+R+PE@?@I8H>+:OZSOK6"1@IVNA\W5+@M%%&3YY1 49%[:QE0
MS0F$CL&&\/F><:Q2TJ>II% 7'-1MMR53IVER!KV#;K%OUM81-979!W/:1("#
M@.%S:9*_O'[^G-^3?>B]YZBGVP?U0FJ.IV8?Q>/]BRDY,!#.2T?DD2+LX^;?
M2& ^I7@&?A('JR; :7 N>;"/T<",E4S>L"W8!/S)[65==1<HP:@2(!J:-9=I
MLKHTP%7H#%BJQ6BHE5=[*8['2"3"Z1Q4#V&W$V&HCX[.:7(^2.(S\@8\YK79
M9CG":PRRL4KT8@7)LZ%@;L?\-:A($5OPJ*$HSR>DN&8\Q">$(/[:5^NHQ?HW
M0<Q_3'Q+<JN$:-L8T.K,$X!VU7&;P#D>\2D.S\+CD&+^+]G$P,#KZ5H*9_0!
MV2JA+''C3/+*WB1,164V584@*Z\YV0C5IV!6IG/!Q+_%7,8D;6W !'+5.R.4
M?#V+>$QS0FC,:4]K..6%S_'.D/PIX@//[:Z%@5;T=4;V%QI_U&:=M[=Q?1PR
M=,"QDJ?B2Q&R Z:_=^K!7RZ@ N7#RNS:0T[ 0+KPL=ZE7T!R9$KZ(CP)X%6!
MH&^S]^0P"T@]*\0G J-&L(7QR9B%?%3(U_=N])[W=@[<Z@KJWCNCY7>\^&(V
M4.X-:1P$("@@PD!YK\JLV.3E"C@4L @!R@"%'-8J3OZ#_4U>(_"RD;BT5^ 2
M@NE9L&R6ZN=]3'AT-K1N9V@-[/JA'3]NDXUKI9,YJ')0(#D8+YI5[YCJ-0]D
M7_T<5@P(I,A<5%@_$!HTI8$H'."MA>]TWX,>0TG=5XLPSCE,Y1V;=4S(2J<+
MC]WS_] 0Z%'%<0I(<"GROV$HX4LYXNA< DZ,U,3'F]MS8*6!*X"'W>,;S[EW
M6V)UUZPNK:%9T%0A$. 071+ "2+4Z4"D<_;7Y^#GOT$9;3X!-@K^,5R59(U"
MU^(I]4X9V0-@)V**(RC-J+;X=[C:?*6(IF=KNJ $5]X#LZFP'\$F*F#B,6*!
M29M]P%0K]"6&3&J1\;7IBVLAT]=P4]_ XNT:<536 .AI-6\4,LL-(%CMKZ4]
MLOO=QMBQ9X7=V!83B%@FF2;AF+,/29%GQ$ $KE#&A!#H)%' T/Y!@<ZS#U"0
MN:4UL,I&EQ$WKH9SJ" []01W>=ET-4!N[>"J50ZU2L8NAWV5RD7!V. J >@Z
M:LYED5]0L0I2ZF%]$JUW#:8A<O31U<3!41X%GQE>.MK /.0%4SM_#YMZFISK
M,IVH8@GCM[Q9OAY7UZ#R3+DH5]: 2LZCX^)V>Z5Q!%CJ39@P?T%'9Z<W%#N1
MK3&M1@J,+[\[$/ D_3%53\RG^"K+"SE6A]Z/"V;W7,5:$&_-Y<12 RB/:C*2
M<'L/%OMX5X,=Y2NQ!QZ/RM7O?9L0'FW6S@B@$<?4__JT;8V5.%0M>DD/#6QM
MS+:ALHY=G6-9V]U:C6^.["8W@[5'P=I?/BA8^[^ABA!K@W9S=8@B4!MIH<%N
M92]!0)"%?A&Q#RH!;4<YW*='[HA^0QND%QGZSN) C;6NFQ6P59CA8S]G>#!L
MURB]'7:V6-BKD?@RRPX[QD*^<+CK4AA>6>?6:8 W41G-T(*-N&Z9O0BW'5V0
M+G%)3PCF!3'VVK29%+ .ZFGWCE[$WCM8X6.Q\H?;>8XNRQP4NEU0R&Y/6;'Q
M@V<Y&RK(BN-$[F#S$1YL%H6%[_8E94)5V".G\T0Q]U$4_P]K+!,4Z;%F3B;5
M(64Q49G8=#781Q-:*0%P<@T=G6;1\!'!I.[>&T#K'M-!;9*7D-&=S@[@W?$H
M5O#LY826C4"LPX6T]EK%E+4PMSA@$=LI2XY[,NATE-%UN!/CS+-Z;ULXEVW-
M95L/6[;U:B[;FLNVGEP0H4_7@H$_B)QRJX:XUB =3(2[LI!L:=4 5&7H4JU6
M5;#<Z)&/,T5CJ<@QWA45@/4*=MX,A\G1B*4ZI,><.)R26^7SM%&NQ^X2VD?K
M.KM^Q$CZ:25IT<#5A]E\V.6U&6JJ/5#".$>_[QC]_NIA&Z8HI76+ /B3S,D_
M%%\)MX>/P=:DQAJ5IIRQF ]*6>*S_SM7X8!Y1Y=+&+4J7 \(04U LM\.U3X:
MX4W#;<>%-K)OO&PZ^SQ^5Q3]TIIXZ0>W]AQ4 5;IAER&#R?H%$.8?, #> #H
M?YK\7-D/92MIMW=XC=R(OY%K_ 80*C4,&T^(8!WOT#[V\AN,;B"F[J;;;.PW
M#!D(;I,SM?ANS'%.Y:BWR?FY5>%WT$X'<O&YJ9TRL ^?\6@/301-T(&-'6V3
M@)&15'8DMSADGJXY3**IL]35I4*ZJ*UT?1MRB$28IF5F(NOE&*I_R31ZVX%#
M"%?EB-L;Y++E*/_CC9$G9R\F=#H6I\GW#AX[<!"*?&.81_C0K1*0.I.F=$S!
M"GA'D8O2WAU6XB_S+2O?&3+Y">O%?]P,5$2XRZI)B*I=]S8*[W?X\HT!B;@(
MDRJ,A>H<+B'[R\"TP%85R#Y&]/''O(7J/4VM\6-H, "&*D)E5J/0C\B4Z%U=
MCMW\F"$=-9 ^QF&L><<(<<C)AX5KI>%H>03]A2J94'7P(4"E9P!AA0X:"L]X
MU 0TXH1&':]?W;/_PIKQ'*W[KLR1<-1UZ,A\C>0.C2Q:?.R'VM@YTU_=L1Q;
M"#Y%]L(@R%]F)W+1)T7A8S9&MQ]B[8;W!T;F"LP&*6+LHBK^$3HW^WO;IWE?
MQO?%538DPO=_\_X\XD#:UQ.R'RB0)D<:5-9'G.AQW8P GE'='.PA@6FEIV<#
M62_$CD>]331H_5]N6*K4ET<'4@;X_HQ*_@,5'O8<]?1$GD.]T?Z10[6%\YN#
MB'<,(G[]H$'$[TUAS9]Z/V-G2=+/B?@%K@%(7UE966(7775)H(\X1//EB8*.
M"#M1?43:ORNSNO;]#WAW'+&8=CA#/>.#25C\H0L_5/Q'.JF W8M7XDU%Q"?#
M5Q^1]&C%5'<%-&F5-FP'VT!H1<H,;]BA$#UB1I/1K+#F$:L9[ /7]J^K5JHJ
MLV195^\1]^^:J45MDIEO7G_":@2_=*ZUCT3S],"Z-B_LZ8F(WSDV"*8\%B@T
M;HL3.\.RL9J[/\>1F;G(%,X'E2=/"5Z$ R4F#S7^G<MC$BL+M5N*.N!AZ, Q
MTI.U0<MLQ[AZS[67=C>!)#G?8(]$5372.+ 3C16#A..,B]2/*26(M"G7JFY)
M]]O@QDBQSS0B'A&\E<^MX,6CFTIQU8A;#H-;&E,JN8!-9H$:CN!$P;@6Y.91
MV4R3,IGF>_]N]_[9\\&+_RY!D7^Z6/1\W?-UWV-8D7@]6/2I8XQGR (D\>#7
M=%?HI,:QQ$J@A."!>],F'1?R___LO6ESVTBR!?KYSJ^H<+^^(4]0-#=MML<1
M,BVWU2U;NI(\/1,O7CA LBBA30(<+)(UO_YE9BTH@*!6DB;$='3;$HFEELQ3
MI[)RL6OU]$)=S,/DQ/MC8(<WKY(NL,A<1QBH$%"3^]($WNFC"[><REV4H;R@
M2N\>]52<%]Z_GHK )%BS#G8>-TG6-N#Y697%PDIQ+Y9(>:,GQ#=*AQ6EX;Y'
MF<5=H:WFFCNMS-(?U+2LV;.$PLG@[!/27%HO.YM33E.'P]O/O:<=K4H33*C*
MNW$ZEJ6EXM4I7-\4;)AZX@QWHDANEF7HG.&/G2\@6JDU?Z6\L=D9FYVQ%^N,
MO<7.V.R,S7N(^^XAFG/?0YQK@J%-RLH%&TDE;RG4(OAU$L[R-^D#5]1$'8E;
MB2=[35=^N-&\LB8NZ90KOLR<4##/A>:P:.4PZ;?P_-GL70I^A]:Z-8L,S^2@
M4]3XEJ)<9J_D;FV*[A)%,T]A?U/F9S-%OG6I";RI[TU9. ?22RYM:C9=23TT
M-=5C 9+J)Y16#%TWX#+5A$IQON8JD;[:O78Q=^U6* &-C:FG",S<I)<FBRA(
M3[:_=.0AR>.5M'AE\[P7Y2L[TT(/'DQ_A\=X96$GWH7G!VSH>NHBU9K[(G6H
M7?!X35(Z^B7,O!+5(5._'Z7V2#J_,(3%?;VS@79]&75.2NO(V+L1^]DA]I%W
M72M/&I\[=?&'L"')/4,%IESK=JC :MP2Y-*KU70J5CPUI].QL@I!*M)Z)*^P
M$W:UDF7)R#._3,X2]1,0H#UW!"!ZP0Z7RXZ'<5+-.AEIZ$0:>&" )0% ,?O>
MA)*=_#?G,&-.3"OM$[]*L99"5<9]3)1MS@1\M[>GS8MMR^ZB=ZM-LF4_)6P'
MTJ4:@/Z=34QR1(F.M"-ATQ;D34*0D=+V'J>)=73*IRH=P\X(4_^-BI6>^J,P
M=BS*=%;O]4L2T>"WGV5T >_<-[77:BN5"FB4QJLD9.0UC'H[R]5V,%!5YSPR
M\X^L]T4V0<:-36STX3.5,7ITH^06-Q(MBR^S>]Q9] 3HM>J,?#U.PG"T0I-
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MS^F&.OF*S0CEXME)2O10U<P5T_%V]@J,UB9A<;:B_G@"O7F)JRJELM GR$;
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M]?RP>U83AU^Z]3O3";;NT\!\R^YHRMM>].K=G>]=UL"H[+2?3XZ._WUP(,X
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M(.A1&.B<#.,TQMPC(I)]Z5_!]_#8YFMHK%<?UVOB,^:2\& "4.EJF)YD/[W
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M*5L0?8PSD2:7 .[_A3;1^#0;C5I#_4^/!]VFA#Y;G2WS><U@.%"R<<E4_O;
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MH7,H"1AQ1B<W[JJ@'D<G$CUT<O<&*.NV+R/?T^5\BTT%]*4#!?2HQ_*]^A)
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MEK;R:D\FUU(&BFSB!Y_]_J4G1^)]Y,=)>&V*MWHQ65*G^.5#/$SQ =.<MOX
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MUVRV&[NM5Y1X2[O0'@''#&))?@5G:6^D?[7TM28&1#N/^TF8,<1=9(@-X(G
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M@7^E/K02?G3ZB05[AF!C^0\9S1)M/5HPKP@O\+_^(4$$*KQ0>*-K[R9^(W*
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MLW/W].1_-9O-MP0J,W:N]'/)RPRY:H#L_6IU 01KY$UBD$GSD_GJ-:D5Z8?
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M$"O/G _B.CXF?Q]-1S9RB>P\;WQV<O+Z^OIE^HSM+PX>G)!(K)U 1-?-3'I
M&;T S][X,?]B.%_"F- .CH[>;@,!<\Z#CQ8?0GH*'.P3)WT4S JL#>P"\\O
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M)*67:0Q3C>/5FZ\&MI;]W8%;7SCOZ <P99>,B:=.ZD&=\E*G.$/'Z61=[GF
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M*KPSR?&C!;^3J@\G\WWU$U!+ P04    "  .BO98MN0BM>X!  #2!   &@
M &5A,#(P-3$R,C V97@R,RTR7V%R8V$N:'1MS51-;YM $+U;\G\8^>"38QR2
M4TR1#,8)%<8(B*H<UW@PJ\(NW5UDY]]W"+6:I&K50RJ5 \M\OO=VV7$>\FWD
MCD?.0[!:TPK]X^1A'@6N8PTK1:T?8<?;K9\@RY^BX-.DE,+<P?6B-9#S!C7$
M>()4-DS,!L<,,E2\G% AE2:7.H-G<\5J?A1WH/BQ,DMHF#IR,JG7Q'4\-SA7
M?,\-V#=SV[$\HI*\:_*F8BKVNEW^FO2W#-\0@,427E,L4!A4$]??Q5D0Y[#;
M0!BO@R2@%YEI<!]F>9 &:T@>O2CT8>7[N\<X#^/[\6@3IML/X_6/A=98TEY^
M0:A0X?X9"BDT:0<CP50(G4;@@CZYAA2/7!O%#)<",L,,-GTF&1NIFO$HN[H%
M6<(J]5>PY[*MF&K8#$)1S'N_[!0H;*4R<*#: VS9,US?S,!>V+<4J:FQ.%Z
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MVLK2Z:*A"].>P[9FU,M%I3$H^RR.04M,/HUVM^A%1__F([T@^5]02P,$%
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MFSMGSLSWS8_[\];33_=^:N_5M6K5DG?5J@U=A/X!8"O(RLL"X.#AX-C@V
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M/A;@'QC\-^?*8AL)%5# 8.#^DEO+N,/:TN7,C,.2M1 N<F4%FX!9-&5V%#:
M)DE(2KE$WN&M?C5)_4+3(*)Y0(N8/X?;O;IKRQXE5CI;Q>IF>8]K1:#<7B1\
MIFKN7*RD?$D>LQS8[R8ZM86.RSZSLN2"15%6Y:K0% H@9[UQLR:76%OU6]4M
MU&NLMQ"N8F-F,+#;[G!=6E$SP>MH'*4MUB+^8@X*+ I9@=<Z#2X5G7D$#XE>
MV#,Z[9#6+$1*Y$SKT_]N%1LD5]+^\8;:3)A7.\_T+[=+V/5(BRCF#KFIZ1++
M+O\C!A+6E1+63DZ8D<N>A'_GWU6?&I_;3T=KSPMMM]UNI_]_Q[]U'%0(?>^W
MK^13<;*TS1_8.)OE)29+<9.@8=$7U,W4*[:GSAZ2N2H/&I_70HP72?U+.K T
M^J@T?M\QUGR3F@#S-+M1"0/%&7&+*,N>Z%<%T].;#X="0M)<BJQ(6F2*N.*"
M!;D)N;3\6%X.!&$$H+YC827I8$?[#6H- 755BP8)S*CO50K^*== 15+/K58N
M>49LT?, S\['M=_W5>S$)WRO@6**MNKH(22OL^+?3;^[TV%]D\VJ_?9OVO>X
MH9N/Q6;D/Q,OQ(7EF7LAA)0%<<N#C$/P<W])!"G<_OH?K7X(2]C>"41X\%=Y
MI!QL>@<6+B57^\ZA(&SV6EY+12#00FY;.Q697KL M^_J].<;6E!(?<Y[Q$<\
MN^9? P^L@]_D0#_KR5"DPK_]V4@M=_YY%;2K0L 0H_2*2#1\**YV\NK9Z*N=
MF^_5UPP3([S9AOB*6QY>IT&=V,IIXHX #REA%VM&]<,&@ 1%7WL:&^1@I:A>
MHPHY->;\(7ZH@HY+%5?)N:T34[8<&Y6*)NALY5?]F0"B-U=B9=,]-C"_1'"'
MXMVS'!3P$2[@KK0=V/34=IY6IAB-</ %<@T!+S<MUYU! 6]!%M<B;/S-;_3M
M^LDTV+.;8W^""%">YC[U@MU4*=6#QW"9H0!ONB_'YA-";/%_W]%%)[6<L-_S
MS5F,/D5  ?3>K,MOU15US(496BDS5Q2P<D$'!'<]0X3=#^LJ1Q/7-Z_\:G:F
M:K- 7%MR#^Q00'%WS3440&D^8^\Y=-"?5DW\04A-!JA\9+U;'$TMN#X;K1^D
M3^='5VB;;[5K-!(YQ$<5J'1D_/#:QT<6+U%:;\7;,X^'Q3KX0=^,PK2?:C((
M^:3Z2=L#N?R5&F0!/< >^/@I,06/4ATYZ1DX\]QR=?/J!WB96U60._;S*D^'
M/7'#ZP"I9[]4KOI,BEQ$"G*GVT\M,Y"%5:%@"TMG<)KMCLW94H>AI*;:@MIP
M@;39YP\N^1U:>#-P);I%VE&:](8*B2(17CJ9]^&)'F!_\QW;TH;.YL_#-"1.
M5"G&/0EELK)(NL:!Y#0K?(_L\[^/^5'[ZN281GKOXR2%(X8$4"IF[U;7[[JN
MEMDUN#1,/7)0)53:G.*%/'N'B*TOB7:2,S Y:$Q-\-*LZ#!(N?4,'V-N/6_7
M;6Y[D_U_A#2O'C<67]<GR9@:<DMC^C*[)C:5R:*'U!DJ17R_'FXA*VR]4_B0
MVJ#93WU%IE9VE]K-$H6-+,[9=8&2)_;I]K1SH?.QYM_TV0<&#/[[#A6QWZ7W
M&:=87TEM*VNSC9KY',Y.UL:KQLR8K3U&+&S=QU>6VJU!U$,[7)Y5G9G@#._E
ME7DINN19.-NR+62T2%*C"%G(T2KIWT!*MG,H@-?_W3'%;32^5$O#O<7HR?-E
MT_FUHYYBBT?)\I!B[*C:C"*WB*3J]L%\+CV0K/(2*&6(-C2V$7G[:7_[G[J=
MZ);AORGDG##MK5QH]IEPUK)?+1;=ZK=G\S$]UUKJ*-%QMJ"NJ2SJWW).O]O.
M*<DS=>9U4_=/4?#6(\J50UGU*7@5!_$Q&O5OHK/)F5\C2I5%J]L6S*K=]@HD
MY"#N_^SB'*K1,S^R\&20"Y,/:CKE'O]3$S^NYX&_DLD^H[Y962K;K>'-S9IN
M,)YV\.FE$'PTI9H&:6<&=:9&C[$;"4R.K@R]3Y/=:6/G,ER^C0<[\H7RJDH_
M*')4ZYG<WO2(T'WIH4*9C2T_]*3"<82-8 8%A(M C')O4SMYH8!\+BA@(0[6
M37V+<AD ,6BWIO>-&S$L5J^=C0*2!MC>B!Y_85XXBA*I:.#F4E':%^L(S'_P
M;B6$28VC!N(%!8R:)-ADYK9Y4*C^G$9-# :U:_-5H>YHE2FK6&TE$*@=&G&&
M!#Y\%7YQVV$<>Q-/;72I[]<#W/'0+FAXIJ\_'7-*5OXD-L.>_LT9^\[!E98W
M') C IL2XXG8GMA3LX>;B>E!%W!R@Y4N2=JV71 *:'3O)U8_DZ7WG3<PU_AC
MO<6E8JNH&0O?@(]:_"(*;\'V;1296S?JJ@/(QI'H[T X;HRXSN;3G;(B%EX>
MMUG=RE E<\2ADAV&6'Y D$P<;'U#_[6B_J-#QK;;W^Y)_:X;+[BC?=3D^%N!
M.(N.K:CLAYN[G.QHMB\S=H8-R)8>$TIT49H*C;+LDOVA+R.4TS9U;\AV$]ST
M9:")EAZ*@D]L1C2=@?%C? A5S5W*3D5]U#4592N/F9DIF3TY=EQR'0FDND8P
MS9%JZ]Y0,%S0G<Y..,^M<+](3A?GUSY;S>HO3"B$SRZVD^'KQZ73,,P6_S;4
M%:_Z\"( 7"A@$BC&W[TW[ZL%NZ1M$7OT?(0)7R(0"@BE]FTL331M$U39JC9A
M\/ZBG$[F:'[22A.CK]*N5S3D_O90;\V-B=9<KD]&WI@ACW#5)W_/-N!7FLL!
M#XZC8\3B8::["XNM>XNSYN1O>!L3"O1/!M47S)H;;,7Z]=A*8-5G49C)\("!
M$+POYX3,],*DO:!'*,!:GO,UN[88?NVM\MOXY9V]#(\!0H:S:/USM:%M\(QM
MPFGG5,K/ !&CG=:,6,*A&\CA<@RSX.;$-:/Y[+"*C5OF)7E5LP?;!_1O)L_-
M2;=P8@7C?@MM=3EA]TBS8HR">Y1@$?+VL-NCIQ(IUJC\B6\$.^ PFR=ZTTFS
M S!N>^TBV0IR9CE76U&)C/.AY(B$Z-$J>M>_0AC[C;Z_[NF_WB6<=S<^/HK)
M8ZK:&7:9__QC4>;-N]+>S:ZE$K8LY%9N$E;B;<4%#NO*$=B5*[;Q-J5;EOOV
M8DS:ZQ<I$)OVWKWF@";!O1]\N49VIP-+[WT=KL"L"ULB$C$K/GR^D;V6Z(M^
MH[DKK:@5S>/*#63ULT#M*>56/ HF!?^]MEL=CW^*B& 8>!<!_(75V/L+EOHP
M7OS,J>'&EK%U#6N QSD7SGCZ,D%E"A9BICNEU-],HX XM]T@(0XKO@Q47)9/
M1C/G3%^N:BEOALR-+R(>KL4>.4=MUCBX5ZKD&)AL=^)FG>^Q\Z" $G*8!G69
MN,6+N&A9FDNKC_6QE$<GJ@  HD6/];1#&]AOY/,0Z)(6(@&:5T?RTO*(%P%K
M* ^#2RG%D<E!P ^*3)^2&QOI*^%AN0_X^6BQ><*^F'/*-3%IL!B?3_CUQX_G
M=U" 5\O>8LZ,717G-# U^_6T_=Z$VS7R5JD1_:>)(8:%\8(R2Z)O#7-F-P/*
MIH?N39^K"RP8/SCW*A(]@%=^<[QMA@).KEO>]?$J-2A>Z=#2/0OW[]9G=$F,
M3>I\U0Q$>N]*9+!AV=D9O.&0-A WHP](!%ULY$/,6@^H"=Z=.]]!<N-NLQ[1
MI)I\VWBL)S1PB<1@O!ZC0@$.'(ZV.C80ZAG9@-S+?:/3JGI.GVYR^#Y3[<5.
MS_(N%9I J89W/[[2VJ9-%I*6SKJ]>?6 <VIPFY6RM7Q?OX:G1'4"_@Q?%"5C
MBO$C?S@/>T: IR97(E:CFU_(H!7F=(E:[WTUVJ& B6<$QV\$?)1_R0):MG.=
MGK+42C%#:?QSW?U'#4=S@V)!PY@T49D-_#]L-@F\1=I#2])HTW+XJ/) -G(D
M[]V<KM_00 %6/@([F')Q&5Y!0D)MQ46OZ7^#OQ&=L,^."B%L*Y1IUA":4_C1
MKO)KU]9S#4JQIL12!>!5N^9=%RNI#.%.<PA/[W)YH1>=#>*E7+OARZ)*H3*'
M3!,JV)A;F"3/3B60*08H,%%*'..,2=KON;6N5N.Q?I2[L-8_$!_(?]-4 "H
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M3U_9C1XUXC^ )[:Q?^@;N*@)3L*-.;9C$]7[7%C\H21TMP)#M<"&Y$:KJ[3
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M$'U&>LZO9%Y>)#F!0=6HP1_V[7&!F,79!G*OU>49 5CO%O-*O!E(:[;MB.[
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M!MZ#%.I[VCY)">1YH=C[UJF3D_YDQN")569*)LVOW;9BC^J"\![(GVR2/:U
M^T[),L(6T;AX=:]H/DL5:[EISGGI;[N;*$RHT<#;Y8L#Q#OZ.U=6:)<7I?!#
M6TD^N!^.EGV)9'#W*D(N*9 G!L8# $@W[J#D1&WK[R2'+ABB_7!: <L@T:9]
MYB&97N=G_UQEL;6)'P9N83&?0MQ/HMSLH8#1"8A9,PS?]>5G0@%K&N8^1Y2W
M_E# 3-8*;+7<G*$ *R$/W86_1D]5,&1R.91[[>T?%]ZQ=TCYS^-NE;W8ADP
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M#4D()8W;K[/Q/JD\T'Y62-B$+/9GS]0@K8Z')>)EW>1OA@P'%!SU+49Z1"O
MFR.OP?A3G]-ZYP5;5?R3M<1UC?+X(A4I367\H[@O43@O\W*%)IA*O1+-V^65
M^4,H$T=0 Q4%*\0/@3/Z03*F<78U<6#J&HYQ3^=H"A[C-25Y54:\)\";GUD]
MMS>(I^V+%R/UQ=20@F3J62&.MQ?YMEMS1Q6[X[-]/ZZUW^.MOPLF+%:\R486
MB5K[95[U[']_WV!/(+0GGMT\V.><CY[9#66^[WL .5[?53D(.%HL,=-^P;K9
M4DAX<'N_IVOE8^4DBOB,CO:U%6]1]E@&WC<!)Z$^X1XT.$;\KR'Q,I=DIFHO
M^QX;'APJ'D!.]2?T!E%EHU;CH!@EKJPS[B? "Q^?2![3,JN)5F3*#)W3\WN\
M_;8IF%!."O!^_RC+3^+ARQ-@*N.?PP"'IXK0LN?Y70R0/1IDY<V<\O%_Y_\O
M#0ZX!N8$I.OK5?Q&$JX<6L[I<]$H>8\_OT)/&U6>6>2II/D$\';Y(,3+H=+^
MUG1BRRPX=R]VCHL]"7V/:-FG3!<8!^I#.$?8U?@];&:)5V/N*D\CZ6+/(01,
MBM,K7"XNR)MWI=6(I93I:CO'4?_Y3<HLD(PG3\K<T.VD8?4?>K.L ?I^;G,X
MK:C0.V0KDS VLP/LP67>N8+]D8JP/L0HU:HR!;77])R35QX2*F/YL;)FYT>B
M _CYQB(X'[H<ZX[,-\(@Y&ZJAGO6D+)65Z##*=%/*/7M,%6!?%=R*GJR@?JK
ME0$:/XGS/E7C=1XD54;F"C^ZY\%?_/>*?[#C'__&)>_$3X6R>,YO;KN"0MR.
MBVMPB#CH9/5#PP7"XVG$56GOEJ5)A/1?JA."O99[ OC_HOL"I]58P%6KQ,EH
MS^%QH*2PF)]#6UKU'KV2K*I^"X_P6WOEJ5ZUQCCO]!XW8C8*==JC7UKP3$@Q
M3!DDL!HDA! VJ&S+O(W57]X3_!=^6]5,(IE/'6$Q-!RQ*7.,\\*.T->^,3IF
MTW1PEB[_L3T9 Q[1$6A7]BT\'<O,@#Q"C_@8/?"V!H=_8 3.^4B$T&D&+\XW
M%;7AS2P(N-/U:TK3?.H6G/2_,G,39644L$([:9NI]<6$?5QN@"1Z"O?>.;/[
M<<PB3FX5WR^B4$;7WR0R4KN]437[3.G)#WFG1,RTZEZ12DC*6EM@+I/X+%4.
M_M4'L+;]C/ &[RGP=?!;XR/YXH^-4,Q%R&6X='1NH*XL9\70M,86(]C4ZP!\
M0*H#;@XEM<J/T_1XML*L0O],T< ""?I-<6_"3)<A(N=,M2T\*#,".E\GS5-\
M@7LM5O8RC4=^'SCY_/I4(L)_F5'?A\)S<%+PE;L"K0O.X]>0"7%HH]!WC]3Y
M ]U)O0E87SU(6_, #>U<E!"S6_!"G 4UHN<>6N^YX!^#1\?_O>EW35A-@]B[
ME?>OD(2V'$Z]J^.FG1MSP!B*BRE/)<:#],R8L]=)ZO:6&N7DN0,JF_ Z_@9>
M]>YXQT>@-#)&CK1$J]26*IC$#2+.#^)/==BR&'ABWB>HMJ3C$#9U)N;W/<?W
M#*F"OJS9U2I3Q>1PO&,H29ITT-8TL2PYVR90:\)V/%JS(.!BMI$1B^W=^ &_
MV=9GJT3PLX9<L(:G06&A8FG\X(F7R;-\Y/# JP/1=BOZ?K:K^'XZ%4Z*2K%V
M:8DVFS6]UJ*4E^YP3Z^T;XO#DY(9P7'3C<=05&2332I*%6<XZ'G^WBO27/)Z
MCXG#^O>&HZ(*]$FD-30T "7T>.3G< K_-^'<H^6^R<>B.;^&6G-+#U9=!Z&F
M-L?K3&O3S!K[;2MG*S%U:O1J0O2PJ53O;]MF 9H22%J!\/".:ND#@H-[G[ZM
MPMBB.F6%K3OI&"1M[H42@79^M[VM.*WQ%]GLF)H"(>/2\"M))/GO\,"(+.@_
M[DJ9.0*]JFA>)ZFP+&\\M.%-V(!WR.9C_X2Z@0#6Q#W6Y=;#7>]VQLZI+;_=
MY%^$=?YE9;4[K;QC.,$_;OW)DA2U5T$.Q(<K6E[N+450MY#CS?&VP%6"5&W$
M*F4[9(<"L/>-T6S?Y1,@BBO-VA,$// ;?J 3.E7BC>/E/E<\LQ-0C9Z_E@,F
MBZ:594Y^8ACC?6"QU[PKS<OIL_.P/^@I_9B%,M<>-(GJ=C*5<T5*'3>?;B[(
MV,]")(7J<'DC>#[6)CA6+Q'J8%8729G18I:O?6$M2BSR=E<$>2@[\0E ;S='
MG9RZ"SR_X'!<$UAH)OL 9/ HX&=2%_"Q'$(ZS0T+IXAT5B13&U!$1@7@11!A
M.IPXS\/.ER#X;Y:UM-F])>*Z00>'T<E=X]PWD+;B <O='V3[[ W0>ZR+/;TN
M:&91\623?!XG\4\K2_8!99\X%)PK'+5%NYX.UU6HT*" Y@K#XE;0DGM]]+WR
M,-GQL>443- ;4]_'CUJ[H0GCW)3J+ABXMF>^2))2?]/SZ0?4VM2J!(DX45%1
M'Y&-#%4:AQU_.R"WD,YHBO[E6N+.$I&L;]D)9N?H6Z[,%9HHI:#!_FP2\B!.
MAE&L;L%;5YRE:[3C L2I1--I)+7X.!1\<C*6GR&$-9N,X*HZF\V2;'!F5*$
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MH-U"R!/@[JX/= 6_UO9XM-AQ,67W!(!"-SONB^"&97<[6>\(%-=!)%"2Q]A
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M4L%/<''BYP#\Y /3)$U4Y"OA03*GYJ63/,A1PA#G23$ABW9&O[J2D#3GOE0
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MH7Y%:]<Q<5YG*5/W=2%ZUN(D?6EAQ>_A^(]J@B9B9++%PH?+N!7/ML'NX0F
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M=N,_?0NHHP73 Q"SMWP2W)E/;2$!;9&5F4;(!WH3,SKI*DO^F?CI,N8: .R
M?%=Q-SO.&>PF=:[?1EEUMT^ UGVJZ;-])]KM8?-(MD%3ZQ+L1'0UUW-I:_Y7
MTG3'59=LW_+Z5.GOQ1&M"&& :Z"]U4I#;\3)G(I"%:K$MTG>Y%N*4,O8HMQ<
M<#3%A,Z\SF+PO>5OO*'7 C_N:XBK[N(49>3\%/?)G^W<P!/@>\/E-1.D_"M
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M:+_7_Y!+U=;8$,E)K(TF;XXC$',D_+WY1Z@KK75<<'6CIW9<4YV!, 40&&N
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M[;&I['OY>JI[[GY+ +Y&3-A?#HJ_TW'0XP)-MVWDHX"O865=OLZDU)D4-K]
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M[>SFAGO'E"G3GBL#/@K^V R6MBZQ*;$NL*))DK"BC@UGHXZ'*X*"OF[ARB?
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M]O?U+<M?[N'M*,M,.U*!%\V+VAD9C3 A7Y8E=>W4LA'I&,ACT$JMZXS6D;T
MDB;.-(%\Q\SY3 'WQQK6A-!,^IK<]VL%A79:-ZE6*N#XYZ?\?3*?5]8 XUW@
M55%7>?>10<,I*KR 3.M&U\YJWV-PHLT,LW]%P.*VAYGZ(8"0P<K9Q-Z>@7@A
MV+O@+3/B]'B+1(RTJB"\["^^4D"RS$<73;&)OZO27=/8[OYG=Z6YN\+>_T/>
M6T?%^3U]@IT 00(A@H1@P1T"08)#T,:E&Y?@[NX!@KM;@ 2G<8?&@KN[!PGN
MWNAT9^?[GM]Y]YVS.[,SL[.SY_#7 P_/K;HEGZI;MZK],-PP6+:^N'UZ^E=Q
M20?=E_[%EVAU<'"4].]/$W?*6+^W'\P3L*7YLX:UK>NM648:D '#?X:-']TF
M.%4)RV5\,QAX\40043=N87"W[Y,BW[VT<%+G<J>PTPSS/5@ZFYTK2>4RUC0T
M)!O:/TBJJPT\ZCPRCM5>$*I18QSV;N6J*33#"PQUTT S3)0*"BY6'(%;_:Q_
MYL65',%,'@&<<AW7-.HLNC:,QIK5 CS&1<O0,J.)F2Z2]5ENJ8:F%*RV&3 !
MP6M?Y??:.<4=(Y0X3@EX"=2Y*5N)-G#4\_P:=O?K@=0SO5L1?"'H;AFZV*4E
M=6KIU9>0/[?D*\9T/H1\RVO?PL6A5#T>@:4())8E3'N[Z61D#(=<?_Y![L\;
M\1MO3 I,3?J<ZRPOZC05)NC9IWCW/ Z:(6$;:'IB!$T);Z0YA&-$[0I,8M(_
M^ZDAP<EHSARL@OT^W]D]N!H3?'F&V^S;[#),2%5UA6JM/#JC[ZPSLC#73__=
M^G><*7@& W-X;6E<4>98:4H$6>U&/!XLILS;64'J=%CSYA_GZ^'3_Q%6I>>-
M;W!&C+]</[BIFLU%LIKD\,5%?-GW=&ZY9M&-MF#[[*DE4<*K6E5C(Z58GI2L
M;/+2R$*C1%KSU-P8.)!=,,E_,+V3.^J7<B_-AJ%/:7:[)U,4O.7Q6@KO.MQU
M-0)TPX@3TI/P&RO<^\IQV5F)A<JF).&0C^!?YQ)-UZR,'/V.NKHR4/0<W;/D
MX3S<L_1B?@XU-34+*5SD]]B,S$1O2J$;;187T9\:^5WLK&+<*4?I(EGQFPMZ
MI?$5P=587G@4:=F[W;^]W:5-+&ED9/2^B X?V1YQ-[=6_IKP[L&%1>VW\R,
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M*^#MS,.64NK9&G7MUR&L;DT<6O%.DTYHO7WD]K'=DD_-S8-#^W"*'!.I595
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MBJC+'& 1_YIZWM14U+E\DW!%?=NJ9876<G+FB4*30N#<:ZC!)O:>_BK\+8@
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M,LLBR-/L7*S5K+36E7L45I4J6^NO7CQG)@]57VKG;DY) 2TBJJ:(K.&*^>W
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M6F*40> P"8P*P%/)I\M[2SHVG?>A"T@_G5^P97TDD6")X*VB)<"TQR@9W&)
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M^MU;-@ >RH?)08NS."P\*P6]0AH[?6;578%L.//CUR,_&4329DMFA>!]RHH
M4T2R*Q02F?Z@)Z<% !@1I?H-_Z/<T?_:#_(%-TGG='NX#I?VI#"^GO,R$-^I
MLL7T.M:N+;[J8OP $D=7NMXGLFVRZL!NCD9<!W!_T"&VNL/^8DW27_JUQ/FR
MS^=YI^2N=:.'C33[ZP%TVEPQ9WO@N-!SI,N8S )$LS0); <77<7]Q9!.:^_>
MN5G+RL%RV?"B$06,&W72\_L+(@>@HE#F@3*CN2 B+?N9"<L)3RXRC2RB.+=7
M0:6-6);8"4L4[.CD>$;K"J&#?'$CRT!7\"LM!OO6(R0OX1]BB"J[D)7D^6(Z
M,%F;JF09BNW$<,QU@)0QO:(1+U\#WP.8O>#:]N[+;5$A%_/OASVKAYZYN8A?
MVME!!%'#HZ 157H*("4(BZB;*#PF*W8 21)$5X_'":=7_E\]X9?"PKSL_-32
MRBP,*0W39?/0U!0#OPPT Z5Q:?;QRAX<TZP_R5\1TN3G!$,:.XK3XG$>T:WQ
MJ T0AMH]2\^9IG@9>@2]1>*5M*0XW:/91B 0YNR<@ECQ/4I[^B9["E0)B2<)
M8_$)1D9<R+:(N\8-_[IQA0NPT$O4$Z]'0(W[8:P7J)$7$^:98]KY)&TQD"84
M?6);)PY+ CDF\U>1#:*8)+>N;:EK\EZQW(7D<(7PUO0W%][Y !4_)UOK1U&V
M4:NEIG&E\<'9J52I:[Q&%DV0_,$32MML;;\;N"NLE,V=)23T%N:0&UA:<''L
MD@&!?9 &Q@P-<YCTBU11V$?X*3[PH>,"_T\XKB@*%FXSLNJ!;W)QP#AO[J)C
M;;DI^_+4CM">2O)]NL^KJ3^5K))!IY-!-X1PVC$> <P1 7>JWM:'[9!\;.GJ
MXQ@]N]C>)F83N]YNL\+9,K;Q-5KJB'VQQ&+="P2RF[D2OYB[I8[EN5^%.C_,
M9*>$"BMF#HSJ9Q?$"#$1LY9DO%&D17975O8)@J\EY5+7_*)5GU]&D\+]8&E(
M4=Q/ RJC(X5>5/B3Z:=)ZK?*:0FYD9W7.*/R@!7$&*='P'\$?JBY L_F;Y&>
M:$)=(LWCGOCV7 >H?"[O5=1QPZ,E"T2C2(5 LLS>(H=2NA$>8R%.L/SE&F!D
M$UYEZ9E6EMI+=[K<6!QBMC_2T.OMY/FQ&#['@2<&$KL4VN@9Y%HB]+\P2P%8
M_G8M_,_?G<!;7[QU,-7/&[8N/J2Q7MV94[),-&Y)(Q:O!/H0";@74HAG:%.2
M/]7N+4=<0Y;19*EROZTP*(HSL,%\MG6+1>J%1T.&)09^UZ^N[PZ1E0;+XPR&
MOUIZVO"L<Q9QMKOB:(-55,EJD[IT&X1=6R&YQM(Z9$A7<7XJUS\</\HA$VQ.
MGP.BT@]GCS#X@M"8D<I&P3)> @M" QNB%UN6;O(M0;BZ.!>@,!I8 ST=ND;!
MC_A%QH"G'Y\^H7P)]TO:_PB#V=!6>9H% 3AU4=W3^ODKT0RII@R-VDQ289F<
M &4.,"CF<\#LUQ]I%>^?(\Y4R&OE[2YL#%0FUYW%80NW413 YY,C43^+GS:;
M92<+4RF-#9=/#D@3Y0HGX$9;:*;QK,"E^T&$+*IS#+1163/INNA$)&X.O0N0
M87<$E9?42"N#E4[:D*6]U9.?(&J4_/PW7,2,/D9;#?J866$4UX#ZY*5QW#AP
M$L"O!\U6\_/Z>4KIL[+<BBNR9$;(*"1Y N $O$/DHG&/=(YWY:!%G^ZW9@D=
MT&-!0,HN:0WZTS$).D6B./V*'=680&X.;?6L)U\I;=%)]I:8.+OW%C0GL.4S
MY]47==;:I_#5[-5">RW,-"3WJ7R7\6QP91BM*.7S)$<P$8UJQOW_(ZPM3&/L
M4@9V0AIKFR6L3$/7C,DWAV :.KKQE<I!TK77;GU%0K)+,]Z9I%*+)2H2R>S^
MXFBK@U[)I]O!?6%M.9NUMG^:UB8UQAQKC;)7H@@I![7X6[I=XZR"W+YQQ<F<
ML0XPH1:=N J*NB_BHG/2?]@;X7_H@[R(MN\]5N$O+.R--G&NFYXQD*7T#EO=
M@C[U RWH,V.95=[*!B$*(_<TP[M%[%Q(3:95D3D(XRJXW'"JCRC8[:9-3BU0
M4%[&2;,[.DKSV9;A1;[MP4.8(L'&K=JKEC\R7-WR(=4I&G<J(QU*!X,/Y^UL
M2B,QEIY ,74F:KN<_)RVU0U(Q" ,+Y&ZI" Z6$TB-Q]NZ".=CX"7--)&K-6$
MCP!"%(8MLUT&5C<,^FM[$#>9U'&)>X_RJVEZTXW"J/Y8^OI3!K4B.H&])0V)
MT^,E7%CDSY&#FYV\#*;"QMTO72DO<O.ZC;9I3Y^&DJM%QVQ$R-26(PWU7'N4
M.?H@;/Y4^O :YS I5?U'&(:E'#ZV!(>W-(4Z361&;&SZ\P'&"/W.676PL(D^
MKK#^$[C5@]PVNE^6];:TKMQ>H6JX7ZT?#O@.TQ/]A&3U7GHYXHZ.Z1CEJY@5
MSI<*Q8AV*DDH]!&<#E;RP1?WVB?J6BO1IQ%:1!AR6J*WXF'?-/"BC(J?A)3J
MF0&5"I2 \"Z*4)@QK],V4_$"45_=^T\DXU\ZN7]?-DG(0M?LH@T,#0WP!($4
MXF_OIE5 ,07EU[/??9F,-,7=."7756+ZLSYBPYU3*UG3;>;FB,G8_J[[3.=!
M3T$2&=[31. CH%%3'DF:GG*NJ5U<SW)9*I4[ <^L^'12BOS;YUAD7:?#*.:3
M:^VQ6]T\EWC0)WIHR4C@W-Q^#?5I6;^AX4"M 7YH)ID\F(H15T%?*2$_!VSN
MZ*O<*7EOB.@;@':-OD(0,%('/+2,$/-F(!-1UZ[0*57-T ([LZ7OL;U]YQ)=
M1<U61(!<\TK"-EH:"86TR0H>)%;]8Z7HO(9.C_2= JR<IQ>JP<U1K=NQ58>U
MFXM,5-0$VWJQYAV9 R(H&N,<F':\\IBL(^P\;Z4JGB#JC4&%C5S4?PX%^OJL
M,>I?>PVU<N$PR L#-S[DJHB[LEX7@TE3_J0=[.@?3W05IE2_;T! &Q4GP=/%
MV8- UYW&-TY=]5AO7TW+BP47=#"+"$U1K!ODY9:XLUU58M38"E9[!\$CC#Z_
M.@_'*,.I[\:?+4E.9],"6PF89"D:0B G3K%C4^W]NR':H:6O7O:1)V_YPE 0
M8Y(T7UP8P_+V6QKG;@\3J?*U![[EE!7D?5:G8WLG*Z 40A#VL4<B-E M(:01
MN0$QKV?'ZY^4B?^#N<W*T8BW=;#9+IZGSD!HG)%!*,>882<Z]5 @(/XT;[6X
M*#RF3VV2-#<(>B7.6W:K(ABA2\(I-SOO6E%_6U:WG.VZ7OYA JAC-YFR0_%C
M :9QPV/,D?"YZ+F(S"0(@C_R47+EIR8\= 5ZM1VWMKHL+PY?VN@?F?,TW\SN
MAE?S:E*QPV2^G0B_ 7\'-4BY&73JF3ONJ=&99:?&<HZGKB-OPW<[=-]J*WUO
M:,%WV<.Z5(.O!8D"Q8NWAZ([ 9WPB;(P^(<_TXO/R4UONJTKQ2CHD$GAUM1R
M#JA0XU@]95I<");'^LR@J50\5AQ:HB_^@S -0;;$?[9(/Y+J;LOTSC.6'OB;
M3JFH"T\E G^-?BL8-C'/UI9](1"1$R&JJ.5FDI"='Z: N9J""P_ZZ:Z=8.JG
M^K@C$;W>O$X1]BFV\=>I[H5U>?H!_?P</HO%LX,%H88M(=/9Q#C!_6-M]*_(
MX"0$>J;]V->I7ZI9$JYO5'9R)IG/_N0U)GSG0Q53""XL^@E1VW#GN;F+SB[,
MYW#"$%5*WE!](61@!']SSX?YL.CA32T7OI5A8?7T84BFM55=S+/JA6MH@F<-
MB,7BNM*M0(5<$)74YR<B$1*'J"SG/M 9G;\7K#SU6'":9%-4" B,#'P6=73&
M#9QZ&'D3$:DJEEB:\Y-Z2\:.HK>3G!7NP)3K^F1\[(]D,^L\5JKM0?6>X@<C
MX3H]>^#4:M"7#V"UW;L 9ADE:1Q0+WWA2;]1PI&R8"K7EU 5=K@TY:]V'_0X
M#=\L>\5D%J7&6>T_0 <G#6/Q%9EUJLAB.\96G>\9K;?C-M@2]C$QEJ-'D_0A
M"&F2\]@S]HR#<44-7:4;+Q9#YN/I-#GGVYC,R?)^*?<.*;\8[Y#2+^SOD2;"
MSW",,"I+_;C^^M.K,NB5@L"+=1>P?*]LA>I7?[([+@+@=ZLEY:>?LO+:07I[
MJY&8V3NLU[N5[>GZXA?O L0U<29;]I9T$5%G-'_*'*]NX:6SLOOA_$AMMT&<
M*/O)VPAG30KZANQ._=^)D@%RGRNR>505,"##?Q2)X:L$$YPRIS4T"I;L-!Y5
MVCNFR9M.FQ2PWKM,H^QV9G;8Q\SP$3@0NJYYQI\[#K%D&)Z!E8-BD#\$9R,J
M)W1#"<,(*FZM,RL<+D:$:R]?S"VI+ZY&=KM?%WVHT70@#,X)R0TPMSCE;OK#
MUD; R<S!F:#B"-^^:6#Y[=GF5I++EH/"1:9RS@0\N/X 9IT&=\2H_7$*;8(O
M-'C36 AJV#O99%:<D!LE7@ZG4.5R?Z%&4\3)VBI?DY\#;#VS2)#>J H6'SY/
MX%"3B9#CS')7B:&(*<Q+3*[$ ^OG:"$AIA<7G]&=HE;6J0SN#OOM=.C&'WQO
MZ9S/]CH\HWUM9;K1/@K4Q$QY_BF[OPT98L\1Z_V'D"M$1*7A):(-N("XI^4B
M_W.\R;ZM*[@N@&VXV0Y D]47Y2!EPY,UOZR&#/,YHR0JS)%8U,.WHOL=DU\1
M90UCD >-A)1G:76L#^:!76)XP\4X&U5*'=$%7EU/4H11] H*\_(PIBMB]/%;
M?.%,+%']U[2)LD?''W'\DM/CB\NNCJ'9^[K81!XIIJ+0TTFEM5T(X .SM08K
ME8@*&U>,Z4\2XW ="5\"8KC2/H_[T:+DG$#4,#QRM)^IJSK5Q5A-^%%? I2\
MJ"R%'#\Y![1-"2>F$E'L98\F:>X/N^^S@*O1;HZ+SOJRY@0_45H1;](2;%?M
M]\+YU!S&?/'PYZQW/"'ZN3F!$ ,F[2]FF_K?$MT(COH0;G26]P=TF#EGU^IG
M9?_[OO'UZ5;;WF]<:79&\BM&CP!;S0%<)IF\#.IRZK?*OH@((.I_>G+7453
MYU+U2KZPX%(6YX&OS,"PB[(_;YQZH:U&0(3E_1=T97Z'L8EHJU(Z0_R_\PY!
M1W+[S>NS<'R$5>-,9^J0(EJ:9QGS@JQ#'V*ZF3UH!,D5TD"CLYMBPQ*9*4DP
MN!]'Y&E:6S)V#K+'&S_'F5MI@%GRN*O<&K(B[-."J%^&L!&@*VU),K:_%7F[
ML\Z#?ZH)=WL7#X:WB9&6^:H':*DT93VCA\1=6AQ([.QSZA6S^Z;C6&,T<6^4
M9'N*A.I&$2;.Z_I)E7GMBJ1T>DE 5IK'87BB>320-%0DZ&=@$JJH&E=)K$:3
MDTQ!=UMV@E38RR&XW*W_;;&ZF,X??%B,1VAYB#EL0>C[8]'U;E.7.#C=;'W1
M,9[NTP-63.RR:&ZLF8K0ME-W+X'EC3H\+BY;R6R.$P[X,4^,6C7X=E&..3+L
M8P-K\M1+I0DE9?%R*T;TR->0<N4NH@0;I*>"OQG]HQ'6)M,G*4C!E?8L?20E
M]W[^J'[^EJL_4^J3D>X1GC[ADGQ&*5561%<*'RZ]%R(4+!+Y9[]$!-EX(?DU
MC?(403U3599+ 6#-NF-;,4ZHQGX 7S?FLG>OC'V-DY; )RV\9XEO>RN<6Q'M
M58^C\G_O1>9F+<YA**055:SG+>*>]GZ3E?8U-%YPK9G$R?$Q8BVR^[*LD56L
M)IX(YZ .C"8SS,J1Q=)P,UF(<D[].Q];HA&#:L/[A\/1ZSD" F/SP6(]-#YN
M4MU\1!)">LTWV3-XM^Q)M.!5A+]KS;/C[\9"(*3L3(*OM:W=82MA"'"E]\\L
M:U&#36+QD5WFU!4.7LTG 6W6+6M#U*AT<=WK.V:GZLX#?'/\ ZK1!:+JN^20
M[G&0!!F-?$:9^KOO<?"->G']<2:LN7&$(*DHGVW-&05%?+^ \5O[G.0<K?,=
M55>U/(E4 ;A;4-#X[S=W+Q&' :69?9!9AMM'0&U^_L2Z[$YBEA5C)-_U'#ZQ
MLOVWKRL.4E>D8"[4:$19IIT/)EU^SO78-"NH>TSRV#HT0>5]'(KUU6)-?*4[
M\)UQ7CJ1M^7B&7Q+LD40M>N1CX"EZC1L0^NA+<UU]EL3FS\.U-QJD$E9$0G&
MR<FO?NBQM;E*E  _]5]$B)C6@B.V5\6H$A>F]>U 63>N!-*K"FJNF511&;[@
M^-A<S"'-'MYSAV@]7+JUEO1Y^F#>^5!N,/^V=&1ILD(Z*J<HX/-^>NUYA;)!
MA2/HE('CV6<90S/"@O?CX\BY"JG&,W#^_%JL^3!F-7AO)&+J%X>>4)C^")CL
M0,$\[5V,YJ?]AM@&=::&;Y#%A2"DVFW!W\Z_!]>.X[UC'P%_U#6V:>GN 84V
MRP5$6KH(Y"@TT4;,Q(<S]I0\/Y"6 M/I%9%DQ0^:4\>"+?AOU1'& M,EW]FJ
M-'R.@S>?RWPQ 1@;9F5UG:NV>]9@]201UZ"@35CR+1#,'QS*\L/L';N/TV$(
M5W=D]N+2!?0/C'1Y&-:O4N0TN^!#]MP'L_!6*H6$?IOU\ !+8+8#5-4C(2."
M$?KUM*^ N1!N,2J+#QWP:VT;K+J^%T7Z8_OWJ!C9.U7NLDXHC K!>8>K,/R'
M/#P:\ISU]U-)1-@WX^%L7$?:VW)<4O8SSV>=. 2Z8W>M0<?1RSH+H_0G"/++
MS3J=)Y(C1QL2#67W)>S[@A"4\L2A^>22B!K.PY&VKK4NJR:Q%^3A9F WBFQ?
M<O.4\^,+L/VS1)6;ILA!:R B4D]"!.9<1HZUO0?A>;U]1SSF\Q>S#:'AW8)O
M:XQL85R%H52Q<5P1,53Y93EG$R)4Q9&>QFS==%02<,DL:TVVT6/VJ/I [",F
M "$.", E0(M))M^ZHI^8[GO3#9!@GY5RIQ9OH#=QPMM\V%M"6L%S#Z-9:NSB
M3)!/?-'<H;I^9?R0^H;/IY/BIP9$AH1@4P*MQJE$614'Q=.&Z U8ZCD.&([=
M=".PL$C80N.((W/S?_[XD1<8&1H:2^F7&!N;RA&8D9J!EF 0B*8O!($ P'_#
MY3XL?G[!N#;D#VZ&; .K(12G4BL0(#O]7DPKY=]*5V.$H:2;N\>OX;5QL"2Z
M/(+TJ1@X4VE[V5M]I)2O<YCBT(__!0OE-O"AS4E,  )\V8VR/;)?PNUD<53F
M4BF7JO[ZS0JN<AGZ3/2;&#7#)ES"(@9,MJEGZ+?V1.*\74_O->AR"N2P$.C#
MWR:D^;GZT@)4=%!"&5_3"@+E*]V+X8ON22D+H-926?9SHO=>^TF=D&O(\R/7
M#&MJ(S@3#@FNFCQ(\<?2!=,7XQW/'>W7*J*_<#I3HQGX16^:Z]T2X>+R,W[^
ME!A&%++E&B>)4SV,-_U77.PY^HPK@RM*=%19$\O HJ#8VD:JV+*")R"JG,32
MTDJ(IL;@.*\W8M>G8)Y:VQ@ZL7.?/3OMP)?,.Y*5A!WT@PEOE($T1QUUA>:^
MT374[*U'/(T8J5FG6F41RG '5@@+6-BJN?6A3;Z)XYR:H_8JJ?O,\;O 7;UW
MR&@=$&\0UT>!;'>S\S,(<4]F=_*![(+0B4MN]7>?TGW+]M)@8YE=D"P'SOA,
MV\NN-2.FVV [UYH(G8_MH*9.[VRX6D7\,[DF"_]TZP^6JL[.;FE5\M2ECO,G
ML[T]4]#DI)6&9;1H5GYV*(>71R9]%5V^G$8&I[KCKBO"VB1EXK5P*IQO(EM[
MC;PVO%6UGT@Y@VFDX%7*4(+#Z2G;#"#20)=I$95)!KS"[Z2*$<IPN9?23?!J
M1E6X('$@DU=>6[Q-?!=154,>*:;QK<^0+E<J'$*'V<Y(1> V8,:P^8KL?2]"
MOU1:T6ZJ[LE=! 19=*6W%I;<,#V*R+5Q?R0Q$;4PU7R^\<>F3*'B$'IE'!DI
M;"N)X/7A_SLG,) 7L/0YB@K> =LN">6M=LMXV910VIN?;G;V4C!H "!Y+G=X
M1,%W^F8M]*/'$S@0+798I9'LF$ZWD&^R/P]N'"C?H6.K>2W9VAJ^H/2^L&U-
M62/(=Y<\&CQ94,$F&?S[_[BGPC=L0%!70<!W:%Q)Y$V!):P:US<#X@RFHS7]
MXAX*"=$\CA$AH%Y,LQN!+ZK 6<IJ[(QPP\DQ_M64DL*6O8YJROJ+1N4O>O/T
MDN;TGY-\S?5^H#'9QFV8,Z*=(JRW:N/7-OW+;NQ7=1_B"\6"VPQ,*S[UB]Y_
M4%10[I&5)7XH'L#1WW<SL'=#X%(7A#73]#B\$V^;YPUSV\H]7G->IB^B4Q%6
MI&S/8-/+R9\4,H?N^D6WM\XGBI'^=65]R)JM&X+VQ49-"]F5+LKL42:)F80H
M,H% PPD[FN.2QJ"OZ>^7S J+N1'Z-1MD<J EWC,_B_73U__@^-8!5R+D1_AL
M[^A8>X7;EBUJ(J2P+5:5KX^ABN2O944 7^$1F\.46GD59[S]7/N$9*:?&64]
M]?H!]HKK^5IFT]RZIU=1,;UW#HAS5#?W,E.N+Y<JO7/%Q%F+:9EO(DN_#!*S
M3JB(SZEW,##L^A-5]K6A3K0ADINUFGYH9C\#4S-H?^?GAWYZ'TB%CO.AT^]3
M5@0.BN2Z&.#)+\1!)'CJKHOW-:-*UP*Q!9#G$?!J*44OO;^].'?]UV]FNEC7
MH\+7K1Q\-F^\T+.BO1'Y.TW!I!7=H?I;[SH/V6?%NKIZ],; 7N@C@&31=E*?
M==2,0MJGODJ7Z:%@K(S(CW\&"EWYIP=4W5V[!_(A\W3GOH;ZQ?KEL]<?P:]C
M<JR)>^-A].-2QVM\?(X8+/91Q78(4K-U[UJ@YP<9N7U'&OT.>!+E#C;\O% V
MR04/&X*3^E'PK_? N%BH&$50Q&A8&"+=0<+7K1&$%-R_91]7POGQ>43I@*&Y
MUM?J\T^[ZA;T6_I=($;0<15A-"-"/TL8!](/2-H+/MVH%B]Z/ )<)H?D)?.5
MI1,6Y]RHT<91GB@?6O#+"8$5U&:Q$9F4H(K+&I*>N49-$X/9/HG:#V^_XWS$
MQ;A (A##H@!+HI*8YP?W/@*FDA%I)<0,UBS<N[:KK2N7 KLTME20QO*OD38L
M4?>O,>6:5C\&9G@ 3B>)M\A\9J/[V).Z\+_F/\[.-3@0&)%M2\L].WC1S)[2
M%&[?4YI)\]U-Z^!.U+<9&[T@W[UP,D@E-+.[?=P? 92G$5&D%TR^<6W."V5.
MG3JS0SEVX8+0@#3W7);*>IO!3[?N?>"9<ILVY141I%/-"T&VNN#3&XC7UOR6
ME\HON94]5S'7F-'KW2MF<?I02R;RUP #L;>I%:&Q!J[ZR!I"")3H@A#I,&U-
M8'A6<>\&/7GVCY[Q297IJ>&U3W1F=.1NN^;4T<<QPIB6@_( !*,4IW5Y4V#I
MIR9886PJ2I8PMM=C^H5(.)^T@P+99@R+P@VK%8P=V,O98UFGS NSPY0I[7SA
MMN^W_DGR'?5'TL#.<1'AL,XQI76[2?:]K(S(P%#DO)S< .X)G)?BD.P;Q!?
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M@@3$%R].\$"J/Z#[\N?^B(:32$1T9W\=LP4YNZ$E5?]X);LAN(+LE*$1X_<
M[JBXUK?OAJ+.$5[2':RC,S]$9-:N[.1*M+WZTNO0JY.GHA7,K$%@1QQ]U\"@
M$B77M)SP+3HR'-G847P338TE&W\MX1">_2PS]=(WK&3T::5^5LJ+B,T71>S>
MJ<]3R_GRU>,ZE*E8XCP[%&!4)VVUY,C&S$"<YA^W&H@?2!MP],HZ_7', ?5
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MG_QVO#>7"WK\#C91_T>'7V&%QY?.,D,L"6]-*R:@'L/:>Y=.8"V@(:QEIH'
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M:[.V@I-+A047S<E)&,^V38LCDU68LF6$#U,U?,)EY$PS1SC+Y(S3NK_^!O"
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M(R_+D@O]["(MW?<'>M_'=D/VI%,_O[@6XY)%@(7T93IPU2B)X0$RJ')CLW!
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MB9:%#>47KN0A( R6,_FC\":D(.RX#U4ZRM/\Q>W%+R9FC2D[SCA$492ZD9[
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M$^TK&NPRVNYH:7HY]H*CA%2*KJZJXU1)X&C/RRIYIMS(_H*5B:H.3EJY"1M
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MGSUX)(JIXH27O9;)-Z=A)N#>>L^KL?$YT;SV&W0*TN$Q.?EQ1;*T HP']&T
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M_;]VM6%$M*OL9G0L -0KA48HA?&-@H*+CH; G!KW?Y\*C(:E8U[9';\ OKT
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M_S^/:JI3WIY$ (Z*=UP((/S!&@%T*![S32" "\7LIV<EB_D@W5X'WY. IR*
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MVE+2'&4C>$3@9;RC#>U7$#/2DLDWZ3AJF>YG%B'=PR?WPQ YYQATMR)++O^
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M4^.?W5 B_1!\&JRFVQN!$F*#*!XR5VP4-S(%]@1UJ9Y\(;W^:+^FZ@R[U>)
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M>KU "Z/6*?N[?(I^1#_@,"RN[H.CQO_6_L1:>:S,\^Z9/LT8SH80 +[^%@*
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M-"@YM,D0</T9&(-)^2 ZYNEFC7B#C9>13$M^)+:SZ,67K[WT[;BETV^7?B
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M[=M0YMX- @2@;'OL(1A5G=P4M\4F)L>A%W"D)(SOT$:6=9?[P23"34TN7-6
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MRG,4\61QDFCBEGBH;]_[!'EVB#OTS-'^-?!E'0@74$XEG'QI*Q>!RWPCG^0
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M00"*&Q& AG1!?%#"Y'/;UA8Z7*OF^3ZK&2JZ\7*QZ1;< 307_@!:<H)IV2,
MAW1P2.EA(=]TZ9'RO;J2GY,]V;?@WC.RIU]^S:2Q%S+8=F>BA7&NVSE?WI"H
M\KE)N7]7%](8-&]_=_%(.IJK.2I_>4=(D\];#MD>%+Y:EJ72X+FL48TF",!M
MQ:6@C *F))O&E?=_!6&4^E90).H0Z)&Y=_[?$PB6A29A&O]>*CD,7C,V73+]
M8N+>7L%]AIX+]:XS[Z%8(E4( "8[##UK_7HL<=BC@S*-;R2,[GVYO-728H?1
MVN (IH"%.A5[@8T9 (DB;D=?-N_1S5U,;G2*U?NMX%$)KV:1F_&$S#%RN;T\
M/ZZS$]DW<!\2IRWO])=FB9(.(7.SN$W&B",KG+6#M>JS[(BD(]&MI73%Y]_U
MO.FV*ZG+DX,0]0D^S#K,97Y1_EAQL_*0#W4M.!SDH3&K9,#ZCC2G> 5D+H$J
M4D4,, T"0.L[3#GFT+RZ8><'AN@LEID[DRJE8@%Q\P'7)PN=;@N=8G47E*!Y
M(2%[C[5>J*H6%M_<LG<X'UPPP<XJM;JXH+14=E,ZI\1F+^/Z,%&7/O7SW^/!
M-'ZUM=9$2RO/8MT(2QX 9I)Z$).HSN$\'YZ#"^N[Z2+5*O<B6W"4FLX4$T C
M4;F,_@8\*;OSP U+ /'DI@9L71($WIR2Y_$Y&3L9U1SI\'==#9[<EQ\T$Q$9
M3?4JQNHM?8O,X^.L7\JVH1-A\Y^%E#)0?E"<L-I1S%Q>7C4>3)1*_5PNARH;
M_WT70Y!XEQ#N/?>;MZ;%?QH4X'[16-7!YH#AI4(B2X6GE>YA<9%3E$FL)MR0
MWGVO7..;TWF,F]0-X)?>SUOA):?S.8VYF\_XY2ASGX)J#>4M"UJ)BLDPS_P%
MT1 6*'_0"-'2U9(?#0;;N1J?:JW?J$)/P]N^@*-H$SZ_86^L>:7X6DUV,%X$
M7;IKT(FZ?;=K!T:MKS]!USO'H$OTQ,P3_=-0P@#@:FZ623 ]@P#\1'^)EK;Z
M]?LTWW9X\^SC^]L%N/Q+TRI*@@OXDOAM(0# G:$';['#2W<?L=2AYWC<OIHG
M[=AJ!&#54*P.QP8!2$Q9>%I(@XOZ$E_B/L7?(@"PK28$H()Y[CWH8\TCJ/L2
MC@#T*1>(W=6LB0YUO 0G<.+L:19TOTWYA>(ETEA.EUY\]0$"0-U^0'K9%IG4
MTKWQI1-U(3LE&LY<UV1/:8:V-F")HJXZ*Q,"G7ML^U4IJJNE0RW&&D&K0$:J
MQQ=3X!TI''>\O>3:V5]+)E1O2]M(Y!X=8BV&6RR%2S:+\C0NYG/U'$V,^=6E
MOY@(K)$2:?,=\/K)!"M(3@D%E=%>+]/6=]1G_X@FM#RQG-2FO,S65'<K\=-L
MQ1#M1^#^H:P%3<AK%/T586S!$2Z6[_,EN2/4$_/=$P2P$'?+H5 FWS1*1>@1
M"J$U N!$>IC36]KO,!5;M8&9?MREJ"J?9D$_V*,F/L,AAN11O[@B*Y<<?O\K
M]RVEDG(ND<'35;]'M-$DMXX;^YG%*R1',K>?-.]#]XOD,?Z0F?MB:AP, $2T
MM8PW2@Y@;I?-L%IMCRJM;WYN^7Y)K4)F-;\7,_K9DOT]$8#QXD!1(8YD[1%I
M,CT"BLC=:J:"SF*&+T/IQ&;U4"V5$M+\V$^V+$7>G%//03D;DJI&01>N^E>.
M6]TBK1YMC>VI=@'8BHHW_"@UJ4H)12$8)M@V*E*@;)"P-=SYI7K$8CWTLU@4
M^7UO.(:_LH^=4KAD?+WAPJYID>9VW@=0H_GFO*;\&U^ACVTOSR,=/0RS2\-E
M/U,'?M^00^:1&<VA]S!NE"NM8O)_X-S[ZZWDM:.O2U(S*^5#X86!(^E-3&:4
M?A*/&4?CP2:GYKM8N'?68Y [F1NRZC+OI^!LQK=@=MR&TWVLU%GYMZ%VJYRE
M]EZF((O:F)Z9];?ZO)JVTCN+4$G",8)D<QR1@8ZJ<;K4L_'QXH1&^B!UK<0_
ML]KC>-B<1D24YN@MPJD^>S;OPGL8/B?^=U9TF1XOM[26114VD"PT^3##=9U+
M[!=_[]]V\&%NNMC;EW+3B(IL\55KFSMA_3U8K'/$%.QL1*5/AS&S\!O-Y12B
MHO)<J]'R9-B;7TTJU>QJ)8_1QIDN>K+=*K_KW<E+KZMC<F PIZ>@#^+DI0[>
MQ\52\<!;N?+B=TT61;LP24O-9Y SELZGI\'S&'GM/6TM<UO[:AB#MBV\TWC'
M8BV70.AQJTG2VU_Q4)A8TI1N+<4].WN.Q)[R ]Y6,TE!P:7B^X)8H/T/3?<W
M7VR.$GFO/D=11&"=*RAC^4U /4Z7W.FZXL>7D>3>O)NC5&2NH UM1 \N(T(A
MX/)SZ3S1OUVS6C;1-[\@4< <3#A(!\[GHZ66'[S_:<N$C0%DK5_4ST< _K\R
MQN"WOTMM?GRQ(\7RH;'OCAU[.%=)D/P'M$N. 0SVH'6W,R8?RT\@3[T45_0?
M#:14N6D/]?-,;L#%L9:5PV9M-]:VK,88R48!C5@>(N0= YS$P3C&5SYK\M_)
M*:G<Q57JWT#55HQ6GF60EZXD/YZR*OH_=:=)C-E%2;M0N PRJ^"7XQZ;B 9V
MB[;K9>;])/-AU99[GZ%,K02B>XYK1NT/=D_E>3IZM)NS6H3X? EA&N#RQL\1
M8)GYH5E%8=)Q8Q_95FUKSO=O/6AMOL<UH<I8M_0Z#H8K6\/'3!'\%EHM!9(7
M_*5.%A];JY"1_UL[8X@?4V?D!IX9,_2PL!>W+]+RV('JONVK5OK$6#1OD.9%
MN ;$DZB20'7U?Y3"/7Z5*UHJDP--7G=BX-(DG0:!3LUU53-7@H)9*^YW(JBC
M\$&.$AVZO;9M1U<(@.I^&P*0W%RQV*_$=A!<!E 7#W O>[09*CF./2S,$"].
MU#,WAD1QYX@W$]/H']UOPF>,K[#<V.C*G^ZI8C[Y05N/H9HCV,'B !-L@6VM
M0IX\HIL#8=?7&J\S;9SNT13>!(H6Y=[%W5(-8R]F;3+>WKR7:@K >(VGABJ&
M!NH5'%/&YE[,D$\"72  $9T(P*)?@VKA!<]AFC8W\XEF*0[UKEB]B*POV1>U
MSQF5Z+/[#W .O_4XI\8&EVC-[K3)HC*0IR@M(4$_9N[[O=@6J5M%>A=>P2_(
M/]DYWB-U,R;X@91$IK&^]L@'[^PJ:W&/Y@W7<6_FRZD(P%3EJ!U]"6[_(N.G
MEX6$$K (R>KI19R\W9?J2I::]6@,1ZG=CD5G.W9I.)GZBH8$:Q)^\;E#8/4L
MGT+GWRG!)LD41!61VC$X@7]85#!$,*E7^H+PM$1'Q_?VR_VKY&>)D*63$V8C
MC'*8Z6."U3ZWH":O!TG<OD]SBEWQ+*"NR]U% +1Q"K^-WY'G4!V7H7]OIU )
MWA6;Q56\/R:0>V^PR\_<?*&DYI%8(#5EO_%5+S-5K89AF&Q5NL+XD'W648P,
MU9A3 EXM8A0P/%CZ)\7*7R5D11%I2STR"6+L9WE[@SD6"W554Y0U!\@!91AD
MO?M>?:V5><N%!UINI9;BOY7K<'0>Q)#7GJ'$^B3SK7.E2-=B'L\R+T$Y)= #
MMI5GK\'7[%8N#2\87.B^OX)W=H;XN[ZV3YK=0OVMQ_Q>6X"7Z#G;)]4F/4<U
ML.!I>7U^[:EGY].? P,6)_L\VMDXY=SQR*3;FU\TJJ8D6=#$ON=FJC6=/ST'
M% MI:"6\-7O*T.^S<E*_#KX=O.K3OGF(&X#=IDK\HMZ#',F1!%=2*@[%  -E
M8!Z)&*+_?ON"\\F"G@>=17.-D(Q?)!O_]+S?\DD\X,5(1QY43;H;E@<5BBU&
MBD\NX];4[,TNN=RXC]:IF^>G\CMB\_1?YH;JAU(;5V=1]W0W4BNS?JX=V;N7
M0P#>[Y=CKZV[,U@T_J&.QIV,O'CN%JU75^!&(\*J\10TOLZB'FJ\37L+*L"S
M]<YE=5=MT]$S>'^^Q32*@=F8#_A^[Z*7Z=_F_LIZ%>O3NV#J,  _"L"GEG@[
M=ZC^0\3W5XE3%!1F"[/N[^1H$VGK]313?_@FZ%'RJ@4 T:$S/PT)\VG+B"[F
MAAAC^7QHWI3*H@0?^OV<NT< '$Z6'+:K"S;"<ICC]J:_$-\J84F3(L/Q<)!]
MG"<IG*^*?6TX!<?-M K [R5CB(!L.W1!O"RVG=4\",#OIT=674P1(=Q=L<DA
M2LQW@Q#9OI$;3M/2AH0XO3+P9%6 S6S*J)P<^9 ZMD&4!6?!'$E(CJ.]YG=D
MEWNJN< K.Z<(,2LH[!IZ64F>+J;L(FG,2[JQ+R7\$##D.!IIDP^.C#"/4N78
MT31S\5M,.'"ZI3ZZ.![$7BTFTN"!Y=X*(CL^93-DX9WI8<[I$UY6*;KUW5XS
M3)W>EQ1XE$7JENT@V9K:+/,AI1L8;9-3?IAOIL#O08-_RI"247V>GYU2$!_L
MML3-?:BX]4BM:DIF5E!;-/CI[O&QHD-MNZ#4XG=KO;>E79(=I5BL3',&'86&
MQS[5ECI[FUIN6,1SX8O]2RHRDF24D&$N[Y^;-=FCE=;)WBK?_FZ!52M]MR%S
M\+22PZK OATA01;"'Y\GMKMO5M=KX2$C\XN*3IT9_@6V][0JG7=\,M&\#/I=
MWCNG($A24E8.3=9%K\>3U2XK3<YOJP'3^!D0C+2BW'51HV'#J,3^[>LR-O]>
MM^B_F-WY.FY=A$/X[<_6K:][Y-^SF+FTRM3J;@ZQ1#4%C$FH-+(Q)((XED=Y
M(D6\>Q,^4LW_6FX35503'H#-%R@-M=_ 'R GT$L<U[W*$>SH_B/\H%BMUM48
M[E.2^TAC9P4P<#EB^P8?6O8^HT\+R\U# ,1DU%T;L\-QMH)>Q=K*(>_DLA.*
MB$ZH\LR"Z[0FL5P.IG*D?XO](PQV.;XUT0.F32M_!@W+P'QQ= * \M,8_HHR
M9$&V9F,Z] ')A)>4]$>V3Z9:!M&^P1OF:%IVB;CTK>\0 (. @-#J#]-Z H_,
M:B '7VJ'>:1P*JPP"JE7-;E(!8V7/1LSO"+LR@P?0Y'454Y*IJM@<W  7&S^
MQ4\/U6U'ZB?%R#RM4BGPD*L=)22@.?_1R$WUOIGX>!H=N!'AK/2[F>]))VFR
M&35%E%V,@P,Z(S?.:5AS4&9$6$8*"Q*;7" +3T5AQA:4'3P 9UO!F>%7IXE,
M$N+<D"S/BW KUSRRF2!18Z=)L"S0G-C# 3GQQ\'+*YN(?UBX_8/E#?]+R>(9
M*XJ"_*11)99F,-Y+@Y_G7)P>%23:?4;OMQ0@*E.TB=9"7]0H@);" P^0> SZ
MI<Y=9N+!3%/SB&0JMM997Z/<!TEHSI@PSR]%_HQ[;S?/J6.OV<OY\%95YDFF
MVSML!H:3_;PB$!EW.P162_8T<Y1K^0?J1SH1FLKYI6":8SR. -3/\]I1$0F(
MG4O"5_S !]HA-ID(0%BE)E<[$ZV-1H+=ZPAJXPN^.SF*7.Y'7[N#AD;WFMV\
MW)T9KT3%#S/=U"'CH"VCY;*;@VD2*@7XI6 4:_5".__#"O3Y;)4DIYH6>3A0
MW'V=\;;J6:RF25E+;.<0&5X([UMO:S9P )5V>QS.5!4@ !M\8N/Z&]U_Q&[=
M$("EIE..:V5XJMB2!P(@@P!<Q#5K/<+?/_?#GQ$ (@0@S@H]X]&X$<X=@P $
MBU)S9-WZYWQRE^F U:XZ&:'/?.BD8J_>UK,]/[BHFV]3Q@GU+VS7/PGDB'WP
M\/;UTZTH-0S$"Y"A:FPY>3IE<?><M':T)])>_\9/;.ID?TK6W,/ GYG$D5@&
M+DT;XI+A"90UEX9<5%0=CU9B($=A+)/021.RD+T2P5#!Q0EI3GQMF;#P/CM<
M-*^6+NXS M"S-KC4*7:EO8GN<,MG]MB^L*I_&?>"B&9.G3U/HA4<MP(.">V<
MGX2+K995>C0--6\;>.I'-DM+4GUX]B.9Z8'%V6OH;0V93 .Z&PD:&ICU= "@
MM4"NL/LN% A=D:++! Y'#WT(^LCX4QEIKA\!Z(T1]?+7@&VM@ZB::P:H7FA5
MOMW*S /-R>[T5^X=M<NQ4V--Y82R-@45Y4A8WZQR>?;<31]A0M0!.]G6HG*"
MIWYVYB>M'9YW%BPK,2I(-;T31WM345E>LOQ\T7^60T+1&U-3Z.Z#K@__! )
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MT9) I*E=D*VON6"\!,A:15$2QH_*_@8/)K<[M&U:Q!XOR=W)/0OL_ZLUV(X
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M%U%9D4:GJJJ_D5K2 >S[^EN.=B;T+ONTSPRJ;P<MXB;%MD@;XYF3%!=J" *
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M_<:UI)<2 G_]R7$9-9&;=OB--*5"<+DCBUXLW=BX.^XB7U2+S^[#R;\,$[\
MYO\@F+M>)#I+4<Y,D']<_GZ7?=SW+ 0 EH, <+T4/:#]\@[\N% 5*.1PB/FD
MK<^^!_7IJDQC4/A>%H;=1#.HF#*H?A1BX,'FJ=9(LRN8D2R:KZ(;8[6+ 5.P
M;@[IU<GQ$MP&JBG2QRB"T6SQY,$U>*4_!6D:MY<"!G<5H%6;:^X-$?Y,[R1X
M!'N;?C#)?RA^;R2=W^-!BM:)L_[R_'CMP>SZBZRF9NV!Y\YE(I'UAENH8TQ:
M6/6J!WF'>2R:=;F=2_S6/&IB05,W-:4&3_F/UC+KSQ7&<NR+G<.=?BVI%U.]
M$\6/FM;D2.7HJ/0$EY04;DZUCVHG,TU+;ZI&\[V[U>1X"=]'VECELR.I[LN*
M&@(%)\%=1D_C<*5[G,3*HM.X.!#0EX!?+GA9T@_BJ)0$7B'L#"!,,+6Q!%>0
MP&QK8=B-280?=*GTC#<URG@VQ4B\TSO::Q>]!G]AE#:EM8;<N_Y<2,TC"P)N
MYID<#"&GM%NNMUV!@ P5Y%%"]TR1DS?OQ@<IV ODZUD3\$C;TPSU4O0 Q"7=
MF=I7-/<C<T+J6[DV(+:NG1.JT2-["B&"U]V[Q2O7EEW8G20E>:G5F(:-&7&?
M6#4.,$>TY3(UJC _X) N2W-W[E"6>F14?^L.%=@VA9.>/WJ8!^OB@6L VLB4
MZ+?=KI_BTJH*:]N7JDLS"?$SDL>_9$HA,9BD?RKF_1@?RBM0A90+EP-APB4]
MJ(Y@!)>3VTWS295>I<.^@_ W\UP0!  #7!K&E@2>V*ZH<.F2(R>ITU+$XG%/
MPE='D1/+P!.T8]I;?9B'F=0U.-@X-EP('!:4!V&C6A,S!C-2ONXLV*'LL_:;
MF'15)5RHLSN7^4>V'9_(RPLT/U&34^&RE27Z.;^$ &2"T+LSC"=J$O2)_W$,
MQUX.W,J8/D4OM: 7'2DN10XJ1Z]"'UB/27V%?U)!1X8,L2XV;3JP22_D" >E
M/,D"HO^?8UN'K%#&U5:6]#NV7K;JRWU%WEEK+>8$3#F/33LLFB0506(Y0D+Z
MW<(*:B@",'$&^[%3O_A5$W09<?9+!$V9(V9H?J?<F7Q%1@';?H0BA8MX";\D
M'#\#JA'9I.ZI.OQ:>83<7K6^>N<-D=KG[T0ZP7H@>^_SC=DDL]/J.P\>%]$!
M+[+V@OI<JG#2(%8[:U1"LLR$OO CTS.7./7F_Z9C:NVT@V2/2"$ F/BG7=M5
MAT8318<4.;UZ7YULY^R%JT2AX+3'[TU,3\Y65/%F#$FG_S*Q6324,_DCEZ>3
MY9J;S_E9>P")W$S)220>\^A1G&5ZLR;?^X(I)<BEI[VH1=96&[@QR)8T+3E;
M(K)Z&@EQM.5XU9AP\0)P]4G]HMNR'_[?Z37^]X'&"+A%-OX:^19LX@GM>#5E
MQK"J0Q!JK7PA?OJW=WG5)VV%1%@'NIJ?63-,$:N7&&N+R5&;GPJ,C./][&WB
MD:G(^=N,W35GQ\GI]YHD?6UES(V@:K8F5+,-28J>0#U8(BFVMGW%(?;V+NNV
M/=UA+Y$$'M6?0INPI4A<QVWKH591+&NFQH2M)+@$79&9E[W1H?ZK_>TL9QQN
M **YU=8_GEA8%!KC%%/])0U9(O>L]]@^#!7R.VDK_ZXH(8$MI0''U/F0J8C/
M%U[H0S8<+=Z=P&[6L/HM44M#=7,N.P3\O]A[RZ XPN_?<P@0 @F!!'<"@UNP
MX SN[NX0W#7((,'=+;CKX!H@!+?@;L'#X,[ ,-S\7FS5;M7_UKV[>U_<K4U5
MOSKUZ:KN?DZ?<[[]5)]3K8:D)O.B>/8$^NG.<]!_++VVH#5V+_$[)OM@S.E<
M>V@LGBAMX'OKCTA"GQ&*CSB^-V67F_<'#;X45J>U/1O>QM==\,_69PY=VLT<
M*7G]K?M_JLH>*S'N3:I")F4%<:1K:19Q$X=;I=4\)KW8UT\;1W"8"L[+AWM3
M9@A["U!"Q%X]?MEL\N0\^=YE@]GOA!N] XV3L/"H&1]GK$;"0WFGFB#Z^TLM
M.#:';%T'=+!\J=S*:2BZPAM0/G'R!,,G:6S( :<-G4!;JH=,WN.53,C+9*R$
MI6ZGJDBK#602LHQFO_*2OP?N=5KCRXQ'4[(0>K"^K&BKL>6-9V.? IFLL&X=
M9!^U!EL&G5P7#_*\8Y^VI2>M3?)50KH4#B^$-0B_=7H&[/O"QQ"*MV=C&T5G
M1LWW)ZWE3!>&]IUY#OL/#0:IK&]+23\MA1!]TB92KD5WF6M>EIL+R8!:J3R$
MBEIQYV50[[$4;KQ&-_-9.TJHD.5*XOZ43U0NRECX72P7]T_P8K+E'4DFFV-K
MM,_,#,UYOB[*U!'&"G8!?59*J ]Q..J<!?&U@-\80M28V'-RT'%EW9C@]LY:
MXRY@=M6AXY,1>:?'G.-%$B]1847-H'B\#KY<U K<ST-EIO+]?DD!1HT_L-/L
MCNKF=%M_2/SUI_03S7S[E^6DN G*P^XN$]U#)_*M2JL6K*V,H=M/LL YE3"&
MDMRO;:C2!90P=ZL LA.L1 K&GI1<Y9WXSU->=$.L3ROZ9CWEGJ>'&YU@UQLI
M&>'^M&3J)HY$94%W/H;ZP2Q!2TSWE$L96ATF:@_3#Z%17LL.GOX'4-/SLJ ,
M.4T%UP]8*D>B%:*U-90QGGGB4\DI!3W[ 3H/ CWE31TZ*YO]'KGHFD4%47))
M<3^#N!/FW&J4&+NTTX><<D#CG3!/>UG$Q[OX'[5;L-?J33SXOH^92QKM@C>B
M:6^>#.8A& ?6=22%T<ZS_KM778*)FI+,JKRESH)RY71K[6#K?1OAVHU+)F=H
M1Q%C\%> \/N+U!]XO2AS(;F!^FQ\;FQ4XH\M=W;MW=;+UP;4HP_3&755U9SA
M(URC"1T:Y=0%8S C/R.8_BJ%8*<3+-4O"]JQ&7_MVT?4MK4BY)4T..?0L3):
M,ZDL'Q?3\JFN5(SX30!C"HRN.IB@ILH;^B%>J2%T;;U35_=DVN&3J_<&R8O+
M%QA1^+S4*$D;$H'L:G]+UH-T+\6A+^W[0J,4)1=3Q<[$X07O G5P5$O, 5!
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M([;4C<\?;C"5SUAGKF1J[&UCBQM?_?QF%IKB5Z4>HL)(+T/4^1#/V;)22B_
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M]#52ST)/TTQ'+4$)4A+O6$."])O$H>'XFP!#"[T2XM><WZ-N(RNFDV[W=Y,
M!W^PA.&0QP!#;B?K,G5,:K6Y,& ,/!(TFO.FDV 7R^HFS8CYU^1:JC<T'F-6
M.;XVC+2925JNP#2BUXB)*HEW8>$EF_+T*WSA<;-UJ]9[POA)!%L^B-U7L^E*
M@@5SKTF-X/>1)M^.(K]DP+IQ^MM4W[Y=++-;6BU#6->Y/HG+;DE4.J:BL:8T
MEZSR^TA@'+^?.]$KZQD@E17=<2:WS-XSP.7L1'3MU.))EO[FRCYO5UIRE:*9
MQ(E-@MD^:QM/KIDZZ>M[6]^HY"1)5'"Z@GB=ZZ',C#"R!3,W .C1Y,L1)Q6Y
MT6_S.:*(%T,J?8Y9MI7@]LJ(W2 4 "L'[0D1QJFURM*3;ZW;+3/GA^%MNQB/
MJ_A5Y:9[*TY'U/9+RQL&;_HV$LF,:=S#/:7B'<QG?);*4@M+!^?HYTZ(F0SU
M^F0$R]7EY6/E5VH1^;.R3X'N1&LM!,T)H6F_IK-#"(O3Q-A__#?VWCLHBB]N
M]VQ%0$% LI(&":)$09(C,*"2A2%*!@D2!00!E31@  1AR!*$(0]YB!($1D0R
M2!B2Y"AAR#"D2<OOUM9NU=;6UGUK[]Y][[V_/^?IKN[3)WR_G^=TSSDU/5FK
M?8[UR/11RA?WGX3DM&Y9M_R9^)-@6<M9D//]KK+R&)-1)5M< ZB:R6:?/M;H
M[VWDEWF-7!Z'(DBRJLB06/^TA:M!P/>I+Y<H31W>"?Y8FOP]0DQ5:M;M'6P6
MERUVVY1J5- ;7[B+811H8F(S__K9EC6(-^.B-CCI,TII.NW&PL/V)?PE5X93
ML(I3D$N L%!XH"\7ME'\76:(6M ;S.K@_:3^9>R\^1U7V3!%NV<#"M?/)E-+
MLT+?.D96AH^0PK@.2$H_#76DPQN^;&9#EA6U_!ZP)M(/,%E)VNJN7[L)D2RZ
M0AB8PCSWT$5?C!U9K+ME\!6L534079S,-%F?0N5<N'QYH2QK8SY6^Z*G19CD
M[6?]9("UL]O_;LVDP2Z":9;JRB,U/0T]AMWJ52ZO4YXXYM7GR:GK<2Z3<E+5
M'"GV3O:\E8YVC2C;]EELM\$5I=[,M?J"VT'*J(<B0>547H*7178_BK*J9[$B
M)V]?.%POYIH>--!\Q+YE"&6,*9 WS8KS].8J2VUO[Q)7J<-,T;XT]J'GONU>
M/+/,?.U)U&Z#0 5>1 _""XXB/*4D-KHJ?S;B7*_M/SUC(P,!QS;77U+D_^S[
MIHV8A/2!NQJX,B*1,2S>]Y\;+1&TF3N;/UG:4QSY(JL_K5FZ8MH6(?,'&Y>&
MC3:,BQ)K^[N253RQ/]!<L/"SV;5^FZA\C9MZ/F4,7;#*,0H!O\OY4(&$(O75
MO=-CJT=(U0M%*"3BM/'GSN7YXH1GBD\@(*S7CK&-4J;:I;=DH&0?&^K@(4T;
MI!I-RB3"Q4M-W^*Z+N1':(= 4,U,8-L4.0;K>DDVI5AY=./A@'YW QH_CO;=
M;OQ_L5C2?S_A%1R'.B,=OO'9!%W'J]L\E5A9(@,.%W;=R #+P9(<:<\4^F:U
M&=:00 ;Z76!+6R-;W\A _1ZL7YH,Q,3$@*I^)^/^,SW/O\+_8H)1)6$1LH0E
M&4%.QFP^H?$)-IO07@5Q,K : SL]SM'!?@8=#(%._0<-:V6_XC)2_V!:Q97R
M\S:C3[:8Q@3$&ZM9FSBKSM H 1C\L,LJRMUET_9.'BEMOH(ZO"\F*V,UA:^J
M/DF ";G1/<WO9#@]][/49? 9_FDCJU]R9(/R,H<+R@.6GVZ"A[DA7)/O:HL$
MVVPH\D:E;&Y3NT_#;+<4E)Q "K[I-R*+U/@T7S$^YG(%/7-D.X,]/R4#;]"8
M&=YO7C9PXC(.-:O/F-<D"F48 Q"0!3) K8589.33UF9AZE5P>MC#%R^(GJ]B
ME:VOY"/UJP[2&-T1E;3$'%SRT1=$1"QDA$273&HQ!5;\B P]H"[T4M(U2XE8
M+_]U>S_,BI]P682$@[T0T>9_>0.'TKJ1]?'B:^">ZL4\ K88O;$P_(ETP$C3
M)[)KIVG[<N1PT,@(LGWQLIU'<7\0_ZB'ZF$47C)6TT&^0Y.+A4V149U%X2=Z
M6W&Y1L'ASN5.&J-W:B)Z(IUYJKKN:_E4_FQ?XEY+%_!F$>^/C8'VH [[5BDZ
M6N/[R%/_:P5_7M[DU:=R9M._*;W/K]&U,.9R_-'U5\YEEY_:ZWHF?1"*9, 4
M5GFTY&G J'H1\=Q?9.K4]A;X[UMA.M4KAM@V?58\L&']P-?C,A!)][O^\;/2
M/?L55T? \N(O<$(K?]SAL?/K^UTT@KN=.8L9]WTKIGYO_NW[K2OS_<Z(,I+J
M*O7F1F XN[0,D^&JF]1;OL+'&/$/HOT;'!^>(<K(@!ZI3FDN5DT%(_+ /T[%
MYL\0-+Q!5<!+0<3]PGUC'[_\VPR@6)9\+XQ@$-5:5U"C9HJS"U/:XTAY <?G
M,<JT(A\=C.D.@W2\E;*(BE_ZW11&2F@8EU]!$5^VULYF1%]<H?E4**O]WF V
MJU* 4%,&=HURM\T.^9J\;+IL1KE6:!O?Z"C;?$)[,>3%_40>F!(F77[P=3="
M=1LRCSQ8&SV^7P"VK8L+(7A+J;W_*TP+^C-B/M;VL(3^ =>V01_NK7EAK6SF
M%<;HBW?5A[0E5S>"OOV59C$F3*P>V1<LQCR;1*:Z:%W.CMYU,T\&E^A24Q!.
M<ON%0[D&AW+$-D?V617HY9\^YR>&-P=IS"LC>VHWR,#WI/Y'#:@$&C+P486G
MR3_"Z6?7K">MBGA.:T[&HAP$\<0!_Z+&23H;#YM8U_K3K0.N9>!=HX%/JD]A
M2BURG)>NJ:?U74[2RGI1V@>0DIU1'HHM$G32&ZZP B%"QJT'+,H;SEO=!WFW
M:8/R&,<8EDI67-0>EE:;RIU:3&'.WNR1(!VDPSI5^JQ.XAH92"\AK7P@Z#]6
MWTV\!)-5U(4K3 :]=5V_\8*=4/8)"%8*L2"&*FV+KTGUP902@I??32S>7L=F
MP[K P=:M7:)B7 '5KQX*X(Q%S3X-"31^)+:K7XB)<TNO#;DT0:OD.1K",1WL
MA,GSK"JI#<Z<0'U9+R]7*H4XYXL@K!,D8MMK?K[ET<Q(^5Z3H$'K2HB'CI"!
M3T?I'9_3TA!]A\VB!.G!XA)=%J/.90!4E:$3V,)X6*O(,I23$RV\<U_,C<FT
M:DJ_H4*/^@3_:H-OWY $VL>]*4,:9X.+WQR%0JO/C1R#69%K9=+P&Z;'.4FA
M0V):W](G%\P^P N.//5M.@\O1956=KGL(@S) )N_Z_-D3'-BXVDAOTF^\J#(
MT5/TBF^[H&6MU% MT],G']G 6II/.3Y1IB0 <;>8S:>+._J[*LYB-[VE1C5
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MSI 3M.!^Y?*GY1L9 &W!?N&'!'P&*>5Q0S<_HN>SR$"ETA&=OSL<::DO(XM
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M1,600R/^FVPX**$L1^ ^%7C"!4EI8:3L(F:<E'X3.F4.JQX4/LYX(7H=&>'
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MABS/HUDB1O#5RIAS9,(A9&D;VUE .$MXR1X53-=<#WZ^OC+.$B16@H6A\*"
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MB(6PU;6;6!P_'9[F9/;NUCGV>6<949C;-81U,&^DF71QR"O/<WHHHR[B_-)
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MY,#L^0'P6FD"-]K,>A#_A3Q+;B:I!4LAJ/L7I&!8>*)P2&]#>W:7=W$/*3Z
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M\?VP''[O9&(%G6*+ 9TU?ESO3GA1R$=J \GUJL][B;[M=);,[(UN$SV,/$X
M >$&]/SJ5A:KYS8L_A8%J%Y;TL7_/8%(:A0.B*Y%G[Z\_<A/KS7-KBS%K"CQ
M/5G3+3<DITQ+293C-#E/LG?6FS24+973$7>$WC3;4//[YZFN37_YPE<:XHW,
ML.7CF[_)#=DF3,UA6A88'+& +%Y241X#0K;T1^.&N!YF5_E1/NB.JJBU^4G;
M892L+MY4C4RD4WQ,K/>PL3/\Z-)$\3HD39<'SDN:,*$NFO-#72.M&EV,NT__
MJ"TWU;*1A"@NBZ,D+7F*JQ>@7I!4P9K&OA.11-3]K-A7K_2CZA,"7WE1;!S+
M'Q4_C+8J<J/_[;;??_6&BH=C& IPK0BB[#@#N*PB+QI7?4 WQDBMC!UD<DLH
M(G]X]I-8(PJ0Y&V+ N2[IB!RI<=0@$.TL='_2%&3_U; 1CRL*,K'>][*1W+>
M*THLLZ!+\X)"5^5O*4 "V;X4H@5SC7N&E\<=U_6.#\,WR%6>3C<Q%Z#Y#8,&
M@T@2)%[98N( 7M%GM3G.'Z,"^7=O;LLAP]C!+)/_Y$\$..KO$++M65]'C@40
MS0N7D-S?KX((WYICAF[:@#B:9H=$=.<YC]F&(3+6=!CPDFH<")<4_++\VG-<
MX'\ES&A('=/:4BIRKB@PK8_N)P_;*/9Z\[VP/%9"GG#Q;W;?:/%&7O$/3]Z/
MTKFV+0"[9W3$0BT_FF*^;L,;Q$IN?N%I_-'."G.9SSM2IXVKE2D@4(GMZV_7
MGFN@[DC*61%@E> R]'NCETH)L\<9HR!RTKP@I_F<38PY V2WYOEA4S;J<-0\
M),:O3:V6G!=*IT$WJ(37-]E3,J<SG;I.D$5!\L+3XNZ;PVS_PPWF$*=SLWZK
M(IL]"_97O7=_JTAK#9***(!6&V.?G;;;/Z:M@ ,=,BRLEF2ZGV/&%N,H<:0#
MQDY!)@>K;"W$7H<&O=J_ZV#X;@2OIN#3 [)R=+0FBAQ"9H3EP,NPO"<S"-D5
MQ.GV<F^R@]M4=<::;IH)DVJACA;L27/BZ<R2F-=-;6NMR=!SX_I#5N8PT]-!
MFZ.IV@0%HEXY1(8,/&Q>9*,R_Z"ZUIW:#6"AX<K_0:W,?HN7D6I]=C,*!9!-
M5H3\CD(4WMS_%.  \P-;"CU$C8O/>(.%ZWS%T_:UUHJ0*YG7BDD-2/.7'88X
MPVL(\2CI%M?;N^*\:&'9P]TU!X6P8OYCKXHTF9"<=-S$H@#P76DG1F0DJ%L'
M_=AOF=[*WM*5UR)<\NGYFV?818IV499-8>1@WNH ,8E/3W<K?"166SK]CLI7
M]5MYIE/W2_".2-E?37]#BQ9BOJJI")(P74*(_5GI=)9& 7CG#14;/TYR*Y?D
MUT6QK@4JCXF.JJ^V&;18#*:XC<]+5I7^&?IM&T^3U"]N2+7JW*L*^V"[*3#P
M]$OL9WZ0GJ(A_V[/5+]LXPT;R? KG8[J(CG+:#I:(/VVK>0$Z=F;+T0K,I1<
ML&5'SUE[^8;EGRT&/=V?&S6%V>ODB/RGN!>*@B8E$]XK/L=  8XJZX;]QAVH
MBB0<]BG)<9_,4L;6)$@%3ZY@NE*"_7/?\N34>MKW3J73"?VL@#(F]ZWG9S8W
MYX5X H_?&GY\_^0.3%@XYIV,@"U]7KX6$4E/X5:DU\M8C*!62E!PI? .-"&8
M;5W67\R2FWA/]#(@"L?IWHLSX\WC,G[U"3_RS?^YY#K/WA2D=#GW\^,!>31Z
MY,B$AD16F0T*4(\1'7#H(;HT=Q_NV[B#/^BQO3SR9]L]?@58=IKSQJ4PU)/$
M5H%)4(N.<51,7A0QL.@W.TCE>]3*DC!XF4GOWU!XQDX?5ZHNHX/>68@"I"S>
M>-BQU]>QNOEYU:)K&F>4YY>E1;[AEJ46K]>:B6:C@A;6&OMYYCS^)LO*+1:W
MK71W+$R;E?-/^PN_B)OEK%IXN@W^.#XV:PNV! ?K2FECM+$&B#9['X],KBQ2
ME?$G:8WT:&VY:^UFYV@/](8GL-194[.I@\'-]([ C)4/1&%8@>ZFY;GRO#=4
M/V\X].:/5AW"MIH:P32OP_*)F")YA-#DIN31I,SHQ_:R.3?%U:JV\1?6.//D
MCOY:TO*\CNS[&%GB'T\0B\:F+8HI;3N&WWI#V.\77+A(->MV4N9PU+UU_D[5
M_/JRI)9VD%Y%J-#M7D?!)EKH?3(VI:XG7@,^N3/9T0C-'$/[!L2;>DJ]KWH0
M[<FW\)1Q8WRY(JW<-R1TWUZ9*T78;1D[47KCLLJSYT7A]KZC?Y$=8(/>93-6
M<]W8)RKQ]_-];2TK?X><]DE;O?KM885ZH$,_;#N9?-MJ48Q=Q" O@M[N;%*T
MW#22H^/0=ZA]P]DGG9%#OFF^(8SZ];L7)$D\W):1Y"^(PK(QP*[$YR]9>EM.
M]F#+'(WCV\0 ':SGI?!B#<E?>,^MO#B\W1*V"W9^F\#(!'S69$ B$=E#JCA%
M3JKR?_ME:KI&H']&XOM^+>PL*=8MWH>U+G2[XQ\*OXUB4%*TH_H03F$C_F,2
MNUC$&1K'GQYF;U&78J NZIBW1#H5"1Y#O"]_NHLT2Z[FNGP6ZQK?QK2GU2Q=
MGV8A_:*JZDGW%0T .$;H*65#;2K!7!IL^'FZB/5/IJ]91K],W)!I6'%=C'1Q
M866*AEC')/5_I+35_PN"?Z74?WI*'QT*0+'Q"&K.F-P(D4<EOGT-.<EGD+Q_
M"A5%Q!Q9H !IE4CB,5D4@.YZY^/5O"5(BQ'A#/$[ !<:_I,8^0=LK)5!8EIV
MQ;PK7Z)'^RY)JA0:'50RWD):[WW- .8$;;.!!M!?L(GK&UT2M,Y*U_6>7V2-
M0(E2S8X5L?KGV)6NG6K(0D0'+.V=K%&A/BF$$[I9&GH47=+]D :/:/]J:#(U
M;Z#A4-Y6<P;'L:_7U@CY<-Z;.F+)&O@[M&?J UY<3Q4\K] BHX0YD,E>HN%9
M2!-!TL8FBYC-%^Q;/T,9T?%C8OL+!-DJ>?(GE]KG.MAK^9I?AP_2T,-?39HN
M5RX" 7[*]G)^K*K7.PH/W[L[8;OO.I;PMJ^R5^M3<7R+JO/X6"X&KB@H!XPQ
MG''Z#'>TU< ,^/>9(V@A%D0OR%5Q:-Y"03P/#W=AA=7+;I[X\'"=9Z8+TPHL
M*4(8>$Q\!0DQ+)XN1C6@%Z#DU?.-3(Z';A^'%;Z6G!"]5+<VH\4%D<5-!GL&
M)5K>P6MFD6VN1N'2)V_*2S._!^Z1FD'M6I_KW.P)KG6A *&DEY4RU8[IO0*$
M^6=CS+?UO(^ ED>)K7,:#+QL,[ME/H_9P1X8N3U<Z5Y!/$> 3@<J,>6##WZJ
MF$ZV8W\I=WNK$!I#]R%*)DE(9E!:-?<UP[.8 J+)M^(%NB:E]\.Z2XI?M[[G
M>&H_9': ..<S+L3[&P[=JCM?K3#,F1IDXP6K/'>6GE1>[?JJHQKU!M@'#>_H
MNW=UZ[$E71!)R+E;A-5X>JXM_4"4KK#/UD@;&R"U26\'#$I,G*8=Z;L7!Z5P
MF[S[2R=M!DF+[&(+-[^ _F KNI4?I-+ZD\?KT@*LIPF:O^VZ')C H2D?<%O%
M"=U.SOU7%]UWM#L-5PT7?3G#QT,.E4J;U\-K&J#HS>9!K4*4K2YJ&N9?-&MD
M%0O:*;T\BTJ0(QIX?92?AL;YDNBEU) 0O4^!!S&#U,_XCTT#,TWMFQ&BS$H*
MI$68,TVJ7;&=8GEIX3N#N=JQ\,\/R9 ?/3Q$S>(?/UV?&+N5\_/C^;J()3QH
M5UZ0C(_!*=XH3?NG948POX^VX.WG_U"EC;F[MYG0>S3IY.B<0@*"WLH"DR"?
M/\0=/EH::WRR>3^I#:^5!1\R*(G%UR5FZ,I<!-O,U5WUX?UJ$G1@TNK28:=_
M^E/-E?X3.[*3C]></.G=V873B:/T5U<4!L&O"8I)+:4=N?/9IGF=> 8ILP*8
M^OV?^"U,(9I&OA">[S([.?,A'LR\/#4ET/;K6$+'K;+0M\&OS+$$]V V1]^]
M __.C"? BP^CH;VSD_8E'T=-4 "?FB^F>U9Z3'A@N,U X4<?;V<G18S*&]R8
M4N.&--GP3/.93S%R[?12^\S7/X$I^<_@D.K)A"$[@;>(OHE8I>>OV0VFBJ@7
MQHBBI%Z#9Y+XYAN\-^ O?=#*^MQ49-\NKF3DJ\C&(I_PBS@0K X&TN-4$@BP
MIF<6$@;SR(+"\BDHM>-HK 85R,#@@>M3:H5G=*% ^%W@Q<98CGW+#WC2!VWZ
M/-GUZ;6>1G$3D?1@:TE6J4B:<)BAC\/QZD[*TKQC$O5.8K^+>_=P6>VA7\,O
M^[W<06T5E8ADF:+LSD'MY_D7[!^BWBIRBJ'GU:-9ORYP"90F9L5=;?I\A$[3
M$8L",%^=GV.[>]?#8%J#GQTP8/@K6U4L3L5%2H)JJC04C'QFL&D084=<C+%;
MR/("^=')Y/*WA;E7FSH+>,J(DYYER5S6#W\X8:4]!0KX'?JZ.S(:\@RXS#]^
M(%=5/V@^<W0H")H]$D2"@2D2!\L7J1PYUJ)"=)+/W@JZQ+;:/,/\59AA@V4[
M#H4C5HT%D.^.VS,/"6/:J(*.()'>8 _O0%M[')O(ADWH,=\D/:ZTBLR$:;4+
M;[N0M4WQBW)I.=IV0>O<J,]NQ[KLNWTBLL^Q;WW%9?TO*@G"X,9VB[ ?6^'[
M&M2=*(#ED%7@2%:"C*G?ZREZ'Z'B9V6<<A".RFWH"W>:W=NM]F*!(=[&[64*
MZMD:F*."^<?,-\]S*P95^4'XC9\+GM*R8RDTRR7SH6W$R/%&F70<3]CN!(#F
M0&M[\),;!P44X*7N6(%+L$<^^DBV7D7@$0 ,SXQ\R(@ZY?S;OM1[*7P-5/"Q
M[QU6Y+,G&#2<EH?9]IYI$OU,7-?-J_0*"ZB$VVOPM >_U7K*=I9,I3P0#-<6
MNA!5V?9Z2Z9?R"/4?+K5F%W01E_!D_>%!!E^=SH*1KM(@;/9S3?7<ITG_*TT
MV[JWM7ME*>6[[29MN1E8#66.>5/"4B-B)B;OR1W_(8*M7%YU6I-/MN]32;P3
M-5N^@+X'^.R-<"@E^,O%ZVC>2Q3@6:]Z*(=W\)N?N@Y.WS.ST8.9T+^@33WP
M79&@DP+,;<$ZLJ8Z2RNSH,EYQJGMU-Z[-J^4(.':&1Z6E1N!.Z.[MJFEXOT#
M^WU"G?9-AE^F2LBP$],]V11EW*]?L'5H&KFJM?CO;!R$4 !]).N)O7N1>N#1
M@:V#[&"9S ?ZN%^B,=84W5X>LLI5U0)W+T#82-F3W[-#D^7?8_H0N15R*J71
MO)F$#05.MRK*/8GKV(<'W/Y#=^'^V?85UW>0T):NGD!Z/U]UB=P*HS?.$(I7
MBTJ(4CT"#*3O6S,5CJ;@)TO.CE>($F4QC].U&1<,JM4HNEU(L?BRB=J$62_"
M*,-2"PD317 >)>6D30ZYS(_J]O)?UL?<H@ ];<5G8W#"+:1?>K[HW3"2YO M
M_L$TLW(+_;D@$BIQ]'N2'K@&'"QFIL4$9+Z_TU\L^460P$]H4/\-<A-SO3*5
M7;274R_F+,.X:R</>^4- ].I**/O@F9HI@@:=*"#Q=5DV!/-E5?;*\L.D6AT
M_I4[RGG%IK[R>1!#[9LM%$!+>-Q25!HD?,4-NC ^A*S[KA;D\VI,_?"'39Z"
M:([S".K(GWC=T?C\W=N/V:E_2!<'N<5T&T2S.KFKZ+>/'SYMOKH -]ZD?[$?
M$IU36JNUL?SY&Y-,F=G&/#-XY][#QH>DO(1%;S/C$R+MX"ZWJ=D YTT)63:O
MNA2KOV DSADO(RFU@GYYQU7\;SUTK<ZB(NI?S\$/Y[+YUK'"LQMP1Q3@C2/4
M^V";4&FS92,;!I)V&=5QXY@Z5.Y;;HO#9V?14K/[F2'FO>;$6ZI!/X]SV+N8
M9AY'ZV7CXEZ<,:_VYJ=C^T5^_()<5<?WX[)PDG<%63(Y<B1/Z@N).Z?\"\8'
M;HQ5HUAVP9^ZX@N:E:P C#&'Z" Z6^ (:(MCX&AT)_TA#RERN%1.XP:)!#'>
M$=C?&,94Z#46"V [NM&,9.82K%$DV>QR_6#[6!LS50Y^XRV/6Q(*U_I]=)T^
M/Z>J2/+-=ILN^B,BJ!H8M[OQPV'&OF>&H3_Z _LYQUY,0X3QD L'"O G")0*
M&P)MG9W?K-NA *]:^$Y%1!BGK^Y;O*\RS?"E?_YQ>,;5!,^RXN8":[2!K<5H
M?U#J*91X!:G34)C%:?[A4-RZMS]_UG6PA!/T18Y5]2N/5.<039*SS(7X)-M;
MN@4I,G5,RB"?$D&X2SW2O(VBKB.S\KQCKH,7R6QQ$Z5M[WK]#-9&J"S?7KKO
M=*%YY+$5X6HOW/IR6?Y[A(M9;G)]]72U:J^FOM6G"]\""0J*.4?]A!LL6!,.
M20;>G?1[(2TL_SU!^B\%UJK"[N[U1A8UNEF,JI33KI_B O+,;2@ =W!_E0\Q
M_VUZR_T8@NO88'S7.Z[RQ@F*M$<!9I1S'\B1?AF+R4A'P]1Z/_ )BXU*-&*G
MM408V]J>Q3HS!K.:Y=I-KSG!>G8\;R))*C:SP,MNVAS:HLM@P,<CK+YAM6>]
MN-PDSK"0F[RL\CV<P;D[CR +EK*6Q2((('PASW&TU$_GP$G26_VC)]!?LDP2
MCF0+\(B7!0 P&>$G$$;?U4F(H->)YX/-?#&GVL/N$1O'R/R<#4 ]'7ON?J6L
MW BC&U.(]\=2KMQ77F'-RZR^]]^K50MJE96W$Y.'-QH=[EW8C?G#9 B4Y6ZM
M8SKWO3BW'8PMFK2#\'G>Z4'P0J,!?V5=G6\;S<KCQ5VN9<_3;UG/7F[LG*_
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MFD\*%*NZ-M9,(=E-#B&V47^<6PEKS%E'EB6)R@F\,/8FC*\V^+<W%9>T, J
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M7FCGVS>V[(4V7YQ/)/>.LE\ R>\^GW6^ !XSY@V\'-QE)Q])HY;KS=L^!'B
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MH;(;!B-=W?[*2?(U:HLI6.7\MF689J="AU%,_?"56E2'TJ[GQ&=:\C_WP=E
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M_75< ^_/M)FH8FBX3XOY8BP6$-93;)66BO3R[T%A5B*$<N,SFV8:/=EH2'@
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M?&$K:PT:DH<T8!TDPHRP@W4/.?OA]R%Q9I.@D$\#6-#B(T.\7#T?)_2YK'A
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MW="4?"CEYU519IXWBQ-NYL 8)*CYLO'R9Q'YHZCE^NEH=6G%Y.<->S5/8%!
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MXR@)U/G/$3M<,@G]MEL+\X]0@Y$_N:9PRAUQ99,C PGR>"3HQ<B<*>3X#A$
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MG]RC'%.4F)U.XHO)Z6<J>)4@UH?J2_&ABE)12)K0>"RO_K$]:&F1>WX_ABJ
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M'^M=)K,6XS+7S9+8B#EXO<_[W=D'2OSOO+I_V-B:_.T;I&+,E\?-@^,AMD1
MG";.R+S>ON7=>[]RLQ-"6\[4+/E7J\WO,<N\OVH&C))[!_0S,YD2)E;1:_)N
M?(PJTN*"%E7150_6?MO!4I<M]I5KQ U^J(@#ZC=LG.[BF^\Z/Z=T.A1(%PLS
M)!MYFYAH_#(6;&U,!'AAJUHSK?U-JW>V=J+ :?I!DU/28:B)69; DY@GJMH.
M=>4)-S[9NSX3JP@<3'I5WC7>(\J]2?6GO"Q:-%UX;ZYOT/:7"#^3AZA$H:/?
M-WF*HK 5V)1D_6!5_>CVPH.<GV$>MKU/Q<=]K$^/M:%+>E"R]]O9L5O@+]CG
M5/2937D"MGX#]?REI7D&=A*Q)Q7@GW9HK@-,X1OVE9+]SA 5WL:,2*7-U^^L
M=_YN_5&=C/6W9$Y=1<O,> N#1&79&-V34QKD?T;5^MC=3.+9'J19)>'Y2AXC
M63I*'VSFL[X!GJ)Q%Y+\/*,Y[R:VST=V]]-!MWX2;F;P!"R+6L?_"93>!IYZ
MEJR]LPOT"?C^QW8<?4^-D2L;@D6Q'^LV.W>:^2TM$P$Z0IL=$8@\TZQ%A_6"
MT6S^G?(M]5(T/<VC7_P:>(8J33@H;E)%DL(/"/"5W6:)G9\1P>2E)DRUF\U[
M@Q'D^%8>_,KL^%6/7$LNS[9V6BE3?.0E)?*?#$;5T:%X-_/=/)]&DYD]%/8W
M[ B3@I_T-/.CRA[?:M.KO"*F3M5; VK_9U'=./8$6!F+DET9=Z=S/7Y"2/VG
MJ:.0;_(DN^%\9CT9/$RYB-]:+$6%IOR1_%6F@&1D!3F5=$GZT)@T?NH9QT,[
M%HYC?]AO$=B;1LG_P$\7SE3K7J+!\+<:#)&DL3Y$P'PG?T.R(&)]TF?YVAE5
M5VL-]!SF':T7XS?WNB70S4('I F=4=H\LU:7/,YG#;@X++M0;.79/#E3X?!(
MA[UMT(">1+12B[&)ROMUZ\/[D%AG[ZWQ_V<1QG^2MOI_ Q4KQ_)$0$@-!VD&
M=Q 0J6KM!S3''8BRL_]N_8;[?YVD^._ZC7^!_Q3@?WK]!N&Y6R[,SLNN&ZQF
MZ;RO$+O^I>LR 2PT_\8*:/:3;-Z&K4I&.@,)RTJHV\I8S^RXXYI.ILB\FZG-
MH4Q#%ZBJ2[^VZI5W$\!]%VJN\]4[GE7$1,5F<W2,6N2GE-VVU>46M,CJ4_>M
MZ[V&(@)DA.P)B,5#^N^G8\^61KA21QVC/XM0_[8I^Q N4\MPN)*(.9Y]R&\9
MW8M0X:UY?#5) 3KK;_EU6MZN(+"9M2NHTF,8=MP><0Y1<20!_!S(5V1-P+/^
MJEIKHWBE0,G^*GX!T-4WBB2*Y+"3BG[P[.+B!]*!HNN0IU)//UR#VDC[2;KL
M"C&I+YJ(P<Y16*@_A:3G_'L&W$'B>$:TV0<I%64!!MWWK$A<( 6T%+3#B8\\
ML^4X+M[90* G!A4\$0="X#::HZT- UPR-)O<$%>QU0P_@*V9['1L0Y-F]2AC
M9]*B3_<JE6YZFXVJ=R8-3XQ-C%=XC.Q&TM^?7%F-D_;X.#$L6'8B-JZ/_<V:
M+/%[Q_5*(HEXEV)48RZKQ\63*6I;@]"4QCRVD3M\; &&6K'LV>: WGA@+?W2
M\S4B@'L@L,33^W4O<SL(/F\TL%R_,J>F99 \Z\]()__=*[>\I$E<1^+:UU+K
MGJTXM)_?FUKZE&5FGX=J]5X(%V&OU5L-!DDNPL;O_.S(P;97CT]7^B60VV_M
MHK,E;0O@AJ!#S6;.%D$B\%.?P'3\>[?=.0BSG44$#J-:282H/%B>"T44;CF6
MZ^B\'E'BZC4K08L^8YZ!BEE$*3X.SU"8ZM!AT[PS?KJ^*[Z&3HK4I+5/+G]Z
MK6'<AGR&GGE5J\C!]^'D>'A<[4<M*MF/*V)W<9&<D\TT\,%9S)B'\^$A^M>>
MHL<#:]L]X13Q3)^=F/AOIV6:JZY&S.*QDC[5S\,E;>]DAU4=%]1=X],>%*OZ
M^2"$^?XH]F4_KE"""' DR.K2VOWV:>VS[X0_;@L8)(&F-:8()=_@9M;D+5]M
ME2@&I")NN_XL")BK>?;E]^8O*^2#Y0'=O^[81 '3S*&U:ATJ PT#@Z1T-+]=
M&;>;B<%Z-B1^/E)P6[%1YI#ZZ20W10- !K@ -VC #W-UH27FG!E57 D^XZOP
M(42%*Q% ZNM?.DLK$<!D^7>506/&"&Q$ 'P23XZEP2")@,S)H6%Q;D)9'K-'
MRM,?HQ!0@M:*CBB+<5I<6?Y%XA[O3SLQ-G.C1A-Q7 UJ!$*@F\<-F&$LAT],
M:9YON:P@00$>$E.AE.$#5@+@R*R=:MM\PZ=V\-V>A-9['W5C([B,6<=EQY,=
MCA3%#6*IUG_K.B8XEWX*BO[:)7_5S54@%EA%3,DNC0_V?>G/[(2JW,/;H.ZU
M\$2_>T*735*M*B<VH5KW@> /[S\T73LX-#%>0C'=35Q>#T+]?<*HIZRHT UW
MMM#XB%')%\O;9,JU#9B:]S-T<!>TLTJ)JE0S7U#YJ]%L='XI QQI2<K<MMK
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MSV>[.[-WN1+\1.#;76?..-S;,ZP/=&OHF]K%[A$/KGCPG\J,',D[T*\I[42
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M^AD+6*3(?+@)WZ<1E13\-FLUM_A*H 23#=!HJN$,#LGSB<"A-X:<"(A>)M#
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M01&=6S ,(.(&>@N>/=^[E7R%_N'91MZ+ =PS06+,;K^(.F, OLO.'<#[*@R
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ME,^U!W5 L.M\17'>_"P5T$_0R&31]6^X"H6+VG?Z&%NE1[-#,(H!+3AY?\Q
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M5CO6W9VJTG[SFY>+OYS$M46B1.W<IB?GQI4Y';GX65#Y^:Q&71?OGARL #"
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M@'W &A(4Q'*E"#^:^=P:_ZHU$'IZ1D%&K/PP>222N">4.]JG*5*:RZGPMU#
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M5F?\N*WY5QGO%"$A=.-\.H& @(>X>0L6TJ\ U5 D8^015U6*DXO#!0]_*)Q
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M>PC\75OO?L! :TII:4 Z[6NI: ZI<V=E [(7":^RWR*']+B<!<JQ#25E9N.
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M?]B 81>NT&*:!3-2O%BDI,#Y\AX#)[25!R8%W43?!IOH1$!?:'Y:#=&0]DI
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M2?/=ZDL*W<X>%JJQ=[S6(VC/[,$+MEY2Y+-(+3."7]3;OE^?Q8A<C,KQQGE
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M:?2O"_%@L1,CQMH&!QGUPN"NR>5'P-$CH!/2%'Y2,U$N21?Q&]%IQ#O(5?R
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M+'Y/%R,'L79H+>EA!KO(-]\;&'@Q/4>]]N#9:;LQ.V4M^V3D2:6L\-&*U9S
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M)M<9^:*JE_VY= 3CQ^-Q]B@ OA+06F<D]T?N"#:W^M1WFQFFQEK.JT> SR/
MY436X5=(\7/2";#R2X,*3A4A-_)^R]DHIK(,\VE,\ICJP[(K2%DPV&XOAC#*
M%?I9@"6H1H$R38%01R6_LQV3\4(F8J/UY3#-P48[=M92^%8 Y,K/,C@LY$_-
MW4\T\.F6?5+M:SPA3HS!K=]22Z)';>LF=ITYYU@K_Y_B,P%:@TL8*BBI,SJ-
MC\OIA,YAH</.4V& Q+48@,_?>#BQU-B7I(+F+J$,)N$) [_2RDED IZ-[79T
M?H_.\O,QY'\[IR\)G?R8$B;*>LYMRH$B%]LB:I#C/S??\0KBS_<(8"T!1I5B
M[88))8B2(#NGVV!N3V?9XR\\>D6O9??!-V GCV:1@OL;Y7^&TN?_YDTO4JQ*
MZ?&6J$= D$V=Z+$8-6P S3^;_<N,DC]H9&'NTYWW(V )\)G\$= O=#OV"/BN
M3;C^_LSDU/(1<*EO<GOO^<ZIZU3(Y%))=*>@(/RXH:CCGV%4?X7_0X4Y#M"[
M^%OX(R 5'\GW==L%N;MP3W@Q@=UUMP-&^A\D^^Y@/L!DD<:EH I^A+#S6$E%
MH@T^U^Z&'(YIMOA'GP_@DAGXA<B7C54PQ#"]RGSL R;E53P% AP)$F&'Q[C%
MOYV\:VIKYVO9%.U^D]H$V^6HGQN13VD<!# ZE'\=>(*-7Y.<@U)K:N#N[/2C
MH+!YQ7R^[>/E@?E*MD_MFSD4 >-]N?K1\QX,$IMI?N,*/9DVH!9CW93$: 5<
M';@6V5I?W67+U.8U(<,*H:6->0&=7FZO:(NJKK*NKECC/:6W/I_3F53@GI=$
M854T__(+">8VZU_,\2]2N/-&05+G(%90R2%W@OW7733\U1_ZF:?6,I9W@YIT
MM)QGQ)\<(;A8H0?Y.;)*9C*M0\P+DG[9<[^0\4O&59PI:L]8\/?F[4_FYK1F
M:S4L^/=D9E+8)-\0$9R^,UZ.3,K5&E-GHCU2XI\9&U0 ^TXNMX!7YCQ>B\?H
M?>84FDO8N9%13[-,."B(I\![A^'S]+MY]DXTN.K4(YHML+.0NXQ*RUQR?S(>
MTN!MU[G\NFUT1+\T<;@I(^J$+9]'E:GH]\ V('#X&)5UQF7X?7:H.\A%OB 4
MI0AE"WHT%;>X&-"RII5Y272!OY+AP,Y6S\<SC"V2GGIZ+*2&S\#*H1><ZV0_
M[I_O0^H#7IF>L2,;W#D0U+/Q*I%V&BI;(*+8]S &LJ%3$3&BF&,Y:]D59O30
MOL+GE903S:9>U".-8[G.Z=A"W\8T9.4QLMU$Y"STJ^<6ATJ%4.!:QJG2K%KP
M0-N? ]D+_0$FI1^8XL$&D_@)1UPN3I/.6':E!Z8KZ=^-I#]\2TDRI0W.EQ@.
M8IV6C5.CQ(./U ]7BKW0V[$CJM@FA1?(X*OH8KFOJ&ALE9\WPB[J(:=J&MI]
MBL^B( E]UB[DH=.D<.GC"K_[BE'+ :5;^DZ36H\VGW.?:;-54CAO>97;!ZLW
M<V/ G>F8BFI.=!QYW5BZ$..%AV1I)XP.?0<5[H<V<V$]'35]@CB&Y)*Y*NN2
M"M,BV:D,O289KFM^.$5<0-%$:0UPGO)7TX'*BA&5CL%6Q9MY#8UIGG9>N8A$
M*&50:4,[0#,PHCMU+\7M3$+?%7JN%A=+Q6*R?5BG*2%]7QYA&DAHP/9SOR]X
M/^)GTJ[AN0NT/U#QDLK87W>1-\=(K!***$AX,Z:F/#U"2OE*ACL)A8FFOT:K
MFV5>!!QOARQ]^),"*&4].Q]8FK9Q.\DI7X(5N2?HD,C;E2OQ:KV5US.GW# ,
MYJNKW9M]A9 68S2RM!.T5N!31EO8]>7T:_""[8+=<#ENEV_-[B/V\BO&=M*?
M<Q5Z+[L;/:4,0A_KIJ[ =[ @?SLGA-+]"  +DU2F[=]NR:J>&"UXMZ4O"IDK
M6CW1A#*&X8@.2K]A+"/I0';MG$R0;02)-OXQKZ*P--X90)AP!>'VK_N9N.BH
M('X>Q6CA4C*!PC6M#\J.6"(+!%JD GO(:YA0PVCUX9&TY7&K0VG,W]_=><I\
M9Z!"OU-)/->95S!J:2;&=Y>#\@CJM#'J4V+GS_2\Y#U,PX:KB03),N^I+]O]
M2+[SB#Q[^5G, YS5X17K(.0 <;\G>"_U9C3;A0KCK3Z&*[4/<ZP]2TH:(*QT
MQMIJQG0Y)VYJ)=37S-EB)RZK;/=H-09\BM^T\T-++K>2*KR9#6K>3NRB94SE
MOMF^:L^<^#S0I=#M9#XHG+IYNFSP/72&;MJOETW;4(E$STM(E75.H5Y B\_3
M(")UXJ7))^E$;6S0G1AE J>K_QQ7SA, TI\Q;5$.B[Y@/)ND8Z!VNU\'J-#>
M''"R;,:8\$$),VH8R%C)EW+^]+-]-8#H>R"*N3CM#^&>B)%G<% I+-BH%8L^
M_-V=3:'1)_W-H^&AR#5>$8F3W7 ^<:YG*@=YI'Q&;^-\F/.<7:#$(J-;:WKV
MHA-3AEEL$/S?'M\J#ZD6L84QJ O>#0XR&V+/G+I1UY1Y_1S1CRQ-Y6<T2))[
M.+LI_W.@OYW6XQ>@P:H11QHX64(#MJP+,Y-TB]\,X0RK:UHXHSF7>V*O+F8E
M=!O_&#DYG;J<QNXH%GOGD?-.?_"+^WM/)6F,0%)?8"W;3I(/?2^B:V'EER=F
M)**#/FI$&8N/E/<*.@YVT?X0*>7DZEB7?XA6BIRB33* 6EPA Y-/BEOS!FY]
M?1Q1^ H\180[[1037V;_BET_HB=P#E?#T?,D('TB+K"]Z_]:XV,%S=Z O$C(
MR:$G+I]Y3;S"B/LVG]^+2E?'9U\,N.O:[JUV-0X$U7!X!F+ *E]5)N?GIH1>
M[WF+C,M5T0^:-_2#]*RLZ"(Q#V070DX8>]#?B)H>G*[M2;";I*G(+%0%*'@1
M\Z2%H^KON)J3V=4M.Q1Z<&ND3M.E&4S@3'IWUT^\A!C08HFQZ7QTK(^*8Q!^
M:HYAMG%'(_+-3];%,78-C2*D9N+WMX8?<WIK70IJN)1NJ2@%OO(VY.1[TO/9
MK0;(8=UXJZG!25.\;W WLB&6RX/R7X0>.SC!\N7+&J61Z%).:+FR?L2QDX0(
M4:7!70K#>YY@U^TO^\7D_!J!HM:^<@O.V6MH\I'?1BK=HWU,*WP=PAY\GX&:
M(3,Y 9VS4.H.'<G23=9)G=;ZU(8Q*FT9^^-8R:=DECE>I5ZT-"/V@J&#K0]^
MJMDLV1DZ3\#6HCV3"B;4ZCY%:6QV#]-2XY_5ZM/GJF5%@\S<14(N3U1?"0)E
MJ#L8V$OW/C)J9#"GB><RT7$MU+5TT?_:6/CMOZI84"+!3<47-;80EI>66%9/
M8)HYP2S*+7'EH>+JT<!8EO\AON!);( ._'XC*K8;Z:]=R:VRS#[-7"S$K%18
MFXRMQLX?7#GG$;CJ5EJ622O.?'J!XD ,F3YB57SB=GED34<_&XB_-"W 'C0T
M!?7*NQ]<23\\O_3O<RGNJ:+'QJ;F&J$ZZ19-Q1#SAGTSX/EF4^BXQ\"CQZQ*
MYIF@@.J..1/BAU#J.%9KF$XPF SH03IG[>7P] Y:>H]0/-70.GL$T.'?AIS"
M2HS+A*1%N?+Y>2++?E7P7KD4?Y!^*9LF"NY=I+EE?02@G%E>Y;+V4K&4(R]R
MJ)Y*XI*SP<G+@EQT1(N"3'W@4-2U!)N*6? EJ!]&N3M+\+0T=M%?^]VQ2-?1
MZ_T'X>\!Z]_$9+_"NVR @C]5I2=VSQW\03L!,W*VO@)-F"KWPDQL^-7S^\F@
MJXG&M=?1X6J(^Q+!?Y8;X/])&!:5,ME117D$Z&('(;LO3^-[+Q\!M-!;[QJX
M&=*XLY+F/W6N6/A?.U?,_.U<\5?X9Q+^7W>NT**BTHOKO<)8+8]&$6>64.Q$
MLK D8C2??B)6K(XPC)@UYJMET[ST"Q8G+'CS##T [1& J89Q)M66,H-X_@CX
M6A3V:X,"PC:;H+UGE1:<DZU._C+6=DM*^H$M14*!N_V%^3N:!,5-K9W]*:$%
M7-;NW#N/V+!\_:B(*.[H ?H7'(:O+/*ZU%.[B!V,D5F+!J&,SVR*YPMWBC"T
M"Q@TJJ63"@9W[4N#R+#DM'_L@O.P Y0> 24B,S])=)137=]Y3.T.*JELRKH3
M$)^W!W<;XJLC\'*EKXA;B7=69E&+1]Y#LZTJPSRC> [,N8A-(+ C?MH&:@^V
M<,BFWS+*_K0UOG*+Q4/]7).2<]G&PS!0B0$7^%QCD$$B(>"+7OS<B*_8DB>5
M,U/9@<9*TVL<B3!Y6Y'56<GM-(,?1(7JV-'8;J59Z$(AB-?'G1;)4U]T&0IP
MZ^KX6N UG7$DF6$J+Z5_D,3UIRZ6X6 F0+'=QK*R@L64O?%B"R@%">IU(XO<
M&:41-[I!VJU/YEN9 @(#.!V"00/+QM^LYF8S*1FW=4RPQQ-O827A)@+\+/"X
M@+R G.,JY8XMXJW)5(FY:!G6DMRH_FAT;AZ>HDB:XEU!8K0L5]F%]2QA;X.<
M;W9O/TA@L*<'9\:LJ:%49):+/14M?6*@:293$>+N#;^O$KP)*A%F+;OT]MG3
M[MF!LO4!?Q&J*"HDD:BJ5A<&0UPF:!'>-Z>-VAD':BMD:S<)D:\*[6P/&+V5
M/M!SB3#"[;0UV1D )5I#[#W,R*M>80TJ; ?Q3.FBJ+9RMOI*Y732OFYN.A\O
M\W!)FGS\@?D%P7G!-90)> NLM&2UI9)<'$^229;0WGNOJ,2Z+*7!L+2Y. &N
MZ2\[>WZ%NB9'8.IQ 52F$E!9?E? ,$#DH-JCM"L?WUZ<9*>8U)SZJK1(,LC"
M@:^_AV%-)-O7_#SZ,]5SEZ0/[6Q+D2P_M28,8JMR><CZ0LF^AS;^@$=XHFL>
MM2W5(%%7ZFK"I['R;- @&<+/<2=24_MW,N7D#SU?Q *^<+QG-^<0ATP?^E?&
M'!ZIEZJI[$]J&"171]%> E4].].CALH7.F(SFK"Q%X.=[IIZV+>T2J1'851,
M):-6HS%2EUB]\D1"7Q)THA</,6YH3B:(KRN(!N2:")0$K<K+@A[B392>D)V4
M%3 _?0](>'8H(?(]8H VF)3&WH+2UUKN05XG$%I<0J:@86=7= ZTY):EU7!
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M _S/,&$D-S54_KZ.!2B3T<V"S@FUU<<QSK,]FQSV5JE%\D!)05R1]PP6RJ%
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M#-84?V?QZXLG+>S3F+6NMBBBB0=D51L(Y^G*D#JO5_6C9'%'>1:6J'+UXZ,
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MO_-1GPI8_7$"VL,9S2,@;P#(C&W_SF[%/TD;K/UWTC@0DP(4&,"+7?1X<#K
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M"@)IP8E^F/J++@-)GGF\F5_BW<-XYG+3)-S8OD_[#&->0I5<]ECA:YT(2_?
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M'$S/4:"CR;%H-GQ"3])#4OZ.F^:''PWR.E+5H94/.^CJF+6;7GQ<ZKJI?Q8
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M<7$#3#K2JO5Y^VD:IMDE4\8ACHW@JPH_:$50.^Z]?4/RID;(^-\)@W)WODL
MPL0IE7<;/X-KXPM8^$[Q)'/T'"W'C<;1Z4#6P"_V)R^4(5TB-.]^J#^XHN#S
MJK)@WOJ/OOL%0J>4JP&"&A(@DCT)JC.+6X+[UKZJNYPM^Q,LB(T!GVY\(DN%
M]Y_9P-0:(P)6W%-E*%R_7:IC]O?4RF8#]T"*+1H9>"A.KVW4-KAOB$#$MMI@
MS;9>EBYP^_3?/W(\4=ZI&,@1X'L3&BC*KWNO?V48<G).$3\JR^$KL0\V=Y[,
M7BTF+W>1QWP,E17 HSXN%5A!FAJW%-\KD8I^CC]XPLOMUQRU@]CZ]GY7S-4.
MF?@ 0(=F?[@[PM^XN\HX4RRP,R(DI:!F".5MMY**G8(;BU;[KB1^CHZUX"Z/
M-A#5OO7[H_MGN,0Q!R?/5P6PK/-*S0*I"5XZ^\.MQ:&K/&GH;^M%;2.Z*8>H
MAY**CC<DO90-KK)@A6A\O*_/OM[NZS'(IA^\> >JJ?ZB5"31"JCTOM5"2<L"
M+-IZ1I(M!\MJ 6LQW?@M=$1Z9^@0Y0^?X:4W6DAA"\O+STI1;]I54TFCB0"J
M_-W:<-=4@+%;#;>O)(0V'L'T,)5L;')>("';=6(*57:8OX+4F@N.>W-]+H:;
M**P8VL8X1KZE,/C\/G5U@@:>6WZP:&F#DL%/XH]!5FM'3:-X/Z?<H1'F?DR>
MV!%DNKU?6Q/\0.2"JH&4R'SYM9Y^W0%1:3[7SE(%OJ:S+A6TT(UJB$SWJGHJ
M9O]JX\1$8!FJF+QNO[8A6("RF9VHO"F%FL\?VU6/:NO_*32H=TW?AK/%LG<%
MF9D58)N;JY_V(NKTR;./?(@?%6+BL2V_*+YSBZ2.0B\V'^5&D0HJ#^SJI9R?
M'%8PI:8@AC?5L]/&X2V<#+<Q?(FI_EK*(=GM+1'A-67[>?'U;SM[Y6@Q1'T&
M@J3OIOH$P2 'SEJ#5?I\* FW\>JFJSF\@*(^V0#/UKG%YK\ULJ\M'FK_<?\P
M#--^64[KKO%WS*>MDUFEQKV[\Q@4> QB$Q?[.0IFK=?UAF[2S%9=FQ_'Z^0=
MYD)@ BKOV**F[7B6RF[Q8!+O7V]>+IJ]F*^R4HT&;@^D636(:EF;P(,#V\VV
M/.WY*](*FA;04L<@A[#,_)SLN)_(5E4;0D]_>P'[>M9RT*N1L9/M\X+O4)^^
M4" TSMZ8)@MNB\^$SZP7SX_N6M 0^Z53Y(]:)FLP4M;ZEAR<)GIS-MGIDJ$A
M3$J&AJP!XG&O[1;RXYZYG+S2LJ2T#(Z?8J J6XF+<<YVMPD$;JH5=^8EIWA8
M' 2BMJ3#=$*]/,_R$WLL>%?FL\&\/.>C& P_7E)O 1RO)OZO/!#-3Y^-V*$C
M@[<E"WP](;\=.DP3U19]Q1 2TL2MF&(BPF-(??C0'ET,DYG!TZL&BSK)R),
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M^WTK6RJ#8@H6* FPO:6JU\'J)9/'"?V2QKKDL^9E2MG;"]9V?RA-.K^KV!F
M"VF4)O#AKOTX2K1K9L$\J>Y'M.0^*?#\G[)Y\_Y+"?9\E4,3J^(7U^.*X^3B
M"<7,L/Q"-P+:3@G+'4E1^\C#?=G5V_1-8BUMLLV$9@:/]?06M""7M!\,ZS\E
MS&E4U][.K<R/=WO5^&N[YK*2GPY?>3R_1YZR7DL1\Q GO%=/H&C3DAB )5WF
M80Z[UD)42*U 9K+ _ZP/#;W,O"&*X&5I+ON;Y^[SJ* LRG2J4Y;K<OR J78<
MYY'=N4JK G,K>Z8J,"7)+0WW&P[2VEX=GZE&)MF3CBBI(5M1'#V+Q^RD1!;:
M]SN4Y[%VQ. "4]V$CMV^Y\V!$'YHGVZ\L8;3F.OR/;&2+(]2T:-P&:;4G=?0
ML<$H!!M/W9,YUKQ9%NRDMN\\M:M7@;6Z^CC$H-Y.)<,@*DF9>^U+=O0VOR-;
M?'7TBF2/WDFF?\5;^GF:*#,L[0?0U"&H+^P/UI9LMS^#5&E&^QZ\/ZP<^8)/
M.C)YKFKO?;^CR;O^O!YKVM?9\M#G:0Q 4V7!DZU\ ^_3;Q]^R\,WD\T9@'V;
M.G6!XC9QYK'+(H.LB/"NSKZU-BCM[?;"X P?JT?&7,O5.0(0,RD ]5]="HM.
MJ-028A&WYWICZZ2=G&]ADA'>3-:1HAZ=T,.[8$]:'*S2.WH"J#6AOX>M:F!'
M=A\S +4J4U*GD@K*BOL=[OP>T4X/.5?6(T;,K\P(:7(J3EK5W"M,:ED29;JD
M#R?9JVJIJZC]!+I))KCY$"+P]=!HF'*#9%][OFM!23^M?;5&W0+C4"GM7#WN
MD=]K^M327,N>C>=._S\5^06?N^SX9H.GFS>J_Z(KFI%T;D*KVE%IP]71[6PL
M$;4:"YYIK?UZ:(<OP+TQ[,SNABJE_:-X#VYXR]AQ^[7Q2XF5'.M/$@.Y:?T<
M%5P&MYBA%$J3IZ1^16@AY>0HQG)/EJ'#YC2'>6 J;1&9IJKCG4V8#_@C\#"<
M,TJOK:TL!Q>8SO-,M!!WC3_#*3<[XAJ; _^G^THD_0(!IC95?4UL27T,P?^0
M1*ZC:=F'OET[JH_@,5LR)7M5U _P,X1R"-CCJ<_@\.6N%7?_-Y]O/9,AH!LT
M'>HWW:6*:Y:]( ^=GW@4NX:^Y!':7O >MW^@E9Q3T;EVNT3AV4"RJ.%Y':"]
M07*<V8-GT8(C@VP1H_ULU;52>1(6)N;O_J?*W -/2VO>K?K=JD4[]F\,CJRM
MOM?"LN].=U/G/9/>Y9TAR5HJ+:;.]9\'7$/TT=-;$S/%?(G 6SY?;Z@^^WZ2
M>:KXD[-;J)CRB1G(J_G4_KWM@D,1^'(NW3JK'_<L-G[?JU2PB^:5HN.Y2E)*
M:G^E"Q9S@%N<YW\>J''^CMEQ>4#:EI[;$C\+$R>CA7^ UGI_*]9BXV/U7L"$
M<YL3_8QI412M:O7QUB/]5][S"%,_)]54UYUFP^^HA0-<X1N\K.IYD+SI_:_3
M&F^*<Y1&M06ZXB3EF,=7Y_<9SPD:C2A' 8NM4M'UMW;*ISBIKVE=BY,4H<$2
M;P+'JL^7Q1EICOY!XNUM:[/!5CL%-K&?X%;KR%6+E$K#P$OE>4Q*N;X%^F#/
M7<0$;C;X=\4 ^^>ZZ*]X%H0"]*IZE=%$CH"=!KY14:#(N[]Y"'>)39%X^T[
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M=N/#+GXS<ZPE%BEZS[Y4E$_J*YKWU3"#R@LO05>CK0P7M1\OU(%25$DTNKW
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M&BKA>:9>M9ELHWO$9(3_D$O&^,/EV,]XJA?^B-)\=%)F'MZ[&QML3-*B]C
M$M%Y"P(Z7#/JPAYP=JK,[!4OP^$G37 5$ZS[JHKP[_H!1^=)W:2"[E5)"=*E
M\8EVZ8NV.KI/'14>"##%S/,&<;L=NX],$:)!))2-98KX',1,$$"KJ?ISQ]$U
MS;L\YX<Z7<F:+$VKWT==2'>W_EG*+>D?7Y9XF1M1L3DP^LV6IT*ZF0EO1@S
M#<YHX&6F"G%91^C0*G\MUA.JF,MZ5QVTQJ&S?GYCAQ!IV%@;>/#F^*A9A28
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M?C@SP]?6W;%NS59@IZI(<D$#S_MDWCCU6(^ZZ61=O"4B^:C\UD/VDXRH  8
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M C4-\"M+OR!K@MNW[@9Y.9'TE25-I1TN%*2X_>F7CEG<7A LKVK/(X&H+ R
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M5'\Y&Z)LF]*;R0YE67YWB;)?DG[F,QTQJ3=BJ[Z4Y5?]YU82W7N2L5]IS\<
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MM)G2JB@Z<\?8V,X1Z*1OEPP>74W)VI=ES5;38VN#G6DZ'%KK*%SYDO<XA*V
M71D(_C1CX')3(7M[@9\S#,NJQO4SULSB0.[A2\6OHSX::XU'<M7H(>I\O?I&
MH,_Q>,LMJ]<XIK)E70^:G_*_OLF7\O;9N4<QMQ/NQE]B(L7T_\_ YF%W$ ,@
M24#-+.RVMND&J/;))2-9,/;H5Y0!5=@TW'H!A^2*Q+.PG#9Q)#7MB*WC8*G\
MF$3@0Y0W."4W+*'\H;?Z4*\ TV7KV[;22MNNO4!P;6B>&?Y*/K_QBS"9-$ \
MGDU=.,*)H!9F#6=1?4C!$KQR9J5NV+-=D<_/MI=[=92\P4K&.D;Q)AU)VTRR
MY$<J(M?R9H#ZF71CS%^Y>*1:F[_/8A/]%>C\(5VS%H,&RM+"77:>; Q8NKY6
MOGN,:OC*MQDY^?+K8ZR?B[MDV<UG"3P516&%N6HGI:##:SJD[AD&X":&[$,K
MV]Z-PXLBKL/C.P[^!&LWJMNLB!':7VS,PTQ8>U]?>JEZ5?'53RB'B"B0W8LT
MJ',OQSH"ZGD!R'.9&:.1>_94,-R?$MY,M]RU0R\&[S6AY08(B=-'6BV*"U6S
M4K/7)+>RP@V;KGO_4&AB9>G3S^IOV.S1?7:@G,SM1RF1V/MCIA2P;< <"C*+
M[]O.40';(647ZSMWA1:+?R!EV-MUFX)4*K'JH0EE<AIB<WT$9\.9O9\.80U<
M6JG%25%POJ[]<N^R+GX5IJ"'[HM0D8'" Y^++'QI742"7=PN_6/9O'FP* G\
M!>KA%;V"YH6.5\A:,_$XXGF8JNC'OD?QK*5L82JE*8: #P^?HT^R\3_A^U7+
M-!7)%F2J?@O,OJ7M&:T6C],,KZBQ%T$8^$2P#V9T><.]M<P[&U0&SPOSAG[S
M_BPP65V<C1*.^#!AQIL-?7LK[H2N%&VT=1+RRKJ=F$)][^#/^*CETZEOR4\'
MV4WXUL+<\MD2M&\J2DE)6)@\.'OR5&.\;D.]] ?C1>@=L1%9PP]EEU!T6TKW
M99KHG(%D_Q''!JT5M(RYMIVISU,GCU?F-N.<]:\3S(V2WY1JC/(H_=:543_%
M5B/"C(-7ZE)4)YHK06;P=\5^DDWXM7'0:84D&.H+79IPT/[T8-D5<GBOV@:F
MGM:E'U[<[Z0@8!$_O_QP/:<HQ.7M6LC_^?7Z_+OO@M7%!X.JLMY(;[SPYAA>
MR)(!:4$U.W&S'J=J81=9P%*&GU+?OBB33W;!RJ'G=/.^5!66YY=8NPM%0(OS
M?$\J2C[&@*F7 H+M</.MUSY2'?<3W6@"B]?F=AJ@/Q]/$)\C1*HZKYKX-I7-
M479"?G(<=>S,]27>2G20@,)?Q=^*Z]HSO1/*/!A?MZI";4'BO4/OJ8:1F?Z$
MUND]; Z&9:7(9L>PU3CV"^XR8;$#Q:+4KW&AJ]>6S'WQO]R(V.^)(?\LR]8\
MD!@Q78#EZB;1]8XU6\/G[]FU4O7W;?+_"J\^/IIO35_$7O[KWU0">=PU[(+&
MI"ONCP^?YT%#YHOFKPBLOOA!]'J3O1/?<KGZ)/MKG).6H2F\W'9Z![\VY4KX
M%.1?#A-Y!6$ 3';+(918MUWOG"92)D:N98_:6HOZ/N+(Q6N/KDDO+:ZND;GH
MEF\6EF_.)9W ),G],0:@;^-4#0Q3@7@(_X_J3.I?GW;\$ZP)T?P8NUJXB0-_
MF#VPR4@P0&@I1_WPUJAJN+U%YK%0LY*P$8WGJ;_\;:"NZSS4A>F&1V@&E/ I
M%,??JH! %EMG:-C&' Z-5D<U*8P= EU \B:O-3905?-60=I*=^>]Y;O:+>,R
M)-T6T]>>G2X?-_J;[QM(?+>[MD:K12@S -(5J3@<[PK<IL] Y_7AH7T#^9S1
M4?^8RU;QH+FHS'E5GQ7G_.Z5%'8TVDWB"HK7\-;KP;-@\91"E]<GEPT<1^U4
MBYU@!F 1<[2*?@!/IFK]1C9A8M[[KF"F07OOH4M^,X3MXZF"A'"@;?8W'_CY
MU7;!!1ZNCR][34;'+<X:5^IX5C.GU V7HFB,, "G_Q:)3V8)Q,[7&V*@A4L[
MQ/&=ML[Y28%=Z*[A-";_RAI4<V=XD@%(=MY7)I:M)O_(+0V-4>)E68 5,0#I
MV"M!Z V=KI@Q2O5\+5&/_=U<8XNMD(YJS;:[7WJYK06^Q\2Y.MU+P];[ZN.,
M5(FHWA$3L_%^4>Z^A,<7'@N>W+=FP#_0]?&<" .FU\#&8OO]:PIW\']X]VJ$
M,H'!31 ZE"MJP1!DN.+4H6UE&9]XP?A?R?W&OY^CK'0E_,P6P:W%'L9/#!"@
M0&+,1B_GIZS+).R76@: 7[W,N3M["TXX?R6!S4+UAB:^K'.XWCD,KJG#'I>?
M(-EB9\II"@8K PVNE,?U\F<F2Y^T V>; ?5.5]W<J4S;029BI=N<X+_MHV$9
M[V$TV Q6"G;Q3!8.YP_Z^&DI9W[R[B"Z 3)O@_)?&>W-ZUF/#JB+L;9VCG!]
M>W*[@/W_K* #N?+;@ >NVKL,0,I"*'H;;;%12<V:F\AJPO$!=S75Y2-#&E*]
MEP\Q3QU*OG29J#D4=3ODN+\LSVC02=%%0COZKS#'L$UF>OK,7$\5.\*ONP@3
MVEPG37(>W[WZA:(1290.%OO6S@ (ROP?['WG5U-;MS?G>)2C@ARE21=IT@44
MI.91!$2:]"8@O1-I 2&0(RA(E]Z)@/3>$D@@41%"1WH)(=)[($$@D1#>\-P_
MX;T?[QCYM#_LL5;6G+^RUMQSJ04]VD+_RS>+#8B^BP\W>ENST&85>-]*XM[V
MO3]*-79PUP$BZ'2'GH9,P""V!)W-Z.Q7M(HY$L,8=$R&!]:>\GAM'(2>[1AV
M ?Y-]QZ?U$NMPD[EQ%0._*R6])1_HL9K;,1NML/[HD:BX:+;WN#^FC_18;WW
M-]D:C82P(SR:H9=.+;GF"R4?M\B;6<5;0SG(5>F,>>Q6V]OQA6@1B^O,#UHG
MIQZD]4VFUABM7'3+_K&#A]Y"[*Q:NH,M]GRW\A?;Z[J)+.T!A3,S;+8.@IHZ
M.G89@[Z[]=@TJ!*?O0HL+/YRR>#DLRH]8YW[A4+.<HD/+MIVVQ!2UIR;X><,
M8&!#*I\8*60-\FV/LO KQ\OH8RN4 S["ZK,,G]@CWRTM&7 E4G#(]KN?%H)F
MR;2QP-NEC^U_0'%YNB;*K+CP,L8>.LT3.9=3GH#SR%];7_,T-*J(K:4X R-[
M]GS?+O"DG![QULW:AER'-;?/-K/\Q>659U,MQ<O:;^K@8)N1A@C+ZY!GD2Q.
MH>,GZF*]RN$W&-U^S?A0$93!10ASV.G#MA8>RR4QSY,;2M)--M))TFID?46_
MZO0_M)!*,MCO!KKZO]H[BU:JRK1CK@0',FG1L;SSVO/G-M=LO+BYO<(D)"1"
M/>]M;@G:>)3$YS[183/^9);\:.Q)=>4?_V%@N."/!+''U.<[#<E=A:2*-I@]
M,&PMA&5P9*GGQ,%YS"_Q/;,KWPU35GB3K9\*6#@H9UM\:Y,[X::1D(BYEDMO
M2.J[;_)-]+75,D)$B@:?8.P_TES/RIH1 N'@F0'J]P$+T(D_U7(A/)]'\\;:
M@>^0]E3_WE[SP2MJX]7C8[F-BHK*TX&\^ /!F/J"0=9N0M=T#42*!@!K4_*)
M5E0YLB86,HQ918>!M+>WAQ-^0#E1AJ:@& 7G()4??FH<>OYNA^E^=;G_8LYB
M\-A&UR:B0<%"Q\1?MXP>O\W+R!4U"B; U?NHBCOZ#0,:<11?T\+%,9 29C%A
MU_[?.3*WVGNF4(D"';?)5]O>U0%LXROK?8,?H_29[U6$-C=^KR;%.>;&7YR0
MSRE]XZ_-I_Q+)Q2YW@6[?U6KTY>%P'(IGO5&O(I-6.E.X47T=^[$Y1&K#4C\
M\[$W,1XF$77INU1X#IV&C.0 _3S+F5<V*%\YC"+!,3B[2]0OS6>Y7>$;RQRK
MN\]5ZI$I(:"I2!:Q[,59;@]_MM-T=H3&Z64C:6G+DS2S4E(_NYKQ5SXI,[H1
M=9F#]..]'K?_3C8\I=0=IJ^=6 3=.,"&GU3\YEFU=/5=F)[[/.3CKJM(, *(
M<GHY!F('D,!._WYM2NW4RTC_$_9_1C5R.7'A-1\N#A'8R1-4M$K(\L@D):GE
MF&-SMW-:87VCOXA&,9T/)%!A,C P"++J^I!/QBL!V,;!'Z7BHRX<9,Q];WNY
MOBHI(7>[^O$?]&#CU)"CVN\TQ.,Y?V<O&PY6+?"@:WY#:HEVQC&5N]:5+=:\
M,;*<AIYU65XJO!&7]=O^:9$J40/+W1<._?>_O5R=IB%W[7-430-_R2Q2P@^1
MKF#^Q8=SRH'0OXZS@U::\MGEYOJ9IDZ=>=)5PPQ.XN8H5Q?=J[Z;$#9_IHH6
MY<B;///$($YT9E@/)(L5,7T"2?@[,"T.X*MIJBF9B(J4"V:QW%W'.($R1:?Q
M\C\_A[I@(,QI[4;)!F@M=JY8,29QKH]Z3$/FV?14MI\GQ\WPV*X#/*@+GT:
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MV7]I;#4[Z03ONJRMB!(A8:0<Y_/*_U-6\KK.3<+WXBLRB_IYFKX *^R$U+4
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MY?U<I6?>&Y&PT!3$B077Q#G#D%@YRO-7["#8W<XY7*?R%+T"F\#EVW;1U$]
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M=&TR:+E=_%DP<6(4ZM4#23"300NN5^?_\+*;S/T:$RUU+DQ<,TO@4T#*J_'
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MIE\9D0ZG+4_H<W&2QS# ?3[D"QB.6PJU_V>=4_5G"4H)_H_G/5 *":1\P+(
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M%RY,.>U"E/;X!+Q]I1OK]=549@:ZF1U'G/?*)L@H724[TY)T=(Q/B F)>[,
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M!&8,>:WT&*9V?A)C7DR$GT@/-3[UNO\)4_GYGJ(G6U@,":([0FTKV\Z6M^;
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M5>N^=,4,J_[W\LRB(1!"C 2OC5$REL2=8&(L0*)2>P@:XSIW'Y6*!4JUPG!
M\/:3QMND81\-]'RJE%9#S7V[EH30SY_G8J0_3]89Z0O=S %2Z]4WKZ(U$1!B
M+,QKF_V,T["A:N:E@.FCZLP,OZ ,,#2(CJY3DWIM?.$#OO[0[$M3T4F7VE^7
M+F[5*>[=XSO^KPW'#\_;A$#O#JLD6$--].5BCI/5WOQ0-7DS.>SY5P3G2JM1
MG/:5W-FJ^8KQ;!&HB(RF*&YB5TUV8R^WM_T@ WDU07_T7KS:3_A5./N 4:5J
M$[[>C)PG7HD-='8LA-_X\\?6(,%:N(Y+-W&(,_ZNHJ2PIBV/A_8408X@Q'U&
M)Q>41["72:4]%XNX>Q(,M.5VUNR>Q6!F:UP]*9,7S[0(2WO;@Z]:)T:%Y$F&
M<YM(%VU:<+Y]$U<?'($XXZ>&6P+;VKZ"UFR/IH3O-?C!A(*,GUL2(L;[<$XQ
M[SKJJNMOV90O":O\U5!K:*;A8Y-MW!IU.NO.>,B+GYRA6SQD3ZR@- 1,8>)%
MVIKZMC_"<L"4I]A+V\=RB_B+?@XFH)_O#7X&9Y"B[L[T_,%"?N^$_(@&ITQP
M#N04)O@N[)T?8@'>)T*;"4.KM^=IN9/A1HOAX'G!B=<&$G?# @+W]ZWC='NJ
MAR8'+).C\E!R?Y4DM!;AHA(>_[AW,X>];)5GZ85!+C_H@I0)NBPCB(:=R_%\
MPXB9!=T/8@$&A0C,A)+H\&%D:T9E39;Y(I_U_.<P<^W(;F+?EH2?8IV%X9GI
M$6H)N?\DA_=Y@ .C_/#8=2[*P)">_M_.4LPW>XOWZMJ?G78JZ=H+&D_/ONI;
MEG!:RF..Z_? ^J$>IP>G.%E]L4V[\C5J-*56[9C_DK)+YRQL5)">2)+!M^W+
MZDIKJO%]0LL3#A82=#NJ@AZ[EVZ4W<QV+PH^?=UMJ O "8^FD_B1KMG<QEIJ
MM0LD@<B6C]7!/9>B_;T(FPWD))?=K"<11L=3]QJ4$A4ZS8Q4+_3?>F!I>DJ4
M#8/XYZ1UL5_A(608?1YVJRJ.8(&)KT&.3#)?.:HJ*S.&]M+-A9"U[N0_\?J?
MT7NS"^UG9;Q/R <8VP+3;^P85O$[<?KNU%75,G40@U;?VEQ?[8?]6=PC^/1M
M?8]Q:>V5)U]&!:_W"82CP-?_[$DE=B_O!^$&E\OPN+*"PG35R$?CG=(7!L_J
MB7JPK49Y$1'X"0&,<(+]+-CWM6.DSOI12\![+ "Y:K8=K3V-CFFP($ [;#U\
M-^ZFFA#CSB7I&S:7NE_U'[4X(6,FX%3Q3D(LZO7?U:W[VBK=1DN93 .8:BDL
MO<3;Q5^/#H%V+LS%HQF-:N" YD.CI._!,H%3_%7POI5%5Y"WDH7Y/4)/V6Z_
MR*3VD^3IR6GS,YSB#UZT$&4</=,8)E6@#'??-AI<R%71;\2W.7Z[FY.>(?(9
MG4CR>(RO(;OXC3V>NO^G?\SP^I\>MXGARUR&U9S[N1N@47$FY@2C&[1KJ:;&
M KSFW!A5(->MAD<_V%6SL?I@%'> J#] A\GU@V,$U7#1/<S"^;ER]?1@B0Z5
MJGO1OK^5\T ^G2(K5BKOAT]U6XC/?\MD >KR]+OTGQ([\)C3YFW'5!I .2AR
MV-Q1PLOA(*[G+(#D:'+FBS4;.Z5S"LW /Y#H_NE'OY.J'&5"KQS'W'[-G<,.
M.E/_<1ILR6RV[+O_X#)3:^\>[8NQ"!*.DCJ?:J^D8/,?F--!(=]O5WLU.A#:
M2?OZ7=/=EX<MRE #!;@KXF'!D2N:=Z"PC83F3I+05_V: /J+P(;#43_?Q@69
M*QL#O?K"6IL;36G7ZS2<SL??S')@:\Z+B^^Z35Q12[+@$T'%F\65P]TFC#[5
M-B_2=7M2KR*?&0MP@6Z28C/@52DZ^L#@T]+GF,P\:^F1C9&52^&<#'TZ"^ H
M3Z^.//*-'C352NQ>[7C#.-GC5"J9:,C[9^^H .F0S<^[,]8O6%?#>,<9NIC_
M_YIAZA@I&9V, U!ZP^(#YUVH*)WTOY$8K_Q@/+:GV//Y63+G-.0%BE?S>;#>
M$"A&L',M?8?IDJO&*->4=PA&OM'47H[N97[$QVGNSO/F<('2>@V-O^]?.;3[
M.>83]RTP:44X+];=9%!D^I^-<?[TFVP>#/R3?C7@!SL2)IC&F-J4'']SB'$7
M8FV_OHVR!AC$X5]]*YEM$VQKNW*.$!'Z[J:52'=\Q> R_MZ%485NXZ_E8JGM
MDD@. %31M2BC2^VR2[2W4V\&AC^08<@.LV!=[ ^H,UKCE45CFZU(5(67BVZY
MSWB,:CE)6.VO>K^?H=D+E>J( -Y+#8'NZG6*,NSG@;!U!U0-5] AQXZC.&,M
M1CR!V+BYN$]SG$5)!*T/$FKGVM# !O_GYY*IY_&CYXJM_2TNF ]K6;_M<RPN
MZ:N[YE%P7$>*UL=><7-O^[YMMA/[&&86ZE4YE8N709#7Z:LO#WN7@H)E:D5[
MAAN#0#[!F@O%<W0;+V$M=^%0[:3BRI'QSCLQJA\]<!:^9RO8\%S%0_?_9<0H
MTWQ-A9'[248S5ATU6(4 M8+5DBZY#(VX!M[#DKKZVHEQG5E;4(C39MEFAL)W
M94:%L9V.U,%*MWGOF5N29MV<<(XD<S'[M9E\)2S )T<5%J CS(F3Y#4&^_FO
M?"9#CG$;WE9#RWXL3_MN_(1QI<?13>*9#B_O'Z'XZ8O:YSSN/\?%\YE' (YQ
M,!M).3V;6Q3)#(-="+O7MI:W2KL\'8YB- ?K/0S$PIX1-,K:=RF^N67?"Q?X
MVW,E?1>>6GDN>2HT"VQ#S"$V(I7?/$Z5?DTM<\O!A'T-PV'9,@-!"4'7$F%K
MKHLLP-"Q595>V">[HI,K!=V!,+M7RD%3\YAZ19/;5X-\[#NZ7Y6Y*TRUJ!I(
M'IRS>%Y:(5]N_NW9C[MI;"2N8C-ASKJS#P]--]K':^@*"<U?N33#F;WKW-U!
MK9+2,$SL?V4;0'5].8W3M8R2L"\1]N>%H8S68T#J5LDRCT]SM%F4IJ?@+^#(
M^F^5\'TBOFL[+XJ(6)EC#G+I^1RMIMWW$@.YO-R/$ E8J06&6-[J_N5,47-P
M8V(M'I=6/[?)M7A_D9-/\QSXDC%(TT$C;FC:,T)Z(>J(6P'M*CL!:BT1ED$S
MQMX,8;J-4$6;R\##7 N3]/QJN(99BX+Y,9F4PI\36]$_ZPW&M2QW>^78WNHR
MN/WPZN^9_[S+*-J<DQ[EHT@R_'?$S&R[K]44FZ%SUD_VS+=_2OY6[%7$:WYX
MEKOM=?TX<2AHL[-+I,>Q!O1CT>#)!RD=$RD^JQ(VX04*9655+MB"W(GG\LY4
M>ZX$M'F>R.KSSB:?HVV2 VN-98[/_P.6$4T8T_A7('&6XQ0,V<%3S>%*CE#;
M9^^V]O_?_>'+(<]DNS4R[')($/5899/PY<;#JU>1KW/?SF7F%FC!%_@'9+[
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M[@AT_VE95%WTL#-<1I5O:\1;3'E3V\>2&% W]R*/+'KHGM<I3%YHS6M;W07
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M=$C]5+[6UHH'P#\>)E2RLE_KHUJ)&&%A+JE'S&_NU?59:;)J2S[ZD%4 TW.
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MC8KUC\]M!>LMI5B:7W#Q/J21 =HR3=500F1O$2^-_>#GK!ST7G!4FYCGY=M
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M>QC [MD$PQA"/?+CH"RS+KQ :NT$-8\\GO$H*X !6#_37K:?WH"MA.5S[&8
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MM$N+\G3+9'I]0Z\F/.4UO5"^,KZ5B,L^.6.OELXAT.:F)GYJ]7(NBEKARL,
M3B&?\LW2RZ%=JJN$"7N'[@6>Q1]U"PJMZ*6 RMGC :Z:(;<.>]%E7QP;"H_C
M$H%KGC1=+..YRG6\AYYDSU+'^E$_*!F%,_2A1Q$BY+^W/D%^SYI -V$6L^?B
MJPC%[L..8Q<':$@O@VG2'OT/Y7P(G? '*;3=Z(3SM^<.M[D="/S8^=H_:YH&
M2N('^%_5ITT&TU>A5FUT2R3$/4E2+(8>J-.;?C%7YT7H+94O_+NN\[GA=Z2^
M/G<LSF6TJ?UZ,K&R,\OU^2/73X1@76/UT9@'@E818N''G24[UY1TCXK9:[5Y
MK39PPIJG:=XBZ^ W9RK335] 16R#_806VB0"QEX$;QG]]%6EBQ86F';),#C*
MZX+G8"FVG[+P8.!3K4:#.N^#JU8[@];@-]JB[?5U6Y!BX!/+/&Z+4Q"(+-^.
M["I@NO\ 9!3*CTD[46'H U771TNES,=FJO9Y3.29<?>:?38OYY#<F[9'\]G7
M.JVEZ *#LJ?*5H^^1!^N/&MPZ;4(6@R[XO8^-=^DK8A],</^H^]6.2$0R5^^
MJ0Y*<F&'#\NWZ.S>0!G34?U^E^*3@P3.^;%:K2@^N*PHRRLR<#.],'>2[;6F
MF%:XWXR8[;1.?N$Q.<[C>:2LOJ[=X.>'S-F*_]XZ:4V$"7@T-%;"(QSD;<A0
M8S_E= _Q1Y8;BM>"V-1J+!R/^1RW2]6](_O6%NK4+/_5 UTUR+JNDX@$X>,]
M@2(LY"R\H6TY8501_:-XE.M[[?=A!M",K_*F[>E1I)U[4X>_7WZ_W6$APM&O
M(9XVLUJYH&VU\[V<[X&&?3+MG\Y+2NG,NRQ?+1VG=B=Y^K,[+V0\0@K0O"\1
M6KBI[+[400+"?7,- =WV"^@VX5_]UK.@3?MPL<S^H7+)B8/5T@H5(KEK)L'Y
M47)Q X$R@F?OJ67DBIX^]"WP(E:G0-AED8H9*G/;U3EP@;U7R9;4P/EJN,5Y
M@HN^Q/3N#;<6AR:I :2\#(_EQJ3B\(;%'[4S$KZO%Y-R HF5Z%,M]W5T@G@Y
ME=;6NFH5]?3'TR\4RT88QQCP+W5=.FO<<1(IX:9K),O*7SD.\1<@IX^0BJE]
MI#KJ$5]'RAE;[\?;"3I9C:Y?%$NMA\@&B8]27^78OC=9Z?0ZG-;9+G<@K7N7
M?#:7YA%^.MIDSXT ^G-?!H HL;0A7U)*]_;J!./(ML.-66.@G>\)R QW$G%N
MT](1OY[222ELR!I4MWV0Z&9Y3%YROF7*TL3.UR#MFTN?X+N=3_W<*U<++"KT
M_5F8?MX(V"4IHX>P0$_/]?EES@_:Y TP:30./66Y$CNEMD8-I2=BU!=O<R H
M!=\[=-V";)Q.:X;76VY>O-;5.2)\PC]1.&# [-'>TM#LH7?QJ-"3F>^$W"0
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M$0TCK%8I=GZ;EW('N(T?V'4)-4T_-CR==DBM42<\+T^F.HG_7-JY!OJV"8>
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MCZDVIJ:0CUQS8AJ;E\-.Y*DMUA.5V6H=0_%J#7K3#_LJQNW>N"%N2D2Y7G+
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MIDUELG.<S8,!CY9O&Y@0)06)_/RU\Q*@-<6VXZ*ELXHF:K-ZK61SERS'.JN
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M()*< GH*82[:$(PL!<DM0>?G:EP._30(&&GG$EX#-Q!+]WGG/VD<FY>'M3&
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M/\,L@M?\E3H&U3[NTZ&PF1_$L+ $4,<=]HEI-$B<X-^FALL2%H"/(GP(#H>
M,^+I*\DXBG8VN=L_S.(^)A;"T5./!-X;T[J935!4%:/)%;,O' WHS6N(1=K]
M1P.X$%!G8L7F\F\C0JBAA!\R?,>"QHE_HKF,</_:BDKVZL"]U)P"%\+!AD#6
MG[A!./^$';00EI2#/@9JFJ_[=F.?&BLWQ/[6QU9]B7*Z.C&4('YQANLLK?,V
M@,YE4HMF*GK/ <LF+-GDL93'/4T7:%TH,L*#S3WS&[\AOOXJOP@"F8*P'HKV
M8 C\,>9,Y3(=ZF=GC34"R<N?G[WB>1F!8.R8K(;=?2VC$[<(,RB[\OBS#O5E
MT\L_]VXW@-[/$\'&I!XN15-!>_2SPBG7:W8OD462AM=53JB<F!Y.B4&EXD *
MN:[W9IQ5R>-'V4:6S$\N1HZ29*E,07H1U4U]J258/WQ!V 8^C BL^1K0GE5V
MP/6Q\1\UY>_Y /13M(,R\CUJNI4.)6D_=B%. Y8K#EB_I+4B6OUY\G'M']/@
M+A*B&FJB(D]0;K^C5OKE \.&/N<+<.-V NNO^6#!.!@8?52VKNK:%%5*ZFR"
M\]Z#N6S<'T49RI+(@72V/\Q:=T-$_XF? OE[4.1$QXQ[+I$<-KJ1JJH(C;U\
M@%:);L -_$6>-*E0-HQC*9-$206;Q=:A6HOA6H:S--CZ#6:/@<J?,;S1,F1_
MJDCMD37F"AL1(FF9ZG8=:E#L4GITC.4(4Z@9JU,NA]FRD[2T[S:$'7#S+U=*
M>8<9788>\UT1M# 5RI)OT13;%:  JEZMWC6E+@U B(+UF77!/;'6\P-K'N<6
M: /OD29OR) ,U127P2Q#8)+IG.R9%FQ-+@6DLF=YW<;W7.'3';8KGI4/#=8Y
M6PH1=_IYOAL [_5:(@JQ.&LF_/F0@88.36-LF#2JOG^_J;S"8*<C2MTI\JP/
MO4  >E:GC<-*B/"\ZN0BH[YF_]"4%+36[4A:3&)\Z1C&Y2-8 'ME7E@;;7MI
M\_Q M8D\)?O'?=*8=A$Z9-C):;Q4>O5C5O62Q8"D7!&U2VSM M^'K;6=/ZO/
M5U/-3RQ*"5] SU3'G4KHRGB&C4NGGBL8+GH=WP#(M#%K($80,)P,4[I;$W)(
MNSZI++6XTXEG?;+-3>>\$7ZS!_,'.,]> LK2[<H#PRKC,9*B7= RNH7M*[B(
MH/BTS&*6YLD2P->@37.*?0L>/3%,)/<Q3=L;\%:4_B*$X@Y%'PD+W6B@>13-
M?8'4E^2+4<Z[%#ZCSF5L:_/[D39Q\$I*R0%5WVZDG)%O:>,.I992\3+K<PJ2
M:C(A.3O*9Q,B&Q._WK\!R+VW-<$3EDBVOB>)E7?!<PCQXT>-XHZLTNI07089
MW:&>;JY8OQ]R[M7-> ;4EXO +",)KZ1$[.I+UA!&1O#R:T+&(+XLN;_(Q8ZN
M<#QS.4O]AWNLLCKVQ%/<)TKO:=SD3:P<3N'$AW<E%C60%>:JBJP2C@@XLY+\
M 22GKS+MG(3<ZG[O?KF>"%0A-H%WVO7>BMS%'4Q6D*01&66<!LP"XA$XZ.G#
M"/*)3L8CAR)%WE%JYZV[0Q[J^>)KE:M;@%\!\L%TCG+I2!^I&$RJ/DQ\*3RT
M=[-(>@C>H7U]<:L.E8"E_C%,R(714M"NRKJRH)ZG-=!.>P_\C/?=CW?TK"GP
M'5<8U[]'*+ KA(ME0+BBM-30AR%M^FU-A='-\(._IK97WV*5?42W!3;.U*L5
M2<^F9NC6%UJB>P+OR^0C-&LZ\#&Z<?NBPWA5]NM4>0GM[D,"59/$@X^Q(1P9
MFYP3ID/-6_&WS/_=)M-@JZK((_'#EMH4?^7K4^D(5<>,ZU >/1G==J_ 2D.$
M:N"9MT>^M+%8F&[RF/SS]I_BQ_6(+\M>?$4(&CC0L1L\8IQ@^P82%@=PN^.O
MT#HT-F%\Y7J&VEV_1HC\/H+ N)-;SM+$[$Q>GLR<=ZAT+="IJ;JK_SS00<+W
M(Y9*0SFM0V&:LNN7L8M]M[1WX3T)C^6$]++512?Q1@]*5(.86^[Y/[X9P@B=
M[0:I=@RG[\I$3)X55]O=SUA;\K[?#_O]^ALB"S,FJ^]Z-3):^@KPD^R*O]<\
M7D8K*ZL!^ DD)0DS*"IFP4KZC3"8(H^6#3PRF!H_<?08N!N,33=:[#)RC>>T
MV%6L@:;/Z<GB=.SV@-B>H0"32ETY=(A6RO#5H9;RSV@>+AF7H%GG,0+H]<9Q
M#8;H0J*FBF=]]]R> R48!I[?_!0IH'<SIT%EBC7L@(T!;R%#FH'43&NRL!K*
MQ2W,(_J:JV0CD<\1!=%BSV:74>0[1$="8%H<7WR*+:&B6Z#!5(7,:V7)&6BY
MMN(&[D-4_H%75D'J3[[87UXS"_E;]H/4<OVT2E:D81,22 .(KSIZJ?)+M*X5
M)&CM'V1Z&H0[RELT7&#B_>P],)&ZUZW4 ,XZ?@,>%R_8G306?(3XW*1W'\")
M+]  WY#$)!5-M@5^0'3/,M&/KAPS)"(LQ>VLU<4PBP$-IK5Q+)B&%-4/1'6C
M!#[;_ZA _']9F;Y<"]V6IGX#QQLQI(NX0[A)4EC;19>M^4"7H^N!;GIGV*(O
MXHRA4YV*'740R,3A&RY'[\Z//AC$_#KX]QCZVXK'VQ?U/8<)L0]S=*B2N, 3
M&(JZ4ZTY&5G9"'CD$,[?=U.LX3\QN\ONVLOCF+B1W$.QW&G=!FM MM,Q)-X#
M1>^DH4XT33A, $R&)K36N/&DB/E6I9$)PU_$S>SXKG*.\_>TG0[-]TT!;>ZS
M7VK=8L#GK>[:+K:TKKJH,E#!:4:3U"FS0OALHXF!J2X?-EP^/#C!=[KQQ?6K
M<]S%("BV[& 'W+>5'40:I0G1DA0#-5=$D)QE!Z;J4,$;+3+XTX>><##CST*D
M!IC^GWM2>V+HLY**3(ZM6XYO?=C54?QR$>*7C(NH9!TJ#^9V";@OB<F:& (H
M4(5[A%PDC57;_:EGR\X _\FE/8[C-D9L:E*=!P9'72>A\^()8'I<@15Y]VGT
M)-;A0<'7"3P]ZU'4[8\>W,T/ =>0^!P$"V]D4#4-)5ND(XS+M3F?"GHX*K2<
M2+A@VU/$TZ&NQ[_^1N;?9T?$0P!%Z\K:6?U%?W ;O[^):A>NI;NLB[EZYZA#
M)_M=]LL]EAZ/%R1[)29#=A.YAF"^_H""_&68"9(Y%HD%]F0[N%5[G8_QY)07
M,Z(];U'CIB3NK#[@GL96?[I?3M-@?*3ZA?(_]6?O&1QV2UR^^\C\B068'[1^
M?H)S)^=JQ%S[JDWK9=M9GOCGWTR!8:K6K3LLK%0< M_ J&D;G^8W^:4NUZ%*
MS\'[HN_.<;W6T:LBBG/4IP9+_US"I6A+%2^"W) "\^80(M+"96\:ENI0WS C
M/H+3\:OH2:2A4%9]\],,0+(;K-;X^3M]YL()N*9,ASK:HP+H,=CBB92/=6F(
MR/[AT+99AWH?\%H,2\6/[/K GX/:BB@M#CZ#U@XA?/JO7=RM\<7KNXT%MQ "
M^8-J!$N--@,2T^_&!(Z8-K 7*8(]RQ?]&C&Y&,H!Z\*%6(XF(6E+7(@\I9]F
M!.,\2@2-F+U7<Z\HRPC?JA !1Z =HF_,4=G M3#QZ9CRP:[ZQ19%+-ZS@#F\
M+Z,GR[6>?@YQ14> J/XGL)F,,?&VHA&O3#?3]MA0&NW*?*865JZ-HVHIWGZO
M8JRPD:44V3G&_-#779/17Q!"6_$0_'YH!15RS]:A>O,M)/31FL;==Z'7ET)?
M\_L,Q/IEA"]K[,57[^P(L""<F_J12<@P0_+;(I](&Q0EX:(# FD'UFP$+*9I
M,].]GP;-.31-09:&LRVO#EV<?M:9QOZ(F*LV!%R(%(&\7Q<K3A'890CBW%T4
MK$,UX^?G)+BZ^#L"9Z>E0=CS%T,;EV>)E[J[X@^+ I^=>#)5J7Z)5^GWQ]_=
MF1K,(1$0&MM,DL]YE8PO*<:\7486-^J/5WBP\@7GUO=GN!5*EVH=BA.<7=?6
MRY4[PI,Q!W9?<;Q/+%$7YR[HVY^JDI.@9</6LV9^,)YO73K=G1-D(JT2=&8G
MJUGWEKX#EX42:;@HZG 3Q('C?NI0]*-(MAT7//'T^+).9#P4'ZOQATUO956
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MOG\Q0CT\M+*"77P:T!N4P6<TY6T7G83+8>MW_1W:U+_VBLMBY;<]2_K?-LT
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M*TA [<SF#)O)'M=_>T"TI?]= HB9#M?DX'-:)KY,Z'8C84?\3M9]<[9SYT1
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MQR$<2H;I\D_=&4U^S%M@$'_0RHU8[*[R%][& 3,W4AI)P7!&T#Q/<WE 2M[
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M220D9PSUC\-MV).KPZBA.B]\[Y%/QPRW9'=B1SZ(6^+<N-BR3^? !_<1.]8
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MOMG L=MP<C",FP_9U>$4_O/J=0;G!89%=L3LVL!5"A#W8;]($KPJ80(\W=B
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M3ESAN2W0ELYFK%3O94QB5&!2V<P>^3?Q=]5GID?66&E()"Y'?/ V;*'\W6+
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M.;@RWU_^ZQ5I8UWJ45#:'.(4HX\/#Q-W CF8"2V&$N-!SKXW-<SR@F,-3:-
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MD$L/=F<BTB -I.5*YL1@-+!@ 18L\KUGFB)V823<*4N?6-J0:;E;YAT%R-P
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MKE/G&I<V74%7B"'&VI'42EEW$]OH,F$F28>H56FQAC1K=2,JBT":X7[,1^<
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M M8RQ>XFR*&)E_11Q ]4$DL)TP<X+'5_:G 0'.5_FGQ.>!@LC\/X=<EK]I6
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M]+D!7OS5@/TE 73XB3)>KA#7=E30E79 (WJ+;W:J1W=AHIAL7WR'<@BOZYR
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M^JLW#)[ 0)?@KU[]>T!3Z,8#Z38KJML3%> #J7,UR0W\XJE4X9K:[G']/@1
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M>@>(&4L,==&_L7S:?2L+5KB9CRYHR]4 (UB6GZ,T,\QF0]$7,,D#LJ!-EVW
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M2Q^74_LX;31GJ !?>S62_%@4$O.#.DL=<Q^"8PT'%O,9GH#1Q5I6T ?P&T9
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M$F@ ;+'(G8.G*#C"=50B_@UY'9NY2ATVL9X2R_X4N4N;C9U/]P*7"COAI#Z
M25C*(P=K2XNZS>]8XN^+4D@AA'8EXK 2P50B.BT'Z4AIC),4)"LP*9=T#QX]
MN1)RB<XJ-(%#R+N#@M,+[=]V2[5U6%!WS\Q ?C9ON0;B^W8THQX=B2UAP":\
MPZ.<:5GW*#;&=^3@&K.9$'O!B^(CS#C\":E:5"/[:JB&9H],?ANY2@+!(WH@
M4CWC)_MNM=:*TL+45ZJ_&[T3L@D569_C2*$']HH#ZU'K;>W!<:-RL106^99C
MOQOC-&O"CX(I[WXP'[<S_HCZ :;E\##4"Z!@M%D*)UU!K.X>Z"&K6P=-=%U!
MF%\+CP'OTP :BNYYOI*FP+05'VN#T%!9;:T*%Q:K&&:8@5&K>_4_P>VKZ@BS
M"0BI ABU>)=*YU"[(=J9];?<+7#7E(B$;.@L'!0<XQD=<_Y_T)ET3GN5$O',
M!,4#V.[=S?2##^J(?+1=R$^?@BQ4KA)Q@4D0D^Z,KV%!^T).)21VU[?ZL&-D
M+P=KS"]32EQ>+!?Z><E?E2*28;FVP!+8QSW]>90[@IJ62]& KS!]=T0]<CU.
MZ\X6@J@'ROR%IFV]%+579NID? $VL)NH3737P79&'.1U%)-4,+;2NGHZ1O8M
M3\0SYZYN97/!.GU@'%4,<.KOPF%%Y)-;;/G8$9EE/EY%.D2_\/.7$M%HPT=-
M3C??!DV1-.@QUT3JGIV2ZD_H3]H[M8Y'6V*1@>+["6L61(3YD,O5OVZ^XZ[@
M\>J01@;.HJK3,)%L_VZ-XO:B%<@ZJHEK7K._>2L?F. &^84NC/HF::X\J=IJ
M74OF'_"JC&0'LZL;#5&BX]A:XTF! 1E6[4G?RR_@E CR<AL.WEI9?-7/<6'8
M''(]#1"XH5Q: _W5#V__(^CRA*4CR2IS*(\S_=7G=G_78*"#'8Q)_UR5.@+<
MARW47MDN_S*^(1S>;#C]O-^[O#79H#B%[8_\PX?#&1E=IW.P5?CN2S2T4-2;
MP+H%1Z\\48&I>!^Q-W-2L0NZ"1(+.BCFWY&+HP,PQ?GF]C_7-%H,^5]7FINK
M%CSNE"RBN/ P67+664%*!(>D2@&Z9:9I:[4A!XDYD1_(ZSF8I>5VX# ^,F.7
M$^797F*>##DG&CT+LA3:F>OF.**WO[E/.G:$DY?+>?.#_P";I:<]UD/94%3&
MC;A,=:1TF'#CH-[ XO4.EP1$,!LY&&40 #"1'/[%7PJ;J<5_=]Y<1,WH%_=I
M_+.SXYF?TPA"B4#^'+:9JWME8[[0$@,G U>&G)''>(:;^U!M<LJQ9*?P-=F_
M8I6("EFD]?C=^KP;]!U[MD/?/I_8.PN';/UW^VF*$O'C_@FI LP2H8'9G_8_
M;+Y4+XL8JN7K]U=G59;0[X8?* YU 8N#M87:_UDG,,-5FS!)6]]G-<T8BC&+
M,GGZ$LC"6R21:U/(04M'@N7,/UU^N_K"G-N<TV4H7HT7CH9N74O($QS.<7*!
M*O_X761@VQ8Q$.[";.U8Q:W^^T3Y<AMA#S-,I:^>JO.-7Z/4YI7DX]%0[6N7
MH;0DLBYK$90TT\L#-/SSX-2*W%L<XXE=J43\9N82] +8/G(6[&%?@J?X<J7C
M0V%X4Y,V3S@5]LA;[8[ZZ37AP)R,^1727GN"=-BB "IT0TE\!F''ETR=CU'A
M<6$)-P!3CB@,E$5BH3P12VB/E9YT_U_!?[#1 ;H$@QA14C=C0:BS)'*\(I!S
MW6@EHFM(*'OT___':KP"_F<&3#*0,V?@J!++8?1>>)0(Z<Y0:VXJ$=GI+#A[
ML>).F"5V 6W%X$ )S() -#Q%TX\3EQ_U;0J"KUR):%-DIBDXOI ,,PD%-*0Y
ME*T]H,8H49D[IG$_$3H #9BM9LCDPLNU_0D'@;W0)RZY;_"1$C$IN_YQ&&RC
M!MB#_^'FQML_P;^829;U_)H[)4D%7PC_%7ZY[>&BW8<3%2<NOOO>,0I11S;C
MPJ0E$<O#!50H$C(T\F$(MX:\Y93 @!SFQ_S\HH%Z\>'5)7(KG&,<ABC<JQ#+
M/N='&(.+$3/+C3'39__U/(T447G"A("7O>LOW86994SU/'Q_80)3FDA$QT59
M)*("1$7/ZAP4-^I_>P.YV:;DAV)W'WBPT$*VN"8%,>@J%!>LA&G%$U*KDDWP
M!,MLX0VS?X=^J[;0.XJ8T785G"(&:)UEEIJ29W6I*<OOYT_FAYHLTI <"#I/
MDQHRHYFRRV\\IK/#ZQ:6J\%;A$%/JP$A38F8LH7!V5W!E,;[0DM &1QO$_?_
MN3,PJST.RKX'3EV 1<89F9>42(X44H?$H,%RMPY-Z_*833VS<&IK/"H'1Y'U
MX)62!PUH9@_L\P>)^Q49H1GHZL:7X^+Q/7*0VE\"3"7.P ID/482#L\"?<HV
M$5C1\S?7] Y6A*-_G%(BFL(V8J0&T%XFV 5GYG^UH ^W.4SO2Q\2G@';>I S
M:C.YVUI";P>]PI^4X[<Z+)<U0!O3<%A%PCB#&OE%[J\R=I:;:B^:V0KTNF77
M-:DV&>&N%Q-$JT *\2YR5E$#D9=H?,[1(Q?->ZB>J''->TK$^<WLTK" IL&K
M:U#S:58)T$('BRAQ&,8QA'6^H-@8F0,K*F%0Q1.H/:GQ;QCR4_(.@[XAC3;1
M#0?_ 6)'Y+J*"0]\$8$8NJ!HF-0\'LJL&@9><+K%,U]W8R*&'Q<?EJ"6DE!L
M7JN4!:LWTNIQ\L(TJZZT](C_.05Q@I,;U<TMW&\JCC)B06^WCZO(\"H*;I]?
M [LJPBV/9W$MU(PJL8;P?UE0GA1AQ*K581/#L.]\Z2_] B-9\7_+O9T"W.^4
M[JX1U.'$YUS+'64P1GN5JN!"->\FQDZ3*AVU*E('@M^P:4LK@F"-M(79,Z]$
M"'XC8IVV!KK<_.8J6;=\OC=L)A:6W$?4#(@<QY0#+/XG-O-%<SV&.#Q-'3UO
M3ELN_W/5Q4>DY_@XS(OA<)!"?>A?>/C2* MC25PBAFJX"Y'K8T/.U#UAS:T4
MO0)I735U7^I<4H>^L:IT].X=4]D$]9I,$G%0$2U(05'08*ALJ/](6G5*Y%VL
MVB4+!C_Q6QH+F=-J-KANL"%PAIV(EG]P"\$.W8S:#G@L5\> 9[H:C A)\3 3
M9Y4XRQWZB=-HN:4[6?9#:@7- [0>KY[M=\$EE=2A2F*<%UD/_@1*/""S.XF"
MW)FP K.K'FV.KT150 ;%18RW^S#S^DV\?F/IU?$['[V(PG18;%+4T'/A ?;!
M38,M9B6;)80Y89/(:28N-:J-=F0"GHU'NZ*A?0*(.:C6C?,G#(59''0;UX#^
M1'[-?"->T\]W>/;#ZCG/(;E0AII?MS)A>X679,%=S.ZWI=]B:4-?V'(+"^^P
M6Y<N!DO8\LD/I7TT?UNBW9X?PB&<[\T(&4\1.@ 9"&& ?&T,!P(+:;7ID<TT
MB[;!S+* B[DPHS=CT'ZY20LV;8DY"Z&-38F+,SNWKB(LH<0Q7*AVN=HZ#<:5
MTYSL-O*%,5 G9&=>1?6Z...9][N@U%4HPMP8V AE]H#7>7\")=+!.WXIES:L
MPU?"()%;8&;F>73?C-65<%@6G.BOHLHVXJ4!(<S6\U^^!3^@^FB:9/[LNP!Y
M>.O0_EPT"RV/HG(W\VM/]BP7*%C\R+I9HV4E$CZR:^O73K2NCV''4Z\M[V:E
M29G^,.,O]P.E!KE*5D"+D:W:-WGCQDF^=VB3LX(DHL!%YBMEW@$[:/,<FYD+
M@D_(<49:6>B5ZKV!J0X*RQC%]%#7J1^AL&?)%E94#&S@D%P3!/V&KJ=JCWZ"
M@($DZB@XBB^."2F7""O( U)0_Z/UF_^^ MZ&"44K_U%#2Y</+)?$CNL#'?]K
M19]''T :C$,!.1^6.-3A'9/3ZP;P%C6W\J0 ^I!0,Q)M0=&6<D0#[EL4!T>:
M\Q]OV"W9?M=<@$.*>T3<GP^D@PW;IP^_.O5I_UDIA*XWB5M6,[?P-N<B><8H
MG15%'[**)CX1Q"P8^HA^ WZ0B5:2RP ]]Z3Q;1W]@W>+ E.VZ5J]6EXQ(O'J
M+%VD42G--8E3H'ZY\6^E1\Q=B*9@\S=0JJO ML(AJ>T%_RO--'LE829DQ]>Z
MGM @&3H!IK S_ _GQ_=60#"G"!TI*^<(;9!N 3"X!YH9.%D!8X(92"'@S'R4
M"'#Y)(&05$+_!!:)0A)L\^)WM;T>V I16^!X/!.3!G3AJX?<3M3_.W0!4JLQ
MIC]5(CY9-*7O)9:$ X+EXPL\XVW_^QK+-)-.@0[@;5TT/F@9$,<."VF2.R7J
MG@]=P\;._PA(! \Z*1$X@$"2,L2^<;KUX>VW\_.%0IGIIGG;S] BN47-QVH2
M32X)BZQHQ*G<"$F8Y0R51N^]D,(O+MF@+FE052)B=V+) E"U9?<DS3'*9I*S
M*(T9K<WL/[ A_->FL3MH5')D6\+M\0MZGT5#XF#20]6SPF4PTB)LFW__-3C7
MK(Q<;1+B->7!+[<AW9HP!":>&!)'M\!S4^+X51T85UV".?\1NHH9,-I1'C)J
MK8**@W1COC?BS[C+^MR'3F%QGI@LTO?THZUMDIY,Q^EAW&2]8%"W<_!A7VP!
ML81YXOMB<T>GL\#2FOKMZ'*G1'N#*/PS@["K.4Z@X2G,N S!U3(.<#+OP&%O
M'M%U(.AK+V@77N0TQL^@TK>X$,CU)F.A-M[FUR)_K!G(RR_)#\W/SUZ=N]Y*
MT__@N]9.)"GF8: G[]$? =%'[YWXX_J_2D0A,>7:BA_,)"*YPJ6WB;PT]&X#
M^!$T7;S1N.;!:UZQBO\,+<ZB([.4%;)]<_J'OI-)I2>ECPM[Q<<<],X!XU<2
M.P]MA*WWYQY1?L!$[YL X-(NAWADV[B\3A67]/6>17SCI)?4--_N>!<J^6!0
MNO-"GK59Q*R^; !C9+:79$J."'B@-3S$I-WS,]]OY!20JW/1;\??N@Z7O%!S
MZCX%:..M*_M#7=)J3S<=+?&)3DRUS\NJ[FMS,1YL>R^2[NSXN_M=SFE!*W^Z
M1:HQ"GP%G]?O;?C8E9%DU:?!#?0L+V L75N(V/?.)Z/8]ORXNDIN_GK,O!ZO
M);2^=L6I^\<.!F>>E*E<QAKBHC\&O1;--9,5A^\EVI^QUIV*/ CGQ5JSBK!?
MD[!__DY];1_B-)U<VM"QJY3CR@NYDEQ;-/\\9[5Y\ <!+E$X*EK]+)1+-DH.
MO/C@VCY%[91M($W#GS#%JU;9=>?$ XJO!$\)A-QDLC*39"$_ZF'[;/H77^RY
MLK![_9*[==.%(U8.-I=%ITM3SP'?K?6LVVT?DUJ4B+Q*6>A@2)BV2!Y.CUFW
MZ#,3-:B>$=_(5:5&O^RX"*#(.29MA20"AG. *ILP21NF=KH5/E B[M?0:N 9
M^YW!Z.!1>!=3++5TKSL<7Z)BYTGVJBFF5D%MN3(.+;KU>\.)P!S0] &GHU/"
MKPP#K>4A2^V5(+4V_0F[J6>\6N02V'F[\$[A1RO>ZV>N.TAY%Q# )]RUAFOO
MFS4/?2)>,H3LWK-\VHE&F( #=\ZM>;U%_9/,7-":%3;V^NU%<)XW/3AY*N,G
M6ZQY!ID[S0WJ2NH^4*S@[XQ8D<+AE)51R5C1?/7PVJ:B7?BJJ<07["?<5,O8
M.W=?S[,?F>H1M: 3\D>2('IX<:8W1;R&WIMF7TW>5''TGO,51AO&X>_?"XI)
MQ%G*;DPS#C4%M.+.T Z7&:X[8]CZ./"?0Z)@_4D*_=:8+8,S$GUBL43'!S,)
MH_K\(HN2]N_L8*N %8Y-;[3QN_%E+O1]P<\K/<]#HEJ*=77M?U=]="ZGD>@B
MLR5;[ZF[6N53D+7X=;E31./H-7Z*QJ&A=^15!" )_ %BS[:W]6J*%^H;%P:/
M]N F]:I-LS<[9H3XZ.K<.71&-\#.YXO#OM>(KN[NKAHEXD#,.9/A0+ZB6H/?
M\M\Y8'-LXG+][91XE0LW^D/M_F8"D0')H]?*'YY/=WI4.6WB%Y+RS6"\KT8T
MM,#4+$D<TG"XWYUN:]]V[;)(B;A'7A.]EU"4_'[B ZKOS:.U)BI#9 T71:Y1
M\LG%5ZKKI!%2+UJ.>46MW] T_N\# _L-3Z]!YD_Q'Z1+4FI#"2TS%7P["NEX
MQ-#\^]QWS#_?/T6._+DNT/*,M?'$]=OD?Z#5- 81ZZ['+ZFS=?W#%V(H7IDF
MG#1++!''=X[^'B-" :,CT 8&C?$^KB)JS8,G,VKY[O/M85&C=I\&WGA1YC1L
M%W9LBRR\*^NB5U9]N;^WJ+#\ST78P6%*"F0?98'_?!LE)-UOG?Q5'SR9D7:G
M<>N13P]0B^=7G.) 63")>T0V%S5>QQ+CW)K*ZY/C<#RWOG//<DG3)31,#4HC
ML:"@M:P@X56^O9U!\W;K3PL[EFJU9GT^NIW2<,*\<6C><3Q_ ?5CT>:';-8@
M?KK?%\6[NVKQ9%8+&(#^JE4'.2E2WK*8N'+3[(@ BXZT 3/T(<+@=@S[K33K
MX*/*I5L)G^+P);A#\BA\-KE,RK>]OO&(2KZB(;!',58>V^^+F]K]P="CRR-X
M=0AD%?@@"_*,N.MW8'QPDS#J&\V)X4BWOSV=\^^-R"Y\@XUC,UA[OF6EX$:/
M5!:@X1!X,FM+@9$$)0*:?Q$B$VA)M6>0.]>YV4*DI$A=2EM'/?66O.Y+<%6H
MO.A'0/H$[G:)ODR).+C0I%ARO&OU34:<W\U6$"K)9C>/#*C?^'UDTJIY?(%F
M#QY8B$\>;\L=U;BQ)^9X:\KD13HC)L_)8-Z@O'[S,+6E_6W7<;-1O>Y^9OV]
M@(-J2D1)X^E(OXC\Z[&ICV6E#UH^'/\U=X)",%^[R\87%;-%P4_,H[>UT1@$
MK2PUVSZ/R?99;GRM]. AJ;:ZY9M%Q=NI"N"_J+[H_$-1IU&O0P2BM\SHBI^=
M&H5YW[[)2"@!LI$JV+2MD'5WCWQ:E!X>6_=J!.^S1 &P<L?([0,+CCD_1:%7
MC>=WDQY>!XM0TR/=": !*>FM)31=W!FJCM>8;4]RC&^Y??_8D=;45-?XHZ\>
M?4B[^N.#"V<18#!%LM<!Y[_=M]D)1DNTWH-!%E3SDCK[]2#YB>I]P)(P$.%G
M;6V18G):9>F6BJQ/J^="(U.;#;DA&I-'68^I]N9+8:.1/P*5",1R%UE7%A-H
M^(.M6%GDD_%@N;IXU-N))OZZHG8+K;6/H@I!)ABS7#<6BQVGE[NZ(MT33^Z,
M?& ^M,O=V<(!XPA^?/?N&[BIJC%E\PK^JD'B#'#^H?0E=.3HY'C7]#I_[OYX
M_UNK]6*VM8+J!4I$N!8'NW4RL%M;Z@D5!W/EFW6=S*_IM;@-0Z^O-L=I*T+)
MLM:*K]4:5#$$&,P%_SM(V@@TT_GZ74WV_5GYT,P- [&P>2E/MGDV5':X#/2%
MM%[1:C9/TGF!:X5X@D3]&<($-;M55+=Y ZKO5(=GP6AD:$[B[F9HC8'0^#)D
MV:WPL_J)9M)WZG+D=404Z_O)8A2&5T)E@601+7Y;RC.Z:; TA.A*G:\@_*\U
M;JR,$8]<E#*N9:7F)6QQ4>1!1F" KQ*1FG'<,R_/WKP1*SE]@/4((05AUX *
MGLXX'ZL#C^O!?5<%"@L6;/.=%SA(K96ER7$H/?E2I$:0\!8PZR'K*MO?ZO3'
M -(R8R1ZQ]J-#I?U2,UWR3(PM#J)O[3XBOTE[QH/G&#( OF8'C>PD')42@7&
M?WGVVB=:7Y.4+R\ABS*H7TSIS]F%3V>O$U"#KI#-$A[(LQ1NZ$!ODU),S[9U
M%X8XNIE;.)=9WPJP3%"$55"W'NA-Q8HFFA6$,L=!876Y5+'+Q64@_$ST#]AB
MY^#/C#&/YXG)6BNHGVX>;)7U4N&@ Q0^00HL+TP603,UP+\0363JEU@6JGZH
M@9GPE,6Y29;-BH;:;DWRZY!+&?1HGZ E]*7]?*CAM%[RURL$DF2-:1GXG^QP
MRD!:!%A)Q%Q1M <"HM\RPDR">=G03>]":HY B6#T8[CC;V *<.9-+[>Z52*$
M*%&D"HY:73WDG&]V89MM[.!9WTBQV5_KV<7Z/J_GL0K0\I/EY,*SNG'9/Z_;
M]'X_OO+XU$)*:*+62,#M7$-(ZPDJ/H[$GKV@1%0*[7[G"Q5'-D.MO6W]-HPV
M$8NS'8QY[WXKY=-  $A'2L3O\L8C;6)I<O]!]9OZR-_[*[=<J^MH,3(0K-^)
M%ND@C5'T7H.!MMNQ"WZI?LVCQ+G%?6,:3[/=OJEL5K/P/8^:2TCPVAGYYG>$
MHJ ,(,Q1I0.X-R6D/:_0J/S/>Q:K%Q>F]L0$A4S>.]=K<4W=]>VZ^'H"Q,5>
M1X_T?,B523'Y5),ZHIC( 6^:)8RH6'Y@!@-3.U#D\86IOXQE":YOPU!B3OY/
MM#3F[X_$,L->UG,)1#!2SZLLMWAN:=QAQ+_D\]'(^$,A>1':G*\&YLFV.[6^
M.:!@R C0_H-S/D18MQW]-<'V5[FO09!N:)[V=;VR#DRFZ.' DNK,_G:Y>?^+
M&V55E]CD5_P'#XM;F3,^^4=?$K<PJ$)@A)]YKR^T/77!/S;<O C@<RR;:ANX
MM64'7O,7\K0RX5F(]11K?V\<+QH(C]WPV/N:9^B3_KZKU^LT[-GE55WO(O)'
MY5)P",F.0\W'-M4&J?YP-H8.I"YA3M2 ^B^&!MM]JOJ;_8:V>SGM'LLTCP)Y
M(0:''G_AS;YQ\[7\=7V7JLU-'F7$MD'0>\'K4%XN4YKS@92\&S2&8$NN@?>O
MN4ZK#KI,+N,AM_\$ 0PYMY@$1OCY,2R&-A4RX@,)S%AH*+7Q(*_][67DW=O<
M>UW7S.6*M-[MY[]/\T(.7'*@>TUO;]D L,&OP"S*$6+<'\SI8AQ1%U!=415/
M(L%4,-Q%8:2==^?$OBL0QGN!L_+9A^S/'I;!(=  EMP7OBOR]EQOW/74U%SJ
MCO'B6!1ME,6G_+O[T9V4T(\FJ/?H)565>4[P? ].XY'.P.]Y;7*%Y4SJ3*4[
M::G*IM;X"Y>GRK] GE.O-R25)6Q-V^,0_T$KXN/1BSOWG)-0Y38=CF.RBTXN
MX3BPH*'44P@#YR7.FST#NVLHJ>V/#MR%?/^Y!Q+/!71_#U6S"5]T#PM;G.B:
MKKL;P&1VA9__$7H_9<_;@G4]QQ\76%92N8K# .K2Y+&!(7<T&;WXY3LVW_+*
MHASZF>)G'-B^NK\IA.UHB/EW ^0(X7]?7N(,#55I",,$A&0.]>'+U=B?A\LU
M\FX&7!\Y<$'3]B_$GV_!"3Y)@7]>V^Q)989AAD(Q[-=/.U%O\WZ ^L^*9WGZ
MHA&?X.O'U';<0Z(JHVPDBRUE8<:MW_T)B2<&,*[=0N=;FD5)[:%K>HJ5B'\^
MK+,:+<Q>7L]]:D1;WO"OYN7]T1L0NG4.KSEAA+HXF:W+?X]OG/2OR?@O.>2=
M9=Z\#*E6WXN/J/)8,MLWB65/?ILT;;L?T/#E-!D569CZM.^OE/8HO2 /H%F.
M+_?^)CKW+<KLU- &8HF$KFD$-E0.T',/M/RULNUQD%PZ7+_9UWK._OV=>V\.
M3>M(T_;7%1TSJF$Z=HT]/I(R\Y^8$O-G#WE2CN\S5B5+DRY5XK<(*(;TS>[
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MB=8\*E_V+C&T6[3!L0M;'6CFE+>]9FZ-U4F,\_.]SJ*SVY2(9\92HJ?6#<J
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M=X4W2<<!X#_>:-0E?,H#I/_B18N\"Q5$M6S@Y7)MVWNATH8]['P;RD&AHR5
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M($R5Z[?1Y$TRHT_53@7]^8(?RH:5;E2.Y& G)S&I2!0<H78XGX(^_@JM?2B
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M%'@-$%:J6\6P.9WU1Q.YBX)Y;S&L&9B%"Q$8048E\$L7S!"-G$^NJ?"3N%1
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M)M4^7%#1SK!!JU"-NSK]>G"__GU-Z4,VUOYWT!V3RRCXHE*_<4D#DCMRE/#
M]YVNP/[@"?^)S'-DO*4# U)F0"U#K[1I6>#^,-,C,Y-'.,KM#Q[U? (>RT)4
MO.=GDL3M-)V7L,C6?BDN9>BS5!!9(=R?4\"FV!GJ>_Z^<\H@0L[F]1^*Q13[
MW3FTF^T%]*-W6I*XFMPR_S=$9J-\80OAM4A".L/Y7-]$T3]G7UO$1HP0*"D.
M_>\D>MJ@L$)CX&>/U-5W XI$U 4K+HW1W-XJAMG3QA>;S>Y#\BXX2D.&6ON$
MT.^@>^7:TG=D6[JGJ>RG_X[?*OA3J ZML.+:3B'^A6-NG8-+3-D;.5'/F!##
M?NC7$PB2^.[XR*3!:P633>01N!!C@F,_D^*W_'WCH7:;ID@)3*)]6BMO?0>+
M&0&NWP(ZS_)#(M<NVT?@.1))3"OK7NQ[ S0!Q92GG03-6:C#X@^;ND6WK7-T
M]O%Z5:,CWB/Y@WH_'M5 <G1<U]B3)'(O7L2#"Y!4)+F W'L]!>Q%"O!V;J/O
M8XU&HP_MQUT^)<FV/F:_M9<"[Y0YPOGU&6(8[CARUI8@80'/]>NV;*C,&.(S
MT%6%R.CL:]R%/975U5=/&EU@G7@B\;@@0D$5<EGS+F]XD(/.& LH:?$6N-IS
M-'V;2O+2,Y<L)^EY>I4_'5AD^((IDB&&%7%#RUGRMZ$AV:75)H'CFAQT_9F^
MH_._AZZ=JX3^1N+YC[&I)_=&[/P.7YF+]7C/1H[1S[L4@404<I&<RRV4MU^?
M;CG;;1XPV9,7\B.ZG D017C0%:+2WGF!1'/4J1L][Q<:WO#(')G1[R\#WK0O
M,S[]E_ZXTB$5::HTL,\";Y3,1N7PPU+CGH\E '2O=6@6.DBU]]I;A'4P"Q,X
MVLETJ!'H<J8F9-^=0/8R>GZ^*M7ZMF\&&MF%15WB=(;]X-<&NFOM1H< *K1E
MS4!Y+4ELHP*1!:!9:$!* 2,FPT[KTZ5-ZE?V"D5RP%:(\)*XD.=K4Y$LA'-P
M?RHT"V64'N.:&2?+M3994_V+>-?/@?**3O%ZFGR"FWL\RX?<)7#: U9E9^U9
ML\V+9\TK=:?'YS<E?KM+7]BTC$9S=03A#W4UT_B?VK@!#:P@F7%2CJU.#[(Q
M*4^?Q$H6E8)*WFP'@"Y2V8HFT#'!H6Y G^^?+\<-=LGFBF&;YZ[-R$$6VZM(
MLT,>1&I>M$=U_ F/=C%LN,^H$92V N>A(9\1A#[JI#]'N0TEAAG\QD!85!E0
M1Z&L!9K+<=J<D"*6Q*C75B3!-!R<A>=8"\)CGZ+?V%@O!R3YBF&)DXS-#/5I
MES-WQ;!?ND@45Q0>BQBMJZB:9A#8^$;R^-S*NX)9^9@*9-)U]$%1PZ08=HT?
M*>K&?K&%MG.9F&!NXGV4)A6*',<LI2:L: 2K?20@EW=$$A^:7,+^OUJB_[<>
MZ?_[ TO$B.YJ1NYYSTH%N^,Z$H'.M/8/N'6HPSY)XH2O:KS"@O!AH@N0HYUZ
M>^H0PGPP?%_(HV=KNVM0QTY19I=JM$/F3LN'YKDJ6?UW+];CGJ7 3?K<B0#8
MF;,#+$O2B,;6879&C8+HF$F*7Z+21<NZ#7J)JUWQ\']W/RJV0I$0EES7<7A3
M;<5I#S^LN7%_Z&N%^U2'T,!4%Y*W^^E ZZG],]&'49J)'AFB*TBEE1V,>&WP
MA[)<XQX/OO$VPSS9V1:1#,*$4,=2KP^=[,T7PS3P,]01PDX#-6(]7 P[[02^
M88IAL2,?G.L R3;,.$]^$2JD[J@H 99]<@?^@5^R.7J!'&7X::'\1-J1>-15
M6/0^Q!]N!N\4>R%7DGW<C^U>$L,^TS!QHLK82(/+JT=8?JE'0_HBVCHEZ76V
M;]*$NZF ,PL= M A[=7478*S =H5E3TG]#G$]A;#K>KD"6R"T]=3.+S934O_
M?F?9G'PZ1%DO_"^!=T82%5(3Y#,"F2//*\Z&4X)]KZD,##F$16A5\78PA_4(
M8Y755Z\=MOF85UAA++1(O+UGT^*##8:R[A4&MHNR7;IKJTZ(=ND-JON;<'_*
M46MR8MB6K:Q1UK PX8Y$[A<2J+>8"2\*?[J<(9S%_6=E0_&1I.72[>;EVF-N
MR<>>G0Q*M'OV3X[H\\7K9'\Q3"4<X5?U,M5BXX5GS[AWY6RR'5XNKQ"-MS)7
MC)D%P#/<!54\<:WC(AP0PT[!9TM+@RZOC81C9O#6F(6BH>18^Y@X%+M_>_GO
MTVV;\O**WFT]FJ1ZL=:*<=!G=6)R.%VGQ&* ^A3_Y7'@IO_*Q;"K6P]:=6?7
M._VCR"(_$["-R/.2['0#2$ O2S,PGVCR#^&Z.%O18^95)H^VYM-0J5]ZG#(2
MIZ+\D"FH-<=:ZSE"4[]:]URK4F]S<E1>Z3KPEY7:WX5W;]^))(8^G;WSN='^
MS)G,CPH'XT,.]K?M;])'D,IT?-+/-ZFA"3EK@DJLA*(W1_'CM+"[03%L&3D#
M;UU (,['(][5"J\Q%<E6BIO%L,=K?Y^V4/LIVRF8<$F+7OY;M9;G'YCRE^,5
MYM7.<S$'H4 DV]GI1&22LE39A@;DKK4'\R)]9(:^_R0&[2*H2:LFN0;*.M\F
MM%\JYRJ-9+18[I6*>F5_X&Y8M80@K3O"PTR[8;L2F;6HH,^FV5L0L#F6FNZ;
MOA/%'-WUUA^7>X)XH '/2X?@B^3^S</#(,KD)G?UV_RY>*PNM]],'\_,=9.X
M[HC^_\&Y<4-+V9502_YMO[G(>Z5VGU =%XP\\R+WF=FP2\T4'M=%3T$$AK!E
M<S!RY!/M%CD">C07IA[3K]GISB$S-"^7)#^X?:)]CJ<B)<D_!F9 [:[%?R=F
MHK?&/C;QJ5(RR=F?=SQ'##O[(2U?!#3UK(,/6;C\+32@RRR.T3/.@S-5:/T$
MWX9S9U??/M4W9:D7E\U_4?,B&<$W'J?+BG84J.[AD"8AK05$G4]0T!*?$N#N
M$<!)(YX_::U5GK"F'Y6 [9Z,Z1CMGP*>3R(,"2LTRL!?!J$L%3$L0 SC2JS5
M*>P?DP=IEC[(VQ-A<J>%X>5NCQ5R7"K4EM7Q!ZS$L)W(4>PK]:K@L"2AQWJ+
M*\NMK'SL'>3DCRO;,[:]O9YT+\3.KM"$[Z0I?+C^A/UUE!E>(L:@O "T!F_+
MHQ,R5Q>N-PW97?#V'4G+RIUAY//+;2D@J33?U[*B.#*[4,<L26^]G$K^P)A/
M?M5GD;++3=I2$'S1,%S>G@I42^R+HBH*"=@;/T'R6!/#(M(CAO,[@<\%PQ\&
M3CM\CG_U);_DG9?QZXT6DQ(@@#.\XEPQ+13VHB(X6"=0^R68Y7(.+3_U0J^_
MRIF&R_=CW9*0^@.JR>'U:QL-27R.\F<I5(X0-9#%Y7.A&SV-U%*+Q[U*!CY9
MN>[H_-/;X]'ZP&B]5*S*8"5<"3D@K.@'M ?!,D4]?U^-&"]*4=Y(-ZV!=,Q#
M1L%V"@7ZD<JMT#24#GR:HNQ5(86W@ZAAN]J==[Q!KQC?8H[L4P4O9.*V%W/
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MSW3S#IHMFP==&$RIGSRU,E>/K06*NY\F![.,P[MO1_+C%GHQ642Y[LU?;<*
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MDSI!Y>,R]I5%3V>?,#YB%#97[7FW&DE8"P*:6X3]Y=OK&E2Y*5K20S[DHOE
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M:97[=#9>XZL89J]4X/7;<D3A">3\2>;.S0F30=_VF$]-6XR_I2$;Z7H0V0)
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MZ-^I+HA'#RK[V.&_,@8=XZ_((+BL.XI0-GZ)XC>*-X!W9>4]OKG=1T.SN[M
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M<-/Q"]\+\L35<&G$N=74AO2%,D L@WCW9QTK[$.S>^IV U-&&[&?\\2VY_U
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M_YU/K447P+@DE]XQXL1Z28K1#GE9M4TU;R(W. 9&"J5@+H%$$2OYM8U&QJ@
M9X )M+&RTG.P>[0M&\&>9- B6TI=>T1 7*51;FRK&);OGB&"5Q4ZF#W=I+I4
M=?Y9B<#)G<0P1N)8QVAL3K&R1X)8 L$79\$M;'**N 4JY=L]U)@15Z79\@P5
M$8#F&2CYTKQ[\2VC:6%G;T4><I(ZVJF?P)[U\><2B((W?++A7H+_'&A34;M/
M6P?VC8L^%\,&-TN]F;J\O(+]9P"@V HCP^]\\?T<VJD?NV78ZZ.P&"/PAW^3
M0,901)8=E%?^5M"2>I9A?P.Z8P_6V\:_<[,$,HT>N."_0^GZR&Y2:4LO&=X;
M.J[>L\5>TS8F5]C>2CXF)H$:1'PEA2:2QR,W1\H7<\O#"L/5:&HZ[LE 2ZV]
MF"X0;NYH0EF>-S&Y$D@SLL\:6</R>"X"X-44$5]M(/?(D.6]:>>.GKR94/1C
M9EW),F\?F-.A>D80XK_I,#\$FV&4DP#>.S@A-F>E+,5'O1 ;&\6VRW3C_:<U
M@V\1FTJGQ;SW>E1$_=3H!VS;6=JF5?NX&QKFR1)(*96.[C'(H'07AH?TG1Z'
M_;S9+(%\!;O)4-R5B2^+L,J6-%;7*]*]$FG\U2QX7R2"<F$>*Z^?F44Z3D4+
MY+A*RMJ;O(&8/J=[$D@'TO7BA5=2W$?R/99-SKE@KFIEYK&8B6W^(U("'2E
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M&=9LDQ2DE+)S.J[O!DG#=DW?HHFM/9-]#?Z%(^'O_MV;Z@  J7HA,'?X4P\
M=XS)XOR>J1-;.EL3;8 ^4/G#5%75O8?J:@1]U2/QPBLRYS3GH0QCE]U\0=0I
M"@$FDZ^M7*YD"_*6L?P1"611#6@SPX)@0A[UTNA]3)"[E,TRVO8N\W\B:& K
ME1CM#&6%"P:Z=TT#7C;)3AZSZ\TSSQG59%&P+=*81I7JV%!\/G)BG7464#Q"
MX[^"I'VP!7&STQ?E;$L)1*^3+@XP*SZ]2%-#%LSK=?IKX<?Z[Q>9D[0T))"9
MJ'C\(FMNT"280OOSK%]T(UO?ZB7Y(A@5<!\"S]R[OD&M%=N^)'UE(=6_33%W
MIKY[Y8G?A,U>DO);LY74:C U,,LPX _PI:\C26_1-,HIL ]HCU7IWX>70(*P
M#-G%E0H_0LKZ_W>-[(E@-7^]J[X:8@YKV@M<>R(#ZDEO78*DF&=\<!%B2VAT
M(; &%=E6J0,_NPV-2=-GQ'"<@&K+Q8;\9XX52O&OH^?25&_HJY^;/)D)T)]<
M7$P/;M(GDZ6TXE>VY7Q+R@9SYV<I<A*(S&))H(BR*(3WP^ZZ%-V-[@3Q,UV9
M,GX:6R)ONC\\??951 71G1CS:DX3).R#32U]_3-$D4 \^I0925!^9(3CLV-B
M+7,B \^C5CE6"9(2YLZ:A2IF(S XUGH56]@#Z0M*JE;!6_.U3FEJ "/YL-'@
MJ"1SXB+FP6,%'02(L:6,I/V@&9QJ^X8Z7$*V1\%GID >],%4&G%"K+$;:SLS
M0*RK*PI/+S%Q!&C)Z]<<G,'@%CX&F\<4I5(,9*Y*(&K/"E]M$$Y((\4BUO?>
MS.+=/OF)P#F;U$EM*#\&M 9H8B2YZN&22/[UE:'%0WY_":(B9FEF=?@;IX!6
M\2=.UAVIZX)X2C=19@;$#_5#UY +U#5;D>^H^0<8__(B8(."]PF-D85E[_\=
MCFS?/D9E!*X/A5(>S BJ(M#$6I'RE?5W]MSN<4D1RGV1HD<J]--/EV6I8KR&
M;C4XN2_C4OKJW\;V'EQY^5)L50FI6QD^LJY=[V2AD4LNWG5#/'.H=:K/@%3U
M'9%R"6D:BA="/4]W[)! YL7Z%DJ77@DN2DEX#DSCE,PO@IB!.CX05VKN"1N6
M$?\'8I>@RE2Q(KJ95%!:ZXS=9SO[)K/%\A &5]E)#A;(OUPNJV&E%(T:>6]=
M[?K33<6L43O7#QW\<^<+6VE_=I.\WH(VXQ==5.XA@3#[B2QD(\I!FCI9W"ZH
M[2J050JT56'7"!)(,9R!CQ0,$7N-B=W:]@^KV'\/='7U;Y/AWH1=1:'J?>N)
M @,7_3\22&$(+C42*5;,6N\@$N_>*$A*3L/9B8L9:)2O!:WEXPD+*\#LKAYB
M8!&DB,PRQ'ZJ0N4,L1%SP6!TQH?,5SK\419TDGIZ9_/@V1Y6R6>8^V+"U-IN
M/-_3N94&3K41QU"\86LX9XCV!V7<J:"XRT:JZ)\_TH+"&8A53JW:)"$.O[L$
M;W4!0S@; NME('&$Z&,##>7867O+38!BMT\DHJ9%,*Q* _,((J?1#_&'90>!
M+[T9RV8V<[;L0"4M(&-T#Y[A6[IP%U^.RZZ,^K&PL14\U=?">;6(<BY:$\5=
MS)D:2_"?G91!@L4L"_._=2V8B.H;VQU^<LW*.I=9O\66M3>-+LAP %+DZXC?
M!,5-RE@<J/S.W-7>213-CQL #E?L[[)].3)TS6:N\&.>P,'!G[.'?QF-74O;
M:B"!;#0K4;O:;]=ZM G>YY8YG2OVGN%S/D73$*:KZZ,KJ)#:&B<OKH%_=/S(
MC@\?L-JWK[X0=E\V4F+<N/_Z%'S/(/&XI3BN4IB6;[7VDR]5<=.LCZ.*U 5V
M6FPG--515">!Q&;+4G^59U>(*9\>U!<F&W.5'&Q%BL>N P."7<NW?:0RW"F9
M9EG-.4KWJ6/#9N<9='(ZZD J3]A N*\H33].+O5AERYA=E6K0^X,_EAI1U1%
M(JI@]7G;L\1;%< ,__?B"RJEJ\PVTY\3(D%B[9A]D\$G*.XL8T.Y8705:%-"
MF1RP#T -,!Y/E]U4>599\/'15!BH[7?0 F@$I^&C4@7QLS9.,/*4SRF[OG^1
MEK)6M'!Q3BK1OXZXKS?I>T6+F01NLF3])G5#S-(H)EEXPDW-4SC%?W.I"57J
MQ6I;#TNST0MB^[=^7> _D!BKMF1U=O^!PX?$Q/'Y 2PAL<L<^R7F>^R;O)!<
M46RD#OQ@F&K;(?R/D2T&95QDQ"QWA5P^8K2$]C"N#JVSFO@N8WW2JFCUM;K6
M7_]2*/,-T(?Y#S=#\/AAXTW,VIEZRO+'Q6CXQC0<+LW,V#+@BB&,7^2AMI"_
M%Q(&#MH[LF3$I#*R$,K#^)U[S4L].1L,4CY^;\8=@VZA=H"HA3%A"FR3JQ4%
M?=VG!.,:,""!),3UB+($P!.1E&9J\JXE\D.W^9<&:)>)36V9;&N@(Z&^@5YN
M8,.B9 G5KQ*<'GMPEMUDM5/+A(?N]?DC3$X:I:*.PX/91.6>+\B=)^2W^'ZO
M9R^$<A,\,NF?=]Z\%F'_A%5FG,!,B5Y&@WS9/J%3H:_-<E';O7E]PMB]2_&1
M[PH>J_2UJ/F<,L2]>")"P0>%CF>_ZDRHO<?-2H-63O8QSDI_@%MU78[P19GO
MM>M0;(>9!O V[;A#HQ!7<04]:QKP.1+>!%O>>TV6+7(9G<WX:L@'4J59H$QX
M"_KTD>U;Y)I\.>$OE_B4@(.[;W,^.=XM?(A$OH]T$</[CXWA6L369A:/;WZS
MGH+9B\@.1@QMU#CZC*A@:8>VCP/P>+?:V^5D1'I1!0Y7: 2KPZ6[H+Q]I:K*
M3"PG;D:&'/&7F_G^+ARZ:E\D?=:3*G-*F1N\QJ+CRM5!^5CZK,F:;"D!_#,T
MZEM!L%;F_.RL4R-<] _H;WZ@9V8FI[;SZP8BW0'UD]B@^^&?L_<A01?/!/[Q
MH)QR;OZ4&4$G6L*P:WB[1@GDOF>#!,)_'*I '6$!K4Q6%MG7Z7Y%3?3!NW4*
M'][; W@E(FX?V+(8TIQP;:,S]HV9YO2B-##.>L^ /0=@=R'KNT7:?G9?)9#V
M+[CX<Y<7.[]M4A \?9/1!WZF4JRA#X \X^.O@R+*I<OVCZ&H(1R\U<<D=;F,
MW^KMP7EZN99)(#X^<&YC5#7J:48_=H)&?XSI6TEG\GG ]#P!.*5[%?P5]S C
MS?OI,.434P+QW;5<=R+^[Q9M0<6?N)&^\B$Y69S%OA]R'PF?L'K<)).JX*%F
M0B4AC)EB<KO^$=^V,B<I)O3<K:M[;>&S/OLCB/B&GP:]Y*_51IL<W@V(E ZM
ME38813^77;0_\+[,\-'G>>L5-QQ/M\_AS17_5HJ8,@C%QC:JN0\)Z4I-;9OV
M*'Q*A^_KOX%2\ T$?#XFWH5<WE T^7[;?8RIDRA[=Y"8>AKQRROF'_--#N)H
MI[W?#3W3R/*QVN\,E0C5+?M9RD/#<6<;[97J.*(W6+KKUCM/8N_X6R2L^$DI
M& -+0*%H'W;^A_M[OP02\P'FXYDY%5&?Z=?]!*/E)+;\B%SM+BIL.<G*-]-#
M#"]\)O#$057K6U07 J-.(__7F9AN-(BA.L&0(H%QN8UH2:F#0CR)S7],?>@I
M()44&M@-Y]+6"N+?QAJGV)46N_S7<GY 58#U#/MU>[\#VKTKV$:F2#4C[)8^
M&A$3_$SF[+@@_MU-[.R\/#^T?U2IS]'$WH>M,E$Z&O7>(_AV)R/]AV?LS"-;
MPXD3_^CG"[/<)! Z>F7Y!A1VY(DL+.,\(B"O960S*5&P\\_-]P-\5@3X -K$
ML^Y;NV@GA'^+3-V.$=R%,Y1[R.F(*E'V!B-;$>*-JO#^O"=/<Y!R[!@#_Y ]
MJC__N9=^S7-TM-.N9KBVYPO'T50K&0P]@/PL@;S@'"$\\DCT"#B.A5<KQ[A-
M+Q,4*-0D]_>;4::B9I2Q.JQ]\ P7B%A\WH$F%K#$VJA6,3 HO/BPY23ZG 3R
M-/)OX9=' ?[Z$H@V6SD&F:38"F/$S(SQ6\.:$FN/M/<%*.5*/=,E$YBLOZ49
MR.80=!QV0@4C"<*&TT^)#KNF49=TA>I"8_BLR^WZN(SEEZJD50W+WTVREZ#\
M)-%_"XG+_8K(LMHPVC?DG1$A;E=#E6-66-VT>M'XUU.O-MM!DNV#>5.TY;CT
M3<LO;SY+.T8^1N:P%#@E:=KZB]3R%O%6I@4&7M7SA*8^TBBK.4#L $I6&]/3
M\7OKG<(]F'O/^M.*<'?$KA?/Y1\3A5 7Q6:UXV>*#DQA._*;" WA31V!>E&;
MX<GS*Z(M[Y^"&J&IBXXN5Z^KCESIWZ?@3SJL*@9(<PG"FNK0%*E'J9Z#!VF7
M-)%I]J!RR=QXGCU0E3'4U>;*J7I*>>SKQAF120+P1"ODV<,=>UJB@6'VL> /
M3SLXF^98*8> ?4XIB.3V[L\[)I^5YY3N8A/7QW%FO? <'[4(W@ ^[4$(,9GN
M1UJ3D9WRMD["@;EAY'++[U+YG'S[/UGH[S CY/P9+PK5$L&"KH9D+9B3AWI_
M,.[L5I#*HPW<(6W>'RY]U-Y6>IV#17,];S_B-TH@$18O"N"V$SSR8X5]CP#_
M_A>L1:B04R2WZ-.REB<V%ZJ*UGMH':]RMA!7BU7VFLH*B*=R<LGCN>;%Q3+@
M02G)[EZA-B^1' 5A$HBC<;)"E$P;\ZQJPBH.5!V30*+;P(_=MOE\=JNP]4D"
MS=E" KDE)-(_KM&P>>M]QJ9$Z$R/R$,740BA%4EF&4/=A'X1PV=1>Z (-OIW
MI:7*3+%!;%+,WBL!\)%G$L@>&/W8J$J$%_B-]>>)/'P!=+V<H92S"H)3X!,
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M@G_IS'PVSH5O6'ISWV9YS6G!YCQ'D2.UR6 2X)CY)<2;!:3ZV3O N1JU)ZM
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MTWZ+0)<@\IJ_+CL*[0:IU>^?<JGIO8&^=P*^A/17^EDJ@?TQZ7) H"-<^M]
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M>3YVP@1_(Z=YTNLUP_"NM\C/\S@1Q4&,'#^\#)\5U5E[K,XFB)N]8]"O3EL
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MA]]ZW>O&UW#T]X2XU1CNN'M1Z[-B$2;/RH:5K1%O!#7U1"7M+<";BX7O-*9
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M&-@]KYREI4_I?;>&8^0EJK^"KCJ''-M9_,(\9]W2?;.$.538*7DW;'.&R"9
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MVXF_TM+U$Q3>@I>P=Y2F1Q#4>]B6SR]N7,FQ<TI8S@8JR?-TUXXY-F=%EI&
MLG3D3 0/4(9_E@M/3;8"M_]^KGSK'*2V1."%[Y# %D[DI!<&GD:_)ZY$2&#(
M18[JI$Y Q92.M^%_6_X[BG#8J"74-(I@^W:XU?1SY+9-LQ\+SX6Q'FP0#-P?
MDL#"[M^0PNB+U29<RUE^OA52T1&A3L.',1,**XSMC:F?1@4+<UND0OS/ZFE'
MT#-G6LF:($S&)$ NYA+8Q<90<&I_#D")^?_4AX9I/Z 7:G-6LB+AK@'=62W
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M'L^]W^_7*W&LWFD,1;U@:C8!1DH!6O$UK@^_M4P:RE8_&NH$C2PJU_<,/J&
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MXU*"XSL7'?U7!PQJ7$<-Y AZF]/OYC>-:19=UBC1#CNW::W?6Q=)(MMX3AA
M+#C3]SW^^]Z.]7+$I<@\]-'(2OS<8\5)&(D##@8%F7C_28APZG9]</#$]CQN
M"6]IYZ%?Q[PPKT_5S<*19,14CK@GC0NA,J.3,$\V9)EY_<$_J,A>)S6@?YA$
M-=WF[)^_M>)6O9L'A"I*=:1/S=1(:<+[-OMLMFF<[)0Z44P?#C2_(>IL[6%+
MVS8PZ\_)$5$$?&3I0()EK_JYL!NIWT:?8.*SMDY"<L1':D[1.C\YXKJ;X>DM
M2:^#;Z^Q#;SO8Q=NH_>D,L#%S:<G*ILJ0F'.. _O(@G5F_/R-A9]6+?IW*7;
M;U,_!82%E-<5F[ !Q7^I(?Q\(.VL$O[IVZP=90\.Q)Y\EO_5X#K#\"=ZT2.:
M!?*$>R>LKL2_(9NF-1Q:'P$QQR;JDEF:BU?&IW?,*I+B3>*- YX2EL0#"UO\
MVF=#C]QC)D2C3$W.>3Q=?08:NO[RI1P1 AIQS%)AJO?3V[^@BJLJ!\IW8,2E
M%[U/KWS@RFA.UM1?W%@:QLV^0D(LK71G.S<O\2_^G92219CC$IG5KO,)YO0E
M,RE1\H):9OR/BPY9:5P]@,^HRWH[NZ *M$,& ;HB^J4QB9D?EUOYOJG-&\5.
MM%Z=^/64I?=.4H,-2C)X)QS582?]>U'[<+]?_?.W#Z=-CI+Y+9FV,UF="TO\
M+:-_G","B\J2;HV,$GMC/DF:V7_$W*.E,X.-3-;=@[I>A]JNM=_H=H?V69L^
MR)Y/Y86:6Q&^B-B]Q"-A0-#O4K_!Y!F*?L\CG0.''QU>F(6WC(,^M9@P<S:Y
M$)Y\^9H(82N!$?.H_X;>;E)NK7,AD -OS['BP,!P:[#QPA<65@#^]Q"L&G0(
MWO_XJ:5B0^H!!9GA^KF@ Z;O@ A(.R6L*M0Z@,^Z+T?X'<I&OS)]^S7E-S>W
M165IYJGN>3%Y9%6?!RL:AN*)WKG3?D_I^YJ&'/^Q3B!^5ZQ?F[4WU#J9OM?_
M]& >E#+1X&8\LK96,34?E?>@R.%F39@%*O;+,\/H<I_3X7_4<X$X6*0]MH'Z
M\>AN**F7,M:<6&D<ZO9S17JL^/F0T3EVFLJGMC4LGR/^Z3Z6X05FJ(]DA\!(
M!Q?IV8*'VK>=LY5.9/AU9T?]@G71BDGD4E]F31*N%_4-;<1I#J=JGQS4R?UG
M93UR,IYM@L4T6!EJC<?<C7S/A9*[[JP.K>U1"_HXK2:H*%US^UK'/=U/WV_8
MM#U9;7IF_%#RIN=E&M-<S6,S"]PMB>[9ZS(5HB(<%49#P^+/_.=8BPL_K:(X
MT98J?E&LHM)W.J'J2]L]#L7VTJAH;-\..2(.$&D* <:T5!.DEFOT&7Y1S>N]
M\R'\T(V:,D7A")5T#NL;M'CB]F8(5+M9P)0^.-ZX/QKVXZ/MZ%''!>Y#Z6DY
MXL)V'0'2DM"UI)G+JCLN1RRD$>$(XK;\<@_@Y,D18_!V'9>V3XB)-QN4%1DS
MDXJ0"9I-X$KSM):+IB27EQG I$S;:R=>D00,\TLE3!G0 T16X.\_ 9(#AE14
MC("QJ>TMW"B/D&_B0R;T-@L\NHM:#*,6DIX''C=07(!U96;OD1A&_]:1F&_D
MU=:XGTTH6KN(4GK4*$&BGD116=>Q*^#,#" +J1S="9![;(%R=(9T0YCW.C(\
MA&^DO)($:OUR(R0]\_7XZ1Z[K( N[J]=H+;PV88]OB2,@#J"?^XTSOVU:BY"
MR+<-*[FP>$U!:AKZ5Z$J[["NTDS39W+"DW!=,]7+Q[Q:KD]HV%X.?X1?\7(E
MT*78_\Z]Q2J$$#:G$*$IPX=+-C8Y'>MOO6YM9"?&T+_Z*@KEB%%89H4HH*YF
MF&ZHW!1N'SF[M__%H[I=!+VYC<"\)BF8,8>2)BJ^PBP$:BZ8&IPTMK9N5=QF
M[7[-T=-Q()_>L;F!8$Q%3\-JO.X-M@$'QD\'[E;=9N#;P=%[YE\K/9VP'BN)
M^8D=<!G$H5OO<-ZXU;A0*?G(*HKV*E@.]R #\72_,@['*S97J_($]5;_!44M
M2W MI4N.:!^457ZJD^(RIAFWB(?X7[_^X%[N7+W?:I<%8V=.-PHV8U\2MYIT
MR^MA-RJOS<3A?'6&3,T2FEONT]9 ]G-U1RO.R1']&8K,-UY%]O >=;U\Q)O:
M_<O[]Q54_;QX)NTX>AZ]6HY8"=O($7R1[G (18XH8DC:>(Z?>1]GK&[($?=O
M/B!EII"7BRG-G!9F,WTC?2!F*J_1.B-G^ZLR"4 6"-TTY_5[E#G/*+Y#L.W!
MVK'1:.&+'#&OH(Z.0L++.^?X*VWP$JC^>5MGRW+I?V](Y]//Q9=,F,BO0M@D
M] ^(.BTUE;8[R1$JG49Q2IKY<L33V5M4<;FW-FQC)<AN* ->W&J]+FK\K6QF
M2.">325/:#" 6)J*[K)EE0;H*"6@2\AM287E C,P4XV('%L*W)81.N3V_1FJ
M.EL%-:^@BEM"?6NCVO<%%-SL=PA4E/* Q=,)K-+JO!SQS>7Z#;T36^'A<*C]
M!>'4.ECP<8-DBX"D'<W#AD(%+9"8PQKX*J;"HY]07X*][WN_:4C&$/ Z-D[(
MKV*>VO7/M(F7(EVFD99KLU7P^FH7:2'[0550*TK$PMP]_5G/Z'4PHR^ <;64
M=X(^_M\G*[-HVU8MVC?J@.)\@+@?S0+OG!_HD2-Z4$ZD#-0"28[8]BL?S;1G
MAL[>$4P3-A5RHLC^WOHW93H?HC9N.DU9"@R&- &AB-+=AQX\>9O8Q;GPZ'2@
M+G'3BY8MNIAC)X> 3KHL'DH%\>7\8W0H)E3TS/:GTOO-;<87P[>ZHBYB.J#3
M0E<OY6*U?9_HCD42.:(/&,1_P)O)VL'/>[N6&S2$3F&0XEN#TR.RY4D/D@6N
M^<J!I_C71TK#=CXX24,S2*%EE1*C3Q1L-F>==<U&$L^EOKN3M-1CRU(1"'<E
M?DPG$9<DMW6'T!T82QO5'']S+43MM15 ^C$"_OVFOOF 8J]?!&!*JA\3M&;F
MO0(T#ING(8M']H;X5?#VP_$M46*C;@;K6E)NX:QA+U+C^'E@2D]M^0=,6E<+
M3!<<;"LY68ZPG6AGN8]=\(YL@3]A999'UZ/U*^!_S"W?>#O %(50T *?R;?G
MM^&-+LH1_^* 27R"A1>G/3#ILTE6_<BAR"7O_4]R9.AG;R !=VO7,7KG^U$B
M6D 83%!JK:^[ZGG__L/#4+)?T')_^F(_+FHN*6Y=#BUWBS-%CRD&HJ]XKX<Q
M_*AL5G_Y"3H+B"RV[6H75'H\;G>)]QHYE -/I?O:#:[G*UO9BE-G4"/%);82
MH(;Z[8/G< ;92O6)$=X0\,UB%T*\&Q"ZQ&R&(2G284U;YT$+V\JFCX0AU8^X
M-+L^*!_=+-.&#L]A.YT5K5ZQ9SCCD1Y>"<?V/R/*X!7XA0^!M 1LF6$^A6E)
MEBB:%LTV3M"% >#, HH'B(F=P4N"Z$:@;D '1&=8!M^*O'KX,(]?=>.&,P>.
MXC),*1!<!Z\GY.!A;*!X]2!%;5,XM$M'/0CM#?0KZ6'4YX9 C-#P^L"D6@?*
M70U]C3M(:X8]0.V3.-L#/-FK+1G"YQ7UBFXNG[5!_K:I&.HMS6U@'$>BGCI8
MDKYDR'I4CZRM9?/EB"I+W%U[;=PX"?Q=)D=HFXIV_?[ZA$1/GYHC*N_W?=LH
M5/<9/=B028 'LU]&$@ZVL\(N*DX;HY<DUK@_?94W3_,6.>N2D@>8%]^4%^H(
M@F?7_ADB\LQ-@(P9(&]F4T@1BTOZVII41RBI&0(T(MKU#=(/'PPI+(G3P<ZI
MUP&VQQ8G+R4'*J4?ACUXST2OPB ^?' =)USC(EE2)<$THV!]1OYVL)DA&U"K
M&PIHLE;.1:-;Y8@:& Q[S\=:&^Y:8?6VW.#]T2=(D8:MZ26Z#"$!\<DV41.1
M%@A#S9T)$2?/G/[\,>'/8\$I>P CD"S22A[**&&!1,6E;MEG?69F<9/3$EM6
M;61:2(DC\7 <23V4UG) AC\C=%*D,/.Z)<@9Q51<2U<A[XX1HX-1(N)J+D$%
M?]HAX^1;-B+W,XJ!1$BC62;Q4W<N**=WQ,26A+C0+J_QWUP^?W)>D5==?5T1
M3JK&Z*.L/CG"RV.W3&)'*169E X1KD]9[G>,*ELJ+ G0N:*.[EZ>TG%L!CLF
MCC^L\0BPR8,400%8F'\T<1XIR>G63@'G,C0E$'ZN 284[[P)Z'BW8Q:ZTU&.
MF X+*]<73=[F#]PT,W5 1NXS-SVS"R\JM6-$6C'G88<D7_I]OC>^:9<5(_WW
MW$O\L3T542^!S5MIT!>0U+LPT,7^4$#XU9U]F]73>*@>^?$[V7QG;H/C8:%_
MF5?;D[*).2%8)D/I5 \:W4KZA5.W=VIWPZ7XFI8K+DXGW#OP #>2#9$<\4D6
M*ZS>R1&XNJQW!V()OR=@J,U@@',#C6_:L5U&U<<[N"]MPM6WR/Z-3UJ-1,]1
MF=)#_4,:C+0"QX!.L*YABW3)LY,Z903]V+(.1B $QZU?0M_VZSMQL;$B6X85
M$_E03;M]_5'T2$7_XA]]_)>&D4E@2%EGDS9,GCI<3,>6>3Y6%Z!,N:&M,Z8%
MZIW5- 9$M+)<'>J12W<^D'$*"!+9"&!Q].8*<Y\UA'K,K=W0I!<A$RO%MF_P
M=8P+_ES8$])JI>'^Z?ZQB3E1-3 _B.1'+LXX.7.AX:")):7GWB'9/QB:2TKQ
M'7BUJIP/1\-"VZXE*@CM#!ZFT/GO[QJ^\L)_W"Q'>.AQ#=>0SWR_O4NA_4D\
M>YR5J2BN80\NF>VU>_7].%L6##MXX2Y"B]=>V"!\(20\;-09%O/E:A2<6B/2
M?U%?VA]T66SWWL2UL+; %6F]WJ%-EGP?A!ATKG*D9!/:U6)(I"3S59BX#9#2
M/2.O"'61C*A?3GI/%3NN=".'WVE">@*9%.D-]3DP75B5,PN<R^&3\7:?-B\Y
MISK8X"_\[;MMA-G[>S6L.L?.JLFNQ<D1,.HJ]'O:GL4)"R)D1#,?K''@:V/.
MG$ILP^C,@85BG1MZ<L3NGW 0WRG*E.V&7LDJ/#2:T_S9[M-#J! S$QM+?C6
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M$PSP*4XH%SC[_'7.14\"@=CR+4SN^X-G(FOOVIX[@OD<?HB/'+=8! J"H0K
MZ0/0$/"1=<(X?@F_$*;Q=D_ZIL(.P_]\MTFVJ.^)6H&;+P'?A[W>7<[*CYL_
M>EB8YR[[P'<NO<%R8[Z\[=  &*&'II]U-[5$0/:JP_<\&LK#]H3K;$=C%V1/
MSZ"[I]E"=]=0SS-&0PRI_5.R]/QR.PW+JCT3B5[01> C#<92_[L<(6 A.]+,
MSDY4JSSX\ _[UYFONIE/D-49S5^5@+^7VV2BG-1QI9'>?4=<GG?=R$GHV'3^
MW2K(RS$FY(!:W<-^CQ]?-I/>K06CN^U>Y<30PG?-S#9FHT.29I3HC<Y/;^JB
MO5[^?()&)U"K$L%(:9!GZ4/\V[#>LY6M2,K%Y;.K;8N!<* Z'(:;"5?67-1,
M41@M?@='F2U&N[D[:$O>(Y'*6%LSG,0%=JVIN4+T*1K.M3G1H>KD\/M+T+\E
MMZ +G[?Y9>J=%0QP=JU%_52/ _?9Z68THV(KB6J6IL/3->7]@C;%R@W<K\0-
M- ':':)\(WEMG3G1'$;BV5\@]\:4M"A5YC=[K&BL3%-8Y*!:*V^0-'@68[9!
MKCVC%-W)U.8[[#P]*=%Z?063)/'(R<'RA![-S%6VX=2R62O 9NW*#,3;DY@B
MHKE>;\LS7FF/<=T+\#_D/&JL]4S, Y!35',H(+43BS,IUTL/T[IIP0=?EH;-
M/(:JK+4<J#UR!-:WK-)KZK3NY-1E9TNSV,M*@!O9C-=;]\T2J&C@0"L<8VQK
M*W:&LN*P>Q=/%3\AJ?WG6;HSYK]7YZ_5V#8L0:_;PQ)KYJIJM"B<.R80V_0P
M2I0=J!;V[J&W[C1.E?</BO?6;'$R_3I-R02YF!$X^CRS^:CSCJ?VOG]L Y[M
M!0J^P,%6M(Z^N?)]B&OM#I07,%+QVDF.V!;I]A=LTZ>N3SK.[:319!O%@O\F
MYD1''ZY?P!&.4^M-J=/'1'L7O3KJWC^T0X\8[I(C&BWU-WJ]/'HFPJ]\$8%D
M8A8#%<?V'9IQ;)CN8G::J7W.X&PJ?$'.346/J3RP)L*Y'+IHVQ\TVX'JK$QT
M0MZ9WZ*<G*8JTYF\Q'VI$6#_^2;X\ R<P!U?B!:O]XD'4F0?]'[0+J^QP,]X
MC54\\ Q9?? -G-P%%AY H2@6^NEUS,O9I2IZ),%]!3PCPPN?IA\&);;\!I*S
M,U'%@8YRQ'Q2_>WN'TJ?^MZL>I]2XQRD''C)8).6$8LJ^1YE E&*YFI6M011
MN2_T5N@:M6\'(K[@//)JDAHO#2^\)/;H]UBD!>TC]$RSXE6[D=</?CF>MUKY
M?@,GVZ\D9 5?DK1? IT6K5_8-"-5&JCNUY8\0[>T3@>6.K3+$1X4$A>, &,>
MT=\FFNV #3O.M>GR1"^*RE+SJ/8X-$W--%_GE(K-&&'-&8TA[^OZ%GO..ZP]
MR/;^!__HDK&L0M%_+^.V-T7W&NF9)@Q#'HXE?#GBOP(NOQ^T[=E>59)][,/@
M G[,<(?LY87.J%R@JM&L$#F87HL+B?1XAHWD'$5/M1IJ"L>G'+[]F+WC/O+K
M$2% 06;H%3E_ZU:?5<DLE[U"^O+IA1LU^AODB-M>&C> ^K!HPASS=MO,6=KC
MT:\RU$R ALCP:>.PJT((:=Q2/Y_3KB@FE_N=:(^-_RWZHR<K1BUUCSRPI#(I
M5?B+_-Y<P<]$R* D@^N=FNA^:<  Q4>M8B^BQB<'PJGO+^=CAVMJ%6</3]1Y
M_>ICT7.T97MBP<CUZ)ZP#V?ZFCF-;:4AJY\3!K9"-I.;FFS55]F_:SG8S_J9
M%*W=G%W/).T.^Q+I>1VL0>N]2D[]C2<)FMH9-IUUT(]@#FW;1+\]737\K./L
M?(/XWFF#8S=(8X;(ZFI-OYY: W?(MY7:GZ@;[3X!;1% ^R)9=8^9O;_Z>LQD
MJ;/A>1L9YH2J)X8O0^+CO81 ?PN<C_WVO&!B/EN&KN>JUHL*YDZB]M\QP+W.
M,)<CWNAT],XE?M1R%2>AR1+B[ILTE=,#U5A[,?H: Z (154,5>A.V3;9 Y6%
MS<3% %+LGGGA7_;@3NQ\M2)W<G>??896$0$Q9Y-ZV%))PEW%U!)FO+D<%\>U
M@72-_C*D?!O4(1[%/F_*%5WIJ@E \1RT[-V.BL8TP95_F_5A9%ASY!LUX.4T
M[@5+M>#47[%Q_3?-!C[FYI4EY/@ZAW_K 2^U7['G9<CPK,\/*_$4E\*WQY/8
M,MX2\FA.4_?BK'UUE\\!Q3'L(I]9GI$8+G+]J<9ZK[F;R)E-;;KJQ.4_^:KR
M<GOH63QZ[,2M;*)PHD=W 37]"[-7L,))A__/9ED9 7^ N4?5\'.!>A!VF"Y6
M-!%9,"PIU'BTL\M!3X^</3/9]>C71XLMH?GF6:^Q1'^/GR(]+.T0L7DKK-W/
MJX[5V\I8GC57"L!JFFQ@RYG) R-3<L3S./$($.T:-+Z03]XFN0ZHT=K(8OP_
MZL,6:[]&+31:RV!]W7@*.A=P"&*)_D.[BC>%Z@]P]GC3Q]7:[0XLOXENK>?F
MIKG+$4]V/;."^1V_5G3"_U6<;7_WIBHYHJ<B699Y"0J81!8$7UD0U+-7P9"Q
M2=$&K'$?R^%ZU_:$W8ZRS*D(*S7?[I;YXI3PS(5;:(%L3RZS7QDH?3JHWJ#T
M=E=VQ_CG)ND:]XZBDOZ;T%1A-=3+T!0JM W3O?HV*BZNY^212K@8TR*A+I.6
MIB-'C*%V1)'1<U1:?[-K<Q<SZ(RQA\OA'6_\%^>G0F.XFI^7=(>9Q"!96#*J
MZ/"!(OS8XLD F\W6:P9Z[2.1F[%-YK\O[-GR7<(A]E_]XU/2.';*8^( 3A0K
M1Y@$[&5NO]7CM2!Y+*M%CTZ>%^=MN2)4L5[R@JQYT8?MT-T_9]>G+ NJH\)O
MO<FLY-< =2T8D2IK.W7V&<M73W8L\%ZI#)P08Z>76T<=E:$R(%HFD:A>L;\?
MC!\$(ME]Z](YY]0=5BC?E.6[A!8:W:I4P9B?3DX9\I]%EU5+Y @^X;]6^U6[
M])_*=!^I8F?ITCD!6+GIY0V99G?[R']+@;\, A5EV5<!8[H,QV15TB34D8KT
MKUWNQ_GH!',D3X'D#KVE@ZKI@7KQEC:OV0<CEU1D#K,$VDQ9UD3?I:LP(A=.
M_WL:HZZVW>"$;=WS.N#O;3_Q+Z12(-^L$&J/O>3IE)@L>[/!XV7 WKL:_H5Z
M@:UV]WU"+6&R#MX%/"4OB31NVC>!U\LCZ7SJU-#DOB/M!"E&R.(-OL)4O9LZ
M-)D5E*1$\G7)<JN5WDHP7[^>0>/K4J0;[,'(*E]1?OL.UXC&*:M1E]V;##'G
M5E_H&H@K&MQIOI',)T,:(#!87<M^\!?@W!$I_:YW94^M]Z40Z&]@<11?9>^G
M%C9MVRU3LXIVG>7 X+0[%7K?!&!%I%"P.P3MJ&=>K<_P/'JY-Z'6IJ5EM:+T
MI1R!%%#5NY@+HDM']8[&MYE:(9^0IL-\M& -Y#QCLP74G.1;L_%6H76S V'D
ML*OMA.3[/CV?2B;R4DMLQZD<@=!"&DV;K+VOD9KG_6M_,MW$7G8C$;I^LGP/
MFH7'OW58 ,?*.'ZS__#'7ORZZY;QM1'S_/1&H@IL'F\6N=(=*<4@BL90T7.9
MKGS.N0KB7PPGJ+]6KQ#E5S/V<VLMRX[S?:V['-/?EW7#(Y4C[L ?:O@&MRWV
MMGK\K3)L;VNP;\@4MI?D?0S'.6?XS#EF <E7BDFIOC$46L?^)4?\(1G*$4F-
MHKDU@(CF*&F3F63]-4PY5652N@ #PZ])X4CO[W!)QR+1,2GKH4V@@YGT8X[4
MW.>(FQN!RJW^P/0B7:U+#5(YYP-CZ[\;?7>: ZM0\]OQ*X0:3PV47B3<XDV9
MQ6 FT:-?E]\0RA&PX,\!3=()KX$<Z'"FSD?S]2L)"V2450;T<.7H<ILNYX9N
M1BV!%'GUX#<YHEXQ>A-%S_O&!S\"S9LHX0*ADNO]0*L^$[/J;MHC6,;V3&\B
M_.H/41B+S,'T/X7^7(A5L<$)4JB[PK[Z><&?U\/OKQQX- +4627PQ(Z-WS&V
M1JY>WFW/V++_(F*%;QEN Y[[00^K4N;3KR]O$RD9H9:T*#*8F:-]6O>4,FOV
M: YL2VQ04)U;7EX:XW42\)KN2J%$^;)# GC_' ?(?+V)WJ?%QZCV":4#=[(R
MGM0DY$=](\YRILJWH=YP]X$D(J.+FY&Z^@(M7XZ(=[3#ERP?RH ",'*B9_D^
MXF2K(_)X!V[6<0QE_EM%NB%,.]&S"A;ZV5BC5%JA/[P"2<VM;42)$PUH4#1B
M1=[[($=X0>3Y@#:J0J35=:FJ.CI,TQ8;AQJ&1FA2>@E07F$5!& 6U-_'=;PV
M6;UK*W8TKJM0J/&L3]7J-6C6(>A_[D15*9=%PVY(KP;O+5_?"&A9M_P8]-7&
MVY:VQA> NCT F\ $YS91)6C[M9AXRP7OW+WH0M'=G.@M)M 8N@M*8D"B&$*N
M,S$K;L%[X_>_N&#*YVS4 M4!8A\,AFJ<<"*2ZV:ORA*6\%A G2/SUN@;2#V^
MYT]L_D^69B5E_Z>G6C6-D2NI=>X'O: ZV;>NY:OX=YDH;YRK'/$VWC@ZR?U*
MV)K3'4OLI<#&H@R]SRLTMU3Y]MXO_V>B< P8W$T52TW0)7JEK#PO]"1L=/:.
M]\Q0[ TFTXQ33,VBN_ Z&W4TDT?9(N1\,U!0)I%>[(\M]P)WUOU.] @A]3J^
M5?Y[=KC<3>C4IRFEV1B+ZH$M<L2^4QE)+E1IMY15T&Y2B<>U5:&F,B[XXW0K
M='[  D#;(LJJ=.;WA_U%QXN%H@[@3=E/$#V(?YDL[/8;D",HDR_*2T^+'Z";
M98:'4R;[+MG>&.KOG:E^/"$FSF<[AL@1@;=!8"?^LYW4L11><CH[P-+W=^R6
M/@3LLA8&&#O/<*WL \)9@XXM@3_O87AW< !/I1S.D#U?E&P*BJ$^I6CLPXJ*
MY1>@%C_93TY)@Q4SWZ3A^(43O0TEGW0G^*&6/@U/,9*B+@N"HK2[9%!/*LT.
M"8QRN3]ZXC&.$Z8 )Q'^\E,6?1RG@F;M84CM T8,NT&:X:&IU2US@-O]&-6D
M)![=F# QK19;/G%R["&X^O:8MY_"3M_ <W)$,XY>@*=KV@\X@S%$KEYEHJ/B
M4D> 3<I40M99E _WDS?O-\-KQD41]>G(B1M9Z5E-T76F3;!L@@[/JD8RG_8'
M:8LT-<8Z7KC^.<&LW\[D92[M]#4\^*!B_U4Y0D<U4(Q&S>H30<I4->RP83>2
M_C 5SDC>2)$63J*5_AB>I\0VTX(G]?ZUKL5;J^V3QP;\['DV=?H*B@NVL_KR
M*I@KP_$1LA).>7DM_36*+ALX/.]@7?BPYR2[8+N^>U:93B1*=B-;CI@Y@YHQ
MC!9"MPM+H,;U_*>BZ<2:O1._8-QW%0;DQS'^U5ZK8F"GCF:&V0^U*%[/- Q^
M!/Q6N+@:BI<1!<M%@DI.O9,C;*5J]M__UP-F6CV*2&;I=2^@V036TW"ZI1AE
M5,A)O^/T^>E=$(GFY4COCNL1/E-BW!2-A?Z9$I$??>PG5[+[]7)QC#70CNM
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M36U_A$(Z?21NP?&0N?E4U@PA QQ]"Y!+TQ(S#';Z:F0NR!&;"9JY*0W6D)8
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MU,?K/454LZK2X/O+FXNRL_M7NINB#\3!N 6 /\IRQ[HF9P5WMTXSI?O50Z=
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M+G2E-E\ [AQ+;J)RO+MQX/R=C@=3U3,U1YN8MF5J6OZW_DV]BNWP"]SZ[??
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M8 J(8/!1R4]_X 8).I&<??K&G'RA?< 8(^#2OF/S=@!V2H@0 3/+W'%2$U,
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M7<!RR:NG)"F:S3<P*BQ85OX),"7IYB6&R//(FV#+LG'3 @!I0:KL#GFZYLL
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M8\%TA4BVG;OIJ1/FY2W=1)%JG"R(KK84@X[C:^NF=R!&P ,.6J:B)H\$MF.
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MZU/>!]1=EB3K2%?LU$1_Z^R;D]XS@)Z2EY>(F$8QB"K*B_HUT$_\Y]?UXH4
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M418/*Q,TTMTV[:^E-Q4HQNZ#E&U'OUJ+P%3Q6SQ28SMOH$+*[XM!DB!\PSX
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MM$XIK?QU/9G[N/T_5<$B%X/P.HLT9TI4C<VN?!3J_6!/VVUDW<&W4 A#HGI
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M@Z6?&*0@C)U[74\LW[ I;(MY1UBJ)+T1_S@+%V8,VF!#?W[$L:T7&YR10Z7
M(MBGO+S&\L0SN*<$N$Y>Q;+UP^IIG0H1 G?HKQX%I>VZ/X=6\-B9+D)$APOG
MC"'F7.0/06W _2/1=97E48)=!N]U)*%"Q1*^NY7S3T9.6*@8KG=M>Z#_$:$K
M+%1VF%4W*J-3A.'M (X.W[BPWB?2+ZS><OLXK++/=:>:SG3GMJ>FPNTCVI\@
MK-=UK]T@3K7;HG9]LM"_(*/?R946J.R@-BRC$S)Q;X353]F<>W,;-B'19(%K
M$46"Q7WUU)3\U0->YKH):E9&-\PEQ4FC14(OU]M\\-7FE<82R/7V[7N=[O<<
M?1A I:KI9G?@4QM,JYYJ?]0A"AW=\0W )P6BH+,,VD^&,0Y5BD&Z-MYU2<<@
M@^CF[@JU)Z]Y4K/2$.S2S'"3:^2$ /SY?NA?HRTD\E,82\7V8 "4+++\(8=T
M$8,<UT<3^2 8:(0U?.7]"^9PLZX+JT N=?LU2DBWZ7'N\&60&/3P-_6W@"A,
M_+:..$G'CZ*_2C,-9, -7Q58BZCY$9,O+USN^&S;2%O4)4JJ<DUR?<::JA 9
M<EU9;UL0XE'/@V?[PL*VO5**\$7&%>Z[=Q523A 66ER,$HT*MJTJZ '3J;,_
MWM?'>NE@]BD\O'RA79/MG^S=2NXY\3DW\+\C:;N@YJ[7?47J: Y&<M)4I08Q
M:/Z7]#5:5?K&5P3R;V+)U\>93.7ZO:$7PJ2])I9M^V>XTYO1;[II=,&Z\0LG
M#9E3,?.Y8)H0N2*C(M]9=.KEOV+H4<R*_X4_9ZHU+VUX%JQ D%I"-E&UMD$Q
MTE?]^7>,^T-.NN=&I7U3N3**AJ/:D'=LYHKTKDP%96TZ-9JYPP:'[>L4--1C
MY\,RS,:69LT?M*(M/\U>:)HNL<N+M>QW_B+:5[3>TO%D8J\JCR]O7$X>EBRG
M;+-MDEKY!B;\/GI>>UK"FBT!VCSB@5)>)QK $S**R=[=R]!URQ3&'=5; ;IV
M8I L:HGO&C'PXRWX TE7PF?K@;19???0]$/^\QC2(\\-2W<HF(+G#NB_-/(;
M]1D)D9M-">/:2-B=ZLUA@VP/D""Z#X2VZ@/T)7RH(/9$^+[92"17^5=:XEIR
MGGU8L#M7#/)X(*E(</+"6\A5CM+'!I(%Q,*T+$VV]RD] W:FI/F [L'+$EX)
MYV!"+SGIE>C>P4*N@\I!3C826=E)**BH/!.K]V/O?N70C4\';\JDDDG,$RGQ
MV)#[)?MI][V(WC8Q>9MVHUY92T1"_2?#B:]8KZ@D#H);_VXRD3*$SM(2>$AS
M3PFKSQZ=0P^L.QA.*ITQD&_NQ0;2ZS,$SRR^8++Y>(Z;,&)]FELN":?GA<8)
M( C_!_T:H=@W\R.Z_Y>?9)6+JK938I .C0&EDBHD*,*OT[/KA09:J)R@*U17
ML'9-_^X=+RGCX'8 E_NEF,&36-(:0!QCI(9*F$Y(8;1_=<O,+$YN@,D3\C<'
M?OK=.)F3]SV%<#&F[6&)HC+8?V+%B)B[*>R]SAD+ O\B@[_7V6\3:^<)HW05
M_=;^\N764/.1+T7K,X2\E=;?I'LSZ+S#&T3;A)"IGBZ_?7^#-'BA$[J.DS+U
M$\'6LIU"![II1=2Q%NBX/W%.R+<4/0#>B'#"$;^8'^<DC.1G6T<@_CVH&>MY
M>&K' Q'^AA@43M'%23BCAJ5<H<X[U(<K'C =[:&;Q0 '[=JU4H?A1UE=:AC@
MYPZHZ8 '),>U-7W=L6-]Z.  *TB"YN$!>&J0,[$SN[KN1<7QN[L.]3CRZTG_
MN0 KZL#R JTO52("BNE7%H(,T:/K,N4EWJ7OK[:+YOYONW?<<7O3@JXX.J0O
MQ!\[$)5Q0??MDQ0DT3!EEZR?B>!(?&3AP'34?P@\G\TV]RVCK8\TBOU&49<
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MLEW'<I74L]RL; NG,V M2IE4W0BH$&[D/=P&4O&UO'*AZWTD[)FJB<J%,-A
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MHBU;.JU6[IP(W)4CM"]M]QNM'O6G.K7RMIOKY[TJ./2N:-UK*65 QLZ,YX7
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M'^EF?EBZ^D(2%291?.Q%YU=TQD>2'ZYTL+/TV]7AXIX&FFRU.GF<*HG;'QD
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MOGPL'@+(,HQ4V?<V1OW#4K)92\K5-HD9$483$KN!6JLL-F'O*X9U*%/H&QI
MZ'F9D;6<]JP\%O;H4M,B,[XGOYPI\_[66_(PG)J<WA7TB.989]NOYS@93?]3
M7)#[D<7HMY,1/H?<!IF>4*'I0@TR>FK*_*G4G3#R[I1AW^4Q(8ET=4_*)*J(
MR/7DDPF3@^C!*OL2[Z+:3D>%/S6_/-":D&;O2/?4*;7CL(J=8 EL0&RM3$U'
M1:O8;+#@>OKO8$T9:X#3";5UW32EAZ],>O7/%4+*%$]#0VY%R/9; =#G(#/7
M!E4'D4PS*;5+Q]+@O$&)]966PV"\M9?$1-J!G,'>>X*B2-4S6D ]I(!0'^>F
MGJAT]&JDCAF]$M)D?3% O3?2:_6<V!A382I'[,X99BTLV@4Z@[0E$V9-C\-
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M8O2MR/IV<=>_$AB1*ISC49Q69YX/N$I@'] S 6&1%RRG&D7BXTQG#)->0Y7
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ME>]>83;*D4;6\9G^3<X/7WG(&;]"E;V>VBAKN5OHDYHN6!"&5A187./?![2
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M+4Z%#-%Y_ZSYSK&)4(F7RNDMLY=Q2KY0>=5JU'CI0Q.^XB<40>T0<=E7O?X
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M.$C*+/#S;U3G+Z=7":S70-UB8!3;'0S,S29/J_Y[C9/X/;HB/H^5%P)@O7V
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M('I7^PS]AQOMR+T+4_D3W.4MO)<NX97FE/+B;K2'KJ'?3+ZGIJ<54\-PEBB
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M_NRUZVCTO^_X]?/NQ?XGQ.'?>XJ41&=)_66)"SD*RBE6E&.<$/_U$ZF=WO1
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M37$_?>;YP?9Q+ZNS_K$^/@>[/1\4EE1J/3V\VU*CRU[4V.TH7 :D>T5A*Z+
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M=WI,3- $7]Q!"ECAQ=H.:=&YL]+%/0GKU0R"D^+R[Q^#]W=UN]NBHA24K*P
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MXS.2&.<*4"'V[J  $AIZ'2&='W3."0@1'-9P]$S/]>RO2K#$0@)3J9SO#OT
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MJ7<EK^W$7NI&.3AO3Y5>P:'#%+&F+Y*>PT=FRAWWNHMADC7[I#X@AFLX[/A
M!%_*]-O,%(CO[_8(("?QZJSBJ%$!MI_>E:;Y=&:G#'LT]Z7A0TY]RGJ$1VIX
M9V\4F ?=$<&$@C2A+W+/D2Z],>1],2ST.V8X;)B&&2_5U63KW7@5%225?K[+
M*P1$T382$'JWIP0*);URTH_F!A2"ZEUGW?1\)>W=7[]\ZGXO=_AZQ;>3L"DL
MOK??KM=>4!4\&CD!C<KA=NR0F@=9&_/FBVX<XL;SI8QE1F>V<T'?RMKNDCM\
M='+WQRE0BVE0WQ;297*:YQ47[WO3!!$FT\US##NEK_\!//X?EF=N&(+X76^L
M,]K%<>B50-OMC_G<[,0ZV^D&6G#.K7.:$,MD_YSB T34P-W.44QBL/]SH(E.
MF1SX>[-)S\3 X*J2DQ)B,-!;>C)&#+/3#>E/'V@7PU*\/DVN031VAE\_>TC!
M]JV-B"LI!(;QL\/-WJA]EP+*O+L^X]RO'Y8TAH^YBX!>;@DZ/3X]&7=GYBS%
MXK=T$"JBWU"H)_1G]>ZZ[_WOM)S'8@M\W).<@^7B\<4[?SVECQC:?F6*8N"4
M(& :[Q_>1UUDI(\2/0468!IB=:4Q!6(R:S[6KL>/S)GB2W/JAH6KX<R-X'C_
MN0HH&ZZ(H,^Y-,$I"S.H6W8Z#[8'(X_3NN KO:550$8;<H?=QVACH:?G+=&7
M;/<^B4\"QCP%M/C,QSZF@[-I(C5JYUNISBV\!3FUT="NVO(1^1<0BO[7H?YW
M\[O.T=>TQ;'CF?&B14ZT,6NU-AY]R#[SGM2*P#>](GJ/,C8'/JU+6E0 %880
M=_CLW&T5[0CR<)4"98!L%_X=P++V0I=:/=072DFO&-M^^V<G!D<1C2\S+4N7
MMY6,A8#)721"00&2=Q'4FOO90I%P\F/@K*+I:&N(B7$8QZJ*I7#OT*)3>J^#
M\RN/W59R_-JWF2I\L:HRN,P]/5-;U+WUG) 2G0A[AY^W'F&')Z;77\FO5+#E
MP']C2+^AJ.CMUZ7X;MG.=JW?G[@_";3=O'O)HOD2:[P[\ *1"0X/MR4/'L8)
MY".,= &&&"9EH>"V6P(-*?:48W[.6:=__QB4Q4@)C3D=E?0$W4"S$!9\M=60
MGWRSWRG&X__9[8YK^*^W G?4[\+:1%? :S',F+^N4NL4EOPH.\=CS^?]?YV<
M;>8CQ; >"&!)I</_3JUV(QH8?KEA&9]AZ3O<_3)WT@?_PC77WGRLX-RCT-!-
M-*[<K9@,L%0H"GQ=W.:N%@''+=$=8W;O1A3EG)D9ZM@*1WDW?Q/>]G4-3X@M
MJE_G[79.QGS?'C.IGIIAF@T(4.LJ8R8%@?3%!V6(93>SUS'8S9)7SN/.S+1G
MK'=8]Q$Q?M=I4[Z:ZS%@-+!D&WT+B&*($@[(/B)J_^H2BF%?QLB4J$_=<S/
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MT?LWQSYEIL#J!M\(EJ8>E!HQ'@':EM9!RVS$A$!;;>_H_$%3V%C-XA(/"$Y
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M]-V$5(MB&Y2<(#["W9#SXM4U].X'0.5])<<RX9=WQ/0AK6/58=S'YC]9&O>
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M&-9!'CC\Q,%3#-L! 5_A$S$LB5_N>_ @ED.;]=[DFEPX#FLC<&:GZ#._.T/
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M2V3Y8@6JW[0MJ&?:,M?[U\L?3@5KB]X$[-&M2,[,SZ4QU);;/ER"B*AI8DG
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M#G[2Z 0E==:E)>+2,!PDECCVN_()V749!@H4/GB-Y><S47A! ']FXVQ&Z"P
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MW*O-\ \Z+YUJ.WRDI_T&3!Y)UKA]FV<R0<OSKKC3PP-I@#FS/NGQ6U\#+:\
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M!YO*IC)2PK9>M07= FES:9) '= O(.Z9IC-FZ@R"SMX)"I2SL204[/LL.ZY
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M/KU\IMR'<CHH_22RJT(YWL_@RJV_"O>N+ AJ5G%_J(2MWE^-]"IXQY^]=\L
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MW\+>H]=?U?WYJN3MC^C<$L.7%XW6.[V7A'+IQIF;#IN?/738%'T>O'\"^29
M@[5;?R]X@I6(T3[CZ#J3'Z/'FG41XGF:ZUS9.N?1859C:U[V)H3&YF"5,4?C
M&QHVW.O\5L X4C/E/(ZY[O0@97ZKC_O:CM3G\R2BA7M='<)1UV5$$JE;A?L;
M,F;]I7]9M0$YNDU"/<.@P-Q5W6?FJS&OHZW/93Y>ZXJ<@TMFX+:M[?/<OCKS
MJTHG3DO6N3RKZ/6?&#,[F61S-.'V"U7SD]9$@(?WYIQ[?2AII[>_W5UBW-A\
M6D 7JD^'^G_A;%V^8$@4H^:W20Q+ACE]IC,+7?K(%Q2/W:.L?2)C>?':EW'
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MM#X5W]43U0/CJPW='0Y\.B4/F;E\UE*58H6HS^_R<_ELZ'AKZ4,U]>/89BL
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MSRS712GP_[LR#5_)=U'RF%7E86'^>7"Z2^B-1>7[_2_.WC.LJ2U:%X[;PK9
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M@490;HXU4L2O;"J,H;),+F$#=)F*9>-/J8P3'RO_;PW"_QID(;%E8]\YG*S
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MTH04H=B^_T(_X[X4D5SK/=7J(S??MP=>+I3[G5ZO9M$J[)18KWSPRR*ZF"3
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M$)B&NL09C/:&_,+;W81%_A58(AU]XW,SOG1!U!5ZB^@"1K_H+C/]T/QO^:2
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M"J_K&-:K8]IG95UL9-71E?'C?_%+%W#S)#[^6.OU1YKU6P+50))*G3U1/YB
M7Y<_A ]Y=O4L8E,:@R,K@2\[9?&_UI[6SEA*FE;O)"K=GOWZ?CN\4%M*U<-[
M4!34PO_#V9O'0_G]_>/36]*F:1,EIET24J&$28HV6T+91@DA)EO6F:M2J2Q#
M1-DFV=<AR]B'Q"39E\%@[(PQ]AFS7O,;[\_]N[_?/^_[^Z?Q>,Q<USFO\US.
M.:_7Z[S6Y]63O+X#LNKM&<_RK\<=@<7=E,'J&+VK'YN=??N>F/C6C3!U)INP
M3[A&RZ?_-$FUAU^4V5J0JB(+7[;1G+RPXT.&ZC[@L[(8R[=C0Y["6+BB$Q88
MN=FUWEB*VHI"AWREZYS+5R^OW=V=)/L0V$J.-G9>NY82>_F9%>*>>!A<1^S5
M%);<\?Z]>/KAN2-\ ,=S[>^Z!>C52!XR3_+BP[I;D4LSF!=47.@\U::XS$T/
MG>YZ1IJN,FDY$4JFU3%G$?O6$!LFZW@MDG"+_R[ _-&LLVGY^98;>O+.*H'[
M9,*-4>J7+5L$D/P-H)0NBW#VW;ZVN:)B>;XQJ%D V02?G+7EH "<+-$+F@4V
M?)?-A/6"=4(YD!EG:./O_7XXX<*>*@_:C>AN?1,];>$;VF#D),P,3!FRTBM^
M,*M5L EL(!<T,Y+.EM2JZ:6N'M:1V:)87'5'-E?B%,+9B5K['2^'R6WL!?+T
M&4+).7_0JX5< NLW$HHM,PTX?J2%IQ,RO74.K9[G>GY@N_4[CA#!)-Y%E%L8
MCZJPQD*;4&3K';$"R"M2$=S0?V8P0?9&@M=&WT,!I)BOFQ8G7=G\GCAX*SM3
MMP*0FD0I71;^AFL@["JEBE TBS7,8\A"#!8,Z RQP>;'7 U'4HCA!X<3PLDL
MLTN8\R!]L<A ^%"3@[=_$/7U-F[ZMNE#/Q#4)( DICM@N!1>:/^9<2_A.V]4
M>&GH_ DYPGV Z9<'#=]2:T/!*@&DABL+HU=>U5A/X-\&"@D\UQ'"$$#G,#04
M!DY<P17Z2IB;W&4-)UB%I=9-  9G>O&+J#$.!D?B+PZI!KIR_ZPW):2\&);L
M^G5QPGBCULE,U]\14A;LTZ8)4&%^6DH3'19VD5JL\#9E:/\._4^IJI<&VVYM
M8>*Y"W#ME@(F(9<O&YWSU2# W!O4JRU^^N7\9ZR_&5YAQ4^Y!B)R7Z5Z%<1/
M\)&/;:_5<,H5>#*BZS=%4T<]V@<0\/:4P/Z6[__NK7RS^O'LZR[\;\OQ.,#>
M!"=\BC,Z  O[R-"M_16(4XJEIQI[S!&FM':> Y"@SD91)P6JY#VM_VJ(^*\?
MVI63$QN1V'/?_)"&W;.M0I9Z#R93QSE +IM16(G9CK7])!<T7^&P6YS\FDOX
MMB/*1+@VK5]NU"3*IU^:WN$:1.)IG3X@><3T%C^8QY>W_](#7;%:429NY'Y\
M^_<0Z?T%#B#)F*8J=_-/76*<W@&$PM#) 6N9>0A;:%6#JL;3CZ/+LW+S<T.)
M,5)NZ>]RN+?YB[9/#Y35UPY&DA>!?C\";&S^X%\2DA_"I)AVT3:)WF'+Q0F'
MW"S ULXCAG76YY02AA>1'!ZA?M@;O,4#X124%K;_621]B64,8FZL^^J9)B9_
M#AG\ C16DDQX,#JP@N0A1Z;AIGVT'@ -4G(]:'W(6<(*HH;5"31H9#Y$VH"=
M[3S]&M:Q"1+..*B2Z()E427Y=Y@C7U :N.!5&4<5?_:)@@(AE]SQX*-(]2%\
MN'F^F#%/=Z.B('Y#<_O^Y&K4&&6NS"$_$'K5N4@6I<;O') E@!3U:GQ0'@G.
MQ62J;1350FZV1H>89\D<6Q\9!%?IAPNNZ'!QA:H])Z2CS(3J\0*HN3P?%__X
M'1.VOA[<766:("?VU@#:#XQ71A5Z1;MKI> OE-[5GE#0P4C0W6_<0R,W=H-D
MAP9/ACX/:8+-:;E[[U$QG;HG]B=)@1_? "IW'[]$"UO]> 99CJ7Q<Z4WNA!T
M%% X_,L&CDF2EDG-U>J3%(\W+4F9Q:)-VGA9-PLS 40=!\Z&\#>ZH'WP562Z
MC0=8>1\O)!_88Q65Q=AND"#: @3YCN:(@$IBGN8P)M@?^JQ"Z%#U9_]$0G_"
MXQ[.KI^:ZG]X2*]UX6@EL]3Q:L<35UI33K6-^9U0X4A)'>8&NE*0+VX1FM#0
MU;5W,^YW1M&))K766V4.^DUN_H=@E*D]517XT5O2._,>GY;QW_N(:-JPB-9G
M+MLVKPDEZLAI>G)3 "DUDYKA3W*W>[U NHT&DWC#4FXV[^>#8@20-\EO%^W%
MQKK4QC6>,TD&__9RTMG%'6$?5KPA.U)W3P Y,/Q02(U')-+B72RMEA]:N7H)
MT9M6=SAJ5?^B03$8IG7([<4QV^E+J^DN1ID\"YV&T0L#CZ:'M##).8F?W%[_
M ;8+)8@;5+8NK.K=&+]D76O;O2OW97)2Z1,DXS%UP\/LLEI^NW\[[YN3U"05
MH H@W"HJ*#L;2^(Z/DHV3$B^XMJM9V(4)QMSWXK I932Y/)308FOC4_01"U=
M5D:.T)4SQ8;>ME2U]S9,&% Z I\7<_0.&6K6MN6L3_KRMFW<P@P\ &]@>QL2
M!D'47NS4+):I.@A;8I'BD9Q6,=[-]9-$R>!B(M@O@!SMN^)V>2:4P/Z&79ZA
MN;8_D3&L^5]N_6QWF7.QTU4EU&]00U1@QK=+/H7;9G-X.0MB5#!N^,K,YM-G
M?,_FAS;,X[=+*>EZ*IB:PK++HKSJI_N.-0SI+OJ6BY##/UK->B@SKR]W;;D%
MMY-@>\S:_TZLX=L-W2@..I:GGW]:GAW=^W"^H"B=C/4O5[<2GQJ0?FO@/C'L
M'\TS_!X0EM[>9=]\/(', ;66Q7RG PO<RR4EE1PBYBKOE8O,K#+@3@_Q[AU-
MFM*G-?>_]!CK3F;19')K9]?4SC[RVGWZHC]/9?_!G:C; DC5W1*LR1J/S%\D
M[R#HMY!.7.NMOJSVKN0(3&7&Z$>-K<6[63\+?]@8=]L8N.M=00P[H=_)I9,>
M3NZN:2%S&^S,26Y)S96<D==8!2,3K4W:!UV"/A$#VA3YXKAF;0Z*KCZBL>I=
MM*14QL8]"7,1/ZCQ4N[5]\2((M]$5'E96?ER']7ME0!R]3AL;-:T-6@EGRR5
MD]<VQBJE2+N*B+]U=%6_@6GL7N7?,7\P)(#4@JFM+8LR:NU/E7!E7WG'KA[4
M!%2)UU^,C(BW9B/]MVD^%05:.C6'K0@O>"E#Y:W4FF4SJ\#L0C.L%TG&PN2)
M1+<P4(>2C?-Q#,U5XC^4Q*WKB)$6BL_"H0,5.S8_"8F4%7EE<M?B=[*L;M[K
M*:B[(MN%(O(K\I6IT;PPP-%/=GV^$O=L5-WQ$&Y;.35KY9++J.(MCH$:YN\I
MRB(AL]JSOV!RZ;K'WD,]HQ])V8>F-\&I,/A,QZOEEDET8&;QE]K/BSNQRXH)
MG[(OV68L;.^"OE>'_?SQ]OT!SG;_9@CJ$/5QC3BWA#_U:7@7L899.:TV,>88
M_V[;&=>IR.= >D3M;*"=!;^?/@1TABP!VO"67)_7/\($D!CKN>X, 81.Z%OO
M5-@TU7>9P"%@3;7!!#ZB=)!X/X66I'4U<:\80<$"M\<PC4NP_!^<'FD*(/W_
M=K36PLO9SF$(R3]I+&S?=;3V7>]!(<[GY DI5?87#[]Q<-$JY,X(O'%F+6SE
M5ID DDPSXMX*R3TUQ!5 %$Y=0^&*LD^[>'E_X2&7AQ:N8DJ;SFT9!2SKO0!&
M;6(@4<EU9I\,O_'ME\4,QPDCANP/5\?^V/$AZ]_/76^,Y::5]&O1+X(N;;_;
M^?7'*(\BTAJ[@)Y(MWF9M81$ IGB?83SI(QE#(2P&:WJMOS^,4^KU^6+-NDW
M[UN(A(,2,6GR:WF'@5@K/GZ"W%QM^^P"J]NW 41'&942SWUG%O&( UW!1;EV
MOT>C%6Y8K7N7^E%JO^%9L,R)H>9'%;I5]0_L9M6?OU-+:7+N/<Y[(WMICJ!F
MQA- ?M?,F3),_&SN Z$^SV5.=@\'!&#S\(>Y?@X_5%%N)>=/. %#WWIY9T1<
ME2?X@)UI,]>MM9V&+G4&=\4E_='9!WEZ1D^[NS/VMF7 &5.=&[K,F)^3$QZ9
M#S4(^2SFJ=!G_.Y0E36*TJ<#O;&JVIE\W>Q]]=-%HSN>&PD-$AZV2" QRZ D
M_L%*RLZ(U,L7NO@UAE<62]ZI"_\SCLI,8'#6=Y*^I5[N"E27MS[O1Z@9^%HO
M@,A769U1L4]6$B?@6-!UK)U;=^2S L?E?$(9O^80&7E>CS!Q$*:M);FP\I/9
M-D25I7Q+\+1?'QF^(J*AT(J^]'@EIH?B(DYG?-F]C0-J)T(]<)6!MFSG'^Z[
M^?KAG,<$_$P']G-!7L&ZM&FF4-BFP./TI,=+,4T+GP60726#0FGPR'!D&GB2
MSHFP(->Z %&PF5F)5M:P4CNGFG-A9&KD-?__<0O^.F':J=D:WFB$X;\=JK"\
M=$&\=(EV0&[;>;&#FLDF._=+C9_U.=$=^<"CD?Y;EC1/]AL:(DK"CLYYRB<'
M:U+_YO[ITV//_?/ZENQ58[8_)V!IKA1]*LBT@%RQ;\5U\G$74ZPEN?W;%=P+
M][SA/7],QX[^ABJJ47XVN!K?,UGVW"]Z&+*)J1 [2=:_N9)KUAZ7.0 :RNCP
M\(4BEX:15R6C7RE(J.[_]O/3IB[XUV:)N6S0ZC90#6@Z9)^RA[?AWL,\]==
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MW)>[/1[RS34K15:+NA<"0J>=1<W8*80M<?SWQVD>()%2D/^X*C0E*3RE9$P
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M8W8KH65Y@F5C :=9!Y9<,4LB,'?[H,=^">62CZQ,4?*O53Q^.B#BGXO\B"#
MGUIQ8*9UC<>M*<&7];]#QY>_/:'U1V'NBA&'H)TX,3R<].'>9U;8%KJQ%J+.
M$_[3Y;T $GL!P/&UWMO-B+>-;.,]U43NW=B>LIBG[G S+MI_TID6U:>)M7,[
MNR#'DN62+],)!A;(&O!*6/<=8C?OQS\;18SY(<4GIUT5NZ!;5M->,*%/!B-)
M72'PXA"#_J3O"F*A#B^^AWD<N,19U:^(CQTBSXEQA':VB&FB]D<=NKX+8*#;
M8I-F]&PNK#0&W'M<B94^91DM7Z6NB)[+;MS]]*E"SV/G;-P:_,FM&A;SY&#%
M[DRABERVD;1>W#(J(V+@UZW*XTC51 #Z,[S*,\06-F/1C04W(F7;;C1\-)N5
M7H"SXPY^ $H_% RR=P AP]U $_^=_RCP@36L,/A[&<+8"7>Z]O9$LNO]J#3S
M+&-)[#?F$;(C7S;Z7 I7PYNY;D8E# L=F=0<48I:Y3FFAT0ZJMA16!EPA:O5
M9%!ITHK&UTH;.<H?@[[J?02(OUK+7)FM?7:;0B#??QZII[_?<,<5G36N9=XC
M-4WNQ\LN@]#O?!@GOV/^I^X,G7@'*HKHL H%G 9^F0#?6++J9NR^I"-5AXS4
M!J7*Q>>*&?WSHO]@TG]\?K-1Q5*!(L?!=@H@>@)($,-/;*$;<31^S5G^*-=/
M%-Y7'R([E044\HA7?=WT4K-K>[TI5\N6D+OX<]M7&:ILCK(08L:7]>#$_GV!
M HBGH@ "%SJQXLYT##=<KC^3"31ZG[N64FK+LP+E^B?O2G[O.[$\9U3E8YO*
M->J*B!<RS3,]C6(Y&S-F3$__U._)\[H)GVY"H)EJVN2**HY?D'/E+??XB$@%
MZTV=038M!-^:'U_F&ONE W*-^LL;PS+,<[X"%Z2CQ?/Y[EI-%IKU_E5"81(@
M65^<=ORX";$?^A >O/!E:^PNXO"'\WS1H!A_(QS+EK*HW7+T-6^&-@=,Q]T)
MDG8_)*JMSX^(D39%SQ1Q@\6+U_/5-'L<;H*BR=]<NWJBU^26%(3&Z-:QI- O
MF58"R+>$T8U^H+>T^W N[N8$E8W*:ATT,6$ 3<)86/L&]9ZUZP%1BS:N__\F
MV[KP]7E(.C7<:;FR9NO^6=C:XRM?4 :G5@?CQ(3NXK.;93$HA!^[0%&#!^MP
M:;X TO6'?_\BN _<TS$VC^C:E>IQCT#; 5@)EY ;,A.?\HO_+%Q+<KBSQ*O*
M"?ZP@IETNN61K_B/@ZWI7NN +Y'M)L7;^P!51^!0$O2NS"@+$=1(-8ZCKL^T
M:#GV-EK4"*;T99+2?\0_=;BDU&+ZO=N?(@NP;F@9) X8,3+(3_G2[=G+A)F$
M5+OE\JQN(YO[<^;*HLF4 6LM]SM[K/!EMF>J)*V?*@@@H^;W< >%3J8'ULV!
M!I8.G!K.P-=DS@H@O8L,0"ERV";OS.^MBKK8D[ Y?LW!3>(_LSC64>Q)T(CU
M;R]B+TV]:!9_\T*Y:79MU]K,O]5=5"L%$-\2C?X=V%+BPAT0/K6C_TX@?.$/
ME!$@&T;?\H4RK;\JEV+13_K>EKBQ<W=URQ#F13PL:VXHX!J2GV!0O?S/T0<J
M!\^:^1?46\R)T%T2EHFP"9 Q'QK_ D'!YG?5%"RN^TOEZZ&<.ZXFY"J_W1**
MHE?R#&^^1(,ATCPC20MT$+&>O0Y+_T4&F!UW.B(.'D"\>L5;Y7%&U=U>/$#%
M_B5_)H><)'*C<(T['105:Y.=,]36[X121@20U)U[U^;;CK?L 4V[,C#.XJFE
MN?)3>:!"9/9OI4 M6T70S#2&K\F-]-=WY#<[C:[IEMOP7>V,=VXR,LSA3B)I
M>4)1P)9MW$;\?G^L4Q:T)3"9F@"H$"N,L*$O6G^$WJ5Y%YR=11FU+?K3 "8K
M4GA+^D)4A>47H=X&)&O\SV_S9Q4+F=Y4 !'%\.<#4U@!ZY;"8;_06O%0Z#Z^
M6A 7NOYDYY*U"!WDT+S9QCIKM*F3>4_?;2BKS>4)GD%:.+3^C]1X[?MH?D;4
M:OK.Z^CKKP.HR.$=/E<P\NY<Z_W\@V!&2-APG0#R$CO0Z;Z@G89N_C6:6S0P
M%/%[/NGME]1A,A1MG[G<:^_IK4E\ 5\)0[+@+_4G^M5]2PWJ;]\:VMJ5XP*Q
M#+X;5'>$+?M#[FD-/HRE;@YJI?7';^_F)0*]AI^X5I,DA_E#BT7T BQ=)K0B
M\\7!)':'7Z4!O]1W?_/O@BNH/GD5'T46UW\S!/AS#FYM/P/8,^E=)A[NYD-A
MX5LJ@8E'4FC [J"6R$(--I;_<7Z]K[ANRY%*AY & >0M*X1A]/FY1C'E#1=>
M 'H]J[CBZXD<%D"JU$;ZYJT7FEI]9)'[[A29K 3Z[\A]4MN7NG8_P#UV<[0K
M!E>$+15 ?&S*GAZK3K97. F_9:PH\=+.+"SC\YBQ:[!IGRQWYJ]T9AF)Z++#
MP'695W_DY<49@TUKOXD6I1_J.QX5]7SYZR.S15GZUK6>^Q<O'KA8TE-G#9M_
M3;PI.2J-0M>N?B3%Y3%G:R.DX$;M,PCL@TB2V]&>ILSP#9I_L!]S4XP&(+@D
MV;^B,2+M[(A/-+D/<]7@_2#+O!&?DIJ*[M7.46Z"N&[!S4XB>>&,![&?Q(>X
MG0G:M^I%A;]6,5H4F3^V&LGA5V9,QL<'&0+O_>]#C[_6^.POA@6>,VV"-,5B
MXX%H=C O9[&8.W)W5]\?<X?98BVY6Z\R<@S;1\CD36815QR37_J%72SD&-Y1
M,%,$_\3&!)LR)GHLDJQSYYD,[=&^N(Z+M_.^JU__V]N\>33GH\F'(S-2OUO"
MRWPI4Z])0J%X,!; BM :V#,YK0VCG@*(_ \_&4K-TN76I.5V^RF%8AN'GJ\Y
MX6970N1<908JYS>;L0_E1F(>312^WBO_<I]3W-&59]8UR/U'8WJ<G4RN-K#V
M)FH_>?P%=C:-?-FRA?S@C0=82U5S=\)Q/[KR8]!W?WZ!PZV#4[X6$!\_-R69
M'5():[P77UDE;\]<@V#;U_ 5NGMNG8;M>@6Z?[)LO-B]J<'D"*H$Q];0!'[C
M-\42@U1Q(Y<E[J(52J^D%JDSZ\GSS> -G:@DE7D@I2CU(83G;(4N. &X?_-3
M^RI;FO+<ZK)*4PX1KF+4DK>7.[=0Z)XX?U.C6CKP*;K]G&9U.*"-,]P02S0Y
MGE$1'<<6+OJ^8_X^<H-MI?_K)DI' *V,[N4K>40X\Q[J,!&\EIT'7T0W:N;+
MO;J 80FYC(C(LJ#(TG,H8* 0?.C'9//$_#HLYI,Z?!DR<L-TFWI,D\G"X"'9
M&ZIW=C1$BU ?!0*_5K3&L9?IQ9[,,5]_,+C/9/[*^_+2,LR1"(G#^IFWK6WO
M2'P.7O0P^\+)$MMY&BHW[+8NY;LUR-4=(W?M7100G5:[,H1MH+9)[P0^+ 1A
MV5O$1'58!&XYAD$0\H^*#0K)BM&R/+HVW/I2]):63S(9.VSS]DU=<-[CY>F/
M HA5+W952+6/D)Z8LY8HT20-,<JM\6:$->.N\+7]+E^%-]#F0=T)G2ZCM4<@
M3J<W96VD<8 PFVMG+D,(YN8D?2[.S:6M7%I0_-QH"M0$OL4/?VH;'PWBR S^
M_:G6/ Y$45TC:3:?$<ZSSEM$CMR$!P;_ 7;FP.BLC7H%LMC/X[9Q!;.4^4/>
M>33QL>3,=C-&WTKNY;N-JML*ZIW@JO<ID7X\*_Y$?UPD?B#!DT]60\'XMK4V
M>]VK7,A9G\\I1*T*(/8IXSM@^6 (%214."))LW)NKT"<;6:@:[J6).43A6FD
MU2Z O,?Z"B +9P(A@;G_'V?O&=94%[4)!U&Q8P45(2HJHB(V0%J.R(/8,"H@
M"D)4$*1&>@G)45!102*@H" $Z44(/?2H"!&17@*$$'H+'=*3DPG/S#OSO=<U
M\UTS[P_X00XYY^R]UKKO>^^]UA+##EG70$_P\^'A_M>@JW<(D^3? 0%<"?>R
M&VR'<]_Y4* AP7FV,F3N6B$Z/8'_0A[)]&:#,<D&LPX3&O_5K<BDS<+OU9J/
M<::!3@Q]6Y)*"H6]O?Y*.5LN(#4B4+NJXGQ6W?ZR"L7KK5*852:4Y:V+(B'F
M/@4E%3%Z>S/8/2$_*ZO6W(BQ,I0Z-KUA*M4K\I3CX@]AN2IY*PYY,S"HYW@P
M?6=F@2[S6[N@L+_J83R2HQI>;TMN^OBB=[GS/O?Y3;,%Z- _-+,L?O(?C8O!
MP<&3'5?^5-8(?O89ZBM7!A%N?RU^\DCJJ_+(T\"Z0'[J7$R"HY9L,_?'.JNQ
MYEI972RN^R3UMYP8YD^=-G_TX724\"!YON9&8H)?847?"2V6Z46WP3:_R9M2
MP"AKN$6]K+ [/C_\S_A2IU=I%3GL ),Y]2KIWKL74B[H[&<GM <P._Y9'\H*
MH+C^/!Q2^AY6Y^'DM\$_RE+J^A>ISF7P"#$,$Y/+7\K#7?2QUTQ'S^'?[]FP
M+[KOY\@ZC=V-52])\ZD?I#/O9#4<+>^>W+097YH<YQM5>OWF!L=$^*0GDVE3
MOH,3. ),X>@LTX[BACU*E1IGGAL@C6"V;P[Q6 $W?\)6AR,2X<U<PH/'EB.L
M]U57V7/_E0R^27(OKJK384X_)Z@?CCB>;Q7T?F0261?O(\?/-0ZF[%L$NP4_
M^]U[3G#$L*>5&W^?<OTQ/+:S7:C"X[-.=U]M\>A/'1X6PUXL'YUSS?PX]>7F
M7U=$+?W%7J'WYK4=330/4:.I5;CL.+01HDQ.FS1BO"HC9-^5-$.AT/#306&Y
M2MX'FU/WM@:J5-K*\'A>Q'1Z5<.SQ)08?:J75=(7J929JV+8XE<(L4VD_V9_
M/\F:/"F&U0J1K,#R&UT^'G+)DX".*2_\R_ZYJN3UU8,TP;"SF7N3YWJSGXS@
MY95# (YP()VO4<G0 PN[*"?NA\NNAZO*W".WS]T3PYJ&B&*8P1212RS>+@A]
MB![5$@Y.!7^<%<,&@:5/8%P:3[<NH=*OA'!_[MWW9(&*HO!DE.AU[/ DFE+0
M4_;'M4:@X ]VLKT8+-"X;@JH$;A#6TIYF'&OOIPC[<P \]MN,IRD%#&L4NN0
M&)8CPJ8#7=8-HI\D/GJTZQFI8.B:&!8L#,Z$3UP\\69I3G^P0LL:29W&B6%<
M<[5F88\DLK7WQB$,%R0J(E\O!F"CQ; [Y3U]OZ'&BW@;8'#2_Q63'E/\MIK>
MZV?I#P45<I]JH)@B#13_7H[(.%^ILQZ#:Q7AER:JY[S*8TY0IO<!/UJ"-R53
M[FVKSGGZ&Q@I5A$B2MBGY BS1?AX@&!D#RR\%9+KVQC=#4ENH>JN=@4"1(!^
M0W CP.@2O=H2ZDAE*)M\J$"QC9X+FD"].)LQ:' 60[>GB6$V\/&$%Q5J!8W=
MQILZ'H2G/ZJXMJ539E=5QJ*"BOH]6_:]X:QH,0RY>*QY:3^\GDTGZV&-V2U^
M^MKN)=L^' C)&.;QET\8JYT;S5)]^7VH:QS/%F+DOI680F2CZ.]A2JE.8I@C
MFMT_,R2*/S9E4;[\O\KZHCGWP(;.2C+BO7YJ.*16H+5+GIYS^.)PG2'<QFK2
M_*UHB4*=EQ&&]JAKFFRN9@Q[0;V7RU8E!"*LST^[UH?W8VRW):185=\.1FK"
M#07C?)P^XR/Z:W5(W51%3N$_OY0^_K(*GI[=4YV<5LH"Z '$_Q4<_Z- S4J4
MO+!**.L3BTZ?ZM.Y-JO&*_+YK*P136G+?6^AE)5C[BF&:1H#R/I54#U:._8/
M0X!F!_CHRL0]$PKQTQ.58=7+O]F:#@$S@4#OX&+WB<=2"L7@2TA&D/ZF.KD/
M$3?-($,%3;*M*Q+S:(CKK77&VC+/FJ_>*TF[=N:K;_0(\4];J%10LHKKHUFI
M51"<"(^WD"!3D6_,HB&D"U!4^.3.&]^B\ZP>[]SD/@0Z7--S@V][D;[P*/-H
MIFHC-TE:%")!LDH!S3)@I0RTLSI3XE#G\2PXNPYBRH;IY,_I^VV_,L3AX]/;
M:8NU+$737%X>?PM(+2'PY"O^ 5I";*8V>^MKN"%RUY/_.$YEO!/#M(9%"QS'
M$IKVX&3MHW5I1P,VE8=_LIW7?IU](?OWNY[W% N<FSNA4%[P!/M*VPW(>.5/
M9@!C8IA#^APSP]]G>&D8VO*R"<@$J)!$SBBPCRRD$5+B'_V;<?=_0JJU& DM
M-"(Y^>#&HO/:P/7T!\%HGM&?VV T0P3:+<X&/Q:Y$7>556:U-PA7MZ>O)\E-
M,!)-PK[]=M6/E=JYBZKVX0^#R<I+2MJW]% ,V[D=_:7>_Z\$FM_@\$9R<8^^
MZU;$\639 1'X;MVK0>T&;RB='0IB6(R;M/!V=AQ.A2288XD^8D_<AL(8-*]'
M=LX@T'-3UC2]%V.?P3U,P^!R)2*"<BL8FL=.S/B \PP6SMK5[??22G,%Y)5]
M>)OO1YT=V0D.^@5-=R@'PK_^_I*J2A+VP",\>>R.Z/;77CW(]I+LVT?>KU5^
MWFXX"65YQ??R[I/NC.=\IB7+%WJ4FWB[KH..7[OR0:OXZ3@;!-R;!6!ZQ?3]
M&M']N!\K@2[N8T8?5:;4_LMZ^#3/RS[_\PF$91!>]5TV9=2]V"0=_CX1U2R
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MU:(W5U55T.QG[C<J2R&.X/.<\XKV:#U_K1,80>W(OK_U&F$"^^7:9BN+)L+
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MBDF-/R1X^WU:S08$OE@AY)EV]18D SP.C"'&DCN,FFV=J(*\^B ODRIK\9]
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MVJO,H%C3)O^#9(@\L #\1M'E*3$%OG:J"!;]M!!"M[(20H(0 9XDD6/_$N%
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MQ::W&'RZ7XA6_4),.E&=Q[ZAQ28&7 )RP+,962Q?W$_$N&AUUR4"&\@30N*
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M*H*NV7?;?,<M@<"?!^ G[@6?+>H;UF%XZO+0:.RR[YY@PPOX+Y" H^NI&J"
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M0OHA#"RH(C-F!3*D:^8&D5Q'T)X @[)(DW*/[V.%D*<6P+(>R!B>!;U!^]P
M9BYRY44#[#/LKS,G3<0GAYJ/M#@6"DJ4:]%O]W3_ZC",&K [G_KXU\?;+M[&
M\K?+@Z[8G=N#^EYXO,CM_9:"/@2:\U1 =#-SLN2W(/J;38!_YA3XIQ7*M16"
M&<ID(6023V^%Z<=QI/F_M%'B12YJ\8T2E>)L[3R9M9Z1FY]"RUP/W;ESI2.M
MM2%AKXWA!BRQ]Y;4& 9^%C1/_MZ4\FG%+(++ 6N?ZV*LQ%=5UP3\19[SZ);>
M6C3B%; UJ,0U9$]VGX#7;3N>'HP_4<&^-HB,NCMZ46G/JXP/T5F)LLB#UV60
MG*_.^XX--VILVH!$KI7T?'I4MBG)L/4E,&S83T[K7V%/MLAR4OGRH#G&J'?E
M8QPGA?]N=B"J^^?X6<1+"S,:*O)=8G7IJ<]EI'B'BW?3WW10*V\.Y!KJ,@Q4
MGJU%0B?)?-6Y;ZQ*Q(N#%MP)X B2D(E;3AU._<F&_49,%'1^XL4$,!<5 OFD
MP>"3.5Z^'KY^K[RE372/P:1\[^J$R=AL?_K:1#<??N3N+A/^ECRQ7AC]:T]_
M1&YX1[@"]UR09K V9SMC\=<PQ3ATO$:D&53.=7LT#VKD3>L_'Q*A]I&FMAZ+
M,>>>TUXJ[>Z1MV_%;5?8;G2[]Q#6-TO>F155=E7G,F=D&4_I%M0*2!QQ4('B
MR0S]%NS]/P4W*T4KP7=-@&X-<!ZPPT/:A9"SL_]*,&AW58OL_$R?$'(3T=A&
M[4#1%T0FN2QH%4(6[[*/K3CO%D)415>\1;JCRT=%"/EC]>^BF08S<5GVG8RT
MS&+%GY0Y7Q$)IA,%PR&AB5]<R7HXIZ5 5K)\U"'WPUF#ML^)F4\"0(@T2A\D
M]]E^\=?D^,%DU[@7^FB;Z5D:8@H'Y#9+V05><0)/5ZLN-M=S<^9SFK,"A9"H
M\P)DQ;Q'G\)W@5M3A,]11\;/UQ<Z/K$:!N)8SI0 :+EXI$:';DUS1E$X>$2O
M,W561.UE[SPMZ'OA@7ECBS)FX28Y$O@<?FSV1\ V%!Z^Y#<_?%?@ILE#E,<S
M!F.;O ?&)Z#X:Y**TY>UP)P0$;>J&#W2/,OUS@0(.L$)<0FC@A9_A X0GA)C
MO3M Q/X^P"7 B<7G2?^73,3C53P#O?[&;J$DS?[[9=SU0U$F6)&$MJ?.0X/#
M=8(,?0WD9 1-1&].;@W*9:&*.BH&,9%'^UIE_<95N0$?S 9CNX%E<;[XE#K5
MOQ]?N7Q?"+%:F3%\6)9-F0_I?;[,;S6:ZJ]Q#!H:K9F;,U+_+??[ K"D@+O?
MSR+@!/+3H)?/XTUBSS/7MV+]Y33/]Q*:&C_G#R=:)E#)CRY"#B4IJO/]7]W2
M2YP7 'V\4(H?[KX W968H70NVJ-M(^[,DX(^Z#6U5S6QQ=NU9J +EG<=G^UC
MAD*G!ZNB!5?55@&8GNVSC)PI#<:8RGN#/#*3-?N"XC-]3_#?:STO$J>1,U1:
M.-]*9( FS+)EAZ)NU4]E3M$)4>%+.3GSX9T"SWJ2*,S>9[)I+7?/':&'FX@8
M&Z?-/.4@_@)NX>UVY3%9Y$.,+F_VXQ\7(@E18MC*I2Z)#2H25W5ZEP52<N\9
M)TJ+[YJ8[ @*W0VV (B2]%?:TMA?'4+(SI0TFQNNMD+(^W9U)DN.XO?;;RUD
MZW<4I[$]\89M]8'58WC8(;&YO8(WK(GS&(1-UGSR,U"W:ZTNVW?_"=(%47C7
M'_[:CNXI,Y[OV!M(6_K^/.;)?5(C8=_&[J[+.[9_%8$+2L!FCB0&$$1*+3S=
MDG"RRO;P^,)Z*7.KIZWFBX=,Y&W>)@2E&BH(7@H^V]ACKL)5VF<5%F8G=7$+
MF,S$<!-FZU#0_]U1V[S[?=@#JI_*(6,7]P^.\JEK[B@^NM]0W<16XZ3($O!(
MBCPWJ"NT#6H<%+BI,#!\0B2>AUM.][1 *5TB$C*+^%=&_^0'Q=\ZMH+I(>>*
M9:V:L%[9'X_U#@LAD:V\UO+1ZK \-I"=Y,P2K<R_.YG,]9N7LYHCV5N"#[K1
MR!RE2^PI(<06]R#DI]N(?L?K5PFD%)7UTOE5>Y"SB'D<F^2PC53&QQIQIVDU
M_[54ZWK^;?WX2RLS9IT2O6;5DW'3H'VF!I#3FW*L1,KC,:NC_WRW96QV_H'O
MHU]A*Y%1(E:"U*VS3158#$,-$Q\+(==WC+>)7(FX9>_>5\^QLA%I4A^E4CX8
M7@UDVLXSQF=IWI2 PC4GDFY\Q,2/$&6$/5'UU%0*+G.=:&"$D*,$)BMZ;$ ^
M,N7+\@QB2!:YM_(P[UZDPM!N;X-[&ED9%;#E/6[ +SI-H@%1))K/U9F.X2!G
M%A=&^.:$"'3VV]D5/\2S\ H.&7CU-MBU:)H>3Q1"5M,$ )UU:=+#:QD;YM^M
M5/YC+(N': 8]PG=U,3^"CWRZ?YC4D[2 ,<P?V)UQL!0N#1V%7VB&A4<;37.#
MD:,,TIQ; W$?.#)P($&G1;V(%:LQ>>;\1\67@VNNRG:F^@<?B\M,9;\7!+(V
M37N@W$B]3X$<P=T9VR;94K4Y=[R.JU[M#K#>N^.L1!4+',/WOOW3)JF9U@F:
MFZ"S8F&>F&(7Q+@<5"5Y-U 8%+/E&NY$+"CQ5DKSIN#6#CU]_?=<'(?(X&DA
M."X@N7^17"[7,VY",M!.GE"K!N1#)+-MO840Q-+D#KKZB?C9OU1_-#@R'!_2
M<T-NM8KKG3>G;GE@Y47\F>%$99U2-_O7,W,T4S/;N5R]2AS']OT#BN),Q\%D
MR';'U3G(%."5Z%FM5'CTV;L$W&0$5LLJY\*:,?\'N ^X0"RH6*7NJ;96K[%Z
MV!J9.6PKZ^=@VCZH<>/QV](K^3=U#8V-WCD?M,R/A1_OT[#-3]/.MXX=O&/B
M62>X,YLHZ:]^,NJT^:\G!:VOD LSI)!P\ %.#-P3\@L[CO9G81W^"2ZI>#)D
M+*#^< =S"H88P-+BAZ*[SR]:C*2^R;AZ/ Y=,(%]Y!ZH5(*YKWM/%T5(,Z9Z
M[LC^D>*I<K+&5SY<E3DS$9+&.=*!VA%T*8#_EB-;=8EGFUV^S]S5G=@<3:%8
M':O*Z<'[/WAU]+40(DF.'KT3#V]Z5E_AD$9I<X?9/='?&R$*&\W=[!HW[M8[
M;=L3Z.1X(63;L0PAY WJ#*C%'YN9#34,\1X./%=@MG-QMK;'(W*I_**<UZGI
M@?R8APF^?Z0]K[>U0!-_7S\NUEJFSB==JRTP4M3\W22]M?5/C?/"@<RY IXA
M*/65GUQ5$-+S^%%U8C'OVKT3#_K^9JS.2V9F-=VW(G]S3<O*C?Y\48JM1E2Y
M^N2QR>L=YK'W AG7-"=;H[%_<5/B'*XN%:8;&G*'4]8=:/][S99(]LJ@_C9S
M]'_U\_<MH^)+LGZIA;/I![YCO,^5^O@B?6W>JFRO,Y[5"=[A[4?5;4?G7T+=
MNXV;F+G_1Z=14H!XYA6BJZ*J:$:6]^7<2GY>\)'T%_9-=YM[,Y&HZ^QO^7N.
MHU[ZY(&?^FV:'>$.B6!Z&[L/5$_>Z7/F@=3K!X>[-7955J6HN>U[K%-6L>BJ
MM"T]P*JUM?4WP_GOH?XRVJ7]NRZ9O\G7:..KJLI_G"'RG46,>+,0<D[YH^WJ
MYJX*TXFA)."[NH'-"*O;WXW)KQ:3MKV[L,DB[<*YLOBY V<^]UY/RM<\T>6]
M@%)7--E.+UB=.8UN:6]6T@';@',[P59"#D"38/?:;2Y6Q[O[9ZQ1DNRZ>3"9
MS7X,*J5-Z6#4NZX@L_VIVKT3!\+Y6S)N(V!MP8:$!;1/_P]Q+/<[:'<(Y7US
M7UN[%T87=6E"USG[MDAL+&? )CB)PYZ//P<#Y<MWY]X@7@DAH:MV%]Z'[]A_
MZ=&*\<6O!1G?IAKTK_X)8*R(ETQ.JC#77V8%B1NW*O^Z7?,\C9]D9XI6[ZW,
MCVYF+6J'N-.H';Y$D^_56F%%Y>9)5!/S\JQ'("OMB('<>:N\#Z>NQ>YPB'QR
M70<RQ%8\T/(,Q[3Z>H*@T;;&E[AVEJ<!Q&3'B0C>=!8_762&:,D.5(SU@F7/
M;)^:4].?=H_\@J9_+G)<^9_V$E6T_:6N]$[:JV:<],JU/''FX;D#V[0*)\K*
M(EY,=_(;2'2[O1[R8T9^W6*;1%(2\0B\4]#T-6T4L?H1O$?ZJXXQZ2+!>/Z(
M5[2![R:6AAMZAFI+OO5+!\9<O_=Z675O%USI2OJ-LMEZ8R1S*Y(XM)+0<.8;
MB''M3>Y+'M%]X E#0U>8-Q'+>-P4YM-,9-+3-64ZOIHGDQ,,%BAYHX[3$R]M
MMBK;;-DR=#=#(P*Q=+3XI7')@9ZH?Q8?;+RU=42OF(:[2=+IG:X3H! X/=/[
MPRVL@>^%%I[X@\GRSJ\\5^3D<1-L?ETHE)\)VG3RM=,7,'Q_ ADWN41ZP(%O
M?'SHG;/TTTQR=[OS'/T3TR!.(0:[%F;M,O%>_6Q]V.8W!.S^2G OJD1@F!I.
M<GYW]72LC7-+&'9A%B;R\M\BTORGT\E#^4,TH-@RQ]E,0<;89Z32_!:;DP0#
M$6_.G)TCA2? 3LJ_?/CI$&)S7\SOG<H.-(&=,[;N-^>=$)(3;JSVXI+MO2TI
MC*^<@T&!5GD!B#CU)TR8GA#R\V6HK;]"X%)D94^269$72OV2;9V_AY$#_FI$
MNMOX]7]>&KEF5V5]VR8!UUBYV?IMCVZ$DA\VK]S8267--?3&V4X_[>R[=FLC
M5B?#>K[Y%DV+6)&.\J3J2H&W!2.T?2ERM+<Z,4A7'[V05S>8Y&Y66 Z:'_GT
M^<A7[-JW&"-)^&26[YE/3[.FS9]8#1H%TX[KJD<=Z@KJ%.AS0+N;U8@JV@'I
M9]=U3MN,.+WZJ*/AN#K3!VAZ$-?"K/BE0D@5["^BL!J96X60'1 8[#/T8;!Z
M94L02B-IUAVODK)BMX]]O./:68$VVD(VWHUV!)&41!=SC[[6=*3D4QUFA4'5
M#>=W@8$)VZT6-)GDJZO2A-#3[MBUFZ0_]Q _AYA$GL(X!D8F10LA@T/C%!Z:
MEY>8F9E;X!VS\7W]-?!4>L^O"*<)@:%8WYO%Z]^7>T?QN!;<U(S*'K62K7T.
M;N^6N]Q^F!_G^HA4]NB^>> M225AM_FU\1HUC97;T7\1U.*)%>3T0&,%K@D,
MG3T.ZX>6E8"KG4+(RM5^1&-B@:Y]2-HP;A.H'Q*W4--2RT#?=^)YBP_:N2DI
MR!@1Z)41FJM[+I-W&!Z[DV[AZKCC]*$-@@T>K!,?5&(F0L+[N]V5[(=1>\[K
M'KFQUUYC1=YQNOL4_QOHQPNN07QIU?-_03I<C=3D$X+$*ZOJ0MSE4BGFQ]ZD
MIWW[V9XVZ84L\U&\9GCBI'%KALW7X_DWL@MO7_>2-5AF)$,Z%Z3GV+(O"%#4
M19WOS1I?+.C\[U4#B2*9B4!/.CX+RV++FY=68_=B.6)8S%"WYHV6IRT';>;4
M6II?6ER4[MZ5UEA[.NOX9G=URZXKD*36L^>8KK@2V/2,=_EJSJ]-ALAT[VFP
MMR<Y?H;%LN0-"5S*>7N+U:<6^A/W9E?AG!_R9/R=LXK*M$64Z<7HHXZOV>,2
M3']+LUT5$Z [\.2G086'/^D*$8>63.]G)]5T4,D?][C=O&7>VYG:2!?G)/']
M.4VEU?J^(8_^+"D-UC*6V)9P7FSV7&[#CZAWBX4A9K=W)MHJV%B*G<)O4'UZ
MP\Z@D<4K;V[:M1;S7H^!:$TU"0L-^XR^NNL?W*N4:>E1/7Y)=XQ[9-W+H8";
M3F,_+2*^A-[ +IW*B;<9H3<+(5\/K2ZVM3)W@7&P%0;&T\/]C00KU#"S?R'S
M\*W:AT02K!-4@>>_.N.3_>=/Y>S934&1!0Q1-%^OK]:OM<O4K=-IO*GVQ=,
ME]"Y&CP(:8L!N8/!3-8XCY1M?=D#U.?#+U/BMSGE\K*SOYK'91^VLL3.KCV%
MXBLZN"-D'!-#/%==O6_LJ4/\3%#]V,@W_'E]-X%!/@#K[;,W)DGUINR;5N]B
ME*8]Q2#P<P@Z; F@%[@JQLUR3R0'+<^N*)Y/M)^>%R#P)1J=J8&3LXN)5N-<
M.K@JXI"IU ;\]:G9$U4L]RV3^%5,[_+?!F4^03SIZUAV+%ZP2$6ZL'<@83SY
M>.OK]6>V?15_B>B>[)+[6NTV-S]7WC/Y#92IRA(?L1&I98S;*1)$ ,C3"!Z
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M[ZP(]</VT07N]:'.[RPM27=> E59"2HF$U'[IM6*<FX2M-_OOT*=WGXX<&]
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M^[:]LW^Z#8;<(',1%?:^IC%8E';6F("7EDE,#N;*H(^]H4_N4\%+$H_!-BM
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M9## !*#28EUYP74A=I^>JG[ K/N="]5@^X X9ND[ZD>%<!3 @"$"4Y$%U.'
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M$T.QAQ]U?8PMOIK?W]X.8@-0CM8SXU\6SFN]"-;^<HH/65C'&>.?*)1:AKT
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MGI.,P[.Y8LM'%4ZMFAO!9[#<8/4E28WJ^C$$9X8"EB@:'*M9HY:+V?5M535
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MW5?W_Z&$5,;#NX&?T?@9$L90OX4%:&<\.6RWS_%RG[75I-M\X6ZSQ!8(@FO
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MWYD3R]FIT-SXJ @^9M1^NT\&KN:NN]763VH9MF3 ;D3O^DPLLYB^!G\WK^,
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M4*\G.!K+_=WHC'C?.Y*$6PVK%(P)M&3 =7H^Q/$LE0'\ ,OI'8N%8P5)GPS
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M^K_'EBY'R$$;X?+9+7 3(-:!LR[[[YQ-O_N), .[+$%5A#_)BM"'Z'=WG#L
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ME5\/KEKU,#D6.[244C\W60WOE@%:_8^%[A]D@''FQ>*PN%+/\4N4<7)H/2_
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M4:5/J3* Y ?U2S]P<B/T#;3; ZP_MZD0*BIH_XL1X4O"Y:Y!,XL=38@O%F1
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MS;27A(+YR+LX7C^S+R:TKZ04DCLXTAQUNZ"@VT9W6O60HU5B!>J4]PU.1"Z
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M$YP:7/VV.USO$W<7Z ) (ZYP<.5+!#35<\'R*K'HQH"=\%(399S-,IGT\\G
M%O4J[Q,]ZKDL_XR;K*6S]F=.#&@KOV3/I_EBR)K,WR_Y*DHGV-BO0&NO'<6U
MS&'A!J2=72=9J,5W#-<QG*71W*,T;/*BUH7H5R']8;]32<,O>:#D[Y$ N77Z
M+)0,=_C*YI;]9 "??;Q*/*M9PKHAH33:]MA0/GOI+B14+0BN=,XG\RL<-)QJ
M)N+>684-=^UX);R^_%2-O6)9_R65PT_?<<YK1DW*4T+BGU .?+O7XDT9&\+
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MKQ'S;;HFT7S3N):=_S1_J>!V*KN@YTO4'L@='FAO =,;5XRH^!3 <L)&<7]
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M8D:#:EXX)>?)EZ^.O[_)V!?OC@RFY^4['Q<['UTHH?>TYNP&+F93CF.0'[>
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M;0GE@_$0B;Z\>O'B#BDX&R!"'%0(/-!+.9*/XQZF2_6J<?"AH9TA,_=WY/%
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MEC@'73^=.HI[K*Z3BJ;6-6NU5XR^6";6.KRM[MQ4+]K2T![YH1_SMCN4L"F
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M%$@I;1>MI\+ /6+8>_?*=D,DCF)EG8$-Z=+"XL+[XDUO%1:)I#.X[0ZC,9Q
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M$#6;6V1]TOZ&P\C&=R57XI4GWF*2]\?+_/M+0!M$A!E?G#8U^S^G;ZLR6S&
MV0HKB+K[2,$W[HO/L+4UDX$\D?RBCC)7,:#8( 9,40R1'-F'KJOSOZ4Q?FY
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MX[%3RV]-^:.BQ5I/Y]./0S<@E:-'8@Y<P0BN%]-G(4],/J-O\M:QFTKSYUL
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M=?&;QDD;U!GCO8U6C"CGS>K*]\;FNUR9\YQ=22]R&V)5>;O(3[\_/<]]U%$
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M\\Z/M;T4)&:F[LF?+" \_DM;Z>YUZI'L<\OZKE"/HR>];L.:]<Q6DPE0P_-
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MMA!G==[*W[^CU=['P!33=^+(MR<&XD?>C(_$+TH$IA_CD8[Z$$(I:W7X(66
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MNY<5>7FH%(3:F&3AU6'U0S(,BSZJ4S$5<?Y,*S/Z-HD*GAW]6+,(\<=^V1T
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MQH/U/]521Q?6^T%=O3K?7<OU3-9:OAV16,*PYF^\#?8@[,T.4MC]$M"=G*[
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ME=/]&14PY.BC0+#^CPX;TU8+;P_Z2M/=W0V@$$L-G"EFSJLCDLOANT3 ?6N
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MK9R5WRSL"57R?5,B"97LK#\LK8NODZH"[Y],RDI;Y[OM;I(E;=H7?E#@KFM
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MAI&&_C[_X:VHYIN#X<=1#GL(5PO3H,YA&KW[@O'"N)4IZOK8,CTF=M+T"54
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MI?KT U[S#W6.Z69'F2I8[87_U%B%91Z"S6V,88*T?N+](2 \R*+"202%P:?
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M?HXQI2\&KMU7$>Z)"F6GVK__$"@XD)#S)0I4ZB^04J33'[K]AC5CK8_ZNP2
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M#%?V4M/7>W1HG1L?D.%':#\-EP0>UB(0B;N*Z6%?_?\)\!(>X,'G.AIV@;Y
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M$*Q8-<I;6@G./I6H= );^,N_B-II_KK^UK<7-T,*5?<I02>GIM6QW0 [BKG
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M95V16W(\_E'T5CJV R.ZKZ=C3/U5CA?) 971TM'/VO%5O^<%*X< )^_>RMF
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M  ^/@9\PYNB%=V%/0A+XX>4/BM.H^G+/9HXK%"$8*Q"$2!;?!=_6I0/\RI!
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MI\%')X(YNI=FQ=W)O;K9^0/V?@:F"9G2*/>%LI&?E7R:^5O3-&&#@%JK+NK
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MPQL%2*GH=E-T="%TKM6,.'MRBGQ=^471UC&WHE.VA-+[WPX@3P73A_,<>FJ
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M!]NZ!^@LDC!:M>LD,3JOOD@G7#\JJB#N15O(DC5V81C5:\XAP>\EZU"'+RT
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M5.7YT?$ZM5X$ 2KY=AU;?D!Q<X?&Y]K-_J:FMM;C@8T*I--Q/ZXJ:\[4+A>
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MM6M$[N,=0VX+T]8H&G1C&7KKQ==2R-ZV_C:'P)5 A,+\Y#W!0&0!J;8: .V
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MME:X6Z"=S(/"GJ7MF*%?LE2Z<#II'V;:]JCU1SNU>@=6M465XPFX&/<*]SL
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M?W_?_GLT+9)32YBX3!@OYR#^'#_/_][XY3L-T\20"6/1A(C*KV?H:0N*@.R
M>,&$1,JJPIC:0@N*$P&#DQ (R62#PB@@40)]_[&UE+^VUND_04<6PJ@Z&-XU
MV((DW1LMAL!@?3J<>>R*8)_H5 A8T"DG]FCVYT;WV;\D"H L//Q8;RZQ3(*
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MH8D41$4KERH]#6C&-U'5G>C:%>?]ZT@LV)PH;<G8A*F4R?^+"Z/*,9:=4I&
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M"V#9*Y9+^2ED9EIZM\/&@LS"Q]<P9?GC+X!LPDIO<7'E"^5]B/TB,]S])K)
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M-'C.;WO58=B3J<,#A>]]=T-G8,-B2!_2O?U,*NTWWU?-TWII,]-J*H95^$-
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M_K9S1_%+XR77=5)"6#-KUP+^Y(%7HV:K>"'D.09=>QGVV=(*T')Z5>F%CX[
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M]FDE;-!3XP$^951SR2D+TL;:$P]SX^?%ZJD,ASB.W:O8-?XL0&D@!*26?+B
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MRZD@S%,RJJC]/"2[DL(CHMH_T5443(]^B'9/G)[=?U,&U%8H0(;2W[1\$(R
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MV@C^&\,>Q[#NS9X=W1+_609DP/;2YSS\*+_SG?#)SO@<VM+3RTR;M^]+C7(
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MG9:9VEN_&J^!=8&CM2ZL,B+HM8 BSL.YY]'2VZCM[?>ER?OA#*@QQ!W"C=X
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MHM,&OAXA=)T=,Y]<'\L^T*LTB'1LS3.]RM<?2XHN3&JN  &4T >U"U1B%[\
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MB/ K_7F8!&@%< 55&?$UNQ[^;NN6.I> 8*!LO#/\<&\I=#&I?8)8"<0J&7B
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MOG.F6340F'./:KE+%C7BB1Q229'5TT!B#/-,/$PL->F.:D<4-N%UU]5RJS=
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M%Y?U*CI.N%2A^\R[=T(+.T8/^CYYI7-=YX*$$7W8R?YHM_E#+J>09H]5&T[
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MY&B&J"@H-$P!G$8/@_CMK^=AL>5;WNEMF+2-32@-DCYIV&Q]-^+PQ[N8F1$
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M^E4:<AE)(=X"GX*7@>8% ) [^H[>\Y+.@?1>,? T_1K^$%'.]-M96/A6C3*
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MX.1KZ(?7H_ZI*_\?A%+ZPQYJPO=O7/[0R_%W47N2KR"7&C>\FO&#F@ZBC;1
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MF;NY!AZ5/G:\ MNKOW@:]IT40^C"R5=J@F"$T>FZ/'+,: && Z'I)]$/86U
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MV9-5(?FI)AESXX5FBEU'1MV1W-@G*<G@"(4BA\$2SJ"Y+=VZ:=GU+B>8;K*
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M"H66LX;31EZ_.C:G==YQ;P93!"Z\:T:O8/D%//V^7//5=_THL._5<A3XEO-
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M4JL6LTR5WNYGR5^W".C&OG>:'CD.\ :.KD]Y+5G*R%.$-^^+4U3-;J>]WAM
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MX?I\\LP3?D;!.W^);+G915)[ I.(N.J4A70\U9KQ3]#X5-QAM8) WY134O-
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M$*QCA_"P:F-.Q2NVQN<@@GHW+. NN3)#%_D_N??228LZLWFX2!N+D^]SE=$
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M7+=+5;?E,>"Q[A-%YZB6^IM[\T-/S#C+9XMYG"X,$IV"GH7]= F#?FKVNA;
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MOD$4M8>\:3^2#5U:I-0C-F?!:2R*KH@_2,CBZ=WS]?COLP\R2ZAW[H/7'NR
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MLRJPR13*8-.8((+8;5DUF<,!#->]#M9[3M+R/S^/(H#V%^< W1R@>CV%^G!
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MM/R*!A<:+ *Q6@%_RY?+NFRU>$D$^LK4AZ$(G1+Y/,GP_HE/A-_U>9T[Y3G
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M4@J3?/2L!LV53IUMS9'B C:O!).^X1@XY!J^U.ML- >8XP"VN=]DJ81?WM_
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M).9Q(#,/?I9OD1?-<_A-W?CIB[=?*Q_-J!W-NKAVDW\[JW-B=Q,7^K87:AP
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M>&L7T37J33]3TSE'Z@#3UW'4T7$\(QN]6>NF0]VK3MT<AL?:0;$D:G#+/@M
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M.C"0.K_I0@O,&O8'CD]Q\)4L_VWKW#LF;BQ6RM 4I[G=;GU'DN0^#YKH:5Z
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MU"\"[PDS(9$?3Z>V1X]K"@;W(@3C/UIDWHF-P7Z-H L(LW!G'8\H0WYZLE"
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M_@1%1,0-4 3B"H(B B(* @HJLH3(OB8MHJ(H1$! 08B($O8=PAX5(2)BD"U
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MV/\ QAF7V&MR;VL/?F[I\)V:?6@3&^C>\S,BBY"!&%P_/,'A9JGIA8PH'37
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M*Y!)0P,B,+RHN169\4H"I",'F%=&GY2P83Q/T0,'Q]/!0U.B/O'YMJO]E<S
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MT)7[==Q?KNSN.ODEIK@OPY%/R2U:C40.<B;?M[R"<+%NI?<5RL64KHF4FL5
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MOLP6K#"X-<^I;"_D[X''9:TX \KOIB\TMKRRB=&;%QM3S7LD #-C!,U[H=_
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MQW)R<NV/+"4Y&R;=(9=.1FQNH'_<^G% EB]0S#>#J%!7L/$0W+9#&&0[A.>
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MT;_#.V+[["3Z5ODO\0'] \MU[6Y7'<[5GNZJPT^B$IYOI0K%M6Z\"\NLVC;
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MWV..9C!(GJ&7I2V4G_HEWI-M2/C[JV LR%@M$Y3^ES(2G7I"B-:UPP<V(@6
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M?AD&JJRCE9#A-Z(U$K*L?!:[[M)V?M6\E;EP6/-H][ZR7T;LWE[HE6U\!:/
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M:FUCQ*Y)MAPUTKK:R82(-CN^J[?";YY\(U+SWIJ'VSAM6>/3E'&S3K0B/Y\
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M+@DARF7OFMZH%%4-?U.6G&ZIN^%TX-?TQ,3]CQ?VMP=EC,6:$%U[W3:I\6V
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M>2*K\G@G=!ZQDEYLCJ,)XA4KA)!](G0\Y<A2G8+_<6 UE %=D88/)7<[!(P
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M>+E(&R;S$)SR+KY4INA&,G@:Q)3I\4O949*<#[*.0HBFE*-@"L S<MEG*^/
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M J ;A?B)-=;ZZYCF?V0I,J9(B4N$TZ&$P.S\0GW3P%B#[.B=%I,?(WG&8.W
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MTVW"8YWD9*M#FKJ'QB+2LW5NL+ZNZQ8W6=8ZW95^U@C&Q[)=2<MD 8([A&I
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M\4W*2^&VY/;C2ERJB8-JD\%M,-(Z9ZD[Y 131\VTI-1N ]TT=SFK5YVD=]'
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MQ[KIQ=\&LQ&6?19"ZK,+CCW\4ZBM,W6#W7H$7*M"U,_5^[QD%=X2L0REOLA
M)KZSKBXU#QR2B ='4(@2O5/>S8&U,I!Z)OS]-ZZ"[)=31G3<''YH8ZO^2V)*
MRW16AEL,-?ZR8T:ANNA# P946HEF8Z?DYQ0F IE(%+Q/RLOL0_Q1YX_]9@0=
M&6QIK)Z(KQZ4<B+\'R1])XL]8;J IIY7$?_:P9_?;T4B3INP,;_TJ"2 !>H]
MPB918$N'JB/7FY#Q?ELW1'X>H,G#QP6-,'8LD#0\'OLS+31;-F]NV:2WKM/.
MDA8<@AZ8DK[$UIB6Q_X;-I9OC\%]!'VBG<IWSUP'.G]K6&\54=[W P<;)C>/
MP^Q)5>][:;'%HE)=%',CWMD6NED?9)OX9OKE0^CR.B8?*.HINQ(Z0[<L05 Q
MDGDLT"3I)[R2'!N4%?_^$GF%J_[V"SDC*T/K<!GA-#X)U; PAC%UM^V9MD"]
MEI,"_IRK_@EQKLV#B<IYX]T"$[X\6W3J3?OMG9VW<*&O&H,0E_;F7!&A%'_H
M3F+B/Y=M_'?8HK\GJR/)$3R]9B&G288]) &9RM!%ZJ 4\SA?V?I*,5S*>;=>
M]O5OOP;&FD(UB[M5'YXXLP6'7I$BT_W;P)7M9B,:7BL-?<Q;>AER8S-\4?E4
M _41#S:OD#)ZN"'._R28'+>!.1218N*4)C>-,YIV^ZA^[E)#$QXR((PDJDSD
MN?XH82S%GWO/".%\7-JZO[0T" 0< K+IU:=Z-.2N<'+2=@[?#CT_H9V\L%VW
M#T4 D'DBI#6@:W#+GP4J)2VR0/UTZ@OKG/A>]IO]\]CP(\=:9^MMSD4H&>E@
MM5'1WZA$G=]E-LV,VC/* N7YD+)%OH]KQ6%>R90OZ4%GZDT?%D%BC#Q68/W'
M/4P#9?(5W:'/%B_*'C(J]3YHXP 9F.+<2?"64A[WE5,Q???%YA7$*G! Q>U8
M9'5!#/*#]NRH&&0\V-2J56X;L@2'@)$^$5#I@75"A-&$'+7&?*?G[0E@I0;S
MD 5"$SMZX,&/0N'Y_M9I?ZM4QMBZ>CK[Q\B?5M7\%_!0/VVCWM"MKJE1&#!M
ML<;_ A_9M5WM*\% IL\;T>\R,OW+ H3&JZ]_9P8;1- ;,-$UORG(XL4;/O(9
MQ&;?Y3:90.M5D\BL2*E'I=!5IGM3NN8I-)]PO?\QK5BN<O W%]_G$T$_56[4
M;K2R0(8J;0/[2+'#-"GW7 -0;F<Y=XY\9MVUP+E<U0S?Z8Y=HN#)X%^PC8U#
M/@,!CREWPT:'JE$EA9W!0:B;?HM$VZ=67/)[P&6U9KMY I<( HSGL+E6;P_&
MHM/^QWWKW _. ($Y#XFT4<'Z3RB^*-^W@1=T@YXTG;R3>;JVY?B)+7EI8<5+
M4S?T3X\<=(HZDQ8JK!J1+//%T\,7/"7=+STLE?63*Y?,Q/2.NIVC N'(TH3P
MPKR'R<![H*X^G3\6=I< \V6!#!B009(FL "3VR93PQ/\2:9X('NQ$3.XT\^9
M% 0I71KGF.RWI@^2S_K/2S%_*(C(J!? [TQ>;F.!!'-8(->RW/Y]TJ_ZAI&+
M&:%J^CXB&_!;J*?CV[S'RPB4 .;OI?E: @\-N?)D7D(Q:/2VF4AM4_$/U^Z)
MHP:0;X\])5\Z0$Y@LO-I62[5JV8GC R\QO@H@EI#OP2E^VT.?<^Q^6BH.();
M8O@2I9Y\IAS$OME_,X.PQ(>270HWJ= -,#!_G=!O8"6_>.%@;X?.T3DEZG$<
M"13,**,"-?,,0G6%U3K$*.52]!!>JIJ0]\>!#;;QL,!;!#*%^A>4SW?[344/
MDD]:$G;JQ&P36U0XM7=;E'6L]ZJ1#"QMM>]J23QY\H0YS5;)(?^-T.8NNI'6
MR=^1#_S6!?=5ZET<8M J'"JFIYI&%*=O/-HU1SN6JLG-N?\VKIUT9_'DW,PG
M2"9)(V_?0$7J"94JD!!&,HQB]V5N7C$(7? LU>'0!D=FK=[4^:3BVBWA8"/+
MC4,3<QUDM)I1N6/V]'+\XMAQ9\;FRI7M[[^AS5B=6)[21,@@8N&*/)%C7"ZJ
MDG$C)%Q%;9FM>E-^[4)WB-3!KT>2'"*61CNCK;<V:<=UN$'<%VC2[[1ET80"
MXJULK13%]TH(<PT;?Z 800JEZ4V_6+K%;]F>MN9$J/E3JYP06Z6(RV,J.RFA
M[;SRGJP;7[$^<JNGY.:96 LQD_T(2EMB)UL!G E$QQ+C$JR]90OW!7J%".YF
M$B[*.:RS[F""?M0$)Y**:1\H'PK@:P'F>39O9IY](Y'>6^EVC50B=_,@5\2[
M/(4/D!]!^):P>X.51VN/[!,3QT%[(R<V#J?:"FB0'PS2,5W+DQ^5J@O-&5/>
M:L+VL+*,GH17ZQJJD<V5$"N)JP^/86T]O-4)F.;X/.R8]L!Q3NB*8-&]2#W=
M:[NRTC+E<S*R9<\X9&$>3:^KO!D][#LGR$ OWNT+W+UU@1)))/R&/Y[UN?F@
M?N'*+1T0B..NCCP'T>.J"#'K%5LQNJ@-;)];$]]VEJS >TN<DUH#\Q]3P/U?
MG0KY)P>.(Z,@UZBQ4Y<&:I_['U^%]9;)C;N8E_=7.^:7;JY*-,:WW/,H/NZQ
MFFC]P?(!8D46=?^"<:@L]Y/*\6YY:11HK\9"J,?X9(FT&4=#_.Y?2/SF0N0,
MYGO>QE+(A5&<,!"-:6.^PV=FCX=DEXC!V_WNWBNWV&MH$A5AE9/XV.D6;RBB
MYP!1+/)3Q,+O,=7SR!M7H2/'IY-.W4RR:XA00#[@J%\6R7XZHM@%];K4A_5?
M>^JB8-Y;1%(Y$RI:ZEX64_6R3]6B W7AA:\A=WI@RQ1]8U5^5#;3R>66M8[;
M_NT%2SM_VL_=5\Z_/0,>[L'\.XY/>%T%C_X#QWO^M:HE$KS.3U=!KF&F:MB3
MW!3&;RVD$=?:QK[U,B@;S=,#$UALMD09\Y'!;*97Z62]JH;*C2-7B]_LNWD(
MGH3*_=XP9(K,($J.E)ZH#IDRW)>K([JY(%>V^EST[$<!OS/S74SQ9",HSS),
MJIFN3E?/1_=H0G\ORBQ@G,,W [V\,<^W[T),O<)WN62/&"MCP8YVLIO3Q &G
M5?!I:?*5!(ZL^= V+K63%[<U:@N(GKX%"Z^Z0/)I,#_Q8+>-V:.?N31%Y^0W
M&-]8()Y[PJV-+2R0[XZ)O< "?0:(8X)T,X4@2+HP ]@@N<LA>H_W1@S"%_O_
M4\HEWBZ2#AF'[81K_U*SUP.9,%]4>8BWW]QV2+F@[+*#@RL,5N@MN=FEZ]QC
ME9D=[*AW\"M-'9UF&J]1C9$3\)<9*?TZ#GW"_R:$V<$<KRYWN=1T).G;61Y5
M,X\(\M*XJ?4,<(> \EU>5K'>^V89EN8M*^ZR>M^>5T3SP=>YFT*Y20S=&Z)G
M7_KL68>NK&S9FT>M6'TN?J9KH7P>2^+U/?JY7,@W35VMN5 K[+\ P'^"07'&
M1C,E<W=*:3*)L"!T'IN<"0HZ [.+,LN1_T.[,__2,/C?#MC]G5-W%M*G^_(^
M=8M A<%*IGT$=5[YG<5=QD3+W:/'9.2.ZUSWM'/JHRZ1PGN:HI);"PYKM$X;
M!^IT.#,?GWKD>X5G<"AD,.:PP$N8^EVW%==?EQ6CR=I'B4)9@\+TBAI@V]S
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M4C(UFH$HG=I<<B6TXRJ@F07]^G5,J[(-%RF /(@QA.=X(-E$B+L9+Y2V\B/
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MV&=FN3VTNZZ$\=Z)XCNG(BP(?E9+TZ:\QDO/(=V=;FH"]V5& SD,/*]-S^J
MI*<:I+JRWN2M@.<XZ+UH3\/ZI>H2/=7^?:CE[/Q8TRZT5X/']"OWV*!I<OHN
MICC3Z5QU<]$BM!2NI9WQ@*$>D_898[_% NGB3Q<@8QGD<G_?$^>QF[N-S/2D
M#A]13=Q*$/ HD%9F(]V?R%E>-I[@Y\/XR^MX6[[\*5UO$)-\_=G+Q/V059%C
M)XS;GS'A,/$6I:OE(3?31VDU5BI[8-D-/#\Q3PF4^,+@$:G*J-Z5G^2>S/B9
M5V?N)48$I]X#43B0US5YC$#G7V?M7<D(OR5"O\G' IF.FE[[K$:-LRE\+Q&\
MX'EJ])/*#P8<HPW?J()G@02?D;10__,678N-$>"Q?^K,[>:I_U83QH^J%=N_
MQ307)LW5#L$R2]P4#Q5ZS8WB3,4EF4Y-X^/Z?</T@.6DR8@GG^\\8ZCMDF)B
MB@YQC6]%CY]VOG3TUU"8Z5DVA9CME=.I?QD@FB4Z=XWF=]'?CL)V'9*,U+)S
MXSX\'\S=8M^$IZ\^0Y[]II0JF@6^=:W?T],C)YUZK)[QK+F@A.VVZ;^OK0OY
MU$%7- ],+PZIW^EV<QEV9%XS@84D,+LY%E@@O=[O#_PNGRT1T'\Z:KW*0]>G
M@<RZ"$SY(/CJ6T.B?BM90>))5S#DJ)S6DDO=*.94!52QAFVRCS@W1PP-?1\)
M9,H<O6(%V;@0V$5E-A!'UZJ<O0 -P1D;X*B.]DJZ:FLYU*6\C(K@*/CXO]A[
M[ZBFOFY=.(J*%6R 2@F*BH" *$U:1*6)$!"0)D61+D1Z3:*BH""$(J @1$5Z
M"3VT$!4A(E)##Q Z!@@M)"']XN\]Y[W?&:?<^][O?/>,;XSSYUR$L?=:>Z\Y
MGV?M.9_I0CN5$>@A0R+])OV>>K;IY F9(K;4[?K378T'B-1.M%?$MVMW_N*(
M?_?F?PI@>??>_\'6V$K-F( ,7P7'.RA:-]\I7LD,N?OHO?M81NY\IP3RV 3Q
MSG-D(9-UF!"038+PXT_V(*=EY;@"L0@Y,EH-.%S;\+BP5&=T4W/%!%6+SA:4
M0:/O'CC4J$J;_FQWNQ88V-?GJRXK\\;F9*%LELUA&+)G R3QPT=MGW,=\^5$
M):/?$DCH;2H_.;FF\S[V<=[>[7A[35AJ*OV[";96[>[7;VS/Q8/ZO<114#/+
M+LZ];V:P25_KI]RLI^W6F<F=\E1AG>[Y!9\.W/I3!^F7'X18'H#?"1(.U0U1
M7R_5&##\V%SHWOJ$%!)[A;SD0\I<ZBQ.GA WI"ICW+-*6ZM5(KS2+TR< +TH
M4(UI&[VUR&_D> +H\6D<I2 _H?[6RR5J7@.V,B&4(=BC_-)]'CY ,JVGQ1A3
MG?SZ)I4XI4,$[XK?P6F/?-GB>^9;FV^[7+9)K4Y]DZ>I+5N^DU3 YVRHQ3)&
MKXB4WV(^4>Z*1&R0"*P3#]?V9UC_"K=@()$6?E#SP5 )7'?PRK'[DVN<=TV>
MGN6LI;#>:=N-=S9*JL=[+8T>)U4W",_*3WQ!KMF$Q+T0.;PCY24"><N=\.!R
MR>=)=W#B$L(N2-$Z<' \W9<JW-;RZ/4>>[4WXU9OY4MC4XX<NFM_X:-W\0U#
M(^N;NP  ,\#TEPB9IKKFL9S/,X:H';<"YXD^A]Y8O>Q?ZSXR)%[3K^U=%=*U
M3A8OKE!M$X31 J:)T-5(X7/K#*VAM9PB8#,D=V4/!G O)6*=W,%9]&D;(XS?
M^H!;O_.L#F=BZ]-[LLDK6>MII\;-5:=8Y$E-D7"7Q@/EX<!"M3PJ;@Q7'V+:
M\GW0RA!^\/>&K-4QC@W<6- MK:D7NDMB]XL^99<=L<_@W7WW*_6K0@>D9@69
MA8S >H*VQ9"H<= JAH6NC>[_ZIO0<^\6S=$M2MC#BP+_1LJ(?>-Z>!N86%V?
MJP: SXZ-L>0;YO6:+>\BR5HJ4(R=>&7?-]NY6,P(7[Q&]R#&=I!SHY94"S(G
M^Q0.1=@,N-+/UFVO4Z2):/^\Y?Z&-L\#1Y0]  !1@,X3@#:Z$7*$J-A_&$ B
MU[6*D SNA%HF2.%10?0[0=9W7M.9BB.:]O=Y *B:/ACF6U#;K'';L'VV,ON=
M?Q#,1%^CCGKU"#'^W@%1?K72Q9F :1D+B]N6ZXNUP6;#^!:5#WGP@:1^'V1_
MUOT*M9#[$).4RN#F_O'QCW47U/@?K#0I**U1W(K]?CU,]IIS.Y-[LD.X][&1
M-]*J:Z7^]8I7+?K63A3M(4P1/51D.])Z7YDJW?AC;9O8"Z:/]'C:K[5,F_A2
M>0##&JQ( T0),^.$>41U:V]]U>G$NK-K'<DXD++M!L\N8 :%U@YMNH+BK@^Q
MQ<^*57CH2T((<WU]0,2XJ+!U)5W,P:I*JH,VH9JR@S#@3\9Y9;6"C4UHJP(F
MOL+^9A._^8ZYN4D/D/?,_;).2QJQ,_8_IVBBCQ32#K>&5'\WH.W:O>41&C;S
M6=5^"O[]/4W3\\Y\LVK@A%UZZ84+Y=J1_A$[TZ5I)QH4+2T#TQ(9D@,!(77G
M7KF>9:EH<>IPTQRQUB0#'TOGR(J6SRWI/O(\ /I%D;?=$1R;<W)45C9\KXQ2
MM;(-\UZ0MN!P;X]+QP.2C,PC[7N4@/L<>"GFA>\Q@ZWQ;OUUO6TO.FS) UP9
M#-BJ(<- 1*A..@U9Q1',!SEQS\(5/K "BO^JV]70Y8;'<6U9_GC$0E]$&3#Q
M]T/ZF7^O/\#_DF+_RQ8$?T\>_]^0&_K/'/C?(-B?0'@. F."]Z/&$<2O_J?&
M<,,_5<A_9X-2?U+&X/_/E+&_C]S19GWF&/R;.N'_H-+3?TS__VU $3@/0RZ#
M?A-A6F F)CP85WH'E*4;Q'4>WWU*PL NZ/$,6^U@-N7 2)4B%<8#+ /7N14+
M8Z=@FU4\@"EQTK&VI1W>VM=,O':-#>-O,HU0C_3-%WT02.5?@P\!UW4Z[(!\
M.9HICCD11*._/_G"/UK?D#\31B)_@_[2":B?#ARP+I$@D";^_"!?<'LB)MQ_
MK,\S"-3SU_E 1,!W4A'*@04I^M>KE?)U,Y_I+X@G)/( +BR-BJL<C%?ZT<O;
M(;?WF#U^0ZQM]U8=X2[0G@N=MQI#VK;K -F*["R7T@R.]&7D#34V:W (PL51
ML4U*R*_HS))7%86+(J19*$AJ?"ZNF.T$L8'B\__U"_YX^TW8)/YGG1]%AK Y
M$#^(%0\P4;IZ!X:R>\Z1P3EL@49Y@%GB%K%6(Z1E2:P\[L PU-<76O+,B>]S
M-D KW*-[<BT"?<2J1DU? 7'U27N2GL6+3C.Q5!4+N%4L3'>;'K.YVHT"4P'W
M)YX<F=]+4AG_+++P]6T/0@//%K?XTTUA]MTZ'BU5V!$X[WVZ)RSVV7-SEUDA
M@E^1I3^RQ=5Y,Q?!+A8VWV1'O%&%^)5)_GI]%J1DS@)U)E1TC $;@\<[]TV-
MCFGG7O 6]7 !SQJ@WE$7BRX#C_( &: OS'<!#BZI'2OQZ7I%Y?V;9#A3[VL=
MP(M56I/H,BVKTU "4M4"^JN@E<D1N(=K291'@K\LV%*4)7$ZV)<Q1%"B"E_.
M*9@1N^ FW5%M.(GZF6RV4)W2\VJ0!^A"E >W&?H@$Z'GC!W,CYS)/UVY,;,[
MJ9+XSN^D<3&\U(^+11-22HELMX&6\+XBN!N\!9^FP^AVD:P:7W8\KY)[TL&0
M+^%6.2>F^,02?/[I&J%ZMY8G5J#_A['S8\Y3/:M:7UCT1AML0(\'*/ASEGT#
M^I.>IN6%)16#"2V%:NF8Z>'ZYW?WF6^M*=^G%0.('3F--9I\]U?#[>PZWS6H
MUKHEP"FI;R/GY#V!5'EKSLR(<FUEL^U.SO- [>KQ$I3>_3K0(KO;V(E_BP=H
M^K-3\"VDNU5#0LQM1'MJ^ZG1%];"8:?8S)4%)I".V$)AH2=Y '@VQHGJPAX/
MFOS3[JB;;4& 6J-"@4P4:_N_CO_9#"+K-G!3'S@=N87PQ>7D+:R!!K@X!TM#
MS]/'!E_[G -QU)!3\&5%B&^KSPQ;_))T/HT*ZF9SCB=T,+#K!OFQ>AC-JH>M
M2;G&>0<$[X;L=NVFF:@<4*\#.GF+I*,4X!7F#/=M4*@&\J/![+FCY#M-*I6E
MGB0+9$?1Z(K@@GOU^IKEG4"0^<,K Y^F$8$T>3C=7U2P@+5W\^$<>WA1>OC9
M4&K318<ZH"IHUFZ;(Q?DP%A?<($9M9E7I6>>2VR'^J(WH J;0#L9&HIRFWL_
M^2+<N\X/:I6J-3BXA^102INJH]I8N\:N/SX5C)X>BPBW[RQ.2_MP!=3U&@FZ
MQ6WI-9SS#:$+F"BL&[A%)F*J<?C.'XRY'5P'6\4VQ=D0O'A@==AJDFWO.,/.
M2@CG?=_3FO])#',L52A,[HG@"B"L0F=FG#(>/0;&M]V&GRLPYZ(Z"K&$[H:R
M\0XOZ2;S2"JWSTH_?";&(W_!@I*GT4@NK@UNPQ$N^6BG/OFZW%FL:T +O:<O
M_&3&DS0<YY#% ^ R>8!6:)L:(6I%X2323(R?)>XJ/%3UM?K&U W(9,;L.@_
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M;-]K-,^?Z_9&ORAMQ(+ ]@+&#@(7I_>^_8BHF#[?;1R8GLL#G//>0.D_BWH
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M[J6OZ>-QF8^=A(KWP1=='^L]EAY(O+#!U!:Y64O%_@VS%"]FEW*\RCOHB5R
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M8>W3MV2^V;6B$C=Y%&[[^/P_FO#S.G7]2H:T::JNVJ'H]LW%M%S1B/='5%1
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M)BE"87W%:FB1()S]:\5F?_?.K_-Y!3J6E70 D(B=+K\%/&0NUA_;C/KW1ZC
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M_$'_[6-)R9H_X*JBR,_X1SH/]50';D7[(SYII;)A:8)</^S.!2^0=^F ,_^
M^DH#@U0]<V$$DTZJ)TF76HZ*YW&@\N-*TZ>KO7B@1-63*7?K2X:N/VS;?VS]
M]6ODM@GOP$Y7&9KL$\3E?\1T<%4@!][&JZV#G6ZT?=_?J,P"7WL(DF4XF[#
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M0MVVEQ&R'G$==W$K>QDB+YLR="^\LU<+B\GLX*.!P#J$C)C+^87G<\CO[YS
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M)H&]V0OXE YX,OB#$SXM:7^MBH\F#TTO3A_HS,UN1Z[W3(RJ0%ZC3/W>EJ1
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MOEH\@UP%C[K9X-Q7'(X"4C;2\O]73YC\TQ:B70@LI(D,P2>;T,M("_F%,.5
MN\37L*YCHW],F_[+ #<_3(DWCZ"C98&DQ,)(?]3/QPM[IQ[Q[EZ $)J=]O
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M6%^0XCE?<V[_@$76%?2M4X2/4R5\)!\R*WROSRLG5,'&]B!P9&3DIO)Q4T
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M77DF&@'D%S'X.,J[_^G^?@K4CZ??/_OFH4DVO+( CK&'V[U(88O&NS=F^T7
MFI4WEN^OP*/@<C)G+08WP8O?=L?R8$H4G6Z;/8.H]V.IX0JJ?!T071VT[^>L
MGLYDJS,%@ZDW]CL0/^^O$E%K_F73%V4K5:ZT9AL<#2Y< 8]CU7*PGE974W,L
M?YG[?Q$SUHY^K,/E]5=0*.E!&NDR)8^F98%1LZH'^GN%^3C3&K>F0\KMFUN4
MX%%##*O'?BOC1PY!.P7JPDKI\G9:"%M.UEZ'FBWW?G^!Y=Z+6AEQYQX6@4=(
M^PDN"VM2I"[^QAN6V=%^<#E;=)>71_V"%?P)QT#5A#<W=)?IMPXU4*J[%>YI
MGQ^ N^\0RJ59@D?HH+?9M(PT1-2V#J2)"E#O,J-9U3,_9]DZ$WXK/69>61Q:
M\_-UB@3S".+T/%_KH04.*,<"N]YJ^EIP?O@W/W;9P)S 1/8OLYP-'E:>5('8
M@I[Y,O3,E;3S0F4B_4"2=*AWU$=6KNO^\YW2TA[&;I=E'F$$0J?\-.(W>;ZM
M%)T1XM\9"67T9O!_<@#*@IF(@I,J93=SL\&Q1:)O=!4^KX=.3;M$K24W?HZ<
MS^J-J@IGT=81FU,37Y&+!N7N;2@+S2A4&F_>U->\9+6-'0:*7GG"1[3+D5ZQ
M%9N\R 2K6&S7+*34LZ(3N1F5.\#Q0#X:+^5C[H\^2M+Z9/!T@^J?MTG#:A./
MZT=V1[7H\\ZI:(86,-['G0!<7WPU&R[T$'47QGOAY]#XP*(6W!V)GOP6,@-2
MY#-)06G"5\+C!%#'>$25>]_QV#PH1#[ >&/"(6P/-_M%!'E7>4[DDGWX;R>/
M8&JM!GP<X9)8PU7FO'T"<#YVV)5!]X_\^)YF4?=N^PJX==J<9AX?IP5_B%Q\
M\+$FF _H1+S@[:[H)N>%2[Y>_K5_*QU!9"6.U8SZ:COCX_;4#.O2]\^HQWF>
M;RV>NU'+I?]I[[81U0QI7,HB<0.)#2QS2D9V2P'G8 SH*Z]F-T(L7_Q=PJ'Z
ME>J/7IC,=^4/CC<$BK+1$9U6A#7>]UDRT\@_R)+26N2_OZ1-V83]U1V3FU$0
MDS)?8F<]1UZP.'S<[4F,.U7?-EKR5;U[O3>%NKD,3BE1#+)RG[8KB%(\ 4AT
M4<(C*50/TE$;C4N6]$H]ZQ':PJ<N:892]$": JE,FZVT<FA*-MOP[C8[_#H4
M;=7?9_[VE!*=]?H^T[0S3=Y;.@'X>R-VCXX(@VV5]6,N+JEENP)_$,[6=SJ3
MWYNNZ:I&A-@'B>OQG_MX:T]ID_80PD!?Y<-IQ5@G>GA3)V0I3N%:A\28QD9W
M!PPKXV7B#_64[ZK!][+;7QFZ>I8$K$XZ4[M<:U<&OK^-[N<C^>."ZC=HF;,I
MM)=D9;Z/DZF0JAR\5XH;R_BABZ2@G*4#C%J55&L)&I_=<=>42N1\</A+$/?\
MZ?P[1K <;29"WW"VC=SJ@;--,TS.0-EEBFT;FI2#OR'V]/("G+WP:^254C-.
M9G<Y/]Q9#AQC!VILJQ'\UIGQIS)AW//;?",GSXSH79Z_7A[X<^CW4IHNU@4L
M2VT%GJO* ?4XL)P 'LB\)=ENJU+P\ 2RRYLK\I%7?VWDUZ3*/TC.EII12E8Z
MD].^>T?R#.>>.9B5:%;VZO:DB$N:VZ^S[0+'+^"%]+F^M4+0:Q^MWNWOG@"L
M"M-V;L]OT,C4L%K??;M5A7QN7P)D>78CC**/A[HIK$FCO=7_"?GQW\"_N>:_
M@?\:H!V"U#E#P:^"2YJ@UGC?M><CS8S!O\Q)TCM6.2A3[ZQ4W6DVL806C.9=
M?6=;GQD#=X.IJUIA^V/SA=;G.B32#;[6WIKI>%>:F2B]\L1U&>MX_\Z<F^$M
M4'HT_2ZE7F"V.J_F2$B:8$I/A/,R*G]=CL11KM',.1VCD1;K9DL(]/Q:-^\K
M1P=I48-?2[Z*#VYF?VA+,<PX?D:7K??#S6+%E+[NC(C')%I)Q?EUM-G!<_6O
M#Q%C*KQ-%XJE&)MC+./.T//<0DY )IF4I.?UFZ\6',76B:=^@]36E#@?#JSF
MV$O;^?H4_S9I24B[<*!SD5E;:Q!7>U:[FZ]FF#D+/VX60)":$3IGC6^?G>A"
M_H2LLW%SNGPO'S57?9P.#'M70H+U,24^90TD:5OD!PI B0)/*06D2SMP^HF)
M@&G<A(G32%4ELFWM;M'PB!HB3LXA(CR8FU?1Y?ZD8D>+=,WA#5?-D/:K<XP:
MDO<@O6S45)9I#X/J1F;%1[&O["A5%] R7&FAV$AD[PD@GR;@ _';G"GOMO.0
M?5ZWG:),9U#N^P&ZSK*SL7H^H=QQ]7!,,R%O@'3WAH,F!^!R$5J%J-IG_,>7
M_.:LQ4*V<OS37"Q"J9JKTJ=A8DFB,#E&#DMFPW9YF0G"X\:.03V;DY H,RF0
M=I#M6A$N[F?/4GV8)80;!F)?:][E/Q?3?7VHZ-U-K[NSL:3KO9N/S/CK:D-4
M%3OTDLCWQ<@!?-5_X-.S6I;QXSU.><GOWZ\RTG=9UN4$R'"+;:?\D!'-..4U
MG-6;X[0#YP?;OF>(<@T]3;XBRN[#=A]. -?S>G5O:4*TWBN]RT44'1A_L24/
MW R,]1MM$XCR,$3E9E(+$VZ75[%^I( 9A9X*[2U@$"\<@8O,7UHLRDV,QF:?
MH'2]#S%RD?I4S O+O4J#5V^6U[K$-8?&G*)?6@A\,$SK;/[B7]JY,*WIL6.B
MZG"]+PDW=Y<^74#^1K3>=]AG<<%/;]T.SL M,(E*L_Y!?ZUR(5N+,-MV/VU_
MKM JICB=K7YTS8T^Z/V2%;^ZO&;;I5^D'+7+SM"<)_#"(NN\AC-]:3SZ\;3D
M#JJ!8[SX"\O;?J>]$J7R]<%^I_W2I:1]KHNYJ:!9\6&1Z2/%D(T^_39A13<+
MNVW-(*D9(["'2\_J%9NK.JY/JA7Y+T@N%#%F:31B 9=S-6X]Y#T!*/[R+)P(
MSXE +]R1^!HT3*>-D^8J6ZC4!4Z,+;X:"RMAQHV=>D;8./"42RT7>BP<1OOF
M-B1FU?B(!AWXOG7I<V'5%G@N6R&I][#-X(Z;MLK7.*<(><L^)IX<'OQX73SQ
M8KQ?F]B(A+DU\VN-'7I<T99QN31VU&*N]\(MZD=]P/L/"B2O&)+1]DU'2LH,
MU'/ZL<C0NNM'$O.HGXRSDGB=3'5&&*>LYG!P04S&AXPWMV4NW\BU3C(VON9R
M6V?=F"85'^C 9^#2G.X-[@K^ ^_%R>8*0HT'3;\:. :J03CTGY1<&78'(A7N
MCM%T&YPN339)S@0B_P!=?1#N!V[F"DV'=A9$+QURBF#M7 ZD(J?U@FU D)00
M6_HKTPB53U=>C#+4ORZ&=JL4N;K,O5.\@@R_*#DOV*R-4)E?O*\ZW_]P[#5=
MA-50&BRI:ZXS)_+F#IA98<_-*VC 93J%)E@GX\L^[#!&X'Y.K/REF2$P0]TL
MN1?%*GG+8=C5'PRQT%NZF>@4T0RWXV;>95\>7D=O8E;S0 RCC9YFNVGU,T@6
ML13,4I@6I:-P>B+B2JZV=RAAC<,E[*[4QP6A].D=?:6#0N.2PQ^0&;%;G4;O
MNZB@B>JEFY63?_!8>JUT;18P%IO+/P&>1HPPB1N2/N?OTQ!OR-AY/6!# WD>
M#=/;I(Q>K9G?]/6P+</K13(CNH8(B;Y/XW8D-?4T%?]\E:A.;QV[;"E?./DD
MN[K0H2B3UE_%+D<3YC@(I.:N98=J+T+B[PD2R %T@5B2XX(L<U/-S:X9!(D=
MCV0)M IL48N>_::>D9S(KYP4S6"C*#ZD(Z/&%?/X?%S% ]+9E?5-#/*C9DI@
MKV_:W78;OP?T4$>9N^A%" ?D^H!W1%HE_6+[M<\DK_")$T!/I,WZS.8*^JN8
M[VG2H"VL]>]\F4[!!Q(C,4V.A\9:./Z'[17W_'987G(4Z>:G.:T>(]324J8,
MHN)'OD2I5O,^3WT:H?U''I![))-E7'2.V:]#\2)?)ULN,^D$(%+A9K9H4%WC
MYN6;V-5(WS4SMY8VNV&RGA+LN&7:&)%XTZ":-S<G0#CZ5KR7\R98X,]^ATYS
MO*GW&=>.DMJ!087JIH8;KZS]+>-(P7LD&*QND>FZP=).PN=[3H05HO8>L/='
MQ?P)H)D[9*?"?Q.V@-W:V-N]^4>)W(EB<O>E=]'%H13<RP&,K"+Q=V.$@YP!
M6CM]&,5A@S<?D-_JIK8B][^T#S:W1MVQD]AG8P$FOJH>T(IT2.E,CE(_BR@2
M:AM[E[N!U6.WH($WL*7T(4S'8<_JTQJ(8X;_J,S^OSDPQT2Y].,$8$03VM M
M82:> &*S#L%,QTW*S\W*#A5H__+'Z5AO>,<DA*Q?0V5>%VA\N[SEO+N"F "J
M!OQ36O5OX+\1R%L/DF9M.@U74!IF6L25EE+RM$K>4TQG@([EPG\4G,^GC3Z7
MUN/[V9EFCZ&<Z8K%$%O ZX\/T=G^IY_5[S0D4G5. **:BQ%YAIE?K9J!.Q '
MN7N_5YNGO(?+_.BG IQAC0@L&>Y#%6=:I)FFG0#82A)WUSY1M-]$\BB#$=N'
M#9'(0^S+I>"Q?'%%K?,8PAZMAHP=FUXZ)5;D $-PY_$6WN3.?]B,P![/QL(Q
MU111YFRO8_6ZBP6W3@#OS^WM_X'"YQ.(F6:X_9::DJMU2N<5(7C<!W\T*Q""
M)2]LH#>.BP1'^=QJ1_:YX A<)(RIJ=Z)RH.L"5OU) ?$;DS4[J>4!-K]?TQ;
M*=UL>G>,3Z&ZG "8#PX#PT%I/(7"W#8[.OA-4&7\E.$)8 N51@2_XDE[!U59
M$Z@^=ONG/-M_ _\.D_\&_FO"Y,/7MS6$G9XTQ3%O]*K+/_&DF>UZZ\KG;@NA
M*P+#2AMNTE%Z038N#%S9L(79.+P 77P6QJJL%%2 +4T7E'!/>E**N_X E1X8
M3PI,NOV A1EOV.2IPC (,U@%31/]WS$_?]#\^R%=R08D$?^+\>C\$/ ^RB'H
M;<;6Z\,]45)4J4>=&JY!JMZB-*4:R7\6[N-X^U-_0486C]P[(S4,_3(TXDFO
M)Y[H8^155M[-^^TLV[X\B\=!U<PB,'+!^+M>O5XC?.C Q<2E-&,">.?X!' I
MB93;=#AP,#E]'C%)@D>1*SRT5K%P)F$C^-B"S;=5]">'WWPO( PO$@CC+%-0
MG5ML?W7DA#B*[^62N1E8QYJ_?'UP7^6*7$4K>AV7#B$Y$.UL?4#K-',6([+?
M9A-9I8QFL%F47V9_:&M0/MN\@\OJIDA]?B)CG_5"\?:KR'NEA*@]D69AEPQ6
MPH)6NGOZBJC(UG73(]2]LZB<=PQS$%* V A<'L:V,3"=OF+2L1M<X,Z=J)_$
M(D%6Y^Z93W7BI&GB;Y55RSL^-WC]0.<&Y)RQT83/1'=@EGODI_6N"+ZG]1U.
MN_U"I'UW:!\Q3?K#W>YSI+.0BBBP2 1XMVVS?Z(NP&S1E;REWC=@MU)_ E@4
M=;=8F.'^5H<3N\#DYK(\9OQ7O]; <%+/!7.->[>JXS5$UW%3G#<J[ U[V/M9
MQ8[3;@#HL<H4?<6@.I@TZS?%\_KO#DHF:%AE.I@+136VC&BFB0OZM%J_V;'.
M(>QJ9?5[6?QR7'ZW8AS?!F]60<CY<UHZV[?T&!2DJC;>TN9Z]/4>]GNG+R/N
M5W4#[^MX.3_Y,)*S;1^TRGA>D/#]-%CE3^/VPN8%,-]C768.2(RCW"ZU?&Z-
MT)*OO=C:\C-C^\,M"EQ8=?BD*F)M@UH14\/8(WKMEC4HI((LD[TE:;#16@'1
M;,T*82&Q\C:)UF,: S)14K;Z 5YH:Y=BS.3VYZ2@T5]=*#W'5PF94FXL[R3E
MBMSR-9Y('=K7P?9<4X<V@@7WZ ?B5SJFYZ9O(5M8'E,ZH %\\!ZARL,M.XH0
MC7(:4"U<Y:EUS-7D@*\U>B> [F*/ZIC@,[^ZWNC=M"._<O1]X.K:'E(*&ML+
M26Z38*W^[E4-Z:6DLNQ&'<_@.2>>LK'Q6,?0,]AE,DVF(H?E]W9JJG;E???.
M,HT8226$/#3 QDQ#ZE?F95]EA);*N5!>LN69O&')YI%64PA!_+E5/E%<_>TU
MXYDURE7.H521F,T'DV)R6C'?9%ZR8PAMB%>KFY1EU^A);JOP#7!L"@?B**$=
M/T)6]76CXB-:1EP##!E>V7"^F[@3$%*$L[GZ5 8RO'KXQC_@!.#C@$J^\+7_
MGL&',4(LKLSUEXLFLT2[1O*@CB@'HA>;4V_V'7VE\$Y.=B;)Z)<D<Y^]V+":
M@)WET,@$<+0]^2T N!KI $1NFWNXD'*7N[^KSM31H#I[YVO(1Y0&R-70K W3
M)F19SJK;5O%$P0:7TJQL1F%QBG!O<DZG=3,8#GJX/?C1?-(9>H>3?!]IA0J'
M95P76B$\_U6R=4_$9ON3Q)S9?022%+ E.\'M5'$HTC,16 -U,:EH"KQ>C$)8
M;ES9).1D%&)UYEY>W;]6\&@XW/A=_:=1M9 M-U?&A/G5MV5_\8(G*=C>(I5
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MG8IZV$:2X,ZW.\X2BU$*3:YX&@#<H1FCN>!6;*3W]PN<ARU3I]?":  [S;I
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M7L6QSQOE3&+W^C1WRQ^!36;2 $?Z*5-4H:5H5N-5<+I.TR -("^)O T]SQJ
M!"0/&/H?JU:XC(LT);#%='%_.".L(,61GQ!]RO"%U59;@)&VZXZZ:.F2)&KD
M 26&UT%70<>HWME.]O<BI#$!U]+[M;2[B7R%;K,H&T0'4D2!VU,^<\ PQL'.
M+M*BH("S':42FOC^WJJXE_4.L?MF&8Z!O:$"(YG[PU]OLU8?>DE0.X:[EZ+W
M@ID$ND#>2NEO[$TRZ%!57%!-!$4VPP9[0]^=OY--K>6AU[) R]ZJ"OU^K1N
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MV+G  Z(O'#G#\]1D%$_VO3)@?Q7&M&>HF"FYOY5\"GD<PB)EMZY A:#9\%?
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M,U4REZOTEM< 8?!FV2])2#\D-G.[Z>]FQR@\A4FQC',?5%'=Z>AXUNI]J#^
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MX!?WA')FU*2*Y$Y.@@7E[ICSNRV>$=9!JE"I\[WO[<S0CG^CD:9"B_Z&F&M
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MHE-):MB!16]Y(G0-_E2$3*L9&Z6O#Q,:US-O'Z!^PL %*[O:J8+='\KURW6
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M-KOX!@>3)-A1BL6X=L3X(]K :/>TM4S[L/:G+ZY0/*',9>#"8;LSU,5UD 3
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M^R#Q.2VEJ_*TN>.MGI* -,SE$%$[1L8/SH ZWQPNZT%&9(8T+#VW)E^;J"8
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ME-W,1;MG;[74$@>.Z\D&ON^<"--,*]E-9D]]]BM[K61;?05>#3>JJ>7?/*[
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MARM1O<+9HVJ7C.C,R7=4+&(-+EO]#.-6N_E:32XYK36:Q_  _:/M^\]YJ?7
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M<QO/CJ:DI1B$Y8X*J!GT+"0^-L.UR5YXD4I/,5_U]7J!*D0@C3_]K/4EVW:
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MS4((JS0N.R^S(+M&RK%++=;X,:]-S(.JUNEL&PW/#+U/QX:=QB"'U(685W\
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MH;\U=#:N-ELQ>/.N?KFB\%7)F.NS4LRG&K5# V/S+5WL%I/F7HZ:GAX[;/!
M)ZD[Q?]#U.W>&.-3/O)!BYM?0,#V>2?Q8AA1D#:*VI'J;)3 * ?]9+,U =(2
M*BW$_B%YR0+5."UD!U.7$E70+^GKMSB36;:MHJ7EIE0C41LDWC2)NN*II<PN
MQ*5XMKN!^".*Z&<*O^<L1=3O99BDHI &E#7D8X_E%M_"CSOME= 8&?<%1!P'
MO;-34<E0\MAJT;D(\\6V1-%*MO0F-:.@C&&VQ7)%&;9S^BU9R*NG50X_.NBG
M&,W\"E7Z>#%$_$%NV!N;^P?O(3M>\$Z?M^JASV>B:EA9KJ^13MAU56ZGTH90
M/,J1;5LWA!0E#7C!$$]L\BQ&!@L+^\KUO48"SQ2IDM[F?)L64OPE5X V8.0-
M4;YP"P?COV'D="ME.>&BVXW@NT<]Z&[(/MQ_45&MO2=(/X>M]9J#,0*YM0'S
M.^H1WP8-A"A,4 VAE^"&I1CW?A 8)'(U;6-&2/[V>05?RSRWG\+4E4VE-'M[
M*>5:_$S2@4)YLQV<3H>S,W-24K).Y8B=#U]CR MPTREK21\K$H<^9J;KG%!?
MI_E)0=-;D)4!BK(%31PJR/R+Y*2O00U3O+IPL&JX;3G!4,8:MM3T52L)QQ$O
M]*!1ZP#OQ3)7WIC.:R7B:L<O-_+VM,TR7_D<GN=RSDGXH(ZN%L!E6_@BGZ[0
M2EZ8RMRC]1;/@C7Z-=VP.#3L::^2XZW54$VPJK+?^9KY-K^3"]_PZ^F:7O?C
MP_.\"= +:_M$3HFSN H][;K9)YF'%-)G^%823(DE:1L9Y'[()4%_12C'?]7>
MUFF^05 D-\,0K2<+V\@6(U=]/M59ROBJSIE.5Y[)4^<)O/AT4]QR56J0WRYY
MW#8NVON>FY>0_0=5%P[6S]5\Z/FP5R$:B4?9O5_HZ6RQD]$_-,8[?X! ?H21
M[UI,S?@V=A5357NCH:+'MZ&/TS<)7^SD69KN4J3NRNAEF/R4.^:\8-PC!XV+
M4\"SU)IHK/+F:1%85M8Q,\G<[/9"H0$B"%PP*X\$@0]YB)4#T*W'4 HGB69>
M&$#',*L1.Y"\#2&8+5E()JN4V"9T\N=V,<:[YX1!5%8F$EI"XHXH/RC)5")L
MH*VI$X25$%?.'>IF$@E@W>H;>;65XF<8*\&1;_GBH)8O_5>H'><]P&=]RY)B
M'F\TC<,(;<4;^T#QR,L5+-+RE16&@W-R1?CAWJKDKY??$H=9,HW1L!!N06%J
MEST/;#-1T%CB29?]P>M^',]$\AD7^?P30_VU9"V#LLV.)?IB6HS22.2/T'<(
M\E4&+9=:+ C<A,S8DF*&RGV?4? @< LRR[3D-\ 2VDJ9IHFJ W6>,,3IU>W:
M84W/3>*=FJ/Y;K0F[BT\?7EY[&79I]5R-^9J6/%3]\GS<@BB[])B=5_5B1#Z
M%L6?^>5^FX.#15],P\Z,-/<J3V3&\$4]D(8A7O>7JG;=I>2U"+;F)OQ2RS(.
MVJI)( B5NUW\V5NH_8$%DC#7^%B8)/<1!%XK=-$Z.[\#==B:?KIQS,?ANXLL
M5O3E_+EP2HSOY/G&3A  YDJ:;A^BVW8RM?!;ZSK+%W?63*SJ<=[QLA_QIC<C
M;^E [IWMT]CO=U^62"1:%C+>"6%=OTZUX= C.L"RS9QWJ+41E3+Q-B[L'=45
M.XLR(_#]1JGUNE)W]"[98UD3HG)7U]K#7L2Z+AR/_3@7K2@E/+S5/S*2(W>=
M152#\O)U*\DGPHPN&SH906[>0J[SSIT8'WQ7^%) W_D[9G2Y3,;63-_E,*%!
MF<5:Q,!SY*W4;'BCY-N$P\-94@P1;^*\-=XUE=V,G?^TV.P4>4'N!<NAM\0G
MG=FYC7*K9U&&.@O5A7_L6#W6]=-4MQK!%1G$.%J38: Z9(+>Q]!RE2@2^&5X
M:+"BCU_$9I@G/*O-FCU"0/+^N5!Q8NZLW2I,=_NS[NT+&L$V;\>=AS(PNIN'
MGT]&M(?1MW_/8)CN\Z=\&@L>R%A>(U(]?276'<HF9D3G^SF"QH,\^Q3-%"K+
M/+BF(CSN6O/7'4E!0;1C9!>D;K.]/N]_GSTZG>7,AV@1W5;NQ_(C[D;%.MR1
M,W8CU_+KTV45;S(1]6&+T#)73DXH$OH-D@X"\4A#2WFFRI/F"HDXK_N7?1$#
M'/K*_"92>AH\WI5!2[S!1^W/^8@W\QGH%YU6<+WIK_'F9Z"^N_1I9X8TN8?Z
M,<_IUVG>>UO-XZ/3[7DO9B';NLWZSJ/M6'GH!*3)='IUP&;Y0G@,W9 3)A $
M,L.3Q'BC]"9*F)\N+F(D90.M-@UT6Q^<^7[3L;@4+E,UV7Q3E.G-T0'=%S<.
MK[%)07F4B>/YC\DU0H(Z5%3[=/\WMS[)OK+>S;>P4P;=!G4L6J(&DOG7GC;+
M!:KSP/A,.6\)?8E4.L !/[%Y)R^"F$RS8BY]I)ILF\8H\W=E+(6/C!(AHF)Z
M/Y9;*K14N,Z<G5JWF9]KDI#B$SFA&Z6DQ6&YK#]E>>Z%7>:60_FBTZ=B8/:N
M>&^1KVPHU=?DCC!)$3$' C)J/>/:3T&@E'%U.1,^3OI$H7W(;W-:E\(Y2/ED
M2U(=69Z$4S[A,D0A#/^@X+'$,B^_[Q"^<L_HG1O'7M>FJ(:7=W\K'S,^K>BK
M/YZ*P2K TTS6H=.$)I<76/$D-\+4IOVY6N<8 <76^<)/ZN1G3Z8S&C^(JX6G
M,K"KG:D(E\[/S\E*"U>[&9=Y[**PR((UQNE*\ Z2#Y5+,T@5KV\^+.]48V Q
M2WA@(R]PSHG9B_VHW,:;%HNT$JE(01[_ZPZ0QSNYS7J4_S"1 $:46<-\J.7:
M[$U.7V/Z6)ST_['WWD%-1>_?8*PH@HB TB/2NTB5%A'I0H!0@_0. M([05 0
ME-Y!BK00>@>I2N\]E-!["3740$B6[V]F=__9G7=V9O?==W;??^[,/7/GMO.<
M3WGNN<]Y9"]LTKF2Z&75JVN!-J25^]VYBC!/K6PIR!:D"G]:D65K9;.B\_FZ
MN3K)(5N8)\!(=G-+>J'V63//)7M=.0,!,,Y@N$"GRY#<X9 Q,]WH5"Z"%_RL
M0")\J.%8J(?FS"Y6MBVT'4,P)=PM8GA?4/:Y4CRPJ^J]B8=LIQX"3ARLUN0\
M4K976O-_FTE!@(__$0!U-X3>Y@LZ<FCX00 $#!M=$;L".S+-85_=7V)$__%?
M6A  =]R;Z\JG9/_'7Z'XOQJP0[C#7:=$4*\9'#N)L]AS^J&/G[N(P2%=;V#:
MES\_0/=33U['Z-YN78_RIQ(6+?V&WTJ&<J!#K"!EO*OY#M?1*;>P4$*UL3.I
M3U<+>EX<Q[D/2E@<6N7'Q>)?N?-W^H]/@,A!"=JZG:7M^XOQOO^L^C4<>5H[
MY]0>/>*A]AFN^MT-H?]9__$;+Y\T;=,W<R4=;JY$:N>QK@7TO#^%_W\S[/[G
M:G[_7:<+^>R3732O@O:T0&BWC$Y<XW4<+/\F4'8$-V'G+T%8. $ $I5AKR![
M^W\>_MO<+6<)]_'35_UFED:*1[Y3=HX,>;&QW#M0_VX%8?J!!GTZ]4BKET,W
MYWTGW7)&2NJ#JHTE^UT&1<#X01N/:F'QE6<*F"V\B9CAX%2"H6Z+)^,Z6FUL
MMM&QR,.L4BQ]G@N)L.'0R6[>+MJPM;>QR\I+4=9258+&NVM96E(N3HL<J*3Y
MB&3=X7W+]1<R%$Q- #PHD#(,O 'J =WC+9_%S,'VM=9A-63<JC4F8.95-R2B
MB\\)YO=K;Y>$^I)$E2X^PCJG:VVI."B67/('M<^N@Z$A)$PSB5*361.2/\X0
M=)$4DB!5@;B7&CIPZ1\Z8$'OOD1T]09.-FM\:MW+V=!R$ZEBH'53@]JZS6%+
M=%FR,;7H8Y^H>PUUFYJ:8^,6M;LS+R6YJ3YX\>9OL^0JK7Q,Y%(6#WLWQO8N
M5M^T>7)LW(W5H49^R=1XV5'XV-QX.#2F%_WNJS76&;@&?U?7VWJAWMJ.]6%V
M7PT0F#P8&CHH.:ZK-- UV2/.J.\S9>ZV%*4D55'1CD]$V*X@(E-MM3NE[IX*
M:BD6$2<C!WH&Z%O?.*\$?G\]B @@[XIG[Y^ 3)44 ([*\F[UX@W)^=<SCZVJ
ML&^T#XR_M@XHF!_P%7<[7OXB"]AEF(KH;CF/8A3=X(M-K(PL)?%+$)1ZI!2N
M%SPBI_ZB3R8FQ$+\9T^K2]7UL<H/J##73VD*;;$W>9\5@%S^P1WF[+CLC,S:
MUIW53&PB;J4(_QGC  Q>["\S/9!&YLXB4]1.%QL;615%A/0?U#X3+R6VXU+V
MRQD;9'@Z&"=G:_^-/^WEB=!AE\S3VMI9_KGN';Z"UB]O]X6=)+5,[J##<45+
MKVR\CJZD0 X@))21[ ?P\#<XK/PD8.ZO7WE:@#L9['2#-LW:Z;H\W3-^6#:N
M=\]+)]&GR7545MTFXF,%!2^;[!Y++N+U7ZA>#C2%_",&]P_]X'$HU[^D+\O0
MF/6-5[ DJ,G#$ZPU<'DGOVI13%IQWRF5'[=?N]G=/+GXN&'*<R5 LO.^6F%0
M>*E#75P6HE.5,C'5ZFJRJ%=*1:N-)0O>IP4Q)[7X9\$RHM=1?OW0>:7&XIB+
MVCO 3A)7:/O7W;1]7=EOR NO</W1IW[_1M%_8\ QS/IK\ZUL>TE0U/K:<T>1
M[PV5E,YH-XII3B$[/G"G]2*9LI5MK,9B"8#':4S<=?E4EM+:G#^2'&D*EEYB
M*TSDI/_:7]F>1192ZD8$]&UBW<C-G6&'N?B^6>K%:&I\^\7!I//@3__.B(MF
M@[HCL;F(]Q1V&>(T*Z6S?XSK,@J9:'G<TU#$WV]IQRKKXSK>%#E$(I0,0"@?
M_Q3@H,\,@-8<.WYM;"5.(7X'3REU5.I?EX3*%*K=W[U8Q!"55;Z10DS3&=!4
M538.4T$29JN4E*#UJ[*DEA[2&A"2(E8&%[(:WPYNKJ"4"/9U;"$MK>+/6SH%
M$-E?(<Q8&!^#30$C+ FG^W:JW;^S'I0*/[: X\W2/$WW>6..@E>B#'5/B:!6
MHLQRLOKI?:HJ:8JF!2$4XC3C5[,)91EB=OJVS!_]!#_L"3(W>H'<4?[<3XSD
M'__]K!$%,AK%X15*$@"Z&" H<V8=GWU_I*7=_W\WVG;N! !QV/[\\/<9 H :
M+[U26,AQUG7:=Q YM/#PGE9T>*^'2596!Z3ONS9KT/->"S:+Z%>8$LEPJNR[
MX7^@@'T,(Q< N%<$.3L;WV4O.C2N)@""\3P!0V446%N<-!H4VDIQ&67C0%KU
M-6=A]H>9@S\2-=N7&B9])9@^)Z2N/:6DH:,RR,HK-$9MRX1)7@X2:^-@3?GN
MM(\ZT_%@#QN3>E8/W%EQG<K]-[X&0AH/%]X(O&] W%NTU-21!UGB1<2?;__.
M-C4/2']_F_,M#/G"6>@JX>FM#2/& XV.JHW=69]IE@&E>,:*A^^:%5*WY:E4
MIF'F9^5$OT'R_G5'FW ;3W.N?]0-1&L7#"<]3KL$-9[S^\#:G*_L!9I<8JWJ
M1-JWC%9W['!Y[RM5>:JOB/411R^MXZLD1TV-Z>BD:R<A^DS)!<6'O"TK5)\E
MWX,.Y)3PUD"^7S3"IYJP&.#:5BFL#8;W\%.XJ#KRK3LS[N$[1DD9-KA>G\?,
M4_N)+$?6K&<"11;^:O)J^M>POO,:E.-][U<N*MM9K#QD5I6XXFXA;YI%'*CF
M+@J?1=Y^QFB<<@?'GK6*/2$ 7H&"@:_$X87BQZL>RSE[&<NS#"TN6/_K</1<
M!HFZJ?-%4ZDTG/P9A#>B>S@ZBCNVN O\=-1_D#N<GUL9_F_-UV1VL\HC5B-/
MV3NF*VOM3CC :RS=5RC/[\)Y9^3(4'5Z_D9>/$3.,SC,DEMRBBZPKUC;;+A,
M-XVD<PL<.GU*U)6(Z$3*J?M-'*]4I'")BWX)NFY\:T+\@UI=?9RW:XF!4Y9+
M\Q?I RI<3]DF,C#'9XD Z(;U(A_[W<;;3H/6KW -OJT6GP0>6Z_]IQ#CPE(A
MNMA0%3BOL72T5WNVSI*6Q$;OE:=H%>FUA6@V=M6F\WZ^MYRZ0MIOY]"UK=1V
MES:JS-7$CP#X*[A%*@= 7&?N8 @ =2P]>(WF< HA#77"]V,',<SEG!*M?T38
MK6C#I6OF^/DT?4@F#>7E&5;K.Z&W8@H*?TW B+6>:LH*"QU7]>J2:(QD+Q[0
MCLI5V_\F/@)^_YR%]9EBW[UH4KIHAB6 D%A8L,NBZ6/$9 )0%)V'MUD<?E3<
MPFN6FR8\GLY4O]4P[LI[)S755+;<Z..!J58O#XM_,9)"1B/DJ5 MQ;@FQ_44
M>7E71P"ZW#N2!@]DSD"N=J4X)6^/AOM5.FL8GZK[-XO">'?QLE@S N#- NK"
MN:$2V.[37><IK5!0 8Y&Z&7'753]W(1:9$ 3E"R*B_**@^G)+2T%URV-%RTB
MKF==@,T\L<Z)'S*-%?YV/Z%;(TJ",D<-,U\K' .=#*I][[LM_M=7J_C,_F=W
ML7=PN!9%#P63?_=A_)7GP-[KJ[HAC?=ML9_X7'BKPLG90N3%FHSD3.%(<^KP
M-]JX"@0SP_")R%;"9SJY '?-3>PF7&E,SP]Q]0"XM W'HM>=,^D)@+3NKJ&3
M6;?A.GM.GZO?$E&NED="72D[]F=61\-C8(EJ%>\-L6+>NZ_O(#*$WYMH!3I5
M_/Y3F2C-D@0 <F7!9S(W)^/7=$/)^H=Q4AR@C*](J7[<7 O+"=]ZPLX9\- Q
M: 8=G&A.PG[-Y41;7WF\(V=+CN:,H'_]ZL]#,(UVO6A^]Z6(JV*](^[&8+]5
MV&4Y7>]*/2RQQ8[CTH' "PC,V,$+_^R$[>#W[/3.IY9^+$7=F?S3RE Z>J!E
MZ%R:@<N@AAQY!%%01.&KZ2+Y!G-2>I-'W\ZB$E!QY6648J=,2=<919HRU_!K
MXTP%@V7&JWU'-%[Y6C]M:P"I=U 8]=.WK%2\5<)  WRW8E^M-HZS^JBJ5UJ.
M-OX!M[- ',_.:(*A4XEJK_NNBI-7F\SLBM87W-V03LXUGXH7F3-QZ \$@'2-
M%][:N)^[$@]T>_872X71;:Q,'\:$-DO$5-"ME-+GJ3DQR"G=?UR8^VZ&YZ<Y
M<U*/-V<61+T?#";AJ!Z!5+Y([S10VZIS2<Y^&U/XE"A%/,3Y2W>(:RS8R.X)
M.%T>QHQWNBBM$\1#C<\.8-]@%\7-P@1  Q>_R7SW=4\2W@Z$\SJ5'5TXBRIQ
M_PW"<<1]QJ7TX^H[S*[@=F:'_G)UIG,G,)JJ> U-!6F#1UKU*2[CR%0?5,K,
M4F_,4YIMA,%;6DT9[P?H1!TF"DJ6/_GE7B0UG%\Z_(;50+?4@.M990;,?E98
MA>-@1,NC<P5_OZ,MZ/@,@T/,=W==G=-GQ#PE'DOM$^:?3R[<%3^[-T:,%KI2
MN79#U-%X)>4H;:';U/K) JX.=P80CJ>:]_2'HDE5O;[]I;SR(EDM(R\8#YW)
MQ&0429CZ==W0 Y%?!AIWT!,9MZV6C6HV !O7@QIG1>".9D=8XHM:Y,>34[<3
MM\8?7#,^O0B+_,2'#!'\<ZIT)3R6>]0"L>-.=:9TO<RTQ)4C!05ET:"^9J-
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MB^-'LWAX0$<<8GGQRD>M/5R)R;^\1F%P/1PD^)=E?,DN/G)W).Q#]J#;/3V
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M]<5&XLST-60:B8D9X1E*5G#;KX<Z#W02M>-F"8#ZWLEG[]D$YUYS2"G!\\%
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ME2\%=._&8R0YHSMU'YA>I<IG\#I0:BH(W9B3N[X!RVQSEW$OEN,/F7&K/01
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ML 6K)_7:#ST99L]_VA176^*@]1/JJXIYBD21XJ7%Y#OV5]SX@%__66<#DT8
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M@U;)4ZCZ7X&L_/W.$OCSQ'H4 1#*I>W6%[MR]#;'D1:ZTTK1H]Y6LK52$*>
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MNW9V]>H*K$F9[7_@[ZH?/+][UX&])$V!2BNO)J%G@]YQL*] FMY6GS2O( Z
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MC*6NRO ;CXH&_UZGBZJC&C. )(>9C 5?^@1&[$Q,SL$D]O1@:.UX>TNF8XX
MN"A)N=#=(14TT0WZS#<__SAMO;[NL%]O;*.T)-'Y<G'FI8B\PC#3F_MC<H:V
MP8[&6(-^*N)C->D^?[W;9K9-HX>SC"9GAZ>F^EQJ)TRUJL2 %KL!9R97E%7-
M?N9GM-5YE)38*OLR*5_R<6*93:,@VFK"# )B\6] PGXD.:N[71#(7N)GB<S
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MBAM.O[(-(WJ7JTB,R_P\H#?IV(PJ9%.42'*3<P$9\%%X0&F'#O5->O>E]M"
M!H![+*8B9JUS=SFV6F*^_GBM)R>% &!IUEFC\'(NBPJ2L[)IUJYH%4S+*#=5
MF!T9"ZR3$\SJL7;D+ .^SMD1 MDGI*0-T[QWNVT"62G4H5>L9 V0!92>*E["
M7HBB]YQKHD 1 (FCX/YCM3&)OTJ4\?=7_)=;F_TSNRDOF8^U O$/Q4OFN>S/
M$ON!%S@V.RZ[!7%%S3((O"OOAY<;'_+I*]DGU)52]2SS5C=<GKEQBC;;5% D
M /B85I#[]1[\Q^NQH<![3?7^S\J3$!,.GEU7F=+?T7^VWZB"64^1&F;E1V>(
M.]ZB239*J@J6GFB2Q/_SV)92X*G>-=9GC^"5<F2$FF^'@9DSP<C9D#JGW(+\
MT@JO=C?3[;J'B)C7214)Y;K-?C NX03!O4YZ%[ZGM1+*Q42N/?&32/M!F;">
MG ]GY@>T(=@$ZR!F[Y2=3?[6N< K^\#R)B:'M2:D_:\NQIAB%Y? !9VL;H,=
MT\[D[(_;HR)QD74Q]SA2#$OVM\F%G02:T,^@*VX#+BNX[\ $8&?,.):BNL0/
M5LT%2I_HW(TE 'B\O1&E"?G4-^U*)66D1(.4W?V2A*EA+BHON*)JX[6'[A<J
M1P[5*T<$3C1-2Z[&B-U*QW@==%,T< HVOKAIL*3@;^7AV]+)JP=/%DY&F/!0
MJTGK4H+E1(1_5A>4LB1Y\I:3)D@3GXD2*.X'UC%V&8EK*1C@4QX7Z&8HOLQ2
MEK.=N<U56!KS-G0D->IGH6#T]FG\AG\=1&'6'_SJ/+9)F!]XA-T+F.HYXD#1
M8L*!!T^Q:G)C(K,>!ZBE@'E>]IG,VKI#23\P38-WNS?=$[]0P6)R1I&8EY]G
MP&K'[4J]'V!]Y^^(/>P?>28Q,V@XU8P8KL7:$@ >=00 &O>3S U=CW$&^2]<
MLZK/F)A8E %R8(?N;CONGP2&P\K\[7:9B%&YRM5Q3-#=,5^G)?L%-4\HF4&T
MH+%5/FA^ J9TR"B5HP$V#RG!^('-F%P=OC<6>HP@)\/S8OYU*Z[8MEDK :"4
M:1Q[@=&B[LQ;P-^K[;1C]?9[ZQ:]0+<&P73,K06AK];!D/UY%W%*YH=J]\FN
MHRMC:CR&U=L)  '&LJ[VZ!#F*=.E)@M$Y?8T0P[CZJQX9&>[U?&V3!![E]4(
M&;D0J7(IFL'KV;;$D+:9A")S25A8"NWSNC9P?B'>:<% ?<>8KSUBQF-G:X["
M6X78\19#Y9E"%IVQ;_6B(B!STL=DPK?4:\;2Z*-5=.W3K46,K2,5+4DH(0IG
MYO60#0;67,R-B6J9(>C,&606L>1Q1&Q7.J(%S6_BTIG0H9;1YZQ:(Y*D%C6-
MF3;<K#QB"/R@:#@B!)<S2(YE2R8.]U;SQ '3)A1[<IQS! )O;;11K$S!XS1W
MZ)6/Q=Z(4GI[IL@MK2Y_J]OKBC2&5,<7#(R*,#__SJ/3U-\@I.>7ZYN\.?W8
M1NFR8L@<,W$\C']*:&]K!,\ZU*[[M HC3AOJ;>6^[+<FRC:A&0]FQ7%S\D7J
MX].9DO8V90,:>Q_"9S+($Z.RZ;HL(LL<FY\Y&&>D9#Y'8D&?<@Z.OM1L4$^9
M]YL7^,M5<4L"!5LEPV]E]KC^(-GZL51W_*M=>]A =+++F=>+G&I#ZVU9J?(U
M:V16J[$^:8E-2CD\HB@A?K$P^/M3:>"8.>HH[RV1^Q-IA)@RI'C/S7&KXMMD
M\Q+=M.GG!OMCT=6*'TNB17A([HRGIZ<1T](8:K&20D4N*CN2-*LW-:]/C5UG
MF=U\P5.7*BPA^K)3WA'2PF%X :T.^2LY]']?<;?B%P'P<>X1?DP.7Z^T9=X/
MFQ([<3NXF2_C0P"\9B4 ,D HE.=M_S\.;_PO0N-X^)K^(A3_ C9P?@Y@6LP^
M(ADK$-5Z-@X_NX'(S''5EG;1IV-7N>R)]RNSMQH38N<7NVI$NIGB6,)Y\,<W
MFHSL*^[DD4'[M4XVP!+H(J?4/>VDJQ,<Q['<PS\=9;YI5(M L<"QQ,"#)>P8
M[A:2(@8QZNE5[[L5M+$E/5!5K2OM-F'"[5#M)6+$VRG\4YOLA^4MW)VPZXH)
MT-T6RFMZ*9R%68N1SU*:13H[WBD+1:ZD_0% %3KH'##H\B?JJ 9T8WE._4J!
M&#70MYF;JV6S3%(^/T:6A>@H7NWPYVZXM K+YA6493*HB7I(&8VE]1XW>L@J
MWAK3[(]WT)O-M1]\G(().42VDZW!L13+%%N'R)FK"#PQK,R&;4J3S0]E%OG
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M'='7ZZA1T:+6C?N*1\ZZA/^?N%OOO[3BW<V?'WM3NW,VHIF.ZC0L71)/10D
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MT]5)I_K!B$Z%YY+5M\N,"L3_97#YN,(K!L9=ROB&ZL%BC(^-JNB"4D74M$P
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MUGA.E#;P_YZ!PB[Y:<TQM0B#[58?D3470;,V2ME.:3.VW6B1/([VMC95*&\
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M;D%&5967O3V'>2(,#H<! U^N?E*3C)5X6/@U*]%"%O!8XR^<BD-(1<PT3^?
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MBG" 3S,:T=FP\M1R!J':"@6=8T8\!NS^7ZS7&UOY%6$US(9%5V2&9&+-N'"
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MO.MZ5G \<76W_20MS</9+**YN%9:[=QS)JE,?*S JMLYHCXP9[NEBY",*[Y
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M@]W='^^5RZD?W^"3B+J*Q]#.FX1(U8HR]#H7A"U(V K&(^;VWEZ6-+<*@YY
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M&NW0,-,C7ER<!RJG7(6T2(^Z$R%M ZH=0TR^IFI++_D#K-0R;XS6.$44Y22
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M8+1XI+'J3:E*?HVLZ[^E"LY)!PA5]_9O>E^M'_^0F_CU![@JX;/M>'YT,>1
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MSUG[ ?KH\R/RB],YI-!AW<;*6>LU<))&<UI#FM_MO+]P]J0@1^$O%ZF5&)-
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MKOLW&>QSAKEGPA?TE6EB>AF8V,@):"4I,+Z@$:A)[DS=KJKC_3-IRG\!_TV
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M*33RCNHN;V^;!U9VM\>&?ZE1H:H/%[F^Z:Y[_<\AA<[_M)TC ((]^&2;9\V
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M6YJ*/XUO/,I$<1/?+S96"4.8>M'B1$R<N*8TC/#U7O/3V87(!DN8 .V,R,Y
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MGO1]"PLLXB*V>+6-T@EXK)U;W3Q\C]!3V.:PZ:'5H_+RJZ<*5(CTFXV)FI"
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MDWD*7[E-F6Y?\M<DJ-#3"L^AG16@Z?<)JST.O@'?,T?S)"2^4MWS]7"4DJB
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MH)@:UYI4G157X(3XGL1?<UA48F3'4'P9(]F7[#B(K9 M?"?$STT7>N,R^%/
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M.#4VR.P)ES%TO/SZ(8M5*D*W--G SWV4\U:O!],$7]T%R6RJ?J,\EC0]BR'
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M(QN%9I;-CEUJC1.+9]NUZ=0YM6R%MJ3OIIK$*B-(F.:EWXT%QI6^R7X8E*<
M\T]\' .7&G_:/G_[7(9+\&PUZ2^]B'-MP5*!2<6=N]1],KGW:J(;KWVXXW<A
M]?U-3+M1!_X;+L/[R(.GS:%7D@W_8X8FV'SU1,9\\Q#$(Y40'5X5BQ$'\0 3
MBC.N-9+_SHVVI0YW2RHM-F-+CX)FFMKTG\S-0#M$43JHV6Y:22W%;]_<N[,
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MQ5CE')8Z\U.^_O0[S"-0B\">(D\6>I9A;RYY7)YV0]9Y>$[HNBTSY2]F764
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MQB'XLVW%: B.,WQ.^-(LW;<,.O!8__Z@.VT$&3:6"EH44,STKN50DO%HY.6
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M1?NX-+UG"[NG'([/@7>V8]CT6&JYONTFCX[H'W>:JS"I87@R]'&!@BW\"?%
M?#0-.W&422)N)YKT#AC?VS8S@Q55?$Q.I>AP\8(GS0,3OP'W.$22IX^#M@]E
MHQ@W>H^SXKJ711\NBIG@T*89+V=O=$BI\8[K:&HEZ \KO\ C1G;2N2>/NQ7/
M!P85_H(DY$C+77Y#!0@-Q0=%-RF*+\IY,(R:*S0ZPB8>9$,OM\):2:YMPJNP
M!_;PL_HQWSNT8X=Z(HN*RRM?L_+H$Y@X-S!,G']NMBWW %VI /HZORSL1!#]
M)RH@[/P6) 2-],!=(<[*';AE3#0%5W5YI&S(*UD-W610_-C:2+B^0([I[=$T
M5[S,)9&RHZM$<]S*47B;3* WL7;"4A&DI')P3M]:ZIABAAF%NP3?>=+BO/M*
MP_&@B%\N+H@*B/G<8V T%%E:Z=P;:.<QW:?]PH17=\Q 6?*-$RUM]=&%I!3M
MXF@>ACF6;&CSMA%#V" ./-K=PS'8/F1AC7F\-G2*I-7"S/Y VLN]]WUNYB/8
M+5>]I9^=C1:R']>=I%;$D+=N7L3BQ?P$D2=KP+L%Z";$_"3RM%2<MY\=Z!P;
M""*A_2' 1JBE1BX5Y/XT.^>M8G"28RW)>KLOMMNH8$#SA;ZV,#!A2,)+ISLU
M^C1M+$,W00/? KDHC@CCD9R;HM/]QJ_ J^TBR>:5,UE<Q[N#'L*V?EOQ+(@,
MS0:PY#EI_N0R,R-C,72.0%QU>62^#.@::V-26=9=FLVO[JTC\C,I:BQ4P$IM
M\Y%(</ON?K @7BDCB0Q-KH?=9.-71AY\9V*+@]JUJYPSD@]Z,%8TI*?6&#=S
M]"3._^U8 V.ET/,3'_6C.'!QP[T7L2[[.&-UL-;/=7\1Z,E>=1+R8X"U5##8
M3V48^M2U[3R#=*!U(*?_?:@YAZ*W3%@Z?OQ-YN?V)L$[J6]E!.)IF1@_3BMO
MZI%[U/>]M,FRWK[)TY7(IE?D"M,DURK58K:DS\YJU:Y]K0U,&8+=*_Z10G-J
M:?Z1K(68K#XN(+Z!:98*X&VC,31_8E^#0$ Q6 ?$L*,^!5V$*WKWF21W-X*!
M/=N7&]^: Y]!0]XYEY<)U1RM5DA-.J\D3"*>->BKQU9'MB9$1=#8R?+6('%&
MH?.+W&A;_1%J">N($\F@ OJA+F1+8N0/R^LPQXV7,"NK-J[%.E]93!4Z0A+Z
M5>>-5-O*[)%'\#+XBC)QA4-(5,)3-S,R+==QA6"Q!OR=E [R2=_-Z-L[=_GS
M6C#'OH<]Y/Y<YY8;:GO2(S TI[F6Q#[7CN/(:I3"_Z[XCGK61%_^\9%9D77L
MZ(V4,J;N[Y-I_K+JMK3&O;-2E'D"0R9*.Y,W4*!B[Q>[IO6-72O3UPAX2QC,
MW86HR I';!/[I:39&IVE3^-*;K<OUC+_FGB^/3QFT$N26<I@$T\P04RV-![O
M;_>](8M1K)%]IT6W*?!@M[+X)/C6$E8U,#'Y+<A]">NUU1J,6;\_CQ0U4>B=
M_H1P-6$_D//$O399Z.[1<DX5%'0:>;6V)$IC=.MMBO)68.-N1#HY3'81<E#M
M3 5XR8F(D@?*Y,K9PC=?SIVK!B^"= >TGX3UVI6(232+U#(E_"#YC*6E10EL
MHS0ES4Y\R7>KO_$W4;U9*=.A"Q(KA_0#&C\=:H:D,-GSB;(E"Z52 :K,V*R
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MDJQEZ0N,Z%1:CE:?5N*"J>)G%;:PF ?C<.."S.2S7YS4C-W8W;2T'1:DC!S
MPTLQC+$I?8^;R/8/BA(6A6S5C7)HKH3&N>W?W=NH)NKC]6"MTFK=R5"*.15P
MWJ5Q"(0/KN\":BKB4%:_S<NU==/1$LR?.*]'(5U'C;7&WMK>D3E3DBGPU+8X
MTB:."XBO@"Q5V7#_X.H/M0W\$Z^=OH^\(/NB5BE=^N6^MDY@^"P'! 9V'X]X
MZQK;E]/K/I!KF8&9J@B_[&*WRYCA!D\H&K\O,?VQ9(9Y.:-VX2S!XE<U&+#1
M*Q*"&-V!V($<? ]RU-VK5^E_JRU)$4GG9S V(>L#^>FY&T&KDZ]PDU/P.]&
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M_$ICJ7O'O%-#<!5G;?1?3:K;L.E9\B-%YJ/J8UR7?[U*OT1&FK<Y*>(=A6*
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M7$%Q:4+AXO0SYSEW<YY634W5^_SS *DOK,WL>2(?#;VH(![5T7EGC=_!5VD
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M(['FG#,_W"CYH^Y4RWV$9\D$PV&"E]=*N&.V#/F7)=1\>$#30CG--N74<2.
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MR@)=*"K(R+$26UOU'E 2=KJ=F%B2)&F!#]"Y%I)*"/C$]@#! M&@[#WX)+R
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M-LE,3<WXV#*T4@SJ(B3-R(5OS7BR#@^ _@<8_JL-<-;$?P-02P,$%     @
M#HKV6 E/E4;AI0, 6^$$  X   !T:6UA9V5?,# T+FIP9^RZ!U13T;<F?A'I
M(BJ@%"$*"((4:2(U(M)[ERZ]@]1(C8* @H @'2G2.U)#+]*D]QJ*]!HZ@9"0
M3'SOS<Q;,V_6FG_YS;RWUCMKY=YDGWWNV>?L<_;^OG.#F\'] 6XIR2G* 037
M" BX";@! (< N#7L7#U=/>Q<WSX0Y'T*/'^IJ$J( /Z66W\U  * X+_><?L
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M0LAFGB@BHX[N"%"QC'W" 0$;AF^M*4"N*<)3_=+(Z)-311+^6>.^AU&J:HH
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M*.6*_]3=1U?<0A%"*2/SWCX(.B&FQ&<N(&0X;1BI4D.K^25F30#L*@NBP!Q
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M^S;B<^V))$1&0E=165N"OG2AU5M732Y%O#JH^+9,3*C.RQ$)V(NAGNK!!Z4
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M<6> E_&]W0U\5GZ_A1]V/]$7*=EP#!._?VV#C>4<^O%OA2M*A:Y6X#30A8;
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M?/>MGA?/ONTFI!*+!3!&T]$60Q!\Z$<:)680:/2R"+($W/"Q[Z\##\).Q"A
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MJUJ!89#8L\-F5O*AA"([-C>J6-#I^9_U?4?B$&9<D2#\ &->=R#464)%G<9
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M%E#Q>ZWCT<0 O$^>YL7)-A:R68P $7LEM;@O=5>VVL!I,K8RG7;A (RJ&G9
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M*,LX*3XM:>OOLA5-='],7K)DPJ </.()'AS>"D\#-PFZ=@=28]VV.\I3?9W
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MTI-H^[3:QN_-K3:M_J]RIOG/VINZ*8&2U7J,%R[4U@O1@)N3:G$7:)XP\_F
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M9P'%9 XEJ[J]L-'4F5.0Q3V?W' E3U\6=,W.M_@^S*2FT!!>^%R,#8N$Y&F
MQ>G5VFRYJ"7\9ZH1=@%^G0.N+$<@GOSO;%(P3K!6A#.9*;(2Y4^72??4(VO
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M_2B_/L8M5V+#E^;O-#.M_XPTS,>^U)LT2'2\F]+NEUECN,[C?@(,S.^@(C2
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M%:=NEI5EF^QGQF&[M@KTGS^&Q_S&%LD6%!4<E6'>O\_910/^2YEV%"Z-6A%
MG0VHX7^'S)WT)>2H$;CU5OS&RA$]9KMLYGS3<Q8N@M6=N"]ZBPT5+=UU'F]^
M.YFN,&1.]YDI68\>\?8,1;+R;/>P6/FE=NE=XG?<]#4)12OW91V.M,M,)UM
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M3L9DJL3*4L6'ERF#N46S\&G%\B^GC!:7TD-#"#<1& _FFB-U5\8^=N%;X-.
M]R\G^A+UUZ(4"V/H0XB]+1/U]#?"1*:;!Q@:'^F\98Q]"_ U+UBVA:[0"6X-
M@[K"I"@.]5$J7]BEV.U7\E;3HCZ:B-<((6E$9=H\R?I.?D\+-AKWF$8-RD46
M]==6;OPM](N?4GRB%#-U@SRLINH!W"K8>FKC3 D4HP%9V0Y;=ZCKH%<[W:<+
M8<%RG+HF AL=FBT2#5>U'BM+OKX>:T7"M-.C:U"AE<$_4QO\S;YLLJG=%I\5
M+;YM9P^:6T&"+ B(Z*V7 RT9]@FJP[1R?@KV[^W\CZ\&G;66-@(-44;?]R4]
M1)1:-]" Q]9HP-;WK*N:A\"'_WCM##4:\/\\1ONP[]\\0F3*'?_!0_N%(ZJ<
M169V'@UHL&$'G27#FM$ ?R&[Y>B[?QP2I'>.BZ4W_T^#A/ "%B1S'VI9;AIT
M$^/[,/D"A.Q6H(Y'8_/2'6+_G#P[("5=AP;L;[AI/O Z_=,_J\_:)%7-(L;H
M!M.U>8<U/E;U2&MZI(T0?I#K:@1'5 >;:2C>/I>N!EFO[H$&Q;AW5J]?2F]7
M/X".K@AT6E2J:U*#</"S'M"8F)E>?RA<KV^W/X[(B4G$WYP9369 %*(@Y=IM
MWVT^=<2)X# F,$S3:NO"A]^FM-G:W"D8[11P??W^1(8][IR2VNKBH3$8,?AY
MCQ[=3XQ+TC5Z%,H'\]1=8ZF[E]L!+9TU&1N&$Y^SU3C5-:0>^L4$%E)\3A7^
M6?1$F<"2#X]3YDH2-\?Y-0?;TQ?/&%X%L3_;8X&M<@<(7=)]O@+I>-(Y.IBT
M'7+OE20&EPCU^A^LEZ\T/JL661+I6]L"YQ1]GU;42RXH  <IFGL79##\,AYI
M/:*W><2._>07K;&@X*;N(82AN":5E?%QW^/@Z<V E;I*1 T:X/P6#> 90[Z[
MDT;5(1/@CHZHM?9;QUNL[( U-(!I"(3(!W4*&^D[+DID*IB=? P@3AB>.Y+L
M4_CUBO]E7''WK,S;=_FN1'?EZ4_-45A[APE>ER+VP7-CJPBZA^]% V),>6_!
M+0=-'(@T3V@7SFCK8:D\B_>5J?8D_%&HE L,*%K9#!.GG3@9+=#)5.C3,X^Q
M966GQG5^[&LB0'1,9O,$3Z-D6IM(S30U,S? < '<_FO8DT^F8##>^),UG\UK
MJZ'0)#V]3)2\J21;I4%QY,1#.<1 >*K50\Y$*:#$B'V3K7 ,?!QVT2PN;MM/
MH2-,8$,YL &>LNI[LS<]]\+P0* &J(T( 1JG>1;-L8Q8'4$#J-" LF4JGJVJ
ML^["]GBRSHK8NQDI?8>L!&.9D,'CL=\+K2=SS<H8P06]6@YM3=T:%O7;W)QD
MEG +G2MW9P=KJ<6K<1/%6%[R1@\53]'V&.LF5=*$BJQY21^!!?CE%LQ&4+%,
MQN8Y1@% XQ.F+5+ZT-T$1.L[A5A' T1878UWSM" IEOP7\\_M2L&K=#:+H?T
M!U)I<%,Y0SR@?JGC+9G1<'!>H\%[YS-895Q?E)\U0JS>&)DHR-?G:+ZX;US$
MD?H(53&6.Z2<T0>B%>!./)T)@H=ZY#PNK*.6^:M00$ ;!KWXAC($O?9Y\G?E
M%O'\'(I(NKX>;#TA11Y\HET\X)S1-;)S6R)9&.XA%8+8U --?8#S[+:0W=WB
M$K/8H"2"@\B"6!8.AO[[R$5%]ESY8E;7G@:B/A1/+NK+PC:T-M;FV#*A.-XT
M2*(Z.BA?;XQXU.:@:J<K@N4CL'T+XXSCJU^P0[Q/L*^?T%Y&7BM$_ E75)>#
M7R*+Z.R-H8'S50IGAN7C]R>^'7L"+OEA%42<8:4XY;\,ELILJ6/4H#D!L[^8
M(MC_DKSI?2;QC)4W$Q(JC@9@+QS2?#_SM#K/1IF+3Y56^LY1R+36ZPHU>P-Q
M_,L:SRB\M,1K2ZI:9R87WJ1(<,DQ64A;"<! [#5:U?U3TZ4A![W;5/5>W5I/
M)[_[_$6@1H/!"88OUQVN><@EU]P)(S^5:V\%6 @J5&2J1:$!PR!$H1\NHG6"
M#ELZU8%T]H@F\IS Z7.]IXDG,VT:L!XH=@1+[SLRKFMP2BOYJOX9<IZ\;U_G
MIRU:3+W-G,:"HUUFFO[N=Y_!GL.7QLC\H.QRI2RUL<,*HKDR3]^CZFUQN].(
M:AJ.UV><-JH LWPV#.WMNNP!-Y2+OUQKLQ4"@50]2.?Q/8Z.H(B:WLNLA-V[
MKQHIX78N41%QZ60=?](5^$M'T-1T6U!LQU<E)#2]D&IENO[VP.[&X ";5%R7
M$3//4BVK^USZ[_D>V9O%UMD#'(9:N;S<?@YUA9_.[QK/.R_V.]K7PM" Y.C[
MRT<7"@]STO>!@30K+()6_@THY""=$^DM*<>;U7O@7OL&V?G7P4OH!>$^04Q&
M.Q)6W*;I%[B7):EB:@@/F;7/<MSV*+>S/(X@P:2TKS]!\,\;I%+2JS05LT,4
M>[7EB9O?EY3V"PJM,_[,[26F>^-L&"U'FR'Z98C'SB.)<*FV-' M?C]'EQ@2
M\Y/FS^GN*HCW9,OXU!>1YA$EE0IM/,O0NB"S=!"[#N69;4[[N@T]TAV%N<\W
M"4 .54LA_3U&QM%=<\!A'RY[3;-ML%^DI/@LN]K3@*G%%45K/ SMLZ>4VFA
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M' O&'LJ*405#%KX?[Z8)?$NC2XG9TC1I^M7^8R_W@J(HOC+I(8;E%)23Q7<
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M4T^"M$&*."7J0J2$JB U^&B5"Q5_ZMSZ>5+]&?T^SP?=A*%'\9?JGOCW0-F
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M!4A/7'B?W"0 1CA8'@$/.665H)LT!@0 AGO_<-$92GK]D^.3Z(M@6YPS?H(
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MCSCXK6<4^+Y@$G901DZ:[1S?_T:7'5CP*_)'X:@0_0/ :3%P:5@)Y)(1\<G
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MZ/C-V.(HO*2%@?+EW('_P+Q,=.B N>"E]T_MWYE_QF1>K@^9EZ#JCX;9=*C
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M6WD[LT!C;4F?XJ947SH8&%I[;C.5YGVAO=.KM\=HK8TZ9J'$K?! 4X#=:@1
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MU#(TB3/OL;YK_^:["->8NGS'P]A.RH@CX:T9 H!K>/V* KUY[E/?["*B]6W
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MOA !=_ W&".! PMRQIFBFU!#)[ZF<R>GX=Y@&KJQHC5#[6SP,[CVL2[4]TZ
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M-!:=PZ>Z3S!V6-^YPAW*2MTH&F]2:)>)$SDH\<#5%T%B83RP!270]7,Y5^^
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M1I\7W0IV8E\[$4*@7EN4Y#7&N AMAL,6%. G&S21IF?O74P)1( 5>6)1#7-
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MTT(6!%_D0K].#I%OBT2&'VAD[=:^; + ACA 5,C-IR4H9]Y>C0#/<$P9)'#
MMC(>?=R0^8]EQ>Z0_!J2\5L^^0B*5SYK'/;ZFYK1Z -\+!@.AO="N""(.<@)
MRRG_I/^?7<[D.8L#Z#?.+V?24P@)0-CB@%I-# D.:+??FC\;@]KH0ZQPP$8R
M1I3"!KI##3IX"3Y9W^QI_G?OA?SW!0E<.N^"'[PJ=-?V[8ICN*R+ [2,%NYB
M'^1CL\ZO%&14JG:,O+MX:Y1CH?-1QQ@.($O(!2]<PP]IY))/3WYY>G+X1GH
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M]21;H*9&?*9/]#8XJWB/$MER)#*B!*$/[R<)Y+W)^;@36$-$!^;(EPB]9V$
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M]90^;*W;)J^H;>^"B$=F7:@<+7#'XAK/_046Q0GNT<B;(:0.]!>4KR@()%U
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M%7M$_8>'#9Y.SL.8'5/#O(WYS1GL#J@HCW)V#S9[9,3J*7686'0I!Y_:,"A
MS(/H<T9)'&_FOR.&RL, DJ?5,0 ^PF\SA#'7[OY%,]ZA@4)ZT]<MD\FLI7PV
MKZ8IDK]D=IDZ)WEPDQPI^Z+YBE(YY0Q">FIX61055+*UJ LC/5Y?Z,,'_SMW
MXE^7.Y'_:4J;T_5"CTV=\?7]X;4C,R=T'GA)D6JJE_U LA$U? NM'S^G2QZ$
M(&#(K)2AU/2D-?>D-3[8LQ\8L)<1;;?MC%"D_!*:)8E[:YK0:]?W[Y@[5<7Y
MTV=5?.8N9EM*UPG&B1+JG$4IX2 ?5OK,7I6$ES+X!66XH_Z,TQJ&,I[!QL')
MK!N5W]UZJ@M6P[E*1*W? 45Q[_YQ^G&HZGRVX.[H(VTCWA:W$H?ZUMW_K8="
M^6!PUS8=OF]KH*RV/I:@>&BN^$!7G;R7EXZIJ[GW>VE6R*2X],C*<"0\I>]#
MV;MGSQ6JG">:\O=2A5J8A*,K[L8;$+32,-*$:!U_UF$46$G2K7LC5;L/:636
M_*,B>>]S9*,EOE04EP5]/*WFT.4Y&O=9S5%2:=.7/%G6#T\#4LDA>>^E@Q(2
MZ$+?#$VS=K MSL0,R!')B)YF=_6QU9+4?7W?3?9%DE(V.Q#-,0S1,O#VI%_C
M'N:<..%T8QBH*,0 ##WQ70_WL0PVOQ7+PBO[(!@ D:81>*IE]) 0H8C6!%Z%
M-V, =Z_-W+FQ> /% )028"O!Q7$7213&$+7$$\I FGB$6&.%AR=ZFB-F45<G
M\)GZ5DSB?B5O4@F."#X&X'+? B)1R>+YF*BV?MW[UZ'C_D;39DCVEYWHS3KI
MN3S7)JG[JLK1[\4*>M:F])UIC^>=U[ED>5^+<PMD\DIZRI (\ )^'V];8P!F
ML1M0%-9NN [1Q0)A@6\$>&HZ%;P!1 ^S@[<) H"[P?U4)\$8@'D4>$3O!3!B
M477!USUQX<PWHQ$#:';U9+5[),K,<?C1QM&W5)Y4I5>9(8SE[FL1:3@O76\-
MI(%JODQCZ:V7=JIK_?'DY%V3[@0]6J*/M,JR 0).<.#6@=F<^TR67B/5@^BD
MAB.3T$S_>THI6],Y#@?J<,[M[SY8BS:9C@I-Z4%UW=GO_<WW  .(>84!I!R#
MAQ=E6X? O29H6QDTR?;;2]!8FGN]8%^Q^\%@>=#B"_E-&SK))T/*XC&!%!%=
M7W(CR02]"A9IHM>M3#VC;*@S\7D(C98MWW+8M\X_VIAX,G32 Q=6(WA"7(V#
M?_]N2LP'#PL**F3QX/2YT+>:VA1I%8%12%#G0Z$+M7CJ*!P [DNG]- /,[N^
M+2D($>4I+G$>;Q7*P44M58D:KI(8P]I-10YACZTBLMSK'B<Y8H%7#?5F-F]"
MW%H_U;5NNLW??WW+4]A+_&7GPYXVF^[7;QZLG>**R" C,0"1#/:(CL?F?%&]
M10$!,LKWBAS;O,:#>\)=S41M0>8_9YNXS<S/$R9_[1>-UAO@"AE9&G67VI',
M-#9V(C>@]^FC*;]8);P;-C<JZEI:S_#R-'"88[7;J@X0T.TZ@@1]YF6*F&]2
MX'VLI)22_A8./ ].YJC3;?IFGQ^C?M0LMLIIQTJA65N3^:H>C^#Y]H2/9A^O
M>W=K4UD)*,*JHJ&(/T;[WK>='_,0_O"0):DQ4@DU9L^5=S67L :IN=T<E_[S
MR,ML05.$)&LT9#TC4;FNX>FO1R<[Q+RNUK<Z>DGLP:E^OAKQ;N=SUSDGA@Z/
M#I.@G7L.ASKJ9"E_TJT=#H9F569\O,?;%)6F2C_Y*/<4!4^JK$?W>W<AZIKT
M+3;!)2U1=#_2&U/R?)[C&H_<.=XF)5GMWM^ESIH]\'1)]$L8?+C@P9,]PA_&
MWS5)ZT,6<J^9Q#?M/HS+W5W]G,Y\=+&)$+16Y=DHS?SC19^.CM>VN8^C>7G'
M9$)Q;MY=2=IXSCI6Q611?V?J"PAH#O&Y]&#/0H9.:52ZB"Q/E/?M'3P0(?";
M(U1"=,(N-:&C:F[IUW%7AQPYIPHOBO6-XI-<R(\_OGX\;M1[D5GS+V1#4(CO
M/%2+WQ'F'^+6CT8[\28&LY>*0MT#<H_>)GW^ VN8GX\T0E?:/1[HJJ0^,ELQ
M('J#HR \ZPI#VF<Y./)QP-$[/+),Y!E/.12(B"R!8[5YJ,:2@_S=$BD+5&R?
MW>#/"-%[CWJ;J[2M):*SK.&V9KZVT<HOE(KO)KB'F(V)>_1_998VBF@N[O]Q
MRL_5Z^#(0C3HPE)J54)3\S2GIX(4H68"T<8=F/_3W-2_(WPOYGEF!%G\F)Y&
M?O  P&I#1Z-9D#^#59"JS&E1)GX1J6IES#?E8-D?FLX_/W/)66@ *>E3,K8Q
M[&F3CLYM)/KQD<[QTW-(T<#/?E'X"?OBO7&ZQ=)FQ_Y;'^Z1J$V$P\.?,P)&
M^(J^ASIE\8:U5&W)(2XD:AK2-B(=?X=HM2:H6>#($4G*[F2VE>,3Q,+(3E*+
M?7T^[>W'AJ=;57EX\(OBVO(GQZC*);71V;&SOTWK2N">4.LFARL%J+V\"ZL6
MG=?3<V@N][1X0:_5<?331ESF-7ZQBM/"P*W.6Y1I[!>WY^;--X7D&@!/>HP2
M;(T+Z6,F3O?QI$^IC\LE@?G>0*L_:*FWX7OLF9WV5PTV/EP3FY;;L&9R-QVM
M];S"K( PWLAB27R]+P6/N(EL!W[B/)&B=Q&!,LC0ZD8$?)S;UI$T(".ZI9)E
M*M[-2ZJZJT\ATSS;7R<\^=)9:UD8[VGFA\$5V0=W.3D;,V0I5[9Q*2,(-3J/
M6?S._81 ^T6#O17\G_M,*@444C5YV6?:Z%7"._-?OE\S*?@:?L)0%&T3)TWU
M_MTM,ZY@EG*FP_D4O;GJVFFRT;4Z8^IP003U.S7XZ;L_AI;$M*"7+C0NHKUU
M(C6_.IWN!6DS*)G'BFNRE03. 5_(J^354Y8$+TF ;O\=Q$8-.9-Q_DD  T#)
MZ1E@ +I\D&;)32!";QSM70+>-RC)GP%N?'1 K&(1K.3ZT[/FQMVG7K(.I1>5
M7NT6]OKM>Q&+M;5/?\W6>RVV-;FG'P^NU6Y.SVNQNBJ(^!D(I?5/J*BJC+\/
MU9')CR:5FD#.%9J(Q4XE!X1^)ZB60]L#CXK8)EM.M<O#,OJ*6$N432O9JBJ7
M&;LHRZ!N!PN18HGDE QKK>.6\G^69.!W21#P;<HB=]C1E8!40*U)F%V3HFM&
M%>J:>.& KLGDNA6<^#[QY.(R\:38"^65#^?8//RVJ >+W?/KG6NJ>C0-HW%G
M5_V!9''8PSNN*WZCIKO&D5)6WCNJWO)>05L!4M CHHZO^HU.1QL_KL)XNF'^
MUXP+J'A_;U2V^*Z+H%OP,>WK[\["?'A.&6DL4[)(NVI>#(!E0<KOJ59ROH<R
M,M12=GH=%/#!"3%>.M@HE^UEL^;PR= K./.JW^SLF;9=?"'Z0:7;TWN!]K\M
MMTK3X)6\@S)B)/K6186Y5G#X%I>B<-F8 DW3T[<O#TQY350G;O\M@W6D_*!%
M]Z]I(2U7,U$WC_DP2<AKJNV>ML3KW<7XT,=23]*+X"\?^W0*OK""RJ9X6!/_
M42"2QEVW47+-.'Y6<<X2T1'ZW#/T#TDTOJT:@@R4L7@%_:<09C6L,.'1+&9P
MG\-.5H;'?.X7'\P91 LMUS7VEQ\5'Z]1U+,@]:OL#@JKU%*S$^WE:ACA)VH2
MX]WKL33O)\95[J-VE!\H4F/G^;$\% ,XBBG?=#\E=N=P]+G<7S#HMA:9%'[[
M:#9Z3V%:]^3A^M":EV"XO>#W=:?ZA3-]/FX^P02Q1QJJH!8%_M!T)LZ]O [1
MW46[MJ-@-#$OJM#O:?>W(<6QTA/WJHI2135OJO7=5>1SR>C\,ML($?UG9;'/
MPN8F/CS@P;/2).15H94I*])\1(.=F@D&,,"Q"OF$*KED.@&N1?Z&?S?' +(6
M6NAF!)8:9V>:^<9>V$H9C>WM_=RU+?_4NOG9*:EYD4!SGZY]>L P* 4D%3WV
MY&^)8(S@7UK 1,V!Y8W9XYSUKA%$[.2DGDB]$']C[=+A#%(4Z@LZN+ Z$MC_
M*A;28T_O5[_DW9<0*1O2-]8BHCJNA@%$%7H,^-%@1:$TS_>_S;%_B3F6/34E
M+J9 )[_9$_CUZ<0!6-X*W(L!1"#MM268M1!@T>^A--PXE+YWXVMB-2=Z587T
M%F;5#.0M@=A/)@RE.('$5V!*#J,";HRD/_^"1P+N/".>UQ/ZSVQ#\IXQ7">H
M@2]CFAZB:PX@'N ^\$D#!C!AMG7)L,O2D(%6!UY]P<X:7^03M/GG+HG7WP(&
MR@N!>Y4Y&$!'_(S!6;FK=SM:%0.('T;G< #;@-IZ QC "=:VF: KOS2";XAL
MXFKE3#)=;)JS-9T4.QX\6(G)QG]Z,O<BN7"%N7+X*3=%7;%I$+TSP/PQJ8I'
MP];2"Y=]^'[S-%O[;0G-IV./!:)"'CYFV;2:^G2BD 7;*,A4N17S8.WN$<Z2
M>N%U"QD&<.GX"&LV"5/N8@!# U+7?A?,X/*-8%3.)[\9#&";/0=X%H5%H+@D
M\)(!:I%=<'GSP\1>VK[_[//KK'JGR>2KT"3JTM*BKA:>>RE!12TI:@$:+J!<
M9E;17#^1=.?EYJ<^_=ZDX4KR$4R&+T*MR)0S>&B/]$,N, !K^P:_(;E>AI"$
M-P_4"54UU#LE@<^DGBTT3:B/"MSD=G+) E'"1T!D6,+%8^3-X7GB& #O*@:0
MT1CO^QUKH'2C9F)13./07QF(J$LPTN! \7J&RMHW&?L7OL&IBL-5O9?BP18J
M 6L9ICB!N[WHKK%2:]86A5WXNED,X*S)#1G4X(+6=,< TG</D5IPG67PQD<#
MQ&H5UF2D>*&8D7'*YN:.IN+$BG@@[X'TQ2Y:QA$\K((!3!9Z0:YCL/U\P0!.
MA\#P/=]7C$A<9."1G%VH]L#;B#EWC;&.. MMU<O\/XMV\04?(@=:!1FM>7J=
M\C]\M']'JX%J0P9&&S%;T:*%GXS5E"02PP56)/#%3G@0KBY\W<C#[QL3S%&7
MW#"HZ>.=%VN:+,J;+&.X:YJ==C7S32ROFMWSY5R-?R?R\O'?>KI<TC&&5Z3S
MW(1TLH:JPQ'A_'.8*>A-J]!SRM\!T%G<6O24KHM9F+Y^\S;^U]=/>&P*U0!:
MNY&*G>HO18GA@D(7=Q92(S6;=>4DOO:$\P2IN^5P\MR1#[F45*2DV1HY3;Q\
M,F5"'"L@T@_[8&FR2T"]7NGM[ ,^YE1DF/']\\;.B]_2I]$G-%:BT_Y.X3I!
M64O0O###D7GC,4]=<.D*4UGPQTQJ%4DKI?L\IR^]<.:0T_67A6N2=BMP/2\5
MI3EF7BMZ<\!8=<'K5JE,H=]H9,%<6D3ZKGR_""UY_H,($3IESAKVG?E?YEX.
MY.5Y&U#2^Z@ G?M3'7,_RTWKNN;J'KCU%F4;RA9V):^42HK(PLL'WVV;'!(,
M-,5_\?ZBUT7$W,X;I*-T_;EZ?+WCSR/;B-VDW<BK!=W=9\'%0\K[I6U-11=L
M.&36L<@JS?C"3E.XG)6@L-2KE]\V^RA4M1\4SXB;+>5O+**]MW.L-%[8DX'T
M1>](*T/Z90S%5I28WY6_;UFS#/.;?5T5(QF1%XH3DAH<_E@0DN8:)45&+#^>
MA5R']%.DSE* ^#IG_KR%VK4I1V2\U4W.AF;)D@F;@?@TR!AI(O-+>H74E#M+
MX[ZHO[\C6H;KMX8L-AO0=:JHT'X0EQ6=J_29E,(48#H9QECZ!L?99H0A2J2J
M:8:C<W_M@S#U*N\'5NTT62)'QML5T&0&?ZBX>[==+$P0NM;EPALZ?S3ML(>:
M]&ZGJN7J55:DK8X>5U8U.08]N!6I+%S]1T417Z)P6BFZ-K"H'>S )W>@OK%#
M%TD]K9)0KV5:%,-35$1FRJD^<2OO(< JY4[#H7OEIMZY0&Y<:;61H57,ESL:
MK+_J,\WQ%+-C6"(_E]:=Z!8W$<@?"*W7&>P7V<:+*$-(H[OMF!$;N=!03@7U
ML!(L\7K!R/QDI;5^46VA^'X?(_5^W4)I>1)^A0M;"3.\@X:MJ38*!R]&KJ?D
M_BHC(1Z>J39X_WRMXO[ZQFZR-M[D)%3I>:S23T!%990'60:GSA]=?DI<RT._
M]4Y#]-O5T^KZQL9P>8]VI=D'>;F]G?P)=;QWX\](>=^,J48054WTX'FD1<:/
MB70A@Y:M6@XYV_I#F+,X=QBTQWY/YI+U&H8%:@AD"3--?#;R!E7M<_"ACZO\
MKW9R[[UG?+QS2XY/DL0\TW2Z>/0B]=H(]O=4)&@)P>J<=JR"[:B9Q.J<*DMD
MASZ6S<0O K<:N]&35WUV@6BU3:P&8AF^&IXHW_R*@HM2@%E$ROXL%M<;5'BO
ML81#>_:&(Z[!T5W#,\FALCOT08$BC;0%T;_G9S2M/16/A4/A2>*,6=#2%+[@
M):/YN9:V+MS"E2G&3WJEL)<98MU%<8=>^AT8P%=E#(!)+Z.AE6L:\BUUV!B5
M6A;H=1;L<" RF *_WDV>2>4,K[<2NF-N>\GL++"=6,'90(:?.:_Z6D-%;:SW
M0^Q[AA!95?N8B,5(&HA,>E,X2'_A2%A0-*-/"DV, 1RK(HS6*J[#$G3\, "$
M@;K,0S/O*K=5IIPNVY#<?.E=QT7NFGSDU_;QIY/E=$(3Z]")N:)74+/<B-34
MJ?KN6SMHO[3:2EV?8]'6# MQR+_-%FO' /[W=+$?_UZZV%^RARQRJTG/ M-\
M\R:5_IUGZY*\B^#UWTO#M;V\^1GB*(B$T'<O*LT"M$F>9A5[F-<_):"+&<B/
M-OF# ?P$AK74G'0WPRN5SPY5#8U[U8V/E,8F#A2FT_HTQXSXR@;F26IJU-[T
M1O6;5O),\+1Z_OY*YL!ZTGE;YC56GG+O80'P:\?Y@\$-8".XO]]"JK83I+("
M;C9X5>5BOMY5<H+'Y)S1[I5]G\C]&XO<2YW1Y_&:CG>H0 =)>=@+VR\X(\4(
M3RYWGV\RKC(DPMS51G._2DO%T.Y*RS'RT8EGT42([]YPVU3PBBAPX+ 9EOJL
MX^,N@F%9R*",3]_;SJ=^^5J\ZKQ;RX2['D5)4_Z#0G$4.?U )CK#Z>!1IZIN
MM$YZ6QFI>I>L:^)H=CJ.4N"B=_'B?Y=]^M=PY>VH6[3^ -H86\#+&)F;/&.]
M]/Z7\1^_A2"E'VA)T?0L?TC^C(;-H@-1,N<O6QJN@C(OI0@SAK,HXLO'2Q4[
M/%"M>F^0DF-+_]DP,SN&3V<'0"Y^BGL=LW&Z7]0F-,+/Z*=_J9I+FAG$J4^&
MY_(P 1,,A!"TTX4U-;T-YXK/..S.3WWEW:9V^?(=2(W"90J+"W;QR/+S\VMX
M>==&JYO._AS["BT,C2IQ!(U+FXQ59X[IQ)&0D&1F[ICMK66G_VMZC6K0+]^5
M/W@/9?N^VQ*6W#?%)6*NR%+]X\7+KZK=9.\C5'4U(2DR>+G6_E7D.'>V<2N%
M6K7G'=:YAJWL:&IXA:,D#B8 >%6O& #XZ7=R4NU-%EBC)!]-=EC"\&A/F$L5
M'$G]7_!V*V"YN D4MC4!*D?[-V$M_%*_<0Q U0V,$,/2U4I+\#9!!KK6'G:2
MBJ6S9L3@$5\!XT98Z1MM/-M:PK)S=G*6#T-_/(4UQGZ:5)*4TSH\K.&UHQ=]
M0<,:PT54POX<DB4ZH>,\-&]$G?!0SG+1)F\M@!940#T:?^LYK>&1"*?+@/=7
M^//\QOIH\E6I] \:667BG+BO&W9 >Z?9]LE532X.!Z%/PA=F6/E6NT)R"I^C
M#MC#.-XSOR:H^,C$]5A-JE0BG/3/@C6?<(;E82W2=U"8)2DGGID@1-E4)_)>
M^/V"LQV]-!32Y3+A1(9X)$*YB4;IF%3ED:B>RR_#-[K6GSEU71Z&_#1>BY$Q
MZ5KAK/8HNIM@/LU3*"6._R3(I?^-;FSO11/+?;Z9#HWC;J+;TM*CRF)O!93N
M^1Q/E7.8+U!UUD=O. ,X:*HJ[@1IQ48F6UV=&BIOD;N,V=IER#7HEQ53(X,R
M;%<,AWA]G9*FIFIUF.D*N!4NB#Q-N:Q][0I24W,@B7NO,N Q<XOF$X.KWTR(
MX-9P.R.0>I&UC:JJO@A+K&]K A74)F1 Y_WE!VU\+XTX,CFKS,S,/!P<0><%
M<EU;^SY+R[J/"S\/= 2M.M5%Z']WF)SRC*A]6WJEC/^"S"M.FT>ZO_0=GS&'
ML6\A;&Z_3OT!"%^543"@GTPZJT#RG>,['EK-"$*9/7>6B(JP>3E:><F'$OLO
M7M=D,8N]S@E6(!6QF>:M;[8GJ#*T+6IF)RU:)OQ6.%?/=.R16)XTH<G'3\5V
MI_-6RGM]52+Z6L&4K0S+]8V61LL8W)I:R[4)D_"V)Q*LUG-JI4^A]/YJZW^*
M1 UA05+)[/9/97AVG7@^+TMGPPTGK?'Q8L7:\RAI"+_]-"FL>/Y2@_]!2 X1
MGKS^ZZ!$\L@\8@4ZB5\IH9&,)@K.\@=S:GI)%>NQ>UUC0^3W.]Z\EB*;EOU0
M]*V&-H79'T>&=L2)=P=G<J%N[(6Y>_1<2MI,$QD 1XY( 7!']'W:6V_5,;]H
M3A#T4UL2>2C%YTJCA=LM)X%"3R?;I))>O*6W#N&BH8^[#1:2WIBS\^HGDFF
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M25DXBD3,CZ0+>2DW"'+\_GUIU=N;Y:#PT;SFN.L/;NLHZD;+4PZYY;<3_L
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MR5<%!6_E+$NFRM_[*B)P)89=V-:4F47%4=#R3"H#'^[=P<4?HBSV#LEI%F-
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M"9J<-Q. !_8>>;#AF Q:<0=WQ:8?G%[' RP?$,OAX),&R+"2#\%E,^<BEHM
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M W7;+(+_CJ?^G]3H;QOR0O6NV.U.,=Q[,R]]''&(S@067E=_\6+:/:/"$(,
M\6[1RU9QRTFZ"R)>65ZT!"PJ1BF,!R ;K!L&T;[=WI3WWP!D]Y3+?$JT_KSG
M$L&-!R@+T[ %Z] C&K#])-1R9E4?0P0C (E*X_U.W$VD,H8(#R0VU8)V:)9
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MMAK"5[//':RU2"SPJH#^^F5<G3#BI6<5KOJZI\1[<@BY D)E'MZ?2'@AO:2
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M4M!%7'Y^O6H8"T8D.%<[PZPVXC\L.7;9JLNS,Q,_^)FJM1L;05A>V.]Y^$]
MV[E;ITYR/1!,-01' HIH) @[^OQ9Y@ %QD1 47V(S@(\0*&8#SJ2.JN3+I+[
M]Y7ZG W\X5\33O=@PP-47.^P<IJ$^9^E_H SC(N<1<*OKFA"L$EX(-MXFS3]
MU KVVU/\H:^3_E<PWT#CJQ\T,$?_;=[44,D]$MGL_X^]MPR*,^C612?!$D(@
M L&9!'<2/&B X)#!-4""N[L-$B! \.!A<!O<'0($!G=W=Y>!@6'FDGVJ[JFZ
M9Y]S]M[W^\[]<;^IFC]O3<W;O;I[K>?I[O6L_#^FCR(2SY[(D-^Y4'51Y-74
M&^V2HJQ;L! EA;;94V+(^,8RH"..\G__E_^YH97.2"E\J0/J6!)*L[L-3ZMK
MB&8I$L3SR)AQ<9FU4CRA?7-]B6'\61'/(;*4\>IBM'["URDNY2R=T-^(Q7-R
ML#*2_(#J'*7GX9-^QN"I9"M$-1$H.&E@M*AD$R9P4*VUV)^6V7%PTPR=U#"*
MS6)X+DOYT;ZX ^ING!=1&KGE2,-&1#*5-'PMH&D#X,1*@/)O U?W/]L%&_1J
M;B8."U]R]* !$-VJ"L]]$UOKY $3H%>_NO*R#^3'YA\UDL'?<90MD0)A$JJQ
M^?@56;E4PH5+[T>@RW9><:4J'Q!(:>0B^6?;Q];<4@]$V?_J;'", "D:5=>V
M]0QOBC)OKC"F4SE>%6R%/,=H<=5OEJ#@W*JCMRW98^%4/RN6HRLIA7@D,:K<
MJ*M1=;WHX"[(V G6UC$JC !)V-4)V!74U%2[SS$W1TI!(2' J-R"DM*2HA0!
M3SD! 2V(9PH4&JI-1!-!8^9F^-!/EI<*#M4:,?Z%7ZW(Z3FMNS%]'GA@O74,
MG5E^>:K&7TRK/DDB1WF5\!O6X*:_WRNO]%.-*%755@.F*@O"BW)2I-2C<QY'
MT+!1T'(KLAPL!!(Z7-=M3/F'88]!^=.DH^;%F7ZE,PZ[;7M0@;"[Q'KUC"U-
MC?PS[&^9GSKX;SV:]HY V>F*/L:^&^I<O!"TQ?1L#%O8EEZ)%(!$_NPS3>>3
M5"['&!NO+ (*BW\HSM4#_K0S9:EV1!X8JKXJ^SGXYX;2F6&#!>[L=^1UP4SW
ME3[]%]-O3[\4/]A+4,SJZ/&U!')&M;[.E;B@]</:6T%-=UOFI'>I$CXK0A/D
M9O:F4&/S@G+2 7471>7,HD+#&)5APC,)H2'JTP_=HJ^MDM^3'(XF'\H+L.N1
MLV9//)?SW_;[,"1I_GH3Y40>_IU=/+N6*,BYH@R7;.3&., A\ -H>:AT<:GE
M^:EN=9-NZ3[CZ2WL'MHXB@9.;KR[F-61 4>Z\H[,>Q#P8.DT.UKF#GPJ*O#4
M#L3_ "?9+&D5'H/STY4&3^N04<W,!ON."#P_QT*FFOR*@RG*9\43D;JH[FYX
M9MQE(OM%DZ;O>=)SU,IHZQ7J.3R]JZV1D@U[$T5ZA08XP47_@ /66+Q%P)6I
MG1OC91TW=KDE] MGKJ-F(-(^C>KIMSIC\7E0C7BB6\\H-D23<U-9$(FG2B.U
M::Z5W$B*1D@NE2XB  W@NBN4X%U9N&40#&DWXI[8<"0/6;_SI7GZ5,B:M%N"
M1N25OV&$7Q5?"N>#5?_M^>=GI?WO1V(#8 #6/5G1-Q"(K^G2&RS("T O_6,
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M-23Z_F#4CRSQ]?-8%FBN58Y>#V2SO^5S6IO#A[C8#EYU$\P"NIB)N-R@QSB
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M43IH !K A>SBZ+;;EICW0@/,VI'\E\=NSHDNG:^HL7)BSI.?QD\NUJ3%,JI
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M'L4@+1$181)!G)>.4$S8XSTL2G;-8B^-%-R;OB!\ZN\@/#64K,Q3-@5S_#Q
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ML(M/5R=;D)+7H-/E56)]Z>FTQQ6[]N\F65_8IJW&G!I?+=WTB&T:]QP=#IS
M>,2D(!(@A0!F2_N#ZI./.0&M3YSK")41"$CTL/T5=C%X0(!79&GW?Q.2_X,>
MV4X"Z1-;L7.5=Y<Y*MXJ4$RU" 7I.=F?;'">O%U[WBGYJ>/,-_^A(*O?W3GX
ML=:7]RM#0JT2VWO>S56_C2H.L':YURG4"=('D"TXZ1!^2#G;[Q5\ ##JBV_P
MOY]E^T]YH >MJH0&#/QAA@;(O^,%/$#P7:VP3(7F>1+9NU?\R,%=\1F8BLVL
MY^6]^/,(R88&S,?ZA%H?HM*<_FS<$]^S'3X/A\NG9R24PEZ:8Y_^SRSKC(UW
M20O5#Q-9HC)[QQ^_4@9%YP14/F#&?OPZ..\]L1+^!][ZAOMNCG-<T?PMI_+F
M;SF5]K_55$!_-UI@X(0A%F)E-. )T<%G12G> &\5Y W*RIZ=TU+ PV$?BQV&
M")L8">.+R'Y,&HK+GLH>8Z7U]^V[77<]L^#S'ALP\L00?!-W;SL0_X$&QW,,
M54.':I)&L_A\3V\72F%" D%JJ7%NM=$_N7U_H%KALQ^0!/?O!?TK?_V?F;_^
M;_?)*7K&?7)=U/E&)+F^W0<F:Q=I-("^'$X($7W<=P/<'($^%E)[NB>:KM12
M,_Z?:/S(TS/B32#,+K2)3I!\(]_I\ECNH*'(J'MTVPO#8>1+1N]&#B,Q94A>
M0=RPKK(%!C=WC,)>G:M21HQS1 ZW$FAVDC;&D,CH4XTW&A!$A<Q#&9'OE_FR
M70+/^CI=1;\B[1$NE8[):<-+P%?P+3!XD^]FD^6=FI?=%Q57J9Y EE<$CV,S
M!KOT+Y\-2M++\<4"&V^9/7?HWE9$/*"7>]@J3;C3>B/]^M$90=).'1K 6G8M
MMZ G-GT-C 7R[U8(^Y\]A)#IP>I0[)WT7/8NW1W?<US$G][&YL9"4QV.!+YD
MW,4+C:^N.=!*7*<F,7_EK5A\\]+_]<%JP0E.3\PN&D \JGXT_<XO:1A,23/@
M$7:#!G2Y>,H^5*4>E\8=AWTJ>O@AYGLLYO='4T2AXD&XQ#)*6"5V1J<3OIZ;
M_X"%GCNBI&EBQ50Q,R>7<G/3JX&K(R!C7%!8D(P&*-AWOJBZ#[$ X3'95W2L
M?P"<LK\I]?GG-' S8NT!O<) 2/+UNF+M4IRS77WA_OGISP+8RC&EE"C!ZZJ<
MRQ\\=))RP#&L]1_A 8>YT4^:G1XW%"NI<3Q<>.(#"42D)TJTI"<&U=!!@NJ#
MUH@/+T5[O&]X(1UIN/^!=N,T56T )9'6<_5WYV=/ZF[6<UU-->U5#H5,=P_N
ME@-GM7#OAO4B^[88:^_H-45U)?#B8\=6BBR-\C791\?Z5BPBOCLRZAM]Q(HB
M WP294^&; DJ0Z74B'*U@HC6%<;'<Y<&EKSD*UP3YI>;GCA^Y4OH7=)2L-V<
M\ZJR,2YT(O=RM#GH8E6?^;7TDDV"=61B;**34Q[S5) F&UM%#&>15.[%HTR2
MUZ<X^<__^'%&BQ%A&C_SALG9>>[]O]Y"J9V[#H^)*]#'ZJ)^>U-.R[T!#BIN
M.P!=P.WJ=*8OR>_*$#>,"[9M(]-W=8BVX;']V>&/_P=]D+H/<@D-2 8B>:0[
MO=OZ#2ZX4!!P$)RJ:P:\0' 1B@IO1@.6=1KG#-;:ELJ.. PM;NVJ)E=09$N*
M&F?25NDN1S4?[X'[MNB))OA64!15@+H?Z2F<=="Y+AI@LHSHM17=FD7Y@UN!
M2P310%:O\;M$-. B^V[Y%@0W?ZO7&X3:!^?:7;BDGH$QT !Y7X-6U&'^?8,(
MQN$7$!^E^X967=WAO$<# IK0@-G9>TX@_1>T#R_WJB)*T(#.=J36\C+=/:7@
MN&5' Q; T>3Y66A @\&N]-U]2"9$'5Q.J]NA <>@JZ@[2I?$P&%4G._X@6^'
M#=!D\S;XW'WM2G]O^1]I4R4")+,@:D'Y/!4-8+O_!A*L'__=POGP-Q#=JJ(!
M-,NWSAQG>_?N0F4OZFY$XN_.J_+_=_'GWZ9HRA+X=/MH&,E;U79;!+TZJG9W
M*2-&TCFA%M4C[AOZ[8CCAMC*BW.QK4[TR[UGV7G7NWP&BCH$7R/VC3E,6G %
M_O>KGZ#.A4FN@'G"TRR\>P,,TP)AII]J ,#M/C%',:.!GF&^1MF#I7*%!A(&
M/1?1<,W1_/_@Z5Q]^C &BO!Q>5N\CYH>QE2:CZ@ULFE)V /[>OZG]D9L7$'C
M]./4GLWR5+"#*Y$-E7A8&YTRZXQ.X>X)?^>GLRX0-*_1WR3?8EI'FSQRS;P&
M.2QC>RSY?['WGF%-1MD::"R(HH (B$A3 >DB2!.$B$AO(H0J17I'I-<H*"!(
M%Q"0WD,'Z4*DAB*]$XKT&B !$@(I-\R]]]P[=\[,F3/ESOR8/_FQGB??M[^]
M5WG?O=;:&VI+;Q\H5ZHJ\Q L(+A&"AX4;+N)6"V45V6=QN &+EW7,K[93YLE
M+MCQI1/J;IQQ =*K\)Z_NJ@ZG;5$SG@T@3'\1LG(V.1@K$'.UU[5L)V0!,9#
MME7IFXH7DPJTF7TS4!Z'8<>IR')S?ZEC^"CPEN1 M73<%)ZKTI6)[4+"G*C[
M$3Q:Z.9CR\1JT=2BG-S,=V,3.F/J(&'MT58*D;R[X1()-$JY,;V=T<D;)Q(=
M*G0^[J^;1XL/7S9-+A_/]FO_$),7T7(^S^K?12_2?O/-.X-B[GJ*FI#Y&DE=
MEW%7 5Q0<W3@B;V<T,[O4AR0'44$D$__Y&EQ!&H;9+'@#, 1:S+@Q5/O&,;?
M*2EV=ENO$].SK[ R_DX7#[>UB@Q7IJM4HD_X$L2H=)'&8L>[Y):.)>O%-]*
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MQQXTNNLGL/%GD@O_K8 +<_/1WL:O6($M.P]EEE!A19?9"'P8 ]N2 !8=<K(
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M?20"OD:MG57J]CD$>$Z:+#_T>3".*-VN:WE\Y#-WBR)@N ;I%U]1850G_6W
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M-CC4XUR6U5I\!C26"TA\%]J2RN<F=XW\V;SG;AEW%V_\A_X!"(LMF"<W79;
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MK_U#5ECH_6HY4FVOM7A&3>F:N]T;"W*=1H]6=SK%S5179^S"&^MNJW<0AE?
M!1T(5X2(KNF=7U_HT!6N#O\-HW;M+<W3O:Y-+/CMFB[3#6:LWV;HR3?;43&N
M6G6PAKER)R8A_[W-'$[O66LLCB3RD*FWW'UX)A+(S]^7\\JQNYQU:&@H5W(8
M#&&1DW2F^GH1/5Y">;AQB*6L<G\1_.GU\;L(5FH-M;_BS);K _=$9X?6C'8U
M*[%X0PLUBQ)R"O%(1L6)VI/J+MJ4]U3BRZ^CR[XV-5XIDNL3#*!;]W>H6GN@
M;=]IPEB379Q@)5R4>4STA96"R<+UT=J@3M-ZLCZ/G+J:FY"0K19U9M&@TF^
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MS-$?1L,NSWV>0W]YGQD?L2_";]:O+^-LXJ4"#1?U@-%-V07E[Z2^?IU):HZ
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M#E?VB2)B=T8"G=<?8G!:>I'(3S.YG+RNIZ02NF3IW"W!2J!A *0.EX# HO$
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M7Z;AP-J*4Z7B\!7.L*"O[1J%MK'B#10<0'Z80?YN9+1!K E&HLLW%M517T>
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MLQ6MX=U(-*ED[,-/G38.[V;?:LG>W79X[E=NRVM@O.=-(BQG*&X91A#!.0F
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M2NW\]+HMY%F KYT5%A"RMAJ11T2/9*3-:EA1=>0NB$:/2=&5)]X9WX0.A'S
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M+GPB!.-W0;G)L3X.]Z;8GPE7^!G=&-RT*2\<-4$N?0K2'[$F:C, XNZ\<T[
M$^?F6?.GD5S%4)*AV_SSJWS$C/9BHRVXJN%BE8UA\%FX/KGZQ^U9QZ-67R>K
MK4,_)\Z\\(9\T,.)T=X4$'YL<8OH,,\C=3XM+6U42[#L^]JO+\L]/@  MU\
M;GT(##+T/39&K4Z:VZ"7I>SQ)B<#LFT#S5'P%L]+AIH&WS4Z\./4N8R!5H[$
M)08C.0M20K[$PGNJ\0/K/HU\3TI+!$CM"!,OY!U 3:8U4+W)R>^.I@^[)O:
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M2Y]<?9*?T'^12J2G:*C?8WSG3MH?)TE5V%'^:I2YO!BLKQUXFA1T3Y\S/;^
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M@:DB<&B"QAT4'D0H&*3ZH*=30\U-UV?V"S<3I"IGMOPKA]^*66AA<VJA?&
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M[VC[V1%KI;DPGHIF_EZ2NTT?Z;K<?I\W0<EGP$GPZ7%[7&'GE%=.59N=Q8=
M):46,;?3:F"#\Z95ER]=DTG]"8AHJ(KUI-*)XM UQP-A$Z+NG2^;\:W8^W%Y
M]<WQN/PHWM=86A";)O=%>;X'FKJ)!>6:/XU/CA/,I]/L]9%D"TV8U%SDU*8M
MQ71M=[(WW!BC%D,B=7\Z,/'ITU:^6]SU3#I8KSN#0*QKEU: ^_ZHG?5AZ6!(
M-&2SH.)W-4&NI]&[:4E!L0!T\#"XNI.JJ='T 5CRU&Z6Y_)2-4JZ/G *2C;]
M&K?A:^ 42-HC6.36='M+YVD'?S!9:C[L(YRY?:.@7$MMV?%>F9O(=6 HR%O3
M,U@C)Z+XQ<Y92__SS8>/I_YT:*Z>F\WPA$J<QG=Z5:J??-KF?)XWIO3MC9BD
M<ZZ7SWQ\>*8L_U?69GYC <.6*\-VI0%@BF74XNT@NT6XG.2#<-SF&\+CYFE*
MBT6X. H%GAS'"[@*?39<$A4UXM2*]I^YC[RFW5@2<_M<U^-8SI&W*E/(>;:_
M/,,UP(.E5.D)F.SC;8IZAWQ>CVMS@GJX"<$]8F$:PEN?XV:$"B0'+]T+P[@X
MD5,E I<2:N_>?6(\L1#X(4/43?1YIMV%D&MON5Z'L#*S MZCW]!\9[@B6T)N
M9@;+YN:UKGID]2JCO;WA<&B\<ZE/C^QCZ':[K&X\I7%9KN&ZU,,/Z^I+0*3?
M8H(6)+C6LQF.X"$L;%^<6V"!W[\-H0(Q<GS.U<2%<TC4KB83=:=,/C7B.QMK
MA.1&J\PO& ]77].>U;_W*NU#'I143Z=_MD=G:M)%NQ;!G?&?:1+$G;T%-C.#
MP#O43=T),;7?>3MK:IRHE])"6T3=;B@8#\FZ6#UQ7#_9Q)5D8!!L?:>I#HTD
M6]:2JG*:Y(?&A@DJ*XB[J$(G4B6_FB=)KR('8[A<>W6P/:TPG2^I<WD':J!U
M87SLD[2ZX)W7VG4G6>OJ%L]@G4[^$[:7(!GDO=<,PSA9O2N8#=+<O/7,:+9[
M>>B'SXUA:DZ!#_ET$N<,7>S*>]26>XG$B:D:<5G_B)F[H W!F&(' %T"(7^U
MH/T*V3W1H8A:9(*T#J-[;#;F:HD7R]>/,[/PEDO/=4X>)!G8W0VH,A W_OGH
M89H[LB]]1$=-_7&"K-[#D0?G9.IO O[N\+0=Z"\/ZZ(FTGFH071:I.F#-CG5
MZ<$MFZ+UX97NKU>OKF&>'#!!F*/<I<YO#7ROLXOBSYQRG'%U+HO/\A5\;S)N
MYECQ>]('NSAYP.V;L%M;M("UW7DFJ/LV!<<$=91ZLM#; IR7\<YL[S: D$_#
MU2@&TWE.[1VJX;]L;-SIQJNX916[/C\1;') 0-^\-VQV2D]06#3S2^5FS(6<
M7](*DK1%)<\73S;+LUS*-]'07$*=#3F.;FM>Y0GP;)^(ZO'*Z6WR;]FP2CNA
M@*@?]UNJ?VJ5>Z=<Y$965O MUZ+77^&FO\2R.J'+0=&M#JU8%-[C9SQ']QF4
MP NFCZVQV?TH12,O$WVCC+0$5\_JGBBXGU*,+D'6_$QXIDH[$GFP\J;:!W4+
MQ/<PT;@2<+XWYM^$"OU?#X*H,3@=\5WH#Z7TVY)LB:F_#-;TX Y'G^C<D[6$
MG:7J[YY+$+EM$CA9.VA][M'&H],F:^.2@/@ALC9I1\48E]]O.W:$P%3G)O&.
MC/7A7;"=RD^EF@7%KO<B>O?.U?@T!L]<SGE_SMUM__1;W6<I-W2> J&(JOG;
MQMHT X2.*1.$38@T@RV,[&"8H)>0"A6 I0;]IRQBRH/!_1C?!<F [)X=<G32
M5A8$"P2%:=D:W-/48MNN)E*BS%/23%WVQ9],_+:K!!+7O/5E'IA:/&M'\"9Z
MX9'/*=@>(.Y?T>R>$V)1'#V1C6&?$W2,:YU4GP98W\(Y)(E<PY)</92?:>L^
ME'[_XI,/E(2 _BU+@,:2]#5(;I >$R1VW/!NPSHJA@G2SU.DV2=*M4OO;+I7
M9LY6RJG=)\9BPS"-9=M[U_H\PP]&-?7??1X3<_3G!M=I7NY,-4GIV,1Q0Y8A
M]!P:NBA,K1&6Y;(GW#OA([DJL&MO13*\<,6^]9Y1P..9></&S"-%1&%%6;[N
M_&]IBE8! 0%JQ-J,<N//(USQVAGI@ C7HG_&4O3IXF#J4U,G(6U%W02,1%++
M>KFS>CRLHXJ:$%48<]-JIKC*]*6,G,2-6K8G@#BLPAX#@RHRZT5$"3-!Y[4I
MLEJ(&1ZA.,J.<?;O?R:H"^=F+]GV?9AP'S>^]ZNP,*<R*-7MQ(V?YE)O X"*
MF_I;*+-'*WT<_9Y=<D\=WYZ(EK<=AB2WZR7@>#T\%PZCM;S*>_;0UP,/'5R_
M?7?;X<T..'BL(_\H,Z;7SWC0UDQ6PODJ[N0E 4WQTR6V_WJA@XL^0*IY:2L7
M)$D7;E@5MMV?GQF$1N('IL)=B:22&:VI?5QS2WL#CWTF645"Z!2[JE_-<V*7
M68YUE_B3R:P!+Z];&A:S4Y<U2>VC/(L5L'- 0GRD'Q;V::<TA4#BGU0K7EW5
M%W+!!;!]GEL1-%ZR='=0/_'X)S\!#4%V00X@/'V H4TFVO9[?>N#=:*9H*Q!
M&YSCS[,<"7Q_9+YXG*#&JZ_6TL&WX']>0JE8(>5='2I'G ^3<>6*/_!KI/_T
M!-__TB,-DHSPH#M*U V8M++P;OMT>][KV;Q^V,*=C7R"3QXN[B(CUFV4'.1(
MI.=X*W&/T ([1"O#)M6U;!/RKEYZ W>P>-7G9)RY/=T P)!&-(/[5(NB/@<]
MCF94&5KA>U EQ^GAC8Y3\G#QC$C-PR89V35/SA*(^6KO/MO=S<B:N1#0:)RB
M==T7PY^Q]$<$B+6T!X?=8M]L\,OKPU.A7I7.1*P"'R:!8K0S9_;MMO1T>1ON
M;.$&L>K4L\INHXE>91OAYTD><0%U/U2R;GYIPE'*\9WH!5>(2MEN4K&$C?Y2
MBEC\FY#D7G.R]0\[\@I:W/<G9S-&?AU[=?V/D;<GM$[\GPFQBPV^E[==PP2M
M-I@AS$_+12UA[&\],RK\^F7L*TDR.MBJL__Q^F,G 7'O-1TVW]53KS_\O97X
MOV'0&.HEB+/M/@(B5>&0K><.$]2[W SIDER-FL@45>3O=C#,YO3P&2@.LC0F
M>0[MQ(DZ_='!&>BE$G)N,LZ2[]T\W'C6;?D#B\[]P@3=A:VN;4]]J^G6(^*I
M\T<;@Q,YY3,S(4>:#IXY.TV(^._$=J+1KSM>5MXC7=]VS:_ "]V1,4'5/>LT
M;8L(?WW1CVNXL/(>H*1_")<E#,?9]I<^)^L'&*Z6A0FLIGM,D3\$A*4IOF@=
MJX9O[UN&V3N2N=6]K$T>3BB\O=&[-FI.]Y-5M3D-G31G*=>"OUS1_1^&ZF&Z
M*((Q%[:+8H(N)L1#Z)>.S0'_%K;2$V'$$4A_(1/$+5G*!)'3BUA1:\8$=39U
M_'(H#&."[N0T['*4+O1K3=NRA1GFM7NXR^VGRM 2>"=2?[9H@]AY7^=VXC81
M']]=$([F:'$7M1?*+^X:UY7). #*1972-\B>'\5A+VK1N9\J]'HKMW(F];WG
MAFC'YDS89@11+[\U-"QD<:>6"8J04L)P9_4]49$0Y!:123&_I5Y<4>Q:_LR?
M=P<H'2W6^NT[>4,8!M=(78?^_A5-"12#FPD2SZTJ^@0KVM$Q#+RRCY^&H\YY
M"F+OC@]KYUHUK^!72]*:[!(W=E"Z^HQGH_>!6 K.^ZO=/8G.V\Z'K5V$I')T
MB[M#WV,<.TSIT1&8!N2=F$:'31$YV3MB8/UC DEY_F9=$?==.TCL"":A..FJ
M/;S'9*RH;W]DG'4IJ#03)!1NMNM#R33B&,)G,T$#>8LU/;:K=G/?CZ/:$6MV
M0;>&YC9'0G +FLK4\-,]N4AS+*WSESZMA$&7R=\"H@LPYT+! $#60!LFOS">
MP_J6&H*:AS8C.ZCK.]'!/O.?<$HP1\^XPM^)>JV)0Z0</')W/(.O"7&WA2*:
MN591757S)BN+ZU2NEHDFZVH;X[. ?$W;&.K^[HUE6."'.*N>MU9.2G_;"O52
MU@P:(_8N%_;=P502<O+;FG^;G!(ROBEN'>%UT<5SZJQ!09K>H)Z^Q%).8OL4
M<CJ["L ,GC\OCE"FXJA>"(990 FDL$*N776]EV0]/,WKXFU&_'FEE-.8>+R.
MJ#>_7U'7FN4F:SAN+_H+]TWHCJ!WMRPPJ,KA7<,$%?H0+-=E&+\F]0?&.TL_
M%FL$BH2$^_>1VJ F'.3<-F)[0MUM=SFB$/0WV>O&V# '$R>_ (_'%Z!*]9)2
M%FEEID! 0(?_\H HMQU&K07MG6&80R08Y\/+IU&; 2M,4)J&T7.OG.3=&K@<
MW@:Z^L U2%4^=,K,I5Y!]4\X%JH4<U;^RMR0)O_%Q'M<C3J63<MQ\P=$KMQ-
MG,W0#,,!_V-0D(;:KMG9O1-+;3G@6T(-G(?L09Z><Z8"O%P&2N,.#5++N_O)
M(\MVKK-7ZZ!WNTV315[G7SX"N"ZT3/_/JI4D1@!DNT1BD-ZG*.9#$O?IXGB%
MO85P_(:2E$; 7C)!18HO)K!+%<TJ/Y3V?(BPEK7YUN/3-O2]^&5)F@724T[Q
M6O@K&5FCSXD =[[+!"F&?DC8;6:$H4'H#X'?/LX1=X+JMB&$=OJ;?B]M=R3B
MBTO!#&W/T3%=):$0?JM-=6JN48%@*O/9HL K\\G7-[EG^EB1FN#!!,E(_FZM
MM-.!6@G<H%J.0G,D^&<B^E_.\;K4!DZN5L_G[U0E8;R(B2^ZEMTW_4)":T\:
M4_I<^0M[ MK<BO>!P=5HTH4:2FEJ+31Y:B),/G*\TZ69R#/$V)OSW>^0]K\1
M7HF]>.=/'';/?[EL8[[:*[BEG'Q:TF<I[?[2:PBJH4@H_^E+H)D6V%^.:Y9W
M^@$<*6*"1&QF"5Y,T&SVL%?0BLTV89"(1+%!)T;(IK^]3*KPVU(F1BX-C1M^
M-5JX<E\@M#*E\OW'<S&_U8!89TSC(7F:=.%8JB\3).FS4C>+OJVJ0&3@,8<E
M7^=SM**ZQDFDL1K<?=F/\RJOH[ AQ? N8P>1- V9F;,GO2I=/>3E6&M4U34,
MS@GZ1\;U< <*;4>>^@KJ+%8GHJH>_HIB-*59M[EGN5$JU2@:[4DDH?'8-OO
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M[R<[EF*^[39*J:AUJYW4D[[A][X@V?&)RA02B:=HX?<"JZA!.V2);8<.\NM
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MLZ.\UY0X3]4VY^)[%A:B[:$N%JI;V-JQ)UURBX4E^9@[%B]OPQ=#'+/<)L<
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M<)NJ"6F@B2=P2V^D8[>U4E728:NJ(J,RWVK^6H=N142W$.?7FT(/704RH_A
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MNQCKQKJL01-LVN+5<JNK-7_>VBL1"7QF>ZGYU<8>YIW^8Z<.A^S/;;QJ5YD
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MW[[-Y^0^!->7N0)7V/R0JLY\U_KI?_3\P3\3L[^OH1S<"UL&;Z[/@K=TO],
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M]T?I*\L<\YTO:%L4_DG\5/[Y)]$ %>>NFG)N])>9R:B)GIM0'+]9!'-,+F$
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MID<"4C4Z",3>R>8C&5/8(4D]?3TN[6>)VY]__VXISD^+SU24ELJW7&0.4+_
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MX_,\S832-"G(HYFANS6Y8A@-XT+(]JPGP43H][>EH58[I3+K;3LP.Z^0L.&
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M,TM$Z&T:!,_QH:EAB#=&O8"4/N]C][Q_.L4#=*?'^@0+.8VM>*"1A 6'M$;
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MI4%^Q7A3Y98ONXF"&B;29,%GJO^,1##SGU%H:,?-VH^<#)\S*/>?\0"(D*U
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M#!I@UB:. 0'ME-=B)(08G5M\#Z]*>_50VHH&X*%TJ#T";7IXOW;3#-G)[C[
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MRDW^0DXJ=T<UK!I\H<?.'J&P1I'G"*#JLSB]N2@!B<PKVDTD;: [6+^\LNY
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M@:_M8;4VLL_E('2X8UX&FMRPSJ\S_Z,G/C\)?Z7',>\<"X-$:77]W3V0_Y=
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MAS&,3X.QQ'?3WC[0/JOTW+*W:]5LG1F"!=]WFFMC'@7/Z;#5^'\E?DR2>J4
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M$GDN4#+IK)9-_/*&6"(GZQ[LO&R7!OD&UOJ['!2)3EL&VX5L$&.3AD8[XK;
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M@>@R>&77I('Z,7]^64&">>![\UD)\<M8 2V.\M'(?[(0Z1]#*&>G F"3 52
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MOL?R< X]GY4\">,<]5)/NIGS;14^EZ56*ZO-E]O@K/_H?A[L5E*4\H((^T<
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M0*?FN^[%Y4Q@2H<Z<U*;:L"<CB^N(I7T<93FK?$_*7]2 0!H0L6U+P3<&DF
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MC9Q_?6@/!2^["*0&0%KJAMR%I8C/\_0';IC8>;$D&8W<,4<ZQ2$)RN[!RU1
MTF5;:)L/DG]9S7*4_&P-O:(\$J#XMG/[(Q6@LV55/*7$)0D50$(#(,UH5+%L
MI?56,H85LJC3(K,M$OJSM*Q?W]AV)*4")KV0_@7^H7D2.;=*"O)O\%XBM%J_
M5[I'4+P1[N;FMD)<'E.(;*Q*R]"I:O_AB!#M;K?SOOYS[2_=<KZK6A]K%.A<
MD/KQ>5>? 6 TQ,/Y=]*R$8[.0N\#2))[^^*[^S_GO^W@** 5]/Z5K:U*:]I&
MO70KL[SI?FXD*Z0A]=K-DVW6O4?FYELJ?A8,LL(LS'TF8$L=( M]<&=*KFE.
M! V-13O2]DE@9Z5U!*C>3'GLP[C_C>0_ Q5M6!F&K"=.975$S:171I]F?9YN
M=-Y<G08I%WJ%*R&0$9D^44KU4;GIKUA6/0[OUM8-!U7ZV+4(40$@2/&T=<]Y
M?O)44.2KQ0>O*:6;D%_@&0PGHZ5.V#<< WZ*E#\5<(JH+?%FE?^8%FP"<2\A
MZ_]:WR@1+%F_Y'+'9ER_\XX[31M,.MW#YP=*23'!P=-0^9,^4GUP(C%R]A2#
M*$7Y+R*ZT+&-O4#4'@8>2 54>8K;(2>O8!2\]1_L$X1'?CKDEP;@\0J6%[RG
M70I+),Y:_2I8]UQ;G>\>2GBHDXAF"/7O:L@A;9-;0'+AQ2>5TO5?I!JMIJ>;
M>LT)FQ6K7R(RZ?]J%<8T_O2ZIMNX]C+BF4U!A8OYN?BH!"7:U& FKE8+%%]K
M"71ZIT$0>9 4O1?T19&!_ 8[?SGTH2_L>\7"@ ^+);^3;[_7CR/_X"/IT/%N
M.^OJ6G>DT\M$M_;G?9J7Y!S5X!]FGIXIP1Y%95X*Y+A$BY5Q\QWDK'E#B]4F
M"DLP?"<N\K1X-OGA;.A8WM;2NIE'NI:.LYW3RQ(7.HLEO\)5>!12==>E."?;
MT=HDGF9%'"E&)T,UBIX$0A_GRNM&!/IE91?XI*F4(D6^MI$N&[N1ORD@=[FP
MMOYAS#R>0QL9+8>1Y/Z*:J]9$^+)[1M;Q @I1^9)_="N&Q>MI&&3M?^^<?Z_
M2OAA,6W)/V[9J@;DM'7]*+JR6Y'ALKZ8$2VIFA%^>ZUVJJ>HUM 3=%\X7KOH
MZ/ \KC4]@*/NL7S@'^*F)>P,W&Q_M>MWJ7]LMW7:,RWA33!@$6&02Y'3N*,G
M7.C\T6.TK;@XNO[=P!#R$%V;"XPB[41@@AH0]N2PC5/LB-FS31>N+]U&(E8K
MK6-Z*D)<1GUZ.N\[[>SAWO:QN5$I#1DO-R>B(-OS5W.+7HU+K_QED#?Y9O8V
M>#RBRTT$D9PS^ (_MFD2T[LH:%N:4PZWZ>6%%WU(!RH7&Y",+[#]H=;0???'
M8>@CH'S0Y/]Q5_>_07@CFDDRV$,M\5F'0N82=AAJM[!#XZA:#U>WWID@';\%
M"0O4"[?MTI3B5L==4)^+B 9.!&$=VSNB?H4EZ4=I,O*F_A4:%JT@.U.,E!A;
MN,AY)&D\(L?/0=D>-Y\20*?*67_$+!VPD5UJ/L-^Y.[I@+@T-K-O$TIPFW1W
MC75ML(H7LOO>ZYSK$JCA[SQ#LT]%B<%40)L4.C461[KV:?NYM3NALV]#N&4W
MSG>2'( 9J+/]IJ_7%\_*GMV'0<T]5Y\-$(&92ANTWXYU.98S$:#7M8\9Q0:5
M)Y^P-85R0<5P'V>H@'7E:F3X A6@?)@R\<W5,DX%*<O 9K_]571FIA')?FEZ
M&B/+9*0'M )7!Y1H!)IKA5PP8N&];L1]AC7O*/W]?5^!%Q'NG!FW"_8T$CN6
M8WCVP, #,$>5CT:JS$L;L;.2EM?HSU3 OG:?;PS-9HM WTZ13D9)Z<&%;7;(
M'2?7F ]&<=V(KJQF5#4C.'D[>[ <BNS<UB"KSE8DH&^!/^WEZQ7U&#OEO _I
M0A*,/,F3BI?TJ0!A-%%C4&=!07$9,MXDTW"T+DQPPF6\:E5N0K&%!+_%H(8"
MH(P?[A4X8DR#!\QU;;[WK+C0^4H.E(2XT>SSK%KNVKHGEGLT[?A.@/-]I\#*
M2J>U=8%AF[",E$QGFWMP>)CT.=N(V[J"13_OG[6J-F\G_SZP[*&T6XI>?3(Y
M]=Q7Q:IW=OX6DBED=7^W7%/7UC^6L3*41Y3_F@$O%YW&Q%*7G6.V=%I4KOBH
M4W/)V=O-,0WK1""Y+Y0]N((4.:?4.^H5_&BVV6"_'20+.3+1#JY.K6FPLQ3!
M.^\)Q/0<X;[U'<I,S?('_42=OV=DD#3[L#]J> QL&O^^4/9U""T0UPU*7;RY
M2]3<+<U')Q TC@[5;,B+% CP=#HH;FDR>,'#Q\*;7[T:@04KKI/*\8K@Y@\%
M&<(WV5@G3'M#X!%F!^IZRW'?-X6MSHZVJF/FR5/0%'_\2G$1T01!!8R,A\X1
M;2?9V-R.OBI<V2/4@^(J6T1=S9]?4VE@0Q)2K;>#"V\Y]1+E-<?&7)Q++J7?
ML3,[7T1##+_D1FL:+GOY4@:WW4JQ1.#I)# <X1E4:^^N4/TI7.#-;*:_I";0
M05;H8P7<(=8E,./U.01#C*]'65G>V?/"-#Y] I:G;RF@)C()"F.90DS3P)S(
M&;/9.&M7NJ.-.-N7LMF[^5TZ,O.81Y!545E)CO$N!R]U=B8[>J!N?DQ_MH#4
MFN(FUJ66O$QY"I4%CI,K0QTA<P<4BY"+8UGJ*1N/UOWG[2!Q68USO4/;[ *S
M#V^Y5HC9J R?>($'].O5V:%N0L4?3$0J1VUI@CUY\E_H_.M_@:")VTZLDSWB
M<+UTB#&U'(WXO!$<Z@T$?X*;75[//J?'5B^MY9B4(E%S;]F4,^A"^-_:'9G)
M1 QAV"Z[+?JE#+8-0TZ;WJLO=MEXKO5H:@FZ.)07VT^,/,,;&HWU",=N#>(?
M.? D[GQ/< G<9?ZVEG+DV.?6MS;W;5#O"*;BP+/Q)"E 9M7&=0/>31*WW]8T
MBC?_U A=D'9J.T@TLEW^$'X17T3WW+2=832[Q#0\?KA\HV)VRG*T/C7 =\7)
MP6.AQA5BG9!2$H$ )L*CKFR(3U\5[,[)SBZY[V(+S5%3,U&U>]'YL0#,:'R!
M WA%<7/B^-_&HGKT]F .+>;6F/1#.QH?P'NAR]81ZR6#[7/)ENKOYT%!#05S
MC14U1;/I GXW90,T8XG+R5T]2">_TA&53TZ")2^E7]U3M[-X1-."2L4_R/6T
MH1Z1B=AY$3]'G> XBD60N\#N)!K!WR4Z!*NAQ2G!+]<D4?.OEO;3RB),7O;5
M'[L'C-G+E(W?OI+!BK]NLS'->LW@GO M;%!I:,&4TFX>F?&[V\B7(8+[-^#Z
MOB*Z0>XX-'O -5A[J6"#74S'P%9BL>8^H<ZBO>@H6]5RR#HQT."Q<[%@6\FU
MK[;=;#3E0N\32*-X-9(/5"0*EF#-6<MFS32;UC*X(0(SLVAJZ 3YO;#/Q^I\
MRI^-9U=PC$JK2S2(B'IZ7[<(D9],TRDK?QJ/PC@_!:$?36*O8$\(KD/THDO3
M0.5I"[2[X9A!A]E%16^(:_^$(Y/\06)IJQ&=](%>K>K/O")!E3C:IZ4$$D<P
M"F>=S=F[N<C8.__)B$@'<_>#'[M0"":0C_0RTZU#IUTD1HRE^]L3=B!WCX[*
M H9-\0/O2%>/Q-?(U+\!0,:_SXS=@#Y"PSBY6IB.*O$U,UG7TS&F9;)]C)]1
ME[^ PH#M]=4GL2Z4EEE,G-VBE_B+#2$('^.#NJ:,MRQ:3Y-%KQ@+-M!VZNCL
MJIX*%9 6PCCT,:[+/,I]&9&V\?Q6C]]<IF51#7":6=*5>?K^J\&MV":>#@=[
MZ9&NG\QS]Z^1(%Y,?PLJI[Y_?--A>\DR+[BH:Y@N4^7+T^ESX-OE3E]=BA>E
MY:+6 19K"K2_^/5OR_GL45RAW$&@!5G\"ND5WJ!0:,]T<'@=5UZ$/1%%/7I?
M,+1PMV]T]<%8.#&" T'.:$G1<&FZ'O_^U.3"@PNTH$@L^-KV]BK^VL^A=H;C
M+9>HJQ5MN)T/5  P*"C4R*:(N\-FPQ]F[WMI<"XH-X\M^ET&.^3"]->Q;;K?
M-=I9?Z<_J]J(.?LI09'@4-FX&%BOT,M#G9?D^&G@K^:JYE94;:8D1/\@8F;*
M(E% .>G;RYQ!8YVLR% _:_,1 UUU]0>F&=F!Q72I=%$*5K1E%2C]:XG%9BK@
M22E42(RT>_;>W8%QL.]9+NML4]%4@*#.W]*=K50 O/+(7(:QFSZ.TG?VE-(Q
MC0(NG[1P),*/+:B 9VCL$ Y!.%\?)+L3VG?*:G)*P)ZFQ@WH+.R[)':<C77&
M7Q/.E4=4P)6W:V))P-;/)/==-%*VZQLZM:F\(WVNJ7RQBG_0:$L$\W5_K2]K
M=F3! Q4)P56@L!;1.$&PGZ;[TLNP0I?>#QOBAY(#PG&T097<Q*+0NW5B46ED
MOJ&-^?A#*H!'9E#B\XARDPS"E>R[;5[RK/KPC]:GZ<]A?<W5=2?*#P_7CD=4
MP^J(GT[[5%WAV*!B-LW%(;*(P=*'/@CEV\X&.LY4XQ</DUL(!DT1.&STMGZ0
M4$G4H@)89;(WMX2?Y.X)F#FO"_SE="R01EDX*Y\H_04E\ZJ5>  C8TF,Y)$6
MM2/.?>".QK/U#M'9^==9XR9C#XD_I<:3#BQ2*@-7")PV1]\ZEK/K?[(<-I9)
M[4X@QUXN>2Z=03=,R]])7[F+TB\5I4%NVEZ(4IHW&&.@0(35X-2\<(OETB"3
MV]'@:7&80NH>HHS!'=A0VSS:E)/)!(O9N*3)-38UD1%5F)$N\&HS6S#BBX8<
MC!;L0_'5)%X:YRD4,RPTM;*08F>I,(<6.K&T[2?'DYRG62&_,K8&)[&^6D)>
M/@=-PA-"8LF8$RX8'^Z@D0I 9>?:7#@\9/%].D";6BDCQ3[(O40I*P[O23*I
M;[EQQ,#4@OYZVZ3/5\;15JM8'0GRST5HSVZ5B(1_+)^MFRIYMDE0L3KG 1&.
MH;O>\'0C_;=:,23A"16 7Z,$P0 (_U;MO#YR)LEDE)-#\<^#+I-M"H($' T9
M_KH78C\3H#VUL761;V+^0]BFY6)\>+!;@,1TF?RXE(?ME^YQL30#38H)\W E
MDO!8#7_E&RXNF5.8"LA0V__8O2W<T+<!S3@MKT<.+6!O_LI)B00A ZUSUUW\
M<K8"WPOJ"ZP7(>QN?Y3B^B/C7H_MYJ\;6O%J0D&5OK6#0:#(&:+\X,JLF: \
M#=\T?H[U!Z5U:]4=W"Y3Y(IUC=#AM=1=XF'VD3+<$:X(,/Q39_3L@BTW.6?W
M$6.&PBD>1AH^$N4HE-.)?\T:^BB8H7-USUT]:9KS M+"<VG-TR(W B;6X &*
MOFR&YZ^Q[7;+V'">R7L:>HZY_'PE30*B4O%WY[,,1IK!Y.U=3B%9M][IH#X'
MJ!0L'4,%+/&*V=KM84SNRL% -7XL1J([LP_<GG\V4K;#Z7V<96$V,M#AE7ZJ
M(Y2/%R+1?$V>-&W?'3 6\Z]HRC$4E12$N9Y)4V>F?D+$\HS4HQFYLI"GF=S>
M_@[DP1=>!U+)\<H/V]R46E*YE65@+/8BYH;?A^B&44'_92I3__,(44XOBR/,
M ]_G9E^)S\VXDJ?^,D7VHM4C6X\>+KG,/YZ<M4I>#W=UQ>;4%&V(GX!>0;#%
M3TQ,>'V-;F+:%JN2ZJ5K3=5-%!1E,C($7("/[TS=' $TO^$X4I</_ 'P6"LG
MX,@DRTD0$N9Y&&D%R1[:*/+T8,_^+2*C"5''TK,BW7\#QC,^KG7,/-H,!.K_
M99/PV/3*G8T_HL1S-N"ZTNQRQL&O22KUBD]D?G[7V\9VU<IF#T>E@ ?J$<SB
MK_*E)?JT!Y0M6&,U&ITW;,1[5N'Y6>S1W\]=6/]1&'!8_P++.N3S;SF2<RFF
M21/-<Z0?DHG0O1(%FB0UI]J?U7;0Q.N=P='JJX,X?.;LR4XA"%1U'!ULX-^E
MN>A,2#5U!_=4^3^_O16K*7GSSS!@1[V$Z>>OAD9[]\URS<(T<OM_/\O!B%,!
M5[^GF%$!">=UY!/ 4MCV/:198?*,NGV*:K=\@CIWP@YW$T^".L_L">T?W2BO
ME41"3?A]@V]0C#DO!<DQO-]!KUQ#$<)VE#Z)CRCX_5R?2]CLU7@>N]ZS110H
MX2HOG'W]V<MNXT8ADXYNU<M\.+PD/R/?6)^&"<Z32RE@8--NXH*8#V&^52G+
M6AJ!#O)%/_$K\'?TG>_)7NGU]]<CE\[HNZ9HM[6Z-;]-B&8"(_SK4"8L2@0W
M-)."U%A]_&CKO4^<@K3A4!1E5N%8-@K3K3%2L$J(FY!(U!H4QBIL9<!FI,"@
MQA:?0[J(CRV):@EK2'E6XK3IM&%CQI4B8Q(S)O'I\1FZ*H,N6^PRKHCMPXAB
M/ZP%%#6I $G&U--;$9OOO4_U]MK/[6W6$E@N+?3:(D_$$S&9.T@0+! GU_N9
MLKL-WD9'F"<\,O8^,C6_XS3QA607I>2+JX M$]I@*Y+[Z%4%65V<&P7G_A[6
M&U>*C#QGIM84*D50/>]"#B=QS^Y.V,0X2/J[/>,><,=6-ZP7EPKFIN*,UEWN
M=>8C>4HKQ)1IGE<0*MORIIL*X *CQF /6RY Q6$)I4@/X'Z-S*1=,(AT'I\=
M.CZCT%3G5;4B89%OX^?P,ZQ2.JE[W/#%S\@']57C]3**)8$SYE%R4:8)[KZX
M.%FR@)#7PF0M%?"I<[=O?/B%1RFY7\[;:VFSIG[L((TL*NS&4=MK/+Y48R2B
MHZZI$IL_MJ]S[]GP'[5_G$/0#(T6H2?TD!)*!7 33+JH@+"L173+0RI F/,C
M&SZ<%6^QHJ3MUMN<BN7D!\DR5SF(GZKM40$>MGR1LG7(E60M(Z/7 _<E="7
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M3.Q>W>_[5("V7]!^5][CR=6.>W56Y8&>^_C?C^X0#Y69R[1*@L:WZ><DC^K
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M0+ -],$:N"L5_ZO1QJ]H-F+!Z=J%X*V4=3ULPFQK=L/&CO('./D:9>Y!2VN
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MO+GK9GYFVA?# 7VKI*Y:,>[%Y;@6YJ<ITOCI7MR-=4BP,R@=-02-4=!_BWO
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M]8FT4>?=)TPY4LX4L1^[5B4S;HJ[ #73.E;N">\&6=EH9'+-ANMP)Q0G)2&
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MI.S6MI>SS%DD38R@LA+QD9FP.PZEQ2#LI;ZTG6<-:7S+;[A'-$O9CQ^=Y'7
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M$$XIG6&_]ZG<AC3H$:VKJ^QOBES_UIT\9J0?4_%6>]\Q.+- H$C?GU!>3+6
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M%Z0AZ^ZZ?S0QE7IEW*7/P'L_&5XS0(3%U-^KIMCL9)RO01^_HAYN0':ZW.F
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M=26O2DW+GYMUL^80EKR:)"6M6USMNC?^NHGMB[?(3U/AW^IOPOZ9KI<8A-,
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M^;PM"%1+MSDM_<>K1O>2,Y?D1=3K\\J2RX5OXAEQ9LSR_QSN_?^]UO*WX']
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M+R9K3*)0,$KC!5/-,=-!9JC:54>?U2 WSM\D]N0"E7#K)]W&*F&S#S<OB7.
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M@Y+WUTI,5#04P'\"ZP4F!CHV&@XJ"@#W+XWYKY[_L_)O%1H6Z@L4;  .[EL
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M;6NM^<[T[K1UKO6ATN,L\&C%[[^)_R;^F_C_$S&+ X<;DAJF'QZF^PHS"_O
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MZ;LN:IV7*)A@^FM%#IB $(NDPOG#S=J5Z9/S,T""]G3U],FPG>!)9/#"LE@
M4^_S2>B93S6A7X+G[,F]9K.A,%_ALK?^:SE8D"^)811U**F6%KG$A?#WL<)
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M?E0E;?D^J_TX>AU!\_V@K.W^:4]WQO*HJ./DX.*&0TK9GLD*2N)*.!$:1R&
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MG;7&SI6KM$FUU+BB>C3;$DY:AVV;%HG9>JQ9.M9+-CJ_4DWFU0I>'=X:17Z
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M?8F:P'7 (#E=UBV+YGLY' 5:O1%4K)-2 -8[8[V"RCZU79$+W)VQJV5RVZF
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MR#U("EGA?X+6>*Q]<5!SC$XKA(+!J_S8OO-G^T.;='=_NM7,)68U<-F)_ *
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M-E9:9IVV@6B;N)*YLDW62'C.&.).%X%-)J0FMJV&,2*@[G/:G0</3UV7&2\
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M;.BKCC'4=:R?PS5*0/^=+J^[U7.$,BF\ #@&8"[,$<@#+*G\\OO['K"F\1<
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ML/&=RUG^>(UX:D\DIC:U)%]MI ^%V9PTL^7)6-2KY)^<+O&'&ZF ;-+8HO
M4J;UI?AIU4PW,CYE;W #:MR<ZZNV@J.Z1J1=0)3,S2.>H:-'*8=,?^;3*B^O
ME&KK4@]LZN(<T(0T<UTYDW3*>*(=,K[\KBR2XZ,-,M' Y5!ON.D,_I00=?<(
MY?:\6()))GR3$_X)(\= _&@K26<K6ZDDN:)166X_3, <E%[PY:$+ZTN4*(E7
M!*IJ<,'^A.$U7+-#^L+Q'TCI-F9 @'LBN_UDO7?H)"9(4$EE):WT:\+.7;(4
MB:)84;7[/L/147(,?N+HS!8,EXE/PA:#1UI>'.TO,M=OIK]'9UM:<95IV :]
MZ1PUFD2=.&^IF2M4&ZJ)--M"Q@H[VE7*&/^D,M*7?*7V@'U3?.>VP%')XZX-
M'JUV]&OO!7V-V7EJ"5!S9^DQ#,_@O JVFW'W-(1I@2D2QI2W+_A'JM(+(=FZ
M1>G1\<WI984$">*(3F)X'7)0PJQ>DO;YHK\/>@T3,AA-B72(B>GIZGA4)+8*
MSE-2U]O/!KFI4EUE'+^&J-%5M%0H[+)Q$,!"%<C0()@\5%X)-L>^\164O ""
M:9R"$FZ?J61_GQB%"O9U>9P9N<Z8WHW1"N/N]AJS:]#R"3!Y%PX,7S^?8976
M,3'XS]:: \/J##*<FOR;=3<&V/JVYKY$R1A(%3<'QK_SRTRZ(I*6THO*//;>
M7A:P5,*(PLY,^AS4C#@S)E7-KC9S?E4&!1GIP+J?(-O%PRR[ W/"V*#4Y/VC
MDZ*[58.LN<2W^ HMF_G%_?.RXGH?YG<_12=WII/8JRJ)9U3DE98&>229E"&V
M^?4T5G@X3]B[7>LA3Y;<EF&K74T0S:E/1JA_SEQF699/B?#"HV] 8FS(#Q0=
M$,I+,QD()-4$7S$60 T6%\DR_ ,;A*C\)*$LR\1/K5=N&^17+P"ZMD_YI@YR
MO/<XG+B-S4LUT_9^1P,1@^; N@E6Q[?RZDD?E8@CM&^RKW\UA51NLW_[%5O]
MDU+D0(0#D0R+781'"X=S0E*_R2K.TIGD^QB55_IB_EL1F>+0Q5+A+&DM_Q<
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M@;C439GSUJ>$5$J;/9(:<=QJD44BI(D(5N9H/HT"NSZ.%BWZLX0[JP+EA=1
M$;1 #0S++#8#H;+XW1M/[V-;_Q< QRVCQD!"0)6=\(='Q.=JJ%U";WT]:Z:P
MU=9V?EH4;KE)29")1J"XC;:$$M[ I/3-+QGV=2V+["$2CS0L^AZHO8A"1 .:
MD[]D5/,O&W5_F)*J+.:<(*'M=OH,!4[Z,]CW8_,-S.JH>27_B"J4%YHYV0-"
MI5<0:JYQWR#U7OTJH<M*H-:N;A4*M]!1D8^@2.AS_K):3J\W:C:]..LR"86^
MKB/.^OXZBSW.^DM.=2@3=ZU<D9+2@?[!4W[:M>@CF=VIWC_F>T>P-+-LJY7L
M7UW5,(L84M\L_JSD\GQPBA%AZDP7*=_)"ZR<@=C-X([2%B89E0)3"4TXZ7X/
MOZDM4-K:U&Q =8SN1A543$X6*4J--Q:B</NRGL%@2/8123<W-5>6<9NEA+0O
M?M9#!!3!76Z&PS?I?(D.JV*,: L+8=U=#<7U"$54)U9B7D/S'VJE4<5.S0K$
M!7HFKY[Z8I>&V7]E-X1O0,N=+6>>?8(4,4VI,'_F23!O%R:\ -YJOP"\7 \R
M-^\9D?^$/^YY'R',Y*%3Z./MM&QF:VL;VL+2D?^1U0?9=<SL2)+0.Q1F9E6[
M2U6S?^90+QI,84!/\<V"5GJE$)B"YCHE9N+K4<A,N7"5/T*)*9&J75>8%8%+
M&*M/U,.'M9C?\#4)UBV1"IT([K<C2DHH8JSUERX3%HJRU?=*/#TNN!S;^)^G
M(:C>>/A:NKX OJNX"&LC?]RGGZ_Z?#W\VZ9QUF3)Y1;<K3$MY(HCIR.;\ZXX
M276K6(_P\%U1)DWJT?>X60M6,T?21(OOB4YU(%15"+P*M5UMK(CB<]B!6B9W
M<Z@8"$(?6<=FKA5(&E'W_K)" F7M6>P^<JO=SI?'IOMN=W85H\',<.!2U<GY
MY'G,*W7%L\+2)DVPJ29B&D%%%1U@:\3)P;X0C_J&#<PR' FA8]64KCWG3#T9
M,F:SFM3X_7DJ2)F4EJ'>4/>6SQ5:1)-"N$_TL^G\1 N?QLOPG8N)-3!/JC,R
M\MO'#45)N4TS>9=9G.VQRZ\K!IS\GFN[<M];YC9L!'UDKVU[HZ[[IZ>/T^#R
M]GG1E37SQSU1/4*K47E6ZAI#[+(6W& F[6!#O=4%YZ/S 5MKBNK1;?H?9 .D
MD1"@%VA\#!ZYO5VR.SFDN<R0NL-!;3[=G!=?F!94/UTB6Y%UY:/WNA&K"=G?
M3HFD42@9O3KM'-NI0E:[S(%[Y[WFM&P6/&J<C!]V,A.VHF0+,PL.7)X5>*LZ
MMCG8!4L.8)J3/_0$3O34AV_X$^="*#WEXC^QDEM*)+6^(M5S[,U[<P9P2J)O
MKO%C2"G_A X .M70\\8X,_?%?$,^S/NNWYH[)SLA->[N%[TY&AS(A.$\%<I'
M5GT&5LC2]XJJ(3VDZ$;YW<.A(/$?Y[&]S-%1N9IC8>?]YXF&.$ML*Y/N-#'^
M!T>E4J]%J#-1HBDIT,L8=$+BQ-^P "O?AKQ1PQ&"!^RTCQ]:[R+/A!-FJ(S+
MV0M9>=2\RI?Y63ZD2!<$E=@=+P+Y(@Q_)>Q[A(&Y9E7GB;7VC9Q($W!]Z^7H
M//56@[4_^'VCE)5[ 20%7,(D-(JBO6TK0K3"D(@:9*)PHH>R+W>(A5T6GW \
MP]G\N;+*K;?MT,C?JLGF(( #A/\]*"#&5MM"P)I\:F-_;RM,!M0BH7"1*HI_
M0M$6D537IEX>C:JS18=/+7:SA>PO.GC,9*RG26M5$?+ M-*Y^"-LS5=A$'"/
ML\,3=_\7N=Q"L)FEXP5<S@AG' %/S+4\"EZ8N9^TE36;W^R,<JE:>?D(8;5%
M]'>WF,H3XM9Q5W""U&*J?M!,=0\ZMK#%U-7(Z-MU*'P4-X](6PAU7-I?AF>'
M?5?-1: X;BY5TXG?=>,?#2Y")*,#R4@=N+HS(S_TV!3=T]?XF/IR^O2?EJV>
MY5G:E*_<584,NO3U?0ZG:$I>3L5@Z_/+/C?D<3&S-;5W.VC]/OP#"%27K9^Y
M=>24=>8N?Q[B(0NAJVN(PN-Z$]LYP K-+IZ4?5TZ,^FH"+QJ'F16=]=71">6
M@$MNA]#D*:.J)Y+<3VV//_UCS>-#MMB:%T#";H] /8&MT:?A4W1/,I\3@:'-
M_1$]==5/S8Y7_H5:DW2N<9G^O.;KAG(%K!9XIH"X.=XE[L>$AV@T##0+"27A
M!6&ALJ&84G5EU1%GJKI0X8-[9Z>/1\143M\O=<SL-HL=[K!Z0OO7:E+2YI&5
M,\K;ZQX>:>[)C\J*F%$1PL!N3TP6(A )+6U>-4M4[5WN2>;?N\TSG&W%"[N_
M9G"HC[SU6.K\Z?;E^7%!"7QPRW1>F!,(Y*%<77+VITY4FSX[.H@<%2B!>H@'
MQ7'0% ;>TH*J5Y9[FJJ?8P,.3/Y SJF/3"BEU'[ZF&E@_SSDJ/\7VBNZ)?^1
M3_I$?Z)^3:J4E6Q+&<%SJ7O =CDMF(@,:Z='^BX\*38V=WV_8=_[>Y21=8'"
M:!"UX$Z!F/)T1)&HREVJF\:=-::#QWVK^2SOGZE>7I88]P/8FB15J4L_K'%+
M4!-LK*+]Y?U>G.S ?[)A&M+_G'L!62G;^T4)_&()H_^V J=#%U0E!5CD26/X
M/)Z_4]@B)QZ3H5?L4EN)!A>E=RO+.A<&<)X7@/*M((_OJ5YQ4M[2?#/,_,M=
MVO#*2E2:>\UTL2J*4JC&R:"DE38A<'0&%%DCL_:DEI8;JR5 LJ=602 #?IT&
ML@AS.K[04R#HQF5(Q0MPBU82LR.*4*N$3S:5\7'IE:QP:?ARK:PO9J'XD%C9
MW-X7SU)\K'1)[G\!Q+8-+%UG6#9\S7SK)J!EA;U0\-/"T1D$ 15OE&9P-![H
MZ=X;9TP:D/*R<<_GZ0U/_+G@DB!EJ'=1(DIG]7MU-AWGC<JG3-];4JA)JY&H
M+-;R-0;>'5.'T0N+!,"*]^J\]'WCQ)X)/V>6WFO)G"/>(1;&MIUCB_O7A;BG
MS5@JSXPVCP2LW Z\"L7LZ 5]-/B8]]6U8(^DYNHI$R*$K+6K]AR)MWY?_V,;
M#D1=&_XIPO@7E*WR'Z5:\0C8\;\@1 ]_@<DXV7XCO31*3R\8Z'4HLB^O%NT[
M%%]ZHV!P7_H"X,_L&5KC:/*>D5MX 5#4,PAU,(J@6A3VFM27F4"\0=_B&.*X
M^X<H/B]5Q.27* * W!32/.E!3ZM&5#$R.F-T@U(7A4)3DR/-1 \ML$LVTF?1
M+[Y#64,E2 C&ZR(,^&MX427 &T#E)_CK0>BPX_] .K/_*5"I0#(Y6A@W^%[\
MNC=#HXFJ^63@%US$8[LX461T@W#TMH9'1$RB/._G]Y:9B,6(O,<3F/<';A6K
M4XR^[O5+-AC)<Z:JC>'[M&,^7,\9./(Z:T!/YLF/8#P<&=]B5.&Z>E%R%YF,
M\"QYKR4QU\8?-8_81M"_)I>4^^YNP>ETC[<E;&QX]K$O)0>J15-4&25!_YE;
MIY7_U_I/U'Q3JB^]V=&UE E6#J7U]D2@?"A.?U'.TR_G?Q'[V6_M8?7G^SGD
M-K^OY>!"1F*S9WE4#?0$_E:[U-N$_72%_P7 C"*BBA>7Z0BBF1P.^J;IML1+
MKZ<9]FV-Q.J(QHJS9PGV!C<6,XJ6.KK_2F)P2\;>Y3"1\WO4VV:Q@%U_85N1
M%\#%IP6]S\W"Z;:7[@.GOXE'1F^2$"<*0UDE1DM.3O>DBU8^BKXG_:YL"IS
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M[099L@U_6>2@M!-@>5\EB,!_B;)3PCVR[L]Z'+Z<F<G/]A13YPV/;9<$S2^
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M<NGB)5U\A\K^3 7B49\]2FTW4;&M7[:S+N6^+IX;WS!;*+K:M!):_2]A0+"
M#5P<OB";8@.N#]<!-3YD""L4>.&G@>*\9$.%B<NY^[!C%\KV,]=SSD!NW3QA
M9.HQ:-$!9_N\%6-S>55G 84^WX]7=[:7](8N^EJ$D_6H+&VS0MR6&Q:R*'P^
MV>HM4[JTDV,[XB-</;9O9@_Z"E3+Z+\ED]\+;] ;A4&UC6%H+K%AMY;I4H@X
M%LT3I]*MTAJ@!6G,P7_]%FEH4XJJ^LG'9TMLFX)=?]5#7L<23YO/&Y)H$-'4
M75$81!OZ#G>L&MR9V=@^=6;-@WBC:YUH!?@*Q^X4"M^6VZ\.\FQ:/5)FAA[P
MT-O:F/ 3PX[7HW)A@D_'(Q,S3W<1'BL80"BI.6: CI*8-/COFS#WF7SK45N"
M_B(#,!]Q5JTQ<F O/ E"/"A(^7UN3CW/8-Y.2.U05W_-^_8%@-5S$6#H'*FP
MVHLT\+U36ME:T''F 7/#3,0J*;4'TV2]_"?@\@@:ML%T#VA@CN<]9!8_[@,F
M5SW'^_F, Y.G>;+:9UAX'O>FU(2VQI8W'[8\_=?1<#"5KD:CBYL'\@[B/%E[
M'ZU?KKIC^R\@X!N=O M>>E*]4'1X = >!YR/?9N#:%H?-VLW--3W"*WTJ81$
M,JB$E;<'P<@BB[H5*5BO' 9DZ+Z,$(IW'W#CGBPXUNKH]M&]?LK'QBC[1!_I
MIH0+=L/E]/C:%FR?]D$&G"V:S_$D(J( HO'_+7*QQ_ELR$]37;/IBF0,+N>7
M\[#2OTJJV.'II$AL?40Q,:/RL%Y&*"I']"E-;W/<\X5\]VKGXI'M-89[N(WH
M.KI'6&Y-4LPOO8\<R%./\!8<4/M1$-^<C9>&UYFII^'\ILN4(B"+$J,2I,X-
MHKX/Z&VSAA:%/BBK#Q9Q%Y'3'_$BWZ?C]#4^YMBJ/2)/'J1<7#YT+K9?'H1H
MNH[]/?FS2,71[%+-5)C:?EJX TJ%6M#"XIAAL"PTRRUSHK])FM0 _U>OV36:
M-6U^J;P S/AJ\>WNC/^ 0*\CQ0S80V\;2:5!L#X\?!@E<YH2GG98F-<#B[<]
M F%TG_?/X:U&"496PN=XSF_77+OU*BZDIZ2T)SN7$R_Y"3!;/*GB"SAR,7ZS
MST0>;'#RC<GH84[L1:1.5Z0MU+.UB\>HR(5&Z*+1-@A."_-0&Z%E,$0Y+[-/
MQ,S0A,AT;^]0U!%>_*?@N#SC[<M BK-+I'KNZW,R%@[*&A)RY_'M7]D9N)T5
MVR:B,NZ;=["=K_[$)=-$OVA?#U37'&&M_8O.C+E&A*E9M<M9/W/]RNRAF54Y
MI)66*GC='-7I+O6Z8K2-\&BHT8VNY^J:??LZ>&[#DGI.4J#J B8U=>]I]?0"
M.$^N%/Y-Y>C5?W+ZRS.+(*7/NGS]_N/$/TMVF[0YIGKT.V@.@8CR'M.+_V-6
M5.3@QE<V%0H#O4E;V.Z'J$X3N4GP43.LK/#?'6W41JVIJMFW'F3WOR^/*<T/
MFI0A1P7R<2&(Y30:/8.#^?1F&;A%":=C_J-5 B#W/-+/-JLZ4OJ@7A:'N@U_
M7@!A!J_;WWEQC*F8-N"H3MT&W2X]I:8'6.^R'+)D<7\A,\0TY03^+KU44T^Q
MY&+.&Y6OE@;$(I:R:^HS>I;F/A"P$5T!X<F UZ!^K1!ME68N>=62!3E[;EGK
MS3"240UE5M$X:3Y<IN)-L%NY1QYR*98'23_7D%=8VCVG]/?2DH58*,]6%0/3
M4>3I,=O)RIFS-10LQE!]UET.P?-[\R1=OM@Q2W) 0H4*)9DIN7HV(Q*"S>62
MA?GL>BA%XQ7G*UMLWF..>SBW*XPC4L %=5_;YQ I@_*2*%;'1Y*K?S;V<C1I
M"O)Z5'M0!068LM^$,>5&BOZT9'K.W' U[(Z/ RN*S0!>*23X[,_\_U]4R6<T
MOK;5<F4?'W ^M;V>[3ZV#DA)\O=J[SO*R(M>Y?6 ]2A20%BF-SD3KM54ZT#R
M'& \-Y(^(%VHF9+8N*X,].^&J211'@O1#V4Q470!+#X;315GIH./BKA_<"TR
MW^;V_",N&++)]Q3@0_ "V <>&3Q7/G[Y!Q#O%P SUPM@U$)XCSWV>;_N!>#U
MKR[O%'+Y?8(OD1#[9G,\VSC)"R!R^:W8Q,>C7^Y6N[+*5S<K!8N@.J4950UZ
ML#Y"WF$=#L5O#HO*EJ$GX,U$-WD[@,]9P!_Y-[F/<V #&]_2VHCPKD0?[;>;
M$>PY"H\J,(?;%RUQJK>56>';HP>ABU#W_)-)[5GZ^[)ZF^G#Y<AZ"^'@X[;4
MJIMKRJGNS37V23<F^VG<J8E)L2U7:SS1\.+4,@?%VHO!J2I7^I2T)$,9QNGX
M^*G^<%R,;, 7 "' RV__4WOS^UQ/,=<CA;]'HXD'^MVK;3IQA</72;>K>O;!
MRPN135I2$%0GD!MYDFA4;@.>*I$U&TA43H9;H4:,$-XI/1%0N0*V*8UM@3?F
MP6N8?H@R_<%%SZ$5@L%EK,E[M&8TB^%QV8F\H#<1=N1\UKU(Z-UVT#'\^:G;
MZ:W,1LL<RZU!#W\)V8PFD *A>CL]),6S9,-;](&#)RV6^.V<IG/G&[#3*^_C
MBD*W7PQ2'!$A0_4_N]<M%845:MF,-#A_*>VB7D5*719X-?^=%_[PS.TR>XMH
M2UWLH'C@JN&G,BOD^)K\W05'Y3M/IBUQHW9A61[)4;D<E:J!.#,+Q>XO,:5,
MYI3!--VDVT;;W7HQ<@=I^,PT_ @^0P@"^-E'W#OO6QNF!C2S<"+I$_"Y=/&!
M7/OCN\>,BE>OCFS#LCYX=)F>9C8=*OY;\;D,SX6[AV%%DR-PY!3"T^)' Q&[
M:!*4-,SJY#-5%"QG2'5,3%E0('9&!"B +T. 0E:=&&_#\P&[6H8UXA#,.MJ3
M%)3[*TX"VWYWTOQH/5"6AJ9$0R50J3 W*!N#W$CPL\<8G*^AP"61\N]^>]T\
MA5P5QS5H)H&,I?3&A?_'!G4Z(RU8E95W"0*B)U>9EA^^J.XDE:)/2:)[-/4,
M94]I+1WM330U'+:(HHN?JA*-84]0@O.B E[IGE$P>@1LCOV'],H>WFC&R?/P
MS.=(CRI/_M1HORPRZZ9?Y]_N06>^GEE/SD9$Z*PJ1E:=-UC:GP^/>4=YZN@)
MVL?BCO[TVJ^%"U<0+=<CGW@"@2$9YI<6 R<DN'\U#NEX1O&B.M:[%S:_,>L6
MCFQYK&)A+"BN6/'L*+BY6>N?D1.W):QS!JGARV@ -0&7'ZR!)=[ ;&'L8V>;
M3')'V9+,F5C_W:A7^TVLU*EUK>8C41MA"D+&3M]L5W(.;*;GXZ]MS:Y]]6Z$
MM2!2H4&P\H:3P=Y33,S0GTG,>Y#SCQC0",\RPG$1.L!4[/L^,JF"6&DYU.&D
M4;K(5!+UB%)(H 2VR%O0_OT/F3FQ(A,!B!_UE  VGY+54WHMWZ7E6KW0G\46
M6Z.CMK+(PB[KC)R:,Z<6LP]1>7FD/_*S^R8D4.GIN>4Z)0B9PG@A*,MTB86&
M)W(<(%89NO@=F0%!+5S)UT6 5_\!L@'N #[VIZHSU74SSY/+>8J)<^'-#HO3
M9'\,:.1Z!Y\O2M.%8X_<,Q28MMC\$0HT#(\)98TJ>H\*X'I=CW!IKM'#'0&R
M6190)&@<O7%*LT1GUU&+S:,D,E:QN \8W_VLZ5PF9="A.C:73FI3&H_Z-!M?
M1K_HA&]]TVM^_@+ YC52L.\-Z-M_= 1O3/6&VQ^3)'998CJK-\.=-69;+2_W
M%0)IP:C,LJJ$CWROO_+\.?W59M;0T#LY+XSWS&,-KEAH'/1B-+)&"LL='T %
MKK%H4VERAJ=> #@<6T6Y,<FR'H%Q1 ZC11]#61B6R\L_:LL4& 85R4?(9BG)
M_.W#^X=EZE^<^>8H&%_0L[^,8J&Y90J^=VL/V4-2J4=%=E[-J:T_*)M;5EE.
MW;6W=AO=5!8.C-&#P;R(<^5".A%E5>[)(:I%\S@-=W)B4WJN93FZ3!;^#V7.
M2?0EA]IS]U<7?T*:7Q?ID_[WRN+&;H_\8,POZ^V#F,O$Z4GV7>3Y4%G#*$C/
MWK//S.GF[=N$@@N[WKAF#*+B C-RCC U5EZZ*$%XT_))Q0?Q&MG#/CGI8>$?
MW/LA+G=LHT6;D8KPW(#'__8LCMOC]T>1BPY'"F<'[:W'3\D@<5!T70N+F=%M
M'2 S*^4 /YE649G0&8]2!:),0PGYN;NHXUG,1J:KT-]USD+T[=Z?S\<<?]VI
M/^?GQ7?TI^#\#ADOW;N%\_+TSW+GESE\ 04T2SB$J9<S3^YA"Y]U+4XW'Q?L
MKRKEU&B:QNE=WSGFOW]T.'CPW,"<%/CU_8,I%"=1YJ!2NP?*C ]$Z9,-K#A"
M*:98.,_:[!@0,&7$NL#):\YK/G?#:+(\X_;.J:Q*7S WRW"28?O8KZHP74'C
MH=NMUOR@O1GM4=>>UIT4)!41*ZH<%B?D1%NA:$TQGE]4_JH(,\=/.$50(O^N
MXCS,'P:W-'_F<X* 7,4GGY*EYWJF&U&+%LZ))3F.W9^[AOS4W29"<MS8!TF6
M_+R/5D?% N@28F9%REK&*(]N?9P/.V>IU?;TAQG-C\GY[:.'<G87%;+VZ.?;
M4"<$#5IN5[]?9\E>?]8[79D<4-OQY/$\TF_L.B;OW2PMA6<V0UMOY*BD%'62
MBY/JX84YVR5I&A:%2>I&=%$]\G/QNL#\J*,BIK#A84(E#"8Z/R9 7_9^RG'>
MKQH:>!+(D/!U'T/^STS&:$WF=H$K+"I;8R$1Y2M;11776>U8CGO]D\)# 5:R
M]D+TO>S>4B*R1/,@4W,-"C!8%N]0-LP\SP^'$)K7>V,:(FKL2 +".[ &3*<%
MEO'&N;EGUK+E_9,=/;-_LB/^W7BR7>S&B>+D-& 5B^<%8"ZVG+ZY >LK6T94
M&G,T.1]E#$R3D(^:E'P9IHRJEGT(^PBD+RTPB>CB;Y'#DQ[DNYN2F[!)_M)K
M*&.L!D)%J=2FY$5+O3R(-L(LIS,?K\S!A,AAV(VP1"66G)MMXI\H#*S(G0_E
MS+G>?D6,'*VL+5M.\WL9-^A3.4K&&E?I)+7<N2Z;V3>AYT8"+4I,,M_-$)E(
M80!L#W<QPC=DI$?S21=#_LS"60)TIY6N;?-#DJS?:1 :Y4,"F<4BP@R#BQ&>
MFV9]>GDS3>U1B]YO)UN,"GB VZKV5\\K!\/$'RR-/_ 164K8K!9FAQ.HL1#A
M*M#GVS(IT<W\.%7TYJY^ER;%B8&[/=](&TB2MCG$>VAI3<H85)2#):*4S89#
MKI)ZN6\QIV<Q1R%<8_?D/-V"8GSM:F"]ND&U_!0ZIZ,>8+Q>Y!L^HZBG<>/6
M:DQ8R]WAK -15?X<A7JAR%K=MA6;TB#8G:Q@G)@Z/UG:74.*@1$GL\9\X^R6
M(TU(PP0A?^T'**YX%95YR[Z(2)^RL<'*:'5Y)G"QIECX-7A<-E77P [$/.%A
MC!S]2\_F(OQ)#$)>6Y< 2J@>PCP#$_1P*TSTET:(Y#MPRW^4P42G#A!%[Z>.
M>N-.6;I'AZKY&IW:'XC.2QTP+BAUKKIQPE_,N?PJ^FYYW$D0+[-?*FG4J8!*
MT?I +T\'@@4!.:C-'-?VL9,6YK 4%1V\B5/F"ET+4O**I07&-RY]]')DS:1>
M9ZB?Y5 ,JUNSZ OB,]I;Q[O3)I ZL] 3L.Q,V,QJ@+'">L>BFD8+^ZX8;+,?
M-#@FW!)SY0WDMOEJ4&,6G88B?\^H8G@W@5#6UPFOQ4=(9#ER58QUA(4.&J;H
M,CG[-\14C+'_'MAYENC>[Y: :FTR/THP_\PN8A'I(BP4:-97OG[NZCO2IJS(
M7N"7#"[C\#0,-M[D.XFVGICZ7GS6.&B<6]@M$B*M087-GAG%NQ:6R-R-UUF"
MWXLG&J2MX<*NF41792ACV#T=YS;;5*' "@TC!/PSDA@ -&9%A? Y32^,.ZG)
M]-&L*H_@#9X^[)K5!$G'J!4RJD*7Y\7^2>^9;O^P\CA_YJ* 8J X#@G+_I.
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M<P''R0(.*G:ZU._YKZ4B2I8SOK(?#LOC'=;6'QL,L/^J(_@5;P.6.NNK8=8
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MQAW&,Z=9?%2L6QM"O(Y20M7\3)39(OX[PL6/VLKQQ/4<<IO)YRBSD]F?2I"
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M9H#?4%CX0M>Y0&;-, !TXS*V-80$>-V?9B$!<F4F2,#5W4+7$LGJ>10(OI:
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M@9S8=/& ]OVDD0 SP_M[=YKS4%O$V6Q7F31"U0&TPW1'Y?-?W+,_H@T7)M&
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M'0=1COYD")3XW/0RW@^5-.O4K8ZI&O3>_S\^"-*)N5%8$4NIN*V"!?JZY4N
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M5Q*_#%6!%+^V)7QTV'-G_HBW4N5T+QB+'T)*=6OW]H9 UA2,J[18:8DZKJ:
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M(#FK9EOU7%$$X2^C8Z,N]KE)CA];3/:EK[0()\%?<\(.3SA#'7D.FT(G;C(
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MZR6G!J[QQ7=#+7'%)#Y5,2$.J[W9ETH1GIK,!OVTZDI'P]4\G=BVT7)"UH'
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MU*/<Z)J#6C* "0'7=(WXI'X'^(IX0;)DYZF1\B_.?UQHUPN%!:=0(F!!G^0
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MW[W7>I=2I((& F%G9V!Y(@5^\#+RGQ'I9!]&'>W254B14<[=;S$*'&1P)WH
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M<0WX=+P;U:YO=='6@ O$NB+1K+9'/!B>1"/_@-4FZ_8Q&\]B^3J%<T=R(O4
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M4'1_JX,C!R^N7_U-8@8\\>,^:(F0.[B,TC]Y->C5V2J?\<"86+.H8)*=Z-:
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M/02KMIA"Z&I:J)S;?'W7D#1F%B;$;JC.>ZA+>O16$D@_,NXX3^R%B%H"?YX
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M5W%MK_OD-\HJQ_=2ZIWVJM4,B=E!!*7N+CS@YWU%XP!85V!1YTYY\[MG"@I
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MC-32Y8ZO 4)RW M_"OX;@^BBC]4N!FL"C:"6>9N#J^'[U!G/$96UM4M6%]>
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MJD:9)!XX@=-N,CY83GDBO<'[V(P/"PVU7S")IJ9_R["X4?D[/M+5!XPLZ*
M-F80L]/?'6D+I,%!9W.E@BI]9"[/)44YY8W<5T0)"-&Z>A[[2]0;)I7-\I&\
MXWH\>JDA3,GHB(LW9>&,^ULA'#_C#5*%65#%'^_2[&ZW&-D2(-V_M_%;CGNB
M:TMW=\,3$L:U*55HH!H0&?US>?GW;?B9XW2ENNAR=.#:HH#XIXT)H+E8_)7#
M4Y,C(M,",M>OX64JLPHY>G\!C*=>^H6%S58QV%):[<W6AJ$L<KJR+H)*LU-W
M'EP2RXP,TGUO=.54+3.)IDZR0@@@.2ZN"0&CT2^X*V[/'OI=:03*R3Q)&0J\
M4:=&D+\<V<JKK<>P7S_I/HG4F6GPZJFZWK'U=C]H'6AA\,*M*;G6HRVYMN/[
M^EI#0RJDD"X]'/S>D%0<X\?2!D7\%7CH.%+_TWP7F634)^F@K >5JJZ*3]<=
M#L;D?VI[2=*YFID'<%LE^P]FQL@_%$K3/*FLD/C'B]/_I09KMC^J@MW*1T)C
M2 44@&I;A2R-ZWS'W/B16[SD;R4[[_#%X?XG#R3O),S%Y\,$0IMP_(SV-]+E
M(FO=*L-QK;8SN!Y)(+PO"+??__32$IA> X#H*#-@JP=F8 .[[^1__DYXQ?Z(
MK=TSI9:;0WR"]?R@]:AVGF:F*&"]6W4LCH*=XFB[<EP4+ JV$T&2EG@^!QON
MEW,]$-)5HD?0WOJJ'*, 6UIU5Q<</9QI6DMW/97[&Z).^$DDQ;K#U.#Y\$&C
M10?00<+XQC1HJ/O=#DQ6)Z8*84F*FXCY$L'HB>,8ZW<8B?MK&+=WGP6)06X#
M.B0<3?B[>U""N,#Q&=W [9>I^T%M&DI7(".7$Z61I+X-/M:06B<=#E.S:BVI
ML_..V"4B&RZU9^8E;/J=OYVILDLZ\-74JOJP!I0[?&::]%QFH)<PPDEWM+J;
M@36W+I\(/XZ[1=A=\ZB7/@5]:G<427"!K'Y\>5YV,">'[ D3(V/"ZP\4!TM*
MCY41^DAU_2'";8US)EAG*E)[2>6LIA*<$.CHO,5-OXD"],A-MTHTUV.X56\N
MPM^X<7'>@A[567UN%-"U6W@9T=2[_?WCY0-S!AI WW'K]$@SCQW8Z2I@:EZ_
M^_PVY;8,<NKE=-O3! 5V52?AKL96J?A<29=\!#OI:ZQ#)V6RO&,XVJ*\_ER-
M*O5G+PB*-,G@WA4B= [@\VG4K3:!/UO6";G#19@MM'YM>@/Q?:$[EE00+9JR
MJ$6RE^7_U=*6D2:%+;6(-NF-I=X;9>FDU;#[5YH5$1*)T(!-( Y\WQE">OK;
M2HZ!ZRL#/&T'M_6;NF![@QK]%:'I(YRQ!2[>EG"9UQ@BTD0U'HU#5$I&ZU&^
M,^04(*#8 V45%?&V@R7-P(ZF0<@VTDM_Q*C9L4N)_S)#%\PDU'H07%P7/PDC
MGZFL%U_KG1A/TDHXVEE\H=:+)&=+BKIDB)7L6?(J;7^VDX&+N *E7LUT,8T>
ME<XH@EF7;N.ZE24I<[V7Y&='%&6BK3Z+W-V9$@@*J,@7DJCF!YF9L779NQR7
MW-:#UR3 @[AEM\8U-R=VX%]>OL:NK,NSNH&MKGK/*C^G5'B)2:3ES,\Q)I-\
M&J+J&+L<96%5?O(B_S6YBPAZG(@"X[SXO8_IZN\L(19\5<#OAI-@"S.ZEX@2
M?A1@E?NA$>);]G*#WL^CQ>7U?J7M YHN]=%4+D8SSPW37W5,V+)Q/.%-61<?
M.W^^@C+>E=SU!R*M[KDCD)RF'?E+ 9Z/ IQ-3$]DG,;KWU*UW=SSN^Q!\ E]
MG<\ !0S<)P^$;^G?-+_]@&O=OD@,VFX&3S7<S#4OLDW&_04%/NK#@Q%4<T A
MY-L3W[#%LS'%XPCTYHRB^C!9.O&.8V_9EZQ\D(,#SAH/D[S24"=:FG/&>6'2
MS(18>+2>>JM,X?X'/A/IB=^A447@.(D<@"?=RI7%]8)9O:?J%DG<Z"H)S_E(
M(8W'I0:P5V&[_.2^-O-! 5A7HI555Y&2"*'2WB/F5Z#/4^),COS6ME-]$9Z/
MZ-2MDM-RU$B4:JA^#/-]<A(?WTW_P'DMFF#D+WEMS;R@!]@LY-0BPD#4?2W$
MG%%T$!8>M8ZZ#HP#VC?^ONJ1MU3_8,&P[7Q*EXJ9'*V@0W@;U 3\YQ(C[1H4
M0, B[\A^6Q"1Z0O:]438ZMN.'F-M4_=L!A5>^Y[.U[JXO!3?KY*M'#4X" L-
M[_?_@">0T<CE9?5KP&+I6![W:Y[.<#9#X>/$$CZD\\5OV^'@&?[P)<Q)9)&1
M0"$%E<+F0S!(#V*WHL-D<R7?MTSNULJF.K>4T<[=!C8[+F6QD>'D<C\:DF$A
ML.4L[(C+24_VP/-3?B(0\7FIKG->LKI;NHF]J;(#*_>YQ"#>9 BG#!_[^T>:
M! :.3ZB^ 6M=2C*@BH?D0Z?FVQG]$5O 1;AT;@#Y2O*A0H06<^W:JY;1\3S9
M/9FB6 X[ED*V)/?L@$>2R2'4F[7#&HM3QUS%3D)+MNT+?LHA!+U*I\FC+[^>
MMBKG3OK']BA5T,LOD&_>?OP]RA;]0.%WBR39^S*28 ;%RP-K^\]@9;=_)6;[
MUV:,A2W][K(<Z'E.O7G/$0K0W PR.[2%J]2KN,VX8-R6'-A,F8&>1N7UJJZA
M *&*!*4%W=O1L6,FRH02A9GIV8F2_LJ=2U[92Z.@?FJX$<*XR[BJE>O4>,,,
MHX X6):9OP0T373\:Y%=Y4O3>(&CW9OJQOUV-C5+V3E"]NJB&"6U^ONPS-@&
M:H'I6D?.4]9WH#MP7$3S3;//=<(@1?T1\XK6E=#2KF#6UZRN=;Z,EQG#)F^@
M.N5?J0.6B8HHR,PDQ^CXPK->%9LXT?)Z_)&G*^-86_DM5 T3'+\  CW->>:T
M*(H7DDK#7'_]=#5# 2H.@R#'?! ^YT![(T=B*;KRB(?A[WCF5&0$VNVJ.:VV
M'OC=,__\/]OA3NYV=Q4SMPI.]JU'Z=VVMFDUGWEMQYKJ6:V*+"QVV6:):(I+
M2XN3>C4S\PN"I<B#*M7^W,>G_04%8+LK:A(R=5ZYKRTXTC>Z[,EK:B6&5OQO
MF> ^SL,[,]^0:)77^I9'WWNO6(WQ2\M3ZFL,I#V,@NN$-O"^A(='="FH:40J
MW$^/5L*Y;$E(-2AI!$H*2VO:HQIP4;!T0P$&1B(7.M'TNJO]FUE.-\IF/MM^
M+.NI?*Z>)Z3#:F7$7J5)Y\^+KLQ5>UOAO(48EGNL<C\D%& S"_K,>FS+@I_0
MU3OY"!C$7T,+V:-*EH4,'I=E1)84=6UMO)8S Q$G=VZPLW'T@@-WBXO\L,+_
MJ$R'(&W I]D*X?K]HIOJ ["UA;N72VD9C6X5TD?+QUDCEZWBF"1$%FYT;@ZK
M1CFQINR<+D W<O&%HJC@W\9G P2)D,K[U*82Z [^->C[RC5!^@H%T#)JHT=D
M=6_QDY;4(W]W;SH2-,M.="@UGW&YP\Q2)9(]L-BD%$MOE%(D^82Y__07Y[;#
M9 4Y51!PF&/<.PE.\!XI9-]8:_T%:[%N5@,%+_X[:E7'[M)27@U%872OM*O^
M"II/% 21R!$*/&2/DMRV1S;P(N,R0+ZM.'TU/,_N/W#LVCOX]]KK=J@HTL1=
M/\T'5,=8(D3@G=8'=N5/,+#]BHW-A>UK4Z>N3_B(+NJ1P!X7V[ AQ=CK2 VC
M>&E/?6H90>C%F%=435KQVI<6R*-5USY3(@(!RS0<04Y!HE Q_A;[OI0?BU3*
MM@6OS91@FIO)*EM%"DF3==KAD*E9G0.+*]^^>9^P2J=)TAP3^[+F'TM>"@Y&
M6^<JTQOGE;1R++)R!LX#6#]L?K*GE !^^CU:7) RIQ9CC',V*LU5+&'(>GPH
M**TX6/^D^C56Z4,&8G0\18F%\?H%<MY_!8#Y;X(Q\'9/+\P7B!"#OX8&^S2S
M'I,_FT@YKUF;/Y-G\$7:%@ESR>*',3"M!UN.<T5U3!9JQ;X" %V.ZP*7$C-@
M2F[J"+DA,#<6"G .W&7I4ZCUU ;'IW2N?M-]%IHS%U;#IIFW.,?2*M$83US=
M78W=$(?]+ >SB#'*<H89J= H=+!DRW8FVNX 9&Q[A_"$L_EUSM@N@L#.[=K7
MCS"6^ZJEE(2!AD8,[!FF'.)#I .25K*RO5V:^7DT>/=^F(/V#R^XA[2GNMTU
MN?UIQUV/\8Y% 985&/X()02A $^'\_PSX':V/-\?D)2M*2B] XH<U')_TWBX
M*XA7, %]>TD_!T$!D#M_K@?U ,>D1]EF'-, S\5!L-U]F&#L1?W_>C^JD%@+
MBC_;$B=.Y4^6KYWN7^UMQI[?##-QX<(3'\)ZH0HKN'5._E X#C,Y\]<779#Z
M(UVZ?KI"7=@F?()S%+-!USG1W)13<3.UF]!T#T!.^"D2+ T'^R4F14@T#V5(
M!I?$TPA):Z7R?-/1HD^75OX,HW&)L)G$@\5\"0^$RA+1<>[0)GT*==I^ZA!Z
MDGS;\ AELZ X25I.BNV,[")$%'/R\%@VKC;I&?IUDTJ@SI0>Z/ B]V D^OUA
M]U[>?MO2 I<@<(D+_VP@8HX_A4TN*FNX+$-7?&SHMW'>(O[>AM$9LZ+&1)&*
MANBCKCN]6HV1G+?_\ S!WPS^2RMCK?2SO. 3#.3><=DR_*3./Q"V?')P*+]5
M>CKQBJWSFJLV9F@]M-E2SE-]^^>G6PULQ%6GK*-D3AC!G)CO3PDY@:>O2QAC
M]C^ UO9.3"X3="[S!'WH/[E<]1[<?,H=G339@\A/9,Y73?;)YQE'.V<6^)DY
MJQN4KL:A?_D@M)"^KY.-53XB3Y)8![(4M*72;'O^>!:  CR6 =LX[_R]Q8S(
MU4WR8L9E'07P=R-4<:FW6D=_^\#8B]!X@R?W335I%(F)9?$K(8^F+Z):?N@/
MCW33UX26YU>C)1>F>4Q =9)[(2&:Y0FRA>6XS_N)?'_A:HM[EZ  WRX1F85P
MZ_BL@[*]LP3;0W T^=)RHU[$3]43\BGB3H.SLMC%6'S>R&:1@J/M_%\TJE<%
MZ8V^:\[$VJ 57OJJVT9# O^GT5OI3PRU-&ET1\1"X^X,M2&.A!1J/8J0O:.E
MQ1GYLQ8TTWCQ#]K2Q=&#:+EFL41=3M,C0.!-/3P,H;&K%[Y?[-D>I$_CD*8U
MI6LZ<YGR><H.' $G>>,J_R*!F(6"1\C2+0QCD_-(,DA!0Z/^%*,,-][=8I%H
M_N72":3L^-@KXBQ10(LVDHLZE<WC&6:9X9LWC@_[1#LUE%V7K'T@.EVXNP-9
MU"*,9XJ,CSBMI$HGC8KCR"Q'2U$ /IQ?5&^C]8F0,L[X;"8T76HGJK-2RPL*
MO;G?BF17]";MI/L%3*Z:U+9.&_(^2"SF\38\ 96L**7HA'@TNUC.K/8*:9OC
M/>B$*:6WJ>V9GR@\N[7(BVB6Y/,6 _']_O0=WJ#M,9'S=%*?3DC@>M,E;'QI
M9EHP12DT;8^#:"BM99>#:Y)#G*B6&,M;A60?\]N3KNS"@F"QJJ80H&G"@MST
MG$)AL.0E9I&S*19N(HUB1&+AGFG=!4_<::[$N,6\YHM<#Q(R8-2(:& U,LZ9
M^!ID8RL?N*_7>YQVB5"X39CR8G*P/YK\/&E,K7%%JA<OW9\CAQ;]FO,748:(
M!Z%294-[78I/:$KJV4*7G&-3=QTG2>)W B$M0?JF1IDWZ9;O"DL//Y01B,D+
M=4RA(320[J G]2N#K",+[O1'*^L@IMO C>6>_:\ZE=0%H3/JZVRD2J"@=[U5
M.8&PDF<-6BRXQSJW0IM+.PN"X^-=-"[A\6>RT/$/DHI#K_,Y%I!V?A"RD_K%
M1:*Q^>H6J[101DDU"LV1"AT:KZ F\O_86BD.C@?=-=>O$2(93Z3!Q_Z!LPFI
M[9L57BB X'T---6]FQ!_7P=EV*( G%0H0/A;B919ZYSROT0YS0J=D)P;?<_\
MH:X=T\;WQX:'<AVSK;Q3.F"7"N>Q([Z@<\&IM"[;4BNID(1GFA<7D=N.%V=#
M;$5&KS42Q3]@*D#"LLG'B\U&#\C&XTX'L)]W0R&B6'&BPO*<!+L0)+ST@RU)
M;(O%$P.<(EUCH@+,RHJ!@1RF:?ZO53RLB]Z!YI=3CS7MU/JF5.@6ND]^>#V@
MRP^CLBC^[HVO>8FA;HG_V[*3+F3?H'-.;M*A>S)HH$R(JHEC3SKC]**)SHR\
M4^JB#-S+AR=8L#?\7]JD\.DM3#6_D[0$;JQBMYM;Y%]?Z"OAPGJ76Y0;*=+O
MJ I/JQ4%!4N<[2\^N9*B$E(-0GRC#Q=NKS^'>7V1?D 3-CHS>H]1YSLC!+ML
M0V/6-6^5,?G>%90YHP C*Y T&]*9E&SLLTIN[LO\>(:]>M^1!?[L='=R&@FY
M#K%'VGR<-F?5U8-/& ]S'7-#@ :-A*)XNY)W:4]C]PGV#(_3[/^]KZH=)K>)
M3XH1 D_S]NSI>(3-(^>-."1B<(BM[)0C$" HHL/!#W\C3>-0?.087"*';T")
M%P_(-0YW96&KC2N6F9=0MI+BI8^XL?M*5HMNM$:(9F>220;X"5P],%,P\/WW
M:YC^[22D/)@;=YMI17^@WM"%[F17_XMNZ_DYV^QMNR#D?$&TT'$N54U^);]S
M3$*-0KIR#:)^&;=:'(=@I,G+_[ 1]"GM3R6;LW+S=  >B@*L\*QPH0 7[U;T
M[[)\[MWW#0KPR]YQA9K?>EOBO !NO8("X'G5K)W<<I$'GO'XVK+X+?(K\ ?6
MG\XVLS/>R+IJ<-5?K9R-W/,RAX]6M(&DA"''AB_$TR4'[NLB2,'?U)NVH,#U
MQUT9\1>DQ@30KQL[2FY7'*;J)E!2\:\0"!W(NS,L@SVR1X,+W^,)O;:'%77!
M=Q,30'6VO\V?#4#E,S"50HB.&SSA\G$_R]<S_;7P<5C=#(B$AWNB9+]40W/,
MJ'IE3_#:E8G'?YDS<9;[^C1[ME1/<#6X]9QM1D6RF\_3";^ZUV>F">C[P5L&
M;CVUPNFF,9+Q!>K,>KPL.#)!"LQ%2GM[PI\E]E]NO_U<H:ZA/FFK._-MJ0%+
MW+&9./WW^%9)8;'E_AF7JDOL,\S7_MDT3L>MHQ6GN.N$UA>^:W FJ,86W<[!
MTMKYXVUYQ'QS30,C7[S MQ05NS6^3OP&EI1J2)>\&1$'5V(H#O]Q?G1Q<7I2
M,93@LHXJ&I<V9<FKY/6?PU/)*Z<U+AJPC%,U<K4QI.5&7%Q IJAM2P/EUPYT
M+Z[9+]8'G\$KI_<8TK6'L6]IS08\*0)M!.;4W-=AM@$$L*>++L_PC3Q\#>P;
M3%(I<?HP!F:9@X=LQ91R(POI?M;@W81MH@!>([=U(4B/E\@*A5'2>10 3M]W
M#TRX*(#Z^H$I[N>5?[_TXJ_++3_!_/I!2U%GMQ"^ W@[0CC[_?'$GFPWAMV]
MJQCM:DM"W9N>QW+"YW<MYWF++84Z4O!2%66$6#7I6=!575X29RR$0<FGG_*"
M/W,%?_;&H%^-O+8D6)4Z4=CS?R,S4;B1"NGCAJNXU0"+\"C8_<[R'\D)8I "
M<:PX+SW!F$C=RX1A8/C"RTUZ#37T[F,K[NS%!:MLE_B:AZE=WV7S7S6*!0])
M\;;8*:GGQ^WMKV.0_)CM]NZJ'!G0L+=\?RP: 'R6U5\)Q[O%%NX5Q.8.FV;9
M7V)]+5C*CDM@Z(\[".P](T"G"#.OE@^]^:>U5=59P*-)*T%KTJ !%,"B-K\X
MQO2BG)[Q#?-459>*7T@U#_70JIEJL&LXILCX6\8HT==3&\^.K;=.6>#<2&G%
MVHN*!\+<O8]\V!W.A5K%4VJ(>:/'F/R>4GH\E.KCO/QY]W6B+._N5YJ4C_5]
M(&,^@JVT<W]LQ4.,^0ITT($:A!CLTFJDV@_>4+ER&!CVL<@3OM8B8Q>CE:/@
M8!&H=:EZ('M!+/$23T;VQ@QD5>]>[NT3?3I-6F=+D$\S(?+("LT44 0UT3:Y
M)'?:7J&A8AF?]2UKQE8M-RYSDGZ!UD$ TRH)K]!?E^@+"SI_O%&A[AUTT"BR
MRD]MJ[*Y[_"6;U(AI$\YOJ!_G3'8X?I]2Z@:Y_$'3"0;HQZ/.%L\O&:@4G?
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MIW9,V>[C8F4?7+#0L@@(5BW<0R]448 U(5W@%"<*\,QSHXWVP"=\:40[R;8
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MH\OP0G&_D:O91!R=MH X/TA!2A]#GZHW[O.'LV!BE]JH^S&5V,5L8=S!O%"
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ML9)@*=WSUM:%).VXZ&F)@";&YT4&.#'D9+9]]"H\W)4/4 "W#/5KRHMP/!2
MZ#&B];F79^U\-KPV$%G\[O[]: P=L^W:_N=2?RIMUM[\^QEI0*!;X ?7*5)6
M'EX2DRO(7O9WBG:TU.[[F<4=W)A#QDSP-\E09-9QCBO(,)S)(T=XW< 9\7;C
MQXO7K,0*OW;=2[PCCC"^F>"$\/CDL^POE6V3E_T,9^S\BIN(],9Y2JX$A"K
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M#?M8V[J,*=T -_>7RB<_\PM*8)8!%WN0N^XU@IYH" + \><F@&['K;O7&\O
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MJGJ[OV\!M:=R:^6/_69#.YF[;^6?R@?)VU6N%U5XQC)V?\B@].\/3LLZSQ"
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MS/K&CH\.OC,["KDAN7T%:\-F\0G]YCQRBBS,)1+47MM093__1_#B_R54;!$
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MO?=> @+2I4L'Z1!ZJ(&0G+AG]IR9Z\P[WW[WS.SYYOR[<EWYK?*LY[GO];3
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MOSL[6,R?%]RFJI=)R8?<X:9)*"]W\[1FIN,0>STT/D(7P\.%43'Z?TA3#?W
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M/URA 48TKN<@P]4/*A%UE6[@[HS0U-!?\:HJ]GLRJLTU-U.:DJTXTP-VA6A
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M]$H8OR>U7=6N_3R%K5P+"R2UYO,(1&0/&3OQDOJHJ*20+;AI/M/Y'2A']IF
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M@IDAK]E8,(NKU?D/145S^5*;^B;VXMLR4L]N&@UH57%?R-C'12:LH0$I3FA
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M?B6U\I^/SYA7Q8-?7)2<X5['+4G@MH.%OPB,F_DPXLZ$\K8($-EPX!K&NB1
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M!0Q/7:=6O68@CIX98!3-<!2MU9"E>N.E]F5?8'$_F+('Q5ZJ)=>K.C/3ZMT
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M;,P4!;G<-:F3TV%M[8FRZ<JTMH'&F_$V;V^V&O^DX /Q@7GATE1GV^WYUN'
M.XK,9&XUCE=MA8,D3A'G0Z3G;>4H8KUIJ5HNIR0ELC&S:":*-8@X33YB_&4:
MWWD#56G6Q_B7L1_P'-K^I2RIOU,J3#UFY>9L,H]H0'H?=([NR^V:?,RXKE[6
M?E52IX6FU08.U50*J9@UG&MCT[5.Y"W187BLHEG8BX^[*]=V9>B'L((W(PIL
MKT^F$EWCKI4A@T';+7CZ^UUKMR,6B">+04-AH]K8@2C&5;Q>-C9%@]LL=3R.
MI9%5^5P,4+IZ7FJ-A__"+RX*WI'5&LR'\%T* L%:@V/V#KHGLY6RYK)9(0O'
MSOYWD+#AG]QG:Y>-KB\R,K/P])IWK$-"'%G2!Q087[W^4&%^^R#Z/?_N&] #
M?W]>XA\'!G.MII&?!8'LC-U,3F"K)*\6>7\$C'OO1]NNC[@L]'>/"Y=W6SNQ
MVE9\T\[XS6I].C7V'$X;<>$8\X3 H^JWIX4?EB1?;452#X/^AA<N_WM9K-<6
M4K).WV[.E;KTNWU<Z)7(A.4+64R((K,99@APA'"I0BNZAMF*1)S, Y]=9\\%
M/(>*C-BX(8>NAZ;@N'VKY$H6:TTK5A(:G%29125CUCN_:2N'1V'/E5C],S:M
MZ-N3H!%<GK&_/8/ [A332G1RGD(QIG(@R;67^6$,++FHA%\I^4>\7R[,]YS(
MAH]CR\QK:+=.X.B_P^1GCH/NCM]]])?X5^&SG=H+ZKMDXA$UA+#( TKQ(\/S
MIW0^MQ/[=^$">=R!W96.@^5VIA_[027AR[ZV*4!H_I#D[4SCLWC+BMRRZ")=
M\3;T1_G0XDS6-7,R8<*HVTFB/?/I_+5S:MI.$93KYY_ATE/G5D8N^S&!2O,D
M0/L[51:V,E,LR@,E+"<V-..9#'.4_A1A5@/U@$]&O8%=W3-JF^MSY,R!@5([
MF1P%;2_G;^[2?I#3.QSN!XLTVD#[K=W3KZU2$]MRUAP-7#\F#48RAE=,$D=,
M+HXD_%A2SXD=Z+A0_2\JS<Y ZNC,!$$1>_> ["/7Z>2R5VQ>%VF*6(.-+V6[
MM3=J4IX1T']$Q6P23T5[ZAB^H, ^);2>_FSQP"C0CHB@0UQ9Y_U=W(25@SO'
MW3KVQ+>N=,T2>+41;P#J.?-?OO'#"DG8%UVT7U6%-*.F!";/R"U#Q/T723FP
M1AB8]),H$[H5'X6SA\9\)]:<D1TIGR+)UHCU(Y-V81P=Z>.PIKEYIO.)^KP#
M#9[/+2))_M8IO)N:CH3Z^*)>HD90ZI_Q[?TE2*G=]4L7?*EJ1M!U8N[#A3R=
MI_:8K:<^U9<X&V=&^(L7K'I*;'R6V*H##YA51G<"P?-<@:[W@&^8TZNWXU8=
M_>W-MRF""%@24MR?TA!L#?E-C$#-.YH'*_XUW;6,!ND==[<.O7:'J7Z3[&J7
M\_QR!2; JW/&Y5=J"TO!J=?4+Q-\%%-5AD,]4I+7IS92OA3+%T' DD ?RZ>_
M'LO_I*R4G>AU#>"1.<;T\HU=F2/2M8OB+*,RN[[3]$)J)/:@.E9G#M&IQ1@3
M(:/<PNZB7QE9K='JLSB/=UJHR1?IMV=2G:<].0!1>[,B]W[W:S =(F;Q'L!Z
M0VSMO44*=3CU ^)'K;2(^ 5^(O_<!RR6C0[=TT<4JJCJH_L;F">_KUK9Q_%W
M25,HD35;N?D/#I&; GL?1C,-++2G^;L:SITL^MC_Y"7/$HO/2'F!)4HDFJ+#
M4VM9]OCMMX.11P,,#Q0AW0UKFX4OVO L)X5 &OWYO:D'EK=;=R^WGM;8[^Z=
M\O-16]:PG^FH'C/B&NWGE"4:SD'I(QWUF72U2\%DW^>"(2]O*"[ R3H-?D 1
MY5CQLIRVD,Y,K 6R!07=?-:\LM<G2A21BE\\Z-G84"0?/W,.:IVF_%,M-H%Q
MRKMV)8EHV-O]7@/'_&'D6=<4(Y^I*,_+=T!D\OBL.%0O<G"Z01A;Q][HD1B'
MLJ;1E'X>4/DR>VO/*EW-@5YV?4SUR;FY(TE@.'VAWJT7>:$MZX0(A'[S#"-<
M_(-Z;&/AJMGP'CP"##R83C]<W=19"DAJ]4\TCK'U]$58K)2V*@[E/R584!;I
M$.<"#=)$]3N6ZI%FQ[Q@L9_*K6\;U47L-9SU<#3=/HM41RF:\46-RU&T/A99
MAS+\WGV5E>J#JV\E,$V;R*/@Y,=KBDJ!&I1;KOY(=^<@4/ >\/%1H.NA\\B%
MX @%CD\/$M&WB;LZ_+.=RC#=^QQ64QLK_]VT*C%6&4>J#<(A8)J30<-H:3B<
MUGI)OD7MQ"4 NXEZ09RZX8A']'3ZCH6C-'"B&8I:D%V04UEMU-V&OF!NKZGX
MWNS\&P?>T#MQJ2_^78Z.F8X+CO[#(N' W\"?D<6I99DZ.<)6V=(,"6V)5;&%
M1.;R-"$X'7T;6AAY7_GW)#K^G=".O@?PQMWZN(VM(G16'B3/,II/+1?3/6#(
M= 3IGWL/*(^:Y.(!#XEO(^V5[@$4KA&K".9VY++:R>T] )?SSV"+6;%]Z<,!
M1)JK^"!X]UO0\U,,1*+%K<W#3ZMAL(!8?U)0CX%E""M3IORO,)(5 YN4;X[E
M).V\W#4ZZI@,68_^X'Z_'V82XHQ7& X_SF?-+B_I!3M_E5<7]&M2!+E04NF<
M./G'_80+0Y,H$R?M6&C+;+/QMXH-<K6X.M QRI.!0'^AE:M_N*,_Q;2T"G8C
M$4$?FBB^ M_9&$T$/AU:QG+Z1QV=QXDJ[S;^@(WF"^91O)CLO2\^G%]W.Q<6
MR>M]#AS+%OSW&=GKID;4TP_H_"LL2F,9AB??C-F6%CCD49>;ALFZH.#I O7B
M9*RVNTY3KU,07[EU6CF[%[J6.#<('="?=_C?)$)(/\= I<+IA@N8%^UVU(%Y
M8;5D^K\XDT%\L3TZI*?-8F:G!9H8LT0!>8G%O&;<F5!X):]B"/>$4]"FDZJY
MV0\3KDV@NE!)BKVCN.P7%19/& WE!6))(N&';FI<K?E(X.TU8UP!OG3+[XVJ
MTM+%<Z\(^F>P4YGD4><S^03HB1X8_VLZGZ22J YN/R:-X3[5)E9O<<\YY-WT
MFP_Q:!B6'>""8L69%',>'$'R9D8(K'*S%"'5-F&=J.:NSGORPA" RN$ .PZD
M1SI*X';ZK=L[^$?5.AR;9#-2I B;)NVC?W)Q];=2#)_.])?-E.<YG\1X/&.U
M"[34H1^V#-*HL!G]G-3B44\-C4[?D^31R>>OY%6=<NA^)\$9MLC%:W T<H/+
MKUDL<!#_MDKT:S6^QMEN?\>'MO\NE+/3ANBZ!]0IP67N 9%[RY#;,>N[!W%;
MZ89@Z);R8A[V(J85+%%C8;XKP4F@V@+[AJ754J46(.A+UQ>3]*O4$%\$KS&,
M7 /"1!+^QKC>_2B1J(Z\V$1:73X\(4^^V^U:[Y;8XCP^LR'. &8)LG0X@["0
M\KLD)X[TY:H%+\1<[NZ5A^^HMQ-Y?._FCH.'[^=&'%->UIBJ]XZYI275,?DY
MF/EO->6+8N9-])\-R].$'GQ/WS,Y_#"L>P]@CX,$9*T7_ZZ$AJ['#3H.8QU^
M&9D53>R68S+TH^O^?J9 _]%?)"P+/SXAW XEI\DR/C_ V3O3ZS8X?W845 MN
M%K'Z!^X.)R"N4:!9'N1Z<U#Y6]U\,0#/=7;[%"L6RG"@VN:P\_.'5&;9;EI8
M#AH#>J:VILS=3B:HAI\,I$S)B]@ZA>?T+'!?W0,4>V?NF!= K;XBM_4LNTYE
M>>^Y+R"6-N70LC 1XVP.2D-1(AAA.=Y"+>ZQ@R8.ZOF9M"J&F!D[K[06M@[A
M:9^8Z(D<W_->FA1*QD<ID\DI-C8/TB]\(\"S6&3H3[6@6I>XL!=XF/*]V0_*
MVQ]99O5-)L&MZ%SN$W#KHHSXW/(!6+]51?^L;(64]M0XX9 'T5>&@)>+@D[9
MF1IB%3'D<?Q\I>?T[ZER9Z@23>=Z6_HMLXEFX"^KMT_%/UB#*O',P4RK69"1
M<N]-\=</FAX<WP[QM*++.'U5L%Y\EY-U6.?EE0B7>9'QV!=G*H=2HTQ[RJKN
M&0V'C Z'=E2Q9=/54Y>MG;ZJ>X!K[E24)XE8<7(5<.ASY@M-WR(,C:6E/+^1
M0[L%)@;=RL?)M!^=)(VI:;/9T>PO=D8#91\4#^I%; !(UTOP#&/.0")LE:9I
MT_\7+V@>H1)$-9=:RN#\HM&)Z#3+TD]7!F0XDQGU3==L[;5\Q#XD^++,UXHX
M0"MJQ/M!]Y*^KGR)3O7Y54"Y86F)["LS<6GZK( +@6G6/#R3QU-?U'HU<O8U
MDZU,FX@7 ])<CRAPF;T.*"[)O5P^7V"3BE+]6IP7\N3C3[Z@.QE7TE$]E13E
M%-:3LY$(/61-97H?*03\.E&.\H1^,+0W;^TOL\"$'UOC3Z\VW33__7)NM=NN
M[;@^2.SB$?&/N^KYF1:.Q800LK(*%W2J=G<*+QU+@9(D%O=S&-,';8;(DXIW
MPE%7BN&1[?8UE/JTKI1D2YQN.*W<)&/=S1YS2X<8_-)*R;U;-1>U&U @M%Q=
M 4>&_PW[B0IV;5V=B+"NYA,&ZH#=#N';?UADY)XUW)I5W6A9;]X^;V@VY;)S
M1C XPEH#"PM13LT&U-0(,'+*RBR?1#ZQ\K-VQ2>YO<)M0O/U2MI93:1D/%5S
M^^'JFKR/K7K=OPZD*QSI4T)3Y:R+5.@E^5%/;8+& 1),IK]>4 0I2-7&?&:E
M?SU;69>R/K%Z%*3WSPJW<L3&KC$D*% 0+C'58A(:<L ^ZW!N9^.L+&'BZC(I
M/I@["CLTUE'AX$?3M<U(+7A.>";_[L>;P.3^:1K;UW\:*OC>0$#@GI:;\@IO
M#(,'.7F J AX)( ^^=7YVJ?X9LE@8W1C;7%F<JI/+Y&$XRRT-W/(*@([+ E?
M =,IY2.7VP.1G7]/$76T)OYVS1U$O/OF@M.URG]G5L,6T(PZ.S4F@/+)1\?2
M@6$IV5<06E95&B@F8%-N5>#@Y,C -T+JM^DTN+*WC$7U]\X93GRF=P]H=@@\
MO0?TJ1ZIW6V7WV4Y4Q^"FA&SGY!57#*WS;=1@HBI)*20?QJB\AYPL$2-WG6B
MZZ]V#_#B,UW9 L-93>X!X\KW@ O0C9/E/>"MRSU@ZX/9A8N_N.G@#?^_@NE=
MS/&]/;N&5&8^T=QB&3TYFKT]ARPR$RT]P4J'DB%!6U02Y$X1^6UQ1OQ/+@OK
M[=,*I):+Z\@J^39SFS]*752]YRT;;3L+BT#36J0^ZV4EFCC'-,6IC<'CJ2DI
M ^7N&469_CBU#JUR A'ASBO8WP32=HN[/KN>'7:DG;A1&LR ;I,P(P?=1H,%
MZYO1IW,<#=N<W\R 8B@\QM4<H+47.N6J2<-U-,Q]JON:>0EEUY2OGCW>+IM#
MJBVK?+E-=)T=F;6[?6HSY>PLNS0 :G9W$:U?=SHQ8+5.*.KM@>&K269]$V-W
M5]"*K"XISWMWO1&;@UD6/:8]KI<^7=[]J:.=K<#8,EC[8,'A\C--)<:0>&TW
M#.8R$$G)5NUM 2OG(1<O_L:7PKA;,_!CJR[Z$:##8:#8P92ZOL#ST^BOJQ=L
MU-F+<&-7'\RTPI NHHS>69FDPK*0(FDY,;$WV,=CV)&2>G+ KTL$8D=EYYO_
MZ93]X81\[G].CDR#YP3&YB9B[;17;Z^:BY*6V845 :$GY9S>Z J_<.OE7.9.
M60VA5@UM!5@47PIBO7$P&SZ6\1G*J3NR>)1@?.J=L$H-CS>69P$9*TB)]C\9
MW_XQVOGU#O,O0*0Q%?F6!'80M[6'B&XSAFF+B2\>W)TM^U'H<$@9RBP(BU5G
MOM^E915O43P@:QGR!7#S2\FQVQ0F<H]S#)VWN_YB02FBCR80A1B2O472!"]H
M>Q&O: UTU$<GJ:B>4Y42?;J6L!!SGM['F2CX9V]"A^M:!W*7E/:M&J%/^:?(
MM4ENJ7%_ )&*AS@;N@=0Q95>+8W#F?'@%9"3V3WS>T!<P(#]/B22FJPN:QSD
M,E80G58@XI'('KO]7?.GN8.9J]6\I4'99J1 ?%DM%MD&BLM RZP/7UL6TO%A
M-VHQW(H^2[7S*.2CR<PP>T>+R/P<_9*2'):M$%]K@H+"7)XVGL2*BL)GDK44
M<39W+'O,_].]8)/9+#A>O3E29P%CTW([:,PHBT0[44R&J\Q_>C[,X+XF8MXW
M.IR_CT4.G<F=;(G-B?OE6@U>OK$K]<,.0C<,:2=*+B@:7.?Q @DA8L7;T,K"
M?-DT"C))\]\.,6CVCU95_.FN1?-'%1G?09/&P*QXF7Z4&2UD;6J?(/0\3[7>
MCZB]@A4S6J9H HLYG'0.YLM2,UM0QC6B4\GR&;(M/I)?XXT485S(/6"Y1GX5
M,1M1HF3/7AT%'6P=OD;MJ8J3(8I=4H:8F10O$$WY'_O<Y>![TD76?RC^H#.$
MF+W%->V\%EX$.PB&,G92.U]L/LV:J]H8E+S:<=:&, &Q0V)=/# ?H^#H3WAM
M2%5..,UT/;G\Y/J 2JF*=L3&Y-"I^2%[P[@C7P^Q(J5@)-E]7T;G%QQG'V."
M9!!R!XY6+5:*UB7G-UX[6+%-IC&FH=2;&J?2/A8\Y ,_?8*(^[R;Y=42\N<B
MXM.T8)9OX_++"1.;B[W[4"EFG*,#K^>E9?/)> XVQ>4JA[O"_2Z\@X^F_]H4
M;1(=7H"H1](&GG3#IJ_B#";E.E50)BT"DFPJ7CEY6WT ZE)3:9BG..6^>YZ?
M1JMF(,LI7X)CBQ)KO$V.U'O[HXZ2J/P-S#[KP#!2#R;O!GF3-<YEZ 8M_O6(
M+]==DNXN##(XXQ\*P] -5$2^E1B:I6=:O_;LVD,Z(Y3ZQ[3,S*;\*D"ZILV4
M"E4*##'>;; A$S7@F]=$ 1Z-T6>..?4D"2S10^M!FP\J!SVFG]O&ZRVS)LHK
M<QNHJG!A*"J*XCG&':S]- %F>P_0<968R&R#>=BC!;[+G?!0"12OD/XU@&#!
M^ 497/@<W'=H6'84D3T%"WV:L!!4J5'P^.+D9:R^@Z!$6$XB1'DAOE@7VSJO
M.T97ZI%YR<M;@Y;]GR.N:#-\,PR?. HW"%*8PQS;/HK>B"\([XY[B%,4=G-X
M)2>AZCYZ5".T%E/4:6*:PF'" >(7<\%Y8"Y*;>X93=C4:".^ D4NSQ</6N#.
MUY G#/B#XNM26)E48>]FH507/VYHP&-*=-?5F]UGIL5"/W33UB&V5I&M0)0M
M[M,I7G>XS.<:9"' ]Y)E(V6V?3X.[O<!.8"!R";P9"U>]KP'\#'> V*IHB1.
M ?EA:7 5A%D.W<TI*'O;2 M:Q3\P%U"5[O#3(-#KY&1<4'#KZ]&RE<G-]N;/
M>\""J!RB@_#T2?$T!F+Y'E ^!?+(6?\>)J:W?29U$!VG$<AZL%],T'7M#?:9
M6O-?Q5<O+%\,T)%32L!/L#4 AX()N%MH$[Z":$JO=+_^'NPS*JLJ1^KG5\/!
MYP->($)A9;EA#FB3PZLIYS >AU(VGF,[A%^Z^^0'"PYQ+1PI5G**R059:)A^
M.)YV-8[7>HFHZ1H>+J41QND>W+6+,UC"2I#3V]!K_RY!X\7W_5UYE&^,E<41
MIEEL%(Z$#*3^+KSZ=/G:E=KX(?%A EJFF0E\5'$E[:!_P#6]VPK.''?3O<#K
MZ1Q.PX]7M@VHW>6FU(KXW)B1Y%/_N5 CKCI1F4A 1_(QX9;D<$ Y&>[G<)TV
M:,PVHMV'6250=$<M;1DS><G7+=[$L_Y8K'UN<FI69$B,RD_5I*3H?2.#CI%_
M8ID0D%:3MB(OK&"((@GG^;0*FIQJ!#_!PSE-/_6L)NOCI2[C-;V2H+Y,-LHD
M(@^H]3Y@.XG];F45=[C^QM;'T##%=]=!B9>Z.8,H?; .L)9YWEL5JAKCE3#
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MGSC<V^,<6Y"_)R&66_!+ R!$380JVI?&:(,*'*YK"'2N-]>8O7SY*O  I1:
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M()'L+SD1:>?\V4S85[$P^?*A_-E  '84B<4Y;&2G<\VRV&1 99T][CWA:61
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M[R"*O-[>.4/^#_;>.J#-+ML73DLIA992P8J%8D5+BQ=+*<5=@A9WU^"0MK1
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M[=:]B4GO@7")/GX/5JQ3:&K!]I\:@?TG]ERDLV 65$Z7H@@8ZJ((I-1\IU&
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MK*(M2=_8=U^<G=(;ZR)I7$'EL:/[RN40T99!X#XBMY[\G,UZV]109_- KT&
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MP/%MX>\JJGB%>OKJ_(R<XH/KKFH>10];\F>0ED3O+%@*%+%C6W?X('F.'1G
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MPXJMC-MV=8KB0Y_%?AU?+%?L>2QS:WAD5&(Y]Z-$H.JO;DK<3;]:*IV=7V
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M3?=0;SBEJ#C==Q+9!FYRWB61+#!(>+ASE77#?^'RY%<7X[?^I: 84'/Q#\O
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M4OR\Z^PHIK!&M(Y7!]*U0A^MG#>E=Q<Z.'ZAD>2D[TGL>^/9A76K7$(KU+7
MPHJA4VTCZW.;WNRP"G*UO&U%N_1ZS3L8P+0&%$DW?Q5$]4M'7%5=8XB/<AC
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MB77\[.\$V/E$:''<"/+4<[A4[3WH7#;:/95'683EIR7T8S:G"65MD:&@"@:
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M$H[AU=_N>:ZC)_Y-NTPMA,U-.%H!9_DN(YHM\ZXVW4,UWJG%]+Q;S"SMX?9
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M>.LBMI[9K;JW]:Y/#S<[3H6_D(KYQ)6GIK9::ZUF9*,?SN=FF/:']HNOMVE
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MA.Z9>"2=5[[-1;LWCV5_!M]X(G2"LG*W,7- ([@_%? >>P [W B[US=U7$7
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M=;7L>3U'SV='[^O&TWA&*?\_-Q'+3;$T$@W_A/:G OCX2,'1TS>1H56I4).
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MOU>FF%SZ7!S,G?,!EY.0]N#48""(YV/Q9L-@:*.B&UR'V+/CG;(8Y':P<'Z
MV&,2N+;QX]&D9(J%[#>N_(P-U;L9W_5T+5Y[=B?89XN+1&<*S;651<B(=W,'
M\[C2/%.;(W2E1I[;<GVS96*DBD4D$^U>/3V=8L)M$%+T0UU1QG50R51)LE+V
M-P&'Y:R$!,^D+_G9@1G7-%R>LH6TTU:A]R]A4B'3PEW0'%"5_)YXO&-2@1(Z
MJL!#!! -R&5N<X2+QWD;XM;AK5.Z\53 FT]DL!DKR\'7W_&;2MRJ\[^4YD_*
MSESM?/]KG.S_2P>>'"ZI]')$4\PX.5T@_(I/+B\QZT%[FJNEIQ'<90<#N'C7
MF,U?T4]IAQGZ\-HMFR+/VS:/6\UL-^LOB=,V/YC$1>[T$X(;$@VJ&_T. I=[
MU7>Z/#<V<W&L)L#*^XCID,E?BJL1(8[TE7&O-<[.9J35LWS.:A%^-'\N'D9S
MI.&#^.Z^V41?./T4LCO@U2:TB]+%T3^.:QTWB11-F=PUWV6L9&?ETW^X6LW]
M(E;!D')59[B?NV*X\#OW?B<CS8$*D/E)\4-HH.*#=62\ D#&M>'I>!6J.M+6
MTJ,$)V]<7N3XN0IVI?&5\I#&RD4KL9%^(?G3;3=>UJLET+1X[%_"Z.<450XW
MOQ/+!MA+"1)5$ EFD[VVCA[W*X<I3G.(,'U,.'8@J6 ^)YOPQ)XGXG8W]Q66
MHL>X(IJ+U$3?H*BZY78S1.),"!:Y5KV@4?;FZC%WQ[I#/IZ?:VG!2\FI9AE1
M'0*Y[IYL[^\]TQ&U>$U3?\[_W^BL=L'RBM#*=$Q]0G)U@A*KJJ;!Z>&VMAM7
M/D0W"PBN%MU[\/*W>0;:WP*0@G+H.E1BAL>8*=R7Q))$3,4>^2,943*-7TT]
M@C:"O[X9T!\"/3=QLE&S(#P?T\9HJ]ZIW%:_U;>4FR8P&XZAL1LJ@.2$$+U7
M1S$Y9JWUSK5QTL1B68?*4>H^'@@/#WTJ(#"!?GH#ET*QBD$+F;+?XOE=L)7Q
M]^:+B?W1:UX\R:J6"+?-R+(V"TWO!2W%]PLW.*M?1&>%#?]&.BZ31M[6 N6"
MZWZ=Q&H\_J\E6KP<B@$<%<7GF'@O#@]W&>E4NG9H\"0[.,0W":Y%[X5KP-J:
MEB)I"WS]H-NN]$4^IO]S1O-!5XQD=/([3F UW]#\A8Z]U1H@B/8GE@F!(=[)
M:A/+*]9%7W:/PU]4KO!\/1Y\G]C*=6Z.</=4973>ZS\K;87^)7?V"(^B0QPD
M:AS(F.U#G*Q^,93)P":+FC>N+'Z'3IKB3&J$; 3-.X8LA+)"(JH-)5.>2OI+
MHPOF FA^R)YB@CXCG4N8(S9_)"Y4^W!Z'NQ;./D>3Z#P%1XC"E+G_!Q>NVL]
MUHC0JAS4.0-2N?2L/;JI7.UQ3CYOC+*'XAJ.(X3>'<BL)2 6Q^BY"K9VR_F2
MK?:@&2C\6+F@!A@+.]'P>8S%;'$*/_LY1B_!3S$7P_QU,D!W>"LS.YG;VR6+
MWYF?"]H[T1<!6]O<_*SBM(@$^TX&X/A(EU:,.@/NKBI<YW<SX)VWK*JW@L[/
MT9:L<Z)8UR(Y'T4:C?J'Q'RPM[<JRC>6L\RYIBE5U3G#Y-;^2SE'QN*5R\D7
MR;+_GD3<_Q@8U:5<'PC-Q#5TD&<;E95NQFC])*VA=IS'TFW"9[ 3IGVI3S\2
M!SE+-H<GA0TEO4?T5)S[9-7TA6Z"SE8IY_:\U:4"V-C/D=Z(E:P^:BUA,YC/
MBJ8".!0<Q]8O]V?^^2M&D*6H"8YVTA$YPN_A7%J$HQ]B(=7)%K9ZL;#+6S,X
M94*XA/L\F)MH-W7[@IV:_++VG=O(\:5XR1\V"'G]C%,W<\GW'U !OT$4F4BN
MS/@J31>[W[+ILWL0,]X@X@7R2G-Q<L.[>L:_VX#\1Q$OF(9UT422-HZSD[G,
M@W*=/:9H&GCC2+> \@>TH$A!?7!X$*/R NLDJD</"WN5V;PI-UDGN^=;WJOP
MW)]FF;.I@#37"D33AT8K*D 4$IIBP6\:.>D#)#T\8.AE[])QR$K+"/6%!TTZ
M#_VT<\BSLWF6]H)O.?1ESP.I++T?N@9J%[F#^6BN)?V OR/?#T$%\.+G-<F5
M BX3(5=Z-_"I-[>"CVMJ#CZ+1+7/?47<7%VI)OC^4F6D IJS,1L;I')"#Y,>
MET&3O>1QL23-1:V]0B9">F3FVQ8H=B/ 3HN?03#R<V)HC9_,GAN#.?D#B9L0
MP'J\D!MB7"^"EA9RA,+!5G[\G+H*(GRSWX/!A98)SKJ&:[QWF[O8G>H/'R\1
MMBDNJ"XW1]%%2%FCB^:(24 M(EZ?071< 3F%8"T(!-DX;22/=R\Z<29A^T6>
MOJ@D264V2TI)?OG473%(+)88UM7U*773EQ<B#2*D.5J(H'ITRGF)!G3"XN2J
M(Q]A6AY]CERW>S9U(VJ<]<SKX5>$^QUU/%U/XX-<RI^/^9:'*8>TFT?RTE^]
M^*GLY'E;"KD7^ GT!Z+9G\8Q7=%)6N2.^?K=.8K3'*8=$BV;F9C%PA8A'>2V
M<>OB<$N5%*N&X.XE P,.!2Y_%:.UBYCK7T_R"".T,Q,I7=3<#5K,;4,G0KK'
MW->AT2H[0HZOY,?DM]&S-2]><772V$I0MMV;@AT8?*)C[)%F;(?!+&4P.?"B
MH(=WAT:3;B1C6PW.IR"#&$]> ";1]7 TCC<4#Z*["TF:@^3 :1]\&[[+I];[
MB'?(36\O2(CG<G NCO2YX9Z!A,&5F[PNBG(Q6;+76D&Z.CM,-#=2XXG=9TGN
MOG*MU'G.[CXVL/!J>%[?JV5QSM8O-$/':%]@:Q_V//G3E\_MP:*!P#MYOI?^
M6SOG'L_T_L?Q;[\ZJ51.I:0RY1(13M2$8SNEDBA1B%7*+89$S0JS#M$)N>52
MQ'*_S";D3LM9+C.F7,)FELN:C&'"QGR_O_7_[_%[G#\[CT?_/O_Z7CZ?U_OY
M^CP>WR].E1U<@/^!=M*_ UPE=(Z-!854@HYXN#'L\'7DD70V;NU; Q/=:'7%
M^[%C?!&R(=A?L)-I:"70@-%5<O1_W:WMU,H.)NTWYC2\ CT)VR%@Q #?#@$:
MEI'T)@>A3 @/_&,$S3/:$-DO0MD\HXYYJ>6L84- #&8J/=PF/M>_/>V/^R^8
M2(P@OGYE?*>#D U>4>[J$5^@O2QLNA4TPX/3!I3D+%]V(5""*FM:>X_:@.22
M]?&B0-RSLF(^VF4NPJ&]T]:.&Y0"X[.O8>>/B^.&G&E^GZV%?X)7E629K%MC
M/,\E^X$!4Q,F0;OZ3%NX2=R Z,+;;-;Q3G[M://EAC(J"H&]A]]63[7_8&/K
MH-Y\]4V?A;39Z8VTSMMU?7L\?U:4,*=<BDQ+ 'V5%1"NH]7KV]F.N+DJ3?_T
M G)URG]B'2>T#PF/3V%4^UP-^GSE+2Q,SB9<$C/*=+0Z;:1>8<)T[H2 >Y*W
MH"L$&"_C*_#I& =A@JA^EH-SK[N;/8LR<W75FE^9"?!-FR++'DIO'_?V*M>S
MB\EN_UQ<G)NCLNZHXV;?WZ+VY!45^V$$D8P,T*VQ5-)$&4$J,[37#M=ST(L0
MX!5R86!U]6.RTDIYF6SUA,G:7\X_>O#:I'[J0%AF2B)10Q[CU+TAT?#I@9?-
M.SHFI.%,[N)Z21B(LR&]T6(47E,N$@+V%R,V^C#R)CLJL6U^";7[KFNHURXQ
M+-U.7TIJ]XFMSZ9_X/J?M[&,:MMHUG=&/?$T0646EZ^E=;6K;LE>3L*$@.?6
M;5U/G3O N#$L;2:%HXM/G1$RW]];WU/\-2X!N;>.$5<^OW<LL,]V-+<DU?\6
M\;6C<6%:6I&ATK'3Q^0Q!AH#W=;J6LW/#$Y(@Z@;KRJ89V>P/ZX2XND08  K
M 3U6D(H4UW12L+8?AH\)_,82Q?QM?0RQ-W14/3(R^W!2_*8'62LQYX_.4=BG
MW(J>W)R5QBOV?_[DYR?X,<'9Q?5?\P=8<L%^3C25R+A;TTJT.G3^BP0;5=:W
MNW;U1@FC,5HE:HG=V:S)=B.%TY^:<&>5JTE'NK4_%4/ ;'IIDK(<PD3J&FRJ
MS'W).Q&G7RF/B5<--JG PEC3;R& 66]BNL?R=/C?EVAVYJDTF_%'=I810<^9
M[O@#F18I)\N]''=DPE>(+,[',/NS8Z=L$XR<W%]?WA;6V[KITBNL]C"*Y03F
M%BJQ,\+;LHC7$&[[(L@X[SX(P%-3\+K.*UTSCR!@V0ZE  &EPTV<&CT*=P]>
M3-587?LA>JFR=&593]Q&X/$YLUP"/16<7QE!@LGVS1# 7Z*$?I9>7I(7!/ V
M$[[)75^=]@;!:#! 0[R<K<N=@9'$W\\=#4#4<\:3*4&E0$":@("XC"R*X?J%
M27++^\6MNJG:\2TS52G)Q?YV??(4S.8WP:XT^8 W(^B<Q"LAAPJCIDL(WH.Z
M,9-S#>4M4>28W C-OK;/:,YA_])3!M=T0![P%['$<ZJC9/>6$RG/D>IB'HF$
M:V7+_C!KXY^!Z-0.6'BSI%"4)S0?\W!Q_#IAPLI9,2MVJDH>BT4[8EOV5"A;
M.ZZU*MW4:]-K+3^GN"UG^YF\OI1)G+1FH,#M8Y(LT$6Z@F((] L\,:M?']/O
MO6BO6FC\C'BG%M;$PF4XP@8&Y!<"/EE*K'UY\]\^V)R#@'>>187C:0IAAVTC
M8M[=^"A-_1VS<>+-(?D3!-%%BHN$-&R*2\L2;>M?)0G-QY&MJUP]]VFKC)T>
MGV<.HWNH<7L]4H_!1UO3-#HN1.9?W7DD5;1%(0T;3>5*[?<!>)/3'MU0UR,N
M\4-^P7\DT%O'>//NDQ"0D&$7PP^=%$4,KX1[?=:"@WA9RX<Y^</'M9Z*3Z0V
M$8_MZF_M>7(C.[/\I;W;?J>;EI?GJ=*VV@PZ<^B4^GJ9T6I&X]-Y@Y'4=UT/
MY3E'JP(7)Y7R>I ;EUU]ISKI#P=7*I13<R.P# &S<F,TVVC?'?HIS9MAFHF[
M"HJ*"@/$<A6OI)T],<A9?!.OKQ>%4[28U?/%J^AQ(X31%8&A8*?M5.F75,Z]
MC)L4?T73^IJEG1<P?$-=9N<H0U2:&1M9Y7,5815VV>82U7H+ E%N?!\FE3V2
M+ \OQ$P1GG&.4A*/P:9%K!Y<P9SLZ.T6#BJ86X4D><(AX)S//HS5O2O%)>XP
MY1O6-:IT/ 9=,?!^=E1SI-U,Z5?Y![LR9=+ITB'.E]X;)9-##_]2S1!$B-(K
M?KN,I#_FPC\-7>/,A5?<?>%;^?S=-Q[:O? @!-Q98!VHWJ6-=8<W+/BW6JM=
MF;R[(??QKV66F\/5?Y>ZTJ6"=@ZW0-+ZUATS/#=Q?1(\B=RLB;AQ>YIJLQ9_
M-/2I6*FRSLSG/3K IJ^Y1FOQ]L%U7=Q.A!HN*;LJ.^@).W2DC*0A-I%Z5KT>
M=3AY" +V@IJ2VZ+51BS;_)8 3)H 7T^R.P<P*AB?SL 6JLT8.@"PLS0]&YOO
M%'AO>X?PD9::A_?W#QUW_RC"^.\!L5>R,P_MSSS^)=)S^%!6\KHH_OX#R4EA
MBE>V;U!Y?^?[^4J1C- 3 A[Q JN%@Z"TK^X'70(/BB=B>%;VT^#X( 0H5"FC
MW.8'7P[KQI49JNN<@1./Z]=L/K\5'A+8FYL2>5:37ZYB0723M54IV'))T-A+
M^:(# 1O[I_5>(!GIKZ1RY-$\;"KS!C1U,2#L68JC*1%KA8KOV8-#J>9<RE"8
MJW]2?5#I1CN8@\]HU:*Q<53)JO89N@'-BK_.A<@.)OX&!G#:B?X0<(14--=?
MOFSPNHI@&](B<F3)9_3-Y>#\)+_7/FV$GTPD*L:G;JS)R2\@$N-VHN*;1FYY
MC683[\.2\(F7S0^7&=8MG9BA<J(Y#+^ D!RFZ=P\!(S+4!DED[IUK.3=:'P,
M<GV=L+QB;X.V). 8W-7_2S497J#S) C]XGU,3?$ \U5/LYSXF%'R+6DVD0(U
MA"] %\Y6,""$+,9*<K$.34,"NKCO6>[PM86/%'B58!SM Y_(*J390X BRP[E
M(I.8K542Z6=TF69JI]^DXWJRM^^#B)G*#L[!64AJ0V\+_+BF0LZH0IM><KWJ
MN"'=^5FC[V"PQV,\%YZ'=/0AU>O.OCI:,Z2N>F-QKK-WQ+^[H=LBOJ35;OR@
M?OQK<WG_/][RV=O(TJ$J'<5+IPAT93$68VCFEQGY->Z+LZ1VZ8("'N/WP+=.
MJMJ>]N-",8?"OE>[CP3[9!)6'*ZC&%9#.SBDW^=V:%=FWJZ4<K+T37[,$1O-
M!8LG'!8#=]2!B)"'(C/67@?\ FR093HXJ_P%-M0Q@RAAK;S\<-$\O=WGY:+L
M[1'#,W>5='#RB=T'/8PMLISJWO$/VU(M+ 6-/7%"9]"&39HUJ0!1$O+WP]FE
MB!G*\]J8S6)!K.ANI7>5L[W/U&UF84EA0>Z[[O$;N25I^?E.%6IY7VT.I=/V
MV?8INA=+'Q?IX8^TOWZ"_P_N/9X:.M@VQ/8=0/E5',S/Y^.:RI8\=KQ&:V/7
ML<[MGGW@M.DO_2Y=^[3\J!S%[1<M+CJ1M=K4"BYZ6&2[;26?ZHC-0^P_L9M\
MHF6+]^*#!8<U?\K\N;XV'S%<60H!;C+@=A($F/+^QJ\:>4A+9E5IV=(,V154
MA("I9#S?^H0R.]VPQ'G^)01\8C2";7(2=108W/7=50,Z6B' USET=:$#3T6N
M)I:N>O$Y]7"_*Q2>$020,H)7XY5%YZHE2X2-$/"-^R(.9+Y=7>$_AX!(_(JZ
M\W)//R709[@,S[@+ 2AC8_Q_0K4@0!61.5-3_5BXRE;>(Y0F*:66%:?PBX:#
MA%8Z\WOI++KG0H!/C3%IOL9U5B^60+MX9#E[W1HM&>,H0U(KMNZ1SFR2>>$V
M\IK=?696?_4?)6M_C.V_5<UJ<^K-PJDIZ:<:H[6?^O*L>HB5B_)2"_X1K/,G
M^ G^$8 &_PM02P,$%     @ #HKV6)- OCP(@P, !^H$  X   !T:6UA9V5?
M,# W+FIP9^2[=5!<7[0FVG@@2((DP9/@FN $)P0/-- X 8([!'<ZD*#!78)+
M0V/!H0D0@GMPA^!NC30-3??PN_?.U,R=.W7_N5/OO7JKJL^IVN?4WNM\2[_=
MYV#F,'\!CU04E!4 6-A86-Q8W   Y@C K6'KXN'B;NORZ;D [VN Z%ME-9PC
MP#_RZ)\[ %@ K/]^QAP#*&0M7<RM ):?_QG! V KO\,L K[>W_(?"#86-O:_
M_/Y7P;F7?SG\3_)OM^-@__L+_RJX]_)O)]Q_/?Y[P?P"/'Z G8,_CH/U&(#]
M& OG,1:F&ZO@7DM\;!PLP/\0@@?X>+B$.$386("']\/X_ZS\/R[>7\(AP'Z
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M?;0+PF6L8@>.1FLM:_[P+MD\^-ZXNW 7/$\?'/L>!DR83R+Z<&0EV$ M1JS
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M>L=J'Z%Z16J<!&ZVG=I[-]1"E5<&\-7._*C]B6VHV+_]-.N=[)Q.%E%#L9K
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MDC)1+#= DJ VVKT#OB,[.] D8':&@H/E-= DX4^^;,A2=J$\@G*[R4Z[+V9
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MCY ?R/P-#\W;AB]"73Y,;_TI[B.3HPU#"[SE4Z<CHYQZZKA)9M EF&7R4>X
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M**>)9V7AO+X(K&/(?WT/AI^7DL_< $AU\<I8(8_B4\V1'RV0;2[;8Q"O+-4
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MA=(L]JDO2EHJ.PJR5;Z-V_<&!Q$E3+W3KJ3:43$Q_RSQ9BYJN-,6PC6N[AM
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M5A=!6,<P3>KP18I['E5)/GS*CZ?ZA)POM\T7UZ2+\JJ4#:S5V/F%"FL&IM\
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M9*O<2:?-P7,K>3T=^6:)=[4&O7G&"/-<<1DU7:*5 R0W<.T6"N&LUW^!33>
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MD_F^B>1/7;;UH:8;=A>!.;'%#%KETHCN*F7GZ;]14FH[DYV]5DK]^''Z.:F
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M+H4:>[H>2]KYGMQ,K4H='[_K(5VX[R-EX5NB]JB4E7K*/':;1;VN[LYC;P#
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MM3<?.EK!!'B+6K?J_;RDX=PL[VY?5X:V!QL($ ,9E<A];3U$ALQDQ,7_V9=
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M41_&/"J TB#8IR;K^DC/W6JM/KE8[R$R\9)/?U05 E@'.^0JI><=\MOK)V\
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M'Z>.O^<GP>>^>?+W ]G XBM0YLK]1G$!<XI&CG?S3&WOSGV +BEYCP=76SC
M_SVY5NX?ZJJ9MLC(Y>_;:(T*9KF89[QTVVX(/5]8RF!FL6!.['&7"N#AV^5#
MV!M&Y257IANS)4OJEL?(,_U7F38__D=<MK$]_:YH<%<(SCJBLO&D][#']9P&
M2!6HMRT;RFHM#TZ*&TC,*<BKZMOD&^$T6 G@E4.W-_BG!Q2(TMA"@;Y'E1YK
MQUT6T/_#WGN'-?EUZ<*/%44$"T6Z4D2:2%=:5$":]"Y2I$H7(8 $"$5%J0("
M"M)[**%7(2+2I/<:(KUW0BA)GA.GG&_.=<TUWYPS,^_/F9?_X+ZR=W;NO=:]
MUUI[/_M!G?(2<,"[[:.&RWR@0XSF3W[NIH27>-=9^?AJY.E9"5635W/FM5KF
MT>NWB90PLK50J#!=EK\"0T(-X=<A'[B:63HW'$%@6W\&U:H>CVEOJ8)%\^LF
M;4AA&@0^0(VYY>MX$>C,>Q3S=_KT^PM>Y$9EO1RX&<Z-L%NQ6T[)R4=$_:[%
M/@KY1;:=LE^+K]UF#JP_',HK.W*=)7O1),OJXIUT0(-:6%/%5=,&RG*(?K:=
M";C&[9T3WJNM)3MG^6Z@;.TT7](*^ISI151<G(HWRRKK)W3TP%%RF3BEZ_Q&
M*WIJ&U:>*TDE^KY=RV+G:*CRAJFN4F5Z\Y2@L-:SF03.N\$\;2O+NK1WL%IW
MK)VAZY$#IC^/TL06=JZU@8"P6NTDH6709_AKS61R?FT04NRLJ=/,GA@^,R/<
M8*K5J4/5>K2P?=#:_$(HKZ%"<NH+EX]/#?/>V-3@Y*_6@\ 'JN;ZU@UBVX'P
M%F8VNXMJ;FD,C8ZZ5[^;N\^]?=8INMF9(D0JFBG)AJF,YAWO6)97[JR=K>VO
M^*RLPL+G''F(^%22;XFB !"(46^AFMOZN.KT?90QHKIV>%;=M4E6?2*9QU=M
MCZ^N?(0QBL*(.R,UOT/I#,>=F25:GN<S;\D5QQ27<GW7E7-M9S["D&[WB7!'
M.:(Y:R?RET?#U\=NH^&)^Y=C4H@6K *()M''Q?TVM]HM:A+LVS2B"GCTK!!J
M3RJRH@P^SS?1QC!?DE#]O962](?4)?_V0(KP5QDA;X\#P?!OYC(/=^,,/$P$
M[/6&+-TG)4O=K2BW ]ZF7W]/O:/59$S11E'2PL KY*?L=[ZR7*^RWR"JIW4K
MZI:RH)9"UKFE]VL6-8!R\"\&OV]WR':0LH]D D)H'LB'-/<UR(8W]VEK:&AJ
M/V(+OW:KUR+XUL"+7"8[1,H+X-28N7U2\K)IW?_-#U@6=:1A40Y',D=F9"%;
MAOO5Y8UEC4[JRHJ(*EK$TJ=]$%*B?M>1GY]IJ'3ZDL\1TNWM<E+V2GC8"AHY
M0) M+:KS&:KE8L6S/W=(K'S\O'C_YP/VUK(R'1RWJBICZR&;BL(U"4W=^Z?0
ML-0+_]G/NH_&-\Y44K+R^W5H$^;9[X4B&^>XI?JT#VQ+7*2NMLR^C](9OEJR
MK*!'5U-T_7<U^J97=WX-+LN=LG^Y/GL4YEQXB#%_9BNVWCG**'N5DHHQ+#7M
MM+RJDLK)#(T?E3<;7ID;OC=7PIDLN?Y!%O;? _#SQ>_7;2W,W3YUOKQ>WFVO
M<=VXNF*'*OG;E,<>I116FM/A0YT@(N">4ZY@@!+[P+V^'[X^B++Z^(:0^VOT
M;*_3:3A<LF2Z/E65AR_:QNA^$SWAQU9?O;21Z74AP_?NZNS*^NOE,/_^(VY[
MA%!$Q2'.OL_1R] .L<J)R%$V2!<5U>))*^N+^X! Q/8ASC@YS7UU=)64A%^]
MTL(J/)CJSQ_WV XA30U XAYNE!$D_R^M[X'-BUVX&CYPM'.X;F%(DK52C'=V
MT56]3/*"8]_Z5U?=&5%"G8J6G@+?V>=2$:G!QE#&RVM']KE\XT\?MS8R?(RY
M=Q#L-M##^7TI4E8@'7@DHY#YJ&FD5CC?W1>]LEX[ML\?75SQEB>!K+PB=K2Y
M*:AE)F?Q[2?;YTMF.F^3DCBGV.7(T_T G)*5[4AM5$=S1K26T@['EK3Q98L3
M.@"0 F@ 4D'**$>LT]^! /P?0(]-L80]XK#EQ9[)VH@DE>.:\>!$0HDT=JPV
MFB;"( ]W]@FYP?,;!3\'$[4'VU5EU<^(G)CE/GTYXTZ^2\[O5^Z=__M=M8Z!
M8^#O"5B,]<86'M1%++KG$$VK?*N[O/V(!VL#X2%E<]E!5_$T4=G[T=6YB'1U
MB:*LK3%'?:X^?=U0]V([:U:]IPJRII3Q>7/* SYU''7"Y[K[EX8U5:']RO-E
MW92Y*D?]($">"0+)SIMP$) L3B; ][AZVT&@R0,$KH% BA?'8.VA$;P9!+J'
M4760383IP1X(D(' 3BT]" R#@.__\>F] DS?.%&<Z%M'6 *!-UJD9I7[$!!(
M'.DFHH[VPDV)O*C]%L*IX7(G8BQF"[6#W=A0Q_/$$7U0#2" 7V^&8T$ 4_82
M!+:,0: 9LLA2E^>Q6P$"8:0Q(N%>\"D=U,X:D0H$%MR%00!))*3'D5+?#:(@
M"-S'KAFA,BOQSG@"[%_Y7;@U)A1>'[X5<4B&M$,3^%$S\(45S&3ROJX _@@>
M" ('Z% 06 $!U/,Y$)BN!8%0>(\T3&]CB90&,H( Q(2X"P+?<^$+XWA6$.A:
MM0$!4\*1@@ (T&#P%D3_E;%*N(KS/N;@$(?+)M*H@( ,YA<($#TL((<@L#%V
M#[Y?" (SK+M4)L><'G-ZS.DQI\><'G-ZS.DQI\><'G-ZS.DQI\><'G/Z/YO3
MW>*5ND[2[W\1723&YQ,]G$RQ=+BL.E.A#5</+&@6M7OVI.)$C)<@WF5#ITS&
ME2X5]4(@@R!=+N%@PNCIZ(I4ZL]32]1I>GY7/T+MH8>J?;[14LZ@*K3_:5]V
MV%UH";S(YN'M_[K-,E3MW)J!A%%E]B+"@=G9HW'PB&B2D#ZQFA<6!U5XGR?I
MQ>?_BNV![,VGFOESF?);=+4YLQ#[J<_:S85A*DCUIK1T71FW AD?49FZBU/]
M>M'9^A=UFFSG3*3MD_\U]JXM_HNY)CLVRF-'/^;TF--C3H\Y/>;TF--C3H\Y
M/>;TF--C3H\Y/>;TC^!TJ(?E&^'\GW!@Y!@X!HZ!8^ 8. :.@6/@&#@&CH%C
MX!@X!HZ!8^ 8^&.!Q6Q-/'I_./K@O?ZF^.41M\_)T9_J4PHWF/8:?VBV1SZU
M/OFV/H2ISS(O32\CM3#*.^RJ@@)?GM:F<FF^-7L>I@:G[/P1PU</\>9;IACV
M\HY9=3!]@NUB0(305C/\?/*EW-A7@<?P>?'=4./3HO?XZI]4#\:2*RL;9D>K
MW%$]MUJ_@J8U#0&!SI"IN'89='**%PBXN:NUKF/6?R3T7QRL.^B3K$P1I@]5
M%>35- W,0G\*U=]Z9WONZW3,;!0'VZ,'UVY+#]?0UYOAU_=;-O7MUJ2[MP5\
M!QV7DQHG/JRNEXV,:]M9P1C=G!PR,D4U'0GE_NFMUB^COD6Q=_7TB;S@Y8[I
M?W(69[+$N$5V$.W]^ !5!3MEOAN^A7;S21V,G,D3W]!P'S9T8OF(_K3,5V5:
MUB:#05^;,'GD8"4K]@;QEOZ&(<3ID8*5'HG'_:,_9U*/@;^%Y[!OA.\M1X2B
M95&UX[6X6"XSK,<3QXFW"^CQ9.&[;^_:+EZJ>!>-'=#5D?F4^ROLB>&\6S"G
M#90,#<LGT*$9R6:='V-M?*$FCTH%AA+;BRI05@Y\A;+T8K1>7QYMIP>C6*7*
M8KB9Y46B^M49KV7*1Y[O6[YVB63MA9-[1'<X( /9@UMB6:8G";DHG+Z*I\4Z
MHBMD_Z"NMOMRZ4*,I4?ZQ.<Z9&";>7',P)8\>[<ZIWY\HL[[2"9JEA6TP8:&
M!ZN^QX:!0]?B4L%.Y1%=GN2%4RK5[DZX<=V PN":X/PK)<VSO,VMLAR1K>_Y
MA'B;>#C>_21]>1[S*)X B77OF3C*NZP[AHY.'(71D9PV';V&D128Z3J<K',,
M_BDKHH.],[C187(RS_'=<YO/5[+2) ZXI\5O:B$,8$CH"P,*(A74;',\V6%N
MJS;0R8G/^*SSJ<3&H9;(C/STGW*E_;I: W+=U+L[WQ>W6D-U!P.YKY.\:VG\
M#WDKU-\GT.MSH#[,W#M>1U5?@YE9@.EXVZPYCKA70,@F18QN1Q39%8EHSA?W
MVUBE-EFR2'"7Z";X\F4R,Y54Q#]!O+-;;0:RT; "(^)%/.<RRI]U,]-JR:2P
M>T]L/TX8G[Q3%S>:F#W!^#,=[E2 J15WMM5JB9NH#>36S.Z.1#[AT7U&K2GW
MGMHN]T77),E\J3H):9*X@VTXMV\*>DMWKJ8EI89K+JX=-^8ZI"!VN_*E)H7)
M:(.ET+6EX29-3;^\)/)@^H]2NSO*\P+4ZEJ6.)-E??PMX3.:)37)OW =_-%,
M586_]C_C?_C>7JCH6FU^Q[T<3E7F2F;G)'5&5>[=]A<Q+Z9,#NB+%!EMI@<#
M3;,D%\ZI%7X>O@X";VYY%&(GBW7G7X  .21.7-U1+?V')2\[LF5Z!W(#1ZO
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MPP*ZR6A8Z8O5Q1*:<FQYUO; 0,>"3E1U>1L( '=9.LTP OP?%)BV$:%G],V
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MYDFW?DD$ 0Y""_$Y?.A>#9DKUU&<%0B(PA?V:\9*)SQZ6OZDV3\&_BEE@X/
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M ^6BN8K)MJI:TWJ9Z;D?[.[76#@YF^D9.NXX\6F=MC'C>1C\@><,_-.2=-.
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M)25J_5C/V.T: 02NB,.!')MFV]<_68/YWS\N9)(05'JXP*KT<?(5_-> Z&!
M0"Q\"FMX49OZE8AM9H"'Z4/!:HVO3W#782,T*W+]2">9QM$C==&*O;U?[2!
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MEM\5F?L6YH3SE[&G1.H&ZLRF0=PH%GZZ:<D?*KOF'88XJU.6YT4\K=DHETR
M6A2CHY/2Q_:=$"T6PJ*PM\_3;.T6C.O4->QXN--O&^HI5X4^KRFLN=@XME$"
MM#PY_67W4\9ZTMX$S$9T[!./[]>6U0X=;+G&VM,PN6A+ZXP?D3B*_!K9&-UH
M;?H;YIJA+I<SQ,O\P^MRONPZUFQX:;JSM']S9C@7G\34R:C$SP[YT"@M_%7T
MTG+)\F5UIF!&Q0' #)!9E)>H$EUD6^^:0#/JNZQ15J^,43@Z[4U2,15WQIQ5
MM$V)U7LK?HO^MJ7G/.=(C%Q85RR';4G!2Z\\T3L2M]%A$!N!E[LWA4M3QK5F
M;U7&4GI;V]M]Q3CJTCCILQ:*A;N%]7G9A RX\934&+PPS.>654/8:YH$J?U8
M0V]HCQ9CN?2R1C,Z-#1NJK]89Q[F+1!A4XRU>J/[X/JY.;]2'N6.[=/G_)G#
M'DYGY]%VDFD=]M>4:EN+S[>MG=LL.XI#;NE*OLT3J,RPY>99Y-;DC+6D<&"X
MF^4?Q&-L.LCD$ &GV6'V%(]<(GN["@*1QA%ONIP)_N]&RQBUF;4-6;B<+=.2
M4.Q/JJ9RAP2N\8HT'RH. ]:[<A<N*KB=8K;+6,AEGAN]MTR9.3(>#1E.<)):
M5Y?>^RQ=7K]YV>E<;D9X4L9GLV %"8JD.YKOA]A?AIY U9U(JE"36)DUQ7<E
MAX' OJ<&?'V<9J/]&W9^6L*MPQUGM>'4A&;DS<T8]71P;[6U%3I SXC$V_&8
M?_B^]>,R\T>^-J'K!I_NA&784@L)H#1.: \CE%*6C(:8,<;5[A%F ^NA<H).
MQ/P(+L)L\[.)KU#31O,<J)?]9\ V(R,G0M'CQ,<[$L8ZSY%&%WO$*V!Y-95=
M/,:-%>)TFO5RLX:V-7U9K@I1SV,U&7)$A>^S:MPH)_<CWV8VW6LJ\Q^$7NU%
M?QNTLG]159._+OAB]/-B[NQ/\RB$Q&# R_1V!E5&(47_C4S_.<<7%[^E+L]D
M.WNM^/RG[P:K"J.V8!T@,#9\ P2,DB<B;0E1\ S33<J4NA9":QS1#H+WW!U<
M4U#\=YR#]M>,:>JSHWG%0ZZ5G*^CIW"QNE+BDU$29'@&S:"KQD%5%IZD\HIS
M7S=B) ,$_-S:-.O='06MXEQ_8066#;8%U13$RM.MQ<F69=+'+_J0;T$)*2 0
MF&E;9JSTG1LBPHZ_[M8"<5@]=X&[.S\T?;<A O&)%?O9C!L$N&#/*NVA>'B1
M(.EOE:NQ2%,"9;+]=1"XH)^#6G*U5P4!VF7'ACCG[Q8O^I35#\<Z+%:>80^/
MLC>>1WQG1O7E@@"_A.MAZ0O4V+5^@I0?/* .2HQ:B(N7#D39Z$VQ/.9Z X4_
M;$#?_X=74Q7A-B;E-H.UB4/)<RN8JI-X?;'&U:AL_"DDW!OW8T_$Q\I$=S]L
MQ;5(\Y+14BX+KW]KW8BO?!-R V,HZ7TGN=./-$@3PJ!U,C,IOBL/2S@('$:%
MNM>I7UK%4PHO"T1VDC<040=2?N,[Q"+2G&"^VF=-,2#'!D& S.30N$)&N!4$
MEMC[08"%&:;@HN.;6W%3&JXDR&E90' Z=9X:!-04?S?+]9QTH<*E$WWKC ND
M"AG7-K\1=58P:&)/_*0Q"$1DXFDRQU^H8@]WV )=]@]AN'ZT^.$M5O-31)8Z
M;*W79H4U"*CR4FU",3C>5VT@<!(F>8O4;-N!3\2;%;D44PT"K"UU!.J6T,Z#
M6ZPD(NH*Z*;*U+L>.6^&UX# (V=(WHWZRD%MHI1AJEH::4 WPN_?!NK>'9KN
M-*/<[?8S/X) 1?:!!&YC,_E,7=6112ZAG/D\LTM/+:^+OF5JA[[3SQ_9F<&*
M_A,OOS^J++W0?.F#PJ^CFY..M(,ZN19:"B[(N(=)^A,8EU<T@]0\@2,UGLDR
MTO1H_P$CJGRK-O72+>V9^78%]8L.T;/+]EA^;G._\W-0(SKQZR<]JW_!**--
MWJ:<Z/F\8>S\;R?J"=LCH6IP>N,W73."H_DR:O%/I&*Y^.59'L6GT3<E<?_Z
M;,)M[M+(FZIUE_UW"8TW"QX7\0T5GC"Q9_K0^\Y^;;]QT-Z@CL:&;\EB07E)
M25'#TX:L@'@4:UA 5NSY=\8NC6SL9^[_?'B+907-(#U>)A8+ N.&=7'U>_7H
MR5K)ESVJP1,P=?<I[LJ;PC=4M/@Y11W/6&IK#6JW0G1>_FC%?/ A^3#9+EDC
M_#V<^JV;M_5^?Z_/Z:,OS1Z<"AI8)SKD//+28D],],RMI:S<<*%@70YW^6>Y
M.H(<I&:6_U(0GJ! X+L%?)YD&G>Z\287T2!0=>>(R1758@\"4I$@\*:&8GOX
M0L3!4C319^4YE9GOZ[\ZN_R3 +<WD^47R3;;KX@2YD!@EI6.E.VN]CL^',O=
M!@$!.<;9>I:().0!+H-KBXR834#A[4>3?Y]CEF/5\8$,'DG@_AG&?&4GIDC@
M!EG5L;Y==?@'($ 2)^=_J/6? X$<RCJL0C_!M!0)OP1?AH^#0'/=T>\S[4@?
MS5T0T%]=P?Q@/4PFQ>^_:_D1AWXKF./^_Y;]+\MSPLIUA:(<!B]%[*U"&M$F
M[!F$H%:H9Z'2L[V(34+BQ?I&8\I_QUKZ7P)PH?OQ=?7GO",FB]P5X'C1_4:T
MM/\9&C$19Y.>171EW7:$J@)[^T61P5$FJ+R\O(B6"B^'5NM6;I3*K6T9)'0]
MS.DJV>OQN][6D^.>WB:8;\^>YVY5>;-<9:6\&1Z5%/E07EU5]:0"Q:4??CQL
M; B_?[QO!;G^W^Z^%<34R$%7Q[),P]KC3"[EC0*T2HT'S:NL^&2Z#\W-[)F%
M^9&<X?+-NOEM0EWDD<_,SO%145XZ1[]4I,C%3,\?B#9:<7=2]A;[M;@V4U+\
M4DM_H+M*2,54D\DZ^&:D=O.^E]D&MT9PFK'\._)\AZQ,VX7!0/WV-%RM%ZY,
M$B=<5]EI+2!=:C:FHZ(P-$+1)>0@JJJMI;1 N.J)YHB_,_OS[DX;];.?#X>J
M;GBEGJEYM28]58WS:+9[+YXUUKU6T!_<Y=CA_D1JGC:=DB?^WMG@5JFM1\PV
MFJ]HX)VMUPQNA%9^U,#.BS*+68LO6*RO?QZOTU48-"KQGH<[.4I<$V?2:<YF
M%CW)*3* ?:^1-Z.?=&UF^STS[94NPP9C=AU@J,XI(U@[$VGCEK61L2*3ZIA[
M^E7!X( O3V[QQPJV5$28")8?X*3(XD'H\'R5>F>0,VPE<U'+:^O)B3Y8D0>=
MA7=0BYD$CF:P-L'FAS#U/>GN+Q,?H[3Z^WU*I"P?];4 EK)\!1F1(O$T6I*Q
ME6_HNI$,E7'J=>5O T)<9NZ,#V?RX"I-+3:I#;ZP;([LQM#0Y]3_O#MT=\&3
MZ\W#'^VWMI2RQ(8*PUYL)9_:6?GA73.W%6+EQ,>R/7EPR'=S><S8-C*->H3O
M[,97FI<#]-QH'@IYO>EK4:G>L<6&NJ=:-3^]ZO3:)G=K*K:OK%39"W+0U,7&
M;J)=G+\LMOZR=U^[H'HZ@"%X*85?H_V78D9X)<Z@S9/\4NLK]I8JRJ^22DN0
MX@H%,RV'C8\?JSM3J[A=C=[<@@3UW[R)@!8F\KSL%-_$"9K4W^GCIJ(M^MF*
M4: ;94LO )Y["?K8%J^\9&42/*+BEM>OW+YGG%NU)=QOF9.1&IOD4#;XQC*6
M3"=2\97>0_* ;R @N_YZ(<\_//CV5;NFTB+1! 57O,N$9&4QMSV"K=EZ.AN)
M:-%5D*H,5^+,C"0+%[E](OS7&X9)8:1JVP'VOHRQ@8"!F9'CJ@.EF'%M^!@4
MXLQI98UITE4Q.L-7WB>"9&@7;EUMU!A>L:+*X>8U-[J9G0VD+)[8Z$36;C%'
M#!-ZR\4(ULNJ>6J?ODXR,B!%%0+H[3@H(YN1-Q3""S,-!Z\]>DBG]?JHY(LV
MHJC3BZJRP-G,/<+6+7PM,%\\]H+=5*4UL];3\)N&-@_.*K^UJZGY$2QVQ*,1
M &%4?E@5;DA3%IAM[@=-U_+J'$]T&*%<*%A]O& \!Q,V6_>ZIE?+'!!N%QS,
M4Y7R]J(C$U^AT^99K8[B2-[;*3]3OV8SOWKKI8-]U)B)5AH1:NK?Q)J0B5>4
MPO3/Q!1Z+9:XRB:'?I]7MOL<+WWAVE#7Y4=I(8QW*2?QZB:G,O0:)WUR^\9E
M!8>N0F66.YQ(*7">8^@\6X!#S 4QY3E.O@\2G=2N)@]2Z\P6(\W-6C#O+B9]
M/?_4;0G#"*_P<'[L(%@EAK5V]JI?\ XWI2N_$ZW/8&"9A3"(-5BJG^X([GW/
M<"@7EG+53/VCG]?.2065I(-Q6(C@N,^IJ!]FPH:/W1FAFCK6O%LCU2LI&6%"
MGJ,4,4)-C HGS\VX\ZVF*Q?7^>,R[TH[OE6X/P\O6)+8*1.O5X%!Q6"E%;XK
MR+SVM8ZWZ("T@ES.@B3EMP'R;_I53O"ROV*ZPJY__UM%@EXZ&:(OB#T5DR&V
M9\-<+O[6-S!WT]@COEWNV;=G]CQY@4.<#,J;H:^A6I+]S2;W_=X\DJD4?-/K
M58S4TU0+WEL<]PQ=)T6[D?L;*+%N.ZGR%YKU+4TZA32)Z%"AC[8V[Q[EFA&O
M?>8HE6CU\XLE6QA4/'#S]8)=J-[;>.+()+:5$Y7MTC.3\3A0!8*6.&\3JWC]
MU6W9<E'AQLLWWM4P"E.J.-AYN<B3/=2O@];_IR]V-R7?*DYWS)OH*_98O:1[
M=>WZO T^2;IU+^M#)MP?_DTB4*#!_CTIH_/]G>&&(= ))F^GD2[/KC\C!+4U
MYA&5AG,("C.3D^NW]FLB]AJ1"A43*IM--XXNYQ(IHTOW"K]EF2.KGKDOX)MH
M5!5G"(B[AO!)GVS'(33\&MX?\HOYMMK3NF@V]H,2JLVB)12!?VT4-3T:-C&*
MQ'+1O[%]< @"><]!(!4/<\:5V4Q18I9T0" V49KP)!%2YID. NK767^1%9+6
MN*.W+EZW*]!7*!6/UNY.0I@D1,-(J5=_,NSP@/&UP$$/=&.BB*L%2HI.5/1!
MX 0S% \KL[^7.;*?;Y[<=_!T61<$3!'?>U$S!$4<,J?&]S(/"&2]@#<,UT<X
MA4Q7>8" $KWI/E;!F(!ZH8-I^S!Z[=<P9+9'5T>"R&][F92EF0Z\*CHTQ91-
MBE^]='2*=1.[!GOJ33M5W^<'9Z,R(:ZZJRIDY17/^#/,Q88X:D_  \IG[(VV
MU8].;6!47DY89X\$DF*M(O6W \F[?:A](0G<X=W"W.J?[F>QN:CE)U+O6C@W
MX+VV.JY$%L)1=<)TK.P> SP9Z4N0(W:-G2!^%F4=UQR&+T;8=X( '4-!0YS%
M80+GYR@M^' /.WZ'B$+Y+K[#RX^O61"5H1LKHM]!P)I=?3?2G\B E4A [-'<
M,F;TI3> VV4ATK)PM+-2^:@-6M1UT_&0<J/L7ZR?N?!<69;SDJ-W?RJ,4,/]
M*).6]O1Z,BN#',P^(I<\FAJ%*?D/$^GKDV?6YDK>W&4#@:_A43)K4"YZ2Q"
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M"$"3<PX-DGU;NI$V2.:0;2[>9O6:3<]SX]C&BCU1:8\C6QYOH8B4P[N'"1.
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M4BCQ-#QH@?+HKDX@2W98B F.T6A&K9(A:\^O2O27XW,/K_/H/A?EYK"I*+N
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M_V&:[L?>MHN;\%O4]^.4)I?6YPY5I_CP<Q!R36),]GBE4&@TQIB#>:TII"1
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M\$E@"4JV DA(.W9KO<1/C -.#&:1U+[_+?FMY&1"F>D=,8.43\!A=S" 5QA
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M;AJ5YOG#\'3+VA5*KP8*ZG+S+!EP)'<+CXS2/0D\S33<B#&:N%O8>8.%2LX
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MK7 488T!3%8@O=S<VGHRE%%_M[]&8M3%LAGBX$YK<\A^5+3(F\$1"(L\2CN
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MJ!_@R)\8<#P5M;<O;\(;:/?X".MSLZU/D<( -BA S4FORKYBY;@!LID# 0#
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M948M%2[9_!HL-WG1&&7%@NY904G.@H7>S_A%["D0OQR&G#B:/76J*2CIP\(
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M^&F=-T_J.$U<ZT@F)J>EU>Z+TY]/$\F<U["&DVN'O56@=3^L12^+CZY>UV,
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M4 \T,>]+11X<'1:H!#[IJGRJ'Z/@.+@?W?/]HAWHYFX)I&KB@#B/FS4R+U9
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M:_-^;C@DS3+ZD9&"5_ML2Q7-WVRXC*L=JP31/$*I.(I:_D90G+!LQ/@X#@D
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M,1HFE!I2\A OY"H=3L =X=\\5[5>->[Y=F)F%!3=4_!6*;$0.AR=3+Y WE;
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M@F52<.3KJ& JG"0\LYLK^&UJ*V^3L&W=:4''6AJ13G<0OE2%_VS+7 3B/AK
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M9@)9N!,,8RI.Q\##>11%</)W=(5V39*AKD'=96\,?HBJA0N?6 _V7I=>@50
M;:2Q&/(#XX?J RD>?(98B5^9PF4%M'Y1<E2D>=?B,6Y^?%2;T8HLK$W/0Z@C
M$V%*Y2>AY0%T?E$($KR^%=[SS-%#P_YYM2G%26_K6GTGLO1!Q\@C9]9]#NP3
M4AS^Z<+DJ'UBFWP;O_&?CQ.R1*DN5K854U_\:GP1)!/^JM5"/7H@#C*3]("
M?<$F4/GSHP%Z0XB=UYJBC>7C'F*9A!9!G,#401_5R?OYX6?D;FA 7]8.1>9>
M5@0-5H<HDFF5AO 2#9 U%1XM:S7;''5Q:'+1EWE'HJ/:$TY@%F+\'"G8SIM8
M%Z=B<'7= LN^_@6=+XJ&"+1&3P^>+"T=>7J&N5)NZ](U?$I*-RC3;PDIS:\G
M406<.&(JZ%/<+J\%]3ZQ#%Q_EE\[@"&= Z#J4"K&V6.,!DR%8'B>_H15)HA$
M^("Y,A#5POKU 4KG5M".+;&(5=(7WQ: *YPK;XLPXQ8()GG7=NDS*XC[5,=W
M)DB"2/(#MYTUS=24=5H7]0=9<Y?HTJS+MYH^]F"\ZU'%TK73>O6#[?]@[RW#
MXF[>--%. A$"(2% <()[<)<.P;5QE^#N%K23$-P;A^#2T%APAR0$&B>X-.Y.
M:+2A:9;W/7N=:V;/SIR9/6=F_WOM?JT/OWZJ^I'[KGKJ+H/U\8;F'1M1Q(+H
M[ "ANPH%[Q-&O0E>2 4E<P%C@2DNSF;:-C_&"?A8%+A^X8#F0JWA_\HZ0+ZR
M6!$I>%"'44 +B<X%9K:45*<_K!@:EU*=\>LW:':_[&_#O,/IANOT,2VJCT(C
M\R-@EC&F-"=BHI3MF[-G"LX'-/[^G?A&,MW/IS6RIQ[C[!H ]%9*<((<9RP7
MK!O:_Y!9:8V+=T;D_8S7TU2Z5ZI$MN,87\"F01IT'_UB!].%TJVY!MN!F3E^
M_+D%%%Y!'%4O$8%12(?&5BJ\0T2MPV2]K(BRR7"?<T3)(@D;37$"52?%Z7&Y
M;*E-BMSG5,37R2%![RF0$^-NH\: UH>#_(]=*UQ#5GH3$Y\E<1S6[1(GA<&I
M!\7-^N,N#A_&HJO$()<=KQF3HEMQ<+2(42_&I% ?1M%(C([O4:(I_K;$/1]0
M;]WB0FF3X(6LSYN%7@US[P[)&%;S[:WYS.R"FZXUYC([9K=ZU2J=Y-/#,V[Q
M5_$E<LT-*K59*0A7P6^(I C:;&(='HXG%BNYA_;$[X'/'OEH;<P<-1M#:Z_T
MK?'9% CS4J7NWX]QM'WUD2G*<E1%A#^G]]6::>!9)?XF9V].XHU#ZQ6B":-\
M847LWA <X+3;7J2K+2=%Z>QL<.GFM4,42"1NHNMI25A^3%^4>]R;MTPWR]EB
M.%2Q-Z<_*U\CY?3PHU;H/1A!2"KNNU_-1*0EPMOP^/.^ YW5S1T<);&Y(4DB
M V(LEOX+T?>C;>%PPV?^D7[4_W(CJ[)_II/3S4XC[S70>Z6Z-<[!N5P Y'RH
MTIE6J'BEN(L[P:FBJZ"-]:D@(SO_"7VL]'LIMN<R<7?%/2+G._7&WN_. 4-H
M+>63XRJ:V;U)??&=Q*4D<L/JBW4$BEM[MO=]9#TWP<3/Q-^CVAFVQ9!T2ZZ;
MOHPB=9O24HB+UV&<W+^/L?Q/N8J1[SO?R<8B\' 9-F<(PE-JXKGL>6'-0XH3
M%IF2;68^L9WP\:3WXU5O,A'Y^-[['\ZE)B4CJA 2SJ2;P)D/N%/3ARK-5#P0
M6.P%'*Z>5%S&W"]MFU **RK5'3N6:%#3JDX1P"&W8NFJ>%1%]0D-AN^'7@_4
MNQCN#PV$SIEXV_+<E";'41/"EL)W6%@@]6L/KRBMDLCOT2TN([2%SHSY5T:K
MNP,<@AE DM0V+C%=[7;;=)]%C*OB4J^KOGQB^?Z$0DNKR+/\O1T>N93;F7IW
M:=EXV?;9=B"B5=3>B<RJ$"'J@Q_\28V&9.[Q3OJ!LV6";A\;^=/:6FYTXF'A
M=-D]U:3LLZFK_\?2,(/YF/JZ)R]+2@;W)#5;JX^MT()C%HI^T BKQNNJX?"?
M: <M]$[[>)Q6$*7V4J.?0YGM9:)Z<DZQFP6]E>WK0>N=/T.<@H4*DJ>9$'5[
M@SRYT_HP@+_=Y>FNZ_:@/U3W'XHB_R\^4/\;98A.:[4"9DS#XS:AZ+;&+0U/
MT_<6>[NV&$NOQ9,<M@8WXY H6$E1;'.!$3$=8TS*/$F$^W-+1E@8_**NJ1Q&
MGSP*8KO+&-7@?Y\%VL"MVEN BP)&TO2R(0UX<YFE?RB]?H1B.@2>2&&JAWZ+
MI@/G6SE19;< 8/?49/9:Q[_WLJKGUX7,1I?]:$KKU?E9$K<T&$-;HJ+S\/ZS
M\'Q)GQ2[QS3JDA:8;_2..&?Y=J..<*>%)21M98[K46]9 U2]2TS;W\,,3J<Q
MN9$BRN?E*TSX^1L0FPBT<PO@AT9&5!@#7;2+JVJ+P8E9+Q(7TBJ:,_?01@1:
M3F*.:78"D_<Y!%J>+\IW#',7BWL>6K69#]$VYN]_,NR?V%.MWTYQD@@_$$>D
MA;U\.#1B_GRX>FK]XB%K #^_R+R#'54>W42O\'&N'?YOEO.5]R+%$+\FX]I/
M17,(#^R&$OWUPN^KW#.1OI8 WDH1^G!11(P+5-,0"6IXYO?! CH2M/<O=T7^
M+SCP*B?I1GPFZV1,M+'LJJK]PJ6G_:")_N=0^"%>7*RP<@KWM\EO.CNA1)4]
MM5TZ=E,X208ST75C*L_JD?8/,SG0AD[]*F)LKE'&ZL+YWU['OB9[81 L]>Y>
MWLH89?^44J^!4*&MT1B$&:L4B^I1.%\>E7E^09Q,%<H3_(:J'6-B*%I3?<EQ
MW2H:7-.:Z:-Y]&;\H/U$!4] B45=DJ),Y6':HF\(W\O)=7MP/YL]U"]CKM3$
M^QDL3 PQ=.)AF9 J'2FD*:TN9_R8+5NH%( +8(:QQ$8)^Z>:;ZR[1H^)Q50J
M4(7,C$\\(Z)?3]1A;-[M:?_2\OS_RY42R<JKPZ#LW5T8#M7@05#]7LM\A5C]
MAQ;QLXYJ?UF#M-SW<>POUEE+%VU'>W4LL1[\$/R+M+^\R8R+!%XDYE!UGGHZ
M=6*:[V)S!_X"&;8FL3Q@_D>(.D'\5>:P-9)/+_K-JQ>(#[C)QL8FBC*A&2DI
M&13!0^KJZKR%;G RWM8:6*GY7T\#AH'^494OQHDWYM.<\C[W.:O\,$@BB581
M+BDO=37X'@^#Y>\CY?=+(N^Q#Q(^S0E:FV[R*L1',UM@").7.DE\0E_=<43;
MU=W8[EZGK[*7^[$7PRO'K;5,L7E#(*[<KO?'S3A^^]H<7D:$51Q.VC(<^I$9
M^=CYW-JOLG,L-6&E508_ PS_>MXWX&BW8PU^6!7?GIF*HIM$W71QV%@>&(^'
M=TLEV7H0$:@8&G[I'=?X/0!*B(#ZTH3:942JL*F._@RQ"OVQ,Q6I6U50U>WW
MI)7Z6\N>^X'2NO?5':E?PDN-4?ABL<@'^ZSC I\ODTZ(*[6A_OA+J">X>$+K
MS%-B9@?SKV=EJWE#GZ>M7,UX[4UN?RR/285PB9(\@JU?8>OK/>^CY=*1T\&-
M?L"">^_BD-(_3L::.F3!ADI/1R%](7$-*U\]S*_?$^LA?<]X$4^_.6W7YQH]
M\-<)9\[R,Y4'!681O]9<]?HI!*@B<8,XR56(&/"(>&SEU[[H:^&7W@((%.CG
M(0I,"T)G091"_P"U\)]O?;=6^1V:U.]4(O:=4JN165EMWH_T71;VZJZF'R83
M3!U29$]V:T^KO=^>@F0TE,)J)M5DE)Z'QOHJ0TIB24UZ![P1ENU-D:04LA#Y
M\#%^OI[R'TIDR81J]O9OX2_&#&?GID@99-[TQO9_KG>'R:N_55$@)'P4]V"J
M#?CG##Q8A3GU18;=Q4#F]2V@OJK9X<:I 7PE;H"9 1Y 2TZNCIK!HY5K&-@M
M8"JV_1: KXONOP4<R>4P@T_Z.CNO#:XOKA".MX!3O_J;;W_I_F!:#TU/'9IN
M ;#.LX(J<-?D+8"G\WITJY\:C70YPDQUW& :$, ;J@JPX]^Z0I77J3=DA\#=
MJAO;O:7_CD&=X(J&D3OV7&:*>/27:M%>Q\8M0+8U[NJN6!N(7*#%34_8;@'M
M5 %YMX 11LPMX,#A:&G/Z:[>C^Y.G__X6Q?I_TSB_TSB?Y])B%,/G*!"T*TH
MF_G6S$K_"Y3[!><OCJR0/?;ALYYS7;.U1G$&(F\09?+/WUW!$;6&<O<4[6%V
M[MK)B@35&\=W!9OX[1&)109*L<NL4;_"Y['S?.]S.&F<1JFNDW&BO"W.IY]9
M71+0MLY!'_^V(<)S=T3)NQ]+QD]P"T">\JQ2+^$#8;J/#H';9O^S =U__MF;
MU#F^V4%E'>+DD')(Q^R3X0\9&0"!EO;P]^3/V3RRC0Y&D'?Y"UG)DA+GV'ZC
M?-N$LS<^3==2@G*S"T.@->BGCBV+LZ\?,QP]5:7DQ-V?=_@UWM-/D>X<[P<\
MQ1)@3*/42>[;'OT( #R]]_U!'+3%*^A_H/#44:&2(RYWVCK>!0P%K6)\;@&#
M:QO4_;BJX&\\"W:CU/U+MLZ>"''_F/Q$.BI.!V?EH,7NPZPZQA_K=AL%92\.
MOQJ;Q69M]'[8+;8/O3#9WKH%O+GY<2+XMX2XM<^F.$;F0C&@;6X$(:3Z]8BC
M?58?#]JZ5T-)#@GC;N2>Q8._TV32<I\XCF9PDCY1TM16$NU35SO#M:':6R!Z
MMHCQS&I?HOZ331UJ*)77*NC9A?XIH7]^"S %<S+-&YKZP"5;WL\'>NC'Q EF
M.H:(%3?$T31S(9U<.-X]AJT$CN,I<Y!_^%LKE@6YME[I0(>&-]@@(U%$)]"M
M:3FTR"7V<7#%MK]4+88E:[:SE;/6GZS1R6DP*P@LGO)]15#"X\"!31#$H[MF
M?_Q'G/Q++.O7$+X$_RHOFYS>5W<!YBIY$K;1^)WA #\5R-Q!<% 1)C.?\ZQ#
M"=VZMS#4>"%M)^U]*GQ3D=1W:"1!3J=A43XRG)0P((/[UIP56A#):E"2;^IU
M6):*<@YP0$6A%X-D[]Q,-?\ M"EZ$E<H(8K6115TL%UAGI7L1\>(6WE[!-GX
M6/-0&.GO1R=S$#^R6SZ??R?&P!<!4D5]@!$+*>?V';:/]F&L9O!C_,/N_@?K
MNXR39#I<NS5QEN1OXV+A1XT*N@6P*S-NY/@XAA^3S/LLP5NIG<T;%P04:VEK
MU:<BH]LE>!G4)D.2YR#,8YQ>AU% Y S&,8>I0PC,4+7U!.&?4RN:VM+XZ,?P
M4519!]<A/L3SZ.LBB>>A6 /0WNG21XQ4H>-LZ5YZW[BNML7NG@U?2@G\>Z<+
M+E_7@C\T*_,/]<;F/$;1\!I5^_L6( #,X4%W[(-#Q7.00.]E]ZQ>'WS3H<;6
M!WB&R94_Q]\7AR#3!M&&?@YJ&]L76/@1@_3\GEJN'")OQ:=;S ;!_$?)U"\Z
M5YB6\$27[,\;;@'S2RP8Q?,CMU,._$"7K '-3I^'K$]$7]:SV==L,61 6HJ+
M.U(?-&B^>HOL/9)E_*R'<_/5_NY3K*A; &2R<V"X=17>!]PX.RE M:.7#F%O
M>F8O7=)-J234S^2L+<^]U^>:Q0)5=#8JNC0.C3,C"N 3W0G%BO8T J8,\9_V
M\DM#RV3$-57NDLLH,K0&-X:(ZEU2JZ:NQOB49FV/N7DR,^43G7M)R6:N;^FV
M?>\\\F\5V?_0+#?AU]^O',B@'1BHS8^'C<=WEEQ?GUC!Q]6E7+2>HD\!DZ.P
M+1\<_*$M2?]1?/]^3S#]'TK;#,NSJL2[OV8DU?1-*],W 5UDR65$0VM990N"
MY<W\<$#2X<T0X\3<&>D]BM@RF7=L7(D@56VZ#Z,\58;TFC+L$YYN8NX*++<
M=4?OQQ:I 2VVEO'VAK::1G.L#T&NFO#(<:S[\J_O 2MT#=NJJ";O]X=[9D90
M*QMLJP+RS+H^5<J\Q2(019-@[,0C%JCI&Z$_@>G4E!N7C<A&QQ5J+Z>;5H6F
M5^[FO!.$=3N:FN?\-$71(T2B_,HJ(&-C%6WEQ!;5..7M[J\#?>I.#7;-3A?W
M=R<SI00@<>03O[F$1W!#7H\3OCYMM=RTXW2FZC]\Z2)2^:TEN Q:8A8=$$'A
MH?;V<9 [F ?TU9 .%;8/_-B)+5*P=F'EO- ]08BX$-:<U_(M'>('1PDFED8:
MS#MO_!BUL,WOLBC)PE-V1DY,RI$U\?PLMQ@0*V@P.B!P;BVL[2D3#,U_24+O
MC?M(CMT>'L),F$,W1GF2YK(RK^GR+9;1.NJ7!;/[(_BO,@YL0LNIHH_PMT=6
M8+Y;P&;('UWWLR P*B9 Y7(K>MMD8(DD)G;AT^_6A@:<:*-)6CL',EM8(^.F
M??IR7J1BTXJ]HMZF/$,,:]N7RU0#=YV!H2>T^Q>"5&+J==E$/UFFL %Y6M&X
M&6Z,A>99#$V;3B-FM@B/4'P<.:UC&FNR)Z6]UN:N;.O,SQQ&>S%WI6X0U-S!
MB Z_9#H>R//.T7>.F40VUMP"6EH;RJI=44;'/19E'H;^3V4$)#*)TKNHQ:6;
MC8+K$H?H;5D Q_'[O9)]\U"7CCE3X_FVR(9JA[<ANIK;"25*;!;?<.YIEH6?
M"&ZJOL^T:ZYK_*0>\RM#[YM%D13M,HO11:*&+4O7*/!D!%7IG%UY:%S_IVL9
M9/B^0PT]-4]JNS)/;M(B KMIK=LQD\G0S,Z.;"6%U?7LCLF@=3+('GN!3-6?
M?K#;I=B(E8\]7VCD&)-RLBZH#Q%3R QY_GP&3LD(Q<%W,W#Y^OM\G"/Y\Y-#
M0P853^FZ"J//0"M9'GE8:'UVNO,VW,OZ?M5Z@P.,M56?^\32IUU7_;V[/\A)
MO?8!#;30:-."UYA/2WV!OBP#1B.LR5Q<K+FF)KMR>L0;2-M+6_%<L1])G<X<
MSMOST2($1!5"_-DJ.E#RW2T@O*>\%/706NB,2<Q6R*L2K@>64)TYI-[DG::D
MJ;W:*K.3(/!N#'!^$[VWB!A<]C"%GWB)VD=F9^T>HZ1'WA!&#@Y+O6#GIB 7
M49L>ZV(Q".,IK_4_2"(/&F&8@,B[F(<P0HC8\OD3OI$J^\&(#-J7"')HTJZF
MLQG;YL>PI(EKY(_I"P6@MM,,\H%\[#I94"S?/W,OY[DG4D<=4%[(G'(,20!X
M:8FFU=RO\["C-S=\W.PX@ZR5(Z%/*)@R(E>?] 5L#Y;U0HE+/M$(6=/]\IO@
M3(-^<^BNJ)(K?Z^=YA]8= I?):#O!$FZW>DUOSI[L+CI$H)M*Y3X_9XICZM(
M09O<221J:%(?%$LY><*YLF3H>?'S%I LVO6@7D!B$W'=GU_EY;1](:VB+@49
M+M+VEU%7$7]QO1&]?#Q&)L3D7][#;"*7&.\]L-'4B*A<SSB<)%TPX*)-HKGW
M68W@L7C]Q/=JPF[0V^Y-Q)[.9P>$9>3BRB1A6'E"2BGVC]P\TJ)[:G@>DJ-_
M4#?H7A]3N.KT+C "^,H/$K8.',P^BD#Z.[Q?]Y![$?G3/''$L<'/=I$%2P-'
M$:[7L9G&(2YVQJLE'44P3+H1JZ$R]\3EB$'@/'ZE\&EIUI#H<]^OT9O))*=B
M2\*?&E 6=0UQ/4VIK!EUL!*T<D H/D)J'!^)PI@OP!?!KUNG5S@'38IGC?F1
M:WG?] )7DN!>/>8!E8]XP_KA,<F[)3K%970,O#^(;?"XI))*3R3U8EMP>5G;
MAXR*'L[:/=PPHQNP$^4I37C7&UL40I;TL(7\-6XI2KLB+,VJHRFEYX!8-/Q=
M+19]01DVO\&ZIMJ/JA?9XH"EP4S414# 94+4/*7'\31;'>8=.AX*,7(?5=-2
MR)P3]<O/<"&\!2SBIDC ,H_L<UEX*+RP?>;981J5?F_XR9 N]=-??P[P_[;E
MB/5Z4:Q_CXB,Z-./DH)OX\HQ1B)O-IT#&F:U"SZ6U_[!X0FWE_-]U!\*>P9;
MWJGP:Z?J+%_0IPRK<2??Q35^<U$Y)^I<^V%LA<4Z+S^.35ONZ3I=06B^7^E*
MD6)#FC1$:XA6ELA$G^05=_)WF80O7N.E=5-?=DJ+; $50LN!6<_RV;7LBV$X
MXR%V.;P8JN3%V=V;_V[-T\I"SP(3?'IR-N]RE8BIE\^1O4^.L8YGT -?IYMZ
MT 0I^T,)UI+&>AEL%<UI,-GW3?WUF.K?X6TJS^_EZ+EK5=U]82?A%O#%%,P>
M+4M<X&[581CPO?M@3I$& ANQ]&DT'5674=7BRE8L]5;\'K_S>H\'N_KA^5_@
M,N+/$8:@"OW-;ZG]2G/]%O .W8]ZBFA>BJ6<GFR'AQ3V>)N:'+&+-3M7#:G;
M')\*ZW0Y::?;V<.X>Q/IO5R5?Z<>]\;8W$'!ALO_=D[2([4=06B]76 J)?8?
M4U]O:?6 '!13Z/QU7/G5R,O(TB$M\+.YI.3)FNF-8FC,<I>&=E=4?R0+ZWJX
MCH*,-J5$8\CW.TPNB5)!#JQ=_!S.'?*!]IGT=)]5&:W 2JH=$LJ+2@>TI]?=
MBU*B7H9W_Y;2A QLE&7IOR\L+,KPY:O%^AT[<(<IK2X[T3,=I &U![-7CZHN
MY"SW8P\P^PKM7 N&2UETK7X/N--^C1/4$UV*.,V&=X-)0N.CAEE,%&C?T5N^
M^+RVX%_&\,](UU]2T4]B;@'I/N@NX/$'01_,<M>^V_ M@+(*C93#$&_S#AB]
M 6X5@U 7%;GBGZY>_AN!#XT@W-HQJ*GP<]4'FQTWH*=\0=$H@Y7T7%"QR <"
MA73"&=[MWX4QRF_$]W'.\M_NU)I?4!N=BTN?&BJY2QHG0&.*4TDU500$"MYE
MDA*PAJ_:J3OS\_E]GK>OIEL*IZMZ^"B/UB^<Q0R2#_M@5[IJ[#XB%H7#C"D?
M?%=R"S"ZGC;<FS@C/',MDF'_,_'C]23%*;*\]SM&.RF9[L;B+TTYS8"+X?&Y
M^BVG]WEE2_Z[^BK\C&,(' =Z@KC]B>'(X_$0S$QM;T$BY2?:'PZ32IKY\*6F
M-ZCY++!VJT_;3/D;?'+CN*]GY_/3>F:13O+V>[M$65:01[:?[BO0W<MX2SLF
MV1+_3*3@P=;T"!1#"$*W7E_X^H32;3*I.08.S%Z3\WYK.!S9=S09[AIJXA$2
M.2BE_ST^-2"CS !+?64HQR^27O I)=O6BA^;0"]MI]MOCE^D8.2.X: K@\QN
M =S#.W/&ZK\7%-JI7:P$Z4FR+N;3G2KT5>J]B_#XE5W7D<+1=1%X)(F4+ULC
ML4KY)S68H<4A&^\?! I/S_F47$%M/*'&CHNU,S,M1LX/K X"6^MM,\CT=C9*
MHIQ&NV1PSU3(JC+R5C\IM1HE!@5>U>]-0-^!_D%V8O_W&PA>G.]R/H!/4F8U
M-CQ4_Y9Y)#[=.HY7XZ$0GT@PX1M0+%",ZZ0&^\)7UY-=O1*O&&DB+C)!_.!O
MX;9;0)?T'>MOZCRR%L:_X;C9N05,<?X5J1@R)@Q1]RW G[L7O.-R!,)4__6+
MMG'KF<<CJ$BTQ65%Y_FK$_XCX8ZW/CVFZ\2["]=*OJ"Y=(D%/H1LI[.3(BNN
MS3%[/0.E]'V*82 0B&"7Y;N.8S8?%[K+FI4O_^FQ*Q8Z'<4VMH3?PED=)(<.
M6;P\;-]]4_'CZ^'^?#.V;R_! "4_ R6#F"2THL_2P1I:E%\80F4/*\W_3&^3
M\%?+1\Z58(OWH][*U-W#6\#N?+*);GEKW/N#V,&9]( 4 4?Z29+ %3FB0&SI
MB60V2AFV 24^Y]'^*'J?L=WRQU1["]KG^YB@G %16^? R7#8@7/?\'Y[5#MX
M]/#\*"OU>"O0Q:2AVXHF@]4OS?YBD_.>=L,O/M[!"$UURH"D8_)$%FWV.T;:
MQ/X0_*CEVP>GD0;WRX4?C8+$;X(%/PVO[%GTCNFH;]#J[\!*[6EM(OU\5SP_
MK,NR[OY(B@^\F_K!?_SIMKSSSWV.UJE6[\"N)IOW>1U+E+'0V@D=+2$)$;\/
M1][>0,TK=>?!=W'^]]MM,SP)O(Y,#CF6FG(/%A<^R7J^:4^L,3D"!4/=22E'
M0S)?=RD1#)22#7Z7?_%ZEN_[;JXN4P'+8;OI_X #5[[Y+/UAYINNCBSSP4O]
MD)AT>2O@[\^/KX+!=W;;G?VI17'= H3 =PE- >FP,M+3F6B*<PQ^C%$Z5SU=
M2,^!!(;5^9B@#MOXGQW_E SQBS9A_&HN4(Z(956T]WS8T@+[9!_03/*3U.#C
MW5(XY/1JHOP#(C%Z.=CKEV5()<&QUAPOL^NHH".GUJ86H+>-CXX$E*AM%:Y<
M9N"!<'"<&%M_71E9C^NF.?+T[>MX97H[.I#789G-6@Z:Z:6/)_RD8R$'Z.Y_
M7<DJ0>14.71@FB!^;W2F8B&KUZ;Z^J*QVO/Y] #DI\[!^O??:\Q(R#K,;C-O
M7D/[6_?!:;*RNA*6Q-X":=776T!_V*8J$RIB[*^=E0U-1-:+;T&@P\H:Z [F
M9M<T48CUJCVOS<WS=$+HRF^JZN>8EI4=F]WVL1Z0WF[%SO"5;)\^#DZ&P8C7
M82PG<N@2@1YJ&7&[L/&X!? <I;:"FGVFG2S- U./CPJV=]_O583))Z;3D_A%
M5XJ$\6IKBJF/29?27NZHVSRTWX%1_=4<+1F&=,88&.^AVR[ )R_G*<=;15(]
M1M%-*/^6Z^N*U5WTH04_!S&YL'92-IGCZL8W(>GB/IBN-)6(;OG'YU?V) ##
M!?_\5W7@I%O B>TE" T/<D&G84R,X7_"@.-+@^35+->/:CR 7&ZB Q[.65F,
M(/Z,P:GQY>-K-^;2&H6(''$3[C[U##W[9456@^T\>Y=VL-=A(O!59Y+)&L9T
MZ<DM(,ND"V.]<#1MN+6:VM]2<8P0[HR_T>!%M>_(17#;/%/R/,2#>7_(@V]M
MCQGI6+,:J<BZ$U899'@IAM.$[-Y%*33";VGC&36*+0 R5P<<H5X=<;@%L,4V
M[#AAVI]&[@U%"P"M7/3=9F#5X;OH XG#[C6>:UYRS5;Z'IJ>"A,;3D,0G06!
M'ZO"6B30Z[#"87D:F?8+S)USJ535!0YKKT[/+/<ITGYS@WHPWHKB=LC$/$F9
M1UP'VGA/J=H+BW%H2T$0ANG+L$CA_(12A\(_@Y4O;NY2@+5(V<H6FGGKV\4M
M !X3ATS<BNL.^GJY]SM=67^Q%;'ZAHW_!K,/H^RHFXA2R@H6_%C\7;U#(S;;
M)L//=H>V,#NO*(Y:;>\Y]"Z^;/#_4[;A]6\!PZ(?7"ACT#429C;>'!S&)GY!
MW\(<59-X,WSINH^^-@@^R2I]EAM?ER86*NM37YGPK65QV>+@IDW7<"A?\:TI
MH8",I"7V!+C!ZBGJE&)SI[ 1\8:,2^F#Y?O?'R=T^#&1D*54=6"B[-#>33*Z
MMH-!XVSZSXX;"E-7O&B8TDC].@LZ3UZ9[S=X,3]0.KMKYP[1&N.R;F-13=HE
M$(+P+S4)\LP?"5K;3RCVUG?3J4Y !^0?;1FL9YQ5@CX+"0RX43\@J#XY#+KC
M'#$OSUV762:-IJR.33EN 2L*AD_=SF3DCL5+_V3F\EP;UOOH4+WDIUO?+A74
MYJL#>Z>&#Q%K^H_]EB=9B,$SDG_\I8FLQ"DJ,5NXF^Q\F4]1U5.'#O;53O[.
M51VA([E=]UI.6-MD\Z?NUSS'XZ=^;E>%@ZE"6\;1O0--ZN5\[7P#_(I_\A)%
M_>=5D&?#P$*[3).]2!1-]E&>87Q^)IX",X)0(3(R#CM+DL-VED>%-$6([^TZ
M,3L20-_A5&N^<= QXJ6094TE1'PE]1!8NE Z_O$KOEA<_#9D>J_1>!.YY6*;
M!)<'Q<$RY&R<X^>5Z5'OKQ+'QE=3]= 0C.,2MZ#$=XRE*0-CWA :9W_.:--P
M9?-5E5U#/:/FI8RT5E5B:'&$;:F]6^WT]X0177;^,UE(!4&LO;U1M"J!2V-#
M0$QC8:9XNPZ&(/^X<&K  )(T1/+@.Q%9J!0/5;*3P+38N-] LXIL;1)UL=98
M8:3Z7F3IZ^/2O!\X"XS@=&?!]<Y!X%9>HY_+*J/MRC5P[4+=\:9,J6T7E@()
ML^]*SB\9W/2AZ^_C##4*,.Q))O;[8%E&9*="*<3_XMT+.:;ZE!_]1VY-E26'
MC-:/)5@\XV%I2$;B'Z\U.IIMTD*F#CKI!52*5L+OPU>BU!@RPB(*R[[KU%'I
M4=P"DL0%I%"N=PDR#@(>V%O7\@<#9P)G%6(7;T!(JK)7Y\T<X^<)(PD&-A6E
M*<75.[5U$.U)$JH&25 *?$JS=@+$E: DC$K-//=W6AS1@#_A5G+&TZ#X^!@
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MNIL[] EX1:RSS]L9'E6WA )[;L__AL',5WL/2016<#8EJVP8G;RCP]1?I_R
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MQS'-T,DE58-YT#7O(T'53KAJ/D;M9(6FFG#\(I:%>5N$Q1*P"QDV+Z<;E<>
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M*E"PW;R2?0)\(*[:.I&]:E',OY!W=J=[ZZYB>\!0?BD]DFK0HR@JCJ]A1B8
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MA<7%\5^-GNW&XN&'T.RC0?9(++P 3(E(LM,3O@237=Y37'AO%2'GI4> 1I\
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M/,.[ZC)[% -_TA.TBGH\,:(<N4)7:Y:-1U\12F8(;E_>D=DK+"Y/SO)J<(U
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M5\&7Z&+61T[XZ8&%U#.><SWA:L*DA4B-[5V>WIY_L'O['49#!) +%3%EN0!
MVG2?OSCZ=O/S\QN:EQ\C9;XB1#%_)0[1-0.T\FAF-B8X-]UM;D+ZCM\DO^WZ
MJ]%FW)I ,;/R!&C_6^DFM+06&V\J9]YC1CVD51N8NU>HGEZ5GDP]]X[!81J
MLA+:N!(=]98OE>X\@%,:)4^6JIC,6O0'*0-(92%40O/'L84K8Z]$[5WB>9;V
M,"WT$=EOJC^II-!ZJAMN?[6QO=#S:G$Q9F$0AGAV=Z?HK<-"C4>&E4MSOL&M
MG-&Q+T9G/[=^>AM.!A&FG9&(ID&1,G^#%V2RF]'Y=7[RY>MWJ+*FKC$??VZ6
MI@9DBP*G^O<[]$Z))0HC960D)"W<*=6GU'%C#<E0NW"$T^G[-U(>PK,/;5O"
M3V$99[;0L SAQ,.W<0\^:U8MDIC\'[U22Y.K.B$.M4-OQH@U&XY1(IDD2DCS
MQNX36&_0DC='@2)CA19-<?+8(,VD')I1TS=!2I!3@2'[MI9PB?CA?-4(4_;!
M]PV5'&CWKPLEK2:+9R@^\V5T/"KZ0.YJ:QT$_5=FMD9L2_AIW$TO4@?=3N;X
M<S'$I2/+BT=F=RQ*@[=+8\Q*^H",LLI\Y9\U6",==H=N1IB\#XFX#*S/9]]?
M *(FDU^* &:QI3[3A,K9W*965UE 199SIBK#B+%J5<4(?P"Y7PAUT/U-@'__
MD^+LDP+GO BR_NU-'>J,4!K@$8>ZP]QQ(XI7"**WHP\OKEV6TML+YK 3@*7F
MO<"2>]V LJ- :7NXX;9=76-'?#Z3BTPXDCUN$SYECLIGM2B/F'*K3G%/9\&R
M4$S43!NQ Q@^'E7X/>@55GB3]G,L>@($=[2$'A^ZF4_ <>,V#'*75*['QP^7
M?8-"1^P\\].K<6-)(LJR25J8:CW&FIV(S(KD(D8;\'''Y'4;9A/0N#^%/ %6
M, =LK5!B 3+Y\Y?'9E%DK'^1/.;2%1ET&>->L,A42\SK7UCXE9CHN,K\U11$
MRDI/PHB+^:GROE [T'(6-9.U[1Z^@F ]\/NUGFDM*[]F<)IYM-QBY1U$<W%6
M&?K5N-$_WPJGSN9&TR>$)X2P]E*<4<.W?8X-I926-<NR,!K7UG#-CK] EOW\
MJX[D-P(<M&5C*Y%(*5JH5+H_IF@EVN']HU-]K5N4!R1U[,.YRF#MF]F6;H#*
M_/=X)4)![0TQ]P4-GXPC@\RU!X;60_=L??NRU]8U7UHM30NLIT<^""IR*PH<
MDOZ!)KJJ*J*<RQ.W.^4SD"*+Z64M"8WQK^CGRKZ;2GQ(0L%6$45Y)X7&38;&
M;)^WFJ?S^^O@5EG/C>?..P?1P<^"G]W]SE<?/*?7.KINE%;Y!SQ/[*HW[GLL
M3]\]"F^U*-:'EU?F]!_-IOO]K4++[80VMJWZ^C8U=:< !TBC<\DE-/WX\%.1
M-^*X#T=*=0DSIUPYRCE*$!+((F.??[@6"JOZK,*55[G !/S\!8\N/LDP\![#
M&MF,CFS;(Y5*;D*9 [\\2?;@])?Q3:L2$J*HPJQ 4E_Q^0*GV9DI=7DJ;1_V
M.=*(U1;0B"TOSRV/YOGI^2]T@_0']03"Q.@W^@1\X<2?"F)'2NQZO%M647#%
MG9E3((/B>NB^?!(?N.=SE0**,I>\2+VN.Z3;04?6_PAIB_][8$X9?O)LK]/@
M.*U'EJ*W3P _>DWO^"_\C[+WL8C))T"%LPO6GO(MZ\@CZ DP<>$*M6@^RXW]
M%WP"/RH68>YW&H3U:M7U5D']@Y_NMKI&6Z#:KX^$N$42^9/+(0D%!8/K:2EK
MC]@WU\IA#YG$X/^E/[K_6P+(%%2/7UP6AM<KQER*_6Q?\V[HV!&OLHIS-^(Z
M[=ZDEJ38:TCJ24UH?:_N7P@.*2,LF(2*$L6[EB/9F^LIG3G6*C7Q5.=)SN(W
ME -5&!V.>BCC>PKT8M:PCE\';KK2J)5KZAY2A:@'];X5^BX87-M8K&UCFS'?
M]A83=6WQP1?J]CBTM(AN55@2$TH M:+.S2F0I8?H[.AZ:5-'"4#:HPB ;>S,
M:@;Z'3NQ7 7U;9QMY,RC\KBQ:M;3851ZIMJ3JAIB):3()3D4<61,@K4S'?\Q
MKVB#RD_R3V@?5M[:VL4E?9W;!-"5M;\PL-SI3'%!TZITD[NN4)!;0+6_3EUC
M?EY]"(]KMN%\1%65LT"E]_(3$-8QYW(]<37Y:/ 0U/5WI>J2Y+CQKS?5:@NC
M INJG5$\!:G[@NCIZ8@!Y#R=CUEJ<^TSJ3FU5]EU24!I/JB!,U24;&U*;\T[
M__ R8S=EX"PX4S3]3!G2$1UY;-C2HZ%JO$"C(P],+J\>W)5G>4^/'9D34OPA
M942+K^ZGK*P\UZ65^>M<LI0U[[R1"S"\UH<#;K%2_^>M$2QF:(ELY6$QP>M;
M:U,7G[3;'U03]O"B#R"F<Y>5>NR(1W9,*H(?:NT0B>\R@S0O!UIO->7_Q89]
M CSBDCP!.,[@(>"M<[NSAY^AB]N9C_Q&\)U8!,ND17*S/GA"(?OJ3$_$^\4?
MNG_>]@G>/:[&C4I+H["*V4YF-^((W1812JZHSS&$,!&."2J925SC45:1_?\C
M"_R"#+^!P]4Z#L8"*S*X6L2N5.3B8,"([I,15U/MKG0*E)FGM[XJD*JTP"%8
MH6 MRY_()X!U_.^ZHF= N3H]C2T^:>,\IQWO7IGMPL+.;KWYD*P\^:Z%?O3D
M9K/O9+A,=Y2FTJ8ATM]19>EZ? &6+Q&;Q\;R.M6PC-AZHKTY6?4RWR/O$"(?
M0B L4YLF^@8]T+0_FHE,F1CZ&7=6MH-[Y@KY3@HP!/CD*_XY*A#-&-F/+P7@
MD+<0AO=I@Y!':U#H_M%1SV*GR]$'\FBXU'%[,5%XRV9XRZ;CPSMV5M&01)B.
ML'-C]H$3\;XGU[=*SV!H+E%4/VX.[&W@FLVV@;[^,,Q;/L)2G[(\O+R.^- [
MPLRQ5D&)^I+;ZGRY&(KV0GF+KJ%8BM^@< T&8RU.GVQ@)]R)61R4!99459H0
M?;4N/P]0$@0*7R7"['+@WZZDO6]#)6RJ^D;^O%6<=HV50=2<5557A!^X$U4,
MCU."OD3(QK:I37&C\I75R3(<[^44.Q*L]"C37E(TZ?G<DZ\F+RB_:_XQ)/@#
M)TA[N!AW[_/1UP;&UV/R *Q]^>9;^?ZLEW$]:#)V1='!I)R:08,SE+@JBHP?
MD7CW$6NWL?(^7H\R4S8;476V#VTS#_71AX8-ATTK,Q4UFM^:7!7X(9X,NTZG
M.D)&KZ*&Y(%<P7NIBJHJ,',Z40)OL*UCFS.E=_<8LR)7/0BU[  =_;PHA1'P
M&^U%"!^Y<W2OGM_@B(V&ZOSGK1DY/*?7+Z)! =$>T\7[D[AM?B(^_(?@.Z6J
MU:54S,T%(H5L"X1ASPFZ8&3PL(FU4Y)O>)=5OL_]6*RLHO3Z-]XW<]=0M2%"
M#YRXSWP(QGX56ZW[%-[ZNJ&_[N9B)X1(]B1N>]D8E!I&-"I\XBP/A2FL']]D
MWOQ$#F0T=\W_ZAE*VY2:2Q\JP;9+#X2M)]^%(_R]@#LM@]M"0HK++61+ES3W
M:Q1+TR;;)RQ+P>.2,>.R:LJ+C026%E=_IOIHXX-#^":'0-X2#(O5VVMLMRL9
M?!Z/K_7LL5I3:>V"X[#X=F26VT&2GW="W>M].V>L O<ZT1*)KJ<C=)(":P60
M\_EF@I&JD:8NGEDSBCVL#4X!%2)&4-[MIB^M16[</P&ZW/J/EPD-NZI#!1P)
M+1W@^BP"4%SCY (3QSG@+F5),P#=QF:.SX>KK]MHV=N3Q[UM%38'6>=WE[;
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MH./)2O^B*#8G,URMIZI2X#O1F&'[>!"W)MW*519?0#W'@B 3D(HV;J8-H0_
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M)5#Y!Y[?D$:BTL-H0>4+(T'*0)1""%[@!_E59\--5Z^V[PGLS7)6D#"N0SS
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M21<!#7_*&2&_+ ."[*CLD=A-^IX?8X:[=_L75Y;7-T<5A>6Y*>X3<<-G-L/
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MMA*_)1,,0($M%=42A"TM Q[*G&?T$!'FWS2,8_^<7G8'[<W#6K3O:'%29;[
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M4I?7GU\\V-)O]H?,B2G4QW?G4<>(&(D F9P<=]I+H<MA//#@1]O1XK- 8C"
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M I7:"FQ1SC.0OFS7]9=#JX)<GJGMEWNB ?T^]>0;50,&^/#^^/DJ)'0"[<J
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M+EA;IUZ07Y5X")\^4+FP$?5\-$IE5>OH%<P85='D@GH_F= <K.U^ZHP!'F.
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MC "D8L * M%H:?I2B]@R" 1HB<YMPBSQ=F#N:3;UZ-<.(NW;#4$P.)V@?[&
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M! :F$,@(2-%G9V5E!X 7 D&.^ ]LVS^") (!->#WG]!@XE%3Q?D_OT;:WRD
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MTDVPD<%DE+0@ (V-_[+%O9-K4UB/4*]0?"TZZRP71B%\L\VI<6"%8#%U<SO
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M'%"G722@&5^XVE>>^%?.'@N4.+HAL2=0]C$TP*\)=OFM%3$D%\(@JVF.,QX
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MOY9\U2"<39'73J;?J=%[F%ZBDMR0?/(D5-7K<6HF$-6S+%"ZU/8JI7*,GL;
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MVSKC5?_>20WG,42,-=?YF2CXCT ;*?8FA>4^$T?12VEK6P%;7;Q-*%X_&4!
M9O6@Y$@17*&P;9Z:7SL-KHJM4'*5Z1BB<7%2WLK'UW,]YN&MHD%H1/=W(\>G
MOHX>^V,N(A>FU#,_XL?F>CW@Q?"W&Y268?!#E)Q/;$C4C[B.JO10TJ<M51/H
MME1Y\)KRR:[.'SL'6!%##%68&"&?-D6 '==X6T+D:2R[<F/>5#JZW40'9J _
M:EC6O@;H]6_;+)"J&K_V-\GM%]!WRB>4Y!7%/5UFXBR4FJ;U;!DW-_S?W$;Q
M\)0[LD#=YSEH/EL^S8=Q==N_0@%U;AOV)PLDS5ZWP[$HU9OU?K6BK88:J,=
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M!N+(^-[L.-L_MJV'IU4UZUMAC)@OWP%^S&$_*SO14HWMK"A=X-'C2^M2L^6
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MM^!G$HQ57QM.C+0HLQ%G_>5H5V:X&FY$\N5B6VKR7!M74YI?B\UV^M/>EK)
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MO+928?+]WZTBYK\@%J?X>.IW>%*]*5XLD 3\J;I&PN3D2F,KE >FN]O[+DI
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M0/TGCO "VMK1(AO8]"E" UU[F8J+Z5Q89V0LYCA Y:T>QK;J8D_?]'#&>.T
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M9=W..'-D^!^[QH43[P!"/M,%RB+\%>;IAIP76P*%4"5F!G=CGHG&'O&\Z7@
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MUNX?1&C;(&D2+5]'Q\;<<K^[JPN-'50L9@3R-5_/-JY(G;M[Q%-=)GBY^=;
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M&4<\5Z15(SH[DW.)3<7>:+6G^<6R=LVB'V_O._V*Y-3,:F7$;2A2-HBAV%K
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M]3WB#-A%*U&IFH]__]_'H'-A]L[X_A4I4!\]!4@$7#@4EV!_X&\X2A .P0<
MTQVW:%PSBI(,7O9ZT39; 9_P[:GGH'!P8T$%/23-M"DJ*CE-9MO,\I.3_'H)
MP()@<@_3F0ZPI07X5/-!#<*:NE%V4!=B$BG<K/;X@)B4H:<86V3T%I4>PH$]
M% V9O?=-0RGNF?GFU]GOQ\7I[+/B6>T<PM3"E\S0&7(?/Z6<QG4QU2?YZ! 0
MINU9PQOH?KIL;'NCCUJY2WC-:K?S'NV:G:[O_6WW+T.ZQB:2MN)??I@#G-4P
M3QY&OV,M-1$^3KU$5TT[TN</HT=#P60QGY5\.HOXXP"WK&6L39L/]7S]W=C6
M7J=Z:^9LDO*]E6)(D]U=+\I']^3K<4K90(>&F1G'(F6QKE# TMNFEVB[!7%_
ML*49(&]J?$)H^QSH+V2*<4>]!K.P* .]NGS;;Q"O\[Y"++V"/X*X93&EHZW=
MLESLY9G?HR-N=2%K@X1,8]4QNA<@3"%6-%-,DB&V+#WDF#>?.($[P35JM_EQ
MH'/&JKZ>MNZ=V3%U4)T?6:R&(.5A>>L;8N5UI1"F<K&%#L9"+X-/P7G%)LX>
M7T>#:'&U31G"%#T&9Q857<XD$O->$H79_\+)\.6?LV.K_M,<"&RW3NVB+)KT
MI"#]S7OE+J^UM>2B$6]W7H'GTX+'I^2OT,'QF#N:W3\K>N0'R:$R)+'H5JX"
M!8A),F-Q;?9^I)75E2':=[0G^]04*KP:[PK[86%NFEA,U J74(=-]=H*))BW
M"DT=#$+_X'T*-*I:?F%&<W\Q<H"/0@X?XGBP=6;O*:;OD)1FP +*CE(CP=SA
M=EI46<WHM#:A%[I^V!N7&TJH?=FXR9WV+/3EFHH]KE6M3?*Q[/-X!OQ;H=;"
MMLK*#=>??#Z^GY#="MNX5Y.8;ZY ZU9-1J"(]8$Y029=HI6L%9XX!/U3YGJ.
M?CXIM?GL&J6PXYJ:@6I6ULYLP;_@YGT;U%NB5A)#DYVYEX*$V^_O=Q^&SQWQ
M]'8O#8ULT#^(.'THFMUEW=K_;;_YZ0O@4!?P&R?4E'%PUZJZ6KC*HG)JD_2;
M<ZD>1;G;AB( >7VTW\_7'%M0'!B.QBBU/4( =,*':]6I#@E?43>  8E6=WN5
MMPUITMZS[^YG/^6\(8/P-/,M13S&G[25^#$X:NWF56DUD3@ZV2%N*"\0=7Q_
M.Q9V&$DD$;?.LPDTXY1MS64]1U,R80BTB'L)5[2BT6*'J.+#&<3+L8/;Z=XD
MTL79A+<OH_7L+YY13RY7-+C1S2I9ZI.2=^1%W^%ND(Q)EX=6UB5(9'O^1:0C
M>GZ65-"L'=B);^!C[-+),59@*>Y]CY_SF9F&G^:TLAOPB HW!9#;TH9_G:TX
MT<1K'QA?X;23 DI54X^]L"14[K#$805+AY'"QCU%^@$ _(&T](#I4ZTF#-L1
M^KDV'&^/;?,G$L7/V$)C(P[AF;W0.1/K:&^;Q9?XL&IE=3'7;;_8WFX;0;>J
M,N_C.SP6@+AH$##P@H[A5?.,37IDT*%M+1(2@KGJ201?072)BF:FV>M7_0K3
M>%YCS^^^(JOT#(IOO/W,-TG0:8XQ.J(;K_^/=_"UU^8Y$#@M3G%XATP>D*AI
MT?1<BNP^XDDX0+Y H[AF1SR#-CG[Z-:,[6'$#L4320<PV?"4<=UOIB_TL/U=
M-Z7!V%JVPM=Z?%!-.:X"M!\X,C8R83GX5/BX9.$JD.0<Z1=_S#E^C.OD(*BP
M#B(JGFV%N9%54?[Y\_K]-FIV1:^O:7(B>W"JP3WJ?N@C0:MI:*U;CWNAB)V=
MT7/OXI[<O);CG6F\R?*T5@1YD+R4X@W5KAN&\=8T'/$D'_$,'*9!FK$GS(7^
M]'AY,%:\X6^/DLKXZXB'+[>H5U[HH8%W\+K@_$WO_/<BU]( 4UN&4F[T2VS%
MCT#.J@V&B:V.BQT4<CW1?\\=4K?L2X 9JU=9LGFX0SW=N1DC,%.X!?<LRQZ$
M#9PFI6=!JE/\]FX$[EVA^/SQZH6LJ"*<5D9<:OCJ1B._(0_Z+94?3J=Q"^9P
M,H34!J;,IB.AB6GOD?O"+<Y&<N:>[%#C\3.5=T9,[WY&:T_V/:\V/Z,7%Y>0
MD^ 2+18/IR5C>EV5B(2;6YE3G#YM/3@33H9QHDRJ?XD7U&[('O&\,WXW"_E[
MNWI!N5)/]H21\P!B$.FQO)#,:VCU0$W-^L/;J.-3X_05X6^#18P&=F?0BA]B
M%S#N\UKG&S#)D) E3%NJ;_[&=&J((]%JUO[4-JL7J4 L__YOOVD$^OO6$EFJ
M_-FUY")GO_J_.P&C+!C/1NUAN@Z3.%/@I(HG.UTVDC5<?S24=G&$%<X\C8=.
MNJ^_5#VH$4_XW \7]D7\]::X'AU!+JDX";59]?F27''2\1:OEJ[QE3X@V=Y#
MNV^4#0-"\0\POK%"IH&8N["N.;#P?H;?X5*-MC$G;!IR64W1;,(9H>T'LS2W
MAAEH?YS5;\LI-8IA&3C QDE-HG;3GD;1XX>QMPN/RSQ6-;7=0-[CNHL0(I[1
M2N;/L#%[^WT2K5P_^Y(:84$;BSJO&A+2R$)]\C_%=PS.78GS:]S"2Z.TSC_1
M#56UAMF\)?2)YI)0.9EM83<YJ85KO[D_/L^2I?=.2W\&+SS$#9Q<4=ARPJ[_
MUFJ?[J_"\ZD0_%/#VJ=1]@AH66<\J?*'>+?>Q_?.Q!F1C0 ^&XM_XW+J9,(!
M.U/K]UZ,N=S5PW4ED2:"%2EGYQRS ,#C:BYK:R*[AV!-7]'!H3/3H+\:%%RK
MZW5/DS;F;)[M1JQ9$O%Q6>G)#D/VHM=Z])*PXOJ4@H),0#%R5M)9&4S#FHQ\
MO'&8*NVP(HL;+&*RM$Z@W'N+@ZU6WI-HFK;ECGZC#>83\W*_1%4(.T;_\C:>
MJ1/9,%:*E'<T?)+0L!D!4($W^%.F33,>\I/0WY:XWDMI]W/J9)7,'[I/!;H8
M/M52,X5#[^>K",@,R(M]?YK_2O"<1O5V=N+_])KW+0-((%#S&#L&"F:9M(BE
M9+_,G-DVE'LW+Q;9N$>U'NMWVTK5N!L"NMZ8JJZKJ_S8_QL6_M1L1&\?VUXA
M>>XI:<7O^,.&-N:VZ4K_"$X,"%G3$ ""O_I%!VS^SNI@\VZYHE9#-K[L#=D'
M6KFMS#C.3$[ 9\ +/U1##6,\+D:4YQ0_6SS/*WX'.V1]662,A/I23B&CPA?\
M8$<\ZL9-,R!A[@/._R!I8K-X?+-G2%"%N16BC4\S^HCGD::?U[BO(ZE1YE*5
MIF@);((Z^^TT!2<>GR*2$%$<5UR:WO@9R!C3&&G:1'8W^B37)E-:H7]SAH''
MLE_N8%S'Z'U:[VVM:KV\]BCG83]Z8WM@JI#*G*$)[8<B13>EGFM9W8'S?Y/0
M"(X".G@3<P><<CBV+9Q3/V^X-/QX+_+EWJHOXK1DJ;](9N0(OH)0E2&:(G.E
MQFU_:.WKYJSLW+R.\)O<][,XD,DUK#1$2AZ4E2XB71Q.0A4G'+==L9'+B\P:
M9/5.X.YIJJ^8C-$Q0)\T-*=JVNS03J0C'@DD)) &BR:CD('6/US7]]LD82[Y
MI87MU.(6V/FST:^J7MU\K/'F<I%7IAT@[_%@&[\KD4,$BOT/\DT->O$!_?G.
MF>^0*/+5^AL6P<@CGL<P7+SJO5@JPT>I^IRS?ZKCTOL.#X9,0R51K=JW+,0<
MPQ<5TBSJ;1!59%="!?A0GR- :RT9"84R Y?#?G?ZE>*>HM.X@8X=K]>.>&B4
M\8R J&<-)C]G,^_%#;08RDE)D ?HK0T)Y0>[\+>N/9U6UP/Z;W4<EP2U8(_!
M$=NTBI5X1DKQWD4@V9; Z6BP_4)5JE/-=RM/E:&*5K7E)(LEF<*B]76[_+B$
M>^LG\^Z_$7R?#Q\1.]Z<%IC%18LHK@@RP*6HD@4_2X0)DV7+.%?P?"=^<"AR
M.H@]-#/@'+@3T*M3CZ>\>0V.\E2Y9Y#F%BG>MBYI%S67I#GJ*7=_S&S"$I#A
M#(1-NSR3P9_;AOXYJ+W^"_P!Y<DNYB2R'VQ5-"-/3Y5]'5] 2LC?IM<CM?XL
MBLIRR!H?*IA?>FEX*<0H_T9^VX>TDW^U;9#^IL= 1+E0NM];5GP"*G<)L30+
M4FB[>\2C"<*2!_CEMRUN@WSUFY4.QE2;J@Y*3M15!]=U/YT4C5&C]H]#2S]A
M]>)[Q\V?RA3:A=3</]Y_QZ3CKB%!3$W6 H%[DN/.ZF<<\4#IB@F7%II+FE"2
MR^ N\:GM#=_=Y.E^&XNVM?X5Y8/Z<$&=K,&GB\ZET2)Q7X>3O/O69*9[$NW6
MCT^1ED1+-X&3SPPI)H=B6T("V_ 6B]*#OS3X,=2P;M;!Z$'DLH*I.SWK\VP0
M44SU#2E5OD 7.V>VP&QTN$&NZ%S.[C V%+>;&K4RO8(U?PP0YFFN'QV3 AX
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MQ/98<D @Q#D0F<BD[D.Z9JI6>Q>?@9O;LF/Z5B;X\R)"#)LK"IQX7Y1T672
MS0QWAF^STJI-PG;NZFS?FD.TM3'NF:] M=V^>+=V(DF"^=A=G?3L&NXM95++
M<&-]?_VK8\"JR3:H(^O#ET7_GL27$D+J7AO-)0:BCU\E4-O&C!F)!V/3@F\W
M)^B#T&)0@88P%$2#[Y0>=&+WF0-^S;VN#D$^S8'A/,G*65U#%R2$Y=$W\K_X
MR6$K7TJ4+L0(OU,T+#< G532I\+BE\L/P(SOV(@E4Z^@0<0^IQXCY@#^/4=M
MHBWGNQU["U//M+&^C;T97:4OTZAP8)<>W4^5!H@M103-EWNPE-WK]RY[W- _
M1D='!@4NLF#C+T4(PWCCX2];>L 8Q#3A<#9*&'/,-O<7X.U.KE!.MT^FJJ"5
M+?28S2.\.*>O28S(;>$_8>Y;W&&Q]*R1JZ%:X'%KCJLFIS3THSX+P!,,=^T7
M8Q;#=ZC$H=WE .6-]I<'&W]/\^>H[W\\NYONNW?VQU>@;EPEM_,A7O2,\9"9
MYMV^1T]3AS-3[5X*0ZFQVIV">VUALN'BVM'9M% H9Q DOO?G,=O2V!9!!!,B
MY[/^/MXV;!%]MI_<>@OLF_',_(M"^*S:]KNVVRD[7^HZS!VH/)H!MBQ2>\"T
M!Y!CJ=7)_$:+\+[9 GI;*AT__?A26A=YW9)Z($@(=1BS$VZBG7:^Z5#?U 4/
MH,2&7;^.PM6_5CRLOFG& _M1'GG]L19!(.7:5Y;9;ZU?@GA#SWW96!9A%&^R
M1%:[WH9V8IXX%K%<?'$AGDS(N=FLF'U.K;$=3C4><!;&!N1$Z2:@IK#>@@T>
M--<@VY>7BNV3Q4]GH"+T[UMXU<Z7$!$EN'1!6L:ZT$HET^&(,$S2A@UN'QY0
MZD,&W6 PHP],+EBUIP7R975!YXBR)1$XUM!T!)6]6B[_,V733:2H@D^PQ]Q+
MOEI&Y;IZ:L])+=JPA\BWJ^SXAB9A"U9$V>=T3N7UX= 8*3?J+#;]ZI94,)S'
M1#O0]SH=R<\?LB<K[#U.!:0#9%4$ 'Y7\LNY]LLUP4ICD)CR@N*3BY2QY[;3
MR ,_US9>9QMYPK4X@]<_<SK#_:R*,!-U=;[I,]E&%8'9:#FK\4,K@%*R16^F
M-.]@.H_AZ/!HC\PE3YY+12[%'BSYA+I6<G#$:!D,.6:[>X?)(OZ2"2D.-P\+
MPAA4.GLS3(\Y[=!'JS_4DAX?F:E;2&?SYQ^\&!ES<7_'6,J8*_:;?&=Y]]CE
MCQRL\%8Z9KL<8K3<WK,>OGB8N!&&7H^EDM=P+)72C^-45MG+ BZ8-=9DKP#&
MN?:$>DG8NO<6SMJM.*) J)#:<EFEI]<2?MS>JZ?,"^7 ZM9V[UR[^?Z&+O(V
M0?D DO<(0BV@YVP:!=+0G_VJF?:3@W%V%T<:^*_6W06Y%7P>RVV*4L;>Y8=Y
M!8?UVN$F,P<G S,K+L]]*/5@:9.[X;?AY_SW\CZ%KVAL7DF?%^ZC=M*O$O-N
M:F?H>P4=J5HC@V8.)[Q9UMZ.@D[XS=@OXB'J3X()E_PG*V8VQYP(8HH*+J7N
M'S[BQTUE;I2RW V/7#PH(8'SQ'_^,BW!X,(6M;3#[\7G_Z2FT\O:FY85,,;V
M7_/FCUSYJ15=_F7F2AWC^_HFEJY-18"@>EV11?E[6>8#7SC1-/M5PG*U*<S*
M(%QAG=83$C] )PP)"R.,YM FNY8]Z]5+QVQ;(Q>W;<JOIJ^&=F "E#7TH;[T
M7]B&^N8G;H;9SX8L'<GRD]%/?!K_&!]91%FZ?+!DM1GQ ]<EV[V&2W+H.Q50
M8L:H(&3?H52O "8)6)'M!S'LZ8..J#!=/V9EOY,84=S=MPW;N.]JOY>4+9/V
M@;#\,BL_U@"L]]/+4S(_XF25DA'_=.90=4[45 _&^0168@VS>HA,H2>\GFTV
M^4;6'/\<[SPIB&U'PVZASUFGY!<5S#S.FN%%\&D&7_+9L_ 9OO:U<^AOELUN
M'N"WUA*P8<HLV<KY,B<!8&=/(3DH:L&>TI2F#"2?YFPYR/KO'G:X+#DE62WG
MYD&H2#! ,]%@SD"^[J^/FC(GMX\LV@%("!V\PT\',9A4CLVU./+(,9M*F(73
M_CBD7'VG#@;5FQWT_7;,]CFTJ&G+SI__OJV>MVNT_< T7UQ'0JD7UU*,0NKE
MCALI)S?(?R<XS.7U"*?A>L\MBBWU^+BNXK))\F&ZKK@,>ZXJK"J7=5-AEY]]
M*^D>L&-<0S]H9!Q_!BH6][%6Q>]ZNQJOB.&@2IJ.<,H)>Z)%[1A1<_O)T_;U
M!T6;D*59\14Q<ME7WX<PU1[M&%L<BS5^[3$U.ZT6N[Q-2KWX=EHMKOK%FS&3
MN+^)8*A:8_SO6_?[+0)8!$#WF.TW4K#PZ[S^>GH!3/P9$DY/;=N/ZA8J9]HU
MV#FV:VDR%-?]]KZX284$>D/NJ0HHT=EK(_J&0 !!2[CPM7@ORGWB@JP-W\GF
MX@\6@:IJH0(/MZ-6.'?.43EJB42N:+JNZ1:M+.1<$4**A^,BW+E)%7_)ST4_
MA]C O9<ZM!!P6/#,#SGVU[W]3*\[_M_-=*T$H*8*+,")SH,SWI!)<<*#: 1D
M]O/JP ]2 S2OES,?=B1VS+:J%3W(^+N/LF,UTY8CCP=&3=^K&%]Y&1$ /'/7
M*PN)&"H"GI&T:KV_>E*KYV]2E/8?V 0_1B_SB2!V.I2K=;_K;$DM+O>8K3>G
M!;V3_<"F<*W7-(,?[[BDHD4:&+O//<H/][?R_1;O-6IN@;^7N1V42/:R266U
ME8% H[#PA97^O&759CC-*UPQMV4Z3Q;=](DBFRI\6DN:DI=T" \;>K3'/.?>
MW["S1^?(74<=U;9L*4_:9)EQ.(B__=P36UZ$*@P@?<W2AE(3%7;Y&3I=#)O(
M;$[&2#O7OM[4 >>0'? 552B!_!B7L73V9^$D3_!TZ:_D1ECD*#D.CYX U/$K
MF"??2+EFHYFC]2 _-^+F[>=TI!"9*+I/LD%^76/._1Q,<Y LIL=LEA\IA<O*
M)=BI-IMN?SMH_'OCFDHQ9<UXG]P[L1[:4Z__&%9EZ_G=Y2=-2 LGX/^X%VD1
M_/NV!<_>@\?R<T<3&(&[PI?1[2(+5MM)GT%!#CV,>/5D^J)V'_M*4YC>TQK$
M"O2'/W^>\,Q4X2RBFK\>UL4)\8F6;-TWXD^+CZM5ZOC-.KFPH#1)X._+XAC:
MDV.V+"N\R>YZ[.#.LJ#O<$YF*S]:.PW^Q;=E(HGB^SJQIWBU?UWF\]1>L(_E
ME8<2F8HMK7[J7EPR/"*FC]\"I,.D!O^%P] ,JN8I?CO4@2GZ!Y5QU96)+F.K
MYS]@[7,'A'&'/[33=85.21$/9B9LYU8E MK*IK)I%6@ !V$FI<70)WXV+1F0
M,ET=V6EFKJ^=JC7[@15-J#5*WK2@Q@AI,SWGL/673CON%0-&L!9JW7AO.;L*
MZ&_9L=40G\KY+7MR\G/+,Z5[/3O7;/Z:&:LQ!X^-#>D"=0-%G]3JNYT< =$^
M@R&CM02#-K8?THUFA06U'KAB#@O:V1DI!_TS&D8>NVZ+Z^RKX]CD9MK9R7XG
M55Y]1V?Y1EO\ 13*,=4]7U[RX<OHZ% 62J_LA<=RTG-6+LENUM*"7X4AD\D;
MJ18D :S[Y2' ,1OCB"G,2)H4#&[_%2/QMF\>AM=EA,P0-&Y.80M\P$-9E!S]
MC-E[O9*HX.W=(.5GW?XC8Z( 75T%!$O'S8<85=-RA>EMR,-UK[;$EBW;4PCD
M7P<\$9\AO3F-8)VHOB58I$/3,=M;LV'7ZSSYU=U.J]ZU>8'<@3W*2F#N=O!?
M:3+V9"(OBX4-$A%657#5;NGQI4X(*@Z[0Z-_04[@D>X]"_N%4]) =6C8ORZ)
M0H&ND-2Y3F>:*.0Q1+KH]*=7E3LS>JE<#UF<Y^,"/9<"6+G?BDM?Z4$*VU.I
M2U,.E[6>N&@X-V*2JS;=@ZDVW[1^DBFK#2!M-&S180F;+%5/KM]M,9W;O2AK
M:/@0M?BAN!P5+>G)H@1E=GLX!9R,A@Z3VS5E[9@M(6>U(1#PFI&%B7'S$4S'
M8;)%ZM!I6U7?UIFTHLYQT#I]=2+P/CBYM#3FJHZN0WR$^"./A:&'M](R6#Q8
MSWN)7=P]2$R5_M17,+,!"UI(U_-QB+9-KX(+]\K%.OS.M93GL2Y=R2OL-#+/
M8LCGWP)SVE'[]J>"'CDK:'=Z#?241WO%6FHE+A5DW<MA3:58&W@KO6WY()0Q
M=@A2K&>:<!S^%%Z6^)OI+,P%K^X3K']+!JY@4>JGJILX+*-$E/6NGGM!2/D.
M>2\FYT^9;O;8&NV_KY^,^NIV\V6[P*M31$1Y+=.<WSG074N-BDLG)C>Y3Q,;
M&5^P@7#D%^*U)^_"V[LHQ U!6<6*&N67?VHJ7Q.J_NI[P>;-Y;_\)RYTG;5*
M,EAB@7;*!GM_^H'KM'9_N<<^K@N2V$9/I$_@1"F#\8UM,END 'B::O!"70ZH
ML4G!QV<<<B:Z\JNO>H6L^[EWKR,7*KL6%KK&BD+&&F0>.;-:$_U)S)P*Y]HO
MV9:F.Q!RSLT>%E2&B--M+9 65-_&&HS#LWVW33* ,&4+KY J4PP&Q+S!6_KM
M%4&GK6.%S'X^&U-^3E\N,>SU6,WU=&2UQT,=P% KEH5Q6M!YIB;R=6<0Q.V8
M34-NZ<4VS7U/4-70[WKE0?;%!6[^<Z=::11].[/O@YA2@JK5B_)J&XEGJVE>
M#PM0Y86O ,E$1!&D_P#=]9E*RN8?64C[SGP:JD/*67CUV>\H<R@C+YK%$Y34
MKRY&/JAVFO>_Q@<'"UIV]LW_&L=XUNYB _WOVV%JN+Z;?R^V+%:-]%C)9IF_
MD+[0I*$:%B[AD(F]NR[AK9$>'"Y;G:CA?'1UKUBV(* 5F^</+79*/N @Y1?$
M>Z%HR J2I\[IRYKUR=S^!1HG)7'!VGT.L4?)8]G5=&-X\5 /LN8G\]7!V.9A
M.-)[MH7TZDCB#55F8V*L[474)/!M:;JS*XR5_"K2?<$ZC5ZU:FK^_.8^N5KA
MM=L'M1LV9&K;D""%O0PX<J\ZAG1;U<J"L4PE8@FDS0]R\6WH"TC4)+^S($YU
M@L99H+HL)',8L;9^MFMR3 .ZRB&9Y"7M"_N7)M,$*0 >^C.5QR+WOY;M0WW]
M>NC!]QFK8=:[*\:TJG-EAU;T>]2$* "PD;9A0/6K(N8DMNU'BC<%<KG4:H@
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M1CZG;Q2 ;6\2_TK%T-L:L:9!R)48N)_P$IF$NX8*,V(\[__<IJ&>KM:,T('
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M95G.PW=GC#5Y^I2C%M(1>7N$;@T!MDV2OA5@59J^4.SG/ZS'KL 8U_,/XB8
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M INV,G[9. 9+>GN312/3TG+E?Q6F@749B2?7J;P_M#]!6M.M=/.ZD6YTOF'
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M %$UJB8K) UQ'TA.3C,M[['5CRV[](9G&EDQ<LF$1ML\X;,.?,"<#R6YAJU
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M<\ U! 'U ^QLA2\E=$2SW->NZ.7,(0S-(53M]KO_M6]GUZ:X@_:@FU9G2OO
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M*MG>9-H?U.&+!R)O_=:L_.#?BP7%O@]*;"L?=+4P#0Q+(_S8"5S\],$P [/
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M;6 F%LZ'_&0GY+<P\2[Z,AA-QK40/! C;*4Q_B,CX,7?VE>")86U*TA8IDJ
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MH01&QY3$8@W\6(TN80G;34L4GLD!/]T\%$B5<"B G1POZM@34NGI!,845/8
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M=%_\#/QMZS<NQI2/'T_0O(<@/TRR(T0_@:W <%\\%(#L6E#9#KE?F/KM941
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M07_PH\_HW+2+&$?PP6!PMVV.IJEC>/4=:X[!%E3%5O_(<]CD#.ZP6*#H>O+
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MIVSULBOINX]4FRR?]3T>P3+87D0"Q_0Q&G,J,;SFG9]B!MSC>TWGN 7?R1I
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M_>C\&P*DWKK:5N&)$1_I>O*2[WZA=>U?%B8DS:I?T2C=3Z3CXW\ZQ^XWL==
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MN3+$1?M/MTH\WGG^@'OKO@!L@J"I6:VT+ZCSQNS%J/N/GI@"E7EIU!K*]_6
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M\*PD,R>Q&8^M@C(#_ N6NSR)1S)4M&(,XFJE8,0+"I4L:2V#OJXV[D_\US6
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M/R7@6"/XXX"UP=V'@=PSP3%;,!!VBO;CWTVC)\/+/E_Z;]JN%G_O4T0?6GL
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M5IPH.:+^]?$;-#9#$3HOO0,?#7RA'O D&&K?:?^I'M/?9E5/HG*WX;KL\B+
M38?R$DZSX<ZY0?9"?NYB[S:6. %'@["9)QQ#Y9TL%_:^%>8PR]]=N%B_V5?S
M0H&:D_UYRLL-5NXTP[[?>K@-<;K;8GA\?M=.X)V#1)I!3EQ.]7ZRR!_UEJ8
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M;=\=^#[V0I\7%U[X;/O?3;,FU!GQ?0!D>+B"&Q@?$Q7%R%(KHAV.@I^M^T_
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M]54%^''.SI=TJ:$SI:-0T1U;5HL^[V*RKMQ5]7M;W69E8'[9B.O3>BE0*[A
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M"!USB%4\Z;X$(2NZI=)GB?S*X]PT43BG4;W U^//GU%RMFMK+E&B,[JVQR)
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M.$*\7\K5\N"C>EM9H4U&4>^2BD%#C7 R,1W3\$]%KT"-?2W1,86"&L1>*YG
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MHK,J.D:7#^\%Y?7M?&.R*\%C*T</S$(*!O9^L3E5G>.KQX^OJP",O\L#CXV
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MQ0^-C@K57I=%,3$]N:411S%Q5)4DU"$3'BHZ3!;G3DLV81FM$J.]^T5X.&P
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M1(B$Q+?JA/G84J_RJ+)RU\X&9&<4 60LUIA4!6!YQS+1IPB82\XVHE=QR0L
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M.NZ>,(3FIR,N4#JIKASJ^7\LN>O55B0#'W]BX6CESF*\0V;;#'"<S7-,NWG
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MAHVU4>H>)!U986*6%/$G>P&_>$IJ!-"Z?[7GF->2O_$3IGL+OB^5N']Q1CH
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MK>PN>^H;W/ U?"KGW-0T%=E[20:S401V:1/_Z&F>U]WMBHL>O+5N]\\+]XI
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MF@Z VG8<SC-Y@;BI=VJ#5K2''OOA5A0QGI;I7I9XM,F<T!((^Z@TIN28=QG
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M<+VX5%XT9QZIQ;$ S'%:M83(SY@IS"T!)W%X#^A4M$6JHRI^J73Z;4*>46Z
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MGA6_Q$.CU613IF95S6H;, 'P<@LXO]I=*F M,BXA#*_8WD%-))9;[G3XA^M
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MGH(% '=N%[]\P:VM(<[-QI*6JWP*>GS:OT>7%[J?(.P*)T^^\FAQ "BK.\L
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MOWO-ZA1,='B^709=DG-"Y;BXU*'\T0^$QHR!J360,Z#KM+YD^ X<+Y\T8.7
ME?:-HUA+70NHRA1?IS$K+._IX)\:\7@/ULG@,C& ;/0[H)61!0_C4^09P=;O
M8#FE;K_6+@@R=*ZZN#'9%(:4125_2EX3'9\&RIT8>:LS=_*XSH[H,9[FD367
M,UMBOM?69.9S=AS>+IZ3I TG=G>F2:9U<-!;M11W;0^W175,!^,O=!Q9?RIX
MT#PP85C $M2MBK[C2(:RSSF[;K -9M%RZ=/$ADXH>VB&4>:P'$N3\U+W!0T&
M65/\*\<7?9^;3TB]L>:]5=:+0* \.A-&'UE\7G^F92J-!J#2=Q#?C92#"3^H
ML$^[A/&.@R:%,R!DDL?H=-6%EO6X8_O+7K&;XN/\MT<M5[@JG?N)9#;^-\"'
M[+ML-U+WB9W-X?"XZ@H=-4%T&?7G.'P1(&VVTSJ^]]&T^=TY%]SRX966[[C$
M6A/K8DHQ"^U/:?PH,O^-*L_"E(=[FDUC64L[#[]/+XQ)G4&A.A&'@1VA_#D-
M1W[K9_S9?-53@Q.H_N\'4;/\,!AFX!9GO.[Z>KV&UPH@OJA6($$:N9H:KORJ
M"=W4]T4TQHS$Q5DVOY*#N.B2 =H 2Y.+3N,+@8;-C7965?M'ZD?F1$KQ[V/3
MQH@'P?J03ZHV+6O\;1(R@#$ZX6)_'X6CJ9CGT'P\ $;ZZX00MF?*)H3%Y0YQ
MLQH2 (IA/JZ8R?P)0*U ;=;!TIU1MEBX]3QS1MZ)7(R@X4Y!;_3H7'.A[FY(
MJJIP%\GTJ\3D#%DE.D[)] MP. RJV;/=J!Z *'"&X BD%#RS_I*_XH,'E4?[
M.?F_I'5X=.K22^N87>&JBU3\Q"FAH_KC0".E#R9>DP<FX2CH?CS:!#JU7CI[
M$[3^#;%A1BPMV)9\+"][[CA:YG1L%>GL=C:DVZFZF\N<0$,DU>Z=@BM'$Y,O
M4KT4*+N$E?SJ##D7$JQTTT,=S.]36RB<4-;]H5!47E9=%MFG;S'4QRO'1UFI
MS%Z#ID.I$G)(5&419_O/$JYJVHU=I73")*]8)6M' Y^RNA/W#8T/#X^R!!S<
MZ'*:<O&;G)FK.=]]7R'%)J11Q2Y;CKVU"MX!-4#^;<%<=I\X'!]BOJ#EG/"3
MCQ[71X%O65(H\Y+H3BW$^V=!PG[A.&?K146'DH-"*[V$Z$&P=[:-3/TZ_D](
M=+_\",6H[JYI.M-^8,?7EY&[J.6L@Q2_55HEIYM#64=949&UT-24)PFL$*Q:
MU]J@J27#-X#-PH1R6TNZ<\3@6O"QVH1V0D:V?>FX>M7#4Z3X(IU#<-#$DO#A
M;%MA=^X.[O+?DW?1:R7QXEQ+K!>DV5/":-,8?^J-1HKG]:1F\VX:Z(M=1F^2
MPTFC5'R9[ JK1K6.]>S*\T'^[<_V0+W\*"[:++SZAK*ZGD8"6S.=Y%5U%AWZ
MT*#B&UD\'Y\Y>7BN,=Z%N?\26)O0X^';UJ'-WDTOK5O#V-@B:^B&PBV^ONUG
M_=C,F@_2B0/ DG)ZMQOP3_,$R06^Y/P(GQK_-?Z5#=;]CP(_W@_;ASXU_BT=
MLP_^+:I$6G0VPNMR+<L/A7."Z7P0Z0?7W2@DNC(LWH2-=$;K6#9Y1\%9FMFV
M'*[E@R)(9-(!@$5\S221Q>;Y%5%M:^D/G:T/@/>AA3CK B3=<^>&$ZM*DR-7
M<*.,_WPA&56]*W=LM?\(;%"I;3.V_C G$H&8XU&<L%_**RI&ZN:LI\O<QWHA
MF,N=SEH5Y/N3IW4:\6=O24MI_6^C"-1HD7A?[8$TSF22'UBMDVNJY!N5\WPZ
M5UTLNYL"XX7\A!XK,:6?07+^Z->Z+$Z!&TU&3L+%$I6H0XQP1JHJR]+[\IG;
M_16NJEH[FA@^M?>!,Q_MT0>:/'Z'Z\49D*:3-WW-HJ<*3.*MB])\LI+"G(&-
M[CL8;SGKE'0*?ZN4/JSIPBPH>$[40V$-R&!QN9(O&^I8,<8NT\7$W0;A:\C*
MESV2UU3:'^5O"-NXG"M:7_;E#%@VC.&?F\.>%"H,$,4SPHH90X:"]F1?BE8V
M-U8_50[1R*G6@&5#Q#J(&IW5783E5CNEF/"GNCS"_E1+:T+Q2U5?YSQM_C?/
M)G0G(K\'Q-:-XM%L<RJK6EO38Z.5#<7AD'4=[YZ:.V"6B1WEN<3F&B>J8O,L
M0\O> '1"_;5!.I+3C1_)2N9PVJZ*,*?;R"ELY#_L>LP+?-Y90A?3NWJ\J9K[
M!$L!I\LNOQA"R3D>$3?W:D(P/H'W6_LMXVM7BT/2NU5-1IOD(= V>64+O\'4
M5PZL'\\W:<\=W,%]04K_<8U?(H[-\E?(]2_?*0GG5)I29Y;& :#0[2>GX0'$
M&3:2R>608_43 0BJRA.L:D5 WMAD$.L@0&S.;0'5Z!"CP10!PQ)75]BXB[<=
M]=.!LP3;7M07CS%2R#5TE<VYR-@=,EIY,B[Q:ED\<TX2>+$#V9*Z(OTCKQ%B
MQO=G&4+&]C_Z<BH"'@EOW'UTGNTIKFFH)!+[$Z]&Z]I&KT@Y*/Z*TKT!<!\/
M7Z]84F3B)H35,G9G!H,B5VJ?O^28V72RP05$3PYOP<0).$/FD2TQWP DM3J?
M+G=#+3LLS7NQJ#(^JIOT(A*#5!F,DY:\GF+<--!?\^;C J+:?YF2?!?X4FU'
MJ7J?IOT&8-"W@5J7-=V] =(M/BBK$84<T72E3=?47EO^V^07[M_*!O\H>!,S
M9SBIO1Z#B,(4_F?)_@W0Y9L>(5?(BE=NTRK&N65:6F]#BX+) _U%D=X0/(U^
M^EIK4L3A:X!P=YH9Z*8F0V4WHIM(D+?B^URY&!3H#$X7.UM)T"_M=^"N+RDR
MO]> /C=IB:?=!IV.N)R$U,ZOM_\.FV8]+Q2/4Z085<CJV>,[)7@ILM5=5S'@
M>28^>-\S:);*\.P(JH';%+[-%?VOG5W4?&XN5G3>'YU,)H101?0NCA]X/FXP
MH0-22=#-9&7*@T-D>PCN10-"J(*-(I6T:&N*#G*T7JI-IZL8[W_#1^?56.D=
M6[=$R8D/2J763B,C'<P./N3P\7;S?%,@0FMZC'_F*PC16&B14_RJ+U[Y\N-O
MW@,3^5YNB*Z)53L[1@JI=? 4I>4U4OGU*A%5B$O+07R"G<@IG4CV("O+]9SN
M5:F<Y@I'N<M_NK,&U#55@;C3VB*\,W(H?A5T"A82[VB[P-R%H4C[L ::T3YL
M):YM0/F?=NM8/#OZ9 VNH<Q0I#45(9>?O\TJZ?^J?^'BT\;Q__JO.#P, '1T
MN7W^O03X (%,.W@1GZ1ORDH>_E<<>OYW'*KNH_M[W^7][/X?2:OZ!J U :N<
M;3G)E_:S<"D\*8]L#+5>8B]O[C]%N@-#CH/VY>EBD%B=I%3CE/(F!H/$+[.\
MPC;/>=G..;@SF8J,).8?OF(CO0$2EBLI'E[34.8# %I;HZZ12_\$5NB5SN(8
M\ ;N55U?=$!D3>V:_,SR(=#T2-+TR*1A&8*0YH>4-KA%,?]>?"[=HN<RRY,3
MAG$C\K\P[OJF.X6>*-*S\:N_*&P_-A>WI=$Y5B$,[5IGIX)NWK6^:Q$?FZ<.
MP)7@XJU^KGNW["G[M%$H5\1UN8LT#1"$V;XK7?,?=NFB8%<X;?)0[I*IX)@S
M2A)$S8A)S%_X7?R41FZ9#]F]\+"\0]1IM3WWCRR&&()KF+.,XM/Q'@+/O_T)
M7$P8B8V@425UFV!JBRQ( *5R"_VX7F:;ZI0DV+/(JC77J(J(*U%&JF0JA_M=
M^CLB/[%1;-O@:NA@>*A+D6:-?1\CA1Q;6:(Y1"99 J$'19L^KBQ.&*1P"/I4
MD$P7JZ5/G<ZO"U+8D*9-[@#7@(JQ)"DCSK&LF17KJ,(*D":JAG1TM3W-U&+#
MN9%%D,7,;J<W.UIE!KK$-#2A,2?>M49CLBF_9?>C&=HRV4P$,#G92.;V=BG[
MDD<'93<@VB)RXS()Y1K @V#9@ .EEP-]-A4-<K2]Q41\39CJJ$;;R[E UZ5C
M@W+#59$\_WZS?DVBIQLY@IJK'])W/FW!(N)0B4;A.*\+HZ2RJ8-&X40&=:I+
MU(K8K#]>/; *<-9Y73XIJQMU!0@ M][L9&/>(J6QM,EH!B<DH7Z7<G276Q_A
MNG&_:=F)XRRP_-''.4"Z\5-M(;L$!1T@L"/.N+65@)SQI,%79(G]X\S?!5U+
MEK)")ZN'S4\5E#&&FDQSDOL@T7;\@YP)PNV.6+EM;2*]Y[\H?[)S2GT@LPQ=
M$':S1 03O0U$7RR]=WGLD:\MC[@K00':JGC?A7*F6],6M,QXTMP7RD+U\(>M
MZ'$7=_>U?X5&YB\XSPK4G=^.0<0N2!IZZTS\E+#@Q.?4);;$Q:6$R*XR.IX7
MQZ\'P2:BYTN80<T3!"//[-+E133C::;:H@88_6=DC:N$A#RP+^WVYF8QAK)4
M6J,6%:MPHAARF3R$#"J.DERCB,5?-##;!+S6.%H<2II^?:L,)J#X@+FK>2B>
MN6WK/UFC?YB0E^T]VJJ<NR_R)5QABF]X85RA)S+ZC(99H>"/TUEC ::DB\-=
MS=9)=[MZZI@J_&/,=IHK(14EK*O:MH$!6KZ,CR#<9G?(KR5I[L-8%5#G*!!P
M>R+Y'ML9^=+Z2A86\NT1D^>J_)CH]_II\Y7./!MTOV)YLMC04+=#]VH$*S1)
MO^W=B0)B83F3QTM,EV5IG';P[L;CTA=WXKE][F8G-EF98D0NS<&K)M"6PIZ&
M*MRFE,)=MMB:<2<K='?GN((1<$N?2EY:A1].-I_]*<Q"<:+3=!VL6CFZ^$7$
MMK X3Y8\HK(6LF)@W![6#WUBR?I,SD(14V+QOG$@L3@6+."*<CM:;]PNDE=^
M'[_LP^'GY>'#<0<>G1-8&TQY)>\@:X;^A0I_V6J&O ',G=Y+Y%DPJJE.ALV/
M-+UPG!9*A4]* '" _  ,(.U? /G+4@P 1T6H.B]-=!JTB<^;C6F_)&L<,; 4
M]&K#I$3?X9ANPK@?G@L&:U$Q%([0SGUTU:?['F9Z+9EEMR]FD.T,%#!\&-]0
MZ*!.:*L@!<NG\"$@80E>#M,&+)\CE,!82>L;UE'XCVDOG;](:X/5D+4T.,<(
M:5.2]&(#^>@HL--J^JS=VJL<A_-HOM46CZG]1GC6]M0<T50Y4$4CT!OJVP:)
MC@I@R7JYB#:=ZEE)Q8M*HU(<+.";!WFTF.J?\[O;=89K9_'?6%&%/>Y[N7<;
MKY$$-+5L\#M@BZCKCN"I'W%64_)E^E_UM*-]<[S24-C.9("3*7\A%6(7N.@D
M.QSROUM&_2R3@O=+Y9>,/_:A2.+XUZ,W /TU:/%WP&?#A*_Y1J$(0^VBE^*9
M-#$:P03;\K_S44S&_#_^NX##NO@.(_<KA 1%RKX#"PE"G([(WM$36F4I3K))
M5Y1_P%Q7UL3MQ((;PWD#V :D!35OX!O<VR:7Z3W,8FH@D 8UH=H=HYP2!_\U
M:J6M=Q)9=,'7H;K)H/5CHBNTO%K0!]Y:DP<AAA# $LGJW!=AJAZ+/PE6USU^
M&HNI^/%JF%^[25%>+=93F1>.S<LE YG:$G:_-:<8EF^)NN]#FKN$(^.M:\V)
M]9$^2CE(GHS;2US#/\Y@^322O@'L)@26#0FN.1-M.\VI/P_'X?5J5._CR ((
MKIB;H>4$WB P-9"D*GFTXOBX+WDVU-K3FDY?7[F/%/L<BS)<$H\&GKR12(\3
MK1B?.C]1K#U@V?#X^WWB."-_M:S.PFD[8X/?@PN!DFL>OC,/I@#5']O"V_E]
M=]?D4[8*9,.9?GF,<EKW'AK1IY^O?ZO2HYDPM'_XY_%I'ASZQJ+B @(2+W@-
M21L=?U3,3G5P.+;*)9+*3VFY@F6OJ[55D"W5D!%=W,ZGH"GXGR9;;-SV3VC-
M41>UM)85B,;$B)G5]"GC3>=)&<N*0@'W;!!])Y@1,9O37A0"T=S[5\? USG_
MH9<1GRT_\%]@VY:1\4:G=S3K8>D8EKG\F 3<J!=!C[.SR&<F[93>P\O4,QJK
M\MJA976I?BF9SRE:DL189\5,2&#!>]]:QQK"$81UE5?[^*I@7_B;H:7ISA6Y
MQDVH#^=0./F_E%2M(>P?)3UO?<1>R0G2AE=-+5^'!.GK!&*X5]C_U/.%MW3'
M]:OD<J?>4I":L1>PS5X)\-^'YOG(6X>9=5VE4R*&%!>&]0P<RTO_TK@WS7HT
ML9U36NY>.Y5K:;=8>0-$CMK/)A\HUE;D5L%J.W$=[TS>D[ZN5ET->HX82WY*
MX-;+:D"Q%TG@!C)$F0*9>YO<:\N),O)<O2\:MQQ;G>P"R$ABVQZ,_,N'Y*])
MT84F0;J'U7G9=VWWRKE!ZC^ N&I 7+_B6)2"FUWD45J;G],-O[X&(9)5K@4$
M5-P=R!FRB/!8T\=J]6Y_'6_^[C_3(JLW7$Y=$+FJ++-O&Z/<[BUC.15MT;55
MB[.Y@1R*99V>4]9S8+DO\CJ>A'&DXKG6SF&7_O2D[3"LP59=*9_V'$HJ!:>L
MK,AX2PNGCM>T^CJT"827K+PGOY@6%M:+S*!*K[2K8*:=(QE0QAV?^]22N:<1
M'+$I-?HO)36ZTX<,A1V7,2)-9JGYY]:I$/JH.!XB)+"P0T/<@6*U--J9EX6Q
MX,#P1,G%9:<S-O;UWAWO%_PI>DS\Q,%YKG?Z.R-SLD"2-OBG?;V:]5S5!=BP
M0V=&5T=[9P8,:&5' K4 O@$PC3'6[AZ\<QI=UJ!O@+J6,$K5>CQ&AD.)/WMK
MP1FW_^=WYLJ?S@A8/,RO!-$V2+4??C2SIGHM@+<^UXV*59Q(#_&JP(U0)UV.
M%J1& 2()6C57C:1]'*B4OD$TZJ[$#Y F76F0BH73(=:=*\;0[/CWADPS(]0"
MF>)BE"#*^/!W\-B+ZO=($LZ_ZJHJ:DO"2X4;#>3\/]^RHD&E/[06Y@FC2;X.
MVT[ 7Y-(<M5K5 WSY3[Z9#L*C.Y%R>NU,JL76EY2:#'L(LU_@_$LX5Q?-$.V
M&%3Y%K!%ISE2M-HE-4+_ZH?6A O:/QCB4>90430)9S3RLPFI.U5#DHI&"CHL
M[3526!*_&1$H^G^N%G7DC;T[ZJ<1V;P_6@7M3030GQP:;G036PXM58Q F27%
M<_RI5H)ZCS ,8IQ:$JZTFI"PVO2Q M.L=%$Q;^P6H+.;+_5=3%\*)B]8H_\^
M?;4]+!B6E8\LS?K8YLM F&7_R;[ U5%'QW4@P@U:2:Z]PG^D[]2R<!DE_8E=
M\I9X#/"2^D?E^MQ&Q*5NS"FD9YQ-3[WH*ZVB?*88<;E9X #NC/R9] QNP7P%
M;(MO$7CW,%7?=,7;4 \;.^&:5LXIEQJZ(86*]+AJZW>S,"L18^#+U[6\C*=#
M+I=%;_L5Q+"(R\37L%57),6Z@49IYU]VQA2IFE:KK$/_$??)R"_F(S SA[OW
MA)B40G4U-1=.B9 D,6Z FV'H?'O5VJ,'7JTZ1N*68Y!<6NG$''-*&0)0*MR$
MSA 7RZ6KLL,=AK)UR\8"$?'"$S.(QA.?F$E9TKRR:3=JG>9J+A8OZK"K2O>8
M 8N,"PPP/_TUX];"B-L:"XY8:_O!9V,.U><*L%#4E4SK[:I3L[CZHN.$&?'U
M*RB/U:^;U1ODJ:&NO? H^YPRE7&]/M*X%<.@\_I;[0/W_,-T5HC"/CD?*?66
MSTO]JN,=#.2P:D(B("428*%- _[E&H^0^@8 #&  ^+QPV+K;[S'F:XU*UJ:L
M7--..M!5A"H,;,#"49R_Z^L4OQ&&*BH0H;>3[\,F2$3[:1"@#4H?R=C?E4[Z
M4V2>DMY5'WFOG$<>3K<I.7DH?HR)7?#G)#2_XB/[,'WET6E5!./I&J60UL@4
M;2<SERB0"?8<C")HO@VE93@96?%TEV=%$5'=Z($JC:FNUKXD9DBWW">NZT3T
MBO2]KDL#[/VU9)\?GI\^ #9>HMM"?[EXGQM5A4E^J1BWLD>N^_B%6\1SAN%V
M'H]1O*$HXN+>N''U#5!@N"HGIECTD@(#WHJ^'[DX=]B0> ,0_MJDY_U=_@\>
MHV)[P&4W<)5T#X^7K^1-H<Y!DW6++OYK/C$T"4OVRIWR@DVIJ7-L<X$)4FXB
MNR<5G]5SA#;U#+/;FUM;^?EE:I9*F@6YL0^#\/PP)P]#K4>:?RW+CV,'/VR^
M[^$:_2F!6/F>G+DT0A@SIEM8%Y_U$4)!<^>BK\Q/#!\TW5%(D($N*32@#/JB
M-LK]2$,Z.S?:NS5 K,1)L%!&I%>R\HG'?7/16>^! .DKB-GPA7JWQX[2'W<V
M0R2@L<[=$ZPG5W+M#\=_B84O*J+/*)7R3,GC'XHLBEO5,_%[;52+B.NBM4YK
M!Q3KSRJUF/-12&;>^DNM'2W<B98<RNOH4T!R]4O7P8-&"LK/$.YIU14LCD?_
MT(N7^Z.X<B6#(+HF[?X1@JK R<B38#/,.D]"YU_G4+93)3;$[4TBHOIY>WVW
M!:[9G>.2F!@QU$PWW@6I!NP N\RQ@ _KUV=7 ^G\;/5+ALKM\ ,1[?]D*\*$
MVDOJ,4DW+.'WCX$/:^<!-]6VBXMXDM0:F#OF."7-CWS^$8O&P0$<OGMW?9-[
M?Y,63.RS*M:^@0OUJ*VYYRWLC-,:B#[1T(X0UKU3X@*XG[]T)J0X9\'^Y.H0
M:JO9HFP;O>*3VUR1,>R#=%[;7.XZ/ZU3MR1TYNR;$9;MUC,][-.$[H2K(*J8
MA@3ZKN$94J./-'\9AOKG9'\#@7VO\+$U9H^.*5G5F9F+/]2Z38M$#U&U5R0/
M.HW)Z4%2VP?<4CP"A&_]Y@ZE>O/IBBR/Q;?,T!+[$>1SW.'6WP#V+81^WFS+
MUF 2II8'>$<ZLW)N#L!DR.P$^9(X"1G#-\JP'9[5ZM:D:+;0\7W.549VZNKA
M166@&E:2"3WXH]3?L6(DN0[!G3#2@/2::K9:<X> 3D\P[I#1>['UQT03FBI3
M2*OHB&T'".;0G;X)]05^P+?W"Y<<S[(BI>":V9"]2NDXWE7(]IQ?JL"?6VQC
M)07_44.,3F<-Y%9 ;_]"]_@$0U,:[6JD(2!  +X2D>?5U;\!!#3X6KO)=R"%
M12Y,C$CQ2?W*HBA:&B$BST^$+:J3SU5\6!HN+YWR^G*3Y>RFSH],+&:J#U!V
M]AJ_/Y6&N@OR;'P922@$5%/3$%LB<N62RW05ZD\-I?N$ -UKI()[]J#M6AR]
M[<.$G^3O;6V:*AH2-4EP:J^+V 7A>G-B[:=RU@RE='YFQ;D[&0_)L[&N>1$>
M)'1S#[ ZXQ2"6M(E,-)16+D913B1UJTNSX4)M@ME;5UVS 86_+'W)9_[R*Q$
M>,Y$CNJ%I6E] MC6K8E_( M21DC5E([.IB92"U6Q[S^\ =J?^ELJJ601=#RL
M1:H6]$=IKJ828Z;F,D3QF,5^^]86JQ9K3O4AZ,<["%YM\:]<),NCU=0[F_G(
MN!(^#:MB!0DF9HX-@$+N.OWV(3$UT,* 7!,VO7,\K?PK_5"R8M=%9380_!_D
MJ:+U[NSZ\KU"2$ G'3 Q[EM]FE0V"RB2[Z/MG[*&.IWYV>+XP=9(2]KLS6<8
M]_HG%ZL-THF UJ+/OAV+A"]5Q;B/R_FO0^=(@E?K0)>FBX:?A<^<O[[3P,WJ
MR+J&/OXIK24O/7=^@.9L*/$AVOCM!_>[CK$1<!.SLN(,KM7"CV KR?)]AN>+
M'?]-&.3BXJ1W5<H!/6^ .)7OQD>Y__X/'R__X>-%TC]\G,1Y83'_AX\2B3MB
M.$6<CS@.1W.6M?Q&.6&=;L(Z(K\X$-TUX>V?JT[1%&-UC;22"71JQCYC9#(M
ME*<KH2NR]WE?MJ,7N;3U\%^PA_V58WE,>=#RRZ,Z'2ATUCHX/,RYF[!6>G"*
MKY9FA4JJ<A9=CH:@QMH+EN%3K[74#)W^RH9X*$LJ)PRH[QU__9XS!>9$BS08
M1@*7TJ6FZ4C1I=74%>BE97^V9?^X*6YZGCW"M5DQ?L%:LP#"JTF^TB;LO=X[
M5-6?:'#?8K["F+MP0-/Y*TOFS$%?TE)* );^D8O*6-BD)NBI _MP*,L)KL6O
MXS]@5TFJ[%WMGDQY^6G R<00 8>K^7N&.T])E1LW1(OF6#Y O!53X6BCEHAV
M;T=2,;%Y2C:X-UAY@6M*[ T@11S KKNF86M7>N+R;FZSPYQ8+U%J4LQAEG#J
M(.]3:M7XA&S\R(0A4Y;B9U$TO75/%0DDJ*W92ZP5_Z_4=RY3-:KMBDOK!GUD
M'>/G%8S$<JPC4,N4Q]N$SC28LT_KQVDG- V%M>]L,_*$XK.2D3!$H:G0]<X(
M^^4:3:=#=SV1\-KX14OFPV*P0AQ+$ZYOCHZ_CQ5"D>OHTCZ%9V=#4\^WO@!'
M\,"(4JC'"4OO\["_A\.F@#'XV,2)Y.O2LE9)FUXYS<P\6@^-^M6Q64A*SMI-
MGJW/=[B;K-0^I\%*KF-DFNL:2FP'4[WW2B^&_P!7_/\#KM>_@/OH^N@IXN+[
M,F0K@GF*!'-#>U>NJ/'KX_7>]3$K6R<,TS7_R]3YQEA*LJ6RBW;JJ.K)39D-
M-Z_6S.D_I\Q8VC> 1M'J+3\T=S*)NK5!4E.1.?$Z!:8*F6'O? /PG5=\,-HZ
MOR9&34_^'>Q5&/N<)I]_,O(J\AQ$YD2T85BFN7"AN.:!+BKRN7$>V@&<FY\?
MX-[\=)7&O,;P'456:80$W\:."N1RN-=-D5]7 :U8I-T>E7\O#P91DBXS\,*Q
M!57>M;F'DYWZSSP/4-MI&U4ARVF1H].X?B&$:U9&8;4/"A/*^K\9@G <VEL)
MD(3'DNU#"D<6P9+O\2K\IP0'?1.88,:H6VM;0_-F^6+&=-^RYUV)__! 0?@P
M:<Q[;#,*5 :!T]-+:JDTH@@GZ]N8Z2U/WE^-4"K],IUBG3_7R&D@W\#PLK?@
MS&]60.6VE<_0F[B([&%P3/=>:@GLL>\:\E9ZJ.>(LDQ06*3"3M.Q<9XM([XG
MIRG,6PHR;P_0=$4CWXH5W W#*6)+KUABY.)U?()?1 OM:ISLK>(LK=%!.JXX
M+WJY"&Q8<1*K@,98V)$Z7'ZZ(0_URX6#YG/Z,+@[7_SN+#V'5K\?#N6][O:4
M*;ZT=[-\T+).S(>/0X*(8W>48LN3^AUS=[:TE<%B*];3G.DSQ\P(Y]1W[&US
M<TGB(L%V*[@3>6[X%VW"+X.1U>3"OEUIVD;SAT9\JBM(JTN:3N1#5[*1'24'
M>,O+XK% 6M^AD,*D!K7 .*['F^GN8 I'TF;2Z49FA[M<;?RL+*:*BD9"O]S!
M*FVN924Q1;HO #\<[QD4>H&G /66@)A.P]$B=YFVB$NL]X*/"91,,.3ILC](
MG##TB8]+Y^L]K"T"^3AAWW]^RY/#^!P!10?Q.I/I+NU 8)55K59M7>"%'1\"
MU!KF6/L*8 Y&L3D;@2J1/GD$G4B?] CURBNR#EJA<6-GW1;_;2Y.P^KX3WV]
M8%D]/^Q#\;'<>A?/M?M?REODO\]$?T$==V9GD@>8:!V9M$4DG[_!8U$$L+3X
MN-@M63*WLLE0LVK#XZ4V\2K,J*.&X;!Y*_25IURX\]2T4O?I*C*B%JT99V3<
MO41]FAO#*"=MY+$N-UFL_5NV U-1E3/:FB8Y$IJVX;]@_K;]C5J6D(I/S0&<
M]K"^_X3*V'O<[X4Y>%(]#?J'.!&&AA'#2\7:O(2H^""1(6V6-86C4:T%>5;?
ME5+0D 5VUQ#Q_F#_(-6DT1N +'Y.WPF[JI&)^5I4$>X0#]6>9JD)YI_ZB+OR
MV!JG%+25Y4S;VI2$%+O$C**O(IF<B4UH_B#!)@TN)2,:5XT+8E <O6@ZJK*:
MD=\X1^\?UT<6VA3D=I5[&KUE>1_]QR$ 'CAM-+D=UH: ]&"9^%RAJHE'/@GS
M^<!"EO C-M#CMYRH1!*<*:?;U;$I)%O8'HKJ_7,-%H ='J7DUQ,UTZ?,)@D
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MBIDY8G6&EP2$,7\_>X?X.N;LR%'U!ECO9+)X V1]FW@#D,,5.$7=-CHW"YM
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M;3K_23D^3?/[CP(TO^O%^HH<ANK(TF4^]9Z0T[J05+K0!NNM\>GI<U$77S.
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M;J<X;1#'G]XT  A!5M$<;O7 TJYJS#!R5%&^,+OE^S2(C"E@G2YR&K]P#!%
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M+Y3JUH9MW;'"5;\3D8?)KN#QB"DRB8&R#_Q-W(>FB$P5:M=,6&]/OE3B?3Y
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M[P<MQ9G)-KN8&0Z]M$]U]5?@-+)2DM%OS5!2^@4F#P+XUFVG;/4I!P)S^HB
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MI&^T-DJT;.8I @.D-%1TAD5ST^!52!];08$X:3'V[$#;(26-^TCN$$'90++
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M2O5.X\1VW6K %8HR(I?&G($127ZBJI;,YAG,O0X%S-,U<$=\FLD1:'';">H
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MM<^9]%0#4EG?:V>&V*'E[^RFTW2PWY$5=BKES-+-OG$/H\.9^VO[X&7B ]$
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M1WQFT0^:)>DCIP2W7^?]N3,8^4/Y8<X(=MHQD#3+BMSKY%XGZZ^'OLQ<9\S
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M+O?OLB^/48P.A9G/?JH"KLY**[!&6WU4D+I9ET#RO/^;'?@E5?C.1L;3?T;
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M2S*X47/CK$;U"D:S 9TQ,H,DJLBKO;FEZR(B]WL-:-!G=X&]F%,'(N#@-R2
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M$ "J;<CEC%AENB.1K4?Z$-T1A4V[@:LA_J).1/Z)@_0-U^V"AU>S0'.04X-
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MVVQY_5';AC7-8_#I)V(.+NPVOI6E)MVTP26ZRG=1#Q\KDS;@76ANT@W.M*3
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M%"T?@&)5R*(3"UV!K_/ZN^/_EO]XL0B<0*(= -!B3A'!G) ^J\T#9R^4;P,
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MF@3$\6Z>]&B#HD8@7X)RRPO6H6T  .!Y7V4L#I ,G\-1U6M&.:];++V&5CV
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MZ;\#<.5%A)+:4&<5>VV_G8>ZNT*(55T>#]!7]?9#X2_LM0:'=[M8884,2=&
M>[$?:OU0AM_WYA97E0]X3%1/C$PG]\-E!T02]#FJK1V]!+EK:DI\WI0"9019
M@&;$NZQ9-5$OLHZD3;$5H]QV@8-NO;AOSE,*: >K>OY49BA_^DZM2OKX)]^H
MK)VJA07TYPJ$W]I%AFNL,V)LV%"O/I2MKJ5>WYK^;B(LA"M:9EA$ %;\;&9F
MCQ=;9M9':^O%4!@=440=?_[\B+U?'RAH9D>RONZ$4AKLVD.P5<N4)"T/?%E+
M1/XQ9-6/V956N#9>GA!2GZ@ZN\]_J+0=+&+37*%)$J#"JO.)5>[NNO?ZR+RI
M3_6,Z.KL_NN"H#DD _)D1*3H$4NY]3S439Z.-4*IOU@]@>81=%(0"[)4^7NB
M49.+@X:IWB<%QG:7$9VC,Y<B]R@*"*#P5M>BR 6% ]4\$"^'.BWO09!.YQMN
M&KJ)>BIT:9.^49^)<0H+;TM3BR#A\42'PA9C?%:>WQ/=H^OE^9,J%_ZCWJ@Z
M%*F +>Z>XWAM[?RS8,V".3EN\ESC3U],\%4H.3:]'XA#7P,]<#LO!EU2-V ^
M3!8?]?/K<?#6!2SP62+S>/K$.'*^:&BI=1+&3Y+#;";>5P)FT'QG1IXU[0A5
MFO3GY :OV%X&[P(B5?78GBF%7UU20[P@#3[W>7WL.>J&1AR:D^RG.$UJ6^L:
M8M_#G?&M0F7!-!7WQ@)RIG,(?K6"9FO$!VPO*L#]J*9%5Y]O[F><:LTVQC:5
MSQ_L.#LJ\@MT\XO%;W6=5,KG;GIJ3I;8 :,J>M8:]-OV:GH9PDO<3P-D'N>I
M%'.]BK#*]0I4\#HA0B</-_.--*?/@> 0LS]Z>_PA+MS(=Z/Z0AP]>?&=\1$)
MV5G]4%7#.-#%%"C6Z(#L@L6$V?O,5\O<7?GC'JQT(SRW:[I/-3@4MS-DM?]]
MW+K"@R7FN3FW<(;(;':_^CK44P;,\;K<SP&"WQ%AA42DSAHLI>09-&Q&G*&M
M51L<Z=/IUXB&F,LAVI:*^80QF<;/IDV6EZ6TI)SW\F"\7]B!TFR36$XL#"IH
M\B@_O 'L4K96NT_]1C9>EN[4,>1U[(4*I5SVD;)WB\34N$Y4#O"4.!59O)+3
MO)=Z!_*QW-X^NWJ!)L92XQU#L3".JHX!7@(-7JQR?8D<!M5Z.I H.E;1/,])
M4_L9+/!TW$#Q)2&+K3R)A)>N!I'<7P7TORQA+AC#:_DYA,?%1P@/N+1!:*"B
M0C_#!3P1!=X;'"9C4#2*MNC4E"J6E!7EUM",??7KGMQJ?<$.O')?$)4P+8Q9
MY'61VHQX7*]+"+469%+_ZUUF7]%2>O7&OOI(*M7^OD#]]%1J1/C4U%&@DQ,)
MLB7Z'<XR%[=<#+'"HS/"\#];1Q>X;@+6V*[4ZBJM:#'->H:",8-E='1TA0DY
M8Q?)QVIN$&P1>K\D_ZL%5"- \Z$QP1ZJ#85*0'QQSUZPRAL[M/FS*CNN$E<6
M8ZWG=0RZWA3!!KCAT$!?+3; (ZAV]VCGD!V.INHX=SX^BM0@8GZ8N8,0+FK^
M\'H59P[I]UK/_9[^:4&+=3%+G5227>C::K#]4*U@/%=^DE:+R8,YX'ON)I+T
M2PWHEH>BZ="6TXKTDI5X\3+3-\QRU97F./REYTJ4X6+CCEGLOFP=:J!!)Y5D
MSDRKA<R10M,!J;TE*1"R%%@4\*O6[>G;:"$2]%&)\.M7#9 ED2B)Z=3U6J%]
M@FFVF2?R(>71QA$BUP8VN,9YPH\^?E)37D5G4$4]:BI=\6&:\Q"V@K^Q27BU
MXHDA,5-=GM[>RBYH:OK*.U5+E9.I7?=RJWH.X;/.T%ZM7)[H=TGIH?)ZZCQD
MT-L_O4P$;,AJ_>=$6T^MZ:O2]!7SZX_[Z1WGY1/D:5^K!0S/^L=\/^?U3J[P
M!PE5,ZB2".T-=3]3IN=5&:)]3Q__M/&.I% IZ@>1D75Y)N+LN:$7$1__<%:N
MVSOE,,(\G<]Z?UD?BDJV(RT'T0ZL+FU;8EL>8,MG=LX]52!EDA;PJ_8*XZQ\
M5YQ@+2&)TCN\F:+:3)*N-P#P+\BKC!0$7G.Q#VF8[SH&:%+E"4[6_M('3RC.
M5XI2XYE06TF/MV6ET<S]GDS$_^Y57*S50B=PVJ,F-J5D0W>)BZ.:38Y>\D6:
M@ X'[-/9HV?KHK*ZMB@'\5T!(Z\R-23M? E5/Y5A8Z1M;4N]K4[N&Y<W#XX>
M/K+I&B#'&R0 <<VS#ET5>[O4NY=W0]:'0I"4VC-H![9F?T9-$_=\'O' OM$)
ML^W(^44G/#M?/N+*/GT5L\(0$<=O?FHR=<V%PANMRV,[3G.&+$MND1L:X3%T
M]XQ(YR>#38A5GJE_N#^>=P/P@SCR4QZE75>G#S@C4+2UZQH)ZW*O.=8B%\3+
M9_4-2E^&TRG(;*A',Y?82O.>.1]OV$_= &@A(:E$43 T5;FOB9CN:M4L.%4Q
ML*\O/B_/=/:KC0U7GX(M3<%'38)<S\DG*6S4\XKH?PYT_QF<JVP[GJ% M5\@
MKG 6B879W*?L2I[TZ#@E#RW)1Y3$DDFKGUZGB"V4TT2G*%CO:SXXZ*-M70^+
MFE<,."W>I%NSG7DA153;7]4#DJR8M(VN+:(LH/&BEIRB1]L.49B7(P?2^/OL
M]]0.[3]R2UI-$W(,5IY_;W'+E>Z*;,^][L]UY_<!/C/ZDS7<LGC];9*:8K,.
MMV>!8KV:<L8+5O*5<:1':W4M@+%GG+:/UU7EPX',R-:C'W]YXF*0IS$8@K93
MBX:8MY^#/O5N?TJSLL(G_.ZXN8&&>57;K(F>^2>ZM=14R[-S:%*AEBG<W,D>
MRZGS9)K@6K%:IX<$.10)Z]X HA-^S3R< GU!'U)#JZ85J[3Q8P3=/JU7Q82D
MOF!I.S Y>.-G(2KTP'8F</=2=&S&Q<7 <]133[SVX%GG#< IWI]U:R52Q E>
M\AG1>&1JU'(RM>U!06CFSB?A=>)^ U PVBP=ETOM^G-B@V,-J[WGM+.(YQU;
M6P'I?W(18G>UJ.M.2NUAS]']*!5B:_ZFD=4WPCE%A!8W)RLEF=7FL^>L1 0Y
M2,=/X@QEA^0H$XS\:;4>DB,=IEX2W%N3\M[F1S3S \:";X;H[J-U>"/ZI+?Y
M:]V**4?)4T+106WW0_V?4F=?0AAT\1C)J=;):2Z.N:^R=SC[^FX G"-K;/65
MK3YMW,^O<V9\/A2[&V\Z\1U.F2P7P/OCB<RL<PJL"W,^]^J^,'_W+8@&S30G
M\( .Z>'U0NYG'\$F%MVT.6A8B:?"=<SNZ%VX4:'YAO5%,YH6UI%#?A;1(!W[
M8EN>^1^5!C6)>"KO=Y?,V+FS\$F?DVQNK)]J'4(VVFL$QL <@VA:ZM##I;4%
M-@D-)T4MZ\,O:G7OI$_#U"WN=YE-]QX?BD;#/9ZNY7_3\\P E7=.\&W^B;,9
MUQMK*&4QK#RS7^=H]=\CT__85$_V+5E+U7I%]H21%1%APF'(&$ZU)^3H,DI[
M _CZU,W!XI3)U-<\H_QRPV^_T,F'S4DZ-M72A/LY7[ZU;6400UIAT<;3FL_D
MA3ZD>%V&\)GFV>MAA+U^>V$"<RVYZWD,JTU!F)X-;4UAZ5L--^@- *DXC!!@
M 1O\;"Z]CH<FH'[T<*(RZ[EQ@E:Y5'E#"@G>UY2RLL%SF08Q^7LB&X>&Y_>K
M_K1:SSSW6_FT.%&]49?^F@!:V#=*:W+F:W_B2J@NJLE=$BN3VQMZ5^CN 'YK
MOT]>;3NW$9!^E-V^VAJ:*RU3,DHH0W]7Y2&QX%^M#\7VL<@&;O<T=)NW]\ G
M+V6J2O[8%(.Z5Y]4.S7U0Y9-CK#O01>.J4KNG_N91_E-+O56[5#Q =$0W4F_
M*/DV[AL ^T&CW8<A6,?J2O^D6M$.]R3O^48>2>QX85[*(;U=8"?'R%YK^!EP
M>>R#376:Y9>NNL%2&N@CFSG["GW-.RARID'OR*]M2SZ?*^:OURY,7:.<$0O#
MG'H-H?JWI=9JE2[)*NI-=$^9KU1V]=V%!A0)#Y9,429&SXO_29?-W!DZTDOS
M"-J)W[V/I5*];V32_<OX[KY12PMZ\X.%Z=!O)$HV"*1UT!K"GS8\QS7X(B_8
M<T'\JRZQ9^UEDU41JBP+R%<J6[A->=J9QN^C[^#;57]J?7*XWRY9MHUSN4@H
M&*4\/@F/*.X&BE'!=A2T58I2SD<KSH8%+G9]D8M>E,E-F_QB#BO'GKN<AZ5P
M+>G0DL*[Q9\#$NGHV615W_!67])!4T_-5TX7NIIKCXF<2[_CTS[76DO.>9PO
M_:*L2N/%YWENV:032LFV?1<QA,>9U1I!&5NS9<LW7VO&&OEEVZ0<IB1T^M-U
M*:/)#^LJPN.B/VNQJ89W;PN#V'V2+&J=/ /2GVE>? (\2"0(+^K?>\FHS "D
M5+ OW6 ;;SG6J):*S567V7MNO$0O0SN8&R&:C]SCOVZ22O<T-77>)94G?(C+
M+&TU2,#ZH+SW)*$=Z3""?L**AC3HHU+COWXO'11P9M?63C@]Y+4$SVF\U<V5
M8=4EQ_WK2S'>!%5R>_+B!W?4YKGJ58YCLR4,3>UDX1X%WVT3=C=QU!%) VEQ
M9E4@O5YT0 /2$^2M\BWSX]\K%79G1]]QM76 "H0I@@;<O2R_DBI&CU;+A;[T
M3&2$*0)^AG.S=7D?MZ-L4;B=53XA*+\AU%H]HMNM35_>EGTZX4#6A;QE4:>&
M_9"U-U/NFQHIL3E?#AZZ$0N\MA"H>-=0B"PV*+7;N*C9#W7MZH;R.E97^\?&
M*G=_UO*1K^;Q1:M7P(+&1&R^#9%$H1BN:_=)H4>:JWLBM(QUFKJ/@NDLQFT_
MS14J6_\0D_UULN_@]V,&W'9X-=(DWPC>LGS-H=]-@C#4+ZV)N3,P*9742V=)
M13&I&;)KYYZB1];O!VWE;A^2O3"S+['XA7S.45G'S^ JG.CTRW1[/1/>$FU.
MREM6$LE8D&MI<4>J[&L(P "*$IQ!+8>9SF=;OD--S3VM>'1I=F_KWL0OL_%O
M.OJ[!=S@*;%^GT!3T<D:#P&RA/4%Y$8(TW?VA-6D'(LG-  BA4 )>$'&)Q\V
M+V-(<L:1Z'SC4%YC!<+%U9[=(-72T=R*M6BSBHT$[ $M9%T/H2DFW'X1KK1D
M_]HVRGM=L2%_]K1W=#2-=$4O""=6/>O%)SZ2PU*V,>J6?2XP.J-Z84$7 =(?
M< +CS#0$L.3$6.'+/H:RTI%&UO!.X5A'%J5>+![7.^UG9 @WBU9YIU8+1!)<
M'H'5\FUMC9T;\23974ECN-3E%7D9Y?I>)&I.77U& 4^K/:LK$'C*(ESU$:_&
MZ0LCWA>E\-Q5<MK)7$1VHEZ_/ARIXY]J3MBJUU-ZO3_3Z>(#OI>EIRJ9K:M:
M:!VH0,T9+GXTM1TYMMB^&PMQ\IZ&["O_3F/15TS&;"U5"5+7Q-\  C8CBW>W
M\M%>U#VGVF,?$BJ.4PG1LHT(\ U ]X2HFS3_FW((+2/,LS8_FTTA='S"C1CB
M'B6R^[W\VOYZHT%GSA-10D V">IP6"Z\[(\[, .^LR%A4V$5E56@NMQ&#95A
M](WZ(?8J)U/HDGEAQ48G-T3Y7<7@7GG]\ "6*D/=*N*B#Y;9H:*2^H.%Q4[.
MG**9" ]\5V2]]:/*KS$+NS+=$VP)YC3_UL&%7%=O@%(0R!%GU&I[E1QG76I-
M77)9IDX9:&I1H6OM9^^0Y+NO(5D%LG"!JGIL%R=ZG=46:VUO.?OT2COQ">>!
M'EY.J%ZU<AQM?-5?KVOT4M^(T3&VR19 =X4IYR434BBME_W<VY^H3.?\5"T&
MVBHLU^1Y]T0T)]6=H&M X*#M>4,J<UWI@@CJB:1B>[[@6L^4-SXU6QTCAA@@
MFLW+[AIQU9&';%9T 7O6/^D/G>_Y"]@MH2E5.Q&EGLBB*6-C$JPQ_M982^?D
MU3W=QC.4=W/H%O\-X.'HL<[/J+Q :T?N_"^_HMXX"YTM[B3576/@T*F?VPNK
M'0,JTF\#K-;?]%<B-.G_S-:\S=<L[!R'X6' K<^0Z.:+;U<Q\_K*^6AME[VK
M!,M[,[LH)&+6>T[H,]5DA^2K(%A*I [#0W:[B+S(1"UUBWL/PQ!#A_TCEO61
MML&$\#!-+U,MDI3WK,\_D]RCKB[+O.[V&UIK#9R+"!B[ ;@C. HBV1:)GN_O
M?8SGL_<HXZ./*>;0#,3[K")!3I?#=W4EY')[6'+(KSQE)@W+WZ<)GL!W287L
MZL8Z5@\UBE22T_KH?HR/C@T1#8:P\KP"2X#D23\Z*UN?A0';P5"F=/*9^6:<
M&*GW$I&$>CQW%0(SH-M4F-W7COQ46J>H=83K?!U:\,.%%TWH]N'"@N3S:L3$
M&UTS&5:%"@(%H@>E$IM#'ALZ[H:2CC> GUY4@>4"0S9N"Q1EVA54L<^,:#I>
M>%TV3#SJ4' G[P3D9O2=B8E2/7?3[SFE_Z=]7*$'XK'K[!ZX]8AH<;9@>J#M
M^G%S(=F.K]2ZJ+BR-A5_.0GON7=Q*0OH?;YM?AW513;&/X/][,1B$.F:2O;Z
M $T1V;6O5^)FYID"^XIHM:204([QE'YYQ!Y7S2(%3>+E#GA-,9/HVA;P0;/Z
MLYDDZWPU[\>)WAS-*86I3(]'4&P3I;+?8#!2-W\]XV5J&XF:W3=9Y*1/&+4,
M*<L)7\ V4'^^<;-":9\.9JI.3#=H+_[) 'YK\T8OMSLL>Z &D3YT;-J'N,5T
M\N'(\^U!L%3-7CW_KJ*(XU3GHZB',4SO?I.PA]<W18NBAHXI@E:>==#*9<\2
MU]B7W3DPYX7%L+TG$#,MAWA;\NRU3 ^C#= @9.VJ8F4WA;RMB#9A20#F.C3A
MZSSNG;@MQAJ:L2]N,L)1V3ZM-X#4!!^/ N!I\9X QM1-'RKP?F^W$?[2:7<:
M1K)<HWI=F<V[V+HQO7S@OU[Z$AV'>V%^#?KCG_WDV9E[!!6[]\DU?YJ0F[:F
MDX)6PTYNLU%C2UU;EV1]&L+NLGR;&,O?@2>G[:HGU)-+U%^7SINN@'XIO-N3
M"(65+)?_;$G=+9X;6A[NM&,1^=.SP/M-*2:;#R\?"^=<\$RF,T=TV,!5]5Y$
M;=E:$W@J%A]]^F9^ 2'!K!6GLIF@8?/">.S;0+'9Q9U*CS;9BX3;U^F&HF81
ML&;PGF&A-WBT@?G@Q/G7BIGWHP!ZMQ-K? F9W5UB]K(O,0 RL150 HJY#CC,
MZ/IXSR$+'S"2K_(A&@C$!;YU"Q2;<N%'6._> !I)G9$(AN[A-0K]=T==U0;,
MZ41*J@D$- "-N'MWTF/;J=T?7\)].S"NR=^#^I$U;_TVJHJS9R]L!L%F&K,6
MQ,EY;!%I2SK%23R%-8_6=W.V9>L]BGO-YTZ3)G_56$ ()5G,2H)E,@FT,C6T
MXC>GD1^L$)P7]^=\K,KV#/45:P14&;J #!4\>B\&LP:DF!_NXW_R$^*[ ?2Q
M6:/2XJ_:+]$.#ARU#?P)_HG>*"^;"I_TR/R *KY$+E5Z( .?AI-2&+W=<WF5
MYW*TOQ?GGCB59;<L,,60:;^GS:'#59=3>4%"_X)0N;Y0&]TM@. T/5/ [#LT
M!&SCUB "AAS87;JZP71:=Y8MU"3NO7A)*)E>.WL^,D8Y&HZQ%U;V7&WZ5L.%
MEA8SM'#>;[*M>&Y5F1UC, S,AO&-J7$P%T!!"GWEDKAJY &B_>B%(\O7[,&D
MGDH9BO9MY/'XVZHD,M&3A5F%>=)"VXLM8JO.>_N59!2^POE(AM$U'^:O54;Z
M?!WQ8' @TY>JQ"F\:&V@!&X.I<_&-SD/&8^+XE-#5,?)$RL+]]SK@[J=W_/G
M);AZ.2__2#Y^!.2>ZI0['GHD(_!XZ;A(:T(FUL%Y^,CR/L<#*D\MY;]6/<&L
M]XMY)UXH:N5G!R07%ABB:WR@ \V65:2D9%CM)+]F/8CYQQ;U9=]Z^(S!3*TE
M@\"2<N/JJA+0R0V+_U2+UGV [!*TSII*9YJV_7-"X"W"\*)FJJ:,34&[S&YO
MOKN^')F]8R>@M?SGB+6?0\0*D]NM[U0B7=PU&H@L^/#8F[Z=\K*^V@DAB2$F
MH9(LJT<^2OMZY8(.I+2@>_7,4B0>!#/%/*9*^Z#<R_J;[70!:&A5"J$UT&]&
MN8]1&8VSRW;\\=63*_A9,*8->@+F3=DNN+OIW3OBUCAMT=QZ^JX;8K;<N=G6
MD#?QB/T8/J#7EAU#C9O^;+IK'/C$Z,O8>'M<V]0\6O;"^#AA!NGC(EHGP/"8
MPI?#?6&>UXU8\U?R6?Y..B$'@Y*3AHQ%D :4CV8J,K)>ZUZ 7V=3Y)%7 S;$
M)'^/C@:RY!+>?9\;^/Z!.-<4Z?7%6;/H#6 !N'S8XVD/7@#E2/U1B'U_R9]6
M2Z$$K689Z^^?>&LLT2MJ:W25)L33[.YQ1'F^U2C@\>$T?1(QL[_O<?#H=!4+
MHR^811#/7#K(4F"P&&;:PQ%6F90D&^@DZ>Z/Y\7SP,/^(XN&2(I@RI&OTO*F
M%KSIM%8D(;R V$.2G7)Q2+N+H$.2:-ZBW:X J&[=2]SMW%%_46^(9W/!?0/,
M\K)D*$\SZ=<+9OK?5,GUU%)G/C<  ?;3_0^I>]IS#E<]V_6T]E\1LRZ1;U=F
MRS78NJURT*92UNT^(^7=R]=#>H)GE6VZ$&U?ZL+ KFMDCFP852L$6/ A37/2
M0"V^3 A4BTX=L-V5$O9"UHW ,%FR#L>+1K8GU*K7AH3GAM1AY5W3LSD?2D$U
M94(MJ)09G_6PBTO?ZL7)5!ZW,3N#=OBNO?"S5IO*2>BR#8S,_N0[&$=,?HG8
M9;!*;3"/2,;X5_^#%@>K]G^&8@9S9_C)IXB,YB?L8"<D0G17?ZTK9H[]@&_"
M*77AXRMLAR:M1O_^>1R>4,H9WI01'/-];QYR*'0Q66E[65ZY65_GL?H8T;O$
M[V;XA(E*JRI=!*XO$CNVLA!OL_U**B\Y>24B7DHMYEW$+A_2(TQ>,+_?+?T9
M$4*H)D"*N0 XA6^3*=IY[R)*=<K$)P?;&;F=05?WACD&''S>N@N?KS?K#[C7
MA<K4K@-(UHC(1T.@ "UC>3>X8]E/4?Q/PROM\?7Z>]^#R#@D&UG$GHU_M#D]
M,><=U9;6:7[[<R)&38CCO4;)0B#ANZ5K!C<GU,M%1GD/VQ"2S^H>;+CW2%@M
M3![0W2-,^5-@4'(F[EK7?);JV!)JE8Z\:-)-<(6^( U&-75][F!5*7<T=HT?
MLIYJ,NI-S&\._'BU+CAT-"D:6_VF=%P_X*L+135.'%PM>36#=/0G*QO+Q^#^
M[7!-/IM7.I_L_ ;;=O9)$]$V],\ZZ?"_,)A"*3\1]K-)FUA#,S) 9IC#V_?>
M'EN=SNN#4],7/=X@2PRZ;7W 3HQ?(U=)1XDCYR2,'^;AR)9+R/[ 1*/"R8ZT
M=X#([]M4OSK!<L(KSMHCC8<-CVK%!&E27OX.LBA-@;(D/%<*)AS8,AG(37N_
M?\1_9"G.04[DJ:?\UXRG+2L9K(;OA:16=E!V4E:YI%%+>^/+YD;T*\A'<!-X
M#$F9:"\!)CFIB4V4K6+/YHMK-!]S(^ CYB,7-?3X(1K?4B$^.'*1CC)8'YN?
M 3<V"9!R JL;N&M(-(YU24+KFGLG2%RDHC6#3PAD&!WKR6KA#>W)G,NIE@@Z
M61E7_0@;<E+@AR\V@ GM_IIR@UGT\!'I8B-:=&\MK7:RI9[T%R@LF#9%D/%3
MC>,643:7U8XDT%@K:?N/WR>A#?'_"IN[_WL)WMVW]HW=L2])L .[N<Y>]SU]
M57=Z5ZI*:O&S)@]W)W!D4C<\TYGV(ZK#=E+QSBC7O+A@,U&=%RX"H6]T5TIY
M+W1)%:0BN'QX8?U1Q ]B>FV*6KJOP>DM"ZF.1RX>52%N !?[81BV?>_[>E/>
M9VA!$/(&(,S1?@-(/V]?;KO.=-NS+ D[(FM)W8K^ :F$2]\ 2,[V[I;;BII3
MOQ'NO0$,##A -MI>GY>WGD,X6TM.6%\G7&^P:O0VBK;F)Q"*),*E1!GEEE=B
M76 2F)^8ZZ6H$RKL52^OVO<)C_OV;@!79__]D?N/((4G6%7@(_R6;U<M[A<W
M 'UJLBOMQ9H[T[7I%1G)E+_;#2(!D/+(V\'JW3><\MZY_EZ&N@&D)2S> $9\
MC0Z,_'\)G5:/1XJOUSNK]I=K4XWU=\/V",R)0YRZ?]AX)ST0_Y5Z[75_:W_N
M]FYN2I\C6PO+_$#*]C<GPOPP19H!=1XM%5+&Z5@E6W6EAR+>#*I]7L3XZ*P/
M9=0Y.9&]*X?'O(TBFF!&14K]!^F134'2"<]5KJD$GU8U96P_:7+SS_\O<KC^
M_Q1!&&0@*KZ5XT_L"MS"-_7B3I/U:8;.B3M.U85-P2N8+2N]>4 @243 $NPP
M66^6+C_WLY\:D#8P3Y(;FSP%XH?C-X"O06#[\0N<-J'.BR]VUY5CU_HS?E!=
MU5'*OIJ50AO1XK#2$L)E]].S\.<IGBS&9D2H!UK,HR=]NO($G+!@T>FF!?7[
MWW_:^W(R.8-+>M@<]^8Q_(^&\44#"X/*0NLB\QE24LIB8&FK ?DIV62ZM G\
M9E!R[DJU)]BQIXG^_U\X_A;\+?A_+M >Z5N,K?6$M7S3/VF3W-NQ/E&SCQB5
MZY*_]VEVL_"[#GTO3GZ201;CV_[>DO[E\N2M.H=7DP[5/-7"U<+-I!ZFSO*K
M,<KTL7O#J3M1V(2HAM_MP]Q=;#A!Q;UM$2R!;HUQC_?A\PF<< 8:?A*O&<Z$
M?78V**3^M5_NQLINQ=_ M%@\W>2HY$"=@Q'8!_GD,5(_68.CDA^Q+H(#(MT^
M0B0$15R](R)*I%*\EE?]P=C:D8LVA<R173MA?Q8ZF\I>AE'[E J=Z>@_QB&1
M5B^=[JV9Z&A@Z)O:S<3D17)9UF]QRT(F1"];?7+G)Y0*/FG< "3W)W:0$N;F
M_!]-L1K+Q+!EB,I;LJU>_,,ZK51"#D>U+>M=B]/!*+?*)1CSR0&.6J1GE0)
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M*?D*17QTN^:6I7)D85YBAR:0CWT'K#)!1_?I'4V\,;D!]>D\>MIPRU1"053
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M\Q%50K(RWGWL5VC/3F%) 31M "5J*8Q4*N1%,@EH/EI,3&HBC^/A S8A#&=
M)NK[;9@=V/@VK+='-F5&HG.Z,;H&IM<OW36S )/,?:Y7@M07)R=0_TP033X1
M KAY4QLED-Y7%N1O=]BV=7G>;NH-39;W"@&5@&@$5.\.:@?U:ZWE%8>+</_.
M+!I'9MM7>EO(ZEA^[%WTRS9?YAD8VNHX3%VBD=3[: HI2<\3,Z1IKGG=1"Z;
MUHYG(9 >^I2DG_,)DB^%&C(@S<7Y\>EG[OJ)6XYAS('C\!=8L[73(5=90OZP
M8\;\E[R%>7?^]W/9)3\K"J,AT044F G-\8'HPI/2VYHIZW\=8CUX/KM@##[>
M*A(3:T69\PO=Q(/,F4:5OGV"<PDN;?>_ID<3;M/K[/'1(=3A P5?DAZZDCV1
MYYA7LAEZ<SOOT+V^KXN. 1YR@H0Q$=']6,"^YNT;L("?$"P@;NMZ(WH3"_CK
M.@N\#K\U\](9N<F).!;04K6P=,4MQH(%5*G>K@KSI00CFX5($KNIUJ1[+;"
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M0PB=%?5I_\DWTI;_2JIE=<HW2A0<7<*D'Y/WHU?]F>#8L+P VXTU_M(@C;"
M%SR?VP=6>-.G31T-RC>0#!2O_ZYC9"ZZ7"8V3&T)VDRAO!$53^M^>B3F<,F4
M&7-2A)2W%0?>)/@/E/_.#-L"\/"T<.Z,@_ !^;Q"2-Z>TH&RX'O&DEY&[Z9"
M60T1@M([#X]N+Q:VX7WXM[XZS&1 )PU/=<,876=6$/8R"H-S?E^1/H @P1.S
ME*:#!1AOQ*5@ 6&W%J_\GU\Z_$\%VK/H&4E'<V!RULDUDN4DTRY<:Y&&P:P_
M9'<.KXZ[+KU=F-Y,:%@D[*V/J5*=!?_$)PFRV F%*;F9VXZN&?CHAW,(,B8S
M:[@S;P]:)^@%GVE]FE:$-%D4^;%>I]FJE>X+82]EUYZH=2^SE#'TF5B35M+6
M*%S4"#CE[U//3;@EW& !_W:,+8$K>F#"T7XL8$.Y!25U)QS2=T'9.;PBM>3]
M]HWME/ZK]UC @\4CA7-\<'7![^EZ XNHM;@E4J*@EW>?WC@-4N36XQV6+F5[
MAV8P0##?\_[C$E>+Y>Q9.H&FQ8M\>J7ZA]Z.Y&4C!X4^@_>C&+N'?^2^9T#8
ME=C&R=ESW [C.?[7]#>$PI!98@%XE$C!!>/\19/!WFRA)0NTUDXF='%RT7X!
MR?6[VA31=I[VQ>I+#FZ4>($1\W#?)Z8OF4^5D#_\8P<-Z36T!Z-NFQ\=Z/;V
MS";_7(R2R1 Q$H2&+A64K(\:H''W^T1Q*J&."M=3F'FJZ_0D\'*=(%^BW>)\
MO4VND)E!(4O8U\G!3<C/ODG5&S08!O[-V+X?&O@!"UB=ZL "6D*(;]9J6/@_
M<F(@DAA?+&#DH068K2(\<1;-Y40I<E((W;:O'^W!M)3]5;=;CY"6V1GXBWPR
M?P>:9K/^G0:OJ; P1T==(%[Z9N.]>U5BQ/Y>4VB81/:L7R%_*PJ_$L1E=01K
M;G<9FB2?Y<Q\!X*4ED)2&WT*,V6\Q._XL>(!:&_0[BO@B@1X %0*_*[:;=R/
M[L8$6%R =$&]'_=5#XED.6:YR.\%&%?;T4=['PN2ZCP^FT_F$U!,>*^=R:5U
M^35RF%QUP:_"0[D-C 7\'O/:G!_:].(Y6=Q6LC:5DA+)BV@/E.V.S^N:M$G$
M&0Z;3=DMM;*RLS6=^IC%$->K%$]F>^P ^=O>A-"B:\<"5G2S1I:\-\SZ')?B
M_8@A; RRNAT.1,TSB0+E^N<<_/ ?1!OEA%1GW&G!]WU<AG=OFS:=EZ=8 +XP
MQN(Y*+6WL(^HZ/+X1,SF?9I;[=EW\F9^%Q4I-L(')N3JQJ$%3)X/)H-^D&A]
MJG_9.MVTF(PTP (DB(.6AJU)T91%PA)@0Q",_RFSICO:]8 R/W]!_2T.NZKQ
MMWC<O)R%U[76&M:Y[@*LV_:V-HN_;\/&I?_:(7JIFR=DB4U2V;&4B,,#3O1Y
MVWA\_M*Q[H=/3FY%\?RE;\L/ 4\-S3AQ%RV)5[(6HHEZB>NWY^ =\17A_$;A
M]0JPUP1]#3>Y0MX&(_ ?IR4NX"$N1A0+V#ITPP*F1_\9(@1Y(6VQ &_5XVDL
M .B7C&G[;R,'&NB@*NHW.+H=B5IH/S^]G0V*H". *[+&>^C9-@LX.+(U[GBZ
MV#?+>5F44GC^V,DX+FY(>TI>,V+(<<C"P_&Y7PH%KJ80?.C.Q[^LSWAOM>F$
ML0<>0;+BL@;GM[" OIA0/Y[5:04OHID=_S9BNC 832Y;1D%%F5']5 <<ESJ'
M6A;E86,U**Z8^R6NA$[]-MQ5J/Z7=^9KLE%Q4N+NOW3)=5RQ$7T\=\F5W-@\
M6-%S.NAH7,/TOE: 3]#3DJ]#F4M3XOVWJO%BSLV-,"%URQM?IJ7[_Y\]\2_!
MOP3_HT ]BV>XN9<96+[4"Y[*/3A;N:V5@-1@V4M\OR7M'7"D\Q]GY"TE4W'?
M_G,AFO"67<)X<%9>!"D,HGFN-3DF1Y$I^JI'!GCP4D(7>H98FV[BG^7ZW.0>
M(-WFU68',6@I .'R'/D^W;0U8%N+'%2ED1L::-HU5PQFY&%>C\<Q"+83]6 K
MU%;\6F9C)/N"MY_&&R9,8?G1X>V#KL>RXWL'L+1MR]^6;_[NTMTV9_$:6K;5
MVBI?__,9"IW>AF_J>T!%+*#MGW%%=;/+ \V]VP0Y^>=R8&"7:SI3YA5U40\E
MI=:OHQ4#>:, 7&VOB.W [- )/\=1E1>G.W?:>6E*B-77%E2-M6FJ7DWW,R9(
ML6V=R6V=&^Z66=%I<)DYL'I[OGNT]H<A#CP)[D<XU8WA,TX37O/<8J<7?++)
M6]?@V[_<E&_@QYW>UG-X!<@*W)M5BP4<S?W$ A;T6@O%??U==A0/C9W_;Q5(
MJ2 YV9G'Z>3D*"$7%R>7NJ:FVNV/Q;-9Q\N:D3\A(QF2 ]R5O^W,M;$OC?AM
M"3J?$F',L0#&MO?CZU'@#_5'"65-"JP%IYK=U1>#DCP/!7EYN]>,AESZD]/$
M'B?J4W]ZWOWCQL;F643@%:TL<0P!VFJ7+OPYS?'6<CY0[VQD!G-P<)7148?H
M7-_+2\KQG4.7&SB S-=L('RS#E%:YXD)4HHJ\1/#C%\8"?-N4JD5<%O0>3,=
M"Y D7GZ(^;(8@07,Z_[WZ?-D>YHS^A+XB>X*WXL'"W"\K4QU*4]%L(#@1^A6
MC(,Q>;TO_GJAHK_RO!_(ZD*:Q=8Q8'*"RG@C:D1]O=B&[_54%#L?ZE3BS9FV
MAX](O+=%;L![:7H^>9+7B ^[H=<WVZA&H)EX-IO\U3%V8@QEPD*^G*KZZ.[Y
M!'3@:,$[[Y]YQIV<$7&SGBP#?8QE6<)*K\X@-)I"5N_?@SQOUQ)@]9\>"$TH
MFI44LS"*[F@_OB^/!30;W?;LV_AH;TS5@ 5<JO9,SXN-(WO]R>90O4[+4*O9
M(2\GA2PN*$B022* 4,N^KN:$76M,6Y9+?+N:OI(H$H?5W@CG-KM 1LXQZED#
M@Y6Y@^6[&&,3/,ANS:2FKA7_:UCMW.N%Q/?G!*,24ANN#6GBR0N*##6U.:XO
MW8SJRV_;F/G6:%9\#.G#*DE^3Z%C9#.ZV17U);G4%Q-?Z(Z8[C5JM9CE67XM
MIZ$0WCI<=R)8W1^;0!X1I;C.>ZXQ,7A?LJG)-^8>GV9A$\) \)9PN@2,MSZ5
M@]$-I&_VC,(M$YB2MQ=1%]?.)ZIFFLK Z';[2>VNT:3"_!@CS2VA+FA%+T5D
M/W/:#]_!>R+48;?<X0N5&1J$Y45!S^QBZC1-%F'K#2:L].HF.IT5ZW0:211X
MJJ2CDB8Z@'<E^JU?OABR8R7/X-K)<:N&?-"_*VIV.-HN$ BH^2%7<?$X:KB.
M3\Q/RZ&H\]!FLZ"IF0-2>>*B4/DP_M$_+'"<IEWJ!4M'*V$F6>V8OK7=O.R*
MG^51JVFX.>[/*H?)/G]@,_-DW_[%5_GBTVT9E',+7 \2T*D@9>XCC";=8!"7
MO#JAEE86@>BIO7CE]Q>*0?.OT8S'&01K1OSF,.$M-4O1+W43-_6X)>9_OQO5
M!@(>U2YEG#IQ#U^BT,U>5A\T@_=*1=%A\!DV WZRQI9JK36O3"$K^<A^]8C.
M,D^/RGZ2GN.-;69=+\7;ZKL1.%"#_.,?@U&+!S&!>MIR+Z=;3Z^74WR5YQM1
M@^1-U8D39][\'\X\J#J_P,2<TI*2Y*LU!B4;+)-L*9YK;(<(F'C"RQ]B@G0P
MMNVGRQ@ >)MKIOVZ[K]UP@D-D058P&C0Y9V;(PHUPP(N)F\\?XRN!KQB1C?D
MUR"Z5"F:7!DH".9Q[*YL!EI:^B+\/G+4)W\<)'1B$922%&.0YW2[^!XG[DF6
MR"<SL#L@]7A ]O9<3.S=&.A=EBR(XN+R=.%:=4G"WI (6"EJ756YF%W#ONO?
M0]Z_7$V&9.=5JU16%?A>(<&7]S>O*I7>6MD><JMMU$^TUR%AZHEYMJCU.M!X
M4O!##QQ>V7&1-)DD;1&K;LT[@:0R2Q/6BF?_1I';R^D$.>Z+CH8,W'ZUS>)_
MFMX,DL"_T\!Q>LC3R1/TP&5KW1J0]TK7H<6PQ-8T)XJNZJ*,/E49AU6;WZF4
MP'2]6[%(PI(WBY(U PL(";@Y,2;<U&EV:>QIX:(#/COL.RR^-WGLN\UZN-Q,
M22_]*X+HR$>6+QZ_O6=RZZ.RP,OW@5C +!_:$!DW&=;D$EI5Y'<5!)YTJ! E
M"%]AOX +/W^@IA'/:,=2D9.&P_ZEA/VK6_ZX[DVAU?[OW2C<>H0N]9H-W8[A
MO0@=B$8-U8N9>]8_V=VI/.,!]&]55W-P\SBMF!8E/8*X/PW_6:F9*RJ3;+L5
MSVYCE0:\C5;M0\);69Y8 )])HG'H26'+WA-^5+UEUX%$KA3'8,R\F%O4YNNH
MYDCNHL!QNF<CH\Q?[2"-=O:,;P65,F^6,&>"(>E&Q[.B-"7>HO\&FCHJL*M$
M[5XAAM"6<V+]Y&PULRU:44PJB+ZW&E](H1<3E5DK(^ME*@IL['+1G!Y6)3=5
M8CTFX*9*3*@%IQ/W*[05[')&K^5=ND_1S"DW_VUU#"%)%?92$<G\(K&4D/=9
MJ6Z6H(:7"J*K*R#@EJ?>4^=)[LQS4R8LH7/:5U[,TU=8'L#/,'9N6_PBB^.A
MH2S!ES$U;MJO4RJ/E<LZ%E$)A(84,H4,C(1/4 1&9_;O5J9\YQJINF^*VJD9
M/W>D!)B=JR2\L',-F+34L0M1L,!]-A]3*N1D5?0)0*NPWT;?5&]NVA^OPW@B
MSWA[T>0)%I!J<I1ZN,%SLF2O.V8J*7+0'I'QM994\V"D[[+_GN%']4'Z*]H2
MQ[]?YY!R.M(ZEIF?5//XI+0?0,UO9SH<R&]8 -=H6E;?X$;F@'_!SN#:$ET&
MS=::\$!@+;]Y<0U=IV54MS9WZBY+IU45?#MQ9B#L^1H17JLQP;'6S:*G_R"0
M E@ +ZP*$P >+*D7]5LOP(L.G/WMB-L&1/^>T?,M[)'-[';BM%1FI$DGFQE(
MX3A.N?[[KD[]55CQ>F[?V'2WROLG8Z,W&E0!GN$5_D/X4EE8NN)%L6 !U>TW
M6WR<M9F !>!V8=2P &I@LLE0&V9G-,HOR,$K2]WCP?*2(;[+A/,P*C8ZAN6M
MW-C8R)D^8;^FM%950V.T=UY46V3>K:^JJUXJ(SHJHNB&&)#A6A[$ P=AAC,9
M^G1OG +.FGV#>%,Z^M&J-+I?PZ/!K1W3YB4>78GQ073)/7/ENPIE-Y7M4BCF
ML]8M[2QL_@9$R !O:6>Z-_$T-_0H LEPH\*EC>EYI"3B,N'O;"9T?[^MNVS/
M/\2W'>2$WI6D>ZD?70')1XE?.#/(1#'IL*=VE3Q.]+?4_MT<<K.VS<]8 )XI
M%@!=01]A 9WI5EC 8?WL+4R$F:QEH9GQD5P7#WO;OBVEEZQ.K?4Y11V,&YJ
MG)2^!H3.Q'*>(SF9"!TM!@EH<EZ;DDPH[9,(:BGN2/_3AB!H_X]5ZO<?;Z:D
MZ7+K^! 2R'H68X3VVCYH5:\338:\PG'8-V[4-3:,CX_^ILSU)KBD6IM<>Y)1
M7BS#79EA9J:J\A_<^O_I_&2W%)6^B; _GSY]=SE^E(4+O;HH@:"2BY<"X/X8
MC01&U!>\;AK8WS_:4DE!S\F%41?% 7Q_1K" 1B#<-_>8R$'$"K\L?,O#*E:1
MX+>@FFXGNQ+.BVP[3/%RYZ=>ZLUD*!8 XDI(NT[9)'9U8FDS'K1;F!J /=J
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MW5#]<AI*A'J.56U&60R1]PM8BK$BB*M8CE?6<_!H'T!9#C3S*XN M+"P5Y^
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M%VC-;PJT-I>&$ K&[H]"K$UFP+N'ZNB@[+=]GR/ ",887#S:H9"=2(-F-+U
MAX[ O%N>'9+ 3" B0U\<JAZC@W(+@P><'('&.F )SPB8;HA#-<\4):<R0&,
MW#V!B:=P'#F PYH1"-4\QA!'H\,4_^HE.&&&CD 9D%5?*& W0/LAB+WY+?DA
M+3#.Y=T,09B?$3I96P#[P4.1N)%*:*9;+Q*JG$03K:G(=E^VJ#(@GQ(NQ?#,
MR-,OY27&CL!=E%:D?5.X(7/36.$KP >V"ME&_*,H@/9%>-RQ$9[S\QJ+#@S]
MH>"?9 H&4A"7,^6=]<E P6SA,%[ 3#NCQ,3)%*P'A'^'*-.PPP2*2P)63*B$
MF7Z%.#[E ^EA$"#[2'J)!!!'ULJY1C:K'P@4+H":M=I0IFVBA0('4.C;K:@W
M),B<@=@J/4G#9 "7H0S IE0+\%!QU8U&-I 17K$G7')&$64%EK2I2E1# 5'[
M0@-E@'GY_D4(NP\O5 &!@+XQ\$&IXQ ?$$E;41&P520.>>7E2!I,0TJ/CO+1
M[5[? )2Z;,4\X-$T@\(E'%CBRZ:00#<?XNH)LR][<<Q5ST2** %J2I5B[LX"
MS82LEV*.^N#>FH4/C."*B6*'B7T\1=3420B(W8,BR2@O),K\HY>X 9"!$PTW
MJ^^:ARLB<\Z&(EOA.<_R&BP+^/.T-'E$4U=>,!5D5?(>+_:6XVI(,36Q.LC[
M=V(L-TZ2+?83V4$3DBK7VCYGD"XK/,6-DM%.G0!+$%Q!$(N$FUD /*SP(),2
M@!M0$ $W-2EOB.T#^M0C(EHL'-.4 M'+L4('6.C+9POI,#"+GCB0)'T#LLPP
M0OK+#\# *T\52C$1)>BZ=ISXWAW>K]_@H:A*!'#9G*]Y_F@/3N07/ U1 2 [
MQ%\2<?TG"#PS.L# PVHB\G5(/Y?G@9I80=3=4,>W<F=QLA0S?+4/'C>'>0G$
M%H5N G]Y&C"  7\@NK[:*Z25(&;1S(3>X'@/D(OA.\ W9SS)LVE1*%,QY#"%
MDP94OP:]3A;DVD%("P]?0+P*_UGS2ZO%C%E.589,C50DE2/%. D5@*!_%<P#
M1J-8!G3OT[,) 0\T,(+^Y1&5"B?[VL![\%P*H@;X1GQL^$MVUQ"$?%29!I__
M"J1&=[U(^AG0+"<=R(9J(L74YNC5A+M!,VO*"M X4QF_P5\5_U6R7 :2H09@
M/0T*!=2+\  1.0IU!K]AL$A23&()^@;'CQ]+\H.0&N$T"%$4Y%51?D\PE1<N
MM&=#HS&XP>)$O!--=ODCE_ C*OD^7'V7<@?F#8:/J *9+@<]]SFXNQM_ &IH
M X%.RAV4TOQ5ERW[3KD.YM;((2DL^C+@8^&I""@"BRHE@('[5'AT;P-C45'B
MHY>!!^_X#/!HA=K"_M!H'!!#80+Z9-,2=&!1'R1(;X%8!JK=OY YF11D.VYR
MB<_/+((@U)<L*"P1> 7DA@LL<1(J_ 02/+B.%9?%?1OMQD_E MOYA"[2:\2S
M  ?$> 2#GB7"R.LG\5+,LQ*DK$UX"5@HB!K\7X24<W"2;%HX<@Q@S>0&A06H
M$7![+U8$GJR(5MJ61^#+;^,"#HD#'_A](WL! M=\#0P')S[M%<;7D9C0\*)3
M)<A+A]G :D"+W4!!RD3)SG2(OT1N2B$?JE?U%X, ;V(JT5FA$)IE(=]!# !D
ME<5/U O<#RA** %V^''+4Z#8N#-BQRJ@K%? ?O15);I!.]FCZ&\_?-  5I3?
MI&]#_$>(]Z0*^,%(![+,T\VY;RJ0%V?@QGOH4"O*1[\6]U5)>G%3@.2CJ*CZ
M,&!Q_2!V7Q]4CP?!<Q)%U.C353U YE23 ))#3Y+YUQ@!).$BD!7Q)&O!F-,;
M956_I<@D8*F8:C'J;X4>=&V5=P<^5<,?L-6:"H+8:-@INVM8%?DH-XT#GS3@
M^;G?>+]TP\.G@)=/ @%,^%F?D+_&_%UP-(0 L^?>EW$S<#)]77D@$,8)58"C
MXH)WVGD&\!D4-!$J(L^^#$>9!Q5.&THFI1CF"$,%X/ZD%,. BO0;#?X4[=UH
M%%= XU^N P]M!K'X93> G^\_1N#N,P 6,+  R,C7Z-ON;N)_@:,6RWH)!*>Z
M"\@6)S;27XS; D^%01$$=&M.%N#+\U4@ N%8,*"1>WQ)X.PB'@5-DJLDS^;2
M(:9'<LUMX(5N^Y%1C3T$<?A#WJ8HU-KZ7Y&55WXCZ,5'>T!3GU+@&N]6#^%2
M@"B@Y($&+&I"\NL-%P)Y4G_!#8\QQ$W0*+#83_[0I)R-[?0@BJ.2<8+* _((
MC^XZI0[ <!Y@X5 (VJ8M^HB'<$-Q]01!.@B_H^1VS-X,"BFOU?Z?<%+R?_B:
MD=O"IYYTX2IDQ[H_71H]K[_OL5M QI"&_^KVFL[@2H5KKW><V/1R8RC#N*BJ
M=\[I7N4F7LX'P);Y\PT83RF/A\;?16TVS+EFOWF759E"6>KJ"4:,B)2C1P_P
M"56U=3QH;=-QVL;ZA(^QA0US:Y@4L\!/=@L'H4_493*QF)*&DYW\M#$WL6?%
M^1G70-;1-0J1+^I#Q:TKSO\1NB%.YUS.CGVF/75$ZM,S)7MKS=52 V[4\Y?N
M?7XVT(51^S[B9>P;2W,AII'_V]'!E@W0>47;CO>JG#\<E"Y/?D+T?N>I?LPM
MI39:)]"$BP(X18UF5CSW2&>OSHH-QINV8."OAMLM0M%0\;1W9\/RVR>"%5D%
MXFC@\KRL6W5WG%ZHH6"'%MO$&.%:PD4H,]O'42XEM5,0\_CL0 (9>IR14F!]
MGB<Q7A**?1-ENH>5WIF/Q.!:;O%?(U=4CQYW5GTRSOXN6)91LK/PIO'FO3X:
M2X2NYS[O6[9[K6^TFN7%IW6?O]NIY7_=4#ZC=U7O--6JF.3LV?&UI4/#^O6B
MR -75-^\F/>J6\?W<4*&ALG;V)_N!.V-UB?*MVSN;8_Y=C+&5U5U25OGUZ9S
M\=M$#D'KS;+K)HZJ;]SUU$B.]JXK]4':X>8@0Y;.[)"8[S3Q"XU]M<UBJ4,'
MX].U)4'K'@]H7=)SL'MF^?*$F\.3O>^<GP:O(W7H\0\G7:"LL',Z<2YJQ4[$
M0GG/[,=(Z+"G]8[?<DI=TEVV#4<O]^LJ7YKEQ%FS=$.3>4I5^.RA;UQT,ZE[
MDD[(_3^X+X6PG2*P)7]Y'GQ"BMGI0/RLE1._INK2=-9E$(AFNKF=>;R+[?FN
ML$R_Q2+]P)/CR<GA"F&:::?7K+8.S>ILJ)ZD7P%)RJ)% G,I9B,4^\5TR&7T
MHXK"^< V1BMQ3$,US<X]N;N"Q-I1<3;6EG.">U2?,',E>_FQ\R\;#"^7<AIE
MARD[_=TJ1D RM<1<X $<N.X,;03MKC%=NP0NWDH_W/U\PT7\SRS/Y-<.9F96
M?V!9G(KK96X#OSP]_T'13<.'1/%Y0Y9-;$5AIT/)\83Q50-=P8%*O3&Y(%UY
M8M]CT#Z9GKI"H[JK;]>7ZZL+OYNX/!W@:ZD8'IMJR:3,//*QO7[&BD[*^:;_
MOYNU-V=,OP0!(HZ[ /#@&E64>4TV]2:HDYT+,HGKUR/P1/ ?D"#Z+5E<S_IQ
MGW+4O]NQ4> &HO85RL*4P,U3U+#U0K6K%>@>1^2KF).YQ^4=^Y"#U3[M5XG)
M,5'82&.7SQ<+U9\.9KF?U'-?NWX5D$EHUR6?SZ)QUOL^NE4WS5GS;85"KJZ9
M;T.?V'3?;;U*7RM%"Q45SXT32W0B%S]X;FQST</]^*4MX>5\![W)/#YLP:8G
M].B[E7%H.GGE?&\+HE)<Q0[+FUD[NP_Y'+&VZ+2J>K#R\"'W=SLT.EL;&DX8
MR&Z"!E2LRCW0C6O&]^_[Q'X16#I%('K&F%<+U^2-FV3U\R]M7!'__-7=W;L&
MO)]&USDG#0>NBG<AEJ:DGP R*=;YL^R^D-&U:=/WLSS\Y&JQ(XN*U1;2$E/^
MP"J*;2Y7>FRT#UT8TQU68+UY1?;;]I$=9@1SNXK,3W<?'DEAH9/TR[!L/O(#
MU+^1<$!=3V<4YRPYU+?>Y4T/=B?OI/=4=$; _?OZS((+E'J+PQO=*:9F$GOB
MZ6'+,^3/+DE1V)-*]%>/@0IFV?^]NU)O!+Y%KQ!^JI;G^^$EWD(=QFDEJ#=Q
M)#I&4>Y2VX7=W0][R%NBUSD$N9B<U-Z]9?F&1Q7;5&XOFDQ:F+*GXV2V9;P+
MWH>53?AS\QD4B29C](R +JF8!I$H[\GE4SQ"LR,#^5IWV!CW)'59>$E\@GI9
M)N:T[TQ79_7NU6.?=^[=ZW-N^0?5L*JN\DX_= 5W^@/N*=1TYWI@=._-.H]B
MHP]?2H.Z3W#*\OH.%GE<);EM4G2+W3_S=%1SS4,D,U[#9;'9(]D9R]O_<<07
M&_KPVD I/!9JP%44/'NT4(,_^LFDAQ@M-G&[>+/0@EFG\8K^J'E#6<2"+Y3Z
M+_D[9NHM\.9VKPQERP_"U3+#O$ 0F'8UXWFG< ERI[[[+;@\(&H<MM%+'C3G
MFS34IKTVF6K*.\TTZ=ZBRDS-#/=NL6@QW!I_=MVNO<&Z!.4W20!8-_Y[*V3V
MA"\'4?I!21TT8URA"4+:0VDRL];1:G-\6:6K4(=GN3B*G)R:HU+#SW]0#EA8
M<NQF>H'SDE.6QV/CWP:>3$U]<?)!S,Y/5CRF^IO,7T&#@ OK5855/"(G2FAZ
MM!K\]Z$7-0Q)MCY:A!K/G5R)Y?2>]-X1HO\H+/RA[K;>58WZZSTUK5>==DZ)
M7#>!#LB#E]<H&=/T??H0Y_R#<>E\+^6@.?(EYB.SP;>ZOHOQ*EK!!L4J\8L&
MO=8;V[2.]5]\\GM+7>9$@TQT I I9H.HT1#GZJ*KRGDG2*SJ"PHI]$Z],\R3
M8FA6ZG=VQ]4VK;NB=S:]<;W:CHX6N:9G=2N'-I\D[30Y6Y<J.T:*?8L@)ZX0
M/@Q,GL0_JEH4XMY,AZ]ON](YF/7(]K-GY1KMY[O$47OWF!CNVZU@[F6\94)C
M4]+]9\9G;,V6RJ2>@"X(W#).&.Z?(66CFK/'=YW8%_ONTT^QO?Z_W+MN'[);
M+^N2WW+'_F/&NPZ8/+UX]:71XIOC_:=OKXL( AB$T;4%H74=D!;A29F>N][#
ML9V$?=.-D9GW3+=BK^67#!QIC0A:I)S[1VU;=N:JC':L#PNPX+%-4SUS!,7@
M&U-G7=\HMLWK4R3XN@S:(-S0QG/N8S.7HDX@KVSOU<T_AT\OW7)EB>R$_S]?
M^S2Q%J]R]/[GH5U"O6=C,Z69ZZ^?65Q/>:VV.2PE_GB>ZLEK&<[G;LI.U1.
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M/T5'HLI'1T'COWKA0)99W<-/1K= J60T;]8"&8>X(*!K[1M$V\OY".T5\'&
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MPZ:U&M[5?DVP9V%^073RJ]^XES);/UJV'3_!.7:_SP69-[M;3;O>,C#$7LF
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M0P(89>H>]"(-U8S%@M:#HJ9HO3I_4OQ1G6H^<HCB#G0(8.Q6"7=5@[2/=M<
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M= 5F]=7;$+#>HT":;YN[*&S1 W CNAR\DJ4]0M=+LEBA2;.C1_[3(9U=Z![
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MT04Q;_S?*<E/5\IEX\\4EDO]TEX@T4"@E8K$-W/I;PGC=N"&G9\!XDQ,\3'
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MEN*BS<0J(45O:=JL,EJU$OLI"**^_MN@D6X0DQBV@_XK_Q@%7CB]J1A:C;D
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MX[AZ@W0 /\%DK0(UMN[7"YK?:SU_9A%4VG/6OB(N[\<@<"8P3VGV25U?=#U
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M'>![ G"VX]/>%%7@_X?/$M&QWF;I^$N%1\5<HG$EH$SSY'A;JZ_#I[WH/_R
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M937FJ>?ZT]JK"*;)EH6P)W/0<&D(U<M3@ZN2(NG?AA"/OVQ<?7^?7,=L))!
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M#MI^+8V*M+/-_I89BJT(-N1PQRI21'YB><4H&OU/.[NO=_:O^Z.>S#/W0,\
M1I+YLUX?TWU;WV= 55EYJZ]82 )E:=!)AO *W(OQD&%&SJN=C7MJ^_!@^J?,
MPY^>F9#HH>\N2=I"A\"I%G89-4E737/D+W3]GSU1(&54+)_$RP O/:_E89[&
MOO 6,L=TF$67C:<,[<N"P-69Y:SA!(*4SZ64'0UJG%G*>:LT.O2J[8&IUD,3
M5?MV?[V"]J[TL,'&^'A" \37U>5S]D1&1V5&16B"BRY&,3NN-)[S5H):<4:$
MGNJ[% _.GIJ/%$7JJ#S+1JOHN@YPM?%ELY?FL\*R:BC9Y'/]_1(^WTI9 &5F
MO8;?3O1'#/;&1H>AJV6C?\YB=L9\+5ZABZ&[U$<4L4OZ7\J,C7/,$R?&AT0.
MO.CL +%T/Q@A2D6E_#P/JDY#@XD5LC(7E^"S"7WJ\KNQL:TV^"YXSF.:;VMG
MM*FGF9*U3(+JF'!RL=J!>[9M&4M91GAQI!!U%2UR0HV97*UD[LLC9/^=J]..
MDMV.Q93EL0+'SN8F65TW[IJ"G#>?&@45$I)<D,AQQ66&2452W0G=WB#8P,:D
MO*%W>8>/B^L=8DUM5+3#)*]Z)AT51&C-M)(;>J)BL^L$.UP;^^0+- K9HSFT
MZFZ:VLHVN0HY&^1#$\Q=(B7Y:_"(I7%W!>.;<FP%R@-@9#ZUR]?R4:^/JJZ(
MT,N &O3EN)Q?IJ<ET4DT5*0@&FY4CHH[#;Q &I: DS5?D-W4HD8D(^/:L*'\
M9[Q9SOH*55E-9EGJ(KP:39IPE)6?]U()#6DJRDM,3YC!ODJ]_EU"DN9 D=[\
M5+=@ EI+<7'F'AZSES+X_&7()<03]AA0YV3ORNZ4 9.:I9N^QEN'L5.U6?&B
MX%<9WFN4,?+L@'HD%]2Y.'=-9AM.?U199M[;:]V4]04!VN1Q'/Z$PH1QM'S(
MB[XIW*^]D.7;A+.M1R)/K.[*]-I[:PLSCU3'Z^\<'EF:HI\)3VA7(\-.RD@@
M&5;WPI;N4EGJ99JEDJ=H"D#*YCBKE9?''UP$.=A_$M!C(*>;?S:PBAR/FQRM
M:+K"6OH]#L/B=R2*A7FR3"S6UP-'3'^\[+3MX\1 0HW@ME%\-U= (NG^DG+D
M-%W8T9Y,,K77@MYEJ2*94\N\SFO8/#O;RP()K&,5D2U@[LZGI:81*W%%3%Z6
MUWV$776\ ]OQHI..E5DJ'Z2L$^3,P+<T>1/O) &(+?%=E+W[%[C)^2\'0&![
MCL^ )[K6JQ/#:0V[(ABW\< Y1]ZOA07Z/U11!L)X)H*93QF)\#D2[KT2ULSU
M>_,M8UF,WQG%!"37*_AJ%E=/J]%IN^#@^$8>ZF1.6]!+\OA1=A>T!$O-")WR
MY',,Z6J&&4$ =&_(\6E"J]LX934ST5IMH7IMLW;I96G?;%H5LZD%@XB"Y],<
M>#2P"#[8]A(9DD)7CG.3N>(],7D4&;9ZJ6C<S#M@6M.HRP# 4D>*%"C;394!
MC%O;+*W MS#[ZFNO9B-)?WPVBOG0>AF0<:Y;H;3:M[CGVGBQU"[%F@XY.CJ$
M*3@/=*DISX&]-#]8F>%+F"%=DW;T0@9/Q))$\GX4%)4ON1&L12P*R+64UL J
M\VWL.<>52T9.-;!]=#1J9FJRK,:KU-S[8D.0BZ-PIUK^)-9<(RZ*-M+@L.P1
MA-Q;(O/=@<7=(I^(+7 )HJ_6?ZQB9BBZALG6"HABH*_;8:!>F4=7\!N1)?"?
M5QM5 \3]RGK=%6:!P&IEV>;KJ6C"M!(SF]J5D$7$F$,UB\1[RI<6%#+6;JWE
M:VH=JME9+S/)JIX4KS$I64Y;A0J<W-=XU3CB8<T5:N,$*7277\YF5#6V-H/3
MY[X1N'+'IEC+O].W"#D[$L>=K1X$)>@75_LM7FS8::OON+HU7NKXD>[&:!KI
M0>@2:(I*&6L+\R4CHCD/M*T,.>UMD8PY;V/;*[=]Q$AA!Q/_$2BY!?6^Y=6M
MV1&[:[HC;B,B AG?'*=S6-PE:J?>X[TUBQF"IAAB/_IK;ZWW+$)2D"'JO;^A
MVDX>Z.:G"44!A^O>D16)M\:?""S.M32&$(O3A/0>U.L_ _P[>HN;+RS;A)#.
M%LMKITXP^KN@>&EVWF;%&24..X<8-$PR;I\2I\E+0OF7ERAKOO=]S+=#R>5!
M(6VR$R3K9'A(F?# 5%)JWSCOUV^6Q$MN?GL'^7)I^R(T)2.??UYE3OJ=[7M)
M9#VJ(\)%]8.4],.1^4'IO^;\_U)?0=0))/9+1%>R,3>^TNIZO$@X'".B((]!
M4X L\4GUZE#Z Z9CX*M]KGGB"WU1(C43CWYI$\_W)Y H FB3(S[['PL["49&
M)@/A3CSQ&5G!?IR!TMQZ_Y^:6G118B6:"M9%5H@3XP3#KE?F-+-MVDYP^+<H
M65#B@ 21ED:A7B-T;4AL$L#V*[\](4?6FU_T 0]3Q*M6Y(6__%E@79,CHG_.
M$0C+6A/2J^L@7_WXV*M*8ZKG3<R<J"XK)!P_^@*\#QF)E@HE5!P8^;;P#7M^
MVM>ZY+_OZ=S>>M] LTM6#DZB-J;-LC(UYS3!=S15Y>1+X>1SG4&*T;'#.)DO
M?D=^JV%:B%+/W_IQBW3V2OB]M/^F#^U;I=Z!6?^'1J+\<D7G(C4V%=LO<XUO
M0C#KB]'P-0X7]HMB&N*,RDI/]Z,U08C)$\SYDN PI[W31M\NI\KW5/B2ANI7
M-W?>U'74=G$X-V7DA-LFI<;R0^)6HJM%J!I;\ZOFI0-"9)_C\/%YS$)C&3DT
M]>#4,S<)ZL/,T?*R3 =M'-3U.,IT,!*QN<F H[5W57>W;*U:)*,A!X*R1Z4>
MX'Q0[$#1=PWU:>ZZ\/?9">EZ+W8_%Q6;/ -@IRSQ8\2:EP=-(*6OQE$D\\NZ
MF$L%/0C@7OH$W*]8B,HPY^E<<UB5A-JM07V^4L-%0\@?4E@#85>KW?=H_?,&
MGDIBJR]B>4*6['OBJ;5C*UA7P 7UP'R?JZJ!\#-PD5;59.+03)'KUY_J9B"K
M):R3V9JG,ORN>JOVP^?4YZ+AQGYU+:+ENDK9'/$#H>QN1@923"\I'QN9Q]>H
MZ^81]NG<U>(:1BGG39%BLYX:+O3FL1TT^F0_G^@+*O$1]U"VA#N6P]01P'FM
M:76F2+LWA":DQ75Y7QF4%;&9JJ0 8-DWD>A"+U'NE_"/OLQ"JA#&\?ZWQLU@
MYBRE[<-6 =O\D=]7 PQ[N4EJHZ6]S.>ED9"B0G3K!2T1N6[3N+G.M3>"-K4B
MA.,19X9-)>+ F,4E?'RA')]=)B9G7VM\S*^ZR7B7:A)X=3;&7SC83^4%/LE*
M6*98U6M4*@G6V&%&;CA==8W06P[N0$.4CH[\E/R$EX@=WPY'QZB^9L$&H^)G
M6[Y%9_F2+4]T\%K\V@15D_K"HI/](:RZ<HGD6P(\:W O_^B WHYR<IL[(]VL
M6J\FJ>13&.2'O-07SWFF]!>K(>_+V4JTM"[WR> !M[?H[>SX^C#[WU R8W?!
MN4@[YB8!84V<\N9(AD.FD!)5YF@\;D)R;=,/8&VDB9ZO"U&XL]>]3XACX3V3
MK(A6SU?Z[IN<2QD9([;G+L.:JO(BG!&?(\ODQTS![$-#QZ.E ^JR<V03S4=#
MKO,_?.U+?/[[AOG<T'9NX>XV97J8 74Y83RKW>(U@DFH&E(-FWY(0B[.LC![
M<=@>B[$9*?^.^7V'1J,@&VQT6WO(,"$TR@MAE-3SBS?&4&_Z)U-Y=+)S>^GX
MFXG:R9WP6O6QI%)6[G<5H[XO42$I5/DE4^Z&"2N/\]#\RO6VUCS;HXF#5<W\
MSE)L>9DCJLH410;BL[2#>0T48WJ5%U'HO*B:!"(&>TT^_Q+6X'\14/X,N"T=
M.GT&L"DG5Q*U._ATZHQ2D!_XC/!8-C]P@E\_!$O\NL<Y STD \7V\MEN_AS1
MB^Y$DJTIZ:$@/QW'[PE@#TD?4Q;L3>??W.(Y7=#)?'YKB\?ACKD229^/I*GI
MU""AJ:'#6/H>X(1:QU2O:Y"S!?J3G1?GNCH\UE;/09TU\0!6E*4]5).EFZPT
M/ J+VQ0;,^#V^YUXN^;?[@8\C"CPZR0Q)--\*!U&T7ZK0\(8T)X>N_\,B-4E
M$UO]LOB45R5XW$ZG+7Q6V?VT^&C#\_Y7=TC6;Q2U#!G69;Q-:7W3D]<F92M"
MQ=E%G]4U@"/[=GC@W()9N2KT%Z];$X?(XXX0[]4_B:XWA]4.31O!6OWDA26=
M#2+PH@EO+R%7$QEV.=N&IZRQ1=$-83N=K-_@V\B??ZYE9J7GNS<61H^-]?'T
M/P,6WJ=?5[B*_"8[BV)X!K0&&I;N:NATGOE-4IIVE?.QE3IC"KB,2Z .'0 T
MU,E ^BK_D-''_V14_?\+1M=]+<60FXV'. ;&M%%9Y7,LOPPO:D#NZ6[]N50W
MT,IF+WE99[4<UTQD[&$Q9M";ZDF5Y1F0WG#42'I/V3O^=-)J&L?DL)+FC&B$
M347>X:N\_B4^J7W^T)<77/ K;G3H$(_;_O3(72$7+.*\R6@1OHI]D8 'VP_X
M_@Z(X-WYK#@S^>23^PPH+U]D[SQTX3;:.6M1$NORZ.YIMB^=>P90!DR(:/YU
M?UKN)0]TZX(#7'2G'1 _M:\E#ZGF4Y5,MDW@J?P8#/NX4CZ^*Z;F_HE;9=FN
MK M_*S!E=_O]JGGW'RASK%A9AXR!=LS'Q%(G8<%&LEV:M_AD* %&TBIY!<9Q
M^A!+E(2C.&QU:JE?<87AQ1N?+\B_@4R5-+C7F)\!>Q"LN]8.4]":DE34:J<V
MP^ U8HE?&\.=,&=;>7D04E6683?1\ SX?C^H,V#QQ->H'*G"_0P '_O@%P%Y
M9_3P5/,JG2]?[3[U>WYLV6 XX#OOC*N8^:+#E^,;[27Z?B=A\)*O##WRM #'
M'1,U3*O@OZ+:,<-(:&91SL.EQ#- 6[N"Y;YL:-HW=62'_^D1AOKF=U6!^D/$
M/?^EYL8'JXSZ[8VS )X*:SOEG6056Y3<@/4?(B\%&\P6M+CW2W5<AIAE2?M]
MKRC6;/=:JA]\]B\SC,[SNT=(]V^\YA%X/F4WY>XNVV2J%2EY/X4%><0F&3_2
M/.G[3U)#WB;!XFS&%60I)SR5:#G%4>P>6XAU5EU]#5Y@^YK9=L"> >,G=[5L
M*H/7CD/#",34AV\2K:\&4Q&PXH>Z@@<2]R571<.'Y2><<8,![\&^F -C[Z"+
M22;*4<;*2N+8PG)\0/+%(_^5H6U,RF'.6;*=V-8'$KZ1\*:GP7.[P:^/5BNX
MI#;E%"K^X@* 18&MQ<#_"K&W_K7<Z_!GP.[UHTYJB5B;AY2RIT=0.R'&%*]P
ME\<:WTXRV:_#Q1KU2?7OO1KS7"**4HS9/F$F2)S"]!,R ( \;G]8#?;1:\^/
M"TP1JNSE5"&D01S(M^Y:'7(H.1-$.Q5@P)FZG^K2Q07B(6W+9YHJ'W>DH/GM
M"#,Z>D*@65N]8@KLR:<J\'"M2S=K$E6ZIKWN%;(KZY\QU%>F;TKIYKX&*8D/
MRH)V?S\I@Y\,6@A=U&DD'P8$[X\MC71!- :APR-0A"3!-I$.5AYYN@O90X/T
M(Q5KU]Y$G.CF,Z#L@^B7Y9A;=+\%X9CWV(/AO7PY-X(:E_0X@?R@E#H9Y&'%
M4VGSV=FV,_.8HR^QX<J,L;^XZ&N8624?4]8R')HVSN==GP%:\#NJO6\%2T:Z
MR$@MJ5Y6R-_80S1P#\5_TI&;%T+/G9X!=,.!K 8Q @S@_"=S$O\KSFIF*+CJ
ML\6._C5E]!E&!>I4O$(+UI,>U5-"JO'YGG2.<^!<5 ZEP\!#2*<]J534ZZT^
MT\S)!Q)&GR0TL1]\H[K42-O%-P6U!P=KMQP#E_G27^B2I9T(DG3>?Z!\&G4<
MY]4'W1ZV_,T,'H_8Y]W3QVS,7X-61]NYD+K3/D'0+LE-<.,Y9O1OFP,3M[M2
M6:5^) VK!G+$=MX3:*?H#VM3U+E4WB=(>;]:0-Z7H34(>P:P8#\#9$:K;\\+
M)IN[#B4G$WC- SYM\,1127YWWF0?WWO"3!8;W4:]57R8.21&S7I2-2];\=@9
M<S9]'8%.IBK3^Z[<EY[VI_$RB(/L5+$]</1OV15*;Z6ZG\X23H7/O*7?@84B
MCZH;-14HJTNH]]U>I-Q^>Y)_6 A,EK1D8- 7P;*?5CH:9B>I*-4H:P84GD4%
M843LS3!;CMXN7:L^ X3%+OU;A:\^7': KVGY1E!W4I'# D\H[8T;/Y"Q96O^
MF]D_S<R1:@FU NU(;P N%FI,V96F/8JQ<]Y6?U?;Q#?0,?A!_,'CX&FIZH\9
MV,\O6<7QH:\Y<JHAN5XV)?]U/3;E".$,A9P>+<[&%,)7=-Z>%(;_TS>9[P/.
MS^_@CT^1J+$5 +E:-4ET[0@3P6,!IE4R.Y'RG<HNF&*;ZX?,!XR.D[;B9<RV
M%-D^D*DC*T5%0FFP6C^26ABCNSS[@?Y,5OJI>L'?&EJM"&3[)A)3Y]I!=[9A
M:7UU#;K4UK.D+.LV@=*N#W8J8V05Y:M3:ZAOFP7->%'9),J6)2"3<+SG0R=Z
M'+7* $X(:.E+A_<R#VWJ4J:/<%MFA 378J+-2?<&^5!=8R7>PE8#K3WMGP$N
M#FP4:[=FB '_:I=5EFPA& S]MK^COWS(K2$*G3]3'Y7\QLZ&<0UM@]N%IVO4
M=Z<2]?S5"LR5*VL?<0I3=P\<84EOPHX.$Y&7YI&:GV2VEJ16U])0IR&:4Z:D
MY)*#<B[BJ)P=TV4>=[F]5Q5FVUSARL!X*YXAN-  N EB!+M!X_>)KGWKXTY
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MN,WII[>=_<*<[:$-HU>.*'B#/7 X,&/RK+2BB(;).@_NP[#F38O<F/PFF0^
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M#;8P;>GY0$9."?S>]ZAR.=6TYJUB6RG2D]?8?WU"J7UL&QO:_*1PN5-@XS-
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MGR,OC3]7/:3N\K5$L>5A0]1T]43U"V,@1<MIXU68;5V0-H.P,#>59:==UE@
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M195>%XC :T5$*.X+.(J5@&R>'+VD*&&$0_49,^V#[!7JMZ#YUJ7GG9[#QE7
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M;@3%)?W*W?(D<8?898##B;L_1$:IP.XPK84C'.?-H/FL,F=(N;CD^S>8$D^
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MM7872OE%_N[5B9DN#*M&ER5[/P%8:[%V41*3:])<C?GM9@BWZ3F1>=P;<#3
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M)09+'6186&G K&?BY_M\/!?AR"FMNM83K72^155T/!>0</J[3Y)8^9W5$Y(
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MLLIH*?Q@OO0NB\$XH9(,D/>[9V6QU(F2P.# -1,!V45NH;.'30,UVC%$SLI
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M,SF?:4MU@^3>\Q@KMTH<(Z<=NA_8F?22FM4_TD=Z1GY2:AQA",Y,8)?9<YN
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MF<2&5%W6D#JF&]-%(I;K(OD_FGWFIO68?E$G,L3EW1VW$=+TR^&&7%:(I#H
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M?P'_$Y#ENBFT/N*1G#S=30#AY+.4'HH<6[6)#1HQ$/E@]]/4Y?N9(<7@'L?
M\4,*GY;Z^Q+9,*N()96':>?MGBOE#"TI#2%]!IJ#(ES6@O%DFLG")\!/Q.:P
MBWJ")#7RV\N"$Q[2E^"U]B\NXI/$43A4. Z5297P2*@P5)1@"LAPQP)'4"/V
M#*P%[,#K25C-/,S14Y<D0>.=,ST7OE=!GFNE!7YP&W#E>U/E\:SO."C:'[C1
M 7U'!BHGLC=X'\RX1/3>L,TT[4OF_GDPPB66/$;K7W1EEW-.XWY1,TM;!V36
M,E@UU$)!T9H[O8ON6#4>C7GYC8DYP=K(((W0,!&KZ O/A;@OH6N"<_?,KJOE
M)W1HF).V)^?Z;CT]#+%E0 &2H<%3PG__0E,SU:1:Z)$@FF<Y:-EE!OW=R*ZO
MJ3*F $\\Z2?"[]//%'ZBZXQN.SF@87N,MIL*ONV/?B7U$%W'XKFTS;39:6A2
MZ48@6L&$:RC8DFU,_DN N,XKOS4B21Q\C+?#=I;IC'#,/FJ$1?>ZYX&^O+EW
M$R3/;3P'SVM7R]*?/70+<(B]#7"2K@-Z5<,G_8N=]W*SWYRPX%QPY3$(RDM[
MF;(/S4<Y#-:-34.&)PH">BRZFD! #J31^@2E(Z8?,Q<,VH%;U;EA0)E([,E2
M3N5\T_L[33@1N@%U]6<9$6)K.M<'5L:;#]'F1]F32[YB+9.D,%*D-4H4']1L
ME,=Y%XYW+.X!S6@C$WR8FSM1]@>O2W$[SK:63/Q8%JZH]?IR64,9<)QD'O;&
M+!YJYZ4S8Y((%[_[=%BSA;<=T+"PGI26F)-G^(8FZ>2@TF%+9M*0V%,YSW3/
M:)C"CA\^CN>@:)<=?/"FB9<PY\R6Z0N?&I6OO N$4^=N^@)W-Z4*Z-:T@=#8
MUE#N$ Y=7Q]S 2V=C^VX5X-5WQW933\!/A5.^6Q<PKSZU7@Z3#)3!E15K##>
MH/WA>S][_1'$<[VV)H4*]T"0)\1R6PR]"K,X2H"WMH^W(3(R'8V&$@\Q(W03
M:IGT,#JFY9R^_*HU%WDF8+ :1OP$ />LKI]+Z)$I7)#PSA"5;<BT- N/]%57
MH6L3$XG0?N_O I=^R7,+R S5A"",YF5@1G+/9Q[&!#>8R>\-5^ZK8S5\5B6]
MC^EW$+Y7X8B^%R6NH%9BU,ZP0"/]N")6X"+]Z\!P_F;0^Z^E)V&\[*J<3C_4
M)V-%6A(5"_<3^C/DTGV2."6BE*Y)L>-XIU4BU9'Z&(VM\1X3*MK>+?2/6A8T
M$#F:W:.<7N_<7["';[LQ] R$W?JR]@XP_B/LP!\UG_#W6,5N:S:&IW5]ZPW"
MWMA?E21EF,ROP"B"$/0\C=436[X)5" !G4)4>=ETYW,@=1X.53$D7(JHK]BI
M?2/CY7>P.D$B?P*B.#Y^^7>.7E(!==,3(-V9?B?AUX97&PK)O+Z;H(:&W@ $
MNFX=,^M#X$&*56L8B[$MS3YY [9T\#)##3767"SQE,.3=<5I8J^N"?#XPZO7
MUV=LD.%HS1K6U">04",-+QD64I:6W&7"O[/6?#1M?(9(#;X+ZX W,EB'^U6_
M2, 5M<VS<#,F3@X7&U8H .6N=%1]6SSBVN&@_@,^G^P,HK!R"QFR%10(,.:<
M+:XJJTJC51Q+J<T'TL\71K3X?E>DRR)R\:.8ZU\C8/FI.0+N7O  YSP2*IU=
M;"^9G==^"@9WW7WS_4%WZX2[-X&%=:V['%0#%N$L4J-' 55KOH?;RV7_J]_,
M9Z.TK+(#>X7[D@%)YUC)R27:D#FW K<KT0R&^&2U2PO\PG+G^1J.H_"F5PI9
M%1>'S8%6 @9K!>QAJ:%^ 6,WSADD-Z$VHA@Y15:W%R"H:QRQD0G=6\7LPS?0
M@Q>HBJ#,-&ETT=@$R+QO%/6"T)F,FF19BK%(;,X7(K):CPMQFR= NR#^N3I#
M4+53&PJ1YT5W:]Q;2HXWO>T=B;1 =M0&U-9*PX@S\NPGP"\O1E.^FS"WZ<W8
MRCNJ_H8@$IM3JM84';V4G![<Z<1PK,^MZ[J*P\JOE!KH#G6B!#F1/QD[UG_&
M#&O)YE'JQ%9+,<J_]5H0?5CG&0U!I*=_.JK#AE&MS?WD532@#>G<6C5,8Z#!
M<:==^D3I0]@>*7'^Z+R)LC,Y'T,+HZ'T^SO0]6D=6B9;>Q(5T_!_<F\R3#]N
M,Z72E3J4:Z;PGOX;YI&2:\:&]-NQ'_D_!$/3:';GOWR8:0BB^A:.4=BQ"5%F
M60NO1R,0&$C2O(W3EDE6^LWTEY9Y4^G^,[L/O4*AK.7'?AC]QR:97;Y+0$U3
M)<=K(4&1%ZQTRSX&],3L4JQ]<95:I*M/ %<ZH[R-MU] #,#98<6J%@(=RVAQ
MH7_-DIS:JP;!(U9-N*2?E[_+Z%MB;*DT5A]@#" 7G5;,5BBW:^B[(@YL_:M-
M7DZ:$L\-Z=WXZ'2[R:GF/'J%T5]DDSYNTS>%DI^8U+8Q6KJ@,ZGSO99NE$[1
M,T[G024%@)0KMC:VL;-SQ*->1 ]<-4/Q=!4+00\?9VX_' D*-QW\W3PH<M )
M?YYJ4P"AQQ>+U059RD>S[;+'__:.4#H47WYSKQ)<LP;=O'$^G9(M*N"+NKEI
M@:RI_$WZT4)4JA)J68K]+7(&RBBQRBR"YA.@9!K' ";B#M41(6(::'F@SKUF
MBVLY=3S*$^"EB-$52TM2$*SCSKF=O"@SQ4\Y').?T*!%2_H/FLXH_7/CN:)/
MK]353/Y-2SNHL[5'DM+18&]\.Q8WH(O40SZ7/'Q68KSJ?1>V?F?1^OD@\33G
MBBU[&-W4R$D=E<^4_\4O2LQ"R1?%;A<Z8TLN)J?W$+\].DWU[,'@^S4C%R:0
MB9M,;F)9 ;,*@_D:74WIAV'&M%QN&]8QO%:Q5"QXV39%;-+Z?#=KZ-LU(>TD
M>< 3()J*XRYM3:'[!/X ,<;55!X7+>U'R\&L66-Y$XC*:@6.J'/0E'[!7,[9
M5E0V'2;<"[Z9B@_S *]*XOK6+<%2&@7#4YFSX][H%P+9ZI2R/N( 6$L7W$^]
ME_GX@W#P\2)/[7RI:\#2U7?/"BY1YCB=.T-Z$0\-:T/>HW[30>E3/\/K.5K+
M/Y+5DZ-Y):)]+_BDV7939>TD6'?U:"1Z@?^V?&JK)]2% Y+*6M=6.#VJK9Y:
M1L#M@J^KU6>9,J&:Q9MN_7PM'QCIJNV1,*R .-A(ER1RH:@<+0:$#29F/$RX
MT&\@$:$P3HR*TIV\N1_AJFA++D3)W2C$/&/]R_P5A6B$\YE]2JS.T5.]>Y7=
MK,7G"/)O3P!8+J_C$@.,)K)?G0KM+:8(/X>,(]W:<>9/?A0A'I5-*<C@M2ZF
M,=X!T(/6ZF:?YI"YQ"Q@LASREXRPA Y<6M54=ZC.U\<-Q#69/GBDA[34W[8
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M^!.@MX?P_JI^\&K3;J^)YJ6$ZG'5=/_277'P G^:*(W7R353_;C%$^"SZA,
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M/NQU4Y+!#^Y!MS^JOC1?>.+$27W_6F\AQT5>)MOV6;RYGV/_PH?3O&0J:KY
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M/I'.#3-S'P2,P RRL?2%^ZMJD(Z/APH*39-DB>('7!$5MT$*^G?Q.3[QHH\
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M#>QN^>H%8\7OPXU=DAD#C'H/623<\,<Y?[?'E?K.@'');2F,GWG,(:=9[<W
M']=I\^X%0F\F80D3=6T *SA<#X]"1J?SPM7]V0]ROBF2YQG%(7CD#>77G]\S
MOG+Y]L2('!,#V#Y[.COV:;()[@ +F*\[;CQQOC:HV6URV)IU6J,S^2X--<;[
MU7!8%8IM,<=2T<A<[[AVZ! ,SX' .M*:/"[Y#I9\MU]?._P(*[.A.Y?NXU(@
MF&IRU9CK!5;5C;]A352,I+>ORD=A+1N-MGY,^MYOQ/>JBLE:;FB.*ITZY+W,
MAWY*V?W8V54'^*+?LI6=W:J@MC6#:G5Q^ NPR<BO;REN)EIS*282=!4'_\<$
M8/E'@']- &$Q^@!>=_Z1D[JA2PYG4V #S+:F.X\[OJ9O3H0(1))89/8G@Q5L
MK^.C/^(R]DPO<3J7V1S*Z&:R-]\QV?B1L=6DZ@G)DY24,*R&.NH0W&?(J->X
MNKL(1AALO\%@S'>OEVO0J>SL XAT'+T//Y9+BL<A(K8?^%[B26+*O"ZA6#S5
M*%7%K5!SO>%ZIY!=]P/(PW%F0/1-]17ND/W-1&PC"#A*4(B+&<(0[FV2-F#A
MLO6>0X4</;M^#S'QYB2!S"(*OL)'4V1@W4G#3&+H;1LF^.QI24D1EE+WD?\9
M?X\S4D'0Y8?]LG<@I#W1LN>S6?TM!QR?6=NXS,%13RM-5:U43:S,*%I*[UQN
M6T?#K^;H5;SZ%1%^)4M+Q='!A<#ML9+4M$5]!JDLAP)T0+O?L[BJE/4;;P8%
MR5:J(*VG+-U*JQ[2)A1Y3!A$1\W54%>@K8WV6N)GP+3DDT-\9-+Z^L4RVY[(
MA4F&>9NF5PY#K&7(%J9L!DTFWX^!K11BZJ"AD<,JK+S!^-WX>7^*E:6:$SA%
M\T8@ XS?QIP*<P$5L</GMR^[7)P"CE*+".W%_R%<!]KF$G0F?EL:]W1"]\)C
M'_-*'KM!!N) ]GJ&K<GH=7),36>S9'9PL(:&.OJ[#??NZZR--A1]=KMIBWUG
M3^O:4*-Q;[WN_=M33()*CCF^5M:*T3*FV;*\.0Z9@I ;P3.JZ@>=P(+3/Y%9
M\&O('\:5ZX?-E9ZUCDRLP+;A;<C/SS172VOQJ<&7 5M2/Y,? 99@I$[C*?0X
MES_T]?5O$=@1VC1]L>)T&HSX7>&.3[1_SM6L)Q)T57M29K][?]JBTOSI_I.K
MPE?X5F8FQ_,M;*XHC\8CB;V(L@V6;O)+QM'[^M;W]Y'L1ZN^66:69,Z7/9:7
M"Q)G!M$0"Y*GO,I\[?@R+ZDU.0CJA\EXG(<(P5',;U;94:+]=,+Z)(9NP^1?
M* 7Q\P_ 8IQ]JO%T2;/=P[XWW2A<;Y&!.;8:ME-:HBN4_]W3O>^W@)40)3R@
M<PYK5=4SKKE*KH3]K=KSF\/3:-2DJ\>X+ I1<W.*O1QMV 4]4;X>S=YS?*5_
MK?)[A"23J9^73@$+]F8GIT?JHZEFK#;$;U84&8WSQ20,TQ2[,X  /,&;J*%=
MPJ+_Y!M69K3_$6KFU.@<@421+CMDL4\ZT.2*5(*;B3P@+NZXI%JO5G8*4ZBP
M<&AX4\WH_&JN7>?R.) #:S^0]+!:AQ.'R'2'P87[K$4]C'Y'MJX$BQ?S BL[
M"@2LP:J=ZH/T]M.#U%JI3$72OO^V E.@98Y _@W34\:VE;#F_JX=2?@C -(3
M]&G)6)Q,5>$K@S)W<4I*D*5^BJ4Z^9W6@[&(X5F@]XGC<MF&?_.&R":,TZZU
MP7!X@\0U>[PWVACS@42*6X:XI,B&1L?,+ZGUETT,,+%B_#33"CYM.OWJ=0$K
M36O\]YCV@0:@[5R_G;C $PTU2%>@C^$1W+![P]R K1&\C"CB'FRV;_DZ,7ZB
M7+"M6)#U*=FE<%.B[UW#F#0D90/')VGW86DU/: OS1W1-5[/C=UVN]'H<T1]
M7=W?VO JF+24[%,D;5@"\&V4[DYLIL .5D,_P9=X\(;54I%5M!1+309=XK-!
M6DT*UM(]@2B\'1<?3%^&TSW4L<C.%9EJ2UMKYQ>##<35[Y=9+W\]L\7DD2X?
M<&MHJ'LUJEXU(I47U3.Z7]G-<2HROLI+=MH"V^_DMV3S0(+:A;;973/:..TV
MQ7XP65H7$LS%T@./5: >]]B<8>J\>ET7'U$KK!]H0@@80OG.KM72!!9DE/33
MJZTQ $!;MJO:4U"7[VCKZK$=N,4>)M(4[H6L3IW36^X:GA.VT>2V@\9I^C$)
MA"[H1=>./ *"<W3.&_F;6B\]CH]/LD_\@V78.2P]=13!.]^M#ICV ^F;N":B
M:35GN(F 55]U8Z#7X!@0DP=2V2+/')NT2$-ZYVVX5U\B-Q,U*>EK&:\0EJB%
MST6B0_=[_+46U2<M0]4MB$7;+G?HJ<TZ0OM\0$_51N]IO3KTB6*"6TO*0G6Q
M6[>?XC5H;N.U,^I[H=4N?X^)!Z.%A0;+LN'@RC+N%BI+B%6)N53Q[XT2 )D/
M0L?H8O'< [,SBM,S7OKNOY_LX?(*$=B.L8DBUOD1_M[%K5I9=P>JP+@#0.^^
M\=_RG Q@:#:X/CZVMZ?C=$!IKV+,(!9L>]W3M^;V-5+0,])G-\7+GH:+I3P"
MGGVHW;6$V$ .$<O+ZX)KJ*=1GXS&3FJ21X=#)V?4)AX4K,$Y1-+E19:L6GK2
M]20,OT>)4U5/[+.'10=(>>5+(H<X7IU%TEJJBO/P4$>=H>D05F/(&OTCPW\_
M&3Y''$>7O?U*=5Y[XW>),>*PV )3=)A>SF&$&PA1+L7"UKO(4@2$;Z>A?6I:
M<_3J41T67&)QF^^^R!^1#\7]^JZ4E,G.)VTMV<_#[L[S)A]*^TU#]7DR))VV
MZ:\4>FS'>?"T *3^R#;8P+_'<_FD"'^R"4+T_;QO#$!)2P-FVHNN""VT41]2
M#&&XT[Q&GWT$$+:^^W6<B=W_5X)UV$J0&;^.YU6 WD56G ]#(ACU I@K $U-
M+(KC2Z#-L.24V<]4(Y#@[;H0&4!6OF%5_1ZAWHMFQO093W*.D*';(E-S)D6$
M^]08'AAP53.S89V*W6.[PD8^ZM!XC/PZTOL.J--O\:I_!U"G/JAHZX_5L?(5
M5_I._BC@\W$ $K%&:><+41ZYP871K9-=>"*Q9="U-)TU*HN)J,CNQ$ABXM)P
MQ>.T7^B!T^1EH-YH:J$*;:?J)ZJ]S]#E$5-%UIE!E10?]S5X#>-THUZ9X(3
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MFG#>ZPJF5IJ^=?NLD6,A>+%)>Y%OL2"M/I\3GBK+>M_364W?<F2J9QHP0IU
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M07^BT'X:C#JD&&T$X1"OB8E;NWPA62-I[,/ 'KL89](Y6U*I<)%D?NM_/G#
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M8-5T<GOING;OK<!+/'5^DXI\&QY)LVNBL8ZO8@8WJZ&_Z7WGI&\;]U>AVEE
M6SPZ\Z2N. Y&,U4!MB/A<7GU4?N-MM8NUP]\W5M%0V=M1Q&G*6 ZJFGT6QD4
M";Y/F;3H$*/;QX"W(I#_&:>+NOA\%^F&*@TQ91902H)3_KBJ,ITRQ>)G2@:<
M8>\&N!/L8C>]"[WZ$!C47=8CRA=2.09:>Q+/]*)T_6:E55(5H4I;4T5<@%.4
M41PH'(&Z:5%O^F0)^?)B9GZ!+:FY_LND1N4EAB=6K>O-U$K2^'+2$S#%,^!
MA\Q WS]5%V&Q\@DG?INB"B^E+&.ZT4 9J P,8LZKN8MY*#[)OT($/ .B-PD,
M=@D-?/1W*U>"QUO\E;8K?KQQ$4])8QZW%ATDUU9DL\UX"0SSF*T=)?WS17?>
MNE01BWO%1)'43:Q0@W6,U7"1(KOT8VG)B%X$==59?.-\Z;3S'#B8?=TF75P=
MA&"[8<CM]7*3G,#Q=X(AEE5#%B'>50'L76!19@&^W  ?[9@E':TW G2G";*\
M0<=[LHK#Z_=!7.LEP*\U(Y9P%D>4O=X(*&2(\>78]L4(.9[.[(?1MSQ?IS1X
MM+/GS%/I-J!&4,EH=U[J(B,Z+_#0BH'"?L5\8-2[Z$7Q^[D3/^1)@R"]*9S3
M:[:6U-#,9+ZO?77=&N>W"!-8'M>RD82[O*2\V\#JR;Z7YV9_?2V<\1_Z[S"3
MYC &D.OD1Y_[>[9VRV&WT('8X:[#M*DMT=W4Q^6R,F%P)&%\N1&U2M1*2:VQ
ME='N/8V!B4G-;OR?!I\P4F$M%:<R>LUYC"-R2]PZZHJMA<S>,_H+69[UOK&U
MF5^>H(<Y3S*[VI*FP.MCFHXH2I";._F#M/MV%7^U\/L&X]C/X\[Y(IMFH(U\
MMM:P]ZZNN^1TOG!HBUNEER_/]UEE0*87V54DU2)UK1E0:OY*U7L[ETKSHJ<O
M.'9==,GC>J[*B+BU^>'AZQ4&D>X98]3;H/Y"#^F6]<>V?>YZ@[4MN]ZV#HI)
MZJ@0I= W[,G?*5339E5R\_\<#:3HZ8?G-(Q+W\'\&49D(FX9(">%7Q F0CIT
M,D^C;I0"B$*/K:93"5OO6V 'JZP?IQ.0];O"=A5$"<P(=3RFR'8,E!E:6%P\
MNF/NY%YG^#Q)IDWMI)PA\D(BQA"M1JGJUM<>]H#5E3(NYN$%$_;^9A(NO*9(
MY<)Q8A[:.82RC*4QR1L,)S2YK58_2B+B7BPJ$ERM /HOF?A7J((84FEHQ#&5
MS=R0M8AJVGQU#N&T'VRF,=*62KZQ-:]U-$2DM4UORV-UI1H:S;=@P+8UZ=8C
M_0\@GEY99FDY#'(I;,9$^L:*-4+7FW!08/QQYLT[(W>DFV*+TO="XD+5N)U*
M3+"M#_A-19!$X\Z"7N&^R\54&&A]^(+PNPS6'IQ]ZWIQ8GY8H[?9)!;/[V#M
MG6OPKQS:)U(W5<+U>&,=50ZBVVJ[M-*OO+D2@^74]/\G5\-&=<^ %Z<L%Y-K
MM'63M <4FY-BQ$K&8Y*O"]V:X-E,L8O[YQ8#BT]<X'\E'W"O*AT_0I5A828^
M!;NWL-<37-)CRNH$W94GS@_-2O:5Y17%JHJA9!EG5%3-/GH>ZLIL$A2>!C3R
M?!O]WJY9;\U#T9E(;Z,88Z-J?V*.?B_1)5K#377Y>!4G"6OJ&FSU+MKEY'T&
MK,.6E"W32(M8P=8]9)&;*D0CR2T\L0E;;\/H]-.? 4*]62;!]EMA0/=G0$1@
M-_QL7$2S[>)4 G]8U03>A @JVB*3S.T%I-76*!C0Z7H%=*DUE>I(+F";0P('
M>^>/J4I%/39+UN-?4,5!7F=)E!BI:W^O>\'XDNW]*)/7>=B!5$(GBN0B;.G7
M])JWJ9H6B+[?T ^>L$NXO3+H-Z$[$BMJ%I3</$(A;:VK7KX*+W$_#6V"^1?,
MC6LY7$.1?=IN(-BWH<YQ#2,Y,PQ?W4Q-E=+:U'F=L>3$=UP_[@' 5PBX,B/7
MF%IS(V,-NCRV. :QO,1!SU6+F1=R]S[TKP;F9.LL8DV!.1/,6>27_,'2BXI*
M+36 >.X&^H_GOSFG6&=@$750=4/%+R-B$_C3UGH9X7Q\K2O"R[L6>-Y?>_;K
MZZ'^EDQ1D P*W*(-(URE(MVNM/H61&FWJJV:4ZPL\:CLY^;O%54U*6=7','A
M2*4M%%WR>8=QJZI[,PC9;M;Z^8BS5BF..G+MURZ:Z@O]6E5&;DH&QZ"$?_]O
MJ[SXGP4U-G>I-\^ X+^Q[-LH]!U4N!,HZ6#S&<#I=R,/S-L(F-INU6U$81]M
M)1<=?DZ3O9/6'F1Q!"F2SWO]B'3G0%(@6M;RON\QMN;^QEYF$?A:SJ4WB,T^
MGB0QWM"IT;;6AI)Z&/2>?+MN:NSZK2.\&QO$)Y-K1#]8[!4YUGXJ?\3%01D5
MX%/P#%!DF.Q]NIC;[GV*('\&/)JA"@U:PL=$EAXSE9\!KNN4SP"S[J1G0+E#
MCBPJ$.NQY>_PPXR,Q<WF 'W+[24\J) T;@-1Z'T]*(K8# 95LE:)Q^.: O75
M68#RS*H.14&%+<&?TD:FE=3_@&06O/3[7":$)LGG8]E4J!:!:F@]K8J\U1'Q
MO;AU0$QEI4)O?JL.AU/,+G<(S<GL"@*!!)L:K06,4[85J%?6;07Z9AJA!?17
M&BFTO=9L4"Y.@7O0)9P7AZ?2Z60FP[':.\,:FD7-E1S[N,)C@$:?VHC>_9T"
M2@0<Q S.Z@9\0RL-QM.POC; =W];4AHK1EZ'#6)GP4)22MO8+<'\32LF!S)O
MVL> [IW*5OZ4;L(=AM]J^,E])=*6\,J,@-A_:J<?\I$2*7NVSP!>UNK^\+*K
MVQHM1'&MUO?A9P!E"C&O,VSY:.9ZP_9U@L'A]C.@T*'"_K.[!?R^B[^62+_$
M/(5F8$=-O\"G+*0SMU[ZVXK-3:D7AU&O[S/ 2,=E;KN0X= 8:25;I78\&\;E
M.2G!GV_Y#)B\;/DG61L\;N]_^K.K-C]SD?+33/\)[URKEX^:]:2U4W/C3K47
MF2])9@Y%F35?)%$[;]WK0GN#\Q._UUZKH_A[S)G;3B0!<2=>G5&M /O,(O>I
M*N5OZ<O)'_>!PY ;_*R<'9JP'7^8>C"HT^2CK[&9JNMLJ?;/-IVM+%Q5X4&<
M/Z@'SCL#_K%/E;\<;L*FTVON_:MOZI6K)1%UQ[3-6V)O6.1JDZF^I8E@G(VE
M*W $DKT,^-@LS+<;G2WJOM:"H4PRR,S3J":P_>&JB"4^50ZO_#-12-6BQ.-6
M=X:%O5@[R)4O=J<-)9KJ9B+R#X"_O^E;J62DI*]G9^O#!'P/XJ(EB'/;1#'D
M,\@VT\P%A2@B09'G)MO[J^N9)D(-D@8>H#%I1(=8]Z<WQ<ZN$./D:,99:T?H
M2:;6;=4X1Q4(SRB!BBE"CBUY?6R5I3=6O08<N?=9;5H1.TV!2P#;K!2P4"D?
M'YE+XD7JL\L/ZCD^-P8]W$ WO=D%3$V4_4.A"N%\*S D\;I2LP(&^ ?&A=EG
MD)?FK8TF0)-[1"3$XX[M@M#Q(:;ZUNY2(L]F5U*(LWG_1"85U=.=5.EILDG^
MX9]@1HMU&>M.RVW3_>P SODHVL0QF>< [8)B7L&2BTAE;Z,@!@%++A7'U*NW
M;-B^KZKH$U_,8C/'EE[1W;<@V;G=OU7W_ X.6XJ##?M!)7OF0OI=\@OVK:JQ
MC.8)J1>#R P\JRSD(?9^A@,;*%1XCN3P7?32@]+M\:J9Q<*]/_&Y=58OUP7B
MQO7;Y;C6XZXIN:(@Y3$GJQSS0A_S6J8%:0+)CMIDKTM3@M/CC@]X9%,?U#_,
M]1/MEEEMGU/(.&4BR-8 N0GKBFR\U_]V,QGLM],^Q2^HVLRC;_*U^14#ZAE0
M:R!1E$U-F?_IA436K==4#[SBX&8 =#"75[,;=O%GX]_MY?)C6?P1'3+C^ '?
M?.T7LK/K;W\65:;*7EU56<WPL,[/WQ OX>)JX03FH]4!UTWF'%Y( 'LR>PX&
MF&=FK(G3W[A6*Q/$7/.3FL@I.<MK"=:S='\/0T%-*URZ7.%[L>O>G4;#H<'D
MC_D/^BIVN6CZV 7B:O9"[[M463FUG7M\0U)./D4OK[O#.C5 EOZRP2%1R&_N
M*KX\--T;4KPOE=G(@1\Z$N$?1H6F=ZJJS%;?Q:7M.IXD1\YG>J&6"/9XDKQ.
M4OM(@9QR1E1ZF?)EGE4Y/S K7ZIN?2JR@+NW(C0Z$)F/2P*F0%"+:Y[M?<_^
M8C4URI$Q8,<DV.-')<0A4U=H1D_!EIK^ZXW#:<J^U9F"&VR4_NHTN>'.8L8P
M=#SI2T?0Z:O6*K]]'7>K"Y'IZ1YEUT4;SBU([PD7-PM!V[Y)?_Q)37W@-O$*
M BGUJ__7ZH:ZT9A8-%/AH*JMWCS%^RWYH]GWG&I"'LS1M<F[&Z;7T:?\?N+*
M$*C9, 26 T(1+(3R';(]MEVM$;7VTXR@S"#\Y-:@-YM NJ_D+X@3LRXI[DC7
M'Z5A3YP[/>)NTB4PF,9(;SK<O23=XY3':DQ+3KV#L3H9M[R,'P\:^UV!VXEI
MPBKU%0Q3JJS5!-7@Y1:=$37K$J_41Y6H**!=SR$G8^H8]/7I\&G>ZT!VW9NU
M:P5S_AKQF@]%,QSIY,&['\A#_\9VJ6S8Z[66UON?].CE[G^U'A#/@%->&>YG
MP)\7%L^ A8W#JV"QAQ*S\!7=\.O)V<UC6%/OWXE+]L<IQF< -"R]<%)A[_7H
M5 *=\DS;)GTR8MPO[/Z$8E6\4C#@CPMSK1JH-W5T_C%?ZE*>):VLF"^>$DZX
MJNA@AZG!=G)M\O,BX=HG_EW;D8(\#N3=8+ )W5.AQ&PWS>/88\[N:9#8^K:,
MBQ@Q:%&?^>A-O%]<L1/_=Y@&<1K]=YP(&S7T-15 06UX5; L.D):=DEZ\&ME
MO#1\V2PXX81:M>!/DXYMT]G2JAQ;KA#NF-[ 2FH5OC5A8QVR9!G(2H(KY3;3
MV%?"0B[UUDNJ\^>O@%U$O?)FP_6KF#?!-,=YK]$^MT(NN][-:?J25[)@$"D1
MZL4\-/1X^<M.F,_=Q<FMO-URO!8SWQ>MWSY4P\4+FED8AMXXK77PJ"^IL3I4
M@RNP@$F9QHK*U-F=-7 .ZLL4'I.+Q^Z\GZ:C'#D.\S^J)U\DT?*268I[_HR6
MDU?Z9!MZT8-\Z#VA'QUK1N(+;5@H=LC!X5/;/_WQ&VY"N[:92C%PO-G&B/Z3
M(6NFOF ZE;\NO.2[LX+<T14>$]S=/B[!A2K#M$\)/@]LB?E-%O2T;2$NM"8U
M-*^$%SQ+CLI&%:DZ8_EIFK8B"-P0?@M-;)40[CCZ8!4WRMH_\7C?YP&6WN]U
MYZ0(Y5.\.]A7&6Q^+_/"\O-">N#KXMXN&V6Y2W[)V)FG$%T?'%8\1?J75KF8
MEE(I^B+G<,>0880X[P+_&-_6T:?IP87I.>56SLXEMWG+W=)\UHR%4?W+J;>5
MJC8"G]%6<9O$YGE(U_:;LS1F%7E\ZAM(],!=G$"!837[+I=DLE]O[MMZ+BC.
MR1MW)QN\$:4&J>NB6^%TVV.?^2(B65+DM"F;1"I98B28-\?G[N+=?SW>$5](
M[J0$:MF<KR ;>F%T%@IN7-0X')R7AK0OK4-D=&AK=9!'-6<G&9?":2.S']/G
MG9,%5-1Q.@HSF5=KD>Z\A9I@CIZB5YR.91 !YM^:,9[5$8E.M\E%'S/NYQ[G
M_:9<[G0L]S=,TG9C]X?Z_"OI[7+5)1'''^"QVB\6TTS1F3'M<&/?_9FP ]!V
MKZPC+@DOYRJ>9+5T=Y1-3RV2[PN;A7S .BQZM.4L_(DEI0'5]?3O0LB3Z26)
M?G)N#VTMN[*DNT/^+!EKX-E(=]JJ9L_K)-F0337LI2 88":@_VRLX IAE>90
MW_([F*%\OSS+O^ :DRI;O(PBD&8]9!!3R9G#O,=F(5S O!KQ^+C1;;)I]BK^
MB+YM1=QM^,<)?E^KLXLW@TW,3VE?1=H._@X5ULI*<*X%309NT;3(W_23I:QB
M!/]>U&) A: ZUX=9UC^5>&!,#,Z8Y!?DU"T:7%=<P>CN2 U)LY-O;=VNB/F\
M@JU D)7("4VII_$MS%^>+,WJ;0NF8IHO7S6X-%GXN'"@.F6?=]60/N+TT]QI
M_>>QJ]=V)Z[*=@[0EQNK(L*!*4V36W-,0&5ZE?DNXOFY4;W7:?WDELDU ^BG
M:P,4*U8\UXV*[\"<YFQI!TKR-JE5;!^XO%Y\7XB_FZN^OR-LD\KR[;Y8'&]Q
MUT(%A^XM;N*?W)=ZK=XN^MMCI?8SZ7-LB\UV5HN@!>C4:%T3';\* I[RY.N_
M=G2KG7S%O&3MM^[W*:E4<XPM"F)DPU,1J_F'3Y8EQ4^N,O*2COI$-*[=PJ2/
MS4=52J -GR K37?ZSO*OL0SFS9OK.\SS5R62>4W5 E<FB'"DJK=D;(B>Q.R<
M\ "3$=JMTW1F' 6'KO'!H9<JZ_V[?6Z,U88*:'PG2V::+W4N9[D*NFR6#M:&
M0ZKHJ4O@:>#>8ZD*%"(F3XE1;YNN'$UZ(X"N54-J3! ]M8]SP=T<)HY\!B1T
M$+15#<SI7D]-(--G[CM:R!+T:3 +HH6O#C]19<CI&L?RT_;O\6RDA[MTV#@D
M!/SK?6WPQTC#(U>%[OQ/F3.^0?N\Y<,_\L<EZ8I5Z97._7<P3VZ^E;'@GG.7
M+17KLKWT5>R$:3I5U3QMZ_:1"CG92X.[+^N%^%#V#Z=\X!\[-_8ZOC?"P<$^
M2*Y.3FZVT6VGIK8<B4XN_1BV K!320D+BB59*49$M:CUWF#4!!/V=E+80#M
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MK=K',#-WK'8K.P;CW@1F"#WP)&\FHC8B>0MT?-6H">1RY"Z(?5J]D![N^#8
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M=D96@B/ZEIV077=0V(D\PO$ U/P,R+Z+-3%$^7._$\,1A>,7'FT;645(J>X
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MW.M=<*K^F(]SK A>VGH:J_<-J9>[V)8?@V8%?;<*.[5-H 5Y$(P+Y*3,3</
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MJ9?<I/K\M4"X<@6$8+(0K"L=K]G$W]@_G+%;RI7??QB<S7"?N/4T=:8IH*,
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M-5Z*-.*..OC7/*!&PL8QU9"B6Q;(-C6_E4M4SIX%M[^E9L;AI3!\\KN+A-4
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M%7O</QYO]AZ#%124K?)'591*).!3=3&N%Q&C$+YCGR88'(A9F]I&G[38;G]
M9+ WIYI*SC#A(J,BIWX'U"_ZU\2TU:X*>053=@NFGM9#&H;17?NH9QR&-$<I
M%@XJQ+%CN6K9CLRI+-ZPWP$%<O;RE Z01\AYTB(1:515/".'^K=QOY]6,N$)
MIEI7T],GB3BP:]+&Y^\ A]QC$'>[D8SN@#-7IKB4>&C?GB(/P,SLUYTCY!S.
M#HKA.,^4I9]FM0'E'Q912;U:E8;YED>=T:ND+4(7R]?2SBA51E].;[1D5% <
MF_B9HL,J!I:U -#6<--[C_#M%+&&EI>#*V8HO;X4N?Y?'N$5OU>;3QO? =ED
M+D8NES,P$+)0+9+9IM-BE00YIV^#(XLJ/[QO9"13343T45#"\!BEQJW\[(,9
M8,B*?1DY'M^JV.N$*9[,_&;0A1I]@<W\T(T;F_:@Y+?3P_5UVV3$JAY=\[VB
M\+"4_M)LV2AB#")@QO['[F?0H^EM"U]).D2P[T869VTJSH/Q"*WA>,K#QMU<
MFX"03Z:!JMW:^P/"K'J$\EB#/TGW@4MO,B[;1W(GW_ ?(@>#P8JCA'!S,VV#
MI:EMGF!6XPS=XYT#INQ&+1S8"\]X,8>28A&$W4J+?!%RK._'$Q;+-3-O;OYC
M01,# DBM 3A&GA+S-2DRXNR]1Y_)U*4QCZ882+4C$=R86?'URAD.PX=7*.,Q
MGS0;"MER3P:(X*[)2B0G+V^.2=\!-IX7'8>+[G ,K\M3H)9E>C3M@):)$6ET
M-*901;XT[*_D//\\;/2S/]3Q>N38SEV>'>P;<IC*U)Q%>J8^360^GWFV<#+>
MP,'EEF(FZ39WC8%24(E1F&3VQ.\_?A!$SVR ]7T;^BDB9"(2/C>>"ZDXUS52
MD<7EHE5O@ ,T/S"NR6]1QXBP>4$>MB$O$XPRI#$E&OR=.F@^=:I6/_?E[W,2
M7%J8%[K3"V,O)*94GS$YRC1HFE:H(I%J)E-%H!$+^:^6WI<V%=4I])@Z<7*J
MVUIS"4/AQ3 >I'UAN;B,G:,YP;>%BRW/J8H31-7GVBQ'^QHEPH97^[381%)"
M3>0<=U9ZI^_V;Y;QM,^0K8.XN9633--6*-(4LZ8MC^!*Y6^>B5+NU?+%%#,S
MJV/&T=CCXGUR/'$-"DG:L5N/YY0)6"6M3NJ@/@@))E(:UD=A<BMT6:$CK!R=
M@RVGMC!SQ]+PY!J/*2,UE*Y-$;3VS!1XO*CJS%#X0&FX4K;@YE.0T+^AB6NS
M=EQ,D-9#875-OS;6)H4!Z@6^_V2A&81V1\,@E;*_:,&9!\#HI3O\X'[>8;<=
MC*HZ^'VWFABR^OPC,.A-QBWN@LK&T]'>OVW3V-P*Z.'@:Q8D+Z>)JUFI-#+:
MZD%AK82QE!>L&R#6FQWZLM4->RZG+L]UIT\U[Q\*UIU+9L<2B9M2&@-=U2!7
M!7:V:9DB$$L(B*Q\8ZY0L^?P)QT(F$:CRUS"GV*OX?'.[/Q*?UTC-9(K*UB>
M? VJ>SGUY:O3WW)?::F4*%8_:DHWG$23V3&R&%T$JV$@2+D\,!ETN!X9WLB?
MO!1QSEF:G6<7KST<EJOD_L,!HT-S+XPM%97D2 -Y#5,^  PJ;(!1N,%ZR_0'
M\B&!'Y\89Z?/<YND/I#METJ]7?.4>MPOKV<?XFJ$0RV.6J2P%X:<S7V:4?VB
MPTUP4V#0;#[0@/8%/JX83CUOLRX,J<TKJL\)\J[H#W4QB&%2X[\LHF8!";<K
M1E$F4L*^* ^:#I*$)(X72\S3S9[QGFW/>5<;_YHGW+/,J!P(CF/<_^5]V[B6
MH<CDBSX-:JQ$V(#J1]LTV:@;^$J'OO0NU. BVL7H#XD U,+__U]#T#O R*!.
MN-JIF^&6SN6>;$+QT#QPC8SCF6YO$S+@5SL*\5N:67T TVII[G V+FO:=_Y*
M/,S+=,-4^E:".625+[6GF*_H4O(.:%L?, =]:XQ2XXD* H_GEG_&B8?!+D/W
M=)>77E0=J6E\WH!XLEWW4#W[N_N/9P5 ;=E81!QQ%A>@J9MH!YE#:/O?M4<C
M;.FO9 7U)SB=%V=K"A[B1)K>S/UT-TGN7OIXX^R@!F/\X2QS^L8]]?P^P85T
MLIK1.5E"3=(QL:G6ZO1[UZ-+KF2!7V'$],*AIQ,@\("M.;'2V/;#M>1>=S:'
M36R)-#&+3IY3M?5(F>C>EK1G]_=#P9[4;[3S=FN.0L&"6\X-K3W9+/M1!]3-
M'$3A*6H9GT))\IL3AI.1>[(12843Y]TD^S\5K>.?'UT[>AW9^DJB:].HB_.=
MRX/BAI?[XFO&Y&5J[V_;;BK":,HU2C,*G32GFR;1!#NSH$3R[7I8+;-ED8'J
MIERQX^K8WW#,\N)3^)+IK^GR1Z!^#DBK5YW/<=W_J'UB*7X )!/\=9\_Y06*
M(: LVI"R<-_::HJ)14[%AQJ8HW@0LT&$TB9$?">URF_RJ;OV!*QR"S6Z2QS^
M(P^"(L)R%8\J3RDR"?XP='-;&CFB=<61(8Q6\U87T]MHD6W>&F_HB:(6XI ?
ME"?N&M^^Y*[^B$,8!(AG6N)]O1+L K]V'YU/0&/&NN6'Q=JU('PAU7<QQ]:4
M"?K?-6;3=26/PV-^NL=)4[!=>T=I";'?<WT>H>84NVZL+\@D$-&0T%M%K2J"
MK2K2"AD5('.\2:B> \ZPY+X6BO_9NM@_9?NJQ1$O<M 5&(PF@C@F11Y+?F=K
MT.]O+/F?W)*HI8V>W*T:3J4] B%V39PEG^O;L^J>"LD2&34^N"@I_RJ2NO8)
M$51._(K%S[!,V3P>-L>QEO^4G?H "Q.E*RUU8TZK%8,T.OI1^,S]=\Z\3H[)
MO7!V-;GY516O8+2KUZFFKV=*=7I0%/Q$HYFR5!]E_3_$2([)>E!]BV1OYHKL
MZ#CJ:%%4L_-A;/A>-J9VQ'"-F<](*AYC.L+/7R&EAF)-$]Y,NB$\[V#KUIL,
M"MNUYHJ*CT8)&<ZQ XR.$1R_ _X;6&BOCCK$"/C-867-^X.-472S$,;Y&62J
MMIQ0Q1CDJKS'R(!9;7U$WR G-8=I[#0QGCAXY?4,KQ(L+'.O9G[SJF5J%"!V
M._J80^JOF5'H8/G<<YXVBT-G?_C\ES5!7CN@>^8$<_2%20E#H_F?,UJ3/>9\
MS[KH *8*RYI66,?N@<FXZO6K5J F-4[KK+^7+4HUU!,2"HLJ*?E+TN(#]7&T
MPA]Y% M!X!HMK."A'>I/Z$Y_(P1:XZ4?X;[[ "'.# <U^E"4= N-)R]OF2.[
M)83O'1O[&.OEY4HB7A6K94I2\/%\+O\Y<I/QSK]J^5 $'Y!R5C9Q]%0WW/L2
M?IQP(R#P)-FSEOT,>6S6_SX.=+^Q/V\>A],PK&ZXFA,;D-E1G2X>^O0!K6?R
M&G[+?_VE_DF71%7.DW3[L3CJW&*D \<U;-7ML(.;KZ'J5PP)C3;F!E?G3]B_
M%8/T^ZM"L5LN;48R*'@_X[\*#A207^^*T.VCP1Q;@G=5)_0Z('A?)JMO+Z]3
MIE>KD(,\.T8I0*HJ><%7ZHU*>?$?R=T.+C6Z/(ZF>PZS%A^E+(NFQ];Y99NO
MIE2*A2Z(<OHFQR\INHN*&; Z,ZN&W0"P^/ O?9^Z0/:_,42BO"*(U0NSUX6M
MXC&$QQ027O?M%<[/:T'\D\S5Z)"I&;MXAO*HW?$[&_Q'O$^#+(RPA L8LHZC
M7I_K>K*@O?KE4>4E.95%/HYU'=$^*F&44NR/%00\;]Q]ZO%X:4RH1H41(Q'\
M2#0I,C$EBH4KCJM]13<Z P0EW,,SG)KA"*3J8_@WQY;-'#D:]V39CI8:*!V0
M#MQ%JX6*SOLDE,>@<CUFU%7"CJA@0/DG0P3;90>_TS?K+L/D,!^YL^S&I@Y#
MXD5&5<A5VQGQ9"TLT8F,2@+36,6DY7< 1:#B),;INL=J'SQ^:430D,ZWC<;[
M2!BXE^1CLDV)!<CFVK-K9__XG[<S\/T8;&9Z#7.M1GY<@M.9Z%P>1;4(?,M+
M>! _RF./'\):>D6F]4F[9,DS2BNHF-Z$.H0L,S_)<4\/1QO&VZ5N&/GK+Z^0
M.A=MM;(ULR?!L-??A(K<5>R9IGIV-]Q>3LH'>@EQ0JF^J@P'CL:/2_?N1AW=
MI_7V&C$RE3/67WK2"5/Z>Z<2*EO+R)'C_R<HX3ABE_.&ZK5C)5-^3ISK'?J4
M0>_:XQ-?,0/5QU.&2NN3%XG#KZ4WTH2P4ZYP=30RB;G9QO,L3;W!M W-SG+S
M<B:4Z)/X4_Y"FPFOS]7R2]")]06[6L=VE]015Q2&BAB,3G02OU4YXU@$N$!Q
MD6-0;9[\.^#EM./(8]?&NN)*'^\2!+?(G]P_HO<MN^]W"1A;":/BF/(=@/:Y
M*<W,#$CXT_8;,JO9DX%>&!T\P451!MH7%7H-6N$+>9&0WGVWQDP:@7JHYVH5
MG8:V9ZQ]%_C\A-]@;GCLS,PN7N0J"B'/Z+NI<J!>3S*:SUY[Z?Z6AJ:8(.G1
M"5EF5U#SS:V[C(K$YR55C?G%AYA)9\7#1"Z$S$,D(YD4&F&^@1)=ZR!X>7.;
MW8R2],$?9.GLF4_^753/4)VLZHLT4-FJP9;; 4OL(:ZJ.B&%%RG?8T/Z #$R
M$B J9-[1\'O6.^!QV7/Z?'!A7GVWG6W' :G"DR$TMM65/^2;?"M]'H7ZG/@;
M(9TUZ^CH&_>')1=LO;';SC94A0^<6](<A$9%2E5RP,W,$*2@T6-++AEO4\A%
MHY9"5<,%\;IOV_J"1U=Q3-+*Z"IYR!XVRO?>P.%"0!N0GO!NQ%UQK+NJ)LQ'
M<&9!F-L7SO;H[TERT2^ZJI+JTLHKHO3=W"EJ*Q3NR4^]*8PR >[A<BWSL!\R
MQQ>'..79(R*$OYARWS[[2$(AS;RZ6VR.R@U=W<?CNB23S"457**7 NXWYNQA
M7[$_P> @E6QV!_&^ VYJ+K+7(\M+*H?<#/O!Z&H05102IT-/1)<L)^7OHI5%
MT2]<"G/Z"0DO-IA5^_1M2<?>+OB_,2R[$\VX^J3RM=+? 5W<B.AP"7/35LG7
M(QM;%G79VN:;WUJ@KJ"R<U]9(KKZA 81I/^-G;<,BBOJ]KP[!")(2' GN$-P
MAQ""!W<GN#7N#70""01W"01W]V[HQH)+@.#20.,$=QIH9/+,W)J:I^H^<^O>
MJ?=]J]Z:+^?3V6N=\]]G[?W[UZJS^UA)/G]^%"/_J/'%7.>,2W;5?E5='.XT
M.L["UDV /:HJ>CI]-\/ODW%UOIG,1W=P47_M!YY5&#3OZ25-[6PBE'$>FHDS
M&/R,!V@;D(''JQ;K*?N!AX+F6_AI\%*C./3:)]!3H$Y)Q;#I>-XT)K-_[-XG
MN^%5UN#X0&*9+NM$/X4:452Y<OER;E!DRR%B!PI*T/A9>$(4BV6C&Z\]BZ=\
MW"<V&->1VLO<>]A^2Q6N\KWJB"XAF#3R<'39AMW1D:CNG1]!8;1V/O+$'*CC
MLSV(ORT[!_+(I[@5NEIL'HM#.Y;''IIS082J]8G3U,G.%>MT="<JG>N793>F
M2K$3K7X1!G$CFXR;Z29$2P17\_TOF*1^?SE>4: IB@,)>VT$:UP6.,#UE"H/
MJGU;IH^Q(.LMB,5.IQX211M.[,L8 :X,<OR-.[B]K^OI_M66@V5B:H/3:CV<
M4C@NY_9 TI9!/*D@@4FK7+,H5N '&ZE.BF[;6S3W-MRU>.E03O9)4H^6"'&*
MGHRZB2!'-]DN"_K:6<O9;._HYX!72\;R*3GIJE_U_L&65G%QG@H1RV=VQ5ZQ
MRC9$$P<<1/P P'YRP%6]E]JU^82ARBUQ75;Y=.9BYD6Y:3=MQ"-]@QXW3I=$
M7M=%*[+S,))N#\X.-\0 =CW_A]Y2TN[F%BR\X![&*:TO=C'\CZV0]!M*;0GS
MKC*1]C&CJV_BO^J&![7' (TU!YBK?V%_>A)/MA$U=177_@9]MA;>+WD=DRC"
M:[@<A2#7)Q1+^-"-(\]ND:K"OE?XG3%2?M5;OL?]4&B9BZ+KT)Z26=3ZG0*&
M[D#I-86.]TA.X+5+L/XV$.6<3I*(M^X6F4L[1:O/'::9I*!561!#YG\A=\??
M<&H:?EO2D8%OL_)S8!V-:@7IPWRT?S,,3(L8L95228=T%M:KAE>MTF@PG-0R
M-;&TL'BT& <=.7W]J0<)ZR+WUL *%!W+)<">^?YT6-(K:9'ZGD87U8%HR]\^
M1UK/7]LYM!*\S!=OT7-V+"O_"@_G)(5K=!9X!]"^0O71!@=J7&UW\-8K/.$0
M'P=9L:_9:;&E?[3O_4 P:&/JE<28H+C(73H7*]F'^'<:4BW0HQRNL:';@_:#
M)(P)F5:75SJ/;T)W-W\/\=GOZB:[%^!+E784^P2KU#X DE%G,ONM9*)4X&!4
MG"-*;2@ TY^B!$=.\''XL0%1JE+M12O#$&:P$":D$,5XJ,_AVG;@ULP^\WM.
MEKL<4!,N>HXA8S3Y^MJN.A$4VM$]U(Y"^S::W&?N9TIS'@B'O"-2\&4?B=$5
MU("Z;8:@',F(7&ID_S,-MV:$7Z,33DNN<_IFPG.JY_KT!1L.FK-"=V>;+=?F
M6="E>@LC1>&8+O9/8(T@$QBYO"JU<GVLP,?M&8A@H^!?WN082Z9E866S'04&
MS=^.[@:K?$PB(VM26RI9(HM6'NBLSK +.,_>I] QN+7YQG0^_$$B:&NB\U(Q
MTW)!JA4KY<#FX^4#P+Y@8";W!?%>,NFKFM;%EL'ZVK M!&+@.L"*"Q![KUJ_
MNQ425HT)I&&--M9X_-4GY""V&P%2*1"G;&*O3QYN$GH Z-GX3FZ)\ H22[$'
M;'[W)IIBC)#1;>9RR^]!AW,!LW>MOS[B/"PE<N?L8:5MO.@;5=HT;D.E[_L8
MK%MY2JT#;>EOS032V%XDO;67I2#,</^3] !@"?J[+= .QZWK\;^I*Y85_3SL
MFL7+SW<' ;O9U%^M"3):\UMQL U'O63D)O[NW*-[2+R&=!562\EUIP%',AID
M_EK7H@@LZPXW)$9=;1GXERQ56V0OP^BR%\9>/UXS-$ 8J79").RM)]R4)W(I
M8HO (KC,*V,/ *ZC9!UQ6R7+@9]-)^2PU#"%;S^"^3T_\HG:<-&6%JR5L1/'
MWUAK68%EA6%HL(";JU 5:RD?,<8G%(R/;JR@/N.$J'1@)Z?9=M.A"=0RG+@,
ML'+*3-<AQI4 Q;0?+C^6[WU_VB>S5OB$_'$NJ*"=^39B>8EG"@'_".8_/%=-
M:1%#XGQ?J%V'S(PFDI6R]&L/JF"ZG*O3O7ROQT<=%5(H.H/?MGQX.7.F1)7I
MW>SMH_=$)5?VR>NX@_X<V1SWMJ---;,MO*%^S\LSVQLX"-U<_2$S;+]ZDO&4
MHP[#33R=I!/;2;=7C##XF;/+MZNVJ0YF:/#C3:ZG_D#;0]7N^;;5^>_)N85D
M0=U86)SP1,Y0C=J22(.U,+$(J]]A_"Q%7K!/8[QFID>>QIRI]SC/Z".7F0S%
MUZ:Z^&##_'J-F(1& ><OT4-G//R@D7:/BYA9;JDQ-Z%,:K@=8O5D0UB/1Z#"
M=OSY9Q]<TP+Y"L?)) UUG8MC6O<5F.^VWN--M<N=2#/(']HMO&94V*^KEN93
M58,)8$;Q2)4NE2"'83&5M?C(4B_?>Q/EL[CZ5U8S(/SK;)*.A?L04>\Q**>Z
MUR<N1BP, MAS;F#GL_VWN9AUTV\]$4>BC8MG*$B#A]X27/ >-7 ,] WL=R7[
MQKU*.WZEQ4?F."FT2/3<L"M91XK784AO_@&0+J&5DY0SM.9.%49VKZ?;R]A)
MS3[VQ3+2: 9W3>@UC:(>PY^@3Z)>#X#(0]JSH8[+I*<&PB@3;ZJ<0_HIG=/%
M]]@;GP,^903@O6M/H6DSFJW-,=#\?_GW+<>\MG;1_9NV;7@Y\IY(\&[2,6O,
M7 .A?W6@!<;ET>>@"OZ\<&R/I@\4.E$ DIR4[! &A1UJ/9N]Z5B;$*!A"34G
MB!2O.(\Q-?'+EE WK=WL\''-1519/0 ,QLHG@1AW^K_[D-J*R7[3]Y5M@>JQ
ML Q8.T-/L?2\XWP':GSV'KK;@79!ZZ/_/  F_V*5#OA@K*#F8KG] ="%\P"P
M??4 V*R9[?CGNU%'!0^ #\@[S0< 5*KM'CZ+O)(![W=)WS;=H-!<QL+W-V(/
M@)D[_0< $!E\=P[>^8NDY=*7V[,=LP'H!\ SGKMTA0= :H?9 \"FPO8!@%0P
MOT&6/P .X$?(]K@[?O"%POWB#>KFR!R\BO4 :'CV #B=W4/N-SDCT7_V'@#&
M%^9WT" T:OP!4.QZ7_H 0.3\#66Z=W3[NN/R(^V]T1T0V+BJ#*R"E*T//P#\
MK$H0YV[].2W2@66J%)'#WYE8#M^>FAO?UTPAM1]#"3>S:;+<&0+BA_W%R5H)
M;)/3P<CW<&HJTI4KOQ=43U\DT^R-V_V?SK+N]IGD+@UZOU6X%V_^Y*@,V>)K
M]^ZV%M&VG3#OE-F]@GD^AQUP\RUE[TSPS=L$5>.5B%LGSCQKSKHY$LT2)G.$
MH9)7FM8W+9"H!0'9LA$Y!>]Q?\X77G*, JEP?JFM1=0P59[[+XC$=$M,,2)@
M,_,@0[S!SCLH7V7^M3P]QWL?SKH][RE-]ER2$6R&NTS:K9\/@(#*OY<_J_,=
M%V<+.;OW_0\ !7,T;\Y]R!^%^[K[ ?"JXM]9HS9%W"[AT;(&Y+3 <SS!/$';
M$7/T[,NUUZ^^'G!O]?0F]NT@SG,Z*RQK&ANF96Z5[/?*W]-N.$DD&@_4);=@
M9LIM"&DN%PA?0K9$T,9MK7[F Q0^>:*YO1Q&WM0@P5'T4^AEX!%T#*2[Z,-1
M!7>,_RGI:G,S1R,U%7-+R*B9=F<9V?$<:+"7<\9]E=4BI1T(*C>KR [4'Y J
MJDFJA8D+RDCHI!!86WU>J?YY-S4YJ=VKWFQ/OD.EHYS<[@I-+#_N64<L%K3V
M-RS%E3VJVJ0A[DK07*U[J@NPTK&@<J"HDWN=W8:20;6/S0<[FB,=Z_=!&3C4
M:^2OBJ*-&\)CM]\QQII-:#3PA!6;TLM%QG:>Q^5>72R^>0"P/9?B5VF8![6U
MT^E<?)NG!4>S7&VD&SIHA5]]JQ+)S A[OHFN ;3]RO._S(,:O+B[@'4H['U9
M.(=>!DNU&3E4K(ZPF;/K%Z!SO(7()<^IUK@[EA0NBH1I*X]=I!=Y_>J_!_+@
M]%]A>?F9L:1FK.=O3BYEW2)@V\4!)7F0N-/CO;L689,+'](*M[:4N:SOD+T_
M#/?/PXM[)ZU/#5H%K77K"W/LZY6P!#(B@,]V)=]N>];/51\RP9/<?4^8'(Q8
MJY@4Q!;K=!V,%==#D+7'NX;;]VJ7_)FBH1Y;H/N MF92=,SRNA#RX_#L\0>D
MH3=3=S?NK'NCHT*DKIE<+D8A86S<;!=ME"@X>DF]Y20K#F8/9VA!)]76W_4N
MHQ<R2&.3F)KY8XO][%?24S]X$W.Z:_<561EB#XN$_%"SB&;[)=YU1,@6@>LN
M1R&+:QVB)T!CC57!3V+I-UVFK7P13>O7$? :%0J"9CI 0'@ECG5-"Q G(8N)
MGS:V+U(3X@$V"?,;5GH<91JM&8)UG OBM%M'IWLU2UEV)]OK]Y1;3WMQM_8&
M70X+%II'1N(6X$E60D8!D3>M>!^^4SB4>9"9KVFG%:>R;F0()AHR.]5W8?*;
M A>G")SF%V8V-0GT>25.%C&Q/Z/5BI+>'CYM^D;$KK1'Y[ML?;EW9$H,.1D!
M+2[6_*I%&"\<IO$!SP[U*#LABBNQ.UBM48SZ4MB/Z.MT/$I+GYA$TU('/-TP
M!P8F%%W7G,FZ')C!ES)9;*>=>6*1-)=5@>3-/C',F@HGE:/:O 2-Q)E1#(2"
MS##Y5UP,8B); E^?[+0L&"Q0PUWL$DR[%TW$TG_U<N3I"E+(-TTC]7BR%[ _
MW<V@I).O*9,S$1VN=BWM$#@\%A6$Y/X($EYBA+#L5*U K<K%%569"G-;TCFP
M-:,JW$V)%QJ1(TX>@?&9CO5>$-F5Q2!9I38I%)7L(=-R,KEV[#T-^ZBF8N[G
MS;.F-\7G?\[\G\EJPV30X7^:@J&S5PL"T$MS]0)=AY*U7@YS,>U\E3$/B%)0
M0FBRWA:\WC-BB6*R*X?DJ4,&HO?D@]FC._WGN4IKMC"!J?/QVRXI$9]EU,"Y
M_N #(*KY&Q^2I9W?M=DCG1K.9,,M*JPV,S 0[T)=HVML*BF)RSO][GT$YWZ@
MYMV"3+[CUP3O(4156W/&Z/G$PJ9 PP[GQQ1VJV0LBMA$1?9GI:*E1!S!>U('
MSB8M)&>#K=ML46DM(2,%&>Y$25E0]\\J"V:%;@5#?4+E]?)/&E9)IQ)2V'E^
MT-**E[0*U<BAI/LC*TD&KR5/QOS[Y]M\O^P+*?3K]B?D$8'"G6SL"AR_Q5NS
MSKV;Z.:)6>8AT-4N[((\$77U@B V4BE[?2'9_$3MM'V-%G_VM/++AUZX*T_1
M?DF^6VR;V#QR<?6--=]JS#A*@R+D$4>;=9@F[W^KKAN9==9_&^15%OSJ7:HW
M91E?$K+)7XL"G_VUC;7\#P!R8>FNF*(3D/.E"S\Z:V$)V8+JXW";'/_(GBUR
M1OO3K7F@]_T\=@9)HIB%3>DW<2,E2]H.\HNV]I'ATZ(-_1JODS=^J\8.]-/T
M*.:2A-*7;RA*!5]U>HN<0KKWD;7&A53K-B.S)KWNT,$+8Y=QUP:3N59H0I@3
MN+2Y&8B#K4Q<1&?E4=!DO/+1^#KTUOO0:+3A2D[VQ+-T\^#F*)*6WL?7:F)?
M^T>WA41Z54YT66PDFP=Y9&2 5ZS2:G&8.L$PJ[ZMP3X..[?Z$M=*QM$>\['<
M2.7OJS#AU!B.(I#5B$-I]&<SEH&0]MW[/8^[ZI.1"<_L/T*-6Z;AWHB%LS^'
M1UZ+AVFO!+[(V<?V?'&@]B96+OU;5&"TD/1(Z/V%8>@#8+R[ ;RW#>VH0-/>
M48/W^\ W.$7@/=K]\'NBB(Z3Z:6.D=_CI^%EZ,P6E/ I:MDO*X2^:@\_@<QL
MXM#Y@R&G2U:'TBTVA!VM(JE#VY,:"RN4N9=O&&1JC2)7B5=J-).UH=[E!SNY
M6,4UP1']7V\_ES@29N!J-95HSC:8'-6"P':CZ$!4DVF_)0P!*<,EG+DTK_J\
M?J"(_,DG1PZ>8:TX3IV._1QT<MP!.7T _%H'^G)3I/X(-%@<@<*1D/=-XX0\
MEON!-*L+:!>RNAJ3AK[B) X9DTDYY6,E+@"_@&<OY8#3BSL7(5MH0&8R#RZ+
MXB-@L=^69RD;8UC,S)<0S.(48@S9S;%6DEZK_8-^GD5^L,'!/=P6P?;\D0_7
MVFF_.]R*KTOW6^*"WSN)\MTTS-?V\R&QYM1B"HU"/*-'6PR+H HG"$<5>OB.
M&)R_-.#$>X9;@_)TF+'RU"LL*<^ Q>U7V!@\ (960X>#W/Q?DCSWC1G%J:IP
MA<14,-+JKU6G4@0:IB0Q ARQ0$HE6?B:LW":=>?%X8,<^M.[E/X(\%]O:PCV
M-[[2+ID,"MXF[NT(3*CT\$LH<YWPG5262NU_3YN[=F\#QC^39KK,,0?S+$BM
M+ 25G78'H+(I ZQ!_'8?HZ?F%R*- @0C/^_NLH0QY_=U\QSQ#9?KZ\?RP=ZF
M>5!*OU%P/'.AP>FVP\0C:\Q6)IM*TL-\O-ACH?7)?7U&#?3C_C?HPG48A:@1
MATQ[0DY'QQM4'&AY7* !C VQ"O&-^0)Z'YFZ2RS8Y##Y]8H'@[E]A7^-_EI$
M)U&>6JUNB:_;(OHM]. NAQ221R%+J@G5@J_ZIN0S"0Z86)5]' (3\;A*%+?G
MQ$&(2DY=O)3M:0*UO/-3V5QL#522T78XMO>W]C-TT,%?(VR(&!Z\G4#?GG[0
M\J.T:T6\?_F%DW'6@_7"D3MEH,K/:^2V#>94#U.HA(>[^H0M &O2%_\2!11E
M:5&Z4!W6,!8V8B.GQM>H%%=>$<FK_;2B9[]!X3Q5P$5R+_W(LB-#**()"P*)
MSGBE$$LD3_[X,Z;^YU-&+_B1RAA:H1G>-^O=8!+T7N^VI=[@US+1N#V\L>EX
M*S:IGY(:+T896YC8EOQ/CA=^9^S,U<'M&,K<'B@!E#/OD9@U=C&Y' 1WY!(A
MK"1AIV1#E>U+A7U*)AX.ZDPNHGOT]FQR1&YC1!][]G@_OMC^Y8,N'J3"E_%I
M>%]/S5S?C>O!Z:*HT:3Y^D/BMJH:F]+>WS=JG>D_A#;HP07/RL_>BX<A\;;_
MC*RY"!G;M/W20WE\J+UBFA'_^C5TR,Y.WE* J"@U$#Z'*&EH9P],VHN)B10=
MV>D(X/#>/RCY2J@]F=&:JO+45$'N SO[9D@JON3[@8RM5)'$FZQIF=<<M:9,
M*7>-$UELU#W<6U_&M>0L[1\Q?W(#Y*C5$<[%6M=O+/O,"0<-J3^9&/9'N%3;
M_#[UT[M$Q0\S[$28(I39Q#0-8UAS,U[4WRK-4Q94WG,$.NUE'46)J&[7PDCM
M]T<08?S:4Q0?4OD?R<B9?G!D8\I.!6-]X,Y6M$YDF2P7MJ&+@Z(+VSI:,AC*
M&)N___X=63'P"^\9I@X-YN.]:<GS+7%NMVW@ \ '47A2Q>-;-7&X8(I/&^7J
M#I(8;_^N2^W-4.'@K4=<P"I(C=_AK?H X'@)'G1Z !!?:DZ9KW0<Y\P%J+F*
MB9YE\ONNN:M0V\HR03A.IG3^_!$<D60<?_]U*870N);4DBA("4!X.& O<QT;
MXT,^Z]H!R7 L5W#'@;]4)6;4LWK[7.#Q)\P;;[F_@5']9_I7W2>HBAN"N&O[
M-6B,L)$%+=:+K;(#8)H<DX5C>60-@U:5J5:73.EDH?)?BX7:ZE)?KO217#LT
MKED.D-"WFSS7AF3)-]8 P19[A?<7'K/U9B=G:NN_3D&?F2I<""-&8*<S1V^B
MSB<DZ7ZYIUYQF'+TA\OK;_;K!V9=J_XU;4_Y)L^C00J-E^8C7%&+=[TSC2VW
M7); 7]RDZ-X7[PIMK"N+"H:P_78=?A0QJ$B$.<GA_ EB7.P(LJL?"0X#:@[:
M>&+R^;FT<[3'2#9:PDJ#V1]M!7R3C-Q64[LT3K_NPUH:F5GR'3(>G6QRP;/Q
M?=4!A]^01$A@12J]GK&*U],HA8G_T-%QOTZ9-$U9R,H\=G7;YVJ<OY76""S.
MVU?KK32"4;BNSMG7&5(X<'SP3M$YG<;*]C(GYAL1+E^3?!VO7K_<ZX"W-C#%
MA_!SCR0LN[4W2W^2_L[1GK>O<5?H\FG.9:S*_'77K&?SL<V2J(<3)?%Q<5(_
MW*G"'],[4EBGO(!:B^B#MJXB-1^8[R@"D;0IW \KVFW9[@T,W36Z%L<I:- A
M[%729)87H<'>IUU2E124T$&'?<Y.Z'U?IK*%]F>OP563+-VDWI+,W@]2Q'-E
M/:XFBHS#^R96^IBB +"N.!W)AGEN\Y^Q-;KBB#7A :[-V\P U%K[TVJ6850Q
MH97S!RF[&HOAE9U"I=KK:%,]->)AG=EHH6:VG0V+/4UZ7F.%#2$M4./1#*2U
M#W7PVN##K%H]D0]1 M,SY<\U3&&L^%5BF9(-J-F4%C 2?>C=TF$ \:_Q+;-L
M=S(>)"I:JOKE5A<B$IP??<HZ8:5'?#C!_O;S_4C<F<4#H$WO[^7<;1]Y<WT@
M?0&V>@ 4U-RECST 9+S('@!_=REKZ>/"OZ426WUP[U)94>(K;7G87CN/SFR&
MW626HFEYXAQ0=J:]R47#_9%EA+^B/K0H"PDT03\3J+IG2=5+Y:*?F/42$8J]
MNV=_0L<XH6UT3<V58"Z;,$/G>3C2Y)PY,IW='8C(^J*%!6D7.C7*3#\OF_F8
M[!37G#(QWQMX0Q"\FWFO]_H!D#A[SW' (T.+]0#X<M\]:YO_P\WN"^5CR^%S
M^I4[, ,2=AP1EW 77CWC1QU2."Y.FU^! 48\/EJR[QM.?'8;9_*_QCE:<OT)
M7I6NO1A0?Z3W44!.:R']36W'Q-:M.1(V'A/&ZGDJZ8XN=[TV"+U7,;^JZ?#N
M^+>L#!*/=*/'L4 [EEU]2&/*,]?@O7="(GG] Q?]AV4=FY;XUUS@M?:[F5O2
M>T(TOFE&I#>3D9_,DQX2X] [?*F[V2\? N/V)7T:.F<G!52+O(52GW0&*6U_
MDD17D<VY/[VD:;Z;%KZME'D ,-7<ZB-AR) '0!?XXUY:-I[8[;C]=(E9GM,=
M$+1PB3IL6FURD#57_E<CDM0Q$#KCW$53L'2<T'.&;!G482.#52?M7, ?'>TZ
M[(8N)2$ WV+.'U'4(<3RX\;?$36PX@= RC?IC:8'0"0:979L?J6^+^E!V*F;
MKOI*!U*,R\ESWM)!^C>.U<=(JG\IZ!A UTI QNS&H+8..M-WBT#"?L?$LKK_
M*T&9LS$M:P04NW<K.VDO>] HHU<-UAA@AMEW^3^.6;YD$EH,GV-LW($?(V'S
M$>'_F-[V?\H*^A]9$QB5GI0N43VVU CAN1-!'98/Z7]C./B#?2T]+N*:9$X+
MM\H[FQZ+S-MO*Y!Z0@5C21[7>Z+\(\@W2LL_>)@.DS_]@KN.)DL%%$I=X!Z4
MO\M12,PKUOP4\'N#-H'L]B8QZ >*?7W^T![AGS&-&0==8MRB]XJP&E*A*:>6
M8E3;*0_+J)!5]C8TYFF3SD3I  .%/QSFA(H_;45E+_3+-+DCZ7SN'P"]EL?D
M.B$"(;AMP>SE9/44D?8!>8&>(_1#QQ.=U0FE?=O.F^@^IV\UUI_)4DG&'$\5
M?X!D*_X(W@HR?_KT2Y&ELGN+%A@4MNTTZ!\R_,/5QTDE')0VMSW/[>(*C*KS
M@4;Z9>45.=)+KS\BRO4W">EQGT-2H[?7]3MI-N8S21)#&X*-+H.X]_:=5Q8:
MQM?_V"&-9_309747Y([1-GP:'_'>";AJ,G()Z 1\L50BH;4AI8RI/FKIF4B-
MG<;EQ=.U,[9_EUO]:>E7A?9;^7R'V (7:Y1V:M R2MIQ49@YJ"/5YQ+A3'>3
MG.J?9+N@@VFH-\U-->S&0/?%<97&T9&]Z$:H@^A&.7-]NV\Y?L?A=7YB1S5L
MEACJF4)TDE]XK;BC>=K$_G@(4#ZH)-$J'F>^ZUK&LNR+OSSK:3*1S5F]0FA*
MEQ[/(6.$_>)Q^(O<(Y!D#]CK&NZ[]=*$Z7[5TQV[@4!KJ? C!L&[V?=TA*NT
M^(^Z\T=.,G/AT@7!QK>(_K$&-N,UU(#$J# <(N2#'>U0$NZEKU5%<]RG8R5G
M99UJDKS/_CY&F<V(]2WA<]H^56C,$/5HWUASYC?BE7AJ^3H.IV^AQ<D:OY*G
M37"UR\#+^)X05P]1RF0;X^+[.N?X16=4?+UZU>4?&W[@&6/[R_ /' :-$1_R
M,F ",:8D5>%0*= #@/M/PQWM.)+LA)8O^$WQSH"=&'MY*$@3F-7=>#(O5F#,
MO#P"IBBJ$#S6TIM6O3Q[5^\8I].@TV=--+6M/=QT9DBJGZ;JX*;[_@&P=L#I
M*18C-MGUL3 ^M_FU+V%Q@:3*[3 <9(6JM/=/^NX?9J:[10C$%!]J'Q-:M6I9
M-.Y?Q8&#"Q)YGA?&"IQH#HW_*:/$XA/]=N5^<M;!+E[2).48V):W@/!M1<LZ
M:GIG=^^V%6@2!S'WS7MYTP:_J;<NX%,P3ZJJ&9>TKE-A9+:?7_6._:BNIMUQ
MF-KU['(/XP!3;4*B1E>8L!;;>M)L&IOU4XR,TG2B4F3;'4HEE7[S (H8E05]
MOP3"MH!=* ^8?)CIMD^*Q&,/.D>RO%CV?@R^BB\65"2RC-\? *EQ[WSZ99P[
MDN=BEQ84'&9]A$> )PA*J>][[DU=4%>;G3>\5J<4=4TI"9WL9K$?5W[T:V3P
M,+*2JQAGHA2%96TM@&;$,:U\/O4["8*[9BL<RM&1H1L!KD=!AS[]A\&KPY[[
M^M):J50%#0=I'^BR:9_<S*C,I+*;R+T"8NB(_18 FLT*"%A?E?W.FC[AV90&
M>8=-SR=NWN-?;DSX*I@<*CO'"I+:N)3/XJ0CGD=FM]I0DII8.:PF9J=/3OY=
MDOIW_1TWHHQ'UUW;#&7XVWCH"PFXDVY^EY8K&[":*K.18Z9:/.H$$.('W(UL
M(@-%.6R775UZ3) 0K 6>@X7G@TN0.3T(JM@K_"?A>S+Y/<9LQIS2.=T(0^T3
MNWRX?G6["YBW';%LK%N[!%J>KVZJV*WJ<G*??LQ!\_A1>O[PFZ*BBFQ(U &[
M8[Z*;O>C)+W2]Y'DX="L"9RV?_:5NFG_TU>^OS\'I=1[VD$EPNN *"FNRQ'2
M-]R;3[^*!?&;(8U& +.,2E39]/(C-^JOC33/$Q_Q@]D0$.EYS\, ETB$-V5#
MLT=64,)/[V62C/*PB%%MNN=Y)>7$HF(P"M8T&D<\;7\6597G.C/[I3W&[SIG
M-7&*)_&_M7-HQKQ\:8Q--A6-_3@[;\QFUDIBOA'*MX@#K!;_P]SQO2!#@RO/
MG;\XRJ\X_OL[/UEE09P0^]P$TK4<)>W P"O$!#47(Y&6_L6LT1KDT",_6T G
MAXV:74JOZ*W_6V)#-I:T</>].]4+H7^Y?F2C&A854.J9T."/6%WFAZ3"+RMX
MF;@6Y%_2,7)YO7LE]>KXF$J,$TD.PVFX$=[L&&D-1/.EM/,$AOY:!\&M["Q*
M^S+\?.6\V<>/<&WD!?2$E&P&U;H*%:?R4_*_/'J3<&N-\%O,6]QW1D<T?S9[
M_FC*B0#2_$W,00YW4%6WLU<L[6X%)6Z+8DAHD=>%N>Z1#.+UC?GC,-X@7<*T
MA9!\*JO/O+J:HA23A\@K"A2GQQWG0)[;':>'4=+C=]0G<:_.6-:Q77Z$>>:7
MEPHWD<POBJM3)Y4+U@/W9T_*C1K,L9B .DA7 0[FT@L5P0^V,JIJWA)P<\$$
M;W^OF30L'?5[[HE^_M+)*@EF"B5LG)"G[F*._%,=O^!0B'1 7_AWT;1TFTVS
MCT*_95LK]L]<2,2S>EN#7\*A-Z+TQQF*Z^K$5%4TD0FUV@SI<>&TM.*G!3"0
M]E;)\ )U%10TUBA41&JX+U6Q(/A*?\(9F*:@B5K'85;F9_2^%ENX(YQ1(:I_
M9QN336JP172^*7Z_X_PZSJ66^_?[ X:A"VUW<4"QJN"!1OZW9U-$68:,Z15(
MI%>+);<9(JAU0[@EQQ91;;O(X\M1:&^S[.N@W2E,3Y(72;96Z<; WBS_Z*<U
MGQ+#FOZ[RS'#V^E[JZ6&MLO,CV)_V18E;6X=4.!&L>C]=ECV2X^=0[T+6QD'
M2V4^VG"/SEBW6VW"J55FVJ *VO:W3FI<_E$G&'N]IIP"5XD5W(J *8Q_U(F8
M*Y+6TT?*]?(H'B()V^YKGZ]"]2SF'MO%[62<[HXJRK=8*F[,U(E6_J-,&A,?
M6?9ZT7K=^MU;7$O-[%"G,>]<#9[VOYR69GPS98@+)%L =5!$-QI7IX:UMV<8
M38T\?Z>G((>;1.((B_#FT^JZ">I#>BY\$<8O7ILN<_%*6I>EJY!7KI;@U],:
M4:9^[?ZZ"[5X:(;27ABX5+."DRS^'-;Z.F=CSY)\"#+M?LP4-8C+79=I"<MS
MR-+*)G)X.P&;1RYI@X=Z:$^-_E)(T)> [II_@R\Z"2S#+^/$*HX675T/ )7,
M$W#PGKP06=[8OX^S)M''6'K\[XF/BJ)P*(.<74?:T%7/YM;":1EF:?\9'HW_
M!SSZ.+)-I3BL8E*^-'3!/Y?X"Y6O>$__XMK"V&/S#^-"*5,+!I2/+EBR ?\=
M*GO^PNDZ2@=Y6O?T-K7CQ#QX+QCG ?#\+_.9^0GLG<D5Z&4%?*VY:#IR^@N5
MLV'317A!K/]B@*H$#E#[/2Q-:]>"&_]WK/_3?U!H'. OY>9IJO6PCSUGG ,,
M>X!SM__W6/G_K#LPR?![%=DZSH!?W@  (PC_.A7YD?CGMW&FV)&>G=D$SJJA
M/+]QDBYN\8/W;)EI%"YI8/^4].C?DO)(4'A?YX]7J+6]F[U90#4='"TY=3M.
MA+4G__M/.6,A"QB2P31Y=<YP$Q>\^T6[^@Y=]?_UB:J:3J7VIUZ"Z8LQG,1S
MMS&<R8)3NLHT;'G?<3UZZ=^PGPQ$ZR8?R[Q&SPD,[.PY17!N&.9;QD97QQ:&
MZ6F1O927P<3 3]A-<02G*(" 5"X;.VJAU]MSU K'Z( M#J<S258XF#)^R,K^
M-"519Y.7#&_@3-8X+K]<J>@]*Z&,QP7OK/C0Q !#%K#Z67-K72RH"1MSRY#8
M(/^K7J)$18),Q6OA%\LP<GRD>2ITWF*+QFX#3CV9 :3_2K\T<M%#@B) O*_[
M*3F=KA]K^#(_M4RL%!/X#)ODUS&8+,#U\4E[VEJ,T&QL<%K)WNR>H<^%U7?&
M[!![,[$(VQ\W"[!\0YJ\;1+7%BN^'2<#:NX]=Z[Q-NY *Y:H2HOPZ?+\="*)
MIX^Z*R47V]:0*"F@BR\H4=BVG?)3%D CJ2),HZ)3/N^]XP^)-R^GO W^T2F]
MOQH MO+TFZZ>H>I]A;LX,<^GSN^8WY -25SHT<=-JT)W438"93IS?TP93*6$
M/G5EB]CO#/6<1".R#D*;%GU><>V1N):>,-K/R(NZXSB:&C+J9 C[^'E_YPM"
MM=C.'+HXUVYDM2,SMPGX71X QNY<R;Y:JX<%=0E&O/P8?;"F<+%LPT<V3EY+
M03*SH+$RCSO*;(0 _T6PDW5V:]E"'49\,<L!%I'7[VPC'NAGG7>=NS$)U&I%
M3^<(*%NX-@W'OR48B+B^Z9SI  ;\5$W*1IF9(^FWQ)W"3?LHZP*AC-,C8Q%K
M::YK4SU[3W&?/WU:'A5^K8[JDP6N!HL=X>>T);6TO[)@*2XIV>']U*>Y75Y'
M%%P.[-"'LQ4I%_>_VZ'8.6E\0G32K:"FQQ+MLWCD3%V]7AOA:M 0I!#!(%_/
M._S-6&MWD+YP'-[07;F7=-0V+ 3U]+0)9SRXO$6*)&3ZWB BG M@:?C>U-&1
MXQ'I)(+3E:)3IP,X',;%>[LOX,M!*FE_%B_G\W(JSHP9+S;5IK\1?>65MF<M
M*/YR.A[4BIU/\E3'^=NN-ZM49_S2H"O[:/3[R)_=_F%/FM!.,]C./U"PT_MK
M4EZ$B=CAFZ6HS1;F:I= =2(XF*28Q4#$0E%$4L=$>@C<SD?IBG,RZQ=XMY\U
M<ASU2%)04EHI^@E?G*3NMX(+;>!-V[PJNZZ0&*GBK'I,[IN26 HQCSH)*\@V
MR.+ E_J+2D!OYJZ$$H5@0JS)NX4T/25BYIBE;&H[DYR@0\,F>&8FIRB+*W3K
MNB<:T3&SJ&)#/=4,*MVWUHO^T%E77?5QM"3UK:'1+]#16K_6;=C5Q8^K\=8W
M1S%[E;&+18@KQ6,ID=TW)11UN*IZO,6Q]FLY9+_E+6=BH\NM$LR$O2V"IUO5
M&Y:8-E@N7C79%@KZA>5AAF&&QMO[A<[0HJV.Y*\/] 5E1RD#VYEN?0G4V3*U
MF9"Q!J-)6-:<#4\MSMEEQ)+# )%WB ? ,$<;JGIW[Y?K<-P/ROZ-<)GS^[7B
M101M22%B2H0_L:)?B=*R<$E4V>B[HZ?F!/LK>AW_PN^Q>9K8C0D#+)F90(N(
M^Y ^<8?-=W'"D:?C)B_7!-P5A]TP"725'@]$YR])74DT#,\(3YSRL"SL4\[L
M8*:B,DO;,\XZ([T_BM2'&$QS1:<<V)^SX]I[$*?VWG\(]-KK2&GC: O@;]@I
M1SH=L1-'6_.&"5;UZ[W=$R11#E&R2A6HR"^52Q L* ",#\11PN(AX["1>I-^
M[T<%?=/$5<]6='Z'R&+(#/Q<$^O%M[N;70I*W.)0LY[_+C=2D)2O*L^VYJ:E
M:(,]],&#CGW*HBOO'T+\^3\4@NT_$J+F_PKQ7Q$B^>BVZRJN0<K"&\)A>XCW
M,WO.N,'698B[:W=Y?$&*-Q7Q?1\4P>:T(Y%*0'?'UUO.MV<;:U <RV;U8A^T
MF$G4IX.]^^=$B7+V?4)S 8=&Z!GYS\???O9+?VP[6Y0,7]I8Y+((NUPXG'&B
M[G>!39_/7FI7IT6JBCX=,8I^U,V19VU9,]DQC&PI/ASYO&S.?V^\':RS!=-=
M+BGR2:8,#G=>==<]3'SOJ3N5?ITAD:W*P)MN[65(GR X**A:<)+E(C'F/',$
MA!IQE0_+\/O5\,/*<(GX/^<YLG<&ZE !7H](W*&*-\\W__K02W0JW68SU*("
MOIBY Z6$IQ-5X/AM9,F$$2PTE2=6%T<FH!P%:=^T,^R/I5,#(^?AH6YV$)+]
M^<SZJ%H8M-$G+MH&L@6B65,VNE%G^O(-_*'.,1HV7Y#*5A!I,.@C>:@::<6.
MY>WE5QBSEZ^XJ)E2*G,=O?*YQZ)KN1NTW0S"AP\V&_W$.VA:JIP1CUWRKMBI
MV2\QY2'*\,#/:")['*;_;J#7O 2<UN&INI3YN+7=[A8Z>ELVXE71IJY\P"IT
M]V*^:ZUBB?';5D49[YF OT2&O-6;@3_U<O1.B8Z9"NMBB_[9\U7+")=&8]W4
M$-L3,SMO+3)6N\?OIG0_796* &0R_-%'JL,[P]!6Z &*4W;8W>6GOF^+\*2+
ML.\;-CV2DT&Q4%RF)B==)E-58H;#*7LI_5O[)21#Q^\2E#H<1:L"SL]>ZK]4
M Z';5+2U[]9R"SIR7*?O(':OU@JJUHV54)K'@MK2]<!,KRCGDU8#/5>2IQ'>
MVN=9.TI8FNC4]*(7P713@OMI< C-Y#WJYB ;Z7.WV30&_;D^2 66D9B:]*6-
M</(V9!B-;R>T(^!14D]'8N\$JT][EWQTKAY9I,8_I2ST\#9T*3H$5JEB64^!
M08]E].,&-$;'JV5)]0K]Z4[[P%J)Q\,2_-*U1]NV)_2)@MG/NRI_P_G"L']^
MQBTDMI"G%"CKQZ8!/45] =M.NBU J=OQMJV6UF.YQAQ:$A6US+&Z^SFU^LAZ
M):Q]VE-/!5Z4_J&YM;QBZ8"A8!Q2:K?%U\29UTJG3ZCKN ?F#1>B59F170>M
MJF_5X5&D87D)97J0JM#*)M;X)Y'RZD\@B8;$1R;]>!L8$T/S0(LI1N\7$ZV)
M@+><AX\F<B]K $J"@D1$Z'Y4\L)U1=ID4@N/97B:D*P;-,VM:@HZZXM2JI!5
M=><+Y^U[QO:*1UYCX0^QSKOKF./JM(T[?2,?DJ']I9^_'P!T, 46W=1=LZV%
MJ=]ZJ@JH6@%BO]NON <4&[S>C@J)M)QV%VP\N W=?*KA8''A"**$RF,U8MNO
M\\EO]'"?V;RNP'@S7Z0FHL&U3[O\ZBY3M=MQT>=*."O.-U8$*EF\I42G%$B*
M3U6G0F9%=)*P<&,\\%NL(!=T$K62?;^W_*?R6OPT<T//=9-E@,RG!\Y@8^?(
M*Y )QH&<"#Z2.N0THPB3+S):@+RHG\I_2\%&+D&QH&2MW^9))1R/H\)ATQ2J
MD3 EKGRJ^ C0T/Q4.72A]1'CU)2&]A'MLK;35K6YFMI&6R2-R3Q>U[)I%U0+
M:8I<8J["$^P9HNHG>UWXOHU<UBE75Q-G2[@+9IYT8>HP9\S1X/M4]C9LARI+
MS[@,E.FD+6,H2+O<^5MW_92(O]$IOG>ZC$8QL"YGJK"5;PQW4(CZ=G^944N^
MX:>(;@:IK<9/@S=TR2&5S[IM4T16WT)KP7X*ET!AO IWQ,JRC^2RR-KB9>9W
MQJ],QR82'KV<'Z.U^Q2<=EP9WN[&?C[JXPD!H6M ^0T;1T.N"88=R3FO/R((
M]F-2LDI[)H"WW(B>*4QT<YV?(SE%BI/CG-BP5@3 OM#ZV,F!*<'LXI?;\ELN
MSJK4&;QW"AH''(.O,3%&5ZC9\1V/,9.T-6746\'^JC49+4&BXHF7K/Z>UL(X
M_K[82RI!OF"OC$:!64)63RJ+D 2"<QN\ZL^Z)L&ZMR2+62T(2KN-_GZURY%;
MJVO^ILO"3 (@*JIWW+:NY1=C4N$Z]8^>F9W(4NT!:)@\'_U-8+RR98F]0[TG
M!?"XJ6@1Q]-YE/%X?EE("2-E*CH<DCM>ZXC%FU%TJ7W$9#< I^YG.;,=P7]S
M>M<[M!S%QFW;F#UZHEEP4E425ODU>7P*H.8%>^*V2QO>@>UT+WYHUG^HACCD
MZC[EV"AQE5./0YI"F]GH^V1IA&+E R2D* DQ&W[&]/?_<7A%^R%1/CKA)T4A
M^\Q=1_5NW4]7; 2B5YN*O7>TN+C8UP*GKNB1!!% 8I =M7>$1PJ;2:5\TMLD
M4^=,:>A;CWB=4DU>S:3!V-R<-4WC8$QG^%77(,0T2E0]L.**JT7<$R(T-A@7
MFW60>=5_:N=TH"3$B#@BC<H?L?),5V)1ZA,7C:B:)-8H27#%C;:6.[]^G=RK
M]AO^'TB2@69#)39LF,:N)UTWV(:G^P>O;;K*):?Q&ZG;^96.7\U,=NN]&[+?
M!;"(F3X6\<;O1GX5? !0HWBL4"Q %,GJ-?&I-C2_I/^H&K%(E&!%%T>IP"!)
M0XL7$6*XTK>^?B[P+:Y8B4%><25&B]@I&#GK;; "_0H\6"N+);;<UM;6%J_%
MFIOXE(T-H+%. 5V@PJ*6G%3P0BT7<N<@>)7P>6"\\BSN+$$I@8F)VFZ<0%5\
M95=YI0QW[X^2]O_Z9V(Z+QHC=&4T<8C5 K$C\',^HF3\K+PK+XO0L)\3Q$@?
M40U*1@\:GG+WNP_>SC?(_I+H</> Y@^I?*]B:6C5L;]U<EBMH+,1\ 809G%_
M_B$6OGK4E?$ B$6GU:&3(.@HM]O(:S;$N/8Z:A9XB*U8%]\?4Y"0'8<?UO.3
M\]C*_>2&XKW")&-" :.;?!EV4X?K'JS2S;@+<GFBTX]=YUE65I8UA['O\%8=
M"X#/I]QV@^Z6.VPJ"OM9!]1P-GXR8[H/&6!R"G.*T'G.S<WBK9"A-Z#W45?O
M=9KEJ'I)+=)@9-HA,./>?/ZPY_";E-:MV5'T=J]Z8OV*MM/A 3*L=V++G3(_
MA"B,W=[SRK&%H;B\M"@LFW4]6X;O:O4SS5.!\Z.7<+NMKXW0&XXYDMTY7J^8
MK *_]!D8M4=NDIX9YH9&DDG;)>A(#CC4VNK/\^/2WC\IK:=O:V;&Z3N0&[*S
M"!<W6GQ//DZ=];W E/K7IFF@TF/UJZ9C%N&IN_ZL:]E3GC84Z1!^DG];Q5UO
M'M(P$,A-2!K:36[DP.K6;,02$.#)7S?+RIYGI(GY,JA7*3MSEI_K#C9O]!8R
M,\P2M5HA$#WA@%.6=6HO G@ZVDBD>J2P[(+(%GKFSY]\:2_JFY;7<C-;'[EF
M/)PYW/8($TK*#S@J?#&=)XAMBNR.>QO^6_K%4YW K]?/3T-K040^*!??H$"#
M2F9;9YE>N29($9NL4M.)^V#RL+CV;AA)V7?KSXYFV>04WZE-LY@WV^]L"DDT
M6;X2O6[@KC+C'#'5$B3FERV2*=,MQ97YPW8([NB8==&=NQ9VJKN;A0"?38R\
MA-VD+D)%'1G;TJN::J?EO2.P!RSUO0GXXI_25%RYW?&>KL/;Y2\> #94"N:W
M(5T3ZG-9+]U01<!A!0MX:A3G=\695(?Q(OY.]U-RZ])L^>PM7M(:X9]@*[S"
MA.D5V^.MZ9SG#:LID]KR0UD&9#C;,]>SR)^'3^D/J$I@!GY0..-$%/7V;MEK
MQ-9@0^)CY]YI1?,7ZJ6FV-_RI;_5?CR)6S&[NX*?BD/AI/:!26,V[5(^H\=C
MET#]?N=L>D%ET\&< /F,CJLA:QZ1(B,PD7[AN]_/K-*5..F+4H],ADE0#I@\
M+B1^!")?.Q/@^=%O<%83WH(^,Q=.46A0/$IK-?>O:EAVT5J 9-Z%D$%'ZB>&
M74POQ8N9C7'H6 W:O^?F[_$YNDX[*E4E*4N'<3;,J53*_B=/J\S/.L-9D_IU
M_7EFKBJS6?@)Z*/+R'<X*QRG J1@?]5G[&)7=\A85%-X:J 8?CY,4CI<E2%J
MF2%2%+UMM;PQ5\R7JZ^O$*FX#&.,Z24W^D*;/OJ,2AX7N2_<#@JO1;=F?JU\
MN8PP71BQ:CZ8-6K/N!_RGCA1*GE]7:'Y2<3&BS-:]\;W&H026)JO%1_> @\'
M'@W]F%6&3YU73X2Z_C[XP<W>-J$8ZPA+HN572!HLM.7'C8UBU&)N82YK#.:O
MZO]^D+%T -F3:S*T9W8EWO+5I0L)<Q/@DC/ CPS]A$E>DM-^OMC^ PX:#D9Z
M]$A 2?:)?4%)04+KOIX8*1]=J9)*WW09ZS5IZ4Z-:TD=R-;\<OWJU<&R"YNL
MA>C;'KX(O\:;$!6KA&JAA&:*0^H=I=L^YU;T;[#:V<_2155H2<1?6TF7*?G9
M9)-'^?SO,$(1,2?=RH 6R@R;;CXX=A6G.:)R=P&I_DI\EWC%32-JF?JFCVV=
MH>D<FI#KK? 6M4[Z4_)NMFW<\-1W4WB@$CFD'O_F(,)'?FATRM)!Z)X4N.:(
M$;1HT"J(&Z/<U.1,;5/V_I. %I^?8&/B0$W EHCK:Y)4O6&G)WD,I3XI&_$8
MC^S<7J0\;?+#4"HKS2U9EFXMGATQ:?^1-0@BDFBII_S:"O_J4M0.[X"I&E$X
M122+QKZ148P(X N;?5N>3_I?EB316?QZOE6Q,,8NQ*U"@/M77DBMA2P;EL&K
ML!%V]Z[/KA;WQW'["RZ4>NO0GZW[H%;WWI8#83XE;)659K_-2(-NLI+HV-F)
M9?G/T]2/D='FF"B4&4K.;A"9C*1O +-)O>V&,,U3<HAK1A0BKDRA$:7/4>Z6
MQU-\@NPST[7>J44$@''%P969"17ZMKWTU=9/1H;&7)447V+S%O03WS[#RNH4
MTZ&97GG.7)P?DN-W?YII+NAQX^'+M*]QNC7@0G)Z2 Q+O3F\WQ&T=ZAFUM@2
M^8E%S_1GB-(4H[SY]K^.$9/66P*(52>59I*M^1]*JPVMSHE8'&7D^$"9 HLI
M;"M!E?V29>6Q!!_Q6/6MD0R:CYOHJ)0V$BV3$0?)K+4"A75C=3Q#'+:"4L"/
M'2_<U2EI_&"BV5O?Q;:XQ2SHHG'XAOZ@VG)D#FT[W-5-2RXZ3 )(%7WN%RC$
M_-PNE#(N[O<$O=1WQAARAA!!1=TJ--ATVBIDF1@*C2P6T8W*4E7]<-A):J6,
MX<<*\$_4/9I=IN#QKN(4PHMR#+6<$ZH_LH'(<)CPFRCG*KF[BY=+3$#>-6"7
MUV'"23RRK_6/C3U\MIV!.4FTU.((X9.XC='9A41G)>@R#ZE<1M_VFT2UI&@?
M3T+C8O8\=?IE<K*!J)U3&;;(K#S?_T 2P?\+F_]_@<VO;7NW'?!W'6W"KH.T
MX=*LGM+$XN*-=8T&P6O]T4^$W5>@&+\Y$[2MS:G-B\4"&WF52G[IF9H5QQUL
MI/HS&3>=2? :,Q6O.D+=WYOF5=:_/TG+LR#GT&'45Q7)F/WTQ^&@9CG<MFD3
M;J:Y?6@:]5WH *94M)"S5\W)P_EATW"-4$;K-S^7E\\D1:N<CNX;,%[PZY5[
MQOVV:04AU*)IP\)204OLS:'+ZE*W:O#*+P%+Z=>APR(%N<58O8+"J=HO$RY4
M&'A=;8PO+Q&+Y>\X->7;J=Z4=%-9)&*Y&48P-E#5"7;FOK+K6$8OHC>;$8H0
M-V"FRY+K.4AMVBG=&?C8L;B*;4WYBF^XR#N>M1Q 33IZ<6^^E&>^G G=B.O.
M21;-B<S*6C!8X)1VM^I[3-E\;/S9GD2QK)XGMF:26LJ(K'!RBX.[1EOA\E1%
M(C'C(' ,5V_0H=FH:E&3U-Z),T'"YH_!$^7IY\23:LQ-*V+)=TWHW_LSK5"G
M(8F[X3I/YB6HD@!<^\Z[]^MFQ(\*B7?V[$9/;*IC%ZSTOY5'%N.OUO10T?9D
MI<%*MY;141"0<:,O+])T9%&\V:%FD3PL6F'CI;\=D1=19W-Q\>F0)8%4F;4M
MUWY%\#("E*(H%\DZVQU&=&453?"V&H>7,=4JE;F9"(,3A4:"<@*AE XDHW@-
M0$35?9S#0I4G7DPN4&>Z2$+)_(FA5W4]%O';Q_G7RQW#Z$8.]*3/;<*5YVDX
M_XEV UR%4B[\D-.OT\J7!L>-"V.06$CN9/K&JF18EB@CL-=F>M?^?EG)+E';
MM.;[:N0\ES".+CR2_@#/)I$EN@T',&B41P]SZ)EI?:J5 ^D(H,Z833WP5\AI
M\>&V1D!VF-,<P=7-M:UU_"EVWU2Q5-[^:AI'?' \(=;4^7DK>!4:>I54C]*E
M0B#=?<:<?&*WQ/=:X.&^>(+HT#?CWVY#\#G78D/228FFE@T_O%.8YHSN;4MQ
M12!</<J>U<E17+EUY>"ZAR@2_[1E3/SET3.+\4DN^P$ .O(\2ET'TL__A #A
MWAWC!^*ZU1_K&O'*,QI+(CA6AKE39M[FEP*\.=;"^V*63OKO_M8L2+S#':5^
MHW>P&&Z] FX5:!) +BU@#_L)W;$L;GG<&XEQ>PF G6A95/E U6<PN98K*2(.
M_*\8[Q<<;JI3*L.^98V8S)30OMJ) P4MU:*L4 J_]R_1ZH=+U7CM8 S%C9OK
MU>J*%@EQ8R,E9L$G)\;D"3 6RO5K9]^PB?T7$XM@[':[0^DH<=HV%+':P0%W
M [ I9I'HY6:%I6(%'RA ::LHAU!2+T9]U7Y+;X*A0C$_C.P+R0^$$Z=F?XMA
MU>3;$)'"D\*O7RP2B<]W<;'LFXG(\LHDU1>AJ);-MC,G1)5D]Z:(:.R9+31V
MUF51VL_$8'2F3ES ;0G3D,0[3I?4P)H>EL\YNA_4SAEH-V=. '/%FLP":Z8/
M_5[?<VQ A'H=*@5>2\Q8T?%DTJ4._ +HEY<G=@UA%#I067UIP76E;(0O=9NH
M%!*^)7Z2_%Z#6%<AL12 OZ6T1RZY@P)[HOK!F> E$M;E][%D7%6S<FU%E3CY
MK'0FXZ^"5%5(K)+&GR-IAZU:A=(L?%+7KW3/I-UO#>?NCIK+?5T=O#.!E2XK
MN>%<Q@1RADF("75!SJOONXV.8!P%/D@"M9$<T9L>EL8MA*%EK.30B$L&YJM>
MEAA&3@;,^)H2#0L.N<[<7CRE/>9KUR//8=#6+-0(%#[DYDF]->)*7;W4''S<
M7)=59>ECOPI[5L^Y1U/.73L@Y_W>,&ON,M#VJF$&20H3IQXWEO$0C\(P@]/!
M&S);9LKA;M8>E6,I YLF,82J)L:RK!0DQ(J?Z%QDQ=N/N,_<9OEV<+V^ZE!H
M$K_5U7W\20- $VR=E%U7L8P?( SV;XE5L^DX7LF(+VH4*K<,&\*QP'S9^:B\
MTD*'8JJ.TR.@ZB9G4W,9H4#9(J:=>^]_^53S5FJY)7+A=DR9&]FWP9>^(%%D
MG2+Z0?ZQA\3OF?4_Y8D.FMB8OTW:/GB/GC;FKXY"9C%-S SZ)1>^8GAR1E9J
MOJM0HM$=R)V.IPQW-03^)QO4L["2(ABJ& :V/S<;^MFK/FLL[% \VK^Z-[;H
M7R;AG(*G-RH]Q%SMSYB8EVYDR)3PC:)J_Q4HB'N5?U%Y.F$.+OQBS2G2[?I1
M]W E_;:KFZ^YF_!>M?6B+1?8U\.E,$5<8+B4^/?3SKJONM'X7W7?KDYK3#T
MV&,O%T26!B>RGIZ-U8K%K5Y>_-*;W0K0]+D7IDON&]_D8"P;LGQ#F; 5!J65
MTTE2_J;!'+*Y:U7MFU)$&>L-::9?.^T3/9QB)?QO[+UW4%-OVRZZ5!0;HBBB
M(* "(J!@H;>(_&@B(%UI04%I M)+A*4@H" @(" @O==([P2D":A(#1 @TDL@
MH0=25O;R=_;L^=[W/>?,[/>;V?.=,]\?S)!G\F3=SWU?UW5?=U8R2; V?!+*
M;J*^4:)RJ.C5N)SOCQ%_"JVRJ8?YQB9"8(3X><#NC-!9HG/)Q>J:N#&!B"/$
MHJ\-KM^"SE1J#-WAL[WSH*IQ2.$ZME%B@*J6L6-T0MB_;K1>2](3P6KA/_-#
M8\8ZS[[*!=*5<.OBCSW^M;_KVOL[0\Z68;@EKR,ITT9%$>VC-5ZGS?1#OIW@
M,7_,(8<*K*.^QIB[79FYZ4"MC_'@SQ_-,;]3\DKQX'OA(LN7P@7,)PJ"<_<,
MO*KZ.HC:'Q<1*7ZO!T'6ZI(G59C;_6'5Z[7'<R0CA1X):.N?>C4>*2Y10Q'.
M2C2X^UJ<0TR?VZVA^.JX6W%E"P='W,U>S_0[GWLN%YYY4-"O%NMZ5<+ZT!1N
MV*F5C)TKWGDH$Y*P)]KI/I^DGJY>[>;G<K"QK:KOV@L=CV?L,W%_7<TNT"[8
MQW5W?U"Y/&\'3U(SS3E[-U.K<B8U>XFR31DV;WPXKR&8EL@1D?$H5[&J)"].
M+<^G/8GX\'N=R3"S9MVXIKNS9NJYKFG"N4O;]GDY!UGW-;\@L'J)>5?3>Y-,
MDR=GPT?1P;\%[YSA7Y[Z*+QV*D^7,Y?U.),$M]'Q?__>M>3_^[WK9_?_=^Y=
M+W]Y**\ZTC)5-;D_()7]-6ZDX"7/:0YU\78M#8VC^@/Z;=62$>>L#'1W 52D
M>4]TVV",GDZ"@ENOZ[C-I*A ?9UGM-VL3W94N(F&]1/B=[]'GV(V%2S'J3;.
M)*WJ&DG/E=9?3MS%=6NQILZNEJZE18.5%>R_%"3,!?[2\H@^&NIC(:7?*G+2
MOVGU>*\3@=^Z4.AX459 $8L2D_5)%:6EB23ONCE"C=C*4V]1QYP(E$_&DVAE
M<5'^B+\>?_C6?5[]]QT%?7_$WI.7F<MUQZOU:#;0$RYJ'G3C66%!=B[A0M-8
MIXWKKO"]T123S_ZL+H:&:DC-(VR(=U/VQJI6_ $^)AK\/!CI1TC_2B+^ E:<
M_9,FO_K*P0/R=F/:PN,'7C03%$N:=L<3?I:I-;F%7!YU^MS.ILKE$O:BIJRR
M(8[_:/3XF K77ZMC$B%LAP[<6WQ0D.FT 3U"F>@$4\6F6+5W4KSR*(F1;OU/
MJ5:BMB>,9>H7XPI)915NPYW1;>T1J3>-3F4G/,X+N)H9D2B+J-+E*%N4:5*N
M:5IRX>RY:;36?K?S3*([GYTPY8W5JSS^5^V$&.X5WI<B0PM4N'O3Z[A[W5 ^
M5K@GZT&5*=B;D2T!*N'%Q/N%SMQW+WE/)+\OEGKKX2Y'2]]]-(SG@\0TUD/#
M\^MZCKWNF$Y?]FNI7HQ[-A;[Z1+;U'+IX#N%\S?[E3AP%;J]!Q3$H_\J5WTH
M?6VT>L\SJ<\7-(BS$JY%OR\SD'ZB;/Q D/_"?$C>P"BZX0II54PFPC7&:$J\
MWRRY^\B<L)0T6H+K36RW9L+YRA#K#]=>/\S4>R.VI[5FY?LR=5'T_4@"^&%4
M"XTW/UC_Q3RR$L4 CKPQ9#<-.:+]ZT*L]I&RDL>^.<XU/,(;OPPS[A7S*RW-
MFG_9O(!B'^POVO<[1>:Q-^==UJ!+S.HO,B^_.IU[N88IX)!%-WW6DP$\\TGU
M'O\],E,[ZE5H.M&T8)VX%L,=-!.RIK=HRJ($K'79"O&K? QRY==/'<#I^SYW
M0H_@U$J]MB:RFZJ@B4"N.BI;QH<'34\J.<B$Q'";?!.WVUR+CXY&K@29"H<X
M"T3X)$_KL)S_E.4;9JMGSZ&;+GXNOXO Z[.)PNU%^C0TC3T/GK"1)PE4AG8_
M._LE!G?R0];3K??VPD<V\[O8_'(6!?X/?H(L5\P2_.H+V1 ;]QJK5>7*_6\H
M1XXGU0NDI@=72]0-6P>75=F_C3/4BKU\K2 ::#'_*-'\[,+GMS@%'.YY<490
M9NWU"[KIERZG"Z=KB=SHN/D:ZR^C3QWT:QRIJI<[7P4]N64ZAFN>NR[9'S0=
MQ/<DN_JI@(;^W3OBT\PGHA%;)VQ^8/8H2'8&L$FN!ZG,._5T'TD,>0A+;4-N
M8S(9P)Z<5#5BRVE>A\J'0Y!<L)C%"[U)X.96DP@#6"#!E=QA)>$)794,H*D$
M,WGYS\\=HB#M'ZN]=*[:&.C;3B]UW(-$8;X]CZ?1Q4+AUZ-.8.B!5#)EPQ$D
M%:+);S$$T((!Q)2CW!B *M&: 90IE$-D;A3T^OM>-0- :$YC('^R,P.PA.A0
M0Q*2NDR@3XM1\%C,[,KD. /HJT] K$0^9P"-G?#KI+DI.C* WOY=- -(;<0Q
M@!$$!D1?P4*4.@;@'095;Y/^Z43#LTERK/K55<%#S48-;,.6.Q,G>$I,]'Z<
MUM32/'-+_/ERA)7HF_RG>BHE:>LDSO%E?AIECXYWCG%OJJE]?[)<1[R \W5
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MCGD2.7["L-*4N_J3E*F#NYWYI6"B0;B)CX7/8<.+^S?4B9-%;>L*MWZ!HIB
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MU6@?B7#S*YB!2C":K.Z+8<5P%5.EZ-]LH&NPU,TB:V_CP#U;L)<)/TO(YYV
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MV]](I78Y1[IBR\$-@WC(!PF5M& ?@'4V4(HD?+'0B07Z^(Y_H,[N RP]B@'
M4-:LP%![9NFU*WC:QQQ8ZI\Q@,)2]VO0LO,>$HZ18@C+LQ>74U#O0BT#X &_
MIL)ZHP9-_UC)Q$5&4*%8,N^4]BMPHA!:V/2"A+'@MHML$^C2:?:38)*ZL,T
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MY]2:J,J[QNND+>>D%18JC;5W!X.B\;R^A; C*W)&5E,CJ]?W7NKM;CNL-U;
M,XO+*H0&;0NU0.W8;+O\DT:Q[-E^OD=AJRX&FT%S/U+%:(,.,V%Z]%J#(X]@
MT+;>+N>60Z1%N&_%LKE!3KK):Y332]CAVO3N&=%&B+U;=E H)F0+:_=<C-B[
MGCI3!W5::1J3011-A#6WAZ:F%M;LOKOMPV4>*_^YEFZ$7[W^4N=LS%A3,:>B
MD/&909H0X1>7)[4!;.XAV0BYDDBLDR9D)[-&2F061=8;][4SLY625+"T)E)H
MX:&OGJWN0,N1NTV'HQ4LPKLP "9H TZ!F> S3QNR&]&_=S=D[?RM6F09M;>Z
MD*I31T5R)+5(A1EASB2ZL\MO6U%[$TQP1JEG-1]6ZM6]5)\VZ<^H*+;31>K^
MJB=UP@@EA)!6S# S?@B2S![HO$Y#<#13!BNKUN457 A]T_9]Q1+ZVMG%2J7+
MSO.7H(]@?-7&WA3T%@&/?^Y5D_/CB$4TM86,=*&/Y^?GK#& "] 1G6EJ;]40
M>A>U6VEZOZKVTKB/_J)4T%B#N4E6,()#16B&2:*O: W;:F37YL&\V3NA0XDG
M9J.KP$9YY_P:7!I];LN")Q(=(23A)S74A&9MRU9,<\BVKTPCV3& &PR A-B8
M*(#@J6,Q<,4?Y_BLFH/"!ZWY>("')]BISJTT<)??DQI91DT&6R,CD2&:2QM5
M)!^=17)4Q6YE491@6$;J6(:"NX.\1']BN8YH91-]".&*JFD:]M_"%DS_Q)-S
M^^QRAQS7D,L49*%S8,?:TC;WF,>00]99G4^IE\'14DB#.WV#@YI*A]V-AIQD
M,(::3E/>18_ZQ5L^L!('3U(O.(_O*7;V@%5AVHUG'65'<)9C&)=-?J/$REW]
M)6RN=LE7AWN5TI24'#%+>M[?/Y+88#'1C3'<QM23!'0*UA23VM<]'Y6(3'D/
M+.:&YZ3P&<7F%1_P:F, ,;PK*2 ?5+#'1>]F .JIBP1G*>HFYAUXF-H[38_7
M#8 GS) 1:P@/:^([>-S\+=ZDPQ'6A_X6Z405W(Y,R"G#3NU&(_R3W?N.^'/&
M50YH\X7[FXN0ZT=)VS1JIY-9]C:HM$WF)1H/T(V#MNKW6X!/9TP)V"T*HL)<
MMO)9HL9'//Y[/#6<5E>5VXO9NDG3I_:JO"MB '_!PYX8<^!NCM6N=NH,ICEG
M8Q?Q$[_KZD _JX-=B>O\Z%_M[9C;GA,?*X\\4;DVE%@G$2%KI_40G:K+*N('
ML[VH:<6,BJ3B6BD^HC'DU%_P18=SYC%:VV%:!@,Z>;+^U]:6\%7@IQ"**&2!
MDUH(H5R$9.BK.)3-"Y@-&!+S&!U#CLA)3&JEN>T*J,6O0 M&F*FEN0''FQ;3
M25["?OYK...PW/LQ:M.+Q2]/SO^YOK1]NW?*APTI&(%+Q&SL'P3RYM2,6_Y!
MX!5,6L2C/PC,23W="B-PL=A^,%T \?-T.6+ >"."P#,#':&/,0!-0W.7T=2)
MWEIJ+SQ-=Y;:B.P@?7:V4KUV,![3F]Z7-I:PTY%&K_AFN7@G/G<X5MJO)<Y?
M-\A!'Y<=CA4O%KF7Z)M2QDMD_T-$'U(E Q#;Q>M2OSCCP,BI70M$G[9C@PZK
M6:+$KF^%@Y_$0'Z^GK6<VCR:>BFUQVK:RQ/,U-DJI"F74 B/04\0GLSV]Y%Q
M"")$(H%!SR2\,2&VZ]Z'T%?0EQ?+V1SE:^EV$_.5Z_+"#:1"54S03Z%\:2PV
M+S+:G\2[IH6J__ZYGMI*=@I;W2$O*\801'X34W@B69<=[0H[2XJ]![2N5.Y'
M_(B<YX6Z\.W:J7M2L KTBU&,Q^M!)P;@"C;P?E5LW26.=Q-9I=;%?B?\D:*I
M5.?,U<<;>R_K,OMF/&4T/S* 8HYH$^\FCA"NID9.0G:?D);=/4*QO;=^&IQ$
M8CZ$H:W6N7J1=-+H.&>4RS:HLFTAU8?'/;);\R_!JV+RUD6FFY)E;8<&ST-P
MU[Z%W-'RE]FR@7MW>N16))0HXE(!3B!('&O@%*;MAMY\I1\#6+N6.^G]TI_+
MKX&3-%N'4ZH6<HW<SB%J(CF^KO6E&H>4U)GK?1S^N%MHDG)F"9S $.%)E8E#
MTOD"FHI;1'BHP0#3WT(8;O,<G#;1_TKI<68U*O98Y_DXD!J&!F\@YS6A;ZG&
M6VAK$ XA%_HD\C038J%/0\PTN<Z(7/00F;>YG-<+1$1,7G7,-?RQ%>GJ=94!
MF#KQ![:O-8AC"UNQ%K\K<BIR.8=ST7[#BHMPP)HDTZH^*H[L3*P9HB'3*;T\
MY0WB?=MQ=8K<AH,TN\TE?5HK _C$3+TDK9WR'<Q ;A5#<5(55,0J)A+<3V5E
MNJ%)EF4 @<\4"<:)DPHWQK##SI:IL3Y6E.^;@F%3NP\J*OO01M$'%<5S>62H
ML@+4 C\LYG=2[03LDGR@5?KHLVK?IC""O-_]GHQ48X>,1(<"=.<4 :\(PM?D
M&\5$C(!;FA#LOP:(.X6C#,"-AMH56TNM3&+E&%^$6.*H<*]:=]C=UE]:-WV$
M=2=?=^W<?B>*;%^#4DY?%W? WNE(Y1P(N4!/1A$[R;"?"I#$^=70%ZCU9('/
M7K[^8<M0;IMI3A^RL&HM?VMP2$.D<(K3+6F>U(O>T:+*37N9@1G@5CCTXP2M
M:!31 48P &:(>2>!I52)C'2F<0G1=+KH,]B9C7X[JI^B\MS0Z<_5W9CA8PX]
MD1RM%/4W?[ZK(EQ6*5(,6Q.;>WTU:QUV9#?J%Q -_?B.PY 0:5#)J(K/E!_O
MD)_-NT-3DN&@L?/O@47QY8'K+^\M<5[]S@ DX/2'4 4;)]8#<Q%]S!18_YXI
MNXI.0NNPJ4"\ 0\-Q;=--^!M:*<%::KX=ODZ^2W,?(7]-D%K8T$8?'C=B?@2
MR;IDM2Z^.#3MJ3Y84CE 3Q91G6D]CR1[4?,9 !HOZL9QPW^+PCM^=AX\L-A4
MN+SDX.&6VT:I!X_1.P;,V6@F^3AE/-P&8$+V,'=C0O'GX4#(,_2$Y)Y@' ;O
M3&)>Z_V=VD[FEL1O@BS0D0^0 .Q$7<B<BLOQ7;GM^6*S7'.0/IUJX^4UO4AY
MV+/85]B6(==?A]5I@7."[2E&\9(-&("%A<:\M@M]:0L<(J *88LBED?IS?D2
M1]8)WW[A+=N .-%TILZA(#A1&Q&-_ZY#CP<3&  G=!E,AUMU"/4&O@6<N01Z
M(T+^%$DLI? KV)Z[*^"USEI-14K1CN=LV*]3Q/=8//T-Z(1J,R*/:"KLD)7[
M"BWV[5:&RX-OMIUM88].*%XEWW##DW2RZ>W;R&F$\@S=>.!1NQ<=,]0Z9;\N
M#EI=2;3_X1YB 4&6O(M2\]A.WA#D8CRU#_I^0CA&$(H"(_WBUR+KOLTNBH.'
M(19C,H28:M*DKTJBKR2Q<"8T5L<AO%>KY2+#<I=&U4(RZK;9:2;MBF)3"I=W
M6HF-4 TTX3P.#QZ]2W *>_A!I2T+J2';X$G[709@S!&$Y-62/R^44RF1]@.'
M5\3T&??^?+,K!;UC )%@+DO(63CQ]W@[_;&[R#C'/M:Q/R:.19]<!]9[;?C1
M.*AAWIW!&[56W9A'%3IUNQ5K3T_MFH@4-)WU<#@#88-C6B-<M/^"\6G>B)YL
M[*(O_(86&AT0$WBU:3_56%P2<I!NYL]+^RB4VQQ#181AJG&8!2Q9?R_,PZ89
ML:5#9@!+8H\'G9VW2FE>[3M(Y^!Q'[ 2.D#CU*G%TO'K/HBW[<Z(F(Z7)OS;
MN<)THU[)U>F!EH]J4[8E!16:YK[MB,JIK+69SRA+ZA=_VDZJ*UF9G!(Y02X=
MA58H"A:2]87''$'];8>,5/-"G8'*EPJR]07%Y_'SO#2.O:CGO7/KT%O%!>I$
M5?8X<LF-VI*Y2C-%7J^51S0C A#QQFN8*BQ-Y?K<IIVLO(Z#DSXE/-$<UYX;
M=%'GF(J'X<P]PK 0/=LN:VUORA-+-J#/K7(OU(&-XO3K7W$0@2*\FUA]S)0%
M:;AMI:68VY8[4-V:T3@6C-AU05#/B]&DJBF\,%%1NV2*.;0&CN;3%]9! #K"
M  S&8-?T8Q5!1'M !6 =.#DI1A$,F;*%XA()6%H%Y&<*'13;>X,DY%,'('YO
MWCHH!(I&U&_[&<-SP(]N/\26R&Y=<7@8C(;+9 3$9X*D;U/U1WIA?QXKBX4<
MJND6M031O7]Z,\GD[*^];3H!>C*1N\9*/TT/H8B/N%-Q]&L@]P:=-/ZX:AZY
M"KYB (<B5RM ;WD+G>E;^);9]4C1MRWQ+PNWZN7EJL.0G/J\01F)MOW%'@0)
MJ"<XJC/B=C \BDX$DGDKJ,YUO W;T%IC="_9IF]IS=T<B7.@I!8Z>E"X3?R3
M[:;MAG!&Y <T"HQ'#$*.]!M/$80.0($[%^IQ]*L@-Q4]G2)4U8!PH)W>E9 :
MM8<VD%WD3=SJZHRB0SN!:$A1R&#!MJ/#A2*_]FF)K[L5/D+OF(E'R+NDNN$G
M BDQJ_X]1!T2@HO<OCP*$2D(UJ5MT>DQ*'=Y=ATQFZJER 2.O31/;BN?$J0W
M:>[!0C%5^09NW2\F?\K\A[LPUAR3(M!GYFK,9A_<OGGJ%L=?VD%/P)6VE[U[
M0NNGZ:QPQX&G81\(5N'SQZ@ML/WN7'N_?>4T=!W1<A4,H7=.^&!^/]6)U(G$
M%GX[0HXPH ]5FSKQB*+S_TA+KNJ1W<ID,\0;CT-4#%F/ 9BD.M>"*0S U\^8
MA(=G]%,4W@-+_CD_33&K4(DSATY()O7<MK&14-;L;OJ?QCN:NF>\D3LC"%O0
M&7CN_5'K)N=%7:7_A@1ISKNJ,_DXR'D*TW*3 ;3ZSZQ",VH3AM[;WI4*#<'C
M+=U@3=&J*,T<-#SGQRF^Z_&7K[&I_>Z2B=C1O6WD2\7E5()$EWSU3T2C8CFE
MU=G!92M598L!J&U+GK)86F\J ;ETWDUAOX892CPP5B\6FX6#?5I-ZP77^348
M0*/3RHX8F0O20*G1-AG L(A_&97:AE@:IWK!Y88;D^</=#K'WDUPU R4ZJ4]
M' >AK8GT5;0+.)M0S@!ZA>!!W:CQ(*+A-&2 <, L*4G1<;5>V38;]V$9:]V+
M!*?'9Q%DD=LKZ''>0-@I9+_D_;T82&T#QT_<90#M)GBH&.?N!L:'; )P7\4=
M&9>)A%U"*-BGN!-H0Z]>)\U@P(5@'_\%Y-ISQ-C2&JXSQV&2TEZDOE<8AR@4
M.^K=)!AVM,><4WR97W_&=VTFLCSO ,GXCS]X';U@7PW[@QYR<I+Y,D4L<TV\
MK"34SWRX;KFD()<U)"MU X(>P\9IRL]X E=./PEF\&ZY&"1YK2 :>#NA39++
M$+NBL]C:?4'<+LW7W3;>D)3O^(0!R+BF;M^=EI9'<I@X#&6VYKJ8Z)MB0SBW
M/,@YU *PN;C149*W$>'KY\L5#JIL67 $R:KEZ@Q-$(H=3(JE'ZPOO@8O1E(O
M1L)&:#?>#4_ML%0(4_B/]]2*TJ$M,8H/K1'.?Z$8M1[I/D<+9@"K.(0 N"Y%
M$J/_AF<.%#Q'"MB""XD(2J.4!MB AU+FX:5[?H4020X-3X=Q'/1:L5ECB'.B
M&AX55R8'-A=H19ET!?0N'P'_$D-3+XZ!?'ULH &K)05: V*UC?<:N,Y)5H,V
M8OV'-XUIQ5]@R4*)K;7W82;1#(#-)@[N"%;=(-DEI 1Q&D'DF9QE &W.HQAJ
M>1<5?1/LQO/2MA[!P\QC@C\\1$X;K"*WOLR1J&I5RU+M(#4DLP9<:UYQIH]C
MJ>3_^.PE/ I<%Z["[)%&$*MG\9G<-(P<GAZ'F W$3FS3AR#8%69R5S:0.<CZ
M)$PPG4RS#N]B#B$U]5[:P2]4.E!]_.,&?K1XR:SB&_>25SULUZVKM0R&<@U.
M'>TO1)9EYJ62=%;1E'6_&72MU;)_##F\8\!Y6Y%UT%MBQ'-G:,K["V'73N>4
M]_J2XX;^K Y5$M&%JH+N_JT5-8@EP7P1 @.HXVU#A-+C1YWTW_?1E%=<,&ZS
MU/_!WGM'-=6U^Z+QM5<4Q )"5$24JB)%6D1%!,0H54"("E(%I)<(2T5 0$!
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MW,) I2(#I#!O)J"?].!S@")4.[20"6"M1YW#<(QT"HY3_YE!!P'0/*S [@,
MEILD[ <P9>&,3QCL )SZBHOO70C<R'+97D]G7Z\!]KPZ7:S2%<_.*X+:L.3Y
MEL[#?Z/)=)XE  !E.NS'7$1=9CZ!&=&*U: &L^,%.:= 0 H=A+R(')00$_8I
M([,JS=R384\D8Q8'9G\UNG+CZ(;?3PJC;-!Y37((:ML)S;)5@8CUTN2HU6Y4
M,SQ!4GM1R_)1'4P@W,8A(-R<X443'@\&%M:. 2NFS$7T]E>2F4!O=/^<0J\;
M#T'#[>1\S'P:>2V&?&2#C&U03&-=VD@K5-$-B)5GO3')@94"33Z8XEDW-H4&
M=99%(35GUIL.MHDZ$(B$1VH I5JNPMZGN0BQRV1:.X!2<"/_%)@NSC9"!P6V
MX5GLVD"52@+3CBC<5O./M=I/\1M;=\TU-!Z.1"F==9U<:0PIXUEGR9. I4,F
M )K7;#?!.I BUTX#Z%YJ1<WV$J]!_X$CB6OET !(2S$<^^X@AD/U90W[56\<
MC 91JD)8":*DH5S0ZQXPX)>N%VA6,;U&#/H/5<_'B\[L-TS,<A07\7Q=EI4$
M=4<P!6&??(C6QQ$E_)T>!Y,!VL=Z 6@U'A42XOPB+"!!E^$,'-.F=%:S \7R
MYR(6V1N'Q$L@9@YY9&B2OF8 %,7&:<*M>%W.(&KA: 49CE..Y)!*;\4B 8G2
M3L@$X58#T#!%682DC&)G'R8L=1$6*+="5 $#U1M-=:R;RW#27+D(DRHL/"ZY
M"K+BU<:-U<Z6K!&0L^)^T^QE/.=>,>7>!E\GM>*6*P-@6M7V*Y'L,S9PHP[
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MBKF,&%7*]^=P$>4>2JEPS\:K1]@#<[K [S6/ S5I2H'S6OJ,_[DNW5O_=,^
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MXN(>GZ*5XCPOY%R[%ACR1$N-3=137LV=L_A(D=0Q>-+F$&J)-P=/*W>2J.J
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M-@S7./<=2?I4CMLM@;YA_R<K^FRX2L<Q&4G3GIF'KV[ C8R#9.<8UYKD<:7
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MBW5/>)?[O2BJ]2AMF%J9%Q/]W&32WL6+7%A_^E#G*JHGCO_Z)4.V'HO+F6+
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M*ID1 H#734+@\?T.ZX2IB1"/+NQOV%2WZ+TM<2F!+4<P0E65,=1]\^"3U4,
M'E%G&Z=X(6K0:7 &U08V.M&@8&7_XF&QP/*N4@$!6OI[Q8Z9Q?<VQ[>PS7*H
M%M-YF?V\_LX.XT_[J4\*!X&L%9A1!/+:'4E(RJI@PZB1H8E'HU^OL6^1BJ\;
M<^*SX91,A9@(?Z,.77_S96<)\I:EC>BO:PES7P56 )%> BB5W]LNW+'C-)!
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M'^SQB&>%;I^!;)QL)-L28T!,Q3<O>!W)IX!H&QGT[VGEY'\/_,<<&%NALI(
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M>(.5( RS=V:H4R ?7OJB7(@M]QT6^:UH55ZI=7$==L"S6W$ U\ $W?%6TN\
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M%NLCBY<R SV]D9*,<=VVN2G25).]:=L!EE,"UY[U)C[.OD7U)]DZ04R!E#+
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M&B'6>E5FX>H!ZCQ]DF-D"=B\(H(1<"3SNS/6S^9-H]W 7V"VY^F#C5E,I,B
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M<[6"H\%>I$PF CIA$=8KN5CW1L+Q'KCVX*P>(U6[TP9A@&N3:C"8\,IBP)[
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M50F?IG6FY8[_T]@?A\.N$0%8#ZP9%I))!*Q+S."7P7MQ^43 21EVD@B8L!X
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MO6KNMZRE.R?BA&=^+&*/(*9(7EIV0+_(J4BHX[ =T540] J[+5$"N<M,\]3
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M<N5/Z?:67C?-T*:N_/:WZ)"#9.E>V(N2.KN1\&N^[B3'#XZ5J6GTM'.RIT*
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M#GJ.GHD%A]A;1:GRJ\YUGQJT5(/][]KF!=C02_RP)I&$,C@_$5@./*A9T#B
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M7[FOPK1;EP1%!M.4P\Y2A9W?H^_Q+W<]WONP,S"'#$IFZ*NR&E*&.>)$X8<
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M;>_^U7D/>YBE80B=0<UA[>GT+7K&C.P^=9]K,I+K82JW(-HLU*!WZ*5HC&
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MBQZ '_03@6R37+SY>LUNT_Z!!,&KWX@(4.R^$8&?X(I3B$#H< (1\.72G^O
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MO>SKT!A.V$:3N4U.3AL:*2>@7F6X!0A;. )NM6'!F "^X#/KVZ,+WNR7FC_
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M*?K>$YNX2AU.8Q:]L7U=%MW*FSY"1GG0*G_1_^'E9RC6,@^/T)8,%'[2YW=
MQ.AL'8-3X(5U%%/R"0%"+:1F4B^54N^KIJ\+8MG?U]J,DCU+O W>,?;."7;B
MI+P[(M@!:M?"41Z8#)9B!85XOJ<YV4Z6K$]A9!@S&',%EQ9*F=24^W67,H\\
M_M*:("=/^7/N_VN(W_Q<Q5T>(0/L>ZPPV7GVLNI3)$<+0OU.]_3:2[-OVDHN
M4A\RY8+9-.XD9.WL-\G!"\%QJ8FRQ>YS/!_./I[G\/]4E&,*$:IOZ56L4_HF
M#9?$7O;)^C(+I:J:1.3DY#"Z\N0$%3C%\=G'ZLI77RF]*@;<H&1='AG8ZU]9
MZUQ(:Q3N;6H7P6)- N<ONJRF>7N5YYJNEM32+VUQ10\R,N6Z"L6>RV%M%?K-
MU5=I[S(\09E#U[^[GU?[..81#N;C9-8U9(N[/81GLJ)/+>S',J)=]8ITCZ.
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M.5?=T@'7Y6X5L AY=#M%:/\OQOCO[JJ7UNF&%,J"L"['F4NI,@TW\1BIG8!
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M(J6TK,RMB+NP)$OU;0'7\W<)G6P^>7=CL9[S2R'9E5Y63V,?Z?\5Q?<)X .
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M*Y@[1 "=H+)^KHD;KTI8?&SHF04S@2$0\;HC*; 4PY*-Q:8 3T 05X!+H/V
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MUPB(JD9-\HEDJ^^/3O;;=VC*"[7V.?/<&RF\]9MP<>Y/3\_>?6CY WRTI[-
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M_)] (,59PS'KNGT(--KM2!7-B+V_]Z92_;RAK^Q^1ORQ,.Q#C/X-]<698K3
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MO/$N\>N\_I$ _M]!EA\NT>?N.J]C%MI8CY_3\P4NHUD7R4*[-MXGJ#V5=7*
MRBJ^8OUQ^NOQT/K)6V]0!C^%5VUT3R8ACKHA[H\,Q7)PHH>Q/Q<--U<W3&I]
M:=?DQ;:2S<V.1(_-N$XDM7D;LX<=%Z8D^<$Q?:5KAQX:-VZ^9E3@*B@I_XA;
M+A D[  "61;*(#EFV/ Z>8'VPV[ZE5:6GEN;./-<+I/^Z5U_X+U:#O<K?6K:
M8_9!?E&@L6-?2HJ:BIJ,3TC$M>7^/<E!1E,"129?X@$"E1NO%@DAK^KFP0GC
M[GU(1V2HAU>WS_EWN$"M9_1*W\3^EB L+MY75S$TLT*L<T(UKG,=^//9SU><
M.9@O25^[0=]T^.4(1#5,QG(/KU;Z^ROA+++(@=\%C#S\C8HF,6\=L+KV@]0/
M,\.\%&8&O&T%7^S8MIX_?X9I(P/?(.'EXY#ET7EMIV.5:XIH&:W$&4(.L]>)
M&1GIB[Q<WU*TRDH]4MGIT?,(7V?'2K7H!;KR2D..U/>++]YDM[__,3-8% '-
M*<M-9)39*,!J:TZ*R?W^1#RZ;\0#A,A0FAXWIP^R4DUN05(JCY/S$ =1*0'(
MA,[3^J4]0=UZ85?3HV/EX':$P?#J\X%F$;\(SIB*GA4W[[RHS.@X.S>YR;+<
M; *IT7C [8JMH;E?X_[;:(IO,YAX:W=Q:PM/1,^N0X5=HBVWF_XC]L"_R4]2
MD (;/8H-8^7<UK%%\]H3&NS2(F,@"'DT,?0$H3GG#./S9:217BX.0PWP@,Z?
M$NW0$]BNG8="9WYQY8"35)(P@[:N[)=NS;'\1#"U/D]QW'4ES74)/,!)W(^%
MH,(;[-A!2-;-/SASR(,:([J3:VA;A\&FDV&K/IBA';9@'DPFRP$O[=#IP$3S
M^*MYROCOBTK%:8-')E8X!W0T_QSC >1F=:"JUX0HFBZ+H.XW L$.,2@5Y*]9
MKVEM9P<GZT(9>2M8#<0!FT"A:5&?.0J/<XI9UO=O?89F*\Q/W+5-LX$X5;]P
MG3@#'_U^7O&%H%S0@PT/[(YXV\EME.:A\W*71A%7/1/GRLV1>=3@_$PJ]$@[
M%8Z)N5>_/@?IM-UBB0Y*OA>9F99DNV.K0[]A,-OQNB)-PCVZAB"J;_& +U).
M[S*[YR ])MYF[W.3A6MPC.;(IT+I? S[::7,:C_L<E1BJW_A;B:1LUU5&DJ?
M';D(;4;*AVY:$RA!".'N?D"S8G^V2GJ(=RI+Q/_PW?&?XGQ\^H)F8:8VRV/-
M<W;!+ZG$SN7Y*.G,'],?>GW;K,5"(K;\H*=G/*?'_01E(,0$?^K$+FG&T3'8
M5,]ZD1Z7>;OH4N<1.F4^TSRX)$\:OUR<JDWDNX43@H$L6D*!R"Y;86A1R%RW
M%>1@MNC?$MEO@><7!VN$,-*>,14/:+/*(AJ?_TG.IA$B';B[Q-R?AZ.J&<V2
M<@L0;Y3DM3*]0-HZ1^5]S$MS<# ,2<NZ9U)3/9&@;_[*1#WQE-H-GDNA L[/
MU]<1+8TBVF1S/&!(NQFSBTXF;-_LO'(@$@]0)FT>1B!F.I!3]J6>^74OLOY*
M,L5X(OAH:%GY/X19]K"E<!\UJ<RU:RA3N4P,\HYK==Y[XE?I;@))T!U C!&/
MKS=K(7&X>ZLAK.6>$$4\@.][_6 O,G-[$*3;G;8DDNK@R?!>"P\@#8]Y@'(
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MPQ/;46Q9EOU@)XE9HQD)AAW&;,00B>/4*H_M0V4<;_ZM(^LQB%K]G@V=33%
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MG[X5V3>A>767FRI^6FN8_YE0;M-1]<5'Y^);Q#*&-3S@3X4Y6G\&TM]NC[5
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M]G1V:=N"]T/.%9OP@,752LC(BZP[P,UM_V(\8'AQ# _88UYJFXYWQP,"#/"
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M@B9QX\R6_B_VWC.LR>Y/%XVO8J6H=!!1 >F@5*5%I'<IH1>E2B]2I$910%!
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MB@D9[P)A.ML:GQZA-5ZA<(@2A#U>>5^!7^&F\LI+>J#Q7P<O2[*R!,D%O"!
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M1%_&PVV(U!;(N:1;O2P?3W.DSP??][MQ?NRK2?$Y?6.A]&9>V&/CV3<L(<]
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M/V=G45_#RKB)89&1U9*#196-*,58Q>0*Y-7M57VN>9>T5+'NMA0OTUD$C<=
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MG5T$.F923,7ZOR.4*.3_8!:Z%$S,N!+;\V,3Z#(2Z;VG>&+)DG1O4C6C(0:
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M]D=QK7X7L5^@@N*% P&I6\WJ8E<$J[@=W<>]LBH9B]Y(^ON\I#17/CQ:KYR
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M.X=0^S>9DG/=/__S$:$X;#P$RN.Z:8;?:!C"8KR.6N#>/7W\QU.>_L+"([C
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MR3>XOWL4E>@K<5[*5^9TOPD^R]G4+';J#I@Z!K5KS*_\HJ2P"O+"?F02 S]
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M>5(ESXX"B3N9Q/1/4;WXH/XZD\^]#)3]X%U)"&WF(-E;RJJE1:T@;-*28Z&
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M172+)&]-=5V+;6C I$#>ZR.:QOD'*[9];632SS($6XL34^TY\SU-H7-]%([
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M>BR??W@F-B_P,3,[&^V54MI%DPY@^/YISW08K@'$@>8*VB[=;Z@*'O"L&%K
MMQAQ"_.\6RIUN1L==VOVB\1U^]51W_4+WR36'\M_#$KV!T8)VC5$S]$BM_-#
MC7\^<GKY/<E*S"?/1%%!WE%E@0/5BIAV6)&OL:F<)K)F:4XW7""7.E4WI5H4
MOQ_4%U?=W91)G1> 3!D8%[2RH&(1,U2.3G;JV<D./.H^Q,1]Q&15]OK#>^1'
M9E/6[C8]2+_-_;0BP&W<I%G OEB+L\Y=QWF2>50B3DA'EL Y'W+YJ /WSHM+
M7(G_V:M$X<^9]L9\=_3>23XM.\>,LXO438/9.>)PR&4,6\2,2RV657OYW$P;
M<KORO*#('5AL;-W&\PM7VVJO-N/<; ?-PVF5-/Y?#TR6#\\6DL&TQY.ID;X!
MJ7Y2_M5[^$<X5XO]FFI%6$AP1M@.F80)ZQ#AV\ZX'-'S:V[/L:M1Y]!"/F6P
M>EY3V#81HA)O-EZ__F*R&5(G^7N2Z!&&./;<5U!\1^BIEX;Z^CKY'D8\JR,_
MPL2-0Q]=[GO7N\C/Y .SRFD=L>!6=V$KM04I5W8GYGFY!J%FV#=_>=9SM'!&
MW87PZ;.^B_+MW+Q7I7;ZX]T2II</>F"W9=ZU(EFEX6THCE=;4@-:A8&S <Q2
M0T<HX.LG-D%GY]R!4/T[JN\/O[Z?@EG<L!T_+]. ?9E5^:R$GFP7>CB#7(/+
MB$.;XV7-WJVCXE&",@,74:S)UXWTM/&QR*9]1@J@P_^+CN;O.HG&C]>U3#Y%
M*SL3)VI%^VXFW3%66G%C!8%<%A8E!^3S1QJ,=9^[,&H/B;QZ) SA%$@L4,>;
M%*!\44 ICQ<KL6N^J)=F#5K8U*8(R]0%T\2NBID&<U7'-IL[W.R@A(39YM>S
M-IEO75Q9=W!L?H-9?X6-M;^!OP2PA$G,[>,L\^K.GY][S7C*6TT.0#O^A_=:
M#TU0'<5HLBI2Q0<C5&RY?SI7P++>)P44UL!=YZ],&K#CY\G-4@]R[''P0KH6
M<B1_2UP6.FLI.#IFV&GL&F0?-8*<!Q70G]!!\>S@!5.,)^DF6S(%,%WX3Y%U
M1A0 )X(PP#9$ >0L5X,)C/_8._C-#T<'40!!=DWP@Q?^.A2 [3^%W)D0XQ6Q
M@@'2Y)BX/@I@RX!JETSF)^<3*PDQT",GUT/_K7;/MJ8M^3J5%BGM/:0/U??3
MN&5]VE#?6'_PBYS!LWN5K>E!QG3?PZGD$?G?-7LA,'BV]4MB-/X]=0PD<C=%
MHMA 2K.AB[OUD<Z'V4K;$.4>-*N 1:V7^)&"$?_O/9]GL>]%'WV,L^L[,UPV
M,EK;K:7?F4B ^I[RI74-F3^VH;;">MRPQXF/\C.2UB&&8\+6N^UA*HRE'SI[
MI&Y6L=0XH!NNYK5/(>)V:YD.O9EL!^1J1TL*YTJ:J>Z0E_50MF+,#'RG@GZE
MM2F "QOS?=SHX&@N1D#"F_FRXS,OQZK:W5M,ZO%[92D/$J/&Z-2K^_5E_R1[
MK 2+"<W4!:@0!2_^$I*:F8.!O0R!+&3H+*CB$A-0TF)9K'+2@Z[8*_UL89)R
M3J^2AIF.^-@@@T-TH/U]!D,A3.O8S79!#&^9XJ*#XOW*^2CFSA799_[^5A>A
MCOWIRV;\>ZS><B2:)_?"+[*T*,CDW'_>TXE98L8:OGQ&'>6TQ=0E)*&4?,-G
MSTVZ;K\QM.]]4?Z"[S@^Y+(ATZ=J-8TITQ+UHM&<3'14%J3DPMV49]=O5[5X
MT.2>PK2.*QYK'F&0,!T\F@)XJ-7:M/<*2,PR89H&=<?ZW"SXL.P56JXEY&>!
M>*#*&<TL]FG?<MHU?-9^@M%;ACJ#LF2&'UD_,- U;B)*6F%Z<"F ?7;.RZ/E
M:&'N(<L'M_MNO]UDM<VCU6?YFP.2LDJ22K*>I][*\8]3G;&\E1*NL#G/ X8X
M[?$. MD[\&>)5*.;;#*P78'Z'1.,J1C#:#?/LI8\],ZX^>@U^8'T -"R[V-Q
M\0<%N>BN-,^IT$RE,WQF:FKRKEI:<9'SH&]CCF#QMG6R$\=.&GA5$=:F!+XX
M$,"KM/ARX_((O$I/13- 4,"H3LPP*.0]D[P0&Q.[U1.3>X;YM\'.&PF#$.Y4
MY[LXJXV?5'?I/K+&[26U*S=[+CFZ>;_T>B0T,!_ZOL%_59;;1.?,(9X>>\.\
M\>?(,ZX8;B/3;V_4DR\]R6/<[1/58Q"G]\/4O_HCWD,#^+>8N*4_%ULI  7X
ML4=Y;BO.:OSX_6YRZ&HP@M,D/)8EC3E#!<.Y=1DE,_SF5G639BOC=(O!0\@M
MN\@;3#<>\9?(4P<8CNW$1LG3[,3D'H%[XF-#P3&;PS4SGUPN"YUE6RF%ENPJ
M,2F;B%AR;W@'N:(8TC<*'0-&BYIM59=U_#"UI\DO";F-\,6G%  "2F8M=<:&
M3M4IW VQ1P5EU?1._+)3SN_F&2%\(- $#-=\C7"O,!!1DA)A'.:),%WL>J\4
MIU[RYY#:D[ KNZ3SF'CO-RE[=WG9VGKI9+_LR('EF<83E2#7S8T6/26]E($I
MM> O6>8-G07!Q3.9!R7"GY,>CLV#\JUNHCU[RGM:D67U.-#!,*CZ.J?1A["V
M=LQ';N-71C^CS.L_+;VL2&HQU"MC2%_>=?N@<C?1Y)D%=3K3J)K"6EIDE;Y9
M-H;,*$(\H<Y,<WT<;AYDL'2S6PN7OBD7:W5.PO6%+9"C,;Y2.F13YKQC_XK8
M@8'MKN:2LT/<;5-#4W1)T9]S; H ?KV-ZX"^73B>*F/L"I*'9!&H#,)1+T^B
MEC$@M:*MM(O1Z-:+5M^TXKZ5TA!UIY+,=)1ZSGH49ZS\5#-5)LC7 UI$%:]3
M -D]^S>.LV?\QBW<'DU[^]-; F_.(6[(0#D;Z^N)\=Q:\5_SBCZWZO:]-."V
MOOA\5")!OXO_G%J=2#/. ,3I:Q/F!&X?DID5KBDKF)-URVG <%PP:?*OK4*[
M0,+JIL?0#;RHH3-9<@'3'BRN<\\BA,-6S]O=D5<O 4%]<ZFR="<D%0M=%2>.
MR0C@.8F^PZM>L.L>'I8U,=L035,;C81Y0D%6O !1Y\&19:!66MT>XS[#Q_9'
M)=XV2UF!OZ)"IYJG8;Y@D;O$$G RO$\[GFQL"6KT@?-L!+NZ>W"&VA:-PD >
M\V-6(\NNXJ.]J1,)W][>-3&*+=#06U8OBF"[R)M&=<SO*5PXH "(]V_BK;8Y
M$L1\1?:&Y@XX8?YO;4 &84?:G;WHO:LOU^]4!+EX[15XQ,5?5[Y1H59XU: X
M<[' ]>W]O((_UWCE%7<^QDWAN>MD<]%AO3W;ZBS@]T8$92!A?KXNZ=N83L2\
M:?1SUK"X0EEN3=_&#=>/+_ L40RJ<54Z94,LN0)450VG !Z'0(\']J"WFGP4
M66#88A#R9DWUJR5I(T^C-:^9O!Z$P;6B/'-X59;=:1.#MY*"'\_XZ;X5DAW@
M**5*EC+M7\B=_RL!DRGSD<03!?]MJE_?YC\LX0NSJU_=Z?M5Q%+JJ3WZ^?ZF
M4^&'WH%/2BZ7O&*?WS\S]UHA:T_$_2C#O;4^V@GT>E2)-8%=QBA!--_VX;#X
MU$\$']A?L3YC=<(!)#K?F78C=:S1XG=[9"IC8M'EJCM&L:=XV9WRP*0SE_<W
M22JJX-^/]"B *4\W^&2 &UDV&]_'07+]1Z+/FJ..XX9X@D@,>288]Z^+_\F_
M.0\]QH#7N/X1 MQ71JHD"RV3!ZCZM][J#P6B":&J#[U1CI,KAN!#).J?-[^)
MVG-3=%>,":0 JH_AVVE0\,_'* 7XN&\D^6T*!\D?ASW,G*4 XM;(WBH4@'DS
MC@A!(.F7%A2WVD0(#G\R>THCH(=L=RF KRO4 I:M!)*3/WRYB0+XDOA/D<+_
MHO?S;O8KKOLP<><U@4&@=3J2\9;Y9)1O,20GB2^/OV7=TL-=D28^\.>R&N=J
M,'Y^]2(7TA,#7*KX4,$3R^_JF_<QIW#PIV\ASBI:YM])2C?>@9[5D[4Q.JO
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MMU[Y?-2OLA)O&S2\L<*LU((APNMFFMI;ASYN-VFI[XXQ1(\-[F[+<W!\LLR
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M-J( SJJT9A\$H!373E&]C; _=WJPQ&+XVD!(" 6 J*( -AO@8 M</%Z]D0(
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M 83-@UN[* !S&44*(%F3X$,!J+#;4ZG<4 WY@ 0BOQ''4TLK-"S!R4'2GA2
M$SN)7 .R)AQMDC B)R-3</28PAP%,-*3KKA5XTX!M"I:40!?/Y*!% "B_!A*
M 61I4?]XI@<.+EN8(I.:*0!0#+G6#XN70#0H'GBMZA $D8I8G2GX;T[%#/#^
M9I@ !;"6[$\!''EA49O2=10 W .^L$0!E+.!R%KBVPC2[:!D\H 4@C!VB#TY
MCUA%$4]0T10 'CT/)WT!X4Z&ML%8)!37"-]4L?HWOLA#K::&23;2&?B"Y/J$
MR=$'^'.5?RG_4I5@G425UKWNBN&E!YBG$8YWS+=T%';+NY-4$-#L^:,N*=AF
MC'.?P*7]Y_E%IF7>8J>= >7GG '0A'4U3"O3?[1L_0W\GPV,:H"=2J4J.A=@
MV1QL$A,$'Q?[FO$'D^><K5QE'I7<,S-BEW9.7S[UIKG*XG5_T.7^$\;*O3/D
M'R-K@MM56(N4_"_Y;W1\S@CKOO[AD'(UA>O!F7-=3YB6Z,T3@=9K(\0NZ2D4
M!>"M(.>KO$=F6B+SDB9F+=8XCQ; O)&(HXQV3_J,#IY8_ZEO!R@-TR"?RFFS
ML>[/^6Y:WLIU^0):Z@+JT:36 )T0\A;4I<E)!2N$"ZK=E0P$&S1M[01")#;&
MEK9=2K7K)M3'=*'71F%D]EQ\$06P<.<03G[-%DO5#2:U<%@]%*]NC1^BQS??
MH2[:8! O!:"E10&0AH\X").'V./@^-5<"B#P[20%< +PEZ8 '*Q(!)@K!? I
MGP+X\I,"R(""^UKEDRF @@(*@+P&HB=M!C_(IJ'^R#L 3Z0 ))IARR+>ATX:
M[A^E,,GR5];B:=_.'<]M<RX=U3O):A:)P;*:^?V3<CG.)VBHKWP+N/@MW=X<
MM57_<[:N\\KP68F$WG[716TCG[6UGJ(:K"CN EK1);1E+J@GK4%H=L]"SQXX
M.)41VO4E9]FKML9;JQYU\<$%V12^^[GAYJ\-MU*2^I9?C4L^TFQ[&LGT,2=^
MR"RQ3^/VU>=I-"]JU =NNWD_LJ6M3'Z@9Q"^OYEHG.J-ZJW\'L\5YUS,4@/C
M>%QR@1=-^^3*'M:CL6/[\D0:<CYV$O^"+ "<LJ\,A"\=7"<-V3-6#VC1OJ'K
M@GA*]!?G2%W!C;X3I9T-$DXT3.A7/?<F-U9A(=*"MIY01SJLO6DLO=O!M=,C
MD:TE%N@E%UTQFW6O-%]-YO-5/GV^R2H*8.>08TB%O$M;3@$< +8\R?VMU'D*
M %KO?8+O0SCV_::Q>.G":O#!.%5NYK V5*WO:9Q+'(&G"_\^#IB2=V@FRQD?
M1-H[XOR/BI#(B$A?-;W/T9!4?MKB.-.E'VM>R<\X!YO]U#'O7IR]C*B6CYZ4
MG_S5.13.*J\;/2YV"NTU!W8RU<.)$'+-0"08YH;<.*SUG52]BQR]>]5L;5+M
MP"W]J=0 NN]\Y8PT+R8_;_0I//07]FRD"K TT,/\A=&5Y6WVS[/S,8WW*]4D
M#'4G5W=\'\DT%BT7994$KMME%:=R)[G8F[9'IBJ?C;9H?-\"92YGFE$*_,D@
MTQGOC]=&)C1!@Z?+9E7>>LPWL)YGMRT7[W *DFR6>,\@*6S\X$7)O=1BNEP
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MV.([/1N-...E.[X)D2F9:>O**?2+-H_WP]3O_]=.E7,,H];D%UHYB.OD:Q0
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M5:!Z9KYYJ."H'/.0%!L/7\MFQLR6]0+4ST]A<NQ^=Y5[$BQC=1<4+OJ!\:P
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M>ZA) _SA@Y)/XRB?<-17)!EJ/KP=M8&@,$\JTP#_(P+4(E;:R;_@"[^.;]A
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MN3_:NZ2^/I4E6&]$*8G2\3GFQ*![2!>UH[BRM[/L: \-?K_7[C3N*^NQTZ?
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MD=!A#TJF 8(/$V^X^>:YK=AT+^?7'+N>J=X];)SR>E:A]_U<B#[*QQBQL*D
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M'URY-YM5;VSF7/9-O"K95N2YWM-K03+\I)+XTG SH])B9/93?HQN-@SI8YR
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M_S90^KXQU%<H\71GA_^%_O<R:5SD?V724FB [;QM/WPTO?4;!D+X2 /4Z'X
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M"I5Q,<I_=TT]1UJ 3A/'I_)#7@49[E".6AJZLZ@JA]WNOD SXA7*3#"L;B_
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M;L0=+HI]#%PC;VIL<!)Y&UPHL6@F9<V2H#.<@LV+PUUWI+C72KGAU3.:O>
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M%8L8D"N=FSW+UP]#FUR%*K3LQ4>A>C*$M6GD1I<=N><&6OO;[N$^HYEK8!-
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MK11-/CMW_[-S!_67?E$ K/"Y)M$EK,H)NX(3?C/2":53*#'/[&1I9F//6N#
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M<G]<\<A]@^RHT;V_"4[T2D''^!;X\S.<W3WOP]"\75ZZ=6MU]H%<Z^ZMANF
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M!/SKCU. U$K4VH!_R"DLN=[@WO4"&%>FRNLXWG>L*1<TA4<+41ET_R7[_)+
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M6II,\/PG;&VXD281$_8F=[1"':31)/=.:@EJ@A[IV.A6URC$9A8\"HL?#BN
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M]/6,H@ J"G#!8?A'T6W@+YL.+5,QV>TNUWDNHV%H#U_U@@@WH[/W\&D8-*J
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M'R\GW+5&!O5>O5)7N='+HJX',E)26TUZWCR;\H4*GR'](#P"+$!V9!9R=X%
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M'ZVW=69ID9CHS-=C=("_392PR=[@$])\A_MNIO&<V^BNK29]ONP48M9U&3,
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MZ)(??:MVMK;YA\,,-._'??6#,@MT7E;]W*8NHH0=IY-,:K8ETP50 .$5*13
M_%;V^9N(:M=AH56& Q#>V:/^S L/FJ:MD8AT<9&MJ#MX#E6I-OJ^JJWK:\ :
MVJ43+:CWNHUYD+]&Z>+M7!69D1\7J>'S'23)]F@>=X4X@;WL;T[TG0L(KB9
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MH<;Q\8:O_TU^\<XEB<7)L+O/SS9<#../]XNB6A_P[^NEP6./OOZF +J&UBD
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MZ0$S0\ '/5?/.=D5O2K)!W THDZNM_$PVJ?RJF:(Z-YV+=K1Y/POT38OCT?
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M083Z"O\/NSOTV_#;\)]N^/^BB5NATFEL>1H'(13-CSRT<L4"U7[T +Z."@G
M ,?HM:T"Y+Z&GP<5H@,30<[N@6!<6U:&(5U'O"71C5 AHGZL[XXGE+R@)BZ]
M>U$D!"/3KVV+TO1V/1USD;6IHYM#G2;Q7_("-8ONY:6JA#WO'NH4#!9DO<&V
MZE1?=D^/-8?C!HO@GPYYIW0OMH #F"?)(.L,XU_/UV9TN6-W;+V%9%CE>N(8
M9^J4Q<7-!SC/TS[@?R<9XG%^+/CUD<GI=Z]/5,CWV&8T8=).(3<(4"\X!<O"
M:2WW/5GD(A>&"I%GM0*TC?V=]?#G'N-"6]Z2P1(JYB5AO&V&/%+U,,?6UG?O
M0J/G$<]AE-/&E_)@>QQCN:EQ@H&>O,?-2U^27ERO1(F+UWWM5>&Z;S<\;304
MQ"@K4,8GV"$$6<(O3?#YE\_X],V8;K>T31^;3^U(DUK+!$FU6QO2B0_5?U;$
M>2NKZ]G0LFZDV/_Z\O);=/4>8 V]Z*NT@.Y73%SWSVKV.CQU0$M+S\[-8-Y[
MBJC=&*L6_#1WIU_ZZ?-B![?;S?Y2PM)0IKAB&(PW&B84UX2Q>7(4O26UDEX5
M;/# Z2?J=HC /W_G:4CQ?+JD:.$UN)M!B%^%(1O.>:TZD;7NUYM:6DU/FT\^
M<;^?/.,R[N4FJ,8]]KUL3[CMZ2V5T4:COQPKJNC(GA.G#4O ^[4SMTTI4R$#
M!@ H@KV02T-@G%E0KA&9<=BEAG)B PD@$+U(S!$[ I1@--X$#"TJ1$GM&+GN
M6X.PFG8LE2R_SCAX<YP#N6A!A8R $NNCR6X6Z3[R1P-Y<(L*F:5"2,];JS8#
MTM:WP5<N['2C ;7E3,(/]BA\!X"-* 9.T:JA0LCY25-V E1(0RA@WT.%<(1^
M9B9H4"&]0ZU4R' 9!UE+-WC^D)0U#;T(3:#[UCJ]^>)ZVZQYC)LS>^D6:EJD
M,Z][;$B8T<K<V&8YD0^7\D)YR[!J\;Z1;4K.S>K/WY\7<R;.^+J:C*C=?WE.
M?2[WG-X]]I<GAQ>/)W8)E:?+IWMK.A'^J<>7[[6LRAWZ7;D7;BUI3C%>>#YK
M;L'_M$Y7_3+K,_W;D">T)ULD X0W\%J.WIXRO5NZ,DNVJ@E0^\7?Q(QP <JZ
M?ZW7'@D[#PG+J83G]KG,SFM>??9I\^FHB6%/887XQ[]H9O;>[3PIS;EL_-CV
MV?-;W[W+NR(OX=FN/2[>:QA >K#U;LV4651/NTK/A?@X"ZW-OFQ./5'7ZPO)
MV"G?N6]7G)K\*\Q!%VM6-'.J N;?>2HD0[%[<YKMR"!T4R072[R*P5J@XSM'
M:N0?6\0K)1<F\<=K.JN*\\75\>&ZYOD,U1951;GG!N$K21XS4L'%5;R.?P;<
MF?B[YU<--&5+NL[5#PO@L5X1+9M:4DGNL]OESTQW/ G7V4KK?$J-7OW;XR%!
MS_;5EF4V<52%Z6^KT%YD%)1=T61U&7AURC%%LMS9+0\CGQ_WN#BY<7><[IT+
MHG5],M[&JPO;]J:P@N'.W1I_HP!SSO-&AH:F K(-&[R!LM8PR2*YFZ:66J\5
MXU0NQ]6YO34*;+GQ40/RC.;6Y7+VAK#M\B;*Q';PU^."%.GUXZB"%/A3UR36
MEKR5D"6G.KC@Q4&/]^>3#)Z<UV"XH8[3D:H>XBK<X?T0;GW!KJQ5R)/Y(*##
MZ%CTX,Z6ZRRQK^7$BX\L6/:6#1Y:-O5V&6>$4[(P,C72:JV822VK?8X:Z:H<
M[J,1J%.+RAK;W?-LNM!Q[6FE(.:.$,;BCMF+/X/5_A1XM.PA>6#78FXR*[[B
MF>50?OSC5=7<:_,FTM[NE[G4^=5+WOJ2_JG^K8_:(C?Y!9KB/[:Y#>F!=>4\
MJ$GG21)G8XHN42%-LN5.CS%D=>CP '#;-PW=T@&HOVBA0A0(Z.,89G-7O\M'
M[<#_!?Y'J9 E*PSTH[<HT3CKX *)(WT]<Z4#X3V?=6._R<G.ZX>)T^K&L:4Y
M-]/@QE4'-^+ B-35EUM;UD7?)Y1_/M''EU1[N"70PA["/'93D"E[71R961?1
MJ<?G2&-(T:RH6XCO'7M I.LGTBL<UCZ,_IVQ,"VM K>(9A3?0GGOA+#.=6::
MK[6*@;6H3,13)6')T:._>1L)^J RQW269UI)(U,#M@"/K'[84CA"-6^JY5X+
M/XYY*7%=+=YMJ0C/,-*A:%SC="N)-\I1R-9<&":#??;3V&ATU4XE-[<@1VQP
MM^4G&_Y<$3*% V\ V",E%#T1G$2%^H  A 'PTO!P!E,A6U5DW.S*AFYN)8X;
MP138Z=GJW[]+ZE_&)V3GWS4\C!]9L=4,+4B-[ 7E/UO!^MYJUMFO3C^I#8HD
M J\4%$:Q=YM@RVQO5$T6[0R6\HNR>U[S?TUYX;DQ_<E\O(RE/_)M]NY=*6[9
MWE?1%1O*52;#_.X1H,HWHJMIPI+V]P97HIK0\9YT)-&]N=+F1L(B>!IW9&1Z
MYML&M*)GC)I>)UV1?MA9M^&(<W]$<[S4_7(!X-#2BYPE737LT6&T4)$UV H#
MB\?ZO;^A?53(\@]F@%[E(V#9DE2!'H+UTL[@TII/VFECFU$;VNZF4=A&\JTJ
ME_RG=:PBJIFR9I,2#!(:0CH22C0KD2X/;I]-7;B ;+>KBSFXM_$C8PK=E[:,
MP:]OPZ+])7!.+G"S'D7=8R,5G9NSIOWC1T6SU<E"NDSY(:DLD^Z[J%I ,*:D
M^Z?\\R6VI50KM4;"7X/=\U\ &XX>.U(:Y1MI9]]\P=9\#=,INGH)IM9$MLZ7
M3158GIWQ\GUBL)I99J8M(J&04F36/&[%'VN&TK8PO-417QS=M/,F6[,!#%(T
M<B46B^X77(XQ]>1X284\I/M@#EW8\=3R%71'6UA+#"8.M,X[&FJ8N W):_.A
M%HJC4A]G/G^#,DVQ8G[Z"==CLMLR7HZEK4TZ" 14_4_Q:;_H.JU6\I))3CC0
M;<CNJ[L]Q"*L]?V$G&DY6]EI%E\^P;J0Q< 8"168BE)H+F9D3&\%];:FTFAI
M,XK;Z-W8")E@N?D#Y'P![.4 0\H-HAK6_Q5^ID#B5! M8](;OD.N.][]5=1E
MI&7T(<U^1Q[A4<0CTMCZ!ZNQ->K!\+#0W]\U_LK3\BOWJ)HX>[+J):#.<1,P
M/I*A\*:1,(?E#A1KTK7QC)XI\ON&7UN6>=NT20T/9]+>MAKDBB6GOWZY__BN
MB[2)$.ENB8N:)O_+3Z-&Q0:=92^?^96[>U$AB7M@.ONQ K?RYK!LA#IE@L@/
MTA^)Q%"\N<OK1@GW'<0\U'MTN6I@$OD-=TBV+0NY.SK6D-520+Y]*[G/A'#C
MM+%G1<<2#'<JA*BC]LQS0AG)"X\\M9YGLYALD9IZQ(9!%_SPV'-Z)>[G]5@Y
M(8W\SEBOQ9)75$?-2CO!\'VG/(_Z)RV:, %'-6/%K3E+3R>6AG1%\QO#R<R"
MD5DL(X6CSV#TWU\(=V4WECM%G(J>W87A0R\\2E,B%5 A(NQ=\\B^:[6@ME3=
MS]N(Q/9$869;8@_@G.:F.C5NHW$[0I[L*9Y;L*C ((^V9-24NX/V:$V/J;JX
MD["GHAA'Y%F?=44IRGO2I4"PPG8 8\4JEO0C;/>%#"9J T=WK;;6"['BV>J:
M]6:E4L\9^)B?Q!$Y)_$L_WIKK6RZCKO.>491@3XUDSO/1@_.@Q")90$>4X+:
MD.W55$BR:#=E#70GZU+7(3$T>,9<KO5=DY4,K!(_Q5>+5#?0BNER32DTN&1E
MSJ;+T\@3>#4IX4U.<62AHT\@>#)7$5&;'*M/*(G(%'0_72;V0BO3FU8$0A]X
MZ7[HAZZ5M2[*+M,9J//*951TV%S);5^2F$I-*!YX@T]A1.5VCCT1>BQ;O]4Z
M;L95G#7G5TP$GI\UW>A05/,H>.7).[CW(4UI85SI?HNQ;L)6O[&O=IE;+2Y/
M^9.K@'18,.,+J=@J-0DMFC$M"<'%=?U,?@$PJ:J@9^W5'^.72 D@08B4_"!0
M(5VM[8":&Z)P,B.O109J=5ANXT&K:O#6)>PXVM$,Y=^:UA5T)V+V,.ZT5;KL
M? \L-@L^HCGT@SLDUD,6=+R>(S*!N5\T'+D?C_Z$I)>Y].(89H\HWOWQ<WIN
M%91=LKVI53ZV#P/K*AN;,UK",2\=G'@R<),*U5,OT@U?HUA\BRK?^\PS^%QJ
M)*AYK?Y7&%<!MTPK@4<NKF&[%GUX]J1%#LQ<C='/&:33ZI9,KH^0R/Z667J7
MHDZICA*/FZ";Y"BC^/A?#O]65Q@,<FU&T 2#Z"A$A<A $S']/X8! V1W?&N
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M3<&5J) KQ\ U(-1A$WB*K((3H/.BATGBKZF0?Y%OFSD<CJW:?\&A6"K$G^?
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M&"VAG-K<3W&:0?KR[[J&E;C>R302C)8H&.C"7]B^<M*K8U6)?+\)#T\FRJY
MJJ-VHE=)HP2]6EK/R\+BDM&CE"DG?+VS+;3GW)7Q3V.M3S9Z86RL&"%A7G /
M;/^O]O $=G 5L,7>0"<R&UG+F:\@7QKN3%L,?$RB^WHL/9'W6*&G'O4K4DOO
M(B=3G,JRIHV[Q.B@L +;XSC&S'SIU'O UMPY=)\2:1C!##@9^B4F+?'LS25G
M?I]*'OWANINRD^[^R'](Z0E7T9_+%Q2X/0V8K91Y8SGC'*]N5H>H1?&*5<>&
M@($X^7^,NM*/Z46N$2A- 4*4K"DH3:7<FL<Q%=*CLS1%]BHJEB7GBPTM+WQ[
M(\-NG$6OG18J86(2TS'4HR;\M,=4XX**L>IY052$ 0J,PQCDH%5JBRFX$J]G
M7;_EUC?/B^M;(EG A=.5-@\7$=DZ.2@AZ-W"<0WSY/!*9;TVHE4HQ/4*#WZ\
M(S^#VQVO7L20"5)%$$A2Q4A!4=(^$L300Z:M<F"Z%8R>2<\DT@>$V6>BW 2R
M7[3*:]K=K@OHWDR_Y/KZ0*'1P;Z2H=H\,3RSB3&J* <SML)9^.-'#?^MH6<Z
M9OA![XWIE^<X0&A&%X,T9([M(5>28V43"[P(2::+3N\.Z[5Y/3Q#QD*";,=U
M3(6>83B-AFW%[S3KW-77(1^9.ELJIF;<TLA/N6_ "^))K6-^44%)06!EM+=C
MD< 7S50SE)U)M/J<$E=L8UQ9="[C2_5[@;1GZ6@*[<\B?47X L8,<^?22+P5
M3>6"%<!?G@QS#E';KE5?9L:271IBP^Q73>;HDF>) IN:&NN; @(Y<>%I]Y1O
MGXP\P#P8P>B!E<\XZ1J6]=J2Z!,OYA[VGB2NN??#;*]2=S)F/0_U1B=THMJ6
M"GH,E:(#-8H6"DN+PL^Q2<(E-;@&6:HKBIG9M^:884%9_4K9@ _B<0=B;?)V
M!B@6YAA36*.+G/PV::39:U-#G6P$*QH0>7;[S:M>K+#HD )6 P<=A_OW/6.M
M:\XN17\4N5\RN+QEBJTX_'L[<S;_FY99?2&@;.RBP3EYL:B8*5)YS+:)/'"7
M&2Y6BGBP-)Y^Q^RK*.BM4CM2$%)<,1!XP<%HLLKQ=M&/KL(WSK\S:*;^:'T3
M(6U^W]CK>E5T2>Z+LO<7HC+_6;*PU3-]%UG*HGXV:*J0#@@R!HRM#GX!2%#[
M"$]8G=:<Q:TC$M0VF=CO\##LGZTB2#&1SJWRV*FR3R07\Y#/6U'EE16LM@7N
M0XKO+\3/2H;*J%@TX>I3WT1'T(OK'#<(M%=5.P:J]ZF#X69D=WJQE%*"7FNC
M4$'"_6E>AB8[DD$VAV/!U)"R>U]O41[4O^O2DXAYZ;D[UVEH]Y[4WSPT,JRG
MI__TB-'(P^A69><%!?F;U7'JRP(/JL0@9V.7LT/W9=:@!E3(0R"RF,0X-,EV
M&K79(R?W_NC'R"SK9@@+P^RSG?0:56["]1M*1H:.;TWO.$R.]/&%O(GE*<B\
MG!^H IZ:$7.O*-$P"_^96(1GYL7UO8?K3F_/86J\N"V'MET.ALF^:5*UTO.J
M'Y0%^(OQ1G<0'KH:BQGSF;!?U0UZM,KT'8_#EBK 1#]LY&B5C5A>TW-V):Q'
M'01O1Q=L1PJLU7KBOE4E"WP6P3WB%U!34%"1QS5+M(FK2=*KXC3#'HC'>.R&
M>1W<!%RA%Y$)J]AO-JTFGKF3_B/-#OG%4VP&E?9Y Z[IS<^$,C7#$19R#_3U
M?#@?AD^3"M<CEY4(BDH%9_UYZQ:SNDL+\&M+< U$QF2R3E^=M)6?QP^)JMK:
M:]X8'2;CQ"!AW1K#(1.,FH&Y>H(6?903S8$JW7IL9S)XR)I0/O2"/K(W:+&@
M^T461GB@1<ZIRHM];#;!3ZVB;E!K9]-Y?'+&A^7^C<+\\A[#-[BQQ[SA7KX^
MT,#A%66I&S":5=YHS)Q?<?<&[&.+,%XPKS:F.SIEVZ*AU=<*L=,UY_<>N92/
M^]FCQ/'14$/.\+)EU/K\'<ZB\"^OXU+5<Z/=HY9>@O+V<_0OD*MMD;SS.;N/
M&N.N?]L!)CX'\>J%#1*883O)E4URK-RR$=U35R/+H+R)>2D]ZJB'DY1T\1O/
MH1]*HG9;QGZ]!"S<?P#$'),#P3Q\@PAY(W]S.]39I<@W/-U&W*=7R$581?OP
M4;._\B=74H9[I8'_IQV8I(?CZ,B'/&,C,!1C.JR2_,4.JI;@)I2<=7D";KYA
MAX8#)_ (1?.ZCM7\6HVB&FU"(#\70X.VD?,[@U&5PK\W2J]]7]\!D2/K/ZV"
M^FWX;?C?87"\"4K-ZH(=E@$,)<U!5A'MLDA&%9,"EXI.@GB;E6H?I+G+$R_,
M'*P8W2_R[.I(?*B@_CS/^O);SO<;H%Z] EWO !B/J! ?9DH)\B!4E J9/./^
M%B 2NF!E18A%]F*HD$?OJ)#3P/^ZO_F_Y.TUFR#2<#A3(6L9=:WW#P>L#I1V
M8"%I>WFVI/LJL JWK+M%6U_Z.ANO3\[NG#\J-:K=[W;+N56S_DUS9]4;%OFW
M*5BDG+PB_T]O#:<7',#:/*ZO@=_FYLY^#OUP#E[O"Q<T'Y?,"/UWYP3QQG*J
M"",]:2UDBG(>U@A/_?#50DL__X&+FQ^XU'H=%2+/5K#?9(N4$_W'FV[%_\F0
MG]_;9\N^)\)S-0'B';7\M:U0/T62#^[/Z*0++-9%7N</Z?4T)/5,S['PWX]R
M6D$Y@+#Z%^(7R10?LS!!X1]9(3@CQ+<<V>=(=^*Q=F6RY'+4OH]")\]3;:#[
MFYZ1,),@O:F:J92[88C&/3@V7%KG_4C?#3^_<H\* OX> %8XHHKVB+Z=F+\Y
M^J^AI%7;=D^_U.!)Z6P!0UV&+YWLJUA=47SOT^ *H26])@]1F@Z91O9Q3+F)
MX=Z.RE$&-_)!CH0=E(#.N$*)(*(/SKD@16 KQ</)K@<D]1R&TS"K^.\V,H(&
MRQ*&MG6LM0^]Y57>2(ZLJ'"K,+YQ45Y5?YU?*+EQ"U:6GS;G5T:%Q*$I?-!E
M9 \Z.2V&Y(84;_WT[1#>RW^_%S;1<%=7O,E5GD2C<,MD6;KU_:5/)<5Q-,5Z
M'1:F&GKG5%A'1JYJW/>-,!P$64-KSXIH #\HPV)%6Y\@5(D%N,'L)J3[MN+\
MO#FOS<N3@W*"K=<[Y*69QR51?]HXQF5YC@YST##\9&FP#'X)Y]R0+!FZ"2Z#
M0[9[0#.9WR*ES*P^6FC@W]ML6Q1C%2XGS[6Q.Y6]2HQ@2^J8&-1[8EAEC1)_
M?,>AN,*4Q9U6TK7ZZ*:Q"HMJI;Z.L%HC09F5]($*:8]J]5YK]3_F_5:^?("K
MH\.:QV0+OG_$WC5;6O?.#W,_J?>ECI#IE%CU;=2)NMBDT 6?(HR._,E\6?U?
MKU*YO8LVP1@4S^H[!S"8S"(?!O!1")CCP;]V3NA6&?>1V5YPCP79]XXJ'POR
ML.[/934[8'=9_5&"7HP7E1B3R'<]7]^FA$E,Z _^-:2@-*3G5^[.AVQWA::'
M]L-6:U3POO$K,F;;0LH*,M)S9=.GP>/UJ&V5\P.9VO]&A1;FEY1WA_&$)R8*
M%-K<$JP69X(+5-X&-S/-@D)EAB?FUY89!B;&74(59<*&8[ORYF8HC$]XS_IU
MFB';S4]F2@-<CND.I %'"TQ-D1QKG1]F)=_@]<Z=)L7,& F]VJ^B,%@C>Q ;
M]PLC6HW5_-G;%#\NV$)(S$T5+<V*OR)CP%,XI-P!=*&WJ9"DNEYD I(/D'<5
MZ9VI0GPM<JB#J980"X]Y&.[&]BE/RCL_S^L=[M,R57A9H-I=PR:EX'Q8/?JL
MO7KK4B-!18;T-^(7@&"5:)6[5 A-@N+SM^8G)EGIB8C)P5B+J28W.[J&!T5=
M;1]1CTI87>>"#>B'-23T*M.#E='OSP>UMRW2[K;\[*-\HD+27/U(.<[0CT3=
MZ0U'T1@KG@#NXQ)_@WE_TZCN5M7,3-\8='A<)8>\VY@>2?RV<][=3\/5P.-"
M+GX#\;J<.;]2&^3'2Z<=$A0<%;(_L0<_W;]]UI70BD#AU@)F_7!J5,CU:!#Q
ML#&-9WA\UIHRW@?1,PFE;4*^IUS:#$#O8N.KW>LW_=,F++(,+O"PE',8?,HI
MF#48A1DT>$8*"E_$)E:B(._>)F;RC5D7O>9? 3%,<X^H7NZ E&QF_XDY*E"E
MN&RXK%"JZT3[!C!Q)'X\_3L3O<YF:6#));AF'!'P(%SG-+PX-99__9A\4:<F
MSL)HS&I%^$MB#*@(OP,OT3^J5A/E5O./@1=42.^EA:Y)$A)OE>?Y1OJ8=*Y)
M3L0WW+^B-ABVO_D!YT2'&_ARP4)S:+F(4D.7%BA55!2=>-FQH* X7-1C-QJ&
M]P%<I9#]$:Q8"]B<!6<<L>U :]%X+^8-Y<-ZY+\)4C<,[JR6Y.?V6@L(."S$
M[^2A,*-M4H+-P\-]M\12'7U1FF$M$XV%5D1=Y&GK)8 AYVP&A!45@E:J/QL[
MLT=4)IPVI2VO 2*M6E2(MT44".&E%0%/5_V27-V9O5TYHM-@\#WL1V^1K-FI
MS+#)IDKUA4[;N@01IEK_BK"> 1'8-8;GE&@7_J)--CS#U:_=VV.?/M\9 7D@
MTX3".U@/36>B)R4BB!%YB@*'/'N=GG4_7!(X#LR*9DU9;F>5;*QA9RAV6397
MY#B9G.;#94^'7Y'=YWRCI</[H+$7D(T$DY$#9A(9@0'):]4+KT9Z05$$+"H0
MJ-WKE5/U0A@S.[&F\.P,1P'Q&37[W>G^D-4<7UDS>>-+C+!Z ?Y^#"_=K)':
M$UV>$,V?!G-^.0L@O:3L^5*> X;FQ6OE!Z_77ZAAYK>V3E 47;\O)Y.&=(LI
M3+TB',[/%H-U#=QN<\TFZ*O=BRUV_)R3'XOB3>N$28"5"PKNA&P/HD)2+V$&
MVH;GCB@_T(F*6.(>I4E1RS62B?D50?5[]^B8W;$_NV<LBO^=>6VJ]KBQ8X)[
MG&R\CDG8#&.$%N.SP*O3U6;6NRWC/4@%P.,0BR<2@Z>H$#&_U[Z1\UV3CV0=
MTYF871K[C.HK4S2^Y+2]%JO,'F!JKG'15A>X?9O_E[A1?WOFG;L@3Y7FCX/T
M<HD*D:2+20O*:]HB92"%_-$X+,D3D3AW6TBD8S<J++8(-;A](K_#::B_7.<B
MF5)2,B:PP>7!DUI.7RO(E"CPY3QCC7TU6-"4=O$+;#AM.!07.CILV1<[#)=%
M5\:.J^>%J]#=K5 /!@M159J2W)#S-]0509 ;.P<PNE'0 0_VX"L[>#CIW]V
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M+M<)H9DCG.F[Z%4F 6C8[:**(>\P0'@B]CX?B1) K#BZX)EH9C7A,:'BCD3
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MLR_.#4JF%FQOID:&1L;6I^J==%4].^YMFS"?"BB]SYC88.:++G=$)?D64,,
MOJF\V@H/[G7AT^2KSVK%BZ) >>6#SX\2+=U6I>YK7KU?+'4K-;\^-/+*R>@R
MF6?C?;>+W#\F <HSBO2(KH^4;#F+E,Q<$2/YXL[/3%_Q+Z:*&WS=\/F.<K(M
M)'E4AV?0X]Z/E#ER00AZ-996YR;O7'KX/&V&#@PM%2 5PI 4V"E,BN[>):H2
MB<7Q73@$BD@JFO50>F.&DAKS?C"MIHO4^&IG5!^:2;X]755]VB'Q[/7;VML
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M/E2_)VGN]?&>5SX5*%!4%$N"&AG>LRNV]6W:ZQ$H?W:?N:LWOR(\DYE_GS%
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M_-OC.YB(YJ"-.K7\!.LP(;TZUXL")Q14GZQ?3S]G.'WUZ<#&6G9X"!@(!1I
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M>UA>'_8>Z5LB2VS]H0M]]::L2V_44!]G]R:W(*MXE%<O.LJ#$,\LOC1*;48
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M09S> *'YA]0>M@F9S+)WB>[-VT'+>V! _>BT@(\85^(9\9I;KY;CZ[&?]7=
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MKLL;TXQRNOHP0Q-!V-XT[T.[5?5;"IJZ]ZUL<'7?D3E^XL]CS"4?+^1=+AN
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M2L!Z.G$/P[R$@M296XNX)P_YJ3%(T06*WF72;T+F2B#I<B$Z#8&8SRM:>\<
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ME^/KGVMVC)J5]WIM@JBVJG)$E>"*\Z&2HUW:4D^S+&R8?*B3 >I!T^?NTU!
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MXT$[/,MFB['!^[87/[B?;(F)Y=Z1?1#YO;#<YM4($'\?DK]1PX/L,C'#+_S
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MI.'0R$1PV&,-V1Z6A3(-!XY C1F!>A:[T(OI2;UGM #=<6TP%KOW87!5<K_
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M?8/[<XNDG4!S/B0V)38[F^9!4>132/"<Q[ (P,ZT\=)KJ"Y8(G8O;DZZZ][
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MB)X[B:0QR9X[Y25N!ZX)%)<4.ZUTX*21N4G:\I4M0B*Z7*D15*_@1 $MRE!
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M?2#2^;A YPBEONLD$!0[L(.K[3^,W?Q<_(C;<[EJ:N:CN8T[ZZO%HLV/STX
MXUR3V\MR:R<:U\&2C?&<V!N-3PH)UJ1A.?N H+BVUC-$V8!7K!PEG+7341IQ
M:MIJ9@9FS:)JN%LV 1QA1E7R24A@W-]A>X4W;39% !+29;]6OE>2U_$3T8G]
M*)&$R<DLN1<1^Y?WX=%VJ+VWNCOCA\R\E/B!3+W(IQ#;B<=0I/<T!42SLWT9
MCF=>%OF&?)>IU%1C]',7%H]^4%.SLJ6-?-O=\NQ0XIKKZ7#UAB#&H7ECDM,D
M;=Y05.7I']<0M][9W5U4F*QO!2[BV<;^!C])9JB;E@LMS^"<,%<YN)-SM1DU
MK_&DJ'#_U[&T]F2KY-, S7;&#Z=U<85V-T>X\V%<H0:6]<?JNP1]Y(MMA6%2
M/[7:LYR9J[L"LE::=X;X1A'Z:N%+\L]QB*&$2?#IR+#59O%"J''"!3&Q)6>C
MS+FS'T8&KJ B=H!0U;J./NW@).6B]S7X**#/(4I4U^=I"3B1*_34K*);)=D6
M0?C$WDV-8M26(IMQZ,4'6*Y?X#+J$;T/VJ/U)YHOEWX$_L4^&T"'"2OA?U+U
M@@9GWIT51IO[IUI60C:2*2ZWJ"!B&:_+!)%[G!!@?1DPE8M!?INEG=3>?(+-
M?KCMCX/"S(&DLM:C<HSJVS:NG)R=>^G3=)%K:DR@%2E7 R+HX:4;U8E7_8"Q
M^8NL8(!A?22;80EY[.X44&.^./4U7, QW7X^,$= DS: @3W$WI!S]G;MKYH.
M_HPED+>VMMTLBO@!0UZ<:WJ=:9K^;%-"J)(".K^MI: 5+UC5D2CZ2.@)'EE_
MK(].T;;C7!4A"?@1ZT@-&Z<M;S 8SHFF\W]OR)YB7W\T&AE?SVT_')@+$]#X
M8+R35Y!04%X5LVIR@[-&[THR6T_6%L;@^&"U<%MW;?V@<^WHE(!Z.\UBD4=6
MA[&DH(-WZQO=1+@S$D5CYH:-W%S,E0QO)G7I+=_2VAX;.Y08?W8$=[7E2I D
MWRLE WK\,ZE!T0JXTE][!9]"#+?A7Y[#G+9O!J!TL'D56CH+.9?A<_[J5^:Q
MK>*,AXQ;(=P1ULGN;)& ,[.4H=ON\&567U$$I/QW[U];G)'?;$-4*" 9B\:R
MS1_[>X83'1GT/NV69IIBPZK\IA]??FIWT:B;8KES1<'%V#!2( <0/F/.R!K%
M^2WA=Y6RLPY#[=$SP=!JT09.%^L7RK&R0;Z\D3=I[EY[,,ZE')F>R2A07/AG
M#^@+]?F^ .Q[RJ\";]]CO!ZQZNW,E3P=,\>=IKJ9<>_RFX-1,V:M?]1ZP8O<
MGHZ^]#B$@*;"[K^556)AP$ +D*M^!]@ECFZR)N+/!F1ER,-#M><^Z.<DTZWF
MA/F&#+^U'T6W.G#"=>_;M^NW72V31YX)4$#10V*$-,D+4]I]G(W!D_6EG 2(
MB,.:=,@(M5X;0_#8#O8=!72?;*JWV*QQU#S4:S ZI/YW;(FS6G285K3+SP-K
M05&9N1H][HDQ5+N*> 334[@/K@A*9B22"M')!?@50OM^#GAOR\KZ5V?3"4.M
M,7U"ZV"S'^\B<L"5)K@II;#+3I7OU7IE3])/HE=4S-;=SP6O.8H?O#]=H4H%
M%/(_:TU0\@!@GC(^:^O;\)7X \W_*&3/7G5"5Q.*Z+BQ=$0^F971&E<MXHYY
M;+WW<UP2WFT7FYD@$<!"[=:MAU64VRU$K9.XG$NM9D\C*ITKF; ,9'GO-3DF
M]>3LE/P<C^W^V8FIT];PL+.IO;R:UV<#FS6*;0V$Y;U')2*O\[H#UNWB_CO7
M\QOX#?SWP+XYV:[):RYXE31"/>'D;+_3M#H]\G.W)W9YV^U[<6=$I>0#UXR_
MMR.;FCT-/CL*&%]^'5D9FMGG-#STM#!YXN9-$YMP0"*G@Q-@^$_D1XC^DN53
M#@U:Z0"7P:13C[=Y^<0_1I9#=!GC#..^9+:$1IJJ\Y3.RLBT+\6)=ZL)!F="
M<J^J@^N/C6TIH(>A%! ?F+@6H@+[X0.F@,S^,<Y?9YBI6F50'"]( 2D544"_
ML-3$"FSH%KI[D!R B+?\Q:Y+ 4U00-2ID5^?)>O #OI(D130T":,C*+2)^S/
M"R+43E]9]BO&Y' #"N@0#2S!,P'TXFT*J#L_+"6_!G463Q<;&7N^N*2D&%O9
MR:BGFK>2H,[Q]QW5]Y?$1?]XR!UWGOJR #/9+EADSUH:/PKU.8_WGU9 S9B+
M#)G;?\2P(V>(\LFJ2WE]-;.Q)5QUQ[P".:V,WK."?\2^O@/GNO5D:QW?KS5J
MH!M+;391M@Q>9&;YV&% -/1CI],53N@:=AW,;*BZC"K<*DAQ*+R[,H5QC@_4
MN+OBJV%JWV4\-E:M=U9)3T^^/2CQ23] YS A_Z,#@,5F03!>;/3),3%]![Q6
MD;#-<=I!>COSH-3M)L)F$0_U\(4\O]%HO;214L6N]]7)*_=#FJW7.:M+_=>N
MYHMSZP+7#M1=9=[_Y9I)&I7=NFV2.MM@0,P]BO$E;I/"S=3@'6L>26GF)>'M
M-I]SBDL[5QPYFH.[ZOJZLK+3L\6EK![O51%9@*&L[V<0Q4F2A&$2^H2>Z-BB
M.=4TNI]8C3<IS3_\A)L+DT6*&MQS&>[F4HF;)03776:KW8RD"?P8K*(@#S'T
M>=IIP$9V&)[$0(L?? 84G#Z@V^]ZUCE6<O(HFALM"O"GL_$JTC3EG84($J+5
MA55>SHJU/VO52TMV_&24:2UP[:.ZM@B@+!SKP''TCR$P_CIP4MC0[KWYEL.K
MV][;_@U*GH_>]>!4/KJ!=X62^I*J_5VLE<<1U:6WC)[YRV(G@37-I>^V).AT
MZI.2 'E#!TN5<E])M=K)3-L[>&7H=AD]?:/QGIA+EN-ZE,B%V,H$IWA-K<(T
MO[KH"NN;G$^X@?OQPY3\$MTELD0!'7!M@,,QFG.9B;-FNL)[H[:=7Z1X3[>Z
M18=T$]N[HUJ6/0V)&C2_9'_I"YJYZPW +\::^IDP<3NLV%+I!8KD\R/XS3XT
M6Q:^C#0:7>&OW\T[.B=>7O,V(."=BDEV^RB/A#Y$J^B:NL%])>Z\:P\.J_R7
M8R2R3Y#>\42O?=;/S5[>4CC",-[287RW_",6XM^S,UASUS- 7C[YVDN\=UIT
M  NM@CG=XZMTC\-8+L3:T#$H;<:D :Q*(Y]P,.:I3X+F(1Q')D3:2W--LN*R
MFM(#]L;O[PAU=*E;%WYH'*F;39OI\;W7UB#;T]85V8J!?E)SA(G01\QRKE%
M#C!1UZ^3 33T*9CN"L=?V"\-+ =IW45;KWY6L_JQG!5[D=^E'IIGDS-3VX9O
M46?+_?:LSC%?#(KTL<3V"9(9\D@H6)J(OWY0-,ZU8<8<.GLH9CT9@LN*Z==;
MA#6-$;J,TE,0'B,K'BS%)A_U.MG%C88[51*=_%^\G70(O0)PTQLB;Q'=UL1
MV#WR]ASGK1#>0SK[<CE.K\,;&T+MSV>CI!.S$\_8SQYZB4S9.#LYIM275[D,
M&QI"-@[ZP5EJGN/7-H\M-B#_C]611Y"&P,D4T".8E$7H#">[H@J.O# -Y;,]
M/@>NWP_02>IZZ3%M(E:[?6^AY9&NGJ*?.TY6K;.)=[G(3SE?/;K[+Z'-*&Y/
MX,;VD]I@R9R=\#7(%UEZZV..G[AR5!?):3O08G SMOM'7PH]2]U=3\8DU1@K
MR;JFAMJBL]SE2>/Z0H853YP*B[A-(%P.*P#YJ6@V"Y+"(1(X]W)U5_NG9)H;
MYNM@46#Z$)9Q/T6ENLH,MTJ7RQ9$UC=^RT7WQ7&&^>'N[76W2\AGTV+?T8RK
MT(J-=>I4:+)] ;QT%56EEW 1HV%WW=]@^T7HJS<4C0^/H()U-6=YS,^U; ?#
M/Y2VVK_:,_I5_#D_A3>#T^!,9;&&55EN<53O3:G8"XI;F+.6O8+$ZZ0+9,.T
MX.XF19F=II.&$V>?!:RS;4-.@YAW6F9;;9% C/6R0ZP<\]O697[;Y)<,P5F*
M%YV,TC]"-$7?BP)69T$PHQ;'#V(B<AU 5^GUW3E6Y\PHH/5.A_Y9\];WVRYA
MUY#T,=W:67,-[S[-&A+ZF]Z7Y60S-127_6DTOL*SIZ:3;WU'G7M^"_-T\""7
M;&&YA^",43BD@.C^.$AI"-G&36-]QD_AS!W:[Y(R"-)N]H4)*2SI2'>5\#*D
MLF2"@7I"(F=BZ]/JJC1\F($Q'P(#S:$>'Q0A1,R@F=#)[:KVM;Y']O8XW03S
MW0^[YNAJU%F)))]JLY#GBMC9J32!#3L]>0,;]-_]YAQ?<D<,1Q W,U6 G5.-
M_A<I^L^):]DZ39PY8? _A-NZ!MT[WIIOF95LD(:ZG';^:3ADLV\B$, O6.A\
M*XXQ)2L_W3AF[!0"'SJ@9M'=CXQ)W'Y$69=3"JCI.,^N<U=A_QVFMJ?1@KE4
MNAR?_OS<K&F/^H^5C',_&6^<M@AKJ<LD7*RLT\H8'8C7O:ANK4H]B$#^1=:A
M@*Y(N^,[>V#\S\__,MBD@"*(].=G8!Y>'H9N3IS,+UJG/8/+[;VLCQEUC^52
M>/&G_<(J13P)%X*45;@MMC!W3V!4>\8A5Q,CR(8-!?['PN<[HZ6-74+R\N;-
M8+??1@5*2;]8E2);TLNGW<QL,GXC^552SC/-F<WJ.O^=@+8KHU6J^U"DM[VL
M_1+2X&=G&ZZ6\%)=#0BT25NQ<9VDX,@W59?9@RVLW8:LN%H(7F$)49Q*QI*N
M?SH6B>J/MFWO9M\8>P?,14_JO[X&KC;L3HC\X?D>7.*V.YS]L,H!M:OO6SZ7
MZKRK4&'&/40L6A'8$%: 2,1#](Q&!B(4)+6NJ2G([W=*W$NX\P4@'9;E:& .
M<& .PJDUQVYS@]N*>SL&]=*E<LWAX"G6GFRVE.L7;I6$"M'=*7#5<QVJ?70<
MPQUEE.R3V,LN-V:D?;3WEEHK-\09B.^(*' ?ZS+V1(@"NAMXBD(]'YX87JMI
M-V<RK);YR&' >29I+,!%RNA/OFQD9);C2]_#=GD&;5T#QK$#=08@9&B; PSO
MXAVR#BLKLF!J-@K94(7RE#0A5%4=@:W=90NE_[C"X^+QM//>1.[L@UK11></
MW6P2HM4[3.)CW>*C';U K.TC'1,N[J.)B4&!O4&.1*4:3Y/3-V:U=X]CF?E0
M3D;AXF_ZET>R!>0'KC<M%)G*OS4<3Y983>?G2DG)ST]W6 D-L';WP<6!>U'$
M%T'/R,^P'*CS'<A8_Z;%U*F,06_#76T**'[G8[1)7RR4SR2J<[%X4TSV[@\/
M1W95,,L9=VUU%>TG+BL/:>'4TSN#HL!LQ,DZQ*S3TMV+@<LHA_N2Q/.]8R3_
M5EQ^[A38A\?9J#%N1.EA0TK*QY3[PHPLM17[!G\P&L;_?0&X,=9->=5'$ZTS
ML^[6VXW719RW3S-?Y\Z<&+N^O*T1*!\B&YHE:RH@\(3KC]OY>?D17#&,H,)/
M=%2*FT05\J/.1#X?NF]$!A(1G6EY0#=U8G;[[59([78Z-B;82W_K29*,0K>E
M):W9I.2?WWC\"@L1#C1CB;TL$K-O(,JZ\FT&0$BH'NS!1F#.'KCG^*5VBB2<
M!L=N9Q5@KZB*30E,\Q6DTZ3[71M>\3@<JU0R@7<_[3L39_CHSI,8'YX</U5@
M2Q0U@RB@[Z\HH!0X?A-W2&0>RS"KAG*B/%AH?LTWS6$V/N;UY8\^?PMVYWY
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M77[:H3F?'5/@4I2)T,K,E+'QVRD]0,&3 CH'UL@.& Y,FOH:@.F5\6<79<W
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MX)\U\%/D)Q20B'S02]\4_,SDZ0N].0I(8$.F7\GMJQ/WZ]5]M,YE,\ZI]N4
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MB72[O[$&4)XGBY'\F (2I);[#M+_JJ6 NH.6+FSUP*R),<88%B53WV2+\&J
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M0_R()E].ZY!DO=8MS:)J0/\&7PV1@KFL<X6?\E0JR</\)V]ZUFWHU[6)<GE
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M9]?);X9X5YZ Y-Q--;F6?8B3-51:K$^;>D7D8_;)7HM^JF"IPW'?1+,TK-3
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M?N; G?UX+>F5=<QZA'G2X#TW,#J&XC@=+CFC"54;,_[0KH];070$<[SJG+E
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M72!?/4_W5DQ$(@'&]PW*XXABV&" N4DZ^R $.W7;/\K0';6D4M?L8[K=W)U
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M!]=Q<C<P".@A[Q+.;=Q^'OI37U!9*"NM\FK NICJ&6>D2V%.N:W4=\"ZGLZ
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MYBPZFEIN%H38!>Q29[7-I!?5G%;<E(O[J1U"J*:;U:!&?'-OE)[4P=1? "A
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MFK&9#%NE<;.US!\N10JO!$>YMW$_1Z=\.NE7$'8T-AFI[F2GW(SP_<\GQO6
M_&)_+@"-,OM>1-/R+Q< BR-*=39+Z$\MZ%Y?!OT%(%*S"HHKZZ&8B /M__P4
MW?]>#_QTR9%>CO34L=UI[0*0?+JX&VS5>93E=O+Q'-D>?'#SRC@T\+#Z G#9
MF5W2HL"%;\=M:=[H_KC^3G J?Y%&_+WGO9QD^?GFWR9RPPMSJ66#MK<+89EI
M20^+BS,-Z PD#(9V=2^!E+A( $HZ\P4>C.U?8<=>F27K3.B#P-V,U.E0LWG"
MD\^#!Z^*73>+W7Q3OEG?%S'')Y5'W7##V*8K:'&4F4XQA1])RJE?5[>G<+37
MD#_XYJDLT6#VWXHKNQP7 ($PE=\U9[65?[KOJYB A$PA3YAEOB'Z'78XO^Q6
M&QF.>\QMELB/12(0'/;OZ5^MPT7( LGDWSEP%)4+9!^/'%_D^W-_R1.[&_6*
MI$.,+T+TG4 -;']GECY^(@#[(F.EZ/MHM BU(LH4L <1U=7G8$J+"GI4J)XI
M\Y(\)5=0EPD%$+U=Y#HS:K&?V6TM< #)TV)861)"&U#N^= T@%@U?)7&2OOJ
M;=,^:_=PL1CAF,R\7ET:P0)W=3402$(RSH \EW9L_PYD>%HM-J8[!P^P3I +
M@$AHQHR:#S%GFY29W'HF[FA;C%A(OARNL=>F?$N&)>]E@F B0B[S_=O-7+C9
M5)*N_ ZUO")9&A9 B@F+F ]+24ZY 8UAIPI/IA:0/"&*'XIE>6U'?T@Z@GT<
M2VO>?M/7$'CU8"NW>]*)+^Q/C6-46IR C5@?DVD<)<?[7PYNLYGXC1"(B5^*
M ?.Z$(L/;G_?'(S4AS-8>OI"3;HUW':^BAE1W[)Z-&V56"EQV"N"TN^0)_&M
MQG?G,$:TX)Y7=HBL?SJD)WQ426*G;==V5USN^^UBCI2L*UGNLY&^*BPVX#)H
M?^;E8W=(P!=_[="8D&1X5_')_O$(97,)]>_,74DM! <&0SRW/"<.2-.]DTLM
MPX4!MTUJ&A>,WR<%S_[NM-E<JRB',\D:P7,+;:X(YTH8#$RQA*J1!]/X@SW]
MG)/8J2AZ<@'HIXWQ:(TO#[D^-3:Z$KBNX-T<13WO85G'R!+P(DD@:DZW.;?L
MW7(0ORNBQ%ZP(K/0N<>7;.7_4$Q=E5"/S5NA/\)L;@_'+@J%L+$U[C@'TCP9
MZC3J5K. 5_:M[^0@BG,[EKV;-@7<!'WH)(Y!]UV,[G;JZNH;ZG-)C&B+D3W-
MM=J,00S_W=,\U4'#O>"*#)/?-\ 2;[3#\R6SA&?&]( X: Z0$ET 2 &2J1_5
M3YT8=!:7HJ[7P;'#V!E;*;-*BW368=F4VYY#_VJ)-\,)B;6QNMF][ +@'5L>
M+MBA^2@&##>($VPA(T/]YO[>]@4 KJ \;84=:T4('TR<U];S2[?_@XX=F]:+
M(CJXVYJ[?E")+\SM&1/G/U$VU+V%><HO]&J;D@"V^G-&B":*[NFF9.0<WG\=
M^%(N9JU(:Z^WT<G!7XN!=9AZA8^_BV68?WABR09%YW5C>*2T0S,NS2$H]9;-
M[V)3LIR0R_POK2IMSRL+3"^-',S $MM. VU8^X\B2O\$6Q_L#J9&Y98&6]YF
M%&PXN?5TU2?ZGEZ%<?%^\(V5W"AU)W,S>6P9WR&!<BTES 4J41G%_I=<S+*3
M*N3OOH,T!2Q6L,I^9PAA5? IF5=-4\)7;_2<Y)GC\'G,;I$_,3L'W*C14JE@
M[U,O,$J&$THMK*__*Y&+_\"#*"KLC3UAW.CBI; W.+#Q!K3E/'W\ G!'3J2N
M9<?GO)S5ZW!W?W$VJ*R!HW6W1N+D[1]D78^!BD@XXD;)VFBN<_Z_RB"9-QM"
M^DC^Y$ -3(9V0S=N+%P 9&3SUJ>[V@@-+>,U<OTKM]>VR\MKL#/:M<C"SC&9
MN;-TY\YHR\* J$8Y3>ISHM'Q5ZKY!Y>8,LEX5#&^=#"0N74 7-\A3K=+>(;V
M*X%&LAX$8W.X-P?+E6**"H.# A?Z$.CT#[Q@LQ7)D\GZ$_^X%Z5"N9F92?#,
M9_S+J8CU$K*U]!\#L?HD:R1OV,M3JL[;X03#J;;$Q7.G=1+6G86Q4EEDKE32
MZU"K $2G2.][ ;A]?3&$R%2!W(V*,UEZ1%$HO"2#"X!TY5KU86F]*"OG4<@:
MTL+?Q,U1<3+9?KH[L6=RI-OJIM'HA".,F34NPFML8CR&RW=U ?Y0-?IC$EQL
M80=-38Y%T!3=GV0"AU9OD!M?O0#T*,1,MEFUWP+/6W7KXYK-Q!=<0>5??U<W
M"6AEFH@51D_Y.)<4W;R?__5%2SR9#WYP@2SC(]O;12<A@W/(Q\'=_!@W]D^(
MX=56)#Y*Z4-^4>ZWL<FHYNV78@9&XZ"81GB:O49B"<>WCO7'Y)71!MXBA4*
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M=AJ(!20W<'_KDJ[S[GXB0?T(6=824B<]*2\YHYV3Y?HG\G=!"3;*=?=7T[;
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MY2ZWRQ^/>08GFWV_:W^8>NOVW:KE=C]8$MR<>GY5;$J;Y9[FM0)?\J^D0"7
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M0\+_H_U1C+IR:L_(R*2VLCZK3&&7R806OYLC+",W+R,9'5($7-,EKK?$$S)
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M_O#<F7$$)W!H\3,X*./7Z#BW(<A!BLC(^H-Y,M_6QQ7[&0MZ[*9NR!!TR<^
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MXW@93+K?2)$?<^ QZIC5AS0+0+;'S"B6"#*@#H)#>5*WBL11CQ6@Q4J7$61
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M0(Y"+'BK&L).VB$# BFBQ:D4TPX[WCXA#A,UCK.)%UN)X$,G(HOA)&FV5(I
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M!5/+&J8)R*.:A$[=A.D)5&=,06KY2_G+WJR^XCTA16E<#.RJCLOW,HM2ULF
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MLA:<FLH8VQLVE/<K0PY3[&G,<4TA'?Q+)".]/7[-)?HD^L=&O4#R5=/:G=K
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M-?*TY3"$@4$VJF]*RTK@<QM'[>**]V,G,K*+$Z;^9\_[OFAQ%,:]+^3 !P,
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M>*6I;F1$IJUM^>LB[<6X*J]2A-_8=(=VZ!D>DWS66TK5GY$(M$050X?H(Z7
M:$:75V$D5#E?P.6,T0_+'B?C"'N#CB203Y<Z!Q=G<E!PH\7Q#>&XT)SJHF0\
MNJDC/NNX9/GW4\T1T:=S^GT^'"-/'Q1BS//&4C:O-O[8!4;>GO*1<FU\;NKV
M=-&,+A[NJ4K@*"X7Z["Q?!V[J*S.ES9+E=2?L;B$(LUH'EJ68'OW3]_X):Y6
MQ[O94D4R".U#OX?B8Z.05M]:TXO/*X8>0[](>X2R.Q-\;EJKC2-T3Y^;F'R0
M5]#3J2@ 5%3 [8C"CG(@9R_+?11=$83NEJ+Q+'K*\9G3RN7@39^PIC"?V+1S
MS3E%EH]^<\5B@-?(A.RN!;Y13]8J&)FSSFD!K1S^WZDOCX,2C)\@LY>K>Y>D
M;;NW<R8BG#@;GNH::/D9/V7*? 3P&J7ACA>JT'(DEB.N.RHB^@\S5FE/$@J]
MT9E5I26[.!4Z'^?$+X\B>/.&_B$X3%E&]GCU[3-^-SBM>;T /AA']0TU +"A
M+$3G1 /K'H-OVP7X[-A9H"6*5WX@BL*KRV-<9[PQS^Q$<8%9Z>HTVUQD4]9L
M8>E:<H-D+Q0WX_Y^.GN[R2@B VQ:+9VS6Z/R;B$G4?TW2&6AT?@L+4"OD<4]
MOU\]Y"[[]DN@)^()KVQ'X,^KNK5)6MMM)#<64 "MLLGT)O!B"K3V?\DUR=W5
MI"< YG_!O*Y^+G'\3-%K_89X>[@&8C+:\FKI(ONK3(RQGN?3#'"215'IB-8?
M-=6:=/\MI9R2+VQE?*S)<L^#6=&KB.W,>M%;96I-U3J>7!97ZO@=!9XE0Q*%
M0D(\,L:'N+?S=[_]%3VW#5I'H9JTMO-+QZ9KRX>KBV9+?:7*]&N*Z8Y*454'
M).^3PSG*::M]^)%/+GMSHXDG^%/$L(!H&$.SF7GQ+*3C3#.G>GYQ)$9TQ1:\
MF:@]<NK/[,!9SJP/_HG[,IZ4\M66ZO>WZN9 ZZ[X17UY;Y7>D[Z&N2QJTI-J
M>>$7QMXI9EX)YCNW?9XEN2,C&P-,?$AEO:+>VO ,PXCI/]:9T;UTLD728'*]
M@\[N5/WA(Q3J:=MM4TRK! -_5X5/UUK/G+GY4*\\_LRPKK9I2ENTBF.P@OR7
M)Q#=AAL73_?F5G2SS>@&=&_C!"TGTK7KN']2<5JOE96 [SYI +G;[OKMX5L'
M!?;S<R,2$<?>G@$9A*1C._+1W!ZAU]/#[TH6-])JG&3EUM$][>T!04'798LF
M"0MO_5Y+G*6W$T="J0*B PQK'S>V!H@YTCDX6927Y,J^LYNN4Q@IG=#9J\7S
M^#1#A&SM=7$C4%@>!:C,\@!_ZVB$*I$7X/[$@Q-+;]//N)A>!L8T.P=N\;HW
M-_C6K[ZO4R6.2C08VWN6*.G!>-K!E6:NA"B?,VVLPP(B]5&G6(#,?9TP";Z/
M%(O''5_O\= D!:/9?=" !5PVUR! PVV=V5A *0AS -V].VQK5M\6/=O=XA^.
MFURE/#HZ9#BNII_^O5[I@Y;I<?.#-:?7%'9RT>@QT[R;1I$\IDAL,1'5>"H:
MW3FQG4UO2@%39(C<H&I$#EW.K&MO^I0(TY-MYK96WFUB 3XURE<O@8N[VU+M
M>Z9G.U<2Z3>CMY 7KZ)7$[7.#O[Q$M2"<=A:V;Y6_D*2>H_0_U?;5 W&+6]T
MT!D+$$B(:,<"JC;[IF2\#G_:Z-U=HUI9IFAGVY/C<XIC:"_9. TE?8*9;ZD;
M:Q]8Q^<3\TK*._9TNJB)@R'7JOP3A'.K#-3M_.O-]J.)P9>G!.SR]"-Y/!'B
M$4NHR,KH/'(N56X=ZIS&](**LF#-OL2I.:N*Q#=RKY#%P@<3DC?+V:LW9?_;
MCP+YQ0<Q,M6=6( FR3VE2ZX=H,7KW/<. NW*_E<:=_(GFT&;_2.@67E1S);B
MT? @N)OH.ZRYS>Z_VD<;NK.[>U86)O-".V&G<#LUY2?6>E.:KO$U <C/_U)D
M0JMB6)7E>6KP?V?:%V2%CCC_NEM(BT]EW ]7--*66YB@^2=Z#D!IHO-"5(Z?
MU:PM-Y*E><R6#AX?A1[Z<0GLIR;02([3\9K;QYER\\:E.\2Q&C(+X3KH%N;F
M^ELD)7I=[#]HNY$!\:GOE)S:H7X<XN?T3P=&&[^T1(#%2@]#DE:/R21B<"=+
M@C987>FUGY_]4JH3ROIGRTW;DUNF*]Y!W2FDE^/HCP40 +" NNSK2"P@BED
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MMM;1B(2L]2%QGBCK6I^2>VO]BS=C-E"6>UQAP/N,/.*;F@&5/R%C(H?E*TL
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MN>F*HK8AR_+-\PZN(ZTJ97S R8F:-!-W;EOPW99D]@3]]3'T):M'=2PRC,8
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M@@WFKUG-2UW/-535BEMHQ9=WM6<O^5V(16-&K#.N*6.MNUVGHW/T3250$[$
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MRI=ZN'/;B=2MU+E/.>9FK3QKTBSF<K$ $=KNX8Y.406OO$&<M3EUZ*ZG7)>
M! 53([G.]3S4227-@ 7O>L6G*K:G("L@P%^S0:==WIN1 <@$91)]&9@4ZR?]
M,G*#.KHEO>$C'#@EJ\ <15Y B\$<T=4G^@R+8IQV\PIDZS!PIZ>0M=I>UK\K
M8Q%BE$F2%TVQ?8\]5&+;"A_L!>039YB1GW>_:$XPO3R"3TS9(FUW#@+X>E9&
M8Q]/:^K.V]3KL#.H<>,X_MA?'U $6U;6Z"6"OST]<M^6MJ&=>=:,%_["SCZ1
M(0I<[**W\8!U A>07[$1*(ITO.U=NMOV&1\-@+ILA4TL^.:Y- KFS>=2\O(
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M&;6R=26MQV4N$U/L9Q9$KRE6F7,5C?2_C]6T&W6>)]U1/Z?Z;24M/LH&%#]
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M:0Y):MA_\MZQ(SVA6H:^&7"UJP/?<<4"\".Q@.9?QWEH.0E^+,"[+M#F^N+
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MCGCVP#2/+8?D)P]-LZ^.2V['GR8G"39%3TJ1]+\ER09604T6Y?;&4].. KQ
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MHDC>A="M(E(9M2(492'>XG%]+*[ \=)P3L/LLF9*J/&I.:$)Q6@YN]I\POO
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M@:P'G\_V^9\(+LM#_CUALAC*1T0%S:9\@@&LKG6?C@Q5_Z_^A/\_!Z(,I.3
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M=5P.EBU\'A%;95%*L*MZ@/L1&_H:GZ:6QK-AY^!OT2^8AW^$I/A7.8\W6"[
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M6YEM4)J.LJE05)X-] #]O['WGE%-!W&;:.R*(!80I46E21>I4E5$!(1("55
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ML/JS73>+LRVAYBEJ7!L)X&Z%KB8!Y.9V20"4S-FPQ$Y8/S^^!133?,*'@9$
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M//?>GNNM"21_F9N^/0-5<N>"0*UE2N0+RYS>P:6<].2%Q"JQK,@8Q.- C;Q
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M;79 ]4=)IZC\HROP9S>,#(O*;[^,!2Q46P.D6AT9-'.'^(H,ZBP%:(37K75
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M_JL?#HW3;E:XDZ:[M/=2W.41M"'=$XZ5,1%<6SB=BM%!WA/7W+OC]"N4W3+
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MMX*[+YK1@C0G-!45A0/+1]+-I^+BO6K:>IJ,5\5:61-M6OHRNPNZ*"TEC4Y
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M$[\/N0UYK#Y<FWUTNU-.1C:P?5)K\C>Z25SYQG!M_D W6XCP#4UNW9+6\4_
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MX5J,^0JEO(ZET\"_*6C=_PJ[17)&L,!.=2$2<(679%!N5$(#8G_]S_..L25
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M]F-3_/P;A:A1_+K<P /FR":+AL#3I<G3I7$H51H<8UR#49! \D@97]/?=Q]
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M_J(5\Q)I1D+#F:NN4JM=7MO9=>/G-2O*^\VU*/YF2O7L)T^>5)%\A)V'9Y/
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M'!_0:!;<3%N#WH,T6=?/N&8T9SA:C6H_IXICAAJE#*DX&FCL%A]M3.><,]N
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M.32,AS7>51V)*OQNE6H/87E\W*S8@*1_^+VB,!G):?RNQ6F3N:9]0&\#[O@
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M'1^=W48 ;%H3]ZT1DT",F,!X+<OH)HD(D"M+DGDY5X/D[!IR<Z8B)K1Y;E=
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M( ]B4[PO%/DN-4E_C7,!7_Y\8\+RM +!.2$[[D94E>S)7&F(+.)60AZTPZ'
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M91^H_B5E--AEA=/;2?K+.;<4 @\H+NMVQL6T= O]YI\A0V7V0$4L$>^G&/C
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MXR3U^APVKMP7++6S&JZ81LX%%PD)^=4D9*F'^&KAK6VL%A7,>=GI;++6J6)
M0LQHQ9FK.(=&2SDQM^TPX;Y)1BDRSJ/0[/K3<DL"0%!Y.VYI%;>'W%_J\H6#
MP(=<GJ,&KG7#W'&:*JE)THABV''9 J0#*1"H9^?(Z_BBO=]T$71Y]#N[?VJ&
MZNZ6V$8;F@EXS&6].;<BBNM1,'"-RV$1]P11G8H*M'A]4JB8:<BCQ)F3I^-T
MK."W0V<[1WHRD$H(AV\3&-NH=-M4VM3'QSD^FGKSA;!QRNS2[]:EO_'DP;<Z
M<=QX$\OW>SE-H89N2O=U+S7NTVV?HH(*.1ZK5$D<V8H=2@7VY2659,1O0?DE
M9O,@73*M\X5Q7 +>?R#JMRNEKE[73C(8>RN_]XNE!VGGPV6W38; ]4HB.Q53
MI*#UC65<+E;U&Z]^'W<\#ZP_RN\9$O02TE-XC.8*<(*2:56/P(S@Q@6Q-Q5.
M48;,3=(&@[^QQ5.9JPC%>5DBR7&7GF"($ZJO8@ ONVU.'-*Y;,YY '&RE)IU
MZT4\V2$W!LBHI>X8\%QIU61\Y/3RCK7U[M'7/1\7 F#WR_;T%KX%_PS4@[+9
MU.K7)1EO0E3#X;-;T(_>,3?*PN*LK:%[GP(CJ8=[=(V%LK\6=X*%)B-)IRZW
MNG[W,5RCQNLH=JL52Y9[X@RQL#U1;(S1L=W !);7=7#?'+KVHFP2-4 3'Y[H
M%%7"H2PF[81%OYJ,&8S-SR_5B+O*J41)K1Z&X+LRF+0,4H#W+8\=S$ZO-]<\
MP%OG]#MCZX-?8@MGY:GW$/,2G5MN21-T<BJ<'7-8'?CF]):JJDQ?PX<NH^IT
M"_)UY()3GX(&/!?@N+YXX^%=*4>]R2)U)@M (#OX\$[AP3(!T.1QA,1'D2\1
M )OCLS4L.HC\P*-*FGTG+&3_=)4&V=RUF9/>Q!JV%MHV-=-C4'$\._Y]JW2@
M9A'Z$_GNIW'[\T-9&%]J6=9L?3.414X__\H3MKN1; D9:&<DD=*3EZX2V9^9
M>/ = J"V1,&4:*=;IUA.WUZ'1[2/#K2.4V",MF?+9^8>MJ25C;1KJI ;>&TU
M#2 JJFS*C[OTS+-0R;]J5#\5N%_NXA9R6))QMW$?\N,RUS*&;F"9=HUK"( $
M72)_WZN5B A>.J7PV.F-I?%>/N&\E_YM-ZJ><9F331J15Y 8N K]J1E;JN'%
MWAL'5 ?*RS[6^8(NI@^<D'F#;@//J[=P219Z!V]C3G"U!HU[EC?W\!G1KJL-
M:7[V3OD%;<,V55@QJ,7QO/Y(PMBSK6!Y 7E;:JFBD5$A/6O&<A+!Z9'A4LZK
M@0\( *K3ZW9@GKF5G;T-&YP$-B$*Z[?7TLA[W-RUQ5@V6 *!M(TM^C';E9/I
MQ?8,*>G%YR7)UD!MD@3^2A#SJDO-EEI6[APUZ)J?"IS<IMM8Y]J:S=A0'L 8
M=ASU^2 .*/"@D&CX;E?MR?T?$U2RXY<0^::6SAL>Y@L::#,)#3!1K>5NW;V+
MGR>S.3)'Z;X='1Z IF!W<*VG<UAH\"<,HC+4U77K[>Y)>3TQJH<K1#_$N&S)
M_'YDGE%%WA MG_!6E"/$R$SI/AD]M9G_^MS60N'=8G%*S5P?'Q^J^;$?H-W"
M\A2FI/$0GSVAWS3(F8'$]M^G![</=KQ11VP[7AC:&.99%$:QKMIPV-H32&FH
M;E20RU'L[PAL>=$3)(V.'%4._H5AV6?#4PY.$0!D"GH^%)V;96?][A]CM,S'
M6<DH%SS64SJZPLO[M[HQB0VL"KKN;C=H!0L^](AY5U97M(L9KF@D%,*NC8Y6
M$P"*,9&[J"5.# 8\W72 :S^Q[W"%-,B$I_EJ#WZR4/ +!HX, MF6/$QQG)?#
MZZ/>NAK9./!5BHE+TP_0S(74\'N/C X-:P.J[ >@Y88'N%P_1<M#FH,FS.EX
M"UFSDGOS-.9L0M_0!5TZ6"L\O(6MHD7/5*5TC2Q42:D/CNM(<@0\- Q1]*$2
M1T2]Y!!Q]#^RF\].!@GA[[C-K3 1Z?A#K/I>M+WOM5LPV(G$@6QL2_"J(U<9
M%96_:\[[3ET.#B;1'QS:'GN\/W,\-/*3H%_OSS?^N[/)P?WX0U$!3K#?C^\*
MUIDX0V=N!..ZL7J6YHU!?-2Q)6VZ!E5%\&;!Q&!J<9$EWE@Y6>MU?8A-,2P\
M-]&I7L(HO%#Y.=O3C;_0\@:K!Y3X9[(]OW7;A#[,<4M2>/WRO85+[UB 2=HA
M@ZT'1URGCT$D@@N)&1F('9&[R\4/\X>UQ76@:JFY.7W'.XP5I8)1P_*F9DTA
M_,T/P9-<N!=$_N(_"3KMLY:OE_(>,#SOVGJ)K9ALN1=*[EJ:-VQ>AK#>(1['
MK"@),M7--DU^.E+MIL=J'*&N'L-(2@POC'%(OS%CP1:2G:\ZJ_\.V'?=6$?>
M:7@?A-4^V=GOQ>CN"6$S7"@2&,JB:Q"JYBXKDO?G4-61'Z&3!MMR'):^-W]W
M(5.@IP?JJCH2U3<.;T+E]-BK/9^N/ZFF1O^ .@[-8;<W&^V##LM_"*V4 QN@
MO(B=7CRL?4M@IX+;\3Z_JDB+T^^BWYTCUFA&-6/>4=L,:!>[WH>%NT57POI6
MCC:ZO700;'A=EAX_>P) 8"<6VP2I:I#T/+85\K7SR/J1 )T>$:O6?V8X\GN-
M)SOVDB9_-#_IM^+;W^6[FMI+T#'R$MJ!<D3O3+2A27@BU5MH= >=K52&XOQ]
MRFK\"8!W(>!)^> N J"M#P$^43/83CCR6QPDP1M5&\K>PJ+!X@+OX47K'B9:
M=F-8NDH'QXI!B)SP@H=LCXK\O6%E&"FR+#QE&_!B9*-K[$]C8R#J%1,K 9"T
M>E;'@ET$+RA&$  !)2U-0B3CF1_6R/% <"<)F  0 <52@]FML$+P/Q'.:A,I
MF11TE;]_C"[!*OD^FH _])@^KZFFPHPG\G],,/A6V)58,JML>)8',3NJ/%S[
M3@!(/)_Z@IW!S;5,,FW-):/ "X4_RV.JU,:[ZB0%U"U4'P9+S&58]#]>0Q<@
M6\UK]X]&15X6FW1O,/']I>X_!&%Q31I/(X&H[6OM<&&D<?-5<U=E0$LA+-T4
MD4PS0#T$#R)[KO3]*_&Z&_!Z^T>9271_<90J9>2+#;[8&$OUOLQFR'7Z::^Z
MG";M6E9 )=]0*S8&.=/2+XE=:-F?[SCN4"O_0U/@Z6-":M?>+F IR(7AG$YL
M\+%W%O8$+GXM[QTS&C#X6)! 5_U8GI^_X^XSM7,&]7SP>>Q.FQ!&9[4[]',Q
MMG4/"0YN"4^;MP]RR0AY@YA''=XSLD50.K<;#]FC']6(+S+ ]Z4HYM?C]@.<
M;:$J&5*II*HQ2Q-*8]'&T)MXO;DN%)$!IE,$!,/1ELO3J.%2;@4I0_T?$3U;
MGWW(7"85:WOMA-^-((&\[#(&M&5BE&A?EK_D1XV-C00T?*S!O2%!55@D6$X8
M5^LA7Y&TL?U^/1 =TT2ZF.M4+V<P_XC2>+NO%1@;4)&+$#65U\+46[&GW.?*
M_U#9-NHF$10C\TM&)7 'Z\GE#>927(U53./4K*D\)0"^RJ9",UW[TY4#S?BK
MT_N:M$$U?M2"$M+.0]&BZ@::UP0]!^@Q]\LNL;55#TE&.!8^YWJV5H1KP3QN
M '_RPW%'+W-U"&1-T J6E4^C>K=ES@ZR\K-KG^G-PT-I6.62D[T'KJ2((]M@
MI"'MO(DZT'?FX7O4\B[TY!%Q*VF[L#IP$G*_; I,<XSP 1Y+3&$Y]@^$ZQK2
MOKU*-GBQV+GH",^FCW9S+5Z;K:_)*R0 /(! (<T3ZB=&$=VT:@"3QM:G&]_1
M\F0$0!<2^_2(\V@;%)4C'LH)%H;.]DZ>LG!HURMH^EC>ID;)!BSLWQG2U@.^
M*PJ/$ #)ZS (UPN/)*<4Z_W.[[2R*GYDM/PB0\07MCJ6WE@_&X3*DAP?*,02
M +C0:3"?8G:+&N[5E&DO\^2TY> (BO*%M23YDKI-;JX3+O9W#-H^]D9!QN/;
M9NE *E&I9\RR6.K"KO5V,2:FOO%=V#<B@Y&9ZQE8'?!UU4U(GJDB1L</U^'&
M.D=&>$CKR&\(*K'/]#,=Z2>>YP@9'967/:.C^OU.<F ?75VV?(GXKGI'IL#Z
M.+/));S48;_H[^7K_?,X)!P"ZI>).;B/R5F48'C0,HLV+)[19%)0$1FT#=?:
M?NI,)WEELT+5<=XOS7A&OTI3PQIF+._"<Z"+;<6%]1.CD)S(LXCWL]1!!DM"
M79:3H,&0E):*%&4;M ?J<:58W4<(M9L$J8.CYVF83+#%:+.P3CQ]X_N'#UY0
M6<!EBNC6KJVS8+1U>UW4+'#L6)4]Y++E_;[MD#V)Z4VWCKR^'P81(6_CNJSP
M^,06NGBDS89=__C+(OO3FVN#CHT'AE1AN;RZ8K#2ZZ4;:U;XT";8ON*R\4#<
M!\5N(>OCS]6T'U=$[0U\W73OZAQ2U<7,U3I;Q[LQPL6YE&D;J<GX37F=N&&<
M#O0:N=GJ0QEXEPR?_._E*KQY!0U!>,HZW"2>WY4L?38=W[$V>_36'1S*NV]8
M2*GR&37)..IV2RBZ<Z$871E]@N&-2G=>LP'D:HN+Y3Y>@CX]T^8J'7^V3K(_
M,']M'O^R93=W+BF']OB8Z,..@MPL=R4Y[8.6'&U+$Z-9WD_1:KTW>*;?-DA7
M2<YJ^,8LT+OAWL'5JRQMAD>_'63X<A@44]5<<:_QMDS+.)CO0"=9UQB*I"A(
MR'M)TFBEO\8EP88;KOWB^] VK<0RU:]!(]M*;VIA\=NB(T^JO5,\N4N3.@9'
MUP2T929=C&&N1$^ LPIBF3\Y2,+&[3YP;VK-W(B!O)D-\FR@?LXSEB:L,-2_
MX+!K#C5YD6V;5YY)Z4[VR#%T-H=57JXR@/5H\E$@C#X6)KH WF_N XN5KW@=
ME,,<&]S>%DH,6/C"S^:"JCP^!J?+?=S3;JPTZ0[D]^%.3>33%M [C4B%W+5B
M5)&]<Z^Z>".P.C:^I3L::^,[?O!LLWEDS6*UDZEKR-)\KS(C^-COTB?QNJD,
ML\VS$"#[B/\F=PY3U&E]_>>7>"ZS@[]6?Y!&.65I'C<#1\<FBT='P#_-9$]"
MC\+G\%8S+R>PF\2K]@@ =WW?*I?@Y#W#UO=EN6E>9#\X.(#2"7;%75$<9@AE
M[I6H[*?1$;QP'>B9/L+(]2P!-Q4$7G;OTLUNZ?4J5WCD;N;T+J?P4<,?J#0E
MEZF>@AF"*;)#Q=@R+HFR1J)7Q3'/Y@V$)9B)IHOZ2<\S<1\K[R-K< _;"LC6
M[_J^.MX%1!U$J9@V4PN*!3%"JRSE,P?&!+0MF4E$E1(AF>[\1J)#"WN4BU]3
MW]BFOLB%%Z1F#65$T5I5?F:&MK)!.S#+1$+H[D< \($3YGK3@Z*BKZL-^0"W
MJF72J)78=),8?#6D1:DGY6":I'KJFIH)J1IB4:2%:6W6 >OOWJK\551N))#A
M4XW8_X$=GSREP%.63X(>5J%B+3K^8 ;ADLVM&TVM]:.5EZ6YZ6F/*T=5:,(T
M,A@MC:RRL[G%><QD_(O?O7DF]4T*_<[PJ*0%".9SF\:"<;6A^F )IM7]N_WH
MB5.8I\V&K^!Z7@Z;PC+R9?&+\OXE=-6.I=R>#;HR9?-%E)/TK1YU]@,@?XK'
M@.ZS&FKTGR+'L4EB0)M" )SZO&?!\ROL$@"E_G%^.DP2N,!JT$ID-3P5@V'8
MEW1SUXT_FJ.NH [B&M">%3.EW_1<</X-+<QA(C/IZ$RIXP\U@DL5\59\*ZFR
M<43;Y(71V6>(2;@Q$3GP@2J6943QDDQFT2/9O,7K \T=V+MSF!!D[)=>U\W8
M[STNT[+63)#2\*J[!I;&\<77:<3%%3<-9>Y[K=CF98OE^CYEDKFYL9Z&JPAB
M\#U>W3_ .$XR'$@F3&>V^N+\4=+RK;6B(C<WG)T4(Y0H@4;]]Q1K2SZK,@=$
M%:?J[U-?_7"\.S^L%@>D(=+2@C7#S;GE.B742$%4)L]>:]VCAK+Z>BB%*)SA
ME>A68#VW#="^(/!SO^9=KOA7*HJ1FXDT&K5((Z7L8EWL1]Q(4A5X7FZN>P-6
M05>2S>7O&[L44>[5$%K_=!;!&HF6T3@KY_?1K]4T  (-?U=>?@E9,N51>IW8
M>U7].[I;)) TU/5%4*MTZCD)ZRF6)#FR0V4623 [PX_[F4VSLQI(ONU?]UH6
MD8:=9=HX2%2GN)I>+EE18H5]4EL]M:574"HG:3O,+5HOFR6:BFVP!#B:0<G.
MKP!<42_9] (U-Q?5F,+3-F@O<:PF;A[6L[ O!0TLR3W#D^86F/VA W G:6MS
MQP?P)LH/JV^,CL@\)0 4<I:Q-3*GV(HC3H7,"DER=? G"JO!'<M)_D/OP:P&
M3K!O.V+I+>-]U=.V@C>-T&%'_H6VJW\"P@.'/OM8@7N]2@Y G6Q8[5&<'J9K
M%C4N61]JB2LJFTXG[^MZ?)]+-+:5 /#]9E@W==O<^MU@VQ&)^Z\GPV()BB@C
MHX=,H8I!;$\+GQL4'96#[;US@#CZ=?</!(!P*#^1G,KG3;0(0 9>BC*<0&52
MH:ERS<A.PWETY=T/3KGE9:=H1BWAKO>=-2K"!1FF[ZYE:\AT/= 82D=_'R\O
M:&DM.RC&BN_I+K9T\H>+)-U,W2;/^NX^O<W \JBH(+]S2?B7=@($4FPNH,U/
MW6$8_K*M@O>IE+O;Q\-!I.%7HH9\(0 0)D;@A=9- N#/>-J)\?S8<!Q0$Y?2
M\MF^5^8Z1FA7AN7#1&0@O5:S+#0N4$+1.R!<L*"R0%T$["T0/A;'\VQNQ>TJ
MMO8$Z"X([QEA69%_TD2D,Z2QF+<5"!5- N#2% I1G,G">)G*-_P] =!( -CR
MQU%6)]?X_%E,97MEG6W[L6._ZG0/4[\KW\22@S'6N4XG^9TY;$9??[C9F7K_
MA ;NX&P3*Y$HHY7=-YN2DH!DX_%_-SSOJ.G 5Z1*8N&Q/3">E/L#UU<YM$(D
M)$+@&WQ+JI&*[WV8J)EDI>-;-34C.O6'#+#T?0\*(>%2K<PF @-<LYFO-UH7
MT.D5H-TO"EM3.3TZ$=A7+LW1&Y^-YD)3N[P%%[9<^M78+"V-PWJ1YMHII\$V
MZDJZ*J9 )9#8+3[=9Q77!"O22(WJ*W1*\\0WW$$8'<0/Y@F,]*X?C^;,Q @J
M*W(V*T[(Q=!EN$^5BW9BZK:O".,;T]6/-KQ6^8%IRGN8+QG9=+FQ93+OCQ=(
MR8M6"F'Q6(KW*/.DKPUIEQH;^(2&S0U$QZ1[W1:V&LE-OXDWV,6Z^#S1S8;T
MYA\BZ10X19STOW1'TWVDD7'?1D)CFRW._K?SA53,3?+_)?E"N[G=O(%3;]!^
M$P%0=$;4L>9N]R W$F@A,WP6$TD V.3LO24 J!=MP3OB'T\\6J$^3UMVH11$
M<VQ/-,<#1',< /ZW\8>CDM0@[,SP=L[RK4H"(,7//#AXAM)]JB_F(]IR8')T
MDMZQV";? FU#NU#Q3*]'+L7G2-%=-<SQSL,^-K: 1HF"$@/8>E_@<P+@T4[D
M3.3N ?96\*6-_HDVH&OSSUD0?U43HA9>"HXWM+[FY[9L%IX(E?Y2D)%1CK$5
M%QL>UJ3OT12K-- ,8+7R5;G^_%HA3 YOK-CY]E6P$)'F,H/3!UQP\:A,%,G8
MF63:#FY R[6$PY6=ZBU7I<C!KQ*Z=!@[=1X3LY5ZEJK(AYMO]M*TU05'';.A
MSYN ]C]WPE@>@N>5F%H.:)8E/7"Q79M:V1WE!6\=1NGO=PUJIG1VI99_W^IU
MJO&Y4IO5@EBW]A;DZ:V 6(BH)O8>&171UU?(!%;G8+1W>K)G9RQO'F3^GO/8
M9BSSQWELH*?GC >W;V8X;7(*.XK0\G< I"C_^M0;XBK -Z2<<N^&34;I,W\M
MM9GX(V-T9$LRR[[]#+B/QB[XPRRF?R<7K4&>4EC0^MO#L+:+;Z,JZ"VKN@'H
ML:Z!Y/2@2EP;DE-!WNL:-,4F1&^81UL7:&EIF9%E-KY/A[>=R1PDZLM;;,*"
M5YW)B2#7_*JYP3$">5!GGVB8"^MK3^I 1A5!=!M2,^_4U0J/WJ1R7K0O*A^$
M*O&=5F:0C)K8^!#%1$< ).^ P:*Z[^<$B>_7.OC##/#L*[Q2-D<<#A]SBY+Y
MT[=NC'@5;VQO6]2MH)_E<!^:IBH1I7CY:VKZEW@EU6]=VU^=^,9ZGAUY@GL:
ML/&XSULL2Q0'<5*9B^)U"LK!JJA)^<(:67IH *2G'5%I6#UJ"#Q*J2QA-_KM
M .FZX=38_Q*2!TE4)VE;G7F#-'N9712'=0<+--?@K<U9)),GP+W7:499%%Z=
M=L"D/ZS-]G0,:.JF02@EU!A T=/Q2_G%I27!67*C-0\S8@L*4A:O.='F)=Y^
M=W3K>8FVS!0)%AOLN'8?D[E'4B;;@XUTGXO!9)<40R:&Q]U%:Q%CFM^XBRHF
MT &BIDQ5:DF%1?UN+KYFX>%?5F!.#PKS3__4%)=%0K\8-Y 7%9;JU<.$?H%H
MP.DT/RV1N&8%$]\TKZW/2-<M?S^)M1E_F:SB1 BTQ\U)S@A$ 522T62RD^3[
M"W9R;1Y=O!SHJ"]N N7\\@.-99,'L1Q0$P"UD.:KX)'KYN!MI,=IE0?3LV!Y
M([\#@6+4G$!+MJZO=US_0))LTB)8<RMK5-'8!W]H8;ZR]DWL6FSD\:A8[4Y+
M >VTG5VE62"Z_B>]^'Y4][OP;+6R@N*N 2-:V@TWEJ4$7)VDT/[).A[58:>@
MK;9O['3<C,V?GM',GDJGGY2HWRI:NZH58,:HE0+\A+[=[R>06)[$*L!_Y*RG
M>TV,?A)GI$9E !4N-W;>GC'^5RBV7@#_6X#IT2HN%.6%'^,C )X@ZEO(2SX'
MRC9/KO]+;&[< $]M30"X_875)0 BW"T(@)TVU'F/*):.N 3=#TZZCH1CU7&C
M"C>]A_,-K#US6%^AYCR'M%E2G!XUB/4T'E1#Q!^P^(5_!SYAG%:U> K\F>SN
ML]U<"%(@ #)H]ILP7ON@Q1R=X%]]"SP-?WP*-O$?H&531]*3OAOV3I7F3^2F
MI1T<G6A<NTSN-<>@,Y[>TJ>'V#^BBS@O\C<0 .\;@[U/9QLPBOMC;]@B3A%-
MDA1(UXD5/B*M0G*S33>$!/_H>)^'WUX!N\"NB\LD%T3L!Y7['/PZ[RY-Q8"(
MY"MR3Y$ N&]N!=XQB#JI0)8R,X4D-[4,,YW/^YG1@G^ZR+24G"IA7Q/)*2]Y
M[T93]$0R;8F\I9M@=(B5,-;?L<!U0S]&[.X2#_H>G:D\1_PUOA\2QT.DV673
MU\T;CNW8*%^ODR-;7U3X;PJR,(V9UKN$\E%>,1SYI2J<8A1+RVH8Q4XS#_R+
M *!P.]*ID292^R!P;QRVE "(-'<";^?Q;-7^:=A;JR$ I+,&]7:#\%1D>Y(K
MS6<==KIZ2QZG0GXV!X/ZFAPRBQ5"QO 3#G'&^%(EX+*#</<HR'E1[>S/XV)]
M#U[';X%32]X4!("X8K*E*6X*G)GVG;D0$U27O\645N/\C4%5?N/M%]A'[81.
M-\5%TZFB]?V[SW1Q0K?"\\*<(O-O#'[@RVG3YYX"2WIL?'_FO5BK\-P[[2<%
MQN"D$W^,O971ZUI6FMNW!,]V]WQ9<22M^B5)H$)8;&14G,J01SRX&J:0DK3U
MM2C=Y_*WRG"^!8>9P!0F'ADEN&_+P26B"+6M3E&+LT^>?U_?*K?$^=$U[E6'
M1]UXA5(K8T6-ULE LA,SH- XUEK@E_Q4W9F7("7[W8YO@C]@/@O<35;3(0-P
MQ50N'$]+K:S?DJNJIH/WN/.RR%$=$Q:D!&2_,W_23)I1%L&EG/S,J >D\CCS
MJ:/34HS>USMCEIK#&,@XR?AKZ%&TV\GS$;Q=SFY!6<FV3EAG7VV@>:%=^S:O
M )9,+'X8/C?ASU7<N;Q_N6KK>7@80EJ/0URLK*3=R4$Y <G>'W^Z(.\?):3#
MTEM530#$&Q^P3EF>S348PT4) 'J\O<M2+Z. C8E9YXO-[A+^FD,3R1)(?F'G
M;_37Z>8;.&GJ8J2MX]?LU#R12@/]?)*.B'+2V-?;<=LY\2'$\.!F'#;F;<]V
MTV3V5)/LOJBS"QG$G$-YB-%N\O0,8JIP7[HHS/#QQ]Q.X' 7DUSO B>4C"_J
M9EZ4(D5$Z6?FUUHA?ON6Q#",[4^DR$1I73K>+F "+3RH$KS9D)WY*JM;A<GL
M#*(L12_?H%V=&_7$I%0.[E,4%3P]K,99H9OSO"_0&DM) +Q:(@"$P#C+F3.B
M@=H&!RE2/&>A,7</;L1ZX.KKA7Y?_[$=@;=F\+3<&<WA#M1U=5U$%*VQ=ZK'
MY+>ZX&PMC5:3]0R'5XHH:8#R['> "S7+;%!89-&B56*EV9=+SXN^9#,YZ7T
MQQ  9 3 9YHV7/E^!E:S(0A<&L12>0QGXY)E&QI0SHSS--"S]>4P3/G4Z]AO
M[>1 3]S9);94Y2(-ZO@E1[/"&2E&[]6[V<V9S+/KV7]GU*J=,*P$@(=)<!4!
MT!I1K7ARC<*5(AJ6$P&)P/&:XWLDL1;@D5!B>!98"MOQ]%G^'7CR]_C0.<Y+
M .Q^Q1=M9+?@O5I83D%+8ZB!U5 A/[NA*6KYUY@Z)X?@6A<!ZQ=^ A(*S9$Q
M>MW6#JGTK:3\X-V'"5K=-;<''=]3F.LP,0K%G!=J;KZ;512N-X JR+DQG>9L
MU1V8;*V/F8\5OG+7D&_TD[_Z7)'UW7?LP9">N(X=_$GYE6OIZ^P9G$AUJ<XN
M)LI-QW(S\4)SR*D7U">O$,?SUM^UOQ'O .X1!>_<CMN-@514T#+-UWO.TJ$5
MQID^;HJ7EA7MZK?+:^%)'9APKY#LY85:#MM/4E%QQKH*T7$X[AXB2:3#6YD[
M+\"1&)\ZSNWM[DD44AJ4/GN(LO?XO=RQ""MV6!^^SN"FI4-?5HZ!6*GI_Z2%
MA+-4&@58.XK!/X_#N-D@UP]VU_OG,<@:Q42$CSNO%GQQP%L-*?]UI.%$V**J
M1TO2K3/"S09MS!4/KBV.S1/0'ZZV,[$)>"^O^6=60FF%JM#,P.QPAA@S4^!M
MP4P$0+H=Q6\"0!DG.1T@.-YIO#V)"%_Y@K3:^-(YM%*UN_@-PU1'QN%-95<H
MR%X,T_B4TO;$"/*T(,TBAN(3>L.!YQ?)5 /78N@/?$BUI1ZNM_)RU6*:^98E
MK/)$.;,L.-DDYX1ZU%_&LNRH(/4QD/F^2PW'+2DD(NQIE( O5**+9/%M=C6?
MEG<I9B<%HYE*-%=<.'_P\L&'CH5F\6<[G7O^-Q_Q)$?3&*>\M;$UEC2.C!,6
M2\ECQE(\5)UB#5.-68;$%.='.09++9;3#\NSN,>PG-Q?[6SY\WJZY71'F/D$
MTS*Z/A;7.AA%_&=?'_C"-.A>J*BOJF LM/S6>-8J*'R:3//V\ U5K^M\PWVB
M*HQA-PSG9[02DZ,->)WWN^ZIK\OL^^C.]:=A\X)ML2TXHDM,0QKZ^&YWKC8@
M;'^]0"!\7.&Y)5%,+?&0J11S,,?'HO*2PEPS=,4G4S,N2-132/[=4=DG-6+K
MG-&&/K9FS(C1OXM)CW_/#ULZAQ %,H_6[FMH9L0%;;D(*G(EM/I(^HTL(HQW
MU^2ZU*_-MZDS4H_&,HJ+/S1<&*,03 6):]V%)SW,\?$8'8X#PG 3+9\E.]Q3
M<KHV%EF0SV&S=U9E5SV94O"9<-W)I1?X+0+ NT*(68],&WA5C)JS2I9,^JM#
MR+U?6+OX5LX/[,7B3*Z/K^?K'A2CR?I^$0!=+5CA([?]O/*.[9B6#[W&J\*F
M)BKREDRJYG<?IP?RUMY7?R=N"&J[0LD)'V1W0; ''9!>&D^+W AESB*JE,IH
M#B;V$?BT!'*\HWW(<O[>*G6Q1"80M=<$/LGH.AV<'Z\?3,-3MN*&\;0$@.!.
M'(B_ L01Q,*#0/3OS$G]/^R]=U23W;<_F->&(H((J("(2N\=% @1$9$:0B\"
M2N](AU#R*AH4I'>0WD.3WH1(#55J"!WIO82:2$@FO/?W6^O.S%TS:^Z=F>_]
MK>6_.\]YSF?O9Y^]/WN?/,_IG\+X45Q[_W,)<= M'USPKG"]: T[\AI[H*K3
M35FCTA#"(;#D>YO#YD9FOH9H-/06<AXX=;%<[H5_--&:!.A3<C,?N5;I#O1L
MVMN7CPC7RRB>E9FM4.\VXMY ,%JYPSO;1-) MR)%#TN?4^K=F;3$E,E=EKX,
M^H_W=3=?L^)42("SAM8(,I5A]8&-?5=JY*)&$*"8BZLV&O[&&V4X31<W\B)*
M+.5R[<#JUTG)GL4E3,=*,+[RDU>J?_NBB"XI*^$J9Y?^X.+!4#6+5F<!!EZM
M]R0G/XRKD/[)QB)<NB%B.64$N9<&[#VHI9'?L^!J=B J'!9K[6I43J<$ QOH
M:-.3>-S$DPK>BD]T+_I7U273L<?DC);SCPXS3?OICFCKZ,A;Y;JBU>W2BE9E
MIJ=L\):PUJ\R$36!"F/Z6\24;4>X=:U0<X6.YY7D>W)'/[0MN2O$'909+),H
MI>^-OM76%;>/8(077[)[;9!7U@H=[SFJO-,&7K7:ZUT%]PCVXQJ')!IWA9(F
M=-@$*OTN%-$8WJ?P'&I17^[1M5@6H>Q[9;#>\D%.CY)[8Y<Q)UH_^7%8FSXB
M+J/,*(,$8"];N8%UP7L2<HG6S-G+UK@>Q^?3Z&WU*N&JN_YY&D@!DT\SAB1
M8\>P@H*JN";&M$'@4:F*K=.2=Q(;7%_E8;X>GZ8T_4$ NA84#R;P9-<T!B]%
M]6P%IF\W$$J5^+[OQ^K>ZE#_//>8TKY']N.CQ84NR6<QS%\-"C;9X;-"EUVH
M]GR63_[A(0GV)YQ31)NYO7SJO.VR" ;/E/S\W\F5=,D=+BJ\REI/OODQ7QG!
M6/&Q(>B'AX8PJPC3^+@)DW&=P2+4O1C9M__&0Q1V.R-.0]V7S,Z>.IN=G21&
M^!',-@XWE>8W?I, *<C>B&7T4( %)I6&T"FYU#A7)*>YLL_LL[TA?4WTEH6=
M\*AY:9%[#S?"[D#G6B@B+?HJ+]9H/PJMVS[J6JYLR-].#;23EY4>#KY) C 3
MF4F QT*?\6;+$OL)7L<D@-$QR&K;\86&EU)NVF>I^TMY63U;*H5\(HDC7SM'
M!\6YB!>4^#]KQO(][!JN!M?@_EW&KDHFFB-/Z&M_E/W^>]/E;'P'Y%1+BT:U
MH7^0 *W1#4&NQYC]K)V0L&I%LRC$1ABZMA'&I?#ED[J81;EG9P*;R+-U>RB3
M[)<X3QJ_#G6P>(/9"WAE2'C55RA:=3Z/CTB7R]5R%H>4LQKQ,L1;?5#IXR0!
M-@6B$F=?-$KIQ54/A)=T\ LHUA;:;6 A[2.,&^NO\PH-']A8"+#I:FHE;:Q4
MKQW 9,U"S)AK\O<#</K(P+_DC#T(ZN-GZ/B9NZ]2+^M:.[T)\AL>[8881A:7
M)> ^TGM,?'T5ZTG[,T]%95T/[C,?::?^K5-Z&#N@9S,&VLL%+>/'D(S-3) =
M$U3C29F#<VIU]>_3NAK!U@[T *32)K=C9'!%[,FUS4+L81P.)TI[\9*XFZJQ
M-E@HBN=#5/?5\;<41H/*&PAD2IG5($&-Z(^\3H3M4 );M(>,I^P=J0<C7/N_
ME.1K!^6'9U.DA%SES#]=3,QN3V^TO[:>41B6GQ<.H8W][NG(=%3=E2^/.=#&
MDT-B?SZ^WO^O#5AP8[+&T(2?7N-?51:S==*4=>T3]^"+1(E41'CZ0X9+Y">R
M5V?_F+,@^6G8W??U!,5'8?D'WO>_7Z9X44NN.3KJ]X6(&5)"Q-,^I2:BT!'4
M,WOO:'<93>9?JOY')$ !=3<),!,^?;*\ ,7BH"?[&__T7* DP"B%)0FP@W+V
MV\<"?0A /R)=/@G@XD%T9#UB;02=K SL]K8?K?R2/B%PY)]SLVSRD$"I<W*&
MWATZ_^$&:%Y:YE%VI4P9?N"HB7U=77]<AKK,4FNTR[&\.[[7Q>B2EZ3D530@
M_:@)+V;Z?9I"EX]0\GL5KPK9 <4 [0C3(]Z>-3N;WWL4,1/*#E).5-V2'/L>
MC0D7S4(G!\<:K.Q6\]YE**S869V&Z+SA'2E1UTL+,"E:'OL1X#LVUQ, BHTX
MT-F!+2=<P7;HV 3*KD)/:VMFB7U+#A6CKHOZ7(+46=FL9L:O>'A$!ZO0XNZM
MR]9?>B_EVJ_SVJWO\"AH%#A 3(-8EWO)G+N*L'QN*;+19KR$9A/>;:(6-N=Z
M0TLKFXK(K-$3GU)QC)8]\D5\C3"W*>3A,8_WM7K%^ZO278G^)GME/UM+^-OR
M]@B^\NM,,G':F7M'BU@/!;E[)( X:QC0A/ A\)4_R[8 .JZ5\*'7\@3>OC'S
M#JQ@#.'4"/8:;#-1CY)XD485<$/B-L1-1$^)0SY9B$7FD;* )Q"$O))!#G?:
M8ZW_P9ZAEP8+!'=X#=9::^]M)=5R_PN15D[K1AFH.\3>:>@X3*MJE^_\I.1Q
M)>U?CR3YL_*?C09V,VW)SK(&!K(X/3XJTQ^PWUUJ#"?JI3-@0?0BQNX/#XJD
MU*LW_:2X/CV9<(^5$%G@BO&O64TV^OBC/<;&DE9KY <[O)^Q[4?BFMJWP>%4
M [TF%Q A#;:-8;U( F"-O :(\URU2M0ILE!6HHN'L7\2+F#?(F-]+'%91CM7
MBGIDRFWL:35$(3&=6>:-O6G2F5@)IR'/"C9: G<(UW*6580.HLP$YMZE*$#]
MV_ \>S'SDGK/9V?4P_$7!:U-:DW9PIEDG=T:&00/"G._ME?#P]4$K_#&YSD]
M4LX.L,^L9F-[O'[PY>A;PD'\]+X_.51^O$!0Q6<WN_I:;3#U6??,U-_K![)'
MJ"7VJ:*W2SK4G^\)*.A:KHD,56OFTF8''G&/%@K'\8]+;(1&:;P76LG?#RT"
MI8 /W' 71TD &F_QU.R*XQ*OB[:HIK<>#*Z?*Y[<0!$<9'19Y)[Q7B-/-O]V
M]*TZ1/P=D\AE=UR((C-X90?H0TG]19_ D^#Y!CJ'_PKC+^V;I1LU/];KZ9BO
MU9OORZ'3>)35=DQE2/7E,SUMM\3SV-$@PQ .7^I<RMQ4^:G71SD,91JL>YES
MD2Q2!!0RX;@3KXR5 J9OE6;@JO=_5^9Z_\0%,^@K*' $VC@N%+$7P_FCAY:N
M<";;]P7<+8Y.NF7?4Y?UCOUSAQ)2TGUL4/-0^W>""ZS59 EWBMUU/_ZU+;%S
MMOWAQZ]3E]=._K.$M%=7[!8R\Z8-I>OGMK!S+=R(?&A!OWBT[NCPC.V:=0$<
MZN,A?K1UU#30F5:_H9&#(P%&4ET'XS0QAVDCFWVF4@B']0H*OALO ,,H04$?
M42?V_(>7#MW8.B EA/**YIJFWNR\ 1WC_V#73VD>'1.A5(M_0 ),Y3=3PQ88
MR<S*RY#&3X/%%KMIQ(J#2,[-IM^$I2BU[JXPADU.R,);X2S9#8B#N[Z\&6*K
M7E<6#"ONVD_FAM@;^? )5RRBZ<,\(?V&='SLKT/D;D ;++4S-HGTEPGCS3(P
MT<!J7#769=Y+_\D4 Z/@5!#,N9"]?=6U6KSQXYKU%([J\FVYFO=I:B4>P2"C
M2G5 <@KDO30C'Y-=<DH?>M.^:J,+E%:FMDR^4RLL$.AA_:LDB*,>6B:#3N'S
M7"K48==] N4'>AC:?XI2Y564>ZZVEA&)^''AZ4G-CXUL+L00\37RSO*6"TZC
M=K\+K_@N+W*')NSQ8Q&9Z%+I&(WR[?Z9F((,WR55AL+DE+?#"POYEXI0)W%7
M)!NKW&R_4-?D<Y44(*-9>R#[&+P=P66.[#I)+,OEDJC?=%L418B0F@++XXP(
M%BIT]<V/&./H-DJJ#Y-H=K3^IB:&<\->NHCR_CNR-<\TMG*(D+E']I+%>!6K
M"""Y2O\>LS"92[FHL='^6;;_Y?.LBSIV+?58!VZNLP@N)(CZ^W?HJ!2K"2'A
M+0G01<Q2J^%SMH8EI7E)?_& F,D(KN9-<[E%*>DA[2#45R*<1YRXLR+C^< "
MJ?:/TJ7$A[IF>0XV\&5JL$>PG7OIR[LD0&@C$KEF,K!K,W^^$3J+G%=*/UY#
M+ON1 )!3!1(@(';VF)PM-(!.35@Z8C=HD8+(U]E# LPZ,/[S[F84;%Z']7B3
M<H!@$)!.YD'[Q V"=(7KVA",+2UA?=)L.7<OIH('FE["TWBKLD"KHBRPY7U'
MGKVAQHOOC)8] MREOE<UKXOG%@.0%V<'+4KN _4H"'R+Q*[=A54B?]7<::\U
M<!WG:;DX]N/,JL)!1@CO?G3RRF+%"$K\@8-\GA 7JTEAGS )!<O3I:H56?FV
M++U#L5,'C%MZ:E21L\D'<M85W0U']MHX^6/6=A-3@H30C#XG IR$R;O%I4(/
M\)2$TOO)M0Q)4\/:(\/]#-2&7W3,'./HBC4Z<V2CKBKT3*8"'[<V73?;2V[*
M_^XGY Z3,$N84/,XE/'V<>0O';%/- >]D;.1@<1,'U6-ZE);Q.MW_HA,BFQC
M#9?NT>/<7U//V!P8),?D:QU$.Q!-X%]' [W I'UO_Q4O3A>_I?*FX'+V"-K(
M+BVKA&O!O0$_>9F^>#!8)_"(V1IY(%X^2%T.?[QJEX+:?6F'27(8M".DR4D?
M!W<)+>\2=D\TF"EBNWN;I&T8W[59OM6)I.]?%3ZP.HGS$J,-ATM+,$2-M #V
M'BBZ+.BX*M K>B!C=>Y_'\]_(837.N>N86;TH!@,F8^$-64WTKD0@B=+FA;6
M4X,@"E$)IS^F*AD6.^ET&2YJ:0? O50BD,H<0@Q,'?SFANRG'GOB++[ON++)
M<?W:UAPSW:^(_41\Y4'$$ER*^XRC7H:!A[OF=&A877(QE%;I_E7-!;M-7HO<
M;JJ?#N*NMERV#T\3[2T2/[V)-O-[17FTTKV1#DH.G"&"%5RVS.)!/5--M=1=
MVX2R-R,8FT 1+8A50>8/:56(F2#LCN2S<*G6_K >=I%<%F" $UWQD!SK]EJ!
MH5$)6+"X^A=4GT#8RMD!)Z;W* 3"A&7'UOH.:]_XRZTW#<SX&JUO!%E*SEB#
MN:4X==0C;C[;-KNH,Z"M^]F@:,F.,_F#$I_FY8G]306&?$.B#YF+Q3N!#PQQ
M7"%$P\>I^:J8.M/.39R,D@BF*.'5#>M DUU5?IYG$W:)8 E!X1^\'#F?[4*[
MRI.L"D,RWQSSA7_G4S MX<.'D #36G,7D!L72Y G%G5GVW7A"+G['V$K?M.P
M+BG\W\<G_D=2W??'^@DN>$4LAL,,G1@1\U@-:+D>GT 5NVO\(I\!')\][4/0
M,^B5/\9SV^Y3C1ZYSMLOPGTY8!(TI@PLMR)P8*D#ZJ!YFT[8"ENC#,K3I60"
MJ[VHYJ?MOFU25LL6Q &YXN!AXY9HR_/6HXQ#5$N]WGZ2CD]'!_5\F^:K[(6T
M4F5Q>*KA1^A4*-Z-!!"9C21: X72=C1B.G;.ZE6KO)LT?LSX6?BUJ3,X"3C>
ME->E'ZKF4-<1@^AIC>9\:Q1W-]9,3GMT)?^O,O4HC6*:V=^8?_4'"O\(_BN"
MX8$RT.+Q5/IQN=EOAB;T>> =FCD> /]WP#;6D+Y7Q'KJ1M$#(\A 5TF 0,[Q
M\^NZ>LD7Z,41,I!)ZE+[N7@'4,_(X/AN9)*M=)$8QL_;?LG[XG8U"KW"ZQK&
M^89OL<V&29D--30Z["-[E86/L>^'TF+,C%^>V<H0H<<[X< 8'YR*-VZ$'@<5
M%EJ/U\DU3+*X1/2HIKS2$*/1V&9WB8L/O>MPOU+(T,3855FC7$!E9#VRW29A
MQJ_(@&B)W,O]3@(<<!+-NO<BOC7?>RV9%LCC!3>_OQ_JKV/%%2%28Y5K7YSC
M\\2KY*ZAF'BOOD:7VZ617 ?BTF\!KH83H\;3$].U7G\A$J"B'4=.IZ$"Y:"3
MP@Z_\<6Q".KF'M.Y]?!_/N<W@7M#*&SF\J?:=I[8,7V7M<6DOCHC+JKIDC]3
M'Q.=&V?9?:_0WH<IF;7&5:_?2<")2J>P(DJS:M,24T0]_5A:H+_V(,6%W?KN
M=EMP80LFV?KZ W@I17Y"9[NP/K;+(_KJE4[4^LZ,0Y;8'AO>WM^2:-SH7>Y5
MVQG"LJOP:9L*30WS0#6Y]<>[:X>_AT*]\KW?TU'B$'=%]^^.8RT"+H^,=9<]
M"^Y%?H QRGEZHKD,_%,W[[F8.WW7@[BG0#/S"C.[%C;I,R7N;L61(UKLK!D3
M/Y9"_(B[B$5-[,6%4RS#YH^1#*YY[_T8'.L>C;O5"::3F/R*F@3H-[\RAY@S
MSN>*_FGU*!/#'J&N)*F2Y[-VVSON^[ VBGXD[Y-UU'S(W<5!3>D)<RA:G7CS
M:.XG$J>5W_?SV\Y.]0S+NZ'$B0VWJ?VBO^3TX.F,!I+6CU[15]??L_QV]BVM
M.;%89/0)/'.T<ZC+L7E#T;A(+ZBD5HX.)D #)P%Z9X/=.[#!B!@[:^_BM]H[
M_?,II26]*WRO\W1N#B=/XO/$1]]E&]ZGM(+S6%_PC5;^V_5MAN>S]J.$E=K]
M49P+H<56LA_43<S+GWT2D%C142T5>+^FEC8I"^[Z(#[. 3O2PJ'(G&32 7R:
M?'?%15;YWB\567+&OAM>29 @&L-N-%_\Y>U\?5$*O%CCMSO'Y&+2DH@H[EL6
M?=MVJXV!0]%+"UJH]1'RE_@W7.%2;-/S\J;GT2I$2@I3?O#SN2H2X/SOFW[5
M)[E>N&Y_!_7TJ.ZQ#C,S^*;:K,7%8"$JVI'.6!R4J0IE4:C''1E00J\SBKE,
MD)Z8J,[P;+(I>K0)^I3.U!"T6 6B@Y( ^9*FK(L53O9-*<;H./&Y@/ N34NM
MY]V<QKN3>?[?\2)\U5:*EC&C.HV5_7SU7#.%: >T_A )T.H(BP5RJO*\(@%8
M3C@\!5]\'6F!%\_Z58U @A@_&L5E]Z(,EUXF_6V7GYCPR!NM&=43-RA=4SDX
M,F'610+\HK BO-ZD"8XS9@O<#H=O4+=V>P5V3S%;N%O)K=QK-N2-KS'<]WTB
MZDOY*4>B4K1]?_T9,9)!AX:A5'HL&Y7-.F?6ZSZ?WT.=LODS8G<VL>78='0C
M+%^^XO?)DX1HJ%-;2"8*%1'^>.WDBK0*?\XU70)O7-%#9;WDZDQYW4L%F5<.
M@S#O\I^R=K NQ1#JB(Q>G:#O4.-L2XV1%I1.BH7G[JM._<?C\&(SEN>X'J/?
M2=QVO'U2(=(?@W<>?,X-OV9NN'IKC9O%L1QH?*?1T_3_M$U79%,"BI-JW\G#
MUS8A$ZD'L[;N-BMXW?"R1[KI68IQ^C\/2P]M,RVWN"%:K)PC%*&6\"QKZ\<W
MB9'DHP:\Q_P!&/_*7Q^/'3>1F$ ^X*[=-EU;\XK[C3\.?U,>^7P$ UEBMR_0
M2W-IX,QZSWSEP66M#.AG&;ZBLHL:3?^9H7+_# T&Q\.H B7]YS<-?F<O80S-
M3UEMAZW,!]Y\WQ\=PE@495I9%J*6;*WS2W*M!V_;CH%OJ%FT:=,/QC#^L\"S
MJK%W\&+G&PP?_%;N#Z[]A&<'5Q0PQ%QN]AY3>EC'AY4?RY/TA_3H@,$1"%L'
MK@]C"K?&JF7+U-"<7W%-.&X6GW*@$:CIJ!2QNYJP_Q[G3D!Y_^S: D77S7:6
M30,#JI8F4MYN]6TNO#;B<> HA?$K@Z7BM67[-]@-GP("E N-CK[9#?IB'? T
M)(" T*=3$L#E./^51YC7TA8P7_ODU,+]&&Z.E!YE,/=!/"K)SRR(EC6;U>J^
MI*XN-B(>6W8W/BDK:3D:?/EBV6VNHMOX.]C:G$##([G%=9K(U(!/6VE5,]S(
M]AJB;O['Q:2+GQRXB^PX\DM1^C]8ONN*5RK*0A/YWQF^F_C'$JQ8;3P'3! $
M/RN4GTD5&ZH0LGD3N+1=,M DQJ@VT0$T!(N/;ZAL)&3D%^J&Z3$2KMA;C?'D
M!/=+Q<@_W;3ZO/8,7TG((UXG 81-VFJ]\[M-TXE[+C,E'V1L[B"]FE4??NB5
M%!ZES$6A1Q?S/SJL9Q2,'B[D<D#-)%1&9/ETM2JV2J"#]AZW#[GVQ8E&K(R-
ML%*_U;S?K#S5C<9%O.D/J[P5G)LP.FR%\90(NPU>;MY*T45[RV3>B=BBD<1!
MT1P>)L5;J%\9G@OMAP);N\NN6#,+_[496)_2946D_I+7@='H3WW=%28U,8%
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M9SP)L'GG?'82X$8]H1VY>T'.#K96,@<Z,S_?[47.UX(2$\Y^*?4+G3$TKI(
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MGK]I\#)(]XB(WS3)A8P_"6P*=CZFTY1[.A!LI !4Q*(9=&:O&15?JOK8=*.
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M/K^3U2SF'_PP?VYGS [1:KG,^43AD>S;SH:1&;_L%D(.*)'U@&]C;D5WGP3
MV\)$PZ>F0&S>8.U#!A<?Q^+FGYE_ZP;,/BEP$X,L.A2*&*P4HC +^POBX?5R
M"SP/<FBY[7C/SP(N0N%]"3@2X.-5F-@.>K;I!-NXC$(Y!E(X>,>SV3B[A# '
M,==T6,],3MPC =Y7/HF9-+Q6;GA-\O@ZP^/3PO5*[15$=%QFIG=WN6\3IH$7
M)ME,]D1)_A,"CS$(8^*TCRFJ0?9J=&9,&Y, "S8.>KTZ(C)FQ:*,)FB3&LE2
M+9<=*R?%VTIW:A;3DB'4,OR7.MXP,B7.;)P?+9PUU]E?/74JME@FOT4"1*8@
MZ<:!^*K?^O;;I7MS=7=\N=U3FH,NRZO6N]-K*<N'1JV+&A8@[!]:9V5;W LQ
MBO\ZRTXF>O9DEC9*5:K-^J%CJ=+0OLY6Q"#D6D62]$:0[7Q^?EANLK[L!%O8
M==8]"C);,7LXFX_GFO"[B,_TU#](G^4QP30I32'[3EPUG2DG)Q.Z>V\_<;O;
ML+T>VJU1W0F/CTYW<;:$ASV*-\B\KGDX)"$H&?V$;(6).T0&7>491O"*/"'5
M5DYJ6:3.&=]]8TAAI+XO>;C[\OWY=)F:Q0X]VU+]C*AU1"K'9_NX0B-%>:V2
MOZ+ #2<*-ONS1 L2H)]B(>' 8$MHV88PVLAU?5_,=:<YO&2[N6#:!/8EQ""K
M>] )<;8U:.'NNBCL*;90)*+#,(YD<:)*WU$)B>-9?C?I:K;3-,1)-(7)@>:?
ML?:=5GN7!1"<\:[8*=9WDS/+GR:F4A;@OSJWRPUKO6J40+^*?UH>QS]SU'NF
MWO2^0T-N ^HXBD?DY-K:FNP[FKIX[H2D]Y>%(_M#R0R,4F_@"&/L7[VQ7;8_
M4EX@=9L$P"5-HBO05!J832JXOJ>^4UA1;,IIDC%$,:ICNVXU+U8AO/<O$8,7
M+_*DH#GDV&,YM\)03@*DWY_>I/G82)$5Z.</(OOA;:&%9F8[_ZK=V5]%'?-V
MHB;5H5D=FM85FCNRS4RU?'(R[CJC_;J?0AEK[*BTM4;) V@YK!ADR77#+9KE
M(<)PL]\Q""6TZH+=7<)X.^Z@=T'O3?23>XYLO+>_7*'.$@YB^(K"6X77O"_Z
MJZX@I[@#9:@2AYO\UJE2MVE9DA.??)?\_!XQ5^*1Y^>P5!&?P7K;EI2TO?7&
M)H"KTV:B)^E*SE3',Q/&;-<^^TN(3[USC8URVKH]F?'#8C@>:FLIJJ6IQ/Z%
M<>5 K+F,3#QI6ER^IO^\LP [>(<;VE/"QQ.")V:P%41S3T6-P]:A00L1D5'S
M37MA=!RN)B^=(B0G/*2!LD\V$J-5'!%Z]KM2E?TS"U7PC%_)1,!_H\+SC^"/
MX(_@_TU!SAR!4\G2L6GU@ L_P[DW*6/FF0=:H58NWZQW/8QKO2BX,7M!^RHB
M!$(;^:*A:DHOKFD+>%KF<7MW(,K$D/"5!)C7,.-J'%G.Y5S<C @#"?Q^$9[O
MZ$VIJ;.$/4S?H: DOA1)5)$N_EH%L:PY>R'<P2!;_2CKD?E[VU03(*:AM"FN
M7FQ.ZE2)2#]'Z"'G;Q?TD/^K&;,;M>%M$S*(AF0$76QI@;\$YU5Y]IYOE:G(
MFHV-?>'22C $\O+SPT^S8,^=FO/SN'I(@*EX(ID#3M:^)0%VE>/..R3'_T>J
M7L#X*@]T+;3;N@+]=M"\G)[.2M03?66H#0QF5A4O]:U08KH-^D5#OKC9U.PJ
M,MZF#[GJ.P7KO[-*HTZ(F3:CK2$!+$ZH?TTQ9]OI2CIPG1'RIB7B&H-Y*D7#
MOO0-+V[6G-$-6[!%O[?N,I]8@M_-N*G9RCSCEU6F--Y864VV%"ARZYVD<;D4
MQ7X7T=JG!%WG:I!!*]PHY#=?,3B_R6>:I53DSY^2S1R="_>$\SQ*KKC*%"FO
MSKY-UJ70_Q?1)OTV*$G_0)?XG#'B2V.$3)U9@93>=9K)P65L]>/#]M5*QH!*
M;4EJJ2*#%#9)GK7<$&B/3@*CC)UC@*>]@P>9D32=5($N-V+P2)AD%.'@-*;!
M"RAEO'+PF.;S8X2R:)515K"((1B>V:X4UK$DH=GQ$1Z*LZSLC&40EM'5'[TS
MC)KQRZEMY2FO9MU+FEN5D6,R2MH[(-2V](<DE^?8I27%V(G?X%-1*V%[KE,.
M@SC$KYSWET2!120 JQF!;8H$H*6^3@)X-RJ=?RE'?<QXSL$SG<"7LD("6+I\
MZ1"<G3"![>E+-9W  ^NB;E +T=4>!P0^JS#_ZQ&OO8HONQO%NO9YG^HJ\0V(
M#99P*743N[@*VM?==B;BI@[$W+V^& H.XBK#VI=$(A<=B&>?8\>&U"/;VNWS
MH0U&7W7I)_H4]1Y_!U]FH!L9QIPS=%B?TM*N&4&0S$"E";)XX_V-YNPBZ6TY
M!B>R![TP2@LO>L!3M%DHI2?J$QW_CG=#'2BIE]-ZP(#E#G]F*2=52ZYM.CWF
M;%_+( N@10U>N=0PQNI3OY*]@,P:;",B:DTT]I"18"5H%$X5=^E#MZ(9 ]!(
MX#FUJH*PS_C,.;7_$$%>BSKI!Q@\#;'WSGX2OGK\< ^MNWS (J./OBO-'V S
MKBM[^M/ ZWO%B-ZUPN6\%%:%N(*2?85'HUG:,EH;A;1LY +HH&/.K%MI!:Q'
M K +Y!):*TD ?E$/%LZ8Q>9G6@29@F"YJD3I_I:O.5./S]!JQ@]P"&"W6=C=
M,>BXZS=='TZ5:[P$VJHPLH=]AHFRIC'?@>VDX]2D?C:=UG/^=)IFU6Y>W79J
M^0*_NY(B5%5[9;QUITE\7X_)WCXFK6WL88@1DNJ6B16"-EN=_&BR]=$@D08S
M_'M8:_H"O@4[)3LQ$$P"W" R6[G/8&;J&Z!]5@)R="[;]PZ/\"'VTAL&?,V3
MZ6]7,SIKD[G'#-81FSRS!DQQ>>0R+ N6".Z:6V[A@A)\\ .$.#]C9+,DH6]Z
M)ONV:I4<_Z+K$RK+QY,D -+<2J)*VU(8RU0X6QJ?SZ HZ4ZK&RY$UZ+X_/"P
MFK@Y\\KL@!8O@R$!KB/G-9 T<GJ$AK*"C9^-X(_&L-.A^/QL1!>E_>\-=?27
M-/;<#)6&&+!Z7*'P]PY_%;;())HP\M(;DB.:SY1C^5:4#CJGZB-6&L?/%D?G
M>OW<"$\F9SJP4RS)>7WSBO=D$BQ>NX_WP*HZ-"U%"[4E57F,W'BHQ$9;$I2Y
M.2SS/K\G!\U0HHK.F81B%6S^I3@KRWX28>[Y8B";>NB&;/-ZU'+7J--OJUEA
M\^7BJ.%'(TWLMD9=GW%AM.(%Y)7[[3CBK,V;D W#YIWVD@#N4D)D!ZJYA.\G
M 5R589P@@KS.W&G>;"!YP<U$_#?(*G\$_UG!\P%\R(G>*6YFCVM%J>M^61%J
MT ND0K"?-<DL=Q ='1K3ZHAK?>U0(2X$41;:'OU1+;Y>*CD_MNGJ=]YG6?7%
MNA 9M DSC0Y+&)1&T<S9N^%A)[F^7:=LS%26;""J0UYS?.OG+]2B@]ZU(!&X
MA;K6_'V4@F&QDPMY_@"%L_^_]/5@]AIP.R0!Y+>^!EN=Y#MXUJIZ_N3,2POE
M09[:R(1.):K8(594H"_M1>M#$-)7K1 %4>8?336'7_9\8OQT?@ 2?XH#/@TF
M8+)>=TS\.3'7)_9K=FMFJE)*N::F9FS*I/J;P[ZA;)P_=GAP$7LH7H^W+^)S
MX,U]^?H]O:]UW-AC=.K?Y,+M/O@_IPF;E(O%T<J/2>:R;]ZSA(D4OC>.TKQ?
MPW&SI[4\"F'M;PK71DQ>X1WC+/>&+#)SP3H#$':'6_O+2N1%FU[@7B>;B+KG
M;,,0R?A%\^?"C1O/1<_0UWU*#-47O0Z&667UDB1>^$?];G* >>ZDDHLOCZ[3
M!&>ENO4:_R0"NU]#Y37)Y9S) 7U 5V]X7EI:?/9#EFLQ.Z8A:7FE5RU3-=NC
M^^D=6Y:>!F :^MSK%/M1-2DB(28H09Z#<J<#R-42>^X5%5^^VS%FJ85:OEJ2
ML4)AEI[/6A(O[C2-E/W[-T'NE,NPE9ZJTAC707L#MYH[?UAXWU:R77)/H>-3
M2,C.[S7G7<[H-5\M1 U J SOF7C<TM8=$;M6F!\VGW1+T>K^YHP \/^Q8PPJ
M8=(?2+/6>E_9GPP SZ0J39SFEQ9U"GWSPI@ZJTDZ/'R/>%U<-9$LZ^2DKB'H
M5IJCI!7UA.I&_;D_W#F?[GYI:?S[^+R&AKRTD)"0U(U-/MX9BQ#N;*U]5?YP
M7;9P<:V^OJ>:U]C_(FM9;# =+R,6GM&[P+=64?>UA-Z0WU2;F1<,U@9+\W\#
M7\***8J+/>]96^LP>6G%?O.\"I;ZO]7D4H#O_L7,4^^W+@+YHV<3HP'I#="-
M[^:G%$Z>*TMMUA5W>?,H>]63LCO'1D<75GDWGGORT$7^F(HBX\ET_Q\W&Y*<
M3>\SQOL?-9_V';F8^V_AG+XU2CE;7YF=!KHWR8 L%RI'&2]H4C+U*7JY47T4
M>",JD!G-$3/:G';N7V$U=Z3@TXE? _V<E[&^A/M&<0ZNOE\%GNOJQ G7-:B#
MM2]V4PT]7A(5T<;)D<U&B2"^)'AG;*L(AI3N-B=D[VS%B>E9-+B5>?Q:G-&]
M681B5J6>A<XGQ$M$VXY6C,11K>7,G*^<&_?_:UWS/!7UWEI1QNDQ3,; /)^W
MY%1.=MFTL5=TZ36^@@==9Z@]?)'=K1<%N?#&K=53[S@&ZSWU18'% /+,P'_?
M3TYV3=JZ;^_8(<DL]KE7QVFZ_,?.59&XFS\/)7K!8+U1W5"Z1BUTB%$=IW#7
M;7GZ(>7\YY_ #2<:Y\-#=4T4%8Y) #]#5:63.&4%Y1,M]D##)63XW:.H4OWR
MX5 O2<DKYQ>J6YQ2O%ZNC9_?_*IW,LDHUSKY>%+VY]9X(B&5?N*KR?WG3U#H
M)5?7/O2H#KI52GR__Q;[I'%G?\[4C%\N['^H6ZP]<)F?3F>TGP$H(:L.5'R^
M14M[\[:WMSD#1.>6\@. X+E[T= FM.]0:0@!W_585/K(SDI3-=^1^)0FG:S2
MH)(X9F^/,$HTG"_(+_@X]G(I+(F%T="@\+QUJ''^'"/T]57E5;5-3+3!BHJ*
M&D>><7'.Y1WTD$)?CG@EWB@4$X^U]0/N2]$ LH,-"R+_-_;>,ZKI[EL7C:_M
M%4540*2+]";2E185 :F1&@$Q2I4NO07R"@K2I0L(D1HZTB&4" BA([T$B/3>
M@D B(3F__/>Y]\,^^YXQ]KAGWWL^G(]DD&2MN>9\GF>N.7\SU7^PS-!ODB2]
MSDG?:<I$8NM8M3$I"B[M8GHS87?JWO7N9^6I7EG@MVJW/W\$^U+PQ<#W: _^
M>PSOKJN[.S,[67"0;@A^/T/4+-HHN-/GO%$O:F_FSU98X/C:+,*>_T-^3FE^
M6J8G?9'P0KSP7UU1.8 YZE\<,;@O=IJ[V+H]()N;&%M-\'\H""WZ,JIOK*MF
M"DJ[&"\MRV^C]$TG90PX-<8/GC1$4?S/N5DD0H/\D-BZ7^SA;7NPIA*]V9(W
M:]&?2MGWK@VP_JFA9E@O2EDH*]^5BM?HM] L+"OXU'5L>?" #T^SJ045M ]=
MM.LIQ:C6!#W];0?U\;[(=- B$%+Y=M044B7[M&(L\$N-I-)H<)&,T9?':P)J
MQ@D&_] PB)%EGWV!<CG;AZ&3$_/3 E(7I+2SP4;V7E]O;GR?]15'$JHLL^D)
M/%*(N?6J*$%0E*4X_N&P4:.TSL[S!-KHT]P_TBB*_&'GQ0(%WK+:.J/#H F'
M,%PCB\V(.)?<Q[%1;:CAT6CWVD==0^FN5B=92;E58+V/Z_Z]!2QG%>W.-GL/
M+$PU%K/HID^?U)V'UOH(L%5!0\N"6S*US'I,/9-<.=64RMF?A^1%?U2BS?R\
M3=S>MULL_Q&= !NG@EC1CJ\\@]I[7%CK7JK:'XZ=>[XA["[="M&5M6J]1F<;
M3_<T+G;IMEP#'^ *+$Z#R_M[5<7W,I8_;N C.1EJ[%74+1WVF\?>L0?%ZZCL
M,,,\"6H-^U'1VLEY:6;=385BSJ7\22YGD8!3.<CNM9-NDX=(G.0>M,3R:B\L
M#,^*2$$\).O-_G0]S1B'L=[&_M1M/+C5WVZ<CE6%<;"*C5L6<A4*8R)T/Q7$
MQ&=?*'CAI%]J]'M]IWD<KSR[QSC/W:V[KCJ)OZTBY'G1W;4D\%8G%MW([F@I
M51,_(L9HR"_[8LRSDFWCS?H&?_B=0D)G7.^=.T5=OX #Y*:P'\S3>5*.B*>Z
M^] <MUG^*58%I0'*QHSZ'';HM32S[Q'*020J^CS?O59C<>&\L,Z!2_HW)-:?
MT4Z?FY_<K')MA7_M$@%Y2R$8[1I1[4FD@J()HY:O;:>>&8R.C(UTU$$FV#ED
M9;ZA/Y:<B9#\_? B$%QPC79\9#WWI_2$Y5#N;/0J)T';]S6WLTO,1C[VA_SY
M()6GPO8O0XLPJ39Y#OXBGI+<:EFQD06TT'^X7;[<N\=M>]2GO%G=P@%WQBDW
M:L<YC0F0OV^1^?F=9'=-Y=0J[]T2&A:2 JR5ECM^1QPRHRLV!^,KZP<\KG=)
MH@WY$2-6=%2#Z$9&-TO,C>%$-)Q+3:<5$9R?D\/Y)I91$5I=_!X:\G%-U7UF
MF1:Z2]%E-&%B+>G;Y,+('M,V[S9Z/TKE3BC'2T'&R% %?P<S!]]Q(>'U7^$&
M0K>#^8QB9(R?J-%]!5T$O!0%>.C:5=+%_9RO+5 GIHW!>&7=RI.<,D9%W09,
M@_F?.,>*4IAZ@H:V,;]8&)8O<5-?,/;YJY+I?T:+--#'!AYX3@4)3T]SN/5,
MH'%E%8(;:6/@U7MX52]"^)MN<%;$+7M)Y\>_.D<3]T>>7-?=SM+=D0#"(IL*
MDB!@*2^]S!GM#D.UY\.P8JL6AX><08I66\W8&C=3,1>!=&$CT4J9^C]F?_P_
M%]H[%C/IR@B=<W\J6YE :^+X@(_%7U>Y2S9LM_.F@CKG_MEPB?^Q$U%EWF#O
MOWA)->K!)5FM7Q/:$+I^HX*#+GU^[Z=]\4S&X\? 9A5PL-Z47RK]VY\#)NSA
M]XFXV@#OE#M31;JD=U-$+:U)Q[E*ITCK5_?T<Y]9I_/HRVJ6/#%#UJ>9-K5H
M6J0#))+2!?L OAYD:KSM0 4E@-G]8<W%M48Q.+.J:F^*HJ3X#<WR7@A3TB>M
ME1A77C_[SS5*Z/1N]A<TGKSH1>8F^A$4TFT,?.HZ]3YM/U=8B+_BW6JQ6B?I
M%<:@J;6O#5&-\4%-:,>&/K_CE1L5\6JH<TXT.PZ0@R^[B9?WTDOEZEYOQ=02
M43^;O:H5[=Z 84=ZN$ES*^;0G/Y72XP7?DRT1N?G:U8<%2;^_?=^05Q;P2C-
M-:*ZJ2 QV/)!ZGI_W/ZN\/[E'$>T:JE/X$LJ:)+37/\]ZOX+%9?&'@?"YS\2
M!T9C5:E+XB*@B;BNVXV,@ XL;@AB)YO.*2].X/F/(4^\.A$8= [CU8NEC1Z"
ML3$O=FY$G"N*$7'R\@C:EA%)&KN<Y\1J^TFVG1O $E;$_V8)W?]YX3_S@LG$
M00P55*='!4EQDPU<:#_Q !&F\5K,X'<JZ.2N1"B26-/L0P4U!W$#[X5Y8OZK
MES:>@>\7+6O1VH*MKI.3?%QMR-7]WL=/CC6Z3W'):P"T+SHNUE+ I9W3[4X;
M+SX0)O^LH^:\4AL.RD7&K>VS"K&=L=J YMYBF0TH_4$+#0:?<NQ. NG!A!]7
M#NGB.+MBO3]6TD([H6=+]T2#2Y7%4/E*KZ&&V.^$LTRENL\BQ?S?C=PICC4(
M5IY CU21A.#*E)<!/DL,!]T[080UKO?8;8E@6%\OW$8A)]"%K'NC=?S$SL;.
MYZY>LHZL3B1E?NWM-4O+3(GK^G_G/V[Z2KL7#[9$S&L2;PG+"79Q=5%>(D7]
MRTE.1YG'^9.*9U=7EN%.G[&9*'[3J%C)U.FWZN[W=2MD1KM>=35;]^L7/5W(
MDU:/ VACO)\IR;/F=_78J*S,8;5Q]3I4P_3I)I]!QYVPF.>YC[OYW'DOF!BH
M_O4W'RTJC<+ZJ:"5!X2415?7<:^+G;O+%@3$2F*CA^5"@*COT<NQGGFYEI\A
MS'%%72/]NN%]T'R#%W,+62^L^XCO\X/SPM_'?X+0/\G<G&7FZJ*"/K#!/::0
MO8J+*0?2.$[&&>7PBI:'Y/"0Q?L;8GSUDSYR[&]K;JX7%\4\)&AKQ.W+37BB
MGEJ8%3JLO_"M49  U!*J [&JG;Y=GA9@/L_0@PRV(.U)5YQ465DK2B^T:#<0
MGD=]4"'^6%C_8&'#_W@QGJ_5Y8U]=E&FCE9_G(-O8>RLT<B@LLP-X"Q-?:!D
MH13$<H#\"A8*?T,Q1HH$0:#P2SO]W>/*FXU'07:7U()#F&ND_73TH)(:!J,U
M8X=^]O/MH\8_?WW-22XJXJ^"_$U_!_@D"9\)LI#'(M8(KDMD/#A;IB#8J/+$
M*3;S9.K/KI47%02] L=A63-0R0H*,V=?/QGI2)YA(KV6>R!D[X#I$;5\^BMU
M,8.?ED-_,">OBRIHST-MX<VDQ;WT9A56.[E!WW+50PDL)]94,W-..3*Y/#>_
MZQ6C0SLGEP!=H51BDOB2L52'MNQ5$XGZ+\]DX@/*O=H74 =9?4?('MV:O;H5
MAM:!70H,<Z?1\<VR/!XK=M'51K(AZBX)NWA>5W7HYVJ!<"%/SHQF;,B.B%OI
M%<R;-BV? K\G?Z& M#8E!Y&^JN'C2OA-XB6WO9Y4/+'9CHT(^U81V#JB&/]"
M>Z?)UJ-LG:N*IT[D9@PZA_4"C)?1D.V)/Y+5;-J4/U[&'3H;\+6\G@K*&#0_
MQ'2"0S):JU0>'$N\]3D^8&\S6 T2A"M,W[#JW.P=,7DVLC3>*/J"+8<S[(>^
MU6;!:EF9BF]A3B%A^NGM@C0)KYTH.\(:Q99=='5)>:J"T*PQB6 -@L!?SS&=
ML"RY=JK@'$RE ]PK*X4%L!.&QL-)89+_]/#=2..(<GN2),J:Q'NM^UQ"0+EG
M"<6!6VX-D^+ZW34.?Y<_*Z]WU7_03D/[VULO=)0Q+EW>0CL85WU0=,%#2XIT
MBZ]P^&YU11_Y/!]@5N@!_.4:+)2[2P.]0GEMX5-/,9)_X[4!+Z&\EJD8+V$/
M\W=MQL:UVTE5M2:C$JY8%>$>,&7EMFO%&_@*[_U6,)._@@7,(;':\F<*P41A
M $@V=C5DK]ARR3_E-=QEHZRXS?5E_(>S*JZ+Y78CVQO6DZE/Y[M*.4@65::I
M6-V/F6;AKW.[E0Y(_*:W-($@'C5'*$;.WN(06&DSYG=A<;,4KJJ/^'$J;3#6
MEL1$B-V+%V8.^T,KXPR%N<+;2*TUB/EG5)#0\< 0Q0Q75R$_@V>$?MU$9Z=_
MVY<Q'#J,ODL%3<4-^[ M\7TWTI#E>DS'IO !UPTJB5IZ;UN1>5$*,![?<I#-
M<5@'@F@@>!!=N#88>KI\4%SE005Q^>>P5BM@2BJ9[I<$B82Q3 0P2)CJIPU:
M=QCY*L%KF)V$AS-#*\V*IL.>%D[;*P.H L,\1#Q 1F9TD"M]6 [4YQ(5JW+^
MN):O>QAEI%8=_\Q+D WOGY="ML+.TK7>"^'YU&O#GQ_"<DM2&\KOS&>@"GFV
M>P7XE)M44 Q^,/!XU8\,WT FX<\&/2'?F$+(2(G&$%_/G([!P@K;=]G"U]:*
MW":;?LAD9UKDU7M(F>3>)SL-/C^$\ N9/DG2_E<O&NU2OJ:$8@&[CTAF^4$%
M+1<>;"Y#.S'1)^4+@YWX"+"(S\#T#OT'?:BF:=R,XG1PBN-9\E\.,Z-[,J8]
M7RBBET/R"HIRGZ;:KYN(O'G, *R-TW5YD]S7>++B?9B/XVPE5P7IP95QBI@2
MVYV6O.T,*@@6UK<=-3?M_\73M[JL!'5KND]@K5M_V7Y#C[G0(2]?_WYRX/5+
MUH (K?HM<8"?10HUYJT'*2'$(4F!V+U*0(UQL[EAY&LY@V:+.XQ61Z0^IWT9
M=A[/%*#,?T^2&4-@0W536L7B>C7I=>C/ EM\K:A-BO :V*;86F21OQ76<AWE
M;JN4$P<AA#">R83FL\Y_2I35(2X+*=QTI1K[3-WBZ@O1']\H<=U_0?*2HG7O
MIZMP(:1<6D@932U^6V6-&W/=G38M9\D?9KC9C_/DGBUD!O:FX6I,';3"O;?<
M)CZVS-7JZ#-A F1%I76"7_]]Y5_]X=8  X".3+YOP6*'X6448X28"B_9DJ0Q
M'8#(1_LL@1V7OR$"R0%N?OU7V%.L.Z[X<=:'"NF,)U<ZA*)B\O4A#N[E0-J#
M7XH]&)\+M#F(73HF'!'QY/H@=3@6R$LPMJ^.:[2].NTN1WXW,;#U;CGKZ>?N
MIS#I8/=]I/5"D,ASW+:C;7$QA%E94>8CK1:NY 4[:"96M6"2DE<H#B>]KJX[
M)1O-D5Q6]$WHQK=Y5W!IG(,?>^28Y6K^*C5BDDWE&- M7,!65P[GB!M)F!_Q
M.)SCVIR]1^:AN'(6$SR6KHZOZ9U0S#"B%%9-W*ES_(YK[.F'2<VK'I>_X&Y-
M5@SWRBVE<ZL^/>&6:N>]=?_/O,*/7=US8VYC)L,CW3O-0Q9SX+U<^L+8](J3
MXF+*!7+FSNYR__!IB/%X8#'Y>RT3,>6[JH7FIZ_8_D0<SJL&ZF)1?*XFRJZG
M'?J7^DWQ>UJ"%\!>.[7BDP&;=D>AV*GFI(G&V.M-<BROG9V"CJ84J\XH><D\
M4-(SB1?9\GX<DRWP!I57DIOYP#+N$E3#Y%P(K43K2XHE+SKZ:R]17.>A/[A#
M,[#DMJ!GARN=6=M<>Y/-JHF=KR4;!<];\/.V29LVO9<MD#[TW>C:6*O0A"P5
M:18:]K/,B):CC]5.EL ' /79%I/ND,=)KGO(P@!!WNE&WE(?#,2[W- E8MJB
MJO$/4EHWI#C$PZY*6%89#I%KZS3Z0C 4Z20)K2?'\>45^SP-G$#_!9X79G^I
MQ?V!Z<'T[O)4#46DJ=FQ9N$[N0%KL\^JE )_9/II5AIJ([K^9M_33TG+.;70
M?C&"[D_1K"H/1>?5TR530'W5(E?LR?VU5!!AI\U3;_;[[Y@_)%6"X3+,<M0+
MTHF)X72S>!3=M<-1(RL",38T_51V@+C\?7&E*#L8P\/)[SHE&RA3.4)4BA=$
M'QL=DE>#7G@/]C 0(1</&.8RTO?!+93KWBI]LZ>(<?:<TL8(IP"(P>Y4AIVL
MC<EEX8A"7MDZ1R%"9Z*)K+*8ETE!.&_\[1^ [XF362D^#PXP5% *YH<>@0(#
M\[?(>0WV9&:U.Y5'PG@55:JNWIY]('9AZL,&A0IR-F0I_/YL7$P&_YH7:CQF
M1+=A;YV-RA/(H97D60]B22'D/")NVBA#8S^%](*<3&I,TXV-W=+9(4V1HC$U
M1U[BYVT"G9FJ[ZT6#QAD%[L9E*F8(D+9;EDGF9WER!36H3G@TQG\7A8EI!TA
M,@U>28A<BQGI=HZXN\EY!J,@*F@>]76FGKZ;TWK4R[/&@]%0_0G/JT(UMRN#
MVL:,W4PW-MX##"%Y*'@0,0 91HJK/(,/$B4(["0XV86(KWH;&%[E,]CE)YS3
MZPI_N2![STJHX-LE;1W)]$+",PTU ?9=1_X(%$]$A&:RV3P' )_G\9R8S)/=
M@0,B:0PLVG*!'$[DKZ2\L89R[K4WG!1A& S#YF09AX:,%BO\/MJK*35JOUVQ
M+GWJ1IS*K-C(U'I6&2Z2S'?\<@/2!5L-;SSRZ0%_0K(%W::"[N+C$$I+1(?Z
M%%) LW^(8 26"O+FEHSILK87>GO?+,U_)G.O-PFK>RT;Q52I*2.K_W!$Z8P-
M\$E[?]K]C;PUS &W?CWF-(N;\%+<M5DXCCJYB-#0N.KQ-TE!2)2=.362VS0N
M*U(X5MI7)#ZS*)LI@],JS?C,(/K8^/(!-ZES_'=*-QG?5OX13*\82WI/SMKL
MCU:=5IZO\ \3CFJS\M:C0VMIO+>M\OO;\9G=QOY8W-B093RRVRC! )4F40^%
M>>U$'G<A5C8I_5""&JF4@)\'&QSI:=1X:YCM!F5NO\R?9:YNM/,Y5+%-OPB]
ML#)H:^#@3\QT_A!5^& IWSB:H#\B?D=3VV3G$^"!YQ!M!G)-B6 Z(8\:?&^5
M(]G8SW_"L>,=R2.F=T'*[RXQN(H';5O6 QT>6E@C^";BI U&L$S,A\;H4%7R
MY^]Q794 K]C!!A%+1MPL5%"BST!,UXMF;T;Y]'4Z"G*:]8IV-[.37^#O(:<_
MK 7+'Q:3Z2(>2*L7Z$25__5]1+C)"O!<XPXJZ-*;$GRS^/[$"@-A?D=D1G,;
ML@P$*EZB&A,Z="T!X2WOK&#[K4'^GW[I4CD[\0NV1:GIJG];O(Z[^89?<#8@
MNXK<TD(/5R*AR+_ \VI,&/$@I4.[@&&GNZ3-B,!TL+553G$*/9=+V+>4N\2>
M; .X9U)Q5)Y4[Y6X+GJ9NYQFLKR *L.0S.%1_7!ZHCT51*>01<35+\V!F2CG
MC]6/N\CTLS@4CXKV=>W/!5DS/3B7:$<I64;CA;>F(DI7^I4,.U.GI!BA;2;9
M:%J32U;Z@CQ9L'T!V8=?.MC?A+N(3#<C#Y!+XW@<4M(#J7PCT^ST,'8F'26N
MV524&_':-,8_S;-SK)GNL6VXS@]K>/ W.EIS"2<51-3G#]H%G%/L:@Y1\=&4
MJ1C*"[Y%8AP%7WR;$6+(.&*T+,7*L2-7)_ZY/#CB&: -\R^-HV_-QC\ID[%[
MX<$.G*\HHLTQH/RM=SDA=9T^#,,6@:Q1$=S)Z-]GK/HF,Q!]5Z#1QB8?U6GE
M>/.!G5%Q/H[Y>07_E]SWI)QJ=Y%8KYTR9&TC]-5O.^@1@_M1_F+V-*?S6".8
M!R,_L-JUL?=S8=^STL1DM/[A .7^'<OK9Q5KXIA3:04F?8T.[M6.IA9M;PPV
M0FR7T$I*'4&R!+UV.5,3= ^>-]BNEA(B82+L+IN?X[9=HB0]Y@P7&YT\2DOA
MJVE@<XB W7V\OUBX7 (PJRZ)GDQT]$;XD(,W8L.09U2>D/],X^G=L0P'#'5H
M!PRK:MBT\5M#D_ZX'_.6!<&U*!^7*T]&(?0N"E\,JB4X(;O2AHD(KYTD*D@
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M3.N1*HT/4+5Q>MFSJ?)C,_-GIZ6'A3WFZ"[,QEN 77GQA*WI)I1;7S4EKY1
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M(V&$<F"U6$[QDY<X#?BWR_J_D<G(XW1N3L1!=P-B$_]O98"'3\C55%#3)!$
M_4S=7MH ?6!5Q8)=Y9&-8?/00?'U?<!.<+G?,X$L<T;F#)+HVM^&K6H6LLH6
M[-6_AXS>*;G=2P1Q_^N*L&7I/ZQED9H H3>+V2I5803@' WL_S@O@3:U8_/7
M13(_>,GN $1\-XRY)P?KB4F<5+1"5[!RM B^<8DR\<YN"7>;:LJ\/ISM\$1F
M9U@WRH_ET3>-9X$/:0_>+E!!/Z^#Q<&[<BH*0/ FN/]KI#^MQO-/.,F>"O*K
MV <LI)2>0FFF@0[^]SE(+^2D/S8&0UJ:P1SN DMX&-N-)&I@NW>C,.R41_"X
M07+SFG-O,/%D6+&\\2# @R%L1M)X25@N\P)&V5!5FZ^+)R:_C.U"A$#"S[(>
M\V$:TX9($#4NGC8/R@/\&PWL]-BUFF;!PT?_X35YIS9I>8%_!CQ0OAKZUZ4<
M5/H#0FCQ=?HG7Y/4"YGN%7_C2#(XEEMIIS6BP<#_KX]Q]\]?@LNHTQ4L%D8F
MN,#^'-,"NYKB M[+>+E/T4>R'T&ZN7I)#&/*-<%SL[/1ZW2Z#15N4_Y:]2*$
MYYR]F3%H32FZ;S4R;[<++6U@IGXYO,.E-![.P<S?P!\]P@ *>-\%0=+%_6N&
M#L-_KGQ0ZGU(\4$J5.&%*"_@?D0?\A=Y^3[EFGV6>EC^<8JC<^9:ZW97?A>=
M=2'DKJ!PI0A7#/3Q?'9,68GZL[!$^5P@"P!PYKJB8Z/BX"+VY1&RJSR:!/YX
MBD6#(Q%P%65;>7JNS4) P-A\Z5ZLH.A05,+8-6%D<V9-W7@8ITS0^1(S[_$]
MVA2GH7\ASCG$/<RJ((%E 38X5TV!<=]"I*A8K0HZ>D,['1#QU9"0+31]@I*,
M;N;L?;-I'K7X:=8B4Y-0Y6H1W4?EX;DGY3=&SC+$PP!4PD<C^\R7U1US55Z1
MWU%>87H1@5201'_(OG91>OW:^_2#RY,UN$:&R!\N3G/KMWJ<;+E=2YE?7H@\
MJYO]8.FUN8"Z+/3]PRW*YBPGY#U>1 [?CX^8E2 TVCG#5_JF ^=KD'[._54-
MN:@47NTG8S5&H[TO1DM^]QKS&6WRQ?T@8!D;HFT_WZ9US,G\WX74B56) \;-
MV."3Q7FHA:MR=+-\[0JIE5#L#'^^.8X35Z/G$JD#)V*M\GM7!(LR;)D2+\5I
MFK#YVB5G)7;XGB$  B4)HT)Y?@1K=TG&-1>/P:XWHE:"%OI]+DQO.E!*UC ,
M^TY!\O(F>Q,N6K%BLBQ9'=A;#[,E.9*2F-R,1Q<+N,J%@51[:"(_"84*]@EV
M@*8Q)Q4Z>))XQ;Y^7OHYD/8S72[9IE[.\@'MT4'7?U]6RIAC+[Y<X9V\-G<2
MGSOD/)M1YUAGXE]A5!$1R:TK;F&4I2%F%7S3,>A?XWB,&0B%E#?-L>2?M4=+
M.SH^;7>QQ--]J+BN*73_&",_#N0!T+EVEM2"[S:%*[C/]91CE_%%@J>L?F6W
MLHU,]H5[8T^]1 +*/3$45T1?+(4M9[X%MES^AY4*@H#;3AC.?P/D,_><Q XF
M@3A:U7&,Z$"\<Q$'.\]C(K<&XX\(&HY(KYUP?"=B-:ZI"B_VIWQ>_N *!=;<
M0:X[&5SBDTV ^Y3.L<>R-WO';,;'W^_N[$!+$ILX9*8:\J6>5$="GH7SY$3X
M?T1U#;4+HH]-5"<QXB?R5N2=-<C'Y\BP4WR+?UT].EUQ,AVY<G.6B0J::<Z*
M^]$OYMF(N,LIRX;^$6(4-79-*]H\RDQ$)UXW+H49,/O2_U!3/AW#]"F6 (0>
M"L^D6*2;V^T**0*._WR[K'V;_N#SR=.W!]KHM0K6%R\5&3@\=*$F5IVVKY/S
M_>)3K9+WGB1$&Z" M9W]_V=\>(3&("R^ 1(&OM*B14:U;9O1[R>MZ>7T>CM?
M'>PQZM: Q">PGOFBWPME,NS62S"'Q%FYU[6$UL2BC\U2O#!DX1%2S?'=_G9O
M>3TJB"=S<WN@:>8M6P8&@ZZ,K3B^>;6!*?'3L,TWW-4Z;H/7GV3<2SRDU42:
M#,['<=)J43F'=]=FTA>+_@SZNXH70RM\@G8WM^369LT%F@5BX"K: #T4EW7H
M<NJ\'>6K_U.8F3'^?/CAT*>UDK\!;?3W_V.G1U$( B&G4K\9NY(RAN@9=/^-
MM1]Q'<!/HK[)H;Q8)85KV*(L*VO:I/A+8P7%-<L[.-QBV/Q8'01#U4?.^+',
M!GRM*T!D2F#G%A-(7T=>^8]\*W#G[OD3^=:Z;D"NK.X,WTDG\OSI_"4YG!D\
ML1ARTTSG!E9KZ@+J+[/ZQ8*]:NGW )EF^(21A3PJ))&])XN005@DOA?9%-!X
MAL#>)&5A=1%F*S)'MQ4$OE6IP>Q9Y5SR<NVOP%88N\%BXI,-)4.E=WE&>0FS
M 3EYD^#^G5@G*D@6$H7LV608FO(]=O7TLO01H(*VE"?BS(R_+Z+:ES<+W8P^
M?Q;.]Y_)*NXD.O"EY6>*O*VTCW%_!B!-!@5"!<DU@1\AI/&AL%Y>!D""=S<%
M&8QT-TAG%"=TJ>I&MBYDY_<-?!M^]B3!>*E2EC[,2YQWN%V/\U;@D%@<X.<V
M2![%](O[$]DG 2T^<H(2F;A3Y0G3H,Z^U_>X&)J+43_T=<WY925F>L_?S[0)
M>\S*]^3<[+_F8PE@>NQ(P=WDP2!VY_*4]E+#0DG<1-".<T/().JV>Y7!T*O*
MD85?_F@JJ#9'*Z(HMDZJ(>;O'(O7S'KQM'F32?_7E!V4Q'(K>5H2T>>ZA!T8
MR)S*T#">F W<&PQX=AAX<VOF 8]ARHQI4OG LY4B@<Y6K43?+UYBD[E::F;H
M;H>SFF+1H$NLQR_7%TF="-DH>4+6FF[(5/3H87-[RTE"U>UU2OGTL'4*0\2+
M9EVEFL<HV7@SG6AC97IE)0D>,W_-W$341QFU\4? >LI_2=U8WGO^HJ2;P]!Z
MGVGJDE7$'^/\#WPVYO&>P>,L?#C\?Q_K\[\T6+^PD$4U?N'[7>.HH#[<*U=\
M+#=#BX'/0$<.,:2FMM_V]WH,9C8]A_&F%M)CUS\B"I[*P74'':.P=KLX6/.V
M_;E"CB%%(=-K ([6A%!!H1D4>\QQ*1A(M_\(G+!0016TB3H"=2F$GQ2K9J_J
M8X'3+>[ETP-'2R>+]/>%,SB,O^O=0KQODYXHN]KE41-K*5.VF2M,GC(RG]2'
M=94(?/KJ)3L]7VD35!B;KEY\@*[Z[%Q1>V_*&=O@PV6&/%M7>W0ATZ%GX\]&
M=WQF?$1$? 9?05%Q44'<G=!;<;GQZD9JMJ\8T,<:* J;#RF?"@*T H(*6DO?
M@E&P_QK>1;3'KZ130?XC)"J0Q&2[5B!..&@ _-.0<N/,?M42M!,1!A;VQG91
M0G;*8W$I;\DI8<K_X&9G:SP:#=#H]\Y.R@]*<W('GSTS,AJF^YC)*_-FB'0]
MP23O-J!XZOY+V@1X\$+@E!1M>!5)?"]L&6SE$O2S[8CA>_1R_3$6,G]D["*0
M3A]?/+/_RZH\UGUDXK64\5CB7ME<_HE7=C$6S8+LYD/G7 ?VWLY(KFN1>HWX
MS+5.L95YWKRF G&A%(2@*@]';(M@Y\EW_Q9:?_)S_N.^VO/?OG]\GX?=,P.+
MC)1J]])J&8$TZ\'PC.#DU4=PI5F,G(]+>Z\W%Q&1>7J:2;H^VXBH<;@W)?;B
M@076,+ZPVW)OM/J^DKG:.X^D-%E460*/9*26IB'/*&PV()N]"C,O!^OEMO4^
MFMER<&Z8)>TT3;&O!ZB6MPCNS&XG=!W>/>MVVJ]FN"*9KNXI)I"F^3T^,[LR
M^R.6R8U.GS6)]LP1F::?]< \B#A$ZVX<AK=NM;MDV[6KK&).>3 :]0,>,9UQ
M?M(\Q&9[H#LO+T_K_NTY7S+?Z"%S075W%F4X_V.?Z=*77K%8VK11'?" (TG]
M$/,((2[Q#G.&PN[%_=8[S&P5D5[6.T/:#F=J4.Y(OD4>']FZY<.LJ^NB\+>C
M4(6D86UAT52V%I]W7-&=9[1[9(O!=L@2<J]J7K"+H[S[])W^7'/>S&:U[:8+
M>A9YQR<?XJ>"G4X0XZGM'&0%A88PA3Y0<C>J<7DLM+%IOU"JI=7PU14(*3*1
MGQSGO[BRV@U;A4Y204)[>/$_&IQ-B#0)V^W^I":%1K?56F6)5UNF\C&_BOI?
MB=KG![\P69LB/;"Y9@1AEO1FA#"+PPVR)&FU90T[A" F[#2L%I,2BFTS]&9Y
M!L1BW$Q  )HB_]]X>^^@)KMN;3S/8R^(A2(@1$4ZB'2EY44$I$N7&NG212"A
M!/(H"M*E-P'I':0W(2)20Y$F-41Z32")D$1B\MTY,[^9,^=[Y]?FG,]_&7?V
MO?8JU[7V7FMYYE8-/-'0D-?R^O'$8GS"V\TOXP->2U+#PBS!TJ,XOB2=WU)\
M6@9MYR[HQLPTO@BSH.EO26;G<'WN>H!(F[U.[]^)([!!>S\%O-0W5&9GFSA7
M1KS^>\<UNA:<6)"IWFUT,NHV3_603"4 UC3HEY%W]B/ )X^C.]94^ROW^7;V
MDYM+9SL<6U0-O.>K5S,7LF&NZ9HG?+3E5'CE%7CU]46*HMY(6AQEY0>7GYP^
M#4@F-6>?EM\E@HBDVS- O,C,M-_5>[^A[\'<S8>"F/G[%T^%":I4IMIX4BNJ
M;,U#>"S"JP>F+!Q%_1IT#>4$'[Z+B$@?N//T;\!K11CFY*%K5\^0V&=#M!QI
M\0M<U,I@+$P#I5A;#_!4$9-_,"$6,I=RN&Z<AB702J*]C/KVWFA?&+QX55G_
MSA5I0*ZL/Y'$O2WH^G8#N6MQ>YCL[]/9/Q\T+S&]H%*)#>D0Z8#+;PY]=\SO
M-7&J3S7SX5 4+<XO?9PP.V[4-U 6 ;GQI(C9T\7[>/M2.U5B(J>20&ZY%^X;
MD/YR3SS/9A]Q/W$YR09FGF2E$W[JD5ZR\?2C^J";N8*6SS+YLP0MKSP%=F".
M!4/2\U[LCZTCY\!#FYNYVTDHIV?;1"1/^VI'NX_<"6_]D>G ^2Q+>1>_6QS0
M,Y;J+62]ZZT%_>;&GQ_<]]$@7Y"-*)S$=TZ8=$%2EW[A;XP1>REV8EO%]*?0
MOYO3%I8P_RBXZ$W[7/JVF./QKG!!Q:=)QC]CQU-3@2)^K]#%3P[L_:OM_#OC
M+$7NJY]: 7,D,<W1#"F 3.[_ADT!2__NV73!C\";>_?MVK\8[=&^Y6ATN+^X
M'[<<WF^*MM0(Q_RZ,CDFJ'6%W?351DE);I18TOUR(@2NDWL"W_F]?XH!0J.+
MV^&;Z4-Y&[S-<,AS"[@A>B2[Z0CBA(O%>0O:UJIK-]9=1]Q5U.-E5[V:+J%O
MI'+WZNER]ZI4!^5:,8T;P@, T/#GI5G232#7Z&(T7ZH2P9#'L/.XL#C,AFRP
MNW]I94%EUR1J\$]O&*'?OB[3QHNK9_F%5/>[Z(N\2A.514WO#>R@G2Y7 CMG
MVD%=]QB@FV/A2+;CPAJE2F?OA-3L'PV%?B:N8<H!8QXPE^5A+[ZNM$*.V:C5
M><JCI$3S7/<'I:Q\#VW^\6E-95FYW,_93K9P9I+[V!W#M<(#5&47/Z*(HI4<
MAL7%1U"#L&UCB9T-T7OZW;RJ:GYMLT>_T?JQ SAEV$Q:-KNZ_'Q!67&$O9%P
MAC;YVI0FFAM0 /2R*_$I)?0@LA4.&5#)SZ5>P(2NMLKGN-HZA)BL]1W68N9R
M4$T[.Q<9($QUI_'!]]@PZ0PPVUVTQ(L8XTZGN#M5 (']RUJ!?BV.UBIOX>?9
M-5$8N>82XA100S/XL9L0LS#YJ<$ROK8;7S1@YC2ZDK^0>4+%T<FIHM+O]MC[
MW#2UW^4QVC*Z 'L)I_;0LE3Y:83]2RBJ&(H$2$H1WM5\&A/N4.N!>+YDEJTD
ME;;PY(>^U8*?I)'A*8MTKB?39E>T!:0G9BBB=^(59W]]=0#05/^J$-&9PD50
M*@XSHOGOJG8L4L.2J.$61A#_0P;(<;/^ <6]L+RH/!\(^^W-FN@OE?JF#_4.
M7TX7)?8^$0U;UQL!-@/I8X"^NB+3'['E^*FU*K@.AWWI]V^FYB^%<D7NJ4Z-
M.?MV"-Y = 5[7IKO&2UDU0B_=D=\X%>#6<O"MXB&/F?MT)GV>KY2NIVMQ"1*
MN<N4 ;J':V@[?MC1'F;GB:FM.Q;R=/7PE<8%<^L7O^M9]IUXME5^D-+F[AZU
M_>*]G*Z94^65]2 KX67-1PD Z/?YB$Q.[XE_1ZDDEBZGFG$^([NJ(_KPU6-+
MG;TM(7FWU(R,7W94))S1LM2/JEZ8S6F3EX__!_=;)]:_LI)?R[PD7VPXYEP,
M)J1(\BMDS?$@X6>"WW?XONT,>=/]2//[?  O?-(2_/ZXKS+ )  _7Q%]W6EA
M03!:QUW1T^"!8]2$0JI[Y>WH@I*S.VGGEO@!L[*>QQY\P*Z/S'<6S^;\8[$&
MM]S#;X[]\.XB4+8G5=YF+ZCX?JY/G9C458'Y>:T./:Y/+W7@_UA1\$_FADO4
MAX?? 0L/RA"_J^2U?.\8SGJQD?+ADFC>A9C27+<*7I%R^\<WM<K*DZRBYASB
MU)(L@F[$&>Q]2P90KB5BDZZ'O40/.0J[T G_ PWXU1^Z#)OPM*K!4_K;=V"P
MU2'<N"+Z[M+P5(^AI6YRGVD?7PZM<:-8I#CP9UG$>#VS>MJ3=3V=H% 6=AIF
M0=S8KLY/VT$F\%9/';>4MSAE:U8[+4KW=KZ8#M3#^];/N2,R*A:-)WYPQ%?4
MG\\H?/XQ 3>?QE8*,#P6!NBRZMT]UK<0KM]^*[7F+@KQR-I@K><EP_.9N5_*
M"BJ&IXR+2 9W!DP=ZR@57.YRHU\:9=\+_//+;@WP)B<0AW3+O!N0C'A(S3K>
ML]1OSY8!FDQV]E#T:6WGA*_#<C?GFRPK'A4,3*^XB]AY>IB:JMUP[ZN/*-?Y
M&%L>5<2\)9:XBKPU]OH7 P0*V:7"<-LAI1X!D8,CR^_V[I)P[;S=^N_W]'OS
M>O W!-=C)*&M?I0/(Q>; LPHUZ^^\%T"7VRR._LLRU$:V P$\89N8?L7T83.
M<WQ\V'$<R<X L70O9)NTM4..2]]_[:99B#0P0&^0%\,#_FQ@:X]WSC% K[O)
MVFHT:==IR>C  $& S+W:3X8.'"]#AUB3'M2FM%6U#-3D['5]Z3?^>;R4MPK[
M,^R)<'5:+7-C8><]?532DU)6$W'V$;1#PTC-3.3U%95'=>6: #<51 -6!T.E
M[V'_5F" B"MSAYCC'TB^$)ZU1V!!4C*.95#=K/7VXA-'PM/&Z'2AUH,@"G\?
MM[B<J*RD[IT6<]_[K@Z X;7E+NQXM^Z'-6!5%!86U%E0[>AZ&,9\?.E8Z876
M>M& XRZ_U-C)RA=#G@'\^9:W$\T?8^YHV ,*]IAF3U?+.TT7(6O9P,V',& Q
MA6I7S8V245K@;NZ/O9&>C'F54 E-B;IK_4T'40*WJY6G_ SXE-^T@;"^HCS?
M;L5+!N SNC217X.[3B-2\9>&<#AT>YCEGMR^%U:03&6?[K2<FZ.YC.UQ;]^Z
MG+>OR5VTQOOQ806A/Z&L_UVTN._S?P*9G4Y?VEI.'Y\H:E]P"#ACYF5C/K#K
MW3"?HB3DZ'7C=N"V+V4X0-%X?.+K.9?;]QU!'0W:_+9K+C 7569[L%'DVLC!
M_B;*]6?'#'*:#-6#+W%Z"?96X/=C0VI*7;V5:S#7JNIQ>R-ZLH<I;<K.>O;;
M6+2!NW&61?SY=UX\0NUD=8XO=$ODM>#(GZ[.R+O>6?-<WJ44PCS&L",X&Z;=
MZ/Y#OT?<>H;%XLWH)H]$6NE@='6OA(3]\YW*F^71\M%GZ9AR>QWF?$@LX<0*
M_@O%A)!7JBIZZ.(8N/F;7 2+]APIS]P['RU:-:(A:BB[HO=64PD<G9]6:+-W
M05W[[Z>L&GC#=K(:!Y5NAY$"0"ODMP4UUOO/V!S5>YE"GJ1ZY^Z$OI5PX3_.
MCHYY0#-0K@D6#_IZ8XP<7Q\C(7<C]82HR(AP-*1Q*FNLG6S4I<8 W5U*H_*2
M3BS/C'1.MQ^;N).%OKJ1K^PJAD991Y9^<]XFRXF;!G'SCAB^[W;:K13AR!1X
M; X S]OG*UY//'@^#, K%PJ*]KG=>L5UT"<;*_)[T^\HPN-36,B^1%N74CAK
MIX>OW'U/+[O9!!7>DR'NN9'GXFH*2S/A+(:+$EYV:HM%? ]N3]Y,QH24C+U&
MH?T*D>EU5 6U\8["1N*"^KI0J'/7(^_XSCW1SQ(NUWPV&H*3NI(])E=?7(^.
MUM-+J=37NU63=TOX=72JOIISZCH CSX7 :8X@!2+P,WCCB\M[G/S%0SYY,];
M&KYM_;-N<49ORMO^:9.ZG.!8?(II$,<='8$"F]<KR7Q1CU(N_/V6F?U."*@E
M[F_?K:.N+R&'=<&M(6*^\-J@0T'.0M<>[^@JY6P?#QSB]LJ00W,J"\>E2/Z$
MT@$S^^V*70VST!=)Q9:KERN? _[/,9T*^U5'=V3##J_$!!R5"'5QKK911M+G
MK^\L*N(NYIZ@O,D4**_]F'SJKAMQ?"K#'\UA+BQK;")2HNC$=#H!9._)!6N2
MA[=^0N>]IYWC#>3XT[4>^.JF[+>BPL3K.[^#1#R>5_Q\SY:550'HYJ-GZOR7
M YE9M:*Q>/!!#G9]AA#^^?=QA[R* A+_ :F#%VE)[U^*P:D<IBRJ(#_)R.F;
M")A#/9^)71MM.Y]9\6A,4+/A5DG)=='5ISN%)'  /@5U%_7>X@LR(V?NL](^
M#%D:7[C4V6!X6FF-_4Q_W+IUT[T_R>J&A@**3_8];2Z;3J[9.P>X.94>*V8N
M"0]/#EQ\;0C@_[PDR-"U%<Z!_5@DI^HM.;[?VZJQE%>8;,?.8#_/7P$NTJ]6
M!G$ZXACV4QP//3? +T(W%#]YGR_?S1 /.#1[9"KWLD,/8*!;IKB$]?4)3"\)
MO=)"NK2XD-<H'%*ZPC>"X0%7-_>=;[G&,5-3A&F-[>/D%WP977C.+*V\['6Z
M@I*)W%V=N*NF4<7Q3A;:*C/M9PZ00^!5EQ,RM,F&E!#LYSN5=.\.C2/7P>L[
M+Y]>X[N:>J!4Z\,E?]^V,2ZN[%AB^>ER?5RFH;)I=6%?4K]"._GQ$H:NS0"Q
M'Q=2GQ_Z$&LP/ S0&LN9_M&B9):["TOW+]8LQ@09O @("$C)"WU?-I_Z5/MD
MTH_6[-ZH2.,WYU9O-@#QU:G#D1KDW^*+(%*J:3TM\INX\WS;E,@&N&;_KE?=
MZ^IOO4V[Y0K>_%)O!P8_%)1]-7.N<+]9/#(Z-:*;5/@H];:;8R;[!"#;J,@A
M0XIA'I%"M<8L['?"97E)TT&CFY6O*]?LT%LJN]"FYG[GT$8_<>W/!U/?1WB?
M$=%D5H$;*3*ZQEU!SO"TCTP0%T<UHI70A6F5E'5"Y$J),2]ITE:"P-EVE ?W
MWYC?&OI@H(#;;791D(K^YBBZ(/5V3$N53P>QB#,M2S37E^Z77"H,0@!\_*QM
M'=,#M'8%(<SI]@O9?D=O6?UIZG,=A8Z'S;/=YBL.\X=3V2U7,KZN.8T:F=J+
MUD_+73;>V'1W*1XT*M!)E*T;CMX&7*OF:D,[UA7.:;-?4[JG9]J&>3MGK7NK
MKJ7D*G?%$$=5[[J(<V%M\7'[N6T/MUX-V3&N0)?X?UW??L&,"4]0G)#W"E^P
MT;9_/M'5<58,4&)H3ENP%9>(Z@//)3+64F*RN7TBU_WZEF#I7&![66&P<%'T
MO9Y]H9KG3A-3N,O1[ "0S ]+H"HC]'L -(I@@$C\"Y8U1_.AXYU"1>@C3JA7
M]8*)_B>XH"M8EY=/02EWP2&G:,!B]6-LUG.K*L>",E@U&R2TH!@(L 8(+%T[
M[T(7[ @'&6 AF"SQ2BR9X *;3^_C?&*SZTM=G<GR"_%/LVP[VZQ$@X?T:J0K
M<F_I2CWGJ)K8?BOZ7MW 'M#Z;U[0];R#;!<:_P#@IH<EM9Z9K)A[N$_CE,E6
M4Z;FGU/1M@J8:2?W^I7BEV,?@G\VN259O:V*J+A?^OIY[O5H0-<LZ%<8('[P
M&^3)D-QP5# >A5*RJ)>/F"S;[<H:H$4NR5E79-?"IDV?] @NS0'.QVC2P1=]
MPR#Q<Z69)9L9^STMTT\&!, 7=,Q!!_:7?PQ3-$AG?HIGTK<Q?T1(%NVD/PS0
M7)#M:N+"(1?-8'6T!"-FU.R^W=S+)Q^M+.$R\[&J+WKH//5VA:;;>GEL%4!A
MIK/\)8V>^)_1#E#0<H"G_=D3UWIRN,%?3>!9:*P4(2HE"&E'Y$>"=2VR!XR-
M',MWZU].?HD(?EL2.2*PYOQC&(A\9C-$BV6(URHRH[27 =I0(8AF/Y^"L:O>
M1%A3LS^UI%F57E%O#T[F-Q'P?Y E8E]4^Y;LTC?\;E=XY3G_ T6'YRY5$?=O
M,A/<5PEY0[L?I:#B8;ZTWE+,GZ]_LDG')8306XN!(O7735[WK?CR>/ TE5?(
MCXCB#@>,UJ#@F&AMIYKJ@:_NW%I/KTK7 0JK)D23+NU-H+CM4URA^^0!UB-+
MY&8;7:P%@D*2I)$3Z30;!J@=A6& *!3(( .T L W#@9HG@%Z!5EGWA0;(]KH
M^DRH[.+ID[ 04N?>D>QPI- [DGJI>VLLB5>H#>H)X[@ YE"\X5%DF:6C\+%,
MIO_OH6TC-7$1&9WO&N<-%9EM^!!@HB_%L:'K;[(6<6>79O',\VXV]0S?P\J6
M%CR/!(OW[U'GETULT^Q46OS*Z!/GU9KAD:,7WP3*B[*$?\;=BCZI\01PCH]H
M[^A:*)8P'1J" O]^W*^"[="2.E"OK./5)=2N&9KA YL9((=EW]980:&_&^0=
MDCE\V=F;IEIUM-VOKWS3-8X3$)>MY.\#M/^**J!VPJR18#2I5<GO<YBJ$:P'
M=B8(IZA2.C>G^AW39CL[)U>4Q!U9DUOX0, V9,VC8B5HQRDX0C.H^/%*]!4V
M(T!W-<FN-(%-JAU^IP;=9RHT^)G3&'9WA4[]3GLQ'QJ5VG>X,3NJXF$VM2$_
M.E_R]G9Q97E<G%!\C=6\COO#V_DE14[Q&LP*3*4$*I06BA]=I-MV#K:2(5[+
M<%8B.IM?Z%_+1Z-:5_@4[K0IARWTH?EVXUM.02W?/W8[ZA1Z]WUJ]:G2E&S<
MS<!O=KL8>PJ95M-^8A5*N\]*YH23+UG0;R!;%*!^\$ARPZVW>11SDT D)UWH
M]-2Q"DKM2/8RDCL/9XRB?!@LD10GN84R!SM<9H $L.$4\+K?*[IYQR;[/*:3
M@*R*MP[ +>;N#DP.=OX<F,)[+I&XN,73%K\M/Z.+:"6.F*GI-/XZVV#TJ: B
MNEJPC 2XN5H4,8\B\X.WA;;2CMR ]JHDDPHZ5O)Z\A+F/ICK;K".#@U3%T.;
MNN":%X2:GY?5I62G1;\V:3G@\7AARNX9!N%A"Y#%=E[MD;M>0;;;A=O@K[&W
MO<B,:\LIB!%XLWB](E;0E5?U8RI;TXO/[)?;C*LXGCHYR]^</6"^X9@V0MRC
MZR*OJ9[U!+^WA8YWH-9L-;NI)YJ)QW?URV=#.DF-/$HL6='Y'G4=?/$EK]Q\
MKZ!5]%*-QXQX [QLM>)V=RHFKO,#;K8,>3"4QP%9+D4MYR!1V)N0.6<&*'>3
M4K-(!US*,& H.E""'WV' 8(S0*L_&2 A!BA&DF;- 'G03S) S,NE+5>J(:V*
M+H#HW^)+HS! & KO<M)'"NX2GT$B3J4Z+?E<9_-TV*6(K-<)8M&+UP?*E]+:
M5@LCM%]_%2G.%2Z6[<Z/[,=W3F3_=^07P>#_NQ<>S =<7PM1N%[P Q0Q$[F_
MLLO\JP?P96=A#%!F"ZT'2;AQN$G?(S-K/+O>V?W7>XE51]H6!/<;*0,AO."D
MMZPRH]V1P;]]3#*R2>? ,4#.;@=Y $R9 2ABISBS6''^F'[-D0'RUJ!P,D 1
M!IL,T-(Q#%A[A_B?IZP\.D&M0RY4H3)=Z<)G7B+WVQ>9+HJZ!.S_/@2'#T+1
M3+V _]H16LK<6@7KO[M-Z9*'C(;3L:4D&0:(\R_D;AASZ G4Z7][\E+&29.P
MIF.<OR,IJ&/@8$-GW)FG^@  [[K(N=,T@%#WMC% ZPI>S)M$?\C_MY[+R0P0
MS]$F:8ZBC<&.3"(1IG0[VP=MP>1&!B@#^0S14+&8=Z>AX?N&0M?W 1?BH?]]
M/E2_/?'78^DD1TD+CH==EB*%254FH2F'H%[F(Y]L5!I\]$\J;4B5P[\?_2>Y
MI4+>R38YNKP88\U1 :_TY$"R6ZK*R$5;;1;GTV\9ZD/U-G++U,Z6E3QWD7HT
M.@X$"BTTLT;1$2G+F@)\XCOP0<E^])^Q9KHL+8+JG/R1;B8$ZH00PD_(KV'\
MBL,HN+-+71>=[TNKL)^U#9 .Y7]XCJE(4X@2ZJD,0.^CZ0'P/F1^1\NJ(#24
M!MJO[=@"X$Y@T L>]#F:I(>/IRRR3^K:*PDA@G =&JI=2<.QF,GV1#';YY>M
M.B/:J-<F( .K5&Z:#24&15#1(O)37WD/L_97"?FNW2RNSG/QRG]?4X91JH@$
M/R68F!E&O2Y(027./+J*7KE=7(X!@H4J W3N&+I&9K;.0>O3/H6@UNDT:C^!
MO ;MG:]-!/,H)714U$V'H,^UW9.;9CM.=YM>?QZNG_W:75'G0U+09X>DS++E
M$I/5BB!@,3%;.3")CPY3B:)]"7OL'TGBP8V]X442(.OFZY2&@YZRX%?/%SS7
MZA=47V?NR'3&/)_7'U'/"9?2DC$>3KTWCGZR;R!D=?\J (K_@5*>C'V[M(;!
M"B(3:ZP;NIS);R%.<-9!>@.EML,]V*6^T@-7C6JWD(NU2??8N_A7=2U]=]\J
M:[@[Z7QQ6=IC_H+^OAO1SDQAOV. E/G05"5:)20I?JJ<<DSL:&_ S$R'9C8&
M,T!_,N^B*TO&?&[@>$-ANOCB,7/G[=WE ;.Q$T4O=>\XY5V5/BF:#X3"8.KJ
M0IXHW8,!DL_)IGWL4D3D8+$LP<F.B']54]V(X1V*TL'/X7@#T>%&I1"NYH-,
M$7XW&'9^)*G?3,[TJH1>C"7_G'DN*P3@'M (K$B8HS_$"UBK=CV(F+VF:;UV
MQI[VF#)I1+1>00[J#PG7+:#E&EXNP"QC,X7=N+*:2SV=/>I^[;]W<+&:27G<
MQ_4\%=A3T6^^?KH[&W0 7HW,M4&-Y*US6#<K]L.T587RI46B]%.AK_+:(./5
M&I=6"DJ*WK:8:^H<6FWM$%&^1XWBE/E'K[R85Z\MM!V)@Q"E\M\]]?KW"E3>
MSF38'CS_ND5 <O1-6E :J8*3J\=Q\D1M#VOKL$)F;R*HE!+K>A[I'-V+)YEJ
MB8!376>1+*K*"%<*2GL)+'KLL5IMR\9S+-3:HIQ"P.$JM=,<R0NNFC("VDG:
M(C/6W9M![V16,P%U$<D^$8SHQ"\UTF'0P89UZ+#=PC LLCLG_0W.X!,U^8?<
M"UP<M4W>''I:(4?U@FPC]Z-$7746EM/&+TAR7I?L:N+S.Z6T 3:GWD*[D[>:
MYE>+3&6 +&@15=0S2]GD<T2.!(ANY)8$(2NKQ<F38QZ3/'L]<WV6 E>](9N=
MI3OC/,1*;!];\@X#B(\*\FLG"C?*TP+ .DX'!@AOZP.(I@[YM?9FM@OB)J6!
MZ.&MP=:90#"AO@F8\=S3N9Y,:Q!2]G4IN&\E\GIHBCAM?EZQ 'U*&^+ ^84\
ME;N+N8Y*8X#$Z.H!^R0&B&X*9H/Y/'<Y0/*%,$!%Q[HOR&<L)GL>_7K0CD$U
MD&MT64V4&XP'K4^FF+7^#M):&#GK=UX\_[L;4W\M:&J[AAL/:!.J=DAY3)LU
M;;'+#.&RG?<..QP>>!AI%D VZ(YG-^J.P1R_K?-/2(<55]JB$OJ?J.G2!&*G
M4M^=K=+F/_T $+=L3@Z*;HJ4-=Q()<&7L=8((@[Y#Y@3E<XW-]NJ[0<&[_I.
M=62'^(R,ZU!;*Z7G@K&\.O:^TJNB6Q52(G<^_>C5=R\!AXC[ IC.Y@ [)K;N
MHP%@(<!OG$.%.$HU=H W#;_XI 7YK#- &O/KPH7YBVV.F87?5LC3!H+<_D56
M6=S:N^O'LMKENR7?^F7C$Z>G! !S,.\Y"*<&(Z51L9C=J3^U\\@1K4:ZX6$?
M89;],.]NL!9*RM=IFP=FZKB5]JK]AY5[&:>KPU;E-/I;UD]"M\"V4/)MHA$0
M-1Y!.2#I-11LWD'1_L:K1C=5!&UVCOT/EY E&6\-]\1@+;7?+S7.?89]QUSQ
M#%T61=>*U=_[OF;!HA8'GSQ].RTKT5KO&;/51V_+QCHU@08@^RS(Z'[D'RV2
M7VO7.9HEW9K"DMA2S^43&\#VWCMG&:5@JTR-#AYNMDUT#;\0D\T*U3"*CC=A
MU_.OY#642RY2W<6 E#RH<0A,/P,D(KFI/H69QN@;D7JHYONQ>49J1%;7T%P9
MA>R>3H20FP]W58!P8)F[]'<CBZ*73ZOUKOQUS[UL9ZYSIET>@BXM1&6X?*4$
M1-)=<\(!SZJ!P.%&,?2GE0NAH0<+< V-B#FB]V+N>#_^3X*V&J^<]7B)52Z'
MIP3LH8Z:O$-) R7'Z=T4P809EB_1_W45\8X:VJ)8NK&Q3'^9\V<IY^U=5SG6
M4<@;ZY7DOP0YKR0]?=GZ694'_"KK@^G>8[<[$:^;2OM,3-321&3KN,VSGC-C
M=&!K;5R>M!LDTV63"GE/C;* 'I2*C=_S% ?WV,<[1\2\_#8U3T+"GD[6N?&7
ME<N)<E2//!R_+_M)LQ\34LGV/][!PPQ.^LH M3QD@*2@-#.)&0:HE949_NV1
MRXIYHPKM\IS&""7*"4M:6T=26,Q;OT\NJB_UD]'=+2(BCQ[D]!O9S&+Q=UK3
M7HN^BSO/L6A4%3LH\AS3M0@HOM7O;%? ;4,WDQO"@I!2G3FT+TJ.JZH36UZ3
M.864Y?$<PXS!6)C^O=8/Q3:M'VSM>*0B2KZB3UV<BC),.C"4?]B@-\W'=='R
M*7"P+&%F#-!]:"9*#)5TIEL5\PV>Y^)/'E@T'+M1VLLWM[?445O=;>JMX^Y5
M0KT19HY<)DUR#Q07#!F+[X>HZD17_ LM[,*WB_'*IV6ATB*':E^_/#(G4R5(
M8ZVJ4 5?3Y4FDW<+/,<OO)4[3Y^0HEN8M8J6]WG7F)4GE<E=?/)#UFA*4<-X
MXHX@G-G1N#/OOXJQ"$P3B?3]2>="RD'7,+1^:4O/M#/@!O@I\[DETFJY: 5]
M_U2#WY1E5>IEMB_O1*6OCRQ8/)2LT#8N&HBZXV_,;/'=V+\EF6&=7-1<2KK?
MO\\RU_9<06@,'-N4K>#CO$N0\QW'<P_7.N&J_L",-3@J2^D"_^2/3DP,.<FZ
M'TZ>3TLMB!<" */[V 9/$KYVG41[#2"CDF^4.<R?30*]!>&#Z4C#/@C+6^Q(
M<')^F7*\?RISB:JH_"%#D6:G<3M;("<H*PDN82AL]DSPW3U \Q-IM71+E84Y
M[$'!5ICL.(*&P^2APLQQ-UH&X[*))W@UTI/%ZJ1"<AM>XA6]DK7TLB>R6OAC
MODY,=IZ4[D[N_;JB)OWDRSNW(F"I'J0"-)*7E$-_@1K<_[EI@2C"6'N@/D'/
MRT=J/:%U)-G4R$@9)2T$QF(N6<"F) 2U;J5:?5Z\/I2Y(SRJZ5(F9VPTY<0E
MD,:<I::#?(?)(_&O1KHB56K7-; ,D&!+Y%!-_99/> <:TJRP0:\>FOI18I7.
M&9T47_,Z6<@ZT=/LKO6UG/)D?AW1"F[%V>T9O$>J51DS<1;*]1T,4;V/%-2O
MI,TI6E!?'=5:!<S8DI/W0J,(Z6XN"NP2$@I8[Y)OSO6[LES7I1HC*L6XN:3J
MC-JG-%1L'=?RL[2%W0%MF$VG H%4RN<#4I(,)SK3;:"\(880PEAC&.(77\]^
M;>*?SA\F9D^4S2S?3%NHQ0U,:NN:9\1Z_'S9=#CEKF[VW5"#15^Y7/(5P"3,
M&:"[ !,D55*?,$"*.86T,E4#6CT&>R],%9&XD]P>7%H7(EU3HM@JS=;J7M$>
M' M3$DD:^>%8433@X%Y6\=Q^0/\&88P\@;90OE4(>.=/71RT 2SJQ&\9.MLT
MD;^\_BE-TMN>KM,UO$/#:^>?BQO&JQRW';Q?M]?)"AYRC][34/&<GC(EJ8FS
MFZ7\^C59%F')!2 G_KQA!8"-CO 54%QIK:INB )J#^#Q!6Y1X8N!^M.6TSQD
ME>S!<=R'U+![%JNBV[VAMEZ"YLV5UT[6&MF6O+8R+Y<5TS<+VET'-'2GI1ZU
M.C(/I7A^1^+%F:3/Y'_JP?!.,^H#_$\[G/J> 5I)AEG0B4',P:4(6-@9!FC.
M%R$+<*WJ7=2?W0-F_=YQ\?'_\9?,KY8^4,^-,T"WRN%'ZH5*)DZP487*#L&.
M4C+=PMZB.ZFHSQOA+*C:P?\FMR:SJ,3]]WG/8I&RQQB:I&3TP_JB=P!PNOB_
M\>;_^FM;[]91F:@O>PKH/:$O66-)(8(^Z4JO-4L^;B/T'EC]GMVY&B6M&=W>
M%0DVB>AS,E!5,VX,2'UO)G??+>T:MY(D0.(Z --3TT3OQ\?OQ1W.=MK.Y(P
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M]]RJ=!-N[E+4JQA'6V<,]"17%@L7.VM[B)2\SJW(RN:78+[EF=RT^--[@9:
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M^H6#PC8RA,3L17KN,)UT8J<F';L 7L;V&.2S9>B/STTA>^I?U]>>L$FY-\T
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MC@*,,,]71O5N?0 -I-A0:%TT0])I_5;FR%M66FR7H;Z2%0J7-_-;&XU1Y.P
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M%8=0OMK!LC6^KG,_;#?<R1:'=>[:'#;N?E'6$0UWLI!Y<:4?;%.^G9B]#9I
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M2!J[HBT;X$ #Q>UUXJ.M;OK46BTF=\)2$LSW&FN9E'^<CK;^S+]?S&J1B9G
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M\T26/O='\%E,J-\1KQ,"T V'':I'9/CP>J_*\@\A,R#,<">H):;=[.+A9M7
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MG50\Z[?2B$\[&CP:F&Z=YW>GDWX8AA.->]G#9[Q/@_\=(1M3%9$K;CIM0 4
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MIT+5'CNZTY4-MS ?Q?"/]7U]5O&B]]X5,H8 4)O@G+B?*1O&7''\K$6AO#9
MR,(IF748C4]MN<T&?EJ1<]N=@=X$42Q""!5/@WRHN,"BH<[QX0FM#!E"-16.
MR6G/-3()3;!@)UB\9E,=ZZQR$\"3J86?.G#,+.ZZ$$5SY?'$;TT2UE?4]0Q'
MVW6O([A$-&G?Y2;=>0G$R3;UO<4,'C\V!R\Z!N7#(S87)RU45,$QV'YD^YN
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MA>]MG?7O[BMU*)Q(U&$14_XO9\H7[$8\4N[C98_U_)OL+CX;-'HXDOPQ-Q+
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ME>>71U8(6@):LSAB@$@B.V.E0PR0\%CEW:7*1=L96G]@,5=Z<ZF;=&;&EF@
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MVN:.EK9_!\2(/KG"/'.\_3_,9/VOUJ'K7X)_"?XCP5_V^\7VL3E&V+PAE;6
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MWC:D-7!7:V&><QK&"9M6^0:7'.M;$U4X"BY7+;J35<=^4X_MCGRBD8J\I@:
M>F[@90G;W07,,2U?.?UYX 7R8D[DEZ- )P*AM9^0@[52UQ"6E.)+9G?X7E95
M%B0FICYT=;SY_<#.\"DC[9#K+, N:_[3S@C7!43 A,N81F89TC;X9%7!'@C:
M91J-'4)>#!!N:A]!94'(@>-/AHF&4LFV[?,(/N7^)AF5BA <\<5BQ]B2#5<S
M3*?^6=^W0:/X?B_X-<OU7@?IST!"N;HMI',C35/G#) -DM8BW&G*]"=Y0#2D
MOOR13KI/[38XF%H)[/S@/("'1)](8C+IL;?K0YIO/)R'T_=S/M5\@A-"/-=K
M>S3D J(B;_6)]_6JIO+C,9R+LZ-C*SM@B@&*]')[.SXID[ ]#K](?==,5_,O
M&5+]S;L<OK2!/]PEH&P;L_)\)\V03G8=J?C"\-9<,]T8&^.>+@,I-6T 3-@1
M$C4XV('?,M1L$KXT1AX?5.M=L$7ME_"^WZ-O[^7V#WR[=X&_GB=F43[3+#>@
M./Z\)';_8<OV3(9.3&%2T<T4GO5$8/^FI]8L A%B O%\9?OX>D3*[#@D)6>>
M5.,%W\"/M5//SV%2OZA<J#,XJ7.D*W&YUXB:Y?2N-!&\7_E.__!_YVJQ^ZEX
M4"E*]'N*80<>8Q-NL:PU0'<"[Q>,KY,.]M::/>"1V:NHQ_Z!YLXKF_2V)>IH
M>S,Q52FL%4^!'%BKAAIK&QGHR=6;"2N_C=/]PEH?J?4)@+G('&X2)U5XOY^J
M#G"(BY&6T"2K+63@JA0),L0  <$T#GP]!"*JFCD2,#_D+'YH:NZRH?RDM'^Y
M:>E[6F[MKS&V2AH0#NF)23' \M3]\YSABG0;Q$@WU<4+BYNG#;AUF/P@CXR.
MVQQD;UQ\C$,:7NA6DL EOW[-5CCG%5]257KEP]'R8FKQU?*4@RFI<#%K=W_=
M\FCF*;3 (+KNF#>0 5*HH3Q:&L$@&: 0[]B\63[J3$IH4*,BEWE',^^K\-:\
M.L>JZ/,:)JH-+2UXH9+($FO'2"?70C<6#N;POF]OI!MM<&":$'N=^@/X&PPF
M$JW6>;"!"R3W5Y*;*(L\CU,].>?M_IX/N5E4X5)5ENOY]FRSXFF8W*6Q/8Y;
M9JF7=#CT<_$8^QIWFO06!%?& )T=IWI\H#S/)I7Y8:H.TKW)1YN+<KSQT@I:
M$K-646CI:2?IS+-BL<X2F4;WB^1J^_FS^\KUV)F@@[')JT-E&*XS0&\/&2"Q
MT%$L7WU#<#3@4*F$(6HW"7JC3O$W!_96Q3X%]7;],$'VA$6C()&!26?2BY&7
M0_?NC)#N[-D+%GDIJ)L E*W6"8C: C @\Y?"(6F]RLW4X,":@8Z^Q>/AIVOD
M,ST7BI:H\2N'?'[?_[ZG<>O,LS6Q-X[O'M.5(UTY-RP+2ZU/A^>(I977-6-"
MRN> %6W!7(CS.[0\PT"L%BV5JM?$ &6(F!]6:7%O!/:ICV"/TSX08DD*?R2?
M:6F^@%O@"3IT.:",?/#3B4H[*UQ0*'./7^N#TVVW7F[ 89*8*;_%.,4,>I(4
M3R0QRU,.%>FDT$AFQ6'W$@/$>=1,^@6(!Y+P7$KVTDDZUA]\K90!2@N3JB.#
MC0\#?HQ[Q9BO9#@U>;/5?IGSD4]9J6>7<6'3_T%/5-.4$$UI\ZE3;"7_!>U"
M9=O6TEH1:0*TV^<]5D(@P5!W*5P>22H(#J=DMB)U"QX?.M]235LV>->PY7B1
M-4E-[9;?+IY5OR]1N"S[:&N+]A8P-4?$L!_UVM/@[LO[)ALZU CBT<7T>;Z<
M9J0'[MM^Y=(\6W?\[NE1KRU\\8)5*WQ!CW6.U2S,4D-;+D'-J"#*0EC&1#.!
M>0'@PKRD]_C" )W+)4@,3X,'$6O^*B;"MN\' SIP"Z$J-@G][[Y)9\)/A*A1
M+LY/"UCCQ%X71-F<D>#4$W[I=Q.@F= @<#B8-S"^]^35 4M]:^#3 (&_//G2
MFX[L%,L#U3A@+Z2:%J934N9>+(1K6CK'O9SH%?KEZ]NDN[AS0LS!T$5<@2O0
MOM'Q.37IA>.(HB-^ASIUY16;TQ,J0QV1CM4+IKY_B3J]89'E74T*?O)Y=&72
M.=)82:_@9CQ =UA6#A]B&*#]"L2Z3<)272/7]VT([N3ST1G=E9*V9R@/W I^
MA(Z08#6SLQ(S!/O.R',O?FW@^'S2TT#J%3:-99Y8OP1_F#3=%: 8+5$JY]<?
ME"VA!KA#OT'+1X*2!_5_S$N0CJ9TA%7R7VO";_TI;O!<7O/3&5<K@-8 X>/M
M-X2$=\4N-)(!.HW*2O<*A S%?:4JQE7NO$7[J^#ALVL!U;*<_-M+*E(4-LD+
MY:(/>U0<5L=4G1&"&_XS;;&L/E, [=,9QV5C; =;&*!$*& 0< +_PLX(X1!O
MMT.UBL'G+&>..[G798=ELTW-71W15&>_H68SL_*QUPP)T>:[DR@A-S)Y__(@
M\[&)!;<?K;SS1\0C@&EH=]C1$I>.TQ7?XF.;,6IE\^BIYZ;F3B3.E?CC"+D8
MTM@,YQ?66,^HA-ZJG+6L!\9!S'8'36ST>S9H%6+TJL@ =KV3J-'J>X@N7+=W
M(M JT<HEOK@;Z!QPK4)LJ/.Y=,_54S/[J[6RW0:12LJ+C6IJIV8X]NZI_G1Z
M500 =*,S=8_(2U6'.W0!^Y2 '2)37\(K"7GK&A-JAXTDFXK/(6=@1S#W "YL
M+\X='.<@7A_TP>DW%MEPZS*'.J.Q02LM9U?4>Z-A(Q7 P'ZD?]HB5.7O?N@/
MF?24J(4L(M\\FX3%>=0+%L4XBP4<GO;2THIGD_!J&XTKKBG/*K@+S7=*7%K(
M8)Z8^>'5"_"263TN?_)9U"D<=7=[>VVE[7AUQZ']\1 ^[Q UJUL:\NEEY^G!
M*%%;\7$365M<ZH*V\#_^UJ,3 ,Z3X68+>#(=@/33F^5$>5Z-56W2^:I=_I:/
M7^Z.&&)WSXR9K7Y^,;!@/-W-KX!LU)?N9E-<U#^\A ^.; #<M)XYMZF!3G>T
M_2U/!K6LB^4,$PDX\YR\WK?I-4S[C W=VTV<4D')-A:.9_$MSV]2:&\S6C-L
M=HCG$OHM']V9NG?NOO!?O]@#=EK]?@@*??7#?K\$@0OZ=H)<L)),HR#V$=+$
M,RMWC@N5DJK&=MX'BA@XRM8[_)E9<]/@GN;[9.%H:XZWO4*RQHW6]3,0,Q4@
MWKVA=B]AL,T,T+*0/5M(-,MB3L7;W<4FC6?CJ;NJ6LO#4][*Z96C+DE5V[()
MWVX9NI1#]'LW;FDN'S*!X@(#)*PNL%NSK@@ AA%5^H"][3ABS7">@H^EVUC&
MS2ZVVT^A43>:?=!QQ7>JQSNK%54@OV>=:]/[L%F5QAE[U;WUJJ!0+*NOID@K
M65]@#%$43%IE@ :E</83 K+-VH-B]FNAWS"_8@"_2!M<Y(TQY1\O</O8Y7QL
M+_CN\M7-+H=]V _YQ%X^8T<+*9-S57]F,1OSO66 -B*U8RFA@+HVYW7V9W'Q
M+P(DQSX1<BJRMK%)4G-6=^@K@]\#+]A+)Q;'Y04],M>6L+MU]6I/09%UT!]Y
M.\M18 %F]A1+)D7N=/0M"(Q6T-D'ZQ72&* EM+W+$3@L($?@Z:X!,K6FH&\C
M/[\$[W:[8/31%(13TEA924S8E:M(V#++ZNJ?17-Y,$)%!'5\'9S0I[?F,A@L
ME8P"JVLS0/7=)XNE5=M>Z0V*+@XXA7Y3Z%6#!A]+=[CIBVNPL%DT;";(W4?]
M?E)U^72-D;B91GQQ]@ =CV&/&]B[<$"-I]6!EZ4,VI'CK4=V!]2SI'QUV2-M
M]\-O6\.K@4YV4@)S2;#%(//Q?B/RY/J8(C>G95E.\=/'IW:KWHVWDLV-#OI7
M[:;IM@+[^5_4?_UQX2<AB"X.'Z;;S,<1=SIJ=]AFDA<O]2/%FF_A/E:.=9ND
M!R^4R9AY- NGZ18GF#;,*[>;R-U@%FI-/ = ;Q\AA@UO8(#4&*#,>,_.6K*<
M#98*N(>,P<8D \1%% 2G2B\?G9SVWNSLU+$UG&'[S=E^^?U--SR7561;5D]N
M#6!&7HJTR3 %F/;PQ9?VMX,1K<^IUPB]V14R*D?Z 9)-)0*B@UX/;7R7G8ZS
M= 0_"*O;<QN(]_$^* \79=':*<&$5%DBDL@6/_:(N\!Z2 '-I-"MG"]&\=30
MCC#)([A-LJ^WV$Z<]GG;1+1:)'+?1M;N]Q$WMY7"TGZ';T\-KQ^_LV(ELGF)
M >E0S$X>CC0'%D DUY@Q0*K>150GHG<A-6OB1]_?U**YDWID8+5Q_>76S\<%
M);RY5?-?X*SK^O"6:UJ\OD,-#:Z1UR;_WA\\YO2,)+1_V[6_=OSF,I%[%?L@
M\ CKBF994I-O/'[S^]=^U=MNB@I_1,CKFU\MLLY(Z;9NTC'5+9RZSOH[LR(D
M#<$%3HGO"@,V[YT(0NY"QY(*+VS6"QMC#,L;BONHZ]6=6I(5$4SP#/BZ1/7,
M>5!K*EKSVJLWO:Q45Z=[LB?N^L.WMTL!TFAKS@!)2>;0'>SW/^5M*,WP';<A
M"[EG7AB^W?8,]WMR:+XQX%4NT:L&M8;M<DJ1(RA^A3@W:>'<@JPTXR?RK%=-
MD_Z<0+62-4LJ$9DB WGQ OL?((DV8)8EZHY]P.$>Z?8XXHYA.I5E/K,UDNCC
M("[<ZVU5!TVMD)+D.PBQOY%:4I(\?+?/9%+HQ_C5[E./@-V]^[^16;=J!_MW
M=%)YI]1*OH:6Q54.'Y;X[MPIL=Y;-%<O=A?=]N')4G*5N:1IH7\P;:(C(4<H
ML,QTO \3_ W$;*G0!=A)%_PFI7 :XT>*IKX;;2 =D,$] !?-&?R:K?C\VMB#
M28W/GVVTW=?"%4JN.B;%%><;WB^*=7@P\R#E]% ID[H&>.9V4P:)@50_LCW)
M8(\!6J^RF@6/I=7Q=Q((B?,MAM_UV9R_QGNME^.Z8!T8_):,TTJ/=ZMM\^\E
M_8/7B#-%WFJI19])P+Z\4*D(\AY?GR$!,-/<C)1J.8XO#1@?A;P*J0BBA4>L
M&JX.[G(-K'U&F_BMU\]M!T99)U^0DDCIFE[=B(/(#<=4E)9$?7PX_ A0.C_X
M@WW7:,7!^1I$HB+Q)V5TD0$2"D:4DYM) I^VFG<DRMK$1<GMOXD'$U2MAUSK
M]_LOL7M1B%UW%--R+;=N%A98Q 6\8V+HJZIQ6G5K-,!G<]?'Z>8G%AA[\2;N
M+D0:]AP:USSH7=45P/5B>H]O5*,E,/84 ]3K!^-D=X);!2GL"E'//LT2*\];
M?%5RJ:X<^#Y)A 0\?9@MD=8!7KZ'.*\NX$T?PX3@E[F'").;\6^EUXAU:WX4
MN((:_C-E1_+7@N="KSO2XL\(S1UJ7XY)?>AZ\UWD+*%]<IC.7C23-^Q23PQ5
MPH;R$BUPDFCZDQR;;XU7['.P5XYE$01KOU;%D3E=??Z5195T5Z>-F;S^51F?
MT5MBED)I43&#IX*N^J3DEW#8X3&>[VC#=!T") (+4K>C9<PCNG^C;"V%CQ-&
MP^=+A<H*'Q,GVM4OEY>MB)&F;ID'^PD%)RC_6B7DKA\-N&B!;3*M(^3,ZAX1
MMHW:B)U&W>DPF$;(6JMGS G((06: KT/A\R?*9H+^)NN^LT@%:5>?1B,3V=Y
MW^UM99X6>UDPRY*?!_RLBEE$8T ;H,COIU/?(%3S<+P=@6%#X^L_5ZFU<.UA
M6LZ>^V-O#Z58);>#$YWDX5VKTHNYYW:NF4[//79]<7._H> 6I]BX4&O[;"LV
MC^\>)+K_JX,HBX2D<IS8.2>_LK?/"_I>UO[,$9-$,-^=9/X7>TWW+\&_!/_+
M@G(L'=K.-H\00:19C!I&;(V<0M8T(+D+?2W;HQL_IN7R^%K]SG]N4WI_V$Q>
M309BZ:8OS2/\@*B\_83YZ$2;!#>A*M*F4,O*+>-OE,:C<QH/6#KHRO[]5H<6
M5L_H^I/:[[,#"':E?2NW/2INESI;XJ7O\G6U1$6)G=NN/9]><9S,OKJJPVS9
MJ 5_54-W0HSUT!0HVHN(X<!F.C\,8AIX-$6XN,Z.;B=*)WD]_A&BF^E2AD;>
M^-T?\Z*J4\*QNFZ*QR'ND\F4J?3KW"8- $%6]!\:WT^[_EAL88-V>H ;O/(7
M,_2G@D?1TD \^OBCSV'9T(-Z-3"WDQK/[6*D-X&0=,<'+-DX[++>$@]T*"D;
MGPK0Y+$\@/&,"*MTFH1;O^X4LRL6%>=/9';/T+)8WS.C#5$B:<O@="@)-(_B
M.$9OQ W_#?^= 7*,;KQ).8&PV=E%^T^9>G](&'>TJRTH*>IS*AF[X=[VQF$S
M_ZQT6H.IO)H0P#C/,4"*P86X/2!BKM=_1GS0O@<WQ2(D?P[7=O#J'5C@H'_]
M\"FIP&;(&B05+\I]&6$[7VE,@ 4=9&S;-[]F-Z%KB_TT+F<VT/TK0A<AL9<&
M'G$1I:W0G\*[MD]3$CM0&=K]OW<(TG2VU7LXK"2ZZXZ*Q?EXC=8"ST^6I,7*
M(-]POQ\P>X018]-4TTN(Y%?K;R7?1Q"Q5"_:;##R&8V/_M@FCVH8X#V[B+UV
M8.-70'] 2]EEG5%0J4RN">B3*3FCD;M@D\[WVWW5I96T-]PZU_L[.2UE?F&-
MY8 =F!L#V8]],S>Q-'D=0NJB!RE54R@,T-R+CCH"-)S7I*SC+CQV$1TB#FEV
M&%G_V>VP2VO2=G,1OQW'(I+5;?:HP5B.S41"\)Z9X?:K<D%FQY;^YX<,$.D4
M]2(M'I5:HW&4WCV>*DW+HCRES?QD@,J/-5R:NC S\KOU >H7X8]6 BN%72OB
M(.XFRS)WA\1B.PWNM$2*%R9H/HH4T@&,ON(C-7N2;ZH5L:R5-XAN4QA_%!"^
MLN5=N]FQU!, @7YOHEO7>.QNM^4.8N4RMA^O?R_YE,P>63I@9M;))@<SZ2$-
MRQGU5!*OJP-Y@V1&,C4*(6382V6 #LBES+Y /O"U;40J5E11>P@:P5<[\5O"
MBG30Z')\E)(" _14 Y_NM?IY?[GT:5+[-[&@W#.7?B%_K@1^B@.@^0S04#8N
M[QX#U.7J&B:K,9V-;J<[!Z0/LT('JQF@><SYY@I%+;O'].6A&5.+MFFT>UR=
M9TJ+YX,K/Y6'YE;=8<&AEP:/RI@C16=2:+4+8 E@/5!2/@8U$EU OQHH,(*-
M \O0)9>#1=H4[/N&=)5/9MYC+<_1;+G.*]K?NZGY9Q^KI$Q4BH5J5]QMX9K@
MC1+KJPK,[ETY^PBJ$ZV::G0@2.<X/842#U/WOAB)W*"^AQ>/!T)-=\>&@_5S
MV+B,45*)F P==N&XX"S]H@O<OKT/D\R-DZL<..6^N[\'<K84+$MP!$]F#67^
M0& MG2:,+?*Q+:G=DLX^C[,?VAV?Y=/XK=/3ZP+XQGW%#A8UJ]<)A)UJNQI>
M PO;R.*$Z:F3Q8U143F4'Y A82E.@ X;48 .QT3:%!4!'6*VO,<V._)[8,W0
MC0"Z=;('X6J;\^#<=.;5Q_S?2S_%LZ>5]L\80]CT_>N']O58:X?*#UKX\9BK
M4NL.Q.:VGQX2-C,\$)S$(GA$8WG#]5#V*7G,OCC[_!=QP^_5 SI_H?W$/[L;
M%W14L*BQ?C50,"W7UH+'/4N[O<;L5OSQF,Z.W&> UJ2ZXG'C,=NH1#14^-MQ
MNE]@P-ZN5_+$E\<Q2F[!#)"GB[N;/4\C[XVSB"])2EO;OK)R\4(HG\0,7;/.
M6("V2*)4@R-P\5WVZ_,-J&QROT","GD]T B*?9]JS]X!^9'W4!LB>=+;JYWV
M!GRO9=^R_Z9MCYA0[^J3XX>7MRUVA6,^6V>P A\ER0"ES/;'IV)R2"4;$)(;
M-7W"#,%#!@\:-#<K"ZY:W-_CN5VA:+Z WVU-V3.[Y5R0JO%(KT7<I^5G66FV
M/BJ0=5?L=\%\$4Q(,9:BI_TP$-(_CM-L4L:CE-\T*&M\=CN>"L)MS.6@FHEH
M#YF45#.Y6#U32MN,,*?OU'1Y,D?X]220KO0_FO;$T4,$3AT'KI.[/YQVZ7NJ
MCY50OQUHAZ4Z'!2DE5N[FMSXHE!A*O"]SWK^XT?M@<GIP2,&R$_(?[WIJI%J
MHF;5+!"DBI8N(Z3W-J*)&M\#K>$1=%O;['W>E?0N^DD?/(^JB40FM? $VI$7
MIC4HADMS/^HG)M4MH*;J]PM8$N.42V\55U6  [5-8BZM 8%&*4<'L)M8( ?4
M@.=3?TG<OO#UXZ97)ZW*YR3T%6$!@TJ+=IUUF0HXQ.A]WR0+I42'EXT(J['I
M5VGS:9B^W]KPX\_X)$YH_QI*^QI,7IOM@VQ<WL^F5OCG]=C]H&9^:Y&*L6*
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M:,V,N9I&T>N-DM"=[:R2/BM;-;\HWA@=:[OSB,1KK\+I-/E]"KXHZR?2?:-
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M*@#GD@]8.V]HI[7<(JBY% >WGVY@=Y<H8*Y.6NADB(T$5,WU MY063U5R.O
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M96Y^E'[4>TN/4C&2C]YP:#SWA3><<UQG"C@.,=V.:-)B1+B/6B(#7)DBX?%
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M*ELG#RPF_"N(+:DHCLLGA;2_XS++(7VPM25\'ES:<+5@$+-TFHR]MVAG=?(
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MSU4[LMXQ.L9]T>S9)IWM]'EIRJ3!"^:A*Z;R=#R@[TF&21D#70M75$A8MHU
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M\29KRW,A^E\0L^&V(0L''AY9(PV(G:.U\+"*BM;8<.ZSHIFBGJ++@+L@L1+
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MSJVR\$S$PRML%=,SUD5*(KJAO*Z_>*XEEQ:?+]8VY@\AGF=S+P403ARIM+W
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M&A,DUD7J!VQI'N9@T*>2![;</(2OEHV.1#GH6:)ZQO^\I"=RO<0M4^LJ_ Y
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M(V*#;\S92,L!Z1#5.&_=4U?L#1+LK)3K# T/[>49)VT.#BJ79+4>!>F>+MS
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M"OC@-\7AP@U/NP>:OWIHI^GIBA<,.&P*Y$<&K)<$Y*HP*MT](T/CU4^%_OY
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M\ ?^(UTD!Q)O!X?0B(_'&,4<JO[7O,>"<*I4(ZW??YF#)N4)T-U^%\8E*E^
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MP94&S^P$BYD#:.RGPVNEFUL\4;M6DYMSTN&]ZYFV[']U\XP_B\.WC8=_1Z'
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MF+_E1(W_,D$XUU]<'5DG]0ZOU-B'>,LF5EQCAV]Q[;PZ?_-G26YJ7I.HK-V
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M:3LVS:O,F[JN!U&PHI _)Y]%N P)TZLF]HPO)Q8D)]U_(C&JG*>6FGM+\"Z
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M@]5F$5EE?S#M=QQ!7Q;=\PVF-6)\N7$0F;\J=]@-3&=VC:)Z9*^JM+;#$*R
MKE40+E- ,@:=,#6G5<@I+2>&RWWH>[I:-/!3CE%H3-7@UJ"VE=9U(5UFSFV<
MA&M@)^3 EO0%2#P%DKCK#0)^5-#I$PI4 =[F5]4UZU,SIF[0XB0?Q=QLDYDJ
M9/&64[Z/_,.PRN% K4LKLBF^FSN%1CD%SK$'Q;FR'N0'B[<QKSF@M3=.*^:R
MN)L<%R=9M@3KE#TW6EO=5P@9%_M8E';Y'Y5MUL"4MW1>6SS0T::)JUX'_S=L
M87XV7]#R%KMT,VJ.OT*692=Y824 B31B5FL.2>420#G3A=BI/*C<"IOQZPQW
MY#'@:N)J! $?U#P.]G*?K95$ #ZH=ZU"EH?;PJ0UF7@7(S4_6OY+ ">9$E[2
MY-.>UR(.BLQ328'$MZ X4T8+A-[AVZ:6?9*3ZQGK)Z2E)WX;&QMO:JJK:T2Q
M&ZBROH\5R/^[E-TS+Q3R_%__@$"TQAJ8+KDD".RC[HM\O$@T*-)OEK<L@SM@
MW4Y,7[A58B&S</CM;)A(D!\JJ#<SKY BJ&E\K[!?B?7]9%>J5HBZ[AK]DC8P
M21V_DX%HKA=(Q<4-\=GL9G(SQ@DIX;J^@'I)AF_+@V,5W;.S+T-W,U_PNKYE
M%3H-F#44;59M7?\4698H\)P7WIF:<O0X8PVP:HR"'W85I0K,&@G.W#!SP"@@
M2HE9H_ 54L:*))9=OG_587YXERZ5N\+?+R!.3O]=;O?JSU@6S]]U/S=7T,'!
MSI[KC8WH:>Z)OG%:D__B\.V5\*>_47UQ1#V#+:7<[5A,F@M22J]VZ^,=90>;
M@YG9E?DWY[UU<^$WUW*+_VF[*-6.9E0[Z#K-E#'<!3)R&@M]#BZ4"KJ63=JK
M9A:W;)I'( %^O)W3E64\\C%G;3OROKF>>V-.UO"JLN>600^M$\N \H)M*HL$
MWH/&(/N^D\H1W#/I.R:SI LOJ*!_83/X<.VVA#,/Q6:Y&R[BT!C83H.JL*D;
MK@/],3,RT_-Y0_UOPTHF>T;&YX'G0)956_EY_'WF"+5?C-JPC2N?S3(L"[DY
M<BZ1V#$RL5+R@]4BHU'V:XY%Y)O,6_'Z(D-C"I],'%\-:-^B 6H+*RAAY:4A
M4H9K(P-[MDV"(/"45W?=MG&U"/GN_M% ")?=*UE,Y]Q#.S^<R9VW6^LQ!S<]
MG 0V)2]E@&%EJ3F)N:I'4L#B/J>HOH*?V2';]4[D]!#O-K$)V;SQO_;6F?2G
MLRV;E)[ODC'S"PU98@&_3L1N?+&M8YP8B[PR_WKB.;=1N4&E*KT.XV >/4"#
MI[XB]PNS$Z90#%10(K+G!7\79_&,%8/N+ G_>9-^TF#L\PN_66?9SCMO'8L[
MIOI#"PL2$5J&A:K_&M?HXFKJF1S?/( ,LV.V<9#P/LKT0O9H,S9%BWR7H@$=
M5%_V=R!SD)QKO(P#42T!_/P- J:5SBL4CN9]F0RKSPV3#+K)$@8R=KZ>Y\GU
MR(Z@K6=UO>Q <K)@((1M_4"3E,F=X*5G5JV+.-4&.<QIUGH"\8MS*Q>'=@ID
MYLPD2_B?+J.GEY[%ISMY?QYPXQF_".70>3@:8UCXQ$NNY40?"./QJ#/OL#$
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MS=YV!=DHB @8E28@(-*D9BL"TFNH DKOB!"0FBT*2.]=B("TT*2&'ND=I->
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MRK"\J$-^VVZ]1X*XJ61$%W#$8<2'$U55D=L+>LQ23\;$95HU='^/Z*M6,_$
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M_=0KA1*Q,T,%3?Z[:T$)&J*H(@[.9-2H(,7C;2IHRYN6 4H%/;.#<VL1*9E
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M[DZ;2CK"VT;X&BC\ ZDQ 4<<C',.4M'QZ1%>:Y+F#+Y8RW\:?B0)UJZF^Z9
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M^I/PMK>0)3G=B?%A*+\_82-=/SEO9EKQ(F?UUZ#' RJ,[71.=X1'&*'Z%T!
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MXJL+*]^>+9\P!PZ--/M?'/O7-2?QHF@VE^K]HOEB89.#R54&XY_0TLSBXO(
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MBQ^9"\DP7WR<_@#5 HEE7%N>0PXI =.Y00-I(Z^7=@HA/E?C]R)W5' R39*
M Z#;@3]VY$H$=IAU!G$Y N>Y0JY?'!$'-JB[ IQTJV_VU)NR$(2L#5Z60\O"
MCFSW<G!8LZZFD]]L=R(P>F.6J;WJ"7FE90-X>M==_0?YW!P8,U&9F[KCOQIO
M7I8N;B-H;)/LX)P[N#=<G*]/S\V Q8+I5L<YGB2%.1WW^ <MEC2=BLW.!FBK
M]^R>UG[X_FS2]N\Q&\\1S)U4*(O1^'AOLSC+(Y_QAH5M[//_+/I?Z2TG1^$G
M2,0O@ 5?P^Z@,[GZ$=&XFU1;][BA&<OU ^_R@SF_S\;N.2,0%C']9D947<V$
M[3XQJ-_.T47B8*Q]XF' 2_9+KXJCZ-H(^O+#1 A^:K:#@5+0=LX>CAP>V:U>
M-3T\[H0N>RLAG8U67)K1Z:'#G6O__G"2(F:%H,OR"C=O-MKT.B:H53[=H9=K
M(VAZ VI.]+G<\)'+%G(MQFC^AM&8;W'W+#JJD?."RAS+Y23M]IZ-_DXW@K #
M]_/K8BL/L\Y]R'A8/.F,R5:SVL9"-=9HH/=](5,P0G//-135'BG\)_V7N =^
MZT=W%T5^-F#^3L;@+2OT R\69D3/EN66R\DG]X\?7I?J:10]5=>SL[0S:J_$
M=TQ^1[/]464]2%]VP*#CIA_MAFY\I< W3HM'V>(&4J/EG>ND49!SC]\65Y5&
MW+2.SJL2NI"F]L3 LK^TYNQLH1R2#>[7[ Q]=M+L[)%;0'5&/%1YZ$L#];K*
MW!K>^Q$U=V#M?W&FLFOLU>I7X]'=2T)SG&*]?;8E,Q=,-#Y-ZBDPKFEIO>\"
MA@%)!/YI;'G/BW*36+J?7DY6JE=YQ/5>"7-E!L&.*G<(*?3S8&RM^5K;8\,-
MD1P=6RFLKJK.ZBRT"9*3Z53XDG4]G ,;7-#\';)2V!:DM&X*T% ),0+I%(=X
MV*FQ&Q];OFDY#)N5?W%-BL64P1Q:+DL?QE2PVZZG-)[Y&1/HTEN25!;HPI=4
M&AU<[7.3 *'P=UH.S2%XY.AZ8&O<AS&+&,QP%FHA'P%O(?9--+24#5KYW[>\
M$ENH,=D_\8AI9RMVR"C3ZV8T/+$L:N7+:P&3M%P SO,+P*GA%[B._B$>47HD
M+#>1< <,[OWE?1376' UA]FG?KLOD=PMVWGSF9R$C_,>ELHN?'">$6,;9_O<
MI[<#A1OUSQ*D4V@@>D3:.ID?)PG.! _ ?@]1$\&+W4J,CGO#>#J"/U&3H$HN
MO[41LPN.IH'.4@"Y !6]QTM!.\3MAW2T>P=6G^4T5Z^]I73(TAT])@:C0[E/
M[A[/6WH^;JN;[AAY@T-9YV;5E;.D=9OPVK'H&$!3HIM2>P.<[]T<Z^.YV5L[
M_L^J+8 .47(#U2M3LSAI1-I%81+"'S&,/9[FS MF8I@FHU:+7^[,ZJ;::^<S
M";?DA3G]='\DRJ<8V3/ 3-\J:!MG/&#$ZV9</ZX#Q)(WB(< F<R!4'I#'^*1
ML2&H3&RV#GOJ#T!DC^PPA#_R(76TMKQ.?5+-FMFC(^W5O?ZV\=O6EN_8D*2P
M)C=/*? &&S>/%;.9&70*%T.G%;R4ZH#DH9K[#7<KSQCE3$\/'33[=7*Y:VDJ
MCMXO*/QF?8,/,P7E%:*!;O9IF5H8)0:4S%K^G2*2NXUEAT710/V(TU0:B.CK
M01Q&X!*(WNY_<): >+O;O#^,AQ#&B 1R+ V4D'#_=(7*0?&FGJ>!6JI;]H'
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M+(W>.\*9.?RS5I(9[U%U&$!@;E"ZP"EQL %T(E;X2'5Y:L!JA"A^2"@Z"8%
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MZ?M-+OTP\O,8O-:77/:'U<$M%NIGU2R:7.P:-*4G8GQ#=YSMD_6J8$%U[WC
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MA;H;SW88C5NXXCF'DIY5/ZHX4M=2C?_R-D=EFS^U=_RQNCKHI4-9KL#;VU4
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MVMQG85U8"!Z#2'78LVA6-*+O$+P#YH5 ##2Y[IK<[[EL(/A2.S7I97CU<!6
M&P8*X4F(CMA88(J?$^]L#-4WGR@;PW)FT-5VIY;$2'ZB<L!:_H*?3"LJ==C
MX9"!P("08*6UR5#*R#"5\6=T51I-YP RS7L2AJ1*!C&>Y1(<C]UQY1@6,FB%
MEJIG."^15@B]\)2F?#[27^LM% I-0@3%%<TE&ZM>2IAJR.SZ%*;[X=KR@VH*
ME6BV(?A[UWO </@R8D>]Y/H.-=L&/JS:5ZEGR[7R?5EG5^U6L90;A\C'WK[/
M.47M!G9(YP?Y0\,30^H)N2^3'SG9I#.. 4BQ]C5)!]&K7$PR]P[K9QLFY'X@
M>$U>G\$.<GSSK&&A<G;;WAU"MR*F:D87$7^=+Z,WFSR-A?<8&OU_EQ0K7G99
MD_#;RO]?W+UW5%-K^S88CT<Y(L5"41!0:8(@TJ7F581(#2T@S4B'2)$24 GD
M*$>0WKL0Z1VDEP"1WD%Z!R'T3D)))(39>6=FK6]],_.;F?5]:\V[YM^]UM[9
M>9[[ON[K>O9=,J[1<H8<T/'HGI/%A3YT>*KU@7_9[]]8>^3$\W$K"33/F]^(
M>HNRQ$GI=_0\B[6FJ;F1Z0:4)_B\3^TLHG=&VR W%9GVV[H!F[E^X$KF14F2
M$@@>+JC.R;J%:,Z3Y0#.U^/(8_M*GT'T:DVXBA(4SA)[Q/H^H2^)$H=S&FKG
MF?;-EE+_\Y6\K;6DYF[CN'+&OY?W-YSL<)Q *)D^I2TONG-@)D;RT?*\'*5D
M-N']OSSB/./BT-:1N=.QM2_:W(?N!O8&I6@D,"_S20!&!T.G4KLW]K[P[&->
M=9)*H34U@F]VBJN&&I'[$]^\CI=.$3O-"?T_QYS[&\NWLEBD8A]/K+F5+RWV
M/<G,"NQ7NGG6*/*ZZ W@DCD4$Y)']0<P^?WA0G/]U%;^=S/HTAGS\]WM$LZ=
M_"W^O/P?:*;9VP^N!.?$"T_W_$XN^-9_9R@H:[3W05,I<C?(;X2J@KEV[ TY
M!SU2]N_PDNV^<NQ-:"%SBG7O^G<;KQRWVA#(Y)HX-1)">T'*1UG8E/*DU[#R
MF0A263AWYX\.1.B/ 8 \RYYB '.IWJ9:-2(I_>X*F,I[>VGEI!5PQQVFX8SB
MMI*AE MZ,0,KKTK*/VGQ)25)_I'Y=K2@EUM?V)7C7XQ"ME'+M(,:S%H2!=MT
M^2AG9:^H5/]P8;!XA_AP#0??O1,^2&H_D+?X^0&']+JL\Z+,4X&(^FDEE-EA
M,.I,.?(T"4Y$N#_6,](@#L+""Q%)9@ U,7N(?K@79H9;7",<D3X>9'[/RO3[
ML?DHO-6YG\PMC\S/"93:3^ZK$I76@-P8-1@V'M-DT+]T 1]FNN,+F?,I1F%'
MR' H$4]E42<,NGDY,W>'EZ^?)5!P7N,/[2E?2>>@K]W;TQ0>2YBQ<]ZZ0QEG
M=)K<@T()UVJ[/JG1F\T66M\E>HVU;N?? K 621);WMK'V:+%PB>I9EQO_!>X
MW@PI+4!>^8"]G$._2G..B,7V:$,>J;R=L*_PO/VNT"/N_J<T'FEMOI_MV@Q2
M/Y^R7&N] VA);J9(X'>_UPOB774IQC\8TG8VJ2D;#'2=%.&]<U!%25'W+YGC
MRS$N!@P+,T-#ND:&X_B\B3U%STB#GCV!X'>9EAS RT!]%*@W;2EEQ_:NS@,=
M.3.I"VE;_5%-"97RITM^._-3BA'ZOV1Y9D=ARM:W*^V?M3AF?;TBM/E0^$&H
M&^1:]O4D(SARM^@/GA7\R(UST.,"S*I![8D]PO758<8&\^'%B1DHTMB*?YH3
M?)6O6\],K]JM<E)>*U7&C/]>/JLT[+UPR\$$K"WH#O0&(-R&C9<P/_8BP+UR
M?G;']L9[ X,=1_ N[OX^5,%V>-G\4:W<<=I0KY(23.=7\73D\&NW)$4D(Y)%
M-VO?>%GB.N2R<IA0TYQU0C_@!Y;H%A,J>$>G@0J?"R2 G9PXTJHZ4/-DU4;L
M@JU3\+1M;LR5\HWRBIVS]'^"6\TKI6(3>X*339@S7A2B(A&?AVF,:^K-?]B7
M[/^1"[J=_U$-7J H.:H79^GRO*3;B;$#\$*E47!F*O.BLL@X)3V='+* ]/QN
M6;CN)J1&UI!WLA"]6*%BP(@8^U407[8\@%]*JT\+OS4LG0!PG[-*].*+1*BL
MP8G@.[08)A;-!4[ H5TVM9-&%A2P])DL)$?;DL*"K.P>%]_&/^B+2VL>_BG>
MJQD579TOG/Y>,)CW3V438+.K2XH!DN\S!0<KJZ+%A(Y?K4^=5?WTU:O!XG@P
M Z/6\-L-,DTHO0[W4W?Y#_D/E[-;)R::55Z-76NY7QAE'=H3'DWK!JA.%"-_
MI3"3'2DUZ&27/;+@@4_UJ?V26,M>+,O"31_7-S^7A=R.9CJ5OBRDO&&^;(88
MQQ.?_ X6EF?(,6.-#C8IV!#6^K.PA7FG%PA.<W,+_?ZVJ!?P?Q88E5DHW-M[
ML:E;,[A;^UP5XVC6>G<<Z\=ODZD6$1G?,C+R!^PEKL @P;G9WSY]T#)7NPB%
M&42P>,!^5L%NC@)4PO0<U&6\O#LWAU8$+[[@$3ZU=G8%AW,:^?LBT5;'1E-[
MM;_:5XZ=F:[>GF%,"GDK;#@ZHI]S_PZJ;Z!""NW*T265/]RT-<<9EGX.HE>>
MKHKSM9U-S=^775X#9..CDOUM8>6R3>CJA4GDK2]OI5F/JJH.#<G:S34E<=@W
M",,JCD9E4T3=\'-'DV]!KVFY.UQP#+H_'!Z$N5OOO=C961IT5DK,765^ZY2<
M-NN?_3N7/ZQEY'6U!>/;S()9A4!PC$:RDQ-2C:.]H^/G+<1FOO)P1LGGS?4T
M@-P4^%-O%L]*GYU2>LY!BT]3&^.VPKLV&7*.=E]ABKN/O%WUVR%UCUFE]KU2
M64@-Q5*LK+J=2G<J^SE(*S8._[C4JP 2<D[R'-32Y:-0_1W<VVN/M)M=[TO;
MW#@[!TT_F5VS/3F\78_0L,B,:C72K[YX5>_3!SGA\IUZCI*\K /#EEBU3X1.
MH30EX"ETYZ#]=+_?9';"3>K-TWHLW?)"VS;PY%?#A618E0P5FNGADQ/AW9/X
M6V/#)J/KZ[@"9U!67N ]M_MMWWFNMMMY(0\!9W54ND[9][Y\1,:.@!FIFH!K
MH*/1].>@J>(6FQKF-K^67>%95:>4 @8=,5*VS>V^1W>A9R/=]WD[')5/^?D8
M#@.^#Y]-7P*DW@<RCM*IK$]QWOD]\(TT1REL@E*&$UR<S*&VKMR]TW7F A/3
MUZS*I4TXWN>7R04?]FBFS!H^#$W"7(O]:5CV.%K_RF)>#!#Y[,"+_SH']=^
MKG)1(NK%:JE*%(_YP0-\DX*-^HQO>AWQY6^-<.PL%BS)Q7IYHFO1,C=?;GRV
MHA<F*FTK;2X^TJI^I[RE7S^?'8C!413>/7CDPGUY^90R92A%O9\BM&,\)\?
M;P]9JU%EVT_C$#9@GK+I<.4*;1O6YG[*)\+[0NSZL]#MB8O F_CA,&M&1Q->
M:*D]DLZ"H==\W\Q<T/C,5H,"FJ[!2VTK1Z/!12-LH[YN/KD\6=<ZF<U&'_;Q
M<NN_:_?0* O2":42ASD'$;[D4N$*DLQ#53@QM\:0<F5]SPAS6*_F/]W.7^TD
MPIU<='*OB!"&]=6X$9MYXW\MAFT^+FO0$(38 8NZ@D*>@SY?/';M39LY!T$
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MUGAQ=S!]'HMUW[WBMA'6KP>]S$70M[0,*##W[_R4US]B8-2PW\9FPCN4;V-
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MG'F6HR-R8TI"YIQ<8V-5;O/(.>A:9R_314X!>HZRD( <8<3F%=4_H\\2 IX
MK+)6>9U\8D I]@IL/0>MM$^<\F+1R8*#1;D05<WR^G.0,TS7LB(IE&DR(_FS
M;,#O 1O^'M6_,TN=;+XG;T37F^9O%&2C>;-" 2.Z#=P_01FN[UP;!S?*#!@4
MG=(M[75A0A3BE8H)FO@([[,JY3=.2L\-^B%1K.*QGW!T9EPBJQP_(S_=?S24
MI6_02V.#V:E K'CPVBC0B_+/UL+*&@%7">!0YZOC2_9F>U",CT59;YAILO"F
MZ>V*)V&9(O"V<JR.D$!,?]QIO=O5CM@='43J8B#@HQ B)_G7MFM8X]P^,;/>
M  ]V0LW,\LC+(S)KFQ3'4#Y=BY-V0@ GJKFCY^YNT$J1+XF7*DS##>(S.\_:
MK=OOYAYH @&GGU)U#DJNIEM+@RP;&WK9/W,M#80_]..U/4@<C()S*R@W)0A,
MOI.4BH'AW1//6K6UGZK'MQORBYRD[&RD2;_,>?=9"28R L0)E?NTOW6D6!>[
MLW"L354O)4S$8,%3*/CJBY;/7@D'> N*DGO81Z16\G9I727DB?U?5>P94@LH
M9=J@1;5"\A>TW%?C'^>@Z',0)_7A#CJ(:X6P54$UV+Z3MK_Y5;!SH^P(%@=C
M$<B_GRV%!+%EN(+R"KOXPA@ORR$*5\+PV38 *_GF78Y+@R"0N7"4RE22V$KV
M@C2F#[)JZ#.06PI.V')1M& RX-(L6^F&Q'7;G=A!V#6AZB%%(>Q*=LK(=BP,
M'SG^15])&-AH4T@S+HZ3N#((7<'>+*<^."EM3=VHQM()C9.IN7NU91MP?B,^
M@_>$=\'!]$GH(.?-('N'O*V53S%[##<&M1DJH=K&>H#>Y$6W%**W8]$)&*KT
M6C[N)&4;"D"C,QVM^30<O'@/?+S&F'T."KG:A#MY1!NO\:_. ;'P.79"!)55
MY4 EG_K\2*=KUZ6JB&H DZMOC)HTO+;L5@X;<G49C(Y.W[ W"LO.]1+EO(X4
MP ,WOU3F.\R%H4# /DCL103!_Q+'6U&<=Q=6EE/'%E*Y:MPE!S_]<)G6;C:
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M@[Z@X%)!7G9PCH901%H2@E$NZH9N])<I5%FG0-[$G$_ZPG]U5N3)1/FT-U!
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M*%OQL\7]#R_C"^A862+TZ+LV:-^!:%"-0<F3CP[8UZCC"Z<S2W3N2Z>Y"&0
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M!^0(?25:#)R";CX'K?KOL^.!1[H025.$BUGH)*W37!>K8XS.-EFFS]>C]GB
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M]*G!GJZ5T G-5*42ITE!%8G.$>.D4*DZX:]+2QO+']Z7'WD+_#-6="BAK?6
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M LN<OO[#/JWX+(/$!XYZMD94YZ&E^)R#^"PB$;WTOB[]8UN!<_O2>0WHDII
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MI=K+V^Y(92'GE-!NM(TZR<\U4?]1\E*&7^VA7!?DKC&+LN?85:W(O&P Z)Y
MGJCW)FBYFJ/)OYKOXV^T8B<'$B01?==K&_AO)*:K/AFI_=.VU6LSE9OSW/*>
MU-TDGH*X#9;/SGIA%QXE.5!O9^:;<D913 *G=K&DPH 0BDM3K:XN>5TJB81G
M#RVOX3F;DT6S?<>2NLT,;'E:L:GBCCI&UGSOL&KBB9=O\3_D7YO_LAI=I#?T
M*0M BC*6K=;U"+;? PSKF[?TFY6'-0C#(Z,^W)<&?^8 V\F<RYQL2O7(=]70
MQ'A0^_T\C-7&QMT/KG=OL7E8 R@=I00^OI>&U_X.[CI=I<R3F.;8U<A-A-L,
M?D>73TC5>]=%=4-ZMJ^^/Y3DP,EU@,$W>(6$+G-X&H[)2QRM*^MJ&7T-K[[]
MW"3<UP8P#18(BG-AX.YD@8-S$#0@A)A*'J#8P1Z5)EC<.WDFA*@7,]]!.WCC
M;X<ZNZWO:VBH:J>;QX1+%FH8TVG^CH\0XM*79.+><!Q7_T2/(A@([7)0_F!)
MU><@W< OYZ"&&7IJ:0R1'M@I#SU1A8/"6QH!.QV QE";G=MY+\+:FZ,I+G-]
M1L7H[_0'W)0W'#TV7L PM/</%CMVU_ ]YA\K"91I7+7!E&"\AI'P5"]D29S-
MKKE:M"K6U_K[2+NDA*CFJ%X]0(*5R<,*0F0E(N8<=#6I;SS@WLZ-/=+U00ZN
M9NMMBX1)A2[2!7,MTS1D\4"K6D1)]*!K4Z$DUSW-O_L$F?0MO 1RBY,<$=T%
M &LT#?U?O!A\.J=%#EZ'A9V#=O,'5N*T]L7+=N55I;MOA*X'6&#:<2&OSD%-
MU<@:+QZ0]6X?HU[Q2_6 /HG1JD-O)DDQ)6EL.W\[)[41K/2"?B)8'#ROS-'+
ML)1C*Q]H80(3%OZ$M;AT$MV8P"-EWE>WDC_#UI&;!@=?LQ.5?+OD4>UX,8I?
M;U2/M:+9R6<"YY]Y<U><]"5 FLA)7D3//P=O37LW]Z^+3[*CRPDOV\QG]S%D
M._8<U2:LI$84'T.QX4N1Q=%GU[C![_5M'Z0_H7WG2'B]D2LM;8RG*R5'--_T
M-H2YN<EG(L3/0?.J=Q!)6'<WM^^1DA)$%SR-SYMRX:^#O_HTS)5JK(ORX/V)
M.J/<^C=&1UH!\5U#?9[_^#"7O#6WW/!I^W7=U!3^]PR"-@CBXOX]?BL-]33U
M?A26H[W<]\NW:WXIS>,Q3'5. CP.L5V,GAW^,L_WJ%7]/6"2B'2.V^@?(?8D
M]8#'1(9)QWWZ,NF) ;HO^[7E#E+/):]+=4[)VK/ <_K'\+F%><];)G3T\'SV
M\4E0I\^G?,R_AC4TV%51!"WT@'@%.!X-U0] [,A7[P\C%CD.WA+IPGH79 B^
MT#0WB/..X.Q.RR)/,DWU++A2/1"K:&'8%7UZ<CL^P.4]0%[*]+(/=X TSW10
MNB(,<W6G)ZJ)]-&GU_.=K,HR"9.V%,@S]2Y0?7IUIS49^.4^PT7+/$F).5_&
MW0E]E5A*)_P9,@-$/6#>FZP\PAQ$4KP1/ 2:UAO=6=LW,C?02] &!6X\Y6"S
M(,1%B.=P2SUJ3^LS9G#%Y(*6O*FN&R$_W.2]A(:P5/UUDL/&?2#F%"#F19[!
M^/L(NUGVA[P#,2M3Y,$@(>_FZ_[2[903BD7?E*/REX[5U'<E/$G!]&7\4I??
M]E47*&S$EQC#NM?6OH\%CJXY\@@ -AXA=V,#M<@9L%3M?6N2XN1I@F_K[JEK
M  >"9(Z_<;*E_J7$C+'!FBT186_K+60GSD#[;NF@+Q$,TUW(R7[48AK[ ODS
M(XT-2/PR^($T-#LXI71_D>)N*CW_>JF/\!QGN0>K0LF8#X2TCRM_&+#?;[).
M3H]F+TV#2W38+3H6&J;U0J[>>EI1916=&U)0B/,O>+WVDKP>DS"WFX#'$C>'
MV*,^;*7OK+E_&-N9,;>O-2QQJ<&Y!-ESF^S9\EV23H*;H%R4S;XI?BE\\"4O
MUY&OA5JY4KD9T""/W$/E2>2?Z%B.]N:?.X')S92G1^[^ 6[)%:C22P(]WWX)
M=V[.I _,<+0O7,W]^'/ QG'^BZVM7_9[29FN6[*E*()1.7E-;*ZS=ND<9(47
MB4;+!*G]"1(E=Q('*AW\>8L;:AD45-W=<#6)>W=S'_TY<%3F 7LPI=WZ.2\Y
M:JC*9[S^;VZ^SP;U4JI%=P2IP>A(==^'J+M/0X*[I7<7S.*6<9)H5C^83\D%
MD=0!=S5X ^^]L7QD2#3<! Z/_,(CY>?9^7AO#.ZP$F^7E 4Y+856J<?KW\I1
M8^8?KSL'7;!2QA!O42\&'DAV+L*2$%X!4A2GN?OH5!'747V8C%9.LW^HY99K
M&-J[?Z=C18KR+IG)6*WL>*5W6I]ILMNL9EAS6?%S>/@UU&-+W\5"QJHW^4#(
M7X#:DQ!$9>TSY>/2,_=)ZBEQI=>4@7G".>A:$,4J$*K$&UX+@W'"^Q)5^?A1
MMMVK*'R(U.AL8F4_W<"%#1_J-65I:-[!36+J"'HW*7V+8FY>/4T,_'A@6J1M
M%>#9'^#1KZR?BCAMC=T6[%\T4&?Z6*TSHK>L"97\&"4D=S@RTL4_ROL5F%4#
M\WX:$&N-84)@LLZ-U'/0'+26.EO(J>G=(!'8[VQ_A4*P1LSOK7/0BBT9G?]>
M5@ <Z\NT?[I9M-)JS;\[24C*R924,)4%'27J#[75AB&=;O?R.C9-H+0.T6?M
M[?N+YR 6NJAST.Q $?45YD>J\#TV'%Y'? #W:=02\":A%\I/*DD( LS*G79<
M7?]3>@++EZG4ZYSFNA(#:^&/'9&XE!C0=>J#R4$@(5B@8KRVP,N6M:?O8=N'
M6%/LBD6@NWLR-ICMUL!=EP9X#8(ELNC3U0TG349?6IZY3&2.\ALZP;+.EAQ?
MK@0@;!\!%C;$-;@7GH:2F G_1^(_,)HRK2WW[C /U[$2K7JBR6-84E'Q]$ZV
M!''+W%PIEB[KDY*;8. $RIKB;)XU@9L@CZ#G'S45C\F6,C6C%@.]0UU7O=SV
M6\35E!(RXE.+DEBG^5)T]'5'+TY<7/?)^UHT6-FVMHUO&GUU;&YA _N= ?[N
M;KZX\84NZ(RB.F8J'%Y5KD@[I=4RX2G:_>JRP*)OZ^N.\:88ZAMA_;]V(=GH
M),,A(GO#B34I 2:ULV*TZ]SD!Q%M.@E=FON%RYK2^HP=;-5-Z[W]$QOHYR4U
M'W L_79^_V:S"K]T9XNQN6XL7*?J"$1EAFM:NZF+$X9D/6+J(.P>2N,]?GM]
M--!R0O_5RP:</SXSOE3$(BS9W)5;RU7YANQ--<%X9?UKW_/71WGB%B^R ;@H
MML# OK%?(.>?@]+I#[)_!\QMR1EAMC,.Q(*+@]0#8%MNO\3:0V=>]=Z0]LAU
M2N8P99)]?K1K4WMWM%RO)F4YZ5/FPR2[FU7-_U'\&0S[UF1Z "'9P?A+$P*%
M[AV^+-]V7VD=>]*7"Y"BJ[%8$F]>#,V41(?JS\Y6QJB+\<_Z+FGR.*GGJ^OK
MZ6M?#.,$8I!U$!0VHX/N))R#F#91YR#"QRUJR1<=[GM@TAOO:# )38 =5&S+
M$,]!*:JZY.RMM)1!4PN8N]9R+>$RF\N\!V.UN:]JA50)&W?4I^8O[_<-,>J?
MPC/3'NQJKC-"__8%%GU^R.)XVYWX0ILBN5)[#OK$1KTD5UA.RJLH:."E,)Z-
MRO^7OZ8M5N0O<QMIUIL17 8[IE.':WQ;ZO\$:E.;%N?BJRA68 8_;\JM$1RB
MI["FP8*^3,$9&K:E'9TR$/VDLR#A_3G(YQU[3LJ,$_)9F50!JY,9,CJW3#0G
M+QWNY\MM\GF/ XK_7)HJ?[\6>3)"N76ZG]=T&KSDWE$:.AFS?%2%HF]0T ]X
MTZ/U::;)/Z'OR/!J39^>'7+/-Z7LT/]33?6Z@)-"O\]2AV)L[OOK/0S2*(+A
M 3DOB.L<Q&]6.G VML^VX'X )J60?S=K!?BO7ZD)6NKR;C[+F*LS82]NR.L2
M$F)7\/52>#A>+&0C*7Y-7; J3F=4/QF99\Q_16$39SQW,$ <:J16#>9#I++3
M34Q&]L_/F886.4I'#V!3/3F-;/9-9=]:$G)NB\&EU2Y6+#E)G8Q<^44ODHQA
MXXHL 3#A;$QN </S.BS2T9W..<U7 MQG>,LIW@$YOX[H,1ONX6Q6K/6U"C2>
MKG3MU6*FX:E"E[0D_\G$C!BZ^B+7-PL"_C%0E3#0G4ZSCP<L%1-HV"EO#_A[
M&.4USFWL,A)U2KH/<0DI$.3H]) -+7>@A;=Y7)XX)M0];]K)" K&^1<C&I)M
M^J8"%:>;/+0>Y>5OW:CIW_K.S_+IRIQ 1,%/(V&]IQDF;]TSBIW7W3.H)28X
MEL+(.(7;,!'M9=<Q&'V0J7OCG"FY@M@RBRU=/#XC=BF'=MEZSY#2NJ:F&M,X
M%Z3P"NE.C6-",F[*QK.A^"M.QHM?[/*=?*@EKEUQ9U.CB!X&"J/%/N<2?7<C
M^4QQ;X241%:8CC\B!+DOIR>XZ>X(A2E_:!EUA:."GR'#?<OJ1 WNE\;SA&2:
M.$11CB6 .104;F^W1)%B  $P#T'TKA8XO(<B;I]:9]4P8YJCME!K7-D9N$0V
M:9;:MPWA#<QTFFI&DMP2#7[1!BE)7$.Q47\W]HA! +^R!\,MSNH8* QQYZ"P
MS05Z"LFU%8!]ENX!MO$D8H&#S$>8M^^$)<B>@]P]T:IN',M?4C?O6CBZAVE)
ML516I6:5.1>(CAA>\EGG4@](O$\/CN:-+TAGC,N%/\;B_#,$JO<94]R)AC&M
M <478X1N:)/DQI<>YL1QA<'Y:D/MU-@D] HT6![^2H0:05H?_AL31&T9K>*5
M9P$3IB?J1<LN$[J+NC9*(\%BX&1]!/MQ: #> (J58!NY6?_6URE20:_Y88JH
M.UG:^==\@=#-)U?,-'Z^Y .\4!< ^]E\-24 )@=>,2#WG5@)CELOWNM9DR_=
M=<]M,.9,HI4Z*(K.N@3',1&/"G-",C,\4N@J&=]V,5P)ZB](M[\QYO$5B E^
M0![[? ["_I!*I@@*GYR#9E BP!C_;?[O/T99(/^(I<R.$KOVZ$F^+HVQ'>XB
M*^('"=:>GHE#3\<J=?[DOWMD\^[)YXX<90$CI:\]S?=\QW)#F$*-XWW<*@#]
M9) XBV:@ &[.S[%224YK=@S()A&^DS UI_2URT3ZY!GMB<GTQD+L=_D11:/P
M7U9.66VK8KOVQX=,J3'W$T7U&[6BDSE6LT-R?7< Q:I:ZGPTCMFV(!J@^^AB
M)E--+S5ZE7B39(<7*QZ[MFC0Z0NQ&VYL^CT)SU[;B(<[A5G?^"E36';1C/K\
M&4SF_<1_%C:"[DT@"1^7J*A)@UM@L?X-I5*1OE]U!DS'<9^GU".%#>*TL0:1
M7]YV+G'=_/I;*2%;S3(LVQPP!8/V\GWR- 7 \,.YY=I]@3^K?:ZM-*\"VBEF
MJ82RMY[L#'5Z*'@E3 $BD#C3X+-%XG>\3[FO^J/;QB;DR:>.\L$>M>14C*(Q
M+9#;1P8.1+?<XV!]#17@6*,V&3-;HY;T(](_[Q&]''Z_'2T"#*'9J1 :8],*
ML<2Z'Y]--0VJ=D>66-8WAV,5C?D'19$^V:<Q4'Q:L[BG>Y?[,B!ZKXFO;= G
M@D7>H<7W87TT"W;+FS.A7CU5HJ=,JS.F_#)F20K)P"B6WWTS&+$J.]7[]"GX
M(8]?TQ/=YX.*&@P]P$J96I,!#ENA2WIR#@H_:@(34KNH+,!B9\E\-.4U!<!'
M W3@^9\*IE>1J]  ;]*ET>\NU;295]>="#QGVYJ2\L_%$SUHR_I>E<0SN=)F
M%+E2FU([M^XF9X 3[4Z)NI4G#*N8 Q>* _AVP]REIM2%<U @3&1EJRKS]^+[
MOGHC!@W%T$DFM@N/[:;'.*!J1H+H94]/3:?F#4^)!"9@(':E*^+EZ+ACW!HL
MTJ([E!1'N"SKJEA.D5EX0UR?EJ\V%;J\DM&Q?1<J/!:LT( /9=;^_'-&LMPZ
ML> G4MU/L"KB7PJ[G/J_U 97G_&S&!+-/CV%(8?<4E.B5-%P?8F  7^%]48P
ME2L(DN/F8B<&$F?.[,/[<L7"FTVZPZ%)-4FQ2PYV^VKNU2:8[/>LPYA; ,-Q
M.0?)GX.^2[<BTL#]VA2&=N8V/&$J$,MK3KA-FFDX=.EZ#6UM1ZU+:>\ZF7V&
MWWXL)G8. A4?Z-T6'_$)3>/<5P7455;RKA%EX0O%QX)8:LYW#FJDMP ,O\8&
M6#P^('@]L';7K^%/OW?9[N.!9'G;.?;0;W-IE_1MV8+9E%7-(\,+[\L_^MKA
M438ZJOIR[.N.%D'K.-VB_O)]?--X(\?_I=;1-#UI#'!Q@&7/2W$0RYH:SD%U
M:99 H"X8(3(=O%] [_<1%\D$"EU ZW:1M#JAAF9%Q,/K<L]D0SW_96U/2T+'
M8-N"5)/*W*?TJ\Q"/"^LK/)OCB3Y( L=G>Q?(9>-J5K "[R;S''JH=J"("/1
MI\0&:F-1Y4T*(\#@;,T!GK9S#NIHW*(_6Y>BWFELPG$0F)G;8&0;*8USD+]"
M/R!6AJ\OV3M!"?M_J!6L%YLM @IZTPN(K0><)*C:WIR#=_^RD7FE8I,H6S)-
M4G[KLL!"6,+M<U"K5^,-ULPAAM@O;:B+"PAJ]>E%A=WI<Y "^'OM00?%[DST
MMK/H7HSM.4AD8RXX4'*ZZVZ996V:C8^,V?A:*:;87%"2Z7IDI^OWK) 7WY6.
MH?H'C[T*(ZG;S-SGH 9&V!QLUI(J+$X"#@ OF0<6)QRV- *L5NA+:G1Y2\TZ
M3J+ #+E(-,.G[G^.O%M^[%C^\4 (^_4TR]+SH66NY7=+7Y8*CVY@83)\YF=Y
M,W+1$ID?G59X<S85G[HMAWY'JP0LQ1R1_ASTUI4,##V_^?<Y"(>GFE -_(W]
M>L4C7P[B2XL>CGB.?RG& ;K$"/0YZ%N,<8#:')JWF=]-&LMTRO9.L=)RP/6X
M:X6!/N7QS,O59/GCZF&)R]*YF>(O=MN5!  F9]1.3FY^< X2<@%WG8/BYD2"
M&,]!HN!D@&3+0MQ='@8)$2YOD^B;\FO3A1[NBVUO3\3$APHVB%^ ),7'>>B.
M#(\IQA9FYM+'9^^%X:V R=O^+PLG_O_EAPLXW#Y--D5J^YH0:4X^H](OS]%6
M6O)V=ZN==**+?H0%O$N\1)8^.BP,P9E8(@K^%)_"G?]-E9/+)7\)X$>/_JO\
MAM. ?9F_*4W*S"E"/ R;ZNQFY22.#7V[6G _*^-G1M:7#?Y-9Z>->S)^)NHF
M/K/&N8GCCQ<-O6T-N("/Q&R\GME\2=AL*L>:RS?N!H:-IPXGF9QE-1WW-@=X
MO83SAR%-"D(R6YP<7SMYW^R%9Z: DGA]TM@!>6W=1_ZX+E^/8Q-83'>NDG*E
M#_#BF2J>;9#.GZWA'9BP]/@-:^P5EA([$K7*\'.T.JTWE/%.8[T8EWL/#,R=
M5N$_SPP^SDZ3K@Z=W308_TY9W-:*FV 17M[Z8:1])"4 G6C1,*HC*+B5L-ZU
M8[C^8IOPA/4$#O_:\567_$*S\LZ"H0>^:;#]_]&Q1&9?;9 -V0*'YI.EGU>9
MP4<A$DFZ8[+T[%--P<.C.X^[%]^FZ%X8&NL<^'NH=X45I9:7%^++C^3;+!^3
MU&F]K!*B#J3&R 'J@/'=I O#@;(HF3SK8YB#"RZAR7_ *RUJ)!4L:\KHJ]67
MJ,N@I1:"^30&78GCC=IX_7":_]62&O]KKC<8@'>&_B<*AJ]7R6H7^VF4$K2=
MO6^<3<M;CJ=RLKYG:PAR;_PB)<(4G3L>=]5ILY K//TFUS"7;HBKGOHZHV4V
M% +\;["SF\OM(ZSL>U_7@,^^KM4-;_7]4]V6K8QO\CLXKR\69.?K)W(FWG;R
MU?V-*OS@TDV' 08>9M2%7O'=%9C'.!^5*I/C24+E)P-ULEZYX0A+Z)CF$\TD
MPYQW!N)#BQL%ZV\GR1$+HD=CWRHA+<:QIR9J]E$9:G!%:JM?U9[_<[W/ZU[G
MH,[^\#76V9(.;VFGK>;Z'F][.RN4>W[9*;SBL;,TSVK?6(M25*OE6D<!?*-^
MP\G:\"8G%_^"\?3#C\#RC>([=]*_;]"UCYTJ5?I+V[NDX7"I+5[T.MN:VRZZ
M-@1AL\_V0"X_8NT-'E%]T*4WV#$TW-8CI-'.0D>]$.?^GV,9E)^R^-=/.\];
M57\K:&";+K7"N]07/U*.>F^_ZFP5PU=?4?# $?EH<M>DI'&8:Z])HYU-6>-N
M&+=&6^2=T__I2VMQ 9T4&S#-.2AY6:HKGQ2Z+V#K^2TMRN30E),9'L$=V[D4
M (&,C.JW1OP>7-KGY% 3,GN06_W'1/W-?%ZZY$4 '\GL'@?V"\ENA.-38N7X
MV7*%M'VG6^7DX^:A.7.-Z"3+9,P;\7\65S.Z-&@'VV)N1H@\'<EVVQ\.//NG
M\ 6=^>,$(&UK_-_!^W'V!^ ?YZ#[2.]CI2Q9B(U7OW1A T]#'H%B9&G4$I_=
MX19@RZ/0P/DYO20E.]?IY)I+#E_^"QQ91"3\647VUW3 UU[_KSPCPJ(;]MV"
MI?D6=):C)LC0^_;HNC!JANV488SH.M;0IXH=M7_OSK^X=M/Q#1*^S21W),G
M^(^NSHC!Q+B&MK(:1)<915#$]&JO@'=A?VY?L'6S2$8\. 9K+C8\0*[7,$EI
MB;'(A9@I<W-!F1Z37UZ+X/N&_)GE=/+>X-6WE:1$NZ@-GK [TM3:<92IF>_R
MRS7'E!WLDSOO3MVA;]:E>69[(*&O-O*=?T87Q&=<#(^_"+^J^\O6\*\OO^2
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M@V]8'9U,:6XL.2FE1-QPXDV"J%3__;V+*V9Q= M@\Z\(><J>,38[075;_6V
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M31- YO5A$=+2;"^*BC &CCP#JDS)C!"]F1D)5Q%^XW0$\L@T;1PEKY :3T;
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M/0V\\KZAA-#XR:%'.[%2RMCV,%SQKIJV_KVYG)R+&W\N=$B+ U 90P-]Y ]
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M'+_+9ZRF9MDHR%Y16I"RI:LI<PXJ5D4?6.,9 01+Z.^BGZ\:[4D1>'AED*E
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M-^13L.6Y.^VF@.2'-4EZ.A689<9HU_\_5@^6GP2= >[NUDP3!L)+0&ENQZ!
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MIN+5']PQY3M+)8DF^?8U?PP6Y^MZM$VV*-GW0F@$(/THP'0^'[$I=?IE^PQ
M/YY'S'1"-<<"D@01'9[B3DZ4N^DPJKV^ANEI*R/*4FH0GV&T^WN5U5,G':ZP
M==+/.5G?.&W(HI@BWS-EGG0;MR>'2J(A"FIW*BL*/W>^5;I\<%FE(Z$(_8[_
M10RC8S,+Q< %C0U"T%-<E/W@K-LAPF$;'SN;L+R+)R<3S3^<L'#:AF>'..5[
M&WD]7Y<FSZPA Z5[$S\-DT4-U!4B7S@B[YOR:?U&![2)DN7TSSO#I"@:2^M^
M:\-^FU S36\;]X8P@ ?-$O[$@KPM9:[O,HU//(<:C^SQ!%QPW!21D5DI+([A
M^#$"!IOSJC:PR8U?[S?*HZOC(V'5X2MP/S=WGI(Z<1+UC9E$I#@UMFJ7/,V4
M'"JF,+7E[\9(Y-7!):]5\7CMQ T:;2ZDOBA35$K*+].\DP+S#]H0>C,P*GR?
MT>6= H+["BV9'_C1GB NG:0[!-"D6L/,0FAS",$6.QNCJ=[QG9^GJ:C*><L^
MFU4S?ZV4%S,<I7I1I6@BQ!!*<-&0=W'L_26X&J:G9K_O1-&A_KH $L"*(.0)
MJ^4D! ;[< =[,,>&N(;!Z.)\5CR"@YW-VB6UO18;IV:",6P1-.(C$Q.]!B^3
M#]]U;^YZYGI:U3$Z[IE2O]+^W,:%M[%1,]1M0H!DS/2/T'/46NRC_FEN7+[P
MXMQTVW!CRWJ]UP;\&A5=WKW^;)JW75 O7<R(W;0TMXR8"G.W=.H:A3*>V$:0
MSP"D;G?$71S9I+M+*FW^_"3OGCZQ*YSBL=K2ZAN =]V>6YOM=-M<&O 3'S5;
M=.L=^9SZ8H*F>)2(?R)85EAN$:[-$4 '! =&%WLIX$&'/*F ^3YQZZ.RT&G:
MM0/TAN662BSPR'A7%KPNEOSE[?N+(H DJV>V[V/R$V>TV*[04:G"^C\8S?BG
MX)^"?PK^]PK&;QWND7HH(M.$ ;$J6@CU#$"1KU%) L="6TN8]EOS?SIYC_D,
ML$_9#AT,3ZS7C3? #DVG!W:TF#P<TM3$]!KN=LNY&:KJ+= 9W/K_V/R3*I4"
MRG/PW!E@T'P1=\#5<P2U$ =U(#,7N%G\8$5LU[-*5-(7Y#@_WAEG2QW127RT
M_+3IXUCM[8?)AL:FRU>_:K $TE>L1_R?5^$_!?^/P!3!&#-.Z+!?K4N</E%I
MD[4-_ZB27//A8+UE:_D,H/W8;6ZV7U'W7"G$6#]!UT.X['V:IZ5CC-5,GT5A
MDM(OS=?U>ND$H(,2<@:00[RQ'\![[0VL=]DN-KG,Y8 SP_T")J%'"J(%YUH5
M!EU,^CR6^AU%]6=$G(M+(SQ%5DN+/6.LT$^ETW*A= 9?H<'83P2U$Y?E9GL&
MD*C^ 9-R"'E,*2<Q\TY9>.\&V4Q^F4_5:!5N/%0X3PY$)S\?F_3EN>%H5B3#
MI^>J_C!)V;,Q($YC\]CN^V6:#0*O_1Z4B7=8#M#6";&@+$_./I>OJYWM/S_?
MMEJSWY0399?A.55SF/&3M_?-_#19M!;E/Y)_G\=;WF1<K$7U*J-^M57J?\=1
M^$/"C*@S9"+QRI.09S.VA!:2A=HH"8>]:\\3I'@^NFO26;#?-[3];4'W2,>=
ME ]M"NHQ67I3*V5EY6D<(RJO9?I,&$-[IO_-&A1L2!E%>P1Q1?E\#=:(&CM?
MZQV6O=ER6>]TL?E6?F5/_TTB3RH[D/>"G 59U$O44ZRVF<O3(ND>?M>@J$^+
M<W(^.,^\^K@*6!O U[MM^S&UYIOBT7#7G@U/X!V+3?8$,6TFV-U<N4 3I=>R
M50WF3RJ?</[=_(]?[:#4$/>^H6QW^ 8I-UMJN;W.3=F61VXPA>M&=8^OE,MR
MEZLW)"WM__@PTM7+VO"'TZ:+!]KY59KPM\2B'+5;='*JH/ZOV_'%[Y\!UIF[
MJW."GS=AHKJ9>C/GL\T+5?;DB;@7;L^:^@9LGNW:XA(ZG)_%WF<+>6(*?=3!
M]^RWB;RE-_JW^Y?-XDUTU29;<HA[:^G=N)2V>))UA3((/NXGT4X4HB?G7S$!
MXY5,IA+L(-A#SPG<%4-C<QXF>^.8+*2.YVH$5ZKK:5-)9IHQG5)J5?]WG^RP
M(:7ZP&NYFT3YSMM-LEXYVNKUX:N>S11591EW>-HP[3GS$:FEP?:K.C+F%6=1
M4$PS-"+P*I3XMUU@?KQ^ FPW/OU?/O[]E=6;O0O)9+>O](T[K9@1#<-'0\WC
MBWO])+YZB(G-7+>UUXU^_XI+-53-U,70,,P$FY7TVU)TK*'R^2+87?II@+=.
MMZ*V<Z)J@V_Z"7B_8#JM?]HZ>8E/EUTYHJ!ON,/60"B>#XITN+I5:3HG9O/K
M8TEZHF'^7W5$+/M?H3U6O^PSP+TP-8245$)K[$IW;UMOYJRM"^99BL5YP?DN
M,Y?R+1E+3B[1RY?UE._-96[:6ES*7"R)$_$HB?]',Z;F_^Q"C>:#"0FAT:2]
M9BRS]^#XVZ&0</+QAP^G47/!03RA-E +/;5VIHMF7+DV<<1.0U-;>XVD5V6.
M1;(5C^Z=1,4\J,'0M]?]GXX.2@D]T%\FM".;9TY1)"GXN(\M#GL"8AZ9O9S,
MJ6'ZMG+0MX*,]C9CC\Q-4S0M+8N,+':2T&C7OWI7_\Y!5_ES^A+E_Z9-:'6&
M+)(/<R@-36> ]"[N9Z[/@ )'\ >*O4SSF-M=9H(JO(VXF,4G/W84K-R7"[):
MJDK4#(B0T?I5AQNJ.U<N:!_;;:BUA(7]4/A*69P ]9>(Z4_74E_OY&;U'.=.
MH[M\/D88347]'I^&%<&]V?TM9?015.=IZCDNS1-CX9+"M&+1F<W+GM6PW;^#
M$M9.B,CR]4X$:7MJEGLEW0<N.#+HU#CIY[=0-6T::!CUH58I1F?K*32[_SE7
MUM.XDY]P/QXB9&Q$?!AL*/$0)JW*3\>&Y24$?B&2DCU%$%?&E8@$*TAT[T\V
M.W\?FB\C6/O=BN@>S'XS7HCZ5+Z9WIY2@M3[/4WS5^52R,ZF8#$R"0<T-J>K
M9.8_':&].I1:L &*R#DW11 *T]R=5@ 9'MI>% C;GWL[;+;B$DM&ZL4R(U]Q
MB8>PR:?*LTW;Q,N+Z_*X'0N:K/)?W=IM^UH^>3+)/*W"['PDN: WM<]]XKX,
MK[JFFB0.NZ*=6A#9D@'F4BWC^<PY:57>9-9T]9,-_5>K_O4Y73C=F9_W(%87
MMZK@6I.?Q)>,Y]ROW3JF4>?4+\<4%W4M/PZ*B8I)2A)!H]==#*7O7_43'ZG5
MYI*M#:=_B"W-'C< *L=E$*QW)2<W)0LI(A/<4LPIQ26S%%"BBN81>C?$)T0&
MN@QGGT!@JZ-D,22Y'H%7:"76#7]+)Z2A#G9K'EC]'XP=_%/P3\'_O. KTP+G
M&0"9(_:FEUJ[5_W#K7:C1<C1E=V7N)"2HF^+>:+$GH>2U=9,3V.O+BKJQ\?E
M'QB/WI,?'1W17LIRCM!N.;:BG 'XVS#-6*,0"LT#.+CG=WBTM%D=:R_[G!M<
M3;OK>"PONRRFZ*OH[K34Z:+XL2G=\(G)ZN;3&NBHP:Z55<QV#-M'3<)\<&5>
M*-WI[; VB&EAZCO&N. %U,G@"F/#Y0DD/&5=DUK/^&_]/"_IR+ 4/@&OKFD]
M9JII#*Y!7CYMS]TSW(GH*/+.6W8GUA^F]D.LC%\7)W&F 4;K/>GYU.7@[#6A
M@Q*:U4G'(HK.AZ7Y>LD')+&EO0')K5G>6W.A+N,J&B>MZ1L5:\0"C=@$MK0H
M,'' 2#G(,]S<.#4+GN8?I&.KJ<E30]]-(V-X9ZDB)<IG;_UY])SM\1R",\R+
M^O![;NRF1)GM5)OTJ*7MW\V5G6T;3X)MG$GDG-'T(?#;!!Y[X>1.L'&4CLV7
M#[HR?[5,@&&[Y0>KB@>ME'ACZEM<&AQ_!HCS&,]V6O'KQZ7,^BU74=_/6UB*
M-LYE,F.VXR3#1*U$LYK1I<*B&+M^I(XSVXU!)FXV2XY&!C1Q5-50_*ACZJQT
MLN\7;?_'&2 #Y^\OU1N62W-LA02,P8P6-]K>*U2T7GFQH^HCJ-5ZSG#3*JYJ
MUF+UU9W2'EWKMZ7IMY,Y16X7RAT$5_O_ZD"#G %4[-_9JX*R+W6BHD!"80H_
M^#K(O-,G <EN+IBUSX5#;K5"=S-GWAE-(?,+^V,3>--I%\VOZ?-#].5=9"1N
MY;D7!J[2+6Q$J!6!NMGO64T&1_;3G.:#(Z=#34F$BX04!-])@M_JDT';-U'2
MR/X5:<N !):4^A_:_/IL$GZS*O4I+ ,_<BU?"ZS0$]RO1W"/,X#,&6#U#$!$
MK0,'\&O9"SGG2"P^AWN/( 'K9OZ37978J<NV;6F%^3T\0Q.Q8HG=(RLR]]!Q
M?W>V(ZNJ<FMKLH(HGK_<-FEGE#]6+N &KE#6J*KDHA%ZUDQ?5V&/3)@&7F^5
M#$6UG)1\6QB8N>$ O]8QG3UYZ\(]Y3G!-;1[+6PV2T?V'GG+X]DX$UC?S+'X
M-\*J_/GYX/*_-Q)0IYATVG.UY?WS-9X*E0@#7U3$K-.:_9>X-2'V,27^V-*J
M_,^^/ &^M58;H&AH;VI6?M#YB^)7V'C%B6.R R\9'_E1&)2KV*N636T!98(.
MSB_,LKCXQ=E]IDPW8T414H:)C:4"Q8;M\5$@PY>SS3P?$\W&3%UMA:K?CG,Y
M&!VZL:E"O_[E>H,QH1RZX9<!' 0OV@]51YP!.$"91]3O"6]YX=3.?<Y-(RS!
M5JAQUG=PDC<JO'O4Q?/(UJ"@73]K%L]F(U?/UG#Y&:Q.]TX1/S+)-)WNEND,
M#ZQ"',CU(%2JWK^G/"65%-(\0C0V"$@"E\*OB[NTDN_ W5_6X;^29U7,W1#
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MC]H;)!NI6C-NE.XU%VEJP?N^(?63$F;VG1@M.?==C&P2] $0O4R:V^DV^8-
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M4%N!<CFCJY(UW9YQEZT_5\0\55FQM-][?77-C0\!C%=AX1Z:3?6A?42G1#)
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MO^#DU*SQ@CCO[!_&_;"PK!P3./GPZ="XAOEM9F1V+_N!WCH$-$4VF.94<<
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MZ;9U+>7Y]/Y)K5"2S!G'5_8'UFLR- 0#1%C'TV"Z>PS0\@'@_X8CF6OW!TB
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M?'W*([$Y>-T#]U8.JU)<5?;5[WO\E^^'<5D%7<<#4HD[E)<<J:?Y4@2\ !1
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M=T\E):H/=(#G\CC) #T 0%8"<M1=F0.ADB;SCU\SE0%^[R_ /Q<!SI%-K6&
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M7X]!_J4Q?NU36GL?;X9"3:(? >E#OPBH!2_;33C-P // #4YMC#-,?IOFS'
MP)6KF37>Q[$ /SY-A4Y,!6=/WS<^I,K4D#UU*V_HN]Y&=,_7%7$,/W#0L&/G
M\ZFYY>MW_E21S0L 3K"Q]'_RZ9;P@U28/)RT6@4Y.OD?'UT [%W&,$!!<B1
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MS#=Y?URGV#6J$Z>!TRT.T]]_F46+/,@JNSPF+DFX=HX$1)TBORN  RG42S-
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MIVE<56.I090/.7P&:VK.W9'RFE=)C37<,R-&+-U>O]:PP\ LU[!?&!3$0]_
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M)77.[^"P(\<6,Z9A35E1WG-25HAZHE)D=M0M'3X?Z,102V9A64QVW1E;]83
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ML755>I?;=7L<7)?S;55%1FQV;IW_Q*+W'_5C<ER&O?7[1MT3=^4XGR1&F/(
M0-=SY0WM6R"2FG,@22=D!=7 >8K@IPI;N<M*E+ORX'[QPD<L4\.&E740LUMN
MZEW"+)%?JP<3.XT@!I"+WY28_J75%ZD B8 [43-]8:0/A8E(#T*2=7K#YI&J
MM=^W@FX3]ZS*EWX=3OZ5,CY3 YE%_4\=-E]==RPI*BS"FO)P.?R66/_'A'@9
MLQ?T_TTO_G_^H_@"G1U,PBPK='O&0B\J.&&YOPT=F"YM$5?UIZR%.FJGA5\6
MI/(VU)E+;!LE=2M6%I2:VY:A./56'S_RS@E%O"Z8I6_BKV#>)_/(!;] @AF@
M]PS0P$ 5.$WK"^%OPJV[F(%C+OP,#:K9%Z.7.$B]5!56''4JOBJ_N!BG>+.T
M;4M.(C'GY29?;/;+Y_XQQ@FLOCOQF#/@#&2?5!1R((\ZZJ &.5PF""F#J?JT
M#_,HGI]=#<?J&G)/UER>_35[_ 2E:%YWTN.3G%DJ9J,[T6;B970^,N)7=D!7
M1Y%2X+>8H>0SG^,R3PIH4ZVP:C3/Z^TM*0?: *4/E_;!/1C+"9<+*>DWW#Y)
M#>WN@\3BFFGV#?OCR8KG3Q>&%?JX'&M#=+DER_#P?&[:'.8>LU<K68N*WV6
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M,(\O"7]F27+[F?;T#?VLB&V=(51F_IP_)2]/.0&CJ>8645'N5_:6J^I&=&#
MU7/,TB$8K8L.H[VC7IA%]8M]7^ND+_-PU6*&^)Q-CU8IU&OU0Z?-%-$M9-;Z
M]:-WXS@7Q91 2/M7NTN>;^_<>*AZR_G)8-T LY_M XK3-$&2V=36M1,I.IS
M(]YZ8=4)BTE 7=]4'EX,]T2$%>>G!BW5M;JXY'_=UFEK\BN?&T5>Z#6U%P@
MX/8+RX"<<[FM9@ ;R:0J^4Z1V>@. 94K5+$9!F@H<T6P?Q,<"1W$O?(MG*60
MZW,*+&_1>=SDY_M7:Y3C9#BL.?QT63,['9=Z1@V^)G9&9(O4UF@9F-PU!Q1&
M#CP4YS9N"_=LAVFZ GK31N<^K!2S'YA&LG=P;.L3:AH##<T,MG.3S&ET2:6,
MBX>DCW.M(=G(^K 6Z1V'/\;:[7<_,NN*M>GNUO$XZ* 8G4U[5XP:=E@5<+C-
M3>E<)50H*Y?O3GS[YJY*S7CKOR*/P%7Y//]QIPAKXE B.%-E$?UR(488)V!>
MDQOA4P7@F%^0TF[@+\25R[0PNJE3(&QUN"][A6C3@%>&>&UA$A@@7M*>1_NZ
M[M7EK>V8L$JLJI_MS8V 'WF]9B9C?\:=NZSQM!,4_X@9<WY$^TS5)9_!'"=2
M]1@@<7 TAI>$X4$3!Z Q3Q$HJC=)W1G)4CJ?%I0>@=L=HB^*;.PS0*RE>(M
M\5!9W[V<9)=)P1A].=77@'CJ0/]J;R>-+4#(3@2>_C/+57WX [),J4)5=X9G
M"O(:'-.:_^9H7CXC44;^5[3[:JWH15QR*8M:A[>%2LS3PG>/V33TRB  ^L9P
M_=Z!R90*1/+'SM'=J:RK9%+JI1GHC:,=,YE)O';L]:;&$]^K-UMOQ U@6V:$
M!S-S-A:_# A<DGRH%!W$_QY;FJTNE #X'O02)15_:CF\!QI-N/,[EZ8*; J+
M3\?_&E)Z?S&%E?ADKG=-15J#O:[G5GS088IQPB/#LV:O3@&_6%RW%N>!**-6
MT6;]/$DAE'42#(F0V]"/V?L5O5+4S[+UHV\]A]!\OTSZV_:6(^ZS?7Y, 0[I
M*J_+93SQ]'&#M(1]G(.EOPI@(OGIK)[@-,ZXY3-D!;HF08QN>QA,G#]Q&)^.
M':!@R%:N$Z/;.Z.)+W8V E^*EBT4?TSLGPDJLTK,*7J68R?K2])QD/@MB3EL
M0Y@!VHTE1,W0%+I%U*P'2%;+\E /C[;&@_5^STA%O?U1WUC)0I5Y?)5R*R?Z
MW*[13LFUF^-#EJ<!OVK",ZK.;)W8!%]K/%S[<Q_I!2LDEA7DS+8K3,SLC,R9
MF$0;\N=^6MRH3?Y].K#<MN#.YRWMVI#'S&+_;W'4A^[,H65K*)(%U7V:?;>2
M0O?FX5$>]H2EF*:81&:4B5BWN[:>\71(_BVPH/++V-1VI,6"TV4LSSN-@-MV
M@%28,BN9E(@7G7HQJXH,T+D3(J*W<YMEI-<WW/.(9:UB<R>Y1RL3;V$?RU(>
MMWW7/]WE!U]5I?=M,3;C1V<O^D9Y,S,CJX.-'9C#P<GQE&LX%&>'PM&1M@\K
M*6O8\]E4GS65Q/V6%>T]?ISI;:BAK54/98OM7S,WJ=1RP5Y,JC):BQ1Y+65T
M22@6S)R]B$/RZ<RT0JE%#-#G2+4':[^#AJH&:5*]@_H7!M8J\[$'0YID7*Y?
M_(LBD[R!L:??9 U^2+ 9U.N+]X)E & 9S+FB=&U!ZS$BENC>.H7WFLAT<G,?
MPI/ C9N'A:)O_VAV"Y60U_5:K5.,$'9>2.1-J"HF#ZGJS>M$."3W.3HR2QMO
M@I,$1^>0EX(!LR6 2L&_@9PGQJW=VR.W'1X%.#@[F)>4UB;C)ENK_0XMGFJ5
M6F[%J 9/%V1?];KE17EDEG!:!E[ENR_+Y*GU[#?DF*TFSH?/'<-?C1ON<&/H
M9N!?7Y3-<L)Y?_WQ^5#+R?AYF8MT4NY+@]62JAF+XKR$7(448;7)#-F]\1L5
M "JRI6U0V-I:I^@<;-4_NVZ0,U>A.O;*F.\F6H&VK6*%: =3OE=N_:)ZO<0N
MY&OY&!\/*$>]*/2W _(([XA L!:?VGN7L]R;^ NH0<ZEH]='4)I(U$*JMB]/
M?S:6,M$L1#=\M70$@V\IZ07Y;:$NJ+>VJKY^;R?ZNL9$/7; T8+OS!V.HL*V
M!*V2F$P\/"^=EDZW@L&,C9'W41$,D 1=_9"G_W>Z25 9MYG'$<I-]V)Z)#X"
M&C(GMR_;K-<=(Q"LSOLX4ZDRL"62J!(A8+$W 3G[N 20V[*S'8^1<N/T9\XT
M!BB?NMT*10+_LNX7"9'PQETL]:H/8:@CK^H+<<XV)=Z:[SY\&II>OG;-Q9.'
MP H&X!$Z=&/GTV>_80O?*1?W=+Y,#S_'[FZ_TX0,H2MEWU:]]JDW-2V,?X^W
M/)_,^]<OX;<O,"/=S5,T5LIF,K7Y'?V%A02FJ2SXR79E3G D[K@0T>Z%'=E.
M%R@K#CS[ZK-![,4)Q?/I>JLR:LW+)T._"0,<%TUW/D!B&:#E)5H- Y3AA/0!
M#;ESS>#]AR9PN$S5-M)!>H T%PIC((\_;7C/@H]B7_K5H02Z_?SRV&FK<J\<
M;V;@*H2NH0K E4OQM FC!7T/216%8R5,_[4B-4,/G<>B[&-=&/DLH5V]?7;A
M.^H&$.OWJ5Z3?6+H]\;G=&Z'/:T^KO(IH[_DD;K+<Q:YH$_@.%YZ#3!/C^->
M.TRR-DY_"G5=?EFYR+>?*K$W>UG ^'I&=+:@HG")SD9)XLXO,6=YK=:9R?(,
M$*EO>PA+6P1G7?6F=OKRZ!UJ/4&(_8@+)].49JP2ZWM%HV1:818#0^FED<_\
M1%LEGNP]-=RQ?"N#M3!@%\R\E>V7HBVRWC[5PH5<N"NCU7;(0WZQT_\S4 .?
M54##'S]T[S3?$JB(M\W[Y) ;6^AU*]@\MV1.3I_-^:E]0DY(91DS8G ,\]Z'
M=E;%<&$PAV%=FU\_;GBD;0[US;5&G:FM23+7>_Y,4S)/Y'UY!HKKM\OM)GH^
MT-9[IMF.IXR4<<RR7& /A?4+FN@W:62Z+EBB]==L#@+/5[NEM8#M'5+_:'^-
MD8F#&+H"]GQ[J_9CG''#S,W DQI=%?'%^TN[?U?Q7V2FK/]@QGDK;#!)22-$
M!FBM$]#1VUOE#:I\.Y?*6EN09?>2D_4$RN.X(._FKG>Q7_'_5B%>LZTD<\=J
MU*[PX7">!2!0WQD@E>S"C9U&.@0S2):;:O>N:51SK0W,;?7W$W1R7BSV.@C8
MJJ>Z*#KT.;J4/(]$%'CWJ80/&XX^EJN^^ L:$..&Q2DRFNJ D*-K\(!?\0QZ
M+I]QV?(X^>IS!JMZLL?G.V9W9W,N^#,^4U!OE>_26]R^MK9. T6U-2KQAKRE
MG^*S4"V<J;;5C? 'P(+LH*LK=37P,(^"\JWA-:EF9#)40S=L:'M[XNV,\EOG
MK;;#O:%QW;C,RT9_S]^(6/>^3XXL#*DW,3((H.WUL57-4HH2H(!G'5XBDJ]0
MD6!2%!UN[,LC>03Q]V,E'1*SAB88($ZUYP8F=BM#*XW;5TU%]=2L7S<M" CJ
MNRQ]3*B\66$4\;SBK& &1S3S=O0+."6\4RKC9&;/[@4MEWJ--M]A=ZAIMG:&
MM-,]DI79.,^%UJXF<2Z="A_8/AFI+^R=I*PK>(QVFQD;=AAMFY9)O$^6;C#D
M&U.',#7G@ %ZEX-0QM^GJ!G3DL"2:D_-GK>4K7F^W#]MM52I[C7>5XW6-^:$
M.SV&32Y\=OUCDAB NQTEJ-&EK*7])*7E-+"R)JTYS""*&N8;3KY)=[3FI'6A
ML;T(J>X. @%N]3V\A[O]&3M.R__[S]%D5]>-(U\)Q%\[VNAZX9?%0X;E_K3(
M88.; X^_?>[8Q$LATQ3(/ #T,EKT))W:]OR; ;HC@_SCF(T:38N9/=&=;LU[
MW@7)P-J]3M^(5CO%GWS_0TB!O"?/FSE/P\5(;Y[T.RX6]@;\,<R&PM6;4BOW
M(K[0M+>AX0R04H<A#,#%TT$HO \76MX;XUH8SJ>E&U71N;IW[*:K;_W4L:NS
M^9Z1*<6XZXFS2^I5D938]*L0WYVXPCU*ZQC\:%E+&U& YWR-B/-"P&;A18Z^
M@F[C.O64%HF52[^K?1=[E/] 0M]!3?ILBM/IQ[97L)<?9;\0 JB&-B#^#_JJ
M>@=920MT!ZO7N:GN1*E0C&ICC^#N_/M/M9-"5D0EE5@%^.+G?)GQB3$'WOR"
MPI1LX7GH17+?Z0A3IM=,949!<V$]<2N;'0IK-!%EZD?WFQ 46%Y> ZFI/1ET
MG(+'*< F#>T5*N0]N>H5'EGQ^.O4;O9O1<LJ<G0]M;/>[_R[H##?=.PZ,YNJ
MQIW:'&S' ,EC5N/(K0L,D %M;D<J!'D5F4(_9>^^%6:UQ*7!SUGD[SDT!5&S
MS:Z32+6W^/YY<;5K:L38-B^IQXA+%&LT9+_.RKRJHMY"=% %\,JP56@W-+T5
M=V$&)8Q)A?5E[(3@V[,TN 0X/+9PWI'I\H7K?;8EYV)CG[7Y_QQA?TO_3>-7
MJIQ)C_$0LR@/V*1?J9QXU!5,DM, ]#V2"T:'E!W'53% 3<BYDX/PL-C<PG!*
ME>/6H* ZEN5A1F4\?8TCH:3(DQ_BD)SNTV0*91:;KPKYTI:V":M2M/@.WGW,
MT%<"I>LO:NANE40[O,IO2Q3Q1#.WI8JCEG2<R&LC+,/NZT]<XABGK)>L;PR:
MY67[E_&I2\C^":_RN0TXX+@DY.W@JXA>^FOH[VK&B+(M8LJ),JWM)]0#D;89
MNTB<[2Z;VV\ZWY[%LC-HX(CFTIL/K+ETVC">VQ+%[RHAH/'(79^]D U87,#N
MA5SPAVODWW_04^@NT-UUZ\Q1KAQ\4)U!QV%<=W^;]6FMHCU5HQ-20E8U1Z9+
MK+F13$KFN;B$P%M)0RR0;8>0L-S:E%J=\@3 3;70[96+ULP"D&J$6.3 U!)Z
M6&V6XCD6E$AKA;PZO'CBK!'W15O"07)CRU)GXT.0VH,_<P?-#.U>.H\V"UJ(
M\+VQCR0)7]II'\<DS["FG6C/0@?8J-P^#!#YEYW'"DB/[: ]'%*4 4IC.2C.
M*]G:G^8,+A.PB,PO*J\JCG])4KPM\/E!,FG(:BT_M^Q]_^=69G_D-+HAYDZP
MMALXDT<9DPSM9Z'W(\HREUBNN<(@O:CXUJ%BS;4YJS,^1NJK.<.J+/E]D^XM
M/TM=%&NEJ[-S2TJY1FX'&@-Z5KI)K?>P^40AQ%!=":I!@$"H$B3(NOFD9N#G
M">B95U9E5373I2J<J\Z;'V=FGK1BE1IABM$X/6L7UY<W"Q+ 32G18WTJS$U"
MTQV0@Y#68VGH<B@:!NO_.DRW(EP 5A6'/0N/6D;V[^1E7-0TN]8D [\9KO 6
MU^5;SY+IDJ&2_3!#L90O)<OPYE1%RH/3JNG,I@H8R6, FZ22'.AZ&-[65CDR
MJS+Y&/T<7[W4(0-3<!EY7I*?A_6\E2+&BN8M2;U\<63'#V<L8[R27U::DJO7
MKJ/DFOLQX68@<TP0Y/D.)AO:MU0/Z$>P'X;,ORV5I>I+OK#<.T7!DK4*E2/S
M+GK=O[6SW_L+I$G^;)Y...XZOFVZOR]6C95+SLHH-'DQ<-TQ"C (G=*R5="X
MJIS8TMPPG7Y%9[N*? &'T'S-!^)N9\7X[3<,S]8P6T]8WD7R@U<.VKT(7Q6H
MY;^0QU8;O!'\U,N3:[ZW4HAE23#IY?6CF5.-V'ADNT2LGG>DS+T[;&:&L^:*
M1COMHZ/H120<\8D!"N5G@!2_-JP#Z.QD9#?O#.M#7SD/!@B/XLG+*\+?B!>R
M]-VZ'BGZ;'_@B"*JHS3EDI$NS!]6F&/R_ K62SQX$R_^4X8Z1LM9AU @6@/@
MA)/$-D*KVG.:-E6CB7[IA;(Z0EWK8D TV5'^IRWLMY'.RS<>??J.MGQR)??L
M6E7J]1?E=LL)S8#ALO1CV:2NT+*5=:DPV)HK R3]9)0Z-@6]VZ'GCHQ&R@;:
M-97>Q;*]^4K4>\Y^_/9YI&QQ4$T,;BBZ/&WI^]Z82<-]"QNARA1FMZ Y]7]L
MC^\JF)J*H!*0PYFO;3$94WWT-S/(7]6>'\9R+F'-#\J3?'P(O@T Z1!XAUVI
M^T.=^_FVDLM%#=53BSFI/4^CAPT%']W5!U0<3:JC5M/:^Y"?H1T2R+N5%3NJ
M8U,$(=B3'SC<*;A?,@?+3:6YF.!KWA[ZR4V;_!]ED\U#HQ0LT,NEOX@L/>77
M>NR</:(%,)(\!D@.DLP \;8H4#\@[\S';@1_&]JJ+*5JX;/BT*UD)SO>7'\%
M@:LLW)A4#GTS.0WQB5=:CZF6M6JSYA<B\ Z2C:< ESZX>2F4?$S-1DJCUDSV
M*A.I1;0*2L4> [08[K+MIMDYH\JA*G':P!5]94?T@]*(1]*>TUUS<:OMV7CK
M!^KB3J(-K[3$]S0T:P:8J7/?Z09(N8XI^F,J9@V217?*6D>W\BQ"'9ZW$)[[
M.&+SL$M^E4NYUBOH1C]UOFG9W:HXV$H9P1?@=_T+LO%:6M<MO0UN9_/X[I0?
M4==BOU+OD<%T-G63,7R)]1ZQ]KCUM1^WM]MAK\PU]:0RG*'3/2YU*P,K[:@O
M-S-N;-[.SS9^X^#T*"UO4^ 4DVA\08"WB8G0@51J*TR(-$_E(7,V!3O2 K98
MWR;S*/Y$5JMIF(Q.>N";C:*&'$1DTO*21JNL-<SOI5ND@+Z-CHR-?NO1TH7<
M\I5BSEI<KX6_I68AT/1G)U.T0WDB66SK2=26:A[K\R.I1[2K.+L+8 LCMTOA
M&67A0FC8Z3NY]POGT@-;K&MLJAU$;^LTR.^=[7F6$335(HL9Q%'?(>J)53'(
M+V)UP=Q'.RL4UW9,N@+2+2NJC6REZ S[G9N[** +7;Q65(&=TOA=<NDCKKF4
M^G=1EG.H[<,1G=MLC\L 4ON9\$LPW^%P5T<=09FU2<T)AAF:V]G8FATZ"-VR
MH:?V)7<ME0G_,-[^:2NZ,5+\O%_#RHPE[N*K'C.NB[)[G5J7/7UW_JXB?Z+Z
MDM2+[D(O=O BY CF:I54,*V[0V_$AWMR6_R=CTE#JZZ;484*#NUKYR57&3^E
M'Q[6$?UXJLW@JRFGZ=#C+CP\%](@@Y%!)@N1U2G0W:X&^FN8V1 F$CJ(=B>V
MUS2B6?M$,RR.PGH)G"YA%_,GFLJW7%?+L%,F*S]*G&MZ<D(R1!MBTT\9/*P#
MK+$6)IZU4P)?_X_Y)17%U&8RFZ_4YXZM&?.8$>WF(P<3/=5NF"!;33%OZ7:2
M(P.$U+"9=_$VB@JH.IR0[A.-:F#>:;7!_I>Q_8\\%&/825/>F@+=2.J$9AW$
M9"%^#-#")<P>%2F-I,D'%C% KULO,*_X'TK]ZQ4R29CNA3RZ(@0([N+2 9&^
ML,6\1POR_;<7T&2 J89V(0<WZ5 D)0JV1M]N7 />I[$' -,G#! NG0%*':;?
M+F: CEP3F7?2W?]\ ?/W&;+M/_HI20_3GK(L,_LI-3'_#!D/_#H S'#3K3P,
M$'LFC $B6E0S;T</>/_MU?>7/"KP%^<>9ZTQ0%%Q4YCC\#KF=PZF_O7;EF^0
MGR<PVY/69X O,D -F".\7Q7P)HG@_R^ZT12CZ.Q6I,3J#@4 -JENU_W4;,G-
M7%88E/S\"2']8Q;A4_? 6MX*H0^ T8^E82X&<97*K^/XDQKJC(TZ=<WWOY)2
M[VDP^V+:[<8MAML@;E%0(SSL+9\C4S)=]C$VW[:U*D.$;1-%$L^M#3F)=O\Q
MAA545T[+*.PH?7 S0%24WUTLB \/SV.RF0HH. O*;'[&]H+9_ R'.8Z89,;R
M#&C=6^ 4Y* 0@#$@*PY[A!74"YHL96\/M7@BY(\HVZZ*;?!YZKF5O3A',L*B
M&RL$+>(([EG7!Y,%M?F+K#W/9*W>'HZU!RR0+OT)<S"GT9*:!?(>SXH#^5J3
M/95W&OF[][&N]T'XE^@554FP:K.?WV%WI6TD2O&!GLKKR87UTI<73,\DK[BL
M1OJUW=,&K(^9.@EVH0W&@\U>ZSP@!HS1' B*3YK[1]W![^62_/LI\J%PP[[#
MF=D,\;YG[OH2%U,"$IS^OO[V1_8Y6;WL3;S+F4FHT!&RAW4UBU;_<VVIBEQ&
M@ YI%=+=_9X<;$(3<<K^GEPU[?<RD2*1W=_!X:8O%CJ'S;C'"RI*ALYG*%DZ
M1EX1%KVB*&IJ&07 75[?E#[Z<]1@%S4>J505EPFG%B **343/*P O54?:P47
M.^7])6BDS+U6TJTN;_:Y.="ZX8$:(<EL2<3I,2E^',OUX)XAEA-XD@T<1VU"
M+.!1NQF1X$2^%N\@=W)X7K"-$>WISOR7S9EBD=?2R]46.FE.EI3B&(V+O@>4
MFX,^R9T<O,7%CN5%D<)";\R L\1G9:YYDM+HCIB!5#8<85"L1<V9YDNWMSJ6
M^X8GAE-_H=U!\:"/R'9[SHVEC6IJ\24BC>V"T'L6YPV7BN\<>]Z2JR=KR3FX
M\S.'_?I.FWNB"&!D=A$93)&K1J87?<&$HVXJ\96TX/R6#H=U-31?BPDB7VP%
MECCO!I@&ZH7AI5=><_@VR,DF_QI@J?Z':*4%@ 1O'&=C5L,'>58%&AB@Q' (
M;6_'(PK 1*&$L_)K+Q!?J6;CR>8;'F/SQU@)K;B//2/#29HRVRZT"@D'-3\C
MS18??9,RG:&8>X!)M+['(\X I<OW_B"LY=%:CZ[UJQ*F>:3 *=>LO],?T%Y1
MW<.PBWEX7)RSZ>*+^:&(@06!W,K<JC*]W^X9]#VU*\DP2O8=;V#?K],%\'<)
M58C6':Q^A%9G@#X'W47=:'V25W2<2DV$27;/GWR^:V@P;M)7L]NJ(1U4$16K
M,RN27N(L*AT9O"K\/*NPL&AO ++B!:A._I&SW[5^U&H\;2SX%4)M,RY;M82&
MH=]%2@8UUU235^BJ$TLOT8('A-;"%+UEDW2]"O-(_^JT])ID'Y/K?\\_%KM3
MV& D7)$B#* K90;H2]0J!H$H^^$9GZ5+*O):.")^88!"H.)'GMW<V&T]T;$'
MW'MQ'I";WSR<7SKSAF6'Y%89[]?R6RZEC01-OY=3[P+(I4DJ W2!;UVO\0?=
M!B[5+G*<V"@_R5,*AW#6D[B$T+6O'P!4-S.A$M65/)=6H"8>I@N@T@N>"X;5
M[5+SILX,D(H[LX,U0"5N4AJ:Z-S _B"/A/0]D(E(W@[+9>=@,W?KWJQ6$E)9
M;0G_6@-J\70@%B7RE,A?;ZS/>=Y^_^^1_C>O+(#U7%,PHFW3S3!#PU3KK2==
M=#OD;;67OG%DH0&B]9OYS%,M(C4185BGQDF>4[<L5%&AO05799R7\BN'OPUQ
M2*K=;[/-*!\_V32YRZP\(M:W7EB!D!_3G3'WU7A\L</<XW0H<T1ZJMK<]'0
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MU.]T1<3 -C)"-8CD67!\2F0F(!A=U&-_4P/7%#.4F>+O12W5Z?\E*?LMFX"
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M*5,0KU8W%TA>%ZW%D46=#VK%G]Z/?EC<'P_((@"R%B 5I[]N>JY YJ]OO&2
M.MI-:(2?)8U?-<03>V[M<V9*J7@9._N%.I;ADO0F?[L:<3W$@%D.5 FEOF6
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M<.U.SY&2'L=T#8SRH9.AY_S.#^A*R1@'Y@^ZIJU2;!A:N:GZV).W>FGF/GY
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MP8-/.X@806VTO+K(AU@,I=&Q9.-V:6ER20&L*.Z1@=;-?Z[KKW!#+CSPUV&
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MBYV6C1NVPN[Z\Y5O4*M>-@YB)>4'(3SW2T=..9I6VV0<$S35_#S(7!\1^BU
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MP)[0/A<#\M<B!8K^ASO](?_^:]@!.RJ, :ED^T>*W7_ C*F;-"$4G12R!6-
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MSR3>70R)HQU1L56.CD^W7XC^V&EB^O&>D0E<7=VTKW^H]\0?8,CY386--L&
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MI71#F"#_0BN90$'\L\E:UUC_V63+P:<]6N*C#=CO5;O'E2AKKVT]"F=]4ZO
MK)B63.=0(9EW5OAW3H\V]D2N'38/X%Y3/]!6Q@$.A2J'M:3%S-Y9[U3;VLM/
MOS4@&C/G5NWRBM+5D_6LM/;/B=U,F8)Y;804A\(ZYG)AL3USFQL'WQ\?4(4.
M3TH],+91X&JFMTX:N.J4'4XWU;GZB-;I![Q5L3!E'5&3M8ERX./P$Q.WCG,T
M-GW"+!DU&C+']:?* :T3%B=L RB>[:5JD55Y:!T*(S(52KUS^\_7PI<3OSWS
M5C835T&WSE4:\YQD+1O0=?D09]L]J/]9.8^U+^YC.[P(M$G=3L("OPT#<@O_
MAG\+#?TS:'-=$DO$WX):KF^$;Z3V?=>.\Q[H48^[0W-M)/K=T.[_O;QB:+SV
M5 =6S3X[4S,SPMXJ^I-Z/A&5(]%+*ZH-RV5 4A=[Z<:'"")2O)*K 8@GG2(L
M5+6[%C9X7_0=VN3M5JWV"3\*8KF'%R>[38")G_RZ(/7D<[08%C/Y1\ZY4BSH
M]D(,B%3XZ->?&"H(^@W)4*%G2D=*I ,#M[C\ F)6V,(OJ;0G80O:UXDUP>.H
M*M[@5JM5,QV=RW/)D+A;W)F&$>E^@J]NZW2"#F>8LKM]OVK.CGR) J?-U'8N
ML'1.P%.!*9<:.6%G&QR+D@GO1398;,<WR9%6*ZP8'SJ2Y6@Y1UFBH0)1X\I[
MDZ57R%/@4WQXM;:KG !1$D4W\AL^$LF/$I@_OKF*QV N*OV".^"=Y!D4K3YN
MYNWB+(]\H5Z7'X_OJDBJG9_P_%$ CUP?T("./$IS$,W:MUC^99MG)AM&I;O!
M%]7)JPMV;?P??4.GTJDE7X/$:/R-GGLKG>M?$29ZSFM&[',*4'$NUM3+']:]
MA!:R#]JQ5E\WXFPR/AAB[X'$AIMJLI,_;X<"&LRE<:]+#WP\$+142LU.:<*L
ML)-W\'A1NYZ-N-->'4H++J%F*I^-$3" $KNL1M)+Y2O,'/TCR?&Y>N!C#M89
MD/<\ %4-A OD_$(,I7\2+[C/<@ ]R/BBB%MH"FRN(Q^DZ^Q 28TN_HK*>R^?
M?HT#O*+M)AUN73:^;<;[2*19JC"R=M\LB>FEJIL+JD.\7 2\XH&6&R@>BJ,
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M_U3YZH08<I-M:TF]8\!22^6AW(W,/QVY9?,$GV< 7ANQF,XY:N@>2*OPE,?
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M*UEKS?D\SUSO7'-*27KJM*DT'(18:SV1&Q\?,?L@_>;NXZ0)-N?B8GLO8RP
M32[(1;%6US_,R!%AW,\-QPSJ^0XX\F2?<LCD#,Q9;'-PI>!9I)@.U7K/A,1Z
M@+ ]'$/0N F1AI)33S-2!9E^C2Z&I,*799;[$X7:;JRO?4G(%]7L#><V,2S,
MKW$UUE>(6J$=I_<%"<LZDH5\B-Z[L>/AI-C"2>A 59A_JLGJ&FDC(4#5NS%H
M=V<_MNOI\M9JT7?]L7#&#]G7#&N'2MO[/@,L7(4P)"K2B"&.8L*>Y/"RC*=\
M=R0\-&NJK2NM4+-/SW^!+CY@[_8SQ.4KY5J:U1XF19%[_*IF;$5L_M^0#C8
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MS^2"6/S9]P&%SD2@0@R_EB%2.Z'UMW78/^H'INFH+1>YTWH'M0+S50Z=$BY
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MWOA(%,)JT1;0O=9IY^J?I7+=X6;*);<8A&24D&'1.V,V01X@)JY(:C<-B/>
MW=P<COQ.]J(8DN)7P-U$F0B3:^@LSL-X4@7$\JL3G1);QGWCA1G?5U$Z* :=
M%_7)]4RF,[;_O.:-TC!_1FL-GJ=#!5U<)7Q 8S@VD6DLGOLY\19)BYYJY%JB
M+(L+@+O0%KY":0OARPS2WH;3AGH&EQ?+?+RF] P:I.M$KIBF"2Y&".A=!AS^
M%3C;I,-JA AX![OO<>K3H? B(LMD5G1CNPH,EJ-0ER?9XI_UK*83PJ#B4B_"
M8:7,:F:A=G[<_ _>QYJ)@E8T]6W([ZM%_@G/&@%P6XP2N0M?'9F'T\FI+3GV
M,U1CB]<8[?'KLPUB(CES4A)_G2QTQ!W*K'79<PT8CZLDQO*^82N0?N9Z(JE"
M2]'IV]+]N/?)DRS$OLK8>R7^N?\[>F4/QE77^.T=1O^I77*=A6JK4F9CY1:4
M7JV9I^"%M*ZUX(:+O<O#+;8"-8A\VE$7%RWY32Q%)4*0SXM+/5_BP0<V5:XG
M/$)W'?V_+AK>Y']]<9DF,5WA(LB5T,-E8M0X;)2(),^VL_D79,UB)==OGBZ$
M:C6$I'+-9ODU?3T+&WK:Q!:,;HT?<@]X<W[(@%EV?@R )6>(KK[C!P3 #9][
MEN.[<U+10<"&[%(\D -5KV#>1 :C5KD;+2&,7\+N+PG+Z*[$BR#]_<("V!-[
M[&4F90^ZY*M=O3%=9<;EUYB2L09#?SR[[$QS 7?B&2#U5[K$L)X4#3!_,&=>
MJX4W( U,2&J?95?%-'?;&C_EP$;46PV<K?%QPTGT3U1$%PM3%-KH'N&D*C2X
MGVC$5VKVO_P@2+N)T$I>#I. E>P.CF"7*,[P\\&9XC-4$*_25<\ C!&433::
M"@KP1F7:[D==\0V)I^=AE0M<_SP?N&'-M*\C_$1:@3E(YL#(Q$#_E]9>VUC5
MHE@?<BT<E[KN+A;FR1@7>DB[29ZR;W[$8(4IW:A*(+RPOWFTPW%F9*$?#16]
M5\LNNM*Y_.K <C'8/U?RK$(0:Z*<D)*=":B>&8H%O)>TW(-C+B+FXN#$6IC4
MKH9\[8KCL,CQM]-4-[RH<JW<MI?UZ5G&NU=2QZT!G!ES^W]>S"@2\FPN1%#&
MLC\5C-P0J@+ AP%8\]JM!2J(T'<(7@GHO'.TU3ZUO0/I\LS(Q-GZ\JWN##6G
M=O!MS2#J2Z%/LKHF5YQ*!6J/ZM-3^W6%JZ<+ ET$ZP0NV '(F@LF8F$R1 :L
M5E'[_0#DS]C<)[-0[G80^?L<6,Q?S-!X1$>-;[L0-:D$B[@4UU*Z')71H&%3
M4/9X\-FF!J^<"N^SY-\ I-Z#/2'ZX3B);SVO;LY:_B(WR2LOPG^Z5*;FV#=L
M$?E-F] X!'IR?-H&)W5KZ(O >@32350Q/;=W<.+]Z;ULSK:(9ML"@,HB6KS!
M:_OD=B *+7:F@GBR(LG-(9&MI*>!)/JR=@GRS'9&C&^H'4DK=$V"N=XB1SZQ
M/.@>:O;3B]:\FKQ4#LM[WP9+8DF^2=_:M]$,T/O(E!%OF.<6DJ =V9U=O)6U
MBZJC@JY2@H^GEHCTK7*.;JO>IF[<#%V-N!"DGP-/MY[.'79Z48=\;A/1I]^^
MQ[1K1J6?2U<'S'//'Z,>H*M%868X#%FADR^1?XK,;:""L/6]?B<AK4X-%'/+
M?.6<4-0,0C#\RWS"F Q;YH.CXXFQBMN(R_JV)6]^!MO' -'+L_ E*J@;G!@"
M7RXF"YO09Q/P"[>TI_NN;A,Y$83#]P.["L?2QF>%PR];K]_FU1THSGC#BY8B
M?G!U'HO0MIGDM9AX^I7U2G4$K:['?P:'%>-D"^2+?8$0,1:<U!CHGOUYEZ%K
M#&W[*[3M_4XVIL.=7&\UC9H,4DQJ=Q:?:![J@&CP\=_0^UA6_I;-::OXPWJ*
M4_X'LY7' /'P68KSXY@HZEG1M/ND^WI4D&C<$K%O HBSVO4]XI,Q5^5M\QBX
M?MK@,CLYF;S=*3\BIT51/=:+G<\[>4.^&.(4KMX]MV]M"@PE2 5)4D$(V0&E
M<&!VHZ-DA\A2V<80\N"N6,HM3!*@VVI;6#R-/6*^-9]U(LI*JH)*&R8Y[&8%
M7\V\%S_R0U1W3VP=G7(E[>J?HS72":5XH+G0B@CR-'P1;!D]K?ADCIT*JFIQ
M;)-7$YMGW[=W)S>8,-0+2C"A?>N8+5(%E344KU[*;BYQ45% U'Q/8@OZZ;8@
M* 7HF6IW[41EB,+H>)^)U/.Z!/V?>N;&1KRVQ@F)TH[WOM<*O?7X>9E6(M%9
MC]Q3S:E !65>72,@1XUR^O9;*3SDD4W&Q)FK/XJ(&(N$#KL&_YZYIITNT](^
M=S11C:TC*Z-JU]E;I'&FW[F,ZZTUAT&/%JUO(@<5M+;Z5>GY,0LN&(C!!AV+
MV^\%% \LE&_H9,UP:,VT@I<G.634'JE\!"QI>*$+HG=^O%O@<!4O-J]EJ<_5
M,]ZE)HN>,G!5I=6P2B /G7*NKG40*P[HB=]AQH3UC_M#JZ-MGFD;& 3\UHF[
MKI(B"C$KGY%1EB?UP\3H>TZ7D$REB8BE'H>49I*.H?5AG@'D!0W[6Q=[>J#)
MT$$(,2, BE,A.A]&AL(>;F!.U-<(3PX;\UN++AEATF];>3>4\R/F@P9MMT.1
M/(*(ON].6UP:GZ8+>.I\:^M-6O J2"+,'XQSHQA109S^\=C/<U10_WIUF(H_
MOU& E2OG6(Y@?M_XLIRGV-=:U)PV14VV*>#^GS7NC5;5Z]MVQ7D)+L)Z9I8E
MZXE1>8E06GI7*O)"#9(?N:B)N28OW]0NZ:G;0QBI0:;$$.:G[73>#IFX*7@<
M1WN=>!5V3>Y)YT;^-1ME#IOP8YI Z"9%9,15.R/(5Q2G6SBIH$5%^<LKJ5U6
M^40(N87RY#C2RWVH^:!U96'Q.\QZMX(*>ML_MMC8:.YQ)=9?ZR(T?-[@Z0.S
MOJ4OFBT9:=5C_#/*'_.*2@J+L^QH08< <E$KARED>8T?6[RS5T58G$Y?F-J9
MY[1SM^HJG&$WXLX43/C<97?+SH1#&]M]C# \FA21&^]<*<FR<?H=96;V-Z!8
M -"7;1O"RA(CX3^"*1![_\8?T"0.1S1'&8HNM/#0X-7+<HFSN(DFRN2,'VY$
MK^&5;WW0+5XF*811K,Z22X;++0857\,:$15%< O^23%.BG"((>$I;THH2T>>
MK_8A1]=P%D6-)H%PWY-A5^ZSH2X JYJA/[$653L;192]4=OV,7A+214IT)DL
M0;14\/3TVTN<86C#T1,!I 9"C35']#7 ZSTHQ-FO5%#:GIK=FA+X!/(TAME(
M]*8E,G)(+0F5V<.?49(7[KCLPG[W:YNEK0AWQ87K:GAO[5(6P!;6?^=@CX@]
MLMCS%,\<-A+WLNKZ)A64"/  1>L$ZGP<K[ZV\CG*A2 1XEBY)>!<C5 MD[LH
M6%9^,)G,E"15W8U5#KL^#; ( 9PH9H=7W:% .3E.1UHH?/CX+H:>P]1"?VAW
MJ9?BL6K3MY3E\MD0EW!/NUK"H%:>\=AOES*ON9+5<M/"TBO[MU73#":- %:[
M!"!CW*L<[E9^HMT^- Y^4PY9'Z)<KZ1_TC"R,5VX-7@5*N/U4//;MR"W*1.P
M#%]4W:(,9G9QB-G_::%^ME2%*;HGF1:AY2(S.<G\K<O\G?#W\BRK8.P7PH<9
M!%R6(HZ?MO1/01=LOXBTV]_)7M-V<,A@ZV5W-G9LO)B2HO#/T:Q+>%Q1<4EQ
MU+M=/6;^^7P A5Y200(MM:WRRA0F5G)RF.;N</2>6;"C,\QMES5$$ECZ5M;.
M?^:DTW?#VPPXH]"LMO'FM^ET@UL(@OH9;9O%P>G<;VRP+;FT@L!76V1;E:[!
MP<B<$+#'48^+$5F$8IUE%DG4>;<;VMHHZ>T6VSI[:],E2?9][[K@QBJJCC6K
MPTC)O]U+1$7:L/W%,YTKW4X\2MOH\UG-U10'N*#86@>V9YU>F2R[N_\)R0A.
M:QA&(4(+JRFR!J)JP;M7OZ/$>^)Z)C0^Z!?E7[0B7CK]X/),@L?U8[;9EG/$
MHQ0DH._'<8PWR#OR2.(#6.(L%73W=* 18!1>>!IT2),C=3R'K67?<]Q#*#MK
MZU/1;^V1 _3XI]DFD\3;YWT#2YVV:LQL]G64C328+3H,]!2N 7LX3IZA^3*&
M58F=_&0&"9 +PO&G[L]R(O(POKUENZYAE]]\19X?;H>7L)64&IUZC-*L56S2
MKJM>X2\:,+SM)ZVHHF HYO*^5&F5$PACAAN*O/!*4ZB0%&U=DS])D7^H?8+=
M\;]8ZEH2:ZG@1Y=8DY+WT$6P;',P^Y%-RL.5.!4[7^,+:H#PQAX[:@9X<%*8
MSK#%*])0[9."4-9,BM&1_&6/ &95>GZZ\3Z/6XU0RTD.I')SF6!>!R3]X/F$
MNO/-\N'J#JF8J 3U@;VV27<J2'Q';02\UMG<+G;$[(@-V:."/H E3Y57&LY]
M+6T/F%IY92:257U2*2]N+.1M$1"FU_W5T:&<9/XBVOU$(L/E_<LT-</#L1&Q
M%KQ%)2V=7S_L2P=Y@&(&'S0A%JTN4\PY#G']D<37>";+GD-,>W#62:OM.YZZ
M8YQH%X9U?E+GO(7:N;>9/ *E*U_NM\L%!&YN34[1NB V!9.(QC!L/.4&8I)#
M'<G6>C5S=:1+;$U6"R?L"O,?C-)4* J.9U$T?K1HF/&R_D$[_RO#R0)?G(CV
MD-;R:RWITE5 U9!VOC4.[^> 1QR)5K!E=,Z R0KR)SQ&\<9X6W2]1&MYV]C;
M*P5^\N$O]Z.L^5P9K_Q >G;/QL2*,/!(?RS4>?)1]_!I)2T_/4*O+LR"+$$%
MO6,F%Q'_>$TP6H!SG[(3HX\97[BA:^<M39CE?LNH^$]WNS/4(I*"[%PNZR\+
M.-MV0:#<6CQ&24_U%=RO:CX!AP,".6<Q%=!^4\!8;/"'V0?S:$ _!!2VRN>=
M1EZ;0B.S4$07G:HFE\-,?EM].^=7(6_S$A5TS?,YC304I,7'1H0[[DOT")5W
MTU2R&C@E!SNY%T:BZ%)!P_R+)OY^#OB-K%6LQ?JZZYY'<73;R93%7PBVKV<!
M";.HO$L*]<S2*@Y_[2G<]KSZ-)TGINU^A0ZWSA_CM$[5"X)D- "SGM^5<B@:
MI'&B#YY1^>3^-3\JR(1<02R=J;7EW5:9([$(QY<5S:-\N!X?3: B!5-+4$R(
M>M-^EFGME?'N(J$F_FA (G&AX:PD S< [5*4V/RM?FVVCY80IB<!*M9H,?98
MRT7-RL[=VBF\N;QSH>#[Y)Y0,-?;@H$,MBBSF^^*XCQO'\C]N&ZZ#\1*\<1M
MWTC?D_V^^!7;[*VPS[M71SJ..7&:,V?A<[.5WU!$MTF^F>_ZCB<3DV9#G0:Q
M!:61ER.+(B[:I=14YQ;%<B=D/RZAU>%]D:,0]H2<!5FOBMS+WJ:84$&#/JO\
M/ZM>L_-^!3,^X&1O&0 WR5"@\'6G0T1S7%?I8&@LGUS=KR[YY<W2Y8QV 1?Q
M"3_Q>I%G1K2<$E4\,<6W!PA3'V)>8Y@IQGZ1/ZPZ9]LF#\&K]2R];. W&-D'
M4H3;[:<HDG=+\.V]L<&E6B_I*TRHHK^XLIF^:)0*;US;7(F-U7<"+-208CF3
M7;"[G\1N*TR3I_,[F%52H]RZ^ZID/9R?I%S5TNCL^+45Q6$&45.)F_-].,\A
M ^>-+W\_56>V)6@3.WDW\6'[7*X#P)[119@BXC2Y$)R>@V/O!U0X]F0/F9'#
M 4[G?+E(PN5)<IR?27.2H0 4&"DLNE:(867#U!?-39BY=?F.Z'VL2MU]]GQT
M2!<[:6ST.'L;S5Y%T,[IMCHC)) K3_"ZL*2MBMGQK)PG:!)2T:0&_^GR!9M?
MTR-JO!RZR4'7<DM4>,U,H]\RO+\+V&4&8-Q:1Y&^Y'"*H45.90MCB;QR*XDN
MOTW&P8KAPP0[7*391TQ#R\!XTD@C^L>8\;2THL17B=Y[@K?NMEZ.IYWR_>=L
MO"_@L8HY[^!<89"C_:Z% T)"X]?6[96J[^!4=I-5_(MC?Q<G@6G_KD9^4M10
MF\['DL"\O"\EV6R:[P?C[J7IMSVZ8V:="/;;>W\BR8YSI'7=$M]_?38TSWDN
M)/+W>B=\=;9%,FNRJ1I@T-S<^$>M)($>!CZVVW<$NFL'XE&SVF[,@>2:DJ(,
M3D4[MYJV/VF?CF$4/44@>G"E10^/VZ)G:-Y_KJHULTVN56R<M!^\2VX09FC9
M%#]"1]4?6[@*6FI<N.J?_:Z\]-VS9/WACQGOS\>TFQX#-JVNJ'& 65V3I5R_
MC(U<5E5;:NR[Q)B "F\3)\(8>T[1L<U+"Y,3'U!G 4G!98JE?"(^]5*;L;FE
MY<[<A79,$[AABRZF&" @\" =AEQ+05%!K!3YESXSW^)N//IGHRW__9"U]X&&
MCHF&B<[KGDX#+2,=B8*)8R8<MQJ/MU"+7$U-Q/E_F[:",QO5 R#V<&D, 3)M
M<SSRW#^""MK>2]_7_36 IR/-6L!%$)WNFMKO9"U%+ABO]C\?@RB_+:YT84N
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M5O^YOD?;KVI!J]L5O-KUUY3/>V:[M+1LV04YY2?Q<C#Y&25/["O0+N-AS'/
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MO>]1G,FJ5:N?&O;2Z= OF;U*T.Q!T?>)EYN")?E1&68J'JIEV95RYGJ0Q3)
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M$P ;S:V 4T&V_YK\V1^3Y 7DJNM2*B6BG@HZBZ7](.:(W@073 4AJJ*@IVP
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M7S^ R&:2%J?S?9/,:GO^=(JRC;Y"P\.I>&)Z !6$8]YA7)L\I'VX.$>L>')
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M_;6ZHU=&AF,]3X5+=>P,XH%M,1XE1I,QX)2104B$HC5Y,L1V>:2O*A8^R W
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M[<'^@KALDJ-40?F9Y_?C*"6[4 UB*(%_G,[K73&&\:7Z6.>*7)S-1GX):NF
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M+[UAH_U^!373Q+RS;S\5HP%BFR#X4W:@]V\HW?;.$.'> 6;I9"#31%N[A/]
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M=XJ"A*D+D-##--P<R:*M$P>K .!Q+]J+J>WMNE;-]+B7C,!BSZH_\P,6"Z&
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MA!R'A%RW1W,/A);*TL:PO%S([NE5J^@$^B][]FN>K7G%0<-,3PHS:[F?+)4
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MK=T*SA\8R[=.FI-@=[Z7'6KU-5*!&[S+);\,%F;RT(5Y^Q6?BO@I<X*"7CD
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MN<P7_'MY+B%/+S6T@/V@-5A2?:^&/I'+>\=-Q732\5OMBJU9HHR;@5A 4/J
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M9;*U#IE6/IQV C.R'"Y."I,-8*ZK5&D*#G\*6MIL5CQ'F5V;;R+U_A0(9#5
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MR#BCDNE+WK82BFNY;3BQV< XQY;%TN^2\3YW',*."DGVB0+9L:D10K&0AAP
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M,%LM,Z!&KZ$6-?=XQCT:ZHSG%,^5S&"I^$SK27L)^CBOX,7?]36 PQ[!Z*E
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MW^RPF'*';M%+,L/:2\SQK+AS:)-HN'S8 0LUO>[B'=5-79OF$)HTK?75V3_
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M=G5=O3S&0/-A7=WC\TYRX!*8&!:>)_!?O//,&K26IX8HK@U);VX9J51.&5C
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MJ=@\HD2#]B;/H?:/ 1&[J;G9>\:R5],6+C5I0:R=4G)CM[,^'Y_QD;HR:,F
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M!IGI1X>GT0$?[8<12Z\7)E$>?CN_)!U3:YY7QJI?TL;/P\,(?#S-9V;4UH>
MPNTF9_P3C<)D#?3N%C*H70 ;@X4^9J-*J-,63$F9=(!X*HTFT\ZT:2,Z0!F)
MW!1,R+E)!_P4M^59.'8'KDQFQ48OS !WZL4R@@)K%"4;@NP*UD53,G1=GXB]
MX'#^<\-:OJ_X'//TBKU=R@M90WN*&,%1BO<;NPDM\[;VHU!0?VG42D6 U7:Q
M4ZR 4=/A>[N%MW&.MZ=R>:VMQ?$+JN=%PDPHE+[P)T)N5QE/,:0#1&17!'8Q
M%"1"LK*<$D]B<7*%JZ\T]M\@8Q%_P4\OKRB[BD7BY)P/<<YK<NQQSVO)&QE!
MGX 7=[VZB5V/Q">M"ZV>[4YH&2DRL,O;\8RXR1G%O73KN[>>F!8%)/<^9N=*
ML7@M[,LBM36(21%."&$81RKS. 6%N,,@>)2SU'D-G<,=HB>9S]ZD5HW+8:R#
MH2#2<8/]:1I+_)?.^J>6;L84\;?<K%BPNOU72DI=V%]TP!OSP6>1*0WVC+G]
M"YTAIK^%BT;?0?^4S;D!LU/@BR17CX/$RH)&KC] W0@O 8,B>K8\$4_32\NZ
M+$W2$[Y(9F<_&2$X&?JB*?:S\82V[RCJT?/*Q#4,52RY0:\3.6ZR>B^GJ[4*
M^33G"#14;X,(^5SY;/L!E>?6\0C'?-^AAR#%QC2,\;M1ZB0HS:<7O;]60P<D
M[1 '.QV/!$>&R3,)/D:4N?3)=MQZQ1O3F[G%BU9Z/#?.^TF7UY]5EUH\Y^[F
M7%B2T<BG8\/8!B[4Z6Y_'+&(#-KCHYRCAE#TIH%\LSDRJUFT1\$%!" F;*[:
MRQO5.SUA-(-:*@V>=%(T5X)7KY?=L0G],)PP=!'B/P%Y6//1'8R%%\JN-+>%
M7O=D(YNYK&[X1 )71H^+\(LS-)- GQBTP*:RZ'XGX2+,\N:[!74V27#C+D7_
M:9:35=NWVWO-]^I#[ET;LA&+$HDOULPM-&7XYHT;_U>!5!]!)*G%S,8*!F\2
M&R%\F^%+5*AM7.PDF\RAQIV]3YI-140U.5*[MPP/8"HB#R 7I"8FZY3B=!2O
MY;$@S2W-N)F?$:OB5T=I7O;#\*_R%6]F$.KM@3N>2V- N$,#<@?;+%%]QIE3
M+P8H\&C\S_@L38TL":L'M_XM\N5S#&*POL^@XS[0:@A#;-[HH /RF-MJYQ#!
M,*3[B*,$Q" #.C6 872 -C-_#VZ+#F!H"0:EV!%F[*TC6C"<A1;#%+'H6>9_
MWO]!!RSJ,3C%#I5\R';"Q^C<9Q2489YTP)I"M3S1ZV2/-++F/332?<I\X!T6
MCH'BRSA5M8OSW=W[TUS.WR*66PRJGF&^:7-SUP3J;72P&_&S_6C1:C![#7N,
M6:JR\ZZ8;%;P VIY:XK$S=V-;-G8:/EX00\(L34?D:J1DR)L#>HQ/]-HE_W/
MZMK]-!W >D#Q(T8LZ6!P$58[T0(G\P)G,Q<%^II>\95)3U!:J"+:#U,RSQLI
MLA_X?C>Z,'(1K K5%M'D>X-@_-[M4ATH'4T:WN('K\&X!D&KDFV[\5,:&H8]
MWQ?4YT7TZZ^6WHOCC13+N"HO_&'P?3V@7_</YN=#!GFL94X-*^/]K8DT5QQE
M;TOPMPJS>W2 *QU 8V>A UZ+44?0)/P,:-^'N4EH(PQR<IN-1C2AY"#6,%\1
MOW#,\X&3'#J _%CP9#F'I,%0/['/Z(!19FJ8KX++2M0Q4-I:$$*%[7V6R0):
MA69\&&'E SQ*^XS-O!"\PS]EP!$?+E#4))$;61-96JDK<4TM(W#E\<;]!$6'
M_C#F'BKU^5]MSW9WT&Y1SJH6:0</(EGC!"SW=E9E>]M3-]TO9\ZF!P%CIE!5
MLA^ZNR%6,:_=-ZXA(PMOGYF\%I0?HI9&U&/Z9G$\'9"&(.T//'Z\\LK^-B(]
MVX0K,2_J9DR?(Q'UVSTH\G6\4WB@:+2B;Y>4)X^ GH49C]X99BI+P_^[9N?Y
M GHPAT+8:A7Q7ED$2:/3+X_/I^$$]P0ZFOTR5]^&YPPI^N]2-C8R;M\BCDAH
M9Z2YQT]R;OTCR(! )I CJ#C*>^):;:@O7N,Q-8W03L-LQ7RL+CL,X?(D\*?X
MWG.:G+TT(.!4IV=_KS-KPRQ#)*D@ZL-WI?U81J=\U/]?*3A3@EM;':?YG31B
MX:ZEH0 8I@?W$7%COB+3=X<M";YVG9.$7?,5U8+ #D'N*]4'=_6#W,2%S-Q%
MWI;8G2_E-P=#-$TN9F]B;R$234AG*->)C3=)-DOHH8LJ]J,,PF0OL,YE!JM<
MV2B6</O*EWHU5=6Q(4!$0+'GR;IPWT4.6)-0ZN/(NPQDC=0;DF=0HP!FM_)Q
M:T:1-&<^G2_J+,MT0(?]IV/X$O([N78/\U4]K[[E6'P:!0XRW]%K6.3TZM(S
M,8A;F&E-W15%IG( Y5OU?^V8"Z>([A8SE.G?@LL06^K4\5I)B\>:X)#@JD!#
MZ -_L>!]+3O$^;VEG/(&X\F*CE5W^:0!K:0</Z]!#9G<^A?%>P?QBF<=WYJT
M7I/G?,,LKE2E61GZ<)_KY>J1\=R&\>XZ;6P!SHLBNQS\ QU>[5S=?'F@=BMU
MFYC4U#]7LD<BK\50_<J]"A]Y6"7E0 GA3/;Q1U8$,0QO8NI=?OG;=FS<"<\4
M'PYJ'E(Y,]L6@7K)_;12W_YJ#N8!LL])O'13>)=--"W/+V_:BYFG=CVD&2Y9
MV6"SW7N$I,W:&!O]?-HTE)^9*JEYWS=9QO&\"9(#_,VCR$\QR#'"1L#-8<.&
M(3&Z)[/P8UEK,8,N009-:HU-7X_A"LH+(RM!M2^?!UQ2NOPP0^]F\>?RG*N6
MEAQ*GM>^K0M?D^]'(LN_)+TAM(V9!%"KR(W3U5,#Z'9]_\N8* '4>)7O->\3
M?..KJ'.A5D-2@:HQWMI_<#[7CW.P5JXW,#A^+D]E!N :+)S$3*/$KGX<V0%2
M:I61+*"XL.MOAPC!!9?.BGA!S,U,#(STP);W'D],F'==[V-_57OO [*7M43H
M7XYM=Y2C=[BH$_1<K:BII;;6%^N3Q@>OELN"-[U2+8V^?/];+2O_!/=<2[H<
M-)SSVI_N%N*L5^;\XYBXP^(0'/[KQ@16O<P1&O':_\AQQS8*<FB#<]V2'GH_
MZ'QG_$6D_65+P=B*XC+, #Y;9=R4_]\58I85>!>LO#R/BMI!HRA4F0"RK8TC
MT;ZC]'/I\>OI@P>@MSJ[@^@D^!TJTRH?87:,LE(ZIPB&%EOS5D!4#)$.N#J"
MWUQWR2W:_9SB S3WK;L:F/=LIR0\^6;&/TSWF%]D&8 P" A7$4M?]U[<H.&^
M.<C7_JA5M:M<X,[J,-*S-5!,FC2'@I?<-Y:*R@J+PW4+WL\Z(76Q IJ2?S (
MSA<F$@J]HA:0^VJ/^3C&YQN771]Y><\/G[MK7+$ 1_M\)Z@-7>(%S?V4\+WJ
MM*%XK[@(<\$JZX\5)H1<"7!UA@YW573@&QD>:59=X6;SW!?8Y+FM_N^.A;T9
M6A]+NR]"$CL/7))=HP>6V/#7;L)9F/MG:#)D?EQ@_5W50IO0?);# MR/*S7'
M9_F(!;*V9Q,>F=&>HA->&AG4JF7K=&5RW(@O_ROJO!#4&7HQGXTQG__6G?J#
M&YV$YE'(RC(="[2/S[J:1G#7G7)OS^\FG*!-FY=TW#AN&)ZQ8NG/13WZJ??W
M*=-_5HS:IELL?&[\6E]LZ37YL'5C9M,H*KE@OJI5HCH3 XSJ,=?Y^+%0SS=!
MTP9RYB,R9GW%HN2OAX7B?[PTK6!^_;8BG5ZR %7!(KPMJ7GD=<U)@;#$L M?
MX6JU\.VTAD/?FD+=W,+\KM4<T::%+*-'M=KQW4:*R.U;$B52S+KO]_HRNKH_
MJ+]]VB!_CY4!/5'*WGI+[,]3,2O'B6;VG>)4.[1H!2_0LI')^^\?! 3L-P8Z
M^K[.3MDF5&U3M:]+:EQ02-[8[OBXP#Z1/%&K9P31@6B(5E9*!+6X?W"*?&*;
MHKL<,SHA_Y5!T455&OOMHT,\=)KE@3%$A5SE<R 7UQ<-[;N5B_-HGZ4OW4Y$
M!: R2" A!7WSU.-IRPGM/?#XL)G5LH5N?#HSMNXBNWK8Z:0.L'>TM\_5^'E(
M6O>0*4&"-\WE2TI,'DGZ*?05"MRFH+5YK2Q)?..2-]-"M' *B$R#+72&?;\K
M/N=;-N:7#'93-@,MI%)E<U3EX#E8<&Z]^%M'M?8,![<4U%A,Q#0&LRRQ43O6
M]=3=,:7P$YC[BZZH2S)PNJ41>T($XW/,"PF)=?#C K4Y#71>F!!:&#=?=C;B
MJ0C0\-60D<;398_U<&7>#X4Q^*!8WEYD='ZX6<AT2^PG"FBOR-/\8.C&,H5M
M-#.HMLDS")FHBGK)GN"=I2<<=;* S+O)YZJD<[WI^*;2I$ $*S,ZSV)AOLC3
MLYS3P-]'&O-FSL;UDK$[\3C*SP+\_;'9([25N_M&?F3VGYB5K FVS9U_G8GU
M897ED<98SPXM>ROF_=SQ=84K.6QM0=-RR.$EB=%D6[M,D:CBTKPL*^X[XD*G
M_A1Z"V1L C[7T*?4QW/??VRHJ/3A8M5]+PVA\C=/&C4"@KQ:%'M=O_S-()]?
MW*.3/"Q3(]/?5>E<#7H?'?&B,Y-9O;D4E+U&,F90#&F[-/*DU<3\6GZU0!F.
M#I!01ENN%*M+5"98+_C83XZM; 1H$WN6\GO-:L=_KN5_SD\5,>4G]XOU=AWI
M.F5D,1,-)&UXKZS3J+-W:0._VJ<VO=<W/]4;:7'*(@Z4 [B:=I,5S SW#UZ.
MK[P\@"1=-S PY=.2SR_(B[?BESS%& =4SWX81&D8V65K9Z@#%MVM4!QYIW9#
MXSX5/9L9L/((F!S?@^">%S"QS?Z<WT_0<]NHJ2MIO%/OOQGWGI2\OZW'.C;!
M[1+Y1#@!!"54'KO#,!8^PRT],%K/5CMZ,<0@H[-AN>L0.3&(KU&'5?%G'$R/
MN_S:<.DQ>92M,JEF.'I)&K;/C..<G0Q9&PO9C.QU#=)I8BSU;N"G3S-/*UU+
MCRZ+O1P#6X"-1(!:(EK:MRIKN-V?9?,()8@]6[_UOT=3Z%?LM,.8M1\Q,\#X
M5MC_J/V8"4(UMA_UFOV/VH^RIC;Q?99#_]9^/#5FI/B1]S;J#E,PY>XLBU.Q
M/V@N:'ZQA:S-^1R!5S@I$C"^A2B^AZJ2)_<;KHJ]<!3[7(2!Z-07]5MX6_;T
MB)TE*DG>&I!J))9R+YE "4T(<= JB:O?NXBB-(-05@_ (W37&HY( CA[]A8Q
M[V7Y)FS169B@M]=VGFU,S^-"^)V#UX/S?0D5Q5EY"7I.J,"?D7\F*#+VQ>^:
MU^7*7-<MLP=7JM,^"9R]V6NY6N/7?5;XBL2&VVI)\ACW3\@RZLYC55$F_=$]
MJ/*"VOMMURW: F>S0N:.'^J7W';$VGJD8UQ?5=R3+GRA!9,I+$T:N'Y!S6.B
M*!S S&7/C/^9:D"H(;)%:>1DZKH&#T)F,+1W4Q^-Q YHUGW%;L^E_^9?L4!<
M;X:SB#??.09S197F]ILY[+VD["5Q*/39Z#QU*2PI<V;OTQUG/M"=H<CXJ<,4
MR5T%BKNW;)P@N[K0"0=LA<W7"UAB@$*$_5#(N"T/Y="S89GQ-K1PY%Z$QFC7
M&CL9V*F8&3%&486+HP-$Z8 L2^+3$6K@COTG05DU,<J[8-$MVDFG?RS<&;^Y
MX&KO;?3Q,E2"JKJAUU"IEBI E4^04'5-R/O+54_"C-\5>:XJO)+!ILNG*0W!
MORDL>T<A5&6RT6X4UU>/=H_@@ZW2DZKI^=2ZD@V)P\/O\WR^&1(GDRV^["\5
M7=J#U/12MTNBUIWTFZ/]E-3 0PR(@%/1<%E*IS\=,&S70=:D=N9<(FX61&B/
M!<A:T %W-!IFA5R_B^H7B8#U8>$KA=W?3;V@?;I)]=FW;V,6QKKT-($&$]&=
MO/90PEN3+-#(=42P/LT_YR(ZU07D!"VPQWBO?)E[XGVX;7ARV;<,]'&A+2QI
M(2VD)*I[TM19_ ZY*9C<SYJ^7)%7J0 VGZR)=,IW.V'8:HTK@V*6.E)Z&%V(
M6:.VA\IO2XWH;5'%'*@%%!&L.F*)#NBN2&ZFXCJ+%OERK80**P8";XAYABIG
M\SC+41PX.,YEI!=\%'5C7BNVV=L,I0. )E$@8#MPWW)PB_:-LK>'6+%86$C?
MGL0*"'VU\<Q.'WS^(S]!ROMA%4=L88^Y5Z*-C9Z.IJB%GGPZ]X:DQ+?>5_(/
MP(SY2MWEHC1AL,!-ZNA+D Q*!;]V'XKIELV>E8T0.(/*E$;.WUEVZ'2J(0<N
ME_2N$5_XHB+4P087ZN[(:Y?O/3#0SZ\U8.BX764P=UK/D(;V^Y>;#WUC4MSR
MV#O3=%:4SODNW@1$32]/YNF4'JXQ5.W](YO@##)V83[JE=?E',K9,8$*E'((
M^#L!6S4U7WLZJW=I]8/V6%=\;O?TI/FH 6__^P0G[<>_='F93">V-=2,ZK2)
M7L)\U=#VU^[FOC2D65.+Q@G@&O=RG-/[AD0T5*Y;'C7_J3$O%I<MALQ(,5(8
MN:7V*/K?:*7DT/L(M:&8<?OALJ+0BP3[>-#UEK4E".C;;\+"SN7AQ<S,TYJF
MFNVEI;6[SV$IEJ#XP>Z/';I-I?>\C258D/PQ^D[BJS(3B0\3&"(&;G/4U!);
MVJ!X\F5.H&A:P&<JJ4XRJ60+>/RIQV'7=/R>G5-QHFQ\:1$FGXV-</[B%]:@
M-^/_1FCO\>&=O2^5<%+_V;E4D3DSCA=4N4SZYB0N\4I6BU<Q 5*IS9,=4^(8
MPY-A*OK^L=ZS/YA4Y-(K>[%V)=< []&9NR9Q6+XT7,B;R-)A3V!R)+:)-;K=
M.S(\?W1JZKG<U^4;M2(&.A87KP^8\,=WWY'3[:<Q@[S/J^."M[)KYOABO\*%
M K>]VV=L0%>5$0$^(3MQ^=^6Y,S9?]GE-@HE5&5D1X8GG#F;G^%V3=$4]@SX
M+ZGH!5-0'=2AT+LFS>K3C1IJ^':K5;@0=!F,#[!SWDM*'S3^WF/RP 19&NMA
MDE2^4!43;7QAV=U"*\7*9\5<[AM#.S[M,5C6P5!!KO@6 ]G%$/5(0G"WT+(<
M4"MA8497!6A^-0VR5OB/P=-FJY^:X"NNNCP/4NZ85/@P]F<W$^FYG&%5EOL]
M8WT^M)\,H)_DNW[I:HY<&UQ2#MGQ7/PJ)"N[2"2IN"#O#82]6O;6WW^(_<UD
M0UQ""[8Z$9OW8OU74":5<B&J$?\8M!"QM?'#CG_-*S8UL;?.2GS:KS>(?/N6
M_6SVE[4GI@^D?C"5G,=-:BHB8\>/2EHXP9-8EE-)E\GOIQ W&DYD]@8?4-$2
M)0TP+K\M8-;;OE$P_OB"G[=[Z\A19"(;_^N[XF4;'G%+^=GZKQU*\HDAK8N;
M6 E$O"Q)F*)*'3FVK&V_#S,9VHGQS_*)K\"^]*Q:B:K[.N\"/*D_)$A*:NI%
M+#8__?1:]0@^VM0/'H.T/;KF6%22D*'_>MTPQXN9TO*&E_?>NBVI347'9BL;
MM[']<R;S+R$?H_?UC>?$;F9\.P\:^E0HDU#IOA6(V*(L(1D<ETE;$*XPG/E^
MRF@5[F1DM@T^ 6=CETU:Q&9E]/R08U]00"0YU=0K)KW\;9[S-.QOD^_,$Q9+
M#,F8YI!I_Q-$W"#XI&"=YP2N@MNN._5KW#5H]V-7XC::;5JY.-&TI09>>6'_
M:BHD7PFBI_/@,4E/0*HJOYN]@8$PVK0G:/E#RR'<^QR^8P]!+%!K'ML11Z9\
M]4,(__I=)A?>J[R(4\TJBNY;VU/]Y'*K,G][,-I*SQU272]Y<6*%5^@:N9?!
MA 5;6EJL6:TS-C8R@B0D) +*RLO+H,C;N3$&?5(UJN;(NZ,&"G)_W!>.8Y96
M?(-LH"CMH9H;.9?F!$#$"_GJ-C#/WT5?L"C[BD87%O7X[J$K,0410EI15:4E
MN2E*R1>$>Z._?(]3NL#@ABI,7/R##G!!+TWOV<:_9?P%_HR(.?1V-VJ<(B-V
MD-CCBH[X][QZQ7<8"/,M>-9])D_;]6VR<[(YIS/@.O/2ABAM9SAR(ZNC[C#U
MQ9&)V4'#!JX>UWDH,XN;CV6+Z'4I?>0[Z+:G:,7;[_XIFG9;!"&@IOM;*+ZB
M@#L62D@]R,STPA,#6Z5#?W1\7U5XDWGA8WG96XF,?UJK"]XL6[F?BJV*L<8Q
M33K(:Z!1O+8NTRX/]"[,SW*,][< 2LG\@JWBA97643/%M[FZ$>$&+5],\:$A
MTCY00KSD(E "FTI[/]WXNQGUP='8]>1ZY8]O64.'S^(81.#O$]R>2<.9)P,_
M1FF3C&$4M<W.VOI]W7P9N$U"'QH/]GK#BFWK'Z#DZ[C7:T3CG[M7:W(X[;99
M%5CAY<EAY&\?[#J8@9VB,!W$/LC%,QKC D7#H(+/#MH7J\J[78]9G+P-E6W.
M:T*0<5UQA>4#CRTF'H/-'_<72 @E0 *?<L2)GX$?V:UWE<++BM1Q'@_:U4 -
M+2/-,(C!B\)% 7!VM[?4TQB/67GNR-)^'67J>>:13;5LX'X9S/XWEQUN8Y5P
M,T8U9]\8%78M0&7V[8,RVNDC1+?&S%5'V3"=8TOF/03FICZ#K<*%<'V?X/Y4
M]3K !.S?(PM*B+WTM@_6CN_:G@N:ZW.._+-$7'30PA0#!DN-8WBU>%Q=X]G%
M71\S=$UAU=H!=;(6/8#XX6_;N(>I^2UTDF8WN##3:FGRHW'(]K)9GOB[C!<]
M?J#&EQZ)A:EWTSZXBT=-W(*8@GF+K4N5K1PM&*:XIA;5&@1>OCP06_V;JTFM
M$15$=/\=;6YS5,RP8-^?UJ5Q;R"&S89*MEX7S,&<IYY\:\$+LYQBGL@_5N;J
M]7ZS;33>TJ#R)"#5!*9Q,%-O[]QV&-JY,/.T!WQ)^4/![LHK\N^YR-;@=E5\
MB-+5GCDG[?HL9I(-?+UZ:M%O27>(SS!AV[MA?2CV88=D0(Z[ZRLX_/IYT ,9
M'5F(C@Z/"FTBC/$J"!_U )&VXQ9\BF9M$[72V,U*J\9F=DFWPQ8'YOB*7FI1
MX:Q)KS<^YF6*:R<I3>Q/CG>S"X\K#$@KU_ ^<;WOR,Q]%E3DOYUQ;YMSNGPA
M4,)V*+'HN!6&+2DOTM_X$)%"[- =8_WH>.,\4/]=Z#SIEP=#21S_-RO0_5]I
MJ!^D1.VN42*#W6G.J#)* 4)JN'%=-GY@$<N"7*]*1K/#Q>0,ZN0I&]NM#F$^
MW@+H%LDS=^O*(M^F1&8\L#7],Y*5*\+H^=0_,__NW)6!79W5"$R__:HDR6?Y
MG$GA)AV0AALI7<8FA834;TBNS=B8'!>\ZW<,VO$RB0>M0'>U1)XZBD&N73]<
M9W_9.O:(-,1,_8^0F:7!)H(A,T0Z0)Y5IOHSY<FL8?6B(E;_N[+TB\O:?A'3
MAPD&#R7#[_6(L0_O+HBWU_Q@K,L-A HM;+LJ"3$ 6I7%+'Z<0^"R%[>-\S(]
M/:7SCLB#KKAIH!?[  MN55*.W&^#N9X%Y;B#Z8Y:^)MA-!4Y<8C^D15+;SI
M$K<B_7:=.C6SOK/*1ZV&"9K 9#K^V6F9*/['I.40-MCQ\TAY:&AY%\+Q<@!9
M7OKY3A^0GV0&.4'_/?QB(QO*L!W91]1[-&<Z0!F=+MB#SJ$#!M%EO\.6LCO)
MDG4!QGQX-.9&$?:*]P9U>&UAO\:A9CY5*36?--KQL3@_DK5%WS]=8F+\NR:8
ME;WB.H,?O,(-\BUMNP[9OT.+A8KC Z0UA@>.<AZOP&0N^%M@A"?V57E^$AW7
M2B.YD%;BG VW6S=BBCN? C!CC&%-3*\$$'_30@5ET<EH(X0DM;&;[4.(8ZV&
M+'C+N-EXC [0&XCKVZ%Z=W84BEU*[73\B0DI9(W4'1.MY-%SJ,K(Y;ICVGTF
ME^$R_[0]:-?P/,!0);A6+A/)-T?;[(F@^J^X_J.K&MOKP\,+976(:*^\3[,&
M]Y[P;^TU**>";KQ<6I2SVQWMTZTO)F'$/S!!:W:+#@@#W:*)TP&W?=;J%^WE
M2>I\0L3Y-1^# $SOXNP_T+IQR,^&(7ZL5]/ZKHU9XDTEY(.7NWV/'Q6?,15>
MU^-/OI6YPPS$*Q.,$N2F SYQD3AI1H(7Z8#41T#3O2AGZE7"1=%9K'K5JNWE
MS9+@$\Y_.GS4/'][]2F;?R_PV'&JRM7[7!RI%JUDZ&_O96JJ)?)P2K;ER'*V
MI?U/ZIL"AM0\$VQ!B:A50UMVM>?0K,R"7?L.30=_7-]28><YV3'5":==D#$#
M]IEZPBS>TS;X@Y,0J/P)%B2$H=(S:8C@VQ3,%'H05$D'9%H2%^?:?!:!U0_V
MAFN7=GH%([$EF;%>FBA8_[*@2DS)/"J\"*.)'"S4$D]Y8*-HCEXV1YZ_9,Y,
M?]=,@R#.AMIXLL7;*R'28DE_EFTN!/3;9R2K(SQ&_4<L+ U2_O$T2JXOL4[D
M"C.,_IG0T)"K%$9HO;B_LAZZK$NR,*YFL(3[Z$0V8AP%OG>:$DO]N.43!Q<-
M<Z,^)I/J H[TZ0"9_,Z50ZS7)>]9W$E.PF+RZS^0/4Z;"D]:YCP#([/&18RT
M@Z$/_YQR,"IG],@1!5\2)-TBRU*__6_$O6=44VO7-IJ];=N*BHB @$J3(H@T
M 2%;49$N74"(4I46D0Z!M44!J1$0$!"B(%T(/0)"!(30([V$$('0(9!$()&0
MG)7G/3^^\;S/-\X89[SG.W\I:]UKWG/.:U[WO.><S>:(5;:=O<X05.XW:;%<
MR W=B4QLRF_(F[")EUR:3-(6%441F-VU; %5L34:7VIMA;%SB8+*0[^*3M)3
M4=!1E+^<&=59.&&=6R&@D*T)Y-6A.T-8T[8838RVEN6\1\#ZB6N>D;>_Z"N:
MOS,U5]5'GMMLL5T:-.^YX26GD&LD"[J(9P 4&P%<8 >Q9,<; V?KU+PHQAP(
M8YX6^I15OFH?W>A13*T12L1X#+CYK+_*K"MWUWC@4(+2$FM?^/PQ9C[FM.VD
ML^L;\+,LH9G8=O2")>M[^"'$D8]]",?QT%#R="O;J5&(S._KAWFX8<CGH.GA
MN79"+?2'B2T!^<SYJI]Z0Z>YU*VMD_>#74Z/*"LG6>*,),RYPY&;'R 4F;(3
M #Z%:8W 3VC!61YSUAWLK/7CQ43A%);3'T8L0:R/E_!<7-M-E@A:]B @MI,Z
M8?N@]L>/$5W^](<;9YZ*%7(;YC]BF;&]1;L;OVK;KZ/GYW]@SS<_0MQG(FDZ
M*K1 ]YL$H9[=K,Q5H[&&)\.NZ8KG7_!#:W^F"-PQ,CD+[4I*%B^4'T U9(-6
M,I[W@2=$36_+AZDF:MM..[J;^K=F9(@/C:<V$7$K[\*X9/>GX%.)P2^>I#VS
M_V.HN#4:1,02:R8.4( EHR35#GV'9D#WJ5FU30(:S0>WC;PW5AI$\-<*B,1S
MQWY9##>F>+JXQ"Z<LCL@(^=M&%B8UI A<WF^)+$.10S](#OCUL:SH$#S8,9X
M\2P K-$ 'L-?5M9S&P966V[?36*SC;*,.G9]Q;[<L5==F*IGY2LSSS^LEXD/
M,ZRA"MK^3DW3>/U25W]\:1I-#/T(9ZIR)4LU(?/3XTG"S%$.9$H+32MD)FR<
M8"X]+*3&'S1G; ]UN^X<<#EHW1+93797# \)61)=KU(<M))LNF:>)UO"'?(0
M?@=QE^T&@)XCBQ0 7.69)_T@'J6)NB F&'MUOZ._^&@U?NV?8*]XA]4:Z"7B
MO#.7%LRMK5\6M#_RV<PT_+NXN"1X<<S >" 6!SJS%^MX,H'5&9#.DAIBOF=)
M$HE>%8%CO<A4J-JR]FW/A)110M;1LPI22)2OWZBNV UUSRUO(8%$JF[-<WJ^
MELMM,\;C6)6Q&P/?0?8EZC7&^L(V080R^UB9;!?6W:7/*E9JQ<TJ3NSC+-9J
M6&G&Y!>GA'$.I'7)7#0I/[_;N<@G^+IJOVM50UV1HQ0BP<")NCF$LS,1^XO;
M.:C)<M.<V8,X12#U&LS OT^_8E03B<?I.O6-4N1#]JRR=:T=[0/;+:3KGN&G
M'Y[P<+^C:Y_9M7 I+_?50-<!ZG206UIYK9E?I-980[T).9C*6Q]^"$1&=#ST
M3//-^X\4LYM& !)LP__$.!HI=0N%T^0)H.CS'/"3J<27"KPK<*OX=<]!J9L;
MRE[E0+31<=GK=%VF">(S8X":YP1\*E]?0U/4=F1= -ZVF>8=AIKSVAK;8*_+
MC7;N\QTU@J.BI3E[S\+!A#_VBN\-'VS#SM\D^B.&$\V:C*$)37,@QS1,RKBS
M&R2>[ZD-$<R%1TD=5\^1),)'B81]TCDO&1UVLC?_,:GXV&K54U::IOY50WK:
M1CQ&'-PR(?9CT3^:;7:0>_MVV7$->;L#["ZIGO"BM8T4$B70RQ0(N!KJL9O'
M\F[<ZUQX"DT(2]]L0$U\W]N[/:TP'FOOLPH&3U)PA [;&78 #&[2N^'90(]'
M48C;/,J.M=7FN<4\11VKP5B G/\54<A,JFV.O@NH6V';)+^'Y=RJJJL[W)MZ
M9Z$T,4U :%ULA]OBDIG,\F"[<B#JV"3=3A+2/G^8*(QB+A,$FC!VT2L TH;\
MB9 G$+^>758O_:0#'CKF^"1%(F[RR\1QCZX'TBMN!4[W-L2I+6!DEX>DS?T,
M6&?&L3X$0K]]SK%"H36E@A'VDXUG,QL:\B=3A!OJ^E2/2M\T@5G&)OO**S&V
M3\N$C!8^'=2WRM*WZ)A6![?[(_JMZ!%H#JX?G@#LU[X:@/O.@<1DZU6'GV;%
MK3;1ZS'A4VLU72X['\;?Q4?]B=**[)#X<^Y9T%-%_Q$%E>,N3L[.I9GI[6?.
M4/M+P:_3,-IA?0O!L\_DL^;5T-\<HI;Q*9I(_H$P/7XG/YP;!:"$ZTC<4;#S
M7]SLVIY^7@#]N3DZ./9Q]W45KWF;W&D^/:N_A<%%70\+9;T,#:S%IHKVHQ-A
MLKL\C]<YD$Q8KQAY.G"AF4W4\G8O#6@>GZX5:# <Y3EE(&$!!-M$TTPUR(*#
M/:?G91_GYWP:,A\UHC0-D!GI$R0\_MDVRMA_L1L=)WJDH:=(@XUAP#JU=ULW
MWD?!Q9J7YEJ^/B.KRI-PGU)^RHKW&IQ)/9QE87.#3_%[Q:U- RG01:>0K;_#
M%P*I2&;3CAL=PK;?._X#>W';N@^%),"+0J-Y"8V]ZRA*P2+!HN;=6L!R>:*+
MBG^0AJ?5(='#G[X?R<PLS GSJUD_]QGPI[Q0B.1 NH86V/UL?:"7 _FY")PH
M))"DM!UW%A\%;'<6$VS22@F^!E]4%SKT#^74">JYX09'%E77+0R1^_H.:.J*
ME?5%-^S<I<^-W084RT98L9J[,]P9Q@G982/VU%IL>OD<PYRZ6+YMM?G=309C
M[J2!O5CU3-VS^9%UP53K,$5_?-G0;]WN9UX":ZOV6;!X02YH*I\7@;>!?64X
MUD=LZMT?JZ>J->!,) <BM[Z.:<0Z>5(Z>FZ:_E/:-?><#YXV.>'9/U[:9=:E
ME_(I2#A!Q6#(,BB\-3?H8DE:+H\_Y;/O;,<:.RB[C-W;SV:JCXCR:LNTV VU
M/659+/U%-_DJ\S1P1(&JS-ZBA(V]""GQ(V0<=LC4N7G>/_6*X87X.XG%$955
M(JM$ZTB@#;^PS&H)]^= %+Q'F:M4["RNG9C!:M"TWKOBTMB3BWE5_[G0B;S_
M7,-(AU>F>-K#4=)D:H:AIP]9<2+Z;IJ8S&K):P40GDJ%V:90A7!+1&\Y^Y$0
M#IL[4=/D H;#FCNX=E!N6**<W'C;FV^>GU\-;PF$E$RLNG<\753Q^U50D'VQ
M@$_9\O6'3@END:0O.PS&KTE80-)RF#;4O+F['6!(;4^8@$W!*5;=;*GHMK"-
M3>^NB0E6^FXRGJSX(!9>]]VQI'#O=]'7'(4SM@M!<]Q)==@>^#\DN5W->1.6
M%+1*%6H!"$T ^Z%(H-HN@ZU95XQMP(9B-"8CLE@YU4HFUN]I(S]EYSB09U1G
M98:*]MNTLRD@2*H]0? Q#ZBQ+BO-*_0FS(T>"!?97J3UQ<U9R59%>>P/YT!\
M0!6Z8^0@Q% 6L)JJ&<,YEJ(H\Q]B4[9KRDR2[Z6"P"$./=TL ;IL#F2^9^S<
MQGPMU> )PI!($JC#^I/5= U9E#46:6K8JPGYEFBZ2 LR:ALKECAKKIA=QK=%
MWHMHTT^X8N%C_8T#<;%J7B7:XP(M *6@<'^6WJ>E!I&H,L;)@'*]9@>7'<6K
M%.3L;UFKMX^+R3FVKXOQ3*&!,O5WP4:.SN*GKFA"&W:LI-^DE1\Y,E$D?<??
M3SG9X,[M_LJ8? NG\W?O_OJ0],U>-[()S^UW8GN= [E2!D;N1PS9#[7<IH04
MO  I]L?U/B()=@'#TW5B9&U]?LK>1^]-UR+FR$#^K7>7=X]_B$K+?M(2J_SS
M1LJ]N_7G46!0RK]@T@9]C^U38+HCPHC">14:',A,(/TF@SD]C)(.R7-4#4A_
MYO5>9&5B-UW)*.)C>=_CDNI?ELK!>^CMVHY[TT5F8SU_&A=5#-\&'=8=A"/C
M!:LGW!FX:H($H$!FNO6O:)R<=0OEZU2HP5PT;AJ%!X*=NRE]0[R.U;MC$C"#
MI/+<CS@39$&LK:!D3DBDJ'/MJ38MN3ZUAIW;^^!;2#J=D<X:Q&;R]SI$L*VR
M?6E2<%;CNLR5VK'0L8I0&%KQ>7M5@&$M(ZS>\LX^N.VQ5&4[Y/$3JB7N^I-!
M;GF[[B'!O%U"W#/6:?8-A&X/H-C7E$-!+=JSBK3EMC!=1H49#NA5SP!CM-?V
ML1$AP>3]/:9X%DPH':^C=Q*_\+R[QDO9.UX$?C:CC3O1R63N$,WM.^LY&PA+
MH#6BM<_[!UHC1 FD(TXM?MIKDR9UTDN5V?FF*80S]8>I60'IXH1HX624=YWW
M85F2*)_<&R/30U.\]V- 1VK'O5CTGP\H+HCVQ;&)+JP>*/5OS10.)&QTCGL7
MLG^'?:J% X'[]G$@LWEPZ!YA'0H&&F'WP_Z])K%KE<TW!/[ENS4HZZ;=40[$
MWXS[[.5@5@-TG22ZGP.A&C6T<2!![[FT)-'DWQ<P,,<^R^1 G/LV[3@0WO(E
M#F0Z/ 5\N.X^]JEB#L0[=1K*J-?$<2#!Q%1NLXS*O7]? >@-V+PQX!(J&<=!
M'!52YT"^.BQP?S.Q[S]53L*DT QKD[UFIPIP;0<\%?9&]+@+RE^D@2_'(!"\
M'$B[ZBK/WNPS;D<C=>W_16PE?X#D51<@Q&K[ O/7.!!2^QCW&T8WV"=!K%2"
M,Z- <:FOXO<F*'BNN$[^'RD#'5!ASD0S![(9.YD?V/99Z(_;;EUW^P:UQ51H
M\C?B&_U]0F3X+Y6\F_*V@L^F/9E&=OU10/O )]5J;P=^D24'\HI$IFJ*L<]+
MS9GX>AEQ("_9SGLPFJ7:!GW?M-"JDLZ7"],V?02^,&,>O_6I1#6!F+P"0OT1
M=YF,ISX1^R2.& HOO+4L!\V[SH^[& C;$[:]JK!@PX'$_C&%VJ5@N!M?^XC"
M7B,).W$@A^^R']J;CX7BGFU1%I@?ZQMV9SJG"5Y\^;BY'6WKYRZ^Q]5W8Y^.
M)E;S8$J*%DY>3W,IWGUN)IV?!O6G1)DLU&^:S([1GG=S(-+ .]2?#2NB2/N8
M2G80B%;M(JW=:S;NQ^_^FA!"\F45]0]0WI84!2FE3@C:-XF;6PYS(*GWW(GL
M&>?$PQ=!]?-%@T)\XL\:WFUD7MM>%Z4;=?W:H'4Q)6B8)MEMAYVV #3]R$IX
M?:>W<?-XT\>7$[Y./N8FC04])5Z3#^5UA'0LTXH^YD5%#NH]OZ;RO$\)%,$+
M#B0Y"\Y+@S/A((LPU)C[>JF8U*B+";?QE$>MW0@WR_V@ETP8J8]7G2CYF%FB
M?CK_]A<8#;ATK^J/%>MC?X#X:YLVL>3PEFT#;.9#8XAV5!W7'[]P!L!5Z"NA
M1G=X<^KJN&"*=SEY?!E%/+,;9:OP5?_!?(K0/XF99Q.SYR/<2F7\7&0R05'%
MNM&JV=:DP\T(5BVHM"<6PDW]O,?7[2=XZ)?6Y?,F=K-\:LTMO%;D<I:(6[Q6
MCWI53AT+L''/EM!?\AO1G;V3:&'D#E(FRWY0R]5A*:C-=\CY*Y6:,(E4XKF]
M>A8I8 -W)&-57+&?X)W%-WEFG(50.74U]3%NYIKI_2%,_FSL7P-!"0] 3050
M_1L@C.+@9#HK*]S.&9H>:#[3+$?!)M6'O1S870S8RAOA0$Z5M\>769CE6_J'
M>5GJ]TB>P"C<V;EL=(\MIE3Z^7-U.ZA8 !N4:0]I-I#FR)C;]&#^@Y >%\L+
M#9R!=QE%UC;R!&\QW[OL[G-S=LR)\YW#_(FW$S[K));A[AR867%RP,#:H/RZ
M&XR_84?'&A:HP%(]A,<S3*?QI9\_X3S7-CH:H OH 8+""<?8X%*7;RY/,.6W
MDJ^]2;),GD[U\QM*>]N!YE,NGE,RX'J!"J;.S4B&+*C+FVQ]*-\N-&A#'KT,
MRP#$5#'.K)GNN>)57@FH/46_))O>H*AR=>ZQ9T.^\$&X:$B(,M]0N;R&T^<N
M9:50M%_S$D\&T(UV!VZ8S&<ELPW4:R:T_$G7C2:HZ(5HB[5U='W=*(^T'DM#
M(SO!WERGGEIC.DS&QAO)T:P&>"VP;6)\9F=*4F6:QAI(#75U2"%=ZZ3.D:'[
M3DO2G\K*R\N2+D6=<]01KS:2BS2[GG='KO>[3-%_9<::_;!]O!AL"K\_PI(Y
M4*\M#LB@W^ZB);[N: /!7AS(0E)M2,?7K6IXL=J?\]<L+1I7/%M*/WRS()_.
M$YZUO2Q]+%GYUFLS[#2(4W<7F1&>397T0C]0X[7J%KNFS *T24S1X53-N'H?
MOM-X(Q%WS[KVI:E1?75R09K,JXBZ&DRJV9TK0M?<*[DW\'61S!!_'BN$ JBF
MLHA=!HJ:]<BKN7!)NY/M8&>'I34%UHDE'PL3^=GFMITFF5'I5WRY("\O37@H
M*>T> OYTX<K1U@1Q.*5I%+_7/F[O-DPT'=_+F&*RSHZNV,=45=GE5:D=7,1L
M_GYX15B\VMFYQ P]'[>>VO):M@9S*E>SH1CT! MEK-[=+*;S.CZ:^'02Z$$R
MS5A?&>D-O[.P=>GN"'<F?9SH9A\Q*=0L=_>N_C\_X#+QT[?0"B<L:FR.^?$5
MJ>",$PJBGLSE:Z\283#\1BSQ /T0F^_.)JE$6V^KF;<NI#^::5?W.]V1 I>=
M\[AVKFQU$OZWQW)>LDI9092-852._?U[W;D6?@=,P$CDT"P/K9FA.(Z2 F8,
MLPV:-'B]*2+UC.02TKF Q+NY34L!YW<Q?XP+G&_RGBC<19]5N^ V&>0747P&
M?T!;.R=#?+-8A]+TPV"*=$UF!3NC!NT<*MMMJ_ -/93;?(OU(2XOW&HQ !%\
M,#.OX/<8@M*$?=/Q)5<E.-JRU=&G5DGGYM,5YX]7_X[;'Y4$(IO [WT+,%KI
M) K/RW0E8Y/[O51-[ /[>0,0'LR/(YJ:'A2OVI?=9L")Q$(G:XL?%(37&7]U
MA3E>@QNI-;='%#8[VRTB9?+UT?Z4!(5O&_/+FW.+T?0$<*-/*?1HQT[L#1(.
M8>KNCHP_IPRGF4?&!0QL^/=9SMWJ+#9XF\(X?BJBUIHB;7A[J$LTV<AAE6@E
M98=XL::/9.CSX(Q?AZTW5M1P(!+ NS[1%J7Z"G]+T>";M4H"K+KU3E,!\5*K
M<\QBJJ6R@H%P\4+^^P&#PX69S[G#4_$Y0,_8#+9%=%$8M.!I,(Q6R%4-U,OY
MMKY'K<40O/:G0>>NKLMHO?EB^_E-L+U[E0\@4J8T6K&;F7=9Y?0])R2X22;9
M@9MNL\@^%,-\AQZ)8WU>]BJ<OJY=LY18T..Y5]M\UCW>2\75NJR!$E%0N93\
M8":G6-KBTVG]<T/5RA5+[\3C*$TC5Q'^;!CJ-":==IKM*[SZ52-+N"$T97:C
M)XP^#!-ME(5:VUNF3H;"GS3C^APKK]OD%SOG?DJ7J*=56WUZ<L#7VM#]:[P%
M&K0?#H29A9A>9G_[!&+YM"=^0:FIZAPR4AA#53M*ARXD3G[_L;!*;4R_3@Q]
M53HY/''D_+4QRK$H+37UG/>#I0:B2'&ZE<!M66XQV1%4-_\\NL6*';87-P+K
MCO/%ZV["YOE;AYHP&Z8SF^I-31BJ?6'M<\\H#/_K*8LS?._V-%U1YK6GKYS9
M>)LD[)R<>=$ =-7R#!56D_9Y1 3;A /!;\SS/_.SPI-$+X14-[/O<B!YQB,]
MG]!IWX['52C:X>'RE^"2F:)G0YJ#W0WURVS.1.5\ZCI2HM"PHX]>X*G>!H(X
MD MHADFZ;T#Y2.M&^$ Q4W,X;)]ULYJ@GEURUA/+&;415=U#5^PM4HQ_J<,H
M"QKZG3U/<VSOG?NG\FXQZ!<8>WS4W4]LQ:UIS2*VMG]4_S*ELFW,TIEJQ_O8
M%(=L'S*Q5[(8-3@@?N$.K\6PIH'D&Y5[O8O#WT$\KP4A)U(,X;FDM4M78@I[
M)RP/A_+[4N3GV4YV1T%4<U]0LCB)UP:<N^J?16[7F>GN'WG\8+[T<'XH+J2X
M#RT& RFC%//G%MX>E\8V)'41RJA;V0I48'ZC1X_:E#ZVYU@H$%LZ+G2@8N)\
MW0\>76L#.QV3M!+BR5J-(=29:ZVUQ_ODKO: YNQ+XYF#@Z*345C,8*%\27]M
MJT+GIEN8,T;C'(A(\UU_-;O2FYCJ7XV! AC2/AO3V#0GO0.6\B;/S8>;[EQ/
M=/QU<[S3I4B?.]6\;JV\=EP+5Q$(M]I.&VR%]S>0WNG53=,GLI+YBG%DZI9L
M;FYL7?8>[Y!Q3H:81VFQS+=B;L=&6Q3HX&]J*[(0T<Q +W3JU5_LMCBR/\Q]
MH[RYE/*NZ))]F_PQ2Z?UF)1+D.RE/V+^BHPQNE?FI?\72(B*PX\#"B;1HA>P
M(,>@[S+O3 GS5>_@.D4^;V"3L$M#M<^79><K]CFN';.B$WI>9W451+?GH'-L
M4TZ76MVY6%A\[58):#*#A 5DK]9'4U8F=D93ZR@-5X=)ZV=LT0*AT=VLKU/7
M7V27E?1MI5L<LS]A=]A.\F*)TE"=_HV.ZY<+G"X4Q\JD&BFW\(,;LL-T0W2S
M[<:1BWMC>V&L_$#G+_!80$5;VE6UT-LOD4 (3?'V^BW?-?XK.*'G9G9^A[>,
MH'B^>T+AJR#XS3,^86TC7>K!J]P&579X+K%:@-+'R-&X\)TV0%OT;1EI+ZQ.
M^_%CX!W<$MWF74O,0!B&(AG6M\9 ;I3R?%U?9F)?BG5T/UDF0J8B]?)"0:QZ
MB7BJ."BD/=#?[_5AFN\"K:$:B^2#0R6QU9X[ 8LK(N,M%K>3[QZ7G\E5?W S
MUL7FHY_^A[+SL55WOWV*+?]\""2+_%_&N#,7E4T6/*A#S)L<B*H@*8IX:LS>
M#=G.@5Q]V#_(P,5-C=0(9\=]L^Y)B/;4LEJ<4C>_+W,A7;ZJ8[/-Z(C9R+ >
MW\,?9@? E7QOME6.9O.%LC[?9:0U7,GC_];'VA.1'OWC3-;(TNXMK=Y4GM."
MU?P[NM_^+GIL*'ERKY)>,P-&(9,F7'ZER('D8,6U-7>:A9B;K'QO#F1UO9)^
M]"BK+:0L7,B_?*UGUFD*:&TXB]W]G)7N;FK5>3[SJW;@18M3EJ^*=5643?M,
MQ8M!V@K3128*<^6!"%W"OQ$R+I'IJR82=3":3@=,3^N=4VZ,YM%-?76NP#*3
M_W;)D8'.4G'/(_=*5KZ%HOW+"^F_GD)G.H 9]9A&E_*7!='TPSEA+5>.M  ;
M[X,=OFJ%E$\*-CU&Q)39( (*KF88V1QX.A'V?W^ [7&6,MM>](0V#+1^AH64
M.^+ULE?3A'U<A;9;8.+X:A@IZ^EDJ5>N\\ZHB^RS1_<N?.R6OWLNG\]1227W
M06V0[3TR*,(>(!W5A8[S 5IM-!0JL!E:8>(HP=7?:GZ(P#4YH[\Z,WO+17F;
M,7=;".,(0S]_G<L3]=3Q6)47RZZ1'W*4+'D'=4X4@0LJDN-Q1!CELWU074?5
M-M.93UFY;&LZN=$\9"WG6]Y&?U,6&CMXD-#Y>'M+7K#DQ9AT<IQ/K&W(UUSK
MWD$].=?RA(5,0$ZN>94H;!*!ZHF;L<:C%S4YD"/'T$S@QV[@UZR2T%+'GR'L
M+-]1EP\O!<ZN%DZ;9&7^Y5-_1'QW!4DA0F*+7Q3G/R#;VCSFXV5JC378(TH8
M!E11D%/,6&KQC-JG4@DE:CA8 (;65[I.Z9QH3#EE9(GL\PZQQV$5E>M[(Y5C
MG8HZS9VN_E*NU&^E#@V:?T^[]X8'I$KP!1PM[J?D(29E*U /5-WW0Z+_8$^S
MCYM33E0LQQ<<U?H2, ]W]9:+?]9B"8LB#/MO!1_ULBD3LA8;^-O')[?$0',/
MU[!CBDU!=<&167$5 &JL _LR=$CI"S:]":JK1U.8[1\M_]#MM+2];ASH1OXY
M_>M!PXTM%7FXZ*V)[M?+COG9B#]ON)L8EDBEV8*^/@''DL RO5ABHCVH&2@^
MIN&0IQ6KJ7Q*.*G>),C:TD6RJ\W\!(6D!9PV;]U:%#UPR<O=I>!,C['T]_;5
M5XY-"=RCC;JB_[?.U1YHA0?HXD@)J*Y#31Q(AI^P0G4^\^)@*+01<\4$/J?X
M-MD[]KWD:)OJL\=650&O+<PJ.R1CGWYZ('C'R,6K""03HK\X$%HNHYZ VGSO
M/<'<(F2Y[(#HZ[5!W:B"OA/1F9_6+Q43H;\,?)0.K:^@#KJ<KBTLR"W\U&9N
MUF<B8.L>T[O5\==BJB%(BKTL69]"22&(3+8-]J_0GBHEE<:4BIT-7!C6NGE'
M7N]B8I[4N[S\<U-I^GX1/V*>\[U];J%XYX[DK=L^L Y0USS$6$2V+8L7R62
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M36$.1%-T%Y_3 <84(CT<R)K;?W6F^)#(@60C]Q;Q3L BTH4#V5;B9E. '[I
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M-"WULO/8T;9+]=GBO-SS\%SM?:"OX$ R]F19'[B=7]JG>Y?1E+$05MTZ/HF
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MDMD>G7F+TTG$ Z?R\R/9[ =+O\S,:K^Y9SNL$FWX6[+QK&\[B3VDW13FBRT
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M<P<Y%5Q_V<=.733\-K>Y@B5D<AT5-7;VO+**'YL<O'QS0FGL@2[T <SXF2E
M>W9(ELL9W?#7D'[7!1;H,>P]TU7==(EJNW*-$G3A^*J]@X7$](XA>=+G?(U]
MY^,,"?$[#5.[RK]<BIJJL)CN:^[7>,;,Z&* +XYS[;)?R6"T1?KL:>VORR-P
M4F'#C<VBY9CEBN^S!MZ]-AP&QF.M8J9+E:Z7='4OP,\=F1@GZ25VM3IS^_<E
M:2QH%P.$Q9:!9KK#^V?GX:Y>J"RZ#KD#&^9;W?R'".:SM]"(Z8.)OT?'3Z5
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MU2Z4QW5.F)\[['Q[B7W:)0Q)IY)Q&[CE92-"<]>!956D'BR%?J/E'R)81,N
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MF'*' Z2TR9,[T!EB\!LFF $ -W:C:17W97XG[.M$:"Q[\B7C)=,D/7R0Z7@
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M>>07CG-DF.ZV$SD6HI4J%$?Z24_M^K'==F47?EQ'8J3%R%W\FMN=B[M2^62
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M0FRZN/QK-:X+((@AB)FK#/\_C^<"=@V(J<Q,WVXD9FBO)VBW?-?*8WB%CF>
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M0-LF-XV$UU+.+!SE[@D'^6E^F<]UGD"/U+1E!@<P0 1"5H_[SJ71P54?+M6
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M2\?/6]O[/4<$7IJ?O^R2DI_0^J;Q.**@O*CT7;WO.,2D/T7C!D=E7'GA&W9
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M/O3!I53X36O6,\>,R@^RQM* 7]*5N*E/:,*4];W=4!KGC*JZOB5AM^$V2?J
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M"Q.A9,W9P.%J0PW==+1^L^W/SXMI8F;1^;<G2@P^3"T_CV6MR#4N*.Y3^#
M *TL!R/VK^8&P%]!(U"L81#D';Y$.$> P_>O?G:,\  V@V@CT2_@/8<'&1.N
MH]R)(:]>_24B_GCJZ82,2]"UM-P[@+!O4749:QI#%&]O = #ZD".W=U/1=VA
M&-YF +23:2XQ,?"U.;1QZP(O^#7C/[V#AKKO>M4X<\IT#8T/NB](WO<N8]ZD
MWDNQ(-.E.EJQY!Z*D+O4NY. -4%X+WW^G'GC%6%/W%=YC.NQH62]5WUQ?/E"
M8 _7ZW.LO(AZ.TFQ8<L[?9W'D?J:M^5SE JH:<T=Y&_MR3VCI&QRO<(,?F8'
MO1%+7*CR.5&UV55):/+B"I5);/%AJ@X0FAU9+7*JNH;U)_M\FPQQ5CH/*R]\
MQJI_Y_JEK]1QVZ_G4 /KE1<.,2N]PS$3F->!*VU""-:(98*E[]A\3RS[(8,9
M=P,Y0C: QS2_>-#&-EA4NMWZ]KO'<)PZE <%!&P;/8S8Z3,0-X6:,0[/@&4.
MH%^V@X/M&GQ6/7WVL+T3NV56@]^GEJN_3!91Y.!"H86QCKQ!43:)44]RM7Q;
M% $5;/@-Q;L/^"+QJ:0KY+KBL*?]30K[_<%6'0FU8)BQZ\0%-7^-:N'T^Q5Z
MA<[T,])%Q3HR^;1G(!_-]8/(_FB^2P ,KJ[QX?6VEBC$OWYM+,MF=LR>NK2T
M7?[A6E;8.QJ/#N!F#MJUWYQ+#:SVQ+'VRH[J8+KRU<O2TQQ,HG*[?A]Y?16_
M";R'%]'O%W3-HR>==QQ]6DON"7N(Z-@?Z=]!A'7GH$,G8GO&=RU;#2,Y.!R]
MO^@U=4P^[8;*)C4)!Z^0(L5<G%;#TW9L1-?!.^AK)7%$:$_G(G(0A=WOK!@D
M<:%V,?&0>RV\O%LDFL,X'[<Z#M>*O5[<99UUUB;Y,N6W-_*[K,<3]IYWJR;%
M9AKDE.<&)B.IK5Z#+)FJ"%#CWRA]OV0BYJJ_^\%.6VW'KMOH[._9SG"=(W]A
M#MV'AJF4ZR[X]DYS08F+V<5O[9Z\S1.IO0>BEDK'[6*P/SS;AQV "#C]XN[>
M=B@F?@G"7@UG_5-:N+P0]T@^F3>YD2=Y8!KZA<_3Y+9WK6A*7E&R"OM7Q_S"
M$F>7R;NMCRD[Z(!&2(J$+-]P2%5[NOPFCC8 #%4XT(M809G^KGMV3>/B?*]:
M8N[06DWM1H:,J9!50T/SY9=T3@_CHM(O]^<BFS\(= )QBBR5F8B>@23A:X0$
MBEEH]J+'#.IN2P""K+UT4JK\-;AQ.=:#*3IGH>51BV>;2JF#:Y[,J&F*;+_Z
MK[$.[GO;[-F9>5FQ!5\Y-X /^[P/)>I6_/W9WT/3M_+P/$GS8(,4&!!.+,6<
MUO]2>/[P?0*]',P-QJ.KI^#N+KK&DN'C;G1:*ZBNL+O#7Z3^UC;A\5]\ -)$
M_<DM;>![XA<']]TP<9N7S)_A,:V5;D56^X_<XZ-G$&?29*&GO\LJL;]2^/*O
M  G<3("]OP  3L:0(0^2SAK%@_R.B,(O%(59^,,[X?%\3",V%QJ4Q2NK F.^
M384@O=2=? */<@<&H2RW'R$01XF31]YREK*BYHHHKF>RU,;I#O@)DHTF/@&K
M@6\AR2@@UOS+V@==_-PM1V_/#OXT5S1IR_#2W]-29S%M'+5!T>K_M<!K*NRL
MDU8<7"!X2]J*>H#3$("?U2TF+[0@2?F:BRZ)<?64&X9D_81LE/NEZ<CG0WO1
MU2.90SXU4=4W%K*8'GE)F^/\3N<.'('8,8<7\H%W;\>B]_FN5 1RF&9=ZOL9
M*+RULOEN2V\ &;K5U<5>+1<45%Q0_/HYKKF2P%\C76$0ZOM[<DJ"\JPWS8!5
MD]H*"'DA&B'$Q!B>()HT N9G@48CIOT?)S=437S_R%G2;Q/+OE92)+J6E"QK
M_#&U1.2F1C-!K^U?I#GEOQ?^O? ONO#$ ]PQJ^(5UX-M80S9HX^(&MK8/,[B
M%_Z*]WW6'%Q6H YG@'#IROG^T  _:O98*"Q\-*%#21W[C[:ZXO]G]?N^_9\6
M6WQ<5>.*%IO(0DN%@_:;Q]-B"*P%<Z3AQ[Z1Q"_D4&4C3<YA<TO#6YW0OYDD
MQFMZ.6L_,#83H&'_^0EIH@JW%_L<?,RM7D/>E"\NN,?'MGNYS6M]$:CX_)J?
MP->Y7IZGR9F3S+E?B]I;,H)E="A$-\;\!GZ;\+^4AF/N(CM=K(G4J][U Q;2
M<%O=/JI3?[)3TO)2J2EOXK1A;MWD]_P7/M<^FO1=&[ 0;6PFJ*6L8X;!410X
MBIN0,@#]V(18XBN5!ZLR10WT-SC"!3\F%\HEYG6-J6JH<O5,,1)8W@O\<V?L
MO'?_R'MJA>#Z%8FT75XN11Y652Y>!Q9H<AQ/2K2JB5[]G;SOG$6J]Z)R;ORQ
M?3"<WRDY7$EMT@;_WY*VK#Z.[J*&>$J'S6%@%'D=8Q8PNERT;9U<\096%J?E
M(CHV[VQM4*WXKJ]T[1+V-O/"?W9_^Y\VZ3TF\^-,J.F;@L565+L_W,)M8.@8
MXCRV05@WCF!4NVTH9<H 88J)+;VI<I\1GE!9%)4>G_ELT%!?P/-[''\)R@^7
MX^_A<N2AY4I&61.$[5P9\F?9GS+8(([='7A>=HY?//_:,&%@<ES_H6=>C+?D
M+C(;^.'Q]Z[NF;6M#11^_]WAWE?H!1//IP70<TT-W78J8>#F](>!VR([3@+)
MZ06T-.("[@.85]1$[A- , 5E]@&T&8B\0-<>\=O$^V6I$N,V8C>+9/VJ!;RU
M-8QN!<@>Z??*NHYI%JB9J(N=$P7HD]+_LHURNDOM['TK5=K(_G6O>[L%V+(4
MOD;I^JFKG?H?BEXE.\_]S G7,!5;#X]--T7?HNNG,]#Z=DN&$?"3_Q=WF;+8
MPUF55GH>/:1,9,?$VMW)5$Y:_-'5"8&CJ:-KXT_''DTH2=3[U1ODW7F4UR];
M4=U3MOL7X-P7_JL'/RY5(?>?@5+TII=(636+9R!P&XO;2-]"1DGN"W?>ME'_
M@N[<D:<.(ML8/I/P\JY)!YO*_('QF9[?$P;:UR<UGI9?Z:D1I;8E[.G&>@4-
MN3$XT,9_'GIQ-['8,GI@93TV)SV'UNB^S\/[$@>ZS%$/ :%^>T5+S4ZE+:$\
M(0=\WM.Z'56QWY:2B]M-DC&V:?:N]/VYBH9=+>WETF98"EY.29:+=YRLF4BB
MV\Q#_P-L!SWOOQ J_GOAWPO_/0LY\,,0+-0& =W)+&X.+ET1#B$/8+@V0M5F
MB R-F]E1FD[.]I\K*W7"@UM$3?]^X>F<R,A=/WA!ZZ%XEY"1B3%@&,P0[!1Y
M#L\GT]+>UB9$V.C*&B*JX%=7LX:_'_-2MD9ZAE\T7A!49Y)EZH[O=/#ZM7H&
M>C=AD+:%P*>+9/]=\TF@@N*X L0RJ$:R2,EK'QP9=[*YCUW&KZX)?[/,7M0>
MXT)M0(P>ZL;G%(VT&40P\1C/SODF3BEFCC6F%]1@D+KZW-'K69<VUXI*8N6
MYVPC[_"M=\<27\ZCU0YL<L!R_LCAT?33C=K2$#9KLO,.YX .=UV(=\1(# IM
M6O:)1;2A&L8B6]M!5S,V9&;F_-96E9T1USJ!,CX#*82EC"#H</ L^,W@PI:V
M&VX>L2VOY6J4<\M;%J[(7;2/@[PM>\WI%:B8]T2D4;$?*[9U\)M)ORVMYCHG
MA_'EU/P8E9EF$1Y!,L5AE,#7&_H1OT *0R02%2?A,K5U(<@5OC[WN?+NM3L9
M\:6BVMI@SO=>AF-JYW9WL^RV7QD8#,NY*,G"& Z^3:A F@G:[<G($8RWK]0(
M>I_<W"Q#0I+?D"+QRK3C=9D==47!*-&([*XI#=/S3"*+IA)1U^KOU*W#SY-,
M;<K42I*CDL5,"\LCV8#]=J.VZO18S*@L;!$/\RO$5Y!TVP(PW6)?2\Y =WCB
M99XUTT'T'S9NKQ6,[*!E5GE5QN":/#R( _V'#]6D7T4YN="??Y@']</%20U*
M;11.M'.&*5.;F<6WF'\.*6P_3CF\/K3\ZU2WYL_F4]7FYR@%U=CR[!SV]#EC
MNG SA[[+C_.B2N3BJXUE/_7>2 J=:38A,U(\6,Y HF##8W@')A[.>.+PLW!0
M)6$&OM4(^&=[.Z^%5QG>KBE]%>#[(Q"YJ,+\/*W9K& ?0]4"-?6@U8+2TA/.
MAO?4NK3U]L/W)+X#2&C EWGX !0;YT,.)G[!SQ :^]-\E)%NUK>Z#'^*-EXP
M]G$<,RK0R@VP<2S:3IS2Y$YTT5S]9)1:^.H9&W729.(9:#0@'ZQ$]J7 D4(-
M$:H!&GTJ:>1. JN,^Y'QZ(Y^K.X$U#"I(#LKZ\T+%R$S1*QU89FLDP:/Q2.M
MR:ME?_@&VG;08+( Q8LK;@TUQ#M(Y,$++[-YDOE)*O7--;FMS2>V_GH.'*C\
MQ045[VL_)FS91-_EAR?PP:46U>T*#$UUZ8I-=>H/AY]L4W;0=$@.9(:)&B*6
MJ(K7V*!7'ULZA=91!+$MYSP"1LT]PGLGW24N:E1X;8AF]$ZIO2NIS ON=QSR
M-E2CJ^5X,W:AI>TEKG7*ETPFU?ZZ@H7B?U#@<(DP3P3_+FYHRR,1+G5LKY#S
MQ]S35OH'UDMQ-T^YM6%D>;1-7)D5G/M78J?UMFU1]DE4A\I%/787D>@EQQN
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M@EN"V;</KF.GQ0(?XY(J."A_Z'PBM[U^Z26,=P)BU2$&D=<4,+[DD6[R%5+
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MJ_+UQ49>:LQ;L#5^HE=#;.RG8UCBNP?%GJF7P+2SQ,PAD\TP]JTEPAN*SCE
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M>7 9JL:W*-[BO 1A^G-82EI[]6XX.B@;24"2WOA(]*,']\.]CRZO8"U*Y7X
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MV488YH?M*MY.YK660DK]#=D_8H4)&D^9/0XX\.(%#)Z"D$;0Y ,+&2#/9A;
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M)=Z]S?/S:V6;I74O.1J5?=DXFOZXHH8\167,8XNTI_^X_%F]'>D;=G4BYQ^
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MBW3HQ,;W)2E%U6X*3=^W['\[RY,JJ!,NE^3_E[OF0EQA>D'/U5PS>[.'T6H
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M%U*^@W8N'Z^AKJ4)BY-CI4^AT/AT?8?]^?$'BMI-<-<Z@3(]G@!.I@(+BZH
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MF.J8&ZFHO>^'J)\H$0$"H;=5" BI720><>\H8H^+$D^#DHD C!,DF.;4W#C
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M"$]5D1Q;4'KB0LZ)K%ST>MX&N:*AV';92=099<UZ[6G5:4MF1Q-+"!#%@AB
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MGQ$Y#_R2$MGQ3*-O $YA2K*:Z(8'T:V;V6XUWF4'4A.EP7?07GZPK+0P2DP
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M"^*VKW]M>WB,KG@,W$A^W%\W;Q:K$IJ3+Q.&-.NX0L_VN?B^.VPO%]Y&/'>
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M3G2KDR-$E5^8V4C(6%;Y2HA=$Z^I2MCI^V=(;JV[-\1_1EGEJT4Q W%+?ZI
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M1 '-_DXL =P_0 H@+^P$(N>Q@D&",*3G"<12A>'F F8^6G[&R3(ZO2@#Q9[
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M/U'H$/WE5WX>Y25<)+ Z'E/+R19;6CP7$,K8>"^($LH3GC<P]6RM4,_1-J>
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M[!X_2T%-L_N"YS6*($ @$?"_*.[F\]6-JJ006T0R!'I<KN)3CJ_'^&FK][N
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M<V&A9*VAGU)7DSD[ &(%B?(-FU67(QUSG\SR7];6_D&KWL9_SI@/5/O8DT7
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M+5A6Z$S,IWLG9_$T[](ZEM/<7!3;YR9_R]^D^"K[WGN/[M'B\<<#VD8W>:.
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M$]4RW5B-C ]0+B]'+*E##U"EP=#T)"]C%\1'I<+J;3GI@U2?WH'(;9%#-=Z
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MZX?X)(99*!MASUAJ"J,1S?JU[@QV\U83&W*@IW'VWF!:UM9R[P O@^A#^<C
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M[I6ULY_GN<MU[7W?UVUJH"G-P6;DZ-AI)R^_&'DR9O(>_UVV1!:Y6%C;P@Q
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MDT+=,H_Q^9>6CWJ*9_Q4U\HV?C:XH)>%N_-+<R0=N.B;L^9(FAC/KY7-K\Q
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MGW";XNY*NP!_SX@R>3 L3KQ&Q'YRL"FQJU\;$B:JZOIACN^A7\I+5>8NJC$
M/6DK13V@9!L)DEL!V@I_7F.?*K,CM(S>I+R94D^+B,Q.0-EZ]/[DD^DTCRF*
M%2^6W'#0+;6\HDC4=^[\ZX5P33=K!@8_G6N] 55(WHY;"JC]C4.8^AG:>F)6
MO!O\?W[;YE.5?)K<XJ9HDXBM:_Q"L]A8#I1^]R%PW;;,RC746<SY@7$(_RW6
ME((W1%D_6A/=A@'X'N*&D*&3J6DS0/G@._ N2GTZ(3MA#B'BYER&>B8$_W5;
M1?++"J? TT0M-;LT]MB*4H5+[?O5)GKWQ>V*](.<$7[XJ-BOLQ!UT$=E!Z9I
MW*1O0%?TIH&G]GG:AY*LJQ;%OGU/7J?N$.=KIP;3HH\&Z'37^EB;P=@9F>2\
MY!_ZB2/#=:O?1M6YC)FP>7R: 1#&9!VBJ'$(&4P<3NP0"(SJVB]T3).JACV6
MEA*;'G/R_VE6Q6Z2%"8<R9W_=(;K\U*,N(%"6/FHT. U'04F 3,W)\_C@>EW
M()F87MC"04=5JMKF@CM$5DVO9A_D@-].U[F7:%E2G5<I&)N;QYL89J6[7KU+
ME23J)KIHI>;7/CT&97W1?>:+) O.( 9]EE9)5HA57O+-"V^^PMT*J9E:<WZ7
M[39@QJ#FTF^VPE@%Z[;AVU<_^C;%S!^\9).X_J"@:WCD2>=??([,G6GTP*R$
MDQTY*/H'W]%4:#RL_3I9;)ZGCT@T0C\:_[& B+"G#]6I+LAB+!R+RO)+.#UL
M5FF*RZ5%AV'#0H\<TK7L65,EG<B762"E$+$F0-AU8H(45P:@%DK:+ D<78).
M=]X#'52=;40T8;J<7P(#=$ Q;NC?>:9U=-ZT/KK*95812CDA"_)'0%H@ _ M
MUQ]H8:?A ^]?UP\/H+$5$_3-'7Q_;I5V>+*G:^E\F*5 \0^'*V/Z%QI"]7YE
MHP.%586K>I:<1MCO'9^%E;V;0XK2'VXA*4:@#D*(:5!WLQ1:B9FL4KEFJUM4
M?]>+STFCM_)F^,F7E4_Z68^B=39%"CI&-@V;=](BGG;9MR#]\-F@%$@? Q _
MNTS[#LI.T_;O=G8\J +#G^*_-V)G3]?6> T+\WM&J7 \UTLIS,_(3N5K6BR#
M@Z^#?*273YRIYK(.89J)' .@A![<AH2I22VM]CVN8@!".0G!(]2RX: D@VPL
MZ+07?YJM\?,_IZ?P[=\67?;G#"OD3/H/J$$M?P]J*CJXC^6^?EZ8;5B?7YC>
MQV0?+]%_00/13$(4>I&Y1:_5;J S)%7Q;12;J9:YAEB.8:XFSXJY/=+#-.%U
M[6))E=^L29O:=(M#" P*895]LA5/"[A\D1> 31ZF(?Q6.*L.5G *&%C8=]-?
MA[;2CXV3S36-[I.?3-292)IVRJ@E#RM +SEH;,Z>'$<.'B['!-!$VYUI;]L)
MTMFRU$0\?367(O^^QV%]G5,=Q'0I!%+ B&]!4J+$97&F7NUF;&Z=D8Y^PLC8
ME8"B0&=>(#,4-C8CW/&M*6.S+VH/5G;Z_05_3\\&A6&Q$PBG&)7*[PYKQ+%=
MJG0K9&K4R"CR8XK[2]-'$NOKZ^-+4B<N=EQ6_$>;.P/R=%'9L.?:56:27UUM
M :4V_)B!"5W2'D4(^"MM3F5R7@<W%V^6H0GJ-BF5Y;G?\>R8IZYR._VQR4&-
M":(ZDE_D.PV!S0=@]7',]Y"5?-Q.ID<<Z9&_AI \N:H>K=N] RU1<_,W7J35
MJWRL# 87#!CH#G<SL_(/#PO7 >/>$PE!@Y+FX-&QKJ1N)I&[#W)SQR 9@'X]
M:BI"Y/L;YMDH5*6 )'ZGK8"\/2=;0IP#3HS=%.[]9>(^[K 0<OV:3&*:A[VK
M,A?B143VZQL=G?H[)BJ1.3^8 /1HT@**Q($0V45D$$7Q,R*]J <3CN13%2II
MQOHO[@_I:3U\*26*>+$56.*R\]HL4#]L]O;R2VZ_>D6%E#]>6VE>E*QDZ1A=
M;=GTHK52Y6F=J@?4>WY#9, V+C;HWL[FKY^SVXA4A'0@O8A'<XK_,/!GY'E/
MT=@B,;43;4-)L8_D4\X^BN,:1M_/UKK4__#%P;-UFYT0:C'\[4;5WYA!#[J-
MY]W3"'@R_8DU%K8EF46OT'DO$!?=9>>ZZ7_%3>3D'Z;WHCSZU>5-TF\<1IP_
M)ARO9R'*P70!-VCL/-T)> F3YJ2-4(]IH_6U\*,#\/BX*E@F)OB<)_1779:+
MT<0A65;G"LC38T#K+MAX>Z!3F#_[K4K-Y_OC^F=?I][3OLP:"Y]#ZT??AT=0
M7Y#+J#!6HH^ B 4@.F4R2; \99Y^V42;T3%.DU%"7U",@;:1(#87^UI>R" ,
MWAK$[FX UK^"$'_[JFC':'P4S-QN4U!2G(F_]D/$MW>@CQ#3_0DX03;)>M$)
MCM@H547CMU2M^/3QKF^#FFHW=J)2X_BYN'S,%S[[<7U8+TU4<)W(5TR,4R"Q
M5#O;$/-&N/V%N(\XJC[F@.C'>NM<ZN2/1(+Z(#RT3VAG/&)%;98!$/U=M,SA
ML8?HC$O$7&NYB>2.FZR[D[78L.$F)[]%,[BFIXWB][1SWN@WU;H\/C%F/-QK
M;B;Q;JR*N8=YM'O4]AD!9?(0%0MWIX9.\X?[[@UUE#^36E&^[QG<IL!U(Z3L
M-H6-1G_V-C$W.RR2KUQP'-J0QWN67?^;5G%8<TZIQ!R3$W. >H"U=$OXWW3K
M66^2VPKD!9[]D)7*#AJ6MK\(W'1DX[."7QE'BH@J>\P3N<84ZE;NWDV^@ULP
M'02+.+A5/B2/-[_/#9F%Y9"I[;04!L"!GVH+GR0$NM<+<GIYH,,'/&;CXLN7
M3;SQ%A,>'B,E>ZGW,OI'N0WS+FW4N HQ(X 7 Y!@J(]HMT<HFE),K*/BV.G?
MJTBAZT/)F8F);*$*.X3!(AT:I_I)MC/Q8R83]B(S?C6ZVTO<?QB_OYXLS0Q%
M+ZAJY"$'Q$T,Q039IT'%'0%)$+3_3VWJB_D&$4\LI;ZA1/FAS]5:)Z5GCOHK
MQK$HN7=%>=@Q7XK.C9(*UY#YXN)\35Y+RT4FPIM "$=6D&E?$>G0[W&K(3$;
M@Q,C()[@^[O[G(M.70.BJ^Y@#<U7]U"E.Y0M_-(,UZOFC-WB_A>;^_=_M!N/
MGX^_![ZI=-8U,7J F?ND$/-B*;)3H!-H$UKZ]T)5FU'2$#5L'^3C*6D?#S8=
M$?$3G(VVW=PXH4 <ZV=_7EYL;G'=/+;:NB.CCLGVRM.H&=#L,KH5I@^T<@&_
MMITY(<"#"B1_JCF$E"EU=73\>/%YUSK\I9;@!+8KDS?F;<:'/A]>74V'OYY6
MX06N?X!5^?V%Z2DJ!,W7@#)*X1(5G=UA#("3.?7^[FJ?0:_.R?L9KP)61O/I
M9[/?AIYXY"JQ67,9KSHEXD]B>R/QX&+?%: ?OG)HU:R-F?"DH,L^M,X6<ZKW
M7L/]I)8#,Q]?6D[/D([T:SX&@."_U[]X8XY_YJ89'T5*!'O'"2ECJ"E\^^NP
M[?RG2"#OH^[F@[^*2(J3ZC%??A^^@#>U(Y3I).K1F$W+:)3EM !H>C.\IQO5
M(BM,*8\UW)9<XN;=+M%Y%S\QK(52;&>_K7/6/./,/*OMKCW[OY"JQ/^4"^*@
M6\''X:K4@UHYV#DF-OEK*Y: I9PME52::7D''K$G&IKS=9I2HO&B9<"/'?6Z
M#]^::)MSQ'=SJD^+L\# G[ZX3F@L"*BJRQ%S)#<R^WJBE?."1@NOF-FOZL_G
MM?150&)$.1N#V_TT+9*&^6&)9/2(Z:D;CMZL_H8V(H;Z@ &0@;QO;4TE5,5"
M. *3REJ@,@JCHN2.-DNPDAK>920QY]9%>S<I\?TQ^='"B!L=[5J<X6G&G/]H
M_@%O_2<U_^+YM:E0VJW)3,A*\,!TJR)-R@-QZR-]G4D"98F8.9D)T &Z)=!D
M:5U9@>[Z<6O\*L>"*36C<S@4[NY+]S M.:[-$I,L.:3^0$C=Q=C1..E/,:?H
MY^!!_$EES=K44+^5@.L_Z]-Y>NR\;!#1V*,W@B]1\@FSZ9+-D5\,U!P253K!
M6J;DC.3"6)6Y1_-,*%V!6J@BM=(AN#,!^-_;P$@D=S.JX/!<=:JKQU#+_KBZ
M?CW&Q7C,T"BJ2P]B8N%EH;/2/:I/&7":6IQ[9>Q?*/_'ZBRLD",9TF=-]:(-
M;T7+>L&S*#'C0553DTI%.P3WC^ QQ;V$D39U144EVZ<&GB#*'O==Q?-"!;UL
MS;XWE"U"VL^Q\ 1'$*MV-Q0C&GS[.9K/_^"^!SRMB[W*)*H4:Z-<LU&#U>2.
M=9?PB=8%XH,UCX-U3DHDO ^32.21UG_/0M 6!Y!V8 SD!BQI$=)S87$300CW
MA-^?40F:(.*8E/#JT"(#T#).7>HL-$-\[EQV]DZ'-C]5O#J<5%01*\L^_V@@
M<9,9&:L.PDD6=#!&Z/ -;+,)?7&WD+C]6GX$']VU9F4UX+IRF[/++J/*VZY:
ML>YJQ:#TUPV?E,)R#EG"K=M_LQY",>AP9W$!UZ>15$19Q+7R3 2EC7!='&X/
MW?PXSJ:E&447T-]]1;W5%3UJ&%K\*2_A4V%&F.[K3Z$9=[(NO6?&^&,X 5"*
M&&F#$H=I*'*AN5,2QF;5IOAE7<:VHJ]0IG;'Y1Q 83]?AYJ"QQ/!>DIF@:%9
MJ;H9*R6EOA8)A1+GI9CP3I?/<+E@YW'(BH#V4)]L3"9;VO(R^'IA9M,O][?C
M5,'8/ &9EXNAT)T'_4.QI8FI[HG#Y]_M=MQ3U.MX'\6DG1$CN'-T!=IKO&QB
MZ]'HD:M2G <<,W,U9I0DY==@IY[ 'XDYD?Z(:/(QV%S")JHCTG30C$/P=D:L
M"ASW)?'JPC"^==AK&MB+HCYSETTXO>PY1#$<L1#<?_H%%ID48#1LRJ=[]Z,?
MY[BH-1"U5!J$BND_&M3L<RMQOE[F<L)]E).+I25^F_]_B'QME;MA&(BO>729
MXQ5\:$H=2N-9JNIE;WTWG34\!>J2WP-U.2MMGP+QA(50U)^9P4^I;:UYFU:[
MY>04)$*N-,U9"FHSO37ZYBJ6WP?FT=I6BXH]S='LG[KY;=QC<*@A@%T!G,Q[
M+<B=P\!2RUKG2>(]$QVPH5"WM+&4\/N!\@(=5D=MZ5$9[3TH^4IOA7OV)(5C
M^,/ 9QS74916^B$\>GS,TDH[4=>IRVS,7J2TTTA3.EOK4UXBV[$;6F)8M[ K
MK [Z9SPLE:56TFH ?+M]#S-%*\,%:?)H>J)9*DM)^(:/BHU?WKVJ^O5R&>)Y
MK["675MLICTN]C/%E^]MHBX3/TV@<"Q9YC12>![=B>")HBN2S!>#YP:W'Z?]
M(\L,_37&'QER/6J@C2:8)'7JN-!!LHI5<?W$DW$=GK2G'%P1_$7-!T\TGM&N
M4E+($U4NJJAEW,,M.G[J0]_4[5>J!IT'OO6-?>EY.X,F[P=L-XKE[T2FOS@F
M:"59+.Q[S/(]2R%QG9>(HKK0V"BP27!K!1&V@#+:=;*U_WW4C!)K;B8(.DNZ
M>LF"8RM3PXH>A$G&J3N*)KH4)?#ENCS73G7R>, JA_N,2*EJ$_Q,\6AE -+P
M76N87XA+,%[2;>C- CJ9P(?\HF*YON$V1-P8;#=J*J&11SIPU0E1#S.U<RS?
M,!\ P=+%1-_$<X0E,P <*$CW1Z 'S67S<7ZGNWK:C]<-Q7UNG5M;#NI*TUU/
M)I:E['L17/GA H;L(O!Z3*#H.8648&,2DQ;7K]*-$/W'Y5"(])N:JY5S= B!
M5ATLLXOKK"96+1*Z6Q<30\30RHX0,<A-0QET@'L=5;_"RDQ;&Z*DF"EE:6U]
MU^C'I^0*7J:+C/^B1;)N9KU<Y&W;<KADWOX]9_OF;*<A%PDJO:S^]+:]@;K4
ML$EA<&ID96K(RWLGI9QCK]5Q5VOGBC[@.*^?O3E['B.LP49[0G6;L#$8R]H;
MI;1B?\[R3#7>_+5ADQ72X^@_?H7#RR-#DN;/5IF@A-9C,U!2"A<S.>][.UV<
M[<Z$[HIX)),)K*/I5VFN6YAD=2 9!//#$*L2,?S[^U!77XP]*V2.(DY]FC'E
M/?_,D>/7;KK%+5[@EYR^<:W*YK#21U^:?[W*?S3+=-?- C0/S85"GH&(P Z+
M?H]Y"$Y3$8UR_$5+9ION7; ;RMS!9V\G+!3=H54:M_!$<)5DE O>=5"\]I**
M>2TLQ]+?S&V-HNLB^S+9YTCPE&XX]]HCM5#2#EZ<'!>3^M1=136PEW3)0:)A
MK%ZV0>)EF?634;Y);^*X0M0YA8I?(:R6PUP<@IF4_2%]@G%49&LSCC+1"XDY
MA"G7JT)J$-%.ZYB0)YZ2Y\-DY4_O!.J77ST?-_=DV35WPD83+/S,QNNNL; G
M<T]AMG YROA/I#BL?26X=Q/Q"R,2_,AC2W0,']O+=+<2NOP]E+,<Y8L"L&V#
M5/M+#N>D&5D09</.+IU(J?].ZB&Q9IH+^!Z0ABEB/X#"AVK+!'V:VZ3Z:Y)4
M8\E&"8RCNH':(_2S(DC/S#[Z:J^4_;=%X;YQ5#9:ET_516K%-+&Z\-6B S,)
M74JC A$2+K!OX4OFA]=;SYYVM:OA^%!0F=L]9C*/WM>MJU0D>=R17)PV,:]X
M:OMHP[ZKCIAU7X6;9>T;XZQZ(O-:"',_/(%I:MJKGG85=/+RLXX-WD!^5W\6
M2$&XU:U4]-D+,T%*E&3FRR!P>D:OQHH[/"5D\)/IB5@19N1YBTO#]!__)3;T
MM&MB!B%#O^4W\1(?].&S)BK@F87Y(NG'Z"B8;;)8N&_>S;N)[0MD9C8[+-?%
M>>FR;N)?ZPHLS3X9F-XO4,>%14I2/$6D];>LFVQ'=+8L9R@RW]]T2J B.C;M
M;,:GF3L]+D[3>XWPF,MMZ5TFXW)%)>^_K_6KI*HXZC M2[Y%V_6YDN@8EA_H
M^@3!-GVH##7R,$!%D09!V"=V);EY>2%#)L+CG*]<YA],2,<)84U:Y%@3A %H
M4[@"999LY[)E$$4*J+2N4T)8^Z=*-2NESF;*(SM&.IMN)8QK1U>6QQU/Z8PN
M5^BU5J9R(V9^]$!,ZT9NYT#\\!_I9C1]RB$Y(%_9L)LC61T&=/;]OEO>-8$W
M^$B]^_W:D)*8D$%*=T^Z#":ATZ$D@VWC3OY19/&7R JNYOG$1]A96#["CG:1
M4H;-"B4JU\-XRL5FCM[L> 9.5T5A$\N\/%\58(V77+RY_&ITN)5<^>"T%"X*
M'[?C0'?"GU]M'B5:3C-/X6.+R;QRE\8FE?,'2%I-JIP!B*.%4+ZD/PI4KBZI
M50OA5[IR=TP4*<;Y8X$T9E'^A?M6;5&<B('E-3?A7!%#Z8S6B69-6B_=&G0*
M\T'DYF@A-9S8;1_P]/#*0X^<S/[>A*[E:F+K VX3XU%'+[_)+S5/3 T-^ UU
M#D13O=@&S^4UHYH/] ^Q5!OX2=P1QQCBJCR2K\%3;7%5:S^&P]<OS<@]L/S[
MY#<C3W>?"3V#Y+)\[.N[NBM/!Q-+4E^]?%B34>F2X5KLF*;'Y'EAA!0,IX8&
M;7:=?938OLSQK'M:0+Y52J[^,,E)PU ^7'XPHF?4P9LDJ@==\K9T=7S;'"L!
MLBV5O5&F=;/1/E&)Z17>6!B,NZX!?]SU>4YVYND&K[H6&+LAV,C(7-HW^8FV
MP>-$L)F>NHU^Q'E7/LOE1)<SLD(MJ7;,X/#J&TN/$X5^BB=D-0:C#D$I,$*Q
M[9K'Q#2B2YX4]',T#,43'\=-N_"T;+M'X>>+XJ7##][$G\ +(4^,=<#,+&ZW
MP?$&<NFW*"(YR:](?YZ8 !_;TI]PI>5TX:^%.7D]\=Q:67!='1PS6T1=T).Z
MIZ>30!<QKOEAI&GPE[%9C(O9K5)6W3^_.?4B0EPFR6I*O7H'F">7_@(M<7@E
M2GZ?REM67%,7)YP\%%U1W*,'CLP-L[P;=4];F.N/!Y&&#1/G63I!U[[(,C.Y
M-6SY.YZ*#=]$U%+-T;_#;H;-!A71[$!BLQYWW+Q?GR%"OB[WH6="#!SY8@V;
MPH$"+W;6%$\*IT"8YGAJF,X$4N>51">HR%JE*@,$&Q8R( 9J#@#UTZ '47Y#
M1X3*N62JJL$@**-(3?'A<4J*AF.U[PL(OP H$RSYUW"'R2RL(/7<K]6.;0Q1
M[]Q.H&#"].NJ2&N8JW:-=Y!<:P;*VRZ-EUNG/"S;A;SW6CK&I-T4/CRHKI_4
M_:>Y#CCA$0L,[#  5#<:%^6\LC3F(EU^;TAWZ2#D44OFRWFALLI!,TV9IRF%
MD>XKMF5"'^Y,ECK(L%\LX?(Z&7OGS]@[N:9,*U F&"X1:=5T_8 *\UY/"L5A
M-"M]UE+:S9;<TNYE E[K*S,Q&1:FEIMRQ\_7@G=WD^/;#:TA.D:6>M=<D\D=
MN2S^J2)PFL@ %*)O^MT<74/&M<+^WD#G3.(01\.3UB_L=?DX%EZK#G0BWC@F
M6IZ>M2=Q*W($@)KD$UX\9[UD#/H/A8C# +H[9']3=L62-51S!GF(1P&9A!=]
M%P/ ?##O!2X7S#9!XT%7:OG-STY2*[]4;K)M#.(B0N1TO57XMASO%RH6E$CQ
M#8S?B7Q9$P36%)]GM;-4FM#?KM-]@.2=WU),?BQM?@1G%4%BUFXB5^48 !!'
M+F;WCT[$!*O&%/;__*?&!T,@).0&(OUTH%A/5=)44'7&5N.^&>BYC.-(9]O[
M?+I =&JEZX-#W9=VI+*?_27T\C.GUUAUT/L?*6\8 /LT8@ #P#W!Q 8$Q6C6
MVB/_8VFFE07B&Q:Q%1Y\';'P<X@!^!+FP[KZ!LY-1V &K*F^OC+ +D+T84O9
MSNP+S6:2=5]VE+^'Z[56B\J^.D.+KIJ<=V%*SN:Z03R904'_>V'L?W+-__K3
M8?O_$9H4QS,YZ=Q0&DYUU6YKKA6KQ@#DYV!AG*YV#9ZXL"J[A944<6]?KQ\C
MTC6U&ZE:;T^<7TU5%MMD201#CDZ.TE9 J_.[YO2_+:I^4UFO1Q _;$#?[>C!
M0"W$VDGFOU7]\R+H7WZ9VTD6HW-!: /H )KG%B(2\>=!FLER<W@]*(0!@%4?
MNKG8$5-&$,>'; ]$3K]M/GV[+4\BO-!I1-T[+'IGE57S!$!\XT<LDNC,;:"X
M[QG2E_UY6#;[[MG_\I="%5:(>?W7;-_+!Q@ <5!JTW;ME]NS(D0@-<6=OD!H
M[:V3\TLW;_/8\M3F3"GN 6OI<%)R;KU8C55*R=.1M.+S@PKW<#0?/)*E& ,]
M/+X?T"&(OL7&AF!EOP7_(CN$8O:G6?Z74?!%2:^I%YI&*+6KHSK6$16F%=UZ
M=Z\[<.U)<.OK;M1?;+_U*FD6EJ.Y:LYJ?HM#$)^U5+&:WU@%X.,7;.D7$9)Q
M[S"B&E!?!H",I B0E.O43L/AE3.S.3O=7YJS-7Y6?".T)C3FN6=SNKSHZIAI
MA/O@(Z_DEA<71U9>DGXY-J9I9+._Z_V9N7A_Q'+X,(9/%3@?;C1/%Z7Y;55%
MVFABB(CUEVFY:K$&'=BB8PDSESI-(#I9X;Z.\NE6^I&/WCC\/=[+EC)^.N>-
MQN:L$9+\N\TC*Y/6!DIQZF4 TFT,F@[SJ):[G<JV(_#4-M&9LCEKN[/(WNW?
MI4&8C%DUUPS)L>P8MZ6<%,?LQ$<=OHH70X1ZZDA,_X* DD7$]/ 8BA&T#S]'
M26*&9P3<E)*93;=^.>\O( JMD H<.I?:(X ;3^%^K6]VX:FG:D8J4K)7.GGC
M1J3N^Y*YO&^E!DR<40Y:)M.^$B&\B/CP7L@R"A,L!^]A !R'E@KYZP-#%AOZ
M.O<*ETL+YNJ#PO_.O#P84FEE&ONZ88E;D?LUGQW=^+.)_$B[V=8-EG,.4-V(
MSZ!O=R$[V7?3R&?7M]NPR/[^!9[NK/YZ#5<//FGNQ[^G,]V"'?8+'B3O':8=
MUQ: *XYQ68<U?]0&BTC'*UBLC]Q>,2U*8YYI._6^L2]ZD^F_5VB5VX0($,?!
M0:=A1!-A&763Y\6(X^\15/E.D_N;V2-+(_/DSN?+78LE)2ZD\L3>Q[GB^<61
M61MW)?.9:"XWYM\F*L<,]<N$3V*/4ST9@&_VF'0QFSU'_/8T<!GW6=7.]T!C
M9G(,S'LW2\S&<ZYI\C/^2X6&4H;S4K&K$:KDA@ZWB$*MJ9;)[4CQS:M,,E9
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M@,[0#=FCCBT&@!E3G_S3<<,)N@DBOO#&'!ZJLCINM!>I%;3KZ^4X5LLY%,D
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M^&$BRL%3HL;CO%]Z1ERK7X.&5?CI[?RW?*4NKAO>3!IN5$2J8P!0?R"^Q3
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M%. "R_VTD2CA2VL_&!5GAM 7U/$?N).J*#HG#^VKFM@O:(<&D>(QD36/#F0
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M^Q[W/&J0)^Z;KXR.;KK(1_W[%?R9T\.=>!>L;EC0PM<70N__BC8^KZ9<U?%
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MU(R9M?1<NIN;7"BT,\X:=T(6?+_6W,CG)N3FS@\@.8*9K!\Y7Q] !ZE@,+N
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M<#>O%:Z+/ @Y^SZ/#A*[I/Q<R^+;8$*/.2.IY#UN485:#^U;:4;=Q=J%)I"
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MTN_=9=*SW-.7U$%Z27TZK'Q79R^#/8(+@V5XM+2-RBXBFXEF5!;_S7ZO;S3
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MN>5M2 <"=R4VOR@_K!=]J@\^_X>*YC:$6-0TBQ=[<WC,D]'(U(*YD\A*MNH
M&7ZU-*9&(4&>7^MPB2/#I$X##A%"RXU.$1]XBR=3,_%E_.9-%$;@CQLY R)B
MLP$=@[">!&XP65/TY]"?IZU0J-9K($Y0@(I6\]NG(C+G/:4N0-=G;^-QE_L@
MM@YZ?+QZ.DLW16(9[UU)\1,8N1,@^2,-H #*4,3L1S11)3TJ4S$7\0B#HOIP
MO'NX8P.W0>3LW?)6U?BX,*3!UR+H4QNMV,@\\XMFZT4E.9HW*T+^DQ# DN,2
M!4%5HRA3C3!]"/*[P\J.17PN&;6_N2&VC^'B#Q'WV@7_"3#>F#D9"/&\5I6I
M.93G_'IX>EIIN&.IQ)DRUO'#%KY>;J:?GL&.#BT-(]O5*(' JM3 1NA&4EW;
M=2)FF"7^=&(_)&*5G^O,:-"V=AQVY@1NU?F93K(JVAWL<XN[7FE=NZZQDY%X
M[PF!=<],^B^F:!M_7(IRKU>^DN7N7A9R.&D-TL_R"=&SPBRP'N]^U'VX79[4
MM.UMM-^G$>O9Q_I5?^WMQ%!<14[DU>PKJ+XSUX/A91^C&,<S]7M0C$#X2XKM
M?*MWD[SJ4N ;\/8,(D(FX5=@&WK[6P4G5/G?CO*+(2&#GF?YAV2W,^O?[&=>
MO*[Z,('ON3:^K&T';4 #$ 1)B$6@S4;\P0-RC7(G=I72HL1+J8AWJ'P.5L>,
MCML2]J=7JN!-V>UF=8]2>.:]C,Q=7:])5TWTW6]Z6I+X]&'1#:@_+@I*,G#J
MMCZE!]\*(HLNV'V[?'8A#&J#/E%5U*@^MK^B:*<W"C+C<]!-"QJSA:F=STB_
M\O5\'X"1N4;J*WB-Z@$=M"/[.="]-3"0J6,DWF8@IJ8:^@"QZ0/^F,8J\A1+
M UP <O'3 \L]^)V2*-]5[Z:0("?M;.X3-;628(>BTN\P6 E=]8Z L?$9T'Y5
M<@$81PZ=M+F(B-F$='EMJ$;-6L3S?"&-L8JJ[<S.[[@9&*Z4_"8T1J*D298I
MQHYM</ W[T\NKTLT7._6W=^ ^./><]93#;F>(M+(QI G5ET+0-^;DS;*R$RB
M_12Q0-$VIKPG;.K.M8]]!@[U,,MU*7A1PE1UML^3@9<['#+\!L2U]T6:/?3
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M1S*"\CO\%:6.E-W6QM]%.*AMG@#[%XTM^ONQ\65FW0-R" MN$8)F"PLJLKA
MB=]E0)S)9J[/RG_*TL-]AW(.T\_R34HO,G4SA.*P<YFBI%POC+D^PV'N^^=&
M'$RF0=*/_ 1?HWM\"]+]:*7XNV;61UAB(5^:H>!#93HREA,N(,DI- #PYO[\
M,I<W#2"ZB"$%HQ3U,/.@1N5TD">QMUNCSG<,*^20 _/<_< ]X;_2<*XNL7E
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M2)HE/3%*(J4@3L32YYG0SEKFY.'>I:+B4CK$UK2Y4[3)>LUT'Q&@ ?Y6DO>
M?*$!'@0*]"K6&%59^/CIGG7TE!]:C[^5\6VRSA'A;K!J/S1^V;10/6M .T?&
MSVG\/R6')ZBNRDQR7A8T@/2U?,HH9+GY>/- C[3<HB0Z@-]9X^KVPDVAT0BH
MISW^Z9G4KKWLFOH&#E8PVS;Y48EMC_JU^P];>62^BC0+H^@F4/J,:F2A[&"X
M%.I5[ZW<?[8"DB*F*M&</Q<JP/YE_N3LI69B^&1T8F*%T&F7>HUWK9&IR\.!
MNF=7'=R3SEVZA=?B#A"F8Q#QH(WA9?-<_8&;<I9'CG0G2YNQ0!0*='GH1$V3
M^A>&G00,?6XQ"U:16OQ895!UYZ^GJU_571.4_<$ # [E5.,)M,45L@<-()X=
MTU8_M30;.N] >; =!FL)"-C-*^EQ\'YJ&=#Y4V]-(D,AS/XM:M3^D=!RXN7H
MX%6-[QF<@GI69NIT16;R_PHS"Z7>&*-#,_Z K.<1U[PW_!W+_'7W7OCA8G#P
ML8 7EE(_-UC(9Z3#HX]2$J=[NV7MD5!!%_<GWG]O?'%G[,!JTP#9QNODSP<3
M<,0(.<03M!:+MMBLKK&"2BLS*YDL$TSOU_=WVSV2;"068=A$)W159F9=OSRO
M497E#(DGD#+-@_F<Y_(R6?QQ'[PVD/BL#3G]->6O\?U#:1.M30<U?G1NI=@M
MV]#G43EQ&,&-:+C:M'N[HW,:%ZWY\J&+T)4UV5;#@]]%^\(HWA2#5WIE*+W0
M2O\:Z*L]Q8&95IL?@1OXG>SV22 T"&NNV).YC9V7$56S."-C+_RTRX$O-]@Y
M3O/3D[B2UXFF^OX)#S/MC5+H*X0*)&?LB2=PW4(N/[-A;_/=K7P'D:&^/IP:
MI5J<A=6D(&_5,_OZ%; -IA)V@Y7Z+6/YV%=R2PN*RHJ*<S(U/Q:_%'J=UE-D
M.D#OB>.I(N5GJ!PYXE!N2#'>C-+4!@:_Z/> Q 5/SD-V4>Z6D0L>**N,3L?B
MI2[L)VN!)&&;<U_%,^^^2] ^W"[NUO/RQWV"$LBD(PQ"G'H#@FR3]^*,QUV#
M$9AKEIGZ6F$:8\ T]XUBN>0F2ZI3/5^['<\\JZ&>(X8[,X;GY>&M'6W',G-X
M $SC'/XV7:G(TP #=UK:'&B #NL_XLOG$"9RDU#^XSWMI4#/Z9E61%Q9N_$X
M3J>A$2Y9&C&H9[]<6/X+E/K]YAAO4@'$@\_0Z$;ILXIR7.N45^2,8LR\U<B8
ME4,+<EFXU0P_X.M!69, )Y*OM#9O%C_.LG Q'K.E(XC!QK&8QMLK!JTWM#%S
M< BS<T$^RP,-@9+"A)OHT))0S/D#9;(&#2 CGD,#",O'+%7Z4[9)[92^MZ%<
M/NU<W8V_MWWG0>'8$/,R;5/*QN/MXOAK-B89%:7%_>F)F9F9\*?VP=:)C,I2
M:OGD+WZPX?B-IY3W)XC2$Y[O]2,&E!EL6]T\8JIA=>/7D)C/H]+Z8=+\29L(
MK\S1L\B+A%D%ZXO/#S'>!JQ\[AO9;F[GK#7HO*"K#BB^9C, 6A,DC#CC1B)H
M )YPN8!A9;+_7OB[6;3@W-W9 O0\3 8T:91>EW2^0=#%1/9P5J0E+X;MO Z'
MK&Z]ORU%7O05N76Z632(!GB?G;L(W4\14?[%L3J1_?GSWJ!<I]."12!,[K8
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M"==*^=FPR0429BMQ0P.37SM?',MD%8D.(?'X]?5B:=A#!W,%*Y$W$J\>G'Z
MW$8PTN;GM;%Y8=*A@SWKF"$1QT.JM_(#)2;P/(E(.'B[&UY.4FY8:H<$\.Q<
M-?)DRZU@YWD*XN#<+<]YM/.(+IX&.%6*+0WLX=]+"GLOAU3ZX\K4R>^(7GTV
M:<I#7I4T0+*)&N4'1OE2<Y0S^)]RL@W!JZTY!/X^'NSPT=$J "?NONQ3=^FF
M1STLL2*RO%30_N1S./ZPZ]YX]SA=N#^""(BGV/!DK<L=L%)-D4+ /)LDBX&E
M;NP<(JU$2</Q_%6V\K%JN>Y'ZU6337/N8 T=61 3B(\KM<D^!6[=M)+,7:A.
M][/<'NHM84QV'SZ"K$Q!["G'GT8UAI0VR"H3F4X*D0$%GUG#F/!*H[.F(33
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M)>2Q51_>#D8<>1-M'WEI6P+M%5U0$ATMY'WF>\>DHV1PL3=5,DD^TR1H.:&
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M?O-5H74YR5DQZ6A$CCXD:K2 V&K_?<2P<--!AKN':JBN IA)(I.[XU/I6N\
M^37=/0NOWB(S!#O/ J59#)"N'TQG:/-9)87QSK0O^-RT_OC6W#P.$L-U4OC%
MO*NU8GQ^=J$%^?Y+8,<CF0&'M?7JQ#K(K')F6_5.4P57K;H@O71O; 6?:+/,
M;Q;5<T8@MJ<V5C'I6_JHP;1_]4]>$V/3.//6\A(3=@6V]X"EYE;/9<X!ZV&!
M/D9UP;><)X\*M[-[83\Y%TVV4Q8Z^D@HIA\+= RKNQ_]= N9A,^HT;Q(33'K
MF!K]9DNM4N'V3/CI*:TZD9'"B0@?O#,"3>(Y#_UY%6&=_L[M&G8&<=3_PFN
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MA8"CE:1]06[BFPZS8 !/Q\8@\;AN:\CBC<R7F,T&3LHJLB:ZYP1=4&R:6-&
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MP3\^E6.!"&OL>YJM]\U9H&>)W;\6R$3_";?F7'YC&]$G@KUQ[Z^,DS#CN"1
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M*2PX:LXQP?HQG>/V@8C-U]Z7LG0-K.1]WU'D'N9SG+C5[%;%^>"]L8;A[5Q
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MEQMP!);/'+XH(KWUU[?#,]*J:1V&VHGCP_W7<C)S+YF*C=:*M=PI]C0 LHK
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M5,3+Q8)JKW>75'@X6HF.6HHN1E@?%)3#79MK+PSVG7X/T2LY'0ED;LE6[J!
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MO?E4G&WU^'% HNG/H=);]ZIJC&M>1(H#SN&NF;PUL\<ZMZ0[55L=.C)EF3V
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MX7W(W01E@DK#6)^GR\61 -;0[(T498(&W&N8H#]C_[)V_6^_GU=.-7Y+&@;
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M-M?YBMSJQIYMGK9:O0Z6A5Y\VJ)2YRHNDCP<=*TH,:7F0]@-/6TQP *C9\F
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M9$!5W;O?3)/*<^L=TOS8-9B5R[*O!=7ZNOVO'>DI^(TT"]^;A@XW4$#T%]K
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M +%N3J)JQ!8P<OF'-%(QG@+Z]#=\/,$8YDL!S:$)'O/G.=BH\]&]BN4#15J
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M&MK%TKT</F>RAH1RRKR=N^!NZ^)R,N4>*N\FI<[]IBSL:2FDNA0BIJ49,]8
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MS%1?6"'Y](IUBDY-O7UNUPJHK&H*:$7:2F$A.WUE60,F00$EY0W7;IR^8D<
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M[&)5E[CD&S*GDUH2ZV'X\M=&L3>#+^%J>J2@UTOV>)\:!C7&HM=VFA%Q&%\
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MGK\@]7DOLRH^=&6=DHB3DG-R&U[RN*#"]S#(@\D4>J+Y_9N7><6 MIM4N8"
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MM$_GFQ_3CDMTB!?F&LF9> #QJY$]$[/Z53)H N6%Z;/:E):7=???A@-L,YQ
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MTP:GJ=9PY:/+X@%XY3O&V^6HZGRW@N'O1G952A=%X5$=/U=*OIH+51KO3_;
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M"BWOTVD2<#E*GIZ9>AZ=UBL4S2O&EYX54,:#UQUK%.IZF\67+&^52:O'$G[
M3[BZX(401J^)4UI:H;X0\[9T\CNBNA\E=[/B^Z96#6ND5>/QP:E8<+%!8F&O
MK6S'X\,#A9BR+FZ-"R[^3OD2&M;6)@\!(_W3@^"'K)V#")!Z1/(YR#9HB;R\
M[QGDCEY=)E@Z'772O3ST'>DW'&J4F(6J?*QPF[>44Y9FX-L96'[81S^VH7%;
M,MZ<(R?>'<H-0(_]63#E6W.A\SE(>9Y(=6CD&!HG>LLY4)CR2.WO9HQAC0ZX
MG^L;QY<'>UNL[/],?;HWO#B@.E\,2U;.JU/5_(?M63EWUT[+\(O?"ZN,!&A9
MDR>5F6$R#;\[?.B/7JN?SASX1E6&O90TWQ!\-=82$3DO+?_T.'< 4[S:96S8
MU^ \X+7,W9?GE'"7,Z_,%? CJ\ES$ ^R:Q[5F_ K_,>70O\7BJYK0__>2V:O
M"1!>23$1M79D^#C_UF6F<<+L5^^SE\*2J=HS 1^U<K*2_["/9.6\:LA$3SMP
MCPWET*.,R283%D[7R1%!Q:2-F=1O$S/Y,\UW\JER;IO?3.ZPJ%Q^TFK0F#_'
MZE?8/Y38;[OY (EY5SP?28>4*4@DT=,ZV[*(?T#T;F&I,N>@]@E$2#T":H]8
M[*+J'FF^\48<0[G24203\;<(?VR86A.5Z/DS."8(W/GU-.\KE?^:<TJ'\HP1
MO.E80]%S17C><I+*U#<![Y4*]CTV<,=^;G%N)&3L@J>:K6K\W3/%GNCWXM@[
M0Y,*2SH6I1XE%S)F66A'#,JWB!KX/R@H1?)( 7&* #-B=OOT:H;9C<#$P,HF
M5#55\^G(^.Z78TU;E_U DP>+MZ^)Z"I<R>XVUM"/\!<JX?ZXZ>#/JQWPU$+H
M*2!1>;&#&>0WGN@UV_V+#&,JZE.SKB6GHT6G6,^@^-^9RRTV11G7;VS,&I,M
M%.6]^O2@5@\,C T=7&R=0WI;;+SBT]DR.;EW6GXZ$W+)+X/>4U\@_CC!%E.?
M!WV:F@U<]]0_:F'LSBHF"P)IZY*1>CVFXNC[V/@7=MO*NL.K5I\[U)!%>[#@
ML1Z10_CJ?I?^SU&C=N"?J>_/DBTH>]N[7S+O$-'DBJ#\#=4='(3Q:"W0@V*Y
M"8Z9ND:1G<M%#W:.L31C%52UV10CWIC3![W246%^V"(B\WGTK1 ]\U-:BYI*
MVIOM(F&R,4($E8[H"\>VPMS3T9^MF+Y1_SR&A.Q@$Y3$[18KTYZ>7JB7W49&
MQA37R(Q_FNJE?\+-'I$3+<JK83=^*''6YA9D[6*!\MGYHGKSOS"-!#@EH_G9
M">Y,)0G0 &"RU#3' )"K<,IA+HA%LY;%LS4JZ^6MTP&LVI','H+M_4[\>](7
MP0(X,]%9#P#K.ZUHZJ-3:BE9C/*8"C\KQ[%#*U2M*1+X?G0W,IH,'BG RH7/
M-N/\J#LXLVLDKOYES)F#Q3^V<FQJEE #+9!%/J%]5;J6@&TZUB0N.FJ?@^2_
MT+WIP*H&4_I([=@FM*=;&::OXR"VBR'"*#9*Q5S%76I9+L3SE0.#:(B<!%13
M\S3UY*Y=ES!L[%'Z-V=#ZA;.#!VTV"SWVAOQVGTGN63F0*4]:W/[B*E4^+A%
MS_XV&^K5^-)F\=XXJ\6WX-M/6E'@RX^>YA4%!%A$3/#:,NL?T>$"2Z:HSQ?Z
MKH9PGX,$SM"4^F8_WIKZ>5NI<:59^^,GIG^,LS2()'E02@?'5I?R%>A#% L*
M62^I.AG\<,P-U;K_3K>*S@&8#VR9D>!(QJ:<@SZL[B!6+[8H:2Y/6*Y$V@E(
M9( KD8$^,+>5MI^^:^#*C6)7R21V596VB\-+Q25.@MFQ3,H&;W__TKJ5CJ=K
M.GY22,Y "%'WR(@]V\58LX,GE"V&".*=7PNVAVA/[R/J@DR:=G"95* 2^+(<
M/X,5[/)%T50WG[_AS04W?W:(U!E[/W((Y7Y(.]OKHHR>@Y)EUZDOS\SWE[W=
MD MYI ZBWY+?R^53U/)N"#Z *R7WNZ/W\)<UOJ<E.85EI;.-6D[%*\).:>O9
M7Y-+L@JR%"/98GUV_H%_P/9)K=.=*HTM]!>2<X/"-L0VR,*5)Y+H;$7V$E5Y
MVVIO=B;G9Z8PF%9\7X=E>G9.#\Q!LG;\EH9(:"@3VP3L,0'6SG#-",!\(+_S
M>:[BYU 7 BQ7[""\?J86N_#/**%6JUWQQ+/\I$V7N0K-"_3-B<.\JHIA:+FP
M?U<<G]Z.U\J7,B@F&O=FKVC0*E<6+*QT4)I/F\G./KM]^G';HD/CT_.9"W )
M/_A;BO7W0XRZA,DLPG%](OZ:[HTG4?RA[:,VFX(O.]NE#&WSRW,L(C8S^40&
M>.:W<'>A:QF49E]^H@KI8W.KU,[ L.6D99;R#J1:T16SSSP\;NHNNOK!&7XS
MO2!B1I!-ZMXA,RR"?FS\UC,36 <4IB>5MP]$K!F.@5)T#DKC]Z34DE $?G)5
M4.<&Y^$, N2EH%S8N=/X6YGS4?CI4&9Z<GP4N/7X[(EV..N?2DA(';)\0^!%
M<>BU[@>GBMV+R55"@!Z4P[(C4E*\#W:)"51;2+_2&X\0=,6&9TJF^60&N!S3
M>:U>5.QW=NF,I:.KC9>DHT#)P\2&=!?_S<J$.BG#E5*.I;?I9HN^WK& ;__:
M@I*@<O8[D%5WXB0900G'4^MG9]M7AH;*>XC<A<W<1;/\F=G?>:W$AI\S*S0]
M'P1[C.D8V_\+:_M<D#\6I6<8HV=-V#0^MMX@5IZ#$K%$?W+P_$(?MCG$*VB:
M%)':26$BFV-.)SA+?N-24-D%_2-X7,>''JW$HB$[1^WB8SY7]H]7#A;L]6*^
M9OD_9E0$TZH$_$N5_0_?W%A8YZ=T(E)]U^;.X%8C"^**-6A9B*5[-(N'A=6P
MNFDM9G#B^XK=H(&QC>!KZ3'BN V_BT-^CXG2CWWIJN_;&^"F8ZT%@#]0,-3'
ME!% 1EUNU:0HX%O+-N%)B(O-Z=C*DXGZ9F=)E@PX=\P</QWGK^SNKIC\;F/A
M6C,VAR@][F_9=H7(0D[BM2G ZA[D;$JUZC-*Y#G(+F%5$Q:4/<UA0!FDLK[<
M%,S9&=K9+J^2<V.=X7WOB_]6,:=54%8PZR^H&Z%UFB1C[%VCWY1?F@BC,8@A
MTIT)1#_C"[SH60K5!L%]\N;;J7CPCI#(T47G@R<3*1<QLGK*\DTNBOVRW+P6
M^VMRESA@=@S&_-V&;<_BO^7_C82%,?KL1($)O%1KJU%*9>O%%U01O[7US3/<
ME/S@Z%S&4E#7,Y/5TKW.! D5Y<2J_">N5^NW8AZ[WB04YUW)B[D%X0%2K!>M
M]?E7]*H!I3H$X$1BG%0R#./2JN:M3R0QS9V=-E%UMUL2PK[;<V]?GINM5A22
M+>B?-.&V%9"X&^W!%_FP-HDEP72LZ_A2U;Y_L0M@'K' 9K(\0A(<F[&UBNFG
MFL'E VQS6GF#MK?[L2Y'K1T[''7PA+D6Q)>Y1%&=1DF<_^>N+AZ9)%8)%N6;
M'5:BMPQ&NAA##8R>)D!W6L9G$>)#'\[L*<VM7 =#/\0*2KI7,?5&+PI#T6\<
MWI;WKQ)@=0IN\R^+U;L?!"$MFOSC+SD@DV]')K.KT[\ %)V^JA8"\)\=<<!_
M&K&IOM. _ZB/+/QU4E-Y!+'#1^,]+$2'K4R;?0<WOB_GM0T;+0I5R4COP1Q^
MN227]!@T/8ZO->C?C !HFC9TS9."J:_O=Y_>1ZR@.RMV\TGC1-?%D/V>'>MP
M_+=!P3>IYOOD$R<G/\ZY.;,P;Y:W<W4\U^\F^?3IES^+R[8H5@,H\6,2ZSBX
M_QSDY'C*&'P.DD D8L&G+KE^^#(Q;H>#V$Y\MM&G627#&L[Q>#LOXXQ8D9\>
M]/V-B*:G:\CJM)N7E W5%B]ETR ;(-00(/(INF0B92[$Z$AV?9,R"0\ZQJM$
MM2HB&*M+O<85OKCS3;WWUX1SKA96?+=U<MKD<V_7.]K2,/VL>142_[2VDP<8
M$3TI@9+A)_;SQSE(<;"6;/-E*W-V=&& ?]6!C&\I5A]/HR^;UC69POF09THT
M^F2-+D6]!S=*+//^V2T(YM)CT56,+X!IB.^T3(I_0%W"?EGHC.D#V%#>\3F(
MR$@Z;FG]BV*?'LM:;P2N="E1X@_ ![ I9\F&.WJDEVSD="P)5!G?^EDNIAU:
M4M"JF1]1<I$$WP'<\3GB(6(U@^!7I6KC R7R4Y^W[(_CF(AR%4TAV*]^870M
MKV%DE=A63)*&+OF:B*][E;/1YTX]M<]%CJ?I+EIK228IX^"I'[0=+W0"^36E
M> >Z&D7(6$SICTWWX=A?  N^/BW(*<6$_9&>X+&]07PC:BU\M?ZU\5*4H!'F
M5=VKSAX.=\NA[)4P%-[9\)H3,"!6;.)N%S@=Q=3*NRT>>PZ2;K;-;8;(C ::
M7AWC4&VYCNP>L7T]*^6RM/C]Q2B_97)^3D7O>DF1,U= 3^M\UI7>/ E-[KSQ
M)( 9/:&^ 5]KAI(C$**HN'/0C28CR.0IO";P_2GJ;&;P*,GD2=0ENF-$"-Y]
MU/)XW.R+B2?7G13PARSY(&,CEZ*W<937-7T G,$@U8B$+J(BV2:5A*K&9ICV
MBD>2=R,0-^IEK[_%BT<C_JHRGQ:4J]!Q'5;3?)<2L":GSW]3.7'O22R+AO0S
MO3\/"/J?/NL9K(?C DO!5/N%/K\Z5<.C\$YPRL)?I_\?>^\9U>36M8UF;WM!
MM@(B(J)2E")(EQJ1)DV$$! 04&G2I22T0/9& >G2!80HG=![)R+2N_02(KT'
MD@!))"3?G><[/][QC&>,<\;XOC/..\XY/[E9N;.RUEQS7M><<\TY>IE0MW;F
MQ\5:0_^^(+<YE]3HFHS9Z745G'PU^:G"E;LI7!]CC41'SL1GW$43- 63Y9GE
M?SL0%[; JV?*X<GT/@;H 2;N6'X^,*65S'$UX(_JWWS.NO_,<@MFWK"4X;'G
MOAQ?XDOB#HY!5YY&LRT+O2S0MC+ZHB7<#J :X_ )U%ZF6]\<LG=VK8S( %%9
M9X_=Z^K">E HBX15+0.XEF&M@:+:>YU&RZSZ>U[>#9]5L 7)!7U_%[V[K:];
M>#4M]WI:R\I8(;YE=.T5 R2$7"41CUHP*4@X;9E:16"3B*;<)5:YDHN5H2--
MXF U_=3<V:;(<_$)0H:9W8-)$+S>A-SYRQNMO>G<JDK$#S>]5?[5&96:34.1
MPWIVUSCV+E##%^7$7Z@"H.E&!3MN8[9,SL[*E))I*EXM.$<-:NC[17CV&KU7
M4T-!X%?B,O,J*T.=[CW3?N*0<!C;2'[^^P+U$9SW&5+9.@D\P,:'.3RM^U4Q
MH2"G Y9B,MR7I!AYN;GJVG%T]%R#3J^C!V$A*Z<XTFE<<@PRW@-Y)O(R](T-
M>Z8VH&<U3 "L+KXJ0!A:Y>Q_^HO^@E=<1=X;HT6CXVQJ X!?"._J=M,[',".
MJC[LP2LG75)I?,?UJ;C7=&)LO-G,;&,C:5D]63@YMA\ -U=:IAF@<[-4+2U:
MN#T=:L'=^/N"A\\5VM?89L<C-KAN?7F38T5>,5179S7V3&:O@.<%]!]/"."Q
M/MYAP(14Q)+.4#0FP/VFB[P>"+4==',RKPL\[WK&&Q_-JYUU%SYUFHRNO&V(
M@-IK)*U+>K_MX;_8QZ/WI[F9080#\U;_*4H* 4E=V+8:W>AWZ#5892/$(FBN
MZ[]QU=W#L'S+,3'2SL47OG)=$+5FYTIW XW:S8TMAZ-_9'DVKYL)O4K[FB?5
M<]%J"VO%;(52,[&%6R[#5 5FTXXX,7*';6%YR'3OH]<)14[^G45\%O6'*RI7
M(_W:[]O#8T6"NY9NE>25#(T8&W5H0S]&N)_L$RTWEP38PE^EQW1UW"#WBGB;
M2B/=LJ6)M+4P(;54UF56VSJ^,6.94$Z^LNHCAINY%A<Q2]H5S=5_2>>TC,B_
MPY_5V6[*\BB8:],YT_(1T]6$'*RB@G=95\,P]!/X@=0&_Z53X92=^3O(C]S(
M2F%BN1'>K:IWY;#5VN/EQCJAOCA7UN&6DVRNR,\16Y6)"&VN-)WN\T7,U#7>
M;O#*'U.!&-I^ZUVDM)X* S1U#?]A8[! 3\OYP.WI"S3^8BV^W:9N4-%EI6)_
M>&FYW1ABU-58"-.%FK)H"(\\_:CUH.@8H'EEN/_3$,<S5IJP(GW.D)0.'*$4
M.EVLE>F/;$+NA>(H-$PJF,ZM#&& &BQ#F'EU7SG_/<..RHY\B#D*9VMF@ @>
MOP%C\/;0A]GILI'^G_+QJ%,,T/<%S"J,F5U/TV@B,4#P62]FGL9KX!]!#- .
M8#+[UAB@OXR11S4]S-J=BX'_9>;J)Z@5R-EB3*H#_=X93^1NXQRSB0@5#WQ8
M OCPMB6@L2/TFQ@@<O$4,WKW^^-_[!NU;$A;9(#P_$^![^_HVL(=MT\SQ_S>
M^O?1)8\P"TZXPRVQ=\! !F@&=X1O,@7FH8VBJ#- QTVQRY-TL4$#!LA7/Y(Y
MO/OX?RWX9)Q$^X%)7NMQPU&1A'QJ).T</@:UP0"EH&[^)HO_3'UABGSE3)Q5
M\W'9;AZ'7HCJ[0OED]"<:OR<^=A7Z7RGMI.I7G6>%'_F%O8T\@0X<;)G/H7:
M1JI;-1A QEFJ$DVE2-GY#UH<6P@9L%KGVFKVOIBN)0_7V%AN9:O'O O2GR($
M.D>[G:S06=?NH-%_9F79&3#C)-[ \@8P0&E:1_P9V;2"P[M#NS'LF+ZJHQDY
M]V<0_#$J&;U]/LU/KGP>B1WH,M,1(GSJAUVU-!4B^QX6I37=*CN7]R4K*4YY
MLK':/1/9^VZ9%>8JOC(]!QB@OM)&Y[4PXMSW]O"M^UM3B1SC1XH>P^.NO3<$
M?WU;M<D+SFM,X$E$^)]"QT2@?0OO%H?<TD9?\4?"\ F8/\!)R %Z,OV-<@^M
MO]615K21>32/'25H&L0>'!D4'G:JN1DMW'7!#_09C=KP%69^=?B^Y'C8/]PE
MO2WB9/75/A5:PW0WG\&Q@^--O6%DXG>Z _B/ $RU/_J=)VV5Z0GI*??!/>_Y
M-+"T5X^=#ILQKN=+R>]9/!S02SVOE(SU$Q%RI'V\=EV"PS8*7P$P64^5LS1Y
MZO@HJ@_I29.E.L[Q\@:P!;C._Y.RI/5X;'_EM/F[4Q$SE)(BL?%9!\6/W38+
MO;:559!<I8;S'];C'R:=--XG]=RH@0+[=SFF@:XZNW6?EJ0BB!17F<>[%DY:
MWV_E.2RUP?PV6';0;M62^# [.[R+Q34^@(YM)'?MS- RSG;@U8-KSQ46[D/+
MTD[P&8WV_\_[<SR8I+*A2X/4GA&D K"1:[U6"?B=T3T&R,VA=K>C]2L%^W=9
MNVNO FW;5=6BB92P_#6[($4&@.LGJT;4+OQL-V.1"_[2IAX);B1K\E+]F4B;
MDDI:H];3\K==A\:II:W4W9D 3H0WG=?.9 7M]7!&O^(T,:95N<_ \GWG\,B8
MWFQH^LY$1-FMF"M(_CC'*&T \3MX&]#N1M;?P\0GBU#=R0[>!VXC5.Y)Y-U5
M*O1GR^Q84<*<K^BEY>SB*PN;5C=6>5TG!ZV"LVIC<NXK^"87]7"/G7K#+#5@
M7DR'6@^8+OL, #)%XET#]^$^')4:O%,DB]0+*41^/80C6=4$5 PE#&T]V:G%
M27KC9A<'73V\!R#L8]7&TO8Q_-F/A>\RW[1%<V7RJU',H $U"D V.P,-OUN;
M<ENM8 Y6+D&UL]>$YZJ;LD++'%TS2D*Z>SYG%7PW6G0L7$-_?SHVH!M?[!.^
MZ&@3,OT3#,/_ Z88^QS79Z_)T2'BQS3+0&8I^&@ +U.-F84#DP9H-9XHI58'
M[S 7VFV*F^S=GM;,+7S==(VO_D:SW"5%4*5KO=P/HKZ@9"A+>67;7YG!>86>
M8S\GV\VT3A+;+3@;R2:ZD[B^OD8XBC2P"UYUC@/XCIP:W+U-P2#J(4^NAD6R
M*_92$.JMRW;1^,0S[?>Q+#=OC.YL)IG9].I"EGW_R#W_4PD0?G[D)W%B+Y5S
M&GS?OXX*P%2Q><H6_A]JPT2&ON5(0 (W]F%O?^D/7+JFWZ;(QH/9"%'/(>MH
M?[UHW2<BCHZ;@G;FR$?^"O;6,/QG9 J2^'.W+,P/G&9]7[&N45:KEW=5CJ2B
M@YC8FZ^"0'=*XA[#Z;)9"8X[_B?S<[IM'1^PN^VU0YY7&QD'?F8OY&%K$:=J
M 8"W +>703\HH)NE#K86X%6RPZCE=@"67E5F[=ETBAK=,7<;?$%2NBUR]YO*
MZQ>2.SW\KFRO<J+L[9SRLI,N,T..@"T!K$%*76]L"J\8 Q2/Z>V/<?Y2F^'S
M;6"HT6>RU[7$('5.YIQI'/8:-N[&V.QYKYH[\A$*+J'S)1?$H&\]I5EU5F_S
M]=U0 92#Y1:MHM4?QCI@=4!%T0KIAMY(?2CB>_:W=F)"3JO>2T^SDAI(:GM2
M=FR *U7B@@!4!8[BY-^N]A0U'D^"&)"AM^]&%P*:KWRG8]A:3A+U)^'X\@=J
MD]I[:HE6I4?]--U1M4)"GYV*/C_CWU/)4CE?4;Z9>O:EM%?AY 4M_JKCO/P]
M@/H7=2UBB)W4R0;P)W<KI 1RU8MX=PGC<JC5=:EDCD>.4/::]F8V]8:F6'**
M(GD?9I$N TV).5^16OIC17@Q+52@(#??*;CZ0"\N0;R1;.H\'\![?[I%8,[2
M]9^"+B,'Q3-%<I>ZOH^OS#_9N%/4]]II72@''7_-25#'.^VK7O0-HX>/.FS@
ME<R6#.,,4*@Q%3!XCZ:1[8 J0;:"&: J&09(>8A@V74,<,O4 WHB9G'M>)R^
MA^S"T(&A5ZTI]4&3M-, B&5"BPY+K@HBUNZGI>+$]&84S,JKK+'*W04Q;G5[
M.3[>O/FI8'QPGHZ98&BF0[Y?X53G3PWN1&%S:><"  OD8P"00IRELI%T?6C7
MJ;Q[:[6_JPJ#H+1+>"=Z^Y;Y_$Y.MXDK(D;N[><; <%A?#=E4VX_*QUYZ9AV
M7SJ&&!*?J? YH%_D%=EJ0X[41W6CU5(C/].?'@W=G@GD3</A3M)?N6#B&:"[
M=8)FDD=!"6\UWG?_JN2JGGZ>=O&I-_^HB@+L2TXW%'*G\Z7.YW?RR>[  3J+
M?<>,,<&12O-1=/OZG:'QO7TY,P1;$:4]<P9:TV"''778E#M-Z,VUY#GIJ_W@
MYZL.E84\DV2]'*B*^N?S1D7</0 N5@:6]2O='L=V9+H<Q$VUH"VN#\90<HFX
M6LF,GB997G]7X9:.C"WE]LR<1 ?)8]B"5J>M56V-4+.QO&9^=E[HM2=7>DZB
M_( W?:6[ P@J<MF4=(XRLC=4T$BN],^TZJ0<D>3*5+0.0P^WVQ)FQ[B:@\:^
MX1'V3GJ6E]@X&\S31>)+!IC%&M=S8L#",IZ^2U< 2NW) 'UB@-J4_Z%UM=Z!
MNW=8,D 9O=O+V"VMS&D+!NA/&5-7;$\8.O;VNP&(8'T4QM'L2GC6%4V'/+^%
M*YVV1''FM?A?#% 7;NU^^9&SZXJ*-V*-LC ;R#<Q*]ST^O6AEH&+>9K>_%&R
MTPOS9_B6I=3N-/ OO]_GT[2G1A>-LB)@:9"[4NB?P(GV8(*R\4N1U-L,D&1,
M_ ;K)Q2(SH>8I+1/8OI&EP_L?_>[TDQ?N2B50I"N$<H$;9F;!K;/=+4LM=_I
ML5BR1<A[1J^5Y,=H.[TIN)VNPPO#O\?.TN);-7N&,=UA>;)U#ON91ME44UKA
M3,8(-OT=&)+1)8@\]\_<<UJ-7H!Y&NI,HB-@IXT4.DXA$A_XZ129"%_9 BQ8
M^[\437# "6HL0GT;%P$ 3\6DZ9ZFB5CERCKZ2:?2V:8$5NA-M3-I>?H>7$$_
M*P78U/FCAO1(WP6B>I8!I1DQ]+\EEKNYQ 21I3[MK,Q Y5(^@&1<D.?)M>1U
M6KXC#;\]>#@?J(&:F1;=/T+RZ$X?!T3,^)XE\T"M9KYVCXP9+K^Q3;A5;2Q_
M,N)3]JCRBYSOK5O85P 0Y\-2IU"]SK]0[2T]V'2? KH]XE3?KR:+;!7U@RBH
M6;\@)V*'%F)I)Z#G/>UT0]G$X++"P,V:S.0S.A^^HMKOO6N7:R3K,$"1F-ZE
MU<X#ZCC &T6H18B4C5;"CD&THHA,.?W^ 6_715D#UJK#_=3Z38]IGM$75/4<
M=.G B@0DX;X4I)E]7"R:0[U(];$-<&J'LL#)!@/@*/! V0JJ;SZ->FKD 4*>
MVM<HNVN#"-Z*[GO?:^R^W./JKT"1F$*P:&N_K=[GD/$K?C\NSUG %MA<I'U5
MWO[YU@*P8L?<)@DY?T_L)W."Z&)B8N"IV ,F=B]*Z0.O:-#6@AQA]$,*E'B"
M&HVPP5F?5E0+A.!;"*VCI4X5@>A/S?8;7^8^!5:H:6CS-WD4K.=^>:>!:&!M
M93&X 3M=>4X0&#L23\72T*W/W, )UN=4G)#W@S8V5%*I?Q#8\H1;)4Q>TS5>
M2YJ)"BY/P;0/QZK'#WR?Y)3$N]R0:;@>X0]Y6C%F8JQQ![JTKPBHAY]E5(!M
MB*#B47\V;5%#:<%45:+%:UK*MGB&19>].R)Y9?K3N<,ER(1K>_-\$UZB1'0_
M<6_@>"U4^'GALEV,,*08&P80FA0&J,> ZN=C0/RU(9YX[#K/C2HBFW@UJ\#=
M8Q-FGY:AG3W'QQ(I+'WA,]7L[*E<DA2]&R/V=]+/R&?>>YV9:K@@,:[3O\7+
MO)&G@P2@!S+EC#8B?\MM#X >C549"Z0J!")S!A8(L4@NS<G_YO;BZ?@70%_V
MI'Q_N1HIP3XEWT]08]_OC3T7@S9Q> X<Z%L83N0"V*(WC,IUR$M,I]I-6WH8
M3''7550I)]4<6>3R]ZYY/%<JLBVH;/*Y56%/2#>I;=I!OZ'!]C,5/)1%JU0Y
MS*6#F4X[!<P9E7O(AR4H7)-:.3T0^4"L8'L^>X->5;:YDSV&O'DX5[^,JQP7
ME%9M5KR2+:YZTKLI.*.0Y_VU3[U\&T[^,[["E=),E]UI\!5D@MO*S#74FMD$
M2E0JPZO)/X":0RO&*=?5W/.ONIV4+A0QRUV*480^:;#O?5GQUH8LJ&3[)?44
MW[)05F&8D7%O02XPGY6]A%]UI'3*2$,0>#^3 :*_8H!NDNN^\T95&2[);MH<
MLD"U;'<MR]2T$CJ'MW=&H9;2SYLUK@H'FW/D]CR#&D]V[U?(/$)>. 8HH5KL
M_Y9,G-V5#::=6G080JTN$5$5=6#3U<:C-8SCMB5AE!*89)%<V+_D*/N#NU>!
M0KZO#&?C5M,RE'*[[EYG+MP<_%";%J^1)\%,Z\,0O>C/<3*8Y-,+.ZVA@[2P
M]0$RK=61C%_"87AE;V*_VZ8$=1BB4J[OM==7CE=H:>FK1<1D?D7\I1M?4%S@
MNYG6FH8Z[F+6?C_XOZN-\_];'@1?FE^_E+A+\3],:?+'V!WF<AK#[<YX'LR#
M$</M<7D=;I^A]P-O2BGJZS\K.T.XB.#2B=/GRZ98&4B_LG^R#%#W$ 8(D.I3
MREXC&> QL];^.:S#)+>N'=YM;;[R$&#&>CS\'K9R5YV@A,^AK^M#T:5I]S!.
M?XA40AZ?E-YB?W07F$.(^W^C=-S_[STP/L$ G8]A@.K8$:L,4*\= X2)+/N7
ML<?1;M?1P>*K , .'3)F@/"FKYBRLZ[Q[U+4JL$[*$Y?5-\%TUX$M3! <\K_
MNE5;BOE/(M<*!^_5NU,SD'V[#-!E-QH#A*V=8Z+V*<P>"G/D!292&: ?'+ST
M'4^FYZT>]5\F/@*BNU@?;HFOFC% $7_,H8[P=;S,5P9@]J*01P&<-@S08H(;
M W2\)<O*?)ZC\A]=A/^7'8K/Q"GF=<>-?5^ D<C#.OI1Z3@PBY\.],L )W%;
MH@*L)+(J@0&:9WO-].MY@O\?V4IO#A\'S8,S/9=JAKQQB(.)\9U,-%;F4^_.
MP.3L?))(A3QGNUV!UZ?QTNSDO7$U_:3.46/?7!;VZ"O%!81D3;+5NEY65G;G
MR$^;BK'$L6N_S[]9+WCS)OO)U]!K'[78'W1<,XZY-_(877 >#0(Q"]X5_L=%
M_?\?_/=_L-FB@F2 I' 1J#[%RZ-'[U9,;! OWUK.MJQ.<:L)5.[)-!"3AC5.
M$M,:]=XF-ZN7#U[SO560M%^IQ=9MR(L-^$+^Y4/ZFY).:PL0J?+7*B9D3(Y9
M[HX__*=)[HP6+7F&!. ,PSJKDGN_YNJW70YDD#ZA:=H;G^KBA!TG*F-WA0K3
MLF2868$L $P\KTVW4D[%IKLOD<U<&: DGO"IZ9CC7,I&_9>9@#]+7> S [:5
MSN]_F+B)%H^7VVQXR",6G,Z;.:Z@/P_<B-?5Y[ASS,Q7B](:8(#6K/>Z?J6X
MM0]S+T8V'^4W%\)SE,.:&_.7!$?0\URN9;5VR2<#NQJ2A2,4]$S$TLZ'H!.5
M=HR%='02A];RV  6VI)"Q2!8P5RM8 2F$UZK^Y861!69K2\-W\*2Z\H;=')R
ML6;A3H4;$A8QJ4(=3V=]-]_DA6:]"%8]I82.%"U:_;L/4$WO\+OIRG\0R)A6
M,83-=F!;>A[>^E-#U"%WMFPG)Y>95<U0K>.Z, EB"H5TCDVAG11>1'F&"V?*
M)!F]8HU;9#;J_HMUA237YAI"NDO]L=PHU1+TR&T>^X,<Q%O9ZNH:M-UCYS#+
M+777,G8H\.,,)L" A76O,ZMM@KYL-*ZM'9O3M:14/CP\_+,=4*7(#ZBAIE]#
M T'$F4#>45_61..=&2Z]3)'L /< 6.VO+I?H0XK.=32M;V=NL\MH1"-"YWP]
M.OV^023!0%]4_<4/6X )M2]%L[9+T=8 AGX?^8*,[.&9),F^RZD5Y%WFU,%O
MQY@U;KF\RN]PI<5<RG=[UJ=_6A(1JAF1%_KZNU/G%[]*1_U#Y _G;!0@-K.U
MF 4M9)]U?M,['UB,L_C\4;8]+.]W0M&1U_*DM0LBSZ:H-GDY)B\MA2+H#(.T
M9IN/&F^<#HVO!;W^*-T[+Y. #<@.(;E3RQ R=.NCNU\4Q9<O$>=*)JT%J@@O
M&^O\87DWB[P-Q\]M"'G^-<G^([##=HQM>()_KX6?PT#!XZ*GHF8LH+1/_!HB
M)5,B2;BF +XE'ZM7 4L%BELE;XUV%5KSJ/>KT;)P=Z$Z(_3YY^2K=V*R\@I7
M.\?.-YK]5(BM+37W+[!+B[B]S&P8]^>A->U>/M7_ .7C_A2%XB&^"]R9K]R&
M;PP.4R^/';MGS+7XU-5Y3AK:G)XI&7C]@WJ]N+GA_/I&5B1O3(E9_LU[&?/F
ML'1L0-&,UI4[3[X&-X8]V^R=N+.X^4T2M7GV9.!9IM$L(*^4T>Z)_#)HQ\0%
M]A#N!BZV/CED[<:G=+[V] LJW-"/M*@OJLR6^J?#3>?-WK@01#<Z+NO'JF-.
MQI;PFR_1D5TKHK4J_W++"V RY-J1D0&<2R8K\V,\6TU'9U;*+$;@.&V$VV8+
MRN+S-IIVREY!M,ATPO7Y:N@+H^$1I5CCI(3'A!H96YU*76T% $=KSBZQ#L9&
MHAZH2!DB6M8'Q]H=&J_J6>D*I<W+QPF*4^ZU:Q)77PZ.3A9?673HT.#6-JH*
M@4;J;0Z=C.NE;V$A,1 ZARZMN#P C@E<?4EU"-^<&>@2G-NZ--=S$.2/<G6O
MS6NT=8+'/'T=:7A5F'EE-?+6I\WNU5"HN>DSGI;)QBK>3&0_[@O3X_H;W %/
M[J1RS;3\,[//A8@U.[#NW(E,G>?J'_.]K3FMJK>_H?L^+SG1=#19IS]$RO&C
MMOLU!^!P\:L\1,KA0AF@>_2[M 3JNTFNI[V=VZP?GF?TQ5.Y*GTFYHI_N.U4
MB(VVZ==7L7/X:D^_'Q^Q*5PFE"BKCRBK>T+\U$=TPO$MPYQ[9.H1[285BU.V
M',9PP\MZ[^-,9Z:B!MRD:B0M3MR.FGX^LWU3I4C$(J1O;<OI#CM5]DM6YI.H
M!\:&35FC@3/C^B>9I1/->0=BZ>P2!'$/Q&,JZ2>.D]S5,V?]<L>R(GXC(YVX
M5@(O7<R>$L$LENHXM92%;M^P.;=."M?E5H*&"KL$:BCK*^W+"RTE/@3,M^GX
M'H!A:! &Z/T/]Z%4'@+1X35\8S9##,7%AJZ<SOTZSQ/6X,\ V2T9A06TL,MX
MZAM8&%I<;_$F0NIS"WM'^DSN$9/VQ@#AAK5"D6!,,.Y*JR;9](?K=%VK_J%/
MS\V8;TL^5W]M!H5/R;,,6,?E][C2K-8U?XRI*:L\S!7C%C=0-AZOD3;>\Q_/
M:^0&7N-+ET8^0$58B[3>TB 5%2L*G^>-+G>=6UV=.YI%JHI=_"54VP<56Y#O
M=GY\G76!UTYJ0##_GZ_0@F"SPN484\!.%;]E@/;RRU8*DXMG(F595SIQW^ ^
M-H8'DT_<6\8GS#X'G0B2>1&I3[-VMG.RT_$C2-<,5M?P^K]QSDJM"4QX5"()
M+' %DUN@Q0%,2RJCV.SIUKU:9R%HS >.SALW&=ULG[>$$!+>C+M?K)V<E>S[
M4V5IKH]#@T=0A%/_U.-QG9MP-'NN@(X#:?0<('[JM'8ZL.8,T$7"/*Y?:V'>
MV9^L<D%\U"*,<TPQLDB"U>)C&SXM[?JVW6G(V\4B)XD:W\]NP_WL)4/5*(QJ
M;&X!^OG=LQ' 27#B)82M.D 1=G0MC'A365XC)Q7ENIN>09WP?5J(!S1M0-K%
M ?C<H-O]V:N$ D"S'+>9-MO[W[AY@:=VY4OID.'(STF(J>G+I3CAS">K><!*
M]:A<>85,WL?M98@=S_,TJ=+:@KA@EX@=L!KPP,W- ?U,_9Y&GW$?LJ!3"772
M4/<C%O4#KH+'6L3<FWA>4+A1R1YOG)9V=K^96:1C*K\%_*GL.P.TDD_@6\1O
M;F.W9J:/\Z>:M%Q@^9T#&5K:*?,9":T"]#]T*&FP?)]T@:2!<4-^7C_KCP71
M_&6%(<)H.K[V%*#<<NN^&ZRF$,37PHP/RYQ@H3Z^!SWKYT.SJ:R3E@S0AP1'
M-]<0:>\KMJN60ZJFHF/5Y>W:)[</C ^@TOZ%:$,GL\*5"X!%?4,9 =@!)L6]
MMY0VC>+]3?:$'\[W'*Z:"OQ#H4ZWI%<1/_&D3'-,^9E?++G9,\?A$RM@J&K4
M>NY*EO#C@U.WPOI$X[(!Z]Y$':7MJ+ BQ2\=S3! 7/3')F3VXZY6A614/?SI
MV!9+=OQ<I5V!B*1?OP8'"U?7YET14\NZHLMW/FI=06?W*;TA ]J#!Y@U^![<
MO9\!BLEP)5J7'?J\V6;)G1Z#UCP?R, ^]/A[CD+NLMUZ>Y X[?*DL-C<+*NL
MJQ]MY/<J[4$2.['/0-2(652I: U%LJ#DTYJK,ES+FP*.A0[O>AT>RU@9E/B?
M6%J=*\3.CMZ/[0ISHGU^Z&3V\J^E0KY0O^N.JQ\41HTI)TL,A/,;R;I6%70[
M,)MBT8)L /4?V-6#@4-P%T]A365Z'6Q%-N].:[Y<]+N3>7H'RE8X@IBAY#5?
MCK6"W.=I]O\@JOL4M,^E8 -R!/%T-^O3AV%/:(]V-V-Z!QS@<H/'.^%;J,BQ
M ,BYA&X[\DUGR0&6^Z .M:=.!0*A=?H\ANB_<@5LXT8'NW<!,)DC-UBVIK:'
M^\7[9L%?O,)1L:[N",-7PU8A%:A-*'(RQM,F3CAS_9#"![;?@+)[US=K\+_:
M%)A4A%Y_TU]AU'OS,F!4=%FHM%\JIPYVVZ*C:5V2+366R934*3,%0-B1KB]4
M#/@@/#"8AB7KU,3"QL:LD+:95MS7S/A2SO?:^H;<_!'L5YFIBT<XW$.Z$LUA
MES<"PQ-@X[%*L"PB@;U7X3ZJ"Q*?&F>F)*'U?X2YH,<G1G^,?>K>2%!\TK9I
M)7'+X;*SK0BSQY,AA434#5P"+SSF'2P-JSIB#7(32Z)@ (5:0K[:.24U,3:^
M5'LHJY]41=;\=4U4+^$^S_VG3QO]TU+[G6(A4@7)CSFD 1F[Y0JF&,L16[#C
MEHX)^<@$7[&<;<N.X_Y2*F^3PJY(]-9 Q6?_\9R\=KQK'T120]<4PGT>(\ /
MK4X<>]]G"7G2P\\LDE>*F*3B1E!_^@^YP)&PD<-,)$]K72*/7WDM3M]5;V*W
MW]XKR1@&VZ^?47BA+#K<+J-__^(.&W1 _V+(>?Z08R8ONXOD1F9R_L E8IV)
MZ3ZP+G-$2><AJGVP5OGK'(:-/-&1PC8CI+X/A58;?_I\LH&S<\4S];;.Z[R\
ML+M>TM7?32(4/O$C8?C"=#K;*=J %';T$U6?0*J&WQU0)D\%=I&<*YMFS^&P
M21$I E7EOB&SZ2K7]>,RL!S4S;1^JZTOD5RW7T@;5ZF>E%)=^BSZ'MAFDRU:
M=27J%-P4H.6RQ]1AZ]M'#%#02CFO&&F< 9)T4M%8(;K6R<JN?E-Q4^J4<BXU
M.B\L_.+2@U&35.?1P9\C:JH&,M[[]9O\^0 FY1D'[V4/K13-!O94*I1Q?MIU
MS:T.L/%E@+);4Z@B4[.\0B%;+"N9'#77J!(/64:,?\]G7:\_:2!@)\#ST"]+
M5=[K3A=3:$A>U%&$*.4,D?<-PG27#YL:0]Q6*<S;&<1,'6M4>3:A\V6T+!(&
M7]_SF-KO".=/$/^70K@->Y($O6FVI%4/V%PWNI5U?\*2#TEJTW5H!L>#*W^[
M5E;7C'6>X?&8?>[P#1]847\K+Q^=SO&IB[HEA"!T//O2HPV%&BR;O6+C^I+*
M!F!:,E, ;>@^QN"+1.43A._O5B=]:''K R&)U,)*B0SW3Y2^N#X;26KTUF'#
MS)SL"3[(A[S"@OP.4\BS"?DB%ET!#F/I&N/QZAJ)#J:M^ZQB@51"AC! EU0T
MW5G#%1D@=UK<-F]<DTW)1I,XZ[@R1SDQH(ZOWG'KE@[:Z>+=/:K*W&2+?+RF
M$_7>O:_/;:4F-'R;,[>PUW%_H_K%EPQ(=S<4,@\H??52!T<!%YJ<:B_MS\Q.
MWIS*:*NK2O2 C!F_KGK8%?_*P*CZX%EW&7N5ZAWPCM[*"V8!?A^ X 53W5M:
M19#"E[!A1>B /F>XNY?;_89)1=U:A>?Z>NE/9>:F]))?5[U=W7!>+WK[L'CP
M2GS9.0[U"U(&UO$Y7^VBA=.8"1-1B&]T^_2F!N2"-.Z>XKLOLK'][A]:$H:/
M6 L4($=+L_7)T]SO!,A'Z24$+L3$:$F7O2<'S (I%=$[_E/PD;:^:!'_)M]C
M&6:Y:"I2'+R&V?-IE&/]81!27TT]5Q? 6=FH>RID\]+@=DMLRG>7 7+B=]<5
M+K1^17HW>TE)?(2>2^^!C+%QM5?_B)H^5(E8[ #L&XXT1"VA0>A69H.U4Y8M
M],0CMH:CH+2RNQ,M?Q!(;L;XG8WDKJ7VFJ"G-V1$R\]ZC,6U*T5+D]1Y'-&(
M/TWRDR# .SCWCE;%NS"9/*PU04\0-KB/\#,F;M-.]QPKK<ZM;ZYO%<QI643U
M#$/YH<9<Y^7/7E&[$UFD)6K_Q"Y""[#Z *%20TK*R;5;K[S#R>^$A^S>W;Z)
MFQUO$:]L.I&]GN8GZVIERFTFFIZNF!!Y6Q5:]V!_++%RM-3H\X"R<J#^7S$/
M!OF9>5<,$)6'ED8YL8>BJJZUOG3+R"="%@^GOF;-P,!"<D.])P>,:QF@;862
MDI"2'C=\PQ>4%*J@;V<'ES*HX^'YK%W3^9-2K 97C+8!<-"_[B50)VA2U)&Y
M!MZ8=+&P%@5=S.O9)&Z<ZSX#U'.<#:WR"@AS;^/_XE!+@QB;0)8]2*/J3DNJ
MDB:!>84YN5%JSVXSN_M260#A4:%;\=Y0K&MLE<?K&?1@R5CE$\U\,\=Q%;_3
M7YDX".3EFADI)2_HU!3G=R%!W_GWM"VDDRX;.Q:$"PDYY8DS(\OW:"7T -PY
ME9NTO_L1D.T2#-$ AHC+V3*_V3,;*#%FP7:[H<HBQ).=CT\_]'N7JGR>R]!T
M,;&WILIPY%MUS6FG[F]1S+"Y4PD#%**)%.W^W7YN^IH>N!>[8LT]</<M+&AH
M:S,".S"^GYA4_LQ6DB?N#.$:P2(H-!C].H9@*W+=B_U[N'#J(W<8OJR](,"A
M[&@)_7NWL3'?PPB/K]YQ38W99@EO*)A0CVGB2,J-J(WXHB6I):W/SR;T9ED]
M7K;Q"7J3V0A %">/^<2JCA0OB:Z4*X,O*7IY&1\&D=P:MW@B?Z8;2#1Y3=,V
MEXHDLSE4M:/_'NTR%6 Y2>P41@LE:T0\COHNI .L!%1%F0%2+ M'"?XV73GC
M! NSHGT-!/ U ^38WJ18M1BZ,JT?O>.O@<[/S H-#G,9BC\23=9I*<P)/ONU
M.]%QC.])\)-49O4Q<<I3.5+( +)2>V96MU4!20U&1.X,1//:T_+F+:D:@*2T
M7 N<OG3?XX 7JW1ZN1O_L$B*>]47%!IV9:_M\O!MG4_9&G6 X1^BZ'&2I(=\
MGMJLR'4-CDRAI,FX5V3>@=+>79>[2+B)\(ODP;9%3C<7BJ.LIH^WZ1K:62*@
M-%C4-N3MB-' R;\&SL2\K?P+T%06#% ? [36M;>UD.+N3D_#\=B1>"NE N5D
MA'8M)T>57Z7W[K3$Z9I%1,J<UGKKX(R[K.XQ%),IA* <EEF*>\"T]8( =><V
M1G_# )WS=_Y%GZ"_5B35+74AS'$!/A?J:V7Q>9W+>=VKX.:+X9%?OGS+%2?X
M><8WE:>E?C'->>YD7[RGJFLH:K6%O17T)U(.'('I5X,?\IH>P/F:&A.:&NM8
M3V_.\[ 139W&=G@FKUXJ+2Q\XS5LJ*P!$[ 7*Z=D6%W/3[NVZ1B$O^Z3\1>S
MD,$9HAX@;G_1D)3I/9$;09[XW13+GAGNL.68Y7YR'7)X1[^MJ;S)T(LXR@#]
MB?)U2TNU@7)4C(I*>S]OBT-'7WS0I75#FQFNG$U8!9/^HI3MF>;*H@+(@]32
M,$>XK!=/36/VN8J*<;\Y_$[ORM>C*#<YMU?KES<K9:!O@Q9GU9^\EZZ\90<@
MU2>HOS$#%Y;.D*[F;"LA=1F@G)WP&65E,95+B^LW?\^.*YH&[#CT?AL=OEA[
MTT_XMH2QJ-M5)YTTM.>Z:5_O)J"A(I'IO+1[-HM6BY00TEINJ_AN;$)]:]M,
MDXW J*+<RI#YCF6'5KDILN-%XGB -<O4PTZVD;4KR;*^11>-IWY'^*?YK7M"
MNNXQFR,>(45$2R&*M I,BIB7?'Q9_VH5^,3O,)&4OA7[^"QT*3J[K'9_G$-&
MADVJ3UF=V*04KRC55&'/'\_L=9!.7:,-_&:E!B"S:::.+NYQ&453/&6J*=T'
M*"C-;:HA8^'S@%8PNVLB^]#3Q'H=1T>-0'G;XFZ(;.K)9$(H\/5CN^]0_4N+
M*-*?&_@^?%#<D/O%TYPY9&5X/[ZE9';*J:0N8\9,"79]<N+GZKIP5-P/QT*S
MU.5@QP73"%^]X#>"T< I%@%?!J-\VE!IQRO5O\%Y>[SW"F>K)5.53#4/YP^W
M7-MBIKEW]A)EH-24V8;QF-RL2/9$#@^HK#F*<S$S[?F'A@^ )AJ?8#IPOS!
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M)'3JG;59RG,&*&Q4;_K\F7#'-(-ZE2?\!$JN*7/3'."3M'N[5.=]\ELW?,6
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MZTY>&HX+Z <1YY(6T:&E.O)?"Q*P 5_ "^*D,DH<*;*5B..$U_92989QM][
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M*SH^'!\'B*Y,WE\!%T)/D ,K@+CLH.W?#F5>?RKE36X)!5PSJ,[,S;WVT+'
MWKM5^(B^O<.N2&V\@TB2 00N9G:0/_+PDU%@,CY)9'E)/>E=N*]K+S8]9S)V
M^EQN)D94^W/W:E%AM7O-@9D'$U4YP79JPWX6L_:2%U[KF-X6@9:HE93J "YH
MH "YR;F^?F%),+XJI^4GYIA"H#9MSPS<[UG0+:_'!LOGQJKOQIXV8W301I-
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M9XX<6,@G#@P);-P$?H2RKB#(KCLUP#&VQ.X@&Y)D _@J]E7VR *;V_^R')W
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MC[BYE_9!DS,9O$@=PY.\AO>D]*_)GX.,TYI;-&NX_1,28>359I#B,;E"V%T
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M/**U)!3.YX\KO=0@OT6 3-]R3^WV97%5%^&.PXRBUV]Z?]E[-QE7!?RUB?%
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MR8#:2: %1>U&S7V)2F9D_Y(#3A@^T1L,>;1[7,5E$M1CL993','N/;ED$VS
M^F1@MWED-I_D.IF_ 8TW>Q)H2Z0C4!);9$2);E-T3W],^BTM\\9N),S1]778
MVQW$ZA@%2B@C%AH+<4('@SW!9U-=KPM0[1C>+787)#_ KI]&DQ"":V>12RV=
M!"<B6D;9GVF3/VER2AI]0+DLZCBVB*-3ZX+%YN9F4,C7%:YGO3_QA#X_EN7B
MLDZN3F/@#O&>M_M7>.[<*N80,0T!!QI:D&X2M?':6(2TC-9O.(WT!6C2B!(E
MF!A0+E]3XU&OK/H&5=AME55,Z\,,BY+RT/Q1M)J%%"D,']F,G/$K!#^!I*8_
M6(S$]4V@>R.K95B)09-"?HWN2R)EVDLNUHC;V+,Y"AD5EJ^85P1NS^26]$3!
MWP&_WO:_+CXS6+1/]E6.XF,#B#M+H.@%2-(XW]*_;PL< GY"NNK_!<^71A &
M\%GMPN[V;F@OS-?%7DI&^CD\-LF>2:MBAVESZ(;1-GL1ZGK7;<&1-FT]M<N
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M4V;.Z='2+>N^B^Z(7HNW>@;#BJXSVN?@P6G3(L:H5/6GAYP<JN-29!JC7:3
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M_,/ CFV@O*1M]F>>+;V*EZI%\,HRE/0PZ!HT"3\G+BVMO-??$4  OF?-,WZ
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MT[@K5NBR4/NITN+?5Y^'M=%=C:Y>U1YP7R8 '\X ;&=)U?&;*P0=LL&V_;C
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MR *X1@NH)S=A"90-P*[(_O:S*ELHRJ5V=V/D@+_I8G\'!5T6-3XU_*M0Y /
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M\/L<C^"\B3X..R4E<EHS ]0]L%K4.229OEW>@PBI-3X?U%%FYO)3@"$C5Y/
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MR&82]$@X'Y$#6P)C05\]3$Y#/+1]P_<K(MM)@!G=6VOO<?(\K;RVYN?>#=.
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MJ>7ZWCWM 95(6J6EAB8=IZJ#LN8*QW?;@Q$)+\*I-GK,GZY:J;UX3.V;R#%
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M:_@TN[Z45Y/S7N7+IC?*,Y#HM_NO;9+MFC_J'_*]W+-^ZDT+3=F&2ZWFX=S
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M#^W4L)3S<6@0CV%<<W:VXP.[^Z4D'GOWAX [GM0GL>(K1Q;PNST6"S2^,--
M6\&9^_#7EZU5'6$V;/S*OAK?M15*1H6?.<JQ2:F>N(E];'VVZ/ =5?_>_D5<
MFH,M9VX<_,M.&*V)SE:EJXNVIHA(3"@%P<,D>Q"EJ,]-_0Z4&H<<H<7;8E 1
M1R<(]$B>I=S'N9U[P<5^TZI6C]7JP#ZK)N@EAY[^%S4R$'&<;D=6'W*GM2EM
M&0O2\4T]JYW0Q8+B?:"0QOKZ=_^#F_>,:O+KML5C%P7YH32I*D4ZTJ5&1;J
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M+]JI2A(KIY?M'RT9<2>AHDU+.XM.0JZ/:>$;5\]/'!42B")3N_ "SXRU3-H
M\<V.0F:FI9;<Y=X^?42E&U]CAG*PGX&IQ8^.K @1A%+MD&FE>\"JS 1'V/V/
MOFB.];H*U-XXMY9*_B$[8<0G!R%\$(="O[FZ+6>^@QAN?*1@VOLZ3'Q)#<;
MD/GE^[W:+#8_.F)4]8)!\.9FEEAK&7"!ALP0@#$=_5*6C*I[M=@'DO@0M/3J
M'WAT,Z,;=+QF\;<4Q,2!PQF46<3*$O V43&<%1L#"/7C=KTP\077F$9P)X":
MM5I@)W4'@2*B$Q7D@EEI]O+/@H"O%8+2')JL99RF,-4C"N!'_+?NG:L*$\T(
MC=Z1U?8/V?0J^YCV@PP,2K&D]4U$-PI+:^-.G]%GM"0GQB-^/')^=$SX;JFC
MF^>MAH@>Q>*I%8_2GHA7Z!LP.CO-V.O,Y4P6G RQ>L4=]W&BC^^ KX@K#ZTF
M>,O;6*7-RU:&X- 6:J,-\!E00'_ KX"LN5YWY?;NJINZSMY7/G",R-,MGN>;
M EQP:IPL]M^8+G*?.$2N3J].XQF/^ARTEZ+2+7_N5.?LUD/76B]X!K=NYRR-
MY0V?MU[(RV:?)67G810#@DW\,C]C5(8K9_QAUKJ-I;.[HX/GQ\<[RX7L4<D]
MV_<<4RV7?!L1ZG5Q_.@&_J:E>'F&LB3I CO&OCH32$Z96:P'<XX_/F"!U+D2
MHR-<H_:5FKK:F.%/=!&>=6C8^"I?8WV*5X)WW,OD(W'+I[XB,/6XLK&ZFGSU
MO/37\>$4P*NM)95)LATF\V/I[*$MC21=DYPNLZ]R0VV0]996TU<_"B!([]>+
M5#[[ZF>2CB61619%:G'9IB5JGDZ$*ZALX4S9/AW@Y!.F9P9S+4_ZO5S\>SH_
M/#(7*"^]-E&&_Y4][TPN.+B$:VP-KO:9PX#OP"&*HN.+:)>TGE.B+$O ?H^V
M))IGH*SH*V.^O8(<D.7L^JE7@)PU'CQ^TI\.[OP%.<N^W0CQ^R/7L3]H;J2L
M]DKEZE;E@:^)_1H=;[)[01J-N>N^Q#D W[PG7C&HP!VU6Q0/8W5WL5]\5&YP
M,XK),O RAT;FYG5\^APN(,@H8%:\N8?[2WN=>TQ.?<_,<:7MSGDU8>GG,P5Z
M[14-F9SJ?F]U_(S>5)[Z$)_/(6547O@SN[MZGOWLV,2V;XD<]WZ+PW<42IM8
M1>?Y=MBHFC O:@\D&9_,^C '.9DW,%R-E3H?Z#_,DK1S?  +YUQM-O,L;ASH
M@:^HT4HS[K&_O3@MD[_ILV;;GJ (XIKW^4GP]+5/1\=1  ^^!\EAK3/;S+=M
M0?_0T=DYZ)Y??%90#K)>*1,(1&8SF=C</_4G?J[H,9ETV%R'@Y7&3<8&]H9O
MOSB^<UG+Y'WTM]#'R!/"G>6F*>NIR1>7+YM<_.<JSRJ]^1K^;K@BSO_TC7RJ
MHUEKMJ%")<\%9Q\7XVB&_6*%->*TL+OWPD7"*QBWF8FJ<78GC$<[2YY+\'S_
M#$1%D%&!R:Y.?3M6_)6I$)B&B]2_5X789#VO)%SXY!P3<SU#[^A;C2\CEH1D
MM$8@5@_-4593,A'"9ZTJ*#Q(*+SPY&K9'8;U1SP\!;;M+2F+^CY0">YL/Z H
MXI4BO5I# -1(:ZHA:)B0-E/KUO=;RED:-;9T<&(,>R5MK&+XPXB^8%:IUP+3
M?C2%;K1LS!(4%QU-S'Y=PGL_K%12_;"DI%C0\BA1Z?^J>?D"(ULV9RE\]NP?
MKIYNQ0-G*  .6>X^03BN%[21,S"2I]&M<IW>*JUW26I24E_6EC[F)PK5J:.H
M;_"R1D)Q7?;^:EFT3*L.6[?B-[9%F<=,W-VIQ@UV NHNDZQO*RTC2_V?\>!;
MT,OA8)LVC$<^&K$UG.2\ +H+U[F'N'>,%>#+FI)1"P^J=OBX\BCI5#:L\B[+
M@<O)E_$@S_@\'A6#D0B,=#NFL64QMY"F98\]W<?@\:TQ71T=O5X&K;0H.F%1
MQ4_\VJ9B(N9IUYY@M3"K\?OS(X=#AGIADW\B^FD?\1CU_ 3R,^ZO!^(Y\8@,
M#_GZE\O=:3/PF)SO:>ZN :0.YY>2?5BE(%#NG\=V5Z\+7!AXF[6"58GZ10'0
MGZTY^ =V9>#SS' CV1AT@\(5;]S:7/8[>>NHKJS@*2.)C.Z<SN1!OLOJ*30W
M'@L6E6KVE9=%FE$ $NP:.IS?\?U<D 6Z\?';]Z_6JOT3(,KA4OV[Z,VGOOZ*
MTM]T1>$^"W<AZ4V$O58;3Z5]D-QU,8-9.=W-ZW<1OV8Z_7T7+:VLT".'S,<E
MYH[-D( D1X<S[Q98S_?\X+@3*Q0%<$W!/8 (.TE1:WXSV*P@ELPU/#=SJZF^
M\1,!QQ)79AG7&37_P-&]LMRG5"+^35VC^)4YHZF^U'^4/ I&0%;;Q$YOSK@]
MBWL9'YZSCKZFXV-@$[VK?1'$6Y!J:C*J]E#H. ]WI2/DSVGX=++\R@Z>KO)U
M +IZ8MUC,21K]0]M ((=\IA6'(#(4#5/[?)Y4B)X07!SK@?;V5W70X1E+,&)
M$%L"QL+ Y.7O0L:\()Y^]X39\)5J$OU7V7"]I)X&XHE_^$+36D@GWL/A1<_2
M1I+9WH#C[EMN=[N0=B/@/G'>B@+PP'>P^!V;+O\T6T1FZANMAAIN>_"[/96P
ME\P(Z30R8>:*D'D0+[N%&0[W29("'$I)76?R45C5,9^]K#EF4L5G96'A?I:5
M&*=Q'EE)VU,JG63VEG$$UTXOOI.-%-5Q:K#ZD>QS8\U],#WE2:D)BL54D/V%
MIHN0^A;"%O#S7/&/<]_>/EA3@(&)!Z=.^W+V@3^< N_WZL?0P:E]B9O?D:P>
M_!U+-L8B5DDQ1;Q):G3)J3BW:4FP4J!<HE;K^2A/"&I8CV^4/-;]>J[9^2*\
M5[?[6[*JZ#F713,7DW^R-D3Z5OJ8A/,O?[%[!/%4L";-G/*\G#MU[/7L.&"=
M$P<'JB.BW6-TX5,;QR>B($O_)/N]W-LKS?ZQFH-_[J3H%6^D-\HZ.T'%N>.1
M?.P%B(+)H^.MP1WEXCT-.VQ+UO;[UNO*+3[2BI9UK/NW!86Y=!'Z%HGO[JII
M/D6ZC.ES91JZBU:MQ61B_YP5%PJD8AUU[XQP:$[<*KK$)6CL)&JS5)3USU /
M1_H0N\9\:=;QN2%XA">H8 [;G'8\<_>MIZF5?QLZ62+ZTH?KO?$T=[+<8'$U
MLGP6-$(O$/N-6W'%" &YD2?@84P=V?YW19D4-5(%Y&Q\%9/[G>N>&QOI).O.
M:.$I .?4SM7%B(+R?,U[8<][OHKHW$P P>2&Y7=KF&Q0J!#)B@+UJ](2 ;4:
MEI.V(KK^Z:A)@5K"&AB],K'3-@P"!0Y,B(SF6L,;ZA&(NK!QM?>_D.&.X8N_
MFEQ*Q?:948YBUI6W@%.O;7.!(A *H%IQ400.64)T"W%6UWN':"7T33]_B6#>
MFV-]C> WDLFVI'$5\I'XO2$DX%J[JRL>+6]9X'L#;NJN&D!$.%^<ZA+M'OFP
M:GE^[T?\:,47F7'KM"?+CC5OV2+"#!H/0GHQA<FRNDMIS[QP;7V$N+GL[.^T
MTZ;L)JD3H%TT^G;:TX\UCO%!8KQ/I_IX8E5R5/,1@3M2NVM!^)$>E:9!K.D)
M;@YZ&8_W\"_I_>GD7N?L!*8K56\B5G/=+.61T?57N2*:,&0X]*GD2V%Q1;&#
M/IO(/K?G"06 ?*G3''ZR9]W)&,]@UJ/5V9)^#2!6PE_)4-X9]W2#Z;8'9.V,
M#$++/<2.69&)L\U()[3<]3[0%P0)Y]3<-_&=;^!1;0_^N8ZKD'0'JZO]I]>Q
M/3*;&OM$K (Y[.367 :(D#D(#E[KYN#4.RJH&+K]JKKO#T)OZLNV-;S02%=Z
M6#H[_)FC:5.0JW9/6;YZUJK5RQ8L0__-7M:6<6E1)AZ_1'2CUWE4[R+;[@V:
M^Q_=<6I]WI O6/"T+UR5J4%I4#H@-LE5$X0]WND!16]G730!F%=/F DEAW?E
MKMXY"I&8;8:ND(SV<#PS[&7'\T:G64AK,\\QZ0U+WY0_^FF/E[+D3>D7JZ"N
MCH8\AY%TF\<!V8UM5AEM5J^)=UU8'ST2S \81;'!\[JHC:E22W^&<N>,B/*8
MC5N,)YPTPXU8/!71OANU/K[5$,ASG@S@7-&UXF6(3Z  !LF'P_B%_<G-F0"P
MNW COG0 E*)F\*FJ*Y(P!%)90#<2T)"GEHJOV01DVU^):=AWR+L9,Y2M\UHI
M9^TH%IY$IXC6PUF/-9^%,_*<1)8SK3\L4S%1=KA2RS6'ACA@L8NM[R5>S/JL
MS VR:6N\\\(C1G?8?0$+K.)-G7X5PN4\]R/5:5782E?2MD_J]ZX$K<CQ*I^K
M)5_;X4[DQ(1]=Q2JW6F3O)WQY;N=+-:T+E[3/9N&UH_I:#*1=^Q:L\H,KUC9
M=X\:67.GCECQ6+RAZCDA]N\,83PM[]Y2 .5L7[Z,RR2IC[]Y<T923ORZ*@9!
M+[W%!7Y>:M[.?CKQF&/)/7PLZW@3>W6%CK790;GM05]?#]^>A5_ME2]L"66R
MO=^@G[C9O/*X(ST]@J&G<GG#1S?(&]JQ-1IWHWJPUX)% Y:_8STNJ>@5-.ZE
M2G(X.?$_$>"-OO9ADR=SR?6EZDXI,M2QH<F]0NEX,X5WUEBSSU'34LX)@#S^
M,#!<5A->$/:5L6EM<*1M@1^'5YKX\\(S&'DI=\.IM;KA'\P+"ZW &PN^SG['
M&U<SKZ Z15O[:O8R,IG"%?VN$0-.C$:A JWB:P'D'>(K\H G9^T!(FA;M_$S
MNK4SP&[XLFSV+;C[QI_2XLY5ES+53K.4\D3-7<4\_C21Z.@2]C2\RHBG$\?Y
M.S"7FN_5OQ/K;Y=:IO!ZO!;@<(TOTO</W6T;WIX:Z6^U^7$L,3OG YX,\J8E
MF,X$+;W0\F_ZL8T+=)5N<-E9,OSRC<T-P)LL=>C9!\+L'2R.#--"P=BY!4>G
MCLNXN+': "P!<XM/S\'[CZM7 _L[9[BE_:<-%7OMX&X5!5>Z][AK0_M2_3R0
MQ\V@\E8;RVPG\XYF!T^ZQPS=/-J[*I]K:2HD?X?^,_LHGRDAI.^XIA>CXK>B
M%<#N$G!R^G,$W)8[@*$-2&/QF==W"+UCV6<ZIUR4?K60(.,3_<5$0Y,^0EG5
M.KPW<&3_]%0N=R[D P%6#8_J9TGG2ZXJK"XKQ: ,#,%GEFZ;U[*>I4H_Q)R&
M527SAYN,<3IJ<UH90GQ#6BUB%7.*W&]^Y'LO\/R;-"TG#>VUK&X1-[<;!;'F
MSE_DYEER"^=69MK'ET]$MR\UDC>^1L1?+8[@G5V1_*78*^WS9$=L!G+MJ[]"
M%HO]U2_K#S9A*X-[JCY$U*DWRJ*Z&+FE0*ALP5?5H[G/R\V?Q8Z9@(5"?IX&
MT1E;?1064C-:<NVS6$FU'WUZ[\$03<2TM(T& OVSXVI@UHIU1]JT,!LZE?'!
MJ%$7&'#KQ=2[+S %TG80VN7X("T0#<EF[)CS/(V\WH_TV1Y>[+4GN+QU<;_
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M4Y-S+O4]FUO^!V/X$JK>I@X##Y$8Z(XL.)?L1XW\F\$]%$"WV;8X:;F.?#2
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M1GO3K7::^B#3FS5X1TCP&J;]=&_!]5@,539KK:$_B<YKA%>+Z7.+)+V48[1
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MTG!0><;IHMOS0?>BI*X+1:.YTM*_W]P\.,8[!>Y !<W5O"_,H;$O?N*9-T1
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M"+_O!Z!_Z$B,M%;5=)UXPX3.SD \^< U:#S1=%DTG[NSY$&A?R!NI9LMM#Z
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M"EI\.8U:>8S:2X6.IK-O:9<>[C8D;@'X@/"?0VV*N4 /V2.G!8B B'@+X(,
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M/.E":PFD!C*?<A4K;NP_VV@^#TG(*3A0V+KS-M%5E)DYAT+_,3TXV"BJ0JV
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M9A018;IHJ$\%T28J:6B)&#+G>(1%C>\M&\DZK;@)$CQ/\N2%=Y^POBVM_ES
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M"Q[P5JV-HQ/K'-@R'_A"#CUI6XQLD?@E$@\H)+[9!L I&3C:N=UT\T]2V$4
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M>[2=AX#/=0*V[MD[G\7Z[],-'8VQLSY4T!,J:#<C/_)/!O-9*NB'.W@]5 8
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M:%D+OQVX=R)97A[(- J,R!.2TR6*X_3% O_S5&:1^T&4WQE(2BJ-O4W-S97
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MYKS3WH]?3$7[-P?NAP_ -!=I6N47IW?]$VMJ_.Y+/Q+5=EATF'][,]O&9\5
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M+ RUZ%'++$D3NB6M+<\:).SDJSK;9\N,?M@%$D^(O-N> )=Z*,]J;::W+"R
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MB%_+U )<\Q+D_DWUVT)I:D&6+.>5],/V4E7>-]=87L49'6(%G!Z@?E4$=LI
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MN*A\VU,U,]TI;%CG^#A;BL!D394UF'1X0N)#65ZV@-"'LI9FWD(.'6'*)BO
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M2DUH@.K&A>?UX>!J'RK+@1<T4\]_^?NB,^UV2!MEQH &<&:?:J/80.,;5VA
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M)H%6["851XME=M]<J& V]A@%Y01^1&!$>G\/Y:B)T26D,@SQ&&4(G46E+/;
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MKM[97:HYH:'B.?D#3959W=S;+D9(FQD:X%?;L0K]R>_R^AP-,.:PO<M0GC!
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M-<#[.]$+ Z-;EL0;X -[.#G?KPV\GP"X"7R%V@1!_[:%+P ;XF-1#:$:T4#
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M\EWNT$(/,64^L6\&$_ S]PG/6UFOKP!5PT'!DMMED:35DAENB!%4MHQKN<#
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MNH_F7/0&/CKRZ?]]:GG3]=F^<.I,&KD'O DGQ=% @2(+]%6 _BM+8 Q+O;A
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M&*ZXI<B6R._Y([(I06: VHGU@L]7&]'[$HLV7 TB>0*0$T25&^MD$Z6!NHF
M8357X?A?C?88<BX-A%O@8@7_/BBF2[+IS1CZQ?U)OJT4/6SDLE0'!Y8?>C1T
MT$"RT330I"W"J."_=1^?+_^+PB2R^.\D.B+Y5@_5AM@U0%9_!J:,#).(#300
MWH.+SK@#6U")T(-G/G!JPAA\+S;= +X-#(,(A7*155"6P-@KX]N37 <\F0?E
M?&0O^2K3OR^Z] LX 4Q!=<QG4KEU:2 4 ^$5^ %@51/"GT1V3CE7'4(Y#:1C
ME )?>S&[^U(D$FI' _76;(#)=RMG26]T-QYPM<K_I')6$./!BZ6V-)"<U^RN
MC_2!OU__3%-?/;)\49@&@IZ?F-V/@*E2L1UUB&G" 4_403D7V4L;2:"L6.ZL
ME\'7K!'PD841X(G?(]$;,8?6@+M) F;T2>_!R^XY436 @^B ( TT,NZ[0@,1
M >?M/JBG@0;?0DEUN&F'/ *O[^$IK$?4OK8=)8;/ 3X__!)X6^PX=;/@;\0Q
M[$H.:0*]M@"9W2^= +9KP!MK,?#?>G63_M:KNXCKG[VZ)X->P3&15C10NZTU
MF(AYZO>F@UP"N+ X#5135E=02P/-JW&1]X&#PF(SGPE@03Y&DH]J.R/)',](
M690ZB5SX:^=@\Q+J;ZY#CVLM-)!X"1B/M1XAP__3$+Q_-\02\9]V8('O:TF1
M_>%WX#CU"AH(&[B^%T"P.P,^?$\#E7!HP6>/4.>W$.21&?!"FIVI.>E-_3R?
MR4D:2)HNSHGH@I/CP,19G(Z/ RZ)'(VCYXQ<S;%A-J(7#33T:8D&.DP%3$9P
M6R^F1$GWN30E4X"@MVD![+C_ILJ2-*!/:@ZWQ,51@.$Z0BTYR.% , ;. J$2
MKD/2BBI/Z6A8P6X\*@9,_(Y, TT$@*DWS@%Q@;R<Z:K:8+FEJ7.P%D4M[1F[
M#VX4HZ8#&#,XWT(M-?>TA?^'PB337Q4FK\/_+C 9C_Z=-DNZ]2??KW66D;KJ
M2IVD2S<_ 4QW#S#=A.]M*I'QP$S2\E /0<F?\BQG^\]FXY9_;3;^[!_-QF.!
M69^F@7H>T4!+8C/\P*?*#P!;@'>W@<P0!&S/52BI>S<'NH7^<UAM^K *P+!:
M!$$Y8(]CA<<.@8&*/XP-ZLR"J>EVP*P&*RWWMSQWM(GO _RS/<M@9/XSU"[4
M9_"F5!\-5'\M% F;*#_@!_*&+/"WT0ML"7R:BTXRWP56[4DGF0=6_R;&!L#&
M2A?1T4!$$X#2X(.?._S'3N"FSC3X0%B3&BMZ6-OHCX'[ "XL]P"]9HSXL].Y
MB>A_"8#[?P^ KY;_#("2<NNF*J[R',+V:3I=^2" 3E<&;$!4-26<0>K]BX!\
MDF)NT:06B 7O;"%-J4DD(TI^RVBJ9=<CZ@QD,P<("C"%2"J?T2 !(, C\R>C
MT8')<X>),F^YL_(@B)IG2?3#^%99[C\= -R:$8U3;P)C T?VCN_I!*]0 .N/
M!GY=^&<'\6'X=U?X1@S]95;)<GKHU&R$_NTVSSKS/[6[3_XW['0;JX5O*0&A
MG#:[&V@!0-,_[C<-@I,0E.CR5BZRD7 6G48KZCW4!]_2;_@_-<U_$O/I/-H^
M\ YZ&HZ3=,F@TEMT7_2GM^@VVA"E+%92=[O1_V+>%L,/Z].O_]F?NWW)DFPL
M"28A)W>W[8BIY@%>NW[HWQFB)!%ZU@I; I8VO3Q&O.0')$R>.AIHI1"\/CSM
M+D4:I8'6)B<!;Z+V4'\@1$JD_O-V0^-?;S>T@?]QNV$TNVE+IHS@V8C>X@%\
MUWT73>62 8P(\Y3?E)FB@0Z$IP( '!M)/CS(I&[-'OJ9AI*W(.B]4#:3=+@X
M(\F;KX>+K D@\ Z/_,HL%+P8[D2-0:\O[$Z!D:$4Z7X3&BC/QG)S!?L*P#HF
MH+K)QV>2C7IU2#-\,Y)NH>1$8?A*%GAA^I4@G@X[5?; ^Q>!PJ$.:QSU#R1!
MCOT%25 L?T>2+_#_Y*ES_96GKO>_#['.I7@.;'2C_RXZS8[28+T$IG*)9Y)R
MVT@]< AZ\0-D3Q-PLESL>AQ>D'Y!*PF\$@LE/4:NIGATD/LYO]!G!"2WZ3S1
M"DZ@"/M%ER4^C5['>$9;S /YO+$>/EA/I/[,PZ[:D;_#-X(#+>'S2!<@ZGZ.
MDEJU]?\MY?LO=G("N'Z (EMF2!?_!8SN\'5W^RTQ52X Z@GG^OUI@"3<-$CW
M-"!E$$PK**U-6_ N$=&#=9W#&K!9$YU##9.!4842X43G&>F[Z-]YF?O[5"[X
M9)P_?)12O!$^(<^6N<M( QG3$00)3*%M.?.@&'#6#BGY2"XRGQBU,ZX:O>DH
M!B=U.<-M./^B?/Y$E*[WVHY!;]*5[5$9FZ-?,N^"-\KD]>#S[00X9:TR<(6N
MPQ]K6T#> B)N)!>+@,, !WMR *7&LX,IF-+#6:,5+@JJ9Y%(%6@"X&?&K6#F
MEAN"G  !_UN-MCT @UY;=UNA"J7!* 5M]-320IW1W0RBCOD%T6];-!-X WKI
MMQ3_)#$7;])SRR\P$,6A5(=G\.G1CO+/E@T:V"54*3"5N<=@(B_X "B##A2)
MLGZ\-- E^#H[M6IW<@#O1P.E(ZBY8&(J_<J5>X=Y"3; <A&8K\O8ZBP ZH!M
ML-N!FV)3!"!"_D3U"C;+NYDS<H 3TQ-NJJDE9;+D<$AS18>2.-L+)9M$?@=6
MA! E\/H84=6]X-L]4!K(,*[\<Q3*DB*3 3RD#0HX+\JVW#07SLM(\M)ICR(#
MCDS\Y8+V'L)#R4E_JLOFM(T-J!(_P(<6EAD/$^#3<9#U8;G7A]\S_G;X."$3
MM A_Y \OP3K#O+QF6M;)H:[0(HN*]?IS*]%OPR#-=4[FW+DM\R\2@D;'AF7?
M%S(_3Z[Z<E@Y.^V75?Y7<=)GAXS+H6U<\9B@K[4%'19 C7%^::I14^\$FYV5
MUWEMAL.&LR-BHWH*YPU/?8@-<W"\NZM;I,$2/M1=VP"!>N(_K@"GH'"PEW_/
M?O$FRL\384H<"/3,U(/.S)=>QA=-RLSRGCL7./?%L=[QB,[[@OC0LD^CHPJ,
MD=<'%E-Y:Q9-@1F\E/OWX8=9- 9 W$ 6_X=3['Z.Y.P#F:'T,W4(ERO$/\9;
MO0)?IEV2"&!VKQ&O$7^;%ZUS3:]054 [I/:SA#!@#Q'+WT3+;C[JGN@F4,\_
M.FM)":2?P]+V*=NH.:/NJ>"7[ M&/8Q1<FN9[4,,4XD3ZY3IH%Y;A\^V0E7#
M\ZM8VTZ%8R><U'D$WN6\'E,]-NV78_EO<Z]6^4<?I&R:SNW^,='CGT/(J%LU
M4]DJ2>.H<9=+MT@ND@W6DA:J&GHZ,AR<GUAT.UE&D:OS G:H(!-8T66.QKH[
M?E7'@J=EK$6C!G"-'6$%_;_$DE.>^IIT"]3%^CH6.2P(7_NA<S9L=5VC\NOU
M<?IQT$*3-[+%NGCKP/=0R)"/15E$DS^^2R-:;TCO6X30]H!L";UQB: ,ZJO^
M$^/W(/ISV"PC $P(%")_:\<_'FOKW\.6'7QW/ERM\,MY,"JQEI#UN2@#+*2?
M(!$_5YA3[ U_I6C9LW!CQ_YZ)K"#Z/_;1]]<+_*&5O (RNY& TG0%P()JJYP
M*+^!E H.D)0.$Z1&[TJX*5^ R0K,ZM4D*/ P0DTQZE[S]Q/2QW\(\+_D6P3Q
M[,![S(J1V^GS$))R7ANN-S\&,]G"LPT>CQ&4.)F2!^JZ[G%R=ZPO\WTZ NG@
M96?J'[/6MX 2;+Y/08;T_Y"#J',9Y!>("26<E\^S/CNZ/+IG[?/5$K(VKP.5
M=3!Q]$XW+%C6/Y_KXDQ";<_>G*B=:W"6*<VK]'?OLY5N3:!*_5",2KL@+2[?
M+1WRMT6N?O4"]T'?3S]""DA";<G1:XTIJ-OQ$H&8/KN*-7.M0'T#/:$^";$[
M2X8&*MS#1ZZ1I*K&11''-Z\C,I1*)7BT>W2W&53UN/@#9GRPF<)LKR;V.$;Q
M$Q$7Y]GY)Z_P=SQ:9?CED\!S+"@CV*(,;Y&'WSB&S\C<*(V:P/CR!PMKFUK;
MK&Z]:KY[M8'ECUAC+?%#G[O=%Q\^$,2Q+'TD^>W#F!H@'8_#.H?!MT [#"OR
M#V?EZNL/A4G0!LP*]],V'Z@PJO+W<+:!N2:%MXA\>+$Q;Y7[?[Y[L"HJRLO*
MSZBLS6>0EGYFDEU45CAZ?R'BB)T/CQL+D[Y9[,-CL0'[##N+=QI;WB\\[6T5
M*'K;V_H+=$*=K_/\AR7H-M,^?V3W0'#) >2'KM'@Z%6&8/:TRYL\6=5W)$[+
MZ*T9SJ59)%0,?V_OZ.I&?0J[ A%1N_GYO4TG&.>;@6M:SU@R_X9@VFK?TXTS
MR9P>NQ$6\T0QN<7FU55'_Q!?2>]SS6^FO9U=%B8/&E06,1.I!F6M=E]9[HSJ
M&GRC@;(='8M@L:?GH2TY]S*;]U16?\:6G+K^X^UMA8.@80XD#B8CW)J8%-US
M?/.N^O-4J;!G4ZY&J@S=+;T73JW-3OL^^A\;<,,(+S8X2S 2I(%*8O[8N(PF
M:U8E>QQL3,]Z-1M9&?JE*/9VT(,YP\/DWY\SY!JA$%[,^WE#F/7#+WG)F=&@
MN)\TD-!6_DI_T@<$CC6)#7'OJBK4Z6P<@$(O5$J&.5_&'^/[K%DF[T16P4WW
M:55)#RW"M:%R&)/@5<D9-KF'NS72\"?Y^0Z))DFZ7<^"OII6L!XGW6T8%ZW=
MV>1#9(B72LAJ%^MM"YQ\*BI) 3PH1@CS:D:28W1PXA2CJT0\EL$H!/'#X,B6
MT$,^EG(5^(3JD]F_W3DYEH[<8L^NOQCY%E7O!RL[;#I;G2&K07"NX90WJ3Q]
M;N^KCH#.DXL=NA&7;Q^O.#:)Y:A<<7]1^U.=_VBNRL=%1KW<JQ[RBU#'@Z2I
M"4X1BTD"@O6]H65.;:+G1Q\G^^$BHQY=EJURK735K:"%@D#]17M?2U1]1Y7;
ML_>).?QA$Q.I I/=WLG155KJS.UY-UZ<NLC\0^VZ1#,G(:#:'.<A=:>'M6CM
MGDKGU?A2B2,F^H;I0BOE+P^J,,R1VL\GI3CJ'Z@_6T15IU[.?1Y;A']SAN&M
M_M77"OF^'(U)GE?_)C[^4V<&+2-_U;-_M6NC=',+EB<Y@_T^L)?RZ;SJ*^LV
M+9[99,>8EU!$.KSF6JJYB,3MNCU/2$]:\/SIY[7I/YM8GZ7''U@%9Y'KTY P
M_!C^I.2$:AVNH1$U9?JX/CM#YDJO6_GFC=L2A5NV7^25=FR\:C<F22O0%S"7
M[JEDCMD:]V&'F&:\>861CJ6"L<[U>AU-8TV>ZEVF^X?2,OQD+ELQQ3V\=8Q&
M9>R59RRVW,<OV"MP6NU>))CR$H2G-:WKFB5*>\];I\[,\X78I[\R6(@Q "IT
MJU-K-! F@.5_5V.=%9TT+8<D;2\@GN]*]I4T_W#1&B/S[4,L%A*][>,VQ))[
MXV<<' J+ELV?Z-;G)V=LL9S4B&T.G/"HU2LI?\IFX*"QI+;-/58('2_SJ]H;
M2"V!H793?M4>9C)9Z?OH1-BYNM0KQ2KE1PC$&7+4W,Q_#92X&Y]=P'OPQ0-5
MRCP]0A_X4H5ZTTZVSP;ZW;IZNO:3Z4<:*,Z[0;"BB#.HB\BIV/;DF\%%@WN4
MK4Q44YRF=Q.OK):JSM!%GM_5HYD8QDNAG+FBN\1J&LCT2%?&\=F&-JR2J&=@
M%/YDBA2WG<[%^LC%<%<=1C66&^L:T3U%3<Q[31U=<)'UAB:GYSILK;B6R2L6
MG9</ZXF.=<1\0;E'89>?W[IWX^GOOKCW(PQ!&MRZ-][W*H8\P2P^3BI6+>U]
ME6UEU2&D[0FSTCW';S98O<6VG3G#9K-\V6?Y_LW&DRE62ZLE$FVGF&J'/&W%
M:2#=_+GJ/TSM?C> V70%+E_G>4.HD)>#OF\R PX<W2*9G9!/-NCIR?[< VZ$
M6 U+?'&=9 FBI-5PD,'$,=FN']=;M%Y "OZHJ2D[#%27%]?JV2'=X.S$0:L.
MI.V;UR>5LL-^#;]E&IK/][QY]0*C;J8 J0 !YG;YE(;F;0WJ"'<?MPN^&3WA
MHJE6QAW7&BMIZE1WCN=W#TOB_<7?4V,%Z-B ,T@90H"_=>Z7.&?-H6ES#/V2
ML:-5%51FV-;1];[OJF3C.;E3^8F1M:FR(VZC^F&%UL\B>"ZJQ&FPM<],U)7-
M<K0=\XY5GE/YGOXF_4SJ:/:7DN1YCC?BS2)[<5,].LY[,\\]V(YY3'G53.ZM
M99VZ."F3]L5B3R6ZLU(%!SD= C[][&O*2 IK?2QE8?.E\YB-_PL<_GWS;E/W
M#(5CZJ0H\NP/^.DH_JHJ[\D2E;4VAH_FQ[<:]9J%Y0R$]%0<9K(3)6*RZQ*N
M81#*(8+O^4:[Q/5-=*N[(\LB5*[[W+MX3A'%9/GN$\F5< ^'4;VS(=LE09G.
MV*S9-SRT7-=JPCJXLHS$+XG<>GCA7A=SR4>>9\LOLBHC^)8L58@J6]-RCV;@
M5Q%> YC&V4&]I57[6L)+82=<Q,#K@68M5M/3"<Z!1=W\Y&KQ$6;/KQW<S4*/
M/X8\2(_SD]MM$.1AL^]CSM+^LK-?H?9NS7,DA/FEH:+^'8DO @7Y 0E$]J3:
M,W)#B0=-H^L!.3!3(X>][5-37B0,7\QGY&L=M45S,<UK/V1NQUR[8]7Y.2&=
MM!FT3.ADX!S>*/O9NV-I!CNA^M"%,9+"5%4_R_LIC>5]WHS[_)B'B^S,K\S+
M*5?<"M4?LG%HJ6O<>-=^96FKV_;=#,;K*^:LJV)E#UL42^NR?H1Q[]4=E2\<
MP_P7)2M[U<N83^1H7:LB<"$LQM1K<>SBINUS-65$ZR:"E&EP8ZK9M'IUWL#/
M"<QD7HOB5[9/:1]XXU'KG[7X\WIGW?VOKY<2-W5@_EX3?N 7..>2=%W.+BQN
MJJY([5;[TEV/Z ATK&.8O3Q>,KOSYY#VP"4?E;>Z->,D/@RB"R+Z=$MQ0-VS
M\PS7L*'<NI,)]FFWTQ,%B>.>C'X!Q+ 9I%UZJ4_YJ_H&Y$<7E:W#\:E.K"O4
M53! 7]HFX+@F<^7UL^+I^C<35B]UD27Q_=_'+46M-AX3S*U)?(M@P]U!W./:
MHV5-]7%L35[R,PJ<3WT$*L1C\ZZQUZ9FE"7JAQDWG%[T?FK 5%D'\Q:^];J=
MQWX^UOSASZMJ/+XL.&M%H$H0?!SS5&PXV):P(K)5MM)SKN91 &](1QTA4X]Y
ML^4L0D:>X.]T]'V9K273!D\LOWYE?NT@1_SZF;+2_="F0RKJ5ZFGEY^C;7&3
M_)Q4NPZJ\J?LIF;*%&GE,F_/8L6K/ 9E<4^_Q*+*?+V[N8+,85V<Y9.&HC![
M?$1_@E5E]0M>/L/WV>+*/*E[GPVN>7M<6P$'>,W81WWBCF1/CO-+LX^R?__.
MLQJSYQ<A^;NW_46W=57DY235<,.G9_3JPBW_.!3T]G?:[ZGPA08:0382US R
MH5Y+3EC)DA$69F%.F(_+N6:5FXE%B6%>'MG=BI4AP8J]E0)L#RO%S)J1MW >
M=A_OZ%T[K0*ZVG'<E?-XF,$YL>\)61T/HQK@2$-._';P,@U4R[.)F5*H5?K@
M]C[NC\K)$F>;X8JN>Z]M:MWBW?4%U)YJO!Y;5E7SCYI-+]W4J6^2.)]*[R+$
M03Q/Z!Y]CBI"B3V*+(YRQ[5COJF,/_8,T&Q@TM?B#5<\5F)6GVCIN,?Q?714
M,%F$_*2JX^H?P;H3&AJQOV$*C[(_^1^RD8[AI?C=^GMZ/S7VT4"-AF,!0<X?
M;DT^KT[U3H.B33?"4>\O_'$W^[<_ZS=QN>.-+4/H7D&T;Q!+Q&PR^OTSD2%L
M5#3J$O)P-,[AI92?5='<Y 3_O83X@_K47K&QUFT=%FG%ZA_1/U/"NS]>FBP^
M,XV ($?8S:IUCF^JF=Q_][KO4CO#E_C"8P9N+1NKKIUF))Q=K0PY#A+KKH2!
M4#L:<*9!4Y.0%WM\4Z5MU1#G&//WR0*HJI1KNF]UGQEE(8JWX+VU 93:;'Q
MSN\<KE%&DQ;8J&>9G9_^"G?![\XG"Y^[Y@N_V"0/>[?XY!HP)=W<8-$X,[Z7
M]R&B(>GE8X>+R@Q9G:4:O8LOJC\_*, ,P_J]+'YTU$Q)B9J[.Z>]5]@IK#.!
M,$U484WV2Z&>/%D>CMR*L2:O?UQ4;*ELDEV6L5RRT]I+W JU6ZZWRSM$N>O]
MVLLP[3(RT&N \:K(?RA>Z=#2&"=4=T .'\R_S<KW?2/L_#.7_XH/AUSM?&VM
MV[?4=[%=3$*W06%W%DN=+%9L7]SWXN_*.T;.P7^Z%M<E4]9CY9(]#8-T0!W*
MK(>NN>(,3\LV7>R./>W9XRGDLAG,E/#F<M4=AL\T4*=H""K)=:]=IN*0(:JD
MUOS6VO[T./@:"G[NV:U6W@!6.*> 9(VS8'C[B+*>)/<K;A]#SZ?5">X-YVTL
MF8M*I-Z%37S.-'WJ;?<^[(ZAHJ'"E/*QPC]RPE5>A]FJ9HR12';5&VZ0:[V8
M8(PI%'.+4M,=+/+XWL1CZ\:(IFSO;N&VXG.W[CD)W2TNBRN]2T[85T@A#+Q%
M@1>&KY!=)O']%5@S7BXS AEB8"XA=WZA]=="JX' 6+,665%6_F7,^A>!L&_F
M7]93)M/36<$N&WZ'.)FHX4IL\*?]BLJ0L4OR10X\1[L?>A9^]M2S^+071&"#
MXD*14K+#O]5=JUW8B!"X-8^KVO8SLQGVW!(=OG<NPE/*L@^;8L0?GCX:.\V+
M"J5_W7>;'YPT@UTU]A7CF^!BK*W5/%FWV5@>TS\XY[34[1P6D".CV_.A=7BT
M[QKL2\+9\,?>[RK3ZD]Z-8[^E*^4*;_,V_GDK,9';+YGLK[L>_"Y^QF1R&,S
MVH]C#B8[4MHW.4+%S12$+D*^_A_<O7=4DUO7+QJ[HH(BB'0%%&FBTI06$>D"
MTJ5&>@V(]!H;($CO17KO4D//1GHS2I621+J4A$Z M/-DO]_[WKW]]KWWC''&
M...,\P>,P<-3UIKE-^=<:\TY#0>\:*8WZ)INQS@[6T:HY-E-/7TG+/^Z4WX5
M'(7AP5?Z8#EC,N_#>9^..LOF3Z<$((8##+_?7>)IGRT166$4A[PT6-B9DUPE
MCBF*'U.@BSQ[H[ P-=_ 6/5YE5^CT?1T7?G;@0)%Q53#L#,O$_C?6!;ICGK<
M%3Q*T6IV'\DJE/'+[I=N'? R*>R]Y%QZ>EFFC-"VV-):@C;ML3)2%K(('M!U
M-2Y#SLL6\_CP*(<.7Z(-X?BV@AIJ#7SB#\&&6YO1"M6,G/"[.*D4G>A1]LGY
M*:/L_??/.N.'VR4BO4,S!P0E+:\7QE1D%:!7+-X^CW#D#5'5?J=&[Y@YV5,T
M']>XC4QJ-$CV5$FT=&TBKQS9*LC3!YR:GU&9NQ=CZ%!VW-Z@],4*\Z^W6,AB
MQZ2?YCQ\@+;@H]>Z4_<B-K"]V_Q(NR*_Q+YH,\"EWHO!L+P<+F =PC*B)"OF
M^"KC0TY1A)GW=UN[PP_R/H.N)DB7VP;/8N+$C+5B%R>>QD:H1_AJM\AR5+OX
M$7Y@69?%7J'WH2Y<[Z!5#4E>>M]YX&GD68OQ)'A,Z5>&LFX!HT2['Q\FPTX?
M1(YI*KB<:_,T#WQ:[HEF/<&Y)<#[76?>R"%JKN>>88LKZUN^\4QLX.A\$..%
M#\,L,;>3<S[07.&*+UCX")?)9S4VZ;DKRN*>IYW-6.YHP-#%9W(T/RB[^%P)
M6S:3H0TKCTLIAR?$/0Z0&.ZH0QG>3]H2.VCC67U\X"NJFW3RE."TX_SXP1HD
M)6VB^6CC1KW]D6V;.,,E?'!?>5%9<+70?!"7H.Q2QXB2NM#)H9AN*2VKCCYU
M[FM916-2?)I^2:\B5[N$%B_.==S8-#FF>:K]3KBCV<2QV(03N@GY2FIXF/L^
MSGF?/)(DH=L G;!I=:LUS7FR)3[F*69B^!7+U9_#]SKU1TEOKDG5]V.5VO:!
MXN,XER333 RI-.H'H=2.(VNZ56ZXV;=>O'=(7OVBL[Q(XUJIO:-=%SNCAA*O
ME@J#3?J2??&O'/MTFCPUI9FWDTJ.'/DN5U6LG4"=)3R6IPL?T2IX,[.\XTFT
MQ3O+Y,9XD@TFS7!3:_C\_95FC?>/XI0WV^UMV5P8"E3HKVG;REY_%*LQRS"6
M//^#DZVF56^;4.,',Y>K?AG -],*?M?I LT.W_ZNW]'BB;+696 V,J)Q ,_6
M:(__% A$Y^@G\K^/301=M9O>+W=M%!H+?RE;(ZC=JQ5!DYQ'HSJ:&G$G/QXD
MM\6VGQE&1.*ZX)+;')C/.!L<=-H!)7RSMBGNZ>>V,1B#IB"=8.Q!R19*?DXQ
MF^-^C;)#N-07\I<51!))$Y,>,T,!77$\<O3'TNZ&,!I/MLJA&5/";3>)^UQ!
M]YXMB^]#F-2BOY_RE#Q+7QUF=SS4?.=+5\&+,&REH#,V]GP[O[3">[?'14>Y
M-F/9WU,E$RRZ3&3LII2O"YTV*4>VA'R=J3(?(.+2RM/'OT[PP7%ITOIP#IF$
MT>[%\@HLCN=M.0.26UY2Q51XMB'GN+P@7?N=V1GCI#(O P^<<PV*,:UFD0$A
M**O]8O.\*0?+TT16^PKT)*NCL^5J,>=! 3>C%J.8NIZBAK)UHJ]>\:7FY/D@
MW9;V"XX\GFM<0?5'QIY0R2\M9-'(!3:18/?AY+-':BST'1>1&[R?L?II04EW
MIG%75Z #I0,FS:)+5SSK\7XI;3,N=Q8CY7XB):6KE-BKF\I>)7\,NO#5@M S
M-SA9T7O0-8VZ_&XM(*'U2*J!%O**.8M\A4/'UF:K[GG$2!CCM:9SB[Z%;XU\
M2YX7A(^T*@@Z<BNX\C-BIW,Z&#NOK%FE\@O=GK)6,E#,O22=<NYTMNF'RB\6
M4<XR2Z;-=DOL(2FW$,TU:'$$#4:-I )'0>]P-55_RN_L/7[:D"LAYOU'MD%=
M<:V/$\[^3+B Y>\RA#KQ.P>34A*-7A*#X85]Z'#TMLS3T8,/V_>'M1Y4V':K
M\#!N_^3M&U&.D==A7-;=KI:JO@9M7FRM&]24=N'A.G;A^XG"3A#]*?D+9\[.
M*!H4J\4$;A$1 \2!:C3.T\O+3QTA8+Q-WK(Y:8=7/)6H-3L\*_\$K@+E3_2>
MWAVPOP#B2EPX<,G(G_%[FUG)+YXH\**+V"H@R[[^">H^]@RI&4,(!8>H2VMI
M(1F\BU:D'7F*>>)"3M)X<>2\\8*^8/802<MDGSZCY[V0^2$U<WOW_%0 L3YU
M^ Q*81!>F#ZW]+'QLJ65MZAP6,D0_[U/?44E"8 ''_WRUW>BXUK9LB;1_=>=
M_)F]:_VM V,HOCK?M9=CYCR)1GR.GY/Y+UB;Q,<.790>UFY5$$A.5<[Q?)R?
MJWCS,71USXNU#W?I4O608!C+F[?--33?8HS8OL5 9+,Q7HW5TYD^-7X8IW$%
M^(Q70#_Y5(J>]7,7X5L-X<I%V[=?5H/:35\[O!Z\KW)Z8\4E'>6UC5R ^/H[
M9!V4-WC" K'8B+#2;%Q+_6I>KU9?354*RW7+D',A&9]N/FTT#!62?E_RY%%X
M$L0V$4_P& L7AT-?E5^(:[C;<Z7T7 MX/N&B4LC*\KC"NNRLG_V0?T35JPD)
MQ+UVCVIDBVIE[12VNIT?![^ZO5B!F_?-JI=[;U)C'43W3 *C00'=+<E874'$
M$GB9MFARZS9A'#4!]R:;;=UL)/RE A]6IV5\%&-4I%=U$IUD>1^9Q*01/B9T
M>;OECR>ZW'Y[^;BI^ATCU0DN\0P^"_?(6Z^X5;0C+Y0<DQ5Z:1S"$;^-E"48
MT@D[MV0WJ@R=KQ]J,\0U!W2U%HSCRQ*G_??#X0(WIYZ\;QU\?W9OOT3O3=&O
M::)_^6&Z0<Q,[J+LB7D;)H9XW65;A/R"EY#[MBY3$J[[B6V17>P#?3#GQX[R
ME(]KP\=7;\T,=[F36#5F/ Z^=\?/JDORQ+9YE/.%&?1?P&M,3Q]PP<GYFHBA
M&SZR12[B^Y=R\IDZ-MO"?#[>DZQ;&P:-J(Y^YQV%7*.5JF][AJ?S,)<D^#K+
MKF!9)"/B(\YL:7V<G(:=5_@PO4M[R'^;/%ZAHE]?79+Q24Q24W_1)F5R!DUP
MNR+G<M(HP3SBW4N6?!_FR:+" ]6;&LIR?X".3<CX=>VE<=Y9ET8(8?-8-5#\
MJ'28YAYK.79FPD#[S<GR\N/)-R)5SD;G\=-DT62UX#;>M6:)&WPU*UB;(M=W
M>H3T1O9,FS://@@+"UN]%S20LAFW(6DTI>IDLCM:ZU'W7,Y >;= GF?L?MEF
MIUS*!)D0)N_('7)?GK7K1OMX%B)83O#<#8C<F;<YWU*_6ZO';3#7B,_V$="_
MDK9QK.Q!Y(DF57KFP(H?0E/0#;98$^Z6F/S)8+TD9=U0&BG:+B/8/<1[YLQD
M*5[SL;UN&&N-GU\%/."FAL3#^)+2[-P^Z%3J*E\- <8G<TK,],FHWO%(FEX+
M.ZOP<:T_RK@->6(\!EB/UJ.NIWAT"5)3#P5N!5_NS?YP++Z*I?19V2CR":?[
M1HLIXO-TQ+I?+;TIUFN_NBRZATU'S07&)B)4/BH@&L/?&VP0-"/Y.=C^[*B>
M;KY$E"IQ<PV3".'V0\[+<'9)XT8VL,U556(,K9@$E'O=J(X3T4PQU)!O\WEH
M]M:H>D)*ZA[M8"A[B]-S/QTH#&[RHP/JZ:R7'6M;=J]S]8O+^:'%QV<W2=)'
MTC]D.O9'4ALY+1;;7@9:!2];-Z!OZD\)U4^:IWBI??2Q,]K&LI34]YY9>7U>
MS(.&(SRJ"Q8EU5/,[V=<*Y7D_4+JS )OH+.J4,<D(=/^N[I<<'Y^I]8%S_,N
M+XI+\C.J[OYPT.3[,*H\HJ:EHR,UF?^9#X47;;W<<5STY>-\2\47@VI5-E[7
M;]_I?AV=$U;4.*)SF3""2P^1+IBN>44JVY?B&' 19/5H'1R0&8TU?6K;V-SH
M/<8MP427)Q&<??5!3H0#?:L2A@)B*97B7A#?P_@E[)-L]5R0(8><$2GK@EC!
MA&W-N*_JQMI8U5&,W>[%R/3HJJ)MY@!9=@Z$4WM#VG,]2\%JGCEK\S![H^,7
M'9\I> <&0!)E9C2T%QW5ZY$]ZOW(E)^8[)3'9?R)^X[TH#EU"RW^TX4AA1H>
M$_ <Q"CG*:DD*W?AGO3,5GQ;/UJFJZ;-Y&>;@I?9OB%_3N& ]HMA)P4>]SOW
MJ@:T()KU15NZ137R&N&CVXYI*SS!A,1#%P\W@7;6GG.ONRX\6=W<\V)+_&EE
MZZ2?VN!QWVT9K?1B2=8&([P_+=6L7K*6Z"(NDS/X 86U:N'SN!'-W/L\8]NX
M^'EN[Z,8N\P@==YNX:CFN*+\0WM:<IRCS58 8;O2W4OQ>,C5'3TEXAFID.F#
M7T7;,6/:.ESCB5U?>8.D-[TGA416K;5)F%=JNW67@T^?MPX*S2H-M?8M/]?%
MPRPJ5B$]*+'!V:3_:;^EVK/=[4*:L!"6\'3CNC)RW!"%,1&-3EZ,3EYYE<I>
M*YLUII#%>Z;#+&1=,X)5#;8[[B7V!KE'BUKW#]:<#U)@UW,Z?.HYVJ_L&.=B
M/5=:^'S>B=%I1$YQ$RFIHFBA_3GY+:=+6KA?;>B#"S?M1DUT;^LG..2/AVP5
MZ?N^]G_<<SVR<@/?Z&?0/#%NT@YE^(:+^R''0:QDXW.177:6ON)U++0/K,?"
M$W?FB8!XC<&$65J;L+]N_EKYQV9^ @+J4;&/XT!B21/3I'?I!7E/RQ\4(VWX
M>;.R\ROZG[4;"HD+GV=G9#//"7TF-Q]Z4C5I?*,IP"GTY^KS^;#;,1JWN1]=
M^ZYRPGC535.<)U9%AA\?ATY:&NJ??.CI1U"O=)[:1U5T7XV>!H=8.[*H<?>X
MB'17RO1EV.3>L[Q58-&YN[6)SX)[]416HDE"3?SU7S5?6#0[ND_LUCX_MYJ^
MXFGF=N.. 7MHKYR8D+2[WO-&QQ)[?4G[6^^P\T&Y=C@+=1>_,.<XP;4B*85+
M:7HB]Z\KOI"[6;="JP):M3E=._J,L(?SB&IJ'BJ\.UG>Z56-37OEW.T>?D["
M\<'5*?LYJYC!4,D.MOP\W;A.VPLLJ3\*H6;A9,M6]NK[G"Q-L%=$6W2Z@*JC
M. 5DX'7&#ME@@?)S<9[05;7,[3=?X>/MP;%%TB=ZAL6:ZVDD!-Y.K>PI'M/@
M;9N",S&)E']1?72_B[[3(O;1?;T!O@\/^R 7=W57BK*N>.[AP+7H>1S?T/0>
MXJZ1\]"L9@/6[]7S^FE8 ,V=XAL-B;J)PP(IET2+9Y7-1[\(Z6HK#!5N>HAC
M+/W5.JWX/?<W#DA;K//U!B^P3Q57Q_3B^G#K15US&!'C"%_YL.?VF[J,Q_F>
ME NZ&2 O/.NA+70WD#ILC%SY(" V]J5_\67.7:M7KT?KF%'JM&!U%9[AU]"=
M#1:OB,*4P@B;.O1A9D!]:V/B5,ST-#9Q:6EY93Y>;3X6K]-M2!-D!8] 3?XZ
MZ1(-N>AU9QX;[F6YR\AIZ-2D/K+5_#GPH2>9Y;/Z!]4C0;*T+M3AAP%31$E8
M@9/B3\7MLM5\>_YE;[;>-CY'\Q8>_:&31U-Q'=)/M-Y6TU?3SMUF5Q9C,Q(]
MJ<._44<F3V*EV-*41,1G/<>G]_L0T%?9:G$7ZG6N;5BZ%&7<_^CJT*$2GCIP
MP6$M;^U)!>1G\/[@?F%[Q-JM7U/N?K:YOLUGJMH4H0V=U?4+:=8**DD_>MBY
MO[T3O0:=BQL_G5+,;N%7\C!6.0!!2V)[9JJH-]"_6([1.LYYM5CLD:@LCZY\
M3TBONX<Y/GZZGA3W27P6^@K/VC;OY?-YAKY$?!>5:FPZT'5>[(0)=O'&C9-9
MU=]B\B$5K&FSFHY+]VI'XQO+WU=W$(==.<62D09F3(1"^82<BM0/E\,MB=X=
M&NW7X5.)UUG&3L:L"6T+V JV_W*RKO^#<TI:XS51OKZ,WWND=P^:M'&^&CHB
M&JO@*[>/6XOO3L[FQ<?OUSRNMOD)^^@0K4<!U1W/>ZPA69MI[OP96>)Q,#D"
M&:2 YH6-L6UQ4\F0=SYDQ#1KI4Q<+M*9;>F0+'SSEI^;M=>%I>?%GY]II?Q\
M:,@=8: :_8$Y='3!I1D#E6I."W:LB^ZB7[G\6$?W61[D<D;M30%3,21M#0:%
MANV[H-FG BU:TSY=;VNHJX[(>HNT/=(22D1!+6KMA<W4A7;[!]4U7;-^2NK\
M//([_+@;94=,['=7Y)[]NK"&WMPH"W&WO(7U']\N'-1)7=?G9-H?D0_](L-F
MSMTI,&D5O^I)^B)X0LBG#M/N#!=RCY6G>_]$Z_$OF+XA__FG(23Z3V=H0_$<
M_ONY,Z9)23^7['U*T 3;R>PI*U9HP=C-L@S&,=37.L>TKNA1U.4$D]O8U0Y)
M_<"-XA\/#@/E+9LZF":7ZO.L;Q\%%O(9O#-R%:$1T92UH'%83BG>3:GK+N%I
M4"NZ("_QY53\1TMNI8A;>GJ!Q^O.?CWMJ'HE:G)<P"^(Z8Y\D^1V6=K[-,\/
M1%X4-SQLL^W-G*.Q0>SU[%7Z<!6C*_*O0?YF!\5J$\9,GGKXP*DU4^R,3.8T
MH1)..".EKIQBY*J3,:BK*2>O9AJ?_;;:R,GLJB3_@PX%^JQW/?1G$^X@O%"R
M]4\V/01=NQB4"QDN9UVPRWM3OO>P,(U>A2<C;\-'9B70::8\+LD643NUCZV$
M3JV;VU^L.?#4K\JKEO;<D7;8F4E9<A"Y>M_!1E#SD:8<D0_;EK7.$1E6*3*Q
MQZZT-=\@Y28\(>H]U?*FMZL&CN)7@U=!;&_=X[M>\F5"5W=D@,$#[%P;\\>F
M>('H5@5*H@%^RO,84<4"3D]_-?AY<)+#:O%$WD,> ^.[8@6Y-_W2\4$_#G><
M4)-<;:9(_ZE#&P%\[&WITRA/>QI3Y)Q0NZ?:A_E(!9NH3A'1L+G7ROV#RU\N
M#/'N,*Y%I;!> 4=T.>G4BM2BVC^7E)3,$=*[=(+)YR)GKO6?+<[+3JROX9PM
MZ%43_*S,E5UH+5(;R:2"*(6ZF'.-=7[XKI)'7S66DBNH_GA5,N$1M\Y#T9XG
MS2[H.VB8@_#AB5=O581E2X;JF\<B;VVNT_]"#3F*EG/U5_7<:81^UYLPV3Z1
MQ1\+<E?JP2PE? \ 1QVL5.T@:#S;>GML\#P_T&-E1>B4]"YY]08XK2582/=!
MYNR/,CW%QXDF-3SG>/I WX(A-R-KU =>3>+Y @OD/)&S7PJN?^Y^W\7@"K.O
M4 3]JMRW.K3\$"\S@%>:C'KEM;S4VL\!;6CQ]MR+@RKOIZDQYWVNJJL^.T)2
M&%RY\O'95WUQMZ*@D6<*GX@^*^SE6QWY1_A\<?>]A!_J06^OS2?WV1-:(IR&
M!PSB^L<9CAG!!6*+,BJR(B^,/-RGG\&?03ESS*D>QQK1K&BUZSD:\1?1Y/8]
MXC UQS0%SJ$)-8,2,UV!EV^UIG5NYE8&G50M9;BK9/+A9Q#]M9Y8KLA@%SO?
MJ*/_[X0@4\2!'H34L+,8169#N5) "%X'ZN5E:IGU80H(/D8\00%UYL=30&C-
MEP3@/^LI__N;81R\@XD+$WQ==@0IH"X*"*=).FB.PC3AGYSXI[,&$$CE@5H4
MJ2'W)Y*LBR$13=\![RHE_^.1!.3(80\%--TOJTGM8>]" 6W<@),6*_]ZVKHM
M[_?"V(TN[4B"5U(W)U$OH(X":EF4:'%8RCSD1U% 2%T*:,^CZ1!/Z*6 1D:7
MP$1#"4Z"9E(Y31L[!31IXF\(S"!BDI,P8BFSF"D*Z[N_0?9Q!J^.[.TNXU]3
M0 ET*> 5N188JFF^,C^S17!M@:[D# 44Q$P]J^WA0A92O$*M0KR%,]IW(:O&
M_CL#0W*5#O^4>EI[!K9EW$(]Y(H<3R1O&U=F!\*%**#W<\#CW'@P61 *(>](
M.:+%_/Y:+-R?0 'Y&1 KTPQ(MV\ #T?.CXG#9#,)WIY; .\=@2GBS0)Z []1
M0'T\_^J64+7WC0X'<*)0CYI_Q-Y#KJ0M3IK)GW@L>:2[ 29P_WDV_#L$H$UM
MVZ8#'7:"[$!W@(=<-T%00 (H.$DX&_C,6VI:0MR?]:6?4^M+ R+GGJ+I8XC3
M),;<">Q%K.X&!/"0CA KPSN<Q&UY"L@^$6662>23(%OAN\%$%4,D:6S$+^QO
MI\B7*O%/**#^CD'.W8I:"J@V:0VSF29\&(?A!6_=? %,Q$!G [U# 35^@PW1
M'?62_ @HQ*(Y-:'$P!20 %4/P.K^/5'+$FD'6XB%+;5D;OTX&G+Y;=;U662
MX_L;G&&P@P@E\KI ZQ_$98"TC@AJDI/W7A>X#4&2,;.F@/(_PL:2FQZV9E)
M]R<^4T";W0,PW"FESPNP2P2E ]\>-+4^>%T2<6\:-K:PMKBU(>5+$%]=0D3#
M22U2MK Y,10GH9)C#N.%6(@%+P'#FY1<1N#382,EC<#+(P'9,X@RX*6 :"0I
MH&JEE2CB\RE-TI*7<,,.-5L#8+<T0%\#\S7J@7T!:F[:&@6D>@Z!FX=[%"2U
M)*S]XBX?!L\^S-Q_DIY/S8I+HV;%61*Z,WW "\5,Q.U"DFEF94;4A@TP_P@X
M; YN2P%YR<R7^X$_P4@MN0L4$*EBGP(B;[/"9N!_R?2K*()YX4F2M&8 APP
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MECN+FH?\AE03PKGGX7MX@U & 'K_HLL1! O93Z,SLJ>>O?>!_]?9>PP.X2.
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M-)'F-1L1VR9_MLK8CV*"R'"B 0NN&94,7@5< 4]U>.FS_1-K-+[_:<372W8
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MP83&#7:'T)TKY/[Y10FRH#,>4(0T7IS/(NSPEA'L7YM&S5YX&/4$5B) ;SE
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MK[VZ,"^O7:0XCPLB6_3W#=?X.V^&Q !,3^&*_2#/)T6_[@>6-025\D"G;;<
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MVF<:QW)KB@4,9BUK$P%(A[S=#8+LU7I75BSB35]Q9L6UR -14!GLJRY=BQ9
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ME>WK*KPZ==0JJ7"8/29+SK]B7Q/3*[TIXF7WR9C&W@/Z@?QH5Y9VB^/E7Y0
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MZBR9X<'D1A==8[.#> Y!2&2 >?;>;)^2;^A-XH49E;7P+[IH65ZE1PNM=P5
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M_OY[V%GF^?<>QJ^7>V;0TM.<TT<TB>\;@L)C!3HQZRL,#@[D@S(9&!G6EC&
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M"CT_P0%@W8WQ6!:+2OS1C_<#X:278*W+F22L%+,)Y._;GIYD'LK!+JX=:N$
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MY9-R& ZP5N,+H?D'V&>&_@WVLT_^'?:&1M7+)O$SOU#G^$C,$5UV7'D&XH.
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M4KZ]>K%-1%ZG!YT,++Q@H4[_]->XO>?X^;:0_J >0\P-7\JE)HYGK%$8E:%
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M"M93\M=E \9R%&)3EQ">&Z.0!@UH\*+[/JT%2:8X2A"VG7!_E\7D6OAKS7H
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M-C)]7%HZ1N9@2P$ D.BJ?K\>;_6BXRQT1>*6WWJ%=7W]IJ55>F"#QC3GJYA
M6'Z*B5U5%AD9^7IM:S51:6ZM(.":EI7\<D#LS#"-?NPE6C*OKC5F!0<P@V?G
M[5W9K@2#(]>SF:7,&B^V2!)_&"DH4,\LB1P9JJM^*BS-EE39*HT02TY0JE$G
MIR9Y?)T#K=4DW^@A)-.3V%,X-RD25USPJ2K=X"-5+GNF$ZD%+7;?,F N\%8.
M\$!\L6O8O3$T;)<R&XL@?FKIL.!71%:VH$J7RD-?]<R72NFACH8H/B7LS#:7
M,2MC0_$8FM9&?/5A.B*]F*K' 8;L*S&?%7$ ^=-%K3,VF68<H+ L!5^* QM
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MB42T[:VY$K4O3J,7:B/LQSX@CF'>82]]R)#%C@E>/T.U2.I_79(#Z/H8OD\
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MU-4%9& WBOAJJB3EOH<MVI_"TNRLA?[W?SO& BS  BS  BS  BS  BS  BS
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MHQ,TZ_N%(SP!BPM.TX;>ODE(-%,7OX+\T>/-P=>$?GOIX,#=+G4\%K;U>(<
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MR/$ESXNS>SOU97V<[RU@Y&[I$>=-+RTN:@PC$$?9GFAIY.HPO[N'6PH[)7N
M-U!%^!Y CM*RTZJ&F;:PM-D#2%%K"LE]L23MU2,"V */7:W1+4K$*Z+:^E,8
MCZM$<KU05'Z:EG[L^[S\Y)IVDZ*+EW74\=@QD7^1/,L"+, "+, "+, "+, "
M+, "+, "+, "+/"W8&_L_P%02P,$%     @ #HKV6,RQ$'+*]@H DO<1  X
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M.D4'.DUWBHKN%+GI5#JP2NK35*= _VL[=Y[Z[)D+5!=/GP)= F!JRI7_UX_
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M16KA>:/"KD+@L*S,ZXTZET5%^N6UH%K7>LYL/W1S>\UHRJBLKZ]]_D[$DVI
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MZ,+DSG39H:*J Y'+\*4/;6W5]'.#P;_"R:%\R=XMV8UD$'UF7DCV>Z<^\YD
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MRU6O#W3]PIO*.7E0.MN<S#3$O9 7Q9OU_8>MR# ":BY5:JY@$Q^TXT_ 37[
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M-0JQ>V+<8'BO>T9;(;OUCZZKB$MYUYD8!B4+P" .X/DR(&8*1A'\XF@37T-
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MPLJ1Y&#W_%\#;5M>I7.+:<^/-;$-&;.VC4?N&D-(*R??]4(V:(7[@96:]^?
M5ZDQ[/F_;L053N;EYO/8O?*D=(Q? %?LE)6RK.W!![L->VK/KK@0J.H;Q.9>
MWV*TE4N_W=!>5-"R8#,7]#C@UK*+Q&U>GI:G8VG>IP:Z #7\AG1LX<O)H'M?
M4+LC*ZP]^)NFVY@7'E!]MU0!FT-KW:6#N"G2X>"F3$UP8.A=L9N@D='2Q-:R
M,FV_0?IRM"NS7[N<](K6[35P[:$!+3%?U@#!7XPZEE+>=9VQ-MPW^S7Q:,5R
M#' '6RW'^OJ/4U+:I28E+5;Q#-35LX6!HG&,+Y.,):M_":JRR=_# .6@)Y3$
MT,&L2EP2)ZIHBJ0P?S?7X>6YSQ?Z6E0J]IF9E]6=4VUW*#.R98[M*GR)+P.>
ML<Z;:A:&D=T9]UN:$$6SVM;==)\[6NHQ?5*YC7/0X+R8*&PD'X3SDWU2:G31
M3A!IE%3*;2:G0\]Z!PPXYA?,KAO@F)&2@"/<!']''])Z4JC\P+^C\@5 QU8G
M!\'2HXF4>=I0+6H[O#[*1Z 2D@A[SILP_EWV)DM4*>\9GC<UW+E4U'<^LO7X
MI)X;IKSV($#\**NU@5H8)4Y[\_H0/^5EKJ6$RB=.U#-,2IAVAZ,F>^8>_0AD
ML2LP958_XYGRN]SZKDC^3K\6QM"2;D4(T$OO(1GTT=YW&5>%55Q4Q*S"0OW*
M*NNJSO;+W-2J\H@['M&[.KQQT+8@#-=K0V(L7T1^;5-75;[]1E<9Y&TA2O<L
MNDU(5_$<X' '_SE!]77T-UV8)]D@>M"E@B(PUXC?Q'@\&12^/$%C=G?J:[+#
MD^H= C.C6=2SM]]L*W?^#-0AG]$5"+Z)3*3,8RH$L&^ 7%.'$$!^1G<D+RBV
MHD(?I<ZV'"HJK9\GB)\5VYV\;EG2%=YDD6MW>$W]V<#W<ZY5VM5-8_77/O@P
MFP!:>L9%HI/9Y>%#[1XN!+4\")/7UO% *,[Y0$X7<^$A.WQA<=Y&=PQ#@;A+
M^N:TD6JJDKW3^]"=21,,W\R[6U5HL/N'Y"^A?CQBF-2N)MZ"7)2*ZG8:4ZEF
MS\N+M\W>SQ.%Q_S1B7PPR%!GG)>_K!(XU-??,1O)W$):FX1!B;P8?(3O [S/
M,(+FZ/WLM+^#!ADTX0/QW&3MG))P*BC,Z7@EJ"N:,';QXD6[B5CI[+-M0^U]
MI7V*\W'G5Q9$7R6FIE@?FBVW^@(=<K6 K#)BIF9DFK!M (CUV(!X=XED#<.>
M(8.:3+X#K8)C]3%ET#0M2P9M<F[^)(-:DM>WCE<.EO[Q]A%@Z ;$J+#O#6#W
MM5K((>H?:=3DWTU+(-M!E9<F89T,"1_U5KL".[M^@BRK6-H@E/>_X7XCTTO[
MQ$A93^N&)[Y">)UJ,=F^,8(S8JEV7=LW-RV--+NEYLY::GQ>G)_6);Z@\4_S
M<P&MQ_8Y& LM1L[LLRU90)0M"1,G:I/_HI5\5S9,0XDU/@[NARV2WL:74R>[
M_@PKQWUM&1[6\2KUO&WFK^ ^\:C3OC93M'G!ZLK [H!N!Y3C60-0%3C$<XCW
MP7^KFOS[E@7>DT%BP@0T57T5K"DLN-['H$HH(:MCXXN[QYO9%]<WZ@=5Y0XE
MC'E6D\15CA*OR*K<RBMX*7KMZ>=FH+7O5R31%PY"VE"T];7)=8@X 1?X%?M2
M*0_AZ+S-*11N)S*K8WV5Q^9OH+'OGN#<?#RXXHVHJ+8GF(%*GN;QH X+BW"C
MYCY (TQR?CND+K8B?@LU&,FA<HM1+"$9ZY(TJ;QG(P5[?BSS+!J[?Q>X9,53
MD)(0)VL5 PNEA6^&WB2R"5OH'%AYX+/@S<]#&01>^+J,F]S+UN?_:M[>5;O,
M$JJX=DH_+;DXUU^",K'B(H,XIJ-BP.T%> S<:@[_ ' G]>)AF?=ULN+$3TG9
M8(E?QQNR4 ?]@4Z#0[:<7YOT.7D%4:*V9SE$'RM-5+X'3E&)^%V#2"2#,. D
MG^E9Y!-?G4WUKY/,-[,$"4'?"6!/^-[>Z ,.#7L73LYH6D7E^(_L1JL/<>N.
M)KJ%TE-71^_/)2A+W\@!LEG?D6*:."UF"Z> ?-V[6:NT7)92URL5A%:C2_ST
M:&.P=H57C+C4?F/:J[(?K&6II\EQ6]C.'?#FI/]D1KA!G 4\EUT#"Z00S-KT
M<>,H9;I[M/8?+_?TSOW[0:0B&42Z=HD,<G(=A^!*3-9(57.40'@,^7>W;.)]
MT<MA;4!]W0[O#@ZUU;H<;I_KS[>/\JEGS=9_-%FAI2CF;=GW%%7Z$VJB*Q>0
M]>(%=?T9@'%KH[8C48M!.SDS_FMXV,[6@K.30W?DZ"1&N8H@7%BU]0)Z0_Q*
MS>>+%LNNM]HGOC4]4=>*P QKJRN4E;L(IN>&@7NDM=J [-Z-H(?,0*=/R6H1
M#Z=A%W-W&9(%J**FW'QHYVA;+Z]_2[CRNT.9Z9=.>"^?M,"[U"H>IMNW8X5$
MC#YZO@+;FXCRB1H E9D)(5I4V7@H3KQO,!\$W62:B!,_-38MO2/C^*5U)HGC
M6TY&]\+KD=K$%2;/G(]VKP+SDMC8W]QYG=4[M HXO#89!$%_B$#P%"^6F9S#
M?/.=-!WR6O<'V/1.MFD]?=+K5]3AJ39Y5KFV;%%E#'4/X='W;CA>K6=[Q*J9
M,>E3& &9461N0>'C$7>FW\,Z70OO8 9?N0_AQL>Q9;;+^9=[9ZXLM.AOL+0A
M^338 Y5+6-XS<'*JOV1DO\P?9 PDU5 #(D?/TM9NPPB$@0";$^A1085,NHXR
M@\L+ZMB*JI9:I65/WW(U<1:00QKM[%B7B?0UBJE>C\O,=5'J5WP0,QAQT=!J
M>T (L$DIY"=Z4908Z^]#_++1$XYFDAS_&F2U-V7$>\!ISU=2N<C)MZ$L?_O-
ML'6E2,_C6+V8$>]!"T?;LT;A@K S L\Z-&6&:P</23<VR"!+VVT4&<0P+$X&
MU3^@E*X1>SS0#XAN!>"</T+:ZV9DJ7Y48E[Z%D[[00-6=5=, _LL2@V])\0D
M*WTW%&:2DKCO?R\?J7U@JO97MS-J\/ZG/LP#[6 #0%W),O_-.N(3X 3X[P6X
M!:Y/E:V1EM8F%P99"LNVI<B@0L(EIT%'F;720QE)/4V+DL%($5&1BH>/[D8]
M<SI?Q@9:;E_]!D1O+^^" ?'>JP?#%M;BM(W0^)&4Q"&OD#;[$C_[*9SWV%'G
M_<B%Z/65PQOW7N$E'SE%_K2[SY:G%+0UH-=^N13H\Z01 C"< EI_S\-YPW\*
M_VN7ZM*N(EV94(E5B>F%DNUKYI5#VME), [)38=P[?SL,H%/KQAR6N05%5DT
M4&?UU-7I8^G+@/6/DD&7O)XAY\"_E.;DPQ\1>ES3[X%.OZM: 8&N@*B6*1G@
M*:+#@'2=PJJ&9]#&Q(8UVIA)T^&$#6R-..MX^[HC(:!#>H_V78?N;)^Q-]%/
M7=?KS#<"@O=<0$1CP6.LB1'EM0WP? $166N EX8/'9!H?JSY9,QS.6$4H6-^
M'5%?GUM 7C[NZY!_]W,V+KT,YPYT* NIUE%>^6LY%MZ)OB(#(N6 VJG1W66D
MZQM_T%U]+.C1A(WE:;"_[GKG,Q_7ZQ.ZCW[%?>V<F8W-#J6I<>$U0D8525K%
MP4J_!:9+A@CSKAI7@[+_T:#(R)-!YS]N*$[AJK:07_R\5(>OZGU+S'?*'C>2
M_#*I)X-^PV14NB_B]@@_,L&^JVC\Z;%[=HP9Y<$$9]'MX9EA.>)E'+9$5I#X
M>JQT0Z-XY*'&@*:!KK*1J8F)D;#NO% B3QLTJN N3'OC0;'E$Y?;6LT7%9F
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M"BH6,^!2*W'6E[6V^QN1P,[E&ZH.MK)UJAH)G3^W]E_.2E>;9[&9GC&P/<)
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MF-INM.M8>YB)=<A?0W(:WR>Z!$IQK=.)#1B\V:E]<7#7&6K@G%E[JN,)"GH
M2?\B*H:?J33U$E5I=AR34]3WO-E[>"T@4N</^,KW0(1/<WC'?K(<^#AR%68(
M+=R$UEE:E3<[7".X\MO&/RWCY>.%.^3TK>RLA)DLQSZ(Z!O7UYG\7)@L)":T
MDFS<K[*T@V:$_(\Z@%RN'IX3,F$2>Q?$4QFCGQ@[(F^D,Y%I0:;,=UDX,RO#
M3XIYU*U<2Z2^S''_BV3^9/V-A\WM 7P63W]],J5)$E,@EK&*LOO@ZH/_VZ(5
M[$>%)"_T#K&;#$IG&!&*9HY][>J.V$1\6? 31Y[*W_C#H==>)$W6\$RSD=M%
M/+7T+C]C:2DZ-[^@J"CLBDSYD,E#96E@G>K+ANDZ69(.^"#?C0PBMJ-2L^V)
M3+@[\=M9Q?GM;FBTSG0&TLGNZ-Z:*&-065*(1'<;^&\36[K[?Q[1X0[J?I[?
M*S3AG,S:0=_&C)!!A#.(T-IY<[#DR8;N+S+(_$S^%TZPN4$RZS@'TRB]31/6
M-:J_6O*V1N]';.T4>Q=\@;N"(TDE^)]'=R:"+]_]I/C%_F;F]$S)&^%JY_'K
MW;=BAY/'B[NRR4)L%J5;<%'C -G$R0.Q3P6.;^(+\NBY(CZ4)," X[UM^=_E
M4$4 >%D1/,Q0#TMTZ(DI6 QBGLX0@OK&!N.(]0,+S;'?[>%00[2Y 96X[<GX
MBN.0[%S$%R7=@KM,_<9Y/B+J9[=DJ7"M8\>$FB-1++L*3$"KC\![& J_T:N=
M*..0]S9PQ.'D6'?@::_A#,L+>\]PAFBQX[67-(PF9BDD9M75Y.;=MNX,A<'D
M,\M-2I(21B08 EW#Z^DLHF2;N.6C]XQE; 3K?.$='_O=&LZX%XKSNPUT'%9_
MV&&SJJ/E3^LKWZNP=^B=RK][?V<&,//8B_]93YD!]7$)R;IQ!.MW0%U-TG4=
MRD6>C=CJK1\&^4_?9UV:<@DGR60DJVQM'PV\T*W."PO)NKEMFL[KE%ZQHF;5
MDD?#5!(TTU2VO\9([ 1_*Q[&]64$$'_BR:#:^O".QQWX\V^[N*^XZ"HD&?2I
M2%M*O4FB6Y(A.B97E$[S9S:-64J:DA(GQ+CVBYQ,^=N!#:!HG?YCA)>S.'$?
MO*R:F4\L)SF[P2+0FH=GI<TI3!>JH9B,&9G6XZF&^7F-(BN.1.UEM<1/.?D?
MA&DG#?CU= OHR[R*>VX* I4[FZ'N_<:O>W*!><9MJDC!?9^J5:GI"=WA5\,
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M3PY3M?:.K<QSPZL1F?>/]E=C9_D)AOHG8Q+*@D_" GS.NT5;95/]0P,1WF_
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MF.B JH8=W3T%53,S;<ICOL00DSQ51B;%&P#)"@(20^<TV\1-*X+T)E#!T^%
MQLO;C?6D_ES!V]9S2E@!M*!C+9(8:W&FU9ZTZ2$NYE6GT<?!^4?E]<2\D=L
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MN0-<LF:Y!Y.\0UR?1R4R^R+[GOT&S'M$[G_<*GV6],_H:01RJ'_EY%!M")@
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M3?G-3J0B/Q+8O^1U+]:0^C/[="#+' DNO5]U=(]&BD2Y W3H'SZ[\>T+[SQ
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M@+R\-2Z<9"KN[CH(@4"PYO:ZNFBTJ$RTTB_>88Z(CLK&<L[$:&6.F+,ZS9!
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MHKIL7UI.$_=$)N+UNI5OA':FJ_E6+2W'$X=L=XN;R6%?F&7MF\IU%!YDY>4
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M-$]@)N7E[XT@C/XI8(F-S_U1N=%\@^%A#U^PQX5E HE $> ;!.RG%>K^TM5
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M-+*:S+$U!)00% V4\(OZ&.2N-MP?W&O.IAU9QK1D;O+^V00N]/JSW_X D+H
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MAEA(7%!4>"_9D!X5E\/G-@8--PB^8C]V3?J>/J)=>*A36IENFN_Z-Z4[:4^
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M]&5,2;*FK1UD4TFASDKBEBA!0X#M_/CQ^-H?0L1HOF:!NDKLAQ&ZL^AAVKO
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ML>6[6^NI)[N6"^2.+8&Y83_YT=K-L<- .Z$X=%J58N:)#<9%T0O]THPS_\9
MKCC(^__<%11_V Q+\*XK<M_N1")..&JJ@]2)= 8KU; 9YI(V [37! MB$[TZ
MP+R&NA<15:"JF#).O1@M/:2^47;/LK/P&UB/%+#VJG$K'(OD@B9)JY8):27:
M/%BWUJL4<*'7;OTWIS#GX0S?UPK(W9Q_?HN< Y+V,QR\<YVHL\G[./8)W=(Z
M_AJ"HVK]7L=;@K,=!*L>F9.6F&%C'<VEJ2#F&968+G]5M*5%BVF/ZLM7DP^)
M<!^Q3?:H9,%EQK<^\ G6W,5^8_@U5HZ:,IB'T_C 5\_L=@$AE8I<[:RH#)VG
M[_Y-9']MKP2P%B7:F,=\/X1+!KNF_.F&Z?]KCYGV ;(+3K1LG\BLO?D;V=JR
MD5ZCZ_9HQ3@U\)JPK9[3_0;KQK&-T0(SQ(SG"ZG&W9$7IS]NT+EN?:&+@G<3
MYI ];+@QUNU%;/LF8HJU+D\^O*+/(5)_N=F3SWK]SL 5&[3+\Q'1B YE#=<7
M*1-/J3H>_K_;W9G?J"LGB;O5OXM;'%,\PI ?B98#TH+U.]/P*'2/W90;@0%R
M5PZ->9".3CNCJ@E93WI KVRO<[6UR!$(I_*J1AZ2R[9?(&*!SG%?;F+V]/)M
MGIN?$84B%-#[O?OQYZV3;_[CDLI7J'00>4'.6 VM\WRMCW7:.^OB(!D&OB(.
M;5?!?AT7##/6HX"8\YTA-2NKLDU/19C.O+%)+S+HR"O;-BK1DC>&LJD),BOZ
M9U]XP2W90-VB<+$4WEE.5#?9F9T^A@&L^FSF+;[6][G=&VH7G]4'<UZVSO^#
MMJ1O7X[)\B)]J!@2YJL8O UP0X-I9'?UG#B1>&D,R2]AV0[YE$BD'1[62W$T
M=$M9U4F\(R9WM9MT_PI#,%I*+_T[ ?Q-1D&QJD:"NM\J&0L'>OC- )&WC&SB
M=JG]-!+CI[8_MC-7)AW"=1@D$,84E&3D-'0K7\750)F/R^SB_<N1^Q>'J?.]
M8NZPYWNYG;3?#$?93D:D+]4<'][3O:B8:^4F_@@A('^H5;R871!\I2-;CY_7
MC.5W'N+%+RQ:0F<%<*1GL+9M?RPMF5TU%7W4@$_.\7J$=1Z4#Y^2=*AM>KVP
M;FN-FE%^FYU7%"Q8%Q?%G!.E]2E+Z&&9\@,H9WCO5L,0]"F@!+8#L;?K5,M.
MRA<.@6J/-.1/P5V\P=Z;_?4G4P.%'130;;3-:%Y^FH3U[HMAH2NY'9"OYZEL
MU_L[M<FP$./L"=\)_ D0_6LS(UM@C"RRX6!EQG?+:G01'J(M9JNEW<]:0;QO
MPQ2@N<C=<I8*/.$\P#]H.2R1E@+BV2CZ73BM#_N8RA#;;U8N[$ 3Z_<*>4_]
M4,SYE8U%4@9O&1T-V3JAXNN?CL-[,2@.H-DZ7(.^9P8H(%8W+=D/O]A4QQHD
M2M\6QO.<CJV'0FYS1ZE@ @75]=79[@CYCMBK?:D8N<F8I,.5%8F@CM1%KTO4
M6#ZJG#2.GT:R-X(WP@LWWRR<9$Z<S#KXKLPLASDH'55JZE0J&.'KH%'<Z5^U
MY9[;/>6D*GO!KMFEN9W<%3:'O@Y2^=%F25U7]5N-$76[M;#%2O.\^X4>::C[
M)P;HMS]U/]$5ZR2SL;@V%KMNA3D,3'H[FMC+EI:Z.=P-<=BDC:_.JTH;P1V-
M#$#EP]HU%93DE5Y]B2H9'/P9^;VV+(\1"-J!V].S7:9$L^W-DYH3L#>)]JBX
MKKIO.RK#=R!YREODLO[A[HB:C8T-'RHWRTL2;8DVE>X98#9PLA1<XJ(N,=L<
MRR\<*I*LQE='X7>]0HHPJD4+W5J6IN.GQE_3?[Z+JRI6FM86N";'Q!OGA;CA
M>8<[=_#J#>K@! !B[/_SF<:_AK^&OX;_#<,-<"RRY_/O[:8-\A"._2%9<>-5
M2)]C@0QQ$RG?H. %I\_*3M <[H8(R#*\$#P@"!>$%!O8AI8%1%[U+G;)(=XD
M8.?I6AIF@3RTZ.Z[X9 U([L XQ9!E4AGK^G8+>*U7P\HL['[I[E@1LQ0IEP3
M%U'QR48(UZT$ZIL40N  ]FL2:6WKQ=&P>U5*ZHY%/>EDCA+QM#D#HFW9K]/Q
M=%H%J+R2#D%D]'' =5K'>U>"VZD42?6_:83+!5(X4>@7EEXJVLF]N%-N<-(7
M/"(-N6Y^Z+:5TDJ?9/P\+3C\GU&5^G!%5$RA+!NGIK;68WZ:1U-4?(:UOR*M
M]\<TL(VRWY>*R^4W'C5NJN0];&SIL$"]"<[)9=1%Y:UE9T8DHAJ7KW/I+5T5
MYLB+>[)(RP*4*WKR?TFE<W*J/E&KB*^R#!/LG(W/MPT>-:S.Y#45N7MN8<:7
M4YY':S7)*T$OB(DZ:XV,F0DSN.RYQ/S*[-74EGG\HF#W@=SZ] 781;*/CQ'9
M5%90T,]';4-^W-A7H<Y6G-O!H.O*AK:?A) \F^R+/68:-\4K7FCK,"YS,34S
ME/+;O. 7;C1/ 2:R^-_*MF_LW?!E?OS5N6NV:#=XQZNI%ONB]FW9Z? )-O"(
M1Y9/X&+_F-GNXW>K:=&,:BP&/DZCPYQ.BWR]XG*WI3A1^O_( [EDZG_J,S#?
M5-(8.*Y=S<W>'7* [-T.PW&4X1F&3$5PNI(8H<Y'PCE)#U90.=UJ90V/N+WT
MN)0MPLOT[C+U1SW-NWQW?9J=AMOY:FW)44-K%8&IH:F:D'!45F.T=2.##R/5
M9?!%_RTJ&_UIT3\CS6I<QDFQ)SQ+..H?:AKFF(XE#5) \72O#L0U\TY4ERF@
M-DC0^-&=T(2PUHI#[NUF3:T%OM]A%JCLSGCTSH*-]3W7N!R^^&^K\RY1KF',
M>L"0>7T@7J%IN'!-E\%8*;IU\<]\AZF3'E'#QBO8,](LT(,[+$G2)$Z<)CPK
MGY<FZ[_>0,X!.O9/HCL%1+AUQ(,W]!ATG>THCFNX.C3]R5 !&O79U-&W/3RK
MYXI7,]\ ])%HSTB$O,';&,WZR(R^=_$_86W'OF,8H09#')O)#"N=HQL"XG:W
M>_-5]70%'%[E/@LS^[-[E'3T6=1NN'+O)A0B&*Y@]K[(0)(A\WU1029 F-@7
MP?WP /@-0@VD<%=WB?VE2\[:E M[:XFW+GR+QO>:1DY$#^]HF8QS[R'68O_2
MS^B$+U#!3?[X"U2>*./J:.<:Y&$GVS I*S;N+5@I->LV<$J>F/7UC<[LGK>=
MIQDHUQC[!9$5;91DB/Q9:[6H$_834P8$I_]V)%Q(CM_G1>O;<AA/XW-7]A>F
MAPHOANO,ZR0DGP7'<^X-?+,)N""FUJFI5U%ZG5 AA/F9;:#QZ1/@RWP8_D78
M<U+:!$>9G+0[HY'[FU9FWI+RK?"*[@'SU7^+<JO3 E%_EF,&=9I0:C&$?Y:?
M=NF#S'D $E_<@4B ,_AQOL/K(P \\ K*?$ @.VZ1?&-3V^?7G.XGTL0JL2FH
M"X_J%CY\VBF9&_R,YFU]]O6;@.+(P[*2K4BJQ,^(WD6RH$_PVMV#SW:%(ELV
M?E5]KQ?1I?EZH7OVD>F!FH9/8ZT*3*SG0U480LTKD@$(:]J%K10WSP9)!Q6X
M(3O[**#Q5.G:NJ0B=$C^CG>."J*VIUM)]H+8\\%65>CKV6KUZ.Q0QE]L2V>N
M,O@"K64M_@^"\K^&OX:_AO^-70JA%-!.%3F5(?7>CN&BG1B]HCB=_=:KK,[Y
M-?D*YHM3'EUW1B6YPCC,W3*-44:ZAFT94L$!Y^O02->M/!CY5@!!Y+U/XD;_
MDGO-][[1WR5[L&[3@CK_QGAZZ2KHS;IJ4YTE$8<./NLI[5_/($\C9.?EK):'
M-/-J@J:]\\^3W]9MTY-ZP'/*V"ZLXT;*J,2'.2NOYG1WQ?F@?B6QRTVZ2N3$
M,L70AV%W*EV381\2-5Y^<F35A#)FW*/>5E<V2Q"C@ +X23?(^J<C$NV0?O^-
MOJ,M-5H^;;>[$VOG6Y-\*X::E+25Y6.*.Q<?S)/Y=96-8J]"KG3=#X!MF?N;
MTH@ &.B&C=,E>!X%D(:/G3T/L.TDLJ6]&::HYK7[)3TW#8U?*U6#'7Q9Z1TZ
M[5!M765Q1GZH@LRP]J^>@9<E_33S:65)Z#@ZURV4;35VSHP"ZHXN]+9T==V:
M6&.//"VL="ORRSP_C:Q O;_^VBPN1C"N_*9R1,^0=J_JZ^/,;+'[4?\'>^\9
MU%;3K8GJ=4X88S(8L,D9DTVVC<F(G(-EDW-&)(%LL,DY(W)&B&"B" 9LHLDF
M@T%@LLD@3) 1TDC?G*_JS#=GJN;>>V[-G*KW[ZJ]=^]>O?I9S^KNM5J%P54K
M.8&,&.(CNG"4?V%_XD2PY3AS0KSN[U-TR)"4VXVMAO=!4G<6>T=634F5-&-_
M^.UU-0HU_=B^%Q'&['A#!Z8?6@"3C+R3OBI,^+#&X3"Q0M9M/.!V%PZ,HE]J
MNSI-S(Z[.BE3$[++]%'NZOJN\W&[QT&8D]CK-)NI/2R;$TUR:-N.@H+9W*^B
MD'WF"!&EQPDI]2'[;>,<;'C 77,<*$J!8E8NFHE_VY&QY9E5B)M\G5W! ]HG
MQFO&G&<:)IZ\V@-6>KXLL5K1B*=08DY<JND9CLH3VWAZ>M?2<#>G ,/749<9
M=UTI'=7J=W0. 9WY^T=@O6D&8/VU*0^L>,J6=:7HY/AX"A7H)B-#I$5P.R@C
M)CL\X"D>\ XTU(5APR(PALD[CS;]L59=WBZ@2TF(_^B4[HHXY7U#EZ\Q"WP?
M<EJ""UIR:;/[I--W<V0;87X0(3K)9+L-164">^+/[4];+_T"C<WMEVO!66/-
MSNOFLFF/9DK%@XZ7+B.F3S)^B=L<C*ZY/<.^7*NM3OFF%EL,KT04Q,)R<J@3
M83DT6PG4O44$QOL+,0/MG)%+&X#>=0+U"J35%>LKQ[%Z3%X(9>1]S$C6?#B^
M7Q&7^4)^+59>\S$);8RU 1N! LV2,V'G9*EFH )TH WP98BQTE%HH4.CW_9F
M:4R=MA5+->15J_71F)X*V8*@S:K_U3N3HH(9D$$]N_!R@I/51FI!.P<(W$_<
M$OQZ:?:BND16\R1T<<&8\\CMX'.J 'E&9,JFDF]1><\;=$JS7X+Y*U*&:Y13
M0&U6]W%=_4*1*,(4_YQ[6*BYH3\=F(]=Q\EM" 8&=@A^P@/X[W_K<PKZ%L9J
MEZJ.G?<)D&^VS;R3$ZBMI*TLK=P0?-.XR5N?CH@7+8;=<INHP\TU/ "-!^SC
M 1LRK8(7$ZMQ+[S$7::]%G=?3XA0TDIF%<OR.*[!T^@UP\HK39J%/%Q:3%2-
M*#^/2GXSUGFR1@";*6\O<2RO)<;Q% _PV).M7@ST6T*1-"!3_1DZE!884H#O
MG:CXMD,N&S26<?09%?">[[=?OM#5I=.75^%%\%:?DDT:=!&^T@D5U=R8^[XT
MH%;6TM7<.OKV%&GE'#N]>V/G\W4.C:[0\O+(,DONVH*"/!MA&G]HO8._DM;8
M(,N.U6][MK"6,_VN0T,<)<?AV>;!$&/9N=\D'L#4KKIWB5HPOI<J[K0O@[H_
M=V%BV[TLA/G1[R%HB;SN$YG*S2O2W0_DTZZ/_Z1XX^W-EC/39\0@*@>::S@$
MW#GTQ!A""O<7JP?$2!MVP">DAB<Y'G3I]K9]Z^(:BIDD[ :)]JLILA>DT7!$
M=?'SC\7PDDC6\1$&@GF,"V/ >$"G(QR:+HZ.VXW+U3G5M-P(,CB]SGB^ *+R
M[W*<?/OKD+:Y\?-4DZ^@5+#Z\".=1GGQ9K>I2;T)^?C>[]^W2U-+5,.O13$1
MYCT>,)6"!PR58N@)W_0(TK?$Z8@)VYW)W%^+<L0:]EF*OV9A2?Y!<8'SO^>B
M2H.FF>6NT9LC:1.9D]Z[YZZW-JRHH:*4J1X>0="R$I2?Z1P(1N'>@ 8L@R X
M%$/?[%VT$G3,U;G_"&GSLS0_S'F:?;*LLHOO_K9H>N3GK!1C:=S]]E1:.]N2
MT%!A3:F>^.>3Q,"L=?1<<72X$@] Y5)<G*UP6-L(M\86K@0=]MA(CKIM;+>?
M0%L#ZLX+54(*X).[OV=YJYCM4[Q;^J@,;BV[7^EY1'!7+A*PRDSZL$$K^[R+
M\LA[5B>?=#TOXB@TF?NV6OWGGJ_F^!*=VR +AA7*OYB'@S(0HI9!I%PZ$]3G
MOE2=&\5O\S2EQ#F_+&L&&Y-J+\TFN4C#]UG=&]INF;)&G/W%[WHHKB#I_[*#
M4W1I$[J>15">?,"2M]>9-1X@S!]<O0O+Z3\?'F]]^7JZ\X".]M;\L69C;4H3
MW-/7G;M6)Z8KV&@SOD'>L;@HSX".2Y\8F3^72R%%K\()_HD3VXJY1*=MG+F?
MXD8[G<UZQ%Z+;)='6ZH*S[<CN=AODL<.;@@V9WG-^]@ONSW4D7DD A?6%6-5
M,-9\,$& <B4\ /<0.9_==8@'8%*QJSCMRY3F3+FZQHJ+HM7KD#C5F@/^SR-=
MP8B*KE5NCH2>^S^_-KQ"JS&6^OO?>YL0K78K#A50\+&Q788P>Y>5.P[SXM+F
MJ3M:-6O N;V+87'>@Q%X@,*)"/FP6AW8Y76FS5ZT 2F'N4IJEX4';46J(N^P
MZJ""$4/1<(5[T1#Q?UXBT1E]IZ1H,T+7'KLNK:>]:#\.:,V3\F'1GAZ?W-^R
M+'08"M)U8=B9R?#^:$+'FPI.5(4Y6;^J/^PM,!GZ4AQ*84],#ZGJV!S%LBTY
M$E#^8$/N,\[@3&!P9".?6+2\P8Y;.-LS$A%<[;'J,7GKM]O/TQZP10A;6)>S
M<KYMQ0<5H"&;#!"H+ZW7+A&C&E#M7776*Q!SOK1.>/=.^E9U)!.9%,C[U/9U
MU=[7DY%]^+ F@X:!](W]>9&4N5WV7Q!I/9H? UE.XTHFIGL%);'*OTH=C!P>
M:Q.FC\(,9@QR$^-ZV(J)@"BA.OC:3:UP1IOM\J>K^Y4?DX>MSAAU"EW>NL]/
M4!W^G';ND3ZXSLK4,_GB.D<L[''T0Y%KI 13#327^;^#VOTM^%OPM^#_I<!D
ME> #*OQ-TI!R2=2!MIG7YG:1KPXJ<U'/;N7I"X\/WO<@09J#[@K)16LOB_-Y
M)<7S3P87//T&,B%\X_A!E_>9,Z3VA_G!CPRGWO5%;SFR(.X]\_6DDGQCQ,^B
M'^=#IZ,[T6 );NFIE]'?^YJYA*9N1>4I =.$E8#,HR*,.RA0-9:-U,$J2 ,J
M$5,]/W]D.V 3)(PU&G3A:]6]YL'')\/.<S5L.Z9#31AC;+32..URA^Y5@O%&
M;(I#2<K.$[]2 EG-QAI@WK>U'&,*L#\P2@DX<Q&YH<$:<9NS);+)79+!Z$$7
M29)665=OU:F,T_RXZRV/)MND!6)+$ZUBGW%ME[\-'=@FLH!":*>?O_S:Z2[.
M2N[9849U#,/JX46Q[%NLT5YV=>R/^2C7?76;L7G[)@\1X9\U6BI)W:OP6LK9
M6S9&G ZF?7J3GZ9):45UD@G_$P)QVC5#HMD/7F^<AQ&OB$P5,/-94CZ=#F22
MTFX[W6#O<%>Y_V0U-,3#._7DF\[$A/7AT82!"J=R2>F5YD(R_;<\R]^4" [(
ME!K:^=&#Z4X "$?>>C33)$O]LY%=K>AIZV:UY$2!CZQ8+)>0;V!S6)1X1)IS
M^TO$:$JPD[/UM>2Y6VQE/@ZS-GZ+]FJJBSLHLU%TTG90Q;Q</\^JP-N]]OJ=
MRXZ.,W'TG\A<]X,L=GH&E?1O2MK(Q8)\GEHW7253@Z1)W1[>8&,:Z83>W;O,
M"01BG2]WF 4*[6"0?0[E)]T4_<$0-]4J[GY&]?T7=J1_&S<Y^KTOH7]/M&+6
MM*39@]Y7/RV$-KFD_\5U/>_D+4JCQ%OORFZ](YY5$#C7\.G4C,H^PQ;+98+<
M3DLU=B^7%IXYY[?]6;(Z)7A0.FS[7/[K.J<L2JDW:SJU4=?32OKU8$4$+?49
MC/=HL*<:P9=C9&9:=C!\^J-R6'9/S.J$<O_/ N!(O!(=<U!;1'@":H [P\K"
MR<IC--\RSC#VV12!>XKF#FSBEJ_BWC*=5NT+7$XM7Q)3JJ!I IUQ4:8SN(=C
MV"Y9A7W&I%D_?ISKP3"$81 DSZ"Q4F2>RTC.\K&X=VU;NH$&)I(LJ4E"KMMG
M^&B"3V=XC9B/_!C[Z%Q[$3JDA'L8TNZO5 !?\@&/#&&@F;O#437;",LBITG?
MVX)HS0]%\/(V:6\AW9E1458=$?=170JO7COI13L":^3! P9 F"0LV1;?X-'%
MS[1C#]SK;-TITXM5 7N+\A;DNM6%8J;#_G!V>N\ZYQF_A)0B511M9LZS8_<(
M!#>3CG)PBM Y#*E:$4((\KTZEH$7=ZNYY++%T<G/8M+JN.!2](+U'@$+J^Z3
M7(S^)NT3P;3;0NV<+]=9X:7.I&Q*R?VTX]UP8FI%- C+V\O0-MYQ.XC%"ZFS
MVY8[C?*98V+SE#H .Z,^QH7<5=)/^KKW#6Y77EK84\G&IKYX+PDA<C3@_(C5
MN" F"150:1>D?TKMC2TY!Q[IKLIIX@&LP-6CXR='?^Z)NK"L=1@YM8V9-XE[
M7_-5V=I9'YQ^4<=) FE-XA*AA3L"]88:!)M"3K>+.5 !"!B!=%TW/+VOA".?
MQZ9:[3GP+<7LJDI>UGQ$>3&\:U#+"2UEFC%6)65T/+ (KD$C&(0BX1RQ$E:Y
M9HG,=0\(!C(?AK&"\HV^1]W\SG3_HJY4EO-W!\A'E+H/V$R(&]2:[DESM7!S
MBS-.%SHMI%P$:[*;LGK<J'6VJ"JPUCJ-?JQ_EP )K<0-%\.X<\->'JXDG,9%
MI+HUI;65;VZ"% =/BDC"YV Z/:<BH,@/ROJ7B<,T-HZ<K&:+Q##@&=-A5MMF
M0QVTG_QG>P!#4F$(*?+/O-M;X884!?O58GBGRV6_?++H#9T"BLB"1$,AB3MC
M"4]EQ0T(43"YZ[FAC/0% B-J@[YX$[W/';=VOV]!5/\<3/G@,K0B2\Z+]4.+
MS+/4 @$CMNM=KSMQA.8DF0ZS]X[JCZ']I#][U_*J/KQI/-#=./3;CJ#\$ESX
M5XLXE10_J^+ST]CR4,M 5DGC50'Z0G$"\'<3@/^Q((;S0A/S7E^-)3"%OV>.
M!E-&FVO.IV;EN6MBI'R%7"^!4OY/D<@X%U,]D>S]_FNW\BQL>[]E"979]&$/
M^6?'VMIGT=M>$0YD9 Z%?-2*@39P!&?7Q_7_(U=':^E61PIIO^LF'K#8(1*D
M\5M!217R8AO[&OMMIO\EO=!YA'! =JWWY(4E.0G#T_+4Q'O.:L6!9F,3110-
M>F/R+[B'?A,KF%OA 8=9&E]D2-6P6]"4WMWMW0>8NTK?S=-:>:3DG<8Q'N13
MNZI<C8J:MM.&%<.BU@Q4("&'&NVO&LPJ:X,29;G[<'T"!LAT'(8_:A?YK32Z
MASC3YE_M]*$:'%P_(NG^_7OJW DE^J@VOXYY6):_D@H/^!'\XH1X)DMA'N,U
M#X9V]LC:;IZVWFN_ZWQP?SY_@9;7=?\%4(9=U&U*2Y/9_*&1QU&;5.&#3CN4
M\F0H 7$M\( /Z7I*R(Y,N6/5V>8S)Q=TIHVMD%KP-QXE@^^K4LS<3A]*N*Y\
MH\J!9',W/S8:)41Q6L0U2E!V(RKWL'8TZMEP59= P@_ZW'(\H"WY?&G!GQ0Y
M+R_PK()LH=.0TO#:IGF'@UW<V#1N!V6*!V"Y2#$H5]?U2Z28:U=<>*_)$@S$
M#*YO5A9G%^-$<,P%!-7:U^CYW3&QX:5WW^!A*:/I/!ID$-+6U!9YT\;"Y+T?
M+W>8T[%VNPG'N&$OERX^LK7M$S<2U%WTS<7L_OQ"BD!*Q9R.RZLR'%_"T#KW
M:S\/^DT>-6,1[PG>:"X%?2<!;6.1/5:",S=$8GF.<8-U&'F""OL(N-86.T+L
MUN7?)6+^%OPM^*\M*/#&=DFZM*YQ?"5-;^.(@%)!:W&BKC*(AFWIE]#[%H5_
MF6,9H5?=Q4/8/ZD4_&S,?I(<WT6@!/3097&YP;1ZGU+T*<XKX?3^X,@NP\0B
MZ@E'W^M2J<)[A]-?$TOG,S-91#UZM![#VA,\3IJ,F>-TNH=5-[AN9F012(UM
MQS(U$V4K1P4;9F_!/'<&DYW"9JXQLAV3IMU<XSV[O=T0OBF4,1UU -^"J;O)
M=4;SO@_Y-K[]7=N;P-"TVU]Z@8Z?XYXS#7>M@89(0_$ FF,0NZPL-B?3W?HI
MV1LP;GGD3<>[_7O#-SQ*738?_]BZEQZ-6QHTYF1/KC_1FSPP*?&UZ>\B: "Q
MBC/(%9?+U>PGC>V0"/!90W;Q(3^@R(@I\!#.K[;V$V]'$Q=KO@-57M25/37&
M**A?R)3#+2KCA-.JU-J40GE+#.@RF(BYK[50T8YTZN-%C.Z1'!@/X-=,7QJ4
M]P2/G)0-32QO2?5+YGJ3[%#:W*EB\)-^WCT.]>D(M^8HMF/Y9EGS^\AP97NC
MI$2E?<LAKN7,H!3-@0%"AF=S#U-($HYL$)6>K8BU&3.P G6_\\X$O0H>$&MC
M[SZQB?86I8FT*M9R1*>;,>IPPV"J"MD%#OZ1=(J53_N(.Q&WH8>Y>$#BTK!P
M_1]+/ZPQAN6HO;"@G0DB?7ZU27+3:K-62LK]S3$]TB=P7>;^7SQ"?KWP(D02
M+=+>P\+?S*W0DC>Y(4E)1%1DD)K@.*-P#_& J;;L&F+X<YS>Z?JZ>2E 7CAW
M]D3^>@2*)CI4MKP^IQWE_I>*IJ'FO0;QE&!2.F3%QS_$Z_6\6*"=5BVC-:>:
M:$><DZFGWPGN[(=4F*CIYXVNGSZRW.W!C95LVTUY$7"XP]9*CG>BM]UDP2?[
MOUZ B?=(_H+C >RXDCT@$@^XW8?SH1=W]\Y]\T8\: UW"/4!5SF2)!3W&V(:
MQ9AO!0V$^MMMEW^N*U3,8776X5)HO4)LWE$NU=7X5)84]]#\>.?M1@L>$+ B
M/J(1U;C<NSM4PMV>RZ=U8K0@.<%+LV4_7FM0YL)\FU:(\2'Q[.UKG'&;[>RY
MW+F*SVAE&&SG\B!\24*2?SZ,ODXHO?P/I$%^RM)M1_V397&I:K])?E,XJ]4W
M7S7B:?(;N8,AGGB J&M4[F'6KJ(F)M"+'3. #>O";HRZN'1U3RT_+AM=!2N*
M)48)QT/ X\,Z*N:Y:7+Z<<7=Z9R<VXB@'XT%JG8I,_O$NS(0<3#33,Q7/$ 6
M=WC>,'6QB;'IT/"A-ENG=UAO3;)U0LW7P]DCFR:&=<U;?10#/1(LW(S8"ATB
M%8Z!I\*34SV:#.;6@3)/SEYOH^26=9D>M(/V7- XHPZ>=K'?B\<'9J#>F!BE
M6D<>,9>[3[)#0]QVL6V,:UWMC@R1-M5Q#!G*UK<&+!4=[.UQRQRI *)M+7'*
M\N,!P@>;4]BTLS0G;/C69U)MR)<=/""-EG'R?.+H#R]ET ^5/SO4[_O>;!]^
M8E\QR8(/V* ?KJ'U&M#ZJAD"#?G!,!-_R0X*@J[(1J/P@.$^'$6&P@P>0"O[
MP&L)?88BVW=)#''9]?-Q.=]!S6O"AI>?/M!A%R=I\6@MJ+I'11?J0'>S;[W6
M,S!%>0:0QA%3]7!2/X# +D&'GV)2%BX1V(Z@!UTW#38\LE,#3N]M7,[)@!CE
M/;LB*I.LK6\HWO$?</*647"1C&VWO*:?J*/K-].[=X^/(YSP">O<(:D-4E\\
M0*!ZC6\Z]_$? >&PV<OAVA:.,C<:WISCWA?QI46P\K"_@*9JNM%5FH]2*/5V
M^!XY_!31)V>93?^=2PB^J-&4&&%TWX8K>GE'((7I*5)6V..4P\L%U0/[,1C^
M1=MYUEYL0YR#_TKH$P7%\+H[L"&@N94WOTH.K.3F<Y9QHMW:X $P@4YUPV.*
M<WJT\ H;^&7:W=0]AO3:76"7Z=KA*E*6KC93O'&'^]XKM5-[6)]NI4GQW!:C
M[^X/XA^TNV6[H_" T4&,)\0=<Q5;_$F._"((:7G:8+#\(U'C@@5L<YS^RY/F
MW%Z89V8^Y+KNZ8TH035N>&*VAY9THI0%:TE5HD,&(?2:R\2XX0&/7::*<2_Q
M #;<?6S>@-C@_D%Z,_6>] W4P*"A"/U=ED@<9<*<2,KW+I"(FBYCP$.>6H0R
MU^#$-!U=.)TOAQ"!]E?B 68^N5A.<8P;UNE <UVX(>CQ&;N\]4%+6U>C_1D#
M>\^BQ%Y79-&HMI):HD;[0B:XT4SR^]JXX=&H:L9U2F$-=U&1DZ^E!%[J(D>
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MY#<TVJL9;ZZVF"QEX<MU)KBCCKJOX^2IW[-9)/I[\E@42&<@?Y%\(&*7E"=
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M<N&D-MU\V5SC@*;T>/N+9P=MFN*(*#N*XRHHJ:A0+C3>C!5-U8\539C3?DX
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MO1/ITB$(22 DY\[[S7O.^?'.F3/S?F?FFS/?/\C G7WOO=:UKFOMM??BKAR
M*P>_YX)&EU.O&Y@^.]344#"V+TID@.@-%S@]$Y#F^5 &@&G=#1KH[>O0=]\]
M$.\1@U>6TWLKITKRV^P4G-V\;4:VYW_TC)G\4&EW?#8V)1P!'1T?-QKD0OW5
M9;Z:FB3-S"4(!*H&1E+Q0?(BXL>]^SNS--!-3+%G0.3T9*9;Z-7-686G]Z(F
MATV-GQY>-V!K;A9T"T)URD<[1/(E/;=/NIUI;_&.,7=SCNU_]^'[_\<'/[JI
M-Z5H()_;-)!T D6M988&PH[8T>\OLJ>!(OZF@68VL<FFI^7^SM33+'HLNP4F
MZ0=TA<(&D"3#XD[$^[MS,ZF3&:+$S:MUF^4[6]]5.'0]69G"35\5.J1\&>1^
M6:<Z<C%>ZJ'+V$>%;L'2:  ]SBMK4_Z>@?684EGN4EKJO3MTUR?!OXF(WHF0
MOKSBJHWA5A2:HSG !F;O58$U@*HD?'[]F<"2L8%FOV1@2^72X^Q*K,7MM RU
M 0.\9>3/>7"3&L+)@$BUQ;,GN/\YY&:'G$WO>C&7%YG;$#C::NJSXQ>;A0JF
MQ-V:>GVN0',]]5&P2>SS:%/%,N 9AN32/1KH+ UT>8+J#^O?#*2HXCFRY)VK
M5[\Y5TN']+5(FK,U:WVD8&#!GLTT4&UQ^_"$_O@B*C_MMAWJKM#92V]3?+3!
MS40S!?RO"VU4)_!>&3@5R7(""=F9BYY0B HRVN58^3#9"Z$85K\_\V7O"5=L
M06Z%8U%>\-0+-1E)%:.'^N:N4W^J@1!KBTB*TNJFM"(6],%<K=</;19QQG!1
M=M?=G#C-JS:5YLZEWS7>=7H-"#H\O5/J1F!9%920IIX;D];[R7V]YP5]+8<2
M@%6%/4&NK>=255(X!V]6!:SUW*':!XB]C&M(: \H-J:8H*=)<4799:QZC=&%
M?:LUVJ):'H1%P]=LS5:VA061^;?6C6&\?YO8=S<3_W:F\,@%P ?E#K[N4&YW
MK8><O;R/A_O=(J7;;Y_20$:<HB_]IG(:E"49?Q9DD\(<_7BX7 5O<3L'ONGD
M>*3)(P<@W3_>*]V4_&,D&4,#R3&O6HY93TS/)8^'7"P-@7Y1N(^Z7Y; UJ13
M:'4:]:%SY&G=E)M'*BN+$?X5X8FTC!B_LK2+J!6]^1T-U!9' Z5/6(<^*J*W
M\OLK^+V_%T,%$(%I(%O/6(#CS0ZIB9I8Q(U-FL7FZ!DVRSL71@:7N/D*^W78
MQI8_3[S$=2D:X!'#G.< .JB O 5(RCI31&CDALW,CM[X%M/(/K/OGR/;H_0]
M.PT](</W0C#8NS>L"9_<'D)EV?@[9)@MN7UNJ:%JM%< C64$6<;M=X8;(![@
MU\HF7JJE)S]I@+D'R$XJ!',V]=3Y=W8N!WA/_QR9K'LV9:&C2#J*$.'>-^YE
M]$ _^@((]8LP"J6X ]&FJ?!FR=A&9>^DA#+]F=1;YW)TZ)Z5*6X^W1/B99'5
M<I7P<V1BS*YF-/7:E^NC*B>A&A:L@+RIGL/M3Y #*"% #&BA*$SB!^3\=TX_
MIVQOCR,%FW_D+\7QRGMNI@^N"O*5QNVQD*-+]WW53,?)#%9>ZA@>0?W/9<5)
MP\:]\06 W*G05';<A:W$2IRJF%,:CV[W5WZ=9]<0,M:="D(FW=U2UZR1@&H\
M]VG2@>O-6$'MW39X#[+>QEQB3<E7Y3CS7E>CF6AI@&@K)@0QXGLAR]Z9_<:#
ML-3^K9[J(,&--T&\)26X+7.G-%5R$/>K 00WO?XG[,I_ED.'DA$+SA@+W0,"
MEFRSE5'M'9$>:!N@/IX@=<_)J< C<GFZ]G7ABQO?',7OUKV]H5&FE^,:ICH7
M@EJB!N+[L+8 8_LQ3;4Z[=_#U6$,/:>:RWSOSL93MX+6-Y1'X!YLIQ56F3)1
MK'%%%L'W$O9_S[D8Z>Q7L'RW^=0H 0S  3S [I.S!.CL+JI)2.-(C&IS/9^N
MEY06$P46!FW<^!K0U)H@TEJ\3B]:O$AEM23P>1'%#OQ(4WO$Y=ONN\J5)/BP
MI:G[,N9%F:NAD8F107?SY@6HKQ<#PYWSKY8/5+W5-#7_KAZJAN+.]P2NE0"^
M.>;K!PFAB)*,*7O4VT=\A'^V?TS/X3D"O':GV2]^N=GTJ=_ I/?6)DYY?F[&
M,%#WZD-"RN&=_/-.RL$9/ 5O'AIH"*'3[Q+/ DQ>G1J>N;M\5X4RI' [//3?
MA%6Y5\1+,X$4N6 XK-/M%/UNVK6YRFCS7995I;MT]7(13I2'_V%981>#Q7,W
M":]48X+#>2=% &XN(-J@ 0%6(PB%'[O?0[W2OX@C.8BF*M[1_LIX_*$*8>VB
M;N:,[]*#009-;-2XZ5-#V:3/+]0#WBD:#',G0>FGHNJ.6@=)CLV(+-R@314U
MX*1F><)J8J=U;"XD.+E!?B>/P=6_<C5;SM3R/NSED,.>N2!J@+OVH7U^5GQN
M(+CO08ZKX&^W6_4)@"&64QT.UTP0/#0025?,;1ORQGJ3V?TGY>,6YT(C+L52
M8'W9X_ ^#=3+YFNI:1K?!SD'\YR8=)&EP(T.Q3Y_DO'IO#?P @+?J<4,;(%7
M.)D)G7ESM4KD>3)^%6V0F_#2*7C'2C<TA&L+U?#7D'9$3+/5H^]$%G:?= $1
M^PEP;IV@RU*SMAX]_;5>!T2"2;+,)$((FV+:J=>U[3'C%7?2(!$47S3@%>U0
MGNOQEMU4RCJJ$V)J\"');:,\QJYT_4%E:9;F?52]8 R2J[RO&Z"7.,"V?M!
M#8(!Q50>T58::+Z&@RY'P40T0>SW8 []6SH0LEFB7=MAO03UZG3O(PZ3<YJ:
MD(:2+^:Z^]K5MV]KJ[)R'^XJ/W%_4)G4K-4OJ2(HHB0O60OXCB X@QBZB_Z
MW,MD7N%I5F!_+"?[>PK+1^0SK ^-/@M)F'F\/177KB&6:A [29$VJC449[->
MS_S9+(D)0<._!! & / @4\RI-NQ"G['9A@%BOD<X?SBX<P#7\[%R9'9O86'F
MIJES\":7(@UDEU!8I%.AF,+29)[$!4VNN/'\7'T,A%T-@-,L[/4 /L(PV15+
MM2?B#A+)V@1V+^)MYQ7> ;\5;W,[@KF4LJ^4LAY6('?PM%5*LDPUOL3M,7^5
MCY'JG==:)8?GX].>T3.7-%!B>@\V18%(ED/(TT#OE%0R9C,M*FO7M<(GUX5%
MF:J-ISX^LXP@^,VLQO][G8\)DMQA_W9T-'#RAJI9DT#G$Q3:-!F AE,J%'$#
MFSSQH[*I_+=W,IX/@UP@XKYVD5.;&^H"6,/9;)IQ11H4Y/7H^%Q44I*+Y)\Q
MB=N!;J_\=(VA!MI'F6QIJ?M^])I@=SHP;&O2T_6"L%A.AE9%(X?@F4K,;?_%
M8.\M<:9'<D0N]-Y+3<@_P8T;#],>.Y=:V0],.\@(:.WU*?KV09J)%A:4G&\(
M01L4J7"?+YQRD\Q.8 ^@4&>>E-\R7996B'PC\J9MV.&JK$>=EZ7;\@6^FS(7
MB;ZOH*JJJ@OE;DV?TMB&! <A0KT ;/0@VMYA-/Q#IS>1) C1V5MG\!8XG/*>
M5%^GT.]G)U#(DB^363F5DJE8P7JO6D5^N/]#D-NG?Y?CU>*2^/Q>F@%^SHF0
M :_\.X'HF2#_2P,):>'?<R1,W3W.6<CX[GVO:PW/FEBI;CU43XQ\)-_7 X[H
M5&&Z+UHMWV<2\UZG558S*6@C_V7^7,CG?"I+*@5+53HD'GPBO8F?&<W^!J50
M\9-AFX2;NZ\\A70M&^4HCQG_[>!DH($8WY-\7>,N)JM.[=![Z%JN(\285]KW
MR\BV?I5KO\'OI15&."=F,+7N(0B)J\?]RB_*5]WW'^N(J&H8[GVS+Y*V#/\@
M;/'<](;2J?_]S;D+B!]BBQ?U*,-4&.R!_"Y&@,BC-[.YG9"Q:XV]/UGYF(Q-
M\-2Y\ )S;:3O44K_\SJF(+MJ,HC![ J]QED"L< '[HM:A PH(1O#78BR"E\$
M,0W KV$-R V&BJ:L8$8'8_97Z6>;]XNY$LRX+9:MFL\^2H=PPQJ^T6_2_+LX
MA *:A UT4UF="36+2-?=L)DJ^;67NX(Y2U^KV>\*T$ Q)@:VLO<O<OND)(^5
MUXY"+(6?%Q4]%WPK>$5$03D-P*589H+^NAG 8' 4P8O+ 6W*9;/F&Y6%[9Y*
M!U6E#_O'^H4/'_/OWZF8BM!YI\HJ8O/T8Z<Z+_);5E'T]+G73QCI9Y'T$6WA
M#_!P\, NF3H"=Q_5F!KC\)G^"1](B3 QQH%M5VY?LQ=FB+[P=X=1[IDZ$CWB
M *16Y&HVU23L$'O2GD\#9>V^"HT@#>%#W@<PA%?M=I;EY4]/QN9P:(\X^H3,
MOY&)"DUE\G12MW7(*OWU^K' QJ.2TC8(PZ I0"S'<.10"G33^RV245F!\F(C
M=OO^[M2I_811[5+XS[?7=ZS2U KZ5XF/KX\:=UU8&I@8<WA:?I GHM65_/Q=
M.<!:1, _YB&1OL" 8(D8Q)H7H7?+)GXNXXYXBODI^H:1%W_#,^/+2=.$[> G
MW!%"OJ-!'J'P1#7N1&B@*XH;G8ODX+#:!^(VH9ILW01.'LVY&?F-<F^3!LIY
M#/L0J#2A!K6<@G$?L!NB.=([!E*E3+GL94?]#%Y4LT!/F__^65[R#GU3QO=Q
MCP8 6H,TT _("M)Y&T+2Y2-$;89Z[<UF'&.3LME=1KQ1&^:A@XGMGDPUK+K*
MC^I152@A)DF3P?@2#7/EA<+ND?2/Z!1-8&JM$$^\E]^,X/NAY+#0<V2QJI/;
M-34MGPD7.1KV.'9K SX7)-_)CL&X&7NY]0T\^JX65]IM:#"JF')]V+C0:/[2
M0B+J!J)91GES[AZ>!!4=3P[]10-]D.U]STLR#XCJL-+[3QKT5@GQ7-#DH? %
MZ)EL,Q7NX-KU\?11I8GF1_@?EF310S#AA'RZ!UV(>KZ;LP*K;M7;$OD<-\=1
M/*E[58.+=V5@-VN[)@-%O:G"RYNEJ,8A';C1[,:=](3-W.V1V]'(O0\ MWZA
M'$@O]6BE:H%_J)(-MM"QUO].!85>)?XX;#WLWQF<2(WS30U)$NT)-3'3R=B"
MWU+F:#+6O:"4%F%BFFG3FIMGS<3X!F EPE1G&HAX>XVP3 /5!1C30#LC?G01
MF8AH*\1&V6%SL%I.X>YV)T@?"B^RS+_01NKLV.%U_>4RV17V,2:<;KU[M5&U
MW0]+TFART.>@&]:2'35&]DNHHG(8? <=0):@@40Y5U9&Y@(.8*O>A"2R4F.K
MUEH(=*E2NS0X@!VS\MES:.))[_JK)VY?E2'M%^2?N_N::WE<?FML+\"M%6JD
M5V/::3A&O_(XE0;J5RVB@5*18=[4O=\TT"IF%ODP7#I@?G&N#5D>LN_VN^2H
MGHM/P_#/E)4-\=.@'9Y'U=(\,>,N+RKP03Q#\#N4X,ODMAICP!ZK^"@"R$6D
M92@W51/?M[MTV\C9A1B.V[S_6\L'Z_+T$E%4FZNVX0),KNE;?%ZEN-Q]I]:R
M1ZS..=?=3*2SGJG9 _HS%M"PCR@E6U<_4-6P_=T%]8#[>,*.G(_TVK_MED=>
M+XBQ&&QID)45$C!^EU0D^,[A=2Z&QT"%^YOPZ\#2W,Q1->ET((1^!&<V$*YM
M[JZL4 K"N4)IH(T?W[<?$M3KL8X.(7],5O)UX.=F^J^+ZEWVQT\ME@BY+,],
M^>HF:"09)Q5RGU3_U.:<H=? @-=Z9S%E:U&:@. *"]$.<MYX@ \[V,<\?#VO
M\'W]:1^Y?E8!YKTBQ1LG6%&9SZ4KXASMQG+CV.39+:ZYD!+.00C9%HXGR%!M
M$7W##8O=]D?JX<6!3N*6W1)-Q$X']\1T/\^6A7?QU=7,"S[ZJAKOR^.K4_/R
M1L3BDAQR@TMF^0$"MF%)3^OE<E)$Z)"_Q32S/[/JA2^>?3\'>R G$F#ISZ3K
MZ)-^9[*E['47+P__;T6MVA'^S-AJ=_N'X+]!]-QD/15'-0+?0*1%$12ISI;Y
M2[<4OO!+8OG"F0R<3S0;6ET)^[T&;[XY"?(S,2A>.\VZ+*?D57>^[LVUI2XQ
MP+7OAUJ2U;#*@L 4J&#:7\'3%OH\.;:G82('2NRQ<W<<+Q3%I[\T6KAJJ]YE
M]A4<]C:O/$\R#G*M5%*]2,T2"+>%)': W.EN>G^$]65_;M6%$KM.-A 92IO6
MG,[V!YG(6U 7?<]HWYIA-4W>^X)LC'7J3XO/@'H[Y9=O4EK-UG4BDP[I;Z$%
M?'])\&RHX"RR-Z""GYA[N/.N5>;/D3VK"@8CBTIQDO+QG-T923J/1A44O,X"
MV1=;!,:TA;)LLE5E)A8@X#M(\(*TI= 9RA@VN[@?O2I'F%"*GE<:&ADS"AN:
ML+Q:SWO)ESVW1BSN4^_W*_V2K4+H?2-]_:5?&3_^)$$BD^Z.+BV- >:I07V)
M?!"N0*D'S)3AR*:7:J_4/VT=M.>[Y.79')SWII*_3)!@5)L=P'@@"V;6U+U@
M;1C6C4%Q)]4\<$UZEI?[S)H9HM4^%U+(21#>I2:3 /1E8.DZO$T@;6T36UN9
M*$EN.Q6%R36+O08K4H^[IY-W!)F;NF64E7,D9^S]1C*X*LH*F'@8[S+7N:CK
M=P#D3(.L2BE1YOZ):,N2GR$'M2=LW2)MSDXI>FW,CR8Y?5QU*,=Y*M:O]LC(
MZD,CB]7[GI7'<#WD^FH?3]_@_.-'@NU?+%8^3W'=](X^/:/=^/LX 86(1?B5
M-CCZ.E1?H02 4V<!A/"Q&.H8@?%EE C V;@$..6]@!A6C"!!I9']K9A?YR_,
M46T51JKJ<UA:<E2;C]7OQT9Q&+=N2@46!%;__"7PZ@"Z&#Y=[+WL5N*.DKQ1
MR/087<S7;_6'90P@,Z'C_VW1+8]H:Y1XHCRZC5B>>]VSAG*54DH8&6O,VL8)
MWEV-*9-(FGK9;S,4;2OU/&GTKE8TUWC;]/!Q5#/Q&99<2@,)7\50U;$#S&0+
M$XK95G@/;G27L>M*X*J<,JD\[I7D3ES#5XGKXR8J%%'!2R[[\,1QPUHC"\?]
M:IUDG#%[!/ &G&B2O@F['T(B@:1OVH9>2<^9G\%Y^PV*RCEO6U'EO"K$@Q\'
M*#V;>1_@+.'Q)_7M2M%,[9=G:--[HR][XPM2?PW=V^8#!G/"1VD.;B##$&VY
MU#.A+NMA^!:Y*(LQ?YONK=,J/ELEQ2E%/_.OD2ZR@F[-9NOKFX9)6E)+.:[K
M[_-+TN0R'7*]X3NMN;F JY"_(MK>M$HM4AT GTE5%J*8_=B9K>SX'H U@Z.M
MG0.<&"YMN+N4N!,PJ4+<A9&N7!&H^QF*/IE7U,L7YI\8ZT!V6GX*$&"+%Z:I
M3[%[GW KVS7AC[SUOM- &ABJ'F;>F%4IP23UT#AP>Z29<,(.]SR.R6(,8V1E
M_E#0;1PX^?3]Q7VVEU3IN"+ ZXH#L-^8(B@#B 43A)"RP%$N<0YSLS+@*J%T
M7J'_8542DE3H>.NLW:]7&G<UE2SZ=9\=5G?$N#F\+GGZJ7JD9MT!B)C?:"">
MJZD)9 #%VSZ%:X1R;;1TYJ(VK&1'\ IL2?=:K*IQT-<)UV/F,HQZWDH8CBT+
M#!B]<*5<1KGD?'K.]:&3GK.XN8!HWQ*C\->0IT*I\V"QD+.U43IPCY,W2G'=
M6WVDJBD&-\%0PG98>CU_^%&ZC'9"M_Z2;5)0KI*8]*A%EN1AS5> FS C>WR=
MO#C?@7_XDM_30+R>. S19)&T/SW#^24XJX9Y+01W_SI/-E/CXJL7[^^FE$T_
M86M<W8=J5?!8"&GR%T1J "^3%LI#A2"9,'@JR\V#BV0?[RUG>]W]LD(7XNC,
MHZB;.4G9TG'_5+:I))R4?REV+KG"$=JJW=7\([F+GBUBAZP%C9(Y$VF@00S9
M$<%UM7D^9,2%8OU;KWA3^?5,AJM@KKDK_R9_Z1)Z-GE@,8^QR^V-TXO?2Q$H
M 2X#&>Z8^S+EN8# _,WU/RG'"]/% Z-R$:  ZGY'#+?22P.Y[9310'-%OP&^
M_=,;P#:&=J^$50GZ#R1C2O4!9B9H>R>SL&OKM S9M3U6Q*QQ=:TDV\=K:U4D
M-^G+Q]H9_[1+J1M+6?%W)4:3OK)QY10 PT4"=IP.,0&TVBX)BO\F%L<AAB$6
M[6U:5/9/GB+KN;<N%F?SQ;^7^S!XH5/75)M#2<G-4%,]U+="2<(/?J/K0#AY
M<*=E^ JY+?1?TBYAALHB-!7"1XXEBKG"U[[CXIKJUS=BKC;FE9?U&@Y[SDH-
M3%*4>*3OPC6)]W=*DK0&_BW2O!$3=-U/24F(&;Z3@NBIP1Y#EN0H_%#V45C_
M4DW#_#%)CJ!9UER?IH=[SZ.1,K#$Z09I+%%>NS=*.O;K]XP;T;.-KZ_\()TB
M[J \]OFNZDV 9Z)V$?^P7R%GT)O\44U"H=M*NQA_/JL=CA7HUX T57L>\+Y6
MG_"%]F_+\9))P75I6=&;CM$LH[WG]2-4'(N=AP$M_!-)*6P5\=R-1NP!:B83
MUF_IML,Q9KY_X@^_Z/3'YD6N&UDMS&2DSQ-U;X41;EB495X]NJ<D'HQNN%42
M71#YV-[W,C"[:,I_PR(YD20C9WT/? +B 0V4"%8Y'#6_(W^2?TQ-+Y$5?A(]
M:&QA5S_N;;?@\][8T)A)36O(X!E/"BJ3$SII0S_^+P;;*Z"!_L%R'HD=Y)'^
M57M3-'^!$YF]>1E#56&;34PL*OOAW1?69$EY\.Z:_:,[&&ZW<Q%6EZ](V5#I
MSD R K==C:/:P/HL%RYV,<>GS*"2RV0;!C[._VH?\1;^M\^4FQR':13:5!V7
M%J]-K-.I[&&8.S/,]$]#,U&5WIR)<T7,UB^=($ZUSA'Z(L<+<Q?KK4BO>AE"
M0%^3K@N?FYFYPO$!U3[X./4^0_! CO6Y'0/K I9<KJ(G]Y#PG0_6IC30I;V-
MBI-]W*\$MRUT<EC9B/5A<N=V_ ^R6G(E2Y,65#.MLS,#W;W5'+A/:JHR_ZCD
MD6A@,&KR=4]1W0*%"DB3+DJ?"RE'[A7V099;&J@ZH:X)J^%_R '3G(^":XI=
MCC3L/7!QA]DOA.L1ES4]TJ9*MH1WO%(,AAS6#I;O\4J^,X7<LN;-V9?V3B@!
ML+:DG_S8&Q^7@M_[C(PB<_X[&;ZVB4C(KO$=LZO*AC96ZX^MK5-W[9TON,4T
MU]Q]G-=K6*>2]3@T<=W,2L"<-UJ(#K;A_QTZX8#=*\6_4WJR)T9O-"6&_C\9
M1;C)&@W4;#13W51M?IZJD#"OD(3=$;)XG.6^?,!Z7C3_F2/7FBZNF?AW T5
MK 5CZA_Z$M!?_9OHFBD=D[--X4H>N=_G,AB>.!46_5@NDPAD0M?;HDLC5IR*
MNG5Y?$EL:7Z21MWZQ@7%$< P_(P '=Q-^#"-[)%2H+2V&E/XMW],6_\XZ?PM
M%[X_5S=Z,*;R5;9MT9<E2)#!C4'1 =8NI4D,]_"K<7E6M">=>MVH"1!P^0#G
M9Y@:$.M5'J+JWCT6S)1M)J[IC*T*"-WBXK*/W.C9:LI/45F+*W!3L6'7R-1F
M&5FY/4'?2'>EC-) :1>M:2 NV.I%2H50N+ _V,%Y(R#2_OQ77W9DJ(EZT]T
M]9GY.^\VA1Y0;[.>DPYL[MD4L! 4D21-\6JNH>+:Z(7SA:WT$C@HE?4BC))6
M0 X9,M_--$<FGY0M\_9O)K[>NE]"2E2>+4C"GN,+_3$9%;A"O&&D&ILF8?S!
M(M!G3S,Q+5V(,16ZY KC- ;8A9$(Y:/<;E>?-TD?UTY)^+8%]CW$=@].-6U\
MF1PLG37G=SOX0P,%5-6\D5&S-H_]:.!0:O%I\)[R\S_EHBSER<]2Z1MRX-#/
M5"/.&R[@!5T.3\K7A>ZC*Z'P'8]<.;BWFZ:4GJ^DB7-]KJ6O ULVOT [--_Q
MD8G:]0^)\Q+=]&J^8_E0,=*;$>1?5.G#A@[J/X6S?F$:8^ N\/]E%\B^'8#F
M-U:X++JBDP>,6)KCKJ<DY,@!H1?*21&4HJ>\HJBF8=_G6N(@3;SS--"U^C&8
MPY^#A;(X$>X@G3K_VS=-R((^-T__@)U?)J;]70ZWRK:<"T&UTT!O\V@@0<[H
M)PGQX+LT4%:8E\(7YK[MLE:%VV>B>[JSX-]B@B[\FM+A;@^45J"!SO7J?/Z:
M3XSI/[2F#ST?OY) *98W)=?00(_%5G7'\0\"UNRVE6O7J:-;HCT5W^%EPX83
MJ^Z""A>YHO,C",9?3#I5(<_=<IU'-(5K?-@T0<) !!I:!X91XSW8NW>R/'&0
MOJ%)2'TRE["/*SDX&<;>O)?*FU6)J92[Y<YY;F^XUW"H:P2J;23*T->F7ZUU
MK(\&EI!C__8KA(A86C:@T<$ &WK"F8)]6+_KXQ]NZ-&M9W*8QLF3++4F);6\
M2<C<PL\L20G6/MZ(S'_]_C;K,XEWW*@$?;-U!PA\IQX@$&_U0K/Q)\655'N*
M_@\GWM[#!N.5(Z(G//Q1O5MS3*PT)L:JA3<\TR$GCMN,\K;Q6/"=Z_H-%JW:
M7F/M:VF-O?0NJ%^(Z91>O5\T4(=E(Y@(-:7KU'0-"E\Z^;H?Y"!\$J!M1%QH
M@/-+^ ^Q0KG[["[;UIC1JH7%I.#9059'ATR&C8'!JS9/!!:U^)=.S%QM@5&9
MEX'. 82:.SS4H95W#?NQ:):$.$ T*]C;(D2Q*P=?OH"O?1'W$&3K*^\(#/\Z
M+:ZOJAM?4/1>]A86OE,8_#%>[=.-&+?,?^RX67# :/)O4MX#BUE E4*T14BT
MJ%%:%13"=M%O$-Q9F#)7ARU2M5&0S@^)HX*3F#<[/H.0A&*=^LDYZ=5+FV[K
M9S55+ZAN6UQ/D0!XCOKM9:3*=\HV=L&0 [,OU]J <]2GA*R;O9JQ?!@S?6-H
MV-3^B^5-[ROZ+P0+NB>^ZT+2Y@[G@Z,W%M/TF]A&BY/N<A==!W!I@I(5SNN)
M?8W?*QT\W!=SWAG8(4^W\-00*R=F,,6^W2Q!;*@G_C*\3Y&[)G_9RHAWFCT,
MB'X1HQ[[51^:+TQ_@@=V00Q_=+R[)D0#N7, F(IURL<W$RW^;(=E[_7[T4 R
MR*P6>\HNT;FWL@D]%U;6?'3(YP6?>\8RO&T]*.M56:_8NI#7^ZO:V#A#T^5I
MMX8,A^(>(D5%?MCXYZB()R>PJM(4 E4;<4X>3+U9\[6!V>@H M;C9A-9.HL4
M;O;%'IEH90E[_>[UOM?*?%'-VJ)6YJZ\3JJHE-//)1\)8>-'O,&W2D;8^WYV
M[[2,$"D\M\GZ%,V!4!\2CC*RZ3/W3[BII_7^9".CGKKB2.4Y:(_<A3X[7O;O
MG_$D7BU'IA7.KR8PU#H]57N3!A(%KW "2#J()S<B).=1.ZWC6[DUDTK:TSG_
M3A[J'UH%CO4Y"JYM*4:*9K%6]D,=2DKRBD[2$WL_EP:I[.>KO%J;"RE+I<(Y
M+R.2B(13TL,]K@5$[WP_6>##;-B91J*Z;]GB;]:9J"JY"]-SY#Y*[E+RRU&G
MS\EG8CN,G.>3S#:FDXK\DUF%S3XZ5*E9U;9NSKE-U6"$?IW*'3RAPD)P9#</
M?!*'5,UZR"[Z\UR@#7G08/G5WAJX=?3::>=5[2L&;#(LM39WF:1C^GC'N8,6
M4H9'@ CI@]@K0*_00/N[:&S.Q8Y[_O,%\W\AUXZH[;NP#\B09%<+M[GOV(5O
M#E<?D$Q)0&3*UG%1S+J/\Z?#D#ABKQ#_/W8-$$+@..N+^TY1P?;')P&AU#Y_
MZ@N.P[303O.!B<.AME%IN!CC!7E[M8;UOSH+(GRX\!/T3@ -_POEUH:ZZ1F4
MT/A9&DB$!OK 3 @F7V_9Y.G=#>_%FVT,;F;D7M<[G,IBRD9V.KYB^JM?OF.,
MS'#9C:$\MFRE.ML,8.)E8'(S@C>^@&H![J>!R*\HF(W*GUMA:S/@!QO\92$(
MJ::U>$!?1KJ[CWB5>Q/#TSD62SJA^A&HXHQ^<U/H$_&^NFL?-N8WY\)46T5W
M*'A;BC-I&QL@ IWP4MH=LM0(6-MTX,ERFTW#=X^/:740+#17G;@)FO3Z2X!B
M5>V,;+5V[,!6\'M<#CN*79Q79NYJ52REMHVHH]62^E=KI+,USBKIQ\A5IGE8
MM+Q28^$6ZOY08JIIGG<9L&]Y&D@>MGPR!.X36RTF'$S#.#',-<1ZW$Y+9P)N
MV27$T((!M2&<=D6I7F(,?FW<WE6B=E@U+3BA42+LHR>$M_:F]N5(>8#R52Q1
M;Q42 @*''959*1+=NXII YO62Q>@F!#5[:1/(Z:2)MW_M/=;"3A)C4$7\JD\
MX&GA&Y=M/G-?[&>D%UE;C(26;#&OM.RU+S.W[7[@[+5<-@WU.CT9"SK3>"+V
MDE@/%GEO<>_HEH?SI,-?T!=?DL=?!$C+R PM5]7./X]0O#G<5STR(4S?A-<&
M5E-\1\?$GMQ&<=E"9+$CFJL!>AR0H+IEC7\WW>(,9;IEZ%G[4QO:5%(_%JZ>
MIB/DQ#4P.L 77: IPJTMHJXLC[+H)-ILVB*7&RC-X%2LE@<XBU,&F\[7^W6B
MMR)G"GM_\[CF8C3>T*"W\7C=H;AG5>X6N[C 0C>$0\]+RT,BSLTGY56%K*"<
MYN92J0P3O9(KVX72N<T4O8>I#V?=UEQL/YP((IJ<;5!0K[PU)FLM^T.V.?UF
M9"[7;RNX3-C+G@_]#Y/JLR)=IB]^OD#/I71S]LTL(+1"KY#D?IZ>'3)^7'XT
M633-,H,'3P;6R<YE#ORY[O J)+$@L2!SH:=?_(0[29,MFX.#@PVCH4=/PWSQ
M_E^@FNU_?_#?_J"_N)!J.4@#7=X";/Q"Z H>+]@,JY8SZ=[:W3T:NU(U'KLB
M>-1%FK\3M]] ])]_+V 0W>4H4,9^\9PDM,Y#6\>QO"BX5(B?6X-^:>C75G<
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M<^L4SU![\NZ'W4_.;MX<BUJE6B3 ;?K)4P";MP9\D^'LMMA*^T\8PW%4,W]
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M*=W@'$Z".M7-6FJ>F6"Y@'T%3^]O*7L_L-0J%I#VK>AS4@T?D_04]V2UE\Z
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M]_HO:/-%%YU81<@H_OW<F4UY5>!NZ MU"'P'"-XDJ(;W:.C;'<CR0WRJI8+
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M8HY7+W11SBV$RCR/?9H&M;@;?!%)V-H^IH%B8>LOPL<95A&1B8DCO&]/^,&
M^<CNI1]!3N7T/D[*G(]4<8$LHW9/RD<G-WED',I?^M!LA[:I*7\L.#OEE_^%
MJ$J"=:>'X>L)=M/UT\=P9/]13)&?;GZ!-\/$PR!KOKR7.OU6?*42R&B=/IF
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MIO#Y,\,5F.&:!9SG^T,2#/'H[!%Y_>/]KW::
M
M
M
M
M
M
M
M
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MU;PZP';_?7.B9:A$./W96IP^Y[]8R/BO F,2[$#?^[@&40_'\'OBB'L?R=V
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MW5CB-&(_%_R1/D I7?[:9[]BCX1VE+S(@9YM6R?>H X>SV[FSO@\(>96S'0
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MG-%MN@,/;O##)P:&ALI]*/U]IPV@<T*CWL-W;+?N$:%40JI!E?!IAGGZH(?
MU+D\8&%3QWI5J.9AYFU6 ]8//S8WLGP;BAP2!^,EM;]F.FLT/,O(/WK"(F!X
M OHWKPY/9D!7=X?C-SPK4 ,E+O\%_W;\@OI77*4B;7EMV(EO.)O)=EO'DH]K
M FL;RM^;+2RRO^NTA:;E9],)1 ]\P4LE/+)J3WQK BTB& F'1#Z4)%LDMN;
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M6%!!$!60)J#2I$M7JH!TD);0(=([J!"0&L6?($CO18IT0N^=_*1WI-<0Z3U
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MH"^0:_EDEZ!GQ/N(M+I80HZ/A<>=S;_-7[A,&87Y^U0?00SGV:]YKNT$D=G
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M _1D [K&<PD*S6V\!)U>(09^HTO0?E0C(B5R!5VUE)[EG96%N]FZ:9\=/Y-
M%V[SL.OY)S9E^A0'-NY:$M3L;%(LP#-^_9,KM+K#'Q2:X/S@;=V2>@5B'=J_
M?4Y7.*TP)4WQV<63%:W"59X>_O'AN9E1S3I?%U&[$4'L3R"DU\:>'I)X .NY
MT?MOP^ DDD"3=@ER!>]IX=7,_"]!+;:2@,TILQ"H3H%F.P)4]BPP^Q*$*M4"
MF@VH_M4B]_^=#=4<..]+T+L?>*5+4+N[$WRO=;X5^!?Z_ZO#!\Z8[J!W(\^,
MO/I<T-(0L=74XE.DT^!?O7JO:;B$Z/Q+SQGRGD17.^CP7:>!@ 6HBE/8]*,3
M>V]% TS\#_T_=TFFL@DT"G+2=EA17+#.O3#ET('C&O_7E7)/4=E5#DJ?K#RQ
MX/P;"ZFI!U;$PIY+$.D8ZKG_(CX^X,IJN5Z_CJ+J1+)TB52LTDBT42#*]S-I
M],O2*SP/%%B$> (2(7=RBJX!@\M&'S8MVFG!G[E]8RH[4&X6Q&I5-0E?=RAP
MK[Y]K^=-%?7Z</ \72&[LDKE\Y05U>QQ\O<%,2FPF'2';#@P&Q4 TN']^G>'
M5YD.T76RT1G#O'&^[@ZNYL,%WY87#H8G^NJW-.?,?\')\MN;=]GN[:8/__C@
M>-!71ALL=/#WOO^)?ET[,&F_>/ZY0YL)WT=HK2HKSZ-N0O"#K<^7'3V]^@!.
M!@8WH<O%[_39=J\<-@E3<(]KQI_/>A=:?Q.ON!I6(OH6WJ !XS.]5]5+0T;<
MZ2J%/\Y8LT4/LN+@SJ]74*,CG6@FE_C$/)E7VCI<$>+S20@?AZR!O]/)["<S
MWEMR;PH9/]8/3,G+0@2^8!-Q[0;0(Y,HW^C@;?%B=W>T5F(/R^YR9_[((*T6
M&[K(*RH(Z[DRE[KMM,X> C&Z%5.:$FALXQ05Y&+]3#<?Y9LU JP%R[SP&C+V
M)L3*UBA!.ALE>>ZFF\PN="/"="?9TDH^\V6Z:6K@QW)>!O4%^6P 8)/_4X.9
M(QSHT1R.'DO9%. +ETU+FT?MSK<T5/NXK:[QN,#^<0@E=7C9LU1,<QT%KK0Z
M0=W1;RQ-O*G(SL\=^B PY%%(5G9N6*':AT!BP5 ,(/CD?B,7C>']V\M!E"U-
MB10'RSY^"H.N9LN_IDM&4O-GO)WC3&2;MBQ[K$^J17L_EY5$Y%,I< ]+"_=5
MCHRJT(E*L4M/-<Y2539I%4O8V5N?WZR79+$X5FIK4[(9V OH&[#:-PQ5)!LR
M+F*/*\C-RM?^.N@5K11O=703&)G1G]-*G^TZL0C&<HELN'/IT+1O:#3/">%D
M>[[DCM,]L^L%E=VBS.J,TII,8"&EK:V#GKZ^OK^CY(CF59I&@F5M$9_"\_BN
M#<NY+LR@DX<B-[7^2CJ8\%<VBBX@8"S8>UTP28-3DR.+(Z/!9VFVRM*FV"DI
M-\.#X9,N>&WH+2O .VVE#[$W?_ATN[F&HV;,4.-FOC5BK]!N+>(RN/EZY]>R
M]S@*J;KC2LI*\O.Z6^NMS82;[<"N?# G@,[7S*2B;4YD9CKVS)M1Y]  Y_F+
MIR4_75')43E]5CP6;F.B[/[D5:/C'7!*QLJ,;<!%<Q\>_E2_/B$JK*BEJ46E
MI:,C>?W5*Y(TU/07,.1ZC KH-K%.P4'OP U7>JSD1*#^>8B4G;L$#8CG![=1
M%.T/[$2&ST5ZG;BB<K:.RPI+-IO3S/AG>C23/CM-V6[Q*-FLQ9#:ED4[;"UY
MDX-='@(AF!YYIL/2=V=W.S(QH\>@\,_G^CK]T<U+4 Q<^'YV72VAN^S<AV].
M,6@A[?FS7RO<#K=2ZJBC7,F6'/Y".H!K)!!/4E\1EW=&N2Q $^^R.[C7[-./
MD)$[@MMY*IO97X)4I/VGFJJNI0R]:0[K9SGX_EJL-0])OV+]!NE.;?SUD2DQ
MO_A#ZSW&OZ9R_X7F6+/7'4J'W3!VKI)!5^E^ RTY.>5;C^@11=PYH>GICPRO
MCDJ4]-"N X:AXIJY9QZ%(ZUA1?O?G$^#+# R&X=P/5DPDZM_QYA(/=K)%M5_
M?^5M37RUK4I>T"O8?3,S)A7R'$H8Y@OQ]UP$,6;#M;7F-[D:O2(6?^Y*5_R5
M*]I0TMW@N+GQ].GB]6NB$!MPM-Y8QVV0L3*DX2H>@.E-BG&F[5&6QV(YOGN9
MY[&(IG:K?AUV-I/^ O$[K.^74@QS8N@M32,>5-:&]5+_ZHG(4B_*+KP2]PG3
M,EHGT')BCN[AX)1N.FFEXN&0QFZ&]:]P<2$88MB35Q!W![E5');5O(UR:K_<
M4U$'A;O!,)\)V3C6@[D5$K&-D@W7\TW7W>QIG-?<^6A9P>EKRO>*P67AL%Z%
MN%@*,^/Z/SWCJ!_?NY]$J'T"9K/4GQ,KO+S>Z](0NR#[L&DNK^D29+\H[%);
M)9F?<ZI$!;-R$%*]3J,5B2C]:6 P.C:9RP<6IF.#Q2F*Z-*,/*$"/(>I8N'B
MYCQC6?4?]Q+?[2*O?#O81V=:YYV &M1STXBU65$:#A_[*=&PS&)$SQN>Z[_Z
M*LAZGKCQ:EQ-4+J&\D5D$9186 +$_?3/.A?H7#\1K%3Q[3Z7($$L[;L3L=7=
MK>\$<1ZY.F[LW3%KQ#NJ\1%;8>KRE7!1>>LJ&C<=TA[]B<%8'S7%PGO 8I48
M>. SSL8J*DTX*5H"%(YLA_M/S.4.S-Q#49)U5R(+YVETDJ_'3:L +^N/+U @
M_Y2=:V1*_?;EZ"2P8&XS9OF33,+50OZ?YYDBR_]D6UBP"JUY(6UL!<]X%9]\
ML>.#Q/2!=4?T"E[9-O5DJU7\(4;)TC]SU3[]#9X!/.6-GRL\.1UW'A[)^S&?
M;3NWRDH&E\C3?!ZU/H#1@"&W()^:WS^KN+FA#'"%>HS,Q-;%]Z9/IU[6SGR(
M5'4Z=]_"4V8K)GG!. M+=X,H4<@],F[MV*XNH^I'1G>WJDJ H.^TQ;R_Z19E
M(G.G?<,<O87!3-.(QEH5UG5K8\A?K[;WZFBL<7^EX@PJ*LGRSHQ64PF4[_F[
M"*1(1'I*/_RG#?.*N;EL+T\#+QBM^:YFM/C<GN9PJQ<_(U5DARKBU<$JC].V
MPV;%7BD]K<8>_03C-S/CA6V4"$8K]A+$X.EF:-74Y(4/WA@L&J,/?6?T=1?5
MV_266M(<P>JKKIF!Z%$,31>VLE6=@1.W,.5M!Q?FA"MJNUA\CC&8.<8]6PR#
M'/0CJDFL-9$KK/1CS/5QV)'0L+K>O4<? 1!6D3K_QPVPT)@,)@E.]IIG*#2Z
MA6O,VQ\7'TQ246%6U%ANXI,O:J;'JJBE'/)9 *K,KU2:!>%Z"-YFB_@;4?B(
M>%;IMJY-A?92SE!_;'?G7]^8WX^NL:6(YAI#(@<F^+0-Y;DZ6(VB:C^F%VT2
M >&E*Q[G=&!0Q#X3Y0GOS8AL>2=K96- ,E6^-[A>]VPOO=0[7$AG,?%Q3/X+
MM?R"&^RAJ?V/HZAO%Q$_]-07W?"G^\>?8&_/;J>3#"CL1N??%GNREI[Z=O2!
M;:/@29K<+MX9C1I%,9D7/#SK060P[ROIWJRASS!;  4H@< 7.9$#XE?F,QY(
MECG[E>'2JD[K!B)6<8N-=?PST]*]K17OW09.),R^3 T_K.=KBNGEM\RF>'CT
M@B3O&XOZB3:9<4'AJ$A>-"NQ0H58^NVH-X$6\%6"GD$RAB)R,*_/^RQ;!?#.
M9Y+J"=.IXA]6%[M<F,J%4KURA5]H?(\>9.>7D$"$1;A6++06M\CG*N@5;[^^
MSPZ\S'ZH%!.0OD>1H37MSS=[X31W?K6\/ <M;9;6B2&7RB695X[MF(",R'SJ
M-U:P. 9BYABMJE_4V0$6>B4!!7_HNYU+>.GB?.?-[L[:ZB;?V&?4AS^\'X.X
M8Q4,C )+R_+SBJD/NP6"E(VDWK-NCFYI >%:;*HG(W)NK.8T0V$'<[BY.[<@
M_4Z^X77'9DE%0WD#Q=3'7'CMB%[JW'A\E<V!R.YI]4\;1'X(:<''&\TC08#%
M6 &=^/5X#L[1*NY!8CO3[87LX8_:U @Z[NG\.E,M7=?T3-+5N<44,]*N'O9-
M&/KJ^)A*0BCG+2E3L@J$C;C333X.J?;FEM"(D"A-0;) -9E<*&#4(;S""MRD
M3U+HK7AC%)\\L[%A-U)Y%.5_7N9QJZP/&A8^A]YI%>@9^NIZ3MU5?A2(N6CU
M@O^E8BET"?)$?H4S'(3(R:-=<F3S3HDI<04.*]'@N>FML"XX7]C/I:='_@MZ
M@E+@\1%O-L-LK)9DCFJI =A,@W\ P:]"3%J3',IR$P1<ACIFTA3J U2..&[7
M2C*3(+:'R@?V*%K4ZZM&I,RM8RG^RGB2S)OC0HFYD1>DK3=^)YW8/;$5[(=Y
M#@FD8'*/]I(@7>,+(7JIO->&FYN%A8L*;%7#4L6 %%?)34,%(@)508!VV6#:
M$HC-8)21TZKG:J1=X53V@KT>ZU4/1HE<* )S%W\0_]:>:G2%BB*JQ%$B2:.P
ME"M0PLE,3?0V\+'JG=*Q[3O)L_0R/S%WNJ?]=<K+HY/=)=&5573X!T^BY:L2
M$+TVW%SVA>-/A,U6='(-+ZX0:59 RTYZX^Y@=M#.G0+T'$]5+?-2CMH%LJ7Q
ME$<AI<- CINW8E YIFM83QE"'MW8V/Q>J+*RG.TN,>W+\NZDS&!G=9ZRJ8G5
MP@4\:]B>BM*J/Z3;NA>6?9LJI?D3HN"KCNY?Z6)"@S^N]@1#TMP $Q4'>R&5
M3[MZF9)'4/T3TH-3-WQ"=::9=.HK&+^1KN;8JM5?@D*7>'B>2L65AE66)1S$
M/_[[$5%F:95]@P]Z(82A^WF4:3@"FF#1(B5SUP4:9&?MYSKOBZSRW.4T*/'7
M=--<V=KT'))W[F T;Q+7,186$(E2%_7[IF5 U6.9;;]X:KZU2+QAMYLR'/U8
M1AW.8]Z_Z[:F"MG??@O3\E-O]5$H%FR*9(P,KG5<2R1Y/3U/#J/W\^U-LBO+
MZK[8Y35Z,CV ,A??N03-9VFD;Z/,;*&^.RW(*(W7OEZ[?ASZ&KZK8_2)/;IZ
M8%$V=>%>\.,4<-185QRV2M6%[$E4PA4& ,,?^<!7O+K+HLHQQA&!>Q')>PS^
MB<DN#<UVFQ<CG^=[0WHRR8_HQ=JF]$M('+FN_WRA^O)1/-&]ZUQ/X>I^ ;,T
M3)_1TBT3%^SE#MP6V44+%TWU@I)NE-03]W/N*G)H"1LHOHH9%@EYZ&A-CMD*
MO?WL)LHW'T]I"2-L(8*"G=W2TNJW'=]5K#EL[+^0X.ZUSDYYGA=:R)J?KNSH
M8)DBKOKR:>^39Y;TJD ,MB+F^ 4(9G!A_\2OEZ O\OA[TSB6M!;WP#/-,2;V
M9LO=>5_/!_>#RSPO06_4JYO@MZ-S%D1YXH)OJS=L%A4>B*BK)R1B-A#6^8%T
MF2D%Q<#@71EK?!G+O!8ZVD\2>M"IPMZPA,6Y[:9G3-]JWL>]>$CCR;4DG/<Z
M4D!5:OK/=]^_R;_I/"PAU3+T)X:DS=OC< Z9YUX7^NL_-N!1TNRH^"96=@Y&
M'YUCYNV_,:KO:**?J3H(12\6;9L'YHF_*:->$M=]R4U*A*4Y8"AY#[NV9L\]
M\VD5Z\4YKI$8??\^NN@@3!-W5#FI5L(@XE$Q_$3TU:>\,)HP09)?QCMU@$?*
M;@]'F=V>2_WV8?=. 0;S8V=W9BH>V>Y[S>EX;;7=MO(Y=^KC<[_.!V*U>?GT
MTCD*6;FL3D*I/E\ Z'!&78(X \1@I]8NZ:EH]&,?26M/PO&=.7%$7<#.WU;B
M'(;*=PNBEI_!&FZ]CU]Z?BNZ^:Y,TH5M_S! 2(*): @Z7UZ5[>*OV.&K&_>/
MQXK_^'-:4Q=^"6IDLFH5#UCHP#PLC3,R.7-]@&35BBD=8RS*(!>P>8.6)UX'
M%4R,C%?F*%?VNH;&T+YE13[=*P+*GK*V.\(,>Q&-T[Y55Y*&%L-ZL/)"TV$!
M\MF/(X1R7'M/[RD7ZH3.<]4UGD+4\5,$0;S/GD <M/^:OY?L(7TOGF>!211+
MEN_I<:K=F9'9R3S6D[SOX6[Y;'S"V]09W:WKN"7E-#'6'@U?G$$,6&2W:MIJ
M 2PP5A(KN]PUA9$N.IAS]QK6<$%'2>Z1>SWHV2C&;/P<=>,=DN+S3=G1GRXH
MC12/SKX=6B+CZ./ 6L.D,^'H70WH6-;J +DC%F5K,0[.QB9D@02<9];D+Q?F
MRB[/B-6VW3_AW?%V@>Q=;W[TZX^J)O:(Q&MGYN7<'S"V3U1<>>D_U;@^#W\D
MP;)<._?-&_\),Y2]49(AK9T5##ME7FEW"7,:&&3@Y3%++?F1ZV"TJDC&HF.G
M33(-!80-R\VT-E=GS1MPE[5W)I])XO-I/C1/WLEB:%1+2OECDU_X:27(?K#>
MVI+R'\&W#)CU0)EEW)5?ER"FVGF3X15*3QB+HC-NZPNU9%G]*0>CLY6YK?V(
MA?$.RH6"1VV8^ZGVGV\2'_G;"-NH6V=2&"IW2WOA<S?AT'DZWI+G19UKY;"[
M$Z/@CJDQ/FD-2C9A)9=VUKMPXF=JP)>@O\+P7_>TXC+( TQ.:7M*9]!I@S--
MP6L+X!6OX#<KCD*BZE3.@ZFZU>!T+_N*LSYO1YMS1P9P4$3\PV[-ZSH?B57[
M\4T&*_G=KT-Z733$O4[WU#P6H $V%C^=G0T<,<4/%@H'#< ](WHC2V_ZIT;Z
MHXL*XM64:21Z6<NY$2K$[2L%=E%-XIGO./=VB"J$##PZH2?Q'Y[YSA3W\\L_
MZYR4_E+[)[*R5>E(UORD]@!YJE#LU;4W-YW6'C_ZC0=.T3:UXH"%S%K!W!>_
M[!0S;A#3 !/"\+8D@@T$KT70;T%I3LJR"9I18J$57;<IQC_L<"S_:-LS[1*L
M<T7]0 W7.!CG/9S0R?JYDG,^6^Q(7_ XZ;5MO@0;\S:*,7(%A<W(:CK%!?CQ
MSC+>7''3/35X"ZMK<\W-W=,LJSH-8'F',;UA4_N:.:%1>D91,;JXS[+2)2X7
M$03K8=-+*7!DC?+.C@(D3:38*4[V(+]XGUJRJ%)&X<@.NNN7Y\-7$C:?BO;\
M+2A"0_]BEOTS$XE-@'QZNB,NY4.;7G:R:<\G[403($ASK(GG#<TUZ>?[NU+,
MU+[U?1))EXQH64XJR\WM5%1^4J1LP"'OK1O-E6:FUC=Z_7%<T#^8]),_[LA&
MSI77,[$^^ !,:<Z>9BJ-B;9ZDX_[>XM3&4$[)8\/QDA2(S,U#F4E?06.3,@G
M6F+V19VW]73&%_XHZ?O)WNR91G'2:7^>L$!43EZ!HTJ"74R!@DCAX_QPKE7;
MF%EJQ<>\5T5;IAI?'EV">O8BH8\MYFN82-!,P@LBYP)"<^X?AL?.LV\VQ%)%
MOZ3?$'+Y4EIB3#:N2QKX/N:C' ^QAB%ELRP,SEP[?#B 4\=JD>"[WON>KBB=
MG)T'S?J.X7P&,S+3\QVM"C:?N8^M;AU$KUKW\)-)&/]1&[!AJ^_S^%$XI#_)
M9_.RK]@!6//N$P.'XV"-7?*,-Z<WK79D"J8-508:TO9FC,(";M]3^6'4#[&N
MC*>N!F_=HR_%/ATM#OA(9 @HIUE_B_DY!?II:=GI<\J:DP>N@OR,OL>E5BQI
M'9!"R-OQ!EXS10B-?!S,*2=,I#+C!Y'@F?^G):+-9<\@?&:*XMCG.&]RH:3E
MLF%8#;OQQSOUW7;.N+;4P)?WV\([(_.F*AX!ED%,1*ITC6I?@MB@83#PAK[S
MT/&.:;POE;]N'L UP!;!1\QD*MWGMPE$ZE610:S>3<0!3PF&0;$_SZ[-(5D+
M<SO!GK7R='^ZES'H_NLQ$A?;J:$>75)Q@R(4!LI!^8'Y?$9D$LW5'E1=8:5;
MQ-<H0O<3AE>=8G[,&D'72;%'-G67H+Z,>,@+S?YQ>A<,^ATD="[9)X2Y"5;9
MP'JV=IAHTJX-%I5YV%7=]1PK^I08S:'_;WF P)ENY!!ABO &SNN3CR/WNY<N
M/?%]GNE;>#;NL9X&FYK:Q3!EL,"WN1J:C<J__MY!/(>^J&>/H.^ :,LGJNX?
M:ZL";'0!VN_[6QR8!#ZMKRBK ZW\WS1@2:5P[/FZ][A2Q23&9=C\OL9D0/.W
MBH12V+V?]+;4U=JC(TH+W/;$(@!2N!0"X:BU2H+O6"TJ"$S@/*MJ*-15"P;K
M\1ZETUF1?+VAFA=MI?BGJ1(1V'$-TS)R"X#19$MD\"6(72:DZ)QN4S;B)-+"
M1E/^22%BI.D]6,;+AC8Z<0<OD;+S@%UK%$$\$5()_^<:I^4?]HI*NU^"R$H(
MQDW=)#JB' JR#00IUX>?K7)B4E2C3F !=_)2'+)=M)AL93Z.#?#E;JX\:Q1*
MH,"T3(T(_-O,;PD<SR-)F"]<R#B+:SR_!/D,> %?B9#%<^X1YH?QK? #$N5+
M4),I<=E+.?^%]EW_+VZPU\0>$I85S@!"%K0V>0E"^S<0?:IU^-]BP'KD0?[;
M.@UXV[AOAK,M5TRN+S3 S;^YIK(B>/>&5Y&)U_*J85O_NE -+_4G=:5;!8?S
M]@?BC:=0A7_>]@*1PQ_5/MV!KES@.SQQN<;#@'BA$W_PYT!*_2D+Z@.MN[='
M9?D-RD7FER?--M=#(7'/ -+Z"=ZF)GF;OD4V!OW:I9$\G,_%0.?D] T,XYJ2
M;A._L87P8M??5O,>L8X:ZQLW24]_Q\CK;)7^PH,FWAH.PX1##R,(;Y R :26
M$D+PSQG]5>4R,+"G8L![YO8^Y^^NZT,<DW3C76)B9-^51CM7WFNX0[W!O0;"
M/S5O3B>5B,3?7@(&KC"\MMMZ"?I.>ZBYXUJR9]Y&4)=EE7GA)A,Q&[/\8_=U
MU=;KW]]D=92U#/A?WTL8,M#F>]JUR,&G]Y*$S?W7()]S6TUVX8$B\6?99??3
MX&OKJO@1&89?2^<\8C'XNK-%]<AIIE--$W:A<<RM<)GO2KA ,CC=7==;F=$\
M\IWWVQ/R2UZ%<*5'YP!JKQA0>^CA2U BG V>0?LS8_4S'BD)]S^>-R.=_B"]
MBY7EJ^1!;+X[GB&+SYM/GG7I)G]V46MUK<:3^O%"BE=Z1%X3)T1.ZFII.@_
M1!LYW&Z'SB<YMZ*&?HVM/DO>,5.B%0Y#,&05Y")"?A<$RG4NI]#3TP7($3>B
M?XD3[CLENT5 !SEQI7A0M_[:MECK7-Z0[=MM21S7W6,W2_7*9NR# G8>Q\U3
M#W'K$'SO%6Q?.ET"0)I;/Q(W*Z?."304R*U:2NPK7-B[&2[!9+.-<Y8W.IIW
M=:V_L4\SOK'>+-Y:UM1G8.A)W?AI&F_SYA:P_.( K*7N:F'VL-H;#Y%SMV21
M:8G3)L5JY/F#BPLO3%GB0D"*=?MN3%G-\#KW\[R7Q!V _UQ0&63!^7OF'Z9M
M"ZP)X_?ABUD!HAX9/?!EN"@6OO/S$I3'@&>GW8?7HLV*+L8(3'@[^(Z;P %E
M_<!%=_">QT6UC%;M>,8[0,5M'T0&P(5<.P M:@ 7(-\[U-PTK]J Q]S%^R_0
MS3/W;X4VF]D*F>6SF)P*+PO=5P]!-0TE08:C$UD9"\M4KRK0.]J/%_5C6D;7
M<<U^16=<6 7<']L 0;@8_]J"-!S?%$#IX2]LT7AX3[/9IAN3WC-/YW?'@K#B
M_%!?V?W5;N3\B:AQ(6O(,XY;CEG&.*K'P(N"<4_\LL\4#TYQ&WMNP>C^VT@O
M YM+D(! \@6K4;-GWM_SXY*3=)ZG-B[%-IZN>1&?SY=#NVQI-D_6;CX:--..
M8;?ATV1G5W2!0"B>1:)\LT,.3 C+$@0;Z%DN'<O%D@21R4&&\97(^(P.Y)H=
M?@F9\86V'W_C:(<B>!0M)AZ@X 9+IWJ[>D+@J.))WUGH_^).+_X38H6%B-;[
MF)K^TOZ"4-$1$FTU7!6@!]Y?1 L8!\&2ZC?\\"W!E:6/T6E/NC=UD[_A&SV6
M,^ND="5^*X-&@?7W9'VN=OBO80YQW]^;CL:J.EOF01)?/O<XA@)+6[\*HQ%3
M"ZUB,J%-B6A-4..NAPEMAX*YGFS)%S=&?ZU_%%GPCY3-.O2 %O?B$L3/3_P)
M.G: JPA\3%U?SC\8#C&C.?!A[MQJS2><NC6Z+1HEF*?P&>$](]W',,;;:5/Q
M%XB!\%<LJ] UI&5J.Q"I9X$7F'N<W*R0T8&WP26NDK>N3)];^7NM[6YNN)]+
M%+0GMO^R/J556M2OHC'1K>'@39!)A[.+C(:H#3*H+.[( 5X!(EAD]*\O*V.U
M",XL/9'E "*LH5#2>IQP?$S1-O]$N_7I'7=Q9CVF.RO;S3=>2N%"_VQ:$/C^
M0D/&QSJ90V%<Y(5W:HB9A#T@XAOC3$88D;AX8*$S5E</9>M/X9IP 5/7,;=8
MH,GII$7,$3;8/"$9D>J\Q)TU9SA0NUR@U3";%QXPE!:35H7T,><J6"[Z 70K
MPD\/IX O"@#614HV< R@(GM1C%5<![YKHKIX:YS1J)$C<S^!5C5I0%_NVPSL
M&0"J'3HV3AS%PZM<MOG?-4WPHIO;^JJ%3YU60XFX$1X X,8(FD!=@ZW+$H<?
M\A"@LOW]:_!W&$(*P;P>E8?F))A/[?HXCV^G>B.\F,1F.B"*M17)+MW:&>XU
MF@P7:9+LDG8!1\UZ.MT&"L#4/SS+QP;C]/$"A ]PDGR".OJ1N*W>TNF 8^Y9
M+[8JIW)<.A'/'RN85/R9MG++PO\2]#6K;U+3**-/=U#K>4K=F=/89'&LKO94
M/W4Z(,2@ZU8'7F4!#O"V+-F$_"Z9F1[7>;B19UF;S\, O&:T^5GS%T\>EN0]
MC4[7AP8=Y$='1CWO=B-*!:F3"QP1]^F?1"<0?S\6Y7V@GH^,4\9S?UM4[D+_
M=8;Z.86BPF8OGBCSS*3YQ@VL5AZH.=J?2]%-5@F80$UXWZUZWA!^3)>@?-#'
M$2KPT*V[\52I#$=K]R[C)O'ZU<.5,XI&][/O 4/3%]\S!/^@W3KI\M-37:T9
MBA['I),Y+1C:GYPLS]U5T^\IC:X$57UL!20[=#\V/#(.W7+[, /WU8VI2N[C
M E)6QA%C=DH;:(M(/!,3*BVM>'.>&,'QH;!.;'FP+2=+)%V IV \%'@:PHD%
M78+J;>'IL@0&XMU@K=>(=4,_N@E4V?AO 23XW+-K![[KXGZ_FQ0"O,:E2U)0
M)L*/^3=Z=99J=WR%_5<6.RT/DGR40@,UG&NFZWH@R@9,ZIH&)OJP8M>*LL93
M^;K^@/)9^% V@3JR 9D8V=,\=-+K)PX8 RVEHZW$YYO1&?>4Z^OXE6(=^HU,
MCSWNZZXLN8N_L>(R!\=IE"^QAT9GAM9F$:_!Z3R@+!9#8O4!#V3=W5M%'Z"%
M6P71%,@DSBZJV229[&%KFP%=EXMN.>4FSJS2B-(:A)"NB/L.>=K#]\U!7I]Y
MJ&&1.DQ,4@>^91Y&3;2_9>4!',@X,[AY> W [?T]WFZMQ58)E]>#\R:<]FL\
MS]YAZ-^UN(Q1@Y\/M-B*J0C=I"6QU96*C$C_P.;81R8F]&%4905PFTXX)W_!
M++I_CD!=B!] )FIUVPTN!O *=(4)V%C4/K!Z;!)U+A5C^:=;5NXIHC0=@<BM
MV&Y]7^W -BHU*L=K:T37=05X2S*<=WC5[D 8EP)_GK&^K("]!)&TU&$Z-N$I
MYVU(U^/2VV]7R^D0S:6^5;[\U ,K&3<A<M&%I>VC2VM!?Y'%?:%B-5D-M3PX
M UQ.'LY:MK*]?[I.VW<)6JLX&%XU-:N:O:#%-[6^')[(8)2H]5^L%TSZKNNJ
M.8,\F#$MCZ2!JHIX2R#,6[M"C.E90W-K5 V8%+I?_P(0UEEV/]ZL1^*S#UR"
MY:\C^H?S%\+[[6MZ\&S5P_C826E^2=9X=#W9U_O?L^G4QHXOI#7RQ-SJT[,,
M#GA3TJ$P3,&U)73/\ H<__/\]MHEJ']XO0A[NV(SX.4I%&:P*".Y0U=PKJ8X
M(WDU)?3%6U&Z!HEMMY5GMFI*/?\/>^\9U&07M8WF>:PHB H(4A\$0;ITI45%
M"-700A61+B7T)BTJ M(A=)#>0^]-0$ ('>DE]-XAU$1".'>>;[XS9^:\/[Z9
M\[YSWF_F&_UU.[F]]]YK7>NZUMYK[1H9;I6O)XZ%)JI:Q_PGPV/:P+=\F.\1
M6"W8+5V1))S)L V[K>DTNH';6"(NNFL:;OBL6SEIC;DR&=<WG/DPI1O@4D3Y
M7FM5#-8Z.6L,]3/"GFU]-,U$IB;=+# &P"FHI35M)>T@N@6\^&P60VCU4J:8
M],I;(8YMW-G>Y:^>K3:(%K@C:7NG,<UUU*1LLHB&"<;/H6(.?W=+'Y6A=TVK
M&!9=',NN9JP S/>D._[%R5HKT6+^X#LXXD+]2,=.ZXP?73#-X&=A4>Y:[STG
M9#UMUS#_,>'43SFJS<PQ4<M;BX[16H_[RP#7BP0I)\5[ #DL!"\R _"XN&_G
M[3A(.-F122<>>)=M()(,XDU.H#8(#W$YSH,B+4-$!6=X/([FCETR7,<JWGD%
MTZL7D9]PT1_Z5?;-(P"0O"]!)$EP>Q+QMP05/A315H=(H'WMG>#GL=;@18;%
M6)VZ+4^>0P4-_$(<E<.V?1,R,SO6>!R1FBMON.G[LC]2,HG*287IR<IW&M%+
M.0&N8N9+[I+;3H0B#G*EYG^"(_3ZAVJ)O(197,Q%5.6?"'%#@[@O?L^#,_HL
MK(YU8-5PVPK3I:G$1:BTV29K;HGUQYS4U[E"P'NX@("BE-!\_1(D4;H.)S2=
MO;'.HBFK%3.6L3UY(%,15/"!RT%S'$%3Y G1Y%:P*DM>IY'C*9QV_A8U_(2>
M*QU8M%CP09QA5NQ^T=F1--'&JR;"Y242WWYX)!BZ77=F(W\TLOM=U<?7)4>2
M1_4#6^%,^5(/1'A$EG"/:W.,S6\,8/ SKF-5D]/<?6&VS?02M_1XK->&^S.?
M1/X(R[DB;"7'\?.^[Z=_>^Y>;XE&'V[@ (%SB[(0CR?TMB3$BIN[C=O[>N?V
MN.RKP+_.?.2EW]GA%Z8(&5!O57H:Z](MB#85EY<(2"+[6N5XZ^%C#Y1%01(4
M6 E#]Q[I+$ ^G^.O>'_!&%+-,K5/>87DU[A@=/(:*2LLTHMZ%H\8SIS4=G=L
MZ[JTPQR/=6<KQ=SWK0J8V(-\IW[>&?Y&ZOTM$D^DPF"5B70<X#4J9D@UY> J
MSJFE3Z[Y5=A( @W%6X>63;[R=?HQ-(-YNSC&9R'4K-\D>+_AB(H, )=IPF^\
M>Z.O$Z)-7!S25=+>I;TFR>-@R_QCRB<JN2M;<#!J8)?YSS2#)EM<K%56<(*,
MA:TX]F]6.;GS%/I[L5F 'Q=2K1H=ZN$,1HT.DF7JB>8&EDQ3K@BAY<T[R7L2
MS3,#>][]LI+V%.C*@]*O?O>K'8T_8#VDWBTJO34.CH2]O",3*2K;$@<!S+P/
MG#)WBD<<ZA"I* X:Z\7DM-<&M>R9F[?N#.-3U*O'/UI72%K#HZ3EH:Q&C((*
MEZ#6SH/HAT9&/46L;$@=D:$W4"!>(O \A(< >[P$G0Z:G@@,M*SZ1\W4$6<W
MI1OUDVM19]>/9FCT^J3E$0]U CZ*^X[UKZ!0)D@^5V4Y&.B9=6+L>K:HP#6I
M42(0_-!''GB= \V5P*/C/H()T=:P_X?G)0CO1F#>^&/1[KKV*-FC-V)6.JKN
M*8ZQ_:)K\EE1^%H0AJ5^Q[I: W+_O<K=L=?5AQRRLUXY)&4$.0A9WC\:FING
M;(FC]=TKZ26^,Q+^(U_IL:OZN3[?O>CI[EX/1K=G9U:5Z<89FB:TCV=DM^_.
MRZ2&#':E'OTD):7@:12*WIBEX4RU*>2 )0.1,$C@\<-_/@9W>[C'F>8=S#.)
MY5GL\457.=,D/#LCKYNKV0SF9K1X5\G _O!*R)=*+F8(&BIU7]3\&L-#*2MV
MDO^^!\?<4-V9_\QRD(U8\R'4>));8!%4/+X")NZ[E.\LA$1/YFW>3H97#*B7
M%145Y!>EY)O,?[1FC]/3=_^BVX>,^T;:#H[TEB.^0?2&5%Z"%A41?<H+''C<
M)L%Y24?.^UU@N6=IP26H";.7C-,VC\\-T48P9<T<G\<UK+NN(JPKV=1OX'7P
MI9.Y!P"&FQD=Y(3*2-HCGE+B5.6O4$)//4)9^E3"66@52Q2EM$8Q$^D+7\#L
M18?-WZ)T-"L%JZ>"V$E'0/XBNH%I/<_6X@G<;'AK;]/=[P&[Z)-X:P)G!GK_
MUQ3-?DB7CDDY/O6X3WNQP_O%(%3N>R#SY-;R/<6D %0&*Y+KH3F ($T3:=0-
M7OC7B+;\9FIO. X:-L/D,P3FEF$Q<VI*G*A7&3 0H,[-C:AL#;,1.JD^J4 S
MZ[PW%;H79(9@S/R0B>TD !/ZA!"S65)%=$X[R+4;P#T_1*GN-O@^(8!POHW+
M#*-T1?UVM$R),P]OUJB<G#CW!R.C.2F1666;<7I66U9;YD0*92#FR;(+ V^B
MN@1Q08-F50^<B32F1Y5+ZW*R=042\44R= 53=+MC4?D]X^K#:UA#OKJY3Q-C
ME6-:FFI:YBMY.8>573'EL@S=;*QN .)[D>YB\3XEDF[6COCBE4>D,<<BE@*\
MLF0N0>F^NL>IVWB:^?/;Y_T_3(C@'Q6Z[]9F8NLCEB+WZ(YT2\5L_GJI?IHP
MW2-!?>"AD?@^[@,I4]$&7GQ]=\CE$@0E?>%*&-;T<5T#3UZSE?>G5L+'WMR9
MXL(29*#QDA!&TW;X/4?7&JK0R;7JY"'3O+(64;\6F>%H<6LJ*35C.7G6*].8
M,(^(CT ;X:!B!@N<1X)$PYBF^#$]INA#Q,/AB\6JG!E7?%=M'"7GM^YU'BOK
M>$EUK;)F'=H:)Q'8O5=L64U:-'?;%365KY+2VO,! 37)C^4@49GQ_1 C928X
M^[2>:P?WC;"J.FU#A9^3GR"_/Y%R7]GK!!Z#XOSS^-7YP_N;A/"%F60HR_0\
MVUF>@<Y><8J$QBHV<MT=#%E:[3)!F86;Y76KYZ@G)6F'C3^/HLOZRW2O::SO
MY!)TN(OC)'R3$2<LX+VP+,7N;E=$:V6>6M36[&7,?"3D+CR$[LFS"7SO'/E5
MK[AVKE?(HZCH;4_-:ZA<9$5G#BP-9#Y4U*B+<B6OS1>S&[$6>W2C(I=H,\]Z
M=OUP7F^NJZC#;=<%H\GS&&[(/QW^3*QFM'!R2D*IZ\/F]EJP7(GN/R4B=YMN
MYH:GQI/*OL'(^"/9N>1V(M7@%)C'"^ID=BY<2;SA.F]F&S:4T)/S>HH\^_R*
M'?\Z1FML3-3;S"8'4Z\B)U4= -%+.^/.%65Q:0<"23=1+:T+LA1Q])[X]CDT
M)>VY^ WX*;0W+4ERWG</)7,:Z# QHKW;+7@>P5?]'I77\5(MX6WV,I=??I%+
MET8_9;#NQD)P:BI=-V E[2V++WP*FUIB!@\?;\^'S7+.&-;6N;N=].^F!=+Y
M;LR)#L'V:EH9Y8WX4HI0W=EW>87&%P_N+PTMJJNK4EC?LH1\TB+EU<J,^"OG
MNWB62CN) ?OV*R>'Y^56X,2\3NG%JEH9L%LN3QV7/#Z5C"O_C$;5TVZW-&RZ
M[A</^UB$JI)C5;6622$#'Y^25A%I!Z4Q;;U_ABXBLN4Q8O')Q47MM-C/LXB/
MIN=^-W^CI9Y8B8LAEINM$XI$E:H%N0*J;9'YL9#<%W2D=DE9XD"L?QW4S$<8
M)RJE]2U%\P5C/'P3\4:4K]WF;#CI@$#46+\5_+8HT[/=^)J4I&^(,X\-1=:>
M2C?\#L.L5P&B#WQ7QA+1E@R.%>B\T6IZ9$"U:*2\VFRV[^W_MF^;R14&_+F*
ML,F2]6DVL(+'0^[,:;Z535="S #S&-N(6(4<IN,;":LM"7.[1/>FJ29'0PIL
MLFL_%K'HKMBA/+D;ZO)SS2D!CDX(^]-[3P>9'<7C\*CN8A<F#&N&:RML:7QY
M\D%ZHJ$"@5.>Z+&+^^G]FVB2UINW5.IM9W>,DZOA6L0_/T _;MQP/J[6HK.R
MP=;M3BG?LG1,2)I^8MQMIV(N]5M+8X0^J>'CH=80>'9L4*#AS*"2E#=>6\5<
M@KC!L3?ZY]?Y")UG]D=->_W;P1OVH9@2^Y!+T.V&-]SOT+:FN3>$8]KMI'[9
MC^L&_XAE#S+X3(/>MRY(*CZRKH!HQ-R3?0GX5/0EJ.U=LZ9+S96UP"-JHB&8
MQFO9V3VOC:\<2MD]&/"<;UXV+0>5WJYL%(:VZ]'5E S]-3XD>T?9R91K[4MF
M7,+HV,@@,C>(N%?R$="#!L#;>'BLREMZ+5=EY&N,*)AN],U4P]].ZU7)/6B;
MW&>S>M$WK:Y8=C4M_2H00[;\B7R$4"+D$M3'4M9L3_A!]&SYIY$Y?H72]0SF
M2[7<W!H<495M&%W&E9\5?T4])+JDABA[W2S;-L1T*;L+JD-?PSX&?;5OR >S
M;SC3L;H$D1T0S:TF6'HF\+EP3]^AWK.]'B*,HM$=C?892\SLEC5 ;@>5)2?S
ME&]6K7(5/ Y/:FBQ6J%XS/1*5DSLUK>-]0!D'/V'+""XW?E/\\F-*6!.(EOB
M*=$#.41Y+P/1NIP=YNT]@<\,!A]<H:_<:ZW6#RO7"S;$F0^G)N$_IVYY^\"N
M4W'C&7U$'#CGU;6J&17IAZ7>Y,H#TS4*CLP[/,1Y8<$+9YTL489_C;+,,*_@
M;0YJ"\0GNJ27+Q9F'QKM7]<N_6!Z5$UCU'ZD]R..AV:E9XV'$VMJE;]H)!YF
MJFL:+$*J2DO#J: /57'2A+YFUK,)>T)3^ZG;>==.:>2)H5%93?-MYY4RCU 1
MJQJW.>U&/F75$$_W9+Y8[Z]/M;K5CEZ_1P^A7A6%#P(&5(&0\.8%BUZ"DMT/
M,XARK@9Y'W?!P5-P/P$?]]Q9# T7Y&(QL]6T%O:.YYZH!DJ+[,G3)B]#1KO
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MS58IEF;NS4W"OA@KAJ246#](NFECE4GJ^=T2:]G5LF)^Q+#"<0DJ(1JTD#=
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M57_.G#7A.W/&3M5ZO/:J*T]6L@*I9'6DCC4H"F-RK;/E\X)KD/J*9N$?5K2
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M'0R;-P8NUICXGD^/5JEOHXHQY4/5,B<=;5>=%*;+;R6^9'3[F/?KY7VDD3)
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MM.J,SN09B+YO4>HTT$>V:JO2:[Q^ U.'_@#NT(-*W##5K)"]0669,JU@Q#O
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M6B$B4#,H%*;Q<< Z)U$=EML-,X2:2=1X;?Z,!*R.B?HVC^$"=!8]06R'?9U
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M)PP,Z- 5 $31RA3[]'%R'!SE-7X&$G%?]9TVN_X1]]I%]O[:]\6F\%K7>F(
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M"-UAPAR.SNNK^?0]]1"?V/C4_94K,;1SO:<EJB SFUTQC?2P9KCZ\< @RG!
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M_,!=3@KMVC=A.?K$<]TP;=E9N& F*&O,"J=H5+-V([\P\WRUV9@_!&3RK[=
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M73SK>]?PI*S75^V,YM W90TB;UO[7FM^J1GWBLJ**S.[\2;;)S?OZ$V?WE6
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M>N>Z6@JAI_&XGS2F-S;>M\NN+@+0H6-?\I^E, \4$Y=QQ%? <B&,X.?S6"3
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M0+F%)6U@]5["M;]#KPL_-<EH^E4(+E8)"'"[='?\"B+C*4_6.A!WZCS_A_8
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MN^[$BY[*'X,7\:=SGW@P&R1^XR*-T!);>G4=IG&WZ7G1RQ5#0>JG+KJ]9>C
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M\NGC7ED:W)%H\H/>G P;FGIAKIBTPCD=W6\O@66XC%,A1 -?<#O$[?@%1JW
MNIN#(,[6!\=^GZFLW)P;#%^O'G@='^#*].@X#!!Y/-Q02W[J<3:K$KU>,>&A
MNC%U<F$^J: ]HI'\=52ZW/QL8.#:;TV=$[;,6Y5YM;:N9MXA*E1I71F-[$6E
MD3=3>! )>2;&UDG(.2V[8N-)J:2/4,M(&Z ?6CCO_7?+>U]=BTF@YR@:*?B-
M"7J*H#6#C7[=5^I@8^/X7H.G"7E(UOBJ;$1SI5[P[?P^R\*WUH4%D11&>6$
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MYVF.P#]'!FGE5*]H4ZGM,JKU1,>G_=GTI<2T3;7#2*!_ N; 5-6)O!$!";!
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MRHC9Z9,[XWP?\CA?-=M^8O;&M!UQDA$:OS;-_%!:>M5G9#XST2](94$L\ZB
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MN_6_2RKWOPW_-OS;\&_#OPW_-OS;\&_#OPW_[QM*F(FA(CA50+<@UU2(_N(
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MP:UQ(-7+Q FG-)0D=)K^@$Z;Z'7B*<)T]-;;/'UWY=<6CL)JEPD_TNXW2+C
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M[>_LHFLLP&X+)Z=\-S4C$5;P?!G5/M!<75(D?]+;R18< ,'HGI,1'JL7T&.
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MJ@S/[.W]6N&?1$A;C^^W70%.",OI3\K0'XOI*SL?8D=B3)("VQ2@FD@>@2L
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MZI= 8:5V5&R!A9VT47&%CCA,@@WX"*R2TSLV>Z\".W>1B;5>-]^:9?O9Y$Y
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M%]9I\*$-BM,:DS?XIDJKI"C0KS"B$J26&E>8Y+[U6,:*<2/<-'P\4%JI5PR
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ML&]"*#8'VH,1957^?9DSEQS;+0'@8C?=DBK-,046G8*B]BCTNCW:(%/"9&E
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M+7CFJ+M=C=)U([C,I6#"]<QE=RTZZ1R7G;WFD7KOB\O.OD\;]/PRAKQX(;O
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MYA:59?W*Z(.30JD\%8^2DE*FO!PDDPE'SP'DQE8S$1H.Z*?Y3U(UHH!L"PM
MEI/DO1F(%Z/3/)F:Y9PV29\\@I?,QIV[W5\CSD0_G.1'M"9([]_;I%'_. "U
M^F^3N=?G$6Z7][?\-A#><W6'QH?HQO'&TQ(WO %OP!OP!KP!;\ ;\ :\ 6_
M&_ &O %OP!OP!KSAO]2@2MW7\FZ::K)</%[DT_1$L+M<7O<JYZOLW,^=+<S$
MDK(=)/'NM]*_UM^]VH5S'2(]%W6%G6&(BK" @?>D6,"HW_EXW>&)\SKH^(S>
M$ O(N,:&!<#/+VZPMSR4MGLD5HT%/",$80'@TT/CC;GUGASIU=]NCI@/5&F8
M@HM@FH?CE:']OY!SYS?XI,]UMQ#>)5#8HQ@L(*UEM/GDK@GTI.0B;BQ S8@#
M"Y!^7P#=N_\#"]B'-+NA&S')=5H8Z'4=+&!-)@@+0#9?_"I\B/@0\2'B0\2'
MB \1'R(^1'R(^!#Q(>)#Q(>(#Q$?(CY$?(C_/4)\=HV9[],,%?)%^W6NT+X%
MKH@N^9@?(')5P>Y"]0JM[_UD;\5B6?7>RC"J^YZ6N"Y??(LW[GZS%]%=_);_
M_PWCCAAR?2S 0?+X%180*/("NM4UE8JS'Y.?_G,#PQOP!KSASS2<BF !W_VP
M %0O%M"SB@7<U8:>5G;A8(Y<\/WGJ_9R6ZOQ[0X1Q]#M<!]7QLZB:$S$2;S'
MTNO]I!!K+("D9\%OX;FQ<0C;LSGH^Y)VL_G?NIKR/)EY3T\$E1B$S80UM$;U
M!MQ*^L^O1)\E8 %;1-('#]Q+L !+AID!,4?]C;D](M".)1;0\ 0+F/@XU7R>
M['WP;KPRM1$+>+J$!3R$GK:&GW\R*L ")CN:K>B]\1YX#[P'W@/O@?? >^ ]
M\!YX#[P'W@/O@?? >^ ]\!YX#[P'W@/O@?>H$CUZ/T0/V:Y?M-3<<U1!A:,M
M=?:;9J,OE1TTSR[Q2YL##V.UCIH.>72-(O/.)U,J01I<N_8Z@&L3ZGL+O]<Z
M3TMT_MF%@O=2""P@G)(#"] @FSN-9*QG8X"?B;'YS:ZG_G<H7> -> />\"<8
ML@K&(-L+J*V3@&A,=0\J?G&XJS5GKF[?X9\<Y)H :NYHVSEM_YXJ%E![[[3,
M"5G2FNF!0B?\Y5+>-*ZFIR883A][=$GD<6,]I/[K.<_X)%%+%RI9>WM8>ZPE
M/*2/58*T-YS,N>Y]=EUL8\FKSNT.8^H-7= )(>7B^/E\M0MT3?[B%9V.]D<I
M$)FUH3,P%O!1U>?.5E-KVWZ_G?VC]J-Z8;]TS5?5JZ:JGXNG>@2ZZ)QDHWO4
M1[B/PCDBTFKRLLGN,8F/C#T51$YX[2\$%B5D18EFA>EE TUB"2)5J D+"Q_A
M/K<B'&[\"O= IKC\"551;>*S.2P@M6H6 Z;/&$E14=G>25MB0&Z&!NI.>,(%
M9T,J<[ZK/Y(IG>ABN%=9S0S.U<R,JV&.5KL[6'/92*Y#QUY27U=7<?C8Y.R@
M%<H/"J)56;[&^Q*FHVMQ*.5BA9:J?='9GZSJP,C,PZ\PJ1'22A-7V)%H,$WS
MY+E)MOSI.X(R.YK]3(X![[,1Z42B;HR.+WBLL:#)J\#UH$F\3/R:6E-VF[WR
MB?+-=<OG]CI*VDK[D4"Z2*IU?6[NEN!4>=2*F-=O<F0H%K#V&!(..0Q ]&$!
M&13$6$!^X_ /Y!2QCOU9@_2\#.06] N;B>D)B%:^R8NMWN73JHU=V+ R*3 U
MZLE9V="\P).3_'4D5Y:\!=DHWV _9X&0A(OUZSABXPKUL&+3RGK02]=P0T<'
M!$JR+W2RT6/<T+G ;>M.7YSO74T-306S.(7*240AQ9,!P:C.+C*;(;'\:J*"
ML3C?>2S@%F;FM>-9'W&']*=ZY_K"-<ZEG.\.CW[]U'EHRD:R/J@O+'#OUM""
M6XH.[+1N93CG,[(M2Z=G;S5PM!(+X& \4E?4@/+UH3#OQ'E?M@PP,L&==I;<
M XBXH\V^&N9P9*5F%J<1&TH*L<H+&\2%I2 -_,TCNE3IRK5&5'^E,$U5>@WS
MB$T$(DY@!K$^0[C5"++?"F;DK.]?=)@XL@?-3/R,F8N5])0V'78WF!]J:F:(
M;(T-/S+9Y/Z6[>.GKJTAYKOTHU&<CUVO/897K9BDT=ZHS,.=%KK9E]4LO*RL
M8X]"5;&+N-\JYJ<VS^S2E-=782I#Z!O?C'U'=]=!<@[N"L.MM@'J'=.EA]^/
ML@8:<W9X*TC%'[4@)8L>;<X,V">Z%G0""1SIGG$J>SZ$A>DOQ6F#B;FM>-W=
MU)4&!3>^Z<+?833F?KKPGHW6;RS-(EKV]BDU][" YR@Z(BW3CMA"F_.VJ"0N
M2#0LL8!'4$K"C>G(*FM[2"N[Z:'EJ+[ZK?6AJN+"'EC!]J%#P>A=J+CT*@_D
M+'^;GOG#I*1X.*JX"SWI0LU)6L<%2V\UV7[SL$-1EV4E3@1>6%20QD8B0V9/
MHA#$70YT(M,")X%TP*.#F1@-+*#7)N0XS4<Y9(EKDV5#<KK:FY)C!!%4P8[,
M+LYXS_<YIWTISL[>;$"K3Y+>@DU 5C)54EV5921GY;?G\E3B?BX9LM]WJ^B/
M@"P&[4)Q3^CR9O]R8[,SA,YK$>:,*-H1=:^D6/)"C#[N0'&K2FE2Q 78!%DO
M^>0:9RDC;90T(P5_VT8V2JWUJQ46&%?=V#A;=EB=,&1V7HJ[VHFFSPK]J5O$
M&?M955?^CERFD(5)'H-L-@7+[<N@<<1)B?+_Q^Z*L;QZ<0S9[CGJ>+G2[QX6
M4"9[)GW:MX,,7&@^P6VR0&/(]=DM]JKX[:U?S3,WSE*EV1#G\7.Y!6^D4(XK
M9..);KY4)89&WLW:_QW.+;P!;_B_DOD4-:_>P0(<:HYQAU7P<&WSX<WSM=\;
MIN$&-Z'??9IN^[AB7J8)> OD^JFBDF>1$]Z6BQ2VY:549T0Z]<3\YFO5.CUM
M6KVC3XXS$A8-N$<UOR0$"XC5TD0J65_U<NL3,\("OOM+QQ*K80'<35-KO<T=
M,V/(Z/PFV9<"NXM5%MOYU+<*'^K:]@4\_^QZS!2IJA56 .L?;.!0+P,1YFO
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MQ-D6B7VV)..!$5Y*'F'/JJ\'Y<&#Z& (K04#F[%[REDO5"2?D\1R+8=1CH1
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M![R9*&BNNL[RXDID%1:0+')>M[@:B.%26\$"9M@.LUJ+PB1]YIMC''>YL8"
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M,A:P0X@@4J&43J.,R@\\S,\>7-I1S-0.DQ^F(:K*A!5=EUYC=ESEPP(\P[&
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M0C4=(!$X J9KOF9#Q NO6PC)J_)]#@](?5Z\7GBZ^;E4,B2XP4& (/()P=5
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MCE&ME'+;C$DS9NY2$,)/$2PR(^SB']2G/!6.$,N'A'=6<+4R0:,,=8"F6*)
M#] LA&3)V;W.$//WT**'Q_!"X6I2X<WE()NY^?@K=VRM(W,LU"_,W)#?K+N*
M^NQ;"\9K%46W$K-\?4ULU;+"RJ5'8GKNT* *ZYU[Q!^4T0#J^?Z6QSR$(1?&
MDA!=IFBZ!G1:1MO,6,]W]>#I1^D[&-:3^MJ%8/Z(JV):S$M%2.3.<&4KS>"@
MB8F-#9O@M9S\B]/.'4CV$*4.HB G:;:U&;%+NX$^&>O:'N@HYKM:\S>E55Y
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MH,=\I<%8?'(M"^GW:M.83LUG7S%LYS1I;F^&#, [X$ G;@/'$WC?X=UU"XI
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MP9%/W8KG;ERJI?QS4$3E4)ID!6K=^<A=#Y8P5-*EGZ(5X3;Y;3Z?)_]#FHI
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M$H[*#5&\KL]>[CIG$A.41MH(;C>W*6=DJS3"'N7U\U>%)+LJ4WU.T<U5CT?
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ME[BNW0PZBSXA(G7^+ G$+QJE? N_@*2U:SM)EI 6NG2SZ>1DJ6#F+-(TP&/
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M;U&#=NA@UF"Z8U.%H_5'?GC"K'A#-Y>(JHQ87&ID9IK::&E0J]I4$" ,Q_?
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MJ]C>:P_>I.66\I0)X'N2?"\I@<?:_<C&,N^V&GE 418]^]#TSUO/^A/Q>NB
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MA:QX67E7U)LHED1LOW):&798@I.37B+%G4O\VM'8=4 ?NN@Z3I%SJ-7@ZDV
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M^;@JA?7U>FXDE*/V&ZH[./+BJ]0BV^<"RWSYH8N<)%#WFT*OUI]AJ.9"<$1
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MV+MQC1==QK'62C?%:8Y%(:&_2UXPV'*:"L;V[&NQ<=]3,J2S3WKF1;&T_Q'
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MD4$Q:6#>N*[M&U0.//P93KU*#:XU[T7016T:&9*BX7[1/Z-"O&W;H)"@O&*
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M6#7DC]#L2\[-P3UW37 2H*ZXK>_S"8\#%+:*28\Z./I+!BV10>&3.!;Y,-X
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M&6#L ?-2&3J6TN:MJ>50<7+,7GF;EB.ND?;;O"+>^]H^@[>\K0C[[:*'?A5
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ML/*6-[KXVA1DMV-M]HX>IHE$M5BZ#4H<09/7QN 0,QT856IIAL[E>_$\J<V
M0/)W/H!W2R,F#VQ7S#II0SSF+GN.F[7/L04KE:^?'%%9P);ZQ;>S8@WY+3LT
M*BO(H+=#R3WX/J@%,<0 9 S@P,1_>KLH]/U\?A \-26[H* @I"#C_<3#A_<%
M^S=_\:,*N6+_!9E0".M\V<$BIBC@#7&2\&7?.;5 I-YU!CDKFU9>SFQXWSN"
M!X?JKQ'&&25'R,C+R_.PJU/?_=5+'[R;&V[-;0:X9C&"R(M>TN3@)H/BYEI-
M%VR+DT0J&C#GE[:O[D.NK>L6F.M!MU19[%4VX,7.PHE(#5#'TQ$#&LHT1]C
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M_<+L7<%C]< B\'7+L71[./PO_=T7T0G1HY !73*H25P5D*<(9OY-XU119:,
MP?)8TL^"98M2RA/:,KP%LD\2,-,V>SC!=%&C7ZD4,4YY^#?K,D_[<^Z+L?ZB
M2JOI9&T G_N5N5DV)RQ.N[Q6X:AMRT12RH4MO0Q77;DDMFMCD6N2U6655YRA
MWCWK&5NR[(6T-PRA"#R#PJG0F%2._3;\.7%4X0GLD-?[&22H=_ZM4$-#6G5Y
M16Z*5LFW6]7_5*:S+1KUL-09M)B^V Z!7;C,%8AB,4)1TFX;,N@!B8<,DAK
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ML7^KE_[=1?")]=[<HP/W0XFP.53Q]<D4VUG&^?,#5@<4D#4UTST));-@@]L
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MQ]^P7L):>;8-W<Z,?5!@DQ@F>*U/+N8^K(G[ZF)B"<P'[:[4;(YL"3U1;::
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MX<>T1*-:U:E0@O^@"(N$6SS*_L/!$)4;[!@(:B)G]?V. /BWNZ!/<%'4WZ:
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M"NMD]JGF9.S.32A?4J_^<FR5Q9M([VY6>YN4B^:5PWUT BR"0FM<+;'4S2-
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M-D,$QSWM!EN479#N/;,$=+>5M- !<[FAH?E>'R],V*3O:FPJ1QA+@E[+S9<
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M$PLV[#-"IHK,H99<^5Z9.;\5ZY%?M6E'GNT-CBS:"MRW-9<Q1LGPSWB$J@P
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MLK)J<!^U_ V4 O)\AZ1FDR@@@/X,SP!D [1FG4OC/@4D&$Q>15 [Z #^_<K
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MRD/CSD&$ZF$?1($WAHX+3GOS'$^B_60](U<J5U*7@28TKG=Q16W LJBTH*#
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MU)PI= ?_(U5EHD C8-E>*@H]R\0^E+=@#GO*C[39:O,7N;6U.H"EMFW:F:6
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M4T3=+CTVL;#X#=@L_IL&'W6T2UU#6=%X<2A ID]-6$;4-);UA;Y^TY<N8O/
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M%WK(FNOP3&/LB;]VCHY<3X]\&[<O%KR+77CBR"#F9[Q>#.^YI;YD.[9>=QM
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M+ZH%_TL\ D&$5?Y\R;A+M]N>BS=+.I$PHXC(# Q_Y;MO[_HRXUJQ\%HM0[)
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MZKN;"ISM[V5GO\A72'2:EET)2WUSI_A\RY?/5]I4C1\(+\\79>0KP'R(T>Y
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MVR"V!>.!T#\(.@:]'7%I+IT$[Z#<WP<'8^_Y;_54^=7.;D478WSW3?DR$NO
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M8CD''ZVL^&9.GJQOR[P^QNR1Z3CQGI]*QIH.>K'&G-,B'"]ZZW/\"=GK\A>
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M+$(">R^*^3]5-&B(S^]ZYCCC5B4;#YMW]MZ?B%CRS47]O7R!Y^:8:?*#M'"
M7L;30NF0/4)/!=D WHF,Q5SS])F.*U)!N!WXX68?1T:FY#K&%C8J3>:EI)3Q
M">9W&=M=.%VTI%&N7#_G<^)O%D"2?MY0ELI";"=E3_Z:Z8<LYGO@H(M',UE5
MS2[PT>"<L9E V8 Y8[B*K74D:_JM]5LRG')CK>I7L9$]?7RN"D 03W_N#,3O
MLGUFZ88\%IH8A_\A1Q<\"=)#I'C27">:-)I4$%Y$-G2W\*^C/D5UY2"\%2^;
M^T1!3YVQ< 3V[MO2/*S[\[5W!C!ED_L)HB.:"VY,R^'&]:_0/9O_H(TBD@]W
M1>FN#-"E ('Y#145M#3^/,NS_4X]CU&;]8./Z<JY#9]Z6WB_^.<:CMH>;/W"
MX;0,C?8J;[VZ*J1KK!T%F.^0L:='<&I-B1]=R=?]J*+.2P5]4[K)--333N16
M0?<8GV(>ML-8WL/2R)=CZJT*24V56;!6E-F?@G&:1#@=W[<3QYQ_7@;HJR0%
M<(@?)VA+RL) \!.26CY&^P1)=\3B&Z<Y%@HMC>?IEPZ?'F,;$C__[(5/\@<-
M-7U.^66T2$+/QM<4ZWP':IP\65E+^G0$<Z^C":*MNI'HYZ?5);7XKMD/[;&L
MK/7,H>6N_>^MQ,6QT6SHS5:<NRO! C:O%'S&>$EZ.+(W^))RKIB>A)KOQ<2(
MAO(\:[9V?& ^V!71!@MQ.6P^.?S]$$F[I;<DY;6@6+!9.$OEYIWFA?MMW9)I
MF-)VI.JWW+R*#3#5TDK)+TSPX(+=UGV_X.2CC1H H"D5TLN:4A!*Y]JG?:Y.
M'MD=M/8"GUW;KJ=U6,C[5(_=;SX0R@O[_"W2HJC_7JJ);L?XEM-6;A]_A>]6
M3M!>B@ADS@;28RV0H/12_1*4<^WMA6@;RJFY)\=\;6++;/M36'YI,5?*5Q:Q
MK<1XA#!BSABI^#NPK.65WR%ID6!5N3-P8LK*#=^L=].<U(1FN5O;./LFN/C"
M'+J@ITOM&#2BK"A!L33YDE7]J<\)"I$%'+Y;Y;8_4VG"48M2'1[+8@ <L30C
M,@N]@T9F\3HUWIEB(G6!+JXK9XUE7O=M'G6$YWPW<7^"=79'-08]D!-+N_-<
MY&E"3A9J52?VM@.B/@H?F+.P8TE?4*;;P\GYE\%'\\HL -99)C!!P!1#-H;W
M@#^H'#M/^ZK.N0=Q(#Y]%T5Y&_3IX>>-EL,)$E3'/*S5>%&QY:;%*9+)[K#>
M PJ/O]<H5ZSV;$"0O?[3^]$] ,J4N6+F[B.[5G(@R=#ODMD;_6D4&1*Z1DS%
M97'QI16U4F78T[KJ<<!,K>GDP*(HVE[BK-B)=W:]</Z:(1,3!;O.*P5:18O,
MG8Q$R-Q#^,$.DFQP2)=LL66  LO?,5$:\V\?CR#)1DFP3']*)H"L7H%R<NP6
MOK,3E-:KYC/=.NQ\G(,'+ \7^42%GHD\RR@/2S"+L!HMT-7I.B$R4]%X: A\
M2C*<$HMH\Q0X6W"?4I+J%WV^2,RC)9Q5^_??'=HLN[8>GYFA>Y%9'7AH@=)J
MMCD00=@ND%H<W56IJBH.72OO7N^)#2OM-7TPGQTE#+5L/*#M5X^DGL\7NKU!
MTQOA_<. T\M$VYP?,.2R9/47#)!L7 0!UYB8+Z;^D,C7_C??T03RUW#YBVFI
MTPDS#<JH.=U1#EEK3T_395310GSQ:GK1JF@>%35U^_[]_E/,"Z''B,&IT?C+
MP7$)>"H<W.S/?K7AZLD?95U&FDGEA:&&V0&J08D25OK2;]T\KKH6YZW]<QY4
ME^GRYZ^:[?*3F](HN_68E#+%>7P2 R12AS'GG^A^YE6O&G/IQA/S_.]F#V0F
M&^L_Y^!&]+12S=WN.=^('AIOEZ\T&=(#OK]N!?VPQQ6(IE]RVGZ0Z]9!L^&O
M(-])J]A@R;.'M.443?'A],Z,_OFM(B&X(^81IQPBY=[8D [_.MX,VAT72KA!
M?PA,4Z&ZV]ZA91!ID[C4W=)DNY!]IJ9QNBD@1;]ZR=_];*B+;_-QJI%0NX=!
M\H> D\B+EH:";N:BXDV>YS4$7;CT@<:>8%NER%#N+G@DH=>L$)+&$<  *3U<
MIA0W-R8^7U$T-78]&)OLOUI@>RQSFAK%H?F^:*8A=@0/\R%'.YA)>_TP:A;2
M5($-)5[U[&6 7C"W$F"7H,RH78O8T94C4+_[_U,3!Q!8T@P0^AOPDUTP.[Z_
M((>_?%: /R2#MVL]J+ZI=QF@>09HT^/HT(IY1+'LRQ>36E^\?5@.=B1#]'=?
M!%1/\W%IETV&?H"@5SC4(FTFK/'WN_([3&/N"Z2<0HA49""D @06_80!3O%1
MJGM@J;U>67B1;EQ&A2X( R/URKZ0+G&)]\S%+=<W;K,CDS4E5E9JXN0"O\_I
M69Z1EQKM8&$ DR]K020JD:QG,#W=(388:UK_ &V< 7( >F:M)+F.]-_,^,AK
M;+\3TYCXPLXEKV0VLZ/ZE=KPS9]WXXN3AD?D'@G/-!LKD]4  _>N1#^ED.>V
M#RDQB+80Q7*I:T>9$^!^+9M]1X,Y)46=:&,W]F%+V(=O8T.-5R:OG/;B"ZXK
MS%9\O!?3RJ?GC#+_#,3^8#5EE6(_]-T]M)&/.S8W%%P=X%TF'0RO+2I.RM&*
M^[8@4ND3B3*?".D032Q.CVAPL-$!WKI0L2+PSZD-.P@YGR^>>6J#67[L_C'Z
M1<-F1;0E, 7!+=</SI+[;>O&^B95 NN43%=G[C@9L5J(![.X^4D86.F3NGKB
M.]C.5\L(GN$ S-T00W)<X\.3P!1=)ND*@;E*I-;O!!:NE&O52>-?1)2:%SO@
MC&SKPM9[!Q\9IJ("[H0N^N^[*^1'1$N85 \;P&Z]3@'[;OU=L5A(RU9WHLW3
MG^!U9JS.T,@M9K2'ZSTSLYM37 1NY2HU@N&;*9A/8*9DK4E\@4"]7[^:I0IG
M=T;Z2=$/U4M\68[BSH4 KM$"#BEP8&)$H&3HX>XC,M:8=*]Z<5D%8!'$\L7I
MZ<[@KU0;-BM^VZ*SJG.W*F,:_/41SK5I3B3^YZ@<'8<N_9#))ZK#3!8"[Y ,
MI4"W$?-($@-$#^&TQ HT!(P7M%CSY[7Y9M^X[;PF0_V3K=]UN;W/%'=6,=%K
M!>6O?OW3X]EA>YM2"Y3YBA[02IT233S3;W/SB/997<*C+#^QL,_-8'77V\X=
M7YF>IYQ3@EULQ-:(W4+90-)6"M+YH(O,&L6#G'3C8#B)ER+, "FW)/Y") 5'
M&+=L SJY:>'$S:U97IR^U+W >SD6,\1I:&)ZS%-=# \R_'KTQ1O#1]TS-4,X
MW86.1\RRA AU<#2^'0\PPESBTGBMHD>/P=%V6 B57!0PCE(W]]VKQ70HTEVX
M#2>'S6QDHF)G,HVOU?*$X0;GE[2]?$H$S:D<C1(*@H!2X,NN8(#>]M$J6FF-
MY!A2*D!OL[F[/))Y*B+P@V\W\;FU3>&N[OI9)F2:@\?%A(&?+QI<Q[T<[5L'
MMYPM3OV2O=!N(._!&7'(.:I=<B:PPN<#N>R?6A2R%32C: [Z#M\QIF]W,]?;
M[R.W\V?+9JRJ:8ET-^NZ*BU%8^?-OMHI&"<I2Y2\6?*U[B!0=NIO0?G+SJS%
M'QZOO1P]_:B#*2'AM PE/Y5 A ARJ36]H^_XW@C\3,#Z\YZ]7C[-!X0I\@:[
MS873?VJO[50)5(Q:F6L?/P>,T2</LK['T5='.F<H Q15 0B2V?66?[0*H-0.
M+R-("0Q0QRTD_1V%G7EZ(^B0 :IO9X"24NDB]QF@/:DN#^;%!!7_.^.NI=[_
MO4)=#1L6(44$VD;0N5QH0[\A2RMPLP.HI1L\IKY_K.W9SN37V1/S_8_F&S7.
M&YBZ2-]A\[6+X#OI525WIN='99+*]9<+]LQC?X0P NYP;H!$FZ"<;2&_^S&M
M5.#YJN$ZTMO,FKZ&EDI+2#>_EBB3W3-BYE 5]H< ^9V!201' I2UD^\U\+H%
M!_DAXJB%A<Z9RQQV. .$T:AG;A&4HG-VZ!C7,$!I"("9??6'QV86!.RN<,IG
M3JO!Q5TT8I+16.,EPA9];J$PPD7FL7.#0O5QF1^X93N3>[/K>&5@!GISXE[1
MN,BOAE0<4JX2/ ["!X*.6_G7.DW]8?7A\4'(_G<HEU+*_6=Q20,+UVV_W]/Y
M3&K,X@:B_C#P[F>5\8I&),7 @:Y.C$&R>/H[XB2PZ "-7+^K(N;F<..&XI);
MLL9;5TX5?Q@?&9D+&;7X*+I6U 5[9-03QV?YG;Z.Y_0@ZWS]$F3QB7)$*V]*
M='0KQU!>[[0OWL]ZC7F@^&HYT_M9U>49!_Y48:B"?MFAS^WN%SLU4E N<;!]
M"K9WK]@,9JR@U7CX*"20 9JQ9H!Z] "-G(/XS;VHQ&2_X__;LM_/<91*!DA
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MJ^2QF!)U+JKLF$6"S:)>/\^/!.6),(^"K-#>,$!;E^ KA@Q0*A\#]&V]FIG
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M.78/BPV/J/J0^MF&#==*5KM^17"A3%QT_#._"R.XU"F*UK,VG-#Q31F=T?.
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M<<(>)#Z"/>B[](D_PU?81/8$$#.%.T1L,NF77M!Z9GD$DEG:>@4U<Z___?P
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M^X\!2'J< 4K&ML:1W1!O@GFV2XX 65<0MR=UM,P 1:?2+E(;:'I4[%?_LQN
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M+:K$BQS;U[YX2R:SR$Z8P*/^[3,J0_<)8KMAH=.=[8VJI]KUF+&4K(SA:TE
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MO894;_W*C>;BV9WN&4<4HKE40E:X&-O=%?HMD%G3B"-DQE>2]UIK6&9N;I"
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M^-J=Z B<T 8)W?O- 4$?!+'G2#/* THFK%!]*)>L]*OD(IQMWE 7?QU1C;@
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MQXP3C9D,9H93V)1;";:(,%-C4W]S),N%. G7IL7,Q,&?589A?_;QR#Y_VP"
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MIR/X4RT-]9@P'_O]-"32K0'U4D;9:8-\L!!_.3W.OWXN6/V:W4:$>W\G9SP
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M@?!BBI3QERU>M _43=HG7%KT"U0TW88P2FLZ5NBGA,T&_+_FMU#FD-@E>B7
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MVENR/(GC\7>I,%6XFU)T)_I.; 8&G-:C?MGKL7*YZ*=H3AOQG,NHP=@NF!^
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MO&-53&Q 4.V*==HYJ^"<S#07@$!,FEWO!946<BF8I?&H/P=,.I@!6MFCM=>
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MA*:ZO!4$<FDS?3$R_0Y,;+O41#^KMW/U/92Y!8'J;)%!RV-2K+QHOX+>HO
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M+P,T;VW!5NT_Z4["A1'[Q%=\>EQ7RXLRBLIKT@6TM3_B?:7/>GQ/&W3CK?Y
MO! =VMAE6;77\^@W.J_AOBYKD *S&QJ8;@GM5P0T64I2^VD.>2AG?=_"PV7E
MK=+EZH:CJ%VYOCC\=+&NV))["DMNJOG+O0X)X_O]I=>==<+]>COMI?. X(?-
M0G>+@LIG3F.G_-BB<: 6(QJ6XC"BTM#XTL=Q8*XDLG.R<VQ8X]*M/:[[XU-Z
M[SE&X> HEPP?EJ7<.*[NZZ\<PYC[I.T!4BM=G>DGN[_"5J.(6_VZ-.N2#;$,
M4E*%..=\5-(Y#5TU$\TBT>F@A0P<UUCEJ-%PQ6F[<4S/$[O] B:;O%JFS>'F
M'QY ^\6I#JB6=0)NEV59T1B%(NE%#;72W*CO&]:=Q;Q+UTKQO+'5^V8-JI\_
MA.:T/]^P^_B;V64YSY2(_C@X.#Q')&><N:M8%TUV8X!JGZ(E=VB&4;6 ]43<
M8AKIH?U_Z'8GT51C&A2SW,*^N 7F+_>U[F]UB216+A%<J[A"P&F<";O+B]V7
M*QLT$9J).LH(G;'=4//*^P7G?V,%YOU&].H-VAY@"J@Z!\<=](G\]=J=&4Q\
M6J&SWI7>W-F];?]?KCC-CU]['&0/.BVO>[T5^KLB>8TK\5,L:V+YZZ*/[X!G
ML-KTRU*+%X+8CH3).QN$[%'T^HD? W2?3N\Z('5T(DA"^"[.\,*";Z,F;L$W
MD*M$_O-*QX*7M'5,8CABTPNS_@ \CF<PW9D!&NPK0'\*6MZ\%XU/EYZ&2@6]
M\'DJ@]HQHUFM>[=8NWC>+;C;X^"0E]5O^L/ 9-Q@X+(4?E%\0_C$N>=NWJLU
MYJ+O)G891MM6#J&FD)[VK_,P0$^]M=J1R5;B$6'R,^ ;C2GO^M0U[N2%NX0*
M.:WM<5(O*G,5UMTI.OG\$I*;7BC*9^X05<@"A"*F 4NM88"^$O]K /*( :I@
M@&CLITE1\5](X*/G#% SVH-FM_,F[0R3:?).\7ET\ *=1@E:I P\Q5:0?4U)
MGLRZ?*0BNBMN7?&_'B &T"T<(&&8Y1^^KJF$G29#=VQF&:";)[-"W_H9H"OT
M=0;(&_@71L'A(. ZNBRB:*LI@_,DG8.^24 XTH2A=.(9@+<,&*".22P#1,R<
M9?8Q@&+ZQ>D<@I4M8%HE^&*0,DII!X,Y/:YP][3H6[H^N295[ST=X)\E(N9<
M&.&[Q;=0U.OPRDD\/S<N<3XS,_+U[:@B*5T57^9A0!/H;B)IJM5G<O\Z/4AM
MM<;=C'9]EH2.J2--X2FP:?A1BHXR;T=+HYVTMF[<US$&R#4F+[C<+O\CPG?%
M%/9XDGEXA\2\J#1*O &\Y\84+ZZLTB)^09C<2ZTFFWJY?,;.>H=.MAK>U=^.
M;%X(?[8_C9K#=^Z(K%\K-ZPS_"XOI[,=E2\[-OK8D-EI]1NNSY$:<\"V#Z4T
M_DO5&H8GM3X/=:MUW&E.:N**E<$[*D5%7=B4KH=7Y^?G@9<2C0[?Z&%SG77^
M%:JX;@_W(N5CZG'SSZQ>U*AHE$.GWU ND3V6<>U!,03.-)O&((?#^*8 )->8
M-K>VQ8<G97ZJL""UZ9YP5,;K\Y4(RD8F65W.A5FO%SX&?1 DZX-NFT4.GGZ<
M?E9 ES4^=-.M)0><W#81[+"]GW#H=>NP[V$)OX'I<_/@0M;WLNR":IIR/ZJG
ME8!XM(1A@*%HR2%:5"3YNMHLJ^UW>=*D^EX.XO%$L9H@F3R1PVI<1Z@@_\<S
ML&#ZV>^Y8Z$/:A]5V^9?E-899<\#J#B2#C#Y0%\.+C':S$MAD9@>,!7X?19Z
M^]A@6HUM;['TVIDZG_./!;/E0\9&*4[Y+[N'$3H_-,U4C">&1[_#9&$%@&@Z
MBTZLW4\G$/OYJXYMU(_9R+M4JUUT@T*85=^,GP3:U6[366%TX8;H%9G/FAF]
M+Q0R-'8V^7(50]/W_A"\.N'KD"BR' ,DZ3__?U(%9K0&0&B+S_O[+,.=:6:4
M#S1<BRX .Q*U7;R$ZT-4R19_!*E3UL58H/)[8G"BM(J'EY'I^$*ADY@HKWCH
MW0SS&?,&SZ+1IZ/,#6<V-T#\1^^C);FB5V*G&S5JE:6RI?%"6)]E!4?GA2]=
MI.HXS/T3_R1N>.3)1'!6D=+G9^ON$H[A8COU.<FJ^H,\ 5@O!(X=/:][$KWD
MZ'MX_OL<M-=GE<W0<ZCG\E[P%!$,T=#4,$WM>(F!S#C)W+JY@J=(&)\7Y8S+
MTBED;;&5RV*?4'KRW!88'5<EIE+FHXHS-8()6@T3@NX[%MZ[5*PX^>+8I\LR
M]&2&*+4O+Z?;X.UUSGU+5.8!ZZ-KKC.%.V7=BM:MSF>5_)^L.']Q^'M C IX
M@(EX.D?S_J7& NCG6O+F3-O/(6>W8K96> RWC]^!H.-)4ES\$J^;.;;0QRMH
M9N8JVM,QC)3O832\G?IWE&L7O\E@ALZSU>HS #HT[GS#QI[FD8D+/D:T?TBX
MB,"_=XF5 6<H.\=)BV@G!<W]1@^*R7+_"Y$6:@4>_=J>;0\5I,#Z%6)I)455
M<U%7'5[+3R($?&&CEJ'EHO+HAE#>&L=N^L)F:?L6H;(Y((]WQ.@!7]6#89O+
M0;HL=?O#QGTTPXI0S#9_'MZC<\9>QD\PO-O4C%G;IX^YC5&_H>?X]K!9T9UV
M@?KZ!YI5I4A%\]T&6UISCJ:"[(54SB%?#_&(TG:#'S6S<DA>IZ+L@4FC$FZY
MG;_^_@.R2; F[K/1;:&\#-"GL$[)-G+T$I]M!0RK90:OK7DZ,K.2ZC*X/CBI
M*3=%NW>%*SS<UUG,^4[>IRQM+G5.-1Y.SK=EX=>950P*L("9V<VVPI+!RT+M
ME$@R\2>Q>V<9/]V\:68$D9WT:??"M=8F7%JD<[-A1&N/FDU4Q)/M!#R'->$V
MT?Z)X;$R%<9 .#/K[%^BEC% RIAH:"^[_-Y',)FE] 3A9]NBMZPHR:<(G1BV
M<XQF@5<[S/3$%_<@)B8-C08SU$998[5T*I\L9#B,W.SD!@9WD8H&'O(+EXPE
M]WGZ(%N?_J+<&87>\)_U$4@O("N2UD:EJT<R*DJQ=P\X;_+8>\K\,+0K=!;C
MSRWJ:8TIEA SR_VC99-@"AD"4LO&<*=D6K=) 4O.8!:\O+%<Z>BZO9-H ;V%
M2/"?(2ZT78OM^#OW._KWYZ/.&CP66>;E1N=NYCA]& 62DP%"W\>N".X=4YU0
M5H.H'.HMLZ1L_$$U!Q[]:DOU08[K][K:<YXR YJU>W*C8VUGJW=XV'55;J&,
MQJH.Y0UQH>>9@YN'>X_9S2F))X*%_#<76?IP_T!OXY(RUJAG/KGX=,((!+*1
M KO/A:^A$D:&8P[>]/$T7JN45/N\')U7%9YP4P&.[-L.^>^@P-@F_0_&-DM^
MCY_.D1V\ TT+#-A=7/+Y)A4//H]9.N?;0;/?ND+9']6NW[!ZN:L9WVI__\'C
MMG#JB+*Y]BMQCY@^,[DWVA)<B4,-QR9JM %<RJ$/>3MSD^?E),6&C%N!VQYS
MF(5-J\ 7HX@88:U+\X:1A0C%^)RP.P813I=1$,ZHX%)M]H&[CQ_=8V%>6&)6
MZX*Z" \BXY6D_B'>;KGA,_D-_>D +]18)IUN/)N;Y5NT)L*C.JP.@;-4R^I/
M<OWN/*$<H:K?I#]&V1"X'PT$FS%ASX*^J$QWL*'DW 2?+BBS ,;1,D@B";Q;
MB5XQMS/V8VEUN1IIF6A(G(WZNTR",SPXZ.L99$GT*//LGRPM!YVF15,J0?9M
MQS<VW U9]/&@R>V<7X_JWA2#_?3Y$ !Y&*=:80J9FGG[_>RTY;VGL?S.6KCI
M%-9WW;;1A(!2Z#E<FI?4( .40832P8<,T&.M?S:1?ZLD*@BAEP32,LP[9Y7V
M$TM;>Z)#7!2FOUBZ*IO^W/]-K-.Z6C@J6.E.Y&(1&[.%V!WF<0&U/?1N:<G?
M^)-+\O60NV@);)J-H(])3^]IURM7E.!=P2M3^#F1G&BUI('M)C=R5*PXI_A[
M"7;$H]*IC1 UF)R#   &5BR=-JOL>WG+:/(4";QB.IX<N&A<UL!6XI-+V8[*
M*WZP5[]G=OEC[>JLGRON;H[%C\!#:^4'N9F)N4\<@TM3':59O "]41A0B)XW
M.D$LY6ZLT> =N.7R_1NUWF$OO&$LYMY##L9_B>PV7J\5CC^Y:%34O2 =$,]M
M8\"K>N!W,7FYJ$L3KF$2Y<SW;.XJD#VQ:+F=53B01'T^WEYA&B[TZ&UP"EBF
ML9+=N$ZY:Z%6BR5)'J*0JMPJXZ?U-;-_Z=4KY]S,_*C/HW;B&T(<U95:3X<-
M!OM(S:,8<A[=PTJ;-EAX8E%4Y(^N#!*E5:X]<!(F17\D#$:D?':1OROR%=L%
MEQ>2*;H3^;5;^RB^&G8>4I&AE>M<R.59DB/#;)4-&#(X303L2A.A2EOL8A<=
MVZS)].<8<>_.@6QB<_1$H)0@3 TRVS69(PA3MG<N][V,3SHASH\?5,?=M86I
MZD_\H(HE;E1U 9\6B99D@%8N!]-MT\^D[W#=>[]C$XEPO?*MQRN*-(6Y(^WT
M+S9$]$/>UWRLO[",=2WO4_%K0@6O"GJ-N@Q@ MJ2JH4 /!D0WS! K26_NEX?
M:;U8@D!HOU,19-Q\TA/2QG8* :/H7Z/(;<.-T&25<&Q_U6;Z0H8# 5,-4JKP
MFP7'I3YY?=LL,P,LS&Q!1V:A8FFOUVV6$VUHXT=-%FF-00^TJHXZ]UI'#G^-
MM"65YLZ>9%^NRGJGGI 1Q:5#,T%(+W8CC+1YJD8,QQ$-U,4? ,-F7QX V&AK
M<U9/S1%?9[-<M"\LN)OGI:L5001+>KQ14+P5WF,D'(KE?O_N19$W?;F@T\'0
M_T*;&\]KU8-JL$O\>_7_NJS0.:[N7_+>@B]?F YH7&2 NM*WR;7/:74;/#@K
M1\4\2XC6ML+C'D(CNQ*SYU"]732>.AZ(B\C3\9 B0&023L=>ZB4JC8 !Z0 (
M\W\R4)M4]@:(#,V'(IS$W$6LAB@?#ED=\9%GB/UL M2VBEIYU.F'E#[MD*ZO
MC??2SHJM;WJ,)Q_MDI0+5*=2T[Z5.H2F =DU&/C_7!)R/B5CZ1P.>"M^/&]*
MN;(%51Z06O 8%?;LVB-3AV,6#Z-YF1,TB^:5*^7YY'I+/<IV46.!C-Q5.;==
M75/CCZ&^38;4Q2AC=U+S<%D^_>T#7 RN5]&; 9(>^H?(V9BT?,]^//*]8D?$
MS8(P'_4X%.'Z)26.+N1\[3\1R<JL?_?+)1QX="FH7=/F2[36"@->["5T_BY.
MF?[HT/M'%TUT!MQWTA!@]Z4Q;WEE<<[B>-4$C_HY?<+58O6^>A[%9R7J;:U[
M<=Q=B) 5<]KYLZLG3U;7%W15WK3AV$:#N;6.FJ"[_'<0\P1)YR",H86D;?K
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MS;TO]W2>123*T3<)+LVT273J ?@&+E&QG5E.F1^7)#2[Y;(:Y$WJ;7.+#F6
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MQ%$$56)0XGI>GZW =,#0F_E%\GWP4K4QA^=AMUS8RYQ_@SFM+ @!6?S[787
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MKMYH+Q+V!O-"KP>09-XRG&JQ- )N_K%5]M1+U6BG>0A"WXO$SQ_SR'Q&@B<
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M&Y\@SW'XQN[8TP+)S;>4%5H85RNHC> 4<G"^J_VBJ#!<4W]O;/"] Q -U3;
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MN=7UP($JQRZ(V.7FE!+\(7GA]C9LM<YY7]XB+NF2NL"PQ*XDC\'UW'>:@N8
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MN.=+"EX5(0$_857'>OSOS5=2/+);[]=+&DD6//YX/Q#))FEU1/GGH;W9706
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MY9-4_#"GIU$NM\[GFKK")TV0:*/5LM3M7_?]ZN^/T08:#Y^C8(_8B&#J8_2
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MTA-C=S>]^SULCK10:1A=7!80Z2ITM[ H!\DS<;]7::J9Y0R4@*7ARKXD^1]
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M9F?A-@QU-U"A4;=<$0@W!G.=".V!>D\%3IWCEZYT43?Q9:AP 4N3% V'1S$
MX8*[0U>/L=@#>OP9B&IK$U>#C@D:Q+:(^_C?<'(Q<=P;-C6=N;[[ZKB;+KS
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MW=Q#*M4&+BYH4">L\BBM2LCW1%NLJ+SL'S/+F]M0J?[^3G-='G"2UK) J$7
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M$9."UZ\ Q'M2%?;W&ZD<P$$3QQ"=XS8[0N2>9&I/% D\#"6I XNK_U?7ZL'
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MWIKH69]L&04KXH=%R66S4\^V:[(+,0KNAZ!/>_9P%EF8@67B]TZM5Q9/'JQ
M96\7EH9.REB<XFZ? >8H$S)]?4H8D5RZ/1+(-R/WG5I:<V'A.C&8KV'?%*]J
M8NK6G7&2W%UO-,I*W*Y)4]G02RR8K H3>[KX=:"*3?><^.7HH&FK+ZQK!D#
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MM[1IJ"I7!D2PM]D=']Z4;Q2X>S5QUB^2-!K[)/#&Q@0B@>K<";(N[H>U'BD
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MS6\^6\TLG2+RL>#A<ZDWN0(DXUM+U*W$B%LI"Q&B-T6*G 0R,[,YL+E^3X#
M7<P\&(8I0>;WZ<.J? #,6' $@!C_*B&15C]'V07_F%A@*?F]5U(>@9I0^!WM
M:[>[HW%7O]'(%-G2=([5Y[8_IJ0D]Q5O]I]T_#R3N7H4TNL@J9!FPD)HG^<4
M[ J.-Z3N:&3W(<@'5_UC<ELT>D+II<1NK\E5!YM(D<B.>_+C1+[<;1^HM]&Y
MIZ<+O571/NL :-J29@2!CT!0&C-??0Y!;>Y-(X$#.-R5R^)]F@/!UR-SNQQ_
M-G<;[&[.N8X+)39:>Q&W\!V]>8_O"R\^%'2Z_O[F( #D^JE*6^,S&UM7ED1"
M&%3T2._NB2;.CIBB#V'Y:3E@5)-]H8D\FC.UV83?QYO-AC,[\_:R;6:FDXOP
M7-(I0PW 5RPN_'N,KDB!QK20%L.4<$[5U(A^;\WCZZIR [W%8<I]-VQ[9>*J
MOWM9^<K0G0^&'F[AY-,!"P6#$I%F9!ESTQP4O_9.[DWF*9+9U&;$QKZO?'L/
MW2HHF;%9Q\T40(]GNNB3J7CP9F'LO (Y>2Y,;_;ITF1]?4.EDNE+J!NC9?5'
MX;C!_&[2>%MO'(^5;+!;JK9ROE;ALNQ V\@3.-30+R\FA94I;(KOPG24AG^D
M5M:H.O5Y3H0L4DFX !T!RHV<\NKHEW;6!6-F'V0U BH%U/7TN*%0J5EG.Y]7
M?%N59>$M MO,G=ZW==P,MDYZ!OS&#C%%%^A$R8F#@J,"$D]61X^,RTPA#.X.
MUD7R-,5]-5;CXC(IV _@6%D90V5E*LJ;3U\ X&>SBOP$CR?E*!:_7Q> \-'W
M#"E;4\&HU^_>6FTY=85KU3U(5$5F1B%>8?I%C/,-U&6SW'-7"^+Y;@()0YNY
MG=XURV"[-')0-H7N/H/'"1FL7ZTZ,<XPF.(,V/!SH&QONPOPBKY<=]_[W'7Y
MGC&Y_F8[T7B#+GH\$=^6XO(NZ09Q"P78$O'%M]NC$C:_P[YUL1C3X_@;^6:&
MA=[8:;L;HRR!*F@T=-N=9/N<\ELYU$3UPDP84OAZ9"8V/_6X>G:FTUU?F,_Z
MJ\DW#!<(6%7]$"1>,D7OEWO\8_T)K/4 -4AZ-6YNA<9[41_*1Z=,XA3Z/KQ&
M@[5J7#^564(/I@KV68,JU&_5A,RXN.O- F-ZQH!-*>"3:;%TDY6-Y PPKH[=
M90=G-[Q 'E$6<C6TO?DR3O6D_/NO0UQX-PV8PCTN+7,D:EIR2-OBBH87=U(,
MP 4*D=\!;F* N!E20>.L;U#V.-^SVC$_PJH@F;&^5EX]+E0^)1H1\+;PJ[ZI
MP;#.A[8Y.Q?X13V]B 0V)2E^<\&XU\Q;%BL;%Q;%-V<! "JVUDD?J1Z ESG1
MC<9]$K?!&ZV-S;JUKG;H( .?K4AEU84V]Y&_\GN&8H4+L)AZ&</N"Z@O!DQR
MTX1CWL)M_8%BF-]!+U3AX;XOANE^73OPUC6L53J.3-7RS9[UW37RG+F]J84L
MG)!)D;34-:I92BL_896-Y/_0**LFYBP!$&/W'OH/AN#.XE>>4'K[OJ/W(CY]
M-MQF)V1B3?Q+W8\(NPGQ*\NYF*)OTX2WTUBI3J/,0C8M3DQN9CZ_?;R:P6Z?
MEB+ _#140<RGB4#J[MEBWWCDV?(CLWW/X?NZ;E]\N[[/^L#ZN=+/:B\T(S^F
M"T&A426-=CBVLQ?/!HNKW\_7<#F-9E/NVEZR/\<LT@[;S 4OO.HU(RQ*TVLW
M4=QJ-;Q%-(,@5..N7EO$]=;I1_YI7*L$4T]J]J@][H]JC9+G(X76/NVE-R0M
M^EHJ/A_'L@"$:0R1C.EYBF;8P]BKPSL?1XT')U0I+@8L2M\Y^Y2]VHGLK5"S
MT#B'E?1Q-] -[W(LN"PL(IR:)6RVVH>Z55Y^$T A7"&/MNLUVPBQ]4U]QL&H
M$1XET['QHWP5SH%JV!5+GIK;+TSO]@FJ<9I]_&ST[;L+J-"OLX7GS K@K9]7
M:0";..7!L"1<@:!ZVB>G\TD'S2DTX3ZK2S5UD9#WEL->#S%*Z.]&Q 46'N@K
M)-];9(*"<534:YFW0S<SKP0L8=^BI !:\ S6.8NI0],:$=]>J"KZ0/ZN/.W]
MXQ"TZEYN_GFEKLS.%*J.[ORY&[;;.4V&M/!6&!FE9G6OK1I?-*4Y@K_KT2P?
MM@L#073Y(R)C@R[4^?,DI8=AX7\A&7Q%7NBESW [))9[W$:K.I!%MLY5L,W#
M+=1ANMEZ(;V)U7@[I6M0GJ3J<:K\TFS#I#:[I,CW8[: 8?L0R1N.<$V?(%:J
M^P1/DXXXV!4>WKP60:CC$IX.<'0;LG2;%:TPK)(AU#YR+,J8WZP?$P^1XR]D
M1D-YYF6RH_^?V]7;C\%U"))<WUTZ!%%U'O,M)KLOP 0F>:S(/=YKW>%U^ZR#
MCT?=4"<V.E9OU;;-6Y1ZF<?'5]A&F-OYTU.%OG3>E+T>#M"#6'(X@\6]GZG:
MDZA&_[%V< @:5VJEQ0=E+(\=@I+K- G8O?,/#T$7.NV%89!J,LML4[=N?%Y9
MF"*\?5#O;*U$33'6A0MK'XFZ <S0#"(>Y[][<@O.>-#GAFS?X*%5[J?>5L+,
MW&)L/"YI:U?#E^^,I$PSSJ2P-<^G2KM72_FE%MF)\9;GICWK/6CK Z"5/9UZ
M"'J+0XA/18$[%N<VG@]X,&:Z@A)_E;Z;L&H&MXFOU.0:9?3,""^_/(7$?FV]
M]$U3ZP-6O;F1Z[XKJ]X9%>_!^]JI@.?7'8+FA"FNB%T)BBZUC,(R#U\KS&MW
M5ZTD7?)@=$U5_JC0JY9SF)G@^ !'B%O"^%$LEW! B#&P%*W%DNNM;029SU?[
M ^?UVI%S#!M$-X+FBY D3<5AQR&<2FJT9'=$#("K\0,W:Z4-+"L59X-6=R<"
MRR];* :<YF^SQ[$=-0Z#8Y.O0TUCN3XV,L5^R@HA!)_U]U9Y8SR!_<$OZ^M>
M5LM[<%OOE#U9P]=/U>\E32<TJ\>T]#T8,!XTOG-VC"]&%Z6FE'Y#5$D$ #(%
MHK..=!%;VN.@#S3N:.IXM7R9I]O9H>4)[W3-TD"^:CC1+Z:P5@K:/9N;^[$T
M7-@JH:5=Y9[9I4ICCH))?[X8GJ@28#Q5B$Q"E\3,'F5PZ0 WB1:7#WEI[_-C
M935--?_;_&T.MZ07SM(^(U]:;-(R"B6]=V0O?=_FX&J5EGHW&*?_R?DBV&<]
M(KE)8G%V\^CB5.=!W^; ['G3*MS0[KB2WO4O Q6"7S4U*RN,_0KCT==&)M[2
MV#HZ?R8YW6^7D^,*>*6LJZ/\RSP90#T%S"TE'$P8,0V%="3,X%YZG(_J7@C<
MJ_)-:IM"!;\<V0G6^7SE40BI?18[%BZ8>CJF'35N.)BOB%7@0U/MH!NEPE?X
MX_YB%J5M7R<L@C<)0 H2[1ZE_Z@.L0WQ%6IQ%KXV?H8179XXZW5+3>(#9@SB
M*,?G92?WVY!H6S&XM.?58\ B=GK@KLC1^P) 9C>&4!^6;3VCKO6.JX'I97LA
M7>L?DD/H&33_FGT):X\U'+*QNW+IIM"(Y=/4&YUS(C@>7I?,8M7N$@%G,M1@
M*2DQ0LO_ 0#D@\\S;U:8([I>TFKI0@P3#G%4 LV^'O>43WXTD2:263.R#SX.
M2^U8&+XL3'C'9<2E%H5A[;%\'#V(^ES Y1=6)-N*W[OK2.ECA( []VD%&\H8
M$WI0]VY(Q[JRR3AV4FI'"#[M3%;P)WM#)0>,APR(,Q7^$VQ.[WI88\XJL!<^
MM+NL+'(9!@8^TMHV137"43Y0.VL"]ZP]>3O7SG6/3?$HZ?$-* T7[IKTMZDZ
M5$+>M=F7^RL&R=0Z?K=V=78J>C[0*FX[=SW7<'NJ/B!%#4B(/@TW$'*QD03%
MD*N[L*ZI:"^XGHU[9O;XJ%O^(6CI>TNO@2?^:A+?^9<OUIIB2CKOA29+FVOE
M.<T]JK05L7]>&-]?\05@CZ<.09T8VEMOSRU%:N<;&I2\Q4[8Y+X@C:_8E[*J
M'9.IP8OM' _APJPMWRC+:UJ0_GR1EN.'M>XSYY.5V:PK=FMF2OT>@F@O$3(]
ML8CN$[&$K4,0MQS.S= M-C8#>W /M<IS"-)ZA6E:?Q3M+-92Y*(7-F'>7D1&
M.'TRCEB>^0@/JXZ+O^*8^@Q +9N^$FZKF6^6&$,;CSO;C&<"%O/PXTKC2H<@
M874]V2?$$=W:*&R7O<OU7(R6B$A>V&NDJ9F-2;S&D4LZMWG_UF8/!C "CI"
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MXX7<:95W4[PU]3D=</V>V'($KZ#@&8]'.IN9\MKK%[]%IG[MU-SKX7'<M$
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MNU/,>XKEVN.= LZH2=A.5?2R?ZV7';O\U/04.L2G91",F/OR6$O.P@V_6CH
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M.ZHA=^_94F84%_0+ ,#OU%*>=T^UA@(+)#,,FV&!6W!LR^$,FJ5(IOJU@HH
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M6?VFWH=G 9< P5Q) Q;^QGH33#>,CH0=X0^8S6\_G]L#$E,#(*7C.!B\O-Q
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MQH3PN:F-.\,)R>EVLNP/.P+FZ@XU#!]#N,(^LD]&+&D1G'U5Y_6E]1?CQ4L
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M+R'CW(=IT^CP4=.EL(LW70Z%9.?<&^(>/&B/YE3!R-F+*D;=S9=S$0BSTH(
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M1GYMC*U"2\7S= _L8U_)OP(Q'GW9_]R49O$D%2G-2]J?@%34%@.JJF%]8K;
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MEG$XM2_^%0QV<WJEZE-X8"C)H@?@%J^1ZF@X8G#O&QQ)L!_\81M&*:NB!0R
MU84XN,U0X3_-+H8E+P$@F+M_ HIO9Q9W2=*6Z-RT4,G>[0^H 1S-_R"1O[E-
M@RZ>FF-_R/%,QRJ$OZD>;CM6+7Z3EI?)JC;=F39@V <^[U>GAR'\RNG1^:4-
M_+A_J'.C?/WAM%\G(%F^SVHJ#$^D<#_R C5KYV(4QOM  7S8 BUKE#GJ68]U
M=AJ/5G@<-/!ME-;OIB1,\;P99N;HM&M4.1S0,8;V!>2<1@%M&3$4&P [ 5WT
M8+Q2"=WE*'Y 6".?LT?>R9I1$BNHJ=-5O[&0GS_@G9[V@?6*#?COX471PY_=
M$I=S&Z(P6_CO$ 0FB>"?8[J+J5!+4=O[E^$*NQ[H2\=1U0!"D(3M@BT=8&K>
M;@;6;9TK*1PB61 L* ]DXPM$PO&-FGER&^JF%/T(,[;\+@&C&JCNJ[%K1Q4>
MDD@7Z@J9Y0RPIA'&:RS_7@;K3 ,BFGMD_A8'W)5$Z]U"$E3[^FRSIX[OZ-]7
MXVRRS]+C#7#U?)BZFGI>U!*:&%4NG56T? &@@FUR3% !8N63TPGH 2R&-AA*
M>J6 BUS;9;E47^^-7/)J<T/;+54;N#*^Y"?Q11!D7N1?;:M73-?WT#_-+BG:
MIV7"^6)T[S2@,?]%\G^@U9V ;F<.TA[ON.2JQ>.LD2MKSTFT:XE;X,B @0G:
M^CK/%=[+^[+)ZV=G_(-4_@=[;QW6]K;O#;)WG0(5W)I=W"E>?%-<@P67%BL$
M*UX@D%UHH6APE^(.Q:V0MCA!BDN %()[0I&4-$QRWOL^SYVY\[XSYY[SSMR9
MY_#G>OC]LGYK?=='EGQ79V[_MWNK##]O[_(V2C!(%]6$52N#0!3U>D3;J @_
MSD*] RAT"YV?G[PZR,\+ =#K>Z!2K;\T7E+?2NP!V>^^"AR)=NJTY&SG^LPI
M!.0TI>++*_.:;'Y:S2M25O'VX6$#+5'>I.,Y^-'Y@XIQBK^'JK@=)791+W7]
MUMD(%19E3J=L[FQTW3RKU:ICNA1SFBQ]EA8IJZP$,E Y-6Y\QAW'Q"X@VL]L
MY7&+:+Z(#?000FRI9;@\/$$2LY,7=6BSM"@OA3WA;P\.]CV-GQO=PG2:,G.=
M[%B48YF3.FF53;7#"Y/2:2U%QRV.528,9C082N1*B/A[?K)+ZKTV:!8,SXW^
M^#.Y,#B]J>66#N13X5)73W?0ENOFR>N0LCB]_MWHS4$/JSS1B,J8&RI-9KL=
MX?)N"2I_E)2GM,;?80SYI[Z*3S;2&2H*6X?AYT-#\>$7H_@667K<6SR8X,A\
M%E,O0NU'I<W1W&8]8)V$V.(W$@/%(SM+BWZ[P17P:N-MC;42G<CV9D&:0+$@
MRS2&&**"1 ?G&:TX@H'FM8X"-SE/X&L0P"/)K2'AJ)DV.:O. .&8X=7R!EK&
M^++T.RT/@R"YUGXFIJRM+>L)ZWP6MRM*ZPJKDQ[0&"K][0@R/2Z 2*'PU'Q1
MQ6SUDZ<7]>DV,.C[*[+K)PW[<H]<G==$HSK K;0F8!U'RD?:@D(>9728;U=D
MOX_UF21^^\);4?;&^%W\*Z(Q<&,EZ2 @08O4E[G_+>J%ZQ(O%(A1/SX0EXZY
M)]'2"H.LM71[%#FN>1ON$XY*8P#)RT^^=5.%M6CE-%-H7S_EY=<VUV0PG+D?
M28PO%!-!&A_^!?JUZ8HL0W@0OZ5R+L2,[O]Q$?D.:2G;[=UI*P5LP"[PM$ U
MC+1A_1Z9Y4:W;"U9];@ZN,+(TU,=BZIBR\&!841L/XJ#LA"4OL-7+: C].NA
M/L2^I,2@@R#*7P]J<E'2UG7990N!;BF6BL6\)0-H*9UIWO"ZFO@R:FMJI1O:
MPPT3,_W&$G)?B $F3!R#,NFXQ"LR3L7-R!.QK9=?%<.1D5M;?8J;-X"ZGX*I
MJV127?M7D9>(HSA'XY.)51%DI!0O9 S(:\'WH@^H*:]@XE >%%@^4D<TL&@B
M0E-])[@N=V$Z/P7[;(T_\U/7.BL-]G,Z@=,'\=--36WP',-=!=IBG3#E%C_G
MBSSA#Z;ZA**#-LL> LVOZV$^$+%!C*".8H-G P;SZH_PK2>@B]/8[=SQYDO0
M$WE9MM4M9.J"%D^?&V.;[2WQU,<8AN%%,\4(Q\E2!X0RB".1D?=[6$,C4=[U
MD:9 8/DW@BYQI42/<;3%B.\)NB)S@@H=H+%WBXD=T(I8LGW1@PV+;J@-=W:7
M3PLHW1^*^V*03&#E$FU\#.OQIZBS?)?7$-9<6=_0IS*CGT@4 [Y@:.91/R O
M_R8\Z^P:;@8JG!_W$-+;<T2(]4C!O<"@G*.HO4T$*2GE.86TXGA6ZX;G!'6I
MZ"D^MBB$M53F09XI"XI/G_[%W7%N2#0; WUU>;:2T*S0/8)?_@@0'0U1*UGH
M^J.+%T./3MM63_9"5V!IIGH43)I='Z9SQX$%G"P%@5(H_6\FH.G-EZK%Q65%
M(N/$SUP@D+(;DG8WZUZ125Z110*./QQE 48!:S L?A1?MYT[-\WL:6>,MD-\
MTQ]O?S4T]\L]=EBYI4\0Y.$D,"OK?3#S6(_KXSA0W9+&>,PI@FB&MI>A?.,P
ME'SHRRLR"9LQ M$+R':+.W33N^]#!]I"Y?%.%ZN?(./MCTO+GTCHJ7/PNW@%
M:OD6QS7(C(9*1A260FK?NZR6%CR"^AW6D[@U!BI+> @5KVG%[\'3H0/.W5:&
M1WHP>6;L'MID5I-M:4$+S&26E"^B=/;*Q$&4K33\;D19K/Z$R=R4\1HO^E*K
M _RUB3@FS:'8!EP4?ESAQ5:P< AD@F!K!@^7I[ETI1?6L9-R\NZP/C)*$3I*
MA/&'UPWHSY:P-$VQWP'O/#DQU"8KL["8S7*I( 9].^E253 4_RZ4.!QWCC:+
MB.1X:U\!213)N\MOEHC#G#] &.B9U[^(^\0%\+>WK>^T:?=F=N5.+B@I')N0
MH%-+^@!4Y< P\%5L4*+S)(G*K^N?^;(WP,0N9?R@8M+XB13NS0GR>^O7D=9Q
M6+3M"%4>+.!L0,=/'#34WG+X(ZQL5-ZJ*</**5C,L#FPNMN(K=DXHZ.<,Y+;
ME#5@$:&2ZD.T7U  @AE.C/>7@X=-^T*]N%\8:F>(S*"#5.709%=@]+AFZICD
MBGAY4ER?VL23PJJ(!DGG39<7615.CA!K<J,^3MN.<^/5*[([%!<;V+MHV\^P
M1$NQ]4CE<X"2Q\@1XE/$>J^[WN$BKJLJL;I_J%'2G6UN2G^KW)D/S&-3FN:L
MLAWW((W7GL)&ZMIR<"'C,=(%^E1X_24*Q=M-A@<1+,QA:7  01W_5^U^?G3N
MF2BCA7Q1BWU-05EA6.=K#QZ>$W'C'\9/@W1"Y$&/+,KN6G+:*)1/@DP%K4G;
M:ZN/" ]KCB,W@%_NO0TYGP4(=O@H3G:>^$'*:U&=4(]#\AQ'XV:SJ);XJ8$!
MBR2[O:KO#YJ=9 H%!=D&*512R(U;.\XM&<\!INZAQ[M"TSO61UJI2.'6GVCI
M&61WM*JI>7UP.",H:E!E<"7]H2%HL 1X\TR.M-JB2B!U[#@*IX(/W@=N *;S
M$9Y>^)+200]W=/Q%XXG8BQ#D0:R-\*NFYDD';Z>\M+*[:E=D 99&UMI4 8(1
M:>0=$47)1^QE?Q+VEJT\^^$;/O, Q!&!.AN+6OWT6FP>RB4KNSKGYRGT%;EL
MJ:R@528"EXKH14P8?!>AF>8U,,\=-)CX$O/%Z!,O1R9C^41%H7$6 _5R\(>7
M. ^21*N'K_)9+V-0P;Y [_VC!$;/]U#.EEG^(BF]N5'T>9R>MMQR)/X> -@"
MWGXQJFN9>;D(K7_#&]L,];J'K,XS)N5(1UV1O9WVN^7NJX[UOQB?E5^=68Z9
MLDY^LQ3\$[)E<]9"S=WJDZ)I#F_E=&2>6?/^,>WW8PBD+F?TU2%*Y>-@4FFQ
M'\D[K!' P5/-+?3835QZ]G9N]D+V%5E' ^NMO(40@^:? 9X;4FKH]%>',B;(
MBZP<#_I[RHFUE6Y^'GHR[3E&0[02<@]GC'=*(TQ)&S39<31$CKHBB[F\AGN.
M]XK<W/JL&(?L69\]#)>&=](25/P\5H8.1\".C3C>XPQ(=7:C9XM'4AG@+QI>
M"9;=L+0/H^2\(*QBQ[E*.$X"\A#WVV37 /X2FGKD_D/=VV^NMR[1&-F1CRY[
M[G26AQYP(U^2-&_E^E;Q5'Y-I&F^H_)3_,Q2&_M9RFF=(1N1.P7 SE761"7$
M?D7&2(_#0 ()UM#'\,3^%8(1<[J/-FBVJZC>)=3PI;?/-_<7K0'-"AYE@L"(
M04U5.N128/31&FC"CD*Z?%TK>IBVIC#N<8H4,1"IH5RV?W7E-\ 3A>Y]!XP(
M=8R<>F#V*:.0(: %)(#?",AIS24,V3IWT+@B\XNJSOMCA@$RK,O\Q:!& F;L
M77&72 0MV=S!5V0R@ T4OE'!"\K]:P/?["U;5.%_[]FYDVZW]WI5 \.OQ-@]
MMUK^5^M2\HZ"0?J@[ZTW/5J8/KTSH8L2G3:7"!HVX\-0N.RR$)'#'H[@7UW9
MQ"T01S^](NU9":7 Y5R+/]S>]+1$R*Y0B]RBZTMK,%2Z[>R'IUF)BKYV_N<O
M=S5Z/S.(CE$\(]U9.1/H&9M^LH&SQ!=@%8=V\W'//&M@RA.=UQS\0D\.?QW8
M<CVR'HJ>O\SW-'GA?!9'99=-^V[(06)MFZ.JMA#A4+Y>6#2HD<69Q0GT.VR1
M( CBIQ4HH3SC&\VMW0#(LT5K#"I7>+H+VD P^"&$1QA-;/ >M]7DM>UW2]WA
M8)0!!_IXO518^M4K9E*M/S6*+JPQ?P-;#JX,7;"&XA'07.$3IXL[V*E/5V1I
M_;\(%JRFQW>#%?90RU%PKD'TR65-O;25AW_D;T"#+&1V,&]>W^RL(2>-U]2$
M=KP6TSX:^N"A#IO"WC(+_,)PKJ\NH[.L YKZ<AP:!7C4:CH<!/NKZ])HP?*H
MM.,G^>+2Z8NR\7WWB0CQ>;P[J_^S*E93A8F*HIJTM#N[+A9!Y@_3? ,M2)?E
M4%](+.6S*?P)<9D/Z<2FHW/5>U?65B2DM7(&E$S7YT3,WQ26#<U,VA'.__@X
M&05N>/KS=54FI;SL9SZ3/#,3LQPBH*FRXPY'EY.NR'B!V<POT7 3?W5?_RU'
MO[>L2JT=6Q7UC#J;WAVP@,WZ8$]%3B$I2N7$NO+X2 ^'O=VR.W>,*$1OO4[(
M-"(*7S-XVMR))FE?(2)X%:8+D2,M3^8"LBWGF&>,I>F&/2N.K8OB\J63$1M5
MC8PL.3]T9\S%=#E.)4:J[E>FLL6Q1XO6%[*1LL["<R)#H$]L-Q_CPR5S,J ;
MQ ^KOCQ:]QP6\.C?/XJ^]'0]TNUI/R-,+S;C1DX5@KGCK(M@(['^ROPM7C>E
MR@<F/S.U7&/![B@11XD2=S]\*P _$_H$'[P#B ^F)U";GQB[4\7M5M\#N>/4
MI)J*Q(R>8YKFURL2.7;Y,J_/J.6,\@:6^+#7!SK869'H\(I, )X!\__Q$FNQ
M@AJQ%YQNNR*#0?^H5P0<AR0%*796-"0-M 9(^G!&]QL=Y"QSZ@1["@H^FW.8
MA/5CONF==%QC<?.])"JD(:*L5#@]NB)+ 2 NU\Z' ,D);DP*WX_BF\-;O"\.
MZP=FT4^:YD?63^8.!BM<O*4I<I\G'"R4YQ6LE*HFE6PZ-WVU-SCL^@; GSL=
M#D%3RD;C&C&H*EGV#EF?AHZO5!^0RS[3\[&E/M+6ZITG9EVM^4GIS!$%@W/3
MZLJMHGZG1F_?5D0P7ONDH5-!NB73%N&*(ZI:\2NRC:[C@=+N1V[0"SW8:,U>
MW&XE2XRCU/2%T$3_>,[0!G9F(39>+XAKMSJS-"DH:Q/T'J25J);8QV@V\8"(
M:(NNY:+R,?CO1'E:YG0 3(<SRG)_7]G#2=6?EP$]0G-03S;8EYB]Z=):J6/&
MJBTCK[7N,9F(]"274-M/<C4]#RPZ)<:@Q9?3T@O2=6EXJ8N8=FC2X1#!9F%E
M8NG^:J,\<$)1MN67JDJVS]T&'XDXFB3M% ?W-O[M"E$)[>BT3N[XRO[/+F_;
M*N&KHZ25D+E+Q/=T+Z*OJ+O0&?? LU^<-P3?7<\?C$W7T?PH97*K%,.H<V@D
MG;U_,*6IV5W2B_YXT5$=9\)]Y_WX.MW=20%8S$ _.(^7R9R4'_T&O@6>!3P!
M$BQ1%$&NJYL#1);;QB^NM*U4%@RV&(4 PPY8W' C>;:"UAF#ZUN%'I5#62[<
M%;6.9N^,*VA<6 Q2XQ[0$\=&9K>0[Y8J5%(O:AXNK)C1BLW9$RK! =((W!_!
M'5,;5",PD8Z/%U:/[!_3\7%7+"-M[V9HD4^(-T]C)%@,>"K]WP^R#!*IWR#]
M9(B@+V^N3)1Y@DK'C3CWY_GE_-UZZX6X"!3SSX_3[J=(Z$IM*<W6QV)DF[DS
M[S'J*TH*[5:A!6TA<!E?S!:3TECH+61+N9S.CB_FAGST7Z%VVK>.:BGW]T L
M,H.S^ 0\^*EC2J(C6>,&)CY7W."DI61Y\.6Z2.4 C49Y-.V?)(PF>@9YV,90
MFV+6/>S1/C3^%U2!/+U=<G.][YQ;0[>=O(3]4.=^Y5O](</#F&<^3]WBE9F:
M=2"^!V:<*>+:;/E^A\WE1S4#>#PT!ZARFH_-/H!M]+41V+Z+!,<XK1$L( /[
M*M76G:D%R/Z\&N_Y][N\]?/1$^?S/P:-#;Y[FY=EU3[EF=2Z[4!*)F<&P/-I
MKT)=/. ;#S  -'T/#/:K=?GN)(#[C.[:M3EKUF;L93YGW&*G:W7P+<_)&40L
M<IHVE69^49&35DS/3NOU1M[M9GYM)I*NLW;;YBY9E+7(*F5TV74YVZ"@I3FI
M4%?7<DZ=F/C+T>^YTO7?;Y.2BGP+P"J6?KPB8U>0"Q@?Z.J12VFC.MN)FY@R
M'\[(G"@J6F:0V>?4B<8DLC4H6?72/GY#;Q3\MV.@GAM'R/QQ3YPGQ'<(RB-?
M@,]O_%7?[5^J'6!X"D0L[A^X \R^31RZ=86\Q+BE:3X!AH\;&JZ+BLT.:&7B
M]4PLN.+S=" 2MS\3,0D,/4[/#U?D4:"](A.BNMB&IRT#<[<)O2O$N&]5.^TY
M6#I5$VT(?!(H&#5W$01)DA3JZ,CO/YVO' P3K^(J9T@E'QPE]F0H]*N79"0Q
MO*WDXTBL1N].?%W<JO84(SR9&=8>S+ZYHM;2D U&5W NFNW+BQ[,YC/?N+D7
M+@)JV)[,K'!-:DAPF+78A]@I,I*N9B)=U.V"P/<%V6^U8I<)?N9'6_3'1ZM4
M/W ',_F/N^4-?+<"_ ),C-=+EU*DP5HZ-^_+&3^M5EA%&$PAE)M?)7\QU8X>
M- J=59/I+7:*#B0:+XINV1_ $T^<(]$C,5Q8XL<)IO@;51?U$]FV95)"P^'4
MFFTB@17^I8QG *>U>O'LPH)*YP9:<WS\ZM+-9W_T30G0-/^X/PJD^3C]D0C
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MHHNZW"/=G#I,,&?U25P)KNRL:^GM<LU'9M/5/3;E>A36#>=L-^GH@#%@L_C
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MI7JV,!?IL4LMO;X&4];5J0_C@P?R]&=G9U0E(#9JB-L>0P?LL27S*?]-!(,
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M$9ZICS+E/]Y4?#G_>JC;>;Q;[;;HX\0=SF*HD=4']FL+2F\_*.6ZC)(G51X
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MSDEVM>";4H_@M^LI+%Q<ZY?FRI8AN[]RHNEC9#Y:U?.N?J1O+JH84E TE%!
M]-7.?;U"774TC&F=06<,$W^V4<+,45,7AECV3:E>\^0]OD"DVC<FY4:I3(J;
M*7'![FQZAJU"K^N3_-@0CGY_#]Q7CXJB3;I*36[7P"SO1GR)]Y3?R\,-8F6*
M6]I:+!6T]'Y4H?Q2\RM+>A0A@NJT )-2(OG^D^;/]R7.X 5CTDVKZ0I)<D].
M8XIC;9)I(G-9*S/UB%;$/6@+)AJC'B#@]DAXJ>WM+-7;[KRT'$W\]0'6JKL"
M(7JF)"7:*=(L< /1G4^TC;] =$I2&T'4)=R'Y-*5+U>1PW9XQQ?S$R=3Z&=!
M0KWS[UU9,0D$X_,D6I74%T8B/1^V")6U)G7]6=4BC J4:*SH-:U],JCJ@W$F
MW(,__O:&]VJ%F;F@>^+]"B_Z7>4O0;\OBM(S,_V^GS+ O T6BI=2$ YYKX=@
M\;+Q.F&?XX0%UY]S: .$QA XN::V6Y<@L>CU(VQR[I_%K<V?\RUZUC#[!7>?
M4<]3V^>;=[JB:-02"\QZE:/>Z>/>#*6;U[#&Y[^L-(X@<6J6Y2<!>FL#X.LT
MT64[.H)UL(:]]H_,IA+39L70DME1HU2@C_4^WZ,D8==5#ZWH#AT#%R+S':.T
MONT2Q7L0+?X;,_[-_>LTCSG(:*= 8M;#.\,+M$XX2:/@[H.3@HL-TB;@/(';
MC"RDCMQ:2,Q$J>%SN-,YN@O9!Y.WX$;#8QT(E?/GY/8(&->S;;>H].LM=0$'
M=5 *C=-,H8JDCYS(%GY^Q9#.R5%3T<GQ;LF7;?:\5OXE**LO8L&8@5(HN93C
M=XH"<0V<*&?@=KL!8&@I;EU\Q*1?\ <\:PTS?^>F+M$@I"J"ZU_S<$:(UN17
MY^6*MGQ6,@!4EB6H?S^H:GL$N<1<N2CWN?K/;%E]H1AN9!U-6.-4#N\<F_CS
M<E0OIBSMH5$>U%N?\\)YX&M)Z@O@@S5>6L?LN-M83__,AM^LR:B_%E"?+#-]
MH?+C2XW;V,ERKN@6\<9C40@D383MX0=*E;?WE&QN,-\$?G./O-X$'^0Q&^[6
M4:C7U)Y%#/@)2=9;\CRG**2&L\8G9+M;;Z-XI5B@%CNS]EEA1D=1MZ^#/O/I
MC&X9NX#^(BH@)[FH30/FAZ>8];NS^!NSNRLTM_M&3M&,Q<W?66#XCF9P,,R?
MD;^D^K[N,/<<1*='8OC:\RBCA! ORI\ V(4)&AXGDO1.ON=WXL-@<I74SR:_
MO$\_=EOGHMHK_IR=75Z209/O_7SO U5$;,C,0!'@>FLU!YG WLXS,X;BI5K:
MGGO?0>%.&ZN,B,M+&.<*.-.#I;Y)FPBG<%B0#D)^IJE:2Y13X+UXG"9@0"/6
MR>U_4N2EB"C<Q^-K/M0$?B3''Z<VK@7M=D@SC_^@W(L$1&\GA.-(=\I 9W)H
M6O]D6DQ/XY&8K"6O=8C]^/QJS'_Y6#)ZV0$<(H#T%^PMKH'81_)TDT\CV;^'
M]:-/%NW>.VN@)J=2AE LCF$W&Q*I3HV7?_9;I^\=RZ1]Y'X^I61B/<FI"/$V
M\KJ?0FY\'.IC=^Q%,@Q@XFXZ-*W\G_2[8&H\H@.3425/6#Q(S"G+27OMOV-\
MY&ZH&F,2QI@;Z\A^-_EC[^.$?Y38R0<RAN1HOK(AU'<)4@4_"HBOD&FP%%+\
M?HS)K!W4V2AY7*:2FU'"9QYG?%M".]BWX'#@GA9ME6K1JR\ [HWK_5]FH[3!
M*SQK[L1,W OB6A6J%<4<'[8D-R\A.8V6(["\KJB$KB$CG,WZ(TJ6#FT0YO[S
M-2F-G(1&/FL'+HF[^1'&38#<&X42.3^NG/>RA@?"CRD>'VWA/[D(?SL)6//?
M]Q<<5YU)@8U0N^V'].AMF;**Z=J:K:=+?"NLL()PO.5X/S[9CG@;_ABPNJ<!
MAOC<2Y!04/1>1)8V]& X.C(P8#Z%[X-RHZ3M)BHES7_)>9FVQ-?#WI%RS28D
M2;\XE<^$*R1398?SYBVR-Q6I>80QS]EM:RC%R%TL!'I7^T=]I$R/JJGU,7=B
MBEX<M]J(T*#SW'3<L>RE5+5\NRV<KE!RS2B83,=TGAW@ 5LF:#Z/GHLJW\WZ
M!G\H9?'.E>J':<!?M4>+E0_X=JOI_EI("XZTR90H*2^EJ2H*EG1P%,^BE"/'
M/A%:1$&FC9'K0E6X_2.%"IG3WPUEI@3NQK;G)Z[3P_IZ4QI?BKNL$/4HI8VN
MR>&'D#'948%:RP+K+VI^=V_2TI G<F3]'61/U,9;3:6\T>I!QLB9H5*%LG<S
MBJ+W*85^#+R(C;\FK\ H[B5B/7,O:'XGO\N@[%UY\:2&VQBYF.@>]68.L8%/
MQMC_&>NW+ :.?1\4ZU+*F='R4XLF6'L%0WNXLL3+#.SM!+#E/\94A0W$"-Z2
M"W(DBM7!)NQ&?IH#>PB#E>B@0#X?HKA%3.0[1%M(]1<U\/^.8I<@RB<D9S!M
M@P6V&W]M!GV7Y'=J;HJ$M[4HW]9K:%8(F(0S(7K4&NU#+,.XN@U*UWGXW',M
M6H*YDQA_?UJV]G?[KV&7#.G^\"7(U8QD@<:%\H'/<X;)M>R;Y&QPKO#_Y=E-
MCQ.326];*5!9_::;9ZLX+6REPX'F .[T$"HMI;3RN[RK4ZS6 ]("10@X5YI&
MIO']@#A/6#J]NL>>_Z&DD.=G#CFV53J*4U<^YL,I'LWBK2><1Q-8GS3+E!+L
MO(C9RX (N4"%-K(+AP8\BN@YZ.IJJ]4=>6<YQ3W%1:<$G+1U]>[+AY(["&?L
M!\[6G;?-M[N9I38>FC;8N49(R*\NFE:Z0-K-(ONL=E:-MYV*2TORD](0<;D4
MQFQI4O8HP"O2)<<ROPJP#BO@7?6AU2=>8&GY)ZH+!\W@)I&]JA_OD1[XCV]$
M/CZ(<OPLL\[$$]3UO)I1PPW/H*='(%?(@LD;F!@E/7!"!0Y.H.@./=DG,QKF
M6S5B1J S![G#AJ>9 ?P?TJH9ON-2V4(0;R!F_%.*3%4VQK?XJCA 6L"WB\&M
M_E?P6#@7)@5W1.SS$1[9 VCKKAFA27(*!S,?WA.\:%[YW'#]0:585.^! -=V
MI[;E0G!%)$?D>#=4NO0>1^+P\^S[@$^$/.B-WDP]JO2!W< E'YNNH]V]D#UO
ME/OED;V&7UM8W^N^_;[?I"B0)Q'696#'F>N?\JL\M]31RWW+T:@KJH$*8" O
MDPW@@-!MS"\S)W_87L[ EQ[5U+2(>0^=+!K:.P?.?^G7W^",RBPL6>E),TE]
M7)GJ\'N'M?=*WUE1YJ"OS2U,Z^0Y'"X"#P8_D$ID-8-]Q3N-H5[,T4UI6V?/
M,\VZKVU[=&26Y+]6+>CU2ZO(?#8;HJ,^T1.<W2T5:A&F 6"9H SKID^W:R'N
M@'70Y7@9Y1>-&Y1C$6/76O9-&T]>U)W8="SY[0YQMWFR:Z$ER!EH\^:)PK.J
MKQMI/)T[WA2H@'RN89*5!87,K36E<WQDC;SZ:=0O7._,]"E#.7[)"Z)[";K9
M#=&3>ZBA9F3]@<^RA#JVX!9-^)LL=XI(BX%D0"GB+D'?LMY>@H0/ *9#1+3<
M"VHA61'$BIHM2H)>[#M';1Z$/10X#1J/?Z]X#2+Q8!PE?E+['F(X#NG-#*EC
M_]CG(/IDE=_F9?%7[N9S@P_$)'^[BB!YN  X+- 4<$C8T!MV;_8O<N++%^4.
M>7>*[8^?&&*HVEZ^ZM&>516$W&&EEU-/$-<>V!N?U%/N>T#FMGG_7[EMY($=
M--GDI*)K*2-GD4"P.PU]XTST&\"4GR(]Q%/*-.6_W6TS:?XS_Z[PL_&\CO=3
MH;WB[!IR+9Q X'W )%^!?5LN*O]#L7'^'-KPCJ$HDSFZUD?H&:QV5S4/,RPD
M.Y0(L8U0"<E^&<=P-3;U)<5+X#<E"2W>OR2YII8(:U!K/9JZ>M?E<E1 LL#1
M(-_$VM'4Q(R!/D-VE/'Z7;V7& -Q'Q=)1=M_ *89)J4*>'R7H(\6[,WQC0'H
M_""UTP9+;XI>(L3<IUGJ[('_Y^S%!'V&_F.)1&.NDL)@E>RB[HEAW1&ZY-[[
M,:JZY.!V? DX9;2#Y?SW\BR>?\J"_<\E*-!+2VE\=EW&J4:$VD!D[JE(RL%J
M'79&_*1*73>=A6K(*A+S%V3J5R5P5G6)I"")K$$[? ?,#+>RT&*(_WY:I' *
M5X'].^*]C4J5-5\=WEO">$H$=ZWSBYPFZ-.>U-3__KG*DU?2,Z :]4P]ZF7&
M$-R?,QH5D*U HJ,1"LB^!,4E8Z>V,\L/VKK0&0&25@[>%4[?-97:HC1_MEO^
M62["!2F ->,KT>WQCKZEI(7*H1)>I;<32I7DX!S@PU(RH@D['^D!@=W<]6?>
M:BYN/G[O%32RU'3Q53FF-)S:+#8OZ$=85%O#P[AR9HC-(]V^& T!-PY^CF!)
M[0.X-Z8MG Q.8T[X'EAX5@5\1<=BL".^4:;\S+"7I:A@-[._K'!/X!(TYW*[
M26":D"'J5YU*65SUM,3QW:O7B&PVAZ2GNG;NM"^ 6UW*6FL8!5P*M&##'4][
MH@->=2)PN@6*XFBBVIR:,]YYN%0@(7ZO^^JIJ-6,CO'9F):L3C]/1"_3X+T6
MWJ0GR[NHI\3/^.G#R55OJ P=UG"#0MDKR4WX.=[9?'E/HS>BUWJ'9]7:V.EQ
MS[ V_WKNUWR(_P>:S[=X[*[]"P""\DYEIL5MF<F*%N[Z9Z;KE3K0D8[MO:N$
MHEHQ,_>4PF'5X-[),;4$_[+(.W((T2?*7/(WN8,/S0O%N;ZI.9&=,M9NZLPL
MZB!/;3?GK*Y,TESKKN(LG9>XS&9@(J<"G"J9*U'7:J+ T6$;%;3/4R02<\/M
M5CA*A5S"3*T"%T%^ G.T=/H377XC8UMNU<B,5MA[^,D=S1"<9UJ#)--OQQ1T
M6V\58R<402'Q[*97J7;9^67'?PLPD -MHM#D8R72&Q3[O+%\QCXZ'?[PV6[-
M>XCEQ_?.^_,MWT^\?>>':*;%&<&"*M%,XOHURK(END?BVJJ/)CY%CD<WGRL7
M1E7'LZNJQ?1.ZQEJ&^IQVM"Y,)5]'Z9"L$A;QM[BB.V+8#16-="]P4'^&CN!
MO:89721I[E-%\(3OM57N[E<IS=_N;9.YQ:L8TJ7]/#LIJ88]-C,S+O,)Q8PJ
M+=EQ2?-&'YN13%IKD%7,IK/@IR1QU[:.)4;?^K,K#FL-Y@*066N^*W42UQX.
MRCKIF1JP6VE==9Z8<I"G)7?4__T<STO\&?20*(M">7YO4R?^.\\L\T/&L^_9
M[)5FTJ%&J@A$;URE%NZBJAW5#S&DLGZ@^_#5:A=YK0'K1>3 TN&QC_=(!UX,
M>\7:"W.X/_K/[IL[NX1V2>MNB)8BV_A%'>=+&4[(&Y$88Q6'^^'_U6WGSQ)Y
MX9ND]B7P<!;>W3MI#L^K'+,#C\HHJ/=D9:N_(RPG=2A8U51E%JHFX6*[UL/1
M$98E^.+S%Y%,^Z$J7;3")ULDX&8_!M3K"GYC)F.<&!6D? YOMTA@*-_^V'/.
M-;9CUCDO=[.1XRC_>/-0SU;R% *5M)^/*[V?6$084+9Z=%*G]JCOZ#6YM]TV
M,1R>BL8>; /VTNF0/T]&>3.K!_5YT7>Y/(LZ9:XE#VKIP&_/?\>37VK!^E4=
MFX"W[@M9W1\2PK1?:6/[=HIW>@'^G^'D@2MSY2N2CNU?^_TD05\PH6S(8/B1
M_O=)-D;S7)-0FY"G]YZ8Y=O>H'7D6B*/,8DZM?A/JE;FGV*R=EC3+1[*W*\1
M@[B\^'>^Q12ZRH? ZI7IZM]P?\?G9;V1E,;(_9G7Q#8M4YKO,36E3+0W)C2*
MA-<XJEDM1+=CD/',1U,HBGHIH;?[^ZV-,CYRD8LGWG6[5Q.YHI**N'4TJ*9?
M9G+'=Y59O!0S?1TG-]O,$4# !\,%*U,"*!J"N$\KC^]NTRZC5B;3:RJ.I)<3
MEI\B6KL56+1<-E800R[^87Q?XXK$0G*C$,W)^VG&#TQX&?53. "6,,T!N'^N
MS4XKW-@UW.EQ30OTX/CY+G4\2NUB8Z'FK WSTPI+L+-SMA<93 EE,C5)[6=$
MAMOI\95"1*]%\6P[9 OSO. %K#4"O/(4/%23_:QER^U8&5.9CA2!%B[&-_&]
M/W(.ZCMP&3H0\J=D[F_*Y"EVPNH-"KZB]=W>_J13:A^2D:LR;469!]P 6EX"
M+D8=S/JD1=CS!-U3&<_LMRA74B-Y:K"+,J4 .>4.:%O]=MH6\:Z3H*V;\HIC
MT[7FW][>?#!-6\/6'$P6RD$P<5"><C\Z08?(/PR+FTM \]DL,0PC,MC_7N<3
M>XD44U2.Z]6K]9H2>Y[I3_6)CFJ?)XHA?U:FA^8$$"-[&:>&9X,Y?[:\H0<>
M;I$M,RBKJM_T_"WG(WO%)NK09ZF;81EVI<7P5R*,A:^F?%MND5_R;'4"AJ&=
M9)/QUS1:!IX&]H:A\.%UDDL9_7JAX59GR@&N=GZ>8]H8C:$C106+N$QCQW_R
M>K74V2)-7XGOWU,J98"P[*("K[1D_?ACMU;8V0^-AITE=6Z36KJT;G,&8??>
M%'!QL]1,#7S7G2A7M*[BJ//V;.[6TF(I*4I,>AJ+"@;\O6!D%*NT/#,1"2.R
MTI/43GH##%R,'I<N^8[4CXY9E_)D%_M9%2%*<D.L#.DXL.T"[E,,1&$!W:X*
MZ_\:H4:PG"S+N%5*0O?0A$&N%(V<JOKAH".4<2I[&B2_9XW7IKP"85^REI8+
M*2KXL)2O@GUBRB9VE[KY7+%F-714*Q0I72Q5K[6J!7<V/\W=#6M^R'PL/Q"7
M@PQ1BW]=(K*M6R=^@D%"$_12^JY*?>[&Y)/?"(7F@U/0':QQ9BL >)]8]*$^
MSV=LS8I+RV;B=@/KG<R13!HA?;JKU9Y3?@YL_RJHQI8'7_>.3<RT/WE 1782
M4F7T\'EP(=?HO6_16F?GPY61S#[S*29UV:-[J,D6=]HZW_D%GATJZ>>GST3B
MNC7$/8<2-6XI:'%XW[_Z>7RT^?Q5.(F6YIC:F@@E0<!LU0RL,8VDO/VHS5W&
M]UG,8@%VSW!#;=#O,Y;6Y>'.UCQV47Y%3_V+H(X."@_]&!-KX\BR9@;^_W7U
M[AC\F)T]I@NF@-=+ZIHUL,0V(B,)6^P1_6L%OGR\._\L,JJ^R[R9:Q/'F!.K
MD)=#57:%]^H5\K.79!]L%8Z;N 5.K^C9#_J)6R1V>1*X;T\N5G^T<W5T/=AO
MF^Z9UH+$YL75,_+<O_)EJ4KM[VZ:.Q/]MT*_Z[_; :3=65 GA?0.? @<WH8>
M=A).;,0+5K>](F;BF98"?,J#..RJ6HK\#L)@G(%*]/Q<+RL*SBL6<L1'PWK&
M9JUYWSDZ1GB=CNLJF'AI6@'TJCA/>!Q\F,.<>)A.1]RKAHO(5'^L=,2*HU(6
M'<TN?FRA#BT1YPQAH6#3>A-&=^K:4F[[Y\JEL2%LOFLEV>JL2:\ )8:"/\"'
MB@2)_9>@6+03+*?/VGTNZ&3!@K7E?H5,0;V5JE("TZSKODES:'F>T3QG;YM2
M<"5K4MC3/MJ>*JO/\^RJ3 !\T2,3X>U96V#B8CW8"0KNR=IDRIR?JTA&U3+I
MN6O[1#N?)5[3T##S?I1XLJ]PAXFFR<&NB*;+0*LQCE7G5DX,.5[L3 > 21+)
M*DM2;[.RWV)#[%CFNP^%Y_JSE\D^]?2^;F6M2E9R'Y9DI#P40T;?AKRLP?!5
M/U6*R\W1;GT3,];**4!+<U&N\ R0SA\1QYV T9 04]32TKJO)7O\_=6KY\89
M\U\@$&U5CG]!3>0DHB?&8NLO8CDT:*-T029TZ[S[&=7%-1M-^>9(J<R'7B'^
MW%X5829I_JD.5O[T7[NU'2@6:>'@:'+B$X&^!'V6]6&QHB/&$M*KFL&UU0S$
MH).E]#OQC,AGE5(<VAOOI3.ZHU37"@=6'5\:K'I,Z?Z.4>9OAVANF/;?CR'7
M_EV"\*EN%Z>U\!6!K'ZDV[[&5G/]R"WXP>L?UPF=+L3/9G1"CL$\4AGZ7M+V
MO 51 I$/]7OB;_!=C;VIPS%>3A?:?&[QDO73)>A,"7X/?&1T1D_"-I)+(=SQ
M?QU;K%)T/TJ:[R2FXZ7'P:S8](FX7*3]V/F#WYW[\Z+:NJJT$#T=(8.*A*EN
M#8[QLK)DFN3GZX[T@%67VQ;>-",B@U3.^$ZY%8C=N/.%UF19O=&H>1D93RO'
M:KJC204Z=:S5/\8?!GKIQ/O%)%@S7G$/PAD$ *,<1"[;I3G46Y,_OP0I9;')
MOR6Z_L9TD&Y?7V7BKVN(HKB2($['!2DLHS7FVW$8EE!XP=;[CYE0WTY^=2R@
M6T6C45E2I,>PIBRH#M$&SSQEAC:K>EQ4LFR$^3$T83BUQH9(*J1T*.7-@\O>
MU9"C>Z7*_T_$X-6JG5DF<BMWWDM0J#[)E'5;[^(FO&;T*.""%^X';T*BJ ^2
MZ(>)IL#B0N&WCP/1"Q?G1\)85NKD_G/TNDG0[AGYO<C;@/,-Y9[*L,6 :RU!
M:CZCNEY",TMXSW\7T\/KCW%+U^B\WW_8T6 6U'R=F\FX$[3,G=P38=$3<39!
MGJ457M]!<D(/*M>VT%^90GD>EZZ>G>XQSYI=%W;<WV_Y\>24F]=0UY;VQ'<@
M94>#Y66U3U$L>W"F,:<?3:Z^J#_Y\X%88P$H*ZM9TN#LN&65T8 J/]98-J'D
MFIPL#:^?;::#L5483ZR:3!4EXG\Z.N1*3,.'F?">/J'6:\WPXB 7F/V>YM P
MI.[Z%=M]E\4OB-)^S2I5[<?=GTK&XY-,[*TS:0L<TAQ]UXL_R?)@@+L29=[
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M\"D!^N W.JN_M^+WN:1F#2^KQ;GYZ5R+>ZEMFD_HH\0I/.23+%9EY4&-H/;
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MZV7=&59;7, :A^A?N8-+/;Y9>-99+2R3K^CU'2,MD>H,-L(90*]6NM#Y^76
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M&IEG^V@\D)IF:5\K4V\9$R-;EFSUIC!'Q.CQQ(Y(W:MK+WN?TC-2D>AT%XK
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ME'*RBY^Q<Z-][K8K3C4N)T?HY5S2$%]>5+%OIK!P4:863[9C?OXCRN,A'I_
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MF4^8.4K5P3U2WXU5!-9\>I2=VJR=_(D!%KA?44U*ALE=1N-=@1@R#8T^^$+
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M=@Y/%N:'=#/43%JH*,9U)84O\5-,EN5H*MM]#[$>(,H(4 !=O:P184DI!6?
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MKI*3AW+'36*J[VRWTNG1ENGR,CZ+0)SV+=LWQIA\K5,2N;V-7%/=>. .WBN
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MH?]NN<?0Z[ MK2'C+)SU&AW#U:K,T]&J1L$_($>I?5U=4X5=B JI! 60#0O
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M8G9L;5^Q5$UZ.#4)I=0RBLKU8LN,=2P(_$I>4#Z@\(!23#^^YZIK,X]7Y!V
M@7MX$&9_.DDS<3DZ.7*R.3G]()7E5[SIXG1F:[MFF_=0[@%5171T)Z.,F+10
MKOYB&/7=9S!-DGH _+[L,,5L,$?X7A,$O)017^9JR5D9 1E%4TL/)N$H@= 4
M>\DO&VL;].@J'G-J4?<W[3+275=+U(/Y7Z)9B15@D>87H"B;_?3F^<:ZP\;N
MN@4216X8<AX2-Q9/_M&;2OG>H%Z_SA^V\!X>Y2/<HEVV)<PN4X#8)'V'.<R4
MV5_N* NL<1*N[E[MZ&Y,50%[\C>HT97*@-^)?VRY/SPW(R</J9"1EPY1IY1/
MUX^.4=)L 3 $Z3Q)@)AV5=NI?,K[B1 T_>+FS5AM<$O^6E*2N=-9:)CH80\E
M5#V!-Y$G_W=T#QFM038GZS> C@&O^QL>AHO"1BVOC#<[SD9-4X\8KU=5K6BK
MS\RT>KSDC6.OH'X'[5014Z#\$VBHPI45LQ#=TKD4NN[W# 20X-LG$OM'.)4Z
M_R?5+=*];2;9IJ$#-FQ3@X=5-/3Q/QZ,<V\BOH1^.AQKRQ 9Z8RX /'$>M-E
M)2*F$Y)/B0D8&NU$1K"S&_)=\+-1%. P=.-U)\'VCXVY8">I3>N?J=\MK5-3
MVX]D%LK PR1)H]\O,>@3_RWM6?7B!4CML%A]^P(4SF@V<FYA?Q@X.GG$ +TV
M\OB9O>OC1=[,%,/$*P#I9[57F<DV=NTR-C".#N,DYO4*_-7 %P&8I?3"0Q9<
M[>,Y#VYKJ-WZ(?:F<TXB973"*]%GRDJUB8,7@HR 1B(!)IX9P)EY)_X;6MF<
MAPH%4+<TD67(+P2R4:*J:GP<S"\)L?4,'!R?_%"M._YSET5GZ-";)AL=B5DP
MM$]\:RTZ*.UI/J+W&E1#C,VMAV[^30[<Q"-TS?=$HXT1R/%^=X*4X[.!ZRS-
M<B^^K]G>K4SXI-7/_871YS!D8YA8?ANRVRH8T'BWX9:Y1."5!9L76PVAS1ZD
MJG%"/THG'\/XO<DPM%F!L=ZM, U($6V..XG;E(1$277MB8H3 '$$$.#-IBXY
M[^$\L:OO/#^;S.5,QTQ')4W@:K^&O=2-R6-*XM(9^-D/LWP=QZS&[BZ<\;ML
ML.FQ*[_R)K%>E7FOHC?BGHUX>!/B@Z\>S:W%Z>28"9CQ45R[18)U-U1%_BIP
M7 KRX7HHU8RON5-/OT>79_JK<H22>E,3>Z"\07QN9!)*O4=@A[O@^H-MES]F
M^MBX'"U;6:K=(\/@_26OE[FW\@QP4V_NL_H$WDU7PD#38([$@.\[(LJ&NUV
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M(!'BI=( /%9&#,;0<,,PD7?"EH\[_Z&/8:UJI@%K+ ]59F0G0T X0QIOU\_
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M%%3L=D?KYA9M9LW-G8]ES??^$E&Q_N5R%"C?-I$\;#A?)/D^OY";[OG](J3
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M3H!SNTV@5%-Y2QD_;E88^L*0B<?$:;M>^H%=<3)+146TTU8^CZGXL;7^#XH
M1_Z_E\0(0M!3QWTF<I(:9/U[$Q/@=&TXF_U.+/&ZNG'KMN3I?D*+T$GCDT:K
M.J9=T?O99B:"V,!'W0CN)OJV'IH+^8(:=M4,ADJ ]!G#^NXC-I27.)CQ2\MD
MQSR>F%^(]SG^'4(GZ?/HAR'.J_=KY[W<JLMAJAD_[AB(Z#R?V*B7,X,+WZH0
MG!!14-\(-Z5T;YG]_UP%%RAI&YQ[#O(+N4ST/U1?]E<[WA_*$<..!;FU+.5U
M?+9TGA-G>I2.+4%#7YFX"@I+]0D)ZW!'FQM+/_T[O/+D5AV6KPUO)$GZ>0[*
MY/4@6I/^WCT'9;"ZU(B'(EN;$SRHFCQSC.4LI*D8%S:QC;-E.\[%R$C3[7L?
MI-G]2N++EY#J;Z'C.SAD&UX3MLZ'=6D@4^Z73HR%\0?GN]Y>S%MDY6T)<.]J
M%J"Z+"^ 4$A#QN1'I@Q(JFAI:5UZWLN=;IK%12LUH3G&!6R!-?G_=ZA&6&[N
M.K8%(]MAS9O?!O*C*H-F%&8G7A9F&D@[+XO[FLH4FT7<_GJY_':G.&?"XW=-
MMUV<@-W0.P>1^-#$*GP4SG,;EKJXMQ ,L3G> -OB28J!TQ:A=;?\(QC?,;'0
M)%>[JU7/UXJDI#M/XR;3D&]^\X4GI/D*!=>^HB*%D1U@(^UPN&+"%$%V#DYM
M/8^ZW#RZO=BJ[>!0NCBJ]IO5A3ZNNF)>847GU['(F_Z:P_R8#%U%3J.WZSI_
M ]C?I]WWWS46_WFD Y=/W 0O(O[JM"#=)%C\Z BNWQ@B-2SEN.&1'AZ,V<W:
M:G0\G\O]IBSNL%+'THH/#M%KW#>:&M&[=*_B[&U52#2%\3O_Y_"DVKE3F^)B
MY^!C\!4,-GDGOV,NX$;SHN_L\(RG7[/51O\&=I(H4INR($485A0PX?=,/5+D
MUC,<NU=35J:_=+GP'J5Y77WM_U+,R]\D"8')2T.DBG/0X6P7_&"04O&R=@YZ
M!X%+(C;^.F1M"[OEBGG;L=KZIYG]YSQK/M+7;:3E-=IT,&XD](XYE59<PNVQ
MEY(I(JJ5MC$/MR8#S1ZSR#'Q R(':C1$=D&-G1)=20>$P"94UBAYV*Z9;R D
M'3.VKY2/D6K7?[:&9JZJ_XFE5Y>9[Q7_LOG+UDGP3J1 @;-9Z]9J)3(FTCX<
MYKO?F9P//#(O9IC5E52V!*-5.' -X5I(<J-+"XPO8I#5<C?==BP;3^27D!+%
M=NBJL<3P9^PF>VK7R;]_M<5-N2XMI V<@H2<@^03^@YJ,P,0Z_'HV:6V?;9/
M!L]0O/5-GRPZ'G]B=!VU%[1.WA!OFCQF\4XR0A'EU5_^1&@\!_QF?2)!/])_
M+6P>6)8;OR^[K%#)K%02E=7'S_SD!6F1RBHI_6P#HA#O[GBI23EYS5U?%>[Q
MRU8&UQ^7,:^)%V;1+P87N9%:P-EP7#+A$VE-OI+H#9=*Z,H(ZUED>-7NH=@@
M>^NGX-I7J+NVRKK,J,J5//1O=L$BMN?AUXI.![8>W9I6$7#^Q2E%WEED%ML4
M(2W!LR  )TO&UY$*X*FN8XVG*M3\$\$'%?SB0DE#&W9=4'>:M/NV_FR/,H>-
MT&@3AYB*BE)%R1%S+0.=M72>4TV$[SZ F\E@W!NR5; -,<GC'+1^G83V,61%
MMKG<:@H:\S=2B7TQ*NMI\T"KM?C+U+3;X+-#XB-V'W<#0SM^%P?;,HWA!UTB
M4-$GR8)B ,AWRH:L$X,_G8.6C6&<2NSN'.\7$1D$5+,C7GCV1D)-?_O>'[72
M6::J-+G(?^*%EFOS-;Y;#G'= M\!\#U5'0<XH'?W0SJ)0]C5E9:NA)T]T?&4
MRN#$8'V;D^;I+\<U,HB+S8=H!%=,7_9(=WJ7S:TDJZ9'SZ6-=&PK7AVU367X
M4JB0"!Y\DK%Q!OYBF9Q"C-V0F(-E0"?V!9>&D:-=L9&U'-?=7=M>'DTTLU_E
M=[8M_5+"M@D1>%_'6_CA+TD .&PI$?8C@]AS#I)!;,0O@$?,Z4E(<&JI.5]=
MR_1W9"QK[K!UT?P1=%]XYA!\H&M?H=V[*BT5,,R^\$WM,-6C/ETS4^B8)U@G
MSJ1CIJV*;DTVF6B<!LQ+;%U(R5,944I\(7,'7[3?%CH&4=9YD67FED$E(?QC
M96OK:+\PAO^1CT%EG]Z=Z.G"R@&\!/ \/K##_+%<E%B8!EP&O)$S$8K#LC:<
MFE<&A37XJDPKL ;:6M9RO#53&LAAT.3G?'G)DL:;^I4LMYK4.8ABF*%+/\G.
MYZ"Q"6)%R#;1= 8UQ/&Q7(9]E' .TDOI=ZN)ZS'>?<1F2Z 1=7[QR/L:7BZF
M73I]Z-F/ 9,A_9<E;M?N-EX3%M<!5O5;AQ:ICQQ&$B"KAY;@8HDEKE5AD#6\
MA3TV1Z7VY,KA'8!2<OHR2N8(+/$8U6>3D^Q!NR3?+*?2/OW5<H1[C%.!6M;(
M4T"^NUQI1&5FD 03Z_^(L9&^R^]X'BCBCF*]3GYUN9V5?_RH("NBKJ^[0K[5
M*&4N&L4!;=WVU$JYXIZ=="F%&*$P[-+53^>[7Q5+),-EQ39ZCK0H'3C_=):-
MNL.C.GY@Q8JPZ(C./ZP>*\V1F[GNV4$D*F%#J;'DGOWJ&^-&6B>_O^MPES5=
M@QCRE$>_!HQJ,-G8 D,Z4Y)S!]( +H#*G?)W6NV\YTO7+3*VF-IN[C7A&EC1
M8)Z04'1-+[Y/;\(M0%#(<TZM();+6:"SY]OQM>OCC9KE6OL=4^(_X%((@CY^
MA(PD2I*&E&0.HN51*V#ES4I6+[>SO,L#VDK4.<QQQ?VV G6$LVYE@_0%S[UM
MEG^\F07;TO+@@YF#8UK7#?2#*1T5P\Y!#U#9B)$=,OUI.%%R/#"O9>8WF]PG
M63I3N%1\4HL@9U'O6E%AK,OD<G&/OKV 76U9R8",;M0]SJ+4LUSLY _JP=02
M"0U*;1%!,\H0_O :DE ^'V YU==-*A;PA]E,[)-KY!Y=+<NX[WE:&"-P6;JN
M3_Z+1SE_A7N3U:N"Y*6_^T-GVN0Q_U.A=YLC&S6R2?QV#A(7VPA=X+@ 3HDT
MT^U <[ )^5]FKVE@/)LKJ!D3G2\O[K/'&]F(M LT/E^A?] ;Q7R)YB.$S8V[
MH7A*^O8(!&"A'O)3Q.C8!E__BW/0\#GH->I1A5'E.KS7LG$1W>+@Y_Q=3W^-
MI=85.FWC@_8!WY#/?J2U[G=FVXAQ$HB#Z-%*.]9(3CX9'P#6HP/#",_J(PFL
M;B)A^'PL 8^5K&_I["(L-SHKL+;XK[-?J?%,;:UPEM? 7LC.+Q5I4#9.&QQ1
M537<BBV13H$P30I<_*<84%%N9X#>3R8[+FZ1AL/8_.R,!^)Z%?SPD,<G<<%"
M0IV_G)Q^E0Q;2Z1>>]\#>5]25%)4H/WN4=W41,-$[QTSQW)+ZV/[4E. 4.;$
M_D.UC+20[\ :E1Q7R4]]PW"[.FA:_ZZS+BD33$+.0^CJ6G+4*_V7XMW^4)9G
MY3,\NFFZ-@T0R=YUC6CZ9&"KZJN3ICA&+U:#D_UQKRO(3GF5B;MYR$]D^F5G
M)8'Q[VN'<A?C^I3?+NH@$E2_KI99YH[I0"- AEFFG[DY]9,!]-TQ\7@3NDXB
MM/$1_4[@(2'\&'-<E=)%DMO2E (R>-]94[$LU7NC'BIU>PY:$,L9EZ'0:J6B
M]T2HD;K--8!E>/(?9Q P2!AFW8FT( &^ATK>,\;=(DK22+>W%,JX'^GNYC@:
M_(.6-:\ORGZ5'1-#[6@5Q9?WP?G!H3*U?MQ;;(QM0N8WBM0J,H2-\)%O=^#@
MY61M2K?4^/85W5I"XO? [=X%<[B#<KT!77AIKXV !#.U:QC8\[OA>LM=A:#(
MPKN1FC4E#C!LJ43#^-?)R?R=1?<B4CP\:^(<)(T(5S!'M2B)76PY1=CM5XQ^
M.*BZ/*-9=I2TK^TF0NM9W=MG4FA;.+0B\0H:_@#7IZ4GK4IM.'E6D 500>N_
MLN$(OFPQMZLV378\!PVQ^NRS$,1-:#]]] K<W= O)<L[RRM]"XK)6AMG;E2A
M<=U[J?/FHQ+PVPO@92@"''8=R&:+B<,BAY![NS204#Q[_X [L[_]Z8[FW0EA
M0^:(Z%C:R%N\2K+#,R)N5*K:7M]2QA*-P.Y_]8\B%X,KJ0'NN/)O#NF0&CW!
M@[6EG2+^^;^VS^8^=TK1T+GLD>[0N>U3?YY>Z>IN$M<KA <\8!Z,,')V%N12
M?:.<M<:RFM;X9K]CW&$5,G) > [!GLQQ"'0"G"!+K=0S^)OW&Z$!FK6UWX#1
M<ZUC7]OMZ&J5Z>1R>FXH.H$L[W>;=4ROZ6SGH4%9"=^NE#^K%-8KD6W#0PM1
M(Y+DVY,8UF*R^V9CGA(CTODL^<ND OUIZ^$Y*("1X>1ZR_3[]5X,\P6_@R69
M+/*ZYMG84:AT%""&LSMU0EJ(4-(@ZKW:#/DEYL*I6#U9-B1YCM7I-#AH3[2Z
MLNS-#JL+"\GXI5O=W52&8V::(-6[Q"K-OFN5%6::3#99.B^Z@-6=PM2AEG6
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MJ2WDW;.L2I>-(Z:71X]\4\MX_2AUI43P&GQ94X%UTXU.$\A$P7F1]:-@GNG
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MD\ZV(N1@\2?^LJ+R%->)GUMVY5^G;;<L(P6)OZ2&CY6N5O Y"6 H1UP42*G
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M;&MVT QL.*7POI:@A<)%$05P$[5AQKXSPQU'\;N/-GL'0XQ(Z+,Q*2G#IJF
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MAE?:V,Z;NCQ2$]3Q69!?P*?ZF<R>_$C$PD.38K,WZA"I"_F%I=P5I4&!XVG
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M3<W3:0_$YQ$BX=\FIW^Z?"X-E]D-FYFG23[V%)3M8YC4A71QT-ZE+J?/#RB
M)- #Q$?Y$D2BY4/!X+GX:.^2,F]&3DA9[W5D(<>57U4/K2ZL+_Z5?88M/1.\
MT[N[OWH%(SL<KE%>_3U$<:>[GXV:WP!!]:C!VP05@&2;UN<74BB_;<DSGRC@
M/%#-"V@I$(9T3+?HE)ZJ:L*$W2,;CM($V[\VJ!#FL[\T['C5O5"G"78)4>&#
M\\WR73E[^&7(8++CN$9MA_GIJ(&<VX .KXX?+GJ$R"M\)6.NE5R].<0PPC-<
M!+L:9)0HWHR,3C#K*9NI6DS7_M*5-<>NY$CJ>?:1;[=8*>;\S^WA!=>)[/S5
M_E+/0Z1)#LPULRVI#VJ"]LN@;?.+C(M^ZP5W]6RKC%L;LDK+2W)4?JI2R ET
M3W--O3!^'3K=S)][X^0:$3@/(!R3==\_$FN5+->Y2!B)-G&1&6JHD;IU0U+B
M(.#K>]?=['1FK3__<N'S2:=T]B;TSD\K<V@G%]U39M8&Q0,DZ!($*(7WW&SS
M2!3P.:?N'"#WLH;%IMW[IM[;'Y(#M=%,C6?)=,4I)H^Z)JOSKKU*Z%T*<68G
M7T$;J06"1*G07_B:9:GNY]C=^ VKUV6;.7L=NQ?M$\&R3:G>$\M(G_3?5_,Z
M7_+PU 0/.8U[C:E;27+)&+^,*^.DI8FB9.50 BC@$8GF^H]TUM<6?<1H_P=N
M.,Y=B]S#U"_UI,&%BX_:VE84+-;UY6=%%8,3?]W30&W:H3[[)>>K<R(?Q<<6
M^/UKWQLUB7:@I1[QD_"+6.B5QCS24!,H8&M@[VU,5':7T#H^;I+'U*YU3XS0
MB'[]-+[*%J&*2/BF/LJ<)T3[ 3#P3?K_1%3_+*[%ZVMK O9.(-EZ0PP4M>E[
M_.MRH 8L,7&S"4TVUQ'B#N!12-K!#7(KL"ZQ1PKW?3;WH"SW[<5BBQ@&QCG>
M,E>!%#M7"OIAI&CR,2.\/KK(\X=#/JH0[I3Z0"?+,&D2SENK*+"N>T^=#5#C
M/> _(89_MF@2>F "EJD[B(+!D^&%[^Y9_OY\]"M&<46O_/]4N$DM,+C#9 +B
M72W6\.[P9/;C?\>&N U86N@MLA9%!SQ"1KBXI-D4%Q5'?<ZY,2$C\X2O=_M;
M"3_OP_"_'LZ0B="*/EX,NF^UECP#'F8GN-J<3!G=GKJ81&_^3F2"3Y<&TG2Y
M+72\]=F[U8MZK*F@29V(F?!6Y1!57[UK]U5/=(!3DSQ2W("P=F@D]</J(![]
M\=PP6@;5O-7@T$F@G:&_%>,<GZ;OZ9:CPZ]T:H /2.<H*!I9KMJB?BLM\JR<
MP741T#-AX3#?=["#F "4&6>T^%'(*^;;=Q:FE,T\K5O;NI!3R>'#DR)35](?
M/F+M;*^X.F9*YF%Z.!_WC5>L!W'8,K.THD-=#_2ZX,4J1E\ R:>MM%'14_O!
M%FHP;J6H3_WE$=P8:P'I_(/<HH8>:"Y_"_B9A^!89MTWPTN%N^4=)!-Z/N:$
M6MN2=W8EJ_'.$R^T!3G9T%AM6DYW=SFQ 0;13H$?^<F!?TL!-)G^$@2$.VNQ
M>"5"K"U)=6\D+G?0TR=$9%Y>.:ECM<&P<^X78X+^*SV[>VU_'>EJ-IS>9XFK
MEO,]=LAQ9'UE34O3E7T/Q4KNZ,@&P"8 EGA;%=_>1WRS)P >]"@CN%:VC-]5
MK'G5= >9%R!R1HR;'EASKCXIT>JVC$-X&9K"O]C:P>F1M[RW^0O)<Q/.R? !
MO@2=F5QSB'0F=I @P9@G@./K'HV73I^G5UM*,2@*S_5U=VFZ<9>]1LUYR\$W
M5C'PJN<78R2@I.,P(G]^X"YQ_^@OD@&CXXWFDRE;;_<:(;-7>T2(GZ"R'P67
M&73/L<M@:DR)?T13)U%#>@ZNKJOW65'D76/L,:!?PH1*<MH&MF2>.]#IY?'U
MY(&;.]%?"HEYE#TO\4)7]QOGH(>QK1C$H(_F[@VNA+M^CR=V44*#?YQ:;I'S
M*S)]UJ=&1)X!@NG>1>;#T$75.IE@=P=\VN^>!(<<=(.4H/:UO\;UOW7G5)O*
MA3<Y)*?DW2KC27]9I".0LX-U)#G.EG(_!\38&L;@K^I:)REF[> CKVORL7^5
MDX7N47$!$E,[2]^1XJ+!)_!;K$\<]>ESN+/%U),U/T#K(XE\F;+A>\(;S,2J
M(*ORC$0QC&SPW7JOV9EBQUA+F>SVF;_.!+1JQ$J][$!%\"^\ S>^^DV4_QV=
M)@&8)D>([B6H<5SA!6RNQ>\2M%_=03:DBJAM@!_?U"+\0PM1[,%U/U)NDG>,
MX+@$E:L#/_1'_I/S&O4E^%7+4%6'/89.=1$T4SO<%^,PN27>9\/+\YF17&D:
M6@XWD!PN\UGIZ9SO173BE,_32B20B!2.M+][R2O7CEX3O [X-P &7P/=H\I&
M4RC8V@3S+[,Z>&993G7B2B7L'[FMZM4;"0,A:8^[<VG[QN'X\E2E8O)GN/$<
M!%46+2#X[#B!/#.;W,'*3"PN(G"A>_77Z]?;56L>7\2/=39""^]P0 Q';=90
M0^Y,<4\IU4VOEA0C5!!(%T4.=7WQN^$_2K^, IY&S.J@/':CY@@]R$YXX9[%
MM8,QB>VK'VQR[VPXA$S4T4[0I+LOUN72ZINIWZJ0%U30YMEP4>=4UGASM?O>
MLM0XH((/CN2&EF0\2;0[!^/5P;:[A^?7)=*V,THM=3@?'[33:M,^QQ;V#;/;
M<G(R7PLU5<UX\>EA488)DS+38-L.UC.*-.CY]!)4]/8PX/2ZI7#OE\K4VNN:
MDGJ?/"0Q^[J</ -< KU\EI]TJ*_9ZT'<=O\4K0+.274Q&GS*X-A/=6[D@;XX
M,29/#O,[E(? EIQS>?Y$%3^YF/G.T\!=>O ]]U<?1^XV.?:=NB#7^:< 7X(%
M_,?(ZE(KO]=C@M,).FPWM+.Q4)1#D_9N2>EG(YO=+[^,IL=5BH6&V#]#!*W)
MQ5+:_S)TV[H$]8_[NSN!$Z8[W9&2J]^ZFL5@ [VK!QCW[:VN4(BDK*>X-&5&
MD!CWO+:.DH26R(3:!SUZKB@.^W^#VPZL0R[9ZF?\D8DJQ,XM0MK$V/QO?_^5
MJW\'/"1G%SG12YQFP1(MZ)2-HP]SP1XW7!KN;W0*+7P;:R\Q3ZYKH?+5U^O.
M\)A;"#2XZ>/30YY'58C^/\'7MW\WQQ,>3\ $6-=$B&OGFE1'C"5AIKM"QV?0
MK-E&\TB#43DZ8IBJZT@:8F"N3(P^2":]R\1%XWTL7,VA0&2@N#P)>,<0;(GE
M$G2RT2],-!G:OP29'I"/=,X5@%!%ST#88!*.BJC<\O82Y"=![F,>8R?=E4:?
ML& V8>NTL?/!/:[6.X>R*ZZ>,?7\O!::M%IT&EI<;A![1"%<46;EI4ASWPO]
MCD(3S7ER-@9E3M)XLEW:@/]%+B%-NL\;ZGWTK.B4T?(7=AJ04'97D31_K[+I
MPJ#.(3ZQI0_1I6!46HV32''(MQ40H:(DY]3>$ZMD]<N]<@\26-=E8P?WM9M>
MEW[WL!S>B4YKH#479]'">5ZOYZL\:S8L"3 L;^!)Y_,MB+ZWKRN;$?!V,.XC
M@#+1)%4K)A)/"+EW:WH?%T%(GPF(R]\:;B<8Y7X;.PG3D5!ZG7BCB:_D!"LT
M6_*Y=S6;YWU(4_0'YWQ$ICED0"Y)K_O00";7#X?BKJZW.I(!7O,Y)&F[='V(
M0%';DKEL%8QS*:WG]M2;'+D_MYC4B#*'2)I [\QF,&4[3 V.C4Z\2"NIJIY2
M9[JM0\NE47</1<[T68,/2K$]VE_#7L(X]["J.O*<+%L]!AXRIJ;97&KYY5A&
M+B3[IR_\9?=?,'S_^-:&G&A(LAH$6/\RD62>>U*^C;Z8\R#KHM__#Q/Y>NBL
M'OP?[2%;!/ \6@26XMB'C7I#:)D*S#+4:0N34V_\^7X9:T"35MK-SJT,SRO.
MJ+'ST(BF*$1IF&ZR?RDK3<E]R.\%ITQW:9UN]B0I@0>+O"Y!8E;O+D'@L >7
M((GLP[?84.CA.>I^:F6;TOZMVB>F)[.SNNGY%:E>#N\,Q&LG@_VJ$D:4,O!U
MMM5ROT8VPGFW 1!'"*>R_MD6##A25ZFP'P3,@?ZZ)'=UVZ,3!T+7GIO"=J>A
MWOUA97Y[[[/8AJ_^4QF#+#!F!4'7J_2F-SAC"TU1,WD=$SKJ#P"1M\6P7FM3
M'0*BF:7%[MPD6F-*^3*KA5:Q-[LQ"&SW@,!QK5\Z'QVBM"@_)^^)"U=>7'$O
M[X+32OJ7'_9QTC<?DH=C[C+WZ-;4WS_%3B0=3$'<+;[ YWTGDBG>>?<I*4OH
MJ3XR>ZSJ%%[%-)-)WJA8D>J(KR29MJR0:*SGT5)AJB%5A+*OS3N5,@T2;_H<
M^#:K?MAYU_G-=H]HQY5F1#3PJM^_3M' _MV@75N3NC>ZYJ*0*6TNY)5&A1\N
M?H/(;N2TNRUT0G*1I1).;?>T1!?L6+34>J=OQ?#'#%BO#'KT2V_/E!Y]JZ4]
M5BR0S%#[KO.]O*T&L#1_PA+QBVP/0=^FQFKH$D1X$K+:C;L$19UM)\\G81H<
M/31,O^(6.G&W<O@HW0(J8JN?"'5BZN@="B-\I&GO\>LI6\66F+J4O@7LHV4#
M;TI8^HI.I\+O;"XF8>-?=^SANN<CA6NA:PISHC J9-\>L<R0S^6WVEH<]VNC
MGN>) R K)EHJ\<=RM5LT%;C62229BRCJ_,\^[B7)B&9B(O>@(G==EE90CF94
M7MAMHM9WLQBA7L/HX%SPZ!^*]0P5J&>)K)B(@#HYX6OU\\Y*\>SB 4!KU@M;
MD+Q+I:BY5MC\>5P&_'-EG F/(Z9.G>F]6SMS'N5W'QMW,L,IL2(8PP0M#@&C
M>XRSRD2SMQD3IQ8L_&:8S3*^K=;0^AIOBDJ;-N^N.")Z#+65S)(*/EX)QR0L
M\[U$%$:M*IN0QN*TW!6><!H!&"A\"?JK\INMY'Y?[KI]W6%3_VUL1+O[[<+7
M/3B-N_2%?6-CN-OC.K2^_$R3(G3\-HI\%"D&/Y;'GM0 $4G=%J$F=W=_S1;?
M26@C7IVUE+MN<KJN88F(='>/SJ?@O#^9&/!3BC36]Q[.BXBKMBC481%"O ]Y
MU2KI4"O0S<-["V"8H8_02S)HVDO0K!9)EY7:OUXE)8YY<>[<U"K!; Z5$E7,
MDE<4-$ THCT5QQ?X7&#O3[M!;E6(EE8S:#]/2%RQ\L.5[Y.KTE=A'9W>3XC@
MH9$U_I0!H]'E0^,F'Q.F'!UV/D4=;9UKN+E[0W)'&@-,CSL94J'>M#3W;4#<
MP(/&X"7WX'&[C3R24=5>Z;IHBX)9C92_6.!+O*5IT"V%?WYMZTZF;5H7!_[L
M!SS@1+*7NA_=7&&X])R*2'"%;PP!'5_V';#J8EA2"C^G#B>7*OTD,VM\14'*
M7%X&=6Z<\=SW6+5MQ4O0O^H']8"G@KKO+O@0GGAJS&LIF,I7++:POL+Q:D7=
MZWKFLL-#.]/"$PKY=3R*NEFCMDFK:4QFD.\U%[,?L1+96?A2^FQBY1:9KBLI
M-=0E&&)F/#VK7/P*7];4:?F]7E?[2_7@P+5=/"43^"R(SAM,X/QU(OL#F.$Z
M+]' K&+=7N@_W.;BM-UV[IE("\JYXC,RZL>G/@&/<M32:P"&NV15*YO'&DAW
M%2-ZZCW_:-[6,7%GCKS/>B,9<?X!R@SV6=X)&U,"H7S+OBNI<SU%1(UR!IFJ
MCP[R#(D"AJ7(*EQOB<LD46L3BZ$3W1K8"F7\2KT3YX V_SO'7D.C\17D"NV?
M4LD A7IM-/Y.V9U?74RI/$-,&-#ITF!G0(P>YSMKCM\]8[);9EF'T7^8C<IC
MWL^>ORT^@?H(K2&[]#;$CF\H1WQ[H>MPFC&*6"F M[EI^5:V,YMJ\/'>HU%0
MBVP^U;X$'7RAB@M$?\C,)U$?'L9[[S-X=(P<0RU8F@?V,]2X$/&"NO'88!E>
M_JF</)>H+^<IOY(#[5ZJ4V!^ 3K=%A6Z=@D2U6\$']['45U,3)(M7=/S[!DE
M1RX+*:2'32"A;UY6FIGI3SHFKI?D2I5"/EG_2HFS(R=0?!7!FK@8]J=;!<N5
MTO,C3F%]I?KZ+MUP^$>7OJ^O "_I;-?11S.N:B(T5A3_0/]IVQ/+3#'3^[8T
M-!$ZP/_^M'B0;15]"=I%P'CBHUK,V#55[^SOA98)]Y;M032?35#IZK?:D_BC
MSS,"]:1)N(^N]7P11NF&)K>YBM3Z#BN:3XV@_V[]^Z\G_$JP,XT<G^M3N<.,
MA,^^EZ"7\D+<=3X!%D/J$='5]OZ!_L"OU&:)OCY()[M25B]:I<Z*H97\XD1%
MT\#!?U&-<I^ Y^1R.#1D8)>4?VY>9&E])%_Q?U<2*00EL;F".H[7:E@31F0T
M:9\I+ODAPR&AHM_):Y+B_]?U\'8 W @(1!ZACSCOM+GULR"_ -4YKC<VSM;#
MI-O3<AK.X94'*O[PF>(%" 2B: 6B3@I8AVO]B2O4WXK(P^^\U\B)FC?++10+
M#KZB>:W,VW!J^H160L 9L5>VD?Q/@Y0<V4&BRDA*Y/&QJY%'##W$>$PN,SAM
M8?W,MC'H(^_[/H^RR+IM*3;$SX)>SI"[ZWFIGC@!>6:[@*W-(;EAA9\=?+P?
M93@-%(#3;Y %V-_!)8B+(7[M;2+ARIPQ+ UKAI^VAB+8WCHL>3/K/SNP/20P
M5Z3VC]OO&:;'M#)K+9?6<3[M[N,0TZ-;FS#2 &RPACSYO_8O0) 1JUYGL,S<
M?B/!E(K\KN4J[_5J:;D<%8/PG(R<V]A:SHS ]>24)]81$D*X53X>@>\@'>#)
M2EC'W"FB;T296&&+,1FT]P]I</#8=<"WKWZM/:8+>;,SD5\B\J/SQ5%[$C(O
M$,FW#-\6J=.\ZE,;8P/ 1R,X1TIYO[63>-K&Y]?JZ3$=8CT(Y5;W18S-,4_!
M(5'UM>/+MICKPMP'<_U\OS5,Y28YG^D;%!PHWRM\5B930$T.(7[42Q$Y*U99
MV-=S>X8NYA>',(Y05;]?EJ[7,6E#46BD3]-MK%6M?]MJ04E9^,>S<EQYO^);
ME_YI1* A=WYTT,:MTB,9]+]AH)CU/!2*=R'7NP?)]6X=X+0*'(G\6U]F60==
M">;^PT>?X26E58S^7/\M<1VJ:U=C<*BG7(XP- \U9_BJV\1E/)YJIP^H6,TE
MZ*;EGD(-EEF0V%K/LCC\LN$:'LNXX>T?L5C6/:G(H;N'/*1#J978%5/]#(^4
MT#>Z.3;$7NIW4_G%88V@'#F5Q \^*/AZQ]7E1(K(W>/FH>%<W'!_?NO6_>M@
MU1=^ZK3NS%#+\<EG>S[0N(!9=33'OYH7=OX_;U[ CI"H+T'$"E=T\FD7]N*_
M=R]<Y./<W\YD0U4%A3B6^2IK#8YWGNW!^Q6-- UL);QTKB[P7ET+GT_U],-5
MI)(A$E#*CB^%<:P;$&*F0\:S:+J2>K?J 5Y*5 GF[_L.MB]1G\T3OY'-MI'U
M##*\B3%97.W#ZU._FZ?3ZM9WAK):6)\:RCZ 4#P[F^N#LK!5RVB<Y4&#9(KR
MBR/\HE_ Z>RC7[1)W\T$+/(UP0VU>/ 1'$>1K*X5UFW'$4KU6POU@/7'3 *I
MBGP_"])$G#KI]F\A45L1HZ5"Q:4PF3Y230?IT:D)NH8U/-YC*RN4@W+5??>%
MRI*-]-_%J=[\PF$/N.)V=_"9]F)H2.E9[&%B0S [8?HG?Q!WRZL6\"L_EF&<
M_7S=$Y3Y>M@;GLH92DJ!A2-3\7E?N-%05%P*'7N)NK(RV]/(OK\!M P=";=B
M.H+=56 .\3KK:8+&2ED[_I9%>87ZI2Z*?]+69C'-9Z6*UOA55)R1YQ2VUFIO
M:4)W3]'_0A4;G$_>T%=&H<!S"9IWSN4![UDT7X).9ZW)#?UO">;Z^GJPCC98
MVJY![8'^L^/6&KW1\;R\=*Y!]W3$I_>@!QG.]-BVTMW![U5D]F-R"4JY?M%%
M('9?@O8LYG+/:^?(BVKRT&N+Q-8VQ9 ADA-8JDW0SW$HN_,@N%DR96.A:3!%
ME4+!5[,QCC&@3SVQ0_SLUA1S1O6;[; ])")%W5?1@$0A7G<-[(>K?T&RA!WD
MD/K/[&>MGB@\&PWYO3.2)CLN=EA2UWRS\@0QG%_F-AB\[_U3KU$A^!$73(1G
MI""97^ 0\KG,$WTD=N41'@"TL@H\*\EXD0.<-@5>#9L_VR)VGTIU,G=.F&@)
M:?JYR5?H-M%*47 I\O^,EZ!I@7E9;^ZP]^BH.*][G5Z[JZME,LKWA?R:VDL0
MOHFD)<$Z<'U9ZDCZ?\@%+SO@_L?\QHH4Y']?D%0T(K*-^+N[%QZHKJTK^7EH
MW<%\!@L=IG65CD#&QYZY>)NY7E&.0QCEJ$VB^'<LG+?RKWX]JNZ\]S6&!G N
M?Q#_5RG-11H83GPDB?6D' L[WZTD3\?960XBMUT!?TD!>>%U7O5!UT/'9"D*
MO -7!T\<D;MV]DGW,IO]3TUADK#U_,F+* FAN5V&BZ)&GPGTP@U.A%T!)O3U
M3HX51R'O7SK+$\EW[#R%([@R^+\E"P$>7A"V)$AO;AE,&((]D5NGXHP?7/(1
M;/%N#.GF<]KF==ERD35T1FX[HQXY1@<%+OL%K*K8^;[LU_A$5C'T(GE%WKO_
M,B)K.A'R;R;+)?O3WL,FMTL94/=T!=)\IHM],J=Z,:PE\%:P6H24G[;$,:V(
MS#UZSMC)2?/'+$!DH4'&K5EZHMHEJ,MVQNJ\?YG<R>A(3N^B4HG\16NY 2%.
M) LS:M=CQ&[_;OS)RV"40MUNS,F5 6:[%G\!+KVVHOM\>2F\/%NB$"_],GU>
M:UT:1U91>4'WI^1,W@?88YU5R#3@%\!)J5U ^,;+.DC9UK%P"6)CFX%L('-9
ME5E8G$[#YDN&1T=_XO,%7/!Z>UFF ::P.FL(C?X$IY#,_0/RH!\BR<_J]#8K
M7O 2U.=Z"0I@(@=YL45$/HC!)8@3O$:S9F2Z*JE18O:)2E]#[?J.S3_HWYV_
MR1(%[/<]-]$VL0:6((P_(4B\Z5ZV\B7JS85Z$+1^F7VE]35S#'1GDF1#[SIJ
M6@9"!846K6Z]8T<T*)W>[8@'XEAE&)M I"UY)\I&U>@EB+T%;N(#6,H]DLS>
MT'03++[]M*/Z>>-LHW9D0_5CM:11W:4=O%FWJ44?A\:P7MF.+<+9=EK<$I#U
M4[)4(8LC-TG8F\0NV*%!@Q7I)WG?6UT620W[?BJ)]2 9O2X1/;)^0%^$P=Q$
M>YTW..BN.2/QCVJ":9VKC+=\*3-B_ S]73YL;5K\=(";Y#O9)LWJ-)\^NT)0
MWQ.<;4(O"8.'TU]U:T5K?MU>S9\44V86I],2&AMT>"AJ$/ EROD0-PEWLKT3
M_;&&P&  \*DR*A+U-*!P->@E29BHRZFE)JVF]KAC(_M>J;Q94@X2?^X@4VK@
MU;%D^>4H:?+Q2O&[1Z3M\@<%D1;/O,D;38SBB=Q2R[#NQ218/SL!_BMRR((0
MM2T<+]^)Y[=URV[!F#"=R%Z;<5_24?NTS/FEO"+=Z6?_)8AZ<.6+J6E"7AM?
MNR:'GOX$><JSP$5R-?D2')'SRFH1Q%'2LU>P<'[QWOFB#\2^2C8HI3R@?HI8
MV*6WC*P>:/0?_+&Z(UGOD!*7]Z[+(C:E6NVG2P!2%%*<;- )Q) 4Y)JS1[3@
M-'$1!A<ZCI 6.=OKBYYAS.,I2;^B2.'H.#J)&OR6UJG,E.)])S/<TX-LM;ZY
M!R79H_4UZ+[$503WC<;'Z3&(,9Q"<R>NU%\(11EU6 ?'R2G;^28?/L,=^^FH
MZM[:H?G"\7B YDN(-SMY,X#7G/S[J63T0?0M2?F:@-O3>D$#3KM/*L^TRJ3F
ME1JWSG,?F)W Z2CT"SW8&-1%:<6?1_&/C3V/LU9Q3L0&Y_W1)IFRVP<@FDA0
MA?"-Q$?QW2$-H1BK!+C#,[JTT[:?[46HHN_#M4WJ;%^,OST<H#.%L?V5#LBM
M5CKXJ( =H,6V77JS KI%F2NO-YW\3ZKY,,&W]TX$G]>6WO='QE4R]?WQ%XGE
M=@ 7?)Q<1#:-_R3K*?L:>*PGY%;9H/Y9<8/5$?<B)M%=J[H *4%UZODHWOGO
M;AP2T1:.X'ZJQ%'5W%P2<060+0:0K08J=[6(F)>%VC&/Z(.X>O^Q[:P.NG!3
M>W ),H;I )2,ZQ*TI)]I*VM!_ )+C-M'1)S[>+Q\1:?5I=E;7&*2M&,NT'C6
M44,E4*W\L<0>,K'$GM"QJ4X?.MT,JL\E<NVWM1F&J)SU85H3B#L'M*W4V$:+
MW$:9>$>H*,XT"R+D _XGR=B-@N*^9V 9@X>,.O_Z]Q[-6W<G"_+R$AXIK7X(
MKO!=O 11_GVVD7D6U0Q> K/2G0H=(G8%+D&J?J,[I6V$@G 7)_PDW<5T31Z\
MU7F;JSB#M<G3Q"A%Y>HG"[0N !J3P$'D;B$3"<#G<OWN*GKCRHV:I1F?Y.-)
M6(FL'UV.G;^ME2 ^1J/GAE!]^.<0S ]'GLWP&;;W:[&OA#0E*W8)"ALBV_:'
M7")/+N(TC'RKD=E/<C"^R:5-4F?AW+;T<?#U5N1:Z3WW*E/XWLR1XYF?/6TH
M)[.D98YO2B%7.$^R"Z?SY,LLP*.J'MG".DQ)BLL*SL201>P0$5L/]85:0=8K
M0YMB9C)_I\I^PDZ>J[KB-#2:9WC0T;CMW0(ZR=*R(,=DFZ G1>6O^D?$2@!8
M7SQ4):UH$10O02Y[ "2W#9#W*Y>W<:,JB()B:R (Y#IK"]W[^ZN_<N@224T<
MB1<ZY-+)RO_3IAK/_(93E3ELK9\T<UGCX\Q45N64DO_>4!/Z+.E_WT^C\Z\M
M!QO$)T/6,A])]TWP5O1S@MK1??Z2Q[M,0IW(\B310@^86WMJQ_6$FV5R37(:
M$O*B6K:BZA =RBL<!QPY.]A7A-#L=BB8*%"QX@%&SB6*64V=3U<<M.!;&.7"
MI$O\3V8S!7-$U$L%M=*RS$+K#+P>.!7DH2*4;^L\!H#P7?R9YNE%6PNAGWQ]
M(! @'K/%_RJW_6?C[?^9_?#LSY?)FT3)"^(S=X;W=I[7M8>X=*P<$K*K6GGP
MR;2!TCP-NO.WG!V^Q"Z]86%\=G,^DC-ZBPDXNR\D?UB?6 ,LP[$7]CY[:-IB
M=)K9*NJL0=Y>)9BJU0GO!Z'7U\_J6'LZ)G_+G>8/MN_5U(^DG/^HI/3$M4ZC
MLW/Q6GN+Z^EXUB5''[]I7[\>H^4PP1$3W9S.?5.Y;(B*P<3&XZ87M?%*C,H@
MM2J!=[W:<_^X_9D)P&+5QG]6^3'+OB7=+0O?!:=9Q&,P/NMT<Y<@YF"E!I=@
M*MF)25D/E'GMDY@(%T ;YY;;/DK$%2$+C@J.CY,YE#AE&/@BHIVW&'& B0.^
M,P4-?$J8\B5(5C@&/"1V'<OLU1"T__GG[ 3!HWQ =W5UR.X:IJ1_8J).WD D
M@R[VGSZ*#]*2(O#O+BN 2$/J2.K9+7AAPFR(-<DY36%S)[9E.O3ZM>&B 3]_
MTWAN+M>'DEA+0T0A<OM+S(_O+M?4!!3[JF)2V(T QB,"D]$Y>ZYJ!!,G_<"P
M<@:--W*?C> =:2.*YC#H0-683,'8^<9^.KY'71=[$@J:C!)WS!@<GM&.U@[)
MTXC\Z+OW+CPO%QN,@*T"IWECN)!D=+&635"=!0N>4[?)Y@N^[MMK#I&<-YV_
M-NODPW:]WV#C<RJGE4DS:JTT:AN9@OQ<B,C1U960< ^5H T%G(:F92;Y8Z9R
M1V#UZ,PPU6:9%<ZIUMAK+CD?D4[%>-<L!+T@4KG!VMF5(^:%M'HQ<9B&%#E6
M4'U$/M6D>/*IKHT?C6RP#K02 "G.F+FNQ1#F8M&U_K$LSREW%0<\N></!>TF
M$PKEEOD"Y01LZU897H\% $II^Y\]MZ8EER!ISS.M=2S)WHJS6,':U[/7F"1^
MFJ)Z-Z;'_\'"$OB#+?Y7H]K6EI=L!-_74$-90>6,PFX]_=$JT2'J'G55#K84
M8Q1#!3:X (J' Q[ENR,ZA77X=N[1M99U!=;&XOKZ]B&W]NFD3+:2F_SU5G^+
MA'LNC^/FOUEK>'RG5)NR.C7W12)H -#MO03QL:Z^P: '-C981UB3,X^^UG,=
M8ZR$E^=U]RY:*YWQOH%N=X=P!"B'CJ"%W=/L-411ZG>.&"_12$JC+8"J_7."
M)K)=@OQO$YJW2?*7()%6;'WS.-3N$;SFYNR,1O_\RA@GBB-2&-ZY[G4LO=TG
MZBYA-9_!1Y>B'I?QN-\.<,-E[\D3N8%W1*-IP2FIUI<@P;(1JTQ<:_;"1%V3
M\"?F-SFQ/-LU)MN;3@FBC3'! PD(S($U5_>8SH<"(Z2I:;0=*D>CN<FE"%"2
M,J]+T.8-[+?S$R; \PR*YEG%'9\/.K+-H;%\Z.6=IR[8!8ZH!FH;]G[8+1\5
M_C\3UAS*'@=<@GH9 3>K2+*#'61]+>H7B,?/8G(?!)N]/)X&0B-A;"G&--7S
MA(E>($)3-#:STWX-*?'DS/"NF8F0I#.JT!X"1R&Q;+'_NCCK3MM<WX9=9+3U
MVBU;C/@\;Z8#_>DJV;:)(1A_KZT[VWTOEY1<ZR<BA= (0CGG2/]]T/N=E7PE
MJM82%W^FG%:Q)[^C>UBTX:"*;+X>Z#!7'U\&=5CL77,]%#="%!=^R6C.?36F
MU!@AQ:Y5)Z*IEU2M47)5RR:'JC45^/CXH$2"Y'$J!,:':R=!8N>RF]ID%FLD
M#7]^<SP7#C(L\]"+9V]DQ&G[4[%*)S)']MA4J]-"[H@^M+ZG,@X9,K* F%GH
MD]GW)8A'YTPSQXK@%C*^LY]J\1X_0C^_,SZ3/<1JX::-;G ]%+F%V,3LU[N*
MU@Q(>N<Q^&M!+,S=J2**==807ZOD[ZD+-Y^J[!" "(=C&$NR ,N1O(@MB]D
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MM3M22V]HH![[=:!-5?L0BKB\SXAP9[V[4HA(-UFV3U&S]P&(>;9 3E9655:
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ME]CP<[>H]P;?HG!K' ]^A46*]B1Q[,R -9]> "*[P:$W_(L$ <HV,D&,BZ2
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M?,#C$]*TX1J67#3=PC_=L':+ &4)Y#3Z0]F$X2>=GIK'K>ATY?,S^OFZXH
MZ*O._>LT,-%_PL[#YVX?0PI"'N[7>P KUXC<@VE=);V7:<D<''_/[7J6T59-
MMB ==5$WN=/(3B!NQXF)O]M@82[_FE&$ALGJ]UCC-6!PJ\ K]M2=#V)!4,21
MR33>&WB5D2/D6\]1 _N*X]$X7J@>0E*FYYZ!,.>W]H$_KPMIWQ6C]XEG 14
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M4;8Q2^<O74&)A\!MK)6ZG8D4$(E$?CI+@PGY[@/7=&$]W+MYA*W>96DN>*8
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MR;"G3<_M6% S4M*^;.SG5,5$C,9I"WW3IN46-D CW"6HQR!7R71P?J4T<SK
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MK%Y/"%*5<G1,?YA=4JJC:U8J$<W[\.V3A)R/MH"H9PK^KU[77%R@R.XN5*W
M[CM(,0_YB;K'?E[6?E%:C129,YNF&+GI&C/UKJQB(V F>S8M%MNIG)33ON7B
M>ENQ^6Y8>A4BKR!@C=FE5/!10O.;=!@] L'U\-#BA\W__V?.9!AAFF!!!W&6
M/PNZ-S;3FHYAA;L-T_4.&PK-YK1V*NXJJ0&=NZ&BC'(:HGM&DF>5HYBB=+KI
ML7&J[X[+O82/_ZO=B@3SMQ-LP<-RG)X^,*?MX*(Q-O]J4?T5:;>CF?V?#1\-
MI6*OH4W3)W_A+ M08></,C\U@I[$*P /EEHN=]K.I_W3.!XU)A<>ZNN];;NQ
M8?_416$L2LC1P\^EEX&)U>*O=TVYZ0&3S.\*HJN*^.:_WP:N]*KX7]ZMQ7Q6
M010_$ARF/G22674L]:APQG7,_*U41WDH]SE.!38VX:#Q@":T86*:A\1/Q#?Y
M':$8KMM03<3M-86QIAO_$'L?,)IAEP[AW:!+5G#?J??WS>J<HH#XCGT=H>ZQ
MS:M=J[QD[L3V08DWA)+(TX^'=)5>^>05%&8QHW^L.MOFA/O]0$^R>V_%4(]N
M7YDTKQ3<W0J@BRV=F+KWZ #GTH5I0ZV9.AWQ]-\[%^XDX/2^34V*)R!*QV/8
MAG]><\5X(443RF'_]!.P6H2I,\M:U79&'RR?T'I9-,TN79]1S^!Z3X\&#?HL
M3OX4#GC60<[20/72YE3[A>9+1=);WS9Z(]\5HO._;@M')N1WS:]E1:&=!&I1
M93DI3HXD1B_"PR6V%UZ6U%)J]T[^&:/]&_@-_%\'0(=(XYCG Q30/?@+=@ZR
M,8V#AQS*RI6KU3N%(T=<"!I8+@>]PN+6H<=^4/@=-]H&,;RGA+N#U)W24%S'
MWXQ;U-X9X]Z%?(_%S6;FZF5,PP45K6N4A!2-MD_PTM/+'F8H'XAZ?'AXE54/
MI\X-V1P!Y3,V?R)@_K)\ 47:@>7>RNR=<9@#>!L\$;F#WDYL"8V9;HQY^VWV
M+K*N/H37KE5;+Z6H_;NO42<KPN;6N&"QZ+"G(>ZLG!"_ E1>]^[C/;6\BD.+
MM09L_-A>TQ%J-X+X&B[Z/NMDG0**3_-32C?J*2V&[1*EP@5=AQ79Q#)F*Q91
M+%\-MWH"%B9NABR0D*V/C$_3VB62']"J-QV:;9 (9$L8(P64,J8-1[DC3EX<
MBSN,+B],'L/HW^1E<*?UV7*K(YZ/!]D^((P8"%W[.-@L\4R91B*IEQD$;CI4
MU2;:PN6Q+Y5Z/3D;#N(ZV/HQ/BA75WF6K9(5S4-#L53:1J/KB/#(*J^W<3B[
MB@DMC24'G?:(NQ!N@1']DT6O;3$4X&H3L2+P.65X-\OW0Q]?^XY[Y,V6N==;
M91%31Q\/-L<;7,O32E,JJXVG;\"8E,-+&787Q&1HWOO,Y[UO%]"[&VT@3WB8
M/%0%>%WC"O:=XO[%_?2C0]BL-SY[8@K&J]S(.1FQL 5W$_1AJ(7H@\T8XJV>
M3S"3'C:,1F4.$#CY28I,/08C@',&G]$'K,02UBU(;"%)D5W,1 +<XMZFX5=4
MLM:=HAX$TA4W:[.=$_2P'.+@>? K/2I EE0F51!;,:23T*]N!KF:R,3IH\Y,
M'12Z%2,2/XQH0SJU_6L[ABV[00Y>>:SN8E=TWSQ5<] L)%58I689_3 MW*F9
M._5+JT3R8XU$*&1!Z<U(:_$7Q]Z_<#2 G;@A&10-?[KWEKT>A_,H/G!;K>\'
M^Z@J&$S!G@\_-EK@2O@AZ"3:>($[%P?1'U&5O*(6&^"HK,MA_(3S 7-<TZ'R
MS3TN8O$(LGMAKMZ=5+ 5=/ZIFQMFPJ!ALP71NA]V3[9>G.LXB5^]WL$T"RF(
M^#(@KV>XQ.'?/=+>_4?G0$G5V4B EPPVDZ\+DL85Y;RDOG500((GL]5R*.Y9
M+&^(A9MB][A9L^M"A:?++ZV+!S?&"C2JB#2E'>KIJ&*Z:F=-TR"H08!M/H>^
MA=YYP,X>P\655C[OT!,-W(3.PTCATPH1+7*!SRTY\ S!TH.WT#KM(9>?C+"[
M7U%KJ?+7N7&3#2Q74DICL,B1Y?7*[A73'S$6ZWA6]I<44 _O?/T>U^KS&2S]
M\<7ZNH'<'LP$_E9)*=?1=-\E059'\07/6UV(ZX/#MVPUK;W%(/WT)<E[6A%&
M@)G%4CLT87S@W8?$LB UL@&LIY_,H#D!Y]\+Q"UM*&4V]O":[6^;6=,+-GCN
MW]K";:Y%O\A^55#.%A/.S+?V= ]L9J;YA\+#:T3O+G3P6!/>FA@(%XN+8N_9
M1CD?H^93]KK<+O/,]I9-S$S!O!_CWO9]%P/_89!_P_#EC/%(_LO6-@7Y$88D
MT#QSY&6/LP"U+*6 _OU!81,)Q2I@[E% HFZ)J.WMR),8NJ<NHN\+)QL[G1S1
MHL0G4J8(:__=M/=0*W4C9<.[Z?P+5PID5I?#<[(TGR*XW+VWHF^Z'TB*@+V5
M[ Y&?";P@:,1);+ [<:AS4I6JNJ*[OQ76-CU$E+9(T+OFL5D(WE-V$2C4F2C
MFAPL[%03_9)3;Z_C&;>7*"#29UEI8BP),@6_'Z#.AI5"&6\)%7A>/0H9RV__
M9K>[Y_KK5SK-[+S$472=)SM- ^KX3;1W54I!"N]SEFJU+$"A8+M#B?FD +(]
MGF4"QAG ZW1XKG7-HFJC)-7$1EK:?^'YK8>=X,CV;[;%5<8#<?UVH59W<W%_
MF3H5Y"/8.Q/_C&&9P@>BO\&.#)4(_DIWL=]$-[+&G]#M6K^B@.QDZCI(UOW-
MC.%O1&:C(Z>1#F:'JO =\-RL6]!RB;HG0,9S<!00#8'8.]3B3FJJI("N$F[A
M-Y&SLY)C;!^;(GPWC441<G8T;)'-/A:!_#P6F">U"EZP8!43]IT]==4G20JD
M?C!;'A A6.!'C^![3X\V]S+F41"2]IIY&EXNL!)S,4AE+;9FLV?,:J'"ZYU.
M3/"YJ5!7W7O31>UN\BW!YIQ&WP6XU$IS.SJ?^IGDF##-Q^$#LR$K]22^0Z(#
M7.0*,6[!W=TM:W#VI#0:]_BQSSWVO J#B7=2 8M7=9+<!)HVRCA PS][DOHU
M8V4N1S_79F+0V:)^:VTXNYNQV*\1]&65-I0@LE! ;O,Q>GQ@R+?D4[?:=M%Z
M9 &QNE8DL.IT7:#I<LS9)_J0D4$#==:?0QU<^NUE>0"-7<O!F%! 7Q+AB.U6
M,&(8&)A LPHY.A&L:%K]5'!VB^SA^=MFSAL!^[&\#!D9=TE_936B);7G4^1U
M;T!_+&E>;W&DH7[+8"A-X@@DXWL)GA3031@W!?3Q7CL0F4<73&C6GIB?=7O4
MI$)[0S91:PT'->]JHY%(O*\QLNA1F+<*%?I_V'OOJ*;:;UTTWZ=8$.13BM)5
M>E>J] _IO88.4>FA20D=\BD"TH)T"0)*[Z&74*(@O4DOH8BA]YY$0G+";^QS
MQQGGWGONV./<,_;>8_@G#R/O>M=\YWSF,]=\U[O"_J%]<;FMYH5_$4%@&B^W
M*SR<N[WCA\'3H/P(ISZ&*[*Q#CLMNS&T=R!'.AG6E0(^$YU\^N@@07GSY_WS
M0C-D,H7(5Q.^M7/[+G6($;XUFMGW@0Z?G&7/+YZT)=8_::;*'(E?L' SI:66
M>]H/]NN[1\Y[A3'F<0)"3T0#Q\3H7I.CO8B (@@HXY_^/%=W@ RR9J!GRX7W
MOGU?V3X/OE/'#YOZTA8J+Z%C$EA87%HT?].,$DA10A=0.K/)!7,&.\289Y%)
MT,SU"+KFWS/R3O&>O]D@;'/1V" D=!;7>MM3H,VO@M[4LT^]N6:FG)NA$);.
MS*JJ:R^1.HO\FXWS^:/D08UXBR@DUB0UG02(<(;RL("<=RJ;PVME@R4B%F;@
M+%E0SY>2$89S,_<0184E,0GBD_0FYZ_YE[4^U3]*H+=BY:P>HM:IUJ;]1"Y+
MGK=M+V3I3LO+9^/_:#N_XK8[G(:693P7D9H%GMXB\%-1&E'N_X2^@G]+&='J
MT!A\,6?0SV'J:$"V02X)$ L]* :MJA_UK,#$,-R#2S8558UJN_,3P;)EV!&/
MW=Z#%CO(RG9GA1"#P$,VK89&=KE)RI1188\$6BR]L9*^[EH:$$3V!DNI$?8U
MUD,SO!ODFFQ+N^5^:UKWK/3"*%LO6O%K-:/<D*/^$PD)7?N +2TW=R&UC,4D
M6&"]WO=O')%J+M>2R<Y0BL;1D.,52+14'!1KK5IB"4()S%^ T"TH/K.8[:'F
MQ>"@!$8&3!(L=1N$LU6^!9]_BLL&!S@X/ZB$QQ2:QB<^$!4'$[<7F$"9J.$B
M?!!9#2YN?2% \2_0&>TM._%#$[H+,V#^T#9XG^'0F^,]2@V:)<S&%I]I>TVM
MV]2X\=@]VB'%-Q)6$ZIE"\$%44=#1#"4"0K?MS@3<278??/KYG$]37BN:.U!
MOQNGR\!=J+6L5Y\XH)8B;=TJ9C2B*FA<XF*7<==YROEENK7+7MMDZF7!:+V4
MQ'Y0DK J?9B^$JF/L=U<;&MKKY4U\P&Z$;MWADO0AJMG:>C>[XFL-A*A;AE:
M<H6:)5L2X[TSUGY HX""^ ]T"N2DC1PLZJ^,^H2K;5)P'O6<#UO'+30&:7,=
M/<JK;HCSL7]1/&?^44(MJ)9+55^?&0@4Q;C80UYS'-<BHKJY3BX#_FT+,Y%^
M@)#E]^ATXH,N>1(5URZ*KW")6._,_H$67X(:_CW9$L/:F?C%1)F)R;3X/.C^
M]O9<ZN=L&2F+91IR2'?)2\VS>AY=*46>MP1!(0:>88A=^2+5MC/AG>Z;#$P[
M[B$"\N(_I9.DE[WC71ZEWC7/IV8I3N+@):=$*;S_T4 ^D9H0L".2@GI4BY='
MC&>!"#SGRUF=F#+1^L=0YF$[R3W%'J6$F*!F0K-UF[@[1NU[Y9A$XOT$R%YI
M>!YT61,T(+(R,F";AH-\#TYODE6L:AE.NC=WCKK9P)3I;FBJ&V>-.FBM,-5K
M#^>C"*%[9%K\E]W6@\*T[*"@:$RQ_AWR-"R(CM"1\!\\1\7SYK=1>.JF8)H@
MO[.?':I(WE^>^4],,N((]YM+%199XH/MCSX("LMD^UM8TI7TJLIM7AVZ*DK!
MU#:-?++$1@)DK'<IIBW=/K^WUM.U\+4Y>+HB".7AP=*].2LK&2GCOLRF[(ZQ
M[Y]R[PP?!KZ\FRD/U*JNIP-"Q"?JM0UUQ2%0=]&1R_<#18Y( .+S+&9"3QC?
M+NJ#/ =L*=.XW)_!6/I=B*+K&,99+ #?<!&J2^%YR!2B9B6=$&%M?/%-3696
MVUB;MBE^-N_R+:.EU:^$,:(\5&PO?@>1V$9;'QS^XE3$PL]4N[R&.;/UL"GN
MD3W/-XRSZ.2LH'//>JU2]5^C*Y^%)(R-^A-6-!^HQ>^2_=3].[0#H9C<!>T=
M.0.1 &,YCJ/+F8*/_PJ!(=!A"LU)32OWV*JA=!+K\M0/'8])@+N9-&Q<+DK%
MY/3PC:RN_4""1)L34 <4QKR]&@7U"!JDT3@=?!J4-=)\=DIMZJB2( _OVB78
MIYP$S&SQ@Y/RN#X4Z!H*4,0/EJN !^6GD:5A\60&Y((*HI(5A8*LEJ>5]FQ_
M[! []F4T0*Y[!.X9L'N]JH7D$V]RRCJJMY#Y195/?V 0;?E)*:'X#=PR<'.+
M!_993GTAN!@D@UK6(@$&>'[00*=#G'>IOZ(O$N9D[20TW^P@]9+0)\U@UB()
M(\Y!,>"L8#L#8W[N&Y6DTAQ&@EHEJRVM'IA!PW@AN,P)UWF$Q6 '%6&9VJN>
MS_:;L(JJ^SHV859WVD0G($V^&H<20!/I%\!KIMFP(+NXBL_%;SXAWTUI<-;6
M5"+(1&AD<YW ?XR7,R/$D0 .), %WYD[&V--YQ_7>[<N&C';&0(P):_M>X?*
MMC[?QQ@\%0_YJ@Y_FJ8P12',=\BEAM6C<9/Q*>.O%NIR$B:I!@6Z0D"QLAY.
MC\])&@N:9NI&E%6<?RE=NWS$>%LVIUEF #-MLD_<WW-?CIV1MY@\?UD6X%FQ
MG'$4VG9;(?'6 )^&D<5Z8I/&YTAI[FQ3C1<P39L[9$_^3!.O>%!" JQJ'X6O
M2%[!A(V/^ \/+,AB@E[^PI9AG5ZZ7PNG0(HQPE^KPW*[-=_U.7I/>)N8]M'+
M?*Q49"JTR*,T9[ G1Y4!7F!1<<#?#2J/>!MZ;PY%)\5]1'PIN_Y)0$I$F9#U
M^4T"3O**IPD42I4B+6_QRZ+4^['P:'\%Y_Z[BK1H;PK>K9*QRCH:LF %'<L2
M?=EO0E.F.)Q0?>5GV)']X2^%;MG]F^TY/:.KC:IA"OS%F_RB4,_$ON5JWZ<;
MG$X76W._7DA'!I10J!R*VY+M,=6)-R24;$(SH0=EBIDD "]1WH._;7*"M?K
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MR53Y/UP@)%89>S2VXPEONZQEV- Y(D?L?>02/N'H<!.5=$'1%!2^\O?"N7]
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MW#D%N8N\%F3S?JM2Z1YJ5C&>=WT_U/7?0=+/%ZP0KCLVS?!%9K37CX;(,70
M7A0=Y;,7A RB"J46Y#"IETA--5+5U[WJ.B '*\W;"CU'^(Y.7216MP3;N6</
M;LL/Q2T&7P_$W).HPSK29VP<B7L,5@/'M/K;P2YU:3% "JYG-6I#S +LD+VT
M?P6RW[W $ZS+7GO/+*OK++-RF ?L<^_H<K#LO;KM1XBG,ENX]31X^$.))TG9
M5*]A<+6D%%0V_9@C[ EGT 5YH2O^_4GHC6W'?O:'K?B^Z1:QZA991[>+5;0L
M/,<)DC8R./TLP^U,K=20S@37ZNQ844[9?:S)HDLO<X5SGP5L'E2WO7#+]K\/
MD[6[&"H[S3Q2^0L3<J8W@I:/0 ?Z?3U-Z^J;ZFB.V]7Q:JVE<GQB40;.+8R1
M#%S3&'S\* VN8AOZJRWXL]7_$%&^]&03^&)-G)!8\)F4O3OK9V2+$V1\!U8[
M-POO3>;)[@<^A?'KV,HQE)<[\)@@6-Q9Y9X/R/8PI;-5R&"?79ZV]%KA#,_Q
M'7K?+U7R%_X6^OQ*D5^6GSI.04H,56,R<U)6]I>VB0MODM/=J8D*(;G:.@/.
M),$GV@*\,"F'0_'M+V;E6?1'(KGM>FYSE5]Q^+ESCB9)X#6OLZ&PE1G(]^EQ
MXY67!7F508R+CW3HM57?%Q0?/C4[F% 6JM.*"Z$..J3;</[_H5WZOY/>(CS_
MAU&_&YN1%T89_2$LO'@G*X<(/V[Q+@JP0]90SC@,?]3E3E P<O/5.17_<.I"
MSY +@3%R.L"D F^ PA"V&Z;_OGE3R'N2+S5OH7L1N97=-WL1:S/9$N\'?4&=
M875;C47/XC-M@W!-86I^H<[;)W^-&T=3?0<;BJI9*)VZ3B/I__L@'&+R\=,M
M?NW6IC^6,L4H4B+HU[K7O%/$ZV]4?GY?)S:<Q MY4,+Q7HGE4G!@*)H;%C<+
MDAK=]JBX?^9&>C:F(2C,*.RU'P!27/A6$NF_/)C)G F_M,<#V5OM07:E4CRV
M.\/=.[L9M=ATMSUP:-:4E:*8#:5#[2Q3B8JA\<_#S_"&*@'F(4XO<9,-JN16
MKY(76^/_]NVA_\^@VKPS<Y$^G:58<[P0/X?&@"'#'6@ZW??SLIU!T^-V7A.O
MBIL#M[968NA0HTKN>M_XWWR[LM<V/CPYCQ/:;9!<.YZ;O7&$=O)_[HQ56.C_
MEJ16;T)_<C@Y9L*OD]@?*R%7O&Q#_T72P?@R/85=+JW_7%OSY )S];%-QGQ6
M>.TO%.)LYYGUU.&2!:6;HT*.89WSJ821.F.:Z4D/4S)GY3.U\F]7+N^FIM/A
M\#S\3LS(2WZ%??K,[J_IW4#G $+=Z1/![WVY0$U::X\B[=*JM@RE)O)EQM/_
MEVS.OW?[:',_X=S ,VQK)SYO*MA6)^X^6*YPMSPF!3@-U*@V^F[0T;,GL+WE
M\.K]N#%G;7]W'S-[&'=6<,*_HO7_&J@=HCC 'M>VW]9RI0)I1R;V.BDL<%*>
M_:4[=6+FY]Z5)S2L.BE&%ZL2XB./.(&)XG>?4MQ]SN%WVX35M,TC9>,K61G]
M/^2:&9OU\84BY#F[/01A[TZ-1\I$<:A'[.S8CI?'M/[8+L-D6X*IWDYT:P6(
M7I-Q8=(R(@:8:<*??DO</@W"/FO\M[$*;7J:)?=&OCKXZ^V-+/LUS'X95="7
M;FID-:$3IS,9I38R 4Y.]-'+R]U!"'&2$T'2Y=>NDN4MYMH@"RVW/,\2C#T(
MDL3MH6E6E7.G@-U9J@G&&R6E1;EI0=(GI1/&3#$N#-+))L:\=SOV:?,:FT[W
MWM+\)]FN\5\&\&W=9L<1&[ 7*MHD0--Q<-G!5E]/7LEN=O;_P1I-+F> AK@(
M)+22 (>!,NDD0/#.I>YLS\L9IL%O/U=,\?<CZ&^U31YFOL+"%O!"U_003Y -
MV3_I&.6H[L_#!-A^1GEDM241CX#Z!'UK7\Q#F*/S-ZV=L6L@R%XQ,Y&A]I"Y
M\(PXA4,<R[JYQYG.[0G-SEC<3MH):6#(OL'L92#);=W-CQ"TB[<M;*'"S?YX
M\SDZ<7-K4%1,75>G.A@!.<9=5GQI.! )X!!]J$@",%B]A.X;QV"K>RK86$-3
MVE#CK)=&!"DDX,QX N.7CT@ S/HS(W5U!<4"&=-0M(5E*D51K%"KMXXK[V*J
ME<Z3.-,K]$]3O[KHS)EI=2RJ?3S9NMT03E0G 3B+6^SPJ@27'9:)QV-#XUD.
M-I/!Z8Q1F?L*<YDO!H Q/3W,<A&$FMU^)D:"J$(3W/-6"]V1Q,0$1(U.GF:)
M$@57[(+F9 7/RV<>;C6&K4BBU,4UV]G]7J 9G[H4@X]NU+WO,^299V_,2UK;
MN$)O=:0QXV[C'..KTB*+7R50[[/_ Q62S;3;RQ[J<1MJ>UN\H5D3.-1LH6]X
ML;YHY2_Y^"]E"KE4L0#.I,2WJ5<%7R45Q%>J:O\I<Y8DDY> TP$=L^'*#L/M
M/7)BLE MC;?O-8=I$<J^OD!F7H_O6"G;=.49'GOAMR8-]J:KTM1^QM5?%0]W
M,H@^C[=?7WP_7M:$T-S)&6!+PSF1 )2^>.W%I4=2D+#1K8L&?)RNHV52.$>*
M0WF_FPXK-9V +JRH-$G,6!HF(OCF*<=)1D$\@,.:&6&45X%4N L5%XE #?+;
M3"H=1M7;+P3'.AATI<UG*BO&]2[7O#?4%D%7@(U67'Z<EP(_EGOW7=%Z$/B
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M(< O,'$7J*6D_2TB"_4<"?!C@FSC=$)0;"(4W:.*P5^[PAWJ7>WW2X9'QB2
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M8F]I]1?WUKHXN[,GIE1MBU] P.EZLH/'L7@,R-C,X*"',Y\]@J"C+*'9+>/
MG0B,TT;>A(W1XC$D@$A4&&I0>)7M\&!>X4'],-Q[R?O6:M&OO8='1OYEC)MK
M97,75CD)Y#9\66J= RK#KURV,\0=Z:^W#V-2C__0D97G_&MX<Z*.[JZK=I$
MGS!DC+\7>9HD@\OW?0D5;3NI= ADKTT5U/#%P2BVT#(#:;39&3(QW!\_N=5K
MGPIT+'XU4?K)/ S5*;S.3F@FOMM+_HO*;EJ.K*\J?N*XGT8+PU;)PCGBC9:0
M10D>? D%B# .74H)RE>'>FT<Z![07;3<M>0[4?^K:"T/YXC\3#0$FA%^R5MW
M[0_ " ESZ1W3ICZRT_BA(LRDOOY/P=K/Q%-=\#2V$E)SJ&;\(T7T-_)#-K+8
MB@1PI/\M/L)9KDP'-(Y0-;Q^>(;O(0&$R[^TQ($F62[G0=^W$_,1I7T[6L4A
M_79KW3T&GTW<EV.MB^P*LA*-R(>6$A5E%)_2]MU7 FL?SE6PZ/,!>0/Y2 #)
MJ,]P23&SI/K6Y]X+IOZKC<&V [^93Q.;7-S\17*[E(0_JTV?+W"PG5%Q8;L>
M-*BNDJ&N#"^-]O<3.($/A'\YKA-P(MQKADFJ67Z0E_T[;8I/?/[ZZX)Z,C6*
MSV)/G%ZO.'YTM1+]E +]MX!6_/:\YS I)]#J1(BMB2BS-TO5@2L9<E7AEZOE
MA-!-@ W&$^C%)28A,8J&RH:W8]AZGCJ7,5H6AO2!Q$5;V\I-GJ0+RWY+@<75
MI*@9F#<,557M*S[L+[X'O^&W:()3) '.M5%'ZN<^A):_42NM#*ML;W<I*].W
M6WLPT L%EI!VVZI2(*L"&U@9+*L/!DL\TAT'ON&W<OS:+E9J)<+QS)%2Y@K.
MIX[A#UO!QPJ#@7GM/L$]\K]ZO(7-[+EASP_C8_3')_70G97-QXQ,Y+\=<94G
MHT\+AR@..!ZN1-I,4U3V[EXW+U26*1/"_+]%UM;$G:=G>FXD0$R5H1M+<9R+
M/'9@>PB5,6S%YV0=P94AT;=\</+,X++Q]?5:MCD.==8,R=@<:2NM_QBLX0IR
MPNMWA[9)@)5:U 5MF90!-6P;N-?X]^+=CAFFCC^GN&?%@;^>5<8)EFJ2S)B3
MRD@7=(.VM[+R!K6DJOD;UHB1PY?]UL_@_7>7$ITEHG,ZE_8O)4SC!VP]]?+H
MCB<G\>&#U9,@\?#*#@H1#MFF>\BLZGO_R!.:9<:PX]>)GUF(8(M-A<L'\&I^
M$@!^N4K<@ONAFIJ"+UK.+'Q.F4B ,#CE04#2 BQP#X3Y !_P1UD2(7NS_P;_
M,P4AA335CBO(NL#F>QOZK)V5/"-\[!BW;YP(<"'H#+CV(TWZN_(BC47W(4]%
MGMQY4FA?S9Z?*!V3#KUYX 0ME<!%]:/6,/N+2X@^H8KSHOFF)!^LGWW=NW.7
M4TSPG5"G9A>ZAKDA[[MLW!J<Z'MM*B;U+-)0F73V.WRF:@_='R#,R4'&1!42
M0(($^)[)(&\(%6XG#I1LFT0>[3;4K7)W=KEJ,D^/#N@V5H/?/CM&7XFL!]T[
MD*"_4F\>VR,]90[FYZP$DZ!T6'#QTS.WVO^;?B+Z?]T.C>%*$B *YPZ??(6Z
MB))J1%&5_(#)9,QL_A\]@]4,= Z)NFRXOJI 9&EY3P*@:%W^W;UB^^^[-/L(
M%23 SJK%P!41,<05P<]:?_U[$"= Z&HUA_.ZA['L'7@7X\/'CJ>D&H[$(%,$
MQVWYB=\2S#EO[@2S1P8U-H9Y*'\<4*[)_=P(4^-")L(DHM0G:T*CQ6.N!E;J
M0Q!$(2]07--P<MGEI(!1 W];S$6/&!H*]'T=I\0E?SQBO2@6-:PAJL4E9,!/
M>+!04O!1SD->;,?V&?#E*O*F0N.9!?#??T@QNE_QSJE1)BT)<&!;QT,\>5[N
M]P@VMC0]HX&Y%/GO+A[1[I7UG!\<7<>WP$6H1O#LL[(\R+J[KFYCLV:FR7,9
M_AD*8C]^[<!*OT_%@1[1G>CTCNJ/846)U"^[!.ETS<(]M79BG6 ?WD+=%_<3
M6[="$<L^1[3G:)UC9^Z1^V?<]TV</CTN86QI,O[</UB1)/ID(J(E0I?[:R0D
MY5H4IR>M#1#2HP=?$F [5;$81!!S#TB B_[UEK_R-028H$*O0FYC&DHAD>S(
M</:RHW+_XN*?.L[\[3=4 E*K!V"[?0R/%RBL-RO(Z'M&J)TP:XZ^%)=6< MO
M(=!W_RH%["?L!5DP^ T4R&JT-CGGGP;]W66-QZN%]D$-B$."BF7MH+ NR^KG
M>(=!"$TG4Q)O3KY$+O'/&C;*3]&\>3T'GWH>,XZZ"N E'=03&:45*@:^AL9V
MLRZ+YB-9:T932:"GZ%*=)&M58F1509JR478B%"PZ,7"C+/=UBGZ%*XT!#IJU
MH40T25>J:;V2N?8?LGO8,]!8&6:+(,0!6ZI(\[[;.+[,[WVJ\&[<:MQ18Q((
MO+%'SA>SH":_(,WMR\5T>4[.VJPMH[$KGS2+&CPBTF$QEUJ'DI'5/EXD 'C:
MMM*8)<;84)<.\M LXFMH)EMH06J0"5.H#/_<SDL(^DESU..,&B=*W96P.9#Y
MK;!I0=2$J07>^M\K^?L%*2^CJ[]#E;D#&Y1G8ZX2.0'+Z5A*M9*KFQ#,]&MC
M#4:,555_%, :;>TB7^WKQNYP<ANW_#K90L/(4 F&AR?G?80V$B"UYXAQ%LXG
MV;VTT"1;4E]W-G_EPX('#2V+MIR1]9<&"GVFX-#$).Y-$$7X6)Z$CE"U[ROD
MM:A_P-/?LUA81\[U2(#NW?SS,$*U/(V_S\;@#8Q]L<SZ2J!VIM.2DQ-G<2)]
MKY6/D$GA $1$;+)/T-5_>+Q_2" 1S=$4V^/&*S/.E%%& E3+R\"%=T[V:;&+
MO2,99@I5LK0._C[G\/KWNNOU+A TK?4&FYL53V%>SX3NY*L3^A3^PJR@VS2L
M3JF)GV]WR#Y)TP$#]:$E[H?WSH&U1!_X,_EN/%X8Y!J9<=YQ@*D&>YVPF6YC
M?NC,>^@'K$UUOG)J/A'F1N=$QO$9ZY1J/4WXPL;1:56> AQ3!FF+9"&4Q?"Q
M_M$;+JBC]3WM=OS =!,)T!RH<%QV$E>*&B5.E@3=<2[RWF7;?G=\1P39%5#V
M>,U&FO]GHC<L&!8R5Z7?R_!JO9R*A1<5']QKGIU/#+CT^$E\L%TZ,[;X2!;%
ME_!;GT6M88&\O[/3<$?:6>!  IWI^V932:/!X=;+J"ZY2(,PMD=_TP:QSCTL
MOC_M<P,OV2I0*2 "WT"K3--*'1M[Z]_@$F>?:S:2MU0%+"BYS!X,8XZ3PR&/
M!+5,5<'*KV;4''&(@ERH\8IQ^,;!)$3DC':J6#&R&BX8%17@>@ BTBW.+++!
M/H=QA>.T:W[M;AN,=*]NF53EI,;FVHY-A_H@8U[5WJ5(</G.F;]F Q'3>-JX
M"O]'!3?H)+,(QK1(326P#97C:?UC<<(QS/7X&!+@:41/@_8N<ZS;W#R+4K53
M0=;\<_^5LO'50S])Y)TB#'M$KRKGX:05I,N$D3L_)[(N%2DCHS+C&#,1NM#"
MG+F"(ZS7HT8",_;^+;SP%%H&KS+H'VN[>RFW\/*V]E.B@_-SZ"1JH9/'H\KA
M6<-@"*3]4%7[<5 98ZJZT^NI1)^ 8L-2T8D<" EPQWD!.O]^_PO^Q^D#$;D4
MP1!'GPQY45>DO_G8'/W8W>@7S='_^+&=M*!%S)L),.[%WD6\B[\S\6WF(U2R
M82 !@6F*JO!)9&!_P%#F(X[?CEVI:+A=F7 1Q9%P/[2'4>;O;'"V:A*/%H2Y
MAV+LXW)!*76",SJE:(IM!4\"N*D2/RR>1RV1  O.PGL#OTX*EF6T"$)$$S;Z
M"Q#^#F$ 7][D':DJ?*CD++E>.&.ZT-B:U?$%,6M-;\PB+\5,JZSD_T,/1*E?
MJSLYY.@.XKQ)"_I8B.NJ1O?#.>$Q+2*CB[UDE4T*J[+@U49AJ[W+@^KZ!U.%
MG^\$&7P1DY2/!#: - 3:0'(S<Y&.19_[#SIMD+Y.MI'L3P=JG^.TXJ9*6'H.
MA9=4X-A@6Y>,$*(^?*.#S=B"5<'5OW#$76N^X>A#<]*<GMH_R+(^'>6OK4KW
MK.US(LF-DG9K%;7CZ,K%"[>.);#HA1,I3:B[RU4"@KR__/*[28"RL3Y*:7*O
MM&V2<>YS;]5; :>S(2"+%H3\Y<&K:GUP;)58[M;377>.)HE-#)J:-3*8P'.Q
ME-0UN[<:44>T0A^WCF:N+# %UU;^;%V!%A(%*2@?_/DE_KH]"[SYW*FA2#J$
M.!EQ6?QLEEJ^9AW(L'>NWG,9DW1TE8L+"7#B8<,>+*H4Q=IR-?-&)$"5*-%6
MX83MRO4N& +WQD[6L6,"5_2X>L70F4&H00Y+0N;"U7:=P<8BN@7:4&&J8&]5
MV4 HN!\9(RH..8'2UW6 E""Z)JPW](] 7,\4AZ2M3!>B#4NK:<:4\>4SF0_^
M+N)']N1 _64EBRWU!QS+SWO\H3.7]#4XQZ78-U2=F'MO)5NY>.@?>FA]CVSE
MZH5TQFX5QB Y M0@3\JB6.M$91[\SZ0$!-N:>UT%G!J>?N;JPS8B'#:3&6O!
M=/'%"[*[4_]MV&!5I,;8K"$N/R?K@G#+X'/I_1R4@^"+D-%AR(."YW^\\FC'
M;.)>Z:R74T36;1'53,7PSI9$X"DK"4 T24@QECFK:V*44OF+P70[KL[)NK-K
MA>?W3.RDGI2!XR*#'_&M9T1/CIAP)U95Y9#_+5R=>F3B"U4ISU3QP6=Y3?>[
M$<^-9\T,]SLJ#].U#CG>K9P>7P@$6IYQ@QPG=3N4?U9"9VPU=]DN>_7(2[2
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MMT)Z0^=!C<2_ZXFRU.D&WSWDZ8[=9?<^G6S: 1TR<7&PQ-U-O+F^T_[,Y%Y
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M50ZV$[SHSGP74L^>KBI. AH+&8*J#7FI7^_Z\8*E2/=(CC=ZB[-/S'+.55W
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M5GJ5\PK@JNQ+=-UFKB%4*'SI=-H5^-Y7$F#2?^O&%$./#7:"=)596DYV^@I
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MG=J^5"DR%4H4YJ]S'_'<QTVPG:_1T>+R+6'>T!+_:>@>@3D0G.5V6(>NJ\,
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M3BETT$QV6B@(R+]2>N.,$):F#MTU'.L,)7QGF#"-N1JJ(-K^Q_=?OZ='C!V
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MOYXA-+>U4J7YR2<].F_6-1@$,G>#]@&N;4_JA]:6H^_NC%&>[7I54[YVCP*
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MO$] !PE68TO8CAM18>>-$(Q[KRUC\-JH G"M'2U1=-&Q/W:QGO$C](([BFQ
M<9R%M:]'+#'KB8'$_!^#MDL5A7KH<7.>G/8W??VG2.[SR.;'9=@R%PVC+)];
M;_DCGF&!<<REK/IJ%_V'F<I6^/XKC4R5=>TDO.="+%4U?A;.VW/C=&YFOX-7
M57IMQ:960M$K^?1;1879Q3VV9FI4#:7;MU*#EANI."SM\34'1Z#C)E'^+F0:
MX"!@(7H2;:Q7)X%ZI1$[-X?I%8M<*RCW14@J6.R]*NG1LY,MDXT3R"%0?RX)
MK]@E%LDG5O+!81KW+$SRJ?K <&KYY$X7QA=Z"V.R")<HI,[X1D*="E5"^NQ6
M:E&NS8>_\'UK!(D-(M>*A3:?EB6/Y/4:?8UG.6X(-ZR_,J,!(:>X9A9<S4@
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M$\J^)AX?@KUC'9?Y,Y:=M,>5Z^2EVRV?FY/;,S*_ TU-Y,CC<5$ &K1G5BY
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MT8)[)V-+9Z8MHFN=O"($+-RMIN?DCF>]RDNMY?RP(%(P[7[T8F&AF?2;MT\
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MWR?[IG[?D"=??E=*CBPILU&_\1.H.^6C- /^SK;)N#?KT'YM\NKZL0".LO:
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M'QGP7[HY7=L\Y++@L&-J>WM:-OZPJ\XE6W^-O2OQ*&,!D@;K^]3;*;_V'1U
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M[3*R%Q(.%$X6Z&6@RT\:1E/X_.\18ENOW1W8JR[SM0V>_O/G.%7\^1XF/5&
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MASV8V#,\8^KKVI R\O*KR2YCZ.5W<_&'<PSS,(?<'1FA89D['*9#$U-3X\E
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MG(" 'N]2]_18JQE'YO+6L)*.B$5D5:* T5=!JTU  ^=W,M8"4FU9(%7X&\A
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MZ0]R'$ KO0"J_>[8'<!M@!F=&E!ZL-<(;@>]=C!_<!3N\PCU+4!70NG]M]F
MM^QNO;?</7VK-?(WS2!8DOS17#*Z:3JVB(N/3_B8.D!Y=H"F+ F+T$=^ELY(
MF6M]<W;H>BTKQ#/"(:4IQ%8H#2.@'MJF'9=2_(_;-KI5J9?O'Z]$\^)YD\&5
MJK+W*D[*U;>/60,IZ@80O%+DO"0+='V4X3GJQ0(1U6;9Q_0+LE'(#Q"P.T!<
MJ-I()?@KNQBR(SUCO[?_S#R>.RX=D?-H=E]U>=%6$<41]\9S0S5VZ\90@=6G
M:_+7Q<M2OIY>>/GS1WFQG0])Y=:3'>R-_6)MJI8K\VP@B>CJ^*?QR]6EK"",
M0.A>:P#LEU<J*9+SH29F3DXS])$2/L9+N>XW_:2'<_*JU6K!U<*YNRILADN
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M&A"!VJ\X+(,@=',Q*+K'-L Q\$[,]4G[Z\KS4@K3]5SJ>MJI[Q)0G?J\TQP
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M#.Z))-M[.$S *KJMM_G+<6&@K])^"-YL7RW?7]X&&EC6<:C4G]GK.ID]+8O
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M57OQ,9UT1J_3N:F $JQ:='IJU+>Z==5 +)"8KI@BO5OT?Y))Z^CB_];BO8R
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MA,I3T?Y:WKO$"ISJ-&-K^WK&4.UJ=ROOK>!OVQ^!.XB>%5[(.X5*\(O]W\7
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M-L9H/GX'&QOHVSD]+^P1ICY\U8.5 C;&D4W"#>NP*N)63U+PF8 2/^/[T5D
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M9 4?].?O+BRSAK3)0]V6W%+>MK5=632&%EJAT3&KJ1F,^<6%45P)Y"C="$K
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MHO6^]+PL]CGMZYDJOZ0>^-K!TV#"Z-7*5Z,IC:C/WQY.P@S.,]4L&28-%"F
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M+[)^,[NUNL76ME)"2ETEUCB41D:+CX9)'6\Q?0!ILWK<[N9V4+:':JMNOWQ
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M?F#N9M;T+!7T5P""^Y$/JXS%_.LU9@F6+!G[B"NGZZS!@JG1$H-&=%>Q7!X
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MV#G(IQ3T\!_-/POX'']6 9CAP4/3.Y;(-!\= /O33?&/9Q#]4LX>J,$I.$O
M=+X3!09_V(;Z7N GQ1G)+>K-^XRQ19LXJ!$;>H]0*V.45UKB5T)9-U3K_50
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MK7EX0OH44,K);Y>5>SI.5.,SGGQ7VU+\X79N\M,XVCM#_$K(\O#))EE C@2
MMMB5!X(2D'O(Y+WSIHE@A!94O[;./[HI:<#.:[O%+D>4[V7.X H5%&4T9JQ=
MSI7X;"N=X_/]I_T';1/<N8<NI$TJ2&)XK>JH9:6=N0J90.%9]K4GO]X9/O9*
MB"^LW6I ,\K]*7M@=(71L)F[*>5'9S,%S\Y]R]&H4Y')E"^(I<LEAG9=$$BQ
M#0PD_>N*V?0F9\MB>_<G#W]GM%5!!G>5:N3AGD'?*<>R T68B5K2@'ZO\Y73
M<[HCD_[I_=[LYVXYT9F\20(QLLF\-"[?H$:FHSB<&^# I)R@8])L6_NE:4-R
M/.5%TV(YAM-TN5O_]":TV:>'C?O.S,#TR$%YVY.J,DYS^AW_=<H]D2';[!OC
M?T4V WAJ%:R:,#.!.?S$5>(1\/5&3__4V2J["J.MQGVN->1].88EGAA9)LIS
M2926J$Q8X_H-??H/C,#N+- M*0L'+[4S!(G^]$G\65CS&L,LO\DZ4_?'Q5>Z
M^\K#G:HI;S@Z=8LK[\9GWG_P;]L'1R4>=&!)(06@J@/8-? K,N(G7!*S'HF3
MNC%B-<16&K CUK#8HN//"VO1J)(MDPPF<WIX_MW_],W8!-'@IM/=9,%D(9/+
M$3GQ&3Q0(/S?I8)D8S?8+<G#R&5Q!:MU'[C=F#?E%$5.GK<0^%X_Q3LPLX9:
MJCXY]O:^70@P]=52HUZ#FYH'AR2.S+6X'$DY /AROV^D7 .4PL)!'EKF85=&
M TEI3'7J"+8]>;^WO3XQH5>G6&4*S)[X99MWRZRI_ALP;5'('\Z".[3RF3^;
M-_*S.%*#,NS%1:Y6-.?.!?=R119K<<2KV5F?F%SDO$[#_D^QYS.YE#,*G@G@
M/R;=&*0PQ<WCSC+%Q&H@<&G3VPW^*:.E/>3R2HB:C\< :KQ.4.[C"\B53QWI
MSJ[\DS_7CZU=<#6H#T4R_2*1TM)U+/A>&4&84]MT\P4J*$'Y!]:]'$#G"_!'
M=Y D<<PQ7%"AQH7LO>,:@L>6B#:HU+*]#JWW>9O:GS??V!Q1<M4;=N>.MKG\
MNZL5_$4%R=^^X!\"\'<;3M2$GC=U.L%7?F(KSP=S:"0MA H2)O%\H_P#/LSC
M"G[[6<U*#8,1RR[++KW_.-L_P./"12<1J$-T7I9LM"K(7,V6[>7?@&VW;U!!
M>V&092XJB(@\?T,%M=5STG)?A8$E1D6&0' ML^-N<K.C^]J0=&X/HP6]&8/)
MP?><'OVI,1?2S!_D?UT)VTZXZO)GM)XVW[,3W=%<0.6RNT/?60W[KIL.0=:1
M.)UU 0?X@\;ZPD[EL_S]A1?053LKAXY&3TZ(A/*ME,#5H^B,>5@BZW;2_,16
M8O]F7J%SKO8XC-?V(8#,+O]Y ._(^7_@BD4<?M=RO#U$+VB5F%+=<BO!?<*$
M"A+ K!>WALA@G^0ZY1=WG8JI-L@Q]N05W'RD.61X4C&1[WW>F \5>1=5+/D)
ML"-/8AR@WCJH( 9%VD4G+H$*\C^@7?9- MI$&'$6AL^''/TMYT#9]:6IO2(I
MRIX!%10,_%0X[:A_&S],&0RGW!0$[ !*P7$KT#YD^%_PN&GD\CW(Z>:U?"HH
MDJ$=21"+I)%QP'* 4<\^H(+$(62782,X5F[F/\6ER<+SE(7E%OB1M8\X97V*
M1N;^%Z<CIK&= ]#-*W+XIY2 U-A0!03)99FP@)$0]+2LC"$EW*&"*$<3;NKL
MR&,[,3Z? F6_]9\J]<[2VO;G,IY-.MW2[I1=M%4LCH_(@S,E^02)+U!!X!#=
M@XIW"Z1F[)<S1)W\E'ATDG\SJBIR;CX^Y9H%HU@F?N8YJRWTLI^=70QOF*-A
MC//3.LD^VRL';:.W@1DQZ;" A>#+RE[#O*\[F?#>,Y(HZ3RAG(K5N?RTU"^L
MQ@SQ?A=H"9GYX'ZBP!#\9SXD^?7N[]8'P_N0=Y9Q25AB<4[T[J]?1;&^AFZ-
M0AMG_I9W.=NK!8LG^F\8.O_ULB9U!]@['?A/!\)E3K>W6/SKKE-E%SI5Y"D$
M[[&_W[$@:<<AY)N;Z_IB_M/4FLF3T/TM\P;69"%;S56C:]#\MX\ AS.!_!3[
MN<U8 3#_9K@D$'YP4JRQP,Q9 S609P&1*X4O#'IFMM=['(0?$O5B/V5306_B
M!V/*(ZONEI1'%'::OXD31_<]>>M!*[^GH4&YF:T&FS2V4J3(!R5TN"N:XKGF
M+-]5R0WW1?6<E['K+NK8VYWR<^BWY@>E%9CQA?^A/1FG<V'25!HF$VLH9"Z_
M1>-D\ZJLK?5AOH\;3W\Q>;NU_EJ;Q74P[L\32W;,(_8L)M7M\W6C>25;CT6-
MKHM?3[O>]V_U<R_:(@K\7Z^.M8. I")P%L0S<K]"98&RBH]<,+EMZ\7X5G!&
M_,P9G5>0"?J17CF,E=_<+*M92]BEOL+W?A*SFH&H@HR,GKR2=+P:KSMW)4"W
M28=T)&NR%L7\S"ID.4363?2GKZF;PRI:J6/^/"FQ:$&AUWOM_DWBCI3_P/=J
M[;A! \5^Z,6WQY^-8*:&WZ_LE/ F .0-.@L_S 2OS\ZV;+8VB#ZG@OA/3;I(
MG&E]V#L+1.P4=T*C#^'YNJ^85I99@^*\#;>(0;LY1[)9=H06@I.SEP/.Y*CR
M"0@GMF=6)$6R] %T?;J."DJ^<]CMPW0FQLG IJ4V/2OB8\WV]N5.U20K[-%>
M/J-Y@'R$DR0+U$*RN"2WN#!9P+'$:3,ZTP+8C5KDP/C*BR6B@CCN;-]5EH+]
M];E<RUF*W?UHP8R+<E#1KV5.NH@:;K:-YTKTC]!. ;LH*?PM:*VY[;0:DW2+
MYL^7D/1 /!'O!H>V_5# VWK $X,[YE/W$0F[P9DM%/53?@]O[K8Z7-V7*;WZ
MPXF+(RLK73\G:D=_UK%,ROQ5.ZI@K*01[P_84SWMA-8XUC2(=Q\3987B:0K1
M/N9QHT=\ALC[<)EAD\[]D\M+\OO<?HW.[8Q:-V3-%;0>P[Y[<'F[3C2EVT6D
M&YC^:<M;DNBW36LU6Y%#T0*\X[<5R?$T!5<Q=T8%K5V#]_Z:3Y 26UM\3*Y8
M2/'_VROI;5(2W.9+X5QBHV:7Y^C=\,'/&=HI3&N\DL "5^]9K3,=U=3X@'%]
MNT.G!"R]KC@N#SW/X$_V*^FR_2XQ:>_<?!![2?5#;(#BO'..2+22L47 UVDQ
M2475/JS$N^U0]2K@SSQTBUU?'YN'DB).Q?$RO>XA(QGM@7*KB>#;7O/:]0TW
MY]6Y+BE#+R5I-\O_=1BW83/$$=VF6RZ2IN74ZO&()3M=#B#\W^ 5R$1(SZ_J
M&?@0IO*A J95Z!")\O#U0&_B[I2*Q__HAX65[&DK[C.Z*R4?[I?X54T<5[ES
MA/[3] B'Y<SC]RUFN ]0TE'1 ;@ -^8]28+\-6#7VN'5,%S<:MWZ/2"F.^;9
MZ:_&["TH'/AM4+9@>FJQ/U\=58K-5[Y/;Q9YGW='0.R+H4A#$0UJ*LGK1)ZC
M7M+GMW:FO=@$"T/DZ[WUA42+>5?[^GW;U*&-Q6&;#X.J7W_865\3@PA 674/
M=^FW^13QXRBN[ZC[ (5ZTKG"A),@6A]VKJF/D.R^^\KUO^@EL=7+'U265V>6
M8Q1VD-YK7A-)W_OU9$SL7.[&I& O"<;<G@H3XM"T>2_.*E25ED]XL<V,$Z P
M3Y+;E76" '2)XZRC/'$MB^V+,%1^<N+PU&.H8FXVXZ#NON9V=4L*T]^1!D86
MF@/X^RJF4 U1W1-6F'$2\[!(-.#5HKA>DC#,05D,8/OBZS5'VEPOA)?@*N3V
MO / L!^USPU^S=(0KW4D,)IZP_;SWINS4>2ES**[GYOQ!_@)Q@N]VC6\KD$[
M#OC@Z[/1X5I>W$1(WBX/Y:SW25XL7YB/Y#$V5H.JJ.B)PFS';MU[\L:H:Z_K
MB\@UU'\:-<N1^1"KE(G=X?7S&3C/:4]'\>YS!Q066,ZV4Y.^\@)S_X<98AG"
MRIBYVYIE,H.J6EI11<7Y7W[S1C3T7RZRI$64/ *^9<>]@11*'H3$(3MWSK_.
MAP>-DM\M8 0:DC<*"F,*B9 7K@.*[A92D7V7D?.KOEE0)AU-NR]_14T(WDS)
M7(D&XN6LBZ^[ZZV!N0R$OWOZC$2+@Y/;#AK56"VC]L3XF(5E;-)$[]XK%@U6
M1?TAK3]_+- Z"YBOPG^:42#[^JT4*W0X#N+JRI%5UQ.T2%)K:\'8N4;,V14F
M7*G>KJ[9/\_^$-'YO%8Z,74@(MV,*4>S-.B+\\<Q+<#KH7"%]H)=>"IDJ(;$
M25:NG$4U^J+ ?=PH7*"_N[.SWPX\]&1C*+=GO>91Z[\NY^UR_FN'Q[5A9J!/
MJ'_B!/T7'V#0@:5V%,<V<5SL&K);=[,'&IDTK^-L&A2Q,$/YAF4<7VAZ[.A<
M'VN^GKFZV)2)U&#EAAZ5=XC=LP)KJ./&[CI/%<O0._T$E)\Z-EM>M:)=^K@0
M%A2\HWAWOLUNW(*!?5J!A]'6/R^2.R(O(O[KL(&PXB3,L"Q$:S,IW6S#GS\I
M78-6=)OA?^ZADL-=#TE)T7&#; C/((>FN9O._G$G[6%BG@99#[L)S2WHN-U^
MS4)2O 43VMKB^:F1%OO06?9$LK;:CJ_@J'7),,QQ$>)]$$T%O=H+@MJ?G)[M
MNIZHJR?0S2C("5;A87[A,?*-Q9(31B/&_3J\(Q/_)%VYIGI[3C/O[V4=]5UO
M8#"FX@"L", _G@F0W/:1ZQ8MLI1#P)8C U^(]![BY^LFX@^@C8,'4>W8QY<&
MER1:0H048Q1$TU,-C W&C;18KG!YLFNE;0 N%KMLA;,CYA[Z-M*%N$9C<;&-
M"E[<-;A@CYH&>-]B%^H@MZ&^W:2:H[]^D>/?=*[GSU+-D],?F>2D%V3?2A=P
M#B_"006:"5J(+\@^Y!*A#Q,WCU^;\FE8,WV&O;/9,[ZBK.:F_WY/M*/Z=--V
M;&PLG^NZAV+(3>> B ESVQ$JR,GHB;T(3M\N62,.D"^9#5107,,//>2AO?CZ
MZJW9??GAF%JEDL!*.MTSI)1&9J^[@:2Q2GP^ZE5![\3C_$S=+]U/:W[&R]:P
MVW[J/6@;RUAJP'D2DPX%:AM\0URC,(&$E+[@[?JU&9(8A:37XNR;M1,*.M$R
M2=6F[W<J*G8LNO^P\[KC]D?=+QTL7A,ZN^) !/7;]R#J>^ V]E^,[>G_$,8I
ME)WZ>FWNREGYD=]N9_U$[6<U+III;SOE9[4\KC]:YS73&:^Z,0(S^%L7+_7D
MUSW'X.GFUJ%;;-SUAZG!+>%AYD'Z=*S0C]WCP]*3C(D3W_.N\TP8]XL^V:M2
M_]8OW!JC7NCS2@M@-$;P#39RZSW2*B"*%(A4D.K,/&?K\E9;"KE\><"V9;Q(
MN&;>6:^P^1XF.(E,[ZR$^?QP?&3S29U*\39?O)&TZ\%$=5=4/RWAYJT SHL8
M>-2RO#G %(9V5#!^J6SOBD;5M6L3PO9^%;A4->B]V)L_"?02;A3&DX0X(IA6
M&;2L# ST/\<\=Y49GX#!&1U*2I@!8'NC?#?(<@9,'R)UO-G]HFS( U!P+XYC
M1O72ZJ24WAFHP=**\K4VOFI]*>JU.3*6G'#)?.?H=%?GCZVV?D#VA8U10;Q4
M4,1QI@%Y("! "6"TE^J'\3H'5S'>Y'<5014+,C-!%8&"L)2RPMFQZ"+!(R)Q
MQQEMK9OXV"GY8?9FW#LO8$L'D1  %X?CX-=#6(.$%^<QK1+!9H<:OMX]^!T1
MRE3_RY<+[!P5W^=9,Z!_W%DM*9V'S>P,! QYOXVWO141?@<W\2' (>_3;8 (
ME6$ 294HT W=8)]78E[,;/F*U6_>Q\163;VJAUL'!:&3.'5$33_V\6E/[9.C
M@V5DU,Q7A:X]'WH1ILUQ<A/%XET,-3"XVKZ+-CL0Y]0(ZUFMNKUED@&.R [G
M5-5':BZ_EXG@!2\5?8-_IV&H1M  11/!$.)&CNH.*L:0&,]W#M;<$&P6/OQ+
MQ*,V24Y%C^ J>LW/#;Z.V3%:I1)#T1Q]QYXC4WJL,B+,,"VHWE4= +A2CKQ(
M3\A@8NR10 N%T1OQPD$*PM&NZO[U8'?O_.-,6D!K1VG*ZV4)3OB]BS)CMTN=
MBJ<Y0_.NLR0,7^QSYOFJYV#E??"948["K$!NOINWFWZMHT79YO2R0GX#BA&_
M-02Q/BT(%(Z>?;BZCA]_Z3-UQ_MV@,CMM'OV&OGIY>V+O#)94D+ ,$9[29OD
M;&4A^,-?LUM9Q_L+FP'>T^[DX)@:UIHSAM6-O:(Y,^=6,14ADP:/-9?MXA*A
M:?:GSANOCB6?3A<E.^:6:P=$?*(5]//]!5WG/@)OMF9:-K;<4S J4?#->PWC
M="@*42%[+1BYB1XU')T8[^N)LMZQORVTDI7X!)O#T>R<FBLYG TJ^JH%#"69
MZ'V(R6MG>(N24SOFNW-4.%O:A,M8%;9"-ERV\K2K-FM%ZYBLX^IF1;IAQBC3
MN%+[=.OK8;>2LE2N^_/: P%/"M^[Y*L"EVA_7TJ<Q>DG^)AZ?_39Z\'*-^NE
MQ;O";*9>I9OF4D$BF@7>'U^\&BKYXQ6(?YH.B/@)1V 2-[ 77K@[&6N4?J7-
M.:7\VN\R"@IYSNVJ'KH%^+S=YZQVXK/&RSZ\CQ_:=X_VZ^*[^$J2F^L?.>]L
MKY3&I.=H0IL)VL@,>'_O"OA7S/0\XJYOLFJK/&1-?6'^T'4"BXP,;*ZQ/4C?
M8Y$QF*AG%C338=53_N>]K7JAJ.CCXI@L4VWG3^RO_(!(>>M4 #=%1$TB+YRI
MDGR\RR'6^XRA^XMU&&Z7%DEP[ZX49XJ&]:CMMISL"X1$(Q44E6.WDS=H#%.W
M+4R.D2^8/G7]N.+A?1 G"1<4#YO%K*]_1R:;VKL%HQ:L.)LQKH;[J$K3&=C(
M-=3%6AE65F,SOYI'VB)"AO9.=L5?^-3X9"1K=0_[F3MY^VG!7_P]%=2/6,;^
M"!E;0.._"RLT-+5005YNL[):6/&$C(I"OX/G(1@G<M5+"9B1BH:>2G1!]/U"
M56X(6DE:HE=)=[$>[GWP\:L&;HRX_X%BJU!(RGUJXO-G4,0B]PWPWQO?1<VB
M*#MM%PU7(^S5Z%?8Q,^76/P:'P2A$IRAM88(N_5Q&IE/)':2"Y4?D'7VF1#<
ME5-79NK\,1LRK3MRA4&K<NJ&Z>;T J6(-Y.P$3?;[%Z;G:/;OR/:)K]\S:MC
M]>+IOZFF^'J\\V9@Y5MQ\E_$:T=XDOO;2T#8B691: XO_[9H9GEJ&FAG-SC=
M%O)*<S&O3O?SS3R)[HM/N[G>Y'R(4B )^!?0GML7_O_<H;@QJ(J8- *6:Y;S
M)7N1)*9G%OMW,K?BE'6NF./&AZ$P_45MW1C9YK25TE[;HK4352/H?>T4NZ9H
M-"<ZL&2)""6_;[\0Q(D5T>A72F/S]=7P=27#?-"[HN<XJ/=@<XELC%@#ZG;/
M?K-W;N_3D0XU+9B2J,B8JHRM\0DK T%DDED!V </GUX<;MNMD-P=R$9*7VV
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M);66T8.QU;%IWK=]B"M ?MUSTM%LDF!WQX/;42 O@A?=UC<I.I\IN_%H1$#
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MWRHVFC48Z_VA.8QTR4>[#@3.^8# .M^P0=[6D&]GC6!*RQ8;TB%W6$?[HZ>
M%:\F-X^<8N*P:4+*-_V)]Z_BK USS)(R/'*98;Y)J5 _W23W4#1X&6K=?%X.
M(X5V),_C&?,4O=D*(K((_D[OY4K5; 16AJPW71B**OI"Y2W1K'B]\Y$=+5?T
M%1KW22'4]YVOKUW GH$"LV^:/Q('*<:8T[!H0:0V-L%]K6P2;7?;DV<[>[C*
M/[K(I6MJ]@*7W.F#]5-R!_ADM/?SE39\_;+6<[NGX'G/G'L<(@[FOIR+<G+G
M:?Z\,7TXR:X@NVI[X7!?<0)<)W#T?'??D43.&#:>T^^;KY\*BLY>$4KNOI7$
M'*3MN$\CX ;UAF6*$NH+2GFOC\4*=PA6R>$-29I8FSS*.)!PNF,XH%". 7[?
M_AVY49A@X%M59AH==V/>CDGR5D2C@;Z!UFS#-4#S]@Q4RPIU$.8C6V!$[9EZ
M= Q2W#M^VF.2I+I.R/"VJT$>WR4DSRHME3YD1_.PT0=_ZNCN5E/^VC1)P5JO
M'9,/3:I\3Q]<["?=R0F-9S<0B)[!9\Z'34508C&= =^<8FK6*?&H*DPC;# ;
M6X[M)HONE)$]ES"_@@#C<#ECP<[*!'YW):)]>L=+FT>2B3JG%//^;KAW'EVB
MYD)@&]9;QLO6CXY 5%O(.WV<IPW+Q9M;^O50&1-K?UX*MOS55S8^ 9>@9'I$
M=&;&TQ@Y11T9"8V0$[J!J:'F^M1-8V7JK1\Y^<&P9JMQ5 ,J%";H)SQA0\"X
MN>6W),YA?<=&C*QJ;)WE8>7YHQ<79:5$0Y(O^D@<N'C^^)5GZ5X(M^A"^I86
M0LX72;9*PF6VK[R3'*M.XV@W]T9W^]Q.?)%7GYNCK?U*8VC%DF/KB'Q(<G]7
MC^GP\4O>R(/A=T2ZV]2DQR:^:;YF()SX4'V5?9RZH$)Z0TZL%2!WKQBGXYT\
MK2#2G%JU8[_$OY 38$=^,#JH'1+[?2DJSN#[R/=>,Q7.5O,PJ0/6]2S^2L</
M?6!V3H+4'3L'FW0GUU8R3C0VHX/B^<P\Q-6N^7QM%;"J\+ <&^78CDUYY/Z(
M[WW;67..V3-!<RAQ^Q58B-_4#*,<]2AO>_W*I-IJS+C^-X8RO!5+(NDTCCNW
MGQEQUR^LR0>-DQENCLE?ZXU$F0DH6M_NT>EJ4-7FEKKQL0E!B+KU.&5-5_"]
M8"7A7NT=U!G8,YQPU82[3UA>LT_@K./WQ=D/22L*[:^X9LX6SN[\$GI(?;8O
MS+.CL_$22Z?ZR>9N32UAD?1'R>NZ"M)-DI4$O8".7=X^'&>E7:X"7?K#*".[
M;(4 JTY[I1=E"W8+>)?.B?-K!VULAC#".@9(G?&0RPS2WS\97#G$0ET%0D_1
MX?%S3M&HL[7'R.F+#NU#[/<_$X]7E_$0Y\C*S;GUW2:%"._$2T?<UY8-O18%
M-"H+$UF&>W".Q8A'A*OK)/X875-H&,9NP?'=1!#HQURL5?=9&99/;$['(26\
M\KE[4:>\_$J+F!#]P_Z7$#(L#*R6R?0ZSR/.\MA><C^88ADF$'FAX?;=KH[J
M31TMB/6>$(^%7%T3Q9B+KFC5>]A>E_S^J_O7[D7#HZ.#:%8;13D7G4T_+K<)
ME\+I3*ER;)6FC)*YC+,YI^#=X5,;&<6K.;JS1RA0M)I#-V.%7R!^)C=X\'0.
M@ !?Z5<_V]$R[!NG[]F+H9AFW1]R]WM;Z]*OJ^U)2 8!X:1X7>>JTR>NXE7V
MA3&I[]."B"J;^ MR1:4HR9<L0$HH\=*7PB8\J_2V2BN3G5Q2;E]Q&(S"[B2[
M6PJ56MP7",><O:W;>>NLU>#GD[+ODY*O(VZ0O<Z\H/*64%0$+UD0-8$V)0-$
M@T$0N"@KV;0H:1+T;L5Z"U4'<=[*HHN4VC8+?6_+J<'!I<[^$HUKCUF&CDTP
M=Z5$NFU*%U5:6-N>C3:A9KRTO3G!?V-"-?1B#[_S^SV(RQ^!H\#>7^FHCQ>O
M3'OB58C/UI&54IC3GI9$$J)KMZ;&8TO2PL-RD3@U4)%0+'<=5__L))>W3-A;
MB_,.+^/>O;4,BHZ+5M.S8=7-\'@+>3+%:DRXVA>>6<I];WV2F6E!37 G"+"7
M>DPW+I.EN<^'OP^XY,(L$V5 EYG=O'SI^I3&'%ZF)+S%0.;:";CH.7HQVZQD
MK/?[.E(G68S(,E0E^H#<3') X&/RY&*^VFX[E!56E8UID0:\#\2%.4\)6\-^
M;3Q*QQ63E=UHD9W5P.&L.9UBN(TNS4[:J9B$.O&E)UDPGN2F7K =0(KV/#HU
M=W..F-^#;D6B\OKF1J.6LN9F1HFUI5_,RB1@;(EMRM;F+M+#,8H2J]]TX80N
MW0_A[&G^ LF/4C*@;OB.&8M2%D/5P5%U"B" JKV,*FP! :7V->.*W1T0B(V@
M1&+&9W9[*2L@T/B9 @<!5B2QC-)/I@<!4>J]*2U35OA?B?%X@K6/?9W38HS[
MXLTZXIO2S*T8%;+_''>G<@^.:,B>85VP>2S-E5M+>(KCD"WS^H&4KE?K,J?2
MI-2SL=Z9J(.82+DZW!1AI*8,!^.9VWFX!7NTY*54-%B1V(X==!B4T.K29M"9
MM,KZKJ[_VB?!P1Y^^[:H;F%QQ(V"1N8S0DD0^42/!>!=B&]6)2<E77W\B3O1
M*Y<LK%RM+E2%9F=XLBYFY X8^55=[)&,SAVNLK#)'$O/R[U([%X1M<C/>9J0
MDI2:>.B$,.3 DCJ'4*OQ*U-MP]Q%HPFQD5DD^>)27)/(8M[T\OUG"WX-K3\@
M%B=3<:';MR<^*7__U8(>S>C47!L1X1]>C?4YA1<CN,1,^*#@XQ7K-$6+]P2!
M$0D"$GX?4T:,!TNVG/"?EM_)/?9Q__I#BCW=:R2:450S)ND#5H;CTH'K/M%"
M/5UG-"+#PK*L@_?HY:F$0>,565T)RZI5W^2AS.8M#[Y-_#R?]WVXR,%WKMC5
MUO!0I?JOERZP1!]ZR8^(IA\WCZ/ODO_@]H8E &*Q^:O9)'X?1:+X"'O>\@)W
M+]X3Y<004RI:R@:_Y>ED:DDXRFNZ5!TELU_&<62H_-<>W5LFT_?LQ2?R-$C'
M>S4TDC@MJ)>MHJA9 CZFL.B81GO!]=-86!OGTZ*/3)-ZJ[,OM^EDGMBV6A$0
MLV=B3NI<$-(_5H%: 9(;/JM,V\??\4V*W)&4B(54FH%BP$2S?0U[NKNVKC.I
M=@/S0'F'-#QT>ZO=J7.9_(+%4HX7R>WG+=3C;1D7SZ$BJ\@AH>G2KWM)ADE/
M.3U(.NK44W8H1LF#<4!$0+ 1'CP(2V2I0@H.*J[SDNMWLB'6B5K*^Y[;T#LQ
MD8<MM$">#_HL(,H0D)'RY49LT,MPD8KLK&BE/5G89]3H@)4L3-'F95'>[R[G
MLY&O[B3YYK'Q"YRWMWA1UIIQ0E6\(FMOG05.DI^8&Z,FON]B*[>"9ERB7E2F
MK<B"Y0V!9MW^EF.NRS7=:N0+Z0UA1)L5HA5RA?"-<<L -5-!$2V#85#K%U!=
M,>1[D/_"8$& 2(1!W'T<&E.L(# $ D]@4]0,+=8=)Y*Q&YVK1SY^9FFILVK'
M_YD+"(@Y84#@<O'%D_ZL(B<Q:R<=AQK:=U>"DIUZ=?7GTH=Z7J'KTAH,U44.
MV^J'4 ,NBS]G1^H^Y1ZJI265VDGO/!M"GXWL?JBJW.&H+AP>/]+HU#=NMRZ0
M?Y[_#N+Z)OL] =P'Z;5BE?JDUPI/W;^1CT,>(&"F_Q,F# 1:(R8LYXEE>$W>
M"JN%W9;7*>V=EAX(6[.BN_8E>UYW6*S)N.KH=34:J4^_%NGI1NC<"+^$8%Z_
MM@C965+V*++):AQBO[Q3F\\H]Q37B_S@\&ZB[YS: (MQE/)B:JO' ;BPFI'.
M/<%F1Z7VY^UU>H4MNF;"6QH?NQL99(32G[)/(*%!!_]S%E$!I#0LO+T.'>_;
M>P4/\S"OPB57S7DL27S#*A6MN3[2L\_Y.CG<TWONY@!#@PR_S'GS@LWSW:G2
M^1.A'W7$G!L0QY_&CD'.]7.M MEO'A=4P]>'X=Z&TR-+M],S/>H55<Q^%#X^
M&6IH:\LNPQRR@"]!1'5O)[SL%]:ENV;[)NL,]65K$'C+B/],S"2WKNZJE-7J
MCGOV.=%UQ0\Y[!3-RM[T*@+:C&\SG],D(.Z" +?SJSH L0K?%YB9*,]Z.321
M^CX!/4HH+!#3LO-QAZ_2JZNHHLJIMDKSA&SBQ HZO"HM^['C0.FBN[J^9JG0
M!?=SW>(\)Z+>IUT.9!O1/<O"AM/MK1&["44DOV D,*_U/Z'>)@Q6*ZYXH-)#
MDT=KBN '%"=9Z!I#IHQ*SNU&J,#A9Q5NK=C?.Z;;/6EBX6YCGKZC$#LJU-K]
M[0AU&<;?;Y5R"W5<L3&[EG-COX4R92$_!'-P1^[X4(WK6G].]GFW>!T8\ND#
MXI##S%%-AJCF:6N^QR+WS?TK0PTK1+.F<Q(?3ZI#E&%6LPTE$1K]#76>(9W<
M^M$;4U(JAS)1N)X\,;TV7*5<=)BG9]3(UB ]ZRE#;UCN)WT+6Y$,4<XX+Z^@
M(]'*VH\6?5P?OW_R 7(EF;Q<D"LA?(4'803]],D5\_?N;Z0N,\;&$N4$71".
M1WJU_1273V=DY%@TW&K^I:-!R>%>46&1EIGD>/HY'9%/D%IXX?^?7A!V#3.3
MWG[S*>6>TGX=/'PRX>9R\@*G$C9D$"&C*,KI4I)I%"65*T@ZT[Y76JSC0I'H
MB91,4;LWD.?F X$.)+*IG>+E] :Y_4L[1$5_.P)/>;I-N8E:[_8)@@JPHBCE
MU$0-W 9;/]X5!!+C)_4IOQ:!P&;=/X[:O*_%1*#)&[@SF(W]:!#(HRXI$W;W
M;Y+?@<!,&HD%*B$& KL/?SNM,RN9/SD#,0BY;_F[>ZQ 8('ZO%\-"%SQ10G"
M2'.UJJC9PS 0N/?;*LWVX062/ BT:^-%(<=G  +;8]0L$10-- TT#30-- TT
M#?3?!?1%S'[8V%5D2Q4IB/RLSL>2.!RS+!9F-2,[K>-^1Z7:H_IM%DMRO<YN
MFUF3_EG[]Q<U]]UZ9?#RY&'J/#VV\T^)DKF690%D4162ZJ+Q<*7'];$1V&F;
M]1U%YWZ'>Y/,.P(&9AJMOEK%44+A:==27A9]^71A]=,O%ZFKD3=I?4(#30--
M TT#30/]\X'66R=7PF()#9CI-_U&A&**2-]*M7_7@N]\_%X77:=619,T#K8/
MZ=^>/Z7+2$A]J:/[57/[>EJ7Q)4RZ*^\OS]1<!K="B.%^=A2[G*+EBJN3\EX
M;#1N;BTO<4J\KVLK<)9\FRT?1[[I)'.S4(>_@WTNA!67+2Z1Q%)OXV3<6$G0
M[:5U%@TT#30-- TT#?3?![1E6T&YD)SE\/!P-K,@>TW;LY01]D[=#V>/Z74W
MZAQ\L_><P247ALLG]I174!\@G5O_%]>?LS%DT07*R$P%9LVT5'+7Z1L5@RZ:
M"">0!7<F<.N/B00LMFY$"3M28QP[OSP5ENM\-Z\D[.!&B73^\\8I!M4KS68+
M9YD"[3B4CF1^T._V1D-?0*)V]YQ=]:3@"5-.NS>&>'?-_J%)>LEG&$(,1A0U
M?[T#4B3O/Q1Y6=V'&P2J:TA&('!'-@ $[N[^ILI?-'^L[$ZM-..VWQ3#MAO_
MH<<32#K4BJ2?'@CTA'P @3[8;XK\-9RH" */O?%EE!0'1DK!;W=";>R+^8S;
M:<%%83;YK%&;8?_5]_RU1T%@]#XY%P0RN51 (.>WZQ1H@&F :8!I@&F :8#_
M&L!O=B&$!TN)VD6E!XC8'J2XGPY"S\$!'3'B%EER:TF2.;RC$XXXZ6+]1?01
M-FE/SI4"V5._752-)MXHVZTURX>M[7?"[?92[W_*SY'\Y_/WQ"J?>\2P8F5/
M$) 7009R[;@Y:L<4*Q9-26P/Q[:U%^\7-<\83XMWGNS3N&+$H"K\)O6#KO*-
M 1O+CS4OH2I<\W]2M?WM^ID&F :8!I@&F ;X#X!U!==K0>!Y#]F"HL^['X\3
MJ<R?9/3VD%ULW K%#KQ9ROL<[)0GG[E^03>E^_S7"6%;G\Z#!X+5TR,R>*C1
MM1-J-5!RYS0N!D,L^8A:.?V,^@;$'.7W>ZJ7,6.VN*T%B6>_/=LZA-M9KJ(^
M2&BX  *GD$0XLM%I>F;-JK1JH5RQI=(+ ^N'FJ7?<W=1TDCMF9?\[-S6,K8U
M5W=&.#0G?MG0OO5-@@33-1N+W@RT^W*^T=]-W7\[^Z !I@&F :8!_H\%;&@*
M HKPJ:E^9#,(S/C-$#_TQB]X;4ET?78?'1G5W8E'Y1Z:O&_?RZ7;SO3*749<
M+HC5Z&PR@U./.K4! [ADU+2&&PA0SF Q(% 91TUA/G3_7[O/+=<8!,:0R*T9
MI380"&8I0"WXJ5#SE2<HQ\^"@+DBG@ "K*6,NY/GJ(K%PO[JC&DW%=A;P75^
M8BZY8+O*W).NA;L7/<PE^5%1(2SKX0D'>^/KEA\G1687\(PZ9_=SSV,";G6:
MI46G67==AP\%\H4_'@N$8,HFZ P9T54KM)MXLB$<-8PG^A+0Q;-R?5^P;N=[
M5(]J,D6DA^8]K62?3WKZX4QF6A3_%7[K[;O&U!<S8BC_FC[_WP79DN/ZZUY$
MT76S22<O'^U9Q_86RZJ9B6EO6-#HL)3XBZ8[C3IJI>O'?[@\'E&^=466C^_%
MO9Q.E9/9=R+DXMBD%TYV2D$ZLTS\MUS[]_\L>#J*!X%8X1%>8K G'67>ECJ
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M35#+651V[ZNU+4<Q3X>#P+CX,*3PS!3(Y72D_KO,X4]WFOJ"ZY:DS@#*/0Q
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MP8>XO='# *>V;KOM0L;,,[\)^U:?J46^=;7XL=HWMEA6ZV@&+IN:0,S>EY2
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M*G]XS:YOD:NV6..(V]14TUNS8.(&BZ5.IZ:%.'>'@\?E]NCL I*!IB[KS:=
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M&;X)+Z<+TB3)=/D+-#@Y;&,74;WQA 8";GKS@]/1>E"2"@)T+C^*.6KR QU
M?4]9*:&W,.J%_';2^L=J3KBL%;TH]1V:&D4*VZ_M2N245_CV9V!:;$JO%?K(
M>#^A.4C#-'AD7I_;/7[;]FE:VM&^<Q=N10@8&3,B1":N6WYF\1:M%W**(R @
MC(J$">[([VHM76XG;X_#IJSB:7I70ZE3W\8?/EG<Q!&T][UJLE^J&Y>,R$;O
MB&40GWPR6'DV%PD]_Q$HZ_TKXI&=-[B=YRH0C9+1$,-]/UI^;$(6&>12(%4-
MK[!BA]Y^KU&7MZ%>HM,'OU.QU1\2?,\ZVD YUM?#E3;K;NL@<.P]_5'9:CM+
MA8%$'(W@)[0[*7/M25::ZI^9NJ6AQ1EF,S5[V0<_/AH<T,S*^N7S5EN&2!HC
M[,Y5PHG+A)*W.=/<I!*:J&-!\&U7E\D?XW !92F?C_"[/MW':QX33I:J6,;G
MT ]<QJ]JW?CP\775]8($)WV7,Z^E-97$M0\^@ SAHIO;*]I2?@<!A<E-NA4^
M9ZM\+NPSXB6:JT[";7)^Y:UP,^]4](CEBS*IT2>;@^=OS(V'/EFQ*VB\;\FO
MKR9[\#7QU]C?C2_>U%\6@/PH#P0NOA5N7'9/AY[P =>2^-312B1B1MEP$8,L
MKN&<XT2ZB_%KU[PWYTFP9=7&EE/S146^\Y5[:NOK65!NVSV5*\CC>/3IMP))
M+$F=F^)/L.ZA6Z"Z&HIPKUL, S%Q"]'0$X<>6O3UNJ6E>Z<<+T1U$W1?GW,B
M^KRZ:^*0FR.D4Q)+YW/Z_C6:O<3\-^?<[UU*]NJJ>&3^--T4S[$E9;5.ZPLH
ML('ZNGJ$V#U1JTW[4@/S\B6UK.T-<;-Y#\[E%23RV:Z&E]6T/)XNF&U86'+J
M/'KFNL@9KH-%6@D<<XP0[@*?0V\D.M,.TA%X^]Z@(*+7 >)6<9EY9\G#;1#P
M6[MC=.ZEB38;5OA.ZI7F_GYWWAX]";X\/J/<J.H^6_%KM^9@/H3\%4KDNEOJ
M,'H#@YH+P_HM+(U3I=U4>H,JGZ,?N4=4B3AEYK>O\6Y&-/>W&1IL?HD=MEMQ
M7KIO<M\NS6G&LB97>05_J>[LXD;0$@@<=Z [X-L&D)-HGVV4=B#?"(H/>2;3
MK?OCM8C4Z?C6;V4#"7F8W "+Y$*ER_BVWK,BZ^P+V+<W'$1-H.DN _7E)FJM
MFUL;!,YR!J$(5@S&^6+X<P_U,HQLBJ!K35%;_1C8<\3>2":=2M]BA1(YC3C*
M\_E22]/Y=9I HK_[RS2XVQJ+6K 79P+>?RDSL[EOT,ZWY*YJ-":W.-=IZ7Y:
MG=FHZ*R?:=)@PI7.HXQ"O6]5KD/<CVU%I2U1$B^[IU>^MJDF-.AQ&,NT%[9:
MB'[SBU [E:UI\NLO&@.,+.<A# \C<7(VHFAV<I"A2.5NQC[@_9,O:FN$&27/
M W(>5E_MR\9KA)^/;)M-*!\7%1,7MTUOW F]61&1D,;=I:]D?_+2UZRKH;$&
M,S(:#HQJ&?4?8?7%4Y1U6K;R%1^T(^I+M$*F$TV;H%N\HIR;16ZKPJ84 ^.4
M5;NJ0Y^WWW=CZ%_<+X5Z>+C?L9(XJ*NCY*N9=ZO_LVU>K!SD]*:0KQ^\+XT[
M3NW)+N?656H;24W:BJ.HKTO.PR*+FV\Z'Y[M2>TH72HE&AUS3(Z*"GRMF(SQ
MTTK.4N&5RLU-OAT#PR/?^=7N:@CW(;I:[J.$==)-5<*7<'%PR3HA6GV]&XNN
MF$QS:OQ K4]UJ=4?+S9'Z@^:7\I!S&!"&B\X#;U6O_6JY88GLL0'!P(,AKHR
M8> KO'6#[@("76R9RAHHJ9)XQ#X%6XI?6UDI[XEA'$?-J9#"1'[MM&:[?"*U
M\O&0<?_@VZG1+A4-^60KN/-9 Y$'"3$"%Z$\)E?[X>IJ]P\0^+,*!*1I"1T3
MUZ/:&U=QBU<MZSRI[1=(A@N/VJ*6V]E2\EW4S)(5DJ2NF.J(J!Q_T6'WVWGH
M,8^(4_"T-]^5R13&EZV;\I:5)U?JZM%/4-)\96N?+LL[+8A(R4I4EBG&.18)
M&4]GICE&13D[F,5J'"_YU=O G >* ZJ2NNM%)9L== [^+>H)//?""Y=^VD>R
M\# ^J4]V_$M96ACO3HH%^D %\9J+^8K8H,Z=[9%[Q3=%9F^ILU,.WQ?XK1]*
M=G1JD=4[A!VZ-6*CQ&VQ?.M-4<^'2K]N)4KU3MU\O1ZO\2D-7D1-V:"1[(#/
ME?(&?4U3'3%M]MS.6/7E9:U7#-KWP:.%-[J6JDAG&_Z*=QOR/UZH9^?+270:
MH\)*RCZ(""2GR"<L<7&QZ-P2L;Y";$#HLV4DW#7;EQND 3&,@L"CY/@)M SN
MM3!B6VZ%X2\^ZRVL+T>_!5_WU6A0_K)\JFYKC6?+/5U'I[SL_-O0'Y\)USW-
M63I_Q'M[*?0;#P2MR3S?QUC,=-79\J X!5ZE'.A%'*-ST9Y2T-H#:&7E2S^$
MV ,=*(857D:*\/<Y>6,CA2:<TMC-$?.MPY@"MK@VFXS"XHR<XE@746]99:UC
MAH04R.E8*9:!_2V!=6166J.",.7]SKK>#@CH!NI0CE4IG_,U[9!H,5<-&4LA
MN7(]+V6_CEW-,NS_VJ^I#S$3M=@HIVTU8Q6C?O_&>%8H_S*E?2)).H* !'QA
M>FBJW3:OSE!S2X."(H% R]LI[Q_%1Z1?M3CZ"6NQR/@KM(J(2QL9Q@D-MZ%8
M9;R=-"),"]_)#'@[I)5E7H#B0R?N,GSU=; N:J;60V]O@<@X?-DGGJNL[2W4
M!?FBY7R%'.J#G,J4<8HA<IN=^S":7TW.R?T&R0]Z227Y1DKA^*Q%#JM3^G_H
M:$:=M-@7[L$HMFOI[ ZEJ/2!@#((O"J^6+X8I?HMP1='L9H.ADTK&ZV?3'T^
M:72.WCX^XG]XYET)9H+B<L?[O,XVG_K3/P1S\[<BGL]&R:=B7D&4T52)5@Q/
M++F_+=Q3$H>0K9&D5$)<94%^3#$L1Z1.RL]D=$R1U=5-M/2\@DODQRHYO(F[
M3M$G:>\8T]E',GTJ>CJ7E8]A,&W^R5G/#WI _2V4K3GA[X$FZX1M_8EV['7P
MU"Q%I0[-3=54A!QC+Z]YD-M?Z+PBG!MQ=L IEZ],K&VB(.MT?W+X?@TV'1AD
M31LT"W!19'L1,LJG SG)\YO(:M^%;8)D*EQ2H;ER=J[6%*']NG-&Y$:<GAR!
M_<WN2$'N3'V;N=[!J!*]2[+23\9N!QJS<F))MW"4'%>M0,ZM)(A!AYBEYB"J
M<E&IIW;(X3B_T+/Y''&GA=@*_3"^2BOFIKQWV65E/EQS2RL?Z$^Z0>1*/-U_
M1] 7"AGO Z7&:VHD:22Y1.)TF_U+Z@%*4"")<GV+[-;\3E]G;VQ5J;S\H4+?
MN07/!86W?,@ .XP$M]BU/):-,!>_%WAD46<%8\TT<B\=CR_?K"Q!IMBXTW>^
M8[44"!/+JX(V7?&?FZQ+/TH/_W;H->S2PU_5O4ZT\7@=Q0]"J:,ZZT^PNO'/
M D;0['-<=ZEPR@<$A!!OR$&53[FCI4MW"-P5,RU*FEEF2W+=J/.O.^;XD'\>
M>_ZEP=RZ0WBM]4.SO BL-6T%;]32@"/KHYNBPZ=:9V?T[A-XZHY@ZW1\.A6]
M9A-FR:6A$^Q57;-&3F7]-HL]:NH_9.-/1%J5JP@&R:IDW0LR=KE\X>&#I&0S
MB,*)*ID2&XH4D'0.&*R3->Y:<O2+/?B6]+<%_%2MSR?%I:4K%Y^B/;<G!XJS
M$ST'AFYXCT2\O#?B\NFD>8(ONX>6\H)6@/TK%<9)>58[MY(WN*Y$R@X-_9VG
M6U7Q:PV,XN=!Q[6ZTRZ>OW)^>=?5FO\8AQ''AI:HR\%M&5FV7A=SOB<'^ULP
MLI<G5_"'X21[/;J5, C(,DY;GIJ2Q:UFPJ<%T>07OCWTQ55&'.5!A<!)[(E;
M;T&@D<,0!+!N25",R$>0XT'@T31*$01H5C?\]ES'&(=>C]*-5@G-7SR@;%_7
MSW:F)E-P\\3Y6G@BIGX%'[TEI^51]6XL22NP>#K*)R:V.,$)>GGD/,62$R2Y
M&G02J&\L3#5GH5RKN(51Q2;YTG>5[FP6G3@>1_E&\Z';6X% +Z_HFS8"BW('
M"'@FY1=5QH^/QSWLUWDYX>U/2Y#"\B"'C P'LZ6-/@H8'A4_=*T P^"E^JAX
MSKV&<6CT(9;1,!L$)<87HAAGD>TIWD5':$(=%%%[S&$>$^X%$ZU*R;C$?CU-
MUD3O:-D[S;WU'.2!>1/PKT.E;DM;+56X.,360;KUB-L+(G)NV,(NX, C/R'\
MDA5Z8ERK9/WB>&JV4"^F<R:GQ?Y"9G%F5E[V^'BDFH[=[W<;=&)B8S&88T(7
MH,G^G<=</!%60S\* O)[:%K.[O ""0$"5SQ"\-EE6XJ)]AY!(:DY/=.E&9>$
M$(^:+$.20UT'E:4E-1$O$WB*%1(O.O&'8HJUPL7R\YS&H"RYLF7M<LYR]^9(
MTF01H>[#"OW;BD3O#F[2&KMV24[QT?TRN+VY7DP&=57=(KD$9KJ3=/RV6#JQ
MD2[VW"9)IHWK"I2:O4,UZ(* N"1U"/V9=8\M"'I)1AB7=+\$ :W @.^2D4C3
M"Z7!"MXHO1^GVCK<C_DY&#IZ8T:_K-TSUC4)<-&Z3O0Y1^/@."0P>BQ/1/1=
M0-C+SHW^>K;KMVT9]<F6ZV23NI'Z=8]G\$,[#HOI=.&*2K\MRQ6)TJK'=>;I
MU BNO9Q1]OA'_GES$1F2$C>*L3/>,1YYO&;[E8:Q%5-AZ+8:BD/@D4DV7U@3
M/-R2LXAZ_%:R6-!>?,D$=\YU#=X[XH=NF4W4K7<Z$J_ENERP.J.A(7.Z]<2*
MX1RC#N)N,[_M>G WW6]J(\>Z8N7&,Q/A,L43E,=N)Z.'1RW8S^CHI'1X-_>_
M:QRX^6R6]9+L]FD%4?M#OW.%#4"IHB5BO[*@GW"7Y/RQX3T=+,1F57B1FPVS
M<D]@458Q&SWOL2$EGZ@:-\9S#0U=5T,=+]1>48RZEZ JK21HQ=/]8= 'AM2Y
M"""@ &32M.62,G<2WBDY+TV+K3S27?R=W+8)D>N->''JPWF4YG"OJ\[LF&6!
MW4QV/8:3(S&M1%1H/"\O"'?6 !-I5QCE1,1$=OD;V4'#]0M=Q_)$X2XW91JE
MH%R'BJ7.SB-,?,*:=?X(ZPE\MK[7IE)3;G[#Y_#DN*.D3K4\QR7V'^8P0JOY
M1E_<F7/W6X[[#W>P,,YSG%(TB;9#"1!(Y"1B"$6/-C"^5[V!6L1UX*L'N:<H
M@;:5IZ1]W?K/?J<V%TS@@XRUK0R%E!.>]TO(Q_!OU9LJ*\065^2_;M)DQ9)T
MN.6SZ>;#*"406)082C6F#4"O=\*IO54>$+#>(>R/\_59Z)^,'J5:O4\ZFY'7
MH%VS]<3^:8J#8$"_)DTI_^"ZI9C144LN(^B9!R':6+\U2\\<KJ<8CIA%HQ45
M*<]0Y5Y$2VE\34-5Q>')QC6: 6$PK["%,!AUZ>S2!#D\?[%+0W*B2-I 34<
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M\]<(CJ%Y27*VO-5E049O=L7N1?*9'GF;D9\K7KF272S5_V06@RG,R6[[]'[
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M[$/!W--,V;.#H>:>YS7S'K#_V#Y?.!@XF%2(-[KRM$ VR.I6IF&JGY\$H78
M$04_I"P2>&<E;6SY<N@2S:%OQ7IG]=.ZQ\YD=Y>=EV54]/4J>=F3A^4538UJ
MT())/CEM=V=%TV,CA*+^T&>-2F*)382>VSGR%"T#E5#2:#W9X3?<(AE6JSF(
MKTQ(=H[SG[E?F)_"2Y)9TKS[YJB4;/QKI,OYI?Y;,38/,L(;.O*.)1O05_"L
M2G$;Y;,P=UKL=X_$U!>#KRWCYDR;[P7;<O8I10MI2^N2+0*W!7Z87QOGUHC-
M:; _^&';X'F4>FQAGR:_SNW[;RB,%>87+C0!<GE9L,6.1W=1T< U5XV.4[,K
MRY<+5XNG0\O%MOWOG%5Z?+6O5S,ZH>Z.#$O,_<>]M;?8'QMU\7+(>.E<O!D!
M#83/,BH,=2Y LI):B0MXD>VK6T^ QXR:E0>-CYP[RJ>PUV!\HDVLRZR+OXE;
M\T:?WI4_+IHO\RX+G]'M8MP/U_X3U G\#P;"43UZ::F':%4!QW/FT&T*J7B-
M(1ED#7=9OHNOB<S\0X-*,4<+/:):VF$G\W?V#B:"F@8FP_QX9+X&"+RKP\6A
M:3^F+N)^'$*#0#$?H\V]0]NTMR"PB*%P0!*70&#O$6-! ?==LF1N$024Y%M+
M]O8Y@L!*&,,<$% )0@G#*4MU:JCO)^ @<(_A5>N[)U88M\'VZ!#%0> W<Q#8
MG688COJ*0+3UT ,\8A"[^WM 8)AQ_QV2_G27KHO:Z@^, (&O9U'T*D;_IGYP
M#A.]0" M9<Z4_GLY"&PW,-8VF$8SC68:S32::333:*;13*.91O_?8W0U8GZ:
MUE(GBY*FQT_L438=:@+L%*A..Y$>=QV$ILP2&P9?=AT6/I:<:[:4YMSY^LN+
M1P8<B7=9%FY59BSBD9F+?T^=A]8K<=/&B':_+$7'#PJ6000^6DB@#ZN-PR[.
M7^7E:)Q1OY"IQUS^X^OL.;D6V^;?+-HU#WH"!XK> (PUI1 <<[R81C.-9AK-
M-)II---HIM%,HYE&_Q1&>S^H$T%]280GP#O77^U9;89DE:=.68X%X=XF>JPN
MN[5]R&[Y^F&CU]BTW>4A7_70T:'D*).Z!('?WYUA?#BM8O^_66_FL@X"QW=!
MH/(ZP8-F5O0"!"R)C*X-"M/9]D#@&)U,HDT&*Y'\'I%8_?PD31T":JIM5^Z9
MB!?9?E&2T!&?ODI1U;_K^6:W[=:,1;.>JIB3\8_)14B+Z10T IJ!O"#PJ9;Q
MA1L#N3 0,-O[:Y3V:W];WYM?;Y_:C?D WVWYUQ"=01Q!K4L&FX# 0&0Z" S!
M_QJCWV/)BB#@CR16TK/<6.FE?]T>\.-@8OT4M6,J'K?-[X3:COY?(R10=PH$
M)JUI12"0QZT* H7!?XW1/L$-/SJ1-.^Q=WL,MF?[KP$Z)AF"(R7BQ%'+ZE^A
M\8']:WR8!C,-9AK,-)AI,--@IL%,@YD&_P0&#[*# +R$K(=H\9@_O^F8AUS)
MH79@D:KP$2L0T!PPYY&T:PG1NB:R+$>8Z?QH=(0S*C.%8.(J\SA2U_!6M,\@
MXY*9"A$0^-,(!,8+:[;^NHK'&P36L<LEC!OKJ']?9R9C=TBWO]'OH)0(7\G3
MU5OGW6HKZGX# ;G5J=L$'OK!FP]SG?P0CP>^N:R(/+NIK>NRE+<R>?M6[B:%
MPZ= HAYJQ0OW'W]B_^.&F&DPTV"FP4R#F08S#68:S#28:?#_N\'Y\L2KHQ^L
MO$#@^$%RSG#5&#:?YMM(D:C9<3ODX_N'S->9C?'\4%&'T_DY";=^EU[:Y\-V
M_PAC29=Z\-\L7?[H!P+/@E#C;TGR]$LF32!01&$LI+-%DV\E[KU:[YBB68S
M2:_J&4\%RJ]_LE/53. ? H92T!L5K%0_6#."9O76D;Z1L@+]HN5!5M/;PW;@
MX)LHDAZ=6IS/$)VJ^[NS1=';0: JV3>1+F\3 @)/]TM"S08]5_HY^L4$_B-
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MTB]W2X/ $YUMZ*=L>=K%'#K>?@I-QE%S0"!HV)@A[#'U=W=K0=FC)G04M4&
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MCT_H'+8SGIYTQ$2Z2)OIU-\2S9*NC->YX LXQ5S'84D6NR#PE0/>WD%'+?:
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M9L\)3ALG)JLP(I:&,[?QT[09?6 4H_GA&.491WV 4?4U^O+X[&AZ/,%<JSD
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MBAL>9!L@]HT7U54YAGUB[YK%S2SORK9;9QQ17[/(U2XX 2E7!B05CKE PPT
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M-OM3<8'YV17"\RDLX9>)?K[&2X]NY5GIT\DLRW .U24
M                                            @/\5</M_4$L! A0#
M%     @ #HKV6#@:QW7X$0  C[D  !$              ( !     &%B:6\M
M,C R-# S,S$N>'-D4$L! A0#%     @ #HKV6";95A\^"P  5'X  !4
M         ( !)Q(  &%B:6\M,C R-# S,S%?8V%L+GAM;%!+ 0(4 Q0    (
M  Z*]EB9Z#X"X3X  ,3J P 5              "  9@=  !A8FEO+3(P,C0P
M,S,Q7V1E9BYX;6Q02P$"% ,4    "  .BO98EOW\R'^/   H#0< %0
M        @ &L7   86)I;RTR,#(T,#,S,5]L86(N>&UL4$L! A0#%     @
M#HKV6% N[F^W/@  C L$ !4              ( !7NP  &%B:6\M,C R-# S
M,S%?<')E+GAM;%!+ 0(4 Q0    (  Z*]ECY &:N7,0-  XIMP 0
M      "  4@K 0!E83 R,#4Q,C(M,#8N:'1M4$L! A0#%     @ #HKV6(T,
M4S!\ P  9@T  !H              ( !TN\. &5A,#(P-3$R,C V97@R,RTQ
M7V%R8V$N:'1M4$L! A0#%     @ #HKV6+;D(K7N 0  T@0  !H
M     ( !AO,. &5A,#(P-3$R,C V97@R,RTR7V%R8V$N:'1M4$L! A0#%
M  @ #HKV6.2_EBIA"@  )RD  !D              ( !K/4. &5A,#(P-3$R
M,C V97@U+3%?87)C82YH=&U02P$"% ,4    "  .BO98 '&UN/\,   G-
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M7S P,2YJ<&=02P$"% ,4    "  .BO98TQ%2ZJ(L# #%"PX #@
M    @ %5+Q4 =&EM86=E7S P,BYJ<&=02P$"% ,4    "  .BO9842VJXU]
M @#_H , #@              @ $C7"$ =&EM86=E7S P,RYJ<&=02P$"% ,4
M    "  .BO98"4^51N&E P!;X00 #@              @ &NG", =&EM86=E
M7S P-"YJ<&=02P$"% ,4    "  .BO98(9V6[#]* 0"5V0$ #@
M    @ &[0B< =&EM86=E7S P-2YJ<&=02P$"% ,4    "  .BO98"<81J6+E
M P KT 0 #@              @ $FC2@ =&EM86=E7S P-BYJ<&=02P$"% ,4
M    "  .BO98DT"^/ B# P 'Z@0 #@              @ &T<BP =&EM86=E
M7S P-RYJ<&=02P$"% ,4    "  .BO98TD>?/B)I  !'<P  #@
M    @ 'H]2\ =&QU8VED7W-I9RYJ<&=02P$"% ,4    "  .BO985QH>R>YK
M 0"O?0$ #P              @ $V7S  =&]R=6MA7VQO9V\N:G!G4$L! A0#
M%     @ #HKV6. GWRYP+!@ BE4>  X              ( !4<LQ '1P<F]X
M>5\P,#$N:G!G4$L! A0#%     @ #HKV6,RQ$'+*]@H DO<1  X
M     ( ![?=) '1P<F]X>5\P,#(N:G!G4$L%!@     7 !< O@4  ./N5
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>ea0205122-06_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:abio="http://www.arcabiopharma.com/20240331"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="abio-20240331.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">abio:ClinicalDevelopmentDecisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-11-30</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2020-08-29</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-29</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">abio:UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:PatentAssignmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-22</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-22</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-10</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abio:IncentiveStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abio:IncentiveStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndThirteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abio:TwoThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">abio:FirstThreePercentPayContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">abio:NextTwoPercentPayContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:EarliestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:CapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:JonesTradingInstitutionalServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:NewCapitalOnDemandSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">abio:ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:FirstMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:ArcaBiopharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:FirstMergerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:OrukaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abio:CommonStockAndPreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">abio:OrukaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SeperationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:PresidentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SecondAmendmentOfCertainRetentionBonusLettersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-20</startDate>
            <endDate>2024-04-20</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abio:SecondAmendmentOfCertainRetentionBonusLettersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-20</startDate>
            <endDate>2024-04-20</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abio:ThomasAKeuerAndCJeffreyDekkerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-20</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-32">ARCA BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-42">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-160">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-173">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-188">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentDescription contextRef="c0" id="ixv-459">The issuances of (i)&#160;all shares of ARCA common stock in exchange for each share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre-closing financing), (ii)&#160;all shares of ARCA common stock issuable upon exercise of pre-funded warrants issued in exchange for pre-funded warrants to purchase shares of Oruka common stock sold in the Oruka pre-closing financing, and (iii)&#160;all shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for each share of Oruka preferred stock, are intended to be covered by this registration statement on Form&#160;S-4 of which the accompanying proxy statement/prospectus is a part. There is no difference between the shares of ARCA common stock that will be issued in exchange for each share of Oruka common stock issued in the pre-closing financing, the shares of ARCA common stock that will be issued in exchange for each other share of Oruka common stock, the shares of ARCA common stock that will be issuable upon the exercise of pre-funded warrants that will be issued in exchange for pre-funded warrants to purchase shares of Oruka common stock sold in the pre-closing financing and the shares of ARCA common stock that will be issuable upon conversion of ARCA Series&#160;B Preferred Stock that will be issued in exchange for each share of Oruka preferred stock.</dei:AmendmentDescription>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="-3" id="ixv-37899" unitRef="usd">37431000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-37900" unitRef="usd">42445000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent contextRef="c1" decimals="-3" id="ixv-37901" unitRef="usd">161000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c2" decimals="-3" id="ixv-37902" unitRef="usd">254000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="-3" id="ixv-37903" unitRef="usd">37592000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" id="ixv-37904" unitRef="usd">42699000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="-3" id="ixv-37905" unitRef="usd">247000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-37906" unitRef="usd">343000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="-3" id="ixv-37907" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" id="ixv-37908" unitRef="usd">25000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c1" decimals="-3" id="ixv-37909" unitRef="usd">12000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c2" decimals="-3" id="ixv-37910" unitRef="usd">18000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c1" decimals="-3" id="ixv-37911" unitRef="usd">37861000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c2" decimals="-3" id="ixv-37912" unitRef="usd">43085000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c1" decimals="-3" id="ixv-37913" unitRef="usd">362000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="-3" id="ixv-37914" unitRef="usd">334000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-37915" unitRef="usd">100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-37916" unitRef="usd">173000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-37917" unitRef="usd">0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-37918" unitRef="usd">216000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-37919" unitRef="usd">175000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-37920" unitRef="usd">625000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-37921" unitRef="usd">637000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-37922" unitRef="usd">1132000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="-3" id="ixv-37923" unitRef="usd">204000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" id="ixv-37924" unitRef="usd">280000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c1" decimals="-3" id="ixv-37925" unitRef="usd">841000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c2" decimals="-3" id="ixv-37926" unitRef="usd">1412000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="INF"
      id="ixv-37927"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="INF"
      id="ixv-37928"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-37929"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-37930"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ixv-37931"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-37932"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-37933"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-37934"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="INF"
      id="ixv-37935"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="INF"
      id="ixv-37936"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-37937"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-37938"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ixv-37939"
      unitRef="shares">14501143</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-37940"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-37941"
      unitRef="shares">14410143</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-37942"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c1" decimals="-3" id="ixv-37943" unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" id="ixv-37944" unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c1" decimals="-3" id="ixv-37945" unitRef="usd">225747000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c2" decimals="-3" id="ixv-37946" unitRef="usd">225061000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="-3" id="ixv-37947" unitRef="usd">-188741000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" id="ixv-37948" unitRef="usd">-183402000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-37949" unitRef="usd">37020000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-37950" unitRef="usd">41673000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="-3" id="ixv-37951" unitRef="usd">37861000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" id="ixv-37952" unitRef="usd">43085000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-37953" unitRef="usd">6283000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-37954" unitRef="usd">5847000</us-gaap:GeneralAndAdministrativeExpense>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c8" decimals="-3" id="ixv-37955" unitRef="usd">-91000</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c9" decimals="-3" id="ixv-37956" unitRef="usd">432000</abio:ResearchAndDevelopmentExpenseReversed>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-37957" unitRef="usd">1013000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-37958" unitRef="usd">4749000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="c6" decimals="-3" id="ixv-37959" unitRef="usd">7296000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c7" decimals="-3" id="ixv-37960" unitRef="usd">10596000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="-3" id="ixv-37961" unitRef="usd">-7296000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="-3" id="ixv-37962" unitRef="usd">-10596000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome contextRef="c6" decimals="-3" id="ixv-37963" unitRef="usd">1957000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c7" decimals="-3" id="ixv-37964" unitRef="usd">675000</us-gaap:InterestAndOtherIncome>
    <us-gaap:OtherNonoperatingExpense contextRef="c7" decimals="-3" id="ixv-37965" unitRef="usd">5000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-37966" unitRef="usd">-5339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-37967" unitRef="usd">-9926000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-37968"
      unitRef="usdPershares">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-37969"
      unitRef="usdPershares">-0.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="0"
      id="ixv-37970"
      unitRef="shares">14415877</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="0"
      id="ixv-37971"
      unitRef="shares">14410143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c13"
      decimals="0"
      id="ixv-37972"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c13" decimals="-3" id="ixv-37973" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c14" decimals="-3" id="ixv-37974" unitRef="usd">224505000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" id="ixv-37975" unitRef="usd">-173476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" id="ixv-37976" unitRef="usd">51043000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c18" decimals="-3" id="ixv-37977" unitRef="usd">556000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c7" decimals="-3" id="ixv-37978" unitRef="usd">556000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c19" decimals="-3" id="ixv-37979" unitRef="usd">-9926000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-37980" unitRef="usd">-9926000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20"
      decimals="0"
      id="ixv-37981"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-37982" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" id="ixv-37983" unitRef="usd">225061000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" id="ixv-37984" unitRef="usd">-183402000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-37985" unitRef="usd">41673000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c23"
      decimals="0"
      id="ixv-37986"
      unitRef="shares">91000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c24" decimals="-3" id="ixv-37987" unitRef="usd">686000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c6" decimals="-3" id="ixv-37988" unitRef="usd">686000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c25" decimals="-3" id="ixv-37989" unitRef="usd">-5339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-37990" unitRef="usd">-5339000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c26"
      decimals="0"
      id="ixv-37991"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" id="ixv-37992" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" id="ixv-37993" unitRef="usd">225747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="-3" id="ixv-37994" unitRef="usd">-188741000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-37995" unitRef="usd">37020000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-37996" unitRef="usd">-5339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-37997" unitRef="usd">-9926000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c6" decimals="-3" id="ixv-37998" unitRef="usd">15000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c7" decimals="-3" id="ixv-37999" unitRef="usd">20000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c6" decimals="-3" id="ixv-38000" unitRef="usd">96000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c7" decimals="-3" id="ixv-38001" unitRef="usd">94000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="-3" id="ixv-38002" unitRef="usd">686000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="-3" id="ixv-38003" unitRef="usd">556000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c7" decimals="-3" id="ixv-38004" unitRef="usd">-5000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c6" decimals="-3" id="ixv-38005" unitRef="usd">-93000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c7" decimals="-3" id="ixv-38006" unitRef="usd">-808000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c6" decimals="-3" id="ixv-38007" unitRef="usd">-6000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c6" decimals="-3" id="ixv-38008" unitRef="usd">28000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c7" decimals="-3" id="ixv-38009" unitRef="usd">-783000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c6" decimals="-3" id="ixv-38010" unitRef="usd">-73000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c7" decimals="-3" id="ixv-38011" unitRef="usd">-752000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c6" decimals="-3" id="ixv-38012" unitRef="usd">-526000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c7" decimals="-3" id="ixv-38013" unitRef="usd">-934000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c6" decimals="-3" id="ixv-38014" unitRef="usd">-5014000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="-3" id="ixv-38015" unitRef="usd">-10912000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c7" decimals="-3" id="ixv-38016" unitRef="usd">2000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c7" decimals="-3" id="ixv-38017" unitRef="usd">-2000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c6" decimals="-3" id="ixv-38018" unitRef="usd">-5014000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c7" decimals="-3" id="ixv-38019" unitRef="usd">-10914000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-38020" unitRef="usd">42445000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c16" decimals="-3" id="ixv-38021" unitRef="usd">53359000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="-3" id="ixv-38022" unitRef="usd">37431000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-38023" unitRef="usd">42445000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c6" id="ixv-21138">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(1)&#160;ARCA and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA biopharma, Inc. (&#x201c;ARCA&#x201d;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical&lt;span class="nobreak"&gt;-stage&lt;/span&gt; biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#x2019;s lead product candidate is Gencaro&#x2122; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#x201c;AF&#x201d;) in patients with chronic heart failure (&#x201c;HF&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp;amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#x2019;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#x2019;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the market price of ARCA&#x2019;s stock and the availability and cost of additional equity capital from existing and potential new investors;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to retain the listing of its common stock on the Nasdaq Capital Market;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#x2019; attack against Israel and the ensuing conflict;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to control costs associated with its operations;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the terms and conditions of ARCA&#x2019;s existing collaborative and licensing agreements.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#x2019;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#x2019;s capital stock and could contain covenants that would restrict ARCA&#x2019;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#x201c;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of ARCA&#x2019;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#x2019;s activities through the date of filing of the Annual Report on Form&#160;10&lt;span class="nobreak"&gt;-K&lt;/span&gt;.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accounting Estimates in the Preparation of Financial Statements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Cash Equivalents&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off&lt;span class="nobreak"&gt;-balance-sheet&lt;/span&gt; concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;property and equipment is depreciated using the straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non&lt;span class="nobreak"&gt;-owner&lt;/span&gt; sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#x2019; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA determines if an arrangement is a lease at inception. Operating leases are included in right&lt;span class="nobreak"&gt;-of-use&lt;/span&gt; (&#x201c;ROU&#x201d;) asset&#160;&#x2014;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#x2019;s December&#160;31, 2023 and 2022 balance sheets.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ROU lease assets represent ARCA&#x2019;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#x2019;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#x2019;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accrued Outsourcing Expenses&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#x2019;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Segments&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#x201c;CROs&#x201d;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre&lt;span class="nobreak"&gt;-approval&lt;/span&gt; of any changes in scope of the services to be performed. Certain significant vendors may also provide &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; awards on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the requisite service period for the entire award, as adjusted for expected forfeitures.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <abio:DescriptionOfBusinessPolicyTextBlock contextRef="c6" id="ixv-21141">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA biopharma, Inc. (&#x201c;ARCA&#x201d;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical&lt;span class="nobreak"&gt;-stage&lt;/span&gt; biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#x2019;s lead product candidate is Gencaro&#x2122; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#x201c;AF&#x201d;) in patients with chronic heart failure (&#x201c;HF&#x201d;).&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp;amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#x2019;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.&lt;/p&gt;</abio:DescriptionOfBusinessPolicyTextBlock>
    <abio:LiquidityAndGoingConcernPolicyTextBlock contextRef="c6" id="ixv-21149">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#x2019;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the market price of ARCA&#x2019;s stock and the availability and cost of additional equity capital from existing and potential new investors;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to retain the listing of its common stock on the Nasdaq Capital Market;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#x2019; attack against Israel and the ensuing conflict;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to control costs associated with its operations;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the terms and conditions of ARCA&#x2019;s existing collaborative and licensing agreements.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#x2019;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#x2019;s capital stock and could contain covenants that would restrict ARCA&#x2019;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&lt;/p&gt;</abio:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:Revenues contextRef="c6" decimals="INF" id="ixv-38024" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c6" id="ixv-21199">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#x201c;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of ARCA&#x2019;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#x2019;s activities through the date of filing of the Annual Report on Form&#160;10&lt;span class="nobreak"&gt;-K&lt;/span&gt;.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c6" id="ixv-21205">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c6" id="ixv-21210">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accounting Estimates in the Preparation of Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c6" id="ixv-21215">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c6" id="ixv-21220">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off&lt;span class="nobreak"&gt;-balance-sheet&lt;/span&gt; concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset contextRef="c1" decimals="INF" id="ixv-38025" unitRef="usd">0</us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c6" id="ixv-21226">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;property and equipment is depreciated using the straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <abio:ComprehensiveLossPolicyPolicyTextBlock contextRef="c6" id="ixv-21245">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non&lt;span class="nobreak"&gt;-owner&lt;/span&gt; sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#x2019; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.&lt;/p&gt;</abio:ComprehensiveLossPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c6" id="ixv-21251">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA determines if an arrangement is a lease at inception. Operating leases are included in right&lt;span class="nobreak"&gt;-of-use&lt;/span&gt; (&#x201c;ROU&#x201d;) asset&#160;&#x2014;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#x2019;s December&#160;31, 2023 and 2022 balance sheets.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ROU lease assets represent ARCA&#x2019;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#x2019;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#x2019;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <abio:AccruedOutsourcingExpensesPolicyTextBlock contextRef="c6" id="ixv-21260">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accrued Outsourcing Expenses&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#x2019;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.&lt;/p&gt;</abio:AccruedOutsourcingExpensesPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c6" id="ixv-21265">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments contextRef="c6" decimals="0" id="ixv-38026" unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c6" id="ixv-21270">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#x201c;CROs&#x201d;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre&lt;span class="nobreak"&gt;-approval&lt;/span&gt; of any changes in scope of the services to be performed. Certain significant vendors may also provide &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c6" id="ixv-21293">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; awards on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the requisite service period for the entire award, as adjusted for expected forfeitures.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c6" id="ixv-21301">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="c6" id="ixv-21306">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(2)&#160;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#x2019;s potentially dilutive shares include stock options and restricted stock units.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Potentially dilutive securities, excluded:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;704,960&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock units&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-70; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;795,960&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c6" id="ixv-38027">Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Potentially dilutive securities, excluded:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;704,960&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock units&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-70; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;795,960&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c62"
      decimals="0"
      id="ixv-38028"
      unitRef="shares">616707</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c63"
      decimals="0"
      id="ixv-38029"
      unitRef="shares">704960</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c65"
      decimals="0"
      id="ixv-38030"
      unitRef="shares">91000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c6"
      decimals="0"
      id="ixv-38031"
      unitRef="shares">616707</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c7"
      decimals="0"
      id="ixv-38032"
      unitRef="shares">795960</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c6" id="ixv-21371">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(3)&#160;Fair Value Disclosures&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#x201c;exit price&#x201d;). Inputs used to measure fair value are classified into the following hierarchy:&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 1 &#x2014;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#x2019;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 2 &#x2014;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA&#x2019;s Level 2 assets consist of corporate bonds and commercial paper securities. ARCA does not have any Level 2 liabilities.&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 3 &#x2014;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023 and 2022, ARCA had $37.4&#160;million and $42.4&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were &lt;span style="-sec-ix-hidden: hidden-fact-73"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-74"&gt;no&lt;/span&gt;&lt;/span&gt; transfers between any fair value hierarchy levels in 2023 or 2022.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Fair Value of Other Financial Instruments&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities. As of December&#160;31, 2023 and 2022, ARCA did &lt;span style="-sec-ix-hidden: hidden-fact-71"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-72"&gt;not&lt;/span&gt;&lt;/span&gt; have any debt outstanding.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c66" decimals="-5" id="ixv-38033" unitRef="usd">37400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c67" decimals="-5" id="ixv-38034" unitRef="usd">42400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c6" id="ixv-21392">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(4)&#160;Property and Equipment&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Property and equipment consist of the following (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Estimated&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lab equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Furniture and fixtures&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;44&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer software&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;229&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accumulated depreciation and amortization&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(212&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(204&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Property and equipment, net&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;For the&#160;years ended December&#160;31, 2023 and 2022, depreciation and amortization expense was $15,000 and $20,000, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c6" id="ixv-38035">Property and equipment consist of the following (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Estimated&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lab equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Furniture and fixtures&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;44&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer software&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;229&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accumulated depreciation and amortization&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(212&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(204&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Property and equipment, net&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c69" id="ixv-38036">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c69" decimals="-3" id="ixv-38037" unitRef="usd">39000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c70" decimals="-3" id="ixv-38038" unitRef="usd">39000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c71" id="ixv-38039">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c71" decimals="-3" id="ixv-38040" unitRef="usd">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c72" decimals="-3" id="ixv-38041" unitRef="usd">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c73" id="ixv-38042">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c73" decimals="-3" id="ixv-38043" unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c74" decimals="-3" id="ixv-38044" unitRef="usd">44000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c75" id="ixv-38045">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c75" decimals="-3" id="ixv-38046" unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c76" decimals="-3" id="ixv-38047" unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c1" decimals="-3" id="ixv-38048" unitRef="usd">222000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="-3" id="ixv-38049" unitRef="usd">229000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c1" decimals="-3" id="ixv-38050" unitRef="usd">212000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-38051" unitRef="usd">204000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="-3" id="ixv-38052" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" id="ixv-38053" unitRef="usd">25000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization contextRef="c6" decimals="-3" id="ixv-38054" unitRef="usd">15000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c7" decimals="-3" id="ixv-38055" unitRef="usd">20000</us-gaap:DepreciationAndAmortization>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c6" id="ixv-21552">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(5)&#160;Related Party Arrangements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Transactions with ARCA&#x2019;s President and Chief Executive Officer&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has entered into unrestricted research grants with its President and Chief Executive Officer&#x2019;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#x2019;s financial condition, and can be deferred or terminated at ARCA&#x2019;s discretion. Total expense under these arrangements for the&#160;years ended December&#160;31, 2023 and 2022 was $(91,000) and $432,000, respectively. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c77" decimals="0" id="ixv-38056" unitRef="usd">-91000</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c78" decimals="0" id="ixv-38057" unitRef="usd">432000</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:PaymentOfUnrestrictedResearchGrants contextRef="c79" decimals="0" id="ixv-38058" unitRef="usd">125000</abio:PaymentOfUnrestrictedResearchGrants>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c6" id="ixv-21565">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(6)&#160;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has or is subject to the following commitments and contingencies:&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Employment Agreements and Reduction of Workforce&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In December&#160;2022, ARCA&#x2019;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. As of December&#160;31, 2023, the unpaid retention bonuses totaled $311,000, none of which was accrued as of December&#160;31, 2023, since there had not been a change in control or clinical development decision.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA and Christopher D.&#160;Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#x2019;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#x2019;s existing employment agreement, as previously amended, ARCA will provide Mr.&#160;Ozeroff severance benefits pursuant to the terms of his existing employment agreement with ARCA, as previously amended. The severance benefits include severance payments and reimbursement to cover out&lt;span class="nobreak"&gt;-of-pocket&lt;/span&gt; costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out&lt;span class="nobreak"&gt;-of-pocket&lt;/span&gt; expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). During the year ended December&#160;31, 2023, ARCA recorded an expense of $159,000 for these severance benefits, &lt;span style="-sec-ix-hidden: hidden-fact-75"&gt;none&lt;/span&gt; of which remains unpaid.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In 2022, ARCA implemented a strategic reduction of the workforce by approximately 67%, or 12 employees. Personnel reductions were primarily focused in research and development and general and administrative functions. The restructuring was a result of ARCA&#x2019;s decision to manage operating costs and expenses. During the year ended December&#160;31, 2022, ARCA recorded total restructuring charges of approximately $755,000, of which $470,000 and $285,000 were recognized in research and development and general and administrative expenses, respectively, in connection with the restructuring, all in the form of one&lt;span class="nobreak"&gt;-time&lt;/span&gt; termination benefits, none of which remains unpaid.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Operating Lease&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On August&#160;29, 2020 ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as ARCA&#x2019;s primary business office effective October&#160;1, 2020 (&#x201c;October&#160;2020 Lease&#x201d;). The lease term is 42&#160;months beginning October&#160;1, 2020 and includes an option to renew for an additional 36&lt;span class="nobreak"&gt; &lt;/span&gt;month term at the then prevailing rental rate. The exercise of the lease renewal option is at ARCA&#x2019;s sole discretion. The amounts recorded assume ARCA will exercise its renewal option. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in its primary business office (&#x201c;2021 Lease&#x201d;). The sublease term was 29&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non&lt;span class="nobreak"&gt;-lease&lt;/span&gt; component that is not included in the lease obligation.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;93&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2025&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;96&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2026&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;100&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2027&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total remaining lease payments&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;314&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: imputed lease interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(34&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: Current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(76&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Operating lease liability, net of current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;204&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Rent expense, which is included in general and administrative expense, under these leases for the&#160;years ended December&#160;31, 2023 and 2022 was $119,000 and $125,000, respectively.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023, the lease liability was $280,000 and the current portion is included in accrued expenses and other liabilities and the non&lt;span class="nobreak"&gt;-current&lt;/span&gt; portion is in operating lease liability, net of current portion in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the&#160;years ended December&#160;31, 2023 and 2022 were $127,000 and $131,000, respectively. The weighted&lt;span class="nobreak"&gt;-average&lt;/span&gt; remaining lease term for the operating lease as of December&#160;31, 2023 is 3.2&#160;years. The weighted&lt;span class="nobreak"&gt;-average&lt;/span&gt; discount rate for the operating lease is 7%.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Patent Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In July&#160;2021, ARCA entered into a patent assignment agreement (the &#x201c;Agreement&#x201d;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Under the terms of the Agreement, ARCA received exclusive world&lt;span class="nobreak"&gt;-wide&lt;/span&gt; patent rights relating to the use of rNAPc2 as a potential treatment for COVID&lt;span class="nobreak"&gt;-19&lt;/span&gt;, and other indications, based on the research and discoveries from Univ.&lt;span class="nobreak"&gt;-Prof&lt;/span&gt;. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#x201c;CTH&#x201d;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#x20ac;1.6&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Gencaro License&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has licensed worldwide rights to all preclinical and clinical data through the BEST trial for development of bucindolol. The patents that were the subject of this license are expired. If the license agreement is deemed enforceable, ARCA would incur milestone and royalty obligations upon the occurrence of certain events, including if the FDA grants marketing approval for Gencaro, upon regulatory marketing approval in Europe and Japan and based on achievement of specified product sales levels.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <abio:RetentionBonuses contextRef="c80" decimals="0" id="ixv-38059" unitRef="usd">265000</abio:RetentionBonuses>
    <abio:PercentageOfRetentionBonuses contextRef="c81" decimals="2" id="ixv-38060" unitRef="pure">0.50</abio:PercentageOfRetentionBonuses>
    <abio:RetentionBonusPaid contextRef="c6" decimals="0" id="ixv-38061" unitRef="usd">86000</abio:RetentionBonusPaid>
    <abio:RetentionBonuses contextRef="c1" decimals="0" id="ixv-38062" unitRef="usd">311000</abio:RetentionBonuses>
    <us-gaap:SeveranceCosts1 contextRef="c6" decimals="0" id="ixv-38063" unitRef="usd">159000</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c7" decimals="2" id="ixv-38064" unitRef="pure">0.67</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated contextRef="c7" decimals="0" id="ixv-38065" unitRef="pure">12</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringCharges contextRef="c82" decimals="0" id="ixv-38066" unitRef="usd">755000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c83" decimals="0" id="ixv-38067" unitRef="usd">470000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c84" decimals="0" id="ixv-38068" unitRef="usd">285000</us-gaap:RestructuringCharges>
    <us-gaap:AreaOfRealEstateProperty contextRef="c85" decimals="0" id="ixv-38069" unitRef="sqft">5200</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c85" id="ixv-38070">P42M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="c86" id="ixv-21582">option to renew for an additional 36 month term at the then prevailing rental rate.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c85" id="ixv-38071">P36M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities contextRef="c87" decimals="0" id="ixv-38072" unitRef="sqft">3000</abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities>
    <abio:LesseeOperatingSubleaseTermOfContract contextRef="c88" id="ixv-38073">P29M</abio:LesseeOperatingSubleaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent contextRef="c6" id="ixv-21584">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.</us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c6" id="ixv-38074">Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;93&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2025&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;96&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2026&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;100&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2027&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;25&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total remaining lease payments&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;314&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: imputed lease interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(34&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: Current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(76&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Operating lease liability, net of current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;204&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c1" decimals="-3" id="ixv-38075" unitRef="usd">93000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c1" decimals="-3" id="ixv-38076" unitRef="usd">96000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c1" decimals="-3" id="ixv-38077" unitRef="usd">100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c1" decimals="-3" id="ixv-38078" unitRef="usd">25000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c1" decimals="-3" id="ixv-38079" unitRef="usd">314000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c1" decimals="-3" id="ixv-38080" unitRef="usd">34000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="-3" id="ixv-38081" unitRef="usd">76000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="-3" id="ixv-38082" unitRef="usd">204000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost contextRef="c89" decimals="0" id="ixv-38083" unitRef="usd">119000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c90" decimals="0" id="ixv-38084" unitRef="usd">125000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseLiability contextRef="c1" decimals="0" id="ixv-38085" unitRef="usd">280000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments contextRef="c6" decimals="0" id="ixv-38086" unitRef="usd">127000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c7" decimals="0" id="ixv-38087" unitRef="usd">131000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c1" id="ixv-38088">P3Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c1" decimals="2" id="ixv-38089" unitRef="pure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations contextRef="c91" decimals="-5" id="ixv-38090" unitRef="eur">1600000</abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c6" id="ixv-21695">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(7)&#160;Equity Financings&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;At the Market Equity Financing&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On July&#160;22, 2020, ARCA entered into a Capital on Demand&lt;span class="Superscript" style="vertical-align:super;font-size:58%;"&gt;TM&lt;/span&gt; Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with JonesTrading Institutional Services LLC, as agent (&#x201c;JonesTrading&#x201d;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#x2019;s common stock, par value $0.001 per share (&#x201c;ARCA&#160;common stock&#x201d;), having an aggregate offering price of up to $54.0&#160;million (the &#x201c;Shares&#x201d;).&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Under the Sales Agreement, JonesTrading may sell the Shares by any method permitted by law and deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule&#160;415 promulgated under the Securities Act&#160;of&#160;1933, as amended, including sales made directly on or through the Nasdaq Capital Market, on any other existing trading market for ARCA common stock or to or through a market maker. In addition, under the amended Sales Agreement, JonesTrading may sell the Shares by any other method permitted by law, including in negotiated transactions. ARCA may instruct JonesTrading not to sell Shares if the sales cannot be effected at or above the price designated by ARCA from time to time.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a)&#160;the sale of all of the Shares subject to the Sales Agreement or (b)&#160;the termination of the Sales Agreement by JonesTrading or ARCA, as permitted therein.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA paid JonesTrading a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Shares and agreed to provide JonesTrading with customary indemnification and contribution rights. ARCA will also reimburse JonesTrading for certain specified expenses in connection with entering into the Sales Agreement.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;No sales were made in 2023 or 2022.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#x2019;s registration statement on Form&#160;S&lt;span class="nobreak"&gt;-3&lt;/span&gt; (No.&#160;333&lt;span class="nobreak"&gt;-254585&lt;/span&gt;). The amount available for the offering under the prospectus supplement is subject to the limitation of not selling a total value amount of shares exceeding more than one&lt;span class="nobreak"&gt;-third&lt;/span&gt; of ARCA&#x2019;s public float in any 12&lt;span class="nobreak"&gt;-month&lt;/span&gt; period.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c92"
      decimals="INF"
      id="ixv-38091"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell contextRef="c92" decimals="-5" id="ixv-38092" unitRef="usd">54000000</abio:CommonStockAuthorizedOfferingAmountUnderAgreementToSell>
    <abio:SellingCommissionPerAdditionalSharesSoldPercentage contextRef="c93" decimals="3" id="ixv-38093" unitRef="pure">0.03</abio:SellingCommissionPerAdditionalSharesSoldPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c94"
      decimals="0"
      id="ixv-38094"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c95"
      decimals="0"
      id="ixv-38095"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c6" id="ixv-21722">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(8)&#160;Share-based Compensation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Stock Plans&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s equity incentive plan, &lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;the 2020 Equity Incentive Plan &lt;/span&gt;(the &#x201c;Equity Plan&#x201d;),&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt; &lt;/span&gt;was approved by stockholders on December&#160;10, 2020. The maximum number of shares issuable under this plan is 1,167,425&lt;span class="nobreak"&gt; &lt;/span&gt;shares.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Equity Plan provides for the granting of stock options (including indexed options), restricted stock units, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, performance shares, performance units and deferred stock units. Under the Equity Plan, awards may be granted to employees, directors and consultants of ARCA, except for incentive stock options, which may be granted only to employees. As of December&#160;31, 2023, options to purchase 601,900&lt;span class="nobreak"&gt; &lt;/span&gt;shares with a weighted average exercise price of $3.45 per share were outstanding under the Equity Plan, and 459,718&lt;span class="nobreak"&gt; &lt;/span&gt;shares were reserved for future awards.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In general, the Equity Plan authorizes the grant of stock options that vest at rates set by the Board of Directors or the Compensation Committee thereof. Generally, stock options granted by ARCA under the equity incentive plans become exercisable ratably for a period of &lt;span style="-sec-ix-hidden: hidden-fact-97"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden: hidden-fact-98"&gt;four&lt;/span&gt;&#160;years from the date of grant and have a maximum term of &lt;span style="-sec-ix-hidden: hidden-fact-99"&gt;ten&lt;/span&gt;&#160;years. The exercise prices of stock options under the equity incentive plan generally meet the following criteria: the exercise price of incentive stock options must be at least 100% of the fair market value on the grant date and exercise price of options granted to 10% (or greater) stockholders must be at least 110% of the fair market value on the grant date.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In conjunction with the adoption of the Equity Plan, ARCA discontinued grants under the 2013 Plan, effective December&#160;10, 2020. As of December&#160;31, 2023, options to purchase 14,807&lt;span class="nobreak"&gt; &lt;/span&gt;shares with a weighted average exercise price of $57.73 per share were outstanding under the 2013 plan.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA did not grant options in 2023. ARCA granted options to purchase an aggregate of 60,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of ARCA common stock in the year ended December&#160;31, 2022. The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black&lt;span class="nobreak"&gt;-Scholes&lt;/span&gt; model with the following assumptions and had the following estimated weighted average grant date fair value per share:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected term&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected volatility&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;107&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Risk-free interest rate&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.56&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected dividend yield&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;0&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Weighted-average grant date fair value per share&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.87&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;A summary of ARCA&#x2019;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:&lt;/p&gt;
		&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in&#160;years)&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2021&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;904,123&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.59&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;60,000&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.31&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-76; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-77; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(259,163&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.74&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2022&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;704,960&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.62&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;8.29&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;18&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-78; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-79; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-80; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-81; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(88,253&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;11.68&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-82; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options exercisable&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;463,068&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.28&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.29&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-83; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options vested and expected to vest&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,661&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-84; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The aggregate intrinsic value in the table above represents the total intrinsic value, based on ARCA&#x2019;s closing price as of December&#160;31 of the respective year, which would have been received by the option holders had all the option holders with in&lt;span class="nobreak"&gt;-the-money&lt;/span&gt; options exercised as of that date. As of December&#160;31, 2023, the unrecognized compensation expense related to unvested options, excluding estimated forfeitures, was $367,000 which is expected to be recognized over a weighted average period of 1.1&#160;years. ARCA recognizes compensation costs for its share&lt;span class="nobreak"&gt;-based&lt;/span&gt; awards on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the requisite service period for the entire award, as adjusted for expected forfeitures.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA granted restricted stock units (&#x201c;RSUs&#x201d;) under the Equity Plan to employees during 2022. The fair value of RSU awards is the closing price of ARCA common stock on the date of the grant and is recognized as compensation expense on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the respective vesting period. The stock awards granted had a requisite service period of &lt;span style="-sec-ix-hidden: hidden-fact-100"&gt;one&lt;/span&gt; year.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Restricted Stock Units&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2021&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-85; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-86; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Vested and released&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-87; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-88; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-89; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-90; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-91; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-92; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Vested and released&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-93; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-94; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-95; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-96; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of December&#160;31, 2023, there was no unrecognized compensation cost related to unvested stock awards.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Non-cash Stock-based Compensation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non&lt;span class="nobreak"&gt;-cash&lt;/span&gt;, share&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;General and administrative&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;526&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;423&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;160&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;133&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;686&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;556&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA did not recognize any tax benefit related to employee stock&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation cost as a result of the full valuation allowance on its net deferred tax assets.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c96"
      decimals="INF"
      id="ixv-38096"
      unitRef="shares">1167425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c97"
      decimals="INF"
      id="ixv-38097"
      unitRef="shares">601900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c97"
      decimals="2"
      id="ixv-38098"
      unitRef="usdPershares">3.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c97"
      decimals="INF"
      id="ixv-38099"
      unitRef="shares">459718</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c100"
      decimals="INF"
      id="ixv-38100"
      unitRef="pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <abio:PercentageHoldingForStockOptionsExercisePrice
      contextRef="c98"
      decimals="INF"
      id="ixv-38101"
      unitRef="pure">0.10</abio:PercentageHoldingForStockOptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c101"
      decimals="INF"
      id="ixv-38102"
      unitRef="pure">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c102"
      decimals="INF"
      id="ixv-38103"
      unitRef="shares">14807</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c102"
      decimals="2"
      id="ixv-38104"
      unitRef="usdPershares">57.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c103"
      decimals="INF"
      id="ixv-38105"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <abio:PurchaseAggregateShares
      contextRef="c104"
      decimals="0"
      id="ixv-38106"
      unitRef="shares">60000</abio:PurchaseAggregateShares>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c6" id="ixv-21753">The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black&lt;span class="nobreak"&gt;-Scholes&lt;/span&gt; model with the following assumptions and had the following estimated weighted average grant date fair value per share:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected term&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected volatility&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;107&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Risk-free interest rate&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;3.56&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Expected dividend yield&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;0&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;%&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Weighted-average grant date fair value per share&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.87&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c6" id="ixv-38107">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c6" decimals="2" id="ixv-38108" unitRef="pure">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c6" decimals="4" id="ixv-38109" unitRef="pure">0.0356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c6" decimals="2" id="ixv-38110" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c6"
      decimals="2"
      id="ixv-38111"
      unitRef="usdPershares">1.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c6" id="ixv-38112">A summary of ARCA&#x2019;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in&#160;years)&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2021&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;904,123&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.59&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;60,000&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.31&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-76; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-77; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(259,163&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.74&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2022&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;704,960&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.62&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;8.29&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;18&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-78; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-79; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-80; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-81; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(88,253&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;11.68&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-82; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options exercisable&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;463,068&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;5.28&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.29&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-83; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options vested and expected to vest&#160;&#x2013;&#160;December&#160;31,&#160;2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,661&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-84; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c16"
      decimals="INF"
      id="ixv-38113"
      unitRef="shares">904123</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c16"
      decimals="2"
      id="ixv-38114"
      unitRef="usdPershares">5.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c7"
      decimals="INF"
      id="ixv-38115"
      unitRef="shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c7"
      decimals="2"
      id="ixv-38116"
      unitRef="usdPershares">2.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c7"
      decimals="INF"
      id="ixv-38117"
      unitRef="shares">259163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c7"
      decimals="2"
      id="ixv-38118"
      unitRef="usdPershares">4.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c2"
      decimals="INF"
      id="ixv-38119"
      unitRef="shares">704960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c2"
      decimals="2"
      id="ixv-38120"
      unitRef="usdPershares">5.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c7" id="ixv-38121">P8Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c2" decimals="-3" id="ixv-38122" unitRef="usd">18000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c6"
      decimals="INF"
      id="ixv-38123"
      unitRef="shares">88253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c6"
      decimals="2"
      id="ixv-38124"
      unitRef="usdPershares">11.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-38125"
      unitRef="shares">616707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-38126"
      unitRef="usdPershares">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c6" id="ixv-38127">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-38128"
      unitRef="shares">463068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-38129"
      unitRef="usdPershares">5.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c6" id="ixv-38130">P7Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-38131"
      unitRef="shares">616661</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-38132"
      unitRef="usdPershares">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c6" id="ixv-38133">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c105" decimals="0" id="ixv-38134" unitRef="usd">367000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c106" id="ixv-38135">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c6" id="ixv-38136">A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Restricted Stock Units&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2021&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-85; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-86; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Vested and released&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-87; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-88; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-89; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-90; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2022&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-91; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-92; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Vested and released&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(91,000&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2.21&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-93; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-94; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;RSUs outstanding&#160;&#x2013;&#160;December&#160;31, 2023&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-95; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-96; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c7"
      decimals="INF"
      id="ixv-38137"
      unitRef="shares">91000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c7"
      decimals="2"
      id="ixv-38138"
      unitRef="usdPershares">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c2"
      decimals="INF"
      id="ixv-38139"
      unitRef="shares">91000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c2"
      decimals="2"
      id="ixv-38140"
      unitRef="usdPershares">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c6"
      decimals="INF"
      id="ixv-38141"
      unitRef="shares">91000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c6"
      decimals="2"
      id="ixv-38142"
      unitRef="usdPershares">2.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="c108"
      decimals="INF"
      id="ixv-38143"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c6" id="ixv-22234">For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non&lt;span class="nobreak"&gt;-cash&lt;/span&gt;, share&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years Ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;General and administrative&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;526&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;423&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;160&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;133&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;686&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;556&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c89" decimals="-3" id="ixv-38144" unitRef="usd">526000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c90" decimals="-3" id="ixv-38145" unitRef="usd">423000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c109"
      decimals="-3"
      id="ixv-38146"
      unitRef="usd">160000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c110"
      decimals="-3"
      id="ixv-38147"
      unitRef="usd">133000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c6" decimals="-3" id="ixv-38148" unitRef="usd">686000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c7" decimals="-3" id="ixv-38149" unitRef="usd">556000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c6" id="ixv-22297">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(9)&#160;Employee Benefit Plans&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has a 401(k)&#160;plan and makes a matching contribution equal to 100% of the employee&#x2019;s first 3% of the employee&#x2019;s contributions and 50% of the employee&#x2019;s next 2% of contributions. ARCA adopted the plan in 2006 and contributed $56,000 and $96,000 for the&#160;years ended December&#160;31, 2023 and 2022, respectively.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans contextRef="c6" id="ixv-38150">matching contribution equal to 100% of the employee&#x2019;s first 3% of the employee&#x2019;s contributions and 50% of the employee&#x2019;s next 2% of contributions.</us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c111"
      decimals="INF"
      id="ixv-38151"
      unitRef="pure">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c111"
      decimals="2"
      id="ixv-38152"
      unitRef="pure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c112"
      decimals="2"
      id="ixv-38153"
      unitRef="pure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c112"
      decimals="2"
      id="ixv-38154"
      unitRef="pure">0.02</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c6" decimals="0" id="ixv-38155" unitRef="usd">56000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c7" decimals="0" id="ixv-38156" unitRef="usd">96000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c6" id="ixv-22301">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;(&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;10)&#160;Income Taxes&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Effective June&#160;1, 2005, ARCA changed from an S&lt;span class="nobreak"&gt;-Corporation&lt;/span&gt; to a C&lt;span class="nobreak"&gt;-Corporation&lt;/span&gt;. As an S&lt;span class="nobreak"&gt;-Corporation&lt;/span&gt;, the net operating loss carryforwards were distributed to ARCA&#x2019;s stockholders; such amounts were not significant. As of December&#160;31, 2023, ARCA has net operating loss carryforwards of approximately $208.1&#160;million, and approximately $2.4&#160;million of research and development credits that may be used to offset future taxable income. ARCA&#x2019;s net operating loss carryforwards through December&#160;31, 2017 will expire beginning &lt;span style="-sec-ix-hidden: hidden-fact-107"&gt;2025&lt;/span&gt; through &lt;span style="-sec-ix-hidden: hidden-fact-108"&gt;2037&lt;/span&gt;. The net operating loss carryforwards beginning in 2018, have no expiration. Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#x2019;s net operating loss carryforwards may be limited.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due primarily to ARCA&#x2019;s history of operating losses, management is unable to conclude that it is more likely than not that ARCA will realize the benefits of these deductible differences, and accordingly has provided a valuation allowance against the entire net deferred tax assets and liabilities of approximately $55.5&#160;million at December&#160;31, 2023, reflecting an increase of approximately $1.2&#160;million from December&#160;31, 2022. The deferred tax assets are primarily comprised of net operating loss carryforwards and research and experimentation credit carryforwards. As of December&#160;31, 2023, ARCA has not performed an Internal Revenue Code Section&#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. A limitation in the carryforwards would decrease the carrying amount of the gross amount of the net operating loss carryforwards, with a corresponding decrease in the valuation allowance recorded against these gross deferred tax assets.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Income tax benefit attributable to ARCA&#x2019;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of 21% for 2023 and 2022, as a result of the following (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;U.S.&#160;federal income tax benefit at statutory rates&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1,121&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2,085&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;State income tax benefit, net of federal benefit&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(192&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(357&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and experimentation credits&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-101; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-102; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax asset adjustment&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;47&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Other&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;107&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;186&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,159&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,254&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Income tax benefit&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-103; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-104; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#x2019;s net deferred tax assets and liabilities consisted of the following (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;As of December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax assets:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net operating loss carryforwards&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;51,190&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;50,008&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Charitable contribution carryforwards&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;371&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;393&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and experimentation credits&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,420&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,420&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Capitalized research and development costs&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;951&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;979&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Capitalized intangibles&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;354&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;356&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Stock-based compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;232&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;205&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lease liabilities&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;69&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;94&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total deferred tax assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;55,594&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;54,461&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(55,531&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(54,372&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;63&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;89&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax liabilities:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Right-of-use asset&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(61&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(84&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Depreciation and amortization&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(5&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net deferred tax liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Since ARCA is in a loss carryforward position, it is generally subject to U.S.&#160;federal and state income tax examinations by tax authorities for all&#160;years for which a loss carryforward is available. Thus, ARCA&#x2019;s open tax&#160;years extend back to &lt;span style="-sec-ix-hidden: hidden-fact-109"&gt;2009&lt;/span&gt;. ARCA believes that its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and does not anticipate any adjustment will result in a material adverse effect on ARCA&#x2019;s financial condition, result of operations, or cash flow. For the&#160;years ended December&#160;31, 2023 and 2022, ARCA has no reserve for uncertain tax positions. ARCA does not expect that the total amounts of unrecognized tax benefits will significantly increase or decrease within the subsequent twelve&#160;months. In the event ARCA concludes it is subject to interest or penalties arising from uncertain tax positions, it will record interest and penalties as a component of other income and expense. No interest or penalties were recognized in the financial statements for the&#160;years ended December&#160;31, 2023 and 2022.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards contextRef="c1" decimals="-5" id="ixv-38157" unitRef="usd">208100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="c113"
      decimals="-5"
      id="ixv-38158"
      unitRef="usd">2400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardDescription contextRef="c6" id="ixv-38159">The net operating loss carryforwards beginning in 2018, have no expiration.</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:TaxCreditCarryforwardLimitationsOnUse contextRef="c116" id="ixv-38160">Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#x2019;s net operating loss carryforwards may be limited.</us-gaap:TaxCreditCarryforwardLimitationsOnUse>
    <abio:DeferredTaxAssetsAndLiabilitiesValuationAllowance contextRef="c1" decimals="-5" id="ixv-38161" unitRef="usd">55500000</abio:DeferredTaxAssetsAndLiabilitiesValuationAllowance>
    <abio:ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount contextRef="c6" decimals="-5" id="ixv-38162" unitRef="usd">1200000</abio:ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c6" id="ixv-38163">Income tax benefit attributable to ARCA&#x2019;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of 21% for 2023 and 2022, as a result of the following (in thousands):&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Years ended&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;U.S.&#160;federal income tax benefit at statutory rates&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1,121&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2,085&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;State income tax benefit, net of federal benefit&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(192&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(357&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and experimentation credits&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-101; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-102; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax asset adjustment&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;47&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Other&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;107&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;186&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Change in valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1,159&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,254&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Income tax benefit&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-103; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-104; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c6" decimals="2" id="ixv-38164" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="2" id="ixv-38165" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c6" decimals="-3" id="ixv-38166" unitRef="usd">-1121000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="-3" id="ixv-38167" unitRef="usd">-2085000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c6" decimals="-3" id="ixv-38168" unitRef="usd">-192000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c7" decimals="-3" id="ixv-38169" unitRef="usd">-357000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset contextRef="c6" decimals="-3" id="ixv-38170" unitRef="usd">47000</abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset>
    <abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset contextRef="c7" decimals="-3" id="ixv-38171" unitRef="usd">2000</abio:IncomeTaxReconciliationAdjustmentToDeferredTaxAsset>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c6" decimals="-3" id="ixv-38172" unitRef="usd">107000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c7" decimals="-3" id="ixv-38173" unitRef="usd">186000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c6" decimals="-3" id="ixv-38174" unitRef="usd">1159000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c7" decimals="-3" id="ixv-38175" unitRef="usd">2254000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c6" id="ixv-38176">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#x2019;s net deferred tax assets and liabilities consisted of the following (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;As of December&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2022&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax assets:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net operating loss carryforwards&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;51,190&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;50,008&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Charitable contribution carryforwards&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;371&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;393&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and experimentation credits&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,420&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;2,420&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Capitalized research and development costs&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;951&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;979&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Capitalized intangibles&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;354&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;356&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Stock-based compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;232&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;205&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accrued compensation&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lease liabilities&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;69&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;94&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total deferred tax assets&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;55,594&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;54,461&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(55,531&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(54,372&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;63&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;89&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Deferred tax liabilities:&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Right-of-use asset&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(61&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(84&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Depreciation and amortization&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(2&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(5&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Net deferred tax liability&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c1" decimals="-3" id="ixv-38177" unitRef="usd">51190000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c2" decimals="-3" id="ixv-38178" unitRef="usd">50008000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="c1" decimals="-3" id="ixv-38179" unitRef="usd">371000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="c2" decimals="-3" id="ixv-38180" unitRef="usd">393000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c1" decimals="-3" id="ixv-38181" unitRef="usd">2420000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c2" decimals="-3" id="ixv-38182" unitRef="usd">2420000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <abio:DeferredTaxAssetResearchAndDevelopment contextRef="c1" decimals="-3" id="ixv-38183" unitRef="usd">951000</abio:DeferredTaxAssetResearchAndDevelopment>
    <abio:DeferredTaxAssetResearchAndDevelopment contextRef="c2" decimals="-3" id="ixv-38184" unitRef="usd">979000</abio:DeferredTaxAssetResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c1" decimals="-3" id="ixv-38185" unitRef="usd">354000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c2" decimals="-3" id="ixv-38186" unitRef="usd">356000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c1" decimals="-3" id="ixv-38187" unitRef="usd">232000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c2" decimals="-3" id="ixv-38188" unitRef="usd">205000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c1" decimals="-3" id="ixv-38189" unitRef="usd">7000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c2" decimals="-3" id="ixv-38190" unitRef="usd">6000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <abio:DeferredTaxAssetsLeaseLiabilities contextRef="c1" decimals="-3" id="ixv-38191" unitRef="usd">69000</abio:DeferredTaxAssetsLeaseLiabilities>
    <abio:DeferredTaxAssetsLeaseLiabilities contextRef="c2" decimals="-3" id="ixv-38192" unitRef="usd">94000</abio:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross contextRef="c1" decimals="-3" id="ixv-38193" unitRef="usd">55594000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c2" decimals="-3" id="ixv-38194" unitRef="usd">54461000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c1" decimals="-3" id="ixv-38195" unitRef="usd">55531000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c2" decimals="-3" id="ixv-38196" unitRef="usd">54372000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c1" decimals="-3" id="ixv-38197" unitRef="usd">63000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c2" decimals="-3" id="ixv-38198" unitRef="usd">89000</us-gaap:DeferredTaxAssetsNet>
    <abio:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c1" decimals="-3" id="ixv-38199" unitRef="usd">61000</abio:DeferredTaxLiabilitiesRightOfUseAsset>
    <abio:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-38200" unitRef="usd">84000</abio:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c1" decimals="-3" id="ixv-38201" unitRef="usd">2000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-38202" unitRef="usd">5000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="c1" decimals="INF" id="ixv-38203" unitRef="usd">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="c2" decimals="0" id="ixv-38204" unitRef="usd">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="c6" decimals="0" id="ixv-38205" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="c7" decimals="0" id="ixv-38206" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c5" decimals="-3" id="ixv-38207" unitRef="usd">35903000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="-3" id="ixv-38208" unitRef="usd">37431000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent contextRef="c5" decimals="-3" id="ixv-38209" unitRef="usd">767000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c1" decimals="-3" id="ixv-38210" unitRef="usd">161000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c5" decimals="-3" id="ixv-38211" unitRef="usd">36670000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="-3" id="ixv-38212" unitRef="usd">37592000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c5" decimals="-3" id="ixv-38213" unitRef="usd">17000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="-3" id="ixv-38214" unitRef="usd">247000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="-3" id="ixv-38215" unitRef="usd">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="-3" id="ixv-38216" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c5" decimals="-3" id="ixv-38217" unitRef="usd">12000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c1" decimals="-3" id="ixv-38218" unitRef="usd">12000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c5" decimals="-3" id="ixv-38219" unitRef="usd">36706000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c1" decimals="-3" id="ixv-38220" unitRef="usd">37861000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c5" decimals="-3" id="ixv-38221" unitRef="usd">529000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c1" decimals="-3" id="ixv-38222" unitRef="usd">362000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-38223" unitRef="usd">84000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-38224" unitRef="usd">100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-38225" unitRef="usd">968000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-38226" unitRef="usd">175000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-38227" unitRef="usd">1581000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-38228" unitRef="usd">637000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="-3" id="ixv-38229" unitRef="usd">204000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c5" decimals="-3" id="ixv-38230" unitRef="usd">1581000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c1" decimals="-3" id="ixv-38231" unitRef="usd">841000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c5"
      decimals="INF"
      id="ixv-38232"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="INF"
      id="ixv-38233"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c5"
      decimals="INF"
      id="ixv-38234"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-38235"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c5"
      decimals="INF"
      id="ixv-38236"
      unitRef="shares">14501143</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ixv-38237"
      unitRef="shares">14501143</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="ixv-38238"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-38239"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c5" decimals="-3" id="ixv-38240" unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c1" decimals="-3" id="ixv-38241" unitRef="usd">14000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c5" decimals="-3" id="ixv-38242" unitRef="usd">225861000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c1" decimals="-3" id="ixv-38243" unitRef="usd">225747000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c5" decimals="-3" id="ixv-38244" unitRef="usd">-190750000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="-3" id="ixv-38245" unitRef="usd">-188741000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-38246" unitRef="usd">35125000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-38247" unitRef="usd">37020000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c5" decimals="-3" id="ixv-38248" unitRef="usd">36706000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="-3" id="ixv-38249" unitRef="usd">37861000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-38250" unitRef="usd">2317000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c10" decimals="-3" id="ixv-38251" unitRef="usd">1406000</us-gaap:GeneralAndAdministrativeExpense>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c11" decimals="-3" id="ixv-38252" unitRef="usd">0</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c12" decimals="-3" id="ixv-38253" unitRef="usd">108000</abio:ResearchAndDevelopmentExpenseReversed>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-38254" unitRef="usd">165000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c10" decimals="-3" id="ixv-38255" unitRef="usd">390000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" id="ixv-38256" unitRef="usd">2482000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c10" decimals="-3" id="ixv-38257" unitRef="usd">1796000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-38258" unitRef="usd">-2482000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c10" decimals="-3" id="ixv-38259" unitRef="usd">-1796000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome contextRef="c0" decimals="-3" id="ixv-38260" unitRef="usd">473000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome contextRef="c10" decimals="-3" id="ixv-38261" unitRef="usd">450000</us-gaap:InterestAndOtherIncome>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-38262" unitRef="usd">-2009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="-3" id="ixv-38263" unitRef="usd">-1346000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-38264"
      unitRef="usdPershares">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c10"
      decimals="2"
      id="ixv-38265"
      unitRef="usdPershares">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="0"
      id="ixv-38266"
      unitRef="shares">14501143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c10"
      decimals="0"
      id="ixv-38267"
      unitRef="shares">14410143</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20"
      decimals="0"
      id="ixv-38268"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-38269" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" id="ixv-38270" unitRef="usd">225061000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" id="ixv-38271" unitRef="usd">-183402000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-38272" unitRef="usd">41673000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c30" decimals="-3" id="ixv-38273" unitRef="usd">204000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c10" decimals="-3" id="ixv-38274" unitRef="usd">204000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c31" decimals="-3" id="ixv-38275" unitRef="usd">-1346000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="-3" id="ixv-38276" unitRef="usd">-1346000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c32"
      decimals="0"
      id="ixv-38277"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="-3" id="ixv-38278" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="-3" id="ixv-38279" unitRef="usd">225265000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c34" decimals="-3" id="ixv-38280" unitRef="usd">-184748000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c35" decimals="-3" id="ixv-38281" unitRef="usd">40531000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c37" decimals="-3" id="ixv-38282" unitRef="usd">187000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c39" decimals="-3" id="ixv-38283" unitRef="usd">187000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c38" decimals="-3" id="ixv-38284" unitRef="usd">-1480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c39" decimals="-3" id="ixv-38285" unitRef="usd">-1480000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c40"
      decimals="0"
      id="ixv-38286"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c40" decimals="-3" id="ixv-38287" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c41" decimals="-3" id="ixv-38288" unitRef="usd">225452000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c42" decimals="-3" id="ixv-38289" unitRef="usd">-186228000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c43" decimals="-3" id="ixv-38290" unitRef="usd">39238000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c45" decimals="-3" id="ixv-38291" unitRef="usd">154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c47" decimals="-3" id="ixv-38292" unitRef="usd">154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c46" decimals="-3" id="ixv-38293" unitRef="usd">-1424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c47" decimals="-3" id="ixv-38294" unitRef="usd">-1424000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c48"
      decimals="0"
      id="ixv-38295"
      unitRef="shares">14410143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c48" decimals="-3" id="ixv-38296" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c49" decimals="-3" id="ixv-38297" unitRef="usd">225606000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c50" decimals="-3" id="ixv-38298" unitRef="usd">-187652000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c51" decimals="-3" id="ixv-38299" unitRef="usd">37968000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c52"
      decimals="0"
      id="ixv-38300"
      unitRef="shares">91000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c53" decimals="-3" id="ixv-38301" unitRef="usd">141000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c55" decimals="-3" id="ixv-38302" unitRef="usd">141000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c54" decimals="-3" id="ixv-38303" unitRef="usd">-1089000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c55" decimals="-3" id="ixv-38304" unitRef="usd">-1089000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c26"
      decimals="0"
      id="ixv-38305"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" id="ixv-38306" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" id="ixv-38307" unitRef="usd">225747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c28" decimals="-3" id="ixv-38308" unitRef="usd">-188741000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-38309" unitRef="usd">37020000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c57" decimals="-3" id="ixv-38310" unitRef="usd">114000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c0" decimals="-3" id="ixv-38311" unitRef="usd">114000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c58" decimals="-3" id="ixv-38312" unitRef="usd">-2009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-38313" unitRef="usd">-2009000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c59"
      decimals="0"
      id="ixv-38314"
      unitRef="shares">14501143</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c59" decimals="-3" id="ixv-38315" unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c60" decimals="-3" id="ixv-38316" unitRef="usd">225861000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c61" decimals="-3" id="ixv-38317" unitRef="usd">-190750000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-38318" unitRef="usd">35125000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-38319" unitRef="usd">-2009000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c10" decimals="-3" id="ixv-38320" unitRef="usd">-1346000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="-3" id="ixv-38321" unitRef="usd">3000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c10" decimals="-3" id="ixv-38322" unitRef="usd">4000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="-3" id="ixv-38323" unitRef="usd">16000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c10" decimals="-3" id="ixv-38324" unitRef="usd">25000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-38325" unitRef="usd">114000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c10" decimals="-3" id="ixv-38326" unitRef="usd">204000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c0" decimals="-3" id="ixv-38327" unitRef="usd">606000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c10" decimals="-3" id="ixv-38328" unitRef="usd">598000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="-3" id="ixv-38329" unitRef="usd">167000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c10" decimals="-3" id="ixv-38330" unitRef="usd">32000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c0" decimals="-3" id="ixv-38331" unitRef="usd">-16000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c10" decimals="-3" id="ixv-38332" unitRef="usd">62000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c0" decimals="-3" id="ixv-38333" unitRef="usd">803000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c10" decimals="-3" id="ixv-38334" unitRef="usd">22000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-38335" unitRef="usd">-1528000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c10" decimals="-3" id="ixv-38336" unitRef="usd">-1595000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-38337" unitRef="usd">-1528000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c10" decimals="-3" id="ixv-38338" unitRef="usd">-1595000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="-3" id="ixv-38339" unitRef="usd">37431000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-38340" unitRef="usd">42445000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="-3" id="ixv-38341" unitRef="usd">35903000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c35" decimals="-3" id="ixv-38342" unitRef="usd">40850000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-38343" unitRef="usd">214000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-24534">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(1)&#160;ARCA and Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA biopharma, Inc. (&#x201c;ARCA&#x201d;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#x2019;s lead product candidate is Gencaro&#x2122; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#x201c;AF&#x201d;) in patients with chronic heart failure (&#x201c;HF&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#x201c;Board&#x201d;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly&lt;span class="nobreak"&gt;-owned&lt;/span&gt; subsidiary of ARCA (&#x201c;Merger Sub&#160;I&#x201d;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly&lt;span class="nobreak"&gt;-owned&lt;/span&gt; subsidiary of ARCA (&#x201c;Merger Sub&#160;II&#x201d;) and Oruka Therapeutics, Inc., a Delaware corporation (&#x201c;Oruka&lt;span class="CharOverride-1" style="text-decoration:underline;"&gt;&#x201d;&lt;/span&gt;), entered into an Agreement and Plan of Merger and Reorganization (the &#x201c;Merger Agreement&#x201d;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#x201c;First Merger&#x201d;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#x201c;Second Merger&#x201d; and together with the First Merger, the &#x201c;Merger&#x201d;). The Merger is intended to qualify for federal income tax purposes as a tax&lt;span class="nobreak"&gt;-free&lt;/span&gt; reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time&lt;span class="nobreak"&gt;-consuming&lt;/span&gt; and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the timing and outcome of the strategic review process;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the consummation of any particular strategic transactions, including the Merger;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the market price of ARCA&#x2019;s stock and the availability and cost of additional equity capital from existing and potential new investors;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to retain the listing of its common stock on the Nasdaq Capital Market;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#x2019; attack against Israel and the ensuing conflict;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to control costs associated with its operations;&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the terms and conditions of ARCA&#x2019;s existing collaborative and licensing agreements.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#x2019;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#x2019;s capital stock and could contain covenants that would restrict ARCA&#x2019;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S&lt;span class="nobreak"&gt;-X&lt;/span&gt;.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#x201c;GAAP&#x201d;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off&lt;span class="nobreak"&gt;-balance-sheet&lt;/span&gt; concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non&lt;span class="nobreak"&gt;-owner&lt;/span&gt; sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#x2019; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA determines if an arrangement is a lease at inception. Operating leases are included in right&lt;span class="nobreak"&gt;-of-use&lt;/span&gt; (&#x201c;ROU&#x201d;) asset&#160;&#x2014;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#x2019;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ROU lease assets represent ARCA&#x2019;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#x2019;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#x2019;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#x2019;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accrued Outsourcing Expenses&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#x2019;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <abio:DescriptionOfBusinessPolicyTextBlock contextRef="c0" id="ixv-24537">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA biopharma, Inc. (&#x201c;ARCA&#x201d;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#x2019;s lead product candidate is Gencaro&#x2122; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#x201c;AF&#x201d;) in patients with chronic heart failure (&#x201c;HF&#x201d;).&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#x201c;Board&#x201d;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly&lt;span class="nobreak"&gt;-owned&lt;/span&gt; subsidiary of ARCA (&#x201c;Merger Sub&#160;I&#x201d;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly&lt;span class="nobreak"&gt;-owned&lt;/span&gt; subsidiary of ARCA (&#x201c;Merger Sub&#160;II&#x201d;) and Oruka Therapeutics, Inc., a Delaware corporation (&#x201c;Oruka&lt;span class="CharOverride-1" style="text-decoration:underline;"&gt;&#x201d;&lt;/span&gt;), entered into an Agreement and Plan of Merger and Reorganization (the &#x201c;Merger Agreement&#x201d;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#x201c;First Merger&#x201d;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#x201c;Second Merger&#x201d; and together with the First Merger, the &#x201c;Merger&#x201d;). The Merger is intended to qualify for federal income tax purposes as a tax&lt;span class="nobreak"&gt;-free&lt;/span&gt; reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.&lt;/p&gt;</abio:DescriptionOfBusinessPolicyTextBlock>
    <abio:LiquidityAndGoingConcernPolicyTextBlock contextRef="c0" id="ixv-24552">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time&lt;span class="nobreak"&gt;-consuming&lt;/span&gt; and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA&#x2019;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the timing and outcome of the strategic review process;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the consummation of any particular strategic transactions, including the Merger;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the market price of ARCA&#x2019;s stock and the availability and cost of additional equity capital from existing and potential new investors;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to retain the listing of its common stock on the Nasdaq Capital Market;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#x2019; attack against Israel and the ensuing conflict;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;ARCA&#x2019;s ability to control costs associated with its operations;&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and&lt;/p&gt;&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;the terms and conditions of ARCA&#x2019;s existing collaborative and licensing agreements.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#x2019;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#x2019;s capital stock and could contain covenants that would restrict ARCA&#x2019;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.&lt;/p&gt;</abio:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:Revenues contextRef="c0" decimals="INF" id="ixv-38344" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-24614">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S&lt;span class="nobreak"&gt;-X&lt;/span&gt;.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#x201c;GAAP&#x201d;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-24634">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off&lt;span class="nobreak"&gt;-balance-sheet&lt;/span&gt; concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset contextRef="c5" decimals="INF" id="ixv-38345" unitRef="usd">0</us-gaap:FairValueDisclosureOffbalanceSheetRisksAmountAsset>
    <abio:ComprehensiveLossPolicyPolicyTextBlock contextRef="c0" id="ixv-24640">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non&lt;span class="nobreak"&gt;-owner&lt;/span&gt; sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#x2019; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.&lt;/p&gt;</abio:ComprehensiveLossPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-24646">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA determines if an arrangement is a lease at inception. Operating leases are included in right&lt;span class="nobreak"&gt;-of-use&lt;/span&gt; (&#x201c;ROU&#x201d;) asset&#160;&#x2014;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#x2019;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ROU lease assets represent ARCA&#x2019;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#x2019;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#x2019;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#x2019;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight&lt;span class="nobreak"&gt;-line&lt;/span&gt; basis over the lease term.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <abio:AccruedOutsourcingExpensesPolicyTextBlock contextRef="c0" id="ixv-24655">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Accrued Outsourcing Expenses&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#x2019;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#x2019;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.&lt;/p&gt;</abio:AccruedOutsourcingExpensesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-24660">&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0" id="ixv-24673">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(2)&#160;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#x2019;s potentially dilutive shares include stock options and restricted stock units.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;March&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2024&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Potentially dilutive securities, excluded:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;664,857&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock units&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-110; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;755,857&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-38346">Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;March&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2024&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Potentially dilutive securities, excluded:&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Outstanding stock options&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;664,857&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Unvested restricted stock units&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-110; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;91,000&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;755,857&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c117"
      decimals="0"
      id="ixv-38347"
      unitRef="shares">645845</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c118"
      decimals="0"
      id="ixv-38348"
      unitRef="shares">664857</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c120"
      decimals="0"
      id="ixv-38349"
      unitRef="shares">91000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="0"
      id="ixv-38350"
      unitRef="shares">645845</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c10"
      decimals="0"
      id="ixv-38351"
      unitRef="shares">755857</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0" id="ixv-24730">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(3)&#160;Fair Value Disclosures&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;There were &lt;span style="-sec-ix-hidden: hidden-fact-111"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-112"&gt;no&lt;/span&gt;&lt;/span&gt; marketable securities as of March&#160;31, 2024 or December&#160;31, 2023.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#x201c;exit price&#x201d;). Inputs used to measure fair value are classified into the following hierarchy:&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 1 &#x2014;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#x2019;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 2 &#x2014;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA does not have any Level 2 assets or liabilities.&lt;/p&gt;
		&lt;p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="bullet" style="font-size:10pt;"&gt;&#x2022;&lt;span style="width: 27px;display: inline-block;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/span&gt;Level 3 &#x2014;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of March&#160;31, 2024 and December&#160;31, 2023, ARCA had $35.9&#160;million and $37.4&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were &lt;span style="-sec-ix-hidden: hidden-fact-113"&gt;no&lt;/span&gt; transfers of assets between fair value hierarchy levels during the three&#160;months ended March&#160;31, 2024.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Fair Value of Other Financial Instruments&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c121"
      decimals="-5"
      id="ixv-38352"
      unitRef="usd">35900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c66" decimals="-5" id="ixv-38353" unitRef="usd">37400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-24759">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(4)&#160;Property and Equipment&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Property and equipment consist of the following (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Estimated&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;March&#160;31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lab equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Furniture and fixtures&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer software&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accumulated depreciation and amortization&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(215&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(212&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Property and equipment, net&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;For the three&#160;months ended March&#160;31, 2024 and 2023, depreciation and amortization expense was $3,000 and $4,000 respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-38354">Property and equipment consist of the following (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Estimated&lt;br/&gt;Life&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;March&#160;31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;December&#160;31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;39&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Lab equipment&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;130&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Furniture and fixtures&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;5&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;37&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Computer software&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;"&gt;3&#160;years&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;16&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;222&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Accumulated depreciation and amortization&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(215&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(212&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Property and equipment, net&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;10&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c122" id="ixv-38355">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c122"
      decimals="-3"
      id="ixv-38356"
      unitRef="usd">39000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c69" decimals="-3" id="ixv-38357" unitRef="usd">39000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c123" id="ixv-38358">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c123"
      decimals="-3"
      id="ixv-38359"
      unitRef="usd">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c71" decimals="-3" id="ixv-38360" unitRef="usd">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c124" id="ixv-38361">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c124"
      decimals="-3"
      id="ixv-38362"
      unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c73" decimals="-3" id="ixv-38363" unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c125" id="ixv-38364">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c125"
      decimals="-3"
      id="ixv-38365"
      unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c75" decimals="-3" id="ixv-38366" unitRef="usd">16000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c5" decimals="-3" id="ixv-38367" unitRef="usd">222000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c1" decimals="-3" id="ixv-38368" unitRef="usd">222000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-38369" unitRef="usd">215000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c1" decimals="-3" id="ixv-38370" unitRef="usd">212000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="-3" id="ixv-38371" unitRef="usd">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="-3" id="ixv-38372" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="-3" id="ixv-38373" unitRef="usd">3000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c10" decimals="-3" id="ixv-38374" unitRef="usd">4000</us-gaap:DepreciationAndAmortization>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-24919">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(5)&#160;Related Party Arrangements&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Italic" style="font-style:italic;font-weight:normal;"&gt;Transactions with ARCA&#x2019;s Former President and Chief Executive Officer&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has entered into unrestricted research grants with its former President and Chief Executive Officer&#x2019;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#x2019;s financial condition, and can be deferred or terminated at ARCA&#x2019;s discretion. There was no expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements for the three&#160;months ended March&#160;31, 2023 was $108,000. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the President and Chief Executive Officer resigned, see Note&#160;10.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c127" decimals="0" id="ixv-38375" unitRef="usd">0</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:ResearchAndDevelopmentExpenseReversed contextRef="c126" decimals="0" id="ixv-38376" unitRef="usd">108000</abio:ResearchAndDevelopmentExpenseReversed>
    <abio:PaymentOfUnrestrictedResearchGrants contextRef="c77" decimals="0" id="ixv-38377" unitRef="usd">125000</abio:PaymentOfUnrestrictedResearchGrants>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-24925">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(6)&#160;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA has or is subject to the following commitments and contingencies.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Employment Agreements and Reduction of Workforce&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from the date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In December&#160;2022, ARCA&#x2019;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. As of March&#160;31, 2024, the unpaid retention bonuses totaled $311,000, none of which was accrued as of March&#160;31, 2024, since there had not been a change in control or clinical development decision. In April&#160;2024, the retention bonuses were again amended to increase the aggregate amount of the retention bonus, with the unpaid retention bonus increasing to $444,000. See Note&#160;10.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA and Christopher D.&#160;Ozeroff, the former Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#x2019;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#x2019;s existing employment agreement, as previously amended, ARCA provided Mr.&#160;Ozeroff severance benefits pursuant to the terms &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;of his existing employment agreement with ARCA, as previously amended. The severance benefits included severance payments and reimbursement to cover out&lt;span class="nobreak"&gt;-of-pocket&lt;/span&gt; costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA.&#160;During the year ended December&#160;31, 2023, ARCA recorded an expense of $159,000 for these severance benefits, &lt;span style="-sec-ix-hidden: hidden-fact-115"&gt;none&lt;/span&gt; of which remains unpaid.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA and Dr.&#160;Michael Bristow, former President, Chief Executive Officer and a member of the board of directors of ARCA mutually agreed to conclude Dr.&#160;Bristow&#x2019;s employment and service as a director, effective April&#160;3, 2024. See Note&#160;10.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On August&#160;29, 2020 ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as its primary business office effective October&#160;1, 2020 (&#x201c;October&#160;2020 Lease&#x201d;). The lease term was 42&#160;months beginning October&#160;1, 2020. In March&#160;2024, ARCA entered into an amendment to extend the lease term six (6)&#160;months through September&#160;2024. If ARCA elects to stay in the property after September&#160;2024, it will pay rent month to month equal to 125% of the base rent paid in September&#160;2024. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in its primary business office (&#x201c;2021 Lease&#x201d;). The sublease term was 29&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non&lt;span class="nobreak"&gt;-lease&lt;/span&gt; component that is not included in the lease obligation.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;49&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total remaining lease payments&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;49&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: imputed lease interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: Current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(48&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Operating lease liability, net of current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-114; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Rent expense, which is included in general and administrative expense, for the three&#160;months ended March&#160;31, 2024 and 2023 was $22,000 and $31,000, respectively.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;As of March&#160;31, 2024, the lease liability was $48,000, it is all current and is included in accrued expenses and other liabilities in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the three&#160;months ended March&#160;31, 2024 and 2023 were $23,000 and $33,000, respectively. The weighted&lt;span class="nobreak"&gt;-average&lt;/span&gt; remaining lease term for the operating lease as of March&#160;31, 2024 is 0.5&#160;years. The discount rate for the operating lease is 7%.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Patent Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In July&#160;2021, ARCA entered into a patent assignment agreement (the &#x201c;Agreement&#x201d;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Under the terms of the Agreement, ARCA received exclusive world&lt;span class="nobreak"&gt;-wide&lt;/span&gt; patent rights relating to the use of rNAPc2 as a potential treatment for COVID&lt;span class="nobreak"&gt;-19&lt;/span&gt;, and other indications, based on the research and discoveries from Univ.&lt;span class="nobreak"&gt;-Prof&lt;/span&gt;. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#x201c;CTH&#x201d;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#x20ac;1.6&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <abio:RetentionBonuses contextRef="c80" decimals="0" id="ixv-38378" unitRef="usd">265000</abio:RetentionBonuses>
    <abio:PercentageOfRetentionBonuses contextRef="c81" decimals="2" id="ixv-38379" unitRef="pure">0.50</abio:PercentageOfRetentionBonuses>
    <abio:RetentionBonusPaid contextRef="c6" decimals="0" id="ixv-38380" unitRef="usd">86000</abio:RetentionBonusPaid>
    <abio:RetentionBonuses contextRef="c5" decimals="0" id="ixv-38381" unitRef="usd">311000</abio:RetentionBonuses>
    <abio:RetentionBonuses contextRef="c128" decimals="0" id="ixv-38382" unitRef="usd">444000</abio:RetentionBonuses>
    <us-gaap:SeveranceCosts1 contextRef="c6" decimals="0" id="ixv-38383" unitRef="usd">159000</us-gaap:SeveranceCosts1>
    <us-gaap:AreaOfRealEstateProperty contextRef="c85" decimals="0" id="ixv-38384" unitRef="sqft">5200</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c85" id="ixv-38385">P42M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="c0" id="ixv-38386">to extend the lease term six (6)&#160;months through September&#160;2024</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend contextRef="c0" id="ixv-38387">false</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c5" id="ixv-38388">P6M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <abio:OperatingLeasesExtendedExpiryYearsAndMonth contextRef="c0" id="ixv-38389">September&#160;2024</abio:OperatingLeasesExtendedExpiryYearsAndMonth>
    <abio:PercentageOfBaseRentToBePaidMonthly contextRef="c0" decimals="2" id="ixv-38390" unitRef="pure">1.25</abio:PercentageOfBaseRentToBePaidMonthly>
    <abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities contextRef="c87" decimals="0" id="ixv-38391" unitRef="sqft">3000</abio:AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities>
    <abio:LesseeOperatingSubleaseTermOfContract contextRef="c131" id="ixv-38392">P29M</abio:LesseeOperatingSubleaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent contextRef="c0" id="ixv-24953">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.</us-gaap:LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-38393">Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;2024&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;49&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total remaining lease payments&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;49&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: imputed lease interest&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(1&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Less: Current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(48&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Operating lease liability, net of current portion&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-114; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c5" decimals="-3" id="ixv-38394" unitRef="usd">49000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c5" decimals="-3" id="ixv-38395" unitRef="usd">49000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c5" decimals="-3" id="ixv-38396" unitRef="usd">1000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c5" decimals="-3" id="ixv-38397" unitRef="usd">48000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseCost contextRef="c129" decimals="0" id="ixv-38398" unitRef="usd">22000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c130" decimals="0" id="ixv-38399" unitRef="usd">31000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseLiability contextRef="c5" decimals="0" id="ixv-38400" unitRef="usd">48000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="0" id="ixv-38401" unitRef="usd">23000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c10" decimals="0" id="ixv-38402" unitRef="usd">33000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c5" id="ixv-38403">P0Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c5" decimals="2" id="ixv-38404" unitRef="pure">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations contextRef="c91" decimals="-5" id="ixv-38405" unitRef="eur">1600000</abio:PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-25026">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(7)&#160;&lt;/span&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;font-style:normal;font-weight:bold;"&gt;Equity Financings&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;At the Market Equity Financing&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In 2020, ARCA entered into a Capital on Demand&#x2122; Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with JonesTrading Institutional Services LLC, as agent (&#x201c;JonesTrading&#x201d;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#x2019;s common stock, par value $0.001 per share (&#x201c;ARCA common stock&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In 2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#x2019;s registration statement on Form&#160;S&lt;span class="nobreak"&gt;-3&lt;/span&gt; (No.&#160;333&lt;span class="nobreak"&gt;-254585&lt;/span&gt;), which expired in March&#160;2024. In April&#160;2024, ARCA terminated the Sales Agreement in accordance with its terms.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;No sales were made under the Sales Agreement in 2024 or 2023.&lt;/p&gt;
		&lt;p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="BoldItalic" style="font-style:italic;font-weight:bold;"&gt;Merger Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;See &#x201c;Financing Transaction&#x201d; discussion in Note&#160;10 below.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c132"
      decimals="INF"
      id="ixv-38406"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c133"
      decimals="INF"
      id="ixv-38407"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c134"
      decimals="INF"
      id="ixv-38408"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-25040">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(8)&#160;Share-based Compensation&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;"&gt;For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non&lt;span class="nobreak"&gt;-cash&lt;/span&gt;, share&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense in the statements of operations (in thousands):&lt;/p&gt;
		&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Three&#160;Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2024&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;General and administrative&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;114&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;163&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-116; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;41&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;114&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;204&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#x2019;s stock incentive plans were as follows:&lt;/p&gt;
		&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in&#160;years)&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31, 2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;42,000&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.64&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-117; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-118; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(12,862&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;17.45&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.30&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.82&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options exercisable&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;502,517&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.71&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.55&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options vested and expected to vest&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,816&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.30&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.82&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c0" id="ixv-25044">For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non&lt;span class="nobreak"&gt;-cash&lt;/span&gt;, share&lt;span class="nobreak"&gt;-based&lt;/span&gt; compensation expense in the statements of operations (in thousands):&lt;table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;


				&lt;tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;



					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Three&#160;Months Ended&lt;br/&gt;March&#160;31,&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2024&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;
						&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;2023&lt;/span&gt;&lt;/p&gt;
					&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;General and administrative&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;114&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;
						&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;163&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Research and development&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-116; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;41&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;
				&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;
						&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Total&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;114&lt;/p&gt;	&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;
						&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;
					&lt;/td&gt;
					&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;204&lt;/p&gt;	&lt;/td&gt;
				&lt;/tr&gt;

		&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c129"
      decimals="-3"
      id="ixv-38409"
      unitRef="usd">114000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c130"
      decimals="-3"
      id="ixv-38410"
      unitRef="usd">163000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c136"
      decimals="-3"
      id="ixv-38411"
      unitRef="usd">41000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" id="ixv-38412" unitRef="usd">114000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c10" decimals="-3" id="ixv-38413" unitRef="usd">204000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-38414">Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#x2019;s stock incentive plans were as follows:&lt;table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;"&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Options Outstanding&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;"&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom"&gt;	&lt;p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(in&#160;years)&lt;/span&gt;&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;December&#160;31, 2023&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;616,707&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.76&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;7.35&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Granted&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;42,000&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;1.64&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Exercised&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-117; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-118; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#x2014;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Forfeited and cancelled&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;(12,862&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;)&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;17.45&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options outstanding&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,845&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.30&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.82&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options exercisable&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;502,517&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom"&gt;	&lt;p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.71&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.55&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;"&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"&gt;Options vested and expected to vest&#160;&#x2013;&#160;March&#160;31, 2024&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;645,816&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;&#160;&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;"&gt;$&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;4.30&lt;/p&gt;	&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;	&lt;td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom"&gt;	&lt;p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;"&gt;6.82&lt;/p&gt;	&lt;/td&gt;	&lt;/tr&gt;	&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-38415"
      unitRef="shares">616707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-38416"
      unitRef="usdPershares">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c137" id="ixv-38417">P7Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c0"
      decimals="INF"
      id="ixv-38418"
      unitRef="shares">42000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-38419"
      unitRef="usdPershares">1.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c0"
      decimals="INF"
      id="ixv-38420"
      unitRef="shares">12862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-38421"
      unitRef="usdPershares">17.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-38422"
      unitRef="shares">645845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ixv-38423"
      unitRef="usdPershares">4.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0" id="ixv-38424">P6Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-38425"
      unitRef="shares">502517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ixv-38426"
      unitRef="usdPershares">4.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-38427">P6Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-38428"
      unitRef="shares">645816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ixv-38429"
      unitRef="usdPershares">4.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-38430">P6Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-25254">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(9)&#160;Income Taxes&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In accordance with GAAP, a valuation allowance should be provided if it is more likely than not that some or all of ARCA&#x2019;s deferred tax assets will not be realized. ARCA&#x2019;s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, ARCA has recorded a full valuation allowance against its net deferred tax assets. ARCA believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has &lt;span style="-sec-ix-hidden: hidden-fact-119"&gt;no&lt;/span&gt; reserve for uncertain tax positions.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-25259">&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;(10)&#160;Subsequent Events&lt;/span&gt;&lt;/p&gt;
		&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Merger Agreement&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;3, 2024, ARCA, Merger Sub&#160;I, Merger Sub&#160;II and Oruka, entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger. The Merger is intended to qualify for federal income tax purposes as a tax&lt;span class="nobreak"&gt;-free&lt;/span&gt; reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Subject to the terms and conditions of the Merger Agreement, at the closing of the First Merger, (a)&#160;each then&lt;span class="nobreak"&gt;-outstanding&lt;/span&gt; share of Oruka common stock (including shares of Oruka common stock issued in the financing transaction described below) will be converted solely into the right to receive a number of shares of ARCA common stock calculated in accordance with the Merger Agreement (the &#x201c;Exchange Ratio&#x201d;), (b)&#160;each then&lt;span class="nobreak"&gt;-outstanding&lt;/span&gt; share of Oruka preferred stock will be converted into the right to receive a number of shares of Series&#160;B Preferred Stock (as defined below) of ARCA, calculated in accordance with the Merger Agreement (c)&#160;each then&lt;span class="nobreak"&gt;-outstanding&lt;/span&gt; option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and (d)&#160;each then&lt;span class="nobreak"&gt;-outstanding&lt;/span&gt; warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and form of warrant. Under the terms of the Merger Agreement, prior to the closing of the transaction, the Board will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option (the &#x201c;Out of the Money Options&#x201d;) to acquire shares of ARCA common stock with an exercise price per share greater than the volume weighted average closing trading price of a share of ARCA common stock on The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) for the five (5)&#160;consecutive&#160;trading days ending three (3)&#160;days immediately prior to the closing date of the First Merger (the &#x201c;Parent Closing Price&#x201d;), in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, each option to acquire shares of ARCA common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Under the Exchange Ratio formula in the Merger Agreement, upon the closing of the First Merger, on a pro forma basis and based upon the number of shares of ARCA common stock expected to be issued in the First Merger, pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger Oruka stockholders (including Oruka stockholders issued shares of Oruka common stock and pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants in the financing transaction described below) will own approximately 97.62% of the combined company and pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger ARCA stockholders will own approximately 2.38% of the combined company. For purposes of calculating the Exchange Ratio, (i)&#160;shares of ARCA common stock underlying warrants and other rights to receive shares (other than Options to acquire shares of ARCA common stock, to the extent cancelled at or prior to closing of the First Merger in accordance with the Merger Agreement) outstanding as of immediately prior to the closing of the First Merger will be deemed to be outstanding, and (ii)&#160;all shares of Oruka common stock underlying outstanding Oruka stock options and warrants will be deemed to be outstanding. The Exchange Ratio will be &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;adjusted to the extent that ARCA&#x2019;s net cash at closing is less than $5.0&#160;million and will be based on the amount of proceeds actually received by Oruka in the financing transaction described below, as further described in the Merger Agreement.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In addition, prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger ARCA stockholders equal in the aggregate to ARCA&#x2019;s reasonable, good faith approximation of the amount by which ARCA&#x2019;s net cash (as determined pursuant to the Merger Agreement) will exceed $5,000,000.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In connection with the Merger, ARCA is required to seek the approval of its stockholders to, among other things, (a)&#160;issue shares of ARCA common stock issuable in connection with the First Merger (including the shares of ARCA common stock issuable under the Series&#160;B Preferred Stock) under the rules of Nasdaq, and (b)&#160;amend its amended and restated certificate of incorporation, to (i)&#160;effect a reverse stock split of ARCA common stock (if deemed necessary by ARCA and Oruka), (ii)&#160;increase the number of shares of ARCA common stock that ARCA is authorized to issue, and (iii)&#160;such other changes as are mutually agreeable to ARCA and Oruka (the &#x201c;ARCA Voting Proposals&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Each of ARCA and Oruka has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1)&#160;using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2)&#160;non&lt;span class="nobreak"&gt;-solicitation&lt;/span&gt; of alternative acquisition proposals, (3)&#160;the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, (4)&#160;ARCA using commercially reasonable efforts to maintain the existing listing of the ARCA common stock on Nasdaq and cause the shares of ARCA common stock to be issued in connection with the First Merger to be approved for listing on Nasdaq prior to the closing of the First Merger, and (5)&#160;ARCA filing with the U.S.&#160;Securities and Exchange Commission (the &#x201c;SEC&#x201d;) and causing to become effective a registration statement to register shares of ARCA common stock to be issued in connection with the First Merger, except as set forth in the Merger Agreement (the &#x201c;Registration Statement&#x201d;).&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA stockholders of the ARCA Voting Proposals, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#x2019;s approval of the initial listing application to be submitted in connection with the First Merger, (4)&#160;the effectiveness of the Registration Statement, (5)&#160;the expiration of any applicable waiting periods (or extensions thereof) under the Hart Scott&lt;span class="nobreak"&gt;-Rodino&lt;/span&gt; Antitrust Improvements Act&#160;of&#160;1976, as amended, (6)&#160;the subscription agreements (described below) being in full force and effect providing for the receipt of proceeds of not less than $175,000,000 (including in the proceeds any notes contributed as consideration in the financing transaction described below) and (7)&#160;to the extent ARCA has declared the cash dividend described above, ARCA delivering the aggregate amount distributable to the pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger ARCA stockholders to ARCA&#x2019;s transfer agent for further distribution to the pre&lt;span class="nobreak"&gt;-First&lt;/span&gt; Merger ARCA stockholders. Each party&#x2019;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the date of the closing of the Merger.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;The Merger Agreement contains certain termination rights of each of ARCA and Oruka. Upon termination of the Merger Agreement under specified circumstances, ARCA and Oruka may each be required to pay the other party a termination fee of $440,000.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Pursuant to a Certificate of Designation of Preferences, Rights and Limitations of the Series&#160;B Non&lt;span class="nobreak"&gt;-Voting&lt;/span&gt; Convertible Preferred Stock to be filed by ARCA with the Secretary of State of the State of Delaware (the &#x201c;Certificate of Designation&#x201d;) in connection with the Merger Agreement and the transactions thereunder, ARCA will establish the terms of a new series of preferred stock of ARCA designated as Series&#160;B Non&lt;span class="nobreak"&gt;-Voting&lt;/span&gt; Convertible Preferred Stock, par value $0.001 per share (the &#x201c;Series&#160;B Preferred Stock&#x201d;). Holders of the Series&#160;B Preferred Stock will be entitled to receive dividends on shares of Series&#160;B Preferred Stock equal to, on an as&lt;span class="nobreak"&gt;-if-converted-to-ARCA&lt;/span&gt; common stock &lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;"&gt;basis, and in the same form as dividends actually paid on shares of the ARCA common stock. Except as otherwise required by the Certificate of Designation or law, the Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend its certificate of incorporation, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;B Preferred Stock, (e)&#160;issue further shares of the Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the Series&#160;B Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding&lt;span class="nobreak"&gt;-up&lt;/span&gt; of ARCA.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Following the closing of the First Merger, each share of Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the Series&#160;B Preferred Stock, into a number of shares equal to 1,000&lt;span class="nobreak"&gt; &lt;/span&gt;shares of ARCA common stock, subject to certain limitations, including that a holder of Series&#160;B Preferred Stock is prohibited from converting shares of Series&#160;B Preferred Stock into shares of ARCA common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 9.99%) of the total number of shares of ARCA common stock issued and outstanding immediately after giving effect to such conversion.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;At the effective time of the First Merger (the &#x201c;First Effective Time&#x201d;), the combined company&#x2019;s board of directors is expected to consist of five (5)&#160;members, all of whom will be designated by Oruka. Upon the closing of the transaction, the combined company will be led by Oruka&#x2019;s chief executive officer.&lt;/p&gt;
		&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Financing Transaction&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Concurrently with the execution and delivery of the Merger Agreement, certain parties have entered into a subscription agreements with Oruka, pursuant to which they have agreed, subject to the terms and conditions of such agreements, to purchase immediately prior to the consummation of the First Merger, shares of Oruka common stock and pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants to purchase shares of Oruka common stock (together, the &#x201c;PIPE Securities&#x201d;) for an aggregate purchase price of approximately $275.0&#160;million. The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the subscription agreement. Shares of Oruka common stock and pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants to purchase shares of Oruka common stock issued pursuant to this financing transaction will be converted into shares of ARCA common stock and pre&lt;span class="nobreak"&gt;-funded&lt;/span&gt; warrants to acquire shares ARCA common stock, in accordance with the Exchange Ratio and the Merger Agreement.&lt;/p&gt;
		&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Separation of Michael Bristow, M.D., President, Chief Executive Officer and Director&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Effective April&#160;3, 2024, ARCA and Dr.&#160;Michael Bristow, President, Chief Executive Officer and a member of the Board mutually agreed to conclude Dr.&#160;Bristow&#x2019;s employment and service as a director.&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;In connection with Dr.&#160;Bristow&#x2019;s separation, ARCA and Dr.&#160;Bristow entered into a separation agreement (the &#x201c;Separation Agreement&#x201d;) on April&#160;3, 2024. Pursuant to the terms of the Separation Agreement, ARCA provided to Dr.&#160;Bristow a lump sum payment equal to (i)&#160;twelve (12)&#160;months of Dr.&#160;Bristow&#x2019;s base salary as of the last date of his employment and (ii)&#160;a cash payment of $25,000, less applicable withholdings. The severance benefits were conditioned on the non&lt;span class="nobreak"&gt;-revocation&lt;/span&gt; by Dr.&#160;Bristow of a legal release of claims.&lt;/p&gt;&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;ARCA and Dr.&#160;Bristow entered into a consulting agreement, effective April&#160;3, 2024 (the &#x201c;Consulting Agreement&#x201d;), pursuant to which Dr.&#160;Bristow is providing certain consulting services provided for in the Consulting Agreement to ARCA until the earlier of (i)&#160;the completion of services under the Consulting Agreement, (ii)&#160;a termination in accordance with the terms of the Consulting Agreement, and (iii)&#160;upon a Change of Control (as defined in ARCA&#x2019;s 2020 Equity Incentive Plan (the &#x201c;Plan&#x201d;)). Pursuant to the Consulting Agreement, Dr.&#160;Bristow provision of services under the Consulting Agreement are deemed to be a Continuous Service (as defined in the Plan) and, as a result, his equity awards under the Plan continue to vest during the term of the Consulting Agreement.&lt;/p&gt;
		&lt;p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Appointment of Thomas Keuer as President&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;Effective as of April&#160;3, 2024, the Board appointed Thomas A.&#160;Keuer, ARCA&#x2019;s Chief Operating Officer, to serve as ARCA&#x2019;s President and principal executive officer. Mr.&#160;Keuer has been with ARCA since 2006, and as its Chief Operating Officer for the last nine&#160;years, a position he will continue to serve in. Mr.&#160;Keuer will not receive any additional compensation in connection with his appointment as President and principal executive officer. Mr.&#160;Keuer&#x2019;s position will end upon closing of the merger transaction with Oruka Therapeutics, Inc. as previously disclosed on a Current Report on Form&#160;8&lt;span class="nobreak"&gt;-K&lt;/span&gt; filed with the SEC on April&#160;3, 2024.&lt;/p&gt;
		&lt;p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"&gt;&lt;span class="Bold" style="font-style:normal;font-weight:bold;"&gt;Second Amendment to Retention Bonus Letter of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker&lt;/span&gt;&lt;/p&gt;
		&lt;p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;"&gt;On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of certain retention bonus letters between ARCA and each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker to increase the aggregate amount of the retention bonus with respect to each such executive to $200,000. The remaining portion of the retention bonus with respect to Thomas A. Keuer and C. Jeffrey Dekker, consisting of $165,000, will become payable consistent with the original terms of the applicable retention bonus letter and first amendment to retention bonus letter. Any payment related to the retention bonuses of Thomas A. Keuer and C. Jeffrey Dekker will be paid by ARCA via payroll within&#160;30 business days of the date of occurrence of the applicable &#x201c;Payment Event Date&#x201d; (as such term is otherwise defined in the applicable second amendment to the retention bonus letter). Each such retention bonus letter and first amendment to retention bonus letter will otherwise remain subject to their original terms and conditions.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <abio:NumberOfConsecutiveTradingDays contextRef="c138" id="ixv-38431">P5D</abio:NumberOfConsecutiveTradingDays>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c139"
      decimals="4"
      id="ixv-38432"
      unitRef="pure">0.9762</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="c140"
      decimals="4"
      id="ixv-38433"
      unitRef="pure">0.0238</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <abio:ThresholdAmountOfAdjustedExchangeRatio
      contextRef="c138"
      decimals="-5"
      id="ixv-38434"
      unitRef="usd">5000000</abio:ThresholdAmountOfAdjustedExchangeRatio>
    <abio:ThresholdAmountOfDeclaredCashDividend contextRef="c141" decimals="0" id="ixv-38435" unitRef="usd">5000000</abio:ThresholdAmountOfDeclaredCashDividend>
    <abio:SubscriptionAgreementReceiptAmount
      contextRef="c142"
      decimals="INF"
      id="ixv-38436"
      unitRef="usd">175000000</abio:SubscriptionAgreementReceiptAmount>
    <abio:PaymentOfOtherPartyTerminationFee contextRef="c143" decimals="0" id="ixv-38437" unitRef="usd">440000</abio:PaymentOfOtherPartyTerminationFee>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c144"
      decimals="INF"
      id="ixv-38438"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <abio:MinimumPercentageOfOriginallyIssuedShares
      contextRef="c145"
      decimals="2"
      id="ixv-38439"
      unitRef="pure">0.30</abio:MinimumPercentageOfOriginallyIssuedShares>
    <abio:MinimumPercentageOfOriginallyIssuedOutstanding
      contextRef="c145"
      decimals="2"
      id="ixv-38440"
      unitRef="pure">0.30</abio:MinimumPercentageOfOriginallyIssuedOutstanding>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c146"
      decimals="0"
      id="ixv-38441"
      unitRef="shares">1000</us-gaap:PreferredStockConvertibleSharesIssuable>
    <abio:InitiallySpecifiedPercentageForBeneficialNumberOfShares
      contextRef="c147"
      decimals="4"
      id="ixv-38442"
      unitRef="pure">0.0999</abio:InitiallySpecifiedPercentageForBeneficialNumberOfShares>
    <abio:ExceptedNumberOfBoardMembers
      contextRef="c148"
      decimals="0"
      id="ixv-38443"
      unitRef="pure">5</abio:ExceptedNumberOfBoardMembers>
    <abio:AggregatePurchasePrice
      contextRef="c149"
      decimals="-5"
      id="ixv-38444"
      unitRef="usd">275000000</abio:AggregatePurchasePrice>
    <abio:NumberOfMonthsBaseSalary contextRef="c150" id="ixv-38445">P12M</abio:NumberOfMonthsBaseSalary>
    <abio:CashPayment contextRef="c150" decimals="0" id="ixv-38446" unitRef="usd">25000</abio:CashPayment>
    <abio:IncreaseOfRetentionBonusToEachExecutive contextRef="c151" decimals="0" id="ixv-38447" unitRef="usd">200000</abio:IncreaseOfRetentionBonusToEachExecutive>
    <abio:IncreaseOfRetentionBonusToEachExecutive contextRef="c152" decimals="0" id="ixv-38448" unitRef="usd">200000</abio:IncreaseOfRetentionBonusToEachExecutive>
    <abio:RetentionBonuses contextRef="c153" decimals="0" id="ixv-38449" unitRef="usd">165000</abio:RetentionBonuses>
    <dei:DocumentType contextRef="c0" id="hidden-fact-0">S-4/A</dei:DocumentType>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c1"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c1"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c5"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingExpense
      contextRef="c6"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="hidden-fact-7"
      unitRef="usdPershares">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="hidden-fact-8"
      unitRef="usdPershares">-0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="0"
      id="hidden-fact-9"
      unitRef="shares">14410143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="0"
      id="hidden-fact-10"
      unitRef="shares">14415877</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c10"
      decimals="2"
      id="hidden-fact-11"
      unitRef="usdPershares">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="hidden-fact-12"
      unitRef="usdPershares">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c10"
      decimals="0"
      id="hidden-fact-13"
      unitRef="shares">14410143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="0"
      id="hidden-fact-14"
      unitRef="shares">14501143</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c17"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c19"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c17"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c18"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c23"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c24"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c25"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c6"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c23"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c25"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c23"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c24"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c29"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c31"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c29"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c30"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c36"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c38"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c36"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c37"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c44"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c46"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c44"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c45"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c52"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c53"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c54"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c55"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c52"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c54"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c52"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c53"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c56"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c58"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c56"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c57"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="c6"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="c7"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c6"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c6"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c6"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c7"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c6"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c7"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="c6"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="c7"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c0"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c10"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c0"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c10"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c0"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="c10"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="c0"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="c10"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c10"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c64"
      id="hidden-fact-70"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="c1"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="c2"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount
      contextRef="c6"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount
      contextRef="c68"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestructuringReserveCurrent
      contextRef="c1"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c7"
      id="hidden-fact-76"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c7"
      id="hidden-fact-77"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c6"
      id="hidden-fact-78"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c6"
      id="hidden-fact-79"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c6"
      id="hidden-fact-80"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c6"
      id="hidden-fact-81"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c1"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c1"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="c1"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c16"
      id="hidden-fact-85"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c16"
      id="hidden-fact-86"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c7"
      id="hidden-fact-87"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c7"
      id="hidden-fact-88"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c7"
      id="hidden-fact-89"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c7"
      id="hidden-fact-90"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c6"
      id="hidden-fact-91"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c6"
      id="hidden-fact-92"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c6"
      id="hidden-fact-93"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c6"
      id="hidden-fact-94"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c1"
      id="hidden-fact-95"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c1"
      id="hidden-fact-96"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c98" id="hidden-fact-97">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c99" id="hidden-fact-98">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c6" id="hidden-fact-99">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c107" id="hidden-fact-100">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="c6"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="c7"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c6"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c1"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c2"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <abio:OperatingLossCarryforwardsExpirationYear contextRef="c114" id="hidden-fact-107">2025</abio:OperatingLossCarryforwardsExpirationYear>
    <abio:OperatingLossCarryforwardsExpirationYear contextRef="c115" id="hidden-fact-108">2037</abio:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OpenTaxYear contextRef="c6" id="hidden-fact-109">2009</us-gaap:OpenTaxYear>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c119"
      id="hidden-fact-110"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c5"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c1"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <abio:FairValueAssetsBetweenHierarchyLevelsTransfersAmount
      contextRef="c0"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c5"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestructuringReserveCurrent
      contextRef="c1"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c135"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-117"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-118"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="c5"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-38572">true</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-38573">0000907654</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857374823616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARCA BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-4/A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">The issuances of (i)&#160;all shares of ARCA common stock in exchange for each share of Oruka common stock (including shares of Oruka common stock issued in the Oruka pre-closing financing), (ii)&#160;all shares of ARCA common stock issuable upon exercise of pre-funded warrants issued in exchange for pre-funded warrants to purchase shares of Oruka common stock sold in the Oruka pre-closing financing, and (iii)&#160;all shares of ARCA common stock issuable upon conversion of ARCA Series&#160;B Preferred Stock issued in exchange for each share of Oruka preferred stock, are intended to be covered by this registration statement on Form&#160;S-4 of which the accompanying proxy statement/prospectus is a part. There is no difference between the shares of ARCA common stock that will be issued in exchange for each share of Oruka common stock issued in the pre-closing financing, the shares of ARCA common stock that will be issued in exchange for each other share of Oruka common stock, the shares of ARCA common stock that will be issuable upon the exercise of pre-funded warrants that will be issued in exchange for pre-funded warrants to purchase shares of Oruka common stock sold in the pre-closing financing and the shares of ARCA common stock that will be issuable upon conversion of ARCA Series&#160;B Preferred Stock that will be issued in exchange for each share of Oruka preferred stock.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000907654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857374352304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 35,903<span></span>
</td>
<td class="nump">$ 37,431<span></span>
</td>
<td class="nump">$ 42,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">767<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">36,670<span></span>
</td>
<td class="nump">37,592<span></span>
</td>
<td class="nump">42,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset &#8211; operating</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">36,706<span></span>
</td>
<td class="nump">37,861<span></span>
</td>
<td class="nump">43,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">968<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,581<span></span>
</td>
<td class="nump">637<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,581<span></span>
</td>
<td class="nump">841<span></span>
</td>
<td class="nump">1,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding at December 31, 2023 and 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">225,861<span></span>
</td>
<td class="nump">225,747<span></span>
</td>
<td class="nump">225,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(190,750)<span></span>
</td>
<td class="num">(188,741)<span></span>
</td>
<td class="num">(183,402)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">35,125<span></span>
</td>
<td class="nump">37,020<span></span>
</td>
<td class="nump">41,673<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 36,706<span></span>
</td>
<td class="nump">$ 37,861<span></span>
</td>
<td class="nump">$ 43,085<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857373738192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Unaudited) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities - related party (in Dollars)</a></td>
<td class="nump">$ 968<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities - related party (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857372633552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 2,317<span></span>
</td>
<td class="nump">$ 1,406<span></span>
</td>
<td class="nump">$ 6,283<span></span>
</td>
<td class="nump">$ 5,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="nump">1,013<span></span>
</td>
<td class="nump">4,749<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total costs and expenses</a></td>
<td class="nump">2,482<span></span>
</td>
<td class="nump">1,796<span></span>
</td>
<td class="nump">7,296<span></span>
</td>
<td class="nump">10,596<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,482)<span></span>
</td>
<td class="num">(1,796)<span></span>
</td>
<td class="num">(7,296)<span></span>
</td>
<td class="num">(10,596)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">1,957<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,009)<span></span>
</td>
<td class="num">$ (1,346)<span></span>
</td>
<td class="num">$ (5,339)<span></span>
</td>
<td class="num">$ (9,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in Dollars per share)</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_WeightedAverageSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in Shares)</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
<td class="nump">14,415,877<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_WeightedAverageSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_WeightedAverageSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857373959552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Unaudited) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
<td class="nump">14,415,877<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ResearchAndDevelopmentExpenseReversed', window );">Related party expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
<td class="num">$ (91)<span></span>
</td>
<td class="nump">$ 432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ResearchAndDevelopmentExpenseReversed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense (reversed).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ResearchAndDevelopmentExpenseReversed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857372140656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders&#8217; Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 224,505<span></span>
</td>
<td class="num">$ (173,476)<span></span>
</td>
<td class="nump">$ 51,043<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">556<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,926)<span></span>
</td>
<td class="num">(9,926)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,061<span></span>
</td>
<td class="num">(183,402)<span></span>
</td>
<td class="nump">$ 41,673<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,346)<span></span>
</td>
<td class="num">(1,346)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,265<span></span>
</td>
<td class="num">(184,748)<span></span>
</td>
<td class="nump">40,531<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2023</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,061<span></span>
</td>
<td class="num">(183,402)<span></span>
</td>
<td class="nump">$ 41,673<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,410,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of Restricted Stock Units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of Restricted Stock Units (in Shares)</a></td>
<td class="nump">91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">686<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,339)<span></span>
</td>
<td class="num">(5,339)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,747<span></span>
</td>
<td class="num">(188,741)<span></span>
</td>
<td class="nump">$ 37,020<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,265<span></span>
</td>
<td class="num">(184,748)<span></span>
</td>
<td class="nump">$ 40,531<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2023</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">187<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,480)<span></span>
</td>
<td class="num">(1,480)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,452<span></span>
</td>
<td class="num">(186,228)<span></span>
</td>
<td class="nump">39,238<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2023</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,424)<span></span>
</td>
<td class="num">(1,424)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,606<span></span>
</td>
<td class="num">(187,652)<span></span>
</td>
<td class="nump">37,968<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2023</a></td>
<td class="nump">14,410,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of Restricted Stock Units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of Restricted Stock Units (in Shares)</a></td>
<td class="nump">91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">225,747<span></span>
</td>
<td class="num">(188,741)<span></span>
</td>
<td class="nump">$ 37,020<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,009)<span></span>
</td>
<td class="num">(2,009)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 225,861<span></span>
</td>
<td class="num">$ (190,750)<span></span>
</td>
<td class="nump">$ 35,125<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="nump">14,501,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,501,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857373580368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,009)<span></span>
</td>
<td class="num">$ (1,346)<span></span>
</td>
<td class="num">$ (5,339)<span></span>
</td>
<td class="num">$ (9,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset &#8211; operating</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="nump">686<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss from disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(606)<span></span>
</td>
<td class="num">(598)<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="num">(783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="num">(752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">803<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="num">(526)<span></span>
</td>
<td class="num">(934)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,528)<span></span>
</td>
<td class="num">(1,595)<span></span>
</td>
<td class="num">(5,014)<span></span>
</td>
<td class="num">(10,912)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(1,528)<span></span>
</td>
<td class="num">(1,595)<span></span>
</td>
<td class="num">(5,014)<span></span>
</td>
<td class="num">(10,914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">37,431<span></span>
</td>
<td class="nump">42,445<span></span>
</td>
<td class="nump">42,445<span></span>
</td>
<td class="nump">53,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">35,903<span></span>
</td>
<td class="nump">40,850<span></span>
</td>
<td class="nump">37,431<span></span>
</td>
<td class="nump">42,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Income tax refund received</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets and operating lease liabilities &#8211; amended lease term</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax refund received from tax jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857375775088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ARCA and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ARCA and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ARCA and Summary of Significant Accounting Policies</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#8220;Board&#8221;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;I&#8221;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;II&#8221;) and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka<span class="CharOverride-1" style="text-decoration:underline;">&#8221;</span>), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;). The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S<span class="nobreak">-X</span>.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(1)&#160;ARCA and Summary of Significant Accounting Policies</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical<span class="nobreak">-stage</span> biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#8217;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of ARCA&#8217;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#8217;s activities through the date of filing of the Annual Report on Form&#160;10<span class="nobreak">-K</span>.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accounting Estimates in the Preparation of Financial Statements</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Equivalents</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">property and equipment is depreciated using the straight<span class="nobreak">-line</span> method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s December&#160;31, 2023 and 2022 balance sheets.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#8220;CROs&#8221;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre<span class="nobreak">-approval</span> of any changes in scope of the services to be performed. Certain significant vendors may also provide </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s stock<span class="nobreak">-based</span> compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857375567120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(2)&#160;Net Loss Per Share</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#8217;s potentially dilutive shares include stock options and restricted stock units.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">664,857</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-110; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">755,857</p>	</td>
				</tr>

		</table><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(2)&#160;Net Loss Per Share</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA calculates basic loss per share by dividing net loss by the weighted average common shares outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period increased to include, if dilutive, the number of additional common shares that would have been outstanding if the potential common shares had been issued. ARCA&#8217;s potentially dilutive shares include stock options and restricted stock units.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">704,960</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-70; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">795,960</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857375788672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Disclosures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(3)&#160;Fair Value Disclosures</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">There were <span style="-sec-ix-hidden: hidden-fact-111"><span style="-sec-ix-hidden: hidden-fact-112">no</span></span> marketable securities as of March&#160;31, 2024 or December&#160;31, 2023.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#8220;exit price&#8221;). Inputs used to measure fair value are classified into the following hierarchy:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 1 &#8212;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#8217;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 2 &#8212;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA does not have any Level 2 assets or liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 3 &#8212;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024 and December&#160;31, 2023, ARCA had $35.9&#160;million and $37.4&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were <span style="-sec-ix-hidden: hidden-fact-113">no</span> transfers of assets between fair value hierarchy levels during the three&#160;months ended March&#160;31, 2024.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(3)&#160;Fair Value Disclosures</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (&#8220;exit price&#8221;). Inputs used to measure fair value are classified into the following hierarchy:</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 1 &#8212;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities. ARCA&#8217;s Level 1 assets consist of money market investments. ARCA does not have any Level 1 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 2 &#8212;&#160;Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable for the asset or liability. ARCA&#8217;s Level 2 assets consist of corporate bonds and commercial paper securities. ARCA does not have any Level 2 liabilities.</p>
		<p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>Level 3 &#8212;&#160;Unobservable inputs for the asset or liability. ARCA does not have any Level 3 assets or liabilities.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023 and 2022, ARCA had $37.4&#160;million and $42.4&#160;million, respectively, of cash equivalents consisting of money market funds with original maturities of 90&#160;days or less. ARCA has the ability to liquidate these investments without restriction. ARCA determines fair value for these money market funds with Level 1 inputs through quoted market prices. There were <span style="-sec-ix-hidden: hidden-fact-73"><span style="-sec-ix-hidden: hidden-fact-74">no</span></span> transfers between any fair value hierarchy levels in 2023 or 2022.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Fair Value of Other Financial Instruments</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The carrying amount of other financial instruments, including accounts payable, approximated fair value due to their short maturities. As of December&#160;31, 2023 and 2022, ARCA did <span style="-sec-ix-hidden: hidden-fact-71"><span style="-sec-ix-hidden: hidden-fact-72">not</span></span> have any debt outstanding.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857375836800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(4)&#160;Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment consist of the following (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(215</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(212</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the three&#160;months ended March&#160;31, 2024 and 2023, depreciation and amortization expense was $3,000 and $4,000 respectively.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(4)&#160;Property and Equipment</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment consist of the following (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2022</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">44</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">229</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(212</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(204</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the&#160;years ended December&#160;31, 2023 and 2022, depreciation and amortization expense was $15,000 and $20,000, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857375558608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Arrangements</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(5)&#160;Related Party Arrangements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Transactions with ARCA&#8217;s Former President and Chief Executive Officer</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its former President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. There was no expense under these arrangements for the three&#160;months ended March&#160;31, 2024. Total expense under these arrangements for the three&#160;months ended March&#160;31, 2023 was $108,000. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements. In April&#160;2024, the President and Chief Executive Officer resigned, see Note&#160;10.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(5)&#160;Related Party Arrangements</span></p>
		<p class="H4" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:1;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Italic" style="font-style:italic;font-weight:normal;">Transactions with ARCA&#8217;s President and Chief Executive Officer</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has entered into unrestricted research grants with its President and Chief Executive Officer&#8217;s academic research laboratory at the University of Colorado. Funding of any unrestricted research grants is contingent upon ARCA&#8217;s financial condition, and can be deferred or terminated at ARCA&#8217;s discretion. Total expense under these arrangements for the&#160;years ended December&#160;31, 2023 and 2022 was $(91,000) and $432,000, respectively. In December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857375806592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has or is subject to the following commitments and contingencies.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements and Reduction of Workforce</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from the date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. As of March&#160;31, 2024, the unpaid retention bonuses totaled $311,000, none of which was accrued as of March&#160;31, 2024, since there had not been a change in control or clinical development decision. In April&#160;2024, the retention bonuses were again amended to increase the aggregate amount of the retention bonus, with the unpaid retention bonus increasing to $444,000. See Note&#160;10.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Christopher D.&#160;Ozeroff, the former Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#8217;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#8217;s existing employment agreement, as previously amended, ARCA provided Mr.&#160;Ozeroff severance benefits pursuant to the terms </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">of his existing employment agreement with ARCA, as previously amended. The severance benefits included severance payments and reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA.&#160;During the year ended December&#160;31, 2023, ARCA recorded an expense of $159,000 for these severance benefits, <span style="-sec-ix-hidden: hidden-fact-115">none</span> of which remains unpaid.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Michael Bristow, former President, Chief Executive Officer and a member of the board of directors of ARCA mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment and service as a director, effective April&#160;3, 2024. See Note&#160;10.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Leases</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020 ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as its primary business office effective October&#160;1, 2020 (&#8220;October&#160;2020 Lease&#8221;). The lease term was 42&#160;months beginning October&#160;1, 2020. In March&#160;2024, ARCA entered into an amendment to extend the lease term six (6)&#160;months through September&#160;2024. If ARCA elects to stay in the property after September&#160;2024, it will pay rent month to month equal to 125% of the base rent paid in September&#160;2024. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in its primary business office (&#8220;2021 Lease&#8221;). The sublease term was 29&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(48</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-114; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Rent expense, which is included in general and administrative expense, for the three&#160;months ended March&#160;31, 2024 and 2023 was $22,000 and $31,000, respectively.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of March&#160;31, 2024, the lease liability was $48,000, it is all current and is included in accrued expenses and other liabilities in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the three&#160;months ended March&#160;31, 2024 and 2023 were $23,000 and $33,000, respectively. The weighted<span class="nobreak">-average</span> remaining lease term for the operating lease as of March&#160;31, 2024 is 0.5&#160;years. The discount rate for the operating lease is 7%.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In July&#160;2021, ARCA entered into a patent assignment agreement (the &#8220;Agreement&#8221;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Agreement, ARCA received exclusive world<span class="nobreak">-wide</span> patent rights relating to the use of rNAPc2 as a potential treatment for COVID<span class="nobreak">-19</span>, and other indications, based on the research and discoveries from Univ.<span class="nobreak">-Prof</span>. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#8220;CTH&#8221;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#8364;1.6&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(6)&#160;Commitments and Contingencies</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has or is subject to the following commitments and contingencies:</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Employment Agreements and Reduction of Workforce</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA maintains employment agreements with several key executive employees. The agreements may be terminated at any time by ARCA with or without cause upon written notice to the employee, and entitle the employee to wages in lieu of notice for periods not exceeding one calendar year from date of termination without cause or by the employee for good reason. Certain of these agreements also provide for payments to be made under certain conditions related to a change in control of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In December&#160;2022, ARCA&#8217;s Board of Directors approved retention bonuses for certain employees, subject to continued employment with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions totaling $265,000. In November&#160;2023, the retention bonuses were amended to increase the aggregate amount of the retention bonus by 50% and in order to assist with tax obligations associated with the vesting of certain Company restricted stock unit awards in December&#160;2023, a total of $86,000 was paid in December&#160;2023. As of December&#160;31, 2023, the unpaid retention bonuses totaled $311,000, none of which was accrued as of December&#160;31, 2023, since there had not been a change in control or clinical development decision.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Christopher D.&#160;Ozeroff, the Secretary, Senior Vice President and General Counsel of ARCA mutually agreed to conclude Mr.&#160;Ozeroff&#8217;s employment effective March&#160;31, 2023. Pursuant to Mr.&#160;Ozeroff&#8217;s existing employment agreement, as previously amended, ARCA will provide Mr.&#160;Ozeroff severance benefits pursuant to the terms of his existing employment agreement with ARCA, as previously amended. The severance benefits include severance payments and reimbursement to cover out<span class="nobreak">-of-pocket</span> costs to continue group health insurance benefits under COBRA, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such out<span class="nobreak">-of-pocket</span> expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). During the year ended December&#160;31, 2023, ARCA recorded an expense of $159,000 for these severance benefits, <span style="-sec-ix-hidden: hidden-fact-75">none</span> of which remains unpaid.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2022, ARCA implemented a strategic reduction of the workforce by approximately 67%, or 12 employees. Personnel reductions were primarily focused in research and development and general and administrative functions. The restructuring was a result of ARCA&#8217;s decision to manage operating costs and expenses. During the year ended December&#160;31, 2022, ARCA recorded total restructuring charges of approximately $755,000, of which $470,000 and $285,000 were recognized in research and development and general and administrative expenses, respectively, in connection with the restructuring, all in the form of one<span class="nobreak">-time</span> termination benefits, none of which remains unpaid.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Operating Lease</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On August&#160;29, 2020 ARCA entered into a lease agreement for approximately 5,200 square feet of office facilities in Westminster, Colorado which serves as ARCA&#8217;s primary business office effective October&#160;1, 2020 (&#8220;October&#160;2020 Lease&#8221;). The lease term is 42&#160;months beginning October&#160;1, 2020 and includes an option to renew for an additional 36<span class="nobreak"> </span>month term at the then prevailing rental rate. The exercise of the lease renewal option is at ARCA&#8217;s sole discretion. The amounts recorded assume ARCA will exercise its renewal option. In June&#160;2021, ARCA entered into a sublease agreement for approximately 3,000 square feet of additional office facilities in its primary business office (&#8220;2021 Lease&#8221;). The sublease term was 29&#160;months and terminated in October&#160;2023. The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non<span class="nobreak">-lease</span> component that is not included in the lease obligation.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">93</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">96</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">314</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(34</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(76</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">204</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Rent expense, which is included in general and administrative expense, under these leases for the&#160;years ended December&#160;31, 2023 and 2022 was $119,000 and $125,000, respectively.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, the lease liability was $280,000 and the current portion is included in accrued expenses and other liabilities and the non<span class="nobreak">-current</span> portion is in operating lease liability, net of current portion in the accompanying balance sheet. Cash paid for amounts included in the measurement of lease liabilities and the operating cash flows from operating leases for the&#160;years ended December&#160;31, 2023 and 2022 were $127,000 and $131,000, respectively. The weighted<span class="nobreak">-average</span> remaining lease term for the operating lease as of December&#160;31, 2023 is 3.2&#160;years. The weighted<span class="nobreak">-average</span> discount rate for the operating lease is 7%.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Patent Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In July&#160;2021, ARCA entered into a patent assignment agreement (the &#8220;Agreement&#8221;) with the University Medical Center of Johannes Gutenberg University Mainz, Germany.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the terms of the Agreement, ARCA received exclusive world<span class="nobreak">-wide</span> patent rights relating to the use of rNAPc2 as a potential treatment for COVID<span class="nobreak">-19</span>, and other indications, based on the research and discoveries from Univ.<span class="nobreak">-Prof</span>. Dr.&#160;Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (&#8220;CTH&#8221;) of the University Medical Center Mainz, and his collaborators. ARCA has upfront and potential milestone obligations to the University Medical Center Mainz that could total approximately &#8364;1.6&#160;million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Gencaro License</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has licensed worldwide rights to all preclinical and clinical data through the BEST trial for development of bucindolol. The patents that were the subject of this license are expired. If the license agreement is deemed enforceable, ARCA would incur milestone and royalty obligations upon the occurrence of certain events, including if the FDA grants marketing approval for Gencaro, upon regulatory marketing approval in Europe and Japan and based on achievement of specified product sales levels.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857375527888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Financings<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity Financings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity Financings</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;</span><span class="BoldItalic" style="font-style:italic;font-weight:bold;font-style:normal;font-weight:bold;">Equity Financings</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">At the Market Equity Financing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2020, ARCA entered into a Capital on Demand&#8482; Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as agent (&#8220;JonesTrading&#8221;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#8217;s common stock, par value $0.001 per share (&#8220;ARCA common stock&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In 2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>), which expired in March&#160;2024. In April&#160;2024, ARCA terminated the Sales Agreement in accordance with its terms.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No sales were made under the Sales Agreement in 2024 or 2023.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">See &#8220;Financing Transaction&#8221; discussion in Note&#160;10 below.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(7)&#160;Equity Financings</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">At the Market Equity Financing</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On July&#160;22, 2020, ARCA entered into a Capital on Demand<span class="Superscript" style="vertical-align:super;font-size:58%;">TM</span> Sales Agreement (the &#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC, as agent (&#8220;JonesTrading&#8221;), pursuant to which ARCA may offer and sell, from time to time through JonesTrading, shares of ARCA&#8217;s common stock, par value $0.001 per share (&#8220;ARCA&#160;common stock&#8221;), having an aggregate offering price of up to $54.0&#160;million (the &#8220;Shares&#8221;).</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Sales Agreement, JonesTrading may sell the Shares by any method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule&#160;415 promulgated under the Securities Act&#160;of&#160;1933, as amended, including sales made directly on or through the Nasdaq Capital Market, on any other existing trading market for ARCA common stock or to or through a market maker. In addition, under the amended Sales Agreement, JonesTrading may sell the Shares by any other method permitted by law, including in negotiated transactions. ARCA may instruct JonesTrading not to sell Shares if the sales cannot be effected at or above the price designated by ARCA from time to time.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a)&#160;the sale of all of the Shares subject to the Sales Agreement or (b)&#160;the termination of the Sales Agreement by JonesTrading or ARCA, as permitted therein.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA paid JonesTrading a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Shares and agreed to provide JonesTrading with customary indemnification and contribution rights. ARCA will also reimburse JonesTrading for certain specified expenses in connection with entering into the Sales Agreement.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">No sales were made in 2023 or 2022.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2021, ARCA amended the 2020 Sales Agreement and the amount available for the offering under its prospectus to ARCA&#8217;s registration statement on Form&#160;S<span class="nobreak">-3</span> (No.&#160;333<span class="nobreak">-254585</span>). The amount available for the offering under the prospectus supplement is subject to the limitation of not selling a total value amount of shares exceeding more than one<span class="nobreak">-third</span> of ARCA&#8217;s public float in any 12<span class="nobreak">-month</span> period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857376756432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Compensation</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;orphans:99;widows:1;margin-top:8pt;">For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense in the statements of operations (in thousands):</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Three&#160;Months Ended<br/>March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">163</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-116; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">41</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">204</p>	</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#8217;s stock incentive plans were as follows:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in&#160;years)</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">42,000</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-117; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-118; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(12,862</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17.45</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.30</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.82</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">502,517</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.71</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.55</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,816</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.30</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.82</p>	</td>	</tr>	</table><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(8)&#160;Share-based Compensation</span></p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock Plans</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s equity incentive plan, <span class="Italic" style="font-style:italic;font-weight:normal;">the 2020 Equity Incentive Plan </span>(the &#8220;Equity Plan&#8221;),<span class="Italic" style="font-style:italic;font-weight:normal;"> </span>was approved by stockholders on December&#160;10, 2020. The maximum number of shares issuable under this plan is 1,167,425<span class="nobreak"> </span>shares.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Equity Plan provides for the granting of stock options (including indexed options), restricted stock units, stock appreciation rights, restricted stock purchase rights, restricted stock bonuses, performance shares, performance units and deferred stock units. Under the Equity Plan, awards may be granted to employees, directors and consultants of ARCA, except for incentive stock options, which may be granted only to employees. As of December&#160;31, 2023, options to purchase 601,900<span class="nobreak"> </span>shares with a weighted average exercise price of $3.45 per share were outstanding under the Equity Plan, and 459,718<span class="nobreak"> </span>shares were reserved for future awards.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In general, the Equity Plan authorizes the grant of stock options that vest at rates set by the Board of Directors or the Compensation Committee thereof. Generally, stock options granted by ARCA under the equity incentive plans become exercisable ratably for a period of <span style="-sec-ix-hidden: hidden-fact-97">three</span> to <span style="-sec-ix-hidden: hidden-fact-98">four</span>&#160;years from the date of grant and have a maximum term of <span style="-sec-ix-hidden: hidden-fact-99">ten</span>&#160;years. The exercise prices of stock options under the equity incentive plan generally meet the following criteria: the exercise price of incentive stock options must be at least 100% of the fair market value on the grant date and exercise price of options granted to 10% (or greater) stockholders must be at least 110% of the fair market value on the grant date.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In conjunction with the adoption of the Equity Plan, ARCA discontinued grants under the 2013 Plan, effective December&#160;10, 2020. As of December&#160;31, 2023, options to purchase 14,807<span class="nobreak"> </span>shares with a weighted average exercise price of $57.73 per share were outstanding under the 2013 plan.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA did not grant options in 2023. ARCA granted options to purchase an aggregate of 60,000<span class="nobreak"> </span>shares of ARCA common stock in the year ended December&#160;31, 2022. The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black<span class="nobreak">-Scholes</span> model with the following assumptions and had the following estimated weighted average grant date fair value per share:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Year Ended<br/>December&#160;31,<br/>2022</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected term</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected volatility</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">107</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free interest rate</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.56</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected dividend yield</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average grant date fair value per share</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.87</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A summary of ARCA&#8217;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in&#160;years)</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2021</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">904,123</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.59</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">60,000</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.31</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-76; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-77; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(259,163</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.74</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2022</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">704,960</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.62</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.29</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-78; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-79; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-80; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-81; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(88,253</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11.68</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-82; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">463,068</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.28</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.29</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-83; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,661</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-84; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	</tr>	</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The aggregate intrinsic value in the table above represents the total intrinsic value, based on ARCA&#8217;s closing price as of December&#160;31 of the respective year, which would have been received by the option holders had all the option holders with in<span class="nobreak">-the-money</span> options exercised as of that date. As of December&#160;31, 2023, the unrecognized compensation expense related to unvested options, excluding estimated forfeitures, was $367,000 which is expected to be recognized over a weighted average period of 1.1&#160;years. ARCA recognizes compensation costs for its share<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Restricted Stock Units</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA granted restricted stock units (&#8220;RSUs&#8221;) under the Equity Plan to employees during 2022. The fair value of RSU awards is the closing price of ARCA common stock on the date of the grant and is recognized as compensation expense on a straight<span class="nobreak">-line</span> basis over the respective vesting period. The stock awards granted had a requisite service period of <span style="-sec-ix-hidden: hidden-fact-100">one</span> year.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Restricted Stock Units<br/>Outstanding</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-85; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-86; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-87; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-88; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-89; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-90; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-91; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-92; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-93; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-94; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-95; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-96; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As of December&#160;31, 2023, there was no unrecognized compensation cost related to unvested stock awards.</p>
		<p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Non-cash Stock-based Compensation</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">526</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">423</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">160</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">133</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">686</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">556</p>	</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA did not recognize any tax benefit related to employee stock<span class="nobreak">-based</span> compensation cost as a result of the full valuation allowance on its net deferred tax assets.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857375751024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(9)&#160;Employee Benefit Plans</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA has a 401(k)&#160;plan and makes a matching contribution equal to 100% of the employee&#8217;s first 3% of the employee&#8217;s contributions and 50% of the employee&#8217;s next 2% of contributions. ARCA adopted the plan in 2006 and contributed $56,000 and $96,000 for the&#160;years ended December&#160;31, 2023 and 2022, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857375781840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(9)&#160;Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with GAAP, a valuation allowance should be provided if it is more likely than not that some or all of ARCA&#8217;s deferred tax assets will not be realized. ARCA&#8217;s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, ARCA has recorded a full valuation allowance against its net deferred tax assets. ARCA believes its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and, therefore, has <span style="-sec-ix-hidden: hidden-fact-119">no</span> reserve for uncertain tax positions.</p><span></span>
</td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;">(<span class="Bold" style="font-style:normal;font-weight:bold;">10)&#160;Income Taxes</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective June&#160;1, 2005, ARCA changed from an S<span class="nobreak">-Corporation</span> to a C<span class="nobreak">-Corporation</span>. As an S<span class="nobreak">-Corporation</span>, the net operating loss carryforwards were distributed to ARCA&#8217;s stockholders; such amounts were not significant. As of December&#160;31, 2023, ARCA has net operating loss carryforwards of approximately $208.1&#160;million, and approximately $2.4&#160;million of research and development credits that may be used to offset future taxable income. ARCA&#8217;s net operating loss carryforwards through December&#160;31, 2017 will expire beginning <span style="-sec-ix-hidden: hidden-fact-107">2025</span> through <span style="-sec-ix-hidden: hidden-fact-108">2037</span>. The net operating loss carryforwards beginning in 2018, have no expiration. Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#8217;s net operating loss carryforwards may be limited.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due primarily to ARCA&#8217;s history of operating losses, management is unable to conclude that it is more likely than not that ARCA will realize the benefits of these deductible differences, and accordingly has provided a valuation allowance against the entire net deferred tax assets and liabilities of approximately $55.5&#160;million at December&#160;31, 2023, reflecting an increase of approximately $1.2&#160;million from December&#160;31, 2022. The deferred tax assets are primarily comprised of net operating loss carryforwards and research and experimentation credit carryforwards. As of December&#160;31, 2023, ARCA has not performed an Internal Revenue Code Section&#160;382 limitation study. Depending on the outcome of such a study, the gross amount of net operating losses recognizable in future tax periods could be limited. A limitation in the carryforwards would decrease the carrying amount of the gross amount of the net operating loss carryforwards, with a corresponding decrease in the valuation allowance recorded against these gross deferred tax assets.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Income tax benefit attributable to ARCA&#8217;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of 21% for 2023 and 2022, as a result of the following (in thousands):</p>
		<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">U.S.&#160;federal income tax benefit at statutory rates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,121</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,085</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State income tax benefit, net of federal benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(192</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(357</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-101; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-102; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax asset adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">47</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">107</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">186</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,159</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,254</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-103; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-104; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#8217;s net deferred tax assets and liabilities consisted of the following (in thousands):</p>
		<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net operating loss carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">51,190</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">50,008</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Charitable contribution carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">371</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">393</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,420</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,420</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized research and development costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">951</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">979</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized intangibles</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">354</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">356</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">232</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">205</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lease liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">69</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">94</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total deferred tax assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,594</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">54,461</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(55,531</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(54,372</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets, net of valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">63</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">89</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(61</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(84</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net deferred tax liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Since ARCA is in a loss carryforward position, it is generally subject to U.S.&#160;federal and state income tax examinations by tax authorities for all&#160;years for which a loss carryforward is available. Thus, ARCA&#8217;s open tax&#160;years extend back to <span style="-sec-ix-hidden: hidden-fact-109">2009</span>. ARCA believes that its tax filing positions and deductions related to tax periods subject to examination will be sustained upon audit and does not anticipate any adjustment will result in a material adverse effect on ARCA&#8217;s financial condition, result of operations, or cash flow. For the&#160;years ended December&#160;31, 2023 and 2022, ARCA has no reserve for uncertain tax positions. ARCA does not expect that the total amounts of unrecognized tax benefits will significantly increase or decrease within the subsequent twelve&#160;months. In the event ARCA concludes it is subject to interest or penalties arising from uncertain tax positions, it will record interest and penalties as a component of other income and expense. No interest or penalties were recognized in the financial statements for the&#160;years ended December&#160;31, 2023 and 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857375775616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">(10)&#160;Subsequent Events</span></p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Merger Agreement</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, ARCA, Merger Sub&#160;I, Merger Sub&#160;II and Oruka, entered into the Merger Agreement, pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger. The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Subject to the terms and conditions of the Merger Agreement, at the closing of the First Merger, (a)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka common stock (including shares of Oruka common stock issued in the financing transaction described below) will be converted solely into the right to receive a number of shares of ARCA common stock calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;), (b)&#160;each then<span class="nobreak">-outstanding</span> share of Oruka preferred stock will be converted into the right to receive a number of shares of Series&#160;B Preferred Stock (as defined below) of ARCA, calculated in accordance with the Merger Agreement (c)&#160;each then<span class="nobreak">-outstanding</span> option to purchase Oruka common stock will be assumed by ARCA, subject to adjustment as set forth in the Merger Agreement and (d)&#160;each then<span class="nobreak">-outstanding</span> warrant to purchase shares of Oruka common stock will be converted into a warrant to purchase shares of ARCA common stock, subject to adjustment as set forth in the Merger Agreement and form of warrant. Under the terms of the Merger Agreement, prior to the closing of the transaction, the Board will accelerate the vesting of all equity awards of ARCA then outstanding but not then vested or exercisable, and cancel each option (the &#8220;Out of the Money Options&#8221;) to acquire shares of ARCA common stock with an exercise price per share greater than the volume weighted average closing trading price of a share of ARCA common stock on The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) for the five (5)&#160;consecutive&#160;trading days ending three (3)&#160;days immediately prior to the closing date of the First Merger (the &#8220;Parent Closing Price&#8221;), in each case, in accordance with the terms of the Merger Agreement. At the closing of the First Merger, each option to acquire shares of ARCA common stock with an exercise price less than or equal to the Parent Closing Price will be cancelled and converted into the right to receive an amount in cash, without interest, equal to the Parent Closing Price less the exercise price of such option.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Under the Exchange Ratio formula in the Merger Agreement, upon the closing of the First Merger, on a pro forma basis and based upon the number of shares of ARCA common stock expected to be issued in the First Merger, pre<span class="nobreak">-First</span> Merger Oruka stockholders (including Oruka stockholders issued shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants in the financing transaction described below) will own approximately 97.62% of the combined company and pre<span class="nobreak">-First</span> Merger ARCA stockholders will own approximately 2.38% of the combined company. For purposes of calculating the Exchange Ratio, (i)&#160;shares of ARCA common stock underlying warrants and other rights to receive shares (other than Options to acquire shares of ARCA common stock, to the extent cancelled at or prior to closing of the First Merger in accordance with the Merger Agreement) outstanding as of immediately prior to the closing of the First Merger will be deemed to be outstanding, and (ii)&#160;all shares of Oruka common stock underlying outstanding Oruka stock options and warrants will be deemed to be outstanding. The Exchange Ratio will be </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">adjusted to the extent that ARCA&#8217;s net cash at closing is less than $5.0&#160;million and will be based on the amount of proceeds actually received by Oruka in the financing transaction described below, as further described in the Merger Agreement.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In addition, prior to the closing of the First Merger, ARCA expects to declare a cash dividend to the pre<span class="nobreak">-First</span> Merger ARCA stockholders equal in the aggregate to ARCA&#8217;s reasonable, good faith approximation of the amount by which ARCA&#8217;s net cash (as determined pursuant to the Merger Agreement) will exceed $5,000,000.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with the Merger, ARCA is required to seek the approval of its stockholders to, among other things, (a)&#160;issue shares of ARCA common stock issuable in connection with the First Merger (including the shares of ARCA common stock issuable under the Series&#160;B Preferred Stock) under the rules of Nasdaq, and (b)&#160;amend its amended and restated certificate of incorporation, to (i)&#160;effect a reverse stock split of ARCA common stock (if deemed necessary by ARCA and Oruka), (ii)&#160;increase the number of shares of ARCA common stock that ARCA is authorized to issue, and (iii)&#160;such other changes as are mutually agreeable to ARCA and Oruka (the &#8220;ARCA Voting Proposals&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Each of ARCA and Oruka has agreed to customary representations, warranties and covenants in the Merger Agreement, including, among others, covenants relating to (1)&#160;using commercially reasonable efforts to obtain the requisite approval of its stockholders, (2)&#160;non<span class="nobreak">-solicitation</span> of alternative acquisition proposals, (3)&#160;the conduct of their respective businesses during the period between the date of signing the Merger Agreement and the closing of the Merger, (4)&#160;ARCA using commercially reasonable efforts to maintain the existing listing of the ARCA common stock on Nasdaq and cause the shares of ARCA common stock to be issued in connection with the First Merger to be approved for listing on Nasdaq prior to the closing of the First Merger, and (5)&#160;ARCA filing with the U.S.&#160;Securities and Exchange Commission (the &#8220;SEC&#8221;) and causing to become effective a registration statement to register shares of ARCA common stock to be issued in connection with the First Merger, except as set forth in the Merger Agreement (the &#8220;Registration Statement&#8221;).</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Consummation of the Merger is subject to certain closing conditions, including, among other things, (1)&#160;approval by ARCA stockholders of the ARCA Voting Proposals, (2)&#160;approval by the requisite Oruka stockholders of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, (3)&#160;Nasdaq&#8217;s approval of the initial listing application to be submitted in connection with the First Merger, (4)&#160;the effectiveness of the Registration Statement, (5)&#160;the expiration of any applicable waiting periods (or extensions thereof) under the Hart Scott<span class="nobreak">-Rodino</span> Antitrust Improvements Act&#160;of&#160;1976, as amended, (6)&#160;the subscription agreements (described below) being in full force and effect providing for the receipt of proceeds of not less than $175,000,000 (including in the proceeds any notes contributed as consideration in the financing transaction described below) and (7)&#160;to the extent ARCA has declared the cash dividend described above, ARCA delivering the aggregate amount distributable to the pre<span class="nobreak">-First</span> Merger ARCA stockholders to ARCA&#8217;s transfer agent for further distribution to the pre<span class="nobreak">-First</span> Merger ARCA stockholders. Each party&#8217;s obligation to consummate the Merger is also subject to other specified customary conditions, including regarding the accuracy of the representations and warranties of the other party, subject to the applicable materiality standard, and the performance in all material respects by the other party of its obligations under the Merger Agreement required to be performed on or prior to the date of the closing of the Merger.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The Merger Agreement contains certain termination rights of each of ARCA and Oruka. Upon termination of the Merger Agreement under specified circumstances, ARCA and Oruka may each be required to pay the other party a termination fee of $440,000.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Pursuant to a Certificate of Designation of Preferences, Rights and Limitations of the Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock to be filed by ARCA with the Secretary of State of the State of Delaware (the &#8220;Certificate of Designation&#8221;) in connection with the Merger Agreement and the transactions thereunder, ARCA will establish the terms of a new series of preferred stock of ARCA designated as Series&#160;B Non<span class="nobreak">-Voting</span> Convertible Preferred Stock, par value $0.001 per share (the &#8220;Series&#160;B Preferred Stock&#8221;). Holders of the Series&#160;B Preferred Stock will be entitled to receive dividends on shares of Series&#160;B Preferred Stock equal to, on an as<span class="nobreak">-if-converted-to-ARCA</span> common stock </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">basis, and in the same form as dividends actually paid on shares of the ARCA common stock. Except as otherwise required by the Certificate of Designation or law, the Series&#160;B Preferred Stock will not have voting rights. However, as long as any shares of Series&#160;B Preferred Stock are outstanding, ARCA will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series&#160;B Preferred Stock, (a)&#160;alter or change adversely the powers, preferences or rights given to the Series&#160;B Preferred Stock, (b)&#160;alter or amend the Certificate of Designation, (c)&#160;amend its certificate of incorporation, bylaws or other charter documents in any manner that adversely affects any rights of the holders of the Series&#160;B Preferred Stock, (d)&#160;file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred Stock (as defined in the Certificate of Designation), if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series&#160;B Preferred Stock, (e)&#160;issue further shares of the Series&#160;B Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of the Series&#160;B Preferred Stock, (f)&#160;at any time while at least 30% of the originally issued Series&#160;B Preferred Stock remains issued and outstanding, consummate either (A)&#160;a Fundamental Transaction (as defined in the Certificate of Designation) or (B)&#160;any merger or consolidation of ARCA or other business combination in which the stockholders of ARCA immediately before such transaction do not hold at least a majority of the capital stock of ARCA immediately after such transaction, or (f)&#160;enter into any agreement with respect to any of the foregoing. The Series&#160;B Preferred Stock does not have a preference upon any liquidation, dissolution or winding<span class="nobreak">-up</span> of ARCA.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Following the closing of the First Merger, each share of Series&#160;B Preferred Stock then outstanding shall be convertible, at any time and from time to time, at the option of the holder of the Series&#160;B Preferred Stock, into a number of shares equal to 1,000<span class="nobreak"> </span>shares of ARCA common stock, subject to certain limitations, including that a holder of Series&#160;B Preferred Stock is prohibited from converting shares of Series&#160;B Preferred Stock into shares of ARCA common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (initially set at 9.99%) of the total number of shares of ARCA common stock issued and outstanding immediately after giving effect to such conversion.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">At the effective time of the First Merger (the &#8220;First Effective Time&#8221;), the combined company&#8217;s board of directors is expected to consist of five (5)&#160;members, all of whom will be designated by Oruka. Upon the closing of the transaction, the combined company will be led by Oruka&#8217;s chief executive officer.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Financing Transaction</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Concurrently with the execution and delivery of the Merger Agreement, certain parties have entered into a subscription agreements with Oruka, pursuant to which they have agreed, subject to the terms and conditions of such agreements, to purchase immediately prior to the consummation of the First Merger, shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock (together, the &#8220;PIPE Securities&#8221;) for an aggregate purchase price of approximately $275.0&#160;million. The consummation of the transactions contemplated by such agreements is conditioned on the satisfaction or waiver of the conditions set forth in the Merger Agreement and in the subscription agreement. Shares of Oruka common stock and pre<span class="nobreak">-funded</span> warrants to purchase shares of Oruka common stock issued pursuant to this financing transaction will be converted into shares of ARCA common stock and pre<span class="nobreak">-funded</span> warrants to acquire shares ARCA common stock, in accordance with the Exchange Ratio and the Merger Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Separation of Michael Bristow, M.D., President, Chief Executive Officer and Director</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective April&#160;3, 2024, ARCA and Dr.&#160;Michael Bristow, President, Chief Executive Officer and a member of the Board mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment and service as a director.</p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In connection with Dr.&#160;Bristow&#8217;s separation, ARCA and Dr.&#160;Bristow entered into a separation agreement (the &#8220;Separation Agreement&#8221;) on April&#160;3, 2024. Pursuant to the terms of the Separation Agreement, ARCA provided to Dr.&#160;Bristow a lump sum payment equal to (i)&#160;twelve (12)&#160;months of Dr.&#160;Bristow&#8217;s base salary as of the last date of his employment and (ii)&#160;a cash payment of $25,000, less applicable withholdings. The severance benefits were conditioned on the non<span class="nobreak">-revocation</span> by Dr.&#160;Bristow of a legal release of claims.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA and Dr.&#160;Bristow entered into a consulting agreement, effective April&#160;3, 2024 (the &#8220;Consulting Agreement&#8221;), pursuant to which Dr.&#160;Bristow is providing certain consulting services provided for in the Consulting Agreement to ARCA until the earlier of (i)&#160;the completion of services under the Consulting Agreement, (ii)&#160;a termination in accordance with the terms of the Consulting Agreement, and (iii)&#160;upon a Change of Control (as defined in ARCA&#8217;s 2020 Equity Incentive Plan (the &#8220;Plan&#8221;)). Pursuant to the Consulting Agreement, Dr.&#160;Bristow provision of services under the Consulting Agreement are deemed to be a Continuous Service (as defined in the Plan) and, as a result, his equity awards under the Plan continue to vest during the term of the Consulting Agreement.</p>
		<p class="H2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Appointment of Thomas Keuer as President</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Effective as of April&#160;3, 2024, the Board appointed Thomas A.&#160;Keuer, ARCA&#8217;s Chief Operating Officer, to serve as ARCA&#8217;s President and principal executive officer. Mr.&#160;Keuer has been with ARCA since 2006, and as its Chief Operating Officer for the last nine&#160;years, a position he will continue to serve in. Mr.&#160;Keuer will not receive any additional compensation in connection with his appointment as President and principal executive officer. Mr.&#160;Keuer&#8217;s position will end upon closing of the merger transaction with Oruka Therapeutics, Inc. as previously disclosed on a Current Report on Form&#160;8<span class="nobreak">-K</span> filed with the SEC on April&#160;3, 2024.</p>
		<p class="Q-A-Style" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:24pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Second Amendment to Retention Bonus Letter of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker</span></p>
		<p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of certain retention bonus letters between ARCA and each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker to increase the aggregate amount of the retention bonus with respect to each such executive to $200,000. The remaining portion of the retention bonus with respect to Thomas A. Keuer and C. Jeffrey Dekker, consisting of $165,000, will become payable consistent with the original terms of the applicable retention bonus letter and first amendment to retention bonus letter. Any payment related to the retention bonuses of Thomas A. Keuer and C. Jeffrey Dekker will be paid by ARCA via payroll within&#160;30 business days of the date of occurrence of the applicable &#8220;Payment Event Date&#8221; (as such term is otherwise defined in the applicable second amendment to the retention bonus letter). Each such retention bonus letter and first amendment to retention bonus letter will otherwise remain subject to their original terms and conditions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857376507552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ARCA and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DescriptionOfBusinessPolicyTextBlock', window );">Description of Business</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:8pt;margin-top:8pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, ARCA established a Special Committee of the board of directors (the &#8220;Board&#8221;) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, ARCA explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. ARCA has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">On April&#160;3, 2024, following a comprehensive review of strategic alternatives, ARCA, Atlas Merger Sub Corp., a Delaware corporation and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;I&#8221;), Atlas Merger Sub&#160;II LLC, a Delaware limited liability company and a wholly<span class="nobreak">-owned</span> subsidiary of ARCA (&#8220;Merger Sub&#160;II&#8221;) and Oruka Therapeutics, Inc., a Delaware corporation (&#8220;Oruka<span class="CharOverride-1" style="text-decoration:underline;">&#8221;</span>), entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub&#160;I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;) and as part of the same overall transaction, the surviving corporation in the First Merger will merge with and into Merger Sub&#160;II with Merger Sub&#160;II continuing as a wholly owned subsidiary of ARCA and the surviving entity of the merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;). The Merger is intended to qualify for federal income tax purposes as a tax<span class="nobreak">-free</span> reorganization under the provisions of Section&#160;368(a)&#160;of the Internal Revenue Code of 1986, as amended.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s future operations are highly dependent on the success of the Merger and there can be no assurances that the Merger will be successfully consummated. In the event that ARCA does not complete the Merger, it may explore strategic alternatives, including, without limitation, another strategic transaction and/or pursue a dissolution and liquidation of ARCA. See Note&#160;10.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Description of Business</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA biopharma, Inc. (&#8220;ARCA&#8221;), a Delaware corporation, is headquartered in Westminster, Colorado. ARCA is a clinical<span class="nobreak">-stage</span> biopharmaceutical company applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. ARCA&#8217;s lead product candidate is Gencaro&#8482; (bucindolol hydrochloride) for the treatment of atrial fibrillation (&#8220;AF&#8221;) in patients with chronic heart failure (&#8220;HF&#8221;).</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In April&#160;2022, the Board of Directors established a Special Committee and, in May&#160;2022, retained Ladenburg Thalmann&#160;&amp; Co. Inc. to evaluate strategic options, including transactions involving a merger, sale of all or part of ARCA&#8217;s assets, or other alternatives with the goal of maximizing stockholder value. ARCA does not have a defined timeline for the strategic review process and the review may not result in any specific action or transaction.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of March&#160;31, 2024 will be sufficient to fund its operations through the middle of fiscal year 2025. The future viability of ARCA beyond that point is dependent on the results of the strategic review process and its ability to raise additional capital to fund its operations. ARCA expects to continue to incur costs and expenditures in connection with the process of evaluating strategic alternatives. There can be no assurance, however, that ARCA will be able to successfully consummate any particular strategic transaction, including the Merger Agreement. The process of continuing to evaluate these strategic options may be very costly, time<span class="nobreak">-consuming</span> and complex and ARCA has incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal, accounting and advisory fees and expenses and other related charges, see Note&#160;10 regarding the Merger Agreement. Should ARCA pursue additional clinical trials for its product candidates, it will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">able to execute any strategic transaction. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and it could exhaust its available financial resources sooner than it currently anticipates. Depending on the results of the strategic review process, ARCA may have to raise additional capital for clinical trials of Gencaro and to fund its operations. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the timing and outcome of the strategic review process;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the consummation of any particular strategic transactions, including the Merger;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:8pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Liquidity and Going Concern</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. ARCA has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. ARCA has historically funded its operations through issuances of common and preferred stock.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA believes that its current cash and cash equivalents as of December&#160;31, 2023 will be sufficient to fund its operations through the middle of fiscal year 2025. ARCA&#8217;s review of its strategic options may impact this projection. Changing circumstances may cause ARCA to consume capital significantly faster or slower than currently anticipated. ARCA has based these estimates on assumptions that may prove to be wrong, and ARCA could exhaust its available financial resources sooner than it currently anticipates. Therefore, ARCA will have to raise additional capital for clinical trials of Gencaro. ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of Gencaro or rNAPc2 or to otherwise continue operations and may not be able to execute any strategic transaction.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s liquidity, and its ability to raise additional capital or complete any strategic transaction, depends on a number of factors, including, but not limited to, the following:</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs and timing for the potential additional clinical trials in order to gain possible regulatory approval for Gencaro, rNAPc2, or any other product candidate;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the market price of ARCA&#8217;s stock and the availability and cost of additional equity capital from existing and potential new investors;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to retain the listing of its common stock on the Nasdaq Capital Market;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>general economic and industry conditions affecting the availability and cost of capital, including as a result of deteriorating market conditions due to investor concerns regarding inflation, adverse developments affecting the financial services industry, continued hostilities between Russia and Ukraine and Hamas&#8217; attack against Israel and the ensuing conflict;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>ARCA&#8217;s ability to control costs associated with its operations;</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and</p><p class="BL_m" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;list-style-position:outside;list-style-type:disc;margin-bottom:0;margin-left:48pt;margin-right:0;margin-top:8pt;orphans:2;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-24pt;widows:3;list-style-type:none;margin-top:6pt;margin-top:6pt;"><span class="bullet" style="font-size:10pt;">&#8226;<span style="width: 27px;display: inline-block;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></span>the terms and conditions of ARCA&#8217;s existing collaborative and licensing agreements.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The sale of additional equity or convertible debt securities would likely result in substantial additional dilution to ARCA&#8217;s stockholders. If ARCA raises additional funds through the incurrence of indebtedness, the obligations related to such indebtedness would be senior to rights of holders of ARCA&#8217;s capital stock and could contain covenants that would restrict ARCA&#8217;s operations. ARCA also cannot predict what consideration might be available, if any, to it or its stockholders, in connection with any strategic transaction. Should strategic alternatives or additional capital not be available to ARCA, or not be available on acceptable terms, ARCA may be unable to realize value from its assets and discharge its liabilities in the normal course of business which may, among other alternatives, cause ARCA to further delay, substantially reduce or discontinue operational activities to conserve its cash resources.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying unaudited financial statements of ARCA were prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to Regulation&#160;S<span class="nobreak">-X</span>.&#160;Accordingly, these financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United&#160;States of America (&#8220;GAAP&#8221;) for complete financial statements. In the opinion of management, these financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim financial statements. The results of operations for the three&#160;months ended March&#160;31, 2024 are not necessarily indicative of results expected for the full year ending December&#160;31, 2024. ARCA has generated no revenue to date and its activities have consisted of seeking regulatory approval, research and development, exploring </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">strategic alternatives for further developing and commercializing Gencaro and rNAPc2, and raising capital. These unaudited financial statements should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December&#160;31, 2023 included elsewhere in this proxy statement/prospectus. Amounts presented are rounded to the nearest thousand, where indicated, except per share data and par values.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Basis of Presentation</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The accompanying financial statements have been prepared in accordance with U.S.&#160;generally accepted accounting principles (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of ARCA&#8217;s financial position, results of operations and cash flows for the periods presented. Management has performed an evaluation of ARCA&#8217;s activities through the date of filing of the Annual Report on Form&#160;10<span class="nobreak">-K</span>.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact to the financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates in the Preparation of Financial Statements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accounting Estimates in the Preparation of Financial Statements</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United&#160;States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. ARCA bases estimates on various assumptions that are believed to be reasonable under the circumstances. ARCA believes significant judgment was involved in estimating the outsourcing expenses, and in estimating other accrued liabilities and income taxes. Management is continually evaluating and updating these estimates, and it is possible that these estimates will change in the future or that actual results may differ from these estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Cash Equivalents</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Cash equivalents generally consist of money market funds and debt securities with maturities of 90&#160;days or less at the time of purchase. ARCA invests its excess cash in securities with strong ratings and has established guidelines relative to diversification and maturity with the objective of maintaining safety of principal and liquidity.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Concentrations of Credit Risk</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Financial instruments that potentially subject ARCA to significant concentrations of credit risk consist primarily of cash and cash equivalents. ARCA has no off<span class="nobreak">-balance-sheet</span> concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. ARCA maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Property and Equipment</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Cost includes expenditures for equipment, leasehold improvements, replacements, and renewals. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">property and equipment is depreciated using the straight<span class="nobreak">-line</span> method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the shorter of the life of the lease or the estimated useful life of the assets.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ComprehensiveLossPolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the three&#160;months ended March&#160;31, 2024 and 2023.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Comprehensive Loss</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non<span class="nobreak">-owner</span> sources. If ARCA had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity. There were no elements of comprehensive loss during the&#160;years ended December&#160;31, 2023 and 2022.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s March&#160;31, 2024 and December&#160;31, 2023 balance sheets.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s leases do not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate a lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Leases</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA determines if an arrangement is a lease at inception. Operating leases are included in right<span class="nobreak">-of-use</span> (&#8220;ROU&#8221;) asset&#160;&#8212;&#160;operating and lease obligations are included in accrued expenses and other liabilities and operating lease liability on ARCA&#8217;s December&#160;31, 2023 and 2022 balance sheets.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ROU lease assets represent ARCA&#8217;s right to use an underlying asset for the lease term and lease obligations represent ARCA&#8217;s obligation to make lease payments arising from the lease. Operating ROU lease assets are recognized at the commencement date based on the present value of lease payments over the lease term. As ARCA&#8217;s lease does not provide an implicit rate, ARCA uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. ARCA&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that ARCA will exercise that option. Lease expense for lease payments is recognized on a straight<span class="nobreak">-line</span> basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AccruedOutsourcingExpensesPolicyTextBlock', window );">Accrued Outsourcing Expenses</a></td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p><span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Accrued Outsourcing Expenses</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">As part of the process of preparing its financial statements, ARCA is required to estimate accrued outsourcing expenses. This process involves identifying services that third parties have performed on ARCA&#8217;s behalf and estimating the level of service performed and the associated cost incurred for these services as of the balance sheet date. Examples of estimated accrued outsourcing expenses include contract service fees, such as fees payable to contract manufacturers in connection with the production of materials related to ARCA&#8217;s drug product, and service fees and pass through costs from clinical research organizations. ARCA develops estimates of liabilities using its judgment based upon the facts and circumstances known at the time.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Segments</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA operates in one segment. Management uses one measure of profitability and does not segment its business for internal reporting.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Research and Development</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Research and development costs are expensed as incurred. These consist primarily of salaries, contract services, and supplies.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">Costs, if any, related to clinical trial and drug manufacturing activities are based upon estimates of the services received and related expenses incurred by contract research organizations (&#8220;CROs&#8221;), clinical study sites, drug manufacturers, collaboration partners, laboratories, consultants, or otherwise. Related contracts vary significantly in length, and could be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of these elements. Activity levels are monitored through communications with the vendors, including detailed invoices and task completion review, analysis of expenses against budgeted amounts, and pre<span class="nobreak">-approval</span> of any changes in scope of the services to be performed. Certain significant vendors may also provide </p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;text-indent:0pt;margin-top:8pt;">an estimate of costs incurred but not invoiced on a periodic basis. Expenses related to the CROs and clinical studies, as well as contract drug manufacturers, are primarily based on progress made against specified milestones or targets in each period.</p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">In accordance with certain research and development agreements, ARCA is obligated to make certain upfront payments upon execution of the agreement. ARCA records these upfront payments as prepaid research and development expenses, which are included in Other current assets or Other assets in the accompanying Balance Sheets. Such payments are recorded to research and development expense as services are performed. ARCA evaluates on a quarterly basis whether events and circumstances have occurred that may indicate impairment of remaining prepaid research and development expenses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Stock-Based Compensation</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">ARCA&#8217;s stock<span class="nobreak">-based</span> compensation cost recognized is based on the estimated grant date fair value. ARCA recognizes compensation costs for its stock<span class="nobreak">-based</span> awards on a straight<span class="nobreak">-line</span> basis over the requisite service period for the entire award, as adjusted for expected forfeitures.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p class="H3" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:italic;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:0;margin-top:12pt;orphans:99;page-break-after:avoid;page-break-before:auto;text-align:left;text-indent:0;widows:1;margin-top:12pt;"><span class="BoldItalic" style="font-style:italic;font-weight:bold;">Income Taxes</span></p><p class="Text_flush" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:8pt;orphans:3;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:24pt;widows:3;margin-top:8pt;">The current benefit for income taxes represents actual or estimated amounts payable or refundable on tax returns filed or to be filed each year. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. The overall change in deferred tax assets and liabilities for the period measures the deferred tax expense or benefit for the period. The measurement of deferred tax assets may be reduced by a valuation allowance based on judgmental assessment of available evidence if deemed more likely than not that some or all of the deferred tax assets will not be realized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AccruedOutsourcingExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued outsourcing expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_AccruedOutsourcingExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ComprehensiveLossPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comprehensive loss policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ComprehensiveLossPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DescriptionOfBusinessPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DescriptionOfBusinessPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857375541776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Shares of Common Stock</a></td>
<td class="text">Because ARCA reported a net loss for the three&#160;months ended March&#160;31, 2024 and 2023, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">664,857</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-110; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">755,857</p>	</td>
				</tr>

		</table><span></span>
</td>
<td class="text">Because ARCA reported a net loss for the&#160;years ended December&#160;31, 2023 and 2022, all potentially dilutive shares of ARCA common stock have been excluded from the computation of the dilutive net loss per share for all periods presented. Such potentially dilutive shares of ARCA common stock consist of the following:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;"><span class="Bold" style="font-style:normal;font-weight:bold;">Potentially dilutive securities, excluded:</span></p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Outstanding stock options</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">704,960</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Unvested restricted stock units</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-70; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">795,960</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857375567120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">Property and equipment consist of the following (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">March&#160;31,<br/>2024</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(215</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(212</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table><span></span>
</td>
<td class="text">Property and equipment consist of the following (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Estimated<br/>Life</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2023</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">December&#160;31,<br/>2022</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">39</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lab equipment</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">130</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Furniture and fixtures</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">37</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">44</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Computer software</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_centeralign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;">3&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">16</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">222</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">229</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accumulated depreciation and amortization</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(212</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(204</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Property and equipment, net</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">10</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857375842672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Commitments Due</a></td>
<td class="text">Future minimum commitments due under the October&#160;2020 Lease agreement, as amended, as of March&#160;31, 2024 are as follows (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">49</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(48</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-114; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
<td class="text">Future minimum commitments due under the October&#160;2020 Lease agreement as of December&#160;31, 2023 are as follows (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2024</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">93</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2025</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">96</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2026</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">100</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">2027</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">25</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total remaining lease payments</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">314</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: imputed lease interest</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(34</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Less: Current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(76</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Operating lease liability, net of current portion</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">204</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857481398880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The fair values of employee stock options granted in the year ended December&#160;31, 2022 were estimated at the date of grant using the Black<span class="nobreak">-Scholes</span> model with the following assumptions and had the following estimated weighted average grant date fair value per share:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-13" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Year Ended<br/>December&#160;31,<br/>2022</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected term</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.5&#160;years</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected volatility</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">107</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Risk-free interest rate</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">3.56</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Expected dividend yield</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">0</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">%</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 83.33%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Weighted-average grant date fair value per share</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.87</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	</tr>	</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activities</a></td>
<td class="text">Stock option transactions for the three&#160;months ended March&#160;31, 2024 under ARCA&#8217;s stock incentive plans were as follows:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 46.15%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-15" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(in&#160;years)</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">42,000</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1.64</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-117; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-118; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(12,862</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">17.45</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,845</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.30</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.82</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">502,517</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.71</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.55</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 52.56%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;March&#160;31, 2024</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">645,816</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.30</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6.82</p>	</td>	</tr>	</table><span></span>
</td>
<td class="text">A summary of ARCA&#8217;s stock option activities for the&#160;years ended December&#160;31, 2023 and 2022, and related information as of December&#160;31, 2023, is as follows:<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">	<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="10" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 61.11%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Options Outstanding</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-17" style="height:12pt;">	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Options</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in&#160;years)</span></p>	</td>	<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">	<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2021</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">904,123</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.59</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">60,000</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.31</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-76; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-77; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(259,163</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.74</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2022</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">704,960</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.62</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">8.29</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">18</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-78; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-79; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Exercised</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-80; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-81; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(88,253</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">11.68</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options outstanding&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,707</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-82; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options exercisable&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">463,068</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">5.28</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.29</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-83; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	</tr>	<tr class="No-Table-Style _idGenTableRowColumn-18" style="background: #CCEEFF;height:12pt;">	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 37.61%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Options vested and expected to vest&#160;&#8211;&#160;December&#160;31,&#160;2023</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">616,661</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">4.76</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7.35</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>	</td>	<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">	<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-84; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>	</td>	</tr>	</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">A summary of RSU activity for the year ended December&#160;31, 2023 is presented below:<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Restricted Stock Units<br/>Outstanding</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-19" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Number of<br/>Shares</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2021</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-85; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-86; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-87; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-88; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-89; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-90; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2022</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Granted</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-91; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-92; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Vested and released</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(91,000</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2.21</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Forfeited and cancelled</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-93; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-94; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">RSUs outstanding&#160;&#8211;&#160;December&#160;31, 2023</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-95; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-96; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Non-cash, Share-based Compensation Expense</a></td>
<td class="text">For the three&#160;months ended March&#160;31, 2024 and 2023, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense in the statements of operations (in thousands):<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-11" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Three&#160;Months Ended<br/>March&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2024</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">163</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule1" style="-sec-ix-hidden: hidden-fact-116; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">41</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">114</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">204</p>	</td>
				</tr>

		</table><span></span>
</td>
<td class="text">For the&#160;years ended December&#160;31, 2023 and 2022, ARCA recognized the following non<span class="nobreak">-cash</span>, share<span class="nobreak">-based</span> compensation expense (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="5" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years Ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="2" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">General and administrative</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">526</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">423</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and development</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">160</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">133</p>	</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 12.39%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">686</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 13.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">	<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">556</p>	</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857375650192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Tax Benefit Attributable to Our Loss from Operations</a></td>
<td class="text">Income tax benefit attributable to ARCA&#8217;s loss from operations before income taxes differs from the amounts computed by applying the U.S.&#160;federal statutory income tax rate of 21% for 2023 and 2022, as a result of the following (in thousands):<table class="No-Table-Style TableOverride-1" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-5" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">Years ended<br/>December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">U.S.&#160;federal income tax benefit at statutory rates</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(1,121</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2,085</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">State income tax benefit, net of federal benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(192</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(357</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-101; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;text-align:right" valign="bottom">
						<p class="Tbody_rightalign" style="-sec-ix-hidden: hidden-fact-102; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax asset adjustment</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">47</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Other</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">107</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">186</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Change in valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">1,159</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,254</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Income tax benefit</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-103; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-104; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Net deferred tax assets and liabilities</a></td>
<td class="text">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting and the amounts used for income tax purposes, as well as operating loss and tax credit carryforwards. The income tax effects of temporary differences and carryforwards that give rise to significant portions of ARCA&#8217;s net deferred tax assets and liabilities consisted of the following (in thousands):<table class="No-Table-Style" style="width: 100.0%; border-collapse: collapse; border: 0px solid #000; border-width: 0pt; margin: 10pt 0 10pt 0;">


				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">



					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="7" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 30.77%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">As of December&#160;31,</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-6" style="height:12pt;">
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 14.10%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2023</span></p>
					</td>
					<td class="TCH" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;border-bottom-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TCH" colspan="3" style="border-bottom-style:solid;border-bottom-width:1pt;border-left-width:0pt;border-right-width:0pt;border-top-style:solid;border-top-width:0pt;padding-bottom:4pt;padding-left:3pt;padding-right:3pt;padding-top:2pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 15.38%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;" valign="bottom">
						<p class="TCH" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:9pt;font-style:normal;font-variant:normal;font-weight:bold;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:center;text-indent:0;widows:1;margin-right:0pt;"><span class="Bold" style="font-style:normal;font-weight:bold;">2022</span></p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;border-top-width:0pt;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net operating loss carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">51,190</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">50,008</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Charitable contribution carryforwards</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">371</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">393</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Research and experimentation credits</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,420</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">2,420</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized research and development costs</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">951</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">979</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Capitalized intangibles</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">354</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">356</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Stock-based compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">232</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">205</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Accrued compensation</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">7</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">6</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Lease liabilities</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">69</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">94</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Total deferred tax assets</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">55,594</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">54,461</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(55,531</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(54,372</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax assets, net of valuation allowance</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">63</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">89</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Deferred tax liabilities:</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;margin-left:0pt;text-indent:0pt;">&#160;</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Right-of-use asset</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(61</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">	<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(84</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rightalign-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="background: #CCEEFF;height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody-ind_1" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:20pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Depreciation and amortization</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(2</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: windowtext 1pt none; border-bottom-style: solid; padding: 0in 0in 2px 0in;" valign="bottom">	<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">(5</p>	</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule1-bracket-" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">)</p>
					</td>
				</tr>
				<tr class="No-Table-Style _idGenTableRowColumn-7" style="height:12pt;">
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;width: 67.95%; padding: 0in 0in 3px 0in;border-width: 0pt;" valign="bottom">
						<p class="Tbody" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:10pt;margin-right:0;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:left;text-indent:-10pt;widows:1;">Net deferred tax liability</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 10.68%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-105; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.28%; padding: 0in 0in 3px 0in;border-width: 0pt;white-space: nowrap;" valign="bottom">&#160;</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;text-align:left;">$</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 11.97%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;border-bottom: Black 2.5pt double; border-bottom-style: double; padding: 0in 0in 1px 0in;text-align:right" valign="bottom">
						<p class="Tbody_rule2" style="-sec-ix-hidden: hidden-fact-106; margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#8212;</p>
					</td>
					<td class="TB" style="border-bottom-width:0pt;border-left-width:0pt;border-right-width:0pt;border-top-width:0pt;padding-bottom:3pt;padding-left:3pt;padding-right:3pt;padding-top:3pt;vertical-align:bottom;padding-left:0pt;padding-right:0pt;width: 1.71%; padding: 0in 0in 3px 0in;border-width: 0pt;border-bottom: windowtext 1pt none; border-bottom-style: solid;white-space: nowrap;border-bottom: none; border-bottom-style: none;" valign="bottom">
						<p class="Tbody_rule2" style="margin:0;padding:0;border-width:0;font-family:Times New Roman PS Std, serif;font-size:10pt;font-style:normal;font-variant:normal;font-weight:normal;margin-bottom:0;margin-left:0;margin-right:3pt;margin-top:0;orphans:1;page-break-after:auto;page-break-before:auto;text-align:right;text-indent:0;widows:1;margin-right:0pt;">&#160;</p>
					</td>
				</tr>

		</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857375483520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ARCA and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>ARCA and Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset', window );">Off-balance-sheet concentrations of credit risk</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial assets, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857371476528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">755,857<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">795,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">664,857<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PotentiallyDilutiveSecuritiesExcludedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857373717440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Disclosures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FairValueDisclosuresDetailsLineItems', window );"><strong>Fair Value Disclosures (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount', window );">Fair value hierarchy</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Debt outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Fair Value Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_FairValueDisclosuresDetailsLineItems', window );"><strong>Fair Value Disclosures (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 42.4<span></span>
</td>
<td class="nump">$ 35.9<span></span>
</td>
<td class="nump">$ 37.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value assets between hierarchy levels transfers amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_FairValueDisclosuresDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_FairValueDisclosuresDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857376501296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857376660848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(215)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857372486432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Arrangements (Details) - Chief Executive Officer [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ResearchAndDevelopmentExpenseReversed', window );">Related party expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 108,000<span></span>
</td>
<td class="num">$ (91,000)<span></span>
</td>
<td class="nump">$ 432,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PaymentOfUnrestrictedResearchGrants', window );">Payment of unrestricted research grants</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PaymentOfUnrestrictedResearchGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of unrestricted research grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PaymentOfUnrestrictedResearchGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ResearchAndDevelopmentExpenseReversed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense (reversed).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ResearchAndDevelopmentExpenseReversed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857373810096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th">
<div>Aug. 29, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Amount of retention bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PercentageOfRetentionBonuses', window );">Percentage of retention bonuses</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RetentionBonusPaid', window );">Retention bonus paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Remains unpaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Workforce reduction percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Square feet (in Square Feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">42 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease renewal option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">option to renew for an additional 36 month term at the then prevailing rental rate.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">to extend the lease term six (6)&#160;months through September&#160;2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities', window );">Square feet office facilities (in Square Feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_LesseeOperatingSubleaseTermOfContract', window );">Sublease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">29 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">29 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent', window );">Lessee operating lease description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="nump">$ 127,000<span></span>
</td>
<td class="nump">$ 131,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Indicates (true false) whether lessee has option to extend operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_OperatingLeasesExtendedExpiryYearsAndMonth', window );">Additional operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">September&#160;2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PercentageOfBaseRentToBePaidMonthly', window );">Percentage Of Base Rent To Be Paid Monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=abio_ClinicalDevelopmentDecisionMember', window );">Clinical development decisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Amount of retention bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">One-time Termination Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">One-time Termination Benefits | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">One-time Termination Benefits | General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Amount of retention bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember', window );">University Medical Center Of Johannes Gutenberg University Mainz | Research and development | Patent Assignment Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations', window );">Royalty obligations (in Euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of real estate property sublease additional office facilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CommitmentsandContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_CommitmentsandContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_LesseeOperatingSubleaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating sublease term of contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_LesseeOperatingSubleaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_OperatingLeasesExtendedExpiryYearsAndMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_OperatingLeasesExtendedExpiryYearsAndMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PercentageOfBaseRentToBePaidMonthly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of base rent to be paid monthly.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PercentageOfBaseRentToBePaidMonthly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PercentageOfRetentionBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of retention bonuses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PercentageOfRetentionBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential upfront and milestone obligations and royalty obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_RetentionBonusPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retention bonus paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_RetentionBonusPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_RetentionBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retention bonuses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_RetentionBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of assumptions and judgments used by lessee for allocating contract between lease and nonlease components for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=abio_ClinicalDevelopmentDecisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=abio_ClinicalDevelopmentDecisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_PatentAssignmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_PatentAssignmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857374503184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfFutureMinimumCommitmentsDueAbstract', window );"><strong>Schedule of Future Minimum Commitments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed lease interest</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfFutureMinimumCommitmentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfFutureMinimumCommitmentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857373531808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Financings (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 22, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsDetailsLineItems', window );"><strong>Equity Financings (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abio_NewCapitalOnDemandSalesAgreementMember', window );">2020 Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsDetailsLineItems', window );"><strong>Equity Financings (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abio_JonesTradingInstitutionalServicesLLCMember', window );">Jones Trading</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsDetailsLineItems', window );"><strong>Equity Financings (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SellingCommissionPerAdditionalSharesSoldPercentage', window );">Percentage of commission rate equal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=abio_JonesTradingInstitutionalServicesLLCMember', window );">Jones Trading | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EquityFinancingsDetailsLineItems', window );"><strong>Equity Financings (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell', window );">Aggregate offering price (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock, authorized offering amount under agreement to sell.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_EquityFinancingsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_EquityFinancingsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_SellingCommissionPerAdditionalSharesSoldPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling commission per additional shares sold percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_SellingCommissionPerAdditionalSharesSoldPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_NewCapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_NewCapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abio_JonesTradingInstitutionalServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abio_JonesTradingInstitutionalServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_CapitalOnDemandSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_CapitalOnDemandSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857373180896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Purchase options shares</a></td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">904,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 5.62<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 5.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options award, expiration</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 367,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Stock awards granted service period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost (in Dollars)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options award, vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PercentageHoldingForStockOptionsExercisePrice', window );">Exercise price per share</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incentive Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of exercise price</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incentive Stock Option | Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of exercise price</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options award, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abio_TwoThousandAndTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,167,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Purchase options shares</a></td>
<td class="nump">601,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="nump">$ 3.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved shares</a></td>
<td class="nump">459,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Options granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PurchaseAggregateShares', window );">Purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember', window );">2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SharebasedCompensationDetailsLineItems', window );"><strong>Share-based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Purchase options shares</a></td>
<td class="nump">14,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="nump">$ 57.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PercentageHoldingForStockOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum ownership percentage for 110% fair market value on the grant date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PercentageHoldingForStockOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PurchaseAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PurchaseAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_SharebasedCompensationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_SharebasedCompensationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abio_IncentiveStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abio_IncentiveStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abio_TwoThousandAndTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abio_TwoThousandAndTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abio_TwoThousandAndThirteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857479176464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract', window );"><strong>Schedule of Estimated Weighted Average Grant Date Fair Value Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">107.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.56%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share (in Dollars per share)</a></td>
<td class="nump">$ 1.87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857374515920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Stock Option Activities - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfStockOptionActivitiesAbstract', window );"><strong>Schedule of Stock Option Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Options outstanding, ending balance</a></td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options outstanding, ending balance</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 5.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years) Options outstanding, ending balance</a></td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">6 years 9 months 25 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">8 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options outstanding, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Options exercisable, ending balance</a></td>
<td class="nump">463,068<span></span>
</td>
<td class="nump">502,517<span></span>
</td>
<td class="nump">463,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable, ending balance</a></td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options exercisable, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months 18 days<span></span>
</td>
<td class="text">7 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Options vested and expected to vest, ending balance</a></td>
<td class="nump">616,661<span></span>
</td>
<td class="nump">645,816<span></span>
</td>
<td class="nump">616,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options vested and expected to vest, ending balance</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options vested and expected to vest, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 25 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Options vested and expected to vest, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.64<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, Forfeited and cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,862)<span></span>
</td>
<td class="num">(88,253)<span></span>
</td>
<td class="num">(259,163)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited and cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.45<span></span>
</td>
<td class="nump">$ 11.68<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfStockOptionActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfStockOptionActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857371764192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of RSU Activity - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfRsuActivityAbstract', window );"><strong>Schedule of RSU Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, RSUs outstanding, beginning of period</a></td>
<td class="nump">91,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, beginning of period</a></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, RSUs outstanding, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, RSUs outstanding, Vested and released</a></td>
<td class="num">(91,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Vested and released</a></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, RSUs outstanding, Forfeited and cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, Forfeited and cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, RSUs outstanding, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Date Fair Value, RSUs outstanding, ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfRsuActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfRsuActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857376516288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 686<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857372913568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans', window );">Matching contribution</a></td>
<td class="text">matching contribution equal to 100% of the employee&#8217;s first 3% of the employee&#8217;s contributions and 50% of the employee&#8217;s next 2% of contributions.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Company's contribution (in Dollars)</a></td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=abio_FirstThreePercentPayContributionMember', window );">First 3% of pay contributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employee&#8217;s contribution percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Equal contribution percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=abio_NextTwoPercentPayContributionMember', window );">Next 2% of pay contributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_EmployeeBenefitPlansDetailsLineItems', window );"><strong>Employee Benefit Plans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employee&#8217;s contribution percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Equal contribution percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_EmployeeBenefitPlansDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_EmployeeBenefitPlansDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of defined contribution pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=abio_FirstThreePercentPayContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=abio_FirstThreePercentPayContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=abio_NextTwoPercentPayContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=abio_NextTwoPercentPayContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857373181760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 208,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Operating loss carryforwards, limitations on use</a></td>
<td class="text">The net operating loss carryforwards beginning in 2018, have no expiration.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 55,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount', window );">Increase in net deferred tax assets and liabilities</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Reserve for uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest or penalties recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and experimentation credits</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax credit carryforward, limitations on use</a></td>
<td class="text">Utilization of net operating losses and tax credits, including those acquired as a result of the Merger, will be subject to an annual limitation due to ownership change limitations provided by Internal Revenue Code Section&#160;382. ARCA believes that an ownership change limitation as defined under Section&#160;382 of the U.S.&#160;Internal Revenue Code occurred as a result of its various historical financing transactions. Future utilization of the federal net operating losses and tax credit carryforwards accumulated from June&#160;2005 to the change in ownership date will be subject to annual limitations to offset future taxable income. The annual limitation may result in the expiration of the net operating losses and credits before utilization. As such, a portion of ARCA&#8217;s net operating loss carryforwards may be limited.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember', window );">Earliest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember', window );">Latest Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets and liabilities valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IncomeTaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_IncomeTaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation allowance deferred tax assets and liabilities change in amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_EarliestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857372293200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract', window );"><strong>Schedule Of Income Tax Benefit Attributable To Our Loss From Operations Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal income tax benefit at statutory rates</a></td>
<td class="num">$ (1,121)<span></span>
</td>
<td class="num">$ (2,085)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax benefit, net of federal benefit</a></td>
<td class="num">(192)<span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and experimentation credits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset', window );">Deferred tax asset adjustment</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">1,159<span></span>
</td>
<td class="nump">2,254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment of the carrying value of deferred tax assets during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857371305296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 51,190<span></span>
</td>
<td class="nump">$ 50,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Charitable contribution carryforwards</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and experimentation credits</a></td>
<td class="nump">2,420<span></span>
</td>
<td class="nump">2,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DeferredTaxAssetResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">951<span></span>
</td>
<td class="nump">979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Capitalized intangibles</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Accrued compensation</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">55,594<span></span>
</td>
<td class="nump">54,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(55,531)<span></span>
</td>
<td class="num">(54,372)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxAssetResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxAssetResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from right of use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857374620800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract0', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">755,857<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">795,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract0', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">664,857<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract0', window );"><strong>Potentially dilutive securities, excluded:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities, excluded</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">91,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PotentiallyDilutiveSecuritiesExcludedAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PotentiallyDilutiveSecuritiesExcludedAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857373068480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(215)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
<td class="num">(204)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857525383056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfFutureMinimumCommitmentsDueAbstract', window );"><strong>Schedule of Future Minimum Commitments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">$ 314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed lease interest</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfFutureMinimumCommitmentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfFutureMinimumCommitmentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857478858496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 686<span></span>
</td>
<td class="nump">$ 556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="nump">526<span></span>
</td>
<td class="nump">423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857375682304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Compensation (Details) - Schedule of Stock Option Activities - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ScheduleOfStockOptionActivitiesAbstract', window );"><strong>Schedule of Stock Option Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Options outstanding, ending balance</a></td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">645,845<span></span>
</td>
<td class="nump">616,707<span></span>
</td>
<td class="nump">704,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options outstanding, ending balance</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 5.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years) Options outstanding, ending balance</a></td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">6 years 9 months 25 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">8 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Options exercisable, ending balance</a></td>
<td class="nump">463,068<span></span>
</td>
<td class="nump">502,517<span></span>
</td>
<td class="nump">463,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercisable, ending balance</a></td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="nump">$ 5.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options exercisable, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months 18 days<span></span>
</td>
<td class="text">7 years 3 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Options vested and expected to vest, ending balance</a></td>
<td class="nump">616,661<span></span>
</td>
<td class="nump">645,816<span></span>
</td>
<td class="nump">616,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options vested and expected to vest, ending balance</a></td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options vested and expected to vest, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 9 months 25 days<span></span>
</td>
<td class="text">7 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.64<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, Forfeited and cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,862)<span></span>
</td>
<td class="num">(88,253)<span></span>
</td>
<td class="num">(259,163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited and cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.45<span></span>
</td>
<td class="nump">$ 11.68<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ScheduleOfStockOptionActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ScheduleOfStockOptionActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139857373727520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 20, 2024</div></th>
<th class="th"><div>Apr. 03, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ThresholdAmountOfDeclaredCashDividend', window );">Declared cash dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Retention bonuses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">ARCA and Oruka</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">ARCA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_NumberOfConsecutiveTradingDays', window );">Number of consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ThresholdAmountOfAdjustedExchangeRatio', window );">Adjusted exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">ARCA | ARCA and Oruka</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Percentage of noncontrolling ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Common Stock | ARCA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares', window );">Initially specified percentage for beneficial number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Common Stock and Pre Funded Warrants [Member] | Oruka Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_AggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Merger Agreement | ARCA and Oruka</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_PaymentOfOtherPartyTerminationFee', window );">Payment of other party termination fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Merger Agreement | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubscriptionAgreementReceiptAmount', window );">Subscription agreement receipt amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">First Merger | Oruka Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_ExceptedNumberOfBoardMembers', window );">Excepted number of board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Seperation Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_NumberOfMonthsBaseSalary', window );">Number of months base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_CashPayment', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_PresidentMember', window );">Thomas A. Keuer | Second Amendment of Certain Retention Bonus Letters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncreaseOfRetentionBonusToEachExecutive', window );">Increase of retention bonus to each executive</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember', window );">C. Jeffrey Dekker | Second Amendment of Certain Retention Bonus Letters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_IncreaseOfRetentionBonusToEachExecutive', window );">Increase of retention bonus to each executive</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=abio_ThomasAKeuerAndCJeffreyDekkerMember', window );">Thomas A. Keuer and C. Jeffrey Dekker [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_RetentionBonuses', window );">Retention bonuses</a></td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_MinimumPercentageOfOriginallyIssuedShares', window );">Minimum percentage of originally issued outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_MinimumPercentageOfOriginallyIssuedOutstanding', window );">Minimum percentage of originally issued outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | Merger Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock | First Merger | Common Stock | ARCA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abio_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Preferred stock convertible shares issuable (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_AggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_AggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_CashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_CashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ExceptedNumberOfBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excepted Number of Board Members</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ExceptedNumberOfBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_IncreaseOfRetentionBonusToEachExecutive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase of retention bonus to each executive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_IncreaseOfRetentionBonusToEachExecutive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initially specified percentage for beneficial number of shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MinimumPercentageOfOriginallyIssuedOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of originally issued outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_MinimumPercentageOfOriginallyIssuedOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_MinimumPercentageOfOriginallyIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of originally issued shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_MinimumPercentageOfOriginallyIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_NumberOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_NumberOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_NumberOfMonthsBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of months base salary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_NumberOfMonthsBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_PaymentOfOtherPartyTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of other party termination fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_PaymentOfOtherPartyTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_RetentionBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retention bonuses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_RetentionBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_SubscriptionAgreementReceiptAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subscription agreement receipt amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_SubscriptionAgreementReceiptAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ThresholdAmountOfAdjustedExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold amount of adjusted exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ThresholdAmountOfAdjustedExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abio_ThresholdAmountOfDeclaredCashDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold amount of declared cash dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abio_ThresholdAmountOfDeclaredCashDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abio_ArcaBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abio_ArcaBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=abio_CommonStockAndPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=abio_CommonStockAndPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=abio_OrukaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=abio_OrukaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_FirstMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_FirstMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_SeperationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_SeperationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_PresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_PresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abio_SecondAmendmentOfCertainRetentionBonusLettersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abio_SecondAmendmentOfCertainRetentionBonusLettersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abio_ThomasAKeuerAndCJeffreyDekkerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abio_ThomasAKeuerAndCJeffreyDekkerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>154</ContextCount>
  <ElementCount>248</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Statements of Operations (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals</Role>
      <ShortName>Statements of Operations (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Statements of Stockholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Statements of Stockholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - ARCA and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>ARCA and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Fair Value Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/FairValueDisclosures</Role>
      <ShortName>Fair Value Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Related Party Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/RelatedPartyArrangements</Role>
      <ShortName>Related Party Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Equity Financings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/EquityFinancings</Role>
      <ShortName>Equity Financings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Share-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SharebasedCompensation</Role>
      <ShortName>Share-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/NetLossPerShare</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/PropertyandEquipment</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Share-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SharebasedCompensationTables</Role>
      <ShortName>Share-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/IncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996006 - Disclosure - ARCA and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>ARCA and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable</Role>
      <ShortName>Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/NetLossPerShareTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Fair Value Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/FairValueDisclosuresDetails</Role>
      <ShortName>Fair Value Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/FairValueDisclosures</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable</Role>
      <ShortName>Property and Equipment (Details) - Schedule of Property and Equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Related Party Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails</Role>
      <ShortName>Related Party Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/RelatedPartyArrangements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Equity Financings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/EquityFinancingsDetails</Role>
      <ShortName>Equity Financings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/EquityFinancings</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Share-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SharebasedCompensationDetails</Role>
      <ShortName>Share-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Stock Option Activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Share-based Compensation (Details) - Schedule of RSU Activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of RSU Activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0</Role>
      <ShortName>Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/NetLossPerShareTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0</Role>
      <ShortName>Property and Equipment (Details) - Schedule of Property and Equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0</Role>
      <ShortName>Share-based Compensation (Details) - Schedule of Stock Option Activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SharebasedCompensationTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0205122-06.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arcabiopharma.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arcabiopharma.com/role/SubsequentEvents</ParentRole>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>abio-20240331.xsd</File>
    <File>abio-20240331_cal.xml</File>
    <File>abio-20240331_def.xml</File>
    <File>abio-20240331_lab.xml</File>
    <File>abio-20240331_pre.xml</File>
    <File doctype="S-4/A" isDefinitelyFs="true" isUsgaap="true" original="ea0205122-06.htm">ea0205122-06.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>tarca_001.jpg</File>
    <File>timage_001.jpg</File>
    <File>timage_002.jpg</File>
    <File>timage_003.jpg</File>
    <File>timage_004.jpg</File>
    <File>timage_005.jpg</File>
    <File>timage_006.jpg</File>
    <File>timage_007.jpg</File>
    <File>tlucid_sig.jpg</File>
    <File>toruka_logo.jpg</File>
    <File>tproxy_001.jpg</File>
    <File>tproxy_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="650">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>141
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0205122-06.htm": {
   "nsprefix": "abio",
   "nsuri": "http://www.arcabiopharma.com/20240331",
   "dts": {
    "schema": {
     "local": [
      "abio-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "abio-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "abio-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "abio-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abio-20240331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0205122-06.htm"
     ]
    }
   },
   "keyStandard": 209,
   "keyCustom": 39,
   "axisStandard": 23,
   "axisCustom": 0,
   "memberStandard": 28,
   "memberCustom": 20,
   "hidden": {
    "total": 122,
    "http://fasb.org/us-gaap/2024": 114,
    "http://xbrl.sec.gov/dei/2024": 3,
    "http://www.arcabiopharma.com/20240331": 5
   },
   "contextCount": 154,
   "entityCount": 1,
   "segmentCount": 50,
   "elementCount": 409,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 650,
    "http://xbrl.sec.gov/dei/2024": 9
   },
   "report": {
    "R1": {
     "role": "http://www.arcabiopharma.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Balance Sheets (Unaudited)",
     "shortName": "Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "002 - Statement - Balance Sheets (Unaudited) (Parentheticals)",
     "shortName": "Balance Sheets (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:OtherAccruedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement",
     "longName": "003 - Statement - Statements of Operations (Unaudited)",
     "shortName": "Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
     "longName": "004 - Statement - Statements of Operations (Unaudited) (Parentheticals)",
     "shortName": "Statements of Operations (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c11",
      "name": "abio:ResearchAndDevelopmentExpenseReversed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c11",
      "name": "abio:ResearchAndDevelopmentExpenseReversed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3",
     "longName": "005 - Statement - Statements of Stockholders\u2019 Equity (Unaudited)",
     "shortName": "Statements of Stockholders\u2019 Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.arcabiopharma.com/role/ConsolidatedCashFlow",
     "longName": "006 - Statement - Statements of Cash Flows (Unaudited)",
     "shortName": "Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies",
     "longName": "007 - Disclosure - ARCA and Summary of Significant Accounting Policies",
     "shortName": "ARCA and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.arcabiopharma.com/role/NetLossPerShare",
     "longName": "008 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.arcabiopharma.com/role/FairValueDisclosures",
     "longName": "009 - Disclosure - Fair Value Disclosures",
     "shortName": "Fair Value Disclosures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.arcabiopharma.com/role/PropertyandEquipment",
     "longName": "010 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.arcabiopharma.com/role/RelatedPartyArrangements",
     "longName": "011 - Disclosure - Related Party Arrangements",
     "shortName": "Related Party Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.arcabiopharma.com/role/CommitmentsandContingencies",
     "longName": "012 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.arcabiopharma.com/role/EquityFinancings",
     "longName": "013 - Disclosure - Equity Financings",
     "shortName": "Equity Financings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.arcabiopharma.com/role/SharebasedCompensation",
     "longName": "014 - Disclosure - Share-based Compensation",
     "shortName": "Share-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.arcabiopharma.com/role/EmployeeBenefitPlans",
     "longName": "015 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.arcabiopharma.com/role/IncomeTaxes",
     "longName": "016 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.arcabiopharma.com/role/SubsequentEvents",
     "longName": "017 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "abio:DescriptionOfBusinessPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "abio:DescriptionOfBusinessPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.arcabiopharma.com/role/NetLossPerShareTables",
     "longName": "996001 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.arcabiopharma.com/role/PropertyandEquipmentTables",
     "longName": "996002 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables",
     "longName": "996003 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.arcabiopharma.com/role/SharebasedCompensationTables",
     "longName": "996004 - Disclosure - Share-based Compensation (Tables)",
     "shortName": "Share-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.arcabiopharma.com/role/IncomeTaxesTables",
     "longName": "996005 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails",
     "longName": "996006 - Disclosure - ARCA and Summary of Significant Accounting Policies (Details)",
     "shortName": "ARCA and Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
     "longName": "996007 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock",
     "shortName": "Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails",
     "longName": "996008 - Disclosure - Fair Value Disclosures (Details)",
     "shortName": "Fair Value Disclosures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c67",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c67",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.arcabiopharma.com/role/PropertyandEquipmentDetails",
     "longName": "996009 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
     "longName": "996010 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment",
     "shortName": "Property and Equipment (Details) - Schedule of Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails",
     "longName": "996011 - Disclosure - Related Party Arrangements (Details)",
     "shortName": "Related Party Arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c127",
      "name": "abio:ResearchAndDevelopmentExpenseReversed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c127",
      "name": "abio:ResearchAndDevelopmentExpenseReversed",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
     "longName": "996012 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "abio:RetentionBonuses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "abio:RetentionBonuses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
     "longName": "996013 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due",
     "shortName": "Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
     "longName": "996014 - Disclosure - Equity Financings (Details)",
     "shortName": "Equity Financings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c133",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.arcabiopharma.com/role/SharebasedCompensationDetails",
     "longName": "996015 - Disclosure - Share-based Compensation (Details)",
     "shortName": "Share-based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c16",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable",
     "longName": "996016 - Disclosure - Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share",
     "shortName": "Share-based Compensation (Details) - Schedule of Estimated Weighted Average Grant Date Fair Value Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
     "longName": "996017 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities",
     "shortName": "Share-based Compensation (Details) - Schedule of Stock Option Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable",
     "longName": "996018 - Disclosure - Share-based Compensation (Details) - Schedule of RSU Activity",
     "shortName": "Share-based Compensation (Details) - Schedule of RSU Activity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
     "longName": "996019 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense",
     "shortName": "Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails",
     "longName": "996020 - Disclosure - Employee Benefit Plans (Details)",
     "shortName": "Employee Benefit Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.arcabiopharma.com/role/IncomeTaxesDetails",
     "longName": "996021 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable",
     "longName": "996022 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations",
     "shortName": "Income Taxes (Details) - Schedule of Income Tax Benefit Attributable to Our Loss from Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable",
     "longName": "996023 - Disclosure - Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities",
     "shortName": "Income Taxes (Details) - Schedule of Net deferred tax assets and liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0",
     "longName": "996024 - Disclosure - Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock",
     "shortName": "Net Loss Per Share (Details) - Schedule of Potentially Dilutive Shares of Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0",
     "longName": "996025 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment",
     "shortName": "Property and Equipment (Details) - Schedule of Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0",
     "longName": "996026 - Disclosure - Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due",
     "shortName": "Commitments and Contingencies (Details) - Schedule of Future Minimum Commitments Due",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0",
     "longName": "996027 - Disclosure - Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense",
     "shortName": "Share-based Compensation (Details) - Schedule of Non-cash, Share-based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0",
     "longName": "996028 - Disclosure - Share-based Compensation (Details) - Schedule of Stock Option Activities",
     "shortName": "Share-based Compensation (Details) - Schedule of Stock Option Activities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R48": {
     "role": "http://www.arcabiopharma.com/role/SubsequentEventsDetails",
     "longName": "996029 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c141",
      "name": "abio:ThresholdAmountOfDeclaredCashDividend",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c141",
      "name": "abio:ThresholdAmountOfDeclaredCashDividend",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0205122-06.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ARCA and Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r565"
     ]
    },
    "abio_AccruedOutsourcingExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "AccruedOutsourcingExpensesPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Outsourcing Expenses",
        "documentation": "Accrued outsourcing expenses.",
        "label": "Accrued Outsourcing Expenses Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r84",
      "r413"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r588",
      "r589",
      "r590",
      "r591",
      "r709",
      "r732"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r239"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_AggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "AggregatePurchasePrice",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase price",
        "documentation": "Aggregate purchase price.",
        "label": "Aggregate Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total expenses",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r279"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities, excluded",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "abio_ArcaBiopharmaIncAndOrukaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ArcaBiopharmaIncAndOrukaTherapeuticsIncMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA and Oruka",
        "documentation": "Arca Biopharma Inc and Oruka Therapeutics Inc",
        "label": "Arca Biopharma Inc And Oruka Therapeutics Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ArcaBiopharmaIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ArcaBiopharmaIncMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA",
        "documentation": "ARCA biopharma inc member.",
        "label": "Arca Biopharma Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square feet (in Square Feet)",
        "label": "Area of Real Estate Property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "abio_AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Square feet office facilities (in Square Feet)",
        "documentation": "Area of real estate property sublease additional office facilities.",
        "label": "Area Of Real Estate Property Sublease Additional Office Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r66",
      "r86",
      "r106",
      "r139",
      "r143",
      "r155",
      "r156",
      "r163",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r319",
      "r321",
      "r356",
      "r404",
      "r474",
      "r537",
      "r538",
      "r565",
      "r576",
      "r608",
      "r609",
      "r721"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r91",
      "r106",
      "r163",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r319",
      "r321",
      "r356",
      "r565",
      "r608",
      "r609",
      "r721"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r166",
      "r334",
      "r399",
      "r556",
      "r559",
      "r600",
      "r712",
      "r713",
      "r714"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "abio_CapitalOnDemandSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CapitalOnDemandSalesAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Agreement",
        "documentation": "Capital on demand sales agreement.",
        "label": "Capital On Demand Sales Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r82",
      "r528"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r711"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r43",
      "r104"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r43"
     ]
    },
    "abio_CashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CashPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payment",
        "documentation": "Cash payment",
        "label": "Cash Payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer",
        "verboseLabel": "Chief Executive Officer [Member]",
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "srt_ChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefFinancialOfficerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "C. Jeffrey Dekker",
        "label": "Chief Financial Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r87",
      "r88",
      "r89",
      "r106",
      "r129",
      "r130",
      "r132",
      "r134",
      "r141",
      "r142",
      "r163",
      "r182",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r194",
      "r195",
      "r199",
      "r202",
      "r208",
      "r356",
      "r431",
      "r432",
      "r433",
      "r434",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r462",
      "r483",
      "r505",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r578",
      "r586",
      "r592"
     ]
    },
    "abio_ClinicalDevelopmentDecisionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ClinicalDevelopmentDecisionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Development Decision [Member]",
        "verboseLabel": "Clinical development decisions",
        "documentation": "Clinical Development Decision Member.",
        "label": "Clinical Development Decision Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r60",
      "r406",
      "r461"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r176",
      "r177",
      "r524",
      "r602",
      "r607"
     ]
    },
    "abio_CommitmentsandContingenciesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CommitmentsandContingenciesDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_CommitmentsandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CommitmentsandContingenciesDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_CommonStockAndPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CommonStockAndPreFundedWarrantsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock and Pre Funded Warrants [Member]",
        "documentation": "Common stock and pre funded warrants",
        "label": "Common Stock And Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_CommonStockAuthorizedOfferingAmountUnderAgreementToSell": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "CommonStockAuthorizedOfferingAmountUnderAgreementToSell",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate offering price (in Dollars)",
        "documentation": "Common stock, authorized offering amount under agreement to sell.",
        "label": "Common Stock Authorized Offering Amount Under Agreement To Sell"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserved shares",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r568",
      "r569",
      "r571",
      "r572",
      "r573",
      "r574",
      "r588",
      "r589",
      "r591",
      "r709",
      "r731",
      "r732"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r462"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "terseLabel": "Common stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r33",
      "r462",
      "r480",
      "r732",
      "r733"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, value",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r408",
      "r565"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ComprehensiveLossPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ComprehensiveLossPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "documentation": "Comprehensive loss policy.",
        "label": "Comprehensive Loss Policy Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "verboseLabel": "Computer Equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r70"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Costs and expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r191",
      "r197",
      "r385",
      "r395",
      "r403",
      "r529",
      "r531"
     ]
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt outstanding",
        "label": "Debt, Long-Term and Short-Term, Combined Amount",
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt."
       }
      }
     },
     "auth_ref": []
    },
    "abio_DeferredTaxAssetResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxAssetResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development costs",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research and development costs.",
        "label": "Deferred Tax Asset Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "abio_DeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abio_DeferredTaxAssetsAndLiabilitiesValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxAssetsAndLiabilitiesValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "documentation": "Deferred tax assets and liabilities valuation allowance.",
        "label": "Deferred Tax Assets And Liabilities Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsCharitableContributionCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charitable contribution carryforwards",
        "label": "Deferred Tax Assets, Charitable Contribution Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized intangibles",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "abio_DeferredTaxAssetsLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.",
        "label": "Deferred Tax Assets Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax liability",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and experimentation credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation and amortization",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "abio_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNetdeferredtaxassetsandliabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from right of use assets.",
        "label": "Deferred Tax Liabilities Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company's contribution (in Dollars)",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equal contribution percentage",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee\u2019s contribution percentage",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow",
      "http://www.arcabiopharma.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r15"
     ]
    },
    "abio_DescriptionOfBusinessPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DescriptionOfBusinessPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business",
        "documentation": "Description of business.",
        "label": "Description Of Business Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Matching contribution",
        "label": "Defined Contribution Plan, Description",
        "documentation": "Description of defined contribution pension and other postretirement plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r240",
      "r271",
      "r272",
      "r274",
      "r552"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarliestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarliestTaxYearMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earliest Tax Year",
        "label": "Earliest Tax Year [Member]",
        "documentation": "Earliest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r127",
      "r129",
      "r132",
      "r133",
      "r134",
      "r138",
      "r314",
      "r317",
      "r331",
      "r332",
      "r400",
      "r417",
      "r532"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r129",
      "r132",
      "r133",
      "r134",
      "r138",
      "r314",
      "r317",
      "r331",
      "r332",
      "r400",
      "r417",
      "r532"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r135",
      "r136",
      "r137"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal statutory income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r287",
      "r305",
      "r555"
     ]
    },
    "abio_EmployeeBenefitPlansDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "EmployeeBenefitPlansDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_EmployeeBenefitPlansDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "EmployeeBenefitPlansDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plans (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and employee benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r273"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.arcabiopharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment",
        "verboseLabel": "Lab Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Financings [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r78",
      "r95",
      "r96",
      "r97",
      "r112",
      "r113",
      "r114",
      "r116",
      "r121",
      "r123",
      "r125",
      "r140",
      "r164",
      "r165",
      "r167",
      "r209",
      "r303",
      "r304",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r378",
      "r416",
      "r423",
      "r424",
      "r425",
      "r440",
      "r505"
     ]
    },
    "abio_EquityFinancingsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "EquityFinancingsDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Financings (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_EquityFinancingsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "EquityFinancingsDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Financings (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ExceptedNumberOfBoardMembers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ExceptedNumberOfBoardMembers",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excepted number of board members",
        "documentation": "Excepted Number of Board Members",
        "label": "Excepted Number Of Board Members"
       }
      }
     },
     "auth_ref": []
    },
    "abio_FairValueAssetsBetweenHierarchyLevelsTransfersAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FairValueAssetsBetweenHierarchyLevelsTransfersAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value hierarchy",
        "documentation": "Fair value assets between hierarchy levels transfers amount.",
        "label": "Fair Value Assets Between Hierarchy Levels Transfers Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r349",
      "r557"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r349",
      "r557"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r347",
      "r348",
      "r350",
      "r390",
      "r391",
      "r392",
      "r545",
      "r546",
      "r548",
      "r549",
      "r550",
      "r556",
      "r559"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r338",
      "r556",
      "r713",
      "r715"
     ]
    },
    "us-gaap_FairValueDisclosureOffbalanceSheetRisksAmountAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosureOffbalanceSheetRisksAmountAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Off-balance-sheet concentrations of credit risk",
        "label": "Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Asset",
        "documentation": "The fair value of financial assets, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_FairValueDisclosuresDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FairValueDisclosuresDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_FairValueDisclosuresDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FairValueDisclosuresDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r345",
      "r346",
      "r347",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r398",
      "r556",
      "r560"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r213",
      "r218",
      "r335",
      "r348",
      "r390",
      "r548",
      "r549",
      "r550",
      "r556"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335",
      "r336",
      "r338",
      "r556",
      "r713",
      "r715"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r347",
      "r348",
      "r350",
      "r390",
      "r391",
      "r392",
      "r545",
      "r546",
      "r548",
      "r549",
      "r550",
      "r556",
      "r559"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715"
     ]
    },
    "abio_FirstMergerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FirstMergerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Merger",
        "documentation": "First Merge",
        "label": "First Merger Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_FirstThreePercentPayContributionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "FirstThreePercentPayContributionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First 3% of pay contributed",
        "documentation": "First three percent pay contribution.",
        "label": "First Three Percent Pay Contribution Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "verboseLabel": "Furniture and Fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss from disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r485"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative",
        "verboseLabel": "General and Administrative Expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "abio_IncentiveStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncentiveStockOptionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive Stock Option",
        "documentation": "Incentive stock option.",
        "label": "Incentive Stock Option Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r172",
      "r340",
      "r344",
      "r349",
      "r420",
      "r422",
      "r490",
      "r527",
      "r558",
      "r730"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r172",
      "r340",
      "r344",
      "r349",
      "r420",
      "r422",
      "r490",
      "r527",
      "r558",
      "r730"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r283",
      "r287",
      "r291",
      "r292",
      "r293",
      "r295",
      "r300",
      "r306",
      "r308",
      "r309",
      "r310",
      "r436",
      "r555"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest or penalties recognized",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r76",
      "r124",
      "r125",
      "r139",
      "r146",
      "r156",
      "r286",
      "r287",
      "r307",
      "r418",
      "r555"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r284",
      "r285",
      "r295",
      "r296",
      "r299",
      "r302",
      "r430"
     ]
    },
    "abio_IncomeTaxReconciliationAdjustmentToDeferredTaxAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncomeTaxReconciliationAdjustmentToDeferredTaxAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset adjustment",
        "documentation": "Adjustment of the carrying value of deferred tax assets during the year.",
        "label": "Income Tax Reconciliation Adjustment To Deferred Tax Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r555",
      "r699"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal income tax benefit at statutory rates",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r555"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r699",
      "r700"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax benefit, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r555",
      "r699"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofIncomeTaxBenefitAttributabletoOurLossfromOperationsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and experimentation credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r699",
      "r701"
     ]
    },
    "abio_IncomeTaxesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncomeTaxesDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_IncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncomeTaxesDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and employee benefits",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "abio_IncreaseOfRetentionBonusToEachExecutive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "IncreaseOfRetentionBonusToEachExecutive",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase of retention bonus to each executive",
        "documentation": "Increase of retention bonus to each executive.",
        "label": "Increase Of Retention Bonus To Each Executive"
       }
      }
     },
     "auth_ref": []
    },
    "abio_InitiallySpecifiedPercentageForBeneficialNumberOfShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "InitiallySpecifiedPercentageForBeneficialNumberOfShares",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initially specified percentage for beneficial number of shares",
        "documentation": "Initially specified percentage for beneficial number of shares",
        "label": "Initially Specified Percentage For Beneficial Number Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and other income",
        "label": "Interest and Other Income",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r102",
      "r103"
     ]
    },
    "abio_JonesTradingInstitutionalServicesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "JonesTradingInstitutionalServicesLLCMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jones Trading",
        "documentation": "JonesTrading Institutional Services LLC.",
        "label": "Jones Trading Institutional Services LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LatestTaxYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LatestTaxYearMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Latest Tax Year",
        "label": "Latest Tax Year [Member]",
        "documentation": "Latest identified tax year."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r369"
     ]
    },
    "us-gaap_LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee operating lease description",
        "label": "Lessee, Operating Lease, Assumptions and Judgments, Allocation of Lease and Nonlease Component",
        "documentation": "Description of assumptions and judgments used by lessee for allocating contract between lease and nonlease components for operating lease."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indicates (true false) whether lessee has option to extend operating lease",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Commitments Due",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total remaining lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed lease interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease renewal option",
        "label": "Lessee, Operating Lease, Option to Extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "abio_LesseeOperatingSubleaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "LesseeOperatingSubleaseTermOfContract",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease term",
        "documentation": "Lessee operating sublease term of contract.",
        "label": "Lessee Operating Sublease Term Of Contract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r106",
      "r163",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r320",
      "r321",
      "r322",
      "r356",
      "r460",
      "r533",
      "r576",
      "r608",
      "r721",
      "r722"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r61",
      "r410",
      "r565",
      "r587",
      "r601",
      "r716"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r81",
      "r106",
      "r163",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r320",
      "r321",
      "r322",
      "r356",
      "r565",
      "r608",
      "r721",
      "r722"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve for uncertain tax positions",
        "label": "Liability for Uncertainty in Income Taxes, Current",
        "documentation": "Amount recognized for uncertainty in income taxes classified as current."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "abio_LiquidityAndGoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "LiquidityAndGoingConcernPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity and Going Concern",
        "documentation": "Liquidity and going concern.",
        "label": "Liquidity And Going Concern Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r232",
      "r280",
      "r338",
      "r396",
      "r419",
      "r421",
      "r428",
      "r452",
      "r453",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r525",
      "r526",
      "r540",
      "r547",
      "r551",
      "r559",
      "r560",
      "r561",
      "r562",
      "r566",
      "r610",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728"
     ]
    },
    "abio_MergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "MergerAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger Agreement",
        "documentation": "Merger agreement",
        "label": "Merger Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r232",
      "r280",
      "r338",
      "r396",
      "r419",
      "r421",
      "r428",
      "r452",
      "r453",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r525",
      "r526",
      "r540",
      "r547",
      "r551",
      "r559",
      "r560",
      "r561",
      "r566",
      "r610",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728"
     ]
    },
    "abio_MinimumPercentageOfOriginallyIssuedOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "MinimumPercentageOfOriginallyIssuedOutstanding",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum percentage of originally issued outstanding",
        "documentation": "Minimum percentage of originally issued outstanding",
        "label": "Minimum Percentage Of Originally Issued Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "abio_MinimumPercentageOfOriginallyIssuedShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "MinimumPercentageOfOriginallyIssuedShares",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum percentage of originally issued outstanding",
        "documentation": "Minimum percentage of originally issued shares",
        "label": "Minimum Percentage Of Originally Issued Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of noncontrolling ownership interest",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ownership interest",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/FairValueDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Funds [Member]",
        "verboseLabel": "Money Market Funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow",
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r45",
      "r62",
      "r79",
      "r92",
      "r93",
      "r97",
      "r106",
      "r115",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r124",
      "r125",
      "r131",
      "r163",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r314",
      "r317",
      "r332",
      "r356",
      "r415",
      "r482",
      "r503",
      "r504",
      "r575",
      "r608"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "abio_NewCapitalOnDemandSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "NewCapitalOnDemandSalesAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Sales Agreement",
        "documentation": "New Capital on Demand Sales Agreement.",
        "label": "New Capital On Demand Sales Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_NextTwoPercentPayContributionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "NextTwoPercentPayContributionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Next 2% of pay contributed",
        "documentation": "Next two percent pay contribution.",
        "label": "Next Two Percent Pay Contribution Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of noncash investing and financing transactions:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_NumberOfConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "NumberOfConsecutiveTradingDays",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of consecutive trading days",
        "documentation": "Number of consecutive trading days.",
        "label": "Number Of Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "abio_NumberOfMonthsBaseSalary": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "NumberOfMonthsBaseSalary",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of months base salary",
        "documentation": "Number of months base salary",
        "label": "Number Of Months Base Salary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of segment",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r594"
     ]
    },
    "us-gaap_OneTimeTerminationBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OneTimeTerminationBenefitsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One-time Termination Benefits",
        "label": "One-time Termination Benefits [Member]",
        "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r542",
      "r543",
      "r544"
     ]
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Open Tax Year",
        "label": "Open Tax Year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total costs and expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r534",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r564"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Current portion",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable",
      "http://www.arcabiopharma.com/role/ScheduleofFutureMinimumCommitmentsDueTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r372"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset \u2013 operating",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use asset \u2013 operating",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r564"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r564"
     ]
    },
    "abio_OperatingLeasesExtendedExpiryYearsAndMonth": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "OperatingLeasesExtendedExpiryYearsAndMonth",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional operating lease term",
        "label": "Operating Leases Extended Expiry Years And Month"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "abio_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards expiration year",
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA and Summary of Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r46",
      "r47",
      "r58"
     ]
    },
    "abio_OrukaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "OrukaTherapeuticsIncMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oruka Therapeutics Inc",
        "documentation": "Oruka therapeutics inc member.",
        "label": "Oruka Therapeutics Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other liabilities",
        "verboseLabel": "Accrued expenses and other liabilities - related party (in Dollars)",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r565"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other loss",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PatentAssignmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PatentAssignmentAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent Assignment Agreement",
        "documentation": "Patent assignment agreement.",
        "label": "Patent Assignment Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PaymentOfOtherPartyTerminationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PaymentOfOtherPartyTerminationFee",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of other party termination fee",
        "documentation": "Payment of other party termination fee",
        "label": "Payment Of Other Party Termination Fee"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PaymentOfUnrestrictedResearchGrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PaymentOfUnrestrictedResearchGrants",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of unrestricted research grants",
        "documentation": "Payment of unrestricted research grants.",
        "label": "Payment Of Unrestricted Research Grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r550"
     ]
    },
    "abio_PercentageHoldingForStockOptionsExercisePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PercentageHoldingForStockOptionsExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per share",
        "documentation": "Minimum ownership percentage for 110% fair market value on the grant date.",
        "label": "Percentage Holding For Stock Options Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PercentageOfBaseRentToBePaidMonthly": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PercentageOfBaseRentToBePaidMonthly",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage Of Base Rent To Be Paid Monthly",
        "documentation": "Percentage of base rent to be paid monthly.",
        "label": "Percentage Of Base Rent To Be Paid Monthly"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PercentageOfRetentionBonuses": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PercentageOfRetentionBonuses",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of retention bonuses",
        "documentation": "Percentage of retention bonuses.",
        "label": "Percentage Of Retention Bonuses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697"
     ]
    },
    "abio_PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PotentialUpfrontAndMilestoneObligationsAndRoyaltyObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty obligations (in Euro)",
        "documentation": "Potential upfront and milestone obligations and royalty obligations.",
        "label": "Potential Upfront And Milestone Obligations And Royalty Obligations"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PotentiallyDilutiveSecuritiesExcludedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PotentiallyDilutiveSecuritiesExcludedAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities, excluded:",
        "label": "Potentially Dilutive Securities Excluded Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abio_PotentiallyDilutiveSecuritiesExcludedAbstract0": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PotentiallyDilutiveSecuritiesExcludedAbstract0",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities, excluded:",
        "label": "Potentially Dilutive Securities Excluded Abstract0"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock convertible shares issuable (in Shares)",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r194"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r462"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r194"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r462",
      "r480",
      "r732",
      "r733"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value; 5 million shares authorized; no shares issued or outstanding at December 31, 2023 and 2022",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r407",
      "r565"
     ]
    },
    "srt_PresidentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "PresidentMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thomas A. Keuer",
        "label": "President [Member]"
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_PrincipalOwnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrincipalOwnerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders",
        "label": "Principal Owner [Member]",
        "documentation": "Owner of record or known beneficial owner of more than 10 percent of the voting interests of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIncomeTaxRefunds",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax refund received",
        "label": "Proceeds from Income Tax Refunds",
        "documentation": "Amount of income tax refund received from tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r44",
      "r585",
      "r705",
      "r706"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r377"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r71",
      "r74",
      "r75"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r83",
      "r414"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r377"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r377",
      "r402",
      "r414",
      "r565"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r71",
      "r74",
      "r412"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/PropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r377"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "abio_PurchaseAggregateShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "PurchaseAggregateShares",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase aggregate shares",
        "documentation": "Purchase aggregate shares.",
        "label": "Purchase Aggregate Shares"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r211",
      "r232",
      "r266",
      "r267",
      "r268",
      "r280",
      "r338",
      "r393",
      "r394",
      "r396",
      "r419",
      "r421",
      "r428",
      "r452",
      "r453",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r525",
      "r526",
      "r540",
      "r547",
      "r551",
      "r559",
      "r560",
      "r561",
      "r562",
      "r566",
      "r569",
      "r603",
      "r610",
      "r713",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180",
      "r181",
      "r211",
      "r232",
      "r266",
      "r267",
      "r268",
      "r280",
      "r338",
      "r393",
      "r394",
      "r396",
      "r419",
      "r421",
      "r428",
      "r452",
      "r453",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r525",
      "r526",
      "r540",
      "r547",
      "r551",
      "r559",
      "r560",
      "r561",
      "r562",
      "r566",
      "r569",
      "r603",
      "r610",
      "r713",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728"
     ]
    },
    "abio_RelatedPartyArrangementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "RelatedPartyArrangementsDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Arrangements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r220",
      "r382",
      "r383",
      "r405",
      "r411",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r479",
      "r481",
      "r512"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r382",
      "r383",
      "r384",
      "r385",
      "r405",
      "r411",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r479",
      "r481",
      "r512"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r720"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Arrangements [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r486",
      "r487",
      "r490"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Arrangements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r220",
      "r382",
      "r383",
      "r405",
      "r411",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r479",
      "r481",
      "r512",
      "r720"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/RelatedPartyArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Arrangements",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r383",
      "r386",
      "r437",
      "r438",
      "r439",
      "r488",
      "r489",
      "r490",
      "r509",
      "r511"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r191",
      "r197",
      "r385",
      "r395",
      "r403",
      "r530",
      "r531"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r527",
      "r537",
      "r729"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "abio_ResearchAndDevelopmentExpenseReversed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ResearchAndDevelopmentExpenseReversed",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/RelatedPartyArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party expense",
        "documentation": "Research and development expense (reversed).",
        "label": "Research And Development Expense Reversed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credit Carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested restricted stock units",
        "verboseLabel": "Restricted Stock Units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Workforce reduction percentage",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r173",
      "r174",
      "r604"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r174",
      "r175"
     ]
    },
    "us-gaap_RestructuringReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remains unpaid",
        "label": "Restructuring Reserve, Current",
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r605",
      "r606"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r53",
      "r409",
      "r426",
      "r427",
      "r435",
      "r463",
      "r565"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r112",
      "r113",
      "r114",
      "r116",
      "r121",
      "r123",
      "r125",
      "r164",
      "r165",
      "r167",
      "r303",
      "r304",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r323",
      "r325",
      "r326",
      "r328",
      "r330",
      "r364",
      "r365",
      "r423",
      "r425",
      "r440",
      "r732"
     ]
    },
    "abio_RetentionBonusPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "RetentionBonusPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retention bonus paid",
        "documentation": "Retention bonus paid.",
        "label": "Retention Bonus Paid"
       }
      }
     },
     "auth_ref": []
    },
    "abio_RetentionBonuses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "RetentionBonuses",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of retention bonuses",
        "verboseLabel": "Retention bonuses",
        "documentation": "Retention bonuses.",
        "label": "Retention Bonuses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetirementPlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanNameAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Axis]",
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r551",
      "r579",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671"
     ]
    },
    "us-gaap_RetirementPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan Name [Domain]",
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r551",
      "r579",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ARCAandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r98",
      "r106",
      "r139",
      "r144",
      "r145",
      "r154",
      "r156",
      "r158",
      "r159",
      "r160",
      "r163",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r356",
      "r401",
      "r537",
      "r608"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leased assets and operating lease liabilities \u2013 amended lease term",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r564"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Potentially Dilutive Shares of Common Stock",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net deferred tax assets and liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Tax Benefit Attributable to Our Loss from Operations",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r555",
      "r699"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable",
      "http://www.arcabiopharma.com/role/ScheduleofNoncashSharebasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Non-cash, Share-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "abio_ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfEstimatedWeightedAverageGrantDateFairValuePerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated Weighted Average Grant Date Fair Value Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfFutureMinimumCommitmentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfFutureMinimumCommitmentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Commitments Due [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfIncomeTaxBenefitAttributableToOurLossFromOperationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Income Tax Benefit Attributable To Our Loss From Operations Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Net Deferred Tax Assets And Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfNonCashShareBasedCompensationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfNonCashShareBasedCompensationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Non Cash Share Based Compensation Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSU Activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "abio_ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfPotentiallyDilutiveSharesOfCommonStockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Potentially Dilutive Shares of Common Stock [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ScheduleOfPropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r377"
     ]
    },
    "abio_ScheduleOfRsuActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfRsuActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of RSU Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activities",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r6",
      "r54"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Weighted Average Grant Date Fair Value Per Share",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "abio_ScheduleOfStockOptionActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ScheduleOfStockOptionActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SecondAmendmentOfCertainRetentionBonusLettersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SecondAmendmentOfCertainRetentionBonusLettersMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Amendment of Certain Retention Bonus Letters",
        "documentation": "Second amendment of certain retention bonus letters.",
        "label": "Second Amendment Of Certain Retention Bonus Letters Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r157",
      "r159",
      "r535",
      "r536",
      "r539"
     ]
    },
    "abio_SellingCommissionPerAdditionalSharesSoldPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SellingCommissionPerAdditionalSharesSoldPercentage",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of commission rate equal",
        "documentation": "Selling commission per additional shares sold percentage.",
        "label": "Selling Commission Per Additional Shares Sold Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SeperationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SeperationAgreementMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Seperation Agreement",
        "documentation": "Seperation agreement",
        "label": "Seperation Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Preferred Stock",
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r582",
      "r611"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance expense",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock awards granted service period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options award, vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, RSUs outstanding, Forfeited and cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, Forfeited and cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares, RSUs outstanding, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, RSUs outstanding, beginning of period",
        "periodEndLabel": "Number of Shares, RSUs outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, beginning of period",
        "periodEndLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, RSUs outstanding, Vested and released",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofRSUActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Date Fair Value, RSUs outstanding, Vested and released",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issuable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Options exercisable, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Options exercisable, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Options, Forfeited and cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Forfeited and cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value per share (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Options outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options, Options outstanding, ending balance",
        "terseLabel": "Purchase options shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0",
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Options outstanding, ending balance",
        "terseLabel": "Weighted average exercise price (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Options vested and expected to vest, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Options vested and expected to vest, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Options vested and expected to vest, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r244",
      "r263",
      "r264",
      "r265",
      "r266",
      "r269",
      "r275",
      "r276",
      "r277",
      "r278"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options award, expiration",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofEstimatedWeightedAverageGrantDateFairValuePerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Options exercisable, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Options exercisable, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years) Options outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Options vested and expected to vest, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "abio_SharebasedCompensationDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SharebasedCompensationDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SharebasedCompensationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SharebasedCompensationDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.arcabiopharma.com/role/ScheduleofPropertyandEquipmentTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software",
        "verboseLabel": "Computer Software",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r87",
      "r88",
      "r89",
      "r106",
      "r129",
      "r130",
      "r132",
      "r134",
      "r141",
      "r142",
      "r163",
      "r182",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r194",
      "r195",
      "r199",
      "r202",
      "r208",
      "r356",
      "r431",
      "r432",
      "r433",
      "r434",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r462",
      "r483",
      "r505",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r578",
      "r586",
      "r592"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r33",
      "r36",
      "r37",
      "r78",
      "r95",
      "r96",
      "r97",
      "r112",
      "r113",
      "r114",
      "r116",
      "r121",
      "r123",
      "r125",
      "r140",
      "r164",
      "r165",
      "r167",
      "r209",
      "r303",
      "r304",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r330",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r364",
      "r365",
      "r378",
      "r416",
      "r423",
      "r424",
      "r425",
      "r440",
      "r505"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r140",
      "r365",
      "r397",
      "r429",
      "r451",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r484",
      "r485",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r570"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r140",
      "r161",
      "r365",
      "r397",
      "r429",
      "r451",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r484",
      "r485",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r505",
      "r570"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r32",
      "r33",
      "r53",
      "r431",
      "r505",
      "r519"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon vesting of Restricted Stock Units (in Shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r32",
      "r33",
      "r53"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable",
      "http://www.arcabiopharma.com/role/ScheduleofStockOptionActivitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r32",
      "r33",
      "r53",
      "r250"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon vesting of Restricted Stock Units",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r32",
      "r33",
      "r53"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable",
      "http://www.arcabiopharma.com/role/ScheduleofPotentiallyDilutiveSharesofCommonStockTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding stock options",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet",
      "http://www.arcabiopharma.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r36",
      "r37",
      "r48",
      "r464",
      "r480",
      "r506",
      "r507",
      "r565",
      "r576",
      "r587",
      "r601",
      "r716",
      "r732"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/EquityFinancings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Financings",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r105",
      "r193",
      "r195",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r329",
      "r508",
      "r510",
      "r523"
     ]
    },
    "abio_SubscriptionAgreementReceiptAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SubscriptionAgreementReceiptAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription agreement receipt amount",
        "documentation": "Subscription agreement receipt amount",
        "label": "Subscription Agreement Receipt Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "verboseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r388"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r388"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r388"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SubsequentEventsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SubsequentEventsDetailsLineItems",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r389"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and experimentation credits",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_TaxCreditCarryforwardDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardDescription",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, limitations on use",
        "label": "Tax Credit Carryforward, Description",
        "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardLimitationsOnUse",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward, limitations on use",
        "label": "Tax Credit Carryforward, Limitations on Use",
        "documentation": "Description of the limitation related to use of the tax credit carryforward."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "abio_ThomasAKeuerAndCJeffreyDekkerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ThomasAKeuerAndCJeffreyDekkerMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thomas A. Keuer and C. Jeffrey Dekker [Member]",
        "documentation": "Thomas A. Keuer and C. Jeffrey Dekker.",
        "label": "Thomas AKeuer And CJeffrey Dekker Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ThresholdAmountOfAdjustedExchangeRatio": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ThresholdAmountOfAdjustedExchangeRatio",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjusted exchange ratio",
        "documentation": "Threshold amount of adjusted exchange ratio.",
        "label": "Threshold Amount Of Adjusted Exchange Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "abio_ThresholdAmountOfDeclaredCashDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ThresholdAmountOfDeclaredCashDividend",
     "crdr": "debit",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Declared cash dividend",
        "documentation": "Threshold amount of declared cash dividend.",
        "label": "Threshold Amount Of Declared Cash Dividend"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r599",
      "r719"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "abio_TwoThousandAndThirteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "TwoThousandAndThirteenPlanMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2013 Plan",
        "documentation": "Two thousand and thirteen plan.",
        "label": "Two Thousand And Thirteen Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "abio_TwoThousandAndTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "TwoThousandAndTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/SharebasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Equity Incentive Plan",
        "documentation": "Two thousand and twenty equity incentive plan.",
        "label": "Two Thousand And Twenty Equity Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.arcabiopharma.com/role/EquityFinancingsDetails",
      "http://www.arcabiopharma.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r174",
      "r175"
     ]
    },
    "abio_UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "UniversityMedicalCenterOfJohannesGutenbergUniversityMainzMember",
     "presentation": [
      "http://www.arcabiopharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "University Medical Center of Johannes Gutenberg University Mainz",
        "verboseLabel": "University Medical Center Of Johannes Gutenberg University Mainz",
        "documentation": "University medical center of Johannes Gutenberg university Mainz.",
        "label": "University Medical Center Of Johannes Gutenberg University Mainz Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.arcabiopharma.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Estimates in the Preparation of Financial Statements",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r68",
      "r69",
      "r72",
      "r73"
     ]
    },
    "abio_ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "ValuationAllowanceDeferredTaxAssetsAndLiabilitiesChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arcabiopharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in net deferred tax assets and liabilities",
        "documentation": "Valuation allowance deferred tax assets and liabilities change in amount.",
        "label": "Valuation Allowance Deferred Tax Assets And Liabilities Change In Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r134"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r134"
     ]
    },
    "abio_WeightedAverageSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arcabiopharma.com/20240331",
     "localname": "WeightedAverageSharesOutstandingAbstract",
     "presentation": [
      "http://www.arcabiopharma.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding:",
        "label": "Weighted Average Shares Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
